exposed to plain water vapor (100 ml of water without essential oil) via diffuser for 15 minutes during post-exercise recovery.
219633197|NCT05653479|DRUG|UPB-101|UPB-101 Subcutaneous injection
219633198|NCT02327871|DEVICE|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
219633199|NCT05317039|OTHER|silica-calcium phosphate nanocomposite SCPC|Patients will be treated with the buccal plate repositioning technique and grafted with SCPC then the grafted defect will be covered with a platelet-rich fibrin membrane.
219633200|NCT05317039|OTHER|freezed dried bone|Patients will be treated with the buccal plate repositioning technique and grafted using DFDBA. then the grafted defect will be covered with a platelet-rich fibrin membrane.
219633201|NCT04634344|DRUG|DZD2269|A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
219633202|NCT03432637|PROCEDURE|spontaneous ventilation|thoracoscopic lobectomy under spontaneous ventilation
219633203|NCT03432637|PROCEDURE|intubated anesthesia with single-lung mechanical ventilation|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
219633204|NCT00984542|DRUG|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
219633205|NCT01088763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
219633206|NCT01088763|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219633207|NCT01088763|OTHER|pharmacological study|Correlative studies
219633208|NCT01088763|DRUG|dexamethasone|Given IV
219049730|NCT07084857|OTHER|correlational analysis between BMD and isokinetic lower extremity strength|correlational analysis between BMD and isokinetic lower extremity strength
219049731|NCT07084831|DRUG|Xanomeline/trospium|Participants will receive xanomeline/trospium during the trial
219049732|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique and mulligan therapy|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique and mulligan therapy for limited cervical range of motion
218939515|NCT04023734|BEHAVIORAL|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
218939516|NCT04023734|BEHAVIORAL|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
218939517|NCT04775628|PROCEDURE|Inferior glide humerus in GH joint|Supine inferior glide GH joint
218939518|NCT06159426|OTHER|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
218939519|NCT01475149|OTHER|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
218939520|NCT05438303|DRUG|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
218939521|NCT05438303|DRUG|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
218939522|NCT05438303|DRUG|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
218939523|NCT05438303|DRUG|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
218939524|NCT05438303|DRUG|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
218939525|NCT02659241|DRUG|Adavosertib|Given PO
219633209|NCT01156181|PROCEDURE|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
218939526|NCT02659241|OTHER|Laboratory Biomarker Analysis|Correlative studies
218939527|NCT04655989|DEVICE|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
218939528|NCT04235296|BIOLOGICAL|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
218939529|NCT04235296|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
218939530|NCT00000921|DRUG|Prednisone|
218939531|NCT01233232|DRUG|Placebo|Oral dose bid
218939532|NCT01233232|DRUG|AZD5069 50mg|Oral dose bid
218939533|NCT01233232|DRUG|AZD5069 80mg|Oral dose bid
219049733|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique
219049734|NCT07086872|OTHER|mulligan therapy|patients will receive mulligan therapy for limited cervical range of motion
219359952|NCT02583334|DEVICE|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
219633210|NCT01156181|PROCEDURE|control|Embryo transfer without any intervention
219633211|NCT05881564|OTHER|blood use for priming cardiopulmonary bypass circuit|one arm will have the cardiopulmonary bypass circuit primed with blood
219049735|NCT07086872|OTHER|postural correction exercises|the patients will receive two strengthening exercises (deep cervical flexors and scapular retractors) and two stretching: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall
219359953|NCT02583334|DEVICE|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
219359954|NCT00606242|DRUG|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
219633212|NCT05881564|OTHER|clear prime for cardiopulmonary bypass|this arm will not have bypass circuit primed with blood
219633213|NCT00116974|PROCEDURE|Scaling and root planing|Scaling and root planing
219633214|NCT04132323|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
219633215|NCT05898828|DRUG|Nivolumab|Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
219633216|NCT05898828|DRUG|Entinostat|Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.
218939534|NCT05522491|DRUG|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
219633217|NCT05898828|BIOLOGICAL|Montanide(R) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
219633218|NCT05898828|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
219633219|NCT01422889|DEVICE|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
219633220|NCT01672554|DRUG|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
218939535|NCT03722277|OTHER|Variable load training|Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
218939536|NCT03722277|OTHER|Conventional strength training|Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
218939537|NCT02762370|DRUG|FX006 32 mg|Single 5 mL IA injection
218939538|NCT02762370|DRUG|TCA IR 40 mg|Single 1 mL IA injection
218939539|NCT06017037|DRUG|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
218939540|NCT06017037|DRUG|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
218939541|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
218939542|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
218939543|NCT00528697|DRUG|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
218939544|NCT00528697|DRUG|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
218939545|NCT00528697|DRUG|placebo|Subject will take a tablet once daily for 8 weeks
218939546|NCT00500214|PROCEDURE|elective ilioinguinal nerve excision|
218939547|NCT01281332|DEVICE|Menopod|The mechanism of action of the device will not be revealed in advance.
218939548|NCT01281332|DEVICE|Inactive device|
219049736|NCT07086859|PROCEDURE|TEST 1|Autogenous whole tooth graft with metformin
219049737|NCT07086859|PROCEDURE|Control|Autogenous whole tooth graft
218939549|NCT05306808|OTHER|physiotherapy class|The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
218939550|NCT02633020|BIOLOGICAL|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
218939551|NCT02633020|BIOLOGICAL|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
218939552|NCT01573234|DEVICE|MySkin patch|Hydrogel and polyurethane film
218939553|NCT01573234|DEVICE|Gauze and Patch|Traditional Dressing
218939554|NCT00003206|DRUG|carboplatin|
218939555|NCT00003206|DRUG|paclitaxel|
218939556|NCT03791944|DEVICE|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
219049738|NCT07086040|BEHAVIORAL|RAS incorporated in upper-limb movement training|RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
219049739|NCT07086040|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
219359955|NCT02399306|DRUG|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
219633221|NCT02755467|DEVICE|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
218939557|NCT03791944|DEVICE|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
218939558|NCT03791944|DEVICE|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
218939559|NCT03791944|DEVICE|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
218939560|NCT01136785|DEVICE|active CPAP Therapy|7 days of active CPAP therapy
218939561|NCT01136785|DEVICE|sham CPAP therapy|7 days of sham CPAP therapy
218939562|NCT04834089|BIOLOGICAL|AntiSARS-CoV-2 Serum|Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
218939563|NCT04834089|OTHER|Placebo|Saline solution Administration Route: Intravenous
218939564|NCT03423199|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
218939565|NCT03423199|DRUG|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
218939566|NCT03423199|DRUG|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
218939567|NCT03423199|DRUG|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
218939568|NCT02850471|DEVICE|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
218939569|NCT05430633|PROCEDURE|Appendectomy|Appendectomy - laparoscopic or open
218939570|NCT02922478|RADIATION|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
218939571|NCT02922478|PROCEDURE|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
218939572|NCT02922478|RADIATION|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
218939573|NCT02922478|PROCEDURE|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
218939574|NCT01388985|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
218939575|NCT01057589|DRUG|Pemetrexed|"Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
218939576|NCT01057589|DRUG|Cetuximab|"Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
219359956|NCT02399306|RADIATION|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
219359957|NCT03133845|PROCEDURE|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
219359958|NCT03133845|PROCEDURE|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
219359959|NCT03133845|PROCEDURE|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
219633222|NCT02091089|DEVICE|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
219633223|NCT01231451|DRUG|DMPA|All subjects will take DMPA
218939577|NCT01057589|DRUG|Cisplatin|Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
218939578|NCT01057589|DIETARY_SUPPLEMENT|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
218939579|NCT01057589|DIETARY_SUPPLEMENT|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
218939580|NCT05842356|BEHAVIORAL|Communication Technique 2|A new communication technique.
218939581|NCT02954172|DRUG|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
218939582|NCT02954172|DRUG|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
218939583|NCT03435783|BEHAVIORAL|Brief Electronic Intervention|The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
218939584|NCT03435783|BEHAVIORAL|Attention-Matched Control|Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
218939585|NCT00388817|BEHAVIORAL|Pharmacist intervention|
219633224|NCT00746148|OTHER|Reflexology|10 weekly sessions of 45 minutes each
218939586|NCT00853567|DRUG|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
218939587|NCT00853567|OTHER|placebo|Placebo
218939588|NCT05533229|DRUG|Fentanyl|The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
218939589|NCT05533229|DRUG|Morphine|The trial aims to study the quality of anesthesia, perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
218939590|NCT01643096|OTHER|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
218939591|NCT01643096|OTHER|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
218939592|NCT03636516|DEVICE|SWL|extracorporeal shockwave lithotripsy apply
218939593|NCT02507167|DIETARY_SUPPLEMENT|mixed meal|250 ml Fortimel compact (chocolate)
218939594|NCT02507167|DRUG|Rifampin|oral rifampin administration (600 mg EREMFAT®)
218939595|NCT05266833|BEHAVIORAL|Slow diaphragmatic breathing|"The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session."
218939596|NCT02223494|DRUG|Terbogrel|
218939597|NCT05179590|OTHER|Quality of Dream|"Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia."
218939598|NCT04673396|DRUG|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
218939599|NCT04673396|DRUG|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
218939600|NCT02029898|DRUG|Remifentanil|
218939601|NCT02029898|DRUG|sodium chloride 0,9%|
218939602|NCT00515268|DRUG|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
218939603|NCT00515268|DRUG|Placebo|Subjects will receive placebo inhaler.
218939604|NCT00580671|BEHAVIORAL|MET/CBT|Weekly Individual Counseling Sessions
218939605|NCT00580671|BEHAVIORAL|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
218939606|NCT00580671|BEHAVIORAL|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
218939607|NCT00633204|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
218939608|NCT00051662|DRUG|efalizumab|
218939609|NCT00858104|PROCEDURE|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
218939610|NCT02738385|BEHAVIORAL|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219359960|NCT03133845|PROCEDURE|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
219633225|NCT04955405|OTHER|The seven visit telemedicine protocol|The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
219633226|NCT06385574|OTHER|Virtual reality therapy|Conventional hand therapy
218939611|NCT02738385|BEHAVIORAL|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
218939612|NCT05611190|DIAGNOSTIC_TEST|CT-FFR|CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
218939613|NCT05611190|DIAGNOSTIC_TEST|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice.
218939614|NCT03220321|OTHER|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
218939615|NCT03220321|OTHER|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
218939616|NCT01170572|OTHER|No intervention|No intervention
219359961|NCT03133845|PROCEDURE|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
219049740|NCT07085377|PROCEDURE|DIADEME strategy|"This strategy consists of implementing the standardized DIADEME protocol. It, in line with best practice recommendations, enables nurses to adjust methadone dosage on the basis of a clinical assessment scheme incorporating opioid withdrawal and overdosing and includes:~* initial medical consultation with the hospital practitioner for an addictology and psychiatry assessment, OUD assessment, and initial prescription of methadone for 3 months~* ECG prior to any methadone prescription, hepatitis B, C, HIV testing may be offered, and an emergency NALOXONE kit will be given to the patient or prescribed~* follow-up consultations with an nurse at least every 7 days, and more frequently if necessary.Dosages can be adjusted by the nurse on the basis of the standardized DIADEME protocol~* medical consultation are only in the event of major withdrawal symptoms or overdosing or in the event of any incident not covered by the protocol and warranting rapid medical advice or at the patient's request"
219049741|NCT07085377|PROCEDURE|Controle strategy|The control strategy corresponds to standard practice guidelines for patients suffering from drug addiction, with the care pathway provided by the hospital practitioner, assisted by the nursing team.
219049742|NCT07085377|PROCEDURE|Individual semi directive interview|"Individual semi-directive interviews with a sample of patients from the DIADEME group (2 to 3 volunteer patients per CSAPA for a total of 20 to 30 interviews) will be conducted by a research psychologist and carried out at one month after the end of follow-up (3 months).~Themes covered will include: commitment to care, patient/professional relationship, understanding of follow-up and treatment, experience of care and services at the addictology center, satisfaction with services received, level of response to expectations).~Individual semi-directive interviews with a sample of healthcare professionals focus group will be also conducted by a research psychologist and carried out after the last patient has been included in the center. The aim will be to understand the effects of the intervention and identify its impact on professionals and the organization of the centers."
218939617|NCT04411563|OTHER|Taking biological samples|Taking blood samples for biochemical and epigenetic analysis
218939618|NCT03248791|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
218939619|NCT03248791|DRUG|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
218939620|NCT03248791|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
218939621|NCT03829423|DIAGNOSTIC_TEST|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
219049743|NCT07085130|BEHAVIORAL|Exercises and cold application|Hand and foot exercises combined with cold application interventions are non-pharmacological methods used to reduce pain, kinesiophobia, and fragility levels in patients with diabetic peripheral neuropathy.
219049744|NCT07085130|OTHER|Exercises and virtual reality|Performing hand and foot exercises in a cold, snowy virtual environment using virtual reality goggles may be a non-pharmacological intervention to alleviate burning-type hand and foot pain in patients with diabetic neuropathy.
219049745|NCT07086534|DEVICE|GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System|"The GeminiOne TEER System consists of a TEER clip implant, transcatheter delivery system and a guide sheath.~The clip is made of cobalt-chromium-nickel alloy with a nickel-titanium alloy gripper, covered with a braided mesh of polyethylene terephthalate (PET) materials."
219049746|NCT07085234|DRUG|Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen|"Induction therapy: Albumin-bound paclitaxel 260 mg/m² + cisplatin 75 mg/m² (divided on days 1 - 3) + S1 calculated according to body surface area, taken twice daily (days 1 - 14) + Iparomlimab/Tuvorlimab(QL-1706) 5 mg/kg (day 1). One cycle lasts for 21 days, and the treatment continues for three consecutive cycles.~Concurrent chemotherapy: Cisplatin 80 mg/m², divided on days 1 - 3. One cycle lasts for 21 days, and the treatment continues for two consecutive cycles.~Radiotherapy regimen: Whole-course IMRT."
219049747|NCT06864624|DRUG|Sunvozertinib|Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years
219049748|NCT06597487|PROCEDURE|Full pulpotomy|"The patients will receive full pulpotomy as follows:~-Under rubber dam isolation, the operator will perform caries removal, complete the access cavity preparation, achieve hemostasis from all canals, and apply the bioceramic material. The operator will seal the cavity with glass ionomer restoration."
219049749|NCT06597487|PROCEDURE|Conventional root canal treatment|The patients will receive conventional root canal treatment, which is the gold standard treatment protocol in cases with irreversible pulpitis.
219049750|NCT07085312|PROCEDURE|Exosome-Enriched IVF Culture|IVF culture media supplemented with 10 µg per well of GMP-certified exosomes (Exosmart or equivalent). Retrieved MI oocytes are cultured in this media for up to 4 hours to assess progression to MII.
219049751|NCT07085494|BEHAVIORAL|neurofeedback|\- Neurofeedback Training : Feedback is based on individualized alpha band power. Participants see a game-like display (for instance, a plane) that reflects their alpha activity. Excessive EMG (muscle tension) causes performance drops, encouraging relaxation.
219049752|NCT07085494|BEHAVIORAL|Cognitive Training|\- Cogmed Training : Participants complete adaptive tasks focusing on working memory. The difficulty adjusts in real time based on performance.
219359962|NCT03133845|PROCEDURE|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
219633227|NCT04826081|OTHER|data collection|data collection
219633228|NCT01767246|OTHER|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
219633229|NCT01767246|OTHER|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
218939622|NCT01497366|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
218939623|NCT01497366|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
218939624|NCT01497366|DRUG|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg"
218939625|NCT04824651|BIOLOGICAL|COVID-19 vaccine|Vaccination done as part of France's COVID-19 Vaccination Campaign
219049753|NCT07085494|BEHAVIORAL|Sham feedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
219049754|NCT07086391|DEVICE|Polymyxin B Sulfate 25mg Jet Nebulization / Vibrating Mesh Nebulization|"* Group A: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via jet nebulizer under mechanical ventilation.~* Group B: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via vibrating mesh nebulizer under mechanical ventilation."
218939626|NCT03800420|DRUG|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
218939627|NCT03800420|DRUG|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
218939628|NCT00001062|DRUG|Ganciclovir|
218939629|NCT03911102|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
219049755|NCT07086157|DIETARY_SUPPLEMENT|Probiotic|"A probiotic supplement in capsule form containing 4 strains of microorganisms, with a total of 10 × 10⁹ CFU (colony-forming units) per capsule. The strain composition per capsule was:~Lactobacillus acidophilus L1 - 2.9 × 10⁹ CFU, Bifidobacterium longum LBL-01 - 2.9 × 10⁹ CFU, Lactobacillus rhamnosus - 2.9 × 10⁹ CFU, Saccharomyces boulardii - 1.3 × 10⁹ CFU. Each participant in this arm took one capsule per day in the morning on a full stomach, for a duration of 4 weeks. No other dietary interventions were applied to this group. This probiotic supplement was chosen because the strains in its content are among the most frequently researched and known strains in terms of intestinal health. Additionally, it does not contain FOS or inulin due to FODMAP restriction.~."
218939630|NCT02152917|DRUG|Tranexamic acid|
218939631|NCT02152917|DRUG|Floseal®|
218939632|NCT04409860|RADIATION|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
218939633|NCT04409860|DRUG|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
218939634|NCT00419445|DRUG|GTS21/Placebo|
218939635|NCT00746512|DRUG|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
218939636|NCT00746512|DRUG|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
219049756|NCT07086157|OTHER|Low-FODMAP Diet|A structured low-FODMAP diet intervention designed to restrict intake of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The diet was individualized and monitored by a registered dietitian over a 4-week period to ensure adherence and nutritional adequacy.
219049757|NCT07086313|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 6 weeks
219049758|NCT07086313|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 6 weeks
219049759|NCT07086313|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
219049760|NCT07086417|PROCEDURE|Robot-Assisted Arthroscopic ACL Reconstruction|This intervention involves the use of a customized robotic surgical system to assist in arthroscopic anterior cruciate ligament (ACL) reconstruction. The system integrates preoperative planning with CT/MRI fusion imaging, intraoperative surgical guidance for femoral and tibial tunnel creation, and real-time biomechanical evaluation. The robot provides enhanced precision in tunnel positioning and graft placement compared to conventional techniques.
219049761|NCT07086417|PROCEDURE|Conventional Arthroscopic ACL Reconstruction|This intervention uses standard arthroscopic techniques for ACL reconstruction without robotic assistance. Tunnel positions are determined manually using surgical landmarks and guides. Graft placement, tensioning, and isometry assessment are performed by the surgeon using conventional methods.
219359963|NCT03133845|PROCEDURE|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
219633230|NCT05003804|BIOLOGICAL|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
218939637|NCT00746512|DRUG|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
218939638|NCT00746512|DRUG|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
218939639|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
218939640|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
218939641|NCT03499535|BEHAVIORAL|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
218939642|NCT03499535|BEHAVIORAL|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
218939643|NCT03499535|BEHAVIORAL|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
219633231|NCT05003804|BIOLOGICAL|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
219633232|NCT05430750|DRUG|Nitrous oxide|In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.
218939644|NCT03499535|BEHAVIORAL|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
218939645|NCT03499535|BEHAVIORAL|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
218939646|NCT02117557|PROCEDURE|Single incision laparoscopic surgery|
218939647|NCT02117557|PROCEDURE|Conventional laparoscopic surgery|
218939648|NCT05069870|DRUG|SKLB1028|SKLB1028, capsule, oral
218939649|NCT05069870|DRUG|Itraconazole|Itraconazole, capsule, oral
218939650|NCT05069870|DRUG|Gemfibrozil|Gemfibrozil, capsule, oral
218939651|NCT05069870|DRUG|Rifampicin|Rifampicin, capsule, oral
218939652|NCT04129281|PROCEDURE|Surgery|Surgery acconding to clinical practice
219633233|NCT05430750|DRUG|Nitrous oxide|In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.
218939653|NCT06144580|OTHER|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
218939654|NCT02745080|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
218939655|NCT02745080|BIOLOGICAL|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
218939656|NCT04371588|OTHER|No Response to Train of Four Stimulation|No response is observed during Train of Four stimulation monitoring during surgery
218939657|NCT04371588|OTHER|1-2 Response to Train of Four Stimulation|1 to 2 response is observed during Train of Four stimulation monitoring during surgery
218939658|NCT01256632|DRUG|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
219633234|NCT05430750|DRUG|Sevoflurane|Ventilation will be initiated with 2% sevoflurane in all the groups
219633235|NCT03930355|OTHER|Blood transfusion|Patients who received blood transfusion in the perioperative period
219633236|NCT03930355|OTHER|Control|Patients who did not receive blood transfusion in the perioperative period
219633237|NCT02435537|DRUG|Dexmedetomidine (Precedex)|intrathecal administration
219633238|NCT02435537|DRUG|Bupivacaine|intrathecal 10 mg bupivacaine
219633239|NCT02435537|DRUG|Morphine|intrathecal 0.5mg morphine
218939659|NCT04155242|DIAGNOSTIC_TEST|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
218939660|NCT04155242|DIAGNOSTIC_TEST|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
218939661|NCT04155242|DIAGNOSTIC_TEST|Oesophagogastroduodenoscopy|"* Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
219633240|NCT04947007|DRUG|Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 15 ml +15 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
219633241|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 10+10 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 10 ml +10 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
218939662|NCT00329524|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
219359964|NCT03133845|PROCEDURE|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
219633242|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 5+5 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 5 ml +5 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
219633243|NCT04947007|DRUG|Isotonic solution|In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
219633244|NCT01580670|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
219633245|NCT02097745|DRUG|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
219633246|NCT02097745|DRUG|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
219359965|NCT03133845|PROCEDURE|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
218939663|NCT01234935|DRUG|dasatinib|Given orally
218939664|NCT01234935|DRUG|gemcitabine hydrochloride|Given IV
218939665|NCT01234935|OTHER|laboratory biomarker analysis|Correlative studies
218939666|NCT01234935|GENETIC|mutation analysis|Correlative studies
218939667|NCT01234935|GENETIC|nucleic acid sequencing|Correlative studies
218939668|NCT01234935|OTHER|immunohistochemistry staining method|Correlative studies
218939669|NCT04479371|DRUG|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
218939670|NCT04479371|DRUG|Bupivacaine|Standard bupivacaine
218939671|NCT05073432|OTHER|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
218939672|NCT04286373|DEVICE|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
218939673|NCT04286373|DEVICE|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
218939674|NCT05512000|BEHAVIORAL|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
219049762|NCT07086690|DRUG|Group (1): Patients will receive nebulized ketamine (2 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs willbe rec"
219049763|NCT07086690|DRUG|Group (2): Patients will receive nebulized combination of dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
219359966|NCT03133845|PROCEDURE|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
219633247|NCT00425750|DRUG|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
219633248|NCT00425750|DRUG|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
219633249|NCT00425750|OTHER|laboratory biomarker analysis|Tissue and blood collection.
219633250|NCT00425750|OTHER|pharmacological study|Blood collection.
219633251|NCT03594981|BIOLOGICAL|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
219633252|NCT02861222|DRUG|Doxorubicin|
219633253|NCT05472272|OTHER|Formula diet|Participants will receive a low-calorie (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) formula diet product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
218939675|NCT05512000|BEHAVIORAL|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
218939676|NCT05512000|BEHAVIORAL|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
218939677|NCT05512000|BEHAVIORAL|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
219049764|NCT07086690|DRUG|Patients will receive intramuscular ketamine (4 mg/kg, intramuscularly) 15 mins before starting the procedure.|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
218939678|NCT05512000|BEHAVIORAL|No teaching control|The words in this set are not taught, only assessed.
218939679|NCT06233370|BEHAVIORAL|Moderate intensity walking exercise|For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
218939680|NCT03216824|OTHER|Dressing|A dressing is maintained on the CVAD exit site.
218939681|NCT03216824|OTHER|No-Dressing|The CVAD exit site is not covered with a dressing.
219633254|NCT05472272|OTHER|Food-based diet|Participants will receive a low-calorie (815-835 kcal/day; 45-50% carbohydrate, 20-30% protein, and 20-30% fat) food-based diet created by dietitians for 12 weeks. After 12 weeks, participants will increase energy intake gradually and be encouraged to increase daily physical activity to maintain weight loss for another 12 weeks.
218939682|NCT04440904|DEVICE|CT workstation (Syngo Via VB10B, Siemens, Germany)|Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
218939683|NCT04867096|OTHER|Physical activity|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
218939684|NCT01453062|DRUG|Arzerra|Treatment with Arzerra
218939685|NCT05438472|OTHER|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
219633255|NCT01757184|DRUG|Sebelipase Alfa|IV infusions of sebelipase alfa
219633256|NCT01757184|DRUG|Placebo|IV infusions of matched placebo
219633257|NCT04804423|DRUG|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
219633258|NCT04804423|DRUG|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
219633259|NCT03350646|OTHER|Volume of medium during embryo transfer|
219633260|NCT05460351|DIETARY_SUPPLEMENT|BRJ+Nitrate|Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
219633261|NCT05460351|DIETARY_SUPPLEMENT|Control|Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
219633262|NCT01666158|BEHAVIORAL|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
219633263|NCT01902641|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
219633264|NCT01902641|DRUG|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
219633265|NCT01902641|DRUG|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
219633266|NCT01984632|PROCEDURE|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
218939686|NCT00268255|DRUG|gefitinib|
218939687|NCT00268255|PROCEDURE|adjuvant therapy|
218939688|NCT00268255|PROCEDURE|enzyme inhibitor therapy|
218939689|NCT00268255|PROCEDURE|neoadjuvant therapy|
218939690|NCT00268255|PROCEDURE|protein tyrosine kinase inhibitor therapy|
218939691|NCT00268255|PROCEDURE|radiation therapy|
219049765|NCT07085741|DEVICE|MAGNET System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
219049766|NCT06907381|BEHAVIORAL|Blood flow-restricted resistance exercise|Participants will engage in baseline measurement of blood pressure, strength of target muscle contractions, and level of support needed for functional task performance. They will then begin BFRE treatment supplemented by electrical stimulation, if needed, two times weekly. Each exercise session will include performance of four sets of 20 repetitions of target muscle contraction on each side of the body followed by functional task performance.
219049767|NCT07087093|OTHER|Ketone ester|KetoneAid Ke4 Pro Ketone Ester：20ml, tid po
219633267|NCT01984632|PROCEDURE|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
219049768|NCT06928467|BEHAVIORAL|Building Better Caregivers workshop|The BBC workshop is a 6-week, online, peer-led small group workshop designed for family caregivers of persons living with dementia or other form of cognitive impairment. It is an evidence-based workshop of the Self-Management Resource Center originally developed at Stanford University for the Veterans Administration and is now licensed for online delivery by Canary Health. Content focuses on increasing participant self-management behaviors, dementia caregiving skills, and peer social support. The workshop uses a peer-facilitated small group format with frequent online interactions between approximately 27 participants on threaded discussion boards. Activities are guided by two trained peer co-facilitators (caregivers themselves). Each week focuses on 2-3 new topics and tools for participants to learn and use. In threaded discussion board conversations participants interact, help each other, and provide peer social support.
219049769|NCT06909396|DRUG|General anesthesia|Patients received general anesthesia
219049770|NCT06909396|DRUG|Intrathecal Anesthesia|Patients received intrathecal Anesthesia
219049771|NCT06909396|DRUG|Caudal block|Patients received caudal epidural anesthesia.
219049772|NCT06238921|RADIATION|Stereotactic Radiation|Stereotactic Radiation to intact brain metastases or post-operative cavity.
219049773|NCT06238921|DRUG|Zimberelimab|One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
219049774|NCT06238921|DRUG|Sacituzumab govitecan|SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
219049775|NCT06912100|DIETARY_SUPPLEMENT|Placebo|Participants consume capsules containing only an inactive placebo (maltodextrin and magnesium stearate).
219049776|NCT06912100|DIETARY_SUPPLEMENT|Probiotic|Participants consume capsules containing L. acidophilus (TW01) at 4×10\^10 CFU/capsule (three capsules daily, totaling 1.2×10\^11 CFU/day) plus a commercial fiber source (Fibersol-2).
219633268|NCT03658161|BEHAVIORAL|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
219633269|NCT03240289|BEHAVIORAL|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
219633270|NCT06576778|PROCEDURE|PROVSIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
218939692|NCT00268255|PROCEDURE|radiosensitization|
218939693|NCT01338298|DRUG|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
219049777|NCT07107113|OTHER|Pilates Exercise|Pilates exercises are characterized as muscle strengthening and stretching.
219049778|NCT07107113|OTHER|Aerobic exercises|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
219049779|NCT07107113|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
219049780|NCT07111234|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
219049781|NCT07111234|DRUG|Nicotine Oral Pouch|Sample randomly-ordered ONPs
219633271|NCT04693208|DEVICE|Laser therapy|Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
219633272|NCT00485199|PROCEDURE|Pneumatic Retinopexy|
219633273|NCT00485199|PROCEDURE|Vitrectomy with Gas|
219633274|NCT01509417|OTHER|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
219633275|NCT01509417|OTHER|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
219633276|NCT03877601|DRUG|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
218939694|NCT01338298|DRUG|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
219633277|NCT03877601|DIAGNOSTIC_TEST|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
219633278|NCT04357067|DEVICE|Lingual brackets|A type of bracket that applied lingual surface of teeth.
219633279|NCT04357067|DEVICE|Labial brackets|A type of bracket that applied labial surface of teeth.
218939695|NCT06216925|BEHAVIORAL|#BabyLetsMove|Description of #BabyLetsMove
218939696|NCT06216925|BEHAVIORAL|WIC Antenatal Care|Description
218939697|NCT04770181|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
219049782|NCT07111234|OTHER|Questionnaire Administration|Ancillary studies
218939698|NCT04770181|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
218939699|NCT00334113|BEHAVIORAL|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
218939700|NCT03697889|DRUG|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
218939701|NCT03697889|DRUG|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
218939702|NCT04963868|PROCEDURE|Stent removed by the novel strategy|The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；
218939703|NCT04963868|PROCEDURE|Stent removed by the conventional strategy|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
218939704|NCT03719196|OTHER|Reading glass|Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
219359967|NCT05731804|DRUG|SIM0417 600 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
219049783|NCT07111234|DRUG|Smoke usual brand cigarette|Participant will smoke their usual brand of cigarette during 1 study visit for 5 minutes.
219049784|NCT07111065|DIETARY_SUPPLEMENT|FISH OIL 500MG OMEGA-3 SOFT GEL MINIS|Translucent, light yellow, oblong soft gelatin capsule containing a straw to amber light liquid.
219633280|NCT03691987|BIOLOGICAL|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
218939705|NCT05037175|BEHAVIORAL|CPT-Text|CPT is a 12-session (13 modules), trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one. Brief synchronous messaging sessions can be arranged
218939706|NCT05037175|BEHAVIORAL|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy. Brief synchronous messaging sessions can be arranged.
218939707|NCT05037175|BEHAVIORAL|Retention Incentive|Participants will be told at baseline that they can earn free or discounted therapy for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
218939708|NCT05037175|BEHAVIORAL|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
218939709|NCT05741008|RADIATION|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
219049785|NCT07111065|OTHER|Dietary Guidelines for Americans diet|The Dietary Guidelines provides science-based advice on what to eat and drink to promote health, help reduce risk of chronic disease, and meet nutrient needs.
219049786|NCT06920134|DEVICE|ARC-IM Investigational System|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
219633281|NCT03691987|BIOLOGICAL|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
219633282|NCT06030323|OTHER|No intervention|This is not an interventional study. The study is classified as 'pre-clinical device development or performance testing'. The purpose of the study is to develop and validate the AI models using data collected from people affected by stroke in a hospital environment, to test the accuracy of the optimised models, and to ascertain patient preference for sensor location.
219633283|NCT05961306|DIAGNOSTIC_TEST|SCID 5|"SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone."
219633284|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1."
219633285|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2."
219633286|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1."
219633287|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2."
219633288|NCT04700241|DIETARY_SUPPLEMENT|Potassium nitrate|Acute intervention (5.5 hours)
219633289|NCT04700241|DIETARY_SUPPLEMENT|Placebo|Acute intervention (5.5 hours)
218939710|NCT05301608|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
218939711|NCT05301608|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
218939712|NCT06228768|OTHER|Acupressure|9 acupoints will be stimulated for 3 minutes per point
219049787|NCT07109050|DEVICE|VR Headset|VR will be offered on either an individual or joint-experience basis, whereby the participant(s) wear a VR headset with 360 degree views, to explore various VR experiences of their choice for up to 3 sessions on a weekly basis. Goals for using VR will be ascertained by completing the goal based measure with the patient who is accessing specialist palliative care. This will define the purpose of the VR intervention in future sessions. The participant will be shown a list of VR experience options so they are aware of these prior to the next session. Pre-VR and post-VR questionnaires will be completed.
219049788|NCT06922929|DRUG|INR101|INR101 PET/ CT
219049789|NCT06924632|DRUG|Minoxidil|2.5 mg Sublingual Minoxidil Tablet
219049790|NCT06924632|DRUG|Placebo|Placebo
218939713|NCT06228768|OTHER|Acupressure|9 areas will be stimulated for 3 minutes per point
218939714|NCT06414291|OTHER|Plain Water|Plain water without calories, sweetener, or electolytes
218939715|NCT06414291|OTHER|Liquid IV Hydration Multiplier|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
219049791|NCT07116694|DRUG|BXCL501 Sublingual Film|Single dose BXCL501 120 mcg
219049792|NCT07120100|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation will be administered Monday-Friday for two weeks (10 sessions total)
218939716|NCT06414291|OTHER|Liquid IV Sugar Free|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
218939717|NCT05847530|DEVICE|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
218939718|NCT05847530|DEVICE|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
218939719|NCT05407818|DRUG|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
218939720|NCT05716542|OTHER|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
219049793|NCT07131293|PROCEDURE|Lymphatic intervention|This intervention was made as part of their clinical treatment.
219049794|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
219633290|NCT06768944|DRUG|Psilocybin 25 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
219049795|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
219049796|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
219049797|NCT03950128|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
219049798|NCT03950128|BEHAVIORAL|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
219049799|NCT06936748|COMBINATION_PRODUCT|Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab|"Radiotherapy Phase: Spatially fractionated radiotherapy (SFRT, 10-20 Gy/1F) to the tumor, followed by hypofractionated/conventional fractionated radiotherapy (dose investigator-determined).~Immunotherapy Phase: Iparomlimab and Tuvonralimab (5 mg/kg) initiated within 1 week post-radiotherapy, infused IV over 20-60 minutes (Day 1, every 3 weeks) in 100 mL saline/5% glucose. Treatment continues until disease progression, intolerable toxicity, new antitumor therapy, consent withdrawal, or investigator decision, with a maximum duration of 1 year. Progression may allow continued therapy after patient-investigator discussion; re-progression mandates permanent discontinuation."
219049800|NCT06942455|BEHAVIORAL|SIESTA|Active condition
219049801|NCT06942455|BEHAVIORAL|Sleep education and health education control|Attention Control
219049802|NCT05559320|DEVICE|Ride-on-toy navigation training|The training program will involve a set of activities where children will be encouraged to drive a joystick-operated ride-on-toy to navigate through their physical environment. The training will involve will involve progressively challenging multi-directional navigational games such as shape mazes, treasure hunts, relay races, and obstacle courses that will require children to use their affected arm skillfully to navigate through the courses.
219049803|NCT05559320|BEHAVIORAL|Upper extremity functional training|In addition to the navigation practice, along the multi-directional courses, children will complete tasks at multiple stations that will involve both gross and fine motor activities. The goal of the training will be to use their arm for functional goal-directed tasks and games that will involve elements of reaching, grasping, in-hand manipulation, and release. We will use props such as balls, bean bags, cups, cones, and small toys to practice skills such as catching, throwing, picking up, pushing, pulling, opening, closing, etc.
219049804|NCT06933056|DRUG|Sotagliflozin (SOTA) followed by 3 drugs in a random order|400 mg/day SOTA Each drug will be given daily for 2 weeks.
219049805|NCT06933056|DRUG|Aspirin followed by 3 drugs in a random order|81 mg/day Aspirin Each drug will be given daily for 2 weeks.
219049806|NCT06933056|DRUG|Clopidogrel followed by 3 drugs in a random order|75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
219049807|NCT06933056|DRUG|Eliquis followed by 3 drugs in a random order|5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.
219049808|NCT06944964|PROCEDURE|Single Implant Fixation (SIF)|This intervention involves using one implant for fracture fixation. The implant can be either a lateral locked plate or a retrograde intramedullary nail, based on the surgeon's preference.
219049809|NCT06944964|PROCEDURE|Dual Implant Fixation (DIF)|This intervention involves using two implants for fracture fixation. The combination can be either dual plate fixation (DPF) or combination nail plate fixation (NPF) .
219049810|NCT06171789|DRUG|GEN1107|IV infusion of GEN1107
219049811|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
219633291|NCT06768944|DRUG|Psilocybin 1 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
218939721|NCT06516055|DRUG|S1B-408|Medication with multiple monoamine activities
219633292|NCT06768944|DRUG|Metyrapone 750 mg|metyrapone 750mg capsules, which will be administered in 2 doses
219633293|NCT06768944|DRUG|Placebo|inactive placebo
219633294|NCT03725488|OTHER|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
219633295|NCT05989061|DEVICE|PEEK customized healing abutment|Guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery
219633296|NCT05989061|DEVICE|Titanium customized healing abutment|Guided delayed implant and a customized Titanium healing abutment placed simultaneously with implant surgery
219633297|NCT02299622|GENETIC|Genetic test|Next-generation sequencing (AmpliSeq) \& fusion analysis
218939722|NCT04966481|DRUG|Palbociclib|Administered on an outpatient basis
218939723|NCT04966481|DRUG|Cetuximab|Given intravenously over approximately 60 minutes
218939724|NCT06102499|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
218939725|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
218939726|NCT05920135|DRUG|BBT-207|BBT-207 given orally alone
219633298|NCT05772377|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 10 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 8mg will be taken.
219633299|NCT05772377|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen. For patients who cannot tolerate the toxicity of cisplatin, 75 mg/m2 nedaplatin will be used as an alternative drug.
218939727|NCT00721968|DEVICE|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
218939728|NCT00721968|PROCEDURE|cataract surgery alone|Cataract surgery alone
218939729|NCT03313011|DIAGNOSTIC_TEST|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
218939730|NCT05601544|DEVICE|ACUVUE OASYS 1-Day|Sphere CONTROL
218939731|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day|Sphere TEST
218939732|NCT05601544|DEVICE|ACUVUE OASYS Multifocal|Multifocal CONTROL
219049812|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
219049813|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
219049814|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
219049815|NCT04397328|DRUG|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
219049816|NCT04397328|DRUG|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
219049817|NCT07145515|DEVICE|OCS Heart|Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.
219049818|NCT07145515|OTHER|Static Cold Storage (SCS)|Preservation of donor hearts with static cold storage.
219049819|NCT06949735|DIETARY_SUPPLEMENT|Digestive Enzyme Blend|Oral
219049820|NCT06949735|DIETARY_SUPPLEMENT|Placebo|Oral
219049821|NCT07172971|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
218939733|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day Multifocal|Multifocal TEST
218939734|NCT05601544|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|Toric CONTROL
218939735|NCT05601544|DEVICE|senofilcon A based contact lens (toric) with new UV/HEV filter|Toric TEST
218939736|NCT06108583|BEHAVIORAL|TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder|The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
218939737|NCT04940039|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
219049822|NCT07172971|DRUG|SGLT2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
219049823|NCT07165704|OTHER|Visual arts|The arts intervention will consist of two parts: (a) implementation of one-hour session of Visual Arts (e.g., painting, drawing, printing techniques exercises). The activities will be guided through a theme (Emotions), by a professional artist, to obtain a final individual artistic product. Peer contact, shared learning, and a feeling of community are all made possible by the group-based approach. This facilitator will offer assistance, motivation, and technical training as they lead participants through the creative process. Using narrative-building and dialogue-based methods, the artist will encourage children to share their stories, experiences, and perspectives, through art. (b) Children's final artistic products will be displayed in Community Galleries in their neighbourhood in an opening ceremony.
219633300|NCT05772377|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 40Gy total dose and 3D-brachytherapy of 30Gy/2.5F. Duration of radiotherapy will be no more than 5 weeks
219633301|NCT03507634|DRUG|Opioid free Anesthesia dexmedetomidine and lidocaine|Opioid free anesthesia with dexmedetomidine and lidocaine
219633302|NCT03507634|DRUG|Opioid based anesthesia Fentanyl and Remifentanyl|Opioid based anesthesia with Fentanyl and Remifentanyl
218939738|NCT04940039|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
218939739|NCT04940039|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
219049824|NCT07173140|DIAGNOSTIC_TEST|MRI|Participants undergo an additional MRI scan using novel MRI sequences
219359968|NCT05731804|DRUG|SIM0417 375 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
219633303|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
219633304|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
219633305|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
218939740|NCT04940039|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
218939741|NCT04940039|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
218939742|NCT04940039|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
218939743|NCT04940039|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
218939744|NCT04940039|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
218939745|NCT04940039|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
218939746|NCT00081874|DRUG|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
218939747|NCT06228599|OTHER|Treatment Plan|A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
218939748|NCT06322576|DRUG|177Lu-PNT2002|"10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires."
218939749|NCT02491632|DRUG|Dexamethasone|Given PO
218939750|NCT02491632|BEHAVIORAL|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
218939751|NCT02491632|OTHER|Laboratory Biomarker Analysis|Correlative studies
218939752|NCT02491632|OTHER|Quality-of-Life Assessment|Ancillary studies
218939753|NCT02491632|OTHER|Questionnaire Administration|Ancillary studies
218939754|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
218939755|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
218939756|NCT02117297|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
218939757|NCT00328107|BIOLOGICAL|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
218939758|NCT06221826|DRUG|Mexidol|Neurocytoprotector
218939759|NCT06124508|BEHAVIORAL|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
218939760|NCT06124508|BEHAVIORAL|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
218939761|NCT06124508|BEHAVIORAL|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
218939762|NCT04254549|DRUG|Rifaximin|550 mg by mouth three times daily for 14 days
219633306|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
219633307|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
218939763|NCT04254549|DRUG|Placebo|By mouth three times daily for 14 days
218939764|NCT02773082|DEVICE|Reclaim™ DBS Therapy|DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
218939765|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
218939766|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
218939767|NCT06853587|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
218939768|NCT06853587|OTHER|Current prescribing guidelines/recommendations|SSRI dosing based on current prescribing guidelines/recommendations
218939769|NCT06654804|DRUG|Perflutren lipid|Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
218939770|NCT03120897|DEVICE|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
218939771|NCT01235078|DEVICE|EZ-IO|powered intraosseous vascular access system
218939772|NCT06870071|OTHER|Control group|IV paracetamol (1 g, 3×1) and IV dexketoprofen (50 mg, 2×1)
218939773|NCT06870071|OTHER|Quadro iliac plane block|40 mL of 0.25% bupivacaine
218939774|NCT06614166|OTHER|SBD111 Probiotic Medical Food|Medical food comprised of probiotics and prebiotic fibers
218939775|NCT06614166|OTHER|SBD121 Probiotic Medical Food|Probiotic medical food comprised of three lactic acid bacteria and one bacillus
218939776|NCT01545505|BEHAVIORAL|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
219633308|NCT01276756|DRUG|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
219633309|NCT01276756|DRUG|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
219633310|NCT01276756|DRUG|Ribavirin|Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
219049825|NCT07172451|DRUG|Balanced Gelatin Solution|Balanced gelatin solution (4% succinylated gelatin in a balanced crystalloid carrier). Administered as resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Infusion follows a stroke volume-guided, goal-directed fluid therapy protocol. The total dose is limited to 30 mL/kg (ideal body weight) during the intraoperative period and the first 24 postoperative hours. If the maximum dose is reached, additional resuscitation is provided with balanced crystalloid solution.
219049826|NCT07172451|DRUG|Acetate Ringer's Solution|Acetate Ringer's solution, a balanced crystalloid, administered as the sole resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Fluid therapy follows the same stroke volume-guided, goal-directed protocol as the experimental arm. There is no upper limit for the total volume of crystalloid infusion during the intraoperative and first 24 postoperative hours.
219633311|NCT04403230|PROCEDURE|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
219633312|NCT01877642|DRUG|Lorazepam 1 mg IM|Lorazepam 1 mg intramuscular
219633313|NCT01877642|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg
219633314|NCT01877642|DRUG|Inhaled Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
219633315|NCT01877642|DRUG|Placebo IM|intramuscular placebo to mimic lorazepam 1 mg IM
219049827|NCT07172191|BIOLOGICAL|Fecal Microbial Transplantation|The technical implementation of FMT procedure is consistent with the methodological letter issued by the National Public Health Center of Hungary. FMT is performed via nasogastric tube with suspended fresh stool graft obtained from a pre-selected stool donor. Following FMT, the patient is observed for 24 hours at our center. The process is supervised and performed by the lead researcher.
219049828|NCT07173465|DEVICE|Virtual Reality (VR)|Participants will engage in the VR gaming intervention three times a week for 12 weeks. Each session will last approximately 45 minutes, providing ample gameplay, instruction, and debriefing time.
219633316|NCT05215977|DRUG|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
219633317|NCT05215977|DRUG|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
219633318|NCT04554901|DIETARY_SUPPLEMENT|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
219633319|NCT01957098|DIETARY_SUPPLEMENT|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
219633320|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 4% D-xylose|
219049829|NCT07173465|OTHER|Physical Activity (PA group)|The intervention includes a 5-minute warm-up, 10 minutes of strengthening exercises (lunges and squats), 20 minutes of balance and cardiovascular endurance activities (HIIT exercises), 20 minutes of aerobic exercises (stationary bike and dancing), and a 5-minute cool-down with breathing control. Participants also continue with personalized occupational therapy to enhance their functional abilities.
219049830|NCT07173465|OTHER|occupational therapy|the group will undergo their normal occupational therapy activities that include drawing, coloring, mathematical problems as well as solving mazes
219049831|NCT07172282|DRUG|Nelitolimod|Nelitolimod drug product is a clear to slightly opalescent, colorless to pale yellow solution free of visible particles and is supplied by TriSalus to the study sites in single-use vials. One vial is to be used per patient, and each vial should be discarded immediately after use.
219359969|NCT05731804|DRUG|SIM0417 750 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
219359970|NCT01694004|DRUG|Benzocaine Infusion into Duodenum|
219359971|NCT00294541|DRUG|ICA-17043|
219633321|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% D-xylose|
219633322|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% L-arabinose|
219633323|NCT06510543|DIETARY_SUPPLEMENT|Goal-directed EN therapy|The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.
219633324|NCT06510543|DIETARY_SUPPLEMENT|Conventional EN therapy|The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).
219633325|NCT05906615|DRUG|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
219633326|NCT01359332|PROCEDURE|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
219633327|NCT02527733|DRUG|Ranibizumab|
219633328|NCT02527733|DRUG|Ranibizumab and laser|
219633329|NCT04097054|PROCEDURE|Augmented preoperative planning|The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
219633330|NCT01496950|DEVICE|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
218939777|NCT05073146|OTHER|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
218939778|NCT06170047|BEHAVIORAL|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
218939779|NCT06170047|OTHER|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
218939780|NCT06671405|DRUG|AZD0780|Dose 1 and Dose 2
218939781|NCT06671405|DRUG|Itraconazole|"* Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration)."
218939782|NCT06671405|DRUG|Carbamazepine|"* Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only)."
218939783|NCT06671405|DRUG|Midazolam|"* Period 1 (midazolam administration only).~* Period 3 (AZD0780 + midazolam administration)."
218939784|NCT06671405|DRUG|Ethinyl estradiol/levonorgestrel|"* Period 1 (EE and LNG administration only).~* Period 3 (AZD0780 + EE and LNG administration)."
218939785|NCT06748443|BEHAVIORAL|Support intervention for the use of Knee Control+|Coaches will be offered a smorgasbord of support interventions that they can choose from depending on their specific needs: physical and digital workshops before and during the study, site visits to their team, digital programme material, leaflets and social media posts. Fitness coaches will be responsible for physical workshops to train the football coaches.
219049832|NCT07172490|OTHER|APA-FIT interdisciplinary program|"Intervention: APA-FIT~The APA-FIT program is an interdisciplinary intervention targeting three core domains in adults with chronic conditions at moderate or high risk for physical activity (PA): physical exercise, nutritional habits, and positive mental health. Over nine months, participants receive:~* Individualized PA Prescription~  * Bimonthly follow-up visits with a certified PA prescriber (physician, nurse, or physiotherapist)~ * Weekly supervised exercise sessions led by a coach~ * Automated PA logging and goal tracking via the APA-FIT app~* Nutritional Counseling~  * Initial and final dietary assessments with a registered nutritionist~ * Bimonthly follow-up and three hands-on Mediterranean-diet workshops~* Psychosocial Support for Positive Mental Health~  * Four bimonthly group sessions facilitated by the primary-care emotional-well-being lead~ * In-app materials, peer support features, and one-on-one check-ins"
219049833|NCT07172399|PROCEDURE|blood sampling|blood samples will be taken to discover if there is hyperlipedemia,hyperthrodism or acute kidney injury
219049834|NCT07172399|OTHER|• BP will be measured using a calibrated, automated oscillometric device suitable for pediatric use.|All the study participants will be examined for assessment of the height and weight using calibrated equipment, Body Mass Index ,blood pressure will be measured.
218939786|NCT06748443|OTHER|Information about Knee Control+|Coaches receive information about injuries in football and the efficacy of injury prevention exercise programmes at a pre-season digital workshop, and guided to access the Knee Control+ programme from the Swedish Football Association website.
219049835|NCT07172360|DRUG|VC005 tablets|VC005 groups repeat administration for 48 weeks
219049836|NCT07172360|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 48 weeks
219049837|NCT07172217|DRUG|RC48|Disitamab Vedotin (RC48) : 2.5 mg/kg, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
219049838|NCT07172217|DRUG|QL1706|Drug: QL1706 Iparomlimab and Tuvonralimab (QL1706) : 5 mg/kg in total, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
219049839|NCT07172230|BEHAVIORAL|Immersive Virtual Reality|Immersive VR
219049840|NCT07172230|BEHAVIORAL|No distraction Control condition|No VR during word list study phase
219633331|NCT01496950|DEVICE|Placebo|10Hz placebo rTMS delivered to the vertex
219633332|NCT02446210|DEVICE|Magstim 200|Transcranial Magnetic Stimulation
219633333|NCT02446210|DEVICE|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
219633334|NCT05102682|OTHER|Balance exercise program using exoskeleton device|Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device
219633335|NCT06576713|DIAGNOSTIC_TEST|Combiner whole genome and RNA sequencing|High-throughput DNA and RNA sequencing
219633336|NCT00040274|DRUG|DPC 817|
219633337|NCT00631046|DIETARY_SUPPLEMENT|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
219633338|NCT00631046|DIETARY_SUPPLEMENT|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
219633339|NCT05954390|DIETARY_SUPPLEMENT|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
219633340|NCT05954390|OTHER|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
218939787|NCT05552196|DRUG|Ponesimod|Ponesimod tablet will be administered orally.
218939788|NCT05552196|DRUG|Carbamazepine|Carbamazepine tablet will be administered orally.
218939789|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
218939790|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
218939791|NCT02910700|DRUG|Binimetinib|Given PO
218939792|NCT02910700|DRUG|Dabrafenib|Given PO
218939793|NCT02910700|DRUG|Encorafenib|Given PO
218939794|NCT02910700|OTHER|Laboratory Biomarker Analysis|Correlative studies
218939795|NCT02910700|BIOLOGICAL|Nivolumab|Given IV
218939796|NCT02910700|OTHER|Pharmacological Study|Correlative studies
218939797|NCT02910700|DRUG|Trametinib|Given PO
218939798|NCT00982423|DRUG|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
218939799|NCT04842591|DIAGNOSTIC_TEST|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
218939800|NCT06925490|DRUG|Metapex|Pulpectomy using Metapex
218939801|NCT06925490|DRUG|3Mixtatin|pulpotomy treatment when applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
218939802|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
218939803|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
218939804|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
218939805|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
218939806|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
218939807|NCT06919926|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
218939808|NCT06919926|DRUG|Placebo|placebo capsule
218939809|NCT02712047|DRUG|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
218939810|NCT02712047|DRUG|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
218939811|NCT02712047|DRUG|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
218939812|NCT06924294|OTHER|observation of renal affection in patients with liver cirrhosis|"* CBC~* Liver function test~* kidney function test (serum creatinine, BUN, eGFR (EPI equation and MDRD equation) ,~* Prothrombin time and concentration, INR,~* Serum electrolytes~* Urine analysis."
218939813|NCT02536053|PROCEDURE|Limb salvage|
218939814|NCT05167071|DRUG|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
218939815|NCT05167071|DRUG|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
218939816|NCT05167071|DRUG|Tislelizumab|Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.
218939817|NCT06940206|DIAGNOSTIC_TEST|Multidirectional Isometric Assessment of the Hip|Participants perform isometric tests (flexion, extension, ABD, ADD) to assess isometric hip strength at different basic movements over two sessions. Data is collected to evaluate the reliability and validity of these tests for swimmers.
218939818|NCT06941428|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a cognitive-behavioral individual intervention for children aged 3 to 18 years with trauma exposure and related mental health sequelae.TF-CBT core components include psychoeducation, relaxation skills, affective regulation skills, cognitive coping skills, construction of a trauma narrative to facilitate imaginal exposure and cognitive processing of the traumatic events, and in vivo exposure to trauma reminders. TF-CBT is hypothesized to operate on specific mechanisms that influence improvements in clinical outcomes.
218939819|NCT06941428|BEHAVIORAL|School-Adapted TF-CBT (S-TF)|S-TF is a version of Trauma-Focused Cognitive Behavioral Therapy modified for delivery by providers in the education sector. Although modifications will be determined by Study 1 activities, we anticipate that S-TF might modify treatment pacing, session length, or content sequencing. Regardless, the core functions of TF-CBT will be retained in the S-TF redesign.
218939820|NCT06937918|DEVICE|The AFM and Eadyn - guided resuscitation group|A fluid challenge using a stroke volume change prediction (∆SVpredict) and Eadyn guide. If the ∆SVpredict is more than 10%, isotonic crystalloid of 500 ml will be administered in 30 minutes, and the machine's response will be awaited. If ∆SVpredict is still more than 10%, continuous fluid loading was reapplied until SVV was less than 10% (fluid therapy will be stopped if ∆SVpredict is less than 10%) and dynamic arterial elastance (EAdyn) reaches the goal of 0.8-1.0 along with a vasopressor will be administered and titrated every 10 minutes until the target MAP \> 65 mmHg is reached. After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed
219049841|NCT07173179|DRUG|Papillary epinephrine injection combined with rectal indomethacin|All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle
219049842|NCT07173179|DRUG|Rectal indomethacin alone|All patients in this group receive preprocedural 100mg indomethacin spp
218939821|NCT06937918|OTHER|The standard care for septic shock|"The standard of care group will be treated according to according to septic shock guidelines 2021; In brief A vasopressor with optimal ideal fluid (at least 30 ml/kg) will be given to achieve the hemodynamic target (MAP ≥ 65 mm Hg) by fluid challenge technique guided by MAP and central venous pressure (CVP) changes after fluid challenge. Fluid-responsive tests can be used as a subsidiary, depending on the attending physician. Early Norepinephrine (NE) infusion can be used with a standard dose of 0.05 mcg/k/min and titrated at the rate of 0.01-0.02 mcg/kg/min every 10 min until 0.25 mcg/kg/min was achieved; then, the second line vasopressor will be added and adjusted to the target of vasopressor. Hydrocortisone can be given according to septic shock guidelines.~After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed"
218939822|NCT00212368|DRUG|Zinc acetate|
218939823|NCT01885741|DEVICE|IPBS|
219049843|NCT07173244|DRUG|Adebrelimab|adebrelimab-based regimen
218939824|NCT06943157|OTHER|No intervention|This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.
219633341|NCT05649761|DRUG|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
219633342|NCT01236469|PROCEDURE|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
218939825|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|1% chocolate milk
219049844|NCT07172815|DRUG|tadalafil|Once daily dose of Tadalafil will be commenced at 10 mg for 2 weeks, followed by an increase to 20 mg for another 2 weeks and finally increased to 40 mg.
219633343|NCT06257654|DEVICE|REZUM|The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.
219633344|NCT01554527|PROCEDURE|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
219633345|NCT01554527|OTHER|No CPAP treatment|Children randomized to the comparison group will receive routine care
219633346|NCT05630573|BIOLOGICAL|TNM001|intramuscular injection
219633347|NCT05630573|BIOLOGICAL|Placebo|intramuscular injection
219633348|NCT00755027|DRUG|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
219633349|NCT02284776|BEHAVIORAL|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
219633350|NCT05415176|DIETARY_SUPPLEMENT|Taurine supplementation|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
218939826|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|pea-based beverage
218939827|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|almond-based beverage
218939828|NCT06944314|PROCEDURE|Diagnostic procedures|Diagnostic Flexible Cystoscopy
218939829|NCT06944314|PROCEDURE|Flexible Cystoscopy|Diagnostic Flexible Cystoscopy
218939830|NCT06947850|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|Oxervate (cenegermin-bkbj) is commonly used to treat neurotrophic keratitis
219633351|NCT05415176|OTHER|Pshysical exercise|Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
219633352|NCT05415176|OTHER|Placebo control|The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks.
218939831|NCT06946771|DIAGNOSTIC_TEST|Advanced MRI parameters for the diagnosis of prostate cancer|This study aims to use time-dependent DWI (td-DWI) to fit and calculate quantitative information such as cellularity, cell diameter, intracellular volume fraction and cell density; use the chemical exchange saturation transfer (CEST) sequence to saturate hydrogen protons (hydroxyl (-OH), amide (-NH) and amine (-NH2) groups) in specific metabolites in the body by applying frequency-selective saturation pulses to non-invasively reflect metabolic information in the human body for the diagnosis of prostate cancer and to evaluate its diagnostic accuracy compared with traditional multi-parameter magnetic resonance imaging.
218939832|NCT06947187|OTHER|Pre-bunking video|\~3 minutes educational video to improve vaccine literacy and vaccine confidence
218939833|NCT06947187|OTHER|Video on safe disposal of medication|\~3 minutes educational video on safe disposal of medication
218939834|NCT06947109|DRUG|Placebo|Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.
218939835|NCT06947109|DRUG|AK111|The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.
219049845|NCT07172815|DRUG|Placebo|Matched Placebo will be taken once daily.
219633353|NCT04229862|PROCEDURE|Laryngeal mask airway insertion|Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
219633354|NCT01052480|BIOLOGICAL|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
219633355|NCT01052480|DRUG|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
219633356|NCT02345980|DRUG|Sildenafil|
219633357|NCT02345980|DRUG|Placebo|
219633358|NCT01707160|DRUG|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
219633359|NCT01707160|DRUG|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
218939836|NCT06946407|DRUG|Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation|"Pre-induction Therapy (R-M regimen):~Cycle 1-2 (C1-C2):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2~Induction Therapy (R-MT regimen):~Cycle 3-6 (C3-C6):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2 Thiotepa (T): 30 mg/m² IV over 30 minutes, on Day 3~Consolidation Therapy (EA regimen):~Cycle 7-8 (C7-C8):~Etoposide (E): 5 mg/kg IV, every 12 hours on Days 1 and 2 Cytarabine (A): 2.0 g/m² IV over 2 hours, every 12 hours on Days 3 and 4"
218939837|NCT06946173|DIETARY_SUPPLEMENT|health program|"Health children their age between 6-12 years bone and live in Gharbia governorate.~\- Legal pre mission will be taken from each school movement system to assess over weight among there school children.~\- The children and their family included in the study will be able to follow program of health intervention to prevent obesity.~Materials and methods:~1. Each children will be subjected to full history talking , clinical examination, growth assessment; weight height and body mass index (BMI) for age percentile ( Egyptians growth charts)~2. Laboratory investigation will be done which include lipid profile, serum cholesterol, triglycerides, LDL and hemoglobin level~3. Child history will be taken which include personal history~4. Dietary history of the child which include eating habits"
218939838|NCT06946589|DRUG|Carbetocin|A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section
218939839|NCT06946940|DRUG|Cannabis Oil (5% THC/5% CBD)|Cannabis oil containing a balanced formulation of 5% tetrahydrocannabinol (THC) and 5% cannabidiol (CBD). Administered sublingually over a three-month period, starting with a six-week titration phase to optimize dosing, followed by maintenance.
218939840|NCT06946940|DRUG|Sham Cannabis Oil|Placebo oil visually and chemically matched to the active cannabis oil but devoid of active cannabinoids (THC/CBD). Administered sublingually over three months, mirroring the active arm's titration and maintenance schedule.
218939841|NCT06946212|DRUG|Dexmedetomidine|In Dexmedetomidine group: patients received an intravenous dose of dexmedetomidine at 1 mcg/kg over 10 min in 100 mL normal saline followed by continous infusion of dexmedetomidine at 0.2mcg/kg/h up to 0.7mcg/kg/hr till reaching Ramsay sedation score 2-3
218939842|NCT06946212|DRUG|Ketamine plus Midazolam|In Ketamine Midazolam group: patients received midazolam 0.02 mg /kg IV then 2 minutes later take ketamine 0.25 mg/kg IV and we will repeated this mixture till reaching Ramsay sedation score 2-3
218939843|NCT06947629|DIAGNOSTIC_TEST|Intraoperative Frozen Section|"Intraoperative Frozen Section analysis which will include the following steps:~\- The specimen will undergo both gross and microscopic examination:~1. Gross examination: Evaluation of nodular features including, multiplicity, size, outlines, color and consistency.~2. Microscopic examination: Assessment of capsular pattern, capsular invasion, thickness of capsule, vascular invasion and number of invaded vessels and the presence or absence of papillary structures."
218939844|NCT06946329|BEHAVIORAL|Aquatic Exercise|Supervised WATERinMOTION sessions (60 mins, 3x/week) in heated pool. Focus on progressive resistance and mobility exercises.
218939845|NCT06946329|BEHAVIORAL|Land-Based Rehabilitation|Matched frequency/duration land-based program emphasizing core stabilization and low-impact aerobics.
218939846|NCT06947902|DEVICE|High flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (2L/kg per min with max of 45L)
218939847|NCT06947902|DEVICE|Low Flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (0.5L/kg per min with max of 5L)
218939848|NCT06947525|OTHER|Manual pressure|Before the procedure in the manual pressure group, the vein entry area will be pressed with the right hand thumb for 10 seconds. The pressure will be applied until the nail bed turns white.
218939849|NCT06947525|OTHER|Shotblocker|In the Shotblocker group, the shotblocker will be placed 2 cm above the vein entry point and will remain throughout the procedure.
218939850|NCT06947655|DEVICE|VBM Tourniquet|Perioperative VBM-Tourniquet Application with a fixation pressure of 15mmHg.
219049846|NCT07172685|COMBINATION_PRODUCT|Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy|"Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy Group:~Darolutamide (600 mg, orally, twice daily) GnRHa (Goserelin 10.8 mg sustained-release implant, subcutaneous injection, every 3 months) Docetaxel (75 mg/m², intravenous infusion, every 3 weeks, for 6 cycles) Dexamethasone (8 mg, orally, 12/3/1 hour before docetaxel infusion)\* Prednisone/Prednisolone (at the investigator's discretion)\* Transrectal High-Intensity Focused Ultrasound (HIFU) for prostate focal therapy (ablation extent determined based on MRI and biopsy findings; number of treatments ≤ 2)~\*Note: Dexamethasone and prednisone/prednisolone are adjunct medications and are not assigned as separate intervention arms; urinary catheter placement is a procedural detail and not listed as an intervention."
219633360|NCT04535492|BEHAVIORAL|Decision Making Support Tool|Primary care practices randomized in a stepped wedge cluster design will implement a newly developed predictive model and analytic tool to improve shared decision-making for patients.
219633361|NCT01707173|BEHAVIORAL|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
219633362|NCT01707173|BEHAVIORAL|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
218939851|NCT06947655|DEVICE|Adaptive Cuff|Perioperative Delfi-Tourniquet Application with a fixation pressure of 15mmHg.
219049847|NCT07174310|DRUG|Prasinezumab|Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.
219633363|NCT00529373|DRUG|Odanacatib|50 mg tablet orally once weekly (OW)
219633364|NCT00529373|DRUG|Placebo for Odanacatib|50 mg tablet orally OW
219633365|NCT00529373|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU orally OW
219633366|NCT00529373|DIETARY_SUPPLEMENT|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
219633367|NCT03898791|DRUG|LY3295668 Erbumine|oral capsules
219633368|NCT01094574|DRUG|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
219633369|NCT01094574|DRUG|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
218939852|NCT06946901|COMBINATION_PRODUCT|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy|"* HIPEC (cisplatin 70mg/m², Day 1,3 post-surgery), 1 cycle；~* Systemic AG chemotherapy (nab-paclitaxel 125mg/m²+ gemcitabine 1000mg/m², initiated, Day 1,8,15, q4 week), 4 cycles"
218939853|NCT06947746|BIOLOGICAL|hiSCs|hiSCs are derived from human induced pluripotent stem cells and exhibit immunomodulatory properties.
218939854|NCT06947772|BEHAVIORAL|Skill building education|This intervention includes two session. theoretical and practical. In theroretical patient will be teahc about self-care of AVF and in oracticla session they learn how to monitor their AVF. monitoring have three part. inspection, palpation and auscultation
218939855|NCT06946693|PROCEDURE|To evaluate the color stability and surface roughness of implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing in mandibular posterior region.|Subjects with single stage implant placement and early non-functional loading with implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing.
219633370|NCT01094574|DRUG|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
219633371|NCT05364866|DRUG|Antiarrhythmic drug Therapy|Propafenone, Sotalol and Amiodarone
219633372|NCT05364866|DEVICE|cryoballoon ablation|Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters including 23mm and 28mm.
218939856|NCT06947564|DIAGNOSTIC_TEST|CMR|Coronary microvascular function was assessed using contrast-enhanced CMR after PCI.
218939857|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
218939858|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
218939859|NCT06947226|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
218939860|NCT06947226|DRUG|Other anti-cancer therapy|Subjects will receive other anticancer therapy as per protocol
218939861|NCT06946069|RADIATION|NB-UVB twice weekly|Standard phototherapy without additional systemic treatment.
218939862|NCT06946069|OTHER|NB-UVB + dexamethasone (2.5-3 mg/week)|Combination therapy to enhance immunosuppression and repigmentation.
218939863|NCT06947863|OTHER|thermal cure|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The thermal treatment used hot, chlorinated and sodium water. Every day, the patients received 4 out of the 5 following treatments: underwater showers (15 minutes), shower-massage (10 minutes), hydromassage (20 minutes), swimming pool rehabilitation (20 minutes) and application of heated peloid (15 minutes).
218939864|NCT06947863|OTHER|dry rehabilitation|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The physical rehabilitation treatment was delivered in dry and included an analgesic physiotherapy based on electrotherapy (30 minutes) and muscle strengthening, as well as group rehabilitation.
218939865|NCT06947148|OTHER|Comprehensive post hospital management based on digital health intervention(DHI)|Based on the routine HF management of standard of care (SOC), the intervention group will carry out comprehensive post hospital management based on DHI, including cognitive behavioral therapy, digital self-monitoring and ReDS™ technology, etc.
218939866|NCT06945939|PROCEDURE|Fixation of Pott's fracture b and c|Assessment of syndesmotic injury via X-ray, CT, ultrasound and intraoperative
218939867|NCT06946147|OTHER||
218939868|NCT06946251|DEVICE|Transcutaneous Diaphragm Stimulation|"In the ICU, TEDS is administered by a physiotherapist once daily for 20 minutes, five days a week, as part of the routine treatment protocol. The stimulation is delivered using the LGT-231 model device from the LONGEST brand.~A transcutaneous current with a frequency of 30-50 Hz and a pulse width of 300-400 microseconds is applied to the diaphragm. The stimulation intensity is increased until visible muscle contraction is achieved."
218939869|NCT06946667|OTHER|the UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
218939870|NCT06946667|OTHER|the Non-UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
218939871|NCT06496750|DRUG|Ketamine Hydrochloride|Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
219049848|NCT07174310|DRUG|Placebo|Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol
219049849|NCT07172919|DRUG|Sotorasib|Sotorasib will be administered orally as a tablet.
219049850|NCT07172919|DRUG|Panitumumab|Panitumumab will be administered as an IV infusion.
219633373|NCT06136273|BEHAVIORAL|Treatment measures and intervention strategies|To conduct observational process improvement and hypothesis-deriving studies related to penetrating traumatic injuries using data from the Methodist trauma registry and open source data repositories.
219633374|NCT03692286|COMBINATION_PRODUCT|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
219633375|NCT03692286|DRUG|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
219633376|NCT03692286|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
219633377|NCT02539940|DEVICE|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
219633378|NCT01863667|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
219633379|NCT01863667|DRUG|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
218939872|NCT06496750|DRUG|Midazolam Hydrochloride|Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
218939873|NCT06590051|DRUG|UPLIZNA|
218939874|NCT05286749|PROCEDURE|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
218939875|NCT05286749|DEVICE|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
218939876|NCT05286749|DIAGNOSTIC_TEST|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
218939877|NCT02464046|DRUG|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
218939878|NCT02464046|DRUG|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
218939879|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
219049851|NCT07172620|PROCEDURE|Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.|Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
219049852|NCT07172620|PROCEDURE|Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation|Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
219049853|NCT07173972|RADIATION|Definitive radiotherapy|The prescribed dose is 56 Gray (Gy) in 16 fractions over 4 weeks (14 Gy per week) with a maximum dose-escalation to the tumor core of 80 Gy (5 Gy per fraction).
219049854|NCT07173387|DRUG|NALIRIFOX (liposomal irinotecan-based chemotherapy).|NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.
219049855|NCT07173387|RADIATION|Stereotactic Body Radiation Therapy (SBRT).|Stereotactic Body Radiation Therapy (SBRT) is a form of high-precision radiation therapy that delivers focused radiation beams to the tumor while minimizing damage to surrounding healthy tissue. In this study, SBRT will be applied in two different timing schedules after NALIRIFOX chemotherapy: early after 1 cycle (Cohort 1) or late after 6-8 cycles (Cohort 2). The total radiation dose will be 25-50 Gy, delivered in 5 fractions.
219049856|NCT07173621|OTHER|Amnioeffect|Amnioeffect is a placental-based allograft made of lyophilized human amnion/intermediate/chorion membrane (LHACM)
219049857|NCT07173829|OTHER|samples|A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
219049858|NCT07174102|DIAGNOSTIC_TEST|High resolution computed tomography|High resolution computed tomography perfomed in patients with rheumatoid arthritis and connective tissue diseases with or without interstitial lung disease, and idiopathic pulmonary fibrosis
218939880|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
218939881|NCT06493279|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13vg (3ml), 6E13vg(6ml), and 1.2E14 vg(12ml) per person sequentially.
218939882|NCT00895206|DRUG|individual adapted immunosuppression|individual adapted immunosuppression
219049859|NCT07172022|DRUG|Crovalimab|Crovalimab will be administered at a dose of 680 mg (for participants with BW ≥ 40 kilograms \[kg\] to \< 100 kg) or 1020 mg (for participants with BW ≥ 100 kg), as a SC injection, at Weeks 1, 2, and 3 and Q4W from Week 5 onwards.
219049860|NCT07172022|DRUG|Placebo|Placebo matching crovalimab will be administered as per the schedule specified in the respective arm.
219049861|NCT07172022|DRUG|VKA|Dose administration of VKA will be in accordance with the local prescribing information for the respective product. The VKA regimen will be titrated to a therapeutic target INR based on investigator discretion and local standard of care (SOC).
219049862|NCT07173673|OTHER|Usual Care (General Practice)|Participants receive routine care based on current clinical guidelines. Symptom-driven evaluation is performed by physicians, including at least one diagnostic test within 6 months such as a standard 12-lead ECG, Holter monitoring, or patch ECG. The choice and frequency of monitoring are determined by physician discretion, reflecting real-world practice patterns.
219633380|NCT01863667|DRUG|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
219633381|NCT01863667|DRUG|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
219633382|NCT03236467|BEHAVIORAL|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
219633383|NCT03481972|DRUG|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
218939883|NCT00895206|DRUG|golden standard therapy|golden standard therapy
218939884|NCT03036215|BEHAVIORAL|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
218939885|NCT04427332|OTHER|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
218939886|NCT04075812|DEVICE|Neuromuscular Stimulator|
218939887|NCT04299932|PROCEDURE|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
218939888|NCT04299932|PROCEDURE|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
218939889|NCT02657473|DRUG|tobramycin inhalation solution|
218939890|NCT02657473|DRUG|Saline 0.9% inhalation solution|
219633384|NCT03481972|DRUG|Standard of care|Standard of care
219633385|NCT03273101|DEVICE|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
219633386|NCT03273101|OTHER|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
219633387|NCT01992172|DRUG|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
218939891|NCT02609113|DEVICE|Strong Magnetic Wristband|
219633388|NCT01992172|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
219633389|NCT03627546|OTHER|Rapid Treatment strategy|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during 12 weeks of provided sofusbuvir/velpatasvir treatment."
219633390|NCT03627546|OTHER|Usual Care (facilitated referral)|articipants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
218939892|NCT02609113|DEVICE|Weaker Magnetic Wristband|
218939893|NCT01744535|BEHAVIORAL|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
218939894|NCT01744535|BEHAVIORAL|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
218939895|NCT01744535|BEHAVIORAL|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
218939896|NCT00283634|DRUG|erlotinib and bortezomib|
218939897|NCT06313385|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG)|The ICG will be injected intravenously and being assessed with Near-infrared (NIR) camera FLUORO4000XL 20 cm above the flap and fluorescence intensity counted with application called ImageJ
218939898|NCT06313385|DIAGNOSTIC_TEST|Temperature|Portable thermal imaging camera called Forward-looking infrared (FLIR) ONE® was used to assess flap and normal skin temperature. The FLIR ONE® device was place in perpendicular manner from the skin. The images were attained in two points of times which is direct temperature and after cold challenge test.
218939899|NCT06313385|DIAGNOSTIC_TEST|Transcutaneous oxygen and carbon dioxide pressure|The partial transcutaneous pressure is measured in flap using transcutaneous monitor (TCM) Combi probe. The probe should be cleaned using alcohol pads before use. After 5-10 minutes, the TCM 4 machine monitor should show stable transcutaneous oxygen and carbon dioxide pressure from the flap
218939900|NCT06313385|DIAGNOSTIC_TEST|Histopathology|A part of tissue from free flap is acquired and stored in 10% formalin tube. Later on, the tissue was colored with hematoxylin-eosin, neutrophile count, necrosis volume, and vessel proliferation will be assessed
218939901|NCT06313385|DIAGNOSTIC_TEST|Hypoxia inducible factor-1 (HIF-1) alpha|Peripheral tissue from distal free flap (0,5 x 0,5 cm in size) is obtained and stored in tube with dry ice. The tissue is assessed with human HIF - 1 Alpha Enzyme-Linked Immunosorbent Assay (ELISA) kit ab171577.
218939902|NCT06226389|PROCEDURE|4 different bulk-fill composite|Posterior cavities either class 1/2
218939903|NCT06213103|PROCEDURE|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
218939904|NCT06213103|PROCEDURE|Control cohort|Collection of 6 blood tubes at the inclusion visit.
218939905|NCT00843284|DRUG|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
218939906|NCT02558413|DRUG|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
218939907|NCT02558413|DRUG|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
218939908|NCT03980691|BIOLOGICAL|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
218939909|NCT01984658|BIOLOGICAL|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
218939910|NCT03742466|DRUG|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
218939911|NCT03742466|DRUG|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
218939912|NCT00498771|BEHAVIORAL|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
218939913|NCT02830685|DEVICE|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
218939914|NCT02830685|DEVICE|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
218939915|NCT05025319|RADIATION|X-ray image|Bedside x-ray at intensive unit.
218939916|NCT00122980|PROCEDURE|Red Cell Transfusions|Red Blood Cell Transfusions
218939917|NCT00122980|PROCEDURE|Iron Chelation|Iron Chelation Therapy
218939918|NCT00122980|DRUG|Hydroxyurea|Hydroxyurea
218939919|NCT00122980|PROCEDURE|Phlebotomy|Phlebotomy
218939920|NCT06478394|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
218939921|NCT01437904|PROCEDURE|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
218939922|NCT01437904|PROCEDURE|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
218939923|NCT00547443|DRUG|carboplatin|Given IV
218939924|NCT00547443|DRUG|paclitaxel|Given IV
218939925|NCT00547443|DRUG|sorafenib tosylate|Given orally
218939926|NCT00547443|RADIATION|radiation therapy|Given 5 days a week for 7.5 weeks
218939927|NCT01124864|DRUG|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
218939928|NCT01243242|DRUG|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
218939929|NCT04183543|DEVICE|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
218939930|NCT04183543|DEVICE|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
218939931|NCT03291366|DRUG|UCMSCC|infusion of aUCMSC and conventional therapy
218939932|NCT03291366|DRUG|conventional treatment|conventional treatment
218939933|NCT00005642|DRUG|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
218939934|NCT03180632|DRUG|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
218939935|NCT03180632|OTHER|Placebo|Patient receive one of two tablet of Placebo according to body weight
218939936|NCT06326983|DRUG|Dexmedetomidine|Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
218939937|NCT06326983|DRUG|Acetaminophen|Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
218939938|NCT06326983|DRUG|Ketorolac|Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
218939939|NCT06326983|DRUG|Morphine|Morphine (0.1mg/kg given intravenously at induction of anesthesia)
218939940|NCT02061839|OTHER|Sunscream with visible light protection|
218939941|NCT02061839|OTHER|Sunscream|
218939942|NCT03060122|DEVICE|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
218939943|NCT03060122|DEVICE|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
218939944|NCT03060122|DEVICE|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
218939945|NCT02988284|OTHER|No intervention|
219049863|NCT07173673|DEVICE|AI-ECG Guided Care (SmartECG-AFrisk)|Participants undergo SmartECG-AFrisk analysis of baseline 12-lead ECGs recorded in sinus rhythm. The algorithm calculates an atrial fibrillation risk score, classifying participants as high-risk (score ≥50) or low-risk (\<50). Monitoring strategies are adapted accordingly: high-risk participants undergo targeted and potentially repeated ECG monitoring using 12-lead ECG, Holter, or patch ECG, while low-risk participants follow standard guideline-based care.
218939946|NCT02803346|OTHER|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
218939947|NCT00380653|DRUG|sapacitabine|
218939948|NCT05103852|PROCEDURE|Cardiac MRI|vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
218939949|NCT00002069|DRUG|Ditiocarb sodium|
218939950|NCT05295667|DIAGNOSTIC_TEST|Doppler measurement in combination with amniotic fluid volume|Ultrasonographic evaluation
218939951|NCT01156064|DEVICE|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
218939952|NCT01156064|DEVICE|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
218939953|NCT01511120|DRUG|Tetraspan|
218939954|NCT01511120|DRUG|acetated Ringer's solution|
218939955|NCT01037764|PROCEDURE|alloHCT|"\[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
218939956|NCT00973817|BIOLOGICAL|ELAD plus standard of care treatment|Use of ELAD plus standard of care
218939957|NCT00973817|OTHER|Standard of care|Standard of care in the treatment of AOCH will be administered
218939958|NCT01732601|BEHAVIORAL|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
218939959|NCT01732601|BEHAVIORAL|Standard Care|Treatment at step-down facilities
219049864|NCT07173478|DRUG|OPA-15406|1% foam, topical, twice daily, for 4 weeks
219049865|NCT07173478|DRUG|Vehicle|vehicle, topical, twice daily, for 4 weeks
219049866|NCT07173959|DEVICE|GDM digital Therapy mini-program|The main functions of digital therapy products include personalized recipe recommendations, exercise and diet records and personalized analysis, blood sugar and weight monitoring, and the generation of weekly and monthly electronic comprehensive reports. The content of the electronic comprehensive reports includes the weight gain, blood sugar status, examination indicators, mood, and the proportion of diet and exercise of pregnant women in line with the system's recommendations during this period of time.
219633391|NCT05949346|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
218939960|NCT05730803|OTHER|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
218939961|NCT00788177|DRUG|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
218939962|NCT01856218|DRUG|UX003|
218939963|NCT05011201|DEVICE|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
218939964|NCT05011201|DEVICE|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
218939965|NCT06010043|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
218939966|NCT06010043|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
218939967|NCT06317545|OTHER|Mulligan Taping|Mulligan taping involves the application of tape to the lateral aspect of the elbow to offload stress during movement of the extensor tendons.
219049867|NCT07173959|DEVICE|Pregnancy record and education mini-program|This mini-program looks the same as digital therapy products but only has the functions of education and record-keeping
218939968|NCT00700388|DEVICE|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
218939969|NCT00700388|PROCEDURE|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
218939970|NCT03718091|DRUG|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
218939971|NCT04581707|DEVICE|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
218939972|NCT04581707|DEVICE|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
218939973|NCT03664349|DEVICE|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
218939974|NCT02490670|DRUG|Cephalexin|Administered orally
219633392|NCT05949346|BEHAVIORAL|School services for families of children with Dyslexia|Selected school personnel will deliver services as usual for the control group.
218939975|NCT03618355|DRUG|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
218939976|NCT03792828|DRUG|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
218939977|NCT03629275|COMBINATION_PRODUCT|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
218939978|NCT03629275|DRUG|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
218939979|NCT03387527|BEHAVIORAL|Prostate cancer decision aid|Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
218939980|NCT00474279|DRUG|Orally active growth hormone secretagogue (MK-677)|
218939981|NCT04825470|PROCEDURE|Liver Transplantation|Liver Transplantation
218939982|NCT03637088|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
218939983|NCT03637088|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
218939984|NCT03443583|OTHER|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
218939985|NCT05172583|BEHAVIORAL|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU. These are orientation in time, space, and place, accompaniment of the family for two hours in the morning and two hours in the afternoon, physical therapy once a day according to the patient's condition, medication with conscious sedation, and progressive reduction analgesics. opioids and benzodiazepines.
218939986|NCT05172583|BEHAVIORAL|Interventions to reduce delirium based on DSM and scientific evidence|The interventions are designed from the structure of the Dynamic Symptoms Model (DSM), taking into account the antecedents of delirium, physiological such as the medical condition of mechanical ventilation and pain, and drug treatment with sedatives and analgesics; the psychological, social, and spiritual antecedents with stimulation in the values, life experience, personality and spirituality, and the environmental antecedents with an adaptation of the physical conditions of the ICU. In addition, previous experience with identification and care of concomitant symptoms such as fear, confusion, restlessness, loneliness, and discomfort, and with the measurement and classification of the trajectory of delirium when it occurs, will also be considered. The interventions follow the scientific evidence, mainly from the ABCDEF bundle. All interventions are non-pharmacological.
218939987|NCT00648050|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
218939988|NCT00648050|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
219049868|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the questionnaire Mediterranean diet questionnaire (MEDAS)"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the patients' dietary choices and how beneficial they are for their health, according to the Mediterranean diet model.
219633393|NCT02687568|OTHER|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
218939989|NCT06308705|DIAGNOSTIC_TEST|InBios Strongy Detect TM IgG ELISA|The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies to Strongyloides recombinant antigens NIE and SsIR in serum. It consists of an enzymatically amplified sandwich-type immunoassay. Positive and negative control samples are provided in the kit. The test will be run and interpreted according to the manufacturer's instruction. The results are expressed as OD and nOD. Clinical interpretation of the results will be done by analysis of the Receiver Operating Characteristics (ROC) curve generated using data from confirmed positive and confirmed negative samples.
218939990|NCT02773953|DEVICE|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
218939991|NCT02773953|DEVICE|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
218939992|NCT01505764|DRUG|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
218939993|NCT01505764|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
218939994|NCT04009564|DIETARY_SUPPLEMENT|Date coffee|45 g of date seeds coffee in 280 ml of water
218939995|NCT04009564|DIETARY_SUPPLEMENT|Normal coffee|6 g of normal coffee in 280ml of water
219633394|NCT05330117|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
218939996|NCT04009564|DIETARY_SUPPLEMENT|Placebo|water, food colouring and coffee flavouring
219633395|NCT05330117|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
219633396|NCT03045263|BEHAVIORAL|Pivotal Response Treatment|Behavioral intervention for autism
218939997|NCT01460511|DRUG|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
218939998|NCT01460511|DRUG|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
218939999|NCT01256294|DRUG|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
219633397|NCT02822014|OTHER|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
218940000|NCT01256294|DRUG|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
218940001|NCT02160899|DRUG|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
218940002|NCT02160899|DRUG|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
218940003|NCT01714791|OTHER|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
218940004|NCT01714791|OTHER|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques."
218940005|NCT06335745|BEHAVIORAL|PediCARE Intervention|A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
218940006|NCT03517345|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
218940007|NCT03517345|DIETARY_SUPPLEMENT|Control|The only yogurt consumed as 200 g/d without prebiotic.
218940008|NCT01531855|OTHER|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
218940009|NCT00250198|DRUG|STA-5326|
218940010|NCT02603666|DEVICE|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
218940011|NCT03293901|BEHAVIORAL|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
218940012|NCT05466370|BIOLOGICAL|Transfusion of Allogeneic Blood|Transfusion of Allogeneic Blood
218940013|NCT03140059|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
218940014|NCT03140059|PROCEDURE|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
218940015|NCT02492607|OTHER|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
218940016|NCT02492607|DEVICE|digital mammography|annual mammography
218940017|NCT02492607|RADIATION|radiotherapy|according local policy
218940018|NCT00770575|DRUG|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
218940019|NCT00770575|DRUG|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
218940020|NCT00004040|BIOLOGICAL|recombinant interferon alfa|
218940021|NCT00004040|BIOLOGICAL|rituximab|
218940022|NCT04939350|OTHER|questionnaire|patients will complete a vaccination questionnaire
218940023|NCT00232791|DEVICE|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
218940024|NCT00232791|DEVICE|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
218940025|NCT00749710|PROCEDURE|clopidogrel|ORIF - surgical treatment
218940026|NCT00749710|PROCEDURE|no antiaggregant therapy|ORIF - surgical treatment
218940027|NCT06153004|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
218940028|NCT06153004|DRUG|Antidepressant medication (ADM)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
219359972|NCT04878133|DIAGNOSTIC_TEST|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
219633398|NCT03231163|OTHER|No Music|Participants lie supine on a table while no music is played.
219633399|NCT03231163|OTHER|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
219633400|NCT03231163|OTHER|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
219633401|NCT00184886|DRUG|Methotrexate 15 mg/week for 12 weeks|
219633402|NCT06208917|DRUG|Ondansetron (Oral soluble film OR injections) ,Dexamethasone|Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
218940029|NCT03776370|PROCEDURE|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
218940030|NCT03776370|PROCEDURE|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
218940031|NCT03896256|DRUG|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
218940032|NCT02501187|PROCEDURE|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
218940033|NCT02501187|PROCEDURE|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
218940034|NCT02501187|PROCEDURE|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
218940035|NCT04643145|PROCEDURE|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
218940036|NCT04195542|OTHER|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
218940037|NCT00526916|DRUG|[C-11]PBR28|
218940038|NCT05761717|DRUG|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
218940039|NCT03135418|DEVICE|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
219633403|NCT03288155|DIETARY_SUPPLEMENT|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
219633404|NCT05804214|OTHER|Dairy and plant based infant formula feeding|Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
219633405|NCT03450317|DRUG|Aspirin 80mg|No treatment
219633406|NCT02935712|DRUG|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
219633407|NCT02935712|DRUG|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
218940040|NCT03135418|DEVICE|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
218940041|NCT03553992|BEHAVIORAL|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
218940042|NCT03553992|BEHAVIORAL|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
218940043|NCT01876940|DEVICE|air-Q, followed by fiberoptic intubation|
218940044|NCT01876940|DEVICE|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
218940045|NCT03855826|DRUG|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
218940046|NCT03855826|DRUG|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
218940047|NCT00798759|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
218940048|NCT00798759|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
219633408|NCT02935712|DRUG|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
218940049|NCT05410756|DIAGNOSTIC_TEST|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
218940050|NCT03372759|PROCEDURE|airtamponade|airtamponade is applicated in the study group air
218940051|NCT03372759|PROCEDURE|saline|saline is left in the study Group saline
218940052|NCT04273880|DRUG|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
218940053|NCT04273880|DRUG|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
218940054|NCT03649308|DEVICE|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
218940055|NCT03649308|PROCEDURE|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
219049869|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Mini Nutritional Asessment questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the nutritional status of the patients, their level of nutrition and appetite for food, and the potential risk of malnutrition.
218940056|NCT01677429|DEVICE|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
218940057|NCT01677429|DEVICE|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
218940058|NCT01677429|BEHAVIORAL|Cognitive Behavioral Therapy|For the treatment of panic disorder
218940059|NCT00740935|BIOLOGICAL|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
218940060|NCT05350956|DRUG|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
219633409|NCT03971396|OTHER|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
219633410|NCT00615550|DRUG|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
219633411|NCT00615550|DRUG|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
219633412|NCT00134823|OTHER|weight based dosing decision support|weight based dosing decision support
219049870|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out Nottingham Health Profile Scale questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the subjective discomfort of the individual with health problems as well as the extent to which these problems affect their normal activities.
219049871|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Cardiovascular Diet Questionnaire-2"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the dietary choices of patients with cardiovascular diseases, such as the patients in this study.
218940061|NCT05350956|DRUG|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
219633413|NCT03676608|BIOLOGICAL|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
219633414|NCT03676608|OTHER|Usual educational care|The WHO protocol for maternal lactation.
219633415|NCT00564850|DRUG|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
219633416|NCT03393923|OTHER|Application of the anterior wedge|Application of anterior wedge in tennis
219633417|NCT02640664|DRUG|Ranibizumab|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
219633418|NCT04057742|DIAGNOSTIC_TEST|AlloSure ddcfDNA assay|2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
218940062|NCT04331743|DRUG|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
218940063|NCT04208113|BEHAVIORAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
218940064|NCT00724711|DRUG|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
218940065|NCT00724711|DRUG|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
218940066|NCT06321380|BEHAVIORAL|Complex span task|"The intervention consists in a computerized working memory task. This task follows the design of a complex span task, involving alternation between memorization and processing steps.~For each trial, participants have to memorize French words. These words are sequentially displayed on the screen. Between each word, participants perform a processing task consisting in a spatial location task: They have to determine if a shape is at the top or at the bottom of the screen. After each processing episode, participants have a free time (i.e., available time to maintain information in WM). At the end of each trial, participants perform an orally immediate recall. This experimental task involves several conditions in order to manipulate the opportunities for the spontaneous use of refreshing and elaborative strategies."
218940067|NCT06321380|DIAGNOSTIC_TEST|Clinical neuropsychological assessment|"As part of routine care, participants in the patient group undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions. The investigators hypothesize correlations between working memory performance during the experimental task and the results of neuropsychological tests. Thus, the investigators consider the results to several French versions of neuropsychological tests:~* MMSE (Mini-Mental State Examination)~* Digit Span Backward subtest (WAIS-IV)~* Stroop Test~* Trail Making Test (TMT)~* Rappel Libre - Rappel Indicé à 16 items or GERIA-12~* Category fluences~* Instrumental Activities of Daily Living and ADL ."
218940068|NCT06321380|DIAGNOSTIC_TEST|Clinical neurospychological assessement|"Participants in the control group undergo 2 tests clinical that evaluate cognitive functioning.~The investigators consider the results to French versions of these neuropsychological tests:~* MMSE (Mini-Mental State Examination; )~* Digit Span Backward subtest (WAIS-IV)"
218940069|NCT01945710|DRUG|Eribulin-LF|
218940070|NCT00647569|PROCEDURE|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
219633419|NCT04057742|DIAGNOSTIC_TEST|AlloMap assay|10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
218940071|NCT00647569|PROCEDURE|Conventional facial closure|The abdominal facia is closed with with continuous running suture
218940072|NCT04314791|DEVICE|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
218940073|NCT00747734|DRUG|MNRP1685A|Escalating intravenous dose
219633420|NCT04057742|DIAGNOSTIC_TEST|Inflammatory Cytokines|10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
219633421|NCT04057742|DIAGNOSTIC_TEST|Immune Cell Phenotypes|Collection of up to 1 cup of urine for per participant each study visit
219633422|NCT04902027|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
219633423|NCT03631680|PROCEDURE|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
219633424|NCT04255576|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
219633425|NCT04124731|DRUG|sintilimab plus anlotinib|Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21
218940074|NCT05208840|DRUG|Ocrelizumab|Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
218940075|NCT00375609|DRUG|Betrixaban|Capsule
218940076|NCT00375609|DRUG|Enoxaparin|Administered subcutaneously
218940077|NCT01368562|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
218940078|NCT05554562|OTHER|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
218940079|NCT00000724|DRUG|Trimetrexate glucuronate|
218940080|NCT00000724|DRUG|Leucovorin calcium|
218940081|NCT00979667|DRUG|Oseltamivir|75 mg twice daily for 5 days
218940082|NCT00979667|DRUG|Zanamivir|10 mg twice daily for 5 days
218940083|NCT00979667|DRUG|Placebo of Oseltamivir|twice daily for 5 days
218940084|NCT05330715|OTHER|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
218940085|NCT00771862|PROCEDURE|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
219049872|NCT07172906|OTHER|Measurement of patient somatometric characteristics|Measurement of body weight, Body Mass Index, Fat and Water Percentage, Chest, Waist and Hip Circumference of patients using a tape measure and electronic scale-lipometer. Also, measurement of bloodless blood pressure and fasting glucose.
219359973|NCT03624257|DEVICE|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
219633426|NCT04124731|DRUG|Chemotherapy|"1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total."
219633427|NCT02964481|GENETIC|Whole exome sequencing|DNA sequencing of protein coding sections of all genes
218940086|NCT03201081|OTHER|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
218940087|NCT05864092|OTHER|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
218940088|NCT05111301|DEVICE|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
218940089|NCT00985920|DRUG|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
218940090|NCT00985920|DRUG|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
218940091|NCT05154305|BEHAVIORAL|multidisciplinary intervention|"* individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
218940092|NCT01974739|DRUG|Hydrochloorthiazide|
218940093|NCT01974739|DRUG|placebo|
219633428|NCT03654612|DRUG|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
219633429|NCT00315458|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
219633430|NCT00315458|DRUG|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
218940094|NCT03348189|OTHER|Pulse Oximeter|Pulse Oximeter
218940095|NCT04540510|DEVICE|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
218940096|NCT04540510|OTHER|Standard care|Standard pneumonia care
218940097|NCT02338882|DEVICE|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
218940098|NCT02338882|DEVICE|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
218940099|NCT01328405|DEVICE|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
218940100|NCT01371279|DEVICE|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
218940101|NCT05207943|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
218940102|NCT05207943|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
218940103|NCT00948220|DRUG|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
219359974|NCT03624257|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
219633431|NCT01807754|PROCEDURE|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
219633432|NCT01807754|PROCEDURE|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
219633433|NCT01768377|DRUG|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
219633434|NCT01768377|DRUG|Fentanyl|Fentanyl 2 microgram/Kg BW IV
219633435|NCT01768377|DRUG|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
219633436|NCT01294241|DRUG|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
219633437|NCT01294241|DEVICE|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
219633438|NCT01047566|DRUG|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
219633439|NCT01047566|DRUG|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
218940104|NCT02216110|PROCEDURE|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
219633440|NCT00802048|DRUG|Local anesthetic (Ropivacaine)|Local anesthetic infusion
218940105|NCT02381483|OTHER|Cold exposure|
218940106|NCT03495609|DRUG|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
218940107|NCT04156542|BEHAVIORAL|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
219633441|NCT00802048|DRUG|Saline|Saline serum infusion
219633442|NCT04166474|DRUG|Dolutegravir|Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
219633443|NCT04003883|DEVICE|Holter ECG|A Holter ECG will be recorderd during shifts
219633444|NCT00913263|DRUG|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
219633445|NCT00913263|DRUG|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
219633446|NCT04637503|BIOLOGICAL|GD2, PSMA and CD276 CAR-T cells|infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
219633447|NCT05084027|COMBINATION_PRODUCT|venetoclax combining with fludarabine and melphalan|Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
219633448|NCT03484962|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
218940108|NCT02346773|DIETARY_SUPPLEMENT|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
219049873|NCT07172906|BEHAVIORAL|Nutritional education and discussion with group B patients|Nutritional education using an information leaflet, e-mails and telephone calls to patients in group B only. Discussion regarding their dietary choices before surgery, identification of wrong habits and efforts to improve them afterwards. It will concern all the basic categories of healthy eating (preference for fruits, vegetables, proteins, healthy carbohydrates, reduction of saturated fat, salt and sugar and information about nutritional labels and how to choose foods according to them). The goal is for patients who will receive this education to improve their measurements in repeat meetings with the researcher, compared to those who will not be informed.
218940109|NCT02346773|OTHER|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
218940110|NCT05366400|DIAGNOSTIC_TEST|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
218940111|NCT00561860|DEVICE|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
218940112|NCT02506985|DRUG|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
218940113|NCT02506985|DRUG|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
218940114|NCT02935829|OTHER|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218940115|NCT02935829|OTHER|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218940116|NCT02935829|OTHER|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219049874|NCT07172295|PROCEDURE|Accelerated NaviFUS-ctbFUS stimulation|"Three consecutive sessions of NaviFUS-ctbTUS stimulation were performed, with a 5-minute interval between each session.~The acoustic pressure was set such that the estimated intracranial pressure at 30% skull transmission was approximately 0.5 MPa.~The stimulation target was the center of the Vop, with a total of 7 stimulation points."
219049875|NCT07172269|DRUG|Sitagliptin + Metformin|Oral tablets, 50/1000 mg, taken twice daily after meals for 12 weeks
218940117|NCT02935829|OTHER|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218940118|NCT02935829|OTHER|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
218940119|NCT02935829|OTHER|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
218940120|NCT04745949|DRUG|Brentuximab Vedotin|Given IV
219049876|NCT07172269|DIETARY_SUPPLEMENT|mangosteen supplement|Capsules, 500 mg, taken twice daily after meals for 12 weeks
219049877|NCT07172269|BEHAVIORAL|Lifestyle Management|Diabetes education, diet counseling, and exercise guidance provided throughout the 12-week study period.
219049878|NCT07172997|PROCEDURE|Bariatric Surgery|A surgical procedure used to manage obesity and obesity-related conditions.
218940121|NCT04745949|DRUG|Cyclophosphamide|Given IV
218940122|NCT04745949|DRUG|Doxorubicin|Given IV
218940123|NCT04745949|BIOLOGICAL|Nivolumab|Given IV
218940124|NCT04745949|DRUG|Prednisone|Given PO
219049879|NCT07173296|OTHER|Opalescence XTra Boost 40% HP|In-office tooth bleaching material
219049880|NCT07173296|OTHER|Pola Office Plus 37.5% HP|In-office tooth bleaching material
219049881|NCT07171944|BEHAVIORAL|Structured orientation program|Artificial intelligence technology will be incorporated into the orientation training program developed for patients in the intensive care unit who are assigned to the intervention group. The program will be administered twice daily over a three-day period. In this group, delirium-free days will be tracked, changes in anxiety and depression levels will be evaluated, and the length of intensive care unit stay among patients who remain free of delirium through this intervention will be examined.
219049882|NCT07171944|BEHAVIORAL|Human Nurse|Researchers will administer a structured orientation training program lasting approximately 10 minutes face-to-face to participants in the control group. This training program will be administered twice daily for 3 days. Following the training program, delirium-free days, anxiety and depression scores, and length of stay in the intensive care unit will be evaluated.
218940125|NCT04745949|OTHER|Quality-of-Life Assessment|Ancillary studies
218940126|NCT04745949|BIOLOGICAL|Rituximab|Given IV
218940127|NCT04838977|BEHAVIORAL|RESET|Therapy
218940128|NCT06454682|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13 vg/person, 6E13 vg/person, and 1.2E14 vg/person sequentially.
218940129|NCT06128538|DEVICE|Auricular acupuncture|we will implement 12 weeks of BFA. These sessions will be done every other week (total of 6 sessions over 12 weeks). During these sessions, Dr. Quinlan (Co-I) and another BFA-trained provider (Dr. Wilbur or Dr. Butler; also research team members) will perform the group BFA protocol with all 20 participants. During this 12-week acupuncture phase, participants will receive the same SMS messages twice a week to collect pain intensity scores. The group BFA protocol involves taking vitals for all patients (similar to a regular medical visit) and placing all 10 acupuncture needles (5 in each ear) while the patient remains seated in a chair. Once the acupuncture needles are placed, the patient will be asked to move around and remain in the room for 30 minutes (for any questions or medical concerns.
218940130|NCT06128538|BEHAVIORAL|Visual Analog Scale for Pain|During the first 12 weeks of the trial, the research manager will collect weekly pain scores using the visual analog scale (pain scale 1-10). During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect pain scores using the visual analog scale at each acupuncture session immediately before and 30 minutes after the acupuncture protocol by the research team, and then twice a week thereafter.
219359975|NCT04158063|BEHAVIORAL|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross"
218940131|NCT06128538|BEHAVIORAL|Roland-Morris Disability Questionnaire|During the first 12 weeks of the trial, the research manager will collect weekly Roland -Morris Disability questionnaire data. During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect disability scores using the Roland-Morris Disability Questionnaire at each acupuncture session (6 sessions in total).
218940132|NCT04978454|BIOLOGICAL|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
218940133|NCT04978454|OTHER|Placebo|Sucrose phosphate glutamate (SPG) inoculum
218940134|NCT01600144|OTHER|digital mammography|data collection
219359976|NCT04158063|OTHER|Single Mobility Training|standard routine training
219359977|NCT03064763|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
219359978|NCT02440087|DIETARY_SUPPLEMENT|Refill Bypass|Dietary supplement
219359979|NCT03345056|PROCEDURE|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
219633449|NCT03484962|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
219633450|NCT06265129|DIAGNOSTIC_TEST|Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)|morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)
219633451|NCT05202197|OTHER|Smart cupboard|Development of a memory task with the help of a smart cupboard
219633452|NCT05385263|DRUG|Nivolumab Injection [Opdivo]|Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
219633453|NCT02116127|DEVICE|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
218940135|NCT00786370|DRUG|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
218940136|NCT00786370|DRUG|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
218940137|NCT00786370|DRUG|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
219633454|NCT02116127|DEVICE|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
219633455|NCT04019782|DRUG|Collagen-PVP|Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
219633456|NCT04019782|DEVICE|Hylan G-F 20|Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
219633457|NCT01500382|DRUG|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
219633458|NCT01500382|DRUG|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
219633459|NCT01500382|OTHER|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
218940138|NCT03323424|RADIATION|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
218940139|NCT03323424|OTHER|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
219359980|NCT05524064|RADIATION|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (\>40 Gy/s).
219633460|NCT01500382|OTHER|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
219633461|NCT01500382|DRUG|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
219633462|NCT04423744|DRUG|BAY1817080|Film-coated tablet
219633463|NCT04423744|DRUG|Moxifloxacin|Film-coated tablet
218940140|NCT05433285|BIOLOGICAL|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
219633464|NCT04423744|DRUG|Placebo|Matched placebo as film-coated tablet
219633465|NCT06134427|OTHER|basic combat training (investigator did not design the intervention)|12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
218940141|NCT05433285|BIOLOGICAL|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
218940142|NCT05424289|DEVICE|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
218940143|NCT04190888|OTHER|No intervention|No intervention - observational study
218940144|NCT01145092|BEHAVIORAL|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
218940145|NCT02891070|DRUG|FS VH S/D 500 s-apr|
218940146|NCT02891070|DEVICE|DuraSeal Dural Sealant|
218940147|NCT02945709|BEHAVIORAL|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
218940148|NCT02945709|BEHAVIORAL|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
218940149|NCT02945709|BEHAVIORAL|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
218940150|NCT02697344|DRUG|Dexamethasone|Given PO
218940151|NCT02697344|OTHER|Laboratory Biomarker Analysis|Correlative studies
218940152|NCT02697344|DRUG|Lenalidomide|Given PO
218940153|NCT02697344|OTHER|Pharmacological Study|Correlative studies
218940154|NCT02697344|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
218940155|NCT05648032|COMBINATION_PRODUCT|lyophilized platelet (30ng) and triamcinolone acetonide 10mg|Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
218940156|NCT05648032|OTHER|lyophilized platelet (30ng)|Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
218940157|NCT05648032|DRUG|triamcinolone acetonide 10mg|Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
218940158|NCT00002271|DRUG|Alovudine|
218940159|NCT04509349|DEVICE|transcranial Altering Current Stimulation|The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
219049883|NCT07172477|DEVICE|Pivot Extend|"The investigational Pivot Extend device will be inserted through a small incision in the femoral vein and guided to the heart using a catheter. The Pivot Extend device is designed to sit in the space where the valve isn't closing, helping the flaps of the valve to close tightly and reducing the amount of blood leaking back through the valve."
219633466|NCT01870973|PROCEDURE|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
218940160|NCT04509349|DEVICE|Sham tACS|2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
219049884|NCT07174375|DRUG|PCSK9 inhibitor|PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors are a class of monoclonal antibody drugs that lower low-density lipoprotein cholesterol (LDL-C) by inhibiting the PCSK9 protein, which increases the liver's ability to remove LDL-C from the blood. This intervention involves the use of established PCSK9 inhibitor agents.
219049885|NCT07172568|PROCEDURE|Blood Flow Restriction|In the intervention group, 50% of limb occlussion pressure are applied to the extremity during exercises.
219633467|NCT01870973|PROCEDURE|no root canal treatment, anesthesia, pain medications, and antibiotic|
218940161|NCT02934503|BIOLOGICAL|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
218940162|NCT02934503|DRUG|Cisplatin|75 mg/m2
218940163|NCT02934503|DRUG|Carboplatin|AUC 6
218940164|NCT02934503|DRUG|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
218940165|NCT02934503|RADIATION|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
218940166|NCT04280237|OTHER|Blood samples|Blood samples
218940167|NCT00448318|PROCEDURE|Music Therapy|
218940168|NCT00724867|BIOLOGICAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
218940169|NCT00724867|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
218940170|NCT03049241|OTHER|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
219049886|NCT07172568|PROCEDURE|sham-Blood Flow Restriction|In the control group, 20 mmHg are applied to the extremity during exercises.
219049887|NCT07172750|OTHER|Education on Urinary Catheter Care|"Urinary catheter care training based on the Roper, Logan, and Tierney Lifestyle Model was developed based on daily living activities.~A training booklet was created based on 11 daily living activities (providing and maintaining a safe environment, communication, breathing, nutrition, etc.).~To increase the effectiveness of the training, a booklet based on this model will be prepared and used as a guide in the training program."
218940171|NCT04259619|DEVICE|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)\^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
219049888|NCT07173335|BEHAVIORAL|In-person physiotherapist led integrated healthy lifestyle and pain care|"Participants allocated to in-person intervention will be offered:~A) Up to four in-person physiotherapist consultations (up to one hour in duration) over 12 weeks (weeks 1, 3, 6, and 12);~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text;~C) Referral to telephone-based population wide health behaviour change support services, the NSW Get Healthy Coaching and information service and the Quitline for smokers, by the week 12 consultation (up to 6 telehealth consultations).~Total = up to 10 consultations over 6 months."
219049889|NCT07173335|BEHAVIORAL|Virtual multidisciplinary integrated healthy lifestyle and pain care|"Participants allocated to the virtual multidisciplinary intervention will receive:~A) 10 consultations over 6 months with a multidisciplinary team, including a minimum 4 with a physiotherapist (week 1, 3, 6, 12) and remainder with a dietitian and/or psychologist, tailored to participants needs. Virtual care consultations may be individual or joint multidisciplinary sessions conducted on standard virtual care platforms used by NSW Health. Consultation will be up to one hour in duration, or use an equivalent total duration with a higher frequency schedule. Where appropriate, participants may be referred to alcohol or smoking cessation support, including individualised virtual or telephone-based counselling with access to nicotine replacement therapy;~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text."
218940172|NCT04259619|DEVICE|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
218940173|NCT05220475|DEVICE|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
218940174|NCT05220475|DEVICE|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
218940175|NCT05233241|OTHER|in vitro Allergological test Allergological skin tests|"In vitro allergological tests: lymphocyte transformation test, measurement of CD154 membrane expression, ELISPOT-IFNgammma Allergological skin tests (patch tests, prick tests and intradermal tests with European standardised method) in case of negative in vitro tests."
219359981|NCT05105763|OTHER|Sequential switched feedback training on the knee and the hip (Condition A)|Condition A will include four 6-mins training blocks: 2-mins knee joint feedback-on, 2-mins hip joint feedback-on, and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
219633468|NCT04668079|OTHER|Modified cross body stretch|"Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given"
219633469|NCT04668079|OTHER|Modified sleeper stretch|"Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given"
219633470|NCT06574542|DIAGNOSTIC_TEST|Push enteroscopy (PE)|All patients enrolled in this study underwent evaluation using push enteroscopy (PE)
219633471|NCT06574542|DIAGNOSTIC_TEST|Colonoscopy|After push enteroscopy (PE), all patients subsequently underwent a colonoscopy on the same day or the next day. However, if a culprit lesion was identified during PE and the patient was considered at risk for undergoing colonoscopy, the colonoscopy was not performed and was presumed to be negative.
219633472|NCT02173665|DRUG|BI 1356 BS - Powder in bottle (PIB)|
219633473|NCT02173665|DRUG|BI 1356 BS - Tablet|
219633474|NCT02173665|DRUG|Placebo|
219633475|NCT00180609|DEVICE|Automatic threshold test in Insignia Pacemakers from Guidant|
219633476|NCT06594146|BIOLOGICAL|CM313 injection|CM313
219633477|NCT06594146|OTHER|placebo|placebo
219633478|NCT06922162|BEHAVIORAL|Tickle stimulation|"Patients will be subjected to tickling:~they will be tickled bilaterally in three areas, the soles of the feet, the armpits, and the ribs-plus a control area, the forehead. The stimulation will be manual and performed by rubbing the targeted body part while opening and closing the fingers in pairs in an arched motion. Additionally, patients will also undergo a neutral stimulation (in the same body areas), which consists of simply touching the area without inducing tickling."
218940176|NCT02433951|OTHER|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
218940177|NCT00207064|DRUG|quetiapine|flexible doses according to the clinical condition
218940178|NCT02663713|DRUG|Ticagrelor|Ticagrelor 60mg twice daily
218940179|NCT02663713|DRUG|Clopidogrel|Clopidogrel 75 mg once daily
218940180|NCT00922948|PROCEDURE|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
218940181|NCT00922948|PROCEDURE|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
218940182|NCT05439213|DRUG|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
218940183|NCT05439213|DRUG|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
218940184|NCT03010488|BEHAVIORAL|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
218940185|NCT03010488|BEHAVIORAL|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
218940186|NCT03010488|DEVICE|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
218940187|NCT02881567|DRUG|Daclizumab|High yield formulation
218940188|NCT01290913|DRUG|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
218940189|NCT01373541|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
218940190|NCT01373541|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
218940191|NCT03284541|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
218940192|NCT03284541|BEHAVIORAL|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
218940193|NCT05412446|DRUG|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
218940194|NCT05126251|DRUG|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
218940195|NCT05126251|BEHAVIORAL|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
218940196|NCT03457064|BEHAVIORAL|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
218940197|NCT03278353|OTHER|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
218940198|NCT03278353|OTHER|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
218940199|NCT03799302|BEHAVIORAL|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
218940200|NCT00413985|DRUG|Nutrient-enriched human milk|
218940201|NCT04156633|DIAGNOSTIC_TEST|conventional identification method: biochemical profiling or MALDI-TOF MS|Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
219049890|NCT07173712|DRUG|CSII followed by iGlarLixi|Short term intensive insulin therapy followed by Insulin Glargine and Lixisenatide Injection(iGlarLixi) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
219049891|NCT07173712|DRUG|CSII followed by IDegAsp|Short term intensive insulin therapy followed by Insulin Degludec and Insulin Aspart Injection(IDegAsp) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
219049892|NCT07173712|DRUG|CSII followed by iGlar+MET|Short term intensive insulin therapy followed by Insulin Glargine Injection(iGlar） plus metformin 0.5g tid for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
219633479|NCT06922162|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a portable, non-invasive EEG monitoring device used to record electrical brain activity through frontal electrodes. In the TICKLING-DOC study, SedLine is used to assess cortical responses in patients with disorders of consciousness (DoC) during manual tactile stimulation, specifically tickling, and neutral touch. The EEG data are recorded before, during, and after stimulation to detect neural reactivity and possible correlations with behavioral responses. The goal is to investigate whether tickle-evoked EEG activity reflects residual consciousness and contributes to diagnostic and rehabilitative strategies. SedLine allows continuous monitoring in a bedside setting, offering safe, real-time assessment of brain function.
219049893|NCT07173816|BEHAVIORAL|EMPOWER|EMPOWER, a group-based 6 sessions telehealth behavioral intervention, will comprise sexual health goals and values elicitation, sexual health plan development, and motivational enhancement skills will be used to promote effective HIV prevention decision-making within the relationship context, incorporating the sexual values of each participant. This will allow each participant to develop a personalized, tailored sexual health plan that includes PrEP deliberation to enhance PrEP decision-making, uptake and persistence within a culturally congruent and empowering program that aims to reduce stigma around HIV and barriers to access.
219633480|NCT01419392|DRUG|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
219633481|NCT01419392|DRUG|matching placebo|orally, 4 times per day for 21 days
219633482|NCT06940557|DRUG|Bionerv|alpha lipoic acid; 300mg, methylcobalamin; 500mcg, vitamin B1; 39mg and vitamin B6; 8mg, 2 tablets once daily
219633483|NCT06940557|DRUG|Placebo|maltodextrin, microcrystalline cellulose, tricalcium phosphate, silicon gioxide, magnesium stearate 2 tablets once daily
218940202|NCT04156633|DIAGNOSTIC_TEST|new identification method: Biofire FilmArray© BCID panel|The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
218940203|NCT04156633|DIAGNOSTIC_TEST|new identification method: metagenomic WGS|shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
218940204|NCT04466202|OTHER|Music with Structured Verbal Training|Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
218940205|NCT04335136|DRUG|RhACE2 APN01|Patients will be treated with APN01 intravenously twice daily (BID).
218940206|NCT04335136|DRUG|Physiological saline solution|Patients will be treated with placebo intravenously twice daily (BID).
218940207|NCT00621062|PROCEDURE|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
218940208|NCT00621062|PROCEDURE|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
218940209|NCT00621062|PROCEDURE|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
218940210|NCT00621062|PROCEDURE|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
218940211|NCT01361204|DIETARY_SUPPLEMENT|Theanine|Taking 4 tablets of theanine two times daily for 16 days
218940212|NCT05688124|DRUG|IBI351|IBI351 is administered orally
218940213|NCT05688124|DRUG|Esomeprazole|Esomeprazole is administered orally
218940214|NCT03671850|BIOLOGICAL|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
218940215|NCT03671850|OTHER|Placebo|Peripheral blood mononuclear cell, PBMC
218940216|NCT01785992|DRUG|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
218940217|NCT05949502|DRUG|Beautifil II LS (Low-Shrinkage)|low shrinkage bioactive material Giomer
218940218|NCT05949502|DRUG|3M Filtek Z250 XT Universal|Universal Nano-hybrid composite
218940219|NCT04170985|OTHER|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
218940220|NCT06278818|BEHAVIORAL|Cognitive Telerehabilitation|Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.
218940221|NCT06278818|OTHER|Control Condition|This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
218940222|NCT04313140|DIAGNOSTIC_TEST|Diagnostic test|"The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~* Cinicial MRI (50 minutes)~* Research MRI (Phosphorus Spectroscopy, Sodium Imaging)"
218940223|NCT04294056|DRUG|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
219049894|NCT07173101|DEVICE|Semiconductor embedded headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
219049895|NCT07173101|DEVICE|Sham Headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
219049896|NCT07172867|DRUG|HT-6184|2mg QD
219049897|NCT07172867|DRUG|HT-6184 Matching Placebo|2mg QD
218940224|NCT04294056|DRUG|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
218940225|NCT03304158|BEHAVIORAL|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
219049898|NCT07172867|DRUG|Semaglutide 1 mg|Semaglutide 1 mg, every week
218940226|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (A&B)|An app-based, evidence-based positive psychology intervention focusing on two modules: (A) Awareness \& Positivity and (B) Meaning and Accomplishment
218940227|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (C&D)|An app-based, evidence-based positive psychology intervention focusing on two modules: (C) Rapport \& Conflict Management and (D) Compassion \& Leadership
218940228|NCT02527044|PROCEDURE|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
218940229|NCT06110832|BEHAVIORAL|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
218940230|NCT03935568|DRUG|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
218940231|NCT03935568|DRUG|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
219633484|NCT06939673|DEVICE|Acellular Porcine-Derived Wound Matrix|This intervention is a sterile, acellular, three-dimensional biologic scaffold derived from porcine liver tissue using a proprietary perfusion decellularization and drying process. It retains the native extracellular matrix structure and supports tissue granulation and healing in complex wounds. Miro3D is applied topically to the debrided wound bed and rehydrated prior to use. It is indicated for use in a range of chronic and complex wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical dehiscence. In this study, it is administered in an outpatient setting alongside standard of care treatments.
219633485|NCT06940726|OTHER|Quality of Life questionnaires|Subjects will complete a number of self-questionnaires on subjects such as attention span, anxiety levels and sleep quality.
219633486|NCT06940726|OTHER|Hearing tests|listening to sounds on headphones and repeating words
219633487|NCT06940726|BEHAVIORAL|Auditory prediction task|listening to sounds and assessing auditory perception
219633488|NCT06940726|BEHAVIORAL|Attention task|assessment of reaction time to visual or auditory cues
218940232|NCT03935568|DRUG|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
218940233|NCT03935568|DRUG|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
218940234|NCT02042716|OTHER|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
218940235|NCT02206971|OTHER|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
218940236|NCT02058524|BIOLOGICAL|fecal microbiota transplantation|
218940237|NCT03073837|OTHER|Rhinovirus Challenge|Challenge with HRV-16 virus
219049899|NCT07172334|OTHER|Questionnaires|Patients will complete questionnaires on professional exposures with the help of a trained professional (estimated time: 30 minutes), followed by self-questionnaires on indoor and outdoor pollution, medications, drugs and socio-economic variables (estimated time: 30 minutes).
219049900|NCT07172334|OTHER|Samples|Two strands of hair (or beard or axillary hair) will be taken, along with a urine and blood sample.
219049901|NCT07172724|BIOLOGICAL|Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory|lyophilized antigen for reconstitution with the adjuvant CTVad (a squalene-based nanoemulsion), at the time of use.
219049902|NCT07172724|OTHER|Placebo|adjuvant CTVad (a squalene-based nanoemulsion)
219049903|NCT07172256|DRUG|CUE-101|CUE-101 will be administered by IV infusion with a commercially available syringe pump or IV infusion pump over 60 minutes on Day 1 and Day 21 after all procedures and assessments are completed. It will be administered at a dosage level of 4 mg/kg x 2
219633489|NCT06941467|DRUG|Timolol Maleate Solution|Timolol 0.5% solution. The number of drops delivered will be based on the initial wound size and will remain constant for the duration of the study period or until the wound is fully re-epithelialized which will be determined by the PI either by photo or in person visit.
219633490|NCT06941467|OTHER|Standard of Care|Vaseline
218940238|NCT03747666|PROCEDURE|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
218940239|NCT01536067|BIOLOGICAL|ofatumumab|Given IV
218940240|NCT01536067|DRUG|bortezomib|Given SC
218940241|NCT01536067|OTHER|laboratory biomarker analysis|Correlative studies
218940242|NCT03120351|DRUG|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
218940243|NCT03120351|DRUG|Placebo patch|2\) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
218940244|NCT04668027|DIAGNOSTIC_TEST|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
218940245|NCT04668027|DIAGNOSTIC_TEST|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
218940246|NCT04668027|DIAGNOSTIC_TEST|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
218940247|NCT00617799|BIOLOGICAL|aldesleukin|
218940248|NCT00617799|GENETIC|gene expression analysis|
218940249|NCT00617799|GENETIC|mutation analysis|
218940250|NCT00617799|OTHER|flow cytometry|
218940251|NCT01438736|DRUG|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
218940252|NCT01438736|DRUG|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
218940253|NCT01507064|DRUG|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
218940254|NCT01507064|PROCEDURE|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
218940255|NCT03421769|PROCEDURE|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
218940256|NCT03421769|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
218940257|NCT04765228|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
218940258|NCT04765228|DRUG|Anlotinib|Anlotinib
218940259|NCT01256190|BIOLOGICAL|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
218940260|NCT01256190|DEVICE|Gelatin sponge|absorbable gelatin sponge for topical use
218940261|NCT00576329|DRUG|Ketorolac|Topical use before surgery
218940262|NCT03458013|BEHAVIORAL|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
219049904|NCT07172256|DRUG|Pembrolizumab|Pembrolizumab will be administered on Day 1 and Day 21 after all procedures and assessments are completed according to the Study Calendar. Pembrolizumab will be administered as a dose of 200 mg using a 30-minute (- 5 min/+10 min) IV infusion.
219049905|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified biscuits supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (biscuits). During the trial, participants will receive nitrate-fortified biscuits as a single-day acute supplementation.
219049906|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified cereal bar supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (cereal bar). During the trial, participants will receive nitrate-fortified cereal bar as a single-day acute supplementation.
219049907|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified porridge supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (instant porridge). During the trial, participants will receive nitrate-fortified porridge as a single-day acute supplementation.
218940263|NCT00967824|OTHER|informational intervention|
218940264|NCT00967824|OTHER|questionnaire administration|
218940265|NCT00967824|OTHER|survey administration|
218940266|NCT05895526|PROCEDURE|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
218940267|NCT06173115|DEVICE|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
218940268|NCT01523977|DRUG|Everolimus|Orally, daily days 1-32 per assigned dose level
218940269|NCT01523977|DRUG|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
218940270|NCT01523977|DRUG|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
218940271|NCT01523977|DRUG|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
218940272|NCT01523977|DRUG|Doxorubicin|30 mg/m2 IV on days 4 and 5
218940273|NCT01523977|DRUG|Dexrazoxane|300 mg/m2 IV on days 4 and 5
218940274|NCT02511223|DRUG|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
218940275|NCT03843671|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy
218940276|NCT03843671|DEVICE|Hyperbaric chamber|Hyperbaric chamber
218940277|NCT06121999|BEHAVIORAL|Standard of care acceptance-based behavioral weight loss program|Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.
218940278|NCT06121999|BEHAVIORAL|Occupational therapy dietary and lifestyle modifications|Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
218940279|NCT05374915|COMBINATION_PRODUCT|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
218940280|NCT02423902|BIOLOGICAL|Ad-RTS-hIL-12|Approximately 1.0x10\^12 viral particles (vp) per injection
218940281|NCT02423902|DRUG|Veledimex|7 oral doses of veledimex
218940282|NCT06783868|DEVICE|Catheter Ablation|Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.
218940283|NCT06783868|DRUG|Market-approved AVNB, OAC and AAD|Used per protocol for the duration of the trial.
218940284|NCT06310720|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
218940285|NCT04323787|OTHER|observational|No Intervention
219633491|NCT06940544|DIAGNOSTIC_TEST|Stepwise Multimodal Home-Based HF Screening|The Stepwise Multimodal Home-Based HF Screening intervention involves a targeted community outreach program to identify undiagnosed heart failure (HF) in high-risk individuals. Participants randomized to the intervention arm (ACTIVE) are asked to self-collect dried blood spots for NTproBNP analysis. Those with elevated NTproBNP (≥125 pg/ml) in the dried blood spots are summoned to the study clinic and undergo confirmatory point-of-care NTproBNP testing and an AI-enabled echocardiogram, with the aim to confirm or rule out heart failure.
219633492|NCT06939621|BEHAVIORAL|VR-based physical activity with motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~Participants received motivational messages from a virtual coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
219633493|NCT06939621|BEHAVIORAL|VR-based physical activity without motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
218940286|NCT04693234|BIOLOGICAL|Tislelizumab|200 mg administered intravenously once every 3 weeks on day 1 of each cycle
218940287|NCT04693234|BIOLOGICAL|Ociperlimab|900 mg administered intravenously once every 3 weeks on day 1 of each cycle
218940288|NCT05283577|OTHER|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
218940289|NCT05283577|OTHER|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
218940290|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
218940291|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
218940292|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
218940293|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
218940294|NCT06958107|OTHER|Non-Metastatic and Resectable|"Blood Draw Timepoints:~* Before any treatment begins~* After Neo-adjuvant therapy (only if you receive this type of therapy)~* After local surgery~* After Adjuvant therapy (only if you receive this type of therapy)~* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
218940295|NCT06958107|OTHER|Metastatic and Un-resectable|"Blood Draw Timepoints:~* Before any treatment begins~* During standard of care disease evaluation visits for up to 24 months"
219049908|NCT07174154|BEHAVIORAL|Interview|Recorded interviews
219049909|NCT07173166|OTHER|Physical activity|"Patients assigned to intervention group A will follow a supervised programme of physical activity and exercise at home and during hospitalisation. All patients will follow the same exercise programme, which will be adapted to a basic, intermediate and advanced level to suit the patients' physical condition. The loads, intensity and number of sets will be adapted to each level.~Aerobic exercise will consist of walking and/or cycling at an intensity of between two and five on the Borg perceived exertion (RPE) scale. Resistance exercise will consist of one session focusing on the trunk and upper limbs, and another on the lower limbs. Both sessions will include seven exercises, performed at an intensity of between three and four on the Borg RPE scale."
218940296|NCT06958107|OTHER|No evidence of disease, under surveillance|"Blood Draw Timepoints:~* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
219049910|NCT07173166|OTHER|Physical activity and nutrition|The intervention integrates a structured physical activity programme with individualized nutritional recommendations based on the Mediterranean diet. Macronutrient distribution was 50-55% carbohydrates, 30-35% fats, and 10-15% proteins. The protocol emphasized the intake of vegetables (≥2 servings/day, 200 g each), fruits (1-2 servings/day, 150 g each), legumes (≥3 servings/week, 150 g cooked), whole grains (1-2 servings/meal, 40-60 g), and low-fat dairy products (1-2 servings/day; 200 ml milk or 125 g yoghurt). Lean meats were prescribed at 3-4 servings/week (100-125 g each), fish and seafood at 4 servings/week (150 g each), nuts at 3-7 servings/week (30 g each), and olive oil as the principal fat source (≤4 tbsp/day). Micronutrients and bioactive compounds from these foods, including antioxidants, polyphenols, and essential fatty acids, were recognized as pivotal for modulating protective mechanisms and mitigating toxicological effects.
219049911|NCT07172984|PROCEDURE|Anesthesia|"Receives local anesthesia with 5 cc of lidocaine before the infiltration procedure.The patient will receive breathing instructions as part of SHAM treatment, which will not allow them to achieve cardiac coherence."
219633494|NCT06939621|BEHAVIORAL|Standard Physical Activity with motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°).~Participants received motivational messages from a real coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
218940297|NCT06958107|OTHER|ALT or WDLS|"Blood Draw Timepoints:~• Collect once after surgery (up to six weeks after surgery)"
218940298|NCT06743282|BEHAVIORAL|Waitlist|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete baseline questionnaires.
218940299|NCT06743282|BEHAVIORAL|Senyo App|Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
218940300|NCT06743282|BEHAVIORAL|Follow-up|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
218940301|NCT06499025|BIOLOGICAL|targeted AML1-ETO neoantigen cytotoxic T cells (CTL)|After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.
218940302|NCT06499025|DRUG|Cyclophosphamide injection|Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion
218940303|NCT06499025|DRUG|Decitabine Injection|Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion
218940304|NCT06499025|DRUG|Liposome mitoxantrone|Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion
219049912|NCT07172984|PROCEDURE|breathing group|The procedure will use 5 cc of saline solution instead of the usual anesthesia. Explanations for performing 5-minute breathing cycles that facilitate the achievement of cardiac coherence, with visual feedback.
219049913|NCT07171931|PROCEDURE|IPACK block|After the general anesthesia induction, IPACK block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
219049914|NCT07171931|PROCEDURE|Genicular nerve block with bupivacaine|After the general anesthesia induction, genicular block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
219049915|NCT07173556|DRUG|QLC1401|CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib
219049916|NCT07173556|DRUG|QLC1401|mTOR inhibitors: Everolimus
219049917|NCT07173153|BIOLOGICAL|AAV9.SLC6A1 Gene Therapy|This is an open-label, single injection study of an AAV9 vector carrying the SLCA1 coding sequence delivered one time through an intrathecal injection.
219633495|NCT06939621|BEHAVIORAL|Standard Physical Activity without motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°). In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
218940305|NCT06377254|BEHAVIORAL|Decreased Physical Activity|Physical activity levels will be decreased
218940306|NCT06377254|BEHAVIORAL|Increased Physical activity|Physical activity levels will be increased
218940307|NCT04540198|BEHAVIORAL|GamePlan4Care|GamePlan4Care; Experimental
218940308|NCT04540198|BEHAVIORAL|Resources4Care|R4C; Active Comparator
218940309|NCT04607850|BIOLOGICAL|ChAdOx1-HPV|Trial vaccine
218940310|NCT04607850|BIOLOGICAL|MVA-HPV|Trial vaccine
218940311|NCT04607850|BIOLOGICAL|Placebo|Saline placebo vaccine
218940312|NCT05650632|DRUG|ABBV-383|Intravenous Infusion
218940313|NCT05028309|OTHER|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
218940314|NCT06074549|DEVICE|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
218940315|NCT01620931|DRUG|Placebo|Single doses, iv or sc
218940316|NCT01620931|DRUG|RO5469754|Single ascending doses, iv or sc
218940317|NCT00311129|DRUG|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
218940318|NCT00311129|DRUG|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
218940319|NCT02888119|DEVICE|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
218940320|NCT05475730|PROCEDURE|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
218940321|NCT04764331|DEVICE|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
218940322|NCT05793567|DIAGNOSTIC_TEST|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
218940323|NCT06156384|DEVICE|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
218940324|NCT05052736|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
218940325|NCT05822609|DRUG|Semaglutide|1.0 mg
218940326|NCT05822609|OTHER|Placebo|Placebo
219049918|NCT04317989|OTHER|Practice Facilitation|"1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
219049919|NCT06132360|DRUG|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
219049920|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
218940327|NCT00157482|DRUG|Ezetimibe|
218940328|NCT00157482|DRUG|Simvastatin|
218940329|NCT05416710|DIAGNOSTIC_TEST|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
218940330|NCT01038999|BIOLOGICAL|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
219049921|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
219049922|NCT05414409|DRUG|Metformin|Metformin is an oral medication that improves insulin sensitivity.
219049923|NCT05648565|DEVICE|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
219633496|NCT06940089|BEHAVIORAL|Attention Intervention using a customized BCI decoder|"During the offline phase of the intervention, participants will perform an attentional task while intracranial brain activity is recorded. Data from this session will be used to train a personalized decoder capable of classifying attentional engagement.~During the training phase, participants will receive real-time visual feedback contingent on their brain activity when attentional engagement is detected. This closed-loop feedback aims to reinforce successful attention and enhance performance over repeated sessions."
218940331|NCT02127957|OTHER|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
218940332|NCT05827536|DIETARY_SUPPLEMENT|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
218940333|NCT05827536|DIETARY_SUPPLEMENT|Standard of Care|Protein substitute
218940334|NCT03094507|DRUG|Tivicay|50 mg once daily
218940335|NCT03094507|DRUG|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
219049924|NCT05346406|DEVICE|Midline Catheter|Bard Powerglide 8 cm midline catheter
219049925|NCT05346406|DEVICE|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
219049926|NCT06482944|BEHAVIORAL|Whole Foods for Families|"This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. During the partial feeding period (weeks 3-8), families will be asked to continue the whole foods diet with support that includes: 1) 3 weekly dinners of the families' choosing (described above), 2) rotating menus (\~3 weeks' worth) that will allow for customization (e.g., protein, vegetable, grain swaps) to support cultural/dietary preferences, and 3) dietetic support to help with customization and diet maintenance. Participants will be instructed by the registered dietitian nutritionist (RDN) on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled families in the study, the goal is to maintain complete diet adherence during the twelve-week intervention."
218940336|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
219049927|NCT01659749|BEHAVIORAL|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
219549456|NCT03867760|BEHAVIORAL|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
218940337|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
218940338|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
218940339|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
219049928|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
219049929|NCT01068327|DRUG|leucovorin calcium|Given IV
219049930|NCT01068327|DRUG|fluorouracil|Given IV
219633497|NCT06940089|BEHAVIORAL|Attention Intervention without using a customized BCI decoder|"During the offline phase, participants will perform an attentional task while intracranial brain activity is recorded. A personalized decoder will be created for each participant but will not be used during the training phase sessions.~During the training phase, participants will receive visual feedback while performing attentional tasks; however, the feedback will not be contingent on their brain activity. Instead, feedback will be non-contingent and unrelated to actual attentional engagement. This group is not expected to experience improvements in attentional performance through the training sessions."
218940340|NCT03679754|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
218940341|NCT03679754|DRUG|veledimex|"* 20mg/day~* 15 oral daily doses of veledimex"
218940342|NCT00964171|DRUG|Efavirenz 600mg|
218940343|NCT06336642|BEHAVIORAL|SPOT-ON Early Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
219049931|NCT01068327|DRUG|nelfinavir mesylate|Given PO
219049932|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
219049933|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
219049934|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219049935|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
219049936|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
219549457|NCT03867760|BEHAVIORAL|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
219549458|NCT03596710|PROCEDURE|Image Guided Biopsy|Undergo image guided biopsy
218940344|NCT06336642|BEHAVIORAL|SPOT-ON Delayed Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
218940345|NCT05487196|DRUG|Clonidine|Clonidine belongs to the drug classification of antihypertensives
219049937|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
219049938|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
219049939|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
218940346|NCT05487196|DRUG|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
218940347|NCT05487196|DRUG|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
218940348|NCT05487196|DRUG|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
218940349|NCT06292923|DRUG|Foralumab|"Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare."
218940350|NCT06292923|OTHER|Placebo|Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
218940351|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
218940352|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
218940353|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
218940354|NCT03755778|DRUG|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
218940355|NCT03755778|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
218940356|NCT03755778|DRUG|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
218940357|NCT01670916|DIETARY_SUPPLEMENT|probiotics|Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
218940358|NCT05829044|DEVICE|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
218940359|NCT05829044|DEVICE|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
219049940|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
219049941|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
218940360|NCT00910299|DRUG|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
218940361|NCT00910299|DRUG|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
219049942|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
219049943|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
219049944|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
219049945|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
219049946|NCT02174094|DRUG|Clobazam|
218940362|NCT03849118|DIAGNOSTIC_TEST|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
219549459|NCT06601894|DIAGNOSTIC_TEST|Platelets count|the study include will take medical investigation data for all sickle cell patients.
219549460|NCT06595342|OTHER|No intervention|no intervention
218940363|NCT01895621|PROCEDURE|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
218940364|NCT01895621|DIETARY_SUPPLEMENT|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
218940365|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
218940366|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
219049947|NCT02174094|DRUG|Placebo|
219549461|NCT02243579|OTHER|Laboratory Biomarker Analysis|Correlative studies
219549462|NCT02243579|BIOLOGICAL|Pembrolizumab|Given IV
219549463|NCT04792723|DRUG|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
219549464|NCT04792723|DRUG|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
219549465|NCT00348296|DRUG|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
218940367|NCT02052999|DRUG|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
218940368|NCT02052999|OTHER|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
218940369|NCT02052999|DRUG|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
218940370|NCT00884741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
218940371|NCT00884741|BIOLOGICAL|Bevacizumab|Given IV
218940372|NCT00884741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
218940373|NCT00884741|OTHER|Laboratory Biomarker Analysis|Correlative studies
218940374|NCT00884741|OTHER|Placebo|Given IV
218940375|NCT00884741|OTHER|Quality-of-Life Assessment|Ancillary studies
218940376|NCT00884741|DRUG|Temozolomide|Given orally
218940377|NCT05808361|OTHER|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
218940378|NCT05808361|OTHER|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
218940379|NCT01638182|DIETARY_SUPPLEMENT|Placebo|27 participants received for three months 1 placebo capsule per day
218940380|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
218940381|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
218940382|NCT06314828|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
218940383|NCT02917122|DEVICE|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
218940384|NCT02917122|DRUG|Sertraline|Patients will take Sertraline.
218940385|NCT02917122|DEVICE|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
218940386|NCT04239378|PROCEDURE|socket preservation|Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
218940387|NCT00900952|OTHER|Clinical record review|
218940388|NCT03297905|BEHAVIORAL|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
218940389|NCT03297905|BEHAVIORAL|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
218940390|NCT01224990|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
218940391|NCT02543060|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
218940392|NCT02543060|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
218940393|NCT04696614|BEHAVIORAL|exercise|intervention groups provided different sequential modality of exercise
218940394|NCT04282408|DEVICE|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
218940395|NCT05155189|BIOLOGICAL|C-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
218940396|NCT05155189|DRUG|Lenvatinib|Tyrosine kinase inhibitors
218940397|NCT05155189|DRUG|PD-1(L1) monoclonal antibody|Immune checkpoint inhibitors, ICIs
218940398|NCT02105181|DEVICE|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
219549466|NCT03183622|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
218940399|NCT04001959|PROCEDURE|Silver Diamine Fluoride with Potassium Iodide|Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
218940400|NCT01452100|DRUG|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
218940401|NCT01452100|OTHER|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
218940402|NCT01890252|DEVICE|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
218940403|NCT01890252|DRUG|saline solution|saline solution of 5% NaCl
218940404|NCT02198118|OTHER|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
218940405|NCT02901678|DEVICE|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
218940406|NCT06153719|OTHER|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
219049948|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
219049949|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
219049950|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
218940407|NCT00013156|PROCEDURE|Effectiveness of Lung Reduction Therapy|
219049951|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
218940408|NCT00163254|DRUG|abciximab|
218940409|NCT00163254|DEVICE|stent and drug eluting stent|
218940410|NCT01305980|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
218940411|NCT00499590|DRUG|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
218940412|NCT00499590|DRUG|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
218940413|NCT01626937|OTHER|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
218940414|NCT01626937|OTHER|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
218940415|NCT00000776|DRUG|Flucytosine|
218940416|NCT00000776|DRUG|Fluconazole|
218940417|NCT00000776|DRUG|Amphotericin B|
218940418|NCT00000776|DRUG|Dexamethasone|
218940419|NCT05661851|DRUG|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
218940420|NCT05661851|DRUG|Blink® Tears eye Drops|Control Product
218940421|NCT01212341|BIOLOGICAL|Allogeneic NK cells|
218940422|NCT01119079|OTHER|Normal Saline|10ml Normal Saline instilled in the epidural space
218940423|NCT01119079|PROCEDURE|Administration of epidural anesthesia for labor|Standard procedure
218940424|NCT04146636|DIAGNOSTIC_TEST|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
218940425|NCT04174326|BEHAVIORAL|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
218940426|NCT04583241|OTHER|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
218940427|NCT04583241|OTHER|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
218940428|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
219549467|NCT01665404|DRUG|Fluvoxamine|Multiple doses of fluvoxamine
219549468|NCT01665404|DRUG|RO4917523|Single dose of RO4917523
218940429|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
218940430|NCT04583241|OTHER|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
218940431|NCT01490489|OTHER|blood sample and doppler Ultrasound of uterine arteries|"* 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
218940432|NCT04306796|DEVICE|3D printed splints|3D printed made to measure splints
218940433|NCT04306796|DEVICE|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
218940434|NCT01649206|PROCEDURE|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
219049952|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
219049953|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
219049954|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
219049955|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
219049956|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
219049957|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
219633498|NCT06939699|BEHAVIORAL|Social Media-Based Education|This intervention includes daily delivery of 56 infographic/video-based educational materials over 8 weeks via WhatsApp or Instagram. The content focuses on awareness of breast, cervical, and colorectal cancer screenings, healthy lifestyle behaviors, and digital health literacy. The materials are developed based on the Socio-Ecological Model.
218940435|NCT01689493|BEHAVIORAL|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
218940436|NCT06373133|DRUG|SHR-8068|1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w
218940437|NCT06373133|DRUG|Adebrelimab|1200mg, ivgtt, d1, q3w
218940438|NCT06373133|DRUG|BP102|7.5mg/kg, ivgtt, d1, q3w
218940439|NCT00409357|DRUG|SL77.0499-10 (alfuzosin hydrochloride)|
219549469|NCT02417571|DEVICE|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
219549470|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
218940440|NCT05611333|BEHAVIORAL|Physician-Led Remote Exercise Program Intervention|The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
219549471|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
219633499|NCT06939699|BEHAVIORAL|Standard Online Education|Participants receive two 40-minute online educational sessions one week apart via Microsoft Teams/Zoom. The content includes cancer screening awareness (breast, cervical, colorectal), preventive strategies, and the use of digital health tools such as e-Nabız and MHRS.
219633500|NCT06939517|DEVICE|SeaBand|Drug-free, reusable Acupressure elastic wristbands applied to bilateral wrists for nausea relief
218940441|NCT02916537|DRUG|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
218940442|NCT02916537|PROCEDURE|Prostatectomy|Radical prostatectomy with lymph node dissection
218940443|NCT03241147|DRUG|Lu AF35700|Single dose, 10 mg film coated tablet
218940444|NCT05740878|DIETARY_SUPPLEMENT|immunonutrients oral nutritional supplements|1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
218940445|NCT05740878|DIETARY_SUPPLEMENT|standard oral nutritional supplements|1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
218940446|NCT03039946|DEVICE|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
218940447|NCT03039946|OTHER|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
218940448|NCT02503137|DRUG|Topical SM04554 solution|
218940449|NCT02503137|DRUG|Topical Vehicle solution|
219549472|NCT04636034|PROCEDURE|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
219549473|NCT03420053|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
219549474|NCT03420053|OTHER|Normal Saline Placebo|0.9% sodium chloride solution
219549475|NCT03420053|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
219549476|NCT01257633|PROCEDURE|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
219549477|NCT01726933|DRUG|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
219549478|NCT01726933|DRUG|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
219549479|NCT01726933|DRUG|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
219549480|NCT05017935|DEVICE|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
219549481|NCT06144034|DEVICE|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
219549482|NCT06144034|DEVICE|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
219549483|NCT00757419|DRUG|AZD3355|capsules, oral, single or twice daily dose
219549484|NCT00757419|DRUG|Placebo|To match dosing of AZD3355
218940450|NCT03564704|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
218940451|NCT03564704|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
219549485|NCT00866580|BIOLOGICAL|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
219549486|NCT00866580|BIOLOGICAL|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
218940452|NCT03564704|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
218940453|NCT03564704|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
218940454|NCT03564704|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
218940455|NCT03564704|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
219049958|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
219049959|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
219049960|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
219049961|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
219049962|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
219633501|NCT06941220|OTHER|mulligan group|SNAG technique was applied from a sitting position on the edge of the table while both feet were on a foot rest. A specialized Mulligan belt was used around the patient's waist and therapist's hips. The mobilizing force was applied parallel to the facet joint plane (cephalic direction) and over the spinous processes of the respective symptomatic spinal levels. The patients were asked to lean forward as much as possible during application of the mobilizing force and then return to the starting position while the therapist maintained his mobilizing force until the end. plus traditional therapy
219049963|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
219049964|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
219049965|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
219049966|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
219633502|NCT06941220|OTHER|Maitland mobilization|"The subjects were placed in the prone position on a plinth with their hands beside them, and the therapist stood on the subject's side, the ulnar surface of the hand (between pisiform and hamate) was placed over the hypomobile spinous process. The second hand was placed on top of the first to enhance its force. With the therapist's elbows slightly bent and shoulders exactly above the spinous process, an oscillatory movement of the vertebra was executed by applying a posterior-anterior force to the hypomobile or painful spinous process.~Grade III mobilization was applied four times, each with 60 s of oscillation and 20 s of rest in between them (2 or 3 oscillations per second) plus traditional therapy"
219633503|NCT06941220|OTHER|traditional therapy|the patients will receive traditional therapy in the form of passive stretching, strengthening, and lumbar stabilization exercises
219633504|NCT06537362|DEVICE|Mouthpiece with cheek-holder|A cheek support integrated into the mouthpiece is used for the measures
219049967|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
219049968|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
219633505|NCT02056184|DRUG|Adalimumab|
219633506|NCT04092868|OTHER|Blood samples PK/ PD protamine|PK/ PD protamine
218940456|NCT03564704|DRUG|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
218940457|NCT03564704|DRUG|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
218940458|NCT03564704|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
218940459|NCT03564704|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
218940460|NCT03564704|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
218940461|NCT03564704|PROCEDURE|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
218940462|NCT03564704|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
218940463|NCT03564704|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
218940464|NCT03564704|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
219049969|NCT05578560|PROCEDURE|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
219049970|NCT05578560|PROCEDURE|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
219049971|NCT05578560|PROCEDURE|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
219049972|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
219049973|NCT05664646|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
219049974|NCT05664646|OTHER|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
219049975|NCT05664646|OTHER|Cool Environment|Study 2 will be completed in a cool environment setting.
218940465|NCT03564704|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
219049976|NCT01421810|DRUG|Dexamethasone|1 mg PO
219049977|NCT01421810|DRUG|rhCG|25 mcg IV
219049978|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
219049979|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
219049980|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
219049981|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
219049982|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
219049983|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
219049984|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
219049985|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
219049986|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
219549487|NCT00866580|BIOLOGICAL|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
219549488|NCT04969562|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
219549489|NCT03742063|DRUG|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
219549490|NCT05329311|PROCEDURE|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
218940466|NCT03564704|DIAGNOSTIC_TEST|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
218940467|NCT03564704|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
218940468|NCT03564704|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
218940469|NCT03564704|DRUG|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
219549491|NCT05329311|PROCEDURE|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
219549492|NCT00959790|DIETARY_SUPPLEMENT|Vegetables|200 or 50 grams of vegetables daily for four weeks
219549493|NCT00959790|DIETARY_SUPPLEMENT|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
219549494|NCT02081105|OTHER|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
219549495|NCT03121898|DEVICE|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
219549496|NCT05316454|BEHAVIORAL|self-efficacy support|self-efficacy support
219549497|NCT02708251|DRUG|glyceryl trinitrate cream|
218940470|NCT03564704|DIAGNOSTIC_TEST|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
218940471|NCT03827915|DEVICE|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
218940472|NCT00600977|DRUG|Doxorubicine|9mg/m² J1 J4 2 COURSES
218940473|NCT00600977|DRUG|Doxorubicine pegylated|40 MG/M² J1 2 courses
218940474|NCT01461109|DRUG|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
218940475|NCT03050229|DRUG|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
218940476|NCT03050229|DRUG|Placebo|Placebo once daily before or after breakfast
219633507|NCT06939530|PROCEDURE|Hydrodilatation (20 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 20 ml."
219049987|NCT05871125|BEHAVIORAL|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
219049988|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
219049989|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
219633508|NCT06939530|PROCEDURE|Hydrodilatation (40 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 40 ml."
219633509|NCT06940024|DEVICE|VSP Group|Digital surgical splints were generated using Dolphin software and a Form 3D printer
219633510|NCT06939543|BEHAVIORAL|empathy|physicians' awareness of their health status, empathy towards patients
219633511|NCT06055205|OTHER|PAC-plan|The participants will be asked to complete electronic questionnaires at baseline, and at 6 weeks and 52 weeks after discharge from the hospital. The completion of these questionnaires will take place during the 6-week follow-up appointment at the hospital (a standard follow-up for all patients undergoing surgery at the Division of Orthopedic Surgery, Oslo University Hospital, Norway). Additionally, participants will be invited for a phone-based follow-up appointment with the study coordinator 52 weeks after discharge. The participants will receive the questionnaires electronically via SMS or email. If electronic options are not feasible, data can be collected through paper questionnaires sent by mail. Data will not be directly obtained from general practitioners.
219633512|NCT02835625|RADIATION|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
219633513|NCT02835625|RADIATION|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
219633514|NCT00594867|DRUG|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
218940477|NCT04357223|DRUG|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
218940478|NCT04357223|DRUG|Placebo|Placebo
218940479|NCT05499299|BEHAVIORAL|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
219633515|NCT00594867|DRUG|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
219633516|NCT00594867|DRUG|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
218940480|NCT05933239|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
218940481|NCT00612807|BEHAVIORAL|Weekly marital therapy|Weekly marital therapy for 6 months.
218940482|NCT00612807|DRUG|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
219049990|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
219049991|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
219049992|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
219049993|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
218940483|NCT04063306|OTHER|none of intervention was given|this is an observational survey and no intervention is given
218940484|NCT00849095|DRUG|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
218940485|NCT00849095|DRUG|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
219049994|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
219049995|NCT03169140|DEVICE|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
219049996|NCT03169140|DEVICE|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
219049997|NCT03169140|BEHAVIORAL|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
219049998|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
219049999|NCT02559388|DRUG|Montelukast|
218940486|NCT00849095|DRUG|placebo|bid inhaled placebo
218940487|NCT00849095|DRUG|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
219050000|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
219050001|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
219050002|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
219050003|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
218940488|NCT01192685|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
218940489|NCT01192685|DEVICE|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
218940490|NCT06129617|DEVICE|Hemodialysis|5 treatments with hemodialysis on day 1, 2, 3, 5 and 7
218940491|NCT06129617|DEVICE|ADVOS|5 treatments with ADVOS on day 1, 2, 3, 5 and 7
219050004|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
218940492|NCT02408159|DRUG|Varicella Zoster Vaccine|
218940493|NCT02408159|DRUG|Placebo|
218940494|NCT05539300|DIAGNOSTIC_TEST|PSMA-PET/CT response evaluation|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
218940495|NCT01567839|PROCEDURE|Mandibular buccal Infiltration injection|
219050005|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
219050006|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
219050007|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
219050008|NCT04139928|DIETARY_SUPPLEMENT|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
219050009|NCT04139928|DIETARY_SUPPLEMENT|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
219050010|NCT04139928|DIETARY_SUPPLEMENT|Placebo|Placebo
219050011|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
219549498|NCT02708251|DRUG|lidocaine cream|
219549499|NCT02708251|DRUG|placebo cream|
219549500|NCT01008709|DEVICE|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
219549501|NCT01008709|DEVICE|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
219549502|NCT02089282|DEVICE|Ultrasound|
219549503|NCT04296123|BEHAVIORAL|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
219549504|NCT01427062|OTHER|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
218940496|NCT00749853|DRUG|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
218940497|NCT00749853|DRUG|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
218940498|NCT06386016|OTHER|artificial intelligence-based stethoscope|artificial intelligence-based stethoscope
219050012|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
219050013|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
218940499|NCT03790033|DRUG|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
218940500|NCT03790033|DRUG|Placebo|placebo granule
218940501|NCT02645019|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
218940502|NCT02645019|DEVICE|Cuffed LMA|Cuffed laryngeal mask airway.
218940503|NCT04994002|DRUG|CERC-006|Oral solution
218940504|NCT00705549|DRUG|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
218940505|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
219050014|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
219050015|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
218940506|NCT00705549|DRUG|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
218940507|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
218940508|NCT00705549|DRUG|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
218940509|NCT00705549|DRUG|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
218940510|NCT02452515|DRUG|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
218940511|NCT02452515|DRUG|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
218940512|NCT02452515|DRUG|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
218940513|NCT02452515|DRUG|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
219050016|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
219050017|NCT00133081|DRUG|All registered antiepileptic drugs|
218940514|NCT02452515|DRUG|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
218940515|NCT01215097|DRUG|Linagliptin|once a day
218940516|NCT01215097|DRUG|placebo|once a day
218940517|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of lower mean BP
218940518|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
218940519|NCT01580501|DRUG|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
218940520|NCT04506138|DRUG|Camrelizumab|Camrelizumab 200mg D1, D22
218940521|NCT04506138|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
218940522|NCT04506138|DRUG|Carboplatin|Carboplatin AUC5 D1, D22
218940523|NCT06112886|OTHER|There was no intervention in this study|There was no intervention in this study
218940524|NCT02162199|DRUG|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
219050018|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
219050019|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
219050020|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
219549505|NCT01427062|OTHER|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
219549506|NCT06804486|BEHAVIORAL|Exercise|Exercise and physical-sports activity program
219549507|NCT06804486|OTHER|Recommendation to Deprescribe|Recommendation to Deprescribe
219549508|NCT05564715|DEVICE|NeuroElectric StarStim|10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks
219549509|NCT05564715|DEVICE|Sham Treatment|Sham stimulation for 10 sessions over 2 weeks
219549510|NCT00919113|DRUG|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
219549511|NCT00919113|DRUG|Placebo|The identical buffer used in Uracyst for the same administration
219549512|NCT04571801|DIAGNOSTIC_TEST|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
219633517|NCT04343040|DIETARY_SUPPLEMENT|carbohydrate supplement (Preload™)|carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.
218940525|NCT02162199|DRUG|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
218940526|NCT06086340|DRUG|Palbociclib|Palbociclib with an aromatase inhibitor therapy
218940527|NCT06086340|DRUG|Aromatase Inhibitor|Aromatase Inhibitor Therapy
218940528|NCT02252939|RADIATION|X-Ray|X-ray as part of standard care
218940529|NCT02709382|DRUG|Cefepime and Tazobactam combination|
218940530|NCT01237769|DRUG|Vitamin D3|2200 IU/day
218940531|NCT01237769|BEHAVIORAL|Lifestyle advice|Diet and exercise
218940532|NCT00004005|DRUG|fluorouracil|
218940533|NCT00004005|DRUG|irinotecan hydrochloride|
218940534|NCT00004005|DRUG|leucovorin calcium|
218940535|NCT00004005|PROCEDURE|conventional surgery|
218940536|NCT00004005|RADIATION|radiation therapy|
218940537|NCT00310661|DRUG|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
218940538|NCT00310661|OTHER|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
218940539|NCT01710319|OTHER|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
218940540|NCT01710813|BIOLOGICAL|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
218940541|NCT00870584|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
218940542|NCT00870584|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
218940543|NCT03913338|PROCEDURE|LasikXtra|By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
218940544|NCT03913338|PROCEDURE|LASIK|Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
218940545|NCT04208607|PROCEDURE|Bronchoscopy|Role of bronchoscopy in diagnosis of bronchiectasis
218940546|NCT01886989|DIETARY_SUPPLEMENT|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
218940547|NCT02014337|DRUG|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
218940548|NCT00961909|DRUG|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
218940549|NCT00961909|DRUG|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
218940550|NCT00961909|DRUG|metformin|stable dose
218940551|NCT00961909|DRUG|placebo|sc once weekly for 4 weeks
219549513|NCT04571801|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
219633518|NCT04343040|PROCEDURE|6 hours of preoperative fasting|Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.
218940552|NCT01449799|DRUG|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
218940553|NCT01449799|DRUG|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
218940554|NCT01449799|DRUG|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
218940555|NCT01449799|DRUG|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
219549514|NCT00856167|DRUG|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
219549515|NCT00856167|BEHAVIORAL|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
219549516|NCT05853445|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
218940556|NCT03258528|BEHAVIORAL|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
218940557|NCT05693961|DEVICE|CART-I plus|CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
218940558|NCT02184052|DRUG|Meloxicam|7.5 mg or 15 mg
218940559|NCT06518434|DRUG|Medical Cannabis|Medical cannabis oil three times daily
218940560|NCT04239625|DRUG|ALK-001|Oral administration of a pill for up to 24 months
219633519|NCT05377944|DRUG|BAT2306|150 mg/1 ml/injection (2 injections/visit)
219050021|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219050022|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
219359982|NCT05105763|OTHER|Feedback training on the knee alone (Condition B)|Condition B will include four 6-mins training blocks: 4-mins knee joint feedback-on and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
219633520|NCT05377944|DRUG|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
219633521|NCT01304511|DRUG|Orgalutran|
219633522|NCT02673931|DRUG|Byetta (Lilly, Exenatide)|See description of arms
219633523|NCT02673931|DRUG|Conoxia (AGA, oxygen)|See description arms
219633524|NCT02673931|DRUG|20% Human Albumin|
219633525|NCT03937895|BIOLOGICAL|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
219633526|NCT03937895|DRUG|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
219633527|NCT05189990|DIAGNOSTIC_TEST|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
219633528|NCT04836273|DRUG|Dasiglucagon|Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
219633529|NCT04836273|DEVICE|HyoPen|multi-dose reusable pen injector
219633530|NCT04836273|DRUG|Placebo|Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
219633531|NCT06098339|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
219633532|NCT06098339|DEVICE|Lens B (lotrafilcon B)|Daily wear for one month
219633533|NCT01722825|DRUG|LY2157299|Administered orally.
219633534|NCT02582242|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
218940561|NCT04126161|PROCEDURE|CT|standard of care CT prior to primary hip replacement
218940562|NCT04126161|DEVICE|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
219633535|NCT05366348|OTHER|Recreational activity|Horse-back riding
219633536|NCT05182710|BEHAVIORAL|Stress Inoculation Training|"The SIT programme/intervention will involve~1. 30 minute educational phase of preparatory information to allow participants to conceptualise the types of stressors they are likely to face and the role of stress on performance~2. 30 minutes of skills acquisition which will involve discussion of and teaching participants techniques to reduce stress in simulated resuscitation events~3. Inoculation through the application of acquired skills in 1-2 resuscitation scenarios"
219633537|NCT05182710|BEHAVIORAL|Alternative Training|"1. 30 minutes of teaching on management of a drowning patient (in order that both control and intervention perceive they have had teaching of the same length as the other group)~2. 1-2 resuscitation simulation events (same scenario and tasks as in the intervention group)"
218940563|NCT06273202|OTHER|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
218940564|NCT06486168|PROCEDURE|NIVATS|Non-Intubated Video-Assisted Thoracic Surgery (NIVATS) is the least invasive approach available. It is part of an optimal Enhanced Recovery After Surgery (ERAS) pathway and allows for expanding surgical indications in patients with poor cardio-pulmonary function.
218940565|NCT04063098|OTHER|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
219633538|NCT03916549|DEVICE|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
219633539|NCT03867136|DRUG|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
219633540|NCT03867136|DRUG|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
218940566|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
218940567|NCT06157151|BIOLOGICAL|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
218940568|NCT06157151|DRUG|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
219633541|NCT05330819|OTHER|Non-interventional|Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
219633542|NCT02101736|DRUG|Cabozantinib|This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
219633543|NCT00942591|DRUG|Interferon beta 1b|
219633544|NCT00942591|DRUG|Atorvastatin|
219633545|NCT05048381|DIAGNOSTIC_TEST|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
219633546|NCT00459290|DRUG|mifepristone|
219633547|NCT03840395|DEVICE|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
219633548|NCT02776436|DRUG|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
219633549|NCT02776436|DRUG|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
218940569|NCT03878615|PROCEDURE|elective surgery, according to deprtement routine|none, descriptive study
218940570|NCT01001325|BIOLOGICAL|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
218940571|NCT01001325|BIOLOGICAL|Normal saline|0.5 mL intramuscular
219050023|NCT05437757|DEVICE|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
219050024|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
219633550|NCT05532852|DRUG|standard-of-care plus Paxlovid|standard-of-care plus Paxlovid
219633551|NCT05532852|DRUG|standard-of-care|standard-of-care
219633552|NCT04821180|PROCEDURE|Three and four-part proximal humeral fractures' treatment|Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty
219633553|NCT02498444|DRUG|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
219633554|NCT02228733|DRUG|KBP-5074|Comparisons of different doses of study drug
219050025|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
218940572|NCT05133037|DEVICE|GE MR Scanner|"3T GE MR 750 systems MR scanner~Scanners run compatible software so pulse sequences and reconstructions can easily be supported on all systems. Reconstruction servers are networked to all scanners for reconstruction and data archiving. 3T scanner is equipped with state-of-the-art gradient systems (at least 40 mT/m Gradients / 150 mT/m/ms slew rates) and 16 or more receive channels. 3T scanner includes an assortment of RF coils including quadrature and phased-array coils designed to image brain, spine, neurovascular, torso, pelvis, cardiac, knee, foot/ankle, and hand/wrist. 3T system has several sizes of 16-channel wrap coils that are excellent for scans using parallel imaging."
218940573|NCT05408078|DEVICE|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
219050026|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
219050027|NCT00482391|BIOLOGICAL|trastuzumab|
219050028|NCT00482391|DRUG|cyclophosphamide|
219050029|NCT00482391|DRUG|doxorubicin hydrochloride|
219633555|NCT06683300|DRUG|DAPT for 3 months after vertebral artery stenting|After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
218940574|NCT05408078|OTHER|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
218940575|NCT04226196|DEVICE|Implantation of an intraocular lens|Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
218940576|NCT05780983|BEHAVIORAL|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
218940577|NCT03028519|DRUG|Vitamin D3|Vitamin D3
218940578|NCT01584440|DRUG|AVP-923-20|AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
218940579|NCT01584440|DRUG|Placebo|Placebo capsule
218940580|NCT01584440|DRUG|AVP-923-30|AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
218940581|NCT06453486|RADIATION|High dose radiation therapy|"High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:~* 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.~* 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.~* 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.~These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist."
218940582|NCT03390283|OTHER|Survey Administration|Complete online survey
219050030|NCT00482391|DRUG|lapatinib ditosylate|
219050031|NCT00482391|DRUG|paclitaxel|
219050032|NCT00482391|OTHER|laboratory biomarker analysis|
219050033|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
219050034|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
219633556|NCT04713839|OTHER|no intervention|We didn't have an intervention program, we used two questionnaires to evaluate participants.
219633557|NCT06389903|BEHAVIORAL|assessment|post-surgery behavioral assessment using scales
219050035|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
219050036|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
219050037|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
219633558|NCT04731090|DRUG|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
219050038|NCT00333112|DRUG|solifenacin succinate|Oral
219050039|NCT00333112|DRUG|tamsulosin|oral
219050040|NCT00333112|DRUG|placebo|oral
219050041|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
219050042|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
219050043|NCT04948632|OTHER|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
218940583|NCT02759367|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
218940584|NCT05770323|DIAGNOSTIC_TEST|Uric acid level|Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
218940585|NCT02860429|DRUG|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
218940586|NCT02860429|DRUG|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
218940587|NCT06022523|DIAGNOSTIC_TEST|Data acquisition using DT-400 pulse oximetry system|Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
218940588|NCT04947982|OTHER|carbon dioxide|carbon dioxide insufflation pressure
219050044|NCT04948632|OTHER|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
218940589|NCT00106899|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scans
219633559|NCT04731090|OTHER|Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
219050045|NCT05607303|OTHER|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
219050046|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
219050047|NCT04927338|DIETARY_SUPPLEMENT|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
219050048|NCT04927338|DRUG|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
219050049|NCT05821309|DRUG|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
219050050|NCT05821309|DRUG|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
219050051|NCT05821309|DRUG|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
219050052|NCT06423612|BEHAVIORAL|POC urine assay informed enhanced ART adherence counselling for viral suppression|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their ART adherence with provision of enhanced ART adherence counseling for viral suppression.
219050053|NCT04151940|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219633560|NCT02453334|DRUG|Injectafer|
219633561|NCT02453334|OTHER|Normal Saline|
219633562|NCT03710473|DIAGNOSTIC_TEST|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
219633563|NCT06085326|OTHER|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
219633564|NCT06685705|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
219359983|NCT03313960|DRUG|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
219633565|NCT06685705|DRUG|bupivacaine and Neostigmine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
218940590|NCT00106899|PROCEDURE|Positron Emission Tomography (PET)|PET scans
218940591|NCT00106899|PROCEDURE|Lumbar Puncture (LP)|collection of cerebrospinal fluid
218940592|NCT04234412|PROCEDURE|umbilical cord blood stem cell implantation for osteoarthritis treatment|"The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface."
218940593|NCT02093195|DRUG|Bosentan|
218940594|NCT02093195|DRUG|Symbicort turbuhaler|
218940595|NCT01821560|DRUG|Baclofen|
218940596|NCT01821560|DRUG|placebo|
218940597|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
218940598|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
218940599|NCT02182388|DRUG|Placebo|
218940600|NCT02182388|DRUG|BI 207127 NA powder for solution|
218940601|NCT02182388|DRUG|BI 207127 NA tablet|
218940602|NCT00166413|DRUG|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
218940603|NCT04562051|OTHER|prophylaxis regimen|All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
218940604|NCT00531427|DRUG|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
218940605|NCT00531427|DRUG|Placebo|transdermal system (placebo) applied for 7-day wear
218940606|NCT03196362|DRUG|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
219050054|NCT04151940|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219050055|NCT04151940|DRUG|Chemotherapy|Receive standard of care chemotherapy
219050056|NCT04151940|BIOLOGICAL|Immunotherapy|Receive standard of care immunotherapy
219050057|NCT04151940|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219050058|NCT04151940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219050059|NCT04151940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219050060|NCT06960707|RADIATION|Radiation therapy - 1 week|2600 cGy whole breast radiotherapy in five fractions (Arm 1) over 1 week
219633566|NCT06685705|DRUG|fentanyl and bupivacaine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
219633567|NCT02594553|BEHAVIORAL|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
219633568|NCT06176274|OTHER|Prehabilition program|this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
219633569|NCT03558425|DRUG|CKD-381|1 tablet administered before the breakfast during 7 days
219633570|NCT03558425|DRUG|D026|1 tablet administered before the breakfast during 7 days
218940607|NCT03196362|DRUG|Placebo Oral Tablet|One tablet of placebo will be given twice daily
218940608|NCT06076967|BEHAVIORAL|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
218940609|NCT06076967|BEHAVIORAL|Services-As-Usual|Services-As-Usual includes the standard support services provided by universities
218940610|NCT06217016|PROCEDURE|ICCAUT|In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
218940611|NCT06217016|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
218940612|NCT04306484|DIAGNOSTIC_TEST|FDOPA-TEP|FDOPA-TEP performed as part of the normal management of a suspected brain tumour
219050061|NCT06960707|RADIATION|Radiation therapy - 2 weeks|3200 cGy whole breast radiotherapy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 2) over 2 weeks. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.
219050062|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
219050063|NCT05460065|DRUG|single E4 28.3 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 28.3 mg (n=6)
219050064|NCT05460065|DRUG|single E4 94.4 mg|Administration of a single i.v. infusion of E4 94.4 mg (n=6)
219050065|NCT05460065|DRUG|multiple E4 94.4 mg|Administration of an i.v. infusion of E4 94.4 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
219050066|NCT05460065|DRUG|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
219050067|NCT03758040|OTHER|Slips on Turns|A slip will be administered to participants at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
219359984|NCT03313960|OTHER|"One Drop | Premium"|"Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
218940613|NCT04107025|OTHER|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
218940614|NCT01892839|OTHER|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
218940615|NCT01892839|OTHER|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
218940616|NCT00495898|DEVICE|CYPHER sirolimus-eluting stent|drug-eluting stent
219050068|NCT03758040|OTHER|Slips on Slopes|Slips will be administered to participants at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the Computer Assisted Rehabilitation Environment (CAREN) system treadmill.
219050069|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
219050070|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
219050071|NCT05620836|DRUG|Povorcitinib|Oral, Tablet
219050072|NCT05620836|DRUG|Placebo|Oral, Tablet
219050073|NCT06373614|OTHER|foot massage|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
219050074|NCT06373614|OTHER|bed bath|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
219050075|NCT03738826|BEHAVIORAL|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
219050076|NCT05560932|BEHAVIORAL|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
219050077|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
219050078|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
219050079|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
219050080|NCT06849830|BEHAVIORAL|Narrative Medicine (NM) Workshop Series|"The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools.~Each one-hour weekly workshop includes:~* Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility~* Creative writing exercises in response to structured prompts that encourage self-reflection and personal storytelling~* Facilitated group discussions to foster connection, self-expression, and emotional processing in a supportive environment"
219633571|NCT00839800|DRUG|Symbicort Turbuhaler|160/4.5 µg
219050081|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
219050082|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
219050083|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
218940617|NCT00495898|DEVICE|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
218940618|NCT03990519|DRUG|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
218940619|NCT03990519|DRUG|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
219633572|NCT00839800|DRUG|Terbutaline Turbuhaler|0.4 mg
219633573|NCT01598493|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
219633574|NCT01598493|DRUG|Flamazine|Silver sulfadiazine cream
219633575|NCT03038542|BEHAVIORAL|Gain-framed text messages|
219633576|NCT03038542|BEHAVIORAL|Standard care text messages|
219633577|NCT01767766|DRUG|TGR-1202|TGR-1202 Daily Oral Dose
219633578|NCT06128772|OTHER|Battlefield Acupuncture|5 points of acupuncture treatment in each ear weekly for 8 weeks
219633579|NCT00725153|DEVICE|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
219633580|NCT00725153|DEVICE|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
219633581|NCT04939987|DRUG|Tramadol|Opioid Control Cohort (One treatment selected)
219633582|NCT04939987|DRUG|Gabapentin|Experimental Cohort (Multimodal Approach)
219633583|NCT04939987|DRUG|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
219633584|NCT04939987|DRUG|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
219633585|NCT04939987|DRUG|Ketorolac|Experimental Cohort (Multimodal Approach)
219633586|NCT04939987|DRUG|Acetaminophen|Experimental Cohort (Multimodal Approach)
219633587|NCT04939987|DRUG|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
219633588|NCT04939987|DRUG|Ketamine|Experimental Cohort (Multimodal Approach)
219633589|NCT06371235|OTHER|Pregiferon|This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
219633590|NCT04399018|OTHER|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
219633591|NCT03668444|BEHAVIORAL|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
218940620|NCT04291989|DEVICE|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
218940621|NCT05513209|PROCEDURE|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
218940622|NCT05513209|PROCEDURE|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
218940623|NCT02510677|OTHER|myocardial perfusion scintigraphy|
218940624|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
218940625|NCT00773604|DEVICE|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
218940626|NCT06378216|DIAGNOSTIC_TEST|neurocognitive evaluations|clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
218940627|NCT06662383|DRUG|Retatrutide|Administered SC
218940628|NCT06662383|DRUG|Tirzepatide|Administered SC
218940629|NCT06655038|BEHAVIORAL|Advocacy coalition|"* set up a task force composed of school stakeholders (students, teachers, educators, principle,...). These stakeholders will meet 4 times a year to improve the implementation and enforcement of TFSP through rules that are accepted, adopted and to which all school actors adhere.~* share of good practices in implementation with the other schools of the intervention arm through a sharing platform and two annual meetings.~* support to reffer nicotine-dependant students and staff members to smoking cessation programs.~* support in the implementation of TFSP and in getting all school actors on board, by the research team, but also by local health promotion partners."
218940630|NCT06655038|BEHAVIORAL|Feedback|Feedback on the basis of the audit and the surveys
219050084|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
219050085|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
219050086|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
219050087|NCT04875520|OTHER|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
219050088|NCT04875520|OTHER|No screening testing strategy|a group of schools will not receive screening testing.
219633592|NCT03668444|BEHAVIORAL|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
219633593|NCT05729789|BEHAVIORAL|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
219633594|NCT02659007|OTHER|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
219633595|NCT00746889|DRUG|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
219633596|NCT00746889|DRUG|saline|Single intraarticular injection of 1 ml of 0.9% saline
219050089|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
219633597|NCT05022940|OTHER|Usual gold-standard multidisciplinary rehabilitation for TBI|In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
219050090|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
219050091|NCT02791334|DRUG|LY3300054|Administered IV
219050092|NCT02791334|DRUG|Ramucirumab|Administered IV
219050093|NCT02791334|DRUG|Abemaciclib|Administered orally
219050094|NCT02791334|DRUG|Merestinib|Administered orally
219050095|NCT02791334|DRUG|LY3321367|Administered IV
219050096|NCT05936567|DRUG|Povorcitinib|oral; tablet
219633598|NCT00136929|DRUG|Thrombolytic therapy|
219633599|NCT00136929|PROCEDURE|Percutaneous coronary intervention (PCI)|
219633600|NCT03038867|DRUG|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
219633601|NCT03038867|DRUG|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
219633602|NCT02182115|DRUG|antiseptic bundle|"1. Chlorhexidine gluconate liquid soap for bathing daily.~2. Chlorhexidine gluconate mouthrinse to use twice daily.~3. Nasal mupirocin to apply twice daily."
219050097|NCT05936567|DRUG|Placebo|oral; tablet
219050098|NCT05889286|DRUG|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
219050099|NCT05971758|DRUG|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
219050100|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
219050101|NCT04793698|OTHER|Compassion meditation|10 week meditation course taught in 90-minute groups
219633603|NCT02182115|DRUG|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
219633604|NCT00380133|DRUG|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
219633605|NCT00380133|DRUG|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
219633606|NCT00380133|DRUG|Placebo|Tablets matched to SB681323 or prednisolone
219050102|NCT04793698|BEHAVIORAL|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
219050103|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
219050104|NCT05371054|DEVICE|Vysis LSI MYC Break Apart Rearrangement Probe Kit|MYC rearrangement fluorescence in situ hybridization (FISH) testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI). This kit is not Food and Drug Administration (FDA) approved. It is being used as a treatment determining in-vitro diagnostic device in this study.
219050105|NCT05371054|DRUG|Venetoclax|"Dose Escalation: Administered orally, days 1-10, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered orally, days 1-10, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity"
219050106|NCT05371054|DRUG|VIP152|"Dose Escalation: Administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered intravenously, days 2 and 9, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity."
219050107|NCT05371054|DRUG|Prednisone|Administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity
219050108|NCT05371054|DIAGNOSTIC_TEST|PET|Screening, pre-cycle 7, pre-cycle 13, and at end-of-treatment (post-cycle 24).
219050109|NCT05371054|DIAGNOSTIC_TEST|EKG|Screening
219050110|NCT05371054|DIAGNOSTIC_TEST|ECHO|Screening
219633607|NCT05688839|DRUG|Jaktinib hydrochloride tablets|2 doses per day, 100mg Jaktinib
219633608|NCT05688839|DRUG|placebo|2 doses per day, placebo
219633609|NCT06485050|COMBINATION_PRODUCT|Photodynamic therapy|"Application of red laser-photodynamic therapy using Rapid Podia Laser diode® (MEDENCY). The following protocol will be followed: 1) mechanical debridement of the nail, 2) disinfection of the nail with alcohol, 3) application of topical photosensitiser (Toluidine blue gel) for 5 minutes with the area covered, 5) application of 635 nm diode laser for 10 minutes.~Daily application of ciclopirox 8% with ethyl acetate, ethanol (96%), ketosteryl alcohol, hydroxypropyl chitosan and purified water."
218940631|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education|Participants randomized to receive the Mediterranean Diet Nutrition Education will receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits, which will be created by the PI and Co-I's of the study (who are comprised of Professors who are either Registered Dietitian credentialed or have experience with creating nutrition/physical activity programs), including an explanation of the principles and components of a Mediterranean dietary pattern and its benefits, guidance on recommended intake of various food groups, budget-friendly strategies for incorporation, supporting resources (educational materials and online tools), and techniques for overcoming barriers to following a Mediterranean dietary pattern. Additional educational materials will be provided to participants through computer or web-based sources.
218940632|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education with Baked White Potato|Participants randomized to receive the Mediterranean Diet Nutrition Education with Baked White Potatoes will similarly receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits (same as the Mediterranean Diet Nutrition Education group). They will also receive will 100 g roasted white russet potatoes with the skin and will be asked to consume the regimen as a part of their meals (breakfast, lunch, dinner) or as a snack throughout the day to contribute to a balanced meal plan. The baked white potato regimen will be pre-portioned (in 100g amounts), stored in the freezer and given in freezer-microwave safe containers. The baked white potato regimen is approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat . In order to increase participants' compliance, they will be informed of a variety of ways to consume the baked white potato regimen.
218940633|NCT04516954|BIOLOGICAL|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
218940634|NCT00273793|BEHAVIORAL|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
218940635|NCT03524729|DEVICE|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
218940636|NCT03524729|DEVICE|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
218940637|NCT03524729|DEVICE|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
219050111|NCT05371054|DIAGNOSTIC_TEST|CT neck chest, abdomen, and pelvis|Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
219050112|NCT05371054|DIAGNOSTIC_TEST|MRI|As indicated. Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
219050113|NCT05371054|PROCEDURE|Bone marrow aspiration/Biopsy|Baseline, post-cycle 6, post-cycle 12, and at end-of-treatment (post-cycle 24).
219050114|NCT04016870|DEVICE|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
219633610|NCT01994941|DRUG|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
218940638|NCT02230124|DEVICE|MRE|
218940639|NCT01548833|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
218940640|NCT01548833|DEVICE|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
218940641|NCT01548833|DEVICE|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
218940642|NCT06463158|DEVICE|Family Room Application|The Family Room application is a point of care tool that guides families on contributing to patient participant care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful care giving. Importantly, family caregiver participants receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
218940643|NCT01740453|DRUG|ropivacaine 2 mg/ml|single
219633611|NCT01994941|DRUG|Ticagrelor|"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
219633612|NCT02027454|DRUG|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
219633613|NCT02027454|DRUG|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
219633614|NCT02027454|DRUG|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
219633615|NCT06049563|DIAGNOSTIC_TEST|Diagnostic MRI|MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
219633616|NCT04267809|DRUG|Metformin Hydrochloride|Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.
219633617|NCT04267809|DRUG|Calcium and Vitamin D|Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
219633618|NCT04848051|BEHAVIORAL|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
219633619|NCT04848051|BEHAVIORAL|CRC Reminder & Short message|Participants randomized to the CRC Reminder \& short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
218940644|NCT05190744|DRUG|PB|1000mg twice daily (BID). The dose of PB inducing the maximal increase in urine osmolality will be continued for up to four weeks providing that no side effects are observed including clinical and laboratory surveillance.
219050115|NCT04016870|DEVICE|New Pacemaker|Devices from the four manufacturers below will be used.
219050116|NCT06472206|BEHAVIORAL|CHW Sessions|Sessions with a Community Health Worker (CHW).
218940645|NCT06595134|OTHER|Non Interventional|Screening (Day -7 to Day -1) Visit 1 (Day 0) Visit 2 (Month 3 +/- 7 days) Visit 3 (Month 6 +/- 7 days) Visit 4 (Month 12 +/- 7 days) Visit 5 (Month 24 +/- 7 days) Visit 6 (Month 60 +/- 30 days; end of study)
219633620|NCT04848051|BEHAVIORAL|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
218940646|NCT01955460|BIOLOGICAL|Aldesleukin|Given IV
218940647|NCT01955460|DRUG|Cyclophosphamide|Given IV
218940648|NCT01955460|DRUG|Fludarabine Phosphate|Given IV
218940649|NCT01955460|OTHER|Laboratory Biomarker Analysis|Correlative studies
218940650|NCT01955460|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
218940651|NCT01955460|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
218940652|NCT06864481|OTHER|Blood samples|one Blood sample (20 ml)
218940653|NCT02626624|DEVICE|Implantation of the CarboClear Pedicle Screw System|
218940654|NCT06704841|BEHAVIORAL|Music in combination with mindfulness|Participants will attend two in-person sessions per week over two consecutive weeks. Each session will be up to one hour in duration. During each session, participants will engage in a 20-minute guided meditation while listening to instrumental music.
218940655|NCT06708468|OTHER|Exercise|The intervention includes 12-day personalized exercise program set in a rehabilitation center, followed by a three-month digital intervention and then a second 12-day personalized exercise program in a rehabilitation center.
218940656|NCT06708468|OTHER|Usual Care|Usual care includes appointments at hospitals and in the community health system according to what has been recommended to that individual
218940657|NCT06718972|OTHER|Not applicable- observational study|This is a retrospective and observational study. Not Applicable
218940658|NCT05348278|DRUG|Urea cream|apply 10% urea cream at both hands and feet twice daily
218940659|NCT06888388|PROCEDURE|Nipple Sparing Mastectomy (NSM)|Nipple sparing mastectomy (NSM) is a surgical procedure which removes all macroscopic breast glandular tissue while retaining the skin as well as the nipple areola complex.
218940660|NCT06888388|PROCEDURE|Skin-Sparing Mastectomy (SSM)|Skin sparing mastectomy (SSM) is a procedure that removes the nipple and areola complex along with all visible macroscopic breast glandular tissue.
218940661|NCT06888388|PROCEDURE|Total (Simple) Mastectomy|Total (Simple) Mastectomy is a traditional mastectomy approach that removes the breast glandular tissue with a large overlying area of skin including the nipple and areola complex to allow for flat closure.
218940662|NCT06721936|COMBINATION_PRODUCT|Multimodal pelviperineal physioterapy group|"The multimodal PPT protocol includes:~Pelvic Floor Muscle Training (PFMT): This component includes techniques to raise awareness of the pelvic floor, incorporating both manual and instrumental intravaginal techniques.~Non-Ablative Radiofrequency Therapy (Model: RNG, INDIBA): Applied during all eight sessions, with each session lasting 25 minutes.~Therapeutic Pelvic Health Education: Designed to empower participants with knowledge about their condition and the pelvic-perineal area. This educational intervention aims to enhance understanding, promote self-care, and encourage behaviours that alleviate symptoms associated with GSM"
218940663|NCT06721936|DEVICE|Laser CO2 Therapy group|"The fractional laser application will be delivery with the following probes:~90° Probe for Incontinence: Maximum power of 40W; 360° Probe for Vaginal Atrophy: Maximum power of 40W and Right-Angle Probe for Vulvar Atrophy: Maximum power of 24W."
218940664|NCT06173518|BIOLOGICAL|AUTO1|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
218940665|NCT06767774|DRUG|Combination therapy|"* pitavastatin 4mg~* ezetimibe 10mg"
218940666|NCT06767774|DRUG|High intensity statin monotherapy|rosuvastatin 20mg
218940667|NCT06015282|BIOLOGICAL|Investigational aQIVc|Investigational Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219633621|NCT04848051|BEHAVIORAL|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
218940668|NCT06015282|BIOLOGICAL|licensed QIVr|Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
219633622|NCT03637062|DRUG|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
219633623|NCT03637062|DEVICE|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
219633624|NCT02719717|DEVICE|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
219633625|NCT05669417|DRUG|Magnesium sulfate|Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
219633626|NCT06969482|BEHAVIORAL|measuring knowledge level|The study group consists of 70 nurses, each consisting of 35 people. After the routine training of the hospital was given to the control and experimental groups, their consents were obtained and the pre-tests were completed, they were divided into experimental and control groups using simple randomization. The first group of nurses in the control group will not receive any intervention other than the routine training given by the hospital.
219633627|NCT06969482|OTHER|educational intervention|the effectiveness of training by making measurements after training and comparing them with pre-training results
218940669|NCT06015282|BIOLOGICAL|licensed aQIV|Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
219050117|NCT06472206|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
218940670|NCT06760507|OTHER|Adapted Family History Screening Program|The intervention includes four key steps designed to enhance the family health screening process. Before the visit, clinics will engage in community outreach using tools such as social media, events, and promotional materials to raise awareness and drive appointment scheduling through the updated GA CORE website 2.0. During the visit, the intervention streamlines the screening process by embedding reminders into workflows and simplifying results communication and documentation. Patients receive theory-based communication materials about their results. After the visit, follow-ups are automated using the updated website 2.0, consolidating data tracking and incorporating risk-stratified communication strategies to encourage appropriate cancer screening behaviors.
218940671|NCT06795191|DRUG|Triptorelin Mesylate|22.5 mg in a prefilled, ready-to-use, long-acting formulation
218940672|NCT05436327|BEHAVIORAL|Geriatric Assessment|Clinical staff receive (a) training in GA and workflow management strategies (\<60 minutes) at baseline, (b) monthly facilitation and technical support calls (15-30 minutes) for 12 months, and (c) a group-based quarterly call for 12 months. For 12 months, clinical staff implement GA strategies during visits with older adult (65+) patients planning to receive new chemotherapy regimen and their care partners/caregivers.
218940673|NCT06003049|DRUG|OnabotulinumtoxinA|BOTOX injection series
218940674|NCT06003049|OTHER|Placebo|Placebo injection series
218940675|NCT04083612|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
218940676|NCT04083612|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
218940677|NCT07144891|GENETIC|Sperm DNA fragmentation|Estimation of sperm DFI level with sperm chromatin dispersion
218940678|NCT07145294|BIOLOGICAL|iEV|Intranasal administration of iEV, twice a week, 2 ml each time (at a concentration of 2×10¹⁰/ml), for 12 consecutive weeks.
219050118|NCT06228079|DRUG|Immunotherapy,Toripalimab Injection|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
219050119|NCT06228079|DRUG|Chemotherapy,Gemcitabine based regimen|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
219050120|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
219050121|NCT05773287|BEHAVIORAL|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
219050122|NCT05773287|BEHAVIORAL|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
218940679|NCT07145294|OTHER|Basic treatments|Basic treatments for cerebrovascular diseases such as antiplatelet aggregation, blood pressure control, blood glucose control, blood lipid control, and plaque stabilization.
219050123|NCT01801787|DEVICE|tDCS|active vs. sham tDCS left hemisphere
219050124|NCT01350128|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
219633628|NCT05802524|DIAGNOSTIC_TEST|Neurowave Group|"Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli"
219050125|NCT01350128|DRUG|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
219050126|NCT01350128|OTHER|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
219050127|NCT05388942|PROCEDURE|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
219050128|NCT05388942|DRUG|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
219050129|NCT04199299|DEVICE|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
219050130|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
219633629|NCT03067532|PROCEDURE|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
219633630|NCT03067532|PROCEDURE|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
219633631|NCT03915587|DEVICE|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
219633632|NCT03942471|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a well-defined and systematic patient-centered educational approach which provides training in mindfulness meditation to teach adolescents with Type 1 diabetes to take better care of themselves and live healthier and more adaptive lives by learning to become more connected to the present moment through the use of breath and training for awareness of the moment.
219633633|NCT06566872|DEVICE|ME-APDS|No Intervention
219633634|NCT06968429|DRUG|NBP Softgel Capsules|take orally on an empty stomach；2 capsules 3/day
219633635|NCT06968429|DRUG|Placebo|take orally on an empty stomach；2 capsules 3/day
219633636|NCT06240936|OTHER|Active Cycle of breathing|Active Cycle of Breathing Techniques will be given to group A. In Active cycle of breathing exercises, breathing control, thoracic expansion and forced expiration technique will be applied. 3-4 sets of exercise ,10-15 mint, 4 times per week for 4 weeks.
219633637|NCT06240936|OTHER|Active Cycle of breathing with Acapella|"Acapella device will be used along active cycle of breathing techniques to group B. 3-4 sets ,10 mints foe acapella training ,15 -20 munts ,4 times per week for 4 weeks.~This technique is active form of therapy in which patient uses its own energy on request to aid in treatment."
218940680|NCT07146412|BEHAVIORAL|Multimodal Lifestyle Intervention|The intervention supports adoption and maintenance of healthy behaviors including healthy nutrition The Mediterranean-DASH (Dietary Approaches to Stop Hypertension) Intervention for Neurodegenerative Delay, or MIND Diet), physical activity (150 min/week of moderate activity), stress management, weight management, and adherence to doctor-prescribed medical regimens. In addition, participants will be encouraged to participate regularly in social and learning activities, and to engage in cognitive training via Posit's BrainHQ web-based training tools (brainhq.com). Participants will be supported by telephone-based health coaching. Coaches will be currently licensed allied health providers such as Registered Dietitians. Using the combination of an individual's biological data (including genomics, blood, stool, saliva, etc.), activity data, behavioral data, and other incoming streams of health information, the coach will tailor the lifestyle intervention for each participant.
218940681|NCT07145723|OTHER|Earkick app|"Participants will have a baseline visit followed by an 8-week home monitoring period (HMP) using the Earkick app.~The Earkick app will interact with a mental health chatbot. Participants will complete online surveys at the midpoint (4 weeks) and end (8 weeks) of the HMP. Participants will choose one mental health-related topic to focus on from weeks 1-4 and one physical health-related topic to focus on from weeks 5-8.~Additionally, participants will have a post-HMP interview over Zoom."
218940682|NCT07146386|DRUG|H077 sustained-release tablet|Subjects are administered one H077 sustained-release tablet (8 mg) orally once daily, along with one silodosin capsule (placebo) orally twice daily.
218940683|NCT07146386|DRUG|Silodosin capsules Control Group|Subjects are administered one Silodosin capsule (4 mg) twice daily, along with one H077 sustained-release tablet placebo once daily, orally.
218940684|NCT07146815|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
218940685|NCT07146815|DIAGNOSTIC_TEST|MRI PDFF|Performance of an MRI-PDFF to determine amount of liver steatosis.
218940686|NCT07146152|DEVICE|Patient Decision Aid|A Patient Decision Aid designed to help patients with CIN2 make informed decisions about wether they prefer operation (Loop Electrical Surgery) or active surveillance.
218940687|NCT07144917|DIAGNOSTIC_TEST|mHLA-DR analysis|"mHLA-DR analysis will be realized on Cyto-Chex® BCT anticoagulant tubes (5mL). Each sample will be transported and centralized at the Immunology Laboratory of Edouard Herriot Hospital and analyzed by flow cytometry.~Samples will be collected :~* The day of surgery before intervention~* The day of surgery after intervention~* At postoperative day one~* At postoperative day two~* At postoperative day three~* At postoperative day four~* At postoperative day five~* At postoperative day seven"
218940688|NCT07146672|BIOLOGICAL|Super DC Vaccine|Super DC Cell Injection
218940689|NCT07145385|OTHER|multiplex digital PCR|multiplex digital PCR
218940690|NCT07146217|DRUG|Likmez® (metronidazole) Oral Suspension|Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL
218940691|NCT07146321|DIETARY_SUPPLEMENT|multi-vitamin, multi-nutrient|A multi-vitamin, multi-nutrient combination of approved and/or GRAS ingredients
218940692|NCT07146321|DIETARY_SUPPLEMENT|Placebo|placebo
219050131|NCT03592329|BEHAVIORAL|Stress Reduction Training A|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
219050132|NCT03592329|DEVICE|active tVNS|non-painful electrical stimulation of the auricle
219050133|NCT03592329|BEHAVIORAL|Stress Reduction Training B|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
218940693|NCT05290571|OTHER|Modified Otago Exercise Program with music|Our study attempts to establish a new home-based exercise option incorporating mOEP with video, music and lyrics. Our new approach shares the same aims with Exergames and video-supported methods - to increase the exercise motivation of elderlies, hence their physical performance. Based on the video-supported approach in one previous study, we add in the component of music therapy. Music-based exercise interventions could produce positive outcomes on both physical, such as gait, balance and fall risk and level of physical activities and psychological, including exercise adherence, perceived exertion, thus extending exercise duration. However, exact mechanisms have not been revealed and it may be limited by personal preferences on music. In our video, the music we chose is of brisk rhythm, slightly delightful melody and higher pitch, which all help to shape a cheerful and relaxing atmosphere for the elderlies.
218940694|NCT05290571|OTHER|Modified Otago Exercise Program|Otago Exercise Program (OEP) was developed by Otago Medical School in New Zealand as a tailor-made home-based fall prevention program to improve the balance performance of community-dwelling elderlies over 1 year. It comprises of 3 main components: 5 lower limb strengthening, 12 balance retraining and walking exercises. In the original program, the intensity was set as moderate with up to 4 difficulty levels for strengthening and balance exercises, in terms of ankle cuff weights and number of repetitions, and level of support respectively. It also stated that the frequency was at least 3 times a week for the former two exercises and at least 2 times per week for walking exercises; while the total duration was expected to make up to an hour, including 30-minute walking exercises.
218940695|NCT01395524|DRUG|NKTR-118|12.5 mg oral tablet once daily
219050134|NCT03592329|DEVICE|sham tVNS|sham stimulation
219050135|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
219050136|NCT06483269|PROCEDURE|PRP infiltration|"a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations."
219050137|NCT05548192|DEVICE|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
219050138|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
219050139|NCT01015352|DRUG|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
219050140|NCT01015352|DRUG|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
219050141|NCT05500365|PROCEDURE|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
219050142|NCT04060329|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
219633638|NCT05387096|OTHER|Definitive multi-faceted intervention consisting of several components|The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
219050143|NCT00658281|PROCEDURE|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
219050144|NCT00658281|PROCEDURE|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
219050145|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
219050146|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
219050147|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
219050148|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
219050149|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
219050150|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
219050151|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
219050152|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
219050153|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
219050154|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
219050155|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
219359985|NCT01698957|OTHER|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
219359986|NCT01027533|OTHER|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
219359987|NCT01005160|DRUG|Metformin|CKD-501 0.5mg, metformin 1000mg
219633639|NCT05387096|OTHER|Sham Intervention|Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
219633640|NCT03495479|DRUG|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
219633641|NCT06967012|DRUG|Oral Zonisamide Therapy|Zonisamide tablets are administered orally with the following dosage schedule: Weeks 1-2: 2 mg/kg/day, Weeks 3-4: 4 mg/kg/day, Weeks 5-6: 6 mg/kg/day. After the initial six weeks, the dosage is adjusted based on the patient's condition, with weekly increments of 1 mg/kg/day. The maintenance dose ranges from 4 to 6 mg/kg/day, administered in 1-2 divided doses daily. For children weighing ≥50 kg, the adult dosage should be used.
219633642|NCT02138487|OTHER|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
219633643|NCT02138487|OTHER|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
219633644|NCT03693183|DRUG|Ketorolac/HPMC|0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
219633645|NCT03693183|DRUG|HPMC|0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days
219633646|NCT03693183|DRUG|Vehicle|Vehicle
219633647|NCT03819712|PROCEDURE|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
219633648|NCT03819712|OTHER|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
219633649|NCT03819712|OTHER|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
218940696|NCT01395524|DRUG|NKTR-118|25 mg oral tablet once daily
218940697|NCT01395524|DRUG|Placebo|Oral tablet intake once daily
218940698|NCT01657461|DRUG|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
218940699|NCT01657461|DEVICE|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
218940700|NCT01868542|DRUG|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
218940701|NCT02206789|DRUG|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
218940702|NCT02206789|DRUG|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
218940703|NCT02269189|DRUG|BIIL 284 BS, high dose|
218940704|NCT02269189|DRUG|BIIL 284 BS, low dose|
218940705|NCT02269189|DRUG|Placebo|
218940706|NCT00373568|DRUG|miltefosine: 2.5 mg/kg/day for 42 days|
218940707|NCT04122352|OTHER|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
218940708|NCT04122352|OTHER|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
218940709|NCT05636449|OTHER|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
218940710|NCT05636449|OTHER|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
218940711|NCT03159260|DEVICE|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
218940712|NCT03159260|OTHER|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
218940713|NCT01121809|DRUG|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
218940714|NCT01121809|DRUG|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
218940715|NCT00543959|DRUG|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
218940716|NCT00543959|DRUG|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
218940717|NCT00543959|DRUG|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
219359988|NCT01005160|DRUG|CKD-501|CKD-501 0.5mg, metformin 1000mg
219359989|NCT01009307|GENETIC|polymorphism analysis|
219359990|NCT01009307|OTHER|laboratory biomarker analysis|
219359991|NCT01009307|OTHER|medical chart review|
219633650|NCT03819712|OTHER|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
219050156|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
219050157|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
219050158|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
219050159|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
219050160|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
219050161|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
219050162|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
219050163|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
219050164|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
219050165|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
219050166|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
219050167|NCT04936685|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
219050168|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
219050169|NCT02143622|BIOLOGICAL|LJM716|antibody
219050170|NCT02143622|BIOLOGICAL|cetuximab|antibody
219050171|NCT04054414|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
219050172|NCT04054414|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
219050173|NCT02717897|OTHER|No intervention|This study is not interventional
219050174|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
219633651|NCT03782012|BEHAVIORAL|Supported|Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
219050175|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
219050176|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
219633652|NCT04633512|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
219050177|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050178|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050179|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050180|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050181|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050182|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
219050183|NCT00984854|DRUG|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
219359992|NCT04314050|DRUG|Tramadol|tramadol and paracetamol will perform
219359993|NCT04314050|DRUG|Dexmedetomidine|dexmedetomidine and paracetamol will perform
219633653|NCT03718208|DIETARY_SUPPLEMENT|Paediatric Formula|Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
219050184|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
218940718|NCT01077921|DRUG|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
218940719|NCT01077921|DRUG|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
218940720|NCT05667077|DRUG|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
218940721|NCT04183361|DIAGNOSTIC_TEST|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2\. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
218940722|NCT03625843|BEHAVIORAL|Mindfulness exercises|
218940723|NCT04866745|DEVICE|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
218940724|NCT04866745|DEVICE|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
218940725|NCT04866745|DEVICE|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
218940726|NCT05402605|PROCEDURE|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
218940727|NCT05402605|PROCEDURE|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
218940728|NCT00940667|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
218940729|NCT00940667|DRUG|Amlodipine|amlodipine 5mg q.d.
218940730|NCT04685161|PROCEDURE|Surgical extrusion|Invasive treatment option for fractured tooth
219050185|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
219050186|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
219050187|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
219050188|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
219050189|NCT04326478|DRUG|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
219050190|NCT04326478|BIOLOGICAL|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
219050191|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
219050192|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
219050193|NCT05701137|OTHER|EMDR-RTE|The experimental group will have EMDR recent traumatic event.
219050194|NCT05701137|OTHER|TAU|The comparator group will have usual psychological intervention.
219050195|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
218940731|NCT04685161|DEVICE|Fibre post|Easy approach for treatment
218940732|NCT05828004|BEHAVIORAL|Whole-Course Multidisciplinary Care Intervention|On the basis of standard treatment, all patients were evaluated by senior practice nurses in the Department of Oncology in person at the time of enrollment (before radiotherapy) and once every week during radiotherapy, and once in person/over the phone at 1, 2, 3, and 6 months after radiotherapy.
218940733|NCT02050542|PROCEDURE|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
219050196|NCT06464939|DRUG|Placebo|Applications of water for injection
219050197|NCT03969212|DRUG|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
218940734|NCT02050542|PROCEDURE|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
218940735|NCT03610100|DRUG|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
218940736|NCT03610100|DRUG|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
218940737|NCT00558688|PROCEDURE|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
218940738|NCT06243523|BEHAVIORAL|The stress management psychoeducation program based on Neuman's Systems Model|The stress management psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care. The first session includes the meeting and introduction of the psychoeducation program. The second session includes the adaptation process to the intensive care unit. The third, fourth and fifth sessions include methods of coping with stress. The sixth session includes evaluation and termination of the psychoeducational program. Quantitative data of the research will be collected with the pre-action and post-action Psychological Distress Scale and the Stress Coping Styles Scale. Qualitative data of the research will be collected through semi-structured individual in-depth interviews conducted after the action.
218940739|NCT01293227|PROCEDURE|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
219633654|NCT03316651|DRUG|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
218940740|NCT04989153|DIAGNOSTIC_TEST|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
218940741|NCT00328302|DRUG|Candesartan|
219050198|NCT03969212|DRUG|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
219050199|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
219633655|NCT04429100|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
219633656|NCT01065337|BIOLOGICAL|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
218940742|NCT00328302|DRUG|Placebo|
218940743|NCT00167297|DRUG|Atomoxetine|
218940744|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
218940745|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
218940746|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
218940747|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
219359994|NCT04314050|OTHER|control|paracetamol will perform
219633657|NCT01065337|BIOLOGICAL|bone marrow stem cells (BMC)|bone marrow stem cells
218940748|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
218940749|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of Placebo IV
218940750|NCT02226679|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
218940751|NCT05911594|DRUG|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
218940752|NCT05911594|PROCEDURE|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
218940753|NCT05911594|DRUG|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
218940754|NCT05911594|COMBINATION_PRODUCT|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
218940755|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
218940756|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
218940757|NCT00738621|DRUG|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
218940758|NCT00738621|DRUG|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
218940759|NCT05212870|OTHER|assessment of cognitive level, pain catastrophe, physical activity level and quality of life|assessment of cognitive level, pain catastrophe, physical activity level and quality of life
218940760|NCT02812017|BEHAVIORAL|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
219050200|NCT04457674|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
219050201|NCT04457674|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
219050202|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
219050203|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
219050204|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
219050205|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
219050206|NCT02003625|DRUG|GCSF|
219633658|NCT01168778|BEHAVIORAL|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
218940761|NCT02812017|OTHER|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
218940762|NCT00358540|DRUG|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
218940763|NCT00152100|PROCEDURE|Stem cell transplant|
219633659|NCT04585256|OTHER|Trendelenburg positioning|Women positioned in the trendelenburg position prior to external cephalic version
219633660|NCT06171087|DRUG|Domperidon|oral
219633661|NCT06171087|DRUG|Placebo|oral tablet
219633662|NCT05456178|OTHER|Electrostatic wipe|"The main objective will be to study the feasibility of the quantification of domestic fungal exposure with electrostatic wipe. The interval of environmental fungal exposure quantification values measured by conventional mycology and by NGS will be established, with analysis of the correlation between the quantification obtained by the two techniques.~For this, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks. The wipes will be analyzed by the mycology laboratory of the Croix Rousse hospital."
219633663|NCT03084107|OTHER|Questionnaire|The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
219633664|NCT02960711|DRUG|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
219633665|NCT02960711|DRUG|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
218940764|NCT00152100|DRUG|Filgrastim, Alemtuzumab|
218940765|NCT00152100|DEVICE|Miltenyi CliniMACS|
218940766|NCT02492932|DEVICE|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
218940767|NCT04734899|OTHER|Exercise program|Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg
218940768|NCT04734899|OTHER|Foot core training|Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
218940769|NCT05518318|DRUG|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
218940770|NCT05518318|DRUG|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
218940771|NCT00130975|DRUG|Candesartan|
219050207|NCT02003625|DRUG|meloxicam|
219050208|NCT02003625|DRUG|Placebo|
218940772|NCT02245425|OTHER|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
218940773|NCT02245425|OTHER|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
218940774|NCT03065972|PROCEDURE|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
218940775|NCT03065972|DEVICE|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
218940776|NCT04903743|DRUG|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
218940777|NCT04903743|DRUG|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
218940778|NCT06032325|DIAGNOSTIC_TEST|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
218940779|NCT04540016|DRUG|[14C]HSK7653|25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
218940780|NCT03583385|DRUG|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
219050209|NCT00075335|DRUG|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
218940781|NCT03583385|DRUG|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
219050210|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
219050211|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
219050212|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
219050213|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
219050214|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
219050215|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
219050216|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
218940782|NCT04780919|DEVICE|BTL-6000 FSWT|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.
218940783|NCT04780919|DEVICE|BTL-6000 FSWT with sham applicator|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
218940784|NCT05435443|DEVICE|PowerBreathe and PEP Therosold tools|"Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM."
218940785|NCT00095940|DRUG|lapatinib ditosylate|Given orally
218940786|NCT00095940|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218940787|NCT00095940|OTHER|laboratory biomarker analysis|Correlative studies
219050217|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
219050218|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
218940788|NCT00095940|OTHER|pharmacological study|Correlative studies
218940789|NCT00095940|PROCEDURE|positron emission tomography|Correlative studies
218940790|NCT00095940|PROCEDURE|magnetic resonance imaging|Correlative studies
218940791|NCT03247452|OTHER|One-day Low fiber diet|One-day low fiber diet before colonoscopy
218940792|NCT03247452|OTHER|Three-day low fiber diet|Three days low fiber diet before colonoscopy
218940793|NCT03247452|DRUG|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
218940794|NCT02852616|BEHAVIORAL|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
218940795|NCT03074019|DIETARY_SUPPLEMENT|Xylooligosaccacharide|XOS95 powder
218940796|NCT03074019|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder
218940797|NCT05715112|PROCEDURE|Graded Motor Imagery|GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
219050219|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
219050220|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
219050221|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
219050222|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
218940798|NCT05132322|BEHAVIORAL|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
218940799|NCT05132322|BEHAVIORAL|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
219050223|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
219050224|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
219050225|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
219050226|NCT01147653|BIOLOGICAL|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
219050227|NCT01147653|OTHER|Placebo|Placebo
219050228|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
219633666|NCT00826683|BIOLOGICAL|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
219633667|NCT05139771|DEVICE|THE ENDOART® IMPLANTATION (Artificial Endothelial layer)|Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
218940800|NCT05132322|BEHAVIORAL|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
218940801|NCT05132322|BEHAVIORAL|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
218940802|NCT02314637|DRUG|Teneligliptin|Teneligliptin for 52 weeks
218940803|NCT02314637|DRUG|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
218940804|NCT04126278|DRUG|Barbotage|Administered as per standard of care
219050229|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
219050230|NCT03467269|DIAGNOSTIC_TEST|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
219050231|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
219050232|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
219050233|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
219050234|NCT02690961|DRUG|placebo multiple doses|
219050235|NCT06382233|DIAGNOSTIC_TEST|Identification of Diagnostic Biomarkers|Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
219050236|NCT03302481|OTHER|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
219050237|NCT02617316|OTHER|Barefoot|barefoot running test was 20 minutes.
219050238|NCT02617316|OTHER|In shoes|In shoes test was 20 minutes.
219050239|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
218940805|NCT04126278|DRUG|Dexamethasone|4 mg of dexamethasone
219050240|NCT00177424|DRUG|Placebo|matching placebo tablets
219050241|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
219050242|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
219050243|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
219633668|NCT05746728|DRUG|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
219633669|NCT05746728|DRUG|Tislelizumab|200mg, d1, iv, Q3W
219633670|NCT01156961|DRUG|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
219633671|NCT01156961|DRUG|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
218940806|NCT03029988|DRUG|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
218940807|NCT03029988|PROCEDURE|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
218940808|NCT05189353|OTHER|Ghrelin|Ghrelin infusion
218940809|NCT05189353|OTHER|Placebo|Saline infusion
218940810|NCT03663660|OTHER|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
218940811|NCT01540955|BEHAVIORAL|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
218940812|NCT04133129|BEHAVIORAL|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
218940813|NCT04133129|BEHAVIORAL|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
219050244|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
219050245|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
219050246|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
219050247|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
219050248|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
219050249|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
219050250|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
218940814|NCT00213538|DRUG|Response to anakinra associated with methotrexate|
218940815|NCT00389987|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
218940816|NCT00389987|DRUG|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
218940817|NCT02586649|DRUG|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
218940818|NCT02586649|DRUG|Placebo|Placebo is a non-active inhalation capsule .
218940819|NCT02999438|DEVICE|Actigraph to check activity levels at home|
218940820|NCT00001113|DRUG|Interferon alfa-2a|
218940821|NCT00001113|DRUG|Zidovudine|
218940822|NCT00001113|DRUG|Interferon alfa-n1|
218940823|NCT03539549|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
218940824|NCT03303508|DIAGNOSTIC_TEST|anti-ds DNA|venous blood samples
218940825|NCT01221935|OTHER|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
218940826|NCT01221935|OTHER|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
218940827|NCT01221935|OTHER|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
219050251|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
218940828|NCT01221935|OTHER|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
218940829|NCT04602871|DIAGNOSTIC_TEST|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
218940830|NCT05003297|OTHER|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
218940831|NCT00494247|DEVICE|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
218940832|NCT02239549|DEVICE|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
218940833|NCT02239549|DEVICE|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
218940834|NCT00856232|BIOLOGICAL|Medical Air|Compressed medical air
218940835|NCT00856232|BIOLOGICAL|Oxygen|Medical Oxygen
218940836|NCT02713074|DRUG|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
218940837|NCT02713074|DRUG|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
219050252|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
219633672|NCT05136105|BEHAVIORAL|Preventive Narrative Exposure Therapy (PreNET) family intervention|"Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration."
219633673|NCT03347305|BEHAVIORAL|automated DP|Energy expenditure measurement
219633674|NCT03347305|BEHAVIORAL|Calorimetric chamber|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
219633675|NCT03491462|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
219633676|NCT03491462|DRUG|Placebo|2 matched placebo capsules taken 3 times daily
219633677|NCT04120077|DIETARY_SUPPLEMENT|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
219633678|NCT04938180|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
219633679|NCT01800929|DEVICE|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
219633680|NCT03084120|OTHER|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
219633681|NCT03084120|OTHER|Retrieval of umbilical cord blood.|-During childbirth
219633682|NCT03084120|OTHER|Retrieval of placenta.|-During childbirth
219633683|NCT03084120|OTHER|Collection of newborn's and mother's lock of hair.|-During childbirth
219633684|NCT03084120|OTHER|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
219050253|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
219050254|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
219633685|NCT03084120|OTHER|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
219633686|NCT02645474|PROCEDURE|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
219633687|NCT02645474|PROCEDURE|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
219633688|NCT02645474|DRUG|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
219633689|NCT02309762|DRUG|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
218940838|NCT03241030|DRUG|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
218940839|NCT03241030|OTHER|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
218940840|NCT03241030|DRUG|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
218940841|NCT03241030|DRUG|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
218940842|NCT02864862|DEVICE|Immediate implant|
218940843|NCT02864862|BIOLOGICAL|SCTG|
218940844|NCT02864862|BIOLOGICAL|ADM|
218940845|NCT02091557|DRUG|GnRH-analogue|
218940846|NCT04215302|DEVICE|laryngeal mask|the size of laryngeal mask given to the patient was based on patient's weight measurement
219633690|NCT02309762|DRUG|Placebo|Solution containing no active ingredients
219633691|NCT03371862|DRUG|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
219633692|NCT01591057|DIETARY_SUPPLEMENT|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
218940847|NCT05490550|BEHAVIORAL|COAST-enhanced CBTI|Participants will receive CBTI delivered through the COAST platform by one of NOCTEM's certified and licensed COAST clinician. Communication between the participant and licensed clinician will occur primarily through COAST's HIPAA-compliant text messaging, but clinicians and patients may elect to connect via telephone calls or HIPAA-compliant secure videoconference if needed.
218940848|NCT05490550|BEHAVIORAL|Military Treatment Facility Insomnia Care As Usual|Participants will receive the insomnia care offered at their site following current delivery practices (i.e., face-to-face or virtual; individual or group format). During the treatment phase, participants randomized to ICAU will be instructed to communicate with their clinicians as needed, according to standard procedures in place.
218940849|NCT03828578|PROCEDURE|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
218940850|NCT04504552|DRUG|Avelumab|Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
218940851|NCT03841630|DRUG|LY3437943|Administered subcutaneously (SC)
218940852|NCT03841630|DRUG|Placebo|Administered SC
218940853|NCT04352972|DEVICE|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
218940854|NCT04352972|OTHER|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
218940855|NCT03702881|DEVICE|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
218940856|NCT03702881|DEVICE|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
218940857|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
219050255|NCT05354570|RADIATION|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
219633693|NCT01591057|DIETARY_SUPPLEMENT|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
219633694|NCT01591057|DIETARY_SUPPLEMENT|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
219633695|NCT04712448|DIAGNOSTIC_TEST|Anti-COVID test|No intervention is foreseen by the protocol
219633696|NCT04124601|RADIATION|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
219633697|NCT04124601|DRUG|Ipilimumab|Infusion
219633698|NCT04124601|DRUG|Nivolumab|Infusion
219633699|NCT04813068|OTHER|Semi-structured interview|Semi-structured interview to identify attitudes to re-irradiation in lung cancer
219633700|NCT05560269|BEHAVIORAL|Verbal coaching vs. Constraint based coaching|"* 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval"
219633701|NCT04562246|DIAGNOSTIC_TEST|Serologic assays for antibodies to SARS-CoV-2|Beckman Coulter and Roche automated immunoassays
219633702|NCT00649922|BIOLOGICAL|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
218940858|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
219050256|NCT03159884|DRUG|Conbercept|
219633703|NCT00649922|BIOLOGICAL|placebo|2 injections Day 1, 1 injection Days 15 and 29
218940859|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
219050257|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
219050258|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
219050259|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
219050260|NCT04925297|OTHER|No intervention|No intervention will be given
219633704|NCT00649922|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
219633705|NCT02407925|BEHAVIORAL|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
219633706|NCT03596112|OTHER|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
218940860|NCT02969148|PROCEDURE|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
218940861|NCT02969148|PROCEDURE|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
218940862|NCT03078140|DIETARY_SUPPLEMENT|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
218940863|NCT03078140|DIETARY_SUPPLEMENT|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
218940864|NCT02902341|DIETARY_SUPPLEMENT|Nutrition Therapy|Nutrition based on measured caloric needs.
218940865|NCT02902341|DIETARY_SUPPLEMENT|Control|Standard protocol nutrition based on calculated caloric needs.
218940866|NCT02265588|BEHAVIORAL|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
218940867|NCT01863836|PROCEDURE|Fluoroscopy|
218940868|NCT01863836|PROCEDURE|Radial EBUS-guided biopsy|
218940869|NCT02117622|DRUG|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
218940870|NCT02150434|DEVICE|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
218940871|NCT02150434|DRUG|Compressed air|compressed air delivered at a fixed flow of 2 L/min
218940872|NCT02150434|DRUG|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
218940873|NCT06297772|DRUG|Decitabine|decitabine 20mg/m2 per day for consecutive 5 days
218940874|NCT06297772|DRUG|Fludarabine Injection|fludarabine 30mg/m2 per day for consecutive 5 days
218940875|NCT06297772|DRUG|Busulfan Injection|Busulfan 3.2mg/kg per day for consecutive 4 days
218940876|NCT06055543|DIETARY_SUPPLEMENT|Fortimel|2 bottles/day of the high energy ONS
218940877|NCT00124046|PROCEDURE|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
218940878|NCT00124046|PROCEDURE|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
218940879|NCT04645719|OTHER|Lactate ringer group|General anesthesia only
218940880|NCT04645719|DRUG|Magnesium sulfate dose through real weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight
218940881|NCT04645719|DRUG|Magnesium sulfate dose through corrected ideal weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
218940882|NCT02683603|DRUG|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
218940883|NCT02683603|DRUG|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
218940884|NCT02683603|DRUG|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
219050261|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
219050262|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
219050263|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
219050264|NCT02269891|OTHER|Placebo|
218940885|NCT02683603|DRUG|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
218940886|NCT02683603|DRUG|AS colistin and imipenem|IV imipenem 1 g three times per day.
218940887|NCT02683603|DRUG|IV colistin and imipenem|IV imipenem 1 g three times per day
218940888|NCT00783484|DRUG|PF-03716539|PF-03716539 10 mg oral solution, single dose
218940889|NCT00783484|DRUG|PF-03716539|PF-03716539 25 mg oral solution, single dose
218940890|NCT00783484|DRUG|PF-03716539|PF-03716539 3 mg oral solution, single dose
218940891|NCT00783484|OTHER|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
218940892|NCT00783484|DRUG|PF-03716539|PF-03716539 100 mg oral solution, single dose
218940893|NCT00783484|DRUG|PF-03716539|PF-03716539 200 mg oral solution, single dose
218940894|NCT00783484|DRUG|PF-03716539|PF-03716539 50 mg oral solution, single dose
218940895|NCT00783484|OTHER|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
218940896|NCT00783484|DRUG|Midazolam|Midazolam 1 mg IV, single dose
218940897|NCT00783484|DRUG|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
218940898|NCT00783484|DRUG|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
218940899|NCT00783484|DRUG|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
218940900|NCT00783484|DRUG|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
218940901|NCT00783484|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
218940902|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
218940903|NCT00783484|DRUG|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
219050265|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
219050266|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
219050267|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
219050268|NCT00006482|DRUG|cisplatin|
218940904|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
219050269|NCT00006482|DRUG|gemcitabine hydrochloride|
218940905|NCT00621348|DRUG|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
219633707|NCT03596112|OTHER|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
218940906|NCT00621348|DRUG|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
218940907|NCT00621348|DRUG|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
218940908|NCT00473733|PROCEDURE|GLP receptors expression|
218940909|NCT00473733|PROCEDURE|ESOPHAGOGASTRODUODENOSCOPY|
218940910|NCT03514810|COMBINATION_PRODUCT|Combined Sertraline & Ketoprofen|The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.
218940911|NCT03514810|OTHER|Interleukins in MDD after treatment|Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
218940912|NCT06122311|DRUG|N Acetylcysteine|N-acetylcysteine sachets 600 mg twice daily
218940913|NCT05646017|DEVICE|Intermittenly scanned continuous glucose monitoring|Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
219633708|NCT03244930|DRUG|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
218940914|NCT05254847|DRUG|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
218940915|NCT04013061|OTHER|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
218940916|NCT03968133|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
218940917|NCT03968133|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
219050270|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
219050271|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
219633709|NCT05648422|DIETARY_SUPPLEMENT|Probiotics|Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9
218940918|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
219633710|NCT05648422|DIETARY_SUPPLEMENT|NSS Nutritional Support System|Nutritional Support System consists in NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, glycine, tryptophan, and inuline) every 12 hours for 12 weeks.
219633711|NCT05648422|DRUG|Deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days
219633712|NCT05648422|OTHER|Specific diet|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of smoothies at breakfast and dinner, high consumption of fish, five meals during the day, 70% of meals eaten during the day will consist on vegetables, fruits, roots, cereals, and legumes. Red meat, gluten, lactose, junk food, sugar, salt, fast food free.
218940919|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
218940920|NCT01655004|DRUG|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
218940921|NCT01696604|DRUG|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
218940922|NCT01696604|DRUG|Placebo|Matching placebo capsules will be available.
218940923|NCT05214261|OTHER|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
218940924|NCT06182397|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.
218940925|NCT06182397|DEVICE|Placebo balloon angioplasty|For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
219050272|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
219050273|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
219050274|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
219050275|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
218940926|NCT04582253|DIAGNOSTIC_TEST|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
218940927|NCT05573386|DRUG|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
218940928|NCT05573386|DRUG|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
218940929|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
218940930|NCT04580667|OTHER|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
218940931|NCT06291727|DRUG|Mepivacaine|Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
218940932|NCT06291727|DRUG|Bupivacaine|Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
218940933|NCT05009459|BEHAVIORAL|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
218940934|NCT06535607|BIOLOGICAL|Volrustomig|IV Infusion
218940935|NCT06535607|DRUG|Cisplatin|IV Infusion
218940936|NCT06535607|DRUG|Carboplatin|IV Infusion
218940937|NCT06535607|DRUG|Paclitaxel|IV Infusion
218940938|NCT03646123|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion
218940939|NCT03646123|DRUG|doxorubicin|25 mg/m\^2 by IV infusion
218940940|NCT03646123|DRUG|vinblastine|6 mg/m\^2 by IV infusion
218940941|NCT03646123|DRUG|dacarbazine|375 mg/m\^2 by IV infusion
218940942|NCT03646123|DRUG|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
218940943|NCT03646123|DRUG|nivolumab|240 mg by IV infusion
218940944|NCT05605444|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
218940945|NCT04915950|DRUG|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
218940946|NCT04915950|DRUG|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
218940947|NCT04458259|DRUG|PF-07265807|Given 2 weeks on/1 week off
218940948|NCT04458259|DRUG|Sasanlimab|Given SC Q3W
218940949|NCT04458259|DRUG|Axitinib|Dosed per package label starting with 5 mg PO BID
218940950|NCT01775072|GENETIC|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, \& others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection \& research biopsies."
218940951|NCT01775072|GENETIC|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk"
218940952|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB)|Rhomboid Intercostal Block (RIB) A regional anesthesia technique administered under ultrasound guidance for postoperative pain relief. This will be used as the sole intervention in Arm 1.
218940953|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB) + Serratus Anterior Plane Block (SAPB)|A combination of two regional anesthesia techniques, Rhomboid Intercostal Block (RIB) and Serratus Anterior Plane Block (SAPB),(THE SAPB will received within 24 hours after RIB) administered under ultrasound guidance. SAPB targets the lateral cutaneous branches of the thoracic nerves, complementing the pain relief provided by RIB. This combination is used in Arm 2 to enhance postoperative analgesia.
218940954|NCT01786772|OTHER|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
219633713|NCT05648422|OTHER|Conventional diet (WHO)|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of general nutricional recommendations.
219633714|NCT00003563|RADIATION|WBRT|3 GY of WBRT daily for a total of 10 days
219633715|NCT00003563|DRUG|MGd|5.0 mg /kg MGd plus WBRT
218940955|NCT01786772|OTHER|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
219050276|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
219050277|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
219050278|NCT04547062|DRUG|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
219633716|NCT00601939|BEHAVIORAL|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
219050279|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
219050280|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
219050281|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
219050282|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
219050283|NCT00000436|PROCEDURE|High-intensity strength training|
219050284|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
219050285|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
218940956|NCT04195893|DEVICE|somofilcon A|Contact Lens
219633717|NCT00601939|BEHAVIORAL|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
219633718|NCT05251896|PROCEDURE|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
219633719|NCT03433196|DRUG|HS-25 and Atorvastatin|HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
219633720|NCT03433196|DRUG|Atorvastatin|Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
219633721|NCT01288196|DRUG|Placebo IV|A single 30-minute IV infusion of placebo
219633722|NCT01288196|DRUG|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
219633723|NCT01288196|DRUG|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
219633724|NCT01288196|DRUG|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
219633725|NCT01288196|DRUG|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
219633726|NCT01288196|DRUG|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
218940957|NCT04195893|DEVICE|etafilcon A|Contact Lens
218940958|NCT02873117|OTHER|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
219050286|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
219050287|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
219633727|NCT04828018|OTHER|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
219633728|NCT04828018|OTHER|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
219633729|NCT04828018|OTHER|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
219633730|NCT04828018|OTHER|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
219633731|NCT04828018|OTHER|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
218940959|NCT06248775|BEHAVIORAL|Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)|During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
218940960|NCT01551511|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
218940961|NCT01551511|DRUG|Placebo|Identical step-up approach to the Namisol arm.
218940962|NCT00880971|RADIATION|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
218940963|NCT03689686|DEVICE|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP"
218940964|NCT02209532|DEVICE|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
218940965|NCT00973869|DIETARY_SUPPLEMENT|curcumin|
218940966|NCT00973869|OTHER|high performance liquid chromatography|
218940967|NCT00973869|OTHER|laboratory biomarker analysis|
218940968|NCT00973869|OTHER|pharmacological study|
218940969|NCT00973869|PROCEDURE|diagnostic endoscopic procedure|
218940970|NCT00973869|PROCEDURE|therapeutic conventional surgery|
218940971|NCT05526404|OTHER|Dieta mobile application|Mobile application that functions on mobile phones and allows for tracking of symptoms, dietary intake, and stool characteristics using logs and pictures. Users of the application track symptoms by completing questionnaires regarding stool frequency, consistency, and mental status changes. Users can track dietary intake and stool characteristics by taking time-stamped photos of all dietary intake and bowel movements.
218940972|NCT00775008|BEHAVIORAL|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
218940973|NCT04241055|BEHAVIORAL|Values affirmation exercise|In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
218940974|NCT04241055|BEHAVIORAL|Active control exercise|In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
218940975|NCT00541801|DEVICE|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
218940976|NCT05764707|DRUG|Acetaminophen|Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
218940977|NCT05764707|DRUG|Placebo|Patients will received 1000mg of normal saline within 30 minutes of skin closure.
218940978|NCT05658315|OTHER|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
218940979|NCT01694407|DRUG|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
218940980|NCT01694407|DRUG|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
218940981|NCT01694407|DRUG|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
218940982|NCT01694407|DRUG|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
218940983|NCT01731418|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, \& Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
218940984|NCT01731418|OTHER|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
218940985|NCT05353504|DIETARY_SUPPLEMENT|Inulin|28g/day delivered in 2 sachets throughout the day with main meals
218940986|NCT05353504|BEHAVIORAL|Lifestyle intervention|weekly educational sessions to improve individual's eating behaviour
218940987|NCT05353504|DIETARY_SUPPLEMENT|Placebo|equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
218940988|NCT01802073|DRUG|Oral Vancomycin|
218940989|NCT00003690|DRUG|alvocidib|
218940990|NCT00003690|DRUG|carboplatin|
218940991|NCT00003690|DRUG|cisplatin|
218940992|NCT00616538|DEVICE|Epiceram(r)|Topical barrier repair emulsion cream
218940993|NCT00616538|DRUG|Fluticasone Propionate 0.05%|Topical mid-strength steroid
218940994|NCT05171062|DRUG|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
218940995|NCT05171062|DRUG|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
218940996|NCT00332722|PROCEDURE|Cervical facet joint nerve blocks|
218940997|NCT06007365|DEVICE|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
218940998|NCT01940172|DRUG|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
219050288|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
219050289|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
219050290|NCT02968732|PROCEDURE|Radical Cystectomy|
219050291|NCT05609409|BEHAVIORAL|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
218940999|NCT01940172|DRUG|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
218941000|NCT03223519|DRUG|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
218941001|NCT03223519|DRUG|Placebo|Powder for oral solution administered TID for 3 days
218941002|NCT03223519|DRUG|Ibuprofen|Powder for oral solution administered TID for 3 days
218941003|NCT03223519|DRUG|Magnesium|Powder for oral solution administered TID for 3 days
218941004|NCT03223519|DRUG|Vitamin C|Powder for oral solution administered TID for 3 days
218941005|NCT03735524|OTHER|Exercise|Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
218941006|NCT00000156|DEVICE|Goggles|
219050292|NCT06163573|BIOLOGICAL|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
219050293|NCT06163573|BIOLOGICAL|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
219050294|NCT02545894|BEHAVIORAL|Cognitive therapy|"The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
219050295|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
219633732|NCT04828018|OTHER|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
219633733|NCT04828018|OTHER|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
219633734|NCT04828018|OTHER|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
218941007|NCT00000156|PROCEDURE|Ambient Light Reduction|
218941008|NCT02989428|PROCEDURE|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
218941009|NCT03883841|DRUG|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
218941010|NCT04303039|DRUG|ABP-671|ABP-671 Tablet 1.0 mg
218941011|NCT05709938|DRUG|Glargine and regular insulin versus NPH and regular insulin|"Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening."
218941012|NCT01697618|DRUG|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
218941013|NCT01697618|DRUG|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
218941014|NCT01421355|DRUG|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
218941015|NCT01929499|BIOLOGICAL|cytokine-induced killer cells|
218941016|NCT02123472|DRUG|Cephalexin|Administered Orally
218941017|NCT01229696|PROCEDURE|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
218941018|NCT01229696|PROCEDURE|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
218941019|NCT01852396|PROCEDURE|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
219050296|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
219050297|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
219633735|NCT04828018|OTHER|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
219633736|NCT01906216|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
218941020|NCT00811096|DRUG|Tinidazole|2gms, p.o. q.d. for 5 days
219050298|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
219050299|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
219050300|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
219050301|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
219633737|NCT01906216|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
219633738|NCT00640913|PROCEDURE|Reversal of defunctioning stoma|Reversal of defunctioning stoma
219633739|NCT01019694|DRUG|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
219633740|NCT01019694|DRUG|Combivent Respimat 20/100 mcg|Open label randomized parallel
219633741|NCT01019694|DRUG|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
219633742|NCT05753020|BEHAVIORAL|CKM Jumpstart Tool|The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
219633743|NCT06041360|DIAGNOSTIC_TEST|Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).|Neurological tests for diagnosis of peripheral neuropathy
219633744|NCT03297320|OTHER|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
219633745|NCT01831076|DRUG|Exemestane|Given PO
219633746|NCT01831076|DRUG|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
219633747|NCT00795002|DRUG|alvocidib|Given IV
219633748|NCT00795002|DRUG|mitoxantrone hydrochloride|Given IV
219633749|NCT00795002|DRUG|cytarabine|Given IV
219633750|NCT00795002|OTHER|pharmacological study|Correlative studies
219633751|NCT00795002|OTHER|laboratory biomarker analysis|Correlative studies
219633752|NCT04244084|DRUG|MMH-407|Oral use.
218941021|NCT00811096|DRUG|chloroquine|
218941022|NCT00918736|DRUG|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
219633753|NCT04244084|DRUG|Placebo|Oral use.
219633754|NCT05202067|BEHAVIORAL|pharmaceutical education|The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
219633755|NCT05352464|OTHER|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
218941023|NCT02049606|DRUG|LAYLA tablet|1 Tablet twice a day
218941024|NCT02049606|DRUG|CENATONE tablet|2 Tablets once a day
218941025|NCT04096976|OTHER|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
218941026|NCT02802267|DRUG|Inecalcitol|vitamin D receptor agonist
218941027|NCT02802267|DRUG|Placebo Oral Tablet|placebo
218941028|NCT02907632|DRUG|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
219633756|NCT05352464|OTHER|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position
219050302|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
218941029|NCT02907632|DRUG|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
218941030|NCT03142711|OTHER|No Medical Intervention|Validation of phone ePRO
218941031|NCT02292836|OTHER|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
218941032|NCT00838084|DRUG|LY2811376|Oral capsules
218941033|NCT00838084|DRUG|Placebo|Oral capsules
218941034|NCT04049149|OTHER|Biogenetic explanation and endocrinologist intensive managment|"* JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires"
218941035|NCT04049149|OTHER|Usual care management|"* JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires"
219050303|NCT06139627|OTHER|Best Practice|Receive usual care
219359995|NCT06018649|COMBINATION_PRODUCT|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
219633757|NCT03864679|OTHER|Exercise|Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
219633758|NCT04065984|DEVICE|Microstim 2v2 Stimulator|Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
219633759|NCT01052194|DRUG|Placebo|tablet, placebo b.i.d. for 12 weeks
219633760|NCT01052194|DRUG|VX-509|tablets, 25mg b.i.d. for 12 weeks
219633761|NCT01052194|DRUG|VX-509|tablet, 50 mg b.i.d. for 12 weeks
218941036|NCT01474018|DRUG|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
218941037|NCT03463642|DIETARY_SUPPLEMENT|vitamin D3|100,000IU
218941038|NCT03463642|DIETARY_SUPPLEMENT|Pill|Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
218941039|NCT03463642|DIETARY_SUPPLEMENT|orange syrup|100 drops orange syrup
219633762|NCT01052194|DRUG|VX-509|tablet, 100 mg b.i.d. for 12 weeks
219633763|NCT01052194|DRUG|VX-509|tablet, 150 mg b.i.d. for 12 weeks
218941040|NCT03463642|OTHER|mineral oil|Paraffinum Liquidum,Isopropyl Palmitate,Parfum
218941041|NCT03463642|DIETARY_SUPPLEMENT|Penetrator|Tangerine essential oil (10ml)
218941042|NCT04279418|DIETARY_SUPPLEMENT|Mixed functional foods supplementation|In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
218941043|NCT04279418|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
218941044|NCT01034748|DRUG|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
218941045|NCT02865707|DIETARY_SUPPLEMENT|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
218941046|NCT02865707|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
218941047|NCT00001378|DRUG|fenretinide|
219050304|NCT06139627|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219633764|NCT00026494|DRUG|temozolomide|
219633765|NCT00026494|DRUG|vinorelbine tartrate|
219633766|NCT00943540|DRUG|raltegravir QD|Raltegravir 800mg QD
219633767|NCT00943540|DRUG|atazanavir|atazanavir
219633768|NCT00943540|DRUG|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
218941048|NCT06382376|PROCEDURE|Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group|Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group
218941049|NCT02230319|OTHER|Cryotherapy|
219050305|NCT06139627|OTHER|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
219050306|NCT06139627|OTHER|Comprehensive Geriatric Assessment|Complete GA
219050307|NCT06139627|OTHER|Electronic Health Record Review|Ancillary studies
219050308|NCT06139627|OTHER|Survey Administration|Ancillary studies
219050309|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
219050310|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
219050311|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
219050312|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
219050313|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
219050314|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
219050315|NCT01786694|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
219050316|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
218941050|NCT02230319|DRUG|Paclitaxel|
219050317|NCT04410575|OTHER|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
219050318|NCT04410575|OTHER|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
219050319|NCT04410575|OTHER|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
219050320|NCT04410575|OTHER|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
218941051|NCT02433080|BEHAVIORAL|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
219050321|NCT04410575|OTHER|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
219050322|NCT04410575|OTHER|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
219050323|NCT04410575|OTHER|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
218941052|NCT01345357|DRUG|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
218941053|NCT01345357|DRUG|Gemcitabine|Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
218941054|NCT01345357|DRUG|Cisplatin|Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
218941055|NCT03825861|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
219050324|NCT04410575|OTHER|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
219050325|NCT04410575|OTHER|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
219050326|NCT04410575|OTHER|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
219050327|NCT04410575|OTHER|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
219050328|NCT04410575|OTHER|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
219050329|NCT04410575|OTHER|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
219050330|NCT05764369|BEHAVIORAL|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
219050331|NCT05764369|BEHAVIORAL|TAU|The TAU condition is the standard of care offered to parents in RT settings.
219050332|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
219050333|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
219050334|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
219050335|NCT06225258|DIETARY_SUPPLEMENT|Xanthohumol|Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day \*every 8 hours) at the dose of 2 mg.\\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
219050336|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
219050337|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
219050338|NCT05884099|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
219050339|NCT05884099|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
219050340|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
218941056|NCT01137604|DRUG|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
218941057|NCT01137604|DRUG|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
219050341|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
219050342|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
219050343|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
219050344|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
219050345|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
219050346|NCT01893424|DRUG|Sativex buccal spray|buccal spray
219050347|NCT01893424|DRUG|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
219050348|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
219050349|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
219050350|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
219050351|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
219050352|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
219050353|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
219050354|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
219050355|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
219050356|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
219050357|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
219050358|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
219050359|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
218941058|NCT04820140|PROCEDURE|Lymphatic drainage|Lymphatic drainage
218941059|NCT02149667|DEVICE|total hip arthroplasty implant|
218941060|NCT01961726|BIOLOGICAL|Placebo|Coronary Sinus Delivery
218941061|NCT01961726|BIOLOGICAL|30 mg dose of JVS-100|Coronary Sinus Delivery
218941062|NCT01961726|BIOLOGICAL|45 mg dose of JVS-100|Coronary Sinus Delivery
219050360|NCT06779409|OTHER|Back squat|2 sets of 3 repetitions of a back squat, set to 85% of the 1 repetition maximum weight
219050361|NCT06779409|OTHER|Wingate test|30 second maximal effort cycling test, with resistance at 7.5% bodyweight
219050362|NCT03638986|OTHER|No intervention planned|No Intervention planned.
219050363|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
219050364|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
219050365|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
219050366|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
219050367|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
219633769|NCT02949440|PROCEDURE|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
218941063|NCT03138980|BEHAVIORAL|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
218941064|NCT03688256|DEVICE|Obalon Balloon System|6 month Obalon Intragastric Balloons
218941065|NCT02567604|BEHAVIORAL|Focus Groups|at least three focus groups lasting approximately one hour
218941066|NCT06282133|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
218941067|NCT05352633|DRUG|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
218941068|NCT05352633|DRUG|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
218941069|NCT01057641|PROCEDURE|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
218941070|NCT01057641|OTHER|physiotherapy|physiotherapy
218941071|NCT00229515|OTHER|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
218941072|NCT00229515|OTHER|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
218941073|NCT00229515|OTHER|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
218941074|NCT00229515|OTHER|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
218941075|NCT04022395|DIAGNOSTIC_TEST|stress cardiac MRI|pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
218941076|NCT04919980|DEVICE|Innovalve MR system|Innovalve MR system
219050368|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
219050369|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
219050370|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
219050371|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
218941077|NCT02857348|BEHAVIORAL|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
218941078|NCT02857348|BEHAVIORAL|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
218941079|NCT04036292|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
218941080|NCT04036292|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
219050372|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
219050373|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
219050374|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
219050375|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
219050376|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
219050377|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
219050378|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
218941081|NCT05437250|DRUG|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
218941082|NCT04346355|DRUG|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
218941083|NCT03462511|BEHAVIORAL|HABIT Intervention|Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
219050379|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
219050380|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
219050381|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
219050382|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
219050383|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
219050384|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
219050385|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
219050386|NCT01813019|DRUG|Placebo|Matched placebo
218941084|NCT03462511|OTHER|Standard of Care|Standard of care used to treat patients with SCD
218941085|NCT03462511|OTHER|Education materials|Education materials provided to all patients enrolled in the trial
219050387|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
219050388|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
219050389|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
219050390|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
219633770|NCT02949440|PROCEDURE|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
219633771|NCT00529620|DRUG|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
219633772|NCT00529620|DRUG|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
219633773|NCT00529620|DRUG|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
219050391|NCT03783559|DRUG|TACE|TACE
219050392|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
219050393|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
219050394|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
219050395|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
219050396|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
218941086|NCT00042471|DRUG|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
219050397|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
219050398|NCT05351008|OTHER|Exercise program:|Core strengthening program
219050399|NCT00574860|DRUG|EN3285|Oral rinse
219206687|NCT06878352|OTHER|Educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024)).|"The educational intervention bundle was designed in accordance with the recommendations of GINA (2024), and will cover topics on the etiopathogenesis and pathophysiology of asthma, inhaler treatment, precipitating factors for crises, self-management skills, environmental control, as well as the importance of drawing up a written therapeutic plan and regular medical follow-up.~The educational intervention will be offered as a group activity and will be conducted in a single meeting, lasting approximately sixty minutes. Users will attend a standardized dialogical lecture using audiovisual resources, where they will have the opportunity to discuss and answer any questions related to the topics covered. At the end of the intervention, participants will receive a booklet containing all the points covered in the intervention, as well as a diary to record the amount of medication used, visits to the emergency room and asthma-related hospitalizations."
219206688|NCT07039812|DEVICE|Virtual Reality Headset|During the dressing change, nature-themed videos will be shown through a virtual reality headset that immerses the user in a 360-degree, three-dimensional virtual environment.
219633774|NCT02890576|OTHER|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
219633775|NCT03324620|OTHER|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
218941087|NCT05506228|OTHER|No intervention|
218941088|NCT02428283|DRUG|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
218941089|NCT02428283|DRUG|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
218941090|NCT02428283|DRUG|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
218941091|NCT03826368|DIETARY_SUPPLEMENT|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
218941092|NCT01702493|DRUG|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
219050400|NCT00574860|DRUG|Placebo|Oral rinse
219050401|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
219050402|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
219050403|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
219050404|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
219050405|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
219050406|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
219050407|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
219050408|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
219206689|NCT07039812|DEVICE|Eye Mask|A soft, adjustable, 3D-structured eye mask (Poblex brand) will be applied during the dressing procedure.
219206690|NCT07038941|DRUG|CG2001|combination of minoxidil and finasteride
219633776|NCT04941612|DEVICE|Activa IM-Nail|PLGA bioabsorbable intramedullary nail
219633777|NCT06130514|DEVICE|Ultrasound|Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL
219633778|NCT06130514|DEVICE|Fluoroscopy|Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
219633779|NCT04160039|DEVICE|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
219633780|NCT03185195|DRUG|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
219633781|NCT03185195|DRUG|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
218941093|NCT01702493|DRUG|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
218941094|NCT01702493|DRUG|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
218941095|NCT01702493|DRUG|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
218941096|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
219633782|NCT03185195|DRUG|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
219633783|NCT01684423|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
219633784|NCT01684423|DRUG|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
219633785|NCT01684423|DRUG|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
218941097|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
218941098|NCT02925416|DRUG|Oritavancin|Administered intravenously
218941099|NCT02925416|DRUG|Placebo (D5W)|Administered intravenously
218941100|NCT04705493|OTHER|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
218941101|NCT03595228|BIOLOGICAL|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
218941102|NCT01298908|PROCEDURE|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
218941103|NCT01298908|PROCEDURE|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
218941104|NCT01298908|PROCEDURE|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
218941105|NCT02811874|BEHAVIORAL|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
218941106|NCT02811874|BEHAVIORAL|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
218941107|NCT03716154|RADIATION|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
218941108|NCT02711241|DRUG|Dipyrone|1 gram by slow IV infusion
218941109|NCT02711241|DRUG|Papaverine|80 mg by slow intravenous infusion
218941110|NCT06533995|DEVICE|Visuprime|Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
218941111|NCT06533995|OTHER|Placebo|placebo eyedrop isotonic buffered saline solution
218941112|NCT02036151|DRUG|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
218941113|NCT02036151|DRUG|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
218941114|NCT01415414|DRUG|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
218941115|NCT00200356|DRUG|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
218941116|NCT00200356|DRUG|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
218941117|NCT01757990|DIETARY_SUPPLEMENT|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
218941118|NCT00137072|DRUG|Viagra (Sildenafil Citrate) 100 mg|
218941119|NCT05985460|DEVICE|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
219050409|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
219633786|NCT05822323|OTHER|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
218941120|NCT05985460|DEVICE|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
219050410|NCT02214121|DRUG|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
219633787|NCT05822323|PROCEDURE|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
219633788|NCT05458999|OTHER|Virtual reality headset during percutaneous coronary intervention|Virtual reality glasses during percutaneous coronary intervention
219633789|NCT06207097|OTHER|physiotherapy techniques|Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription
219633790|NCT04890197|DIETARY_SUPPLEMENT|tahini|48 grams tahini
219633791|NCT04890197|OTHER|control|no intervention
219633792|NCT00441129|DEVICE|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
219633793|NCT00441129|DEVICE|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
219633794|NCT01455597|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
219633795|NCT00405431|DRUG|Restasis|1 drop in study eye twice a day X 6 months
219050411|NCT02214121|DRUG|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
219050412|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219206691|NCT07038941|DRUG|Placebo foam|Placebo foam
219633796|NCT00405431|DRUG|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
219633797|NCT04632069|COMBINATION_PRODUCT|N acetyl cysteine + vagus nerve stimulation|NAC x 14 days, taVNS x 10 days
219633798|NCT03358069|DIAGNOSTIC_TEST|Emergence agitation scale|Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
219633799|NCT02443714|DEVICE|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
219633800|NCT02443714|DEVICE|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
218941121|NCT02900989|BEHAVIORAL|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
218941122|NCT06154577|DIAGNOSTIC_TEST|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
218941123|NCT01022008|DEVICE|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
218941124|NCT03495856|BEHAVIORAL|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
218941125|NCT00770419|OTHER|medical chart review|
218941126|NCT00770419|OTHER|questionnaire administration|
218941127|NCT00770419|PROCEDURE|psychosocial assessment and care|
219050413|NCT00715793|DRUG|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
219050414|NCT00715793|DRUG|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
219050415|NCT00715793|PROCEDURE|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
219050416|NCT04578847|DRUG|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
218941128|NCT06119750|DEVICE|NS Solution|This will be administered via skin patch.
219050417|NCT04578847|DRUG|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
219050418|NCT04578847|DRUG|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
219050419|NCT04578847|DRUG|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
219050420|NCT04856033|BEHAVIORAL|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
218941129|NCT06119750|OTHER|Normal Saline|This will be administered via skin patch.
218941130|NCT06119750|OTHER|SLS|This will be administered via skin patch.
219050421|NCT04856033|BEHAVIORAL|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
219050422|NCT01849588|DRUG|Sorafenib|
219050423|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
218941131|NCT01860183|DRUG|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
218941132|NCT02619162|DRUG|Nintedanib|Tablets of 100 mg. or 150 mg.
218941133|NCT02619162|DRUG|Letrozole|Tablet of 2.5 mg.
218941134|NCT04598191|DRUG|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
218941135|NCT04598191|DRUG|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
218941136|NCT00966914|DRUG|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
218941137|NCT00966914|DRUG|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
218941138|NCT01965574|PROCEDURE|Trendelenburg position|
218941139|NCT03219658|BEHAVIORAL|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
218941140|NCT02675556|DRUG|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
218941141|NCT02675556|DRUG|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
218941142|NCT00965965|BEHAVIORAL|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
218941143|NCT00965965|BEHAVIORAL|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
218941144|NCT05395793|OTHER|Support Group|Support Group with moderator
218941145|NCT05456685|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
218941146|NCT05456685|DRUG|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
218941147|NCT04522700|PROCEDURE|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
218941148|NCT03273218|DEVICE|Tiger catheter|
218941149|NCT03273218|DEVICE|Judkins catheter|
218941150|NCT02691871|DRUG|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
218941151|NCT02691871|DRUG|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
218941152|NCT02691871|DRUG|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
218941153|NCT03534479|DRUG|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
218941154|NCT02797002|OTHER|Assessment|
218941155|NCT03998839|OTHER|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
218941156|NCT05187273|BEHAVIORAL|Elastance Group|Fluids are given based on dynamic elastane value
218941157|NCT00830908|DEVICE|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
218941158|NCT06529081|RADIATION|Palliative Radiotherapy|Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).
218941159|NCT06529081|RADIATION|Radical/Ablative Radiotherapy|Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
218941160|NCT00435045|DRUG|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
218941161|NCT00435045|DRUG|atorvastatin|atorvastatin + placebo
218941162|NCT03316495|BEHAVIORAL|PAMPHLET|EXPOSURE TO PAMPHLETS
219050424|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
219050425|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
219050426|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
219050427|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
219050428|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
219050429|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
219050430|NCT02132000|DRUG|toremifene or tamoxifen|
219050431|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
219050432|NCT00914615|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
219050433|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
219050434|NCT04594096|BEHAVIORAL|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
219050435|NCT04594096|BEHAVIORAL|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
219050436|NCT02202928|BIOLOGICAL|DC-CIK|8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
219633801|NCT01156623|PROCEDURE|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
219050437|NCT02202928|RADIATION|Radiotherapy|45\~50 Gy in 25-28 fractions.
219050438|NCT02202928|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
219050439|NCT00002183|DRUG|Abacavir sulfate|
219633802|NCT00534781|DEVICE|plasma microdebrider|Coblation of the Achilles
219633803|NCT00534781|PROCEDURE|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
219050440|NCT00002183|DRUG|Amprenavir|
219633804|NCT04042623|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
219633805|NCT03325634|OTHER|Laboratory Biomarker Analysis|Correlative studies
219633806|NCT03325634|OTHER|Quality-of-Life Assessment|Ancillary studies
219050441|NCT00002183|DRUG|Lamivudine|
219050442|NCT00002183|DRUG|Zidovudine|
219050443|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
219050444|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
219050445|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
219050446|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
219050447|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led education module using virtual reality
219050448|NCT04278534|OTHER|Educational Intervention|Receive the usual verbal and written education materials
219050449|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led face-to-face education module
219633807|NCT03325634|OTHER|Questionnaire Administration|Ancillary studies
219633808|NCT03325634|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219633809|NCT03412734|DRUG|Chlorhexidine|Chlorhexidine preparation solutions
219633810|NCT03412734|DRUG|Iodine|Iodine-based preparation solutions
219633811|NCT00624936|DRUG|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
218941163|NCT05075005|OTHER|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
218941164|NCT05075005|OTHER|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
218941165|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.
218941166|NCT05247788|BEHAVIORAL|Performance feedback training|This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).
218941167|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training for controls|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
219050450|NCT04278534|OTHER|Survey Administration|Ancillary studies
219050451|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
219050452|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
219050453|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
219050454|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
219050455|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
219050456|NCT00472134|DRUG|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
219050457|NCT00472134|DEVICE|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
219050458|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219050459|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219050460|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
219050461|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
219050462|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
219050463|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
219050464|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
219050465|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
218941168|NCT04145518|DRUG|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
218941169|NCT00923611|DRUG|Fimasartan|
219050466|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
219050467|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
219050468|NCT04703452|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
219050469|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
219050470|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
218941170|NCT02462915|DEVICE|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
218941171|NCT02462915|DEVICE|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
219050471|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
219050472|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
219050473|NCT00169143|DRUG|Rituximab + ACVBP regimen plus Pegfilgrastim|
219050474|NCT00169143|PROCEDURE|Autologous stem cell transplant|
219050475|NCT00945984|PROCEDURE|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
219050476|NCT00191997|DRUG|Olanzapine|
218941172|NCT02462915|DRUG|lidocaine, propofol, fentanyl and cisatracurium|
219050477|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
219050478|NCT02627599|DEVICE|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
219050479|NCT02327923|DRUG|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
219050480|NCT02327923|DRUG|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
219050481|NCT02327923|DRUG|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
219050482|NCT02327923|DRUG|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
219050483|NCT02327923|DRUG|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
219050484|NCT02327923|DRUG|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
219050485|NCT02327923|DRUG|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
219050486|NCT02327923|DRUG|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
219050487|NCT02327923|DRUG|Ephedrine|
219050488|NCT02327923|DRUG|Morphine|
219050489|NCT02327923|DRUG|Ketorolac|
219050490|NCT02327923|DRUG|Ondansetron|
219050491|NCT02327923|DRUG|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
219633812|NCT00624936|DRUG|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
219633813|NCT01519219|RADIATION|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
219633814|NCT02467790|DRUG|PEX168|PEX 168: 200µg,Subcutaneous,one time.
219633815|NCT00423332|DRUG|Cediranib|45 mg oral tablet
219633816|NCT00423332|DRUG|Cediranib Placebo|oral tablet
218941173|NCT01297491|DRUG|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
218941174|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
218941175|NCT02874703|OTHER|Cardiac MRI/MRS|
218941176|NCT06354816|DRUG|Xylocaine 10% pump spray|"First volunteers will undergo insertion of PIVC into the vessel of dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Lidocaine spray 10 % serves as a local anesthesia is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
219633817|NCT05732337|DEVICE|Poxclin Coolmousse|cooling mousse for application in the skin
219633818|NCT04870385|BEHAVIORAL|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
219050492|NCT02327923|DRUG|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
219050493|NCT02327923|DRUG|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
219050494|NCT02327923|DRUG|Glycopyrrolate|10 mcg/kg with neostigmine
219050495|NCT01411306|OTHER|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
219633819|NCT04870385|BEHAVIORAL|Control|Control group waitlisted to receive prevention program after completion of final data collection.
219633820|NCT00812383|DEVICE|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
219633821|NCT00719485|OTHER|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
219633822|NCT02304861|PROCEDURE|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
219050496|NCT01411306|PROCEDURE|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
219050497|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant therapy (i.e. chemotherapy or hormonal/endocrine therapy) prior to surgery or over 4-6 weeks if not receiving neoadjuvant therapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant therapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
219050498|NCT01365273|DEVICE|Mepitel One|Dressing
219050499|NCT04043312|DEVICE|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
219050500|NCT04043312|DEVICE|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
219050501|NCT00504686|OTHER|manual therapy|manual therapy - thoracic spine thrust manipulation
219050502|NCT00504686|OTHER|exercise|therapeutic exercise
219050503|NCT00002188|DRUG|Alitretinoin|
218941177|NCT06354816|DRUG|Saline solution isotonic 0.9% NaCl|"First volunteers will undergo insertion of PIVC into the vessel at dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Physiological saline solution serves as a placebo and is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
218941178|NCT01050517|DRUG|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
218941179|NCT01050517|DRUG|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
218941180|NCT03152929|DRUG|Paravertebral Block|20-30 mL 0.5% Ropivacaine
218941181|NCT03152929|DRUG|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
218941182|NCT03276091|BEHAVIORAL|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
218941183|NCT02864654|PROCEDURE|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
218941184|NCT02864654|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
218941185|NCT02864654|PROCEDURE|Liposuction|
218941186|NCT01015638|DRUG|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
218941187|NCT01015638|DRUG|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
218941188|NCT04741126|OTHER|Manually assisted cough technique|Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
218941189|NCT04296448|DEVICE|Cellscope|Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
218941190|NCT02741973|OTHER|Yoga|
218941191|NCT02741973|OTHER|School sport|
218941192|NCT05646849|OTHER|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
218941193|NCT00000176|DRUG|Estrogen|
218941194|NCT00000176|DRUG|Estrogen and Progesterone|
218941195|NCT01455636|OTHER|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
218941196|NCT01455636|DIETARY_SUPPLEMENT|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
218941197|NCT01455636|OTHER|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
218941198|NCT01455636|DIETARY_SUPPLEMENT|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
218941199|NCT03739125|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
218941200|NCT03739125|DRUG|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
218941201|NCT01569893|OTHER|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
218941202|NCT04752098|DIAGNOSTIC_TEST|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
218941203|NCT05099263|DEVICE|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
218941204|NCT01838980|DEVICE|Motus GI Clean-Up Device|
218941205|NCT04033393|OTHER|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
219050504|NCT03044132|OTHER|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
219633823|NCT02304861|PROCEDURE|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
218941206|NCT04033393|OTHER|Treadmill training|Participants in the control group will receive treadmill training
219050505|NCT03499392|OTHER|psychological tests|psychological tests psychological interviews
218941207|NCT02895867|OTHER|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
218941208|NCT02895867|OTHER|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
218941209|NCT02895867|OTHER|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
218941210|NCT00021801|PROCEDURE|Islet Cell Transplantation|
218941211|NCT03764293|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
218941212|NCT03764293|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
218941213|NCT03764293|DRUG|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
218941214|NCT00540410|DRUG|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
218941215|NCT00540410|DRUG|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
219050506|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
219050507|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
218941216|NCT06455579|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for community healthcare providers (BTS-HP)|The sleep health education program includes 6 educational modules on different topics related to sleep health: (1) Basics of Sleep, 2) Sleep and Development, 3) Sleep Health, 4) Consequences of Deficient Sleep, 5) Sleep Health Disparities, and 6) Sleep Screening and Evaluation.
218941217|NCT06192017|DIAGNOSTIC_TEST|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
218941218|NCT04435691|DRUG|Azacitidine|Given SC or IV
218941219|NCT04435691|BIOLOGICAL|Magrolimab|Given IV
219050508|NCT02188238|OTHER|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
219050509|NCT01339390|BEHAVIORAL|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
219050510|NCT01339390|BEHAVIORAL|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
218941220|NCT04435691|DRUG|Venetoclax|Given PO
219050511|NCT00000946|BIOLOGICAL|HIV p24/MF59 Vaccine|
218941221|NCT05989893|BEHAVIORAL|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
218941222|NCT01703754|GENETIC|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
219050512|NCT00000946|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219050513|NCT00000946|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219050514|NCT00000946|BIOLOGICAL|rgp120/HIV-1 SF-2|
219050515|NCT04847674|DRUG|TEV-53275 Dose A|subcutaneous (sc) injection
219050516|NCT04847674|DRUG|TEV-53275 Dose B|subcutaneous (sc) injection
219050517|NCT04847674|DRUG|Placebo|Matching subcutaneous (sc) placebo injection
218941223|NCT01703754|DRUG|Palifosfamide|Small molecule chemotherapy, IV administration
218941224|NCT06541210|OTHER|Community Health Service|Access CoLLab Learning Health System to use any of the services
218941225|NCT06541210|OTHER|Questionnaire Administration|Ancillary studies
218941226|NCT02834936|DRUG|pyrotinib|
218941227|NCT03016741|BIOLOGICAL|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
218941228|NCT03016741|DRUG|Prednisone|Given by mouth
218941229|NCT03016741|DRUG|Abiraterone Acetate|Given by mouth
218941230|NCT03016741|DRUG|Enzalutamide|Given by mouth
218941231|NCT03891446|DRUG|Bimatoprost SR|Intraocular implant
218941232|NCT03891446|OTHER|Standard of Care|Standard of care treatment based on investigator's judgement.
218941233|NCT06395948|DRUG|APG777|APG777 subcutaneous injection
218941234|NCT06395948|DRUG|Placebo|Matching placebo subcutaneous injection
218941235|NCT04013659|OTHER|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
218941236|NCT02361632|DIETARY_SUPPLEMENT|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
218941237|NCT00776919|DRUG|clindamycin / benzoyl peroxide gel|Once a day application to the face
219050518|NCT02281136|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
219050519|NCT02281136|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
219050520|NCT05716828|OTHER|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
219050521|NCT01791361|OTHER|Other|No intervention other than routine medical care
219050522|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
219050523|NCT04779866|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
219050524|NCT04779866|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
219050525|NCT01193491|DRUG|IPI-493|Capsules, ascending dose, multiple schedules
219050526|NCT02702401|BIOLOGICAL|Pembrolizumab|IV infusion
219050527|NCT02702401|DRUG|Placebo|0.90% w/v sodium chloride IV infusion
219050528|NCT02702401|OTHER|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
219633824|NCT00984893|DRUG|zoledronic acid|
218941238|NCT00776919|DRUG|clindamycin gel|Once a day application to the face
218941239|NCT00776919|DRUG|BPO gel|Once a day application to the face
218941240|NCT00776919|DRUG|vehicle gel|Once a day application to the face
218941241|NCT03714581|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
218941242|NCT03959397|DRUG|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
218941243|NCT00003749|PROCEDURE|adjuvant therapy|
219050529|NCT02608112|DRUG|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
219050530|NCT02608112|DRUG|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
218941244|NCT00003749|PROCEDURE|conventional surgery|
219050531|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
219050532|NCT00012051|BIOLOGICAL|filgrastim|
219050533|NCT00012051|BIOLOGICAL|rituximab|
219050534|NCT00012051|DRUG|carmustine|
219050535|NCT00012051|DRUG|cisplatin|
219050536|NCT00012051|DRUG|cytarabine|
219050537|NCT00012051|DRUG|dexamethasone|
219050538|NCT00012051|DRUG|etoposide|
219050539|NCT00012051|DRUG|ifosfamide|
219050540|NCT00012051|DRUG|melphalan|
219050541|NCT00012051|DRUG|methotrexate|
219050542|NCT00012051|PROCEDURE|bone marrow ablation with stem cell support|
219633825|NCT00984893|DRUG|Any oral bisphosphonates marketed in Canada|
219633826|NCT02682693|DRUG|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
219633827|NCT02682693|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
219633828|NCT02682693|DRUG|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
219633829|NCT02682693|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
219633830|NCT02682693|DRUG|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
219633831|NCT02682693|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
218941245|NCT00003749|RADIATION|brachytherapy|
218941246|NCT00003749|RADIATION|radiation therapy|
218941247|NCT00238342|GENETIC|proteomic profiling|
219050543|NCT00012051|PROCEDURE|peripheral blood stem cell transplantation|
219050544|NCT00012051|RADIATION|radiation therapy|
219050545|NCT05069922|OTHER|Fresh Frozen Plasma|Fresh Frozen Plasma
219050546|NCT06082466|PROCEDURE|FRAMED Infrainguinal Venous Bypass|The harvested vein graft will be covered with a mesh.
219050547|NCT06082466|PROCEDURE|Conventional Autologous Bypass|The harvested vein graft will be used without a mesh coating.
219050548|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
219050549|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
219050550|NCT03424031|PROCEDURE|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
219050551|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
219050552|NCT01106456|BEHAVIORAL|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
219050553|NCT01106456|BEHAVIORAL|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
219050554|NCT01106456|DRUG|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
219050555|NCT03366064|BIOLOGICAL|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
219633832|NCT02682693|DRUG|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
218941248|NCT00238342|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
218941249|NCT00238342|PROCEDURE|biopsy|
218941250|NCT03945617|BEHAVIORAL|Unified Treatment Protocol|The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
218941251|NCT03179605|DRUG|DFD06|Apply twice per day for 15 days
218941252|NCT04500262|DEVICE|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
219050556|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
219206692|NCT07038954|OTHER|Stone Composition Analysis|This intervention involves the compositional analysis of kidney stone fragments retrieved during surgical procedures. The stone samples are analyzed using X-ray diffraction (XRD) and infrared spectroscopy (IR) to determine their crystal composition. This is a non-invasive, laboratory-based diagnostic procedure. No drug, device, or therapeutic intervention was administered to participants as part of this observational study.
219633833|NCT04747886|BEHAVIORAL|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
218941253|NCT04500262|DEVICE|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
218941254|NCT02001636|DRUG|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
218941255|NCT02001636|DRUG|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
218941256|NCT02618499|DRUG|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
218941257|NCT00711477|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
218941258|NCT00711477|DRUG|Placebo|
218941259|NCT00711477|OTHER|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
218941260|NCT05028244|DIAGNOSTIC_TEST|venous ultrasound of lower extremity|Patients are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compression and doppler flow evaluation
218941261|NCT02400983|DEVICE|Pacemaker, ICD|
218941262|NCT02163941|BEHAVIORAL|Compassion Training|
218941263|NCT04858022|BEHAVIORAL|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
218941264|NCT04858022|OTHER|No treatment - waitlist|10-week period of no treatment
218941265|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
219050557|NCT01924169|DRUG|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
219206693|NCT06717867|DIETARY_SUPPLEMENT|Palmitoylethanolamide (PEA)|Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.
219633834|NCT04747886|BEHAVIORAL|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
219633835|NCT05901935|DRUG|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
219633836|NCT05901935|DRUG|Trastuzumab|IV, 6 mg/kg, D1, Q3W
219206694|NCT06717867|OTHER|Placebo|Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
219633837|NCT05901935|DRUG|Vinorelbine Tartrate|IV, 25 mg/m\^2，D1、D8，Q3W
219633838|NCT05901935|DRUG|Capecitabine tablets|PO 1000 mg/m\^2, bid, D1-D14, Q3W
219633839|NCT05082675|PROCEDURE|HLA Matched allogeneic transplant|
219633840|NCT00410332|DRUG|Traumeel S|homeopathic remedy
219633841|NCT00410332|DRUG|Placebo|placebo drug, identical in size, form and taste as treatment remedy
218941266|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
218941267|NCT05213728|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
218941268|NCT04006275|DRUG|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
218941269|NCT04006275|DRUG|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
218941270|NCT02878798|DRUG|topiramate|Oral topiramate at a target dose of 50mg twice daily.
218941271|NCT02878798|OTHER|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
218941272|NCT05081297|OTHER|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
218941273|NCT00029770|PROCEDURE|Chiropractic spinal manipulation|
218941274|NCT00029770|DRUG|Acetaminophen|
218941275|NCT00029770|BEHAVIORAL|Self-care|
218941276|NCT00029770|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
218941277|NCT00029770|DRUG|Tylenol with codeine|
219050558|NCT01924169|BIOLOGICAL|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
219050559|NCT01924169|BIOLOGICAL|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
219050560|NCT05325463|PROCEDURE|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
219206695|NCT06874127|DRUG|Nucleos(t)ide Analogs (NA)|all patients received NAs
219206696|NCT06703710|DRUG|JW2286|a single administration of JW2286 per dose
219206697|NCT06703710|DRUG|Placebo of JW2286|a single administration of Placebo of JW2286 per dose
219206698|NCT06715085|DRUG|Plasma Rich in Growth Factors (PRGF)|The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
219206699|NCT06715085|DRUG|Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.|The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
219206700|NCT07037979|OTHER|Not applicable- observational study|non-applicable
219206701|NCT07040098|DRUG|Sintilimab|PD-1 inhibitor
219633842|NCT06368271|DIETARY_SUPPLEMENT|Lipidomics|Health beneficial effects of medium-chain fatty acids
219633843|NCT04156711|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
219633844|NCT00017082|DRUG|oxaliplatin|
219633845|NCT00169611|DRUG|methylphenidate|
219633846|NCT04771221|DIAGNOSTIC_TEST|pH metry|The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.
219633847|NCT04771221|DIAGNOSTIC_TEST|Filling out the questionnaire|Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem
219633848|NCT04771221|DEVICE|Endoscopic laryngoscopy|Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
219633849|NCT04771221|DEVICE|Acoustic voice analysis|acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
219633850|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
219633851|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
219633852|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
219633853|NCT01602367|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
219050561|NCT05325463|PROCEDURE|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
219633854|NCT05137444|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.
219050562|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
219050563|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
219206702|NCT07040098|RADIATION|Short-course radiotherapy|Pelvic radiation, SCRT, 5 Gy x 5 alone
219206703|NCT07040098|RADIATION|Long-course concurrent chemoradiotherapy|Pelvic radiation, 50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine (825 mg/m2, twice a day).
219206704|NCT07040098|COMBINATION_PRODUCT|CAPOX|chemotherapy regimen, Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle)
219633855|NCT05137444|BIOLOGICAL|Placebo|Aluminum hydroxide
219633856|NCT04483960|DRUG|(Arm Closed) Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
219633857|NCT04483960|DRUG|(Arm Closed) Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
219633858|NCT04483960|DRUG|(Arm Closed) Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
219633859|NCT04483960|DRUG|(Arm Closed) Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
219633860|NCT04483960|BIOLOGICAL|(Arm Never Opened) Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
219633861|NCT04483960|DRUG|Nirmatrelvir-Ritonavir|The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
219633862|NCT04483960|DRUG|Remdesivir|The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
219633863|NCT02183038|DRUG|Meloxicam low|
219633864|NCT02183038|DRUG|Meloxicam high|
219633865|NCT02183038|DRUG|Naproxen sodium|
219633866|NCT02183038|DRUG|Meloxicam placebo low|
219633867|NCT02183038|DRUG|Meloxicam placebo high|
219633868|NCT02183038|DRUG|Naproxen sodium placebo|
219633869|NCT04952025|DIAGNOSTIC_TEST|Diagnostic criteria|Diagnostic criteria of ALS
219633870|NCT06428123|BEHAVIORAL|Mirror Therapy on present Lower Limb|Patients will be seated close to a table on which a mirror will placed vertically. The normal (i.e., no amputated limb) will be placed in front of the mirror and made to perform movements of the different joints while the patient looking into the mirror.
219633871|NCT06428123|DIAGNOSTIC_TEST|Mental Imagery on present Lower Limb|"Mental imagery technique in which patients will be instructed to concentrate on sensations from each area of the body, including the phantom limb. Patients will be advised to imagine comfortable, thorough movement and sensation in the phantom limb, such that they could stretch away the pain, and finally to allow the limb to rest in a comfortable position. The actual therapy of moving and feeling the limb will lasted for 5 minutes. Patients will be asked to perform 40 minutes of meditation and imagery exercises."
219633872|NCT03581058|DRUG|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
219633873|NCT03090958|BEHAVIORAL|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
219633874|NCT05312463|DRUG|Tongjiang granule|Tongjiang granules, 1 bag / time, 3 times / day.
219633875|NCT05312463|DRUG|Tongjiang granule simulant|Tongjiang granule simulant,1 bag / time, 3 times / day.
219633876|NCT03738436|OTHER|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
219633877|NCT03738436|OTHER|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
219633878|NCT01417741|DEVICE|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
219633879|NCT00903708|DRUG|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
219633880|NCT02782559|DRUG|Sildenafil|
219633881|NCT02782559|DRUG|Placebo|Color and size matched to active drug (sildenafil)
219633882|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
219633883|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
219633884|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
218941278|NCT01608932|PROCEDURE|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
219633885|NCT05847465|OTHER|Bike stress test|This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).
219633886|NCT05847465|OTHER|Heat Tolerance Test|"The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test."
219633887|NCT05847465|OTHER|Heat nociception test|"This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded."
219633888|NCT04439448|RADIATION|dual-energy X-ray absorptiometry (DEXA) scan|Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass
219633889|NCT04439448|OTHER|Carotid and branchial artery ultrasound|Ultrasound to assess carotid plaque and brachial artery flow mediated dilation
219633890|NCT04439448|DIAGNOSTIC_TEST|2-hour oral glucose tolerace test|Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
219633891|NCT04439448|DIAGNOSTIC_TEST|Blood collection|Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
219633892|NCT06450392|DRUG|Tranexamic acid injection|100 mg/mL (manufactured concentration) local TXA injection in the orbit
219633893|NCT06450392|DRUG|Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)|1g IV TXA
219633894|NCT06450392|DRUG|normal saline - injection|0.9% Normal Saline injection in the orbit
219633895|NCT06450392|DRUG|normal saline - intravenous|0.9% IV Normal Saline
219633896|NCT04997668|DEVICE|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
218941279|NCT00125528|DRUG|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
219050564|NCT02334228|BEHAVIORAL|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
219050565|NCT02334228|BEHAVIORAL|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
219206705|NCT06886776|BEHAVIORAL|Implementation package (training and facilitation)|"Training includes an initial presentation on S.A.F.E. Firearm, S.A.F.E. Firearm informational guides and other resources to support delivery, and recommendations for additional, optional self-guided learning resources.~Facilitation will last twelve months at each site. It may involve 1) a pre-implementation readiness assessment for each clinic to identify potential implementation barriers and develop relationships with constituents; 2) kick-off meetings at the launch of the trial, at which clinic staff will identify how and where S.A.F.E. Firearm will be implemented within the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain S.A.F.E. Firearm for future years."
219206706|NCT07038005|DRUG|SPGL008|Biological product
219206707|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H1coil|Participants will receive dTMS treatment with H1 coil
219206708|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H7 coil|Participants will receive dTMS treatment with H7 coil
219633897|NCT04997668|DEVICE|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
219633898|NCT03200769|DEVICE|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
219633899|NCT03200769|DEVICE|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
219633900|NCT04132869|BEHAVIORAL|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
219633901|NCT05143346|DEVICE|Intubation|Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
219050566|NCT04056559|DEVICE|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
219050567|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
219050568|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
219633902|NCT02374268|BEHAVIORAL|Exercise program alone|
219633903|NCT02374268|DIETARY_SUPPLEMENT|Combined exercise program and nutrition supplement|
218941280|NCT00125528|DRUG|placebo|placebo bid
218941281|NCT00101452|DRUG|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
218941282|NCT00101452|DRUG|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
218941283|NCT00101452|DRUG|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
218941284|NCT00536497|DRUG|GW842166X|
218941285|NCT03292172|DRUG|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
218941286|NCT03292172|DRUG|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
218941287|NCT02236117|OTHER|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, \>80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
218941288|NCT03060161|BEHAVIORAL|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
218941289|NCT02526030|DRUG|Aripiprazole|
218941290|NCT02526030|DRUG|Quetiapine|
218941291|NCT02526030|DRUG|Ziprasidone|
219633904|NCT02374268|OTHER|Waitlist control group|
219633905|NCT00256386|DEVICE|Electronic Medical Record (EMR) to clinician's in-basket|
219633906|NCT00256386|DEVICE|Automated Voice Message (AVM) reminder to patient's phone|
219633907|NCT00256386|PROCEDURE|Pharmacy Team phone call-letter followup|
218941292|NCT02717806|BEHAVIORAL|PATHway|Patients will use the PATHway platform for 6 months
218941293|NCT00409370|DEVICE|SOMA safe enclosure|
218941294|NCT05750771|DEVICE|DES|Second-generation drug-eluting stents
218941295|NCT05750771|DEVICE|DCB|Drug-coated balloon with paclitaxel as drug coating
218941296|NCT01430169|BIOLOGICAL|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
218941297|NCT05928546|DRUG|Quercetin|"Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket ."
218941298|NCT05928546|DEVICE|scaling and root planing|\- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
218941299|NCT01014910|OTHER|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
218941300|NCT01014910|DEVICE|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
218941301|NCT00583076|DRUG|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
218941302|NCT02724397|DEVICE|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
218941303|NCT02724397|DEVICE|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
218941304|NCT05518747|DIETARY_SUPPLEMENT|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
218941305|NCT05518747|DIETARY_SUPPLEMENT|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
218941306|NCT06120829|PROCEDURE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
218941307|NCT06120829|DEVICE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
218941308|NCT06120829|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy
218941309|NCT05262829|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
218941310|NCT04662515|PROCEDURE|Type of surgery|surgical or non-surgical extraction one or more teeth
219633908|NCT00026117|DRUG|BenFin|
219633909|NCT00026117|OTHER|placebo|
219633910|NCT01228890|BEHAVIORAL|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent \[14 modules\] and parent \[5 modules\] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
219633911|NCT01228890|BEHAVIORAL|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education \[psycho-education described below\], provider training \[described in Case Finding and Recruitment\], active monitoring and referral \[case management, discussed under assessments\], physician and nurse education and routine contact with PCP \[study design rationale\]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
218941311|NCT04662515|DRUG|Dabigatran|
218941312|NCT04662515|DRUG|Rivaroxaban|
218941313|NCT04662515|DRUG|Apixaban|
218941314|NCT04662515|DRUG|Edoxaban|
218941315|NCT04662515|DRUG|Warfarin|
218941316|NCT00637702|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
218941317|NCT04521049|DRUG|Saxagliptin 5mg|Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
218941318|NCT00666484|DRUG|cyclophosphamide|
218941319|NCT00666484|DRUG|doxorubicin hydrochloride|
218941320|NCT00666484|DRUG|etoposide|
218941321|NCT00666484|DRUG|prednisolone|
218941322|NCT00666484|DRUG|procarbazine hydrochloride|
218941323|NCT00666484|DRUG|vincristine sulfate|
218941324|NCT00666484|RADIATION|radiation therapy|
218941325|NCT00145977|DRUG|Alendronate|alendronate 70 mg once weekly
218941326|NCT00145977|DIETARY_SUPPLEMENT|Calcium Citrate|600 mg of calcium citrate
218941327|NCT00145977|DIETARY_SUPPLEMENT|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
218941328|NCT06205186|BEHAVIORAL|Army Health|A whole health mobile application for Soldiers
218941329|NCT04813185|BEHAVIORAL|Bridging the Gap|"Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
218941330|NCT03966430|PROCEDURE|damage control surgery|"1. Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~2. ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~3. Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
218941331|NCT03966430|PROCEDURE|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~1. The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~2. After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~3. After the operation, re-laparotomy is performed on demand."
218941332|NCT02202083|OTHER|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
218941333|NCT02966054|BEHAVIORAL|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
218941334|NCT04512612|DIAGNOSTIC_TEST|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
218941335|NCT04512612|DIAGNOSTIC_TEST|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
218941336|NCT04215497|OTHER|PSSE|"Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home."
218941337|NCT00275548|DRUG|Pegasys|135-180 micrograms administered sc once weekly
218941338|NCT00275548|DRUG|Copegus|400-1200 mg/day for 48 weeks
218941339|NCT00757471|PROCEDURE|Brillant Blue|Membrane Peeling with Brillant Blue
218941340|NCT00757471|PROCEDURE|Indocyanine Green|Membrane Peeling with indocyanine Green
218941341|NCT02816385|PROCEDURE|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
218941342|NCT02816385|PROCEDURE|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
219050569|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
219633912|NCT00774514|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
219633913|NCT04398303|BIOLOGICAL|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
219633914|NCT04398303|BIOLOGICAL|ACT-20-CM|100 ml of conditioned media only
219633915|NCT04398303|BIOLOGICAL|Placebo|100 ml of MEM-α
219050570|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
219050571|NCT03494036|DIETARY_SUPPLEMENT|Synbiotic|capsule
219050572|NCT03494036|DIETARY_SUPPLEMENT|Placebo|capsule
219050573|NCT04664504|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
219050574|NCT04664504|RADIATION|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
219050575|NCT04664504|RADIATION|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
219050576|NCT04664504|DRUG|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
219050577|NCT04664504|DRUG|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
219050578|NCT04664504|PROCEDURE|TME|Total mesorectal excision
219050579|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
219050580|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
219050581|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
219050582|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
219050583|NCT03947151|DRUG|Degarelix injection(s)|1 or 2 degarelix injection(s)
219050584|NCT04292730|DRUG|Remdesivir|Administered as an intravenous infusion
219050585|NCT04292730|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
219050586|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
219050587|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
219050588|NCT01527292|RADIATION|Stereotactic Radiation Therapy|SRT only
219050589|NCT01527292|RADIATION|SRT with Vertebral Augmentation Procedure|SRT with VAP
219050590|NCT02119546|OTHER|Aerobic exercise|Aerobic exercise and dual-task training
219050591|NCT02119546|OTHER|Stretch exercise|Stretch exercise \& sitting balance
219050592|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
219050593|NCT03938142|OTHER|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
219050594|NCT06143475|DEVICE|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
219050595|NCT06143475|OTHER|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
219050596|NCT01423448|OTHER|bulletin board|An asynchronous online bulletin board for people with experience of depression
219050597|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
219050598|NCT02102633|DRUG|Bosutinib|Bosutinib 500 mg orally
219633916|NCT05961943|BEHAVIORAL|RESPONSE-2-PAD|The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
218941343|NCT05415917|DRUG|Gemcitabine and Capecitabine|"A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."
218941344|NCT00782834|DRUG|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
218941345|NCT05879094|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
218941346|NCT03521440|BEHAVIORAL|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
218941347|NCT03521440|BEHAVIORAL|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
218941348|NCT02657785|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
218941349|NCT04059588|DRUG|2141 V-11|intratumoral injection of 2141-V11
218941350|NCT06327841|OTHER|sesame oil|15min of oil pulling with 15ml sesame oil for 8 weeks
219050599|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
219050600|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
219050601|NCT02353091|DEVICE|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
219050602|NCT01302821|BIOLOGICAL|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
219633917|NCT02215395|DRUG|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
219633918|NCT02528110|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
219633919|NCT02528110|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
219633920|NCT02528110|OTHER|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
219633921|NCT02528110|OTHER|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
218941351|NCT06327841|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
218941352|NCT02055118|BIOLOGICAL|idursulfase-IT|10mg
218941353|NCT02055118|OTHER|No IT treatment|Standard of Care
219050603|NCT01302821|DRUG|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
219050604|NCT01302821|RADIATION|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
219050605|NCT00423969|DRUG|Galantamine|
219050606|NCT00423969|DRUG|Escitalopram|
219050607|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
219050608|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
219050609|NCT02911675|DEVICE|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
219050610|NCT02485028|DRUG|Dapoxetine 30mg tablet|
219050611|NCT02485028|DRUG|Mirodenafil 50mg tablet|
219050612|NCT00096044|BIOLOGICAL|rituximab|IV
219050613|NCT00096044|DRUG|lenalidomide|Oral
219050614|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
219633922|NCT04510623|OTHER|ARBs and/or ACE inhibitors|This is an observational study only.
219050615|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
219050616|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
219050617|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
219050618|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
219050619|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
219050620|NCT02920983|DEVICE|somofilcon A|contact lens
219050621|NCT02920983|DEVICE|nelfilcon A II 2|contact lens
219050622|NCT02920983|DEVICE|omafilcon A ll 2|contact lens
219050623|NCT06137443|DEVICE|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
219633923|NCT04510623|OTHER|Usual Care|This is an observational study only.
219633924|NCT03231995|BIOLOGICAL|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
219050624|NCT00895180|BIOLOGICAL|olaratumab|Given IV
219050625|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
219050626|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
219050627|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
219050628|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
219050629|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
219633925|NCT05800938|DRUG|Isosorbid mononitrate|Imdur tablets were given twice daily for 4 weeks
219633926|NCT05800938|DRUG|Placebo|Placebo tablets were given twice daily for 4 weeks
219633927|NCT05622838|DIAGNOSTIC_TEST|Alpha1 -Antitrypsin level|measuring alpha1 -antitrypsin level in pregnant women
219633928|NCT01136356|DRUG|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
219633929|NCT01136356|DRUG|morphine|parenteral morphine may be administered multiple times each day
219633930|NCT01453270|DEVICE|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
219050630|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
219050631|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
219050632|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
219050633|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
219050634|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
219050635|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
219050636|NCT03851016|BEHAVIORAL|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
219050637|NCT03851016|BEHAVIORAL|Usual Care|Three weeks of Usual Care with no visits from research team
219050638|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
219050639|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
219050640|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
219050641|NCT01619670|DEVICE|Apligraf|non adhesive layer
219050642|NCT00586469|BIOLOGICAL|Fluviral|One dose, Intramuscular injection
219050643|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
219050644|NCT01971138|OTHER|this is a survey|
219050645|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
219050646|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
219206709|NCT06877195|PROCEDURE|CABG|Aortocoronary bypass procedures with venous grafts on right coronary territory
219050647|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
219050648|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
219050649|NCT00832351|PROCEDURE|Mobilisation|Mobilisation
219050650|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
219050651|NCT00218348|DRUG|Dextro-Amphetamine Sulfate|
219206710|NCT06883825|OTHER|Myofunctional Therapy|Participants will only receive myofunctional rehabilitation therapy. This treatment includes massage and exercises to improve the function of the jaw muscles.
219633931|NCT01453270|OTHER|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
219633932|NCT00220688|DEVICE|Acupressure Wristbands|
219633933|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
219633934|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
219633935|NCT00402688|DRUG|levofloxacin|500mg tablet once daily for 4 weeks.
219633936|NCT00221871|DRUG|Different dosages of Ketamine|
219633937|NCT06044415|DRUG|JWH018|A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
219633938|NCT06044415|OTHER|non-active control (no substance)|Participants will inhale from a vaporizer with an empty chamber.
219633939|NCT04058093|BEHAVIORAL|Functional Training Program|"Functional training program (FTP) include:~1. Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~2. Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
219633940|NCT05320315|DEVICE|Foto Ultra ISDIN® Solar Allergy Fusion Fluid|The tested MD is a very high protection sunscreen
219633941|NCT01308827|PROCEDURE|Blood culture|A baseline blood culture will be obtained in all participants
219633942|NCT01308827|PROCEDURE|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
219633943|NCT06495476|DRUG|Ginkgo biloba extract 50 dropping pills|Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.
219633944|NCT06495476|DRUG|Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant|"Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill."
219206711|NCT06883825|OTHER|Myofunctional Therapy + Respiratory Exercises|Participants will receive breathing exercises as well as myofunctional therapy. This treatment includes exercises to improve jaw function and support the respiratory system.
219633945|NCT05259462|BEHAVIORAL|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
219633946|NCT03839862|DRUG|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
218941354|NCT05901389|DRUG|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
218941355|NCT05901389|DRUG|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
218941356|NCT04828317|OTHER|Pork Challenge|Double blind oral challenges comparing wild-type and alpha-gal free pork.
218941357|NCT05828056|DEVICE|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
219050652|NCT03151356|DEVICE|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
219050653|NCT03212963|DRUG|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
219050654|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
219633947|NCT00927862|GENETIC|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
219050655|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
219050656|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
219050657|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
219050658|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
219050659|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
219050660|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
219050661|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
219050662|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
219050663|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
219050664|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
219050665|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
219050666|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
219050667|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
219050668|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
219050669|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
219050670|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
219206712|NCT06883825|OTHER|Myofunctional Therapy + Thoracic Region Exercises|Participants will receive myofunctional therapy as well as exercises for the thoracic region. This treatment includes exercises to improve jaw function and increase the flexibility of the chest area.
218941358|NCT04239612|BEHAVIORAL|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
218941359|NCT02281383|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|
218941360|NCT03572127|OTHER|Diet|High protein diet derived from either animal or non-animal sources.
218941361|NCT02758483|OTHER|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
218941362|NCT02758483|OTHER|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
218941363|NCT03497312|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
219050671|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
218941364|NCT00000426|DRUG|Calcium supplement|
218941365|NCT02570048|DEVICE|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
218941366|NCT05838898|DEVICE|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
218941367|NCT02633696|DRUG|silybin phosphatidylcholine|
218941368|NCT02633696|DRUG|Legalón SIL|
218941369|NCT02259088|DRUG|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
218941370|NCT02259088|PROCEDURE|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
218941371|NCT02259088|DRUG|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
218941372|NCT02259088|PROCEDURE|Sham laser|Imitation of an active laser
218941373|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
218941374|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
219050672|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
219050673|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
219050674|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
219365984|NCT01447238|DEVICE|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
219633948|NCT00927862|GENETIC|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
218941375|NCT05942235|OTHER|Education|Education
219633949|NCT00927862|OTHER|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients \>=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
218941376|NCT03849625|DRUG|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
219633950|NCT04306965|DRUG|Apremilast|30 mg twice daily (BID)
218941377|NCT05434780|OTHER|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
218941378|NCT01605630|BEHAVIORAL|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
218941379|NCT01605630|BEHAVIORAL|Control|standard of care
218941380|NCT00888199|DEVICE|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
218941381|NCT05376332|DEVICE|Sonomyographic Prosthesis|The sonomyographic system will include a custom-fitted test socket incorporating ultrasound transducers and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
218941382|NCT05376332|DEVICE|Myoelectric direct control prosthesis|The direct control system will include a custom-fitted test socket incorporating dual-site electrodes and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
218941383|NCT05376332|DEVICE|Myoelectric pattern recognition prosthesis|The pattern recognition system will include the subject's clinically-prescribed socket and commercially-available pattern recognition technology (IBT Sense). The pattern recognition system will not be fitted as part of this study, as subjects will already be trained users prior to enrolling in the study.
218941384|NCT00464971|DRUG|estradiol, 25 mcg|
218941385|NCT01924416|BEHAVIORAL|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
218941386|NCT01924416|BEHAVIORAL|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
219050675|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
219050676|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
219050677|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
218941387|NCT05315895|OTHER|natural aging process|To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.
218941388|NCT05386407|DIAGNOSTIC_TEST|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
219050678|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
219050679|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
219050680|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
219050681|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
219050682|NCT01831375|BEHAVIORAL|Speak Up|Intervention group\_treatment group
219050683|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
219633951|NCT05167630|OTHER|prognostic marker|prognostic marker
219633952|NCT00820248|BIOLOGICAL|panitumumab|Given IV
219633953|NCT00820248|DRUG|cisplatin|Given IV
219050684|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
219050685|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
219050686|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
219050687|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
219050688|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
219050689|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
219050690|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
219206713|NCT06886919|BIOLOGICAL|Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells|"About 6 subjects will be included in the study, and a 3+3 dose escalation method will be used. The dosage will be gradually increased in two dose groups: 1 × 10 \^ 8 CAR-T cells/dose and 2 × 10 \^ 8 CAR-T cells/dose. Three subjects are enrolled in each dose group first, and within the same dose group, the cell transfusion interval between the first two subjects should not be less than 14 days. If no dose limiting toxicity (DLT) is observed in a certain dose group, the dose will be increased to the next dose; If one case of DLT occurs, this dose group needs to be divided into three additional subjects (a total of six subjects). If no new DLT occurs, the dosage will be increased to the next dose; If more than 1/6 of the 6 subjects develop DLT, the dose escalation will be terminated, and the Safety Review Committee (SRC) will discuss whether to reduce the dose and continue the monotherapy study."
219633954|NCT00820248|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
219633955|NCT00820248|RADIATION|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
219633956|NCT00820248|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
219633957|NCT04973969|OTHER|Decapeptyl|diagnosis of predictio value
219633958|NCT05393648|DEVICE|Accelerated Theta Burst Stimulation|Cool B65- A/P - active side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
219633959|NCT05393648|DEVICE|Sham accelerated Theta Burst Stimulation|Cool-B65 A/P - sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
219633960|NCT05184595|OTHER|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
219633961|NCT05184595|OTHER|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
219633962|NCT03267134|DEVICE|Hydrus Microstent|Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
219633963|NCT03267134|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
219633964|NCT03259425|DRUG|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
219050691|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
219050692|NCT00079352|DRUG|alvocidib|Given IV
219633965|NCT03259425|DRUG|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
218941389|NCT06210360|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14 day cycle
218941390|NCT06210360|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14 day cycle
219050693|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
219050694|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
219050695|NCT06151717|OTHER|Non-Interventional Study|Non-interventional study
219050696|NCT04921514|BEHAVIORAL|SASRQ questionnaire|"During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5)."
219050697|NCT04921514|BEHAVIORAL|PCL-5 with LEC-5 questionnaire|"This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD."
219050698|NCT02705690|DEVICE|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
219050699|NCT03551210|DRUG|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
219050700|NCT03551210|DRUG|Nemonoxacin|Capsules, 250 mg
219633966|NCT02020538|OTHER|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
219633967|NCT02020538|OTHER|High-chloride perioperative intravenous fluid strategy|
219633968|NCT00018941|BIOLOGICAL|aldesleukin|
219633969|NCT02237196|BIOLOGICAL|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
219633970|NCT02237196|BIOLOGICAL|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
218941391|NCT06210360|DRUG|5-FU|2400 mg/m² continuous IV infusion in 46 h
218941392|NCT06210360|DRUG|LV|400 mg/m² on Day 1 of a 14 day cycle
218941393|NCT02515721|DEVICE|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
219633971|NCT02237196|BIOLOGICAL|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
219050701|NCT03551210|DRUG|Tavanic|Solution for infusion, 500 mg (100 ml)
219050702|NCT03551210|DRUG|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
219050703|NCT03551210|DRUG|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
219050704|NCT03551210|DRUG|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
219633972|NCT02237196|BIOLOGICAL|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
219633973|NCT00641602|DRUG|Esomeprazole|40mg once daily
219633974|NCT00641602|DRUG|Lansoprazole|30mg once daily
219633975|NCT05251961|PROCEDURE|operative deformity correction|"* The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.~* Procedure will be done under anaesethia~* Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod"
218941394|NCT02515721|DEVICE|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
218941395|NCT03323567|DRUG|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
218941396|NCT03323567|DRUG|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
218941397|NCT03323567|DRUG|Saline Solution, Hypertonic|intramuscular Saline injection
218941398|NCT00538811|DRUG|interferon alpha-2b, ribavirin, interferon-gamma,|
218941399|NCT00538811|DRUG|interferon alpha-2b, ribavirin, amantadine|
218941400|NCT05593562|DRUG|SPH3127|Oral 100 mg \[14 c\] SPH3127 mixed suspension
219050705|NCT06670339|OTHER|No Cooling|Participants will not be pre-cooled prior to completing a 60-minute moderate-intensity exercise bout in the heat.
219633976|NCT06188871|DRUG|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
219633977|NCT04441528|DRUG|Lid wipes containing terpinen-4-ol and sodium hyaluronate|Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
219633978|NCT04441528|DRUG|Baby shampoo|Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
219633979|NCT02049905|DRUG|Aldoxorubicin|
219633980|NCT02049905|DRUG|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
219633981|NCT00542009|DRUG|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
218941401|NCT03723967|DRUG|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
218941402|NCT01221311|DEVICE|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
218941403|NCT01221311|DEVICE|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
218941404|NCT01877252|PROCEDURE|Surgical revascularization|
218941405|NCT01877252|PROCEDURE|Endovascular revascularization|
218941406|NCT01877252|OTHER|No vascular intervention|
218941407|NCT03476005|BEHAVIORAL|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
218941408|NCT02106819|BEHAVIORAL|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
218941409|NCT02106819|PROCEDURE|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
218941410|NCT00314002|DEVICE|Mechanical Thrombectomy|
218941411|NCT01717924|PROCEDURE|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
218941412|NCT01717924|PROCEDURE|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
218941413|NCT05744440|DRUG|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
218941414|NCT05184829|OTHER|selective lymph node dissection|selective lymph node dissection
218941415|NCT05184829|OTHER|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
219050706|NCT06670339|OTHER|Pre-Cooling|Participants will be immersed in cold (\~17°C) water to elicit a decrease in rectal temperature by 0.5°C from baseline values prior to completing a 60-min moderate-intensity exercise bout in the heat.
219050707|NCT06504082|DRUG|Letrozole|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
219050708|NCT06504082|DRUG|Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
219050709|NCT03013491|DRUG|CX-072|Solution for infusion
218941416|NCT02560025|DRUG|Alisertib|
218941417|NCT02560025|DRUG|Cytarabine|
219050710|NCT03013491|DRUG|ipilimumab|Solution for infusion
218941418|NCT02560025|DRUG|Idarubicin|
218941419|NCT02560025|DRUG|Daunorubicin|Can be used in place of idarubicin
218941420|NCT02703337|DRUG|LY900014|Administered subcutaneously (SC)
218941421|NCT02703337|DRUG|Insulin Lispro|Administered SC
218941422|NCT03170180|DRUG|Sunitinib|sunitinib 37.5mg daily
218941423|NCT03170180|DRUG|Gefitinib|Gefitinib 250mg daily
218941424|NCT03170180|DRUG|Imatinib|Imatinib 400mg daily
218941425|NCT02644616|DRUG|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
218941426|NCT02644616|DRUG|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
218941427|NCT02897570|DIETARY_SUPPLEMENT|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
219050711|NCT03013491|DRUG|vemurafenib|Tablet
219050712|NCT06671015|DEVICE|Airvo 3|Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.
218941428|NCT02897570|DIETARY_SUPPLEMENT|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
218941429|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
218941430|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
218941431|NCT02897570|DEVICE|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
218941432|NCT02897570|DEVICE|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
218941433|NCT01859520|PROCEDURE|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
219050713|NCT06672575|DRUG|Ivonescimab|Participante will recived an infusion by vein
219050714|NCT06616701|BEHAVIORAL|Follow up call|As part of the standard of care, caregivers of youths who present to the hospital with suicidal risk receive a follow up call approximately 5-10 business days after the hospital discharge to assist them with any challenges they may encounter in accessing mental health care, including medication access. The intervention group will receive a call 5 days after discharge. The non-intervention group will receive a call 10 days after discharge.
219365985|NCT00956930|RADIATION|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
218941434|NCT04458480|COMBINATION_PRODUCT|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
218941435|NCT02879006|DRUG|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
218941436|NCT02879006|DRUG|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
218941437|NCT02879006|DRUG|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
218941438|NCT02879006|DRUG|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
218941439|NCT00064064|DRUG|gemcitabine hydrochloride|
218941440|NCT00064064|DRUG|triapine|
218941441|NCT03407716|DRUG|American Ginseng|Given PO
218941442|NCT03407716|OTHER|Laboratory Biomarker Analysis|Correlative studies
218941443|NCT03407716|OTHER|Placebo|Given PO
219050715|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
219050716|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
219050717|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
219050718|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
219050719|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
219050720|NCT05445128|BIOLOGICAL|MGTA-145|MGTA-145 will be administered as an IV infusion
219206714|NCT06888219|OTHER|Acupuncture and Auricolotherapy|"Based on the patient's condition and the physiology of traditional Chinese medicine, sterile disposable acupuncture needles will be placed on selected points:~Auricular:~* Esophagus point~* Shen Men point~* Palate area/ Throat point~* II and III Trigeminal branches~Somatic:~* 17 Triple heater (if bruxisme)~* 22 Conception Vessel~* 23 Conception Vessel~* 3 Small Intestine~* Yin Tang (if apathy)~* 3 Large Intestine (if xerostomy)~* 36 and 44 Stomach"
219633982|NCT00542009|DRUG|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
219633983|NCT00542009|DRUG|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
219633984|NCT00542009|DRUG|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
219633985|NCT00542009|DRUG|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
219633986|NCT02511145|OTHER|occlusive bandage|
219633987|NCT02511145|DEVICE|ablative fractional CO2 laser pretreatment|
219633988|NCT02511145|DEVICE|Microneedles pretreatment|
219633989|NCT02511145|DRUG|METVIXIA Cream|
218941444|NCT03407716|OTHER|Questionnaire Administration|Correlative studies
219633990|NCT02962453|DEVICE|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
219633991|NCT02962453|DEVICE|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
219633992|NCT00595855|PROCEDURE|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5\_FU supplementation and argon laser suturelysis
218941445|NCT06032013|OTHER|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information"
219633993|NCT00595855|PROCEDURE|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
219633994|NCT06196255|DRUG|anti-FcRL5 CAR-T|anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
219633995|NCT02653144|DRUG|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
218941446|NCT01751945|BEHAVIORAL|EmONC package|"The EmONC package consists of:~1. Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~2. Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~3. Community mobilisation"
218941447|NCT00282308|DRUG|Rituximab|Rituximab was supplied in single-use vials.
218941448|NCT00282308|DRUG|Methotrexate|
218941449|NCT00282308|DRUG|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
218941450|NCT00282308|BIOLOGICAL|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
218941451|NCT00282308|BIOLOGICAL|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
219050721|NCT05445128|DRUG|Plerixafor|240 µg/kg administered subcutaneously
219050722|NCT07007429|OTHER|Ipsilesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the ipsilesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
219365986|NCT00956930|DRUG|Doxorubicin|75mg fixed dose
219050723|NCT07007429|OTHER|Contralesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the contralesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
218941452|NCT00282308|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
218941453|NCT00282308|BIOLOGICAL|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
218941454|NCT03229694|DRUG|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
218941455|NCT03229694|DRUG|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
218941456|NCT02243462|DEVICE|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
218941457|NCT02243462|OTHER|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
219050724|NCT07007429|OTHER|Bilateral Cotton Roll with Jaw Clenching|In this group, a 1 cm thick cotton roll will be placed on both occlusal surfaces, and the patients will then be instructed to clench their teeth.
219050725|NCT07017816|DRUG|SGT-53|SGT-53 is a novel cationic liposome encapsulating a normal human wild type TP53 cDNA sequence in a plasmid backbone. The liposome is decorated on its surface with an anti- transferrin receptor (TfR) single chain antibody fragment (scFv) that is designed to target cancer cells through the binding of the TfRscFv to the transferrin receptor. This complex has been shown to efficiently and specifically deliver the TP53 complementary DNA (cDNA) to the tumor cells via receptor-mediated endocytosis of the cationic liposomal complex. Introduction of the TP53 cDNA sequence restores wild-type p53 (wtp53) function in the apoptotic pathway.
219050726|NCT07017816|RADIATION|hypofractionated radiotherapy with immunotherapy|Re-irradiation has rapidly grown into a primary consideration in the context of recurrent pediatric CNS malignancies. While not thought to be curative by itself, it has often resulted in temporary symptomatic improvement as well as occasional radiographic regression or stabilization, although as with any irradiation, may also cause some adverse events.
219050727|NCT07017816|DRUG|Nivolumab|Given the poor prognosis for children with recurrent CNS malignancies and the importance of p53 function in these tumors, we propose a pilot study of SGT-53 in combination with re-irradiation and checkpoint inhibition followed by maintenance therapy with SGT-53 in combination with nivolumab to evaluate the safety, feasibility and preliminary efficacy. SGT-53 will be added to a salvage regimen utilized in patients with recurrent tumors of re- irradiation and nivolumab followed by combination therapy with SGT-53 and nivolumab.
219050728|NCT07025252|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
219050729|NCT07023562|PROCEDURE|ABC suction sequence|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
219050730|NCT07023562|PROCEDURE|ACB suction sequence|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
219050731|NCT07023562|PROCEDURE|BAC suction sequence|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
219050732|NCT07023562|PROCEDURE|BCA suction sequence|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
219633996|NCT02653144|DRUG|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
219633997|NCT02653144|DRUG|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
219633998|NCT00611572|DRUG|iomazenil|Given as IV infusion
219633999|NCT00611572|DRUG|iomazenil|saline IV infusion
218941458|NCT04965038|DRUG|Tenecteplase (until trial protocol V04: Alteplase)|Intravenous thrombolysis within 4.5 hours of symptom onset
218941459|NCT04665089|DRUG|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
218941460|NCT06577831|DIAGNOSTIC_TEST|dynamic MRI|"* MRI sequences will be performed for patients and healthy volunteers i~* Vaginal and rectal tagging will be performed using a water-based ultrasound gel.~* The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe.~* MRI sequences.~* Data analysis and interpretation."
219050733|NCT07023562|PROCEDURE|CAB suction sequence|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
219050734|NCT07023562|PROCEDURE|CBA suction sequence|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
219050735|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions.|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a Vidoe-call at fixed time-points. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom.
219050736|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a pre-recorded videos at convenient time-point with at least one day in between during the periods of video-supervision
219050737|NCT07025694|OTHER|Moderate Intensity Continues Training|The MICT exercise training on a spinning-bike will consist of moderate intensity-longer (60%Wpeak) duration exercise carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision. Exercise will consist of continuous biking at an individualized workload based on pre-exercise testing, for a total time of 30 minutes.
219365987|NCT00734084|DEVICE|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
219634000|NCT04724538|RADIATION|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
219634001|NCT04724538|DRUG|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
219634002|NCT03547011|PROCEDURE|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
218941461|NCT05743946|DRUG|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be for 28 days, and otherwise identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
218941462|NCT06115148|OTHER|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
218941463|NCT06115148|OTHER|Fasting|Water will be consumed as described during the Fasting Arm.
218941464|NCT04280029|DEVICE|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
218941465|NCT04280029|DEVICE|Control|POBA or FDA-approved -limus DES
218941466|NCT05571332|DRUG|Avatrombopag 20 MG Oral Tablet|p-ATG and CsA in combination with Avatrombopag to treat
218941467|NCT02496052|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
218941468|NCT02496052|DEVICE|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
218941469|NCT02496052|DRUG|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
218941470|NCT00351858|DRUG|ertumaxomab|
218941471|NCT02872285|DRUG|Drug: LYC-30937-EC|
218941472|NCT02872285|DRUG|Placebo|
218941473|NCT05744310|DEVICE|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
218941474|NCT05744310|DEVICE|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
218941475|NCT04772989|DRUG|AB308|Administered intravenously (IV) as specified in the treatment arm
219050738|NCT07025694|OTHER|High intensity interval training|The HIIT exercise training on a spinning-bike will begin by using a protocol consisting of bouts of high-intensity (95%Wpeak) exercise lasting for 60 seconds. These bouts will be interspersed by 4 minutes of low intensity exercising (40%Wpeak). There will be 5 bouts per session. Exercise will consist of continuous biking at individualized workloads based on pre-exercise testing. The exercise will be carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision.
219634003|NCT03547011|PROCEDURE|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
218941476|NCT04772989|DRUG|Zimberelimab|Administered IV as specified in the treatment arm
218941477|NCT07127445|DIETARY_SUPPLEMENT|OEA supplement|The supplement contains OEA, ginger extract, and lavender essential oil as its active ingredients.
218941478|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
218941479|NCT06644599|DEVICE|wireless monitoring|The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
218941480|NCT06853522|DRUG|exosomes derived from human umbilical cord mesenchymal stem cells|The corresponding exosome content of 60×10\^6 umbilical cord mesenchymal stem cells was given
218941481|NCT06853522|DRUG|saline +5% albumin|Equal amount of saline +5% albumin was given
218941482|NCT06523400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
218941483|NCT06523400|DRUG|Placebo|Matching Placebo
218941484|NCT06167473|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
218941485|NCT04562428|DRUG|Xiang Sha Liu Jun Zi Decoction dry powder|the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
218941486|NCT04562428|DRUG|XSLJZ Placebo|XSLJZ Placebo
218941487|NCT06843343|PROCEDURE|Intertransverse Process Block with 1.5% Lidocaine|For the ITP block, the needle will be advanced further into the intertransverse tissue complex between the T4 and T5 transverse processes, and local anesthetic will be injected just above the superior costotransverse ligament, under ultrasound guidance.
218941488|NCT06843343|PROCEDURE|Erector Spinae Plane Block with 1.5% Lidocaine|The ESP block will be performed by advancing the needle to the transverse process, under ultrasound guidance, with local anesthetic injected between the erector spinae muscle and the transverse process, targeting a caudad-cephalad spread.
218941489|NCT06843343|DRUG|1.5% Lidocaine|local anesthetic to be used in either the ITP and ESP block
219050739|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 1 Hz)|Low-frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
219050740|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 10 Hz)|High-frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, totaling 2400 pulses.
219050741|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 25 Hz)|High-frequency stimulation (25 Hz) at 90% of resting muscle threshold intensity, with 2400 pulses.
218941490|NCT06985485|DRUG|Blinatumomab and Inotuzumab Ozogamicin|Subjects who meet the study criteria during screening will receive induction therapy consisting of low-intensity chemotherapy combined with BiTE with or without TKIs. Regimen includes dexamethasone, vindesine, followed by blinatumomab dosed by body weight: pts ≥45 kg receive fixed dosing (9 µg/day days 1-7, 28 µg/day days 8-28), pts \<45 kg receive BSA-adjusted dosing (5 µg/m²/day days 1-7, 15 µg/m²/day days 8-28). Philadelphia chromosome-positive ALL pts receive second-generation TKIs, with subsequent switch to third-generation TKIs upon resistance. If morphologic remission is not achieved after initial therapy, a salvage cycle with InO will be administered. Post-remission consolidation chemotherapy includes high-dose methotrexate followed by sequential immunotherapy: BiTE (per weight-stratified dosing), then after a 2-week break, InO (0.8 mg/m² on day 1), followed by another 2-week break.This sequence is repeated for 4 cycles.
218941491|NCT05306548|PROCEDURE|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
219050742|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 1 Hz)|Low-frequency (1 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
219050743|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 10 Hz)|High-frequency (10 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
219050744|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 25 Hz)|High-frequency (25 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
219050745|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 1Hz)|Low-frequency (1 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
219050746|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 10Hz)|High-frequency (10 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
219050747|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 25Hz)|High-frequency (25 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
219050748|NCT07023991|DRUG|Bupivacaine|Bupivacaine will be used in an ESP block to provide postoperative analgesia.
219050749|NCT07023991|DRUG|Dexmedetomidine|Dexmedetomidine will be added to bupivacaine in the ESP block to evaluate its effect on duration of postoperative analgesia.
219050750|NCT07024680|OTHER|Observational, None intervention|Observational, None intervention
219050751|NCT07025655|BEHAVIORAL|Multifaceted Mindfulness Program|Ten-week mindfulness classes
219050752|NCT07025655|BEHAVIORAL|Placebo|Regular daily activity
219634004|NCT04720924|DEVICE|Computer-aided Real-time Automatic Quality-control System|EGD automatic quality-control system(AQCS),developed based on deep convolutional neural network (DCNN) models,could facilitate real-time detection of upper gastrointestinal lesions, assess inspection completeness and mucosal visibility, and calculate time of EGD procedure.
219634005|NCT06258499|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is manually placed into the joint fusion space during fusion surgery.
219634006|NCT05174299|DEVICE|magnetic stimulation|For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.
219634007|NCT02739425|DEVICE|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
219634008|NCT00863343|BIOLOGICAL|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
219050753|NCT07024238|DIETARY_SUPPLEMENT|SCFA|Participants randomized to this group will receive 1000 mg of sodium butyrate daily for 12 weeks. The intervention aims to evaluate the effect of high-dose SCFA supplementation on the gut microbiome and systemic/urinary metabolome in kidney transplant recipients.
219365988|NCT03617705|DEVICE|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
219634009|NCT00532753|BEHAVIORAL|Community Empowerment|
219634010|NCT04138472|DRUG|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
219634011|NCT04138472|DRUG|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
219050754|NCT07024238|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive placebo capsules (sacharosis) identical in appearance to the active SCFA capsules, administered twice daily for 12 weeks. This arm serves as a control to evaluate the specific effects of SCFA supplementation.
219050755|NCT07024446|OTHER|The time interval between PCI and NCS|Using 6 weeks post-PCI as the demarcation point, patients within 6 weeks were assigned to the observation group, while those beyond 6 weeks formed the control group.
219050756|NCT07025239|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of QL1706 lasts for up to 2 years.
219634012|NCT04138472|DRUG|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
219634013|NCT02037191|DRUG|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
219634014|NCT02037191|DRUG|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
219634015|NCT02897219|DRUG|ipragliflozin|Oral administration once daily
219634016|NCT02897219|DRUG|Placebo|Oral administration once daily
219634017|NCT02897219|OTHER|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
218941492|NCT05306548|DRUG|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
218941493|NCT06208943|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
218941494|NCT06819813|BEHAVIORAL|Feasibility/Efficacy Testing|This digital intervention will include elements of adapted cognitive-behavioral treatment for adolescent binge eating and weight control, with a focus on self-regulation and skills use.
218941495|NCT06033092|DRUG|Tamoxifen 10 mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
218941496|NCT06033092|OTHER|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
218941497|NCT06033092|BEHAVIORAL|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
218941498|NCT01784822|DEVICE|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
218941499|NCT03425253|DRUG|BELKYRA®|BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
218941500|NCT03425253|DEVICE|Juvéderm® VOLUMA™ with Lidocaine|Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
218941501|NCT03581916|DRUG|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
218941502|NCT03510741|DRUG|Sodium Benzoate|Sodium Benzoate will be administered at 1000mg daily
218941503|NCT03510741|DRUG|N-Acetylcysteine|N-Acetylcysteine 1000 mgs twice daily dose
218941504|NCT03510741|DRUG|Placebo|Placebo added to TAU
218941505|NCT03510741|DRUG|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
218941506|NCT07059650|DRUG|DZD8586+R-CHOP|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-CHOP (Rituximab: 375 mg/m2, IV, d1; Cyclophosphamide: 750 mg/m2, IV, d1; Doxorubicin: 50 mg/m2, IV, d1; Vincristine: 1.4 mg/m2, IV, d1; Prednisone: 100 mg, po, d1-5) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
218941507|NCT07059650|DRUG|DZD8586+R-GemOx|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-GemOx (Rituximab: 375 mg/m2, IV, d1; Gemcitabine: 1000 mg/m2, IV, d1; Oxaliplatin: 100 mg/m2, IV, d1) in a 21-day cycle for 8 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
218941508|NCT07059650|DRUG|DZD8586+BR|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with BR (Bendamustine: 90 mg/m2, IV, d1-d2; Rituximab: 375 mg/m2, IV, d1) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
218941509|NCT06757920|PROCEDURE|bronchoscopic argon plasma coagulation|Argon Plasma Cogulation for Debulking Endobronchial Carcinoid Using Fiberoptic Bronchoscopy
218941510|NCT07073209|PROCEDURE|PENG Block Administration|"Policy for the PENG block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%~While these drugs are administered to participants, the intervention under evaluation is the PENG Block anesthesia technique."
218941511|NCT07073209|PROCEDURE|Femoral Block Administration|"Policy for the Femoral block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg~While these drugs are administered to participants, the intervention under evaluation is the Femoral Block anesthesia technique."
218941512|NCT07073209|DRUG|Bupivacaine , epinephrine Dexamethasone|30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%
218941513|NCT07084883|DEVICE|No intervention.|No intervention. Evaluate the automated AMD screening software.
218941514|NCT05566873|BEHAVIORAL|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
219634018|NCT01322490|BIOLOGICAL|PROSTVAC-V|
219634019|NCT01322490|BIOLOGICAL|PROSTVAC-F|
219634020|NCT01322490|DRUG|GM-CSF|
219634021|NCT01322490|OTHER|GM-CSF Placebo|
218941515|NCT05566873|BEHAVIORAL|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
218941516|NCT07145060|DRUG|Yiqi Yangyin Formula|Yiqi Yangyin Formula,consists of seven Chinese herbal medicines（Table 1）: Rehmanniae Radix (Sheng Di Huang), Lilium brownii (Bai He), Adenophorae Radix (Nan Sha Shen), Fructus Hordei Germinatus (Sheng Mai Ya), Artemisia annua (Qing Hao), Cimicifuga foetida (Sheng Ma) , and Bupleurum chinense(Chai Hu)
218941517|NCT07145060|DRUG|Yiqi Yangyin Formula placebo|Yiqi Yangyin Formula placebo,has the same appearance, state, and taste as YQYYF, but contains 5% of the ingredients of Yiqi Yangyin Formula
219050757|NCT07025239|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 7.5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Bevacizumab lasts for up to 2 years.
219634022|NCT01322490|BIOLOGICAL|Placebo|PROSTVAC V/F Placebo
219634023|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
219050758|NCT07025239|DRUG|Oxaliplatin|Oxaliplatin will be administered by IV infusion at 130 mg/m2 on Day 1 of each 21-day cycle up to 8 treatment cycles.
219050759|NCT07025239|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice daily for 2 consecutive weeks, followed by one-week rest in each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Capecitabine lasts for up to 2 years.
219050760|NCT07025239|DRUG|Placebo|Placebo will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Placebo lasts for up to 2 years.
219050761|NCT07024069|OTHER|Tongue ultrasound via submental approach|"Descriptive and anthropometric data will be recorded for each participant, including age, sex, weight (kg), height (m), neck circumferences (cm). Body mass index (expressed in kg/m2) will be calculated.~Submental ultrasound (US) images of the tongue will be performed on a patient lying supine, using a 5-15 MHz convex transducer. The parameters will be identical for all subjects and set at a depth of 9 cm, a focus of 4 cm and a gain of 45%. Each measurement will be taken thrice by a trained operator; the mean and standard deviation being used for analysis."
219365989|NCT03617705|DEVICE|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
219634024|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
219634025|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
219634026|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
219634027|NCT05339633|DRUG|[14C]-D-0502|Drug: \[14C\]-D-0502 and D-0502
219634028|NCT06139900|OTHER|Assessment|No intervention will be applied to the participants. Postural stability will be evaluated in the virtual reality environment and real environment.
219634029|NCT01431716|DRUG|EFI/ACT-385781A|
219365990|NCT03617705|DEVICE|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
219634030|NCT04217096|DRUG|Paclitaxel liposome|Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
219634031|NCT04217096|DRUG|S-1|Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
218941518|NCT07145424|OTHER|kinesio taping group|The original Kinesio Tape (Kinesio Tex Classic Tape) was used for taping by a physiotherapist with 15 years of experience in the field. The tape was cut into an I-shape and applied to the lower abdominal and lumbo-sacral regions where the participants experienced pain, 10 days prior to the anticipated start of menstruation (Figure 2). The tapes were renewed after four days. This procedure was performed three times and the total taping period was completed as 12 days. The tapes were removed on the third day of menstruation and all outcome measurements were performed again for the post intervention measurements
218941519|NCT07146126|DRUG|PG-011 nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
218941520|NCT07146126|DRUG|Placebo|2 sprays in each nostril, twice daily for 14-day treatment period.
218941521|NCT07147140|DEVICE|dorsal root ganglion stimulation cessation|Treatment of DRGS will be stopped at home and physiological parameters will be monitored with bio wearables at home. physiological parameters will be monitored during a baseline period, before stopping DRGS. While DRGS is stopped. And during the period while the DRGS is turned back on.
218941522|NCT07145489|DEVICE|photobiomodulation|a hat with infrared lights will be worn for 30 minutes daily for 6 months
218941523|NCT07145840|OTHER|Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)|Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum
218941524|NCT07146048|DRUG|Secondary Prophylaxis|Continue standard of care with continued secondary antibiotic prophylaxis
218941525|NCT07146360|BIOLOGICAL|Revelise (GENERIUM, Russia)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
218941526|NCT07146360|BIOLOGICAL|Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
219365991|NCT01284790|DEVICE|Cochlear implants|
219634032|NCT05306912|BIOLOGICAL|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
219634033|NCT00857987|DRUG|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
219634034|NCT00857987|OTHER|Placebo|Vehicle
219634035|NCT05027451|DRUG|IXT-m200|Anti-methamphetamine chimeric monoclonal antibody (mAb)
219634036|NCT05027451|OTHER|Placebo|Normal saline
219634037|NCT05741801|OTHER|interviews|observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
219634038|NCT06299358|OTHER|Foot massage|Infants in the foot massage group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts.
219365992|NCT02779205|PROCEDURE|adipose tissue sample|adipose tissue sample
219365993|NCT00715130|BEHAVIORAL|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
219634039|NCT06299358|OTHER|Mother heart sound|The sound recorded by the researcher under appropriate conditions will be played to the babies in the maternal heart sound group from an appropriate distance. The sound will be played a total of four times, on two consecutive days of the week, just before the baby's restlessness begins and for half an hour.
219634040|NCT06299358|OTHER|Foot massage and maternal heart sound|Infants in the foot massage and maternal heart sound group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts. From the beginning of the massage, the pre-recorded maternal heart sound will be played to the infant for 30 minutes from an appropriate distance.
219634041|NCT02239731|DRUG|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
219634042|NCT01628900|OTHER|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
219634043|NCT01628900|OTHER|Care management|Hospital vs home
219634044|NCT00002659|DRUG|cisplatin-e therapeutic implant|
219634045|NCT03916237|OTHER|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
219634046|NCT03916237|OTHER|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
218941527|NCT06946004|DEVICE|Normobaric oxygen therapy|Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for finalization and the decompression period.
219634047|NCT03916237|OTHER|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
219634048|NCT03916237|OTHER|Regular School Based Health Asthma Care|Regular care in the School Health Program
218941528|NCT06946004|DEVICE|Normobaric oxygen therapy|Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide placebo intervention as the study comparator) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere).
218941529|NCT06947265|DRUG|L-Arginine|get 3 gm oral tablets of L-arginine
218941530|NCT06947265|DRUG|Tadalafil 5 mg|get 5 mg oral tadalafil for 8 weeks
218941531|NCT07146399|PROCEDURE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
218941532|NCT07146399|PROCEDURE|Sham (No Treatment)|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
218941533|NCT02728492|DRUG|Quisinostat|
218941534|NCT02728492|DRUG|Paclitaxel|
218941535|NCT02728492|DRUG|Carboplatin|
218941536|NCT02728492|DRUG|Gemcitabine|
218941537|NCT02728492|DRUG|Cisplatin|
218941538|NCT03314571|OTHER|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
218941539|NCT04129151|DRUG|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
218941540|NCT04129151|DRUG|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
218941541|NCT06337019|OTHER|Cohort observational|Cohort observational
218941542|NCT00263289|PROCEDURE|preprocedural fasting|
218941543|NCT00641641|DRUG|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
218941544|NCT02385422|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
218941545|NCT02385422|DRUG|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
218941546|NCT00160472|PROCEDURE|removal of ovarian vessels|
218941547|NCT02553252|OTHER|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
219634049|NCT01580852|PROCEDURE|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
219634050|NCT01580852|PROCEDURE|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
219634051|NCT04245436|DRUG|Duloxetine|Encapsulated duloxetine 30 mg, 60 mg; once-daily
218941548|NCT03264053|DEVICE|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
218941549|NCT03264053|PROCEDURE|Conventional immediate implantation|Conventional immediate implantation
218941550|NCT01758536|DRUG|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
218941551|NCT04249349|DEVICE|Assisted gait with a motorized ankle foot orthosis|The motorized ankle foot orthosis is a powered lower extremity assistance device with an actuated ankle joint. A novel control software has been design and implemented in this device, which allows precise joint movement and recording of data from training session.
218941552|NCT03486626|DRUG|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
218941553|NCT00040560|DRUG|111In-DAC|
218941554|NCT00040560|PROCEDURE|Diagnostic|
218941555|NCT01676779|BIOLOGICAL|Dendritic cell therapy|Dendritic cell therapy IV and ID
218941556|NCT01311024|BIOLOGICAL|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
218941557|NCT01311024|BIOLOGICAL|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
218941558|NCT02706964|DEVICE|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
218941559|NCT02706964|DEVICE|Magnetic resonance imaging|A brain MRI will be performed.
218941560|NCT02706964|DEVICE|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
218941561|NCT01523275|DRUG|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
218941562|NCT01523275|OTHER|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
219634052|NCT04245436|DRUG|Escitalopram|Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
219634053|NCT03966300|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
219634054|NCT06498856|OTHER|Isotonic saline infusion|Volume expansion with one liter of isotonic saline intravenously over two hours.
219634055|NCT00365404|BEHAVIORAL|Diet and exercise promotion|
218941563|NCT06173180|DEVICE|TOT|In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
218941564|NCT06173180|DEVICE|VACS-D|The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
218941565|NCT01788436|BEHAVIORAL|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT\_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT\_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
218941566|NCT01788436|BEHAVIORAL|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
218941567|NCT05526040|DIETARY_SUPPLEMENT|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
218941568|NCT05526040|DIETARY_SUPPLEMENT|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
218941569|NCT00689117|DRUG|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
218941570|NCT00689117|DRUG|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
218941571|NCT00689117|DRUG|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
218941572|NCT00689117|DRUG|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
218941573|NCT01206322|DRUG|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
218941574|NCT01206322|DRUG|Placebo|The acute effects of intranasal sterile saline.
218941575|NCT03260049|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy
218941576|NCT06044051|OTHER|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
218941577|NCT06044051|OTHER|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
218941578|NCT06044051|OTHER|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
218941579|NCT02463890|OTHER|Training|
218941580|NCT02463890|OTHER|Control|
218941581|NCT02828670|BIOLOGICAL|blood sample|
218941582|NCT02828670|PROCEDURE|spleen sample|
219365994|NCT03261115|PROCEDURE|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
219634056|NCT00608777|DRUG|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
218941583|NCT02735135|DEVICE|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
218941584|NCT02735135|DEVICE|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
218941585|NCT02735135|DEVICE|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
218941586|NCT02735135|DEVICE|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
218941587|NCT03635658|PROCEDURE|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
218941588|NCT03635658|PROCEDURE|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
218941589|NCT00802113|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days
218941590|NCT00802113|DRUG|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
218941591|NCT00802113|DRUG|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
219365995|NCT01061008|OTHER|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
219365996|NCT01061008|OTHER|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
219365997|NCT02024971|DRUG|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
219634057|NCT05882825|OTHER|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
218941592|NCT03354507|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate. See arms.
219050762|NCT07023926|DEVICE|electroacupuncture|The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device. The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40. Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6. The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
219050763|NCT07023926|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable blunt-tip sham needles (Φ0.3mm×25mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
219365998|NCT02908100|DRUG|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
218941593|NCT00973297|OTHER|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
218941594|NCT03924895|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
218941595|NCT03924895|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
218941596|NCT03924895|DRUG|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
218941597|NCT05701280|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
218941598|NCT05701280|OTHER|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
218941599|NCT03268070|DEVICE|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
218941600|NCT03268070|DEVICE|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
218941601|NCT03268070|DEVICE|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
218941602|NCT03268070|DEVICE|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
218941603|NCT03268070|DEVICE|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
218941604|NCT05477082|OTHER|Observational group|Includes blood draws and data collection only
218941605|NCT06547138|DEVICE|Prophylactic mesh|Prevention of incisional hernia after a prophylactic mesh in high-risk patients
219050764|NCT03238911|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
219050765|NCT03238911|DRUG|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
219050766|NCT07025512|DRUG|177Lu-PSMA-617|Given by IV
219634058|NCT04194463|OTHER|ChemoFit exercise prehabilitation intervention|Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
219634059|NCT01760135|DIETARY_SUPPLEMENT|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
219634060|NCT01760135|DIETARY_SUPPLEMENT|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
218941606|NCT04748367|DEVICE|Virtual Reality Headset|Virtual Reality Headset running SILVER software
218941607|NCT06157840|DEVICE|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
218941608|NCT06157840|DEVICE|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
218941609|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
218941610|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
218941611|NCT06023667|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
218941612|NCT05491512|DIAGNOSTIC_TEST|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
218941613|NCT05491512|RADIATION|Radiation|Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
218941614|NCT05491512|DRUG|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
218941615|NCT05491512|DRUG|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
218941616|NCT05491512|DRUG|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
218941617|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
219050767|NCT07024407|DRUG|Andecaliximab|Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital
219050768|NCT07032298|DRUG|SSGJ-612|Intravenous injection
219050769|NCT06708897|DRUG|ZE 50-0134|oral capsules QD
219050770|NCT05944120|COMBINATION_PRODUCT|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
219050771|NCT06884423|DEVICE|FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
219365999|NCT02908100|DRUG|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
218941618|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
218941619|NCT05315414|DEVICE|PrimeTaper EV implant|Tapered dental implant developed by Dentsply Sirona
218941620|NCT06567769|DRUG|GC1130A|ICV injection
218941621|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
218941622|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
219050772|NCT07039123|DIAGNOSTIC_TEST|Polygenic Risk Score for Coronary Artery Disease (PRS-CAD)|A polygenic risk score will be calculated based on genome-wide genotyping and combined with SCORE2 clinical risk factors to estimate personalized cardiovascular risk. The combined risk (PRS-CAD-SCORE2) will be communicated to participants and their healthcare providers using a standardized communication tool. Participants with elevated risk will be referred to a lipid clinic.
219050773|NCT07039123|BEHAVIORAL|Standardized Risk Communication Tool (SCORE2)|Participants will receive risk communication based solely on clinical risk factors using the SCORE2 algorithm. The same structured communication tool will be used (without genetic data), along with general lifestyle guidance.
219050774|NCT03108248|DRUG|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
219050775|NCT03108248|DEVICE|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
219050776|NCT06722170|GENETIC|EH002 administration|EH002 was administered into one or both ears via intracochlear injection.
219050777|NCT07049081|BIOLOGICAL|LUCAR-G79 T cells|Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219050778|NCT06893809|PROCEDURE|Epidural injection via Tuohy needle|Local anesthetic was administered entirely through the Tuohy needle.
219050779|NCT06893809|PROCEDURE|Epidural injection via catheter|Local anesthetic was administered entirely through the epidural catheter.
219050780|NCT06893809|PROCEDURE|Combined epidural injection (needle and catheter)|Half of the total local anesthetic dose was administered through the needle and half through the catheter.
219050781|NCT06893198|BEHAVIORAL|Storytelling intervention|"The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered via Computerized Intervention Authoring System (CIAS) on a biweekly basis. A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication and is coordinated with the specific patient stories will be provided via CIAS as well."
219634061|NCT01847586|PROCEDURE|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
219634062|NCT01847586|PROCEDURE|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
218941623|NCT06376045|DRUG|Rocatinlimab|Rocatinlimab will be administered by SC injection.
218941624|NCT06376045|DRUG|Placebo|Placebo will be administered by SC injection.
219050782|NCT06893198|BEHAVIORAL|Home BP monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
219050783|NCT06893198|BEHAVIORAL|Expanded community health worker services|A training program will be implemented for community health workers for the intervention arm regarding hypertension management at the community level so that they can assist patients better managing their blood pressure at home.
219634063|NCT01342523|OTHER|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
219634064|NCT01342523|OTHER|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
219634065|NCT01342523|OTHER|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
218941625|NCT05770609|DRUG|SPH3127 Tablets with Dose A|See Arm description
218941626|NCT05770609|DRUG|SPH3127 Tablets with Dose B|See Arm description
218941627|NCT05770609|DRUG|SPH3127 Tablets placebo|See Arm description
218941628|NCT00354276|DRUG|cytarabine|
218941629|NCT00354276|DRUG|laromustine|
218941630|NCT03777891|COMBINATION_PRODUCT|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
218941631|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25ug + spacer|
218941632|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25 ug|
219634066|NCT01342523|OTHER|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
219050784|NCT06893198|BEHAVIORAL|"Learn More module only"|"A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication, which will be delivered via Computerized Intervention Authoring System (CIAS) at baseline and at 3, 6, and 9 months after enrollment."
219050785|NCT06761937|PROCEDURE|Thermotherapy|Thermotherapy will be given once a week after a radiotherapy fraction
219634067|NCT01342523|OTHER|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
219634068|NCT01342523|OTHER|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
219634069|NCT01342523|OTHER|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
219634070|NCT01994148|PROCEDURE|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
219634071|NCT02360241|DEVICE|Robot|Use of the robot to locate the fictional needle
219634072|NCT02931344|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
218941633|NCT02829190|DEVICE|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
218941634|NCT01999517|DRUG|Intravenous Nitroglycerin|
218941635|NCT01999517|DRUG|IV Fluids|
218941636|NCT04846413|OTHER|Speech task|Speech task which consists of a sustained emission of the vowel /e/.
218941637|NCT03133416|OTHER|PRP preparation|
218941638|NCT03133416|DEVICE|Physiotherapy|
218941639|NCT03133416|OTHER|PRP and physiotherapy|
218941640|NCT02739971|BEHAVIORAL|Low AGEs diet|Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
218941641|NCT02739971|BEHAVIORAL|Standard of care dietary guidance for Type 2 diabetes|Oral and written instructions for standard of care dietary guidance for type 2 diabetes
219050786|NCT06761937|RADIATION|standard radiotherapy|standard radiotherapy
219050787|NCT06908759|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|In the first phase of the study all enrolled patients will perform exercise in the context of an in-hospital intesive rehabilitation after the acute event. At discharge they will be randomized in two groups: supervised exercise in the context of a cardiac rehabilitation facility or home-based exercise
219634073|NCT00792051|BIOLOGICAL|Inactivated influenza vaccine|0.5ml intramuscular single dose
219634074|NCT00792051|BIOLOGICAL|Saline|0.5ml intramuscular, one dose
219634075|NCT00556946|DRUG|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
219634076|NCT05300581|OTHER|OPAT for PWID|Observational: Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
218941642|NCT06095648|OTHER|Dose of platelet transfusion|Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU
219634077|NCT05067608|BIOLOGICAL|Control arm receiving normal (never before frozen) platelets as per current clinical practice|Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.
219634078|NCT05067608|BIOLOGICAL|Treatment arm receiving cryopreserved platelets|Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
219634079|NCT06155955|DRUG|"Emicizumab, HEMLIBRA®"|low dose
218941643|NCT05330104|BEHAVIORAL|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
218941644|NCT00317278|OTHER|massage therapy|massage therapy to stable preterm infants
218941645|NCT00317278|OTHER|Sham|Sham (placebo) provided to the control group
218941646|NCT05605951|OTHER|non-interventional study|observational study
218941647|NCT03541395|DRUG|GnRH antagonist|
218941648|NCT05428124|OTHER|In vitro fertilisation|In vitro fertilisation
218941649|NCT00708084|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
218941650|NCT00708084|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
218941651|NCT04335214|OTHER|one to one interview|one to one interviews with older people from moroccon origin in Belgium
219050788|NCT06908070|DRUG|Consolidation durvalumab|Patients with initially unresectable stage III NSCLC will undergo surgery after chemoradiotherapy completion when the tumor is deemed resectable by the thoracic oncology tumor board and will then receive durvalumab
219050789|NCT03977259|OTHER|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
219050790|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
219050791|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
219634080|NCT06574711|OTHER|Sacha inchi oil yogurt|Sacha inchi oil was incorporated into a nonfat yogurt acting as a source of linolenic acid
219634081|NCT06574711|OTHER|Hybrid palm oil yogurt|Interspecific hybrid palm oil was incorporated into a nonfat yogurt as a source of bioactive compounds
218941652|NCT01538784|DRUG|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"
218941653|NCT05553834|COMBINATION_PRODUCT|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
219050792|NCT06754280|BEHAVIORAL|RESET-CKD|RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
219050793|NCT06754280|OTHER|Attention Control|CKD-related education
219050794|NCT06908330|BEHAVIORAL|Social-emotional Skills for Thriving and Relating at School Program|The SSTRS Program is a developmentally-tailored, school-based preventive intervention focusing on children and their parents at the critical transition to kindergarten to prevent deficits in children's social-emotional skills-which are known transdiagnostic risk factors for a range of mental health problems. Children receive SSTRS programming during their regular school day for eight weeks at the beginning of the school year. Parents receive SSTRS programming via informational videos and virtual parenting groups during the same time period.
219050795|NCT06909188|OTHER|No intervention|No Intervention
219050796|NCT06598800|DRUG|Drug: BG-T187|Intravenous administration
219050797|NCT06917482|DRUG|BW-40202 injection|BW-40202 is a conjugate drug, dosage form is solution for injection and route of administration is subcutaneous injection
219050798|NCT06917482|OTHER|Sodium Chloride|Placebo (sodium chloride injection) will be administered as Subcutaneous injection
219050799|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
218941654|NCT03732781|DRUG|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
218941655|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
218941656|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
218941657|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
218941658|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
218941659|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
218941660|NCT02503657|DRUG|MN-001|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
218941661|NCT02503657|DRUG|Matching Placebo|Excipients of MN-001/tipelukast
219634082|NCT06574711|OTHER|Control yogurt|Conventional full-fat yogurt
219634083|NCT02929589|DRUG|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
218941662|NCT05357261|BEHAVIORAL|Wellness Check and Socialization|In-home delivery with opportunity for driver observation and interaction
218941663|NCT05357261|OTHER|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
218941664|NCT04255745|BEHAVIORAL|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
218941665|NCT05408637|DEVICE|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
218941666|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
218941667|NCT06370182|DEVICE|ANA Funnel Catheter|Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.
218941668|NCT06370182|DEVICE|Control|Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.
218941669|NCT03492567|BIOLOGICAL|Blood test|Blood draw (max 15 ml)
218941670|NCT05871450|BEHAVIORAL|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
219050800|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
219050801|NCT07116291|OTHER|Karate|karate practice
219050802|NCT04597125|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
219050803|NCT04597125|DRUG|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
219050804|NCT07086781|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
219050805|NCT07086781|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
219050806|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
218941671|NCT05290064|OTHER|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
218941672|NCT05290064|OTHER|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
218941673|NCT05290064|OTHER|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
218941674|NCT05290064|OTHER|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
219050807|NCT06923657|DIAGNOSTIC_TEST|PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy|The experimental group will undergo PSMA PET/MRI examination. For those with positive PSMA PET/MRI results, a PSMA PET/MRI-TRUS guided prostate targeted biopsy will be performed based on transrectal ultrasound (TRUS) guided transperineal saturation biopsy, targeting the positive lesions. For those with negative PSMA PET/MRI results, only TRUS guided transperineal saturation biopsy will be performed. Clinical and pathological data of the patients will be collected for statistical analysis.
219050808|NCT06923657|DIAGNOSTIC_TEST|TRUS guided transperineal saturation biopsy|The control group will receive TRUS guided transperineal saturation biopsy. Clinical and pathological data of the patients will be collected for statistical analysis.
219050809|NCT06932770|DIETARY_SUPPLEMENT|Food Supplement active|The food supplement active (2 soft gels) will be consumed once per day with a large glass of water.
219050810|NCT06932770|DIETARY_SUPPLEMENT|Food supplement placebo|The food supplement placebo (2 soft gels) will be consumed once per day with a large glass of water.
218941675|NCT02765009|DRUG|diuretics|Used to reduce fluid overload as evidenced by weight gain
218941676|NCT02765009|DRUG|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
218941677|NCT02765009|OTHER|fluid restriction|Used to reduce fluid overload
218941678|NCT02765009|DEVICE|renal replacement|Used to reduce fluid overload in patients with renal replacement
218941679|NCT05997420|BEHAVIORAL|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
219050811|NCT06932770|OTHER|Skin care product active|The cosmetic skin care product active will be applied twice daily to half of the face and to one volar forearm.
219050812|NCT06932770|OTHER|Skin care product placebo|The cosmetic skin care product placebo will be applied twice daily to half of the face and to one volar forearm.
219050813|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
219050814|NCT06937996|DEVICE|NanoKnife|The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.
219050815|NCT06938802|BEHAVIORAL|Sleep coaching|Participants will receive an 8-week sleep coaching program delivered by smartphone/tablet app
218941680|NCT05997420|BEHAVIORAL|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
218941681|NCT04509622|DRUG|Venetoclax|Tablet; Oral
218941682|NCT04509622|DRUG|Cytarabine|Subcutaneous Injection
218941683|NCT00652106|DRUG|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
218941684|NCT00652106|DRUG|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
218941685|NCT00652106|DRUG|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
218941686|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
218941687|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
218941688|NCT04600271|DRUG|Crystalloid Solutions|exposure
218941689|NCT04600271|DRUG|Colloid Blood Volume Expanders|exposure
219634084|NCT02929589|DRUG|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
219634085|NCT02929589|DRUG|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
219634086|NCT02929589|DRUG|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
219634087|NCT04856267|DEVICE|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
219634088|NCT06120426|PROCEDURE|total en bloc spondylectomy|Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
219634089|NCT02332057|DRUG|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
218941690|NCT04600271|OTHER|blood replacement|exposure
218941691|NCT04600271|DRUG|Diuretic|exposure
218941692|NCT04600271|DRUG|noradrenaline|exposure
218941693|NCT04600271|DRUG|Non-Steroidal Anti-Inflammatory Analgesics|exposure
218941694|NCT05025956|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
218941695|NCT05025956|DRUG|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
218941696|NCT06132139|DEVICE|VisAR|The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
218941697|NCT01989208|OTHER|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
218941698|NCT01989208|OTHER|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
219050816|NCT06938802|BEHAVIORAL|Sleep education|Participants will receive electronic access to educational information about sleep for 8 weeks
219050817|NCT06937749|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
219050818|NCT06937749|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
218941699|NCT00173641|PROCEDURE|blood drawing|
218941700|NCT05342441|PROCEDURE|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
219050819|NCT06940817|BEHAVIORAL|CHEF-ED + Food Delivery|CHEF-ED is a 7-week, digital, video-based parental intervention that teaches healthy cooking practices and an optimal way to involve children in home cooking. Each week features a video, infographics, and recipe content. The content is designed to be integrated into the home food environment without major changes to shopping habits. However, some basic culinary ingredients that are featured may not already be part of participating family pantry stocks. To support participants in effectively learning the healthy cooking strategies, participating families are provided a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
219050820|NCT06940817|BEHAVIORAL|Food Delivery Only|The Food Delivery Only intervention involves participants receiving a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
219050821|NCT06941844|OTHER|Placebo|A substance that is designed to have no therapeutic value
219050822|NCT06941844|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
219050823|NCT06947967|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Cyclophosphamide 750 mg/m2 , intravenous infusion on day 1 of each 21-day cycle. Doxorubicin 70mg/m2 , intravenous infusion on day 1 of each 21-day cycle, total 6 cycles. Vincristine 1.4mg/m2(Max dose 2mg), intravenous injection on day 1 of each 21-day cycle , total 6 cycles. Prednisone 100 mg, oral, day 1-5 of each 21-day cycle,total 6 cycles.
218941701|NCT05342441|PROCEDURE|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
218941702|NCT05342441|PROCEDURE|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
218941703|NCT06532383|DRUG|PF-07940369|Bulk powder for extemporaneous preparation for oral solutions.
218941704|NCT06532383|DRUG|Placebo|Bulk powder for extemporaneous preparation for oral solutions
219050824|NCT06947967|DRUG|Tucidinostat|oral, taking as prescribed by the protocol
219634090|NCT02332057|DRUG|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
218941705|NCT05021237|RADIATION|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
218941706|NCT05757960|PROCEDURE|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
218941707|NCT05723679|OTHER|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
218941708|NCT05723679|OTHER|Room air gas mixture|Normal room air
218941709|NCT06803004|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
218941710|NCT06803004|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Senior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
218941711|NCT06803004|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
218941712|NCT06803004|OTHER|AI-assisted junior sonographer measurement of DDH|Participants will receive visual cues from the DeepDDH system.
218941713|NCT06454409|DRUG|Azacitidine|Given IV
219050825|NCT06947967|DRUG|Placebo|oral, taking as prescribed by the protocol
219050826|NCT06409494|BIOLOGICAL|EuHZV|Drug(injection)
219050827|NCT06409494|BIOLOGICAL|Shingrix|Drug(injection)
219050828|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
219050829|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
219050830|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
219050831|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
219050832|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
219634091|NCT06478472|DRUG|Orelabrutinib in combination with rituximab|"Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each"
219634092|NCT02772926|DIETARY_SUPPLEMENT|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
219634093|NCT02772926|DIETARY_SUPPLEMENT|Placebo|Placebo 900 mg per day
218941714|NCT06454409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218941715|NCT06454409|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218941716|NCT06454409|DRUG|Regorafenib|Given PO
218941717|NCT06454409|DRUG|Venetoclax|Given PO
218941718|NCT04856462|BEHAVIORAL|Education Support|Caregivers engage in a weekly video/teleconference support group with a skilled facilitator to discuss various strategies for managing caregiving stress, challenging behaviors, and personal self-care.
218941719|NCT06543355|DEVICE|Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol|The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
218941720|NCT05372718|DRUG|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
218941721|NCT05372718|PROCEDURE|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
218941722|NCT06279195|DRUG|Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet|All participants will be instructed to take REL-CT.
218941723|NCT04728425|DRUG|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
218941724|NCT04728425|DRUG|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
218941725|NCT05251701|DEVICE|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
218941726|NCT05913193|OTHER|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
218941727|NCT04973436|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
218941728|NCT00566696|DEVICE|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
218941729|NCT00566696|PROCEDURE|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
219050833|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
219050834|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
219050835|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
219050836|NCT05505630|DRUG|Ketamine|A single dose of IV ketamine will be administered.
219050837|NCT05505630|DRUG|Midazolam|A single dose of IV midazolam will be administered
219050838|NCT05505630|DRUG|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
219050839|NCT05505630|DRUG|Saline|A single dose of IV saline will be administered
219050840|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
218941730|NCT00566696|DRUG|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941731|NCT00566696|DRUG|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941732|NCT00566696|DRUG|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941733|NCT00566696|DRUG|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941734|NCT00566696|DRUG|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941735|NCT00566696|DRUG|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
218941736|NCT00566696|DRUG|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941737|NCT00566696|DRUG|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
218941738|NCT00566696|DRUG|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
219050841|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
219050842|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
219050843|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
219050844|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
219050845|NCT05212259|DRUG|Placebo|4 capsules per day
218941739|NCT00566696|DRUG|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
218941740|NCT00802256|PROCEDURE|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
218941741|NCT04309864|DEVICE|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
218941742|NCT04309864|DEVICE|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
218941743|NCT05737355|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
218941744|NCT05737355|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
218941745|NCT05750446|DRUG|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
218941746|NCT05750446|OTHER|Placebo|Placebo
218941747|NCT06338462|DEVICE|Chatbot|The chatbot is a WhatsApp-based, artificial-intelligence powered customer service agent adapted for TB outreach. The objective of the Chatbot is to facilitate information gathering, education, and support throughout TB contact evaluation, ensuring accessible assistance on-demand during and after contact tracing procedures. It operates in a secure data environment that includes end-to-end encryption and has been reviewed and approved by the data protection team within the information technology unit at the Cali Secretariat of Public Health (SoPH) for the study purposes.
218941748|NCT06338462|DIAGNOSTIC_TEST|Oral testing|Oral testing involves collection of a saliva sample or use of a nylon swab to collect material from the tongue and oral mucosa that is then tested with a molecular test for Mycobacterium tuberculosis
218941749|NCT06322030|DIETARY_SUPPLEMENT|FOCUS-15 Lifestyle Management Program|15 week weight management program
218941750|NCT06322030|BEHAVIORAL|Exercise Training|15 weeks of progressive exercise training
218941751|NCT02693132|BEHAVIORAL|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
219050846|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
219050847|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
218941752|NCT02693132|BEHAVIORAL|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
218941753|NCT02693132|BEHAVIORAL|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
219050848|NCT04857866|DRUG|Placebo|Single dose of placebo
219050849|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
219050850|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
219050851|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
219050852|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
218941754|NCT00351429|DEVICE|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
218941755|NCT04376866|DRUG|Toripalimab|anti-PD-1 antibody
218941756|NCT02872935|DRUG|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
218941757|NCT02872935|DRUG|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
218941758|NCT05840757|DEVICE|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
218941759|NCT03854877|BEHAVIORAL|Health behaviour intervention|The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
218941760|NCT00010699|DRUG|Vitamin E|
218941761|NCT03048006|PROCEDURE|MRI with Dotarem|
218941762|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
218941763|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
218941764|NCT05743959|PROCEDURE|No intervention|No intervention
218941765|NCT01321099|OTHER|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
218941766|NCT01321099|OTHER|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
218941767|NCT01321099|OTHER|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
218941768|NCT03867318|DRUG|Atorvastatin|Atorvastatin administered orally QD as 10 mg tablets.
218941769|NCT03867318|DRUG|Ezetimibe|Ezetimibe administered orally QD as 10 mg tablets
218941770|NCT03867318|DRUG|Placebo for Ezetimibe|Single placebo tablet administered orally QD
218941771|NCT03867318|DRUG|Placebo for Atorvastatin|Single placebo tablet administered orally QD
219050853|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
218941772|NCT04615832|DEVICE|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
218941773|NCT01534897|DRUG|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
218941774|NCT00492128|DRUG|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
218941775|NCT06174688|DRUG|BOTOX|Intramuscular Injections
218941776|NCT06174688|DRUG|Placebo|Intramuscular Injections
218941777|NCT01276054|RADIATION|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
218941778|NCT01276054|DRUG|methylene blue|Given subcutaneously
218941779|NCT01276054|DRUG|indocyanine green solution|Given subcutaneously
218941780|NCT01276054|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
218941781|NCT01276054|PROCEDURE|axillary lymph node biopsy|Undergo axillary lymph node biopsy
218941782|NCT01276054|PROCEDURE|bioimpedance spectroscopy|Correlative studies
218941783|NCT01276054|PROCEDURE|quality-of-life assessment|Ancillary studies
219206715|NCT06888219|OTHER|Conventional logopedic rehabilitation|"Patients assigned to the control arm will undergo a total of 3 hours of speech and physiotherapy rehabilitation per day from Monday to Friday, and 1 hour on Saturday.~Regarding speech therapy treatment, both restorative and compensatory interventions will be applied, based on the patient's clinical condition.~Compensatory approaches include postural techniques (such as adopting a flexed head posture) and swallowing techniques (e.g., supraglottic swallowing, forced swallowing, the Mendelsohn maneuver), as well as modifying the consistency of liquids and food.~Restorative methods involve swallowing exercises aimed at enhancing muscular strength, resistance training, and motor training of the oral structures involved in swallowing."
218941784|NCT01276054|OTHER|lymphedema management|Undergo axillary reverse mapping
218941785|NCT03783624|BEHAVIORAL|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
218941786|NCT03783624|BEHAVIORAL|Open label placebo|Ritual intake of 2 placebo capsules twice a day
218941787|NCT02512029|DRUG|18F-AV-1451|
218941788|NCT06425692|BEHAVIORAL|Education|Education on basic palliative care via e-learning + webinar to deepen knowledge.
218941789|NCT05071768|BEHAVIORAL|Focused ACT|Brief acceptance and commitment therapy
218941790|NCT02703441|OTHER|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
218941791|NCT00552747|DRUG|fenofibrate|fenofibrate 160 mg capsules qd
218941792|NCT00552747|DRUG|placebo|capsules placebo
218941793|NCT04780997|OTHER|Virtual Reality|Microsoft Xbox Kinect® was used for virtual reality exercises
218941794|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^11 DRP/mL
218941795|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
218941796|NCT00126724|GENETIC|tgAAC94 placebo|placebo
218941797|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^12 DRP/mL tgAAC94
218941798|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
218941799|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^13 DRP/mL tgAAC94
218941800|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
218941801|NCT03573271|DEVICE|MCD|Micro-coring skin removal with automated coring device
218941802|NCT02792829|DRUG|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
218941803|NCT03173001|DIAGNOSTIC_TEST|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
218941804|NCT05367297|DIAGNOSTIC_TEST|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
218941805|NCT03791099|DRUG|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
218941806|NCT00136188|DRUG|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
218941807|NCT01518764|DIETARY_SUPPLEMENT|Red Wine Polyphenols 600mg/day|
218941808|NCT01518764|DIETARY_SUPPLEMENT|placebo|
218941809|NCT01500681|PROCEDURE|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
218941810|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
219050854|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
219050855|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
219050856|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
219206716|NCT06890078|OTHER|Biological sampling|Mouthwash, nasopharyngeal swab, blood sampling
218941811|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
218941812|NCT06396104|OTHER|Mobilisation with movement|The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.
218941813|NCT06396104|OTHER|Sham mobilisation|While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
218941814|NCT00466570|DRUG|gatifloxacin, moxifloxacin|
218941815|NCT05168111|DIAGNOSTIC_TEST|Detect the serum sample|Detect the serum sample
219050857|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
219050858|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
219634094|NCT01461486|DEVICE|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
219634095|NCT01461486|DEVICE|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
219634096|NCT03478566|DEVICE|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
219634097|NCT02343939|DRUG|Entospletinib|Tablet(s) administered orally every 12 hours
219634098|NCT02343939|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
219634099|NCT02343939|DRUG|Cytarabine|100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
218941816|NCT05701319|PROCEDURE|PCI|percutaneous coronary intervention
218941817|NCT04252976|BEHAVIORAL|Ethical Living|Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
218941818|NCT04252976|BEHAVIORAL|Yoga Exercises|Ujjaii breathing and simple yoga asanas
218941819|NCT04252976|BEHAVIORAL|Mantra Meditation|Meditation with mantras
218941820|NCT05744804|DRUG|-group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg|receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
218941821|NCT05744804|DRUG|(acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
218941822|NCT00644982|DRUG|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
218941823|NCT00644982|DRUG|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
218941824|NCT04993157|DRUG|FIA586|FIA586 capsule
218941825|NCT04298476|PROCEDURE|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
218941826|NCT00132548|DRUG|Pyrimethamine/sulfadoxine|
219206717|NCT06887205|PROCEDURE|Lymphovenous bypass (LVB)|At the time of axillary lymph node dissection (ALND) or inguinal lymph node dissection (ILND) in the melanoma patient population.
219206718|NCT06731530|DEVICE|Pentacam-AXL|Pentacam-AXL (Oculus, Wetzlar, Germany)
219206719|NCT06731530|DEVICE|HD Analyzer|HD Analyzer (Visiometrics, Terassa, Spain, Keeler)
219634100|NCT02343939|DRUG|Decitabine|20 mg/m\^2 administered intravenously
219634101|NCT02343939|DRUG|Azacitidine|75 mg/m\^2 administered intravenously or subcutaneously
218941827|NCT00132548|DRUG|Amodiaquine|
218941828|NCT00132548|DRUG|Artesunate|
219206720|NCT06731530|DEVICE|Corvis ST|Corvis ST (Oculus, Germany)
219634102|NCT04553822|OTHER|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
219634103|NCT04553822|OTHER|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
219050859|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
218941829|NCT04180124|OTHER|Walking|"Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated."
218941830|NCT00276523|BIOLOGICAL|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
218941831|NCT00276523|PROCEDURE|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
218941832|NCT00276523|PROCEDURE|Neoadjuvant therapy|
218941833|NCT00452361|DRUG|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
218941834|NCT00452361|DRUG|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation"
219634104|NCT04553822|OTHER|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
218941835|NCT01472718|DEVICE|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
218941836|NCT01472718|DEVICE|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
218941837|NCT03116152|BIOLOGICAL|IBI308|IBI308 200mg Intravenous drip every three weeks；
219050860|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
219050861|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
219050862|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219634105|NCT05962333|BIOLOGICAL|Intra-arterial delivery of autologous MABs|three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
218941838|NCT03116152|DRUG|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
218941839|NCT03705013|OTHER|Cologuard|Observational
218941840|NCT03305497|BEHAVIORAL|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
218941841|NCT06291519|OTHER|Multi-sensory Stimulation Method-Mother Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated before vaccination.~2. nd stimulus (sense of touch),: The mother applied touch - a light massage for 5 min until the vaccination process. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The mother spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The mother made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
219050863|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219050864|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
219050865|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
219050866|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
219050867|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
219050868|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
219206721|NCT06731530|DEVICE|OCT-A Angiovue|OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)
219206722|NCT06731530|DEVICE|IOLMaster V.5.4|IOLMaster V.5.4 (Carl Zeiss., Meditec)
219206723|NCT06731530|DEVICE|Topcon SP-1P|Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)
219206724|NCT06731530|OTHER|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination
219634106|NCT03187730|BEHAVIORAL|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
219634107|NCT03187730|BEHAVIORAL|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
218941842|NCT06291519|OTHER|Multi-sensory Stimulation Method-Nurse Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated 5 min before vaccination.~2. nd stimulus (sense of touch),: The nurse applied touch - a light massage for 5 minutes until the vaccination. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The nurse spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The nurse made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
218941843|NCT06291519|OTHER|Breastfeeding Applied Group|"Multisensory stimulus method not applied:~The baby was breastfed by its mother for 20 minutes. Breastfeeding was stopped just before the vaccination."
218941844|NCT04802577|DIAGNOSTIC_TEST|FACT-F questionnaire|The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
218941845|NCT04802577|DIAGNOSTIC_TEST|Beck Depression Inventory|The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
218941846|NCT04802577|DIAGNOSTIC_TEST|Beck Anxiety Inventory|The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
218941847|NCT04802577|DIAGNOSTIC_TEST|Insomnia severity index.|The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
219050869|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
219050870|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
219050871|NCT00002604|DRUG|chemosensitization/potentiation therapy|
219050872|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
219050873|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
219050874|NCT06085417|DRUG|bupivacaine|bupivacaine
219634108|NCT03187730|DRUG|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
219634109|NCT04589377|BEHAVIORAL|Mindfulness Training|Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
219634110|NCT05102357|PROCEDURE|Conservative Treatment (splint)|splint 6 weeks
219634111|NCT04668248|OTHER|Simulation|"The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns."
219050875|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
219050876|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
218941848|NCT04802577|OTHER|ESSPRI|The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
218941849|NCT04802577|OTHER|ESSDAI|Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
218941850|NCT04802577|OTHER|Pain Detect Questionnaire|The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
218941851|NCT04660916|DRUG|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
218941852|NCT00430976|BEHAVIORAL|Minds in Motion|
218941853|NCT05504642|DRUG|Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
218941854|NCT05504642|DRUG|Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
218941855|NCT05504642|PROCEDURE|Maintenance Treatment (Nivolumab/Ipilimumab)|For six months after Chemo-radio-immunotherapy, Nivolumab 3mg/kg every two weeks x12 (week +2, +4, +6, +8, +10, +12, +14, +16, +18, +20, +22, +24 (twelve applications), each application over 30 minutes and Ipilimumab every six weeks x4 (week +6,+12, +18, +24).
218941856|NCT04045002|OTHER|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
219050877|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
219050878|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
218941857|NCT02379637|DRUG|N-acetylcysteine|
219634112|NCT04668248|OTHER|Online educational training|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
218941858|NCT02379637|DRUG|Placebo|
218941859|NCT01110148|OTHER|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
218941860|NCT01110148|OTHER|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
219050879|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
218941861|NCT00665808|DRUG|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
218941862|NCT00665808|DRUG|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
218941863|NCT00862641|DRUG|Regadenoson|IV
219050880|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
219050881|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
218941864|NCT00862641|DRUG|Placebo|IV
218941865|NCT03795272|DRUG|Rucaparib|2:1 randomization to receive rucaparib/placebo twice daily for 24 month
218941866|NCT03795272|DRUG|Placebo|placebo
218941867|NCT00420043|DRUG|imatinib|
218941868|NCT05149521|OTHER|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
218941869|NCT05816499|DRUG|Cadonilimab|Given IV, 10mg/kg Q3W
218941870|NCT05816499|DRUG|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
218941871|NCT05816499|DRUG|Docetaxel|Given IV, 60-75mg/m2 Q3W
218941872|NCT03238014|DEVICE|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
219050882|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
219050883|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
219050884|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
219050885|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
219050886|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
219206725|NCT06730321|OTHER|Observations on clinicopathological factors influencing the assessment score of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
219634113|NCT00669097|DRUG|TKI258|
218941873|NCT05587686|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
219634114|NCT03735277|BIOLOGICAL|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
219634115|NCT04084951|BIOLOGICAL|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
219634116|NCT04084951|DRUG|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
218941874|NCT04514380|OTHER|Carbohydrate fluid|400 mL carbohydrate fluid
218941875|NCT04514380|OTHER|Non-carbohydrate fluid|0 mL carbohydrate fluid
218941876|NCT02465424|OTHER|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
218941877|NCT05063448|BEHAVIORAL|DadSpace|A group educational support and mentoring program for perinatal fathers.
218941878|NCT02448641|BIOLOGICAL|SB623 Implant (2.5M)|2.5 million SB623 cells
218941879|NCT02448641|BIOLOGICAL|SB623 Implant (5.0M)|5 million SB623 cells
218941880|NCT02448641|PROCEDURE|Sham surgery|
218941881|NCT05861713|DRUG|Hydrating Cream|The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
219050887|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
219050888|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
219050889|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
219050890|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
219206726|NCT06730074|DEVICE|Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)|This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
219634117|NCT04084951|DRUG|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
219634118|NCT04084951|DRUG|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
218941882|NCT05170880|PROCEDURE|Primary endodontic treatment|Primary non surgical endodontic treatment will be provided to patients in treatment group.
218941883|NCT05950386|OTHER|Lead exposure|The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
218941884|NCT00228553|DRUG|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
218941885|NCT05359367|DIAGNOSTIC_TEST|Observational|Laboratory movement analysis, navigated transcranial magnetic stimulation and clinical aspects of gait function and walking.
218941886|NCT03492918|DRUG|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
218941887|NCT02396472|BEHAVIORAL|Order by time and topic|
218941888|NCT02396472|BEHAVIORAL|Order by information relevance|
219206727|NCT07040085|DRUG|Y-6|each tablet of Y-6 contained 6 mg of dexborneol and 25 mg of cilostazol; Both groups took one tablet q12h for 28 days.
219634119|NCT00708383|OTHER|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
219634120|NCT00708383|OTHER|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
218941889|NCT02396472|BEHAVIORAL|Order by social relationship|
218941890|NCT02396472|BEHAVIORAL|Order by help giving|
218941891|NCT02396472|BEHAVIORAL|Order by self-disclosure|
219634121|NCT02089373|PROCEDURE|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
219634122|NCT02089373|PROCEDURE|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
219634123|NCT04595045|DRUG|Botulinum toxin type A infiltrations|Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
219634124|NCT00306020|DRUG|topical morphine|
219634125|NCT04620447|OTHER|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
219634126|NCT02585947|DRUG|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
218941892|NCT05367089|DRUG|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
218941893|NCT05367089|DEVICE|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
218941894|NCT00959725|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
218941895|NCT03834272|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device. Some patients may be imaged with an additional imaging device.
218941896|NCT04516785|DIAGNOSTIC_TEST|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
218941897|NCT01898351|OTHER|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
219206728|NCT07040085|DRUG|Y-6 placebo|each tablet of Y-6 placebo contained 0.06 mg of dexborneol and 0 mg of cilostazol. Both groups took one tablet q12h for 28 days.
218941898|NCT05368701|BEHAVIORAL|Volitional Help Sheet for self-harm|"The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents."
219634127|NCT01760174|DRUG|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
219634128|NCT01760174|DRUG|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
219634129|NCT05442502|PROCEDURE|The overlap guiding tube(OGT) method|The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
219634130|NCT05442502|PROCEDURE|The conventional overlap method|After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
219634131|NCT01920412|DEVICE|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
219634132|NCT06578572|BIOLOGICAL|R21Matrix M|A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
219634133|NCT01708382|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219634134|NCT00813072|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219634135|NCT00813072|DRUG|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219634136|NCT00813072|DRUG|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219634137|NCT03745846|BIOLOGICAL|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
219634138|NCT03745846|BIOLOGICAL|placebo|Composite Gel Containing Black Raspberry-placebo
219634139|NCT01303172|BIOLOGICAL|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
219634140|NCT01303172|DRUG|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
219634141|NCT00504712|DRUG|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
219634142|NCT00504712|DRUG|saline|Saline injection every two weeks
219634143|NCT01061112|DRUG|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
218941899|NCT01895478|BEHAVIORAL|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
218941900|NCT01196403|OTHER|questionnaire administration|
218941901|NCT01196403|PROCEDURE|quality-of-life assessment|
218941902|NCT01196403|PROCEDURE|robot-assisted laparoscopic surgery|
218941903|NCT01196403|PROCEDURE|therapeutic conventional surgery|
218941904|NCT01196403|PROCEDURE|therapeutic laparoscopic surgery|
218941905|NCT04340271|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
219050891|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
218941906|NCT04340271|OTHER|conventional occupational therapy|Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
218941907|NCT03617224|RADIATION|TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
218941908|NCT03617224|DRUG|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
218941909|NCT03048513|OTHER|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
218941910|NCT01142804|BEHAVIORAL|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
218941911|NCT02024789|DRUG|Placebo|Orally twice daily, 26 weeks
218941912|NCT02024789|DRUG|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
219050892|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
219050893|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
219050894|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
219050895|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
219634144|NCT01061112|DRUG|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
219634145|NCT01061112|DRUG|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
218941913|NCT02024789|DRUG|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
218941914|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
218941915|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
218941916|NCT01983410|BEHAVIORAL|The risk assessment questionnaire|
219050896|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
219050897|NCT02192450|DRUG|Insulin aspart/glargine|
219050898|NCT02192450|DRUG|Insulin aspart/degludec|
219050899|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
219050900|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
219050901|NCT02346565|PROCEDURE|Exercise ECG|
219050902|NCT02346565|PROCEDURE|Stress Echocardiography|
219050903|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
219050904|NCT02039531|DRUG|Hyaluronic Acid|
219634146|NCT01061112|DRUG|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
219634147|NCT01061112|DRUG|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
219050905|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
219050906|NCT02037503|DRUG|Ketamine|
219050907|NCT02037503|DRUG|Saline|
219050908|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
219050909|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
218941917|NCT01983410|OTHER|Blood specimens|
218941918|NCT01983410|OTHER|tumor tissue samples will be requested|
218941919|NCT05477108|DRUG|Treatment A (BGF MDI HFO with oral activated charcoal)|Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
218941920|NCT05477108|DRUG|Treatment B (BGF MDI HFA with oral activated charcoal)|Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
218941921|NCT05854914|PROCEDURE|Use of hypnosis videos|Hypnosis on smartphone will be used to manage pain for emergent coelioscopy surgery of patients with acute and complicated appendicitis, with generalized peritonitis
218941922|NCT06054659|DEVICE|Real Time Continuous Glucose Monitoring (rt-CGM)|Participants randomized to rt-CGM will have CGM placed before hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will provide CGM devices, but subjects may use their glucometer for FBG testing as needed for CGM calibration.
219050910|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
219050911|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
219050912|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
219050913|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
219050914|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
219050915|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
219050916|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
219050917|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
219050918|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
219050919|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
219050920|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
219050921|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
219050922|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
219050923|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
219050924|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
219050925|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
219050926|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
219050927|NCT00194012|DRUG|Placebo|Addressed in arm description.
219050928|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
219634148|NCT01061112|DRUG|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
219634149|NCT03131843|DRUG|Alcohol|Alcohol cleansing swab/wipe
219634150|NCT03131843|DRUG|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
218941923|NCT06054659|OTHER|Fingerstick blood glucose (FBG) monitoring|Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
218941924|NCT06054659|BEHAVIORAL|Diabetes Education|Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
218941925|NCT02660983|DRUG|Donepezil hydrochloride|
218941926|NCT02660983|DRUG|Donepezil matching placebo|
219050929|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
219050930|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
219050931|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
219050932|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
219050933|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
219050934|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
219050935|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
219050936|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
219050937|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
219634151|NCT02359955|DEVICE|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
219634152|NCT02359955|DEVICE|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
219634153|NCT04852419|DRUG|ZN-c5|ZN-c5
219050938|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
218941927|NCT02660983|DRUG|Donepezil hydrochloride|
218941928|NCT05210777|DEVICE|observation|no intervention
218941929|NCT05489133|BEHAVIORAL|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
219050939|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
219050940|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
219050941|NCT04912505|DRUG|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
219050942|NCT05059158|RADIATION|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
219050943|NCT02497664|OTHER|Active Breathing Control|
219050944|NCT00623220|OTHER|N2O|EMONO
219050945|NCT00623220|OTHER|oxygen|oxygen
219050946|NCT04987359|BEHAVIORAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
219050947|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
219050948|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
219050949|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
219050950|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
218941930|NCT04462770|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
218941931|NCT04462770|DRUG|Placebo|Placebo will be administered as an oral solution.
219050951|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
219050952|NCT02564198|DRUG|Ramucirumab|Administered IV
219050953|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
219050954|NCT02721212|DEVICE|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
219050955|NCT02721212|OTHER|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
219050956|NCT05733676|DEVICE|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
219050957|NCT05733676|DEVICE|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
219050958|NCT05786456|PROCEDURE|Discussion|Participate in group and web-based self-study sessions
218941932|NCT03814304|OTHER|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
219050959|NCT05786456|OTHER|Informational Intervention|Receive handouts
219050960|NCT05786456|OTHER|Media Intervention|View videos
219050961|NCT05786456|OTHER|Questionnaire Administration|Ancillary studies
219050962|NCT05786456|BEHAVIORAL|Telephone-Based Intervention|Participate in check-in calls
219050963|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
219050964|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
219050965|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
219050966|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
219050967|NCT06957821|DRUG|Pegulicianine|Pegulicianine (LUMISIGHT) Inflammatory activity
219206729|NCT07039552|PROCEDURE|risk-reducing salpingo-oophorectomy (RRSO)|The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.
219050968|NCT06957821|OTHER|Placebo|Control group for the study
219050969|NCT01019655|DRUG|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
219206730|NCT06296082|DRUG|Botulinum toxin type A|Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
218941933|NCT03814304|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
218941934|NCT05238922|DRUG|INCB0123667|25 mg tablets
218941935|NCT05238922|DRUG|Palbociclib|Palbociclib will be administered at protocol defined dose.
218941936|NCT05238922|DRUG|Bevacizumab|Bevacizumab will be administered at protocol defined dose.
218941937|NCT05238922|DRUG|Olaparib|Olaparib will be administered at protocol defined dose.
218941938|NCT05238922|DRUG|Paclitaxel|Paclitaxel will be administered at protocol defined dose.
218941939|NCT05238922|DRUG|Ribociclib|Ribociclib will be administered at protocol defined dose.
219050970|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
219050971|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
219050972|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
218941940|NCT05238922|DRUG|Fulvestrant|Fulvestrant will be administered at protocol defined dose.
218941941|NCT02083861|DEVICE|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
218941942|NCT03376295|DRUG|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
218941943|NCT03376295|DRUG|LABA and an ICS (LABA-ICS)|combinational drug
218941944|NCT03665519|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
218941945|NCT03665519|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
218941946|NCT05685251|OTHER|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
219050973|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
219050974|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
218941947|NCT05685251|OTHER|Home Blood Pressure Monitoring|Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
218941948|NCT04164511|DIETARY_SUPPLEMENT|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
218941949|NCT03049007|DIAGNOSTIC_TEST|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
218941950|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
218941951|NCT05692453|DIAGNOSTIC_TEST|Arterial blood gas with co-oximetry|1 mL blood sample for ABG-CoOx analysis to obtain co-oximetry measured arterial oxygen saturation (SaO2C) and standard ABG derived arterial oxygen saturation (SaO2S).
218941952|NCT03477539|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
218941953|NCT03477539|BIOLOGICAL|Daratumumab|Given IV
218941954|NCT03477539|DRUG|Lenalidomide|Given PO
218941955|NCT06053242|DRUG|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
218941956|NCT06053242|OTHER|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
218941957|NCT05322954|DRUG|Psilocybin|25mg orally followed by 25 mg or 50 mg orally
218941958|NCT03606499|DRUG|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
218941959|NCT06505837|DRUG|JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001sc and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001sc and pemetrexed maintenance therapy, and the cumulative treatment of JS001sc did not exceed 35 cycles (Each cycle is 21 days).
218941960|NCT06505837|DRUG|JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001 and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001 and pemetrexed maintenance therapy, and the cumulative treatment of JS001 did not exceed 35 cycles (Each cycle is 21 days).
218941961|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
218941962|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
218941963|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
219050975|NCT04669210|DRUG|Ruxolitinib|Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.
218941964|NCT04703114|DIAGNOSTIC_TEST|Blood count|Blood count at each visit
218941965|NCT04703114|DIAGNOSTIC_TEST|Blood collection|Blood collection to understanding of the immunological profile at each visit
219050976|NCT04669210|DRUG|Tacrolimus|Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100
219050977|NCT04669210|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 30 mg/kg from day +5 to +35
219050978|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
218941966|NCT04703114|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
218941967|NCT04703114|DIAGNOSTIC_TEST|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
218941968|NCT04703114|DIAGNOSTIC_TEST|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
218941969|NCT04703114|GENETIC|Genetic blood collection|Collection to further research at each visit
218941970|NCT04703114|OTHER|Data collection|Demographics, symptoms, biological constants
218941971|NCT01165216|DRUG|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
218941972|NCT01165216|DRUG|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
218941973|NCT01165216|DRUG|Paclitaxel|IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles
219050979|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
219050980|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
219050981|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
219206731|NCT06296082|OTHER|Dry Needling|Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
218941974|NCT01165216|DRUG|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
218941975|NCT00141791|DRUG|Etanercept|
218941976|NCT01966848|DEVICE|Wich prosthesis is used|
218941977|NCT00167219|BIOLOGICAL|Stem Cell Transplant|Transplantation on Day 0.
218941978|NCT00167219|DRUG|Preparative Regimen|"* Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)"
218941979|NCT01962363|DRUG|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
218941980|NCT00564668|DRUG|biphasic insulin aspart|
218941981|NCT04408781|PROCEDURE|Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
218941982|NCT03666715|DRUG|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
218941983|NCT03666715|DRUG|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
218941984|NCT06412939|DEVICE|Agile Nail|Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
218941985|NCT04895735|BIOLOGICAL|Pembrolizumab|Given IV
218941986|NCT04895735|DRUG|Pemetrexed Disodium|Given IV
218941987|NCT04895735|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218941988|NCT04895735|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
218941989|NCT04895735|PROCEDURE|Positron Emission Tomography|Undergo PET
218941990|NCT04895735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218941991|NCT04895735|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
218941992|NCT05197062|DRUG|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
218941993|NCT04848792|DIETARY_SUPPLEMENT|Sulforaphane|Myrosinase-active whole broccoli sprout material
218941994|NCT04848792|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
218941995|NCT06455319|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
218941996|NCT06455319|DRUG|verapamil extended release capsule|Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
218941997|NCT06455319|DRUG|Placebo|I.V. Saline
218941998|NCT05704244|DRUG|FE 999326|75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
218941999|NCT06230679|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
219050982|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
219050983|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
218942000|NCT06230679|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219050984|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
219050985|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
218942001|NCT06805838|DEVICE|Sotair|"The device is a durable plastic connector with a silicone flap inside it requiring no special handling. There are no patients involved, only a simulated lung that also requires no special handling. Adult Sotair® device has FDA clearance as a Class II device through the 510(k) pathway (K212905) for the intended use of Flow-limiting, safe, and optimal manual ventilation to minimize gastric insufflation."
219050986|NCT02097134|DRUG|Melphalan|Given IA
219050987|NCT00218062|DRUG|D-Amphetamine 30mg|
219050988|NCT00218062|DRUG|D-Amphetamine 60mg|
219050989|NCT00218062|DRUG|Modafinil 200mg|
219050990|NCT00218062|DRUG|Modafinil 400mg|
219050991|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
219050992|NCT00218062|DRUG|Placebo|
219050993|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
219050994|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
219050995|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
219050996|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
219050997|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
219050998|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
219050999|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
218942002|NCT06199570|BEHAVIORAL|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a second coaching session, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a third coaching session, the stress management plan will be revisited for new concerns.
218942003|NCT06199570|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
218942004|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 of Dose A
218942005|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 at dose B
219634154|NCT03326570|BEHAVIORAL|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
219634155|NCT00128232|DRUG|Octreotide LAR|
219634156|NCT00991237|OTHER|Pulsed Radiofrequency|Pulsed Radiofrequency
219634157|NCT02619357|DEVICE|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
219051000|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
218942006|NCT05469360|DRUG|Matching placebo|A single intrathecal injection of matching placebo
218942007|NCT05469360|DRUG|NIO752|Multiple intrathecal injections of NIO752 of Dose A
218942008|NCT05469360|DRUG|NIO752|Two intrathecal injections of NIO752 at dose C
218942009|NCT05469360|DRUG|NIO752|Single intrathecal injection of NIO752 at dose C
218942010|NCT05469360|DRUG|Matching placebo|Two intrathecal injections of matching placebo
218942011|NCT06176183|PROCEDURE|Arthroscopic meniscus repair|"A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted."
219051001|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
219051002|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
219051003|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
219051004|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
219051005|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
219051006|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
219051007|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
219051008|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
219051009|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
219051010|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
219051011|NCT00225355|DRUG|Rosiglitazone|
218942012|NCT05738837|BEHAVIORAL|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships\&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
218942013|NCT05738837|BEHAVIORAL|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
218942014|NCT06795178|DRUG|FP-014|11.25 mg in a prefilled, ready-to-use, long-acting formulation
218942015|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
218942016|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
219051012|NCT00298896|DRUG|SNS-595|
219051013|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
219051014|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
219051015|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
219051016|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
219051017|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
218942017|NCT06332092|DRUG|FID007|Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
218942018|NCT06421636|DRUG|REGN7999|Administered subcutaneous (SC)
218942019|NCT06421636|DRUG|Placebo|Administered SC
218942020|NCT02902601|DRUG|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
218942021|NCT02902601|DRUG|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
218942022|NCT02902601|OTHER|Placebo|Matching placebo to JNJ-54175446
218942023|NCT02694458|OTHER|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
218942024|NCT02694458|OTHER|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
218942025|NCT04999449|DRUG|Scopolamine|Intranasal scopolamine at 0.2 mg or 0.4 mg
218942026|NCT04999449|DRUG|Placebo|Intranasal saline placebo
219051018|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
218942027|NCT03809325|DRUG|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
218942028|NCT05563363|OTHER|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
218942029|NCT05563363|OTHER|standard inpatient treatment|Inpatient treatment on addiction ward
218942030|NCT06040541|DRUG|RMC-9805|Oral Tablets
218942031|NCT06040541|DRUG|RMC-6236|Oral Tablets
219051019|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
219051020|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
218942032|NCT04303195|DRUG|NG101|Capsules
218942033|NCT04303195|DRUG|Placebo|Capsules
218942034|NCT06230523|DRUG|LY3841136|Administered SC.
218942035|NCT06230523|DRUG|Placebo|Administered SC.
218942036|NCT06227572|BEHAVIORAL|CATNAP MI|"Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence."
218942037|NCT06251206|BEHAVIORAL|ADL/Postoperative Instruction|This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.
218942038|NCT06251206|BEHAVIORAL|Postoperative Instruction|This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
218942039|NCT05672524|DRUG|Trastuzumab|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
218942040|NCT05672524|DRUG|Tucatinib|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
218942041|NCT03155022|DEVICE|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
218942042|NCT03155022|DEVICE|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
218942043|NCT06445166|DRUG|Propranolol Hydrochloride|"Dosing is as follows:~* Patients who weigh 40 to 59.9 kg:~  * 40 mg BID (target)~ * 20 mg BID (half the target)~* Patients who weigh ≥ 60 kg:~  * 60 mg BID (target)~ * 30 mg BID (half the target)"
218942044|NCT01595958|DRUG|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
218942045|NCT01595958|PROCEDURE|cardio-pulmonary resuscitation|usual care of cardiac arrest
218942046|NCT05556902|DEVICE|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
219051021|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
219051022|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
219051023|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
219051024|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
218942047|NCT06729970|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
218942048|NCT06729970|DRUG|Lithium|Specified dose on specified days
218942049|NCT06729970|DRUG|Valproic Acid|Specified dose on specified days
218942050|NCT06729970|DRUG|Lamotrigine|Specified dose on specified days
218942051|NCT06974786|DRUG|Elranatamab|Participants will receive step up dosing of Elranatamab subcutaneously in first cycle of consolidation followed by fixed dosing for 2 additional cycles and for 12 cycles in maintenance. Arm A participants will receive additional 12 cycles of Elranatamab monotherapy if they are MRD negative after Maintenance 1 for a total of 27 cycles. Cycles will be 28 days.
218942052|NCT06974786|DRUG|Daratumumab|Participants will be given 1800 mg of Daratumumab subcutaneously every 4 weeks for up a maximum of 26 cycles.
218942053|NCT06974786|DRUG|Lenalidomide|Participants will receive 10 mg of Lenalidomide daily by mouth for 21 days of each 28-day cycle for up to a maximum of 24 cycles.
219634158|NCT02619357|DEVICE|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
219634159|NCT02619357|DEVICE|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
218942054|NCT06974786|PROCEDURE|autologous stem cell transplantation|Participants will undergo ASCT as standard treatment following individual site's processes and practices.
218942055|NCT06457204|DRUG|Pramipexole manufactured in Ingelheim|1 tablet Sifrol® (pramipexole) manufactured in Ingelheim containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
218942056|NCT06457204|DRUG|Pramipexole manufactured in Ennigerloh|1 tablet Sifrol® (pramipexole) manufactured in Ennigerloh containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
218942057|NCT06855043|DRUG|Calfactant|Participants will receive 3 daily doses of Calfactant (1.5ml/kg) administered intratracheally
218942058|NCT06855043|DRUG|Budesonide|Participants will receive 3 daily doses of Budesonide (0.25mg/kg) administered intratracheally.
218942059|NCT05171049|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
218942060|NCT05171049|DRUG|Apixaban|Apixaban 10 mg followed by 5 mg
218942061|NCT06060548|OTHER|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
218942062|NCT06812650|OTHER|Medical treatment|Patients will continue their routine medical treatment for gastroesophageal reflux disease.
218942063|NCT06812650|OTHER|Exercise|The exercise program will consist of diaphragmatic breathing exercises and progressive muscle relaxation exercises. Diaphragmatic breathing exercises will be performed for 8 weeks, 5 days a week, twice a day, for 15 minutes each time.
218942064|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine (IIV) at baseline|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
218942065|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 3-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
218942066|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine at Month 1|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
218942067|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 6-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
218942068|NCT06593119|BEHAVIORAL|Telemedicine management of Hypertension|TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care
218942069|NCT06593119|BEHAVIORAL|Usual Care|This includes usual clinic based HTN care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.
219634160|NCT02619357|DEVICE|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
219634161|NCT02619357|DEVICE|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
219634162|NCT02619357|OTHER|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
219634163|NCT02619357|OTHER|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
219634164|NCT02619357|OTHER|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
219051025|NCT02912481|PROCEDURE|posterior tibial artery|
219051026|NCT02912481|PROCEDURE|radial artery|
219051027|NCT02912481|PROCEDURE|dorsalis pedis artery|
219051028|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
219051029|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
218942070|NCT04553133|DRUG|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
218942071|NCT04553133|DRUG|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
218942072|NCT04553133|DRUG|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
218942073|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
218942074|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
218942075|NCT04553133|DRUG|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
218942076|NCT04553133|DRUG|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
218942077|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
218942078|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
218942079|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
218942080|NCT01065454|DRUG|Placebo|Placebo three times a day
218942081|NCT03391739|BIOLOGICAL|CART-19 cells|CART-19 cells treat
218942082|NCT05612139|DEVICE|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
218942083|NCT04066907|OTHER|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
219051030|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
219051031|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
219051032|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
219051033|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
219051034|NCT06788964|DRUG|Loncastuximab Tesirine|Patients will receive Loncastuximab Tesirine intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
219051035|NCT06788964|DRUG|Rituximab|Rituximab is administered intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
219634165|NCT05189652|OTHER|Myofascial Release and Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises - Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (1 set of 30 seconds will be applied with a rolling period of 2-4 seconds).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (2 sets of 30 seconds will be applied to each area with a rolling period of 2-4 seconds)."
218942084|NCT06546397|DRUG|17β-estradiol/dydrogesterone tablets|The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
218942085|NCT06988163|BEHAVIORAL|OACareTools+|OACareTools+ is a healthcare provider intervention that combines healthcare provider education, customized patient and clinical resources, and technical support from a national organization to facilitate provider counseling on and referral to as well as patient engagement in Walk With Ease. There are 2 main parts to this intervention: 1) Healthcare provider education: The study team will deliver the provider education and resources (including information about Walk With Ease and the established referral process/smartphrase) in a presentation providers at a weekly clinician meeting and in follow-up emails. 2) Implementation: Providers will use the resources to briefly counsel patients about physical activity and Walk With Ease and use the smartphrase to refer patients to Walk With Ease. Patients will register for and participate in the online Walk With Ease program. Patients and providers can seek assistance from the national organization as needed during these processes.
218942086|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
218942087|NCT06651242|OTHER|Routine care|Routine care
218942088|NCT06986928|OTHER|No intervention will be applied.|No intervention will be applied.
218942089|NCT06986928|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
218942090|NCT04133246|BEHAVIORAL|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
218942091|NCT04133246|BEHAVIORAL|Individual interview|Interview led by the psychologist about the patient's parenthood
219051036|NCT05112497|OTHER|No intervention procedure|No intervention procedure
219206732|NCT04012567|DEVICE|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
219051037|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
219634166|NCT05189652|OTHER|Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises- Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied)."
219634167|NCT00462709|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
218942092|NCT06660277|DEVICE|Super High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is currently approved by Health Canada and available for use across Canada. This filter has larger pores than a high-flux dialyzer that allow for greater removal of potential toxins and wastes in the blood that would regularly be filtered out by healthy kidneys.
218942093|NCT06660277|DEVICE|High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is that is widely used across Canada for hemodialysis treatments.
218942094|NCT01601652|DRUG|Omegaven|1 g/kg/d iv infusion over 24h
218942095|NCT03839537|OTHER|Exposure measurement|"* 2 measurements per subject (in warm season and in cold season)~* Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
218942096|NCT03839537|OTHER|Spirometry test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will inhale and exhale in the device"
218942097|NCT03839537|DIAGNOSTIC_TEST|Exhaled carbon monoxide test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will exhale in the device"
218942098|NCT03839537|DIAGNOSTIC_TEST|Skin allergy test|\- Performed by a physician during the inclusion clinical examination
218942099|NCT03839537|DIAGNOSTIC_TEST|Spirometry test|\- Performed by a physician during the inclusion clinical examination
218942100|NCT03839537|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide Testing|\- Performed by a physician during the inclusion clinical examination
218942101|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
218942102|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
218942103|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
219634168|NCT04952805|DRUG|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
219634169|NCT04952805|OTHER|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
218942104|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
218942105|NCT00758199|DRUG|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
218942106|NCT00758199|DRUG|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
218942107|NCT00758199|DRUG|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
218942108|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
218942109|NCT06606860|DRUG|Placebo|Placebo tablet
218942110|NCT06984679|OTHER|Physical Evaluations in Children with Cystic Fibrosis|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in children and adolescents with cystic fibrosis. The data to be obtained through all these evaluations will be done face to face within 45-60 minutes.
219051038|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
219051039|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
218942111|NCT06984679|OTHER|Physical Evaluations in Healthy Children|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in healthy children and adolescents. The data to be obtained from all these assessments will be made face to face within 45-60 minutes.
219051040|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
219051041|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
219051042|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
219051043|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
219051044|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
219051045|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
219051046|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
219051047|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
219051048|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
219051049|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
219051050|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
219051051|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
219051052|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
219051053|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
219206733|NCT04012567|DEVICE|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
219634170|NCT01736345|GENETIC|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
219206734|NCT06731868|DRUG|LPM3770164 sustained release tablet 5 mg|LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
219634171|NCT01736345|OTHER|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
219634172|NCT01736345|OTHER|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
219634173|NCT01736345|OTHER|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
219634174|NCT01736345|OTHER|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
219634175|NCT00204698|DRUG|Aciphex|20 mg of aciphex taken twice daily
219634176|NCT04471857|BEHAVIORAL|Hypnosis|
219051054|NCT00384137|DRUG|Tacrolimus|Immunosuppression
219051055|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
219051056|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
219051057|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
218942112|NCT05688670|PROCEDURE|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
218942113|NCT05688670|PROCEDURE|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
218942114|NCT05688670|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
218942115|NCT06594393|DRUG|TCP-25 gel|Topical gel
219051058|NCT02483234|DRUG|secukinumab|
218942116|NCT06594393|DRUG|Vehicle (placebo)|Placebo gel
218942117|NCT04007354|OTHER|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
218942118|NCT04321707|RADIATION|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
218942119|NCT06991322|DEVICE|A-FLUX Reducer System|The VahatiCor A-FLUX Reducer System is an implantable, self-expanding dense-cell nitinol coronary sinus flow restrictor device pre-loaded into the A-FLUX Delivery Catheter.
218942120|NCT06997744|DEVICE|Low-frequency(2HZ) TENS|Participants receive transcutaneous electrical nerve stimulation (TENS) at a frequency of 2Hz. The stimulation is delivered using surface electrodes placed on the affected upper limb. Each session lasts 30 minutes and is conducted three times per week for a total of 8 weeks. Intensity is gradually increased from 1 mA to 3 mA during each session.
218942121|NCT06997744|DEVICE|High-frequency(100HZ) TENS|Participants receive TENS at a frequency of 100Hz using the same electrode placement and schedule as the 2Hz group. Sessions last 30 minutes, three times weekly for 8 weeks, with intensity increasing from 1 mA to 3 mA across the session. This group represents high-frequency stimulation.
218942122|NCT06997744|DEVICE|Placebo TENS|Participants use a TENS device identical in appearance to the active treatment units. The power light is on, but no electrical stimulation is delivered due to internal circuit disconnection. Sessions follow the same schedule and duration as the active groups.
218942123|NCT06996990|OTHER|Physical evaluations in Volleyball Players|This study will evaluate pain, fatigue, muscle strength, balance and quality of life in volleyball players. All these measurements will be completed in two sessions lasting 45-60 minutes.
218942124|NCT06862219|DRUG|Enfortumab Vedotin|Intravenous Infusion
218942125|NCT06616987|DRUG|Sacituzumab Govitecan with pegfilgrastim|"▪ Sacituzumab Govitecan group~\- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9"
218942126|NCT00027989|DRUG|gemcitabine hydrochloride|
218942127|NCT00027989|DRUG|pegylated liposomal doxorubicin hydrochloride|
218942128|NCT04576871|DRUG|225Ac-J591|In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.
218942129|NCT06342193|DEVICE|virtual reality group|This group will use virtual reality glasses as distraction during cystoscopy.
219051059|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
219634177|NCT00027066|DRUG|Active Aspirin|325mg tablet daily
219634178|NCT00027066|DRUG|Active Warfarin|2mg scored tablet daily
219634179|NCT00027066|DRUG|Aspirin placebo|325mg aspirin placebo pill
219634180|NCT00027066|DRUG|Warfarin placebo|2mg scored placebo tablet
219634181|NCT01448330|DRUG|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
219634182|NCT05646264|DRUG|Agomelatine|Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
218942130|NCT00975897|BIOLOGICAL|bevacizumab|
218942131|NCT00975897|BIOLOGICAL|cetuximab|
218942132|NCT00975897|DRUG|fluorouracil|
218942133|NCT00975897|DRUG|irinotecan hydrochloride|
218942134|NCT00975897|DRUG|leucovorin calcium|
218942135|NCT00975897|DRUG|oxaliplatin|
218942136|NCT00975897|GENETIC|RNA analysis|
218942137|NCT00975897|GENETIC|cytogenetic analysis|
218942138|NCT00975897|GENETIC|fluorescence in situ hybridization|
218942139|NCT00975897|GENETIC|gene expression analysis|
218942140|NCT00975897|GENETIC|mutation analysis|
219051060|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
218942141|NCT00975897|GENETIC|protein expression analysis|
219206735|NCT06731868|DRUG|LPM3770164 sustained release tablet 10 mg|LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
219206736|NCT06731868|DRUG|LPM3770164 sustained release tablet 20 mg|LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
219634183|NCT04644302|DIAGNOSTIC_TEST|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
219634184|NCT04468347|DRUG|Flortaucipir F18|IV injection, 240 megabecquerel (MBq) (6.5 mCi)
218942142|NCT00975897|OTHER|diagnostic laboratory biomarker analysis|
218942143|NCT00975897|OTHER|immunohistochemistry staining method|
218942144|NCT00975897|OTHER|questionnaire administration|
218942145|NCT00975897|PROCEDURE|cognitive assessment|
218942146|NCT06870760|OTHER|Monoclonal Gammopathy|Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.
219051061|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
219051062|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
219206737|NCT06731868|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
218942147|NCT06870760|OTHER|Complete Blood Count with differential (CBC w/ diff)|Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.
218942148|NCT06870760|OTHER|Clonal hematopoiesis (CHIP)|Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.
218942149|NCT05576480|RADIATION|Short-course radiotherapy|5×5Gy in Week 1
218942150|NCT05576480|DRUG|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
218942151|NCT05576480|DRUG|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
218942152|NCT05576480|PROCEDURE|TME surgery|Patient will receive radical rectal cancer surgery
218942153|NCT03332849|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
218942154|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
218942155|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
218942156|NCT07008911|BEHAVIORAL|CardioHeartConnect|Participants in the CardioHeartConnect group engage in an eight-week digital cardiac rehabilitation program using the commercially available Peloton app. The intervention includes two daily modules (10-25 minutes total) on weekdays, focused on walking, strength, low-intensity cardio, yoga, pilates, and stretching. Modules progress in intensity over time. The program is delivered through the Ortus-iHealth platform, which prompts daily participation and integrates survey responses and smartwatch data. The intervention is designed to support physical activity, functional capacity, quality of life, and cardiovascular health among patients recovering from Transcatheter Aortic Valve Replacement (TAVR).
218942157|NCT07008911|BEHAVIORAL|CardioHeartEd|CardioHeartEd is the control condition in which participants receive weekly cardiac rehabilitation-related educational resources through the Ortus-iHealth platform for eight weeks. The content is created by the American College of Cardiology and is designed to promote cardiovascular health following TAVR. Participants also receive a smartwatch to wear for self-monitoring, but do not receive structured exercise content. The CHE group controls for access to technology and general education about heart health.
219051063|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
219051064|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
219051065|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
219206738|NCT05786131|PROCEDURE|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
219206739|NCT05786131|PROCEDURE|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
218942158|NCT07011524|BIOLOGICAL|CM512 injection|subcutaneous injection
218942159|NCT07011524|DRUG|Placebo|subcutaneous injection
218942160|NCT07013903|OTHER|Standard rehabilitation plus cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
218942161|NCT07013903|OTHER|Standard rehabilitation only|same rehabilitation program than the experimental group but without hydrotherapy
218942162|NCT06682806|DRUG|PRT3789|PRT3789 is administered as an intravenous infusion once weekly for 3 weeks
218942163|NCT06682806|DRUG|pembrolizumab|Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
218942164|NCT06687889|OTHER|Elastography Measurements|Elastography Measurements
218942165|NCT06687889|OTHER|Bone Mineral Density Measurement (DEXA)|Bone Mineral Density Measurement (DEXA)
218942166|NCT06687889|OTHER|Berg balance scale|Berg balance scale
218942167|NCT06687889|OTHER|Functional reach test|Functional reach test
219051066|NCT00130962|DRUG|ALGRX 4975|
219051067|NCT00062426|BIOLOGICAL|bevacizumab|
219051068|NCT00062426|DRUG|capecitabine|
219051069|NCT00062426|DRUG|fluorouracil|
219051070|NCT00062426|DRUG|leucovorin calcium|
219051071|NCT00062426|DRUG|oxaliplatin|
219051072|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
219051073|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
219051074|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
219051075|NCT02258282|DRUG|Etanercept|
219051076|NCT02258282|DRUG|Control|
219051077|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
219051078|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
219051079|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
219051080|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
219051081|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
219206740|NCT06779565|DEVICE|Hyflex EDM system|A rotary file system
219206741|NCT06779565|DEVICE|Reciproc VDW system|A reciprocating file system
219051082|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
219051083|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
218942168|NCT06687889|OTHER|Timed Up and Go Test|Timed Up and Go Test
218942169|NCT05830084|DRUG|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
218942170|NCT00658164|OTHER|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
218942171|NCT03711695|DEVICE|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
218942172|NCT07018830|BEHAVIORAL|Behavioral Treatment|Participants will be provided 11, 60 - 90 minute group sessions. They will receive behavioral strategies to address each of the lifestyle behaviors. These strategies are based on the Social Cognitive Theory and Self Determination Theory. Topics will include, but are not limited to, self-monitoring, goal setting, social support, cues, problem solving, and relapse prevention. Groups may occur both in-person and virtually.
218942173|NCT05933850|BEHAVIORAL|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
218942174|NCT06331702|BIOLOGICAL|Vero cell-drived inactive Japanese encephalitis vaccine|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered in the deltoid area of lateral arm by intramuscular injection.
218942175|NCT06331702|BIOLOGICAL|Measles-Mumps-Rubella Vaccine|0.5ml for each dose (after dissolving), manufactured by Shanghai Institute of Biological Products CO., LTD, administered in the lower part of the deltoid area of lateral arm, by subcutaneous injection.
218942176|NCT02897661|PROCEDURE|WMT|Washed microbiota transplantation (WMT) through mid-gut
218942177|NCT02897661|DIETARY_SUPPLEMENT|EEN|Exclusive enteral nutrition (EEN) through feeding tube
218942178|NCT06867081|OTHER|The intervention will be the BRILLIANT Platform, an online platform which provides five Modules aimed at increasing coordination of care and direct rehabilitation time|The BRILLIANT Platform provides five Modules aimed at increasing coordination of care and direct rehabilitation time: 1) Standardized measures: provided consistently with scoring and reminders to complete assessments, across all stages of recovery and care settings to guide and evaluate treatment effectiveness of clinical outcomes, performance based outcomes, patient reported outcome measures; 2) Communication Module: clinicians can communicate together and with patient/family to clarify patient-related information and update colleagues for time sensitive information, synchronously and asynchronously; 3) Shared intervention goals and plan: personalized and dynamic care trajectory and intervention plan guided by standardized assessments, reminders, and evidence-based interventions recommendations to direct patients and caregivers to the right services and interventions at the right time based on clinical and social profile and best practices; and 2 other related topics.
219051084|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
219051085|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
219206742|NCT06735690|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHSCT
219051086|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
219051087|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
219206743|NCT06735690|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
219206744|NCT06735690|PROCEDURE|Biospecimen Collection|Undergo blood and optional CSF sample collection
219206745|NCT06735690|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219206746|NCT06735690|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219206747|NCT06735690|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
218942179|NCT07017400|PROCEDURE|Local Anesthetic Injection|combination of regional blocks for TKA postoperative analgesia
218942180|NCT07025434|PROCEDURE|Hip Bump Manipulation|This technique is a high velocity low amplitude thrust (HVLAT) directly posterior to the greater trochanter which theorizes the quick stretch of the external rotator muscles and may improve a malpositioned femoral head within the acetabulum.
218942181|NCT07025434|PROCEDURE|Sham (No Treatment)|Iliac Crest Sham Manipulation
218942182|NCT07025226|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219051088|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
218942183|NCT07025226|DRUG|Dasatinib|Given PO
218942184|NCT07025226|DRUG|Fisetin|Given PO
218942185|NCT07025226|DRUG|Fluorodopa F 18|Undergo 18F-DOPA-PET scan
218942186|NCT07025226|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218942187|NCT07025226|OTHER|Patient Observation|Receive rest and take no treatment
218942188|NCT07025226|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET scan
218942189|NCT07025226|DRUG|Quercetin|Given PO
218942190|NCT07025226|DRUG|Temozolomide|Given PO
218942191|NCT01762137|PROCEDURE|Flow Diversion|Endovascular flow diverter placement
218942192|NCT01762137|PROCEDURE|Coiling|Endovascular coil placement
218942193|NCT07028684|OTHER|Reflexology Massage|"Reflexology massage will be applied twice a week for 30 minutes per session, for a total of 10 sessions. The treatment will begin by relaxing the ankle with a few passive movements. Reflexology massage will be applied to the right foot first and then to the left foot.~Target Areas to be Applied to the Right Foot: Brain, Pineal, Hypophysis, Hypothalamus and Thalamus, Temples, Eye area and Optic nerve, Ear area, Middle ear and Balance point, Neck.~Other areas to be applied to the right foot: Thyroid and Parathyroid, Lung, Liver, Face area, Speech center and Thymus, Teeth, Diaphragm, Vertebra, Extremities.~Areas to be applied to the left foot: Kidney, Diaphragm, Intestines, Neck, Vertebra, Extremities.~The session is completed from the left foot by applying to the lymph inlet, lymph channel and diaphragm from both feet."
218942196|NCT06520085|OTHER|interactive mHealth application for patients undergoing RSA|Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
218942197|NCT07033481|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules
218942198|NCT07033481|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
219051089|NCT01860417|DRUG|Mepivacaine|
219051090|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
219051091|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
219206748|NCT06735690|PROCEDURE|Echocardiography|Undergo ECHO
218942199|NCT07136610|BEHAVIORAL|SMART Tool|The intervention in this implementation study involves (1) integrating the SMART Tool into electronic health records (EPIC), (2) educating all NICU staff (about 850 nurses, lactation consultants, speech-language pathologists, and physicians), and (3) Quality improvement to reinforce learning.
218942200|NCT04469998|DRUG|AXR-270 Low Dose|AXR-270 Topical Eyelid Cream
218942201|NCT04469998|DRUG|AXR-270 High Dose|AXR-270 Topical Eyelid Cream
218942202|NCT04469998|DRUG|AXR-270 Vehicle|AXR-270 Topical Eyelid Cream Vehicle
219206749|NCT06735690|PROCEDURE|Leukapheresis|Undergo leukapheresis
218942204|NCT06710938|DEVICE|The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system|The thoracoabdominal artery stent graft system is a mixed branch design with two inner branches for the visceral arteries and two outer branches for the bilateral renal arteries.
218942205|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 phonocardiogram (PCG) recording|Noninvasive acquisition of heart sound (phonocardiogram, PCG) recordings using the FDA (U.S. Food and Drug Administration)-cleared Eko CORE 500 digital stethoscope. At least four 15-second recordings are collected at standard auscultation sites (aortic, pulmonic, tricuspid, mitral). Recordings are used solely for investigational algorithm development and are not used for diagnostic or clinical decision-making.
218942206|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 three-lead electrocardiogram (ECG) recording|Noninvasive acquisition of three-lead electrocardiogram (ECG) signals using the FDA-cleared Eko CORE 500 digital stethoscope. Recordings are obtained simultaneously with PCG at auscultation sites. Data are used solely for investigational algorithm development and are not intended for diagnostic use.
218942207|NCT06714617|DRUG|BL-M17D1|The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks.
219051092|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
219051093|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
219051094|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
219206750|NCT06735690|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218942208|NCT06714006|DRUG|PYC-003|A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion
218942209|NCT07032558|DRUG|DW-1021|DW-1021 is a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), formulated as a controlled-release film-coated tablet. It is administered as a single oral dose with 150 mL of water under fasting conditions for the evaluation of pharmacokinetics in healthy adult male volunteers.
219051095|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
219051096|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
219051097|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
219051098|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
219206751|NCT06735690|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219206752|NCT06735690|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219206753|NCT06735690|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218942210|NCT07032558|DRUG|Pelubi CR + Zytram CR|The reference treatment consists of two separate controlled-release film-coated tablets: Pelubi CR (Pelubiprofen 45 mg) and Zytram CR (Tramadol HCl 75 mg). These are co-administered as a single oral dose with 150 mL of water under fasting conditions to compare the pharmacokinetic profile against the fixed-dose combination DW-1021.
218942211|NCT07037940|OTHER|OpenEvidence|Medical information platform which uses retrieval-augmented generation to access medical literature
218942212|NCT07037940|OTHER|GPT-4|A chatbot application developed that uses GPT-4, a large language model, to engage in conversational interactions with users.
218942213|NCT05065411|DRUG|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm \& Abemaciclib
218942214|NCT05065411|DRUG|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
218942215|NCT06719258|DEVICE|MR850|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
219051099|NCT03050905|DRUG|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
219051100|NCT03050905|DRUG|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
219051101|NCT03592641|DRUG|Savolitinib|Given PO
218942216|NCT06719258|DEVICE|FP950|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
218942217|NCT06500273|GENETIC|cemacabtagene ansegedleucel|An allogeneic CAR T cell therapy targeting CD19
218942218|NCT06500273|DRUG|Fludarabine|Chemotherapy for lymphodepletion
218942219|NCT06500273|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
218942220|NCT06500273|DEVICE|Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™|A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.
218942221|NCT07046429|DIETARY_SUPPLEMENT|Melatonin tablet 3 mg once daily|Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
218942222|NCT07046429|DIETARY_SUPPLEMENT|Thiamine|Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
219051102|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
219051103|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
219051104|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
218942223|NCT06885281|DRUG|ZL-1310|drug ZL-1310
219051105|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
219051106|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
219051107|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
218942224|NCT07042607|OTHER|not appicable|no intervention
218942225|NCT06888011|BEHAVIORAL|Participants: iAmHealthy|Families will take part in an educational group program with parents and their children. These one-hour meetings will be focused on living healthy lifestyles and engaging in healthy habits as a family and will occur weekly for three months and monthly for three months. Each family will also have the opportunity to receive individual health coaching sessions every other week that will last approximately 30 minutes to address concerns and health behaviors specific to each pair. There will be additional opportunities to demonstrate and apply learned concepts.
219051108|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
219051109|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
219051110|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
218942226|NCT06888011|BEHAVIORAL|Participants: Newsletter|Families assigned to the newsletter control intervention will receive the AAP Healthy Children Newsletter (HealthyChildren.org) every month for six months.
218942227|NCT06888011|OTHER|Clinics: Healthy Clinics|Healthy Clinics is a clinic level intervention designed to improve provider office processes using a bundled intervention of provider prompts, skills training and intervention tools implemented with performance feedback. Each clinic receives Healthy Clinics at some point in the intervention.
218942228|NCT02415036|DEVICE|Delcath Hepatic Delivery System|
218942229|NCT02415036|DRUG|Melphalan|
219051111|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
219051112|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
219634185|NCT04468347|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
218942230|NCT02553356|DRUG|PT2385|
218942231|NCT06923436|BEHAVIORAL|Psychological Assessment|Collection of anamnestic and socio-demographic data, test administration repeated 4 months apart to monitor any changes
218942232|NCT06924151|PROCEDURE|surgical aortic valve replacement|SAVR
218942233|NCT06924151|PROCEDURE|Transcatheter aortic valve replacement|TAVR
218942234|NCT04307576|DRUG|Omitted Doxorubicin|Omission of IV Doxorubicin
218942235|NCT04307576|DRUG|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
218942236|NCT04307576|DRUG|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
218942237|NCT04307576|DRUG|Imatinib|p.o. Imatinib
218942238|NCT04307576|DRUG|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
218942239|NCT04307576|DRUG|Blinatumomab|IV Blinatumomab
219051113|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
219051114|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
219051115|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
219051116|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
219051117|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
219051118|NCT03752723|DRUG|GX-I7|i.m.
219051119|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
219051120|NCT03752723|DRUG|Cyclophosphamide|i.v.
218942240|NCT06728085|BEHAVIORAL|Baseline Assessment For Mother-Daughter Day HPV Campaign|"Pre-Implementation:~Identify, screen, and enroll mother-daughter dyads in the study to participate in the upcoming Mother-Daughter Day event on HPV vaccination and screening.~Complete baseline surveys with enrolled participants. Distribute reminder cards and send text messages to mother-daughter dyads who agree to participate in the mother-daughter day campaign."
218942241|NCT06728085|BEHAVIORAL|Implement Mother-Daugther Day HPV Campaign|"Tailor and adapt to context: Mother-Daughter Day campaigns will be tailored and adapted to the local contexts within the 18 LGA.~Trained community health workers will implement the tailored Mother-Daughter Campaign by providing education on cervical cancer control and educational materials on HPV vaccination and HPV screening.~Engage mothers and daughters with on-site access to services: This includes offer of onsite vaccinations to girls by study nurse as well as offer of onsite self-collection screening kits to mothers and caregivers in a private area, along with instructions on how to use and return the sample.~Distribute gift bags with HPV vaccination cards, follow-up reminders, and linkage cards for participants with positive test results, as community health workers continue to provide onsite support and assistance."
218942242|NCT06728085|BEHAVIORAL|Post-Implementation Follow-Up|"A follow-up invitation will be sent to participate in a consultative phone call with study health workers to review self-collection results.~Participants with positive HPV test results will be linked to follow-up care and treatment."
218942243|NCT01909011|DEVICE|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
218942244|NCT01909011|DEVICE|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
218942245|NCT06883045|OTHER|MyChildCMC app (an app designed to facilitate home monitoring of CMC's health status)|MyChildCMC is an app designed to support remote monitoring of CMC crosscutting symptoms to identify signs of CMC's health deterioration early to change their care early to avoid progression and prevent ED/hospital admissions. The app includes the following features: 1) automated reminders, 2) vital sign/symptom monitoring, 3) real-time feedback system, 4) automated and real-time summary reports with longitudinal graphs, 5) automated alerts to a care coordinator, and 6) clinic dashboard connecting patients to clinics and allowing access to patient data to support care coordination.
219051121|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
219051122|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
219051123|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
219051124|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
219051125|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
219206754|NCT06735690|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219634186|NCT02139202|BEHAVIORAL|Social Influence|
219634187|NCT02139202|BEHAVIORAL|Electronic Pill Bottles|
219634188|NCT02139202|BEHAVIORAL|Financial Incentives|
219634189|NCT04454983|DEVICE|Lipiflow Thermal Pulsation System|The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
218942246|NCT01273753|OTHER|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
218942247|NCT03064061|DEVICE|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
218942248|NCT07054216|OTHER|Probiotic|Given daily from 14 days of age until 9 months of age
218942249|NCT07054216|DIETARY_SUPPLEMENT|Placebo|Given daily from 14 days of age until 9 months of age
218942250|NCT07051538|DRUG|SHR-1139 Injections|SHR-1139 injections.
218942251|NCT07051538|DRUG|SHR-1139 Injections Placebo|SHR-1139 injections placebo
218942252|NCT07054385|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
218942253|NCT07054385|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
218942254|NCT04948983|OTHER|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
218942255|NCT04948983|OTHER|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
218942256|NCT03103477|OTHER|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
218942257|NCT04020861|DEVICE|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
218942258|NCT04020861|DEVICE|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
218942259|NCT04020861|DEVICE|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
219051126|NCT03815162|DIETARY_SUPPLEMENT|High Flavanol Cocoa extract|Experimental group
219051127|NCT03815162|DIETARY_SUPPLEMENT|Alkalised cocoa|Control group
219051128|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
219051129|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
219051130|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
219051131|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
219051132|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
218942260|NCT04020861|DEVICE|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
218942261|NCT00695097|DRUG|Rituximab|Rituximab infusion on Day 1 and Day 15
218942262|NCT00695097|DRUG|No Rituximab|No Rituximab
218942263|NCT06750536|DEVICE|MiniLung petite kit combined with the Xenios console|Veno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) treatment will be performed using the MiniLung petite kit combined with the Xenios console according to their intended use and local standards/requirements.
218942264|NCT04994808|DRUG|Clofarabine|Given IV
218942265|NCT04994808|DRUG|Fludarabine|Given IV
218942266|NCT04994808|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219051133|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
219051134|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
219051135|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
219051136|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
219051137|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
219051138|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
219051139|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
219051140|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
219051141|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
219051142|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
219051143|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
219051144|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
218942267|NCT04994808|RADIATION|Total-Body Irradiation|Undergo TBI
218942268|NCT04994808|DRUG|Treosulfan|Given IV
219051145|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
219051146|NCT00718172|PROCEDURE|Liver Biopsy|
219051147|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
219051148|NCT00718172|DRUG|Pre-treatment Ribavirin|
218942269|NCT04994808|PROCEDURE|Echocardiography Test|Undergo ECHO
219051149|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
219051150|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
219206755|NCT06735690|OTHER|Transplant Conditioning|Given HSCT conditioning regimen
218942270|NCT04994808|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218942271|NCT04994808|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218942272|NCT04994808|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218942273|NCT04994808|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218942274|NCT04994808|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218942275|NCT06882356|DEVICE|AI-based glaucoma screening|AI analysis of fundus photographs to detect signs of glaucoma, added to AI-based diabetic eye disease screening performed for routine clinical care
218942276|NCT06882356|DEVICE|IOP measurement|Intraocular pressure measurement by Icare tonometer
218942277|NCT06882356|DEVICE|Virtual Reality Visual Field Testing|Virtual Reality Visual Field Testing by the Olleyes device for participants suspected of having glaucoma
219051151|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
219051152|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
219051153|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
219051154|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
219051155|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
219051156|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
219051157|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
219051158|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
219051159|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
219051160|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
219051161|NCT01540370|OTHER|No Treatment|No treatment
219051162|NCT01849705|OTHER|No intervention|
219051163|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
219051164|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
219051165|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
219051166|NCT01532687|DRUG|Gemcitabine|Given IV
219051167|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
219051168|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
219051169|NCT01532687|DRUG|Pazopanib|Given PO
219051170|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
219051171|NCT01532687|OTHER|Placebo Administration|Given PO
219051172|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
219051173|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
219051174|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
219051175|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
219051176|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
219051177|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
219051178|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
219051179|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
218942278|NCT06756113|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
219051180|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
219051181|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
218942279|NCT06756113|BEHAVIORAL|Usual Care|All patients in this study received regular nephrology care at National Cheng Kung University Hospital. Nephrologists conducted routine examinations and provided diagnoses based on test results. The patient's condition (e.g., changes in kidney function), treatment plan, prognosis, and risks were explained to both the patient and family members. The treatment plan included medication, monitoring blood pressure, dietary and exercise at home, and consultations with the Health Education Center for kidney care or nutrition advice.
218942280|NCT06763939|OTHER|RT00401-GO0046|Cosmetic care product
218942281|NCT06763939|OTHER|RT00401-GA0677|Placebo cosmetic care product
218942282|NCT07060508|BIOLOGICAL|Single dose of 1800 mg L9LS SC|A human monoclonal antibody to protect against Plasmodium falciparum.
218942283|NCT07060508|OTHER|Placebo|Normal saline
218942284|NCT07060209|DRUG|DW-1021|A fixed-dose combination controlled release film-coated tablet containing pelubiprofen 45 mg and tramadol 45.9 mg (salt form), administered as a single oral dose under fasting and fed conditions in a two-period, two-sequence crossover design. Each subject receives the intervention once under each condition with a 14-day washout period.
218942285|NCT06758245|PROCEDURE|femoral and anterior sciatic nerve block|First, in the supine position, the USG probe is placed below the inguinal crease. The femoral nerve is located lateral to the femoral artery, above the iliopsoas muscle. Once the needle tip reaches the nerve, simultaneous nerve stimulation is applied. Patellar movement is observed due to quadriceps muscle contraction upon needle placement. After a negative aspiration test, 20 ml of local anesthetic is injected.For the anterior sciatic block, while the patient was in the supine position, a convex ultrasound (USG) probe was placed transversely approximately 10 cm distal to the inguinal ligament. After visualizing the sciatic nerve as a hyperechoic flat structure, the nerve stimulator was set to 1-1.5 mA, 0.1 ms, and 1 Hz. Using an in-plane technique, the block needle was advanced. Upon reaching the sciatic nerve, when contractions in the calf, foot, or big toe continued at a current of 0.3-0.5 mA, 20 ml of 0.5% bupivacaine was administered following a negative aspiration test.
218942286|NCT06758245|PROCEDURE|femoral and popliteal sciatic nerve block|The ultrasound probe is placed transversely at the popliteal crease. The first structure seen is the popliteal artery. Just above and lateral to the artery, the tibial nerve appears as a hyperechoic, oval, and round structure. After identifying the tibial and peroneal nerves, the probe is moved proximally, and it is observed that the nerves join about 5-10 cm above the popliteal crease. The needle is advanced using an in-plane technique. After obtaining the first sciatic nerve stimulation, 20 cc of 0.5% bupivacaine is injected following a negative aspiration test.
218942287|NCT04614324|DEVICE|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
218942288|NCT06759350|DIETARY_SUPPLEMENT|Soy isoflavone supplement|2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.
218942289|NCT06759350|OTHER|Control (placebo) group|2 placebo capsules containing a multivitamin compound.
218942290|NCT06571773|PROCEDURE|intraoperative implantation of Capsular Tension Ring|The Capsular Tension Ring(ACPi-11; Bausch + Lomb, Rochester, New York, USA) is a device made of PMMA with blunt-tipped eyelets at its ends. It can be inserted at any point during cataract surgery, following the creation of a strong anterior capsulotomy via capsulorhexis
218942291|NCT06571773|PROCEDURE|none intraoperative implantation of CTR|the surgeon did a surgery without the intraoperative implantation of CTR
218942292|NCT06734065|BEHAVIORAL|ReDS-guided heart failure management program|"Remote dielectric sensing (ReDS) system (Sensible Medical Innovations Ltd., Netanya, Israel) is a novel electromagnetic energy-based technology that accurately quantifies changes in lung fluid concentration non-invasively.~Patients in the intervention group will receive a three-month, ReDS-guided heart failure management program in addition to usual care.~The program, led by nurses, will integrate algorithms for diuretic use, a structured follow-up schedule, and self-care support tailored to pulmonary fluid levels assessed by ReDS."
219051182|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
219206756|NCT06735690|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
219051183|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
218942293|NCT05289037|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
218942294|NCT05289037|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
218942295|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.1.529)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
218942296|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.351)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
218942297|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.1)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
218942298|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
218942299|NCT05289037|BIOLOGICAL|CoV2 preS dTM [B.1.351]|Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
218942300|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614|Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
218942301|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614+B.1.351|Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
218942302|NCT05289037|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
218942303|NCT05289037|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
218942304|NCT05289037|BIOLOGICAL|mRNA-1273.529|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
218942305|NCT05289037|BIOLOGICAL|mRNA-1273.617.2|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
218942306|NCT05289037|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
218942307|NCT06247995|DRUG|[68Ga]Ga-NeoB|68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
218942308|NCT06247995|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB is a radioligand therapy drug.
218942309|NCT06247995|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
218942310|NCT06250582|OTHER|virtual reality therapy|A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.
219206757|NCT06734390|OTHER|Bladder Neck Surgery|Bladder Neck Surgery regroups many surgical procedures to cure urinary incontinence.
219206758|NCT05693363|DEVICE|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
219206759|NCT05188079|DIETARY_SUPPLEMENT|Beetroot juice|high nitrate supplement
219051184|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
218942314|NCT05110937|OTHER|Blood sampling|Blood sampling
218942315|NCT07070661|DEVICE|Fixed-Dose Radial Pressure Wave Therapy.|Radial pressure wave therapy will be delivered using the BTL-6000 device. Parameters such as frequency and pressure will remain constant throughout each session. Each participant will receive one session per week for three weeks. The treatment will follow a standardized protocol previously established in the literature and based on patient tolerance.
218942316|NCT07070661|DEVICE|Modulated-Dose Radial Pressure Wave Therapy.|The BTL-6000 device will be used to deliver therapy with dynamic modulation of frequency and/or pressure within each session, following a structured protocol aiming to optimize clinical response.
218942317|NCT06806982|DRUG|VRN101099|Oral capsules
218942318|NCT06751810|DIETARY_SUPPLEMENT|Food supplement|"The nutritional composition of the food supplement comprises:~sodium butyrate, inactivated Lactobacillus rhamnosus GG Perilla frutescens dry extract quercetin fructo-oligosaccharides Vitamin D3 omega 3 polyunsaturated acids sorbitol sucralose silicon dioxide aroma"
219206760|NCT05188079|DIETARY_SUPPLEMENT|Placebo drink|placebo
218942319|NCT06751810|OTHER|Placebo|Placebo
218942320|NCT07073157|DRUG|HRS-8427 injection plus furosemide|HRS-8427 injection plus furosemide
218942321|NCT07073157|DRUG|HRS-8427 injection plus metformin|HRS-8427 injection plus metformin
218942322|NCT06141473|DRUG|Frexalimab|SAR441344 Solution for IV infusion
218942323|NCT06141473|DRUG|Teriflunomide|Aubagio oral tablet
218942324|NCT06141473|DRUG|Placebo infusion|Solution for IV infusion
219051185|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
219051186|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
219051187|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
219051188|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
219051189|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
219051190|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
219051191|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
219051192|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
219051193|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
219051194|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
219051195|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
218942325|NCT06141473|DRUG|Placebo tablet|Oral tablet
218942326|NCT06141473|DRUG|MRI contrast-enhancing agents|IV, as per respective label
219051196|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
219206761|NCT06734832|BIOLOGICAL|bivalent enterovirus vaccine (Vero cell), inactivated|Two doses are administered with a one-month interval between each dose.
219206762|NCT06734832|BIOLOGICAL|Enterovirus Type 71 Vaccine (Vero Cell), Inactivated|Two doses are administered with a one-month interval between each dose.
218942327|NCT06141473|DRUG|Cholestyramine|oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
218942328|NCT06141473|DRUG|Activated charcoal|oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
218942329|NCT05970978|DRUG|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
218942330|NCT05970978|DRUG|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
218942331|NCT05554354|DRUG|Binimetinib|Given PO
218942332|NCT05554354|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
218942333|NCT05554354|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218942334|NCT05554354|PROCEDURE|Bone Scan|Undergo bone scan
218942335|NCT05554354|PROCEDURE|Computed Tomography|Undergo CT scan
218942336|NCT05554354|PROCEDURE|Echocardiography Test|Undergo ECHO
218942337|NCT05554354|DRUG|Fulvestrant|Given IM
218942338|NCT05554354|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218942339|NCT05554354|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218942340|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
218942341|NCT06811363|OTHER|Metabolic / prescribed diet|Instructed diet (400 mg Ca, 800 mg P, 100 mEq Na) and two liters of distilled water daily for three days (equilibration period), followed by a constant standardized meal with the same composition of Ca, P, and Na for one day. After 240hr urine sample collection patient fasted the preceding evening except for 300 ml of distilled water at 9 pm and 11 pm. On test days, 600 ml distilled water given and fasting blood obtained.
218942342|NCT06811363|OTHER|KCit Load (40 meq)|Potassium citrate load of 40meq will be given after fasting blood has been obtained
218942343|NCT06811363|DRUG|Anti-resorptive agents|Zoledronic acid or Denosumab (as prescribed by their physician)
218942344|NCT06811363|DRUG|Anabolic Agents|Romosozumab (as prescribed by their physician)
218942345|NCT06568484|DRUG|Bedaquiline|"CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)"
219051197|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
219051198|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
219051199|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
219051200|NCT03424915|BEHAVIORAL|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
219051201|NCT03424915|OTHER|Blood draw|Participant will provide a blood sample
219051202|NCT03424915|OTHER|CPET Procedures|CPET with 12-lead ECG
219051203|NCT03424915|OTHER|stool sample|Research stool sample (within ±1 week of surgery), if possible
219051204|NCT03424915|PROCEDURE|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
219051205|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
219051206|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
219051207|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
219051208|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
219051209|NCT01061060|DRUG|Prostaglandin I2|oral
219051210|NCT01061060|DRUG|Placebo|oral
219051211|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
219051212|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
219051213|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
219051214|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
219051215|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
219051216|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
219051217|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
219051218|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
219051219|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
219051220|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
218942346|NCT06568484|COMBINATION_PRODUCT|Isoniazid, rifapentine|"CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)"
218942347|NCT06568484|DRUG|Levofloxacin|"CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)"
218942348|NCT07123025|PROCEDURE|Partial Pulpotomy in Moderate Pulpitis|"Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Moderate Pulpitis.~After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin."
218942349|NCT07123025|PROCEDURE|Partial Pulpotomy in Severe Pulpitis|Description: Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Severe Pulpitis. After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin
218942350|NCT06930768|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
218942351|NCT06930768|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
218942352|NCT06195631|BEHAVIORAL|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
218942353|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
218942354|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
218942355|NCT04453085|DRUG|JR-171|Intravenous (IV) infusion
218942356|NCT05811897|BEHAVIORAL|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~* Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~* Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~* Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
218942357|NCT05811897|BEHAVIORAL|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
218942358|NCT04791540|DIAGNOSTIC_TEST|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
218942359|NCT04791540|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
218942360|NCT04791540|DIAGNOSTIC_TEST|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
218942361|NCT04791540|DIAGNOSTIC_TEST|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
218942362|NCT04791540|BIOLOGICAL|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
218942363|NCT04791540|BIOLOGICAL|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
218942364|NCT04791540|OTHER|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
218942365|NCT07132736|DEVICE|Hubbard tank|women will perform pelvic floor exercise and core stability exercise under water each session will be for 30 min
218942366|NCT07132736|OTHER|Mat on the ground|women will perform core stability exercise and pelvic floor exercise on the mat for 30 min
218942367|NCT07137754|OTHER|Advanced practice physiotherapy|Physiotherapists undergoing post-graduate education as advanced practice physiotherapists will independently diagnose, manage and discharge patients.
218942368|NCT07137754|OTHER|Usual Care|Nurses and physicians in the emergency department will diagnose, manage and discharge patients as usual
219051221|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
219051222|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
219051223|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
219051224|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
219051225|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
219051226|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
219051227|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
219051228|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
219051229|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
219051230|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
219051231|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
219051232|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
219634190|NCT04454983|DEVICE|iLux System|The iLux™ System is used to apply localized heat and pressure to a patient's eyelids. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism.
219634191|NCT00554515|DRUG|HD IL2|
219634192|NCT00521638|BIOLOGICAL|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
219634193|NCT03442686|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
219634194|NCT05899283|DEVICE|OCI-HF160|OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
219634195|NCT05899283|DEVICE|FX800HDF|FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
219634196|NCT00003441|DRUG|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
218942369|NCT07137546|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy ( FFLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at gallbladder fundus~* Peritoneum incised from infundibulum to fundus along liver bed~* Gallbladder dissected from fundus toward infundibulum~* Cystic artery and duct identified and divided last~* Critical view of safety achieved before vessel division"
219051233|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
219051234|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
219051235|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
219051236|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
219051237|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
219051238|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
219051239|NCT00014144|DRUG|gefitinib|
219051240|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
219051241|NCT01903278|DRUG|PEG-IFN-SA /RBV|
219051242|NCT01903278|DRUG|Pegasys /RBV|
219206763|NCT06734533|OTHER|Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc|Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.
219206764|NCT06328114|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
218942370|NCT07137546|PROCEDURE|Classical Laparoscopic Cholecystectomy (CLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at Calot's triangle~* Critical view of safety achieved first~* Cystic artery and duct divided before gallbladder bed dissection~* Gallbladder dissected from liver bed"
219206765|NCT04319887|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
219206766|NCT06778928|PROCEDURE|laparoscopic cholecystectomy|Posterior wall sparing of laparoscopic cholecystectomy in cirrhotic patients
219206767|NCT06541054|OTHER|WARM SOCKS|One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
218942374|NCT07094555|BEHAVIORAL|Animal Assisted Practice|The animal-assisted intervention group initiated interaction with a goldfish in a portable aquarium during the preoperative period and accompanied them until they reached the operating room.
218942375|NCT07094555|BEHAVIORAL|Kaleidoscope|The kaleidoscope group was distracted with a kaleidoscope during the preoperative period and continued this intervention until they reached the operating room.
218942376|NCT06927713|OTHER|Bloodletting Acupuncture|Bloodletting was applied to the right hand ﬁrst and then the left hand in the order of Shaoshang (LU 11), Shangyang (LI 1), Zhongchong (PC 9), Guanchong (TE 1), Shaochong (HT 9) and Shaoze (SI 1).
218942377|NCT06927713|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical acupoint stimulation at hand twelve jing-well points.
218942378|NCT07094113|DRUG|AMG 410|Administered as an oral tablet.
218942379|NCT07094113|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion.
218942380|NCT07094113|DRUG|Panitumumab|Administered as an IV infusion.
218942381|NCT00336648|DRUG|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
218942382|NCT00336648|DRUG|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
218942383|NCT00336648|PROCEDURE|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
218942384|NCT07096024|DRUG|palbociclib plus fulvestrant|Patients treated with the combination of palbociclib and fulvestrant
218942385|NCT07096024|DRUG|fulvestrant|Patients treated with fulvestrant alone
219051243|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
219206768|NCT06733298|DRUG|[ 14C]-labeled RO7269162|Participants will receive one oral dose of \[14C\]-labeled RO7269162.
219206769|NCT06740240|DRUG|68Ga-FAPI-Biotin|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
219206770|NCT06740240|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
218942386|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
218942387|NCT06820216|DRUG|Rectointercostal facial plane block using bupivacaine 0.25%|Ultrasound guided bilateral recto-intercostal facial plane block will be done after induction of general anesthesia using bupivacaine 0.25%. A linear ultrasound transducer Philips CX50 (5-14 MHz) will be placed 2-3 cm lateral and caudal to the xiphoid in the epigastric area. The rectus abdominis muscle and its insertion, 6th and 7th cartilage ribs will be visualized. The needle will be inserted between rectus abdominis muscle and the costal cartilages with an in-plane technique in a caudal-cranial way. Hydro-dissection will be performed with 5 ml saline for confirmation needle tip position, 20 ml of 0.25% bupivacaine will be injected, the same procedure will be then repeated with 20 ml 0.25% bupivacaine on the contra-lateral side (a total of 40 ml bilaterally).
218942388|NCT06820216|OTHER|No Intervention as a control|General anesthesia without performing any block.
218942389|NCT05141448|DEVICE|1-Day Acuvue Moist|Run-in Contact Lens
218942390|NCT05141448|DEVICE|EMO-118|Test Lens1
218942391|NCT05141448|DEVICE|EMO-114|Test Lens2
218942392|NCT05141448|DEVICE|MiSight® 1 day|Control Lens
219206771|NCT06741267|DEVICE|RBS|physicians control RBS
219206772|NCT06741267|DEVICE|AB|physician control automatic bronchoscopy
219206773|NCT06741267|DEVICE|ENB|physicians control electromagnetic bronchoscopy
219206774|NCT06883617|DEVICE|Neuro stimulator Implant|Neuro Stimulator for treating sleep disordered breathing
219206775|NCT06883643|BEHAVIORAL|Differentiated service delivery approach (DSD) in TB treatment and prevention.|Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.
219206776|NCT06886191|DEVICE|RenalGuard Therapy|Fluid management system, which weighs urine and controls intravenous administration of crystalloid solution.
219634197|NCT02085629|BIOLOGICAL|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
219634198|NCT04571645|DRUG|Dociparstat|Dociparstat is a glycosaminoglycan derived from porcine heparin.
219634199|NCT04571645|OTHER|Control|0.9% Normal Saline
219634200|NCT00379717|DRUG|Cisplatinum|
219634201|NCT00379717|DRUG|Docetaxel|
219634202|NCT00379717|DEVICE|Tomotherapy|
219634203|NCT04917159|BEHAVIORAL|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
219634204|NCT04917159|BEHAVIORAL|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
219634205|NCT02791919|DRUG|Cytarabine|Given IV or IT
219634206|NCT02791919|BIOLOGICAL|Filgrastim|Given IV or SC
218942396|NCT05429502|DRUG|Topotecan|Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
218942397|NCT05429502|DRUG|Temozolomide|Starting out dose of temozolomide for cohort A1 and A2 for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts, Cohort A3 and onwards, in Phase 1-Part A will initiate at 100mg/m2/day.
218942398|NCT05429502|DRUG|Ribociclib|Starting out dose of ribociclib for cohort A1 Phase 1-Part A: 200mg/m2/day. Starting out dose for Cohort A2 and A3 was 100mg/m2/day.
218942399|NCT06825403|BEHAVIORAL|Olfactory Memory Training|Participants will complete 48 OMT sessions at home lasting approximately 10 minutes each over 3 months.
219634207|NCT02791919|DRUG|Fludarabine Phosphate|Given IV
219634208|NCT02791919|OTHER|Laboratory Biomarker Analysis|Correlative studies
219634209|NCT02791919|OTHER|Pharmacological Study|Correlative studies
219634210|NCT02791919|DRUG|WEE1 Inhibitor AZD1775|Given PO
219634211|NCT01624571|DRUG|LD02GIFRO|comparison of different dosages of drug
219634212|NCT00348777|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
219634213|NCT00348777|DRUG|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
218942400|NCT06825403|BEHAVIORAL|Visual Memory Training|Participants will complete 48 VMT sessions at home lasting approximately 10 minutes each over 3 months.
218942401|NCT06827028|OTHER|N/A, no intervention, participation in survey|N/A, no intervention, participation in survey
219206777|NCT06887894|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy, plaque histological analysis and miRNA expression
219206778|NCT06737445|PROCEDURE|Radiofrequency ablation alone|RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).
218942402|NCT04627285|DRUG|Lacosamide|"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
218942403|NCT07102147|BEHAVIORAL|High Touch Outreach|Gain-framed message, informational flyer, and direct request
218942404|NCT05259839|DRUG|Etentamig|Intravenous (IV) Infusion
219051244|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
219051245|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
219051246|NCT00248222|BEHAVIORAL|Supervised aerobic training|
219051247|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
219051248|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
219051249|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
219051250|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
219634214|NCT01710202|DRUG|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
219634215|NCT00838656|DRUG|carboplatin|Given IV in one of two schedules
219051251|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
219051252|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
219051253|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
219051254|NCT06407778|OTHER|High Intensity Strength Training|"* High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
219051255|NCT06407778|OTHER|Muscle Energy Technique|"The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
219051256|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
219051257|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
219051258|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
219634216|NCT00838656|DRUG|gemcitabine hydrochloride|Given IV in one of two schedules
219634217|NCT00838656|DRUG|paclitaxel|Given IV in one of two schedules
219634218|NCT02218437|DRUG|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
219634219|NCT01307904|OTHER|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
219634220|NCT01307904|OTHER|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
218942405|NCT05259839|DRUG|Dexamethasone|Oral; Tablet or IV Infusion
218942406|NCT05259839|DRUG|Lenalidomide|Oral; Capsule
218942407|NCT05259839|DRUG|Pomalidomide|Oral; Capsule
218942408|NCT05259839|DRUG|Daratumumab|Subcutaneous Injection (SC)
218942409|NCT06869564|OTHER|blood sampling|At the time of blood sampling for biological tests, 2 additional tubes of blood will be taken.
218942410|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
218942411|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
218942412|NCT07124494|PROCEDURE|Regional anethesia|This single-center, prospective, randomized controlled trial aims to compare the effects of three different postoperative analgesia techniques following spinal anesthesia in patients undergoing total knee arthroplasty (TKA). The study will assess the impact of combined spinal-epidural anesthesia, adductor canal block, and multimodal intravenous analgesia on postoperative knee range of motion (ROM). Secondary outcomes include patient satisfaction, opioid consumption, Oxford Knee Score (OKS), activity levels, and visual analog scale (VAS) pain scores.
218942413|NCT07127549|OTHER|Muscle strength, endurance and balance assessment|All participants were administered a demographic assessment form; the International Physical Activity Questionnaire-Short Form (IPAQ-SF) to assess physical activity level; the Pelvic Floor Distress Inventory (PFDI-20) and all of its subscales to evaluate the severity of symptoms associated with pelvic floor distress; urodynamic measurement; a pad test to assess the severity of UI; a perineometer device to evaluate pelvic floor muscle (PFM) strength; the Sahrmann five-level core stabilization test and the Stabilizer Pressure Biofeedback Unit to assess core muscle strength; McGill's Trunk Endurance Tests for core endurance; and the Y Balance Test to assess balance.
219634221|NCT04398004|DRUG|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
219634222|NCT05287035|DRUG|Dexamethasone injection|Dexamethasone will be injected at the dosage recommended by the FDA.
219634223|NCT05287035|OTHER|Saline injection|Saline will be injected for the placebo arm of the study.
219634224|NCT03583580|RADIATION|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
219634225|NCT05705739|PROCEDURE|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
218942414|NCT07131540|DRUG|umbilical cord Mesenchymal Stem Cell|To test the safety and tolerability of ucMSC 1 million/kg will be given intra-venously once a week for 4 week in 10 ACLF patients. 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will be taken from ILBS cGMP facility and will be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
219051259|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
219051260|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
219051261|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
219634226|NCT05705739|PROCEDURE|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
219634227|NCT04143698|DEVICE|endoscopic retrograde cholangiopancreatography|The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
218942415|NCT07134387|OTHER|N/A, no intervention, participation in survey|"A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term BPD wherever feasible and instead employs a more general reference to lung problems."
218942416|NCT07123103|DRUG|XB371|Intravenous (IV) infusion.
218942417|NCT06934356|DEVICE|EEG|Participants will have scalp EEG recorded with the international 10-20 system sampled at 256Hz using EEG amplifiers for purposes of surface event related potential analysis
218942418|NCT06934356|DEVICE|Eye Tracking|An eye-tracking device may be used during the perceptual awareness task. Pupillary and gaze location measurements are recorded using either a ViewPoint\~VoltagePro.EyeLink 1000 Plus system, or Argus Science ETVision system. If using the ViewPoint\~VoltagePro system or the Argus Science ETVision system, participants will be asked to wear an eye tracker during the perceptual awareness task (similar to wearing sunglasses). If using the EyeLink 1000 Plus system, participants may be asked to place their head inside of a padded head-chin rest to stabilize head position
218942419|NCT06934356|DEVICE|Behavioral task|For the visual perceptual awareness task, the participant will be presented with barely perceptible visual stimuli. After a variable delay, the participant will be asked to report perception of each stimulus and identify its location.
218942420|NCT07137091|OTHER|Gyrokinesis exercise|"1. Warm-Up:~   * Begin with gentle seated movements to prepare the body.~  * Focus on awakening the spine with small circles and undulating motions, coordinating with deep breathing.~2. Seated Exercises:~   * Perform a series of exercises on a stool or chair.~  * Emphasize spinal articulation, pelvic tilts, and side bends while maintaining rhythmic breathing.~3. Floor Work:~   * Transition to mat-based exercises focusing on core strength and flexibility.~  * Incorporate movements like leg lifts, spirals, and arching motions to engage different muscle groups.~4. Standing Series:~   * Conclude with standing exercises to enhance balance and full-body integration.~  * Use spiral movements and weight shifts to energize the body and improve posture."
218942421|NCT06931626|DRUG|NMS-03305293|Route of administration: Oral
218942422|NCT06931626|DRUG|Temozolomide|Route of administration: Oral Commercially available Temozolomide
219206779|NCT06737445|PROCEDURE|Cortisone Injection|An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.
219206780|NCT06737445|OTHER|Extracorporeal shock wave therapy|Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
218942425|NCT06412913|DEVICE|MJ-Flex The New Metaizeau Nail|Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
218942426|NCT06936618|DEVICE|Electrical Impedance Tomography (EIT), Enlight 2100|Patients will undergo ventilator adjustments using EIT-guided PEEP titration to optimize mechanical power and lung mechanics.
218942427|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with physiological saline|Rectus sheath and ilioinguinal nerve block without local anaesthesia
218942428|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with local anaesthesia|Rectus sheath and ilioinguinal nerve block with local anaesthesia
218942429|NCT06940921|RADIATION|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|"Radiation: Stereotactic Body Radiation Therapy (SBRT)~* Stereotactic Body Radiation Therapy (SBRT) will be performed first at a total dose of 20-50 Gy, delivered in 3-5 fractions of 6-10 Gy each. And the target area was specifically selected based on the location and size of the patient's tumor.~Radiation: low-dose radiotherapy (LDRT)~* Whole-abdominal low-dose radiotherapy will be initiated within 10 days of the end of SBRT with a total dose of 7-15 Gy at 0.5-2.0 Gy twice daily. And the target area included all suspicious tumor tissues and potential metastatic foci in the abdominal cavity."
218942430|NCT06940921|DRUG|Cadonilimab|· Cadonilimab: 6 mg/kg IV, D1, Q2W, until disease progression, death, toxicity intolerance or withdrawal of informed consent
218942431|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast inducing no reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast without reactive hypoglycaemia at 90minutes
218942432|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast causing reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast causing reactive hypoglycaemia at 90 minutes
219206781|NCT06740175|DEVICE|Multispectral optoacoustic tomography|If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
219634228|NCT03216122|PROCEDURE|Conventional/Delayed Loading|
218942433|NCT06942767|DRUG|QLS31905 for Injection|QLS31905 for Injection
218942434|NCT06942767|DRUG|QL2107 Injection|QL2107 Injection
218942435|NCT06942767|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
218942436|NCT06942767|DRUG|Capecitabine Tablets|Capecitabine Tablets
218942437|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
218942438|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
219634229|NCT03216122|PROCEDURE|Immediate Loading|
219634230|NCT05463380|OTHER|standard of care|The patient will be treated following the satndard of care in the participating units
219634231|NCT00665431|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
219634232|NCT00665431|DRUG|celebrex|200 mg celecoxib qd
219634233|NCT00665431|OTHER|Placebo|sugar pill bid
219634234|NCT00665431|DRUG|Rescue Antacid|Antacid Tablets
219634235|NCT00513383|DRUG|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
219634236|NCT00513383|DRUG|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
218942439|NCT07143656|BIOLOGICAL|Imaging and Clinical Reports|Inclusion of existing imaging data (MRI, EMG reports) and standard clinical documentation, where available.
219634237|NCT00513383|DRUG|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
218942440|NCT07144176|DRUG|DWJ1511|Test drug: DWJ1511
218942441|NCT07144176|DRUG|DWC202501|Comparator: DWC202501
218942442|NCT06945094|DEVICE|caIMR|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation"
218942443|NCT06945328|PROCEDURE|Upper endoscopy|All patients will do gastroscopy (upper endoscopy) within the first 24 hour of admission and specific elements of bleeding
218942444|NCT06942637|BEHAVIORAL|INSPIRE (Integrated Network for Student Psychosocial Intervention, Resilience, and Education)|The INSPIRE intervention is an 8-week school-based program aimed at enhancing adolescent mental health, attitudes towards mental health and help-seeking behaviors, mental health literacy, resilience and addressing depression and anxiety. Trained school counsellors deliver this structured curriculum using comprehensive materials including lesson plans, activities, and visual aids. the program provides supplementary resources for both participating students and their parents .
218942445|NCT06943989|OTHER|Ozone Exposure|6.6 hour exposure to 0.07 ppm ozone while at rest
218942446|NCT06943989|OTHER|Clean air (0.0 ppm ozone)|6.6 hour exposure to clean air (0.00 ppm ozone) while at rest
218942447|NCT07136051|PROCEDURE|Ethcing|Etching: After polishing all teeth included in the study with a polishing brush, Vococid (Voca, Germany) etching gel will be applied to the surface and left for 15 seconds, then rinsed and dried.
218942448|NCT07136051|PROCEDURE|Deproteinization|The teeth randomly assigned to Group B will receive 5.25% NaOCl applied with a sterile cotton pellet for 60 seconds after acid etching, followed by rinsing and drying.
218942449|NCT07136051|PROCEDURE|Bonding|The teeth randomly assigned to Group C will receive Futurabond® M+ (Voco, Germany) applied with a brush following acid etching. After gently drying with air for 5 seconds, the bonding step will be completed by light-curing for 10 seconds.
218942450|NCT07136051|PROCEDURE|Application of resin-based fissure sealant|After completing the pretreatment steps for all groups, Grandio Seal (Voco GmbH, Germany) will be applied to the pits and fissures on the tooth surface and light-cured for 20 seconds. The procedure will be completed after checking the surface.
218942451|NCT06939647|DRUG|Treprostinil Palmitil|Treprostinil Palmitil Inhalation Powder
218942452|NCT07146633|BEHAVIORAL|A-EMDR|Participants in the treatment group will receive Autonomous Eye movement desensitization and reprocessing (A-EMDR) therapy delivered through an app on their device. Participants will be asked to complete 3 sessions per week for 4 consecutive weeks. During the treatment period, participants will also attend clinical sessions which will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol.
219051262|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
219051263|NCT00004026|DRUG|CT-2584|
219051264|NCT00004026|DRUG|chemotherapy|
219051265|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
219051266|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
219051267|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
219051268|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
219634238|NCT00513383|RADIATION|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
219051269|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
219051270|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18\_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
219634239|NCT00513383|DRUG|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
219634240|NCT00513383|DRUG|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
219634241|NCT00513383|DRUG|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
219634242|NCT05536232|BEHAVIORAL|Low carbohydrate diet|Low carbohydrate diet under 75 g per day
219634243|NCT03751839|DIAGNOSTIC_TEST|Biochemical Tests|The investigators will perform blood tests in every participant.
219634244|NCT03751839|DIAGNOSTIC_TEST|Osteodensitometry|The investigators will perform an osteodensitometry in every participant.
219634245|NCT03751839|DIAGNOSTIC_TEST|Clinical Tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
218942453|NCT07146633|OTHER|Treatment as Usual (TAU)|Participants are advised to continue seeking mental health care as usual and will be added to a waitlist for A-EMDR. They will also attend two clinical sessions. Sessions may last 15 to 60 minutes and will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol. Participants will continue to receive any usual healthcare services as per local standard of care. TAU and other medical appointments will be checked for attendance throughout the study period.
218942454|NCT07145346|DRUG|Suzetrigine (SUZ)|The intervention arm will receive oral suzetrigine (100 mg loading dose followed by 50 mg every 12 hours).
218942455|NCT07145346|DRUG|Placebo|The control arm will receive placebo capsules matched to suzetrigine for oral administration.
218942456|NCT07145814|DRUG|dexmedetomidine 0.3 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h, respectively, until 30 minutes before the end of the operation.
218942457|NCT07145814|DRUG|dexmedetomidine 0.5 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) high dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.5 µg/kg/h, respectively, until 30 minutes before the end of the operation.
219206782|NCT06739343|PROCEDURE|PHACO-Trabeculectomy|Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.
219206783|NCT06739343|PROCEDURE|MSICS-Trabeculectomy|Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.
218942458|NCT07145814|DRUG|0.9 % saline|Placebo group received an equivalent volume of 0.9% saline.
218942459|NCT07146165|DEVICE|EndoTEM resection platform and technique|EndoTEM is a flexible transanally introduced port system that allows the insertion of a second instrument alongside the flexible endoscope. A curved rigid grasping instrument has been developed, with a 2 cm long tip that can be rotated and angled in all directions.
218942460|NCT07146009|PROCEDURE|Nerve Surgery|Patients undergoing prophylactic nerve surgery (RPNI) during second-stage implant exchange after tissue expander based breast reconstruction.
218942461|NCT07146009|OTHER|Standard of Care (Investigator Choice)|Patients receiving standard medical therapies for PMPS prevention (e.g., pharmacologic pain management, physical therapy).
218942462|NCT04254991|DIAGNOSTIC_TEST|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
218942463|NCT01217307|DRUG|Metformin|Metformin 500mg twice daily during 4 months
218942464|NCT01217307|DRUG|Placebo|Placebo twice daily during 4 months
218942465|NCT02205554|DRUG|Omnitram|Nine 20 mg doses administered every 6 hours
218942466|NCT02205554|DRUG|Tramadol|Nine 50 mg doses administered every 6 hours.
218942467|NCT02205554|DRUG|Placebo|Nine doses administered every 6 hours.
218942468|NCT04240795|DIETARY_SUPPLEMENT|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
218942469|NCT03574519|BEHAVIORAL|Non-contingent incentives|Incentives are provided for participation
218942470|NCT03574519|BEHAVIORAL|Contingent incentives|Incentives are provided for attaining daily goals
218942471|NCT03574519|BEHAVIORAL|Weekly feedback|Text message feedback is delivered weekly summarizing the past week's progress
218942472|NCT03574519|BEHAVIORAL|Daily feedback|Text message feedback is delivered daily summarizing the current day's progress
218942473|NCT00073853|PROCEDURE|Autologous Incubated Macrophages (cell therapy)|
218942474|NCT03730792|BEHAVIORAL|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
218942475|NCT04606329|DRUG|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
218942476|NCT04606329|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
218942477|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
218942478|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
218942479|NCT03093662|DEVICE|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
218942480|NCT03093662|DEVICE|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
219051271|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
219051272|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219051273|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
219634246|NCT03751839|DIAGNOSTIC_TEST|HR-QCT|The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
218942481|NCT04012164|BIOLOGICAL|blood sampling|5ml blood sampling
218942482|NCT04012164|BIOLOGICAL|stool collection|self stool collection (2g)
218942483|NCT04012164|OTHER|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
218942484|NCT04012164|OTHER|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
218942485|NCT01934270|OTHER|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
218942486|NCT01048632|DRUG|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
218942487|NCT02889367|DRUG|Odalasvir 100 mg|Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.
218942488|NCT02889367|DRUG|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
218942489|NCT02889367|DRUG|Odalasvir 500 mg|Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.
218942490|NCT02889367|DRUG|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
218942491|NCT00632606|DRUG|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
219051274|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
219051275|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
219051276|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
219051277|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
219051278|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
219051279|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
219051280|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
219051281|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
218942492|NCT00632606|DRUG|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
218942493|NCT05194423|DEVICE|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
218942494|NCT02878187|DEVICE|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
218942495|NCT01671579|PROCEDURE|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
219051282|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
219051283|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
219634247|NCT03751839|DIAGNOSTIC_TEST|HR-pQCT|The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
219634248|NCT03119350|OTHER|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
219634249|NCT05738057|DRUG|Camrelizumab|200mg on day1 of every 3 weeks, starting on day1 of cycle1
219634250|NCT05738057|DRUG|Gemcitabine Injection|1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
218942496|NCT01671579|PROCEDURE|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
218942497|NCT05235490|OTHER|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~* Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading of tumor sample slides by pathologists~* Patients follow-up (imaging, clinical)~* Recurrence-free survival"
218942498|NCT04671732|PROCEDURE|Fenestrated endovascular aortic aneurysm repair|Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.
218942499|NCT04671732|PROCEDURE|open repair of abdominal aortic aneurysm.|Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
218942500|NCT03034551|BEHAVIORAL|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
219051284|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
219051285|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
219051286|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219051287|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219051288|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
219051289|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
219051290|NCT00046345|DRUG|Atazanavir (BMS-232632)|
219051291|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
219051292|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
219051293|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
219634251|NCT05738057|DRUG|Cisplatin injection|25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
218942501|NCT03950921|BEHAVIORAL|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
218942502|NCT02809716|OTHER|Biomarker Analysis|Correlative studies
218942503|NCT02809716|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
219051294|NCT01699425|DEVICE|Ajust sling|
219051295|NCT01699425|DEVICE|Classical transobturator sling|Control group
219051296|NCT05541718|BEHAVIORAL|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
219051297|NCT05541718|BEHAVIORAL|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
219366029|NCT05698667|DIAGNOSTIC_TEST|Transcervical ultrasound|The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.
219634252|NCT05738057|DRUG|Cisplatin-Eluting Beads|used for D-TACE
219634253|NCT05738057|PROCEDURE|D-TACE|TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
218942504|NCT05910671|BEHAVIORAL|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
218942505|NCT03101111|BIOLOGICAL|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
218942506|NCT03101111|BIOLOGICAL|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
218942507|NCT05525078|BEHAVIORAL|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
218942508|NCT05525078|OTHER|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
218942509|NCT02524600|DEVICE|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
218942510|NCT02524600|DEVICE|scintigraphic imaging|
218942511|NCT01504906|DRUG|cyclosporine|Oral tablets, 600 mg , single dose
218942512|NCT01504906|DRUG|ticagrelor|Oral tablets, 180 mg, single dose
218942513|NCT00643721|OTHER|dehydration|dehydration to 3% and 5% loss of total body water
218942514|NCT00942994|DRUG|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
218942515|NCT00942994|DRUG|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
218942516|NCT03507387|DRUG|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
218942517|NCT03507387|DRUG|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
218942518|NCT03507387|DRUG|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
219051298|NCT05541718|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
219051299|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
218942519|NCT00706303|BEHAVIORAL|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
218942520|NCT00296296|DRUG|Cyclosporin|Dose adjustment to pre-established targets
218942521|NCT00296296|DRUG|Tacrolimus|Dose adjustment to pre-established targets
218942522|NCT00296296|BEHAVIORAL|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
218942523|NCT01874340|DRUG|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
218942524|NCT01874340|DRUG|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
219051300|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
219051301|NCT06053216|OTHER|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
219366030|NCT00087373|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
219366031|NCT00087373|OTHER|laboratory biomarker analysis|Correlative studies
219366032|NCT04338490|DEVICE|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
218942525|NCT01421472|DRUG|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
218942526|NCT01421472|DRUG|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
218942527|NCT03540836|DRUG|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
218942528|NCT03540836|DRUG|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
218942529|NCT03540836|DRUG|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
218942530|NCT05274295|DEVICE|Diabetic leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
218942531|NCT00753246|DRUG|nimotuzumab|monoclonal antibody
218942532|NCT05948384|OTHER|PNF|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
218942533|NCT04521504|DEVICE|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
218942534|NCT01068964|DRUG|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
218942535|NCT01068964|DRUG|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
218942536|NCT03630770|DRUG|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
218942537|NCT00170378|DRUG|Enoxaparin|
218942538|NCT02469545|DRUG|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
218942539|NCT02469545|DRUG|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
218942540|NCT02469545|DRUG|Escitalopram|5-20mg daily
218942541|NCT02469545|DRUG|Sertraline|50-100mg daily
219051302|NCT06053216|OTHER|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
219051303|NCT00228592|DRUG|HepeX-B|
219051304|NCT00228592|DRUG|Hepatitis B Immune Globulin (HBIg)|
219051305|NCT01045564|BIOLOGICAL|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
219051306|NCT04663555|DRUG|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
219051307|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
219051308|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
219051309|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
218942542|NCT04870580|DIAGNOSTIC_TEST|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
219051310|NCT00518804|BEHAVIORAL|Functional Behavioural Skills Group and Parent Training|
219051311|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
219051312|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
218942543|NCT05409534|OTHER|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
218942544|NCT05409534|OTHER|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
218942545|NCT04327193|PROCEDURE|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
218942546|NCT04327193|PROCEDURE|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
218942547|NCT00755638|BIOLOGICAL|ACE-031|single subcutaneous dose of ACE-031
218942548|NCT02801266|BEHAVIORAL|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
218942549|NCT05197660|PROCEDURE|surgical procedures|number of hospital stays
218942550|NCT05222672|OTHER|His Bundle Pacing|Pacing of the His bundle
219051313|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
218942551|NCT02794675|DRUG|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
218942552|NCT04170972|OTHER|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
219051314|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
219051315|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
219051316|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
219051317|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
218942553|NCT04441541|OTHER|Treadmill with auditory feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
218942554|NCT04441541|OTHER|Treadmill with visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
218942555|NCT04441541|OTHER|Treadmill with auditory and visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
218942556|NCT04441541|OTHER|Treadmill training|Participants will receive training 3 times per week for 4 weeks (12 sessions).
218942557|NCT04709627|DEVICE|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
218942558|NCT01086358|DRUG|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
219051318|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
218942559|NCT01086358|DRUG|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
219051319|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
219051320|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
219051321|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
218942560|NCT04975230|BEHAVIORAL|Sleep Self-Management|Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
218942561|NCT03206788|DRUG|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
218942562|NCT03206788|DRUG|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
219051322|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
218942563|NCT01122056|OTHER|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
219051323|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
218942564|NCT06185751|BIOLOGICAL|WS-CART-CS1|-Subject will be hospitalized for 7 days
218942565|NCT06185751|DRUG|Lymphodepleting chemotherapy|"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"
219051324|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
219366033|NCT01726088|DRUG|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
218942566|NCT05903885|OTHER|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff.
218942567|NCT05903885|OTHER|On-site With Social Media Advertising Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff supplemented by exposure to targeted social media advertisements.
219366034|NCT00052390|BIOLOGICAL|bevacizumab|
219366035|NCT00052390|DRUG|doxorubicin hydrochloride|
219366036|NCT00434525|PROCEDURE|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
218942568|NCT06095596|DRUG|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
218942569|NCT06095596|DRUG|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
218942570|NCT03899805|DRUG|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
218942571|NCT03899805|DRUG|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
218942572|NCT03317405|DRUG|Endoxifen Hydrochloride|Apply to the skin
219051325|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
219051326|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
219051327|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
219051328|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
219051329|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
219051330|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
219051331|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
219051332|NCT02939404|OTHER|Cold exposure|23.25 hours inside respiratory chamber with the temperature set to19°C
219051333|NCT02939404|OTHER|Normal temperature|23.25 hours inside respiratory chamber with the temperature set to 24°C
219051334|NCT02939404|OTHER|Fixed diet|A diet that matches the participant's caloric needs
219051335|NCT02939404|OTHER|Ad libitum diet|Participants can eat as much as they want
219051336|NCT02939404|OTHER|Fasting|Participants do not eat for 12 hours before and 24 hours in chamber
219051337|NCT04910867|BEHAVIORAL|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
219051338|NCT04910867|DIAGNOSTIC_TEST|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
219051339|NCT04910867|OTHER|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
219051340|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
219051341|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
219051342|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
218942573|NCT03317405|OTHER|Placebo Administration|Apply to the skin
219051343|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
219051344|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
219051345|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
219051346|NCT04634773|RADIATION|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
219366037|NCT00434525|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
219366038|NCT04126824|DRUG|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
219366039|NCT04126824|DRUG|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
218942574|NCT03317405|OTHER|Questionnaire Administration|Ancillary studies
218942575|NCT01458041|DRUG|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
218942576|NCT06523699|DRUG|Recombinant glycosylated human interleukin-7|Provided by RevImmune
218942577|NCT06523699|DRUG|Melphalan|Standard of care
218942578|NCT06523699|PROCEDURE|Autologous hematopoietic cell transplant|Standard of care
218942579|NCT04024189|OTHER|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
218942580|NCT02835976|DRUG|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
218942581|NCT00673530|BEHAVIORAL|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
219051347|NCT04634773|OTHER|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
219051348|NCT04634773|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
218942582|NCT00673530|BEHAVIORAL|care as usual|Unchanged treatment of hospital patients without interference by the study.
218942583|NCT01766258|DRUG|ODM-101 65mg Carbidopa|
219051349|NCT06460168|OTHER|Mulligan(MWM) MobilizationTechnique|"Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets."
219051350|NCT06460168|OTHER|Maitland Mobilization technique|"will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)"
219051351|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
219051352|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
219051353|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
219051354|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
219051355|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
219051356|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
219051357|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
219051358|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
218942584|NCT01766258|DRUG|ODM-101 105mg Carbidopa|
219051359|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
218942585|NCT01766258|DRUG|Stalevo|
218942586|NCT03633539|PROCEDURE|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
218942587|NCT03633539|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
218942588|NCT04201808|DRUG|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
218942589|NCT06067672|OTHER|Observations to investigate the current practices of communication and decision-making during Nurse-patient consultations|No intervention
218942590|NCT05536271|DRUG|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
219051360|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
219051361|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
219366040|NCT04126824|OTHER|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
218942591|NCT02291016|DRUG|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
218942592|NCT02291016|OTHER|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
218942593|NCT02825797|DRUG|3BNC117|Intravenous infusion of 3BNC117
218942594|NCT02825797|DRUG|10-1074|Intravenous infusion of 10-1074
218942595|NCT02825797|OTHER|Analytical treatment interruption|Analytical treatment interruption
218942596|NCT02825797|DRUG|Placebo|Intravenous infusion of placebo (sterile saline)
218942597|NCT05986201|DEVICE|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
218942598|NCT03469778|DEVICE|Robotic Therapy|Robotic Therapy
218942599|NCT06312124|BEHAVIORAL|Educational Module|Part 1 consists of an education module with premodule and postmodule assessment questionnaires.
218942600|NCT06312124|PROCEDURE|Salpingectomy|Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
218942601|NCT01515020|DRUG|vancomycin monotherapy|intravenous therapy by vancomycin
218942602|NCT01515020|DRUG|daptomycin monotherapy|intravenous therapy by daptomycin
218942603|NCT01567709|DRUG|Alisertib|Given PO
218942604|NCT01567709|OTHER|Laboratory Biomarker Analysis|Correlative studies
218942605|NCT01567709|OTHER|Pharmacological Study|Correlative studies
218942606|NCT01567709|DRUG|Vorinostat|Given PO
219051362|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
219206784|NCT06735443|DRUG|Bupivacaine with Dexmetedomidine|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
218942607|NCT05190926|BEHAVIORAL|Smart-Treatment for Anorexia Nervosa Recovery (STAR)|"Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes."
219051363|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
219634254|NCT00748462|DEVICE|Fractional CO2 Laser|"the treatment settings:~1. Pulse duration : 5 to 7ms depending on skin reaction~2. Spot Density: 49 MTZ/cm2 (Low density)~3. Power: 15 W = (75 - 105) mJ/MTZ"
219634255|NCT02285101|BIOLOGICAL|PEG-BCT-100|
218942608|NCT05190926|BEHAVIORAL|Present-focused Anorexia Nervosa Coping Treatment (PACT)|Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
218942609|NCT05971706|DEVICE|Ozone therapy using a device (Ozone DTA Ozone Generator, Denta Tec Dental AS, Norway)|Ozone therapy procedures will be performed immediately after non-surgical periodontal treatment and three times (every third day) within one week using a device equipped with a periodontal tip according to equipment producer recommendations. The periodontal tip will be halted 1 mm short of the pocket depth. Ozone will be applied only to the pockets; which depth is equal to or greater than 5 mm. Ozone application time to the pockets will be 30 seconds at a fixed concentration of 2,100 ppm (80% oxygen) through a connected handpiece.
218942610|NCT05971706|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment consists of oral hygiene instructions, full mouth supragingival scaling using hand instruments, ultrasonic devices, polishing, and subgingival debridement under local anesthesia with sharp Gracey and Universal curettes and ultrasonic instruments in a single appointment.
218942611|NCT00984620|DRUG|BI 201335|BI 201335
218942612|NCT00984620|DRUG|BI 201335|BI 201335
218942613|NCT00984620|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
218942614|NCT00984620|DRUG|Ribavirin (RBV)|Ribavirin (RBV)
218942615|NCT05533580|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
218942616|NCT05533580|DRUG|Propofol|The control group was sedated with propofol.
218942617|NCT02262208|OTHER|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
218942618|NCT02262208|OTHER|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
218942619|NCT02262208|DEVICE|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
218942620|NCT00732719|DEVICE|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
218942621|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218942622|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218942623|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218942624|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
219051364|NCT05116852|OTHER|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
219051365|NCT05167695|BEHAVIORAL|Habit-based Sleep Health Intervention|A novel low-cost approach derived by leveraging the science of habit formation
219051366|NCT05167695|BEHAVIORAL|Text messaging intervention|In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
219051367|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
219051368|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
219051369|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
219051370|NCT05421078|DRUG|Obicetrapib|tablet
219051371|NCT05421078|DRUG|Placebo|No active ingredient
219051372|NCT02917993|DRUG|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
219051373|NCT02917993|DRUG|Osimertinib|Osimertinib 80 mg once daily (QD)
219051374|NCT06169267|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration/biopsy
219051375|NCT06169267|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration/biopsy
219051376|NCT06169267|PROCEDURE|Music Therapy|Listen to music
219634256|NCT02060838|PROCEDURE|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
219051377|NCT06169267|OTHER|Questionnaire Administration|Ancillary studies
219634257|NCT04958213|DRUG|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
219634258|NCT04958213|COMBINATION_PRODUCT|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
219634259|NCT01021462|PROCEDURE|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
219634260|NCT05169801|DRUG|BP102, paclitaxel, carboplatin|BP102, paclitaxel, carboplatin
219634261|NCT05169801|DRUG|Avastin®, paclitaxel, carboplatin|Avastin®, paclitaxel, carboplatin
219634262|NCT01583140|BEHAVIORAL|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
218942625|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
218942626|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
219051378|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
219051379|NCT06013904|PROCEDURE|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
219051380|NCT06013904|PROCEDURE|US-trained PEM Fellows|US-trained PEM Fellows
219051381|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
219051382|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
219051383|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
219051384|NCT05304949|OTHER|Lucentis|There was no treatment allocation. Patients administered Lucentis by prescription were enrolled.
219051385|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
219051386|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
219051387|NCT05761873|OTHER|Provision of audit and feedback via email and paper|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
219051388|NCT05761873|OTHER|Provision of audit and feedback via paper only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
219051389|NCT04112810|DRUG|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
219051390|NCT04548674|OTHER|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
218942627|NCT02340637|BEHAVIORAL|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
218942628|NCT02340637|BEHAVIORAL|TAU|Treatment as usual
218942629|NCT05541796|DEVICE|Intraocular lens|"Tecnis Symfony Optiblue (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles."
218942630|NCT03635671|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
218942631|NCT04489069|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
218942632|NCT04489069|DIAGNOSTIC_TEST|Clinical and Neuropsychological evaluations|Clinical interviews and neuropsychological tests (paper/pencil and computer based)
219051391|NCT04548674|DEVICE|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
219051392|NCT04548674|OTHER|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
219051393|NCT04548674|OTHER|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
219051394|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
219051395|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
219051396|NCT01112384|DRUG|SB939|Given orally 3 times per week
219051397|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
219051398|NCT00000833|DRUG|Ribavirin|
219051399|NCT00000833|DRUG|Didanosine|
219634263|NCT01583140|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
219051400|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
219051401|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
219634264|NCT00613769|DRUG|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
219634265|NCT00613769|DRUG|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
218942633|NCT04489069|DIAGNOSTIC_TEST|Drawing DNA sample|Saliva sample
218942634|NCT05478031|DRUG|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
218942635|NCT05478031|DRUG|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
218942636|NCT05478031|DRUG|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
218942637|NCT01018810|DRUG|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
218942638|NCT01018810|DRUG|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
218942639|NCT01018810|DRUG|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
218942640|NCT01018810|DRUG|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
218942641|NCT00662467|DRUG|aspirin + clopidogrel|Dual therapy
218942642|NCT00662467|DRUG|aspirin + clopidogrel + warfarin|Triple therapy
218942643|NCT05025436|DEVICE|Acupoint stimulation with low energy laser (Erger laser pen)|Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
218942644|NCT01640314|BIOLOGICAL|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
218942645|NCT04618796|OTHER|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
218942646|NCT03209128|RADIATION|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
218942647|NCT01237015|DEVICE|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
218942648|NCT02181725|BEHAVIORAL|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
218942649|NCT02181725|BEHAVIORAL|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
218942650|NCT04450381|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
218942651|NCT05311813|DRUG|Enoxaparin, Hydroxychloroquine|To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
218942652|NCT02424578|DRUG|Diclofenac Capsules low dose|
218942653|NCT02424578|DRUG|Diclofenac Capsules high dose|
218942654|NCT03899467|DRUG|GT0918|anti-tumor activity
219206785|NCT06735443|DRUG|Bupivacaine with Tramadol|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
219206786|NCT06734143|DIAGNOSTIC_TEST|Neuropad|Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
219634266|NCT06427746|PROCEDURE|Standard|Basic ambulance personnel are trained in the application of the CPSS scale in suspected stroke. The CPSS scale is a tool used to quickly assess stroke severity in pre-hospital settings. It is a three-point scale that takes into account the patient's level of consciousness, facial droop, and arm weakness. If a patient with suspected stroke meets certain criteria, they will be coded as having a suspected stroke by the SOREU. These criteria include having one item in three of the CPSS scale, being of adult age, and being independent at home.
219634267|NCT06427746|PROCEDURE|Video call|Among the tools already available to improve evaluation of patients rescued in the field, SOREU has video calls between the dispatch room physician and the rescuer in the field. Thus, the rescuer in the field will perform the CPSS during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room, potentially increasing the ability to identify a stroke.
218942655|NCT05755061|BEHAVIORAL|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
218942656|NCT05755061|BEHAVIORAL|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
218942657|NCT01386866|DRUG|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
218942658|NCT03695770|OTHER|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
219206787|NCT06890546|DIETARY_SUPPLEMENT|Nigella Sativa Oil capsule|8 weeks 2 x 900 mg Nigella Sativa oil capsule daily
219206788|NCT06890546|BEHAVIORAL|Diet|Low calorie diet intervention
219206789|NCT06744790|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
219634268|NCT06427746|PROCEDURE|Video call + LARIO|LARIO scale's effectiveness in identifying patients with ischemic stroke caused by a large vessel occlusion in the anterior cerebral circulation. The anterior cerebral circulation supplies blood to the front and upper parts of the brain. Occlusion of a large vessel in this area can lead to a severe stroke. Rescuer in the field will perform the CPSS and the LARIO during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room.
219634269|NCT02279875|DRUG|Linezolid|
219634270|NCT02279875|DRUG|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
219634271|NCT05953051|PROCEDURE|ACL reconstruction with bone/PrP-composite|"During standard ACL reconstruction, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well."
218942659|NCT03684369|DEVICE|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
218942660|NCT03785223|DRUG|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
218942661|NCT03785223|DRUG|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
218942662|NCT05659160|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
218942663|NCT02619916|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
218942664|NCT02619916|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
218942665|NCT00004368|DRUG|colchicine|
218942666|NCT00254189|DRUG|Levonorgestrel|
218942667|NCT00254189|DRUG|Ethinyl Estradiol|
218942668|NCT03433612|OTHER|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
218942669|NCT03433612|OTHER|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
218942670|NCT03084783|DRUG|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
218942671|NCT01302145|DRUG|ASP1941|Tablet
218942672|NCT01302145|DRUG|Metformin|Tablet
218942673|NCT01302145|DRUG|Placebo|Tablet
218942674|NCT02581150|PROCEDURE|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
218942675|NCT00470834|DRUG|dutasteride|0.5mg dutasteride (Investigation Product)
218942676|NCT00470834|DRUG|placebo|making placebo
218942677|NCT00470834|DRUG|bicalutamide|50 mg Casodex or generic equivalent
218942678|NCT00244140|DRUG|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
219634272|NCT05953051|PROCEDURE|ACL reconstruction (Standard)|Standard ACL reconstruction with Semitendinosus alone or plus gracilis, femoral fixation via extracortical fixation by adjustable loop device, tibial fixation via a bio-interference screw or adjustable device
218942679|NCT00244140|DRUG|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
219634273|NCT04387565|OTHER|magnesium and vanadium measurements and compare|Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
219634274|NCT02220738|DRUG|ABT-957|ABT-957 administered twice-daily for 7 days
219634275|NCT02220738|OTHER|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
219634276|NCT02499848|DRUG|PRX302|Single prostate cancer lesion injected with PRX302.
219634277|NCT05520073|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus product 1 pack daily
219634278|NCT05520073|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 1 pack daily
219634279|NCT01669863|DEVICE|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
219634280|NCT01669863|PROCEDURE|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
219634281|NCT05182684|DEVICE|Vital Patch(TriBell Lab)|"Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated."
219634282|NCT04207606|BEHAVIORAL|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
219634283|NCT01226082|DEVICE|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
219634284|NCT00075205|DRUG|SR141716 (Rimonabant)|
219634285|NCT06578754|OTHER|This is an non-interventional study|Only blood samples will be required in this study. It is noninterventional.
219634286|NCT02034929|DEVICE|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
219634287|NCT02034929|DEVICE|Standard colonoscopy|Standard colonoscopy
219634288|NCT06358547|DIAGNOSTIC_TEST|PGT-A|PGT-A is a technique that allows for the prediction of embryo ploidy status through analysis of a trophectoderm biopsy conducted prior to embryo transfer.
219634289|NCT04931277|PROCEDURE|cataract surgery|stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
218942680|NCT05260918|OTHER|Float-REST|Participants will utilize sensory deprivation tanks.
218942681|NCT05260918|OTHER|Nappod|Participants will utilize nappod.
218942682|NCT05983081|PROCEDURE|Injection Treatment|Physical Therapy
218942683|NCT03157700|BEHAVIORAL|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
218942684|NCT06405308|PROCEDURE|R-NOSES group|robotic natural orifice specimen extraction surgery
218942685|NCT06405308|PROCEDURE|R-TSES group|robotic transabdominal specimen extraction surgery
218942686|NCT05152225|DIAGNOSTIC_TEST|Brain MRI|Brain MRI performed routinely in patients with EI
218942687|NCT05152225|DIAGNOSTIC_TEST|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
218942688|NCT04107389|BEHAVIORAL|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
218942689|NCT04107389|BEHAVIORAL|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
218942690|NCT05580445|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
218942691|NCT05580445|DRUG|Toripalimab|Programmed Death 1(PD-1) antibody
218942692|NCT05580445|DRUG|Gemcitabine|nucleoside inhibitor
218942693|NCT05922670|BEHAVIORAL|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
218942694|NCT01174433|DEVICE|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
218942695|NCT06363942|OTHER|SAFE program (exercise intervention)|Participants will be asked to carry out the SAFE program with the help of a caregiver. Our healthcare professionals will visit them during the first week to explain to them and their caregivers how to perform the exercises correctly while using our website. All exercises will be performed using video capsules available on our website (https://safe-seniors.com/fr). The exercises are divided into 4 levels of difficulty: level 1 (light); level 2 (moderate); level 3 (moderate to vigorous); and level 4 (vigorous). Each level lasts 25 to 30 minutes and includes 5 exercise categories split into 5 videos: warm-up, strength, balance, flexibility, and endurance. The exercise intervention will include 3 sessions per week over 12 weeks.
218942696|NCT06331728|DRUG|IGNX001|IGNX001 given as a single subcutaneous dose on Day 1.
218942697|NCT06331728|DRUG|Placebo|Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
219051402|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
219051403|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
219051404|NCT02075944|BEHAVIORAL|High intensity aerobic exercise|
219051405|NCT02075944|BEHAVIORAL|Low intensity aerobic exercise|
219206790|NCT06737900|OTHER|traditional physical therapy|"* Heating pad for 10 minutes~* Core stability exercises for 20 minutes with 10 seconds of rest intervals~* Patients were advised to stretch for 5 minutes then perform lumber stability exercises.~* These stability exercises included side bridges, supine extension bridge, straight leg raise in prone lying, alternate arm and leg raise from quadruped position and prone bridges.~Both groups took sessions thrice a week for a total of 4 weeks."
219634290|NCT05610397|DEVICE|STALIF®|STALIF® C, or M, Ti or FLX
218942698|NCT02213861|DRUG|SHAPE|topical gel
218942699|NCT05986396|DEVICE|INSPIRIS Resilia (model 11500A)|Aortic Valve
218942700|NCT02640508|DRUG|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
218942701|NCT02640508|DRUG|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
218942702|NCT02707575|DRUG|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
218942703|NCT03924856|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
218942704|NCT03924856|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
218942705|NCT03924856|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
218942706|NCT03924856|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
218942707|NCT03924856|DRUG|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
219051406|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
219051407|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
219051408|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
219051409|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
218942708|NCT00932178|BEHAVIORAL|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
219634291|NCT04073927|DIETARY_SUPPLEMENT|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
219634292|NCT02189031|DEVICE|Tactor array|
218942709|NCT03202615|DIETARY_SUPPLEMENT|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
218942710|NCT03202615|DRUG|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
218942711|NCT02776397|DIETARY_SUPPLEMENT|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
218942712|NCT02776397|OTHER|Placebo|Placebo arm
218942713|NCT05405257|DRUG|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
218942714|NCT05405257|OTHER|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
218942715|NCT06584383|PROCEDURE|Exablate MRgFUS subthalamotomy|Exablate MRgFUS subthalamotomy for Parkinson's Disease
218942716|NCT06584383|DRUG|Best Medical Treatment|Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
218942717|NCT03126318|DRUG|COR-001|Anti-inflammatory therapy
218942718|NCT03126318|DRUG|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
218942719|NCT03120195|DEVICE|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
218942720|NCT01162837|DEVICE|BEAM device|A red/blue LED device for the treatment of acne
218942721|NCT01739062|GENETIC|Genetic risk assessment|
218942722|NCT05949437|OTHER|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
218942723|NCT05949437|OTHER|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
218942724|NCT02672293|DRUG|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
218942725|NCT06443931|PROCEDURE|cryoablation of intercostal nerves|"Patients in the CryoINB group will undergo cryoablation of the intercostal nerves, at the end of surgery before weaning from CPB, using the ArtiCue device for 120 seconds at a temperature of -50°C to -70°C, in the intercostal spaces where the surgical approach is located, one intercostal space above and one below it. Cold leads to axonotmesis, in which the axon and myelin sheath are damaged, preventing the pain signal from traveling along the sensory nerve. However, the structural elements of the nerve are preserved, which promotes complete regeneration at a rate of 1-2 mm per day, thereby restoring normal function within several months."
218942726|NCT01469715|DEVICE|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
218942727|NCT01966718|DRUG|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
218942728|NCT04587609|BEHAVIORAL|Free Phone Mounts|Participants will receive free phone mounts
218942729|NCT04587609|BEHAVIORAL|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
218942730|NCT04587609|BEHAVIORAL|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
218942731|NCT04587609|BEHAVIORAL|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
219051410|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
219051411|NCT06237153|DRUG|Triamcinolone Acetonide extended release suspension|Active steroid
219634293|NCT02189031|DEVICE|Bypass Tactor|
219634294|NCT04181476|DRUG|Sunscreening Agents|Four different sunscreens
219634295|NCT00269373|PROCEDURE|PET-CT|no drugs included
219206791|NCT06737900|OTHER|jandas approach|"* Stretching exercise for erector spinae and back extensors muscles~* Stretching exercises for iliopsoas muscle and rectus femoris muscle~* Strengthening exercise for abdominal muscle and gluteal maximus muscle Stretching exercise was performed actively for 3 repetitions x 1 set and 4 days a week Strengthening exercise was performed for 10 second hold and 10 repetitions. All Exercises was performed 3 times per week for total of 4 weeks"
219634296|NCT06416774|DRUG|68Ga-HX01 Injection(0.05mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
219206792|NCT06736314|DEVICE|a removable titanium clip|The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
219634297|NCT06416774|DRUG|68Ga-HX01 Injection(0.1mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
219634298|NCT06416774|DRUG|68Ga-HX01 Injection(0.07mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
219634299|NCT03881189|DEVICE|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
219634300|NCT04102267|DRUG|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
219634301|NCT04102267|DRUG|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
219634302|NCT05629780|DRUG|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
219634303|NCT06524362|BEHAVIORAL|Pelvic Floor Physiotherapy (PFR)|"Intervention: Participants will undergo a structured pelvic floor physiotherapy program for three months.~The program includes:~Eight Personal Sessions: Each session lasts 45 minutes.~Frequency:~Once a week for the first month (four sessions). Biweekly for the next two months (four sessions). Home Exercises: Participants will be guided on pelvic floor exercises to be performed at home throughout the three months."
219634304|NCT06524362|BEHAVIORAL|Conventional group|"Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Conventional group after randomization.~Recruited subjects in the conventional group recieves usual care following low anterior resection such as fluid intake, fiber intake, diet, toilet posture, life style advice etc"
219634305|NCT04471194|DIAGNOSTIC_TEST|Self-sampling HPV test|Tests for human papillomavirus from cervical cell sample
218942732|NCT04587609|BEHAVIORAL|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
218942733|NCT02865876|PROCEDURE|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
218942734|NCT00764764|PROCEDURE|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
218942735|NCT00764764|PROCEDURE|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
218942736|NCT04454853|OTHER|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
218942737|NCT04454853|OTHER|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
218942738|NCT04454853|OTHER|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
219206793|NCT06742255|DRUG|Stellate Ganglion Block|Stellate ganglion block is an injection of local anesthetic at the level of the neck to target the stellate ganglion, a sympathetic ganglion to interrupt abnormal autonomically-mediated pain in patients resistant to medical treatment
219206794|NCT06741527|DEVICE|Integrity Implant System|Integrity Implant System used for Rotator Cuff Repair
219206795|NCT06742138|DRUG|QL2109|QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
219634306|NCT04471194|DIAGNOSTIC_TEST|Fecal occult blood test|Tests for human hemoglobin from blood in fecal samples
219634307|NCT04417855|DIAGNOSTIC_TEST|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
219634308|NCT02588794|DEVICE|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
219634309|NCT02123589|DRUG|Deep sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
219634310|NCT02123589|DRUG|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
219634311|NCT02123589|DRUG|Light sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
219634312|NCT02630173|PROCEDURE|Scaling and root planing|Scaling and root planing was done in both the groups
219634313|NCT02630173|OTHER|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
219634314|NCT00894270|PROCEDURE|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
219634315|NCT00894270|PROCEDURE|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
219634316|NCT00894270|DEVICE|Novofine needle|Novofine 5mm needle
219634317|NCT00757042|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
219634318|NCT00757042|DRUG|Placebo|Matching placebo administered by subcutaneous or intravenous injection.
218942739|NCT04759326|OTHER|Hippotherapy|Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
218942740|NCT04759326|OTHER|Conventional Neurorehabilitation|The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
218942741|NCT00511368|DRUG|matching placebo|
219634319|NCT02915705|BIOLOGICAL|burosumab|solution for subcutaneous (SC) injection
219634320|NCT02915705|DRUG|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
219634321|NCT02915705|DRUG|active vitamin D|tablet, oral solution
219634322|NCT02508077|DRUG|Fluorouracil|Given IV
218942742|NCT00511368|DRUG|Bevirimat|
218942743|NCT02176252|DRUG|AZD1722|
218942744|NCT02176252|DRUG|Placebo|
218942745|NCT04242641|BEHAVIORAL|WW|WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
218942746|NCT02365480|DRUG|Berberine Chloride|Given PO
218942747|NCT02365480|OTHER|Laboratory Biomarker Analysis|Correlative studies
218942748|NCT02365480|OTHER|Placebo Administration|Given PO
218942749|NCT03512938|PROCEDURE|Non-surgical periodontal therapy|Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
218942750|NCT02048319|DRUG|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
218942751|NCT02048319|PROCEDURE|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
218942752|NCT02048319|DRUG|Placebo|Saline solution, injected as placebo
219051412|NCT04487327|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
219051413|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
219634323|NCT02508077|DRUG|Irinotecan Hydrochloride|Given IV
219634324|NCT02508077|OTHER|Laboratory Biomarker Analysis|Correlative studies
219634325|NCT02508077|DRUG|Leucovorin Calcium|Given PO
219634326|NCT02508077|BIOLOGICAL|Panitumumab|Given IV
219634327|NCT04881864|BEHAVIORAL|Tele-Enhance Fitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
219634328|NCT00002205|DRUG|Abacavir sulfate|
219634329|NCT00002205|DRUG|Amprenavir|
219634330|NCT00263705|DRUG|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
219634331|NCT00263705|DRUG|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
219634332|NCT01039727|OTHER|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
219634333|NCT01039727|OTHER|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
219634334|NCT01031511|BEHAVIORAL|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
219634335|NCT01031511|OTHER|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
218942753|NCT02791763|DRUG|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
218942754|NCT02791763|DRUG|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
218942755|NCT02791763|DRUG|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
218942756|NCT06035419|OTHER|education|breastfeeding education for migrant mothers
218942757|NCT02086513|DRUG|LDE225|Treatment with LDE225
219051414|NCT04141462|GENETIC|blood sample|blood test
219206796|NCT06742138|DRUG|Pomalidomide|Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle
219206797|NCT06742138|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
219634336|NCT00150488|DEVICE|Uracyst|2% weekly for 6 weeks, monthly for 4 months
218942758|NCT05243693|DRUG|Brentuximab vedotin|3 cycles of Brentuximab vedotin and DHAP
218942759|NCT04534686|BEHAVIORAL|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
218942760|NCT04534686|BEHAVIORAL|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
218942761|NCT03941704|DIETARY_SUPPLEMENT|Pulse-based diet|Low Glycemic Index
218942762|NCT03941704|DIETARY_SUPPLEMENT|Regular diet|Moderate Glycemic Index
218942763|NCT01284036|DRUG|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
218942764|NCT01319604|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
219051415|NCT02075437|BEHAVIORAL|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
219051416|NCT02075437|BEHAVIORAL|Treatment Strategies|"1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research."
219051417|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
219051418|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
219051419|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
219051420|NCT05735002|DIAGNOSTIC_TEST|13C-butyrate breath test|breath test
218942765|NCT01319604|DEVICE|Tonometer|Tonometric assessment of IOP
218942766|NCT03111862|DIAGNOSTIC_TEST|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
218942767|NCT00635999|BEHAVIORAL|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
218942768|NCT00635999|OTHER|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
218942769|NCT00635999|BEHAVIORAL|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
218942770|NCT05282134|PROCEDURE|Wet cupping therapy|Wet cupping therapy is a bloodletting application done by cups on the skin
218942771|NCT05282134|PROCEDURE|Acupuncture|Acupuncture is a complementary application of TCM done by needles
219051421|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
219051422|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
219051423|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
219051424|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
219051425|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
219051426|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
219051427|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
219051428|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
219051429|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
219051430|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
219051431|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
219051432|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
219051433|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
218942772|NCT04692636|DIAGNOSTIC_TEST|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
218942773|NCT00097604|DIETARY_SUPPLEMENT|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
218942774|NCT02254954|DRUG|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
218942775|NCT01630538|DRUG|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
218942776|NCT02340871|GENETIC|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
218942777|NCT00888043|DRUG|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose"
218942778|NCT05071248|DEVICE|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
218942779|NCT01929811|DRUG|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
218942780|NCT01929811|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
218942781|NCT01929811|DRUG|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
219051434|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
219051435|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
219051436|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
219206798|NCT06742138|DRUG|DARZALEX FASPRO®|DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
219206799|NCT06743646|DRUG|ZVS101e|subretinal injection of ZVS101e
219634337|NCT01266291|DRUG|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
219634338|NCT03177460|BIOLOGICAL|Daratumumab|Given IV
218942782|NCT01929811|DRUG|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
218942783|NCT02739685|DEVICE|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
218942784|NCT02739685|DEVICE|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
218942785|NCT01781299|DEVICE|AlloDerm RTU|
218942786|NCT01781299|DEVICE|SurgiMend PRS|
218942787|NCT04519242|PROCEDURE|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
218942788|NCT03211572|DRUG|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
218942789|NCT02436837|OTHER|sessions with virtual reality|sessions with virtual reality to improve the balance
218942790|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (LAX)
219634339|NCT03177460|DRUG|FMS Inhibitor JNJ-40346527|Given PO
219634340|NCT03177460|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
218942791|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (SAX)
218942792|NCT02657603|PROCEDURE|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
218942793|NCT02657603|PROCEDURE|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
218942794|NCT02636361|DRUG|LY900014|Administered subcutaneously (SC)
218942795|NCT02636361|DRUG|Insulin lispro (Humalog)|Administered SC
218942796|NCT02032238|DEVICE|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
218942797|NCT03277339|DRUG|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
218942798|NCT03277339|OTHER|Thermal cure|Thermal cure is realized for 3 weeks
218942799|NCT05318742|PROCEDURE|laser|Endolaser photocoagulation during PPV
218942800|NCT01612806|DEVICE|PriMatrix|fetal bovine dermal scaffold
218942801|NCT01612806|DEVICE|PriMatrix Ag|fetal bovine dermal scaffold with Ag
218942802|NCT01612806|PROCEDURE|moist wound therapy|standard of care moist wound therapy
218942803|NCT03692819|DRUG|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
218942804|NCT03692819|DRUG|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
218942805|NCT03692819|DRUG|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
218942806|NCT03123406|DRUG|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
218942807|NCT04404933|OTHER|Treatment algorithm for OIC|Treatment Algorithm for OIC
218942808|NCT03114319|DRUG|TNO155|TNO155 for oral administration
218942809|NCT03114319|DRUG|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
218942810|NCT02410343|DRUG|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
218942811|NCT02410343|DRUG|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
218942812|NCT06518395|OTHER|Questionnaire for The degree of knowledge and attitude.|Questionnaire for The degree of knowledge and attitude of Egyptian nurses regarding the emergency treatment of traumatic dental injuries
218942813|NCT03892278|BEHAVIORAL|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
218942814|NCT03892278|BEHAVIORAL|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
218942815|NCT03892278|BEHAVIORAL|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
218942816|NCT00799214|DRUG|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
218942817|NCT00799214|DRUG|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
218942818|NCT00799214|DRUG|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
218942819|NCT02428478|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
218942820|NCT02428478|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
219206800|NCT06743737|DEVICE|Digital skin test reading device|The device to be studied measures optically the size of the wheals from skin tests (SPT) performed for the diagnosis of allergen sensitization.
219206801|NCT06744855|DEVICE|Non-invasive circulation gloves|Non-invasive class I medical device, circulation gloves with semiconductors embedded in the fabric.
219206802|NCT06744855|DEVICE|Fabric gloves|These gloves will look and feel identical to the active circulation gloves, but will not have semiconductors embedded in the fabric.
219206803|NCT06747767|PROCEDURE|Arthroscopy|Arthroscopy
219206804|NCT06747767|PROCEDURE|Open reduction|Open reduction
218942821|NCT02663934|BEHAVIORAL|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
218942822|NCT02663934|BEHAVIORAL|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
218942823|NCT01563133|PROCEDURE|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
218942824|NCT01563133|DEVICE|nCLE|needle-based Confocal Laser Endomicroscopy
219634341|NCT03291431|DEVICE|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
218942825|NCT06344897|OTHER|Kinesio taping|After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
218942826|NCT04423341|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg BID for three months Placebo oral solution for three months
218942827|NCT05339997|OTHER|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
218942828|NCT00935246|DRUG|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
218942829|NCT03309176|DRUG|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
218942830|NCT03309176|OTHER|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
218942831|NCT02720042|DEVICE|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
219051437|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
219051438|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
219051439|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
219051440|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
219051441|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
219634342|NCT04059029|PROCEDURE|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
219634343|NCT01348620|DEVICE|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson \& Johnson Medical Spa)
218942832|NCT02692391|DRUG|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
218942833|NCT02692391|DRUG|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
219051442|NCT00619697|DRUG|biphasic insulin aspart|
219051443|NCT00619697|DRUG|insulin glargine|
219051444|NCT00619697|DRUG|metformin|
219634344|NCT01348620|PROCEDURE|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
219051445|NCT00619697|DRUG|glimepiride|
219051446|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
219051447|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
219051448|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
219051449|NCT00277602|DRUG|Riluzole|
219051450|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
219051451|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
218942834|NCT03381976|OTHER|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
218942835|NCT03381976|OTHER|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
218942836|NCT04952935|PROCEDURE|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
218942837|NCT04952935|PROCEDURE|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
218942838|NCT06081933|DRUG|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
218942839|NCT06081933|DRUG|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
218942840|NCT01110642|DRUG|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
218942841|NCT03572608|OTHER|Acupuncture treatment|Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
218942842|NCT05589558|PROCEDURE|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
218942843|NCT06415500|DRUG|NK042|NK042 intraperitoneal infusion on Days 0,7 and 14.
218942844|NCT00246740|DRUG|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
218942845|NCT00246740|DRUG|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
218942846|NCT05519722|BEHAVIORAL|Expectation-focused online intervention|Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
218942847|NCT03153722|PROCEDURE|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
218942848|NCT06164990|OTHER|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
218942849|NCT06416579|OTHER|Schroth Exercise Group|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. The exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
219051452|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
219051453|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
219051454|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
219051455|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
219206805|NCT06746480|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date is Days 1 through 3.
219206806|NCT02322905|BEHAVIORAL|Emotion Regulation Therapy|8 sessions of ERT
218942850|NCT06416579|OTHER|Schroth Method Based Virtual Reality Group|During Schroth method-based virtual reality exercises, continuity in stabilization will be ensured by using external focus and muscular activation in positions appropriate to the Schroth method and in corrected posture. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Warm-up and cool-down will consist of aerobic games available in Nitendo wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis and Baseball will be included in the program. Progression will be made by difficulty level and positional in all games. The exercises will be made more difficult by side sitting, side sitting on a stool, sitting position, knight position, standing, sitting on a balance ball, standing on a soft floor, on a bosu ball and moving towards the balance board.
218942851|NCT06416579|OTHER|Control Group|Participants in the control group will be placed on a waiting list for 24 weeks. Participants will not receive any exercise intervention for 24 weeks and will be able to continue their routine physical activities.
218942852|NCT02215980|DRUG|Lenalidomide|
218942853|NCT02215980|DRUG|Dexamethasone|
218942854|NCT01510769|DRUG|Lesinurad|Tablets, 400 mg once daily (QD)
218942855|NCT01510769|DRUG|Lesinurad|Tablets, 200 mg QD
218942856|NCT01510769|DRUG|Placebo|Tablets, Placebo QD
218942857|NCT01510769|DRUG|Febuxostat|80 mg
218942858|NCT02402660|DRUG|ALK-001|Daily, oral administration for 24 months
218942859|NCT02402660|DRUG|Placebo|Daily, oral administration for 24 months
218942860|NCT03815318|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
218942861|NCT06803628|OTHER|Point of care ultrasound|"OCCLUS-POCUS will include patients with suspected SBO, with low or moderate Gestalt probability who meet the inclusion criteria During the patient's visit to the ED, the investigating physician will present the study and the importance of evaluating the value of POCUS in the diagnosis of exclusion of SBO. Once oral non-opposition to the study has been obtained, the participation of the patient lasts 28 days.~POCUS is performed only for patients with low or moderate Gestalt probability. It will be performed by trained emergency physicians (EP) using a curvilinear probe . After POCUS realization, the EP will:~* determine if there is presence or absence of SBO.~* collect POCUS duration, difficulty and investigator's characteristics.~* Realization of CT which will be the gold standard for SBO presence or absence.~* The study protocol procedure ends when the report of the CT is available and the physician establish its diagnosis.~* The study ends at D28 with a phone call"
218942862|NCT00964210|DRUG|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
218942863|NCT02230917|DRUG|Sotatercept|
218942864|NCT02230917|DRUG|Placebo|
218942865|NCT02185924|DRUG|Parecoxib|
218942866|NCT02185924|DRUG|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
218942867|NCT02185924|DRUG|N/S 0.9%|
218942868|NCT01017913|OTHER|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
218942869|NCT01017913|OTHER|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
218942870|NCT01656265|DRUG|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
218942871|NCT02269540|DRUG|Sertraline|selective serotonin reuptake inhibitor
218942872|NCT02269540|DRUG|Citalopram|selective serotonin reuptake inhibitor
218942873|NCT02269540|DRUG|N-acetylcysteine (NAC)|natural health product
218942874|NCT02269540|DRUG|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
218942875|NCT01980485|BEHAVIORAL|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
218942876|NCT01980485|BEHAVIORAL|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
218942877|NCT05413174|BEHAVIORAL|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
218942878|NCT00375206|BIOLOGICAL|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
218942879|NCT03195309|DRUG|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
218942880|NCT03195309|DRUG|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
218942881|NCT01536392|DRUG|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
218942882|NCT01536392|DRUG|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
218942883|NCT01536392|BEHAVIORAL|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
218942884|NCT01536392|BEHAVIORAL|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
218942885|NCT02747472|DRUG|GIP-A|GIP receptor antagonist
218942886|NCT02747472|DRUG|GIP(1-42)|GIP receptor agonist
218942887|NCT02747472|OTHER|Saline|Placebo
219634345|NCT05944497|PROCEDURE|Interscalene brachial plexus block|Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
218942888|NCT04039009|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
218942889|NCT03929094|DRUG|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
218942890|NCT03929094|DRUG|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
219634346|NCT00481351|DRUG|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
219634347|NCT00481351|DRUG|ezetimibe|ezetimiba 10mg once a day
218942891|NCT04636983|DRUG|BV100|Rifabutin IV
218942892|NCT04636983|DRUG|Placebo|Saline
218942893|NCT02750020|OTHER|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
218942894|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
218942895|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
218942896|NCT04942977|DEVICE|telemonitoring|"The system consists of the following elements:~1. Professional website at the hospital, which allows:~   * To set up an individualised care plan~  * To establish the patient's risk profile and targets for improvement.~  * Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~  * Advise the patient on self-management strategies.~2. Mobile application software with the following functions:~   * Scheduled exercise sessions~  * Medication reminder~  * Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~  * Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~  * Training monitor: guides the patient in the performance of their exercise.~  * Access to certified health information for patients"
218942897|NCT04942977|OTHER|Centre-based cardiac rehabilitation|The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
218942898|NCT00934440|DRUG|Bevacizumab|"* First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
218942899|NCT00934440|DRUG|Azacitidine|"* Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight"
219051456|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
219051457|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
219051458|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
219634348|NCT00481351|DRUG|simvastatin 20mg|simvastatin 20mg once a day
219634349|NCT00481351|DRUG|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
219634350|NCT01427647|PROCEDURE|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
219634351|NCT05697172|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
219634352|NCT06257823|OTHER|No intervention|No intervention
219634353|NCT00808912|DRUG|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
219634354|NCT00808912|OTHER|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
219634355|NCT00550745|BIOLOGICAL|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
219634356|NCT00550745|BIOLOGICAL|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
218942900|NCT02685982|DEVICE|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
219206807|NCT05722561|BEHAVIORAL|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.
219634357|NCT00994383|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
218942901|NCT01700309|BEHAVIORAL|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
218942902|NCT00163917|DEVICE|Virtual reality relaxation|
218942903|NCT02141737|DRUG|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
218942904|NCT02141737|DRUG|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
218942905|NCT02141737|DRUG|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
218942906|NCT02141737|DRUG|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
218942907|NCT02141737|DRUG|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
218942908|NCT02141737|DRUG|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
218942909|NCT02172534|DRUG|Tiotropium bromide low|
218942910|NCT02172534|DRUG|Tiotropium bromide medium|
218942911|NCT02172534|DRUG|Tiotropium bromide high|
218942912|NCT02172534|DRUG|Placebo|
218942913|NCT04206241|DIAGNOSTIC_TEST|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
218942914|NCT02707263|DRUG|intravenous continuous infusion of heparin (IV UFH)|
218942915|NCT02707263|DRUG|Subcutaneous Heparin|
218942916|NCT00037089|DRUG|UFT (Tegafur/Uracil)|
218942917|NCT01012089|DRUG|Daptomycin|Daptomycin IV 5 mg/kg one time dose
218942918|NCT01269242|DRUG|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
218942919|NCT01269242|DRUG|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
218942920|NCT01269242|DRUG|placebo|bindarit-matching placebo tablets for 6 months.
218942921|NCT04413682|BEHAVIORAL|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
218942922|NCT04413682|BEHAVIORAL|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
218942923|NCT01812278|BEHAVIORAL|ACT|
218942924|NCT01812278|BEHAVIORAL|CBT|
219634358|NCT04577560|GENETIC|First polar body biopsy in MII oocytes|Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.
219634359|NCT04577560|GENETIC|PGT-A blastocyst|preimplantation genetic screening for aneuploidies
219634360|NCT03850483|DRUG|PF-06700841|PF-06700841 topical cream
218942925|NCT01986556|DRUG|Lesinurad 400 mg (Site 1)|
218942926|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot A)|
218942927|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot B)|
219206808|NCT05722561|DRUG|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
218942928|NCT00744042|BIOLOGICAL|asfotase alfa|
218942929|NCT01559740|DRUG|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
218942930|NCT01494623|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
218942931|NCT03098615|DRUG|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
218942932|NCT05420259|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
218942933|NCT05420259|BEHAVIORAL|Standard Care|Standard Care
218942934|NCT03944252|DRUG|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
219634361|NCT03850483|DRUG|Vehicle (Placebo)|Vehicle topical cream
218942935|NCT03944252|DRUG|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
218942936|NCT01573052|DRUG|Chlordiazepoxide|25mg four times daily x 3 days then tapered over 3 days
218942937|NCT01573052|DRUG|Gabapentin|300mg four times daily x 3 days then tapered over 3 days
218942938|NCT01955629|DRUG|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
218942939|NCT01955629|DRUG|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
218942940|NCT01955629|DRUG|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
218942941|NCT01630993|OTHER|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
218942942|NCT03307655|OTHER|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
218942943|NCT03307655|OTHER|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
218942944|NCT00263185|DIETARY_SUPPLEMENT|Vitamin D|
218942945|NCT00263185|DIETARY_SUPPLEMENT|Calcium carbonate|
218942946|NCT00263185|DRUG|Vitamin D|
218942947|NCT00263185|OTHER|Placebo|
218942948|NCT05675488|DIAGNOSTIC_TEST|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
218942949|NCT00660686|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
218942950|NCT00660686|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
218942951|NCT05529095|DRUG|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
218942952|NCT05529095|DRUG|Placebo|Placebo (sugar pill)
218942953|NCT04017845|DIAGNOSTIC_TEST|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
218942954|NCT04017845|PROCEDURE|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
218942955|NCT04017845|PROCEDURE|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
218942956|NCT04017845|DIAGNOSTIC_TEST|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: \>10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
218942957|NCT04017845|DRUG|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
219634362|NCT03801005|BIOLOGICAL|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
219634363|NCT02609815|DRUG|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
219634364|NCT02609815|DRUG|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
218942958|NCT04017845|DRUG|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
219634365|NCT02828774|OTHER|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
219634366|NCT01882959|OTHER|Radiofrequncy Denervation|
219634367|NCT05124288|OTHER|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
219634368|NCT04161248|DRUG|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
219634369|NCT04161248|DRUG|Rituximab Injection|375 mg/m2 - Day 1, cycle 1.
219634370|NCT04161248|DRUG|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
219634371|NCT04161248|DRUG|Gemcitabine|1000 mg/m2 - Day 1 to day 8
219634372|NCT04161248|DRUG|Dexamethasone|40 mg daily - Day 1 to day 4
219634373|NCT04161248|DRUG|Cisplatin|75mg/m2 - Day 1
218942959|NCT03158285|DRUG|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
219051459|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
219051460|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
219206809|NCT05722561|DEVICE|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
219206810|NCT06749379|OTHER|Presence and stages of lipedema were diagnosed with examination.|Lipedema stage characteristics: stage 1: Smooth skin with a uniform increase in subcutaneous tissue; stage 2: Irregular skin surface with indentations and nodular alterations in the subcutaneous tissue; stage 3: Significant increase in circumference accompanied by loose skin/tissue ('dewlap').
219051461|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
219206811|NCT06751121|DRUG|DWP14012 40mg|DWP14012 40 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
219634374|NCT04161248|DRUG|Glofitamab|Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
219634375|NCT04161248|DRUG|Tafasitamab|Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
219634376|NCT06776016|DIETARY_SUPPLEMENT|Butyrate|Agent: The dietary supplement contains tributyrin, a pro-drug of butyrate. Method: Participants receive the supplement orally at a dose of 20 ml, 2-3 times daily, 12 weeks.
219634377|NCT06122610|DEVICE|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
219634378|NCT06122610|DEVICE|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
219634379|NCT06122610|DRUG|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
219634380|NCT06122610|DRUG|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
219051462|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
218942960|NCT03158285|DRUG|Placebo|Participants will receive matching placebo as SC injection.
218942961|NCT02200640|DRUG|High dose of Micardis®, once daily|
218942962|NCT02200640|DRUG|Low dose of Micardis®, once daily|
218942963|NCT02200640|DRUG|Low dose of COZAAR®, once daily|
219051463|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
218942964|NCT02200640|DRUG|High dose of COZAAR®, once daily|
218942965|NCT02200640|DRUG|Placebo|
218942966|NCT04587765|BEHAVIORAL|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
218942967|NCT06343519|DEVICE|Echocardiography|Measuring echocardiographic parameters (cardiac index, speckle tracking, tissue Doppler indices)
218942968|NCT03601884|BEHAVIORAL|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
219051464|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
219051465|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
219051466|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
219051467|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
219051468|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
219206812|NCT06751121|DRUG|DWC202301 30mg|DWC202301 30 mg, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
219206813|NCT06751121|DRUG|Amoxicillin 1000mg|Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
219206814|NCT06751121|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
218942969|NCT03601884|OTHER|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
218942970|NCT02587377|OTHER|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
218942971|NCT01333930|OTHER|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
218942972|NCT01333930|OTHER|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
218942973|NCT06521905|DEVICE|intravascular lithotripsy|The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.
218942974|NCT06521905|DEVICE|high-pressure ballon|High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
218942975|NCT00256568|BEHAVIORAL|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
218942976|NCT02659397|DRUG|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
218942977|NCT02659397|DRUG|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
218942978|NCT02659397|DRUG|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
218942979|NCT03171181|OTHER|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
218942980|NCT03753113|DRUG|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
218942981|NCT03753113|DRUG|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
218942982|NCT01918748|DEVICE|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
218942983|NCT04904224|DEVICE|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
218942984|NCT04904224|DEVICE|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
218942985|NCT04293744|DEVICE|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
218942986|NCT04293744|DEVICE|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
218942987|NCT01441362|PROCEDURE|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
218942988|NCT01441362|PROCEDURE|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
218942989|NCT00932828|DRUG|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
218942990|NCT01764139|PROCEDURE|Blood sampling|
218942991|NCT05170932|PROCEDURE|CHX gel 2 % + 24% EDTA|The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
218942992|NCT01516034|DEVICE|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
218942993|NCT02586779|OTHER|whatsApp|whatsApp application will be used for consultations.
218942994|NCT02586779|OTHER|without whatsApp|whatsApp application will be not used for consultations.
218942995|NCT05591235|DRUG|Metformin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
219051469|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
219051470|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
219051471|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
219051472|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
219051473|NCT04984655|DEVICE|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
218942996|NCT05591235|DRUG|Dapagliflozin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
219051474|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
219051475|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
219051476|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
219051477|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
219051478|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
219051479|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
219051480|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
219051481|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
219051482|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
219051483|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
219051484|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
219051485|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
219051486|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
219051487|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
219051488|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
219051489|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
219206815|NCT06751121|DRUG|DWC202301 30mg placebo|DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
219051490|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
219206816|NCT06751121|DRUG|DWP14012 40mg placebo|DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
219051491|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
219051492|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
219051493|NCT03199027|OTHER|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
219051494|NCT00854581|BIOLOGICAL|PEG-interferon alfa-2b|Administered subcutaneously.
219051495|NCT00854581|BIOLOGICAL|Interferon alfa-2b|Administered intravenously.
219051496|NCT00854581|DRUG|Valproic Acid|Administered orally.
219051497|NCT00854581|DRUG|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
218942997|NCT05591235|DRUG|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
219206817|NCT06750081|OTHER|Physical Therapy|Exercises to improve locomotor abilities of children with CP
218942998|NCT06516926|DRUG|SHR-4602|Intravenous infusion, cycle every 21 days;
218942999|NCT02923440|BIOLOGICAL|blood sample|
219634381|NCT03548779|BEHAVIORAL|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
218943000|NCT01818752|DRUG|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
218943001|NCT01818752|DRUG|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
218943002|NCT01818752|DRUG|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
218943003|NCT01818752|DRUG|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
218943004|NCT03419585|DEVICE|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
218943005|NCT03419585|DEVICE|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
218943006|NCT00043797|DRUG|Lidorestat (IDD 676)|
218943007|NCT03485300|DIAGNOSTIC_TEST|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
218943008|NCT03485300|BEHAVIORAL|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
218943009|NCT03485300|DRUG|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
218943010|NCT01033448|DRUG|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
218943011|NCT01033448|DRUG|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
218943012|NCT05360862|PROCEDURE|Prone positioning session|To perform respiratory measurements before, during and after a prone positioning session.
218943013|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
218943014|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
218943015|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
218943016|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
218943017|NCT04270370|DRUG|LY3478045|Administered orally.
218943018|NCT04270370|DRUG|Placebo|Administered orally.
218943019|NCT04270370|DRUG|Atorvastatin|Administered orally.
218943020|NCT00178113|DRUG|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
218943021|NCT00178113|DRUG|- Certagen (multivitamins with minerals)|
218943022|NCT02948517|OTHER|Time restricted feeding|Time restricted feeding
218943023|NCT03149744|DEVICE|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
219206818|NCT06750081|OTHER|Designed rehabilitation program|Program of exercises to enhance abilities
219206819|NCT06750250|OTHER|Patient education|"The group A will be Education and Self-Management. Patient Education: Providing information on the benefits of physical activity, proper exercise techniques, and self-care strategies.~Self-Management Programs: Empowering women to take an active role in managing their health and fitness. Frequency: 3 session/ month, Intensity: Mild to moderate, Type: Walking Time: 30 to 45mints /sessions"
219634382|NCT03548779|DIAGNOSTIC_TEST|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
218943024|NCT03060551|PROCEDURE|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
218943025|NCT01155128|BEHAVIORAL|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
218943026|NCT01029106|PROCEDURE|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
218943027|NCT06385782|OTHER|Antarctic environment|. According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.
218943028|NCT04735484|DEVICE|Gait analysis|Collecting movement data whilst participants walk
218943029|NCT01324141|DRUG|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
218943030|NCT01324141|DRUG|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
218943031|NCT01324141|DRUG|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
218943032|NCT01324141|PROCEDURE|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
218943033|NCT00250146|BEHAVIORAL|Gluten (behaviour)|
218943034|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C gummy|vitamin C
218943035|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C tablet|vitamin C
218943036|NCT02125591|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
218943037|NCT02125591|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
218943038|NCT00000955|DRUG|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
218943039|NCT04629066|BEHAVIORAL|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
219051498|NCT03254134|DRUG|Warfarin|patients treated with warfarin
219051499|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
219051500|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
219051501|NCT03669445|DRUG|Ixazomib|21-day cycles induction and 28-day cycles consolidation
219051502|NCT03669445|DRUG|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
219051503|NCT03669445|DRUG|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
219051504|NCT03669445|DRUG|Daratumumab|21-day cycles induction and 28-day cycles consolidation
219051505|NCT00378703|BIOLOGICAL|Bevacizumab|Given IV
218943040|NCT03382340|DRUG|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
218943041|NCT00003280|BIOLOGICAL|rituximab|
218943042|NCT03218800|COMBINATION_PRODUCT|Ertapenem|"Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
218943043|NCT03464539|DIETARY_SUPPLEMENT|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
218943044|NCT02756429|OTHER|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
218943045|NCT04228133|BEHAVIORAL|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
219051506|NCT00378703|OTHER|Laboratory Biomarker Analysis|Correlative studies
219051507|NCT00378703|OTHER|Pharmacological Study|Correlative studies
219051508|NCT00378703|DRUG|Sorafenib Tosylate|Given PO
219051509|NCT00378703|DRUG|Temsirolimus|Given IV
219051510|NCT01456442|DEVICE|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
219051511|NCT01456442|DEVICE|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
219051512|NCT00000537|BEHAVIORAL|meditation|
219051513|NCT00000537|BEHAVIORAL|relaxation|
219051514|NCT03856762|DIETARY_SUPPLEMENT|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
219051515|NCT03856762|DIETARY_SUPPLEMENT|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
219051516|NCT03856762|DIETARY_SUPPLEMENT|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
219051517|NCT00094874|PROCEDURE|Acupuncture|
218943046|NCT04228133|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
218943047|NCT04105491|DEVICE|IInvisalign® Aligners|Clear aligner orthodontic treatment
219051518|NCT02705820|DRUG|Pembrolizumab|Switch maintenance pembrolizumab treatment
219051519|NCT03870152|PROCEDURE|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
219051520|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
219051521|NCT01913366|BEHAVIORAL|CM-PST|
219051522|NCT01913366|BEHAVIORAL|SG-PST|
219051523|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
219051524|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
219051525|NCT06416865|DRUG|AJU-C52L, AJU-C52|"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."
219051526|NCT06416865|DRUG|C52R1L, C52R1M|"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."
219051527|NCT05092893|OTHER|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
219051528|NCT01800617|DRUG|Liothyronine, Sodium|
219051529|NCT00247728|DRUG|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
219051530|NCT00501202|DRUG|placebo|twice daily for 4 weeks
219051531|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
218943048|NCT03018483|DEVICE|Variable PSV|"Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician."
218943049|NCT03018483|DEVICE|Conventional PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
219051532|NCT02501603|DRUG|afatinib|Afatinib 40mg daily oral administration
219051533|NCT02501603|DRUG|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
219051534|NCT01856543|OTHER|Eucerin|
219051535|NCT01856543|OTHER|Mometasone Furoate 0.1%|
219051536|NCT01622946|DRUG|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
219051537|NCT01622946|DRUG|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
219051538|NCT01844635|DRUG|Thymoglobulin|
219051539|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
218943050|NCT03018483|DEVICE|Automated PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
219051540|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219051541|NCT03756610|DEVICE|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
219051542|NCT03756610|DEVICE|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
218943051|NCT03018483|DEVICE|NAVA|NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
218943052|NCT03842020|OTHER|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: \[H0-H3\]; \[H5-H9\] and just before the next set \[H24\], depending if the child is or is not admitted to hospital
219206820|NCT06750250|OTHER|Aerobics|Treadmill: A manual Treadmill intervention involves moderate-intensity aerobic exercise on a treadmill for 15 minute with the heart rate gradually reaching 75-85% of the maximum. Training frequency was not specified. It significantly reduced menstrual pain intensity 3 session per month. Stationary Bicycling: Start with gentle, low-intensity cycling and gradually increase as comfort allow the duration of exercise 10 mints per month. Running : The running is a low intensity effort of short to moderate duration 10 to 15 mints per mile
219206821|NCT06781606|PROCEDURE|Penile transplantation|The penile transplantation will take place at the Edouard Herriot hospital, part of the Hospices Civils de Lyon. It will be carried out on the same day or the day after the harvesting depending on the timing of the harvesting.
218943053|NCT00239135|DRUG|PEP005|
218943054|NCT03622476|DRUG|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
218943055|NCT02714322|BIOLOGICAL|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
219051543|NCT03756610|DEVICE|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
219051544|NCT03756610|DEVICE|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
219051545|NCT05827627|OTHER|simulation|Midwifery student directing the birth of a fetus with frank breech presentation.
219051546|NCT01868633|DRUG|Dexamethasone|
219051547|NCT01868633|DRUG|Placebo|
219051548|NCT05395962|DRUG|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
219051549|NCT05395962|DRUG|Bleomycin|treatment with bleomycin in association with electroporation
219051550|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
219051551|NCT00254007|DRUG|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
219206822|NCT06744725|DEVICE|Pleural biopsy using dual-function semirigid thoracoscopy|Patients will receive pleural biopsy using dual-function semirigid thoracoscopy.
219206823|NCT06744725|DEVICE|Pleural biopsy using semirigid thoracoscopy|Patients received pleural biopsy using semirigid thoracoscopy
219634383|NCT00589654|OTHER|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
219634384|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
219634385|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
219634386|NCT06959563|BIOLOGICAL|9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use|By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
219634387|NCT05467930|OTHER|Survey|Survey completion by the participant to collect information about health and social experience
218943056|NCT02714322|BIOLOGICAL|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
218943057|NCT04922385|OTHER|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
218943058|NCT00897819|GENETIC|DNA methylation analysis|
218943059|NCT00897819|GENETIC|loss of heterozygosity analysis|
218943060|NCT00897819|GENETIC|microsatellite instability analysis|
219206824|NCT02722512|BIOLOGICAL|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
219206825|NCT02722512|PROCEDURE|Tumor Resection|Clinically-indicated removal of the tumor
219206826|NCT02722512|RADIATION|Radiation|Focal Radiation Therapy
219206827|NCT05217927|DRUG|Rimegepant 75mg daily dosing|Daily
219634388|NCT05467930|OTHER|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
219634389|NCT05467930|OTHER|Sample Collection|Collection of nasal and blood samples
218943061|NCT00897819|OTHER|laboratory biomarker analysis|
218943062|NCT02276417|OTHER|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
218943063|NCT02276417|OTHER|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
218943064|NCT02276417|OTHER|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
218943065|NCT02276417|OTHER|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
218943066|NCT02276417|OTHER|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
218943067|NCT02276417|OTHER|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
218943068|NCT02276417|OTHER|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
218943069|NCT03009396|DRUG|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
218943070|NCT00530504|DEVICE|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
218943071|NCT00811486|DRUG|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
218943072|NCT00610480|DRUG|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
218943073|NCT00610480|DRUG|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
218943074|NCT01358955|OTHER|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
218943075|NCT01358955|OTHER|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
218943076|NCT06072456|PROCEDURE|laparoscopic lateral suspension|Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
218943077|NCT06072456|PROCEDURE|laparoscopic pectopexy|Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
218943078|NCT06072456|PROCEDURE|Sacrospinous ligament fixation|Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
218943079|NCT06077227|DEVICE|virtual reality therapy|6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
218943080|NCT06077227|OTHER|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
218943081|NCT04784065|DEVICE|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
218943082|NCT03759353|DIAGNOSTIC_TEST|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
218943083|NCT03759353|DRUG|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
218943084|NCT03759353|DRUG|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
218943085|NCT03759353|DIAGNOSTIC_TEST|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
218943086|NCT02358941|BEHAVIORAL|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
218943087|NCT02358941|BEHAVIORAL|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
218943088|NCT05365139|OTHER|Structured clinical diagnostic interview for PGD (PGD-I)|"Participants were administered the Structured clinical diagnostic interview for PGD (PGD-I) and screened with clinical interviews for PTSD, anxiety and depression. Whether the Aarhus PGD-scale should be answered before or after the interview was randomized.~The PGD-I and self-report scale were readministered to 50 participants 7-14 days after the initial administration."
218943089|NCT03727724|DRUG|Afatinib|Tablet
218943090|NCT03727724|DRUG|Cetuximab|Injection
218943091|NCT03124004|PROCEDURE|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
218943092|NCT02035254|OTHER|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
219206828|NCT05217927|DRUG|Rimegepant 75mg every other day dosing|Every other day
219051552|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
219051553|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
218943093|NCT06981585|OTHER|Physical Evaluations of Patients with Chronic Kidney Failure|In this study, data from children and adolescents with chronic kidney disease will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.
218943094|NCT06981585|OTHER|Physical Evaluations of Healthy Children|In this study, data from healthy children and adolescents will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. Data obtained through all these assessments will be collected from participants face-to-face at once and for a maximum of approximately 1 hour.
218943095|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
218943096|NCT06853912|DRUG|Psilocybin 25 mg|Botanical drug product PEX010(25) contains the drug substance, PYEX, which is primarily composed of psilocybin (delivered in a capsule)
218943097|NCT06853912|DRUG|Maltodextrin (Placebo)|25 mg of Maltodextrin (delivered in a capsule)
218943098|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
218943099|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
218943100|NCT06354660|DRUG|Retatrutide|Administered SC.
218943101|NCT06354660|DRUG|Placebo|Administered SC.
218943102|NCT03159793|BEHAVIORAL|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
218943103|NCT03159793|BEHAVIORAL|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
219051554|NCT02457325|DRUG|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
219634390|NCT06466382|OTHER|Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling|The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
219051555|NCT02457325|DRUG|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
219051556|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
219051557|NCT02771262|OTHER|Pulmonary Rehabilitation|
219051558|NCT01541930|DRUG|GK567|Once or twice daily, for 14 days, up to 30 g per day
219051559|NCT02431208|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
219206829|NCT05217927|DRUG|Placebo comparator dosing|Placebo comparator
219634391|NCT06466382|DRUG|Carboplatin / Paclitaxel Chemotherapy|2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly
219634392|NCT04432831|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
219634393|NCT04432831|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
219634394|NCT03731585|BEHAVIORAL|Behavioral Intervention|Participate in psychological sessions
219634395|NCT03731585|OTHER|Educational Intervention|Participate in educational sessions
219634396|NCT03731585|OTHER|Questionnaire Administration|Ancillary studies
218943104|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
219634397|NCT03731585|PROCEDURE|Support Group Therapy|Participate in group sessions
218943105|NCT05704595|OTHER|Initial hospitalization-based management strategy|Direct admission to the hospital
218943106|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
218943107|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
218943108|NCT06607783|DIAGNOSTIC_TEST|MRI|Standard MRI using phantom.
218943109|NCT06998355|OTHER|Registry|observational data collection
218943110|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
218943111|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
218943112|NCT05650073|OTHER|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
218943113|NCT05822908|DRUG|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
218943114|NCT02230228|DRUG|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
218943115|NCT05758935|OTHER|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
218943116|NCT06672861|OTHER|Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)|To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
218943117|NCT03520504|RADIATION|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
218943118|NCT01808092|DRUG|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
218943119|NCT01808092|DRUG|meropenem (active comparator)|1000mg of Meropenem
218943120|NCT07134361|PROCEDURE|Open Carpal Tunnel Release|All patients included in the cohort will undergo open carpal tunnel release as part of routine clinical care. The study does not assign the surgical procedure as an investigational intervention; however, it will observe clinical and ultrasonographic outcomes before and after surgery to assess prognostic factors.
218943121|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
218943122|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
219634398|NCT06052033|PROCEDURE|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
219634399|NCT06962566|BEHAVIORAL|Morning exercise|Participants performed a 45-minute treadmill brisk walking in the morning between 08:00 to 11:00 AM.
219634400|NCT06962566|BEHAVIORAL|Evening exercise|Participants performed a 45-minute treadmill brisk walking in the evening between 18:00 to 21:00 PM.
218943123|NCT05437393|DEVICE|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
218943124|NCT05009979|DRUG|F18-FDG|Within approximately 2 weeks of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography/ computed tomography (PET/CT) scan, participants will be scanned with a fludeoxyglucose F 18 (18F-FDG) PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.
219634401|NCT05769218|BEHAVIORAL|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
219634402|NCT05769218|OTHER|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
219634403|NCT04699123|DRUG|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
219634404|NCT04699123|DRUG|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
219634405|NCT04699123|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
218943125|NCT05009979|DEVICE|MRI|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
218943126|NCT05009979|DEVICE|CT|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
219051560|NCT02431208|DRUG|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
219634406|NCT06307925|DRUG|HC010|HC010 Q2W/28d intravenous infusion
219634407|NCT06117293|DEVICE|Mosaic|1550 Fractional Laser System
219634408|NCT00004787|DRUG|filgrastim|
218943127|NCT05009979|DRUG|F18-DCFPyL|Each subject will receive a single intravenous (IV) dose of piflufolastat F-18 (18F-DCFPyL) by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL positron emission tomography and computed tomography (PET/CT) imaging will consist of the 18F-DCFPyL injection, followed by approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/-10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.
218943128|NCT05009979|PROCEDURE|Tumor biopsy|Principal investigator discretion pre-treatment or during surgical resection.
218943129|NCT07076459|DRUG|HR091506 tablet|In each period under fed conditions, subjects received oral administration of either HR091506 tablet（T1）, HR091506 tablet（T2）, or HR091506 tablet（R）.
218943130|NCT07086261|OTHER|Spaced Retrieval Training|This study adopted a quasi-experimental research design with two groups of pre- and post-tests. The sample was recruited by convenient sampling. The experimental group used the time extraction training program to intervene and perform relevant water drinking training, 40 minutes each time, 3 times a week, for a total of 8 weeks of intervention measures, while the control group used routine care for general water drinking. Both groups collected pre-test data before the time extraction training intervention program activities in the first week, and conducted post-test data tracking and analysis in the 4th and 8th weeks after the intervention activities.
218943131|NCT06923800|BEHAVIORAL|Combined Exercise Program + A specific nutritional plan for individuals with IBS|60-minute sessions three times per week for 4 months, incorporating moderate aerobic, resistance, and flexibility exercises
218943132|NCT06923800|BEHAVIORAL|Aerobic Exercise + A specific nutritional plan for individuals with IBS|60-minute sessions, three times a week for 4 months, with low-impact, non-weight-bearing aerobic activities at 60-75% of max heart rate.
218943133|NCT06936787|DRUG|IGT001|Study drugs
218943134|NCT06940375|OTHER|Abdominal ultrasound , Fibroscan and body composition analysis examination|Abdominal ultrasound and Fibroscan examinations were conducted to obtain LSM, CAP, and calculate the FAST score. Bioelectrical impedance analysis was performed to obtain the content of subcutaneous and visceral fat.
218943135|NCT07145073|DEVICE|DC-Stimulator MC|Experimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
218943136|NCT07145073|DEVICE|DC-Stimulator MC|Sham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
218943137|NCT07146074|RADIATION|Preventive radiotherapy|Either conventional radiotherapy (single dose of 8 Gy) or Stereotactic Ablative Body Radiation (either 1x20 Gy, 2x12 Gy, 3x10 Gy or 5x8 Gy) will be delivered depending on the participant's prognostic outcome.
218943138|NCT07146074|DRUG|Systemic therapy (Standard of Care)/Observation|It concerns systemic therapy if applicable according to the standard of care or only observation.
218943139|NCT07146685|DRUG|Bupivacaine|We are comparing two concentrations of the same drug: 10 ml of 0.5% and 20 ml of 0.25%; We will use the same milligram dose (50 mg).
218943140|NCT07144930|OTHER|MCIT program|"The MCIT program combines motor and cognitive training, progressing independently with increasing difficulty.~* Motor training, based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks.~* Cognitive incorporative component, adapted from previous stroke studies, supports cognitive recovery and overall well-being. Training starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. Progression requires an 80% success rate; if not achieved, tasks are simplified by reducing memory span or providing additional guidance."
218943141|NCT07144930|OTHER|Motor training program|Based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. Progression is guided by core action goals (Table 2) and depends on stable vital signs, balance, and minimal assistance. If participants are unable to progress, simpler tasks are provided.
218943142|NCT07144787|OTHER|implant retained complete Overdenture|four implant retained complete Overdenture versus Fixed-detachable prosthesis
218943143|NCT07144787|OTHER|Fixed-detachable prosthesis|four implant retained complete Overdenture versus Fixed-detachable prosthesis.
219051561|NCT02431208|DRUG|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
219051562|NCT02431208|DRUG|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
219549517|NCT07102875|BEHAVIORAL|Sailing Intervention Plus Home-Based Telerehabilitation|A two-phase rehabilitation program combining 5 days of intensive sailing therapy with a 3-month home-based telerehabilitation plan. The sailing component includes group-based activities in adapted sailing environments, conducted in Marina di Ravenna or Palermo, with daily debriefing and psychosocial support. The telerehabilitation component includes twice-weekly supervised sessions delivered via a digital platform, focusing on progressive motor, proprioceptive, and postural exercises. The intervention aims to improve motor function, quality of life, and psychosocial well-being in individuals with rare skeletal disorders.
219051563|NCT02431208|DRUG|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
219051564|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
219051565|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
218943144|NCT07145216|OTHER|Interfrential stimulation|The participant will be positioned in semi-Fowler's position. Interferential therapy was given using the quadripolar method. Two electrodes were placed on the lower abdomen just above the outer half of the inguinal ligament, and another two on the inner aspect of the thigh near the origin of the adductor muscle. At the first treatment session, every participant will be examined for pelvic floor contraction by the finger palpation method using sterilized gloves to ensure the correct position of the electrodes. It will be set with intensity up to the tolerable limit of subjects, carrier frequency of 2000Hz, vector 900, rhythmic sweep frequency of 10-100Hz, and duration 20 minutes. Interferential therapy will be applied for the treatment procedure of all women in both groups for 20 minutes, 3days per week for 8 weeks.
218943145|NCT07145216|OTHER|Knack pelvic floor training|"The knack technique (Fitz et al., 2021):~* The patient will be instructed to lie in supine lying position with flexed knees.~* Ask the patient to contract the pelvic floor muscles for 2-4 seconds and relax for 4 seconds for 15 repetitions with 3 sets before and during coughing or sneezing .~* Contract the PFM before and during all daily activities involving effort, before and during coughing, sneezing, laughing, walking up and down stairs, jumping, running, bending, lifting a weight from the floor, holding a child, pushing furniture to prevent urine leakage.~* Contract PFM and hold for 2-4 seconds, relax 4 seconds, with 3 sets of 15 repetitions."
218943146|NCT07145879|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL) and 0.012 mg epinephrine base. Excipients: Sodium metabisulfite, sodium chloride, water for injection.
218943147|NCT07145879|DRUG|Articaine 4% with epinephrine 1:100,000|Patients were received Infiltrative anesthesia with Articaine (Ultracain DS Forte, Sanofi Aventis İlaçları, Istanbul, Türkiye): Active ingredient: 40 mg articaine HCL and 0.012 mg epinephrine per 1 ml. Excipients: Sodium chloride, sodium metabisulfite, hydrochloric acid, water for injection
218943148|NCT07145879|PROCEDURE|Free gingival graft (FGG)|FGG surgery was performed around natural teeth and implants where keratinized gingival tissue was inadequate.
218943149|NCT07146646|DRUG|Trifluridine/tipiracil|FTD/TPI will be taken by mouth on Days 1-5 of the 14-day treatment cycle. The starting does is 25mg/m2 twice per day.
218943150|NCT07146646|DRUG|Oxaliplatin|Oxaliplatin is given on Day 1 of each 14-day cycle. It is given intravenously (by IV) over 2 hours.
218943151|NCT07145645|DRUG|Voltaren Topical Gel|Topical diclofenac emulgel (Voltaren) 11.6 mg/g. Dosing is based on weight bands: 25 kg: 2 grams/dose, ≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose. ATC code: M02A A15.
218943152|NCT07145645|DRUG|Ibuprofen Oral Suspension 100 mg/5mL|Children's Ibuprofen Oral suspension (Motrin) 100mg/5 mL . Dosing is 10 mg/kg to a maximum of 600mg.
218943153|NCT07145645|DRUG|ORA-Blend Oral Suspension|Oral Ibuprofen suspension (labelled as ibuprofen) given at 10 mg/kg to a maximum of 600mg each dose.
219206830|NCT06768645|BEHAVIORAL|Diabetic foot care education delivered using the Pecha Kucha method|"The study commenced after obtaining ethical approval and written consent from the relevant institution. The Pecha Kucha presentation was prepared by the researcher, adhering to established literature and the specific requirements of the technique. The education covered six key topics: 1) Diabetes and Foot Problems, 2) Daily Foot Care, 3) Appropriate Socks, 4) Appropriate Footwear, 5) Nail Care, and 6) Daily Life Precautions. Expert opinions were sought from four academics (S.Ö; K.L; Z.Z; G.F) with expertise in the field to establish content validity for the final version of the Pecha Kucha diabetic foot care presentation. Following expert approval, a pilot study was conducted with 10 diabetic patients who met the sample group criteria. Feedback from these patients regarding system functionality, clarity, and flow was incorporated to finalize the presentation. Afterward, the finalized Pecha Kucha Information training was delivered to the experimental group. The presentations were cond"
219634409|NCT06684054|DRUG|docetaxel, anthracycline, cyclophosphamide|"1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study."
219634410|NCT01756794|PROCEDURE|Liver transplantation|
219634411|NCT05567744|OTHER|Registry|Registry
219634412|NCT03089268|PROCEDURE|Colonoscopy|A colonoscopy will be performed to all individuals.
219634413|NCT03089268|PROCEDURE|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
219634414|NCT03089268|GENETIC|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
218943154|NCT07145645|DRUG|VersaPro Cream Base for Compounding|"Topical Versapro Cream emulgel (labeled as diclofenac diethylamine). Dose is based on the following weight bands: 25 kg: 2 grams/dose;~≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose."
218943155|NCT07145866|DRUG|varenicline|"Dosing of this FDA-approved medication will follow the below schedule, which follows the clinical standard:~0.5 mg once daily or 3 days, 0.5 mg twice daily for 4 days 1.0 mg twice daily for 11 weeks"
218943156|NCT07145866|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days.
218943157|NCT07145866|DEVICE|Transcranial Magnetic Stimulation Sham|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days. The sham setting will deliver no magnetic field to the brain but will deliver electrical current to the scalp to mimic the feel of active treatment.
219634415|NCT04191369|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
218943158|NCT07145866|BEHAVIORAL|Nicotine Cessation Counseling|Each participant will receive 6 sessions of brief nicotine cessation counseling by a trained study staff member. This will be provided at the weekly follow-up visits, spread out throughout the study. This counseling, while not the main aim of the study, should help participants manage their expectations of quitting and provide support and quitting strategies throughout the process.
218943159|NCT07145021|BEHAVIORAL|Breathing Exercise Intervention|Participants will receive guided breathing exercise training conducted by a certified breathing coach. The intervention consists of weekly 40-minute sessions over a 6-week period, aimed at reducing test anxiety and improving academic performance. Participants will also maintain a breathing exercise log throughout the study.
218943160|NCT07145151|DRUG|UBT251|UBT251 administered subcutaneously (SC) once a week.
218943161|NCT07145151|DRUG|Placebo|Placebo,SC,once a week for 48 weeks
218943162|NCT07146295|DRUG|Technetium (99mTc)|A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.
218943163|NCT07146295|DRUG|Indocyanine Green|Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.
218943164|NCT07146295|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.
218943165|NCT07145463|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.
218943166|NCT07146906|BIOLOGICAL|zigakibart|zigakibart 600 mg sc injections every second week for 104 weeks (2 years)
218943167|NCT07145125|DRUG|Brentuximab-Vedotin associated with Bendamustine|Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine
218943168|NCT07145632|DEVICE|App-based education and training of inhalation technique|The use of MDI or DPI requires different inhalation techniques and flows, which makes correct inhalation technique more challenging if patient use different types of inhaler devices. Healthcare providers may assess inhalation technique by observation and in addition PIF may be measured by manual meter. However, this does not capture all relevant information about patient's ability to correctly inhale medication and handle prescribed inhaler(s) and do not give instant and automated feedback on the inhalation technique to user. For instance, DPI users should reached a sufficiently high PIF within the first 0.4 seconds \[18\] and MDI users inhalation time should exceed 4 seconds in adults (2-3 seconds in children) in order to optimize lung deposition of the aerosol during a low PIF \[19\]. The app-based inhalation medical device gives automated feedback on inspiratory flows that are specific DPI and MDI devices.
218943169|NCT07146516|PROCEDURE|Prophylactic (non-invasive) Laser Retinopexy|Prophylactic laser retinopexy to prevent RD in participants with SS using the indirect ophthalmoscopy (IDO) to place approximately 1800 to 2400 moderate intensity burns to produce encircling grid pattern, placed one burn width apart from 2 MM anterior to the ora serrata, extending to and between the vortex vein ampullae.
218943170|NCT07146022|DRUG|VDPHL01 QD|VDPHL01 Extended Release (ER) Tablet
218943171|NCT07146022|DRUG|Placebo|Placebo tablet
218943172|NCT07146022|DRUG|VDPHL01 BID|VDPHL01 Extended Release (ER) Tablet
218943173|NCT07146022|DRUG|Placebo|Placebo tablet
218943174|NCT07146737|DIAGNOSTIC_TEST|Corneal tomography generation model after ICL surgery|The ICL procedures collected would be assessed by the corneal tomography generation model. The performance of the model would be assessed, including accuracy,AUC, sensitivity and specificity.
218943175|NCT07145593|DEVICE|Application tACS- 80 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (80 Hz).The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
218943176|NCT07145593|DEVICE|Application tACS -40 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at gamma frequencies (40 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
218943177|NCT07145593|DEVICE|Application TACS - (6-80 Hz)|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at theta- gamma coupling frequencies ( 6-80 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
218943178|NCT07145593|DEVICE|Application TACS- Individual Gamma Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at individual gamma frequencies . The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
218943179|NCT07145593|DEVICE|Application TACS- Sham|In this study, a single 20-min tACS session will be applied over the bilateral dorsolateral prefrontal cortex (DLPFC) in a sham application. The anodal surface electrode will be placed over the left DLPFC (F3 of the 10-20 system) and the cathodal electrode will be placed over the right DLPFC (F4).
219206831|NCT06768645|BEHAVIORAL|traditional diabetic foot care education|traditional diabetic foot care education
219051566|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
218943180|NCT07145450|BIOLOGICAL|ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|"The cells will be gene edited and administered by a single IV infusion on Day 1.~Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy."
219051567|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
218943181|NCT07145450|BIOLOGICAL|ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.
218943182|NCT07145450|BIOLOGICAL|ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy
218943183|NCT07145658|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert colour matched power
218943184|NCT07145658|DIETARY_SUPPLEMENT|multivitamin|20-ingredient multivitamin
218943185|NCT07146256|OTHER|Non-interventional observational study|No intervention will be studied
218943186|NCT07145671|OTHER|Transition program|"Transition Consultation:~Pediatric HCP introduces the transition process to AYA and family. A contact person is assigned (ideally the AYA's trusted HCP), along with someone from the AYA's personal network. Key points are recorded in the Individualized Transition Plan (ITP).~Independent Visit:~AYA has a solo consultation (parents briefly step out). They complete the Ready Steady Go checklist. The ITP is updated, and concerns are discussed.~Joint Consultation:~Pediatric and adult HCPs meet with the AYA. A new adult contact is assigned, and the AYA picks a pediatric contact for feedback. Checklist is completed again.~Feedback Moment:~After transfer, the pediatric contact checks in. The checklist guides discussion; feedback is shared across teams, and follow-up arranged if needed."
218943187|NCT07146451|OTHER|Self-administered parental questionnaire|A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment
218943188|NCT07146451|OTHER|A short psychological assessment performed online|"NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales.~Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD)."
219051568|NCT02915744|DRUG|NKTR-102|
219051569|NCT02915744|DRUG|Eribulin|
219051570|NCT02915744|DRUG|Ixabepilone|
219051571|NCT02915744|DRUG|Vinorelbine|
219051572|NCT02915744|DRUG|Gemcitabine|
219051573|NCT02915744|DRUG|Paclitaxel|
219051574|NCT02915744|DRUG|Docetaxel|
219051575|NCT02915744|DRUG|Nab-paclitaxel|
219051576|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
219051577|NCT00813358|DEVICE|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
219051578|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
219051579|NCT00004031|DRUG|CHOP regimen|
219051580|NCT00004031|DRUG|carmustine|
219051581|NCT00004031|DRUG|cyclophosphamide|
219051582|NCT00004031|DRUG|doxorubicin hydrochloride|
219051583|NCT00004031|DRUG|etoposide|
219051584|NCT00004031|DRUG|prednisone|
219051585|NCT00004031|DRUG|vincristine sulfate|
219051586|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
219634416|NCT04191369|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
219051587|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
219051588|NCT00004031|RADIATION|radiation therapy|
219051589|NCT03261583|OTHER|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
219051590|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
219051591|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
219051592|NCT03497559|OTHER|Music|Classical music
219051593|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
219051594|NCT04596150|DRUG|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
219051595|NCT04596150|DRUG|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
219051596|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
218943189|NCT07145606|BEHAVIORAL|Standard Rehabilitation|Standardized postoperative ACL rehabilitation only. Begins \~2 weeks after surgery; supervised \~3 sessions/week for 6 weeks. Includes progressive range of motion, quadriceps activation/strengthening, functional drills, and return-to-activity progressions delivered per protocol.
218943190|NCT07145606|BEHAVIORAL|Blood Flow Restriction (BFR) Training|Low-load resistance exercises performed with individualized limb occlusion pressure (LOP) determined each session; target %LOP per protocol. Progresses from isometric to dynamic open/closed-chain tasks. Delivered under supervision \~3 sessions/week for 6 weeks; monitoring of tolerance and adverse events per safety LOP.
218943191|NCT07145606|BEHAVIORAL|sEMG Biofeedback|Real-time surface electromyography biofeedback to optimize quadriceps recruitment during targeted tasks (e.g., isometric contractions, straight-leg raise, sit-to-stand, mini-squat, gait drills). Visual and/or auditory feedback with progressive targets. Supervised \~3 sessions/week for 6 weeks; outcome assessors remain blinded.
218943192|NCT07146139|DEVICE|MyPrEP Plus Package|Participants receiving the MyPrEP Plus Package will utilize the interactive MyPrEP website to learn about PrEP and the various kinds of PrEP available as well as information about Doxy-PEP. While on PrEP, participants will be able sign up for PrEPmate, a tool designed to support PrEP adherence.
218943193|NCT07146139|BEHAVIORAL|Standard of Care (SOC)|Participants in the control condition will receive PrEP support according to local standard of care while using the website pleaseprepme.org.
218943194|NCT07145684|BEHAVIORAL|A culturally tailored medical nutrition therapy|This MNT intervention combines evidence-based menu plans based on the 4A framework of food security with individual nutrition counseling and group diabetes education.
219051597|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
218943195|NCT06947239|PROCEDURE|Mirror therapy along with conventional therapy|"The experimental group will receive 20 minutes of conventional therapy followed by 20 minutes of mirror therapy training including 3 minutes of rest period between the interventions.~WEEK OF INTERVENTION:~TASK PERFORM IN FRONT OF MIRROR:~WEEK :1-2~ACTIVE SHOULDER ROM:~flexion, abduction, external-internal rotation movements of the intact extremity~Increase the number of repetition according to the patient progression~WEEK:3-4~ACTIVITIES TARGETING SHOULDER ROM:~Cleaning the mirror with a towel(internal rotation+ abduction)~Lifting a glass to drink ( flexion + abduction)~Holding a brush to comb hair (external rotation~WEEK:5-6~Overhead reaching~(pasting stickers on the~mirror)(internal rotation~/ abduction)~Lifting a bottle overhead.~( flexion/abduction)~Throwing a ball (external~rotation)~PROGRESSION OF TASK SPECIFIC MIRROR THERAPY:~WEEK: 1-2 Increase the number of repetition according to the patient progression WEEK:3-4 Add water in glass Transfer glass"
218943196|NCT06947239|PROCEDURE|Control Group|"Details: Weeks wise:~The control group will receive 20 mints of conventional therapy .~1. Heat pack \& TENS to alleviate pain for 15 minutes~2. Shoulder isometric exercises 10 reps~3. Active and passive Range of Motion exercises 10 reps each~4. Codman exercises 10 reps each~5. Wand exercises 10 reps each"
218943197|NCT06946979|OTHER|Spinal Manipulation|"Spinal Manipulation Therapy The treatment consists of two standardized steps: tendon adjustment techniques and bone-setting techniques.~The total duration for both steps is approximately 15 minutes, conducted three times per week for two consecutive weeks."
219051598|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
219051599|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219051600|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
219051601|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
219051602|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
218943198|NCT06946979|OTHER|Medication|Patients in both groups will receive celecoxib (one tablet, twice daily) for two weeks, with detailed records maintained.
218943199|NCT06946303|OTHER|Survey|Pre and post survey on confidence and knowledge of falls
218943200|NCT06946303|OTHER|Interview|Interview on the learning from the falls ambassador programme
218943201|NCT06946303|OTHER|Observation|Observation of falls ambassador workshops
218943202|NCT06946719|OTHER|pulp lavage Octenidine|Use of Octenidine as a pulp irrigation solution in pulp capping for mature permanent teeth
218943203|NCT06946719|OTHER|pulp lavage NaOCl|Use of NaOCl as a pulp irrigation solution in pulp capping for mature permanent teeth
219051603|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
219051604|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
219051605|NCT05713123|OTHER|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
219051606|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
219051607|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
218943204|NCT06946563|DEVICE|Fetoscopic Neural Tube Defect Repair Devices|Fetoscopic NTD repair will be performed on enrolled participants. An incision will be made to gain exposure and access to the uterus. The amniotic cavity is entered using a needle to administer fetal anesthesia. Then, the initial trocar is inserted into the amniotic cavity. The major steps of the procedure are neural placode dissection, myofascial flaps creation, and closure of the neural tube defect.
218943205|NCT06947616|DRUG|Mild therapeutic hypothermia|Patients received mild therapeutic hypothermia (MTH) to 33°C for 24-36 h
219051608|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
219051609|NCT05356884|BEHAVIORAL|Diabetes Intervention|A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
219051610|NCT05356884|BEHAVIORAL|Leadership & Life Skills|A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
219051611|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
219051612|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
219051613|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
219051614|NCT03421288|DRUG|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
219051615|NCT03421288|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
219051616|NCT03421288|DRUG|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
219051617|NCT03421288|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
219051618|NCT03421288|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
219051619|NCT06998056|DRUG|ARQ-151 cream 0.05%|ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).
219051620|NCT06875752|DRUG|no luteal support|In one arm of the study the patients receive no luteal support as part of their modified natural cycle frozen embryo transfer.
219051621|NCT06875752|DRUG|Vaginal Progesterone|In the 2nd arm the patient receives 2x200 mg vaginal progesterone as luteal support.
219051622|NCT06875752|DRUG|Progesterone plus HCG|In the 3rd arm the patients receive 2x200 mg vaginal progesteroen plus 125 mcg recombinant HCG s.c. on the day of embryo transfer and 62.5 mcg recombinant HCG s.c. 4 days later.
219634417|NCT06621030|DEVICE|MIB Breath Analyzer|Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC IMS and the MIBs (investigational devices). Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices) Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).
219634418|NCT03714334|DRUG|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
219634419|NCT04973176|DEVICE|Standard Bougie|Standard Bougie for endotracheal intubation
219634420|NCT04973176|DEVICE|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
219634421|NCT00373620|DRUG|paclitaxel|
219634422|NCT00652626|DRUG|azacitidine|
218943206|NCT06947200|OTHER|Fibromyalgia|no intervention
218943207|NCT06947733|BEHAVIORAL|pre-class videos|This project aims to evaluate the impact of pre-class videos on enhancing ultrasound teaching effectiveness, particularly comparing videos shot with a first-person perspective (POV) to those shot with a face-to-face perspective.
218943208|NCT06947733|BEHAVIORAL|no pre-class videos|the control group (who will not watch any videos)
219634423|NCT06466525|DRUG|LBT-3627|Synthetic peptide
219634424|NCT06466525|DRUG|Placebo|Vehicle
218943209|NCT06947330|PROCEDURE|Unilateral Erector Spinae group|On injecting 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine into the interfacial plane below erector spinae; a manifest linear pattern will be visualized uplifting the muscle.
219051623|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
219051624|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
219051625|NCT07025668|OTHER|Eccentric Exercise|In the eccentric exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, eccentric strengthening exercises for the biceps brachii muscle will be given. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
219051626|NCT07025668|OTHER|Combined Exercise|In the combined exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, progressive isometric, isotonic and plyometric strengthening training will be given to the biceps brachii muscle. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
219051627|NCT07025668|OTHER|Control Group Exercise|In the control group, strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle will be given. Strengthening exercises for the biceps brachii muscle will not be given in this group. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
218943210|NCT06947330|PROCEDURE|Unilateral Serratus Anterior group|Once the needle will be in perfect position, confirmed by hydro-dissection on injecting 2-3 ml of normal saline, then 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine.
218943211|NCT06946017|DIETARY_SUPPLEMENT|Fermented dairy protein with prebiotic fiber supplement|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The intervention product contains whey protein concentrate and a prebiotic fiber. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
218943212|NCT06946017|DIETARY_SUPPLEMENT|Control placebo|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The placebo product is calorically matched to the intervention product and the main ingredients are protein and carbohydrate. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
218943213|NCT06946849|RADIATION|radiotherapy|Radiotherapy
218943214|NCT06946849|DRUG|FOLFIRI or FOLFOX or Regorafenib|FOLFIRI or FOLFOX or Regorafenib
218943215|NCT06946342|BEHAVIORAL|"Aquatic Exercise Group"|"Structured WATERinMOTION aquatic exercise program (3x/week for 8 weeks) in a heated pool (30-32°C), including warm-up, aerobic conditioning, resistance training with water equipment (e.g., dumbbells, noodles), and cool-down. Sessions are group-based and led by certified instructors."
218943216|NCT06946342|BEHAVIORAL|"Land-Based Rehabilitation Group"|"60-minute land-based sessions (3x/week for 8 weeks), including core stabilization, low-impact aerobics, and stretching."
219051628|NCT07024394|DRUG|Luvometinib Tablets|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, until disease progression or study completion, whichever occurs first
219051629|NCT07023692|BEHAVIORAL|Distraction with VR (Virtual Reality) headsets|VR headsets will be fitted and applied in consultation with the study participants. Distraction material will be selected from a range of options based on the participant's preferences, such as watching/listening to a story, an experience of being in nature, or mindfulness. When applying the VR headsets, care will be taken to ensure no light leaks into the eyes and that the headband and headphones are not perceived as too tight. This is especially important in terms of the risk for motion sickness (cyber sickness). The VR headsets will then be used throughout the examination procedure and removed once the bandage has been applied.
219051630|NCT03655236|DRUG|K0706|low dose, orally, once-daily
219051631|NCT03655236|DRUG|K0706|high dose, orally, once-daily
219051632|NCT03655236|OTHER|placebo|placebo, orally, once-daily
219051633|NCT07038902|DEVICE|Group A: Modified Miniscrew-Assisted Rapid Palatal Expander (MARPE)|A skeletal anchorage-supported with miniscrews inserted into the palate using a self-drilling technique.
219051634|NCT07038902|DEVICE|Group B: Modified Rapid Palatal Expander (RPE)|A tooth-borne anchorage focusing on molar distalization .
219051635|NCT06293482|DEVICE|Cochlear™ Nucleus® System|The Cochlear™ Nucleus ® System is a commercially available system intended for restoration of hearing sensation through electrical stimulation of the auditory nerve in adult patients with bilateral symmetrical sensorineural hearing loss.
219051636|NCT05535907|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in below the knee lesions prior to full balloon dilatation at low pressures
219051637|NCT06887608|OTHER|Husband assisted rebozo application|At 4-5 cm, 6-7 cm and 8-9 cm, the pregnant woman will be given a rebozo by her husband.
219051638|NCT06887608|OTHER|Midwife assisted rebozo application|The midwife will apply rebozo to the pregnant woman at 4-5 cm, 6-7 cm and 8-9 cm.
219051639|NCT06763705|DRUG|Midazolam|It will not be used alone but in combination with Fentanyl in the Midazolam + Fentanyl group.
219051640|NCT06763705|DRUG|Propofol|It will used alone in Propofol group and in combination with Fentanyl in the Propofol + Fentanyl group.
219051641|NCT06763705|DRUG|Fentanyl|Fentanyl will not be used in isolation but will be used in combination with either Midazolam or Propofol in Midazolam + Fentanyl group and Propofol + Fentanyl group, respectively.
219549518|NCT07102875|BEHAVIORAL|Home-Based Telerehabilitation|Participants perform a 3-month home-based rehabilitation program consisting of two remote sessions per week via a supervised digital platform. Each session includes warm-up, strength and coordination exercises, and cool-down. Exercises are progressive and standardized, but adapted to individual needs to ensure safety and adherence. The intervention targets motor function, balance, proprioception, and psychosocial outcomes, without any sailing component. This arm serves as the active comparator.
219549519|NCT07107516|BIOLOGICAL|PanChol|Panchol is a novel live attenuated oral cholera vaccine. It is the first vaccine created with the variant El Tor background that is predominant in the world today. The vaccine has ten different genetic modifications to minimize reactogenicity but maintain the ability to colonize the intestine.
219549520|NCT01900340|DIETARY_SUPPLEMENT|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
219549521|NCT01900340|DRUG|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
219549522|NCT01900340|DIETARY_SUPPLEMENT|Saline|IV saline infusion and intraduodenal administration of nutrients
219549523|NCT01900340|DRUG|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
219549524|NCT06910228|DEVICE|Near infrared spectroscopy (NIRS)|A non-invasive technique that uses light to assess brain function and tissue oxygenation.
219549525|NCT05196334|OTHER|No intervention|No intervention
219549526|NCT02257554|BEHAVIORAL|education|Discussion of surgical expectations with patients
219549527|NCT07140068|DEVICE|Handled dental flossing system (GumChucks®)|Handled dental flossing system (GumChucks®) designed for easier C-shape flossing. Participants were instructed to clean all interdental spaces on the assigned side twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
219549528|NCT07140068|DEVICE|Interdental Brush|Appropriately sized interdental brushes for cleaning interdental spaces on the assigned side. Participants were instructed to clean twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
218943217|NCT06947057|PROCEDURE|Guided implant placement|The four types of fully guided surgical guides (bilateral tooth-supported guides, unilateral tooth-supported guides, mucosa-supported full arch guides and stackable guides)
218943218|NCT06946381|PROCEDURE|Evar|Branch Evar with the e-liac device
218943219|NCT06947096|DIAGNOSTIC_TEST|Radiomics-Based AI Imaging Analysis|This intervention involves the development and application of a radiomics-based artificial intelligence (AI) model to analyze preoperative abdominal CT images of patients with gastric cancer. The AI algorithm extracts high-dimensional imaging features from the para-aortic region to predict the presence or absence of para-aortic lymph node metastasis (PALNM). This non-invasive method aims to assist clinicians in preoperative risk stratification and treatment planning. The model will be trained and validated using manually segmented lymph node regions and correlated with postoperative pathological findings to ensure accuracy and clinical relevance.
218943220|NCT06946732|DEVICE|Acostream aspiration|The pulmonary thrombus removal by Acostream.
218943221|NCT06946420|RADIATION|SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy|This group of patients will first undergo radiotherapy on the primary pancreatic lesion and stereotactic treatment on the metastatic sites before being started on standard systemic therapy (chemotherapy)
218943222|NCT06946420|DRUG|Standard systemic therapy (chemotherapy) without RT/SBRT|This group of patients will undergo standard systemic therapy (chemotherapy drugs chosen by oncologist) without radiotherapy treatment
218943223|NCT06947590|DRUG|mavacamten|Patients in this group were treated with Mavacamten, starting at an initial dose of 2.5 mg, administered orally once daily. Subsequent doses were adjusted based on changes in pressure gradients and cardiac function observed during follow-up.
218943224|NCT06947798|BEHAVIORAL|motivational interviewing|motivational interviewing four times
218943225|NCT06947798|OTHER|Diet|A calorie-restricted diet was implemented in both the intervention and control groups.
218943226|NCT06947798|BEHAVIORAL|Physical exercise|A moderate-intensity aerobic exercise program, consisting of 30-minute sessions five days per week, was implemented in both groups
218943227|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
218943228|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
218943229|NCT06946628|DRUG|Group A (triple combination therapy group)|1\) Initiate with Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, if blood glucose is not controlled, adjust to Semaglutide 0.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd. If Semaglutide is well-tolerated, increase to 1 mg qw after 1 week; 3)If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
219051642|NCT06771843|BEHAVIORAL|Kisoboka|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance-free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol), Social support \& role models for financial goals and substance-free activities (delayed rewards, alternative reinforcers), Financial literacy, Develop motivation \& confidence for change, Goal setting for alcohol reduction \& ART adherence, Alcohol harms \& defining low risk drinking Discuss challenges to change and maintain alcohol risk reduction and improved adherence, Developing \& reinforcing discrepancy between savings/life goals and drinking/poor adherence, Developing discrepancy activity: goals for savings and healthy living and weekly, monthly, yearly spending on alcohol Self-monitoring of savings \& spending Text message reminders to reinforce discrepancy between unhealthy behavior \& goals"
219634425|NCT04189783|DRUG|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
219634426|NCT04189783|DRUG|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
218943230|NCT06946628|DRUG|Group B (standard therapy group)|metformin-based treatment is recommended when not contraindicated. 1).Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After another month, if blood glucose remains uncontrolled, add Semaglutide 0.25 mg qw, then increase to 0.5 mg qw after 1 month. If well-tolerated, increase to 1.0 mg qw after 1 week; 4) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
218943231|NCT07145320|OTHER|Oral Cryotherapy Group (Group 1)|Participants were educated about oral cryotherapy before their first chemotherapy cycle. Individually portioned ice bags (15 mL per cube) were prepared and provided free of charge for home use (6 bags per cycle). Patients were instructed to apply the ice intra-orally for 30 minutes at a time, 6-10 times daily, beginning at the start of Adriamycin infusion. A Cryotherapy Application Log Form was used to record date, start, and end times for each session.
218943232|NCT07145320|OTHER|Chewing Gum Group (Group 2)|Patients received standardized, tasteless, single-use chewing gum (6 boxes per cycle) and were instructed to chew a piece for 20-30 minutes before and during chemotherapy infusion. A new piece was provided midway through the session. Usage was recorded in a Chewing Gum Application Log Form, capturing date and timing details.
218943233|NCT07146971|DRUG|OTC Drug for Atopic Dermatitis in Cream form|OTC Cosmetic Cream Formulation
218943234|NCT07146269|DEVICE|tDCS|Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3/F4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.
218943235|NCT07146269|DEVICE|VR-based relaxation therapy|Nature exposure via a Virtual Reality (VR) headset, for 30 minutes daily concurrently to tDCS, Monday to Friday, for a total of 20 sessions.
219051643|NCT06771843|BEHAVIORAL|Behavioral Economics|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol/ decrease reward value of alcohol), Social support \& role models for financial goals and substance free activities (delayed rewards, alternative reinforcers), Financial literacy"
219634427|NCT04189783|OTHER|Questionnaire Administration|Ancillary studies
219634428|NCT00317785|DRUG|cyclophosphamide|
218943236|NCT06947005|BEHAVIORAL|Intervention 1|The students in the serious game group were asked to download the drug applications serious game to their phones. They were asked to play the game for two weeks. The students continued to play the game at any time and as often as they wanted until they won at least one gold medal for each application. At the end of the 2nd week, a questionnaire form and VAS scale were applied to the students to evaluate the post-test data and their satisfaction levels with the game. The collected data were analysed to understand the different dimensions of game satisfaction and to assess overall satisfaction levels.
219051644|NCT06771843|BEHAVIORAL|Motivational Interviewing|"Intervention activities:~Develop motivation and confidence for change, Specific goal setting for alcohol reduction and ART adherence, Alcohol harms \& defining low risk drinking, Discuss challenges to change and to maintain alcohol risk reduction and improved adherence/care engagement"
219051645|NCT06771843|BEHAVIORAL|Screening and Referral|"Brief feedback on their Alcohol Use Disorders Identification Test (AUDIT) score per the AUDIT brief intervention manual, a referral for alcohol counseling, and brief guidance on the importance of HIV care engagement and adherence following the Ugandan Ministry of Health protocol. A referral coupon with details of the clinic name and location will be provided to each participant and participants will be asked to submit the referral note to the alcohol and/or HIV counselor."
219051646|NCT07065851|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|Non-invasive therapy delivering high-energy shock waves to stimulate healing in musculoskeletal tissues, targeting the hamstring muscles and related structures, administered 2 times per week for 4 weeks, alongside core exercises.
219051647|NCT07065851|BEHAVIORAL|Exercise Program|Structured exercises focusing on hamstring flexibility, lumbar stabilization, and core exercises, administered 3 times per week for 3 weeks, with sessions lasting 30-45 minutes.
219051648|NCT06336343|DRUG|Bimekizumab|Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
219051649|NCT06761131|DRUG|Linezolid (LZD)|compare the incidence and magnitude of Linezolid induced thrombocytopenia
218943237|NCT06947005|BEHAVIORAL|Intervention 2|A WhatsApp group was established to maintain communication with the students in the video-supported education group. After the pre-test data were collected, the students were introduced to the ed-puzzle web page where they could watch the application videos and were asked to register to the system. No fee was paid to register to the ed-puzzle web page. Students were given the opportunity to watch the videos on the ed-puzzle web page for 2 weeks and answer the questions. Each student was allowed to watch the videos at least once until they answered all the questions correctly. The number of videos watched was monitored by the researcher. At the end of the 2nd week, post-test data were collected from the students.
219051650|NCT03865472|OTHER|Questionnaire Administration|Ancillary studies
219051651|NCT03865472|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
219051652|NCT03865472|PROCEDURE|Sham Intervention|Undergo sham rTMS
219051653|NCT06794840|BEHAVIORAL|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) for chemsex-related harm reduction.|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) that uses an EMA-based machine learning (ML) algorithm to anticipate chemsex risk and deliver appropriate chemsex-related harm reduction and HIV prevention services when the risk is detected.
219051654|NCT06766305|DRUG|QL1706 combined with SOX|QL1706 + SOX (3 cycles) before surgery → radical surgery (D2) → QL1706 + SOX (5 cycles) after surgery → QL1706 monotherapy maintenance （up to 1 year before and after surgery); Phase 1 (initial dose cohort) ： QL1706 5mg/kg ；Phase 1 (dose escalation cohort)：QL1706 7.5mg/kg ；Phase 2：QL1706 RP2D
219051655|NCT07074197|OTHER|OOKIE doll|The infants who met the selection criteria were wrapped with OOCIE upon admission and remained in contact with OOCIE for approximately 24 hours without affecting their routine care and position. After 24 hours, when the mother came for the first visit, the mother and baby introductory information form, Neonatal Intensive Care Unit Parent Stress Scale, Inadequate Milk Perception Scale, Mother-Infant Attachment Scale and NICU Parental Beliefs Scale pretest were administered. During the visit, the mother received the OOKIE wrapped around her baby in the incubator and stayed with the mother for 3 days and the mother could smell her baby's odor whenever she wanted.
219634429|NCT00317785|DRUG|cyclosporine|
219634430|NCT00317785|DRUG|methotrexate|
219051656|NCT07079254|PROCEDURE|Meniscus suture|The meniscus bucket-handle injury will either be treated with meniscus suture or partial meniscectomy
219634431|NCT00317785|DRUG|mycophenolate mofetil|
219634432|NCT00317785|DRUG|sirolimus|
219634433|NCT00317785|DRUG|tacrolimus|
219634434|NCT00317785|OTHER|pharmacological study|
219051657|NCT07079254|PROCEDURE|Partial meniscectomy|The meniscus bucket-handle injury wil be treated with either meniscus suture or partial meniscectomy
219051658|NCT06596252|DRUG|Budesonide|Twice daily intake of the tablet 30 min after a meal
219051659|NCT07077629|PROCEDURE|morbidity and mortality|Relationship of scoring systems with postoperative morbidity and mortality in geriatric patients undergoing gynecologic cancer surgery.
219634435|NCT00317785|PROCEDURE|allogeneic bone marrow transplantation|
219634436|NCT00317785|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219634437|NCT00317785|PROCEDURE|peripheral blood stem cell transplantation|
219634438|NCT00317785|RADIATION|total-body irradiation|
219634439|NCT06578494|DEVICE|Ultrasound|Ultrasound-guided peripheral intravenous catheter insertion
219634440|NCT01623310|DRUG|Fluticasone Propionate|Using Optinose Exhalation Delivery System
219634441|NCT02764281|DRUG|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
219634442|NCT02764281|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
219634443|NCT02291666|DRUG|CRCHUM-MT cocktail|
219634444|NCT02898597|BEHAVIORAL|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
219634445|NCT02530125|OTHER|Laboratory Biomarker Analysis|Correlative studies
219634446|NCT02530125|BIOLOGICAL|Pidilizumab|Given IV
218943238|NCT06955195|BEHAVIORAL|School-based intervention program on improving adolescent mental wellbeing|Students participating in the intervention program will attend the school talk and workshops about mental health. They are also required to organize whole-school activities to promote peer mental wellbeing at school. All attended students will be guided by registered social workers and trained research personnel throughout the intervention program.
218943239|NCT06955195|OTHER|Control-no treatment|Students participating at control group will not receive intervention program during the academic year compared with their counterparts in active comparator group. They will live and attend the class as usual at school. After the academic year, they will receive the intervention program on the alternative academic year.
218943240|NCT07147088|DRUG|SHR-1701|SHR-1701 will be administered by IV, 1200mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
218943241|NCT07147088|DRUG|Famitinib|Famitinib will be administered at 15 mg orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219051660|NCT07080580|BEHAVIORAL|Core exercises performed simultaneously on a whole body vibration platform|"It's a method where individuals stand on a vibration-generating platform and the vibration is transmitted from the soles of their feet to the entire body. Its use in combination with exercise has become popular in recent years due to the hypergravity it creates, aiming to increase muscle strength and reduce pain.~There is no standardized protocol for the frequency, amplitude, and frequency of vibration application. However, it is known that when applied at frequencies between 10-30 Hz, it has no negative side effects and is beneficial in managing pain. In our study, core exercises will be performed on a vibration platform at a frequency of 14 Hz with an amplitude of 8 mm."
219051661|NCT06858774|BEHAVIORAL|Circadian Reset Technology|Circadian reset technology is a software used on a VR headset in this intervention. The software is a passive viewing experience like a guided meditation that presents visual images.
218943242|NCT07147088|PROCEDURE|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. SHR-1701 plus famitinib will be administered 1-3 days after cryoablation.
219051662|NCT06858774|BEHAVIORAL|VR Headset|The software used on a VR headset in this intervention is a passive viewing experience like a guided meditation that presents neutral images that mimics the sequence used in the CRT software.
219051663|NCT06786039|PROCEDURE|Non-invasive NAVA|"Initiate respiratory assist with NIV-NAVA within 48 hours. The setting of respiratory support will be adjusted based on clinical conditions of each subject. NIV-NAVA could be switched to nasal continuous airway pressure or high flow nasal cannula, and it also could be stopped after initial stabilization.~In cases of respiratory distress syndrome, lung surfactant will be administered via the less invasive surfactant administration (LISA) method and avoid endotracheal intubation whenever possible. For who intubated in the delivery room, extubation with NIV-NAVA should be considered as soon as possible. Endotracheal intubation with invasive ventilation could be applied when clinical deteriorations happens."
219051664|NCT07076264|OTHER|AquOTic|AquOTic is an evidence-based, occupational therapy-led intervention designed to enhance water competency and swim safety skills in children on the autism spectrum. The 10-week program consists of weekly 60-minute group sessions, each including six children paired in a 1:1 ratio with an interventionist. Sessions follow a structured routine involving six rotating stations, targeting various swim and safety skills, with the flexibility for individualized support by the interventionist.
219051665|NCT07078825|OTHER|Training Supported by Metaverse and Virtual Reality (VR) in the Digital Breastfeeding Museum Group|The pregnant women in this group received training supported by Metaverse and virtual reality (VR) in the digital breastfeeding museum. The training began when pregnant women wore VR headsets (Meta Quest 2) and entered the digital museum using hand controllers. To prevent physical risks like falling or bumping, they navigated the environment safely from where they were seated. Educational content was accessed via personalized avatars. Participants moved between rooms by walking virtually or clicking on circular transition portals. The researcher provided guidance when needed. Video durations varied by topic, totaling around 40 minutes. Mothers could rewatch videos and pause/resume the training on the same day. They engaged with visual, auditory, and written materials, spending approximately one hour in the museum.
219051666|NCT07086326|DRUG|Ivonescimab+Chemo|Ivonescimab (AK112) + platinum-based doublet chemotherapy
219051667|NCT07086326|DRUG|Penpulimab+Chemo|Penpulimab (AK105) + platinum-based doublet chemotherapy
219051668|NCT07085182|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|SBRT:3-10Gy/F, once daily, 5 times a week; Tislelizumab(200mg,iv,q3w):Tislelizumab was added after five sessions of SBRT radiotherapy.
219549529|NCT07139431|BIOLOGICAL|NCR100|Subjects will receive a single injection of NCR100
219549530|NCT07139262|BEHAVIORAL|Climate-Resilient Disaster Preparedness Education Program|A structured educational program designed to enhance nursing students' knowledge and skills in climate-resilient disaster preparedness. The program consisted of four weekly sessions (2 hours each) delivered through lectures, interactive group discussions, and simulation-based exercises. Core content included disaster risk reduction principles, emergency response protocols, climate-related hazard preparedness, psychological first aid, triage procedures, and resilience-building strategies. Training materials were validated by subject matter experts and culturally adapted for the Saudi nursing education context.
219549531|NCT07139262|OTHER|Standard Nursing Curriculum|Participants continued their regular undergraduate nursing curriculum without additional specialized training in disaster preparedness or climate resilience. This curriculum provided foundational nursing education but did not include structured sessions on climate-related disaster management or resilience-building.
218943243|NCT07145047|BIOLOGICAL|oncolytic virus|Intratumoral injection of oncolytic virus.
218943244|NCT07146945|DRUG|S1-221|S1-221 will be administered orally to participants.
218943245|NCT07146945|DRUG|Placebo|Matching placebo will be administered orally to participants.
218943246|NCT07146945|DRUG|THC|A single dose of THC will be administered to participants orally.
218943247|NCT07145008|DRUG|Suprachoroidal triamcinolone acetonide injection|For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.
218943248|NCT07147010|DEVICE|MIB Breath Analyzer|"Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).~Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)~Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)."
218943249|NCT07145541|DEVICE|Aion Tempshield Device|The AION BIOSYSTEMS, INC. tempshield is a skin-applied, continuous temperature monitor. It is battery powered, communicates using Bluetooth LE to a smartphone, then to a clinician dashboard, and is designed to be worn continuously for up to 60 days. Its primary use is for patient monitoring in hospital or post-discharge from a healthcare facility. Through the tempshield system, clinicians can be notified if a patient's temperature exceeds a given threshold. The tempshield system is centered around a non-invasive temperature sensor placed against the patient's skin, in the pectoral region just below the collar bone. The temperature sensor is held in place with a silicone adhesive tape similar to a custom shaped piece of medical tape. The silicone adhesive tape is hypoallergenic.
218943250|NCT07145749|BEHAVIORAL|Transtheoretical theory-based education|Transtheoretical theory-based education will be provided to individuals with substance use disorders face-to-face in 8 modes and each lesson will last 45 minutes. Weekly education stages of transtheoretical theory-based education: Week 1; Stage 1 (not thinking); Weeks 2 and 3, Stage 2 (Thinking/Intention); Weeks 4 and 5, Stage 3 (Preparation); Weeks 6 and 7, Stage 4 (taking action); Week 8, Stage 5 (Maintenance/Continuing).
219051669|NCT07084974|DEVICE|Adjustment and practice session|During the adjustment and practice session, participants will perform the lifting task with each exoskeleton after they are properly fitted. They will also perform the measurement sequence as to limit learning effects during lifting task sessions. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
219051670|NCT07084974|DEVICE|No trunk assistance|This lifting task session is performed without any trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
219051671|NCT07084974|DEVICE|Uplift Lite exoskeleton|This lifting task session is performed with the Mawashi Uplift Lite trunk assistance exoskeleton. Participants will perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
219051672|NCT07084974|DEVICE|Biolift exoskeleton|This lifting task session is performed with the Biolift trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
218943251|NCT07145749|OTHER|Pre-test-after-test-re-test|Information Form, Sexual Risk Taking Scale, AIDS Knowledge Scale and AIDS Prevention Self-Efficacy Scale
218943252|NCT07146373|OTHER|Inspiratoty Muscle training|Participants will follow an IMT program through a threshold IMT device which consists of 5 set/6 breaths at 50-60% MIP for 3 months along with their usual physical and cogntive training
218943253|NCT07146373|OTHER|Usual Care|Physical and cognitive training
219051673|NCT07084974|DEVICE|Laevo Flex exoskeleton|This lifting task session is performed with the Leavo Flex trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
219051674|NCT07086144|DIAGNOSTIC_TEST|Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis|N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel
219051675|NCT07086612|DIAGNOSTIC_TEST|over nigtht ventilatory polysomnograph test|Every patient will have an overnight polysomnography test.
219051676|NCT07086963|PROCEDURE|Repaired with standard TIP repair as described by Snodgrass|"Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
219634447|NCT03747523|DRUG|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
219634448|NCT03171038|OTHER|Telemonitoring|
219634449|NCT02430519|PROCEDURE|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
219634450|NCT02430519|PROCEDURE|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
219634451|NCT02430519|DEVICE|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
219634452|NCT02430519|DEVICE|autologous platelet-rich fibrin|
219634453|NCT00356603|DRUG|Sumatriptan Succinate|Sumatriptan Succinate
219634454|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
219634455|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
218943254|NCT07146594|DRUG|Modified bismuth-containing eradication treatment|"After the confirmation of Helicobacter pylori infection, eligible patients whether first line or rescue therapy will be assigned to receive:~\- A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all medications taken for 14 days.~Esomeprazole will be given at least 30 minutes before meals every 12 hours. Antibiotics will be given after meals every 8 hours and bismuth subcitrate at least 2 hours far from meals every 12 hours."
218943255|NCT07145554|OTHER|Focal extracorporeal schock wave therapy|Participants in this group will receive a total of 5 sessions of focal extracorporeal shock wave therapy. Each session will deliver 1000 pulses per cm² to the affected piriformis muscle.
218943256|NCT07145554|PROCEDURE|Steroid Injection|Participants in this group will receive a single injection of corticosteroid into the piriformis muscle.
218943257|NCT07147166|DEVICE|Brijjit® BP100-6 and BP-75|Brijjit® BP-100 and BP-75 are a non-invasive, flexible devices that acts as a force modulating tissue bridge (FMTB) to aid in wound healing. BP-100 and BP-75 simply refer to different sizes of the Brijjit device.
218943258|NCT07147166|OTHER|Control: Standard of care and normal wound dressing|The control chest side will receive only standard of care and normal wound dressing.
218943259|NCT07146087|BIOLOGICAL|MSC-Derived Exosomes|Purified, sterile, acellular extracellular vesicles (exosomes) isolated from culture supernatant of GLP-manufactured allogeneic human bone-marrow-derived MSCs. Release criteria include particle size distribution 30-150 nm (nanoparticle tracking analysis), particle count, sterility/endotoxin testing, mycoplasma negative, and predefined protein/marker profile (e.g., CD9/CD63/CD81 positive).
218943260|NCT07146087|BIOLOGICAL|Placebo (Normal Saline)|0.9% sodium chloride solution matched to the experimental product in volume, appearance, infusion set-up, and administration procedures.
219051677|NCT07086963|PROCEDURE|Repaired with TIP with GIP using preputial graft|"The urethral plate was deeply incised from the glans tip, extending downwards beyond the junction between the plate and the hypospadiac meatus Graft fixation The graft was then spread to cover the raw area and fixed to the edges of the urethral plate.~Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
219051678|NCT07085676|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
219051679|NCT07084909|DRUG|piflufolastat F 18|18F-DCFPyL is a fluorine-18 radiolabeled low molecular weight positron emission tomography (PET) tracer that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.
219051680|NCT07087288|OTHER|AI-supported case|In the artificial intelligence supported case analysis course, students will listen to the audio video prepared by artificial intelligence.
219051681|NCT07087288|OTHER|Case Analysis|The case analysis will be made through the presentation prepared by the students in the group.
219051682|NCT07086300|OTHER|Electroacupuncture (EA)|"In the electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for needling. Upon achieving the deqi sensation, the electroacupuncture device was connected to the needles at both points. A dispersed-dense wave was applied with an intensity ranging from 0.5 to 2 mA, adjusted according to the patient's tolerance. The needles were retained for 20 minutes, after which they were removed."
219051683|NCT07086300|OTHER|Sham electroacupuncture|"In the sham electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for sham electroacupuncture intervention, which did not receive manual manipulation. The electrode placement and other treatment settings were identical to those in the electroacupuncture group, but no skin penetration, electrical output, or needle techniques were applied to induce the sensation of deqi. No genuine electroacupuncture stimulation was administered in this group."
219634456|NCT02400918|OTHER|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
218943261|NCT07145970|OTHER|Neuropsychological assessment tests for spatial neglect|"Standardized administration of four paper-and-pencil tests designed to assess different forms of spatial neglect:~* Apples Cancellation Test (Birmingham Cognitive Screen) for egocentric and allocentric neglect,~* Simplified Comb and Razor Test for personal and motor neglect,~* Line Bisection Test (30 cm ruler, blind version) for tactile neglect,~* Dot Test for visual exploration.~The purpose is to establish normative reference scores in healthy French-speaking adults according to age, sex, and professional qualification. No therapeutic intervention or patient population is involved."
218943262|NCT03703297|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
218943263|NCT03703297|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
218943264|NCT03703297|OTHER|Placebo|Placebo IV (intravenous infusion)
218943265|NCT03027544|RADIATION|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles."
218943266|NCT03085849|DRUG|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
218943267|NCT03085849|DRUG|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
218943268|NCT03085849|DRUG|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
218943269|NCT02711917|DRUG|MAC 0.5|0.5 MAC Sevoflurane
218943270|NCT02711917|DRUG|MAC 0.75|0.75 MAC Sevoflurane
218943271|NCT02711917|DRUG|MAC 1.0|1.0 MAC Sevoflurane
218943272|NCT02711917|DRUG|Propofol|Propofol consumption
218943273|NCT02711917|DRUG|Etomidate|Etomidate consumption
218943274|NCT02711917|DRUG|Rocuronium|Consumption of Rocuronium
218943275|NCT01930331|DRUG|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
218943276|NCT01930331|DRUG|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
218943277|NCT04608461|DRUG|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
218943278|NCT01039662|DIETARY_SUPPLEMENT|L-arabinose and indigestible dextrin|
218943279|NCT01039662|DIETARY_SUPPLEMENT|Placebo|
218943280|NCT00003013|DRUG|CMF regimen|
218943281|NCT00003013|DRUG|cyclophosphamide|
219051684|NCT07085013|BEHAVIORAL|Individually Trained Oral Prophylaxis (iTOP)|The iTOP intervention consists of a single, structured, 45-minute, small-group oral hygiene training session conducted by certified dental professional. The session includes personalized instruction on proper toothbrushing techniques (e.g., Bass technique), use of interdental brushes and floss, and patient motivation. At the 3-month follow-up, participants also received a short reinforcement session. Standardized oral hygiene kits (toothbrush, interdental brushes) were provided at each time point.
219051685|NCT07086456|DRUG|Surufatinib|Administered orally at 200 mg once daily d1-d14, starting at the initiation of each radiotherapy phase, for 14 consecutive days. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with surufatinib 200 mg orally once daily on Days 1-14 of each 21-day cycle
219051686|NCT07086456|DRUG|Tislelizumab|200 mg administered via intravenous drip one day prior to the start of each radiotherapy phase. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with tislelizumab 200 mg administered via intravenous drip on Day 1 of each cycle (Q3W), for up to 12 months.
218943282|NCT00003013|DRUG|doxorubicin hydrochloride|
218943283|NCT00003013|DRUG|fluorouracil|
218943284|NCT00003013|DRUG|methotrexate|
218943285|NCT00003013|DRUG|paclitaxel|
218943286|NCT00003013|DRUG|tamoxifen citrate|
218943287|NCT00003013|PROCEDURE|conventional surgery|
218943288|NCT00003013|RADIATION|radiation therapy|
218943289|NCT02664948|PROCEDURE|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
218943290|NCT03329014|DRUG|Remimazolam|For induction and maintenance of sedation
218943291|NCT03329014|DRUG|Placebo|Control arm
218943292|NCT00036842|DRUG|arsenic trioxide|
218943293|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
218943294|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
218943295|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
218943296|NCT03844945|OTHER|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
218943297|NCT03165604|OTHER|standard information|The participates will be given a standard information regarding the water drink before physical activity
218943298|NCT03165604|OTHER|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
218943299|NCT02604901|BEHAVIORAL|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
218943300|NCT02604901|BEHAVIORAL|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
218943301|NCT02871752|BEHAVIORAL|Health promotion|mindfulness-based stress reduction
218943302|NCT05654077|BIOLOGICAL|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。
218943303|NCT05654077|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
218943304|NCT05654077|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
218943305|NCT01947413|OTHER|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
218943306|NCT01947413|OTHER|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
218943307|NCT01947413|OTHER|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
218943308|NCT03963271|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
218943309|NCT05363254|OTHER|Marlboro Gold Box|A combustible cigarette
218943310|NCT05363254|OTHER|Newport Box|A combustible cigarette
218943311|NCT05363254|OTHER|Non-combusted cigarette variant 42001401|A menthol flavor variant of a non-combusted cigarette (42001401)
218943312|NCT05363254|OTHER|Non-combusted cigarette variant 42001399|A menthol flavor variant of a non-combusted cigarette (42001399)
218943313|NCT05363254|OTHER|Non-combusted cigarette variant 40007386|A menthol flavor variant of a non-combusted cigarette (40007386)
219051687|NCT07086456|DRUG|Concurrent Chemotherapy|Albumin-bound paclitaxel 50 mg/m² plus cisplatin 25 mg/m², administered weekly (QW).
219051688|NCT07086456|RADIATION|Radiotherapy|definitive hypofractionated radiotherapy
219051689|NCT02543905|PROCEDURE|Prostate MRI and Biopsy|All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
219051690|NCT04659785|DRUG|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
219051691|NCT04659785|DRUG|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
218943314|NCT05363254|OTHER|Non-combusted cigarette variant 42001402|A non-menthol flavor variant of a non-combusted cigarette (42001402)
218943315|NCT06057961|OTHER|Art Therapy|8 meetings in 1 year
218943316|NCT06166121|OTHER|ShenJu|One package per time, twice a day, 90 days of treatment
218943317|NCT06166121|OTHER|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
218943318|NCT01043939|OTHER|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
218943319|NCT01043939|OTHER|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
218943320|NCT06246006|OTHER|Gene sequencing|Next generation sequencing of candidate genes (JAK2, cMPL, CALR, ASXL1 and NF-E2)
218943321|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Myo-inositol
218943322|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|N-Acetyl-Cysteine
218943323|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Folic Acid
218943324|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Selenium
219051692|NCT06938152|DRUG|Romosozumab followed by Denosumab|Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months
219051693|NCT06938152|DRUG|Romosozumab and Denosumab Cycle Therapy|Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months
219051694|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
219051695|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
219051696|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
219051697|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
218943325|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-arginine
218943326|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-carnitine
218943327|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Vitamin E
219051698|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
219051699|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
219051700|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
219051701|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
219634457|NCT03303690|PROCEDURE|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
219634458|NCT01234870|DRUG|Gadolinium|
219634459|NCT01234870|DRUG|Adenosine|
218943328|NCT02754700|OTHER|Neuromuscular Training|Standardized, comprehensive neuromuscular training
218943329|NCT02754700|OTHER|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
218943330|NCT02754700|OTHER|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
218943331|NCT02559700|BEHAVIORAL|Brain training programme|An online package of brain training programmes
218943332|NCT05998889|BEHAVIORAL|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
218943333|NCT05998889|BEHAVIORAL|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
218943334|NCT03968640|DIETARY_SUPPLEMENT|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
218943335|NCT03968640|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
218943336|NCT00693082|DIETARY_SUPPLEMENT|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
218943337|NCT04473235|BEHAVIORAL|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
218943338|NCT04473235|BEHAVIORAL|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
218943339|NCT06515808|DEVICE|Direct Laryngoscope|Patient receiving tracheal intubation with direct laryngoscope, GlideScope or Airway Scope
218943340|NCT05724693|DRUG|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
218943341|NCT01754402|DRUG|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
218943342|NCT01754402|DRUG|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
218943343|NCT01754402|DRUG|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
218943344|NCT03448484|DIETARY_SUPPLEMENT|Intervention (integrated package)|"Provided to all intervention households:~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* 8 birds of chicken (child consumes 1 egg/day)~* Vegetable seeds (red onion, indigenous managu and sukuma)~* Monthly trainings to all farmers on nutrition and WASH~* Micronutrient powder (MixMe, 1g sachet every third day)~* Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
218943345|NCT03448484|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~* Agricultural training (every 2 weeks on average) for all~* Free to enrol for the following products on credit:~  * Compost boosters~ * Cook stoves~ * Seeds (onions, maize, indigenous greens, beans)~ * Maize storage bags~ * Drying tarps~ * Trees~ * Solar lights~ * Fertilizer~ * Actellic dust (insecticide)~ * Re-usable sanitary pads"
218943346|NCT01282463|DRUG|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
218943347|NCT01282463|BIOLOGICAL|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
218943348|NCT01282463|BIOLOGICAL|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
218943349|NCT02726542|DRUG|somatropin|Norditropin (growth hormone) given by injection using a pen-device
218943350|NCT01437475|BIOLOGICAL|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
218943351|NCT00086268|DRUG|zoledronic acid|
218943352|NCT00086268|DRUG|Taxotere|
218943353|NCT00086268|DRUG|Carboplatin|
218943354|NCT05249478|PROCEDURE|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
218943355|NCT03010371|BEHAVIORAL|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
218943356|NCT03010371|BEHAVIORAL|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
219051702|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
219051703|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
219051704|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
219051705|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
218943357|NCT03010371|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful."
219634460|NCT00531115|DRUG|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
219634461|NCT03961321|RADIATION|stereotactic mr guided adaptive radiotherapy|Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction).
219634462|NCT03298958|DRUG|Rapamycin|Subject will be randomized to one of the 2 arms
219634463|NCT03298958|DRUG|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
219634464|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor away from GI|
219634465|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor adjacent to GI|
219634466|NCT00728468|DRUG|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
218943358|NCT00147368|DRUG|intravenous (IV) arginine|
218943359|NCT02051933|DRUG|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
219634467|NCT04947774|RADIATION|Prophylactic Cranial Irradiation|The extensive-stage SCLC patients will receive prophylactic cranial irradiation ±immunotherapy after standard first-line chemotherapy combined with immunotherapy, until disease progression or death
219051706|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
219051707|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
219634468|NCT02499367|DRUG|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
219634469|NCT02499367|RADIATION|Radiation therapy|20 Gy to metastatic lesion
219634470|NCT02499367|DRUG|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
219634471|NCT02499367|DRUG|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
219634472|NCT02499367|DRUG|Cisplatin|40 mg/m2, weekly for 2 weeks
219634473|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
219634474|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
219634475|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
219634476|NCT01568034|DRUG|Placebo|single-dose
219634477|NCT01568034|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
219634478|NCT01568034|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
219051708|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
219051709|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
219051710|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
219051711|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
219634479|NCT01010529|OTHER|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
219634480|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
219634481|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
219634482|NCT00932373|DRUG|trastuzumab-MCC-DM1|Intravenous escalating dose
219634483|NCT00013338|PROCEDURE|Ambulation Training|
219634484|NCT01223625|DRUG|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
219634485|NCT01223625|DRUG|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
219634486|NCT02445157|OTHER|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
219634487|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
219634488|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
219634489|NCT02915757|DEVICE|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
219634490|NCT05769075|DRUG|TY-2136b|"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"
219634491|NCT05769075|DRUG|TY-2136b|"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"
219634492|NCT04121130|DEVICE|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
218943360|NCT02051933|DRUG|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
218943361|NCT05917431|COMBINATION_PRODUCT|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
218943362|NCT00748852|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
219051712|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
219051713|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
219206832|NCT06765798|OTHER|Group A : receive neural mobilization for radial nerve , mulligan mobilization with movement and conventional Therapy|Group A :Neural Mobilization for radial nerve, Mulligan Mobilization with Movement and Conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for
219634493|NCT04121130|DEVICE|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
218943363|NCT01449942|BIOLOGICAL|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
218943364|NCT01449942|OTHER|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
218943365|NCT03522623|OTHER|Non-interventional study|Non-interventional study
218943366|NCT02509234|DRUG|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
218943367|NCT05019118|OTHER|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
218943368|NCT05019118|OTHER|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
219051714|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
219549532|NCT07139691|PROCEDURE|Pre-incisional Transversus Abdominis Plane (TAP) block performed under ultrasound guidance. The block will be administered bilaterally using a mixture of lidocaine and ropivacaine 0.2%|After the induction of general anesthesia, bilateral TAP block will be performed in patients from Group 1. The administered dose will include 0.2% lidocaine combined with 0.2% ropivacaine, at a dose of 0.4 ml/kg per side, without exceeding toxic dose limits per kg.
219549533|NCT07139691|DRUG|Participants in this arm will receive standard analgesia for postoperative pain management following elective hysterectomy|Participants in this arm will receive standard multimodal systemic analgesia for postoperative pain management following elective hysterectomy. The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV. Additional rescue doses of Tramadol (50-100 mg IV every 4-6 hours) may be administered based on pain intensity, with a maximum of 400 mg/24 hours (or 300 mg/24 hours for patients aged ≥75 years). No Transversus Abdominis Plane (TAP) block will be performed in this group. Pain intensity, opioid use, and postoperative recovery scores will be evaluated and compared with the TAP block intervention group.
219549534|NCT07140276|BEHAVIORAL|Individual Therapy|12 weeks individual psychotherapy
219549535|NCT07140276|BEHAVIORAL|Individual Drug Counseling manual|12 weeks using the manual provided
219549536|NCT07138716|DIAGNOSTIC_TEST|68Ga-DOTA-CCK-FS PET/CT|For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, using a time-of-flight PET/CT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min/bed position). Images are reconstructed using OSEM algorithms.
219549537|NCT07138534|BEHAVIORAL|prehabilitation|In addition to exercise programmes, it includes nutritional optimisation, psychosocial preparation and smoking cessation.
219051715|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
219051716|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
219051717|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
219051718|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
219051719|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
218943369|NCT05019118|OTHER|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
218943370|NCT05019118|OTHER|Placebo milk|Conventional milk
218943371|NCT05019118|OTHER|Placebo yogur|Conventional yogur
218943372|NCT05019118|OTHER|Placebo fresh cheese|Conventional fresh cheese
218943373|NCT01779817|BEHAVIORAL|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
218943374|NCT02594995|DRUG|NBP|
218943375|NCT01802164|DEVICE|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
218943376|NCT00391209|DRUG|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
218943377|NCT00391209|DRUG|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
218943378|NCT02069275|OTHER|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
218943379|NCT02069275|OTHER|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
218943380|NCT04830098|OTHER|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
218943381|NCT04830098|OTHER|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
218943382|NCT04503187|BEHAVIORAL|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
218943383|NCT01221285|BIOLOGICAL|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
219051720|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
218943384|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
218943385|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
218943386|NCT02300636|OTHER|Training|Standard ACL rehabilitation
218943387|NCT05949034|DEVICE|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
218943388|NCT00301184|BIOLOGICAL|pGA2/JS7 DNA|DNA Vaccine
218943389|NCT00301184|BIOLOGICAL|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
218943390|NCT00407381|DRUG|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
218943391|NCT00407381|PROCEDURE|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
219051721|NCT05894265|OTHER|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
219051722|NCT05894265|OTHER|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
219051723|NCT05894265|PROCEDURE|Saline injection|Group 3 will receive saline injection
219051724|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
218943392|NCT00974584|DRUG|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
218943393|NCT00974584|DRUG|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
218943394|NCT00974584|DRUG|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
219051725|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
219051726|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
218943395|NCT00974584|DRUG|cisplatin|Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
218943396|NCT00974584|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
218943397|NCT00974584|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
218943398|NCT02872844|DEVICE|ICS AirCal3|Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
218943399|NCT04865367|OTHER|Exposure to culture media|Exposure to culture media
218943400|NCT06429553|PROCEDURE|Minimally invasive hematoma aspiration drainage combined with urokinase injection|Minimally invasive hematoma aspiration drainage combined with urokinase injection
218943401|NCT06013813|PROCEDURE|Radial Artery approach on percutaneous coronary intervention (PCI)|"* Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches."
218943402|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
218943403|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
218943404|NCT02730195|DRUG|Pioglitazone|Given PO
219051727|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
219051728|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
219051729|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
219051730|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
219051731|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
218943405|NCT02730195|DRUG|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
218943406|NCT02031328|RADIATION|Stereotactic Ablative Radiation|
218943407|NCT02265159|PROCEDURE|Focal Therapy Using High Intensity Focused Ultrasound|
218943408|NCT00906737|DEVICE|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
218943409|NCT00906737|OTHER|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
218943410|NCT02150694|PROCEDURE|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
218943411|NCT02150694|PROCEDURE|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
218943412|NCT02150694|OTHER|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
218943413|NCT02150694|OTHER|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
218943414|NCT01795768|DRUG|AZD 4547|
218943415|NCT00523263|DEVICE|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
219051732|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
219051733|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
219051734|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
219051735|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
218943416|NCT00523263|DEVICE|Human umbilical vein femoro-popliteal bypass|
218943417|NCT00608946|DIETARY_SUPPLEMENT|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
218943418|NCT00608946|DIETARY_SUPPLEMENT|placebo|placebo
218943419|NCT03007251|OTHER|"Eurythmy Therapy Movement R"|
218943420|NCT03007251|OTHER|"Eurythmy Therapy Movement L"|
218943421|NCT03007251|OTHER|"Eurythmy Therapy Movement B"|
218943422|NCT03007251|OTHER|Normal movements during walking or standing|
218943423|NCT01539044|DRUG|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
218943424|NCT01539044|DRUG|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
218943425|NCT02491944|DRUG|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
218943426|NCT02491944|DRUG|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
218943427|NCT03636841|DEVICE|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
218943428|NCT06227598|OTHER|Procedure: Additional biopsies collection|Procedure: Additional biopsies collection We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
218943429|NCT06351384|DEVICE|miRNA detection test|miRNA sequencing based on Next-Generation Sequencing (NGS) technology
218943430|NCT03406091|DRUG|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
218943431|NCT05563870|PROCEDURE|Endoluminal radiofrequency ablation|Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
218943432|NCT05563870|PROCEDURE|Endoscopic biliary stenting|Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
219051736|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
219051737|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
219051738|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
219051739|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
218943433|NCT00106509|DRUG|tolevamer potassium-sodium (GT267-004)|
218943434|NCT01239992|DRUG|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
218943435|NCT01822314|DRUG|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
219051740|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
219051741|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
219051742|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
219051743|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
218943436|NCT01822314|DRUG|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
218943437|NCT05181280|OTHER|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
218943438|NCT05181280|OTHER|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
219051744|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
219051745|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
219051746|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
219051747|NCT01825551|DRUG|Placebo|
218943439|NCT05373069|PROCEDURE|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
219051748|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
219051749|NCT04276272|OTHER|Imaging scan|PET/CT scan
219051750|NCT02864017|PROCEDURE|Enteral nutrition|
219051751|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
219051752|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
219051753|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
219051754|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
219051755|NCT02991209|DRUG|Testosterone|
219051756|NCT02991209|DRUG|Placebos|
219051757|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
219051758|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
219051759|NCT05683977|DRUG|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
219051760|NCT05826964|DRUG|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
219051761|NCT05826964|DRUG|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
219051762|NCT05826964|DRUG|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
219051763|NCT05826964|DRUG|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
219051764|NCT05826964|DRUG|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
219051765|NCT05826964|DRUG|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
219051766|NCT05826964|DRUG|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
219051767|NCT05826964|DRUG|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
219051768|NCT05826964|DRUG|Oral SERD|Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
219051769|NCT05826964|DRUG|PARPi|For participants with germline breast cancer gene (BRCA) mutation(s). Participants will receive standard of care PARPi (Olaparib or Talazoparib) therapy in Step 2 and Step 3.
219634494|NCT05624021|OTHER|Scapular functional training|The scapular functional training consists of press up and push up plus. Press up was done in sitting position on the training bench, feet on the floor with straight arm and the palms on the edge of the bench fingers pointing forward and then lift off and dip down just in front of the seat by moving the shoulder girdle. Progression is done by placing weight on the thigh. Push-up plus exercise started from a push up position on the hand, feet or knees and keeping the torso rigid by bracing the abdominals followed by protracting the scapula as high as possible. Progression is done moving from knees to the feet or adding resistance on the upper back. The training continued for three sessions per week for four weeks.
219634495|NCT05624021|OTHER|Cervical isometric exercises|The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
219051770|NCT05826964|DRUG|AKT inhibitor|For participants with tumors with one or more phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT serine/threonine kinase 1 (AKT1) or phosphatase and tensin homolog (PTEN) alterations. Participants in Step 2 and Step 3 will receive standard of care AKT inhibitor as an alternative therapy.
219051771|NCT05826964|OTHER|Step 3 Arm 2|Participants will receive third-line treatment standard of care as per their treating physician's choice according to National Comprehensive Cancer Network (NCCN) guidelines.
218943440|NCT04698577|BEHAVIORAL|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
219051772|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
219051773|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
219051774|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
219051775|NCT05241067|DRUG|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
219051776|NCT05241067|DRUG|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
219051777|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
219051778|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
219051779|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
219051780|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
219634496|NCT05624021|OTHER|Moist heating|A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
219634497|NCT04128046|PROCEDURE|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
219634498|NCT04128046|PROCEDURE|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
219634499|NCT05939869|OTHER|Medical and Clinical History|Retrospective and prospective analysis of patients data will be done.
219634500|NCT02782117|DEVICE|Luminopia One|Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
219634501|NCT04042389|BEHAVIORAL|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
219634502|NCT04042389|BEHAVIORAL|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
219051781|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
219051782|NCT02684591|DRUG|Placebo|Placebo
219634503|NCT04042389|BEHAVIORAL|Control|No messages sent.
219634504|NCT04550689|DEVICE|Bone graft|Bone grafts produced by Straumann LLC
219634505|NCT01971775|DEVICE|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
219634506|NCT01971775|DEVICE|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
219634507|NCT00243295|DRUG|rhBMP-2/CPM|
219634508|NCT05680246|DEVICE|DHOPE-PRO|Prolonged DHOPE preservation \>4 hours
219634509|NCT01497925|DRUG|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
219634510|NCT01423396|OTHER|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
219634511|NCT01423396|OTHER|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
218943441|NCT04698577|BEHAVIORAL|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
218943442|NCT01601600|DRUG|BYM338|BYM338
218943443|NCT01601600|DRUG|Placebo|BYM338 Placebo
218943444|NCT03648866|OTHER|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
218943445|NCT02702297|OTHER|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
218943446|NCT00334178|DRUG|Laxymig ER (drug)|
218943447|NCT04960839|RADIATION|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
218943448|NCT00849316|DRUG|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
218943449|NCT00754221|DRUG|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
218943450|NCT02689921|DRUG|Exemestane|Aromatase inhibitor
218943451|NCT02689921|DRUG|Letrozole|Aromatase inhibitor
218943452|NCT02689921|DRUG|Anastrozole|Aromatase inhibitor
218943453|NCT02689921|DRUG|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
218943454|NCT02689921|DRUG|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
218943455|NCT02689921|DRUG|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
218943456|NCT03645343|DEVICE|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
218943457|NCT03645343|DEVICE|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
218943458|NCT01594801|DEVICE|InsuPad|Use of the InsuPad for at least 3 times a day.
218943459|NCT02763943|BEHAVIORAL|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
218943460|NCT03496714|BEHAVIORAL|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
218943461|NCT03496714|BEHAVIORAL|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
218943462|NCT02165839|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
218943463|NCT02165839|BEHAVIORAL|Healthy Eating Education Learning (HEAL)|
218943464|NCT02775929|DRUG|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
218943465|NCT02775929|DRUG|ART|ART for HIV-1 infected partners
218943466|NCT04340219|OTHER|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
218943467|NCT01957670|DEVICE|Lacrima medical Prototypes|
218943468|NCT01055652|DRUG|Dapagliflozin|10mg, oral, once daily
219051783|NCT05477004|DRUG|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
219051784|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
219051785|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
218943469|NCT03605602|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
218943470|NCT05317780|DRUG|rAAV9-CB6-AspA|This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
218943471|NCT02848729|DRUG|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
218943472|NCT02848729|DRUG|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
218943473|NCT02848729|DRUG|IV Morphine|Morphine for IV administration (0.125 mg/kg)
218943474|NCT02848729|DRUG|Placebo Tablets|Placebo tablets matching oral acetaminophen
218943475|NCT02848729|DRUG|Saline|Saline placebo matching IV acetaminophen
218943476|NCT01126047|OTHER|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
218943477|NCT04111562|PROCEDURE|Cranioplasty|Bone grafts
218943478|NCT03873675|DIAGNOSTIC_TEST|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
218943479|NCT04544215|BIOLOGICAL|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
218943480|NCT04544215|BIOLOGICAL|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
218943481|NCT04544215|BIOLOGICAL|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
219051786|NCT00136487|DRUG|Celecoxib|
219051787|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
219051788|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
219051789|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
219051790|NCT03780179|BIOLOGICAL|Placebo|Placebo
219051791|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
218943482|NCT01904773|DRUG|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
218943483|NCT04802629|DEVICE|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
218943484|NCT00866008|DRUG|Ovarian stimulation|"1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
218943485|NCT04582123|PROCEDURE|crossed pin configuration|comparison of two crossed pin fixation methods
218943486|NCT00207324|DEVICE|Silver Leaf Dressing|
218943487|NCT06480162|PROCEDURE|Mechanical ventilation|After replacing the electrode, we'll monitor the EEG activity of the hippocampus and other cortex regions while weaning off mechanical ventilation.
218943488|NCT03861988|DRUG|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
218943489|NCT03861988|DRUG|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
218943490|NCT06074042|OTHER|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
218943491|NCT00170001|DRUG|Nexium|40 mg bid dosing
218943492|NCT00170001|DRUG|Sugar Pill|40 mg BID
218943493|NCT00220779|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
218943494|NCT00220779|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|
218943495|NCT01300533|DRUG|BIND-014|
218943496|NCT00791076|DRUG|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
218943497|NCT00791076|DRUG|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
218943498|NCT01106469|DRUG|JNJ-41443532|25mg tablet once daily
218943499|NCT01106469|DRUG|JNJ-41443532|250mg tablet once daily
218943500|NCT01106469|DRUG|JNJ-41443532|1500mg once daily (with 250mg tablets)
218943501|NCT01106469|DRUG|JNJ-41443532|100mg tablet once daily
218943502|NCT01106469|DRUG|JNJ-41443532|1000mg once daily (with 250mg tablets)
218943503|NCT01106469|DRUG|Placebo|Matching placebo
218943504|NCT01106469|DRUG|JNJ-41443532|500mg once daily (with 250mg tablets)
218943505|NCT05291468|RADIATION|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
218943506|NCT01464957|BEHAVIORAL|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
219051792|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
219051793|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
219051794|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
219051795|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
218943507|NCT03331471|PROCEDURE|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
218943508|NCT03331471|PROCEDURE|conventional ventilation|conventional ventilation using the anesthesia machine
218943509|NCT01857596|DRUG|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
218943510|NCT04404218|DIETARY_SUPPLEMENT|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
218943511|NCT04404218|OTHER|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
218943512|NCT02248675|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
218943513|NCT02248675|OTHER|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
218943514|NCT04565327|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
218943515|NCT04565327|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
218943516|NCT01097200|DEVICE|Elevate mesh|The correction of the prolapse can be made by this new technique.
218943517|NCT01097200|DEVICE|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
218943518|NCT06237192|DRUG|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
218943519|NCT00102401|BEHAVIORAL|Internet-based Dyspnea Self-Management Program|
218943520|NCT00102401|BEHAVIORAL|Face-to-face Dyspnea Self-Management Program|
218943521|NCT00210938|DRUG|Doripenem|
219051796|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
219051797|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
219051798|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
219051799|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
218943522|NCT03390101|DRUG|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
218943523|NCT03390101|DRUG|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
218943524|NCT03390101|DRUG|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
218943525|NCT01282970|DRUG|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
218943526|NCT01282970|DRUG|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
218943527|NCT03699969|RADIATION|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
218943528|NCT02512627|BEHAVIORAL|Cognitive training|visuospatial, attention, memory, and executive abilities
218943529|NCT02512627|BEHAVIORAL|Physical exercise|endurance, balance, and mobility
218943530|NCT03561532|OTHER|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
218943531|NCT03561532|OTHER|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
218943532|NCT01024621|DEVICE|Endomicroscope|Pentax EC3870K, Tokyo, Japan
218943533|NCT01024621|DEVICE|Standard endoscopy|Pentax EG-2931 gastroscope
218943534|NCT01701752|BIOLOGICAL|FP-01.1 + Placebo|
218943535|NCT01701752|BIOLOGICAL|FP-01.1 + TIV|
218943536|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + Placebo|
218943537|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + TIV|
218943538|NCT01701752|BIOLOGICAL|Adjuvant + TIV|
218943539|NCT01701752|BIOLOGICAL|Placebo + TIV|
218943540|NCT01701752|BIOLOGICAL|FP-01.1|
218943541|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant|
218943542|NCT01701752|OTHER|Placebo|
218943543|NCT00773227|PROCEDURE|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
218943544|NCT04708171|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
218943545|NCT04708171|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
218943546|NCT04708171|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
218943547|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
218943548|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
218943549|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
218943550|NCT00395057|DRUG|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
219051800|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
218943551|NCT06371183|DEVICE|Colonoscope|Endoscopy for lower GIT
218943552|NCT05232370|DRUG|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
218943553|NCT05232370|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
219051801|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
218943554|NCT00338975|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
218943555|NCT00338975|BEHAVIORAL|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
218943556|NCT00338975|BEHAVIORAL|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
218943557|NCT00338975|BEHAVIORAL|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
218943558|NCT00281658|DRUG|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
218943559|NCT00281658|DRUG|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
218943560|NCT00281658|DRUG|Placebo|Paclitaxel Matching Placebo
218943561|NCT04013243|DRUG|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
218943562|NCT04013243|DRUG|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
218943563|NCT03913416|DEVICE|3D printed model|Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
218943564|NCT03913416|OTHER|Control group|The control group is composed of patients operated with standard surgery
218943565|NCT02828891|DEVICE|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
219634512|NCT03258541|DEVICE|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
219634513|NCT03258541|RADIATION|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
219634514|NCT03258541|PROCEDURE|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
219634515|NCT01356043|DRUG|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
219634516|NCT01356043|DRUG|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
219634517|NCT02258438|BEHAVIORAL|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
219634518|NCT02258438|BEHAVIORAL|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
218943566|NCT05011279|OTHER|Move Together app/Garmin Activity Tracker|"* The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time."
218943567|NCT04054427|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
218943568|NCT00310453|BIOLOGICAL|ALK Grass tablet|
218943569|NCT02800876|OTHER|CT-acquisition|
218943570|NCT02634476|BEHAVIORAL|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
218943571|NCT02634476|BEHAVIORAL|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
218943572|NCT03830905|DRUG|XC221|Participants will receive 200 mg XC221 once a day during 3 days
218943573|NCT03830905|DRUG|Placebo|Participants will receive Placebo once a day during 3 days
218943574|NCT00813943|DRUG|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
219051802|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
219051803|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
219051804|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
219051805|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
219051806|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
219051807|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
219051808|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
219051809|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
219051810|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
219634519|NCT02258438|BEHAVIORAL|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
219051811|NCT04660357|OTHER|survey study|survey study
219051812|NCT04506554|DRUG|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
219051813|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
219051814|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
219051815|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
219051816|NCT05919147|DRUG|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
219051817|NCT05919147|DRUG|Placebo|Placebo will have the same appearance as the active drug.
219051818|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
219051819|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
219051820|NCT06023095|DRUG|LY3502970|Administered orally.
219634520|NCT02390102|DRUG|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
219634521|NCT02390102|DRUG|Placebo|Saline solution 0.9%
219634522|NCT06621290|OTHER|Semi-structured interviews|Semi-structured interviews on ED-patients experiences of frailty assessment with the CFS
219051821|NCT06023095|DRUG|Placebo|Administered orally.
219051822|NCT04212416|DRUG|Leflunomide|Given PO
219051823|NCT04871607|BIOLOGICAL|Basiliximab|Given IV
219051824|NCT04871607|DRUG|Carmustine|Given IV
219051825|NCT04871607|DRUG|Cytarabine|Given IV
219051826|NCT04871607|DRUG|Etoposide|Given IV
218943575|NCT00813943|DRUG|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
218943576|NCT00813943|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
218943577|NCT00813943|RADIATION|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
218943578|NCT04153734|DRUG|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
218943579|NCT04153734|DRUG|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
219051827|NCT04871607|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
219051828|NCT04871607|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
219051829|NCT04871607|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
219051830|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
219051831|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
219051832|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
218943580|NCT04153734|DRUG|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
218943581|NCT04153734|DRUG|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
218943582|NCT04153734|DRUG|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
219206833|NCT06765798|OTHER|Group B receive neural mobilization for radial nerve and conventional|Group B receive neural mobilization for radial nerve and conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors
219634523|NCT05500339|OTHER|M-health App|Pregnant women receive the App designed for the support of the first 1000 days of life
218943585|NCT06955481|PROCEDURE|Navigated Total Knee Arthroplasty|The OrthoPilot® Software Pheno4u TKA Level 1 is an application software for computer aided navigation of surgical instruments and serves (in combination with compatible hardware and compatible navigated instruments) as an optional aid for the surgeon during the preparation of the implant site for a compatible knee endoprosthesis.
218943586|NCT02529228|OTHER|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
219051833|NCT05511844|DRUG|ORM-5029|Intravenous infusion
219051834|NCT04319315|OTHER|survey|online survey
219051835|NCT01915277|DRUG|Dexmedetomidine|
219051836|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
219051837|NCT04145791|OTHER|Ice|ice packs
219051838|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
219051839|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
219051840|NCT02494700|RADIATION|External Beam Radiation Therapy|Undergo orbital EBRT
219051841|NCT02494700|DRUG|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
219051842|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
219634524|NCT05500339|OTHER|Standard care|Pregnant women receive standard supportive and educational methods.
218943587|NCT02529228|OTHER|Protein Composition|Consuming meals with higher or lower protein.
218943588|NCT04277923|DRUG|SMOFlipid|the lipid of all-in-one is less than 4g/kg.d
218943589|NCT04277923|DRUG|Lipofundin|the lipid of all-in-one is less than 4g/kg.d
219051843|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
219051844|NCT03296696|DRUG|AMG 596|Drug
219051845|NCT03296696|DRUG|AMG 404|Drug
219051846|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
219051847|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
219051848|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
219051849|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
219634525|NCT05172817|DRUG|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
219634526|NCT06642142|PROCEDURE|ESP block|"The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure.~Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored."
219634527|NCT00931437|DIETARY_SUPPLEMENT|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
218943590|NCT06071078|BEHAVIORAL|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
218943591|NCT03841916|DIAGNOSTIC_TEST|transvaginal ultrasound|transvaginal ultrasound to measure endometrial thickness
218943592|NCT04742582|DIETARY_SUPPLEMENT|Preterm Infants - fed fermented formula|Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)
218943593|NCT04742582|OTHER|Preterm Infants - fed standard formula|Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)
218943594|NCT04742582|OTHER|Pre-term Infants - breastfed|Breastfeeding infants - Reference group
218943595|NCT06343857|DIAGNOSTIC_TEST|self-assessment questionnaire|Completion of the anatomical site-specific self-assessment questionnaire.
218943596|NCT02551991|DRUG|nal-IRI|
218943597|NCT02551991|DRUG|5 fluorouracil|
218943598|NCT02551991|DRUG|Leucovorin|
218943599|NCT02551991|DRUG|Oxaliplatin|
218943600|NCT03689309|PROCEDURE|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
218943601|NCT05676775|OTHER|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
218943602|NCT03540550|OTHER|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
218943603|NCT05120063|DEVICE|SPS monoblock stem, Symbios|hip prosthesis
218943604|NCT05120063|DEVICE|Quadra-H, Medacta|hip prosthesis
218943605|NCT05120063|PROCEDURE|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
218943606|NCT05120063|PROCEDURE|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
218943607|NCT00265148|DRUG|Rosiglitazone|Extended Release Tablets
219634528|NCT04520750|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
219634529|NCT06339944|OTHER|sensory motor training|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
218943608|NCT00265148|OTHER|Placebo|Placebo dummy to match
218943609|NCT02842554|OTHER|EPT|
218943610|NCT02842554|DRUG|Drug Placebo Administration|
218943611|NCT02842554|OTHER|C|No Intervention
219051850|NCT06413225|DEVICE|Synergy cervical disc system|motion preservation disc
219051851|NCT04694131|DEVICE|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
219051852|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
219051853|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
218943612|NCT02909387|BEHAVIORAL|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
218943613|NCT01801345|OTHER|Fatigued|
218943614|NCT01801345|OTHER|Rested|
218943615|NCT01463007|RADIATION|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
218943616|NCT01463007|OTHER|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
218943617|NCT06954051|OTHER|REThink Life|REThink Life is a therapeutic game developed by David and collaborators (2019) and it is composed of four levels, each training a different emotion regulation ability (emotion recognition, mindfulness, distinguishing between rational and irrational thoughts, and positive attention bias).
218943618|NCT06078943|DEVICE|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
218943619|NCT03914222|DEVICE|CardioSpire (Respirix) Device|Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
218943620|NCT04470076|DRUG|Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin|"① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy."
219051854|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
219051855|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
219051856|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
219051857|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
219051858|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
219051859|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
219051860|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
219051861|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
219051862|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
219206834|NCT06765798|OTHER|Group C receive Mulligan mobilization with movement and conventional|"Group C receive Mulligan mobilization with movement and conventional~Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
219206835|NCT06765798|OTHER|Group D receive conventional|"Group D receive conventional :~Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
218943621|NCT04470076|PROCEDURE|Surgical treatment|The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
218943622|NCT04470076|DRUG|Adjuvant treatment:afatinib|The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
218943623|NCT05390619|PROCEDURE|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
218943624|NCT05390619|PROCEDURE|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
218943625|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical creatine|
218943626|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical placebo|
218943627|NCT03006861|DIETARY_SUPPLEMENT|21 g/d Oral creatine|
218943628|NCT03006861|DIETARY_SUPPLEMENT|21 g/d oral placebo|
218943629|NCT01504646|DIETARY_SUPPLEMENT|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
218943630|NCT01504646|DIETARY_SUPPLEMENT|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
218943631|NCT03736915|PROCEDURE|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
218943632|NCT03736915|OTHER|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
218943633|NCT03736915|OTHER|Questionnaires|Patient is asked to answer questionairres at the end of each injection
218943634|NCT01437306|DRUG|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
218943635|NCT06131099|OTHER|Dohsa hou exercises|Dohsa hou is a type of psychomotor therapy that helps improve psychological problems by using bodily movements, sensation and relaxation experience.
218943636|NCT06131099|OTHER|Standard treatment protocal|Standard treatment including soft tissue massage therapy, task specific training interventions, bicycle training and aerobic exercises.
218943637|NCT00444678|DRUG|Cetuximab|500 mg/m2, IV every two weeks
219051863|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
219051864|NCT04792112|BEHAVIORAL|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
219051865|NCT01352494|DRUG|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
219051866|NCT01352494|DRUG|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
218943638|NCT00444678|DRUG|Oxaliplatin|85 mg/m2, IV, q 2 weeks
218943639|NCT00444678|DRUG|Capecitabine|2500 mg, po bid x 7 days every two weeks
218943640|NCT00472758|BIOLOGICAL|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
218943641|NCT00472758|OTHER|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
218943642|NCT03224559|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
218943643|NCT00606905|BIOLOGICAL|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
218943644|NCT00606905|OTHER|normal saline|equivalent volume of normal saline
218943645|NCT02224885|DEVICE|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
218943646|NCT00859638|BEHAVIORAL|Physiotherapy|group self-management classes
219051867|NCT01468896|BIOLOGICAL|Cetuximab|Given IV
219051868|NCT01468896|BIOLOGICAL|Edodekin alfa|Given SC
219051869|NCT01468896|OTHER|Laboratory Biomarker Analysis|Correlative studies
219051870|NCT00390975|DRUG|Tegaserod|
219051871|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
219051872|NCT01824745|OTHER|educational intervention|Receive the SCP-BCS template booklet
219051873|NCT01824745|OTHER|counseling intervention|Receive counseling sessions with a patient navigator
219051874|NCT01824745|PROCEDURE|standard follow-up care|Receive standard follow-up care
219206836|NCT05974553|BEHAVIORAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
218943647|NCT00859638|BEHAVIORAL|Occupational Therapy|group self-management classes
218943648|NCT00859638|BEHAVIORAL|Capacity Building|workshops and case reviews with primary health care team members
218943649|NCT01488123|BEHAVIORAL|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
219051875|NCT01824745|PROCEDURE|quality-of-life assessment|Ancillary studies
219051876|NCT01824745|OTHER|questionnaire administration|Ancillary studies
219051877|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
219051878|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
219051879|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
219206837|NCT05974553|BEHAVIORAL|Supportive Group Psychotherapy for Justice-Involved Veterans|16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
219634530|NCT06339944|OTHER|kinesthetic exercises|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
219634531|NCT01224093|DRUG|Chemotherapy|as prescribed
218943650|NCT04800952|OTHER|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
218943651|NCT02826720|OTHER|No intervention was applied|No intervention was applied
218943652|NCT02299739|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
218943653|NCT02299739|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
218943654|NCT02299739|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218943655|NCT02299739|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
218943656|NCT02299739|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
218943657|NCT00745589|DRUG|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
218943658|NCT02910505|DEVICE|enLighten Laser|Laser for tattoo removal
218943659|NCT02762773|PROCEDURE|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
218943660|NCT02762773|PROCEDURE|control|Dissection of inferior and superior aspect of the rectus sheath
218943661|NCT02969408|DRUG|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
218943662|NCT00539175|DEVICE|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
219051880|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
219051881|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
219634532|NCT01224093|DRUG|rituximab [MabThera/Rituxan]|as prescribed
219634533|NCT05950893|PROCEDURE|pressure support level|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Downward PS level titration was performed from 20 cmH2O to 2 cmH2O at a 2cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O.Inspiratory effort is measured as pressure generated by inspiratory muscles using esophageal pressure monitoring.
219634534|NCT02797457|PROCEDURE|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
219634535|NCT02797457|PROCEDURE|Prosthetic forehands|Prosthetic forehands
218943663|NCT00539175|DEVICE|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
218943664|NCT02694432|BEHAVIORAL|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
218943665|NCT02694432|BEHAVIORAL|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
218943666|NCT00125125|DRUG|Fluvastatin|
219051882|NCT01825369|DRUG|IV L-carnitine|See arm description
219051883|NCT06158880|BEHAVIORAL|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
219051884|NCT06158880|BEHAVIORAL|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
219634536|NCT00717834|BIOLOGICAL|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
219634537|NCT04566003|DRUG|[18F]GTP1|Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.
218943667|NCT02150902|PROCEDURE|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF \>10g, FTI \> 500 g-sec and minimum ablation duration \>10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
218943668|NCT02150902|PROCEDURE|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
218943669|NCT00977301|DRUG|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
218943670|NCT00977301|DRUG|olanzapine|15 mg olanzapine single dose
218943671|NCT00977301|DRUG|olanzapine|10 mg olanzapine single dose
218943672|NCT03480464|BEHAVIORAL|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
218943673|NCT05896280|PROCEDURE|EST|Stones are taken by cutting the papillary sphincter
218943674|NCT05896280|PROCEDURE|ECPP|During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
218943675|NCT01147627|DRUG|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
218943676|NCT01147627|DRUG|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
218943677|NCT01147627|DRUG|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
218943678|NCT06435065|DRUG|Biodentine|DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
218943679|NCT06435065|DRUG|Mineral Tri-Oxide Aggregate|DIRECT PULP CAPPINGWILL BE DONE USING MTA
218943680|NCT06435065|DRUG|THERACAL LC|DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
218943681|NCT06435065|DRUG|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
218943682|NCT00000460|BEHAVIORAL|Low intensity exercise|
218943683|NCT00000460|BEHAVIORAL|High intensity exercise|
218943684|NCT02779556|OTHER|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
218943685|NCT02779556|OTHER|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
218943686|NCT01344525|PROCEDURE|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
219051885|NCT06158880|BEHAVIORAL|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
219051886|NCT06158880|BEHAVIORAL|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
219634538|NCT04566003|DRUG|[18F]PI-2620|Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
219634539|NCT04566003|DRUG|[18F]MK-6240|Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
218943687|NCT01344525|PROCEDURE|Gastric Banding|Gastric Banding
218943688|NCT01344525|PROCEDURE|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
218943689|NCT01344525|PROCEDURE|Roux-en-Y Bypass|Roux-en-Y Bypass
219634540|NCT06383234|PROCEDURE|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
218943690|NCT04631211|BIOLOGICAL|Thrombosomes|Human platelet derived lyophilized hemostatic
218943691|NCT04631211|BIOLOGICAL|Liquid Stored Platelets (LSP)|Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)
218943692|NCT05857696|OTHER|walking quantified analysis|Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
219634541|NCT06383234|PROCEDURE|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
219634542|NCT06383234|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
218943693|NCT01145586|DRUG|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
218943694|NCT02223377|DRUG|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
218943695|NCT02223377|DRUG|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
218943696|NCT02216604|BEHAVIORAL|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
218943697|NCT05808569|BEHAVIORAL|Test|A specific self-test composed by 16 questions , will be administered to BC patients undergoing adjuvant RT.
218943698|NCT00942526|DRUG|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
218943699|NCT00942526|OTHER|Water|perioperative gargling with water
218943700|NCT03972943|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP treatment
218943701|NCT03972943|OTHER|Patient Observation|Undergo observation
218943702|NCT03972943|OTHER|Questionnaire Administration|Ancillary studies
218943703|NCT06110169|DEVICE|Anodal Transcranial Direct Current Stimulation (Anodal tDCS)|Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
218943704|NCT06110169|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of sham anodal tDCS
218943705|NCT00462397|DRUG|carboplatin|
218943706|NCT00462397|DRUG|cisplatin|
218943707|NCT00462397|DRUG|paclitaxel|
218943708|NCT00462397|PROCEDURE|neoadjuvant therapy|
218943709|NCT00462397|RADIATION|brachytherapy|
218943710|NCT00462397|RADIATION|radiation therapy|
218943711|NCT02901704|DEVICE|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
218943712|NCT02901704|PROCEDURE|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
218943713|NCT00846963|DRUG|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (\>33mmol/L) to the resolution of cholestasis (conjugated bilirubin \<34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
218943714|NCT00846963|DRUG|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
218943715|NCT03139591|DRUG|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
218943716|NCT00221468|DRUG|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
218943717|NCT04497051|DIAGNOSTIC_TEST|CT-DSA|CTA before and after embolization
218943718|NCT00194493|BEHAVIORAL|ESRA-C|Graphical summary of patient symptoms and quality of life
218943719|NCT03236662|DRUG|(-)-Epicatechin|
218943720|NCT02086396|DIETARY_SUPPLEMENT|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
218943721|NCT02086396|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
218943722|NCT02948036|OTHER|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
218943723|NCT03110770|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
218943724|NCT03110770|OTHER|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
218943725|NCT00892736|OTHER|Laboratory Biomarker Analysis|Correlative studies
218943726|NCT00892736|OTHER|Pharmacological Study|Correlative studies
218943727|NCT00892736|DRUG|Veliparib|Given PO
218943728|NCT03616808|OTHER|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
218943729|NCT00260962|DRUG|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
218943730|NCT00260962|BEHAVIORAL|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
219051887|NCT03098511|DIAGNOSTIC_TEST|Neurological Diagnostic Evaluation|"Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~\- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)"
219051888|NCT00086580|BIOLOGICAL|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
219634543|NCT03777592|PROCEDURE|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
218943731|NCT01623557|BIOLOGICAL|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.
218943732|NCT01623557|BIOLOGICAL|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.
218943733|NCT01623557|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
218943734|NCT05713149|OTHER|Surgical flap and anti-bacterial agents|Surgical flap and anti-bacterial agents
218943735|NCT01254162|DRUG|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
218943736|NCT04375462|DEVICE|AspireAssist device|"Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment"
218943737|NCT04375462|DEVICE|Standard decompressive PEG tube|"Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment"
218943738|NCT04375462|OTHER|gastric outlet obstruction scoring system (GOOSS) questionnaire|"Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call"
218943739|NCT04375462|OTHER|Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire|"Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call"
218943740|NCT04375462|OTHER|Patient satisfaction and ease of use survey|"Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call"
218943741|NCT00461474|BEHAVIORAL|Shoulder strengthening exercises|
218943742|NCT00461474|BEHAVIORAL|Movement Optimization|
218943743|NCT06092918|RADIATION|EXTERNAL RADIOTHERAPY|EXTERNAL RADIOTHERAPY
218943744|NCT01767142|DEVICE|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
218943745|NCT05693012|DIAGNOSTIC_TEST|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
218943746|NCT05637528|DIAGNOSTIC_TEST|MRI|Patients will undergo an MRI and mammography one year after MagTrace injections
218943747|NCT03753945|DIAGNOSTIC_TEST|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
218943748|NCT03206281|DIAGNOSTIC_TEST|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
218943749|NCT04494100|PROCEDURE|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
218943750|NCT04494100|PROCEDURE|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
218943751|NCT04494100|PROCEDURE|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
218943752|NCT04494100|DRUG|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
218943753|NCT04494100|DRUG|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
218943754|NCT04655196|OTHER|SOLUS-D + weekly feedback by a coach|internet-based self-help
218943755|NCT04655196|OTHER|SOLUS-D + weekly automated messages|internet-based self-help
218943756|NCT01996839|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
218943757|NCT01996839|DRUG|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
218943758|NCT01996839|DRUG|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
218943759|NCT01996839|DRUG|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
218943760|NCT02508558|OTHER|motion perception and locomotor operation performance measurements|
218943761|NCT02508558|OTHER|parabolic flight|
218943762|NCT00154089|DRUG|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
218943763|NCT00742833|DRUG|KUC-7483|
218943764|NCT00742833|DRUG|Placebo|
219634544|NCT04037163|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
218943765|NCT03142685|DEVICE|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
218943766|NCT05873166|OTHER|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
218943767|NCT05873166|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
218943768|NCT01919281|BEHAVIORAL|strength training|
218943769|NCT01919281|BEHAVIORAL|interval training|
218943770|NCT02820532|DEVICE|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
218943771|NCT02082340|BEHAVIORAL|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
218943772|NCT02082340|OTHER|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
218943773|NCT02082340|OTHER|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
218943774|NCT02082340|BEHAVIORAL|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
218943775|NCT02082340|BEHAVIORAL|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
218943776|NCT01814709|DRUG|GDC-0032|Oral doses of GDC-0032
219634545|NCT02027545|BEHAVIORAL|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
218943777|NCT01814709|DRUG|Itraconazole|Oral doses of Itraconazole
218943778|NCT01814709|DRUG|Rifampin|Oral doses of Rifampin
218943779|NCT01625260|BIOLOGICAL|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
218943780|NCT01625260|DRUG|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
218943781|NCT01024309|PROCEDURE|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
218943782|NCT01024309|PROCEDURE|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
219634546|NCT02027545|BEHAVIORAL|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
219634547|NCT02027545|BEHAVIORAL|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
219634548|NCT02027545|BEHAVIORAL|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
218943783|NCT00239252|DRUG|Interferon alfacon-1|
218943784|NCT01412489|DEVICE|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
218943785|NCT00155675|DRUG|GUSUIBU|
218943786|NCT05067309|DRUG|Letrozole 2.5mg|Missed abortion received letrozole then misoprostol
218943787|NCT04872140|DIETARY_SUPPLEMENT|Low phytate pea powder|Exercise performance with low phytate pea powder
218943788|NCT04872140|DIETARY_SUPPLEMENT|Regular pea powder|Exercise performance with regular pea powder
218943789|NCT04872140|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
218943790|NCT04382014|DIETARY_SUPPLEMENT|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
218943791|NCT06445452|BEHAVIORAL|Direct SNAP-Ed|Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
218943792|NCT00561626|DIETARY_SUPPLEMENT|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
218943793|NCT00561626|DIETARY_SUPPLEMENT|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
218943794|NCT03236324|DEVICE|ultrasound-guided nerve block|Transversalis fascia plane (TFP) block, ultrasound-guided
218943795|NCT03236324|DRUG|Saline|20 mL 0.9% saline administered on each side as bilateral TFP blocks
218943796|NCT03236324|DRUG|Bupivacaine-epinephrine|20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
218943797|NCT04950296|OTHER|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
218943798|NCT04950296|OTHER|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
218943799|NCT04950296|OTHER|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
218943800|NCT00450125|OTHER|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
218943801|NCT00450125|OTHER|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
218943802|NCT02737891|DRUG|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
218943803|NCT02737891|DRUG|Placebo|
218943804|NCT04264832|OTHER|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
218943805|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
219634549|NCT04998617|OTHER|Toothpaste with curcumin|Subjects will be given toothpaste to be used during this study with 0.5% curcumin
218943806|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
218943807|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
218943808|NCT05166837|DRUG|Placebo|Intravenous injection
218943809|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
218943810|NCT05166837|DRUG|Placebo|Intravenous injection
218943811|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
218943812|NCT05166837|DRUG|Placebo|Intravenous injection
218943813|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
218943814|NCT05166837|DRUG|Placebo|Intravenous injection
218943815|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
218943816|NCT05166837|DRUG|Placebo|Intravenous injection
218943817|NCT02073344|PROCEDURE|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
218943818|NCT02073344|OTHER|no intervention|no renal replacement therapy
218943819|NCT00165815|DRUG|ARICEPT|
218943820|NCT04459208|DEVICE|Manta|plug-based vascular closure
218943821|NCT04459208|DEVICE|ProGlide|suture-based vascular closure
219051889|NCT00086580|BIOLOGICAL|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
219051890|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
218943822|NCT02895126|BEHAVIORAL|"Appui Parental program"|
218943823|NCT02895126|BEHAVIORAL|Regular parental support|
218943824|NCT01529138|DRUG|Axitinib|Combination treatment with temsirolimus and axitinib
218943825|NCT01529138|DRUG|Temsirolimus|Combination treatment with temsirolimus and axitinib
218943826|NCT03890666|DRUG|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
218943827|NCT03890666|DRUG|albuterol|Standard of care albuterol-administering rescue inhaler
218943828|NCT02152280|DRUG|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
218943829|NCT02152280|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
218943830|NCT00131053|DRUG|Methotrexate|
218943831|NCT00131053|DRUG|Prednisolone|
218943832|NCT00131053|DRUG|Dexamethasone|
218943833|NCT00131053|DRUG|Vincristine|
218943834|NCT00131053|DRUG|Pirarubicin|
218943835|NCT00131053|DRUG|Cyclophosphamide|
218943836|NCT00131053|DRUG|L-asparaginase|
218943837|NCT00131053|DRUG|Cytarabine|
218943838|NCT00131053|DRUG|Hydrocortisone|
218943839|NCT00131053|DRUG|Mercaptopurine|
218943840|NCT05830617|DEVICE|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
218943841|NCT05830617|DEVICE|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
218943842|NCT00586092|DRUG|bevacizumab, ABT-510|"* Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
218943843|NCT02368561|DRUG|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
218943844|NCT01639729|DRUG|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
218943845|NCT01639729|DRUG|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
218943846|NCT01639729|DRUG|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
218943847|NCT01639729|DRUG|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
218943848|NCT02373085|OTHER|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
218943849|NCT03629314|OTHER|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
218943850|NCT02607748|OTHER|18F-NaF PET and coronary CTA imaging|
219051891|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
219634550|NCT04998617|OTHER|Toothpaste without curcumin|Subjects will be given toothpaste to be used during this study without curcumin
219634551|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
218943851|NCT02074891|DRUG|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
218943852|NCT00607490|BEHAVIORAL|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
218943853|NCT00607490|BEHAVIORAL|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
218943854|NCT02120040|OTHER|evaluation of anxiety with psychosocial scales|
218943855|NCT02524613|OTHER|Pelvis CT scan|
218943856|NCT02166944|DRUG|tamoxifen 40 mg daily for one year|both arms with riluzole daily
218943857|NCT00567255|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
218943858|NCT00567255|DRUG|Placebo|
218943859|NCT00567255|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
218943860|NCT05642650|DEVICE|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
218943861|NCT01780220|DRUG|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
218943862|NCT05246865|DRUG|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
218943863|NCT06243562|OTHER|combined exercises and progressive muscle relaxation group|Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
218943864|NCT06243562|OTHER|combined exercises group|Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
218943865|NCT04678076|DRUG|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
219051892|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
219051893|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
219051894|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
219051895|NCT02965612|DEVICE|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
219051896|NCT02965612|PROCEDURE|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
219051897|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
219051898|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
219634552|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
219634553|NCT02772172|DEVICE|Surgical Template|
219634554|NCT01017276|DRUG|ASP1585|oral
218943866|NCT04678076|DRUG|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
218943867|NCT03141996|OTHER|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
219634555|NCT00693498|BIOLOGICAL|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
219634556|NCT00693498|BIOLOGICAL|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
219634557|NCT02452632|DRUG|ASP1941|oral
218943868|NCT03141996|OTHER|Standard of Care|Standard of care treatment
218943869|NCT05282745|OTHER|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
218943870|NCT03052426|DEVICE|Ergotron WorkFit - TL|A sit to stand work station.
218943871|NCT00907179|DRUG|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
218943872|NCT00907179|DRUG|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
218943873|NCT05624333|OTHER|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
219051899|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
219051900|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
219051901|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
219051902|NCT01670929|DRUG|Progesterone|
219051903|NCT01670929|OTHER|Placebo|
219051904|NCT00807534|DRUG|ipratropium bromide|ipratropium bromide nebulization
219051905|NCT00807534|DRUG|placebo|placebo nebulization
219051906|NCT00807534|BEHAVIORAL|constant rate step test|nebulization of 500ug
219634558|NCT02452632|DRUG|Placebo|oral
219634559|NCT04128969|DIETARY_SUPPLEMENT|CS+|Oral carnitine supplementation
219634560|NCT04128969|DIETARY_SUPPLEMENT|CS-|Placebo
219634561|NCT00950443|DEVICE|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
219634562|NCT00950443|DEVICE|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
219634567|NCT02693106|DIETARY_SUPPLEMENT|Control|Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.
219634568|NCT02693106|DIETARY_SUPPLEMENT|Leucine|Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.
219634569|NCT02693106|DIETARY_SUPPLEMENT|Butyrate -|Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.
218943874|NCT05624333|OTHER|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
218943875|NCT00314587|PROCEDURE|1 or 2 elastic stable intramedullary nails|
218943876|NCT01692821|DRUG|100% oxygen breathing|100% oxygen breathing - 30 minutes
218943877|NCT01692821|DRUG|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
218943878|NCT01692821|DRUG|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
218943879|NCT00108368|DRUG|Risperidone|
218943880|NCT00108368|DRUG|Olanzapine|
218943881|NCT04276376|DRUG|Atezolizumab|Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
218943882|NCT04276376|DRUG|Rucaparib|Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
218943883|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
218943884|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
218943885|NCT02780011|DRUG|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
218943886|NCT02780011|DRUG|Alsertib|Aurora A kinase inhibitor
219634570|NCT02693106|DIETARY_SUPPLEMENT|Butyrate +|Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.
219634571|NCT02693106|DIETARY_SUPPLEMENT|Octanoate -|Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
219634572|NCT02693106|DIETARY_SUPPLEMENT|Octanoate +|Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.
219634573|NCT02693106|DIETARY_SUPPLEMENT|Carnitine|Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.
218943887|NCT01093703|OTHER|Medication Adjustment|"1. Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~2. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~3. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~4. Awake SBP\>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
218943888|NCT00077090|DRUG|hyperbaric oxygen|
219634574|NCT02693106|DIETARY_SUPPLEMENT|Butter fraction|Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
219634575|NCT04020692|BEHAVIORAL|EOPC Intervention|"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization."
219634576|NCT03104049|DEVICE|Neuromuscular taping|"NMT applications:~1. rhomboid major muscle~2. muscles abdominals~3. spinal muscles~4. pectoralis major muscles~5. gastrocnemius muscle~6. upper trapezius muscle~7. anterior muscles of the neck"
219634577|NCT01564888|PROCEDURE|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
219634578|NCT06960603|OTHER|Full pulpotomy|First: Cutting the coronal pulp tissue to the level of the root canal orifices. Second: Followed by taking samples of the pulpal blood Third: Placement of calcium silicate material capping over the pulp
218943889|NCT02166671|BIOLOGICAL|HBV booster vaccination 1dose|
218943890|NCT04309097|BEHAVIORAL|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
218943891|NCT04309097|BEHAVIORAL|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
219051907|NCT00807534|BEHAVIORAL|constant rate shuttle walk test|nebulization of 500ug
218943892|NCT02031965|BIOLOGICAL|oncolytic HSV-1716|Given IT
218943893|NCT02031965|DRUG|dexamethasone|Given IV
218943894|NCT02031965|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
218943895|NCT02031965|OTHER|laboratory biomarker analysis|Correlative studies
219051908|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219051909|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219051910|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
219051911|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
219051912|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
219051913|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
219051914|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
219051915|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
219051916|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
219051917|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
219051918|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
219051919|NCT00002816|DRUG|cytarabine|Given IV
219634579|NCT06622876|DIAGNOSTIC_TEST|Computed tomography exam of the chest|Computed tomography exam of the chest done for other indications other than pulmonary emboli, in which incidental pulmonary embolism was detected.
219051920|NCT00002816|DRUG|dexamethasone|Given IV
219051921|NCT00002816|DRUG|etoposide|Given IV
219051922|NCT00002816|DRUG|idarubicin|Given IV
219051923|NCT00002816|DRUG|ifosfamide|Given IV
219634580|NCT03924401|DRUG|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
219634581|NCT05070949|BEHAVIORAL|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
219634582|NCT06483178|DEVICE|Attune knee implant|Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
219634583|NCT06483178|DEVICE|Triathlon knee implant|Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
219634584|NCT02509507|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
219634585|NCT02509507|DRUG|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
219634586|NCT00869102|DRUG|GLP-1|intravenous, 124,5 pmol/kg body weight
219634587|NCT00857675|DRUG|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
219634588|NCT00857675|DRUG|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
219634589|NCT00857675|DRUG|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
219634590|NCT00758901|DEVICE|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
219634591|NCT00287040|BEHAVIORAL|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
219634592|NCT05684991|DIETARY_SUPPLEMENT|KMS-66 Ashwagandha 300mg|One capsule is taken by mouth twice daily with water
219634593|NCT05684991|DIETARY_SUPPLEMENT|placebo capsule|One capsule is taken by mouth twice daily with water
219634594|NCT00302848|DRUG|Drospirenone|
219634595|NCT00302848|DRUG|Levonorgestrel|
219051924|NCT00002816|DRUG|leucovorin calcium|
219051925|NCT00002816|DRUG|mesna|Given IV
219051926|NCT00002816|DRUG|pegaspargase|Given IV
219051927|NCT00002816|DRUG|therapeutic hydrocortisone|
219051928|NCT00002816|DRUG|thioguanine|
219051929|NCT00002816|DRUG|vincristine sulfate|Given IV
219051930|NCT00002816|RADIATION|low-LET cobalt-60 gamma ray therapy|
219051931|NCT00002816|RADIATION|low-LET electron therapy|
219051932|NCT00002816|RADIATION|low-LET photon therapy|
219051933|NCT00002816|DRUG|Methotrexate|Given IV
219051934|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
219051935|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
219051936|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
219051937|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
219051938|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
219051939|NCT02561507|BEHAVIORAL|Survey|
219051940|NCT01978431|DRUG|cocaine hydrochloride|
219051941|NCT01978431|DRUG|methylphenidate|
219634596|NCT00302848|DRUG|Other progestin containing oral contraceptive|
218943896|NCT03207165|DRUG|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
218943897|NCT03207165|DRUG|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
218943898|NCT04699136|OTHER|6 minutes step test (ST6)|Performing a 6 minutes step test at different intervals and comparing with respect with the 6 minutes walk test and cardiac stress test
218943899|NCT02942732|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
218943900|NCT03083990|BIOLOGICAL|IBI305(Bevacizumab Biosimilar)|3mg/kg, infusion in 90minutes
218943901|NCT03083990|DRUG|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
219051942|NCT05199857|BEHAVIORAL|WE BEAT Group Wellness Education program - phase 1|Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
219051943|NCT05199857|BEHAVIORAL|HEART Club Home Exercise program - phase 2|This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
219051944|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
219051945|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
219051946|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
219051947|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
219051948|NCT01552538|DEVICE|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
219051949|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
219634597|NCT02647957|PROCEDURE|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
219634598|NCT05663112|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
219634599|NCT05663112|PROCEDURE|Breast massage|Breast massage will be performed for a duration of 5 minutes.
218943902|NCT05246085|DIAGNOSTIC_TEST|Cortisol level|Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
218943903|NCT03502356|DRUG|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
218943904|NCT04145219|BIOLOGICAL|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
218943905|NCT04145219|OTHER|Placebo|For daily administration (1 tablet per day)
218943906|NCT03672097|DRUG|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
218943907|NCT01290796|DEVICE|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
219051950|NCT02665728|DRUG|BLI400 Laxative|
219051951|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
219051952|NCT01178970|BEHAVIORAL|Resistance training|
219051953|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
219051954|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
219051955|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
219051956|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
219051957|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
219051958|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
219051959|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
219051960|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
219051961|NCT00191893|DRUG|teriparatide|
219051962|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
219051963|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
218943908|NCT03346642|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
218943909|NCT03346642|DRUG|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
218943910|NCT03346642|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
218943911|NCT02753257|OTHER|Non-Interventional|Non-Interventional
218943912|NCT04765085|BEHAVIORAL|comprehensive behavioral intervention therapy (CBIT)|"Comprehensive behavioral intervention for tics is an extension of habit reversal training. It includes an expanded set of strategies, such as psycho-education about tic disorders, tic awareness training, competing response training, relaxation training, and functional analysis.~According to the CBIT treatment manual (translated by sun Jinhua and Xu Wen, the author were Douglas W. woods et al., Oxford University Press, New York). The treatments consisted of 8 sessions for 10 weeks The first two phases were 1.5 hours, the last six stages were 1 hour.The treatment process was regularly supervised by a treatment supervisor."
218943913|NCT04765085|DRUG|Aripiprazole 5Mg Oral Tablet|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
218943914|NCT01920685|OTHER|Anxiety intervention|
218943915|NCT05788471|OTHER|conventional Treatment|It consists of Superficial heat, Ultrasound therapy and stretching exercise to lumbrical muscles of the hand.
218943916|NCT05788471|OTHER|Neurodynamic mobilization|It is the mobilisation of the nervous system as an approach to physical treatment of pain. The treatment and or assessment relies on influencing pain physiology via the mechanical treatment of neural tissues and non-neural structures surrounding the nervous system.
219634600|NCT05663112|PROCEDURE|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
218943917|NCT04332861|OTHER|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers"
218943918|NCT03122951|DIAGNOSTIC_TEST|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
219051964|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
219051965|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
218943919|NCT02909608|OTHER|No interventions / observations only|This is an observational study only
219051966|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
219051967|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
219051968|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
218943920|NCT06396910|DIAGNOSTIC_TEST|Spatial transcriptomics|Localize immune transcripts in the pulmonary lessions of sarcoidosis and tuberculosis patients. This is done in biopsies from pathological libraries.
219051969|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
219206838|NCT06764797|DEVICE|Transcranial Direct Current Stimulation|tDCS will be used during the sessions. The anodal tDCS (2 mA) will be applied for 20 minutes. Continuous, direct currents. The anodal electrode will be positioned over the ipsilesional primary motor cortex (M1) (C3 or C4, international 10-20 system) of the affected hemisphere and the cathodal electrode over the contralateral orbit.
219206839|NCT06764797|DEVICE|Virtual reality|The VRMT group will receive VRMT game-based training using their non-affected upper limb. using a semi-immersive motion-tracking device.
219206840|NCT06764797|DEVICE|Transcranial Direct Current Stimulation compined with virtual reality based mirror therapy|20 minutes of tDCS during 45 minutes of VRMT games.
219634601|NCT02221336|DEVICE|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
219634602|NCT02221336|DEVICE|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
219634603|NCT04220788|OTHER|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
219634604|NCT04220788|OTHER|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
219634605|NCT00938769|OTHER|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
219634606|NCT00938769|OTHER|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
219634607|NCT03357068|PROCEDURE|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
218943921|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin I
218943922|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin II
218943923|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula without Inulin
218943924|NCT05953233|OTHER|Active classroom HEPA cleaner|Commercially available portable HEPA cleaner
219051970|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
218943925|NCT05953233|OTHER|Sham classroom HEPA cleaner|Commercially available portable HEPA cleaner with filtration device removed
218943926|NCT05192447|BEHAVIORAL|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
218943927|NCT05682222|DRUG|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
218943928|NCT05682222|DRUG|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
218943929|NCT05682222|DRUG|Placebo oral capsule|Placebo.
218943930|NCT00079365|DRUG|fluorouracil|
219051971|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
219051972|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
219051973|NCT02247349|BIOLOGICAL|Nivolumab|
219051974|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
219051975|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
219051976|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
219634608|NCT03357068|PROCEDURE|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
219634609|NCT02464592|PROCEDURE|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
219634610|NCT02268292|BEHAVIORAL|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
219634611|NCT02360969|OTHER|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS \<50 Deep anesthesia and muscle relaxation: BIS \<50 and TOF 0/4"
219051977|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
219051978|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
219634612|NCT02386267|DRUG|L-leucine|L-leucine pills per os for 6 months
218943931|NCT00079365|DRUG|gemcitabine hydrochloride|
218943932|NCT00079365|RADIATION|brachytherapy|
218943933|NCT00079365|RADIATION|phosphorus P32|
218943934|NCT00079365|RADIATION|radiation therapy|
218943935|NCT05712707|DRUG|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
219051979|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
219206841|NCT06764797|OTHER|Conventional physical therapy|45 minutes of conventional physical therapy with sham tDCS
219051980|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
218943936|NCT05712707|DRUG|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
218943937|NCT05712707|OTHER|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
218943938|NCT05712707|OTHER|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
218943939|NCT02992444|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
218943940|NCT02992444|OTHER|Experimental adhesive strip|This is a strip of a newly developed adhesive.
218943941|NCT04975438|DRUG|GSK1070806|GSK1070806 will be administered
219051981|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
219051982|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
219051983|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
219051984|NCT02211833|DRUG|BI 2536|
219051985|NCT02211833|DRUG|Pemetrexed|
219051986|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
219051987|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
219051988|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
218943942|NCT04975438|DRUG|Placebo|Placebo will be administered
218943943|NCT03251313|COMBINATION_PRODUCT|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
218943944|NCT03251313|COMBINATION_PRODUCT|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
218943945|NCT03251313|COMBINATION_PRODUCT|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
219051989|NCT00821626|OTHER|Control|No rapid flu test
219051990|NCT06249308|OTHER|Blood collection|Blood sample will be collected
219634613|NCT04850417|DRUG|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
219634614|NCT02779010|BEHAVIORAL|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
218943946|NCT03251313|COMBINATION_PRODUCT|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
219634615|NCT01757002|BEHAVIORAL|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
218943947|NCT04145232|BIOLOGICAL|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
218943948|NCT00534482|BEHAVIORAL|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
218943949|NCT00534482|BEHAVIORAL|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
219051991|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
219051992|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
219051993|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
219051994|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
219051995|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
219051996|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
219051997|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
219051998|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
219051999|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
219634616|NCT01757002|BEHAVIORAL|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
219052000|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
219634617|NCT02510664|BEHAVIORAL|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
218943950|NCT00534482|BEHAVIORAL|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
218943951|NCT00534482|BEHAVIORAL|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
218943952|NCT03555019|DIETARY_SUPPLEMENT|Formulaid|Supplementation with ARA and DHA
218943953|NCT03555019|DIETARY_SUPPLEMENT|MCT-oil|Supplementation with medium chain fatty acids
218943954|NCT00010452|DRUG|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
218943955|NCT00226759|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
219052001|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
219052002|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
219052003|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
219052004|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
219634618|NCT00474071|DRUG|Remifentanil|See Detailed Description.
219634619|NCT04394780|PROCEDURE|cooling|First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
219634620|NCT05600231|OTHER|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
219634621|NCT05600231|OTHER|LISTERINE COOL MINT ZERO Alcohol Mouthwash|Participants will use LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 second after brushing teeth twice daily.
219634622|NCT05600231|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 timed minute, will rinse mouth with water and Floss once a day.
219052005|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
219052006|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
219634623|NCT05600231|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
219634624|NCT02021344|BEHAVIORAL|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
219634625|NCT03097757|RADIATION|Ultrasound - guided fracture reduction|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
219634626|NCT03097757|PROCEDURE|Standard of care fracture reduction|Closed reduction of a fractured bone.
219634627|NCT02259374|PROCEDURE|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
218943956|NCT00226759|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
218943957|NCT06341920|BEHAVIORAL|Experimental: BoneFit intervention|Exercise, nutrition and psychological support provided in 8 weeks prior to surgery
218943958|NCT06341920|BEHAVIORAL|Placebo Comparator: Control|Control group receive usual care (zero intervention)
218943959|NCT01518270|OTHER|No treatment|No treatment will be provided
218943960|NCT04162691|DIAGNOSTIC_TEST|Tissue|Four 4-5 mm tissues of the thymoma
218943961|NCT01098643|OTHER|computer-assisted intervention|
218943962|NCT01098643|OTHER|medical chart review|
218943963|NCT01098643|OTHER|questionnaire administration|
218943964|NCT01098643|OTHER|survey administration|
218943965|NCT01168986|OTHER|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
218943966|NCT01168986|OTHER|Exercise|Participants perform an exercise to strengthen the deep neck flexors
218943967|NCT02842190|DEVICE|NIPPV|after ekstubation
218943968|NCT00079027|DRUG|doxorubicin hydrochloride|
218943969|NCT00079027|PROCEDURE|hepatic artery embolization|
219634628|NCT02259374|PROCEDURE|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
219634629|NCT02237469|RADIATION|Prone and supine simulation|Treatment planning in the two positions.
218943970|NCT00220129|DRUG|Epirubicin, Cisplatin, Capecitabine|
218943971|NCT00220129|PROCEDURE|Surgical Resection|
218943972|NCT03739021|DRUG|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
218943973|NCT03739021|DRUG|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
218943974|NCT04267484|DEVICE|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
218943975|NCT04267484|OTHER|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
218943976|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
218943977|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
218943978|NCT01280877|DEVICE|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
218943979|NCT01280877|DEVICE|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
218943980|NCT02246413|BEHAVIORAL|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
218943981|NCT05241977|PROCEDURE|anterior supra scapular nerve block|nerve block for postoperative pain
218943982|NCT06287177|DRUG|Inclisiran|Injection
218943983|NCT05826171|BEHAVIORAL|High-Intensity Aerobic Exercise Prior to Balance Training|20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
218943984|NCT05826171|BEHAVIORAL|Low-Intensity Exercise Prior to Balance Training|"20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components."
219052007|NCT05256433|OTHER|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
219634630|NCT05111912|DRUG|XW003|XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.
219634631|NCT05111912|DRUG|Saxenda|If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).
219634632|NCT05455541|DIAGNOSTIC_TEST|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
219634633|NCT00004043|DIETARY_SUPPLEMENT|calcitriol|
219634634|NCT00680095|DRUG|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
219634635|NCT00680095|DRUG|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
219634636|NCT00680095|DRUG|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
219634637|NCT00680095|OTHER|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
219634638|NCT00680095|OTHER|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
219052008|NCT05256433|OTHER|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
219052009|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
219052010|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
219052011|NCT00079274|DRUG|oxaliplatin|Given IV
219052012|NCT00079274|DRUG|leucovorin calcium|Given IV
219052013|NCT00079274|DRUG|fluorouracil|Given IV
219634639|NCT01097889|DIETARY_SUPPLEMENT|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
219052014|NCT00079274|BIOLOGICAL|cetuximab|Given IV
219052015|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
219052016|NCT02353481|OTHER|Heart Failure Management|
219052017|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
219052018|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
219052019|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
219052020|NCT01228240|DRUG|Metformin|
219052021|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
219052022|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
219052023|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
219052024|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
219052025|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
219052026|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
219052027|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
219052028|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
219052029|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
219052030|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
219634640|NCT01097889|DIETARY_SUPPLEMENT|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
219052031|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
219052032|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
219052033|NCT06309875|OTHER|Conventional care|Description Conventional care
219052034|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
219052035|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
219052036|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
219634641|NCT00618644|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
219052037|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
219052038|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
219052039|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
219052040|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
219052041|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
219052042|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
219052043|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
219052044|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
219052045|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
219634642|NCT02617160|DEVICE|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
219634643|NCT02617160|OTHER|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
218943985|NCT06516419|DRUG|Concentrated secretome Injection 2mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
218943986|NCT06516419|DRUG|Tranexamic acid injection|"1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2\. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject"
218943987|NCT06516419|DRUG|Triple Combination Cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
218943988|NCT03279562|DRUG|Nalmefene|Educational and behaviorally oriented drug counseling
218943989|NCT03966638|PROCEDURE|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
218943990|NCT00918788|OTHER|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
218943991|NCT00918788|OTHER|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
218943992|NCT00918788|OTHER|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC).
218943993|NCT00918788|OTHER|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
218943994|NCT00918788|PROCEDURE|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
218943995|NCT00918788|PROCEDURE|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
218943996|NCT00918788|PROCEDURE|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
218943997|NCT00512980|DRUG|prednisone|
218943998|NCT00512980|DRUG|vinblastine|
218943999|NCT00512980|DRUG|doxorubicin|
218944000|NCT00512980|DRUG|gemcitabine|
218944001|NCT02481128|PROCEDURE|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
218944002|NCT02129088|DRUG|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
218944003|NCT02129088|DRUG|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
218944004|NCT03453138|DEVICE|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
218944005|NCT03453138|DEVICE|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
218944006|NCT01794286|OTHER|Provider bulletins|
218944007|NCT01794286|OTHER|Trigger alerts|
218944008|NCT03803319|DIETARY_SUPPLEMENT|Fibre 1 (combined fibres)|Dietary fibre supplement
218944009|NCT03803319|DIETARY_SUPPLEMENT|Fibre 2 (natural fibres)|Dietary fibre supplement
218944010|NCT03803319|DIETARY_SUPPLEMENT|Dietary Supplement: placebo|Dietary supplement
218944011|NCT02745015|PROCEDURE|non-surgical periodontal treatment|full-mouth scaling and root planing
219052046|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
218944012|NCT04695808|BEHAVIORAL|yoga|Yoga practice will be done two days a week for 10 weeks.
218944013|NCT01950013|BEHAVIORAL|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
218944014|NCT01950013|BEHAVIORAL|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
218944015|NCT00275340|OTHER|Peer Support|
218944016|NCT00004908|DRUG|cyclophosphamide|
218944017|NCT00004908|PROCEDURE|peripheral blood stem cell transplantation|
218944018|NCT00004908|RADIATION|radiation therapy|
218944019|NCT00002771|BIOLOGICAL|recombinant interferon alfa|
218944020|NCT00002771|DRUG|busulfan|
218944021|NCT00002771|DRUG|cytarabine|
218944022|NCT00002771|DRUG|hydroxyurea|
218944023|NCT00002771|DRUG|idarubicin|
219052047|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
219052048|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
219052049|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
219052050|NCT03808285|OTHER|mandibular osteomylitis|
219052051|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
219052052|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
219052053|NCT00003196|DRUG|chemotherapy|Undergo cytoreductive chemotherapy
219052054|NCT00003196|RADIATION|total-body irradiation|Undergo TBI
219052055|NCT00003196|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
219052056|NCT00003196|DRUG|cyclosporine|Given IV or PO
219052057|NCT00003196|DRUG|mycophenolate mofetil|Given PO
219052058|NCT00003196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
219052059|NCT00003196|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
219052060|NCT05251181|DRUG|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
219052061|NCT05251181|DRUG|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
219052062|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
219052063|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
219052064|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
219052065|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
218944024|NCT00002771|PROCEDURE|allogeneic bone marrow transplantation|
218944025|NCT00002771|PROCEDURE|autologous bone marrow transplantation|
218944026|NCT00002771|PROCEDURE|peripheral blood stem cell transplantation|
218944027|NCT00002771|RADIATION|radiation therapy|
219052066|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
218944028|NCT00851227|DRUG|conivaptan hydrochloride|intravenous
218944029|NCT02751385|DRUG|Microgynon|
218944030|NCT02751385|DRUG|Nintedanib|
218944031|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
219052067|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
218944032|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
218944033|NCT06143904|DRUG|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
218944034|NCT04360382|OTHER|ERACS|Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
218944035|NCT04360382|OTHER|Regular care|Usual care for all cases subjected to cesarean section at our hospital.
218944036|NCT01798849|DRUG|MK-8892|
218944037|NCT01798849|DRUG|Placebo for MK-8892|
218944038|NCT05178797|OTHER|Kinesiology taping technique with exercise therapy|Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
218944039|NCT05178797|OTHER|Compression decongestive therapy|"It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma."
218944040|NCT05927337|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for managing Obesity|Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
218944041|NCT04388462|OTHER|Finite element analysis|Biomechanical study to describe micromotion
218944042|NCT00335764|DRUG|sorafenib tosylate|given orally
218944043|NCT00335764|DRUG|erlotinib hydrochloride|given orally
218944044|NCT00335764|DRUG|tipifarnib|given orally
218944045|NCT00335764|DRUG|temsirolimus|IV administration
218944046|NCT01442844|DEVICE|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
218944047|NCT00460291|DEVICE|Implantation of the ProVena vein graft during bypass surgery|
218944048|NCT01383148|BIOLOGICAL|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
218944049|NCT01383148|DRUG|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1"
218944050|NCT00363701|DRUG|esomeprazole|
218944051|NCT02466659|DEVICE|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
218944052|NCT02937402|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
218944053|NCT02937402|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
218944054|NCT00744302|DRUG|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
218944055|NCT00929643|OTHER|no intervention|success of the initial empiric treatment
218944056|NCT02212184|OTHER|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
218944057|NCT02212184|OTHER|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
218944058|NCT04541771|DRUG|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
218944059|NCT04541771|DRUG|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
218944060|NCT00339001|DRUG|erythropoietin and early iron supplements|
218944061|NCT00466141|BEHAVIORAL|Increased Exercise for weight loss maintenance|
218944062|NCT00466141|BEHAVIORAL|Daily Self-weighing for weight loss maintenance|
218944063|NCT00466141|BEHAVIORAL|Education for weight loss maintenance|
218944064|NCT06462105|DRUG|Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection|"Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable."
218944065|NCT04032509|OTHER|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
218944066|NCT03464175|DEVICE|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
218944067|NCT03464175|DEVICE|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
218944068|NCT03464175|DEVICE|Heated-humidified circuit|It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
219634644|NCT04090060|BEHAVIORAL|Practice Self-/Companion Exams|300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.
219634645|NCT04090060|BEHAVIORAL|Control Arm|300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
219634646|NCT01508091|BEHAVIORAL|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
218944069|NCT03464175|DEVICE|Dry ventilator circuit specific for aerosol therapy|Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
218944070|NCT03464175|DEVICE|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
219634647|NCT01508091|BEHAVIORAL|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
218944071|NCT04735640|BEHAVIORAL|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
218944072|NCT04735640|BEHAVIORAL|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
218944073|NCT04346719|DEVICE|10 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
218944074|NCT04346719|DEVICE|20 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
218944075|NCT04346719|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
218944076|NCT00864695|OTHER|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
218944077|NCT04716296|DRUG|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
218944078|NCT04716296|DRUG|Saline|Saline will be given for the second stage of the DBS surgery.
218944079|NCT00171522|DRUG|Tegaserod and Polyethylene Glycol 3350|
218944080|NCT00750152|DRUG|NAFT-500|topical cream application up to 4 weeks
218944081|NCT00750152|DRUG|Placebo|placebo cream applied for up to 4 weeks
219052068|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
219052069|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
218944082|NCT02057081|BEHAVIORAL|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
218944083|NCT02057081|BEHAVIORAL|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
218944084|NCT03545425|PROCEDURE|Biofluid samplings|Blood and Urine
218944085|NCT02140593|DRUG|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
218944086|NCT02140593|DRUG|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
218944087|NCT03702413|PROCEDURE|Endovascular treatment|Acute thrombectomy
218944088|NCT05805618|BIOLOGICAL|Recombinant Norovirus Hexavalent Vaccine|To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17
218944089|NCT05805618|OTHER|Matching Placebo|matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
218944090|NCT02238184|DRUG|Atrovent®|
218944091|NCT02238184|DRUG|Ventilat®|
219634648|NCT04722068|OTHER|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
219052070|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
218944092|NCT02034409|DEVICE|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
218944093|NCT02034409|DEVICE|Sham Comparator|20 minutes daily for 48 weeks
218944094|NCT03365843|DEVICE|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
218944095|NCT03365843|OTHER|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
218944096|NCT01699867|DEVICE|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
218944097|NCT05673798|OTHER|initial chemotherapy response|Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
218944098|NCT00851162|BIOLOGICAL|Trinity multipotent stem cells|Enough to fill voids which vary in size
218944099|NCT00851162|BIOLOGICAL|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
219052071|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
219052072|NCT03208374|BEHAVIORAL|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
219052073|NCT03208374|BEHAVIORAL|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
219634649|NCT03956563|DEVICE|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
219052074|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
218944100|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
218944101|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
218944102|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
218944103|NCT06389799|DRUG|Pemigatinib|selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
218944104|NCT06389799|DRUG|Retifanlimab|PD-1 inhibitor, Intravenous infusion
219052075|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
219634650|NCT03956563|DEVICE|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
219634651|NCT02074358|DRUG|Apixaban|
219634652|NCT02074358|DRUG|Cofact (4-Factor PCC)|
219634653|NCT02074358|DRUG|Beriplex P/N (4-Factor PCC)|
219634654|NCT02074358|DRUG|Placebo (Saline solution)|
218944105|NCT06151210|DRUG|DA-5219|1 tablet/day
218944106|NCT06151210|DRUG|Stillen® Tab|3 tablets/day
218944107|NCT06151210|DRUG|DA-5219 Placebo|1 tablet/day
218944108|NCT06151210|DRUG|Stillen® Tab Placebo|3 tablets/day
218944109|NCT05737342|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
218944110|NCT05737342|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
218944111|NCT06291623|DRUG|Glycyrrhizin|used as intracanal medication for one week
218944112|NCT01229293|PROCEDURE|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
218944113|NCT01229293|PROCEDURE|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
218944114|NCT07003451|DIAGNOSTIC_TEST|Calprotectin Level|Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score
218944115|NCT04242238|DRUG|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
218944116|NCT04242238|DRUG|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
218944117|NCT06746688|BIOLOGICAL|ES2B-C001|Vaccine; Administration with or without \[adjuvant\] every third week for a total of five vaccinations.
218944118|NCT06746688|OTHER|ISA 51 VD|Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.
218944119|NCT06646614|BEHAVIORAL|Group Advance Care Planning Education|Those assigned to the group ACP arm will receive usual care and the intervention which consists of 2 virtual or in-person sessions for a total of 2 hours by a trained community health worker/health educator. Sessions will introduce advanced care planning, help veterans discuss their goals of care with their care teams and learn how to discuss with their families and oncologist, and filing an advanced directive. Participants will be surveyed and interviewed at baseline and again at 8 months post-enrollment.
218944120|NCT07099638|DRUG|Varenicline (VAR)|13 weeks of varenicline
218944121|NCT07099638|DRUG|Nicotine lozenge (NRT)|12 weeks of nicotine lozenges
218944122|NCT07099638|BEHAVIORAL|Smartphone intervention with adherence components (ADHERE)|Smartphone-based smoking cessation intervention with adherence components
218944123|NCT07099638|BEHAVIORAL|Smartphone intervention without adherence components (NO ADHERE)|Smartphone-based smoking cessation intervention without adherence components
218944124|NCT07099638|BEHAVIORAL|Telephone Counseling|Up to 6 telephone counseling sessions with a tobacco treatment specialist
218944125|NCT07145411|OTHER|Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)|The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
218944126|NCT07146919|DRUG|Bemarituzumab|"Part 1 Dose escalation part :~IV infusion, every 3 weeks with the dose :~DL1 = 15 mg/kg cycle 1 day 1, then 11 mg/kg thereafter from cycle 2 day 1 DL2 = 22 mg/kg cycle 1 day 1, then 15 mg/kg thereafter from cycle 2 day 1 DL3 = 30 mg/kg cycle 1 day 1, then 22 mg/kg thereafter from cycle 2 day 1~Part 2 Extension part :~IV infusion, every 3 weeks with the dose defined in the phase I dose escalation~Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first"
218944127|NCT07146919|DRUG|Bevacizumab|IV infusion, 15mg/kg, every 3 weeks. Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first
218944128|NCT07146607|BEHAVIORAL|Audiology text-message protocol|Florence is an interactive text messaging service, endorsed by NHS England, designed to improve clinical outcomes for patients. An audiology text-message protocol, delivered via Florence, will prepare, inform and support new NHS hearing aid users as they are prescribed, receive, and start to use their hearing aid(s).
218944129|NCT07145281|DRUG|Estradiol (E2)|"Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).~In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.~All participants are treatment-naive."
218944130|NCT07145281|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|"Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.~All participants are treatment-naive."
219052076|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
219052077|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
219052078|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
219634655|NCT03950414|BIOLOGICAL|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~* Low Dose Tier - Viral-Specific T cell infusion 5 x10\^3 cells/kg body weight(BW)~* Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10\^4 cells/kg BW~* High Dose Tier - Viral-Specific T cell infusion 2.5 x10\^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
219634656|NCT00053196|BIOLOGICAL|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
219634657|NCT00053196|BIOLOGICAL|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC\> 1000/uL for 3 consec days
219634658|NCT00053196|DRUG|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
219634659|NCT00053196|DRUG|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
219634660|NCT00053196|DRUG|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
219634661|NCT00053196|DRUG|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
219634662|NCT00053196|DRUG|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
219634663|NCT00053196|PROCEDURE|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
219634664|NCT00053196|DRUG|allopurinol|300 mg/day PO Days -8 thru -1
219634665|NCT00108017|DRUG|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
219634666|NCT00108017|DRUG|Comparator: timolol maleate|
219634667|NCT00108017|DRUG|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
219634668|NCT00108017|DRUG|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
219634669|NCT03337113|OTHER|Working Memory Training|The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
219634670|NCT03337113|OTHER|Sham Working Memory Training|In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
219634671|NCT03337113|DEVICE|repetitive Transcranial Magnetic Stimulation|"The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application."
219634672|NCT03337113|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
219634673|NCT01164579|DRUG|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
219634674|NCT01164579|DRUG|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
219634675|NCT01164579|DRUG|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
219634676|NCT06534853|OTHER|Post Facilitation Stretch|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
219634677|NCT06534853|OTHER|Reciprocal Inhibition|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
219634678|NCT06534853|OTHER|Conventional Physical Therapy|"A comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension.The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises"
219634679|NCT01580605|DRUG|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
219634680|NCT02927951|DRUG|Pregabalin|150mg bid
219634681|NCT02927951|DRUG|Placebo|150mg bid
219052079|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
219052080|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
219634682|NCT06409481|DRUG|Antineoplastic Agents|small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
219634683|NCT02165917|PROCEDURE|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
219634684|NCT02165917|PROCEDURE|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
219634685|NCT04557579|PROCEDURE|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
219634686|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
219634687|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
218944131|NCT06946706|DIAGNOSTIC_TEST|hydrogen and methane breath testing|The hydrogen and methane breath testingt(HMBT) is a non-invasive method based on gas analysis of gut microbiota metabolomics.Normal human metabolic processes do not produce methane and hydrogen, and all methane and hydrogen in exhaled breath come from metabolites produced during the fermentation of substrates by gut microbiota. About 14-21% of the gas can diffuse through the intestinal mucosa to the bloodstream, circulate through the bloodstream to the alveoli, and be exhaled through gas exchange.Based on substrate properties, separate and measure methane and hydrogen concentrations from exhaled breath for non-invasive, convenient, and accurate diagnosis of microbial imbalance/small intestine bacterial overgrowth (SIBO)
218944132|NCT06947070|PROCEDURE|To evaluate the surface topography and color stability of 3D printing provisional material.|Subjects with single stage implant placement followed by early non-functional loading with implant supported provisional restorations fabricated using 3D printing provisional material.
218944133|NCT06947759|RADIATION|PET/MRI|"This single-center prospective observational study targets patients pathologically diagnosed with nasopharyngeal carcinoma (NPC) and clinically staged as cT3-4/N2-N3. Participants will first undergo standard whole-body 18F-FDG PET/CT, followed by localized 18F-FDG PET/MRI of the head and neck within 4 hours. Both imaging procedures will be performed according to standard clinical protocols to ensure data consistency and comparability.~PET/MRI data will be independently interpreted by an experienced nuclear medicine physician and a radiologist. The sensitivity, specificity, and staging accuracy for detecting distant metastases will be analyzed. In cases of disagreement, a third physician will mediate to reach a consensus.~The study team will also record the operational time, direct costs, and potential issues encountered during the examination process for both imaging modalities. All participants will be followed for at least one year to validate imaging results and assess correlation"
218944134|NCT06946459|OTHER|Exercise|Participants in the Hip Strength Exercise Training group performed structured hip strengthening exercises using resistance bands in addition to their regular handball and strength training programs. The training was implemented three times per week for 8 weeks, with one rest day between sessions, and was conducted before regular handball practices. The exercises focused on activating and strengthening the hip muscles through simple, well-structured movements. Resistance bands were chosen due to their portability, cost-effectiveness, and suitability for adolescent athletes. This method ensured a safe training environment, reduced the risk of overload, and allowed for proper execution and control of the exercises.
218944135|NCT06947421|BEHAVIORAL|McKenzie Exercise|"Exercises will be performed in seated or supine positions, 15 repetitions per session, twice daily, for a total duration of 6 weeks. The program will begin with physiotherapist-supervised sessions and continue at home with guidance via a digital training manual. Weekly follow-up and progress will be ensured through individual exercise diaries. Participants missing two consecutive days of exercise will be excluded from the study. Includes:~* Cervical retraction in sitting and supine positions~* Cervical rotation to both sides~* Lateral flexion of the neck~* Combined chin rotation toward the shoulder"
218944136|NCT06947421|BEHAVIORAL|Standard Neck Exercise|"The protocol includes chin tucks, chin drop stretches, scapular retraction with resistance, and both unilateral and bilateral pectoral stretching. Exercises will be performed twice daily, 15 repetitions per session, over a period of 6 weeks. Exercise progression will be adapted biweekly based on participant tolerance. Includes:~* Chin tucks in supine with progressive hold durations~* Chin drop stretch in sitting with optional manual assistance~* Scapular retraction using theraband or weights~* Pectoral muscle stretching using doorway and seated techniques"
218944137|NCT06946953|BIOLOGICAL|P63+ lung progenitors|"1. Patient Screening and Cell Collection:~   Eligible patients will undergo sample collection at the study center or authorized tertiary hospitals. The operator will collect samples via bronchial brushing from three healthy segments of the patient's 3-5 level bronchi. The samples will be transported to a cooperative production facility for isolation and preparation. The cell preparation cycle is approximately 4-8 weeks. Patients will bear the costs of this process.~2. Transplantation Therapy:~   Transplantation therapy will be conducted at Ruijin Hainan Hospital. The cell preparation will be administered via fiberoptic bronchoscopy to each lung segment, with one dose per patient. After infusion, patients are advised to remain hospitalized for 24-48 hours for observation.~3. Post-Treatment Follow-Up:~Patients are advised to return for examination and evaluation at 4 and 24 weeks post-treatment."
218944138|NCT06947941|DRUG|KarXT|Specified dose on specified days
218944139|NCT06947941|DRUG|KarX-EC|Specified dose on specified days
218944140|NCT06947941|DRUG|KarXT + KarX-EC Arm Matching Placebo|Specified dose on specified days
218944141|NCT06946498|PROCEDURE|Local Anesthesia Thoracoscopy|"The patient is placed in a lateral decubitus, with the affected hemithorax upwards. Ensuring a venous line and full monitoring of vital functions. Mild sedation is given and a dose of Ceftriaxone is given 30 minutes before. Local anesthesia is injected in layers, starting from the skin and working up to the intercostal muscles, intercostal nerve, and periosteum of the rib.~Development of pneumothorax is done using a 16-gauge Boutin needle. 15 spontaneous breaths are sufficient to create a pneumothorax, and entry of rigid thoracoscope into the hemithorax through a 11-13 mm Trocar. Multiple biopsies from the parietal pleura are taken and pleurodesis is made according to operator judgment. A chest drain 20-22 G is placed and sutured.~A chest X-ray is performed 2-8 hours later after the patient is transferred to the ward. Chest drain is removed after 24h if fluid production is \<250ml and lung re-expansion."
219052081|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
219052082|NCT00799812|DRUG|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
219052083|NCT00799812|OTHER|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
219634688|NCT03742518|DRUG|Topical vehicle solution|Vehicle solution application will be performed by the individual subject at approximately the same time each day.
219052084|NCT00799812|OTHER|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
219634689|NCT02124200|DEVICE|EGO/CE4, 9mg nicotine|
219634690|NCT03070600|OTHER|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
219634691|NCT03070600|OTHER|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~1. Risk Score \>6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~2. participant declines partner self-tests regardless of partner HIV status, and/or~3. their partner declines self-testing or tests positive."
219634692|NCT00204009|BEHAVIORAL|Disease Surveillance, Family Studies, Questionnaire Followup|
219634693|NCT04005404|DRUG|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
219634694|NCT04005404|DRUG|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
219634695|NCT04005404|DRUG|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
219052085|NCT06224920|DIAGNOSTIC_TEST|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
219052086|NCT06224920|OTHER|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
219052087|NCT06224920|DIAGNOSTIC_TEST|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
218944142|NCT06946498|DEVICE|Pleuroscopy with Rigid Thoracoscope and Forceps biopsies|A video thoracoscope with an external light source, outer diameter 10 mm (Karl Storz), is inserted into the pleural cavity through a uniportal incision (1 - 1.5 cm) and complete inspection of the pleural cavity is performed. Parietal pleural biopsies are taken with a rigid 40 mm forceps (Karl Storz).
218944143|NCT06947889|OTHER|RAGT|Biofeedback based system development to enhance Robotic Assisted Gait Training in cerebral palsy pediatric patients
218944144|NCT06954064|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
218944145|NCT07146841|PROCEDURE|Round window insertion|Insertion of the electrode array via the round window.
218944146|NCT07146841|PROCEDURE|Cochleostomy insertion|Insertion of the electrode array via cochleostomy.
218944147|NCT07146841|DEVICE|Lateral wall array|Lateral wall electrode array from Advanced Bionics.
218944148|NCT07146841|DEVICE|Periomodiolar electrode array|Perimodiolar MidScala electrode array from Advanced Bionics.
219634696|NCT06012396|BEHAVIORAL|Stoke complex exercise program|"1. warm-up(5min) flexibility exercise - neck, triceps brachii, biceps brachii, forearm, back, quadriceps, biceps femoris, ankle~2. main exercise(40min) aerobic exercise(20min)- use stepper, treadmill, high intensity HRR60%, RPE 11\~14 low intensity HRR30%, RPE 9\~11 repeated interval training strength and balance exercises(20min)- program1. upper(shoulder press, chest press, biceps curl), lower(hip flexion, knee extension), Core(plank exercise, sit up) program2. upper(seated back row, triceps extension), lower(hip extension, hip abduction, knee flexion, Core(superman exercise, bridge exercise) repeated ever other day program1, program2 clean-up(5min) - same as warm-up"
219634697|NCT02176655|DRUG|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
218944149|NCT07144904|DRUG|Indocyanine Green (ICG)-Assisted Ureteral Identification|A temporary ureteral stent will be placed unilaterally (left or right) prior to robotic procedures in participants undergoing robot-assisted single-site surgery for advanced-stage endometriosis. Indocyanine green (ICG) will be administered through the stent to enable real-time fluorescence imaging for intraoperative ureter identification. The contralateral ureter will be identified using standard visualization techniques without ICG. Side allocation (ICG vs. control) will be determined by computer-generated block randomization.
219634698|NCT02176655|DRUG|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
219634699|NCT06162949|DRUG|Vonoprazan|an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
219634700|NCT06162949|DRUG|Amoxicillin|An antibiotic of penicillins antibiotic group
218944150|NCT07144904|PROCEDURE|Standard Ureteral Identification without ICG|Ureter identification will be performed using standard intraoperative visualization techniques without the use of indocyanine green (ICG) fluorescence imaging. This will be done on the contralateral side to the randomized ICG-assisted ureteral identification during robot-assisted single-site surgery for advanced-stage endometriosis.
218944151|NCT07145775|DRUG|sufentanil-ropivacaine combination|Epidural labor analgesia will be conducted using the sufentanil-ropivacaine combination (0.4 microgram/ml sufentanil + 0.072% ropivacaine).
218944152|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 1|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 1 (0.4 microgram/ml dexmedetomidine + 0.15 mg/ml esketamine + 0.036% ropivacaine).
218944153|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 2|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 2 (0.4 microgram/ml dexmedetomidine + 0.2 mg/ml esketamine + 0.036% ropivacaine).
218944154|NCT07144969|DIETARY_SUPPLEMENT|Honey|Group B patients were asked to eat one half tablespoon of natural honey every 4 hours
218944155|NCT07144969|DIETARY_SUPPLEMENT|gum chewing|Group A patients were asked to chew gum for 5 minutes every 4 hours
219634701|NCT06162949|DRUG|Clarithromycin|An antibiotic of macrolide group
219634702|NCT06162949|DRUG|Esomeprazole|An acid suppressor therapy that blocks the proton pump.
218944156|NCT05552352|OTHER|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
218944157|NCT05887596|OTHER|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
218944158|NCT05148195|DRUG|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
218944159|NCT05148195|DRUG|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
218944160|NCT05148195|DRUG|Docetaxel|75mg/m2，Q3W
218944161|NCT05148195|DRUG|Irinotecan|180 mg/m2，Q2W
218944162|NCT05148195|DRUG|Leucovorin calcium|400mg/m2，Q2W
218944163|NCT05148195|DRUG|5-Fluorouridine|2400 mg/m2，Q2W
218944164|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
218944165|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
218944166|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
218944167|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
218944168|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
218944169|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
218944170|NCT06233669|OTHER|Analysis of Burnout|No intervention used.
218944171|NCT06023836|DEVICE|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
218944172|NCT06023836|PROCEDURE|Dry needling|Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
218944173|NCT01410617|PROCEDURE|hemodialysis|3 sessions hemodialysis before CABG
219052088|NCT06224920|DIAGNOSTIC_TEST|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand \[18F\]-GE-180, \[18F\]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand \[18F\]-PI-2620. In brief, \[18F\]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. \[18F\]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic \[18F\]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
219052089|NCT06224920|DIAGNOSTIC_TEST|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
219052090|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1\) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
219052091|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2\) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
219052092|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
219052093|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
219052094|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
219052095|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
219052096|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
219052097|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
219052098|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
219052099|NCT00550836|BIOLOGICAL|panitumumab|Given IV
219052100|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
219052101|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
219052102|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
219052103|NCT00179413|DRUG|PEG -Intron|
219052104|NCT00179413|DRUG|Colchicine|0.6mg twice a day
219052105|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
219052106|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
219052107|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
219052108|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
219052109|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
219052110|NCT02144675|DRUG|idarubicin|Given IV
219052111|NCT02144675|DRUG|cytarabine|Given IV
219052112|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
219052113|NCT04640025|DRUG|itacitinib|Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
219634703|NCT02233387|OTHER|injection with [18F] HX4 and PET imaging|"A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
218944174|NCT04788368|PROCEDURE|Surgical resection|Surgical resection with either of the above mentioned techniques
218944175|NCT01888432|DRUG|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
219206842|NCT06788093|BEHAVIORAL|ED Clinical Decision Support (CDS-ED)|The ED-CDS intervention is designed as a discrete decision support aid to influence initial antibiotic decision-making in the ED. This intervention will feature a clinician-facing LRTI dashboard for end-users that assimilates relevant clinical data (e.g., vital signs, select diagnostic tests, links to reference information) and offers tailored suggestions for antibiotic initiation, related diagnostic testing, and in those receiving antibiotics, preferred options and alternatives for antibiotic choice, route, dose, and duration.
219634704|NCT02309476|DEVICE|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
218944176|NCT01888432|DRUG|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
218944177|NCT00000771|DRUG|Paromomycin sulfate|
218944178|NCT03054129|OTHER|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
218944179|NCT03054129|OTHER|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
218944180|NCT00130247|DRUG|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
218944181|NCT00130247|DRUG|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
218944182|NCT00130247|DRUG|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
218944183|NCT00130247|DRUG|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
218944184|NCT04278105|DEVICE|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
218944185|NCT04278105|DEVICE|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
219634705|NCT02309476|DEVICE|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
219052114|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
218944186|NCT04278105|OTHER|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
218944187|NCT04486001|BIOLOGICAL|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
218944188|NCT05841173|DIETARY_SUPPLEMENT|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
218944189|NCT05841173|BEHAVIORAL|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
218944190|NCT05841173|OTHER|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
219052115|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
219052116|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
219052117|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
219052118|NCT00647192|DRUG|Eplerenone|50 mg per day
219052119|NCT00647192|DRUG|Placebo|50 mg per day
219052120|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
219052121|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
218944191|NCT05841173|BEHAVIORAL|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
219052122|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
219052123|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
218944192|NCT01660958|DIETARY_SUPPLEMENT|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
219052124|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
219052125|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
219052126|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
219052127|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
219052128|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06\_002CR (NCT01199705).
219052129|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
219052130|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
219052131|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
219052132|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
219052133|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
219052134|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
218944193|NCT01660958|BEHAVIORAL|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
218944194|NCT05491460|DRUG|Apixaban 5 MG Tab|oral intake
218944195|NCT05491460|DRUG|Dabigatran 150 MG Tab|oral intake
219052135|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
219052136|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
219052137|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
219052138|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
219052139|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
219052140|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
219052141|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
219052142|NCT04307238|DIAGNOSTIC_TEST|PLR|PLR measurements will be performed within the first 2 postoperative hours.
219052143|NCT04307238|DIAGNOSTIC_TEST|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
219052144|NCT04307238|PROCEDURE|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
219052145|NCT04307238|PROCEDURE|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
218944196|NCT05491460|DRUG|Edoxaban 60Mg Tab|oral intake
218944197|NCT05491460|DRUG|Rivaroxaban 20 MG Tab|oral intake
218944198|NCT05637060|DRUG|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
219052146|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
219052147|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
219052148|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
218944199|NCT05637060|DRUG|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
218944200|NCT05498415|BEHAVIORAL|Education|Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.
218944201|NCT05498415|BEHAVIORAL|Health coaching|Participants will meet with a health coach weekly for 8 weeks
218944202|NCT05498415|BEHAVIORAL|Activity Monitor|Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
218944203|NCT00434239|DRUG|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
218944204|NCT04137445|OTHER|Baby Foods|Commercially available baby foods
218944205|NCT04137445|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
218944206|NCT05326854|OTHER|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
218944207|NCT02123251|BEHAVIORAL|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
218944208|NCT05012670|DRUG|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
218944209|NCT05790161|DRUG|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
218944210|NCT05741606|DRUG|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
218944211|NCT05741606|DRUG|Placebo|Placebo capsules
218944212|NCT02704143|OTHER|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
218944213|NCT00679445|DEVICE|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
218944214|NCT01235598|OTHER|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
218944215|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
218944216|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
219052149|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
218944217|NCT02151773|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
219052150|NCT01696032|DRUG|SGI-110|
219206843|NCT06788093|BEHAVIORAL|Transitions Clinical Decision Support (CDS-Tr)|The CDS-Tr intervention is designed as a longitudinal decision support aid to influence initial and ongoing (i.e., continuation, discontinuation, escalation, or de-escalation) antibiotic decision-making in the hospital setting. This intervention will also feature the LRTI dashboard along with additional tailored suggestions and recommendations for antibiotic decision-making upon hospital admission, and for those receiving antibiotics, at the time of discharge. Additionally, CDS-Tr will be active at the time of any service transition (i.e., hospital to intensive care or vice versa) and at pre-specified time points (e.g., approximately 48 hours and 120 hours following ED triage for encounters remaining in the hospital).
219634706|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
218944218|NCT00395343|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
218944219|NCT00395343|DRUG|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
219634707|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
218944220|NCT00917215|DEVICE|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
218944221|NCT03759808|BEHAVIORAL|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
218944222|NCT04982601|OTHER|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
218944223|NCT03619811|DIAGNOSTIC_TEST|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
218944224|NCT02507960|DEVICE|The Gamma Pod|Immobilization of breast during radiation.
219052151|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
219052152|NCT01696032|DRUG|Carboplatin|
219052153|NCT02188576|DRUG|high dose TXA|
219052154|NCT02188576|DRUG|Low dose TXA|
219052155|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
219052156|NCT06550570|BEHAVIORAL|QEVA questionnaire|QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
219052157|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
219052158|NCT03546374|PROCEDURE|Surgical Ablation|In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
219052159|NCT03546374|DEVICE|Cardioblate and Cryoflex hand held devices|The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
219052160|NCT01192152|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
219052161|NCT01192152|DRUG|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
219052162|NCT01192152|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
219052163|NCT02657863|PROCEDURE|Urine collection and blood draw|
218944225|NCT02507960|DEVICE|CT simulation|See arm description
218944226|NCT03073551|OTHER|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
218944227|NCT00387790|DRUG|motexafin gadolinium|Given IV
218944228|NCT00387790|RADIATION|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
218944229|NCT00102778|DRUG|GW873140|
218944230|NCT00102778|DRUG|Kaletra (lopinavir/ritonavir)|
218944231|NCT00775047|OTHER|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
218944232|NCT00775047|OTHER|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
218944233|NCT00458770|PROCEDURE|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
218944234|NCT06073483|DEVICE|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
218944235|NCT06085456|DIAGNOSTIC_TEST|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
218944236|NCT03463005|OTHER|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
218944237|NCT03463005|PROCEDURE|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
218944238|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
218944239|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
218944240|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
218944241|NCT03557840|DRUG|temocillin|Drug dosing and blood sampling as per the protocol
218944242|NCT02747433|DEVICE|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
218944243|NCT02747433|DEVICE|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
218944244|NCT04753151|DRUG|Tranexamic acid|The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
218944245|NCT01651806|DRUG|Tranexamic Acid standard dose|Uniform 1 gram dosing
218944246|NCT01651806|DRUG|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
218944247|NCT01651806|DRUG|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
218944248|NCT01651806|DRUG|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
219052164|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
219052165|NCT01108575|OTHER|IMST|inspiratory muscle strength training
219052166|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
219052167|NCT03945877|OTHER|No interventions|No interventions
219052168|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
219052169|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
219052170|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
219052171|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
219634708|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
219634709|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
219052172|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
219634710|NCT00326274|DRUG|Helioblock® SX Cream|
219634711|NCT06573463|DEVICE|Prefabricated band and loop|Prefabricated space maintainer requires only one visit as it fits into the patient's mouth at the clinic without needing the dental lab. It comes in a kit with different band sizes.
219634712|NCT06573463|DEVICE|Conventional Band and loop|Conventional band and loop is the most widely used space maintainer, It shows high success rate and good patient compliance, but needs more than one visit due to the laboratory work.
219634713|NCT01599858|DRUG|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
219052173|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
219634714|NCT01599858|DRUG|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
219634715|NCT03622684|BEHAVIORAL|Muscle relaxation according to Jacobson|
219634716|NCT06205043|DEVICE|StimSearch programming algorithm software|This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
219634717|NCT06205043|DEVICE|Clinician based programming|This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
219634718|NCT01464593|DRUG|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
219634719|NCT01464593|OTHER|5% Dextrose Solution|Single 30 minute intravenous infusion
219634720|NCT01464593|DRUG|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
219052174|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
219052175|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
219052176|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
218944249|NCT01558128|DRUG|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
218944250|NCT01558128|PROCEDURE|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
218944251|NCT00447070|DRUG|ATAZANAVIR|
218944252|NCT04193514|OTHER|Acceptance and Commitment Therapy|The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
218944253|NCT04120103|BEHAVIORAL|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
218944254|NCT04120103|OTHER|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
218944255|NCT00043329|DRUG|Actimmune Registry|as administered by physician
218944256|NCT03870594|DIAGNOSTIC_TEST|glycated hemoglobin|hemoglobin A1c level in blood
218944257|NCT05925543|PROCEDURE|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
218944258|NCT06163378|DEVICE|Rubato Life App|An algorithmically enhanced personalized music-based intervention
218944259|NCT00551928|DRUG|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
218944260|NCT00551928|DRUG|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
218944261|NCT00551928|DRUG|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
218944262|NCT00551928|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
218944263|NCT03946696|OTHER|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
218944264|NCT04813367|PROCEDURE|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
218944265|NCT03922113|OTHER|Patient follow up|Patient follow up during one month
218944266|NCT01199367|DRUG|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
218944267|NCT05132803|DRUG|HPV 16 TA-CIN|No dose escalation or reduction
218944268|NCT04321447|OTHER|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
218944269|NCT01725659|OTHER|Motor Learning|training of the hemiplegic upper limb with motor learning
218944270|NCT01725659|OTHER|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
218944271|NCT01725659|OTHER|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
219052177|NCT05013905|DRUG|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
219052178|NCT05013905|DEVICE|Companion diagnostic (CDx)|CDx+ or CDx-
219052179|NCT04942938|DEVICE|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
219052180|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
219052181|NCT03178617|OTHER|Educational Intervention|Attend HIP
219052182|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
219052183|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
219206844|NCT05682235|OTHER|Therapeutic exercise AND pain neurophysiology education|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
218944272|NCT05411627|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
218944273|NCT02551510|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique
218944274|NCT02551510|DEVICE|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
218944275|NCT02933229|DEVICE|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
218944276|NCT02933229|DRUG|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
218944277|NCT03994029|DIETARY_SUPPLEMENT|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
218944278|NCT00564057|DRUG|candesartan|tablet 8-16 mg once daily, one year
218944279|NCT00564057|DRUG|lercanidipine|tablets 10-20 mg once daily, one year
218944280|NCT01649453|DEVICE|Pathwork® Tissue of Origin Test|
218944281|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
219052184|NCT05652088|PROCEDURE|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
219052185|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
219052186|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
219052187|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
219052188|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
219052189|NCT00028028|DRUG|temsirolimus|Given IV
219052190|NCT00028028|OTHER|pharmacological study|Correlative studies
219052191|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
218944282|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
218944283|NCT01004198|DRUG|Ringers Lactate solution|Ringers Lactate solution for Injection
218944284|NCT03963167|DRUG|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
218944285|NCT05367258|OTHER|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
219052192|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
219052193|NCT06577298|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
219052194|NCT06577298|BIOLOGICAL|VLP-Polio medium dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
219052195|NCT06577298|BIOLOGICAL|VLP-Polio high dose|1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
219052196|NCT06577298|BIOLOGICAL|Vaccine Poliomyelitis Inactivated (IPV)|1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
219052197|NCT06384547|DRUG|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
219052198|NCT06384547|DRUG|VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
219052199|NCT06967389|DRUG|Ozempic®|The study medication will be given in accordance with standard of care dosing schedule.
219052200|NCT06406738|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform newborn first-care.
219052201|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
219052202|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
219052203|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
219052204|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
219052205|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
219052206|NCT00675116|DRUG|GW823296|
219052207|NCT02978690|DRUG|Spesolimab|Solution for infusion
219052208|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
219052209|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
219052210|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
219052211|NCT04666259|DRUG|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
219052212|NCT06179082|COMBINATION_PRODUCT|Botox then threads|patients in which Botox injection then threads insertion were used
219052213|NCT06179082|PROCEDURE|threads only|patients in which threads insertion only was used
219052214|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
219052215|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
219052216|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
218944286|NCT04955678|DRUG|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
218944287|NCT04955678|DRUG|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
218944288|NCT02721394|BEHAVIORAL|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
218944289|NCT04352426|OTHER|Exercise Test|Tests were conducted to evaluate exercise capacity.
218944290|NCT03596541|DEVICE|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
218944291|NCT02236182|DRUG|Ipratropium Bromide low dose|
218944292|NCT02236182|DRUG|Placebo|
218944293|NCT02236182|DRUG|Ipratropium Bromide high dose|
218944294|NCT05307913|OTHER|EIT-guided PEEP|PEEP setting according to EIT
218944295|NCT05307913|OTHER|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
218944296|NCT06174142|DEVICE|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
218944297|NCT06174142|DEVICE|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
218944298|NCT06174142|DEVICE|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
218944299|NCT05739084|RADIATION|pre-operative radiation|As per standard of care and institutional guidelines
219052217|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
219052218|NCT00572507|DEVICE|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
219052219|NCT06372847|DEVICE|Hypoglossal nerve stimulation implant|The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.
219052220|NCT06372847|DIAGNOSTIC_TEST|Polysomnography|A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
219206845|NCT05682235|OTHER|Sham|Talk about healthy habits
219206846|NCT06792578|PROCEDURE|Surgical Start Time|This intervention focuses on the retrospective analysis of the association between surgical start times (morning, afternoon, and nighttime) and postoperative outcomes in non-cardiac surgeries. The study evaluates how the timing of surgery impacts mortality, complications, transfusion rates, and ICU admissions in a tertiary hospital setting
219206847|NCT06786260|OTHER|Interventional Diet|Low salt, limited caffeine, high potassium, low phosphate, and limited protein and carbohydrate intake along with adequate water intake diet
218944300|NCT05739084|PROCEDURE|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
218944301|NCT04348968|DEVICE|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
218944302|NCT01718418|OTHER|test meal|
218944303|NCT01718418|OTHER|reference|
218944304|NCT04693052|OTHER|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
218944305|NCT00227708|DRUG|docetaxel|
218944306|NCT00227708|PROCEDURE|quality-of-life assessment|
218944307|NCT05729867|PROCEDURE|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
218944308|NCT00321581|DRUG|Cediranib, AZD2171, RECENTIN|
219052221|NCT06372847|PROCEDURE|Drug-induced sleep endoscopy (DISE)|"Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice."
219052222|NCT01482260|PROCEDURE|Biopsy|Biopsy
219052223|NCT05894642|BEHAVIORAL|0|It is a case-control study, cross-sectional, so there is no intervention possible.
219052224|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
219052225|NCT01446731|BIOLOGICAL|mRNA transfected dendritic cell|"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
219052226|NCT01446731|DRUG|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
219052227|NCT05402995|DRUG|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
219052228|NCT05402995|DRUG|Saline|Saline irrigation
219052229|NCT04413578|DEVICE|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
219052230|NCT04413578|DEVICE|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
219052231|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
219052232|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
219052233|NCT01009099|OTHER|breathing retraining|breathing retraining using a metronome
219052234|NCT01009099|OTHER|exercise training|treadmill exercise training
219052235|NCT01841814|RADIATION|Bone densitometry.|
219052236|NCT05130203|BEHAVIORAL|MouvMat Exergaming|Sessions engaging with exergaming device.
219634721|NCT02888041|DRUG|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
219634722|NCT02888041|DRUG|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
218944309|NCT03264118|PROCEDURE|Scaling and root planing|Furcation treatment by scaling and root planing
218944310|NCT03264118|DRUG|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
219052237|NCT05130203|BEHAVIORAL|Standard Recreational Programming|Conducted by recreational therapists.
219052238|NCT02188485|BEHAVIORAL|ENGAGE|Up to 10 sessions delivered in the home.
219052239|NCT00768729|DRUG|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
219052240|NCT00768729|DRUG|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
219052241|NCT03367312|DRUG|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
219634723|NCT04335851|OTHER|Video based aerobic exercise|"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes."
218944311|NCT05869357|OTHER|cream containing 2.5% sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
218944312|NCT05869357|OTHER|cream containing 5%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
218944313|NCT05869357|OTHER|cream containing 10%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
219052242|NCT02788734|OTHER|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
219052243|NCT01461304|DRUG|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
218944314|NCT05869357|OTHER|cream base|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
219052244|NCT02489175|DEVICE|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
219052245|NCT01596764|DRUG|Loperamide placebo|200 ml apple juice
219052246|NCT01596764|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
219052247|NCT01596764|DEVICE|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
218944315|NCT03014232|PROCEDURE|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
219052248|NCT01596764|DRUG|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
219052249|NCT01596764|DRUG|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
219052250|NCT01596764|DRUG|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
219052251|NCT01596764|DRUG|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
219052252|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
219052253|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
219052254|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
219052255|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
219052256|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
219052257|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
219052258|NCT02667938|DRUG|HGP1201|
219052259|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
219052260|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
219052261|NCT02667938|DRUG|HGP1201 placebo|
219052262|NCT03416400|OTHER|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
218944316|NCT03014232|PROCEDURE|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
219052263|NCT06406127|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Single 600 mg daily dose
219052264|NCT02501096|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
219052265|NCT02501096|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
219052266|NCT02809703|OTHER|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
219052267|NCT04028011|DIAGNOSTIC_TEST|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
219052268|NCT05213858|DIAGNOSTIC_TEST|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
219052269|NCT05213858|DIAGNOSTIC_TEST|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
218944317|NCT04143178|OTHER|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
218944318|NCT04143178|OTHER|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
218944319|NCT05779371|BEHAVIORAL|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
218944320|NCT03319745|BIOLOGICAL|Pembrolizumab|Given IV
219052270|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
219052271|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
219052272|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
219052273|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
218944321|NCT06078800|DRUG|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
218944322|NCT00870103|DRUG|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
218944323|NCT03830723|DRUG|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
218944324|NCT01317550|DRUG|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
218944325|NCT01317550|OTHER|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
218944326|NCT01317550|DRUG|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
218944327|NCT01317550|BEHAVIORAL|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
218944328|NCT05356156|PROCEDURE|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
218944329|NCT05356156|PROCEDURE|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
218944330|NCT03872076|OTHER|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
218944331|NCT03872076|OTHER|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
218944332|NCT00121862|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
218944333|NCT03287271|DRUG|VS-6063|"Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
218944334|NCT03287271|DRUG|Paclitaxel|"Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
218944335|NCT03287271|DRUG|Carboplatin|"Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
218944336|NCT01523847|DRUG|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
218944337|NCT06466408|DIETARY_SUPPLEMENT|Supplementation Protocol|After the pre-test, the enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days. The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) instead until the end of the study. Participants returned to the laboratory each morning to receive the daily supplement, which was administered on-site. Following supplementation, participants reported their dinner intake to the researchers, ensuring compliance with the prescribed supplementation regimen.
218944338|NCT06466408|DIAGNOSTIC_TEST|Blood Lactate Test|The blood lactate was measured at five time points: before exercise, after the fourth and eighth bouts of exercise, and at 5 and 10 minutes after exercise. The blood lactate were analyzed using a Biosen Cline blood analysis system (EKF-diagnostic, Germany). Capillary blood samples of 10 μL were collected and added to red blood cell lysis reagent and stored at low temperature until analyzed. Prior to analysis, instrument standardization and test calibration were performed, and the coefficient of variation was determined to be ≤1.5%. The detection range for blood lactate was 0.5-40 mM
218944339|NCT06466408|DIAGNOSTIC_TEST|Training Impulse|In this study, the exercise load was represented by the TRIMP \[32\], which is calculated as the product of exercise intensity and duration. To accommodate the convenience of the experiment, two different TRIMP calculation methods were used, including % HRmax (objective) and RPE (subjective). At the end of each exercise bout (8 bouts in total) and during the recovery period before the next bout (7 bouts in total), participants were asked to report their RPE, and their heart rate was recorded. This process was repeated 8 times.
219052274|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
219052275|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
219052276|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
219052277|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
219052278|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
219052279|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
219052280|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
218944340|NCT06466408|DIAGNOSTIC_TEST|Exergaming HIIE Test|The sensor system utilized two Nintendo controllers: one mounted on the exercise ring and the other secured to the participant's thigh to enhance gameplay interaction. Through the Ring-Con, participants engaged in diverse physical activities such as weightlifting, yoga, and aerobic exercises. The fitness ring sensor accurately captures and integrates players' movements into the game. The gameplay involves unlocking levels and engaging in fitness challenges that are achieved through actual physical activities. It offers a wide range of exercise routines targeting various muscle groups and provides engaging gaming challenges. The exercise protocol included eight sets of 20-second high-effort exercises, interspersed with 30-second rest intervals, totaling 370 seconds of active exercise time. Specifically, the fitness game mode used was the Adventure Mode in 'Ring Fit Adventure,' comprising exercises targeting the pectoralis major, latissimus dorsi, deltoids, and quadriceps muscles.
218944341|NCT06394362|OTHER|Bispectral index monitor|Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
218944342|NCT06074731|DIAGNOSTIC_TEST|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
218944343|NCT06093074|BEHAVIORAL|self-management program after traumatic injuries|The self-management support (SMS) program is manualized and will include eight weekly 2.5-hour sessions in groups of 5-7 participants. This feasibility trial will assess both face-to-face delivered program and a tele-health program via electronic devices. The tele-health intervention will be delivered with the same SMS content, frequency, and in-group mode.
218944344|NCT03359018|DRUG|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
218944345|NCT03359018|DRUG|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
218944346|NCT02065427|BEHAVIORAL|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
218944347|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
218944348|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
219052281|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
218944349|NCT04858178|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
218944350|NCT04858178|DEVICE|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
218944351|NCT04241978|OTHER|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
218944352|NCT04241978|OTHER|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
218944353|NCT01827683|OTHER|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
218944354|NCT00680238|DRUG|Human derived FSH|Customized for each patient
218944355|NCT00006233|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218944356|NCT00006233|DRUG|cyclosporine|
218944357|NCT00006233|DRUG|fludarabine phosphate|
218944358|NCT00006233|DRUG|mycophenolate mofetil|
218944359|NCT00006233|PROCEDURE|peripheral blood stem cell transplantation|
219634724|NCT04277364|DIETARY_SUPPLEMENT|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
219634725|NCT04277364|OTHER|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
218944360|NCT00006233|RADIATION|radiation therapy|
218944361|NCT04307342|PROCEDURE|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
218944362|NCT03179202|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
218944363|NCT02781740|DEVICE|Continous Positive Air Pressure Device|
219206848|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab with mirabegron|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.
218944364|NCT03255629|DRUG|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
219052282|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
219052283|NCT05630027|OTHER|Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water|observational, prospective study
219052284|NCT05058313|DEVICE|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
219052285|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
218944365|NCT03255629|DEVICE|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
218944366|NCT06125470|BEHAVIORAL|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
218944367|NCT06125470|BEHAVIORAL|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
218944368|NCT06125470|BEHAVIORAL|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
218944369|NCT06125470|BEHAVIORAL|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
218944370|NCT06125470|BEHAVIORAL|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
219634726|NCT04277364|OTHER|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
219634727|NCT04267679|DRUG|Cannabidiol|25 mg full-spectrum CBD soft gel capsules
219634728|NCT05540847|PROCEDURE|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
218944371|NCT06125470|BEHAVIORAL|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
218944372|NCT01120782|DEVICE|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
218944373|NCT01120782|DEVICE|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
218944374|NCT05273502|BEHAVIORAL|Citizen Science intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
218944375|NCT00463021|DRUG|Hectorol (doxercalciferol capsules)|
218944376|NCT00463021|DRUG|Zemplar (paricalcitol injection)|
219052286|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
219634729|NCT05540847|PROCEDURE|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
219052287|NCT02148172|PROCEDURE|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
219052288|NCT02148172|PROCEDURE|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
219052289|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
219052290|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
219634730|NCT02464163|BIOLOGICAL|Panblok|Intramuscular injection
219634731|NCT02464163|BIOLOGICAL|rHA adjuvant|Intramuscular injection
219052291|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
219052292|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
219052293|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
219052294|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
218944377|NCT03095196|DEVICE|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
218944378|NCT03095196|DEVICE|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
218944379|NCT03095196|DRUG|HF drugs|full medical therapy to treat HF symptoms and its progression.
218944380|NCT04670250|DIAGNOSTIC_TEST|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
218944381|NCT00977847|OTHER|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
218944382|NCT04301310|DRUG|BMS-986235 (Treatment A)|Specified dose on specified days
218944383|NCT04301310|DRUG|Rifampin (Treatment B)|Specified dose on specified days
218944384|NCT03848299|OTHER|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
218944385|NCT03189290|PROCEDURE|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
219052295|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
219052296|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
219052297|NCT03892811|OTHER|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
219052298|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
219052299|NCT00009919|DRUG|semaxanib|Given IV
219052300|NCT04187196|DRUG|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
218944386|NCT03717428|DEVICE|Daily Weighing Group|The Experimental group will weigh themselves everyday
218944387|NCT03717428|DEVICE|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
218944388|NCT05291169|DEVICE|Omeza® OCM™|"Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial."
219052301|NCT04187196|DRUG|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
219052302|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
219052303|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
219052304|NCT02378766|BEHAVIORAL|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
219052305|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
219052306|NCT00360074|DRUG|Thyroxin, Triiodothyronine|
219052307|NCT02437565|OTHER|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
218944389|NCT00969982|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
218944390|NCT00969982|DRUG|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
218944391|NCT02404090|RADIATION|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
219052308|NCT02437565|OTHER|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
219052309|NCT04537728|BEHAVIORAL|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
218944392|NCT00858338|PROCEDURE|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
219052310|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
219052311|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
219052312|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
219052313|NCT01393769|DRUG|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
219052314|NCT05149417|OTHER|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
219052315|NCT05149417|OTHER|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
219052316|NCT02099214|DEVICE|3Tesla cardiac MRI|
219052317|NCT02099214|DEVICE|Electrocardiogram (EKG)|
219052318|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
219052319|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
218944393|NCT00858338|DRUG|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
219052320|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
219052321|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
219052322|NCT02099214|DEVICE|3Tesla abdominal MRI|
219052323|NCT04078776|OTHER|No intervention|There is no intervention in this study
219052324|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
219052325|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
219052326|NCT03736850|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
219052327|NCT01556204|PROCEDURE|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
219052328|NCT01556204|PROCEDURE|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
219206849|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
219206850|NCT05795881|OTHER|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
218944394|NCT00858338|PROCEDURE|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
218944395|NCT05354362|COMBINATION_PRODUCT|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
218944396|NCT00015834|DRUG|imatinib mesylate|Given PO
218944397|NCT00015834|DRUG|cytarabine|Given IV
218944398|NCT05099367|DIAGNOSTIC_TEST|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
218944399|NCT05099367|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
218944400|NCT05099367|DIAGNOSTIC_TEST|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
218944401|NCT04442035|BEHAVIORAL|5-element music therapy|participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
218944402|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
218944403|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
218944404|NCT02379130|BEHAVIORAL|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
218944405|NCT02379130|BEHAVIORAL|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
218944406|NCT00718588|DRUG|MTRX1011A|Subcutaneous and intravenous single and repeating dose
218944407|NCT04356261|BEHAVIORAL|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
218944408|NCT04613843|OTHER|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
218944409|NCT04613843|OTHER|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
218944410|NCT00003021|DRUG|bizelesin|
218944411|NCT04724122|OTHER|Observational / Assessment only|The results of this assessment will determine the needs for future interventions
218944412|NCT03903224|PROCEDURE|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
218944413|NCT03903224|PROCEDURE|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
218944414|NCT00028652|BIOLOGICAL|interleukin-12 gene|
218944415|NCT00280384|DRUG|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
218944416|NCT00280384|DRUG|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
218944417|NCT04229407|DIETARY_SUPPLEMENT|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
218944418|NCT04229407|DIETARY_SUPPLEMENT|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
219052329|NCT05664724|BEHAVIORAL|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
219052330|NCT00366392|DEVICE|Optical Aids|
219052331|NCT06175143|BIOLOGICAL|GR2002 injection|TSLP monoclonal antibody
219052332|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
219052333|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
219052334|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
219052335|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
219052336|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
219052337|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
219052338|NCT01957475|DEVICE|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
219052339|NCT01957475|DEVICE|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
219052340|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
219052341|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
219052342|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
219634732|NCT02733848|DRUG|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
218944419|NCT00694148|DRUG|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
218944420|NCT04090801|DRUG|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
218944421|NCT04090801|DRUG|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
219052343|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
219052344|NCT05668065|BIOLOGICAL|CoronaVac/CoronaVac|Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
218944422|NCT04090801|OTHER|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
218944423|NCT00299429|PROCEDURE|Stenting and minimally invasive bypass surgery|
218944424|NCT00299429|PROCEDURE|PCI with DES|PCI with DES
218944425|NCT02460601|DRUG|Qizhiweitong granule|
218944426|NCT05541536|OTHER|Consultation meeting|Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
218944427|NCT05541536|OTHER|Pamphlet|Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.
218944428|NCT05541536|OTHER|Usual Care|Study participants will not receive the general information pamphlet or consultation.
218944429|NCT00572130|GENETIC|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
219634733|NCT02733848|OTHER|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
219634734|NCT02733848|OTHER|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
219634735|NCT05369338|DEVICE|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
219634736|NCT05369338|DEVICE|Sham Controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
219634737|NCT05992142|DRUG|5-ASA|Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit
219634738|NCT05732571|OTHER|Breathing techniques over 12 sessions / 6 weeks inc yoga|as above
219634739|NCT01760031|OTHER|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
219634740|NCT06967623|DEVICE|diaphragm ultrasound|On the day of hospitalization or the first day of mechanical ventilation, the patient's position was elevated by 30°, and the high-frequency linear probe of the ultrasound was placed perpendicular to the skin in the cranio-caudal direction, and the diaphragm apposition zone, where the right anterior and middle axillary line corresponds to the 8th-10th intercostal space, was imaged and measurements were made with B mode.
219634741|NCT00406341|DRUG|Difluprednate Ophthalmic Emulsion|
219634742|NCT00119249|DRUG|sorafenib tosylate|Given orally
219634743|NCT00119249|OTHER|laboratory biomarker analysis|Correlative studies
219634744|NCT02801513|BEHAVIORAL|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
219634745|NCT02801513|BEHAVIORAL|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
219634746|NCT01601119|DRUG|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
219634747|NCT01601119|OTHER|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
219634748|NCT04699318|PROCEDURE|Group B|To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty
219634749|NCT04699318|PROCEDURE|Group A|To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
219634750|NCT02403479|DRUG|Silver Colloid|Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
219634751|NCT02403479|OTHER|Saline|Topical saline will be administered for 6 weeks. This will occur before the topical silver colloidal nasal spray. Participants are randomized as to the order of sprays.
219634752|NCT02671799|DEVICE|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
219634753|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
219634754|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
219634755|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
219634756|NCT02391012|BIOLOGICAL|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
219052345|NCT05668065|BIOLOGICAL|CoronaVac/BNT162b2|"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"
218944430|NCT00572130|GENETIC|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
218944431|NCT04308967|OTHER|balance exercises|Three-stage progressive balance exercises will be applied.
218944432|NCT05827198|OTHER|Low-sugar candies compared to regular sugar candies|Acute intake
218944433|NCT01776307|DRUG|BBI608|BBI608 is administered at 500 mg po bid continuously.
218944434|NCT01776307|DRUG|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
218944435|NCT01776307|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
218944436|NCT01776307|DRUG|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
218944437|NCT03615040|DRUG|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
219634757|NCT01535521|DEVICE|Sleep Position Trainer (SPT)|
219634758|NCT05390775|BEHAVIORAL|Written Exposure Therapy (WISE)|WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
218944438|NCT03615040|DRUG|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
218944439|NCT06174090|OTHER|Coronary bypass graft surgery video education|It includes information about surgical process and handling issues within the first few days of surgery.
218944440|NCT00945295|DRUG|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
219052346|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
219052347|NCT00003002|BIOLOGICAL|sargramostim|
219052348|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
219052349|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
219052350|NCT04473651|DRUG|Lu AG06479|capsules, orally (Part A and B)
219052351|NCT04473651|DRUG|Placebos|Placebo - capsules, orally (Part A only)
219052352|NCT04419116|PROCEDURE|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
218944441|NCT00945295|OTHER|Rehabilitation Therapy|Rehabilitation therapy
218944442|NCT02101710|DRUG|Elantan SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
219052353|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
219052354|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
219052355|NCT03343691|DIAGNOSTIC_TEST|Screening Population|Blood samples taken from screening population
219052356|NCT03343691|DIAGNOSTIC_TEST|Breast Cancer Population|Blood samples taken from Breast Cancer population
219052357|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
219052358|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
218944443|NCT02101710|DRUG|Imdur SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
218944444|NCT00846950|DRUG|dexchlorpheniramine, lorazepam|
218944445|NCT05785819|DRUG|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
218944446|NCT05785819|DRUG|Placebo|Placebo matching VLX-1005
218944447|NCT02292069|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
218944448|NCT01105546|DRUG|recombinant activated factor VII|90 µg/kg/day i.v.
218944449|NCT01105546|DRUG|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
218944450|NCT02870322|BEHAVIORAL|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
218944451|NCT02870322|BEHAVIORAL|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
218944452|NCT03438370|OTHER|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
218944453|NCT03438370|OTHER|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
218944454|NCT02656225|DRUG|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
218944455|NCT02656225|DRUG|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
218944456|NCT03673397|BEHAVIORAL|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
218944457|NCT00017329|DRUG|bortezomib|
218944458|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
218944459|NCT02462642|OTHER|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
218944460|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
218944461|NCT02462642|OTHER|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
218944462|NCT00845793|BEHAVIORAL|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
218944463|NCT01689194|DRUG|genexolPM + cisplatin|
219052359|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
219052360|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
218944464|NCT04042090|DEVICE|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
218944465|NCT02685059|DRUG|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
218944466|NCT02685059|DRUG|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
218944467|NCT02685059|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
218944468|NCT02685059|DRUG|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
218944469|NCT02685059|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
218944470|NCT02420015|DRUG|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
218944471|NCT02420015|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
218944472|NCT02420015|BEHAVIORAL|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
218944473|NCT02420015|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
219052361|NCT03680274|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
219052362|NCT03680274|OTHER|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
219052363|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
219052364|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
218944474|NCT02420015|BEHAVIORAL|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
218944475|NCT02420015|BEHAVIORAL|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
218944476|NCT00583713|DRUG|BLI-800|BLI-800 oral solution (two doses)
219052365|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
219052366|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
219052367|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
219052368|NCT01813318|DRUG|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
219052369|NCT01813318|DRUG|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
219052370|NCT02962037|OTHER|Melatonin and light therapy|
219052371|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
219052372|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
219052373|NCT00503386|DRUG|Palonosetron|
219052374|NCT00503386|DRUG|Granisetron|
219052375|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
219052376|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
219052377|NCT01552772|DRUG|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
219052378|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
219052379|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
219052380|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
218944477|NCT04224688|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
219634759|NCT05390775|BEHAVIORAL|Non-emotional Writing|Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
218944478|NCT04224688|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
218944479|NCT02200809|DEVICE|MR-guided focal laser ablation|
218944480|NCT01835509|BEHAVIORAL|Intervention, Camp plus reunions|
218944481|NCT06123234|DIETARY_SUPPLEMENT|Verum|Food supplement in single-dose vials
218944482|NCT06123234|OTHER|Placebo|Food supplement in single-dose vials
218944483|NCT04074161|DRUG|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
218944484|NCT04074161|DRUG|Placebo (semaglutide)|Administered once weekly for 68 weeks
218944485|NCT04074161|DRUG|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
218944486|NCT04074161|DRUG|Placebo (liraglutide)|Administered once daily for 68 weeks
218944487|NCT00669123|DRUG|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
218944488|NCT00669123|DRUG|Placebo|
218944489|NCT01584544|DRUG|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
218944490|NCT01584544|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
218944491|NCT01584544|DRUG|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
219052381|NCT03369938|OTHER|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
219052382|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
219052383|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
219052384|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
218944492|NCT01584544|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
218944493|NCT01584544|DRUG|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
218944494|NCT04430595|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
218944495|NCT00374829|BEHAVIORAL|An IT-based patient follow-up and reminder system|
218944496|NCT02317744|DRUG|Naltrexone and bupropion combination|
218944497|NCT02317744|OTHER|Pill Placebo|
218944498|NCT03549832|DRUG|Sofosbuvir|Sofosbuvir 400 mg oral pills
218944499|NCT03549832|DRUG|Simeprevir|Simeprevir 150 mg oral pills
218944500|NCT03549832|DRUG|Daclatasvir|Daclatasvir 60 mg oral pills
218944501|NCT03549832|DRUG|Ribavirin|Ribavirin 200 mg oral pills
218944502|NCT03549832|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir oral pills
218944503|NCT03236155|DRUG|opioid pain pills|patient will receive their pain pill prescription
218944504|NCT05366868|DRUG|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
218944505|NCT05366868|DRUG|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
218944506|NCT05366868|DRUG|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
218944507|NCT04997356|BEHAVIORAL|Hostile Bias Modification Training|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.
218944508|NCT04997356|BEHAVIORAL|Other training|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
218944509|NCT04769700|BEHAVIORAL|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
218944510|NCT04769700|BEHAVIORAL|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
218944511|NCT04769700|BEHAVIORAL|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
218944512|NCT04876300|OTHER|No intervention|All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
218944513|NCT03033550|BEHAVIORAL|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
218944514|NCT06376903|OTHER|Pilates exercise - pelvic floor exercise - home advices|"Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A)."
218944515|NCT05741554|OTHER|Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.|Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
218944516|NCT04036370|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
218944517|NCT04036370|OTHER|Control group|Standard pain follow up and monitorization will be performed.
218944518|NCT02256397|OTHER|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
218944519|NCT02256397|OTHER|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
218944520|NCT03405233|PROCEDURE|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
218944521|NCT03405233|PROCEDURE|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
218944522|NCT03405233|PROCEDURE|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
218944523|NCT01988584|BIOLOGICAL|umbilical cord blood (hUCB) cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
219052385|NCT02994537|OTHER|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
219052386|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
218944524|NCT01988584|DRUG|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
218944525|NCT01988584|BIOLOGICAL|bone marrow derived mononuclear cells (BMMNCs)|Autologous stem cells from bone marrow harvest.
218944526|NCT04133142|PROCEDURE|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
218944527|NCT05271500|DEVICE|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
219052387|NCT04361526|DEVICE|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
219052388|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
219052389|NCT03620318|DRUG|Crenolanib besylate|
219052390|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
219052391|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
219052392|NCT06383949|DEVICE|Synergy Cervical Disc system|motion preservation disc
219052393|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
219052394|NCT04213898|DRUG|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
219052395|NCT04288622|OTHER|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
219052396|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
219052397|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
219052398|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
219052399|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
219052400|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
219052401|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
219052402|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
219052403|NCT02489227|DRUG|CHS-1420|
219052404|NCT02489227|DRUG|Adalimumab|
219052405|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
219052406|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
219052407|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
219052408|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
219052409|NCT01826162|OTHER|acetate or placebo infusion|
219052410|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
218944528|NCT03232333|DEVICE|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
218944529|NCT01980589|DRUG|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
218944530|NCT01980589|DRUG|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
218944531|NCT01980589|DRUG|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
218944532|NCT00120757|DRUG|Alendronate|
218944533|NCT04847336|OTHER|No intervention is planned|No intervention is planned
218944534|NCT05236868|DRUG|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
218944535|NCT05145270|DIETARY_SUPPLEMENT|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
218944536|NCT05145270|DEVICE|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
218944537|NCT05145270|DRUG|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
218944538|NCT05037578|BEHAVIORAL|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
218944539|NCT02868827|DRUG|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
218944540|NCT02868827|OTHER|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
218944541|NCT00196092|DEVICE|Roll-in|Proctored entry.
218944542|NCT00196092|DEVICE|Surgical|Surgery
218944543|NCT00196092|DEVICE|Standard Risk|Standard Endovascular repair
218944544|NCT00196092|DEVICE|High Risk|High Risk Endovascular repair.
218944545|NCT00196092|DEVICE|Compassionate Use|Endovascular repair for compassionate use patients.
218944546|NCT00196092|DEVICE|Treatment for females|Endovascular repair in female patients
218944547|NCT00196092|DEVICE|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
218944548|NCT00196092|DEVICE|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
218944549|NCT01116778|BIOLOGICAL|eN-Lac®|One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
218944550|NCT01116778|OTHER|Placebo|One placebo capsule, once daily, po
218944551|NCT01088607|DRUG|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
218944552|NCT03162900|DRUG|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
218944553|NCT03162900|DRUG|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
218944554|NCT03162900|DRUG|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
218944555|NCT03162900|OTHER|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
219052411|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
219052412|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
219052413|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
219052414|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
219052415|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
219052416|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
219052417|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
219052418|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
218944556|NCT03087617|DEVICE|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
218944557|NCT03087617|BEHAVIORAL|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
218944558|NCT03087617|OTHER|Usual Care|Usual Care for Lung Cancer Screening patients.
218944559|NCT00749112|DRUG|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
218944560|NCT01896206|DEVICE|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
218944561|NCT04708236|DRUG|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
218944562|NCT04708236|DRUG|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
218944563|NCT04708236|DRUG|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
218944564|NCT04708236|OTHER|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
219052419|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
219052420|NCT02134457|BIOLOGICAL|ranibizumab|
219052421|NCT04675320|BIOLOGICAL|blood samples|Blood sampling during PARP inhibitor therapy
219052422|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
218944565|NCT04248283|DEVICE|Adjustable Continence Therapy for Women (ACT)|Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
218944566|NCT06531980|OTHER|Modi|"The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course."
218944567|NCT06531980|OTHER|Treatment as usual|Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
218944568|NCT02668471|PROCEDURE|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
218944569|NCT02668471|PROCEDURE|traditional method|Radial artery catheters will be placed by the palpation technique only.
218944570|NCT03058328|OTHER|Cognitive testing, testing of heart rate variability and blood samples|No intervention. Registration of ECG, cognitive testing and blood sampling is performed in the perioperative period and during follow up.
218944571|NCT04229732|DEVICE|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
218944572|NCT04551209|PROCEDURE|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
218944573|NCT03279640|DEVICE|rTMS on ipsilesional M1|
218944574|NCT03279640|DEVICE|tDCS on contralesional M1|
218944575|NCT00620529|DIETARY_SUPPLEMENT|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
218944576|NCT00620529|DIETARY_SUPPLEMENT|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
218944577|NCT05525806|OTHER|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
218944578|NCT03091348|DRUG|Testosterone|Testosterone cypionate injection
218944579|NCT03334786|DRUG|FLX-787-ODT|Oral Disintegrating Tablet
218944580|NCT01716403|BIOLOGICAL|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
218944581|NCT03617328|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
218944582|NCT03617328|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
218944583|NCT03617328|DRUG|polyICLC|polyICLC, local adjuvant
218944584|NCT03617328|DRUG|CDX-1127|CDX-1127, anti-CD27 monoclonal antibody
218944585|NCT04354597|DRUG|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
218944586|NCT02722018|DRUG|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
218944587|NCT02722018|DRUG|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
218944588|NCT03144934|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
218944589|NCT03144934|DRUG|Placebo|This is the placebo of GX-I7 described above.
218944590|NCT00706342|DRUG|Fostamatinib Disodium / R935788|R935788 tablets
218944591|NCT01034670|DEVICE|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
218944592|NCT01034670|DEVICE|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
218944593|NCT01034670|DEVICE|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
218944594|NCT01034670|DRUG|fluorescent Peptide|microdosing; Topical through the endoscope
218944595|NCT01034670|DRUG|fluorescein|100 mcg topical
218944596|NCT01034670|DRUG|indocyanine green|100 mcg topical
218944597|NCT04383418|DRUG|dexmedetomidine nasal spray|dexmedetomidine nasal spray
218944598|NCT04383418|DRUG|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
218944599|NCT04762719|DRUG|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
218944600|NCT04762719|DIAGNOSTIC_TEST|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
218944601|NCT04492332|DIAGNOSTIC_TEST|standard lumbar puncture|Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
218944602|NCT03899181|DEVICE|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
218944603|NCT03899181|OTHER|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
218944604|NCT01419197|DRUG|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change \> 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
219052423|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
219634760|NCT04988932|DRUG|Inhaled nitric oxide|Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
219634761|NCT00005606|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
219634762|NCT00005606|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
219634763|NCT02476578|OTHER|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
219634764|NCT01981707|DEVICE|F-Choline-PET|
219634765|NCT06512285|DIAGNOSTIC_TEST|Continuous Pulse Oximetry|The patient will wear a continuous pulse oximeter after their adenotonsillectomy surgery until the following morning. This will record continuous pulse oximetry data to allow for analysis of any desaturations in the first night following the surgery. This study is observational only and this data will not be used to impact any treatment
219634766|NCT00497393|BEHAVIORAL|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
219634767|NCT00523471|PROCEDURE|Blood test|
219634768|NCT02416609|RADIATION|LDR|LDR will be delivered during each cycle of Gem-based doublets
219634769|NCT02416609|DRUG|Gem-based doublets|4 cycles of Gem-based doublets
218944605|NCT01419197|DRUG|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
218944606|NCT05726188|PROCEDURE|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
219052424|NCT00298038|DRUG|Rifaximin|Oral
219052425|NCT00298038|DRUG|Placebo|Oral
219052426|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
219634770|NCT02416609|RADIATION|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
219634771|NCT06183385|OTHER|Saliva collection|Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers
219634772|NCT06183385|OTHER|Vaginal secretion collection|Collection of vaginal secretions with 2 dry swabs in women
219052427|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
219052428|NCT02206516|DEVICE|Transcranial Direct Current Stimulation|
219052429|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
218944607|NCT03584880|DEVICE|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
218944608|NCT03584880|DEVICE|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
218944609|NCT06240416|PROCEDURE|Low speed drilling without irrigation|Low-speed drilling (50 rpm) irrigation to perform the osteotomy
219634773|NCT06183385|OTHER|IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry|"sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method."
219634774|NCT06576609|DEVICE|INJEX [ Needle less anesthesia]|already described
218944610|NCT06240416|PROCEDURE|High speed drilling with irrigation|High-speed drilling (800 rpm) irrigation to perform the osteotomy
218944611|NCT06532149|DRUG|Alectinib|Alectinib 600 mg/BID
218944612|NCT06532149|DRUG|Brigatinib|180 mg/daily
218944613|NCT06532149|DRUG|Lorlatinib 100 mg|100 mg/daily
218944614|NCT06532149|DRUG|Osimertinib|80 mg/daily
218944615|NCT06532149|DRUG|Sotorasib|960 mg/daily
218944616|NCT06532149|DRUG|Dabrafenib|150 mg/BID
218944617|NCT06532149|DRUG|Trametinib|2 mg/daily
218944618|NCT06532149|DRUG|Selpercatinib|160 mg/BID
218944619|NCT06532149|DRUG|Pembrolizumab|200 mg intravenous every 21 days
218944620|NCT06532149|DRUG|Cemiplimab|350 mg intravenous every 21 days
218944621|NCT06532149|DRUG|Nivolumab|240 mg intravenous every 14 days
219206851|NCT06736756|OTHER|Stretch Exercise|To stretch Tensor fascia lata muscle,each participant starts with side lying position with the tested limb upmost. The lower limb (non-tested) is kept in hip and knee flexion to ensure stability. The tested limb is then taken into hip extension and adduction with knee extended. The exercise is held for 60 seconds and repeated 5 times with 10 seconds break intervals.
219634775|NCT02881515|OTHER|Low Sodium Diet|Ten days of low sodium diet
218944622|NCT06532149|DRUG|Carboplatin|AUC4/AU5 intravenous every 21 days
218944623|NCT06532149|DRUG|Pemetrexed|500 mg/mq intravenous every 21 days
218944624|NCT06532149|DRUG|Paclitaxel|175 mg/mq intravenous every 21 days
218944625|NCT03163017|DEVICE|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
218944626|NCT03163017|DEVICE|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
218944627|NCT05625555|DRUG|Ketamine|IV Ketamine infusion 0.5mg/kg over 40 minutes
218944628|NCT05625555|DRUG|Midazolam|IV Midazolam infusion 30μg/kg over 40 minutes
218944629|NCT01099449|DRUG|calcium gluconate|Given IV
218944630|NCT01099449|DRUG|magnesium sulfate|Given IV
218944631|NCT01099449|OTHER|placebo|Given IV
218944632|NCT01099449|DRUG|oxaliplatin|
218944633|NCT03528499|OTHER|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
218944634|NCT03528499|OTHER|General Exercises|Strengthening and stretching exercises.
218944635|NCT00146848|DEVICE|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
218944636|NCT02527772|DRUG|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
218944637|NCT02527772|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
218944638|NCT02451384|PROCEDURE|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
218944639|NCT02451384|PROCEDURE|no-touch surgery|
218944640|NCT02451384|PROCEDURE|laparoscopic surgery|
218944641|NCT04500561|DRUG|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
218944642|NCT04185116|DEVICE|3D Optic System (Olympus VISERA Elite II 3D)|"Use of the 3D Optic System Olympus VISERA Elite II 3D"
218944643|NCT06033755|OTHER|Norwegian psychomotor physiotherapy|"The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months."
219634776|NCT02881515|OTHER|Medium Sodium Diet|Ten days of a medium sodium diet
219634777|NCT02881515|OTHER|High Sodium Diet|Ten days of a high sodium diet
219634778|NCT02262520|DRUG|Apixaban|
219634779|NCT02262520|DRUG|Digoxin|
219634780|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
219634781|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
219634782|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
219634783|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219634784|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
219634785|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
219634786|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219634787|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 3.1 Usage|Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
219634788|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
219634789|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 4.1 Usage|Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
219634790|NCT03068195|PROCEDURE|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
219634791|NCT03068195|PROCEDURE|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
219634792|NCT01050582|DRUG|Risperidone|As per local prescribing practices
219634793|NCT01050582|DRUG|Other atypical antipsychotic drugs|As per local prescribing practices
219634794|NCT03713060|DIAGNOSTIC_TEST|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
219634795|NCT02170974|DRUG|BIBR 1048 MS polymorph II|
219634796|NCT02170974|DRUG|BIBR 1048 MS polymorph I|
219634797|NCT04676269|BIOLOGICAL|Amnion only|Patients endometrium will be transplanted with amnion only (without seeded cells)
219634798|NCT04676269|BIOLOGICAL|Amnion - endometrium cells|Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
219634799|NCT04676269|BIOLOGICAL|Amnion - amnion epithelial cells|Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
219634800|NCT04676269|BIOLOGICAL|Amnion-EnSC-AESC|Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
219634801|NCT06499038|PROCEDURE|Total Hip Arthroplasty|Surgery for total hip replacement
219634802|NCT05484999|OTHER|Meals|12 weeks of medically tailored meals
219634803|NCT05484999|OTHER|Meals + Social Support|12 weeks of medically tailored meals and12 weeks of social media based support
219634804|NCT05484999|OTHER|Control|Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
219634805|NCT00000945|DRUG|Cidofovir|
219634806|NCT00000945|DRUG|Probenecid|
219634807|NCT04162431|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
219634808|NCT04162431|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
219634809|NCT04162431|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
219634810|NCT01859169|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
218944644|NCT03730090|DEVICE|zero flux skin termometer|Core temperature is monitored continously, non-invasively
218944645|NCT04978103|DRUG|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
218944646|NCT03385772|PROCEDURE|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
218944647|NCT04915378|OTHER|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
218944648|NCT04915378|PROCEDURE|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
218944649|NCT00922727|BIOLOGICAL|L. reuteri|The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.
218944650|NCT00922727|BIOLOGICAL|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
218944651|NCT04865900|DIAGNOSTIC_TEST|Laboratory Blood Tests|Blood tests to determine liver and kidney functioning, total blood count, and troponin levels
218944652|NCT04865900|DIAGNOSTIC_TEST|ECG|ECG to determine heart rate and functioning
218944653|NCT04865900|DIAGNOSTIC_TEST|PCR|PCR test to determine whether patient has Covid19
218944654|NCT04865900|DIAGNOSTIC_TEST|Antibody test|Antibody test to determine level of antibodies to Covid19
218944655|NCT04865900|DIAGNOSTIC_TEST|Echocardiography|If Troponin level elevated echocardiography to determine heart function
218944656|NCT04865900|DIAGNOSTIC_TEST|MRI|If Troponin level elevated MRI to determine heart function
218944657|NCT04408560|DRUG|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH
218944658|NCT04408560|OTHER|paracetamol (drug analgesic class1)|paracetamol (drug analgesic class1)
218944659|NCT03386838|BIOLOGICAL|Nivolumab|Specified dose on specified days
218944660|NCT03386838|DRUG|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
218944661|NCT03386838|BIOLOGICAL|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
218944662|NCT03386838|DRUG|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
218944663|NCT03386838|DRUG|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
218944664|NCT03386838|DRUG|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
218944665|NCT03794830|OTHER|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
218944666|NCT03794830|OTHER|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
218944667|NCT02410889|OTHER|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
218944668|NCT01238484|OTHER|Standard of care|shoe modification home stretching exercises
218944669|NCT01238484|DEVICE|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
218944670|NCT05224804|BEHAVIORAL|knwoledge|Knowledge and Attitudes about ADRs Reporting
218944671|NCT03449641|DEVICE|Positive airway pressure (PAP)|Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
218944672|NCT03497351|DRUG|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
218944673|NCT03497351|DRUG|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
218944674|NCT01801267|PROCEDURE|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
218944675|NCT01801267|PROCEDURE|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
218944676|NCT01380626|PROCEDURE|exercise training|strength and endurance training, 5 time per week.
218944677|NCT00230867|DEVICE|iontophoretic acyclovir|
218944678|NCT00572767|DRUG|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
218944679|NCT00572767|OTHER|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
219634811|NCT01543035|DRUG|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
219634812|NCT00912743|DRUG|olaparib|400 mg po bid continuously
219634813|NCT01615406|DRUG|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
219634814|NCT00694083|DRUG|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
218944680|NCT05552417|OTHER|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
219634815|NCT03447561|BEHAVIORAL|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
219634816|NCT03447561|BEHAVIORAL|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
219634817|NCT00570193|DRUG|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
219634818|NCT00570193|DRUG|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol
219634819|NCT03291184|DEVICE|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
219634820|NCT03431831|BEHAVIORAL|Intervention Control|diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
219634821|NCT03431831|BEHAVIORAL|Counselling|Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
219634822|NCT03431831|DRUG|Contrave|In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
219634823|NCT03431831|DRUG|Contrave and Counseling|This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
219634824|NCT00885664|DRUG|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
219634825|NCT00885664|DRUG|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
219634826|NCT00685399|DRUG|AIN457|AIN457 subcutaneous dose
219634827|NCT00685399|DRUG|AIN 457|AIN457 low dose (i.v)
219634828|NCT00685399|DRUG|AIN457|AIN457 high dose (i.v)
219634829|NCT04891146|OTHER|Systemic inflammatory immmune index|Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
219634830|NCT01863199|DRUG|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
219634831|NCT01863199|DRUG|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
219634832|NCT01863199|DRUG|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
219634833|NCT02218047|DRUG|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
219634834|NCT02218047|DRUG|Best available therapy (BAT)|Best available therapy as selected by the investigator
219052430|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
219052431|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
219052432|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
219052433|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
219052434|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
219052435|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
219052436|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
219052437|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
219052438|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
219052439|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
219052440|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
218944681|NCT00618085|BEHAVIORAL|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
218944682|NCT00618085|OTHER|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
218944683|NCT05926518|PROCEDURE|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
218944684|NCT01115322|DRUG|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944685|NCT01115322|DRUG|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944686|NCT01115322|DRUG|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944687|NCT01115322|DRUG|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
219634835|NCT06574841|OTHER|Blood Flow Restriction training|BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
218944688|NCT01115322|DRUG|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944689|NCT01115322|DRUG|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
219052441|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
219052442|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
219052443|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
219052444|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
219052445|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
219634836|NCT01522378|DRUG|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
219634837|NCT04830371|BIOLOGICAL|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
219634838|NCT04830371|BIOLOGICAL|Typbar-TCV|Single dose, Intramuscular administration
219634839|NCT01488383|DRUG|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
219634840|NCT01488383|DRUG|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
219634841|NCT02166398|DRUG|UI15AML055MT|tab, PO
219634842|NCT02166398|DRUG|Amosartan 5/50|tab, PO
219052446|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
219052447|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
219052448|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
219052449|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
219052450|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
219052451|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
219634843|NCT01750697|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
219634844|NCT05445505|DEVICE|intermittent theta burst stimulation|iTBS is a new form of excitatory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
219052452|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
219052453|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
219052454|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
219634845|NCT05445505|DEVICE|sham iTBS|The pseudo-stimulation device looks and sounds the same as the iTBS device
218944690|NCT01115322|DRUG|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
218944691|NCT01115322|DRUG|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944692|NCT01115322|DRUG|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
218944693|NCT02925949|BEHAVIORAL|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
218944694|NCT02925949|BEHAVIORAL|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
218944695|NCT00824733|DRUG|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
218944696|NCT00824733|DRUG|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
218944697|NCT00824733|OTHER|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
218944698|NCT00575484|DRUG|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
218944699|NCT00575484|DRUG|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
218944700|NCT04179292|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
218944701|NCT04179292|OTHER|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
218944702|NCT02352285|DRUG|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
218944703|NCT02352285|DRUG|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
218944704|NCT02512835|OTHER|Community vital signs|We will present clinicians with information about their patients' communities
218944705|NCT00301613|DRUG|Mycophenolate mofetil|MMF,1.0g/d
218944706|NCT05861817|DEVICE|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
218944707|NCT00756535|PROCEDURE|Exercise training|Group-based exercise training 5 days a week during hospitalization
218944708|NCT00756535|PROCEDURE|usual treatment and rehabilitation|usual treatment and rehabilitation
218944709|NCT04944264|BEHAVIORAL|Stress Management and Resiliency Training (SMART) program|The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.
218944710|NCT00651729|BIOLOGICAL|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
218944711|NCT00271505|DRUG|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
218944712|NCT00271505|DRUG|Carboplatin|AUC 6 IV every 3 weeks
218944713|NCT00271505|DRUG|Docetaxel|75 mg/m2 IV every 3 weeks
218944714|NCT02377661|DRUG|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
218944715|NCT00444561|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC administration
219052455|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
219052456|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
219052457|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
219052458|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
218944716|NCT04713397|DIAGNOSTIC_TEST|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
218944717|NCT05379010|PROCEDURE|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
218944718|NCT04556383|DRUG|GB004|oral tablet
218944719|NCT04556383|DRUG|Placebo|oral tablet
218944720|NCT04189185|PROCEDURE|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
219206852|NCT06740162|BEHAVIORAL|PACE Program|The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
219634846|NCT03980145|DEVICE|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
218944721|NCT03891238|DRUG|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
218944722|NCT05692336|OTHER|vestibular training|balance training in the form of vestibular training
218944723|NCT05692336|OTHER|dual task training|balance training in the form of dual task training
218944724|NCT05675644|DRUG|Drospirenone-only pill|Single dose based on adaptive dose-finding design
218944725|NCT03811860|DIAGNOSTIC_TEST|Lithium level|The level of lithium in the serum
218944726|NCT03811860|DIAGNOSTIC_TEST|Serum Creatinine|The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
218944727|NCT03706248|OTHER|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
219634847|NCT03980145|OTHER|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
219634848|NCT00532389|DRUG|LBH589|
219634849|NCT04791189|OTHER|questionnaire|questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
219634850|NCT03317730|DRUG|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
218944728|NCT01146457|DRUG|Morphine|Active dosage
218944729|NCT01146457|DRUG|Saline|Saline Control
218944730|NCT01715441|DRUG|Sorafenib and irinotecan combination|
218944731|NCT01715441|DRUG|Sorafenib monotherapy|
218944732|NCT01715441|DRUG|Irinotecan monotherapy|
218944733|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
219634851|NCT06577038|DEVICE|PCI with use of IVL|Use of IVL for the treatment of calcific coronary artery lesions at operator's discretion
219634852|NCT03518762|PROCEDURE|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
218944734|NCT00119678|DRUG|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
218944735|NCT00119678|DRUG|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
218944736|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
218944737|NCT00004930|DRUG|doxorubicin hydrochloride|
218944738|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
218944739|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
219206853|NCT06740565|PROCEDURE|thoracic endovascular aortic repair|stent-graft implanted to seal the proximal entry tear of type B aortic dissection
218944740|NCT05343767|OTHER|Metformin|A total dose of 2000 mg was administered per day.
218944741|NCT01761240|DRUG|MORAb-066|MORAb-066 infusion.
218944742|NCT02356900|PROCEDURE|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
218944743|NCT02356900|PROCEDURE|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
218944744|NCT02356900|DRUG|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
219206854|NCT06740825|DRUG|Quizartinib|Single oral dose of 60 mg
219052459|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
219052460|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
218944745|NCT03479333|DEVICE|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
218944746|NCT03479333|DEVICE|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
218944747|NCT06171477|DEVICE|Ventilation 20-40-60|The respiratory rate during mechanical ventilation will be altered from 20 to 40 and finally to 60 breaths per minute.
218944748|NCT06171477|DEVICE|Ventilation 60-40-20|The respiratory rate during mechanical ventilation will be altered from 60 to 40 and finally to 20 breaths per minute.
218944749|NCT06171477|DEVICE|Ventilation 40-60-20|The respiratory rate during mechanical ventilation will be altered from 40 to 60 and finally to 20 breaths per minute.
218944750|NCT03894397|DEVICE|Electrical stimulation of the BNST|Electrical stimulation of the BNST
218944751|NCT00504530|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
218944752|NCT02009540|DRUG|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
219052461|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
219052462|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
219052463|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
219052464|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
219634853|NCT03518762|PROCEDURE|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
219634854|NCT02384746|DRUG|Fulvestrant|500 mg intramuscular every 28 days
219634855|NCT02384746|DRUG|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
219634856|NCT04681820|DRUG|Flumatinib|Flumatinib mesylate tablets 600mg qd for 24 months
219634857|NCT04681820|DRUG|Nilotinib|Nilotinib Capsules 400mg bid for 24 months
219634858|NCT00744965|DRUG|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
219634859|NCT00744965|DRUG|Placebo|Sham dose adjustments of the placebo will be made.
219634860|NCT00208169|DRUG|Aripiprazole|
219634861|NCT00000412|DRUG|Alendronate|
219634862|NCT00000412|DRUG|Calcitriol|
218944753|NCT02009540|DRUG|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
218944754|NCT00509145|DRUG|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
218944755|NCT00509145|OTHER|Placebo|oral, once daily, capsule
218944756|NCT05981053|DIETARY_SUPPLEMENT|Wine enriched with Resveratrol|Wine enriched with Resveratrol
218944757|NCT01685151|DRUG|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
218944758|NCT01685151|DRUG|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
218944759|NCT01685151|DRUG|Placebo|Placebo
219052465|NCT01970202|OTHER|Control|no treatment
219052466|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
219052467|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
219052468|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
219052469|NCT02517905|DRUG|Bupivacaine liposome|Local administration
219052470|NCT02517905|DRUG|Placebo|Local administration
219052471|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
219052472|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
219052473|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
219634863|NCT00000412|DRUG|Placebo Alendronate|
219634864|NCT00000412|DRUG|Placebo Calcitriol|
219634865|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
219634866|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
219634867|NCT00747019|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
219634868|NCT00747019|BEHAVIORAL|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
219634869|NCT03107585|PROCEDURE|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
219634870|NCT03132844|OTHER|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
219634871|NCT03532386|PROCEDURE|ICSI|ICSI for both couples
219634872|NCT01586923|BIOLOGICAL|RBC transfusion|RBC transfusion of different storage age
219634873|NCT01137058|DEVICE|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
219634874|NCT01137058|DEVICE|SMBG group|Glucose control with self monitoring of blood glucose.
219634875|NCT03537976|OTHER|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
219634876|NCT05794776|DEVICE|BurstDR stimulation|BurstDR spinal cord stimulation
219634877|NCT05794776|DEVICE|Tonic stimulation|Tonic spinal cord stimulation
219634878|NCT05794776|DEVICE|No stimulation|Stimulator is switched off
219634879|NCT03661931|DIAGNOSTIC_TEST|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
219052474|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
219052475|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
219052476|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
219052477|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
219052478|NCT01678534|DRUG|Placebo|
219052479|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
219206855|NCT06740825|DRUG|Rufinamide|Twice daily (BID) dose of 400 mg on Days 1 through 32
219634880|NCT01985191|DRUG|SAR405838|"Pharmaceutical form:capsule~Route of administration: oral"
219634881|NCT01985191|DRUG|Pimasertib|"Pharmaceutical form: capsule~Route of administration: oral"
219634882|NCT05055960|DIAGNOSTIC_TEST|Stroke simulation and machine learning|Using simulation and machine learning approaches to classify the source of embolic stroke.
219634883|NCT05751980|BEHAVIORAL|Med Wise Rx|The program consists of two 120-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.
219634884|NCT02177526|DEVICE|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
219634885|NCT06303557|DRUG|Preoperative Erector Spinae Plane Block|Erector spinae plane block will be performed bilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the prone position.
219634886|NCT06303557|DRUG|Postoperative Erector Spinae Plane Block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the prone position.
219634887|NCT03313466|BEHAVIORAL|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
219634888|NCT03313466|BEHAVIORAL|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
218944760|NCT03484793|OTHER|AESOP service system|Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
218944761|NCT00977119|OTHER|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
218944762|NCT00977119|OTHER|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
218944763|NCT05155254|DRUG|IO102-IO103|IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
218944764|NCT05155254|DRUG|Pembrolizumab|Pembrolizumab administered intravenously
218944765|NCT03687944|OTHER|Validity and reliability|Test-retest method and concurrent validity
218944766|NCT04343105|PROCEDURE|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
218944767|NCT01994889|DRUG|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
218944768|NCT01994889|DRUG|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
218944769|NCT01994889|DRUG|Placebo|Placebo in soft gel capsules administered once a day for 30 months
218944770|NCT03632954|DEVICE|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
218944771|NCT02969655|DRUG|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
218944772|NCT02969655|DRUG|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
218944773|NCT02969655|DRUG|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
218944774|NCT02969655|DRUG|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
218944775|NCT02969655|DRUG|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
218944776|NCT02969655|DRUG|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
218944777|NCT03853278|BEHAVIORAL|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
218944778|NCT04027478|DIETARY_SUPPLEMENT|FMD|fasting mimicking diet
219052480|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
219634889|NCT04869774|DEVICE|How2Trak mobile application|Patients will undergo virtual monitoring of their incision and symptoms using the How2Trak application(app). Using the app, patients will be asked to answer a series of questions and photograph their surgical incision on post-operative day 3, 5, 7, 10, 20, and 30. Patient responses and photographs entered into the app will be reviewed within 72 hours by a trained Nurse Specialized in Wound, Ostomy and Continence. If a concern is identified the nurse will contact the patient to arrange a virtual visit using the how2trak app or notify the surgeon team (including colorectal surgeons and physician residents) in accordance with clinical discretion.
219634890|NCT05648201|DRUG|Doravirine 100Mg Tab|1 single dose of 100mg taken orally
219634891|NCT05648201|DRUG|Raltegravir 600Mg Tab|1 single dose of 1200mg taken orally
218944779|NCT03767790|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
218944780|NCT00236704|DRUG|topiramate|
218944781|NCT06225869|BEHAVIORAL|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
218944782|NCT02600780|DRUG|Febuxostat|Comparison of two anti-hyperuricemic molecules
218944783|NCT02600780|DRUG|Allopurinol|Comparison of two anti-hyperuricemic molecules
218944784|NCT00136513|DRUG|SB-743921|
218944785|NCT02674204|DRUG|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
218944786|NCT02674204|DRUG|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
218944787|NCT00437008|DRUG|Benfotiamine 1050mg, 3 days|
218944788|NCT00437008|BEHAVIORAL|high-AGE vs. low-AGE meal|
219052481|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
219052482|NCT00466960|BIOLOGICAL|sargramostim|Given SC
219052483|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219052484|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
219052485|NCT00466960|OTHER|immunologic technique|Correlative studies
219052486|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
219634892|NCT05648201|DRUG|Biktarvy 50/200/25 Tab|1 single dose of 50/200/25 taken orally
219634893|NCT05896904|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
219052487|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
219052488|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
219052489|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
219052490|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
219052491|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
219052492|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
219052493|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
219052494|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
219052495|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
219052496|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
219052497|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
219052498|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
219052499|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
219052500|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
219052501|NCT05893277|BEHAVIORAL|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
219052502|NCT05738278|BEHAVIORAL|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
219052503|NCT05738278|BEHAVIORAL|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
219634894|NCT00846001|PROCEDURE|Coronary artery bypass grafting|Standard coronary surgry according guidelines
219634895|NCT00846001|DEVICE|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
218944789|NCT06156709|PROCEDURE|Group I: Lower Volume with Higher Anaesthetic Concentration|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
218944790|NCT06156709|PROCEDURE|Group II: Higher Volume with LowerAnaesthetic Concentration|20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
218944791|NCT01748240|DRUG|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
218944792|NCT04075253|BEHAVIORAL|VO2 peak testing|Exercise on treadmill starts with \~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
218944793|NCT03844204|DEVICE|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
218944794|NCT00272025|DRUG|Escitalopram|10mg to 20mg tablet daily for 6 weeks
218944795|NCT00272025|DRUG|placebo|
218944796|NCT00486811|DRUG|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
218944797|NCT00486811|DRUG|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
218944798|NCT00486811|DRUG|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
218944799|NCT02369744|DRUG|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
218944800|NCT02369744|DRUG|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
219634896|NCT02097563|BEHAVIORAL|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
219634897|NCT02097563|BEHAVIORAL|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
218944801|NCT02659748|DIETARY_SUPPLEMENT|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
218944802|NCT02659748|DIETARY_SUPPLEMENT|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
218944803|NCT01146587|DEVICE|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
218944804|NCT01146587|DEVICE|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
218944805|NCT01146587|OTHER|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
218944806|NCT02845167|OTHER|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
219052504|NCT06806228|BIOLOGICAL|S-Gboxin|Gboxin specifically inhibits the growth of human glioblastoma cells but not normal cells. Gboxin rapidly and irreversibly impairs oxygen consumption in glioblastoma cells. Its positive charge for binding to mitochondrial oxidative phosphorylation complexes is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits F 0 F 1 ATP synthase activity in tumor cells. S-Gboxin crosses the blood-brain barrier at therapeutically effective concentrations.
219052505|NCT05607953|DRUG|SD-101|SD-101 doses are administered via PRVI using the PEDD method of administration
218944807|NCT05149885|DEVICE|SenseGuard monitoring|All subjects that recruited to the study will undergo MCT as usual with the addition of SG measurement after each Methacholine dose and spirometry test.
219052506|NCT05607953|BIOLOGICAL|anti-PD-1|In the Phase 1b, anti-PD-1 will be administered together with SD-101
219634898|NCT04042714|DRUG|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
219634899|NCT01371110|DRUG|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
219634900|NCT01371110|DRUG|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
219634901|NCT04450082|PROCEDURE|One anastomosis gastric bypass|The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
219634902|NCT03711682|DIETARY_SUPPLEMENT|Cinnamon|Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
219634903|NCT03711682|DIETARY_SUPPLEMENT|Wheat Flour|Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
219634904|NCT04691843|DRUG|Iron Sulfate|Early, high dose, iron supplementation
219634905|NCT02994225|DRUG|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
219634906|NCT04219124|DRUG|IMP oral tablet|Dapagliflozin 10 MG
219634907|NCT04219124|DRUG|Placebo oral tablet|Matching placebo tablets
219634908|NCT02342158|PROCEDURE|biopsy or surgical sampling|
219634909|NCT02342158|OTHER|blood sampling|
219634910|NCT04195243|DRUG|Dapagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
219052507|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
219052508|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
219634911|NCT04195243|DRUG|Empagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
218944808|NCT00597597|DRUG|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
218944809|NCT02249000|DEVICE|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
219052509|NCT01755416|DRUG|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
219052510|NCT01755416|DRUG|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
219052511|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
219052512|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
219052513|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
219634912|NCT04195243|DRUG|Placebo pill|The patient will take one pill, every 24 hr, during 7 days
219052514|NCT01013233|OTHER|control group|no intervention
219052515|NCT00758628|DRUG|Bromefenac|Bromfenac BID 3 months
219052516|NCT00758628|DRUG|Blink|Blink BID for 3 months
219052517|NCT06239961|BEHAVIORAL|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
219052518|NCT06239961|BEHAVIORAL|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
219052519|NCT06239961|BEHAVIORAL|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
219052520|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
219634913|NCT03753464|PROCEDURE|Gingival biopsy and blood sample collection|Gingival and blood samples will be collected.
219634914|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
219634915|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
219634916|NCT03991962|DRUG|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
219634917|NCT03991962|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
219634918|NCT06578169|DRUG|Hormonal Therapy Agent|Women initiating either Hormonal Contraceptives or Hormone replacement therapy in menopause
218944810|NCT02237222|OTHER|Gait rehabilitation|
218944811|NCT04650867|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
218944812|NCT04287582|OTHER|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
219052521|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
219634919|NCT01421225|DEVICE|Closed-loop Insulin Pump therapy|Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
219634920|NCT01421225|DEVICE|Standard Insulin Pump Therapy|Subjects insulin doses followed their usual home routine.
219634921|NCT04155216|BEHAVIORAL|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
218944813|NCT03050385|DEVICE|transcranial direct current stimulation|
219052522|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
219052523|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
219634922|NCT04398589|DRUG|Dexmedetomidine injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
219052524|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
219634923|NCT04398589|DRUG|Saline injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
219634924|NCT03618173|DRUG|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
219634925|NCT03618173|DRUG|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
219052525|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
219052526|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
219634926|NCT00911612|DRUG|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
219634927|NCT00911612|DRUG|Placebo|Inert capsule matching the study drug, given twice daily
219634928|NCT00708812|DRUG|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
218944814|NCT04119466|BEHAVIORAL|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
219634929|NCT00708812|DRUG|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
219634930|NCT00966524|PROCEDURE|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
218944815|NCT03276455|GENETIC|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
218944816|NCT03241719|DRUG|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
218944817|NCT04334577|BIOLOGICAL|live attenuated zoster vaccine|subcutaneous injection
218944818|NCT04334577|BIOLOGICAL|placebo|subcutaneous injection
218944819|NCT01785485|OTHER|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
218944820|NCT00351871|DRUG|PEG-Intron Plus REBETOL|
218944821|NCT02779322|PROCEDURE|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
218944822|NCT02779322|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
218944823|NCT00995059|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
218944824|NCT00995059|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
219206856|NCT06798428|DEVICE|group A will receive ultrasound phonophoresis (Glucosamine, Chondroitin and Some Herbs Extract )|Group (A)will have GL, CH and natural herbs phonophoresis .Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm).
219634931|NCT00786981|OTHER|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
219634932|NCT00786981|OTHER|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
219634933|NCT02049814|DRUG|Metformin|Metformin tablets
219634934|NCT02049814|DRUG|Voglibose|Voglibose tablets
218944825|NCT00995059|DRUG|bortezomib|Given IV
218944826|NCT00995059|DRUG|melphalan|Given IV
218944827|NCT00995059|DRUG|anti-thymocyte globulin|Given IV
218944828|NCT00995059|DRUG|sirolimus|Given orally
218944829|NCT00995059|DRUG|tacrolimus|Given oral or IV
218944830|NCT00995059|RADIATION|total-body irradiation|Undergo total-body irradiation
218944831|NCT05800301|BIOLOGICAL|Wharton's jelly derived mesenchymal stemcells|The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.
218944832|NCT05800301|DEVICE|Magnovision|Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
218944833|NCT03111186|DRUG|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
218944834|NCT03111186|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
218944835|NCT03111186|DRUG|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
219206857|NCT06798428|DEVICE|Group B will receive ultrasound with topical gel , same parameter as group A|Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm). Topical gel with no drugs
218944836|NCT01836978|OTHER|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
219206858|NCT06798428|DEVICE|Group C sham ultrasound for massage - 5 minutes|sham ultrasound for massage - 5 minutes
219634935|NCT02049814|DRUG|Acarbose|Acarbose tablets
219634936|NCT03781635|DRUG|bolus of intravenous ketamine|low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
218944837|NCT02929498|DRUG|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
218944838|NCT02929498|DRUG|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
218944839|NCT02613026|DRUG|Pirarubicin|
218944840|NCT02613026|DRUG|Docetaxel|
218944841|NCT02613026|DRUG|Cyclophosphamide|
219634937|NCT03781635|DRUG|continuous infusion of intravenous ketamine|An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
219634938|NCT02766803|DRUG|Simvastatin and micronized trans-resveratrol|
219634939|NCT05354778|DRUG|Hydrocortisone|Corticosteroid
219634940|NCT05354778|DRUG|Placebo|Normal saline only
219634941|NCT00172328|BIOLOGICAL|Hepatitis B vaccine|
219634942|NCT00832611|DEVICE|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
218944842|NCT03666364|OTHER|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
218944843|NCT01415336|DRUG|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
218944844|NCT01415336|DRUG|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
218944845|NCT02862340|GENETIC|Genetic test|
218944846|NCT04620876|OTHER|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
218944847|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
218944848|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
218944849|NCT01642615|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
218944850|NCT00912184|DEVICE|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
218944851|NCT00912184|DEVICE|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
218944852|NCT04221776|OTHER|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
219634943|NCT06389305|DRUG|peripheral blood lymphocytes|autologous or allogeneic peripheral blood lymphocytes
219634944|NCT06389305|DRUG|CIK cell|autologous or allogeneic cytokine-induced killer (CIK) cells
219634945|NCT02292953|OTHER|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
219634946|NCT05969769|OTHER|Thoracic Sustained Natural Apophyseal Glides|Sustained Natural Apophyseal Glides 3 sets of 10 reps with 1 min rest btw sets.
219634947|NCT05969769|OTHER|Muscle Energy Techniques|Short wave diathermy for 10 to 15 mins Muscle Energy Techniques of following muscles will be performed, Hip flexors muscles, Quadrates lamborum muscles, Erector spinae muscles, Piriformis muscles, PFS technique of METs Isometric hold 5-7 sec, Stretching 15 sec, Rest 30 sec.
219634948|NCT04758364|OTHER|measurement of gait speed|Cross sectional, cohort
219634949|NCT06141174|OTHER|disease outcome ( mortality and length of stay )|insertion of intercostal tube to drain pleural collection
219634950|NCT01091857|BEHAVIORAL|STRIDE|
219634951|NCT04777786|OTHER|Physical Therapy|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
219634952|NCT00214786|BIOLOGICAL|Islet cell transplantation|Allogenic islet transplantation
219634953|NCT02993250|DRUG|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
219634954|NCT02993250|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
219634955|NCT02993250|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
219634956|NCT06574958|BIOLOGICAL|CD38/CS1 injection|"Dosage form and specification: injection, 40mL/ dose, according to the number of positive cells 1×106/kg Properties: Colorless or slightly light white clear liquid Prescription composition: CD38/CS1 CAR T cells, 2.5% human blood albumin, 0.9% sodium chloride injection.~Administration mode: intravenous injection Storage condition: 2-8℃ for 8h Mechanism of action :38WP as a dual-target CAR T cell therapy, compared with single-target CAR T cell therapy, its advantage is that it can reduce antigen escape of tumor cells."
219634957|NCT05582408|DEVICE|Measures of Standard Noise Reduction NR1|Each participant will be fitted with the Standard Noise Reduction (NR1)
219634958|NCT05582408|DEVICE|Measures of Noise Reduction Principle NR2|Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid
218944853|NCT04221776|OTHER|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
219634959|NCT05582408|DEVICE|Measure of Noise Reduction Principle NR3|Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
219634960|NCT02566642|OTHER|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
219634961|NCT02571842|DRUG|Intravenous Rituximab|\- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
218944854|NCT03859362|DRUG|Ertapenem Injection|1 g of ertapenem q24h, 30 min infusion
218944855|NCT00410098|BEHAVIORAL|Bikram Yoga|
218944856|NCT06329895|DRUG|BAY2927088|Oral administration.
218944857|NCT06329895|DRUG|Dabigatran etexilate|Oral administration.
218944858|NCT06329895|DRUG|Rosuvastatin|Oral administration.
218944859|NCT01028300|DEVICE|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
218944860|NCT00845091|BEHAVIORAL|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
218944861|NCT00845091|BEHAVIORAL|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
218944862|NCT01214395|DRUG|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
218944863|NCT00715910|BIOLOGICAL|Nimenrix|One dose, as intramuscular injection
218944864|NCT00715910|PROCEDURE|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
218944865|NCT06067620|PROCEDURE|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.
218944866|NCT06067620|PROCEDURE|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
218944867|NCT04136782|DRUG|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
218944868|NCT04136782|DRUG|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
218944869|NCT04166240|BEHAVIORAL|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series \[VBTS\] Collaborative supplemented with automated surveillance data on test results.
218944870|NCT03854994|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
218944871|NCT04950478|OTHER|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
218944872|NCT02215018|DRUG|BI 44370 TA solution|
218944873|NCT02215018|DRUG|BI 44370 TA tablet|
218944874|NCT02215018|DRUG|Placebo solution|
218944875|NCT02215018|DRUG|Placebo tablet|
219052527|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
219634962|NCT02571842|DRUG|ACEI/ARB and corticosteroids|"* ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
219634963|NCT01888445|DRUG|roxadustat|oral
219634964|NCT01888445|DRUG|darbepoetin alfa|iv
218944876|NCT05453149|BEHAVIORAL|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
218944877|NCT02335814|DRUG|FLX925|
218944878|NCT05128708|PROCEDURE|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
218944879|NCT02938715|OTHER|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
218944880|NCT05201664|PROCEDURE|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
218944881|NCT00796926|DRUG|Systane Ultra eyedrops|Four times a day
218944882|NCT00796926|DRUG|Refresh eye drops|Four times a day
219052528|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
219634965|NCT01416974|DRUG|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
219634966|NCT01416974|BIOLOGICAL|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
218944883|NCT05825157|DEVICE|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
218944884|NCT03391245|DIAGNOSTIC_TEST|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
218944885|NCT02479646|BIOLOGICAL|MYL-1401H|
218944886|NCT02479646|BIOLOGICAL|EU-Neulasta|
218944887|NCT02479646|BIOLOGICAL|US-Neulasta|
218944888|NCT05291312|PROCEDURE|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
218944889|NCT04427982|BEHAVIORAL|dance|Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
218944890|NCT04427982|BEHAVIORAL|diabetes education|The dance classes will be followed by a brief diabetes education and discussion session.
218944891|NCT03593616|PROCEDURE|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
218944892|NCT02681354|OTHER|Biorescue training|
219206859|NCT06737926|BEHAVIORAL|Sensorimotor Training Exercise|Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
219634967|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
219634968|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
218944896|NCT00456170|PROCEDURE|Performing Vaginal hysterectomy with Harmonic Scalpel|
218944897|NCT00380380|DRUG|Vildagliptin|
218944898|NCT00624169|PROCEDURE|An optimized perioperative course|A number of interventions before, during and after surgery
218944899|NCT01750749|BIOLOGICAL|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
219634969|NCT05871944|OTHER|KAlternborn Joint Mobilization|This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion
219634970|NCT05871944|OTHER|Post stretch Facilitation Technique|This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
219634971|NCT03172923|DEVICE|sliding hip screw|fixation of the fracture with a sliding hip screw
219634972|NCT03172923|DEVICE|intramedullary nial|fixation of the fracture with an intramedullary nail
219634973|NCT02527434|BIOLOGICAL|Tremelimumab monotherapy|IV infusion
218944900|NCT01085006|DRUG|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
218944901|NCT01085006|DRUG|Normal saline|Tranexamic acid in cases, normal saline in controls
218944902|NCT04077788|OTHER|muscle energy technique|"Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms."
218944903|NCT02551549|DRUG|CD101 IV|antifungal
218944904|NCT02551549|DRUG|Placebo|Normal saline
218944905|NCT01209013|DEVICE|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
218944906|NCT01209013|PROCEDURE|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
218944907|NCT01209013|PROCEDURE|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
218944908|NCT01209013|PROCEDURE|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
218944909|NCT01209013|PROCEDURE|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
218944910|NCT01209013|PROCEDURE|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
218944911|NCT01209013|PROCEDURE|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
218944912|NCT04046614|DRUG|nintedanib-nivolumab combination therapy|"Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease."
218944913|NCT00006289|DRUG|Placebo|4 tabs b.i.d.
218944914|NCT00006289|DRUG|Neurotropin|4 tabs b.i.d.
219634974|NCT02527434|BIOLOGICAL|MEDI4736 monotherapy|IV infusion
219634975|NCT02527434|BIOLOGICAL|MEDI4736 + tremelimumab combination therapy|IV infusion
219634976|NCT05654870|DRUG|Valbenazine|Oral treatment
219634977|NCT05654870|DRUG|Placebo|Placebo matching valbenazine
219634978|NCT00014430|BIOLOGICAL|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation-functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
219634979|NCT00014430|DRUG|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
218944915|NCT02973438|DEVICE|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
218944916|NCT02973438|DEVICE|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
218944917|NCT02873949|BIOLOGICAL|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
218944918|NCT02873949|BIOLOGICAL|Saliva samples (1ml)|
219634980|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for the first 14 days of each 28-day cycle.
218944919|NCT02873949|OTHER|Etiologic treatment|education on oral hygiene, scaling and root planing
218944920|NCT02873949|OTHER|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
218944921|NCT02098668|OTHER|Fertility treatment|Fertility treatment
218944922|NCT06464783|OTHER|Comprehensive Corrective Exercise Program|"Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps)."
218944923|NCT06464783|OTHER|Thoracic Exercise Program|"Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)"
218944924|NCT04241419|BEHAVIORAL|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
218944925|NCT03211052|DRUG|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
218944926|NCT03211052|PROCEDURE|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
218944927|NCT06522594|DRUG|Esmolol|A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
218944928|NCT03807375|OTHER|CPAP preoxygenation|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
218944929|NCT02079272|OTHER|Helical tomotherapy for breast cancer|"1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy"
219052529|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
219052530|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
219206860|NCT06737926|BEHAVIORAL|Conventional Exercise Therapy|Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
219206861|NCT06792253|DRUG|Ifupinostat Hydrochloride for Injection|Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
219634981|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for 28 days of each 28-day cycle.
219634982|NCT02655822|DRUG|Ciforadenant|200 mg orally once daily for the first 14 days of each 28-day cycle.
219634983|NCT02655822|DRUG|Ciforadenant + atezolizumab|Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
218944930|NCT03718780|OTHER|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~* 1\) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~* 2\) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
218944931|NCT03718780|OTHER|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
218944932|NCT03718780|OTHER|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
218944933|NCT04721587|DEVICE|Virtual Reality|"The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration"
218944934|NCT03817697|OTHER|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
218944935|NCT03013309|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
218944936|NCT03013309|OTHER|Treatment as usual|Treatment as usual
218944937|NCT00002272|DRUG|Foscarnet sodium|
218944938|NCT00501904|DRUG|Metformin|
218944939|NCT00539968|DRUG|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
218944940|NCT02465099|DEVICE|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
218944941|NCT02465099|DEVICE|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
218944942|NCT00582075|DRUG|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
218944943|NCT03438071|OTHER|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
219052531|NCT06991699|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
219052532|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
219052533|NCT02292628|OTHER|Infusion of placebo|
219206862|NCT06792253|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
219206863|NCT06792253|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
219634984|NCT02655822|DRUG|Ciforadenant|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
218944944|NCT05448885|DRUG|Tislelizumab|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
218944945|NCT04410133|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
218944946|NCT05092360|BIOLOGICAL|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
218944947|NCT05092360|BIOLOGICAL|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
218944948|NCT05092360|BIOLOGICAL|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
218944949|NCT05092360|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
218944950|NCT05092360|DRUG|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
218944951|NCT05092360|DRUG|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
218944952|NCT05092360|DRUG|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
219634985|NCT02648139|DRUG|Dentifrice|3x/day for 7 days.
218944953|NCT06384781|BEHAVIORAL|Peer Support Checklist|Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
218944954|NCT06449001|DRUG|Danicopan|Participants will receive danicopan on a weight-based dosing regimen.
218944955|NCT04180540|DEVICE|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
218944956|NCT04180540|OTHER|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
218944957|NCT07131813|DRUG|Tofacitinib 5 mg BID and Triamcinolone ointment|Patients in the test group will get tofacitinib 5mg capsules twice daily as an add on to triamcinolone ointment
218944958|NCT07131813|DRUG|Placebo and Triamcinolone ointment|Patients in the control group will receive identical looking capsules as placebo with triamcinolone ointment
218944959|NCT04423198|BEHAVIORAL|Cognitive Assessment|Self administered cognitive battery
218944960|NCT04423198|BEHAVIORAL|Patient Reported Neurological Outcome Assessments|Standard neurocognitive and neuropsychological tests
218944961|NCT04423198|PROCEDURE|Blood Draw|Specimen collection of whole blood, serum, RNA
218944962|NCT07066709|COMBINATION_PRODUCT|FDG PET/MRI|Participants will undergo an FDG PET/MRI
218944963|NCT05629676|BEHAVIORAL|BMT-VR|BMT-VR is a novel psychosocial intervention that addresses the supportive care needs of patients undergoing BMT. BMT-VR includes six sections focused on: 1) psychoeducation to help patients increase their awareness to stress and challenges that may accompany the BMT journey; 2) supportive psychotherapy strategies to help patients adjust to the intense BMT hospitalization; 3) psychosocial skill building to promote mindfulness, acceptance and gratitude while living with uncertainty; 4) psychoeducation to manage expectations and enhance preparedness for extended hospitalization; 5) psychosocial skill-building to promote effective coping; and 6) an overview of psychosocial skills grounded in cognitive behavior therapy, mindfulness, and positive psychology
218944964|NCT06942481|BEHAVIORAL|Girls Invest|The Girls Invest intervention involved: 1) app-based trainings on topics related to financial literacy, gender equity, and health and 2) financial resources/incentives supporting girls' education/career.
218944965|NCT06942481|BEHAVIORAL|Waitlist control|Participants receive Girls Invest after they complete the 6 month follow-up survey.
218944966|NCT07144826|PROCEDURE|Biospecimen Collection|Undergo blood and vaginal sample collection
218944967|NCT07144826|DRUG|Placebo Administration|Given PO
218944968|NCT07144826|DIETARY_SUPPLEMENT|Probiotic|Given PO
218944969|NCT07144826|OTHER|Questionnaire Administration|Ancillary studies
218944970|NCT07144982|BEHAVIORAL|Counselling session|Each enrolled parent received a single, standardized counselling session (\~15 minutes) delivered in the ambulatory unit by a certified tobacco counsellor. The session followed a fixed script and covered: (1) types of tobacco smoke exposure (primary, secondary and tertiary), (2) health consequences for children with emphasis on perioperative respiratory and anaesthetic risks, (3) practical measures to reduce household exposure (smoke-free home/car rules, behavioural strategies), and (4) brief advice on initial cessation steps and referral options. Structured handouts and signposting to support services were offered when appropriate.
219634986|NCT03249012|OTHER|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
219634987|NCT03249012|OTHER|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
219634988|NCT00862004|PROCEDURE|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
218944971|NCT07145307|DEVICE|Sidekick|An app for adolescents used to plan, complete and evaluate exposure exercises completed between sessions at a children and adolescent mental health clinic (BUP)
218944972|NCT07146035|DEVICE|CP369 Feasibility of a newly developed ostomy prototype (only one intervention)|The study is an open-label, single-arm, comparative study, investigating the feasibility of the prototype in subjects with ileostomy. The study is comparing the prototype exposed only to sweat (abdominal side) with the prototype exposed to sweat and output (peristomal side). Meaning, subjects are their own control.
218944973|NCT06946095|DRUG|Chinese patent medicine|This study aims to investigate whether the addition of Xinyue Capsule to conventional Western medical therapy significantly improves cardiac function and reduces the level of heart failure biomarker NT-proBNP in patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
218944974|NCT06946264|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (albuterol sulfate 2.5mg/ 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
218944975|NCT06946264|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (sodium chloride 0.9% 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
218944976|NCT06946121|DRUG|Lignocaine|50 women undergoing diagnostic outpatient office hysteroscopy proceeded by infusions of intrauterine lidocaine 2% and normal saline at room temperature.
218944977|NCT06946121|DRUG|Saline|50 women undergoing diagnostic outpatient office hysteroscopy using warmed normal saline distention medium.
218944978|NCT06945991|OTHER|observation group|the observation group was additionally managed with an integrated nursing and medical approach.
218944979|NCT06945991|OTHER|control group|The control group received routine nursing care
219634989|NCT02549326|DIETARY_SUPPLEMENT|vitamin D|
219634990|NCT02549326|DIETARY_SUPPLEMENT|Placebo|
219634991|NCT00542399|DRUG|Levemir (insulin detemir)|Levemir once a day
219634992|NCT00542399|DRUG|Levemir twice a day|Levemir twice a day
218944980|NCT07146828|DEVICE|Binocular Wavefront Optometry Machine (BWFOM, Ai-Zhitong Medical Technology Co., Ltd., Zhejiang, China)|The 0.05 D refraction group had their infusion rates precisely calibrated using 0.05 D refraction by the Binocular Wavefront Optometry Machine
218944981|NCT06947044|PROCEDURE|RBC transfusion strategy|RBC transfusion strategy to maintain a hemoglobin level of at least 110 g/L.
218944982|NCT07145177|DRUG|177Lu-PSMA-617|Given intravenously (IV)
218944983|NCT07145177|PROCEDURE|Ablation|Undergo ablation
218944984|NCT07145177|PROCEDURE|Trans-arterial chemoembolization (TACE)|Undergo TACE
218944985|NCT07145177|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
219634993|NCT05280938|BEHAVIORAL|MAAP|Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.
218944986|NCT07145177|PROCEDURE|Tumor Biopsy|Undergo biopsy
218944987|NCT07145177|OTHER|Questionnaire|Participant will complete questionnaire
218944988|NCT07145242|OTHER|Acupuncture|Intervention Description \* § Add details that will distinguish this intervention from other interventions in this or another clinical study.
218944989|NCT07145853|OTHER|Mandala activity|"The application will last for 1-2 hours once a week for a total of 8 weeks.~For individuals aged 65 years and over who meet the inclusion criteria and are included in the intervention group, a mandala draft in A4 format (21.0 cm x 29.7 cm) consisting of 8 round patterns to be determined in advance, and a dry paint set consisting of 12 colors for ease of use will be used. Quality dry paint will be used to prevent allergies"
219634994|NCT05280938|BEHAVIORAL|Educational Program|"The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects."
218944990|NCT06185270|DIAGNOSTIC_TEST|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
219634995|NCT00568061|DRUG|Nitric Oxide|Nitric oxide for inhalation
218944991|NCT03650946|DIAGNOSTIC_TEST|Ga-68 PSMA PET|Ga-68 PSMA PET
218944992|NCT03989869|OTHER|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
219634996|NCT00568061|DRUG|Placebo|Nitrogen gas (placebo) for inhalation
219634997|NCT06198153|OTHER|Stationary Cycling|In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.
218944993|NCT00480987|DRUG|Oxaliplatin|30 mg/m\^2 IV days 1-4
218944994|NCT00480987|DRUG|Fludarabine|30 mg/m\^2 IV days 2-6
218944995|NCT00480987|DRUG|Cytarabine|500 mg/m\^2 by IV continuous infusion days 2-6
218944996|NCT04369820|OTHER|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
218944997|NCT02648633|RADIATION|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
218944998|NCT02648633|DRUG|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
218944999|NCT02648633|DRUG|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
218945000|NCT01734889|DRUG|Nitisinone|Oral suspension
218945001|NCT03464292|DRUG|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
218945002|NCT03464292|OTHER|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
218945003|NCT00966875|BIOLOGICAL|LY2439821|Subcutaneous
218945004|NCT00966875|DRUG|Placebo|Subcutaneous
218945005|NCT04602234|DIAGNOSTIC_TEST|Lung ultrasonography|Investigators performed lung ultrasonography on patients
218945006|NCT00288899|OTHER|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
218945007|NCT00288899|OTHER|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
218945008|NCT01788813|DRUG|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
218945009|NCT01788813|DRUG|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
218945010|NCT00408941|DRUG|Propofol|
218945011|NCT00408941|DRUG|Prilocaine|
218945012|NCT01680198|DRUG|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
218945013|NCT01680198|DRUG|placebo|
218945014|NCT02591498|BEHAVIORAL|Computerized cognitive training|
218945015|NCT04657666|DRUG|Nabiximols|oromucosal spray
218945016|NCT04657666|DRUG|Placebo|oromucosal spray
219206864|NCT06792253|DRUG|Oxaliplatin Injection|Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
219052534|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
219634998|NCT06198153|OTHER|Progressive Functional Training|In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
219052535|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
218945017|NCT02386189|BEHAVIORAL|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
219052536|NCT07010159|DRUG|KPL-387|administered by subcutaneous injection
219052537|NCT07010159|DRUG|Placebo|administered by subcutaneous injection
219052538|NCT07017361|PROCEDURE|Conventional|Pre-operative fasting: NPO for solids and fluids from 00:00. No pre-emptive oral analgesia. Intra-operative: IV dexamethasone 5 mg at anaesthesia induction; IV acetaminophen 1 g about 1 h before wound closure. Post-operative nutrition: Levin tube removed in OR. POD1 morning-sips of water; POD3 morning upright abdominal X-ray; if normal, start soft fluid diet POD3 evening. POD4 pancreatobiliary CT; if normal, start soft bland diet at lunch. Drain management: two drains at hepaticojejunostomy and pancreaticojejunostomy; drain amylase measured POD1, 3 and 5; if POD4 CT normal, drains removable from POD5 per surgeon discretion (output, fever, pain). Analgesia: IV PCA until ≈POD3, then oral acetaminophen 650 mg every 8 h. No carbohydrate loading or NSAID/nefopam adjuncts.
219052539|NCT07017361|PROCEDURE|ERAS|Pre-op fasting: solids NPO from 00:00; clear fluids until 3 h pre-op; 300 mL carbohydrate drink 2-4 h pre-op with oral acetaminophen 650 mg + zaltoprofen 80 mg. Intra-op: IV dexamethasone 8 mg at induction; IV acetaminophen 1 g + ibuprofen 300 mg + nefopam 20 mg 1 h before closure. Post-op nutrition: Levin tube removed in OR. POD1 sips of water; POD2 morning upright abdominal X-ray-if normal, start soft fluid diet POD2 evening. POD3 pancreatobiliary CT-if normal, start soft bland diet at lunch. Drain mgmt: same placement; amylase POD1 \& 3; if POD4 CT normal and amylase ≤ 5 000 U/L trending down, remove drains POD4; otherwise per surgeon. Analgesia: IV PCA until ≈POD3; until POD1 morning, IV acetaminophen 1 g + ibuprofen 300 mg q8h; POD1-5, oral acetaminophen 650 mg + zaltoprofen 80 mg q8h.
219052540|NCT00001249|DRUG|Yttrium-90 radiolabeled anti-Tac antibody|
219052541|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
219052542|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
219052543|NCT07024290|BEHAVIORAL|HITT|The experimental group completed a 4-week HIIT-boxing protocol, in addition to regular boxing sessions. HIIT consisted of three weekly sessions, each including three blocks of five 30-second all-out punching intervals on a heavy bag, with 6-second rest between efforts and 1-minute rest between blocks. Heart rate was monitored throughout, confirming training intensities of 88-92% HRmax, consistent with high-intensity training standards in combat sports.
219634999|NCT05043207|DIAGNOSTIC_TEST|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
219635000|NCT05043207|DIAGNOSTIC_TEST|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
219635001|NCT01896128|DRUG|Armodafinil|
219635002|NCT01896128|DRUG|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
218945018|NCT05804617|PROCEDURE|Dome-type (Modified C-incision) manual morcellation|Morcellation performed by surgeon or trainee
218945019|NCT00291044|OTHER|testing for HSV 1 and 2 IgG type specific antibosy|
218945020|NCT02654964|DRUG|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
218945021|NCT03223168|DEVICE|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
218945022|NCT01790243|DEVICE|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
218945023|NCT01790243|DEVICE|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
218945024|NCT02711228|BIOLOGICAL|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
218945025|NCT00985777|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
218945026|NCT03287206|BIOLOGICAL|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
219635003|NCT03656497|OTHER|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
218945027|NCT03287206|BIOLOGICAL|blood samples from parents|secondary controls for children's analyses
218945028|NCT05607212|OTHER|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
218945029|NCT05607212|OTHER|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
218945030|NCT05607212|OTHER|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
219635004|NCT02307279|DEVICE|Gelesis100|
219635005|NCT02307279|DEVICE|placebo|
219635006|NCT00003620|DRUG|alvocidib|Given IV
219635007|NCT00003620|OTHER|laboratory biomarker analysis|Correlative studies
219635008|NCT06574490|PROCEDURE|Myofunctional therapy (+)|A series of myofunctional exercises performed in 10-20 sessions over 6 months
219635009|NCT06574490|PROCEDURE|Myofunctional therapy (-)|NO exercises; A series of myofunctional exercises performed in 10-20 sessions over 6 months is delayed by 1 year
219635010|NCT02173002|OTHER|myIBDcoach|
219635011|NCT02173002|OTHER|Standard care|
219635012|NCT02390921|DRUG|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
219635013|NCT02390921|DRUG|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
219635014|NCT01692379|DEVICE|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
219635015|NCT01692379|OTHER|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
219635016|NCT00356148|DRUG|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
219635017|NCT00826397|PROCEDURE|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
219635018|NCT00826397|PROCEDURE|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
219635019|NCT04067167|OTHER|WB-EMS (Sham-intervention)|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
219052544|NCT07024290|OTHER|Regular training|Participants in control groups followed a boxing training program for a period of four weeks, with sessions conducted three times per week. Each session lasted 90 min and was structured in alignment with the established training principles for amateur boxing. The training began with a 15-minute general warm-up phase, including dynamic mobility drills and calisthenics, to elevate core temperature and enhance neuromuscular readiness.
218945031|NCT03700684|BEHAVIORAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
218945032|NCT03700684|DEVICE|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
218945033|NCT03700684|BEHAVIORAL|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
219052545|NCT07024095|BEHAVIORAL|Inspiratory Muscle Training (IMT)|"Participants in the intervention group will receive, in addition to the standard postoperative follow-up for 8 weeks (3 days per week), a home-based exercise program including diaphragmatic breathing exercises, stretching exercises targeting kyphotic posture, and strengthening exercises for the thoracic region. These exercises will be taught to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~In addition, inspiratory muscle training (IMT) will be performed every day for 8 weeks. To ensure progressive workload, maximal inspiratory pressure (MIP) will be reassessed weekly, and the IMT device will be adjusted accordingly."
219052546|NCT07024095|BEHAVIORAL|control group|"Participants in the control group will receive, similar to the intervention group, a home-based exercise program for 8 weeks (3 days per week), including diaphragmatic breathing exercises, stretching exercises for kyphotic posture, and strengthening exercises for the thoracic region, in addition to standard postoperative follow-up. These exercises will be demonstrated to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~Unlike the intervention group, participants in this group will not receive inspiratory muscle training (IMT)."
219052547|NCT07021365|DRUG|Phenol Injection|n patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar phenol neurolysis is performed. A short-acting local anesthetic (3-4 mL of 1% prilocaine) will be administered into the skin and subcutaneous tissues. A 90 mm 22-gauge Quincke-tipped spinal needle will be advanced via the trans-coccygeal route under fluoroscopic guidance with intermittent imaging. The needle's position in the area anterior to the coccyx, where the ganglion impar is located, will be confirmed using 1-2 mL of contrast agent (iohexol). If the desired spread of contrast is observed, 5 mL of 7% phenol will be injected.
219206865|NCT06792253|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
219206866|NCT06792253|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
219635020|NCT04067167|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
219635021|NCT04067167|OTHER|Free WB-EMS|"Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
218945034|NCT00625664|DRUG|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
218945035|NCT00625664|DRUG|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
218945036|NCT00625664|DRUG|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
218945037|NCT03118908|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
218945038|NCT03118908|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
218945039|NCT03118908|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
218945040|NCT02126345|DEVICE|MASTER SL femoral stem and DELTA TT acetabular cup|
218945041|NCT00322985|DRUG|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
218945042|NCT00862420|DRUG|clopidogrel (SR25990)|oral administration (tablets)
218945043|NCT00862420|DRUG|ticlopidine|oral administration (tablets)
218945044|NCT05277948|OTHER|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
219635022|NCT04067167|OTHER|Flexi band resistance training|"Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform resistance exercises using flexi bands~* flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
219635023|NCT02329171|DRUG|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
219052548|NCT07021365|DEVICE|Radiofrequency ablation alone|"In patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar radiofrequency (RF) ablation-routinely used in clinical practice-will be performed by an experienced pain specialist (SŞ) with at least 10 years of expertise in this procedure.~Using fluoroscopic guidance and intermittent imaging, a 100 mm RF cannula with an injection tube will be advanced trans-coccygeally. After confirming the needle's position at the site of the ganglion impar in front of the coccyx with 1-2 mL of contrast agent (iohexol), sensory stimulation will be applied via the RF generator to confirm that the needle tip is at the patient's pain site. Motor stimulation will also be performed to ensure there is no muscle contraction. At this stage, 2 mL of lidocaine will be administered before initiating ablation at 80°C for 90 seconds."
219052549|NCT07024849|DIETARY_SUPPLEMENT|Ecological nutritional intervention|Patients in the intervention arm will receive a 4-week nutrition management program(1 week for patients more than 4 months post-surgery), which includes providing nutritional guidelines, home delivery of personalized care foods, encouragement of physical activity using a wearable device, and weekly phone calls to check on nutritional goals and symptoms. Management services are also available through the mobile application.
219635024|NCT02329171|PROCEDURE|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
219635025|NCT02087488|OTHER|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks."
219635026|NCT02087488|OTHER|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks."
219635027|NCT02087488|DRUG|Eszopiclone|"Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks."
218945045|NCT05277948|OTHER|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
218945046|NCT04059536|DEVICE|Roxwood Anchoring Catheters|Anchoring catheters
218945047|NCT04059536|DRUG|Acetylsalicylic Acid|Oral Tablet
218945048|NCT04059536|DRUG|Heparin|Intravenous Injection
218945049|NCT00640224|DRUG|rosiglitazone|4 mg daily for 6 months
218945050|NCT00640224|DRUG|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
218945051|NCT02535156|DRUG|Risperidone|1 mg Risperidone
218945052|NCT02535156|DRUG|Placebo|Lactose Placebo
218945053|NCT03613142|PROCEDURE|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
218945054|NCT03613142|PROCEDURE|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
218945055|NCT01331213|DRUG|Pregabalin|FDA approved medication (capsules) at 200mg dose.
219052550|NCT07025564|PROCEDURE|Biospecimen Collection|Undergo bone marrow and blood sample collection
219052551|NCT07025564|PROCEDURE|Echocardiography Test|Undergo ECHO
219052552|NCT07025564|DRUG|miR-126 Inhibitor miRisten|Given IV
219052553|NCT02420496|DRUG|Enteral fish oil|
219052554|NCT02420496|DRUG|Ursodeoxycholic Acid|
219635028|NCT00910533|DRUG|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
219635029|NCT02484456|DRUG|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
219635030|NCT02484456|OTHER|Placebo Comparator|Placebo
219635031|NCT04593511|DRUG|LY03009 F1|a single dose of LY03009 F1
219635032|NCT04593511|DRUG|LY03009 F2|a single dose of LY03009 F2
219635033|NCT04593511|DRUG|LY03009 F3|a single dose of LY03009 F3
219635034|NCT04593511|DRUG|LY03009 F4|a single dose of LY03009 F4
219635035|NCT02023411|DRUG|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
218945056|NCT01331213|DRUG|Placebo|Placebo capsules
218945057|NCT02011724|DEVICE|Apligraf|
219052555|NCT02420496|DRUG|Placebo|
219206867|NCT06792253|DRUG|Carboplatin Injection|Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
219206868|NCT06740955|RADIATION|hypofractionated postoperative radiotherapy|hypofractionated radiotherapy with a total dose of 52.5Gy, 3.5 Gy/ fraction, 15 fractions, 5 fractions per week,
219635036|NCT02023411|OTHER|Placebo|Placebo
218945058|NCT03671317|BEHAVIORAL|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
218945059|NCT01343381|DRUG|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
219052556|NCT07025265|BEHAVIORAL|Breastfeeding Self-Efficacy-Based Education and Counseling|his intervention consists of breastfeeding self-efficacy theory-based education provided during the antenatal period. The education covers key factors affecting maternal breastfeeding self-efficacy, including previous experiences, vicarious learning, social support, and psychological responses. Weekly reminder and encouragement text messages will be sent until birth. Postpartum follow-up includes a home visit in the first week for counseling and phone-based follow-ups in the 2nd, 3rd, and 4th weeks.
219052557|NCT06889753|DIETARY_SUPPLEMENT|Graminex WSPE|Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.
219052558|NCT06889753|DIETARY_SUPPLEMENT|Graminex LSPE|Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.
219052559|NCT06889753|DIETARY_SUPPLEMENT|Placebo|Placebo
219052560|NCT07077278|DRUG|Low sodium oxybate (LXB)|Participants will continue take low sodium oxybate (LXB) for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
219052561|NCT07077278|DRUG|Placebo|Participants will take placebo for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
219052562|NCT07076498|BIOLOGICAL|M032|M032 is a genetically engineered type 1 herpes simplex virus (HSV-1) that has been demonstrated to be aneurovirulent secondary to deletions of both copies of the γ134.5 gene and modified to express human interleukin-12 (IL-12). Each patient will receive a single intratumoral injection of M032.
219635037|NCT00813254|BEHAVIORAL|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
219052563|NCT06787430|DRUG|nicorandil|In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.
219052564|NCT06787430|DRUG|Saline (NaCl 0,9 %) (placebo)|In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
219052565|NCT07086118|OTHER|0.9% normal saline|patients in group P will receive 0.9% normal saline
219635038|NCT05334953|DEVICE|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
219635039|NCT05334953|DEVICE|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
219052566|NCT07086118|DRUG|Metoclopramide 10mg|patients in group M will receive 10 mg metoclopramide
219052567|NCT07086118|DRUG|Dexamethasone|patients in group D will receive 8 mg dexamethasone
219635040|NCT05334953|DEVICE|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
219635041|NCT05334953|OTHER|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
219635042|NCT01996254|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
218945060|NCT01343381|DRUG|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
218945061|NCT02270372|BIOLOGICAL|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
218945062|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
218945063|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
219052568|NCT07087119|BEHAVIORAL|utilization of artificial intelligence powered mental health support session through a web browser|utilization of artificial intelligence powered mental health support session with the software XAIA through a web browser for physicians in training to address symptoms related to depression and anxiety.
219052569|NCT07085169|DRUG|Trifluridine/tipiracil (TAS-102) plus bevacizumab|Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.
218945064|NCT05981781|PROCEDURE|ultrasound guided peng block in paediatric hip surgery|"On the supine position, under strict aseptic technique, a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed in the transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral artery, and femoral nerve. The probe will be then rotated, and aligned with the pubic ramus to visualize the AIIS, iliopubic eminence (IPE), femoral artery, psoas muscle, and the superior pubic ramus.~Under direct visualization, a needle will be advanced in-plane, lateral to medial between the psoas tendon and pubic ramus until the needle contacts the IPE. The needle will be slightly withdrawn, and following negative aspiration, 0.5 ml/kg of bupivacaine 0.25% will be injected."
219052570|NCT07086404|DRUG|GC012F Injection infusion|GC012F Injection infusion will be performed within 48-72 hours after the end of lymphodepleting preconditioning.
219052571|NCT06908018|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 is a recombinat virus that could induce viremia and immunological responses with out serious adverse effect. The virus will be challenged after participants screening and consent for hospitalization. After virus challenge, the virological, immunological and clinical manifestation will be recorded and analyzed for the result from day 0-60 post-virus challenge.
219052572|NCT07086911|DRUG|Remimazolam|"Remimazolam group (Group R) : After intubation, remimazolam was maintained at a pump rate of 1-2mg/kg/h until ten minutes before the end of the operation.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
219052573|NCT07086911|DRUG|Propofol|"Propofol group (Group P) : After intubation, propofol was maintained at a pump rate of 4-10mg/kg/h until surgery ten minutes before the end.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
219052574|NCT06908785|DEVICE|Rotational thromboelastometry|rotem
219052575|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
219052576|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
219052577|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
219052578|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
219052579|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
219052580|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
219052581|NCT00084695|DRUG|busulfan|Given orally
219052582|NCT00084695|DRUG|cyclophosphamide|Given IV
219635043|NCT01637454|DRUG|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
219635044|NCT01637454|DRUG|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
219635045|NCT04974060|DRUG|Remifentanil Injection|Dilute 2mg Remifentanil with normal saline to 50 ml (40ug/ml) and continuously intravenous infused at the doses of 0.02, 0.04, 0.06, and 0.08 μg/kg/min for each lasting 30 minutes.
219635046|NCT03348930|DRUG|Tolcapone 200 MG|All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
219635047|NCT06685263|BEHAVIORAL|Group 1|The development group comprises 385 individuals. Following the data collection phase of the development group, the independent risk factors for the onset of delirium will be identified through statistical analysis. A delirium prediction model will then be constructed using the identified risk factors.
219052583|NCT00084695|DRUG|fludarabine phosphate|Given IV
219052584|NCT00084695|DRUG|melphalan|Given IV
219052585|NCT00084695|DRUG|methylprednisolone|Given IV
219052586|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
219052587|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
219052588|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
219052589|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
219052590|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
219052591|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
219052592|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
219052593|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
219635048|NCT06685263|BEHAVIORAL|Group 2|The validation group comprises 385 individuals. The delirium prediction model created using the data from the development group will be validated by testing the data from the validation group. This will enable the evaluation of the model's fit and calibration in predicting delirium.
218945065|NCT05981781|PROCEDURE|ultrasound guided caudal epidural block in paediatric hip surgery|On lateral decubitus position, under strict aseptic technique, the sacral hiatus will be visualized at the level of the sacral cornua by employing a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed transversely at the midline to obtain a transverse view of the two cornua, sacrococcygeal ligament, sacral bone, and sacral hiatus. At this level, the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and subsequently placed between the two cornua. A needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. (17) At this level, after confirming absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute while observing an ultrasound longitudinal image.
218945066|NCT04015375|DRUG|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
218945067|NCT04015375|DRUG|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
218945068|NCT04015375|OTHER|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
218945069|NCT02937584|DRUG|GP MDI (PT001) 14.4 μg|Glycopyrronium
218945070|NCT02937584|DRUG|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
218945071|NCT00838032|DRUG|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
219635049|NCT04514874|OTHER|Questionnaire|Self-questionnaire about socio-demographical status, health status and lifestyle habits during and following the COVID-19 pandemic.
218945072|NCT00838032|DRUG|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
219052594|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
219052595|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
219052596|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
219052597|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
219635050|NCT06464718|DRUG|Fortibone|Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).
219635051|NCT06464718|DRUG|Chewable Tablet|calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
219635052|NCT01677572|DRUG|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
219635053|NCT01677572|DRUG|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
219052598|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
219052599|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
219206869|NCT06740955|RADIATION|Conventionally fractionated postoperative radiotherapy|Conventionally fractionated radiotherapy with a total dose of 60 Gy, 2 Gy/ fraction, 30 fractions, 5 fractions per week,
218945073|NCT05987995|PROCEDURE|Endometrial injury|A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
218945074|NCT04329338|OTHER|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
218945075|NCT01855646|OTHER|Structured Sign Out Form|
218945076|NCT01521312|DRUG|saxagliptin|5mg a day for 11-14 weeks
218945077|NCT01521312|OTHER|placebo pill|one tablet a day for 11-14 weeks
218945078|NCT00635219|DRUG|Placebo|capsules; daily; orally
219052600|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
219052601|NCT04816357|OTHER|Questionaire|only questionaire
219052602|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
219052603|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
219052604|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
219052605|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
219052606|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
219052607|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
219052608|NCT02753647|DRUG|Rituximab|
219052609|NCT02753647|DRUG|Cyclophosphamide|
219052610|NCT02753647|DRUG|Doxorubicin|
219052611|NCT02753647|DRUG|Vincristine|
219052612|NCT02753647|DRUG|Prednisone|
219206870|NCT06799793|DEVICE|GI Genius|GI Genius software component is an artificial intelligence-based medical device that has been trained to process colonoscopy images containing regions consistent with colorectal lesions such as polyps, including those with flat morphology (nonpolyp).
218945079|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
218945080|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
218945081|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
218945082|NCT00635219|DRUG|Duloxetine|60 mg/day; encapsulated capsules; orally
219052613|NCT02753647|DRUG|Chidamide|
219052614|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
219052615|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
219206871|NCT06799793|OTHER|Colonscope Olympus|Colonoscopy with one of the Olympus colonoscopes supplied to the IRCCS AOUBO Gastroenterology Unit without the aid of the CAD system
219206872|NCT06788808|OTHER|Comparison between groups|Ultrasound images acquired during routine ultrasound scans performed in healthy fetuses and in fetuses found to have CNS malformations will be reviewed. Ultrasound images acquired from January 2000 to May 2021 will be analyzed until a sample size of approximately 80 patients is reached, who will be divided into 2 groups: group A (patients whose fetus has CNS malformations) and group B (healthy patients whose fetus has no anatomical CNS abnormalities).
219206873|NCT06789016|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
219206874|NCT06789016|DRUG|0.9%NaCl|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
218945083|NCT02646241|PROCEDURE|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
218945084|NCT02646241|PROCEDURE|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB \& unroofing biopsy.
218945085|NCT02535390|BEHAVIORAL|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
218945086|NCT02535390|BEHAVIORAL|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
218945087|NCT02575027|RADIATION|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
218945088|NCT02575027|OTHER|Questionnaire Administration|Ancillary studies
218945089|NCT02575027|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
218945090|NCT04721080|OTHER|Functional Outcome Measurements|Dyspnea Exercise capacity Quality of life assessment
218945091|NCT01755000|PROCEDURE|USCOM scan|
218945092|NCT01755000|PROCEDURE|Fluid Bolus|
218945093|NCT03725228|DRUG|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
218945094|NCT03725228|DRUG|Lidocaine|Lidocaine 1,5mg/kg/h
218945095|NCT02323607|DRUG|Pacritinib|Given PO
218945096|NCT02323607|DRUG|Cytarabine|Given IV
218945097|NCT02323607|DRUG|Daunorubicin Hydrochloride|Given IV
218945098|NCT02323607|DRUG|Decitabine|Given IV
218945099|NCT02323607|OTHER|Laboratory Biomarker Analysis|Correlative studies
218945100|NCT02323607|OTHER|Pharmacological Study|Correlative studies
218945101|NCT00426452|DRUG|Vatalinib|
218945102|NCT00217659|DRUG|anastrozole|
218945103|NCT00217659|DRUG|goserelin acetate|
218945104|NCT05454917|DEVICE|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
218945105|NCT02628080|DRUG|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
218945106|NCT04075734|BEHAVIORAL|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
218945107|NCT06520644|DEVICE|Wii-based interactive training program|include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension
218945108|NCT06520644|OTHER|Traditional physical therapy program|Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
218945109|NCT04708249|DIETARY_SUPPLEMENT|D-chiroinositol|Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
218945110|NCT02456363|BIOLOGICAL|TNF alpha|Depending on patient need to use different TNF alpha
218945111|NCT02456363|DRUG|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
218945112|NCT04380272|DIAGNOSTIC_TEST|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
218945113|NCT06412614|OTHER|disease phenotype|evaluation of SSc phenotypes
218945114|NCT04351789|OTHER|Psychoeducational intervention|"The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital."
218945115|NCT01223742|DIETARY_SUPPLEMENT|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
218945116|NCT01223742|DRUG|placebo|placebo twice per day
218945117|NCT05181189|DRUG|DAOIB+Omega-3|The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
218945118|NCT05181189|DRUG|DAOIB+Placebo|Placebo
219635054|NCT05146518|BEHAVIORAL|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
219635055|NCT06620172|PROCEDURE|CT-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.
219635056|NCT06620172|PROCEDURE|Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.
218945119|NCT00397917|DRUG|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
218945120|NCT01598129|GENETIC|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
218945121|NCT02250703|DRUG|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
218945122|NCT02250703|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
218945123|NCT04483401|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
218945124|NCT01672177|BEHAVIORAL|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
218945125|NCT05615519|DIAGNOSTIC_TEST|A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.|Digital ruler of strabismus
218945126|NCT01499706|BEHAVIORAL|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
218945127|NCT01499706|BEHAVIORAL|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
218945128|NCT00000722|DRUG|Pentamidine isethionate|
218945129|NCT00133549|DRUG|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
218945130|NCT00133549|BIOLOGICAL|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
218945131|NCT00133549|BIOLOGICAL|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
218945132|NCT00591318|DRUG|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
218945133|NCT00591318|DRUG|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
219052616|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
219052617|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
218945134|NCT04431921|DIAGNOSTIC_TEST|Functional capacity|Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
219052618|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
219052619|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
219052620|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
219052621|NCT00646958|DRUG|Radezolid|450mg PO QD
219052622|NCT00646958|DRUG|Radezolid|450mg PO BID
219206875|NCT05120505|DRUG|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
219052623|NCT00646958|DRUG|Linezolid|600mg PO BID
219052624|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
219052625|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
218945135|NCT04694924|OTHER|standard of care|"No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician."
218945136|NCT03234283|DEVICE|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
218945137|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 30μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
218945138|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 50μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
218945139|NCT04760743|OTHER|Normal Saline|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
218945140|NCT05160142|BEHAVIORAL|DICE|10-week culinary and nutrition education program for children with type I diabetes
218945141|NCT04698096|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
218945142|NCT04698096|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
218945143|NCT04698096|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
218945144|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
218945145|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
218945146|NCT02113254|OTHER|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
218945147|NCT01342237|DRUG|HDCT 1(TTC), HDCT2(MEC)|"1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
218945148|NCT00077129|DRUG|carboplatin|
218945149|NCT00077129|DRUG|paclitaxel|
218945150|NCT04355585|DRUG|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
218945151|NCT04355585|DRUG|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
218945152|NCT02635932|DEVICE|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
218945153|NCT02635932|DEVICE|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
218945154|NCT01179685|PROCEDURE|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
218945155|NCT05680116|DEVICE|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
218945156|NCT05680116|OTHER|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
218945157|NCT00322621|DRUG|Duloxetine|
218945158|NCT05620693|BIOLOGICAL|NY-ESO-1 TCR-T|NY-ESO-1 TCR-T treatment
218945159|NCT01490801|GENETIC|DNA analysis|
218945160|NCT01490801|GENETIC|RNA analysis|
218945161|NCT01490801|GENETIC|cytogenetic analysis|
218945162|NCT01490801|GENETIC|in situ hybridization|
218945163|NCT01490801|GENETIC|mutation analysis|
218945164|NCT01490801|GENETIC|polymerase chain reaction|
218945165|NCT01490801|GENETIC|western blotting|
218945166|NCT01490801|OTHER|flow cytometry|
218945167|NCT01490801|OTHER|immunohistochemistry staining method|
218945168|NCT01490801|OTHER|medical chart review|
218945169|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
218945170|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
218945171|NCT00104598|DRUG|Bupropion|
218945172|NCT00104598|BEHAVIORAL|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
219206876|NCT05120505|DRUG|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
219635057|NCT06029413|PROCEDURE|myo + fascial injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
218945173|NCT02284841|DEVICE|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
218945174|NCT01766505|DRUG|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
218945175|NCT01766505|DRUG|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
218945176|NCT06001359|OTHER|No intervention|No intervention
218945177|NCT04264624|DEVICE|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
218945178|NCT04264624|DEVICE|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
218945179|NCT02059291|DRUG|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
218945180|NCT02059291|DRUG|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
218945181|NCT01736761|DRUG|Darunavir, Ritonavir and Rilpivirine|
218945182|NCT01433289|DRUG|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
218945183|NCT01433289|DRUG|Placebo|
218945184|NCT01998568|OTHER|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
218945185|NCT02807675|DRUG|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
218945186|NCT02807675|OTHER|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
218945187|NCT01066390|BIOLOGICAL|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
218945188|NCT04608539|DRUG|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
218945189|NCT04608539|DRUG|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
218945190|NCT04608539|DRUG|normal saline|Single-dose infusion (placebo), postoperative day 1
218945191|NCT05902650|DIAGNOSTIC_TEST|imaging|imaging
218945192|NCT02973880|DRUG|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
218945193|NCT02973880|DRUG|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
218945194|NCT02284932|OTHER|No specific intervention for this study|No specific intervention for this study
219052626|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
219052627|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
218945195|NCT04382989|DEVICE|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
218945196|NCT02482831|PROCEDURE|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
218945197|NCT00522132|DRUG|Artesunate|intravenous application
218945198|NCT02215811|BIOLOGICAL|Mesenchymal stromal cells|
218945199|NCT04159753|DEVICE|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
218945200|NCT01763996|DRUG|Febuxostat|Febuxostat capsules
218945201|NCT01763996|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
219052628|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
219052629|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
219052630|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
219206877|NCT06795542|PROCEDURE|lumbosacral transforaminal epidural injection at the level of L4-5, L5-S1, or S1 neural foramina|The most widely used injection therapy is epidural injection of steroids, by either the interlaminar route or the caudal route. More contentious are transforaminal injections of steroids. These involve the injection of steroids directly and accurately onto the affected spinal nerve, under radiologic guidance. Meanwhile, transforaminal injection of steroids has been shown to be more effective than interlaminar injection of steroids
219635058|NCT06029413|PROCEDURE|traditional trigger point injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
219635059|NCT01999699|BIOLOGICAL|HEPLISAV|
218945202|NCT02280018|DRUG|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
218945203|NCT02280018|DRUG|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
218945204|NCT03455231|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
218945205|NCT00865280|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
218945206|NCT00865280|DRUG|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
218945207|NCT00865280|DRUG|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
218945208|NCT00874419|DRUG|erlotinib|erlotinib 150 mg oral, once a day
218945209|NCT00874419|DRUG|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
218945210|NCT02906605|DRUG|JNJ-809|JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
218945211|NCT02906605|DRUG|Apalutamide|Apalutamide 240 mg orally daily.
218945212|NCT06521528|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
218945213|NCT04412785|DRUG|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
218945214|NCT03779490|DEVICE|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
218945215|NCT05938205|DIETARY_SUPPLEMENT|AA-1|low dose aminoacids
218945216|NCT05938205|DIETARY_SUPPLEMENT|AA-2|high dose aminoacids
218945217|NCT05938205|BEHAVIORAL|Placebo|Nutritional Placebo
218945218|NCT05938205|BEHAVIORAL|Exe-H|high intensity physical exercise
218945219|NCT02371941|DRUG|oral cromolyn sodium|Oral cromolyn sodium
218945220|NCT02371941|DRUG|Placebo|Saline
218945221|NCT01788215|DRUG|doxycycline|200mg/day in divided doses of 100mg twice daily
218945222|NCT01788215|OTHER|Sugar Pill|1 pill twice a day
218945223|NCT02299791|OTHER|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~1. EHR tools to expedite identification~   a. EHR automated point-of-care alerts (Best Practice Alerts)~2. EHR tools to expedite prescribing~   1. EHR order sets~  2. EHR text shortcuts for notation~  3. patient education materials (handout, poster)~3. EHR-based outreach support tools a. EHR registries"
218945224|NCT02299791|OTHER|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
218945225|NCT00710216|DRUG|Lamivudine|100 mg/day
218945226|NCT00710216|DRUG|Telbivudine|600 mg/day
218945227|NCT03272776|DEVICE|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
218945228|NCT00815555|OTHER|There is no intervention - this is an observational study|
218945229|NCT01339520|BEHAVIORAL|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
218945230|NCT01339520|BEHAVIORAL|Control|Standard of care for diabetes subjects
218945231|NCT06060327|DRUG|Tranexamic acid|Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
218945232|NCT03535298|DRUG|Early Highly Effective Therapies Group|Highly Effective MS Therapy group of medications
218945233|NCT03535298|DRUG|Escalation Therapies Group|Escalation MS Therapy group of medications
218945234|NCT00612105|DRUG|Retigabine|150mg/day up to 900mg/day
219635060|NCT03445546|DIAGNOSTIC_TEST|diagnostic test of platelet function|Light transmittance aggregometry and VerifyNow
218945235|NCT00612105|DRUG|Placebo|daily
218945236|NCT03803241|DRUG|CD133+ infusion|Infusion of cells cd133+
218945237|NCT03803241|OTHER|portal vein embolization|portal vein embolization
218945238|NCT04110535|DRUG|Remimazolam|IV administration over 1 minute
218945239|NCT04110535|DRUG|Midazolam|IV administration over 1 minute
218945240|NCT04110535|OTHER|Saline|IV administration over 1 minute
218945241|NCT04090372|DEVICE|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
218945242|NCT00770159|DRUG|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
218945243|NCT00770159|DRUG|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
218945244|NCT01105767|DRUG|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
218945245|NCT01105767|OTHER|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
218945246|NCT02940041|PROCEDURE|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
219635061|NCT03058250|OTHER|Transesophageal echocardiography|
219635062|NCT04594070|DRUG|Ferrous sulfate|Iron supplementation
219635063|NCT01327170|PROCEDURE|Subthreshold diode micropulse laser|
219635064|NCT02693002|DRUG|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
218945247|NCT01658306|PROCEDURE|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
219052631|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
219052632|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
219052633|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
219052634|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
218945248|NCT01658306|PROCEDURE|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
218945249|NCT01443624|DRUG|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
218945250|NCT04786834|PROCEDURE|Vesico urethral anastomosis on chicken model|Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
218945251|NCT04772833|OTHER|Autopsy|The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
218945252|NCT00743106|DRUG|Fenoldopam|Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours
218945253|NCT00743106|DRUG|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
218945254|NCT03730142|DRUG|WXFL10030390|WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
218945255|NCT02840617|DRUG|Indocyanine Green (ICG)|
218945256|NCT04611490|PROCEDURE|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
218945257|NCT04771091|DIAGNOSTIC_TEST|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
218945258|NCT05960630|PROCEDURE|MIRRORS Protocol|Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
219052635|NCT02573324|DRUG|Temozolomide|Oral Capsule
219052636|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
218945259|NCT05960630|PROCEDURE|Standard Open Cytoreductive Surgery|Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
218945260|NCT00817596|DEVICE|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
218945261|NCT00993226|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
218945262|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
218945263|NCT00993226|DRUG|Bupivacaine HCl Treatment 1c|40 ml
219052637|NCT02573324|RADIATION|Radiation|
219052638|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
218945264|NCT00993226|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
218945265|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
218945266|NCT00993226|DRUG|Bupivacaine HCl Treatment 2c|40 ml
218945267|NCT02282241|DRUG|Melatonin|
218945268|NCT02282241|OTHER|Placebo|
219052639|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
219052640|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
219052641|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
219052642|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
219052643|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
219052644|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
219206878|NCT02951052|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
219206879|NCT02951052|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
219635065|NCT02693002|DRUG|Placebo|inactive ingredient
219635066|NCT00217373|BIOLOGICAL|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
219635067|NCT00217373|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
218945269|NCT00294619|DRUG|growth hormone|subcutaneous injection, once-weekly
218945270|NCT02379689|DRUG|Injectable placental tissue extract called BioDGenesis (Active Product)|
218945271|NCT02379689|DRUG|Placebo|
218945272|NCT00900588|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
218945273|NCT00829192|DRUG|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
219206880|NCT02951052|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
219635068|NCT00217373|BIOLOGICAL|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
219052645|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
219635069|NCT00217373|BIOLOGICAL|Sargramostim|Given SC
218945274|NCT00829192|DRUG|Placebo|Placebo subcutaneous implant administered every 60 days
218945275|NCT05822765|DRUG|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
218945276|NCT05822765|DRUG|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
218945277|NCT04812847|DIAGNOSTIC_TEST|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
219052646|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
219052647|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
219052648|NCT01697384|DRUG|histrelin acetate|52 week implant
219052649|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
219635070|NCT02295592|PROCEDURE|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
219635071|NCT02295592|PROCEDURE|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
219635072|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
219635073|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
219635074|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
219635075|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
219635076|NCT00557544|DRUG|metoclopramide|metoclopramide 0,15 mg/kg
219635077|NCT00557544|DRUG|placebo|placebo per os
218945278|NCT05391789|DRUG|Ulinastatin|Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
218945279|NCT05391789|DRUG|Placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
218945280|NCT00012597|PROCEDURE|Web-based telemedicine system for assessment of status of pressure ulcers|
218945281|NCT01572987|DEVICE|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
219635078|NCT00557544|DRUG|ketoprofen|ketoprofen 1 mg/Kg
218945282|NCT01572987|DEVICE|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
219052650|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
219635079|NCT06501391|DRUG|PD-L1/PD-1 inhibitor and chemotherapy|Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.
219635080|NCT06501391|RADIATION|SRT or WBRT|Stable brain metastases (BM) patients in this arm will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
219635081|NCT06451419|OTHER|Tests on non motor symptoms|Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.
219635082|NCT06682221|DIETARY_SUPPLEMENT|Whey protein supplementation.|Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
218945283|NCT01307644|BEHAVIORAL|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
218945284|NCT01307644|BEHAVIORAL|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
218945285|NCT01307644|BEHAVIORAL|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
218945286|NCT04491071|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7 (GAD 7)|test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.
218945287|NCT04491071|DIAGNOSTIC_TEST|Background questionnaire|questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
218945288|NCT04491071|DIAGNOSTIC_TEST|Impact of COVID-19 questionnaire|status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
218945289|NCT04491071|DIAGNOSTIC_TEST|Confinement and Communication During the COVID-19 Pandemic|know the experience of containment and isolation during the pandemic
218945290|NCT04491071|DIAGNOSTIC_TEST|Mental Health questionnaire|welfare effect
218945291|NCT04491071|DIAGNOSTIC_TEST|Patient Health Questionnaire (PHQ-9)|assess depression during the pandemic
218945292|NCT04491071|DIAGNOSTIC_TEST|Post Traumatic Stress Disorder questionnaire (PTSD-8)|Assessing the trauma of subjects during the pandemic
219052651|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
218945293|NCT04491071|DIAGNOSTIC_TEST|Experiences in Close Relationship Scale questionnaire (ECR-S)|Measuring social ties and attachment of subjects
218945294|NCT00161538|DEVICE|Pacing leads to be implanted according randomization.|
218945295|NCT00161538|DEVICE|Selection 9000 prevent AF an Diagnose AF|
218945296|NCT01912313|PROCEDURE|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
218945297|NCT00527241|BEHAVIORAL|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
218945298|NCT00274833|DRUG|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
218945299|NCT00274833|DRUG|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
218945300|NCT00274833|RADIATION|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
218945301|NCT02646371|BIOLOGICAL|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
218945302|NCT02646371|BIOLOGICAL|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
218945303|NCT00933556|DIETARY_SUPPLEMENT|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
218945304|NCT00933556|DIETARY_SUPPLEMENT|sugar pill (placebo)|placebo identical to the active product will be given
218945305|NCT04194385|PROCEDURE|Upper trunk block|Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .
219052652|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
219052653|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
219052654|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
219052655|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
219052656|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
219052657|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
219052658|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
219052659|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
219052660|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
219052661|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
219052662|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
219052663|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
218945306|NCT04194385|PROCEDURE|Costoclavicular block|Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
219052664|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
219052665|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
218945307|NCT04194385|PROCEDURE|Diaphragmatic function assessment|Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
218945308|NCT04194385|PROCEDURE|Cervical plexus blockade|Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
219052666|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
219052667|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
219052668|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
218945309|NCT00508664|RADIATION|Radiation|Radiation start in week 11
218945310|NCT00508664|DRUG|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
218945311|NCT00508664|DRUG|Docetaxel|75 mg/m2 i.v. day 1 3 times
219052669|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
219052670|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
219052671|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
219052672|NCT01363323|DRUG|Placebo|
219052673|NCT01363323|DRUG|Moxifloxacin|
219052674|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
219052675|NCT01977911|OTHER|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
219052676|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
219052677|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
219052678|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
219052679|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
219052680|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
219052681|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
219052682|NCT02096835|DRUG|Dexamethasone|will be given after induction
219052683|NCT00467181|DRUG|Fenoldopam|
219052684|NCT02709967|OTHER|Material support|Writing materials
219052685|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
219052686|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
219052687|NCT04852614|DIAGNOSTIC_TEST|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
219052688|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
218945312|NCT00508664|DRUG|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
218945313|NCT00508664|DRUG|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
218945314|NCT02874144|DRUG|AZ compound|40 mg three times daily po for 12 weeks
218945315|NCT02874144|OTHER|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
218945316|NCT02874144|DRUG|Intranasal corticosteroid|QD Nasal Spray
218945317|NCT02874144|DRUG|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
218945318|NCT01937429|DEVICE|Colonoscopy with blue Indigo Carmin®|
218945319|NCT01937429|DEVICE|Standard colonoscopy with insufflation of air|
219206881|NCT02951052|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
218945320|NCT01792544|OTHER|Statement|
218945321|NCT01792544|OTHER|No Statement|
219052689|NCT03468439|OTHER|Femoral nerve block with phenol|
219052690|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
219052691|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
218945322|NCT05676268|PROCEDURE|Implant-supported fixed dental prostheses with cantilever extension|Healthy patients in need of replacement of missing teeth with dental implants supporting partial fixed dental prostheses with cantilever extensions
218945323|NCT02290743|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
218945324|NCT00574236|DRUG|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
218945325|NCT03537300|BEHAVIORAL|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
218945326|NCT03537300|BEHAVIORAL|conventional exercises|conventional exercises
218945327|NCT03370705|DRUG|Sulodexide|Sulodexide 250 ULS twice daily per oral route
218945328|NCT03370705|DRUG|Statin|Statin 20mg once daily per oral route,
218945329|NCT03370705|DRUG|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
218945330|NCT03370705|DRUG|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
218945331|NCT03063047|OTHER|PD21871AA|A 100s size menthol cigarette.
218945332|NCT03063047|OTHER|PD21872AA|A 100s size menthol cigarette.
218945333|NCT02540278|BEHAVIORAL|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
218945334|NCT05249517|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a patient education approach that explains in detail the neurobiology, neurophysiology of pain, and the processing of pain by the nervous system in the management of chronic pain.
218945335|NCT05249517|OTHER|Progressive submaximal exercise program|It has been shown that the long-term results of the use of PNE in addition to physiotherapy are more effective in reducing pain and disability. It has been reported that progressive submaximal exercise program including cervicothoracic strengthening, endurance, flexibility, and coordination exercises has positive effects on chronic neck pain, related disability, quality of life and mood.
219052692|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
219052693|NCT00029835|DRUG|Rimonabant (SR141716)|
219052694|NCT04260191|DRUG|AMG 910|IV Infusion
219052695|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
219206882|NCT02951052|DRUG|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"
218945336|NCT00054340|BIOLOGICAL|anti-thymocyte globulin|
218945337|NCT00054340|DRUG|busulfan|
218945338|NCT00054340|DRUG|cyclophosphamide|
218945339|NCT00054340|DRUG|cyclosporine|
218945340|NCT00054340|DRUG|methotrexate|
218945341|NCT00054340|PROCEDURE|allogeneic bone marrow transplantation|
218945342|NCT00054340|PROCEDURE|peripheral blood stem cell transplantation|
218945343|NCT00924859|OTHER|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
218945344|NCT00003497|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
219052696|NCT02448303|DRUG|Pembrolizumab|
219052697|NCT02448303|DRUG|Acalabrutinib|
219052698|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
218945345|NCT03753789|DEVICE|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
218945346|NCT02928263|OTHER|Non-Interventional|Other
218945347|NCT04273906|PROCEDURE|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
218945348|NCT04273906|PROCEDURE|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
218945349|NCT02975557|DRUG|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
218945350|NCT02975557|DRUG|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
218945351|NCT02975557|DRUG|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
219052699|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
219052700|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
219052701|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
218945352|NCT05731349|OTHER|2018 Surviving Sepsis Campaign Hour-1 Bundle|"1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg"
218945353|NCT03361683|DEVICE|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
219052702|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
219052703|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
219052704|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
219052705|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
219052706|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
219052707|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
219052708|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
219052709|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
219052710|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
219052711|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
219206883|NCT06831266|OTHER|High Intensity Interval Training (HIIT)|"1 minute interval, 1 minute active recovery~5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at an intensity of 85% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 4x1~Weeks 2-7: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 6x1~Weeks 8-12: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 8x1"
219635083|NCT06682221|BEHAVIORAL|Resistance training|The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
218945354|NCT03361683|DEVICE|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
218945355|NCT01821976|PROCEDURE|Ertl Procedure|
218945356|NCT01821976|PROCEDURE|Burgess Procedure|
218945357|NCT03229642|DEVICE|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
218945358|NCT03229642|DEVICE|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
218945359|NCT00139789|DRUG|Kemstro|
218945360|NCT02911831|DRUG|Tranexamic Acid|
218945361|NCT02911831|DRUG|Sodium Chloride|
218945362|NCT01212380|DRUG|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
218945363|NCT01212380|OTHER|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
219052712|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
218945364|NCT01212380|OTHER|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
218945365|NCT01212380|OTHER|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
218945366|NCT01212380|OTHER|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
218945367|NCT02027090|DRUG|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
218945368|NCT02027090|DRUG|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
218945369|NCT01578850|DRUG|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
219052713|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
219052714|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
219206884|NCT06831266|OTHER|Moderate Intensity Continuous Training (MICT)|"5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at 65% of peak heart rate intensity (22 minute)~Weeks 2-7: Loading at 75% of peak heart rate intensity (30 minute)~Weeks 8-12: Loading at 75% of peak heart rate intensity (38 minute)"
219206885|NCT06172283|OTHER|Intermittent Fasting|Dietary intervention
219206886|NCT04227600|DRUG|JR-171 (lepunafusp alfa)|IV infusion
219206887|NCT05739435|DRUG|ESK-001|Oral tablet
219206888|NCT06846827|OTHER|Oyster mushroom|Sachet containing the equivalent of 1 serving (9.39g) of dried ergothioneine-rich Pleurotus oyster mushrooms
219206889|NCT06846827|OTHER|Maltodextrin|Sachet containing 6.67g of maltodextrin
219206890|NCT06844201|DRUG|Ephedrine|Received ephedrine the same day of surgery.
219206891|NCT06844201|DRUG|Norepinephrine|Received norepinephrine the same day of surgery.
218945370|NCT01578850|DRUG|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
218945371|NCT05205889|BEHAVIORAL|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
218945372|NCT06123351|DEVICE|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
218945373|NCT06123351|OTHER|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
218945374|NCT06123351|DEVICE|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
219052715|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
219052716|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
219052717|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
219052718|NCT01629082|DRUG|Clofarabine|
219052719|NCT01629082|DRUG|Lenalidomide|
219052720|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
219206892|NCT05229341|PROCEDURE|Diagnostic Procedure|Analysis via DDMS-2
219635084|NCT06682221|OTHER|Group Control|The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
219052721|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
219206893|NCT05229341|OTHER|Electronic Health Record Review|Review of medical records
219206894|NCT05229341|PROCEDURE|Needle Biopsy|Undergo needle biopsy
218945375|NCT00761644|DRUG|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
218945376|NCT00761644|DRUG|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
218945377|NCT00761644|DRUG|Temsirolimus|Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
218945378|NCT06153680|DEVICE|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
218945379|NCT01032109|DRUG|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
219052722|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
219052723|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
219052724|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
219052725|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
219052726|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
219052727|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
219052728|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
219052729|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
219052730|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
219052731|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
219052732|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
219206895|NCT04277637|DRUG|Sonrotoclax|Film-coated tablets administered once daily at a dose as specified in the treatment arm
219206896|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
219206897|NCT04277637|DRUG|Obinutuzumab|Given as an intravenous infusion administered per label.
219635085|NCT02208193|BEHAVIORAL|Cognitive and psycho-behavioral effects of an artistic dimension|
219052733|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
218945380|NCT00601952|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
219052734|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
218945381|NCT00601952|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
218945382|NCT00254345|PROCEDURE|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
218945383|NCT00646269|BEHAVIORAL|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
218945384|NCT00646269|BEHAVIORAL|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
218945385|NCT00646269|BEHAVIORAL|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
218945386|NCT00646269|BEHAVIORAL|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
219052735|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
219052736|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
219052737|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
219052738|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
219052739|NCT05007457|OTHER|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
219052740|NCT00023673|DRUG|carboplatin|
219052741|NCT00023673|DRUG|paclitaxel|
219052742|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
219052743|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
219052744|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
219052745|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
219052746|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
219052747|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
219206898|NCT06747559|DRUG|Vitamin D|Vitamin D oral supplementation
219206899|NCT06746545|DRUG|Fruquintinib+S-1|Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
219635086|NCT01163968|BEHAVIORAL|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
218945387|NCT03882268|BEHAVIORAL|MIYCN interventions|"1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
218945388|NCT02562664|DRUG|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
218945389|NCT02562664|DRUG|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
218945390|NCT02562664|DRUG|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
218945391|NCT03366519|PROCEDURE|clinical echography (CE)|clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
218945392|NCT02205840|DRUG|SI-614|1 drop in each eye
218945393|NCT02205840|DRUG|Vehicle|1 drop in each eye
218945394|NCT04240834|DRUG|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
218945395|NCT04240834|DRUG|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
218945396|NCT06193109|OTHER||the patients with sepsis and septic shock were performed echocardiography for detecting right ventricular systolic function
218945397|NCT04408222|OTHER|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
219052748|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
219052749|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
219052750|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
219052751|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
219052752|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
219052753|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
219052754|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
219052755|NCT00218192|BEHAVIORAL|Behavior Therapy|
219052756|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
219052757|NCT06663176|DRUG|RESP302|Nitric Oxide agent
219052758|NCT06663176|DRUG|RESP303|Nitric Oxide agent
219052759|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
219052760|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
219052761|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
219052762|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
219052763|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
218945398|NCT01189019|DRUG|ranibizumab|2mg intravitreal injection monthly
218945399|NCT01189019|DRUG|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
218945400|NCT00541814|DRUG|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
218945401|NCT00243165|BEHAVIORAL|Lifemel honey intake every day|
218945402|NCT02744040|DRUG|ART initiation at time of HIV diagnosis|Immediate ART initiation
218945403|NCT02744040|DRUG|ART at 24 weeks|ART initiation 24 weeks after enrollment
218945404|NCT01398917|PROCEDURE|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
219052764|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
219052765|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
219052766|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
218945405|NCT01398917|PROCEDURE|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
218945406|NCT01646489|DRUG|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
218945407|NCT01646489|DRUG|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
218945408|NCT05032469|OTHER|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
218945409|NCT01576068|OTHER|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
218945410|NCT00096356|DIETARY_SUPPLEMENT|CoQ10 & Vitamin E|
218945411|NCT00096356|DIETARY_SUPPLEMENT|Placebo & Vitamin E|
218945412|NCT02467426|DRUG|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
218945413|NCT04499352|DRUG|BI 754091|BI 754091
219052767|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
219052768|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
219052769|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
219052770|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
219052771|NCT00796029|DRUG|14C-paliperidone|
218945414|NCT04499352|DRUG|BI 836880|BI 836880
218945415|NCT01809639|DRUG|Progesterone|
218945416|NCT01809639|DRUG|Placebo|Standard placebo
218945417|NCT00814060|DRUG|neratinib|HKI-272
219052772|NCT02086591|DRUG|Doxycycline|
219052773|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
218945418|NCT03519191|BEHAVIORAL|Healthy Relationships Education (HRE)|Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
218945419|NCT03519191|BEHAVIORAL|HRE+Technology Bootcamp|HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
218945420|NCT02940314|DRUG|HIP1503|
218945421|NCT02940314|DRUG|HGP1103|
218945422|NCT02878057|DRUG|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
218945423|NCT00967954|DRUG|antiandrogen therapy|
218945424|NCT00967954|DRUG|releasing hormone agonist therapy|
218945425|NCT00967954|GENETIC|DNA analysis|
218945426|NCT00967954|GENETIC|RNA analysis|
218945427|NCT00967954|GENETIC|comparative genomic hybridization|
219052774|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
219052775|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
219052776|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
219052777|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
218945428|NCT00967954|GENETIC|gene expression analysis|
218945429|NCT00967954|OTHER|laboratory biomarker analysis|
218945430|NCT00967954|PROCEDURE|diffusion-weighted magnetic resonance imaging|
218945431|NCT00967954|PROCEDURE|magnetic resonance spectroscopic imaging|
218945432|NCT04664699|DEVICE|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume"
218945433|NCT04664699|DEVICE|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
218945434|NCT01192009|DIETARY_SUPPLEMENT|Leucine|7.2 g of leucine during 2 weeks
218945435|NCT01192009|DIETARY_SUPPLEMENT|Placebo|7.2 g of alanine during 2 weeks
218945436|NCT05014633|OTHER|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
218945437|NCT02500940|DRUG|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
218945438|NCT02500940|DRUG|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
219052778|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
219052779|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
219052780|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
219052781|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
219052782|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
219052783|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
219052784|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
219052785|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
219052786|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
219052787|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
219052788|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
219052789|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
219052790|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
219052791|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
219052792|NCT04693364|PROCEDURE|Discussion|Participate in consultation
219052793|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
219052794|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
219052795|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
219052796|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
219052797|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
219052798|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
219052799|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
219052800|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
219052801|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
219052802|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
218945439|NCT02500940|RADIATION|Radiation therapy|Intensity-Modulated Radiation Therapy
219052803|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
219052804|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
219052805|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
219052806|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
219052807|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
219052808|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
219052809|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
219052810|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
218945440|NCT02500940|DRUG|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
218945441|NCT05388292|OTHER|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
218945442|NCT00379301|PROCEDURE|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
218945443|NCT04580992|DRUG|Ajmaline|Ajmaline administration
218945444|NCT03288142|OTHER|Hypertension Coaching Application and Home Monitor|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
218945445|NCT03288142|OTHER|Control: Tracking Application and Home Monitor|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
218945446|NCT04599530|DEVICE|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
218945447|NCT04332458|BEHAVIORAL|A focus group interview|this is a qualitative study using focus group interviewing.
218945448|NCT03903315|OTHER|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
218945449|NCT02047721|BEHAVIORAL|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
218945450|NCT02047721|BEHAVIORAL|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
218945451|NCT03147157|OTHER|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
218945452|NCT01250444|OTHER|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
218945453|NCT01316068|DRUG|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
218945454|NCT01316068|DRUG|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
218945455|NCT02102659|GENETIC|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
218945456|NCT02102659|GENETIC|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
218945457|NCT03336593|BIOLOGICAL|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
218945458|NCT03336593|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
218945459|NCT01622309|DIETARY_SUPPLEMENT|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
218945460|NCT01622309|OTHER|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
218945461|NCT00611754|DRUG|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
218945462|NCT05772585|OTHER|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
218945463|NCT00963118|DIETARY_SUPPLEMENT|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
218945464|NCT03101553|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
218945465|NCT03101553|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
219366041|NCT03162848|BEHAVIORAL|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
218945466|NCT05514808|OTHER|Nutrition education modules|Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
218945467|NCT02414256|OTHER|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
218945468|NCT00946153|DRUG|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
218945469|NCT00084890|DRUG|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
218945470|NCT00084890|DRUG|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
218945471|NCT03904056|PROCEDURE|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
218945472|NCT03904056|PROCEDURE|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
218945473|NCT01030666|DRUG|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
218945474|NCT01030666|DRUG|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
218945475|NCT01030666|PROCEDURE|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
218945476|NCT01030666|BIOLOGICAL|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
218945477|NCT01030666|DRUG|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
218945478|NCT01030666|DRUG|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
218945479|NCT01030666|DRUG|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
218945480|NCT06408753|PROCEDURE|sterotatic body radiotherapy|checkpoint inhibitors with or without sterotatic body radiotherapy
218945481|NCT06532240|DRUG|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
218945482|NCT06532240|DRUG|Placebo|An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
218945483|NCT02594020|PROCEDURE|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
218945484|NCT02594020|PROCEDURE|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
218945485|NCT02594020|PROCEDURE|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
218945486|NCT02739178|OTHER|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
218945487|NCT04049877|OTHER|None - Observational study|None - Observational study
218945488|NCT05509868|DRUG|PBK_L1704 0.35mg|The subject will receive PBK\_L1704 0.35mg/ml by PCA
218945489|NCT05509868|DRUG|PBK_L1704 0.5mg|The subject will receive PBK\_L1704 0.5mg/ml by PCA
218945490|NCT05509868|DRUG|Placebo|The subject will receive placebo by PCA
218945491|NCT06478381|DRUG|L218CAR19|L218CAR19 is intravenously administered at three dose levels.
218945492|NCT05956444|OTHER|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
218945493|NCT05956444|OTHER|Conventional Physiotherapy|Classical physiotherapy applications for balance.
218945494|NCT01859546|BEHAVIORAL|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
218945495|NCT00846183|PROCEDURE|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
218945496|NCT03302182|DRUG|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
218945497|NCT03302182|DRUG|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
218945498|NCT02207426|DRUG|Tobramycin|
218945499|NCT01774409|GENETIC|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
218945500|NCT03698591|DEVICE|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
219366042|NCT00372879|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800IU bid
219366043|NCT01299727|BIOLOGICAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
218945501|NCT03698591|DEVICE|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
218945502|NCT05373914|DRUG|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
219052811|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
219052812|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
219052813|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
219052814|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
219052815|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
219052816|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
219052817|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
219052818|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
219052819|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
219052820|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
219052821|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
218945503|NCT05373914|DRUG|Control: Matching Placebo|Placebo - 250mg tablets (orally)
219052822|NCT02506114|DRUG|Ipilimumab|
218945504|NCT02894268|DRUG|Doxycycline|Doxycycline 100g po bid
218945505|NCT02894268|DRUG|Furazolidone|Furazolidone 100mg po bid
219052823|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
219052824|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
219052825|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
219052826|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
219052827|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
219052828|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
219635087|NCT01948440|BEHAVIORAL|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
219635088|NCT00650247|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
218945506|NCT02894268|DRUG|Esomeprazole|Esomeprazole 20mg po bid
218945507|NCT02894268|DRUG|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
218945508|NCT02894268|DRUG|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
218945509|NCT05225805|DRUG|Lefamulin|Antibiotic
219052829|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
219052830|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
219052831|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
219635089|NCT00650247|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fed
218945510|NCT06423274|DIAGNOSTIC_TEST|fundus photography|using artificial intelligence to identify diabetic retinopathy using fundus photography
219052832|NCT03778216|BEHAVIORAL|Family Based Treatment|
219052833|NCT00414752|DRUG|AFQ065|
218945511|NCT06423274|DIAGNOSTIC_TEST|optical coherence tomography|detect diabetic retinopathy and diabetic macular edema by optical coherence tomography
219052834|NCT06462807|BEHAVIORAL|ARC|ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
219052835|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
219052836|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
219052837|NCT06358677|DRUG|Topical Tretinoin|Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
218945512|NCT06423274|DIAGNOSTIC_TEST|fundus fluorescence angiography|detect diabetic retinopathy by fundus fluorescence angiography
218945513|NCT06451198|DRUG|Indobufen|Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
218945514|NCT06451198|DRUG|Aspirin|Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
218945515|NCT06451198|DRUG|Ticagrelor|All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
218945516|NCT04359901|BIOLOGICAL|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
218945517|NCT01686997|PROCEDURE|Roux-en-Y Gastric Bypass|
218945518|NCT03726229|DEVICE|Cholate assay|Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
218945519|NCT02983929|PROCEDURE|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
218945520|NCT06429735|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface
218945521|NCT06429735|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
218945522|NCT02252341|DIETARY_SUPPLEMENT|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
218945523|NCT00575146|DIETARY_SUPPLEMENT|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
218945524|NCT00690144|DEVICE|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
218945525|NCT04137939|DEVICE|smart exercise system|The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
218945526|NCT00052624|BIOLOGICAL|transferrin-CRM107|
218945527|NCT06248580|DIAGNOSTIC_TEST|Anti Delta|Anti Delta by ELISA
218945528|NCT02110459|DRUG|POL7080|Intravenous infusion
218945529|NCT03400605|OTHER|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
218945530|NCT04578821|OTHER|Educational intervention|Educational intervention
218945531|NCT02481349|OTHER|Best Practice|Undergo standard of care
218945532|NCT02481349|OTHER|Informational Intervention|Receive DVD for home practice
218945533|NCT02481349|OTHER|Quality-of-Life Assessment|Ancillary studies
218945534|NCT02481349|OTHER|Questionnaire Administration|Ancillary studies
218945535|NCT02481349|OTHER|Yoga|Complete couple-based Hatha yoga program
218945536|NCT04529356|DEVICE|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
218945537|NCT04529356|DRUG|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
218945538|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
218945539|NCT05890755|OTHER|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
219052838|NCT06358677|OTHER|Placebo|A placebo (topical moisturizer) will be applied to the other half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
219366044|NCT01299727|BIOLOGICAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
218945540|NCT03631888|DIAGNOSTIC_TEST|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
219052839|NCT05027581|DRUG|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
218945541|NCT00557856|DRUG|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
218945542|NCT03682380|DRUG|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
218945543|NCT03682380|DRUG|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
218945544|NCT00451347|DEVICE|Quadriceps strength training|
218945545|NCT00451347|DEVICE|Taping|
218945546|NCT00451347|DEVICE|Home exercise|
219052840|NCT05027581|DRUG|hyaluronic acid|(60 mg/3 mL hyaluronic acid \[HA\])
219052841|NCT03125265|OTHER|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
219052842|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
219052843|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
219052844|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
219052845|NCT01816464|BIOLOGICAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
219052846|NCT01947400|OTHER|Hospitalists|AIDET Training
219052847|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
219052848|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
218945547|NCT02177149|DEVICE|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
219052849|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
219052850|NCT05850871|OTHER|Conventional treatment|Conventional treatment
219052851|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
219052852|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
219052853|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
219052854|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
218945548|NCT02177149|DEVICE|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
218945549|NCT05036421|DRUG|Empagliflozin 10 milligram|antihyperglycemic medication
219052855|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
219052856|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
219052857|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
218945550|NCT02234895|DEVICE|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
218945551|NCT02234895|DEVICE|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
218945552|NCT00726011|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
218945553|NCT03320577|BEHAVIORAL|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
218945554|NCT03320577|BEHAVIORAL|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
218945555|NCT03320577|BEHAVIORAL|Control|Log dinner times
218945556|NCT04216797|DRUG|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
218945557|NCT02726854|DRUG|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
218945558|NCT04154813|DRUG|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
219635090|NCT05294692|BEHAVIORAL|Financial Health Incentives|Caterpillar Health (Caterpillar Health Inc., Leeds, UK) is a multi-component healthy living app that includes financial incentive (points redeemable for consumer goods like movies or gym passes) and was made available to Leeds, UK residents on the Apple iTunes/App Store and Google Play app stores on August 8, 2022. The app was later made available to all of the UK as of October 3, 2022. The app uses the smartphone's in-built accelerometer and/or is integrated with Apple Health and Google Fit to promote physical activity through step tracking. To offer a variety of popular incentives, Caterpillar Health formed partnerships with two major UK based companies, Vue Cinema and Hussle (a gym network system), allowing users to redeem points for free movie and gym passes. Additionally, the company collaborated with a UK health agency (Active Leeds via Leeds City Council) to assist in the development and approval of educational health quiz content.
218945559|NCT04154813|DRUG|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
218945560|NCT04154813|BEHAVIORAL|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
218945561|NCT04154813|BEHAVIORAL|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
218945562|NCT01675167|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
218945563|NCT01675167|DRUG|Placebo|Matching Placebo Buccal Film twice daily
218945564|NCT02400385|DRUG|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
218945565|NCT02400385|DRUG|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
218945566|NCT04120519|DRUG|thalidomide combined with dexamethasone and cyclophosphamide|TCD
218945567|NCT04273035|DRUG|Midazolam oral solution|Oral Buccolam
218945568|NCT04273035|DEVICE|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
218945569|NCT00392145|DRUG|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
219052858|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
219635091|NCT02865499|DRUG|acarbose|acarbose treatment with meals
218945570|NCT00392145|DRUG|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
218945571|NCT04962256|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
218945572|NCT03769584|OTHER|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
218945573|NCT03769584|OTHER|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
218945574|NCT00950677|DRUG|Byetta (exenatide)|exenatide 5 mcg subcutaneously
218945575|NCT00950677|DRUG|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
218945576|NCT00830778|PROCEDURE|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
218945577|NCT00830778|PROCEDURE|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
218945578|NCT04911985|DEVICE|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
218945579|NCT05993013|OTHER|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
218945580|NCT05090397|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
219052859|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
219052860|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
218945581|NCT05090397|DEVICE|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
218945582|NCT04580134|DRUG|clozapine|Biotype 1 and Biotype 2
218945583|NCT04580134|DRUG|risperidone|Biotype 1 and Biotype 2
218945584|NCT05219370|DRUG|Cannabis oil|administration of different cannabis oil types as compared with placebo
218945585|NCT00062803|DRUG|SR34006|
218945586|NCT00062803|DRUG|(LMW)heparin|
218945587|NCT00062803|DRUG|Warfarin VKA|
219052861|NCT00700791|OTHER|Placebo|Oral Placebo
219052862|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
219052863|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
219052864|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
219052865|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
219052866|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
219052867|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
219052868|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
219052869|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
219052870|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
219052871|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
219052872|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
219052873|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
219052874|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
219052875|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
218945588|NCT00062803|DRUG|Acenocoumarol VKA|
218945589|NCT02814994|BEHAVIORAL|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
218945590|NCT02814994|BEHAVIORAL|low tidal volume|ventilation ventilated with low tidal volume
218945591|NCT02145013|PROCEDURE|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
219052876|NCT02310659|OTHER|No intervention|No intervention
219052877|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
219052878|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
219052879|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
219052880|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
219052881|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
219052882|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
218945592|NCT05138952|BEHAVIORAL|Mindfulness Meditation|"30-day mediation program comprising:~1. Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~2. 10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
218945593|NCT06516523|PROCEDURE|PEMF and Control/Sham|Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
218945594|NCT06516523|DEVICE|PEMF and without PEMF|Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
219052883|NCT01560624|DRUG|Treprostinil Diolamine|Active
219052884|NCT01560624|DRUG|Placebo|Placebo
219052885|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
219052886|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
219052887|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
219052888|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
219052889|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
219052890|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
219052891|NCT03431194|DRUG|Placebo|
219052892|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
219052893|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
219366045|NCT01299727|BIOLOGICAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
218945595|NCT04947085|DRUG|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
218945596|NCT04947085|DRUG|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
218945597|NCT01252225|DRUG|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
218945598|NCT01252225|DRUG|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
218945599|NCT01252225|DRUG|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
218945600|NCT01525225|DRUG|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
218945601|NCT01525225|DRUG|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
218945602|NCT01525225|DRUG|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
218945603|NCT01525225|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
218945604|NCT01525225|DRUG|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
218945605|NCT02499757|DEVICE|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
218945606|NCT02499757|DEVICE|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
218945607|NCT02499757|DEVICE|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
219052894|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
219206900|NCT06866301|BEHAVIORAL|Progressive Resistance Exercise|The exercise program will have a duration of 10 weeks. It will be divided in two phases: conditioning phase and training phase. During the conditioning phase (2-3 weeks), participants will learn exercise techniques, work on their interoceptive awareness and perform same exercises at a lower intensity to prepare the muscles for the next phase. In the training phase, the intensity will be moderate starting at approximately 60% of capacity, with a frequency of three days per week and continuous adjustment (progression) based on the participant's improvements. Each session will include a warm-up and cool-down of approximately 10 minutes. The central part of the session will be in the form of a circuit and will include 6 large muscle group exercises using a combination of machine exercises following the PPL (push, pull and legs) model and 3 core strengthening exercises.
219635092|NCT02996123|OTHER|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
218945608|NCT02499757|DEVICE|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
218945609|NCT05767268|DEVICE|Lokomat|gait rehabilitation
218945610|NCT00452192|DRUG|Telmisartan|telmisartan 80 mg daily over 2 weeks
219635093|NCT01910545|DRUG|OTS167IV|
219635094|NCT01931995|DEVICE|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
219635095|NCT01931995|PROCEDURE|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
218945611|NCT05878262|DRUG|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
218945612|NCT03647891|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
218945613|NCT00243841|RADIATION|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
218945614|NCT01783756|DRUG|lapatinib ditosylate|Given PO
218945615|NCT01783756|DRUG|everolimus|Given PO
219052895|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
219052896|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
219052897|NCT05555433|OTHER|NO INTERVENTION|no intervention
219052898|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
218945616|NCT01783756|DRUG|capecitabine|Given PO
218945617|NCT01783756|OTHER|laboratory biomarker analysis|Correlative studies
218945618|NCT03801057|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
218945619|NCT03801057|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
218945620|NCT00285389|DRUG|Adriblastin|
218945621|NCT00285389|DRUG|dexamethasone|
218945622|NCT00285389|DRUG|Chlorambucil|
218945623|NCT00285389|DRUG|rituximab|
218945624|NCT00285389|DRUG|cyclophosphamide|
218945625|NCT00285389|DRUG|alkeran|
219206901|NCT06745973|DRUG|EPI-003|Intravenous (IV) infusion.
218945626|NCT00285389|PROCEDURE|Total body irradiation (8Gy/4fr)|
218945627|NCT00285389|DRUG|vincristine|0,4 mg/day day 1 to day 4
218945628|NCT05972057|PROCEDURE|cardiac surgery|All cardiac surgery patients who met the inclusion criteria were included in the cardiac surgery department of Renji Hospital.
218945629|NCT05518578|DRUG|SPN-817|oral capsule
218945630|NCT05819489|DIAGNOSTIC_TEST|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
218945631|NCT04596059|OTHER|Frisolac Gold Intensive HA|Regular medical care
218945632|NCT01575535|GENETIC|gene expression analysis|
218945633|NCT01575535|OTHER|flow cytometry|
218945634|NCT01575535|OTHER|fluorescence activated cell sorting|
218945635|NCT01575535|OTHER|laboratory biomarker analysis|
219052899|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
219052900|NCT01797536|DRUG|Elbasvir|
219052901|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
219052902|NCT00231608|DRUG|topiramate|
219052903|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
219052904|NCT00098839|DRUG|L-asparaginase|Given IM
219052905|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
219052906|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
219052907|NCT00098839|DRUG|vincristine sulfate|Given IV
219052908|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
219052909|NCT00098839|DRUG|cytarabine|Given IT
219052910|NCT00098839|DRUG|prednisone|Given orally
219052911|NCT00098839|DRUG|pegaspargase|Given IM
219052912|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
219052913|NCT00098839|DRUG|methotrexate|Given IT
219052914|NCT00098839|DRUG|etoposide|Given IV
219052915|NCT00098839|DRUG|cyclophosphamide|Given IV
219052916|NCT00098839|DRUG|leucovorin calcium|Given IV
219052917|NCT00098839|BIOLOGICAL|filgrastim|Given SC
219549538|NCT07139041|DRUG|Iparomlimab and tuvonralimab plus chemotherapy|"Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (Day 1) + Albumin-bound Paclitaxel (100mg/m² Q3W D1/D8/D15 or130mg/m²D1/D8 or 260mg/m²D1) + Carboplatin (AUC=5) Q3W (D1) Non-Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) + Pemetrexed 500mg/m² Q3W (D1) + Carboplatin (AUC=5) Q3W (D1) Radical Chemoradiotherapy for Patients Unable to Undergo Surgery:Patients still unresectable after conversion therapy should start radical chemoradiotherapy within 6 weeks after the last conversion therapy dose. Chemoradiotherapy follows standard clinical practice, recommended as Cisplatin 30mg/m² QW (D1) + 60Gy radiotherapy.~Adjuvant Therapy Phase:Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) for up to 16 cycles."
218945636|NCT01575535|OTHER|medical chart review|
218945637|NCT03079960|DEVICE|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
218945638|NCT05974059|DRUG|Oxaliplatin|Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;
218945639|NCT05974059|DRUG|Capecitabine|Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
218945640|NCT05974059|DRUG|Cadonilimab|Cadonilimab 10 mg/kg, d1, Q3W
218945641|NCT02667353|PROCEDURE|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
218945642|NCT02667353|DRUG|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
218945643|NCT02667353|DRUG|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
219052918|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
219052919|NCT04485481|DRUG|Placebo|Matching single dose placebo
219052920|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
219052921|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
219052922|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
219052923|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
219052924|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
219052925|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
219052926|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
219052927|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
219052928|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
219635096|NCT02347215|OTHER|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
219635097|NCT02347215|PROCEDURE|Stress imaging|Stress imaging
219052929|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
218945644|NCT04297722|OTHER|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
218945645|NCT00627952|DRUG|amlodipine 10 mg|amlodipine 10 mg once daily
218945646|NCT00627952|DRUG|manidipine 20 mg|manidipine 20 mg once daily
218945647|NCT00627952|DRUG|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
218945648|NCT00627952|DRUG|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
219052930|NCT00305617|OTHER|antitumor drug screening assay|
219052931|NCT00668681|DEVICE|EndoRefix|
219052932|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
219052933|NCT00263523|DRUG|[11C] (-)-RWAY|
219052934|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
219052935|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
219052936|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
219052937|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
219052938|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
219052939|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
219052940|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
219052941|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
219052942|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
219052943|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
219052944|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
219052945|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
219052946|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
219052947|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
219052948|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
219052949|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
219052950|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
219052951|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
219052952|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
219635098|NCT01577212|RADIATION|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
218945649|NCT05525858|DRUG|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
219052953|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
219052954|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
219052955|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
219206902|NCT05848791|OTHER|Exercise exposure|Participants are exposed to three different air quality environments in central London, chosen to maximise differences in nontailpipe air pollution. Participants will cycle at 60% of estimated maximum vo2 on static bikes for six 15 minute bouts with 15 minutes rest between bouts.
219635099|NCT00014495|BIOLOGICAL|filgrastim|
219635100|NCT00014495|DRUG|cytarabine|
219635101|NCT00014495|RADIATION|bismuth Bi213 monoclonal antibody M195|
218945650|NCT05525858|DRUG|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
218945651|NCT05525858|DRUG|Erlotinib|"EGFR Exon 19 deletions in the region E746\_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
218945652|NCT05525858|DRUG|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
218945653|NCT05525858|DRUG|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215\_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775\_G776insSVMA, A775\_G776insYVMA (i.e.,Y772\_A775dup,M774\_A775insAYVME 770delinsEAYVM), G776\_V777 \> AVCV, G776\_V777 \> AVGCV, G776\_V777 \> VCV, G776\_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777\_G778insC, V777L, V777M, G778\_Y779insGSP, P780\_Y781insGSP (i.e.,G778\_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
218945654|NCT05525858|DRUG|Vemurafenib|BRAF\_V600E/D/K/R mutations
218945655|NCT05525858|DRUG|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
218945656|NCT05525858|DRUG|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
218945657|NCT05525858|DRUG|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
218945658|NCT00363545|BIOLOGICAL|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
218945659|NCT00363545|BIOLOGICAL|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
218945660|NCT04162561|BEHAVIORAL|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
218945661|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - low|
219206903|NCT06741878|BEHAVIORAL|Exercise|Involves participants engaging in physical training group sessions in light-to-moderate intensity.
218945662|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - medium|
219206904|NCT06741878|BEHAVIORAL|Psychosocial|Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.
219635102|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
219635103|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
219635104|NCT01357317|DRUG|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
218945663|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - high|
218945664|NCT02264145|DRUG|Ethanolic Solution From Respimat®|
218945665|NCT04197219|DRUG|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
219206905|NCT06741878|BEHAVIORAL|Nutritional|Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.
219206906|NCT06742021|DIAGNOSTIC_TEST|Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer|Chest MRI scans outside of the standard treatment protocol
218945666|NCT04197219|DRUG|Axitinib|5 mg PO BID continuously
218945667|NCT01315561|OTHER|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
218945668|NCT05685173|DRUG|Odronextamab|Odronextamab will be administered by IV infusion
218945669|NCT05685173|DRUG|REGN5837|REGN5837 will be administered by IV infusion
219206907|NCT06742086|DRUG|Venetoclax|Oral Tablet
219206908|NCT06743061|BEHAVIORAL|Post-Op Follow Up|Post Arthroscopic Biceps Tenotomy and Subacromial Decompression in Chronic Massive Rotator Cuff Tears.
219206909|NCT06735040|OTHER|Photobiomodulation Therapy|Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
219206910|NCT06735040|OTHER|Sham|In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
218945670|NCT06645496|OTHER|Evaluation of ehealth literacy|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO\_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
218945671|NCT00703248|PROCEDURE|Osteopathic Manipulative Treatments|"1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
218945672|NCT02854930|OTHER|questioning|
218945673|NCT04247867|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
218945674|NCT04247867|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium and Inulin)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
218945675|NCT04247867|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
218945676|NCT05048576|BEHAVIORAL|Negative Reinforcement|"Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet."
219052956|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
219052957|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
219052958|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
219052959|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
219052960|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
219052961|NCT03970434|OTHER|Venous blood collection|Venous blood collection
219366046|NCT02055404|DEVICE|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
219052962|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
219052963|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
219635105|NCT02598232|DEVICE|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
219635106|NCT02921685|DRUG|Monalizumab|Four dose levels will be tested.
219635107|NCT04350125|BIOLOGICAL|Autologous Platelet Rich Plasma|One 4-5mL platelet rich plasma injection administered to each side of the intracavernosal space on the right and left side of the corpus cavernosum at the base of the penis, every two weeks for 6 weeks.
219635108|NCT05531630|DEVICE|Nasal rinsing with saline 0.9%|"Nasal irrigations with saline (NaCl 0.9%) are considered golden standard in the treatment of chronic rhinosinusitis. Sachets consisting of mixtures for saline solutions, produced by DOS Medical®, consist of 1.875g sodium chloride and 0.625g sodium bicarbonate (figure 5). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the saline solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device and has a CE-label (CNK number 3309028)."
218945677|NCT05048576|BEHAVIORAL|Positive Reinforcement|"Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job."
218945678|NCT05048576|BEHAVIORAL|Silence|No recordings will be played during this condition.
218945679|NCT05048576|BEHAVIORAL|Music|Participant's can choose their own music to play during this condition.
218945680|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
218945681|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
218945682|NCT01798108|RADIATION|Radium-223 dichloride (BAY88-8223)|\- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
218945683|NCT01182844|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
218945684|NCT01379508|DRUG|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
218945685|NCT01379508|DRUG|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
218945686|NCT00343941|DRUG|Tucaresol tablets 25 mg|
218945687|NCT03225508|DIAGNOSTIC_TEST|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
218945688|NCT03225508|DIAGNOSTIC_TEST|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
219052964|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
219052965|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
219052966|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
219052967|NCT01938534|DRUG|Helicobacter pylori eradication|
219052968|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
219052969|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
219052970|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
219052971|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
219052972|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
219052973|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
219052974|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
219052975|NCT01618539|DRUG|propofol|varying intravenous dosages
219052976|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
219052977|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
219052978|NCT03996928|OTHER|Exercise|
219052979|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
219052980|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
219052981|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
219366047|NCT02055404|DEVICE|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
218945689|NCT03225508|DIAGNOSTIC_TEST|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
218945690|NCT05227040|DEVICE|Nintendo Ring Fit Adventure Exergame|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
219052982|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
219052983|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
219052984|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
219052985|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
219052986|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
219052987|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
219052988|NCT02489981|DRUG|Spiriva|60 puffs
219052989|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
219052990|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
219052991|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
219052992|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
219052993|NCT00394797|PROCEDURE|mitral valve annuloplasty|
219052994|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
219052995|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
219052996|NCT05577182|DRUG|INCA32459-101|solution for infusion
219052997|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
219052998|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
219052999|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
219053000|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
219053001|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
219366048|NCT05631912|BIOLOGICAL|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10\^6 cells/kg) ,dose 2 (3×10\^6 cells/kg) ,dose 3 (1×10\^7 cells/kg); Phase 2 : Appropriate dose
219366049|NCT05631912|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
218945691|NCT05726084|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
218945692|NCT05726084|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
218945693|NCT05543993|DRUG|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
218945694|NCT04159298|DEVICE|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
218945695|NCT01457352|DRUG|SPARC0921|
218945696|NCT01457352|DRUG|Placebo0921|
218945697|NCT00040300|DRUG|Racivir|
218945698|NCT00529607|DRUG|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
218945699|NCT00529607|PROCEDURE|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
218945700|NCT00529607|PROCEDURE|cardiac MRI|before discharge and after 6 months
218945701|NCT00529607|PROCEDURE|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
218945702|NCT03437616|BEHAVIORAL|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
218945703|NCT01562093|DRUG|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
218945704|NCT01562093|DRUG|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
218945705|NCT01589991|DRUG|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
218945706|NCT03230019|PROCEDURE|chest tube|VATS with chest tube placement
218945707|NCT03230019|PROCEDURE|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
218945708|NCT03230019|DEVICE|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
218945709|NCT02972567|DIETARY_SUPPLEMENT|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
218945710|NCT02972567|DIETARY_SUPPLEMENT|Control|Maltodextrin
218945711|NCT04424953|DEVICE|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
218945712|NCT04424953|DEVICE|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
218945713|NCT02537015|DRUG|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
218945714|NCT04279106|PROCEDURE|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
218945715|NCT04279106|PROCEDURE|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
218945716|NCT04279106|PROCEDURE|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
219053002|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
218945717|NCT04279106|PROCEDURE|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
218945718|NCT00512629|DRUG|Omegaven|Omegaven is a fish based intravenous fat emulsion
218945719|NCT00512629|DRUG|Intralipid|Intralipid is a plant based intravenous fat emulsion
218945720|NCT04168736|OTHER|Feasibility and Acceptability of Genetic Counseling Materials|"To determine the feasibility and acceptability of a communication aid in sharing genetic test results with family members.~To determine the utility of a communication aid in sharing information. To determine the impact of patient focused information sheets on patient knowledge of genetic testing."
218945721|NCT02277561|PROCEDURE|diffusion tensor imaging|Undergo VB-DTI
218945722|NCT02277561|RADIATION|whole-brain radiation therapy|Undergo WBRT
218945723|NCT02277561|RADIATION|stereotactic radiosurgery|Undergo SRS
218945724|NCT02277561|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
218945725|NCT02277561|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
218945726|NCT00201552|DRUG|Statin|
218945727|NCT03445949|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
218945728|NCT03445949|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
218945729|NCT03445949|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
218945730|NCT03445949|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
218945731|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
218945732|NCT04174365|DRUG|Brexpiprazole|Oral tablet; take once daily
218945733|NCT04174365|DRUG|Placebo|Administered orally daily for up to Week 8.
219053003|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
219053004|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
219053005|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
219053006|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
219053007|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
219053008|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
219053009|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
218945734|NCT06909773|BEHAVIORAL|Guideline education and implementation intervention|"The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：~1. Disease education~   * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.~  * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.~2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.~3. Follow-up management:the subjects will be followed up every 4 weeks."
218945735|NCT06556992|BEHAVIORAL|FIT Teens|This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
218945736|NCT07106788|DEVICE|Aveir DR Leadless Pacemaker Implant|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
218945737|NCT07106788|DEVICE|Single-chamber atrial Aveir patients|Patients will undergo a single chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right atrium
218945738|NCT07106788|DEVICE|Upgrades|Patients with an existing single-chamber leadless pacemaker will undergo a leadless pacemaker system implant wherein an additional leadless pacemaker will be implanted in either the right ventricle or right atrium to form a dual-chamber LP system.
218945739|NCT07106788|DEVICE|Roll-over|Patients with an existing active Aveir DR leadless pacemaker system are eligible to be rolled into the Aveir Japan PMS upon consent for ongoing follow-up.
218945740|NCT07109869|DRUG|Boric acid|Boric acid vaginal inserts consisting of 600 mg boric acid drug substance filled into white, opaque hypromellose capsules with no additional excipients included in the formulation. Each vaginal insert is sealed into a clear blister cavity.
218945741|NCT07109869|OTHER|Placebo|Placebo vaginal inserts containing anhydrous lactose and 1% magnesium stearate are also manufactured and filled into white, opaque hypromellose capsules. Packaged in clear blisters.
218945742|NCT06914765|DEVICE|Endoscopic Sleeve Gastroplasty (ESG) Procedure|The ESG procedure will be performed under general anesthesia monitored by an anesthesiologist. The device that will be used is called the Apollo Endosurgery ESG System, which is the only FDA approved device for the reduction of stomach volume through endoscopic sleeve gastroplasty for adult patients with obesity. This device works by being attached to a standard upper endoscope and is inserted through the mouth and goes into the stomach. When in the stomach, the back and front wall of the stomach will be stitched together to reduce the size of the stomach and help decrease the amount of food a patient can eat and drink at one time before feeling full.
218945743|NCT06917001|DRUG|Resomelagon|Resomelagon 100mg, orally, once daily.
218945744|NCT06917001|DRUG|Placebo|Placebo
218945745|NCT06917001|OTHER|Standard Treatment|Hydration and symptomatic therapy as indicated for Dengue fever.
219053010|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
219053011|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
219635109|NCT05531630|DEVICE|Nasal rinsing with Xylitol|"Xylitol is a sugar-alcohol that is already implemented in the treatment of patients with (difficult-to-treat) chronic rhinosinusitis. Some (pilot) studies have already showed a positive effect in CRS patients without cystic fibrosis. Xylitol nasal rinsing salt, produced by DOS Medical®, is a mixture of 4g Xylitol, 1.875g sodium chloride, 0.625g sodium bicarbonate and 0,03g mint (Figure 3). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the Xylitol solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device, has a CE-label (CNK number 3309036) and is already commercially available in Belgium and The Netherlands."
218945746|NCT06749067|BEHAVIORAL|Mindfulness Based Practices|Experiment 1 Group Intervention: In the first session preparation session; face-to-face meeting with the women in the experimental group and then general information about the definition, purpose and applications of the mindfulness-based practice will be given, and the lack of information about the practice, if any, will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Awareness Practice, women will be focused on the moment with a 3-minute breathing exercise and then continue with the raisin exercise.
219053012|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
219053013|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
219053014|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
219053015|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
219366050|NCT05631912|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
218945747|NCT06749067|BEHAVIORAL|Occupational Practices|Experiment 2 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. Before starting the Busyness Practice, women will be asked to choose the practice that they can do within the scope of the busyness practice such as 'hand knitting, wood painting, charcoal, origami, bead work, jewellery design, painting tables with
218945748|NCT06749067|BEHAVIORAL|Mindfulness-Based Occupational Practice|Experiment 3 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Mindfulness-Based Engagement Practice, women will be focused on the moment with a 3-minute breathing exercise, followed by a raisin exercise.
218945749|NCT06920030|DEVICE|Subcutaneous cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in a left thoracic subcutaneous pocket
218945750|NCT06920030|DEVICE|Infraclavicular pocket cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in the same infraclavicular pocket as the device itself
218945751|NCT06920030|DEVICE|Coronary Sinus cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a coronary sinus electrode
218945752|NCT06915233|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|An autologous cellularized scaffold product being studied for the repair of symptomatic, single or multiple full-thickness cartilage defects of the talus with or without bone involvement in adults.
218945753|NCT06915233|PROCEDURE|Bone Marrow Stimulation|"A surgical awl or microdrill will be used to make multiple holes in the exposed base of the lesion. The microfracture procedure should result in holes that are approximately 3 to 4 mm apart.~When fat droplets can be seen coming from the marrow cavity, the appropriate depth (approximately 2 to 4 mm) has been reached.~The released marrow elements (including mesenchymal stem cells, growth factors, and other healing proteins) form a surgically induced clot that provides an enriched environment for new tissue formation."
218945754|NCT07118839|DRUG|Full Dose MDMA|3 MDMA dosing (Experimental) sessions: Session 1 - 80mg to 120mg MDMA HCl; Session 2 - 80mg to 180mg MDMA HCl; Session 3 - 80mg to 180mg MDMA HCl
218945755|NCT07118839|BEHAVIORAL|MDMA-AT|inner-directive psychotherapy will be conducted throughout the study; Lykos Therapeutics MDMA-AT Manual
218945756|NCT07118839|DRUG|Active Placebo Dose MDMA|3 MDMA dosing (Experimental) sessions in which participants will receive 40mg MDMA HCl max at each session.
218945757|NCT07117877|DRUG|Etoposide Capsules|50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle
218945758|NCT07117877|DRUG|Bevacizumab|7.5mg/kg, i.v, q3w
219635110|NCT05553990|OTHER|intestinal flora disturbance|To observe the clinical prognosis of stroke patients complicated with tumor after enterobacterial disorder
219635111|NCT01307592|BIOLOGICAL|rituximab|
219635112|NCT01307592|DRUG|gemcitabine hydrochloride|
219635113|NCT01307592|DRUG|lenalidomide|
219635114|NCT01307592|DRUG|oxaliplatin|
219635115|NCT04341805|PROCEDURE|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
219635116|NCT04341805|PROCEDURE|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
219635117|NCT04429568|OTHER|Smoked Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
219635118|NCT04429568|OTHER|Vaped Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
219635119|NCT04429568|OTHER|Tobacco Cigarette|Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
219635120|NCT03625375|OTHER|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
219635121|NCT00329537|DRUG|Sargramostim (Leukine)|Self-subcutaneous injection
219635122|NCT00329537|DRUG|Placebo|Self-subcutaneous injection
219635123|NCT02557581|OTHER|No training|
219635124|NCT02557581|OTHER|Endurance training|
219635125|NCT02557581|OTHER|Resistance Training|
219635126|NCT02557581|DRUG|Terbutaline|
219635127|NCT02557581|DRUG|Clenbuterol|
218945759|NCT07117877|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg, i.v., q3w
218945760|NCT06836869|PROCEDURE|Laparoscopic radical hysterectomy incorporating modified tumor-free techniques|"Thoroughly examine the pelvic and abdominal cavities. Coagulation of the fallopian tubes are recommanded at the beginning of the surgery. The use of uterine manipulator is prohibited. An 8-suture at the uterine fundus is recommended. Insert a trocar 3 cm above the pubic symphysis and suspend the uterus by pulling with a needle holder. Alternative methods are also acceptable. Perform pelvic lymphadenectomy. Conduct radical hysterectomy according to the Q-M classification type C. Before incising the vagina, the upper part of the vagina must be closed (using a cable tie or suture), or the vagina can be incised transvaginally after deflating the pneumoperitoneum. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity. The vaginal stump can be sutured either laparoscopically or transvaginally."
219053016|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
219053017|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
219053018|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
219053019|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
219206911|NCT06735092|OTHER|Exercise-Only Group (Control Group)|Participants in this group will only undergo a standardized exercise protocol. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
219635128|NCT02557581|DRUG|Placebo|
219635129|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
219635130|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
219635131|NCT04601077|DRUG|Nitric Oxide lozenges, 30 mg|Nitric Oxide lozenge, 30 mg twice a day for 30 days
219635132|NCT04601077|DRUG|Placebo|Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
219635133|NCT03798509|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
219635134|NCT02420561|BEHAVIORAL|Motivational Interviewing|"* One in-person motivational interviewing session intervention that lasts for 45-minutes~* Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
219635135|NCT02420561|BEHAVIORAL|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
219635136|NCT03871205|BIOLOGICAL|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
219635137|NCT05932537|PROCEDURE|Preoperative visualization techniques|describe techniques for pre-operative visualization of subcutaneous contraceptive implants
219635138|NCT02024074|OTHER|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
219635139|NCT04337905|DEVICE|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
219635140|NCT06061120|DEVICE|Recording of an extended high-resolution ECG|Recording of an extended high-resolution ECG
219635141|NCT01056237|DRUG|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
219053020|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
219635142|NCT01056237|DRUG|Azathioprine|1.0-2.0mg/kg/d
219635143|NCT02746978|OTHER|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
219053021|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
219053022|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
219053023|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
219053024|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
218945761|NCT06836869|PROCEDURE|Abdominal radical hysterectomy|At the onset of surgery, comprehensively explore the pelvic and abdominal cavities. If intraperitoneal metastases are identified, radical hysterectomy should be aborted. Perform pelvic lymphadenectomy. After lymph node resection, remove the lymph nodes from the surgical field promptly. Sentinel lymph node mapping and biopsy are not performed in this study. Perform radical hysterectomy according to type C of the Q-M classification. It can be accompanied by or without bilateral salpingo - oophorectomy. For patients who retain their ovaries, bilateral ovarian transposition can be carried out. Before incising the vagina, close the upper segment of the vagina and/or the vaginal stump. This can be achieved using instruments such as a large right - angle clamp or an auricular clamp. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity.
218945762|NCT07144865|DRUG|conbercept ophthalmic injection （0.5mg）|Participants were randomly assigned to receive intravitreal injections of either faricimab (IVF, n=4) or conbercept (IVC, n=4) based on a randomisation protocol. To establish a baseline comparison, FVMs were obtained from three treatment-naive patients who served as controls. All participants underwent surgery 4 days after the intravitreal anti-VEGF injections.
218945763|NCT07144865|DRUG|Faricimab|According to the randomization protocol, participants were randomly assigned to receive intravitreal injections of faricimab (IVF, n=4) or conbercept (IVC, n=4). To establish a baseline comparison, FVMs were obtained from three treatment-naïve patients as controls. All participants underwent surgery 4 days after intravitreal anti-VEGF injection.
218945764|NCT07146724|OTHER|Exercise|"The intervention consists of a pilates-based exercise program specifically designed to target hamstring flexibility, plantar pressure sensitivity, and dynamic balance.~Unlike general fitness-oriented pilates, this program includes a combination of mat-based and functional pilates movements adapted to improve posterior chain flexibility and sensory feedback in the lower extremities.~The protocol includes 3 sessions per week for 8 weeks - 1 session conducted face-to-face under physiotherapist supervision and 2 sessions as a monitored home exercise. Exercise progression is standardized, and all sessions follow a validated physiotherapy protocol tailored for university-aged individuals with clinically measured hamstring shortening."
218945765|NCT07145398|BEHAVIORAL|Mandala Coloring|Children hospitalized in the burn unit will participate in structured mandala coloring sessions. Each session will last approximately 30 minutes and will be conducted once daily for 7 consecutive days. Children will be provided with printed mandala patterns and coloring materials, and the sessions will be supervised by the research team. The purpose of the intervention is to reduce pain and stress levels and improve sleep quality in burn patients.
218945766|NCT07145398|OTHER|Control - Standard Care|Children in the control group will receive routine burn unit care without any additional interventions. No mandala coloring sessions will be provided.
218945767|NCT07145268|DRUG|Entecavir (ETV)|"Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months.(control group)"
218945768|NCT07145268|DRUG|Zinc (zinc sulphate)|"Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months."
218945769|NCT06944912|PROCEDURE|Transversalis fascia plane block and transversus abdominis plane block|20 ml local anesthetics for Transversus Abdominis Plane block and 10 ml local anesthetics for Trasnversalis fascia plane block
218945770|NCT06944912|PROCEDURE|Intrathecal Morphine|100 mcg morphine with local anesthetics injected intrathecally
218945771|NCT06946134|OTHER|FIT SA|self-adhesive flowable giomer restorative material
218945772|NCT06946134|OTHER|Beautifil Flow Plus F00|Conventional flowable giomer restorative material
218945773|NCT06947343|PROCEDURE|ACTION OBSERVATION THERAPY|functional AOT with visual feedback and physical training after watching a video 30mins session, 3times/week total 8weeks 3mins for observation phase, 2min for action execution Stage 1, sitting position (static and dynamic balance) exercises for trunk flexion, upper and lower trunk rotation multidirectional reaching to pick up any object from different directions, forward, lateral, and diagonal reaching Stage 2, sit to stand and stand to sit from sitting to standing, trunk flexed, hips and knees 90 degree flexed, feet behind knee, 15cm apart, then standing, trunk extension hips knees extend feet apart and vice vers 4phases of sit to stand, seat off, standing, seat on, sitting in sitting position dorsiflexion training, flexion extension training knee joint the right hand touches the left foot and viceversa pick up an object from floor stage3, standing balance weight shifting, front, back, sideways, left and right head and trunk movements in different directions while standing
218945774|NCT06947343|PROCEDURE|MOTOR RELEARNING PROGRAM|Motor relearning program, interventional group B, based on task-oriented training 30mins, 3times/week total 8weeks stage 1, balanced sitting exercises for trunk flexion and rotation, feet and knees 15cm apart multidirectional reaching while seated forward, lateral and diagonal reaching to pick up any thing from different directions butt walking scooting on bed stage 2, standing up and sitting down transition from a seated position on a firm flat surface with no armrests to standing with an upright posture, upper body vertical and feet placed backward followed by sitting down by flexing hips,knees and ankle prerequisited of sit to stand, 4phases in sitting dorsiflexion training, flexion extension training of knee joint right hand touch to left foot and viceversa picking up objects from floor stage3, balanced standing weight shifting head and trunk movemnts while standing with feetapart standing unsupported with eyes closed multidirectional reaching
218945775|NCT06947603|PROCEDURE|inula viscosa extract|the topical gel of inula viscosa was applied to one side after the extraction of the impacted molar in each patient, while the other side was left without the application of any pharmaceutical substance after extraction
219549539|NCT07139574|OTHER|Music Therapy During Labor|This intervention involves the use of patient-selected, slow-tempo (60-80 bpm), non-lyrical instrumental music administered via headphones or speakers during the latent and active phases of labor. The music selection is guided to ensure therapeutic suitability (e.g., calming rhythm, absence of lyrics) and is delivered for a minimum of 30 minutes. The intervention is non-pharmacological, individualized, and adheres to WHO and clinical music therapy recommendations. It is distinguished by its personalized music choice, delivery timing, and structured application within labor progression monitoring.
219549540|NCT03773653|BEHAVIORAL|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
218945776|NCT06947603|PROCEDURE|no inula viscosa extract|the other side of patient was left without the application of inula viscosa extract after lower third molar extraction.
218945777|NCT06946108|DIAGNOSTIC_TEST|Detection of Pancreatic Exocrine Function in Patients with Chronic Pancreatitis (CP)|For CP patients who are hospitalized, they are recruited to voluntarily preserve their feces for the detection of fecal elastase-1 (FE-1) so as to evaluate the pancreatic exocrine function.
218945778|NCT07144943|RADIATION|For subjects on SSRIs: bone densitometry|"For subjects on SSRIs:~Bone densitometry is one of the additional examinations considered. This assessment is part of the routine monitoring for subjects on androgens."
219053025|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
219053026|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
219053027|NCT03022617|DRUG|Apremilast|
219053028|NCT03286140|PROCEDURE|Early endovenous ablation|
219053029|NCT03286140|PROCEDURE|Delayed endovenous intervention|
219053030|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
219053031|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
219053032|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
219053033|NCT01527916|DRUG|placebo|Placebo Comparator
219053034|NCT01527916|DRUG|donepezil|Active Comparator
219053035|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
219053036|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
219053037|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
219053038|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
219053039|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
219053040|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
219053041|NCT00099775|DRUG|Caspofungin|
219053042|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
219053043|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
219053044|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
219053045|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
219053046|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
219053047|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
219053048|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
219053049|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
219053050|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
219053051|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
219053052|NCT05494788|DRUG|CardiolRx|Pharmaceutically produced Cannabidiol
219053053|NCT05896150|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
219053054|NCT05896150|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
219053055|NCT04569461|DRUG|pembrolizumab|400 mg of pembrolizumab (KEYTRUDA) will be given by IV every 6 weeks for 9 cycles, for approximately one year of study drug administration.
219053056|NCT04569461|RADIATION|Low dose prostate radiation|A single dose of 2 Gy of radiation will be given to the prostate and seminal vesicles on approximately Week 7 for Arm A and approximately 2 weeks prior to the prostatectomy for Arm B.
219053057|NCT04569461|PROCEDURE|Radical Prostatectomy|Robotic assisted laparoscopic prostatectomy (RALP) surgery will be performed at approximately Week 9 for Arm A and approximately 2 weeks after the low dose prostate radiation for Arm B. This surgery is part of the participants routine medical care.
219053058|NCT04813770|BEHAVIORAL|Theory-based messages|COVID-19 vaccination information structured to address vaccination necessity and concerns.
219053059|NCT04813770|BEHAVIORAL|General messages|General messages about the COVID-19 virus and the vaccination programme.
219053060|NCT05429268|DRUG|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
218945779|NCT07145359|OTHER|Virtual Reality Intervention|This intervention is distinguished by its integration of a structured, nurse-led virtual reality (VR) protocol specifically designed for symptom management during hematopoietic stem cell transplantation (HSCT). Unlike general VR distraction methods used in oncology, this intervention employs video content created by the research team in accordance with Attention Restoration Theory (ART), offering five preselected nature-themed options tailored to patient preferences. Prior to the procedure, eligible patients are introduced to the intervention one day in advance and given the opportunity to trial the VR equipment, ask questions, and select their preferred video. During the infusion, VR is initiated exactly one minute before the stem cell procedure and ends at the 15th minute, as recommended by the literature. Symptom assessments are conducted immediately before and after the intervention using validated tools, including the Distress Thermometer, State Anxiety Inventory, and the Edmonto
218945780|NCT06947369|OTHER|Experimental Group|Within the scope of the research, the pregnant women in the experimental group will be given a training program based on Joyce Travelbee's human-to-human relations theory, one session per week for 30-45 minutes, for a total of five sessions, while the control group will continue their routine follow-up.
218945781|NCT06946277|DRUG|Preemptive Analgesia Of Dexmedetomidine|Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation
218945782|NCT06955130|DRUG|Glycerol|Subjects will receive an infusion of glycerol and glucagon.
218945783|NCT06955130|DRUG|Lactate|Subjects will receive an infusion of lactate and glucagon.
218945784|NCT06955130|DRUG|Glucose|Subjects will receive an infusion of glucose and glucagon.
218945785|NCT06947395|DIAGNOSTIC_TEST|PancreaSure|Serum-based biomarker test comprised of ELISA-based analyte readings of 4 protein biomarkers (ICAM-1, TIMP1, THSB1, and CTSD) and CA19-9 summed by a mathematical algorithm with associated coefficients where a pre-defined cutoff establishes a positive or negative detection of PDAC.
219053061|NCT05429268|DRUG|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
219053062|NCT04630431|OTHER|Best Practice|Undergo standard of care follow-up
219635144|NCT02746978|OTHER|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
219635145|NCT06577545|BEHAVIORAL|Behavioural Lifestyle (BL)|24-week behavioural lifestyle intervention
219635146|NCT04881695|OTHER|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~* General (demographic information)~* Desire for a child~* Hospital Anxiety and Depression scale~* Sexual life~* Additional questions regarding medical care"
219635147|NCT04881695|OTHER|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~* General (demographic information)~* Desire to have a child~* Hospital Anxiety and Depression scale~* Sexual life"
219635148|NCT02550379|BEHAVIORAL|Intervention|Emotion Recognition Training
219635149|NCT02550379|OTHER|Placebo|Placebo Training
219635150|NCT01702220|BEHAVIORAL|CBT|6-12 sessions of CBT in person or over the phone
219635151|NCT01702220|OTHER|ECC|6 biweekly sessions of ECC over the telephone
219635152|NCT06479538|OTHER|Post isometric relaxation|17 participants will be in experimental group A giving them Post isometric relaxation of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
219635153|NCT06479538|OTHER|Post facilitation stretching|17 participants will be in experimental group A giving them Post facilitation stretching of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
219635154|NCT02263430|DEVICE|Deep Brain Stimulation|
219635155|NCT01916096|DEVICE|Delica Device|
219635156|NCT03550495|BEHAVIORAL|psychiatry involvement|See arm description.
218945786|NCT07145697|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
219053063|NCT04630431|OTHER|Educational Intervention|Undergo clinical trial education via a video and educational booklet
219053064|NCT04630431|OTHER|Electronic Health Record Review|Review of medical record
219053065|NCT04630431|BEHAVIORAL|Patient Navigation|Undergo clinical trial navigation
219053066|NCT04630431|OTHER|Questionnaire Administration|Complete questionnaire
219053067|NCT05462145|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
219053068|NCT04584710|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
219053069|NCT04584710|DRUG|Placebo|Oral matching placebo once daily for 2 weeks
219053070|NCT02242357|DRUG|Micardis®|
219053071|NCT02242357|DRUG|Micardis® Plus|
219053072|NCT00292357|PROCEDURE|Application of autologous bone marrow|
219635157|NCT02869347|DRUG|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
219635158|NCT02869347|DRUG|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
219635159|NCT00588133|DRUG|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = \>6.6: reduce infusion to 1.5 mg/kg/hr"
219635160|NCT00588133|DRUG|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
218945787|NCT07144852|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
218945788|NCT07144852|OTHER|Vehicle|Solution for topical use
218945789|NCT07144852|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.|BLU-U® blue light PDT illuminator
218945790|NCT07145931|PROCEDURE|Neoadjuvant chemoimmunotherapy|"* Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.~* Surgical treatment is performed within 3 weeks after completing neoadjuvant therapy.~* Postoperative (chemo)radiotherapy is initiated 4-6 weeks after surgery.~* Following (chemo)radiotherapy, adjuvant immunotherapy (Tislelizumab 200mg) is administered every 3 weeks for a total of 8 cycles."
218945791|NCT07145931|DRUG|Tislelizumab Nab paclitaxel|Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.
218945792|NCT07144995|DRUG|Fruquintinib+Paclitaxel|(using IPD from the FRUTIGA trial, n=703) Fruquintinib：subjects received Fruquintinib orally, once daily for 3 wks on/ 1 wk off Paclitaxel：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
218945793|NCT07144995|DRUG|Ramucirumab+Paclitaxel|(using published AgD from RAINBOW-Asia, n=440) Ramucirumab：8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel ：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
218945794|NCT07146061|OTHER|no other intervention|This is a observational study.
218945795|NCT07145788|OTHER|PhYoMind|This integrative intervention method includes some specific physiotherapy techniques, ( e. g. self proprioceptive neuromuscular facilitation, self nerve gliding, self mobility, post isometric relaxation techniques) yoga postures, left nostril breathing, humming bee breathing, mindfulness practices and home exercises. Each session will be 75 minutes and focus on different parts of the body and yoga postures will be selected according to these focused areas. For each week, a specific body area will be chosen as the focus. For example, the first week will focus on the hip area and lower extremities, the second week on the upper body and upper extremities, the third week on the core and anterior line of the body, and the fourth week on the back and posterior line of the body and this sequence will continue through the eighth week. In addition to these sessions, participants in this group will also apply home exercises (aerobic+strenghtening+streching) twice a week, 60 minutes per practice.
218945796|NCT07145788|OTHER|Exercise|The control group will receive only home exercises twice a week. Big muscle groups strengthening and stretching exercises and walking planned for the patient will be given as home exercise. The walking exercise will last 30 minutes at a moderately fast pace, depending on the subject's adaptation. The strengthening exercises will last 15 minutes and will consist of 3 sets of 12 repetitions of exercises with body weight and light weights, generally targeting the back extensor muscles, core stabilization muscles, shoulder region muscles in the upper extremity and hip and knee joint muscles in the lower extremity. The stretching exercises will last 15 minutes and will include neck muscles, pectoralis major/minor, erector spina, hamstrings, quadriceps femoris muscles 1-2 times for 30 seconds each. Participants will be taught face to face with a brochure when they come for the first assessment and will be asked to do HE at home.
218945797|NCT07144813|DEVICE|Neuspera Implantable Sacral Neuromodulation System|Stimulation of the Sacral Nerve.
218945798|NCT07147075|OTHER|REACH - Hypertension|The intervention is a skills training program for doctors that includes 3 self-paced on-line learning modules and 3 coaching sessions (one in-person and 2 virtual).
218945799|NCT07145203|DEVICE|Meta Quest 2 VR headset|The VR intervention used a head-mounted VR headset with built-in headphones. Patients selected VR environments from a predefined list of four nature scenes (tropical beach, diving, forest, and snowy landscape) with relaxing music and nature sounds. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/) featured 360-degree immersive nature environments with standardized calming background audio. VR was applied during the colonoscopy procedure, with sessions lasting 15 to 30 minutes and discontinued if the patient reported nausea, dizziness, or requested removal.
218945800|NCT07145892|DEVICE|Three-dimensional Digital Breast Tomosynthesis|Patients underwent three-dimensional digital breast tomosynthesis.
218945801|NCT07145892|DEVICE|Two-dimensional Digital Mammography|Patients underwent two-dimensional digital mammography
219053073|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
219053074|NCT03574545|BIOLOGICAL|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
219053075|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~\--------------------------------------------------------------------------------"
219053076|NCT04138615|DRUG|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
219053077|NCT04138615|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
219549541|NCT03773653|BEHAVIORAL|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
219549542|NCT03773653|BEHAVIORAL|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
219549543|NCT06275542|DEVICE|Train of four monitoring device intraoperative|Only group B will receive reversal strategy based on the presence of TOF monitoring device prior to extubation. If they meet the criteria, patients will then be extubated.
219549544|NCT06275542|DRUG|Neostigmine|For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
218945802|NCT07145762|PROCEDURE|Interventional Block|For patients who are offered interventional blocks as part of their standard of care, we will measure ANI as well as pressure pain threshold before, during, and after the block as well and at follow-up to assess correlation with treatment efficacy.
218945803|NCT07145372|OTHER|Manual therapy|It includes 10 minutes of massage and myofascial release for the trapezius and neck extensors, 10 repetitions of occiput-atlas (C0-C1) joint mobilization, occiput-atlas joint manipulation, mobilization of each segment from C2 to C7 with 10 repetitions each, C2-C7 manipulation, cervicothoracic junction (C7-T1) manipulation, thoracic region (T2-T6) manipulation, and sacroiliac joint manipulation.
218945804|NCT07145372|OTHER|Diaphragmatic relaxation technique|It includes diaphragm manual release techniques and a diaphragmatic breathing exercise program
218945805|NCT07145372|OTHER|Shoulder ROM exercise|This group was given a home exercise program consisting of shoulder girdle range of motion (ROM) exercises that do not affect the cervical region.
218945806|NCT07145736|DRUG|Moxidectin|2 mg tablets
219053078|NCT06178172|OTHER|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
219053079|NCT04233970|BEHAVIORAL|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
219053080|NCT04233970|BEHAVIORAL|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
219053081|NCT03461224|RADIATION|accelerated hypofractionated RT|
219053082|NCT03461224|RADIATION|conventional fractionated RT|
219053083|NCT04890392|DRUG|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
219053084|NCT03012386|DRUG|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
219053085|NCT03012386|DRUG|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
219053086|NCT03581110|DIAGNOSTIC_TEST|computed tomography|noncontrast-enhanced chest computed tomography
219053087|NCT04952194|DRUG|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
219053088|NCT04952194|DRUG|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
219053089|NCT00481442|DRUG|Phenylephrine|
219053090|NCT00774631|PROCEDURE|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
218945807|NCT07145736|DRUG|Ivermectin|3 mg tablets
218945808|NCT07147049|DRUG|HL-1186|HL-1186 tablet for oral administration.
218945809|NCT07147049|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
218945810|NCT07146867|BEHAVIORAL|High intensity interval training (exercise)|One 30 minute session of high intensity interval training
218945811|NCT07145112|PROCEDURE|Laser interstitial thermal therapy|MRI guided laser
218945812|NCT07145112|DRUG|Lomustine|Given orally (PO)
218945813|NCT07146178|PROCEDURE|Enhanced Recovery After Surgery|"1. Before surgery~   * Sips of water until 6 AM on the day of surgery, followed by a 200 mL carbohydrate drink~  * Pre-emptive oral analgesics (celecoxib 200mg 1 cap + acetaminophen 650mg 2 tab)~2. During surgery~   * Total intravenous anesthesia~  * Local anesthetic infiltration at the laparoscopic port site for post-operative pain control~3. After surgery~   * Sips of water and a foley catheter removal on ward arrival~  * Soft meal 4 housr after surgery~  * General diet 8 hours after surgery"
218945814|NCT07146178|PROCEDURE|Usual Care|"1. Before surgery~   * Midnight NPO~  * No pre-emptive analgesics~2. During surgery~   * Balanced anesthesia~3. After surgery~   * Sips of water 8 hours after arrival in the ward~  * Foley catheter removal one day after the surgery~  * Soft meal after gas out~  * General diet after one soft meal"
218945815|NCT07144878|DIAGNOSTIC_TEST|Parasternal Intercostal Ultrasound and RSBI Assessment|Participants underwent ultrasonographic evaluation of the parasternal intercostal muscle using a high-frequency linear probe to measure thickness and the thickening fraction during respiration. In addition, the Rapid Shallow Breathing Index was calculated from ventilator-displayed values under standardized settings: pressure support equal to zero centimeters of water and positive end-expiratory pressure equal to zero centimeters of water. Both assessments were performed immediately prior to a spontaneous breathing trial to evaluate their predictive accuracy for successful weaning from mechanical ventilation.
218945816|NCT07145528|OTHER|Questionary with a case-report-form|Questionary with : Gender, Age, Marital Status, medical history, Socio-économic description, skills assessment test written by R-Shankland, AUDIT-C, fargestrom, HAD, CAST, EPICE, Stroop-Test, Trail making test, Rosenberg Test
218945817|NCT07146347|DRUG|GZR4 injection|GZR4 is a new ultra-long-acting insulin analog
218945818|NCT07145476|DEVICE|Robotic arm exoskeleton integrated with cognitively engaging serious games|A specific sequence of exercises including passive and active- assisted movements, unilateral and bilateral reaching tasks with visual feedback and bimanual symmetric and asymmetric coordination tasks.
218945819|NCT07145086|BEHAVIORAL|Voice therapy with vibration|Voice therapy with a novel vibration device will be delivered for five or eight weeks depending on group allocation. All participants will receive flow phonation voice therapy.
218945820|NCT07146789|OTHER|occupational therapy combined with HomeGRASP program|To the present date there has been no trial combining conventional treatment with the GRASP programme as opposed to conventional treatment alone. Therefore, it is necessary to translate and adapt the materials transculturally so that it can be applied in Spain and verify the changes that occur in perceived quality of life and functionality of the affected upper limb as primary outcomes, as well as evaluating manipulative skills, use of the upper limb in ADLs and personal autonomy as secondary outcomes. All this, through the HomeGRASP programme as a complement to conventional rehabilitation in occupational therapy.
218945821|NCT07146789|OTHER|occupational therapy|It will consist solely of conventional occupational therapy treatment at the rehabilitation centre. The conventional treatment sessions will be based on: generally between 2-3 sessions a week lasting 45 minutes each at the rehabilitation centre you attend. The approaches to be used during the sessions will be based solely on mobilisations of the affected upper limb if necessary (maximum 10 minutes of the session), task-oriented training and training in ADLs.
218945822|NCT07147101|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg every 3 weeks
218945823|NCT07147101|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.
218945824|NCT07147101|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
218945825|NCT07147101|DRUG|Rivoceranib|Rivoceranib will be administered by oral 250 mg once daily.
218945826|NCT07147101|DRUG|Nivolumab|Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks
218945827|NCT07147101|DRUG|Ipilimumab|Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.
218945828|NCT07146711|DRUG|Tamsulosin (0.4 mg/j)|Multiple dose administration (7 days)
218945829|NCT07146711|DRUG|Omnic Ocas®,|Multiple dose administration (7 days)
218945830|NCT03229343|OTHER|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
218945831|NCT05101213|BIOLOGICAL|Virus-specific Cytotoxic T-lymphocytes|Given IV
219053091|NCT00774631|PROCEDURE|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
219053092|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
219635161|NCT04200651|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
218945832|NCT04113551|DRUG|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
218945833|NCT04113551|DRUG|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
218945834|NCT04113551|DRUG|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
218945835|NCT04113551|DRUG|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
218945836|NCT03796026|DRUG|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
219053093|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
219635162|NCT04200651|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
218945837|NCT03796026|DRUG|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
218945838|NCT01528267|OTHER|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
218945839|NCT01528267|OTHER|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
218945840|NCT02957968|DRUG|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
218945841|NCT02957968|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
219053094|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
219053095|NCT03099551|DEVICE|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
219053096|NCT03099551|DEVICE|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
219053097|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
219053098|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
219053099|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
219053100|NCT01032135|DRUG|medication management|Prescription for naltrexone
219053101|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
218945842|NCT02957968|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
218945843|NCT02957968|DRUG|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
218945844|NCT02957968|DRUG|Decitabine|Given IV
218945845|NCT02957968|DRUG|Pembrolizumab|Given IV
218945846|NCT04731272|DRUG|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
218945847|NCT06507488|DRUG|Daphnetin Capsule|Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
218945848|NCT06507488|DRUG|Placebo|The placebo is a Daphnetin Capsule simulants
218945849|NCT03973528|DRUG|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
218945850|NCT01925131|DRUG|cyclophosphamide|Given IV
218945851|NCT01925131|DRUG|vincristine sulfate|Given IV
218945852|NCT01925131|DRUG|prednisone|Given PO
218945853|NCT01925131|BIOLOGICAL|inotuzumab ozogamicin|Given IV
218945854|NCT01925131|OTHER|laboratory biomarker analysis|Correlative studies
218945855|NCT05206084|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
218945856|NCT05206084|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
218945857|NCT04876820|OTHER|Pharmacist intervention|"In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist.~An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done.~An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done.~An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done."
218945858|NCT04876820|OTHER|Standard of care|An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
219053102|NCT01346267|PROCEDURE|Real Acupressure Band|Acupressure wristband
219053103|NCT01346267|PROCEDURE|Placebo Acupressure Band|Sham wristband
219053104|NCT05611580|BEHAVIORAL|Chronic Disease Risk Reduction|The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
219053105|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
219053106|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
219053107|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
219053108|NCT03149237|BEHAVIORAL|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
219053109|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
219053110|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
219053111|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
219053112|NCT00000540|DEVICE|defibrillators, implantable|
219053113|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
219053114|NCT01466192|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
219053115|NCT01466192|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
219053116|NCT01466192|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
219053117|NCT02211469|DRUG|BMS-986104|
219053118|NCT02211469|DRUG|Placebo|
218945859|NCT06540807|DEVICE|Colovac Colorectal Anastomosis Protection Device|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
218945860|NCT06540807|PROCEDURE|Stoma creation|Diverting loop ileostomy
218945861|NCT06080932|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
219635163|NCT05148676|OTHER|Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan|An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.
219635164|NCT00616265|DEVICE|CPAP|Pressure device on airway to maintain it open
219635165|NCT02644954|DRUG|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
219635166|NCT02644954|DRUG|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
219635167|NCT02644954|DRUG|Topical Coal tar|Topical coal tar to be applied once daily
219635168|NCT02644954|DRUG|Topical calcipotriol|Topical calcipotriol to be applied once daily
219635169|NCT00975182|DRUG|GDC-0941|Oral repeating dose
219635170|NCT00975182|DRUG|erlotinib HCl|Oral repeating dose
219635171|NCT04133701|BEHAVIORAL|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
219635172|NCT02263560|BEHAVIORAL|Kinematic measurements|
219635173|NCT01394731|DRUG|Acetaminophen|
219635174|NCT01394731|DRUG|Meperidine|
219635175|NCT03055780|DEVICE|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
218945862|NCT06080932|OTHER|NIH Toolbox|IPAD-based assessments that examines cognitive function
218945863|NCT06080932|OTHER|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
218945864|NCT06080932|OTHER|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
219635176|NCT06283329|DIAGNOSTIC_TEST|vocal cords echography|Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2
219635177|NCT03225105|DRUG|M3541|Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
218945865|NCT06080932|OTHER|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
218945866|NCT06080932|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
218945867|NCT06080932|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
218945868|NCT06080932|OTHER|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
218945869|NCT06080932|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
218945870|NCT06080932|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
218945871|NCT06080932|BEHAVIORAL|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
218945872|NCT06080932|BEHAVIORAL|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
219635178|NCT03225105|RADIATION|Palliative Radiotherapy (RT)|Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
219635179|NCT02922751|OTHER|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
219635180|NCT05661474|DRUG|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
219635181|NCT05661474|DRUG|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
219635182|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride|1.8 ml mepivacaine IANB
219635183|NCT05238727|DRUG|3.6 ml mepivacaine hydrochloride|3.6 ml mepivacaine IANB
219635184|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
219635185|NCT01772173|OTHER|Vessel measurements|Measurement of retinal vessels
219635186|NCT00874627|OTHER|Milk|sublingual administration of milk
219635187|NCT00874627|OTHER|Milk|placebo
219635188|NCT00874874|DRUG|sorafenib tosylate|
219635189|NCT01812954|DRUG|Methotrexate|
219635190|NCT01812954|DRUG|Cyclosporins|
218945873|NCT06080932|BEHAVIORAL|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
218945874|NCT00326573|BEHAVIORAL|Motivational Interviewing|
218945875|NCT03407300|DRUG|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
218945876|NCT03407300|DRUG|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
218945877|NCT05323058|DRUG|tulsi extract|4% topical oral spray
218945878|NCT05323058|DRUG|Benzydamine Hydrochloride|0.15% topical oral spray
218945879|NCT00000659|DRUG|CD4 Antigens|
218945880|NCT00000659|DRUG|Zidovudine|
218945881|NCT01410916|DRUG|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
218945882|NCT05621525|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
219635191|NCT01812954|DRUG|fumaric acid|
219635192|NCT01812954|DRUG|Acitretin|
219635193|NCT01812954|DRUG|Infliximab|
219635194|NCT01812954|DRUG|etanercept|
219635195|NCT01812954|DRUG|Adalimumab|
219635196|NCT01812954|DRUG|Ustekinumab|
219635197|NCT06355076|PROCEDURE|New urethral reconstruction|This kind of reconstruction suture has larger area, higher firmness, better fixation of the position of broken end and prolongation of functional length.
219635198|NCT05353751|BEHAVIORAL|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
219635199|NCT04883983|DRUG|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
218945883|NCT03278067|OTHER|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
218945884|NCT04237142|DIAGNOSTIC_TEST|Vaginal secretions collection|Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
218945885|NCT04237142|DIAGNOSTIC_TEST|Blood sample|2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
218945886|NCT03007004|DRUG|Botulinum toxin type B (2500 units / vial)|BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
218945887|NCT03007004|DRUG|Physiological saline|Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
218945888|NCT05960292|PROCEDURE|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
218945889|NCT03572205|DIETARY_SUPPLEMENT|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
218945890|NCT03572205|DIETARY_SUPPLEMENT|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
219053119|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
219053120|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
219053121|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
219053122|NCT03033472|DRUG|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
219053123|NCT03033472|DRUG|Oral Placebo|Oral Placebo 30 minutes before treatment
219053124|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
219053125|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
219053126|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
219053127|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
219053128|NCT04431037|DIETARY_SUPPLEMENT|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
219635200|NCT04883983|DRUG|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
219053129|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
219635201|NCT05294055|DRUG|Etoposide|Etoposide 1.5-1.8g/m2, single dose
219635202|NCT05294055|DRUG|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
219635203|NCT05294055|DRUG|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
219635204|NCT05294055|DRUG|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
218945891|NCT04333303|OTHER|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
218945892|NCT01483339|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
218945893|NCT01483339|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
218945894|NCT04130308|OTHER|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
218945895|NCT00711178|PROCEDURE|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
218945896|NCT04215965|DRUG|Biphozyl (dialysate and replacement)|Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
218945897|NCT04215965|DRUG|Prismocal B22 (dialysate) + phoxilium (replacement)|solution with phosphate and calcium in CRRT with citratre-based antigoagulation
218945898|NCT01696929|DRUG|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
218945899|NCT04712240|DEVICE|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
218945900|NCT02711267|DRUG|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
218945901|NCT02711267|DRUG|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
218945902|NCT02711267|DRUG|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
218945903|NCT02711267|DRUG|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
218945904|NCT02711267|DRUG|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
218945905|NCT02711267|PROCEDURE|OFM|Sampling method for interstitial fluid
218945906|NCT02711267|DEVICE|OFM Probe|Sampling probe used during OFM
218945907|NCT02711267|DEVICE|OFM Pump|Pump used to operate OFM probes
218945908|NCT02782156|OTHER|Process evaluation|Adherence to screening and action algorithm
218945909|NCT00446680|DRUG|Mannitol|400mg BD for 6 months followed by a 6 month open label period
218945910|NCT00446680|DRUG|placebo|placebo BD for 6 months
219053130|NCT04814290|OTHER|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
219206912|NCT06735092|OTHER|Exercise + Forearm Counterforce Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a counterforce forearm brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
218945911|NCT05503745|OTHER|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
218945912|NCT05503745|OTHER|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
218945913|NCT02522624|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
219053131|NCT02553746|DEVICE|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
219053132|NCT02553746|PROCEDURE|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
219053133|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
219053134|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
219053135|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
219053136|NCT01812928|DRUG|Diclofenac|
219635205|NCT06786195|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between. The Achilles tendon will be percussed 10 times with an electronic reflex hammer.
218945914|NCT03337828|OTHER|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
218945915|NCT03337828|OTHER|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
218945916|NCT05615025|DRUG|Sevoflurane|Anesthesia will be maintained by sevoflurane.
219053137|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
219635206|NCT06778096|BEHAVIORAL|Postnatal anxiety and depression iCBTprogram|The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.
219635207|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
219635208|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - Low Dose|Oxy(Gly)4-sKLH vaccine - Low Dose
219635209|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - High Dose|Oxy(Gly)4-sKLH vaccine - high dose
219635210|NCT04458545|BIOLOGICAL|Placebo Oxy(Gly)4-sKLH vaccine|Oxy(Gly)4-sKLH vaccine - Placebo
219635211|NCT05047965|PROCEDURE|Dixon MRI|Undergo Dixon MRI
219635212|NCT05047965|PROCEDURE|Magnetic Resonance Imaging|Undergo standard MRI
218945917|NCT05615025|DRUG|Propofol|Anesthesia will be maintained by propofol.
218945918|NCT00660881|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
218945919|NCT02156271|DRUG|ramelteon|
219053138|NCT04150224|DRUG|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
219635213|NCT06050356|BIOLOGICAL|H107e|Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
219635214|NCT06050356|BIOLOGICAL|CAF®10b|Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
218945920|NCT02156271|DRUG|placebo|
218945921|NCT00109590|DRUG|Didanosine, enteric-coated|once daily
218945922|NCT00109590|DRUG|Lopinavir/ritonavir|twice daily
218945923|NCT00109590|DRUG|Nevirapine|single-dose at the onset of labor
218945924|NCT00109590|DRUG|Zidovudine|twice daily
218945925|NCT03719534|PROCEDURE|haplo-HCT|HCT will be performed with a haploidentical donor
218945926|NCT03719534|PROCEDURE|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
218945927|NCT02672696|DEVICE|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
218945928|NCT03936231|OTHER|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
218945929|NCT05952752|OTHER|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
218945930|NCT05952752|OTHER|Dexamethsone IV|4 mg IV dexamethasone
218945931|NCT05206656|DRUG|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
218945932|NCT05206656|DRUG|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
218945933|NCT04468529|DRUG|Recombinant human Neuregulin for injection|10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
218945934|NCT04468529|DRUG|Placebo|10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
218945935|NCT06199583|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound shear-wave elastography
218945936|NCT00956098|DRUG|oltipraz|60mg bid 90mg qd
219053139|NCT04150224|DRUG|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
219053140|NCT04150224|DRUG|PBTZ169 960 mg SD|Once a day fasted
219635215|NCT06050356|BIOLOGICAL|H107e/CAF®10b - low adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
219635216|NCT06050356|BIOLOGICAL|H107e/CAF®10b - full adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
219635217|NCT06050356|BIOLOGICAL|Low dose intranasal H107e|Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
218945937|NCT00956098|DRUG|placebo|
218945938|NCT04271618|OTHER|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
218945939|NCT06081322|DRUG|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
219053141|NCT04150224|DRUG|PBTZ169 1280 mg SD|Once a day fasted
219053142|NCT04150224|DRUG|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
218945940|NCT01800175|DEVICE|Punctum Plug|
218945941|NCT02631382|PROCEDURE|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
218945942|NCT00004581|DRUG|Lopinavir/Ritonavir|
218945943|NCT00004581|DRUG|Nevirapine|
218945944|NCT00745849|DRUG|esomeprazole|40mg by mouth twice daily
218945945|NCT00745849|DRUG|placebo|
218945946|NCT04313647|BIOLOGICAL|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
218945947|NCT04313647|BIOLOGICAL|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
218945948|NCT04313647|BIOLOGICAL|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
218945949|NCT04313647|BIOLOGICAL|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
218945950|NCT04313647|BIOLOGICAL|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
218945951|NCT02176746|BIOLOGICAL|cancer stem cell vaccine|
218945952|NCT03861494|BEHAVIORAL|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
219053143|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
219053144|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
219053145|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
219053146|NCT00003268|DRUG|amifostine trihydrate|
219053147|NCT00003268|DRUG|cytarabine|
219053148|NCT00003268|DRUG|idarubicin|
219053149|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
219053150|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
219053151|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
219053152|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
219053153|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
219635218|NCT06050356|BIOLOGICAL|Full dose intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
219635219|NCT06050356|BIOLOGICAL|H107e/CAF®10b|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
219635220|NCT06050356|BIOLOGICAL|i.m. placebo|Participants will receive two i.m. injections of placebo on Day 1 and Day 29
219635221|NCT06050356|BIOLOGICAL|BCG|Participants will receive one i.d. injection of BCG on Day 1
218945953|NCT03861494|BEHAVIORAL|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
218945954|NCT01413347|PROCEDURE|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
218945955|NCT01413347|PROCEDURE|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
219053154|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
219053155|NCT02774681|PROCEDURE|Cognitive Assessment|Ancillary studies
218945956|NCT00458029|BEHAVIORAL|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
218945957|NCT05090176|OTHER|povidone-soaked suture|suture soak with povidone solution for 3 mins
218945958|NCT05090176|OTHER|ordinary suture|suture no need to soak with povidone solution
218945959|NCT03176342|OTHER|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
218945960|NCT05069701|DIAGNOSTIC_TEST|SVV test|SVV test will be done with virtual reality glasses.
219053156|NCT02774681|DRUG|Palbociclib|Given PO
219053157|NCT02774681|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219053158|NCT02774681|BIOLOGICAL|Trastuzumab|Given IV
219053159|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
219635222|NCT06050356|BIOLOGICAL|i.d. placebo|Participants will receive one i.d. injection of placebo on Day 1
219635223|NCT06050356|BIOLOGICAL|Intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
219635224|NCT04722315|DIETARY_SUPPLEMENT|Modified Atkins diet|12 weeks of modified Atkins diet
219635225|NCT04540900|BIOLOGICAL|KB301|non-integrating HSV-1 vector expressing human type III collagen
219635226|NCT04540900|OTHER|Placebo|sterile isotonic saline
219635227|NCT02367846|DRUG|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
219635228|NCT02367846|DRUG|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
219635229|NCT06188364|OTHER|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
219635230|NCT06188364|OTHER|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
219635231|NCT05398302|PROCEDURE|Image Guided Biopsy|Undergo image-guided biopsy
219635232|NCT00990392|DRUG|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
218945961|NCT02825290|DRUG|Choriogonadotropin alfa|
219053160|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
218945962|NCT02825290|DRUG|Triptorelin acetate|
218945963|NCT00642889|DRUG|Safinamide|
218945964|NCT00642889|DRUG|Safinamide|
218945965|NCT00642889|DRUG|Placebo|
219053161|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
219635233|NCT00990392|OTHER|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
218945966|NCT04308733|DEVICE|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
219635234|NCT05893147|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
219635235|NCT05893147|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
219635236|NCT05893147|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
219635237|NCT05893147|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
219635238|NCT05893147|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
219635239|NCT04855435|DRUG|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
219635240|NCT05582980|DEVICE|HD-tDCS|See detail in arm/group descriptions regarding the intervention.
219635241|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral tablet.
219635242|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral capsule.
219635243|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
219635244|NCT06047366|DRUG|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
219635245|NCT06047366|DRUG|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
219635246|NCT06047366|DRUG|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
219635247|NCT06047366|DRUG|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
219635248|NCT05295693|DEVICE|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
219635249|NCT06491927|GENETIC|No Intervention|Observational study
219635250|NCT06570941|DRUG|Chylobinoid Topical Cream|The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome
219635251|NCT03483961|BIOLOGICAL|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
219635252|NCT03483961|BIOLOGICAL|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
219635253|NCT03483961|BIOLOGICAL|Placebo|Placebo is vaccine diluent alone
219635254|NCT06288841|DRUG|Ropivacaine injection|Ultrasound-guided bilateral QLB2 was performed using Ropivacaine injection prior to anesthesia induction
219635255|NCT06288841|DRUG|Bupivacaine liposome|Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
219635256|NCT05869461|BEHAVIORAL|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
219635257|NCT05869461|BEHAVIORAL|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
218945967|NCT02929043|OTHER|air puffs|
218945968|NCT05223153|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
218945969|NCT01129583|DRUG|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
218945970|NCT01129583|DRUG|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
218945971|NCT04672954|DRUG|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
218945972|NCT04672954|DRUG|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
219206913|NCT06735092|OTHER|Exercise + Wrist Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a wrist brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
218945973|NCT04672954|DRUG|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
218945974|NCT04672954|DRUG|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
218945975|NCT04672954|DRUG|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
218945976|NCT00003296|BIOLOGICAL|filgrastim|
218945977|NCT00003296|DRUG|pegylated liposomal doxorubicin hydrochloride|
218945978|NCT04043624|DRUG|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
218945979|NCT04043624|DRUG|Saline|IV bolus of saline, followed by continuous infusion of saline
218945980|NCT00353470|BEHAVIORAL|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
218945981|NCT00353470|BEHAVIORAL|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
218945982|NCT00353470|BEHAVIORAL|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
218945983|NCT05446831|DRUG|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
218945984|NCT03869801|PROCEDURE|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
218945985|NCT03869801|PROCEDURE|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
219635258|NCT05246189|OTHER|Telephone Call|"Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire."
219635259|NCT01597570|DEVICE|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
219635260|NCT02589132|OTHER|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
219635261|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
219635262|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
218945986|NCT03381742|DRUG|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
218945987|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
218945988|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
218945989|NCT03381742|DRUG|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
218945990|NCT02617485|DRUG|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
218945991|NCT02617485|DRUG|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
218945992|NCT02617485|DRUG|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
218945993|NCT02617485|DRUG|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
218945994|NCT02617485|DRUG|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
218945995|NCT04613778|PROCEDURE|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
218945996|NCT00409331|DRUG|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
218945997|NCT00409331|PROCEDURE|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
218945998|NCT04443595|PROCEDURE|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
218945999|NCT01546272|DEVICE|Insorb resorbable staples|Subcutanous suture using resorbable staples
218946000|NCT01546272|DEVICE|Monocryl resorbable wire|Subcutanous suture using resorbable wire
219206914|NCT06889922|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
219635263|NCT04088175|OTHER|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
219635264|NCT04088175|OTHER|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
218946001|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
218946002|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
218946003|NCT05951465|DRUG|Propofol|propofol
218946004|NCT03712007|DEVICE|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
218946005|NCT03712007|DEVICE|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
218946006|NCT02793856|DRUG|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
218946007|NCT02793856|OTHER|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
218946008|NCT01511055|DRUG|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
218946009|NCT02298335|DRUG|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
218946010|NCT03487692|OTHER|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
219053162|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
219635265|NCT04088175|OTHER|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
218946011|NCT03487692|OTHER|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
218946012|NCT00617669|DRUG|Docetaxel|intravenous infusion given every three weeks
218946013|NCT00617669|DRUG|ZD4054|10 mg oral once daily dose
218946014|NCT00617669|DRUG|Placebo|placebo oral tablet once daily
218946015|NCT05184439|PROCEDURE|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
218946016|NCT02889744|DEVICE|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
218946017|NCT00972647|PROCEDURE|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
219635266|NCT04088175|OTHER|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
219635267|NCT04088175|OTHER|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
219635268|NCT04088175|OTHER|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
219635269|NCT02954133|DEVICE|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
219635270|NCT02954133|DEVICE|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
219635271|NCT02954133|DEVICE|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
218946018|NCT05477472|DRUG|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
218946019|NCT03348592|DIETARY_SUPPLEMENT|Oligofructose-enriched inulin (p-inulin)|
219053163|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
219635272|NCT02954133|DEVICE|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
219635273|NCT01262287|DRUG|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
219635274|NCT01262287|DRUG|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
219635275|NCT04411511|OTHER|Exposure to the Dutch measures due to the Covid-19 pandemic.|Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
218946020|NCT03348592|OTHER|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
218946021|NCT00690261|OTHER||No intervention in this study
218946022|NCT02879045|OTHER|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
218946023|NCT04590248|DRUG|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
218946024|NCT02697110|BEHAVIORAL|Edutainment based intervention|Edutainment intervention package
218946025|NCT01109056|DRUG|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
218946026|NCT01109056|DRUG|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
219053164|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
219053165|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
219053166|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
219053167|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
219053168|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
219053169|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
219053170|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
219053171|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
219635276|NCT02492984|DRUG|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
219635277|NCT01842984|BEHAVIORAL|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
218946027|NCT02052414|DRUG|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
218946028|NCT02912143|OTHER|documentation only|
218946029|NCT01303003|DRUG|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
218946030|NCT01303003|PROCEDURE|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
218946031|NCT05696028|DEVICE|Gamma counter|DTpA
218946032|NCT04605991|DRUG|LY900014|Administered SC
218946033|NCT04605991|DRUG|Insulin Glargine|Administered SC
219053172|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
219053173|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
219053174|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
219053175|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
219053176|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
218946034|NCT03263702|DEVICE|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
218946035|NCT05089422|PROCEDURE|Squint surgery|Lateral rectus recession and /or medial rectus resection
218946036|NCT04958395|DIAGNOSTIC_TEST|FFR and d-FFR|Measure FFR and d-FFR
218946037|NCT03976804|OTHER|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
218946038|NCT03976804|OTHER|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
218946039|NCT03976804|OTHER|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
218946040|NCT04734470|DIAGNOSTIC_TEST|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
218946041|NCT04140760|OTHER|Symprove|A liquid probiotic
218946042|NCT04140760|OTHER|Symprove placebo product|An inert placebo
219053177|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
219053178|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
219635278|NCT02792894|BEHAVIORAL|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
218946043|NCT01350193|DEVICE|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
218946044|NCT01350193|OTHER|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
218946045|NCT02527200|DRUG|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
218946046|NCT02527200|DRUG|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
218946047|NCT02349932|OTHER|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
218946048|NCT06365762|DRUG|EDTA Ophthalmic Solution 2.6%|
218946049|NCT06365762|DRUG|EDTA Ophthalmic Solution 1.3%|
219635279|NCT05284448|DRUG|pentoxifylline (Trental SR®)|400 mg three times daily
218946050|NCT06365762|DRUG|Saline Solution (Placebo)|
219053179|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
219053180|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
219053181|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
219053182|NCT04139590|DEVICE|Panda|
219053183|NCT04139590|DEVICE|Visual Analogue Scale - Original|
219053184|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
219053185|NCT02358824|DRUG|Telmisartan|"\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
219053186|NCT02358824|DRUG|S-amlodipine|"\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
219053187|NCT04196166|OTHER|preoperative blood tests|
219053188|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
219053189|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
219053190|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
219053191|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
219053192|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
219053193|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
219635280|NCT00093912|DRUG|clevidipine|
219635281|NCT00093912|DRUG|sodium nitroprusside|
219635282|NCT00384618|DRUG|pravastatin|
219635283|NCT00384618|DRUG|vitamin E|
219635284|NCT00317187|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
218946051|NCT02263352|DRUG|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
218946052|NCT02263352|DEVICE|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
218946053|NCT05919836|PROCEDURE|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
219635285|NCT00317187|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
219635286|NCT05418933|OTHER|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
218946054|NCT05919836|PROCEDURE|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
218946055|NCT05919836|PROCEDURE|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
218946056|NCT02886403|OTHER|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
218946057|NCT02886403|OTHER|New adhesive strip|A newly developed adhesive strip
218946058|NCT02645838|BEHAVIORAL|Motivational interviewing|1\. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
218946059|NCT04647981|OTHER|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
218946060|NCT03505840|DIAGNOSTIC_TEST|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
218946061|NCT00851968|PROCEDURE|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
218946062|NCT00851968|PROCEDURE|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
219635287|NCT06363344|OTHER|Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)|An advanced practice nurse who is a member of the PICU team monitors patients by questionnaires at 1 and 3 months. Depending on the anomalies detected, whether at the somatic, psychological, emotional or social level, the nurse refers to competent specialists and collaborators and continues monitoring of the family as needed.
218946063|NCT00851968|PROCEDURE|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
218946064|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
218946065|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
218946066|NCT00988650|OTHER|isocaloric diet|
218946067|NCT00988650|OTHER|free living conditions|
218946068|NCT03847441|DRUG|Calcipotriol|Calcipotriol ointment (0.005%)
218946069|NCT03847441|DEVICE|Narrow Band UVB|NB-UVB (311nm) phototherapy
218946070|NCT03847441|DIAGNOSTIC_TEST|vitamin D3 level|vitamin D3 (ng/ml)
218946071|NCT03196492|OTHER|No intervention|No intervention
218946072|NCT04395053|DRUG|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
218946073|NCT04752644|BIOLOGICAL|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
218946074|NCT04752644|DRUG|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
218946075|NCT00224185|PROCEDURE|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
218946076|NCT00224185|PROCEDURE|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
218946077|NCT00224185|PROCEDURE|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
218946078|NCT02578719|DRUG|bupivacaine|marcaine %0.5 20 ml flacon
219053194|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
219053195|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
219053196|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
219053197|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
219053198|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
219053199|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
219053200|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
219053201|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
219053202|NCT02089750|OTHER|Orthotics|
219053203|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
218946079|NCT02578719|DRUG|saline|%0.9 sodium chloride
218946080|NCT03923244|DIAGNOSTIC_TEST|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
218946081|NCT02280798|PROCEDURE|Endometrial Biopsy|4 endometrial biopsy
218946082|NCT01604993|OTHER|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
218946083|NCT01604993|OTHER|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
219053204|NCT02089750|OTHER|Wait List|
219053205|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
219053206|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
218946084|NCT06151509|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219053207|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
219053208|NCT02011048|PROCEDURE|Endoscopic components separation|Endoscopic components separation hernia repair
219053209|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
219053210|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
219053211|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
219053212|NCT00399334|DRUG|antipsychotic medications|as prescribed
218946085|NCT06151509|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
218946086|NCT00291213|DRUG|levetiracetam|
218946087|NCT00291213|DRUG|placebo|
218946088|NCT01909791|PROCEDURE|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
218946089|NCT01909791|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
218946090|NCT01909791|PROCEDURE|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
219053213|NCT02121691|BEHAVIORAL|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
219053214|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
219635288|NCT02110758|OTHER|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.
219635289|NCT02604043|OTHER|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
219635290|NCT02604043|OTHER|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
219635291|NCT06393309|DRUG|Levetiracetam|Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
219635292|NCT06393309|DRUG|Sodium valproate|Patients with idiopathic generalized epilepsy who were under treatment with valproate
219635293|NCT01851122|DIETARY_SUPPLEMENT|L-theanine capsule|L-theanine 250mg capsule
219635294|NCT01851122|DIETARY_SUPPLEMENT|Placebo capsule|
218946091|NCT01909791|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
218946092|NCT01268280|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
218946093|NCT01268280|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
219053215|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
219635295|NCT02792712|DRUG|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
219635296|NCT02792712|DRUG|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
219635297|NCT00090025|DRUG|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
219635298|NCT00090025|DRUG|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
219635299|NCT02215200|DRUG|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
219635300|NCT02215200|DRUG|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
219635301|NCT02215200|DRUG|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
219635302|NCT02215200|DRUG|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
219635303|NCT06092788|DRUG|NTP42:KVA4 Capsule|Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule
219635304|NCT06092788|DRUG|NTP42:KVA4 Liquid|Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
219635305|NCT00433394|PROCEDURE|cancer prevention intervention|
219635306|NCT00433394|PROCEDURE|educational intervention|
219635307|NCT03681548|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
218946094|NCT01268280|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
218946095|NCT04175990|DRUG|Dydrogesterone Pill|started from day 1 of menses till trigger day
218946096|NCT00091325|DIETARY_SUPPLEMENT|defined green tea catechin extract|
218946097|NCT03519542|DRUG|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
218946098|NCT02893579|BEHAVIORAL|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
218946099|NCT02893579|BEHAVIORAL|Delayed SR intervention|Activity tracking only for the first month
218946100|NCT01659554|DRUG|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
218946101|NCT01659554|DRUG|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
218946102|NCT01936090|DRUG|Bortezomib|Given IV
218946103|NCT01936090|RADIATION|Total-Body Irradiation|Undergo TBI
218946104|NCT01936090|DRUG|Melphalan|Given IV
219053216|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
219053217|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
219053218|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
219053219|NCT02047604|DRUG|Placebo|
219206915|NCT06889922|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
219635308|NCT03497104|OTHER|Surplus blood tests|Surplus blood donation
219635309|NCT04858646|OTHER|Experimental( Group A ): Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
218946105|NCT01936090|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
218946106|NCT01936090|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
218946107|NCT01936090|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
219053220|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
219053221|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
218946108|NCT01936090|OTHER|Laboratory Biomarker Analysis|Correlative studies
218946109|NCT06235255|BEHAVIORAL|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
219635310|NCT04858646|OTHER|Conventional( Group B): Conventional Physical therapy|The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
219053222|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
219053223|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
219053224|NCT03289104|DEVICE|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
219053225|NCT03289104|DEVICE|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
219053226|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
219053227|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
219635311|NCT02535767|DRUG|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
219635312|NCT05482113|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
219635313|NCT05482113|DRUG|Bupivacaine Hcl 0.25% Inj|Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
219635314|NCT01602211|OTHER|Internet-Based Intervention|Receive full access to INSPIRE
218946110|NCT06235255|BEHAVIORAL|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
218946111|NCT06235255|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
218946112|NCT02730143|OTHER|Altitude exposure|Altitude exposure
218946113|NCT05630391|DEVICE|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
218946114|NCT05630391|OTHER|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
218946115|NCT01004276|OTHER|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
219053228|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
219053229|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
219635315|NCT01602211|OTHER|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
219635316|NCT01602211|OTHER|Medical Chart Review|Ancillary studies
219635317|NCT01602211|OTHER|Quality-of-Life Assessment|Ancillary studies
219635318|NCT01602211|OTHER|Questionnaire Administration|Ancillary studies
219635319|NCT01694160|DRUG|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
219635320|NCT00302328|PROCEDURE|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
219635321|NCT02183883|DRUG|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade \> 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
219053230|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
219635322|NCT00435708|BEHAVIORAL|5 portions fruit and vegetables/day|Participants consume \> = 5 portions fruit and veg per day
219635323|NCT03317314|DIAGNOSTIC_TEST|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
219635324|NCT02982681|DRUG|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
219635325|NCT02982681|DRUG|Bioactive Glass|The control site were packed with the bioactive glass graft alone
219635326|NCT01288937|DRUG|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
219635327|NCT01288937|DRUG|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
219635328|NCT02695966|PROCEDURE|Whipples Surgery|Whipples Surgery
219635329|NCT04242472|BEHAVIORAL|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
219635330|NCT02490371|DEVICE|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
219635331|NCT02490371|BEHAVIORAL|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
218946116|NCT04583709|DEVICE|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
218946117|NCT00945906|BIOLOGICAL|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
218946118|NCT03402464|DRUG|Icotinib combined dihydroaremisinin|Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
218946119|NCT02936661|DRUG|Tranexamic Acid|
218946120|NCT02936661|DRUG|Placebo|
218946121|NCT01579851|DRUG|Sugammadex|"sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations"
218946122|NCT00264459|BIOLOGICAL|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
218946123|NCT00264459|OTHER|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
218946124|NCT05146947|DEVICE|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
219053231|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
219053232|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
219635332|NCT05623540|DRUG|Bisphosphonates, Combinations|
219635333|NCT03219814|OTHER|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
219635334|NCT03219814|OTHER|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
219635335|NCT01251419|OTHER|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
219053233|NCT01206985|OTHER|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
219053234|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
219053235|NCT00690638|DRUG|PHX1149T|200 mg
219053236|NCT00690638|DRUG|PHX1149T|400 mg
219053237|NCT00690638|DRUG|Placebo|Placebo
219053238|NCT00002082|DRUG|Azithromycin|
219053239|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
219635336|NCT01605552|BEHAVIORAL|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
219635337|NCT01605552|OTHER|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
218946125|NCT03141294|PROCEDURE|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
218946126|NCT02117128|DRUG|Tranexamic acid|
218946127|NCT00121043|DEVICE|SimpleJectTM|
219053240|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
219053241|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
219053242|NCT01221259|DRUG|placebo|a single dose of matching placebo
218946128|NCT00121043|DRUG|Kineret® (Anakinra)|
218946129|NCT02294968|OTHER|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
219206916|NCT06883448|COMBINATION_PRODUCT|Home monitoring care|Patients in the home monitoring group will receive a home spirometer, pulse oximetry meter, and access to a smartphone or tablet app, where they can perform home based measurements weekly and complete PROMs. Furthermore, this app includes disease specific information and allows for direct communication with the hospital via eConsultation. In the home monitoring group, half of the outpatient clinic visits will alternately be replaced by remote visits via video consultation.
218946130|NCT05863000|OTHER|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
218946131|NCT04494568|DEVICE|HIFU treatment|HIFU Treatment of rectal endometriosis
218946132|NCT01046435|PROCEDURE|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
218946133|NCT01046435|PROCEDURE|Two placebos|Two placebos 3 times a day for 7 days
218946134|NCT04087330|OTHER|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
218946135|NCT04087330|OTHER|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
218946136|NCT02604329|DEVICE|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
219635338|NCT06302556|DIAGNOSTIC_TEST|Immune checkpoints analysis|The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.
218946137|NCT04510428|DRUG|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
219053243|NCT01578044|BEHAVIORAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
219053244|NCT01578044|OTHER|Control|Usual care
219053245|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
219053246|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
219053247|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
219053248|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
218946138|NCT04510428|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
218946139|NCT04664764|DRUG|Degludec|Basal insulin comparison
218946140|NCT04664764|DRUG|Glargine|Basal insulin comparison
218946141|NCT04664764|DRUG|NPH insulin|Basal insulin comparison
219635339|NCT06302556|DIAGNOSTIC_TEST|Gene expression analysis|Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2
219635340|NCT05726071|DEVICE|Holter|24 hour electrocardiography
219635341|NCT04482361|DIAGNOSTIC_TEST|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
219635342|NCT04747353|DEVICE|Catheter ablation procedure with heart 3D model|Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
219635343|NCT03962777|OTHER|chlorhexidine|patients used chx moutrinses for four days
219635344|NCT03962777|OTHER|oil pulling|patients used oil pulling for four days
219635345|NCT04291183|BEHAVIORAL|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
219635346|NCT04774367|DEVICE|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
219635347|NCT04774367|DEVICE|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
219635348|NCT02041663|BIOLOGICAL|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
219635349|NCT00224068|DRUG|Sodium ferric gluconate, ferrous sulfate, standard of care|
219635350|NCT03005496|DRUG|Zinc|included in intervention arm
219635351|NCT03005496|DRUG|Nifedipine|included in intervention and control arm
219635352|NCT03005496|DRUG|Beta Carotene|included in intervention arm
219635353|NCT03005496|DRUG|Vitamin D3|included in intervention arm
219635354|NCT03005496|DRUG|Dexamethasone|included in intervention and control arm
219635355|NCT04607564|OTHER|Ntombi Vimbela! intervention|Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
219635356|NCT00183859|DRUG|irinotecan|Intraperitoneal Irinotecan given every three weeks
219635357|NCT05185037|DEVICE|Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)|The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
219635358|NCT01245959|DRUG|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
219635359|NCT01245959|RADIATION|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
219635360|NCT00002875|BIOLOGICAL|filgrastim|
219635361|NCT00002875|DRUG|cisplatin|
219635362|NCT00002875|DRUG|cyclophosphamide|
219635363|NCT00002875|DRUG|lomustine|
218946142|NCT04250077|BEHAVIORAL|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
219053249|NCT00963729|DRUG|cyclophosphamide|Given IV
219053250|NCT00963729|DRUG|docetaxel|Given IV
219053251|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
219635364|NCT00002875|DRUG|mesna|
219635365|NCT00002875|DRUG|vincristine sulfate|
219635366|NCT00002875|RADIATION|low-LET electron therapy|
219635367|NCT00002875|RADIATION|low-LET photon therapy|
219635368|NCT01541332|DRUG|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
219635369|NCT01541332|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
219635370|NCT01541332|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
219635371|NCT00985387|DRUG|Solifenacin|oral
219635372|NCT05958628|OTHER|Conventional physiotherapy|"The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes."
219053252|NCT00963729|DRUG|fluorouracil|Given IV
219053253|NCT00963729|DRUG|letrozole|Given orally
218946143|NCT04250077|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
218946144|NCT01222156|PROCEDURE|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
218946145|NCT01222156|DEVICE|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
218946146|NCT03457779|DIETARY_SUPPLEMENT|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV"
219053254|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
219635373|NCT05958628|OTHER|Robotic Hand Exoskeleton System|In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
219635374|NCT00182611|DRUG|cisplatin|
219635375|NCT00182611|DRUG|tegafur-gimeracil-oteracil potassium|
219635376|NCT00182611|PROCEDURE|adjuvant therapy|
219635377|NCT00182611|PROCEDURE|conventional surgery|
219635378|NCT00182611|PROCEDURE|neoadjuvant therapy|
219635379|NCT04806893|DRUG|lerodalcibep|300 mg subcutaneous injection every month (Q4W)
219635380|NCT04806893|OTHER|Placebo|matching subcutaneous injection every month (Q4W)
219635381|NCT05697354|PROCEDURE|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
219635382|NCT05697354|PROCEDURE|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
219635383|NCT06104254|OTHER|education|we will give an education to experimental group about pain and pain management.
218946147|NCT03954340|DEVICE|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
218946148|NCT05063071|DRUG|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
218946149|NCT03199443|DIAGNOSTIC_TEST|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
218946150|NCT01022398|DRUG|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
218946151|NCT05962567|OTHER|Non surgical periodontal therapy|scaling and subgingival debridement
218946152|NCT02651909|OTHER|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
219053255|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
219053256|NCT04035486|DRUG|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
219053257|NCT04035486|DRUG|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
219635384|NCT00439283|DRUG|infliximab|
219635385|NCT00439283|DRUG|methotrexate|
219635386|NCT03601598|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
219635387|NCT03601598|DRUG|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
219635388|NCT03018080|DRUG|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
219635389|NCT03018080|DRUG|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
218946153|NCT00450008|DRUG|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
218946154|NCT00450008|DRUG|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
218946155|NCT00450008|DRUG|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
219053258|NCT04035486|DRUG|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
218946156|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
219053259|NCT00431249|DRUG|Cilostazol|
219053260|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
219053261|NCT03069625|BEHAVIORAL|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
219053262|NCT03069625|BEHAVIORAL|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
219053263|NCT00463359|DRUG|Imiquimod cream|
218946157|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
219053264|NCT00463359|PROCEDURE|curettage and cautery|
219053265|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
219053266|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
218946158|NCT02507037|DIETARY_SUPPLEMENT|gum+PEG|chew sugarless gum
218946159|NCT02507037|DRUG|polyethylene glycol|2L PEG
219053267|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
219053268|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
218946160|NCT03866395|DRUG|Ivabradine|Ivabradine 5 mg twice a day
219053269|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
219053270|NCT06605950|DRUG|KarXT|Specified dose on specified days
219053271|NCT06605950|DRUG|KarX-EC|Specified dose on specified days
219053272|NCT06605950|DRUG|Placebo|Specified dose on specified days
218946161|NCT00998218|DRUG|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
218946162|NCT00998218|DRUG|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
219053273|NCT06605950|DRUG|Omeprazole|Specified dose on specified days
219053274|NCT02680184|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
219053275|NCT02680184|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
219053278|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
219053279|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
219053280|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
219053281|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
219053282|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
219053283|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
219053284|NCT06626490|DEVICE|Prevision Revision hip endoprosthesis stem implantation|"The Prevision hip endoprosthetic stem is a femoral part of a hip joint endoprosthesis. The system provides cementless and cemented variants. Prevision hip stems are modular with a short proximal and longer distal component, or monobloc hip stems. Modular components are coupled via a Prevision specific conical connection with a torque wrench and a tension nut to apply a predefined torsional moment on the connection. The distal component of modular Prevision stems can be combined with locking screws for additional bone fixation.~Both types, the monobloc and the modular, provide a 12/14 taper that serves as a connection for metal or ceramic prosthesis heads. Prevision hip stems are combined at the acetabulum with a cementless or cemented acetabular cup."
219053285|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
219206917|NCT06739239|DEVICE|Extra-Vascular Implantable Cardioverter Defibrillator|The pulse generator is implanted along the patient's left midaxillary line, and the lead is positioned substernally.
218946163|NCT04796870|OTHER|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
219635390|NCT00740792|DRUG|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
219635391|NCT00740792|DRUG|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
219635392|NCT00740792|DRUG|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
219635393|NCT00740792|DRUG|placebo|placebo one spray per nostril BID
219635394|NCT02458248|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
219635395|NCT03207048|DEVICE|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
219635396|NCT03207048|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
219635397|NCT03900169|GENETIC|Genetic|Lipid profile
219635398|NCT01709682|DRUG|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
219635399|NCT01709682|PROCEDURE|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
219635400|NCT01709682|PROCEDURE|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
219635401|NCT03195621|DEVICE|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
219635402|NCT05518240|DEVICE|Stent Retrievers|Procedure: Embotrap device
219635403|NCT05518240|DEVICE|Stent Retriever|Procedure: Solitaire device
219635404|NCT01605240|DRUG|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
219635405|NCT01605240|DRUG|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
219635406|NCT01848912|DEVICE|Zephyr Biopatch Device|
219635407|NCT00775801|DEVICE|FLD|Artificial lumbar disc
219206918|NCT06738654|PROCEDURE|robot-surgery|Breast-conserving surgery for breast cancer using single-port robotic surgery.
219635408|NCT00775801|DEVICE|Control|Artificial lumbar disc
219635409|NCT05708872|BEHAVIORAL|Autohypnosis|Patients in the study group will receive a voice recording with hypnotic instructions with a suggestion to improve the psychophysical state.
219635410|NCT05708872|BEHAVIORAL|Relaxing music|Patients in the control group will receive a recording with relaxing music
219635411|NCT04893616|OTHER|Integration of vaccination services into delivery services|The purpose of the work is to integrate readily available birth dose vaccinations (Oral Polio and the Tuberculosis vaccine) currently given in a separate clinic into the maternity delivery services through improved training, checklist, and job aides.
219635412|NCT01672541|BEHAVIORAL|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
219635413|NCT01672541|BEHAVIORAL|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
219635414|NCT05894941|OTHER|Corrective Exercises|A total of 6 evidence-based exercises and stretches namely; Upper trapezius stretch, Sternocleidomastoid stretch, pectoral stretch; Chin tuck exercise, YTWL exercise, and resisted/isometric neck extension exercise will be prescribed to the exercise group while the postural education group will follow the guidelines provided by National Institutes of Health (NIH) for using computers and other sources. The control group will receive no intervention.
219635415|NCT05894941|OTHER|Postural Education|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
218946164|NCT03643536|OTHER|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
219206919|NCT06738654|PROCEDURE|traditional open surgry|Breast-conserving surgery for breast cancer using traditional open surgery.
219635416|NCT01268618|DIETARY_SUPPLEMENT|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~1. Lactobacillus acidophilus NAS, 30 billion CFU~2. Bifidobacterium bifidum Malyoth, 120 billion CFU~3. Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
218946165|NCT00950885|BIOLOGICAL|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
219635417|NCT01268618|DIETARY_SUPPLEMENT|Placebo|2 capsules, 3x/day placebo capsules
219635418|NCT02973503|DRUG|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
219635419|NCT06110702|BEHAVIORAL|EMDR|Eye movement Desensitization and Reprocessing (as described in the 8-phases protocol), administered both online or in presence.
219635420|NCT05852275|OTHER|Olive-oil|Participants will add to their usual diet a daily intake of 30 mL of an olive oil rich in polyphenols for 3-months (100 days)
219635421|NCT00179660|DRUG|Lenalidomide|Capsules for oral administration.
219635422|NCT03935425|DEVICE|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
219635423|NCT03935425|DEVICE|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
219635424|NCT01531621|OTHER|Biomarker sampling|Blood samples every 8-12 weeks
218946166|NCT00950885|BIOLOGICAL|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
218946167|NCT00950885|BIOLOGICAL|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
218946168|NCT04231552|DRUG|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
218946169|NCT02849353|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
218946170|NCT02849353|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
218946171|NCT04280809|DEVICE|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
218946172|NCT04374227|PROCEDURE|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
218946173|NCT03643978|OTHER|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
218946174|NCT05504876|DRUG|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
218946175|NCT05504876|DRUG|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
218946176|NCT05504876|DRUG|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
218946177|NCT05551442|PROCEDURE|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
218946178|NCT05551442|DEVICE|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
218946179|NCT05937464|OTHER|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
219635425|NCT01311076|DRUG|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
219635426|NCT01311076|DRUG|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
219635427|NCT01311076|DRUG|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
219635428|NCT01311076|DRUG|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
219053286|NCT06663020|BEHAVIORAL|Smoking Cessation Duration|Participants are categorized based on their smoking status and the duration since they quit smoking prior to lung cancer surgery. This observational study focuses on evaluating the relationship between the duration of smoking cessation (measured in days or weeks) and the incidence of postoperative complications. Smoking cessation duration is recorded for each participant to determine its impact on surgical outcomes.
218946180|NCT05937464|OTHER|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
218946181|NCT05072613|OTHER|Malaria screening|Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
218946182|NCT01883076|BIOLOGICAL|autologous cell-based delivery|"autologous cells (derived from self)"
218946183|NCT03133741|OTHER|GIP-A|GIP-A (GIP receptor antagonist)
218946184|NCT03133741|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
218946185|NCT03133741|OTHER|Placebo|Saline (9mg/mL)
218946186|NCT03133741|OTHER|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
218946187|NCT03124927|DEVICE|DCI pulse oximeter sensor|
218946188|NCT02921464|OTHER|none - registry clinic followup only|
218946189|NCT06419530|OTHER|Probiotic formula capsule|The subjects take 4 capsules a day for 84 days.
218946190|NCT06419530|OTHER|placebo capsule|The subjects take 4 capsules a day for 84 days.
218946191|NCT06419530|OTHER|FMT capsule|The subjects take 4 capsules a day for 84 days.
219053287|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
219635429|NCT00178685|BEHAVIORAL|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
219635430|NCT03223415|OTHER|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
218946192|NCT06531967|OTHER|No intervention|No intervention
218946193|NCT00614770|PROCEDURE|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
218946194|NCT00614770|PROCEDURE|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
218946195|NCT00614770|PROCEDURE|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
218946196|NCT05702346|BEHAVIORAL|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
218946197|NCT03713905|DRUG|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
218946198|NCT00361634|DRUG|Etanercept|
218946199|NCT05802953|OTHER|Physical assessments|Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
218946200|NCT05802953|OTHER|Questionnaire|General Health Questionnaire-28 and SF-36 will be apply.
218946201|NCT00833417|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
218946202|NCT04772326|OTHER|Questionnaire|Questionnaire
218946203|NCT03262311|OTHER|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
218946204|NCT03330002|DEVICE|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
218946205|NCT02114658|DRUG|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
218946206|NCT02274909|OTHER|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
218946207|NCT04143464|BEHAVIORAL|Kyphosis-specific exercise class and kyphosis-specific exercise videos|"The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos."
219053288|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
219053289|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
219206920|NCT05466799|DRUG|FOLFIRINOX chemotherapy|Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
218946208|NCT00749567|DRUG|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
218946209|NCT00749567|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
218946210|NCT04113213|BEHAVIORAL|Lifestyle Prescription (LRx)|Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
218946211|NCT03745599|DRUG|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
218946212|NCT03745599|DRUG|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
218946213|NCT03745599|DRUG|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
218946214|NCT03986593|DEVICE|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
218946215|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 8 mg BID
219053290|NCT05419947|DRUG|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
219053291|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
218946216|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 3 mg BID
218946217|NCT00505076|DRUG|placebo|2 tablets placebo BID
218946218|NCT04641884|OTHER|Not concerned|Not concerned
218946219|NCT02661048|DEVICE|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
218946220|NCT02231099|PROCEDURE|Prolift + M|prolapse surgery with mesh
218946221|NCT02231099|PROCEDURE|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
218946222|NCT02303132|OTHER|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
218946223|NCT02482038|DEVICE|geko|neuromuscular electrostimulator
218946224|NCT02586441|DEVICE|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
218946225|NCT02586441|DRUG|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
218946226|NCT02586441|DRUG|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
218946227|NCT05520892|DRUG|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
218946228|NCT01641419|DRUG|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
218946229|NCT01641419|DRUG|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
218946230|NCT01641419|DRUG|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
219053292|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
218946231|NCT04941170|DRUG|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
218946232|NCT04941170|DRUG|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
218946233|NCT04076098|DRUG|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
218946234|NCT02030899|PROCEDURE|Cage fusion|Randomized selection of surgery type
218946235|NCT02030899|PROCEDURE|Plate fusion|Randomized selection of surgery type
218946236|NCT03373903|OTHER|Placebo|oral
218946237|NCT03373903|DRUG|BEZ235|oral
218946238|NCT03373903|DRUG|BEZ235 plus everolimus (RAD001)|Oral
219053293|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
219053294|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
219206921|NCT05466799|DEVICE|OncoSil™|Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
219206922|NCT06738342|OTHER|CHX 0.09% + Citrox + HA|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
219206923|NCT06738342|DRUG|CHX 0.12%|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
219635431|NCT00690677|DRUG|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
219635432|NCT01835873|OTHER|Lactated Ringer's|
218946239|NCT01450852|BEHAVIORAL|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
218946240|NCT03835793|DIAGNOSTIC_TEST|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
218946241|NCT05056584|BIOLOGICAL|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
218946242|NCT05056584|BIOLOGICAL|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
218946243|NCT05460091|DEVICE|PTech Device|High-frequency vibration device used on regular basis in orthodontics
218946244|NCT05460091|DEVICE|PTech Sham Device|sham device (does not vibrate)
218946245|NCT00641511|DRUG|SYN117 (nepicastat)|120 mg per day
218946246|NCT00641511|DRUG|Placebo comparator|once per day placebo capsules
218946247|NCT02849730|DEVICE|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
218946248|NCT03502551|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
218946249|NCT05484544|DIAGNOSTIC_TEST|High sensitivity troponin T|Collection of hs-cTnT samples
218946250|NCT06043544|DEVICE|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
218946251|NCT06043544|DRUG|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
218946252|NCT02141477|DRUG|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
218946253|NCT02141477|DRUG|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
218946254|NCT02205489|DRUG|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
218946255|NCT02205489|DRUG|cetirizine|Pharmaceutical form:tablet Route of administration: oral
218946256|NCT02205489|DRUG|ranitidine|Pharmaceutical form:tablet Route of administration: oral
218946257|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
218946258|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
218946259|NCT02205489|DRUG|aciclovir|Pharmaceutical form:tablet Route of administration: oral
218946260|NCT02205489|DRUG|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
218946261|NCT02205489|DRUG|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
218946262|NCT02205489|DRUG|paracetamol|Pharmaceutical form:tablet Route of administration: oral
218946263|NCT01745497|DRUG|Ferrous sulfate|3mg/kg liquid
218946264|NCT01745497|DRUG|Placebo|Equivalent volume of liquid with similar color and taste.
218946265|NCT02745145|DRUG|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
218946266|NCT02745145|DRUG|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
218946267|NCT02745145|DRUG|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
218946268|NCT02990624|RADIATION|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
218946269|NCT00277875|DRUG|ALT-711 (alagebrium chloride)|
218946270|NCT01757158|RADIATION|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
218946271|NCT02546700|DRUG|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
218946272|NCT02546700|DRUG|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
218946273|NCT01379144|DRUG|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
218946274|NCT01379144|DRUG|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
219635433|NCT01835873|OTHER|HES 130/0.42|Balanced colloid solution
219635434|NCT00181285|DEVICE|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
218946275|NCT01379144|DRUG|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
218946276|NCT01379144|DRUG|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
218946277|NCT01733303|BEHAVIORAL|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
218946278|NCT04696887|BEHAVIORAL|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
218946279|NCT03725241|DIETARY_SUPPLEMENT|Glutathione Supplement|1000 mg/day Glutathione
219053295|NCT05894772|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
219053296|NCT02869490|OTHER|Data collection|
219053297|NCT06021561|DIAGNOSTIC_TEST|Diagnosis of pain|Pain will be investigated - type, origin, level
219053298|NCT04935021|DRUG|ATTR-CM|Current treatment
219053299|NCT00880347|DEVICE|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
219053300|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
219053301|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
219053302|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
219053303|NCT06996132|DRUG|Glofitamab|Glofitamab is administered as monotherapy or in combination with investigator-selected agents (including but not limited to chemotherapy, ADCs, BTK inhibitors, etc.) for 2 cycles.
219635435|NCT02382497|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
219635436|NCT02382497|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
219635437|NCT02382497|DEVICE|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
219635438|NCT02382497|DEVICE|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
219635439|NCT05037045|DRUG|GLP-1 receptor agonist|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
219635440|NCT01562782|OTHER|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
219635441|NCT06094725|DRUG|Relacorilant|Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
218946280|NCT03725241|DIETARY_SUPPLEMENT|Placebo Supplement|Crystalline cellulose
219053304|NCT06996132|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|After two cycles of glofitamab-based salvage therapy, single-target or dual-target CAR-T cells directed against CD19, CD20, and/or CD22 are infused following lymphodepleting (fludarabine + cyclophosphamide) or myeloablative conditioning, at a dose of 2-4 × 10⁶/kg.
219053305|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
218946281|NCT02366091|DRUG|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
218946282|NCT02366091|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
218946283|NCT02366091|DRUG|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
218946284|NCT04636216|BEHAVIORAL|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
218946285|NCT00232869|DEVICE|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
218946286|NCT00232869|DEVICE|bare-metal stent|SMART™ bare-metal stent
218946287|NCT00644007|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
218946288|NCT00644007|DRUG|SK3530|SK3530 100 mg
218946289|NCT02068898|DRUG|XS003|
218946290|NCT02068898|DRUG|Tasigna|
218946291|NCT05122702|DRUG|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
218946292|NCT05122702|OTHER|Placebo|Placebo granules, twice daily for 12 weeks.
218946293|NCT04257188|PROCEDURE|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
218946294|NCT03816709|DEVICE|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
218946295|NCT04158843|PROCEDURE|Radical resection|Radical resection is performed, and the cutting edge is negative.
218946296|NCT04158843|RADIATION|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
218946297|NCT04158843|OTHER|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
218946298|NCT04663490|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
218946299|NCT01155011|BEHAVIORAL|Physical Activity|"MIPARC will focus on 3 physical activity goals:~1. increasing walking behavior through gradually increasing step goals~2. increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~3. reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
218946300|NCT01155011|BEHAVIORAL|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
218946301|NCT01155011|BEHAVIORAL|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~1. health check~2. step goal check~3. barrier identification~4. problem solving~5. specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
218946302|NCT01155011|BEHAVIORAL|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
219053306|NCT07019168|BEHAVIORAL|Jump Squat with Blood Flow Restriction (BFR)|This intervention consisted of jump squat exercises performed with blood flow restriction applied using a non-automated, manually adjustable tourniquet placed on the proximal thighs. The restriction was applied during the exercise to partially limit venous return while maintaining arterial flow. The exercise protocol included 3 sets of 10 repetitions, performed 3 times per week for 4 weeks. A standardized warm-up preceded each session.
218946303|NCT01155011|BEHAVIORAL|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
218946304|NCT01155011|BEHAVIORAL|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
218946305|NCT01155011|BEHAVIORAL|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
218946306|NCT01155011|BEHAVIORAL|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
219635442|NCT05878002|DEVICE|polysomnography|Sleep study through polysomnographic examination
218946307|NCT01155011|BEHAVIORAL|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
218946308|NCT01155011|BEHAVIORAL|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
218946309|NCT02083549|OTHER|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
218946310|NCT02641340|DRUG|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
218946311|NCT02641340|DRUG|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
218946312|NCT06088602|PROCEDURE|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
218946313|NCT06088602|PROCEDURE|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
219635443|NCT03710863|DRUG|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
219635444|NCT04551274|BEHAVIORAL|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
219635445|NCT01560312|DEVICE|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
219635446|NCT01932710|PROCEDURE|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
219635447|NCT03593824|PROCEDURE|bilateral cataract removal surgery for dense cataract|Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.
218946314|NCT05120557|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
218946315|NCT00737399|BEHAVIORAL|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
218946316|NCT05781880|OTHER|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
218946317|NCT02678494|OTHER|Neurofeedback training|
218946318|NCT05647278|DRUG|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
218946319|NCT05647278|DRUG|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
218946320|NCT04286997|DEVICE|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
218946321|NCT03845439|OTHER|Lumbar puncture|Lumbar puncture
218946322|NCT00349700|PROCEDURE|Compression: 2 weeks four layer bandages, then stockings|
219635448|NCT03593824|PROCEDURE|bilateral cataract removal surgery for non-dense nuclear cataract|Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
219635449|NCT00776295|BIOLOGICAL|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
219635450|NCT02714595|DRUG|Cefiderocol|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.
218946323|NCT00349700|PROCEDURE|debridement|
218946324|NCT00349700|PROCEDURE|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
218946325|NCT04751214|PROCEDURE|APPENDICECTOMY|
218946326|NCT02710162|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
218946327|NCT02710162|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
218946328|NCT02710162|DEVICE|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
218946329|NCT02710162|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
218946330|NCT02710162|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
218946331|NCT02710162|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
218946332|NCT02710162|OTHER|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
218946333|NCT02710162|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
218946334|NCT02710162|OTHER|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
218946335|NCT02710162|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
218946336|NCT02710162|OTHER|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
218946337|NCT02710162|OTHER|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
218946338|NCT03905252|OTHER|sample analysis|blood, Random urine sample and 24-hour urine samples
218946339|NCT00653432|DEVICE|Monovisc®|Intra-articular injection
218946340|NCT00653432|OTHER|Saline|0.9% Sterile Saline
218946341|NCT00477516|PROCEDURE|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
219635451|NCT02714595|DRUG|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
219635452|NCT00713258|DRUG|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
219635453|NCT00713258|DRUG|Alendronate|70 mg alendronate weekly
218946342|NCT02568891|DIETARY_SUPPLEMENT|Probiotic|multispecies probiotic
218946343|NCT02568891|DIETARY_SUPPLEMENT|Placebo|matrix
219053307|NCT07019168|BEHAVIORAL|Jump Squat without Blood Flow Restriction|This intervention consisted of the same jump squat protocol as the experimental group but without the application of blood flow restriction. Participants performed 3 sets of 10 repetitions, 3 times per week for 4 weeks. Each session was preceded by a standardized warm-up routine that included dynamic stretching and general activation exercises.
219635454|NCT01832558|DRUG|Eplerenone|
219635455|NCT01832558|DRUG|Placebo|
219635456|NCT04446455|OTHER|InVEST: Increased Velocity Exercise Specific to Task|Functional Power Training
219635457|NCT04446455|OTHER|TAPAT: Tonic and Phasic Alertness Training|Computerized cognitive training.
219635458|NCT03737500|DEVICE|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
219635459|NCT03737500|DEVICE|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
219635460|NCT00892671|OTHER|Simulation|simulation of airway management and vascular access
219635461|NCT05403853|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
219635462|NCT05403853|DIAGNOSTIC_TEST|Fingerstick|Capillary Blood Draw
218946344|NCT00308464|DRUG|PHA-794428|
218946345|NCT00234247|OTHER|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
218946346|NCT05378698|DRUG|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
218946347|NCT05403398|DIETARY_SUPPLEMENT|B. subtilis CU1|2 billion CFUs daily, for 4 weeks
218946348|NCT05997394|OTHER|A prayer concert will be held for the participants.|Participants who are in the experimental group will be given a prayer audience.
218946349|NCT03430713|PROCEDURE|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
218946350|NCT04583137|DRUG|Lidocain|Layngeal direct fiberoptic examination transnasaly
218946351|NCT02782858|DRUG|GNbAC1|Monthly IV repeated dose
218946352|NCT02782858|DRUG|Placebo|Monthly IV repeated dose
218946353|NCT04090775|DRUG|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
218946354|NCT04090775|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
218946355|NCT04090775|DRUG|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
218946356|NCT04090775|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
218946357|NCT01920672|BEHAVIORAL|Timed Planned Activity|
218946358|NCT01920672|BEHAVIORAL|Home Safety and Education Program|
218946359|NCT01743001|DRUG|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
218946360|NCT01743001|DRUG|Placebo|Macitentan-matching placebo oral tablet once daily
218946361|NCT03194737|DEVICE|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
218946362|NCT05246267|BIOLOGICAL|Dupilumab|Standard of care treatment with dupilumab
218946363|NCT04502680|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
218946364|NCT02961101|DRUG|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
218946365|NCT02961101|DRUG|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
218946366|NCT02961101|DRUG|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
218946367|NCT00255424|DRUG|ferumoxytol or oral iron|
218946368|NCT00911885|BEHAVIORAL|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
218946369|NCT00029510|DRUG|Magnesium|
218946370|NCT04218565|BIOLOGICAL|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
218946371|NCT03030846|OTHER|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
218946372|NCT03030846|OTHER|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
218946373|NCT01565343|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi)
218946374|NCT05763355|PROCEDURE|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
218946375|NCT01012674|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
218946376|NCT01012674|OTHER|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
218946377|NCT03149627|OTHER|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
218946378|NCT00352352|PROCEDURE|Tongue Acupuncture (Procedure)|
218946379|NCT04233918|DRUG|Evinacumab|Part A: Single IV dose Part B \& C: IV dose Q4W
219053308|NCT07024576|OTHER|Preoperative casting intervention|A serial casting intervention protocol involving the application of heat, stretching, and massage before casting. This is repeated weekly for four weeks, with the cast removed and reapplied each time to promote gradual elongation of restricted tissue.
218946380|NCT01650870|DRUG|Crystalline Lactulose|
218946381|NCT03965000|OTHER|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
218946382|NCT06099080|DRUG|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
218946383|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
218946384|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
218946385|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
218946386|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
218946387|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
218946388|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
218946389|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
219053309|NCT07025213|OTHER|Diet and exercise.|The intervention group will receive recommendations to follow an anti-inflammatory diet. In addition, they will be instructed to increase their level of physical activity and will be asked to attend the institute to carry out a supervised exercise routine.
218946390|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
218946391|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
218946392|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
218946393|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
218946394|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
218946395|NCT01532193|OTHER|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
218946396|NCT06516445|RADIATION|SCRT|5×5Gy，5Gy/d，QD，D1-D5
218946397|NCT06516445|DRUG|Camrelizumab|200mg, D1, ivgtt, Q3W, C1-4
218946398|NCT06516445|DRUG|Fluzoparib|100mg, BID, PO, Q3W, C1-4
218946399|NCT06516445|DRUG|CAPEOX|Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
219635463|NCT04591886|BEHAVIORAL|mind. body. voice.|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
219635464|NCT05534919|DRUG|Nefecon|Nefecon is taken orally as capsules once daily for 9 months.
219635465|NCT04449302|PROCEDURE|Immediate molar implant with customized healing abutment|"Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done."
219635466|NCT06197230|OTHER|Drawing Intervention|"The primary sections of Drawing Intervention will be the art-making and art-sharing sections. During the art-making segment, the group leader will guide the participants through a paper-warming exercise before assigning them a specific subject to draw freely for 20-30 minutes. The leader will then ask participants to talk about the meaning of their artwork, encouraging them to explore their emotions regarding the theme and their drawing. This procedure will be implemented in each segment of the intervention (6 sessions)."
219635467|NCT03606928|DRUG|docetaxel, oxaliplatin, 5-FU, leucovorin|This is a single-arm study with all patients receiving mFLOT chemotherapy.
219635468|NCT06666816|OTHER|inapplicable|inapplicable
219635469|NCT03779750|DIAGNOSTIC_TEST|s.creatinine|All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
219635470|NCT00863148|DRUG|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
219635471|NCT05896566|DRUG|Giredestrant|Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
219635472|NCT05896566|DRUG|Triptorelin|Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
219635473|NCT05896566|DRUG|Anastrozole|Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
218946400|NCT03956238|BEHAVIORAL|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
218946401|NCT03956238|BEHAVIORAL|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
218946402|NCT03728283|PROCEDURE|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
218946403|NCT03728283|OTHER|Implant placement|Implants were placed following teh manufacturer's instructions
218946404|NCT00424541|DRUG|SPP100 (aliskiren)|
218946405|NCT04091607|OTHER|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
219053310|NCT07025213|OTHER|Diet.|The comparison group will be instructed to follow the anti-inflammatory diet intervention only.
218946406|NCT02173093|BIOLOGICAL|IL-2|Given SC
218946407|NCT02173093|BIOLOGICAL|GD2Bi-aATC|Given IV
218946408|NCT02173093|BIOLOGICAL|GM-CSF|Given SC
218946409|NCT02173093|OTHER|laboratory evaluations of immune responses|Correlative studies
218946410|NCT00830895|DRUG|RAD001|RAD001 10mg/day
218946411|NCT00984113|DRUG|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
218946412|NCT02709538|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
218946413|NCT02709538|DRUG|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
218946414|NCT02709538|DRUG|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
218946415|NCT05543772|DRUG|Normal saline|participant will be given 500 ml normal saline through intravenous access. blood sample will be extracted before and after giving normal saline using same intravenous catheter
218946416|NCT00835211|DRUG|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
218946417|NCT00835211|DRUG|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
218946418|NCT02343549|DEVICE|NovoTTF100A|
218946419|NCT02343549|DRUG|Bevacizumab|
218946420|NCT02343549|DRUG|Temozolomide|
218946421|NCT00197548|DIETARY_SUPPLEMENT|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
218946422|NCT00197548|DIETARY_SUPPLEMENT|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
218946423|NCT02543749|BIOLOGICAL|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
218946424|NCT01040234|PROCEDURE|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
218946425|NCT02160041|DRUG|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
218946426|NCT01403948|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
218946427|NCT02402998|DRUG|Eltrombopag|Eltrombopag 50 mg/daily.
218946428|NCT00132977|DEVICE|Cardiac Resynchronization Therapy|
218946429|NCT05483218|DEVICE|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
218946430|NCT00836121|PROCEDURE|right thoracotomy|complete surgical resection
218946431|NCT00019383|BIOLOGICAL|aldesleukin|
218946432|NCT00019383|BIOLOGICAL|incomplete Freund's adjuvant|
218946433|NCT00019383|BIOLOGICAL|sargramostim|
218946434|NCT00019383|BIOLOGICAL|tyrosinase peptide|
218946435|NCT00019383|BIOLOGICAL|tyrosinase-related protein-1|
218946436|NCT05034822|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
219053311|NCT07023523|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
219053312|NCT07023523|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
218946437|NCT01090323|DRUG|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
218946438|NCT01864005|DRUG|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
218946439|NCT01864005|DRUG|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
218946440|NCT01082549|DRUG|gemcitabine/carboplatin|i.v.
219635474|NCT01700075|DRUG|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
218946441|NCT01082549|DRUG|gemcitabine/carboplatin plus Iniparib|i.v.
218946442|NCT03482934|DEVICE|sphygmomanometer|device used for measurement of brachial blood pressure
219053313|NCT07024043|DRUG|Dexamethasone versus Dexmedetomidine in IPACK Block to reduce pain post Arthroscopic knee surgeries|Blocks will be carried out with the patient supine with the operative leg externally rotated and slightly flexed at the knee or in prone position.with Ultrasound device with a high-frequency (6-13 MHz) linear probe using in plane lateral to medial approach and this will be done by a senior staff anaesthesia physician skilled in ultrasound guided regional anaesthesia.
218946443|NCT03482934|DEVICE|mobilogragh|device used for measurement of central blood pressure
218946444|NCT03482934|DIAGNOSTIC_TEST|ECG|Electrocardiogram
218946445|NCT03482934|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
218946446|NCT01717599|DRUG|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
218946447|NCT01717599|DRUG|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
218946448|NCT04379128|OTHER|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
218946449|NCT00386919|PROCEDURE|CyberKnife|
218946450|NCT00763698|DEVICE|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
218946451|NCT02190565|DIETARY_SUPPLEMENT|Food supplement|Randomized double-blind, placebo-controlled
218946452|NCT03367468|OTHER|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
218946453|NCT03367468|OTHER|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
218946454|NCT04316832|BEHAVIORAL|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
218946455|NCT04316832|OTHER|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
218946456|NCT03970915|DEVICE|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
218946457|NCT03970915|DEVICE|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
218946458|NCT05919706|BEHAVIORAL|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
218946459|NCT03495778|OTHER|Test Granola|50.5 Test Granola
218946460|NCT03495778|OTHER|Control Granola|54.3 Control Granola
218946461|NCT01018784|DRUG|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
218946462|NCT05401942|OTHER|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
218946463|NCT04529486|OTHER|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
218946464|NCT04302909|OTHER|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
218946465|NCT04302909|OTHER|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
218946466|NCT04302909|OTHER|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
218946467|NCT00492713|OTHER|dark chocolate|dark chocolate
219635475|NCT01700075|DIETARY_SUPPLEMENT|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
218946468|NCT00492713|OTHER|Milk chocolate 1|Milk chocolate 1
218946469|NCT00492713|OTHER|Milk chocolate 2|Milk chocolate 2
218946470|NCT01765959|OTHER|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
218946471|NCT01765959|OTHER|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
218946472|NCT05815979|BEHAVIORAL|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
218946473|NCT00213993|DRUG|antiperspirant|antiperspirant topically once daily to one foot
218946474|NCT04444856|DRUG|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
218946475|NCT04444856|OTHER|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
218946476|NCT03241368|DEVICE|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
219053314|NCT07024043|PROCEDURE|IPACK and multi-modal analgesic regimen|patients will be put in supine position, the procedure will be performed under complete aseptic precautions and All patients will be divided into three groups:(Group 1) for iPACK block with 0.25% bupivacaine only. (Group 2) for iPACK block with 0.25% bupivacaine and dexamthasone and (Group 3) for iPACK block with 0.25% bupivacaine and dexmedetomidine .
219635476|NCT05011786|PROCEDURE|hernia repair/ligation of the hernial sac|the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
219635477|NCT04685460|OTHER|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
219053315|NCT07025135|BEHAVIORAL|comparison between use of mobile app|Patient-caregiver dyad receive standard care (optimal macrogol treatment) plus a mobile app featuring symptom tracking, medication reminders, dietary tips, and gamification elements.
219635478|NCT01045187|RADIATION|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
219635479|NCT01045187|RADIATION|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
219635480|NCT01401764|OTHER|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
219635481|NCT01780519|DRUG|lorazepam|single dose of 1 mg lorazepam
218946477|NCT04902300|OTHER|Data collection|evaluation of internet addiction
219053316|NCT07025135|BEHAVIORAL|Patient-caregiver dyad using printed recommendations|Patient-caregiver dyad receives standard care ( optimal macrogol treatment) plus a non-interactive, educational-only printed version of recommendations.
219053317|NCT07023848|DRUG|89Zr-LNCab104|89Zr-LNCab104 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
219053318|NCT07023848|DRUG|89Zr-LNCab103|89Zr-LNCab103 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
219053319|NCT07023848|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg.
219053320|NCT07025525|DEVICE|Ultrasonic activated sodium hypochlorite|Using ultrasonic-activated sodium hypochlorite in the canals of primary molars can significantly enhance root canal disinfection by improving the irrigant's penetration and effectiveness. Primary molars often have complex and irregular canal anatomies, which can limit the reach of traditional irrigation methods. Ultrasonic activation creates acoustic streaming and cavitation effects, allowing sodium hypochlorite to better dissolve organic tissue and disrupt bacterial biofilms, especially in hard-to-reach areas. This leads to more thorough cleaning, reduced microbial load, and potentially better clinical outcomes in pediatric endodontics
219053321|NCT07025525|OTHER|Ultrasonic acivated saline|using ultrasonic-activated saline within the canals of primary teeth lies in its ability to enhance mechanical debridement and improve irrigation effectiveness without the risks associated with stronger chemical agents. Although saline lacks inherent antimicrobial properties, ultrasonic activation generates acoustic streaming and cavitation, which help dislodge debris, disrupt biofilms, and clean intricate canal anatomy more efficiently than passive irrigation. This makes it a safer alternative in pediatric patients, minimizing the risk of cytotoxic effects or damage to developing permanent tooth buds while still improving cleaning outcomes.
219053322|NCT07025525|OTHER|Sodium Hypochlorite Solution|using sodium hypochlorite (NaOCl) within the canals of primary molars is its excellent antimicrobial and tissue-dissolving properties, which are essential for effective root canal disinfection. Primary molars often have complex and irregular canal systems that harbor bacteria and necrotic tissue. Sodium hypochlorite not only helps eliminate a broad spectrum of microorganisms but also dissolves organic debris, improving canal cleanliness and reducing the risk of post-treatment infection. When used in appropriate concentrations, it can significantly enhance the success of pulpectomy procedures in pediatric patients while maintaining safety.
219053323|NCT07025525|OTHER|Saline|Saline is commonly used as an irrigant in the root canal treatment of primary molars due to its excellent biocompatibility and safety profile. It is a non-toxic, isotonic solution that poses no risk to the surrounding periapical tissues, which is particularly important in primary teeth where root resorption and open apices are common. This minimizes the chance of damaging the underlying permanent tooth germ, a critical consideration in pediatric dentistry. Saline is also safe if accidentally extruded beyond the apex or ingested, making it a suitable choice for young children.
218946478|NCT03463200|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
219206924|NCT06894953|DEVICE|Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.
219635482|NCT01537926|DRUG|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
218946479|NCT03463200|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
218946480|NCT03463200|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
218946481|NCT03504046|DEVICE|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
218946482|NCT00213694|DRUG|docetaxel and celecoxib|
219635483|NCT01537926|DRUG|Placebo|sugar pill manufactured to minic NAC 600mg capsule
219635484|NCT04571905|DEVICE|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
219635485|NCT05988177|DRUG|Carrimycin tablets|Carrimycin tablets are administered 400mg a day orally for 7 days.
218946483|NCT06333600|DRUG|Topical minoxidil|Therapeutic intervention
218946484|NCT06333600|DRUG|Topical Vitamin D|Therapeutic intervention
218946485|NCT06333600|DRUG|Saline spray|placebo
218946486|NCT05094518|BEHAVIORAL|Mobile phone reminders|Appointment reminders in the form of push notifications will be sent through HERA app.
218946487|NCT01875679|OTHER|Comprehensive Surgical Coaching|
218946488|NCT01875679|OTHER|Conventional Surgical Training|Surgical training as per participant's residency program
218946489|NCT02539056|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
218946490|NCT03820440|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
218946491|NCT03820440|DIAGNOSTIC_TEST|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
218946492|NCT04590833|BEHAVIORAL|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
218946493|NCT04590833|BEHAVIORAL|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
218946494|NCT00959400|DRUG|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
218946495|NCT02213406|DIETARY_SUPPLEMENT|yogurt|Subjects will receive yogurt with varying fat concentrations
218946496|NCT02902484|DRUG|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
218946497|NCT02147119|PROCEDURE|Coronary angiography|
218946498|NCT02130102|DEVICE|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
218946499|NCT04493528|COMBINATION_PRODUCT|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
218946500|NCT04493528|COMBINATION_PRODUCT|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
218946501|NCT03137667|OTHER|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
218946502|NCT00022347|DRUG|canfosfamide hydrochloride|
218946503|NCT03948477|DRUG|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
218946504|NCT03948477|DRUG|Placebo|Matched placebo
218946505|NCT02278523|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
218946506|NCT00000590|DRUG|immunoglobulins|
218946507|NCT00324259|DRUG|Estradiol|
218946508|NCT05662800|DIAGNOSTIC_TEST|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
218946509|NCT05253391|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
218946510|NCT01425580|DRUG|liraglutide|1.8 mg s.c. (QD)
218946511|NCT01425580|DRUG|glimepiride|4 mg p.o. (QD)
218946512|NCT01425580|DRUG|Metformin|500 mg p.o. (BID)
218946513|NCT05661747|DEVICE|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
218946514|NCT05214079|DEVICE|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
218946515|NCT02313961|OTHER|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
218946516|NCT02310334|OTHER|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
218946517|NCT02310334|OTHER|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
218946518|NCT03021993|DRUG|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
218946519|NCT04122651|PROCEDURE|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
218946520|NCT04122651|PROCEDURE|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
218946521|NCT05171556|OTHER|Cosmetic product|RV4942A is a face balm product
218946522|NCT03665727|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
218946523|NCT03665727|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
219053324|NCT07023939|DRUG|ART: Atraumatic restorative treatment, SMART: Silver-Modified Atraumatic Restorative Treatment|"ART Group:~Selective caries removal was done using hand instruments-carious dentin was excavated from the axial walls with a spoon excavator, and unsupported enamel was carefully removed using a hatchet. On the pulpal floor, only soft, completely demineralized dentin was removed until firm dentin was reached.~SMART Group:~the surrounding gingival tissues and lips were protected with petroleum jelly to avoid staining and irritation (2) ) one drop of SDF (Advantage Arrest ™, Elevate Oral Care, USA) was placed into a disposable dish, (4) SDF was applied with a bended micro-sponge directly to the affected tooth surfaces for minimum of 60 seconds, (3) excess was blotted with a cotton pellet, (4)and the area was air-dried while maintaining isolation for up to three minutes."
218946524|NCT03665727|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
218946525|NCT00080899|DRUG|fenretinide|Given orally
218946526|NCT00080899|OTHER|laboratory biomarker analysis|Correlative studies
219053325|NCT07023406|BEHAVIORAL|Disfrutando|Disfrutando is a six-week, weekly intervention with a booster intervention at week 12. Intervention content includes glucose control with individual goals, glucose monitoring and glucometer practice, healthy eating demonstrations, benefits of physical activity, prevention and management of T2DM. The intervention has a strong focus on mitigating barriers and challenges to diabetes self-care management.
219053326|NCT07025408|DRUG|KJ101|"1. Clean the wound before applying medication.~2. Apply KJ101 (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
219053327|NCT07025408|DRUG|Chymotrypsin|"1. Clean the wound before applying medication.~2. Apply Chymotrypsin (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
219053328|NCT07025408|DRUG|Placebo (Sodium Chloride Injection 0.9%)|"1. Clean the wound before applying medication.~2. Apply Placebo (Sodium Chloride Injection 0.9%) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
219053329|NCT07024602|DRUG|ASC50 tablets or matching placebo|Drug: ASC50 administered orally Drug: Placebo administered orally
219053330|NCT07025161|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
219053331|NCT07025161|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
218946527|NCT01463085|OTHER|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
218946528|NCT02618070|OTHER|Yogurt|
219053332|NCT07024121|DIAGNOSTIC_TEST|Patient consulting in spine surgery|Self-administered questionnaire quality of life scales
219053333|NCT07023952|PROCEDURE|Laser Treatment|Minimally invasive laser ablation procedure performed under local anesthesia for pilonidal sinus treatment. Laser energy is delivered through a fiber optic probe inserted into the sinus tract to achieve thermal ablation of the sinus cavity.
219053334|NCT07023952|DRUG|Crystallized Phenol|rystallized phenol is applied directly into the pilonidal sinus channels after cleaning and curettage. The phenol remains in contact for a specified duration before being neutralized with normal saline irrigation.
219053335|NCT07025109|BEHAVIORAL|Peer support|Peer support counseling will include phone or text communication to assess goal progress, provide motivational counseling as needed, and to provide social support.
219053336|NCT07025109|BEHAVIORAL|Exercise Prescription|Women will be provided with an exercise prescription (Frequency, Intensity, Time, Type) which may be adjusted weekly for 6 weeks to goal of 150min/week of moderate to vigorous physical activity.
219053337|NCT07025109|BEHAVIORAL|Blood pressure self monitoring|Women will receive a home blood pressure monitor and encourage to record their readings in a log.
219053338|NCT07041021|DIAGNOSTIC_TEST|Respiratory variation of the Internal Jugular Vein (IJV)|In the study group, the fluid therapy will be guided by the respiratory variation (RV) of the Internal Jugular Vein (IJV) throughout surgery. Fluid maintenance will be continued as long as the IJV diameter is less than 2 cm and the IJV RV is more than 18. If the IJV diameter exceeds 2 cm and the IJV RV is less than 18, fluids will be stopped.
219053339|NCT07051486|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
218946529|NCT01462253|DRUG|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
218946530|NCT01163227|DRUG|Placebo (single and multiple doses)|
218946531|NCT01163227|DRUG|AQW051 2 mg (single and multiple doses)|
218946532|NCT01163227|DRUG|AQW051 15mg (single and multiple doses)|
218946533|NCT01163227|DRUG|AQW051 100mg (single dose), and 50mg (multiple doses)|
218946534|NCT02065258|OTHER|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
218946535|NCT02065258|OTHER|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
218946536|NCT02824796|BEHAVIORAL|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
219053340|NCT06751147|OTHER|Group A|"It consists of 24 patients who were assessed by prone knee bend (PKB) test and knee range of motion was measured by goniometer. In addition to traditional physical therapy and muscle energy procedures, patients in this group received neural mobilization. The patient laid on their side with their knee bent to a 90-degree angle and the affected side looking up while neural mobilization was carried out. The therapist then performed the technique by abducting and extending the patient's hip. Five repetitions of the nerve stretch were performed, each with a 10-second hold and a 5-second rest in between.~METs were implemented in two positions using post-isometric relaxation (PIR): In this initial posture, the patient laid on their back with the affected leg just over the bed's edge. With one hand, the physiotherapist stood facing the affected side and pressed the contralateral ASIS to keep the patient from rolling off the bed. The therapist, however, simultaneously grabbed the femur dist"
219053341|NCT06751147|OTHER|Experimental Group B|It involves 24 patients who had received the neural mobilization described above along with traditional physical therapy that does not involve muscular energy techniques. The treatment took place in the outpatient physical therapy department and lasted around thirty minutes in total
219053342|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|For non-squamous NSCLC patients：Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily。 For squamous NSCLC subjects: Docetaxel（75 mg/m² ）or paclitaxel（175 mg/mg） plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily.
219053343|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|Multiple doses of PLB1004 for oral administration. Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks).
219053344|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib . Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks）.
219053345|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib，patients will undergo surgical treatment after 3 cycles of combination therapy with platinum-based chemotherapy. Post-surgery, they will receive an additional cycle of platinum-based chemotherapy followed by 13 cycles of maintenance therapy with PLB1004.
219053346|NCT01752205|DRUG|Paclitaxel|45mg/m2/w,total 6 weeks
219053347|NCT01752205|DRUG|Erlotinib|150mg/d,days 1-42,total 6 weeks
219053348|NCT01752205|RADIATION|Radiation therapy|
219053349|NCT06768918|OTHER|remote physical rehabilitation|In this multisite international study, we feasibility test implementation of 4 different digital solutions for delivering interactive physical rehabilitation during or after systemic anticancer treatment. The contents of the intervention follows international recommendations for exercise during or after treatment for cancer.
219053350|NCT07084935|DEVICE|Connecting all patients to the nociception level index(NOL) and the surgical pleth index (SPI)|All patients will be connected to the NOL and SPI during surgery after induction of general anesthesia.
219053351|NCT07084935|DEVICE|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision.
219053352|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily
219053353|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily. Based on the safety data from the completed dose cohorts, the investigators will involve the selection of 1-2 dose cohorts for further study. Approximately 10 additional subjects will be enrolled in the selected dose expansion cohort to determine the recommended dose for Phase II clinical trials.
219053354|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|RP2D of Vebreltinib as determined during Phase Ib oral twice daily combined with Furmonertinib 80mg oral once daily
219206925|NCT06894953|DEVICE|Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.
219206926|NCT06892964|GENETIC|Genetic profiling of all eligible patients|Performed genetic profiling in DNA extracted from fresh tissue or FFPE in all patients affected by lymphatic malformation recruited
219206927|NCT06750692|OTHER|Procedure: Mirror therapy|The first group of participants will receive a total of 20 sessions of upper extremity mirror therapy program, 5 sessions per week for 4 weeks.
219635486|NCT03028688|DEVICE|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
218946537|NCT02824796|BEHAVIORAL|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
218946538|NCT02106858|DRUG|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
218946539|NCT00882297|PROCEDURE|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
218946540|NCT01125488|DEVICE|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
218946541|NCT01125488|DRUG|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
219635487|NCT02175511|DEVICE|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
219635488|NCT06070142|PROCEDURE|TEP Group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
219635489|NCT06070142|PROCEDURE|eTEP Group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
219635490|NCT00149344|RADIATION|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
219635491|NCT04429789|BEHAVIORAL|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
218946542|NCT05243732|BEHAVIORAL|Mindful Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness."
218946543|NCT05243732|BEHAVIORAL|Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given"
218946544|NCT01481194|DRUG|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
218946545|NCT01481194|DRUG|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
218946546|NCT01481194|DRUG|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
218946547|NCT01481194|DRUG|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
218946548|NCT01481194|DRUG|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
218946549|NCT03881527|DEVICE|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
218946550|NCT03881527|PROCEDURE|aortic valve replacement|Aortic valve replacement in a standard fashion
218946551|NCT04961411|PROCEDURE|operation or non-operative treatment|type of operation or if possible non-operative treatment
218946552|NCT00787267|DRUG|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
218946553|NCT04343235|DRUG|furosemide|five day course of furosemide 20mg QD
218946554|NCT04343235|DRUG|labetalol|200mg labetalol BID
218946555|NCT05176171|PROCEDURE|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
219635492|NCT04429789|BEHAVIORAL|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
219635493|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
219635494|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
218946556|NCT05085301|DIAGNOSTIC_TEST|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
218946557|NCT04363541|DEVICE|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
218946558|NCT00755300|PROCEDURE|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
218946559|NCT05427877|DEVICE|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
218946560|NCT00123669|DRUG|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
218946561|NCT06341985|RADIATION|Exclusive radiotherapy|Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
218946562|NCT00990418|DRUG|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
218946563|NCT00199043|DRUG|Allopurinol|
218946564|NCT00199043|DRUG|Rasburicase|
218946565|NCT05261529|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
219053355|NCT07086846|OTHER|Night splint|All participants will be treated conservatively by wrist splint in a neutral position.
219635495|NCT04129957|PROCEDURE|Placement of dental implants|All the included patients underwent the placement of at least one implant in either upper jaw, or lower jaw, or both.
219635496|NCT00735813|DEVICE|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
219053356|NCT07086846|OTHER|Myofascial release technique|The participant will receive myofascial release using M2T blade. It will be applied on the carpal tunnel over and above the wrist creases on the ventral aspect of the forearm for 15 minutes, 3 sessions weekly for 6 weeks (total of 18 sessions).
218946566|NCT05261529|BEHAVIORAL|Physical Exercise Program|Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
218946567|NCT05291715|DEVICE|Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)|Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
219053357|NCT07086846|OTHER|Acupressure|"It will be applied on the pericardium 6 point (PC-6) for 3 minutes, three times per week for 6 weeks (total of 18 sessions).~It is located on the palm side of the wrist a couple of inches toward the body in between the two tendons (palmaris longus \& flexor carpi radialis) that run approximately down the center of the forearm."
219053358|NCT07086846|OTHER|Home advice|The participants will be asked to follow important advices like supporting the wrists during activity and ensuring proper posture, avoiding wrist flexion and extension, avoiding hard clutches, holding or carrying objects for a long time, catching with fingers, repetitive hand and wrist movement such as knitting or sewing, driving, activities and hobbies such as golf, tennis, table tennis.
219053359|NCT07084766|PROCEDURE|ultrasonography, pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
219053360|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 1|DHA Origins 550-Y oil (Fermentalg)
219053361|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 2|Oleo H-02 (Microalgas)
219053362|NCT07086573|DIETARY_SUPPLEMENT|Fish oil (control)|Tuna oil
218946568|NCT03114852|DIAGNOSTIC_TEST|blood collection|They will have blood tested to renal genetic diseases
218946569|NCT03620461|DRUG|Gemcitabine - nabpaclitaxel|efficacy and safety
218946570|NCT00708487|OTHER|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
218946571|NCT03976648|DRUG|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
218946572|NCT02605460|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
219053363|NCT07085910|DEVICE|Transcranial magnetic stimulation - dual coil|The dual coil stimulation will be applied using two MagPro X100 stimulators connected to two vertically oriented figure-of-eight coils designed for bilateral hemispheric stimulation.
219053364|NCT07085910|DEVICE|Transcranial magnetic stimulation|Single coil TMS will be performed using a TMS stimulator and the same stimulation coil (MC-B65-HO).
219053365|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
219053366|NCT04839705|DEVICE|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
219053367|NCT06864819|OTHER|Blood Draw|Patients will have a single blood sample sent for PEth testing, blood draws will happen during standard of care blood draw.
219053368|NCT06908603|OTHER|Survey using a questionnaire.|The online, self-administered, 16-item questionnaire included several question styles (yes/no questions, closed-ended, multiple choice questions, and statements with Likert scale responses). The questionnaire was adapted from several published AI surveys . Questions were designed to assess three primary areas: AI knowledge, perceptions of AI integration into practice and challenges in implementing AI in the OR practice in Egypt.
219053369|NCT06908811|DIETARY_SUPPLEMENT|Novel Plant Protein Blend|Novel plant protein blend containing 30 grams of protein.
219053370|NCT06908811|DIETARY_SUPPLEMENT|Pea/Rice Protein Blend|Pea/Rice protein blend containing 30 grams of protein
219053371|NCT06908811|DIETARY_SUPPLEMENT|Whey Protein|Whey concentrate protein blend containing 30 grams of protein
219635497|NCT00735813|DEVICE|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
219635498|NCT06149611|DRUG|[14C] TQB3616|TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
218946573|NCT02605460|DRUG|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
218946574|NCT02605460|DRUG|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
218946575|NCT02605460|PROCEDURE|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
218946576|NCT02980575|OTHER|Music|
218946577|NCT02980575|OTHER|Exercise|
218946578|NCT01282580|DIETARY_SUPPLEMENT|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
219053372|NCT06908811|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Maltodextrin placebo
219053373|NCT07085104|GENETIC|ALLO-329|An allogeneic CAR T cell therapy targeting CD19 and CD70
219053374|NCT07085104|DRUG|Cyclophophamide|Chemotherapy for lymphodepletion
218946579|NCT01282580|OTHER|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
218946580|NCT00881868|DRUG|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
218946581|NCT00881868|DRUG|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
218946582|NCT04947852|DEVICE|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
218946583|NCT04947852|DEVICE|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
218946584|NCT00115583|DRUG|Drug Infusion (BQ-123)|
218946585|NCT01981551|DRUG|PF-03084014|Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
218946586|NCT03255083|DRUG|DS-1205c|DS-1205c 200 mg capsule
218946587|NCT03255083|DRUG|Osimertinib|Osimertinib 80 mg tablet
218946588|NCT03144609|PROCEDURE|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
218946589|NCT03144609|PROCEDURE|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
218946590|NCT03144609|PROCEDURE|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
218946591|NCT01046409|OTHER|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
218946592|NCT00439816|BEHAVIORAL|Group Visits|
218946593|NCT05926115|DIAGNOSTIC_TEST|Diagnostic Ultrasound|During the initial visit, a transvaginal or transabdominal pelvic ultrasonography will be performed in all participants, based on the sexual history and consent form by trained gynecologists who are part of study investigators. A transvaginal ultrasound is the accepted and validated method to assess the ovarian morphology in the study of patients with PCOS.
218946594|NCT05926115|DIAGNOSTIC_TEST|Venous puncture|After an overnight fast of at least 6 hours (ideally), a 18 ml sample of venous blood will be collected from each study participant (i.e., the basal fasting sample). About 12 ml of the venous blood will be collected in plain tubes for serum cryopreservation and subsequent analysis, and the remainder in plain tubes for immediate glucose estimation in serum.
218946595|NCT00296205|DRUG|Cyclophosphamide|
218946596|NCT04874051|DEVICE|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
218946597|NCT04874051|OTHER|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
218946598|NCT04963985|DRUG|Tafamidis Pill|Oral
218946599|NCT00960570|DRUG|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
218946600|NCT00960570|DRUG|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
218946601|NCT00960570|DRUG|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
218946602|NCT00602199|DRUG|ABT-510|
218946603|NCT00602199|OTHER|immunoenzyme technique|
218946604|NCT00602199|OTHER|immunohistochemistry staining method|
218946605|NCT00602199|OTHER|laboratory biomarker analysis|
218946606|NCT00602199|OTHER|pharmacological study|
218946607|NCT00602199|PROCEDURE|biopsy|
218946608|NCT01451437|DRUG|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
218946609|NCT06811376|BEHAVIORAL|Spiritual Care Intervention #1|Experimental
218946610|NCT06811376|OTHER|Spiritual Care Intervention #2|Active Comparator
218946611|NCT06654531|DRUG|Dexmedetomidine|"Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2"
218946612|NCT00824837|OTHER|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
218946613|NCT00824837|OTHER|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
218946614|NCT01252732|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
218946615|NCT01252732|DRUG|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
218946616|NCT02220088|PROCEDURE|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
218946617|NCT02220088|DRUG|Sorafenib|Accept sorafenib.
218946618|NCT03894007|DRUG|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
218946619|NCT03894007|DRUG|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
218946620|NCT03894007|DRUG|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
218946621|NCT03894007|DRUG|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
218946622|NCT03894007|DRUG|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
218946623|NCT03894007|DRUG|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
219053375|NCT06909552|OTHER|Educational Video on Voiding Dysfunction|The educational video is a short 3-minute video which describes the condition in detail, at the level that a parent or child could understand without a medical background.
218946624|NCT03894007|DRUG|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
218946625|NCT03894007|DRUG|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
218946626|NCT03894007|DRUG|Paclitaxel|80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
218946627|NCT03219775|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
218946628|NCT00324597|DRUG|gemcitabine hydrochloride|
218946629|NCT00324597|DRUG|motesanib diphosphate|
218946630|NCT00324597|OTHER|pharmacological study|
218946631|NCT06335004|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients will undergo a magnetic resonance imaging for clinical purposes to which additional sequences. Post gadolinium research sequences will be acquired only if intravenous gadolinium needs to be administered for clinical purposes.
219053376|NCT06526390|PROCEDURE|f-URS|f-URS with S-UAS
219053377|NCT06526390|PROCEDURE|mini-PCNL|mini-PCNL
219053378|NCT06905873|DRUG|FB102|Route of administration- Intravenous (IV)
219053379|NCT06905873|DRUG|Placebo|Route of administration- Intravenous (IV)
219053380|NCT06646458|OTHER|Healthy Elderly Volunteers|Take the elderly milk power 2 times every day up to 28 days
219053381|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be standard of care protocols
219053382|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
219053383|NCT06909630|OTHER|Driving pressure group|individual PEEP
219053384|NCT06909123|DRUG|Cabergoline|Cabergoline
219206928|NCT06750692|DEVICE|Device: Low Frequency rTMS Protocol|Repetitive Transcranial Magnetic Stimulation (rTMS) will be applied at an intensity of 100-110% of the resting motor threshold and low frequency (1 Hz) to the contralateral M1 upper extremity motor cortex region for a total of 20 sessions, 5 sessions per week for 4 weeks. rTMS application is planned to provide magnetic stimulation with the stimulator of the Magventure MagPro R30 device.
218946632|NCT03939741|BIOLOGICAL|SVF Containg Autologous Non Expanded ADSC|5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.
219053385|NCT06908993|DRUG|Tepotinib|Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.
219053386|NCT06908993|DRUG|Pemetrexed (Alimta)|500 mg/m² every 3 weeks
219053387|NCT06908993|DRUG|Vinorelbine|25-30 mg/m² D1, D8, every 3 weeks
219053388|NCT06908993|DRUG|Gemcitabine alone|1250 mg/m² D1, D8, every 3 weeks
219053389|NCT06908993|DRUG|Docetaxel|75 mg/m² every 3 weeks
219053390|NCT06908993|DRUG|Paclitaxel|90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks
219053391|NCT06908993|DRUG|Pembrolizumab|200 mg every 3 weeks
219053392|NCT06908993|DRUG|Nivolumab|240 mg every 2 weeks
219053393|NCT06908993|DRUG|Atezolizumab|1200 mg every 3 weeks
219053394|NCT06908733|DRUG|3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.|Patients deemed eligible to surgery will receive standard lung cancer resection (excluding total pneumonectomy)
218946633|NCT01305798|OTHER|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
218946634|NCT03339154|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
218946635|NCT00630383|BIOLOGICAL|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
218946636|NCT00630383|OTHER|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
218946637|NCT05364359|DIETARY_SUPPLEMENT|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
218946638|NCT05364359|OTHER|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
219053395|NCT06908148|DEVICE|Electrolysed water|Electrolysed water is a novel antiseptic produced by passing an electric current through a mixture of tap water and salt. Microbiocidal activity is due to the presence of hypochlorous acid at neutral Ph. Irrigation of chronic wounds reduces bacterial load and appears to encourage wound healing. We propose to compare electrolysed water against conventional management.
218946639|NCT06435897|BIOLOGICAL|fetal MSCs combined with 4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
218946640|NCT06936631|PROCEDURE|Catheter replacement|"In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule.~The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results."
218946641|NCT06936631|PROCEDURE|Catheter retainment|In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule. The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results.
218946642|NCT07146204|DEVICE|Robotic-assisted percutaneous coronary intervention|Patients with coronary artery disease will be treated usiing the R-Star robotic system for a robotic-assisted percutaneous coronary intervention
218946643|NCT06943287|BEHAVIORAL|Pharmacist Intervention|If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
218946644|NCT02635425|PROCEDURE|7 eggs collection|vaginal US
218946645|NCT02635425|PROCEDURE|Full eggs collection|vaginal US
218946646|NCT04236141|DRUG|Polatuzumab Vedotin|Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
218946647|NCT04236141|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
218946648|NCT04236141|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
218946649|NCT04236141|DRUG|Placebo|Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
218946650|NCT06448767|DIETARY_SUPPLEMENT|Multispecies probiotics|Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.
218946651|NCT06448767|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotics.
218946652|NCT00449397|DRUG|Quetiapine Fumarate|
219053396|NCT06908148|DEVICE|Conventional irrigant|The irrigant (Prontosan™) that is currently 'in-use' in the conventional management of diabetic foot wounds
219053397|NCT06466005|OTHER|UnityPhilly app|UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
219206929|NCT06750692|DEVICE|Robotic-assisted hand therapy|In the Robot Assisted Therapy group, a total of 20 sessions will be applied 5 days a week for 4 weeks using continuous passive range of motion, active assistive exercise and play therapy programs for hemiplegic upper extremities with AMADEO (Tyromotion Austria).
219206930|NCT06895356|DRUG|Tavapadon|Oral: Tablet
219635499|NCT01435304|DEVICE|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
219635500|NCT06211686|OTHER|Protein powder and Resistance exercise|"1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week"
218946653|NCT03198065|PROCEDURE|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
218946654|NCT03198065|PROCEDURE|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
218946655|NCT04304599|DEVICE|LoFric Elle|The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
218946656|NCT01948193|BIOLOGICAL|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
218946657|NCT03130647|DEVICE|Focused ultrasound|Focused ultrasound
218946658|NCT05055284|OTHER|Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.|Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
218946659|NCT00545870|DRUG|bevacizumab|intravitreal application
218946660|NCT00545870|DRUG|Ranibizumab|intravitreal application
218946661|NCT01794338|DEVICE|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
218946662|NCT01794338|DEVICE|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
218946663|NCT03196609|BIOLOGICAL|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
218946664|NCT02108340|PROCEDURE|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
218946665|NCT06242353|DIAGNOSTIC_TEST|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
218946666|NCT01954927|DRUG|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
218946667|NCT01954927|DRUG|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
218946668|NCT03320824|DEVICE|New Dermal Filler|hyaluronic acid
218946669|NCT03320824|DEVICE|Device: FDA Approved Dermal Filler|hyaluronic acid
218946670|NCT00955305|BIOLOGICAL|Bevacizumab|Given IV
218946671|NCT00955305|DRUG|Carboplatin|Given IV
218946672|NCT00955305|BIOLOGICAL|Cixutumumab|Given IV
218946673|NCT00955305|DRUG|Paclitaxel|Given IV
218946674|NCT00491088|DEVICE|CPAP|CPAP for 12 weeks
218946675|NCT02270996|OTHER|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
218946676|NCT02606942|OTHER|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
218946677|NCT03387111|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
218946678|NCT03387111|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
218946679|NCT03387111|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
218946680|NCT03387111|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
218946681|NCT03387111|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
218946682|NCT03387111|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
218946683|NCT03387111|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
218946684|NCT03387111|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
218946685|NCT03387111|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
218946686|NCT03387111|DRUG|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
218946687|NCT03387111|DRUG|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
218946688|NCT03387111|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
218946689|NCT03387111|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
218946690|NCT03387111|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
218946691|NCT03387111|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
218946692|NCT03387111|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
218946693|NCT03387111|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
218946694|NCT03387111|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
218946695|NCT03387111|DRUG|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
218946696|NCT03387111|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
218946697|NCT03387111|BIOLOGICAL|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
218946698|NCT01180179|DRUG|Lansoprazole|30mg once daily
218946699|NCT01180179|DRUG|Famotidine|40mg once daily
218946700|NCT00594945|DRUG|Clonazepam|1 Dose
218946701|NCT02412813|DEVICE|LEGION OXINIUM|Investigational Group
218946702|NCT02412813|DEVICE|LEGION Cobalt Chrome|Control Group
218946703|NCT03254108|DRUG|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
218946704|NCT03254108|DRUG|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
218946705|NCT03254108|DRUG|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
218946706|NCT03254108|DRUG|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
218946707|NCT03254108|DRUG|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
218946708|NCT00813540|BEHAVIORAL|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
218946709|NCT00813540|OTHER|Usual Care|Usual Care
218946710|NCT02108015|PROCEDURE|Brain Imaging (PET)|
218946711|NCT02108015|PROCEDURE|Aterial Line|
218946712|NCT02108015|PROCEDURE|Blood Sampling|
218946713|NCT03459391|DRUG|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
218946714|NCT03459391|DRUG|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
218946715|NCT03459391|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
218946716|NCT00588159|DRUG|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
218946717|NCT00588159|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
218946718|NCT05909800|DRUG|Phenofibrate|Administred orally, once daily, for 12 months.
218946719|NCT05909800|DRUG|Placebo|Administred orally, once daily, for 12 months.
218946720|NCT03800394|OTHER|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
218946721|NCT02610504|DEVICE|Durolane|single injection of 3ml
218946722|NCT02735824|PROCEDURE|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
218946723|NCT02735824|PROCEDURE|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
218946724|NCT02735824|PROCEDURE|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
218946725|NCT03219710|DRUG|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
218946726|NCT03219710|DRUG|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
218946727|NCT03219710|DRUG|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
218946728|NCT03219710|DRUG|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
218946729|NCT00894959|BIOLOGICAL|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
218946730|NCT00894959|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
218946731|NCT00995033|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
218946732|NCT00995033|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
218946733|NCT00995033|DRUG|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
218946734|NCT03698344|OTHER|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
218946735|NCT01801371|DRUG|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
218946736|NCT02438358|DRUG|LUM015|
219053398|NCT06908798|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
219053399|NCT06909097|BEHAVIORAL|Sitting breaks|Participants will take 2 minute physical movement breaks throughout a sedentary work day.
219053400|NCT06908291|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of breat tomor and Ipsilateral axillary lymph nodes, in addition to real-time 2D PA/US imaging.
219053401|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
219053402|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
219053403|NCT06907134|BEHAVIORAL|Smartphone delivered internet-based Cognitive Behavioural Therapy|The intervention is 9 week long were partipants use an smartphone app based on CBT-principles with while having access to an internet platform where extra working material and therapist support is available on demand.
219053404|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
219053405|NCT02285751|DRUG|acetylsalicylic acid|
219053406|NCT02285751|DRUG|clopidogrel|
219053407|NCT02285751|DRUG|prasugrel|
218946737|NCT02438358|DEVICE|LUM 2.6 Imaging Device|
218946738|NCT00317291|PROCEDURE|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
218946739|NCT00317291|OTHER|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
218946740|NCT05898997|BEHAVIORAL|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
218946741|NCT01661842|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
218946742|NCT01661842|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
218946743|NCT02397018|BIOLOGICAL|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
219053408|NCT02285751|DRUG|ticagrelor|
219053409|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
219053410|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
219053411|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
219053412|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
219053413|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
219053414|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
218946744|NCT00923949|DRUG|Pioglitazone|45 mg tablet daily by mouth for six weeks
219053415|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
219053416|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
219053417|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
219053418|NCT04944342|OTHER|No intervention.|No intervention.
218946745|NCT00490529|BIOLOGICAL|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
218946746|NCT00490529|BIOLOGICAL|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
218946747|NCT00490529|PROCEDURE|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
218946748|NCT00490529|PROCEDURE|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
218946749|NCT00490529|DRUG|Rituximab|375 mg/m² by infusion
218946750|NCT00490529|DRUG|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
218946751|NCT00490529|DRUG|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
218946752|NCT00490529|DRUG|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
218946753|NCT00862797|OTHER|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
218946754|NCT03254459|DRUG|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
218946755|NCT03254459|DRUG|Morphine|4 mg Intravenous Injection
218946756|NCT03254459|DRUG|Oxycodone Hydrochloride|10 mg tablet
218946757|NCT03254459|DRUG|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
218946758|NCT00265356|PROCEDURE|PET diagnostic imaging|PET diagnostic imaging
218946759|NCT02329340|BEHAVIORAL|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
218946760|NCT02329340|BEHAVIORAL|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
218946761|NCT00727441|BIOLOGICAL|GVAX pancreatic cancer vaccine|Given intradermally
218946762|NCT00727441|DRUG|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
218946763|NCT03038477|DRUG|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
218946764|NCT04837352|OTHER|Study of the role of sociocognitive factors|Questionnaires
218946765|NCT00535288|DRUG|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
218946766|NCT00535288|DRUG|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
218946767|NCT06505733|BEHAVIORAL|postnatal attendant training|"Intervention Group: Training and counselling will be provided to the puerperant and companions before discharge in a quiet and stimulus-free environment using the Companion Training Guide. Research data will be collected three times: pre-test data, after the training and on the tenth day."
218946768|NCT00965640|DRUG|Botulinum Toxin - A injections|
219053419|NCT03921268|DRUG|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
218946769|NCT04549402|OTHER|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
218946770|NCT04549402|OTHER|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
218946771|NCT02480140|OTHER|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
219053420|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
219053421|NCT06739915|OTHER|TUTT-PT Intervention|All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
219053422|NCT04320160|PROCEDURE|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
218946772|NCT02480140|OTHER|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
218946773|NCT02480140|OTHER|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
218946774|NCT05279391|DRUG|Dexamethasone|Dexamethasone 6-8 mg once daily
218946775|NCT05279391|DRUG|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
218946776|NCT05279391|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
218946777|NCT05279391|DRUG|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
219053423|NCT04320160|PROCEDURE|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
219053424|NCT00593372|BEHAVIORAL|Spaced Retrieval Training|Increasing time to remember important information.
219053425|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
218946778|NCT05279391|DRUG|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
218946779|NCT05279391|DRUG|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
218946780|NCT02923024|BEHAVIORAL|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
218946781|NCT02102711|DIETARY_SUPPLEMENT|Vitamin A oral drops|
218946782|NCT00796887|DRUG|Extended-Release Niacin|500mg tablet once daily
218946783|NCT00796887|DRUG|Extended-Release Niacin|1000mg tablet once daily
218946784|NCT00796887|DRUG|Placebo|Placebo tablet once daily
218946785|NCT02776748|DRUG|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
219053426|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
219053427|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
218946786|NCT06515535|DRUG|Topical tranexamic acid|Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%
218946787|NCT06515535|DRUG|Intravenous tranexamic acid|Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
218946788|NCT04925154|BEHAVIORAL|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
218946789|NCT02333864|DEVICE|POGO® BGMS|SMBG
219053428|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
219053429|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
219053430|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
219053431|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
219635501|NCT06578325|OTHER|Thai dance meditation|Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
219635502|NCT06578325|OTHER|No intervention|No intervention
219635503|NCT03646864|DRUG|ACT-541468|ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.
219635504|NCT03646864|OTHER|Placebo|Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.
219635505|NCT06237530|BEHAVIORAL|Visceral body scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord \& Garfinkel, 2022)
219635506|NCT06237530|BEHAVIORAL|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
219635507|NCT06237530|BEHAVIORAL|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment.
219635508|NCT02641418|OTHER|Supervised exercise programme|supervised exercise programme
219635509|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
219635510|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
219635511|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 1g|
218946790|NCT02879331|PROCEDURE|10 coils in upper lobes|
218946791|NCT02879331|PROCEDURE|15 coils in upper and lower lobes|
218946792|NCT02879331|PROCEDURE|cycloergometry|
219635512|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 5g|
219635513|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 10g|
219635514|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 15g|
219635515|NCT02260336|DRUG|Celecoxib Capsule 400 mg daily|
219635516|NCT05750602|DIETARY_SUPPLEMENT|LIMICOL|Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
219635517|NCT05750602|DIETARY_SUPPLEMENT|PLACEBO|Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
219635518|NCT00002435|DRUG|Thymic Humoral Factor|
219635519|NCT00002435|DRUG|Zidovudine|
219635520|NCT01732458|DRUG|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
219635521|NCT01732458|DRUG|Placebo to Aprepitant|
219635522|NCT01732458|DRUG|Ondansetron|Administered IV at a dose of 4 mg for participants \>40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants \<1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
219635523|NCT01732458|DRUG|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
219635524|NCT05517668|DRUG|Intravenous infusion of N-acetylcysteine|If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
218946793|NCT04348227|BEHAVIORAL|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
218946794|NCT04811300|OTHER|There is no intervention|There is no intervention
218946795|NCT02600871|DRUG|Provodine|
218946796|NCT02600871|PROCEDURE|Incision and Drainage|
218946797|NCT00204438|DRUG|0.15mg desogestrel /0.03mg ethinyl estradiol|
218946798|NCT04492215|BEHAVIORAL|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
218946799|NCT02363023|PROCEDURE|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
218946800|NCT03515291|BIOLOGICAL|iMP cells|Immunomodulatory progenitor cells
218946801|NCT03515291|OTHER|Control injection|Cell suspension solution
218946802|NCT04743570|DRUG|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
218946803|NCT04743570|DRUG|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
218946804|NCT03537469|DEVICE|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
219053432|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
219053433|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
219053434|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
219053435|NCT02932891|DRUG|DSXS topical|topical treatment
219053436|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
219053437|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
218946805|NCT03537469|DEVICE|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
219053438|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
218946806|NCT01263912|DIETARY_SUPPLEMENT|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
218946807|NCT01263912|DIETARY_SUPPLEMENT|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
218946808|NCT05269121|BIOLOGICAL|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
218946809|NCT04868630|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
218946810|NCT03787381|DEVICE|Ultrasound|Vaginal ultrasound examination
218946811|NCT00057980|DRUG|celecoxib|
218946812|NCT00057980|DRUG|epirubicin hydrochloride|
218946813|NCT01466257|BIOLOGICAL|cetuximab|
218946814|NCT01466257|DRUG|cisplatin|
218946815|NCT01466257|GENETIC|DNA analysis|
218946816|NCT01466257|GENETIC|gene expression analysis|
218946817|NCT01466257|GENETIC|mutation analysis|
218946818|NCT01466257|OTHER|laboratory biomarker analysis|
218946819|NCT02050178|DRUG|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
218946820|NCT00083252|DRUG|talabostat (PT-100) tablets|
218946821|NCT00083252|DRUG|cisplatin|
218946822|NCT02604121|DEVICE|Orcellex® Rovers brush|transepithelial brushing
218946823|NCT05449483|DRUG|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
218946824|NCT04507373|DRUG|Simvastatin 40mg|40mg oral daily for 10 weeks
218946825|NCT02565134|DRUG|PAC-14028 cream 0.1%|Topical application
218946826|NCT02565134|DRUG|PAC-14028 cream 0.3%|Topical application
219053439|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
218946827|NCT02565134|DRUG|PAC-14028 cream 1.0%|Topical application
218946828|NCT02565134|DRUG|PAC-14028 cream vehicle|Topical application
218946829|NCT01049945|DRUG|bendamustine hydrochloride|Given IV
218946830|NCT01049945|DRUG|lenalidomide|Given orally
218946831|NCT01049945|DRUG|dexamethasone|Given orally or IV
218946832|NCT03660085|BEHAVIORAL|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
218946833|NCT04963842|BEHAVIORAL|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
219053440|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
219053441|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
219053442|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
219635525|NCT05517668|DRUG|Intravenous infusion of Fomepizole (4-MP)|If randomized to fomepizole, the proposed infusion schedule for fomepizole closely mirrors the dosing outlined in the medication's package insert. Specifically, the Antizol (fomepizole) doses (bags) #1-5 allocated for the study will precisely adhere to the manufacturer's recommendations from the package insert. This entails an initial loading dose of 15 mg/kg followed by four subsequent doses of 10 mg/kg. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency.
219635526|NCT00880113|PROCEDURE|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
219635527|NCT01368705|DIETARY_SUPPLEMENT|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
219635528|NCT01368705|DIETARY_SUPPLEMENT|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
219635529|NCT01368705|DIETARY_SUPPLEMENT|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
219635530|NCT05724251|OTHER|healthy|no intervention
219635531|NCT05724251|OTHER|periodontitis|no intervention
219635532|NCT06574594|DRUG|Methotrexate|methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
219635533|NCT06574594|DRUG|Methotrexate|methotrexate continuation group : keep methotrexate
219635534|NCT02639650|DRUG|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
219635535|NCT02639650|DRUG|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
219635536|NCT02639650|DRUG|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
219635537|NCT02639650|DRUG|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
219635538|NCT02639650|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
219635539|NCT02639650|DRUG|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
219635540|NCT02639650|DRUG|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
219635541|NCT02639650|DRUG|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
219635542|NCT00461773|DRUG|Letrozole|Letrozole 2.5 mg po qd
219635543|NCT00461773|DRUG|Bevacizumab|bevacizumab 10 mg/kg IV
219635544|NCT05538364|BIOLOGICAL|platelet rich plasma injection|Platelet rich plasma will be injected to the epidural space under light sedation using target-controlled infusion of propofol to an effect site concentration of between 0.5 to 1.5mcg/ml.
219635545|NCT05960916|PROCEDURE|Densah® burs|Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.
218946834|NCT04259723|OTHER|VR during TAVI|Virtual Reality (VR) glasses
219635546|NCT05960916|PROCEDURE|Conventional Burs|Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
219635547|NCT01377350|DEVICE|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
219635548|NCT01377350|DEVICE|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
219053443|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
219053444|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
218946835|NCT00830869|DRUG|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
219053445|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
219053446|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
219053447|NCT02977949|DRUG|Raloxifene|
219206931|NCT03795311|DRUG|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
219206932|NCT06741488|OTHER|no intervention|Exercise Adaptation Rating Scale
218946836|NCT06255366|DRUG|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
218946837|NCT06255366|DRUG|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
218946838|NCT06255366|DRUG|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
218946839|NCT05150639|OTHER|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
218946840|NCT01767831|BEHAVIORAL|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
218946841|NCT04704804|DIAGNOSTIC_TEST|Synthetic CT Scan|method of generating CT-synthetic image from MRI
218946842|NCT01185431|DIETARY_SUPPLEMENT|Ficus carica (Fig paste)|Ficus carica paste 300g/day
218946843|NCT01185431|DIETARY_SUPPLEMENT|Placebo (Placebo paste)|Placebo composition 300g/day
219635549|NCT00638222|OTHER|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
219635550|NCT00092625|DRUG|MK0653, ezetimibe|
219635551|NCT00092625|DRUG|Comparator: ezetimibe, placebo|
219635552|NCT00478803|PROCEDURE|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
219635553|NCT00478803|DEVICE|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
218946844|NCT03283410|DRUG|Propofol|Propofol plasmatic concentration (Marsh)
218946845|NCT02210598|DEVICE|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
218946846|NCT02210598|DEVICE|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
218946847|NCT02210598|DRUG|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
218946848|NCT01594437|BIOLOGICAL|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
218946849|NCT01594437|BIOLOGICAL|Placebo|One or two doses administered by intravenous infusion.
218946850|NCT05184751|OTHER|colonoscopy|
218946851|NCT03674931|BEHAVIORAL|musical practice|Intensive weekly musical keyboard training over 12 months
218946852|NCT03674931|BEHAVIORAL|music education|Recreative weekly musical courses without practice over 12 months
218946853|NCT03745820|DRUG|BIIB104|Administered as specified in the treatment arm
218946854|NCT03745820|OTHER|Placebo|Administered as specified in the treatment arm
218946855|NCT02697669|OTHER|18F-FDG PET|Imaging
218946856|NCT04829578|OTHER|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
218946857|NCT06484205|OTHER|WHO QualityRights e-training|WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.
218946858|NCT06484205|OTHER|Emotional intelligence e-training|This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
219053448|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
219053449|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
219053450|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
219053451|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
219053452|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
219053453|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
219053454|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
219053455|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
219053456|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
219053457|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
219053458|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
218946859|NCT03960450|DRUG|BOS-475|topical cream
218946860|NCT03960450|DRUG|Vehicle|topical cream
218946861|NCT05512468|DRUG|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
218946862|NCT05657522|DEVICE|Rapid molar intruder|The rapid molar intruder was applied.
218946863|NCT01528865|DRUG|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
218946864|NCT01528865|DRUG|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
218946865|NCT03878693|DRUG|Fomepizole|IV 4-MP.
218946866|NCT03878693|DRUG|APAP|Oral APAP
218946867|NCT00507728|DRUG|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
218946868|NCT00507728|DRUG|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
218946869|NCT00507728|DRUG|Placebo|Placebo by mouth for 12 weeks.
218946870|NCT00507728|BEHAVIORAL|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
218946871|NCT03121651|DEVICE|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
218946872|NCT04590742|DRUG|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
218946873|NCT04590742|DRUG|Placebo|Patient given 6 weeks of placebo tablet
218946874|NCT03467100|DRUG|XEN901|Capsule filled with XEN901
218946875|NCT03467100|DRUG|Inert Ingredients Oral Product|Placebo capsule
218946876|NCT05469698|BEHAVIORAL|Tobacco Treatment Research Program Standard Care|Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
218946877|NCT06240767|BIOLOGICAL|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
218946878|NCT03680742|DEVICE|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
218946879|NCT06190054|DEVICE|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
218946880|NCT04023929|PROCEDURE|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
218946881|NCT00425178|DRUG|FGF-1|
218946882|NCT03393533|PROCEDURE|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
218946883|NCT03393533|PROCEDURE|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
219053459|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
219053460|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
218946884|NCT00136383|DRUG|paroxetine versus duloxetine|
218946885|NCT02384915|DRUG|prilocaine|
218946886|NCT02384915|DRUG|mepivacaine|
218946887|NCT02384915|PROCEDURE|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
218946888|NCT02384915|PROCEDURE|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
218946889|NCT02384915|DEVICE|Sonoplex, Pajunk|
218946890|NCT00586781|DEVICE|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
218946891|NCT01533740|DRUG|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
219053461|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
219053462|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
219053463|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
219053464|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
219053465|NCT05378386|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
219053466|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
218946892|NCT00035113|DRUG|epothilone b|
218946893|NCT05546203|OTHER|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
218946894|NCT05546203|DEVICE|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
218946895|NCT05546203|BEHAVIORAL|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
218946896|NCT04787419|OTHER|placebo|saccharum lactis
218946897|NCT04787419|COMBINATION_PRODUCT|probiotics|Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
218946898|NCT04010578|DIETARY_SUPPLEMENT|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
218946899|NCT04010578|OTHER|Placebo|Patients will receive a placebo each day.
218946900|NCT01410357|BEHAVIORAL|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
218946901|NCT03590964|PROCEDURE|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
218946902|NCT03590964|PROCEDURE|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
218946903|NCT00615901|DRUG|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
218946904|NCT01809587|DEVICE|IQP-PO-101|
218946905|NCT03598114|BEHAVIORAL|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
218946906|NCT02842034|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
218946907|NCT04972045|DRUG|CuminUP60®|4 capsules, 400 mg / capsule
218946908|NCT04972045|DRUG|Curcumin capsules|4 capsules, 400 mg / capsule
219635554|NCT02887248|DRUG|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
219635555|NCT02887248|DRUG|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
219635556|NCT00119717|DEVICE|NeuroFlo™ catheter|45 minute treatment
218946909|NCT01324518|DRUG|ORM-12741|60mg twice a day
218946910|NCT01324518|DRUG|ORM-12741|200mg twice a day
218946911|NCT01324518|DRUG|Placebo for ORM-12741|Placebo twice a day
218946912|NCT01561703|DRUG|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
218946913|NCT06390072|BEHAVIORAL|Self-Hypnosis|Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
218946914|NCT06390072|BEHAVIORAL|Ankle Education|Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
218946915|NCT04135586|OTHER|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
218946916|NCT04135586|OTHER|Control|Yoga + educational program
218946917|NCT03721029|DEVICE|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
218946918|NCT03721029|PROCEDURE|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
218946919|NCT03351205|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
219635557|NCT00119717|OTHER|Control|ASA Guidelines
219635558|NCT00184132|PROCEDURE|Psychiatric intensive care unit in Norwegian home style|
219635559|NCT00184132|PROCEDURE|Psychiatric intensive care unit sparsely furnished and not decorated|
218946920|NCT03351205|PROCEDURE|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
218946921|NCT03351205|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
218946922|NCT00985036|PROCEDURE|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
218946923|NCT04650451|BIOLOGICAL|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
218946924|NCT01466829|DRUG|Parathyroid hormone|100 microgram daily. S.c
218946925|NCT01466829|DRUG|Placebo|Placebo; saline injection.
218946926|NCT05884749|BEHAVIORAL|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
219053467|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
219053468|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
219053469|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
219053470|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
219053471|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
219053472|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
219053473|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
219635560|NCT03798470|BEHAVIORAL|Peer Addiction Counseling|After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
218946927|NCT05884749|BEHAVIORAL|Care as Usual (UC)|Participants in this group will receive care available typically in the community
218946928|NCT02642224|BEHAVIORAL|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
218946929|NCT03133884|OTHER|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
219053474|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
218946930|NCT03133884|OTHER|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
218946931|NCT00233454|DRUG|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
218946932|NCT02013258|DRUG|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
219053475|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
218946933|NCT02013258|OTHER|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
219053476|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
218946934|NCT01293071|OTHER|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
218946935|NCT01764191|OTHER|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
218946936|NCT01787162|OTHER|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
218946937|NCT04685239|DEVICE|dual mobility cup|The use of a Sunfit dual mobility cup
218946938|NCT04685239|DEVICE|unipolar cup|The use of a TMT cup
218946939|NCT05468073|DRUG|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
218946940|NCT05468073|DRUG|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
218946941|NCT00190255|PROCEDURE|CY2PC9 genotyping|CY2PC9 genotyping
218946942|NCT05451485|DIAGNOSTIC_TEST|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
218946943|NCT05451485|DIAGNOSTIC_TEST|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
218946944|NCT05451485|DIAGNOSTIC_TEST|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
218946945|NCT05451485|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
218946946|NCT02328053|PROCEDURE|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
218946947|NCT02328053|DRUG|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
219053477|NCT00068055|DRUG|Placebo|Normal Saline.
219053478|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
219053479|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
219053480|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
218946948|NCT05845697|OTHER|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
219053481|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
218946949|NCT05845697|OTHER|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
218946950|NCT02734901|DIETARY_SUPPLEMENT|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
219053482|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
219053483|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
219053484|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
219053485|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
219053486|NCT00529386|DRUG|Botox|300 units
219053487|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
219053488|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
219053489|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
219053490|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
219053491|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
218946951|NCT02734901|DIETARY_SUPPLEMENT|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
218946952|NCT02734901|DIETARY_SUPPLEMENT|Placebo|1x daily intake of 600 mL raspberry deprived supplement
218946953|NCT04869501|DRUG|TJ004309|Antibody to CD73
218946954|NCT04869501|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
218946955|NCT02942940|DEVICE|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
218946956|NCT02942940|OTHER|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
218946957|NCT05185011|DRUG|TPN171H|10 mg TPN171H tablets，single dose
218946958|NCT05253261|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
219053492|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
218946959|NCT05253261|PROCEDURE|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
218946960|NCT05253261|PROCEDURE|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
218946961|NCT05253261|DIAGNOSTIC_TEST|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
219053493|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
218946962|NCT05253261|PROCEDURE|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
218946963|NCT05498701|DRUG|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
218946964|NCT05498701|DRUG|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
218946965|NCT02451215|DEVICE|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
219053494|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
219053495|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
219053496|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
219053497|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
219635561|NCT05577988|OTHER|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.|"* Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel.~* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.~* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin."
218946966|NCT03163797|DIAGNOSTIC_TEST|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
218946967|NCT00380042|DEVICE|Cortical Stimulation|Cortical stimulation of prefrontal cortex
218946968|NCT00380042|DEVICE|Sham|Sham stimulation
218946969|NCT02668211|DEVICE|PROFEMUR Preserve Classic Femoral Components|
218946970|NCT01906996|PROCEDURE|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
218946971|NCT01906996|PROCEDURE|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
219053498|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
219053499|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
219635562|NCT06198491|BEHAVIORAL|Misbeliefs about HPV training|Intervention trainings mentioned false beliefs before or after the current knowledge
219635563|NCT04793308|OTHER|Endodontic files|Engine-driven nickel titanium Ni-Ti instruments
218946972|NCT03868644|BEHAVIORAL|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
218946973|NCT03868644|BEHAVIORAL|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
218946974|NCT03472170|DIETARY_SUPPLEMENT|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
218946975|NCT03472170|OTHER|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
218946976|NCT02495038|DRUG|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
218946977|NCT02495038|DRUG|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
218946978|NCT04375540|PROCEDURE|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
218946979|NCT04375540|PROCEDURE|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
218946980|NCT00006409|BEHAVIORAL|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
218946981|NCT05457621|OTHER|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
218946982|NCT00093405|DRUG|tanespimycin|
218946983|NCT00496600|DRUG|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
219053500|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
219053501|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
219635564|NCT03250858|BEHAVIORAL|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
219635565|NCT03250858|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
219635566|NCT06279546|DIAGNOSTIC_TEST|Detection of structures|Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.
219635567|NCT06035146|PROCEDURE|Mechanical energy monitoring|Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
219635568|NCT06035146|PROCEDURE|Conventional mechanical ventilation|The conventional procedure of mechanical ventilation controlled according to the physician's decision.
219635569|NCT06565494|DRUG|midomafetamine (MDMA)-Assisted Therapy|This treatment consists 3 Preparation sessions followed by 3 Experimental sessions at 4-week intervals; after each Experimental session, 3 weekly Integration sessions will be conducted. For the first Experimental Session, the dose of MDMA is 80 mg; for the second and third Experimental Sessions, the dose of MDMA is 120 mg. For all three Experimental sessions, a supplemental dose of 50% of the initial dose will be available. The Preparation, Experimental, and Integration Sessions will involve psychotherapy developed specifically for this trial and population.
219635570|NCT01873404|DRUG|BG00010|As specified in the treatment arm
219635571|NCT01873404|DRUG|Placebo|As specified in the treatment arm
219635572|NCT04804826|PROCEDURE|Pelvic Reconstructive Surgery|Pelvic Reconstructive Surgery including total vaginal hysterectomy
219635573|NCT03759587|DRUG|Niraparib|Niraparib capsule
219635574|NCT01657825|DRUG|Isavuconazole|oral
219635575|NCT01657825|DRUG|Warfarin|oral
219635576|NCT06004921|DRUG|AB801|Administered as specified in the treatment arm
219635577|NCT06004921|DRUG|Placebo|Administered as specified in the treatment arm
219635578|NCT03348007|OTHER|Taking two kinds of mineral water|1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
218946984|NCT00496600|DRUG|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
218946985|NCT04243382|BIOLOGICAL|Autologous umbilical cord blood|Single infusion of autologous umbilical cord blood cells
218946986|NCT04243382|BIOLOGICAL|Placebo|Placebo
218946987|NCT04781933|DIETARY_SUPPLEMENT|Treatment with Combo|Treatment with Combo
218946988|NCT04781933|OTHER|Treatment with placebo|Treatment with placebo
218946989|NCT00749814|DIETARY_SUPPLEMENT|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
219053502|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
219053503|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
219053504|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
219053505|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
219053506|NCT02736162|OTHER|No treatment (intervention) was administered|
219053507|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
219053508|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
219635579|NCT04933552|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
219635580|NCT02269228|DRUG|Asasantin ER|
219635581|NCT02269228|DRUG|Placebo|
219635582|NCT04204109|OTHER|Interprofessional case-based learning|"The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession"
219635583|NCT04615403|DRUG|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
219635584|NCT03170362|OTHER|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
219635585|NCT03864757|DEVICE|thyroplasty implant|Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
219635586|NCT02858804|DRUG|Etoposide|50 mg/m2, IV d1-4
219635587|NCT02858804|DRUG|Doxorubicin|10 mg/m2, IV, d1-4
219635588|NCT02858804|DRUG|Dexamethasone|30 mg/d, d1-5
219635589|NCT02858804|DRUG|Vincristine|0.4 mg/m2, IV, d1-4
219635590|NCT02858804|DRUG|Cyclophosphamide|750 mg/m2 ,d5
219635591|NCT02858804|DRUG|Cytarabine|2g/m2, q12h, d1
219635592|NCT02858804|DRUG|Cisplatin|100mg/ m2,IV, d1
219635593|NCT02858804|DRUG|Rituximab|375 mg/m2 IV, d1
219635594|NCT02858804|DRUG|Thalidomide|50-150mg/d, po, d1-28
219635595|NCT02858804|DRUG|Prednisone|0.5mg/Kg, po, qod
219635596|NCT04443946|DRUG|Propofol|5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
219635597|NCT04443946|DRUG|1% Sevoflurane|add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
219635598|NCT04443946|DRUG|1% Sevoflurane continue|1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
219635599|NCT04443946|DRUG|Sufentanil|0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
218946990|NCT00749814|OTHER|Placebo tablets|Placebo
218946991|NCT02057588|PROCEDURE|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
218946992|NCT02350764|DRUG|nivolumab|
218946993|NCT02350764|DRUG|pilimumab|
219053509|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
219053510|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219053511|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219053512|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219053513|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219053514|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
219635600|NCT04443946|DRUG|2% Sevoflurane|2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
219635601|NCT04443946|DRUG|Propofol half|2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
219635602|NCT01152749|DRUG|Nicotine|Single-dose of new NRT product
219635603|NCT01152749|DRUG|Nicotine Gum|Single-dose of marketed nicotine gum
219635604|NCT01278004|DRUG|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
218946994|NCT04193462|OTHER|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
218946995|NCT04193462|OTHER|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
218946996|NCT05549921|BIOLOGICAL|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
218946997|NCT00327821|BEHAVIORAL|calorie controlled diet|
218946998|NCT00246545|BEHAVIORAL|exercise|
218946999|NCT03614052|DRUG|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
218947000|NCT03614052|DRUG|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
218947001|NCT02161692|DRUG|Cyclophosphamide|
218947002|NCT02161692|DRUG|Etoposide|
218947003|NCT02161692|DRUG|Cisplatin|
218947004|NCT02161692|DRUG|Bleomycin|
218947005|NCT02161692|DRUG|Carboplatin|High dose carboplatin
218947006|NCT03905044|OTHER|eyes with congenital cataracts|observation
218947007|NCT04475705|DRUG|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
218947008|NCT04475705|DRUG|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
218947009|NCT03859947|DEVICE|Heated humidiﬁed high-flow nasal cannula|Non-invasive ventilation with a nasal cannula
218947010|NCT03347370|DRUG|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
218947011|NCT03347370|DRUG|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
218947012|NCT03347370|DRUG|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
218947013|NCT01109732|OTHER|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
218947014|NCT03171753|DIAGNOSTIC_TEST|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
218947015|NCT03171753|DIAGNOSTIC_TEST|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
218947016|NCT03171753|DIAGNOSTIC_TEST|cardiac monitoring|the cardiac monitoring will be performed through study period
218947017|NCT03171753|DIAGNOSTIC_TEST|skin resistance|the skin resistance monitoring will be performed through study period
218947018|NCT03171753|DEVICE|Music listening|Listening prerecorded music through an individual headset for 30 min
218947019|NCT03171753|DEVICE|No sound|No sound through an individual headset for 30 min
218947020|NCT05731011|OTHER|antioxidative stress|blood interventions
218947021|NCT05731011|DEVICE|electrotherapy|hotpack,Tens, ultrasound
218947022|NCT03531632|BIOLOGICAL|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
219053515|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
219206933|NCT06748079|DRUG|TQC3721 inhalation powder|TQC3721 is a target inhibitor.
219635605|NCT01278004|DRUG|Placebo|Capsule
219635606|NCT05800561|DIAGNOSTIC_TEST|Hepatic venous-portal gradient (HVPG) measurement|preoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test
219635607|NCT04967482|PROCEDURE|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
218947023|NCT03635450|BIOLOGICAL|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
218947024|NCT04704947|DRUG|nonselective beta blocker|nonselective beta blocker
218947025|NCT04704947|DRUG|cardio-selective beta blocker group|cardio-selective beta blocker group
218947026|NCT04704947|DRUG|alendronate sodium|alendronate sodium
218947027|NCT02888496|DRUG|tocilizumab|3 monthly IV infusions in PMR patients
218947028|NCT02678559|OTHER|tee measurement|
218947029|NCT02678559|OTHER|flotrac measurement|
218947030|NCT02678559|OTHER|clearsight measurement|
218947031|NCT01645943|PROCEDURE|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
218947032|NCT00619320|BEHAVIORAL|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
218947033|NCT01317108|DRUG|CMF Chemotherapy|
218947034|NCT06215768|DRUG|Dexmedetomidine and Midazolam|"This will be a prospective, double-blind, randomized controlled study conducted between October 2023and June 2024 .~Patients aged( 2\_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg Or intravenous midazolam 0.1 mg /kg(Group A) or (Group B) over 10 minutes after induction of anesthesia. The primary outcome is the incidence of ED within 30 minutes after extubation. Other outcomes are the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs)."
218947035|NCT00600119|DRUG|placebo|placebo, oral, once daily (QD)
218947036|NCT00600119|DRUG|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
218947037|NCT03927560|PROCEDURE|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
218947038|NCT04084119|OTHER|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
218947039|NCT04084119|OTHER|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
218947040|NCT05738681|DRUG|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
218947041|NCT01906944|DRUG|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
219053516|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
219053517|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
219053518|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
219635608|NCT04967482|PROCEDURE|Conventional transarterial chemoembolization (cTACE)|The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
219635609|NCT04744194|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
219635610|NCT04744194|OTHER|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
218947042|NCT01906944|DRUG|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
218947043|NCT04381039|DEVICE|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
218947044|NCT05592860|DEVICE|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
218947045|NCT05592860|BEHAVIORAL|Daily Diary|participants will use daily diary to record glucose level
218947046|NCT04772638|BEHAVIORAL|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
218947047|NCT04772638|OTHER|Wait list control|not an active intervention
219053519|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
219053520|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
219053521|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
219053522|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
218947048|NCT01081418|BEHAVIORAL|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
218947049|NCT00729469|DRUG|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
218947050|NCT00729469|DRUG|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
218947051|NCT02660840|DRUG|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
218947052|NCT02660840|DRUG|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
219053523|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
219053524|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
219053525|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
219053526|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
219053527|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
219053528|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
219053529|NCT04865835|DRUG|placebo|single dose of placebo
219053530|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
219053531|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
219053532|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
219053533|NCT01867684|OTHER|Psychotherapy|
219053534|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
219053535|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
219053536|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
218947053|NCT02660840|DRUG|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
218947054|NCT02660840|DRUG|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
219053537|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
219053538|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
219053539|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
219053540|NCT02039427|DRUG|Placebo|Normal saline 2 ml
219053541|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
219053542|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
219053543|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
219053544|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
219635611|NCT01662817|BEHAVIORAL|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
219053545|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
219206934|NCT06748079|DRUG|Placebo for TQC3721 inhalation powder|Placebo without drug substance.
219206935|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Cryobiopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, cryobiopsy is performed, followed by forceps biopsy.
219635612|NCT01662817|BEHAVIORAL|Control|PCP manages depression in the usual way for six months
219635613|NCT06382246|OTHER|Exercise snacks|Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
219635614|NCT00006351|DRUG|gemcitabine hydrochloride|
219635615|NCT00006351|DRUG|lonafarnib|
218947055|NCT02660840|DRUG|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
218947056|NCT02660840|DRUG|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
219635616|NCT00256269|DRUG|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
219635617|NCT00256269|DRUG|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
219206936|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Forceps biopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, forceps biopsy is performed, followed by cryobiopsy.
219206937|NCT06754371|DRUG|tranexamic acid|intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection
219206938|NCT06754371|DRUG|normal saline|intravenous infusion of normal saline 20ml 10min before skin dissection
219206939|NCT06754332|DRUG|human chorionic gonadotropin|The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
219635618|NCT06684561|DEVICE|PIS|"All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.~defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.~if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users"
219635619|NCT02145260|DRUG|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
219635620|NCT02145260|DRUG|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
218947058|NCT02183740|BEHAVIORAL|Multifaceted educational program|
218947059|NCT00514852|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
218947060|NCT00514852|DRUG|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
218947061|NCT01809093|BIOLOGICAL|Blood draw|3-4 tablespoons of blood will be drawn, one time.
218947062|NCT00655174|DRUG|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
218947063|NCT00655174|DRUG|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
218947064|NCT00655174|DRUG|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
218947065|NCT02884505|DEVICE|Pupillometry|Measures pupillary dynamics in darkness and light conditions
218947066|NCT02884505|BEHAVIORAL|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
218947067|NCT02884505|OTHER|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
218947068|NCT02884505|BEHAVIORAL|Hypersomnia Severity Index|Self-report measure of hypersomnolence
218947069|NCT03711240|DRUG|bevacizumab|5mg/kg iv day 1 every 2 weeks
218947070|NCT03711240|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
218947071|NCT03711240|DRUG|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
218947072|NCT03711240|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
218947073|NCT03711240|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
218947074|NCT03812237|OTHER|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
218947075|NCT05606029|PROCEDURE|Cholecystectomy, extended cholecystectomy|Cholecystectomy and histopathological evaluation
218947076|NCT00740610|DRUG|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
218947077|NCT00740610|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
218947078|NCT00206232|DRUG|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
218947079|NCT01270802|DRUG|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
218947080|NCT01270802|DRUG|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
218947081|NCT01270802|DRUG|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
218947082|NCT03662581|BEHAVIORAL|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care"
218947083|NCT00909207|BEHAVIORAL|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
218947084|NCT03666156|OTHER|No intervention|No Intervention
218947085|NCT03608358|DRUG|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
219206940|NCT00866021|DRUG|Lopinavir/ritonavir|NRTI sparing-regimen
219206941|NCT00866021|DRUG|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
219206942|NCT06760468|OTHER|Control|Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the control group. Participants in the control group will undergo an 8-week placebo supplementation intervention. The placebo has a similar appearance and taste to the probiotic powder but does not contain active probiotic ingredients. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the placebo once a day at the same time to ensure the consistency and standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise capacity tests and blood sample collections will be conducted again. Comparing exercise performance and biochemical markers before and after t
218947086|NCT03608358|DRUG|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
218947087|NCT03608358|DRUG|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
218947088|NCT03608358|DRUG|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
218947089|NCT03608358|DRUG|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
218947090|NCT03608358|DRUG|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
218947091|NCT00799851|DEVICE|Variceal band ligation|
218947092|NCT00799851|DRUG|cyanoacrylate injection|cyanoacrylate injection
218947093|NCT04634305|PROCEDURE|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
218947094|NCT05667337|DEVICE|CLP-PEG-MPC|Implantation of a 500 um thick biosynthetic corneal implant utilizing DALK surgical technique
218947095|NCT05667337|PROCEDURE|Human donor cornea penetrating keratoplasty|Implantation of a human donor cornea graft utilizing PKP surgical technique
219053546|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
219053547|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
219053548|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
219053549|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
219635621|NCT02116933|PROCEDURE|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
219635622|NCT02116933|PROCEDURE|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
219635623|NCT01214967|BEHAVIORAL|Problem Solving Education|psycho-educational intervention
219635624|NCT04167098|OTHER|PRP injection|0.5 ml Platelet-rich Plasma around A1 tendon sheath
219635625|NCT04167098|OTHER|Corticosteroid injection|0.5 ml methylprednisolone around A1 tendon sheath
219053550|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
219053551|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
219053552|NCT02509741|BEHAVIORAL|Education|
219053553|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
219053554|NCT02509741|BEHAVIORAL|IOT monitoring|
219635626|NCT04167098|OTHER|Placebo injection|0.5 ml 0.9% saline around A1 tendon sheath
219635627|NCT02502682|DRUG|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
218947096|NCT01388556|BEHAVIORAL|Tango dancing|Twice weekly tango dance classes
218947097|NCT03363113|DRUG|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
218947098|NCT03284892|BEHAVIORAL|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
218947099|NCT00811213|DEVICE|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
218947100|NCT00811213|DEVICE|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
218947101|NCT01246817|DRUG|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
218947102|NCT00179491|BEHAVIORAL|Intercessory Prayer|14 days of intercessory prayer from 3 sites
218947103|NCT05412589|DRUG|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
218947104|NCT06334406|OTHER|Biological samples|"Blood samples will be collected at baseline, after the diagnostic TURBT, and D15 after the end of treatment in each cohort.~Tumor tissues will be collected at baseline for three patients."
218947105|NCT02914028|PROCEDURE|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
218947106|NCT02914028|DRUG|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
218947107|NCT02535572|DEVICE|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
218947108|NCT02535572|DEVICE|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
218947109|NCT03685890|DRUG|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
219053555|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
219053556|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
218947110|NCT03685890|PROCEDURE|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
219053557|NCT00040040|DRUG|Bupropion|
219053558|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
219053559|NCT02875119|DRUG|Placebo Gel|Placebo Gel
219053560|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
219053561|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
219053562|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
219053563|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
219053564|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
219053565|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
219053566|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
219053567|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
219053568|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
219053569|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
219635628|NCT04835610|DEVICE|pvi|The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.
219053570|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
219053571|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
219053572|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
219053573|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
219053574|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
219053575|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
219053576|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
219635629|NCT05921292|COMBINATION_PRODUCT|Omeza Products Used in Combination|"Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza® combination therapy which includes the use of the following products:~* Omeza® Lidocaine Lavage~* Omeza® Complete Matrix (OCM™)~* Omeza® Skin Protectant At each treatment (on days 0, 7, 14, 21; +/- 3 days each), the patient's intact skin around the wound/ulcer will be prepped with Omeza® Lidocaine Lavage. OCM™ will be applied directly to the wound/ulcer and Omeza® Skin Protectant will be applied to the periwound and surrounding intact skin. Treatments may be repeated during an optional 7 additional weeks (on days 28, 35, 42, 49, 56, 63, and 70; +/- 3 days each). Final assessment will be made at week 12."
218947111|NCT01297777|DRUG|Imatinib Mesylate|"* In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
218947112|NCT03027284|DRUG|Merestinib|Administered orally
218947113|NCT03027284|DRUG|Cisplatin|Administered IV
218947114|NCT03027284|DRUG|Gemcitabine|Administered IV
218947115|NCT04821362|DEVICE|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
218947116|NCT04821362|DEVICE|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
218947117|NCT00128323|DRUG|Gentian violet 1% solution|
218947118|NCT00128323|DRUG|Gentian violet 0.00165% solution|
218947119|NCT00128323|DRUG|Nystatin solution|
219053577|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
219053578|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
219366051|NCT00537433|OTHER|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
219635630|NCT01109953|OTHER|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
219635631|NCT05312762|DEVICE|MaxioCel|Microfiber wound dressing
219635632|NCT05312762|DEVICE|AquaCel Extra|Hydrofiber dressing
219635633|NCT06449430|DRUG|Sedation with propofol|Sedation with propofol
219635634|NCT06449430|DRUG|Spinal analgesia with bupivacaine|Spinal analgesia with bupivacaine
219635635|NCT00253825|DEVICE|mCIMT combined with or without eye patching|
219635636|NCT05235893|PROCEDURE|Reflexology|Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
219635637|NCT05235893|PROCEDURE|Sucrose %24|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
219635638|NCT05235893|PROCEDURE|Kangaroo care|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
219635639|NCT05235893|PROCEDURE|Music|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
219635640|NCT06407115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT in this study will consist of a series of 6-10, 30-45-minute sessions with the care manager. These 1-on-1 sessions will occur every week or every other week virtually. Content will be focus on addressing unhelpful thinking and small behavioral changes that may help participants better manage their pain.
219635641|NCT06407115|BEHAVIORAL|Enhance Fitness|Participants will be encouraged to enroll in instructor-led exercises classes for up to an hour, 3 days per week. These classes can be accessed from home. Data plans and tablets are available to aid participants that need them to gain access to the classes.
219635642|NCT06407115|OTHER|Care Coordination|Care manager will meet with patient in virtual sessions once a month to create a care plan and monitor progress. Care manager will assess social determinants of health and link participants to resources in the community as appropriate. In addition, participants will take monthly assessments about pain and mood to help guide clinical decision making.
219635643|NCT00300560|DRUG|Colistin|
219635644|NCT00548301|DRUG|cyclosporine|
219635645|NCT00454363|OTHER|Laboratory Biomarker Analysis|Correlative studies
219635646|NCT00454363|DRUG|Pazopanib Hydrochloride|Given PO
219635647|NCT00454363|OTHER|Pharmacological Study|Correlative studies
218947120|NCT00002339|DRUG|Fluconazole|
218947121|NCT06208956|DRUG|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
218947122|NCT06208956|DRUG|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
218947123|NCT02929654|DEVICE|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
219053579|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
219053580|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
218947124|NCT02929654|DEVICE|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
219053581|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
218947125|NCT02929654|DEVICE|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
219053582|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
218947126|NCT03740815|PROCEDURE|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
218947127|NCT03740815|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
219053583|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
219053584|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
219053585|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
219053586|NCT02973659|DRUG|Placebos|
219635648|NCT01463189|BEHAVIORAL|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
219635649|NCT03618394|DIETARY_SUPPLEMENT|MCT/ω-3-PUFA|lipid emulsion
219635650|NCT03618394|DIETARY_SUPPLEMENT|Soybean Based|lipid emulsion
218947128|NCT03740815|PROCEDURE|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
218947129|NCT00005779|DRUG|Interleukin-12|
218947130|NCT00005779|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
218947131|NCT02969603|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
218947132|NCT02969603|OTHER|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
218947133|NCT03462901|PROCEDURE|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
218947134|NCT00568633|PROCEDURE|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
218947135|NCT00568633|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
218947136|NCT00568633|DRUG|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
218947137|NCT00568633|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
219053587|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
219053588|NCT02732847|DRUG|Usual Dated|
219053589|NCT01198184|DRUG|temsirolimus|Given IV or PO
219053590|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
219053591|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
219053592|NCT01198184|OTHER|pharmacological study|Correlative studies
219053593|NCT00863538|DRUG|KPS-0373|
219053594|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
219366052|NCT02529033|DEVICE|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
219635651|NCT01438398|PROCEDURE|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
218947138|NCT00568633|RADIATION|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
218947139|NCT00568633|DRUG|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
218947140|NCT00568633|DRUG|Best standard care|"Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
218947141|NCT00781352|DRUG|nitrous oxide|65% nitrous oxide administered during surgery
218947142|NCT00781352|DRUG|nitrogen|Nitrogen administration during surgery
218947143|NCT01740505|BEHAVIORAL|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
218947144|NCT01740505|BEHAVIORAL|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
219053595|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
219053596|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
219053597|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
219359996|NCT06018649|COMBINATION_PRODUCT|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
219635652|NCT01438398|PROCEDURE|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
219635653|NCT06568822|OTHER|Asessment|Data prepared by researchers regarding the general characteristics of older adults will be examined.
218947145|NCT01740505|BEHAVIORAL|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
218947146|NCT03673761|OTHER|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
218947147|NCT01960907|DEVICE|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
218947148|NCT02360683|OTHER|patients with Parkinson's disease|
218947149|NCT04119271|OTHER|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
218947150|NCT03761862|PROCEDURE|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
218947151|NCT00561548|PROCEDURE|rectosigmoïdal biopsies|rectosigmoïdal biopsies
218947152|NCT04583722|DIETARY_SUPPLEMENT|AX-olive oil-PP emulsion|single dose and plasma samples
219053598|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
219635654|NCT06568822|OTHER|The Physical Activity Scale for the Elderly (PASE)|PASE will be used to assess the physical activity levels of older adults.
219635655|NCT06568822|OTHER|Turkish Version of the Satisfaction with Life Scale (T-SWLS)|T-SWLS will be used to assess life satisfaction of older adults.
219635656|NCT06568822|OTHER|Modified Morisky Scale (MMS)|MMS will be used to evaluate medication adherence in older adults.
219635657|NCT02724046|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
219635658|NCT05069220|DRUG|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
219635659|NCT05069220|DRUG|68Ga-Dotatate|Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
219635660|NCT02256124|DRUG|Lamotrigine|
219635661|NCT02256124|DRUG|Placebo|
219635662|NCT00097825|DRUG|Zoledronic Acid|
218947153|NCT00003544|DRUG|irinotecan hydrochloride|
218947154|NCT00003544|PROCEDURE|surgical procedure|
218947155|NCT02084251|DRUG|PB-119|
218947156|NCT03554811|DEVICE|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
218947157|NCT03554811|OTHER|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
218947158|NCT03587285|BIOLOGICAL|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
219053599|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
219053600|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
219053601|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
219206943|NCT06760468|DIETARY_SUPPLEMENT|Experimental Group|"Experimental:~Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the experimental group. Participants in the experimental group will undergo an 8-week probiotic powder supplementation intervention. The dosage of the probiotic powder is set at 1x10\^9 CFU/kg·bw·d, which means ingesting 10 billion CFU (Colony-Forming Units) of probiotics per kilogram of body weight per day. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the probiotic powder once a day at the same time to ensure the consistency of the dosage and the standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise ca"
219206944|NCT06758843|OTHER|measure the axial length, visual acuity, and refraction at follow-up of 6- and 12-month|the intervention is follow-up with parameters to measure and data to record
219635663|NCT06382701|OTHER|aromatherapy|Patients in the intervention group; ten minutes before the needle is inserted into the arterio-venous fistula, clove oil will be applied by the interviewer as a spray between 0.5-1 ml, depending on the length of the patient's fistula. Patients in the placebo group; 10 minutes before the needle is inserted into the arterio-venous fistula, 0.5-1 ml of aromatic cloves, which do not contain active ingredients and dissolved in pure water, will be applied as a spray by the interviewer, depending on the length of the patient's fistula.
219635664|NCT06382701|OTHER|placebo|This is the group in which 0.5-1 ml of aromatic clove, which does not contain active ingredients and is dissolved in pure water, is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
219635665|NCT05664360|OTHER|Age (young versus older)|Age
219635666|NCT05871762|OTHER|Registry study, no specific intervention|Registry study, no specific intervention
219635667|NCT00570063|DRUG|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
219635668|NCT00570063|DRUG|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
218947159|NCT03587285|BIOLOGICAL|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
218947160|NCT04744090|DRUG|Roflumilast|"1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."
218947161|NCT04744090|DRUG|Placebo|Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
219053602|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
219053603|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
219053604|NCT04574362|DRUG|Placebo|Matching placebo
219053605|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
219053606|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
219053607|NCT00003341|BIOLOGICAL|epoetin alfa|
219053608|NCT00003341|PROCEDURE|quality-of-life assessment|
219053609|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
218947162|NCT05648669|DRUG|Elagolix|200 mg tablet
218947163|NCT05648669|DRUG|Elagolix placebo|Elagolix-matched Placebo tablet
218947164|NCT00681356|DRUG|4975, 15 and 5 mg|Direct instillation into the surgical site
218947165|NCT00681356|DRUG|Placebo Comparator|Direct instillation into the surgical site
219053610|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
219053611|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
219053612|NCT00002526|BIOLOGICAL|filgrastim|
219053613|NCT00002526|DRUG|doxorubicin hydrochloride|
219053614|NCT00002526|DRUG|ifosfamide|
219053615|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
219053616|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
219053617|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
219053618|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
219053619|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
219053620|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
219053621|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
219053622|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
219206945|NCT06758830|RADIATION|Radiation Therapy|Radiation therapy (RT) is administered at a dose of 2 Gy per day for a total dose of 50 Gy delivered to the pelvis. This is done throughout 5 to 6 weeks.
219206946|NCT06758830|DRUG|Chemoradiotherapy|"Capecitabine: 825 mg/m² twice daily, prescribed 1-5 days per week, for 5 weeks during RT.~Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35. Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35."
219635669|NCT03082859|BEHAVIORAL|Exercise|This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
219635670|NCT05988827|DEVICE|NGenuity|Cataract surgery performed under microscope using NGenuity
219635671|NCT06156995|DEVICE|Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
219635672|NCT06156995|DRUG|Oral Mosapride Tablets|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
218947166|NCT00681356|DRUG|4975 - 5 mg|Direct instillation into the surgical site
218947167|NCT06085885|DEVICE|Cochlear implant|Cochlear implant
218947168|NCT04117867|BEHAVIORAL|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
218947169|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
219635673|NCT00697463|DRUG|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
219635674|NCT05191290|DRUG|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
219635675|NCT05191290|DRUG|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
219635676|NCT03093142|DEVICE|tDCS & neurofeedback|tDCs and neurofeedback
218947170|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
218947171|NCT00728403|DIETARY_SUPPLEMENT|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
218947172|NCT01616693|DIETARY_SUPPLEMENT|Probiotic|A capsule that contains at least 1 x 10\^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
219635677|NCT03093142|DEVICE|neurofeedback|Neurofeedback
218947173|NCT01616693|DIETARY_SUPPLEMENT|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
218947174|NCT01616693|DIETARY_SUPPLEMENT|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
218947175|NCT01616693|DIETARY_SUPPLEMENT|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
218947176|NCT01616693|BIOLOGICAL|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
218947177|NCT01616693|BIOLOGICAL|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
218947178|NCT04901689|DRUG|Leronlimab|Leronlimab 700 mg
219053623|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
218947179|NCT04901689|DRUG|Placebo|Placebo
218947180|NCT00117494|DRUG|Pravastatin|
218947181|NCT00117494|DRUG|Rosuvastatin|
218947182|NCT00644085|DRUG|aspirin|oral administration of aspirin 100 mg
218947183|NCT00644085|DRUG|placebo|oral administration of placebo
219053624|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
219053625|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
219053626|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
219635678|NCT03093142|DEVICE|sham neurofeedback|sham neurofeedback
218947184|NCT04863911|RADIATION|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
219053627|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
219635679|NCT05444452|DEVICE|Implanatation of Genoss DES sirolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
219635680|NCT05444452|DEVICE|Implanatation of Xience DES everolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
219635681|NCT03307252|DRUG|Digoxin|Tablet
219635682|NCT03307252|DRUG|Furosemide|Oral solution
219635683|NCT03307252|DRUG|Metformin|Oral solution
219635684|NCT03307252|DRUG|Rosuvastatin|Film-coated tablet
219635685|NCT03307252|DRUG|Verapamil|Film-coated tablet
219635686|NCT03307252|DRUG|Rifampin|Film-coated tablet
219053628|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
219053629|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
219053630|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
219053631|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
219053632|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
219053633|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
219053634|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
219053635|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
219053636|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
219053637|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
219053638|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
219053639|NCT00020410|BIOLOGICAL|filgrastim|
219053640|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
219053641|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
219053642|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
219635687|NCT03307252|DRUG|Cimetidine|Tablet
219635688|NCT03307252|DRUG|Probenecid|Tablet
219635689|NCT03482453|DRUG|TAK-788|TAK-788 capsules.
219053643|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
219635690|NCT03482453|DRUG|Placebo|TAK-788 placebo-matching capsules.
219635691|NCT03482453|DRUG|TAK-788|TAK-788 DiC.
219635692|NCT03444662|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose and Sunflower oil
219635693|NCT03444662|DIETARY_SUPPLEMENT|Citicoline and Omega-3 supplement|Citicoline and Omega-3
219635694|NCT03444662|DIETARY_SUPPLEMENT|Omega-3 supplement|Cellulose and Omega-3
219635695|NCT00624429|DRUG|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
219053644|NCT01719965|OTHER|Interviews and Focus Group Discussions|
219053645|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
219053646|NCT01983800|DRUG|Isoflurane|
219053647|NCT01983800|DRUG|Propofol/midazolam|
219053648|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
219053649|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
219053650|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
219053651|NCT01332305|DRUG|Placebo|Placebo orally once daily
219053652|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
219053653|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
219635696|NCT02568189|DEVICE|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
219635697|NCT03166722|OTHER|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
219635698|NCT03166722|DEVICE|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
218947185|NCT01649089|PROCEDURE|Conization|Undergo cone biopsy
218947186|NCT01649089|OTHER|Quality-of-Life Assessment|Ancillary studies
218947187|NCT01649089|OTHER|Questionnaire Administration|Ancillary studies
218947188|NCT01649089|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy
219053654|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
219053655|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
219053656|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
219053657|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
219053658|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
219053659|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
219053660|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
219053661|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
219053662|NCT03023735|OTHER|None. This is an observational study|
219053663|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
218947189|NCT01649089|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
218947190|NCT02080819|DRUG|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
219206947|NCT06758830|DRUG|Consolidation Chemotherapy|"XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times."
219635699|NCT02246400|BEHAVIORAL|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
218947191|NCT01266187|PROCEDURE|adjuvant surgery + FOLFOX + cetuximab|surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab
218947192|NCT01266187|PROCEDURE|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab"
218947193|NCT05083832|PROCEDURE|Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block|Two different catheter techniques with same doses local anesthetic infusion
218947194|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
219053664|NCT03160430|DRUG|Placebos|matching placebo capsule
218947195|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
219053665|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
219053666|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
219053667|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
219053668|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
219053669|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
219053670|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
219053671|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
218947196|NCT05231096|OTHER|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.
218947197|NCT05231096|OTHER|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
219053672|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
219053673|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
219053674|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
219053675|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
219053676|NCT00471601|BEHAVIORAL|counseling intervention|
219053677|NCT00471601|BEHAVIORAL|questionnaire administration|
219053678|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
219053679|NCT00471601|BEHAVIORAL|quality-of-life assessment|
219053680|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
219053681|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
219053682|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
219053683|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
219053684|NCT00002912|DRUG|etoposide|
219206948|NCT06758830|PROCEDURE|Surgery|Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.
218947198|NCT05231096|PROCEDURE|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
218947199|NCT05219916|PROCEDURE|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
218947200|NCT02943304|OTHER|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
218947201|NCT04971317|BEHAVIORAL|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
218947202|NCT04971317|BEHAVIORAL|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
218947203|NCT04971317|BEHAVIORAL|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
218947204|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
219053685|NCT00002912|DRUG|mitoxantrone hydrochloride|
219053686|NCT00002912|DRUG|valspodar|
219053687|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
219053688|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
219053689|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
219053690|NCT00529945|DEVICE|PFx Closure System|
219053691|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
219053692|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
219053693|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
219053694|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
218947205|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
218947206|NCT02968537|BEHAVIORAL|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
219053695|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
219053696|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
219053697|NCT02104557|OTHER|Non intervention|Non intervention
219053698|NCT02104557|OTHER|Non intervention|Non intervention
219053699|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
219053700|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
219635700|NCT03119870|OTHER|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
219635701|NCT03119870|OTHER|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
219635702|NCT03119870|OTHER|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
219635703|NCT01161511|BIOLOGICAL|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
219635704|NCT01735461|DIETARY_SUPPLEMENT|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
219635705|NCT03139474|DRUG|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
219635706|NCT03139474|DRUG|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
219635707|NCT02157376|DRUG|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
219635708|NCT02157376|DRUG|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
219053701|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
219053702|NCT06300541|PROCEDURE|Colectomy|Observational study.
219053703|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
219053704|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
219206949|NCT06758830|OTHER|Part two|Standard treatment protocols and follow-up procedures are implemented in clinical practice.
219206950|NCT06758830|OTHER|Adjuvant treatment|If indicated, adjuvant therapy will be administered as usual in clinical practice.
218947207|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
219053705|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
219053706|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
219053707|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
219053708|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
219053709|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
219053710|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
219053711|NCT05548608|OTHER|Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.|Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
219053712|NCT02467101|OTHER|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
219053713|NCT05508529|DIETARY_SUPPLEMENT|Chaga Mushroom|Effect of chaga on immune/mood support
219053714|NCT05508529|DIETARY_SUPPLEMENT|Algae Extract|Effect of algae extract on immune/mood support
219635709|NCT02824120|OTHER|Comedy|patients will watch comedy film
219053715|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
219053716|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
219053717|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
219053718|NCT05508529|DIETARY_SUPPLEMENT|Placebo|Placebo control
219635710|NCT02824120|OTHER|Documentary|patients will watch a documentary film
219635711|NCT02885220|OTHER|Conventional Program|No scheduled intermediate weight loss goals provided to patient
219053719|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
219053720|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
219053721|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
219053722|NCT00632697|DRUG|placebo|
219206951|NCT06759688|BEHAVIORAL|Carbohydrates restriction|"Patients followed a low carbohydrate dietary approach (LCDs). It means lower than 130 grams carbohydrates per day with special restriction restrictions on:~* Artificial sugars (e.g., sweets, baked goods, pasta, bread).~* Also, rice, butter made from vegetable oils and all types of oils except olive oil.~They were allowed:~* All types of fresh fruits and vegetable.~* Boiled potatoes."
219635712|NCT02885220|OTHER|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
219635713|NCT04306731|DIETARY_SUPPLEMENT|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
219635714|NCT04306731|DRUG|Trimethoprim|Antibiotic
219635715|NCT04306731|DIETARY_SUPPLEMENT|Ordinary bottled drinking water|Placebo
219635716|NCT01598844|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
219635717|NCT00966992|DRUG|Zoledronic acid|
219635718|NCT01074268|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
219635719|NCT01074268|DRUG|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
219635720|NCT01074268|DRUG|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
219635721|NCT03006601|OTHER|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
219635722|NCT03726372|DRUG|Rocuronium|rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
219635723|NCT03726372|OTHER|continuous infusion|rocuronium is continuously infused
218947208|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
218947209|NCT02968537|BEHAVIORAL|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
218947210|NCT03619057|OTHER|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
219053723|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
218947211|NCT00832624|DRUG|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
218947212|NCT02078856|DRUG|A3384|
219635724|NCT03726372|OTHER|intermittent injection|rocuronium is intermittently given
219635725|NCT03858972|DRUG|Tesetaxel|Tesetaxel plus reduced dose of capecitabine
219635726|NCT03858972|DRUG|Capecitabine|Reduced dose of capecitabine
219635727|NCT01298804|BEHAVIORAL|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
219635728|NCT00880412|DRUG|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
219635729|NCT00880412|DRUG|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
218947213|NCT06044701|OTHER|Hologram Distraction Technique|Hologram fan application during blood collection process
218947214|NCT06044701|OTHER|Bubble Machine Distraction Technique|Bubble machine application during blood collection
218947215|NCT06019442|BEHAVIORAL|Brief alcohol intervention (Health4Her-Automated)|"Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content)."
218947216|NCT06019442|BEHAVIORAL|Lifestyle health promotion|"Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight)."
218947217|NCT06234241|OTHER|Echocardiography|Echocardiography was performed in all enrolled populations.
218947218|NCT04802122|DRUG|Sevoflurane inhalant product|Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
218947219|NCT04802122|DRUG|Propofol Fresenius|Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
219635730|NCT05457686|OTHER|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
219635731|NCT05457686|OTHER|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
219635732|NCT05457686|OTHER|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
219635733|NCT01578239|DRUG|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
219635734|NCT01578239|DRUG|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
218947220|NCT03614208|BEHAVIORAL|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
218947221|NCT06228677|PROCEDURE|Selective adrenal artery embolization|Percutaneous selective adrenal artery embolization in patients with primary aldosteronism
219206952|NCT06761573|DEVICE|Bilateral Bispetral Index Monitor will be applied on forehead of our patients, before surgery begins|In patients undergoing surgery and general anesthesia, the investigators want to examine -using bilateral BIS monitor- synthetic electroencephalographic differences between the two cerebral hemispheres (ASYM) to evaluate any correlation with the development of POD and POCD in the post-operative period.
219635735|NCT02302417|PROCEDURE|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
219635736|NCT02302417|OTHER|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
219635737|NCT02629939|BEHAVIORAL|course for learning CPR|
218947222|NCT03113890|GENETIC|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
218947223|NCT03113890|GENETIC|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
218947224|NCT03113890|OTHER|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
218947225|NCT04814199|OTHER|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
218947226|NCT02395172|DRUG|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
218947227|NCT02395172|DRUG|Docetaxel|Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
219635738|NCT04518241|BEHAVIORAL|MI sessions|"Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence"
219635739|NCT04518241|BEHAVIORAL|TMQQ|Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
219635740|NCT04518241|BEHAVIORAL|Type of compensation|Participants who achieve HIV viral suppression at 21 weeks will receive either fixed compensation of $275 or be entered into a lottery where they have a 3/10 chance of winning $500, and a 7/10 chance of winning $175. Those who do not achieve HIV viral suppression receive a $50 participant incentive.
219635741|NCT05494710|OTHER|Bleomycin electrosclerotherapy treatment|The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
219635742|NCT01731119|DRUG|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
219635743|NCT03000010|DEVICE|Incisional Wound Vac|
219635744|NCT03000010|OTHER|Standard Bandage|
219635745|NCT03828721|OTHER|Rx for Success Smartphone Application|"The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does."
219635746|NCT03828721|OTHER|Control - screen time reduction|Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
219635747|NCT01017536|BIOLOGICAL|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
218947228|NCT06171841|OTHER|low-intensity resistance training|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions performed twice a week for 6 weeks.
219366053|NCT01589484|DEVICE|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
219366054|NCT02185937|DIETARY_SUPPLEMENT|cola|imatinib intake with coca-cola
218947229|NCT06171841|OTHER|high-intensity resistance training|4 sets of 10 repetitions of leg press exercise at 70-80% one-repetition maximum (weeks 1-3: 70%, weeks 4-6: 80%) in normoxic conditions performed twice a week for 6 weeks.
218947230|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
218947231|NCT06171841|OTHER|low-intensity resistance training in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in hypoxia conditions (3500 meters above sea) performed twice a week for 6 weeks.
218947232|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normobaric hypoxia conditions (3500 meters above sea) with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
218947233|NCT00653939|DRUG|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
218947234|NCT00653939|DRUG|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
218947235|NCT00653939|DRUG|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
218947236|NCT00653939|DRUG|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
218947237|NCT03542032|OTHER|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
218947238|NCT02980913|DEVICE|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
219635748|NCT01017536|BIOLOGICAL|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
219635749|NCT02347813|DRUG|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
218947239|NCT02980913|DEVICE|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
218947240|NCT00717236|DRUG|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
219053724|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
219053725|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
219053726|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
219635750|NCT00899119|PROCEDURE|leukapheresis|
219635751|NCT03131752|BEHAVIORAL|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
218947241|NCT00717236|OTHER|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
218947242|NCT05828537|DEVICE|endotracheal tube|pediatric extubation
218947243|NCT00194870|PROCEDURE|EEG|computer-assisted analysis of the digitally-recorded EEG signals
218947244|NCT00475982|BEHAVIORAL|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
218947245|NCT00475982|OTHER|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
218947246|NCT00572754|PROCEDURE|Circumcision|Circumcision by tying a ligature around the foreskin.
218947247|NCT02366884|DRUG|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
219053727|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
219053728|NCT05827497|DRUG|Baricitinib 2 MG|baricitinib 2 mg once daily
219053729|NCT05827497|DRUG|Methotrexate 25mg|25mg daily
219366055|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
219366056|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
218947248|NCT02366884|DRUG|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
218947249|NCT02366884|DRUG|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
218947250|NCT01651962|DRUG|Terbutaline|
218947251|NCT01651962|DRUG|Fentanyl|
218947252|NCT01651962|DRUG|0.9% NaCl|
218947253|NCT02778113|DRUG|Nasal Glucagon|Administered intranasally.
219053730|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
218947254|NCT02778113|DRUG|Glucagon|Administered SC.
218947255|NCT00783198|BIOLOGICAL|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
219053731|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
219053732|NCT00111228|DEVICE|Guardian RT|
218947256|NCT00783198|BIOLOGICAL|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
218947257|NCT00783198|BIOLOGICAL|Placebo|matching placebo sublingual tablets administered once daily
218947258|NCT01318824|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
218947259|NCT01318824|PROCEDURE|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
219053733|NCT00111228|DEVICE|SMBG only|SMBG only
219053734|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
219053735|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
218947260|NCT06332872|DRUG|Oral Ivermectin|Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart
218947261|NCT06332872|DRUG|4% dimenticone liquid gel|topical formulation (liquid gel) only 1 application
218947262|NCT05716672|DRUG|Lazertinib|Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
218947263|NCT01629446|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
218947264|NCT01054833|PROCEDURE|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
218947265|NCT00870376|OTHER|biomarkers|To define a biomarker or combination of overactive bladder syndrome
218947266|NCT03704636|DEVICE|INVSENSOR00028|Noninvasive pulse oximeter sensor
218947267|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
218947268|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
218947269|NCT00432549|DRUG|Almotriptan|
219053736|NCT00678691|DRUG|armodafinil|50-250mg/d
219053737|NCT00678691|DRUG|placebo|matching placebo
219053738|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
219053739|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
219053740|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
218947270|NCT00432549|DRUG|Topiramate|
218947271|NCT05236088|DEVICE|Neuromuscular electrical stimulation application|It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
218947272|NCT05236088|DEVICE|Sham neuromuscular electrical stimulation application|Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
218947273|NCT02989454|OTHER|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
218947274|NCT02345564|DEVICE|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
218947275|NCT00539188|DRUG|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
218947276|NCT00539188|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
219053741|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
219053742|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
219635752|NCT01385137|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given orally
219635753|NCT01385137|OTHER|placebo|Given orally
219635754|NCT01159405|RADIATION|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg \& 20 mg of GP will be injected
219635755|NCT03573973|OTHER|Improved product placement of fresh fruit and vegetables|The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
218947277|NCT02670148|PROCEDURE|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
218947278|NCT01546623|DRUG|TAP-144-SR(6M)|
218947279|NCT01546623|DRUG|TAP-144-SR(3M)|
218947280|NCT04517890|DRUG|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
219366057|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
219635756|NCT03573973|OTHER|Sham comparator|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
219635757|NCT02837731|DEVICE|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
219635758|NCT04323163|BEHAVIORAL|Physical Activity|3 sessions per week, 60 minutes per session for 6 months
218947281|NCT04517890|DRUG|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
218947282|NCT01134705|DRUG|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
218947283|NCT01134705|DRUG|Placebo Nasal Aerosol|HFA Vehicle Aerosol
218947284|NCT05213819|OTHER|Carpal Tunnel Syndrome|
218947285|NCT06250361|OTHER|Questionnaire completion|A questionnaire will be completed by the participant and their gastroenterologist. Estimated completion time is 30 minutes for the patient, 10 minutes for the gastroenterologist.
218947286|NCT04784442|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
219635759|NCT01779843|DRUG|Cytarabine|
219635760|NCT01779843|DRUG|Idarubicin|
219635761|NCT01779843|DRUG|Alisertib|
219635762|NCT00375414|PROCEDURE|PEG-Gastropexy|
219635763|NCT01352195|BEHAVIORAL|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
219635764|NCT05616195|OTHER|3D printed bone prosthesis replacement surgery|To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
219635765|NCT04841395|DIAGNOSTIC_TEST|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
219635766|NCT03053752|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
218947287|NCT04784442|DRUG|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
218947288|NCT04784442|DRUG|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
218947289|NCT04784442|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
218947290|NCT06197919|OTHER|postural exercises|"In this study forward head posture will be defined as CVA\<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Kendall et al's approach. The exercises involved~1. chin tucks ins~2. a chin drop in sitting~3. shoulder retraction~4. unilateral and bilateral pectoralis stretches Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form"
219635767|NCT01119859|DRUG|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
219635768|NCT01119859|DRUG|Adalimumab|
218947291|NCT06197919|OTHER|postural exercises with breathing exercises|"The postural exercise program consisted the exercises i.e chin tucks in, a chin drop in sitting, shoulder retraction. Participants were instructed to complete 3sets of 12repetitions of these exercises. This program was to be repeated 4times per week. They also returned for a consultation every 2weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12repetitions, 3times easily with correct form.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled diaphragmatic breathing, relaxation technique, deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, and segmental breathing techniques. exercise protocol will be continued for 6 weeks with and initial, after 3weeks and final assessment of pain and CVA."
218947292|NCT06244290|DRUG|Colgate SNF|toothpaste
218947293|NCT06244290|DRUG|Sensodyne Extra Whitening|toothpaste
218947294|NCT06244290|DRUG|Colgate Fluoride (CDC)|toothpaste
218947295|NCT01893034|PROCEDURE|Arthroscopic treatment of femoroacetabular impingement|
218947296|NCT01893034|OTHER|Physiotherapy and activity modification|
218947297|NCT00930137|OTHER|isocaloric for week diet|"Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
218947298|NCT03069105|OTHER|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
218947299|NCT00078169|BEHAVIORAL|Behavior Therapy|
218947300|NCT02037555|BIOLOGICAL|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
218947301|NCT02037555|OTHER|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
218947302|NCT00461071|BEHAVIORAL|Guided Self-help for Bulimia nervosa|bibliotherapy
218947303|NCT04109885|DRUG|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
218947304|NCT04109885|DRUG|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
219053743|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
219366058|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
219635769|NCT01119859|DRUG|Placebo to tocilizumab|
219635770|NCT01119859|DRUG|Placebo to adalimumab|
219635771|NCT04736147|BIOLOGICAL|JNJ-64300535|JNJ-64300535 injection will be administered intramuscularly.
219635772|NCT01881477|PROCEDURE|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
218947305|NCT03035877|BEHAVIORAL|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
218947306|NCT03035877|BEHAVIORAL|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
219053744|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
219053745|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
219053746|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
219635773|NCT02789774|PROCEDURE|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
219635774|NCT02789774|PROCEDURE|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
219635775|NCT05337280|DEVICE|Imagio OA/US|Imagio optoacoustic/ultrasound
219635776|NCT00603473|DRUG|gabapentin|Orally administered gabapentin
219635777|NCT00852059|DRUG|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
219635778|NCT00852059|DRUG|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
219635779|NCT04121559|BEHAVIORAL|School Interventions|"1. Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~2. Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~3. Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~4. Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~5. Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing."
219635780|NCT04121559|BEHAVIORAL|Community Interventions|"1. Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~2. Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing."
219635781|NCT04121559|BEHAVIORAL|School System Interventions|"1. Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~2. Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
219635782|NCT04530188|DRUG|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
219635783|NCT04530188|DRUG|Propofol|Intravenous sedation with propofol, as already used in our ICU
219053747|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
219053748|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
219053749|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
218947307|NCT01061255|OTHER|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
218947308|NCT02585336|BEHAVIORAL|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
218947309|NCT00321126|DRUG|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
218947310|NCT02001753|DEVICE|CMR|
219053750|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
219053751|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
219635784|NCT04745533|DIAGNOSTIC_TEST|Antigen detection test|To compare the results of the antigen detection test against the polymerase chain reaction in the study of contacts of COVID-19 patients during quarantine.
219635785|NCT02278445|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
219635786|NCT02278445|DEVICE|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
219635787|NCT02590497|PROCEDURE|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
219635788|NCT02590497|DRUG|Gadolinium|Undergo gadolinium-enhanced MRI
219635789|NCT02590497|OTHER|Laboratory Biomarker Analysis|Tissue genetic analysis
219635790|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
219635791|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
219635792|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo FLAIR sequence
219206953|NCT06751732|OTHER|Craniocervical Flexion Training (CCFT)|CCFT is a targeted intervention aimed at improving neuromuscular control in the cervicoscapular and craniocervical regions through low-load endurance exercises. A pressure biofeedback unit placed behind the neck sets a baseline at 20 mmHg, ensuring relaxed neck muscles. Participants open the mouth 20 mm to activate deep cervical flexors and minimize superficial muscle use, maintaining head contact with the surface while gazing 45 degrees below the horizontal. Pressure is increased in 5 mmHg steps (20 to 40 mmHg), with each level held for 10 seconds, followed by a 10-second rest. CCFT can also be performed seated, reducing sternocleidomastoid activity and promoting longus colli thickness for functional training.
219635793|NCT02590497|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
219635794|NCT05899777|OTHER|Yizhi Baduanjin|Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
218947311|NCT01526824|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
218947312|NCT03812822|DEVICE|Insole|Custom-made insoles which support the foot at subtalar neutral position
219206954|NCT06751732|OTHER|Diaphragm Respiratory Training|Patients will undergo a 15-minute diaphragmatic respiratory training session, focusing on smooth diaphragmatic breathing with gentle expirations.
219635795|NCT05391347|OTHER|Orange oil aromatherapy|5 minutes before the invasive procedure, 3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process.
219635796|NCT00105547|DRUG|MPC-7869|oral 800 mg BID
219635797|NCT00105547|DRUG|MPC-7869|Oral BID dosing
219635798|NCT00104780|BIOLOGICAL|EP-2101|
219635799|NCT00104780|BIOLOGICAL|incomplete Freund's adjuvant|
218947313|NCT05466201|DRUG|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
218947314|NCT05466201|DRUG|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
218947315|NCT03873090|OTHER|SBRT|hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
218947316|NCT04520438|PROCEDURE|Leukocyte and platelet rich fibrin|L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
218947317|NCT04520438|PROCEDURE|Non-Surgical Periodontal treatment|The control group only received NSPT (scaling and root planing) in one treatment session.
219635800|NCT05204680|BEHAVIORAL|Aerobic Exercise|The participant will work with the physical therapist on an exercise regimen.
218947318|NCT03137745|OTHER|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
218947319|NCT01590758|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
219635801|NCT04663529|OTHER|contact lens|daily disposable soft contact lens
219635802|NCT02644668|DRUG|Placebo|Granules for oral suspension (placebo)
219635803|NCT02644668|DRUG|Reldesemtiv 150 mg|Granules for oral suspension, 18.7% reldesemtiv
219635804|NCT02644668|DRUG|Reldesemtiv 450 mg|Granules for oral suspension, 56.0% reldesemtiv
219635805|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
219635806|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
218947320|NCT01590758|DRUG|Topical placebo cream|14 days of treatment
218947321|NCT01590758|OTHER|Standard wound care|14 days of treatment
218947322|NCT03697915|DEVICE|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
218947323|NCT01232803|DRUG|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
218947324|NCT01232803|DRUG|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
218947325|NCT01232803|DRUG|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
219053752|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
219053753|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
218947326|NCT06071585|OTHER|Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis|We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
219053754|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
219053755|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
219053756|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
219053757|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
219053758|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
219635807|NCT00691444|BIOLOGICAL|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
218947327|NCT04855084|OTHER|Monolithic FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
218947328|NCT04855084|OTHER|Monolithic FDPs: after adjustment|After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
218947329|NCT04855084|OTHER|Metal fused porcelain FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
218947330|NCT04855084|OTHER|Metal fused porcelain FDPs: after adjustment|After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
219635808|NCT04347369|OTHER|other|clinical diagnosis
219635809|NCT04846712|OTHER|Collect data of medical record|Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
218947331|NCT02756806|DEVICE|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
218947332|NCT01806701|BEHAVIORAL|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
218947333|NCT04586842|BEHAVIORAL|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
218947334|NCT04586842|BEHAVIORAL|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
218947335|NCT00637988|DRUG|Esomeprazole|40mg twice daily
218947336|NCT00637988|DRUG|Aspirin|
218947337|NCT00637988|DRUG|Rofecoxib|25mg once daily
218947338|NCT05650918|BIOLOGICAL|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
218947339|NCT05650918|BIOLOGICAL|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
218947340|NCT03089385|OTHER|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
218947341|NCT02717832|DRUG|hyperinsulinemic-euglycemic clamp|
219635810|NCT02240212|DRUG|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
219635811|NCT02240212|DRUG|Paclitaxel|Paclitaxel sourced locally will be administered IV
219635812|NCT03102996|DRUG|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
219635813|NCT03102996|OTHER|Placebo|Identical capsules without active substance.
219635814|NCT00733421|DRUG|etoricoxib|90 mg once daily
219635815|NCT00733421|DRUG|tramadol|100 mg twice daily
219635816|NCT03292666|DRUG|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
218947342|NCT01041534|OTHER|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
218947343|NCT02537288|DRUG|Fedovapagon|
218947344|NCT02537288|DRUG|Moxifloxacin|
218947345|NCT02537288|DRUG|Placebo (for fedovapagon)|
218947346|NCT04665869|BEHAVIORAL|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
218947347|NCT04665869|BEHAVIORAL|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
218947348|NCT03083444|DIAGNOSTIC_TEST|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
218947349|NCT01612923|OTHER|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
218947350|NCT00183417|BEHAVIORAL|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
218947351|NCT00183417|BEHAVIORAL|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
218947352|NCT00183417|BEHAVIORAL|Bibliotherapy|Participants will be given a book on how to increase their mood.
218947353|NCT01613170|DRUG|Toviaz|Toviaz 4mg daily
218947354|NCT01613170|DRUG|Premarin|Premarin cream 1 g per vagina twice weekly
218947355|NCT01613170|DRUG|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
218947356|NCT00753740|DRUG|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
218947357|NCT00753740|DRUG|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
218947358|NCT00753740|DRUG|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
218947359|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL|One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
218947360|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL|One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
218947361|NCT05266729|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
218947362|NCT05266729|DRUG|Placebo|Phosphate buffered saline placebo for injection
218947363|NCT01008423|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
218947364|NCT01008423|DRUG|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
218947365|NCT03820739|OTHER|Follow-up|No investigational vaccine will be administered during this study
218947366|NCT03820739|OTHER|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
218947367|NCT05901844|DIAGNOSTIC_TEST|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
218947368|NCT02093052|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
218947369|NCT02093052|BEHAVIORAL|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
218947370|NCT04103788|DIETARY_SUPPLEMENT|95% Curcuminoid Powder|1200 mg curcuminoids
218947371|NCT04103788|DIETARY_SUPPLEMENT|CurQ+|400 mg curcuminoids + coconut oil + polysorbate
218947372|NCT04476004|OTHER|scapular-focused exercise|scapular-focused exercise
218947373|NCT04476004|OTHER|visual feedback|EMG visual feedback
218947374|NCT01522937|RADIATION|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
218947375|NCT00504972|DRUG|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
218947376|NCT05995067|OTHER|periodontitis challenge|control will be compared to diseased group suffering from periodontal disease.
219053759|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
219635817|NCT03832764|DEVICE|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
219635818|NCT00184327|BEHAVIORAL|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
219635819|NCT00184327|BEHAVIORAL|Diagnostic assessment - child and adolescent psychiatry|
219635820|NCT04927780|DRUG|Leucovorin Calcium|IV
219635821|NCT04927780|DRUG|Fluorouracil|IV
219635822|NCT04927780|DRUG|Irinotecan Hydrochloride|IV
219635823|NCT04927780|DRUG|Oxaliplatin|IV
219053760|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
219053761|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
218947377|NCT02917564|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
218947378|NCT02917564|OTHER|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
218947379|NCT03069729|OTHER|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
218947380|NCT01646333|BEHAVIORAL|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
218947381|NCT01646333|BEHAVIORAL|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
218947382|NCT03269929|OTHER|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
218947383|NCT03269929|DRUG|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
218947384|NCT03062254|DRUG|radium-223 dichloride|6 doses of Radium-223
219635824|NCT04927780|PROCEDURE|Resection|Open or minimally-invasive pancreatectomy.
219635825|NCT03377231|DEVICE|Stratamark®|Film-forming dressing for the prevention and treatment of stretch marks.
219635826|NCT04760431|DRUG|Trastuzumab|8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles, administered by IV infusion every week until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219635827|NCT04760431|DRUG|Taxanes|Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks
218947385|NCT05847985|DEVICE|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
218947386|NCT04052256|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
218947387|NCT01798160|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
218947388|NCT01798160|PROCEDURE|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
219053762|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
219635828|NCT04760431|DRUG|Pertuzumab|840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219635829|NCT04760431|DRUG|Tyrosine kinase inhibitor|Pyrotinib: 400mg po within 30 minutes after a meal, QD, every 3 weeks Neratinib: 240mg po QD, every 3 weeks Tucatinib: 300mg po Q12H
219635830|NCT03747380|OTHER|inspiratory muscle program|pre-operative inspiratory muscular training program
219635831|NCT01063192|DRUG|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
218947389|NCT04363788|PROCEDURE|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
218947390|NCT05664568|DRUG|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
218947391|NCT05664568|DRUG|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
218947392|NCT05664568|OTHER|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
218947393|NCT02935283|PROCEDURE|MRI|MRI, fMRI, 1H MRS, DTI
218947394|NCT02935283|BEHAVIORAL|Behavioral|Battery of executive function tasks
218947395|NCT00934843|DRUG|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
218947396|NCT00934843|DRUG|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
218947397|NCT00003745|DRUG|topotecan hydrochloride|
218947398|NCT03675854|DRUG|Cefazolin|3 weeks
219053763|NCT02260427|DEVICE|Insertion of the air-Q sp|
219053764|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
219635832|NCT01063192|DRUG|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
219635833|NCT00373230|BEHAVIORAL|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
219635834|NCT02302469|DRUG|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
218947399|NCT01831583|DEVICE|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
218947400|NCT01831583|DEVICE|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
218947401|NCT02784639|OTHER|Plasma Analysis of circulating cell free DNA|
218947402|NCT02784639|OTHER|Tumor tissue analysis of circulating cell free DNA|
218947403|NCT00123253|DRUG|TH9507|
218947404|NCT05991544|BEHAVIORAL|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
218947405|NCT06173700|BEHAVIORAL|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
219053765|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
219053766|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
219053767|NCT04953767|OTHER|White light|White light is used as sham control.
219053768|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
219053769|NCT03242499|DRUG|Placebo|placebo for 48 weeks
219053770|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
219053771|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
219053772|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
219053773|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
219053774|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
218947406|NCT03456882|DRUG|RNS60|normal saline plus oxigen in nanobubble
218947407|NCT03225040|DRUG|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
218947408|NCT01144299|BIOLOGICAL|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
218947409|NCT03353233|DRUG|Ropivacaine|Local anesthetic (numbing drug)
218947410|NCT03353233|PROCEDURE|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
219053775|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
219053776|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
219053777|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
219053778|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
219053779|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
219053780|NCT04163744|DEVICE|Double balloon catheter|Induction of labour with double balloon catheter
219053781|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
219053782|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
219053783|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
219635835|NCT02174263|BIOLOGICAL|tocilizumab|Given IV
219635836|NCT02174263|OTHER|laboratory biomarker analysis|Correlative studies
219635837|NCT02174263|OTHER|quality-of-life assessment|Ancillary studies
219053784|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
219053785|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
219635838|NCT02369965|DRUG|albuvirtide|albuvirtide 320mg administered intravenously once a week
219635839|NCT02369965|DRUG|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
219635840|NCT02369965|DRUG|tenofovir|tenofovir 300mg administered orally once daily
219635841|NCT02369965|DRUG|lamivudine|lamivudine 300mg administered orally once daily
219635842|NCT05832684|DRUG|ZVS101e|ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
219635843|NCT03404037|DIAGNOSTIC_TEST|serum endostatin level|"An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA"
218947411|NCT03353233|DRUG|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
218947412|NCT01024725|OTHER|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
219053786|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
219053787|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
219053788|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
219635844|NCT05154045|OTHER|Experimental Formula|Diabetes-specific study formula
219635845|NCT05154045|OTHER|Test Meal|Instant oatmeal
219635846|NCT02946554|BIOLOGICAL|HepaStem|
218947413|NCT01800461|OTHER|OPC-Stroke|Occupational therapy coaching intervention
218947414|NCT01800461|OTHER|Usual care|Usual community care
218947415|NCT00183729|DRUG|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
219053789|NCT04122833|OTHER|Next generation sequencing|observational study
219053790|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
219053791|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
219053792|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
218947416|NCT00183729|OTHER|Placebo|Placebo distribution is planned to mimic the active drug.
218947417|NCT01615276|DEVICE|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
218947418|NCT01615276|DEVICE|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
219053793|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
219053794|NCT03376997|DRUG|Perampanel|IV infusion
219053795|NCT03376997|DRUG|Perampanel|Oral tablet
219053796|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
219206955|NCT06751732|OTHER|Cervical Mobilization and Traction|A physiotherapist will perform a low-velocity, passive cervical joint mobilization technique (Oscillation technique) based on the regimen described by Maitland.(17) This will be followed by cervical spine traction while patients continue diaphragmatic breathing.
219635847|NCT01616797|BEHAVIORAL|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
219635848|NCT01579097|OTHER|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
219635849|NCT01579097|OTHER|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
219635850|NCT02461433|DEVICE|Prevena|Prevena Incision Management system
219635851|NCT02461433|DEVICE|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
219635852|NCT02547220|BIOLOGICAL|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
219635853|NCT02547220|DRUG|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
219635854|NCT06575127|DRUG|FOLFOXIRI Protocol|as mentioned in Arm description
219635855|NCT01523782|DRUG|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
219635856|NCT05495282|OTHER|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
219635857|NCT06119620|DEVICE|intermitted theta burst stimulation|Participants receive intermitted theta burst stimulation for 3-4 minutes before completing the N-back task.
218947419|NCT00003076|DRUG|eflornithine|
218947420|NCT03512457|BEHAVIORAL|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
218947421|NCT03512457|BEHAVIORAL|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
218947422|NCT00985829|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
218947423|NCT02878161|DRUG|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
218947424|NCT02878161|BIOLOGICAL|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
218947425|NCT02878161|BIOLOGICAL|etanercept|Etanercept :hypodermic injection,25mg/twice a week
219635858|NCT02253589|BEHAVIORAL|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
218947426|NCT02878161|BIOLOGICAL|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
218947427|NCT02878161|DRUG|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
218947428|NCT02878161|DRUG|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
218947429|NCT02878161|DRUG|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
218947430|NCT01785862|DRUG|Ibuprofen 25 mg|Lozenge, Oromucosal administration
218947431|NCT01785862|DRUG|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
218947432|NCT01624246|DRUG|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
218947433|NCT00635076|OTHER|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
219206956|NCT06751732|OTHER|Digital Compression on Muscle Trigger Points|Digital compression will be applied for 90 seconds on identified trigger points in the craniocervical muscles, not exceeding eight trigger points in each session.
219635859|NCT01889329|DIETARY_SUPPLEMENT|RUTF-1|Made from local food ingredients
219635860|NCT01889329|DIETARY_SUPPLEMENT|RUTF-2|Made from local food ingredients
219635861|NCT01889329|DIETARY_SUPPLEMENT|Plumpynut|Commercially made from peanut paste
218947434|NCT00635076|DRUG|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
218947435|NCT02884713|DRUG|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
218947436|NCT02884713|DRUG|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
219635862|NCT05498129|OTHER|School meal|School lunch was comprised of rice, ghee and beef
219635863|NCT05498129|OTHER|School meal plus micronutrient powder|School lunch plus micronutrient powder
219635864|NCT05498129|OTHER|No school meal|No school meal
219635865|NCT01925729|BIOLOGICAL|ragweed|ragweed arm only
219635866|NCT01925729|BIOLOGICAL|histamine|histamine arm only
219053797|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
218947437|NCT02884713|DRUG|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
218947438|NCT02369172|DRUG|Bupropion|
218947439|NCT02369172|DRUG|ASP2151|
218947440|NCT04371458|DRUG|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
218947441|NCT00831493|RADIATION|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
218947442|NCT00831493|DRUG|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
218947443|NCT04708457|OTHER|VV-ECMO|Early use of VV-ECMO in SARI patients.
218947444|NCT01550848|DRUG|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
218947445|NCT04465838|OTHER|NIS|This is a non-interventional study (NIS).
219053798|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
219053799|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
219053800|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
219053801|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
219053802|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
219053803|NCT03709550|DRUG|Decitabine|Given IV
219053804|NCT03709550|DRUG|Enzalutamide|Given PO
218947446|NCT00620503|DRUG|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
218947447|NCT00620503|DRUG|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
219053805|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
219053806|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
219053807|NCT00073671|OTHER|Usual care|Participants receive usual care
219053808|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
219206957|NCT06751732|OTHER|Passive Stretching of Neck Muscles|Passive stretching will be performed three times for neck flexion and rotation associated with ipsilateral flexion directions, using moderate force within the patient's pain limits, and maintained for 30 seconds.
219206958|NCT06751732|OTHER|Instruction on Postural Correction|Physiotherapists will provide instructions on postural correction, addressing craniocervical extension, cervicothoracic flexion, protraction of shoulders, increased thoracic kyphosis, and flattened lumbar lordosis. Patients will be guided on correcting these postural abnormalities through craniocervical flexion, cervicothoracic extension, shoulder retraction, thoracic spine extension, and normalization of lumbar lordosis.
219635867|NCT01925729|DRUG|pseudoephedrine|pseudoephedrine arm only
218947448|NCT04452110|DIAGNOSTIC_TEST|Ultrasonography|Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
218947449|NCT02145650|OTHER|No Intervention|There is no intervention administered in this study.
218947450|NCT04185285|DEVICE|Percutaneous coronary intervention, stents|
218947451|NCT02371915|OTHER|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
218947452|NCT04367909|DRUG|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
218947453|NCT04367909|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
218947454|NCT04367909|DRUG|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
219635868|NCT01925729|DRUG|Oxymetazoline|oxymetazoline arm only
219635869|NCT00252291|DRUG|Aridol|
219635870|NCT00252291|DRUG|Methacholine|
218947455|NCT04326426|DRUG|Tradipitant|Neurokinin-1 antagonist
218947456|NCT04326426|DRUG|Placebo|Matching placebo
219635871|NCT00252291|PROCEDURE|Exercise challenge|
219635872|NCT04527692|OTHER|Questionnaire|semi-structured interviews on the quality of life
219635873|NCT03093194|OTHER|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
219635874|NCT03093194|OTHER|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
219635875|NCT00660244|DRUG|anastrozole|Oral
218947457|NCT01763008|DRUG|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
218947458|NCT03207035|PROCEDURE|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
218947459|NCT01625741|DRUG|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
218947460|NCT02862067|OTHER|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
218947461|NCT00625430|BIOLOGICAL|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
218947462|NCT02326480|OTHER|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
218947463|NCT02439489|DRUG|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
218947464|NCT02439489|DRUG|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
219635876|NCT03689829|DRUG|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
219635877|NCT03689829|DRUG|Placebo|Corresponding placebo s.c. injections.
219635878|NCT02320305|BIOLOGICAL|MART-1 Antigen|Given IM
219635879|NCT02320305|DRUG|TLR4 Agonist GLA-SE|Given IM
218947465|NCT02172417|DRUG|Cimetidine + Tiotropium|
218947466|NCT02172417|DRUG|Ranitidine + Tiotropium|
218947467|NCT02172417|DRUG|Tiotropium|
218947468|NCT02224248|BEHAVIORAL|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
218947469|NCT02224248|BEHAVIORAL|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
218947470|NCT03745885|DRUG|Supaglutide injection|Administered SC in the Supaglutide arms.
218947471|NCT03745885|DRUG|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
219053809|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
219206959|NCT06752837|DEVICE|Tornado rotary system|In arm one, stainless steel tornado files works by high-speed rotation that influences the fluid dynamics within the canal and improves irrigation efficiency. Canals are finished with a file having a 4% taper and an apical diameter of 0.25 mm.
218947472|NCT00299611|DRUG|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
218947473|NCT00299611|DRUG|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
218947474|NCT00299611|DRUG|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
218947475|NCT03833193|RADIATION|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
218947476|NCT02082756|DRUG|Bifidobacterium viable pharmaceutics|
218947477|NCT02082756|DRUG|Berberine Hydrochloride|
218947478|NCT02422199|DRUG|pyrotinib|
218947479|NCT02422199|DRUG|Lapatinib|
219635880|NCT02320305|OTHER|Laboratory Biomarker Analysis|Correlative studies
219635881|NCT06182111|PROCEDURE|Intraoperative morphine|Morphine dose = 0,1 mg mg/kg (maximum 10 mg) intravenous given 20 min after start of surgery
219635882|NCT03114605|BEHAVIORAL|Mindfulness-based Intervention|
219635883|NCT02913677|DIETARY_SUPPLEMENT|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
219635884|NCT03793205|DRUG|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
219635885|NCT03793205|DRUG|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
218947480|NCT02422199|DRUG|capecitabine|
218947481|NCT04985552|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
218947482|NCT04985552|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion. The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
218947483|NCT04985552|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
218947484|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
218947485|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
218947486|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
218947487|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
218947488|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
218947489|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
218947490|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
218947491|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
218947492|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
218947493|NCT01031836|DRUG|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
218947494|NCT00680641|DRUG|Simvastatin|40mg of Simvastatin once daily
218947495|NCT00680641|DRUG|Placebo|40mg of placebo once daily
218947496|NCT01681355|OTHER|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
218947497|NCT02081755|DRUG|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
218947498|NCT02081755|DRUG|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
218947499|NCT02081755|DRUG|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
218947500|NCT02081755|DRUG|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
218947501|NCT02081755|DRUG|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
218947502|NCT02980952|OTHER|High-fat overfeeding|
218947503|NCT02980952|OTHER|Forearm immobilization|
218947504|NCT05779384|OTHER|It was an observational study|data collected concerning the incidence of exacerbations
218947505|NCT03188172|DRUG|Cyclophosphamide|Chemotherapy
218947506|NCT03188172|DRUG|Bortezomib|Chemotherapy
219206960|NCT06752837|DEVICE|WaveOne rotary system|In arm two, WaveOne system is a single reciprocating file system with a heat-treated NiTi Memory Wire (M Wire).It has a taper of 0.08 in apical 3 mm, with a tip diameter of 0.25 mm. in a torque control endodontic handpiece (X smart plus with reciprocation mode)
219206961|NCT06752837|DEVICE|OneShape rotary system|In arm three, OneShape system utilizes a conventional, continuous rotational motion. It has asymmetric cross-sectional geometry, and traveling waves of motion that are produced along the file's active region. It has a single constant taper of 0.06 and a tip size of 25 with distinct cross-sectional designs along the whole length of the working parts
218947507|NCT03188172|DRUG|Lenalidomide|Chemotherapy
218947508|NCT03188172|DRUG|Daratumumab|Chemotherapy
218947509|NCT03188172|DRUG|Dexamethasone|Chemotherapy
218947510|NCT03188172|DRUG|Melphalan|Chemotherapy
218947511|NCT03188172|DRUG|Filgrastim|Haematopoietic agent for the stem cell harvest
218947512|NCT01446783|DRUG|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
218947513|NCT01446783|DRUG|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
218947514|NCT04028544|DRUG|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
218947515|NCT04028544|DRUG|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
218947516|NCT03478293|DEVICE|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
219053810|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
219053811|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
219053812|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
219635886|NCT03390751|OTHER|Data collection|The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
219635887|NCT01820598|DEVICE|Multisite NMES training during 6 weeks|
219635888|NCT03468660|BEHAVIORAL|Auditory training with feedback|Experimental group receives phoneme-level and sentence-level training with feedback
219635889|NCT03468660|BEHAVIORAL|Listening paradigm with no feedback|Active controls listen to acoustic stimuli with no feedback
219635890|NCT04299568|DEVICE|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
218947517|NCT00000679|DRUG|Zidovudine|
218947518|NCT00000679|DRUG|Zalcitabine|
218947519|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
218947520|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
218947521|NCT01060280|BEHAVIORAL|Education on active management|Routine clinical practice plus education on active management.
218947522|NCT01060280|OTHER|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
218947523|NCT01060280|OTHER|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
219053813|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
219053814|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
219053815|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
219053816|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
219053817|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
219206962|NCT06752837|DEVICE|Cone beam computed tomography|A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.
219635891|NCT04299568|PROCEDURE|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
219635892|NCT01171027|PROCEDURE|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
219053818|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
219053819|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219053820|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219053821|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
219635893|NCT01171027|PROCEDURE|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
218947524|NCT01337037|DEVICE|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
218947525|NCT01337037|PROCEDURE|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
219635894|NCT05060276|BIOLOGICAL|STI-3258|Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
219635895|NCT03459560|DRUG|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
218947526|NCT01337037|PROCEDURE|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
218947527|NCT01337037|PROCEDURE|Open lobectomy|standard lobectomy procedure by thoracotomy approach
218947528|NCT01248104|DRUG|Tranexamic Acid|Infusion during cardiac surgery
218947529|NCT01248104|DRUG|Aminocaproic Acid|Infusion during cardiac surgery
218947530|NCT02129504|DEVICE|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
218947531|NCT01964755|DRUG|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
218947532|NCT01964755|DRUG|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
218947533|NCT01964755|DRUG|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
218947534|NCT01964755|BIOLOGICAL|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
218947535|NCT01964755|DRUG|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
218947536|NCT01964755|DRUG|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
219366059|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
219635896|NCT06450327|OTHER|This is a cross-sectional observational study|There will be no intervention in the study.
219635897|NCT02200172|OTHER|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
219635898|NCT02200172|OTHER|Placebo|
218947537|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
218947538|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
218947539|NCT03736772|DRUG|LY3090106|Administered SC
218947540|NCT03736772|DRUG|Placebo|Administered SC
218947541|NCT04944108|PROCEDURE|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
218947542|NCT04944108|PROCEDURE|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
218947543|NCT05813808|DIAGNOSTIC_TEST|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
218947544|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
218947545|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
218947546|NCT02894502|BEHAVIORAL|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
218947547|NCT05901753|DEVICE|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
219053822|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
219053823|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
218947548|NCT05901753|DEVICE|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
218947549|NCT04988191|DRUG|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
218947550|NCT04988191|DRUG|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
218947551|NCT04988191|DRUG|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
218947552|NCT01198613|BIOLOGICAL|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
218947553|NCT01198613|BIOLOGICAL|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
218947554|NCT02494063|PROCEDURE|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
218947555|NCT02494063|PROCEDURE|At least unilateral systematic pelvic lymph node dissection|
218947556|NCT01008241|BEHAVIORAL|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
218947557|NCT02150538|DEVICE|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
218947558|NCT02150538|DEVICE|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
219053824|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
219053825|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
219053826|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
219635899|NCT00204776|DRUG|Capecitabine and Oxaliplatin|
219635900|NCT02887976|DRUG|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
219053827|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
219053828|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
219635901|NCT02887976|DRUG|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
219635902|NCT03278327|PROCEDURE|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
218947559|NCT03289624|BEHAVIORAL|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG \& PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, \& ending with a review of material, addressing questions, \& previewing the next session. Sessions titles are: Communication \& Health Education; Care Values; Care Preferences; Family, Friends, \& Community Resources; Taking care of yourself-taking care of each other; \& Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values \& preferences are supported when decisions have to be in the future."
218947560|NCT00230555|BEHAVIORAL|professional support model|
218947561|NCT02495571|OTHER|Cough Assessment in ALS Patients|"1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
218947562|NCT02845219|DRUG|semaglutide|Oral administration once daily alone or together with oral contraceptive.
218947563|NCT02845219|DRUG|SNAC|Oral administration once daily together with oral contraceptive.
218947564|NCT02845219|DRUG|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
218947565|NCT03599375|BIOLOGICAL|CD19-targeted CART cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
218947566|NCT06131164|OTHER|Diaphragmatic Breathing Exercise Group|The subjects in this group will perform Diaphragmatic Breathing Exercise Group
218947567|NCT06131164|OTHER|Thoracic Extension Exercise Group|The subjects in this group will perform Thoracic Extension Exercise Group
218947568|NCT01873612|PROCEDURE|Hypoxic ventilatory response|
218947569|NCT01873612|PROCEDURE|Hypercapnic ventilatory response|
219053829|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
219053830|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
219053831|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
219053832|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
219053833|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
219053834|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
219053835|NCT02894203|BEHAVIORAL|Mindfulness|
219635903|NCT03278327|DEVICE|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
218947570|NCT02356367|OTHER|telemonitoring|
218947571|NCT01710137|DRUG|Varenicline|
218947572|NCT01710137|DRUG|Placebo|
218947573|NCT01710137|BEHAVIORAL|Smoking Cessation Counseling|
218947574|NCT03007810|DRUG|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
218947575|NCT03007810|DRUG|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
218947576|NCT03251131|OTHER|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
218947577|NCT05045937|DRUG|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
218947578|NCT01275807|DEVICE|acupuncture|10 sessions of acupuncture
219053836|NCT02894203|BEHAVIORAL|Yoga|
219053837|NCT00237952|DRUG|EDTA chelating agents|
219053838|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
219366060|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
218947579|NCT01275807|OTHER|self care|physical exercice, diet, self help groups, psychological support
218947580|NCT01810614|OTHER|ADPKD Diet|Diet specifically designed for people with ADPKD
218947581|NCT00601042|OTHER|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
218947582|NCT00601042|OTHER|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
218947583|NCT03035487|DEVICE|Ultrasound guided prostate exam using SOC ultrasound system|
218947584|NCT03035487|DEVICE|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
218947585|NCT03035487|DEVICE|High-resolution micro-ultrasound guided prostate biopsy|
218947586|NCT01332799|DRUG|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
219635904|NCT06352112|OTHER|Pelvic Floor Muscle Training|PFMT consisted of both slow voluntary contractions lasting 15 seconds each (5-s contraction, 5-s hold and 5-s relaxation) and fast voluntary contractions lasting 2-s each. A set of exercises included 10 slow and 10 fast voluntary contractions. During the first week, women performed five sets of exercises a day, and the exercises were continued for eight weeks by increasing five sets each week. The exercises were performed as home exercises.
219635905|NCT06352112|OTHER|Hypopressive Exercises|"HE program in which different placements of the upper and lower extremities were used in standing, sitting and supine positions, and the participants were asked to perform the exercises with a hypopressive maneuver to maintain apnea and rib cage expansion for approximately 10 seconds. Exercises were started with three repetitions a day, and then the number of repetitions was increased to five and/or 10, depending on the participant's tolerance. The exercises were performed as home exercises."
219635906|NCT00642564|OTHER|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
219635907|NCT04050852|DRUG|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
218947587|NCT01332799|OTHER|Placebo|Sugar pill administered orally for 3 years.
218947588|NCT00629967|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
218947589|NCT00629967|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
218947590|NCT01198522|DRUG|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
218947591|NCT04347668|OTHER|Virtual Reality|VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
218947592|NCT04347668|OTHER|Usual Care|meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
218947593|NCT00178529|BEHAVIORAL|Psychoeducation, Counseling and Skill Training|
218947594|NCT02908490|DRUG|Sildenafil|Sildenafil 50 mg once daily
218947595|NCT02908490|OTHER|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
218947596|NCT02168387|DEVICE|continuous high frequency oscillator (CHFO)|
218947597|NCT02168387|DRUG|Acetylcysteine|
218947598|NCT02168387|DRUG|dornase alfa|
218947599|NCT06450119|OTHER|walking training|The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
218947600|NCT06450119|OTHER|cognition training|The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
218947601|NCT03660670|BEHAVIORAL|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
218947602|NCT03660670|BEHAVIORAL|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
218947603|NCT00002289|DRUG|Thymopentin|
218947604|NCT01588756|DRUG|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
218947605|NCT01588756|DRUG|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
218947606|NCT03676101|BIOLOGICAL|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
218947607|NCT03676101|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
218947608|NCT06079229|OTHER|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
218947609|NCT02505828|PROCEDURE|Articular punction, salivary samples, blood sample|
218947610|NCT03467152|DRUG|Irsenontrine|Oral hypromellose capsules.
218947611|NCT03467152|DRUG|Placebo|Oral hypromellose capsules.
218947612|NCT03395119|DRUG|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
219635908|NCT05823233|OTHER|Cold application+Deep friction+Home exercise+Eccentric stretching|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
218947613|NCT03395119|DIETARY_SUPPLEMENT|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
218947614|NCT03395119|DIETARY_SUPPLEMENT|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
219053839|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
218947615|NCT01236547|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218947616|NCT01236547|DRUG|Paclitaxel|Given IV
218947617|NCT01236547|DRUG|Pazopanib Hydrochloride|Given PO
219053840|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
219053841|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
219053842|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
219053843|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
219053844|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
219053845|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
219053846|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
219053847|NCT00002312|DRUG|Delavirdine mesylate|
219053848|NCT00002312|DRUG|Zidovudine|
219206963|NCT06841120|DEVICE|Actual laser application|At approximately 45 minutes into the treatment session, subjects in the laser group received irradiation from a 4 W power, 810 nm diode laser (Fox; ARC Laser, GmbH, Nürnberg, Germany). The laser was operated in continuous mode, delivering 12-second shots per point using a therapy head with a point size of 0.38 cm². Each point received 6.3 J/cm² of laser energy, resulting in a total energy density of 37.8 J/cm² across 6 points.
219053849|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
219053850|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
219053851|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
218947618|NCT01236547|OTHER|Placebo Administration|Given PO
218947619|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
219206964|NCT06841120|DEVICE|Sham laser application|Sham laser was applied symbolically as a diffused closed laser (targeted beam) at the same distance and simultaneously. Evaluations after laser irradiation were conducted by a responsible specialist physician who was not involved in performing the treatment procedures.
219206965|NCT05197309|DIETARY_SUPPLEMENT|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
219206966|NCT06842719|PROCEDURE|on-site housing counseling|on-site housing counseling by a certified housing counseling expert
219206967|NCT06865963|GENETIC|vulvar biopsy and blood semples|Collection of different types of specimen from VBD patients and healthy controls: mRNA, protein, cells, blood
218947620|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
218947621|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
218947622|NCT00715143|DEVICE|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
218947623|NCT00000144|PROCEDURE|Argon Laser Treatment|
218947624|NCT05099224|BEHAVIORAL|Mindfulness meditation|similar to the information included in arm/group descriptions
218947625|NCT03069521|DEVICE|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
218947626|NCT00315757|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
218947627|NCT00315757|BIOLOGICAL|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
218947628|NCT00315757|DRUG|Bortezomib|1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
218947629|NCT05302453|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
218947630|NCT05373888|DEVICE|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)"
218947631|NCT00910624|DRUG|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
218947632|NCT00910624|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
218947633|NCT00910624|DRUG|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
218947634|NCT02880085|DRUG|Local anesthetic|local injection
218947635|NCT02653703|OTHER|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
218947636|NCT02653703|OTHER|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
218947637|NCT03775538|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
218947638|NCT03775538|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
219053852|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
219053853|NCT03083496|DRUG|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
219053854|NCT03083496|DRUG|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
219635909|NCT05823233|OTHER|Cold application+Deep friction+Home exercise|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
219635910|NCT00550043|DRUG|INCB018424|
219635911|NCT00550043|DRUG|Placebo|
219053855|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
219053856|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
219635912|NCT02011633|DRUG|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
219635913|NCT02011633|DRUG|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
219635914|NCT02011633|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
219635915|NCT02354677|OTHER|In vitro experiments on bronchial epithelial cells|
219635916|NCT00634361|DRUG|ethyl-eicosapentaenoic acid|2 mg per day
218947639|NCT02226133|DEVICE|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
218947640|NCT05736029|OTHER|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
218947641|NCT01713933|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
218947642|NCT06505720|PROCEDURE|Arthroscopic management of acute pediatric septic hip infecion|Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection
218947643|NCT06505720|PROCEDURE|Open debridement of acute pediatric septic hip|surgical drainage and debridement of acute septic hip in children via classic lateral approach
218947644|NCT00412373|DRUG|Placebo|for 6 weeks
218947645|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
218947646|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
218947647|NCT06257043|PROCEDURE|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
218947648|NCT00423527|DRUG|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
219053857|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
219053858|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
219053859|NCT00222287|BEHAVIORAL|Feldenkrais Movement class|
219053860|NCT03161314|PROCEDURE|Strengthening exercises|Conservative physical therapy treatment with home-based strengthening exercises (study 3)
219635917|NCT02550782|DRUG|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
219635918|NCT02550782|DRUG|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
219635919|NCT05032027|OTHER|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
219635920|NCT01027520|OTHER|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
219635921|NCT04215627|DEVICE|non-invasive monitoring|Comparing the PiCCO monitor to the non-invasive BB-613PW device in hemodynamically unstable critically ill patients in the ICU
218947649|NCT03458715|DRUG|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
218947650|NCT03458715|DRUG|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
218947651|NCT03349398|PROCEDURE|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
218947652|NCT03349398|PROCEDURE|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
218947653|NCT04022733|DRUG|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
218947654|NCT04022733|DRUG|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
218947655|NCT02816164|DRUG|Neupogen|Subcutaneous injections
218947656|NCT05405088|OTHER|Questionnaires|Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
218947657|NCT04483388|OTHER|Training with Virtual Reality|Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
218947658|NCT04483388|OTHER|Conventional Training|"It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training)."
219053861|NCT03161314|PROCEDURE|Stretching exercises|Conservative physical therapy treatment with home-based stretching exercises (study 3)
219053862|NCT00902200|DRUG|AR-12286|See arms
219053863|NCT00902200|DRUG|AR-12286 vehicle|See arms
219053864|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
219053865|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
219053866|NCT02500849|GENETIC|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
219053867|NCT06798012|BIOLOGICAL|TAK-411|TAK-411 IV infusion.
219635922|NCT05013320|DRUG|Glycopyrrolate + dexmedetomidine|Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
219053868|NCT02722668|DRUG|Fludarabine|Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
219053869|NCT02722668|DRUG|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
219053870|NCT02722668|DRUG|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF."
219206968|NCT06881537|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles
219635923|NCT05013320|DRUG|Dexmedetomidine|Dexmedetomidine administration during the surgery.
219635924|NCT01493674|DIETARY_SUPPLEMENT|folic acid|two 5-mg tablets of folic acid
219635925|NCT04273529|DRUG|thalidomide|100mg，po，qn，for 14 days.
218947659|NCT02855541|DEVICE|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
218947660|NCT01417013|OTHER|Systane Ultra|Lubricant Eye Drops
218947661|NCT01417013|OTHER|Optive|Lubricant eye drops
218947662|NCT00033267|DRUG|temsirolimus|Given IV
218947663|NCT01389661|BIOLOGICAL|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
218947664|NCT01131013|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
219635926|NCT04273529|DRUG|placebo|100mg，po，qn，for 14 days.
219635927|NCT03771560|DRUG|folinic acid|subject will take folinic acid daily for 12 weeks
219635928|NCT04145180|OTHER|Manual therapy|40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
219635929|NCT01106560|PROCEDURE|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
219635930|NCT01106560|PROCEDURE|Standard postero-lateral approach|
218947665|NCT01131013|DRUG|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
218947666|NCT01131013|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
218947667|NCT00367783|DRUG|CP-741,952|
218947668|NCT00422513|DRUG|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
218947669|NCT00422513|DRUG|Epoetin alfa|As prescribed, iv, 3 times weekly
218947670|NCT03135119|BEHAVIORAL|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
218947671|NCT03135119|BEHAVIORAL|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
218947672|NCT00440791|DEVICE|PillCam Colon capsule endoscopy|
218947673|NCT00858572|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
218947674|NCT03897439|DRUG|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
218947675|NCT03897439|DRUG|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
218947676|NCT03897439|DRUG|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
218947677|NCT03584581|DIETARY_SUPPLEMENT|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
218947678|NCT03584581|DIETARY_SUPPLEMENT|Control|Placebo
218947679|NCT04120298|BEHAVIORAL|Supervised exercise|An individualised exercise programme supervised by a trained instructor
218947680|NCT00150917|BEHAVIORAL|Supportive-Expressive Group Therapy|
218947681|NCT03278704|OTHER|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
218947682|NCT03278704|OTHER|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
219053871|NCT02722668|DRUG|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
219053872|NCT02722668|RADIATION|TBI|Both Arms: 200 cGy on Day -1
219635931|NCT01095562|DRUG|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
219635932|NCT01095562|DRUG|Placebo|Placebo
219635933|NCT03111680|OTHER|environmental intervention|a multi component environmental intervention
218947683|NCT05975398|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
218947684|NCT05975398|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
218947685|NCT03897140|DIAGNOSTIC_TEST|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
218947686|NCT02576184|DEVICE|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
218947687|NCT02576184|DEVICE|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
218947688|NCT04605705|COMBINATION_PRODUCT|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
218947689|NCT02047344|DRUG|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
218947690|NCT00565929|DRUG|Placebo|Sterile saline (0.9%).
218947691|NCT00565929|BIOLOGICAL|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
218947692|NCT03933995|OTHER|no Intervention|no Intervention
218947693|NCT02486341|DRUG|Insulin|Continuous glucose monitoring system over 120-hour period.
219053873|NCT02722668|BIOLOGICAL|Umbilical cord blood cell infusion|Both Arms: Day 0
219053874|NCT02722668|BIOLOGICAL|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
219635934|NCT05504980|PROCEDURE|Repositioning|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
218947694|NCT05109455|DIETARY_SUPPLEMENT|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
218947695|NCT05109455|DIETARY_SUPPLEMENT|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
218947696|NCT05293899|DIAGNOSTIC_TEST|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
218947697|NCT05076864|OTHER|No intervention|No intervention
218947698|NCT02639858|DRUG|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
219053875|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
219053876|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
219053877|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
219053878|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
219053879|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
219053880|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
219053881|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
219053882|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
219206969|NCT06881537|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m² on Day 1 every 3 weeks for 4 cycles
219635935|NCT03917446|DRUG|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
219635936|NCT02744729|DRUG|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
219635937|NCT05510479|OTHER|Software as medical device|At home measurements of visual acuity through a mobile app
219635938|NCT01653821|PROCEDURE|Carotid body excision|
219635939|NCT05655364|OTHER|Mobile application|Breastfeeding Supportive Mobile Application
219635940|NCT04124211|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
219635941|NCT02887183|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
219635942|NCT05586347|DRUG|Nicardipine|Nicardipine 0.2-0.5μg/(kg·min) was infused at the beginning of CPB.
219635943|NCT05586347|OTHER|normal saline|It has the same capacity as group N。
219635944|NCT01182051|BEHAVIORAL|CBT or relaxation training|8 weeks of CBT or relaxation training.
219635945|NCT02063477|DIETARY_SUPPLEMENT|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
218947699|NCT01258569|DRUG|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
219053883|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
219053884|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
219206970|NCT06881537|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 4 cycles
219053885|NCT06156228|BEHAVIORAL|Multilevel Intervention|Clinic patients from the randomly assigned intervention clinics will be provided with additional vaccine information and will have the opportunity to ask any questions they might have about any of the 4 study focused vaccines (COVID-19, Shingles, Pneumococcal, Influenza). Health educators will provide them with additional information, address any misinformation and disinformation and will offer to schedule their vaccine appointment(s) for them.
219053886|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
219053887|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
219206971|NCT06881537|DRUG|Tislelizumab|Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles
218947700|NCT01258569|DRUG|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
219635946|NCT02063477|DIETARY_SUPPLEMENT|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~\- TOTAL POLYPHENOL CONTENT \> 96~1. MONOMERS + PHENOLIC ACIDS 30~2. DIMERS \>15~3. OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) \> 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
219635947|NCT04412109|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for postoperative pain control
218947701|NCT01258569|DRUG|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
218947702|NCT00204555|DRUG|Imiquimod|
218947703|NCT04263584|DRUG|Copanlisib|Copanlisib vials 60 mg
218947704|NCT04263584|DRUG|R-CHOP Chemotherapy|Immunochemotherapy
218947705|NCT03310333|DRUG|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
218947706|NCT03310333|DEVICE|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
218947707|NCT03254576|OTHER|Functional MRI|
218947708|NCT05315908|OTHER|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
218947709|NCT05885178|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
218947710|NCT03361644|BEHAVIORAL|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
218947711|NCT03361644|BEHAVIORAL|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
218947712|NCT01561898|DRUG|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
218947713|NCT00960583|OTHER|Exercise program|24 group exercise sessions during 12 weeks
218947714|NCT00960583|OTHER|Routine follow-up|Advice to stay active
218947715|NCT03957460|OTHER|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
219366061|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
218947716|NCT02773784|OTHER|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
218947717|NCT00103233|BIOLOGICAL|trastuzumab|
218947718|NCT00103233|DRUG|vinorelbine tartrate|
218947719|NCT00294762|DRUG|Tarceva|oral tablet
218947720|NCT00294762|DRUG|carboplatin|IV
218947721|NCT00294762|DRUG|paclitaxel|IV
218947722|NCT01883453|DEVICE|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
218947723|NCT01883453|DEVICE|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
218947724|NCT01217333|BEHAVIORAL|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
219053888|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
219053889|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
218947725|NCT01217333|BEHAVIORAL|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
218947726|NCT03605628|OTHER|measuring tape|measurement of change in abdominal wall length \[cm\] during neuromuscular block with a measuring tape.
218947727|NCT03605628|OTHER|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
218947728|NCT03605628|OTHER|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~1. extremely poor conditions~2. poor conditions~3. acceptable conditions~4. good conditions~5. optimal conditions"
218947729|NCT04208971|OTHER|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
218947730|NCT05812560|OTHER|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
218947731|NCT02238080|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
218947732|NCT01738646|DRUG|Vorinostat|
218947733|NCT01738646|DRUG|Bevacizumab|
218947734|NCT04640662|BIOLOGICAL|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
218947735|NCT04640662|BIOLOGICAL|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
218947736|NCT06167811|OTHER|whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
218947737|NCT05904418|OTHER|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
218947738|NCT05904418|OTHER|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
218947739|NCT05904418|RADIATION|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
218947740|NCT04691414|GENETIC|NGS|next-generation sequencing on preexisting samples
218947741|NCT02299102|DEVICE|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
218947742|NCT02299102|DEVICE|OnControl Powered Ported Device|OnControl Powered Ported Device
218947743|NCT04304638|RADIATION|radiation or chemo-radiation|standard treatment for stage III lung cancer
218947744|NCT04304638|DRUG|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
219053890|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
219053891|NCT06430541|DRUG|Psilocybin|A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
219053892|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
219053893|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
218947745|NCT03222882|PROCEDURE|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
219053894|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
218947746|NCT06157788|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging and clinical assessment|"* fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images"
218947747|NCT03415542|BEHAVIORAL|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
218947748|NCT03198325|OTHER|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values \>50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
218947749|NCT01712724|OTHER|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
218947750|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
218947751|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
218947752|NCT01707238|DEVICE|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
218947753|NCT01707238|DEVICE|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
218947754|NCT00682578|DRUG|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
218947755|NCT00682578|DRUG|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
218947756|NCT02697149|RADIATION|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
218947757|NCT02697149|RADIATION|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
218947758|NCT01945918|BEHAVIORAL|Self-management support education|Same as Arm Description
219053895|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
219053896|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
219053897|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
219053898|NCT01197469|DRUG|Placebo|
219206972|NCT06886568|PROCEDURE|Ultrasound-guided ganglion impar block|The procedure will be performed under sterile conditions and continuous monitoring. Using an ultrasound device with a 10-12 MHz linear probe, a 22G spinal needle will be advanced into the sacrococcygeal joint space using the out-of-plane technique. After confirming loss of resistance with a syringe containing normal saline as the needle exits the capsule anterior to the joint, approximately 1 mL of contrast medium will be injected. Anteroposterior (AP) and lateral fluoroscopic images will be obtained to verify the spread of the contrast agent. Once adequate contrast distribution is confirmed anterior to the coccyx on the lateral view, a mixture of dexamethasone and bupivacaine will be injected to complete the block. Procedures that cannot be completed or successfully visualized under ultrasound guidance will be finalized under fluoroscopic guidance.
219206973|NCT06883656|DRUG|SAL067|Fasting oral test drug 12mg
219206974|NCT06884111|DRUG|EE001，70-105ml per day by IV|EE001 is a brand-new testing agent for human studies, it is the first time in human being
218947759|NCT01945918|BEHAVIORAL|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
218947760|NCT01945918|BEHAVIORAL|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
218947761|NCT01991613|DIETARY_SUPPLEMENT|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
218947762|NCT01676636|DRUG|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
218947763|NCT01676636|DRUG|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
218947764|NCT01676636|DRUG|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
218947765|NCT01676636|DRUG|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
218947766|NCT04093024|DRUG|Nintedanib|Capsule
218947767|NCT04093024|DRUG|Placebo|Capsule
218947768|NCT05575050|PROCEDURE|Oral Procedure|Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
219053899|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
218947769|NCT03156387|PROCEDURE|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
218947770|NCT03156387|PROCEDURE|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
218947771|NCT04779788|DEVICE|I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)|An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
218947772|NCT04779788|DEVICE|Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)|Bare self-expanded metal stent
218947773|NCT03287518|DIETARY_SUPPLEMENT|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
218947774|NCT03287518|DIETARY_SUPPLEMENT|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
219053900|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
219053901|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
219053902|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
219053903|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
219635948|NCT02499211|OTHER|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
219635949|NCT01277627|DRUG|Nevirapine|nevirapine: 400 mg a day.
218947775|NCT06193551|DEVICE|Ovitex LPR|Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
218947776|NCT02609867|DEVICE|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
218947777|NCT04571671|OTHER|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
218947778|NCT03561688|DEVICE|Foot orthotics|Insoles for shoes
218947779|NCT03561688|DEVICE|Standard insole|Sham foot orthotic
218947780|NCT05916599|DEVICE|ultrasound|a device which is used in intensive care units,
218947781|NCT03145818|OTHER|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
218947782|NCT05506241|DEVICE|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
218947783|NCT03632408|DRUG|Zopiclone|Oral, single dose, 7.5 mg
218947784|NCT03632408|BEHAVIORAL|hangover|as per subjects choice to consume alcohol
218947785|NCT03632408|DRUG|Placebo oral capsule|oral
218947786|NCT00488306|DRUG|tigecycline|
218947787|NCT00421941|PROCEDURE|Tube feeding|
218947788|NCT04508218|DIETARY_SUPPLEMENT|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
218947789|NCT04508218|OTHER|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
218947790|NCT04508218|OTHER|traditional burn care|ROM exercises, stretching, ADL activities and scar management
218947791|NCT00367367|PROCEDURE|Hysteroscopy and Curettage|
218947792|NCT02449746|BIOLOGICAL|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
218947793|NCT02449746|BIOLOGICAL|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
218947794|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
218947795|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Kindeva)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
218947796|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
218947797|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
218947798|NCT06247189|OTHER|ICOPE Monitoring|"At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program.~Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program"
218947799|NCT05317117|DIAGNOSTIC_TEST|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
218947800|NCT01917253|DEVICE|Standard Device for peripheral vein cannulation|
218947801|NCT01917253|DEVICE|Long Catheters for peripheral vein cannulation|
218947802|NCT04845711|OTHER|Control group|patients will receive general anesthesia only.
218947803|NCT04845711|PROCEDURE|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
218947804|NCT04845711|PROCEDURE|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
218947805|NCT05707039|OTHER|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
218947806|NCT05707039|OTHER|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
218947807|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
218947808|NCT00647270|DRUG|Placebo|Pre-filled syringe. See arm for more detail
218947809|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
218947810|NCT00262054|DRUG|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
218947811|NCT00262054|DRUG|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
218947812|NCT02215941|DRUG|TV-45070|TV-45070 8% ointment
218947813|NCT02215941|DRUG|Placebo|Placebo
218947814|NCT01184950|OTHER|Trainer Curriculum|
218947815|NCT02523144|DRUG|Chloral Hydrate|70mg/kg chloral hydrate
218947816|NCT02523144|DRUG|Dexmedetomidine|2mcg/kg
218947817|NCT02523144|DRUG|Dexmedetomidine|3mcg/kg
218947818|NCT02523144|DRUG|Placebo|Flavored placebo syrup
219053904|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
219053905|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
219053906|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
218947819|NCT05862506|BEHAVIORAL|Daily Mile|The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
219635950|NCT01277627|DRUG|efavirenz, protease inhibitors|efavirenz: 600 mg a day
219206975|NCT06766812|DEVICE|epidural set|The epidural space will be identified at either the L3-L4 or L4-L5 interspace using the loss of resistance technique with an 18 Gauge Epidural needle.A test dose of 3 mL of 2% lidocaine with epinephrine will be administered to each participant to rule out intravascular or intrathecal placement of the catheter. This ensures the proper placement of the catheter before the full dose of analgesia is administered.Following the test dose, an initial bolus of 8 mL of 0.25% bupivacaine combined with 2 μg/mL fentanyl will be administered to provide effective labor analgesia. Subsequently, maintenance Dose 0.125% 2 ml/0.5 hr
219206976|NCT06765512|OTHER|use of deep learning and automated machine learning to diagnose and classify adenomyosis|Vertex AI Vision V1 software will be used as an automated machine learning tool and Pytorch 2.5 as deep learning framework. The complete set of reviewed, formatted and labelled images will be uploaded and split manually into two different datasets in 9:1 ratio; 90% of the selected images will be used as training dataset (training + validation) and 10% as test dataset.
219635951|NCT01031680|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
219635952|NCT01031680|DRUG|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
218947820|NCT00498290|PROCEDURE|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
218947821|NCT00498290|PROCEDURE|control|normal recovery protocol as usually
218947822|NCT03303664|OTHER|IMPROVE Protocol|Comprehensive pain management protocol
218947823|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion|Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.
218947824|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion [SKLICE]|Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.
218947825|NCT03337490|DRUG|Placebo 0% Lotion|Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
219053907|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
219053908|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
219206977|NCT06765772|PROCEDURE|Erector spinae plane block|the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
218947826|NCT00002845|BIOLOGICAL|aldesleukin|
218947827|NCT02468245|BEHAVIORAL|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
219206978|NCT06765772|PROCEDURE|Rectus sheath block|the patient will recieve ultrasound guided rectus sheath block. An 18-gauge needle will be introduced- in plane- just below the costal margin at an angle of approximately 45 degrees to the skin between the rectus abdominis muscle and posterior rectus sheath. 10 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
219206979|NCT06761001|DEVICE|I-PRF|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution. I-PRF is given to patients in the experimental group.
219206980|NCT06761001|OTHER|Control|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution.
219635953|NCT06178211|DRUG|Immunotherapy: Adebrelimab|Adebrelimab 1200mg Q3W
219635954|NCT06178211|DRUG|chemotherapy: carboplatin plus nab-paclitaxel|carboplatin plus nab-paclitaxel
219635955|NCT01905527|OTHER|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
219635956|NCT01905527|OTHER|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
219635957|NCT01905527|OTHER|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
219053909|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
219053910|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
219053911|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
218947828|NCT02468245|BEHAVIORAL|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
218947829|NCT00901732|DEVICE|Caphosol|Oral Mouth Rinse
218947830|NCT00188383|DRUG|Amantadine|
218947831|NCT05594745|DRUG|Lifitegrast Ophthalmic|eyedrop
218947832|NCT05594745|DRUG|Systane Free|eyedrop
218947833|NCT05594745|DEVICE|Lipiflow|thermal pulsation
218947834|NCT02855918|OTHER|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
218947835|NCT04493892|BEHAVIORAL|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
218947836|NCT04606680|DEVICE|Heat application at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
218947837|NCT04606680|DEVICE|Medicated plaster at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
218947838|NCT04606680|DEVICE|Herb-partitioned moxibustion at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard\[18\]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
218947839|NCT05996913|OTHER|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz \& Weertman, 1999).
218947840|NCT02619383|DEVICE|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
218947841|NCT06144099|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
218947842|NCT06144099|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
218947843|NCT04626401|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
218947844|NCT05677685|DEVICE|VISUPRIME|twice daily
218947845|NCT05677685|DEVICE|Placebo|twice daily
218947846|NCT00335179|DRUG|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
219053912|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
219053913|NCT00128180|DRUG|Placebo|Placebo
219053914|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
218947847|NCT00335179|DRUG|Vehicle cream|Vehicle cream in 250 mg
218947848|NCT03878433|DRUG|Glisodin|500 mg/day between 12 weeks
218947849|NCT03878433|OTHER|placebo|Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
218947850|NCT01566084|DRUG|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
218947851|NCT01566084|OTHER|placebo|Placebo tablets are administered to maintain the low sodium condition.
218947852|NCT03300102|OTHER|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
218947853|NCT01158170|RADIATION|Prophylactic cranial irradiation|25GY/10fraction
218947854|NCT01158170|DRUG|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
218947855|NCT00474305|BEHAVIORAL|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
218947856|NCT02651129|OTHER|Noise measurement|We will be measuring noise levels in the operating room
219053915|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
219053916|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
218947857|NCT06065085|OTHER|mobile education|"The study was conducted as a randomized controlled trial with 134 individuals with hypertension (68 experimental, 66 controlled) who applied a university hospital. The data were collected by Patient Information Form, Healthy Lifestyle Behaviour Scale II, EQ-5D General Quality of Life Scale, Mindful Attention Awareness Scale and Percieved Stress Scale were used. An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application."
219053917|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
219053918|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
219053919|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
219053920|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
219053921|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
219053922|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
219206981|NCT06779903|OTHER|the psychoeducation intervention program booklet|Psychoeducation Program was composed of nine basic topics (postpartum period and care, adaptation to the role of motherhood and mother-infant bonding, postpartum psychological changes, frequency, causes, symptoms of PPD, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support and suggestions for coping, breast milk and breastfeeding, breast care and practices, nutrition and baby care).
219635958|NCT03649932|DIETARY_SUPPLEMENT|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
218947858|NCT03920644|DRUG|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
219053923|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
219053924|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
219206982|NCT06779903|OTHER|routine care|routine care
218947859|NCT03920644|DRUG|Scopolamine|IND, up to 6 administration of intranasal gel.
218947860|NCT03920644|DRUG|Placebo Patch|Placebo Patch, 1 patch behind the ear.
218947861|NCT03920644|DRUG|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
218947862|NCT02249897|DRUG|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
218947863|NCT02267317|DRUG|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
218947864|NCT02267317|DRUG|D5W|5% Dextrose Water = Vehicle
219053925|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
219635959|NCT02757833|OTHER|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
219053926|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
218947865|NCT00807560|BEHAVIORAL|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
218947866|NCT00807560|BEHAVIORAL|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
218947867|NCT00004913|DRUG|cisplatin|
219053927|NCT00002335|DRUG|Emtricitabine|
219053928|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
219053929|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
219053930|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
219053931|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
219053932|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
219635960|NCT03319238|OTHER|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
219635961|NCT02976740|RADIATION|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
219635962|NCT02976740|DRUG|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
219635963|NCT02976740|DRUG|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
219635964|NCT04454047|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
219635965|NCT00789945|OTHER|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
219635966|NCT00789945|OTHER|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
218947868|NCT00004913|DRUG|docetaxel|
218947869|NCT00004913|DRUG|fluorouracil|
218947870|NCT00004913|DRUG|leucovorin calcium|
218947871|NCT03472846|DRUG|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
218947872|NCT03472846|DRUG|Teriparatide|osteoanabolic treatment with Forsteo
218947873|NCT00941434|DIETARY_SUPPLEMENT|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
218947874|NCT02931669|OTHER|Qualitative Descriptive Study|
218947875|NCT01606917|OTHER|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
218947876|NCT00947791|DRUG|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
218947877|NCT00947791|DRUG|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
219053933|NCT00434668|DRUG|cisplatin/docetaxel|
219053934|NCT00434668|DRUG|cisplatin/vinorelbine|
219053935|NCT00354224|DRUG|capecitabine|
219053936|NCT00354224|DRUG|oxaliplatin|
219053937|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
219053938|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
219053939|NCT05647512|DRUG|LM-305|Administered intravenously
219053940|NCT05647512|DRUG|Dexamethasone|Administered orally
219053941|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
218947878|NCT05829785|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
219053942|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
219053943|NCT00317681|DRUG|Tacrolimus ointment|
219053944|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
219053945|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
219053946|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
219053947|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
218947879|NCT06391632|DIAGNOSTIC_TEST|Revised Cardiac Risk Index|The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.
218947880|NCT06180187|DEVICE|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
218947881|NCT06180187|DEVICE|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
219635967|NCT02934698|DRUG|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
219635968|NCT02654977|DRUG|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
219635969|NCT01921101|BEHAVIORAL|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
219635970|NCT01921101|OTHER|control|participants will receive standard care for nutrition received from hospital admission to discharge
218947882|NCT02720029|DEVICE|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
218947883|NCT04169932|BIOLOGICAL|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
218947884|NCT03506230|BEHAVIORAL|Incentives|A bonus to buy their medications if they reduce their HBA1c
218947885|NCT02366364|DRUG|Placebo|Single oral administration of placebo consumption on Day 1
218947886|NCT02366364|DRUG|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
218947887|NCT02366364|DRUG|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
218947888|NCT02366364|DRUG|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
218947889|NCT00324298|BIOLOGICAL|bleomycin sulfate|
218947890|NCT00324298|DRUG|cisplatin|
218947891|NCT00324298|DRUG|etoposide|
218947892|NCT00324298|PROCEDURE|management of therapy complications|
219053948|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
219053949|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
219053950|NCT03178656|PROCEDURE|surgery|curative resection
219635971|NCT02311127|DEVICE|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
219635972|NCT02311127|DEVICE|StatLock|Device secures PICC however, device has to be changed weekly
219635973|NCT01483027|DEVICE|TheraSphere|yttrium 90 microspheres
218947893|NCT01717833|PROCEDURE|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
218947894|NCT01717833|PROCEDURE|Sham|Sham sessions of neuromuscular electrical stimulation
218947895|NCT03271645|BEHAVIORAL|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
218947896|NCT03271645|BEHAVIORAL|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
218947897|NCT03271645|BEHAVIORAL|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
218947898|NCT03271645|BEHAVIORAL|Face-to-face counselling|Face-to-face counselling
218947899|NCT00109603|DRUG|Tenofovir disoproxil fumarate|
218947900|NCT04367051|DRUG|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
218947901|NCT04367051|DRUG|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
218947902|NCT03002467|OTHER|PESI score|
219053951|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
219635974|NCT00815542|DEVICE|double balloon catheter|cervical ripening using double balloon catheter
219635975|NCT00815542|DRUG|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
219635976|NCT04453449|DRUG|Midazolam|Midazolam given as a sedative during diagnostic lumbar medial branch block
219635977|NCT03327727|DRUG|Investigational Agent: VL-2397|VL-2397
219635978|NCT03327727|DRUG|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
218947903|NCT00796445|DRUG|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
218947904|NCT00796445|DRUG|Placebo|IM solution, a course of 13 injections administered over 27 months
218947905|NCT03238170|DEVICE|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
218947906|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
218947907|NCT01547559|DRUG|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
218947908|NCT01547559|DRUG|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
218947909|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
218947910|NCT01547559|DRUG|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
219635979|NCT02242682|OTHER|Child passenger safety video|
218947911|NCT02445547|OTHER|UC-MSCs by peripheral intravenous infusion|
218947912|NCT02445547|DRUG|received hormone maintenance therapy|
218947913|NCT00511940|DRUG|acamprosate|999 mg/day - 2997 mg/day, oral
218947914|NCT00511940|OTHER|placebo|oral, placebo
218947915|NCT02208063|DRUG|Telavancin|
218947916|NCT02208063|DRUG|Vancomycin|
218947917|NCT02208063|DRUG|Daptomycin|
218947918|NCT02208063|DRUG|Synthetic penicillin|
219635980|NCT02017431|OTHER|Allergen|Subject specific allergen is inhaled on day 1 of the triad
219635981|NCT02017431|OTHER|Saline|Saline is inhaled on day 1 of the triad
219635982|NCT02017431|OTHER|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
219635983|NCT00723762|PROCEDURE|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
219635984|NCT03123445|DRUG|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
218947919|NCT02208063|DRUG|Cefazolin|
218947920|NCT00579384|DRUG|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
218947921|NCT00579384|DRUG|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
218947922|NCT00275132|DRUG|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
218947923|NCT00275132|DRUG|Matched placebo|Matched placebo PO daily
219635985|NCT03123445|DRUG|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
219635986|NCT03123445|DRUG|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
219635987|NCT03456804|DRUG|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
218947924|NCT00917644|DRUG|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
218947925|NCT00917644|GENETIC|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
218947926|NCT05439785|DEVICE|Dental floss/Interdental brush|Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
219635988|NCT04862169|OTHER|educational intervention (SPARK)|"There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion"
219635989|NCT04862169|OTHER|electronic version of the modules|electronic version of the modules
219635990|NCT00736164|DIETARY_SUPPLEMENT|selenomethionine|Given orally
218947927|NCT01260675|DRUG|Buprenorphine HCl/Naloxone HCl|
218947928|NCT00766753|BIOLOGICAL|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
218947929|NCT00766753|BIOLOGICAL|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
219053952|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
219053953|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
219635991|NCT00736164|OTHER|placebo|Given orally
219635992|NCT04786860|PROCEDURE|CPR|Cardiopulmonary resuscitation performed on patients with in-hospital cardiac arrest
219635993|NCT04289155|DRUG|GX-I7|patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks
219635994|NCT06940167|OTHER|Myofascial Release Group|myofascial release therapy combined with a home exercise program: Myofascial release techniques will be applied manually to the cervical and upper trapezius regions by a trained physiotherapist. The intervention will be administered three times per week for four weeks, totaling 12 sessions. In addition, participants will follow a standardized home exercise program designed to improve cervical mobility and reduce muscle tension.
218947930|NCT00766753|BIOLOGICAL|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
218947931|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
218947932|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
218947933|NCT03756493|PROCEDURE|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
218947934|NCT05747040|DIAGNOSTIC_TEST|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
218947935|NCT04062136|COMBINATION_PRODUCT|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
218947936|NCT01302977|PROCEDURE|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
218947937|NCT02721953|DIETARY_SUPPLEMENT|Butyrate|Butyrate
218947938|NCT02721953|OTHER|Placebo|Placebo
218947939|NCT04380064|PROCEDURE|ILM Peeling|ILM peeling performed during primary PPV for PDR
218947940|NCT04380064|PROCEDURE|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
218947941|NCT01517360|DRUG|Oxytocin|Oxytocin 40 IU, intranasal inhalation
218947942|NCT01517360|OTHER|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
218947943|NCT01517360|BEHAVIORAL|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
219053954|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
219053955|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
219053956|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
219053957|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
218947944|NCT01395290|DRUG|cholecalciferol|20.000 IU per week, oral
218947945|NCT04982003|OTHER|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
218947946|NCT00613912|OTHER|Magnetic Resonance Imaging|"* Morphological sequences~* Arterial Spin Labelling (Perfusion)~* Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
218947947|NCT04368078|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop"
218947948|NCT00940472|DRUG|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
219053958|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
219053959|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
219053960|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
219053961|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
219053962|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
219635995|NCT06940167|OTHER|Kinesiology Taping Group|kinesiology taping combined with a home exercise program : Kinesiology tape will be applied to the cervical region following a standardized taping protocol. The taping will be performed by a trained physiotherapist three times per week for four weeks, totaling 12 sessions. The tape will remain on the skin for 3-5 days per application.
219635996|NCT06940167|OTHER|Home Exercise Program (Control Group)|Home exercise program: The exercise program includes cervical mobility exercises, stretching, and strengthening exercises aimed at improving posture and reducing muscle tension. The intervention will be performed three times per week for four weeks, totaling 12 sessions.
219053963|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
219053964|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
219635997|NCT06787196|DRUG|Dexamethasone|Dexamethasone, single-dose, 8 mg IV administered intraoperatively
219635998|NCT05859568|DEVICE|Pinna-located microphone|Sound processors using a pinna-located microphone
219635999|NCT05859568|DEVICE|Pinna-simulated microphone algorithm|Sound processors using a pinna-simulated algorithm
219636000|NCT06022848|PROCEDURE|occipital nerve stimulator|Quantitative sensory testing
219636001|NCT06195306|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218947949|NCT00940472|DRUG|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
218947950|NCT05184010|DEVICE|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
218947951|NCT05184010|DEVICE|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
218947952|NCT00422084|DRUG|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
218947953|NCT00422084|DRUG|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
218947954|NCT06356428|OTHER|Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)|The PACRR comprises 20 items and 1 open ended item to assess physicians' attitudes and beliefs about CR and referral (includes instructions for scale completion to respondents). Response options were 1 = strongly disagree, 2 = agree, 3 = neutral, 4 = agree, and 5 = strongly agree. Five (5) items are reverse-scored to mitigate acquiescence bias (denoted with \*), such that higher scores reflect more positive atti- tudes toward CR and referral. A mean score is computed for the total (where at least 80% of items were completed; i.e., 15/19) scale and subscales.
218947955|NCT00146484|DRUG|Twice Daily versus Three Times Daily Insulin Injections|
218947956|NCT05563155|DRUG|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
218947957|NCT05563155|DRUG|Placebo|Placebo tablet given on day 1 after surgery.
218947958|NCT00915499|DEVICE|VPAP Adapt SV|Comparison of ASV and CPAP modes
218947959|NCT06049901|DRUG|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
218947960|NCT04571528|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
218947961|NCT04571528|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
218947962|NCT04571528|BEHAVIORAL|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
218947963|NCT01944280|OTHER|massage|
219636002|NCT06195306|PROCEDURE|Mammography|Undergo mammography
218947964|NCT03774823|DEVICE|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
219636003|NCT06195306|DRUG|Omega-3-Acid Ethyl Esters|Given PO
219636004|NCT06195306|OTHER|Questionnaire Administration|Ancillary studies
218947965|NCT03774823|DEVICE|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
218947966|NCT02827656|DRUG|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
218947967|NCT02827656|DRUG|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
218947968|NCT01429909|DEVICE|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.
219053965|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
219366062|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
219636005|NCT06195306|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
219636006|NCT06195306|DRUG|Tamoxifen|Given PO
218947969|NCT00958438|DRUG|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
218947970|NCT00958438|DRUG|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
218947971|NCT00958438|DRUG|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
218947972|NCT05948865|DRUG|CPO301|Administered by intravenous injection
219053966|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
219053967|NCT04509700|DRUG|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
219053968|NCT04509700|DRUG|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
219053969|NCT04509700|DRUG|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
219053970|NCT04509700|DRUG|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
219053971|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
219053972|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
219053973|NCT00538005|BIOLOGICAL|bevacizumab|
219053974|NCT00538005|DRUG|oxaliplatin|
219053975|NCT00538005|DRUG|sorafenib tosylate|
219053976|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
219053977|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
219053978|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
219053979|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
219636007|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
219636008|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
218947973|NCT00759564|DRUG|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
218947974|NCT04618510|DEVICE|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
218947975|NCT04618510|DEVICE|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
218947976|NCT03550521|BEHAVIORAL|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
219053980|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
219053981|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
219366063|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
219053982|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
219053983|NCT01675180|OTHER|Control|No intervention
219053984|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
218947977|NCT04813003|OTHER|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
218947978|NCT01931215|OTHER|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
218947979|NCT01931215|OTHER|TAP-block with ropivacaine and clonidine|
218947980|NCT01599364|DRUG|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
218947981|NCT06212258|PROCEDURE|Abdominal Laparascopy|pneumoperitoneum
218947982|NCT03257709|PROCEDURE|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
219053985|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
219053986|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
219053987|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
219053988|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
219053989|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
219366064|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
219636009|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
219636010|NCT06115720|OTHER|Video assisted consent|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA. This video will aim to communicate the same information as that found in the traditional verbal consent, using an actor undergoing an anaesthetic to provide context.
219636011|NCT04817696|OTHER|Patients without chronic pain symptoms|Verbal score \< 3 at 3 months
219636012|NCT04817696|OTHER|Patients with chronic pain symptoms|Verbal score ≥ 3 at 3 months
218947983|NCT03257709|PROCEDURE|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
218947984|NCT03708887|DRUG|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
218947985|NCT03708887|DRUG|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
219636013|NCT05149144|DIAGNOSTIC_TEST|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
218947986|NCT03708887|DRUG|Control drug|Matching placebo capsules,3 g/d by mouth for 1 year
219053990|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
219053991|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
219053992|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
219053993|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
219053994|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
219053995|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
219053996|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
219053997|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
219053998|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
219053999|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
218947987|NCT01062178|DRUG|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
218947988|NCT00329849|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
218947989|NCT00329849|BIOLOGICAL|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
218947990|NCT01705067|DEVICE|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
218947991|NCT00848562|DRUG|Nicorandil|Oral administration of nicorandil (15 mg/day)
218947992|NCT00445237|DEVICE|H1 and H2 deep TMS coils|
218947993|NCT04311593|DIAGNOSTIC_TEST|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
218947994|NCT04187287|OTHER|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
218947995|NCT04187287|OTHER|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
218947996|NCT00493857|DRUG|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
218947997|NCT00493857|DRUG|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
218947998|NCT00005862|DRUG|semaxanib|
218947999|NCT01221740|DRUG|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
218948000|NCT05052931|DRUG|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
218948001|NCT03547115|DRUG|voruciclib monotherapy|Voruciclib will be administered orally
218948002|NCT03547115|DRUG|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
218948003|NCT05929573|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
218948004|NCT05929573|DIAGNOSTIC_TEST|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
218948005|NCT01849744|DRUG|VS-4718|
218948006|NCT04086498|OTHER|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
218948007|NCT04086498|OTHER|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
218948008|NCT04086498|OTHER|KD|The group received a plan for a low carbohydrate ketogenic diet
218948009|NCT02540889|BEHAVIORAL|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
218948010|NCT00794898|BIOLOGICAL|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
218948011|NCT02682979|OTHER|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
218948012|NCT01481532|DRUG|Crotoxin|Intra patient dose escalation
218948013|NCT05062954|DIETARY_SUPPLEMENT|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
218948014|NCT05062954|DIETARY_SUPPLEMENT|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
218948015|NCT00793273|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
218948016|NCT04685174|DEVICE|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
218948017|NCT00744354|DRUG|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
218948018|NCT00744354|DRUG|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
218948019|NCT00744354|DRUG|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
219054000|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
219054001|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
218948020|NCT05690867|OTHER|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
218948021|NCT05690867|OTHER|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
218948022|NCT06138223|OTHER|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
218948023|NCT06138223|OTHER|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
218948024|NCT04150367|DRUG|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
218948025|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
218948026|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
218948027|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
218948028|NCT04150367|DRUG|Isoniazid|. Participants will get the dosage according to the instruction for use.
218948029|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
218948030|NCT01757145|DRUG|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again)."
218948031|NCT00958997|DRUG|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
218948032|NCT00958997|BIOLOGICAL|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
219054002|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
219054003|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
219054004|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
219054005|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
219054006|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
219054007|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
219054008|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
219054009|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
219054010|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
219054011|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
219054012|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
219054013|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
219054014|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
219054015|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
219366065|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
218948033|NCT03489746|OTHER|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
218948034|NCT03489746|OTHER|Standard care|Normal clinically indicated inhaled therapy
219054016|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
219054017|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
219054018|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
219054019|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
219054020|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
219054021|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
219636014|NCT05149144|BEHAVIORAL|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
219636015|NCT06495242|PROCEDURE|Direct pulp capping and partial pulpotomy|Two types of vital pulp therapy procedures
219636016|NCT04152772|DEVICE|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
219636017|NCT05669326|OTHER|NODDI TRACT|"Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study."
219636018|NCT02313493|BEHAVIORAL|Baby Triple P|
219636019|NCT01468194|OTHER|Breathing procedure 1|inhalation during one step, exhalation during the next step
219636020|NCT01468194|OTHER|Breathing procedure 2|inhalation and exhalation during one step
218948035|NCT02728973|OTHER|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
218948036|NCT03498053|BEHAVIORAL|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
218948037|NCT03498053|BEHAVIORAL|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
218948038|NCT03498053|BEHAVIORAL|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
219054022|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
219054023|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
219054024|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
219054025|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
219054026|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
219054027|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
219054028|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
219054029|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
219054030|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
219636021|NCT02731651|PROCEDURE|open hysterectomy|Hysterectomy with laparotomy incision.
219636022|NCT02731651|PROCEDURE|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
219636023|NCT03100968|PROCEDURE|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
219636024|NCT03100968|DEVICE|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
219366066|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
219366067|NCT02909621|DIETARY_SUPPLEMENT|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
219366068|NCT02909621|OTHER|PLACEBO|
219636025|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
218948039|NCT03997227|PROCEDURE|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
218948040|NCT01781273|OTHER|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
218948041|NCT01781273|OTHER|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
218948042|NCT04267601|DRUG|Anagliptin|Anagliptin treatment for 24weeks
219636026|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
219636027|NCT06619353|DIAGNOSTIC_TEST|Blood Sample|Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.
218948043|NCT01246908|DRUG|Placebo|Placebo administered twice per day for six weeks.
218948044|NCT01246908|DRUG|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
218948045|NCT03294577|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
218948046|NCT03294577|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
218948047|NCT03294577|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
218948048|NCT03294577|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
218948049|NCT01214057|DRUG|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
218948050|NCT01214057|DRUG|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
218948051|NCT02402725|DRUG|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
218948052|NCT00002317|DRUG|Trimetrexate glucuronate|
218948053|NCT00002317|DRUG|Leucovorin calcium|
218948054|NCT03373331|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
218948055|NCT03373331|BEHAVIORAL|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
219366069|NCT04863963|PROCEDURE|Milligan Morgan|Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
219366070|NCT05874531|DIAGNOSTIC_TEST|End-expiratory occlusion test|15 seconds end-expiratory occlusion
219366071|NCT04272567|DRUG|Norepinephrine|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
219636028|NCT06619353|OTHER|DICOM Dataset|Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.
219636029|NCT04441320|DEVICE|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
219636030|NCT04441320|DEVICE|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
219366072|NCT04272567|DRUG|Normal saline|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
219636031|NCT06280274|DRUG|Metformin|Metformin 500mg oral once daily for 7 days, increased to 1000mg (500mg twice daily) for another 7 days, taken in morning and evening with meals, for a total of 14 days of treatment prior to surgery. Continue dose on day of surgery and up to post operative day 2, or until time of discharge, whichever happens first.
219636032|NCT06280274|OTHER|Placebo|Placebo tablet
219636033|NCT00343226|DRUG|Basiliximab|
219636034|NCT04858490|DRUG|Diazepam|Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
219636035|NCT06665191|OTHER|No Intervention: Observational study for prevalence of dental wear and its association with quality of life|not applicable as it is an observational study testing the prevalence of dental wear in patients attending Cairo University
218948056|NCT05798468|OTHER|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
218948057|NCT05798468|OTHER|Control group|Traditional education will be carried out
218948058|NCT00203814|DRUG|Sulfadoxine-pyrimethamine|
218948059|NCT00203814|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
218948060|NCT01811264|BEHAVIORAL|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
218948061|NCT05253001|DEVICE|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
218948062|NCT01328444|DRUG|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
218948063|NCT01328444|DRUG|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
218948064|NCT01328444|DRUG|GSK 573719 125|125mcg
218948065|NCT01328444|DRUG|GSK 573719 62.5|62.5mcg
218948066|NCT01328444|DRUG|GW642444 25|25mcg
218948067|NCT01328444|DRUG|Plb|Comparator
218948068|NCT00700167|BIOLOGICAL|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
218948069|NCT04484571|DEVICE|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
218948070|NCT02743611|BIOLOGICAL|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
219636036|NCT03494231|DRUG|HLX06|recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
219636037|NCT05173831|DRUG|Midomafetamine|Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
218948071|NCT02743611|DRUG|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
218948072|NCT01583829|BEHAVIORAL|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
218948073|NCT01583829|BEHAVIORAL|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
218948074|NCT01583829|OTHER|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
218948075|NCT03234569|PROCEDURE|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
218948076|NCT02490345|DRUG|gabapentin|gabapentin usage as adjunctive treatment for pain control
218948077|NCT02490345|DRUG|Placebo|Identical placebo
218948078|NCT04653467|DRUG|GLPG4399 oral suspension|GLPG4399 for oral administration
219366073|NCT00836550|BEHAVIORAL|Video|The participants saw a 6 minute video
219366074|NCT00836550|BEHAVIORAL|in-person HIV pre-test counseling|
218948079|NCT04653467|DRUG|GLPG4399 capsules|GLPG4399 for oral administration
218948080|NCT04653467|DRUG|Placebo|Placebo oral suspension
218948081|NCT02086032|DRUG|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
219636038|NCT05173831|BEHAVIORAL|Therapy|Manualized therapy performed by therapist team
219636039|NCT05817539|PROCEDURE|Fluid balance negativation|"During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion."
218948082|NCT02086032|DRUG|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
218948083|NCT02086032|DRUG|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
218948084|NCT04554056|DRUG|MW05|Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
218948085|NCT04554056|DRUG|PEG-rhG-CSF|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
218948086|NCT00484744|DRUG|Acetaminophen|
218948087|NCT00484744|DRUG|Avicel (placebo)|
218948088|NCT00484744|DRUG|Ibuprofen|
218948089|NCT01675089|DRUG|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
219636040|NCT05817539|PROCEDURE|Body weight Stabilization|"During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min."
219636041|NCT06144125|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
219636042|NCT06144125|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
219636043|NCT01364688|DRUG|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
219636044|NCT01364688|DRUG|no drug|no drug
219636045|NCT06337890|PROCEDURE|Zero contrast FEVAR|Use of automated CO2 angiographies with Fusion Imaging for zero contrast FEVAR
219636046|NCT00129688|DRUG|cloxacillin and amikacin (once or twice daily dosage)|
219636047|NCT04807309|DRUG|Danazol Pill|Danazol 200 mg orally twice a day
219636048|NCT04807309|DRUG|Placebo|Placebo twice a day
219636049|NCT02857400|OTHER|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
218948090|NCT02226445|OTHER|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
218948091|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
218948092|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
218948093|NCT02058823|DRUG|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
218948094|NCT02058823|DRUG|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
218948095|NCT05254145|DIAGNOSTIC_TEST|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
218948096|NCT02744950|PROCEDURE|Pulley stitches|
218948097|NCT02744950|PROCEDURE|Intermediate Repair|
218948098|NCT06089785|DEVICE|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
218948099|NCT04471285|PROCEDURE|acupuncture|acupuncture
218948100|NCT04471285|PROCEDURE|Sham acupuncture|Sham acupuncture
218948101|NCT03995329|OTHER|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
218948102|NCT04933370|OTHER|Stimulation parameters|Different device stimulation parameters
218948103|NCT02587611|OTHER|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
218948104|NCT02587611|OTHER|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
218948105|NCT04181814|DEVICE|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
219636050|NCT02857400|OTHER|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
219636051|NCT00185263|GENETIC|AdF5FGF-4 vs. Placebo|Intracoronary infusion
219636052|NCT05314322|PROCEDURE|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
219636053|NCT05314322|PROCEDURE|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
219636054|NCT01470963|OTHER|Implementation of referral template|Implementation of referral template at the GP office
219636055|NCT03928899|PROCEDURE|New procedure|An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
219636056|NCT03691207|DRUG|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
218948106|NCT02183753|OTHER|wood smoke|
218948107|NCT02183753|OTHER|clean air|
218948108|NCT00329446|DRUG|Quetiapine Fumarate|
218948109|NCT00329446|DRUG|Escitalopram oxylate|
218948110|NCT01566214|BEHAVIORAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
218948111|NCT06221657|DRUG|Vemlidy|1 tablet once a day, oral administration
218948112|NCT06221657|DRUG|Virreal|1 tablet once a day, oral administration
218948113|NCT04704362|BEHAVIORAL|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
218948114|NCT04704362|BEHAVIORAL|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
218948115|NCT00456443|PROCEDURE|Historical records|
218948116|NCT04929717|OTHER|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
218948117|NCT04929717|OTHER|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
218948118|NCT01947062|DRUG|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
218948119|NCT01947062|DRUG|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
218948120|NCT02931708|OTHER|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
218948121|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
218948122|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
218948123|NCT00561977|BEHAVIORAL|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
218948124|NCT00561977|BEHAVIORAL|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
218948125|NCT00561977|BEHAVIORAL|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
218948126|NCT02086643|PROCEDURE|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
218948127|NCT04620798|BEHAVIORAL|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
218948128|NCT02872220|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
218948129|NCT02872220|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
218948130|NCT02872220|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
218948131|NCT02872220|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
218948132|NCT03030742|OTHER|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids"
218948133|NCT03268655|DIETARY_SUPPLEMENT|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
218948134|NCT03268655|OTHER|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
219636057|NCT04056533|BIOLOGICAL|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
218948135|NCT04335305|DRUG|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
218948136|NCT04335305|BIOLOGICAL|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
218948137|NCT00166556|DRUG|Campath-1H and Tacrolimus|
218948138|NCT01037894|PROCEDURE|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
218948139|NCT01037894|PROCEDURE|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
218948140|NCT04683601|OTHER|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
218948141|NCT00852371|DRUG|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
218948142|NCT00852371|DRUG|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
218948143|NCT00852371|DRUG|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
218948144|NCT00852371|OTHER|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
218948145|NCT00892801|DRUG|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
218948146|NCT00892801|RADIATION|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
219054031|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
218948147|NCT04525885|DRUG|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
218948148|NCT04525885|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
218948149|NCT04525885|DRUG|Placebo|Placebo tablet administered orally BID
218948150|NCT04525885|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
218948151|NCT01779791|DRUG|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
219636058|NCT02881489|OTHER|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
219636059|NCT04392375|DRUG|Nifedipine 30 MG|Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
218948152|NCT04707859|DIAGNOSTIC_TEST|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
218948153|NCT05141877|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
218948154|NCT05141877|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
218948155|NCT02527577|DRUG|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
219054032|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
219636060|NCT04392375|DRUG|Placebos|At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
219636061|NCT00220428|BIOLOGICAL|T-Cell Vaccination|
219636062|NCT04146493|DIAGNOSTIC_TEST|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
219636063|NCT00747370|PROCEDURE|movement of midurethra, bladder neck, cervix and rectum|
219636064|NCT00798668|DIETARY_SUPPLEMENT|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
219636065|NCT00798668|DIETARY_SUPPLEMENT|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
218948156|NCT02527577|DRUG|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
218948157|NCT00645437|DRUG|Levofloxacin|
218948158|NCT00947960|DRUG|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
218948159|NCT00947960|OTHER|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
218948160|NCT06427135|BEHAVIORAL|Exercise interventions|Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
218948161|NCT02834754|DRUG|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
219054033|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
218948162|NCT02834754|DRUG|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
218948163|NCT06113679|DEVICE|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
218948164|NCT00886678|DRUG|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
218948165|NCT00886678|DRUG|carboplatin|AUC=5,IV,q 21 days x 2 cycles
218948166|NCT00886678|RADIATION|thoracic radiation|66 Gy over 33 fractions
218948167|NCT02968056|PROCEDURE|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
218948168|NCT00684541|BEHAVIORAL|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
218948169|NCT00684541|BEHAVIORAL|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
218948170|NCT03027882|OTHER|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
218948171|NCT00496938|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
218948172|NCT00004845|DRUG|Rofecoxib|
218948173|NCT00004845|DRUG|Naproxen|
218948174|NCT02984930|DRUG|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
218948175|NCT02984930|DRUG|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
218948176|NCT02984930|PROCEDURE|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
218948177|NCT02890641|GENETIC|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
218948178|NCT00439738|DRUG|HCTZ + Amlodipine|"* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules"
219636066|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
219636067|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
218948179|NCT00439738|DRUG|Valsartan/HCTZ|"* 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules"
218948180|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
218948181|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
218948182|NCT04838080|BIOLOGICAL|Placebo|Two applications on Days 0 and 21
218948183|NCT00170534|BEHAVIORAL|Behavior|
218948184|NCT05777291|DEVICE|Activity watch monitoring|Patients will be using activity devices during the study period
218948185|NCT05777291|DEVICE|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
218948186|NCT05777291|BEHAVIORAL|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
219636068|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
219636069|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
219636070|NCT04112602|OTHER|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
218948187|NCT00978757|DRUG|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
218948188|NCT00978757|OTHER|Placebo|saline solution
218948189|NCT01094522|DRUG|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
218948190|NCT01094522|DRUG|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
218948191|NCT03586570|DRUG|Aprocitentan 25mg|Oral tablets in strength of 25 mg
218948192|NCT03586570|DRUG|Placebo|Oral tablets matching aprocitentan tablets
218948193|NCT01687725|DEVICE|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
218948194|NCT03774719|DEVICE|Hand-carried ultrasound|Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
218948195|NCT00147836|DRUG|Human Insulin (Novolin-R, Novo Nordisk)|
218948196|NCT00147836|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
218948197|NCT00147836|OTHER|Pre-meal|
218948198|NCT00147836|DRUG|Novolin-R|
218948199|NCT00147836|DRUG|Human Insulin NPH (Novolin-N, Novo Nordisk)|
218948200|NCT00147836|DRUG|Gliclazide (Diamicron, Servier)|
219054034|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
219054035|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
219054036|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
219636071|NCT04112602|OTHER|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
218948201|NCT00147836|DRUG|Diamicron and Glucophage|
218948202|NCT00402740|DEVICE|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
218948203|NCT05338424|OTHER|Sprint Interval Training (SIT)|Active arm-- exercise dictated by protocol
218948204|NCT00137891|DRUG|Modified Release rhTSH|
218948205|NCT03869463|OTHER|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
218948206|NCT03869463|OTHER|Control|This group will not receive computerized cognitive training.
218948207|NCT01232036|DRUG|Glucophage 500mg|Single Oral Dose of
218948208|NCT01232036|DRUG|HL-018 500mg|Single Oral Dose of
218948209|NCT01232036|OTHER|No administration of Drug|
218948210|NCT05302336|DRUG|Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide|"All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide)."
218948211|NCT03291093|DRUG|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
218948212|NCT05286645|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
218948213|NCT05286645|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
218948214|NCT01158001|BEHAVIORAL|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
218948215|NCT02974699|DIETARY_SUPPLEMENT|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
219054037|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
219054038|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
219366075|NCT04040361|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
219636072|NCT02926729|DEVICE|nonlinear microscopy imaging of excised surgical margins|Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
219636073|NCT02926729|PROCEDURE|standard lumpectomy without nonlinear microscopy imaging|Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
219636074|NCT00116818|DRUG|GW685698X aqueous nasal spray|
219636075|NCT02149979|DEVICE|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
218948216|NCT02974699|DIETARY_SUPPLEMENT|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
218948217|NCT02551042|DRUG|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
218948218|NCT02551042|DRUG|0.9% sodium chloride|IV infusion
219054039|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
219054040|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
219054041|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
219054042|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
219054043|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
219366076|NCT04040361|DRUG|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
218948219|NCT05519592|DRUG|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
218948220|NCT05519592|DRUG|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
218948221|NCT02569099|OTHER|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
218948222|NCT05921045|OTHER|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
218948223|NCT05921045|OTHER|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
218948224|NCT00638638|DRUG|Abciximab|"* Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min"
218948225|NCT00638638|DRUG|Abciximab placebo|"* Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min"
218948226|NCT03235232|DRUG|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
218948227|NCT03235232|DRUG|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
218948228|NCT05614856|DEVICE|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
219636076|NCT02323542|OTHER|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
219636077|NCT00610155|DRUG|Placebo|BID
219636078|NCT00610155|DRUG|Pregabalin|Dose 75 mg titrated to 150 mg, bid
219636079|NCT00610155|DRUG|Tramadol SR|Dose 50mg titrated to 200 mg, bid
219636080|NCT04059614|PROCEDURE|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
218948229|NCT00182481|PROCEDURE|Induced sputum cell counts|
218948230|NCT00182481|DRUG|inhaled corticosteroids and other asthma drugs|
218948231|NCT05620121|PROCEDURE|Surgery for Incisional hernias|Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
218948232|NCT01930578|OTHER|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
218948233|NCT01930578|OTHER|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
218948234|NCT01930578|OTHER|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
218948235|NCT04387240|DRUG|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
218948236|NCT04387240|OTHER|placebo|placebo or sham drug will be given to the second arm
219636081|NCT06966921|DEVICE|CES|Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.
219636082|NCT06578858|BEHAVIORAL|Application of questionnaires|Application of SOC-13 and BRS questionnaires in patients after gastric cancer surgery
218948237|NCT02459288|DRUG|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
218948238|NCT02459288|DRUG|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
218948239|NCT02270944|BIOLOGICAL|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
218948240|NCT02270944|BIOLOGICAL|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
218948241|NCT05471713|OTHER|Autonomic dysfunction|Autonomic dysfunction
218948242|NCT00605956|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
218948243|NCT00605956|DRUG|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
218948244|NCT00605956|DRUG|Blank Patch|Blank Patch
218948245|NCT00095147|DRUG|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
218948246|NCT00095147|DRUG|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
218948247|NCT00095147|DRUG|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
218948248|NCT00095147|DRUG|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
219054044|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
219054045|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
219054046|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
219636083|NCT06968559|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5;
219636084|NCT06968559|DRUG|Placebo|Placebo: one IV administration per day from day 1 to day 5.
219636085|NCT06314113|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Oral treatment with Epigallocatechin Gallate 200 mg per day
219636086|NCT01488136|DRUG|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
219636087|NCT01488136|DRUG|Placebo|Lactose Ph capsules (Placebo)
219636088|NCT01718535|DEVICE|Spartan FRX CYP2C19 Test System|
218948249|NCT00095147|DRUG|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
218948250|NCT00001272|DRUG|taxol|
218948251|NCT01311167|DRUG|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
219636089|NCT03293979|DIAGNOSTIC_TEST|Test A i Flu A&B implemented in emergency service|Test A i Flu A\&B implemented in emergency service
219636090|NCT00589615|BEHAVIORAL|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
219636091|NCT06048861|DEVICE|KForce Sens|The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
219636092|NCT06048861|DEVICE|Baseline Electrıgoniometer|The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
219636093|NCT05369065|COMBINATION_PRODUCT|Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
219636094|NCT05369065|DIAGNOSTIC_TEST|Arterial Angiography Only|Arterial Angiography Only without Intervention
218948252|NCT01311167|DRUG|Placebo|Daily administration of 2 mg of placebo for 4 days
218948253|NCT02390791|OTHER|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
218948254|NCT02390791|OTHER|treatment as usual standard portal|Standard version of myADHDportal.com web software
218948255|NCT01789398|DRUG|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
218948256|NCT03927378|DRUG|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
218948257|NCT03927378|DRUG|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
218948258|NCT01375075|DRUG|LY2484595|Administered orally
218948259|NCT01375075|DRUG|Placebo|Administered orally
218948260|NCT01375075|DRUG|Atorvastatin|Administered orally
219054047|NCT05468398|DEVICE|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
218948261|NCT04891393|DIETARY_SUPPLEMENT|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
218948262|NCT04891393|DIETARY_SUPPLEMENT|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
218948263|NCT05216354|DRUG|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
219054048|NCT01862172|OTHER|Additional MRI|
219054049|NCT04634071|DRUG|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
219054050|NCT04634071|DRUG|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
219054051|NCT04634071|DRUG|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
219054052|NCT04634071|BEHAVIORAL|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
219054053|NCT04634071|BEHAVIORAL|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
219054054|NCT04634071|OTHER|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
219054055|NCT04634071|DRUG|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
219366077|NCT04040361|PROCEDURE|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
219636095|NCT05369065|COMBINATION_PRODUCT|Single Arm non-Randomized Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
219054056|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
219054057|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
219054058|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
219054059|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
219054060|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
219054061|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
218948264|NCT05681143|OTHER|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
218948265|NCT05681143|OTHER|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
218948266|NCT01011309|BIOLOGICAL|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
218948267|NCT01011309|DRUG|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
218948268|NCT05306119|OTHER|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
218948269|NCT05032924|COMBINATION_PRODUCT|PPR group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection
218948270|NCT05032924|COMBINATION_PRODUCT|PPR group without ESWT|PRP or HA injection only
218948271|NCT05032924|COMBINATION_PRODUCT|HA group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)
218948272|NCT05032924|COMBINATION_PRODUCT|HA group without ESWT|PRP or HA injection only
218948273|NCT05902052|OTHER|Care Protocol|Evaluation of patients' pain in the extubated period with the Visual Anolog Scale Active participation of the patient in pain reporting Regular questioning of the patient's pain Questioning pain at rest and movement Implementing nursing interventions in painful condition (VAS≤ 4)
218948274|NCT03893695|DRUG|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
219549545|NCT06275542|PROCEDURE|Air chalenge prior to extubation|After surgery was completed and the TOF ratio was ≥ 0.90, the TOF device was removed, and extubation was performed in Group B. In Group A, after a minimum of 15 minutes following reversal, patients received only ambient air without supplemental O2. Extubation was performed if the patient could maintain an SpO2 \> 95% for a minimum of 3 minutes. If within 15 minutes after reversal the patient did not meet the extubation criteria, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed. If there was suspicion of opioid-induced hypoventilation, naloxone was administered at 0.4-0.8 mcg intravenously.If the patient was unable to maintain oxygen saturation for the 3-minute duration, oxygen supplementation was reinstated, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed.
219636096|NCT02547792|BIOLOGICAL|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
218948275|NCT03858816|OTHER|Mixture probiotics|The mixture probiotics capsule
218948276|NCT03858816|OTHER|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
218948277|NCT04124679|OTHER|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
218948278|NCT01896791|PROCEDURE|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
218948279|NCT01896791|PROCEDURE|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
218948280|NCT02121613|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
218948281|NCT02121613|DRUG|Tamsulosine LP|Oral administration - 0.4 mg daily.
218948282|NCT02121613|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
218948283|NCT02121613|DRUG|Placebo matching Tamsulosine LP|Oral administration - daily.
218948284|NCT02298660|DRUG|BOTOX|"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
219054062|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
218948285|NCT02122068|BEHAVIORAL|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
218948286|NCT02122068|BEHAVIORAL|Relaxation cd|
218948287|NCT03840434|DIAGNOSTIC_TEST|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
218948288|NCT05072067|PROCEDURE|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
218948289|NCT05857865|BEHAVIORAL|SPYKids|SSIs will be tailored to the parent areas of primary concern as identified in the pre-questionnaire. Participants will meet with the parent coach in a virtual 90-minute session to discuss coping strategies relevant to the identified concerns. Content will be informed by the baseline questionnaire and include psychoeducation with an explanation of 1 or 2 skills to manage a primary mental health issue (e.g., Emotion Regulation, Distress Tolerance, Communication), a brief practice of the skills (as appropriate), and an action plan for the family to apply the skills at home. Families will also be provided with recommendations for relevant services from our family-focused resource list. Please note, the session length may be extended to 120 minutes if an interpreter is required in order to provide equal opportunity for understanding the session content.
218948290|NCT05857865|OTHER|Services as Usual (SAU)|Participants will receive links to the Manitoba 211 websites and a local organization's resource website with resources for adults and children. This resource is used to locate crisis, distress, and support phone lines, and counselling. Following completion of the 3-month survey, participants will receive a lab-developed comprehensive list of resources (also provided to participants in the SPYKids arm).
218948291|NCT01956916|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
218948292|NCT01956916|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
218948293|NCT03219970|DRUG|Osimertinib|80mg oral daily
218948294|NCT00457106|DRUG|Paroxetine|
218948295|NCT00457106|DRUG|Risperidone|
219366078|NCT01880411|BIOLOGICAL|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
218948296|NCT05738590|PROCEDURE|muscle biopsy|true cut needle biopsy
218948297|NCT05094310|DEVICE|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
218948298|NCT03048383|DRUG|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
218948299|NCT03048383|DRUG|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
218948300|NCT03048383|DRUG|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
218948301|NCT03472547|DRUG|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
218948302|NCT03400267|DRUG|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
218948303|NCT03400267|DRUG|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
218948304|NCT06945913|BEHAVIORAL|Exercise|HIIT Group
218948305|NCT06946394|DRUG|Pegmolesatide|Pegmolesatide Injection: Specification 1mL: 4.0mg (National Medical Products Administration Approval No. H20230020), administered once every 4 weeks
218948306|NCT06946745|OTHER|tissue biopsy|By performing single-cell sequencing on tumor tissues at baseline and post-treatment (cycle 2) across all patients, we will conduct pseudotime trajectory analysis to study the differentiation dynamics of cellular populations.
218948307|NCT04148144|OTHER|No intervention included|No intervention included
218948308|NCT01300013|DRUG|Placebo|48-hour infusion of placebo
218948309|NCT01300013|DRUG|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
218948310|NCT03395236|COMBINATION_PRODUCT|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
218948311|NCT00043342|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
218948312|NCT01563614|RADIATION|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
218948313|NCT01563614|DRUG|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
218948314|NCT01563614|DRUG|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
218948315|NCT03116581|OTHER|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~* Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~* Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
219054063|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
219054064|NCT01158625|OTHER|Change of time of administration|Change of time of administration
219054065|NCT00203450|DRUG|Zonegran|zonisamide
218948316|NCT03116581|OTHER|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
218948317|NCT03116581|OTHER|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
218948318|NCT02981459|DRUG|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
218948319|NCT00137878|DRUG|TNFerade™|
218948320|NCT02602756|RADIATION|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
218948321|NCT01823588|BEHAVIORAL|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
219054066|NCT00203450|DRUG|Placebo|Placebo pill
219054067|NCT01769885|DRUG|tivozanib|Given PO
219054068|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
219054069|NCT02386943|DRUG|Sitagliptin|100mg po once.
219054070|NCT02386943|DRUG|Saxagliptin|5mg po once.
219054071|NCT02386943|DRUG|Blank control|No medication is taken.
219054072|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
219054073|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
219054074|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
219054075|NCT00005638|DRUG|cisplatin|
219054076|NCT00005638|DRUG|irinotecan hydrochloride|
219054077|NCT00005638|RADIATION|radiation therapy|
219054078|NCT02660918|DRUG|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
219054079|NCT02660918|OTHER|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
219054080|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
219054081|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
219054082|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
219054083|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
219054084|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
219054085|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
219054086|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
219054087|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
219054088|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
219054089|NCT05257265|OTHER|Placebo|Capsule
219054090|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
218948322|NCT04675554|OTHER|Follow up of physical activity|participants will fill in the non-opposition form via the application and will complete, with their smartphone, a series of psychometric questionnaires. Participants will then use the mobile application for a period of 12 weeks during which time, physical activity data provided from participants smartphone will be gathered After 12 weeks, participants will complete again the same series of psychometric questionnaires.
218948323|NCT03276520|DIAGNOSTIC_TEST|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
219054091|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
219054092|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
219054093|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
219054094|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
219054095|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
219054096|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
219054097|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
219054098|NCT01493271|DRUG|Placebo|Placebo to RO5093151
219054099|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
219054100|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
219054101|NCT00144118|DRUG|sevoflurane or isoflurane|
219054102|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
219054103|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
219054104|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
219054105|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
219054106|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
219054107|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
219054108|NCT03747029|OTHER|No intervention is provided|No intervention is provided
219054109|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
218948324|NCT03276520|DIAGNOSTIC_TEST|ethanol|alcohol urine screening with ethanol
219054110|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
219054111|NCT00395044|DRUG|Placebo|Placebo
219054112|NCT00395044|DRUG|Gabapentin|
219054113|NCT06096025|DRUG|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
219054114|NCT04914572|OTHER|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
219054115|NCT04914572|OTHER|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
219054116|NCT04914572|OTHER|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
219054117|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
219054118|NCT05821101|DEVICE|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
219054119|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
219054120|NCT06323642|OTHER|placebo|milk as placebo
219054121|NCT02263066|BIOLOGICAL|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
219054122|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
219054123|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
219054124|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
219054125|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
219054126|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
219054127|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
219054128|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
219054129|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
219054130|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
219054131|NCT04047017|DRUG|Apatinib|250mg, po, qd
219054132|NCT04047017|DRUG|Camrelizumab|200mg, q2w
218948325|NCT04889976|DEVICE|Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). Active iBT consists of a smartphone app with an electronic therapist-avatar. The iBT sessions are delivered concomitantly to the tDCS sessions (the tDCS device connects via bluetooth to the participant's smartphone app).
219054133|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
219054134|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
219054135|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
219054136|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
219054137|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
219054138|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
219054139|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
219636097|NCT02547792|BIOLOGICAL|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
219636098|NCT02547792|OTHER|Placebo Tablets|Enteric coated tablet for oral delivery
219636099|NCT02008695|BEHAVIORAL|adult microfinance|"Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
219636100|NCT02008695|BEHAVIORAL|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
219636101|NCT02008695|BEHAVIORAL|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
219636102|NCT00845221|DRUG|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
219636103|NCT02337608|DRUG|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
219636104|NCT02337608|DRUG|Placebo|placebo daily dosing in the morning daily for 12 weeks
219636105|NCT05453188|DEVICE|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
219636106|NCT05453188|GENETIC|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
219636107|NCT01482637|OTHER|CAS|All clients will be asked to complete the CAS instrument.
219636108|NCT02739009|DRUG|MOR106 single ascending doses, intravenous|
219636109|NCT02739009|DRUG|Placebo single ascending doses, intravenous|
219636110|NCT02739009|DRUG|MOR106 multiple ascending doses, intravenous|
219636111|NCT02739009|DRUG|Placebo multiple intravenous administrations|
219636112|NCT00648115|OTHER|Basic Vocational Services|Vocational services
219636113|NCT00648115|OTHER|Self-Study|Veteran receives self-study resources
219636114|NCT00648115|OTHER|Group Program|Veteran participates in group vocational program
219636115|NCT06047678|BEHAVIORAL|Cardiovascular fitness|A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.
219636116|NCT01073605|DRUG|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
219636117|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
219636118|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
219636119|NCT00001997|DRUG|Interleukin-2, Polyethylene Glycolated|
219636120|NCT00001997|DRUG|Zidovudine|
219636121|NCT00001997|DRUG|Didanosine|
218948326|NCT04889976|DEVICE|ptES-only: Active portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). The sham iBT sessions are delivered concomitantly to the active ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
218948327|NCT04889976|DEVICE|Double-sham: Sham portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|Sham ptES for this trial is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all transcranial direct current stimulation (tDCS) headset, with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining 28 1/2 minutes. The sham iBT sessions are delivered concomitantly to the sham ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
218948328|NCT05249218|OTHER|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
218948329|NCT05249218|OTHER|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
218948330|NCT05249218|OTHER|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
218948331|NCT05249218|OTHER|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
218948332|NCT00408044|PROCEDURE|cardiac surgery with sternotomy|
218948333|NCT05560308|DRUG|Trastuzumab Emtansine for Injection|3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
219054140|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
219206983|NCT06779955|BEHAVIORAL|foot massage application|The characteristics of Massage Manipulations are an important feature in planning. Since the purpose of the massage is to rest, calm and relax, Effleurage (Stroke), Petrisage (Kneading) and Friction (Circular Rubbing) techniques that support circulation and have a loosening effect on the tissues have been chosen.A massage will be given to both feet for a total of 16 minutes, 8 minutes for each foot.The person receiving the massage will be lying down comfortably in a supine position, supported by pillows under the head and lower legs.Foot massage will be applied once to patients in the supine position at the first hour after their admission to the coronary intensive care unit following transfemoral angiography.
218948334|NCT05560308|DRUG|Pyrotinib Maleate Tablets|The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
219054141|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
219054142|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
219206984|NCT06765174|DEVICE|Suction Drain placement (Example: Q-vac)|After thyroid surgery we pust drain at bed of surgery to monitor post operative bleeding.
219636122|NCT00726973|DRUG|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness \>100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
219636123|NCT00726973|DRUG|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
219636124|NCT01871129|DRUG|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
219636125|NCT01871129|OTHER|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
219636126|NCT00806273|DEVICE|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
219636127|NCT00806273|DEVICE|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
218948335|NCT05883384|OTHER|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
218948336|NCT02695160|BIOLOGICAL|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
218948337|NCT05569460|OTHER|No intervention|No intervention
219636128|NCT03052231|DEVICE|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
219636129|NCT04713631|DRUG|Artesunate|Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
218948338|NCT01103024|BIOLOGICAL|AIN457|
218948339|NCT01103024|BIOLOGICAL|AIN457|
218948340|NCT01103024|BIOLOGICAL|AIN457|
218948341|NCT01103024|BIOLOGICAL|Placebo|
218948342|NCT04679415|DRUG|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
218948343|NCT04679415|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
218948344|NCT03137069|DRUG|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
218948345|NCT03137069|DRUG|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
218948346|NCT03730402|DRUG|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
218948347|NCT03730402|DRUG|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
218948348|NCT03730402|DRUG|Saline|placebo injection of saline
218948349|NCT03285022|PROCEDURE|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
218948350|NCT04835675|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
218948351|NCT03225859|BEHAVIORAL|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
218948352|NCT02908542|GENETIC|genetic analysis with massively parallel sequencing|
218948353|NCT01685398|DRUG|0.5% timolol maleate eye drop|
219636130|NCT04713631|DRUG|Curcumin|Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
219636131|NCT04713631|DRUG|Placebo A|Artesunate looking placebo
218948354|NCT01685398|DRUG|Normal saline|
218948355|NCT02423967|BIOLOGICAL|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
218948356|NCT02423967|BIOLOGICAL|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
218948357|NCT04193618|PROCEDURE|Conservative surgery for placenta accretta|Uterine devasculrization and transverse compressing sutures before placental delivery
218948358|NCT03665025|OTHER|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
218948359|NCT02885571|DEVICE|SomnoDent Flex with DentiTrac|
218948360|NCT00423202|DRUG|ambrisentan|
218948361|NCT06315790|DRUG|Botulinum toxin A|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
218948362|NCT06315790|OTHER|Isotonic saline|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
218948363|NCT03876392|DIAGNOSTIC_TEST|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
218948364|NCT00336830|BEHAVIORAL|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
218948365|NCT00336830|BEHAVIORAL|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
218948366|NCT00038389|DRUG|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
218948367|NCT01788410|PROCEDURE|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
218948368|NCT01788410|DEVICE|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
218948369|NCT04740645|OTHER|NOCDURNA Cohort|Non intervention
218948370|NCT04740645|OTHER|LUTS Cohort|Non intervention
218948371|NCT02043899|DRUG|[124I]meta-Iodobenzylguanidine|Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
218948372|NCT03633240|OTHER|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
218948373|NCT02043340|DRUG|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
218948374|NCT02043340|DEVICE|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
218948375|NCT02043340|PROCEDURE|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
219054143|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
219054144|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
219054145|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
219636132|NCT04713631|DRUG|Placebo C|Curcumin looking placebo
219054146|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
219054147|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
219636133|NCT00643474|DEVICE|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
219636134|NCT00643474|DEVICE|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
219054148|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
219636135|NCT05952869|DRUG|Enlicitide Decanoate|Oral tablet
219636136|NCT05952869|DRUG|Placebo|Placebo
219636137|NCT05533268|OTHER|Mental training|Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.
218948376|NCT05396716|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
218948377|NCT02720107|DRUG|fingolimod|
218948378|NCT00225810|DRUG|Crohn's Disease|
218948379|NCT06022289|DRUG|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
219054149|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
219054150|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
219636138|NCT05533268|OTHER|Physical training|Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.
219636139|NCT05533268|OTHER|Mental & physical training|Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.
219636140|NCT05533268|OTHER|DASH diet|DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
218948380|NCT02649348|BEHAVIORAL|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
218948381|NCT00949494|DEVICE|Synvisc|intra-articular, 3 weekly injections
219054151|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
219054152|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
218948382|NCT02856191|OTHER|Holter|
218948383|NCT06141356|DRUG|[18F]Florbetazine ([18F]92)|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
219054153|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
219636141|NCT04769518|PROCEDURE|Advanced Recovery Room Care (ARRC)|High acuity care
219636142|NCT00248742|BEHAVIORAL|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
219636143|NCT03397498|BEHAVIORAL|CogniFit™|The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
219636144|NCT03397498|BEHAVIORAL|Control-games|The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
219636145|NCT03674346|OTHER|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~* The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~* The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~* The time of return. It is time that allows the patient to regain his classic state of consciousness."
219636146|NCT03674346|OTHER|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
219636147|NCT04543149|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
219636148|NCT01583309|PROCEDURE|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
219636149|NCT01583309|PROCEDURE|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
219636150|NCT05654961|OTHER|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
218948384|NCT06141356|DRUG|[11C]PIB|Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
218948385|NCT01335802|GENETIC||Genetic counseling
218948386|NCT01325337|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219054154|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
219054155|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
219054156|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
219054157|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
218948387|NCT01325337|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219206985|NCT06768775|DIETARY_SUPPLEMENT|Pastured Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, beef, pork, and eggs) from regenerative/pastured farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
218948388|NCT01325337|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
218948389|NCT01325337|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
218948390|NCT01325337|DRUG|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
218948391|NCT02230969|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
219054158|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
219054159|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
219054160|NCT03495024|DRUG|Varenicline|Oral medication approved to facilitate smoking cessation
219206986|NCT06768775|DIETARY_SUPPLEMENT|Conventional Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, ground, pork, and eggs) from conventional farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
218948392|NCT03483922|DIAGNOSTIC_TEST|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
219636151|NCT00600912|DRUG|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
219636152|NCT00600912|DRUG|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
219636153|NCT05235412|OTHER|Not applicable: Observational study without any interventions.|Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
219636154|NCT03770754|PROCEDURE|Clean and shape Control group|"For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol"
219636155|NCT03770754|PROCEDURE|Cleand and shape Group 1|For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
219636156|NCT03770754|PROCEDURE|Clean and shape Group 2|"For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered"
219636157|NCT00249132|DRUG|risperidone|
219636158|NCT04867642|DRUG|UCB0022|Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
219636159|NCT04867642|OTHER|Placebo|Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.
219636160|NCT01779128|PROCEDURE|PET-CT|
219636161|NCT01779128|PROCEDURE|MR-PET|
219636162|NCT02362802|DEVICE|Implantable Cardioverter Defibrillator|
218948393|NCT03246997|OTHER|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
218948394|NCT03246997|OTHER|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
218948395|NCT01237483|DRUG|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
218948396|NCT03930264|DRUG|Azathioprine 50Mg Tab|tablet
218948397|NCT03930264|DRUG|Azathioprine 10mg/mL oral suspension|oral suspension
218948398|NCT04441190|BEHAVIORAL|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
218948399|NCT04441190|BEHAVIORAL|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
218948400|NCT04441190|BEHAVIORAL|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
218948401|NCT04320641|OTHER|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
218948402|NCT04774211|DIAGNOSTIC_TEST|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
218948403|NCT01737229|DEVICE|Application of Biodentine™ (RD94), dentin substitute|
218948404|NCT05056428|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
218948405|NCT05128422|OTHER|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
218948406|NCT01007630|DRUG|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
219636163|NCT01521286|OTHER|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
219636164|NCT03039530|BEHAVIORAL|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
219636165|NCT03039530|BEHAVIORAL|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
219636166|NCT06093516|DEVICE|Tinted Lenses|Tinted coloured lenses with UV protection within spectacle frames with the intension to help reduce the symptoms of Visual stress.
219636167|NCT02220036|DIETARY_SUPPLEMENT|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
218948407|NCT01007630|DRUG|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
218948408|NCT00307320|BEHAVIORAL|Relaxation Training|Relaxation techniques training
218948409|NCT02434471|DEVICE|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
218948410|NCT04451213|DIAGNOSTIC_TEST|MRI head|MRI head
219054161|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
219054162|NCT01430065|DRUG|ASP015K|oral
219054163|NCT01430065|DRUG|Tacrolimus|oral
219636168|NCT02035449|DEVICE|McGrath MAC|McGrath MAC is a videolaryngoscope
219636169|NCT02196441|DRUG|2% tetracaine local anaesthetic drops|topical anaesthetic drops
219636170|NCT02196441|DRUG|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
219636171|NCT05416021|DRUG|dapivirine|dapivirine vaginal ring
219636172|NCT02035202|BEHAVIORAL|CBT2go|CBT administered using mobile intervention.
219636173|NCT02035202|DEVICE|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
218948411|NCT04625296|BEHAVIORAL|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
218948412|NCT04625296|BEHAVIORAL|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
218948413|NCT03667898|PROCEDURE|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
218948414|NCT03667898|PROCEDURE|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
218948415|NCT02575547|DRUG|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
218948416|NCT03663556|OTHER|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
218948417|NCT01696162|OTHER|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
218948418|NCT01696162|OTHER|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
218948419|NCT01696162|OTHER|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
218948420|NCT00439049|DRUG|modafinil|400 mg daily
219636174|NCT05230706|OTHER|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
219636175|NCT06575101|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
218948421|NCT00439049|DRUG|d-amphetamine|60mg daily
218948422|NCT00439049|DRUG|L-Dopa|800/200mg daily
218948423|NCT00439049|DRUG|Naltrexone|50mg daily
218948424|NCT02811627|DRUG|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
219054164|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
219054165|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
219054166|NCT02360618|DRUG|Metformin|See Group Description
219054167|NCT02360618|DRUG|Simvastatin|See Group Description
219054168|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
219636176|NCT05458401|DRUG|Trastuzumab deruxtecan|No drug will be administered during this study.
219636177|NCT05494814|OTHER|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
218948425|NCT02811627|DEVICE|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
218948426|NCT02110602|OTHER|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
219054169|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
219636178|NCT04366843|OTHER|chair massage|Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
218948427|NCT02110602|OTHER|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
218948428|NCT00920010|OTHER|biologic sample preservation procedure|
218948429|NCT00720447|BIOLOGICAL|alemtuzumab|
218948430|NCT00720447|BIOLOGICAL|donor lymphocytes|
218948431|NCT00720447|DRUG|carmustine|
218948432|NCT00720447|DRUG|cytarabine|
218948433|NCT00720447|DRUG|etoposide|
218948434|NCT00720447|DRUG|melphalan|
218948435|NCT00720447|PROCEDURE|allogeneic bone marrow transplantation|
218948436|NCT00720447|PROCEDURE|peripheral blood stem cell transplantation|
218948437|NCT00369629|DRUG|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
218948438|NCT00369629|DRUG|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
218948439|NCT00855270|DRUG|Placebo|IV saline will be used as placebo for control
218948440|NCT00855270|DRUG|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
218948441|NCT00361413|DRUG|Alefacept (AMEVIVE®)|Alefacept
218948442|NCT00361413|DRUG|control group|these patients will receive the same treatment as group A, without alefacept
218948443|NCT03626298|DRUG|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
218948444|NCT03626298|DRUG|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
218948445|NCT03626298|DRUG|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
219054170|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
219206987|NCT06766123|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
218948446|NCT04044144|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
218948447|NCT02603796|OTHER|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
218948448|NCT02184455|BIOLOGICAL|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
219054171|NCT04629664|DRUG|FX-322|Active Comparator
219054172|NCT04629664|OTHER|Placebo|Placebo
219054173|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
219054174|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
219054175|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
219054176|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
219206988|NCT06768021|BEHAVIORAL|Guided visualization and standardized pre-sedation instructions|One arm will receive standardized pre-sedation instructions, as well as one-minute guided visualization.
219636179|NCT04366843|OTHER|the exercise program|The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
219636180|NCT00704600|DRUG|nelfinavir|"Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT"
218948449|NCT00815178|BEHAVIORAL|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
218948450|NCT00815178|BEHAVIORAL|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
218948451|NCT04911374|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
218948452|NCT04911374|OTHER|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
218948453|NCT03515954|PROCEDURE|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
218948454|NCT03790423|DRUG|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
218948455|NCT03790423|OTHER|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
218948456|NCT00672659|DRUG|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
219054177|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
219054178|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
219054179|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
219054180|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
219054181|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
219054182|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
219054183|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
219054184|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
218948457|NCT00672659|DRUG|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
218948458|NCT01347580|DRUG|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
218948459|NCT01347580|DRUG|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
218948460|NCT00390026|DRUG|Bevacizumab (Avastin)|
218948461|NCT00390026|DRUG|Verteporfin photodynamic therapy (PDT)|
218948462|NCT06251531|OTHER|Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)|The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
218948463|NCT03134573|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
219054185|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
219054186|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
219054187|NCT01848990|DRUG|Insulin lispro|
219054188|NCT01848990|DRUG|Insulin aspart|
219054189|NCT01848990|DRUG|Insulin glulisine|
219054190|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
219054191|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
219054192|NCT04497987|DRUG|Bamlanivimab|Administered IV.
219054193|NCT04497987|DRUG|Placebo|Administered IV.
219054194|NCT04497987|DRUG|Etesevimab|Administered IV.
219054195|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
219054196|NCT02258152|DRUG|Placebo|Placebo QD
218948464|NCT03134573|DEVICE|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
218948465|NCT03134573|DEVICE|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
218948466|NCT01250496|DRUG|Aminophylline|75 mg of intravenous aminophylline
218948467|NCT01250496|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
218948468|NCT03129399|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
219054197|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
219054198|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
219054199|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
218948469|NCT03129399|DEVICE|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
218948470|NCT01697410|DRUG|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
218948471|NCT01697410|DRUG|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
218948472|NCT03011944|OTHER|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
218948473|NCT03249662|PROCEDURE|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
218948474|NCT03249662|DRUG|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
218948475|NCT03886545|OTHER|Assessment of physical and functional capacities|Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
218948476|NCT01425463|DRUG|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
218948477|NCT01425463|DRUG|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
218948478|NCT01425463|OTHER|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
218948479|NCT01425463|OTHER|Placebo to Polyferose|Administered orally with water.
218948480|NCT01180218|PROCEDURE|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
218948481|NCT01180218|PROCEDURE|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
218948482|NCT04620213|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
218948483|NCT04620213|OTHER|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
219054200|NCT06005259|DRUG|Placebo|Placebo capsule
219054201|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
219054202|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
219054203|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
219054204|NCT01903694|DRUG|Sorafenib + Pravastatin|
219054205|NCT01903694|DRUG|Sorafenib|
219206989|NCT06768021|BEHAVIORAL|Standardized pre-sedation instructions only|One arm will receive standardized pre-sedation instructions only.
218948484|NCT02224196|OTHER|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
218948485|NCT02224196|OTHER|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
219054206|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
219054207|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
219054208|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
219054209|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
219636181|NCT02506556|DRUG|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
219636182|NCT02875613|DRUG|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
218948486|NCT04176653|DRUG|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
218948487|NCT02395432|DEVICE|orotracheal intubation|
218948488|NCT04610957|DRUG|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
218948489|NCT03532607|OTHER|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
218948490|NCT03071757|DRUG|ABBV-368|Intravenous infusion
218948491|NCT03071757|DRUG|ABBV-181|Intravenous infusion
219054210|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
219054211|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
219054212|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
219054213|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
219054214|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
219054215|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
219054216|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
219054217|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
219054218|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
219054219|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
219054220|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
219054221|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
219054222|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
219636183|NCT06459453|OTHER|Kaltenborn|Per participant was randomized to receive low grade Kaltenborn manual mobilization(grade I).Any tightening of the connective tissues surrounding the joint (grade II) or oscillations followed by additional stretching (grade III).Kaltenborm mobilization is performed for wrist flexion,extension,radial and ulnar deviation.The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants. Each session will be last for 30 minutes .Conventional physical therapy will be given to the participants along with kaltenborn.
219636184|NCT06459453|OTHER|Mulligan|Per participant gave concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Mulligan mobilization is performed for wrist flexion and extension(in the form of fist)MCP joint flexion and extension,Thumb IC joint flexion and extension, abduction and adduction of fingers, The duration of intervention will be 4weeks,3 sessions per week ,a total of 12 sessions will be given to the study participants .Each session will last for 30 minutes. Conventional physical therapy will be given to the participants along with conventional physiotherapy.
219636185|NCT04400851|DRUG|Sintilimab|Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
219054223|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
218948492|NCT02907840|DEVICE|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
218948493|NCT03852680|PROCEDURE|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
219054224|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
219054225|NCT04877301|DEVICE|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
219054226|NCT04877301|PROCEDURE|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
218948494|NCT06224751|DIAGNOSTIC_TEST|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
218948495|NCT06224751|DIAGNOSTIC_TEST|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
218948496|NCT06224751|DIAGNOSTIC_TEST|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
218948497|NCT06224751|DIAGNOSTIC_TEST|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
218948498|NCT06224751|DIAGNOSTIC_TEST|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
218948499|NCT06224751|DIAGNOSTIC_TEST|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
218948500|NCT06224751|DIAGNOSTIC_TEST|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
219054227|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
219054228|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
219054229|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
219054230|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
218948501|NCT03495583|OTHER|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
218948502|NCT02382484|DEVICE|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
219054231|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
219054232|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
219054233|NCT05684887|OTHER|Digital based contact tracing|"* Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
219054234|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
219054235|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
219636186|NCT05969015|BEHAVIORAL|Prochaska and DiClemente transtheorical model|The Prochaska and DiClemente model will be combined to a self-management program in patients with T2DM within 18 months. They will be classified accordingly to their readiness for changing. A care provider will manage the group towards an optimal self-management, aiming to improve their glycemic control and other outcomes of relevance. We will conduct 1 session per week until the end of 12nd intervention month. After, the sections will be conducted each 2 weeks until the end of the trial. Healthcare professional will provide support to the care provider. The recommended processes to progress the patients will be used to trigger them accordingly to their stage, at the discretion of the care provider. We will also consider individualities and non-anticipated problems as a part of the process of behavior changing.
219636187|NCT03462160|OTHER|Placebo control group|Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.
219054236|NCT06263777|OTHER|Nurses training program on early detection of disability|It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
219054237|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
219636188|NCT03462160|DIETARY_SUPPLEMENT|Probiotic experimental group|Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
219636189|NCT04305457|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
219636190|NCT02917291|DRUG|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
219636191|NCT02917291|OTHER|Control group|(Ph 2) No treatment will be administered
219636192|NCT02917291|DRUG|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
219636193|NCT02678169|DEVICE|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
219636194|NCT05121701|DEVICE|Videolaryngoscope|C-MAC PM-Karl Storz
219636195|NCT05121701|DEVICE|Macintosh Laryngoscope|Laryngoscope
218948503|NCT02926521|DEVICE|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
218948504|NCT02926521|DEVICE|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
218948505|NCT05342038|DEVICE|T-02|Stent retriever
218948506|NCT02211911|DRUG|Bisacodyl|
218948507|NCT02211911|DRUG|Sodium picosulfate|
218948508|NCT00732836|DRUG|HAI Abraxane|Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
218948509|NCT00732836|PROCEDURE|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
218948510|NCT00732836|DRUG|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
219636196|NCT04210401|OTHER|Duodenoscope Culture|Culture of reusable duodenoscopes following each use.
218948511|NCT01075633|PROCEDURE|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
218948512|NCT01075633|PROCEDURE|Colonoscopy with sedation|Colonoscopy with sedation
219636197|NCT00004063|BIOLOGICAL|recombinant interferon alfa|
219054238|NCT03527108|DRUG|Nivolumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
219054239|NCT03527108|DRUG|Ramucirumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
219054240|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
219054241|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
219054242|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
219054243|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
219054244|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
219054245|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
219054246|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
219054247|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
219636198|NCT00004063|DRUG|cisplatin|
219636199|NCT00004063|DRUG|gemcitabine hydrochloride|
219636200|NCT00004063|PROCEDURE|hyperthermia treatment|
218948513|NCT03466593|OTHER|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
219636201|NCT01566539|DRUG|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
219636202|NCT01566539|DRUG|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
219636203|NCT01566539|DRUG|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
219636204|NCT01566539|DRUG|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
219636205|NCT01566539|DRUG|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
219636206|NCT01811810|RADIATION|Radiation therapy (XRT)|
218948514|NCT03466593|OTHER|Routine care|Preoperative information
218948515|NCT03466593|OTHER|Extra early mobilization|Mobilization the day of surgery
218948516|NCT03466593|OTHER|Standard mobilization|Mobilization the day after surgery
219636207|NCT01811810|OTHER|Androgen Deprivation Therapy (ADT)|
219636208|NCT01811810|OTHER|Chemotherapy|
219636209|NCT01097590|DEVICE|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
218948517|NCT00918931|DRUG|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
218948518|NCT00659347|DRUG|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
218948519|NCT00659347|DRUG|Placebo|Capsules,25 mg,BID,6weeks
218948520|NCT00318942|DRUG|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
218948521|NCT00318942|DRUG|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
218948522|NCT00318942|DRUG|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
218948523|NCT00318942|DRUG|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
219054248|NCT01383681|OTHER|No treatment|There was no treatment in this study.
219054249|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
219636210|NCT01097590|DEVICE|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
219636211|NCT04414020|DRUG|Progesteron|intramusculer progesterone
219054250|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
219054251|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
219636212|NCT05387369|DRUG|Paxlovid|The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
219636213|NCT06534489|PROCEDURE|neoadjuvant immuno-chemotherapy and surgery|After enrolled, patients should receive neo-adjuvant immuno-chemotherapy and a re-evaluation will be performed after treatment to decide surgery strategy.
219636214|NCT04607694|RADIATION|Proton radiotherapy|Proton radiotherapy
219636215|NCT04607694|RADIATION|Photon radiotherapy|Photon radiotherapy
219054252|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
219054253|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
218948524|NCT04453943|DEVICE|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
218948525|NCT04453943|DEVICE|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
218948526|NCT00755209|DRUG|tranexamic acid|Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
218948527|NCT00828438|DRUG|Lorcaserin 10mg|
218948528|NCT03243708|BEHAVIORAL|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
218948529|NCT03751254|DEVICE|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
218948530|NCT00655915|OTHER|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
218948531|NCT03613272|PROCEDURE|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
218948532|NCT03613272|PROCEDURE|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
218948533|NCT06219798|DIAGNOSTIC_TEST|GFR|Exit of the study due to death, dialysis, or transplantation
218948534|NCT04140227|DRUG|NOV03|100% Perfluorohexyloctane
218948535|NCT05748652|DEVICE|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
218948536|NCT05748652|OTHER|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
218948537|NCT01610375|OTHER|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
218948538|NCT03573011|DIAGNOSTIC_TEST|[18F]PSMA-11|18F-PET imaging
219054254|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
219054255|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
219054256|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
219054257|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
219054258|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
219054259|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
219054260|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
219054261|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
219054262|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
218948539|NCT05171452|BIOLOGICAL|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
218948540|NCT01471431|OTHER|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
219636216|NCT00267969|DRUG|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
219636217|NCT00267969|DRUG|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
219636218|NCT04822792|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
219636219|NCT01309360|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
219636220|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
219636221|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
219636222|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
219636223|NCT00291876|BIOLOGICAL|Havrix™|2 doses at 12 months interval
219636224|NCT06682663|BEHAVIORAL|Live Streaming Exercise|Participants try to achieve 150 minutes of moderate-vigorous training per week. The exercise program includes live streaming exercise by trained health professionals, including pregnancy-specific exercises, with professional pregnancy trainers to provide guidance and support when needed.
219636227|NCT00239122|BEHAVIORAL|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
219636228|NCT05812235|PROCEDURE|esophagectomy|esophagectomy
219636229|NCT01680536|DRUG|maraviroc|
219636230|NCT00802035|DRUG|Baclofen IR|30 mg; single dose
219636231|NCT00802035|DRUG|Baclofen ER|30 mg; single dose
219636232|NCT02951208|DEVICE|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
219636233|NCT02951208|BEHAVIORAL|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
219636234|NCT02951208|DEVICE|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
219636235|NCT02951208|BEHAVIORAL|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
219636236|NCT03083015|PROCEDURE|revascularization|a sterile sharp needle was used to irritate the apical tissue until bleeding occurred apically in the root canal space so as to create a biological scaffold for the regenerative process
219636237|NCT03083015|PROCEDURE|Apexification|a 3-5 mm thickness of MTA using a hand plugger and was verified radiographically.
219636238|NCT02230020|DEVICE|Nasal High Flow|
219636239|NCT02308540|BIOLOGICAL|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
219636240|NCT02308540|BIOLOGICAL|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
219636241|NCT02308540|BIOLOGICAL|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
219636242|NCT03734289|BEHAVIORAL|Caregiver Coaching|Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
218948541|NCT05594615|DRUG|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
218948542|NCT05594615|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
219054263|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
219054264|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
219054265|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
219054266|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
219054267|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
219054268|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
219054269|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
219054270|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
219054271|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
219636243|NCT02914704|DEVICE|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
219636244|NCT00004863|DRUG|GEM 231|
219636245|NCT00004863|DRUG|paclitaxel|
219636246|NCT05355584|OTHER|Cryotherapy application|The temperature sense test was applied on the dominant side shoulder of the participants against the risk of sensory loss or decreased sensation. In order to test cold intolerance, a cold pack was placed on the forearm of the individuals. After waiting 2-3 minutes, the region was evaluated. Individuals meeting the inclusion criteria were assigned to the groups according to the randomization list created by the computer. Then, the participants' shoulder isometric muscle strength, shoulder flexibility, shoulder endurance and shoulder balance was evaluated. Except for shoulder endurance, all measurements were repeated three times, with a 30-second rest period between each repetition. A 2-3-minute rest period was given after each test. Then, the cold pack was wrapped in a thin and wet cloth on the shoulders of the participants. The treated area was checked every 5 minutes and the participants were asked to say when they felt any unusual symptoms.
219636247|NCT04762979|DRUG|Alpelisib|Alpelisib 300mg, PO, days 1-28 of each cycle.
219636248|NCT04762979|DRUG|Fulvestrant|Fulvestrant 500mg, IM, once monthly
219636249|NCT04762979|DRUG|Aromatase inhibitor|Aromatase Inhibitor, administered per standard of care
219636250|NCT01120015|DRUG|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
218948543|NCT05594615|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
218948544|NCT05594615|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
218948545|NCT01642875|OTHER|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
218948546|NCT01642875|OTHER|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
218948547|NCT00391183|PROCEDURE|Biliary stenting|ERCP and stenting
218948548|NCT00724321|DRUG|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
219054272|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
219054273|NCT04390750|BEHAVIORAL|Care Partner-Assisted Intervention|Tailored teaching and coaching
219054274|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
219054275|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
219054276|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
219054277|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
219636251|NCT02713360|BEHAVIORAL|Cognitive Therapy|
218948549|NCT02871882|RADIATION|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
219636252|NCT05405946|BEHAVIORAL|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
218948550|NCT02871882|OTHER|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
219054278|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
219636253|NCT05405946|OTHER|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
219636254|NCT05540912|DRUG|D064+D701|Reference
219636255|NCT05540912|DRUG|CKD-828 Formulation 1|Test 1
219636256|NCT05540912|DRUG|CKD-828 Formulation 2|Test 2
219636257|NCT05569668|DRUG|Paclitaxel- and platinum-based chemotherapy|Neoadjuvant Chemotherapy
219636258|NCT03773250|BEHAVIORAL|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
219636259|NCT03140410|OTHER|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
219636260|NCT05923138|DIETARY_SUPPLEMENT|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
219636261|NCT05923138|DIETARY_SUPPLEMENT|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
219636262|NCT05445635|DEVICE|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
219636263|NCT02302638|OTHER|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
219636264|NCT06576024|BIOLOGICAL|2 doses of HAV|Participants will receive two doses of HAV with a 6-month interval
219636265|NCT06576024|BIOLOGICAL|At least one dose of HAV|Participants will receive the first dose of HAV and will receive the second dose with a 6 -month interval voluntarily.
219636266|NCT03486158|DEVICE|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
219636267|NCT02919319|DRUG|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
219636268|NCT02919319|DRUG|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
219636269|NCT02919319|DRUG|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
219636270|NCT02919319|DRUG|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
219636271|NCT02919319|DRUG|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
219636272|NCT02919319|DRUG|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
219636273|NCT04387019|DIAGNOSTIC_TEST|blood sampling|blood sampling from peripheral vein
219636274|NCT02619864|DRUG|AZD2014|
219636275|NCT00174564|DRUG|oxaliplatin|
219636276|NCT00443079|DRUG|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
219636277|NCT00443079|DRUG|Matched placebo|1 pill 3 times daily x 6 weeks
219636278|NCT05443763|OTHER|An interdisciplinary intensive therapy program|Children will receive physical, occupation, and/or speech therapy 1-3 hours/day each for 4-5 days/week x 4 weeks.
219636279|NCT02547142|OTHER|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
218948551|NCT02871882|DRUG|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
219054279|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
219054280|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
218948552|NCT02871882|OTHER|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
218948553|NCT02113800|DRUG|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
218948554|NCT00954096|DRUG|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
219054281|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
219054282|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
218948555|NCT02248688|DEVICE|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
219054283|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
219636280|NCT03110406|OTHER|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
219636281|NCT00205556|PROCEDURE|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
219636282|NCT00205556|PROCEDURE|low flux hemodialysis|standard treatment
219636283|NCT05038774|OTHER|Face to face Educational Training|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
219636284|NCT05038774|OTHER|Printed Education Material|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
219636285|NCT00248365|BIOLOGICAL|Theralux extracorporeal photochemotherapy|
219636286|NCT00528489|BIOLOGICAL|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
219636287|NCT00528489|BIOLOGICAL|IL-12|Cytokine injection
219636288|NCT00528489|BIOLOGICAL|IL-15|Cytokine injection
219636289|NCT00691912|DRUG|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
219636290|NCT00691912|DRUG|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
219636291|NCT04507386|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
219636292|NCT05791539|PROCEDURE|Erector spinae plane block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
219636293|NCT05791539|PROCEDURE|erector spinae plane block + retrolaminar block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
219636294|NCT02171312|DEVICE|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
219636295|NCT02171312|BEHAVIORAL|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
218948556|NCT02248688|PROCEDURE|Left Gastric Artery Embolization|
219054284|NCT05297045|OTHER|Placebo|Placebo comparator
219054285|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
219054286|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
219054287|NCT00741234|DRUG|SB939|SB939 taken orally in a 4-week cycle.
219054288|NCT00741234|DRUG|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
219054289|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
219636296|NCT00716014|DRUG|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
219636297|NCT00716014|DRUG|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
219636298|NCT06152146|DEVICE|Shockwave Therapy|Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
219054290|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
219636299|NCT06152146|OTHER|SHAM shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
218948557|NCT04110652|OTHER|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
219636300|NCT05218343|BEHAVIORAL|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
218948558|NCT01167387|DIETARY_SUPPLEMENT|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
218948559|NCT01167387|OTHER|water|The control group will receive plain water with the same volume and timing of treatment.
218948560|NCT02723045|PROCEDURE|Open Lichtenstein Hernioplasty|
219636301|NCT02649439|BIOLOGICAL|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
219636302|NCT02649439|BIOLOGICAL|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
219636303|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB / FLU-01L (intranasal application)
219636304|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB/FLU-01L (sublingual application)
219636305|NCT03884530|DRUG|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
219636306|NCT03884530|DRUG|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
219636307|NCT01578473|DRUG|Vitamin D2|oral softgel 2000 IU once daily 9 months
219636308|NCT01578473|DRUG|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
219636309|NCT01578473|DRUG|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
219636310|NCT05591976|OTHER|Exercise training program|16-week, structured exercise training program including resistance and aerobic exercise
219636311|NCT02451774|DRUG|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
219636312|NCT02451774|DRUG|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
219636313|NCT04141501|DRUG|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
218948561|NCT02723045|PROCEDURE|Laparoscopic TEP Hernioplasty|
218948562|NCT00469170|DEVICE|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
218948563|NCT04248959|BEHAVIORAL|Multimodal prehabilitation|"Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital"
218948564|NCT04097587|BEHAVIORAL|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
219636314|NCT04141501|DRUG|Placebo oral capsule|single dose of mannitol (100%)
219636315|NCT05756816|DEVICE|SurePulse VSP|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.
219636316|NCT05756816|DEVICE|SurePulse VS|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
219636317|NCT00945035|DRUG|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
219636318|NCT00945035|DRUG|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
219636319|NCT06166446|DEVICE|subtractive technique|The milled denture teeth are then bonded into the milled recesses using a special PMMA bonding system.
219636320|NCT06166446|DEVICE|additive technique|The denture teeth were printed as one unit using the same method with tooth resin (DENTCA Denture Tooth, Shade A2).
219054291|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
219054292|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
218948565|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
219054293|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
219054294|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
219054295|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
219054296|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
219054297|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
219054298|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
219054299|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
219636321|NCT02888912|OTHER|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
219054300|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
219054301|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
219054302|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
219636322|NCT02888912|OTHER|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
219636323|NCT01958814|DRUG|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
219636324|NCT01958814|DRUG|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
219636325|NCT01063621|DRUG|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
219636326|NCT05865574|DRUG|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
219636327|NCT02896062|BEHAVIORAL|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
219636328|NCT05454644|OTHER|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~* Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~* Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~* Correct and practical directions: Medication Regimen Complexity Index (MRCI).~* Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~* Drug-disease interactions: Beers Criteria.~* Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
219636329|NCT06967350|OTHER|CARE & AIDET communication mode|The new communication mode, which incorporates fundamental communication principles (AIDET) and service recovery strategies (CARE)
218948566|NCT05778383|DIETARY_SUPPLEMENT|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
219054303|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
218948567|NCT04371874|DRUG|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
219054304|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
219054305|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
219054306|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
219054307|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
219054308|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
219054309|NCT00253526|DRUG|bevacizumab|
219054310|NCT00253526|DRUG|gemcitabine hydrochloride|
219054311|NCT00253526|PROCEDURE|adjuvant therapy|
219054312|NCT00253526|PROCEDURE|anti-cytokine therapy|
219636330|NCT06967350|OTHER|CARE communication mode|CARE (C: connect, A: apologize, R: repair, E: exceed) is a standard service recovery communication mode in medical services.
219636331|NCT06967350|OTHER|AIDET communication mode|AIDET is a nurse-patient communication mode that contains essential communication principles. Each letter represents a step for communication: Acknowledge, Introduce, Duration, Explanation, and Thank. It describes in detail the application and characteristics of the primary language in communication, logical and procedural.
219636332|NCT04104763|BEHAVIORAL|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
219636333|NCT00216619|DRUG|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
219636334|NCT00216619|DRUG|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
219636335|NCT04399213|PROCEDURE|50 µg Histamine|Skin prick through 50 µg/5 µL histamine diHCl
219054313|NCT00253526|PROCEDURE|antiangiogenesis therapy|
219054314|NCT00253526|PROCEDURE|antibody therapy|
219054315|NCT00253526|PROCEDURE|biological therapy|
219054316|NCT00253526|PROCEDURE|chemotherapy|
219054317|NCT00253526|PROCEDURE|conventional surgery|
219054318|NCT00253526|PROCEDURE|growth factor antagonist therapy|
219054319|NCT00253526|PROCEDURE|monoclonal antibody therapy|
219054320|NCT00253526|PROCEDURE|surgery|
219054321|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
219054322|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
219054323|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
219054324|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
219054325|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
219636336|NCT04399213|PROCEDURE|15 µg Histamine|Skin prick through 15 µg/5 µL histamine diHCl
219636337|NCT04399213|PROCEDURE|5 µg Histamine|Skin prick through 5 µg/5 µL histamine diHCl
219636338|NCT04399213|PROCEDURE|Placebo (saline)|Skin prick through 5 µL saline (0.9% NaCl)
219636339|NCT00204464|PROCEDURE|Exercise|
219636340|NCT05589688|DRUG|Acyclovir|Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
219636341|NCT05575778|DIAGNOSTIC_TEST|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
219636342|NCT06682897|BEHAVIORAL|Tai Chi training|60 minutes each session, three sessions per week, lasting 4 weeks for undertaking.
219636343|NCT03128177|DIETARY_SUPPLEMENT|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
219636344|NCT04541953|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.
219636345|NCT04541953|OTHER|In-person Rehabilitation Therapy|Range of motion exercises and stretching
219636346|NCT01053663|DRUG|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
219636347|NCT04871204|DRUG|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
219636348|NCT04374123|DIAGNOSTIC_TEST|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
219636349|NCT01544387|OTHER|Bed Rest|"* Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~* Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~* Subjects may have limited bathroom privileges"
219636350|NCT01544387|OTHER|Activity|"* Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~* Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
219636351|NCT02237612|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
219636352|NCT02237612|OTHER|laboratory biomarker analysis|Correlative studies
219636353|NCT05618938|OTHER|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~1. Rest position of the tongue~2. Control of TMJ rotation~3. Rhythmic stabilization technique~4. Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
219636354|NCT05618938|OTHER|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing~4. Tongue up and wiggle~5. Strengthening~6. Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
219636355|NCT02423395|DRUG|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
219636356|NCT02423395|DRUG|Placebo|calcium in muscle cramps in cirrhotic patients
219636357|NCT05758610|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
219636358|NCT03533114|DRUG|JZP-258|Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
219054326|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
219054327|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
219054328|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
219054329|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
219054330|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
219636359|NCT03533114|DRUG|Placebo Oral Solution|Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
219636360|NCT01862250|DRUG|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration"
219636361|NCT01398618|DRUG|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
219636362|NCT00089063|BIOLOGICAL|tyrosinase peptide|Given SC
219636363|NCT00089063|BIOLOGICAL|gp100 antigen|Given SC
219636364|NCT00089063|BIOLOGICAL|MART-1 antigen|Given SC
219636365|NCT00089063|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
219636366|NCT00089063|DRUG|Montanide ISA 51 VG|Given SC
219636367|NCT00089063|BIOLOGICAL|sargramostim|Given SC
219636368|NCT00089063|OTHER|laboratory biomarker analysis|Correlative studies
219636369|NCT03455101|OTHER|There is no intervention.|There is no intervention.
219636370|NCT00331669|PROCEDURE|deep brain stimulation|high frequency stimulation
218948568|NCT05009433|BEHAVIORAL|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
218948569|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
218948570|NCT05009433|BEHAVIORAL|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
218948571|NCT05009433|BEHAVIORAL|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
218948572|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
218948573|NCT05009433|BEHAVIORAL|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
218948574|NCT05313776|OTHER|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
218948575|NCT04673110|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
218948576|NCT06059131|OTHER|KeenMind|320 mg/d (2 capsules/d) during 3 months
218948577|NCT06059131|OTHER|Placebo|320 mg/d (2 capsules/d) during 3 months
218948578|NCT03737227|RADIATION|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
218948579|NCT05290376|PROCEDURE|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
218948580|NCT05290376|DEVICE|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
218948581|NCT03978143|DRUG|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
218948582|NCT03978143|DRUG|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
218948583|NCT03978143|DRUG|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
218948584|NCT03978143|DRUG|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
219054331|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
219054332|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
218948585|NCT03978143|DRUG|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
218948586|NCT03978143|DRUG|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
218948587|NCT03978143|DRUG|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
218948588|NCT03978143|DRUG|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
218948589|NCT04240678|OTHER|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
218948590|NCT03844711|OTHER|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"* Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
218948591|NCT03844711|OTHER|Inspiratory Muscle Training (IMT)|\- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
218948592|NCT03844711|OTHER|Conventional physiotherapy|\- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
218948593|NCT01104376|DRUG|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
218948594|NCT01104376|DRUG|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
218948595|NCT01503671|DRUG|Atorvastatin|Atorvastatin 40 mg/day
218948596|NCT00797966|DRUG|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
219054333|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
219636371|NCT04408742|OTHER|pain|"Lower abdominal and low back pain was questioned. Pain intensity was evaluated with a 0 to 10 cm visual analog scale (VAS): 0 indicated no pain and 10 indicated the worst imaginable pain \[18\]. Pain that developed during the activity was also questioned and stated as pain+ activity. A higher score indicates a more severe pain."
219636372|NCT04408742|OTHER|fatigue|"Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 completely disagree to 7 completely agree. A score of 4 or higher generally indicates severe fatigue."
219054334|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
219206990|NCT06766110|OTHER|Assessment|31 volunteer participants who were followed up at the Department of Chest Diseases, Istanbul University, Istanbul Faculty of Medicine and met the inclusion criteria were included in the study. Participants' body composition, upper extremity functional exercise capacity, grip strength, and activities of daily living were evaluated.
219636373|NCT04408742|OTHER|anxiety|"The Spielberger State Trait Anxiety Inventory (STAI) was used to evaluate levels of anxiety. The state part of the STAI is a 20-item self-report inventory designed to measure state anxiety (current feelings of apprehension, worry, etc.). The STAI state scale is scored on four levels of anxiety intensity from 1 not at all to 4 very much and with a total score between 20 and 80. A higher total score indicates a more severe anxiety level."
218948597|NCT00797966|DRUG|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
218948598|NCT00797966|DRUG|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
219054335|NCT05880953|BEHAVIORAL|Parent-to-parent coaching|Parents and parent coaches will meet as needed via the family's preferred method. Engagement may include text messaging, phone conferencing, Zoom conferencing, or occasional in-home or hospital visiting as preferred. Coaching sessions will vary based on family desired frequency and location, but may include: on-site in the family home or hospital room, telephone or video conferencing, or asynchronous contacts via email or text messaging. The template for the intervention includes an initial introductory session which is intended to build rapport and orient the parent to our program. Subsequent session topics may include: addressing specific needs including topics of interviewing and selecting home health agencies, expectation setting for home based nursing care, recruiting for home health team from inpatient settings, and recruiting for home health team from professional and personal networks.
219054336|NCT06630637|BEHAVIORAL|Glucose-Ketone Index (GKI) monitoring|Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.
219636374|NCT04408742|OTHER|position sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
219054337|NCT06630637|BEHAVIORAL|Continuous Glucose Monitoring (CGM)|Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.
219054338|NCT06630637|OTHER|Digital dynamometer|Grip strength measurements, right and left hand, up to 20 readings per day per hand.
219054339|NCT06630637|DEVICE|Wearables|All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
219636375|NCT04408742|OTHER|balance|The Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used to measure limits of stability. The participants were asked to position themselves in a comfortable position on the platform and their foot position coordinate was recorded. The participants were asked to complete as quickly as possible the directional tasks displayed on a screen, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s. A total score was recorded. The higher the total score, the better the ability of the subjects to transfer the center of gravity.
219636376|NCT04408742|OTHER|dual task performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
219054340|NCT06630637|DIAGNOSTIC_TEST|Blood tests|Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.
219054341|NCT06630637|DIAGNOSTIC_TEST|Stool tests|"15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast)."
219054342|NCT06630637|DIAGNOSTIC_TEST|Saliva tests|Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).
218948599|NCT00732901|DRUG|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
218948600|NCT00732901|DRUG|Placebo|Once daily days 1-28
218948601|NCT00541190|OTHER|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
218948602|NCT02758379|DEVICE|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
218948603|NCT01486043|DRUG|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
218948604|NCT02601807|DEVICE|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
218948605|NCT02601807|DEVICE|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
218948606|NCT00972140|DRUG|Formoterol|Formoterol-HFA pMDI 12µg twice daily
218948607|NCT00972140|DRUG|Formoterol|Formoterol-DPI 12 µg twice daily
219636377|NCT06576557|OTHER|KNEE-DEeP intervention- Knowledge translation and exercise for early degenerative knee pain|The intervention for health care professionals (GPs and physiotherapists) will consist of training and education. The two-hour educational workshop for GPs will focus on diagnosis and management of patients with early degenerative knee pain, and enhancing communication skills. Training for physiotherapists will focus on delivery of a 'best practice' session. The patient participant intervention will consist of an 'enhanced consultation' delivered by the GP. This will involve a physical exam, key educational messages, written information and a treatment plan. Patients will receive a single session of physiotherapy within 2 weeks of referral from their GP. This 'best practice' session will focus on self-management skills, targeted patient education, goal setting, action planning and exercise prescription.
219636378|NCT02701530|BEHAVIORAL|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
219636379|NCT04835090|OTHER|screening test|using three screening tools
219636380|NCT02423343|DRUG|Galunisertib|Administered orally
219636381|NCT02423343|DRUG|Nivolumab|Administered IV
219636382|NCT00177242|DRUG|Gefitinib|
219636383|NCT01180751|RADIATION|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
219636384|NCT02016105|DRUG|GP2017 Adalimumab|
219636385|NCT02016105|DRUG|Humira ® Adalimumab|
218948608|NCT04306991|DEVICE|Auscultation using an electronic stethoscope (EKO CORE 4)|"* Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography."
218948609|NCT01596556|DRUG|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
218948610|NCT01596556|OTHER|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
218948611|NCT00853268|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
218948612|NCT00853268|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
218948613|NCT05940454|PROCEDURE|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
218948614|NCT00732043|DIETARY_SUPPLEMENT|pomegranate extract|8 oz per day, 48 months
218948615|NCT00732043|DIETARY_SUPPLEMENT|pomegranate juice|8 oz per day, 48 months
218948616|NCT00732043|DIETARY_SUPPLEMENT|placebo|8 oz per day, 48 months
218948617|NCT00196183|PROCEDURE|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
218948618|NCT00196183|PROCEDURE|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
218948619|NCT00118521|PROCEDURE|Foot Orthotics|
218948620|NCT00118521|PROCEDURE|Physiotherapy|
218948621|NCT02117206|DRUG|L-arginine (L-arginine Veyron)|
218948622|NCT02117206|DRUG|Nacl|
218948623|NCT05441878|DRUG|20% albumin|Albumin arm for resuscitation fluid
218948624|NCT05441878|DRUG|Balanced salt solution|Only Balanced salt solution will be used.
218948625|NCT00076375|DRUG|Nanocrystalline silver cream (NPI)|
218948626|NCT04227054|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
218948627|NCT06257602|PROCEDURE|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
218948628|NCT02349308|DEVICE|CentrosFLO Long Term Hemodialysis Catheter|
219636386|NCT04635995|BIOLOGICAL|LVGN7409|IV infusion once every 3 weeks (Q3W).
219636387|NCT05872555|DRUG|Psychiatric Drugs|Receiving any Antipsychotic, Benzodiazepine, antidepressant, mood stabilizer
219636388|NCT06097923|DRUG|Active fluid management with BIA monitoring|The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).
219636389|NCT06097923|DRUG|Conventional fluid management without BIA monitoring|The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
219636390|NCT04874662|DIETARY_SUPPLEMENT|NAM/B6|Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
219636391|NCT01600365|DRUG|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
218948629|NCT02799420|DEVICE|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
218948630|NCT02799420|DEVICE|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
218948631|NCT02218632|OTHER|lactose-free diet|standard diet
218948632|NCT02218632|DIETARY_SUPPLEMENT|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
218948633|NCT00052442|DRUG|pralatrexate|
218948634|NCT00576680|DRUG|RAD001|Given orally once a day
218948635|NCT00576680|DRUG|Temozolomide|Taken orally once a day for one week followed by a one-week break period
218948636|NCT03252340|DRUG|ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
218948637|NCT04785690|DEVICE|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
218948638|NCT04785690|DEVICE|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
218948639|NCT05130671|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
218948640|NCT05130671|DIETARY_SUPPLEMENT|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
218948641|NCT00321087|DRUG|T2000|Dose escalation from 600 to 1000 mg
218948642|NCT00321087|DRUG|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
219054343|NCT06630637|BEHAVIORAL|Fitness intervention|90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.
219054344|NCT06630637|BEHAVIORAL|Cold & heat intervention|"Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention."
219054345|NCT06630637|DEVICE|Airofit|"Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use."
219636392|NCT01600365|DRUG|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
219054346|NCT06630637|BEHAVIORAL|18h fasting|Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.
219054347|NCT06630637|BEHAVIORAL|48h fasting|48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.
219054348|NCT06630637|BEHAVIORAL|Three meal phase|During the first week of the study, the participant will follow a regime of three meals per day.
219054349|NCT06630637|BEHAVIORAL|Mediterranean-inspired diet|"Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results."
219054350|NCT06630637|DIETARY_SUPPLEMENT|Supplements|Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.
219054351|NCT06630637|BEHAVIORAL|Generative AI|Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.
219636393|NCT00976976|DRUG|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
219636394|NCT01844648|DRUG|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
218948643|NCT00321087|DRUG|T2000|Placebo followed by dose escalation from 600 to 1000
218948644|NCT03652623|DRUG|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
218948645|NCT00708253|DEVICE|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
219054352|NCT06630637|OTHER|Interviews|Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
219636395|NCT01844648|DRUG|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
219636396|NCT02578381|DEVICE|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
219636397|NCT02578381|DEVICE|Validation of Boston Scientific pressure wire|
219636398|NCT05924425|DRUG|Daridorexant 50 mg|Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
219636399|NCT05924425|DRUG|Placebo|Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
219549546|NCT06275542|DEVICE|Train of Four monitoring device in recovery room|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention. Measurements were taken twice sequential
218948646|NCT00708253|DEVICE|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
218948647|NCT03859973|DRUG|BI 425809|Tablet
218948648|NCT03859973|DRUG|Placebo|Tablet
218948649|NCT02423369|PROCEDURE|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
218948650|NCT02423369|OTHER|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
218948651|NCT02423369|OTHER|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
218948652|NCT05098262|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
218948653|NCT05098262|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
218948654|NCT04334395|PROCEDURE|primary tumor resection group|resection of cancer at colon
218948655|NCT02086006|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
218948656|NCT00637949|DEVICE|lumiracoxib|400 mg once daily, oral over 6 weeks
218948657|NCT00637949|DRUG|rofecoxib|25 mg, oral, daily over 6 weeks
218948658|NCT01160419|DRUG|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
219636400|NCT05924425|PROCEDURE|Polysomnography|A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
218948659|NCT01160419|DRUG|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
218948660|NCT01160419|DRUG|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
218948661|NCT01160419|DRUG|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
218948662|NCT01478048|BIOLOGICAL|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
218948663|NCT01478048|DRUG|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
218948664|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
218948665|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
218948666|NCT01478048|DRUG|Dexamethasone|Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
218948667|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
218948668|NCT06069440|OTHER|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
218948669|NCT00955201|BEHAVIORAL|Exercise|Structured aerobic exercise (treadmill).
218948670|NCT00955201|BEHAVIORAL|Exercise|Structured isokinetic strength exercise (dynameter).
218948671|NCT03032380|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
218948672|NCT03032380|DRUG|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
218948673|NCT03032380|DRUG|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
218948674|NCT05273073|DIETARY_SUPPLEMENT|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
219054353|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
219054354|NCT00388518|DRUG|Actos|45mg po daily
219054355|NCT00388518|DRUG|Placebo|po daily
219054356|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
219054357|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
219054358|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
219636401|NCT05924425|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, M1, M2
219636402|NCT05924425|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
219636403|NCT05924425|PROCEDURE|Actimetrics|Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
219636404|NCT05924425|PROCEDURE|24-hour Ambulatory Blood Pressure Monitoring (ABPM|Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
218948675|NCT05273073|DIETARY_SUPPLEMENT|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
218948676|NCT04038216|PROCEDURE|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
218948677|NCT04038216|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
218948678|NCT01876004|DRUG|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
218948679|NCT01876004|DRUG|Placebo|Prescribed Placebo IM (intramuscularly), single dose
218948680|NCT04121663|DEVICE|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
218948681|NCT02637349|BEHAVIORAL|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
218948682|NCT02637349|BEHAVIORAL|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
218948683|NCT05366504|COMBINATION_PRODUCT|LiST + PRP intracorporeal injection|12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
218948684|NCT05366504|COMBINATION_PRODUCT|LiST + Placebo(normal saline intracorporeal injection)|All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
218948685|NCT02082938|DEVICE|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
218948686|NCT00856414|BIOLOGICAL|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
218948687|NCT05324904|DRUG|Vitamin D|"\- Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
218948688|NCT05324904|DRUG|acyclovir|"-Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
218948689|NCT01839604|DRUG|AZD9150|Intravenous infusion over 3 hours.
218948690|NCT02891928|DEVICE|Rocker sole shoes|Measure of walk testing Measure of standing position
218948691|NCT02891928|DEVICE|Normal shoes|Measure of walk testing Measure of standing position
218948692|NCT05511077|OTHER|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
218948693|NCT00076453|DEVICE|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
218948694|NCT00076453|DEVICE|Standard orthotic shoe inserts|Neutral orthotic inserts
218948695|NCT04782206|PROCEDURE|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
218948696|NCT04782206|PROCEDURE|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
218948697|NCT04287543|DRUG|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
218948698|NCT04287543|DRUG|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
219206991|NCT06824389|OTHER|Consultation Model of large language model in Ophthalmology Clinics|Large language model completes the medical history collection and recommends examinations.
219206992|NCT06307704|PROCEDURE|Lung Ultrasound - guided Stepwise PEEP|After endo-tracheal intubation; A PEEP of 4 cmH2O will be initially used till 5 min after pneumoperitoneum. Then The PEEP will be adjusted in a stepwise approach after performing bedside lung ultrasound. The PEEP will be increased by 2 cmH2O until no lung collapse is detected. Lung ultrasound will be repeated 5 min after every change in the PEEP with a maximal PEEP of 12 cmH2O.
219636405|NCT05924425|OTHER|Biomarker assay|Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
219206993|NCT06307704|PROCEDURE|Standard Ventilation Protocol|Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
218948699|NCT02812498|OTHER|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
218948700|NCT02812498|OTHER|Standard|Group of patients followed in a traditional way
218948701|NCT05867589|DRUG|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
219206994|NCT06769607|DEVICE|Investigational algorithm|Investigational algorithm developed for the treatment of Obstructive Sleep Apnea.
218948702|NCT01541397|DRUG|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
218948703|NCT00313183|DRUG|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
218948704|NCT01128621|DRUG|GSK1292263|Tablet
218948705|NCT01128621|DRUG|GSK1292263 matching placebo|Tablet
218948706|NCT01128621|DRUG|Sitagliptin|Tablet
218948707|NCT02292914|PROCEDURE|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
218948708|NCT02292914|PROCEDURE|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
218948709|NCT04727489|GENETIC|DNA from subjects will be stored in the biobank of our study.|Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
218948710|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy with Splenectomy|
218948711|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
218948712|NCT00036608|DRUG|Entecavir|
218948713|NCT01879644|BEHAVIORAL|NF|
218948714|NCT01879644|BEHAVIORAL|SM|
218948715|NCT01879644|BEHAVIORAL|PE|
218948716|NCT01879644|BEHAVIORAL|SU|
218948717|NCT00837317|DIETARY_SUPPLEMENT|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
219636406|NCT01002430|BIOLOGICAL|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
218948718|NCT05473650|DIAGNOSTIC_TEST|CBC.with with differential Peripheral smear|determine spectrum of hematological disorders in childern with pancytopenia
218948719|NCT01689532|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
218948720|NCT01689532|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
218948721|NCT01689532|DRUG|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
218948722|NCT04139889|DIAGNOSTIC_TEST|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
218948723|NCT01363349|DRUG|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
218948724|NCT01363349|DRUG|Risperidone|
218948725|NCT01958489|DRUG|Evacetrapib|Administered orally
218948726|NCT01958489|DRUG|Pravastatin|Administered orally
218948727|NCT02269085|DRUG|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I."
218948728|NCT02269085|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I."
219636407|NCT04800887|DEVICE|TECNIS Eyhance intraocular lens|Cataract surgery and implantation with extended depth of focus intraocular lens
219636408|NCT04800887|DEVICE|Monofocal intraocular lens Tecnis ZCB00|Cataract surgery and implantation with monofocal intraocular lens
219636409|NCT04913688|PROCEDURE|bedside ultrasound performed group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, an emergency physician performs bedside ultrasound of lower extremities to the patients agreed to participate in this study. The patients also are examined duplex ultrasound by radiologist.
219636410|NCT05326178|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
218948729|NCT02269085|BEHAVIORAL|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
218948730|NCT04226768|OTHER|"Enhanced Haematology Palliative Care (Fast-track) Group"|Early and proactive multidisciplinary care
218948731|NCT04226768|OTHER|Conventional Care|Conventional care and referral as indicated
218948732|NCT04276324|OTHER|Resistance training|Ten weeks of resistance training
218948733|NCT04276324|OTHER|Testing sessions|Testing sessions
219054359|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
219054360|NCT02464501|OTHER|Paclitaxel administration using the OPC|
219054361|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
219054362|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
219636411|NCT06120088|DRUG|Bubpivacaine|Bupivacaine is a long-acting local anesthetic commonly used to provide pain relief by blocking nerve signals in a specific area. It's often utilized for various medical procedures and surgeries, offering prolonged numbing effects.
219636412|NCT06120088|DRUG|dexamethasone|Dexamethasone is a potent corticosteroid with anti-inflammatory properties. It's frequently employed as an adjunct in medical treatments to reduce inflammation and swelling, and in some cases, to prevent nausea and vomiting associated with certain medications or procedures.
219636413|NCT06120088|DRUG|fentanyl|Fentanyl is a powerful synthetic opioid pain reliever. It acts on the central nervous system to alleviate severe pain. Fentanyl is significantly potent and is used in medical settings for acute pain management, such as during surgeries or for chronic pain in cases where other opioids may not be as effective.
219636414|NCT00090493|BIOLOGICAL|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
219636415|NCT00090493|BIOLOGICAL|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
219636416|NCT02071706|DEVICE|PET/MRI system|Enrolled subject undergoes PET/MR scan
219636417|NCT01214083|DRUG|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
218948734|NCT03014999|DEVICE|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
218948735|NCT03014999|DEVICE|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
218948736|NCT03014999|DEVICE|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
218948737|NCT01697280|BEHAVIORAL|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
218948738|NCT01697280|OTHER|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
218948739|NCT01697280|OTHER|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
218948740|NCT00710125|DRUG|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
219206995|NCT06769607|DEVICE|Control algorithm|Released algorithm intended for the treament of Obstructive Sleep Apnea
219636418|NCT01214083|DRUG|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
219636419|NCT01214083|DRUG|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
219636420|NCT00179777|DIETARY_SUPPLEMENT|Hydrolysed infant formula|Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.
219636421|NCT00179777|DIETARY_SUPPLEMENT|Nonhydrolysed infant formula|Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
219636422|NCT01908829|DRUG|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
219636423|NCT01908829|DRUG|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
219636424|NCT01908829|DRUG|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
219636425|NCT01908829|DRUG|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
219636426|NCT01908829|DRUG|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
219636427|NCT01908829|DRUG|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
219636428|NCT01908829|DRUG|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
219636429|NCT01908829|DRUG|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
219636430|NCT04093011|PROCEDURE|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
219636431|NCT04289376|OTHER|Gaze tracking - no intervention|Monitor gaze as subjects watch a video
219636432|NCT01481662|DEVICE|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
219636433|NCT02365389|DRUG|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
219636434|NCT02365389|DRUG|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
219636435|NCT02637401|BEHAVIORAL|Dialectical Behaviour Therapy|
218948741|NCT01208753|DRUG|GLPG0555|two different aqueous formulations
218948742|NCT01208753|DRUG|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
218948743|NCT01208753|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
218948744|NCT01209182|DEVICE|Testing a new device (LS BioPath TOUCH) on excised tissue|Measurements are obtained with test device on excised tissue.
218948745|NCT00233883|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
218948746|NCT00233883|DRUG|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
218948747|NCT04405466|PROCEDURE|Blood sampling|Blood samples
218948748|NCT04405466|PROCEDURE|Throat swab|Throat swab
218948749|NCT00300547|PROCEDURE|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
218948750|NCT02704390|DRUG|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
218948751|NCT03044600|OTHER|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
218948752|NCT03044600|OTHER|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
218948753|NCT01608022|DRUG|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
218948754|NCT00060359|DRUG|Carboplatin|Given IV
218948755|NCT00060359|DRUG|Paclitaxel Poliglumex|Given IV
218948756|NCT00060359|OTHER|Pharmacological Study|Correlative studies
218948757|NCT02470988|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|
218948758|NCT02470988|BEHAVIORAL|CBASP Without DPI|
218948759|NCT05767567|BEHAVIORAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
218948760|NCT05952128|DRUG|Fluzoparib+ Dalpiciclib|"Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390"
218948761|NCT00913458|DRUG|etanercept|
218948762|NCT06530472|OTHER|Monitoring|At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
218948763|NCT02882750|OTHER|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
218948764|NCT02882750|OTHER|PS Q18|Patients Satisfaction Questionnaire
218948765|NCT02882750|OTHER|Decision Self-Efficacy Scale|Questionnaire
218948766|NCT02844062|BIOLOGICAL|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
218948767|NCT02844062|DRUG|cyclophosphamide|250 mg/m\^2 d1-3
218948768|NCT02844062|DRUG|Fludarabine|25mg/m\^2 d1-3
218948769|NCT03595618|DRUG|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
218948770|NCT03595618|DRUG|Placebo|Film-coated tablets of matching placebo for oral use.
219054363|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
219054364|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
219054365|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
219636436|NCT04052243|DIAGNOSTIC_TEST|Invasive exercise testing|Invasive hemodynamic exercise testing
219636437|NCT05695014|OTHER|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
218948771|NCT01291485|BEHAVIORAL|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
218948772|NCT02338232|DRUG|Telmisartan|
218948773|NCT04277806|BEHAVIORAL|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
219054366|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
219636438|NCT05797935|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
218948774|NCT00027833|BIOLOGICAL|ALVAC-CEA-B7.1 vaccine|
218948775|NCT00027833|BIOLOGICAL|tetanus toxoid|
218948776|NCT00027833|DRUG|FOLFIRI regimen|
218948777|NCT00027833|DRUG|fluorouracil|
218948778|NCT00027833|DRUG|irinotecan hydrochloride|
218948779|NCT00027833|DRUG|leucovorin calcium|
218948780|NCT04595994|DRUG|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
218948781|NCT02583217|DRUG|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
218948782|NCT02583217|DRUG|remifentanyl|
218948783|NCT02583217|DRUG|propofol|
218948784|NCT02583217|DEVICE|laryngeal mask|
218948785|NCT03569345|DRUG|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
218948786|NCT02279407|DRUG|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
218948787|NCT02279407|DRUG|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
218948788|NCT02279407|DRUG|Dapagliflozin|10 mg administered as 10 mg tablet
219636439|NCT03391570|DRUG|COX-2 inhibitor|Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
219636440|NCT03391570|DRUG|Placebo Oral Tablet|Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
219636441|NCT03391570|PROCEDURE|Preoperative peritoneal biopsy|Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
219636442|NCT03391570|PROCEDURE|Single-port laparoscopic surgery|Single-port laparoscopic surgery with CO2 gas
218948789|NCT02279407|DRUG|Placebo|Placebo matching to dapagliflozin 10 mg
219054367|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
219054368|NCT01984723|DRUG|Experimental: EVP-6124|
219054369|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
219054370|NCT00006508|PROCEDURE|formula meal|
219054371|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
219054372|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
219054373|NCT05660616|OTHER|supportive care|supportive care
219054374|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
219054375|NCT06266923|DRUG|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
219054376|NCT03851653|BEHAVIORAL|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
219054377|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
219054378|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
219054379|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
219636443|NCT03391570|PROCEDURE|Postoperative peritoneal biopsy|Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
219054380|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
219054381|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
219054382|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
219054383|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
218948790|NCT02045030|DRUG|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
219054384|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
219054385|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
219054386|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
219054387|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
219054388|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
219054389|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
219054390|NCT00023816|DRUG|carbendazim|
219054391|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
219636444|NCT02247440|DRUG|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
219636445|NCT02792192|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
219636446|NCT02792192|BIOLOGICAL|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
219636447|NCT06012890|OTHER|Automation of cardiac MRI acquisition|The intervention will consist of the automation of the cMRI examination.
219636448|NCT02002455|DEVICE|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
219636449|NCT06070181|DEVICE|Enamel matrix derivate|'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
219636450|NCT06070181|PROCEDURE|Non-surgical periodontal treatment|No additional/adjunctive treatment with Emdogain
219636451|NCT02360150|RADIATION|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
219636452|NCT03088124|DRUG|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
219636453|NCT02320058|DRUG|Ipilimumab|
219636454|NCT02320058|DRUG|Nivolumab|
219636455|NCT00695279|PROCEDURE|Venipuncture|Blood draw
219636456|NCT06062121|DEVICE|Motor-cable-driven Rehabilitation Robotic System|Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
219636457|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
219636458|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
219636459|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
219054392|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
219636460|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses 2 months apart
219636461|NCT01339923|BIOLOGICAL|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
219636462|NCT01339923|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
219636463|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
219636464|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
219636465|NCT02809547|DEVICE|Dried Blood Spot device|
219636466|NCT05717049|DRUG|Theophylline Tablets|12 week oral treatment
218948791|NCT04516395|OTHER|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
218948792|NCT04516395|OTHER|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
218948793|NCT02500056|DEVICE|Optilene LP mesh|Lichtenstein hernioplasty
218948794|NCT02500056|DEVICE|Ultrapro mesh|Lichtenstein hernioplasty
218948795|NCT03216434|DIAGNOSTIC_TEST|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
218948796|NCT00186953|DRUG|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
218948797|NCT05343533|DIETARY_SUPPLEMENT|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
218948798|NCT02760225|DRUG|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
218948799|NCT02760225|DEVICE|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
218948800|NCT01671878|OTHER|Reference Glucose|
218948801|NCT01671878|OTHER|Test Food 1 (Cereal)|
218948802|NCT01671878|OTHER|Test Food 2 (Biscuit)|
218948803|NCT01191567|PROCEDURE|VAC treatment|wound treatment with VAC-therapy
218948804|NCT01191567|PROCEDURE|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
218948805|NCT02998632|PROCEDURE|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
218948806|NCT02998632|PROCEDURE|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
218948807|NCT04043741|OTHER|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
218948808|NCT04043741|OTHER|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~\+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
218948809|NCT04232332|DRUG|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
218948810|NCT04232332|DRUG|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
218948811|NCT04232332|DRUG|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
219054393|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
218948812|NCT04109508|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
218948813|NCT00864916|DRUG|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
218948814|NCT00864916|DRUG|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
218948815|NCT00864916|DRUG|Placebo|Participants will receive placebo three times per day for 48 weeks.
219054394|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
219054395|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
219054396|NCT02950636|OTHER|Yoga|Restorative Yoga
219054397|NCT01717417|DEVICE|miniscrew|
219054398|NCT01717417|DEVICE|TPA|
219054399|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
218948816|NCT05482750|OTHER|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
218948817|NCT05482750|OTHER|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
218948818|NCT02720354|OTHER|[11C]-DMDPA|
218948819|NCT04228159|DEVICE|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
218948820|NCT04228159|OTHER|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
218948821|NCT06126250|DEVICE|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
218948822|NCT06126250|DEVICE|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
218948823|NCT03554343|DIAGNOSTIC_TEST|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
218948824|NCT02087267|PROCEDURE|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
218948825|NCT04617431|BEHAVIORAL|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
218948826|NCT01335022|BEHAVIORAL|lecture|6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
219054400|NCT05277467|OTHER|no intervention|no intervention
219054401|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
219054402|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
219054403|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
219054404|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
219054405|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
219054406|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
219054407|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
219054408|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
219054409|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
219054410|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
219054411|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
218948827|NCT01585519|DIETARY_SUPPLEMENT|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
218948828|NCT02672527|DRUG|Trabectedin|
218948829|NCT02672527|DRUG|Dexamethasone|
218948830|NCT02024178|PROCEDURE|Ultrasound Imaging|
218948831|NCT01964768|OTHER|Skin prick-test|
218948832|NCT04716556|BIOLOGICAL|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
218948833|NCT05473078|OTHER|online anonymous exploratory study|online self-administered questionnary
218948834|NCT03084380|BIOLOGICAL|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
218948835|NCT03084380|DRUG|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
218948836|NCT03084380|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
218948837|NCT02061319|BEHAVIORAL|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
219054412|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
219636467|NCT02157285|BEHAVIORAL|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
219636468|NCT06078007|BEHAVIORAL|MyMoodCoach|The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
219636469|NCT03006978|DEVICE|TearCare|
219636470|NCT03006978|DEVICE|Warm Compress|
219636471|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
219636472|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
219636473|NCT05328206|OTHER|Standard of care for intubated children|Patient ventilated through a cuffed endotracheal tube and having a cuff leak test prior extubation
219636474|NCT06574698|DRUG|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
219636475|NCT00127998|DRUG|chloroquine|
219636476|NCT00127998|DRUG|sulfadoxine-pyrimethamine|
219636477|NCT00127998|DRUG|amodiaquine|
219636478|NCT00127998|DRUG|amodiaquine+artesunate|
219636479|NCT00127998|DRUG|amodiaquine+sulfadoxine-pyrimethamine|
219636480|NCT00127998|DRUG|sulfadoxine-pyrimethamine+artesunate|
219636481|NCT00127998|DRUG|artemether-lumefantrine|
219636482|NCT00127998|DRUG|mefloquine|
218948838|NCT05239429|BEHAVIORAL|Transcendental Meditation Technique|Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
218948839|NCT04579887|OTHER|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
218948840|NCT06148844|OTHER|interactive robot group|Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
218948841|NCT01816945|BEHAVIORAL|MOMBA web-based application|Web-based, interactive, social network application.
218948842|NCT00401180|DRUG|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
218948843|NCT00401180|DRUG|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
218948844|NCT02331095|DRUG|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
218948845|NCT02331095|DRUG|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
218948846|NCT01488513|DRUG|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
218948847|NCT06530979|DEVICE|Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter|The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
218948848|NCT02618213|DEVICE|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
218948849|NCT02618213|DEVICE|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
218948850|NCT05324644|BEHAVIORAL|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
218948851|NCT05537870|BEHAVIORAL|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
218948852|NCT05537870|BEHAVIORAL|case manager care|case manager care (usual care)
218948853|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
218948854|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
219054413|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
219206996|NCT06768385|PROCEDURE|Transversus abdominis plane (TAP) block|: It was performed under USG guidance using 30 ml of 0.25% bupivacaine with an 80 mm insulated peripheral block needle. Local anaesthetic was applied between the upper fascia of the transversus abdominus muscle and the fascia of the internal oblique muscle at the midpoint of the distance between the costal margin and the iliac crest in the midaxillary line under USG imaging guidance.
219636483|NCT00531713|DRUG|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
219636484|NCT03335007|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
219636485|NCT03335007|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
219636486|NCT05720715|DRUG|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
219636487|NCT06666530|OTHER|Questionary|Three self-questionnaires, either completed independently or with assistance, will be administered at inclusion (between the first obstetric ultrasound and 28 weeks of amenorrhea), during the third trimester of pregnancy, and at 1 year postpartum
219636488|NCT02073448|DRUG|GK530G|
219636489|NCT02073448|DRUG|CD0271|
219636490|NCT02073448|DRUG|CD1579|
219636491|NCT06580301|DRUG|YK012|The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
219636492|NCT00327769|DRUG|Fulvestrant|250 mg intramuscular injection
219636493|NCT00327769|DRUG|Anastrozole|1 mg tablet
218948855|NCT05464953|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
218948856|NCT05464953|DRUG|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
218948857|NCT00169858|BIOLOGICAL|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
219636494|NCT06341855|DIAGNOSTIC_TEST|MRD-ctDNA|ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.
219636495|NCT04015635|OTHER|None involved|NO intervention
219636496|NCT05730959|DEVICE|Sacral nerve modulation|Implant of nerve stimulator
218948858|NCT00852514|DEVICE|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
218948859|NCT00622271|BEHAVIORAL|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
218948860|NCT02776319|DEVICE|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
218948861|NCT02776319|DEVICE|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
218948862|NCT02149849|PROCEDURE|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
218948863|NCT02407652|BEHAVIORAL|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
219054414|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
219054415|NCT04073316|DRUG|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
219636497|NCT01540214|OTHER|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
219636498|NCT03522714|DEVICE|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
219636499|NCT03522714|DEVICE|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
219636500|NCT00565877|OTHER|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
219636501|NCT03079011|DRUG|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
218948864|NCT02407652|BEHAVIORAL|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
219054416|NCT04073316|DRUG|Warfarin|Warfarin intake, with target INR range between 2 and 3
219636502|NCT03079011|DRUG|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
219636503|NCT03079011|DRUG|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
219636504|NCT06321861|DIETARY_SUPPLEMENT|Caffeine|Participants will take one caffeine pill. The dose of caffeine will be calculated based on participants' body mass (3mg/kg body mass). Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
219636505|NCT06321861|DIETARY_SUPPLEMENT|Placebo|Participants will take one pill with no caffeine in it. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
219636506|NCT06321861|OTHER|No substance|Participants will take no substance. They will just wait 60 minutes and then engage in the exercise protocol.
219636507|NCT06040970|DRUG|Sacituzumab|"Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg"
218948865|NCT04369261|DRUG|Synovian®|Synovian® Inj.
218948866|NCT02156245|OTHER|conventional rehabilitation program (including concentric cycle ergometer)|
218948867|NCT02156245|OTHER|cycling included into a conventional rehabilitation program|
218948868|NCT03741387|OTHER|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
218948869|NCT03741387|OTHER|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
219636508|NCT06040970|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV
219636509|NCT00411242|DRUG|agomelatine|
219636510|NCT00411242|DRUG|placebo|
219636511|NCT01216956|DRUG|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
219636512|NCT00438607|DRUG|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
219636513|NCT00438607|DRUG|Placebo|Matched placebo for MTD or MTD-1
219636514|NCT03995589|OTHER|Walking|Technology-guided semi-supervised walking therapy
219636515|NCT03995589|OTHER|Control|Go Home and Walk advice
218948870|NCT03670420|OTHER|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
218948871|NCT01087736|DRUG|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
219054417|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
218948872|NCT01087736|OTHER|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
218948873|NCT01253811|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
218948874|NCT00665314|DRUG|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
219054418|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
219636516|NCT05946317|PROCEDURE|Lingual nerve function assessed after removal of mandibular third molar with lingual split technique|The lingual split technique is based on using chisel and hammer in bone removing. After the buccal and lingual flaps are raised and retracted. Two buccal bone cutting with horizontal cutting up between them are performed, The disto-lingual bone fragment is fractured inward by placing the cutting edge of the chisel at 45 degrees with the surface of the bone and directed towards the lower second premolar of the opposite side. By maintaining the cutting edge of the chisel parallel to the external oblique ridge, a few light taps with the mallet will separate the lingual plate from the rest of the alveolar bone. And it released from soft tissues, buccally force is applied to roll the whole tooth lingually. The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants.
219636517|NCT05639816|PROCEDURE|Saline irrigation group|Normal saline irrigation of common bile duct after complete stone removal
219636518|NCT06260410|DIAGNOSTIC_TEST|Blood draw for ctDNA and circulating tumor cell collection.|During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.
219636519|NCT00305955|DEVICE|Spectacles|optimal spectacle correction
219636520|NCT06684834|OTHER|5:2 carbohydrate restriction|Carbohydrate ingestion restricted to \<8% of energy intake on 2 self-selected consecutive days each week over 28-30 days. Ad libitum dietary amount, type and pattern followed on the remaining 5 days each week.
219636521|NCT06684834|OTHER|Early time-restricted carbohydrate intake|Carbohydrate intake restricted to \<8% of energy intake after 4pm each day for 28 days. Ad libitum dietary amount, type and pattern followed before 4pm.
219636522|NCT02905981|DRUG|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
219636523|NCT02905981|DRUG|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
219636524|NCT02905981|DRUG|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
219636525|NCT02690298|DEVICE|ExSpiron|Non-Invasive respiratory volume monitoring
219636526|NCT02113098|OTHER|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
219636527|NCT02113098|OTHER|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
219636528|NCT04681911|DRUG|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
218948875|NCT00665314|DRUG|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
218948876|NCT01568528|DRUG|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
218948877|NCT01568528|DRUG|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
218948878|NCT01568528|OTHER|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
218948879|NCT04469829|DRUG|Secukinumab|standard doses of secukinumab for psoriasis
218948880|NCT04469829|DRUG|Methotrexate|Methotrexate 15 mg/week
218948881|NCT01410344|DRUG|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
218948882|NCT01410344|DRUG|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
218948883|NCT01410344|DRUG|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
218948884|NCT01410344|DRUG|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
218948885|NCT02788279|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
218948886|NCT02788279|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
218948887|NCT02788279|DRUG|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
218948888|NCT02872506|DRUG|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
218948889|NCT02872506|PROCEDURE|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
218948890|NCT00386542|BIOLOGICAL|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
218948891|NCT00386542|DEVICE|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
218948892|NCT05908006|DEVICE|Velacur|Imaging Procedures Comparison
218948893|NCT02727543|OTHER|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
218948894|NCT04801264|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
218948895|NCT04801264|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
218948896|NCT04649372|PROCEDURE|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
218948897|NCT05414734|DRUG|HHT120|Capsule, oral administration
219054419|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
219636529|NCT04681911|DRUG|Pyrotinib|Pyrotinib: 400mg, oral, every day.
219636530|NCT04681911|DRUG|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
218948898|NCT05414734|DRUG|Placebo|Capsule, oral administration
218948899|NCT01529775|DEVICE|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
218948900|NCT01529775|DEVICE|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
218948901|NCT03176017|PROCEDURE|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
218948902|NCT03176017|PROCEDURE|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
218948903|NCT05446337|OTHER|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
219054420|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
219636531|NCT04681911|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
219636532|NCT04681911|DRUG|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
219636533|NCT04681911|DRUG|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
219636534|NCT04681911|DRUG|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
219636535|NCT04681911|DRUG|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
219636536|NCT03660189|OTHER|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
219636537|NCT02051140|DIETARY_SUPPLEMENT|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
219636538|NCT02051140|DIETARY_SUPPLEMENT|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
219636539|NCT03761030|DRUG|L-DOPA|We will be using generic sinemet 25/100 tablets in this study.
218948904|NCT03697135|BEHAVIORAL|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
218948905|NCT03970980|OTHER|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
218948906|NCT02372227|DRUG|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
218948907|NCT03996369|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
218948908|NCT03996369|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
218948909|NCT03381534|DEVICE|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
218948910|NCT03381534|DEVICE|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
218948911|NCT03010436|DRUG|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
218948912|NCT04134546|PROCEDURE|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
218948913|NCT03391193|BIOLOGICAL|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
218948914|NCT03391193|BIOLOGICAL|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
218948915|NCT03740984|OTHER|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
218948916|NCT03597646|DEVICE|Kinesio Tape|
218948917|NCT03597646|DEVICE|Threshold Inspiratory Muscle Trainer|
219636540|NCT03761030|DRUG|Placebo Oral Tablet|25/100 placebo tablets
219636541|NCT04274244|DRUG|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
219636542|NCT04274244|DRUG|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
219636543|NCT01860040|DRUG|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
219636544|NCT01860040|DRUG|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
218948918|NCT03693729|DEVICE|HD-tDCS|Participants will complete a metamemory and memory task
218948919|NCT04787523|RADIATION|Radiotherapy|Patients have received neoadjuvant radiotherapy
218948920|NCT02316509|DRUG|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
218948921|NCT00006439|BEHAVIORAL|Counseling in the home|
218948922|NCT05377697|OTHER|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
218948923|NCT02802670|DRUG|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
218948924|NCT02238067|DRUG|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
218948925|NCT02238067|OTHER|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
218948926|NCT02766842|PROCEDURE|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
218948927|NCT02766842|PROCEDURE|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
218948928|NCT02766842|DEVICE|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
218948929|NCT02766842|DEVICE|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
218948930|NCT02726308|DRUG|Dexamethasone|5 mg I.V. Dexamethasone just before induction
219636545|NCT01860040|DRUG|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
218948931|NCT02726308|DRUG|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
218948932|NCT02726308|DRUG|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
218948933|NCT00115323|BEHAVIORAL|Problem Solving|Problem solving intervention
219636546|NCT06968949|BEHAVIORAL|Unadapted Brief Intervention for School Clinicians (BRISC; BR-O)|BRISC is a four-session, individual engagement, assessment, brief intervention and triage strategy for youth age 13-18. BRISC provides a research-based approach to improving structure, efficiency, and effectiveness of school mental health via five elements: (1) Stepped care/tiered structure; (2) Culturally-informed engagement and motivation strategies;(3) Systematic problem-solving framework; (4) Modularized common elements approach; and (5) Structured assessment and monitoring.BRISC is hypothesized to operate on specific mechanisms that influence improvements in efficiency and clinical outcomes.
218948934|NCT00115323|BEHAVIORAL|Attention Control|Attention control intervention
218948935|NCT03480724|OTHER|Google Cardboard VRA|Intervention was randomized and shuffled.
218948936|NCT03480724|OTHER|Oculus Rift VRA|Intervention was randomized and shuffled.
218948937|NCT06311318|PROCEDURE|lower eyelid massage|The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
218948938|NCT00616499|DRUG|gefitinib|
218948939|NCT00616499|PROCEDURE|neoadjuvant therapy|
218948940|NCT00616499|PROCEDURE|therapeutic conventional surgery|
218948941|NCT02010151|OTHER|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
218948942|NCT01133028|BEHAVIORAL|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
218948943|NCT01133028|BEHAVIORAL|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
218948944|NCT01962961|DIETARY_SUPPLEMENT|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
218948945|NCT01962961|DIETARY_SUPPLEMENT|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
218948946|NCT02184572|BIOLOGICAL|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
218948947|NCT02184572|BIOLOGICAL|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
218948948|NCT02184572|BIOLOGICAL|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
218948949|NCT02184572|BIOLOGICAL|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
219636547|NCT06968949|BEHAVIORAL|Brief Intervention for School Clinicians (BRISC) with Implementation Strategies Adapted for School-Employed Practitioners (BR-A)|BR-A is a version of the Brief Intervention for School Clinicians with implementation strategies (IS) adapted for delivery by in the education sector by school-employed practitioners. Although IS modifications will be determined by Study 1 activities, we anticipate that BR-A may include changes to training pacing or format (e.g., asynchronous e-learning modules and videos); adaptations to format/content of consultation; and/ or addition of other ISs to enhance skills development (e.g., development of a learning collaborative) and/or overcome organizational or system barriers (e.g., educational outreach, changes to regulations). Core components of BRISC will be retained in the BR-A condition.
219636548|NCT05896501|DEVICE|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
218948950|NCT02184572|BIOLOGICAL|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
219054421|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
219054422|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
219054423|NCT00568984|DRUG|repaglinide|
219054424|NCT00568984|DRUG|metformin|
219054425|NCT00568984|DRUG|glicazide|
219054426|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
219054427|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
219054428|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219054429|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219636549|NCT05784324|OTHER|No intervention|No intervention
219636550|NCT01937910|BEHAVIORAL|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
219636551|NCT02074969|DEVICE|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
219636552|NCT02074969|DEVICE|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
219636553|NCT04765995|DRUG|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
219636554|NCT04765995|DRUG|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
219636555|NCT04765995|DRUG|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
219636556|NCT04765995|DRUG|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
219636557|NCT04765995|DRUG|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
219636558|NCT04765995|DRUG|Placebo|Matching placebo will be administered intramuscularly.
218948951|NCT04235010|DEVICE|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
218948952|NCT04235010|DEVICE|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
218948953|NCT00451503|DEVICE|Middle Ear Implant|surgery
218948954|NCT02411864|OTHER|different low b-values distribution|
218948955|NCT03726996|DRUG|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
219054430|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
219054431|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219054432|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
219054433|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
219054434|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
219054435|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
219054436|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
219054437|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
219054438|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219054439|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219054440|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219054441|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219054442|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219054443|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219054444|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
219054445|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
219636559|NCT04316429|OTHER|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. \[21\] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
218948956|NCT00685256|OTHER|counseling intervention|subjects and parents will receive genetic counseling
218948957|NCT00685256|OTHER|educational intervention|subjects and parents will receive education re: genetic testing
218948958|NCT00685256|OTHER|survey administration|surveys will be administered to subjects and parents
218948959|NCT00685256|BEHAVIORAL|psychosocial assessment and care|psychosocial assessment and counseling will be provided
218948960|NCT00685256|BEHAVIORAL|supportive care|parents and children will be provided with supportive care
218948961|NCT00002280|DRUG|Didanosine|
218948962|NCT01610999|DRUG|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
218948963|NCT00357591|DEVICE|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
218948964|NCT05254977|DRUG|Standard Preparation|Any kind of intervention received to reduce adverse effects
219054446|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
219054447|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
219054448|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
218948965|NCT04215757|PROCEDURE|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
218948966|NCT05912790|DEVICE|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
218948967|NCT00168129|PROCEDURE|Helical tomotherapy|
218948968|NCT00571168|DRUG|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
218948969|NCT00571168|DRUG|Placebo|Placebo capsules on day 1-4
218948970|NCT05033405|BEHAVIORAL|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
218948971|NCT00677989|PROCEDURE|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
218948972|NCT00677989|PROCEDURE|Open appendectomy|open appendectomy: did appendectomy by laparotomy
218948973|NCT05363306|PROCEDURE|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
218948974|NCT03208985|DRUG|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
218948975|NCT01064375|BIOLOGICAL|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
219054449|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
218948976|NCT01064375|DEVICE|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
218948977|NCT01064375|BIOLOGICAL|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
218948978|NCT01064375|DRUG|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
218948979|NCT00881543|DRUG|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
218948980|NCT06471387|BEHAVIORAL|Flexiquit Smoking Cessation Intervention|Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
218948981|NCT00967980|PROCEDURE|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
219054450|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
219054451|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
219054452|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
219636560|NCT04316429|OTHER|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
219636561|NCT00403481|DRUG|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
219636562|NCT00403481|DRUG|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
219636563|NCT05641805|OTHER|PAQ-C (Physical activitiy questionare for children), MoCA (Montreal Cognitive Assessment), PBS (Pediatric Balance Scale), Modified Mini Mental State Examination, BMI (Body Mass Index)|"PAQ-C will use to evaluate physical activity level of participants. MoCA and Modified Mini Mental State Examination will use to evaluate cognitive functions of participants.~PBS will use to evaluate participants' balance responses."
219054453|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
219054454|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
219054455|NCT00403455|DRUG|Paroxetine|SSRI
219054456|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
219054457|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
219054458|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
219636564|NCT03941054|OTHER|Pressure Release|Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
219636565|NCT05974878|OTHER|Exercise|"* Joints targeted by exercise; bilateral wrist, metacarpophalangeal, proximal and distal interphalangeal joints, elbow and shoulder joints.~* The muscles targeted by the exercises; lumbricals, iinterosseals, thenar and hypothenar muscles, forearm flexors, forearm extensors, forearm supinators and pronators, elbow flexors and extensors, and shoulder girdle muscles.~* Content of the exercises; There will be warm-up exercises, pinch grip, full grip, nerve and tendon gliding exercises, exercises that improve proprioception, functional exercises, strengthening exercises and stretching exercises."
219636566|NCT05974878|OTHER|Conventional Physiotherapy|For control group there will be aerobic exercise recommendation and resistive exercises focused on upper extremity.
218948982|NCT01374100|BEHAVIORAL|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
218948983|NCT01374100|BEHAVIORAL|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
218948984|NCT01644747|DEVICE|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
218948985|NCT00273533|DRUG|Ramipril|
218948986|NCT03288233|DIAGNOSTIC_TEST|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
218948987|NCT04667884|DIETARY_SUPPLEMENT|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
218948988|NCT02453672|BIOLOGICAL|SB8|SB8, proposed bevacizumab biosimilar
218948989|NCT02453672|BIOLOGICAL|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
218948990|NCT02453672|BIOLOGICAL|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
218948991|NCT01621815|BEHAVIORAL|Video Game|Playing various video games: RPG, Race, FPS, Strategy
218948992|NCT03675009|OTHER|Educational Programming|Green Cleaning educational programming to day care staff.
218948993|NCT04034667|OTHER|No intervention|No intervention
218948994|NCT05167006|OTHER|routine physical therapy|Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation. Consisting of many purposeful kinesthetic activities such as Graded pinch exercise, Bimanual placing cone, Arm bicycling, Shoulder curved arch, Double-curved arch, Block-stacking, Skateboard-supported arm sliding exercises on a tabletop, Putty kneading, Pegboard exercise, Picking up a ball and putting it into a basket, Plastic cone stacking. Therapists can offer passive, active-assistive, or active training, as deemed appropriate to the patient's ability
218948995|NCT05167006|OTHER|Perfetti's method|. Only one participant per therapist, with or without caregiver observation. Participant will be blindfolded during the exercises and asked to focus on sensing the position of the limb. The therapist will passively move the shoulder, elbow, wrist, or fing
218948996|NCT06409416|OTHER|Analysis of diagnostic biomarkers|The investigators will analyze TCP-biomarkers diagnostic by IHC, qRT-PCR and next-generation sequencing, in tumor and plasma samples of lung cancer patients.
218948997|NCT01039103|DRUG|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
218948998|NCT01039103|DRUG|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
218948999|NCT00093249|DRUG|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
218949000|NCT00093249|DRUG|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
218949001|NCT02385656|DRUG|Modafinil|200mg of modafinil daily for 4 weeks
218949002|NCT04125953|DEVICE|Andullation|Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
218949003|NCT04125953|OTHER|Placebo|Placebo Andullation
218949004|NCT02046759|OTHER|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
218949005|NCT02046759|OTHER|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
218949006|NCT02740803|OTHER|Sodium fluoride toothpaste 1,450 ppmF|
218949007|NCT02740803|OTHER|sodium monofluorophosphate toothpaste 1,450 ppmF|
218949008|NCT02740803|OTHER|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
218949009|NCT02740803|OTHER|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
218949010|NCT02740803|OTHER|Amine fluoride toothpaste 1,400 ppmF|
218949011|NCT02740803|OTHER|Non-fluoridated toothpaste 0 ppmF|
218949012|NCT04954651|BIOLOGICAL|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
218949013|NCT01629225|DRUG|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
218949014|NCT06121245|OTHER|Proton Pump inhibitor|A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)
218949015|NCT06121245|OTHER|Placebo|Placebo capsule
218949016|NCT03712085|OTHER|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
218949017|NCT03712085|OTHER|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
218949018|NCT03989505|DIAGNOSTIC_TEST|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
218949019|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
218949020|NCT02559492|DRUG|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
219636567|NCT00514215|BIOLOGICAL|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
219636568|NCT00514215|OTHER|flow cytometry|Days 1 \& 32
219636569|NCT00514215|OTHER|immunoenzyme technique|Days 1 \& 32
219636570|NCT00514215|PROCEDURE|biopsy|CT guided biopsy on days 1 \& 32
219636571|NCT00514215|PROCEDURE|cryosurgery|Days 1 and 32
219636572|NCT03635515|DEVICE|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
219636573|NCT03635515|PROCEDURE|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
219636574|NCT03278223|DEVICE|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
219636575|NCT03278223|DEVICE|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
219636576|NCT03496896|OTHER|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
219636577|NCT02148796|DRUG|Broncho-Vaxom (BV)|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package
219636578|NCT02148796|OTHER|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
219636579|NCT02464943|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
219636580|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
218949021|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
218949022|NCT02559492|DRUG|INCB050465|INCB050465 tablets will be administered orally once daily.
218949023|NCT00577616|PROCEDURE|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
219636581|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
219636582|NCT02099110|DRUG|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
219636583|NCT02099110|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
218949024|NCT04241900|BEHAVIORAL|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
219636584|NCT02099110|DRUG|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
219636585|NCT02099110|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
219636586|NCT02099110|DRUG|Metformin >= 1500 mg/day|Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
219636587|NCT02099110|BIOLOGICAL|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
219636588|NCT02099110|DRUG|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
219636589|NCT02099890|DIETARY_SUPPLEMENT|Omega-3|
219636590|NCT02099890|DIETARY_SUPPLEMENT|Vegetation Protein Powder|
218949025|NCT01700387|DRUG|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
218949026|NCT01700387|DRUG|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
218949027|NCT01700387|DRUG|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
218949028|NCT03754439|BEHAVIORAL|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
218949029|NCT03047824|DEVICE|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
218949030|NCT03047824|OTHER|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
218949031|NCT00117052|DRUG|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
218949032|NCT04986358|OTHER|Follow up at 2 years|The patients will have a follow-up to carry out 2 years after their intervention in addition to their traditional care
218949033|NCT01295879|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
218949034|NCT00895102|DRUG|ABT-333 Tablet|See Arm Description for more information.
218949035|NCT00895102|DRUG|Placebo|See Arm Description for more information.
218949036|NCT00895102|DRUG|ABT-333 Capsule|See arm description for more information
219054459|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
219636591|NCT02099890|DIETARY_SUPPLEMENT|InflanNox|
219636592|NCT02099890|DIETARY_SUPPLEMENT|Anti-oxidant Network|
219636593|NCT02099890|DIETARY_SUPPLEMENT|Chlorella|
219636594|NCT04781283|DEVICE|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
219636595|NCT05783167|DIAGNOSTIC_TEST|Self-sampling for HPV infection|After informed consent has been provided, the woman will be asked to collect firstly a first-void urine sample using the Collipee device and secondly to collect a vaginal self-sample using the dry Evalyn® Brush device. Socioeconomic, demographic and clinical data will be collected in the Bissau HIV Cohort database and through study questionnaires to collect background information on risk factors for HPV persistence and development of cervical cancer (HIV genotype, immune status, parity). Questionnaires will collect additional information on the acceptance of cervical screening measures to better evaluate the feasibility of implementing self-collected screening among HIV infected women in Guinea-Bissau.
219636596|NCT06577402|DIETARY_SUPPLEMENT|nutritional support|nutritional support
219636597|NCT05099185|BIOLOGICAL|Water-soluble vitamins and trace elements measures|We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.
219636598|NCT04002115|DRUG|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
219636599|NCT04002115|DRUG|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
219636600|NCT04002115|DRUG|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
219636601|NCT04002115|PROCEDURE|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
219636602|NCT04002115|DRUG|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
219636603|NCT04002115|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
219636604|NCT04002115|DRUG|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
219636605|NCT04002115|DRUG|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
219636606|NCT01959464|DRUG|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
218949037|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
218949038|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
219636607|NCT01959464|DRUG|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
219636608|NCT03146949|DEVICE|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
219636609|NCT03146949|DEVICE|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
219636610|NCT02638584|DRUG|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
218949039|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
218949040|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
219636611|NCT02638584|DRUG|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
218949041|NCT01185353|DRUG|LY3009104|Administered orally
218949042|NCT01185353|DRUG|Placebo|Administered orally
218949043|NCT01185353|DRUG|Methotrexate|Administered orally as background therapy
218949044|NCT00266786|DRUG|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
218949045|NCT00266786|DRUG|Intranasal Placebo|Intranasal Placebo
218949046|NCT04580641|OTHER|Questionnaire|A self-administered questionnaire will be completed by each study subject
218949047|NCT02683590|DEVICE|Ceramic Implant|The replacement of the sternum by a ceramic implant
218949048|NCT05742308|BEHAVIORAL|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
218949049|NCT00294086|DRUG|valsartan 160 mg|
218949050|NCT00294086|DRUG|valsartan 160 mg BID|
218949051|NCT00685009|DRUG|Estrogen hormone therapy|Estrogen pill daily
219636612|NCT03280602|PROCEDURE|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
219636613|NCT03280602|PROCEDURE|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
219636614|NCT00800995|DIETARY_SUPPLEMENT|SOD|
219636615|NCT00800995|DIETARY_SUPPLEMENT|Sham|
219636616|NCT05411783|PROCEDURE|Low tie of IMV|The IMV will be tie under the left colic vein
219636617|NCT00994461|DRUG|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
219636618|NCT00994461|DRUG|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
219636619|NCT00994461|DRUG|Placebo|Placebo tablet three times a day with meal for 2 weeks
219636620|NCT05271149|OTHER|Routine Physical Therapy|Routine physical therapy and orthosis
219636621|NCT02660567|PROCEDURE|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
219636622|NCT03193372|DRUG|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
219636623|NCT04074369|DIAGNOSTIC_TEST|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
219636624|NCT00435682|DRUG|Botox (Allergan Inc., US)|
219636625|NCT02713932|DEVICE|Transcatheter aortic valve implantation|
219636626|NCT03139578|DEVICE|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
219636627|NCT03139578|DEVICE|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
219636628|NCT03139578|DEVICE|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
219636629|NCT03139578|DEVICE|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
219636630|NCT02602990|DEVICE|SQUID™|
219636631|NCT04504214|OTHER|Upper limb repeated multi-site tendon vibrations|Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
219636632|NCT04216836|DIETARY_SUPPLEMENT|Magnesium oxide|Magnesium capsule
219636633|NCT04216836|DIETARY_SUPPLEMENT|Placebo|Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.
219636634|NCT03243032|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
219636635|NCT03243032|DRUG|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
219636636|NCT03243032|DRUG|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
219636637|NCT03243032|DRUG|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
219636638|NCT04024345|DIAGNOSTIC_TEST|Barratt Simplified Measure of Social Status (BSMSS)|Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
219636639|NCT04024345|DIAGNOSTIC_TEST|Global Assessment of Functioning scale (GAF)|Used to measure overall levels of functionality of an individual
219636640|NCT04024345|DIAGNOSTIC_TEST|General Self-Efficacy Scale (GSES)|Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
219636641|NCT04024345|DIAGNOSTIC_TEST|Perceived Stress Scale (PSS)|To assess the perceived stress
219636642|NCT04024345|DIAGNOSTIC_TEST|Coping Orientation to Problems Experienced (Brief COPE),|It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
219636643|NCT04024345|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS)|to explore the subject's social support system
219636644|NCT03793842|OTHER|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
219636645|NCT03793842|DEVICE|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
219636646|NCT03173664|DEVICE|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
219549547|NCT04735172|OTHER|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~* Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~* Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
219549548|NCT03426540|DRUG|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
219636647|NCT04844749|DRUG|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
219636648|NCT04844749|DRUG|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
219549549|NCT06179693|DIAGNOSTIC_TEST|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
219549550|NCT03247686|DRUG|RSLV-132|RNase Fc fusion protein
219549551|NCT03247686|DRUG|Placebo|Placebo
219636649|NCT01558557|OTHER|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
219636650|NCT01392924|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
219636651|NCT06160115|DEVICE|Flow cytometry|"1. Profiling of NK cells using flow cytometry on peripheral blood and bone marrow aspirate samples.~2. Isolation and identification of pathogens causing BSI and bacterial drug susceptibility testing using VITEK compact fully automatic microbial identification instrument."
219636652|NCT02442570|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injections
219636653|NCT02442570|OTHER|Placebo comparator|intravenous injection
219636654|NCT06062589|RADIATION|Iodine-125 particle brachytherapy|All enrolled patients' relapsed or metastatic lesions underwent image-guided radiation I-125 particle implantation brachytherapy (single implantation, half-life of 60 days, 99% of total dose given after 90 days). The prescribed dose is above 130Gy. Technical process: positioning and preoperative planning design; Template reset and particle implantation under the guidance of image system; Rapid and real-time intraoperative optimization; Postoperative dose validation.
219636655|NCT06062589|DRUG|AK104|AK104 treatment (6mg/kg Q2W) starting within 1 week of particle implantation, for a total of 6 cycles or until disease progression, intolerable toxicity, investigator decision, withdrawal of informed consent, death, or other reasons as specified in the protocol.
219636656|NCT05389930|DRUG|THC-dominant cannabis|Smoked cannabis with 9.53% THC and 0.09% CBD
219636657|NCT05389930|DRUG|CBD-dominant cannabis|Smoked cannabis with 0.35% THC and 11.27% CBD
219636658|NCT05389930|DRUG|Cannabis placebo|Smoked placebo cannabis plant material
219636659|NCT05389930|DRUG|Alcohol|Drink containing 0.3 g/kg of alcohol
219636660|NCT05389930|DRUG|Alcohol placebo|Placebo beverage contains only juice and a negligible trace of alcohol for masking
218949052|NCT00685009|DRUG|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
218949053|NCT00685009|DRUG|Placebo|Placebo pill daily
219549552|NCT03853096|DRUG|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
219549553|NCT04688515|BEHAVIORAL|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
218949054|NCT05090319|DIAGNOSTIC_TEST|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
218949055|NCT02973373|DEVICE|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
218949056|NCT02973373|OTHER|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
218949057|NCT05551247|DRUG|Envafolimab|300mg,sc,d3,Q3W;
218949058|NCT05551247|DRUG|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
218949059|NCT02753088|DRUG|BCD-063|
218949060|NCT02753088|DRUG|Copaxone-Teva|
218949061|NCT02753088|DRUG|Placebo|
219636661|NCT05796466|BEHAVIORAL|How-to talk so kids will listen and listen so kids will talk|The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (\> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
219636662|NCT05796466|BEHAVIORAL|Nobody's Perfect|Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
219636663|NCT05383040|PROCEDURE|Percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
219636664|NCT00900159|DRUG|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
219636665|NCT00900159|DRUG|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
219636666|NCT04229654|OTHER|Questionnaire|A written questionnaire was used to capture demographic data, obstetric history, knowledge, expectations, and perception of anomaly scans.
219636667|NCT02555787|DRUG|Tacrolimus|oral
219636668|NCT03443622|DRUG|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
219636669|NCT03550872|BEHAVIORAL|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
219636670|NCT01166438|DRUG|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
219636671|NCT01166438|DRUG|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
219636672|NCT01166438|DRUG|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
219636673|NCT01166438|DRUG|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
219636674|NCT02580617|BIOLOGICAL|ALLO-ASC|Infusion for Crohn's disease
219636675|NCT04630236|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
219636676|NCT04321356|DEVICE|Triathlon PCR TKA|Total Knee Arthroplasty System
219636677|NCT04321356|DEVICE|Triathlon PS TKA|Total Knee Arthroplasty System
219636678|NCT04321356|DEVICE|Persona PCR TKA|Total Knee Arthroplasty System
219636679|NCT04321356|DEVICE|Persona PS TKA|Total Knee Arthroplasty System
219636680|NCT02115581|DRUG|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
219636681|NCT02115581|DRUG|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
219636682|NCT03763825|BEHAVIORAL|Mini-AFTERc|Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
219636683|NCT06468345|BEHAVIORAL|acupressure|Application was made to CV12, ST25, SP6, HT7 and LI4 acupressure areas.
219636684|NCT06468345|BEHAVIORAL|Area different from acupressure area|Massage application to non-acupressure hand, foot and abdominal areas
219636685|NCT05935397|DEVICE|percutaneous coronary intervention|patients with CAD undergoing PCI with second generation DES
219636686|NCT04618198|OTHER|Immediate anti-TB therapy|Study participants will receive immediate empiric anti-TB therapy
219636687|NCT04618198|OTHER|Sepsis-specific dose anti-TB therapy|Study participants will receive conventional WHO weight-based dose anti-TB therapy
219636688|NCT03719781|DIAGNOSTIC_TEST|standardized minimental testing|To diagnose postoperative cognitive dysfunction
219636689|NCT01377922|DRUG|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
219636690|NCT01377922|DRUG|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
219636691|NCT02555150|DRUG|PRC-063|Oral extended-release capsule
219636692|NCT02555150|DRUG|lisdexamfetamine dimesylate|Oral capsule
219636693|NCT02555150|DRUG|Placebo|Oral placebo capsule
219636694|NCT06017297|DRUG|Durvalumab|Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles
219054460|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
219054461|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
219054462|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
219054463|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
219054464|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
219054465|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
219054466|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
219054467|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
219054468|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
219054469|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
219054470|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
219054471|NCT00134368|DRUG|Etanercept|
219054472|NCT00426075|DEVICE|Elastic stockings|
219054473|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
219054474|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
219054475|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
219054476|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
219054477|NCT02591693|BEHAVIORAL|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
219054478|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
219054479|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
219636695|NCT06017297|DRUG|Tremelimumab|A single dose of tremelimumab at 300mg IV is given on C1.
219636696|NCT06017297|DRUG|Gemcitabine|Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.
219636697|NCT06017297|DRUG|Cisplatin|Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.
219636698|NCT06017297|PROCEDURE|Surgical Resection|If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
219636699|NCT06035640|OTHER|Interview|Participants will be engaged in a semi-structured interview.
219054480|NCT00268749|DRUG|glycine|0.8 g/kg/day
219054481|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
219054482|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
219054483|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
219054484|NCT00541047|DRUG|bicalutamide|
219054485|NCT00541047|DRUG|goserelin acetate|
219054486|NCT00541047|DRUG|leuprolide acetate|
219054487|NCT00541047|PROCEDURE|adjuvant therapy|
219054488|NCT00541047|PROCEDURE|quality-of-life assessment|
219054489|NCT00541047|RADIATION|radiation therapy|
219054490|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
219054491|NCT00824317|DRUG|Placebo|
219054492|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
219054493|NCT00058240|DRUG|alvocidib|Given IV
219054494|NCT00018109|DRUG|glutamine|
219054495|NCT00018109|DRUG|creatine monohydrate|
219054496|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
219054497|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
219054498|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
219054499|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
219054500|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
219054501|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
219636700|NCT03231072|DEVICE|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
219054502|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
219054503|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
219054504|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
219054505|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
219054506|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
219054507|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
219054508|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
219054509|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
219054510|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
219054511|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
219054512|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
219054513|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
219636701|NCT03175705|BIOLOGICAL|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10\^7/m2 Loading Dose 2: 6x10\^7/m2 Loading Dose 3: 9x10\^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
219054514|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
219054515|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
219054516|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
219054517|NCT02738775|DRUG|Placebo|
219054518|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
219054519|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
219054520|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
219054521|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
219054522|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
219636702|NCT03175705|DRUG|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
219636703|NCT03175705|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
219636704|NCT01417247|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
219636705|NCT02046590|DRUG|Propofol|
219636706|NCT02046590|OTHER|General anesthesia|
219636707|NCT06575907|OTHER|no intervention|no intervention
219636708|NCT00006178|DRUG|Sirolimus|
219636709|NCT00006178|DRUG|Thymoglobulin|
219636710|NCT06091917|DIETARY_SUPPLEMENT|Betaine supplementation in infant formula|Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
219636711|NCT06091917|DIETARY_SUPPLEMENT|Regular infant formula|Regular (unmodified) infant formula . The intervention will last for 12 weeks.
219636712|NCT06252558|DIETARY_SUPPLEMENT|Symbiotic|One-a-day administration of a capsule supplement containing:15 billion CFU probiotic blend (Lactobacillus acidophilus La-14, Bifidobacterium longum BB536, Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus GG, Lactobacillus gasseri Lg-36) and 250mg of chicory root inulin.
219636713|NCT06252558|DIETARY_SUPPLEMENT|Placebo|Daily fiber capsule containing microcrystalline cellulose
218949062|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
218949063|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
218949064|NCT03678870|OTHER|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
218949065|NCT03127098|BIOLOGICAL|ETBX-011|ETBX-011 immunization was administered by subcutaneous (SC) injection.
218949066|NCT03127098|BIOLOGICAL|ALT-803|ALT-803 was administered by SC injection.
218949067|NCT05783882|DRUG|Prolgolimab|250 mg Q3W
218949068|NCT02303652|PROCEDURE|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
218949069|NCT02303652|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
219054523|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
219054524|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
219054525|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
219054526|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
219054527|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
219054528|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
219054529|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
219054530|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
219054531|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
219054532|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
219054533|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
219054534|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
219054535|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
219054536|NCT02813031|OTHER|Functional meat products|
219054537|NCT02813031|OTHER|Traditional meat products|
219054538|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
219054539|NCT03615651|OTHER|Placebo|Placebo intervention.
219054540|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
219054541|NCT02505516|OTHER|metformin|
219054542|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
218949070|NCT01159431|DEVICE|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
218949071|NCT01986699|PROCEDURE|Laparoscopic Assisted Polypectomy|
218949072|NCT05229497|DRUG|AK112|IV infusion,Specified dose on specified days
218949073|NCT05229497|DRUG|AK117|IV infusion,Specified dose on specified days
218949074|NCT05229497|DRUG|Carboplatin|IV infusion,Specified dose on specified days
218949075|NCT05229497|DRUG|Cisplatin|IV infusion,Specified dose on specified days
218949076|NCT05229497|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
218949077|NCT05881070|BEHAVIORAL|Mobile-health self management|Mobile-health self management
218949078|NCT02806141|DRUG|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
219054543|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
219054544|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
219054545|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
219054546|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
219054547|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
219054548|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
218949079|NCT02806141|DRUG|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
218949080|NCT06044597|DEVICE|SyncAV function on|CRT-D with SyncAV plus activated
218949081|NCT04064125|DRUG|FMX-101|
218949082|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949083|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949084|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949085|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949086|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949087|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
218949088|NCT01227629|DRUG|warfarin|comparator
218949089|NCT01227629|DRUG|dabigatran without ASA|dose comparison
218949090|NCT01227629|DRUG|dabigatran without ASA|dose comparison
218949091|NCT01227629|DRUG|dabigatran without ASA|dose comparison
218949092|NCT05488821|DRUG|QLH11906|QLH11906 only
218949093|NCT00486655|PROCEDURE|NOTES-Assisted Cholecystectomy|
218949094|NCT00554710|DRUG|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
218949095|NCT00554710|DRUG|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
218949096|NCT04847713|OTHER|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
218949097|NCT03917407|DRUG|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
219054549|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
219054550|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
219054551|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
219054552|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
219054553|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
219054554|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
219054555|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
219054556|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
219054557|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
219054558|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
219054559|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
218949098|NCT03917407|DRUG|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
218949099|NCT04792242|DEVICE|cv line insertion|Svo2 and central venous pressure measurements
218949100|NCT04792242|DEVICE|Urinary catheter insertion|urine output measurement
218949101|NCT04792242|DEVICE|Arterial line|Arterial blood gases measurment
218949102|NCT03708393|DEVICE|Imagio (IUS+OA)|The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
218949103|NCT03708393|DEVICE|Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of the reader study
218949104|NCT03708393|DEVICE|Mammography|Mammography images as available per standard of care
218949105|NCT04312646|DEVICE|Elastography .|Performance of US, elastography
218949106|NCT02863536|DEVICE|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
218949107|NCT03603678|DRUG|BAY2253651|100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
218949108|NCT03603678|DRUG|Placebo|Matching Placebo dosing
218949109|NCT00003496|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218949110|NCT03805113|DEVICE|Magnetotherapy device|Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
219054560|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
219054561|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
219054562|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
218949111|NCT03805113|DEVICE|Placebo|Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
218949112|NCT04415242|OTHER|positioning|different positioning prior surgery
218949113|NCT04048733|DEVICE|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
218949114|NCT00362180|DRUG|mipomersen|200 mg subcutaneous injections
218949115|NCT00362180|DRUG|Placebo|subcutaneous injections
218949116|NCT03834649|PROCEDURE|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
218949117|NCT03834649|PROCEDURE|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
218949118|NCT03469869|OTHER|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
218949119|NCT00107484|DRUG|ferumoxtran-10|
218949120|NCT00107484|PROCEDURE|magnetic resonance imaging|
218949121|NCT00107484|PROCEDURE|sentinel lymph node biopsy|
218949122|NCT00481975|DRUG|rimonabant (SR141716)|
219054563|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
219054564|NCT02929810|BEHAVIORAL|sleep extension|
219054565|NCT02929810|BEHAVIORAL|sleep maintenance|
219054566|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
219054567|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
219054568|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
219054569|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
219054570|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
219054571|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
219054572|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
219054573|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
218949123|NCT02006095|OTHER|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
218949124|NCT02006095|BEHAVIORAL|Neuropsychological testing|
219054574|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
219054575|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
219054576|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
219054577|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
219054578|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
219054579|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
219054580|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
219054581|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
219054582|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
219054583|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
219054584|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
219054585|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
219054586|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
219054587|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
219054588|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
219054589|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
219054590|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
219054591|NCT05115383|OTHER|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
219054592|NCT01161329|OTHER|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
219636714|NCT04119297|OTHER|Routine care|"* Routine care was applied to the periorbital area by clinical nurses.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
218949125|NCT04195191|OTHER|ANM|communication intervention
218949126|NCT04195191|OTHER|Placebo|regular assistance in community pharmacies
218949127|NCT03117439|OTHER|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
218949128|NCT00843778|BIOLOGICAL|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
218949129|NCT02027129|OTHER|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
218949130|NCT00998244|OTHER|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
219054593|NCT04614766|DRUG|Lutathera|intravenous administration
219054594|NCT04614766|DRUG|Azedra|intravenous administration
219054595|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
218949131|NCT03386045|RADIATION|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
218949132|NCT03386045|RADIATION|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)"
218949133|NCT02728713|PROCEDURE|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
218949134|NCT02728713|PROCEDURE|Sham/Placebo|A laying on of hands with no actual treatment being performed.
218949135|NCT02898285|BEHAVIORAL|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
218949136|NCT02898285|BEHAVIORAL|Individual sport condition|Participants will choose from a list of individual sports.
218949137|NCT02898285|BEHAVIORAL|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
218949138|NCT04545970|COMBINATION_PRODUCT|Facial cleanser|Facial cleanser to be used by study participants
218949139|NCT04545970|COMBINATION_PRODUCT|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
219054596|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
219054597|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
219054598|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
218949140|NCT04545970|COMBINATION_PRODUCT|Sunscreen|Sunscreen to be applied after application of serum in the morning.
218949141|NCT02555501|OTHER|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
219054599|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
219054600|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
218949142|NCT02555501|RADIATION|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
218949143|NCT01604278|DRUG|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
218949144|NCT01604278|DRUG|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
218949145|NCT00813969|BIOLOGICAL|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
219054601|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
219054602|NCT00058331|BIOLOGICAL|epoetin alfa|
218949146|NCT04076553|BEHAVIORAL|CBT|Participants will complete 12 sessions of CBT
218949147|NCT04076553|BEHAVIORAL|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
219054603|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
218949148|NCT00693862|DRUG|levodopa, carbidopa, entacapone|
218949149|NCT00693862|DRUG|levodopa, carbidopa|
218949150|NCT01915927|DRUG|MSC-AFP|
218949151|NCT04307875|DIAGNOSTIC_TEST|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
218949152|NCT04307875|DIAGNOSTIC_TEST|Blood glucose measurement|measuring blood glucose using standard measurement devices
218949153|NCT04307875|OTHER|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
218949154|NCT00762424|DRUG|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
218949155|NCT00762424|DRUG|placebo|cornstarch
219054604|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
219636715|NCT04119297|OTHER|Cold gel pack|"* Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
219636716|NCT04119297|DRUG|Heparinoids Topical Cream|"* Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
219636717|NCT01509560|DRUG|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
219636718|NCT06256952|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
218949156|NCT01926327|BIOLOGICAL|PRP injection|Injection of PRP in patients with knee osteoarthritis.
218949157|NCT01926327|BIOLOGICAL|Placebo|
218949158|NCT03033498|DRUG|ABBV-951|ABBV-951 administered by subcutaneous infusion.
218949159|NCT01643031|DRUG|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
218949160|NCT01643031|DRUG|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
218949161|NCT03690635|PROCEDURE|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
218949162|NCT02870933|BIOLOGICAL|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
218949163|NCT05371847|OTHER|assessment for upper limb dysfunction|clinical assessments and questionnaires
218949164|NCT05371847|OTHER|retest assessment|For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
218949165|NCT04495205|BIOLOGICAL|PRF under non-eugenol containing periodontal pack|Platelet Rich Fibrin under non-eugenol containing periodontal pack
218949166|NCT04495205|OTHER|Non-eugenol containing periodontal pack|Non-eugenol containing periodontal pack after gingival depigmentation
218949167|NCT03554694|DIETARY_SUPPLEMENT|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
218949168|NCT03554694|DIETARY_SUPPLEMENT|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
218949169|NCT03663400|DIAGNOSTIC_TEST|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
218949170|NCT00205920|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
218949171|NCT06518590|DEVICE|Cycle|Kettler upright bike Giro P:
218949172|NCT00657410|DRUG|dexamethasone|
218949173|NCT00657410|DRUG|prednisone|
218949174|NCT00657410|PROCEDURE|quality-of-life assessment|
218949175|NCT03209674|PROCEDURE|Cardiothoracic surgery|Cardiac or thoracic procedure
218949176|NCT01100957|PROCEDURE|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
218949177|NCT03005873|DRUG|TLC599 LD group|Single dose via intra-articular injection
218949178|NCT03005873|DRUG|Normal Saline|Single dose via intra-articular injection
218949179|NCT03005873|DRUG|TLC599 HD group|Single dose via intra-articular injection
218949180|NCT04585009|DRUG|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
218949181|NCT04585009|DRUG|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
218949182|NCT04585009|DEVICE|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
218949183|NCT04622800|OTHER|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
218949184|NCT00471809|DRUG|Budesonide + Salmeterol + Azithromycin|
218949185|NCT00471809|DRUG|Budesonide + Salmeterol + Montelukast|
218949186|NCT00471809|DRUG|Budesonide + Salmeterol + Placebo|
218949187|NCT05320744|PROCEDURE|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
218949188|NCT00532675|DRUG|LBH589|PAN 5 mg and PAN 20 mg capsules
218949189|NCT00532675|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 5mg or 25 mg
218949190|NCT02558829|DRUG|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
218949191|NCT02558829|DRUG|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
218949192|NCT00097981|DRUG|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
218949193|NCT00097981|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
218949194|NCT00097981|DRUG|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
218949195|NCT04645277|DEVICE|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
218949196|NCT05814302|DRUG|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
218949197|NCT01337999|OTHER|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
218949198|NCT04671472|DRUG|NPC-09|The drug will be administered by the oral route with the same manner
218949199|NCT04671472|DRUG|NPC-09 placebo|The drug will be administered by the oral route with the same manner
218949200|NCT04180384|DRUG|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
218949201|NCT05588219|DRUG|Tislelizumab|Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
218949202|NCT05588219|DRUG|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
218949203|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949204|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
219636719|NCT06256952|BEHAVIORAL|social exclusion (Cyberball task)|Social exclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social exclusion, subjects will be systematically excluded by one co-player, and during social inclusion, ball tosses will be balanced between all three players.
219636720|NCT06256952|DIAGNOSTIC_TEST|Saliva samples|Assessing acute stress effects in AUD and HC subjects
219636721|NCT06256952|DIAGNOSTIC_TEST|basic psychological assessment|"* Sociodemographics~* ASSIST~* Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis \& other illegal drugs~* SCID: AUD criteria and tabak use disorder life time and last year \& acute depressive symptoms \& symptoms for Mania and psychotic disorder~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorder Identification Test (CUDIT)~* CAS -A (Alkohol)~* Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~* Oslo-3-Items-Social-Support Scale~* Social Skills Rating System (SSRS)~* Trier Inventory for chronic stress (TICS)~* Rejection Sensitivity Questionnaires (RSQ-9)~* Need to belong scale (NTBS)~* Fragebogen zu Gedanken und Gefühlen (FGG-14)~* Internationale Trauma Questionnaire (ITQ)~* Zahlen-Symbol-Test (DST)~* Wortschatztest (verbal intelligence)"
219636722|NCT06256952|DIAGNOSTIC_TEST|pre and post cyberball task|Positive and Negative Affect Schedule(PANAS)
218949205|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949206|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
219636723|NCT06256952|DIAGNOSTIC_TEST|VAS|subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
219636724|NCT06256952|DIAGNOSTIC_TEST|after cyberball task|"* Need Threat Scale~* Manipulation check (VAS scale)"
219636725|NCT06256952|BEHAVIORAL|social inclusion (Cyberball task)|Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
219636726|NCT02151305|DRUG|Propofol, remifentanil|
219636727|NCT02151305|DRUG|Sevoflurane|
219636728|NCT05573932|OTHER|Leaderboard|De-identified leaderboard showing average durations of exercises completed by all participants in leaderboard group.
219636729|NCT05573932|OTHER|Take-home packet|Take-home packet of exercises.
219636730|NCT02924285|PROCEDURE|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
219636731|NCT02924285|DRUG|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
219636732|NCT01545037|DIETARY_SUPPLEMENT|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
219636733|NCT01545037|OTHER|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
219636734|NCT03416426|DEVICE|Amplatzer® PFO occluder or Gore® Septal Occluder|The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
219636735|NCT00179972|DEVICE|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
219636736|NCT02764372|BEHAVIORAL|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
219636737|NCT02764372|BEHAVIORAL|Exergames|Participants played exergames existent in the Wii game console
219636738|NCT02336568|DRUG|Oxytoine|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
219636739|NCT02336568|DRUG|PLACEBO|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
219636740|NCT01830868|DRUG|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
219636741|NCT01599533|OTHER|blood samples|
218949207|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949208|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949209|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949210|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949211|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
219636742|NCT02653781|BEHAVIORAL|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
218949212|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949213|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
218949214|NCT03483064|OTHER|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
218949215|NCT00538785|BIOLOGICAL|Motavizumab|15 mg/kg IM administered at monthly intervals
218949216|NCT00538785|BIOLOGICAL|Palivizumab|15 mg/kg IM administered at monthly intervals
218949217|NCT01009840|DRUG|IV busulfan|PK-directed dosing of IV busulfan for 4 days
218949218|NCT01009840|DRUG|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m\^2.
218949219|NCT01009840|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
218949220|NCT00791973|DRUG|fluticasone furoate|2 puffs in each nostril once daily for 1 week
218949221|NCT00791973|DRUG|Placebo|2 puffs in each nostril once daily for 1 week
218949222|NCT00634738|PROCEDURE|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
218949223|NCT04661761|DIAGNOSTIC_TEST|Paraffin Pellets from Aurosan GmbH|1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
218949224|NCT04661761|DIAGNOSTIC_TEST|Chewing wax from the Saliva-Check Buffer from GC Europe|1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
218949225|NCT01057875|OTHER|caffeine|Starbuck's Grande Pike Roast coffee
218949226|NCT01057875|OTHER|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
218949227|NCT05008978|OTHER|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
218949228|NCT05008978|OTHER|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
218949229|NCT05008978|OTHER|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
218949230|NCT05008978|OTHER|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
218949231|NCT05008978|OTHER|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
218949232|NCT02878356|BEHAVIORAL|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
218949233|NCT02878356|BEHAVIORAL|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
218949234|NCT02878356|BEHAVIORAL|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
218949235|NCT01949701|BIOLOGICAL|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*0201restricted URLC10 peptides with adjuvant.
218949236|NCT03549793|BEHAVIORAL|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
219054605|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
219054606|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
219636743|NCT02653781|BEHAVIORAL|control group|The control group will have contents exposed solely from the dialogue-exhibition.
219636744|NCT02653781|BEHAVIORAL|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
219636745|NCT02653781|BEHAVIORAL|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
219636746|NCT02348645|PROCEDURE|Spinal fusion|
219636747|NCT02348645|PROCEDURE|Spinal decompression|
219636748|NCT02251418|DEVICE|Extracorporeal shockwave therapy|
219636749|NCT03340454|OTHER|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
219636750|NCT03340454|OTHER|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
219636751|NCT02567123|BEHAVIORAL|Experimental|
219636752|NCT03682848|DRUG|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
219636753|NCT01464164|DRUG|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
219636754|NCT01464164|DRUG|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
219636755|NCT02043444|RADIATION|FDG PET-CT|
219636756|NCT06080399|OTHER|Continuous subcutaneous apomorphine infusion (CSAI)|the CSAI proposed in the usual healthcare pathway of each PD patients included
218949237|NCT03549793|BEHAVIORAL|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
218949238|NCT04137510|DEVICE|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
218949239|NCT03431272|DRUG|Lifitegrast|Eye drop
219636757|NCT01494883|BEHAVIORAL|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
219636758|NCT03830697|OTHER|Acupuncture intervention|Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).
219636759|NCT01456754|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
219636760|NCT01456754|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
219636761|NCT02746965|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
218949240|NCT01002820|DRUG|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
218949241|NCT04144127|BEHAVIORAL|Soccer|"* Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
218949242|NCT02719873|OTHER|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
218949243|NCT04967495|PROCEDURE|TACE combined with lenvatinib and iodion-125 seeds brachytherapy|TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
219054607|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
219054608|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
219054609|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
219054610|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
219054611|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
219054612|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
219636762|NCT02746965|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219636763|NCT02746965|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
219636764|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
219636765|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
219636766|NCT04823273|BEHAVIORAL|General improvement|Changes to interface to be more intuitive.
219636767|NCT04823273|BEHAVIORAL|In-line help text|General improvement + in-line help text
219636768|NCT04823273|BEHAVIORAL|Interruptive alert|General improvement + interruptive alert
219636769|NCT02434146|DRUG|Topical Phenylephrine Solution|Given topically via spray
219636770|NCT04044040|BEHAVIORAL|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
219636771|NCT03843489|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
219636772|NCT03843489|DEVICE|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
219636773|NCT01983540|BIOLOGICAL|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
219636774|NCT01983540|BIOLOGICAL|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
219636775|NCT01983540|BIOLOGICAL|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP\~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
219636776|NCT03478644|DEVICE|Experimental Denture Wipe|Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
219636777|NCT03478644|OTHER|Tap Water|Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
219636778|NCT02283684|PROCEDURE|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
219054613|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
219054614|NCT00491686|DRUG|AZD6765|intravenous infusion
219054615|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
219636779|NCT02283684|PROCEDURE|Bipolar TUVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
219054616|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
219054617|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
219054618|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
218949244|NCT04967495|PROCEDURE|TACE combined with lenvatinib|TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
218949245|NCT05202938|DIAGNOSTIC_TEST|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
218949246|NCT05202938|DIAGNOSTIC_TEST|FDG PET scan|FDG venous injection and positron emission tomography scan.
218949247|NCT05202938|DIAGNOSTIC_TEST|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
218949248|NCT05202938|DIAGNOSTIC_TEST|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
218949249|NCT05202938|DIAGNOSTIC_TEST|Blood sampling|Collecting 20ml of venous blood.
218949250|NCT02408432|OTHER|Laboratory Biomarker Analysis|Correlative studies
219054619|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
219054620|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
219054621|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
219054622|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
219636780|NCT03640533|BEHAVIORAL|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
219636781|NCT03894189|DRUG|Doxapram Hydrochloride|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
219636782|NCT03894189|DRUG|Theophylline|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
219636783|NCT02903940|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
218949251|NCT02408432|OTHER|Standard of Care|Undergo mesenchymal stem cell infusion
218949252|NCT02408432|DRUG|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
218949253|NCT01293578|OTHER|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
218949254|NCT00637143|DRUG|Tacrolimus|Oral
218949255|NCT00637143|DRUG|Cyclosporine|Oral
218949256|NCT00025727|DRUG|Lopinavir/Ritonavir|
218949257|NCT00025727|DRUG|Ritonavir|
218949258|NCT00025727|DRUG|GW433908|
219636784|NCT03963492|OTHER|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
219636785|NCT01226784|BEHAVIORAL|Physcial activity|Strenght training Relaxation exercise
219636786|NCT06125652|DRUG|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
219636787|NCT01521832|DRUG|SEN0014196|5 mg single oral dose
219636788|NCT01521832|DRUG|SEN0014196|25 mg single oral dose
219636789|NCT01521832|DRUG|SEN0014196|75 mg single oral dose
219636790|NCT01521832|DRUG|SEN0014196|150 mg single oral dose
219636791|NCT01521832|DRUG|SEN0014196|300 mg single oral dose
219636792|NCT01521832|DRUG|SEN0014196|600 mg single oral dose
219636793|NCT01521832|DRUG|SEN0014196|300 mg single oral dose (females)
219636794|NCT01521832|DRUG|SEN0014196|100 mg multiple oral dose
219636795|NCT01521832|DRUG|SEN0014196|300 mg multiple oral dose
218949259|NCT00376714|DRUG|GSK233705|
218949260|NCT01221454|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
218949261|NCT01221454|DRUG|Conserved therapy|Oral or intravenous administration
218949262|NCT00641927|DRUG|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
218949263|NCT00641927|DRUG|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
218949264|NCT06403488|DRUG|Letrozole 2.5mg|specific aromatase inhibitor
218949265|NCT01223443|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
218949266|NCT06492655|DRUG|CKD-383(Fed)|After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
218949267|NCT06492655|DRUG|CKD-383(Fasted)|After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
219636796|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose
219636797|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose (females)
219636798|NCT02067845|BEHAVIORAL|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning."
219636799|NCT02067845|BEHAVIORAL|A group-based HIV/STI prevention intervention for women who have sex with women|
218949268|NCT00740376|DEVICE|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
218949269|NCT00740376|DEVICE|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
218949270|NCT03814421|DRUG|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
218949271|NCT04440605|PROCEDURE|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
218949272|NCT01141062|DEVICE|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
218949273|NCT04570059|BEHAVIORAL|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
218949274|NCT01101308|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
218949275|NCT01101308|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
218949276|NCT00678678|DEVICE|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
218949277|NCT00678678|DEVICE|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
219206997|NCT06768385|PROCEDURE|thoracoabdominal nerve blockage with perichondrial approach (TAPA) block|Under USG guidance, 20 ml of 0.25% bupivacaine was administered between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue at the level of the 9th and 10th ribs (arcus costarum) in the midclavicular line with an 80 mm insulated peripheral block needle. Then, 10 ml of 0.25% bupivacaine was injected into the upper fascia of the costochondral tissue and the lower fascia of the external oblique muscle. The block was performed by following the needle path in the ultrasound image.
219636800|NCT06224647|BEHAVIORAL|Mobile Transdiagnostic Emotion Regulation Intervention|"The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~1. Daily tracking of emotions~2. A suite of exercises placed in six categories facilitating adaptive emotion regulation skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~3. A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~4. A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~5. A recommendation system linking users to the content based on their specific needs or preferences"
219636801|NCT03512054|PROCEDURE|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
219636802|NCT00459277|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
218949278|NCT01695876|DRUG|AMG 357|Oral administration available in varying dose strength.
218949279|NCT01695876|DRUG|Placebo|Matching placebo to AMG 357 containing no active drug
219054623|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
219054624|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
219054625|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
219054626|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
219054627|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
218949280|NCT01873521|PROCEDURE|Non invasive ventilation|
219054628|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
219054629|NCT03691038|DRUG|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
219054630|NCT03691038|DRUG|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
219054631|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
219054632|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
219054633|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
219054634|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
219054635|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
219054636|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
219636803|NCT04798053|BEHAVIORAL|Questionnaire|14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
219636804|NCT04798053|BIOLOGICAL|blood sample and salivary sample|10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
219636805|NCT05729360|DRUG|GamCoviMab|A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
219636806|NCT06941246|PROCEDURE|Non Surgical Periodontal Treatment|the intervention includes Non Surgical Periodontal Therapy( scaling and root planning ),performed to reduce periodontal inflammation .Gingival Crevicular fluid samples will be collected before and after treatment to assess changes in prolactin hormone levels.
219636807|NCT06941246|DEVICE|paper points|we use paper point to collect GCF sample
219636808|NCT06941246|DEVICE|ELISA Kits|The samples are analyzed by ELISA kits to measure prolactin levels
218949281|NCT02886208|BEHAVIORAL|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
218949282|NCT00957125|DRUG|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
218949283|NCT00957125|DRUG|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
218949284|NCT00957125|DRUG|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
218949285|NCT05168501|OTHER|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
218949286|NCT06189235|OTHER|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
218949287|NCT02835079|DRUG|Tamoxifen|
218949288|NCT04652414|DRUG|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
218949289|NCT04652414|DRUG|Placebo|This is a matching placebo to prednisone.
218949290|NCT04155411|DRUG|Dasatinib|70 mg of Dasatinib orally daily for 12 months
219054637|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
218949291|NCT02111278|OTHER|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
218949292|NCT02111278|OTHER|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
218949293|NCT02111278|OTHER|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
219054638|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
219054639|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
219054640|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
219636809|NCT06939868|DIETARY_SUPPLEMENT|Shatavari Root Extract, oral capsule|"This intervention consists of a proprietary, standardized extract of Asparagus racemosus (Shatavari), formulated specifically for women's health and cognitive support. The supplement is provided in oral capsule form and standardized to a specific concentration of shatavarin IV, the primary active compound. Participants will take one capsule daily for 30 days.~This formulation, known as SheVari4™, is patent-pending and manufactured by Cepham, designed to address vasomotor symptoms (hot flashes) and other menopausal concerns. It is distinct from other Shatavari supplements in its standardization and use in a placebo-controlled, double-blind trial targeting postmenopausal women."
219054641|NCT00684424|OTHER|Non-Interventional Study|Observational Only
219054642|NCT04933851|BEHAVIORAL|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
219054643|NCT04933851|BEHAVIORAL|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
219054644|NCT02054364|BEHAVIORAL|FBT and CRT|
219054645|NCT02054364|BEHAVIORAL|FBT and art therapy|
219636810|NCT06940791|DRUG|Tirabrutinib|Tirabrutinib (480 mg) taken orally daily at fasting condition
219636811|NCT06940791|DRUG|Placebo|Placebo taken orally daily at fasting condition
219636812|NCT06835465|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
219636813|NCT06835465|DRUG|Rifampin|Rifampin will be administered QD on Days 1 to 7 and Days 9 to 13 and as a single oral dose on Day 8 as specified for the respective period.
219636814|NCT06829771|DRUG|TQB2825 injection +R-CHOP regimen|"R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP).~TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells.~Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells.~Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells.~Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA.~Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division.~Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects.~TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)"
219054646|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
219054647|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
219054648|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
219054649|NCT02371499|DIETARY_SUPPLEMENT|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
219054650|NCT02371499|DIETARY_SUPPLEMENT|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
219054651|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
219054652|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
219054653|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
218949294|NCT05704127|OTHER|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
218949295|NCT05704127|OTHER|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
218949296|NCT02858544|OTHER|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
218949297|NCT02858544|OTHER|ImPACT|Patient- completed computerized neurocognitive test battery
218949298|NCT00734955|DEVICE|49-channel optical spectrometer|
218949299|NCT04987788|BEHAVIORAL|Motívate|The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.
218949300|NCT04987788|BEHAVIORAL|Video link|General health information video link
218949301|NCT02614469|DRUG|Inosine|Inosine, 1000 mg
218949302|NCT02149771|PROCEDURE|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
218949303|NCT02149771|DEVICE|endovascular stents implantation|Bare stents implant within portal vein.
218949304|NCT02149771|PROCEDURE|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
218949305|NCT02958683|OTHER|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
218949306|NCT00357760|BIOLOGICAL|VEGF Trap|Given IV
218949307|NCT02043600|BEHAVIORAL|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
218949308|NCT02043600|BEHAVIORAL|Self-care|Self-care books are provided for self-directed use
218949309|NCT00520585|DRUG|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
218949310|NCT01246154|OTHER|EXERCISE TRAINING|EXERCISE TRAINING
218949311|NCT00001131|DRUG|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
218949312|NCT00001131|DRUG|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
218949313|NCT02473692|OTHER|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)"
218949314|NCT00021073|DRUG|alvocidib|Given IV
218949315|NCT00021073|DRUG|leucovorin calcium|Given IV
218949316|NCT00021073|DRUG|fluorouracil|Given IV
218949317|NCT00021073|DRUG|irinotecan hydrochloride|Given IV
218949318|NCT04959071|PROCEDURE|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
218949319|NCT00593242|BIOLOGICAL|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
218949320|NCT00593242|OTHER|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
218949321|NCT02299401|DRUG|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
219636815|NCT06829771|DRUG|TQB2825 injection + GemOx|"TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells.~Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription."
218949322|NCT02299401|DEVICE|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
218949323|NCT04136444|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
218949324|NCT00626470|PROCEDURE|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
218949325|NCT04905498|BEHAVIORAL|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
218949326|NCT04905498|BEHAVIORAL|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
218949327|NCT03290482|DIAGNOSTIC_TEST|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
218949328|NCT03290482|DEVICE|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
218949329|NCT03290482|DIAGNOSTIC_TEST|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
218949330|NCT01937104|DRUG|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~\- adjust MAC to maintain BIS between 40-60"
218949331|NCT01937104|DRUG|Remifentanil|"Adjuvant continuous administration~\- adjust effect site concentration to maintain changes of vital sign below 20%"
218949332|NCT01937104|DEVICE|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
218949333|NCT01937104|PROCEDURE|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
218949334|NCT01937104|PROCEDURE|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
218949335|NCT01937104|PROCEDURE|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
218949336|NCT01902771|BIOLOGICAL|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
218949337|NCT01902771|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
218949338|NCT01902771|OTHER|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
218949339|NCT01902771|PROCEDURE|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
218949340|NCT02282878|DIETARY_SUPPLEMENT|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
218949341|NCT04531774|BEHAVIORAL|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
218949342|NCT04531774|BEHAVIORAL|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
218949343|NCT05510271|OTHER|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
218949344|NCT05510271|OTHER|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
218949345|NCT02866955|DRUG|Estramustine|140mg/4 caps/day
218949346|NCT02866955|DRUG|Tamoxifen|20mg/day
218949347|NCT04805879|BIOLOGICAL|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
218949348|NCT04805879|BIOLOGICAL|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
218949349|NCT02599051|DEVICE|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
218949350|NCT02599051|DEVICE|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
218949351|NCT03751306|PROCEDURE|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
218949352|NCT03751306|PROCEDURE|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
219636816|NCT02331914|PROCEDURE|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
218949353|NCT03751306|PROCEDURE|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
218949354|NCT05275361|BEHAVIORAL|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
218949355|NCT04626141|DRUG|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
218949356|NCT04626141|DRUG|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
219054654|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
219054655|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
219054656|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
219054657|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
219054658|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
219054659|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
219359997|NCT06018649|OTHER|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
219636817|NCT02331914|PROCEDURE|Tumor biopsy|Tumor biopsy after disease progression
219636818|NCT04662905|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|ECAP-controlled, closed-loop SCS
219636819|NCT06953141|DIAGNOSTIC_TEST|Ultrasound|Transabdominal and transvaginal imaging will be performed to eligible women following gynecological surgery within 24 - 48 hours.
219636820|NCT06163469|DEVICE|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
219636821|NCT05214859|BEHAVIORAL|The Dyadic Expressive Arts Group Therapy|This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
219636822|NCT03582774|OTHER|Best Practice|Undergo standard of care
219636823|NCT03582774|PROCEDURE|Computed Tomography|Undergo PET/CT
219636824|NCT03582774|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
218949357|NCT01845987|DRUG|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
218949358|NCT01845987|DRUG|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
218949359|NCT02143050|DRUG|Dabrafenib|
218949360|NCT02143050|DRUG|Trametinib|
218949361|NCT02143050|DRUG|Metformin|
219636825|NCT03582774|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219636826|NCT02636231|DRUG|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
219636827|NCT02636231|RADIATION|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
219636828|NCT05501470|DRUG|Probiotic|Probiotic
219636829|NCT05501470|DRUG|Placebo|Placebo
219636830|NCT05501470|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
219636831|NCT06386198|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
219636832|NCT04200443|DRUG|Cabozantinib|Given PO
219636833|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
219636834|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
219636835|NCT04200443|DRUG|Temozolomide|Given PO
219636836|NCT04806386|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
219636837|NCT04624256|PROCEDURE|Discussion|Patients and physicians engage in discussion
218949362|NCT02976220|OTHER|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
218949363|NCT00869778|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
218949364|NCT00869778|OTHER|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
218949365|NCT02856152|DRUG|GDC-0276 capsule|Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
218949366|NCT02856152|DRUG|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
218949367|NCT03661879|DRUG|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
218949368|NCT03661879|DRUG|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
218949369|NCT03642704|DRUG|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~\- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
218949370|NCT00411580|BIOLOGICAL|CAD106|
218949371|NCT00411580|DRUG|Placebo|
218949372|NCT04869748|OTHER|Perfetti method|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
218949373|NCT04869748|OTHER|passive stretching|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
219636838|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
219636839|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
219636840|NCT04624256|OTHER|Laboratory Biomarker Analysis|Correlative studies
219636841|NCT04624256|OTHER|Quality-of-Life Assessment|Ancillary studies
219636842|NCT04624256|OTHER|Questionnaire Administration|Ancillary studies
219636843|NCT04624256|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219636844|NCT06568055|OTHER|No Intervention|This is non-interventional study.
219636845|NCT02625532|PROCEDURE|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
219636846|NCT02625532|PROCEDURE|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
218949374|NCT03997045|BEHAVIORAL|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
218949375|NCT02725489|BIOLOGICAL|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
219359998|NCT01936220|BEHAVIORAL|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
219636847|NCT06316609|OTHER|Gestational Exposure to Emerging Contaminants (ECs)|Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
219636848|NCT06165510|DEVICE|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
218949376|NCT02725489|DRUG|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
218949377|NCT00574964|OTHER|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
218949378|NCT00129298|DRUG|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
218949379|NCT00603772|DRUG|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
218949380|NCT06181045|DRUG|LY3410738|Administered orally.
218949381|NCT06181045|DRUG|Placebo|Administered orally.
218949382|NCT06076278|PROCEDURE|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
218949383|NCT06068920|OTHER|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
218949384|NCT04341428|DRUG|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
218949385|NCT04341428|DRUG|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
218949386|NCT04341428|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
218949387|NCT04341428|DRUG|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
218949388|NCT05134532|DRUG|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
218949389|NCT03490812|DIAGNOSTIC_TEST|PET scan|Investigational PET scan as add-on to standard-of-care scan
218949390|NCT03490812|OTHER|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
218949391|NCT00406562|BIOLOGICAL|Boostrix|
218949392|NCT01962038|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
218949393|NCT01962038|BEHAVIORAL|Stretching Exercises|Gym and home based stretching exercises
218949394|NCT01962038|BEHAVIORAL|Cognitive Training|Group-based cognitive training
218949395|NCT06409793|BEHAVIORAL|mHealth|A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
218949396|NCT06401187|OTHER|Bar overdenture|use of bar attachments as retentive mean of denture
218949397|NCT04040491|DRUG|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
218949398|NCT02804841|DIETARY_SUPPLEMENT|Cholecalciferol -Vitamin D3|
218949399|NCT02804841|OTHER|Placebo -gel capsule containing no vitamin D.|
218949400|NCT00839033|DEVICE|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
218949401|NCT00839033|DEVICE|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
218949402|NCT01600625|DRUG|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
218949403|NCT00485797|DRUG|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
218949404|NCT03121976|DEVICE|Ultrasound|Femoral catheter inserted using ultrasound only
218949405|NCT03121976|DEVICE|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
218949406|NCT02208687|BEHAVIORAL|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
218949407|NCT02208687|OTHER|Control group|Usual care
218949408|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
218949409|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
219359999|NCT01936220|BEHAVIORAL|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
219636849|NCT06165510|PROCEDURE|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
219636850|NCT05894018|DRUG|Fluzoparib|150mg, orally, bid
218949410|NCT03180619|DRUG|TAF|Tablet administered orally once daily
218949411|NCT00375401|DRUG|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
218949412|NCT00375401|DRUG|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
218949413|NCT00375401|DRUG|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
218949414|NCT04520529|OTHER|Biologic Samples|"* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research."
219636851|NCT05894018|PROCEDURE|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
218949415|NCT04732390|PROCEDURE|erector spinae block with bupivacaine|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
218949416|NCT04732390|PROCEDURE|erector spinae block with bupivacaine and magnesium sulphate|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
218949417|NCT02895425|OTHER|Registry (No intervention)|
218949418|NCT02480725|PROCEDURE|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
218949419|NCT04244305|OTHER|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
218949420|NCT02673541|DEVICE|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
218949421|NCT02673541|DEVICE|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
218949422|NCT01426542|DRUG|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
218949423|NCT01426542|OTHER|No medication, but routine heart surgery|No medication, but routine heart surgery
218949424|NCT00435253|BIOLOGICAL|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
218949425|NCT00436540|DRUG|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
218949426|NCT00436540|DRUG|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
218949427|NCT00370045|DRUG|Bivalirudin with and without eptifibatide|
218949428|NCT01716962|OTHER|Infusion of 6% tetrastarch for a total of 500 ml|
218949429|NCT03683732|BEHAVIORAL|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
218949430|NCT06251401|BEHAVIORAL|In-person supervised cardiac rehabilitation|In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
218949431|NCT06251401|BEHAVIORAL|Virtual cardiac rehabilitation|Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
218949432|NCT03540251|OTHER|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
218949433|NCT02663726|OTHER|Yoga|10 weekly 75-min sessions of specialised yoga
219360000|NCT01936220|BEHAVIORAL|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
219636852|NCT04755764|DRUG|Labetalol|Beta blocker
219636853|NCT04755764|DRUG|Atenolol|Beta blocker
219636854|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
219636855|NCT04881578|OTHER|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
218949434|NCT02663726|BEHAVIORAL|Written advice|Written advice about physical activity
218949435|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
219636856|NCT05497518|OTHER|Observational study - registry|The Study is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
219636857|NCT04556084|DRUG|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
219636858|NCT06963047|DIAGNOSTIC_TEST|Ultrasound|The purpose of the test is to diagnose and assess the amount of blood loss.
219636859|NCT06963047|OTHER|Standard care|Routine management
219636860|NCT06961279|DIETARY_SUPPLEMENT|Resveratrol|Administered orally once every 12 hours
219636861|NCT06961279|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
219636862|NCT04797611|DEVICE|TNM Device|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive tvCVS device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
219636863|NCT03867409|BEHAVIORAL|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
218949436|NCT02789319|DEVICE|Blood Glucose Meter Systems|
218949437|NCT04316910|DRUG|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
218949438|NCT04538209|RADIATION|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
218949439|NCT01479283|DRUG|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
219054660|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
219054661|NCT00727857|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
219054662|NCT00727857|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
219054663|NCT00727857|DRUG|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
219054664|NCT05937074|OTHER|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
219054665|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
219054666|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
219054667|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
219054668|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
219054669|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
219636864|NCT04901325|DRUG|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
219636865|NCT06163820|DRUG|Bevacizumab|Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.
219636866|NCT06163820|DRUG|Ipilimumab|Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.
219636867|NCT06163820|DRUG|Nivolumab|Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.
218949440|NCT01479283|DRUG|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
218949441|NCT06192810|PROCEDURE|Laparoscopic/open adrenalectomy|
219054670|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
219054671|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
219054672|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
219054673|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
219054674|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
219054675|NCT05241886|OTHER|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
219054676|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
219054677|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
219054678|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
219054679|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
219636868|NCT06163820|RADIATION|Hypofractionated stereotactic radiotherapy|Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
219636869|NCT05916144|BEHAVIORAL|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
219636870|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
219636871|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
218949442|NCT03077087|DEVICE|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
218949443|NCT03340103|DIETARY_SUPPLEMENT|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
218949444|NCT03340103|DRUG|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
219054680|NCT02066558|OTHER|Placebo|
219054681|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
219054682|NCT03979716|DEVICE|fMRI|fMRI examination
219636872|NCT04509193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
219636873|NCT04509193|DRUG|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
219636874|NCT03300505|DRUG|ARRx|Given intravenously (IV)
219636875|NCT03300505|DRUG|Enzalutamide|Given by mouth (PO)
219636876|NCT02905318|DRUG|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
219636877|NCT06240572|OTHER|no intervention|no intervention
218949445|NCT00918060|DRUG|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
218949446|NCT04858971|OTHER|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
218949447|NCT02907476|BEHAVIORAL|Iyengar Yoga|
218949448|NCT02907476|BEHAVIORAL|Walking|
218949449|NCT02723487|DRUG|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
218949450|NCT02723487|DRUG|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
218949451|NCT05587946|OTHER|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
219054683|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
219054684|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
219054685|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
219206998|NCT06768593|PROCEDURE|RIFP Block|After aseptic conditions are ensured, with high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) bilateral block will be applied to Group R. As the patient is in supine position, the USG probe is placed in transverse plane on the sternum and will be directed downwards and laterally and rotated to determine the xiphoid and just below the rectus abdominis muscles. Costal cartilage and rectus abdominis muscle sonographically will be shown. This region corresponds to the 3-4 cm lateral and 3-4 cm caudal region of the xiphoid. Using the in-plane technique, the block needle will be advanced in the caudal-cephalic direction, and 5 ml saline will be injected into the area between the rectus muscle and costal cartilage to verify the block location. 30 ml of 0.25% bupivacaine (Buvacaine, Polifarma ®) will be injected to each side, which corresponds to 60 ml total local anesthetic-saline mixture in Group R.
219206999|NCT06768593|OTHER|Postoperative pain management|"Ibuprofen 400 mg (Ibuprofen, Polifarma ®) and tramadol 100 mg (Contramal, Abdi İbrahim ®) IV single bolus dose will be given 20 minutes before the end of the surgical procedure for postoperative analgesia.~NRS scores at rest and while moving will be evaluated and recorded and if the NRS score is ≥ 4, meperidine 0,5 mg/kg (Aldolan®) IV will be administered as a rescue analgesic."
219636878|NCT04254419|BIOLOGICAL|NK cells|"The universal donor TGFβi NK cells will be cryopreserved until they are delivered bedside for infusion. The trained staff will thaw the product by the bedside. The administration of the cells will be done via an Ommaya intra-cavitary/a programable ventriculoperitoneal (VP) shunt.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya/VP shunt in approximately 3 milliliters over approximately 2-5 minutes; followed by 1.5-2 milliliter preservative-free normal saline flush over approximately 1 minute."
219636879|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
219636880|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
219636881|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
219636882|NCT00209963|DRUG|Gaboxadol|
219636883|NCT00664378|DRUG|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
219636884|NCT03756623|DRUG|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
219636885|NCT03756623|DRUG|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
219636886|NCT03756623|OTHER|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
218949452|NCT00447200|PROCEDURE|Esophagus Doppler monitoring|
218949453|NCT00447200|PROCEDURE|Fluid optimization|
218949454|NCT04560244|DRUG|SHR1701|PD-L1 / TGF-β RII double antibody
219636887|NCT01265745|DRUG|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
218949455|NCT02830269|DEVICE|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
218949456|NCT05121571|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
218949457|NCT05121571|DRUG|Sorafenib|sorafenib 400mg bid
219054686|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
219054687|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
219054688|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
219054689|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
219054690|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
219054691|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
219054692|NCT02985736|DRUG|Topicort Topical Spray|
218949458|NCT03080077|DRUG|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
218949459|NCT03080077|DRUG|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
218949460|NCT03134079|OTHER|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
218949461|NCT03134079|OTHER|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
218949462|NCT03134079|OTHER|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
218949463|NCT05313100|DRUG|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
219636888|NCT01265745|BIOLOGICAL|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
219636889|NCT02658474|BEHAVIORAL|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
219636890|NCT06339866|OTHER|The Effect of Two Different Video Interventions on Pain and Anxiety in Children with Adenotonsillectomy: A Randomized Controlled Study|The population of the study will be all patients who had adenotonsillectomy surgery between the ages of 6-12 in the Ear Nose and Throat Service of Zonguldak Bülent Ecevit University Hospital, and the sample will be all patients who had adenotonsillectomy surgery between the specified dates and who meet the inclusion criteria.
219636891|NCT00679029|DRUG|doxorubicin hydrochloride|Given IV
219636892|NCT00679029|DRUG|cyclophosphamide|Given IV
219636893|NCT00679029|BIOLOGICAL|bevacizumab|Given IV
219636894|NCT00679029|DRUG|paclitaxel|Given IV
219636895|NCT00679029|DRUG|gemcitabine hydrochloride|Given IV
219636896|NCT00679029|OTHER|laboratory biomarker analysis|Correlative studies
219636897|NCT00679029|BIOLOGICAL|pegfilgrastim|Given subcutaneously
219636898|NCT03256929|BEHAVIORAL|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, the investigators will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
219636899|NCT03256929|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
219636900|NCT05208528|DIETARY_SUPPLEMENT|ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
219636901|NCT05208528|DIETARY_SUPPLEMENT|HT-ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
218949464|NCT01476202|DRUG|nicotine|nicotine in the form of a mouth strip, lozenge and gum
218949465|NCT02336126|BEHAVIORAL|Biopsychological intervention|
219636902|NCT05208528|DIETARY_SUPPLEMENT|Control group|Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
219636903|NCT03124316|BEHAVIORAL|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
219636904|NCT03124316|BEHAVIORAL|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
219054693|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
219054694|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
219054695|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
219054696|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
219636905|NCT03124316|BEHAVIORAL|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
219636906|NCT00400660|DRUG|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
219636907|NCT00400660|DRUG|Placebo|Subjects will also receive placebo inhaler.
219636908|NCT01108341|DRUG|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
219636909|NCT01108341|DRUG|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
219636910|NCT00479050|PROCEDURE|chemoembolization ,Radiofrequency ablation|
218949466|NCT06046157|OTHER|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
219054697|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
219054698|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
219054699|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
219054700|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
219054701|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
219054702|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
219054703|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
219054704|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
219054705|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
219054706|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
219054707|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
219054708|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
219054709|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
219054710|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
219054711|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
219054712|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
219054713|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
219054714|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
219054715|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
219054716|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
219054717|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
219054718|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
219054719|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
219207000|NCT06768996|BEHAVIORAL|Synchronous Rhythm Production|The treatment group will take part in a dyad-based musical rhythm production activity facilitated by a trained musician. This activity will involve two rhythm conditions. The first condition requires tapping along to one pre-recorded audio track composed of an ensemble of Brazilian percussion instruments. The second condition requires tapping along with prerecorded audio tracks of rhythms progressively increasing in difficulty. Participants who indicate proficiency in learning to tap along in both conditions will be able to progress to more complex rhythms. All tapping data will be gathered through a Roland digital hand percussion controller.
219549554|NCT05215938|DIAGNOSTIC_TEST|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
219549555|NCT01487499|DRUG|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
219549556|NCT01006967|DEVICE|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
218949467|NCT06046157|OTHER|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
218949468|NCT01054183|DEVICE|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
218949469|NCT01054183|DEVICE|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
218949470|NCT02963844|OTHER|Inspiratory Muscle Training|
218949471|NCT02963844|OTHER|Inspiratory Muscle Training Sham|
218949472|NCT02112045|DRUG|Granix|
218949473|NCT02112045|DRUG|High dose melphalan (HDR)|
218949474|NCT02112045|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|
219636911|NCT03025932|PROCEDURE|repair of giant hiatal hernia with mesh and anterior fundoplication|
218949475|NCT03774498|DRUG|Sensodyne repair and protect|NovaMin \& fluoride toothpaste
218949476|NCT04585971|DIAGNOSTIC_TEST|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
218949477|NCT00443963|DRUG|Esomeprazole Magnesium|PPI compared to H2RA
219636912|NCT00290134|DRUG|Fispemifene once daily for 4 weeks|
219636913|NCT03780803|OTHER|home cardiac rehabilitation and respiratory rehabilitation|
219054720|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
219549557|NCT01006967|OTHER|Physical Therapy|Standard program of physical therapy for gait and balance
219549558|NCT06512519|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)"
219636914|NCT06290843|PROCEDURE|Schroth method|Exercises from Schoth method
219549559|NCT03495206|DRUG|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
219636915|NCT06280144|BIOLOGICAL|Influenza Vaccine, Live, Nasal, Freeze-dried|The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
219636916|NCT06280144|OTHER|Sterile water for inhalation|Sterile water for inhalation
219636917|NCT01648725|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
218949478|NCT03680118|DEVICE|autogenous rings with GBR and autogenous graft with ti-mesh|"* Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
218949479|NCT04585061|DRUG|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
219054721|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
219054722|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
219636918|NCT01648725|PROCEDURE|usual care|Standard care before induction of anesthesia
219636919|NCT06621758|OTHER|questionnaire|Questionnaire regarding biomarker counseling and diagnostic disclosure
219636920|NCT04402138|DRUG|Acalabrutinib|Acalabrutinib 129 mg will be self-administered orally twice daily (BID) starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
219636921|NCT06613854|DRUG|Oral semaglutide|Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
218949480|NCT04585061|DEVICE|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
218949481|NCT04585061|DIETARY_SUPPLEMENT|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
218949482|NCT02052713|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
218949483|NCT02052713|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
218949484|NCT01661582|OTHER|CT/PET Myocardial Perfusion Imaging using O-15 water|
218949485|NCT01661582|OTHER|Coronary blood flow measured by doppler echocardiography|
218949486|NCT02524483|BEHAVIORAL|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
218949487|NCT02524483|BEHAVIORAL|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
218949488|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
218949489|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
218949490|NCT02775240|DRUG|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
218949491|NCT02775240|DRUG|Maribavir|200mg twice a day for 8 days
218949492|NCT02775240|DRUG|Dextromethorphan|30 mg oral dose
218949493|NCT05577520|PROCEDURE|Sinus floor augmentation|
218949494|NCT02614521|OTHER|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
218949495|NCT05965271|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
218949496|NCT00000973|DRUG|Pyrimethamine|
218949497|NCT00000973|DRUG|Leucovorin calcium|
218949498|NCT00000973|DRUG|Zidovudine|
218949499|NCT02859584|BIOLOGICAL|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
218949500|NCT00348608|DRUG|iodixanol|
218949501|NCT00973011|DRUG|FCFD4514S|Intravitreal escalating dose
218949502|NCT01819285|PROCEDURE|Immediate Orchiectomy or depot LHRH|
219054723|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
219054724|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
219054725|NCT04988022|DRUG|Dupilumab|300 mg prefilled syringe
219054726|NCT04988022|DRUG|Placebo|Matching placebo
219054727|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
219054728|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
219054729|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
219054730|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
219054731|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
219054732|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
219636922|NCT06613854|DRUG|Empagliflozin 10 mg|Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
218949503|NCT01819285|PROCEDURE|Delayed Orchiectomy or depot LHRH|
218949504|NCT00977080|DRUG|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
218949505|NCT00977080|DRUG|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
218949506|NCT05076721|OTHER|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
218949507|NCT05076721|OTHER|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
218949508|NCT00686114|DRUG|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
218949509|NCT00686114|DRUG|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
218949510|NCT00686114|DRUG|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
218949511|NCT00686114|RADIATION|Radiotherapy|Enlarged field radiotherapy
218949512|NCT00686114|RADIATION|Radiotherapy|Conventional field radiotherapy
218949513|NCT06383312|DEVICE|Reflexologic Magnetic Insole Group|Reflexologic magnetic insole will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
218949514|NCT06383312|DEVICE|Orthopedic Insole Group|Orthopedic insole (sham) will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
218949515|NCT05617456|PROCEDURE|AF ablation|Patients with standard indications to AF ablation
218949516|NCT02992197|BIOLOGICAL|Rotarix, dose 1|Rotarix, dose 1
218949517|NCT02992197|BIOLOGICAL|Rotarix, dose 2|Rotarix, dose 2
218949518|NCT02992197|DRUG|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
219207001|NCT06768996|BEHAVIORAL|Solo Rhythm Production|Participants randomized to the control condition will complete the same rhythm conditions to the same recorded audio tracks described in the experimental condition. However, they will not interchange their tapping with their caregiver. They will participate in the rhythm task as a solo producer.
219636923|NCT05215275|BEHAVIORAL|exercise|"the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds."
219636924|NCT03960008|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
218949519|NCT02571335|BEHAVIORAL|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
218949520|NCT02571335|BEHAVIORAL|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
218949521|NCT00441116|DRUG|Dutasteride 0.5mg oral tablets|Dutasteride
218949522|NCT03192358|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
218949523|NCT03192358|OTHER|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
218949524|NCT00578760|DRUG|aspirin|325mg ASA OD for the duration of the cisplatin
218949525|NCT00578760|DRUG|placebo|OD for course of cisplatin chemotherapy
218949526|NCT06046300|DIAGNOSTIC_TEST|Investigation of the relationship between trunk position sense and muscle activation, balance and quality of life in individuals with transtibial amputation.|It is aimed to investigate whether the trunk position sense, including the trunk right and left sides of the individuals with transtibial amputation, is affected and the relationship between trunk position sense and muscle activation, balance and quality of life.
218949527|NCT03658096|DEVICE|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
218949528|NCT01716416|DRUG|Pazopanib|
218949529|NCT01716416|DRUG|Cetuximab|
218949530|NCT00637780|DRUG|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
218949531|NCT01550653|DRUG|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
218949532|NCT01550653|DRUG|Placebo|
219549560|NCT03561987|PROCEDURE|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
219549561|NCT02861651|OTHER|DNA sequencing|
219549562|NCT00781430|DRUG|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
218949533|NCT01251536|DRUG|Dose escalation of cetuximab|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
218949534|NCT01251536|DRUG|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
218949535|NCT00401232|PROCEDURE|Blood Collection|Blood Collection
218949536|NCT00597896|DRUG|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
218949537|NCT05396599|DEVICE|Model DIU|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
218949538|NCT05396599|DEVICE|Model DFW|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
218949539|NCT05396599|DEVICE|Model ZCT|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
218949540|NCT02920099|OTHER|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
218949541|NCT03542396|BEHAVIORAL|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
218949542|NCT01411735|DRUG|Enalapril|2.5mg titrated up to 10mg twice daily
218949543|NCT01411735|DRUG|placebo|2.5mg titrated up to 10mg twice daily.
218949544|NCT06284824|DEVICE|Stryker Triathlon with MAKO Robotic-Arm|Implant is the Stryker Triathlon total knee arthroplasty and the robotic device is the MAKO robotic-arm
219054733|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
219054734|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
219054735|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
219054736|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
219054737|NCT03282955|DRUG|Lipidem|Lipoplus i.v. lipid emulsion for parenteral nutrition
219054738|NCT03282955|DRUG|Lipofundin MCT 20%|Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
219054739|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
219054740|NCT05776030|DEVICE|Single Speed Ergonomic Wheelchair|"Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2"
219054741|NCT05776030|DEVICE|Multi-Speed Ergonomic Wheelchair|The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
219054742|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
219054743|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
219054744|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
218949545|NCT06284824|DEVICE|DePuy Attune with VELYS Robotic-Assistance|Implant is the DePuy Attune total knee arthroplasty and the robotic device is the VELYS robotic-assistance
218949546|NCT01765218|DRUG|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
218949547|NCT01765218|DRUG|Placebo|A placebo identical in appearance to the active agent (topiramate)
218949548|NCT00946985|DRUG|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
219054745|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
219054746|NCT03879629|DRUG|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
219054747|NCT04154631|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
219054748|NCT04154631|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
219636925|NCT03960008|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation
218949549|NCT00946985|DRUG|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
219054749|NCT04154631|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
219054750|NCT02185768|DRUG|idarubicin|
219636926|NCT03960008|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
218949550|NCT04305067|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
218949551|NCT00932061|OTHER|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
218949552|NCT00932061|OTHER|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
219636927|NCT02646475|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
219636928|NCT02646475|DRUG|Saline|Normal saline will be used as a placebo comparator.
219636929|NCT03056638|DRUG|Degarelix|Degarelix monthly for 6 months
219636930|NCT03056638|RADIATION|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
219636931|NCT06330129|DEVICE|CTT Pegasus|The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
219636932|NCT02464423|BEHAVIORAL|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
219636933|NCT06544135|DEVICE|FLIR One Pro LT|Thermal imaging camera used to measure temperatures of the lower limb.
219636934|NCT05034211|PROCEDURE|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
219636935|NCT05034211|PROCEDURE|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
219636936|NCT04917822|BEHAVIORAL|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
219636937|NCT04917822|BEHAVIORAL|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
219636938|NCT01811641|OTHER|season, dietary intake|
219636939|NCT00468481|DRUG|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
219636940|NCT00468481|DRUG|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
218949553|NCT06298942|PROCEDURE|natural band|to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
218949554|NCT06298942|PROCEDURE|silicone band|to use synesthetic band with sleeve gastrectomy
219054751|NCT02185768|DEVICE|Dc- Beads 300-500µm|
219054752|NCT05957978|DRUG|LXE408|Film-coated tablets
219054753|NCT05957978|DRUG|sodium stibogluconate|Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
219054754|NCT05957978|DRUG|Paromomycin|Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
219054755|NCT00832429|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
219054756|NCT00832429|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
219054757|NCT00832429|DRUG|Technetium Tc-99m Sulfur Colloid|Given ID
219636941|NCT04657029|BEHAVIORAL|Treadmill|30 minutes of moderate-high intensity treadmill training.
219054758|NCT05110001|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
218949555|NCT06460740|OTHER|4-7-8 breathing technique|Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
218949556|NCT06460740|OTHER|Stationary Cycling|In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
218949557|NCT01316198|DIETARY_SUPPLEMENT|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
218949558|NCT01316198|DIETARY_SUPPLEMENT|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
218949559|NCT06212037|DIAGNOSTIC_TEST|Point of Care Ultrasound|Point of Care Ultrasound will be performed on all subjects and their laryngeal air column width difference will be calculated. The patients will be followed after extubation and the presence/absence of post extubation stridor will be recorded.
219054759|NCT05110001|DRUG|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
218949560|NCT05364333|PROCEDURE|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
218949561|NCT04832269|OTHER|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
218949562|NCT00523445|DRUG|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
218949563|NCT00523445|DRUG|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
218949564|NCT02237534|DRUG|Lanthanum carbonate|
218949565|NCT02237534|DRUG|Calcium Carbonate|
218949566|NCT06394934|BEHAVIORAL|Healthscan App|Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
218949567|NCT03868527|OTHER|Data collection|Data collection for biostatistical analysis about hematological diseases
218949568|NCT03148691|DRUG|A-101|Topical Solution
218949569|NCT05636800|DEVICE|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
219054760|NCT05110001|DRUG|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
218949570|NCT02956590|DRUG|Pitavastatin|Statin
218949571|NCT02956590|DRUG|Placebo|Placebo
219054761|NCT05110001|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
219054762|NCT05110001|OTHER|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
219054763|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
218949572|NCT00926315|DRUG|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
218949573|NCT00926315|DRUG|Calcitriol|calcitriol 0.25 mcg PO bid
218949574|NCT03919097|OTHER|Medical Data extraction|Data extraction from the patient's Medical Files
218949575|NCT00171834|DRUG|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
218949576|NCT02919358|OTHER|Music|
218949577|NCT02919358|OTHER|No music.|This is the control group.
218949578|NCT00554281|DEVICE|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
219054764|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
219054765|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
218949579|NCT02766140|DRUG|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
218949580|NCT02766140|DRUG|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
218949581|NCT01771341|DEVICE|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
218949582|NCT01771341|DEVICE|MAQUET SERVOi ventilator|Pressure Support
219054766|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
219054767|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
218949583|NCT04345367|DRUG|Abrocitinib 200 mg|Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
218949584|NCT04345367|COMBINATION_PRODUCT|Dupilumab 300 mg|Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
218949585|NCT05282303|PROCEDURE|CABG operation|Efficacy of regional analgesia techniques in coronary artery bypass operations
218949586|NCT00796523|BEHAVIORAL|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
218949587|NCT00796523|BEHAVIORAL|control videotape|a videotape with general newborn care instructions
219549563|NCT06149767|DRUG|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
219549564|NCT01135784|DIETARY_SUPPLEMENT|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
218949588|NCT01030640|OTHER|placebo|single dose of the drug formulation
218949589|NCT01030640|BIOLOGICAL|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
218949590|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
218949591|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
218949592|NCT02252744|OTHER|No intervention|
219054768|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
218949593|NCT05532293|DRUG|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
218949594|NCT05532293|OTHER|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
218949595|NCT02710955|DIETARY_SUPPLEMENT|Thickened infant formula|
218949596|NCT02057328|DRUG|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
219054769|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
219054770|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
219054771|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
219054772|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
219054773|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
218949597|NCT02057328|DRUG|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
218949598|NCT05568940|DRUG|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
218949599|NCT02883257|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
218949600|NCT04285840|OTHER|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
218949601|NCT01352403|PROCEDURE|Roux-en-Y gastric bypass|
218949602|NCT01352403|BEHAVIORAL|Psychotherapy-enhanced lifestyle intervention|
218949603|NCT01494493|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
218949604|NCT01494493|PROCEDURE|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
218949605|NCT01336400|OTHER|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
218949606|NCT05622760|OTHER|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
218949607|NCT05622760|OTHER|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
218949608|NCT00852839|DRUG|Placebo|Placebo to match oromucosal formulation of 552-02
218949609|NCT00852839|DRUG|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
218949610|NCT00781885|DRUG|Beraprost sodium modified release|Tablets 60mcg
218949611|NCT02108678|BEHAVIORAL|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
218949612|NCT02108678|BEHAVIORAL|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
218949613|NCT00115921|BEHAVIORAL|Provision of antimalarial treatment at home|
218949614|NCT01755026|DRUG|cefazolin|2 gram dose for pre-operative prophylaxis
218949615|NCT01755026|DRUG|cefazolin|4 gram dose for pre-operative prophylaxis
218949616|NCT00194649|DRUG|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
218949617|NCT04802668|DEVICE|Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume|Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.
218949618|NCT04802668|BEHAVIORAL|spontaneous breathing and no spontaneous breathing|Data were recorded when patients had and did not have spontaneous breathing
218949619|NCT03011021|DRUG|Liraglutide|Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
218949620|NCT03011021|BIOLOGICAL|UCB-Treg|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline
218949621|NCT03011021|DRUG|Insulin|Receive insulin following clinician's instruction.
218949622|NCT03653559|BEHAVIORAL|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
218949623|NCT03653559|BEHAVIORAL|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
218949624|NCT02547961|BIOLOGICAL|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
218949625|NCT06374043|DRUG|Dapagliflozin 10mg Tab|Oral administration
218949626|NCT06374043|DRUG|Placebo|Oral administration
219054774|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
219207002|NCT06758336|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
219207003|NCT06756711|DIETARY_SUPPLEMENT|A combination of apitherapy and plant extracts|This combination contains the active comparator
219207004|NCT06756711|COMBINATION_PRODUCT|Placebo Combination|A combination containing inert substances - placebo
219054775|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
219054776|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
219054777|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
219054778|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
219054779|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
219054780|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
219054781|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
219054782|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
219054783|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
219054784|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
219054785|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
219054786|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
219054787|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
219054788|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
219054789|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
219054790|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
219054791|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
219054792|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
219054793|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
219054794|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
219054795|NCT00260052|DRUG|Erythropoietin administration|
219054796|NCT00871559|DRUG|REGN421(SAR153192)|
219054797|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
219054798|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
219054799|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
219054800|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
219054801|NCT02201797|OTHER|DCE MRI|
219054802|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
219054803|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
219549565|NCT01135784|DIETARY_SUPPLEMENT|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
219549566|NCT05779527|BEHAVIORAL|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
219549567|NCT04964687|PROCEDURE|Liver transplantation|Liver transplantation
219549568|NCT04605835|DIAGNOSTIC_TEST|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
219549569|NCT03007524|DRUG|High dose Rosuvastatin|20mg/d qN, at least 6 months
219549570|NCT03007524|DRUG|Low dose Rosuvastatin|10mg/d qN, at least 6 months
219549571|NCT03814850|DEVICE|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
219549572|NCT02777307|OTHER|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
218949627|NCT06374043|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken."
218949628|NCT06374043|DEVICE|Withings Body+|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 40 days."
218949629|NCT06374043|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 22 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, CRP, lipid profile, HbA1c, uric acid, glucose and NT-proBNP.
219054804|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
219054805|NCT06445842|OTHER|Exercise|The protocol involves a 10-minute warm-up and cool-down session, followed by two sets of high-intensity circuit training exercises (bench press, squats, overhead press, calf raising, barbell row, deadlifts) that last 12 minutes each (6 stations×2sets). There will be a 3-minute break between the exercise sets. The heart rate required during the exercise will be between 70-90% of their maximum capacity and a pre-scale rate of 7.5. The intensity of the exercise will be progressive each two weeks, commencing at 50% of their one rep max and increasing to 80% in their last week. During the initial phase, participants will be required to complete eight reps for each exercise. We will encourage them to increase their intensity level every two weeks.
219054806|NCT06445842|OTHER|No exercise|This group will need to maintain their sedentary lifestyle without changing their activity levels or diet
219054807|NCT05811247|DRUG|AD109|Oral administration at bedtime.
219054808|NCT05811247|DRUG|Placebo|Oral administration at bedtime.
219054809|NCT03983473|OTHER|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
219054810|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
219636942|NCT03211884|BEHAVIORAL|Problem-Solving Thearpy|"The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet \& greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions."
219636943|NCT00409136|BEHAVIORAL|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
219636944|NCT01934049|PROCEDURE|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
219054811|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
219054812|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
219054813|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
219054814|NCT03734471|DEVICE|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
219054815|NCT03734471|PROCEDURE|Tube thoracostomy|Traditional chest tube placement
219054816|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
219549573|NCT05920395|OTHER|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
219549574|NCT05920395|OTHER|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
219636945|NCT01934049|DRUG|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
219636946|NCT04324970|DEVICE|Tookie Vest|Tookie Vest
219636947|NCT01451528|BIOLOGICAL|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
218949630|NCT06374043|DEVICE|MEMS (Medication Electronic Monitoring System) Cap|Medication will be provided in standard medicine bottles with the MEMS® (Medication Electronic Monitoring System) Cap (AARDEX Ltd, Union City, CA, USA), which is a customizable medication package which records and stores up to 4,000 dosing events. The cap fits on standard medicine bottles and with integrated microcircuits, the child-resistant MEMS® Cap records the date and time whenever a patient opens a vial. The stored information can be transferred at any time through the MEMS® Reader to the adherence software for immediate analysis and interpretation.
218949631|NCT06374043|BEHAVIORAL|Questionnaire: participants' perspectives toward remote data collection|Self-made questionnaires consisting of 6 multiple choice questions and 2 open questions will be used to assess patient experience and satisfaction to guide and inform future trials and use in clinical practice.
218949632|NCT03031002|BEHAVIORAL|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
218949633|NCT03078829|DRUG|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
218949634|NCT00392379|DRUG|Nicotine Lozenges|Nicotine lozenges, 4 mg
218949635|NCT00392379|DRUG|Placebo lozenge|Placebo lozenge
218949636|NCT05728099|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
218949637|NCT05728099|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
218949638|NCT00167492|DRUG|Myfortic|720 mg by mouth every 12 hours
218949639|NCT04231370|DRUG|Sintilimab|Sintilimab, 200mg, iv day1
218949640|NCT04231370|DRUG|Lenalidomide|25mg/d oral d1-14
218949641|NCT05516563|OTHER|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
218949642|NCT01757340|BEHAVIORAL|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
218949643|NCT01757340|BEHAVIORAL|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
218949644|NCT03878641|BEHAVIORAL|Children in Grade 1 to 5 with literacy and language needs|The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
218949645|NCT03071250|PROCEDURE|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
219360001|NCT03886844|DIETARY_SUPPLEMENT|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
219549575|NCT00125385|BIOLOGICAL|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
218949646|NCT02184624|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
218949647|NCT02184624|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
218949648|NCT02184624|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
218949649|NCT02184624|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
219360002|NCT04489979|OTHER|Antibiotics|Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
219360003|NCT03677193|BEHAVIORAL|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
219360004|NCT04153084|DRUG|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
219360005|NCT04153084|DRUG|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
219549576|NCT00125385|BIOLOGICAL|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
219549577|NCT00125385|BIOLOGICAL|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
219054817|NCT04425330|OTHER|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
218949650|NCT02184624|DEVICE|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
218949651|NCT02184624|DEVICE|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
218949652|NCT04359381|OTHER|kinesiotaping application|kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
218949653|NCT04359381|OTHER|Pilate exercises program|Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
218949654|NCT05304780|BEHAVIORAL|needs-tailored nurse-led recovery program|The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
218949655|NCT03417713|DEVICE|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
219054818|NCT04425330|OTHER|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
219636948|NCT00734162|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
219636949|NCT00734162|DRUG|Placebo|TDF placebo tablet once daily
219636950|NCT02076724|DEVICE|Biological mesh|
219636951|NCT02076724|DEVICE|Synthetic mesh|
219636952|NCT04290715|OTHER|no intervention|no intervention
219636953|NCT00596687|DRUG|Insulin glargine|Insulin glargine once daily SQ
219636954|NCT00596687|DRUG|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
218949656|NCT05977244|OTHER|HGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
218949657|NCT05977244|OTHER|LGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
218949658|NCT05977244|OTHER|HGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
218949659|NCT05977244|OTHER|LGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
218949660|NCT00886847|PROCEDURE|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
219636955|NCT00596687|DRUG|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
219636956|NCT05142631|DRUG|Fruquintinib|To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
219636957|NCT02008474|BEHAVIORAL|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
219054819|NCT04425330|OTHER|SHAM PBM|SHAM PBM
218949661|NCT06194045|DIETARY_SUPPLEMENT|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
218949662|NCT06194045|DIETARY_SUPPLEMENT|Placebo|2 x 1 g capsules containing corn oil
218949663|NCT00006050|DRUG|FOLFOX regimen|
218949664|NCT00006050|DRUG|fluorouracil|
218949665|NCT00006050|DRUG|isolated perfusion|
218949666|NCT00006050|DRUG|leucovorin calcium|
218949667|NCT00006050|DRUG|oxaliplatin|
218949668|NCT00651079|DRUG|GSK1247303|
218949669|NCT02365233|DRUG|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
218949670|NCT02365233|DRUG|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
218949671|NCT02365233|DRUG|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
219054820|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
219054821|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
219054822|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
219054823|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
219054824|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
219054825|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
219054826|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
219054827|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
219054828|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
218949672|NCT02642497|DRUG|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
219636958|NCT02008474|BEHAVIORAL|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
219636959|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
219636960|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
219636961|NCT04050878|DEVICE|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
219636962|NCT03831113|DRUG|Magnitude Group|Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
218949673|NCT02642497|DRUG|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
218949674|NCT02642497|DRUG|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
218949675|NCT05813223|DRUG|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
218949676|NCT01294098|DRUG|Marcaine|0.75 cc/kg of 1/4% Marcaine
218949677|NCT02414529|DRUG|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
218949678|NCT02414529|DRUG|Placebo|
218949679|NCT04267900|DRUG|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
219054829|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
219054830|NCT04545515|DRUG|IVA|Tablet for oral administration.
219054831|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
219054832|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
219054833|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
219054834|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
219054835|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
219054836|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
219054837|NCT01876264|PROCEDURE|Extended resection|
219054838|NCT01876264|PROCEDURE|Conventional resection|
218949680|NCT04783558|BEHAVIORAL|Mobile-based NAS Caregiving Tool|The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
218949681|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
219054839|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
219054840|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
219054841|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
219054842|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
219054843|NCT02657811|DEVICE|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
219054844|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
219054845|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
219549578|NCT00125385|BIOLOGICAL|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
218949682|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
218949683|NCT00127270|BEHAVIORAL|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
218949684|NCT04870697|BEHAVIORAL|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
218949685|NCT04870697|OTHER|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
218949686|NCT04504409|OTHER|Rehabilitation|Training
218949687|NCT00361933|DRUG|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
218949688|NCT00795119|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
218949689|NCT03523598|OTHER|Placebo gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
218949690|NCT03523598|OTHER|Placebo Gel + Potassium Nitrate Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
218949691|NCT03523598|OTHER|Potassium Nitrate Gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
218949692|NCT01978938|DRUG|Eravacycline|
219636963|NCT03831113|DRUG|Frequency Group|Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
218949693|NCT01978938|DRUG|Levofloxacin|
218949694|NCT02087007|DRUG|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
218949695|NCT02087007|DRUG|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
219054846|NCT06031571|PROCEDURE|dry cupping massage|Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
219054847|NCT06031571|PROCEDURE|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
219549579|NCT00125385|BIOLOGICAL|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
219549580|NCT02750878|OTHER|Informational Handout|
219549581|NCT02579577|OTHER|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
219549582|NCT02579577|OTHER|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
219549583|NCT02579577|OTHER|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
219549584|NCT02583048|DRUG|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
219549585|NCT02583048|DRUG|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
219549586|NCT02583048|DRUG|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
219549587|NCT02583048|DRUG|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
219549588|NCT02155257|DRUG|Modafinil|
219549589|NCT02155257|DRUG|Gabapentin|
219549590|NCT02155257|DRUG|Placebo|
219549591|NCT05492292|DIAGNOSTIC_TEST|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
219549592|NCT06113549|PROCEDURE|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
219549593|NCT06113549|PROCEDURE|Knee Prosthesis|A total or unicompartmental knee prosthesis
218949696|NCT06306872|DRUG|Sequence A ABSK-011|Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
218949697|NCT06306872|DRUG|Sequence B ABSK-011|Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
218949698|NCT03618290|DIAGNOSTIC_TEST|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
218949699|NCT04455490|OTHER|Self-control|We compared relevant scores of patients before and after surgery
218949700|NCT05807165|RADIATION|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
218949701|NCT05807165|RADIATION|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"* The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]"
218949702|NCT04395950|DRUG|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
218949703|NCT04395950|DRUG|Placebo|Placebo two tablets daily in the morning for 6 weeks
218949704|NCT02121665|DRUG|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
218949705|NCT02121665|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
218949706|NCT04669418|DIAGNOSTIC_TEST|RNA expression signature|Whole transcriptome profiling using RNA sequencing
218949707|NCT04453553|DIAGNOSTIC_TEST|Q16 testing|Nasal swab tested on a rapid near patient device
218949708|NCT04453553|DIAGNOSTIC_TEST|Nasopharyngeal swab and main laboratory|Standard of care testing
218949709|NCT00097149|PROCEDURE|Systematic pediatric care|
218949710|NCT03233880|DRUG|Azithromycin 1gm|Azithromicin 1 gm oral single dose
218949711|NCT03233880|OTHER|PLACEBO|placebo
218949712|NCT00470509|DRUG|Adalimumab|2 subcutaneous injections on day 0 and 7
218949713|NCT00470509|DRUG|Placebos|2 subcutaneous injections on day 0 and 7
218949714|NCT00225264|DRUG|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
218949715|NCT00225264|DRUG|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
218949716|NCT02991664|OTHER|Equia Forte|Glass ionomer restorative system
218949717|NCT02991664|OTHER|G-aenial Posterior|Micro hybrid composite resin
218949718|NCT00093665|DRUG|cisplatin|
218949719|NCT00093665|DRUG|fluorouracil|
218949720|NCT00093665|RADIATION|radiation therapy|
219636964|NCT01838564|OTHER|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
219636965|NCT01838564|OTHER|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
219636966|NCT03484663|DEVICE|central venous catheter (small catheter drainage)|Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
219636967|NCT03485807|BEHAVIORAL|Mindfulness Training (MT)|2 week SmartPhone-based mindfulness training
219636968|NCT03485807|BEHAVIORAL|Active Coping Training (CT)|2 week SmartPhone-based structurally equivalent coping training
219636969|NCT02547415|OTHER|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~* Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~* Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
219636970|NCT04017507|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
219636971|NCT04017507|DEVICE|Side-to-side electric toothbrush|Side-to-side electric toothbrush used twice daily
219636972|NCT04017507|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
219636973|NCT03573557|DEVICE|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
219636974|NCT03573557|DEVICE|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
219636975|NCT03573557|DEVICE|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
219636976|NCT03508726|DRUG|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
219636977|NCT00924495|DEVICE|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
219636978|NCT05321238|OTHER|High agency and immediate threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
219636979|NCT05321238|OTHER|High agency and distant threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
218949721|NCT05513118|DIAGNOSTIC_TEST|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
218949722|NCT04546828|DRUG|Gemcitabine, Cisplatin, and Nab-Paclitaxe|"* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days ."
218949723|NCT05735210|DEVICE|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
218949724|NCT01920646|OTHER|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
218949725|NCT05373056|BEHAVIORAL|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
218949726|NCT05373056|BEHAVIORAL|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
218949727|NCT03154892|PROCEDURE|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
218949728|NCT03154892|PROCEDURE|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
218949729|NCT00936728|OTHER|therapeutic nutritional supplementation|Given orally
218949730|NCT00936728|DIETARY_SUPPLEMENT|white wine|Given orally
218949731|NCT00936728|OTHER|questionnaire administration|Ancillary studies
218949732|NCT03964558|DRUG|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
218949733|NCT02342418|DRUG|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
218949734|NCT04763681|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
218949735|NCT05163015|OTHER|Data collection|Description: quality of life assessment
218949736|NCT00428584|DRUG|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
218949737|NCT00428584|DRUG|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
218949738|NCT03540719|PROCEDURE|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
218949739|NCT03199755|DRUG|ACT|Current approved drug for treating malaria
218949740|NCT03199755|DRUG|DLA1|Experimental drug treatment, single dose.
218949741|NCT03199755|DRUG|DLA2|Experimental drug treatment, doubled the dose of DLA1.
218949742|NCT00200343|DRUG|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
218949743|NCT00200343|DRUG|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
218949744|NCT00200343|DRUG|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
218949745|NCT05705089|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
218949746|NCT05705089|DRUG|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
218949747|NCT04320758|OTHER|conventional preparation design|chamfer finish line
218949748|NCT04320758|OTHER|biologically oriented preparation technique|shoulder less preparation design
218949749|NCT03619967|DEVICE|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
219549594|NCT03997890|PROCEDURE|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
219549595|NCT06266741|DIAGNOSTIC_TEST|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
219549596|NCT04889365|DIAGNOSTIC_TEST|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
218949750|NCT06267378|OTHER|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
219054848|NCT00364780|DRUG|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
219054849|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
219054850|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
219054851|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
219054852|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
219054853|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
219054854|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
219054855|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
219054856|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
219054857|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
219054858|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
219054859|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
219054860|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
219366079|NCT04911010|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
219636980|NCT05321238|OTHER|Low agency and immediate threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
219054861|NCT03580603|OTHER|Visualization tool|Visual representation of past microbiological culture data
219054862|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
219054863|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
219054864|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
219054865|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
219054866|NCT00437034|BIOLOGICAL|aflibercept|Given IV
219054867|NCT06804603|DRUG|Tradipitant|Oral capsule
219054868|NCT06804603|DRUG|Placebo|Oral capsule
219054869|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
219054870|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
219054871|NCT01486017|DRUG|ASP015K|oral
219054872|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
219054873|NCT03273036|DRUG|Placebos|no injected agent
219054874|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
219054875|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
219054876|NCT01910064|DRUG|GK530G|
219054877|NCT03072212|OTHER|Observational study|No intervention
219054878|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
219054879|NCT01221974|DEVICE|Essure Micro Insert|
219366080|NCT02772757|BEHAVIORAL|standard hearing aid fitting|standard hearing aid, face-to-face fitting
219366081|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using average RECDs
219366082|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using measured RECDs
219366083|NCT00464204|DRUG|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
219054880|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
218949751|NCT06086197|DRUG|Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin|"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."
218949752|NCT00427115|BEHAVIORAL|Multimodal exercise and psychosocial program|
218949753|NCT01348477|PROCEDURE|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
218949754|NCT00196846|DRUG|Goserelin|
218949755|NCT01175681|PROCEDURE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
218949756|NCT02158429|OTHER|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
218949757|NCT03002090|DIETARY_SUPPLEMENT|Iron trained|"1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
218949758|NCT03002090|DIETARY_SUPPLEMENT|Iron Untrained|1\. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
218949759|NCT03002090|DIETARY_SUPPLEMENT|BZKL Trained|"1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
218949760|NCT03002090|DIETARY_SUPPLEMENT|BZKL Untrained|1\. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
219054881|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
219054882|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
218949761|NCT03002090|DIETARY_SUPPLEMENT|Placebo Trained|1\. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
219054883|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
218949762|NCT03002090|DIETARY_SUPPLEMENT|Placebo Untrained|No intervention
218949763|NCT04424277|OTHER|diaphragm ultrasound|respiratory loading
218949764|NCT04926402|OTHER|Kangaroo Care Education Program|It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
218949765|NCT02065388|BEHAVIORAL|Standard of care dosing for warfarin|
218949766|NCT02065388|GENETIC|Genotype-guided dosingTaiwan algorithm for warfarin|
219054884|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
219054885|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
218949767|NCT02065388|GENETIC|Genotype-guided dosing IWPC algorithm for warfarin|
218949768|NCT02285062|DRUG|lenalidomide|
218949769|NCT02285062|DRUG|Placebo|
218949770|NCT02285062|DRUG|Rituximab|
218949771|NCT02285062|DRUG|Cyclophosphamide|
218949772|NCT02285062|DRUG|Doxorubicin|
218949773|NCT02285062|DRUG|prednisone|
218949774|NCT02285062|DRUG|vincristine|
218949775|NCT03714269|OTHER|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
219054886|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
219054887|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
219054888|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
219549597|NCT04889365|DIAGNOSTIC_TEST|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
218949776|NCT03714269|OTHER|measurement evaluated with an 2D ultrasound|"* simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
218949777|NCT03714269|OTHER|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
218949778|NCT00256971|PROCEDURE|meniscectomy|
218949779|NCT01557634|PROCEDURE|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
218949780|NCT04033588|DEVICE|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
218949781|NCT00766350|DRUG|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
218949782|NCT00766350|DRUG|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
219054889|NCT03053895|PROCEDURE|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
219636981|NCT05321238|OTHER|Low agency and distant threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
218949783|NCT04495608|DRUG|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
218949784|NCT04495608|DRUG|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
218949785|NCT04986956|DIETARY_SUPPLEMENT|Whole coffee cherry extract|200mg WCCE
218949786|NCT04986956|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to WCCE
218949787|NCT03041129|DIAGNOSTIC_TEST|oral glucose tolerance test|6 hours OGTT
218949788|NCT03041129|DIAGNOSTIC_TEST|MRI of liver|MRI of the liver and use of DIXON method
218949789|NCT02323100|DRUG|Ravicti low dose|8 am, 4pm and midnight
218949790|NCT02323100|DRUG|Ravicti high dose|8 am, 4pm and midnight
218949791|NCT02323100|DRUG|Placebo|8 am, 4pm and midnight
218949792|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
218949793|NCT01947855|DRUG|Empagliflozin|Empagliflozin low dose
218949794|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
218949795|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
218949796|NCT01947855|DRUG|Empagliflozin|Empagliflozin high dose tablet once daily
218949797|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
219054890|NCT03053895|PROCEDURE|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
219636982|NCT04544202|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
219636983|NCT04544202|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
219636984|NCT04544202|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
219636985|NCT00765518|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
219636986|NCT00765518|OTHER|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
219636987|NCT00003446|DRUG|fluorouracil|
219636988|NCT00003446|DRUG|leucovorin calcium|
219636989|NCT00003446|DRUG|trimetrexate glucuronate|
219636990|NCT03617614|BEHAVIORAL|Collaborative Care Model|"Trained care managers (CM) work collaboratively with patients, caregivers, and primary care providers to provide education, care navigation and behavioral activation. The latter includes a stepped psychotherapy intervention called ENGAGE, that focuses on reward exposure engagement in meaningful, rewarding activities for patients. Patients (home) visits are delivered over a period of 6 to 16 weeks. Progress is assessed with standardized measures for depression (PHQ-9), anxiety (GAD-7) and functioning (WHO-DAS). Furthermore, patients are presented by the CM at Systematic Case Review meetings where an integrated team of medical, psychiatric and allied health professionals work collaboratively to review the patient's goals and treatment to formulate a care plan and recommendations."
219636991|NCT03617614|BEHAVIORAL|Mood Consultation|A meeting with a psychiatrist to do assessment, provide education and make recommendations regarding the care of the patient for the Primary Care Provider.
218949798|NCT02595645|GENETIC|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
218949799|NCT02727530|OTHER|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
219054891|NCT02002494|OTHER|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
218949800|NCT02727530|OTHER|ADVICES|Advices for parents to improve the management of infant colic
218949801|NCT06255678|DIAGNOSTIC_TEST|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
219054892|NCT00963690|DEVICE|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
219054893|NCT00963690|PROCEDURE|Standard compression|Use standard compression to achieve hemostasis
219054894|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
219054895|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
219054896|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
219054897|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
219054898|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
218949802|NCT02777320|DRUG|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
218949803|NCT02777320|DRUG|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
218949804|NCT04796181|DEVICE|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
218949805|NCT02885467|PROCEDURE|Total knee arthroplasty with Saphenous nerve burial|
218949806|NCT02885467|PROCEDURE|Standard total knee arthroplasty|
218949807|NCT00886652|OTHER|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
218949808|NCT04136847|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
218949809|NCT03478436|DRUG|Doxycycline|Doxycycline 40 mg capsules
218949810|NCT04105478|PROCEDURE|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
218949811|NCT04195776|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
218949812|NCT05828641|PROCEDURE|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
219366084|NCT00464204|DRUG|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
218949813|NCT05828641|PROCEDURE|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
218949814|NCT02102373|DEVICE|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
218949815|NCT00763503|DRUG|CD 2027|3µg/g Oily Spray
219054899|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
219054900|NCT04103528|OTHER|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
219054901|NCT04103528|OTHER|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
219054902|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
219054903|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
219054904|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
219054905|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
219054906|NCT04648930|DRUG|Xolair|There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
219054907|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
219054908|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
219366085|NCT00384241|BEHAVIORAL|Induced Stress|Participation in an active coping task by playing a video game against another participant.
219366086|NCT00384241|PROCEDURE|Buccal Swab|One Buccal swab collected from each parent
218949816|NCT02665403|OTHER|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
218949817|NCT02665403|OTHER|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
218949818|NCT06363305|DIETARY_SUPPLEMENT|Dietary capsules|Daily doses of dietary capsaicin or placebo in capsule form
218949819|NCT00821509|BEHAVIORAL|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
218949820|NCT00821509|BEHAVIORAL|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
218949821|NCT02880696|BEHAVIORAL|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
219360006|NCT04153084|DRUG|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
218949822|NCT02880696|BEHAVIORAL|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
218949823|NCT02880696|DEVICE|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
218949824|NCT00533754|PROCEDURE|drawing blood|
218949825|NCT04972643|DIETARY_SUPPLEMENT|EPA|EPA 2000mg Soft capsules
218949826|NCT04972643|DIETARY_SUPPLEMENT|DHA|DHA 2000mg Soft capsules
218949827|NCT04972643|DIETARY_SUPPLEMENT|Placebo|Placebo Soft capsules
218949828|NCT00473980|DRUG|Indomethacin, celecoxib, esomeprazole|
218949829|NCT04628377|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
218949830|NCT05712486|OTHER|High force hip Lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.
218949831|NCT05712486|OTHER|Placebo force hip lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
218949832|NCT04049682|BEHAVIORAL|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
218949833|NCT03633877|DEVICE|DuraporeTM and Hy-Tape®|Medical tapes
218949834|NCT03104816|DRUG|Acetaminophen IV Soln 10 MG/ML|
218949835|NCT03104816|DRUG|Acetaminophen|
218949836|NCT03104816|DRUG|Hydromorphone|
218949837|NCT01997112|DRUG|Paracetamol|
218949838|NCT01997112|DRUG|Placebo oral capsule|
218949839|NCT02550769|PROCEDURE|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
218949840|NCT02550769|PROCEDURE|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
218949841|NCT00150904|PROCEDURE|venous blood puncture|
218949842|NCT04064216|PROCEDURE|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
219549598|NCT00850551|OTHER|Early Intervention|Twice a week home spirometry and symptom assessment
218949843|NCT04711161|DRUG|GRN-300|A salt-inducible kinase (SIK) inhibitor
218949844|NCT04711161|DRUG|Paclitaxel|Microtubule inhibitor
219360007|NCT03334084|DRUG|ARGX-113|intravenous or subcutaneous administration
219549599|NCT04408924|DRUG|Abemaciclib|Administered orally
219549600|NCT04842019|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
218949845|NCT01055067|DRUG|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
218949846|NCT06226857|DRUG|Cetuximab|FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles
218949847|NCT00022646|DRUG|gemcitabine hydrochloride|
218949848|NCT00022646|DRUG|pemetrexed disodium|
218949849|NCT04349904|DIAGNOSTIC_TEST|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
218949850|NCT00538083|OTHER|Chocolate|74 grams of single dose solid dark chocolate versus placebo
218949851|NCT00538083|OTHER|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
218949852|NCT00538083|OTHER|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
219054909|NCT06805903|OTHER|TRansanal Irrigation Adherence scaLe|new trans-anal irrigation self-assessment questionnaire in French
219636992|NCT00741676|PROCEDURE|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3\~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
219636993|NCT00741676|PROCEDURE|open distal gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
219054910|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
219054911|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
219054912|NCT03876730|OTHER|ICF CP Core Set|Core set
219636994|NCT04134429|DEVICE|Everion|The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
219636995|NCT06274073|PROCEDURE|Dorsal digital block|Dorsal regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedure mentioned are compared)
219636996|NCT06274073|PROCEDURE|Palmar digital block|Palmar regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedures mentioned are compared)
219636997|NCT03578796|DIAGNOSTIC_TEST|ECAS-N|assessing ALS-specific cognitive impairment
219636998|NCT03578796|DIAGNOSTIC_TEST|MoCA|assessing cognitive impairment
219636999|NCT03578796|DIAGNOSTIC_TEST|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
219637000|NCT03578796|OTHER|Questionnaire|Questions related to work situation and car driving
219637001|NCT00465296|DRUG|rosiglitazone|
219637002|NCT00875108|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
219637003|NCT01515865|DRUG|Midodrine HCl|dose at subject's current dose level
219637004|NCT01515865|DRUG|Placebo|single dose of matching placebo
219054913|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
219054914|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
219054915|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
219054916|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
219054917|NCT02637843|DEVICE|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
219054918|NCT00286416|DRUG|omalizumab (Xolair)|
219054919|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
219054920|NCT03069027|DRUG|saline adrenaline|
219637005|NCT06158984|DEVICE|IPL|Intense pulse light (IPL) therapy is used for the treatment of drug-related dry eye in glaucoma patients.
219637006|NCT05170152|PROCEDURE|ultrasonography-guided injection|ultrasonography-guided injection
218949853|NCT04643600|DRUG|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
219054921|NCT03069027|DRUG|Xylocaine, adrenaline|
219054922|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
219054923|NCT03640065|DRUG|freeze-dried probiotic sachets|"* The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants."
219054924|NCT03640065|DIETARY_SUPPLEMENT|fermented dairy product ( yogurt)|"* The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
219054925|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
219054926|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
219054927|NCT06184334|DRUG|Solfenacin|pills taken once day
219054928|NCT06184334|DRUG|Mirabegron|pills taken once day
219054929|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
219054930|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
219054931|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
219054932|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
219054933|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
219054934|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
219054935|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
219054936|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
219054937|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
219549601|NCT06332690|DEVICE|dexamethasone implant|Intravitreal dexamethasone implant (Dex) slowly releases steroids into the vitreous over a period of up to 6 months. Dex 0.7 mg (Ozurdex™; Allergan, Irvine, CA, USA) has been used to reduce ME in patients with DR and RVO and its efficacy in terms of best corrected visual acuity (BCVA) improvement and central macular thickness (CMT) reduction has been demonstrated in many different studies.
219549602|NCT05440968|OTHER|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
219549603|NCT05440968|OTHER|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
219549604|NCT02385760|DRUG|CTX-4430|
219054938|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
219054939|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
219054940|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
219054941|NCT02803697|OTHER|Patients|
219054942|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
219054943|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
219054944|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
219054945|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
219054946|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
219054947|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
219054948|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
219549605|NCT02385760|DRUG|Placebo|
219549606|NCT01273467|DRUG|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
219549607|NCT01273467|DRUG|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
219549608|NCT02578641|BIOLOGICAL|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
219549609|NCT02578641|DRUG|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
218949854|NCT05857280|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
218949855|NCT03302364|DRUG|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
219637007|NCT05170152|PROCEDURE|pullae A1 release|ultrasonography-guided pullae A1 release
219054949|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
219054950|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
219054951|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
219549610|NCT03184649|DRUG|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
218949856|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
218949857|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
218949858|NCT03777462|DRUG|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
218949859|NCT04320030|DRUG|[18F]-DPA-714 PET/CT scan|Pretherapeutic \[18F\]-DPA-714 PET/CT scan
218949860|NCT00156156|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
218949861|NCT00156156|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
219054952|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
219054953|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
219054954|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
219054955|NCT06182267|DRUG|L Arginine|toothpaste
219054956|NCT06182267|DRUG|Sodium Fluoride|toothpaste
219549611|NCT03184649|DRUG|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
219549612|NCT03184649|DIETARY_SUPPLEMENT|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
219549613|NCT03100357|OTHER|Thyroidectomy|Thyroid surgery for benign nodular goiter
219549614|NCT06628089|OTHER|Questionnaire|A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
219549615|NCT04510792|OTHER|No intervention|No intervention
219549616|NCT01444196|DRUG|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
219549617|NCT04027023|DRUG|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
219549618|NCT05376423|BIOLOGICAL|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
219549619|NCT02963350|DRUG|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
219549620|NCT01903057|DRUG|azithromycin|
219549621|NCT01903057|DRUG|ivermectin|
219549622|NCT01903057|DRUG|albendazole|
219549623|NCT01903057|DRUG|placebo|
219549624|NCT01710358|DRUG|Adalimumab|Administered SC
219549625|NCT01710358|DRUG|Baricitinib|Administered orally
219549626|NCT01710358|DRUG|Methotrexate|Administered orally
219549627|NCT01710358|DRUG|Adalimumab Placebo|Adalimumab placebo administered SC.
219549628|NCT01710358|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally.
219549629|NCT03563794|DRUG|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
218949862|NCT03602560|DRUG|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
218949863|NCT03602560|DRUG|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
218949864|NCT03602560|DRUG|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
218949865|NCT06294743|PROCEDURE|Posterior tibial nerve neuroprolotherapy|Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
218949866|NCT06294743|DRUG|Acetaminophen 500Mg Tab|Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
218949867|NCT05354453|DRUG|BI 1839100|BI 1839100
218949868|NCT05354453|DRUG|Placebo|Placebo
218949869|NCT05354453|DRUG|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
218949870|NCT00222131|DRUG|Esomeprazole|Esomeprazole 40 mg QD
218949871|NCT00222131|OTHER|Placebo|Placebo
218949872|NCT03470727|DEVICE|Citrate dialysate|Change form acetate to citrate dialysate
218949873|NCT06131528|OTHER|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
218949874|NCT06131528|OTHER|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
218949875|NCT03387488|DEVICE|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
218949876|NCT00164476|BEHAVIORAL|Preventive Services Prevention Kit|
218949877|NCT00164476|BEHAVIORAL|peer mentors (control group)|
218949878|NCT05157828|OTHER|No intervention|No intervention
218949879|NCT06021860|DRUG|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
218949880|NCT00534599|DRUG|Placebo|oral
218949881|NCT00534599|DRUG|quetiapine fumarate XR|oral
218949882|NCT00645450|DRUG|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
218949883|NCT00645450|DRUG|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
218949884|NCT04822805|DRUG|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
218949885|NCT01588470|DRUG|pioglitazone|45 mg per day for 6 months
218949886|NCT04686058|DRUG|Propofol 10 MG/ML Injection|
218949887|NCT04686058|DRUG|Midazolam injection|
218949888|NCT04686058|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
218949889|NCT04686058|DEVICE|target controlled infusion pump|
218949890|NCT04686058|DEVICE|patient-controlled sedation pump|
218949891|NCT05918198|DRUG|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)"
219054957|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
219054958|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
219054959|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
219054960|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
219054961|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
219054962|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
219054963|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
219054964|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
219054965|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
219366087|NCT04219228|DIAGNOSTIC_TEST|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
218949892|NCT03571698|DEVICE|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
218949893|NCT03645434|DRUG|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
219054966|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
219054967|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
219054968|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
219054969|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
219054970|NCT03333486|DRUG|Cyclophosphamide|Given IV
219054971|NCT03333486|DRUG|Fludarabine Phosphate|Given IV
219054972|NCT03333486|OTHER|Laboratory Biomarker Analysis|Correlative studies
219637008|NCT04689373|DIAGNOSTIC_TEST|VAS Score|"The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.~The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills."
219637009|NCT04065971|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
219637010|NCT04065971|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
218949894|NCT03645434|DRUG|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
218949895|NCT04796064|OTHER|low-intensity aerobic training|"A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~\- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes."
218949896|NCT00415298|DRUG|DACH polymer platinate AP5346|
218949897|NCT00415298|DRUG|oxaliplatin|
218949898|NCT00415298|GENETIC|gene expression analysis|
218949899|NCT00415298|OTHER|immunohistochemistry staining method|
219054973|NCT03333486|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
219054974|NCT03333486|RADIATION|Total-Body Irradiation|Undergo TBI
219054975|NCT05443425|DRUG|Cholestyramine|Given PO
219054976|NCT05443425|DRUG|Leflunomide|Given PO
219054977|NCT05443425|DRUG|Steroid Therapy|Given steroid therapy
219054978|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
219054979|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
219366088|NCT04219228|DEVICE|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
219366089|NCT02848937|DEVICE|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca\_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
219366090|NCT02848937|DEVICE|Bath with citrate and Ca_eq|bath with citrate and Ca\_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
219366091|NCT04278807|PROCEDURE|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
219366092|NCT03869814|OTHER|Blood Draw|Blood Draw
219366093|NCT05707923|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
219366094|NCT00159094|DRUG|Doxil and Vinorelbine|
219366095|NCT05431296|DEVICE|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
219366096|NCT02690909|DEVICE|Redy™ Renal Denervation System|Renal Denervation System
218949900|NCT00415298|OTHER|pharmacological study|
219637011|NCT03836183|DIAGNOSTIC_TEST|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
219637012|NCT05331443|DIAGNOSTIC_TEST|Reactive hyperemia-peripheral arterial tonometry Index (RHI )|RHI was assessed by RH-PAT using the EndoPAT2000 system .
219637013|NCT04953689|BEHAVIORAL|Conscientiousness Coach|Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
219637014|NCT03644823|DRUG|Atezolizumab|PDL1- inhibitor
219637015|NCT03644823|RADIATION|Radiotherapy|6 Gy x 3
219637016|NCT06557629|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of gastric residual volume
219637017|NCT03520777|OTHER|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
218949901|NCT00415298|PROCEDURE|biopsy|
218949902|NCT04437121|OTHER|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
218949903|NCT00770380|BEHAVIORAL|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
218949904|NCT00770380|OTHER|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
218949905|NCT04646564|DRUG|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
218949906|NCT04646564|RADIATION|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
218949907|NCT00833664|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
218949908|NCT00833664|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
218949909|NCT06946199|BIOLOGICAL|cizutamig|Cizutamig will be dosed according to the assigned group.
218949910|NCT05197569|OTHER|thyme oil|Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
218949911|NCT00105768|BEHAVIORAL|Advisor-Teller Money Management-Substance Abuse Counselling|
218949912|NCT01454310|DEVICE|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
218949913|NCT01454310|DEVICE|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
218949914|NCT05827471|DIAGNOSTIC_TEST|Diagnosis of colon cancer|Clinical diagnosis results
218949915|NCT03453372|DEVICE|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
218949916|NCT03453372|OTHER|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
218949917|NCT01599936|BIOLOGICAL|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
218949918|NCT03995251|DRUG|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
218949919|NCT03995251|DRUG|Standard Medical Treatment|Standard Medical Treatment
218949920|NCT03995251|OTHER|Exercise|Exercise
219054980|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
219637018|NCT02417142|DRUG|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
219637019|NCT02417142|DRUG|Placebo|Placebo SQ 1x/week for 24 weeks.
218949921|NCT00336856|DRUG|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
219637020|NCT00204217|DEVICE|endotracheal intubation|
218949922|NCT00336856|DRUG|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
218949923|NCT04113369|DEVICE|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
218949924|NCT04113369|PROCEDURE|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
218949925|NCT04113369|DEVICE|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
219054981|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
219549630|NCT03563794|DRUG|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
219549631|NCT06038318|BEHAVIORAL|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
219549632|NCT06038318|BEHAVIORAL|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
219637021|NCT05353842|BEHAVIORAL|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
219637022|NCT00983060|DRUG|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
219637023|NCT00983060|DRUG|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
219637024|NCT01168466|BEHAVIORAL|QEEG-based Neurofeedback Training|EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
219637025|NCT03296410|BIOLOGICAL|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
219637026|NCT03296410|BIOLOGICAL|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
219637027|NCT03296410|BIOLOGICAL|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
219637028|NCT03296410|BIOLOGICAL|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
219637029|NCT03296410|BIOLOGICAL|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
219637030|NCT00410735|DRUG|Placebo|0 mg BID for 12 weeks
219637031|NCT00410735|DRUG|Pranlukast hydrate|225 mg BID for 12 weeks
219637032|NCT03443362|PROCEDURE|Punch Biopsy|A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
219549633|NCT06038318|BEHAVIORAL|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
219549634|NCT04385043|OTHER|plasma hyperimmune|patients will receive this as add on therapy
219549635|NCT04385043|DRUG|standard therapy|patients will receive only standard therapy for Covid-19 infection
219549636|NCT00479531|DEVICE|AirCast Sequential Compression Device|
219549637|NCT02889393|DRUG|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
219637033|NCT03443362|PROCEDURE|Blood sampling|Blood sampling
219637034|NCT03645395|DRUG|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
218949926|NCT05049083|DRUG|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
218949927|NCT05049083|DRUG|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
218949928|NCT00842907|DRUG|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
219054982|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
218949929|NCT00842907|DRUG|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
218949930|NCT01452542|DRUG|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
218949931|NCT01452542|DRUG|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
218949932|NCT01850576|BEHAVIORAL|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
218949933|NCT00125346|DRUG|Tobramycin Inhalation Powder|
218949934|NCT03338959|BIOLOGICAL|Pembrolizumab|Given IV
219637035|NCT02694926|OTHER|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
218949935|NCT03338959|RADIATION|Radiation Therapy|Undergo radiation therapy
218949936|NCT05461378|DRUG|Evusheld|Participants who have received or plan to receive Evusheld.
218949937|NCT05167383|DEVICE|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
218949938|NCT05167383|BEHAVIORAL|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
218949939|NCT05832775|BIOLOGICAL|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
218949940|NCT05832775|BIOLOGICAL|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
218949941|NCT02955251|DRUG|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
218949942|NCT02955251|DRUG|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
218949943|NCT06210932|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum videos|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
218949944|NCT04514783|DEVICE|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
218949945|NCT04514783|OTHER|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
218949946|NCT03086564|BIOLOGICAL|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
218949947|NCT03086564|PROCEDURE|TACE|TACE solely in the first day of a clinical course.
218949948|NCT05883826|BEHAVIORAL|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
218949949|NCT03938753|DEVICE|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
218949950|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
219549638|NCT02889393|OTHER|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
219549639|NCT03755180|OTHER|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
219549640|NCT03755180|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
219549641|NCT05740748|DRUG|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
219549642|NCT05740748|DRUG|Placebo|placebo sc q4wks for 20 weeks
218949951|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
218949952|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
218949953|NCT00476671|PROCEDURE|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
218949954|NCT04601454|DEVICE|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
219054983|NCT04672005|DRUG|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
219054984|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
219054985|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
219054986|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
219054987|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
219054988|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
219054989|NCT05940675|BEHAVIORAL|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
219054990|NCT05940675|BEHAVIORAL|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
219054991|NCT05940675|BEHAVIORAL|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
218949955|NCT01670578|BIOLOGICAL|PRP|
219054992|NCT05940675|BEHAVIORAL|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
219054993|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
218949956|NCT01670578|DEVICE|Hyaluronic acid|
219054994|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
219054995|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
219054996|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
219054997|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
219637036|NCT04001296|BEHAVIORAL|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
219366097|NCT05728788|DRUG|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
219366098|NCT03176316|DRUG|Naloxone|Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
219637037|NCT06448507|DEVICE|INJEX [Needle less anesthesia]|already described
219637038|NCT06448507|DEVICE|Syringe Needle [ Traditional technique]|described
219637039|NCT05177276|DRUG|Selinexor|
218949957|NCT00912665|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
218949958|NCT00912665|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
218949959|NCT00912665|OTHER|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
218949960|NCT00912665|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
218949961|NCT01650012|DRUG|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
219637040|NCT05177276|DRUG|Irinotecan|
219637041|NCT02663063|DEVICE|SSP treatment|SSP treatment 5 times a week
219054998|NCT06983262|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
218949962|NCT01650012|DRUG|Placebo|Placebo
218949963|NCT06086262|DEVICE|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
218949964|NCT04162782|PROCEDURE|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
218949965|NCT04193696|DRUG|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
218949966|NCT01436617|OTHER|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
218949967|NCT00603486|DEVICE|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
218949968|NCT01491438|PROCEDURE|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
218949969|NCT01491438|PROCEDURE|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
218949970|NCT00874939|DRUG|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
219360008|NCT05974982|BIOLOGICAL|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
219637042|NCT06534619|PROCEDURE|Electrotherapy|Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.
219637043|NCT06534619|PROCEDURE|Rocabado exercises|6 Rocabado exercises 6 Reps each.
219637044|NCT06534619|PROCEDURE|Maitland oscillatory mobilizations|"Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides"
218949971|NCT00874939|DRUG|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
218949972|NCT00874939|DRUG|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
218949973|NCT00874939|DRUG|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
218949974|NCT00874939|DRUG|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
218949975|NCT01313741|DEVICE|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
218949976|NCT03560700|DIETARY_SUPPLEMENT|lactobacillus probiotic strain|Approved Dietary supplement
218949977|NCT03560700|OTHER|placebo|placebo comparator
218949978|NCT02204124|DEVICE|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
218949979|NCT02204124|DEVICE|Standard of care scissors, ligatures, clips, and sutures|
218949980|NCT02452788|OTHER|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
218949981|NCT00003590|DRUG|hydroxyurea|20 mg/kg/day PO
218949982|NCT00511394|DRUG|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
219637045|NCT02910206|DRUG|Etomidate|etomidate is given intravenously
219637046|NCT02910206|DRUG|propofol|propofol is given intravenously
219637047|NCT02910206|DRUG|Sufentanil|sufentanil is given intravenously
219637048|NCT02910206|DRUG|Cisatracurium|Cisatracurium is given intravenously
219637049|NCT00259948|PROCEDURE|Aerobic exercise training|
219637050|NCT04666701|DRUG|Escócia association|Escócia association tablet
219637051|NCT04666701|OTHER|Placebo Ketorolac|Placebo Ketorolac tablet
219637052|NCT04666701|OTHER|Placebo Scopolamine|Placebo Scopolamine dragee
219637053|NCT04666701|DRUG|Ketorolac Tromethamine|Ketorolac tablet
218949983|NCT00511394|DRUG|Normal Saline|Infusion of 100 mL of Normal Saline
218949984|NCT02862756|OTHER|diffusion-weighted MRI and clinical examination|
218949985|NCT05014061|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
218949986|NCT00883688|DRUG|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
218949987|NCT00883688|DRUG|Lapatinib|Pills of 700 mg/m\^2/dose given orally 2 times each day.
218949988|NCT05006300|OTHER|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
218949989|NCT01656356|BIOLOGICAL|Avian Flu Vaccine|
218949990|NCT01656356|BIOLOGICAL|Placebo|
218949991|NCT05278351|DRUG|Tislelizumab Combined With Cetuximab and Irinotecan|Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan
218949992|NCT05278351|DRUG|Third-line regimens|Trifluridinetipiracil or Regorafenib or Fruquintinib
218949993|NCT00205270|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
218949994|NCT04732013|OTHER|No clinical intervention is planned; study is observational|No intervention
218949995|NCT00575341|DRUG|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
219637054|NCT04666701|DRUG|Scopolamine|Scopolamine dragee
218949996|NCT00575341|DRUG|placebo|placebo, oral, once daily
218949997|NCT03707028|DRUG|Rivoceranib|Film-coated tablet
218949998|NCT03707028|DRUG|Paclitaxel|Solution administered intravenously
218949999|NCT02974751|PROCEDURE|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
218950000|NCT01964040|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
218950001|NCT01413932|DRUG|HT-2157|QD oral dosing
218950002|NCT01413932|DRUG|Placebo|QD oral dosing
218950003|NCT03739229|BIOLOGICAL|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
218950004|NCT03739229|BIOLOGICAL|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
218950005|NCT02396160|DIETARY_SUPPLEMENT|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
218950006|NCT02396160|OTHER|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
218950007|NCT05999162|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
218950008|NCT04592718|BEHAVIORAL|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
218950009|NCT04592718|BEHAVIORAL|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
218950010|NCT03635580|OTHER|Negative control|Untreated-control group
219360009|NCT05974982|OTHER|Conventional therapy|Conventional therapy
219637055|NCT04666701|OTHER|Placebo Escócia association|Placebo Escócia association tablet
219637056|NCT05976269|DEVICE|Dry needling|Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
218950011|NCT01698307|OTHER|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
218950012|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
218950013|NCT01811667|DRUG|Sirolimus|
218950014|NCT06066229|OTHER|Questionnaire- Delphi method|Identify important evaluation criteria for lung transplant patients by rating each criterion
218950015|NCT05860270|DRUG|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
218950016|NCT05860270|DRUG|Placebo|Patients in the control group will receive placebo 2 capsules per day.
219360010|NCT00404521|DRUG|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
218950017|NCT00594425|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
218950018|NCT06089369|DRUG|Sintilimab (9 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
218950019|NCT06089369|DRUG|Sintilimab (18 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
218950020|NCT06089369|OTHER|Active surveillance|Active surveillance
218950021|NCT05532670|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
219366099|NCT02577263|OTHER|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
219637057|NCT05130541|BEHAVIORAL|Proning|Rotating on long axis 90 degrees every 30 minutes
219637058|NCT05130541|OTHER|Supportive Care|Usual Care
218950022|NCT03813368|PROCEDURE|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
218950023|NCT01122264|DRUG|Tadalafil|Administered orally for 24 weeks.
218950024|NCT01122264|DRUG|Sildenafil Citrate|Administered orally for 24 weeks.
218950025|NCT02965092|GENETIC|Second generation CAR-T cells|
218950026|NCT02085642|OTHER|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
219054999|NCT06983262|PROCEDURE|Lip repositioning surgery|Profound anaesthesia will be achieved. A marking pencil§ will be used to outline the apical, coronal, and lateral boundaries of the elliptical incision. The coronal boundary will be at the mucogingival junction and will be used as a reference point to mark the apical boundary at two times the amount of gingival display. The coronal and apical incisions will be parallel to each other, and the apical incision gradually angled downward to meet the coronal incision. A partial thickness dissection will be made. The epithelium will be excised, exposing the underlying connective tissue. The mucosal flap will be advanced and sutured at the mucogingival junction.
219055000|NCT06815432|GENETIC|15.GPC3-CAR T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 5x10\^6 DL2: 1x10\^7 DL3: 5x10\^7 DL4: 1x10\^8"
219055001|NCT06593704|OTHER|PROSPERA-program|"The PROSPERA-program consists of the following components:~1. Health care provider training and education about U-Prevent and cardiovascular risk communication.~2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation.~3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation."
219055002|NCT06986694|OTHER|Group A will receive Voodoo Flossing Technique along with aerobic and strengthening exercises & conventional physiotherapy protocol for Knee OA.|"Patient will sit or lie down comfortably with affected knee exposed and in extension. Start by wrapping voodoo floss band at the shin bone just below the knee joint with 50% tension in the band and 50% overlapping on each wrap by working your way up towards the thigh. Keep the flossing band on for at least 1-2 minutes and perform gentle knee movements to promote mobility.~* Knee flexion and extension in full range of motion in standing position 20-30 sec.~* Knee squats with/without support 20-30 sec.~* Abduction and Adduction 20-30 sec. Perform each exercise with 10-15 seconds of rest between each set. After completing ROM exercises, allow the knee to rest in comfortable position and then carefully unwrap the voodoo band from the knee joint. Also monitor the knee for any changes."
219366100|NCT01451619|DRUG|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
219366101|NCT01451619|DRUG|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
219637059|NCT06185179|DRUG|Metformin|Metformin will be distributed in 500mg pills.
218950027|NCT02085642|OTHER|Sham needle|Retractable needle with no skin puncture
218950028|NCT04269382|DEVICE|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
218950029|NCT00546598|DEVICE|Total hip replacement/arthroplasty|Hip replacement
219366102|NCT04566367|DIAGNOSTIC_TEST|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
219366103|NCT04039997|DEVICE|CPRMeter|teaching resuscitation with application of cpr feedback device
219637060|NCT06185179|OTHER|Placebo|Placebo will be distributed in pill form
219637061|NCT06248372|OTHER|Exercise|Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
218950030|NCT02341937|OTHER|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
219055003|NCT06986694|OTHER|Group B will receive aerobic and strength training and conventional physiotherapy protocol for knee OA only.|"Aerobic Exercises: Walking or Stationary Cycling 2 times a week for 4 weeks Walking: On flat surface/Treadmill~* 10 minutes warm-up, 30 minutes brisk walking, 5 minutes cool down. Cycling: Ergometer cycling~* 10 minutes warm-up, 30 minutes on moderate loading (75% of max. heart rate), 5 minutes cool down. Strengthening Exercises: Quadriceps, Hamstrings, Hip Abductors, Adductors and Calf Muscles Strengthening and Balance Training 2 times a week for 4 weeks.~* Hip Abduction in standing 8-10\*2 RM~* Hip Adduction in standing 8-10\*2 RM~* Knee Flexion and Extension in standing 10\*2 RM~* Knee Squats 8-10\*2 RM~* Sit/stand from chair 10\*2 RM~* Step up and down 10\*2 RM~* Heel raises 10\*2 RM~* Hip Bridges 10\*2 RM Conventional Exercise Program: 2 times per week for 4 weeks Heat Therapy Ultrasound Therapy~* Static Quads activation 10\*2 RM~* SLR 10\*2 RM~* VMO activation 10\*2 RM~* Knee to Chest 5\*2 RM~* Quadriceps, Hamstrings and Calf stretches 5\*2 RM"
219055004|NCT06987162|OTHER|Percussive Therapy|PT will be performed by the same researcher using a hand-held massage gun, tapping at a frequency of 30 Hz (rotational speed 1800 rpm/min) with a flat massage head. Each percussive massage session will last for 15 minutes. This frequency of 30 Hz is chosen based on its effectiveness for myofascial release and previous studies have indicated that a 15-minute duration of back massage is beneficial
219055005|NCT06987162|OTHER|Instrument-Assisted Soft Tissue Mobilization|The Graston group performed as IASTM during 4 weeks. After warmup session, Friction free oil or gel was used to facilitate the device to move over the skin. Gua Sha tools were used. The instrument was kept at 45°, moved over the skin from cranial to caudal for 40-120 Sec on the back, while patients were lying in the prone position.The mobilization with sweeping strokes followed by fanning strokes were applied over the Erector spinae, quadratus lumborum, scrolling the device on the muscle belly from the posterior fascia and sacrum.
219055006|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
218950031|NCT03112954|DRUG|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
218950032|NCT03112954|DRUG|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
219637062|NCT05702801|DEVICE|Stochastic Vibratory Stimulation (SVS)|Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
219637063|NCT00445172|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
219637064|NCT03867812|OTHER|SOBAR|SOBAR is a high protein nutrition bar optimized to delay gastric emptying
219637065|NCT03867812|OTHER|Control food|Chexmix (General Mills Inc.), Honey Nut Flavor
219637066|NCT03867812|OTHER|Full meal|Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
219637067|NCT02710812|PROCEDURE|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~1. A gross margin of at least 0.5 cm;~2. full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~3. determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
218950033|NCT05410951|DIAGNOSTIC_TEST|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
218950034|NCT05375773|OTHER|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
218950035|NCT03611842|OTHER|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
218950036|NCT00631761|OTHER|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
218950037|NCT00631761|OTHER|no intervention (usual resident activities)|usual activities
218950038|NCT05172479|DIAGNOSTIC_TEST|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
218950039|NCT05172479|DIAGNOSTIC_TEST|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
218950040|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
218950041|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
218950042|NCT05172479|DIAGNOSTIC_TEST|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
219366104|NCT04039997|OTHER|Manual chest compression|Manual chest compression
219637068|NCT04767555|PROCEDURE|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
219637069|NCT03507322|OTHER|Ultrasound texturization|Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
218950043|NCT04662827|DIETARY_SUPPLEMENT|Palmithylethanolamid|PEA 3x/d
218950044|NCT04662827|OTHER|placebo|placebo 3x/d
218950045|NCT01031420|DRUG|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
219637070|NCT02337439|BEHAVIORAL|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
219637071|NCT02337439|BEHAVIORAL|Active Control Training|Commercially available educational software
219637072|NCT02696538|OTHER|Functional Gait Assessment|Balance assessment
219637073|NCT02696538|OTHER|mini-Balance Evaluation Systems Test|Balance assessment
219637074|NCT02696538|OTHER|Berg Balance Scale|Balance assessment
219637075|NCT04150744|COMBINATION_PRODUCT|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
219637076|NCT06683326|DEVICE|ROKOKO smart-glove|ESD expert hands and fingers motion broadcasted by the ROKOKO smart-glove to trainees
219637077|NCT04606394|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Administration of Trelegy in all patients
219637078|NCT04606394|DRUG|Ventolin 90Mcg/Actuation Inhalation Aerosol|2 hours after the administration of Trelegy, administer Ventolin in all patients
219637079|NCT03397368|DIAGNOSTIC_TEST|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
219637080|NCT06968247|PROCEDURE|PROMise Model of Care|Patients will go for blood tests and be sent PROMs questionnaire prior to planned clinic appointments. The results of the blood tests and questionnaire will be reviewed by a physician. The physician will postpone patient's appointment if the patient is assessed as stable. Any physician-endorsed medication will be sent via a medication delivery service.
219637081|NCT06966219|OTHER|Intracytoplasmic sperm injection|• All patients will commence controlled ovarian hyperstimulation (COH) on day 2 or 3 of their menstrual cycle. The initial treatment will be a daily administration of either highly purified human menopausal gonadotropin (hMG) or recombinant FSH (rFSH, Gonal-F 150 IU, Merck Serono, S.P.A, Italy) administered subcutaneously and intramuscularly for a duration of 10-12 days. The treatment will be continued until the final oocyte maturation. The starting dosage will be tailored based on the patient's age, antral follicle count (AFC), body mass index (BMI), serum FSH and AMH levels on days 2-3, as well as the patient's previous response to COH.
219637082|NCT04545151|DRUG|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
219637083|NCT04545151|DRUG|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
218950046|NCT03956797|DEVICE|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
218950047|NCT05882721|DEVICE|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
218950048|NCT05694221|DRUG|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
218950049|NCT05694221|DRUG|Digoxin|Oral Administration
218950050|NCT05694221|DRUG|Metformin|Oral Administration
218950051|NCT02528721|DEVICE|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
218950052|NCT02368925|DEVICE|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
218950053|NCT00895011|DRUG|Placebo|One dose 30 minutes prior to initiation of sexual activity
218950054|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
218950055|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
218950056|NCT00312754|DRUG|Atazanavir|
218950057|NCT02617901|RADIATION|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
218950058|NCT05506605|DRUG|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
218950059|NCT03810729|DIAGNOSTIC_TEST|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
218950060|NCT03810729|DIAGNOSTIC_TEST|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
218950061|NCT02270853|DEVICE|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
218950062|NCT03085914|DRUG|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
218950063|NCT03085914|DRUG|Pembrolizumab|Pembrolizumab
218950064|NCT03085914|DRUG|Oxaliplatin|Oxaliplatin
218950065|NCT03085914|DRUG|Leucovorin|Leucovorin
218950066|NCT03085914|DRUG|5-Fluorouracil|5-Fluorouracil
218950067|NCT03085914|DRUG|Gemcitabine|Gemcitabine
218950068|NCT03085914|DRUG|nab-Paclitaxel|nab-Paclitaxel
218950069|NCT03085914|DRUG|Carboplatin|Carboplatin
218950070|NCT03085914|DRUG|Paclitaxel|Paclitaxel
218950071|NCT03085914|DRUG|Pemetrexed|Pemetrexed
218950072|NCT03085914|DRUG|Cyclophosphamide|Cyclophosphamide
218950073|NCT03085914|DRUG|Carboplatin|Carboplatin
219055007|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
219637084|NCT00066794|BIOLOGICAL|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
219637085|NCT00066794|BIOLOGICAL|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
218950074|NCT03085914|DRUG|Cisplatin|Cisplatin
218950075|NCT03085914|DRUG|5-Fluorouracil|5-FU
218950076|NCT03085914|DRUG|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
218950077|NCT01779518|DRUG|Sofosbuvir|
218950078|NCT01779518|DRUG|Ribavirin|
218950079|NCT01779518|DRUG|Pegylated Interferon|
218950080|NCT00049985|DRUG|Darbepoetin Alfa|
218950081|NCT02447237|OTHER|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
218950082|NCT02458937|OTHER|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
218950083|NCT02458937|OTHER|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
218950084|NCT02458937|OTHER|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
218950085|NCT03816540|DEVICE|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
218950086|NCT02766582|DRUG|Pembrolizumab|IV every 21 days at 200 mg
218950087|NCT02766582|DRUG|Carboplatin|IV every 21 days
218950088|NCT02766582|DRUG|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
218950089|NCT04319497|DEVICE|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
218950090|NCT04319497|DEVICE|Autorefraction|Five autorefraction measurements will be performed for all the patients included
218950091|NCT04319497|DEVICE|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
218950092|NCT02776618|PROCEDURE|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
218950093|NCT03126552|BIOLOGICAL|Necator americanus L3 larvae|50 Necator americanus L3 larvae
218950094|NCT00400036|BEHAVIORAL|Cod protein NCEP-diet|
218950095|NCT01106417|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
218950096|NCT01106417|DEVICE|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
218950097|NCT04232969|DRUG|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
218950098|NCT01252667|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
218950099|NCT01252667|DRUG|Clofarabine|Given IV
219637086|NCT00066794|DRUG|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
219637087|NCT00066794|DRUG|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
219637088|NCT00066794|DRUG|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
218950100|NCT01252667|DRUG|Cyclosporine|Given PO
218950101|NCT01252667|OTHER|Laboratory Biomarker Analysis|Correlative studies
219637089|NCT05984940|DEVICE|Ortho MTA cement|Ortho MTA has a fine granularity for only 2 microns. It penetrates into dental tubules and fuses itself to the surface where it is applied. In addition, it prevents micro-leakage by forming an interfacing layer of hydroxyapatite (Hap) between the OrthoMTA and the canal wall.
219637090|NCT05984940|DEVICE|GP and AH Plus sealer|AH Plus Sealer is a calcium silicate-based root canal sealer. Tricalcium Silicate interacts with body fluids to release calcium and hydroxide ions that promote hydroxyapatite (HA) formation.
219637091|NCT03216005|DEVICE|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
219637092|NCT03423173|BIOLOGICAL|TAK-003|TDV subcutaneous injection
219637093|NCT03423173|BIOLOGICAL|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
218950102|NCT01252667|DRUG|Mycophenolate Mofetil|Given PO
218950103|NCT01252667|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
218950104|NCT01252667|OTHER|Pharmacological Study|Optional correlative studies
218950105|NCT01252667|RADIATION|Total-Body Irradiation|Undergo TBI
218950106|NCT04644315|DRUG|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
218950107|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
218950108|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
218950109|NCT04403009|OTHER|no intervention|no intervention
218950110|NCT01127789|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
218950111|NCT04532580|DEVICE|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
218950112|NCT05247528|DRUG|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
218950113|NCT05247528|DRUG|Placebo|Placebo Comparator
218950114|NCT03014882|DRUG|L-Carnitine and N-acetyl cysteine|
218950115|NCT00443196|PROCEDURE|MiCK Assay|Physician determined treatment
218950116|NCT00331552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
218950117|NCT00331552|DRUG|cyclophosphamide|Given orally
218950118|NCT00331552|BIOLOGICAL|trastuzumab|Given IV
218950119|NCT01445548|DRUG|Sirolimus|
218950120|NCT00072527|DRUG|carboplatin|IV
218950121|NCT00072527|DRUG|cisplatin|IV
219055008|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
219055009|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
219366105|NCT04581720|DEVICE|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
219637094|NCT03229863|OTHER|Sweet Potatos|Plum Organics, Just Sweet Potato
219637095|NCT03229863|OTHER|Pears|Earth's Best, First Pears
218950122|NCT00072527|DRUG|etoposide|IV
218950123|NCT00072527|DRUG|irinotecan hydrochloride|IV
218950124|NCT00072527|RADIATION|radiation therapy|
218950125|NCT04085939|OTHER|Online survey|Anonymous survey using the online survey tool, JotForm
218950126|NCT00182585|PROCEDURE|computer-based HIV, STD & Hepatitis Education|
218950127|NCT00182585|PROCEDURE|educator-delivered HIV, STD and Hepatitis education|
218950128|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
218950129|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
218950130|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
218950131|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
218950132|NCT03611257|DIAGNOSTIC_TEST|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
218950133|NCT03611257|DIAGNOSTIC_TEST|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
218950134|NCT02204761|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
218950135|NCT02824406|DRUG|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
218950136|NCT03675906|OTHER|hypoalbuminemia|hypoalbuminemia and acute kidney injury
218950137|NCT01786070|DRUG|Budesonide|
218950138|NCT01786070|DRUG|placebo|
218950139|NCT06370403|OTHER|Cooling of the head and neck|Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects
218950140|NCT06370403|OTHER|Heating of the head and neck|Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
219366106|NCT01369121|DRUG|XERECEPT|BID dosing, subcutaneous for 1 year
219637096|NCT00693238|RADIATION|Low Risk Proton Radiation|
219637097|NCT00693238|RADIATION|Intermediate Risk Proton Radiation|
218950141|NCT05839158|OTHER|HFMT cell suspension|Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
218950142|NCT05839158|OTHER|Mupirocin ointment|the Minoxidil ointment is evenly applied to the control group surface.
218950143|NCT04119518|DEVICE|CSEM Pulse Watch|Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
218950144|NCT04232618|DIAGNOSTIC_TEST|Multi-biomarker point-of-care test|Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
218950145|NCT02815722|DRUG|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
218950146|NCT02815722|DRUG|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
218950147|NCT06519045|DEVICE|Intelligent Fingerprinting Drug Screening System|The Intelligent Fingerprinting Drug Screening System utilizes a single-use, rapid, non-invasive fingerprint sweat drug screening test intended for use with the Intelligent Fingerprinting DSR-Plus fluorescence reader. The Intelligent FingerprintingTM Fingerprint Collection Kit for Laboratory Analysis (i.e. confirmation test) provides a quantitative analytical result via laboratory-based liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is used to collect and measure drug mass in the full set of 10 fingerprints.
218950148|NCT02686008|DRUG|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
218950149|NCT02532699|DIETARY_SUPPLEMENT|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
218950150|NCT02532699|DIETARY_SUPPLEMENT|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
218950151|NCT04009811|DEVICE|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
218950152|NCT01620320|OTHER|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
218950153|NCT02198001|DRUG|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
219055010|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
219549643|NCT04707846|DEVICE|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
219549644|NCT04707846|DEVICE|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
219549645|NCT04516096|DRUG|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
218950154|NCT02198001|PROCEDURE|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
218950155|NCT02922699|DRUG|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
218950156|NCT02922699|DRUG|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
218950157|NCT04204551|BEHAVIORAL|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
218950158|NCT04204551|BEHAVIORAL|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
218950159|NCT03406741|BEHAVIORAL|psychometric evaluation|Wechsler type composite scales (WISC)
218950160|NCT03406741|BEHAVIORAL|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
218950161|NCT04343924|OTHER|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
218950162|NCT04343924|OTHER|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
218950163|NCT02867644|OTHER|standard care|Patients coming for preoperative breast assessment will have standard care.
218950164|NCT02867644|OTHER|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
218950165|NCT02861274|DEVICE|pacemaker|
219055011|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
219055012|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
218950166|NCT00853216|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
218950167|NCT00853216|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
218950168|NCT04497038|DRUG|Cabozantinib|Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
218950169|NCT04909983|DEVICE|DPLX-PT1|A polymer skin patch for occlusional therapy
218950170|NCT04909983|OTHER|Control arm|Standard of care
219055013|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
219055014|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
219055015|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
219055016|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
219055017|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
218950171|NCT03298971|OTHER|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
218950172|NCT04756336|DRUG|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
218950173|NCT02899572|PROCEDURE|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
218950174|NCT00773539|PROCEDURE|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
218950175|NCT00773539|PROCEDURE|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
218950176|NCT00773539|PROCEDURE|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
218950177|NCT01617746|DRUG|Ambrisentan|5mg od two weeks
218950178|NCT01617746|DRUG|Bosentan|62.5mg bd two weeks
218950179|NCT01617746|DRUG|Placebo|bd for two weeks
218950180|NCT00148707|DRUG|CT-2103 (Xyotax)|
218950181|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.5%
218950182|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.2%
218950183|NCT00891540|DRUG|placebo|Isotonic NaCl
218950184|NCT04958460|DRUG|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
219549646|NCT02263768|PROCEDURE|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
219549647|NCT01272024|BEHAVIORAL|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
219549648|NCT01272024|BEHAVIORAL|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
218950185|NCT04958460|OTHER|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
218950186|NCT05024110|OTHER|High intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
218950187|NCT05024110|OTHER|Moderate intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
218950188|NCT02204475|DRUG|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
218950189|NCT02204475|DRUG|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
218950190|NCT02204475|DRUG|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
218950191|NCT02204475|DRUG|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
218950192|NCT03642132|DRUG|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
218950193|NCT03642132|DRUG|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
218950194|NCT03642132|DRUG|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
218950195|NCT02944006|PROCEDURE|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
218950196|NCT04414735|OTHER|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
218950197|NCT03687463|DRUG|Decitabine|Decitabine for injection
218950198|NCT03558880|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block was performed
219549649|NCT04697316|DEVICE|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
219549650|NCT04697316|DEVICE|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
219549651|NCT00084864|DIETARY_SUPPLEMENT|calcitriol|Given orally
219549652|NCT00084864|DRUG|dexamethasone|Given orally
219549653|NCT00084864|OTHER|clinical observation|No intervention before surgery
219549654|NCT01459601|DRUG|Cabergoline|0,5mg per week
219549655|NCT02355262|OTHER|Informational Intervention|Receive CATCH-UP intervention
218950199|NCT03558880|PROCEDURE|Tumescent Anesthesia|Tumescent Anesthesia was applied
218950200|NCT03834558|OTHER|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
218950201|NCT06277843|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
218950202|NCT04195971|DIAGNOSTIC_TEST|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
218950203|NCT02577887|DEVICE|Patients implanted with a St. Jude Medical pacemakers|
218950204|NCT06146231|DEVICE|Motiva Flora® Tissue Expander|"This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant.~Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication.~To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study."
219055018|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
218950205|NCT02135003|OTHER|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
218950206|NCT03560518|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
218950207|NCT03560518|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
218950208|NCT01078818|DRUG|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
218950209|NCT01078818|DRUG|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
218950210|NCT01078818|DRUG|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
219055019|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
219055020|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
219055021|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
218950211|NCT02852187|DEVICE|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
218950212|NCT02852187|DEVICE|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
218950213|NCT05468047|DRUG|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
218950214|NCT04829084|BEHAVIORAL|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
218950215|NCT02561767|OTHER|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
218950216|NCT02561767|OTHER|Saline|Saline as placebo of MSCs
218950217|NCT02561767|DRUG|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
218950218|NCT02561767|DRUG|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
218950219|NCT00875693|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
218950220|NCT06277453|OTHER|surgery|radical gastric cancer surgery (R0) and D2 lymph node dissection
219055022|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
219055023|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
219055024|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
219637098|NCT01539330|DRUG|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
218950221|NCT00028145|BEHAVIORAL|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
218950222|NCT04745260|DRUG|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
218950223|NCT04745260|DRUG|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
218950224|NCT02642055|BEHAVIORAL|Neuro+ Attention Training|Attention training program with Neuro+ software
218950225|NCT02642055|OTHER|Treatment as Usual|Continuation of current ADHD treatment
219637099|NCT01539330|OTHER|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
219637100|NCT03999164|DRUG|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
218950226|NCT02322853|DRUG|Tamoxifen|hormonotherapy
218950227|NCT02322853|DRUG|Ralimetinib (LY2228820 dimesylate)|
218950228|NCT04911192|PROCEDURE|mechanical fragmentation|patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy
218950229|NCT04911192|PROCEDURE|In Situ thrombolysis|Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
219637101|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
219637102|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
219637103|NCT03789149|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
218950230|NCT04769180|OTHER|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
218950231|NCT03081156|DRUG|Glycopyrrolate / Formoterol|Exercise Tolerance
218950232|NCT01832584|DIETARY_SUPPLEMENT|RGC|
218950233|NCT01832584|DIETARY_SUPPLEMENT|Placebo|
218950234|NCT01765309|PROCEDURE|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
218950235|NCT03338322|DEVICE|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
218950236|NCT03338322|DEVICE|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
218950237|NCT03360864|OTHER|Education program|Patient will participate to a education program.
218950238|NCT04415970|OTHER|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
218950239|NCT04415970|OTHER|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
218950240|NCT02185976|OTHER|cartoon|5 different cartoons which will be recorded on a tablet PC.
218950241|NCT04674540|OTHER|No Intervention|No Intervention
218950242|NCT01323855|DRUG|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
218950243|NCT02024152|DRUG|JDP-205 IV high dose|
218950244|NCT02024152|DRUG|JDP-205 IV low dose|
218950245|NCT02024152|DRUG|JDP-205 IM|
219637104|NCT03961958|DRUG|Propofol reduction|Reduction of propofol target concentration
219637105|NCT05265442|DRUG|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
219637106|NCT05334485|DRUG|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
219637107|NCT05334485|OTHER|Placebo|Oral starch placebo
219637108|NCT04762615|DIAGNOSTIC_TEST|AMH level measurement|AMH level measurement using ELISA test from blood samples
219637109|NCT06683066|DRUG|Triprorelin for injection|Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.
219637110|NCT06683066|DRUG|Diphereline|Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.
219637111|NCT00729157|RADIATION|Fludeoxyglucose F-18|Correlative studies
219637112|NCT00729157|OTHER|Laboratory Biomarker Analysis|Correlative studies
218950246|NCT02024152|DRUG|Control: Zyrtec|
218950247|NCT06455267|DIETARY_SUPPLEMENT|Now Foods L-Ornithine Capsules|L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
218950248|NCT06163677|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
218950249|NCT02122783|DEVICE|ADR™ brace resistance|
219055025|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
218950250|NCT02122783|DEVICE|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
218950251|NCT00924040|DRUG|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
219055026|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
218950252|NCT03449784|OTHER|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
218950253|NCT02783079|BEHAVIORAL|CBT|
218950254|NCT02783079|BEHAVIORAL|MBSR|
218950255|NCT04877509|BIOLOGICAL|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
218950256|NCT04418401|DRUG|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
218950257|NCT01890629|DRUG|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
219055027|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
219055028|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
219055029|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
219055030|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
219055031|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
219055032|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
219055033|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
219055034|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
219055035|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
219637113|NCT00729157|OTHER|Pharmacological Study|Correlative studies
219637114|NCT00729157|PROCEDURE|Positron Emission Tomography|Correlative studies
218950258|NCT01579812|DRUG|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
218950259|NCT01528540|DRUG|Placebo|This group will include placebo.
218950260|NCT01528540|DRUG|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
219055036|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
219055037|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
219055038|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
219055039|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
219055040|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
218950261|NCT00338182|DRUG|AZD1152 part A|48-hour continuous intravenous infusion
218950262|NCT00338182|DRUG|AZD1152 part B|2-hour intravenous infusion
218950263|NCT04636853|BIOLOGICAL|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
218950264|NCT01138176|PROCEDURE|Cooling|Reduction of rectal temperature to 33.5 C
218950265|NCT00061412|BEHAVIORAL|Comprehensive program to improve reading and writing skills|
218950266|NCT04308031|DRUG|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
218950267|NCT04308031|DRUG|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
219637115|NCT00729157|BIOLOGICAL|Ziv-Aflibercept|Given IV
219055041|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
219055042|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
218950268|NCT04634045|BEHAVIORAL|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
218950269|NCT04458688|OTHER|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
219055043|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
219055044|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
219055045|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
219055046|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
219055047|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
219055048|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
219055049|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
219055050|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
219055051|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
219055052|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
219549656|NCT05205096|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
219637116|NCT02122705|DEVICE|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
219637117|NCT03997565|PROCEDURE|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
219637118|NCT02478866|DRUG|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
219637119|NCT01895881|DRUG|Estradiol|
219637120|NCT01895881|DRUG|Placebo|
219637121|NCT04703361|BIOLOGICAL|Placebo NaCl|Placebo
219055053|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
219055054|NCT00760279|DRUG|Azithromycin|
219055055|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
219055056|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
219637122|NCT04703361|BIOLOGICAL|Niacin|B3 vitamin, Niacin
219637123|NCT04703361|BIOLOGICAL|Na-3-OHB|Na-3-OHB
219637124|NCT01077037|OTHER|Decision Aid|Chest pain choice decision aid
219055057|NCT00045994|DRUG|ALT-711|
219055058|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
219637125|NCT06665061|DEVICE|PCV|Patients were randomly assigned to receive PCV mechanical ventilation, with consistent ventilation parameters.
219637126|NCT06665061|DEVICE|VCV|Patients were randomly assigned to receive VCV mode mechanical ventilation, with consistent ventilation parameters.
219637127|NCT06665061|DEVICE|PRVC|Patients were randomly assigned to receive PRVC mode mechanical ventilation, with consistent ventilation parameters.
219637128|NCT03734328|PROCEDURE|connective tissue graft|"* anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)"
219637129|NCT03734328|PROCEDURE|connective tissue graft&PRF|"anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)"
219637130|NCT03734328|OTHER|connective tissue graft&PRF|"* taking blood from patient~* centrifuging blood~* obtain PRF"
219637131|NCT00661609|DRUG|AZD4877|Intravenous (IV)25mg/weekly
219637132|NCT03025815|OTHER|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
219637133|NCT03025815|OTHER|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
219637134|NCT05940376|DRUG|rapid acting insulin|Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
219637135|NCT03554148|OTHER|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
219637136|NCT03477201|PROCEDURE|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
219637137|NCT03477201|PROCEDURE|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
219637138|NCT02141412|DRUG|dexmedetomidine 0.25 µg/kg IV|
218950270|NCT02400164|DEVICE|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
218950271|NCT01970904|DRUG|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
218950272|NCT01970904|DRUG|Ribavirin|Ribavirin tablets of various strengths for oral administration
218950273|NCT01970904|DRUG|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
218950274|NCT02870023|OTHER|Balance training|
218950275|NCT02870023|OTHER|Strength training|
218950276|NCT00353756|DRUG|C326, IL-6 Inhibitory Avimer protein|
218950277|NCT03356704|OTHER|no intervention|Observational study
218950278|NCT03708562|DEVICE|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
218950279|NCT03782831|PROCEDURE|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
218950280|NCT03782831|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
218950281|NCT03782831|DRUG|Placebos|intravenous injection every 2 weeks
218950282|NCT06329128|OTHER|Experimental: Study Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization"
218950283|NCT06329128|OTHER|Active Comparator: Control Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary."
218950284|NCT01133990|DRUG|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
218950285|NCT01133990|DRUG|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
219055059|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
219055060|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
219055061|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
219055062|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
219637139|NCT02141412|DRUG|dexmedetomidine 0.5 µg/kg IV|
219637140|NCT02141412|DRUG|dexmedetomidine 1 µg/kg IV|
218950286|NCT01133990|DRUG|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
218950287|NCT04220593|OTHER|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
218950288|NCT05277337|BIOLOGICAL|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
218950289|NCT05277337|BIOLOGICAL|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
219637141|NCT02141412|DRUG|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
218950290|NCT03743077|BEHAVIORAL|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
218950291|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm bevel|Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
219055063|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
218950292|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm stair-step chamfer|Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
218950293|NCT03271983|DRUG|Metronidazole gel 1|RLD gel
218950294|NCT03271983|DRUG|Metronidazole gel 2|generic gel
218950295|NCT03271983|DRUG|Metronidazole cream|generic cream
218950296|NCT00005866|DRUG|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
218950297|NCT00005866|DRUG|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
218950298|NCT00005866|DRUG|cyclosporine|both arms per published schedule
218950299|NCT00005866|DRUG|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
218950300|NCT00005866|PROCEDURE|allogeneic bone marrow transplantation|day 0
218950301|NCT00005866|RADIATION|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
218950302|NCT04182464|OTHER|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
218950303|NCT04182464|OTHER|Placebo|Cornstarch without significant physiological effects
219055064|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
219055065|NCT02329405|DRUG|Rifampicin|
219055066|NCT02329405|DRUG|Placebo|
219055067|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
219055068|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
219055069|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
219549657|NCT04334096|BEHAVIORAL|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
219549658|NCT04589364|DRUG|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
219549659|NCT04381013|DEVICE|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
219549660|NCT01600339|DRUG|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
219549661|NCT05645315|DRUG|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
219549662|NCT00599105|PROCEDURE|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
219549663|NCT00209547|DRUG|fospropofol disodium|
219549664|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
219549665|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
219549666|NCT01229800|DRUG|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
219637142|NCT00436124|DRUG|oseltamivir [Tamiflu]|
219637143|NCT04308499|BEHAVIORAL|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
219637144|NCT04308499|BEHAVIORAL|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
219637145|NCT06682923|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
219637146|NCT03747757|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
219637147|NCT03747757|OTHER|Quality-of-Life Assessment|Ancillary studies
218950304|NCT01552798|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
218950305|NCT01552798|DRUG|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
218950306|NCT01552798|DRUG|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
218950307|NCT05555173|DEVICE|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
218950308|NCT02052765|DEVICE|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
218950309|NCT02402738|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|
219055070|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
219055071|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
219637148|NCT03747757|OTHER|Questionnaire Administration|Ancillary studies
219637149|NCT01430403|BIOLOGICAL|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
219637150|NCT01430403|DRUG|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
218950310|NCT02402738|BEHAVIORAL|Enhanced Treatment as Usual|
218950311|NCT00543244|DRUG|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
218950312|NCT02282345|OTHER|Laboratory Biomarker Analysis|Correlative studies
219055072|NCT01699399|PROCEDURE|water immersion|
219055073|NCT01699399|PROCEDURE|water exchange|
219055074|NCT01699399|PROCEDURE|air insufflation|
219055075|NCT00310687|PROCEDURE|BLOOD DRAW|
219637151|NCT01430403|BIOLOGICAL|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
219637152|NCT01430403|BIOLOGICAL|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
219637153|NCT05018403|DRUG|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
219637154|NCT05018403|DRUG|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
218950313|NCT02282345|DRUG|Talazoparib|Given PO
218950314|NCT01185301|BIOLOGICAL|adalimumab|Pre-filled syringe every other week
218950315|NCT01185301|DRUG|methotrexate|weekly oral capsule dosing
218950316|NCT01319331|DRUG|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
218950317|NCT05214053|DEVICE|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
218950318|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
218950319|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
219055076|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
219055077|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
219055078|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
219055079|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
219055080|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
219055081|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
218950320|NCT02683746|DRUG|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
218950321|NCT02683746|DRUG|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
218950322|NCT06054204|DEVICE|lateral bony window|bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
218950323|NCT01191216|DRUG|1-methyl-d-tryptophan|
218950324|NCT01191216|DRUG|docetaxel|
218950325|NCT01191216|OTHER|diagnostic laboratory biomarker analysis|
218950326|NCT01191216|OTHER|pharmacological study|
218950327|NCT04987944|DRUG|Zavegepant|150 mg BID
218950328|NCT04987944|DRUG|Placebo|Placebo matching active drug
218950329|NCT00023699|DRUG|gefitinib|
218950330|NCT04563832|OTHER|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
218950331|NCT04563832|OTHER|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
218950332|NCT05277480|DRUG|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
218950333|NCT05277480|DRUG|IE|ifosfamide ivgtt ; etoposide ivgtt .
218950334|NCT05306821|OTHER|Comprehensive electronic tool in the electronic medical chart|Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis
218950335|NCT05306821|OTHER|Educative sessions|Educative sessions on thromboprophylaxis
218950336|NCT05306821|OTHER|Pocket card|Pocket card (guide for thromboprophylaxis)
218950337|NCT00088556|DRUG|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
218950338|NCT00088556|DRUG|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
218950339|NCT00088556|DRUG|paclitaxel|200 mg/m² Once every 3 weeks
218950340|NCT05205577|DEVICE|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
218950341|NCT04924413|DRUG|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
218950342|NCT05519293|DRUG|H002|Small molecule, Capsule
218950343|NCT02983097|DRUG|Rituximab|Rituximab 375 mg/m²
218950344|NCT02983097|DRUG|Cisplatin|Cisplatinum 100 mg / m²
218950345|NCT02983097|DRUG|Carboplatin|Carboplatinum AUC5
218950346|NCT02983097|DRUG|Dexamethasone|Dexamethasone 40 mg
218950347|NCT02983097|DRUG|Cytarabine|Cytarabine 2000 mg/m², administered twice
218950348|NCT02983097|DRUG|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
218950349|NCT02983097|DRUG|PegFilgrastim|PegFilgrastim 6 mg
218950350|NCT02983097|PROCEDURE|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
218950351|NCT00790309|PROCEDURE|Weight loss surgery|Weight loss surgery
218950352|NCT00790309|PROCEDURE|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
218950353|NCT00400296|DRUG|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
218950354|NCT00595374|DRUG|insulin detemir|
218950355|NCT00595374|DRUG|insulin NPH|
219055082|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
218950356|NCT00595374|DRUG|insulin aspart|
218950357|NCT05662709|PROCEDURE|Tooth extraction|Tooth extraction in the most atraumatic way
218950358|NCT05662709|PROCEDURE|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
218950359|NCT05094973|DEVICE|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
218950360|NCT03844295|DEVICE|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
218950361|NCT03844295|DEVICE|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
218950362|NCT05535010|PROCEDURE|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
218950363|NCT04272112|COMBINATION_PRODUCT|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
218950364|NCT04272112|COMBINATION_PRODUCT|BruxZir, Glidewell|Type: high translucent zirconia
218950365|NCT04272112|COMBINATION_PRODUCT|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
218950366|NCT00345332|DRUG|Botox|Injected
218950367|NCT00345332|DRUG|Placebo|Injected
218950368|NCT05753579|BEHAVIORAL|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
218950369|NCT05753579|BEHAVIORAL|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
218950370|NCT03096587|DEVICE|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
218950371|NCT03096587|DEVICE|ultrasonic activated irrigation|by Satelec,Acteon, France
219055083|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
219055084|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
219055085|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
219055086|NCT00185133|DRUG|Olmesartan medoxomil|
219055087|NCT00185133|DRUG|Amlodipine|
219055088|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
219055089|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
219055090|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
219055091|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
219055092|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
219549667|NCT01229800|DRUG|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
219549668|NCT02466490|DRUG|Fimasartan|Fimasartan tablets
219549669|NCT02466490|DRUG|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
219637155|NCT06683885|DRUG|Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone|"For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment."
219637156|NCT05339711|OTHER|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
219637157|NCT05339711|OTHER|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
219637158|NCT03817008|PROCEDURE|Ascending aorta replacement with graft|Patient with planned Ascending aorta replacement with graft
219637159|NCT04564378|OTHER|This is an observational study. There is no therapeutic intervention.|This is an observational study. There is no therapeutic intervention.
219549670|NCT02501863|DRUG|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
219549671|NCT02501863|DRUG|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
218950372|NCT03409978|DEVICE|in-Motion app|mobile phone application for recording fidgety movements at home
218950373|NCT05585281|DRUG|Fluzoparib|Fluzoparib Orally twice daily
218950374|NCT05585281|BIOLOGICAL|QL1101|Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
218950375|NCT00499057|RADIATION|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
218950376|NCT02294760|DEVICE|Subsensory|The stimulation is set to 90% of the sensory threshold.
219055093|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
219055094|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
219055095|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
219055096|NCT01889589|OTHER|Surveillance|
219055097|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
219055098|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
219055099|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
219055100|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
219055101|NCT00612066|DRUG|rosiglitazone maleate|
219055102|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
219055103|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
219055104|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
218950377|NCT02294760|DEVICE|OFF|The stimulation is turned OFF.
218950378|NCT02085031|PROCEDURE|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
218950379|NCT02085031|PROCEDURE|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
218950380|NCT04125264|DEVICE|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
218950381|NCT01781091|DEVICE|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
218950382|NCT01781091|DEVICE|Conventionals Modes|
218950383|NCT04012489|PROCEDURE|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
218950384|NCT04012489|PROCEDURE|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
218950385|NCT00128505|DRUG|Mifepristone|
219055105|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
219055106|NCT04681521|OTHER|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
219055107|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
218950386|NCT00105365|DEVICE|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
218950387|NCT00105365|OTHER|walking shoes|walking shoes
218950388|NCT01329835|BEHAVIORAL|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
218950389|NCT01329835|OTHER|brochure|brochure given after randomization
218950390|NCT01602133|PROCEDURE|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
219055108|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
219055109|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
219055110|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
218950391|NCT05577273|DRUG|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
218950392|NCT02353143|DRUG|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
218950393|NCT04906915|DRUG|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
218950394|NCT04121078|DRUG|TAK-906|TAK-906 capsule.
218950395|NCT04121078|DRUG|Rifampin|Rifampin infusion.
218950396|NCT01155882|PROCEDURE|Whipple at the Splenic Artery (WATSA)|
218950397|NCT00260364|DRUG|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
218950398|NCT00260364|DRUG|Capecitabine orally days 1 -21|
218950399|NCT00260364|DRUG|Erlotinib 100 mg orally days 1-28|
219055111|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
219055112|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
219055113|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
219055114|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
219055115|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
219055116|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
219055117|NCT03540927|BEHAVIORAL|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
219637160|NCT04228146|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|"Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes."
218950400|NCT00260364|DRUG|Bevacizumab 5 mg/kg intravenously every 2 weeks|
218950401|NCT04272138|BEHAVIORAL|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
218950402|NCT04272138|BEHAVIORAL|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
218950403|NCT05920083|OTHER|CPAP withdrawal|2 weeks of CPAP withdrawal
218950404|NCT05330078|DRUG|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
218950405|NCT05330078|DRUG|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
218950406|NCT03785275|RADIATION|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
218950407|NCT05627778|DRUG|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
218950408|NCT05627778|DRUG|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
218950409|NCT00817128|PROCEDURE|PEPT|Pain Exposure Physical Therapy
218950410|NCT00817128|PROCEDURE|CBO standard|Standard therapy as defined in CBO guideline 2006
218950411|NCT02664623|PROCEDURE|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
219055118|NCT03540927|OTHER|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
219055119|NCT01305967|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, Intravenous route, 16times for 2.5 months
219549672|NCT04594434|OTHER|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
219549673|NCT04594434|OTHER|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
219549674|NCT04594434|OTHER|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
219549675|NCT05015595|DRUG|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
219549676|NCT05015595|DRUG|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
219549677|NCT00028613|RADIATION|iodine I 131 monoclonal antibody Lym-1|
219637161|NCT04228146|OTHER|Waitlist Control|Delay access to the self-help CBT-I treatment.
219637162|NCT04448522|RADIATION|reduced dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy"
219055120|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
218950412|NCT02664623|PROCEDURE|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
218950413|NCT03483129|BEHAVIORAL|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
218950414|NCT01280201|DRUG|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
218950415|NCT00266669|DRUG|Topical organogel with nitroglycerin|
218950416|NCT05053932|OTHER|blood collection|blood collection
218950417|NCT00002165|DRUG|Nelfinavir mesylate|
218950418|NCT04630574|OTHER|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
218950419|NCT04630574|OTHER|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
218950420|NCT04422275|DRUG|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
218950421|NCT04422275|BEHAVIORAL|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
218950422|NCT04422275|DRUG|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
218950423|NCT04422275|BEHAVIORAL|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
218950424|NCT01940978|DRUG|Methylphenidate ER|Watson generic, starting dose 18mg QD
218950425|NCT01940978|DRUG|Cyproheptadine|cyproheptadine hydrochloride
218950426|NCT02480946|DRUG|MBS2320|As described in the arm descriptions
218950427|NCT02480946|DRUG|Placebo|As described in the arm descriptions
218950428|NCT02480946|DRUG|Methotrexate|Background therapy as described in the arm descriptions
218950429|NCT04517279|BEHAVIORAL|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
218950430|NCT04517279|BEHAVIORAL|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
218950431|NCT05436873|DEVICE|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
218950432|NCT00253708|PROCEDURE|management of therapy complications|
218950433|NCT00253708|PROCEDURE|massage therapy|
218950434|NCT00253708|PROCEDURE|pain therapy|
218950435|NCT00253708|PROCEDURE|psychosocial assessment and care|
218950436|NCT00253708|PROCEDURE|quality-of-life assessment|
218950437|NCT01981057|OTHER|Numeta|parenteral receipt prescribed with Numeta
218950438|NCT01981057|OTHER|Individual|parenteral receipt prescribed individually
218950439|NCT04645485|BIOLOGICAL|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
218950440|NCT04644731|DEVICE|Aquadex™ System|Ultrafiltration for fluid removal
218950441|NCT00125398|DRUG|AQUAVAN (fospropofol disodium; GPI 15715 )|
218950442|NCT05207189|BIOLOGICAL|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
218950443|NCT03040570|PROCEDURE|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
218950444|NCT03040570|PROCEDURE|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
218950445|NCT02946931|DRUG|Prizbind®|Prizbind®
218950446|NCT02769897|BEHAVIORAL|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
219637163|NCT04448522|RADIATION|conventional dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy"
219637164|NCT02100995|BEHAVIORAL|Intervention Simultaneously Targeting Obesity and Pain|
219637165|NCT02100995|BEHAVIORAL|Weight Loss/Weight Self-Management|
218950447|NCT00311298|DIETARY_SUPPLEMENT|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
218950448|NCT00311298|DIETARY_SUPPLEMENT|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
218950449|NCT00497809|DRUG|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
218950450|NCT04476173|DRUG|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
218950451|NCT04476173|DRUG|Morphine|ACS patients who received intravenous morphine as analgesic treatment
218950452|NCT03339297|DRUG|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
218950453|NCT03339297|DRUG|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
218950454|NCT05015985|OTHER|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
218950455|NCT05015985|OTHER|control group|music relaxation using a music playlist supply (control group)
218950456|NCT05705635|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
218950457|NCT05705635|DRUG|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
218950458|NCT01274260|DRUG|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
218950459|NCT01274260|DRUG|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
218950460|NCT05953441|OTHER|AI-powered doctor|AI-powered virtual doctor
218950461|NCT05953441|OTHER|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
218950462|NCT05026814|OTHER|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
219637166|NCT02100995|BEHAVIORAL|Chronic Pain Self-Management|
219637167|NCT00971464|BEHAVIORAL|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
219637168|NCT00971464|DEVICE|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
219637169|NCT04158102|DRUG|Bupivacaine liposome injectable suspension|Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
218950463|NCT02551796|PROCEDURE|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
218950464|NCT02551796|PROCEDURE|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
218950465|NCT02551796|PROCEDURE|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
218950466|NCT02320201|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
219637170|NCT04168502|DRUG|Gemtuzumab Ozogamicin|Patients will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
219637171|NCT03604679|DRUG|SyB C-0501|Specified dose on specified days
219637172|NCT00266578|DRUG|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
219637173|NCT06341907|BIOLOGICAL|Neoantigen polypeptide vaccine|Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)
219637174|NCT04481789|DRUG|MT-1186|Suspension
219637175|NCT04481789|DRUG|Rosuvastatin|Tablets
219637176|NCT04481789|DRUG|Sildenafil|Tablets
218950467|NCT01073371|DRUG|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
218950468|NCT05073094|DRUG|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
218950469|NCT05073094|DRUG|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
219055121|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
219055122|NCT03655158|DEVICE|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
219055123|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
219055124|NCT02326103|DRUG|Placebo|
219637177|NCT04481789|DRUG|Furosemide|Tablets
219549678|NCT02854826|OTHER|SAFE Care model of care|"SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
219549679|NCT06018116|DRUG|Bicalutamide 150 mg|nonsteroidal antiandrogen
219637178|NCT04599348|DIETARY_SUPPLEMENT|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
219637179|NCT06622616|DIETARY_SUPPLEMENT|EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS|"The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated."
219637180|NCT02751450|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
219637181|NCT02751450|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
219637182|NCT05230368|DRUG|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
218950470|NCT00126880|DRUG|AVX754|apricitabine, 600mg BID or 800mg BID
218950471|NCT00126880|DRUG|3TC|3TC, 150mg BID
218950472|NCT02901327|PROCEDURE|Lumbar Stabilisation Exercise|"McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
218950473|NCT02901327|PROCEDURE|treadmill walk exercise|"Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'"
218950474|NCT03099343|BEHAVIORAL|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
218950475|NCT04951323|DRUG|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
218950476|NCT05198544|DEVICE|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
218950477|NCT02199327|DRUG|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
219055125|NCT04623294|PROCEDURE|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
219637183|NCT05230368|DRUG|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
219055126|NCT04623294|PROCEDURE|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
219055127|NCT05831293|BEHAVIORAL|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
218950478|NCT02199327|DRUG|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
218950479|NCT04288232|DRUG|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
218950480|NCT03916107|PROCEDURE|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
218950481|NCT03916107|PROCEDURE|Frontalis flap|Using frontal muscle flap to correct severe ptosis
218950482|NCT04446390|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
218950483|NCT04446390|OTHER|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
218950484|NCT05272436|DEVICE|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
218950485|NCT02575066|RADIATION|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
218950486|NCT02575066|DRUG|pazopanib|pazopanib QD 800 mg
218950487|NCT03288792|DEVICE|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
218950488|NCT02213133|DRUG|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
218950489|NCT03196388|DRUG|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
219055128|NCT03002181|OTHER|Education|70 minute education session.
219055129|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
219055130|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
219055131|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
219055132|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
219055133|NCT01031823|BEHAVIORAL|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
219055134|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
219055135|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
219055136|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
219055137|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
219055138|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
219055139|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
219055140|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
219055141|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
219055142|NCT00475826|DRUG|Statins and Ezetimibe|
219055143|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
219055144|NCT02174536|BIOLOGICAL|Placebo|
219055145|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
219549680|NCT06018116|DRUG|Placebo|placebo
219549681|NCT02109458|DEVICE|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
219549682|NCT01567319|BIOLOGICAL|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
219549683|NCT01567319|BIOLOGICAL|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
219549684|NCT01567319|BIOLOGICAL|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
218950490|NCT02991989|BEHAVIORAL|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
218950491|NCT02991989|DIETARY_SUPPLEMENT|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
218950492|NCT06275633|DRUG|Levodopa|Medicine response
218950493|NCT00157287|PROCEDURE|Evidence based weaning protocol|
218950494|NCT02779361|DIETARY_SUPPLEMENT|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*)."
218950495|NCT03746288|DRUG|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
218950496|NCT05614167|OTHER|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
219055146|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
219055147|NCT03936491|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
219055148|NCT03936491|DRUG|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
219549685|NCT00263458|OTHER|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
219549686|NCT03540160|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
219549687|NCT03820258|DRUG|SOF/VEL/VOX|Administered once daily with food.
219549688|NCT01704534|DRUG|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
219549689|NCT06218394|PROCEDURE|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
219637184|NCT05230368|DRUG|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
219637185|NCT05230368|DRUG|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
219637186|NCT05230368|DRUG|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
219637187|NCT05230368|DRUG|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
218950497|NCT04691947|BIOLOGICAL|ERUCOV-VAC|Vaccination on Day 0 and Day 21
218950498|NCT04691947|OTHER|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
218950499|NCT01741402|DEVICE|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
218950500|NCT01741402|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
218950501|NCT02012582|DRUG|VAS203|i.v. infusion
218950502|NCT02012582|DRUG|Saline|i.v. infusion
218950503|NCT01929941|DRUG|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
218950504|NCT01929941|DRUG|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
218950505|NCT01929941|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
218950506|NCT01929941|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
218950507|NCT00704275|DRUG|0.05% cyclosporin eye drop|bid dosage for 4 months
218950508|NCT00511225|DIETARY_SUPPLEMENT|cholecalciferol|10,000 IU weekly
218950509|NCT00511225|DIETARY_SUPPLEMENT|placebo|placebo capsule
218950510|NCT00865423|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
218950511|NCT00865423|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
218950512|NCT01374035|OTHER|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
218950513|NCT06405945|GENETIC|PCR and sequence|sequence the mutatation SNPs
218950514|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 1|
218950515|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 2|
218950516|NCT01229917|OTHER|Standard fruit juice|
218950517|NCT01277003|DEVICE|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
218950518|NCT01277003|DEVICE|TENS|tow therapeutic points, each for 15 minutes
218950519|NCT00802815|DRUG|Etanercept|50 milligrams subcutaneously every week
218950520|NCT06292611|DEVICE|Battery operated toothbrush|Device on extrinsic stain removal efficacy
218950521|NCT06292611|DEVICE|Manual toothbrush|Device on extrinsic stain removal efficacy
218950522|NCT01883856|DEVICE|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
218950523|NCT01883856|DEVICE|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
218950524|NCT05651204|DIAGNOSTIC_TEST|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
218950525|NCT01794195|BEHAVIORAL|Diffusion tensor imaging and fibres tracking|
218950526|NCT04863183|BIOLOGICAL|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
219637188|NCT05230368|DRUG|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
219637189|NCT05230368|DRUG|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
218950527|NCT04863183|DRUG|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
218950528|NCT00557817|DRUG|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
218950529|NCT00557817|DRUG|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
218950530|NCT05947292|PROCEDURE|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
218950531|NCT02816567|DRUG|propofol|
218950532|NCT02816567|DRUG|NMBA - cisatracurium|
218950533|NCT02816567|DRUG|placebo - isotonic saline serum|
218950534|NCT02816567|DRUG|sufentanil|
218950535|NCT02816567|PROCEDURE|laparoscopic surgery|
218950536|NCT04740905|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
218950537|NCT04740905|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
218950538|NCT04740905|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
218950539|NCT02700503|BEHAVIORAL|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
218950540|NCT06085976|DRUG|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
218950541|NCT06085976|OTHER|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
218950542|NCT01287182|DRUG|Ateronon|Ateronon daily for 3 months
218950543|NCT03051620|DRUG|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
218950544|NCT00594724|PROCEDURE|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
218950545|NCT00393510|DRUG|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
218950546|NCT00393510|DRUG|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
218950547|NCT02700334|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
218950548|NCT02700334|DRUG|Placebo|one per day before breakfast during 12 weeks.
218950549|NCT03313661|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
219637190|NCT01243216|DEVICE|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
218950550|NCT03313661|DRUG|Gliclazide|gliclazide (60-120 mg)
218950551|NCT01368718|PROCEDURE|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
218950552|NCT00003798|DRUG|motexafin gadolinium|
218950553|NCT00003798|RADIATION|radiation therapy|
218950554|NCT01023477|DRUG|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
218950555|NCT01023477|DRUG|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
218950556|NCT01023477|PROCEDURE|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
218950557|NCT02412488|OTHER|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
218950558|NCT02817477|DRUG|Ketamine Hydrochloride|Delivered intranasally using an atomizer
218950559|NCT02817477|DRUG|Morphine|Delivered either as an IM injection or a slow IV bolus
218950560|NCT00742664|BEHAVIORAL|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
218950561|NCT00742664|BEHAVIORAL|Wait-list control|The subject will not receive active treatment during this interval.
218950562|NCT01989468|BIOLOGICAL|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
218950563|NCT01989468|BIOLOGICAL|Placebo|Secukinumab placebo provided in 1 mL autoinjector
218950564|NCT01634425|DEVICE|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
218950565|NCT02409108|DEVICE|Exatherm-TBH system|One treatment of Total Body Hyperthermia
218950566|NCT01402336|DRUG|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
218950567|NCT01402336|DRUG|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
218950568|NCT00289055|DEVICE|stent|Cordis SMART™ Nitinol Stent
218950569|NCT00289055|DEVICE|angioplasty|balloon angioplasty
218950570|NCT01640327|BIOLOGICAL|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
218950571|NCT02864485|PROCEDURE|live donor liver transplantation|live donor liver transplantation
218950572|NCT01371370|OTHER|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
218950573|NCT01371370|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
218950574|NCT01371370|OTHER|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
218950575|NCT03222492|BIOLOGICAL|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
218950576|NCT03222492|BIOLOGICAL|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
218950577|NCT01797770|DRUG|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
218950578|NCT01797770|OTHER|No Preparation|No laxatives or bowel preparation
218950579|NCT03156647|DIAGNOSTIC_TEST|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
218950580|NCT01143805|DRUG|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
218950581|NCT01143805|DRUG|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
218950582|NCT02451371|DEVICE|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
218950583|NCT01891526|DRUG|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
218950584|NCT03396757|PROCEDURE|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
219637191|NCT06619496|BEHAVIORAL|Human-led fall prevention program|Human-led evidence-based fall prevention programs include Matter of Balance, Tai Chi Moving for Better Balance, Walk with Ease, or Arthritis Exercise
219637192|NCT06619496|BEHAVIORAL|Avatar-led fall prevention program|The avatar-led fall prevention program consists of the Otago Exercise Program
219637193|NCT01757938|PROCEDURE|Shang Ring Guided Circumcision|
219637194|NCT01757938|PROCEDURE|Forceps Guided Circumcision|
219637195|NCT03566914|DRUG|Tadalafil 10 MG|Tadalafil 10 mg per oral once daily for 3 months
218950585|NCT03396757|PROCEDURE|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
218950586|NCT06515067|OTHER|back massage|back massage
218950587|NCT06515067|OTHER|no ıntervention|no ıntervention
218950588|NCT01190423|BEHAVIORAL|Family Based Therapy for young adults|Individual and Group Therapy Sessions
219637196|NCT03566914|OTHER|Placebo|TPlacebo tablet per oral once daily for 3 months
218950589|NCT01229462|DRUG|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
218950590|NCT01229462|DRUG|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
218950591|NCT01229462|DRUG|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
218950592|NCT01229462|OTHER|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
218950593|NCT01906879|DRUG|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
218950594|NCT02189954|PROCEDURE|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
218950595|NCT02189954|PROCEDURE|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
218950596|NCT01861951|DRUG|Pazopanib|
218950597|NCT01861951|DRUG|Doxorubicin|
218950598|NCT06405620|OTHER|Assistance robot|the child controls the robot at his parent's home from his room
218950599|NCT02771691|OTHER|Mentalization-Based Group Therapy for Adolescents|
218950600|NCT06631053|OTHER|velocity-based FIT (VBFIT)|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week"
218950601|NCT06631053|OTHER|No Exercise|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study."
218950602|NCT00513825|DRUG|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
218950603|NCT00065429|DRUG|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
218950604|NCT03028454|DIETARY_SUPPLEMENT|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
218950605|NCT03028454|DIETARY_SUPPLEMENT|Placebo|Capsules containing rice flour powder.
218950606|NCT03515317|BEHAVIORAL|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
219366107|NCT01349140|DRUG|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
219637197|NCT05050123|BEHAVIORAL|iPhone Google Cardboard virtual reality meditation/relaxation app|Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
219637198|NCT05050123|BEHAVIORAL|Standard relaxation training|"15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body"
219637199|NCT01535508|DRUG|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
219055149|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
219055150|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
219055151|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
219637200|NCT06441838|BEHAVIORAL|Surah Inshirah|The effects of Surah Al-Inshirah on patients' depression, anxiety, stress and mental well-being will be evaluated during hemodialysis in the experimental group.
219055152|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
219055153|NCT01091311|DEVICE|Blephasteam|Eye lid warming goggles
219055154|NCT00820768|DRUG|ABI-010|17-AAG and ABI-007
219055155|NCT03293823|BEHAVIORAL|VSOP training|a computerized cognitive training of attention and processing speed
219055156|NCT03293823|BEHAVIORAL|MLA control|a computerized cognitive intervention of multiple mental leisure activities
218950607|NCT03515317|BEHAVIORAL|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
218950608|NCT00355836|BEHAVIORAL|Mental Imagery|
219055157|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
219055158|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
219055159|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
219055160|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
219055161|NCT04092426|OTHER|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
219055162|NCT04488731|BEHAVIORAL|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
219055163|NCT04488731|BEHAVIORAL|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
219055164|NCT04488731|BEHAVIORAL|overweight and moderate coffee consumption|overweight and moderate coffee consumption
219055165|NCT04488731|BEHAVIORAL|overweight and heavy coffee consumption|overweight and heavy coffee consumption
219637201|NCT00978081|DRUG|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
219637202|NCT01579838|DRUG|Eculizumab|PNH and or atypical TTP classical protocols
218950609|NCT03208582|DRUG|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
218950610|NCT03208582|DIETARY_SUPPLEMENT|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
218950611|NCT00002642|DRUG|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
218950612|NCT00002642|DRUG|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
219637203|NCT06684938|DRUG|sacroiliac injection|sacroiliac injection with local anaesthetic and corticosteroids
218950613|NCT00002642|PROCEDURE|conventional surgery|surgery some time between weeks 9 and 12
218950614|NCT00002642|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
218950615|NCT01671943|DEVICE|Ice-Sense3TM|Ice-Sense Cryoprobe
219637204|NCT03374917|DRUG|ABBV-951|powder for solution
219637205|NCT06685419|OTHER|Propolis containing gum|Patients with moderate gingivitis will be asked to use gum containing propolis 5 times a day for a total of 3 weeks.
218950616|NCT01762020|DEVICE|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
219637206|NCT03152838|GENETIC|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
218950617|NCT01762020|DRUG|Standard Preparation|standard creams
218950618|NCT06264388|DRUG|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
219637207|NCT03152838|DIAGNOSTIC_TEST|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
218950619|NCT06264388|DRUG|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
218950620|NCT05547009|OTHER|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
218950621|NCT05547009|OTHER|Face-to-face learning group|The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
218950622|NCT02084290|BEHAVIORAL|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
218950623|NCT02509117|DRUG|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
218950624|NCT02509117|DRUG|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
219637208|NCT01290679|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
218950625|NCT02509117|DRUG|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
218950626|NCT02509117|DRUG|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
218950627|NCT02509117|DRUG|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
218950628|NCT02509117|DRUG|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
218950629|NCT05191914|DRUG|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
218950630|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg|
218950631|NCT02620163|DRUG|YH22162 40/5/12.5 mg|
218950632|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg|
218950633|NCT02620163|DRUG|YH22162 80/5/25 mg|
219637209|NCT01290679|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
218950634|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg placebo|
218950635|NCT02620163|DRUG|YH22162 40/5/12.5 mg placebo|
218950636|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg placebo|
218950637|NCT02620163|DRUG|YH22162 80/5/25 mg placebo|
218950638|NCT06327724|DRUG|Belimumab|Start of new treatment due to active disease
218950639|NCT01332461|DRUG|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
219366108|NCT00638937|DRUG|saracatinib|Given PO
219637210|NCT01290679|DRUG|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
218950640|NCT01332461|DRUG|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
218950641|NCT00548184|DRUG|Lapatinib|Monoclonal Antibody
219055166|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
218950642|NCT00548184|DRUG|Trastuzumab|Monoclonal Antibody
218950643|NCT00548184|DRUG|Endocrine|Hormonal Therapy
218950644|NCT01205867|DRUG|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
218950645|NCT02601261|OTHER|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:~1. The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~2. The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~3. The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~4. The short questionnaire on critical events occurring during the day,~5. The short questionnaire with obstetric anamnesis."
218950646|NCT05790278|OTHER|Survey|Completion of a Purpose in Life Survey
218950647|NCT00796991|DRUG|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
219055167|NCT03414138|BEHAVIORAL|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
219549690|NCT06218394|PROCEDURE|Autologous Concentrated Growth Factor|"1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes."
219549691|NCT06218394|DRUG|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
219549692|NCT05216562|DRUG|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
219549693|NCT05216562|DRUG|Placebo Intravenous Injection|Intravenous injection of Placebo
219549694|NCT05216562|DRUG|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
219549695|NCT05900648|DRUG|Regorafenib|Given by PO
219549696|NCT05900648|DRUG|XmAb20717|Given by (IV) vein
219549697|NCT02125435|DRUG|ASP2408|intravenous
219549698|NCT02125435|DRUG|Placebo|intravenous
219549699|NCT02511535|BIOLOGICAL|TBE booster vaccination|
219549700|NCT04468282|DRUG|VGB-ST|Single oral administration of 500 mg VGB-ST
218950648|NCT00796991|DRUG|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
218950649|NCT00796991|DRUG|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
218950650|NCT00796991|DRUG|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
218950651|NCT00004042|BIOLOGICAL|monoclonal antibody F19|
218950652|NCT00004042|RADIATION|iodine I 131 monoclonal antibody F19|
218950653|NCT03453788|DEVICE|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
218950654|NCT04696211|OTHER|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
219055168|NCT03414138|BEHAVIORAL|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
219055169|NCT02687152|OTHER|N-hydroxy-nor-L-arginine|
219366109|NCT01573312|DRUG|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
219366110|NCT01573312|BIOLOGICAL|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
219366111|NCT05758090|PROCEDURE|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.
219366112|NCT05758090|PROCEDURE|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
219366113|NCT06098638|OTHER|Nutritional recommendation and Faradic stimulation program|proper maternal nutrition and fluid intake during breast-feeding per day for 12 weeks and2 sessions per week, each session 20 minutes, for 12 weeks. Frequency of 65 Hz, and width pulse 300 ms, with contraction time 10 sec and relaxation time 10 sec
219366114|NCT06098638|OTHER|aerobic and resisted exercise for 12 weeks|Each woman in group (B) participated in a moderate exercise program (aerobic+resistive), 3 days/week, for 12 weeks. The session began with 15 minutes of aerobic exercise on a bicycle ergometer, at 60% of heart rate reserve (HRR), with HRR estimated (220-age-resting heart rate). Then, the participant was performed 15 minutes of resistive exercise (two sets of 8-12 repetitions at 75% of one repetition maximum (1-RM) for basic core exercises in the form of hip lifts, knee extension and flexion, crunches, shoulder flexion and extension, elbow flexion and extension with resistance
219366115|NCT05632679|OTHER|personalized music intervention|participants who are randomly selected to this group will choose three set of music they prefer among the available selection of instrumental music in the application
218950655|NCT06266793|DEVICE|Holmium Laser|Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
219637211|NCT01290679|DRUG|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
219637212|NCT00562302|DEVICE|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
219637213|NCT01855243|DRUG|regular insulin|
219637214|NCT01855243|DRUG|70/30 insulin|
219637215|NCT01855243|DRUG|Glargine|
219637216|NCT01855243|DRUG|glulisine|
219637217|NCT01219764|DRUG|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
219637218|NCT05133089|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
219637219|NCT04068129|DEVICE|photoscreen|Determine amblyopia risk factors
219637220|NCT01413750|DRUG|Carboplatin|Given IV
219637221|NCT01413750|OTHER|Laboratory Biomarker Analysis|Correlative studies
219637222|NCT01413750|DRUG|Paclitaxel|Given IV
219637223|NCT01413750|OTHER|Placebo Administration|Given PO
219637224|NCT01413750|DRUG|Vorinostat|Given PO
219637225|NCT00943150|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
219637226|NCT00943150|PROCEDURE|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
218950656|NCT06266793|DEVICE|Thulium Laser|Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
218950657|NCT05014737|OTHER|no intervention|this is an abservational study and no intervention will be involved
218950658|NCT05783557|DRUG|Clevidipine Butyrate Injectable Emulsion|intravenous injection
219637227|NCT03124407|DRUG|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
219637228|NCT03124407|OTHER|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
219637229|NCT06667206|BIOLOGICAL|Licenced Measles-Rubella vaccine|Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme
219637230|NCT04411277|DEVICE|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
219637231|NCT04411277|DIAGNOSTIC_TEST|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
219637232|NCT05842447|DIETARY_SUPPLEMENT|367 mg Pomanox group|Treatment with 367 mg Pomanox®P30 during 12 weeks
219637233|NCT05842447|DIETARY_SUPPLEMENT|700 mg Pomanox group|Treatment with 700 mg Pomanox®P30 during 12 weeks
219637234|NCT05842447|DIETARY_SUPPLEMENT|Control group|Treatment with maltodextrin during 12 weeks
218950659|NCT05783557|DRUG|Cleviprex®|intravenous injection
218950660|NCT00313781|DRUG|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
218950661|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
218950662|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
218950663|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
218950664|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
218950665|NCT00272662|DRUG|peginesatide|
218950666|NCT02199717|DEVICE|Accelerometer|
218950667|NCT03567343|DIETARY_SUPPLEMENT|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
218950668|NCT03567343|OTHER|Control|Placebo
218950669|NCT01090583|OTHER|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
218950670|NCT00047645|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
218950671|NCT00518960|DRUG|ProAlgaZyme|
218950672|NCT00907452|DRUG|melphalan-prednisone-thalidomide|
218950673|NCT00907452|DRUG|lenalidomide-dexamethasone|
218950674|NCT00187603|BEHAVIORAL|tobacco cessation program|
218950675|NCT05515185|DRUG|KT095 CAR-T injection|Clearance of lymphocytes
219637235|NCT01871493|DRUG|LY2605541|Administered subcutaneous (SQ)
219637236|NCT01871493|DRUG|Insulin Lispro|Administered SQ
219637237|NCT00811330|DRUG|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
219637238|NCT05555524|OTHER|Baby oil|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
218950676|NCT03543072|DRUG|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
218950677|NCT02338570|DRUG|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
218950678|NCT05089851|PROCEDURE|Onabotulinumtoxin A|Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
218950679|NCT05089851|COMBINATION_PRODUCT|Facial Cleanser|Facial Cleanser to be used by participants twice daily
218950680|NCT05089851|COMBINATION_PRODUCT|Facial Moisturizer|Bland moisturizer to be used by study participants after serum twice daily.
218950681|NCT05089851|COMBINATION_PRODUCT|Sunscreen|Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
218950682|NCT05067218|DEVICE|buzzy device|bee shaped with wings could be frozen.
218950683|NCT05067218|OTHER|Conventinal anasthesia|normal technique of injection
218950684|NCT00834080|DRUG|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
218950685|NCT05483829|BEHAVIORAL|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
218950686|NCT00027872|DRUG|tipifarnib|Given orally
218950687|NCT00027872|OTHER|laboratory biomarker analysis|Correlative studies
218950688|NCT00185198|DRUG|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
219549701|NCT03671954|BEHAVIORAL|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
219549702|NCT03671954|OTHER|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
219549703|NCT03671954|OTHER|Preoperative Assessments|"Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)"
219549704|NCT05885412|GENETIC|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
219549705|NCT03589430|OTHER|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
219549706|NCT04155450|OTHER|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
219549707|NCT04155450|OTHER|McKenzie Extension Exercise Protocol|"Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
219549708|NCT04155450|OTHER|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
219549709|NCT00174421|DRUG|Treatment with Genotropin in different dosages|
219549710|NCT03577938|DRUG|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
219549711|NCT03577938|OTHER|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
219549712|NCT03560843|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
219549713|NCT03358147|DRUG|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
219549714|NCT03358147|DRUG|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
219549715|NCT03358147|DRUG|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
219549716|NCT03358147|DRUG|Placebo MDI|Placebo taken as 2 inhalations BID
219549717|NCT03358147|DRUG|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
219549718|NCT03997019|PROCEDURE|opioid analgesia|opioid analgesia will be used with general anaesthesia
219549719|NCT03997019|PROCEDURE|ESP block|ultrasound guided ESP Block before anaesthesia induction
219549720|NCT05109377|DIAGNOSTIC_TEST|Endocan|Endocan will measured before and after treatment
219549721|NCT05109377|DRUG|tadalafil|tadalafil
219549722|NCT06558955|BEHAVIORAL|Technology-enabled anticipatory guidance and peer support|The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
219549723|NCT06558955|BEHAVIORAL|Conventional health education|Participants on this arm will receive conventional child oral health education materials at 4 time points.
219549724|NCT02704091|DRUG|Smecta|
219549725|NCT02704091|DRUG|Smecta placebo|
219549726|NCT03061591|DIETARY_SUPPLEMENT|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
218950689|NCT00185198|DRUG|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
218950690|NCT03530709|OTHER|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
218950691|NCT00118495|DRUG|Non-prescription Zestra(TM): patented formulation|
218950692|NCT00825253|DRUG|biphasic insulin aspart 30|
218950693|NCT00825253|DRUG|biphasic human insulin 30|
218950694|NCT03707275|DEVICE|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
218950695|NCT03707275|OTHER|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
218950696|NCT00331110|DEVICE|Laterally-Wedged Insole with Ankle Strapping|
218950697|NCT00331110|DEVICE|Laterally-Weged Insole|
219055170|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
219055171|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
219055172|NCT05875324|DEVICE|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
219055173|NCT05875324|OTHER|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
218950698|NCT01845623|DRUG|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
218950699|NCT01845623|DRUG|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
218950700|NCT01845623|OTHER|Placebo Concept 1|Placebo administered via the Concept 1 device.
218950701|NCT01845623|OTHER|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
219055174|NCT01610700|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
219549727|NCT03061591|OTHER|Placebo|Placebo capsules
219549728|NCT02524691|DEVICE|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
218950702|NCT01975857|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
218950703|NCT01975857|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
219549729|NCT05406050|DRUG|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
219549730|NCT05406050|DRUG|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
219549731|NCT00503789|PROCEDURE|fecal bacteria analysis|ad lib feeding
218950704|NCT00948467|DRUG|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
218950705|NCT04268602|OTHER|local anesthetic injection|1% lidocaine
218950706|NCT02996058|DRUG|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
218950707|NCT02996058|DRUG|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
218950708|NCT03977311|DEVICE|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
219549732|NCT00298961|DEVICE|Videoconference equipment FALCON/IP|
218950709|NCT03977311|RADIATION|Radiation therapy|-Standard of Care
219637239|NCT05555524|OTHER|Placebo|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
219637240|NCT06968884|OTHER|Protocol based|"Preoperative administration of iron, b12 and folate if criteria is met. Medication to aid in smoking cessation is offered if patient uses tobacco. Nutritional supplements offered pre-operative is patient malnurished and preoperative drink offered to all.~Anaesthetic method adapted with increased use of epidural, blocks and local anaesthesia.~Administration on TXA and fluids according to protocol. Postoperative nutritional drink to increase protein intake. Early mobilisation to reduce risk of VTE."
219637241|NCT06968884|PROCEDURE|Control (Standard treatment)|"Preoperative bloods including haemoglobin to establish that surgery is safe. Transfusions given if clinically necessary, no other protocol for anaemia treatment other then available clinical guidelines.~Peri- and postoperative treatment given in accordance with best clinical practice, no additional protocol."
219637242|NCT06620640|DEVICE|Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.|Nigth stimulation
219637243|NCT03315286|DEVICE|SHADE Ultraviolet Sensor|Patients will wear device for 6 months in addition to their own method of photo-protection.
218950710|NCT06435559|OTHER|Neurotablet® and Neuropsychological evaluations|The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
219637244|NCT03315286|BEHAVIORAL|Standard of care counseling|Patients will use their own method of photo-protection
219637245|NCT05037357|DIAGNOSTIC_TEST|Plasma EBV DNA qPCR test|Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
219637246|NCT03003039|BIOLOGICAL|GB241|Single intravenous infusion (IV) 375 mg/m2
219637247|NCT03003039|BIOLOGICAL|Rituximab|Single intravenous infusion (IV) 375 mg/m2
219637248|NCT02604498|DRUG|Nemonoxacin|Single dose 500mg oral
218950711|NCT06435559|OTHER|Neuropsychological evaluations|Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
219637249|NCT06968299|DIETARY_SUPPLEMENT|ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules|Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.
219637250|NCT04423770|OTHER|No intervention|No intervention; this is a purely observational study
219637251|NCT03339193|DEVICE|Left atrial appendage closure|Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
219637252|NCT06327503|OTHER|saliva samples collecting|non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container
219637253|NCT00049465|PROCEDURE|fatigue assessment and management|
219637254|NCT00049465|PROCEDURE|management of therapy complications|
219637255|NCT00049465|PROCEDURE|psychosocial assessment and care|
218950712|NCT00003001|DRUG|fluorouracil|
219055175|NCT01610700|DRUG|Placebo|Each actuation of placebo delivered the excipients only.
219637256|NCT03075891|DRUG|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
219637257|NCT03075891|DRUG|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
219637258|NCT03075891|OTHER|Oral placebo capsules|1 Capsule once-daily for 12 weeks
219637259|NCT05852717|PROCEDURE|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
219637260|NCT05852717|DRUG|GDP|Gemcitabine Cisplatin Dexamethasone
219637261|NCT05852717|DRUG|Epcoritamab|Epcoritamab
219637262|NCT06967766|BEHAVIORAL|health education based on the Metaphor-Embedded Integrated Behavioral Model|In each intervention scenario, health education information is set to target key behaviors in the scenario. In the main scenarios for obtaining antibiotics, such as township health centers, village clinics, and community pharmacies, scenario-driven interventions are carried out for two key behaviors: patients actively asking for antibiotics (led by doctors in township health centers) and customers buying antibiotics without prescriptions (led by community pharmacy staff).
218950713|NCT00003001|DRUG|gemcitabine hydrochloride|
218950714|NCT00003001|DRUG|leucovorin calcium|
218950715|NCT00600561|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction Intervention
218950716|NCT00434616|PROCEDURE|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
218950717|NCT00434616|BIOLOGICAL|saline injection|saline injections
219637263|NCT06968338|BIOLOGICAL|ARGX-213|Intravenous or subcutaneous administrations of ARGX-213
219637264|NCT06968338|OTHER|Placebo|Intravenous or subcutaneous administrations of placebo
219637265|NCT04957615|BIOLOGICAL|Nivolumab|Given IV
219637266|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
218950718|NCT04842825|DRUG|Er Zhi Wan combined with Si Wu Tang|"The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days"
218950719|NCT04842825|DRUG|Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder|The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
218950720|NCT03865316|DEVICE|SedLine Vs Comparator Test Group|Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
218950721|NCT00060554|DRUG|fondaparinux sodium|
218950722|NCT00060554|DRUG|heparin|
218950723|NCT00060554|PROCEDURE|percutaneous coronary intervention (PCI)|
218950724|NCT04084561|BEHAVIORAL|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (\~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (\~90%).
218950725|NCT04084561|BEHAVIORAL|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (\~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (\~10%).
218950726|NCT04084561|BEHAVIORAL|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
218950727|NCT04084561|BEHAVIORAL|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
218950728|NCT03914963|BIOLOGICAL|Fibrin sealant hemipelvis|Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
218950729|NCT03914963|BIOLOGICAL|Control hemipelvis|Contralateral hemipelvis not treated with fibrin sealant
218950730|NCT00678743|DRUG|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
218950731|NCT05030948|BEHAVIORAL|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
218950732|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
219055176|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
219055177|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
218950733|NCT03658876|DRUG|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
219055178|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
219055179|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
219055180|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
219055181|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
219055182|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
219055183|NCT01899924|BEHAVIORAL|Event Related Potentials recording|
219549733|NCT06253260|DRUG|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
219549734|NCT06253260|DRUG|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
219549735|NCT04552665|DEVICE|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
219549736|NCT00726830|DRUG|methadone hydrochloride|Given orally
219549737|NCT00726830|DRUG|morphine sulfate|Given orally
219549738|NCT00726830|DRUG|oxycodone hydrochloride|Given orally
219549739|NCT05235568|DEVICE|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
219549740|NCT00245739|DRUG|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
219549741|NCT00963495|DRUG|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
219549742|NCT04114890|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
219549743|NCT01860638|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
218950734|NCT03658876|DRUG|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
218950735|NCT00057343|DRUG|Zevalin (ibritumomab tiuxetan)|
218950736|NCT00057343|DRUG|Rituxan (rituximab)|
218950737|NCT00900887|DRUG|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
218950738|NCT00900887|DRUG|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
218950739|NCT00900887|DRUG|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
218950740|NCT01330017|DRUG|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
218950741|NCT01330017|DRUG|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
218950742|NCT01330017|DRUG|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
218950743|NCT06320925|DEVICE|Standard of Care Treatment|Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
218950744|NCT05552144|DEVICE|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
218950745|NCT05795478|DRUG|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
218950746|NCT05795478|DRUG|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
218950747|NCT05795478|DRUG|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
218950748|NCT05795478|DRUG|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
218950749|NCT04816409|OTHER|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~\- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
218950750|NCT04816409|OTHER|Neurodevelopmental therapy|"Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
218950751|NCT04863027|RADIATION|Thoracic radiotherapy|Patients will have pre-treatment and post-treatment perfusion DECT for baseline and post-treatment lung function
218950752|NCT04650880|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation
218950753|NCT04650880|OTHER|Placebo|Placebo tablets with the same external appearance
218950754|NCT00910143|PROCEDURE|conventional rectal surgery|type of rectal surgery before the introduction of TME
218950755|NCT00910143|PROCEDURE|total mesorectal excision|total mesorectal excision
218950756|NCT04090099|OTHER|Erector spina plane block|While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
218950757|NCT02616146|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
218950758|NCT02616146|DRUG|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
218950759|NCT05202158|PROCEDURE|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
218950760|NCT05202158|PROCEDURE|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
219055184|NCT03866993|BIOLOGICAL|AK105|IV infusion
219055185|NCT03866993|DRUG|Paclitaxel|IV infusion
219549744|NCT01860638|DRUG|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
219055186|NCT03866993|DRUG|Carboplatin|IV infusion
219055187|NCT03866993|DRUG|Placebo|IV infusion
219055188|NCT02818205|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
218950761|NCT06191211|BEHAVIORAL|Motivational Interviewing, AIMS|Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.
218950762|NCT06191211|BEHAVIORAL|Facility engagement|A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
218950763|NCT04463511|OTHER|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
218950764|NCT06230601|OTHER|Cough Trick Method|During the Blood Collection Procedure in School-Age Children, one group will use the Cough Trick Method
218950765|NCT06230601|OTHER|Pinwheel Blowing method|Pinwheel Blowing method
218950766|NCT04444206|PROCEDURE|Transvaginal ultrasound cervical length screening|Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
218950767|NCT01221272|DRUG|Ranolazine|"* One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
218950768|NCT01221272|DRUG|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
219055189|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
219055190|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
219055191|NCT04414670|PROCEDURE|C/S|laparoscopic or robotic metroplasty
219055192|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
219055193|NCT00001022|DRUG|Zidovudine|
219055194|NCT00001022|DRUG|Zalcitabine|
219055195|NCT00001022|DRUG|Didanosine|
219366116|NCT05632679|OTHER|selected audio book|participants who are randomly selected to this group will choose one audio book they prefer among the available selection of audio books on the tablet
219366117|NCT01911026|OTHER|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
219366118|NCT03498157|BEHAVIORAL|Exercise|The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
219366119|NCT03498157|BEHAVIORAL|Prehabilitation Education|Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey
219366120|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
219366121|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
219366122|NCT05999825|BIOLOGICAL|Sm-p80 + GLA-SE Vaccine|30 μg Sm-p80 + 5 μg GLA-SE
219366123|NCT05999825|OTHER|Placebo|0.9% Sterile Normal Saline
219366124|NCT05999825|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
219366125|NCT00453466|BEHAVIORAL|EBW group intervention to empower battered women|
219366126|NCT01262183|DRUG|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
219366127|NCT01262183|DRUG|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
219366128|NCT04963829|BIOLOGICAL|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
219366129|NCT04963829|BIOLOGICAL|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
219366130|NCT04963829|BIOLOGICAL|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
219366131|NCT01777672|BEHAVIORAL|Dietary and oral hygiene recommendations|
219366132|NCT01777672|DIETARY_SUPPLEMENT|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
219366133|NCT01777672|DEVICE|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
219366134|NCT01777672|DEVICE|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
219366135|NCT01012492|DRUG|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
219366136|NCT00459069|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
218950769|NCT01221272|PROCEDURE|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
218950770|NCT01221272|BEHAVIORAL|Exercise|Treadmill stress test
218950771|NCT04609007|BEHAVIORAL|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
218950772|NCT04609007|BEHAVIORAL|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
218950773|NCT04135170|COMBINATION_PRODUCT|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
218950774|NCT03521102|DRUG|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
218950775|NCT03521102|DRUG|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
218950776|NCT00257335|PROCEDURE|IMRT|
218950777|NCT04364438|DEVICE|Electric Muscle Stimulation|EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.
218950778|NCT04364438|DEVICE|Transcutaneous Electric Nerve Stimulation|TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
219055196|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
219055197|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
219055198|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
219055199|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
219549745|NCT01860638|DRUG|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
219549746|NCT01860638|RADIATION|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
218950779|NCT03678714|BEHAVIORAL|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
218950780|NCT03678714|BEHAVIORAL|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
218950781|NCT05001633|BEHAVIORAL|modified media content paradigm|media content
218950782|NCT05001633|BEHAVIORAL|control|media content experience
218950783|NCT00252252|DEVICE|VPAP non-invasive ventilator|
218950784|NCT00252252|DEVICE|AutoVPAP non-invasive ventilator|
218950785|NCT03894722|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group.
218950786|NCT03894722|PROCEDURE|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
218950787|NCT03894722|PROCEDURE|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
218950788|NCT03894722|PROCEDURE|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
219055200|NCT00302224|DRUG|2S, 4R Ketoconazole (DIO-902)|
219055201|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
219549747|NCT01860638|DRUG|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
219549748|NCT01860638|DRUG|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
219549749|NCT04738019|DIAGNOSTIC_TEST|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
218950789|NCT04316975|OTHER|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
218950790|NCT06165458|OTHER|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
218950791|NCT06165458|OTHER|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
218950792|NCT06165458|OTHER|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
218950793|NCT06165458|OTHER|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
218950794|NCT01106092|BIOLOGICAL|GSK2036874A vaccine|Intramuscular, single dose
218950795|NCT01106092|BIOLOGICAL|Zilbrix™/Hib vaccine|Intramuscular, single dose
218950796|NCT01106092|BIOLOGICAL|Poliorix™|Intramuscular, single dose
218950797|NCT00320957|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
218950798|NCT01030081|DRUG|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
218950799|NCT01030081|DRUG|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
218950800|NCT02906982|OTHER|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
218950801|NCT02906982|OTHER|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
218950802|NCT01371032|DEVICE|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
219055202|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
219549750|NCT03073798|DRUG|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
219549751|NCT03073798|DRUG|Placebo|500 mcg of placebo is used
219549752|NCT01250730|DRUG|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
219549753|NCT01250730|DRUG|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
219549754|NCT01250730|DRUG|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
218950803|NCT01371032|DEVICE|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
219549755|NCT02241577|PROCEDURE|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
218950804|NCT04427826|DRUG|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
218950805|NCT04124744|OTHER|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
218950806|NCT04124744|OTHER|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
218950807|NCT01473368|DIETARY_SUPPLEMENT|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
218950808|NCT01473368|DRUG|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
218950809|NCT05358340|DIAGNOSTIC_TEST|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
218950810|NCT05616689|OTHER|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
218950811|NCT00612495|DRUG|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
218950812|NCT04143308|OTHER|Simultaneous training of walking and cognitive group|"Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP"
218950813|NCT04143308|OTHER|Cognitive training group|"Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP"
218950814|NCT04143308|OTHER|Treatment as usual group|Keep treatment as usual
218950815|NCT00003388|BIOLOGICAL|filgrastim|
218950816|NCT00003388|DRUG|cyclophosphamide|
218950817|NCT00003388|DRUG|cytarabine|
218950818|NCT00003388|DRUG|methotrexate|
218950819|NCT00003388|DRUG|pegylated liposomal doxorubicin hydrochloride|
218950820|NCT00003388|DRUG|prednisone|
218950821|NCT00003388|DRUG|vincristine sulfate|
218950822|NCT00003388|RADIATION|radiation therapy|
219549756|NCT02241577|PROCEDURE|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
219055203|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
219055204|NCT04841343|DRUG|Triamcinolone|Triamcinolone in sinus
219055205|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
219055206|NCT02648698|DRUG|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
219055207|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
219055208|NCT03103529|OTHER|Active Rehabilitation|
219055209|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
219055210|NCT01640301|DRUG|Cyclophosphamide|Given IV
219549757|NCT01813864|BEHAVIORAL|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
218950823|NCT05365854|PROCEDURE|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
219637267|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
219637268|NCT00828568|DRUG|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
219637269|NCT00828568|DRUG|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
218950824|NCT04839562|DRUG|Solriamfetol 75 MG|Daily oral consumption
218950825|NCT04839562|DRUG|Solriamfetol 150 MG|Daily oral consumption
218950826|NCT04839562|OTHER|Placebo|Placebo
218950827|NCT04158193|OTHER|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
218950828|NCT04158193|OTHER|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
219055211|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
219055212|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
219055213|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
219055214|NCT06534515|DEVICE|Tomatis auditory stimulation|Traditional Tomatis Method Protocol
219055215|NCT02451657|OTHER|No Intervention|No intervention was administered in this study
219055216|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
219055217|NCT01361412|BIOLOGICAL|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
219055218|NCT01361412|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
219637270|NCT00828568|DRUG|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
219637271|NCT01096719|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
218950829|NCT01627834|DRUG|Ropinirole|
218950830|NCT05624047|BEHAVIORAL|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
219055219|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
219055220|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
219055221|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
218950831|NCT05624047|BEHAVIORAL|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
219055222|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
219055223|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
219637272|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED \< 1.0) for at least 10 items consumed per day and limit high ED foods (ED \> 3.0) to two items consumed per day.
219637273|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and \< 30% kcals from fat.
219055224|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
218950832|NCT04896970|OTHER|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
218950833|NCT05146453|PROCEDURE|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
218950834|NCT05146453|OTHER|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
219055225|NCT01389908|DRUG|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
219055226|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
219055227|NCT03047616|OTHER|Blood and Urine Collection|
219055228|NCT02397395|DRUG|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
219055229|NCT02397395|DRUG|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
219055230|NCT06138574|DRUG|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
219055231|NCT06138574|DRUG|Remifentanil|Remifentanil
219366137|NCT06282328|DIAGNOSTIC_TEST|HIV test|Bedside rapid capillary HIV test
219549758|NCT00728351|DRUG|vildagliptin + metformin|
219549759|NCT00728351|DRUG|metformin|1000 bid metformin
219549760|NCT02827045|DEVICE|Vestibular test|
219549761|NCT04182126|OTHER|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
219549762|NCT04182126|OTHER|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
219549763|NCT04182126|OTHER|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
218950835|NCT04718844|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
218950836|NCT04718844|DRUG|Placebo|Sodium chloride for s.c. injection
218950837|NCT04548492|OTHER|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
218950838|NCT02933671|PROCEDURE|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
219366138|NCT05449457|OTHER|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
219366139|NCT01902940|OTHER|Natural History|Assessment of natural history in IBM and CCFDN
219366140|NCT02964156|OTHER|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
219366141|NCT02964156|OTHER|No intervention|No intervention
219366142|NCT00569257|DRUG|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
219366143|NCT05329675|DIETARY_SUPPLEMENT|Sinphar Lipucan Capsule|oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
219366144|NCT03720457|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
219366145|NCT03002974|DRUG|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
219366146|NCT03002974|DRUG|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
219366147|NCT03002974|DRUG|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
219366148|NCT03002974|DRUG|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
219366149|NCT01737931|DRUG|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
219366150|NCT01737931|DRUG|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
219366151|NCT02288884|DEVICE|Acticoat PostOp|
219366152|NCT02288884|DEVICE|OpSite PostOp|
219367118|NCT05742555|OTHER|Virtual reality intervention|After the relatives of the patients included in the experimental group are informed about the study, they will be asked to fill in the Participant Information Form, Nottingham Health Profile (NSP) and Warwick-Edinburgh Mental Well-Being Scale (WEMIOÖ) after obtaining their permission. The virtual reality intervention will be applied to the caregivers at a suitable time of the day (when the patient's care and treatment is not intensive, the caregiver wishes). Different nature scenes (sea, forest, stream) with different types of music (classical music, nature sounds, relaxing music) will be watched for 10 minutes, 3 days a week. The application will be made for 4 weeks. At the end of this period, they will be asked to fill the NSP and WEMİOÖ again as a final test.
219055232|NCT05203029|OTHER|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
219055233|NCT03028168|OTHER|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
219055234|NCT03028168|OTHER|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
219055235|NCT03028168|OTHER|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
219055236|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
219055237|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
219055238|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
219055239|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
219055240|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
219055241|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
219055242|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
219055243|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
219055244|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
219055245|NCT02855502|DRUG|Prednisolone|
219637274|NCT03864224|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
219637275|NCT02279654|DRUG|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
219637276|NCT04502654|DEVICE|Actiwatch 2 (Philips Respironics, Murrysville, USA)|Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
218950839|NCT02933671|PROCEDURE|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
218950840|NCT02933671|DRUG|Ropivacaine|Local anesthetic (numbing drug)
218950841|NCT02933671|DRUG|Saline|Salt water placebo
218950842|NCT02099071|DRUG|ACT-389949 1 mg|
218950843|NCT02099071|DRUG|ACT-389949 5 mg|
218950844|NCT02099071|DRUG|ACT-389949 20 mg|
218950845|NCT02099071|DRUG|ACT-389949 50 mg|
218950846|NCT02099071|DRUG|ACT-389949 100 mg|
218950847|NCT02099071|DRUG|ACT-389949 200 mg|
218950848|NCT02099071|DRUG|ACT-389949 500 mg|
218950849|NCT02099071|DRUG|ACT-389949 1000 mg|
219055246|NCT02855502|DRUG|Placebo|
219055247|NCT00377767|BEHAVIORAL|To change structure and roles of primary care teams to optimize prevention of obesity|
219055248|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
219367119|NCT01740180|OTHER|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
219367120|NCT02381379|DRUG|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
219637277|NCT05747326|DRUG|oral vinorelbine and capecitabine|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
219637278|NCT00841113|DRUG|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
218950850|NCT02099071|DRUG|Placebo|
218950851|NCT01744145|OTHER|Interventional 40-60|This group will receive the intervention aged 40-60
218950852|NCT01744145|OTHER|Interventional 60 and above|This group will receive the intervention aged 60 and above.
218950853|NCT00828373|DRUG|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
218950854|NCT00828373|DRUG|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
218950855|NCT01246466|DEVICE|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
218950856|NCT04612296|GENETIC|Research genetic analysis|Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
218950857|NCT05334095|DEVICE|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
218950858|NCT05334095|DEVICE|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
218950859|NCT00877773|DRUG|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
218950860|NCT00562666|OTHER|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
218950861|NCT00140361|DRUG|Sulfadoxine-pyrimethamine|
218950862|NCT00140361|DRUG|sulfadoxine-pyrimethamine plus artesunate|
218950863|NCT00140361|DRUG|lumefantrine plus artemether|
218950864|NCT00140361|BEHAVIORAL|Sleeping under insecticide-treated bednet|
218950865|NCT03218683|DRUG|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
218950866|NCT03218683|DRUG|AZD5991 + Venetoclax|Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
218950867|NCT04995289|OTHER|Prone position on ECMO patient|blood gas analysis before and after PP
218950868|NCT00456807|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
218950869|NCT00456807|BIOLOGICAL|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
218950870|NCT00706498|DRUG|BI 2536|
219637279|NCT00841113|DRUG|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
218950871|NCT03328182|DEVICE|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
218950872|NCT04367571|OTHER|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
218950873|NCT04367571|OTHER|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
218950874|NCT00140543|DRUG|sirolimus versus mycophenolate mofetil|
218950875|NCT00743236|PROCEDURE|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
218950876|NCT00743236|PROCEDURE|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
218950877|NCT06665308|OTHER|No intervention|No intervention will be administered to study participants. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.
218950878|NCT02673047|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
218950879|NCT00716833|DRUG|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
219637280|NCT00552643|DEVICE|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
219637281|NCT00552643|DEVICE|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
219637282|NCT00175149|DRUG|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
219637283|NCT03208998|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
219637284|NCT02821754|DRUG|Durvalumab|Flat dose of 1500 mg every 4 weeks.
219637285|NCT02821754|DRUG|Tremelimumab|Flat dose of 75 mg every 4 weeks for up to 4 doses.
218950880|NCT00716833|DRUG|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
218950881|NCT02608333|BEHAVIORAL|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
218950882|NCT02608333|BEHAVIORAL|control group|"heteregenous as usual community intervention"
218950883|NCT05010642|DEVICE|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
218950884|NCT02984072|DRUG|Menthol|Topical menthol in aqueous cream
218950885|NCT02984072|DRUG|Aqueous Cream|placebo
218950886|NCT04062344|OTHER|Swab|Rectal swab before and after the drug provocation testing
218950887|NCT03841578|DIETARY_SUPPLEMENT|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
218950888|NCT00931840|DRUG|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
218950889|NCT01012219|DRUG|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
218950890|NCT01012219|DRUG|Comparator: aspirin|81 mg oral tablet once daily for 7 days
218950891|NCT01012219|DRUG|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
218950892|NCT01012219|DRUG|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
218950893|NCT01012219|DRUG|Comparator: placebo|placebo oral tablet once daily for 7 days
218950894|NCT02941536|DIAGNOSTIC_TEST|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
218950895|NCT00674596|DRUG|ramipril|ramipril 10 mg/day during 3 months
218950896|NCT04028271|DEVICE|Comfort-in injection system|local anesthesia during dental treatment
218950897|NCT04028271|OTHER|conventional injection with dental needle|for local anesthesia during dental treatment
218950898|NCT03010644|OTHER|n/a - observational study|n/a - observational study
218950899|NCT03322319|PROCEDURE|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
218950900|NCT03661567|RADIATION|chest radiation|split-course chest radiation
218950901|NCT03661567|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
218950902|NCT03661567|DRUG|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
218950903|NCT02171910|DRUG|Doxapram|
218950904|NCT02171910|DRUG|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
218950905|NCT00970385|DRUG|CHOP21|"CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
218950906|NCT00970385|DRUG|VIP/ABVD|"VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D"
218950907|NCT00970385|RADIATION|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
218950908|NCT01542567|DRUG|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
218950909|NCT01542567|DRUG|Placebo|Placebo suppositories
218950910|NCT00081094|PROCEDURE|18F-Fluorodeoxyglucose-PET (FDG-PET)|
218950911|NCT00081094|PROCEDURE|11Carbon-Acetate-PET|
218950912|NCT06084975|PROCEDURE|Splenic vessels preservation|preservation the splenic vessels
218950913|NCT03706547|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
218950914|NCT03706547|DRUG|Fludarabine|30mg/m2/d
218950915|NCT03706547|DRUG|Cyclophosphamide|300mg/m2/d
218950916|NCT02775019|DIETARY_SUPPLEMENT|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
218950917|NCT02775019|DIETARY_SUPPLEMENT|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
218950918|NCT00950339|DRUG|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
218950919|NCT00950339|DRUG|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
218950920|NCT00950339|DRUG|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
218950921|NCT02980809|DRUG|Apatinib|
218950922|NCT02980809|DRUG|Topotecan|
219055249|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
218950923|NCT01491113|DRUG|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
218950924|NCT01491113|DRUG|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
218950925|NCT01131819|DEVICE|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
218950926|NCT01593267|PROCEDURE|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
219055250|NCT05631067|BEHAVIORAL|Remote blood pressure monitoring|Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum
219055251|NCT05631067|DIAGNOSTIC_TEST|NT proBNP assessment|Participants will have biomarker assessment at 0-2 days postpartum
218950927|NCT01593267|PROCEDURE|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
219637286|NCT02821754|PROCEDURE|Trans-arterial Catheter Chemoembolization (TACE)|TACE will be performed on Day 36 (+/-96hrs).
219055252|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
219055253|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
219055254|NCT04896957|BEHAVIORAL|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
219055255|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
219055256|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
219637287|NCT02821754|PROCEDURE|Radiofrequency Ablation (RFA)|RFA will be performed on Day 36 (+/-96hrs).
219637288|NCT02821754|PROCEDURE|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
219055257|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
219055258|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
219055259|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
219637289|NCT05724680|OTHER|cognitive behavior therapy|Psycho-therapeutic intervention
219637290|NCT05693064|OTHER|wait-list|wait-list
219637291|NCT05693064|PROCEDURE|chiropractic adjustments|chiropractic adjustments
219637292|NCT02324504|DEVICE|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
219637293|NCT06575010|DRUG|Liposomal bupivacaine|20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery
219637294|NCT06575010|DRUG|Bupivacaine Hcl 0.5% Inj|0.75% bupivacaine will be given in the shoulder block prior to surgery
219637295|NCT06575010|DRUG|Dexamethasone|10 mg Dexamethasone will be given in the shoulder block prior to surgery
219637296|NCT05603611|DEVICE|Pulmonary vein isolation|Local electrical isolation of PV ostia to prevent recurrence of AF due to ectopic PV-triggers
219637297|NCT02432612|DRUG|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
218950928|NCT06418139|OTHER|No intervention|No intervention added by the study
218950929|NCT00646854|DRUG|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
218950930|NCT00646854|DRUG|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
219637298|NCT00766636|DRUG|Gemcitabine|"Arm A:~1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
219637299|NCT00766636|RADIATION|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
219637300|NCT00766636|DRUG|Erlotinib|100 mg daily by mouth on days 1-42.
219637301|NCT00766636|PROCEDURE|Surgery|Surgical removal of the pancreas and duodenum
218950931|NCT00712400|DRUG|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
218950932|NCT00712400|DRUG|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
218950933|NCT02706990|DEVICE|Physica KR|Kinematic retaining total knee implant
218950934|NCT02706990|DEVICE|Physica PS|Posterior stabilized total knee implant
218950935|NCT03680235|OTHER|Informational Intervention|Receive standard information about breastfeeding and pregnancy
218950936|NCT03680235|OTHER|Informational Intervention|Receive information about breastfeeding and cancer
218950937|NCT03680235|OTHER|Interview|Participate in focus groups
218950938|NCT03680235|OTHER|Survey Administration|Ancillary studies
218950939|NCT01956344|BEHAVIORAL|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
218950940|NCT05258188|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
218950941|NCT05258188|OTHER|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
218950942|NCT02051699|PROCEDURE|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
218950943|NCT03908489|PROCEDURE|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
218950944|NCT03908489|PROCEDURE|vital pulpotomy using mta|mta vital pulpotomy
219055260|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
218950945|NCT06328387|DRUG|Hydroxychloroquine|The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
218950946|NCT06328387|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
218950947|NCT06328387|DRUG|Trastuzumab Deruxtecan|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
218950948|NCT00756912|DRUG|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
219055261|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
218950949|NCT05334056|DRUG|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
218950950|NCT05188157|OTHER|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
218950951|NCT05188157|OTHER|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
218950952|NCT02350751|DRUG|MEDI8852|
218950953|NCT02350751|DRUG|Placebo|
219055262|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
219549764|NCT04182126|OTHER|Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides|Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
219549765|NCT04626440|PROCEDURE|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
218950954|NCT04424329|DIETARY_SUPPLEMENT|Fibers and probiotics|A blend of fibers and seven probiotics
219055263|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
219055264|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
219055265|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
219549766|NCT01637480|OTHER|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
219549767|NCT04999280|OTHER|Fiber Croissant (FIBCRO) Group|Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
219055266|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
219055267|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
219055268|NCT05060419|DRUG|Saline|180min
219055269|NCT05060419|DRUG|Saline|30min
219055270|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
219367121|NCT05004545|DRUG|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
219637302|NCT05686135|OTHER|90Second IBD|Patients will receive 90SecondIBD weekly at no charge via text message or email linked to a website.Each 90SecondIBD letter has an attractive photo, 250 words of targeted information on a specific topic and 3 specific action suggestions on the first page. The second page is a seven-item quiz on attitudes and behavior on the designated topic. The reader gets immediate feedback and advice. The third page is a personal story of someone with IBD about this topic. Finally, there is an evaluation of the specific 90SecondIBD issue and an opportunity to recommend topics.
219637303|NCT05743348|BEHAVIORAL|Telepsychotherapy|Remotely delivered psychotherapy sessions
219637304|NCT05542784|PROCEDURE|Modified LERV|"Patients routinely underwent LC. The ligature clamp clamps the distal end of the capsule tube. In this case, you need to perform two steps:~Laparoscopic operation: proximal incision, anterograde placement of guide wire into the duodenum. The catheter was removed and the balloon dilated. The balloon was released and removed when the ERCP was initiated for cannulation. After successful ERCP retrograde placement, the anterograde guide wire was pulled out and the gallbladder was removed.~ERCP procedure: After the anterograde guide wire was observed by duodenoscope, duodenal papilla was placed through a retrograde incision along the anterograde guide wire, and a retrograde cannula was inserted into the common bile duct. Remove stones by dragging them with a net basket or/and balloon. Angiography confirmed that there was no filling defect in the extrahepatic bile duct, and ENBD was indwelled."
219637305|NCT03271281|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
219637306|NCT03271281|DEVICE|PET/CT|Following injection of 68Ga-NODAGA-E\[c(RGDyK)\]2 the patients will be subjected to whole body PET/CT
219367122|NCT00560755|BIOLOGICAL|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
218950955|NCT00706576|DRUG|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
218950956|NCT04844710|COMBINATION_PRODUCT|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
219637307|NCT06353984|DIETARY_SUPPLEMENT|Minimeal product|Intervention product consisting of bioprocessed oats and chickpeas
218950957|NCT04844710|DRUG|standard care|standard care only
218950958|NCT00522925|DRUG|PS433540|200mg capsule, once daily for 28 days
218950959|NCT00522925|DRUG|placebo|placebo capsule, once daily for 28 days
218950960|NCT00522925|DRUG|PS433540|500mg capsule, once daily for 28 days
218950961|NCT02437227|DRUG|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
219637308|NCT06353984|DIETARY_SUPPLEMENT|Reference product|Reference product mimicking available soups and fruit drinks
219637309|NCT01474473|DEVICE|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
218950962|NCT02666157|DRUG|Dabigatran etexilate|this drug is administered twice per day for the entire study period
218950963|NCT02666157|DRUG|Rivaroxaban|this drug is administered once per day for the entire study period
218950964|NCT02666157|DRUG|Apixaban|this drug is administered twice per day for the entire study period
218950965|NCT05382000|DIAGNOSTIC_TEST|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
219367123|NCT00848120|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
219637310|NCT01474473|DEVICE|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
219637311|NCT02312089|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
219637312|NCT02477332|BIOLOGICAL|QGE031|
219637313|NCT02477332|BIOLOGICAL|Omalizumab|
219637314|NCT02477332|OTHER|Placebo|
218950966|NCT05633030|PROCEDURE|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
218950967|NCT01350544|BEHAVIORAL|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
218950968|NCT04825730|DRUG|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
218950969|NCT04290728|DEVICE|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
218950970|NCT04290728|OTHER|Apnea|Apnea without any application of oxygenation
218950971|NCT01444092|DRUG|Entocort|Entocort capsules, oral
218950972|NCT01037621|DRUG|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
218950973|NCT00918008|GENETIC|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
218950974|NCT05170776|OTHER|Pilates and postural correction exercise|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
218950975|NCT05170776|OTHER|Pilates exercises|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1"
218950976|NCT05170776|OTHER|postural correction exercises|"postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period."
218950977|NCT03661476|BEHAVIORAL|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
218950978|NCT02080702|DEVICE|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
218950979|NCT06420258|PROCEDURE|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
219637315|NCT02552069|DEVICE|Tritanium® cup|
218950980|NCT01809470|BEHAVIORAL|FIFA2013|Playing FIFA2013 for 1 hour
218950981|NCT01809470|BEHAVIORAL|Call of Duty|Playing Call of Duty for 1 hour
218950982|NCT01809470|BEHAVIORAL|Watching TV|Watching TV for 1 hour
218950983|NCT05853731|DEVICE|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
218950984|NCT05853731|DEVICE|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
218950985|NCT00373438|PROCEDURE|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
219367124|NCT01515228|DEVICE|Xience Prime|everolimus-eluting stent implantation
219367125|NCT01515228|DEVICE|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
219367126|NCT02344225|DRUG|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
219367127|NCT02344225|DRUG|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
219637316|NCT04657198|BIOLOGICAL|RSVPreF3 OA investigational vaccine (GSK3844766A)|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
219637317|NCT03359759|OTHER|Conected objects|"Every week, each patient report her symptoms and answer ten questions on the i-PAD. The connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls.~If nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. During the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, General Practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary."
218950986|NCT04549389|DEVICE|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
218950987|NCT01518738|BEHAVIORAL|breath attention training|4 week training
219055271|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
218950988|NCT01518738|BEHAVIORAL|working memory attention training|4 week training
218950989|NCT03452748|DEVICE|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
218950990|NCT01812980|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
218950991|NCT04363398|OTHER|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
219055272|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
219055273|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
219055274|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
219055275|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
219055276|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
219055277|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
219055278|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
219055279|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
219055280|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
219055281|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
219055282|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
219637318|NCT02549287|BEHAVIORAL|SafeCare|An evidence-based home visiting program
218950992|NCT04363398|OTHER|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
218950993|NCT01673347|BIOLOGICAL|Meniscal Allograft|Meniscal allograft
218950994|NCT02853799|OTHER|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
218950995|NCT02853799|DIETARY_SUPPLEMENT|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
218950996|NCT00560521|BEHAVIORAL|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
218950997|NCT03105544|OTHER|simulation-based training|As described under group descriptions
218950998|NCT05368454|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
218950999|NCT05368454|BEHAVIORAL|Standard of Care|All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
219055283|NCT01600300|DEVICE|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
219055284|NCT01600300|DEVICE|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
219055285|NCT01878604|GENETIC|Gene analysis|Gene analysis
219055286|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
219055287|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
219367128|NCT02344225|DRUG|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
219367129|NCT00093613|DRUG|sorafenib tosylate|Given PO
219637319|NCT02549287|BEHAVIORAL|Supportive Case Management|Child welfare services as usual
219637320|NCT00944242|DRUG|Sertraline|
219637321|NCT00944242|DRUG|Sertraline Hydrochloride|
219637322|NCT05321043|OTHER|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
219637323|NCT06250920|DEVICE|Virtual reality visual training|Children in intervention group were administered at home under the supervision of parents for 20 minutes per session every day with virtual reality visual training
219637324|NCT01506102|DEVICE|Thromboelastography|Thromboelastography during labor and after delivery
219055288|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
218951000|NCT01934543|OTHER|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
218951001|NCT01934543|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
218951002|NCT05323162|OTHER|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
218951003|NCT03211806|BEHAVIORAL|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
218951004|NCT03211806|DEVICE|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
218951005|NCT00177047|PROCEDURE|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
218951006|NCT00177047|DRUG|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
218951007|NCT00177047|DRUG|Melphalan|Administered intravenously 200 mg/m\^2
218951008|NCT00177047|BIOLOGICAL|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
218951009|NCT02661178|DRUG|emodepside (BAY 44-4400)|
219055289|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
219055290|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
219055291|NCT01086553|DRUG|budesonide|9mg budesonide OD
218951010|NCT02661178|DRUG|placebo|
219055292|NCT01086553|DRUG|budesonide|3mg budesonide TID
219055293|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
218951011|NCT04941443|DRUG|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
219055294|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
219055295|NCT03511521|DRUG|glargine|basal insulin
218951012|NCT04941443|DRUG|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
219055296|NCT03511521|DRUG|Insulin Aspart|prandial insulin
219055297|NCT00439400|DRUG|doxycycline|
219055298|NCT00439400|DRUG|placebo|
218951013|NCT03277820|DIETARY_SUPPLEMENT|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
219055299|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
219055300|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
219055301|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
219055302|NCT00011804|DRUG|Topiramate|
219055303|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
219055304|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
219055305|NCT02442921|DRUG|Placebo|Daily placebo
219055306|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
219055307|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
219055308|NCT04746937|DRUG|Norfloxacin|Standard therapy
219055309|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
219055310|NCT00440271|DRUG|tipranavir|
219055311|NCT00440271|DRUG|ritonavir|
219055312|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
219055313|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
219055314|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
219055315|NCT01980849|DRUG|Nadroparin, long term|
219055316|NCT01980849|DRUG|Nadroparin: short-term|
219055317|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
218951014|NCT03086031|BEHAVIORAL|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
218951015|NCT03086031|BEHAVIORAL|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
218951016|NCT03279627|OTHER|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
218951017|NCT02376959|BEHAVIORAL|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
218951018|NCT01768884|DRUG|Nitric Oxide|
218951019|NCT01768884|DRUG|Placebo|
218951020|NCT01613846|DRUG|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
218951021|NCT01613846|DRUG|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
218951022|NCT04848857|DRUG|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
218951023|NCT04848857|DRUG|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
218951024|NCT01242813|DRUG|ACZ885|
219055318|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
219055319|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
219207005|NCT06758115|PROCEDURE|Tuina (Massage) Therapy|"Operation Method:~Correct abnormal joint alignment - Manipulatively realign the vertebral segments and pelvis affected by scoliosis.~Correct abnormal muscle function - After realigning the vertebral bodies to their normal position, stretch the corresponding tight and shortened muscles while strengthening the muscles that need to be lengthened.~Restore joint stability - After adjusting the vertebrae and muscles, instruct the patient to hold the corrected posture for at least 10 seconds, then relax for 10 seconds. Repeat this cycle 3-5 times.~Restore sensorimotor control - Provide appropriate movement disturbances to patients maintaining the corrected posture to enhance proprioception and motor memory in the corresponding muscles.~The total duration of the manipulation is 20-25 minutes. Treatment is performed twice a week for a total of 12 weeks."
219055320|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
219055321|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
219055322|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
219055323|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
219207006|NCT06758193|OTHER|No intervention was applied in this study.|No intervention was applied in this study.
218951025|NCT00332735|DRUG|spinal administration of articaine|
218951026|NCT00332735|DRUG|spinal administration of bupivacaine|
218951027|NCT01910311|DRUG|Baricitinib|Administered orally
219055324|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
219055325|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
219055326|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
219207007|NCT06751017|DRUG|S-892216|S-892216 will be administered orally as a tablet.
219055327|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
219055328|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
219055329|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
219055330|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
219055331|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
219055332|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
219055333|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
219055334|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
219055335|NCT02189187|BEHAVIORAL|Mindfulness|
219055336|NCT02189187|BEHAVIORAL|Psychoeducation|
219207008|NCT06751017|DRUG|Carbamazepine|Carbamazepine will be administered orally as a tablet.
219367130|NCT00093613|OTHER|pharmacological study|Correlative studies
219549768|NCT04999280|OTHER|Control Croissant (CONCRO) Group|Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
218951028|NCT01910311|DRUG|Rifampicin|Administered orally
218951029|NCT04269083|OTHER|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
218951030|NCT01369329|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
218951031|NCT01369329|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
218951032|NCT01369329|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
218951033|NCT00650481|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
218951034|NCT00650481|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
218951035|NCT01836276|DRUG|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
219055337|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
218951036|NCT01566812|BEHAVIORAL|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
219055338|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
219055339|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
219055340|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
219055341|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
219055342|NCT02691767|DRUG|pazopanib|
218951037|NCT01566812|BEHAVIORAL|Usual care|Usual care applied in the hospital
218951038|NCT01847131|DRUG|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
218951039|NCT01847131|DRUG|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
218951040|NCT01708096|DIETARY_SUPPLEMENT|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
218951041|NCT01708096|DIETARY_SUPPLEMENT|Normal diet|normal diet 2 weeks before gastric by-pass
218951042|NCT00767182|OTHER|blood sample|biological markers evaluated : D-Dimer, sEPCR
218951043|NCT05062993|PROCEDURE|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
218951044|NCT01373736|DRUG|123I-meta-iodobenzylguanidine|
218951045|NCT03951168|BEHAVIORAL|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
218951046|NCT03951168|BEHAVIORAL|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
218951047|NCT01306578|DRUG|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
218951048|NCT01306578|PROCEDURE|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
219055343|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
219055344|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
219055345|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
218951049|NCT01413633|PROCEDURE|cholecystectomy|single incision laparoscopic cholecystectomy
218951050|NCT01609829|PROCEDURE|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
218951051|NCT01988701|OTHER|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
219055346|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
219055347|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
219055348|NCT01064921|DRUG|cisplatin|Given IV
219055349|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
219055350|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
219055351|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
219055352|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
218951052|NCT04938297|DRUG|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
218951053|NCT04938297|DRUG|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
218951054|NCT04938297|DRUG|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
218951055|NCT05260541|DRUG|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
218951056|NCT05260541|DRUG|Placebo|Once daily oral treatment for 4 weeks
218951057|NCT05260541|DRUG|40 mg PRAX-114|Once daily oral treatment for 8 weeks
218951058|NCT00147550|DRUG|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
218951059|NCT00537615|DRUG|PD 0332334|
218951060|NCT01336361|OTHER|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
218951061|NCT00885820|DRUG|Tacrolimus|Oral
218951062|NCT00885820|DRUG|MMF|Oral
218951063|NCT00885820|DRUG|Corticosteroids (Prednisone)|Oral
218951064|NCT03355482|DRUG|Methylprednisolone|160mg IM at baseline
218951065|NCT03355482|DRUG|Placebos|IM saline injection at baseline
218951066|NCT05443139|BEHAVIORAL|Well-being online|Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
218951067|NCT05967039|OTHER|Physiotherapy|Physiotherapy in respiratory rehabilitation
218951068|NCT03160547|OTHER|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
218951069|NCT03160547|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
218951070|NCT02122913|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
218951071|NCT04837326|OTHER|Heel Lance Blood Sampling in Facilitated Tucking Position|
218951072|NCT04837326|OTHER|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|
218951073|NCT04837326|OTHER|Heel Lance Blood Sampling Using White Noise|
218951074|NCT05229861|BEHAVIORAL|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
219055353|NCT01960231|OTHER|OGTT|
218951075|NCT05229861|BEHAVIORAL|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
218951076|NCT05608928|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
218951077|NCT05608928|DEVICE|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
218951078|NCT05608928|COMBINATION_PRODUCT|Placebo|microcrystalline cellulose
218951079|NCT04135105|OTHER|Normal hearing group|Observational
218951080|NCT00146055|PROCEDURE|Reduced intensity conditioning with allogeneic transplant|
218951081|NCT05282056|DIAGNOSTIC_TEST|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
218951082|NCT00004082|DRUG|carboplatin|
218951083|NCT00004082|DRUG|docetaxel|
218951084|NCT00004082|DRUG|gemcitabine hydrochloride|
218951085|NCT02173262|DRUG|G-CSF|
218951086|NCT02173262|DRUG|Ciprofloxacin|
218951087|NCT00729391|BEHAVIORAL|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
218951088|NCT00729391|BEHAVIORAL|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
218951089|NCT00729391|BEHAVIORAL|VCT Only|Participants in this group will receive VCT only.
219549769|NCT02640235|DEVICE|CELSTAT|
218951090|NCT05015413|DEVICE|Shockwave|Shock wave master 500 Germany
218951091|NCT03876301|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
219055354|NCT03745703|BEHAVIORAL|MOCHA|(see above)
219055355|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
219055356|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
219055357|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
219549770|NCT02640235|DEVICE|Surgicel Original|
218951092|NCT02470637|DRUG|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
218951093|NCT02470637|DRUG|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
218951094|NCT01663753|DEVICE|18F-FDG-PET|
218951095|NCT02310009|DRUG|Anakinra (AN)|
218951096|NCT02310009|BEHAVIORAL|Exercise (EX)|
218951097|NCT02310009|BEHAVIORAL|Control (CON)|
219637325|NCT04797702|COMBINATION_PRODUCT|Glumetinib combined with Toripalimab|"Ib：All enrolled subjects received Glumetinib combined with Toripalimab on a 21-day cycle, starting with 200mg/ day continuous Glumetinib and 240mg/ 3 weeks Toripalimab.~II：The SMC will determine the dose group for the Phase II study based on the safety and initial efficacy data of the Phase Ib subjects. Approximately 62 evaluable subjects will be enrolled in the study to receive the recommended dose of Glumetinib once daily and continuous treatment with Toripalimab 240mg every 3 weeks."
219637326|NCT05357703|DEVICE|Standard treatment + Active B-Cure laser|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
219637327|NCT06661954|DEVICE|Bed A - supine|Hercules dream air surface in supine position
219637328|NCT06661954|DEVICE|Bed B - supine|Oncare Skinguard surface
219637329|NCT06661954|DEVICE|Bed A - head of bed at 30 degrees|Hercules dream air surface with head of bed at 30 degrees
219637330|NCT06661954|DEVICE|Bed B - head of bed at 30 degrees|Oncare Skinguard surface with head of bed at 30 degrees
219637331|NCT02880475|DRUG|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
219637332|NCT01152346|DRUG|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
219637333|NCT01152346|DRUG|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
219637334|NCT05131438|DRUG|sugemalimab|sugemalimab (Anti-PD-L1 antibody)
219637335|NCT06218940|DRUG|HY1272|Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
219637336|NCT00250952|DRUG|Botox Cosmetic™|
219637337|NCT03806725|DIAGNOSTIC_TEST|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
218951098|NCT03203343|PROCEDURE|Operation - PIRS|Operation by its known design for PIRS group
218951099|NCT03203343|PROCEDURE|Operation - MARCY|Operation by its known design for MARCY group
218951100|NCT00401362|DRUG|SC Methylnaltrexone|Dose 1
218951101|NCT00401362|DRUG|SC Placebo|
218951102|NCT00401362|DRUG|SC Methylnaltrexone|Dose 2
218951103|NCT01565304|BEHAVIORAL|POWER Through Choices|10-session group-based sexual education curriculum
218951104|NCT01704612|DRUG|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
218951105|NCT04837677|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
218951106|NCT01606657|PROCEDURE|Irrigation|The patient will receive irrigation as a part of their wound care
218951107|NCT01606657|OTHER|No Irrigation|The patient will not receive irrigation as part of their wound care
218951108|NCT04609163|OTHER|data collection|retrospective data collection
218951109|NCT05037435|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
218951110|NCT05037435|OTHER|Placebo|Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
218951111|NCT06523829|OTHER|GROUP GIVEN VIDEO TRAINING|Video-based training was given to this group.
218951112|NCT04260139|PROCEDURE|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~1. Proximal colon,~2. Ileum in cases with right hemicolectomy only,~3. Proximal border,~4. Tumor,~5. Distal border,~6. Total specimen,~7. Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
218951113|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
218951114|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
218951115|NCT03354793|OTHER|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
218951116|NCT03354793|OTHER|Survey on first pregnancy|Obstetric complications were noted
218951117|NCT03288051|OTHER|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
218951118|NCT03288051|DRUG|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
218951119|NCT03288051|DRUG|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
219055358|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
219637338|NCT02420730|DRUG|AGN-232411|AGN-232411 topical ophthalmic solution
219637339|NCT02420730|DRUG|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
219637340|NCT00427921|BIOLOGICAL|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
219637341|NCT04164108|DIETARY_SUPPLEMENT|Intermittent Enteral Nutrition Protocol|Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
219637342|NCT05304416|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
218951120|NCT01074385|BEHAVIORAL|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
218951121|NCT01331252|OTHER|semi-recumbent|Patient rests in a semi-recumbent body position
218951122|NCT01331252|OTHER|supine|Patient rests in a supine position
218951123|NCT02753439|DRUG|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
218951124|NCT05784285|BEHAVIORAL|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
218951125|NCT06515795|OTHER|Isometric exercise|In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
218951126|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
218951127|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
219055359|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
219055360|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
219055361|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
219055362|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
219055363|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
219637343|NCT05304416|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like a moving x-ray of the participant swallowing foods and liquids (barium).
219637344|NCT05304416|DIAGNOSTIC_TEST|Videofluoroscopy instrumental swallowing exam (VFSS)|This is like a moving x-ray of the participant swallowing foods and liquids (barium).
218951128|NCT04849702|PROCEDURE|No intervention was compared|No intervention was compared
219055364|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
219055365|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
219055366|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
219055367|NCT01689896|DRUG|Testosterone Gel|
219055368|NCT01689896|DRUG|Placebo Gel|
219637345|NCT05304416|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
219637346|NCT05304416|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
218951129|NCT03909594|DRUG|Bupivacaine|Bupivacaine
218951130|NCT03909594|DRUG|Ketamine|Ketamine
218951131|NCT04083625|DRUG|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
218951132|NCT04083625|DRUG|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
218951133|NCT04139993|DRUG|Microbiota-based Formulation RBX7455|Given PO
218951134|NCT02508818|OTHER|Parabolic flight|
218951135|NCT02508818|OTHER|Cardiovascular measurements|
218951136|NCT00453414|DRUG|Iloprost Inhalation Solution (Ventavis)|
218951137|NCT02401425|DRUG|Letrozole|
218951138|NCT02401425|DRUG|Misoprostol|
218951139|NCT02401425|OTHER|Placebo|
218951140|NCT02957214|OTHER|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
218951141|NCT00433602|OTHER|clinical observation|
218951142|NCT00433602|PROCEDURE|management of therapy complications|
218951143|NCT00433602|PROCEDURE|ultrasound imaging|
218951144|NCT03079713|DEVICE|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
218951145|NCT03079713|DEVICE|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
219055369|NCT03235024|BIOLOGICAL|B244|B244 suspension
219055370|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
219055371|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
219055372|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
219055373|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
219055374|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
219055375|NCT00036920|DRUG|canfosfamide hydrochloride|
219055376|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
219055377|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
219055378|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
219055379|NCT02170727|DRUG|DCV/ASV/BMS-791325|
219055380|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
219055381|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
219055382|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
219055383|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
219055384|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
219637347|NCT05304416|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
218951146|NCT03079713|DEVICE|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
218951147|NCT00146432|PROCEDURE|Immunoadsorption of LPS, IL-6 and C5a|
218951148|NCT00943449|DRUG|4SC-201|oral administration
218951149|NCT00943449|DRUG|Sorafenib|oral administration
218951150|NCT02767297|DRUG|FDL169|
218951151|NCT04123691|DEVICE|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
218951152|NCT00636350|DIETARY_SUPPLEMENT|Pepper|pepper carotenoids as meals
219055385|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
219055386|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
219055387|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
219055388|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
219055389|NCT01817972|BIOLOGICAL|Certolizumab pegol|Subcutaneous injection
219055390|NCT01817972|DRUG|Azathioprine|50mg tablets
219055391|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
219055392|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
219055393|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
219055394|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
219055395|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
219055396|NCT00245557|DRUG|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks."
219637348|NCT05304416|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
219637349|NCT01338402|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
218951153|NCT04628455|DEVICE|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
218951154|NCT00245167|PROCEDURE|Tracheal Aspirate Fluid|
218951155|NCT02690571|OTHER|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
218951156|NCT04887376|DEVICE|Mirror frame|Combined Mirror and NMES therapy
218951157|NCT04887376|DEVICE|Control|Only NMES therapy
218951158|NCT01416597|BIOLOGICAL|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
218951159|NCT05424770|OTHER|Education with crossword|Afterwards, crossword activities prepared by the researcher will be implemented and students will be actively involved in the process. The researcher will also include a collaborative learning environment where students can exchange information with each other. After the completion of each puzzle, the researcher will make the necessary checks and corrections.
219055397|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
219055398|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
219055399|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
218951160|NCT05668390|DRUG|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
218951161|NCT04810689|DRUG|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
218951162|NCT04810689|OTHER|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
218951163|NCT04831632|DIAGNOSTIC_TEST|quantitative and qualitative iFOBTs|They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
219055400|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
219055401|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
219055402|NCT02112565|OTHER|pharmacological study|Correlative studies
219055403|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
219055404|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
218951164|NCT02431260|DRUG|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
218951165|NCT03267485|DEVICE|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
218951166|NCT04308200|OTHER|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
219055405|NCT00393549|DEVICE|NeuroPath|
219055406|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
219055407|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
219055408|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
219055409|NCT01581203|DRUG|Asunaprevir (ASV)|
219055410|NCT01581203|DRUG|Daclatasvir (DCV)|
219055411|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
218951167|NCT04308200|OTHER|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
218951168|NCT00165802|DRUG|E7974|Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
218951169|NCT00795587|DRUG|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
218951170|NCT03980353|OTHER|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
218951171|NCT05113238|PROCEDURE|Assisted gamete activation|compare two different assisted gamete activation protocols to improve ICSI outcome
218951172|NCT00077467|DRUG|bortezomib|Given IV
218951173|NCT00077467|OTHER|pharmacological study|Correlative studies
218951174|NCT00077467|OTHER|laboratory biomarker analysis|Correlative studies
218951175|NCT00019994|BIOLOGICAL|MART-1 antigen|
218951176|NCT00019994|BIOLOGICAL|aldesleukin|
218951177|NCT00019994|BIOLOGICAL|gp100 antigen|
218951178|NCT00019994|BIOLOGICAL|incomplete Freund's adjuvant|
218951179|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
219637350|NCT01338402|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
218951180|NCT04944680|BEHAVIORAL|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
218951181|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
218951182|NCT03952949|BEHAVIORAL|Default Option While Online Grocery Shopping|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age."
218951183|NCT03952949|BEHAVIORAL|Nutrition Education|"The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
218951184|NCT04375319|DEVICE|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
218951185|NCT00349115|DRUG|Thalidomide|
218951186|NCT06114524|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
218951187|NCT06431971|DRUG|Talineuren|Talineuren infusion weekly
219637351|NCT01338402|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
218951188|NCT06431971|DRUG|Placebo|Placebo infusion weekly
218951189|NCT01138917|DEVICE|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
218951190|NCT02859805|OTHER|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
218951191|NCT02104037|PROCEDURE|Lumbar puncture|
218951192|NCT00286598|BEHAVIORAL|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
218951193|NCT02890615|BEHAVIORAL|Depression self-care|Toolkit and coaching
219055412|NCT01581203|DRUG|Ribavirin (RBV)|
219055413|NCT00077259|DRUG|epothilone D|
219055414|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
219549771|NCT05803135|DRUG|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
219549772|NCT04275895|BEHAVIORAL|Evaluation of different attention or/and postural activities|"1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet"
219055415|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
218951194|NCT00795678|DRUG|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
218951195|NCT00795678|DRUG|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
218951196|NCT00795678|DRUG|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
218951197|NCT00795678|DRUG|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
218951198|NCT00795678|DRUG|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
219055416|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
219055417|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
219055418|NCT02488044|DRUG|AEB1102|modified human arginase I
219055419|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
219055420|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
219055421|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
219055422|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
219055423|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
219055424|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
219055425|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
219637352|NCT05929768|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219637353|NCT05929768|DRUG|Carboplatin|Given IV
219637354|NCT05929768|DRUG|Cyclophosphamide|Given IV
219637355|NCT05929768|DRUG|Docetaxel|Given IV
219637356|NCT05929768|DRUG|Doxorubicin|Given IV
219637357|NCT05929768|DRUG|Paclitaxel|Given IV
219055426|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
219055427|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
219055428|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
219055429|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
219055430|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
219055431|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
219055432|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
219055433|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
219055434|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
219637358|NCT05929768|BIOLOGICAL|Pembrolizumab|Given IV
219637359|NCT05929768|OTHER|Quality-of-Life Assessment|Ancillary studies
219637360|NCT05929768|OTHER|Questionnaire Administration|Ancillary studies
219637361|NCT05929768|PROCEDURE|Surgical Procedure|Undergo surgery
219637362|NCT01075256|DEVICE|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
219637363|NCT01075256|DEVICE|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
219637364|NCT01075256|DEVICE|Placebo toothpaste|Placebo toothpaste
219637365|NCT05184569|DRUG|Verdiperstat|Oral, extended release (ER) tablet
219637366|NCT01296945|OTHER|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
219637367|NCT01296945|OTHER|paper|Participants will receive a paper handout with nutrition educational information.
218951199|NCT00795678|DRUG|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
218951200|NCT00795678|DRUG|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
218951201|NCT00795678|DRUG|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
218951202|NCT05382767|DRUG|CKDB-501A|Muscle Spasticity
218951203|NCT05382767|DRUG|Botox®|Muscle Spasticity
218951204|NCT03007888|DRUG|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
218951205|NCT03007888|DRUG|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
218951206|NCT03841747|DRUG|Pembrolizumab|200 mg Pembrolizumab IV Q3W.
218951207|NCT03841747|DRUG|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
218951208|NCT01696682|PROCEDURE|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
218951209|NCT01696682|PROCEDURE|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
218951210|NCT01806662|DRUG|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
218951211|NCT01806662|OTHER|Placebo|Injection of placebo
218951212|NCT00243646|RADIATION|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
218951213|NCT00243646|DRUG|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
219055435|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
219055436|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
219055437|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
219055438|NCT04865796|OTHER|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
219055439|NCT04865796|OTHER|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
219055440|NCT04865796|OTHER|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
219207009|NCT06758531|DIETARY_SUPPLEMENT|Instant coffee given as a drink|Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
219549773|NCT04356313|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
218951214|NCT00243646|DRUG|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
218951215|NCT01479426|DIETARY_SUPPLEMENT|EFLA400|EFLA400(960mg/day)for 12 weeks
218951216|NCT01479426|DIETARY_SUPPLEMENT|Placebo|Placebo(960mg/day) for 12 weeks
218951217|NCT00528541|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
218951218|NCT00528541|BIOLOGICAL|botulinum toxin type A|750 Units at Visit 1 (Day 1)
218951219|NCT02967757|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
218951220|NCT05282914|DRUG|administration of UI058|UI058 1Tab/day for 7days
218951221|NCT05282914|DRUG|administration of UIC202004|UIC202004 1Tab/day for 7days
218951222|NCT03259620|DRUG|CLS006|Furosemide Topical Gel
218951223|NCT03259620|DRUG|CLS006 Vehicle|Vehicle Topical Gel
218951224|NCT00129662|BEHAVIORAL|Pictorial action plan|
218951225|NCT04623125|BEHAVIORAL|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
218951226|NCT00827931|DRUG|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
218951227|NCT00827931|PROCEDURE|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
218951228|NCT01151943|OTHER|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
218951229|NCT01151943|OTHER|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
218951230|NCT02757417|DRUG|sodium fluorescein|
218951231|NCT02757417|DRUG|phenazopyridine|
218951232|NCT01252693|DRUG|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
218951233|NCT01252693|DRUG|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
218951234|NCT00300430|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
218951235|NCT00300430|DRUG|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
218951236|NCT00300430|DRUG|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
218951237|NCT00000791|DRUG|Glycovir|
218951238|NCT00000791|DRUG|Zidovudine|
218951239|NCT04511377|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
218951240|NCT04511377|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
218951241|NCT01917656|DRUG|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
218951242|NCT01917656|DRUG|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
218951243|NCT01917656|DRUG|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
218951244|NCT02748382|OTHER|higher chloride crystalloid|Normal saline
218951245|NCT02748382|OTHER|higher chloride albumin|5% Octalbin
218951246|NCT02748382|OTHER|lower chloride crystalloid|Ringers Lactate
218951247|NCT02748382|OTHER|lower chloride albumin|5% Plasbumin
218951248|NCT02081859|DEVICE|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
218951249|NCT02081859|OTHER|Conventional Criteria|
219549774|NCT04756921|DRUG|Pyrotinib|Pyrotinib 400mg po qd
218951250|NCT05331417|DIAGNOSTIC_TEST|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
218951251|NCT06333197|PROCEDURE|ORIF through transparotid approach|The Retromandibular Transparotid approach is a surgical method used to access structures in the parotid gland region by making an incision behind the mandible.
218951252|NCT06333197|PROCEDURE|ORIF through retroparotid approach|The Retromandibular Retroparotid approach, also known as the Modified Blair Incision, is a surgical technique used to access structures within the parotid gland region by creating an incision behind the mandible and extending it into the parotid region.
219549775|NCT00694408|DRUG|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
219549776|NCT00694408|OTHER|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
219549777|NCT01674387|DEVICE|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
218951253|NCT05323825|DIETARY_SUPPLEMENT|Probiotic|Fermented milk product containing a probiotic
218951254|NCT05323825|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
218951255|NCT02015221|DEVICE|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
218951256|NCT02015221|DEVICE|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
219637368|NCT01296945|OTHER|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
218951257|NCT04914260|OTHER|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
218951258|NCT01770444|OTHER|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)"
218951259|NCT01770444|OTHER|Conventional cardiac CT protocol|"Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)"
218951260|NCT05547204|OTHER|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
219055441|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
219055442|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
219055443|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
219055444|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
219055445|NCT05731284|PROCEDURE|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
219055446|NCT05731284|PROCEDURE|Placebo|Normal saline Injection
219055447|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
218951261|NCT00322972|DRUG|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
218951262|NCT02560506|DEVICE|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
218951263|NCT02896322|RADIATION|Partial breast irradiation with cyberknife|
218951264|NCT00995566|DRUG|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
218951265|NCT06134011|OTHER|Without any intervention|There were no special interventions for the two groups.
218951266|NCT03158662|OTHER|Survey|Survey Study
218951267|NCT01870076|BEHAVIORAL|Healing Touch|
218951268|NCT01870076|BEHAVIORAL|Healing Touch, Sham|
219055448|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
219055449|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
219055450|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
219055451|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
218951269|NCT01870076|BEHAVIORAL|Control, Presence|
218951270|NCT05387499|DRUG|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
218951271|NCT05387499|DRUG|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
218951272|NCT05387499|OTHER|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
218951273|NCT00492063|BIOLOGICAL|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
218951274|NCT00492063|BIOLOGICAL|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
218951275|NCT05895916|BEHAVIORAL|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
218951276|NCT05973721|BIOLOGICAL|phage|The treatment group was given one phage each time, once a day for two weeks
218951277|NCT03520127|DEVICE|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
218951278|NCT00167856|DRUG|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
218951279|NCT01467219|PROCEDURE|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
218951280|NCT01467219|PROCEDURE|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
219055452|NCT05327790|DRUG|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
219055453|NCT05327790|OTHER|Placebo|Placebo
219055454|NCT06230887|BEHAVIORAL|Building Spiritual Strength|Spiritually Integrated group intervention for moral injury
219055455|NCT06230887|BEHAVIORAL|Present Centered Group Therapy|Active control, manualized evidence-based coping skills intervention for PTSD
218951281|NCT01467219|PROCEDURE|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
218951282|NCT01467219|RADIATION|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
218951283|NCT02434588|DEVICE|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
218951284|NCT02338908|OTHER|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
218951285|NCT02338908|OTHER|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
218951286|NCT00368290|DRUG|Modafinil|300mg a day for 8 weeks
218951287|NCT00368290|DRUG|placebo|placebo pills for 8 weeks
218951288|NCT00368290|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
219055456|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
219055457|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
219055458|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
219055459|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
219055460|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
219055461|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
219055462|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
219055463|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
218951289|NCT06491966|OTHER|observation|data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
218951290|NCT00123890|DRUG|GW873140|
218951291|NCT00510653|DRUG|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
218951292|NCT02990247|DEVICE|anharmonic morphological analysis of the respiratory signals (AMARS)|
218951293|NCT05349201|OTHER|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
218951294|NCT05349201|OTHER|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
218951295|NCT00882570|DRUG|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
219055464|NCT02486406|DRUG|Ribavirin solution|Oral solution
219055465|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
218951296|NCT00882570|DRUG|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
218951297|NCT02593071|BIOLOGICAL|RSV-F Vaccine|
218951298|NCT02593071|BIOLOGICAL|Phosphate Buffer Placebo|
218951299|NCT00930748|DEVICE|MR imaging with endorectal coil|MR imaging with endorectal coil
218951300|NCT00930748|DEVICE|MRI with endo-rectal coil|MRI with endo-rectal coil
218951301|NCT02727231|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
218951302|NCT02727231|DEVICE|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
218951303|NCT02030431|DEVICE|Dynaloc|
218951304|NCT02030431|DEVICE|Cancellous screws|
219055466|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
219055467|NCT00517920|DRUG|ABT-869|0.25 mg/kg QD
218951305|NCT03365388|DRUG|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
218951306|NCT03365388|DRUG|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
219055468|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
218951307|NCT00189774|DRUG|nateglinide|
218951308|NCT01150344|DRUG|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
218951309|NCT01150344|DRUG|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
218951310|NCT00536211|BEHAVIORAL|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
218951311|NCT00536211|DRUG|Metformin|oral tablet, 1000 mg daily for 17 days
218951312|NCT03829800|DIETARY_SUPPLEMENT|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
219055469|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
219055470|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
219055471|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
219055472|NCT00844441|OTHER|medical chart review|
219055473|NCT00844441|OTHER|questionnaire administration|
219055474|NCT00844441|PROCEDURE|quality-of-life assessment|
219055475|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
218951313|NCT03829800|DIETARY_SUPPLEMENT|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
218951314|NCT03829800|DIETARY_SUPPLEMENT|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
218951315|NCT03829800|DIETARY_SUPPLEMENT|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
218951316|NCT00436501|DRUG|docetaxel|25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
218951317|NCT00436501|BIOLOGICAL|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
218951318|NCT00436501|OTHER|laboratory biomarker analysis|Correlative studies
218951319|NCT00436501|OTHER|pharmacological study|Correlative studies
218951320|NCT02874170|OTHER|Spectroscopy magnetic resonance of phosphorus 31|
218951321|NCT06448416|PROCEDURE|UBE|Patients with HDL were treated with UBE
218951322|NCT04363151|OTHER|No intervention.|
219637369|NCT01296945|OTHER|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
218951323|NCT05424783|OTHER|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
219055476|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
219055477|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
219055478|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
219637370|NCT00765336|DRUG|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
219637371|NCT00765336|DRUG|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
219637372|NCT04549090|DRUG|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
219637373|NCT05000554|PROCEDURE|Neoadjuvant Therapy|"Drug:~Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa\<1.25m2,40mg/time，twice a day；bsa1.25\~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；~Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection"
219637374|NCT05300009|COMBINATION_PRODUCT|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
219637375|NCT05300009|OTHER|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
219637376|NCT02909712|DRUG|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
219637377|NCT02909712|DRUG|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
219637378|NCT04455087|OTHER|sensitization|sensitization of doctor to decrease the prescription of abuse exams
219637379|NCT01082705|DRUG|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
219637380|NCT01082705|DRUG|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
218951324|NCT02847572|PROCEDURE|Cataract Surgery|All patients wil be having intraocular lens surgery
219055479|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
219637381|NCT02858583|PROCEDURE|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
219637382|NCT02858583|PROCEDURE|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
218951325|NCT04407572|OTHER|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
218951326|NCT05143710|DIAGNOSTIC_TEST|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
218951327|NCT01444807|DRUG|sorafenib|sorafenib 400 mg bid
219055480|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
219637383|NCT00347009|DRUG|adefovir dipivoxil|10mg once daily
219637384|NCT03483233|OTHER|fMRI and EEG study|fMRI and EEG study
219637385|NCT05954195|OTHER|high intensity interval training|high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
219637386|NCT00502970|DRUG|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
219637387|NCT00502970|DRUG|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
219637388|NCT04042688|DRUG|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
218951328|NCT04157673|BEHAVIORAL|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
218951329|NCT05471583|OTHER|Main group|no intervention; observational only
218951330|NCT02079818|DEVICE|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
218951331|NCT03011892|DRUG|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
218951332|NCT03011892|DRUG|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
218951333|NCT03011892|DRUG|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
218951334|NCT03011892|DRUG|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
218951335|NCT03011892|DRUG|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
218951336|NCT03011892|DRUG|Vehicle Cream BID|Vehicle cream BID
218951337|NCT00908739|GENETIC|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
218951338|NCT00908739|OTHER|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
218951339|NCT00908739|OTHER|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
218951340|NCT01467778|DEVICE|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
218951341|NCT01467778|DEVICE|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
218951342|NCT03513341|OTHER|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
218951343|NCT00949767|DRUG|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
218951344|NCT00949767|DRUG|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
218951345|NCT00949767|DRUG|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
218951346|NCT00949767|DRUG|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
218951347|NCT00949767|DRUG|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
218951348|NCT00949767|DRUG|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
218951349|NCT00949767|DRUG|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
218951350|NCT00949767|DRUG|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
218951351|NCT05337020|OTHER|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
218951352|NCT03417401|PROCEDURE|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
218951353|NCT03417401|DRUG|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
218951354|NCT01523470|DEVICE|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
218951355|NCT02312687|BIOLOGICAL|KRN23|solution for SC injection
218951356|NCT05632744|DEVICE|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
218951357|NCT04612023|OTHER|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
219055481|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
219055482|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
219055483|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
219055484|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
219637389|NCT04459000|BEHAVIORAL|STARS + maternal Attachment Biobehavioral Catchup home visiting model|Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.
218951358|NCT06131671|OTHER|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
218951359|NCT05785481|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
218951360|NCT00384111|DRUG|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
218951361|NCT00384111|DRUG|R-CVP|Standard R-CVP
218951362|NCT00735059|DEVICE|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, \> 3 hours
218951363|NCT00735059|DEVICE|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, \> 3 hours
219055485|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
219637390|NCT04459000|BEHAVIORAL|STARs Only|Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
219637391|NCT03706378|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
219637392|NCT03706378|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
219637393|NCT03706378|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
219637394|NCT03706378|OTHER|Wheat Yellow Noodle|Wheat Yellow Noodle will contain 50g of available carbohydrate
219637395|NCT03706378|OTHER|Beta-glucan yellow Noodle|Beta-glucan yellow noodle will contain 50g of available carbohydrate
219637396|NCT03706378|OTHER|Rice Roll|Rice Roll will contain 50g of available carbohydrate
219637397|NCT03706378|OTHER|Rice Roll with resistant starch|Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
219637398|NCT03706378|OTHER|Sucrose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
219637399|NCT03706378|OTHER|Isomaltulose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
219637400|NCT04499144|PROCEDURE|modified buccal flap and subepithelial connective palatal flap|The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
219637401|NCT02948751|DEVICE|OncoCEE|The CSF sample will be to delivered to Biocept's laboratory for processing, and it will be evaluated for CTCs using OncoCEETM microchannel technology. This CSF sample will also be tested for cell-free circulating tumor DNA (ctDNA).
219637402|NCT02580409|BEHAVIORAL|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
219637403|NCT02619630|DRUG|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter~for a maximum of 5 blocks"
219637404|NCT00466388|DRUG|Cevimeline|
219637405|NCT01972438|DRUG|ASEDs|Experimental Intervention
219637406|NCT01972438|DRUG|Saline|Control Intervention
219637407|NCT02594982|OTHER|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
219637408|NCT00606385|PROCEDURE|Liver resection|Laparoscopic or Open hepatectomy
219637409|NCT04490291|OTHER|chronic pain team|enrollment in chronic pain team at study site
219637410|NCT04490291|OTHER|chiropractic team|enrollment in chiropractic team/intervention at study site
219637411|NCT06575829|DRUG|Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks|The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
219637412|NCT00511914|BIOLOGICAL|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
218951364|NCT00801307|DEVICE|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
219055486|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
219055487|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
219055488|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
219055489|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
219055490|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
219637413|NCT04553601|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
219055491|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
219055492|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
219055493|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
219055494|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
219055495|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
219055496|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
219637414|NCT04771286|DRUG|BI 1015550 (C-14)|BI 1015550 (C-14)
218951365|NCT04733794|PROCEDURE|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
219055497|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
219055498|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
219055499|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
219055500|NCT00725426|DRUG|Bosutinib|
219055501|NCT06491550|DRUG|AZD4144- Part A|Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.
219055502|NCT06491550|DRUG|Placebo- Part A|Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.
219055503|NCT06491550|DRUG|AZD4144- Part B|"Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion."
219055504|NCT06491550|DRUG|Placebo- Part B|Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.
219637415|NCT06485921|OTHER|Ischemic compression|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
219637416|NCT06485921|OTHER|Instrument assisted soft tissue mobilization Group|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
219637417|NCT06485921|OTHER|Exercise and workplace modifications|Participants will receive stretching and strengthening exercises for neck and scapular stabilizer muscles as a 6-week home program.
218951366|NCT05053373|DEVICE|Electroacupuncture group|
218951367|NCT05053373|DEVICE|Sham electroacupuncture group|
218951368|NCT05053373|BEHAVIORAL|Pelvic floor muscle training|
219055505|NCT06491550|DRUG|Rosuvastatin and Furosemide- Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.
219055506|NCT06491550|DRUG|Rosuvastatin, Furosemide, and AZD4144 Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
219055507|NCT02315235|BIOLOGICAL|Normal saline|Normal saline is injected in one leg of patient.
219055508|NCT02315235|BIOLOGICAL|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
219549778|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
219549779|NCT05812638|OTHER|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
219549780|NCT05812638|OTHER|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
219549781|NCT05697679|BEHAVIORAL|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
219549782|NCT05697679|BEHAVIORAL|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
219549783|NCT02095054|DRUG|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
219637418|NCT00251238|DRUG|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
219637419|NCT04309383|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
219637420|NCT04344483|DRUG|2% Lidocaine and 1:100,000 Adrenaline|Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
219637421|NCT04344483|DRUG|Normal saline|Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
219637422|NCT02313311|OTHER|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
218951369|NCT05653531|OTHER|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
218951370|NCT05138471|DEVICE|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
218951371|NCT05138471|DEVICE|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
218951372|NCT05138471|BEHAVIORAL|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
218951373|NCT00878436|DRUG|Panobinostat|
218951374|NCT00878436|DRUG|Bicalutamide|
219055509|NCT04905056|OTHER|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
219055510|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
219055511|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
219055512|NCT05892848|DIAGNOSTIC_TEST|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
218951375|NCT04130737|DEVICE|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
218951376|NCT00535574|DRUG|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
218951377|NCT00535574|DRUG|bexarotene|75 mg/day 6 weeks
218951378|NCT02884700|BIOLOGICAL|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
218951379|NCT06371820|OTHER|ESPRESSO [The study has no intervention]|This study has no interventions.
218951380|NCT05793229|OTHER|observation|observation
219055513|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219055514|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219055515|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219055516|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219637423|NCT06217705|BEHAVIORAL|Project Calm|Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
219637424|NCT00274274|DRUG|insulin detemir|
219637425|NCT00274274|DRUG|insulin aspart|
219637426|NCT05308953|DRUG|NVG-291|NVG-291 is a drug injected under the skin (subcutaneous).
219637427|NCT05308953|OTHER|Placebo|Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
219637428|NCT04955353|DIETARY_SUPPLEMENT|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
219637429|NCT04955353|DIETARY_SUPPLEMENT|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
219637430|NCT01001273|OTHER|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
219637431|NCT02581280|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
219637432|NCT05453227|DRUG|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
219637433|NCT00937976|PROCEDURE|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
218951381|NCT05503667|DRUG|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
218951382|NCT05503667|DRUG|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
218951383|NCT00168987|DRUG|oral nutritional supplement rich in eicosapentanoic acid|
218951384|NCT06051708|OTHER|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
218951385|NCT06051708|OTHER|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
218951386|NCT02133443|DEVICE|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
218951387|NCT02133443|DEVICE|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
219637434|NCT02000960|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
219637435|NCT02257073|BEHAVIORAL|Cognitive-behavioral treatment|
219637436|NCT02257073|BEHAVIORAL|Waiting List|
219637437|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
219637438|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
219637439|NCT00404391|DRUG|Placebo|2 tablets every 12 hours
219637440|NCT04492176|DEVICE|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
219637441|NCT05103982|BEHAVIORAL|Coping with Infertility Program|6 10-minute videos with assigned homework
218951388|NCT03314246|OTHER|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
218951389|NCT03314246|OTHER|Standard of care|Standard of care
218951390|NCT01419821|DRUG|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
218951391|NCT01419821|OTHER|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
218951392|NCT00716950|DRUG|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
218951393|NCT00716950|DRUG|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
218951394|NCT05711303|DIETARY_SUPPLEMENT|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
218951395|NCT00174772|DRUG|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
218951396|NCT00174772|DRUG|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
218951397|NCT00409305|DRUG|Betahistine|
218951398|NCT00409305|BEHAVIORAL|Dietary counseling|
218951399|NCT02557477|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
218951400|NCT02557477|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules twice daily
218951401|NCT02375789|DEVICE|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
218951402|NCT02375789|DEVICE|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
218951403|NCT03070743|PROCEDURE|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
218951404|NCT06401629|DIAGNOSTIC_TEST|NPRP criteria|Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
218951405|NCT06401629|DIAGNOSTIC_TEST|IADPSG criteria|The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
218951406|NCT00217464|DRUG|fulvestrant|intramuscularly
218951407|NCT06430827|DRUG|irinotecan hydrochloride liposome injection|rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
218951408|NCT06430827|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
218951409|NCT03612856|DRUG|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
218951410|NCT03612856|DRUG|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
218951411|NCT03612856|DRUG|placebo|Participants will receive a single dose of placebo.
218951412|NCT05630300|DIAGNOSTIC_TEST|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
218951413|NCT05630300|DIAGNOSTIC_TEST|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
218951414|NCT01576159|OTHER|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
218951415|NCT01576159|OTHER|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
218951416|NCT01576159|OTHER|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
218951417|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
218951418|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
218951419|NCT00169442|BIOLOGICAL|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
218951420|NCT00169442|BIOLOGICAL|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
218951421|NCT00169442|BIOLOGICAL|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
219055517|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219055518|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
219055519|NCT00898976|OTHER|immunohistochemistry staining method|
218951422|NCT02900144|BEHAVIORAL|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
219055520|NCT00898976|OTHER|laboratory biomarker analysis|
219055521|NCT03887039|OTHER|clinical examination|clinical examination for all the oral findings
219055522|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
218951423|NCT02900144|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
219055523|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
218951424|NCT01426789|DRUG|Placebo|Matching placebo to secukinumab I.V.
218951425|NCT01426789|DRUG|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
218951426|NCT04253509|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
218951427|NCT01765478|DRUG|HM71224 single ascending dose|
218951428|NCT01765478|DRUG|HM71224 food effect|
218951429|NCT01765478|DRUG|HM71224 Multiple ascending dose|
219055524|NCT05940974|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
219055525|NCT02072967|OTHER|Ribomustin|Routine practice
219055526|NCT02072967|OTHER|rituximab|Routine practice
219207010|NCT06758531|DIETARY_SUPPLEMENT|Coffee given in a tablet form|Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
218951430|NCT01513200|DRUG|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
219207011|NCT06758531|DIETARY_SUPPLEMENT|Control (placebo)|A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
219207012|NCT06761040|OTHER|Intrinsic foot muscle training|"Technique In intrinsic foot muscle training, there are following exercises:~1. Toe spread out~2. First toe extension~3. Second to fifth toe extension The exercise would be performed in following positions 1. Sitting position for the first 2 weeks (3sec hold; 4 sets ×15 reps) 2. Standing position on the 3rd and 4th weeks (8sec hold; 4 sets × 8 reps) 3. One-leg standing position during the 5th and 6th week (20 sec hold;4 sets ×3 reps)"
219549784|NCT02095054|DRUG|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
219549785|NCT02095054|BEHAVIORAL|Questionnaire|Symptom questionnaire completed at each study visit.
219549786|NCT01193972|OTHER|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
219549787|NCT05247567|BIOLOGICAL|serum punction|A blood sample inclusion and at the end of study visit
219549788|NCT05247567|BIOLOGICAL|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
219549789|NCT04050709|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
219549790|NCT02120872|DRUG|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
219549791|NCT02120872|BIOLOGICAL|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
219549792|NCT02120872|PROCEDURE|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
219549793|NCT00629304|DEVICE|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
219549794|NCT00629304|DEVICE|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
219549795|NCT00629304|DEVICE|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
219549796|NCT01521715|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
219549797|NCT04019015|DRUG|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
219549798|NCT04019015|DRUG|Placebo|Normal saline solution
219549799|NCT00803816|DRUG|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
218951431|NCT01513200|DRUG|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
219637442|NCT03283657|BEHAVIORAL|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
219637443|NCT03283657|BEHAVIORAL|Usual care (UC)|Standard care with routine medical care.
219637444|NCT05945940|OTHER|no intervention|no intervention
218951432|NCT01513200|DRUG|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
218951433|NCT01516333|OTHER|High GL 107|Three meals a day
218951434|NCT01516333|OTHER|Medium GL 76|Three meals a day
218951435|NCT01516333|OTHER|Medium GL 68|Three meals a day
218951436|NCT01516333|OTHER|Low GL 48|Three meals a day
218951437|NCT06012643|OTHER|The purpose of this systematic review of case reports and case series was to evaluate the spectrum of subperiosteal implants for severely atrophied jaws using digital technology.|An electronic and manual search was conducted in the PubMed, Scopus, and Google Scholar databases. Publications of case reports and series written in English without data restrictions
218951438|NCT04975529|BEHAVIORAL|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
218951439|NCT00223236|DRUG|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
218951440|NCT00223236|DRUG|Placebo|Placebo matching active medication in all other aspects.
218951441|NCT03067233|OTHER|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
218951442|NCT00265928|DRUG|bortezomib|
218951443|NCT00265928|DRUG|rituximab|
218951444|NCT00265928|PROCEDURE|antibody therapy|
218951445|NCT00265928|PROCEDURE|biological therapy|
218951446|NCT00265928|PROCEDURE|enzyme inhibitor therapy|
218951447|NCT00265928|PROCEDURE|monoclonal antibody therapy|
218951448|NCT05328349|BEHAVIORAL|Education Program|After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
218951449|NCT04429477|DEVICE|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
218951450|NCT01763840|DRUG|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
219055527|NCT01129141|PROCEDURE|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
219055528|NCT01129141|PROCEDURE|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
218951451|NCT06335563|PROCEDURE|AR glasses-assisted pulmonary nodule puncture localization|Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
219055529|NCT05626946|OTHER|Observation|Observation
219055530|NCT00113256|DRUG|Rubitecan|
219055531|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
219637445|NCT04580940|DEVICE|SpyGlass™ Discover Digital System|Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
219637446|NCT02913183|DRUG|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
219637447|NCT02913183|DRUG|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
219637448|NCT03955705|DRUG|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
219637449|NCT03955705|DRUG|Normal saline|0.9% Sodium chloride (normal saline or NSS)
219637450|NCT06576947|OTHER|Virtual reality|Participants receive virtual reality treatment, 8 weeks of treatment/ 2 times a week
219637451|NCT06576947|OTHER|Neuromodulation of the tibialis posterior nerve|Participants receive neuromodulation of the tibialis posterior nerve8 weeks of treatment/ 2 times a week/ 30 minutes
219637452|NCT06576947|OTHER|Pelvic floor muscle training|Participants receive pelvic floor muscle training 5 times a day for 9 weeks
219637453|NCT03515005|BEHAVIORAL|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
219637454|NCT00330993|DRUG|mifepristone, misoprostol|
218951452|NCT06335563|PROCEDURE|CT-guided pulmonary nodule puncture localization|Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
218951453|NCT01181986|DRUG|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
218951454|NCT01181986|DRUG|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
218951455|NCT01181986|DRUG|Placebo SC|Placebo sc BID/10days
218951456|NCT01181986|DRUG|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
218951457|NCT01181986|DRUG|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
218951458|NCT02639416|DIETARY_SUPPLEMENT|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
218951459|NCT02639416|DIETARY_SUPPLEMENT|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
218951460|NCT02639416|OTHER|Standard management|Standard management with F-100 and/or RUTF
218951461|NCT00123643|DRUG|rosiglitazone|
218951462|NCT00123643|DRUG|glyburide|
218951463|NCT02103296|PROCEDURE|Drawing admission labs from cord blood|
218951464|NCT02103296|PROCEDURE|Drawing admission labs from infant blood|
219637455|NCT05871047|DEVICE|tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application|Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
219637456|NCT02768727|DRUG|Xenon|drug given in concentrations of 0% to 60% over period of 2 hours
219637457|NCT00047073|DRUG|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
218951465|NCT02473146|DRUG|Gemtuzumab ozogamicin (GO)|
218951466|NCT06110637|OTHER|"hard shoes runners evaluation"|"The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
218951467|NCT06110637|OTHER|"Soft shoes runners evaluation"|"The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
218951468|NCT00311584|DRUG|irinotecan hydrochloride|Given IV
218951469|NCT00311584|DRUG|temozolomide|Given IV
218951470|NCT02193906|OTHER|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
218951471|NCT02193906|OTHER|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
218951472|NCT02549599|BEHAVIORAL|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
218951473|NCT02549599|BEHAVIORAL|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
218951474|NCT02549599|OTHER|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
218951475|NCT03720652|BEHAVIORAL|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~* Discovering Mindful Self-Compassion~* Practicing Mindfulness~* Practicing Lovingkindness~* Discovering your Compassionate Voice~* Living Deeply~* Meeting Difficult Emotions~* Exploring Challenging Relationships~* Embracing Your Life"
219055532|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
219637458|NCT00047073|PROCEDURE|Surgery|Surgical resection.
219637459|NCT00047073|PROCEDURE|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
218951476|NCT03720652|BEHAVIORAL|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~* What is Self-Compassion~* Practicing Self-Compassion~* Discovering your Compassionate Voice~* Self-Compassion and Resilience~* Self-Compassion and Burnout~* Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
218951477|NCT03073733|BIOLOGICAL|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
218951478|NCT03073733|OTHER|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
218951479|NCT06436677|OTHER|molecular subtype based treatment|The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
218951480|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
218951481|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
218951482|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
218951483|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
219055533|NCT03994770|DIAGNOSTIC_TEST|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
218951484|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
218951485|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
218951486|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
218951487|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
218951488|NCT02103153|DEVICE|Picosure Laser System|
218951489|NCT01454778|DRUG|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose"
218951490|NCT03254511|DRUG|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
218951491|NCT03254511|RADIATION|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
218951492|NCT03254511|DRUG|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
218951493|NCT01274689|OTHER|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
218951494|NCT00835731|DRUG|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
218951495|NCT00835731|DEVICE|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
219055534|NCT00180856|PROCEDURE|Radiofrequency ablation|
219055535|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
219055536|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
219549800|NCT01370863|DRUG|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
219549801|NCT01370863|DRUG|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
219549802|NCT00000595|DRUG|deferoxamine|
219549803|NCT00375284|DRUG|Pramipexole|
219549804|NCT00301964|BIOLOGICAL|bevacizumab|Given IV
219549805|NCT00301964|OTHER|laboratory biomarker analysis|Correlative studies
219549806|NCT06557603|DRUG|Ivermectin cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
219549807|NCT06557603|DRUG|Soolantra ® (Ivermectin) cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
219549808|NCT03475433|DEVICE|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
219549809|NCT01195233|DRUG|bioxtra|spray /mouth rinse
219549810|NCT01143337|DRUG|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
219549811|NCT01143337|DRUG|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
219549812|NCT03053856|DRUG|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
219549813|NCT03053856|PROCEDURE|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
219549814|NCT03053856|PROCEDURE|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
219549815|NCT03053856|DRUG|Cisplatin|25mg/m2 once weekly
219549816|NCT03053856|DRUG|Paclitaxel|50mg/m2 once weekly
219549817|NCT02761915|OTHER|Leukapheresis|
219549818|NCT02761915|DRUG|Cyclophosphamide|
219549819|NCT02761915|DRUG|Fludarabine|
219549820|NCT02761915|GENETIC|1RG-CART|
219549821|NCT02162615|DEVICE|Restorelle Direct Fix A|
219549822|NCT02162615|DEVICE|Restorelle Direct Fix P|
219549823|NCT02162615|PROCEDURE|Native Tissue Repair Anterior|
219549824|NCT02162615|PROCEDURE|Native Tissue Repair Posterior|
218951496|NCT03558568|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
219637460|NCT03901820|DEVICE|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
218951497|NCT00348881|BIOLOGICAL|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
218951498|NCT00348881|BIOLOGICAL|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
219637461|NCT02295826|DRUG|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
219637462|NCT02295826|DRUG|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
218951499|NCT00348881|BIOLOGICAL|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
218951500|NCT03428919|PROCEDURE|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
218951501|NCT03428919|PROCEDURE|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
218951502|NCT01407380|DRUG|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
218951503|NCT04953988|PROCEDURE|Robotic TKA|Robotic TKA
218951504|NCT04953988|PROCEDURE|Manual operation|Manual operation
219055537|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
219055538|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
219637463|NCT01029782|DRUG|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
218951505|NCT04918342|OTHER|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
218951506|NCT05122598|DRUG|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
218951507|NCT05122598|DRUG|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
218951508|NCT00371553|DRUG|SU011248 (Sunitinib)|
218951509|NCT03093584|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
219055539|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
219055540|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
219055541|NCT00113737|DRUG|fluoxetine|
219055542|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
218951510|NCT03093584|BEHAVIORAL|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
218951511|NCT00477841|PROCEDURE|Esophageal stent placement|
218951512|NCT00477841|PROCEDURE|dysphagia scores|
218951513|NCT00477841|PROCEDURE|complications of therapy|
218951514|NCT00477841|PROCEDURE|survival time of therapy|
218951515|NCT02335671|PROCEDURE|Intra-operative Magnetic Resonance Imaging (MRI)|
218951516|NCT02335671|OTHER|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
218951517|NCT04465136|DEVICE|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
218951518|NCT03053206|DRUG|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
218951519|NCT00668993|BEHAVIORAL|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
219055543|NCT02865031|DRUG|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
219055544|NCT05209685|OTHER|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
219549825|NCT00834561|DRUG|Lamotrigine|200 mg Tablet
219549826|NCT00834561|DRUG|Lamictal®|200 mg Tablet
219549827|NCT03276559|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
219637464|NCT01029782|DRUG|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
219637465|NCT01030289|DEVICE|real tDCS|transcranial direct current stimulation
218951520|NCT05041608|PROCEDURE|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
218951521|NCT00167778|DEVICE|Transverse plane rotation adaptor pylon|Potential future practice
219055545|NCT05209685|OTHER|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
219207013|NCT06761040|OTHER|hip abductor muscle training with intrinsic foot muscle training|"Hip abductor muscle training consists of the following two exercise~1. Resisted hip abduction 90° (2 sec hold; 3 sets × 10 reps)~2. Resisted hip abduction 45° (2 sec hold; 3 sets × 10 reps)~Standard treatment~* Shoe insoles (eight hours a day, medial longitudinal arch support,raised for by about 1.8 cm)~* Stretching of Hamstrings and Calf muscles (3 times for 30 seconds hold) Number of Sessions Per Week : 3 times Per week for 6 weeks"
219207014|NCT06762028|DEVICE|SIMBA capsule|The small intestine microbiome aspiration (SIMBA) system is a single-use, ingestible passive capsule that allows for the non-invasive sampling of small intestinal contents. It is designed to open and adsorb intestinal content after having passed the acid stomach environment and to close mechanically before passing into the large bowel. It has distinct markers built in to allow radiographic tracking of its passage throughout the GI system.
219207015|NCT06771856|BEHAVIORAL|Standard Care CBTi|Standard Care CBTi will take 10 weeks, during which the participant will receive 5 online les-sons and 3 online face-to-face talks with the therapist. The construction of the online intervention was based on self-help materials, research of the literature, and patient interviews. It consists of 5 online les-sons and incorporates elements commonly used in face-to-face CBTi. The 5 online lessons, one introduced every second week, cover the following topics: Education, stimulus control, sleep restriction, relaxation, cognitions. The intervention is supported by online coaching, with feedback aimed at reviewing exercis-es, clarifying information, and motivating patients to continue the course and make necessary behavioral changes.
219549828|NCT03276559|OTHER|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
219055546|NCT01492634|OTHER|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO \< -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO \> 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
219055547|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
219055548|NCT04185168|OTHER|control|2 tablets of placebo
219055549|NCT02751177|GENETIC|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
219055550|NCT01071512|DRUG|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
219055551|NCT03212625|DRUG|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
219055552|NCT03212625|DRUG|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
219549829|NCT05533411|DRUG|Donanemab|Administered IV.
219055553|NCT04089267|DRUG|TPO|
219549830|NCT05533411|DRUG|Placebo|Administered IV.
219549831|NCT04968951|DRUG|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
219549832|NCT04968951|DRUG|Placebo|Placebo treatment
218951522|NCT00167778|DEVICE|Rigid pylon|Current clinical practice
218951523|NCT03355547|OTHER|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
218951524|NCT02654717|DRUG|DFD-07 Cream|
218951525|NCT02654717|DRUG|Placebo Cream|
219055554|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
218951526|NCT00799175|DRUG|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
219549833|NCT04968951|DRUG|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
219549834|NCT04968951|BIOLOGICAL|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
219207016|NCT06771856|BEHAVIORAL|Stepped Care CBTi|"The stepped care approach in CBTi entails a two-step approach. Participants in this group all receive an initial entry level session of 1 hour delivered by a trained physiotherapist. Step 1: The entry level in this stepped care approach will imply a single, 1-hour long session, administered by a physiotherapist. This single session will cover: 1) education on sleep, sleep pressure, circadian rhythms; 2) introducing entry-level CBT-i principles (e.g., optimizing sleep environment, pre-bedtime food and beverage consumption) 3) pinpointing 2 to 3 of the most relevant strategies for the participant; and 4) creating an action plan for consistent implementation of these strategies over the next month. One month after 'Step 1' the participants' score on the Insomnia Severity Index (T1) will guide further decision making. Those with ISI scores \<12 will enter the follow-up phase immediately. Those with ISI scores ≥12 after step 1 will be referred to standard care CBTi."
219207017|NCT06775041|DRUG|Progerinin|Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
219207018|NCT06775041|DRUG|Lonafarnib|Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
219207019|NCT06770088|DRUG|vnacicizumab|Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
219207020|NCT06773078|OTHER|High intake group|Intake of a breakfast containing the foods of interest avocado (80gr), corn tortilla (60 gr), nopal (200 gr), guava (108 gr), mango (100 gr), amaranth (14 gr).
219207021|NCT06773078|OTHER|Average intake group|Intake of a breakfast containing the foods of interest avocado (40gr), corn tortilla (30 gr), nopal (100 gr), guava (54 gr), mango (50 gr), amaranth (7 gr).
219207022|NCT06770881|DRUG|JSKN033|JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
218951527|NCT00799175|DRUG|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
218951528|NCT04187872|COMBINATION_PRODUCT|LITT + Pembrolizumab|Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
219360011|NCT03667001|DRUG|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
219637466|NCT01030289|DEVICE|sham tDCS|transcranial direct current stimulation
219637467|NCT00928291|OTHER|procalcitonin|plasma PCT measurement
219637468|NCT00928291|DRUG|antibiotic therapy|antibiotic therapy use
219637469|NCT05219591|DEVICE|EPR|application of EPR technology during CPAP treatment
219637470|NCT00896792|OTHER|counseling intervention|
219637471|NCT00896792|OTHER|questionnaire administration|
219637472|NCT00896792|OTHER|survey administration|
218951529|NCT02858817|DRUG|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
219637473|NCT00896792|PROCEDURE|end-of-life treatment/management|
219637474|NCT00896792|PROCEDURE|psychosocial assessment and care|
219637475|NCT02318446|DRUG|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
219637476|NCT02318446|DRUG|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
218951530|NCT02858817|BIOLOGICAL|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
218951531|NCT02858817|OTHER|NaCl 0,9%|0.9% NaCl solution for injection
218951532|NCT02291653|DEVICE|McGrath|video-laryngoscopy
218951533|NCT02291653|DEVICE|MIL|direct-laryngoscopy
218951534|NCT02572739|DEVICE|PICCO|measurements based on thermodilution
218951535|NCT02572739|DEVICE|NICCOMO|measurements based on impedance
218951536|NCT05233397|DRUG|Tocilizumab|For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
218951537|NCT06161896|DIAGNOSTIC_TEST|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
218951538|NCT04184986|DIAGNOSTIC_TEST|dry blood test|screening test for Fabry disease
218951539|NCT04809103|DRUG|cis-diamminedichloroplatinum|Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
218951540|NCT01073501|DRUG|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
218951541|NCT01073501|DRUG|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
218951542|NCT02836743|DRUG|Circadin|Slow-release melatonin
218951543|NCT02836743|DRUG|Placebo|
218951544|NCT02739672|DRUG|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
218951545|NCT02739672|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
218951546|NCT02739672|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
219637477|NCT05282537|BEHAVIORAL|In person academic activities|All participants will perform academic activities in person from March to December, 2022
218951547|NCT04096482|DEVICE|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
219637478|NCT03321500|OTHER|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
219637479|NCT03321500|OTHER|Silicone-based soft liner|gold standard for denture relining material
219637480|NCT04438837|DRUG|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
219637481|NCT06535152|DEVICE|Lifelight|Lifelight is a artificial-intelligence software application that enables completely contactless spot measurements (i.e., one-off measurements without prior calibration) of PR and BP. Based on the science of remote photoplethysmography (rPPG), Lifelight works by detecting tiny changes in the colour of facial skin that occur every time the heart beats. All that is required to generate PR and BP measurements is that the software application is downloaded onto a computer device (e.g., smartphone or tablet) with a standard camera, and that the patient's face stays in the line of sight of the camera for up to 60 seconds.
219637482|NCT06535152|DEVICE|Manual sphygmomanometer|Blood Pressure Measurement
219637483|NCT04620837|DRUG|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
219637484|NCT04620837|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
219637485|NCT04659954|OTHER|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
219637486|NCT05930054|DEVICE|skeletal anchorage and rapid palatal expansion|Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
218951548|NCT04096482|DEVICE|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
218951549|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
218951550|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
218951551|NCT00576420|PROCEDURE|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
218951552|NCT05481541|OTHER|written education|"Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group."
218951553|NCT04836325|PROCEDURE|transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of tSMS in the primary motor cortex.
218951554|NCT04836325|PROCEDURE|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment
219637487|NCT06383754|DEVICE|Clareon|Monofocal intraocular lens
218951555|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and magnesium|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate
218951556|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and normal saline|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
219360012|NCT03667001|DRUG|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
219549835|NCT04838353|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
219549836|NCT01437761|DEVICE|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
219637488|NCT06383754|DEVICE|Tecnis 1|Monofocal 1 Piece intraocular lens
219637489|NCT00003853|DRUG|4'-iodo-4'-deoxydoxorubicin|
219637490|NCT01538277|PROCEDURE|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
219637491|NCT01538277|OTHER|Standard ablation procedure|Standard ablation procedure
219367131|NCT03219073|DEVICE|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
219637492|NCT04515654|OTHER|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
219637493|NCT06482398|DRUG|Sericin extract and turmeric extract cream|Apply the sample 2 times a day for 8 weeks
219637494|NCT06482398|DRUG|Triamcinolone acetonide 1% Cream|Apply the sample 2 times a day for 8 weeks
219637495|NCT00687544|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
219637496|NCT00687544|DRUG|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
219637497|NCT01487122|RADIATION|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
219637498|NCT01487122|RADIATION|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
219637499|NCT01487122|PROCEDURE|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
219637500|NCT00511745|DRUG|Rabeprazol|As prescribed
218951557|NCT00006103|DRUG|fluorouracil|
218951558|NCT00006103|DRUG|irinotecan hydrochloride|
218951559|NCT00006103|DRUG|leucovorin calcium|
218951560|NCT02402959|OTHER|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
219055555|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
219055556|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
219055557|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
219055558|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
219055559|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
219055560|NCT01387204|DRUG|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
219055561|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
219055562|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
218951561|NCT02000154|DRUG|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
218951562|NCT00000527|DRUG|aspirin|
218951563|NCT00000527|DRUG|dipyridamole|
218951564|NCT01340872|DRUG|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
218951565|NCT01340872|DRUG|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
218951566|NCT01502332|OTHER|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
219055563|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
219055564|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
219055565|NCT02794272|DEVICE|tDCS|
219055566|NCT02794272|DEVICE|sham-tDCS|
219367132|NCT03219073|DEVICE|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
218951567|NCT01502332|OTHER|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
218951568|NCT01327183|PROCEDURE|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
218951569|NCT01327183|DRUG|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
218951570|NCT01327183|DRUG|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
218951571|NCT01327183|DRUG|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
218951572|NCT00483132|DRUG|interferon alpha 2a|
218951573|NCT05977738|DRUG|Pitavastatin calcium|Daily Pitavastatin administration
218951574|NCT04119375|BEHAVIORAL|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
219055567|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
219055568|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
219055569|NCT00499135|OTHER|Computed Tomography|Correlative studies
219055570|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
219055571|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
219055572|NCT00499135|OTHER|Pharmacological Study|Correlative studies
219055573|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
219055574|NCT00499135|DRUG|Sunitinib Malate|Given PO
219055575|NCT02076412|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
219055576|NCT02076412|DRUG|Placebo|Placebo tablet PO bid (morning and evening)
219367133|NCT01988090|DRUG|800 IU Vitamin D Supplement|Standard Dose
219367134|NCT01988090|DRUG|50,000 IU Vitamin D supplement|High Dose
219367135|NCT01119547|OTHER|Exercise in a group|The patient do their individual exercise program in a group.
218951575|NCT04119375|BEHAVIORAL|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
218951576|NCT04119375|BEHAVIORAL|SMS Reminder|Patients receive a single daily SMS message to take their medication.
218951577|NCT04119375|OTHER|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
218951578|NCT04676256|PROCEDURE|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
218951579|NCT00831649|DRUG|natalizumab|
219637501|NCT01803750|BEHAVIORAL|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
219637502|NCT04153760|DRUG|Aspirin 81 mg|Aspirin 81 mg p.o. daily
219637503|NCT04153760|DRUG|Placebo|Placebo p.o. daily
218951580|NCT00979797|OTHER|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
218951581|NCT03004573|OTHER|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
219637504|NCT02195869|DRUG|Ibrutinib|
219637505|NCT01788527|DEVICE|CGM|Real Time Continuous Glucose Monitoring
219637506|NCT00917176|DEVICE|Occipital nerve stimulation|
219637507|NCT03915327|DRUG|Intravenous iron isomaltose anhydride|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
219637508|NCT04858776|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
219637509|NCT04858776|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
219637510|NCT05944744|DRUG|Adenosylcobalamin|The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
219637511|NCT05944744|DRUG|Placebo|The drug doesn't contain any properties or substances for treatment.
218951582|NCT04865874|OTHER|PPV-GDT|fluid-therapy based on PPV monitoring
218951583|NCT04865874|OTHER|Zero-balance|fluid-therapy based on urinary output balance
218951584|NCT01486082|OTHER|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
218951585|NCT04884451|BEHAVIORAL|Lifestyle modification|Diet and physical activity modification and behavioral approach
218951586|NCT04133064|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
218951587|NCT05236387|DRUG|99m Tc-TM|Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
218951588|NCT01771809|DRUG|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
218951589|NCT01771809|DRUG|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
218951590|NCT01459029|DRUG|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
218951591|NCT03056599|DRUG|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
218951592|NCT03056599|DEVICE|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
218951593|NCT03603509|DRUG|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
218951594|NCT03603509|DRUG|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
218951595|NCT05018351|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
219367136|NCT01119547|OTHER|Home exercise|The patient exercise their individual program at home during 6 v.
219637512|NCT01095380|OTHER|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
219637513|NCT05527275|DRUG|Mitoxantrone liposome combine with Chidamide|"Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year."
219637514|NCT02402387|PROCEDURE|Neutral head position|
219637515|NCT02402387|PROCEDURE|Flexed head position|
219637516|NCT02402387|PROCEDURE|Extended head position|
219637517|NCT02402387|PROCEDURE|Rotated head position|
219637518|NCT02402387|DEVICE|Air-Q SP Airway|
219637519|NCT03525275|DEVICE|Battlefield Acupuncture|Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
219637520|NCT03525275|PROCEDURE|Post-surgical shoulder protocol|Surgery specific post-surgical physical therapy protocol
219637521|NCT00949559|DRUG|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
219637522|NCT00789698|DRUG|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
219637523|NCT00789698|DRUG|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
219637524|NCT04591366|OTHER|Barrier dressing|A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.
219637525|NCT04463147|DEVICE|Needle-pilotTM device|The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.
219637526|NCT02812069|DEVICE|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
219637527|NCT00360061|BEHAVIORAL|Cognitive Behaviour Therapy|
219637528|NCT03424057|PROCEDURE|Asymmetric Primary Closure and Additional Skin Excision Technique|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
219637529|NCT03424057|PROCEDURE|Standard Karydakis technique.|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
219637530|NCT01945840|PROCEDURE|Roux en Y Gastric Bypass Surgery|
219637531|NCT01945840|OTHER|Gut hormone infusion|
219637532|NCT01945840|OTHER|Placebo infusion|
219637533|NCT01945840|OTHER|Very low calorie diet|
219637534|NCT00596817|DRUG|Placebo|capsules, daily, orally
219637535|NCT00596817|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
219637536|NCT04613921|OTHER|Observational Protocol|The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)
219637537|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care (active comparator)|Invitation of all participants to CCS according to the standard of care
219637538|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling|"A self-sampling kit mailed to the participants, with a prepaid envelope for returning them after sample collection. Participants may also return the kits by depositing them in a container that will be available in their Health Care Center.~The invitation for CCS through self-sampling is accompanied by written instructions, SMS reminders and navigation support (dedicated telephone line, WhatsApp, website)"
219637539|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care|In a telephone contact, prompted by an SMS, participants will be given the opportunity to schedule CCS according to the standard of care or to ask for a self-sampling kit to be mailed to them. Depending on their choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable
219637540|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care, followed by invitation of those non-adherent to CCS through self-sampling|Participants not adhering to CCS after the first invitation (SOC) will be additionally invited for CCS screening through self-sampling (as in SS)
219637541|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling, followed by invitation of those non-adherent to CCS according to the standard of care|Participants not adhering to CCS after the first invitation for self-sampling (SS) will be additionally invited for CCS screening according to the standard of care (as in SOC)
219637542|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care; this mode of invitation is repeated when participants do not adhere to the first invitation|Participants not adhering to CCS after a first invitation for screening through a method of their choice (CHOICE) will be invited again, also being given the opportunity to choose between the standard of care or self-sampling (as in the first CHOICE invitation). Depending on the participants' choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable, both in the first and in the second CHOICE invitations
219637543|NCT04444011|DRUG|Anaprazole Sodium|Anaprazole Sodium isthePPI inhibitor
219637544|NCT04444011|DRUG|Amoxicillin|antibiotic
219637545|NCT04444011|DRUG|Clarithromycin|antibiotic
219360013|NCT06320444|PROCEDURE|232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)|"Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)"
219367137|NCT01734317|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer.
219367138|NCT04870671|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)|Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
219637546|NCT04444011|DRUG|Bismuth|Bismuth is to protect the gastric mucosa
219637547|NCT05272111|OTHER|DBM fasciatherapy+ conventional physical therapy|DBM fasciatherapy (3 sessions per day). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the fasciatherapy. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
218951596|NCT05018351|BEHAVIORAL|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
218951597|NCT06516835|OTHER|Enteral fluid|GNAK will be administered to the gastrointestinal tract with EN in the same volume.
218951598|NCT06516835|OTHER|Intravenous fluid|Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
218951599|NCT00008450|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
218951600|NCT00008450|DRUG|Cyclosporine|Given PO or IV
218951601|NCT00008450|OTHER|Laboratory Biomarker Analysis|Correlative studies
218951602|NCT00008450|DRUG|Mycophenolate Mofetil|Given PO or IV
218951603|NCT00008450|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
218951604|NCT00008450|RADIATION|Total-Body Irradiation|Undergo TBI
218951605|NCT01407653|PROCEDURE|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
219055577|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
219637548|NCT05272111|OTHER|fascial manipulation+ conventional physical therapy|Fascial manipulation (3 sessions per day). This technique involves the identification of specific, localized areas of the fascia with limited movements. Once it is identified, then a specific point on the fascia is targeted and through the appropriate manipulation of this precise part of the fascia, movement can be restored. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
219637549|NCT00869622|DRUG|Risedronate|35 mgs/week + calcium and vit d
219637550|NCT00869622|DRUG|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
219637551|NCT03063437|BIOLOGICAL|Encapsulated fecal microbiota preparation|30 capsules
219637552|NCT03063437|BIOLOGICAL|Encapsulated placebo|30 capsules
218951606|NCT01407653|PROCEDURE|Usual care|Classical care
218951607|NCT03167567|BEHAVIORAL|Presence of a medical clown during labor|Presence of a medical clown during labor
218951608|NCT02574572|BIOLOGICAL|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
218951609|NCT03802214|DRUG|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
218951610|NCT00639652|PROCEDURE|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
218951611|NCT00639652|PROCEDURE|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
218951612|NCT00042341|DRUG|clofarabine (IV formulation)|
218951613|NCT02248558|BEHAVIORAL|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
218951614|NCT02248558|BEHAVIORAL|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
219637553|NCT04166942|DRUG|KD025|Single dose of 200 mg KD025 orally
219637554|NCT06922695|OTHER|Pill-in-pocket anticoagulation|Participants will stop their oral anticoagulation after a 30-day period free of AF episodes. After this, they will only take their anticoagulation in response to an episode of AF detected by their implantable cardiac monitor. The participants will receive an automated smartphone alert instructing them to commence their anticoagulation as soon as AF is detected.
219637555|NCT04326361|PROCEDURE|Neonatal surgeries|Current practices of neonatal surgeries in India
219637556|NCT02375360|OTHER|Oral immunotherapy|
218951615|NCT02770209|BIOLOGICAL|biomimetic cartilage matrix + autologous chondrocytes|
218951616|NCT02770209|PROCEDURE|arthroscopic debridement|
218951617|NCT02770209|PROCEDURE|microfracture surgery|
218951618|NCT06147375|DRUG|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
218951619|NCT00970775|DRUG|AZD2423|oral solution, single dose
218951620|NCT00970775|DRUG|Placebo|oral solution,single dose
218951621|NCT02327715|DRUG|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
219055578|NCT01760148|DRUG|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
219360014|NCT05852639|DEVICE|Ultrasound|Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
219360015|NCT06543615|DEVICE|Ultrasonography|Ultrasound assessment of residual gastric volume
219055579|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
219055580|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
219055581|NCT00360776|DRUG|tipifarnib|Given orally
219055582|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
219055583|NCT06109428|DRUG|HTX-011|400 mg
219055584|NCT06109428|DRUG|Bupivacaine Hydrochloride|125 mg
219055585|NCT06109428|DRUG|Ibuprofen|400 mg
219055586|NCT06109428|DRUG|Acetaminophen|1 g
219055587|NCT06109428|DEVICE|Luer lock applicator|Applicator for instillation
219055588|NCT06415643|OTHER|Islet organoids transplantation|autologous transplantation of ex vivo expanded islet organoids.
219055589|NCT04369248|OTHER|hepassocin|hepassocin levels in polycystic ovary syndrome
219360016|NCT03851783|DEVICE|Solar-powered oxygen|Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
219637557|NCT06923163|BEHAVIORAL|Exercise intervention|"Exercise prescription for participant，~* 150Kcal for Weeks 1-4 (gradually increase to 150Kcal in the first two weeks as familiar stage),~* 250Kcal for Weeks 5-8,~* 350Kcal for Weeks 9-12."
219637558|NCT04018131|DRUG|Cimetidine|Antihistamine 2 antagonist
219637559|NCT04018131|DRUG|Placebos|Placebo drug
219637560|NCT02745431|DRUG|Oxytocin|
219637561|NCT02745431|DRUG|Placebo|
219637562|NCT00602836|BIOLOGICAL|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
219637563|NCT00602836|DRUG|Cyclophosphamide|600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
219637564|NCT00602836|DRUG|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
219637565|NCT00602836|DRUG|Pentostatin|2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
219637566|NCT00117273|DRUG|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
219637567|NCT00117273|DRUG|Seasonique (LNG/EE and EE)|1 tablet daily
219637568|NCT00117273|DRUG|Portia (LNG/EE)|1 tablet daily x 28 days
219637569|NCT06014190|DRUG|HS-20089|All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
219360017|NCT04391959|DRUG|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
219360018|NCT04391959|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
219637570|NCT03386591|DRUG|Naloxone|Comparing pharmacokinetics of naloxone
219637571|NCT03386591|DEVICE|Mucosal atomization device and syringe|Injection
219637572|NCT03386591|DEVICE|Narcan|Nasal Spray
219637573|NCT03386591|DEVICE|Intramuscular Auto Injector|Intramuscular injection
219637574|NCT00516672|DRUG|pazopanib|Pazopanib oral tablet
219637575|NCT00516672|DRUG|Lapatinib|Lapatinib oral tablet
219637576|NCT00086177|DRUG|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
219637577|NCT00086177|DRUG|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
218951622|NCT03924557|DIAGNOSTIC_TEST|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
219637578|NCT06940440|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
219637579|NCT06940440|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpointinhibitor)~Route of administration:~• Intravenous (IV) infusion"
219637580|NCT06939634|DEVICE|Hands-free exoskeleton|Having undergone at least on session with Atalante exoskeleton. Clinical, safety and session data are collected retrospectively.
219637581|NCT06939101|BEHAVIORAL|self-efficacy training|The principal investigator will supervise students and build this program to increase occupational, physical, and speech therapy student participation. There are two one-hour briefing meetings for onboarding to promote self-efficacy preparation and six 1-2 hours of debriefing after each clinical day.
219637582|NCT06939595|DRUG|CT-P51|CT-P51 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
219637583|NCT06939595|DRUG|EU-approved Keytruda|Keytruda 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
219637584|NCT06939881|OTHER|"11 for Health training group"|"The 11 for Health intervention consisted of two 45-minute sessions per week for 11 weeks, implemented during school hours. Each week included one session focused on football-related physical activities (e.g., passing, dribbling, shooting) and another on health education topics (e.g., hygiene, nutrition, mental well-being), both delivered in an engaging and inclusive format. The program emphasized social interaction, autonomy-supportive teaching, and real-life applicability through take-home tasks."
219637585|NCT06941142|DRUG|Sirolimus (albumin - bound)|Dose escalation, intravenous infusion
219637586|NCT06941142|DRUG|Palbociclib tablet|The dosage is 125 mg, orally once a day. Taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
219637587|NCT06941142|DRUG|Fulvestrant injection|The dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
219637588|NCT06941350|BIOLOGICAL|NCR102 injection|Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.
219637589|NCT02716168|OTHER|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
218951623|NCT04989452|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
218951624|NCT02656680|BEHAVIORAL|Continuous Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
218951625|NCT02656680|BEHAVIORAL|Closed Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
218951626|NCT02968862|OTHER|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
218951627|NCT05541588|PROCEDURE|peripheral nerve block|ultrasound guided nerve block
218951628|NCT05832554|DEVICE|nasal airway|nasopharyngeal airway
218951629|NCT05832554|DEVICE|oral airway|oropharyngeal airway
218951630|NCT01362868|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
218951631|NCT02294942|DRUG|RANCAD|Extended-Release RANCAD
219055590|NCT05262205|OTHER|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
219055591|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
219055592|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
219055593|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
219055594|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
219055595|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
219055596|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
218951632|NCT02384057|OTHER|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
218951633|NCT02384057|OTHER|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
218951634|NCT04966910|BEHAVIORAL|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
218951635|NCT04966910|BEHAVIORAL|Treatment as usual|Regular check-ins, resource/referral provision
218951636|NCT02876250|DRUG|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
218951637|NCT02876250|DRUG|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
218951638|NCT02930980|DEVICE|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
218951639|NCT03387384|OTHER|Non-interventional study|Non-interventional study
218951640|NCT04810728|DRUG|Extract Psidii guava|2 Capsule Extract Psidii guava, three times daily
218951641|NCT04810728|COMBINATION_PRODUCT|Standard therapy for Covid-19 patient|(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
218951642|NCT04892056|OTHER|Friction Mechanics|anterior segment retraction using elastomeric power chains
218951643|NCT04892056|OTHER|Frictionless Mechanics|anterior segment retraction using closing loops
219055597|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
219055598|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
218951644|NCT02038374|PROCEDURE|biopsies|
218951645|NCT00204945|DRUG|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
218951646|NCT03594942|DIAGNOSTIC_TEST|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
218951647|NCT04095533|OTHER|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
218951648|NCT04095533|OTHER|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
218951649|NCT03509415|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
218951650|NCT01761071|DRUG|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
218951651|NCT01761071|DRUG|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
218951652|NCT04486274|OTHER|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
218951653|NCT04958512|DRUG|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
218951654|NCT04958512|DRUG|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
218951655|NCT04958512|OTHER|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
219360019|NCT05554627|DRUG|Esketamine|Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
219367139|NCT01083667|DRUG|Pyrimethamine|Open Label, dose escalating,
219367140|NCT02581254|DEVICE|Thin Wire Snare|
219367141|NCT02581254|DEVICE|Thick Wire Snare|
218951656|NCT04139746|PROCEDURE|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
218951657|NCT04139746|PROCEDURE|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
218951658|NCT05098275|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
219055599|NCT06316739|BEHAVIORAL|Ganchero intervention|"The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services."
218951659|NCT05098275|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
218951660|NCT03679442|DRUG|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
218951661|NCT06408155|OTHER|Isometric Task|The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
218951662|NCT02427178|BIOLOGICAL|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
218951663|NCT00130312|DRUG|Sulodexide|100 mg gelcap in the morning and evening
218951664|NCT00130312|DRUG|Placebo|1 placebo gelcap in the morning and evening
218951665|NCT03306797|OTHER|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward"
219055600|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
219055601|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
219055602|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
219055603|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
218951666|NCT03306797|DEVICE|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
218951667|NCT06449365|DEVICE|midazolam by nasal atomizer|midazolam
218951668|NCT06449365|DRUG|intravenous midazolam|midazolam
219055604|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
219055605|NCT00955266|DRUG|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
219055606|NCT00955266|DRUG|Placebo|Normal saline, 50cc delivered over 5 minutes
219055607|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
218951669|NCT05470257|OTHER|Cast|Application of fiberglass long arm cast.
218951670|NCT02875574|DRUG|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
218951671|NCT02875574|OTHER|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
218951672|NCT04779749|OTHER|Data extraction from medical files|Data extraction from medical files
219055608|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
219055609|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
219367142|NCT05078125|DEVICE|Holter monitoring|24 hours Holter monitoring
218951673|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
218951674|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
218951675|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
218951676|NCT00911443|BIOLOGICAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
218951677|NCT00911443|DRUG|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
218951678|NCT03409042|BEHAVIORAL|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
218951679|NCT05934188|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
218951680|NCT05934188|BEHAVIORAL|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
218951681|NCT05934188|BEHAVIORAL|Eating habits|Information on eating habits will be derived from food questionnaires.
218951682|NCT05934188|DIAGNOSTIC_TEST|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
218951683|NCT05934188|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
218951684|NCT05934188|DIAGNOSTIC_TEST|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
218951685|NCT00912444|DRUG|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
218951686|NCT00912444|DRUG|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
218951687|NCT06518850|DRUG|Rifaximin|Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
218951688|NCT02127268|DRUG|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
218951689|NCT03821662|BEHAVIORAL|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
218951690|NCT02496572|DRUG|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
218951691|NCT00627146|DRUG|ChAgly CD3|6 days treatment 8mg/d intravenous
218951692|NCT00627146|DRUG|Placebo|6 days
218951693|NCT01142089|DRUG|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
218951694|NCT01142089|DRUG|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
218951695|NCT00697580|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
219360020|NCT05554627|DRUG|Aripiprazole|Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
219367143|NCT01439945|DRUG|magnesium oxide|Given PO
219367144|NCT01439945|OTHER|placebo|Given PO
218951696|NCT00697580|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
218951697|NCT00697580|BEHAVIORAL|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
218951698|NCT05011448|OTHER|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
218951699|NCT01145638|DRUG|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
219055610|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
219055611|NCT02972528|BIOLOGICAL|Platelet Lysate|Direct injection of allogenic Platelet Lysate
219055612|NCT02972528|BIOLOGICAL|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
218951700|NCT01145638|DRUG|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
218951701|NCT05449470|DEVICE|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
219207023|NCT06770816|OTHER|Echocardiography|HR, MAP, SBP and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Changes in LV systolic function will be assessed with three parameters: fractional shortening (FS), ejection fraction (EF) using the Simpson method and S' wave of tissue Doppler imaging (TDI) of the mitral annulus (average of values at the medial and lateral annulus). LV diastolic function will be assessed with three parameters and interpreted according to the European Association of Cardiovascular Imaging guidelines. Pulsed wave (PW) Doppler of trans-mitral flow will be used to obtain the ratio between early (e) and late (atrial, a) waves. A PW Doppler between the LV outflow tract and the mitral valve will be performed to estimate the iso-volumetric relaxation time IVRT. TDI will be used to investigate myocardial relaxation at the mitral annular level (ear
219549837|NCT02225015|BEHAVIORAL|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
219549838|NCT05853653|BEHAVIORAL|Using dolls in breastfeeding education|Using dolls in breastfeeding education
219549839|NCT00819169|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
219549840|NCT00819169|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
219549841|NCT04434716|DEVICE|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
218951702|NCT05449470|DEVICE|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
218951703|NCT00789074|DRUG|Varenicline|Varenicline 1mg twice daily
218951704|NCT00789074|DRUG|Placebo|Placebo 1mg BD
218951705|NCT01490398|DRUG|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
218951706|NCT00531687|DRUG|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
218951707|NCT00531687|DRUG|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
219549842|NCT00406393|DRUG|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
218951708|NCT00531687|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
218951709|NCT01378546|DRUG|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
219055613|NCT00355446|DRUG|Bimatoprost 0.03%|
219055614|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
219055615|NCT05449028|DRUG|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
219055616|NCT05449028|DRUG|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
219055617|NCT05449028|DRUG|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
219055618|NCT05449028|DRUG|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
219055619|NCT05449028|DRUG|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
218951710|NCT05527938|OTHER|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
218951711|NCT02667613|OTHER|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
218951712|NCT02667613|OTHER|Control|Usual customary care
218951713|NCT02891785|BEHAVIORAL|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
218951714|NCT05905614|DRUG|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
218951715|NCT00815854|DIETARY_SUPPLEMENT|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
218951716|NCT00815854|OTHER|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
218951717|NCT02623231|DRUG|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
218951718|NCT02623231|DRUG|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
218951719|NCT05099029|BIOLOGICAL|EV71 vaccine|EV71 vaccine (\[1 μg total protein + adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
218951720|NCT05099029|BIOLOGICAL|Placebo|Placebo (\[ adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
218951721|NCT06372743|OTHER|INTEGREAT-CKD Intervention|"The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status."
218951722|NCT04396184|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
218951723|NCT00813176|DEVICE|Double Lumen Endotracheal Tube|
219055620|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
219055621|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
219055622|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
219055623|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
219055624|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
219055625|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
218951724|NCT00813176|DEVICE|Arndt Bronchial Blocker|
218951725|NCT03656471|DEVICE|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
218951726|NCT02073266|PROCEDURE|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
218951727|NCT01389362|DRUG|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
218951728|NCT01389362|DRUG|Placebo comparator|2 sachets to be taken daily
218951729|NCT02713256|DRUG|CFZ533|CFZ533 intravenously over approximately one hour
218951730|NCT03516474|DEVICE|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
218951731|NCT02230527|DRUG|Ticagrelor|90mg twice a day by mouth
218951732|NCT02230527|DRUG|Clopidogrel|75mg once a day by mouth
218951733|NCT01010139|DRUG|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
218951734|NCT04834960|OTHER|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
218951735|NCT00014755|DRUG|anti-thymocyte globulin|
218951736|NCT00014755|DRUG|cyclophosphamide|
218951737|NCT00014755|DRUG|filgrastim|
218951738|NCT00014755|DRUG|prednisone|
218951739|NCT00014755|PROCEDURE|peripheral blood stem cell transplantation|
218951740|NCT00014755|PROCEDURE|irradiation|
218951741|NCT02426489|DEVICE|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
218951742|NCT04461600|DRUG|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
219055626|NCT00803127|DEVICE|vs-sense|detection swab
219637590|NCT06539403|BEHAVIORAL|Memory tasks|"Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall."
219055627|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
219637591|NCT04672577|OTHER|Observational study|No intervention is planned
219637592|NCT01069198|DRUG|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged \<5 and \>=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
219637593|NCT01069198|OTHER|Placebo|Placebo
218951743|NCT05605145|DIAGNOSTIC_TEST|PCR was used to detect pneumocystis in respiratory specimens|Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.
219055628|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
219055629|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
218951744|NCT05767476|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment"
219055630|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
218951745|NCT01733212|DRUG|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
218951746|NCT01733212|DRUG|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
218951747|NCT00760799|PROCEDURE|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
218951748|NCT00228176|DRUG|Rimonabant|Tablet, oral administration
218951749|NCT00228176|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
218951750|NCT04098055|DEVICE|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
218951751|NCT04098055|DEVICE|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
218951752|NCT04504851|DRUG|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
218951753|NCT04504851|DRUG|Rifampicin|Rifampicin 10mg/kg
218951754|NCT04504851|DRUG|Isoniazid|Isoniazid 5mg/kg
218951755|NCT04504851|DRUG|Pyrazinamide|Pyrazinamide 25mg/kg
218951756|NCT04504851|DRUG|Ethambutol|Ethambutol 15mg/kg
218951757|NCT05955573|DIAGNOSTIC_TEST|xray|radiological description
218951758|NCT05307367|BEHAVIORAL|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
218951759|NCT03851172|DRUG|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
218951760|NCT03851172|DRUG|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
218951761|NCT03851172|DRUG|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
218951762|NCT06411171|DRUG|Pembrolizumab plus chemotherapy (FLOT)|The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
218951763|NCT03443557|OTHER|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
219055631|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
219055632|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
219055633|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
219055634|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
219055635|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
219055636|NCT02348528|DRUG|Lenalidomide|
219055637|NCT02348528|DRUG|Dexamethasone|
219055638|NCT02296112|DRUG|trametinib|Given PO
219055639|NCT02296112|OTHER|laboratory biomarker analysis|Correlative studies
219055640|NCT02296112|OTHER|pharmacological study|Correlative studies
219055641|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
219055642|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
219055643|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
219055644|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
219055645|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
219637594|NCT06941090|OTHER|sampling stool|Participants will receive a self-sampling stool kit with detailed instructions by mail to their home address. Samples will be mailed back by the participant to the treatment laboratory, which will determine the characteristics of their intestinal microbiota.
219637595|NCT04936750|OTHER|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
218951764|NCT05507788|DEVICE|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
219055646|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
219637596|NCT01733667|DEVICE|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
219637597|NCT01733667|DEVICE|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
218951765|NCT04994470|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
219055647|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
219055648|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
219055649|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
219055650|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
219055651|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
219055652|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
219055653|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
219055654|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
219055655|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
219055656|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
219055657|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
219055658|NCT04380207|DRUG|QPX7728|antibiotic
219055659|NCT04380207|DRUG|Placebo|Placebo comparator
219055660|NCT04380207|DRUG|QPX2014|antibiotic
219055661|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
219055662|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
219055663|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
218951766|NCT04994470|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
218951767|NCT04842032|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
218951768|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
218951769|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
218951770|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
218951771|NCT06102018|DIAGNOSTIC_TEST|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
218951772|NCT00775203|DRUG|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
218951773|NCT00775203|DRUG|Placebo|
218951774|NCT00223782|BEHAVIORAL|Gait Training with Feedback|
218951775|NCT00223782|BEHAVIORAL|Gait Training with no feedback|
218951776|NCT04664894|DRUG|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
218951777|NCT05792657|BEHAVIORAL|High dosage in-person exercise coaching|High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
218951778|NCT05792657|BEHAVIORAL|Medium dosage in-person exercise coaching.|Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
218951779|NCT05792657|BEHAVIORAL|Low dosage in-person exercise coaching|Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
219055664|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
219549843|NCT00406393|DRUG|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
218951780|NCT04191083|BEHAVIORAL|Motor imagery|This group will perform motor imagery training on motor learning of different motor tasks
218951781|NCT04191083|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
218951782|NCT04191083|BEHAVIORAL|Action observation|This group will perform action observation training on motor learning of various motor tasks.
218951783|NCT04191083|BEHAVIORAL|Placebo intervention|This group will watch a video of a landscape without the presence of people.
218951784|NCT02454361|DRUG|KBP-7072|KBP-7072
218951785|NCT02454361|DRUG|Placebo|Placebo
218951786|NCT01414348|BEHAVIORAL|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
218951787|NCT01414348|BEHAVIORAL|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
218951788|NCT02512484|PROCEDURE|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
219549844|NCT00406393|DRUG|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
219549845|NCT00002033|DRUG|Zidovudine|
219549846|NCT00002033|DRUG|AS-101|
219549847|NCT01927380|OTHER|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
219549848|NCT05369039|DRUG|Roflumilust|A selective phosphodiesterase 4 Inhibitor
219549849|NCT05369039|DRUG|Prednisolone|Systemic corticosteroid
219549850|NCT02364869|DIETARY_SUPPLEMENT|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
219549851|NCT02364869|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
219549852|NCT04941313|DRUG|3D229|3D229 is an investigational drug.
219549853|NCT04941313|OTHER|Placebo|Matching placebo
219549854|NCT04200872|OTHER|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
219549855|NCT04200872|OTHER|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
219549856|NCT04922957|DRUG|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
219549857|NCT04922957|OTHER|Placebo|Ringer's lactate solution
219549858|NCT05999916|DEVICE|Personalized Miamind Neurostimulator|60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
218951789|NCT00508781|BEHAVIORAL|Multiphoton laser image in cutaneous pathology|
218951790|NCT00692536|BEHAVIORAL|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
218951791|NCT00692536|BEHAVIORAL|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
218951792|NCT00547001|DRUG|Estradiol|1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
218951793|NCT02192424|DRUG|Metformin alone|
218951794|NCT02192424|DRUG|Metformin + Intermittent Insulin Therapy|
218951795|NCT03371888|BIOLOGICAL|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
218951796|NCT03371888|BIOLOGICAL|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
218951797|NCT04717206|OTHER|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
218951798|NCT04717206|OTHER|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
218951799|NCT01105065|DRUG|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
218951800|NCT02935426|DEVICE|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
218951801|NCT02935426|DEVICE|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
218951802|NCT05714319|OTHER|Data collection|"Variables collected will include:~* demographics (sex, age)~* comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~* echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~* angiographic data (presence of non-obstructive CAD (any coronary lesion \<50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~* laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~* medical therapy at admission~* response to intracoronary provocative test with ACh."
218951803|NCT05714319|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
218951804|NCT04925856|OTHER|blood sample|"•Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
218951805|NCT00303589|DRUG|Standard care|As prescribed
218951806|NCT00303589|DRUG|beta-lactam|750mg iv q8h
218951807|NCT00303589|DRUG|beta-lactam|1500mg iv q8h
218951808|NCT01849887|BIOLOGICAL|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
218951809|NCT01849887|DRUG|Placebo|Placebo
218951810|NCT05423860|OTHER|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
218951811|NCT03163602|DRUG|Control group|Access flap and debridement
218951812|NCT03163602|DEVICE|Test group|Regenerative treatment
218951813|NCT04113590|PROCEDURE|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
218951814|NCT04316702|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
218951815|NCT04316702|DRUG|Cymbalta / Lyrica - Drug treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
219549859|NCT05123443|BIOLOGICAL|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
218951816|NCT02636140|OTHER|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
218951817|NCT00228215|BEHAVIORAL|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
218951818|NCT00062816|DRUG|ISIS 14803, peginterferon alfa, ribavirin|
218951819|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
218951820|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
218951821|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
218951822|NCT02984943|DEVICE|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
218951823|NCT04575792|BEHAVIORAL|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
218951824|NCT05191056|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day for 8 weeks
218951825|NCT05191056|DIETARY_SUPPLEMENT|MelaGene drink|consume 1 bottle per day for 8 weeks
218951826|NCT04329689|OTHER|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
218951827|NCT03229174|DRUG|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
218951828|NCT03229174|DRUG|Placebo|Placebo (sugar pill)
219637598|NCT03299660|DRUG|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
219637599|NCT03299660|DRUG|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
218951829|NCT02025153|OTHER|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
218951830|NCT02843997|GENETIC|Endophenotype and sequencing|Draw an endophenotype and genetic study
218951831|NCT01414920|DRUG|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
218951832|NCT01414920|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
218951833|NCT01414920|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
218951834|NCT01414920|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
218951835|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
218951836|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
218951837|NCT05581901|DRUG|Methadone (Dose1)|Dose: 0.10mg/kg
218951838|NCT05581901|DRUG|Methadone (Dose 2)|Dose: 0.15mg/kg
218951839|NCT05581901|DRUG|Methadone (Dose 3)|Dose 0.20mg/kg
219055665|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
219055666|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
219055667|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
219055668|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
219055669|NCT01720069|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
219055670|NCT03445416|BEHAVIORAL|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
219055671|NCT03445416|BEHAVIORAL|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
219055672|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
219055673|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
219055674|NCT00508742|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
219055675|NCT00508742|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
219637600|NCT03299660|DRUG|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
219637601|NCT03299660|RADIATION|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
219637602|NCT03299660|PROCEDURE|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
219637603|NCT01583062|DRUG|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
219637604|NCT01583062|DRUG|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
219637605|NCT00664768|DIETARY_SUPPLEMENT|Neocate Infant|minimum of 8 fl. oz daily
219637606|NCT00664768|DIETARY_SUPPLEMENT|new Neocate|minimum of 8 fl oz daily
218951840|NCT03276169|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
218951841|NCT03276169|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
218951842|NCT03276169|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
218951843|NCT04564768|BEHAVIORAL|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
218951844|NCT00880464|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
218951845|NCT01791959|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
219055676|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
219055677|NCT04568122|DEVICE|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
219055678|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
219637607|NCT06940453|DEVICE|CONDUIT|Arm Description: Group/Cohort Description: This cohort is composed of patients who will be prospectively enrolled (35 total). These patients will undergo spinal stabilisation for lumbar degenerative disease using the CONDUIT ALIF cage system with supplemental posterior fixation. This device is FDA approved thus this is post market observational intervention.
218951846|NCT01791959|OTHER|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
218951847|NCT03529071|BEHAVIORAL|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
218951848|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
219055679|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
219055680|NCT06135662|PROCEDURE|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
219055681|NCT06135662|PROCEDURE|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
219055682|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
219055683|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
219055684|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
219055685|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
219055686|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
219055687|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
219055688|NCT00412165|BEHAVIORAL|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
219637608|NCT06030297|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib"
219637609|NCT06030297|DRUG|ZTlido 1.8 % Topical System|ZTLI(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4. Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin. DO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-
219055689|NCT00412165|BEHAVIORAL|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
218951849|NCT01213576|DRUG|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
218951850|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
218951851|NCT01213576|DRUG|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
218951852|NCT02162407|DRUG|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
218951853|NCT02162407|DRUG|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
218951854|NCT00606047|RADIATION|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
218951855|NCT03207373|DIAGNOSTIC_TEST|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
218951856|NCT00506532|DRUG|Surfactant (calfactant)|
218951857|NCT03098888|PROCEDURE|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
219637610|NCT06030297|DIAGNOSTIC_TEST|PeriCam PSI NR|It is a method that visualizes tissue blood perfusion in real time. LASCA provides new means to study the microcirculation in ways that were not possible in the past. PeriCam PSI System combines dynamic response and high spatial resolution in one instrument, providing both real-time graphs and video recordings of the tissue being studied. To further enhance its usability, dedicated application software, PIMSoft, has been developed.
218951858|NCT03521895|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
218951859|NCT03779243|DIETARY_SUPPLEMENT|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
218951860|NCT03779243|OTHER|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
218951861|NCT01038869|DRUG|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
218951862|NCT04575597|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
218951863|NCT04575597|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
218951864|NCT03138993|BEHAVIORAL|Patient decision aid|Web-based patient decision aid plus a paper workbook.
218951865|NCT03138993|BEHAVIORAL|General sleep education|Web-based information about sleep plus a paper workbook
218951866|NCT05610189|DRUG|Tavapadon|Oral tablets
218951867|NCT02553954|PROCEDURE|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
218951868|NCT00689442|DRUG|JTT-705 600 mg and atorvastatin 20 mg|"* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
218951869|NCT00689442|DRUG|Placebo and atorvastatin 20 mg|"* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
218951870|NCT04970953|PROCEDURE|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
218951871|NCT05240443|PROCEDURE|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
218951872|NCT05240443|OTHER|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
218951873|NCT04142879|DEVICE|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
218951874|NCT03553966|PROCEDURE|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
218951875|NCT03553966|PROCEDURE|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
218951876|NCT03553966|DEVICE|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
218951877|NCT04038203|DEVICE|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
218951878|NCT01659801|DEVICE|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
218951879|NCT05315869|PROCEDURE|Appendectomy|Surgical procedure for removal of the appendix
218951880|NCT06001411|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
218951881|NCT06001411|BEHAVIORAL|control group|Patients in the control group (C group) received standard perioperative care without any prone position training.
218951882|NCT02302430|DRUG|Oxytocin|20 International Units Intranasal Oxytocin
218951883|NCT02302430|OTHER|Placebo comparator|Saline nasal spray
218951884|NCT01779076|PROCEDURE|30% oxygen|
218951885|NCT01779076|PROCEDURE|100% oxygen|
218951886|NCT05456282|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
218951887|NCT05456282|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
218951888|NCT02012868|PROCEDURE|bariatric surgery|
218951889|NCT04050020|BIOLOGICAL|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
218951890|NCT04050020|BIOLOGICAL|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
219055690|NCT00412165|BEHAVIORAL|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
218951891|NCT02776020|DEVICE|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
218951892|NCT00430183|DRUG|docetaxel|75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
218951893|NCT00430183|DRUG|LHRH agonist|Given intramuscularly
218951894|NCT00430183|PROCEDURE|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
218951895|NCT01578512|BEHAVIORAL|Face-to-Face|Face-to-Face behavioral weight loss
218951896|NCT01578512|BEHAVIORAL|Web-based|Web-based behavioral weight loss
218951897|NCT01578512|BEHAVIORAL|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
219055691|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
219055692|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
219055693|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
219055694|NCT04430426|OTHER|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
219055695|NCT04430426|OTHER|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
218951898|NCT01625533|PROCEDURE|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
218951899|NCT01625533|PROCEDURE|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
218951900|NCT02436980|DRUG|Tramadol|GROUP T
218951901|NCT02436980|DRUG|Midazolam|GROUP M
218951902|NCT05628259|BEHAVIORAL|Tele-Nursing based Motivational Interviewing|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
218951903|NCT06298344|DRUG|Thiamine|Daily Thiamine 100 mg in 28 days
218951904|NCT01097083|DRUG|Coriolus Versicolor|
218951905|NCT02542930|RADIATION|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
219055696|NCT03941210|OTHER|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
218951906|NCT02542930|DRUG|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
218951907|NCT02592642|BEHAVIORAL|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
219055697|NCT00029731|DRUG|Arginine hydrochloride|
219055698|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
219055699|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
219055700|NCT01043965|DRUG|Metformin|Metformin 850mg
218951908|NCT02592642|BEHAVIORAL|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
218951909|NCT02592642|DEVICE|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
218951910|NCT02592642|DEVICE|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
218951911|NCT02592642|DEVICE|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
218951912|NCT02592642|DEVICE|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
219055701|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
219055702|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
219055703|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
219055704|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
218951913|NCT05413434|OTHER|exercise|high-intensity interval training will be performed on the treadmill.
219055705|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
219055706|NCT06594705|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
219055707|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
219055708|NCT01157533|DRUG|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
219055709|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
219055710|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
219055711|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
219055712|NCT06987175|OTHER|sadante neo therapy|SAN machine having 3 tube cords on both sides. Each tube cord contains 2 pairs of flat suction cups. We will use 4 pair of flat suction cups in this study. We will place 2 pair on left and two on right para spinal muscles of lumber in prone lying. Due to its automatic suctioning capability, these cups can easily stick to skin. After placing the cups on lumber each patient of group A will receive its stimulation for about 10 minutes every day for about 4 weeks along with conventional exercises.
219055713|NCT06987175|OTHER|Conventional exercises|receive conventional exercises only. Conventional exercises will be performed for 20 minutes, each exercise will be performed 20 times with 10 seconds hold.
219055714|NCT06981156|DIAGNOSTIC_TEST|pNANO Assessment|"pNANO assesses patient gait, strength, cerebellar function, visual fields, visual acuity, facial strength, level of consciousness, extraocular movement, dysarthria, and dysphagia~The patient will be assessed by 2-3 different clinicians during each of 2 visits."
218951914|NCT05413434|DEVICE|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
218951915|NCT05930015|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
218951916|NCT05930015|BEHAVIORAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
218951917|NCT05930015|BEHAVIORAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
218951918|NCT05726877|OTHER|ventilation strategy|Titrating positive end-expiratory pressure
218951919|NCT05264948|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
218951920|NCT05641389|OTHER|Monitoring|Participants will be monitored for alcohol use.
218951921|NCT02126748|OTHER|inhalation 4ml hypertonic saline 3% 3x/day|
218951922|NCT02126748|DEVICE|Intrapulmonary Percussive Ventilation|
218951923|NCT02126748|PROCEDURE|Assisted Autogenic Drainage|
219055715|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
219055716|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
219637611|NCT06030297|DIAGNOSTIC_TEST|Medoc Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds)."
219637612|NCT06030297|OTHER|Inactive Topical System|Inactive, non-medicated topical system comprised of an adhesive material containing, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of the system is 10 cm × 14 cm × 0.08 cm.
219637613|NCT03653962|BEHAVIORAL|video assisted group|
219637614|NCT03653962|BEHAVIORAL|non-video group|
218951924|NCT00216164|DRUG|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
218951925|NCT00216164|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
218951926|NCT01844479|DEVICE|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
218951927|NCT01844479|OTHER|Standard innersole|
218951928|NCT02208778|DRUG|Duloxetine|54 participants will be allocated for duloxetine treatment
218951929|NCT02208778|DRUG|Remifentanil|27 participants will be allocated to Remifentanil infusion
218951930|NCT02208778|DRUG|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
218951931|NCT02208778|DRUG|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
219055717|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
218951932|NCT01976988|DRUG|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
219055718|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
218951933|NCT04037878|PROCEDURE|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
218951934|NCT04037878|PROCEDURE|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
218951935|NCT04037878|DRUG|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
218951936|NCT01768429|BEHAVIORAL|Fatty fish|
218951937|NCT01768429|BEHAVIORAL|Lean Fish|
219055719|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
218951938|NCT01768429|BEHAVIORAL|Alpha-linolenic acid|
218951939|NCT01768429|BEHAVIORAL|Control|
219055720|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
219055721|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
219055722|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
219055723|NCT06990295|PROCEDURE|Focused Ultrasound Spleen Neuromodulation|A portable focused ultrasound device is used to stimulate the spleen area under real-time imaging guidance. Each session lasts approximately 20 minutes, repeated twice daily for five days.
219055724|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
219055725|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
219055726|NCT02777346|DEVICE|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
219055727|NCT02777346|DEVICE|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
218951940|NCT02128685|DRUG|Dydrogesterone|
218951941|NCT02128685|DRUG|Placebo|
218951942|NCT03207438|DRUG|Quetiapine 50 MG Extended Release Oral Tablet|OD
218951943|NCT03207438|DRUG|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
218951944|NCT03207438|DRUG|Placebos|Placebo
218951945|NCT01014923|BEHAVIORAL|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
218951946|NCT03153384|PROCEDURE|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
218951947|NCT05101200|OTHER|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
219055728|NCT06989983|DRUG|AZD5462 film-coated tablet|Oral, fasted
219055729|NCT06989983|DRUG|[14C]AZD5462 Solution for Infusion|Intravenous, fasted
219055730|NCT06989983|DRUG|[14C]AZD5462 Oral Solution|Oral, fasted
219055731|NCT00006347|RADIATION|indium In 111 monoclonal antibody MN-14|
219055732|NCT00006347|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
219055733|NCT05473312|BEHAVIORAL|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
219549860|NCT05123443|DIAGNOSTIC_TEST|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
219549861|NCT01937234|DRUG|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
219549862|NCT01937234|DRUG|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
219549863|NCT00937664|DRUG|AZD7762|solution, intravenous, weekly
219549864|NCT00937664|DRUG|gemcitabine|intravenous, weekly
219549865|NCT03835845|DEVICE|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
219549866|NCT04865120|OTHER|cream cyclic merocyanine|cream long-UVA absorber
219549867|NCT04865120|OTHER|placebo|placebo
219549868|NCT01663896|DEVICE|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
219055734|NCT05473312|BEHAVIORAL|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
219637615|NCT04736498|OTHER|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = \[(dIVCmax - dIVCmin)/dIVCmax\] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
218951948|NCT05101200|OTHER|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
218951949|NCT02567058|DEVICE|Ultrasound exam|"Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III"
218951950|NCT02567058|BEHAVIORAL|IPAQ questionnaire|IPAQ questionnaire
218951951|NCT00892840|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
218951952|NCT00892840|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
219055735|NCT05473312|BEHAVIORAL|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
219055736|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
219055737|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
219055738|NCT06043310|DRUG|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
219637616|NCT02227498|DEVICE|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
219637617|NCT05161260|BEHAVIORAL|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
219637618|NCT05161260|BEHAVIORAL|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
219637619|NCT00288405|DEVICE|Cordis Self Expanding Stent|
219637620|NCT05915247|DRUG|HER-096|Administered as a single dose via s.c. injection
219637621|NCT05915247|DRUG|Placebo|Administered as a single dose via s.c. injection
218951953|NCT01119937|DRUG|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
218951954|NCT01119937|DRUG|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
218951955|NCT03316911|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
219055739|NCT06043310|DRUG|Acetylcholine|ACh will be infused locally through microdialysis catheters.
219055740|NCT06043310|DRUG|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
219055741|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
219055742|NCT06995144|DRUG|Extended Release Torsemide Tablets|Extended release torsemide vs Immediate release torsemide
219055743|NCT06995144|DRUG|Immedate Release Torsemide Tablets|Immediate release torsemide vs Extended release torsemide
219055744|NCT06321484|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
218951956|NCT05916911|DIETARY_SUPPLEMENT|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
219055745|NCT06321484|DRUG|Interleukin 2|Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
219055746|NCT06996015|OTHER|Cognitive behavior therapy|The treatment session will begin with a 10-minute conventional therapy, including a 5-minute hot pack applied to the cervical region and a 5-minute Myofascial Release (MFR) using skin rolling and cross-hand techniques to relax and stretch the fascia layers. This will be followed by a 10-minute application of Sustained Natural Apophyseal Glides (SNAGs), where the physiotherapist will guide the patient's active neck movements with accessory glides to improve joint ROM and reduce pain. Lastly, a 20-minute Cognitive Behavioral Therapy (CBT) session will include visual aids, explanations of cervical spine biomechanics, pain pathways, ergonomics, and posture management. Patients will receive manuals summarizing key points and be encouraged to engage actively. The 40-minute session will be conducted twice weekly for four weeks
219637622|NCT06577077|DRUG|Product CM9241GRU|01 tablet in the morning and 01 tablet in the evening for 14 days
219637623|NCT06577077|DRUG|Placebo|01 tablet in the morning and 01 tablet in the evening for 14 days
219637624|NCT04101682|DRUG|Bupivacaine|Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
219637625|NCT06600126|BEHAVIORAL|Coping Skills Training|The Coping Skills Training arm will consist of 12 weekly 30-minute sessions via videoconferencing or phone. A trained research staff member will deliver sessions that focus on building coping skills for patients with COPD, such as progressive relaxation training, pleasant activity scheduling, and building communication skills. Caregivers will also participate, learning how to support the patient in using these skills. Participants will complete assignments between sessions to reinforce their learning. Additionally, participants will receive a Coping Skills Training workbook.
219637626|NCT06600126|BEHAVIORAL|COPD Education|The COPD Education arm will consist of 12 weekly 10-minute sessions via videoconferencing or phone. A trained research staff member will provide scripted general support and encouragement without using specific psychoeducational techniques. Caregivers will also participate. Additionally, participants will receive a COPD Education workbook with material from The COPD Foundation, which is also available on the Foundation's website. This program augments usual care, providing an attention control for comparison.
219637627|NCT05770271|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
219637628|NCT02986282|DEVICE|ABI measurement using both doppler and oscillometric method|
219637629|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
219207024|NCT06770946|OTHER|Amniotic Membrane Application|"Amniotic Membrane Application:~This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter."
219637630|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
219637631|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|Subconjunctival daily or bid
219637632|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical and systemic
219637633|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical systemic
219637634|NCT06483711|OTHER|Lifestyle Kit|The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
219637635|NCT05162417|OTHER|Methylene Blue|1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
219637636|NCT05162417|OTHER|Toluidine Blue O|1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
219637637|NCT04973423|RADIATION|MRI|2 additional MRI will be done for the CALM + MRI group
219637638|NCT02926157|BEHAVIORAL|Life Style and Sleep Intervention|
219637639|NCT04849468|DRUG|Declofenac|evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
219637640|NCT04849468|DRUG|saline|evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
219637641|NCT04325568|BEHAVIORAL|PsyGist and Clinician Manual|This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
219637642|NCT04390503|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2.
218951957|NCT05916911|OTHER|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
219637643|NCT04390503|BIOLOGICAL|Control (albumin 5%)|Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.
219637644|NCT00833495|DRUG|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
219637645|NCT00833495|DRUG|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
219637646|NCT00833495|DRUG|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
219637647|NCT00833495|DRUG|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
219637648|NCT04606004|OTHER|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
218951958|NCT00329056|DRUG|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
218951959|NCT01455909|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
218951960|NCT01455909|DRUG|sitagliptin|sitagliptin oral 100 mg/day
218951961|NCT03343353|OTHER|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
218951962|NCT00220922|PROCEDURE|Alcohol Wipes vs. No Alcohol Wipes|
218951963|NCT01512667|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
218951964|NCT04235413|BEHAVIORAL|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
218951965|NCT02846298|BIOLOGICAL|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
218951966|NCT03257917|OTHER|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
218951967|NCT05176457|OTHER|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
219207025|NCT06770426|DRUG|carbogen with or without phenyleprhine|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
218951968|NCT03341780|PROCEDURE|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
218951969|NCT05242796|DEVICE|Low frequency magnetic therapy|
218951970|NCT00305461|DRUG|Ciclesonide|Effect of Ciclesonide on Quality of Life
218951971|NCT05262062|OTHER|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2\. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3\. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4\. Once the position of ease was identified, it was held for 20 to 30 seconds."
219207026|NCT06770426|DRUG|phenylephrine|All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
219207027|NCT06771258|OTHER|Red Light (PDT)|Red LED light
218951972|NCT05262062|OTHER|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2\. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3\. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
218951973|NCT05262062|OTHER|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,~2. After MTrPs identification,~3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
218951974|NCT01520428|BEHAVIORAL|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
218951975|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
218951976|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Soda|Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
218951977|NCT04118257|DIETARY_SUPPLEMENT|Control: Water|Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
218951978|NCT00473122|PROCEDURE|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
218951979|NCT00233831|DEVICE|Generator of electromagnetic millimeter waves|
218951980|NCT04062903|BEHAVIORAL|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
218951981|NCT04062903|BEHAVIORAL|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
219637649|NCT04606004|OTHER|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
219637650|NCT05472129|OTHER|self-administered questionnaires|The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
219637651|NCT00415818|BIOLOGICAL|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
219637652|NCT00415818|DRUG|1st line Chemotherapy|
219637653|NCT03187418|DEVICE|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
218951982|NCT01495312|DEVICE|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
218951983|NCT01943253|DEVICE|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
218951984|NCT01943253|DEVICE|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
218951985|NCT00195208|DRUG|Pantoprazole for approximately 9 weeks|
218951986|NCT05557825|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
218951987|NCT04677478|OTHER|Impact of respiratory isolation on quality of life|Semi-structured interviews
218951988|NCT00170690|DRUG|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
218951989|NCT00170690|DRUG|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
219055747|NCT06996015|OTHER|Cervical Stabilization Exercises|"The treatment session will last 40 minutes, twice a week for 4 weeks. It begins with a 10-minute conventional treatment: a 5-minute hot pack application to the cervical region followed by a 5-minute Myofascial Release (MFR) using the skin rolling technique. Natural wax will be applied for smooth strokes. MFR will engage all fascia layers with superficial strokes, progressing to deeper fascia using cross-hand stretch, depending on the pain tolerance.~Next, SNAGs (Sustained Natural Apophyseal Glides) will be applied for 10 minutes. The patient, seated, will actively move the painful joint through its range of motion while the therapist applies a glide force. This will be repeated 10 times for 3 sets.~Then session includes 20 minutes of Cervical Stabilization Exercises (CSE) with bracing in neurodevelopment stages (supine, prone, quadrupedal, bipedal), holding each position for 10 seconds. Isometric exercises and functional training with elastic bands and exercise balls follow."
219637654|NCT03076034|DEVICE|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm."
219637655|NCT01980459|DIETARY_SUPPLEMENT|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
219637656|NCT00477399|BEHAVIORAL|Long term follow up after intensive lifestyle intervention|
219637657|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
219637658|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
219637659|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
219637660|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
219637661|NCT05251831|DRUG|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
219637662|NCT05771324|OTHER|Baby-Led Weaning (BLW)|BLW trainings given to mothers for 6-12 month old babies
219637663|NCT05771324|OTHER|Traditional Complementary Feeding (TCF)|TCF trainings given to mothers for 6-12 month old babies
219637664|NCT00417924|BEHAVIORAL|Patient education|
219637665|NCT04687046|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
219637666|NCT06502600|PROCEDURE|surgery time|This study is a retrospective observational study, with surgery time being one of the exposure factors under investigation.
219637667|NCT06502600|PROCEDURE|surgeon|This study is a retrospective observational study, with surgeon being one of the exposure factors under investigation.
219637668|NCT06502600|PROCEDURE|surgical procedure duration|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
219637669|NCT06502600|PROCEDURE|operating room|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
219637670|NCT06502600|PROCEDURE|type of surgery|This study is a retrospective observational study, with type of surgery being one of the exposure factors under investigation.
218951990|NCT04811534|BEHAVIORAL|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
218951991|NCT04023838|PROCEDURE|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
218951992|NCT05428878|DIAGNOSTIC_TEST|ANS Watch|"1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type"
219637671|NCT05965180|DEVICE|Fine Needle Photoacoustic Probe|Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction
219637672|NCT05802407|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
219637673|NCT06496685|OTHER|psychoeducational|A structured AAT program and usual treatment in Experimental group.
219637674|NCT01113385|DRUG|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
219637675|NCT06468878|BEHAVIORAL|Exposure Intervention Plus Music Induction|VR exposure for acrophobia with background music.
219637676|NCT06468878|BEHAVIORAL|Exposure Intervention With No Music Induction|VR exposure for acrophobia with no background music.
219637677|NCT03449329|PROCEDURE|SIP|The intervention group will receive a SIP block
219637678|NCT00713791|DRUG|ZD4054|Treatment period 1: 10mg oral solution
219637679|NCT00713791|DRUG|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
219637680|NCT00713791|DRUG|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
219637681|NCT00713791|DRUG|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
218951993|NCT03494491|DIETARY_SUPPLEMENT|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
218951994|NCT03494491|DIETARY_SUPPLEMENT|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
218951995|NCT00571402|BEHAVIORAL|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
218951996|NCT00571402|BEHAVIORAL|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
218951997|NCT04132804|BEHAVIORAL|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
219055748|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
219055749|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
219055750|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
219055751|NCT06996002|OTHER|Rhomboids Strengthening Exercise|"1. Seated Bent Row in Sitting position,3 sets of the exercise program with 12 repetitions per set, 3 times per week.~2. Bent Over Row in standing position, 3 sets, 12 repetitions, 3 times per week.~3. Lat Pull Down in sitting position with 12 repetitions per set, 3 times per week.~4. Shoulder Horizontal Abduction in lying position with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~5. Band pull apart performed 4sets, 12 repetitions, and 10 seconds rest for 2 mints, 3 times per week.~6. Prone lateral raise with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~Conventional treatment Modalities:~Trans-cutaneous Electric Nerve Stimulation (TENS) and Hot pack, postural exercises and stretching exercises"
219055752|NCT06996002|OTHER|Conventional Exercises|"Conventional Treatment~1. hot pack for 10 min,~2. Trans-cutaneous Electric Nerve Stimulation (TENS) will be applied, with pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the sub occipital region and the trapezius bilaterally.~3. Stretching exercises of tight muscles 2 sets of 15 min.~4. Posture correction exercises:~releasing muscles of anterior part of the trunk, neck, shoulder."
219055753|NCT07002567|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
219055754|NCT07002567|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
219055755|NCT03967418|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
219055756|NCT07009457|DRUG|SHR-1316 (sc) Injection|SHR-1316 (sc) injection.
219055757|NCT07009457|DRUG|SHR-1316 Injection|SHR-1316 injection.
218951998|NCT01820624|DRUG|tretinoin|Given PO
218951999|NCT01820624|DRUG|lithium carbonate|Given PO
219055758|NCT07009457|DRUG|Carboplatin Injection|Carboplatin injection.
219055759|NCT07009457|DRUG|Etoposide Injection|Etoposide injection.
219055760|NCT06680102|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
219055761|NCT06680102|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
219637682|NCT06683456|BEHAVIORAL|eMOTE|The intervention combines psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills, along with self-monitoring of meals, behaviours and feelings.
219637683|NCT03520153|PROCEDURE|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
218952000|NCT01820624|OTHER|laboratory biomarker analysis|Correlative studies
218952001|NCT06393959|PROCEDURE|Caudal epidural pulsed radiofrequency|The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.
218952002|NCT06393959|PROCEDURE|Caudal epidural steroid enjection|The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
218952003|NCT00002543|DRUG|gallium nitrate|
218952004|NCT00389402|DRUG|saquinavir/ritonavir|
218952005|NCT00389402|DRUG|atazanavir/ritonavir|
218952006|NCT02965768|DRUG|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
218952007|NCT00853996|DRUG|acolbifene hydrochloride|Given orally
218952008|NCT02536404|DRUG|Etrasimod|
218952009|NCT02536404|DRUG|Placebo|
219055762|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
219055763|NCT03071796|DIETARY_SUPPLEMENT|multivitamin supplement|supplement includes 97 natural extracts
219055764|NCT03071796|DIETARY_SUPPLEMENT|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
219055765|NCT06684041|DRUG|HRS-5965 capsule|HRS-5965 capsule
219055766|NCT06684041|DRUG|HRS-5965 capsule placebo|HRS-5965 capsule placebo
219055767|NCT07016750|BIOLOGICAL|KB803|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein
219055768|NCT07016750|DRUG|Placebo|Vehicle
219055769|NCT06271772|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
219055770|NCT06271772|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 3-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
219055771|NCT06271772|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
219055772|NCT07022756|BEHAVIORAL|Honoraria|A $20 honorarium for each appointment attended with completed bloodwork if requested.
219637684|NCT03520153|PROCEDURE|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
219637685|NCT03520153|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
219637686|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
219637687|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
218952010|NCT03907618|DIAGNOSTIC_TEST|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
218952011|NCT00770146|DRUG|Mipomersen sodium|200 mg/mL
218952012|NCT00770146|DRUG|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
219055773|NCT07022756|BEHAVIORAL|Outreach|A personalized outreach service specific for rheumatic disease.
218952013|NCT02439333|DEVICE|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
218952014|NCT02439333|DEVICE|nasal catheter or Venturi mask|Conventional oxygen therapy
219055774|NCT06690398|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
219055775|NCT06690398|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
219055776|NCT06690398|DRUG|Placebo|Matching Placebo administered orally once daily
219055777|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
219055778|NCT07023432|DRUG|Belzutifan|Given by PO
219055779|NCT07023432|OTHER|Active Surveillance|Given by Observation
219055780|NCT07025616|BEHAVIORAL|Buteyko|The Buteyko breathing exercise is a method that encourages nasal breathing, reducing breathing volume, and using breath-holding exercises to normalize breathing pattern
219055781|NCT07025616|DRUG|Asthma reliever and controller|Asthma reliever and controller according to GINA (Global Initiative for Asthma) guideline
219055782|NCT06511869|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
219055783|NCT07025174|DRUG|PD-1/CTLA-4 Dual Functional Antibody|"PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection):~5 mg/kg intravenous infusion every 3 weeks (day 1 of each 21-day cycle) for up to 6 cycles, with potential for maintenance therapy continuation. Used in combination with GP regimen in experimental arm only. This is a novel dual-functional antibody targeting both PD-1 and CTLA-4 pathways simultaneously."
219055784|NCT07025174|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m² d1,8+Cisplatin 25mg/m² d1,8
219055785|NCT07025174|DRUG|Anlotinib|10mg po d1-14 q3w
219055786|NCT07025174|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|XELOX (oxaliplatin 130mg/m² d1+capecitabine 1000mg/m² d1-14 q3w) or FOLFOX6 (Oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² intravenous bolus followed by fluorouracil 2400 mg/m² 46 hours, q2w)
218952015|NCT00918996|PROCEDURE|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
218952016|NCT01073046|DEVICE|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
218952017|NCT00277082|DRUG|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
219055787|NCT07024914|DRUG|Oxygen|Oxygen supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
219637688|NCT03329703|BEHAVIORAL|Project UPLIFT|A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
219055788|NCT07024914|DRUG|medical air|Medical Air supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
219055789|NCT07025538|OTHER|Best Practice|Receive SOC treatment
219055790|NCT07025538|OTHER|Biomarker Analysis|Undergo GHVD biomarker analysis
219055791|NCT07025538|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218952018|NCT02003274|OTHER|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
218952019|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
218952020|NCT02268929|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
218952021|NCT02268929|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
218952022|NCT01836874|DRUG|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
218952023|NCT00040456|DRUG|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
218952024|NCT00040456|DRUG|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
218952025|NCT00081510|DRUG|Lonafarnib|
218952026|NCT00081510|DRUG|Placebo|
218952027|NCT00081510|DRUG|anastrozole|
218952028|NCT01569243|OTHER|Text messages|"* Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages."
218952029|NCT01569243|OTHER|Usual care|"* Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
218952030|NCT01649843|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
218952031|NCT01463137|BEHAVIORAL|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
218952032|NCT03940976|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
218952033|NCT01967784|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
218952034|NCT00816023|DRUG|ecallantide|infusion administered IV over the duration of the surgical procedure
218952035|NCT00816023|DRUG|placebo|solution for IV infusion over the duration of the surgical\>\> procedure
218952036|NCT00748020|PROCEDURE|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
218952037|NCT00748020|PROCEDURE|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
218952038|NCT01525901|DRUG|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
219055792|NCT07025538|OTHER|Questionnaire Administration|Ancillary studies
219055793|NCT07025538|DRUG|Ruxolitinib|Given PO
219055794|NCT07025681|BIOLOGICAL|Erythropoietin alfa|Erythropoietin 4000 IU Injection, for subcutaneous injection.
219055795|NCT07024186|PROCEDURE|Xenogeneic Collagen Matrix|Xenogeneic Collagen Matrix The xenogeneic collagen matrix is a biomaterial used to promote soft tissue regeneration and support healing in dental implant procedures.
219055796|NCT07024186|PROCEDURE|subepithelial connective tissue graft|ubepithelial Connective Tissue Graft The subepithelial connective tissue graft is a biological tissue taken from the patient's own palate or other donor sites to promote healing and aesthetic outcomes around dental implants.
219055797|NCT07023458|DIAGNOSTIC_TEST|Brief-P|Executive function test in preschool children with OSA
219055798|NCT07025486|BEHAVIORAL|HabitWorks|Smartphone delivered interpretation bias exercises, symptom tracking
219055799|NCT07025486|BEHAVIORAL|Symptom TRacking|Self-assessment via symptom surveys
219637689|NCT04136379|DIAGNOSTIC_TEST|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
219637690|NCT02363413|OTHER|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
218952039|NCT01525901|DRUG|Normal saline|Saline solution will be administered for three months subcutaneously.
218952040|NCT04739371|DRUG|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
218952041|NCT04739371|DRUG|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
218952042|NCT04746742|PROCEDURE|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
218952043|NCT04746742|PROCEDURE|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
218952044|NCT02737033|DRUG|Rhodiola|Rhodiola rosea 800mg
218952045|NCT02737033|DRUG|Placebo|innocuous pill manufactured to mimic Rhodiola
218952046|NCT00559182|DRUG|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
218952047|NCT00559182|DRUG|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
218952048|NCT04607278|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
218952049|NCT04607278|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
218952050|NCT04607278|DIETARY_SUPPLEMENT|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
218952051|NCT00003959|BIOLOGICAL|ras peptide cancer vaccine|
218952052|NCT00003959|BIOLOGICAL|sargramostim|
218952053|NCT00641316|PROCEDURE|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
218952054|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
218952055|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
218952056|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
218952057|NCT05027971|DEVICE|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
218952058|NCT02486627|DRUG|plazomicin|
218952059|NCT02486627|DRUG|meropenem|
218952060|NCT02486627|DRUG|levofloxacin (oral)|
218952061|NCT02962375|DIETARY_SUPPLEMENT|Active|100% orange juice with orange pomace fiber
219637691|NCT02363413|OTHER|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
219637692|NCT03396315|DRUG|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
219637693|NCT03396315|DRUG|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
219637694|NCT02448537|DRUG|PM01183|
219637695|NCT02448537|DRUG|Doxorubicin|
219637696|NCT02448537|DRUG|Gemcitabine|
218952062|NCT02962375|DIETARY_SUPPLEMENT|Control|100% orange juice
218952063|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
218952064|NCT03325023|DIETARY_SUPPLEMENT|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
218952065|NCT03325023|OTHER|Placebo|Placebo
218952066|NCT00401024|DRUG|imatinib mesylate|
218952067|NCT00401024|OTHER|pharmacological study|
218952068|NCT00401024|PROCEDURE|conventional surgery|
218952069|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
218952070|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
218952071|NCT01722227|DRUG|Liraglutide|
218952072|NCT01722227|DRUG|Placebo|
218952073|NCT04590846|BEHAVIORAL|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
219055800|NCT07025590|BEHAVIORAL|Moderate-intensity continuous movement and Antipsychotics intervention|On the basis of Antipsychotics intervention, Patients in the exercise group should start exercise intervention as soon as possible after completing baseline examination, and need to complete a training plan of at least 36 times, 3 times/week. At the beginning of each training session, patients need to warm up for 5-10 minutes, mainly jogging and stretching exercises. After the warm-up, the patient enters the training phase, the heart rate reserve is 70% to 85%, and after the training, the patient performs 10-15 minutes of recovery exercise, mainly jogging, slow walking and stretching. The specific exercise plan is formulated according to the patients' own aerobic capacity assessment, and the principle of formulation is gradual and individual. At each training session, patients were asked about their perceived fatigue level to adjust the training intensity.
219055801|NCT07025590|DRUG|Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)|Patients maintained regular medication during the intervention period, and returned to the doctor every two weeks, and the psychiatrist decided whether to maintain the current dose or gradually reduce the dose based on the patient's symptoms and diagnosis. Psychiatrists, unaware of patient groupings, use supportive measures to help manage adverse reactions.
219055802|NCT07024342|DEVICE|Liner perforated with very small diameter holes|A commercially available, elastomeric liner perforated with very small holes (approximately 0.3 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
219055803|NCT07024342|DEVICE|Liner perforated with somewhat larger diameter holes|A commercially available, elastomeric liner perforated with somewhat larger holes (approximately 1.5 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
219637697|NCT06665126|DIETARY_SUPPLEMENT|Prebiotic + Probiotic Supplement|This intervention includes a combination of prebiotics and probiotics designed to promote vaginal and digestive health. The supplement contains Biotin, Lactobacillus acidophilus (as LA-14®), Bifidobacterium lactis (HN019™), Lactobacillus rhamnosus (as HN001™), Lactobacillus crispatus (as CCFM1110™), Lactobacillus gasseri (as HLG13™), Lactobacillus reuteri (as HR7™), Bacillus subtilis (as DE111®), PreforPro®, White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
219637698|NCT06665126|DIETARY_SUPPLEMENT|Active Placebo Supplement|The active placebo supplement contains similar probiotic strains without the prebiotic component. Ingredients include Biotin, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus reuteri, Bacillus subtilis, Inulin (from Chicory Root), White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
219637699|NCT06665126|DIETARY_SUPPLEMENT|Excipient Placebo Supplement|The excipient placebo supplement contains no active ingredients related to prebiotics or probiotics. It includes White Rice Flour, Magnesium Stearate (Vegetable Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
219637700|NCT00262132|DRUG|Mycophenolate|
219637701|NCT04106895|DRUG|Fibryga|Fibryga
219637702|NCT03209622|PROCEDURE|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
219637703|NCT03209622|DRUG|Nicotine patch|Arm A
219637704|NCT03209622|OTHER|the external consultation|without patch
219637705|NCT06666062|OTHER|implant placement and low level laser therapy|Laser biomodulation with low level laser therapy around delayed implant
219637706|NCT06666062|PROCEDURE|implant placement|Delayed implant placement restoring missed tooth
219637707|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
219637708|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.
218952074|NCT04590846|BEHAVIORAL|General Health Course|General courses about health issues according to the curriculum of each primary school.
219637709|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.
219637710|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
219637711|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.
219637712|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
218952075|NCT01853488|RADIATION|DXA|Osteodensitometry
218952076|NCT01853488|RADIATION|pQCT|Osteodensitometry
218952077|NCT04083729|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
218952078|NCT05984550|DRUG|NMN|"NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.~In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+."
218952079|NCT05330884|BIOLOGICAL|BCG vaccine|0.1ml BCg vaccine to be given intradermally
218952080|NCT05330884|DRUG|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
219055804|NCT07024342|DEVICE|Liner-liner|A thin, special purpose half-ply sock which may reduce the effects of perspiration. The liner-liner is worn between the skin and the participant's as-prescribed liner.
219055805|NCT07024342|DEVICE|As-prescribed liner|A commercially available, elastomeric liner with no perforations. This liner is worn between the skin and the participant's prosthetic socket.
219055806|NCT06420336|PROCEDURE|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
219055807|NCT06420336|PROCEDURE|Local anesthetic infiltration|After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
219055808|NCT07024433|PROCEDURE|Tubeless anesthesia|"1. Anesthesia Induction: Implement TCI with propofol and remifentanil; insert a laryngeal mask for SIMV ventilation, and monitor vital signs including IBP and end-tidal CO2.~2. Nerve Blocks: Perform ultrasound-guided paravertebral, pleural surface, and vagus nerve blocks using local anesthetics.~3. Anesthesia Maintenance: Adjust remifentanil for spontaneous breathing; maintain propofol and BIS levels; manage heart rate and blood pressure with fluids and medication as needed, without using inhaled anesthetics.~4. Postoperative Analgesia: Provide PCIA with morphine for pain management."
219055809|NCT07024433|PROCEDURE|Traditional tracheal intubation|"1. Anesthesia induction using propofol, sufentanil, and rocuronium is performed, with DLT or single-lumen tube insertion at BIS≤60 for single-lung ventilation, maintaining appropriate oxygen and ventilation parameters.~2. Anesthesia is maintained with sevoflurane, propofol, and remifentanil, supplementing rocuronium every 30-40 minutes for muscle relaxation, with BIS maintained at 40-60.~3. Post-surgery, ultrasound-guided thoracic paravertebral block and PCIA are used for analgesia, with extubation following standard recovery procedures."
219055810|NCT07025642|DRUG|Urodynamic evaluation before and after solifenacin treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
219055811|NCT07025642|DRUG|Urodynamic evaluation before and after mirabegron treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
219055812|NCT07025642|DRUG|Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
219055813|NCT07025642|DRUG|Urodynamic evaluation before and after Botulinum toxin (Botox) injection.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
219055814|NCT07025083|BEHAVIORAL|Adapted Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. In addition, two modules for Latinx families are being added in the adapted version. This version represents a deep adaptation.
218952081|NCT05080244|DIETARY_SUPPLEMENT|Probiotics|2 strains 10x10\^9 UFC/capsule
218952082|NCT05080244|DIETARY_SUPPLEMENT|Placebo|Potato starch and magnesium stearate
218952083|NCT06065111|OTHER|study tendon damage in osteogenesis imperfecta patients|"* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~* To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
218952084|NCT01597115|PROCEDURE|Duplex ultrasonography|
218952085|NCT01578824|OTHER|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
219055815|NCT07025083|BEHAVIORAL|Original Family Check-Up Online|This version is the original Family Check Up Online translated into Spanish without the adaptions. This represents a surface-level adaptation.
219637713|NCT05419180|DRUG|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
219637714|NCT02175394|DRUG|Microgynon®|
219637715|NCT02175394|DRUG|BI 1356|
219637716|NCT03611777|DRUG|Inhaled corticosteroid|Drug
219637717|NCT02741674|PROCEDURE|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
219637718|NCT02741674|PROCEDURE|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
219637719|NCT02741674|PROCEDURE|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
219637720|NCT00053157|BIOLOGICAL|sargramostim|
218952086|NCT01126671|DRUG|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
218952087|NCT05395091|BIOLOGICAL|AVT03|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm received AVT03 60mg administered s.c. on Day 1 and at Month 6. At Month 12, subjects in the AVT03 arm received a third dose of AVT03 60 mg.
218952088|NCT05395091|BIOLOGICAL|Denosumab|"Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection.~Subjects in this arm received 60mg of commercially available US-Prolia, administered s.c on Day 1 and at Month 6. At Month 12, subjects in the Prolia treatment group were re-randomized in a 1:1 ratio to receive either:~* AVT03 60 mg administered s.c. on Day365.~* Prolia 60 mg administered s.c. on Day365."
218952089|NCT03534336|BEHAVIORAL|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
218952090|NCT03534336|BEHAVIORAL|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
218952091|NCT05019547|BEHAVIORAL|Determining Barriers and Facilitators of Physical Activity|Determining Barriers and Facilitators of Physical Activity
218952092|NCT05866848|OTHER|Placebo|Flour capsules as a placebo.
218952093|NCT05866848|OTHER|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
218952094|NCT05866848|OTHER|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
218952095|NCT00445588|DRUG|erlotinib hydrochloride|150mg Given orally once daily
218952096|NCT00445588|DRUG|sorafenib tosylate|400mg Given orally twice daily
218952097|NCT00445588|OTHER|pharmacological study|Correlative studies
218952098|NCT06171204|PROCEDURE|Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic
218952099|NCT03554486|DRUG|Fiasp|Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
218952100|NCT03554486|DRUG|Novolog|Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
218952101|NCT05796206|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
218952102|NCT05796206|DRUG|placebo|An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
218952103|NCT01182090|PROCEDURE|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
218952104|NCT01182090|PROCEDURE|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
219637721|NCT04498689|DRUG|Camrelizumab|Patients firstly receive camrelizumab 200 mg per time (iv, no less than 20 minutes and no more than 60 minutes, rinse time included) on Day 1 and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
218952105|NCT01509053|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
218952106|NCT01509053|DRUG|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
218952107|NCT04114617|OTHER|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
218952108|NCT04114617|OTHER|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
218952109|NCT04114617|COMBINATION_PRODUCT|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
218952110|NCT05078762|OTHER|Immersive Virtual Reality|Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
218952111|NCT01127828|OTHER|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
219637722|NCT04498689|DRUG|Nab paclitaxel|Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
218952112|NCT01127828|OTHER|Probiotic yoghurt (Cultura)|200 ml per day
218952113|NCT01500499|GENETIC|gene expression analysis|
218952114|NCT01500499|GENETIC|gene rearrangement analysis|
218952115|NCT01500499|GENETIC|polymerase chain reaction|
218952116|NCT01500499|GENETIC|protein analysis|
218952117|NCT01500499|GENETIC|western blotting|
218952118|NCT01500499|OTHER|laboratory biomarker analysis|
218952119|NCT01500499|OTHER|mass spectrometry|
218952120|NCT01738477|BIOLOGICAL|Boostrix|Single dose intramuscular administration.
218952121|NCT00756262|BIOLOGICAL|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
218952122|NCT04291404|DEVICE|Virtual Reality Distraction|Distraction therapy using a Virtual Reality (VR) device
218952123|NCT05140824|DRUG|Placebo|0.9% sodium chloride solution
218952124|NCT05140824|BIOLOGICAL|TJ202 injection|TJ202 injection
218952125|NCT01915303|DRUG|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
218952126|NCT02925338|OTHER|QOL questionaire|Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
218952127|NCT04128813|DEVICE|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
218952128|NCT00568386|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
218952129|NCT00568386|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
218952130|NCT06092268|DRUG|SHR-A2009 for injection ； Almonertinib Mesilate Tablets|"Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization."
219637723|NCT04498689|DRUG|Gemcitabine Injection|At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
218952131|NCT06092268|DRUG|SHR-A2009 for injection；Adebrelimab Injection|"Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy."
219637724|NCT05030194|OTHER|Electronic Cigarette|Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
219637725|NCT05030194|OTHER|Oral Nicotine Pouch|Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
219055816|NCT06878937|BEHAVIORAL|Peer Delivered Psychoeducation Program|The peer delivered psychoeducation program is the only intervention being tested in this pilot evaluation study.
219637726|NCT04696055|DRUG|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
219637727|NCT04696055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
219637728|NCT06966518|DRUG|Ketamine and Magnesium Sulfate|Patients will receive a bolus of 0.5 mg/kg of ketamine given over a period of ten minutes followed by a constant infusion of 0.25 mg/kg/hr and a bolus dose of 30 mg/kg of magnesium sulfate during a 10-minute period followed by a continuous infusion of 9 mg/kg/hr.
219637729|NCT06966518|DRUG|Saline 0.9%|Patients will receive saline 0.9% as a control group.
218952132|NCT03891797|OTHER|Cognitive Processing Therapy|Group-based psychotherapy.
218952133|NCT04921813|OTHER|3 dimensional scoliosis exercise|Schroth exercises
219637730|NCT04629911|DEVICE|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
218952134|NCT04921813|OTHER|Balance Exercise|Balance-coordination exercises
218952135|NCT04921813|OTHER|Brace treatment|Brace usage
218952136|NCT03228329|OTHER|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
218952137|NCT01279941|BEHAVIORAL|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
218952138|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
218952139|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
218952140|NCT00636363|DEVICE|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
219055817|NCT07023497|DRUG|Intrathecal morphine|Intrathecal morphine with fixed-dose fentanyl and ropivacaine
219055818|NCT05987462|OTHER|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
219637731|NCT02767024|DRUG|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
219637732|NCT02767024|DRUG|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
218952141|NCT01846767|OTHER|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
218952142|NCT03817086|BEHAVIORAL|Hand coordination and mental practice|"20 chronic (\>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
218952143|NCT03817086|BEHAVIORAL|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
218952144|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 1|Description in the arm description
218952145|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 2|Description in the arm description
219055819|NCT07033793|BEHAVIORAL|GApp|Participants receive only digital support with health information, self-assessment tests, preventive advices and games. No educational sessions are provided, and the focus is solely on digital preventive advice used autonomously.
219055820|NCT07033793|BEHAVIORAL|GappE|"Participants receive preventive interventon delivered via digital support (smartphone app) including health information, self-assessment tests, preventive advices and games).~In addition to the App used autonomously, they will participate in 5 group educational sessions proposed by a physiotherapist (once every two weeks)."
219637733|NCT02767024|DRUG|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
219637734|NCT03688867|BEHAVIORAL|Prehabilitation regimen|"The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log."
219637735|NCT02656004|OTHER|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
218952146|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 3|Description in the arm description
218952147|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 4|Description in the arm description
219055821|NCT07039344|OTHER|Conventional method of Palliative care Training (Group A)|Group A receive training through the 2-step Conventional method. The first step comprises 1 didactic lecture / week (1 hour) for 10 weeks leading towards the second step of 1 skill session / week for 1 hour under instructor supervision for 6 weeks.
218952148|NCT02422368|DRUG|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
219637736|NCT02656004|OTHER|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
219637737|NCT01920958|OTHER|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
219637738|NCT06967844|PROCEDURE|Simultaneous motor-cognitive task training|"16 sessions (2 sessions per week) for 8 weeks, 40 min per session~1. walking while counting walk 5, 10 and 15 meters while counting backward by ones, threes and sevens~2. balancing on one foot while naming or solving puzzles stand on one foot for 10, 20 and 30 seconds while naming animals. solving simple and complex puzzles~3. ball toss and recall toss ball at 3, 5 and 7 meters distance while recalling three-word, five-word and seven-word lists"
219637739|NCT06967844|PROCEDURE|Sequential motor-cognitive task training|"16 sessions (2 sessions per week), for 8 weeks, 20+20 min per session with 20 min break in between~motor training~1. Standing on one foot standing on one foot for 10, 20 and 30 seconds~2. Heel to toe walk walking heel to toe for 5, 10 and 15 meters~3. Leg swings 10 swings, 15 swings and 20 swings per leg cognitive training~4. Memory games recall three-word, five-word and seven-word lists~5. Problem solving tasks simple, moderate and difficult arithmetic problems"
219637740|NCT06966674|DRUG|Intracoronary tirofiban|Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
219637741|NCT06966674|DRUG|Saline 0.9%|Patients will receive intracoronary saline 0.9% solution as a control group.
219637742|NCT06969092|OTHER|Oral Frailty|The exposure factor is the presence of oral frailty in patients before surgery, and oral frailty is evaluated using a scale.
219637743|NCT01560234|DRUG|AZD8848|Single dose, oral inhalation (nebuliser solution)
218952149|NCT02422368|DRUG|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
218952150|NCT01764919|RADIATION|[124I]FIAU|A single intravenous injection of 5 mCi\[124I\]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
219637744|NCT01560234|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
219637745|NCT06969170|DRUG|Psilocybin (drug)|Psilocybin 3mg Po (oral solution) administered daily for 28 days (Open-Label Run-in Phase) followed by Psilocybin 3mg Po (oral solution) OR Placebo for 28 days (Double-Blind Treatment Phase) in patients with Generalized Anxiety Disorder(GAD)
218952151|NCT00280748|DRUG|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
218952152|NCT00280748|RADIATION|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
218952153|NCT04687514|DRUG|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
218952154|NCT04687514|DRUG|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
218952155|NCT00029146|PROCEDURE|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
218952156|NCT00029146|DRUG|best medical therapy|best current practice medical therapy
218952157|NCT00005815|DRUG|temozolomide|
219637746|NCT06969170|OTHER|Placebo|Sucralose 0.2% oral solution
219637747|NCT02915770|PROCEDURE|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
219637748|NCT02915770|PROCEDURE|hepatectomy|
219637749|NCT02915770|DEVICE|T-tube|T-tube Drainage
219637750|NCT04520542|OTHER|Acupressure Application|Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
218952158|NCT00005815|DRUG|thalidomide|
218952159|NCT01483417|PROCEDURE|Single incision Laparoscopic hysterectomy|SILS port
218952160|NCT01483417|PROCEDURE|Conventional laparoscopic hysterectomy|3-4 conventional ports
218952161|NCT05979142|OTHER|community-based primary care program|See group description
218952162|NCT01040117|PROCEDURE|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
219055822|NCT07039344|OTHER|Pedagogical (LWPPR) method of Palliative care Training (Group B)|Group B will receive training through the 5-steps pedagogy method including: the 1st step (learn), in which didactic lectures will be given to the students leading to the 2nd step (video watch), a 30 minutes video on Palliative care. The students first see the video in the class on multimedia with explanation and then share to the students in what's up group for frequent watching as per need. In the 3rd step (practice), students practiced their skills on a low fidelity simulator under instructor supervision on a scheduled day of the week in the nursing skill lab for 6 weeks. The errors will be corrected on the spot. A total of 11 groups will make with a ratio of 5 in each group. In the 4th step (perform), students perform their skill in real-life situations through the clinical rotation under supervision. Finally, the 5th step (Retain) will be established through self-directed learning in which an additional one-hour skill session / week will be provided to the students.
219637751|NCT04652531|OTHER|Autologous extracellular vesicles from serum|Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.
218952163|NCT01040117|PROCEDURE|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
218952164|NCT00125606|PROCEDURE|conditioning for allogeneic HSCT|
218952165|NCT01775397|DRUG|Fidaxomicin|capsule
218952166|NCT01775397|DRUG|Vancomycin|capsule
218952167|NCT01775397|DRUG|Placebo|Capsule
219055823|NCT06717438|DRUG|BPN14770|Capsules for oral administration
219637752|NCT01284348|DRUG|Sotatercept 15 mg|Sotatercept 15 mg SC injection once every 42 days, up to four doses
219055824|NCT06717438|DRUG|Placebo|Capsules for oral administration
219055825|NCT07038239|DIAGNOSTIC_TEST|Skin biopsy|under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.
219055826|NCT07038239|DIAGNOSTIC_TEST|Blood sample|"3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres.~For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code."
219055827|NCT06721949|DRUG|Taurine|Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
219055828|NCT06721949|DRUG|Placebo|The placebo capsule is visually identical to the taurine capsule.
219367145|NCT06960772|BEHAVIORAL|Flow Ball Intervention|"Participants receive an intensive intervention using the Flow Ball device over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
219637753|NCT01284348|DRUG|Sotatercept 30 mg|Sotatercept 30 mg SC injection once every 42 days, up to four doses
219637754|NCT02166060|DRUG|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
219637755|NCT00060242|DRUG|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
219637756|NCT04138537|OTHER|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
219637757|NCT04138537|OTHER|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
219637758|NCT01620190|OTHER|Laboratory Biomarker Analysis|Correlative studies
219637759|NCT01620190|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219637760|NCT00478816|BIOLOGICAL|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
218952168|NCT06393335|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
218952169|NCT00920803|DRUG|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
219637761|NCT05026112|DIAGNOSTIC_TEST|ECG-Imaging|ECG imaging acquisition
219637762|NCT05026112|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan
219637763|NCT00083759|DRUG|natalizumab|
219637764|NCT00083759|DRUG|placebo|
218952170|NCT00920803|DRUG|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
218952171|NCT01433380|DRUG|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
218952172|NCT01433380|DRUG|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
218952173|NCT02771613|OTHER|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
218952174|NCT02771613|OTHER|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
218952175|NCT06272227|DRUG|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
218952176|NCT06272227|DRUG|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
218952177|NCT06272227|DRUG|Denosumab|denosumab
218952178|NCT05297318|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
218952179|NCT05297318|OTHER|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
218952180|NCT02236351|DEVICE|Pinch Patch/ flat Patch|
218952181|NCT02671513|DRUG|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
218952182|NCT04120311|DRUG|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
218952183|NCT04204876|DIAGNOSTIC_TEST|Magnet Resonance Imaging (MRI)|MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
218952184|NCT04204876|DIAGNOSTIC_TEST|PET/CT analysis|Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
218952185|NCT05605938|DRUG|Tenoten for children|Oral administration
218952186|NCT05605938|DRUG|Placebo|Oral administration
218952187|NCT01037192|DRUG|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
218952188|NCT01037192|DRUG|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
218952189|NCT03068351|DRUG|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
218952190|NCT03068351|BIOLOGICAL|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
218952191|NCT04431674|DRUG|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
218952192|NCT05874167|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast"
218952193|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Reference product
218952194|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Test product
218952195|NCT02917057|DRUG|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
218952196|NCT02917057|DRUG|basal insulin|basal insulin tretament in the customary clinical care in USA
218952197|NCT05887778|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
218952198|NCT05887778|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
218952199|NCT05887778|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
218952200|NCT02605291|OTHER|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
218952201|NCT02605291|OTHER|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
218952202|NCT02605291|OTHER|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
218952203|NCT02605291|OTHER|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
218952204|NCT02605291|OTHER|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
219055829|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
218952205|NCT04458324|DRUG|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
218952206|NCT04458324|DRUG|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
218952207|NCT04458324|DEVICE|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
218952208|NCT04458324|DEVICE|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
218952209|NCT04458324|OTHER|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
218952210|NCT03439683|OTHER|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
218952211|NCT05846607|DIETARY_SUPPLEMENT|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
218952212|NCT04479319|DIAGNOSTIC_TEST|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
218952213|NCT00043550|BEHAVIORAL|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
219055830|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
219637765|NCT05171842|BEHAVIORAL|Observe the prognosis after stent implantation|Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant naked stent (stent with diameter ≤7mm, stents with \>7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the double antibody should be taken for 3 months, and the monoclonal antibody should be maintained for at least 1 year.
219637766|NCT05510193|DEVICE|Aktio prosthesis|Transradial myoelectric prosthesis
219637767|NCT01476878|DEVICE|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
219637768|NCT01480466|OTHER|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
219637769|NCT05506566|DRUG|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
219637770|NCT05506566|DRUG|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
219637771|NCT06048328|BEHAVIORAL|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 6 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
219637772|NCT02702557|OTHER|Elastic Band Exercises|
219637773|NCT04210063|OTHER|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
218952214|NCT00043550|DRUG|Sertraline|Participants will receive sertraline.
218952215|NCT00043550|DRUG|Pill Placebo|Participants will receive a pill placebo.
218952216|NCT00043550|DRUG|Venlafaxine|Participants will receive venlafaxine.
218952217|NCT03471624|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
218952218|NCT04097951|DRUG|Combinations|Montelukast and Bepotastine Combination
218952219|NCT02728427|DEVICE|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
218952220|NCT02728427|DEVICE|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
218952221|NCT01418508|BEHAVIORAL|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
218952222|NCT01418508|BEHAVIORAL|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
218952223|NCT00222716|BEHAVIORAL|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
218952224|NCT03849573|BEHAVIORAL|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
218952225|NCT03849573|BEHAVIORAL|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
218952226|NCT03035474|OTHER|Digital Engagement|Patient engagement to improve self-management/medication adherence
218952227|NCT03035474|OTHER|Direct Engagement|Health system engagement to improve local QI programs
219637774|NCT02390596|DRUG|Anakinra|The dose of Anakinra will be 2mg/kg (patients \<10kg and/or \<8 months: 4mg/kg). If the patient remains febrile (fever \>38°C), he will receive a double dose of anakinra 4mg/kg (patients \<10kg and/or \<8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients \<10kg and/or \<8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
219637775|NCT02361463|DEVICE|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
219637776|NCT02361463|DEVICE|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
219637777|NCT03272295|OTHER|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
219637778|NCT03272295|OTHER|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
219637779|NCT03272295|OTHER|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
219637780|NCT03272295|OTHER|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
219637781|NCT03272295|OTHER|Cigarette with fig juice|Based on reference cigarette with added ingredient
218952228|NCT05143788|PROCEDURE|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
218952229|NCT04066712|DRUG|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
218952230|NCT03444480|DRUG|Remimazolam Tosylate|Initial dose plus supplemental doses
218952231|NCT02444000|DRUG|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
218952232|NCT02444000|DRUG|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
218952233|NCT04565808|PROCEDURE|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
219055831|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
219055832|NCT06732375|BEHAVIORAL|Mindset Moments|"MM™ includes: 1) CBT; 2) resilience training; 3) mindfulness-based stress reduction; 4) peer support; and 5) family conversations delivered in small virtual groups, with a mentor who facilitates resilience-building conversations prompted from Skill of the Week lessons."
219055833|NCT07045896|DRUG|Fucoidan|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral fucoidan Dosage Form: Size-0 gelatin capsules containing 1000mg fucoidan powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
219055834|NCT07045896|DRUG|Corn starch|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral Corn starch as Placebo Dosage Form: Size-0 gelatin capsules containing 1000mg Placebo powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
219637782|NCT03272295|OTHER|Cigarette with glycerol|Based on reference cigarette with added ingredient
218952234|NCT03894371|DEVICE|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
218952235|NCT01612845|PROCEDURE|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
218952236|NCT01612845|BIOLOGICAL|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
218952237|NCT04585503|DEVICE|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
219637783|NCT03272295|OTHER|Cigarette with guaiacol|Based on reference cigarette with added ingredient
219637784|NCT03272295|OTHER|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
219637785|NCT03272295|OTHER|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
219637786|NCT03272295|OTHER|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
219637787|NCT03272295|OTHER|Cigarette with sorbitol|Based on reference cigarette with added ingredient
219637788|NCT03272295|OTHER|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
219637789|NCT01517763|DEVICE|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
219637790|NCT01517763|DEVICE|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
219637791|NCT01517763|DEVICE|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
219637792|NCT02915900|OTHER|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
219637793|NCT02915900|OTHER|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
219637794|NCT00444756|PROCEDURE|J-tip jet injection of 1% buffered lidocaine|
219637795|NCT00452582|DRUG|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
219637796|NCT00452582|OTHER|Usual care|Physical therapy, occupational therapy, speech therapy
219637797|NCT00232362|DRUG|Pioglitazone (Actos)|
219637798|NCT00232362|DRUG|Anti-diabetic agent other than pioglitazone or rosiglitazone|
219637799|NCT00005580|DRUG|bryostatin 1|
219055835|NCT04206982|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
219637800|NCT00005580|DRUG|fludarabine phosphate|
219637801|NCT00036972|BIOLOGICAL|cintredekin besudotox|
219637802|NCT00036972|PROCEDURE|adjuvant therapy|
219055836|NCT04206982|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
219637803|NCT00036972|PROCEDURE|conventional surgery|
219055837|NCT04206982|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
219055838|NCT07042425|OTHER|Computer based cognitive telerehabilitation|An intervention group received computer-based cognitive training with online monitoring and a control group that received conventional cognitive training by an occupational therapist
219055839|NCT07048028|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|A 0.2 % (w/v) low-molecular-weight chitosan solution (50-190 kDa, ≥75 % deacetylation) prepared fresh in 1 % acetic acid, pH ≈ 6.0. Ten mL is delivered into the root canal over 30 s and left in situ for an additional 30 s (total contact 60 s), followed by a 5 mL sterile saline flush
219055840|NCT07048028|DRUG|Sodium Hypochlorite|Commercial 2.5 % (w/v) sodium hypochlorite endodontic irrigant. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
219637804|NCT00036972|PROCEDURE|neoadjuvant therapy|
219637805|NCT04956601|RADIATION|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
219637806|NCT02857257|BIOLOGICAL|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
219637807|NCT03892395|DIETARY_SUPPLEMENT|B-vitamin supplementation on bone health|An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health
219637808|NCT03892395|DIETARY_SUPPLEMENT|Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D|Vitamin D, a daily capsule containing 10 µg/day vitamin D
219637809|NCT02944695|OTHER|audit|Practice adherence to guidelines
219637810|NCT05214443|PROCEDURE|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
218952238|NCT05086211|OTHER|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
218952239|NCT05086211|OTHER|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
219637811|NCT04124835|OTHER|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
219637812|NCT04124835|OTHER|Control Grup|Habitual Care of the Service.
218952240|NCT04160975|BEHAVIORAL|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
218952241|NCT06491901|OTHER|PS was given according to lung ultrasound score|If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
218952242|NCT06491901|OTHER|PS was given according to clinical criteria|In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
218952243|NCT00181597|DRUG|Trilostane|Taken orally once a day for three days then twice daily thereafter.
218952244|NCT00181597|DRUG|Hydrocortisone|Taken orally with trilostane.
218952245|NCT01150669|OTHER|laboratory biomarker analysis|Samples are analyzed in laboratory studies
218952246|NCT05884801|DRUG|QLS1103|Oral dose
218952247|NCT01143701|OTHER|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
218952248|NCT03810872|DRUG|Afatinib|Open label
218952249|NCT03810872|DRUG|Paclitaxel|Paclitaxel
218952250|NCT03310762|OTHER|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
218952251|NCT03310762|OTHER|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
218952252|NCT00692354|DRUG|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
218952253|NCT03131427|DRUG|Standard of care|Standard of care according to the updated national and/or international guidelines
219055841|NCT07048028|DRUG|EDTA chelating agents|Ready-to-use 17 % EDTA solution (pH ≈ 7.3) for smear-layer removal. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
219055842|NCT06741397|DRUG|CAB LA|Injections administered IM gluteal.
219055843|NCT06741397|DRUG|New formulation of CAB LA|Injections administered IM gluteal.
219055844|NCT06893822|DIETARY_SUPPLEMENT|Griffonia simplicifolia|Griffonia simplicifolia 1x/day
219055845|NCT06893822|OTHER|Placebo|Placebo 1x/day
219055846|NCT06550427|DIAGNOSTIC_TEST|ctDNA analyzed by phased variant|this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
219055847|NCT07051785|DRUG|Fruquintinib+Irinotecan Liposome+Capecitabine|"Stage 1: Participants received fruquintinib, irinotecan liposome, and capecitabine for 6-8 cycles. If no disease progression was observed after the initial treatment, patients were transitioned to maintenance therapy with fruquintinib and capecitabine.~Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group A: Fruquintinib + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with Fruquintinib + capecitabine"
219055848|NCT07051785|DRUG|Bevacizumab+Irinotecan Liposome+Capecitabine|Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group B: Bevacizumab + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with bevacizumab + capecitabine
219055849|NCT06748040|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed return of PGx results.
219055850|NCT06895837|OTHER|Severe-energy restriction|The participants will receive only 25% of their estimated energy needs.
219055851|NCT06895837|OTHER|Severe-energy restriction with exercise|The participants will run on the treadmill for 30 minutes and receive 25% of their estimated energy needs.
218952254|NCT02613273|BEHAVIORAL|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
218952255|NCT02613273|BEHAVIORAL|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
218952256|NCT01699971|PROCEDURE|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
218952257|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
218952258|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
218952259|NCT02643069|OTHER|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
218952260|NCT00647829|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
218952261|NCT00647829|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
218952262|NCT00647829|DRUG|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
218952263|NCT04204070|PROCEDURE|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
218952264|NCT04204070|PROCEDURE|APAD|APAD
218952265|NCT05329038|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
218952266|NCT04796987|DIAGNOSTIC_TEST|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
218952267|NCT02101697|BEHAVIORAL|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
219637813|NCT01199835|OTHER|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (\~1200 mg/d)
219637814|NCT00034242|DRUG|high-dose intravenous immunoglobulin (IVIG)|
218952268|NCT03725423|DRUG|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
218952269|NCT01706900|OTHER|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
218952270|NCT01706900|OTHER|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
218952271|NCT05918081|OTHER|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
218952272|NCT04516837|DRUG|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
218952273|NCT04516837|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
218952274|NCT04046588|DIAGNOSTIC_TEST|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
219055852|NCT06677190|DRUG|Belzutifan|A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
219055853|NCT06908057|OTHER|Blood Draw|We will draw blood to measure islet-related autoantibodies and celiac disease markers with a combined research method, blood sugar, C-peptide (an indicator of insulin production that controls sugar levels) and hemoglobin A1c. Additional blood will be collected for the study of biomarkers of T1D and for long-term storage for potential future use.
219055854|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
219055855|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
219055856|NCT02078583|DRUG|Fentanyl|
219055857|NCT02078583|DRUG|Remifentanil|
219055858|NCT02078583|DRUG|Normal saline|
219055859|NCT06928168|OTHER|Total sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
219637815|NCT04054115|DRUG|Alprostadil 5 MCG Injection|During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
218952275|NCT04046588|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
219637816|NCT04638283|BEHAVIORAL|Goal Attainment Scaling|Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
219637817|NCT03910205|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
219637818|NCT03596593|DIAGNOSTIC_TEST|SPANOM (identifying MSI status from ctDNA)|SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
218952276|NCT01089361|DRUG|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
218952277|NCT01089361|DRUG|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
218952278|NCT03993093|OTHER|CD4 cell count|CD4 cell count from treatment naive HIV patients
218952279|NCT00256477|BEHAVIORAL|Sudarshan KRIYA Breathing Technique|
218952280|NCT06022484|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
218952281|NCT03588962|BIOLOGICAL|In-stent restenosis|Patch tests for the metals applicated in each of the patients
218952282|NCT06391528|PROCEDURE|Transversalis Fascia Plane Block|application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
218952283|NCT01164709|DRUG|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
218952284|NCT01164709|DRUG|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
218952285|NCT01628185|PROCEDURE|Repositioning|pain assessment at baseline then following routine care repositioning in bed
218952286|NCT04232293|DIAGNOSTIC_TEST|Blood tests|eLift and FibroMeter
218952287|NCT04463069|OTHER|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
218952288|NCT03583619|RADIATION|APBI|Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.
218952289|NCT03583619|RADIATION|WBI|Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
218952290|NCT02457104|PROCEDURE|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
218952291|NCT02457104|BEHAVIORAL|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
219207028|NCT06772337|BEHAVIORAL|digital cardiac rehabilitation|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
219637819|NCT05393856|DRUG|CG-549|"PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state."
219637820|NCT03567005|DEVICE|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
219637821|NCT03567005|DEVICE|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
219637822|NCT04724083|DIAGNOSTIC_TEST|biomarkers|new diagnostic biomarkers
218952292|NCT01227174|DRUG|Propofol|Procedural sedation will be achieved using propofol
218952293|NCT01267357|OTHER|no intervention|
218952294|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by SpO2|Titration of fraction of inspired oxygen (FiO2) guided by SpO2
218952295|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
218952296|NCT06329284|DIAGNOSTIC_TEST|ELISA|ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
218952297|NCT06179342|DIAGNOSTIC_TEST|Multiple-Breath-Washout|One additional diagnostic test is performed using the Multiple-Breath-Washout technology
218952298|NCT02491229|OTHER|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
218952299|NCT02491229|OTHER|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
218952300|NCT06276504|DRUG|Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection|Pembrolizumab administration at D0, M1 and M2
218952301|NCT02351427|DRUG|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
218952302|NCT02351427|DRUG|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
219637823|NCT03533153|BIOLOGICAL|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
219637824|NCT03533153|DRUG|CTSTMD PBS without WJ-MSC|For Case-control study only.
219637825|NCT03533153|DRUG|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
219637826|NCT05508698|BEHAVIORAL|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
219637827|NCT05508698|BEHAVIORAL|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
218952303|NCT00013702|DRUG|Adefovir|
218952304|NCT03596749|DRUG|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
219637828|NCT04017351|OTHER|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
219637829|NCT00820053|DRUG|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
219637830|NCT05206253|DIETARY_SUPPLEMENT|Whole egg powder|Nutritional supplementation during a 12 week resistance training program
219637831|NCT05206253|DIETARY_SUPPLEMENT|Whey protein powder|Nutritional supplementation during a 12 week resistance training program
219637832|NCT05206253|DIETARY_SUPPLEMENT|Maltodextrin placebo|Nutritional supplementation during a 12 week resistance training program
219637833|NCT04245631|DIAGNOSTIC_TEST|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
219637834|NCT01511029|DRUG|Dexpramipexole|300 mg - Oral Tablets
219637835|NCT01511029|DRUG|Dexpramipexole|600 mg Oral Tablets
219637836|NCT01511029|DRUG|Dexpramipexole Placebo|Placebo - Oral Tablet
219637837|NCT01511029|DRUG|Moxifloxacin|400 mg - Oral Tablet
219637838|NCT03117660|DRUG|Vitamin A|vitamin A daily X3-4 weeks
219637839|NCT00879476|DRUG|Ramipril 10mg capsules|
219637840|NCT01919866|OTHER|Transplantation of CD3/CD19 depleted stem cells|
219637841|NCT02868489|DIETARY_SUPPLEMENT|LactoWise®|blend of bacillus coagulans and galactomannans
219637842|NCT02868489|OTHER|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
218952305|NCT02154828|BEHAVIORAL|Integrative practices|
218952306|NCT01155167|DRUG|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
218952307|NCT01155167|OTHER|Placebo|Placebo
218952308|NCT04037332|OTHER|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
218952309|NCT06434987|PROCEDURE|Retrograde Inferior Vena Cava Perfusion|Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.
218952310|NCT06434987|PROCEDURE|Antegrade cerebral perfusion|After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
218952311|NCT00286559|DRUG|SonoVue|
218952312|NCT00286559|DRUG|Optison|
219637843|NCT01557374|DRUG|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
219367146|NCT06960772|BEHAVIORAL|Straw Phonation Intervention|"Participants receive an intensive intervention using a straw over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
219637844|NCT01557374|DRUG|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 \> 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 \> 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
219637845|NCT00324025|DRUG|Mycograb|
219637846|NCT00324025|DRUG|placebo|
218952313|NCT02243423|PROCEDURE|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
218952314|NCT02243423|PROCEDURE|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
218952315|NCT00649597|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
218952316|NCT00649597|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
218952317|NCT01428947|PROCEDURE|Arterial approach|Randomization to right radial or femoral approach
218952318|NCT01128023|OTHER|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
218952319|NCT00771589|DEVICE|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
218952320|NCT00297024|PROCEDURE|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
218952321|NCT01908400|BIOLOGICAL|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
218952322|NCT03386877|PROCEDURE|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
218952323|NCT02592187|BEHAVIORAL|ReMemory-MCI training|
218952324|NCT02592187|BEHAVIORAL|Control intervention|
218952325|NCT04170478|DEVICE|Echolaser X4 system|Transperineal laser ablation
218952326|NCT01840644|OTHER|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
218952327|NCT02208401|PROCEDURE|conventional cold snare polypectomy|conventional cold snare polypectomy
218952328|NCT02208401|PROCEDURE|Cold snare polypectomy with suction|Cold snare polypectomy with suction
218952329|NCT02907892|PROCEDURE|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
218952330|NCT04199702|OTHER|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
218952331|NCT02910128|BEHAVIORAL|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
219637847|NCT01057810|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
218952332|NCT06522984|DRUG|Tranexamic acid injection|"to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma."
218952333|NCT01974765|DRUG|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
218952334|NCT05324865|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
218952335|NCT00864019|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
218952336|NCT00864019|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
219637848|NCT01057810|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
219637849|NCT05198024|BEHAVIORAL|Nutrition knowledge|Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
218952337|NCT02915328|DEVICE|Filterwire EZ™|
218952338|NCT02915328|DEVICE|MO.MA Ultra|
218952339|NCT02915328|DEVICE|Stent Roadsaver®|
218952340|NCT02915328|DEVICE|Carotid Wallstent|
219055860|NCT06928168|OTHER|partial sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
219055861|NCT06928168|OTHER|Reproductibility|This group will perform an incremental running test, driven to exhaustion, after a night of total sleep deprivation twice, at least two weeks apart.
219055862|NCT05162976|BIOLOGICAL|Nivolumab|Given IV
219055863|NCT05162976|DRUG|Oral Azacitidine|Given PO
219055864|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
219055865|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
219055866|NCT00358241|PROCEDURE|Nerve block|
219637850|NCT04946435|COMBINATION_PRODUCT|Antibiotic Irrigation|The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
219637851|NCT01861899|DEVICE|SI-LOK|Sacro-iliac joint fusion
218952341|NCT04043390|DIAGNOSTIC_TEST|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
218952342|NCT04043390|DIAGNOSTIC_TEST|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
218952343|NCT04043390|DIAGNOSTIC_TEST|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
218952344|NCT04043390|DIAGNOSTIC_TEST|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
218952345|NCT05642962|DRUG|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
218952346|NCT03175848|RADIATION|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
218952347|NCT04666077|BEHAVIORAL|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
219055867|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
219055868|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
219055869|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
219637852|NCT05931042|DRUG|Trastuzumab|Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
219637853|NCT04560985|OTHER|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
219637854|NCT04560985|OTHER|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
219637855|NCT05973305|DRUG|Dorzol 20 mg/ml|dosing schedule t.i.d.
219637856|NCT05973305|DRUG|Trusopt 20 mg/ml|dosing schedule t.i.d.
219637857|NCT05690607|OTHER|Doctors Laboratory TINIES small volume blood testing kit|Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
219637858|NCT02088905|BEHAVIORAL|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
218952348|NCT04666077|BEHAVIORAL|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
218952349|NCT04666077|OTHER|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
218952350|NCT01133327|DEVICE|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
218952351|NCT03223636|DEVICE|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
218952352|NCT03223636|DEVICE|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
218952353|NCT05876832|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
218952354|NCT05876832|DRUG|Salvage Chemotherapy|Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
218952355|NCT04914039|COMBINATION_PRODUCT|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
218952356|NCT04914039|OTHER|NO CTA examination|NO CTA examination
218952357|NCT01546402|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
218952358|NCT01546402|PROCEDURE|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
219055870|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
219637859|NCT06353685|RADIATION|Continuous, hyperfractionated, accelerated radiotherapy(CHART)|high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total , fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks.
219637860|NCT00281788|DRUG|capecitabine|
218952359|NCT05166239|PROCEDURE|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
218952360|NCT05166239|DRUG|Lenvatinib 1|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
218952361|NCT05166239|DRUG|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
218952362|NCT05166239|DRUG|Lenvatinib 2|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
218952363|NCT05166239|DRUG|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
218952364|NCT04084678|DRUG|Ralinepag|Oral ralinepag
219055871|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
219055872|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
219055873|NCT01876121|DRUG|Celecoxib|oral
219055874|NCT00113113|DRUG|Rubitecan|
219637861|NCT00281788|DRUG|carboplatin|
219637862|NCT00281788|DRUG|paclitaxel|
218952365|NCT04084678|DRUG|Placebo|Matching oral tablets
218952366|NCT00332371|DEVICE|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
219637863|NCT00281788|RADIATION|radiation therapy|
219637864|NCT00827905|DEVICE|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
219637865|NCT03395145|DEVICE|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
218952367|NCT00730028|DRUG|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
218952368|NCT00730028|OTHER|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
218952369|NCT00730028|DRUG|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
218952370|NCT00003472|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
218952371|NCT01669330|PROCEDURE|Nissen fundoplication|Laparoscopic Nissen fundoplication
219207029|NCT06772337|BEHAVIORAL|Regular Treatment|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Out-of-hospital cardiac rehabilitation: Receiving conventional treatment and secondary prevention drugs recommended by current guidelines, nutritional diet and lifestyle guidance, and establishing a WeChat group as a postoperative follow-up contact method.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
219055875|NCT02120339|DRUG|Carvedilol|
219055876|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
219055877|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
219637866|NCT02040051|BEHAVIORAL|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
219637867|NCT05138770|DRUG|VC005 Tablets|VC005 Tablets 1、5、10、25、50、100mg single dose
219637868|NCT05138770|DRUG|VC005 Tablets Placebo|VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
218952372|NCT01669330|PROCEDURE|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
218952373|NCT05639244|BEHAVIORAL|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
219055878|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
219055879|NCT02522897|DRUG|Ranibizumab|
218952374|NCT05639244|BEHAVIORAL|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
218952375|NCT01135667|DRUG|clopidogrel|clopidogrel 150 mg once daily for 30 days
218952376|NCT01135667|DRUG|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
218952377|NCT00347256|DRUG|cisplatin|
218952378|NCT00347256|PROCEDURE|targeted radiation therapy|
218952379|NCT00347256|PROCEDURE|tumor resection|
218952380|NCT00181636|DRUG|Galantamine-CR|
218952381|NCT06090292|DEVICE|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
218952382|NCT06090292|DEVICE|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
219055880|NCT02522897|DEVICE|Laser|
219055881|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
218952383|NCT06090292|DEVICE|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
218952384|NCT06090292|DEVICE|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
218952385|NCT03940183|DRUG|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
218952386|NCT03940183|DRUG|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
218952387|NCT01975324|DRUG|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
218952388|NCT01975324|DRUG|Placebo|placebo (sugar pill) twice a day for two weeks
218952389|NCT04246931|OTHER|No intervention (survey)|No intervention -\> survey at 1 timepoint
218952390|NCT01027390|BEHAVIORAL|physical training exercise|physical exercise training at the work site during work time
219055882|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
219055883|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
219055884|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
219637869|NCT05138770|DRUG|VC005 Tablets food effects group|VC005 Tablets qd per period, for two periods
219637870|NCT05178160|OTHER|PEEP Standard Protocol|All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
219637871|NCT02518282|OTHER|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
219637872|NCT02518282|OTHER|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
219637873|NCT02518282|OTHER|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
219637874|NCT03749746|BEHAVIORAL|Home Blood Pressure Monitoring|Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.
218952391|NCT03523923|BEHAVIORAL|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
218952392|NCT00366067|DRUG|Phenytoin|
218952393|NCT01622634|BEHAVIORAL|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
218952394|NCT01622634|OTHER|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
218952395|NCT01622634|OTHER|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
218952396|NCT04352153|DRUG|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
218952397|NCT04352153|DRUG|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
218952398|NCT06081088|OTHER|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~1. Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~2. Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~3. Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
219055885|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
219055886|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
219055887|NCT02010424|OTHER|control group|standard IVF protocol
219055888|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
219637875|NCT03749746|BEHAVIORAL|Heart Health 4 New Moms|The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).
219637876|NCT03749746|OTHER|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
219637877|NCT04544657|OTHER|no intervention|No intervention for enrolled patients
219637878|NCT04784429|DEVICE|Kenevo or C-Leg 4|Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
219637879|NCT04784429|DEVICE|Non microprocessor controlled knee (NMPK)|NMPK consistent with current standards of care
218952399|NCT06081088|OTHER|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
219637880|NCT00003140|DRUG|letrozole|Given orally
218952400|NCT06081088|OTHER|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
218952401|NCT00649545|BIOLOGICAL|adalimumab|40 mg every other week
219055889|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
219055890|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
219637881|NCT00003140|OTHER|placebo|Given orally
218952402|NCT06112964|PROCEDURE|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
218952403|NCT06112964|BEHAVIORAL|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
218952404|NCT06112964|BEHAVIORAL|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
219055891|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
219055892|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
219055893|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
219055894|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
219055895|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
219207030|NCT06759610|DRUG|Tetracyclin|to evaluate the effect of tetracycline socked pack on acceleration of healing during marsupialization as a primary treatment for locally invasive lesions.
219207031|NCT06771375|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|EMDR is a psychotherapeutic approach originally designed for individuals suffering from trauma and post-traumatic stress disorder (PTSD). It facilitates the processing of memories through a structured eight-phase treatment, involving the patient's focused attention on traumatic images, thoughts, and sensations while simultaneously engaging in bilateral stimulation, typically through guided eye movements. This process aims to reduce the emotional distress associated with aversive memories, promoting adaptive coping mechanisms and psychological healing. Recently, the indications for the method have been extended so that EMDR is also used for chronic pain and depressive disorders.
219637882|NCT01585740|DRUG|0.9% Normal Saline|Crystalloid fluid
219207032|NCT06762418|DEVICE|RMR+SME|Patients will be asked to wear this removable appliance for 16 hours daily. The expansion screw is activated twice a week.
219637883|NCT01585740|DRUG|Ringer's Lactate|Crystalloid fluid
219637884|NCT03330704|DRUG|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
219637885|NCT03330704|DRUG|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
219637886|NCT03330704|DRUG|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
219637887|NCT00006068|PROCEDURE|Pancreatic Islet Transplantation|
218952405|NCT01373827|DEVICE|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
218952406|NCT00528970|DRUG|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
218952407|NCT00528970|DRUG|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
218952408|NCT00146159|DRUG|Mitoxantrone|dosage
218952409|NCT00445016|PROCEDURE|peripheral regional anesthesia|evaluation and description of adverse effects
218952410|NCT02723071|DRUG|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
218952411|NCT04280770|PROCEDURE|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
218952412|NCT02310087|DIETARY_SUPPLEMENT|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
218952413|NCT02310087|OTHER|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
218952414|NCT03860935|DRUG|acoramidis|TTR stabilizer administered orally twice daily (BID)
218952415|NCT03860935|DRUG|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
218952416|NCT05675683|DRUG|Capmatinib|Patients receiving Capmatinib
219055896|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
218952417|NCT04321785|OTHER|Placebo|placebo capsule (mannitol)
218952418|NCT04321785|OTHER|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
218952419|NCT05060809|DRUG|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
218952420|NCT04034797|OTHER|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
218952421|NCT04034797|OTHER|No photo|Usual management without photography teletransmission
218952422|NCT05753397|DRUG|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
218952423|NCT03046277|OTHER|No intervention|No intervention
218952424|NCT04671953|DRUG|BMS-986165|Specified dose on specified days
218952425|NCT04671953|DRUG|Metformin|Specified dose on specified days
218952426|NCT03581890|OTHER|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories)."
218952427|NCT01844167|PROCEDURE|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
218952428|NCT01844167|PROCEDURE|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
218952429|NCT03086967|DEVICE|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
218952430|NCT01426932|OTHER|Video recording of Head Impulse Test|Video recording of Head Impulse Test
218952431|NCT05243173|OTHER|Sequencing|Laboratory analysis of samples
218952432|NCT05059288|DEVICE|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
218952433|NCT02744742|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
218952434|NCT02744742|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
218952435|NCT02744742|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
218952436|NCT02744742|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
218952437|NCT02761837|BEHAVIORAL|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
218952438|NCT02761837|BEHAVIORAL|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
218952439|NCT01430754|DRUG|tasimelteon|20 mg tasimelteon capsules, daily
218952440|NCT01430754|DRUG|Placebo|Placebo capsules, daily
219055897|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
219055898|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
219055899|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
219637888|NCT02459912|PROCEDURE|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
219637889|NCT02459912|DEVICE|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
219637890|NCT03292328|OTHER|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
219637891|NCT03292328|OTHER|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
218952441|NCT00202527|DEVICE|Nasal continuos positive airway pressure|
218952442|NCT04306185|PROCEDURE|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
218952443|NCT04576377|BIOLOGICAL|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
218952444|NCT04576377|OTHER|Placebo|0.5mL saline placebo.
218952445|NCT01685645|DEVICE|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
218952446|NCT05150444|OTHER|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
218952447|NCT04643301|DRUG|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
218952448|NCT01931176|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
218952449|NCT01931176|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
218952450|NCT01020006|DRUG|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated."
218952451|NCT01020006|DRUG|Gemcitabine|
219055900|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
219637892|NCT03128138|DRUG|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
219637893|NCT06065917|DIAGNOSTIC_TEST|Measurement of the total small bowel length using CT scan and MRI with 3D reconstruction and AI tool|The intervention consists in performing CT and MR imaging with small bowel length measurement before bariatric/metabolic surgery in obese patients. Then, during surgery the patients will undergo laparoscopic stretched small bowel measurement as the reference gold standard method to measure the small bowel length. The imaging of the training cohort will be used to trained an AI to set up an automatic method of small bowel length measurement via the analysis of CT and MRI imaging.
219637894|NCT04281758|OTHER|Beverage|16 oz (473.2 ml)
218952452|NCT01271582|DRUG|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
219055901|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
219055902|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
219055903|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
219055904|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
219055905|NCT02690246|OTHER|questionnaire|a questionnaire based study
218952453|NCT01698138|DRUG|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
218952454|NCT01698138|DRUG|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
219055906|NCT02629146|DRUG|Midazolam|
219055907|NCT02629146|DRUG|Fentanyl|
219055908|NCT02629146|DRUG|Isotonic saline|
219055909|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
219055910|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
219055911|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
219055912|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
219055913|NCT03258476|DRUG|Placebo|Placebo oral capsule
219055914|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
219055915|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
219055916|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
219055917|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
219055918|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
219055919|NCT00949013|OTHER|immunohistochemistry staining method|
219055920|NCT00949013|OTHER|laboratory biomarker analysis|
219055921|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
219637895|NCT04431258|DRUG|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
218952455|NCT04096183|OTHER|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
218952456|NCT05266573|OTHER|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
218952457|NCT03999775|DIETARY_SUPPLEMENT|Calcium, vitamin D and bioactive collagen peptides supplement|
218952458|NCT03999775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|
218952459|NCT00704522|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
218952460|NCT00704522|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
218952461|NCT00704522|BEHAVIORAL|Patient assistance program|"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
218952462|NCT04841473|OTHER|TRAIN Concussion Education|Participants will receive the TRAIN concussion education module.
219055922|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
219637896|NCT04431258|DRUG|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
218952463|NCT04841473|OTHER|Standard Concussion Education|Participants will receive a standard concussion education module.
218952464|NCT04416360|OTHER|Interview by psychologists|"Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement"
219055923|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
219055924|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
219055925|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
219055926|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
219055927|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
219055928|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
219055929|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
219055930|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
219055931|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
219055932|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
219055933|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
219055934|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
219637897|NCT04431258|DRUG|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
219637898|NCT01985841|DRUG|Bevacizumb|Avastin
219637899|NCT01985841|DRUG|5-Fluorouracil|5-FU
219637900|NCT01985841|DRUG|Epirubicin|Farmorubicin
219055935|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
219055936|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
219055937|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
219055938|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
219055939|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
219055940|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
219055941|NCT02453451|OTHER|Walking Test|for 6 minutes
219637901|NCT01985841|DRUG|Cyclophosphamide|Endoxan
219637902|NCT01985841|DRUG|Docetaxel|Taxotere
219637903|NCT06221241|DRUG|JMKX000623|tablets for oral administration.
218952465|NCT00701662|BIOLOGICAL|Vivaglobin|
219637904|NCT06221241|DRUG|Pregabalin|capsules for oral administration.
219637905|NCT06221241|DRUG|Placebo|matched to JMKX000623 and Pregabalin
219055942|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
219055943|NCT00001631|PROCEDURE|Magnetic resonance imaging|
219637906|NCT04557241|BEHAVIORAL|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
218952466|NCT00635024|BIOLOGICAL|anti-thymocyte globulin|2.5 mg/kg
218952467|NCT00635024|DRUG|melphalan|16 mg/m\^2
218952468|NCT05346822|PROCEDURE|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
218952469|NCT05402371|DRUG|Rencofilstat|Rencofilstat soft gel capsule
219055944|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
219055945|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
219055946|NCT01747681|PROCEDURE|Microfracture|
219055947|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
219055948|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
219055949|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
219055950|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
219637907|NCT04557241|BEHAVIORAL|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
219637908|NCT04008719|OTHER|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
219637909|NCT04008719|OTHER|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
219637910|NCT04008719|OTHER|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
219637911|NCT04420533|BEHAVIORAL|Behavior therapy alone|"1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~3. use of relaxed and double-voiding techniques;~4. urethral milking to prevent post-micturition dribble;~5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~6. bladder retraining that encourages men to hold on when they have sensory urgency;~7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;~9. treatment of constipation."
219637912|NCT04420533|DRUG|Mirabegron 50 MG Extended Release Oral Tablet|Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
219637913|NCT05299554|DRUG|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
219637914|NCT04421287|DRUG|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
218952470|NCT05402371|DRUG|Placebo|placebo soft gel capsule
218952471|NCT05339776|BEHAVIORAL|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
218952472|NCT04551313|BEHAVIORAL|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
218952473|NCT04506762|PROCEDURE|Regional analgesia|Insertion of bilateral ESP catheters
218952474|NCT06361992|OTHER|Blue Cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
218952475|NCT00968032|DEVICE|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
218952476|NCT02829541|DRUG|BIIB068|Administered as specified in the treatment arm.
218952477|NCT02829541|DRUG|Placebo|Administered as specified in the treatment arm
219055951|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
219055952|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
219055953|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
219055954|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
219055955|NCT02366572|OTHER|Control|Non pulse extruded cereal
219055956|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
219055957|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
219055958|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
219055959|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
218952478|NCT01238588|DRUG|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
218952479|NCT00827138|DRUG|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
218952480|NCT03450330|DRUG|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
219055960|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
219055961|NCT02360540|OTHER|Gestalt estimation|
219055962|NCT02642913|DRUG|Enzalutamide|
219055963|NCT02642913|DRUG|Enzalutamide with Sorafenib|
219055964|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
219055965|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
219055966|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
219055967|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
219055968|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
219055969|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
219055970|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
219055971|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
219055972|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
219055973|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
218952481|NCT00321646|DRUG|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
219055974|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
219637915|NCT02339532|DRUG|FEC100|"3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²"
219637916|NCT02339532|DRUG|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
219637917|NCT02339532|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
219637918|NCT02339532|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
219637919|NCT02339532|DRUG|Carboplatin|CARBOPLATIN AUC 6 IV q3w
219637920|NCT03661242|BEHAVIORAL|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
219637921|NCT00887315|DRUG|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
219637922|NCT00887315|RADIATION|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
219637923|NCT05029375|BEHAVIORAL|PEERS® for Preschoolers|P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
219637924|NCT04830111|DEVICE|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
218952482|NCT00321646|DRUG|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
218952483|NCT03449524|DRUG|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
218952484|NCT03449524|DRUG|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
218952485|NCT03449524|OTHER|Placebo|Placebo
218952486|NCT04548869|DRUG|CDX-0159|Administered intravenously
219637925|NCT03612661|BEHAVIORAL|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
219637926|NCT03612661|BEHAVIORAL|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (\~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
219637927|NCT00156611|PROCEDURE|Balloon Angioplasty|
219637928|NCT00156611|DRUG|ReoPro|
219637929|NCT06002451|BEHAVIORAL|WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG|A web-based preconceptional care and consultancy training platform has been developed. In line with the literature, a comprehensive preconceptional care and counseling training content was prepared for women between the ages of 18-49. Web-based training consists of a total of 9 modules.The videos created for uploading to the website were shot in a professional studio environment with professional equipment.Each video was shot and recorded by dividing the training content according to its subsections, with an average of at least 6 minutes and a maximum of 16 minutes. Each of the module videos is based on giving the main messages in line with the purpose and objectives of the presentation.women were allowed to watch all the videos within 2 weeks. A dialog box is opened on the website where women can communicate with their midwives 24/7. During and after the training, preconceptional care and counseling training was given in this area for a total of 10 weeks.
219637930|NCT02582060|OTHER|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
218952487|NCT03079544|COMBINATION_PRODUCT|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
218952488|NCT05176132|OTHER|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
218952489|NCT05176132|OTHER|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
219055975|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
219055976|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
219055977|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
219637931|NCT04219111|GENETIC|Clariom|Clariom S Assay
219637932|NCT00619892|DRUG|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
219637933|NCT00619892|DRUG|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
219637934|NCT00379080|PROCEDURE|conventional surgery|Undergo surgery
219637935|NCT00379080|DRUG|tandutinib|Given orally
218952490|NCT05176132|OTHER|No intervention|Control groups (BMI 20-25 and BMI 25-30)
218952491|NCT04772677|BEHAVIORAL|BEAM Mental Health and Parenting Program|The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
218952492|NCT05893953|DEVICE|immediately feedback device|Sitting in a standard chair with immediate feedback device
219637936|NCT00379080|OTHER|pharmacological study|Correlative studies
219637937|NCT00379080|OTHER|Tissue samples|Correlative studies
219637938|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
219637939|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
219637940|NCT04690231|DRUG|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
218952493|NCT05893953|DEVICE|Unstable chair|sitting in an unstable chair
218952494|NCT05893953|OTHER|Standard chair|Sitting in a standard chair
219055978|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
219055979|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
219207033|NCT06762418|DEVICE|BAIMT+RME|The elastics are worn 18 hours per day to achieve the sagittal correction. The RME appliance on the upper jaw is activated twice daily until the required expansion is achieved.
218952495|NCT04559711|OTHER|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
218952496|NCT00154323|DRUG|Oxcarbazepine|
219055980|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
219055981|NCT03328897|DRUG|Omalizumab|injection of 150mg or 300 mg
219637941|NCT04690231|DRUG|ifosfamide and etoposide|ifosfamide and etoposide
218952497|NCT05734417|DIETARY_SUPPLEMENT|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
219055982|NCT03328897|DRUG|Placebo|Injection of placebo
219637942|NCT02901067|DRUG|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
219637943|NCT02901067|DRUG|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
219055983|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
219055984|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
219055985|NCT00002181|DRUG|Cidofovir|
219637944|NCT00245973|DRUG|Bifeprunox|
219637945|NCT02355964|BEHAVIORAL|Exercise|Aerobe exercise 3 times a week in 8 weeks
219637946|NCT02355964|BEHAVIORAL|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
219637947|NCT05772221|OTHER|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
219637948|NCT00821964|DRUG|imiquimod|Given topically
219637949|NCT00821964|DRUG|Abraxane|Given IV
219637950|NCT00821964|OTHER|laboratory biomarker analysis|Correlative studies
219637951|NCT00821964|GENETIC|RNA analysis|Correlative studies
219637952|NCT00821964|OTHER|immunoenzyme technique|Correlative studies
219637953|NCT00313326|PROCEDURE|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
219637954|NCT02497820|DRUG|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
219637955|NCT01962766|BEHAVIORAL|Myofunctionnal therapy|
218952498|NCT05734417|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
219055986|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
219055987|NCT00971971|PROCEDURE|Standard SLED|
219055988|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
219055989|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
219055990|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
219055991|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
219055992|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
219055993|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
219055994|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
219637956|NCT01962766|BEHAVIORAL|instructions|
219637957|NCT00288366|DRUG|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
219637958|NCT00288366|DRUG|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
219637959|NCT02461069|DRUG|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
219637960|NCT00857896|DRUG|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
219637961|NCT00000825|DRUG|Aldesleukin|
219637962|NCT02846155|OTHER|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
219637963|NCT02846155|DRUG|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
218952499|NCT03853824|OTHER|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
218952500|NCT03853824|OTHER|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
218952501|NCT03005210|DRUG|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218952502|NCT03005210|DRUG|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218952503|NCT03005210|DRUG|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
218952504|NCT00877123|DRUG|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
218952505|NCT00877123|DRUG|Placebo|similar placebo once a month for three consecutive months
218952506|NCT02634190|OTHER|Thinprep® LBC|liquid based cytology
218952507|NCT02634190|OTHER|APTIMA® HPV Assay|in vitro diagnostic test
218952508|NCT02634190|OTHER|HR HC2® HPV DNA|in vitro diagnostic test
218952509|NCT02634190|OTHER|Colposcopy|Colposcopy
218952510|NCT05278598|PROCEDURE|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
218952511|NCT05278598|PROCEDURE|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
219055995|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
219055996|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
219055997|NCT02192684|DRUG|placebo|Compare with pioglitazone
219207034|NCT06776588|PROCEDURE|Microwave ablation combined with biopsy|CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.
219637964|NCT02846155|DRUG|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
219637965|NCT00387855|BEHAVIORAL|SOS program|screening and didactic programming to raise awareness of depression suicidality
219637966|NCT04111250|PROCEDURE|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
219637967|NCT03992924|PROCEDURE|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
219637968|NCT03505684|DIETARY_SUPPLEMENT|CTP|1,000 mg of CTP was orally administered per day for 12 weeks.
219637969|NCT03505684|DIETARY_SUPPLEMENT|placebo (starch)|placebo (starch)
219055998|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
219055999|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
219056000|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
219056001|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
219056002|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
219056003|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
219056004|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
219637970|NCT06575764|OTHER|The Heart Priority Programme|The programme is delivered by the Cardiac Rehabilitation (CR) team. It consist of two main parts: 1) an evidence-based identification form to identify patients at risk of dropout due to being in a vulnerable situation and 2) an add-on intervention to standard CR targeted these patients. The add-on intervention encompasses three core elements: 1) Assigning a contact person with specific responsibilities, 2) Systematically communicating patient information to colleagues in the CR team and 3) Systematic follow-up
219056005|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
219056006|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
219056007|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
219056008|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
219056009|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
219056010|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
219056011|NCT02471924|OTHER|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
219637971|NCT02907918|DRUG|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
219637972|NCT02907918|DRUG|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
219637973|NCT02907918|BIOLOGICAL|Trastuzumab|"* Or FDA approved biosimilar~* Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
219637974|NCT02907918|DRUG|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
219637975|NCT02907918|PROCEDURE|Breast surgery|Standard of care
219637976|NCT02907918|PROCEDURE|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
219637977|NCT02907918|PROCEDURE|Research bone marrow (OPTIONAL)|Baseline and surgery
219637978|NCT02907918|PROCEDURE|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
219637979|NCT02907918|GENETIC|Research blood for germline DNA|Baseline
219637980|NCT02907918|PROCEDURE|Blood for detection of circulating tumor cells|Baseline
219637981|NCT04819516|PROCEDURE|high-intensity focused ultrasound therapy|Patients will receive high-intensity focused ultrasound therapy in local site.
219056012|NCT03405467|OTHER|general and specific data|General and specific data collected
219637982|NCT04819516|DRUG|Toripalimab|Toripalimab plus regorafenib
219637983|NCT02325388|DEVICE|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
219637984|NCT02216942|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
219056013|NCT03141502|DEVICE|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
219056014|NCT03141502|PROCEDURE|Skin grafting|the standard technique of skin grafting after wound preparation.
219056015|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
219056016|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
219056017|NCT04538014|DRUG|Lu AF88434|Oral solution
218952512|NCT05278598|PROCEDURE|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
218952513|NCT04955600|OTHER|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
219056018|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
219056019|NCT02731001|RADIATION|Proton therapy|
219056020|NCT02731001|RADIATION|Photon therapy|
219056021|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
219056022|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
219056023|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
219056024|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
219056025|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
219637985|NCT02216942|DRUG|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
219637986|NCT01006876|DRUG|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
219637987|NCT01006876|DRUG|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
219637988|NCT01006876|DRUG|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
219637989|NCT05371015|PROCEDURE|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
219637990|NCT05371015|PROCEDURE|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
219637991|NCT02022280|DRUG|Lansoprazole|
219056026|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
219056027|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
219056028|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
219056029|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
219056030|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
219056031|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
219056032|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
219056033|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
219056034|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
219056035|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
219056036|NCT00452504|DRUG|SRA-444|
219056037|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
219056038|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
219056039|NCT02454426|DRUG|Vortioxetine|open label treatment
219056040|NCT04824547|OTHER|exercise|All exercises programs will applied two sessions per week, totally eight week..
219056041|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
219056042|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
219637992|NCT02022280|DRUG|Placebo|Vitamin pill
219637993|NCT00018876|PROCEDURE|Lumbar nerve root decompression|
219637994|NCT00018876|PROCEDURE|Preoperative low-dose external beam radiation|
219637995|NCT05498844|BEHAVIORAL|Medical Nutrition Therapy (counselling)|Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
219637996|NCT01091662|DRUG|Eslicarbazepine acetate 1600 mg|1600 mg once per day
218952514|NCT03205592|DIAGNOSTIC_TEST|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
218952515|NCT03601234|PROCEDURE|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
218952516|NCT03601234|PROCEDURE|laparoscopic surgery|the traditional surgery
218952517|NCT05766358|BEHAVIORAL|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
218952518|NCT05766358|DRUG|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
218952519|NCT00287417|DEVICE|echography|
218952520|NCT00287417|OTHER|blood sample|
218952521|NCT02234518|OTHER|High quantity fiber|The intervention type is food product
218952522|NCT02234518|OTHER|Low quantity fiber|The intervention type is food product
218952523|NCT02234518|OTHER|Placebo|
218952524|NCT02113397|DRUG|TOBI™ Podhaler™ 112 mg inhaled twice daily|
218952525|NCT02113397|DRUG|Colistimethate 75 mg inhaled two times daily|
218952526|NCT04326101|OTHER|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
218952527|NCT03045224|DEVICE|PTA, balloon angioplasty, stent|
218952528|NCT05049317|PROCEDURE|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
218952529|NCT02576145|BIOLOGICAL|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
218952530|NCT02576145|DRUG|Daclizumab|The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
218952531|NCT02576145|BIOLOGICAL|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
218952532|NCT02660138|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
218952533|NCT02660138|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
218952534|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
218952535|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
218952536|NCT02889029|DEVICE|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
218952537|NCT04108117|PROCEDURE|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
218952538|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
218952539|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
219056043|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
219056044|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
219637997|NCT01091662|DRUG|Eslicarbazepine acetate 1200 mg|1200 once per day
219637998|NCT01532960|BIOLOGICAL|poly-ICLC|poly-ICLC
219637999|NCT01532960|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA \& CTA derived breast cancer proteins.
219638000|NCT01532960|BIOLOGICAL|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
218952540|NCT00308581|OTHER|Placebo|placebo administered 4-weekly in Active 1
219638001|NCT03997240|PROCEDURE|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
218952541|NCT02403466|BEHAVIORAL|Resident Handoff Bundle|1\) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
218952542|NCT02060916|DRUG|PAZ320|Single-center pilot study, open label dose escalation design
218952543|NCT00899353|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
218952544|NCT02894697|DEVICE|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
218952545|NCT02894697|DEVICE|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
218952546|NCT04583059|OTHER|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
218952547|NCT03027791|BEHAVIORAL|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
218952548|NCT03027791|BEHAVIORAL|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
219056045|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
219056046|NCT03942718|OTHER|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
219056047|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
219056048|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
219056049|NCT02284828|DRUG|BIA 2-093|
219056050|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
219056051|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
219638002|NCT02276989|DRUG|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
218952549|NCT01247298|COMBINATION_PRODUCT|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
218952550|NCT02029378|DRUG|Eculizumab|
218952551|NCT02730793|DRUG|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
218952552|NCT02730793|DRUG|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
218952553|NCT02730793|DRUG|Nasal Placebo|Placebo (nasal saline twice per day)
218952554|NCT00184951|DRUG|Rosuvastatin|
218952555|NCT01033149|DRUG|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
218952556|NCT04486300|PROCEDURE|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
218952557|NCT01397734|DRUG|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
219056052|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
219638003|NCT02276989|DRUG|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
219638004|NCT02276989|DRUG|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
218952558|NCT01123993|DEVICE|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
218952559|NCT00852488|PROCEDURE|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
218952560|NCT04503733|DRUG|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
218952561|NCT04503733|DRUG|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
218952562|NCT04503733|DRUG|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
218952563|NCT04503733|DRUG|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
218952564|NCT04503733|OTHER|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
218952565|NCT06294210|DEVICE|Mobile app and wrist-worn monitor|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
218952566|NCT04668261|OTHER|Advanced imaging investigation|MRI imaging
218952567|NCT00709579|DRUG|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
218952568|NCT00709579|DRUG|Placebo|placebo
218952569|NCT05761795|DRUG|IVMED 85|Eye drop
218952570|NCT05761795|DRUG|Placebo|Placebo eye drop
218952571|NCT06058208|BEHAVIORAL|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
218952572|NCT06058208|BEHAVIORAL|Visual stimulation|Mothers will be shown video images of their babies.
218952573|NCT02384642|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
218952574|NCT02384642|BEHAVIORAL|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
218952575|NCT03900325|DRUG|Nimacimab|2.5 mg/kg
218952576|NCT03900325|DRUG|Placebo|0.9% sodium chloride
218952577|NCT04527393|DRUG|Individualized oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose."
218952578|NCT04527393|DRUG|Conventional oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose."
218952579|NCT05299853|OTHER|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
218952580|NCT05299853|OTHER|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
218952581|NCT02941172|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET scan
219638005|NCT04190940|BEHAVIORAL|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
219638006|NCT04109391|BIOLOGICAL|TX05 (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
219638007|NCT04109391|BIOLOGICAL|Herceptin (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
219638008|NCT00758173|GENETIC|polymorphism analysis|
219638009|NCT00758173|OTHER|laboratory biomarker analysis|
219638010|NCT00758173|OTHER|questionnaire administration|
218952582|NCT02941172|OTHER|[18F]FMPEP-d2|PET radiotracer used in imaging
218952583|NCT02941172|OTHER|[18F]FDG|PET radiotracer used in imaging
219638011|NCT01329874|PROCEDURE|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
219638012|NCT01222520|DRUG|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
219638013|NCT01222520|DRUG|Telmisartan|80 mg once a daily
219638014|NCT02285166|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
219638015|NCT02285166|DRUG|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
218952584|NCT06289205|DRUG|Methotrexate|Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
218952585|NCT00401687|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
219638016|NCT02571101|DRUG|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
219638017|NCT02571101|DRUG|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
219638018|NCT02571101|DRUG|Condencia|Contains chlomipramine HCl 15mg.
219056053|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
219056054|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
219056055|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
219638019|NCT02571101|DRUG|CDFR0812-Placebo|Placebo tablet of CDFR0812.
219638020|NCT02571101|DRUG|Condencia-Placebo|Placebo tablet of Condencia
219638021|NCT01661101|DRUG|Dabigatran|Dabigatran 110 mg taken twice daily
218952586|NCT01311284|DEVICE|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
218952587|NCT01311284|DEVICE|Macintosh laryngoscope|intubate with the macintosh laryngoscope
219056056|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
219056057|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
219056058|NCT04593992|DEVICE|Placebo|Placebo stimulation
219638022|NCT01661101|DRUG|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
218952588|NCT01311284|DEVICE|McGrath|Intubate with McGrath device
218952589|NCT01311284|DEVICE|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
218952590|NCT01552421|PROCEDURE|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
218952591|NCT01376518|PROCEDURE|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
218952592|NCT00067938|DRUG|lamotrigine|Lamotrigine
219056059|NCT02670590|BEHAVIORAL|diet|diet
219056060|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
219638023|NCT01661101|DRUG|Omeprazole|Omeprazole 20 mg capsule taken once daily
219638024|NCT01661101|DRUG|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
219638025|NCT02412163|DEVICE|Ellipse IM HTO Nail|
219638026|NCT02595463|DRUG|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
219638027|NCT02595463|DRUG|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
219638028|NCT03766867|DRUG|Vortioxetine infusion 25 mg|1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
219638029|NCT03766867|DRUG|Vortioxetine tablets 10 mg/day|10 mg, tablets, oral administration once daily
218952593|NCT04422340|OTHER|Group1|"* Comorbidities (CIRS-G scale),~* Functional status of the patient with~  * Clinical frailty scale (1 month before infection)~ * ADL score (1 month before infection)~* Biological data~  * Blood group~ * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~ * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~* Resuscitation outcomes~  * LDH rate at the start of intensive care~ * PaO2 / FiO2 ratio at the start of intensive care~ * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~ * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~ * Delay between the appearance of the first signs of infection and admission to intensive care"
218952594|NCT06113380|DEVICE|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
219056061|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
219056062|NCT03379025|OTHER|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
219056063|NCT02629510|DRUG|Tachosil|
219638030|NCT03766867|DRUG|Placebo infusion|concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
219638031|NCT03766867|DRUG|Placebo tablets|oral administration once daily
219638032|NCT03468686|DEVICE|Bilateral rTMS|The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
219638033|NCT03468686|DEVICE|Sham rTMS|The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
218952595|NCT06113380|OTHER|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
218952596|NCT04052178|DEVICE|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
218952597|NCT04052178|DEVICE|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
219638034|NCT03468686|DEVICE|Unilateral rTMS (High frequency)|The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
219638035|NCT02975986|OTHER|123I-BMIPP|Uptake of radioactive isotope by the kidney
219638036|NCT02975986|OTHER|99mTc-MAG3|Uptake of radioactive isotope by the kidney
219638037|NCT03857217|DEVICE|Extra-Corporeal Membrane Oxygenation|ECMO is implanted in cardiac surgery patients.
219638038|NCT04850430|PROCEDURE|Gastric venous reconstruction|Patients will be assigned to study after intraoperative evaluation of gastric venous drainage after coronary vein resection during TP, and the gastric venous outflow will be reconstructed after TP.
219638039|NCT03146455|OTHER|no intervention|no intervention
219638040|NCT02156908|DRUG|D-serine|D-serine 60 mg/kg
219638041|NCT06192381|OTHER|Web-Based Learning Module (WBL)|To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
218952598|NCT04052178|DIETARY_SUPPLEMENT|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
218952599|NCT00832832|OTHER|Eyelid closure|Eyelid will be closed after eye drop instillation
218952600|NCT00832832|OTHER|No intervention will be assigned|No intervention will be assigned to this arm
219056064|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
219056065|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
219056066|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
219056067|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
219056068|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
219056069|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
219056070|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
219056071|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
219056072|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
219056073|NCT03746860|DRUG|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
219638042|NCT00001741|DRUG|Losartan|
219638043|NCT04415034|OTHER|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
219638044|NCT04685824|DEVICE|Biofeedback Training|Audiovisual stimulation
219056074|NCT01877447|DEVICE|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
218952601|NCT02603263|OTHER|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
218952602|NCT02412514|BIOLOGICAL|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
218952603|NCT02412514|BIOLOGICAL|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
218952604|NCT02412514|BIOLOGICAL|IPV|IPV administered at 6 weeks of age
218952605|NCT05061056|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
219056075|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
219056076|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
219056077|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
219056078|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
219056079|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
219056080|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
219638045|NCT04685824|DEVICE|Immersive Virtual-Reality|Audiovisual stimulation
219638046|NCT00599287|DRUG|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
219638047|NCT00599287|DRUG|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
219638048|NCT00599287|DRUG|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
219638049|NCT01089608|DRUG|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
219638050|NCT01089608|DRUG|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
219638051|NCT06194370|OTHER|Training by BOPPPS Teaching Model|Training by BOPPPS Teaching Model
219638052|NCT06194370|OTHER|Training Regularly|Training Regularly
219638053|NCT05616351|OTHER|Data collection in patients with diabetic foot syndrome and infections in the area of the foot|Data collection: on (surgical and antibiotic) treatment and implementation of the recommendations published 2019 with regard to the duration of antibiotic therapy.
218952606|NCT05061056|OTHER|Russian current 20%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
219056081|NCT00487110|DRUG|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
219056082|NCT00487110|DRUG|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
219638054|NCT03320382|DEVICE|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
218952607|NCT05061056|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
218952608|NCT05061056|OTHER|Aussie current 20%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
218952609|NCT01286961|DRUG|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
218952610|NCT05048550|DEVICE|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
219056083|NCT02114242|OTHER|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
219056084|NCT02114242|OTHER|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
219056085|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
219056086|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
219638055|NCT03364374|BEHAVIORAL|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
219638056|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
219638057|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
219638058|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
219638059|NCT01492374|DRUG|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
219638060|NCT00279682|BEHAVIORAL|treatment guidelines and depression care management|
219638061|NCT04109274|BEHAVIORAL|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
219638062|NCT04109274|BEHAVIORAL|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
218952611|NCT01671527|PROCEDURE|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
218952612|NCT05170867|DIETARY_SUPPLEMENT|Hafnia alvei HA4597™|One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
219056087|NCT01124890|DEVICE|early percutaneous coronary intervention|
219056088|NCT01124890|DEVICE|late percutaneous coronary intervention|
218952613|NCT05170867|OTHER|Placebo|One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
219056089|NCT03689010|DRUG|Azelaic acid foam 15%|Azelaic acid foam 15%
219056090|NCT03689010|DRUG|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
218952614|NCT02650921|DEVICE|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
218952615|NCT00627575|DRUG|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
219056091|NCT03689010|DRUG|Vehicle of the test product|Vehicle of the test product
219056092|NCT02699905|OTHER|phlebotomy|phlebotomy
219056093|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
219638063|NCT04109274|BEHAVIORAL|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
219638064|NCT06023446|DIAGNOSTIC_TEST|Optical Coherence Tomography|The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
219638065|NCT06176404|DRUG|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218952616|NCT00627575|DRUG|atorvastatin|Atorvastatin will available as 40 mg tablets.
218952617|NCT00627575|DRUG|phenytoin|Phenytoin will available as 100 mg capsules.
219638066|NCT06176404|BEHAVIORAL|Rehabilitation therapy|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
219638067|NCT03869840|DEVICE|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
219638068|NCT03219840|DRUG|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
219638069|NCT03219840|DRUG|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
218952618|NCT02032043|DRUG|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
218952619|NCT01812447|DEVICE|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
218952620|NCT01812447|OTHER|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
218952621|NCT01087788|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
218952622|NCT01087788|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
219056094|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
219056095|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
219056096|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
219056097|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
219056098|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
219056099|NCT04543422|OTHER|Placebo|Placebo containing inert material.
219056100|NCT02393495|DEVICE|intrauterine device TCu 380A|
218952623|NCT01087788|OTHER|Placebo|Matching Placebo to CZP injection.
219056101|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
218952624|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
218952625|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
218952626|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
219056102|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
219056103|NCT05733988|PROCEDURE|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
219056104|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
219056105|NCT02691455|PROCEDURE|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
219056106|NCT02691455|DEVICE|Ahmed Model FP7 Flexible Plate|
219638070|NCT06437795|DIAGNOSTIC_TEST|Dry Needling Group|Participants in this group will receive dry needling therapy. This involves inserting thin needles into trigger points in the piriformis muscle to relieve pain and muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
219638071|NCT06437795|OTHER|Cupping Therapy Group|Participants in this group will receive cupping therapy. This involves placing cups on the skin to create suction, which is believed to improve blood flow and reduce muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
219638072|NCT01160081|OTHER|Serum sample|Serum samples collected
219638073|NCT04920396|DEVICE|E>Eye IRPL|Regulated intense pulsed light therapy
219638074|NCT04920396|DEVICE|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
218952627|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
219056107|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
219056108|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
219056109|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
219056110|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
219056111|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
219056112|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
218952628|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
218952629|NCT04276727|DRUG|MINT study IMP|Application of gel for 6 weeks.
219056113|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
219056114|NCT00284531|DRUG|Daclizumab|
219056115|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
219638075|NCT00384839|DRUG|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
219638076|NCT06015074|DRUG|Propofol|patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
219638077|NCT06015074|DRUG|Ciprofol|patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
219638078|NCT01262157|DEVICE|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
219638079|NCT01262157|DEVICE|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
219638080|NCT06264102|OTHER|Physical exercise program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
219638081|NCT04728048|PROCEDURE|Dural puncture epidural|already described
219638082|NCT04728048|PROCEDURE|Standard epidural|already described
219638083|NCT03054155|DEVICE|Alexandrite Laser|Alexandrite 755nm hair removal laser
219638084|NCT06575114|OTHER|Self-determination theory-based health education measures|In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
219638085|NCT06387212|DRUG|35 kDa hyaluronan fragment HA35 injection|First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
219638086|NCT05423535|DEVICE|test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)|Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
219638087|NCT03854825|PROCEDURE|Cardiac surgery|
219638088|NCT06524934|DEVICE|Use of virtual reality during the hysteroscopic procedure|In VR group patients underwent hysteroscopy with standard care but the addition of VRT provided by a VR headset and headphones with the use of a Hypno VR software.
219638089|NCT06383897|DRUG|HS-10398|SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
219207035|NCT06777186|OTHER|10 meter walk test|"The dual task skills of the individuals will be evaluated by adding motor and cognitive tasks to the 10-meter walk test. Tasks given to individuals~Single motor task (comfortable walking): The individual is asked to walk at normal speed, the time is recorded Motor-motor dual task: Both hands carry a half-full water bottle, time is recorded Motor-cognitive dual task (mental) : counts backwards from 10 by 1, time is recorded Motor - cognitive dual task (memory) : The individual is asked to say 3 words that were previously spoken. The time is recorded."
219638090|NCT06383897|DRUG|HS-10398 Placebo|SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
219638091|NCT00280397|DRUG|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
219638092|NCT04821609|BEHAVIORAL|Resistance Training|The resistance training will be for arms and legs, self-loading type, and external weights.
219638093|NCT04517201|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
219638094|NCT04517201|DRUG|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
219638095|NCT04727060|DEVICE|patient with knee arthroplasty|
219638096|NCT03033862|DEVICE|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
219638097|NCT03033862|DEVICE|Drug Eluting Stent|Drug Eluting Stent
219638098|NCT00665262|DRUG|tramacet|2 tablets every 6 hours for 5 days
219638099|NCT05012722|DIAGNOSTIC_TEST|Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement|All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
219056116|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
219056117|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
219056118|NCT04569045|DEVICE|HA+Lidocaine|20 mg
219056119|NCT04569045|DEVICE|HA|20 mg
219638100|NCT06348030|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
219638101|NCT06348030|DEVICE|Vessel Sealer Extend Energy Device and SureForm Stapler|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
219638102|NCT02283996|OTHER|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients\_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
219638103|NCT02283996|DRUG|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
219638104|NCT01892410|OTHER|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
219638105|NCT06244550|DRUG|Ganwei|Capsules
219638106|NCT06244550|DRUG|Metformin|Tablets
219638107|NCT06244550|DRUG|Placebo|Matching capsules
219638108|NCT05938764|BEHAVIORAL|MICRA|see earlier description
219638109|NCT05938764|BEHAVIORAL|TAU|see earlier description
219638110|NCT03757728|PROCEDURE|Haemorrhoidectomy operations|for treatment of symptomatic 2 to 3 degree haemorrhoids
219638111|NCT05021679|OTHER|AMP Implementation|Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
219638112|NCT06389760|DRUG|Nimotuzumab|When combined with the mFOLFIRINOX regimen, nimotuzumab (nimo) will be administered at a dose of 400mg on Day 1 and 15 of a 28-day cycle (6 cycles). When combined with the GX regimen, nimotuzumab will be given at 400mg on Day 1 and 8 of a 21-day cycle (8 cycles).
219638113|NCT06389760|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
219638114|NCT06389760|DRUG|GX|Patients will receive GX regimen as follows: Gemcitabine 1000 mg/m2 on Day 1 and 8 of a 21-day cycle; capecitabine 2000 mg/m2 on d1-14 a 21-day cycle(8 cycles).
219638115|NCT05485168|OTHER|Sequential Variety|3 different foods served in 3 successive courses
219638116|NCT05485168|OTHER|Single-Food|1 food served in 3 successive courses
219638117|NCT05485168|OTHER|Small Portion|Small meal portion size
219638118|NCT05485168|OTHER|Large Portion|Large meal portion size
219638119|NCT02973724|DRUG|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
218952630|NCT04605614|RADIATION|Copper Cu 64-DOTA-pembrolizumab|Given IV
219638120|NCT02973724|DRUG|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
219638121|NCT03562208|BIOLOGICAL|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
219638122|NCT02112630|DRUG|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
219638123|NCT02112630|DRUG|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
219638124|NCT02112630|DRUG|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
219638125|NCT02112630|DRUG|Boceprevir|800 mg PO three times daily starting at week 4
218952631|NCT04605614|BIOLOGICAL|Pembrolizumab|Given IV
218952632|NCT04605614|PROCEDURE|Positron Emission Tomography|Undergo PET
218952633|NCT01409343|DRUG|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
219056120|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
219638126|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
219638127|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
219638128|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
219638129|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
219638130|NCT04144543|OTHER|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
219638131|NCT04144543|OTHER|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
219638132|NCT04144543|OTHER|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
219638133|NCT02587390|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
218952634|NCT02917018|DRUG|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
218952635|NCT00160667|DRUG|Placebo|Daily oral dose of two equal intakes.
218952636|NCT00160667|DRUG|Brivaracetam|Daily oral dose of two equal intakes.
218952637|NCT04810780|DEVICE|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
218952638|NCT06055335|OTHER|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
218952639|NCT06055335|OTHER|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
218952640|NCT05337397|PROCEDURE|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
218952641|NCT04605367|DEVICE|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
218952642|NCT03235180|DRUG|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
219056121|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
219638134|NCT02587390|DRUG|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
219638135|NCT03137472|DEVICE|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
218952643|NCT03235180|DEVICE|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
218952644|NCT03235180|DEVICE|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
218952645|NCT03235180|DEVICE|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
219056122|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
219056123|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
219056124|NCT04978792|BEHAVIORAL|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
219056125|NCT04978792|BEHAVIORAL|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
219638136|NCT06413901|PROCEDURE|TIP|TIP hypospadias repair
219638137|NCT00497289|DRUG|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
219638138|NCT00497289|DRUG|Lipidem 20%|daily i.v. infusion for up to 5 days
219638139|NCT00970840|DIETARY_SUPPLEMENT|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P\&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
219638140|NCT02257489|DRUG|ACE-083|recombinant fusion protein
219638141|NCT03239860|DRUG|GNbAC1 Monoclonal Antibody|Monthly IV
219638142|NCT03095560|DEVICE|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
219638143|NCT04067726|DRUG|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
219638144|NCT04067726|DRUG|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
219638145|NCT04067726|DRUG|Calcium|-Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
219638146|NCT04067726|DRUG|Vitamin D3|Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
219638147|NCT04067726|PROCEDURE|Core needle biopsy|Baseline and 12 months
219638148|NCT04067726|PROCEDURE|Blood draw|Baseline and 12 months
219638149|NCT05040204|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
219638150|NCT05040204|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo (glucose powder)
219056126|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
219056127|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
219056128|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
219056129|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
219056130|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
219056131|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
219056132|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
219056133|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
219056134|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
219056135|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
219056136|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
219056137|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
219638151|NCT02924168|DEVICE|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
219638152|NCT02924168|DEVICE|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
219638153|NCT01231724|DEVICE|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
219638154|NCT01231724|DEVICE|Placebo Nasal Spray|2 sprays in each nostril
219638155|NCT06684158|DRUG|Mecapegfilgrastim|6 mg,HD d3,every 2weeks (Q2W)
219638156|NCT06684158|DRUG|Adebrelimab|Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)
219638157|NCT06684158|DRUG|Docetaxel|Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)
219638158|NCT06684158|DRUG|Oxaliplatin|Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)
219638159|NCT06684158|DRUG|5-Fluorouracil (5-FU)|5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)
219638160|NCT06684158|DRUG|Leucovorin (LV)|LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
219638161|NCT02827825|OTHER|No intervention|No intervention. It's a study on retrospective Data
218952646|NCT04805489|OTHER|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
218952647|NCT03131830|OTHER|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
218952648|NCT00254267|DRUG|AMG 706|AMG 706 125mg, oral, once a day
219056138|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
219056139|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
219056140|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
219638162|NCT05171036|OTHER|Adapted Physical Activity|"* Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~* Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~* Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~* Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention."
218952649|NCT05139511|DEVICE|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
218952650|NCT05139511|OTHER|Control group|Same procedure but without energy
219056141|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
219638163|NCT05040425|DRUG|Zi-Yin-Liang-Ge-San|Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
219638164|NCT04485325|DRUG|Tofacitinib|5 mg twice daily, p.o.
219638165|NCT04485325|BIOLOGICAL|Etanercept|50 mg once per week, s.c.
219056142|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
219056143|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
219056144|NCT02984397|DRUG|Placebo|
219638166|NCT00002943|DRUG|carboplatin|
219638167|NCT00002943|DRUG|cyclophosphamide|
219638168|NCT00002943|DRUG|etoposide|
219638169|NCT00002943|PROCEDURE|autologous bone marrow transplantation|
219056145|NCT02984397|OTHER|Standard of Care|
219638170|NCT05272293|BIOLOGICAL|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
219638171|NCT06967038|BIOLOGICAL|CAR-NK cell|Chimeric Antigen Receptor Natural Killer Cell
219638172|NCT06968143|DEVICE|Smart Knee Implant|"An important advancement in objective recovery data occurred when the first ever 'smart' knee implant for remote therapeutic monitoring (RTM) after total knee arthroplasty (TKA) was released in 2021. The implant includes both a prosthesis for TKA and a stem, the latter of which records the following metrics: step count, distance traveled, tibial range-of-motion (ROM), functional ROM, average walking speed, stride length, and cadence. The implant sends the recordings to a mobile platform. Additionally, it collects and analyzes patient across the entire population of users and creates percentiles for each metric based on patient age, gender and time since surgery. These recovery curves provide more objective data for practitioners and patients to evaluate recovery progress and make adjustments to their care plans accordingly."
219056146|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
219056147|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
219056148|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
219056149|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
219056150|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
219056151|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
219056152|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
219056153|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
219056154|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
218952651|NCT06248047|PROCEDURE|uretheroplasty|4\. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
218952652|NCT03893890|BIOLOGICAL|Previously Treated with EN3835|No treatment to be administered - Observational only
218952653|NCT05655806|DRUG|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
218952654|NCT05655806|DRUG|aminophylline bolus|after discontinuation of isoflurane
218952655|NCT05655806|DRUG|normal saline|given as placebo
218952656|NCT04152993|DEVICE|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
218952657|NCT00304213|DRUG|Testosterone|
218952658|NCT01779219|DEVICE|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
218952659|NCT01779219|DEVICE|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
218952660|NCT00680394|DRUG|mifepristone|200 mg mifepristone
218952661|NCT00680394|DRUG|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
219638173|NCT06967233|OTHER|Multimodal treatment|Surgical resection, locoregional liver-directed treatments and continuous systemic treatment in patients with liver metastatic pancreatic cancer
219638174|NCT05263271|DRUG|Gentulizumab|Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
219638175|NCT00224328|DEVICE|ODISsey Tissue Oximeter|
219638176|NCT04418128|DRUG|Nafamostat Mesylate|The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
218952662|NCT00680394|DRUG|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
219207036|NCT06777186|OTHER|Functional Balance|It will be assessed with the TUG test. The TUG measures the time it takes for an individual to get up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and sit down again after a ready, go signal.
219207037|NCT06777186|OTHER|Social Adaptation Assessment|Adaptive behavior will be assessed with the Vineland Adaptive Behavior Scales. It is a parent interview designed to assess functioning in daily life. \[35\]Specifically, adaptive behavior is assessed in four domains: Communication, Daily Living, Socialization and Motor skills. Vineland has reliability and current validity. It has been reported to be sensitive to the difficulties experienced by children with ASD
218952663|NCT05907941|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
219207038|NCT06777186|OTHER|Motor skills and proficiency|The Bruininks-Oseretsky Motor Proficiency Test (BOT-2) assesses fine motor, hand coordination, body coordination, strength and agility between the ages of 4-21 years.There are 53 items in the BOT-2. In BOT-2, there are four motor domains including fine motor control, hand coordination, body coordination, strength and agility and a total of eight subtests related to these domains.
219638177|NCT01797861|PROCEDURE|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
219638178|NCT01797861|PROCEDURE|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW\*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~\* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
219638179|NCT05007028|DRUG|EMONO|Exposure to 1 hour of EMONO via facial mask
219638180|NCT05007028|DRUG|Medical Air|Exposure to 1 hour of Medical Air via facial mask
219638181|NCT06349993|BEHAVIORAL|Digital Intervention|game-based digital intervention app
219207039|NCT06766669|OTHER|Shaping method activities combined with mirror therapy|This intervention involves the application of exercises consisting of shaping method activities accompanied by a mirror device. It is basically an intervention consisting of exercises that require manual dexterity.
219207040|NCT06768853|PROCEDURE|Lymph node dissection based on the guidelines|During surgery, mediastinal lymph nodes will be dissected based on the NCCN guidelines (2023) .
219638182|NCT06349993|BEHAVIORAL|Health Education|traditional health education app
219638183|NCT04203602|PROCEDURE|telepresence discharge|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
219638184|NCT04203602|OTHER|Conventional discharge|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
219638185|NCT05348291|DEVICE|ventilation tubes|Transtympanic pressure equalising devices.
219638186|NCT03265951|DRUG|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
219638187|NCT03265951|OTHER|Usual Care|education brochure about sleep hygiene
219638188|NCT00955955|OTHER|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
219638189|NCT00955955|OTHER|Placebo|Inactive substance
219638190|NCT05633940|BEHAVIORAL|Implementation of the service delivery model primary care behavioral health|The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
219638191|NCT01452893|PROCEDURE|Spiroergometry|"At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP)."
219638192|NCT01385969|DEVICE|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
219638193|NCT01385969|DEVICE|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
219638194|NCT01385969|DEVICE|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
219638195|NCT04046770|DEVICE|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
219638196|NCT04046770|DEVICE|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
219207041|NCT06768853|PROCEDURE|Lymph node dissection based on the model|During surgery, lymph nodes will be dissected based on the predicted lymph node status by the model.
219638197|NCT03973411|DRUG|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
219638198|NCT03973411|DRUG|Placebo|Pacients will receibe standard spinal anesthesia
219638199|NCT06501378|DRUG|PD-1/PD-L1 inhibitor plus chemotherapy|Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.
219638200|NCT06501378|RADIATION|SRT/WBRT|Active brain metastases (BM) patients will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
219638201|NCT03703583|OTHER|There is no intervention in this observational study.|There is no intervention in this observational study.
219207042|NCT06768879|RADIATION|Ultrasound|To evaluate the different location of uterine fibroids in patient with disturbed menstrual cycle on ultrasound
219638202|NCT03000426|PROCEDURE|Free gingival graft|Free gingival graft removal from palate for socket preservation
219638203|NCT03000426|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
219638204|NCT00887848|OTHER|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
219207043|NCT06773676|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
219638205|NCT05934604|OTHER|Functional magnetic resonance imaging (fMRI)|Healthy subjects will complete two fMRI sessions after initial assessment and training in the Rest Focus Task (RFT). The first session will be the localizer session to identify the networks involved in switching in the RFT. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP\>RECALL contrast.
218952664|NCT05907941|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
219638206|NCT00894608|DRUG|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
219638207|NCT00894608|DRUG|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
219638208|NCT01408381|OTHER|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
218952665|NCT05907941|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
218952666|NCT02386683|OTHER|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
218952667|NCT00534313|DRUG|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
218952668|NCT00534313|DRUG|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
218952669|NCT00464880|DRUG|Aliskiren|
218952670|NCT01773447|PROCEDURE|Set-back suture|
218952671|NCT01773447|PROCEDURE|Vertical mattress suture|
218952672|NCT04089800|OTHER|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
218952673|NCT03665818|DEVICE|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
218952674|NCT02285036|BIOLOGICAL|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
219056155|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
219056156|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
219056157|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
219056158|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
219056159|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
219638209|NCT04061512|DRUG|Dexamethasone, cyclophosphamide, rituximab|DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
218952675|NCT02285036|BIOLOGICAL|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
219638210|NCT04061512|DRUG|Rituximab, ibrutinib|RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
219638211|NCT02064712|OTHER|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
219638212|NCT02064712|OTHER|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
219638213|NCT05364281|OTHER|Intracuff pressure measurement|The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
219638214|NCT03852264|BEHAVIORAL|Pet dog|Children will interact freely with their pet dog for 25 minutes.
219638215|NCT03852264|BEHAVIORAL|Unfamiliar dog|Children will interact freely with an unfamiliar dog for 25 minutes
218952676|NCT02133703|BEHAVIORAL|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
219056160|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
219056161|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
218952677|NCT02133703|BEHAVIORAL|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
219056162|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
219638216|NCT03852264|BEHAVIORAL|Nonsocial control|Children will play with age-appropriate toys/games for 25 minutes.
218952678|NCT02133703|BEHAVIORAL|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
219638217|NCT03169881|DRUG|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
219638218|NCT03169881|DRUG|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
218952679|NCT02133703|BEHAVIORAL|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
218952680|NCT02133703|BEHAVIORAL|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
219638219|NCT05478135|DEVICE|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
219638220|NCT03524235|RADIATION|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
219638221|NCT03524235|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
219638222|NCT03524235|BIOLOGICAL|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
219638223|NCT03524235|DRUG|Bendamustine|Pre-Transplantation Bendamustine
219638224|NCT03524235|DRUG|Fludarabine|Pre-Transplantation Fludarabine
219638225|NCT03524235|DRUG|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
219638226|NCT01028014|DRUG|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
219638227|NCT01028014|DRUG|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
219207044|NCT06773676|DEVICE|Sham|The sham device is externally identical to active, emits the same guiding light and sound but does not emit the therapeutic near infrared invisible rays
219207045|NCT06778421|PROCEDURE|Intramuscular injection|Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents
219638228|NCT01028014|DRUG|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
219638229|NCT01028014|DRUG|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
219638230|NCT01028014|DRUG|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
219638231|NCT01028014|DRUG|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
219638232|NCT02516514|PROCEDURE|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
219638233|NCT00244114|DRUG|blood draw|Single blood sample collected to perform histamine release assay.
219638234|NCT00244114|PROCEDURE|Blood draw|Single blood sample collected to perform histamine release assay.
219638235|NCT01094158|DRUG|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
219638236|NCT01094158|DRUG|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
219638237|NCT01094158|DRUG|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
219638238|NCT02181582|DRUG|Emapunil|Single peroral administration
219638239|NCT02181582|DEVICE|PET|Positron emission tomography, which creates images by detecting radioactivity.
219638240|NCT06314646|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
218952681|NCT04168632|OTHER|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
219056163|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
219056164|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
219638241|NCT06314646|PROCEDURE|Double-stapled Total Mesorectal Excision (TME)|Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)
219638242|NCT03064815|DEVICE|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures."
219638243|NCT03064815|PROCEDURE|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
219638244|NCT03064815|DIAGNOSTIC_TEST|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
219638245|NCT03064815|DIAGNOSTIC_TEST|Fecal calprotectin|A stool test to measure inflammation in the gut.
219638246|NCT06316232|DEVICE|STIM ON plus|increase of intensity of stimulation of 0.5 mA bilaterally
218952682|NCT02521896|DEVICE|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
218952683|NCT02358356|DRUG|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
218952684|NCT02358356|DRUG|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
218952685|NCT02358356|DRUG|Temozolomide|temozolomide 75mg/m2 b.i.d.
218952686|NCT01642628|OTHER|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
218952687|NCT00927940|DEVICE|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
218952688|NCT02672020|BIOLOGICAL|omics identity card|
218952689|NCT04880902|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
218952690|NCT02762227|DEVICE|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
219638247|NCT06316232|DRUG|MED ON plus|administration of a 2x levodopa morning dose
219638248|NCT01581242|DRUG|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
219638249|NCT01581242|DRUG|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
219638250|NCT01581242|DRUG|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
219638251|NCT02557932|DRUG|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
219638252|NCT02557932|DRUG|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
219638253|NCT04303520|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
219638254|NCT04303520|DRUG|Fludarabine|30mg/m2/d
219638255|NCT04303520|DRUG|Cyclophosphamide|500mg/m2/d
219638256|NCT05195255|DIETARY_SUPPLEMENT|Prebiotic|Guar gum (8 g/d) will be administered for 18 days
219638257|NCT00878202|DEVICE|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
219638258|NCT04879121|DRUG|Larotrectinib Sulfate|Given PO
218952691|NCT02762227|DEVICE|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
218952692|NCT02762227|PROCEDURE|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
218952693|NCT03438721|BEHAVIORAL|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
218952694|NCT03438721|BEHAVIORAL|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
218952695|NCT02767362|DRUG|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
219056165|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
218952696|NCT06472986|OTHER|Activity-based therapy and transcutaneous spinal cord stimulation|Activity Based Therapy (ABT) is a method of neuro-rehabilitation that incorporates a high intensity, long duration and effortful engagement from the individual receiving therapy, to garner improvements in sensory and motor function. The ABT constitutes 4 types of exercises including: cardio-fitness, resistance, postural/weightbearing and functional exercises. TransCutaneous Spinal Cord Stimulation (TCSCS) stimulates spinal networks in the cervical region to neuro-modulate the descending motor commands/motor intentions from the brain, which control the muscles. In tCSCS, electrical stimulation is delivered at a frequency of 30-50Hz at 500-1000µs between C3-C7. 12 sessions of ABT (4 weeks), followed by 28 sessions of ABT-TCSCS (7 weeks). Each session will last 1 hour and delivered 3 times per week.
218952697|NCT03725462|DEVICE|Cardioskin|Subjects have a monitoring with cardioskin and comparator
218952698|NCT03725462|DEVICE|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
219056166|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
219207046|NCT06778421|DRUG|OnabotulinumtoxinA (Botox®) Injections|"Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only~\- Abbvie/Allergan drug."
219207047|NCT06778421|OTHER|Sodium Chloride|Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.
219638259|NCT06685328|PROCEDURE|minimal posterior pole vitrectomy combined with a sodium hyaluronate gel-covered internal limiting membrane(ILM) flap with balanced saline filling and postoperative supine position|Vitrectomy of the posterior pole within the vascular arch was performed by a standard 25G ciliary flattening three-way tract procedure, followed by injection of a small amount of tretinoin suspension (TA) to mark the posterior vitreous cortex, which was excised. The inner limiting membrane (ILM) of the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the ILM around the hole was peeled off, leaving a semicircular piece of ILM attached to the hole, and then the single ILM flap was folded and covered with MH. 0.2 to 0.3 mL of hyaluronic acid gel (Bausch \& Lomb, Iviz) was injected over the inverted ILM flap using perfluorocarbon liquid for complete coverage. The perfluorocarbon liquid was aspirated. Postoperatively, the patient was advised to remain in a non-emergent supine position for 24 hours.
218952699|NCT05738343|OTHER|dieta mediterranea|nutritional education or Mediterranean food scheme
218952700|NCT02369601|OTHER|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
219207048|NCT06778720|BEHAVIORAL|Music Therapy with over-the ear headphones|Eligible patients undergoing VATS procedure can have music therapy as an intervention to reduce pain levels after surgery and improve outcomes.
219367147|NCT06960772|BEHAVIORAL|Sham Intervention|"Participants receive an intensive intervention over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach' The sham intervention uses breathing exercises through the Flow Ball, no phonation will be involved."
218952701|NCT02081066|OTHER|cardiovascular risk factors|
218952702|NCT05045989|BEHAVIORAL|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
218952703|NCT03337672|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
218952704|NCT03337672|DRUG|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
218952705|NCT03717272|DRUG|AEF0117|AEF0117 capsules
219056167|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
219056168|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
219056169|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
219056170|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
219056171|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
219056172|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
219056173|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
219056174|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
219638260|NCT06685328|PROCEDURE|Conventional vitrectomy combined with inner limiting membrane flap flip coverage with sterile air filling and postoperative prone position|A standard 25G ciliary flattening three-way tract procedure was taken to perform posterior and midperipheral vitrectomy, followed by injection of a small amount of tretinoin (TA) to label the posterior vitreous cortex and excision of the posterior vitreous cortex within the vascular arch. The ILM on the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the peripapillary ILM was peeled off with forceps, leaving a semicircular piece of ILM attached to the foramen ovale, and the individual ILM flaps were then turned over and covered with MH. Air-liquid exchange was then performed and subsequent surgery was routinely performed according to existing surgical concepts. Ultrasonic emulsification and IOL implantation were selectively performed depending on the extent of the cataract and the patient's surgical needs. Antibiotic ointment is applied at the end of the procedure. After surgery, patients were advised to remain in strict prone position for 3 days.
219638261|NCT06083961|DRUG|Alirocumab|Initial alirocumab, single dose of 300mg, subcutaneous injection
219638262|NCT00832871|DRUG|Mifepristone|Mifepristone 200 mg will be administered orally
219638263|NCT05708157|DRUG|concomitant intranasal antihistamine and corticosteroid|concomitant intranasal administration with antihistamine and corticosteroid
219638264|NCT04644926|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
219638265|NCT02217410|BIOLOGICAL|CFZ533|
218952706|NCT03717272|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
218952707|NCT05307198|DRUG|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
219056175|NCT00207441|BEHAVIORAL|Arthritis Self management program|
219056176|NCT00207441|BEHAVIORAL|Chronic Disease Self Management Program|
219056177|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
219056178|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
219056179|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
219056180|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
219056181|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
219056182|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
219056183|NCT04193813|OTHER|Observational|Observational study
219638266|NCT02217410|DRUG|Tacrolimus (Tac)|
219638267|NCT02217410|DRUG|Mycophenolate mofetil (MMF)|
219638268|NCT02217410|DRUG|Corticosteroids (CS)|
218952708|NCT05307198|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
218952709|NCT05307198|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
218952710|NCT05307198|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
218952711|NCT05903209|DEVICE|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
218952712|NCT02970682|DRUG|SFX-01|Stabilised Sulforaphane
218952713|NCT02970682|DRUG|Fulvestrant|Fulvestrant
218952714|NCT02970682|DRUG|Tamoxifen|Tamoxifen
218952715|NCT02970682|DRUG|Aromatase Inhibitors|
218952716|NCT03772288|DRUG|TAK-659|Tablets.
218952717|NCT03772288|DRUG|NKTR-214|Intravenous infusion.
218952718|NCT02687867|DRUG|Dabigatran (Pradaxa)|As prescribed by treating physicians
218952719|NCT02687867|DRUG|Vitamin K antagonist|As prescribed by treating physicians
218952720|NCT01615497|BEHAVIORAL|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
219056184|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
219056185|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
219056186|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
218952721|NCT01615497|BEHAVIORAL|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
218952722|NCT01615497|BEHAVIORAL|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
218952723|NCT06457672|DIAGNOSTIC_TEST|Group I|Complete Crown technique of superimposition
218952724|NCT06457672|DIAGNOSTIC_TEST|Group II|Gold standard technique of superimposition
218952725|NCT02303418|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
218952726|NCT02303418|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
219056187|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
219056188|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
218952727|NCT03090048|DRUG|Vitamin A|Vitamin A 2-3 % concentration
218952728|NCT03090048|DRUG|Azithromycin|azithromycin monohydrate
218952729|NCT01905423|DRUG|Albendazole (annual)|Albendazole 400 mg pnce annually
218952730|NCT01905423|DRUG|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
218952731|NCT01905423|DRUG|Albendazole (semiannual)|Albendazole 400 mg twice annually
218952732|NCT01905423|DRUG|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
218952733|NCT02796417|BEHAVIORAL|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
218952734|NCT02796417|BEHAVIORAL|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
218952735|NCT03815578|OTHER|Clinical examination|"* Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)"
218952736|NCT03815578|OTHER|Pain assessment|"* Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)"
218952737|NCT03815578|OTHER|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
218952738|NCT03815578|OTHER|Patient Reported Outcomes|"* Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire."
219056189|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
219056190|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
219056191|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
219056192|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
219367148|NCT02039739|DEVICE|Orsiro™ Drug Eluting Stent group|
219638269|NCT02217410|BIOLOGICAL|anti-IL2 Induction|
219638270|NCT03055897|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
219638271|NCT03758222|DEVICE|XFLO Expander System|Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
219638272|NCT06684210|PROCEDURE|Intercostal plane block of the external oblique muscle|Under ultrasound guidance, a single dose of 0.25% ropivacaine 20ml was given for bilateral intercostal muscle plane block of external oblique muscles
219638273|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.25 µg/kg
218952739|NCT05157802|BEHAVIORAL|Physical activity coaching|Physical activity coaching over 5 sessions
218952740|NCT04370340|DEVICE|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
218952741|NCT00726401|DRUG|COLD-fX|200mg BID for 4 weeks
218952742|NCT00726401|DRUG|Placebo|200mg BID for 4 weeks
218952743|NCT06421129|PROCEDURE|anal fistula surgery|anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
218952744|NCT00000803|DRUG|Delavirdine mesylate|
218952745|NCT00000803|DRUG|Zidovudine|
218952746|NCT00000803|DRUG|Didanosine|
218952747|NCT03709576|DRUG|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
218952748|NCT03709576|PROCEDURE|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
218952749|NCT03709576|DRUG|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
218952750|NCT05196711|DRUG|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
218952751|NCT05196711|DRUG|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
218952752|NCT03430076|PROCEDURE|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
218952753|NCT03430076|DEVICE|Propaten®|Propaten®
219638274|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.5 µg/kg
218952754|NCT03430076|DEVICE|Crude PTFE|Crude PTFE
218952755|NCT01220544|BIOLOGICAL|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
218952756|NCT03581461|BEHAVIORAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
218952757|NCT02181270|OTHER|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
218952758|NCT02181270|OTHER|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
218952759|NCT01690676|DIETARY_SUPPLEMENT|Epicatechin|
218952760|NCT01690676|DIETARY_SUPPLEMENT|Microcrystalline cellulose|
218952761|NCT03044574|DEVICE|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
218952762|NCT03044574|DEVICE|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
218952763|NCT03044574|DRUG|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
218952764|NCT05507359|OTHER|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
219056193|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
219056194|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
219056195|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
219056196|NCT01229228|DRUG|Naproxen Test|200-mg single dose
219056197|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
219638275|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.75 µg/kg
219638276|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 1 µg/kg
219638277|NCT06685081|DRUG|lidocaine and triamcinolone|2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
219638278|NCT06392113|BEHAVIORAL|ACTION FALLS|Falls prevention advice including booklet and videos
219638279|NCT00845208|BEHAVIORAL|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
219638280|NCT05229523|OTHER|repeated assessments|validity and reliability of the Modified Four Square Step Test (mFSST) in children with cerebral palsy with the tests of Pediatric Berg Balance Scale (PBSS), Timed Up and Go Test (TUG), Pediatric Functional Reaching Test (PFUT)
219056198|NCT01229228|DRUG|Naprosyn|single dose
219056199|NCT01229228|DRUG|Naprosyn|single dose
219056200|NCT01229228|DRUG|Placebo|single dose
219056201|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
218952765|NCT05507359|OTHER|Benzocaine gel|20% Benzocaine gel (Opahl gel)
218952766|NCT06055738|DRUG|Zimberelimab|240mg,d1,iv,Q21D
218952767|NCT06055738|DRUG|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
219056202|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
219056203|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
219056204|NCT00928317|DRUG|Placebo|Placebo s.c.
219056205|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
219056206|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
219638281|NCT04859790|BEHAVIORAL|Social Concerns Appraisal Retraining|"SCAR consists of an hour-long intervention session, followed by a 2-week-long EMI. During the hour-long intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety), discuss popular misconceptions they may have about publicly observable anxiety symptoms (e.g., people can tell I'm anxious by looking at me), and complete exposure exercises (e.g., practicing facing feared physical sensations such as sweating). During the EMI, participants will report on their social anxiety symptoms four times per day. When participants endorse elevated social anxiety during this time, they will receive a targeted message reminding them of the topics covered in the intervention session."
219638282|NCT02125942|BEHAVIORAL|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
219638283|NCT01455272|PROCEDURE|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
219638284|NCT02067884|PROCEDURE|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
218952768|NCT06055738|DRUG|Cisplatin|75mg/m2,d1,iv,Q21D
218952769|NCT02805270|OTHER|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
218952770|NCT02557074|DRUG|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
219056207|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
219056208|NCT03766646|DEVICE|Optiflow|45l.min oxygen
219056209|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
219056210|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
219056211|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
219056212|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
218952771|NCT02557074|DRUG|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
219056213|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
219056214|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
219056215|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
219638285|NCT02067884|PROCEDURE|shear wave elastography|Undergo SWE
218952772|NCT00403169|DRUG|lenalidomide|drug
218952773|NCT02834845|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
219638286|NCT02067884|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
219638287|NCT02067884|DEVICE|Philips Shear Wave Elastography|Equipment used for SWE
219638288|NCT00585845|BIOLOGICAL|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.
218952774|NCT02834845|DRUG|Desflurane|Desflurane %6-8 for general anesthesia maintenance
218952775|NCT00890045|DEVICE|HeRO Vascular Access Device|HeRO Vascular Access Device
218952776|NCT00890045|DEVICE|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
219056216|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
219056217|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
219056218|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
219056219|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
219056220|NCT00191321|DRUG|Teriparatide|
219056221|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
219056222|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
219638289|NCT00938847|DEVICE|PCI|Stent implantation after acute myocardial infarction
219638290|NCT03468166|OTHER|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
219638291|NCT04515706|DRUG|Iguratimod|Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.
219638292|NCT04515706|DRUG|Placebo|Placebo of Iguratimod
219638293|NCT06293508|BEHAVIORAL|Standard Health Communication Intervention|Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
219056223|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
218952777|NCT01402427|DRUG|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
218952778|NCT01402427|DRUG|Placebo|Intraarterial administration of 10 mL saline.
218952779|NCT01136187|PROCEDURE|Access site in primary PCI|
218952780|NCT02073383|PROCEDURE|Axillary brachial plexus block|
218952781|NCT05725759|BEHAVIORAL|Rehabilitation|Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
218952782|NCT02807415|DRUG|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
218952783|NCT00243607|OTHER|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
219056224|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
219638294|NCT06293508|BEHAVIORAL|Behavioural Change Health Communication Intervention|Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
218952784|NCT04355728|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
218952785|NCT04355728|OTHER|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
218952786|NCT01090895|DRUG|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
218952787|NCT01090895|DRUG|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
218952788|NCT05024292|PROCEDURE|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
218952789|NCT00385164|PROCEDURE|PET/CT scan for RT planning|
218952790|NCT04276909|COMBINATION_PRODUCT|LUM Imaging System|LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
218952791|NCT04641689|DEVICE|Desk Only|Provision of height-adjustable desk
218952792|NCT04641689|BEHAVIORAL|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
218952793|NCT01459289|OTHER|leaflet|
218952794|NCT01459289|OTHER|counseling and leaflet|
218952795|NCT00254579|DRUG|CP-675,206|15 mg/kg Q12W dosing regimen
218952796|NCT00483756|DRUG|Cyclosporine|Standard of care
218952797|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
219638295|NCT00637000|DRUG|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
219638296|NCT00637000|DRUG|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
218952798|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
218952799|NCT05694377|BEHAVIORAL|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
218952800|NCT04825197|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
218952801|NCT00835029|DRUG|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
218952802|NCT00835029|DRUG|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
219056225|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
219056226|NCT00268125|DEVICE|Acupression's bracelet|
219056227|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
219056228|NCT03185624|DRUG|Rifaximin|Antibiotics
219056229|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
218952803|NCT06070220|BEHAVIORAL|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
218952804|NCT06070220|BEHAVIORAL|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
218952805|NCT02518880|OTHER|Parabolic flight|
218952806|NCT02518880|OTHER|plasma volume measurements|
218952807|NCT01190735|DRUG|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
218952808|NCT03971877|DIAGNOSTIC_TEST|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
218952809|NCT02595632|OTHER|No intervention|
218952810|NCT01908946|BEHAVIORAL|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
218952811|NCT00263861|PROCEDURE|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
218952812|NCT04240080|DEVICE|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
219056230|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
219056231|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
219056232|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
219056233|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
219056234|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
219056235|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
219638297|NCT00637000|DRUG|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
219056236|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
219207049|NCT06761807|PROCEDURE|Electrophysiology study of heart|"The procedure will be done comparatively for each patient; before the device placement and immediately after the procedure.~This will be done approaching the same sheath that is placed for ASD device closure (the right femoral vein).~Only one quadripolar EP catheter will be used, it will be placed in high right atrium then at His bundle.~The EP study will include:~Assessment of SAN function using cSNRT (through HRA pacing) Assessment of AH and HV intervals (through His bundle EGM) Assessment of antegrade AVN RP (refractory period) and AVN WP (Wenckebach point) through extra-stimuli and incremental atrial pacing.~Any inducible arrhythmia will be reported"
219207050|NCT06815900|OTHER|one group .observational study|observational study of this group
219207051|NCT06810414|BEHAVIORAL|Food and alcohol disturbance expectancy challenge|The intervention will focus on strengthening negative FAD expectancies and weakening positive FAD expectancies.
219207052|NCT06776562|OTHER|Exercise|Education on activities of daily living will be provided. In addition, a program including muscle strengthening, neuromuscular control and flexibility exercises for lower extremity and trunk muscles will be performed. Exercise Program will be performed for 8 weeks, 2 sessions per week.
219207053|NCT06776562|OTHER|Control|Education will be provided for activities of daily living. Individuals with dynamic knee valgus in the control group will not receive any intervention. Exercise program will be implemented after the end of the study.
219638298|NCT06220175|DRUG|Strepsils Intensiv plus Xilocaine spray Arm|After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
219638299|NCT06220175|DRUG|Xilocaine Spray Arm|After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
218952813|NCT06261281|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
219638300|NCT03457116|DRUG|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
219638301|NCT03457116|DRUG|NSAID|Ibuprofen 400mg for post-operative pain
218952814|NCT06261281|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
218952815|NCT06261281|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
218952816|NCT00917293|DRUG|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
218952817|NCT00917293|DRUG|Placebo|Placebo 2 pills, po bid.
218952818|NCT04762901|DRUG|Niraparib|Oral tablet
218952819|NCT04762901|DRUG|Doxorubicin|IV
218952820|NCT04762901|DRUG|Cyclophosphamide|IV
218952821|NCT04762901|DRUG|Paclitaxel|IV
218952822|NCT04762901|DRUG|Pegfilgrastim|Injection
218952823|NCT04762901|DRUG|Carboplatin|IV
218952824|NCT06433856|OTHER|Cold Water Immersion|Cold water immersion consists in 12 min standing in 10 °C water
218952825|NCT06433856|DEVICE|Percussive Massage Therapy|Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
218952826|NCT02631473|DRUG|50mg NANO-efavirenz|OD
218952827|NCT02631473|DRUG|400mg NANO-Lopinavir|BID
218952828|NCT02631473|DRUG|200mg NANO-Lopinavir|BID
218952829|NCT02631473|DRUG|100mg Ritonavir|BID
218952830|NCT02631473|DRUG|300mg NANO-Efavirenz|OD
218952831|NCT02631473|DRUG|600mg Sustiva|OD
218952832|NCT02631473|DRUG|200mg NANO-Efavirenz|OD
218952833|NCT02631473|DRUG|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
218952834|NCT02631473|DRUG|+/- 200mg NANO-Lopinavir|BID
218952835|NCT02631473|DRUG|+/- 200mg ritonavir NORVIR|BID
218952836|NCT02631473|DRUG|400mg Sustiva|
218952837|NCT05783427|OTHER|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
218952838|NCT03798119|DRUG|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
218952839|NCT01233518|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
218952840|NCT00495040|RADIATION|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
218952841|NCT02615626|PROCEDURE|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
218952842|NCT03231683|DRUG|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
218952843|NCT03231683|DRUG|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
218952844|NCT03231683|DRUG|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
218952845|NCT03231683|DRUG|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
218952846|NCT01724554|DRUG|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
218952847|NCT00272714|DRUG|Afimoxifene (0.057%) in hydroalcoholic gel|
218952848|NCT02867553|DRUG|rituximab|
218952849|NCT02867553|RADIATION|Multi-fields radiotherapy|
218952850|NCT01892384|DRUG|Placebo|matching placebo
218952851|NCT01892384|DRUG|BI 409306|BI 409306
218952852|NCT00002501|BIOLOGICAL|filgrastim|
219638302|NCT04764370|DEVICE|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
219638303|NCT01281670|OTHER|vibration|8 week vibration
219638304|NCT00467727|OTHER|Phase Contrast Mammography|Standard and magnification views
219638305|NCT04287855|DRUG|Isatuximab|Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle
219638306|NCT04287855|DRUG|Carfilzomib|Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
219638307|NCT04287855|DRUG|Pomalidomide|Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.
219638308|NCT04287855|DRUG|Dexamethasone|Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
218952853|NCT00002501|DRUG|cyclophosphamide|
219056237|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
219056238|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
219056239|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
219056240|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
219056241|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
219056242|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
219638309|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.1 greater or equal to 2 during the drug-off period at baseline
218952854|NCT00592774|DRUG|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
218952855|NCT00592774|DRUG|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
218952856|NCT04641338|DRUG|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
218952857|NCT04641338|DRUG|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
218952858|NCT04641338|DRUG|Codeine|30 mg codeine every 6 hours if necessary.
219056243|NCT00621439|DRUG|Placebo|Patients will receive placebo.
219056244|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
219056245|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
219056246|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
219056247|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
219638310|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.3 greater or equal to 2 during the drug-off period at baseline
219638311|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.10 greater or equal to 2 during the drug-off period at baseline
218952859|NCT06087419|DRUG|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
219056248|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
219638312|NCT06685510|OTHER|the score of UPDRS item|Any one of the MDS UPDRS 3.15-3.17 scores greater or equal to 2 during the drug-off period at baseline
219638313|NCT06685510|OTHER|the score of UPDRS item|Sum of MDS UPDRS 4.1-4.2 scores greater than or equal to 3
219638314|NCT06666010|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
219056249|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
219056250|NCT06571461|DRUG|S-1|S-1: Oral
219056251|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
219056252|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
219056253|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
219056254|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
219207054|NCT06775717|OTHER|Motor Imagery with conventional Treatment|This treatment will be given 5 sessions a week in 4 consecutive weeks.
218952860|NCT06087419|DRUG|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
218952861|NCT06087419|DRUG|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
218952862|NCT05982951|PROCEDURE|Shoulder PENG block|Ultrasound guided insertion of a needle between subscapularis tendon and deltoid with injection of 10 mi 0.25% bupivacaine after confirming right plane of injection
218952863|NCT00714571|BEHAVIORAL|Mnemonic strategy training (MST)|
218952864|NCT00714571|BEHAVIORAL|Repeated exposure (XP)|
218952865|NCT00714571|BEHAVIORAL|Subtracting Cues training|
218952866|NCT00621621|DEVICE|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
218952867|NCT04722055|DIAGNOSTIC_TEST|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
218952868|NCT03206164|OTHER|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
218952869|NCT02229656|RADIATION|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
218952870|NCT02229656|DRUG|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
218952871|NCT02802046|RADIATION|Computed tomographic angiography of coronary artery|
218952872|NCT00000939|DRUG|Hydroxyurea|
219056255|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
219056256|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
219638315|NCT06666010|DRUG|PEX010(01)|The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
219638316|NCT00719238|BEHAVIORAL|Nutrition plus education|Nutritional instruction in small groups plus education
219638317|NCT00719238|BEHAVIORAL|Education only|Educational video and pamphlets
219638318|NCT04313179|OTHER|Music therapy|Mozart lullaby music
219638319|NCT04313179|OTHER|Sucrose|0.5 ml of 24% Sucrose
219638320|NCT01666743|DRUG|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
218952873|NCT00000939|DRUG|Efavirenz|
218952874|NCT00000939|DRUG|Stavudine|
218952875|NCT00000939|DRUG|Didanosine|
219056257|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
219056258|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
219056259|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
219056260|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
219056261|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
219638321|NCT02126423|OTHER|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
218952876|NCT00608569|DRUG|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
218952877|NCT00608569|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
219056262|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
219056263|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
219056264|NCT02097875|DRUG|BLZ-100|
219056265|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
219056266|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
219056267|NCT00393445|DRUG|saline control|intravenous infusion of saline
219056268|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
219056269|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
219056270|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
219056271|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
219056272|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
219056273|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
219056274|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
219056275|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
219207055|NCT06775717|OTHER|Mirror therapy with conventional Treatment.|This treatment will be given 5 sessions a week in 4 consecutive weeks.
219638322|NCT06666140|OTHER|Ultrasonic elastography|"The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive."
219638323|NCT00730795|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
218952878|NCT00608569|DRUG|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
218952879|NCT00608569|DRUG|Zidovudine|300-mg tablet taken orally twice daily
218952880|NCT00608569|DRUG|Emtricitabine|200-mg tablet taken orally once daily
218952881|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
219207056|NCT06742151|PROCEDURE|implant can be placed or not|the possibility of receiving dental implants
219056276|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
219638324|NCT04582058|BEHAVIORAL|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
218952882|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
218952883|NCT02577393|DRUG|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
218952884|NCT01673152|DIETARY_SUPPLEMENT|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
218952885|NCT01673152|DIETARY_SUPPLEMENT|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
218952886|NCT02282293|DRUG|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
218952887|NCT02282293|DRUG|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
218952888|NCT02591329|BEHAVIORAL|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
218952889|NCT02591329|BEHAVIORAL|Standard Care|
218952890|NCT00385476|BEHAVIORAL|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
219056277|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
219056278|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
219056279|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
219056280|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
219056281|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
219056282|NCT02863354|DRUG|Aflibercept|Intravitreal injection
219056283|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
219056284|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
219056285|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
219056286|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
219056287|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
219056288|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
219056289|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
219056290|NCT01281488|DRUG|indocyanine green|Given IV
219638325|NCT04185012|BIOLOGICAL|Benralizumab|Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
218952891|NCT06286176|BEHAVIORAL|Videos with breastfeeding education material and encouraging messages|Distributed videos aim to increase breastfeeding related knowledge and to receive support
218952892|NCT06286176|BEHAVIORAL|Whatsapp group|The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
218952893|NCT03829878|DRUG|CP101|Orally administered donor derived full spectrum microbiota
218952894|NCT03829878|DRUG|Placebo|Placebo for CP101
218952895|NCT00562315|DRUG|FACBC|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
218952896|NCT00562315|OTHER|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
219056291|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
219056292|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
219056293|NCT00726115|DRUG|SAM-531|
219056294|NCT00726115|DRUG|placebo|
219056295|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
219056296|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
219056297|NCT02358746|OTHER|combined endo/epicardial approach|
218952897|NCT05622162|DRUG|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
218952898|NCT05622162|DRUG|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
218952899|NCT03190733|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
218952900|NCT03741478|DRUG|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1"
218952901|NCT03741478|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
218952902|NCT03741478|DRUG|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
218952903|NCT03741478|OTHER|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
218952904|NCT02671916|BEHAVIORAL|questionnaire|Investigation on all study patients, no Intervention, no groups
219056298|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
219056299|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
219056300|NCT01599650|DRUG|Ranibizumab|
219638326|NCT04185012|BIOLOGICAL|Placebo|Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
219638327|NCT04431908|DEVICE|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
219638328|NCT00692848|OTHER|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
219638329|NCT00543972|DRUG|AVE9633|Intravenous Infusion
219638330|NCT02136212|BEHAVIORAL|Approach-positive AAT|
219638331|NCT02136212|BEHAVIORAL|Control AAT|
218952905|NCT04161768|DRUG|Norfloxacin|Norfloxacin 400 mg daily
218952906|NCT04161768|DRUG|Itopride|Itopride 50 mg three times daily
218952907|NCT04976270|DRUG|GLPG3667|GLPG3667 capsules
218952908|NCT04976270|DRUG|Placebo|Matching placebo capsules
218952909|NCT05535205|OTHER|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
218952910|NCT05535205|OTHER|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
218952911|NCT00515424|DRUG|RKI983|
218952912|NCT03538171|DRUG|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
218952913|NCT03538171|DRUG|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
218952914|NCT03538171|DRUG|Exemestane|Exemestane PO once daily on day 1-28.
218952915|NCT03381729|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
218952916|NCT02688322|DRUG|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
218952917|NCT04879147|DIAGNOSTIC_TEST|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
218952918|NCT03712709|DIAGNOSTIC_TEST|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
218952919|NCT04140123|DRUG|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
219056301|NCT01599650|PROCEDURE|Laser|laser photocoagulation
219056302|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
219056303|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
219056304|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
219056305|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
219056306|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
219056307|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
219638332|NCT02791321|OTHER|ADS severity|Evaluation of the ADS severity with the CARS scale
219638333|NCT02791321|OTHER|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
219056308|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
219638334|NCT02791321|OTHER|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
219638335|NCT02076893|DRUG|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
219638336|NCT02076893|DRUG|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
219638337|NCT02076893|DRUG|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
218952920|NCT04140123|DRUG|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
218952921|NCT01587768|DRUG|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
218952922|NCT02787486|OTHER|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
218952923|NCT03758755|DEVICE|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
218952924|NCT03758755|OTHER|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
218952925|NCT05429775|DRUG|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
218952926|NCT04178278|DIAGNOSTIC_TEST|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
218952927|NCT04178278|DIAGNOSTIC_TEST|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
218952928|NCT04178278|DIAGNOSTIC_TEST|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
218952929|NCT02817399|DEVICE|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
218952930|NCT02817399|DEVICE|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
218952931|NCT02817399|PROCEDURE|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
218952932|NCT01264601|BIOLOGICAL|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
219638338|NCT02076893|DRUG|Placebo|Simple syrup suspension
219638339|NCT06620120|DEVICE|Insoles|"At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
218952933|NCT06082973|DEVICE|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
218952934|NCT06082973|DEVICE|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
218952935|NCT02365142|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
218952936|NCT02365142|BIOLOGICAL|Platelet Rich plasma (PRGF)|3 injections of PRGF
218952937|NCT00832039|DRUG|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
218952938|NCT00832039|DRUG|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
218952939|NCT00832039|PROCEDURE|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
218952940|NCT00030004|PROCEDURE|spinal manipulation|
218952941|NCT00030004|DRUG|midazolam|
218952942|NCT05397782|DEVICE|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
218952943|NCT04204980|DRUG|Daratumumab dose escalation|\- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
219638340|NCT06620120|OTHER|Without insoles|"At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
218952944|NCT04204980|DRUG|Daratumumab full dose|\- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
219056309|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
218952945|NCT02622906|DRUG|Pasireotide|60 mg per month of the Pasireotide during 6 months
218952946|NCT02622906|DRUG|Placebo|Vehicule injection per month during 6 months
218952947|NCT00006212|DRUG|cisplatin|
218952948|NCT00006212|DRUG|vinblastine sulfate|
218952949|NCT00006212|RADIATION|phosphorus P32|
219056310|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
219056311|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
219056312|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
219056313|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
219056314|NCT02802345|DRUG|Nintedanib|
219056315|NCT02802345|DRUG|Placebo|
219056316|NCT02802345|DRUG|Sildenafil|
219056317|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
219056318|NCT02155439|DRUG|Triamcinolone|
219056319|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
219056320|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
219056321|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
219056322|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
219056323|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
219056324|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
219638341|NCT01084317|OTHER|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
219056325|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 1 will occur in the lab, and ongoing notifications will be made to the EMG system to test feasibility of automatic stimulation
219367149|NCT00981994|BEHAVIORAL|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
219638342|NCT06968936|DRUG|Sucrose Iron，subcutaneous recombinant human erythropoietin，intravenous vitamin C|Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.
219638343|NCT06968936|PROCEDURE|Routine perioperative management|Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.
218952950|NCT00006212|RADIATION|radiation therapy|
218952951|NCT02000908|DEVICE|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
218952952|NCT02000908|OTHER|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
218952953|NCT02000908|OTHER|Physiotherapy|Chiropractic massage and lymphedema treatment
218952954|NCT01410851|OTHER|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
218952955|NCT05367375|PROCEDURE|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
218952956|NCT05167552|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
218952957|NCT05167552|OTHER|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
218952958|NCT05167552|OTHER|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
218952959|NCT06234332|OTHER|No Interventions|No intervention This is an observational study without any intervention
218952960|NCT01924429|DRUG|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
218952961|NCT01525992|BEHAVIORAL|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
218952962|NCT01525992|OTHER|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
218952963|NCT02680678|OTHER|Colloid Preload|preload infusion
218952964|NCT02680678|OTHER|colloid co-load|co-load infusion
218952965|NCT02680678|OTHER|Crystalloid preload|preload infusion
218952966|NCT02680678|OTHER|Crystalloid Co-load|co-load infusion
218952967|NCT03443947|DEVICE|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
219638344|NCT05326243|BIOLOGICAL|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
219638345|NCT00597610|OTHER|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
219638346|NCT00634803|BEHAVIORAL|CBT|Cognitive behavioral therapy
219638347|NCT00634803|DRUG|Buprenorphine|buprenorphine/naloxone
219638348|NCT00634803|OTHER|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
219638349|NCT00634803|OTHER|Physician Management|Brief physician counseling
218952968|NCT03443947|PROCEDURE|control group|airway assessment after tongue protrusion
218952969|NCT01943357|BEHAVIORAL|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
218952970|NCT01501084|DRUG|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
218952971|NCT01501084|DRUG|Normal saline .2cc subcutaneous injection|sterile saline injection
219056326|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 2 will occur in the home and will assess the quality of the CIMT therapy provided with the automated EMG system.
219056327|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
219056328|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
219056329|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
219056330|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
219056331|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
219056332|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
219056333|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
219056334|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
219638350|NCT00396656|DRUG|Atenolol|100 mg tablets orally once a day (od) in the morning.
219638351|NCT00396656|DRUG|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
219638352|NCT00396656|DRUG|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
218952972|NCT01702181|DRUG|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
218952973|NCT01702181|DRUG|Tacrolimus|0.1% concentration of tacrolimus.
218952974|NCT01702181|DRUG|Placebo|
218952975|NCT01715597|DRUG|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
218952976|NCT01715597|DRUG|Normal saline|normal saline 500ml IV
218952977|NCT01779271|DRUG|Pelubiprofen|
218952978|NCT01779271|DRUG|Loxoprofen|
218952979|NCT03413176|DRUG|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
218952980|NCT05599477|DEVICE|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
218952981|NCT04759183|OTHER|Survey Administration|Ancillary studies
218952982|NCT04759183|PROCEDURE|Virtual Reality Game|"Participate in VR Game Angry Birds"
218952983|NCT04759183|PROCEDURE|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
218952984|NCT00906971|OTHER|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
218952985|NCT04253886|DEVICE|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
218952986|NCT06177275|PROCEDURE|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
218952987|NCT06177275|PROCEDURE|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
218952988|NCT00807573|DRUG|Paclitaxel|Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
218952989|NCT00807573|DRUG|Pemetrexed|Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
218952990|NCT00807573|DRUG|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
219056335|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
219056336|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
219056337|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
219056338|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
219056339|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
219056340|NCT00144573|DRUG|MRA(Tocilizumab)|
219056341|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
218952991|NCT00198887|PROCEDURE|Operations research|
218952992|NCT04392700|DRUG|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
218952993|NCT04392700|DRUG|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
218952994|NCT00266565|DRUG|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
218952995|NCT05580094|OTHER|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
218952996|NCT05580094|OTHER|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
218952997|NCT04757454|DIAGNOSTIC_TEST|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
219056342|NCT02242786|RADIATION|External beam radiation therapy|
219056343|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
219056344|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
219056345|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
219056346|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
219056347|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
219056348|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
219056349|NCT01748994|DRUG|Placebo|
219056350|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
218952998|NCT02434601|PROCEDURE|Treatment of Dentin Surface|"* Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
218952999|NCT02434601|PROCEDURE|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
218953000|NCT02434601|PROCEDURE|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
218953001|NCT05313152|DRUG|TAVO103A|TAVO103A single ascending dose IV infusion.
218953002|NCT05313152|OTHER|Placebo|Placebo single ascending dose IV infusion.
218953003|NCT04054947|BEHAVIORAL|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
218953004|NCT02485678|OTHER|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
218953005|NCT02485678|OTHER|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
218953006|NCT02485678|OTHER|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
218953007|NCT02284672|DRUG|Dexmedetomidine|
218953008|NCT02284672|DRUG|Normal saline|
218953009|NCT05958173|DIETARY_SUPPLEMENT|Capsaicin|Oral stimulation with natural TRPV1 agonist
219056351|NCT00658346|DRUG|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
219056352|NCT00658346|DRUG|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
218953010|NCT05958173|DIETARY_SUPPLEMENT|Piperine|Oral stimulation with natural TRPA1/V1 agonist
218953011|NCT05958173|DIETARY_SUPPLEMENT|Placebo|Oral stimulation with placebo solution
218953012|NCT01606878|DRUG|Crizotinib|Given PO
218953013|NCT01606878|DRUG|Cyclophosphamide|Given IV
218953014|NCT01606878|DRUG|Dexrazoxane Hydrochloride|Given IV
219056353|NCT01628276|BEHAVIORAL|Cog Rehab|Cognitive rehab for MS patients
219056354|NCT03128697|BEHAVIORAL|Satiating diet|
218953015|NCT01606878|DRUG|Doxorubicin Hydrochloride|Given IV
218953016|NCT01606878|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953017|NCT01606878|OTHER|Pharmacological Study|Correlative studies
218953018|NCT01606878|OTHER|Questionnaire Administration|Ancillary studies
218953019|NCT01606878|DRUG|Topotecan Hydrochloride|Given IV
218953020|NCT01606878|DRUG|Vincristine Sulfate|Given IV
218953021|NCT00718562|DRUG|AMN107|
218953022|NCT02012673|DEVICE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
218953023|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and two booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
219056355|NCT03128697|BEHAVIORAL|Control diet|
219366153|NCT03909958|OTHER|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm\*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
219638353|NCT03107039|BEHAVIORAL|Exercise|A 12 week resistance exercise curriculum
218953024|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and one booster session|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
218953025|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) without booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
218953026|NCT02203175|DRUG|saline|Before the anesthesia induction, 5 ml isotonic saline
218953027|NCT02203175|DRUG|fentanyl|before the anesthesia induction 50 mcgr fentanyl
218953028|NCT02203175|DRUG|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
218953029|NCT06367712|DRUG|Letrozole tablets|To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
218953030|NCT05862662|OTHER|MOVE Program|Mobility Opportunities Via Education functional therapy program.
218953031|NCT02449343|DRUG|Anlotinib|Anlotinib p.o. qd
218953032|NCT02449343|DRUG|Placebo|Placebo p.o. qd
218953033|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
218953034|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
218953035|NCT04672382|DRUG|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
218953036|NCT05771883|DRUG|IMM0306|IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.
218953037|NCT05771883|DRUG|Lenalidomide capsule|Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
218953038|NCT04806867|OTHER|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
218953039|NCT02879487|DEVICE|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
218953040|NCT00575393|DRUG|gold sodium thiomalate|
218953041|NCT00575393|GENETIC|gene expression analysis|
218953042|NCT00575393|OTHER|fluorine F 18 fluorothymidine|
218953043|NCT00575393|OTHER|mass spectrometry|
218953044|NCT00575393|OTHER|pharmacological study|
218953045|NCT03217253|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953046|NCT03217253|OTHER|Pharmacological Study|Correlative studies
218953047|NCT03217253|DRUG|Tazemetostat|Given PO
218953048|NCT03594240|DRUG|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
218953049|NCT03594240|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
218953050|NCT05668611|OTHER|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
218953051|NCT05668611|OTHER|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
219367281|NCT05902000|DRUG|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
219638354|NCT03107039|BEHAVIORAL|Health Education|A 12 week health education curriculum
219638355|NCT01553422|OTHER|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
219638356|NCT01553422|OTHER|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
219638357|NCT02957253|OTHER|risk factors|monitoring risk factors due to deterioration of the liver disease
219638358|NCT02957253|OTHER|self-care|information and motivation to adherence to self-care instructions and medical treatment
219638359|NCT02957253|OTHER|nutrition|nutritional assessment and activities to prevent malnutrition
219638360|NCT02957253|OTHER|lifestyle|motivation of lifestyle changes essential for disease progress and
218953052|NCT05668611|OTHER|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
218953053|NCT05668611|OTHER|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
218953054|NCT05668611|OTHER|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
218953055|NCT05668611|OTHER|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
218953056|NCT01900912|OTHER|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
219056356|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
219056357|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
218953057|NCT00074698|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
218953058|NCT03870958|PROCEDURE|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
218953059|NCT03870958|PROCEDURE|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
218953060|NCT04357301|DEVICE|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
218953061|NCT06105671|DRUG|Symbicort|Participants are administered 54 μg Formoterol and 1920 μg Budesonide
219056358|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
219056359|NCT03032003|OTHER|Placebo|2 BID for 15 days
219056360|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
219056361|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
219056362|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
219638361|NCT02957253|OTHER|psychosocial needs|psychosocial care.
219638362|NCT02957253|OTHER|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
219638363|NCT05495100|DRUG|Mitoxantrone liposome、Chidamide、Azacitidine|Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
219638364|NCT01045811|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
218953062|NCT06105671|DRUG|Formoterol|Participants are administered 54 μg Formoterol from an inhaler device
218953063|NCT06105671|DRUG|Formoterol|Participants are administered 120 μg Formoterol in a capsule, which is taken orally
218953064|NCT06105671|DRUG|Placebo|Participants are administered placebo
218953065|NCT06105671|DRUG|Mannitol|Participants are administered 600 mg Bronchitol
219638365|NCT01045811|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
219638366|NCT03177005|BIOLOGICAL|CSL830|
219638367|NCT03411499|PROCEDURE|Early surgery|Surgery within 72 hours from endocarditis diagnosis
218953066|NCT05287360|DRUG|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
219056363|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
219056364|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
219056365|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
219056366|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
219056367|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
219056368|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
219056369|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
219056370|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
219638368|NCT03411499|PROCEDURE|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
219056371|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
219638369|NCT05917184|OTHER|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
219638370|NCT01270984|DRUG|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
219638371|NCT01270984|DRUG|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
219638372|NCT03780881|BEHAVIORAL|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
219638373|NCT03780881|BEHAVIORAL|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
219638374|NCT01965340|OTHER|Systematic Therapeutic Drug Monitoring for the intervention group|
218953067|NCT03570164|DRUG|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
219056372|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
219056373|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
219207057|NCT06855849|DRUG|Amivantamab + FOLFIRI|"The dosage of amivantamab will be based on the participant's body weight during screening. Participants will receive 1,050 mg if BW is \<80 kg or 1,400 mg if BW is ≥80 kg.~* Cycle 1: once weekly (with the first dose split over Day -2 \[350 mg, IVF for 4-6hrs\] and Day -1 \[remainder of the dose, IVF for 6-8hrs\]; subsequent dose \[planned dose IVF over 2 hrs\]).~* Cycles 2+: Days 1 and 15 of each cycle (planned dose IVF over 2 hrs) On days when both amivantamab and chemotherapy are administered, amivantamab should be administered before chemotherapy. In general, leucovorin 400 mg/m2 IV over 2 hours and irinotecan 180 mg/m2 IV over 90 min, then 5-FU 400 mg/m2 IV bolus followed by 5-FU continuous infusion 2,400 mg/m2 over approximately 46-48 hours or 1,200 mg/m2/day for two days. Irinotecan and leucovorin may be administered concurrently (via separate infusion lines) or sequentially according to the institutional standard."
219638375|NCT05627505|DIAGNOSTIC_TEST|metagenomic next-generation sequencing|Collection of bronchoalveolar lavage fluid
219638376|NCT04768413|OTHER|Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
219638377|NCT04768413|OTHER|Care modalities. Quantitative and qualitative approaches to analysis|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
219638378|NCT04836013|DIETARY_SUPPLEMENT|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
219638379|NCT04836013|OTHER|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
219638380|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP)|"The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
218953068|NCT03570164|DRUG|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
218953069|NCT00627276|DIETARY_SUPPLEMENT|omega-3 fatty acid|Oral, 3 times daily
218953070|NCT00627276|OTHER|placebo|Oral, 3 times daily
218953071|NCT01301898|DRUG|GC1111_0.5mg/kg|
218953072|NCT01301898|DRUG|GC1111_1.0mg/kg|
218953073|NCT01301898|DRUG|Elaprase_0.5mg/kg|
218953074|NCT01265264|DRUG|ulodesine|Oral dose administered daily for 84 days.
218953075|NCT01265264|DRUG|Placebo|Oral dose administered daily for 84 days.
218953076|NCT03736902|OTHER|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
218953077|NCT01634191|DRUG|Apremilast|One oral 30 mg dose of apremilast
218953078|NCT00551304|DEVICE|Ardian Catheter|
218953079|NCT04482023|BEHAVIORAL|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
218953080|NCT02076425|BEHAVIORAL|PCIT-ED|
218953081|NCT03345966|DIAGNOSTIC_TEST|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
218953082|NCT04006600|PROCEDURE|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
218953083|NCT04408378|OTHER|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
218953084|NCT00118456|DRUG|AEE788|
218953085|NCT02070198|DRUG|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
218953086|NCT02070198|DRUG|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
218953087|NCT02070198|DRUG|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
218953088|NCT02230488|OTHER|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~\--------------------------------------------------------------------------------"
218953089|NCT06981429|BEHAVIORAL|Nourish to Flourish: The Power of Positive Food Parenting|This intervention focuses on increasing diet quality and parent use of positive food parenting practices with the goal of promoting healthy child growth). This will be a 12 - week, 12 session study. Sessions 1 and 12 will consist of collection baseline and post-intervention data. Sessions 2 - 11 will be a mix of online - group sessions and individual online or in - person sessions (based on participant preference). The group sessions are focused on principal investigator presentation of the intervention curriculum and group discussion. The individual sessions are focused on goal setting, coping planning, and working through individual situations with a trained coach.
218953090|NCT02691585|OTHER|Music Intervention|A raga will be played for 10 minutes \& data collected.
218953091|NCT00970619|DEVICE|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
219056374|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
219056375|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
219056376|NCT01159067|DRUG|deferasirox|Given orally
219056377|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
219056378|NCT01849341|DRUG|Roflumilast 500 mcg per day|
219056379|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
218953092|NCT03763513|DEVICE|ESWT|Extracorporeal Shock Wave Therapy=ESWT
218953093|NCT03763513|OTHER|Kinesiotaping Application|Kinesiotaping=KT (CT)
218953094|NCT00156936|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
218953095|NCT00156936|DRUG|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
218953096|NCT02491359|DRUG|Carfilzomib|Given IV
218953097|NCT02491359|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953098|NCT02491359|OTHER|Quality-of-Life Assessment|Ancillary studies
218953099|NCT02491359|OTHER|Questionnaire Administration|Ancillary studies
218953100|NCT02324127|DEVICE|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
218953101|NCT01962324|RADIATION|SIB Dose-Escalation Radiotherapy|
218953102|NCT05917782|BIOLOGICAL|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
218953103|NCT05917782|BIOLOGICAL|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|subcutaneous injection of 1 dose on Day 1
218953104|NCT05917782|BIOLOGICAL|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
218953105|NCT02364401|DEVICE|Ablation|Catheter ablation for atrial fibrillation
218953106|NCT00000682|DRUG|Zidovudine|
218953107|NCT00000682|DRUG|Zalcitabine|
218953108|NCT03703401|DIAGNOSTIC_TEST|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
218953109|NCT06476054|PROCEDURE|Optimal timing for laparoscopic cholecystectomy|To compare early and late cholecystectomy after cholecystostomy.
219056380|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
219056381|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
219056382|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
219056383|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
219056384|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
219056385|NCT04336969|BEHAVIORAL|4T Education and Care|CGM data will be used to create customized weekly or monthly feedback to the participant/family by secure MyChart message.
219056386|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
219056387|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
219056388|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
219056389|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
219056390|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
219056391|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
218953110|NCT02880956|DRUG|ABBV-8E12|ABBV-8E12 solution for IV infusion
218953111|NCT02880956|DRUG|placebo for ABBV-8E12|placebo solution for intravenous (IV) infusion
218953112|NCT06988644|DIAGNOSTIC_TEST|exhaled carbon monoxyde measurement|At the initial tobacco consultation: measurement of exhaled carbon monoxyde. At the tobaccology consultation at 12 months, measurement of the cessation rate: no tobacco smoked in the last 7 days (self-reported), confirmed by a measurement of exhaled carbon monoxyde \< 9 ppm.
218953113|NCT06426524|PROCEDURE|IGF-1 Gel|After degranulation of the defect, IGF-1 gel mixed with Hydroxyapatite graft will be placed in the defect.
218953114|NCT06426524|PROCEDURE|Hydroxyapatite|After degranulation of the defect, Hydroxyapatite graft will be placed in the defect.
218953115|NCT05604378|PROCEDURE|Gastrectomy|All patients in our study underwent gastrectomy.
219056392|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
219056393|NCT00374777|DRUG|zolpidem MR|oral
218953116|NCT00853970|DRUG|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
218953117|NCT00853970|DRUG|Placebo Comparator|sterile ophthalmic solution
218953118|NCT05129033|DRUG|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
218953119|NCT05129033|DRUG|itraconazole|Anti-fungal medication to reduce fugal load.
218953120|NCT05129033|BIOLOGICAL|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
218953121|NCT05750199|OTHER|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
218953122|NCT05750199|OTHER|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
218953123|NCT06994052|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous injection
219056394|NCT00374777|DRUG|nitrazepam|oral
219056395|NCT00374777|DRUG|placebo|oral
219056396|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
218953124|NCT06995066|PROCEDURE|collagenase injection into the epidural space|"The Collagenase injection into the epidural space is a medical procedure for treating cervical disc herniation. Firstly, the patient is positioned, and the specific location of the epidural space at the affected cervical spine segment is accurately identified with the guidance of imaging devices like fluoroscopy or CT. After local anesthesia, a special puncture needle is inserted into the epidural space following the marked path. Once the needle is in the correct position, an appropriate amount of collagenase solution is slowly injected. After the operation, the patient needs to stay in the hospital for observation to monitor vital signs and neurological conditions. The patient should rest in bed for a certain period and then gradually engage in proper activities. Additionally, personalized rehabilitation treatment plans, including physical therapy and exercise, are usually required to help with recovery."
218953125|NCT06995573|DRUG|NSC001|rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
218953126|NCT06995573|OTHER|Placebo|matching placebo to NSC001
219056397|NCT03251924|DRUG|BMS-986226|specified dose on specified days
219056398|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
219056399|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
219056400|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
219056401|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
219056402|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
219056403|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
219056404|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
219638381|NCT03474731|BEHAVIORAL|Tailored Patient Navigation (PN) only|"Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly.~The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs."
219638382|NCT03474731|BEHAVIORAL|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.
219638383|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP) Delayed|"Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview.~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
219638384|NCT04091789|DRUG|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
219638385|NCT06063642|DEVICE|Neurofeedback training|Neurofeedback training is a type of non-invasive brain modulation technique that enables individuals to self-regulate brain activity patterns by providing them feedback on specific activity measures. Effective self-regulation is often linked to changes in cognition, behavior, and clinical symptoms.
218953127|NCT06995001|DRUG|SHR-2173|SHR-2173 injection dose 1；
219056405|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
219056406|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
219056407|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
219056408|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
218953128|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 2 ；Pacebo dose 2
218953129|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 3 ；Pacebo dose 3
219056409|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
219056410|NCT00059475|DRUG|Montanide ISA 51|
219056411|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
219056412|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
219056413|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
219056414|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
219056415|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
219056416|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
219056417|NCT02041455|DRUG|Melatonin and Placebo|
219056418|NCT02041455|DRUG|Amitriptyline and Placebo|
219056419|NCT02041455|DRUG|Melatonin and Amitriptylin|
219056420|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
219056421|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
219056422|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
219056423|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
219056424|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
219056425|NCT00151645|DRUG|activated lymphocytes|
219056426|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
219056427|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
219056428|NCT06205290|DRUG|Rituximab|Specified dose on specified days
218953130|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 4 ；Pacebo dose 4
218953131|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 5 ；Pacebo dose 5
219056429|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
219056430|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
219056431|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
219056432|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
219638386|NCT06063642|DEVICE|Sham feedback training|A controlled form of neurofeedback training that provides feedback irrelevant to the targeted mental process.
218953132|NCT01648556|OTHER|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
218953133|NCT01889745|DRUG|HX-1171|Anti-oxidatant, Anti-inflamation
219056433|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
219056434|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
219056435|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
219056436|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
219056437|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
219056438|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
219056439|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
219056440|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
219056441|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
219638387|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
219638388|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
219638389|NCT05107193|DRUG|afatinib|afatinib
219638390|NCT01365078|DIETARY_SUPPLEMENT|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
219056442|NCT02617589|DRUG|Nivolumab|
219638391|NCT01365078|DIETARY_SUPPLEMENT|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
219638392|NCT01826513|DEVICE|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
219056443|NCT02617589|DRUG|Temozolomide|
219056444|NCT02617589|RADIATION|Radiotherapy|
219056445|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
219056446|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
219056447|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
219056448|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
219056449|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
219056450|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
219056451|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
219056452|NCT00002980|DRUG|decitabine|
219056453|NCT00463450|DRUG|Gynodian® Depot (BAY86-5032)|Injection monthly
219056454|NCT00463450|DRUG|BAY86-4980|orally
219056455|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
219056456|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
219056457|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
219056458|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
219056459|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
218953134|NCT04514354|BEHAVIORAL|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
218953135|NCT05520164|OTHER|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
218953136|NCT02276027|DRUG|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
218953137|NCT02276027|DRUG|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
219056460|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
219638393|NCT01826513|DEVICE|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
219638394|NCT03512613|DEVICE|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
219638395|NCT05679102|DRUG|Amlodipine 5 MG Oral Tablet|one group will be given only Amlodipine 5MG once daily
219638396|NCT05679102|DRUG|Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet|one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily
219638397|NCT04637711|PROCEDURE|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
219638398|NCT03710382|OTHER|Walking epidural|Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
219638399|NCT05478161|DEVICE|(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
219638400|NCT01718678|DRUG|Melatonin|it is kind of drug
219638401|NCT01718678|DRUG|Placebo|It is Placebo
219638402|NCT02976558|BEHAVIORAL|Clown theatrical Performance|
219638403|NCT02976558|PROCEDURE|Acupuncture|Acupuncture according to Traditional Chinese Medicine
219638404|NCT02976558|BEHAVIORAL|Music Therapy TaKeTiNa|
219638405|NCT00666822|BEHAVIORAL|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
219638406|NCT00666822|OTHER|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
219638407|NCT00666822|OTHER|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
219638408|NCT06318988|PROCEDURE|Radiofrequency ablation using Closure fast|Thermal ablation technique
219638409|NCT06318988|PROCEDURE|Aethoxysclerol|sclero-or foamsclerose
219638410|NCT06318988|DRUG|Daflon|Venoactive drugs
219638411|NCT06318988|DEVICE|Compression stocking|Compression
219638412|NCT01218087|DEVICE|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
219638413|NCT01218087|DEVICE|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
219638414|NCT03979053|DEVICE|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
219638415|NCT00552396|DRUG|Anti-KIR (1-7F9)|human monoclonal antibody
218953138|NCT02276027|DRUG|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
219056461|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
219056462|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
219056463|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
219056464|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
219056465|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
219056466|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
219056467|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
219056468|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
219056469|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
219056470|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
219056471|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
219638416|NCT00203619|DEVICE|Wireless capsule endoscopy|wire less capsule endoscopy
219638417|NCT00203619|OTHER|standard care|standard diagnostic evaluation as decided by treating physician
219638418|NCT04402762|DRUG|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
219638419|NCT04402762|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
219638420|NCT03025529|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.
219638421|NCT03025529|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
219638422|NCT04185220|DRUG|Recombinant human Interleukin-15 (rhIL-15)|Interleukin 15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation 3 + 3 system with a starting dose of 2 mcg/kg/day and a second dose level of 4 mcg/kg/day on days 1-5 of each of six cycles.
219638423|NCT04185220|BIOLOGICAL|Mogamulizumab|Mogamulizumab (intravenous (IV) over at least 1 hour) will be administered at a dose of 1 mg/kg on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle. Treatment will continue for a maximum of 6 cycles.
219638424|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
219638425|NCT02097329|DRUG|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
219638426|NCT02097329|DRUG|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
219056472|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
219056473|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
219056474|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
219056475|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
219056476|NCT06966323|BEHAVIORAL|Hold me Tight / Let me Go|"Hold Me Tight / Let Me Go (HmT/LmG) is a manualized, group-based behavioral intervention for parents of adolescents aged 12 to 18. Grounded in Emotionally Focused Therapy (EFT) and Hold me Tight for couples. HmT/LmG aims to improve the parent-adolescent relationship by enhancing emotional validation, secure attachment, and effective communication.~The intervention consists of four group sessions for parents, supplemented by three structured individual or dyadic sessions involving both parents and adolescents. Key components include psycho-education, role plays, emotion-focused conversations, and exercises targeting validation, apologizing, and supportive limit setting. Families complete pre- and post-intervention questionnaires and a follow-up assessment to evaluate changes in relationship quality and psychological well-being."
219056477|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
219056478|NCT05918679|BEHAVIORAL|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
219056479|NCT05918679|BEHAVIORAL|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
219056480|NCT05918679|BEHAVIORAL|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
219638427|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
219638428|NCT02097329|DRUG|antacid|30 mL orally once (2h before palbociclib)
219638429|NCT02097329|DRUG|antacid|30 mL orally once (2h after palbociclib)
218953139|NCT02276027|DRUG|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
218953140|NCT04300959|DRUG|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
218953141|NCT04300959|DRUG|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
218953142|NCT00316550|DRUG|AV608|
218953143|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|150,000 IU orally given once
218953144|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU given orally daily for 28 days
218953145|NCT04450810|OTHER|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
218953146|NCT03475953|DRUG|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
218953147|NCT03475953|DRUG|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
218953148|NCT03475953|DRUG|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
218953149|NCT03475953|DRUG|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
219056481|NCT05918679|BEHAVIORAL|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
219056482|NCT05918679|BEHAVIORAL|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
219056483|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
219056484|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
219056485|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
219056486|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
219056487|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
219056488|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
218953150|NCT03475953|DRUG|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
219056489|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
218953151|NCT03923803|DIAGNOSTIC_TEST|C- reactive protein|the measurement will be done by chemileumeniscence
218953152|NCT03923803|DIAGNOSTIC_TEST|Pro calcitonin|the measurement will be done by chemileumeniscence
218953153|NCT03272789|OTHER|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
219056490|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
219056491|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
219056492|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
219056493|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
219638430|NCT01478776|DIETARY_SUPPLEMENT|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
218953154|NCT01577810|DEVICE|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
218953155|NCT03224598|DRUG|A-101 Topical Solution 40%|A-101 Topical Solution 40%
218953156|NCT02259075|DRUG|Botulinum Toxin Type A|
218953157|NCT01266720|BIOLOGICAL|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
218953158|NCT01266720|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
218953159|NCT03233269|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
218953160|NCT05252260|PROCEDURE|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
218953161|NCT05252260|PROCEDURE|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
218953162|NCT05252260|OTHER|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
218953163|NCT02183103|DRUG|meloxicam rapid release tablet, 12mg, UH AC62MU|
219056494|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
218953164|NCT02361476|DRUG|Clonidine|Injection - during surgery
218953165|NCT02361476|DRUG|Placebo|Injection - during surgery
219056495|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
219056496|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
219056497|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
219056498|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
219056499|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
219056500|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
219056501|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
219056502|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
218953166|NCT04281238|OTHER|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
219056503|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
219056504|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
218953167|NCT04281238|OTHER|Control group|Home exercises 5 days a week for 8 weeks
219056505|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
219056506|NCT04057495|OTHER|further fasting|2 hours of fasting
219056507|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
219056508|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
219056509|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
219056510|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
219056511|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
219056512|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
218953168|NCT04617873|PROCEDURE|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
218953169|NCT03402048|DRUG|Carboplatin|
218953170|NCT03402048|DRUG|Gemcitabine|
218953171|NCT03402048|DRUG|Pemetrexed|
218953172|NCT03402048|DRUG|Docetaxel|
218953173|NCT03402048|DRUG|Vinorelbine|
218953174|NCT00335231|DRUG|gatifloxacin ophthalmic (ZYMAR)|
218953175|NCT00005031|DRUG|irofulven|
219056513|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
219056514|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
219056515|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
219056516|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
219056517|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
219056518|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
219638431|NCT01478776|DIETARY_SUPPLEMENT|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
218953176|NCT06171308|DEVICE|Traditional Chinese moxibustion apparatus|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
218953177|NCT04562753|PROCEDURE|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
218953178|NCT04562753|PROCEDURE|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
219056519|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
219056520|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
219056521|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
219638432|NCT01763060|RADIATION|CT scan|
218953179|NCT02767544|PROCEDURE|Vaginal wound local analgesia after laparoscopic hysterectomy|
218953180|NCT00953459|DRUG|sunitinib malate|
218953181|NCT00953459|OTHER|laboratory biomarker analysis|
218953182|NCT00953459|RADIATION|fludeoxyglucose F 18|
219056522|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
219056523|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
219638433|NCT01763060|BEHAVIORAL|Cognitive function|
219638434|NCT01763060|RADIATION|MRI|
219638435|NCT01045382|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cell injection
219638436|NCT01045382|OTHER|Isotonic solution|Isotonic solution injection
219638437|NCT01600027|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
219638438|NCT01600027|PROCEDURE|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
219638439|NCT00604591|DRUG|Tolcapone|200 mg by mouth three times a day
219638440|NCT00604591|DRUG|Placebo|200 mg by mouth three times a day
219638441|NCT05129865|DRUG|LYT-300|A prodrug of allopregnanolone, a small molecule drug
219638442|NCT05129865|OTHER|Placebo|Placebo for LYT-300
219638443|NCT06349291|DIAGNOSTIC_TEST|Detection of venous thrombosis via US|Detection of venous thrombosis via US in patients after removal of central venous catheter
219638444|NCT01573832|OTHER|integrated client care group|receives integrated client care for wound treatment
219367282|NCT05902000|DRUG|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
219638445|NCT03162653|DRUG|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
219638446|NCT03162653|DRUG|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
219638447|NCT01186692|DEVICE|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
218953183|NCT01000038|OTHER|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
218953184|NCT01000038|OTHER|Walking|Half hour daily, five days a week for 8 weeks
218953185|NCT01653379|DRUG|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
218953186|NCT04652596|OTHER|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
219638448|NCT05421182|OTHER|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
219638449|NCT05421182|OTHER|Hospital Anxiety and Depression scale|to measure anxiety and depression
219638450|NCT05421182|OTHER|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
219638451|NCT05421182|OTHER|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
219638452|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
219638453|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
218953187|NCT04652596|OTHER|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
218953188|NCT00007007|PROCEDURE|management of therapy complications|
218953189|NCT00007007|PROCEDURE|quality-of-life assessment|
218953190|NCT03733431|DEVICE|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
218953191|NCT03733431|DEVICE|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
218953192|NCT04254042|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
218953193|NCT04254042|DRUG|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
218953194|NCT00729222|DRUG|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
218953195|NCT00729222|DRUG|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
218953196|NCT03355443|PROCEDURE|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
218953197|NCT03355443|PROCEDURE|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
218953198|NCT04002570|OTHER|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
218953199|NCT00562900|PROCEDURE|robotic assisted cholecystectomy|robotic assisted cholecystectomy
219638454|NCT00957320|DRUG|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
219638455|NCT00957320|DRUG|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
219638456|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
218953200|NCT00562900|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
218953201|NCT06200142|DIAGNOSTIC_TEST|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
218953202|NCT06200142|GENETIC|WES and WGS|WES reanalysis and WGS analysis
218953203|NCT04048785|OTHER|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
218953204|NCT04689412|DRUG|Resveratrol|Nasal administration of resveratrol
218953205|NCT00103727|DRUG|Talnetant|talnetant
218953206|NCT00103727|OTHER|placebo|Placebo Comparator
218953207|NCT00103727|OTHER|risperidone|Active Comparator
218953208|NCT06246942|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).
218953209|NCT06246942|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).
218953210|NCT06246942|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
219638457|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
219638458|NCT06001307|BEHAVIORAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|See description to the left.
219638459|NCT06001307|BEHAVIORAL|Relaxation and Stress Reduction|See description to the left.
219638460|NCT04211675|BIOLOGICAL|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
218953211|NCT00830791|DRUG|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
218953212|NCT00830791|DRUG|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
219207058|NCT06702046|DEVICE|transcutaneous pulsed radiofrequency acupuncture|For the TCPRF acupuncture group, the investigators choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
219638461|NCT04211675|DRUG|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
219638462|NCT04211675|DRUG|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
219638463|NCT04211675|DRUG|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
219638464|NCT04211675|DRUG|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
218953213|NCT03206996|BEHAVIORAL|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
218953214|NCT03206996|BEHAVIORAL|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
219056524|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
219056525|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
219056526|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
219638465|NCT03232931|BEHAVIORAL|Therapist skin-to-skin Care|"Skin-to-skin (STS) holding is part of the multisensory intervention where the therapist will wear a clean 100% cotton T-shirt with a clean hospital gown on top of the shirt and wrap the kangaroo positioner securely over the gown. A gauze square scented with parent's skin will be used to provide olfactory stimulation. Therapist STS sessions occur with simultaneous playing of mother's voice contingent on infant pacifier sucking."
219056527|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
219056528|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
219056529|NCT04699331|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
219056530|NCT03437200|DRUG|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
219056531|NCT03437200|DRUG|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
219056532|NCT03437200|OTHER|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
219056533|NCT02149342|DRUG|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
219056534|NCT02149342|DRUG|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
219056535|NCT00000707|DRUG|Pentamidine isethionate|
219056536|NCT03467633|BEHAVIORAL|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
219056537|NCT00038922|DRUG|rhIL-11|
219367283|NCT00963950|PROCEDURE|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
218953215|NCT03206996|BEHAVIORAL|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
218953216|NCT01527357|BIOLOGICAL|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
218953217|NCT01527357|BIOLOGICAL|Gelatin sponge|Absorbable gelatin sponge for topical administration.
218953218|NCT02630199|DRUG|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
218953219|NCT02630199|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
219056538|NCT01334866|PROCEDURE|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
219056539|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
219056540|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
219056541|NCT05859295|DEVICE|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
219056542|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
219056543|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
218953220|NCT04897139|DRUG|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
218953221|NCT06129357|BEHAVIORAL|180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).|Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
218953222|NCT02850081|DRUG|Statin|"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"
219056544|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
219056545|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
219056546|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
219056547|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
219056548|NCT02210429|PROCEDURE|Elbow Fracture Fixation|
219056549|NCT00482079|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
219056550|NCT00482079|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
219056551|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
219056552|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
219056553|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
219056554|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
219056555|NCT04596540|OTHER|Placebo|Normal saline
219056556|NCT03228004|BEHAVIORAL|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
218953223|NCT02850081|DRUG|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
218953224|NCT02850081|OTHER|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
218953225|NCT06061614|GENETIC|NGGT002|NGGT002
218953226|NCT02446171|DRUG|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
219056557|NCT05961774|DEVICE|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
219056558|NCT05961774|DEVICE|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
219056559|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
219056560|NCT02044536|OTHER|No intervention|retrospective data review
219056561|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
219056562|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
218953227|NCT02446171|DRUG|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
218953228|NCT02446171|DRUG|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
218953229|NCT02446171|DRUG|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
219056563|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
219056564|NCT02966171|DRUG|HMPL-453|oral administration
219056565|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
219056566|NCT04317248|DRUG|Cyclophosphamide|Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
219056567|NCT04317248|BIOLOGICAL|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
219056568|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
219056569|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
219638466|NCT03232931|DEVICE|Contingent parent's voice exposure|The Pacifier Activated Lullaby® (PAL®) device, is a digital music delivery system that integrates a sensor, a pacifier routinely used in the NICU, and a receiver. It delivers a predetermined 10 seconds of recorded parent's voice singing lullabies upon detection of a suck that meets a preset pressure threshold. The original systems were modified for research use by decreasing the lower limit of activation thresholds for delivering the recording. Minimal effort is required to trigger the device. However, the settings ensure that regular attempts are needed to continue to receive continual presentation of the recording of mother's voice by requiring another suck after 10 seconds. The auditory stimulation with PAL will be provided when the infants are still awake (i.e., at the beginning of the session).
219056570|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
219056571|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
219056572|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
219056573|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
218953230|NCT03363022|DRUG|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
219056574|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
219056575|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
219056576|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
219638467|NCT03232931|BEHAVIORAL|Parental skin-to-skin care|The standard of care includes parental skin-to-skin care and exposure to parent's voice. During parental skin-to-skin care, infants are placed in a prone position with head positioned over the sternum, allowing transmission of breath and heart sounds to the developing ear. Deeper pressure is applied to offer support and feedback to the child's bottom. Session length is set to a minimum of 45 minutes per unit protocols.
218953231|NCT03363022|OTHER|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
218953232|NCT03363022|OTHER|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
218953233|NCT03021174|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
218953234|NCT03021174|BEHAVIORAL|Nutrition Education Control|12 weeks of implementing eating tips
218953235|NCT04531462|DRUG|Empagliflozin|Empagliflozin
218953236|NCT04531462|DRUG|Placebo|Placebo
218953237|NCT00504582|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
218953238|NCT04197687|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
218953239|NCT04197687|BIOLOGICAL|Pertuzumab|permitted at physician's discretion
218953240|NCT04197687|OTHER|Placebo Administration|Given ID
218953241|NCT04197687|BIOLOGICAL|Sargramostim|Given ID
218953242|NCT04197687|BIOLOGICAL|Trastuzumab|therapy are at the discretion of the treating physicians
218953243|NCT04197687|BIOLOGICAL|Trastuzumab Emtansine|at the discretion of the treating physicians.
218953244|NCT00005001|BIOLOGICAL|HIV-1 Immunogen|
218953245|NCT04175509|DRUG|Rectal acetaminophen|Rectal 1300mg
218953246|NCT04175509|DRUG|Intravenous acetaminophen|Intravenous 1000mg
218953247|NCT02292784|DRUG|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
218953248|NCT02292784|DRUG|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
218953249|NCT02292784|DRUG|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
219056577|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
219056578|NCT01985737|OTHER|Sample collection|
219056579|NCT01600586|DEVICE|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
219207059|NCT06702046|DEVICE|Sham Comparison|same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
219638468|NCT03232931|DEVICE|Recorded parent's voice|Per standard of care, preterm infants in the NICU currently receive noncontingent recorded parents' voice during two 20 minute sessions per day. Recordings are standardized and are played through a sterilizable device (DINO-egg).
219638469|NCT04594980|PROCEDURE|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
219638470|NCT04294979|OTHER|Physical Therapy|The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.
218953250|NCT00348933|DRUG|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
218953251|NCT00348933|DRUG|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
218953252|NCT00348933|DRUG|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
218953253|NCT00348933|DRUG|Vitamin B12|1 mg by mouth per day for all weights and ages
218953254|NCT01264081|DRUG|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
218953255|NCT01489111|DRUG|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
218953256|NCT04988633|BEHAVIORAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
219056580|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
219056581|NCT01588912|DRUG|Telbivudine|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
219056582|NCT01588912|DRUG|Tenofovir|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
219056583|NCT01588912|DRUG|Entecavir|Maintain the entecavir through the study period
219056584|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
219056585|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
219056586|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
219056587|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
218953257|NCT04988633|BEHAVIORAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
218953258|NCT05972603|PROCEDURE|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
218953259|NCT05972603|PROCEDURE|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
218953260|NCT00134784|DRUG|[123I]B-CIT SPECT imaging|To assess \[123I\]B-CIT SPECT imaging
218953261|NCT02065271|DIETARY_SUPPLEMENT|herbal supplement|
218953262|NCT02065271|OTHER|placebo supplement|
218953263|NCT01889095|DRUG|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
218953264|NCT01889095|DRUG|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
219367284|NCT00963950|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
219638471|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
219638472|NCT06957574|DRUG|Bubpivacaine|ESPB using local anesthetic 20 ml 0.25% bupivacaine on each side
218953265|NCT02732197|DRUG|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
218953266|NCT02732197|DRUG|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
218953267|NCT04444427|DRUG|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
218953268|NCT05363943|PROCEDURE|double plating|open reduction and internal fixation by using lateral and medial plates.
218953269|NCT05363943|PROCEDURE|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
218953270|NCT00919841|OTHER|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
218953271|NCT04767308|BIOLOGICAL|CT125A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.
218953272|NCT04767308|DRUG|Cyclophosphamide, fludarabine|Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
218953273|NCT04698850|DRUG|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
218953274|NCT04698850|DRUG|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
218953275|NCT04698850|DRUG|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
218953276|NCT00621400|DRUG|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
218953277|NCT00621400|DRUG|Melphalan|0,18mg/Kg/day from day 1- 4
218953278|NCT00621400|DRUG|Dexamethasone|40mg/day from day 1- 4.
218953279|NCT05143190|DRUG|PTR-01|Intravenous recombinant collagen 7
218953280|NCT01991639|OTHER|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
218953281|NCT00333203|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
218953282|NCT00333203|OTHER|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
218953283|NCT02641483|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
218953284|NCT05089201|BEHAVIORAL|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
218953285|NCT05089201|BEHAVIORAL|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
219056588|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
219056589|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
219207060|NCT06740994|PROCEDURE|conventional landmark paramedian technique|"a blind landmark scanning will be done and skin marking of the best palpable spinous process will be made.~the site of injection will be determined by palpation. continuous spinal anesthesia will be performed via paramedian approach."
219638473|NCT06957574|DRUG|Normal Saline (Placebo)|ESPB using normal saline 20 ml 0.25% bupivacaine on each side
219638474|NCT06225011|DRUG|Fluoxetine|Receive PO
219056590|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
219056591|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
219056592|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
219056593|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
219056594|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
219056595|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
219056596|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
219056597|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
218953286|NCT04322201|DEVICE|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
218953287|NCT04322201|PROCEDURE|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
218953288|NCT03705624|OTHER|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
218953289|NCT03705624|OTHER|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
219056598|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
219638475|NCT04556266|BIOLOGICAL|CAR T-Cell Infusion|Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
219638476|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
219638477|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
219638478|NCT06433921|DRUG|Salbutamol HFA-152a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
219638479|NCT06433921|DRUG|Salbutamol HFA-134a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
219638480|NCT06433921|DRUG|Placebo|A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
219638481|NCT04925557|DRUG|Mayzent|PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
219638482|NCT04925557|DRUG|Ocrevus|PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
219638483|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
219638484|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
219638485|NCT06356025|DRUG|botulinum toxin type A|Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter
219638486|NCT06356025|DRUG|Sodium Chloride 0.9% Inj|Placebo: physiological serum 3mL injection in the upper esophageal sphincter
219638487|NCT05488470|DEVICE|LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.
218953290|NCT02316873|BEHAVIORAL|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
218953291|NCT02316873|BEHAVIORAL|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
218953292|NCT05238571|PROCEDURE|Re-surgery|Re-surgery with meshectomy and selective neurectomy
218953293|NCT03117088|OTHER|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
218953294|NCT03117088|OTHER|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
218953295|NCT04653532|BEHAVIORAL|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
218953296|NCT04653532|DEVICE|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
219056599|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
219056600|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
219056601|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
219638488|NCT05221554|PROCEDURE|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
219638489|NCT05221554|PROCEDURE|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
219638490|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
219638491|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
219638492|NCT03431090|DEVICE|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
219638493|NCT03524326|DRUG|Lenvatinib Pill|24 mg oral daily
218953297|NCT05101551|DRUG|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
218953298|NCT05101551|DRUG|Topotecan|"Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
218953299|NCT05101551|DRUG|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
218953300|NCT04941625|DIAGNOSTIC_TEST|serum cystatin C|blood sampling
218953301|NCT04941625|DIAGNOSTIC_TEST|serum beta-microglubulin|blood sampling
218953302|NCT04941625|DIAGNOSTIC_TEST|urine|neutrophil gelatinase-associated lipocalin
218953303|NCT04892368|OTHER|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
218953304|NCT05407740|OTHER|no intervention study|no intervention study
218953305|NCT03811093|DEVICE|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
218953306|NCT03811093|DEVICE|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
218953307|NCT00476567|OTHER|standard|standard antenatal care
219638494|NCT03524326|DRUG|Lenvatinib Pill|20 mg oral daily
219638495|NCT03524326|DRUG|Lenvatinib Pill|14 mg oral daily
219638496|NCT03524326|DRUG|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
219638497|NCT03524326|DRUG|Lenvatinib Pill|10 mg oral daily
218953308|NCT00476567|BEHAVIORAL|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
218953309|NCT00464490|DRUG|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
218953310|NCT00164697|BEHAVIORAL|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
218953311|NCT06406153|BIOLOGICAL|Laronidase|Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
218953312|NCT06406153|DRUG|Antihistamine|An antihistamine is administered one hour before the infusion.
219056602|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
219367285|NCT05927883|BEHAVIORAL|Indigenously Adapted Cognitive Behavioral Therapy|IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
219638498|NCT03524326|DRUG|Lenvatinib Pill|4 mg oral daily
219638499|NCT05707637|OTHER|Ablation|Unipolar and bipolar ablation
219638500|NCT02966730|DRUG|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
219638501|NCT04730011|BEHAVIORAL|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
219638502|NCT05917587|DRUG|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
218953313|NCT06406153|DRUG|Antipyretic|An antipyretic is administered one hour before the infusion.
218953314|NCT05344755|OTHER|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
218953315|NCT05344755|OTHER|Control Group|Routine physiotherapy management of the Hallux valgus
218953316|NCT06339476|DIAGNOSTIC_TEST|Serum ADMA, MDA and M30 levels mesurment|Blood samples collected from patienst, only 7 mL
219056603|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
219056604|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
219056605|NCT02367313|DRUG|Placebo|Placebo twice daily
219056606|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
219056607|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
219056608|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
219056609|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
219638503|NCT05917587|OTHER|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
219638504|NCT06569602|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
219638505|NCT05204862|DRUG|TU2218|orally administered
218953317|NCT03188042|DEVICE|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
219638506|NCT05204862|DRUG|Anti-PD-1 antibody|Intravenously administered
219638507|NCT05849415|DIAGNOSTIC_TEST|Periodontal Screening and Recording, periodontal evaluation.|Periodontal probing for the evaluation of bleeding on probing and Periodontal Screening and Recording
219638508|NCT01763580|DRUG|Tacrolimus|Oral
219638509|NCT01763580|DRUG|Prednisolone|Oral
219638510|NCT04308278|DRUG|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
219638511|NCT04308278|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
219638512|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - standard product|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
218953318|NCT03188042|DEVICE|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
219056610|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
219056611|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
219056612|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
219056613|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
219056614|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
219056615|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
219638513|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP1|Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
219638514|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP2|Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
219638515|NCT01941745|DRUG|Half normal saline|2 ml/kg
219638516|NCT01941745|DRUG|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
219638517|NCT01941745|DRUG|High dose rhCC10|5 mg/kg in 2 ml/kg
219638518|NCT00068393|DRUG|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
219638519|NCT00068393|DRUG|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
219638520|NCT00068393|DRUG|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
219638521|NCT00068393|DRUG|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
219056616|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
219056617|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
219056618|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
219056619|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
219056620|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
219056621|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
219638522|NCT04699110|DRUG|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
219638523|NCT04699110|DRUG|Adenosine|Control group will receive adenosine (100 to 400 mcg)
219638524|NCT05509465|DEVICE|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
219638525|NCT05509465|DEVICE|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
219638526|NCT02586610|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
219638527|NCT02586610|DRUG|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
219638528|NCT02586610|RADIATION|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
219056622|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
219638529|NCT00893997|BIOLOGICAL|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
219638530|NCT04543097|BEHAVIORAL|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
218953319|NCT06078150|BEHAVIORAL|Active video games intervention（1-6weeks）|"Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game."
218953320|NCT06078150|BEHAVIORAL|Active video games intervention（7-12weeks）|"Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time."
218953321|NCT00925938|DRUG|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
218953322|NCT00925938|DRUG|placebo|placebo
218953323|NCT00521300|DRUG|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
218953324|NCT00521300|PROCEDURE|Direct surgery for acromegaly|Direct transsphenoidal surgery
218953325|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
218953326|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
218953327|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean starch|Starch treatment
218953328|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean flour|Flour treatment
218953329|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with no faba bean fraction|Control treatment
218953330|NCT00427180|DEVICE|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
218953331|NCT05228847|DIETARY_SUPPLEMENT|Human milk-derived HMF|Fortification with human milk-derived product
218953332|NCT05228847|DIETARY_SUPPLEMENT|bovine milk-derived HMF|bovine milk-derived HMF
218953333|NCT06506695|DEVICE|Craniofacial implant placement|"* Resection of oncologic process or remnants after trauma if necessary~* Placement of craniofacial implants in the nasal floor and/or the temporal bone.~* Placement of split thickness skin graft around the implants~* Placement of nose and/or ear prosthesis within 3 weeks"
218953334|NCT03068832|BIOLOGICAL|Personalized peptide vaccine|-It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
218953335|NCT03068832|DRUG|Poly ICLC|-Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
218953336|NCT03068832|PROCEDURE|Peripheral blood draw|"* After trial enrollment and up to 7 days after the 1st vaccine dose~* 2 weeks after last dose~* Time of progression or discontinuation"
218953337|NCT00488709|DRUG|Topotecan|
218953338|NCT00488709|DRUG|Fludarabine|
218953339|NCT00488709|DRUG|Cytarabine|
218953340|NCT00948584|OTHER|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
218953341|NCT05761535|RADIATION|Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses|"Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."
219056623|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
218953342|NCT05707741|DRUG|dexmetomedine infusion|50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
218953343|NCT05707741|DRUG|Dexmetomedine infusion|50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
219056624|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
218953344|NCT00779259|DRUG|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
218953345|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
218953346|NCT00779259|DRUG|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
218953347|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
218953348|NCT05824143|DRUG|Darigabat|Oral tablet
218953349|NCT05824143|DRUG|Carbamazepine|Oral tablets
218953350|NCT05421884|BEHAVIORAL|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
219638531|NCT06466681|OTHER|All included subjects|Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.
219638532|NCT05946798|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
219638533|NCT05946798|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
219638534|NCT03318094|DRUG|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
218953351|NCT05331079|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
219638535|NCT03318094|OTHER|Saline|Intrabrachial saline will be given this day
219638536|NCT03318094|DRUG|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
218953352|NCT00259129|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
218953353|NCT04461041|DRUG|Empagliflozin|Single oral tablet
218953354|NCT04461041|DRUG|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
218953355|NCT05480345|DIAGNOSTIC_TEST|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
218953356|NCT04924439|OTHER|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
218953357|NCT02483871|DRUG|Rosuvastatin|
218953358|NCT05459090|OTHER|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
218953359|NCT03513445|DRUG|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
218953360|NCT03513445|DRUG|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
218953361|NCT03513445|DRUG|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
218953362|NCT00654147|DRUG|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
218953363|NCT00654147|DRUG|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
218953364|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
218953365|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
219207061|NCT06740994|PROCEDURE|preprocedural ultrasound guided midline technique|"a preprocedural ultrasound scanning will be done, and skin marking of the best quality space will be made.~the site of injection and the insertion angle of the needle will be determined by ultrasound.~continuous spinal anesthesia will be performed via midline approach."
218953366|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
218953367|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
218953368|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
219638537|NCT05839067|BEHAVIORAL|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
219638538|NCT05795244|DRUG|Nivolumab|\- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
218953369|NCT05440773|OTHER|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
218953370|NCT05440773|OTHER|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
218953371|NCT05440773|OTHER|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
218953372|NCT01534182|DRUG|Fingolimod|0.5 mg orally once a day
218953373|NCT01534182|DRUG|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
218953374|NCT01534182|DRUG|Glatiramer acetate (GA)|20 mg subcutaneously once a day
218953375|NCT04293627|BEHAVIORAL|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
218953376|NCT02660008|DRUG|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
218953377|NCT02660008|DRUG|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
218953378|NCT02489916|DRUG|CM4307|CM4307 300mg bid, each 4 week cycle
218953379|NCT01718977|OTHER|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
218953380|NCT01718977|OTHER|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
218953381|NCT01592656|RADIATION|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
218953382|NCT01592656|OTHER|Lung compliance measurement|At baseline
219056625|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
219638539|NCT06566820|DRUG|Aroxybutynin and Atomoxetine|Fixed Dose Combination
219638540|NCT04286386|OTHER|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219638541|NCT04286386|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219638542|NCT04286386|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
219638543|NCT06372834|DEVICE|piTBS being delivered using the Magstim Rapid2 stimulator|Magstim Rapid2 stimulator (Magstim Company, Ltd, Whitland, Wales, UK, SA340HR). See detail in arm/group descriptions regarding the intervention.
218953383|NCT01592656|DEVICE|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
218953384|NCT01944839|DRUG|E10030|
218953385|NCT01944839|DRUG|ranibizumab|
218953386|NCT01944839|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
218953387|NCT00251160|PROCEDURE|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
219056626|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
219056627|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
219056628|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
218953388|NCT00251160|PROCEDURE|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
219056629|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
219638544|NCT06255522|PROCEDURE|Fully guided implant placement|Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
219638545|NCT03486444|DIAGNOSTIC_TEST|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
219638546|NCT03486444|OTHER|Surveys|surveys assessing perception of ultrasound
218953389|NCT02427269|OTHER|Specimen Collection|"* 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~* Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~* Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~* Two biopsies from normal squamous epithelium, and~* One biopsy from each area of esophageal nodularity seen during the procedure~* Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~* Up to 4 cytology brushes during the procedure."
218953390|NCT01687647|OTHER|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
219638547|NCT01653015|BIOLOGICAL|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
219638548|NCT01653015|BIOLOGICAL|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
219638549|NCT04876131|DRUG|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
219638550|NCT04876131|DRUG|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
219638551|NCT04876131|DRUG|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
219638552|NCT04876131|DRUG|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
219056630|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
219056631|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
219056632|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
219056633|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
219638553|NCT04876131|DRUG|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
219638554|NCT01527695|DRUG|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
219638555|NCT01527695|DRUG|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
219638556|NCT01527695|DRUG|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
219638557|NCT01527695|DRUG|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
219638558|NCT06435143|DEVICE|Prelivia|Pad applied to skin provide electrical stimulation for 10 seconds every 10 minutes
219638559|NCT03295240|DRUG|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
219638560|NCT03295240|DRUG|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
219638561|NCT03725592|OTHER|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
219638562|NCT03725592|BEHAVIORAL|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
219638563|NCT05127330|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
219638564|NCT05127330|BEHAVIORAL|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
218953391|NCT00924170|DRUG|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
219638565|NCT04981470|DEVICE|baroloop System|vagal nerve stimulation
219638566|NCT03226821|DRUG|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
219638567|NCT05599646|BEHAVIORAL|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
219638568|NCT05599646|BEHAVIORAL|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
219638569|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
219638570|NCT03045744|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
219638571|NCT05959031|DEVICE|kTMP|a new non-invasive brain stimulation tool
219638572|NCT05959031|DEVICE|Sham kTMP|a new non-invasive brain stimulation tool with sham setting selected
219638573|NCT00593684|DEVICE|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
219638574|NCT01808599|DRUG|Chlorambucil|
218953392|NCT00924170|DRUG|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day"
218953393|NCT00924170|DRUG|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day"
218953394|NCT02550977|DRUG|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
218953395|NCT01661985|DRUG|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
218953396|NCT01661985|DRUG|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
218953397|NCT01661985|DRUG|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
218953398|NCT00005646|DRUG|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
218953399|NCT04061928|DRUG|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
218953400|NCT03681288|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion Intervention
219056634|NCT02143518|BIOLOGICAL|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
219638575|NCT01808599|DRUG|Rituximab i.v.|
219638576|NCT01808599|DRUG|Rituximab s.c.|
218953401|NCT05272995|DIAGNOSTIC_TEST|IIEF-5|The participants will be asked to complete a validated IIEF-5 questionnaire, an abridged version of the IIEF. The IIEF is a validated, brief and reliable self-administered questionnaire for assessing erectile function. Moreover, this tool is easily administered in clinical setting and demonstrates adequate sensitivity and specificity for detecting treatment-related changes in erectile function in patients with erectile dysfunction (ED).According to Rosen et al the abridged five-item version of the 15-item IIEF possesses favorable properties for detecting the presence and severity of ED for the preceding 6 months. The IIEF-5 consists of five questions, each of which is scored on a five-point ordinal scale and ED may be classified into five categories based on the calculated scores.
219638577|NCT05571475|OTHER|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
219638578|NCT03554733|BEHAVIORAL|ReInventing Yourself after SCI|6-week, manualized, cognitive-behaviorally based group educational intervention
219638579|NCT03055312|DRUG|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 \& days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 \& days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8) every 3 weeks"
219638580|NCT03055312|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
219638581|NCT00653133|DEVICE|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
219638582|NCT00653133|DEVICE|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
218953402|NCT06472167|BEHAVIORAL|Breathing exercises|Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
218953403|NCT04098224|DEVICE|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
218953404|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
218953405|NCT06073223|OTHER|Usual Care|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
218953406|NCT06073223|OTHER|CQUPLE|"Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making."
218953407|NCT05881239|DEVICE|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
218953408|NCT02619539|PROCEDURE|plasma fibrinogen measurement|plasma fibrinogen measurement
218953409|NCT02217527|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
218953410|NCT02217527|DRUG|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
218953411|NCT05478629|OTHER|Survey|Questioning through google forms
218953412|NCT04136119|OTHER|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
218953413|NCT02181517|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
218953414|NCT02181517|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
218953415|NCT02181517|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
219056635|NCT02143518|BIOLOGICAL|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
219056636|NCT06994143|DRUG|CLN-978|Specified dose on specified days
218953416|NCT01203852|DRUG|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
218953417|NCT01203852|DRUG|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
218953418|NCT00936689|PROCEDURE|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
218953419|NCT00936689|PROCEDURE|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
218953420|NCT04061993|PROCEDURE|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
218953421|NCT04061993|PROCEDURE|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
218953422|NCT01204723|DRUG|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
219056637|NCT04862468|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
219056638|NCT04862468|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
218953423|NCT01204723|DRUG|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
218953424|NCT02756988|DRUG|Coppertone (BAY987704)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
218953425|NCT01251640|DRUG|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
219056639|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
218953426|NCT02811276|OTHER|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
219056640|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
219056641|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
219056642|NCT04069793|DEVICE|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
219056643|NCT04069793|DEVICE|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
219056644|NCT07000201|DRUG|One hour prior to admission to the operating room, patients will receive the study medication (as premedication) by mouth with a sip of water;|group I patients will receive two capsules of pregabalin (Lyrica) 75 mg (total = 150 mg), group II patients will receive two capsules of gabapentin (Conventin) 300 mg (total = 600 mg), and group III patients will receive a matching placebo in the form of two capsules of powdered multivitamin by mouth.
219056645|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
219056646|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
219056647|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
219056648|NCT07012213|DRUG|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.
219056649|NCT07013045|OTHER|Structured Neuromuscular Exercise Group|In the Structured Neuromuscular Exercise group, the exercise program will be administered to patients diagnosed with FMF twice a week for 12 weeks under the supervision of a physiotherapist. The exercises will be performed using a balance board and will include sitting, standing, lunge, modified push-up, and plank positions.
219056650|NCT07013045|OTHER|Neuromuscular Exergaming Program Group|In the Neuromuscular Exergaming group, patients diagnosed with FMF will perform the same exercises as those in the structured neuromuscular exercise program, delivered in an exergaming format using the Smart Exercise Board (SEG-Board). The program will be conducted under the supervision of a physiotherapist, twice weekly for 12 weeks, and will include exercises performed in sitting, standing, lunge, modified push-up, and plank positions.
219056651|NCT05242978|OTHER|Nutrition|acute single dose nutrition intervention
219056652|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
219638583|NCT00527293|PROCEDURE|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
219638584|NCT00527293|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
219638585|NCT00527293|RADIATION|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
219638586|NCT02644993|RADIATION|Proton therapy|
219638587|NCT05918887|DEVICE|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable"
218953427|NCT02536183|DEVICE|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
218953428|NCT02536183|DRUG|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
218953429|NCT03567317|DEVICE|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
218953430|NCT01433276|DRUG|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
218953431|NCT01433276|DRUG|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
218953432|NCT06349005|OTHER|Tracheal intubation using Storz VL|Video-assisted intubation technique using Storz VL
219638588|NCT05498441|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
218953433|NCT06349005|OTHER|Tracheal intubation using Macintosh laryngoscopy|Traditional intubation technique using Macintosh laryngoscopy
218953434|NCT06349005|OTHER|Tracheal intubation using MacGrath VL|Video-assisted intubation technique using MacGrath VL
218953435|NCT06349005|OTHER|Tracheal intubation using EzVision VL|Video-assisted intubation technique using EzVision VL
219056653|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
219056654|NCT06694701|DRUG|Placebo|250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
219056655|NCT07024303|DRUG|Psychotropic medication (at discretion of psychiatrist)|The timing and dose of medication will be determined by the prescribing provider. Most medications are delivered daily and some medications may be delivered more than once per day. Providers are expected to adhere to professional guidelines for prescribing.
219056656|NCT07024303|BEHAVIORAL|Behavioral therapy|Functional communication training (FCT) will be delivered for 1 hour every week in-vivo or via telehealth. This timing and dosage has been shown effective in previous research. However, caregivers will be encouraged to practice the treatment procedures as often as possible on their own. Treatment will be delivered by a therapist and/or caregiver for those receiving in-vivo therapy and caregivers will deliver treatment with coaching from a therapist when using telehealth.
219056657|NCT07024732|BIOLOGICAL|PST-611|PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
219056658|NCT07023796|PROCEDURE|Autologous fat filtration|Patients who underwent a surgical procedure and autologous fat processing for subsequent fat filtration.
219056659|NCT07035067|OTHER|No intervention|No specific intervention is assess in this study.
219056660|NCT06878443|OTHER|Vaginal probiotics|Probiotics from Canadian company Lallemand Health Solutions are stored at room temperature and administered vaginally.
219056661|NCT07043023|DRUG|Lidocaine (drug)|Lidocaine 2%, bolus of 0.075 ml/kg real weight (i.e. 1.5 mg/kg) then IVSE at 0.05 ml/kg/h (i.e. 1 mg/kg/h) for 48 hours
219638589|NCT05498441|DRUG|Antipsychotics, mood stabilizers, etc.|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
219638590|NCT02119793|DEVICE|YVOIRE contour|YVOIRE contour injection into the anteromedial malar region
219638591|NCT05898932|OTHER|Medical Management|Participants will be managing condition with medication
219638592|NCT05898932|OTHER|Surgical Management|Participants will be managing condition with a surgery
219638593|NCT04414969|DRUG|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
219638594|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
219638595|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
219638596|NCT02919423|DEVICE|transcranial magnetic stimulation|
219638597|NCT01011530|DRUG|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
218953436|NCT02982603|DRUG|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
218953437|NCT02982603|DRUG|Ginkgo Biloba Extract 761|Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
219056662|NCT07043023|DRUG|Placebo|Placebo (sodium chloride 0.9%), bolus of 0.075 ml/kg of real weight then IVSE at 0.05 ml/kg/h for 48h
219056663|NCT07051057|DIAGNOSTIC_TEST|Survey using a questionnaire.|A survey was constructed to collect the data of oral hygiene and nutritional habits and obesity
219638598|NCT01736397|DRUG|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
219638599|NCT01736397|DRUG|Placebo|
219638600|NCT06433778|OTHER|No Intervention|This is a non-interventional study.
219056664|NCT07050641|DRUG|SCTB39-1|SCTB39-1, IV
218953438|NCT02982603|DRUG|Placebos|Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
219056665|NCT07051590|DEVICE|cad cam|Occlusion assessment in CAD CAM restorations
219056666|NCT07051590|DEVICE|3D printer|Crowns produced with 3D technology
219056667|NCT07051434|OTHER|Regional Analgesic Block|Preoperative regional analgesic block performed as part of routine clinical care in selected patients undergoing mastectomy (e.g., PECS block, paravertebral block, or other truncal blocks).
219056668|NCT07051772|OTHER|mobility skills testing session|A mobility skills testing session using the Qualisys system (Trinoma), when carrying out specific tasks plus 7-day recording of activity using an accelerometer.
219638601|NCT01604928|DRUG|YM178|Oral
219638602|NCT01604928|DRUG|tolterodine|Oral
219638603|NCT01604928|DRUG|Placebo|Oral
219638604|NCT03469128|BEHAVIORAL|Cognitive processing therapy|Psychological treatment for patients suffering from PTSD and SUD symptoms.
219638605|NCT03469128|DRUG|Sertraline|Sertraline for the treatment of post-traumatic stress and SU disorders
219638606|NCT03469128|OTHER|Placebo Control|Placebo Control
218953439|NCT03133065|DRUG|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
219056669|NCT06620133|OTHER|Pain education and patient-led goal setting|8 week program delivered via five, up to 1-hour telehealth sessions. The sessions will be scheduled at approximately fortnightly intervals. Participants will also be prescribed approximately 30 minutes of online activities with each session. Pain education will be based on Explain Pain and the curriculum will have specified learning objectives adapted for each individual participant. Participants will access the online education curriculum through Pathwright. For patient-led goal setting, the healthcare practitioner will take an initial history of the participants physical activity behaviours and problems related to their back pain. The participant will prioritise their problems according to impact in their life. Strategies will then be discussed, and the participant will, in collaboration with the healthcare practitioner, set goals and strategies to work on independently between sessions.
219056670|NCT06620133|OTHER|Guideline-based written advice|Participants will receive guideline-based written information for the management of chronic low back pain. This will include information about the prognosis of low back pain and treatment options to consider.
219056671|NCT07051161|PROCEDURE|bronchoscope|procedure performed by bronchoscopy
219056672|NCT06855147|DRUG|[14C]HRS9531|A single dose of \[14C\]HRS9531 injected subcutaneously.
219056673|NCT06830005|DEVICE|Rho AI software|Rho is a AI enabled opportunistic pre-screening computer-aided detection and notification software for low bone mineral density.
219056674|NCT06491394|DRUG|Lactoferrin|an iron-binding protein
219056675|NCT06491394|DIAGNOSTIC_TEST|iron|Iron in kidney and heart tissues
218953440|NCT00081861|DRUG|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
219056676|NCT06491394|DIAGNOSTIC_TEST|MDA, TAC, and GSH|Oxidative stress levels in kidney and heart tissues
219056677|NCT06491394|DIAGNOSTIC_TEST|Nrf2|Nrf2 expression in kidney and heart tissues
218953441|NCT00081861|DRUG|Rituximab|375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
218953442|NCT01544088|BEHAVIORAL|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
219056678|NCT06491394|DIAGNOSTIC_TEST|AMPK|AMPK levels in heart and kidney tissues
219056679|NCT06491394|DIAGNOSTIC_TEST|HO-1|HO-1 levels in kidney and heart tissues
219056680|NCT06491394|DRUG|glycerin|GLY intramuscular injection for rhabdomyolysis induction
219056681|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
219056682|NCT06620757|DRUG|Single antiplatelet therapy (SAPT)|Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
219056683|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
219056684|NCT06945575|OTHER|Opus loop|17X25SS will used to fabricate opus loop which is L shaped loop with helix
219056685|NCT06945575|OTHER|T loop|17X25SS wire will be used to fabricate T-loop which is a T shaped loop
219056686|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
219056687|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
219056688|NCT06306118|DEVICE|Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection|For pre-resection biopsy cases (3 target per patient), the targets will be selected from metabolite hotspots on MR-spectroscopy imaging and/or amino acid tracer uptake hotspots on PET imaging. Depending on the tumor location and surgical procedure, all biopsies will be performed via one single or multiple entry points.
219056689|NCT04356716|DRUG|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
219056690|NCT04356716|OTHER|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
219056691|NCT04356716|DIAGNOSTIC_TEST|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
219056692|NCT04356716|OTHER|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
219056693|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
219207062|NCT06888089|OTHER|AI-assisted MatchMiner Platform|A medical record data analysis tool that uses conjunction machine learning and natural language processing models to predict changes in treatment and prognosis and ascertain progression of disease and metastatic sites using retrospective imaging reports. MatchMiner is an established clinical operations tool at Dana-Farber Cancer Institute that links OncoPanel next-generation sequencing data to basic clinical information and clinical trial eligibility criteria to suggest biomarker-selected therapeutic trials for participants.
219549869|NCT02579005|BIOLOGICAL|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
219549870|NCT02579005|BIOLOGICAL|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
219549871|NCT04266548|PROCEDURE|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
219056694|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
219056695|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
219056696|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
219056697|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
219056698|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
219056699|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
219056700|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
219549872|NCT02701101|DEVICE|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
219549873|NCT02701101|OTHER|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
219549874|NCT02667769|OTHER|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
219549875|NCT05002140|DRUG|XRD-0394|Single ascending dose
219549876|NCT05002140|RADIATION|Palliative radiotherapy|4 Gy × 5 daily fractions
219549877|NCT04914546|DRUG|LY3819469|Administered SC.
219549878|NCT04914546|DRUG|Placebo|Administered SC.
219549879|NCT04869995|OTHER|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
219549880|NCT01046084|DRUG|Lansoprazole|30 mg Delayed-Release Capsule
219549881|NCT01046084|DRUG|Prevacid®|30 mg Delayed-Release Capsule
219549882|NCT01728987|DRUG|cholecalciferol|as in arm description
219549883|NCT01728987|DRUG|placebo|capsule looking identical to the cholecalciferol capsule
219549884|NCT01942278|OTHER|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
219549885|NCT03618615|BIOLOGICAL|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
219549886|NCT02342509|DRUG|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
219549887|NCT02342509|DRUG|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
219549888|NCT02342509|DRUG|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
219638607|NCT06685497|DEVICE|Mobile application follow-up|Colorectal cancer patients enrolled in the 'Internet Plus' post-treatment management platform use the digital medical quality management system based on the 'COLORECTUM+' model for quality evaluation and continuous improvement. The platform integrates AI, using natural language processing and machine learning to analyze patient-reported symptoms, automatically assess severity, and generate alerts. Alerts are classified as yellow, orange, or red. Yellow indicates mild issues with self-care recommendations; consecutive yellow alerts prompt doctor contact within 24 hours. Orange indicates moderate severity, requiring doctor intervention within 24 hours. Red alerts signify serious symptoms or high-risk medication errors, prompting immediate notification of the doctor and emergency team. The system monitors symptom changes and updates alerts to support treatment optimization.
219638608|NCT05567211|OTHER|Free use of the virtual platform.|Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
219638609|NCT05567211|OTHER|Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
219638610|NCT05567211|OTHER|Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
219638611|NCT02288845|DRUG|ITI-007|
219638612|NCT06084845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218953443|NCT01544088|BEHAVIORAL|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
218953444|NCT00247611|BEHAVIORAL|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
218953445|NCT00247611|OTHER|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
218953446|NCT06577220|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
218953447|NCT06577220|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
218953448|NCT06577220|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
218953449|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
218953450|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
218953451|NCT03182543|DIETARY_SUPPLEMENT|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
219549889|NCT02439515|DEVICE|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
218953452|NCT05051930|DRUG|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
219549890|NCT02439515|DEVICE|Balance|Balance control exercises with visual biofeedback
219549891|NCT02439515|OTHER|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
219549892|NCT06180915|BEHAVIORAL|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
218953453|NCT05051930|DRUG|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
218953454|NCT04161638|BEHAVIORAL|Stigma Video Exposure|The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
218953455|NCT04161638|BEHAVIORAL|Neutral video exposure|The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
218953456|NCT05468528|PROCEDURE|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
218953457|NCT05468528|PROCEDURE|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
218953458|NCT04308889|DRUG|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
218953459|NCT04308889|OTHER|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
218953460|NCT04308889|OTHER|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
218953461|NCT05182112|RADIATION|Whole liver irradiation (WLI)|Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
218953462|NCT05182112|DRUG|Gemcitabine and Cisplatin|Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
218953463|NCT01964196|DRUG|ASP1517|Oral administration
218953464|NCT01964196|DRUG|Placebo|Oral
218953465|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
219056701|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
218953466|NCT05161780|DRUG|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
219056702|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
219056703|NCT03994861|DIAGNOSTIC_TEST|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
219056704|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
219056705|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
218953467|NCT05161780|DRUG|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
218953468|NCT00127465|PROCEDURE|Issue of information booklet|
218953469|NCT01587898|DRUG|GSK1278863|Tablet
218953470|NCT01587898|OTHER|Placebo|Tablet
218953471|NCT00502203|DRUG|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
218953472|NCT00502203|DRUG|Paclitaxel|175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
219056706|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
219056707|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
219056708|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
219056709|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
219056710|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
219056711|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
219056712|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
219056713|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
219056714|NCT00548769|DRUG|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
219056715|NCT00548769|DRUG|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
219056716|NCT00548769|DRUG|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
219056717|NCT00548769|DRUG|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
219638613|NCT06084845|DRUG|Carboplatin|Given IV
219638614|NCT06084845|PROCEDURE|Chest Radiography|Undergo chest x-ray
219638615|NCT06084845|DRUG|Cisplatin|Given IV
218953473|NCT05570461|OTHER|Modified Constraint-Induced Movement Therapy|Experimental group will receive Modified Constraint-Induced Movement Therapyand traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the mCIMT group will be constrained by wearing a mitten during the treatment session and for 3 hours/day outside the therapy hours, 6(six) days/week for two weeks by an experienced Physical therapist.The time duration for Group A will be 40 minutes.
218953474|NCT02578368|DRUG|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
218953475|NCT02578368|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
218953476|NCT02578368|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
218953477|NCT02578368|DRUG|Docetaxel|50mg/m², d1, i.v., every 2 weeks
218953478|NCT02578368|DRUG|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
218953479|NCT02578368|DRUG|sodium folinate|can be used to replace leucovorin (calcium folinate)
218953480|NCT02578368|PROCEDURE|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
218953481|NCT02871037|DRUG|PF-05221304|Single or repeated, escalating dose of PF-05221304
218953482|NCT02871037|OTHER|Placebo|single or repeated dose of placebo
218953483|NCT06149468|OTHER|inclusion in the register|socio-demographic data collection and proposed therapy
218953484|NCT03087799|BEHAVIORAL|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
218953485|NCT01760642|DRUG|Midazolam|Midazolam 3 mg IV
218953486|NCT01760642|DRUG|Ketoconazole|ketoconazole 400 mg PO
218953487|NCT01760642|DRUG|Rifampicin|Rifampicin 600 mg PO
218953488|NCT04096768|DRUG|Dexmedetomidine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
219638616|NCT06084845|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
219638617|NCT06084845|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
218953489|NCT04096768|DRUG|Ketamine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
218953490|NCT02055638|DRUG|SRX246|capsules
218953491|NCT02055638|DRUG|Placebo|
218953492|NCT00346424|DRUG|Alfimeprase|
218953493|NCT03535246|BIOLOGICAL|Engineered Immune Cells|Engineered immune effector cells (EIE)
218953494|NCT05006742|PROCEDURE|CB study arm|Included patients are randomized to receive cryobiopsy
218953495|NCT05006742|PROCEDURE|FB-CB study arm|Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session
218953496|NCT01519193|BEHAVIORAL|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
218953497|NCT01423188|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
218953498|NCT01423188|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
218953499|NCT02136888|DRUG|Ponesimod Placebo|
218953500|NCT02136888|DRUG|Moxifloxacin Placebo|
218953501|NCT02136888|DRUG|Ponesimod 10 mg|
218953502|NCT02136888|DRUG|Ponesimod 20 mg|
218953503|NCT02136888|DRUG|Ponesimod 40 mg|
218953504|NCT02136888|DRUG|Ponesimod 60 mg|
218953505|NCT02136888|DRUG|Ponesimod 80 mg|
218953506|NCT02136888|DRUG|Ponesimod 100 mg|
218953507|NCT02136888|DRUG|Moxifloxacin 400 mg|
218953508|NCT00489125|OTHER|physiologic testing|physical testing of range of motion, grip strength etc.
218953509|NCT01654913|DEVICE|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
218953510|NCT06427395|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
219638618|NCT06084845|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219638619|NCT06084845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219638620|NCT06084845|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219638621|NCT06084845|DRUG|Xevinapant|Given PO
219638622|NCT06133751|DRUG|black chokeberry (Aronia melanocarpa)|Black chokeberry capsules standardized for anthocyanin compounds
219638623|NCT06133751|DRUG|Placebo|Chokeberry fiber placebo capsules
219638624|NCT00030394|DRUG|imatinib mesylate|Given orally
219056718|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
218953511|NCT04334083|BEHAVIORAL|Comparison of biomarkers of stress|Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
218953512|NCT05795049|OTHER|Stool and saliva sample collection|Stool and saliva samples collection
218953513|NCT05795049|OTHER|Questionnaire completion|"Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®"
219056719|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
219056720|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
219056721|NCT02066298|DRUG|Placebo|
219638625|NCT00030394|OTHER|laboratory biomarker analysis|Correlative studies
219638626|NCT00030394|OTHER|pharmacological study|Correlative studies
219056722|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
219056723|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
219056724|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
219056725|NCT05981651|OTHER|non-intervention|non-intervention
219056726|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
219638627|NCT04115475|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components
219638628|NCT05284799|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
219638629|NCT05284799|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
218953514|NCT01096628|OTHER|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
219056727|NCT05095480|DRUG|Placebo|Placebo receiving group
219056728|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
219056729|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
219056730|NCT03616210|PROCEDURE|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
219056731|NCT04756219|OTHER|Contact Video|No additional information necessary.
219056732|NCT04756219|OTHER|Contact Text|No additional information necessary.
219056733|NCT04756219|OTHER|Education Video|No additional information necessary.
219056734|NCT04756219|OTHER|Education Text|No additional information necessary.
219056735|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
219056736|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
219056737|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
219638630|NCT05284799|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
219638631|NCT01728818|DRUG|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
219638632|NCT01728818|DRUG|Afatinib|40mg flat dose, po, once daily
219638633|NCT01728818|DRUG|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
219056738|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
219549893|NCT05472415|OTHER|cognicise|"a combination of cognition and exercise training"
219549894|NCT05472415|DEVICE|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
219549895|NCT00379353|DRUG|Thalidomide|100 mg capsules orally, once a day for 14 days.
219549896|NCT00379353|DRUG|Placebo|Two placebo capsules orally, once a day for 14 days.
219549897|NCT03614728|DRUG|GSK3326595|GSK3326595 will be administered.
219549898|NCT03614728|DRUG|5-Azacitidine|5-Azacitidine will be administered.
219549899|NCT02928627|OTHER|Analysis of microRNA expression|sample analysis
219638634|NCT05088603|DEVICE|Clear Mask|The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
219638635|NCT00122993|BEHAVIORAL|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
218953515|NCT01096628|OTHER|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
218953516|NCT03900689|OTHER|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
218953517|NCT03900689|OTHER|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
218953518|NCT02587182|DEVICE|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
218953519|NCT02835040|OTHER|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
218953520|NCT02835040|OTHER|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
218953521|NCT00527891|PROCEDURE|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
218953522|NCT02319629|DRUG|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
218953523|NCT02319629|DRUG|Placebo|
218953524|NCT03124667|BEHAVIORAL|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
218953525|NCT03124667|BEHAVIORAL|Videos|The video training will emphasize health and educational information.
218953526|NCT02914002|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
218953527|NCT05300204|OTHER|Self-help strategies for depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding self-help strategies for depression."
218953528|NCT05300204|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
219549900|NCT02818894|DRUG|Lidocaine|Spinal anesthesia administered prior to participant's THA
219638636|NCT00122993|BEHAVIORAL|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
218953529|NCT01903252|DRUG|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
218953530|NCT01903252|DRUG|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
218953531|NCT02437110|DRUG|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
218953532|NCT02437110|DRUG|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
218953533|NCT02437110|DRUG|Dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
218953534|NCT02437110|DRUG|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
218953535|NCT03598517|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation."
219549901|NCT02818894|DRUG|Bupivacaine|Spinal anesthesia administered prior to participant's THA
219549902|NCT02958176|BEHAVIORAL|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
219549903|NCT02958176|BEHAVIORAL|Autogenic Training|Autogenic training recording provided on a CD
219549904|NCT01958476|DRUG|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
218953536|NCT03706924|DRUG|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
218953537|NCT03706924|DRUG|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
218953538|NCT03706924|DRUG|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
218953539|NCT01458093|OTHER|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
218953540|NCT00749047|DRUG|Pioglitazone|15-45 mg/day
218953541|NCT05905744|DIAGNOSTIC_TEST|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
218953542|NCT03841084|DRUG|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
218953543|NCT04270279|DRUG|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
218953544|NCT04270279|DRUG|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
218953545|NCT04270279|DRUG|Nitroglycerin tablets|Be used when angina attack
218953546|NCT03467685|DEVICE|Vibratory Anesthetic Device (VAD)|This is a handheld \~10cm long tool, battery operated, which provides vibration at a rate of \~150 Hz
218953547|NCT03396952|DRUG|Aspirin|Given PO
218953548|NCT03396952|BIOLOGICAL|Ipilimumab|Given IV
219056739|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
219056740|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
219056741|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
219056742|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
219056743|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
219056744|NCT00030589|DRUG|bexarotene|
219638637|NCT00122993|BEHAVIORAL|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
218953549|NCT03396952|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953550|NCT03396952|BIOLOGICAL|Pembrolizumab|Given IV
218953551|NCT00566202|DRUG|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
218953552|NCT00566202|DRUG|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
218953553|NCT00566202|DRUG|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
218953554|NCT03279393|DRUG|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
218953555|NCT01701050|OTHER|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
218953556|NCT01683097|OTHER|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
218953557|NCT03906916|DIAGNOSTIC_TEST|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
219056745|NCT00030589|DRUG|methoxsalen|
219056746|NCT00030589|PROCEDURE|UV light therapy|
219056747|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
219056748|NCT06069492|OTHER|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
219056749|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
219638638|NCT03619239|DRUG|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
219638639|NCT05377502|DIAGNOSTIC_TEST|OGTT|OGTT
219638640|NCT01847339|DRUG|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
219056750|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
219056751|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
219638641|NCT01847339|OTHER|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
219638642|NCT01024868|DRUG|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
219638643|NCT00730730|DEVICE|Complete SE Iliac Stent|Iliac stenting
219638644|NCT00730730|DEVICE|Complete SE Iliac Stent|Self-expanding stent
218953558|NCT03906916|DRUG|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
218953559|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
218953560|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
218953561|NCT00323817|DRUG|Z-338|
219056752|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
219056753|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
219056754|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
218953562|NCT01598142|PROCEDURE|Team 1|experienced endoscopist with a experienced assistant
218953563|NCT01598142|PROCEDURE|Team 2|same experienced endoscopist with a new trained assistant
219056755|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
219056756|NCT03391843|DRUG|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
219056757|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
219638645|NCT01841762|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
219638646|NCT03576690|BIOLOGICAL|REGN3470-3471-3479|
219638647|NCT06683417|DEVICE|Vestibular Rehabilitation Aid|"The tablet-based VestAid system was developed to repair, restore and maintain vestibular-ocular function that is impaired in patients post-mTBI.~Each participant\&amp;#39;s treating physical therapist will develop their own personalized exercise prescription. The physical therapist will be asked to recommend that the patients complete a home exercise program at least 2-3 times per day for 6 weeks. The exercise prescription will be placed on the VestAid by the physical therapist for the patient to follow. The patient is not able to modify the exercise, only the physical therapist can modify the exercises. Exercises will be modified based on patient\&amp;#39;s response and symptom reports. The physical therapist and study coordinator will receive an alert on the VestAid online dashboard if the patient\&amp;#39;s symptoms are greater than or equal to 8/10."
219638648|NCT06683417|OTHER|Standard of care vestibular rehabilitation|Vestibular rehabilitation to include gaze stabilization exercises, optokinetic training, smooth pursuits and saccades
219638649|NCT03843749|DRUG|Pyrotinib|Pyrotinib in Combination With Trastuzumab
219638650|NCT06546956|BEHAVIORAL|Integrative Breathwork Intervention|GRMT has three core components: respiratory regulation (i.e., sustained conscious connected breathing pattern into the upper chest where there is no pause between inhale and exhale), mindfulness of somatic sensations while breathing (i.e., interoceptive awareness with acceptance), and relaxation of physical tension. These components are the primary focus in every breathwork session. The intervention is delivered 1-on-1 in-person with a trained facilitator. Participants lay supine throughout the 60 minute session. The facilitator observes the participant's breathing pattern and guides the participant to apply the three core components. Each session ends with spontaneous, relaxed breathing and an opportunity to briefly share what happened during the session.
219638651|NCT05967832|OTHER|7T MRI|Patients and healthy volunteers will have a 7T MRI
219638652|NCT05445232|DRUG|LY3437943|Administered SC.
219638653|NCT05445232|DRUG|Midazolam|Administered orally.
219638654|NCT05445232|DRUG|Warfarin|Administered orally.
219638655|NCT05445232|DRUG|Caffeine|Administered orally.
219638656|NCT02954692|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
219638657|NCT02954692|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219638658|NCT02954692|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
218953564|NCT05834387|PROCEDURE|EICU Transfer Routine Care|EICU Transfer Routine Care
218953565|NCT05834387|PROCEDURE|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
218953566|NCT02856360|OTHER|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
218953567|NCT02856360|OTHER|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
218953568|NCT04036123|OTHER|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
218953569|NCT00131924|BIOLOGICAL|esterified estrogens|
218953570|NCT03497598|DRUG|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
219638659|NCT02954692|DRUG|meglitinides|"Pharmaceutical form: tablet~Route of administration: oral"
219638660|NCT02954692|DRUG|thiazolidinediones|"Pharmaceutical form: tablet~Route of administration: oral"
218953571|NCT03497598|DRUG|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
218953572|NCT02061527|PROCEDURE|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
219056758|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
219056759|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
219056760|NCT00977262|OTHER|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
218953573|NCT02061527|PROCEDURE|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
218953574|NCT02061527|PROCEDURE|Reconstruction with implant|Immediate breast reconstruction with implant
218953575|NCT02061527|PROCEDURE|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
218953576|NCT02061527|PROCEDURE|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
218953577|NCT03986372|BIOLOGICAL|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
218953578|NCT00400803|DRUG|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
218953579|NCT04303728|DIAGNOSTIC_TEST|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
218953580|NCT01948856|DRUG|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
218953581|NCT01948856|DRUG|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
219638661|NCT02954692|DRUG|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
219638662|NCT02954692|DRUG|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
218953582|NCT01227824|DRUG|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
218953583|NCT01227824|DRUG|raltegravir|raltegravir 400mg taken twice daily
218953584|NCT01227824|OTHER|GSK1349572 Placebo|GSK1349572 placebo taken once daily
218953585|NCT01227824|OTHER|ABC/3TC|Abacavir/Lamivudine background therapy once daily
218953586|NCT01227824|OTHER|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
218953587|NCT01227824|OTHER|raltegravir Placebo|raltegravir placebo taken twice daily
218953588|NCT06276738|DIAGNOSTIC_TEST|LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
218953589|NCT04526821|DRUG|Bovine Lactoferrin|Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
218953590|NCT04526821|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
219056761|NCT00977262|OTHER|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
219056762|NCT00977262|OTHER|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
219056763|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
219056764|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
219056765|NCT00013897|DRUG|Atazanavir|
219056766|NCT00013897|DRUG|Lamivudine/Zidovudine|
219056767|NCT00013897|DRUG|Efavirenz|
219056768|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
219056769|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
219056770|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
219638663|NCT02954692|DRUG|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
219638664|NCT02954692|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
219638665|NCT02828046|BIOLOGICAL|M281|
219638666|NCT02828046|OTHER|Placebo|
219638667|NCT03815799|PROCEDURE|Bilateral Erector Spinae Block|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
219056771|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
219056772|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
219056773|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
218953591|NCT03946722|DRUG|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
218953592|NCT03946722|OTHER|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
219056774|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
219056775|NCT05449639|DEVICE|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
219056776|NCT02599792|DRUG|CTP-656|
219056777|NCT02599792|DRUG|Placebo for CTP-656|
219638668|NCT03815799|OTHER|Control|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
219638669|NCT03648437|DRUG|Paracetamol 10Mg/mL|Experimental drug
219638670|NCT03648437|DRUG|0.45% Sodium Chloride|Placebo comparator
219638671|NCT03648437|DRUG|Ibuprofen|Standard therapy
219638672|NCT03648437|DRUG|Indomethacin|Standard therapy
219638673|NCT01760915|OTHER|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
218953593|NCT04184388|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
218953594|NCT04184388|DIETARY_SUPPLEMENT|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
218953595|NCT03836001|DRUG|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
218953596|NCT03836001|DRUG|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
218953597|NCT01961583|DRUG|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
218953598|NCT00289029|DRUG|Iopamidol 370 mgI/mL|
218953599|NCT06341790|OTHER|jowar based products|jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
219056778|NCT02599792|DRUG|Kalydeco|
219056779|NCT00158379|DRUG|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
219056780|NCT05870280|BEHAVIORAL|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
219638674|NCT03170531|DIAGNOSTIC_TEST|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
219638675|NCT03170531|DIAGNOSTIC_TEST|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
219638676|NCT01253551|DRUG|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
219638677|NCT01253551|DRUG|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
219638678|NCT05993897|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|10 mg of Dapagliflozin orally once daily
218953600|NCT00798278|DRUG|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
218953601|NCT00798278|PROCEDURE|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
218953602|NCT01381562|DRUG|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
218953603|NCT01381562|DRUG|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
218953604|NCT01381562|OTHER|Placebo|saline placebo
218953605|NCT02971033|DRUG|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
219056781|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
219056782|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
219056783|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
219056784|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
219056785|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
219056786|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
219056787|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
219056788|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
219638679|NCT05993897|DRUG|Rhythm control and anticoagulation|"In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~\+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females."
219638680|NCT01828983|BEHAVIORAL|Telephone support groups|
219638681|NCT01828983|OTHER|Education webinars|
218953606|NCT02971033|DRUG|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
218953607|NCT02971033|DRUG|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
218953608|NCT01642732|OTHER|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
219056789|NCT00333034|DRUG|Etanercept|
219056790|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
219056791|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
218953609|NCT04816968|DRUG|Cefepime|Cefepime from 3 to 6 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
219056792|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
219638682|NCT00522106|BEHAVIORAL|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
219056793|NCT02188017|DRUG|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
218953610|NCT04816968|DRUG|Piperacillin/tazobactam|Piperacillin/Tazobactam 18 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
219638683|NCT00522106|OTHER|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
219638684|NCT04299061|DIAGNOSTIC_TEST|International Physical Activity Questionnaire|"This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs\*min\*days) + Mod (METs\*min\*days) + Vig (METs\*min\*days)~1\. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week"
218953611|NCT04816968|DRUG|Meropenem|Meropenem 3 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
218953612|NCT04816968|DRUG|Vancomycin|Vancomycin 30 mg/kg, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
218953613|NCT03265223|DRUG|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
218953614|NCT02659774|BEHAVIORAL|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
218953615|NCT02659774|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
218953616|NCT02659774|BEHAVIORAL|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
218953617|NCT02659774|BEHAVIORAL|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
218953618|NCT02659774|BEHAVIORAL|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
218953619|NCT02659774|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
218953620|NCT02478567|OTHER|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
218953621|NCT02478567|OTHER|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
218953622|NCT02123914|OTHER|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
218953623|NCT02123914|OTHER|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
218953624|NCT02123914|OTHER|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
218953625|NCT04753424|PROCEDURE|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
218953626|NCT01630278|DRUG|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
218953627|NCT01630278|DRUG|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
218953628|NCT03012126|BEHAVIORAL|Healthy Weight Clinic|
218953629|NCT03012126|BEHAVIORAL|Healthy Weight and Your Child|
218953630|NCT02438475|DEVICE|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
218953631|NCT02438475|OTHER|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
218953632|NCT04475198|DRUG|ST-2427|Investigational drug
218953633|NCT04475198|DRUG|Placebo|5% Dextrose Injection
218953634|NCT00878761|BIOLOGICAL|STX-100|SC, single dose followed by multiple dose
218953635|NCT04541277|DRUG|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
218953636|NCT01375855|PROCEDURE|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
219056794|NCT01957189|DRUG|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
218953637|NCT01284491|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
218953638|NCT01284491|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
219056795|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
218953639|NCT03618589|DRUG|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
218953640|NCT03618589|DRUG|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
218953641|NCT02802917|DRUG|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
218953642|NCT02802917|DRUG|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
218953643|NCT02802917|DRUG|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
218953644|NCT02802917|DRUG|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
218953645|NCT02802917|OTHER|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
218953646|NCT03005184|DRUG|Valsartan 80 mg bid|oral medication during run-in and washout period
219056796|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
219056797|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
219638685|NCT04299061|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|"The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper."
219638686|NCT04299061|OTHER|Physical Activity Awareness Questionnaire - prepared by the researchers|It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
218953647|NCT03005184|DRUG|Enalapril 10 mg bid|oral medication
218953648|NCT03005184|DRUG|Sacubitril-Valsartan 200 mg bid|oral medication
218953649|NCT03005184|DRUG|Icatibant|intravenous medication
218953650|NCT03005184|DRUG|Placebo|intravenous medication
218953651|NCT00333944|DRUG|Pralidoxime(drug)|
218953652|NCT05117918|OTHER|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
218953653|NCT05117918|OTHER|Telemedicine|Delivery of care via telemedicine
218953654|NCT05384951|DIETARY_SUPPLEMENT|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
218953655|NCT04678687|PROCEDURE|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
218953656|NCT02489422|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953657|NCT02489422|OTHER|Questionnaire Administration|Ancillary studies
218953658|NCT02489422|OTHER|Daily Survey Administration|Ancillary studies
218953659|NCT02489422|BEHAVIORAL|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
218953660|NCT02489422|BEHAVIORAL|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
219056798|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
219056799|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
219056800|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
219056801|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
218953661|NCT02489422|OTHER|Actigraphy Assessment|Ancillary studies
218953662|NCT00252941|DEVICE|Memokath 028SW Urethral Stent|
218953663|NCT06022471|PROCEDURE|Stapes surgery|Stapedectomy operation
218953664|NCT02051075|BIOLOGICAL|PXN sperm treatment|immotile sperm activation with PXN
218953665|NCT02051075|BIOLOGICAL|Sperm activation with PXN and oocyte activation|
218953666|NCT02920788|BEHAVIORAL|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
219056802|NCT01201434|DIETARY_SUPPLEMENT|Bio-25 probiotic|2 tablets per day for 6 months
219056803|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
218953667|NCT02920788|OTHER|Brain Health Education (BHE)|BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.
218953668|NCT02920788|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the Brain
219056804|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
219056805|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
219056806|NCT03792594|OTHER|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
219056807|NCT03792594|OTHER|arthroscopic repair|arthroscopic repair only
219056808|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
219056809|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
219056810|NCT01793064|BEHAVIORAL|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
219638687|NCT04299061|DIAGNOSTIC_TEST|Perceived Stress Scale|The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
219638688|NCT02207803|BEHAVIORAL|Transition Assistance Program|
219638689|NCT02062164|PROCEDURE|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
219638690|NCT02062164|OTHER|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
219638691|NCT00594100|DEVICE|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
219638692|NCT06048562|DIAGNOSTIC_TEST|echocardiography|evaluation idm for cardiomyopathy by echo
218953669|NCT00709709|PROCEDURE|multislice coronary scan|multislice coronary scan
218953670|NCT04922047|DRUG|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
218953671|NCT04865523|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
219638693|NCT01575652|OTHER|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
219638694|NCT01575652|OTHER|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
219638695|NCT04015089|DIETARY_SUPPLEMENT|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
219638696|NCT04015089|DIETARY_SUPPLEMENT|Standard formula (SF)|Infant formula with intact protein
218953672|NCT06174168|OTHER|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
218953673|NCT03935113|OTHER|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
218953674|NCT00667173|DRUG|IDP-115|Topical application for 12 weeks
218953675|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
218953676|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
218953677|NCT03693560|DRUG|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
219056811|NCT01793064|BEHAVIORAL|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
219056812|NCT00278707|DRUG|GTA: Glyceryltriacetate|
219638697|NCT04563975|DRUG|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
219638698|NCT04563975|DRUG|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
219638699|NCT04563975|DRUG|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
219638700|NCT01270464|DRUG|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
219638701|NCT01270464|DRUG|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
219638702|NCT06660381|DRUG|Psilocybin|Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
218953678|NCT03693560|DRUG|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
218953679|NCT03693560|DRUG|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
218953680|NCT02694757|DEVICE|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
218953681|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
219056813|NCT05652751|DRUG|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
219056814|NCT05652751|DRUG|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
219056815|NCT05652751|DEVICE|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
219056816|NCT05652751|DEVICE|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
219056817|NCT03869775|DEVICE|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
219056818|NCT03869775|DIAGNOSTIC_TEST|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
219056819|NCT00059657|DRUG|Ecraprost in lipid emulsion|
219056820|NCT00004129|RADIATION|brachytherapy|
219056821|NCT00004129|RADIATION|phosphorus P32|
219056822|NCT03348891|OTHER|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
219056823|NCT03855722|PROCEDURE|RIPC|Remote Ischaemic Preconditioning
219056824|NCT03855722|PROCEDURE|Sham-RIPC|Sham procedure
219056825|NCT06404580|PROCEDURE|R anastomosis|R anastomosis
218953682|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
219056826|NCT01954654|DEVICE|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
219056827|NCT01954654|OTHER|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
219056828|NCT01448746|DRUG|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
219056829|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
219056830|NCT04830449|DRUG|HCP1904-2|Take it once daily for 8 weeks orally.
219056831|NCT04830449|DRUG|RLD2001-2|Take it once daily for 8 weeks orally.
219056832|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.
218953683|NCT01640574|DRUG|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
218953684|NCT01640574|DRUG|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
218953685|NCT05870982|BEHAVIORAL|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
218953686|NCT05870982|BEHAVIORAL|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
218953687|NCT05870982|BEHAVIORAL|DCR|Participants will be instructed to reduce caloric intake by 25%.
219056833|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with MMR|Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.
219056834|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine administered alone|Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
219056835|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
219638703|NCT02524886|DEVICE|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
219638704|NCT03826264|PROCEDURE|TAVR|transcatheter aortic valve replacement (TAVR)
218953688|NCT01607827|PROCEDURE|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
218953689|NCT01607827|PROCEDURE|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
219056836|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
218953690|NCT02805504|DRUG|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
218953691|NCT02805504|DRUG|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
218953692|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
218953693|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
218953694|NCT01855373|DIETARY_SUPPLEMENT|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
218953695|NCT01855373|OTHER|Placebo|Placebo: 2 capsules twice daily on an empty stomach
218953696|NCT04645121|DEVICE|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
218953697|NCT04645121|DEVICE|Bioimpedance|Measures total volume, intra and extracellular volume.
218953698|NCT04645121|RADIATION|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
218953699|NCT02630043|DRUG|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
218953700|NCT02630043|DRUG|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
218953701|NCT02395302|DEVICE|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
218953702|NCT04577157|BEHAVIORAL|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
219056837|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
219056838|NCT02359396|DRUG|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
219056839|NCT03959865|DRUG|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
219056840|NCT03959865|DRUG|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
219056841|NCT03959865|DRUG|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
219056842|NCT03959865|DRUG|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
219056843|NCT03959865|DRUG|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
219366154|NCT03909958|BEHAVIORAL|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
219366155|NCT02594436|DRUG|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
218953703|NCT04883723|DEVICE|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
219056844|NCT03959865|DRUG|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
219056845|NCT00021307|DRUG|carboplatin|
219056846|NCT00021307|DRUG|temozolomide|
219056847|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
219056848|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
219056849|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
219056850|NCT01304888|OTHER|Control|No benefits were provided
219056851|NCT00509197|DRUG|Placebo (sham inhaler)|
219056852|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
219056853|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
219207063|NCT06858644|DIAGNOSTIC_TEST|BUB1-Integrated Deep Learning Model for Gastric Cancer Metastasis and Cachexia Prediction|This intervention utilizes a deep learning model that integrates BUB1 gene expression, radiopathomics (quantitative imaging features), and histopathological data to predict peritoneal metastasis and cachexia in gastric cancer (GC) patients. Unlike traditional approaches, this model combines genomic, imaging, and pathological data to enhance early detection and improve prognostic accuracy. The model aims to identify key patterns in multi-modal data to offer personalized predictions for GC progression. By leveraging artificial intelligence, it seeks to support clinicians in decision-making, improving patient outcomes through earlier interventions and tailored treatments. This approach offers a novel, comprehensive method for predicting GC metastasis and cachexia, providing a unique tool compared to existing interventions.
219207064|NCT06769243|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat OCD, particularly in patients who have not responded well to traditional treatments such as medications or psychotherapy. The most common target is the supplementary motor area (SMA), which has an indirect connection with the Cortico-Striato-Thalamo-Cortical (CSTC) pathway, known to be hyperactive in OCD.~Another option to target the CSTC pathway is deep TMS, although it is not available in most advanced centers. The magnetic pulses from TMS stimulate or inhibit brain activity in the targeted area, which is believed to help reset or correct neural activity patterns associated with OCD and other psychiatric disorders.~TMS represents an alternative treatment for those struggling with OCD, offering a non-invasive approach with relatively few side effects and significant potential benefits."
219056854|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
219056855|NCT00000189|DRUG|Gepirone|
219056856|NCT02873624|PROCEDURE|Laparoscopic cholecystectomy|
219056857|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
219056858|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
219056859|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
219056860|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
219056861|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
219056862|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
219056863|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
219056864|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
219056865|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
219056866|NCT06077006|OTHER|questionnaires Only|questionnaires Only
219056867|NCT03087591|OTHER|Laboratory Biomarker Analysis|Correlative studies
219056868|NCT03087591|BIOLOGICAL|siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401|Given IV
219056869|NCT03696121|DRUG|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
219056870|NCT03696121|DRUG|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
218953704|NCT04883723|OTHER|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
218953705|NCT02972385|PROCEDURE|Mouthwash sample|A one time mouthwash sample will be performed.
218953706|NCT02972385|PROCEDURE|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
219207065|NCT06795984|OTHER|Establishing the correlation between KIR AA and KIR non-AA and CD56 endometrial cells and IVF succes|The analysis aimed to compare CD56 levels between patients with the KIR AA genotype and those without. A multiple linear regression model was used to determine the predictive value of CD56+ levels, KIR genotype, and age on the number of blastocysts.
219638705|NCT03473366|DEVICE|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
219638706|NCT03473366|DEVICE|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
219638707|NCT05061277|DRUG|Recifercept|A lyophilized powder for solution for injection
219638708|NCT00870636|DRUG|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
219638709|NCT01265979|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
219638710|NCT01046279|DRUG|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
218953707|NCT04597242|DRUG|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
218953708|NCT00952380|DRUG|dalteparin|dalteparin subcutaneous injection
218953709|NCT03400956|DRUG|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
218953710|NCT03400956|DRUG|Placebo|Orally, coated tablet, once daily
218953711|NCT04821505|BEHAVIORAL|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
218953712|NCT04821505|BEHAVIORAL|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
218953713|NCT06071728|DIETARY_SUPPLEMENT|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
218953714|NCT00001012|DRUG|AL 721|
218953715|NCT03364829|DRUG|Indacaterol/Glycopyrronium|
218953716|NCT03505398|PROCEDURE|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
218953717|NCT03505398|PROCEDURE|visual acuity|using ETDRS scales
218953718|NCT03505398|PROCEDURE|automated visual field|recording visual attention based on central or peripheral visual information
218953719|NCT03505398|PROCEDURE|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
218953720|NCT02251964|DRUG|Rituximab|2 times 1000mg dose at 14 days interval treatment
218953721|NCT02251964|RADIATION|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
218953722|NCT00383474|DRUG|Bortezomib|Given IV
219207066|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
218953723|NCT00383474|OTHER|Laboratory Biomarker Analysis|Correlative studies
218953724|NCT00383474|DRUG|Tipifarnib|Given orally
218953725|NCT04597151|DIETARY_SUPPLEMENT|Dietary Intervention|Attend diet education sessions
218953726|NCT05830110|DEVICE|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
218953727|NCT05830110|DEVICE|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
218953728|NCT02004288|DIETARY_SUPPLEMENT|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
218953729|NCT06397521|PROCEDURE|Crown lengthening|Investigation of the three techniques for aesthetic crown lengthening
219207067|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
218953730|NCT05315011|OTHER|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
219638711|NCT04262323|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
219638712|NCT02372812|DRUG|dexamethasone|12 mg of dexamethasone
219056871|NCT05123248|DEVICE|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
219056872|NCT05123248|DEVICE|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
219056873|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
218953731|NCT05315011|OTHER|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
218953732|NCT03157570|BEHAVIORAL|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
219056874|NCT00519480|DRUG|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
219207068|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
219207069|NCT05470075|DRUG|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
219638713|NCT02372812|DRUG|Placebo|
219638714|NCT02669901|BEHAVIORAL|Naloxone Auto-Injector|Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
219638715|NCT03981900|DRUG|Tofacitinib|5 mg BID, oral administrtaion
219638716|NCT03981900|DRUG|Tofacitinib|tablet form 11mg once daily oral
219638717|NCT01071980|OTHER|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
218953733|NCT05908643|DRUG|pTTL|pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
218953734|NCT05212857|DRUG|Leuprolide acetate|Given subcutaneously or as an injection
218953735|NCT05212857|DRUG|Goserelin acetate|Given subcutaneously or as an injection
218953736|NCT05212857|DRUG|Triptorelin acetate|Given subcutaneously or as an injection
218953737|NCT05212857|DRUG|Degarelix acetate|Given subcutaneously or as an injection
219056875|NCT00519480|DRUG|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
219056876|NCT00519480|DRUG|Placebo|Placebo will be available as an oral tablets.
219056877|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
219056878|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
219056879|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
219056880|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
219056881|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
219056882|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
219056883|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
219638718|NCT02155673|DRUG|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
218953738|NCT05212857|DRUG|Abiraterone acetate|Given orally
218953739|NCT05212857|DRUG|Apalutamide|Given orally
218953740|NCT05212857|DRUG|Enzalutamide|Given orally
218953741|NCT05212857|PROCEDURE|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
218953742|NCT05212857|RADIATION|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
218953743|NCT05212857|RADIATION|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
218953744|NCT04838808|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
219056884|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
219056885|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
219207070|NCT05470075|DRUG|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
218953745|NCT04838808|DRUG|Placebo|Placebo tablet twice daily for 90-days
218953746|NCT01306929|DRUG|pridopidine|45mg bid
218953747|NCT05365945|OTHER|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
218953748|NCT05365945|OTHER|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
218953749|NCT02589600|DRUG|Zoledronic acid|Annual intravenous 5.0 mg
218953750|NCT02589600|DIETARY_SUPPLEMENT|vitamin D|800 IU daily
218953751|NCT02589600|DIETARY_SUPPLEMENT|calcium|approximately 1200 mg (dietary and supplement)
218953752|NCT02589600|OTHER|Saline|Annual intravenous saline placebo
218953753|NCT02823444|OTHER|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
218953754|NCT00928590|DRUG|Travoprost/Timolol Maleate Fixed Combination solution|
218953755|NCT04008927|DIAGNOSTIC_TEST|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
218953756|NCT04008927|DIAGNOSTIC_TEST|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.
218953757|NCT04008927|DRUG|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
218953758|NCT04717830|DRUG|Gamezumab|solution for infusion
219056886|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
219056887|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
219056888|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
219056889|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
219056890|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
218953759|NCT00270842|BEHAVIORAL|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
218953760|NCT00270842|BEHAVIORAL|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
218953761|NCT00270842|BEHAVIORAL|Education Control group|This control group participated in 10 weeks of general health education classes.
218953762|NCT03608150|DEVICE|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
218953763|NCT03608150|DEVICE|Refractive Correction|Standard of care refractive correction (ex. spectacles)
219056891|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
219056892|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
219056893|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
219056894|NCT02855294|DRUG|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
219056895|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
219638719|NCT06663280|DEVICE|Digital health assistant ADELE|The digital health assistant ADELE Blood Pressure A0007 (ADELE for short) improves the daily lives of patients with high blood pressure and enhances patient care. Participants in the intervention group were provided with ADELE to use during the study period for voice-based recording, interpretation and classification of their vital signs and body conditions.
219638720|NCT02162719|DRUG|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
219638721|NCT02162719|DRUG|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
219638722|NCT02162719|DRUG|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
219638723|NCT06666647|PROCEDURE|Treatment by ambulance or helicopter services with response times|Prehospital treatment by ambulance and/or helicopter services personnel of patients in acute conditions
219638724|NCT06664983|DRUG|TPC chemotherapy|The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
219638725|NCT06664983|DRUG|cadonilimab combined TPC chemotherapy|Cadonilimab was intravenously given at dose of 10 mg/kg on day 1. The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
219638726|NCT06667947|PROCEDURE|caudal block|For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.
219638727|NCT02042326|DRUG|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
218953764|NCT05806827|DIAGNOSTIC_TEST|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
218953765|NCT02166177|DRUG|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
219056896|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
219056897|NCT03286959|PROCEDURE|PCR with RMGIC|
219056898|NCT03286959|PROCEDURE|PCR with direct composite|
219056899|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
219056900|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
219056901|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
219056902|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
219638728|NCT05431530|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery including resection of tumors involving rectosigmoid colon.
219638729|NCT05019196|DEVICE|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
219638730|NCT01369030|OTHER|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
218953766|NCT06363188|DEVICE|Radial Extracorporeal shockwave|a device used by physiotherapist to treat various musculoskeletal problems and it was here firstly used to accelerate the bone healing process after bone fracture
218953767|NCT03330392|DIETARY_SUPPLEMENT|AGP|take two tablets per day (500 mg/day) for 8 weeks
218953768|NCT03330392|DIETARY_SUPPLEMENT|Placebo|take two tablets per day (500 mg/day) for 8 weeks
218953769|NCT05133960|OTHER|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
218953770|NCT05861622|OTHER|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
218953771|NCT04403269|DRUG|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
218953772|NCT00710762|DRUG|BIBF1120|
218953773|NCT00710762|DRUG|Placebo|
219638731|NCT05201963|PROCEDURE|Serratus Anterior Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
218953774|NCT02700633|DEVICE|Pacemaker|
218953775|NCT04397770|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
218953776|NCT04397770|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
218953777|NCT04397770|DRUG|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
218953778|NCT00910507|BEHAVIORAL|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
218953779|NCT00910507|BEHAVIORAL|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
218953780|NCT01887054|DEVICE|Tower of Hanoi|
218953781|NCT01887054|OTHER|Placebo group - non use of Tower of Hanoi|
218953782|NCT02610101|OTHER|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
218953783|NCT02610101|OTHER|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
218953784|NCT02610101|OTHER|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
218953785|NCT03838809|DEVICE|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
219056903|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
218953786|NCT02346890|DRUG|AZD1722|
218953787|NCT02346890|DRUG|Renvela|
218953788|NCT05736575|GENETIC|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
218953789|NCT02979860|BEHAVIORAL|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
218953790|NCT02979860|BEHAVIORAL|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
218953791|NCT02979860|BEHAVIORAL|Sleep timing|Sleep timing: bed time kept consistent
218953792|NCT03337919|DRUG|Nivolumab|Up to 8 cycles of nivolumab
218953793|NCT05268627|DRUG|Liraglutide|endoscopy
219056904|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
219056905|NCT05466318|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
219056906|NCT05466318|DRUG|Cladribine|6 mg/m2 intravenously once daily @ Day -7 \~ -3
219056907|NCT05466318|DRUG|Gemcitabine|2500 mg/m2 intravenously @ Day -7, -3
218953794|NCT04096378|BEHAVIORAL|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
218953795|NCT04096378|BEHAVIORAL|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
218953796|NCT01761032|DEVICE|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
218953797|NCT05383001|DRUG|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
218953798|NCT05383001|DRUG|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
218953799|NCT02719561|BEHAVIORAL|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
218953800|NCT01816451|OTHER|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
219056908|NCT05466318|DRUG|Busulfan|3.2 mg/kg intravenously once daily @ Day -7 \~ -4
219056909|NCT05466318|DRUG|Carmustine|300 mg/m2 intravenously @ Day -8
219056910|NCT05466318|DRUG|Etoposide|200 mg/m2 intravenously once daily @ Day -7 \~ -4
219056911|NCT05466318|DRUG|Cytarabine|400 mg/m2 intravenously once daily @ Day -7 \~ -4
219056912|NCT05466318|DRUG|Melphalan|140 mg/m2 intravenously @ Day -3
219056913|NCT05466318|PROCEDURE|Autologous hematopoietic stem cell transplant|autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
219056914|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
219056915|NCT03431077|DRUG|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
219056916|NCT04932304|DEVICE|Transcranial direct current stimulation (tDCS)|
219056917|NCT04932304|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
219056918|NCT00408993|DRUG|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
219056919|NCT00408993|DRUG|Placebo|Placebo every day (QD), by mouth (PO)
219056920|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
219056921|NCT06282627|OTHER|Observational study|No intervention. Observational study
219056922|NCT02654080|BIOLOGICAL|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
219056923|NCT02654080|BIOLOGICAL|rVSV HIV envC vaccine|1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
219056924|NCT02654080|BIOLOGICAL|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
219056925|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
219056926|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
218953801|NCT04069364|BEHAVIORAL|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
218953802|NCT03660137|DEVICE|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
218953803|NCT01700439|DEVICE|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
218953804|NCT02275884|DIETARY_SUPPLEMENT|Dark chocolate (85% cocoa)|
219056927|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
219056928|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
219056929|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
219056930|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
219056931|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
219056932|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
219056933|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
219056934|NCT06141798|OTHER|Hemodialysis|Number of weekly hemodialysis treatment
219207071|NCT06912477|DIAGNOSTIC_TEST|Hyperspectral imaging|"Hyperspectral imaging will be performed at study inclusion and will be repeated longitudinally every 1-2 days until delivery and on the first and second day after delivery. After a baseline measurement, a blood pressure cuff is inflated on the upper arm to 50 mmHg above the systolic blood pressure for 5 minutes, and then the hyperspectral imaging measurement is repeated.~Blood samples are collected at study inclusion and on the first and second day after delivery and are processed within the Department of Gynecology and Obstetrics of the Heidelberg University Hospital."
219207072|NCT06912477|DIAGNOSTIC_TEST|Further markers of endothelial dysfunction|"At study inclusion: 1. blood samples will be collected for the measurement of EASIX and cardiac/endothelial markers; 2. sublingual in vivo microscopy will be performed (requires about 20 minutes and can be compared to a sublingual temperature measurement); 3. Doppler ultrasound will be performed to evaluate uterine and ophthalmic arteries.~Blood samples will also be collected at the first and second day after delivery."
219207073|NCT05756660|DRUG|Sodium Thiosulfate|This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
219207074|NCT06737016|DRUG|Tamsulosin|Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
219207075|NCT06737016|DRUG|Oxybutynin|Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
219207076|NCT06737016|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
219366156|NCT06226363|DRUG|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
219366157|NCT00531804|DRUG|gantenerumab|Administered iv at escalating doses (7 cohorts)
219638732|NCT05201963|PROCEDURE|Erector Spinae Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
218953805|NCT02275884|DIETARY_SUPPLEMENT|White chocolate (0% cocoa)|
219638733|NCT03727048|DRUG|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
218953806|NCT03279289|DRUG|Aflibercept|4 mg/kg administered intravenous infusion on day 1
218953807|NCT03279289|DRUG|Irinotecan|180 mg/m2 intravenous infusion
219056935|NCT01006044|BIOLOGICAL|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
219638734|NCT03727048|OTHER|No ketorolac|standard of care post operative pain management protocol
219638735|NCT02796066|DRUG|Vehicle|Applied once a day
219638736|NCT02796066|DRUG|TSN2898|Applied once a day
218953808|NCT03279289|DRUG|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
218953809|NCT03279289|DRUG|5Fluorouracil|400 mg/m2 intravenous bolus
218953810|NCT03279289|DRUG|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
218953811|NCT05849961|DEVICE|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
218953812|NCT02226744|BEHAVIORAL|Focused Breathing|
218953813|NCT01872325|BEHAVIORAL|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
218953814|NCT03896347|OTHER|ViBone®|Viable bone allograft
218953815|NCT03896347|OTHER|Demineralized Bone Matrix|Demineralized Bone Matrix
218953816|NCT03896347|OTHER|Bone Morphogenetic Protein|Bone Morphogenetic Protein
218953817|NCT01390064|BIOLOGICAL|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
218953818|NCT05883670|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
219056936|NCT04532697|OTHER|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
219056937|NCT04532697|OTHER|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
219056938|NCT05809518|DRUG|Propofol injection|sedation after cardiac surgery
219056939|NCT05809518|DRUG|Dexmedetomidine injection|sedation after cardiac surgery
219056940|NCT05809518|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
219056941|NCT00010218|DRUG|karenitecin|
219056942|NCT02621606|DRUG|[11C]MK-6884|IV bolus dose of \~370 MBq \[11C\]MK-6884
219056943|NCT00357864|DRUG|carbachol|
219638737|NCT02796066|DRUG|TSN2898|Applied once a day
219638738|NCT02796066|DRUG|TSN2898|Applied once a day
218953819|NCT01529801|DEVICE|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
218953820|NCT01529801|DEVICE|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
219056944|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
219207077|NCT06756893|PROCEDURE|Dorsal Root Ganglion Pulsed Radiofrequency|"Using C-arm fluoroscopy, a 22G, 10 cm RF needle with a 5 mm active tip will be directed from lateral to medial towards the vertebral foramen. Once the needle reaches the lateral edge of the pedicle shadow, the C-arm will be adjusted to a lateral view to confirm that the needle is located at the craniodorsal portion of the intervertebral foramen. Sensory stimulation will be delivered through the RF generator at 50 Hz, and paresthesia will be sought in the corresponding dermatome at values between 0.4-0.8 mA.~After achieving paresthesia, motor stimulation at 2 Hz will be applied, and the location near the DRG will be confirmed if motor stimulation is not elicited at values less than 1.5 times the sensory threshold. Pulsed RF will then be applied for 4 minutes at a setting of 45 V, 20 ms pulse width, and 2 Hz frequency. Following the application, needle will be directed slightly anterior and after appropriate contrast flow, dexamethasone will be injected."
219638739|NCT06320236|DIAGNOSTIC_TEST|Adjust-Unlikely|"Pulmonary embolism will be excluded during emergency department assessment by the combination of:~1. 'Pulmonary embolism is the most likely diagnosis' as per the treating physician AND a D-dimer result \< 500 ug/L fibrinogen equivalent units;~2. 'Pulmonary embolism is not the most likely diagnosis' AND D-dimer \< age-adjusted threshold; or,~3. A negative computed tomography scan, planar ventilation perfusion scan or ventilation perfusion-SPECT.~Emergency departments will use their local laboratory D-dimer assay."
218953821|NCT01529801|DEVICE|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
218953822|NCT01613976|DRUG|Panobinostat|
218953823|NCT06164821|DRUG|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
218953824|NCT03865888|DRUG|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
218953825|NCT03865888|DRUG|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
218953826|NCT01829243|DRUG|Milnacipran|
218953827|NCT01829243|DRUG|Placebo|
219056945|NCT06004310|BEHAVIORAL|Pulmonary Rehabilitation|Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
219056946|NCT02048384|DRUG|metformin alone (Arm A)|metformin alone
219056947|NCT02048384|DRUG|metformin (Arm B)|rapamycin + metformin
219056948|NCT02048384|DRUG|rapamycin (Arm B)|rapamycin + metformin
219638740|NCT04057547|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
219056949|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
219056950|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
219056951|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
219056952|NCT00274716|DRUG|MK0736|
219056953|NCT00274716|DRUG|MK0916|
219056954|NCT00274716|DRUG|Placebo|
219056955|NCT04812353|OTHER|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
219056956|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
219056957|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
219056958|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
219056959|NCT06309147|DRUG|BMS-9894923|50 mg capsules, oral administration
218953828|NCT05721807|OTHER|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
218953829|NCT05721807|OTHER|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
218953830|NCT05796830|OTHER|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
218953831|NCT00481507|OTHER|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
218953832|NCT00481507|OTHER|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
218953833|NCT04850781|BEHAVIORAL|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
218953834|NCT04850781|BEHAVIORAL|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
218953835|NCT02452931|DRUG|Leuprolide Acetate 45 mg|Subcutaneous injection
219056960|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
219056961|NCT00000571|DEVICE|ventilators, negative pressure|
219207078|NCT07040046|DRUG|HS-10542|"1. SAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1.~2. Food Effect \[FE\] study：HS-10542 capsule (in one predefined dose cohort ) will be administered orally once on Day 15."
219207079|NCT07040046|DRUG|HS-10542 Placebo|SAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1
218953836|NCT05371873|PROCEDURE|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
218953837|NCT01059929|DRUG|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
218953838|NCT01059929|DRUG|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
218953839|NCT01059929|DRUG|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
218953840|NCT01059929|DRUG|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
219056962|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
219207080|NCT07040046|DRUG|HS-10542|MAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
219638741|NCT02490787|DRUG|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
219638742|NCT02490787|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
219638743|NCT04863781|BEHAVIORAL|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
219638744|NCT04863781|BEHAVIORAL|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
219056963|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
219056964|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
219056965|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
219056966|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
219056967|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
219207081|NCT07040046|DRUG|HS-10542 Placebo|MAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
219056968|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
218953841|NCT01059929|BEHAVIORAL|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
218953842|NCT03445156|BEHAVIORAL|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
218953843|NCT03445156|BEHAVIORAL|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
218953844|NCT03120455|BEHAVIORAL|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
218953845|NCT03120455|BEHAVIORAL|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
218953846|NCT03120455|BEHAVIORAL|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
218953847|NCT05208918|PROCEDURE|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
218953848|NCT05208918|PROCEDURE|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
218953849|NCT02292901|DEVICE|Macintosh laryngoscope|
218953850|NCT02292901|DEVICE|McGrath Mac videolaryngoscope|
218953851|NCT00164970|DIETARY_SUPPLEMENT|Vitamin B12|
218953852|NCT00164970|DIETARY_SUPPLEMENT|folate|
218953853|NCT01210417|OTHER|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
218953854|NCT00189410|DRUG|Pegylated Liposomal Doxorubicin and Carboplatin|
218953855|NCT00668356|DRUG|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
218953856|NCT00668356|DRUG|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
218953857|NCT05873660|OTHER|No treatment given|No treatment given
219638745|NCT01311375|DIETARY_SUPPLEMENT|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
218953858|NCT00053898|DRUG|anastrozole|1 mg/day and placebo for 5 years
218953859|NCT00053898|DRUG|tamoxifen citrate|20 mg/day and placebo for 5 years
218953860|NCT00053898|RADIATION|Radiation Therapy|Adjuvant radiation therapy
218953861|NCT02178839|DIETARY_SUPPLEMENT|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
218953862|NCT02178839|DIETARY_SUPPLEMENT|Maltodextrin|8.5 g/d Maltodextrin
218953863|NCT04531631|DRUG|Dorzagliatin|tablet
218953864|NCT04531631|DRUG|placebo|placebo
218953865|NCT02487342|OTHER|milk|small serving (217 mL) of british semi-skimmed milk
218953866|NCT02487342|OTHER|orange fruit-juice|small serving (217 mL) of orange juice
219056969|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
219056970|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
219207082|NCT06736080|DRUG|MUNC-CD34|"* Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0"
219638746|NCT01311375|OTHER|placebo|placebo+ capsule CA-D
219638747|NCT04216199|DEVICE|Point of care Ultrasound|Point of care Ultrasound
218953867|NCT02066987|BEHAVIORAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth! If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth!"
218953868|NCT02066987|BEHAVIORAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY).~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY)."
218953869|NCT02066987|BEHAVIORAL|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
218953870|NCT03780023|OTHER|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
218953871|NCT02630901|DRUG|PRX003|
218953872|NCT02630901|OTHER|Placebo|
218953873|NCT03705273|DRUG|Dexamethasone IV for PO|Common pediatric emergency department practice
218953874|NCT03705273|DRUG|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
218953875|NCT01551940|DRUG|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
218953876|NCT01551940|DRUG|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
218953877|NCT00427401|DRUG|PF-00915275|
219056971|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
219056972|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
219056973|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
219056974|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
219638748|NCT03201770|DRUG|pyronaridine artesunate|Antimalarial treatment
219638749|NCT05473572|BEHAVIORAL|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
218953878|NCT02619773|PROCEDURE|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
218953879|NCT01138878|OTHER|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
218953880|NCT01138878|OTHER|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
219056975|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
219056976|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
219056977|NCT00982319|DRUG|Mango juice|150 mL of mango juice
219056978|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
218953881|NCT01138878|OTHER|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
219056979|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
219056980|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
219056981|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
219056982|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
219056983|NCT01922596|DRUG|Ropivacaine|
219056984|NCT01922596|DRUG|Placebo|
219207083|NCT06736080|DRUG|MUNC-T3|"* Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion"
219207084|NCT06673290|DRUG|Sirolimus (RAPAMUNE)|Use of different doses of the same drug
219366158|NCT03183128|BIOLOGICAL|SER-109|"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
219638750|NCT01728662|PROCEDURE|ELVR Procedure|Lung Volume Reduction Procedure
219638751|NCT00276991|DRUG|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm \>450 cu/mm\^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
219638752|NCT00308594|DRUG|Dexamethasone|
219638753|NCT00532194|DRUG|cediranib|Once-daily oral tablet starting dose 20mg
218953882|NCT01138878|OTHER|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
218953883|NCT03441672|BEHAVIORAL|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
218953884|NCT03149367|PROCEDURE|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
218953885|NCT03149367|PROCEDURE|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
218953886|NCT05054660|OTHER|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
218953887|NCT05391191|DEVICE|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
218953888|NCT00732004|DEVICE|Silicone Hydrogel Contact Lenses|
219638754|NCT02838719|DRUG|Perineural Dexamethasone acetate|
219638755|NCT02838719|DRUG|Intravenous dexamethasone acetate|
219638756|NCT01603745|DRUG|Zoely|1 pill every day
219638757|NCT01603745|DRUG|Yasmin|1 pill every day
219638758|NCT05793879|BEHAVIORAL|Video 360|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
219638759|NCT05793879|BEHAVIORAL|Standard videos|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
218953889|NCT00732004|DEVICE|1x PMBH preserved MPS|
218953890|NCT00732004|DEVICE|1x Polyquad/Aldox MPS|
218953891|NCT04011371|PROCEDURE|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
218953892|NCT00837733|PROCEDURE|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
218953893|NCT00837733|PROCEDURE|Endometrial Biopsy|Biopsy catheter
218953894|NCT05570331|DIAGNOSTIC_TEST|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
218953895|NCT02644681|PROCEDURE|Aortic Aneurysm, Thoracic surgery|
218953896|NCT04801940|DRUG|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
218953897|NCT04801940|DRUG|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
218953898|NCT04192227|BEHAVIORAL|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
218953899|NCT05596097|DRUG|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
218953900|NCT06226532|DRUG|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
218953901|NCT06226532|DRUG|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
218953902|NCT00497042|DEVICE|Self Adjusting File|
218953903|NCT00366093|DRUG|Eszopiclone|eszopiclone 3 mg
218953904|NCT00366093|DRUG|Placebo|placebo tablet
218953905|NCT01491594|DRUG|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
218953906|NCT01577290|BEHAVIORAL|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
218953907|NCT01577290|BEHAVIORAL|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
218953908|NCT03320551|BEHAVIORAL|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
218953909|NCT04486898|OTHER|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
218953910|NCT00889616|DRUG|BSAM2/Alhydrogel + CPG 7909|
218953911|NCT01254942|OTHER|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
218953912|NCT01254942|OTHER|Usual Care|
218953913|NCT02045953|DEVICE|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
218953914|NCT02045953|DEVICE|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
218953915|NCT03088085|PROCEDURE|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
218953916|NCT03088085|PROCEDURE|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
218953917|NCT03273569|PROCEDURE|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
218953918|NCT01847807|DRUG|low dose Astragalus|
218953919|NCT01847807|DRUG|high dose astagalus|
218953920|NCT01077375|DRUG|Placebo|"* Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
218953921|NCT01077375|DRUG|Milnacipran|"* Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
219056985|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
219056986|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
219056987|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
219056988|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
219056989|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
219056990|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
219056991|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
219056992|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
219056993|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219056994|NCT00000465|PROCEDURE|coronary artery bypass|
218953922|NCT03862508|OTHER|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
218953923|NCT06091072|OTHER|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
218953924|NCT03441217|DRUG|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
218953925|NCT03441217|DRUG|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
218953926|NCT04561999|DEVICE|Elastography|Performance of Ultrasound, Elastography
218953927|NCT05999760|DEVICE|evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge|Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
218953928|NCT05999760|DEVICE|chewing efficiency by electromyograph(E.M.G)|Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
219056995|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
219056996|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
218953929|NCT05999760|OTHER|masticatory performance(questionnaire)|Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
218953930|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg single dose|Subcutaneous injection of CPX101 or placebo
219056997|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
219056998|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
219207085|NCT06922669|DRUG|Methylprednisolone|Initially, an intravenous dose of 1 mg/kg/day of methylprednisolone will be administered for one week, with the possibility of extending treatment to two weeks if necessary. Following this, participants will receive oral methylprednisolone tablets, starting at a dose of 40 mg/day. The oral dosage will be gradually tapered based on the participants' condition over a period of 1 to 3 months.
218953931|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg single dose|Subcutaneous injection of CPX101 or placebo
218953932|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg single dose|Subcutaneous injection of CPX101 or placebo
218953933|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg Q2W|Subcutaneous injection of CPX101 or placebo
218953934|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
218953935|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
218953936|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg Q2W|Subcutaneous injection of CPX101 or placebo
218953937|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg single dose|CPX101 or placebo 200mg single dose
218953938|NCT02977182|OTHER|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
218953939|NCT05088473|OTHER|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
218953940|NCT05370703|BEHAVIORAL|My A:care|Mobile application with Motivational messages
218953941|NCT05370703|BEHAVIORAL|Smart Coach|Mobile application with Motivational messages
219056999|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
219207086|NCT06922669|DRUG|Magnesium isoglycyrrhizinate|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 0.15g to 0.2g
219207087|NCT06922669|DRUG|Glutathione|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 1.2g to 1.8g
219207088|NCT06922669|DRUG|Silymarin|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 140 mg, taken 2 to 3 times per day.
218953942|NCT04564131|OTHER|Reflexology|"* Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed."
219057000|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
219057001|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
219057002|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
219057003|NCT00054002|DRUG|porfimer sodium|iv
218953943|NCT04564131|OTHER|Control|No intervention was performed to reduce pain in the control group
218953944|NCT04109339|DRUG|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
218953945|NCT01599143|BEHAVIORAL|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
218953946|NCT02150408|OTHER|PET-CT|
218953947|NCT00146783|DRUG|Sulphadoxine-pyrimethamine|
218953948|NCT00146783|DRUG|Sulphadoxine-pyrimethamine, amodiaquine|
218953949|NCT01908881|BEHAVIORAL|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
219057004|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
219057005|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
219057006|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
218953950|NCT01908881|BEHAVIORAL|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
219057007|NCT04848285|OTHER|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
219057008|NCT04848285|OTHER|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
219057009|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
219057010|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
219057011|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
219057012|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
219057013|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
219057014|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
219057015|NCT00665119|DRUG|placebo|NaCl 0.9 %
219057016|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
219638760|NCT04471233|OTHER|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
219057017|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
219057018|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
219638761|NCT04471233|OTHER|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
219057019|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
219057020|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
219207089|NCT06922669|DRUG|Polyene Phosphatidylcholine|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 228mg-456mg, taken 3 times per day.
219057021|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
219057022|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
219057023|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
219057024|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
219057025|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
219057026|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
219057027|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
219057028|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
219057029|NCT02129179|DRUG|Glucagon-Like Peptide 1|
219057030|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
219057031|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
219057032|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
219057033|NCT00279123|DRUG|pantoprazole infusion|
219057034|NCT00279123|DRUG|pantoprazole bolus|
219057035|NCT00279123|DRUG|no treatment|
219057036|NCT05711069|OTHER|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
219207090|NCT06922669|DRUG|Ursodeoxycholic acid capsules|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 10mg-15mg/kg/day.
219207091|NCT06922669|DRUG|Ademetionine 1,4-Butanedisulfonate|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 0.5g to 1g.
219638762|NCT02096757|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
219638763|NCT02096757|OTHER|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
219638764|NCT06317194|DEVICE|kTMP|A new non-invasive brain stimulation tool
219638765|NCT06317194|DEVICE|Sham kTMP|A new non-invasive brain stimulation tool with sham setting selected
219638766|NCT04988971|DRUG|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
219638767|NCT04988971|DRUG|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
219638768|NCT04725812|DRUG|Eculizumab|Eculizumab Intravenous Solution
219638769|NCT06036043|DRUG|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~1. 100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~2. 100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
219638770|NCT00915486|PROCEDURE|Good Standard of Care (GSoC)|Procedural treatment twice per week
219638771|NCT00915486|BIOLOGICAL|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
219638772|NCT00915486|BIOLOGICAL|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
219638773|NCT03147131|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
219638774|NCT02977325|OTHER|water cure|
219638775|NCT04536038|BEHAVIORAL|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
219638776|NCT05359016|BEHAVIORAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
218953951|NCT05355493|BEHAVIORAL|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
218953952|NCT05355493|BEHAVIORAL|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
218953953|NCT05022511|BEHAVIORAL|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
218953954|NCT00545129|DRUG|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
218953955|NCT00545129|DRUG|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
218953956|NCT03504943|OTHER|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
218953957|NCT03504943|OTHER|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
218953958|NCT00633542|DRUG|thalidomide|100 mg/day orally until progression or severe toxicity
218953959|NCT00633542|DRUG|interferon alpha|3 MU 3 times a week until progression or severe toxicity
218953960|NCT02253927|DRUG|BILR 355 - D1|
218953961|NCT02253927|DRUG|BILR 355 - D2|
218953962|NCT02253927|DRUG|BILR 355 - D3|
219638777|NCT06620445|BEHAVIORAL|Interventiion or CBT Group|This RCT aims to evaluate the effect of Cognitive Behavioral Therapy (CBT) compared to usual care (UC) in pediatric oncology patients. We hypothesize that those receiving CBT will report lower depression and anxiety and improved QoL six months post-enrollment.
219638778|NCT02775877|DRUG|Letrozole|
219638779|NCT02775877|DRUG|clomiphene|
219638780|NCT02775877|DRUG|HMG|
218953963|NCT02253927|DRUG|BILR 355 - D4|
218953964|NCT02253927|DRUG|Ritonavir|
218953965|NCT02253927|OTHER|high fat breakfast|
218953966|NCT01728233|DRUG|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
218953967|NCT01081548|DRUG|atorvastatin|20 mg
218953968|NCT01081548|DRUG|atorvastatin|20 mg
218953969|NCT02841878|GENETIC|Analysis on colorectal biopsy|
218953970|NCT00986284|DRUG|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
218953971|NCT01659879|BEHAVIORAL|Multimedia information|
218953972|NCT01659879|BEHAVIORAL|verbal information|
218953973|NCT04985344|DRUG|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
218953974|NCT04985344|DRUG|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
219057037|NCT05711069|OTHER|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
219638781|NCT06959706|DRUG|TGW101|TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.
219638782|NCT00527644|DEVICE|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
219638783|NCT06731140|DRUG|Retinoic Acid|Retinoic acid 20mg tid, p.o.
219638784|NCT06731140|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
218953975|NCT04985344|OTHER|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
218953976|NCT01362010|DRUG|Topical Minocycline Foam FXFM244|Topically applied once a day.
218953977|NCT00839176|DRUG|RX-10100|Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
218953978|NCT02380768|DEVICE|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
218953979|NCT02380768|DEVICE|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
218953980|NCT00945828|BEHAVIORAL|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
218953981|NCT00945828|BEHAVIORAL|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
219057038|NCT01159496|DRUG|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
219057039|NCT01159496|DRUG|Placebo|Oral capsule, once daily for 14 days
218953982|NCT03337789|DIETARY_SUPPLEMENT|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
218953983|NCT03337789|DIETARY_SUPPLEMENT|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
218953984|NCT04094415|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
218953985|NCT05158400|RADIATION|Ultrasound|Ultrasound examination on the hand
218953986|NCT05573815|DEVICE|BT-M01|Clinical decision support system for detecting brain metastasis
218953987|NCT03001271|DRUG|Angiotensin 1-7|
218953988|NCT03001271|OTHER|Placebo|
218953989|NCT03754478|OTHER|Physical activity training|subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
219638785|NCT04012749|BEHAVIORAL|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
218953990|NCT06993805|BEHAVIORAL|OPA|The Our Practice Advisory (OPA) intervention is a behavioral nudge integrated into the electronic health record system. It is designed to prompt providers to reconsider ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests if a similar test was performed within the previous 30 days. The OPA aligns with evidence-based guidelines to reduce unnecessary testing, improve resource utilization, and optimize patient care by enhancing clinical decision-making at the point of order entry.
218953991|NCT03881761|BIOLOGICAL|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
218953992|NCT01688206|BIOLOGICAL|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
219207092|NCT06922669|PROCEDURE|Plaslna exchange|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
219207093|NCT06922669|PROCEDURE|Liver transplantation|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
218953993|NCT01688206|BIOLOGICAL|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
218953994|NCT05427617|DRUG|Control group|Physician chosen treatment
219638786|NCT04012749|BEHAVIORAL|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
218953995|NCT05427617|DRUG|Case group|Druggable ctDNA alterations-guided therapy
218953996|NCT02326935|BIOLOGICAL|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
218953997|NCT00417456|OTHER|Evisit|Asynchronous,remote care delivery via a secure web platform
218953998|NCT00417456|OTHER|Office visit|Conventional office-based care
218953999|NCT03538964|PROCEDURE|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
218954000|NCT03538964|PROCEDURE|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
218954001|NCT00000158|PROCEDURE|Argon Blue-Green Laser Photocoagulation|
218954002|NCT02455505|BEHAVIORAL|background questionnaire|
218954003|NCT02455505|BEHAVIORAL|bereavement risk screening tool|
218954004|NCT02055365|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
218954005|NCT02029729|DRUG|omaveloxolone|
218954006|NCT03816670|DRUG|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
218954007|NCT00806871|DRUG|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
218954008|NCT00806871|DRUG|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
218954009|NCT00806871|DRUG|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
218954010|NCT06831084|DEVICE|Silver plated technology (SPT) dressing|Silver-plated technology (SPT) dressing technology is a wound dressing that has a permanently plated metallic surface, which provides the antimicrobial benefits of silver in the dressing without staining the skin and without increasing bioburden, reducing the development of acute radiation dermatitis (ARD).
219057040|NCT06205511|DIAGNOSTIC_TEST|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
219057041|NCT04361357|OTHER|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
219057042|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
219057043|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
219366159|NCT03183128|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
219057044|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
218954011|NCT03828773|DRUG|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
218954012|NCT03828773|DRUG|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
218954013|NCT04663919|PROCEDURE|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
218954014|NCT04663919|BEHAVIORAL|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
218954015|NCT00664508|PROCEDURE|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
218954016|NCT05463094|DRUG|Test Glucophage® XR|Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
218954017|NCT05463094|DRUG|Reference Glucophage® XR|Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
218954018|NCT03310060|DRUG|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
218954019|NCT03310060|DRUG|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
219366160|NCT00004433|DRUG|pergolide|
219638787|NCT04012749|BEHAVIORAL|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
219638788|NCT04181606|DRUG|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
218954020|NCT04600817|DRUG|TJ107|QW8
218954021|NCT04600817|DRUG|TJ107 placebo|QW8
218954022|NCT03988881|PROCEDURE|Revascularization|PCI or CABG
218954023|NCT03700541|DRUG|Morphine|Morphine intravenous
218954024|NCT03700541|DRUG|Piritramid|Piritramid intravenous
219057045|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
219366161|NCT04326530|DEVICE|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
219638789|NCT04181606|DRUG|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
219638790|NCT04181606|OTHER|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
219638791|NCT04181606|OTHER|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
218954025|NCT04296643|DEVICE|Medical Mask|Medical Mask (known also as Surgical Mask)
218954026|NCT04296643|DEVICE|N95 respirator|N95 respirator
218954027|NCT01732094|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
218954028|NCT01732094|DRUG|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
218954029|NCT01732094|DRUG|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
218954030|NCT02868814|DRUG|Pregabalin Release Tablets|
218954031|NCT02868814|DRUG|Pregabalin Release Tablets|
218954032|NCT02868814|DRUG|Placebo|
218954033|NCT01258998|DRUG|Akt inhibitor MK2206|Given PO
218954034|NCT01258998|OTHER|laboratory biomarker analysis|Correlative studies
219057046|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
219057047|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
219057048|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
219638792|NCT04181606|OTHER|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
218954035|NCT01215929|DRUG|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
218954036|NCT01215929|DRUG|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
218954037|NCT01143389|DRUG|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
218954038|NCT01143389|DEVICE|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
218954039|NCT03970356|OTHER|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
218954040|NCT00093444|DRUG|lyso-thermosensitive liposomal doxorubicin|
218954041|NCT00093444|PROCEDURE|radiofrequency ablation|
218954042|NCT01238627|DRUG|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
218954043|NCT01238627|DRUG|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
218954044|NCT00400478|DRUG|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
218954045|NCT01165762|DRUG|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
218954046|NCT04637009|DRUG|TAS1553|Form: tablet; Route of Administration: oral
218954047|NCT02562469|OTHER|ACTIVATE|A home-based computerized brain training intervention for youth.
219057049|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
219057050|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
219057051|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
219057052|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
219207094|NCT06922812|DEVICE|Intermittent White Light Stimulation (IWLS)|A wearable device developed by SyntropicMedical (Austria) delivers intermittent white light at 60 Hz using LED strips embedded in safety goggles. The light is diffused (approximately 700 lux) and projected tangentially to the participant's eyes. Participants will undergo 10 daily sessions (30 minutes each) over a two-week period. The intervention aims to evaluate the safety, tolerability, and potential antidepressant effects of 60 Hz visual stimulation in individuals with moderate to severe Major Depressive Disorder.
219207095|NCT01614405|DRUG|TDF/FTC/LPV/r|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
219638793|NCT04271540|DRUG|Tildrakizumab|"Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months"
219638794|NCT05006443|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
218954048|NCT03470532|DRUG|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
219057053|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
219057054|NCT00004357|DRUG|Methylprednisolone|IV
219057055|NCT00004357|DRUG|Prednisolone|Oral
219057056|NCT00507052|DRUG|N-acetylcysteine|
219057057|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
219057058|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
219057059|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
219057060|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
219057061|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
219057062|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
219057063|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
219057064|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
219057065|NCT02840877|BEHAVIORAL|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
219057066|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
219057067|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
219057068|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
219057069|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
218954049|NCT03470532|DRUG|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
218954050|NCT01162798|OTHER|infant formula|test infant formula fed to infants until 6 months corrected gestational age
219057070|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
219057071|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
219057072|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
218954051|NCT01162798|OTHER|control infant formula|commercially available infant formula
218954052|NCT00148551|DRUG|Triamcinolone Acetonide|
218954053|NCT01284049|DRUG|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
218954054|NCT01284049|DRUG|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
218954055|NCT02561910|DEVICE|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
218954056|NCT02403687|DRUG|baclofen 2%|compound topical cream
218954057|NCT02403687|DRUG|Bupivacaine hydrochloride 1%|compound topical cream
218954058|NCT02403687|DRUG|Cyclobenzaprine hydrochloride 2%|compound topical cream
218954059|NCT02403687|DRUG|Diclofenac Sodium 3%|compound topical cream
219638795|NCT00742963|DRUG|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
218954060|NCT02403687|DRUG|Flurbiprofen 10%|compound topical cream
218954061|NCT02403687|DRUG|Gabapentin 6%|compound topical cream
218954062|NCT02403687|DRUG|Ketamine 10%|compound topical cream
218954063|NCT02403687|DRUG|Lidocaine 2%|compound topical cream
218954064|NCT02403687|DRUG|Prilocaine 2.5%|compound topical cream
218954065|NCT02403687|DRUG|Meloxicam 0.09%|compound topical cream
218954066|NCT02403687|DRUG|Sumatriptan 5%|compound topical cream
218954067|NCT02403687|DRUG|Tizanidine 0.1%|compound topical cream
218954068|NCT02403687|DRUG|Topiramate 2.5%|compound topical cream
218954069|NCT02403687|DRUG|Capsaicin, USP 0.0375%|compound topical cream
218954070|NCT02403687|DRUG|Menthol, NF 5.00 %|compound topical cream
218954071|NCT00925171|BEHAVIORAL|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
218954072|NCT04178083|DIAGNOSTIC_TEST|medical examination|medical examination
218954073|NCT01066442|DRUG|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
218954074|NCT00583479|OTHER|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
218954075|NCT00583479|OTHER|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
218954076|NCT05135312|DRUG|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
218954077|NCT05135312|DEVICE|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
218954078|NCT05869084|DIAGNOSTIC_TEST|pulmonary function tests|pulmonary function tests
218954079|NCT04216914|DEVICE|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
219057073|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
219057074|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
219057075|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
219057076|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
219057077|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
219057078|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
219057079|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
218954080|NCT03762538|DRUG|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
218954081|NCT02599675|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
218954082|NCT02599675|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
218954083|NCT04344288|DRUG|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
218954084|NCT04344288|OTHER|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
218954085|NCT05588804|DRUG|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
218954086|NCT05588804|DRUG|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
218954087|NCT05771168|DEVICE|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
218954088|NCT05771168|DEVICE|Male sling|Retrourethral implantation of male sling
218954089|NCT05198778|DRUG|URC102|tablet
218954090|NCT05198778|DRUG|URC102|tablet
219057080|NCT00009230|DRUG|Celecoxib|
219057081|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
219207096|NCT01614405|DRUG|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
219638796|NCT04697563|DEVICE|Laser|real laser beam administered
219638797|NCT04697563|DEVICE|Placebolaser|no laser beam admitted
219638798|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
219638799|NCT06295276|OTHER|teletherapy-guided exercise programme|"Exercise program guided by online sessions. Subjects perform this exercise program three times a week at home, so that they complete four sessions per week for six weeks. The duration of a session is approximately twenty minutes. There are six exercises with three sets and about fifteen repetitions. Subjects in the treatment group also receive an instructional video. The subjects keep a diary in which they record their adherence to the treatment protocol at home.~At the beginning of the intervention and after the sixth week, participants are assessed with ODI, NDI and SF36-Short and NRS-11 scales. At the end, we use the Global Rating Scale."
218954091|NCT02651181|DEVICE|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
218954092|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
219057082|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
219057083|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
219057084|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
219057085|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
218954093|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
218954094|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
219057086|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
219057087|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
219057088|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
219057089|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
219057090|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
219638800|NCT06295276|OTHER|Waiting list/control intervention/delayed teletherapy intervention|Subjects in the control group will be advised to maintain their daily routine but will be asked to refrain from other treatments to avoid co-interventions during the 6-week study period. However, the use of painkillers such as non-steroidal anti-inflammatory analgesics (NSAIDs) taken by study participants in all groups for more than 3 months is allowed and will be documented (taking a pragmatic approach). Any change in medication will be monitored and documented by the PT at each visit.
218954095|NCT04890743|OTHER|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
218954096|NCT02355873|DEVICE|AN69ST hemofilter|
218954097|NCT02355873|DEVICE|AN69 hemofilter|
219057091|NCT04401124|OTHER|no intervention|no intervention
218954098|NCT03639532|PROCEDURE|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
219057092|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
219057093|NCT00094380|DRUG|Cyclophosphamide|
219057094|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
219057095|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
219057096|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
219207097|NCT05006989|OTHER|Blueberry Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
219638801|NCT03269994|DRUG|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
219638802|NCT03269994|DRUG|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
218954099|NCT03639532|PROCEDURE|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
218954100|NCT06482918|BEHAVIORAL|Cognitive Remediation|Computer-assisted top-down or bottom-up cognitive remediation using tablets
218954101|NCT01680510|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|
218954102|NCT01680510|OTHER|Placebo (starch)|
219057097|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
219057098|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
219057099|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
219057100|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
219057101|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
219057102|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
219057103|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
219057104|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
219057105|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
219638803|NCT04862117|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
218954103|NCT02234856|PROCEDURE|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
218954104|NCT01887301|DRUG|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
218954105|NCT01369654|BEHAVIORAL|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
218954106|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
218954107|NCT01678937|PROCEDURE|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
218954108|NCT01678937|PROCEDURE|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
218954109|NCT01678937|PROCEDURE|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
219057106|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
219057107|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
219057108|NCT03603964|DRUG|Guadecitabine|Guadecitabine
219057109|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
219057110|NCT00136708|PROCEDURE|Neonatal Resuscitation|
219638804|NCT03969901|DRUG|IMI/REL|"Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 6 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 2 to \<6 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 months, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
219057111|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
219057112|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
219207098|NCT05006989|OTHER|Placebo Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
218954110|NCT01678937|PROCEDURE|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
218954111|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
218954112|NCT00479895|DRUG|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
218954113|NCT06280846|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The patients will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
219057113|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
219057114|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
219057115|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
219057116|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
219057117|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
219057118|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
219057119|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
219057120|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
219057121|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
219057122|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
219057123|NCT00215293|DEVICE|Cervical I/F Cage|
219057124|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
219057125|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
219057126|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
219057127|NCT02966080|DRUG|HEP-IV|
219638805|NCT03969901|DRUG|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
219638806|NCT03969901|DRUG|Oral Switch|All oral switch medications will be investigator's choice from a list of acceptable approved agents for infection types cIAI, and cUTI and will be given per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
219057128|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
219057129|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
219057130|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
219057131|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
219057132|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
219057133|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
219057134|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
219057135|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
219057136|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
219057137|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
218954114|NCT06280846|DEVICE|low-intensity laser acupuncture and Exercise therapy program|"The patients will receive low-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
218954115|NCT06280846|DEVICE|Sham laser acupuncture|Sham laser acupuncture and exercise therapy program. The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of: - strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises
218954116|NCT03293511|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
218954117|NCT03293511|DRUG|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
218954118|NCT00398489|BIOLOGICAL|trastuzumab|
218954119|NCT00398489|DRUG|anastrozole|
219057138|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
219057139|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
219057140|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
219057141|NCT05074433|DRUG|Placebo|Administered SC
219057142|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
219057143|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
219057144|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
219057145|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
219057146|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
218954120|NCT00398489|DRUG|cyclophosphamide|
218954121|NCT00398489|DRUG|docetaxel|
218954122|NCT00398489|DRUG|epirubicin hydrochloride|
218954123|NCT00398489|DRUG|goserelin acetate|
218954124|NCT00398489|DRUG|tamoxifen citrate|
218954125|NCT00398489|PROCEDURE|adjuvant therapy|
218954126|NCT00398489|PROCEDURE|conventional surgery|
219057147|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
219057148|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
219057149|NCT02233231|DRUG|Placebo|similar tabl
219057150|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
219057151|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
219057152|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
219057153|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
218954127|NCT00398489|PROCEDURE|neoadjuvant therapy|
218954128|NCT00398489|RADIATION|radiation therapy|
218954129|NCT03998813|DRUG|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
218954130|NCT03998813|DRUG|Ropivacaine|Tissue infiltration
218954131|NCT02824172|OTHER|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
218954132|NCT02824172|OTHER|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
218954133|NCT06415513|OTHER|ASMR|We used 7 ASMR videos published on the most watched ASMR channel on the YouTube platform, in which applications such as hair combing, brushing, massaging the head are applied sequentially and repeatedly, and there is no speech.
218954134|NCT00246415|DRUG|Memantine|
218954135|NCT03109314|DRUG|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
218954136|NCT03109314|BEHAVIORAL|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
219057154|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
219057155|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
219057156|NCT00035906|DRUG|DEX PS DDS®|
219057157|NCT00588913|BIOLOGICAL|aldesleukin|
219057158|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
219057159|NCT00588913|DRUG|zoledronic acid|
219057160|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
219057161|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
219057162|NCT02168166|BEHAVIORAL|Executive Function Training|
219057163|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
219057164|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
219057165|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
218954137|NCT03109314|BEHAVIORAL|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
218954138|NCT06210126|OTHER|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
218954139|NCT06210126|OTHER|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
218954140|NCT04663841|OTHER|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
218954141|NCT02480036|RADIATION|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
218954142|NCT02480036|DEVICE|Intrabeam®|
218954143|NCT01732003|DIETARY_SUPPLEMENT|Omega-3 Complete|
218954144|NCT01732003|DIETARY_SUPPLEMENT|Placebo Pill|
219057166|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
218954145|NCT05206877|DRUG|Insulin, 4 units|Topical insulin 100 U/ml, 1 drop per day
218954146|NCT05206877|DRUG|Insulin, 20 units|Topical insulin 500 U/ml, 1 drop per day
219057167|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
219057168|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
219057169|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
218954147|NCT05206877|DRUG|insulin, 4 units twice daily|1 drop of low dose insulin twice daily.
218954148|NCT05206877|DRUG|insulin, 20 units twice daily|1 drop of high dose insulin twice daily
218954149|NCT05206877|DRUG|insulin, 4 units three times daily|1 drop of low dose insulin three times daily.
219057170|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
219057171|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
219057172|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
219057173|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
219057174|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
219057175|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
219057176|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
219057177|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
219366162|NCT04326530|OTHER|Other assessments|"* Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit."
219366163|NCT01171651|DRUG|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
218954150|NCT05206877|DRUG|insulin, 20 units three times daily|1 drop of high dose insulin three times daily.
218954151|NCT05537987|DRUG|ICP-723|3+3 dose escalation
218954152|NCT05423223|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
218954153|NCT05423223|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
218954154|NCT03603067|PROCEDURE|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
218954155|NCT05814354|DRUG|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
218954156|NCT05814354|DRUG|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
218954157|NCT02410915|DEVICE|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
218954158|NCT02410915|OTHER|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
218954159|NCT03565367|OTHER|Gadolinium|gadolinium enhanced MRI
218954160|NCT03565367|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
218954161|NCT03565367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219057178|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
219057179|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
219057180|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
219057181|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
219057182|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
219057183|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
219057184|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
219057185|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
219057186|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
219057187|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
219057188|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
219057189|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
218954162|NCT03565367|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
218954163|NCT05479669|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
218954164|NCT05479669|DIAGNOSTIC_TEST|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
219057190|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
219057191|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
219638807|NCT06959914|OTHER|Training group|Patients in the intervention group will receive AVF care training. The training will last for 8 weeks and is planned to be given once a week. In the first session, the patients in the intervention group will be introduced. Afterwards, general information will be provided about the purpose and applications of AVF training and the importance of participation in training will be emphasized. Afterwards, patients who agree to participate in the study will sign an informed consent form. In addition, the Patient Information Form, SF-12 Quality of Life Short Form, the Comfort Scale for Hemodialysis Patients and the Scale for Assessing Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients will be given and asked to answer. For those who cannot read or write, the researchers will read the survey forms. In the first session, the pre-test data of the patients will be collected and then the training books will be given.
218954165|NCT05479669|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
219057192|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
219057193|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
219057194|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
219057195|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
219057196|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
219057197|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
219057198|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
219057199|NCT03280277|DRUG|Ferumoxytol|Given IV
219057200|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
219638808|NCT06090916|OTHER|Best Practice|Receive standard nutrition care
219638809|NCT06090916|OTHER|Dietary Intervention|Participate in weekly support sessions with diet prescription
219638810|NCT06090916|OTHER|Medical Chart Review|Ancillary studies
218954166|NCT05479669|DIAGNOSTIC_TEST|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
218954167|NCT05479669|DIAGNOSTIC_TEST|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
218954168|NCT04991818|OTHER|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
218954169|NCT02057042|BEHAVIORAL|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
218954170|NCT02057042|BEHAVIORAL|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
218954171|NCT00874614|RADIATION|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
218954172|NCT02489929|OTHER|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
219057201|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
219057202|NCT03973190|PROCEDURE|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
219366164|NCT03737162|PROCEDURE|Stent implantation of subclavian artery|Stent implantation of subclavian artery
219366165|NCT04855994|PROCEDURE|paravertebral block|The investigators performed Paravertebral block to that patient group for postoperative analgesia
219638811|NCT06090916|OTHER|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
219638812|NCT06090916|OTHER|Nutritional Assessment|Undergo malnutrition screening
219638813|NCT06090916|OTHER|Questionnaire Administration|Ancillary studies
219638814|NCT06576453|BEHAVIORAL|Self-questionnaire WHOQOL-bref|Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.
219638815|NCT06576453|BEHAVIORAL|Self-questionnaire Evaluation Inventory - Parent|Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.
219638816|NCT06576453|BEHAVIORAL|quiz of knowledge|Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.
219638817|NCT06576453|BEHAVIORAL|semi-structured interviews (qualitative)|In the month following the last session of the program, the semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band.
219638818|NCT04680000|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)|BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
218954173|NCT02489929|DRUG|azacytidine|
218954174|NCT01003314|BIOLOGICAL|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later
219366166|NCT04855994|PROCEDURE|pectoral block|The investigators performed pectoral block to that patient group for postoperative analgesia
219366167|NCT02417389|DRUG|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
218954175|NCT01003314|BIOLOGICAL|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
218954176|NCT00137839|DRUG|Erlotinib|
218954177|NCT03466515|PROCEDURE|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
218954178|NCT01955798|PROCEDURE|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
218954179|NCT01955798|PROCEDURE|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
218954180|NCT01955798|DEVICE|Trocar|
218954181|NCT01955798|DEVICE|Veress needle|
218954182|NCT06370078|DRUG|Albumin Human|To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
218954183|NCT02882152|PROCEDURE|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
218954184|NCT02882152|PROCEDURE|morphine|Intrathecal morphine injection
218954185|NCT05284032|DRUG|isatuximab 10 mg/kg|Given by intravenous infusion
218954186|NCT02133170|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
218954187|NCT02133170|BEHAVIORAL|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
218954188|NCT02133170|BEHAVIORAL|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
218954189|NCT04507880|DEVICE|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
219638819|NCT04680000|OTHER|BCBT-CP Booster|The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
219638820|NCT06231888|DEVICE|Aligner|Orthodontic alginer
218954190|NCT04507880|DEVICE|Hemiarthroplasty|The shoulder hemiarthroplasty
218954191|NCT00045474|PROCEDURE|adjuvant therapy|
218954192|NCT00045474|RADIATION|iodine I 125|
218954193|NCT05720754|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
218954194|NCT05720754|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
219366168|NCT02417389|DRUG|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
219638821|NCT04411810|DEVICE|Nevisense 3.0|Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of \<8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
218954195|NCT06114901|OTHER|SleepFix|SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
218954196|NCT06114901|OTHER|Sleep health Education modules|Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
218954197|NCT05983783|DRUG|Docetaxel|This is Triple drug regimen for mHSPC
218954198|NCT05983783|DRUG|Rezvilutamide|This is doubling drug regimen for mHSPC
219057203|NCT03973190|PROCEDURE|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
219057204|NCT03973190|DEVICE|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
219057205|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
219057206|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
219057207|NCT05026957|DEVICE|SharedHeart|A smartphone application
219057208|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
219366210|NCT04446364|OTHER|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
219366211|NCT04446364|OTHER|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
219638822|NCT04411810|DEVICE|Dermlite Cam|Dermlite Cam is a digital camera that captures images of the skin under cross-polarized and non-polarized light and is 510(k) exempt. The DermLite Cam device appears as a single piece camera with a charging cable and USB computer cable. As part of the camera unit, an extensor arm exists to allow for the capture of standardized clinical images. The DermLite Cam will be used to acquire 3 images of \<5 seconds per lesion (one clinical, one polarized dermoscopic, and one non-polarized dermoscopic). NOTE - for the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
219638823|NCT04411810|PROCEDURE|Skin biopsy|A skin biopsy is a small procedure that removes a sample of skin from the surface of the body. The method utilized will be either a shave or punch technique. The maximum size of a punch biopsy will be 6mm and these wounds are generally closed with no more than 2-3 sutures. A skin biopsy takes \<15 minutes including preparation time, administration of intradermal anesthesia using lidocaine 1% with epinephrine 1:100,000, removal of the skin sample, achievement of hemostasis, dressing the wound, and providing instructions for home care. Samples will be placed formalin for routine processing.
218954199|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
218954200|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
218954201|NCT01143233|OTHER|control formula|infants are fed a commercial hydrolyzed formula
218954202|NCT01143233|OTHER|intervention formula 1|formula has hydrolysed protein and a different protein content
218954203|NCT01143233|OTHER|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
218954204|NCT01143233|OTHER|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
218954205|NCT03049293|DRUG|Midazolam|The impact of Midazolam levels in follicular fluid.
218954206|NCT04935671|DIETARY_SUPPLEMENT|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
218954207|NCT02648828|OTHER|Clinical deterioration|Patients at risk of clinical deterioration
218954208|NCT06050603|DEVICE|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
218954209|NCT06107179|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
218954210|NCT02835352|OTHER|Essential oils massages|
218954211|NCT02835352|OTHER|Oil massages|
218954212|NCT06374251|PROCEDURE|Discussion|Participate in narrative medicine sessions
218954213|NCT06374251|OTHER|Interview|Ancillary studies
218954214|NCT06374251|OTHER|Survey Administration|Ancillary studies
218954215|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
218954216|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
218954217|NCT00000187|DRUG|Ritanserin|
218954218|NCT02764021|DIETARY_SUPPLEMENT|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
218954219|NCT02764021|DIETARY_SUPPLEMENT|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
218954220|NCT04363229|OTHER|maslach burnout inventory questionnair|The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout
218954221|NCT03893344|DIAGNOSTIC_TEST|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
218954222|NCT03036475|DEVICE|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
218954223|NCT04665882|PROCEDURE|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
218954224|NCT00559832|OTHER|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
218954225|NCT02029690|DRUG|ADI-PEG 20|
218954226|NCT06074770|OTHER|no intervention|Natural exposure of iodine
218954227|NCT02739737|OTHER|Blinded manuscript|Blinded version of sham manuscript
218954228|NCT02739737|OTHER|Unblinded manuscript|Unblinded version of sham manuscript
218954229|NCT03768557|DRUG|Minocycline|Minocycline (200mg)
218954230|NCT03768557|OTHER|placebo|Lactose (400mg)
218954231|NCT01018446|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
218954232|NCT01721785|DRUG|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
218954233|NCT01556347|DRUG|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
218954234|NCT02531971|DRUG|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
218954235|NCT02531971|DRUG|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
218954236|NCT02531971|DRUG|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
218954237|NCT02013141|DRUG|Telavancin|
218954238|NCT04572438|PROCEDURE|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
218954239|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
218954240|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
218954241|NCT04172129|DEVICE|Total Hip Arthroplasty|
218954242|NCT01153464|BEHAVIORAL|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
218954243|NCT00612729|PROCEDURE|Polylens Y30 intraocular lens|cataract surgery
218954244|NCT00612729|PROCEDURE|Orange Series Model PC 440 Y intraocular lens|cataract surgery
218954245|NCT00016900|DRUG|liposomal paclitaxel|
218954246|NCT01378182|GENETIC|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
218954247|NCT01475071|DRUG|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
219057209|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
219057210|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
219057211|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
219057212|NCT00002010|DRUG|Fluconazole|
219057213|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
219057214|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
219057215|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
219057216|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
219057217|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
219057218|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
219057219|NCT00199862|DRUG|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
219057220|NCT01826500|OTHER|blood test|blood test
219057221|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
219057222|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
219057223|NCT00088296|PROCEDURE|Blood Draw|
219638824|NCT04411810|DEVICE|Barco Demetra|Barco Demetra is a non-invasive skin imaging system, which acquires multispectral and white light dermoscopic images and clinical photographs of the skin which can then be stored, retrieved, displayed, and reviewed by medical practitioners. The Barco Demetra received 510(k) Premarket approval (K192829). The system involves a hardware imaging device and a stand-alone software application. The hardware device is a portable, battery-powered medical device for acquiring and visualizing images of the skin and uploads all images to cloud storage. The software application is cloud software with an associated web application; it can be used to visualize images and related data and can generate consultation reports. For the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
219638825|NCT04495972|DIETARY_SUPPLEMENT|Intestinimonas-capsules|Capsules containing microbiota (Intestinimonas)
219638826|NCT04495972|DIETARY_SUPPLEMENT|Placebo-capsules|Placebo capsules are identical to the active treatment
219638827|NCT05670665|OTHER|Threatened preterm labor|Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
219638828|NCT06969131|PROCEDURE|Open Partial Nephrectomy|Patients underwent open partial nephrectomy.
219638829|NCT06969131|PROCEDURE|Laparoscopic Partial Nephrectomy|Patients underwent laparoscopic partial nephrectomy.
218954248|NCT01475071|DRUG|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
218954249|NCT01343823|DRUG|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
218954250|NCT01343823|DRUG|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
218954251|NCT01343823|DRUG|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
218954252|NCT01343823|DRUG|placebo|Administered as two SC 3 mL injections
219057224|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
219057225|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
219057226|NCT03973242|DEVICE|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
219638830|NCT06967376|PROCEDURE|Corneal Collagen Cross-Linking Solutions|Topical anaesthesia was achieved using 0.4% benoxinate hydrochloride drops. Epithelium was removed up to 9 mm diameter. Corneal thickness of the area to be treated was measured (without epithelium) aiming for a starting thickness of no less than 350μm. Corneas thicker than 500μm were dehydrated to reduce thickness by using 70% Glycerol drops applied topically at intervals of 2-3 seconds for a total of five minutes. A schematic representation of PACK-CXL protocol is provided in Figure 1. Iso-osmolar riboflavin drops were instilled topically on the cornea at regular intervals of 2 minutes for a total period of 30 minutes. Thickness was also re-measured every 5 min to ensure that it remained below 500µm during instillation of riboflavin. The cornea was illuminated using a UVX, UV-A 365 nm with an irradiance of 3 mW/cm2 for 30 minutes and a total dose of 5.4 J/cm2 during which riboflavin was instilled every 2 min and corneal pachymetry performed every 5 min. PACK-CXL was performed in a 9
219638831|NCT06967376|DRUG|Topical Antimicrobial/Antifungal Medications|Initial antimicrobial therapy for both groups consisted of fortified vancomycin eye drops 50 mg/ml, fortified ceftazidime eye drops 50 mg/ml hourly, and the antifungal agent itraconazole 100 mg orally twice per day. This regimen was subject to change according to microbiology culture sensitivities and/or results.
218954253|NCT01343823|DRUG|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
219057227|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
219057228|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
219057229|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
219057230|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
219057231|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
219057232|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
219057233|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
219057234|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
219057235|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
219057236|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
219057237|NCT05038137|BEHAVIORAL|Time restricted feeding|Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
219366212|NCT00755833|DRUG|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
219638832|NCT06969365|OTHER|10-pound weighted lap-pad|10-pound weighted lap pad will be placed over the patient's chest and shoulders
218954254|NCT01343823|DRUG|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
218954255|NCT04733391|OTHER|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
218954256|NCT00352716|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
218954257|NCT05392933|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
218954258|NCT06455618|PROCEDURE|not Indwelling the ureteral stent|"Before the end of surgery, the urologist does not Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
218954259|NCT06455618|PROCEDURE|Indwelling the ureteral stent|"Before the end of surgery, the urologist Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
218954260|NCT02794610|DRUG|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
219057238|NCT05038137|BEHAVIORAL|Control|Participants will have a daily eating period equal to or greater than 12 hours.
219057239|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
219366213|NCT01770600|OTHER|placebo|placebo pill administered daily for 5 days
219366214|NCT01770600|DRUG|Riperidone|1 mg risperidone administered orally for 5 days
219366215|NCT04992975|OTHER|MRI at 7T|MRI at 7T
218954261|NCT02050971|BIOLOGICAL|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
218954262|NCT02050971|BIOLOGICAL|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
218954263|NCT03505827|DIAGNOSTIC_TEST|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
218954264|NCT04537221|BIOLOGICAL|Blood transfusion|Transfusion of red blood cells peri-operatively
218954265|NCT04729478|DEVICE|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
218954266|NCT04729478|DEVICE|Natural sleep endoscopy|Endoscopy during natural sleep.
218954267|NCT00923364|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
218954268|NCT00923364|DRUG|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
218954269|NCT00923364|PROCEDURE|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
218954270|NCT00923364|PROCEDURE|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
218954271|NCT00923364|DRUG|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
218954272|NCT03045510|DRUG|decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
219638833|NCT06969365|OTHER|blanket|A simple, unweighted blanket will be applied to patients during IUD insertion
219638834|NCT06123169|DRUG|Antibioprophylaxis (Piperacillin-tazobactam)|antibiotic prophylaxis during surgery
219638835|NCT06123169|DRUG|5 days Antibiotherapy (Piperacillin-tazobactam)|5 days Antibiotherapy from surgery
219638836|NCT06576986|DIETARY_SUPPLEMENT|Symbiotic|The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
218954273|NCT00146588|DRUG|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
218954274|NCT00146588|DRUG|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
218954275|NCT00146588|DRUG|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
218954276|NCT03790007|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
218954277|NCT01011478|DRUG|rosuvastatin|
218954278|NCT01011478|OTHER|placebo|
218954279|NCT02403388|OTHER|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
218954280|NCT00827671|DRUG|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
218954281|NCT00827671|RADIATION|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
218954282|NCT04163731|OTHER|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
218954283|NCT04508764|OTHER|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
218954284|NCT04121351|OTHER|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
218954285|NCT01354054|PROCEDURE|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
218954286|NCT01354054|PROCEDURE|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
219057240|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
219057241|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
219057242|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
219057243|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
218954287|NCT01354054|PROCEDURE|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
218954288|NCT02924415|BEHAVIORAL|Tele-care support|Psychoeducation treatment based on telemedicine
218954289|NCT02924415|OTHER|Control group|Standard care
218954290|NCT02925533|DRUG|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
219638837|NCT06576986|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
219638838|NCT06969144|PROCEDURE|cholecystectomy|The indications for elective cholecystectomy were symptomatic cholelithiasis, a GB polyp more than ten millimeters, a history of cholecystitis, biliary pancreatitis, or choledocholithiasis. Patients with cholecystitis and severe or moderately severe pancreatitis were operated on after six weeks of the event. Other patients received surgery at the earliest available date. All patients with choledocholithiasis underwent endoscopic retrograde cholangiopancreatography (ERCP) and stone clearance before cholecystectomy. Patients who underwent laparoscopic cholecystectomy were evaluated by surgical and anesthesia teams in outpatient clinics and co-morbid conditions were optimized. Preoperative antibiotic prophylaxis was given to all the patients before induction of anesthesia.
219638839|NCT03911063|BEHAVIORAL|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
219057244|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
219057245|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
219057246|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
219057247|NCT03726112|DEVICE|Sham Specs|Sham device
219057248|NCT01809626|DRUG|Zolpidem|
219057249|NCT01809626|OTHER|Placebo|
219057250|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
219057251|NCT04865094|OTHER|placebo|placebo
219057252|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
219057253|NCT02340559|BEHAVIORAL|Psychoeducational group|
219057254|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
219057255|NCT03376204|OTHER|No intervention|No intervention
219057256|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
219057257|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
219057258|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
219057259|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
219057260|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
219057261|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
219057262|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
219057263|NCT00103649|DRUG|xaliproden (SR57746A)|
219057264|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
218954291|NCT02925533|DRUG|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
218954292|NCT04306679|OTHER|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
218954293|NCT04306679|OTHER|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
218954294|NCT01505504|DRUG|mirtazapine|30 mg at bedtime
219057265|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
218954295|NCT04563676|BIOLOGICAL|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
218954296|NCT00794027|BEHAVIORAL|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
218954297|NCT00794027|BEHAVIORAL|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
218954298|NCT02597816|RADIATION|Three dimensional ultrasound|
219638840|NCT03911063|BEHAVIORAL|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
218954299|NCT01403272|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
218954300|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
218954301|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
218954302|NCT00564720|DRUG|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
218954303|NCT00564720|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
218954304|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
219057266|NCT06554574|DRUG|LTG-305|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
219057267|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
219638841|NCT06969248|BEHAVIORAL|Intervention Group|Fathers will be provided with a total of 8 weeks of training and videos. The training will cover the role of fatherhood and its historical development, the developmental stages and care needs of babies, ways for fathers to participate in baby care and the benefits of participation, father-infant bonding and influencing factors, and paternal depression. Videos on the subject will be shared with fathers.
218954305|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
218954306|NCT01919840|PROCEDURE|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
218954307|NCT01919840|OTHER|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
218954308|NCT01111409|DEVICE|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
219057268|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
219057269|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
219057270|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
219057271|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
219057272|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
219057273|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
219057274|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
219057275|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
219057276|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
219057277|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
219057278|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
219057279|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
219057280|NCT00153101|DRUG|Telmisartan|
219057281|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
218954309|NCT04352127|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
219057282|NCT00153101|DRUG|Ramipril|
219057283|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
219057284|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
219057285|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
219057286|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
219057287|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
219057288|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
219057289|NCT00000601|DRUG|estrogen replacement therapy|
219057290|NCT00000601|DRUG|estrogens|
219057291|NCT00000601|DRUG|progesterone|
219057292|NCT00000601|DRUG|hormone replacement therapy|
219057293|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
219057294|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
219057295|NCT02928692|DRUG|Minocycline|
219057296|NCT02928692|DRUG|Placebo|
218954310|NCT01385332|PROCEDURE|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
218954311|NCT01385332|PROCEDURE|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
219638842|NCT02866292|OTHER|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
219638843|NCT06967168|BEHAVIORAL|Virtual consultation|Virtual (telephone) consultation with a podiatrist, who will provide self-management advice to the participant including advice on footwear, massage, and stretching. Supplemented by written advice leaflets.
219638844|NCT06967168|BEHAVIORAL|Self-help video|Self-help video providing self-management advice to the participant including advice on footwear, massage, and stretching. Available online or as a DVD.
219638845|NCT06967168|DEVICE|Orthotics|"Provision of orthotics following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Podiatrists prescribe, produce, and fit orthotic devices to be worn inside footwear. The devices used in this feasibility study will be selected according to individual patient needs. All will have regulatory certification (CE mark) and will be used in accordance with the manufacturer's Instructions For Use."
219638846|NCT06967168|DEVICE|Shockwave therapy|"A 3-week course of Shockwave therapy following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Extracorporeal shockwave therapy (ESWT) is delivered by a podiatrist in an outpatient clinic. Most patients lie down during the procedure. The machine passes pulses of energy through the skin towards the injured area of the heel. This encourages the body to respond and aims to stimulate the healing process. Participants will need to attend the clinic approximately once a week for three weeks to complete the course of treatment."
219638847|NCT05162924|OTHER|Spinal Manipulation|Manual therapy technique applied by a chiropractor in the form of a high-velocity low-amplitude force to the lumbopelvic spine
219638848|NCT05162924|OTHER|Placebo|Placebo spinal manipulation consisting in the application by a chiropractor of a lower-velocity lower-amplitude force to gluteal muscles in a non-intentional direction
219638849|NCT06968364|DEVICE|Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.|The Cervisense Intravaginal Probe V0.1 measures cervical stiffness. It is an in-vivo predictive technology that, by using torsional waves, quantifies the mechanical properties (specifically the shear modulus, or resistance of the cervix to shear deformation (kPa), of cervical tissue with extremely high precision. Torsional wave is a type of mechanical wave characterized by a rotational motion and low energy levels (it uses 1000 times less energy than other mechanical waves such as ultrasound). These waves propagate through the tissue, and their propagation speed, which is related to the stiffness (waves propagate faster in stiffer tissues), is measured using piezoelectric sensors.
219638850|NCT06968364|DEVICE|Transvaginal ultrasound|Cervicometry measured with transvaginal ultrasound
219638851|NCT06968013|BEHAVIORAL|Well-Being Therapy|Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
219638852|NCT06968013|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
219638853|NCT05462938|DRUG|Continuous infusion of propofol|Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.
218954312|NCT00413088|DRUG|bemiparin|
218954313|NCT05438108|COMBINATION_PRODUCT|SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab|SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
218954314|NCT02233764|OTHER|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
219057297|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
219057298|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
219057299|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
218954315|NCT02233764|OTHER|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
218954316|NCT00611910|DEVICE|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
218954317|NCT00611910|DEVICE|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
218954318|NCT00611910|DEVICE|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
219638854|NCT05462938|DRUG|Continuous infusion of dexmedetomidine|Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
218954319|NCT00611910|DEVICE|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
218954320|NCT04687618|DEVICE|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
219638855|NCT06967402|OTHER|Experimental (chlorhexidine)|Test group: administration of experimental antiseptic (CHX 0.12%+CPC 0.05%) for 3 weeks
219638856|NCT06967402|OTHER|Control (chlorhexidine with cetylpyridinium chloride)|Active comparator: administration of control antiseptic (CHX 0.2%) for 3 weeks
219638857|NCT06967090|DEVICE|Implant surgery using surgical guide|Dental implant surgical guides are customized device used to position dental implants to ensure that the implant is placed in the most ideal location, angulation and depth into the bone.
219638858|NCT06969300|DEVICE|Gold micro needles|The treatment (with gold microneedles) was administered on the day of enrollment after the completion of the detection items. Follow-up visits were conducted at 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks. The follow-up contents included visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
219638859|NCT06969300|DRUG|Gold micro-needles combined with salicylic acid|On the day of enrollment, the treatment was administered (gold microneedle + 30% salicylic acid on half of the face) after the completion of the detection items. A site follow-up was conducted one week later, and a follow-up was carried out two weeks later with the second acid brushing treatment. A follow-up was conducted four weeks later with the third acid brushing treatment. Follow-up was also conducted at the eighth and twelfth weeks. The follow-up contents included: Visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
218954321|NCT04687618|DEVICE|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
218954322|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
218954323|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
219057300|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
219638860|NCT06966752|OTHER|NIPPV|"NIPPV~* PEEP 6-8 cmH2O~* PIP: 14-16 cmH2O~* Tinsp: 0.3-0.5sec~  * \<28 weeks GA: 0.3 - 0.4 sec~ * \>28weeks GA: 0.4 - 0.5 sec~* Rate: 20-35 breaths per minute."
219638861|NCT06966752|OTHER|CPAP|CPAP pressure of 6-8 mmH2O
219638862|NCT06966687|DRUG|Ulinastatin and Thymosin α1|Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery
218954324|NCT01437995|DRUG|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
218954325|NCT03850288|OTHER|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
218954326|NCT03850288|OTHER|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
218954327|NCT02856126|PROCEDURE|Hepatic arterial infusion chemotherapy|
218954328|NCT02856126|PROCEDURE|Transarterial chemoembolization|
218954329|NCT02856126|DRUG|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
218954330|NCT02856126|DRUG|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
218954331|NCT02856126|DRUG|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
219057301|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
219057302|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
219057303|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
219366216|NCT03987087|RADIATION|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
219638863|NCT06966687|DRUG|Ulinastatin only|Ulinastatin (100000U TID for 5 days) immediately after surgery
219638864|NCT06968806|DRUG|Ketorolac|patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection preoperatively followed by 30mg twice daily for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.
219638865|NCT06968806|DRUG|0.9 % saline|0.9% saline
219638866|NCT06967207|OTHER|Not applicable- observational study|Not applicable- observational study
219638867|NCT06968585|DRUG|A166|intravenous(IV) infusion (Q3W)
219638868|NCT06968585|DRUG|T-DM1|intravenous(IV) infusion (Q3W)
219638869|NCT06968507|DRUG|Methylprednisolone (drug)|In our study, we use methylprednisolone as a oral treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days)
218954332|NCT05883371|OTHER|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
218954333|NCT05737602|BEHAVIORAL|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
218954334|NCT00710437|DRUG|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
218954335|NCT02906228|RADIATION|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
218954336|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
218954337|NCT05946265|DEVICE|Photobiomodulation|120 patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) The dosimetric parameters for the treatment included a wavelength of 660 nm applied in continuous mode with a radiant power of 100 mW (0.1 W). The irradiance ranged from 35.385 mW/cm² to 35 W/cm², with a beam area of 0.002826 cm². Each point received an exposure time of 30 seconds, resulting in a radiant exposure of 1.061 J/cm² and a total radiant energy of 3 J. The procedure involved six irradiated points per tooth, distributed across the vestibular surface (apical, middle, and cervical regions) and the palatal surface. The application technique was performed in contact, maintaining a 90-degree angle to the surface. The treatment consisted of a single session.
218954338|NCT05946265|DEVICE|simulation of Photobiomodulation|Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
218954339|NCT01924702|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
218954340|NCT01924702|DEVICE|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
218954341|NCT04456673|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
218954342|NCT04456673|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
218954343|NCT04456673|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
218954344|NCT04456673|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
218954345|NCT04456673|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
218954346|NCT04391049|DRUG|Carboplatin|Intravenously (IV)
218954347|NCT04391049|DRUG|Paclitaxel|Intravenously (IV)
218954348|NCT04391049|RADIATION|Radiation Therapy|Daily fractions
219057304|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
218954349|NCT04391049|BIOLOGICAL|Telomerase-specific Type 5 Adenovirus OBP-301|Intra-tumoral injection
218954350|NCT04974775|DIAGNOSTIC_TEST|Blood collection|Sampling on admission to ICU (all patients)
219057305|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
219057306|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
219057307|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
219638870|NCT06968507|DRUG|Dexamethasone|In our study we use dexamethasone 8mg/2ml form as intratympanic treatment every other day, totally 4 doses.
219638871|NCT05406479|DRUG|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
219638872|NCT05406479|DRUG|SDR-PEP|Single dose of Rifampicin
219638873|NCT05406479|DRUG|BE-PEP (Rifampicine)|Single dose of Rifampicin
219638874|NCT06968598|OTHER|blood sample|blood sample
219638875|NCT06968377|DEVICE|A novel airborne pathogen containment device.|The dome is placed over the patient's head during the full duration of a surgery (intubation and extubation included) as a method of preventing infection transmission through airborne aerosols throughout a hospital.
219638876|NCT06967857|DRUG|DEX IR tablets|tablet twice daily
218954351|NCT04974775|DIAGNOSTIC_TEST|Blood collection, serial sampling|"Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months."
219057308|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
219638877|NCT06967857|DRUG|DEX XL|capsule once daily
219638878|NCT06967857|DRUG|Placebo|Placebo to either capsule or tablet
219638879|NCT06969235|BEHAVIORAL|intensive health behavior and lifestyle treatment|the IHLBT will consist of 18 group meetings over 6 months that teens and parents attend. Topics covered during the meetings will include discussions regarding nutrition and physical activity recommendations, family communication, and use of strategies like monitoring, planning, goal setting, and problem solving.
219638880|NCT06969222|PROCEDURE|Robotic TKA|Total knee replacement of arthritic knees either with robotic-assisted Skywalker device
219057309|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
219057310|NCT03103620|DEVICE|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
219638881|NCT06969222|PROCEDURE|Conventional TKA|Total knee replacement of arthritic knees performed manually
219638882|NCT05801783|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
219638883|NCT06966843|DRUG|Dantrolene|Dantrolene sodium capsule 25 mg orally once daily for 4 weeks. Dose may be titrated to 50 mg daily after 1 week if tolerated. Used to assess impact on muscle pain and biomarkers of muscle injury in patients with statin-induced myopathy.
219638884|NCT06966843|DRUG|Placebo|Oral placebo capsule matching dantrolene in size and appearance, administered once daily for 4 weeks.
218954352|NCT03579017|DIAGNOSTIC_TEST|ECAS-N|All participants included will be tested with the ECAS-N
218954353|NCT03579017|DIAGNOSTIC_TEST|MoCA|All included patients With ALS will be tested With the MoCA
219057311|NCT01470755|DRUG|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
219638885|NCT06967649|DEVICE|TITANIUM IMPLANT|The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.
219638886|NCT06966947|BEHAVIORAL|Risk Early Warning Management|"This intervention involves a perioperative risk early warning management strategy for hip fracture patients. A dedicated team of nurses is responsible for monitoring vital signs (heart rate, blood pressure, respiratory rate, temperature, and consciousness level) to identify and respond to early signs of clinical deterioration.~The intervention follows a structured scoring system that classifies patients into different risk levels based on their vital signs:~Risk Score 0-4: Standard perioperative care and monitoring~Risk Score 5-7 (or single-item score ≥3): Intensive monitoring with vital sign checks every 4 hours and immediate physician notification if condition changes~Risk Score ≥7: Continuous monitoring, with immediate physician availability and ready access to emergency equipment The intervention aims to improve patient outcomes by ensuring early identification of deterioration and more rapid response to clinical changes. A red warning sign will also be placed at the patient's b"
219638887|NCT06966947|BEHAVIORAL|Standard Perioperative Care|"This is the standard care protocol for patients undergoing hip fracture surgery at the study hospital. It includes health education before surgery, regular vital sign monitoring, routine anticoagulation, and infection control management.~Patients will receive standard perioperative management, including preoperative counseling, assistance with rehabilitation exercises, and monitoring of clinical symptoms and vital signs throughout the surgical and recovery process.~There is no specific risk early warning scoring system in this group, and intervention is based on routine clinical monitoring."
219638888|NCT06967532|DIAGNOSTIC_TEST|Blood test|Blood sampling
219638889|NCT06564675|DIAGNOSTIC_TEST|C-Trend Index|C-trend-Index is collected blinded from the patients using Brainstatus device. The device shows and collects also cEEG. These are analyzed retrospectively after all study patients have their 6-month follow-up data collected. The intervention does not affect clinical management or decision-making.
219638890|NCT05220449|OTHER|Cross-frequency dual-site tACS|Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
219638891|NCT03021083|DEVICE|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
218954354|NCT06307418|OTHER|Carer eSupport|Internet-based support
218954355|NCT05804188|OTHER|tracheal intubation|children between 0-16 requiring tracheal intubation
218954356|NCT05189106|DRUG|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
218954357|NCT03874429|DEVICE|T2259|Sodium Hyaluronate and Trehalose
219057312|NCT01470755|DRUG|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
218954358|NCT03874429|DEVICE|Vismed multi|HA
218954359|NCT05770674|DRUG|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI"
218954360|NCT04661098|PROCEDURE|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
219057313|NCT01470755|DRUG|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
219057314|NCT01470755|DRUG|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
218954361|NCT04008043|DRUG|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
218954362|NCT04008043|DRUG|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
219057315|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
218954363|NCT02515812|DRUG|I-123-MIBG|
219057316|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
218954364|NCT02515812|DEVICE|CZT Camera (D-SPECT)|
218954365|NCT02515812|DEVICE|Anger Camera|
218954366|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
218954367|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
218954368|NCT05518838|DRUG|OKN-007|OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
218954369|NCT01953263|OTHER|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
218954370|NCT05308719|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
218954371|NCT05924295|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will be given 360mg/kg
218954372|NCT05924295|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
218954373|NCT05924295|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
218954374|NCT05924295|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
218954375|NCT04741464|DRUG|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
219057317|NCT02362399|DRUG|sildenafil citrate|single oral dose of 50 mg
219057318|NCT02362399|OTHER|placebo|single oral dose of placebo tablet
219057319|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
219057320|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
219057321|NCT04369027|DIAGNOSTIC_TEST|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
219057322|NCT04995380|PROCEDURE|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
219057323|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
219057324|NCT06158633|DRUG|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
218954376|NCT03738748|OTHER|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
218954377|NCT03738748|OTHER|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
218954378|NCT05601492|DRUG|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
218954379|NCT05601492|BEHAVIORAL|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
218954380|NCT05601492|BEHAVIORAL|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
219638892|NCT03789760|DRUG|SaiLuoTong capsule|500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
219638893|NCT03789760|DRUG|placebo|500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
219638894|NCT03938844|PROCEDURE|BURCH Colposuspension|stress urinary incontinence surgery ( burch or tot)
219366217|NCT03987087|DRUG|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
219366218|NCT00383045|DRUG|Buprenorphine/Subutex|
218954381|NCT06304636|DRUG|Descartes-15|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
218954382|NCT05356728|DRUG|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
218954383|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
218954384|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
218954385|NCT05660421|DRUG|Itacitinib|Given by mouth
218954386|NCT05660421|DRUG|Corticosteroid|Given by mouth or by vein
218954387|NCT05660421|PROCEDURE|Endoscopic Procedure|Undergo endoscopic procedure
218954388|NCT05660421|PROCEDURE|Skin biopsy|Undergo skin biopsy
218954389|NCT05660421|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
218954390|NCT05638789|PROCEDURE|endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)|EST alone vs EST plus EPLBD in removing common bile duct stone
218954391|NCT02679963|DRUG|Olaparib|
218954392|NCT02679963|DRUG|Placebo|
219366219|NCT00383045|DRUG|Naltrexone|
219366220|NCT00383045|PROCEDURE|Drug counseling|
219638895|NCT03938844|PROCEDURE|TOT|
219638896|NCT03510845|PROCEDURE|Arthroscopic ACL Primary Repair|"All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle."
219638897|NCT03510845|PROCEDURE|Arthroscopic ACL Reconstruction|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
219638898|NCT04511520|OTHER|Physical training program|
219638899|NCT04511520|DRUG|Trimetazidine|
219638900|NCT05368220|OTHER|Whole genome sequencing|Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.
218954393|NCT05688384|DRUG|Propofol + Alfentanil|In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
218954394|NCT01203644|DRUG|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
218954395|NCT01203644|DRUG|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
219638901|NCT01699269|OTHER|peritumoral glial cell infiltration|
218954396|NCT00002671|DRUG|aminocamptothecin|
218954397|NCT04211220|OTHER|A decision support software|Insulin pump Continuous glucose monitoring
218954398|NCT03183154|OTHER|no intervention|no intervention
218954399|NCT05926375|DIETARY_SUPPLEMENT|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
218954400|NCT04618627|OTHER|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
219366221|NCT04545255|DEVICE|Shockwave treatment|ED 1000 shockwave generator
219638902|NCT04481269|DEVICE|Surface-modified composite coated orthopedic implants|The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.
219638903|NCT04481269|DEVICE|conventional orthopedic implants|conventional orthopedic implants
219638904|NCT00502112|DRUG|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
219638905|NCT00502112|DRUG|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
219638906|NCT01609855|DRUG|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
219057325|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
219057326|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
219057327|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
218954401|NCT00645255|DRUG|placebo|placebo one capsule daily
218954402|NCT00645255|DRUG|sibutramine or placebo|one capsule daily
218954403|NCT05453734|PROCEDURE|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
219057328|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
219638907|NCT01609855|DRUG|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
219638908|NCT00510536|DRUG|Acetaminophen|dose to be determined by investigator
218954404|NCT01215916|DRUG|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\]."
218954405|NCT01215916|DRUG|Pemetrexed|"375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
218954406|NCT05028361|BIOLOGICAL|mRNA COVID-19|ACIP-CDC recommended vaccine
218954407|NCT05028361|BIOLOGICAL|IIV4|ACIP recommended vaccine
218954408|NCT05028361|OTHER|Placebo (saline)|Saline Control
218954409|NCT00465309|PROCEDURE|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat \< 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH \> 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
218954410|NCT05855876|PROCEDURE|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
218954411|NCT06449404|OTHER|7T-MRI scaning|7T-MRI scaning
219057329|NCT05234346|OTHER|Placebo|No Description for the intervention
219057330|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
219057331|NCT04023006|DEVICE|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
219057332|NCT03006406|DRUG|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
219057333|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
219057334|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
219057335|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
219638909|NCT00510536|DRUG|NSAID|dose to be determined by investigator
219638910|NCT02913443|DRUG|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
219638911|NCT02815332|DRUG|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
219638912|NCT02815332|DRUG|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
219638913|NCT02815332|DRUG|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
219638914|NCT02631122|PROCEDURE|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
219638915|NCT00005616|PROCEDURE|conventional surgery|
219638916|NCT00005616|PROCEDURE|neoadjuvant therapy|
219638917|NCT00005616|PROCEDURE|radionuclide imaging|
219638918|NCT00005616|RADIATION|iodine I 131 monoclonal antibody F19|
218954412|NCT00618098|BIOLOGICAL|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
219057336|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
219057337|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
219057338|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
219057339|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
219057340|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
219057341|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
219638919|NCT01514539|OTHER|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
219638920|NCT00638716|DRUG|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
219638921|NCT00638716|DRUG|Placebo|Placebo
219638922|NCT00952159|BIOLOGICAL|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
219057342|NCT02327208|DIETARY_SUPPLEMENT|Control|
219057343|NCT02327208|DIETARY_SUPPLEMENT|Protein|
219057344|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
219057345|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
219057346|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
219638923|NCT03028909|DRUG|Oseltamivir|Standard of care for influenza caused by Type A strains
219638924|NCT03028909|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
219638925|NCT03028909|DRUG|Placebo|Salt-water solution containing no active ingredients.
219638926|NCT04623099|DRUG|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
219057347|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
219057348|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
219057349|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
219057350|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
219638927|NCT01859065|BEHAVIORAL|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
219638928|NCT01859065|BEHAVIORAL|Routine|Routine anticipatory guidance (control)
219638929|NCT00627965|DRUG|Sildenafil citrate|50mg tds
219638930|NCT00627965|DRUG|Placebo|Placebo tds
219638931|NCT00746746|BIOLOGICAL|HyperAcute vaccine|1.8 mL weekly
219638932|NCT00746746|DRUG|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
219638933|NCT05461001|OTHER|Warm Up Exercises|The daily warm up exercises for male football players include full body stretch, high knees, lunges, squat and burpees.
219638934|NCT05461001|OTHER|Endurance Based Exercises|Sport-specific endurance-running (duration \[in minutes\], total distance \[in meters\], mean speed \[in meters per minute\], high-speed running \>15 km·h-1, and relative high-speed running \[\>75% and \>85% of maximal velocity\]) will be given to the experimental group. Athletes will run in excess of 15 km of total distance (TD) and 4 km of high-speed (\>15 km·h-1) distance per session 3 to 4 running-based endurance sessions per week for 6 weeks.
219638935|NCT00321295|DEVICE|Atrial synchronous bi-ventricular pacing|
219638936|NCT02299232|DRUG|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
219638937|NCT01443585|DEVICE|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
219638938|NCT04141683|DIAGNOSTIC_TEST|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
219638939|NCT04141683|DIAGNOSTIC_TEST|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
219638940|NCT04141683|PROCEDURE|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
219638941|NCT03290261|OTHER|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
219638942|NCT03951883|OTHER|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
219638943|NCT03951883|OTHER|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
219638944|NCT02763137|DRUG|Standard LD/CD|LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
219057351|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
219057352|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
219057353|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
219057354|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
219638945|NCT02763137|DRUG|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
219638946|NCT02728505|DRUG|SinuSurf irrigation twice daily|
219638947|NCT02728505|DRUG|NeilMed Sinus rinse irrigation twice daily|
219638948|NCT02780453|DEVICE|Negative pressure dressing|
219638949|NCT02780453|DEVICE|Standard wound dressing|
219638950|NCT01781845|PROCEDURE|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
219638951|NCT01473433|PROCEDURE|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
219057355|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
219638952|NCT01473433|OTHER|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
219057356|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
219057357|NCT04955626|OTHER|Placebo|Intramuscular Injection
219057358|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
219057359|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
219057360|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
219057361|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
219057362|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
219057363|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
219638953|NCT02132182|BIOLOGICAL|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
219638954|NCT05484089|DEVICE|CapFlex PIP implant|Patients receive the CapFlex PIP implant based on regular care. During surgery tantalum markers are placed in the bone surrounding the implant.
219638955|NCT05750329|PROCEDURE|assisted liver transplantation combined with two-stage hepatectomy|"Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"
219638956|NCT02159157|BEHAVIORAL|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
219638957|NCT03838289|RADIATION|multimodal magnetic resonance imaging or computed tomography|multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
219638958|NCT02533050|DEVICE|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
218954413|NCT00618098|BIOLOGICAL|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
218954414|NCT05934669|DRUG|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
218954415|NCT05934669|DRUG|Intranasal Dexmedetomidine|See above
219057364|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
219057365|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
218954416|NCT05934669|DRUG|Intranasal Ketamine|See above
219057366|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
219057367|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
219057368|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
219057369|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
219057370|NCT02290587|DEVICE|MRI|
219057371|NCT00051116|DRUG|CC-5013|
219057372|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
219057373|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
218954417|NCT04727021|DRUG|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
218954418|NCT04727021|DRUG|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
218954419|NCT03452449|PROCEDURE|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
218954420|NCT05095012|OTHER|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
218954421|NCT00912561|BEHAVIORAL|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
218954422|NCT03893253|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
218954423|NCT03893253|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
218954424|NCT06299488|OTHER|Sip2Sleep: Montmorency Cherry and Apocynum Venetum|See arm description
218954425|NCT05477433|BEHAVIORAL|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
218954426|NCT02280122|OTHER|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
218954427|NCT02047318|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
218954428|NCT00879008|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
218954429|NCT00854412|OTHER|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
219638959|NCT02423330|DEVICE|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
219638960|NCT06478966|BEHAVIORAL|Experimental|Stoma care training was delivered using the PechaKucha method for the intervention group.The presentation format involves 20 slides (usually containing images only) that are shown for 20 seconds each, for a total presentation length of 6 minutes and 40 seconds.
219638961|NCT02189343|DRUG|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
219638962|NCT01690858|OTHER|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
218954430|NCT04622228|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
218954431|NCT04622228|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
218954432|NCT04622228|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
218954433|NCT04622228|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
218954434|NCT04622228|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
218954435|NCT05088239|DRUG|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
218954436|NCT01830023|DEVICE|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
218954437|NCT06099145|DEVICE|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
218954438|NCT02296138|DRUG|olodaterol|fixed dose combination
218954439|NCT02296138|DRUG|tiotropium|fixed dose combination
218954440|NCT02296138|DRUG|tiotropium|
218954441|NCT00711516|DRUG|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
218954442|NCT00711516|DRUG|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
218954443|NCT03709732|OTHER|no intervention|observational study
218954444|NCT00224653|PROCEDURE|Mechanical Ventilation|
218954445|NCT00177710|DRUG|Amphotericin B|
218954446|NCT00184769|DRUG|somatropin|
219638963|NCT05297370|BEHAVIORAL|Mixed and match Intervention|Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
219638964|NCT05297370|OTHER|Control|Participants in the control group will receive a self-help quitting leaflet issued by the TACO
219638965|NCT04283799|DIETARY_SUPPLEMENT|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
218954447|NCT02921061|DRUG|Cladribine|Given IV
218954448|NCT02921061|DRUG|Cytarabine|Given IV
218954449|NCT02921061|DRUG|Decitabine|Given IV
218954450|NCT02921061|BIOLOGICAL|Filgrastim|Given SC
219638966|NCT02564900|DRUG|DS-8201a (DP1)|DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
219638967|NCT02564900|DRUG|DS-8201a (DP2)|DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
219638968|NCT02564900|DRUG|DS-8201a (DP)|DS-8201a (DP) is to be administered via intravenous (IV) dose.
219638969|NCT01861652|DEVICE|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
219638970|NCT04782297|DEVICE|Long term hemodialysis catheter|There will be no interventions in this study. Strictly observational.
219638971|NCT03612609|BIOLOGICAL|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
219638972|NCT04349345|DIAGNOSTIC_TEST|sperm count|total progressive sperm motile count
219638973|NCT02699931|DEVICE|Electric3D|Oral-B 3D with orthodontic head
219638974|NCT02699931|DEVICE|Manual|Oral-B orthodontic
219638975|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
218954451|NCT02921061|OTHER|Laboratory Biomarker Analysis|Correlative studies
218954452|NCT02921061|DRUG|Mitoxantrone Hydrochloride|Given IV
218954453|NCT01322776|DRUG|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
218954454|NCT01455129|DRUG|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
218954455|NCT01455129|DRUG|placebo|placebo, once daily, inhaled by HandiHaler
218954456|NCT02254239|DRUG|Brentuximab Vedotin|Given IV
218954457|NCT02254239|DRUG|Everolimus|Given PO
218954458|NCT02254239|OTHER|Laboratory Biomarker Analysis|Correlative studies
218954459|NCT02254239|OTHER|Pharmacological Study|Correlative studies
218954460|NCT01431209|OTHER|Laboratory Biomarker Analysis|Correlative studies
218954461|NCT01431209|DRUG|Ruxolitinib Phosphate|Given PO
218954462|NCT03758885|DRUG|Nolasiban|Nolasiban single oral administration
218954463|NCT03758885|DRUG|Placebo|Placebo single oral administration
218954464|NCT01711385|BEHAVIORAL|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
218954465|NCT03631108|DIAGNOSTIC_TEST|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
218954466|NCT05592873|DRUG|Neoadjuvant chemoradiotherapy (CRT)|Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
218954467|NCT04809077|OTHER|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
218954468|NCT02610959|OTHER|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
219638976|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
219638977|NCT05131373|DRUG|ORG101 - Experimental 1|C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
219638978|NCT05131373|DRUG|ORG101PL - Placebo 1|Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
219638979|NCT02807727|DRUG|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
219638980|NCT02807727|DRUG|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
219638981|NCT03090529|OTHER|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
219638982|NCT02954029|DEVICE|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
219638983|NCT02954029|DEVICE|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
219638984|NCT02954029|DEVICE|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
219638985|NCT06178029|OTHER|Acupuncture|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation and acupuncture treatment.
218954469|NCT02610959|OTHER|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
218954470|NCT00703703|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
218954471|NCT00703703|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
218954472|NCT00703703|DRUG|Placebo|Placebo tablet once daily
218954473|NCT01307605|BIOLOGICAL|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
218954474|NCT01307605|DRUG|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
218954475|NCT05858840|OTHER|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
218954476|NCT04501029|DRUG|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
218954477|NCT02787239|DRUG|HLX01|
218954478|NCT02787239|DRUG|Rituximab|
218954479|NCT02787239|DRUG|CHOP|
218954480|NCT02108262|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
218954481|NCT02108262|BIOLOGICAL|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
218954482|NCT03375073|OTHER|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
218954483|NCT00456664|GENETIC|IE gene|
218954484|NCT04964193|DRUG|Elzsa film-coated tablet|Administered with 240 mL of water
218954485|NCT04964193|DRUG|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
218954486|NCT02034344|PROCEDURE|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
218954487|NCT02034344|PROCEDURE|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
218954488|NCT02034344|PROCEDURE|Urine collection|Urine will be collected from all participants.
219638986|NCT06178029|OTHER|Conventional Rehabilitation|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation
219638987|NCT02317276|DRUG|Triamcinolone 0.1%|Topical ointment
218954489|NCT00868517|OTHER|True group auricular acupuncture|Received true group auricular acupuncture
218954490|NCT00868517|OTHER|Sham group auricular acupuncture|Received sham auricular acupuncture.
218954491|NCT00868517|OTHER|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
218954492|NCT05289401|OTHER|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
218954493|NCT04431089|DRUG|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
219638988|NCT02729766|OTHER|Induced hypotonic hyponatremia - SIAD model|
219638989|NCT02729766|DRUG|Empagliflozin 25mg Tbl|
219638990|NCT02729766|DRUG|Placebo P-Tablet|
219638991|NCT01448772|DRUG|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
218954494|NCT01982968|PROCEDURE|Surgery|Full fundoplication surgery for the treatment of abnormal GER
218954495|NCT05834595|DRUG|CKD-828, D064, D701|QD, PO
218954496|NCT00828100|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
218954497|NCT00828100|DEVICE|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A \& B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
218954498|NCT00812643|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
219057374|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
219638992|NCT01448772|DRUG|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
219057375|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
219057376|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
219638993|NCT00179439|PROCEDURE|nasal potential difference testing|
219638994|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (active）|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
219638995|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham）|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
219638996|NCT01579422|BEHAVIORAL|social cognitive training|social cognitive training, 8-10 sessions
218954499|NCT04133922|DRUG|GLP-1|glucagon-like peptide 1
218954500|NCT04133922|DRUG|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
218954501|NCT04133922|DRUG|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
218954502|NCT01447667|PROCEDURE|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
218954503|NCT00420641|DRUG|GSK372475|GSK372475 1.0-1.5 mg/day
218954504|NCT00420641|DRUG|Paroxetine|Paroxetine 20-30 mg/day
219057377|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
219057378|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
219057379|NCT04558476|OTHER|Standard of Care|Gold Standards
219638997|NCT00707525|PROCEDURE|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
219638998|NCT02673125|GENETIC|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
219638999|NCT03768154|PROCEDURE|Supine + spontaneous effort|without muscle paralysis in supine position
219639000|NCT03768154|PROCEDURE|Supine + paralysis|administer muscle paralysis in supine position
219639001|NCT03768154|PROCEDURE|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
219639002|NCT03768154|PROCEDURE|Prone + spontaneous breathing|cease the paralysis in supine position
219639003|NCT03193320|OTHER|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
218954505|NCT00420641|OTHER|Placebo|Placebo to Match
218954506|NCT00004071|DRUG|leflunomide|
218954507|NCT00004071|DRUG|mitoxantrone hydrochloride|
218954508|NCT00004071|DRUG|prednisone|
218954509|NCT05424432|DRUG|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
218954510|NCT05424432|DRUG|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
218954511|NCT05424432|RADIATION|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
218954512|NCT05787600|DRUG|Perhyal rinse|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
218954513|NCT05787600|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
218954514|NCT05787600|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
218954515|NCT04249609|OTHER|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
218954516|NCT04249609|OTHER|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
218954517|NCT05165498|PROCEDURE|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
218954518|NCT03459690|BEHAVIORAL|Meditation|Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
218954519|NCT03459690|DEVICE|Enobio 32- EEG machine|This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
218954520|NCT06044766|PROCEDURE|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
218954521|NCT02358317|BEHAVIORAL|Video Game Motor Training|
218954522|NCT02358317|BEHAVIORAL|Sedentary Video Game Training|
218954523|NCT05185206|DEVICE|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
218954524|NCT05185206|DEVICE|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
218954525|NCT04106024|DRUG|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
218954526|NCT01147133|DRUG|Plavix|1x75 mg
218954527|NCT01147133|DRUG|Kardogrel|1x75 mg
218954528|NCT06328478|DEVICE|Observational prospective study.|Observational prospective study
219057380|NCT01399359|BEHAVIORAL|Counseling session|
219057381|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
219057382|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
219057383|NCT01399359|OTHER|online questionnaire|
219057384|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
219639004|NCT04448444|BEHAVIORAL|Motor Program Activating Therapy|Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
218954529|NCT02586506|DRUG|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
219639005|NCT04448444|BEHAVIORAL|Vojta reflex locomotion|Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
219639006|NCT01895374|PROCEDURE|laser treatments|
219639007|NCT01895374|OTHER|amniotic membrane application|
219639008|NCT01895374|DEVICE|hydrocolloid application|
218954530|NCT02586506|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
219639009|NCT05899517|DRUG|oral lollipop with oxytocin (24IU)|For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.
218954531|NCT04391985|DRUG|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
218954532|NCT06092229|DIAGNOSTIC_TEST|Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
219057385|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
218954533|NCT06092229|DIAGNOSTIC_TEST|Ultrasonography with TACA approach|identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
218954534|NCT01604356|PROCEDURE|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
219057386|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
219057387|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
219057388|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
219639010|NCT05899517|DRUG|oral lollipop with placebo|For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
219639011|NCT01405339|DEVICE|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
219639012|NCT01405339|DEVICE|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
218954535|NCT02247648|DRUG|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
218954536|NCT02247648|DRUG|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
218954537|NCT03956719|DRUG|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
218954538|NCT03956719|PROCEDURE|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
218954539|NCT06492499|PROCEDURE|Zero-Fluoroscopy Radiofrequency Catheter Ablation|Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
219057389|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
219639013|NCT01559025|DRUG|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
219639014|NCT04405635|OTHER|No intervention or exposure|No intervention or exposure
219639015|NCT02293135|DEVICE|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
219639016|NCT02293135|DEVICE|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
219639017|NCT00351702|DRUG|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
219639018|NCT05000008|OTHER|Exercises|Moderate aerobic and resistance exercise programe
219639019|NCT02069808|DRUG|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
219639020|NCT02069808|DRUG|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
219639021|NCT02069808|DRUG|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
219639022|NCT02069808|DRUG|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
219639023|NCT02069808|PROCEDURE|Transvaginal ultrasound guided needle aspiration of oocytes|
218954540|NCT04865926|OTHER|Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises|The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
218954541|NCT04865926|OTHER|McKenzie and Kendall exercises|Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
219057390|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
219057391|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
219639024|NCT03461952|DRUG|Nivolumab|240mg
219639025|NCT03461952|DRUG|Ipilimumab|1mg/kg
218954542|NCT04734678|DRUG|Tocilizumab|400 mg IV only once
218954543|NCT04734678|DRUG|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
218954544|NCT04571983|OTHER|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
219057392|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
219057393|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
219057394|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
219057395|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
219057396|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
219057397|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
219639026|NCT01931475|DRUG|Duloxetine|Administered orally
219639027|NCT01931475|DRUG|Placebo|Administered orally
219639028|NCT03055299|OTHER|COMEX intervention|Comprehensive Exercise
219639029|NCT04453280|DIAGNOSTIC_TEST|Quantitative analysis of anti-SARS-CoV-2-antibodies|Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
219639030|NCT04453280|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
219639031|NCT01910480|DRUG|NBI-98854 50 mg capsule once daily|
219639032|NCT01910480|DRUG|Ketoconazole 400 mg (200 mg twice daily)|
219639033|NCT04003831|DEVICE|Device: P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
219639034|NCT06684574|OTHER|Nordic walking program|The intervention is a defined program of Nordic walking and strengthening exercises for 10 weeks in a regimen of two days per week (two 75-minute sessions per week). In these sessions, they did Nordic walking three 5-minute breaks, where strength and proprioception exercises of the lower extremities were performed.
219639035|NCT06684574|OTHER|Educational advise|Patients in the control arm participated in a single session to advise them on the need for self-exercise.
219639036|NCT03935776|BEHAVIORAL|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
219639037|NCT03935776|BEHAVIORAL|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
219639038|NCT02547389|BEHAVIORAL|Community support group|
219639039|NCT02547389|OTHER|Printed material Supported|
219639040|NCT00115492|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
219639041|NCT00115492|DRUG|Salmeterol|
219639042|NCT01998802|DRUG|Active Comparator EBI-005|
219639043|NCT01998802|DRUG|Placebo Comparator|
219639044|NCT04810000|DEVICE|tourniquet|Tourniquet release before/after wound closure
219639045|NCT05788367|PROCEDURE|The pericapsular nerve group|patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%
219639046|NCT05788367|PROCEDURE|Interscalene brachial plexus block|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
218954545|NCT01367080|DRUG|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
218954546|NCT01367080|DRUG|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
218954547|NCT02815280|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
218954548|NCT02815280|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
218954549|NCT04315584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT Scans
219639047|NCT04240639|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
219639048|NCT05592665|OTHER|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
219639049|NCT06223399|OTHER|Imaging-based programming|Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.
219639050|NCT06223399|OTHER|Threshold assessment-based programming|The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.
219639051|NCT03750149|DEVICE|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
219639052|NCT01417091|DRUG|BPS804|
219639053|NCT01901601|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
219639054|NCT01901601|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
218954550|NCT04315584|PROCEDURE|Computed Tomography|Undergo PET/CT Scans
218954551|NCT04315584|PROCEDURE|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
218954552|NCT04315584|RADIATION|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
218954553|NCT04315584|RADIATION|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
218954554|NCT04495699|OTHER|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
218954555|NCT02009605|DRUG|Icotinib|125mg, oral administration, three times per day.
218954556|NCT00448396|DRUG|Patupilone|
218954557|NCT02257762|DIETARY_SUPPLEMENT|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
218954558|NCT02257762|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
218954559|NCT02257762|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet.
218954560|NCT03127982|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
218954561|NCT05466487|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
219639055|NCT01901601|DRUG|Retrobulbar Block or General Anesthesia|
219639056|NCT01901601|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
219639057|NCT01901601|DRUG|Topical Anesthesia|
218954562|NCT05466487|BEHAVIORAL|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
218954563|NCT03965273|BEHAVIORAL|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
218954564|NCT03965273|BEHAVIORAL|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
219057398|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
219057399|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
219057400|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
219057401|NCT04558736|DRUG|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
219057402|NCT04558736|DRUG|Fludarabine|Given intravenously (IV)
219057403|NCT04558736|DRUG|Cyclophosphamide|Given intravenously (IV)
219057404|NCT04558736|DRUG|Mesna|Given intravenously (IV)
219057405|NCT04558736|DRUG|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
219057406|NCT04558736|RADIATION|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
219057407|NCT04558736|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219057408|NCT04558736|BIOLOGICAL|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
219057409|NCT04558736|BIOLOGICAL|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
219057410|NCT04010942|DRUG|Vit D|Injection
219207099|NCT05237466|BEHAVIORAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
219639058|NCT01901601|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
219639059|NCT03211260|DEVICE|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
219057411|NCT04010942|DRUG|Metformin|tablets
219057412|NCT04010942|DRUG|Clomiphene|Tablet
219057413|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
219057414|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
219639060|NCT02464774|PROCEDURE|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
219057415|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
219057416|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
219057417|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
219057418|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
219057419|NCT06852742|OTHER|Facial Cream A|The participants will use the Facial Cleanser twice daily (morning and evening). The Facial Cream A will be applied topically evenly over the entire face after cleansing and drying face in the morning and in the evening. The Sunscreen will be applied evenly over the entire face after Facial Cream A in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure.
219057420|NCT06852742|OTHER|Facial Cream B|The participants will use the Facial Cleanser twice daily (morning and evening).The Sunscreen will be applied evenly over the entire face after cleansing in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure. The Facial Cream B will be applied in the evening after washing and drying face.
219057421|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
219057422|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
219639061|NCT02464774|PROCEDURE|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
218954565|NCT00603642|DRUG|Placebo|Subcutaneously administered, once a week, for 12 weeks
219057423|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
219639062|NCT02464774|DRUG|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
219639063|NCT02464774|RADIATION|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
219639064|NCT06175026|BEHAVIORAL|Health messages|Participants view messages about the health impacts of certain dietary substitutions.
219057424|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
218954566|NCT00603642|DRUG|AMG 531|Subcutaneously administered, once a week, for 12 weeks
219057425|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
219057426|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
219057427|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
219639065|NCT06175026|BEHAVIORAL|Environmental messages|Participants view messages about the environmental impacts of certain dietary substitutions.
219639066|NCT06175026|BEHAVIORAL|Health and environmental messages|Participants view messages about the health and environmental impacts of certain dietary substitutions.
218954567|NCT01514162|DEVICE|Trifecta valve|surgical replacement of aortic valve
218954568|NCT02571738|BIOLOGICAL|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
218954569|NCT02571738|OTHER|Control|Standard of Care
218954570|NCT02394197|DRUG|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
218954571|NCT02394197|DRUG|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
218954572|NCT00040846|BIOLOGICAL|alemtuzumab|Given IV
218954573|NCT00040846|DRUG|fludarabine phosphate|Given IV
219639067|NCT06175026|BEHAVIORAL|Neutral messages|Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
219639068|NCT04081610|DRUG|lagricel ofteno multidose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
218954574|NCT00040846|RADIATION|total-body irradiation|Undergo TBI
218954575|NCT00040846|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
218954576|NCT00040846|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
218954577|NCT00040846|DRUG|mycophenolate mofetil|Given PO
218954578|NCT00040846|DRUG|cyclosporine|Given IV or PO
219639069|NCT04081610|DRUG|lagricel ofteno single dose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
218954579|NCT05036473|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
218954580|NCT05036473|DRUG|Placebo|placebo tablets-matching the active groups.
218954581|NCT00680719|BEHAVIORAL|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
218954582|NCT00680719|BEHAVIORAL|IBFT|Integrated Behavioral and Family Therapy (IBFT).
218954583|NCT02836509|DRUG|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
218954584|NCT02836509|DRUG|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
219639070|NCT01786135|DRUG|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
218954585|NCT05361902|RADIATION|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
218954586|NCT02538783|BEHAVIORAL|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
218954587|NCT01230177|DRUG|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
218954588|NCT04272879|OTHER|Observational Group|Those requiring NIV following an acute exacerbation of COPD
218954589|NCT02194257|DRUG|[14C]-cyclohexane ambroxol oral solution|
218954590|NCT02194257|DRUG|[14C]-benzyl ambroxol oral solution|
218954591|NCT02194257|DRUG|Ambroxol lozenge|
218954592|NCT02647450|OTHER|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
218954593|NCT05981976|BIOLOGICAL|Abatacept|Specified dose on specified days
218954594|NCT03990350|OTHER|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
218954595|NCT03990350|OTHER|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
218954596|NCT03990350|OTHER|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
218954597|NCT03990350|OTHER|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
218954598|NCT05959980|PROCEDURE|Posterior cervical fixation surgery|These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
218954599|NCT02433431|BEHAVIORAL|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
218954600|NCT02433431|BEHAVIORAL|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
219639071|NCT06967558|BIOLOGICAL|Exendin 9-39|Exendin 9-39 is a competitive antagonist of the GLP-1 receptor
219639072|NCT06967558|BIOLOGICAL|Saline|Saline
219639073|NCT01437254|DRUG|CPERT|Single 340 MBq CPERT scan in first 10 subjects
219639074|NCT01437254|DRUG|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
219639075|NCT00863356|DEVICE|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
219639076|NCT05169242|PROCEDURE|Endoclip|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
219639077|NCT01312883|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
219639078|NCT00860197|DIETARY_SUPPLEMENT|Fully torrefied coffee|Fully torrefied coffee
219639079|NCT00860197|DIETARY_SUPPLEMENT|Partially torrefied coffee|Partially torrefied coffee
219639080|NCT00557011|DRUG|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
219639081|NCT00557011|DRUG|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
219639082|NCT00557011|DRUG|Placebo|Placebo capsule taken once daily in the morning
218954601|NCT02433431|BEHAVIORAL|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
219639083|NCT02920008|DRUG|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
219639084|NCT02920008|DRUG|Treatment Choice (TC)|"* High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~* Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~* Best Supportive Care (BSC)."
219639085|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the first postoperative day
219639086|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
219639087|NCT05323240|OTHER|PM exposure|To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.
219639088|NCT05323240|OTHER|Filtered air exposure|To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
219639089|NCT02737930|DRUG|Fluoxetine|
219639090|NCT02737930|DRUG|Placebo|
219639091|NCT04276116|BEHAVIORAL|Pulmonary age|Communication of pulmonary age
219639092|NCT02041117|DRUG|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
219639093|NCT05429281|OTHER|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
219639094|NCT05429281|OTHER|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
219639095|NCT05429281|OTHER|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
219639096|NCT00795470|DRUG|Antimicrobial|Appropriate antimicrobial based on urine culture results
219639097|NCT00795470|DEVICE|Catheter change|Change urine catheter
219639098|NCT00936143|DRUG|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
218954602|NCT01005121|DRUG|colchicine|2mg, per-os, once daily for six months
218954603|NCT03856268|PROCEDURE|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
218954604|NCT03856268|DRUG|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
218954605|NCT04951297|OTHER|None, just observation|None ,just observation test
218954606|NCT02514473|DRUG|VX-809|
218954607|NCT02514473|DRUG|Placebo|
218954608|NCT02514473|DRUG|VX-770|
218954609|NCT02158364|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
218954610|NCT01280045|PROCEDURE|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
218954611|NCT05520242|OTHER|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
218954612|NCT03460743|BIOLOGICAL|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
218954613|NCT03460743|BIOLOGICAL|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
218954614|NCT01607203|DRUG|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
218954615|NCT01607203|DRUG|pregnyl|5000 IU SC
218954616|NCT00117533|DRUG|pegylated IFN alfa-2b plus ribavirin|
218954617|NCT01986777|DRUG|lisdexamfetamine|
218954618|NCT01986777|DRUG|Placebo|The placebo capsules will be filled with lactose.
219057428|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
219057429|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
219639099|NCT04246216|PROCEDURE|Percutaneous Electrical Nerve Stimulation|Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
219639100|NCT04246216|PROCEDURE|Endoscopic surgery of the carpal tunnel|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
219639101|NCT00436475|DRUG|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
219639102|NCT00436475|DRUG|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
219639103|NCT00436475|DRUG|Vitamin D3-Placebo|Vitamin D3-Placebo
219639104|NCT00436475|DRUG|Calcium-Placebo|Calcium-Placebo
219639105|NCT02698332|DEVICE|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
218954619|NCT03425422|DEVICE|VITARIA System|Chronic stimulation of the right cervical vagus nerve
218954620|NCT03332511|DRUG|Nilotinib|Nilotinib 300mg twice-daily
218954621|NCT03463876|DRUG|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
218954622|NCT02373501|PROCEDURE|Intra-abdominal repair|Intra abdominal repair of uterine incision
218954623|NCT02373501|PROCEDURE|Extra-abdominal repair|Extra abdominal repair of uterine incision
218954624|NCT05810818|DIAGNOSTIC_TEST|Dry Needling|Dry needling treatment will be consisting of two treatments per week
218954625|NCT05810818|DIAGNOSTIC_TEST|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
219057430|NCT01898793|DRUG|Fludarabine|
219057431|NCT01898793|DRUG|Cyclophosphamide|
219057432|NCT01898793|PROCEDURE|Leukapheresis|
219057433|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
219057434|NCT01898793|BIOLOGICAL|IL-2|
219057435|NCT01898793|DRUG|ALT-803|
219057436|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
219057437|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
219639106|NCT02557802|BIOLOGICAL|Fluenz Tetra|Intranasal spray, 0.2 ml dose
219639107|NCT02557802|BIOLOGICAL|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
219639108|NCT04614181|DIETARY_SUPPLEMENT|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
219639109|NCT04614181|OTHER|Usual care|Usual fracture care as determined by clinical team
219639110|NCT01103258|PROCEDURE|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
219639111|NCT01103258|PROCEDURE|FOAM|duplex guided foam sclerotherapy
219639112|NCT00839813|BEHAVIORAL|Yoga|10 weeks of a trauma-sensitive yoga class
218954626|NCT00674154|DRUG|Cholecalciferol|2800 IE daily in 52 weeks
218954627|NCT04637828|DRUG|GNS561|study drug
218954628|NCT01178827|DRUG|trospium chloride|trospium chloride (60mg) once daily for 10 days
218954629|NCT01178827|DRUG|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
218954630|NCT01178827|DRUG|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
218954631|NCT05384704|BEHAVIORAL|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
218954632|NCT05093790|DRUG|Ticagrelor|Specified dose on specified days
218954633|NCT05093790|DRUG|BMS-986141|Specified dose on specified days
218954634|NCT05093790|DRUG|Aspirin|Specified dose on specified days
218954635|NCT02250833|DRUG|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
218954636|NCT02250833|DRUG|Telmisartan|\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
218954637|NCT02250833|DRUG|S-amlodipine|\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
218954638|NCT03889301|BEHAVIORAL|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
218954639|NCT03889301|BEHAVIORAL|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
218954640|NCT00579436|DRUG|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
218954641|NCT00579436|DRUG|placebo|4 inert capsules daily by mouth for 12 weeks.
218954642|NCT04529187|DRUG|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
218954643|NCT04529187|DRUG|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
219057438|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
219057439|NCT01346384|DEVICE|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
219057440|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
219057441|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
219057442|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
219057443|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
219057444|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
219639113|NCT05635435|OTHER|Detection of Immune and Inflammatory Indices in Peripheral Blood|We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
219639114|NCT00824902|PROCEDURE|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
219639115|NCT01665950|DRUG|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
218954644|NCT02312882|DRUG|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
218954645|NCT04449029|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
218954646|NCT04449029|DRUG|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
218954647|NCT04449029|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
218954648|NCT03934697|BEHAVIORAL|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
218954649|NCT02025556|DRUG|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
218954650|NCT02025556|DRUG|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
218954651|NCT02025556|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
218954652|NCT03585127|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
219057445|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
219057446|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
219057447|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
219057448|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
219057449|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
219057450|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
219057451|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
219057452|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
219057453|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
219057454|NCT05797805|DRUG|Lenvatinib|"In the second part of the study, the combination of tegavivint plus lenvatinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus lenvatinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; lenvatinib 8 mg (patients \< 60 kg) or 12 mg (patients ≥ 60 kg) will be administered once daily on days 1-28 of a 28-day cycle ."
219057455|NCT05797805|DRUG|Cabozantinib|"In the second part of the study, the combination of tegavivint plus cabozantinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus cabozantinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; cabozantinib 60 mg (patients with Child-Pugh A) or 40 mg (patients with Child-Pugh B) will be administered orally once daily on days 1 through 28 of each 28-day cycle"
218954653|NCT03585127|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
218954654|NCT00396448|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
219057456|NCT02287415|DRUG|BIA 2-093|
219639116|NCT01665950|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
219639117|NCT04826965|DEVICE|Wound Vac is applied|A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.
219639118|NCT06041542|DIAGNOSTIC_TEST|10-second hand grip and release test|To grip and release hand in ten seconds
218954655|NCT00396448|DRUG|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
218954656|NCT00396448|DRUG|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
218954657|NCT02985424|OTHER|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
218954658|NCT02040636|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
218954659|NCT02040636|BIOLOGICAL|Hepatitis B vaccine|0.5 ml, Intramuscular
218954660|NCT00627445|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
219057457|NCT02287415|DRUG|Warfarin|
219057458|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
219057459|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
219057460|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
219057461|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
219057462|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
219057463|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
219639119|NCT00585832|BEHAVIORAL|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
219639120|NCT00585832|OTHER|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
219639121|NCT02810717|DEVICE|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
219639122|NCT02810717|DEVICE|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
219639123|NCT06140758|DRUG|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
218954661|NCT00627445|DRUG|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
218954662|NCT00627445|DRUG|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
218954663|NCT06326476|DRUG|Siplizumab|40 mg doses
218954664|NCT04744376|OTHER|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
218954665|NCT04744376|OTHER|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
219057464|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
219057465|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
219057466|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
219057467|NCT00265811|DRUG|Folfox|
219057468|NCT00265811|DRUG|Cetuximab|
219057469|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
219057470|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
219057471|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
219057472|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
219057473|NCT05468840|DRUG|Normal saline|see study arm description
219057474|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
219057475|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
219057476|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
219057477|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
218954666|NCT04744376|OTHER|Clavien - Dindo classification|It is a classification for postoperative complications.
218954667|NCT00172159|PROCEDURE|Hepatic resection|
218954668|NCT01077752|DRUG|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
218954669|NCT01077752|DRUG|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
218954670|NCT01077752|DRUG|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
218954671|NCT01077752|DRUG|NaCl|NaCl
218954672|NCT04044443|DEVICE|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
218954673|NCT04104269|DIAGNOSTIC_TEST|Heart rupture|Free wall rupture and Ventricular septal rupture
218954674|NCT04411381|OTHER|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
219639124|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
219639125|NCT06140758|DRUG|Toms of Maine 0 ppm Fluoride Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
219639126|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
219639127|NCT06140758|DRUG|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
219639128|NCT06140758|DRUG|1100 ppm (0.454% Stannous fluoride) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
218954675|NCT04474548|OTHER|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
218954676|NCT01894568|DRUG|Insulin Peglispro|Administered SC using a prefilled pen.
218954677|NCT01894568|DRUG|Insulin Glargine|Administered SC using a prefilled pen
218954678|NCT01894568|DRUG|Oral Antihyperglycemic Medications (OAMs)|Administered orally
218954679|NCT00925743|DRUG|cabazitaxel (XRP6258)|"* administered by IV infusion~* in addition to cisplatin treatment"
218954680|NCT02772198|BIOLOGICAL|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
219207100|NCT05237466|BEHAVIORAL|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
219207101|NCT05576207|DIETARY_SUPPLEMENT|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
219639129|NCT01547143|DRUG|IST and/or alloHCT|"1\) Patients will be categorized by their initial serum ferritin level.~1. Mild ( ferritin\<3,000 μg/L): close observation~2. Moderate (ferritin: 3,000-10,000 μg/L):~   1. Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~  2. continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~3. Severe (ferritin\>10,000 μg/L):~   1. initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~  2. continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~      2\) AlloHCT for refractory or reactivated cases."
219639130|NCT06569706|PROCEDURE|Nipple-Sparing Mastectomy, with immediate breast reconstruction|It is an endoscopic approach for mastectomy using an axillary single port
219639131|NCT05448963|DEVICE|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
219639132|NCT01864070|OTHER|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
219639133|NCT01864070|DRUG|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
219639134|NCT01864070|OTHER|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
218954681|NCT04545944|DRUG|Vonoprazan|20 mg tablets administered orally
218954682|NCT04545944|DRUG|Midazolam|2 mg syrup administered orally
218954683|NCT02994888|DRUG|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
218954684|NCT00599131|DRUG|Cisplatin|1\. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
218954685|NCT00599131|DRUG|Cetuximab|1\. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
218954686|NCT00599131|DRUG|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
218954687|NCT00599131|DRUG|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
218954688|NCT02700087|DRUG|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
219639135|NCT01127451|DRUG|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
218954689|NCT02700087|DRUG|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
218954690|NCT06254196|PROCEDURE|Telenursing interventions for monitoring Supportive Care Needs|"Use of the Intelligence2health platform, data collection forms on Google Forms, and dedicated telephone line for telenursing remote nursing monitoring interventions.~Based on the data, nurses will be able to implement patient education interventions aimed at preventing and monitoring healthcare support needs related to treatment."
219057478|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
219057479|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
219057480|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
219057481|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
219057482|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
219057483|NCT01035879|DRUG|placebo|tablets and capsule once daily
219057484|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
219057485|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
219057486|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
219057487|NCT02575664|DRUG|Placebo|Placebo patch
219057488|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
219057489|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
219057490|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
219207102|NCT05576207|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
219207103|NCT06243575|DRUG|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
219207104|NCT06243575|DRUG|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
219207105|NCT05247164|PROCEDURE|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
219207106|NCT04864145|DEVICE|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
219207107|NCT04864145|DRUG|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
219207108|NCT02905357|DEVICE|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
219207109|NCT02905357|OTHER|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
218954691|NCT05851001|OTHER|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
218954692|NCT05851001|OTHER|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
219057491|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
219057492|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
219057493|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
218954693|NCT06209385|DRUG|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
218954694|NCT00912379|BIOLOGICAL|hemoglobin determination|laboratory and non invasive hemoglobin determinations
218954695|NCT00655135|DRUG|LDP-02|Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
218954696|NCT00655135|DRUG|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
218954697|NCT00593580|DRUG|placebo|placebo
218954698|NCT00593580|DRUG|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
218954699|NCT02339220|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
218954700|NCT02339220|BEHAVIORAL|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
218954701|NCT02339220|BEHAVIORAL|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
218954702|NCT02339220|BEHAVIORAL|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
218954703|NCT05002920|PROCEDURE|alveolar bone grafting|the surgery of alveolar bone graft for alveolar defect in cleft patients
218954704|NCT01514370|DRUG|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
218954705|NCT01514370|DRUG|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
218954706|NCT01514370|DRUG|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
218954707|NCT03504137|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
218954708|NCT01551420|DEVICE|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
218954709|NCT01551420|DEVICE|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
219057494|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
219057495|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
219057496|NCT01769157|DRUG|L-carnitine|
219057497|NCT01769157|DRUG|Placebo|
219207110|NCT06791577|DRUG|Carboxytherapy|Application of the intervention (CO2 Lift) in the area according to the protocol schedule
219207111|NCT06791577|OTHER|Placebo|Application of the placebo (Vaseline) in the area according to the protocol schedule
219207112|NCT06297551|DIAGNOSTIC_TEST|Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry|During induction therapy for AML, researchers will measure the relative percentage of hematopoietic stem cells (defined by markers CD34+/CD38-) that test positive for CLL1 and CD45RA surface markers in the blood of participants on day 3, 5 and 7 days of systemic therapy. The variation of blood cells positivity for these markers, will be correlated with treatment outcome (complete response, partial response, no response), as determined by a bone marrow biopsy done approximately 4 weeks after induction chemotherapy.
219207113|NCT06202560|DRUG|Tofacitinib 5 MG|Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
219207114|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
219057498|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
219057499|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
218954710|NCT05604053|BEHAVIORAL|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
219057500|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
219057501|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
219057502|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
219639136|NCT03636724|BEHAVIORAL|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
219639137|NCT00930774|DEVICE|FM system|Frequency modulation assistive device
219057503|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
219639138|NCT00930774|BEHAVIORAL|Auditory training|Participation in computerized auditory training program for eight weeks
219639139|NCT03200704|COMBINATION_PRODUCT|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
219639140|NCT03200704|COMBINATION_PRODUCT|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
219639141|NCT00116155|BIOLOGICAL|CV787 (CG7870)|
219057504|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
219057505|NCT03046680|OTHER|Health Coaching|
218954711|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Full dose|350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
219057506|NCT03046680|OTHER|Multiprofessional Team|
219057507|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
219057508|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
219057509|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
219639142|NCT05214183|DRUG|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
219639143|NCT01335048|DRUG|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
219639144|NCT01335048|DRUG|Clopidogrel|Clopidogrel 150 mg daily
219639145|NCT03158480|BIOLOGICAL|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
218954712|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Half dose|175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
218954713|NCT03034668|DIETARY_SUPPLEMENT|Placebo|Maltodextrin: 350 mg
218954714|NCT04434378|DRUG|Tamsulosin|0.4 mg tamsulosin will be given to a randomized group of patients
218954715|NCT04434378|DRUG|Placebo|placebo will be given to a randomized group of patients
218954716|NCT05320497|DEVICE|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
218954717|NCT04781777|DRUG|insulin|sonar guided insulin combined with dexamethasone and local anesthetics
218954718|NCT00048841|DRUG|alendronate|
218954719|NCT02241096|DRUG|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
219057510|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
219057511|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
219057512|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
218954720|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
218954721|NCT04199598|DRUG|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
218954722|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
218954723|NCT04199598|DRUG|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
219057513|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
219057514|NCT00125554|DRUG|Metyrapone|
219057515|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
219057516|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
219057517|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
219057518|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
219057519|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
219057520|NCT07052149|OTHER|cervical muscle stabilization exercises|deep cervical muscle stabilization exercises, 15 minutes, 3 sessions per week for two months
219057521|NCT07052149|OTHER|Proprioceptive training|proprioceptive training, 15 minutes, 3 sessions per week for two months
219057522|NCT06738719|BIOLOGICAL|CT-P13 SC Auto-Injector|Subcutaneous(SC) Injection
219057523|NCT06738719|BIOLOGICAL|Placebo Auto-Injector|Subcutaneous(SC) Injection
219057524|NCT06926985|BIOLOGICAL|anti-CD19/BCMA CAR NK cells|Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of anti-CD19/ BCMA CAR NK cells will infused using the dose-escalation strategy.
219639146|NCT06670508|PROCEDURE|Transversus Abdominis Plane block|Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
219639147|NCT06670508|PROCEDURE|Erector Spinae Plane block|Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
219639148|NCT00767728|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
219639149|NCT00767728|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
219639150|NCT00839527|DRUG|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
219639151|NCT00839527|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
219639152|NCT00839527|DRUG|metformin|metformin
219639153|NCT00839527|DRUG|glimepiride|glimepiride
219639154|NCT00839527|DRUG|pioglitazone|pioglitazone
219639155|NCT00839527|DRUG|placebo to match pioglitazone|pioglitazone matching placebo
219639156|NCT05928429|DEVICE|Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA|Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
219639157|NCT00067301|DRUG|Polyunsaturated Fatty Acids (PUFA)|
219639158|NCT00067301|DRUG|Citalopram|
219639159|NCT05588973|OTHER|MEDISKIN cream|MEDISKIN cream with collagen
219639160|NCT05588973|OTHER|Panthenol cream|Panthenol cream
218954724|NCT03744000|PROCEDURE|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
219057525|NCT03964454|BEHAVIORAL|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
219207115|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
219639161|NCT01704651|DRUG|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
219639162|NCT01704651|DRUG|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
218954725|NCT03744000|PROCEDURE|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
218954726|NCT05154370|DRUG|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
218954727|NCT06095622|DIETARY_SUPPLEMENT|Fenugreek Seeds and Indian Rennet|Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.
218954728|NCT02456480|DRUG|CLS001|topical gel
218954729|NCT02456480|DRUG|Vehicle|topical gel
218954730|NCT03582228|BEHAVIORAL|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
218954731|NCT06208930|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
218954732|NCT00733447|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
218954733|NCT04183517|DRUG|PXS-5382A|Orally once daily or twice daily
218954734|NCT05331404|RADIATION|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
218954735|NCT05331404|OTHER|Quality of life assessment|"quality of life assessment by :~* Speech, Spatial and Qualities of Hearing~* Hearing Handicap Inventory For The Elderly Screening~* Short Form Health Survey"
218954736|NCT01887093|BEHAVIORAL|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
218954737|NCT00773045|OTHER|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
218954738|NCT01765010|DRUG|Calcitriol|
219639163|NCT04322019|OTHER|Data record|Data record
219639164|NCT01676740|DRUG|Iron Supplement,|Pills to be swallowed
218954739|NCT01765010|DRUG|Alfacalcidol|
218954740|NCT01765010|DRUG|Cholecalciferol|
218954741|NCT01765010|DRUG|Placebo|
218954742|NCT06505772|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
219057526|NCT03964454|BEHAVIORAL|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
219057527|NCT05131100|DRUG|Somavert|As provided in real world practice
219057528|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
219057529|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
219057530|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
219057531|NCT00270491|DRUG|Paclitaxel|
219057532|NCT00270491|DRUG|Capecitabine|
219057533|NCT03219944|PROCEDURE|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
219057534|NCT03219944|PROCEDURE|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
218954743|NCT06505772|DRUG|Normal saline|"Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study."
218954744|NCT05437302|DEVICE|prism spectacle|a prism is dispensed in prescription glasses
218954745|NCT03570463|BEHAVIORAL|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
218954746|NCT02669485|DRUG|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
218954747|NCT02669485|DEVICE|Fluorescence imaging|
218954748|NCT00512057|DRUG|allopurinol|allopurinol 300mg twice a day
218954749|NCT00512057|DRUG|placebo|placebo
218954750|NCT00000485|DRUG|diuretics|
218954751|NCT00000485|DRUG|antihypertensive agents|
218954752|NCT03050411|DRUG|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
218954753|NCT03050411|DRUG|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
218954754|NCT03473548|DEVICE|Portable sleep monitor|Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
218954755|NCT03473548|OTHER|In-laboratory Polysomnography|Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
218954756|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
218954757|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
218954758|NCT02101164|BIOLOGICAL|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
219639165|NCT01676740|DRUG|Placebo|Daily administration of active drug or placebo
218954759|NCT02101164|DRUG|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
218954760|NCT05146102|OTHER|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
218954761|NCT04564300|PROCEDURE|Training|Both groups will perform a standardized training protocol
219057535|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
219639166|NCT01789411|OTHER|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
219639167|NCT01789411|DEVICE|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
218954762|NCT03086187|DEVICE|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
218954763|NCT05070780|DEVICE|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
218954764|NCT05631002|DIAGNOSTIC_TEST|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
218954765|NCT04930380|OTHER|phone interview|Cases and controls will receive a phone interview
218954766|NCT01496937|DRUG|GLPG0974|
218954767|NCT01496937|DRUG|GLPG0974|
219057536|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
219057537|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
219639168|NCT01789411|DEVICE|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
219639169|NCT03391869|BIOLOGICAL|Ipilimumab|Given IV
219639170|NCT03391869|PROCEDURE|Local Consolidation Therapy|Undergo radiation and/or surgery
219057538|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
219057539|NCT06428747|DIAGNOSTIC_TEST|b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).|detection of micro-particles
219639171|NCT03391869|BIOLOGICAL|Nivolumab|Given IV
219639172|NCT03391869|OTHER|Quality-of-Life Assessment|Ancillary studies
219639173|NCT03391869|RADIATION|Radiation Therapy|Undergo radiation
219639174|NCT03391869|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219639175|NCT06967688|OTHER|Smartwatch-Supported Caregiver Intervention|This intervention involved informal caregivers of people with dementia using smartwatches to monitor and manage their own health parameters over an 8-week period. The primary goal was to enhance caregivers' self-efficacy and overall well-being by providing real-time health data through wearable technology. Caregivers were introduced to the smartwatch features, which included heart rate monitoring, inactivity alerts, sleep tracking, stress level monitoring, weight tracking, water intake reminders, and blood oxygen level measurements. Caregivers were instructed to track these parameters using the smartwatch and record their health behaviors in provided diaries.Weekly phone consultations lasting no more than 5 minutes were conducted throughout the 8-week intervention, where caregivers' use of the smartwatch and diaries was reviewed, and general discussions about their health and caregiving experiences took place. The intervention aimed to integrate health self-monitoring into the caregi
219639176|NCT03626402|BEHAVIORAL|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
218954768|NCT00129311|DRUG|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
219639177|NCT01155908|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
219639178|NCT00778869|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
219639179|NCT03382236|OTHER|osteopathy|osteopathic techniques
219639180|NCT04696822|DRUG|Epinephrine Nasal Product, 1.6 mg|Single dose Nasal powder spray without allergen challenge
219639181|NCT04696822|DRUG|Epinephrine nasal product, 1.6 mg + allergen|Single dose Nasal powder spray with allergen challenge
219639182|NCT04696822|DRUG|Epinephrine Injection 0.3 mg|Intramuscular injection
219639183|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg|Twice dose Nasal powder spray without allergen challenge
219639184|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg + allergen|Twice dose Nasal powder spray with allergen challenge
219639185|NCT03825029|PROCEDURE|Pillow|A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
219639186|NCT06297330|BEHAVIORAL|Sleep|The sleep management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to the sleep and fatigue levels will be recorded to assess the progress of each student.
219639187|NCT00328211|DIETARY_SUPPLEMENT|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
219639188|NCT00328211|DIETARY_SUPPLEMENT|Sphingomyelin|1000mg/day for 19 days
219639189|NCT00328211|OTHER|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
218954769|NCT00129311|DRUG|Placebo|
219057540|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
219057541|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
219057542|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
219057543|NCT03613857|DRUG|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
219057544|NCT03613857|DRUG|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
219057545|NCT02843789|DRUG|Tocilizumab|
219057546|NCT00598689|DRUG|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
219057547|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
219057548|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
219057549|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
219057550|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
219057551|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
219057552|NCT02343458|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
219057553|NCT02343458|DRUG|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
219057554|NCT02343458|DRUG|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
219639190|NCT00364923|DRUG|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
219639191|NCT05468112|BEHAVIORAL|SKY Meditation and Mindfulness|The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
219639192|NCT00893412|DRUG|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
219639193|NCT00893412|PROCEDURE|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
219639194|NCT00893412|DRUG|Placebo|
219639195|NCT04411394|OTHER|Questionnaire|Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
219639196|NCT05217134|PROCEDURE|DPEA|Dural puncture with 27 G Whitacre needle
219639197|NCT03902873|OTHER|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
219639198|NCT02912975|OTHER|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
219639199|NCT02912975|OTHER|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
219639200|NCT01217164|DIETARY_SUPPLEMENT|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
219639201|NCT01799512|DEVICE|experimental: real-time continuous glucose monitoring|
219639202|NCT01799512|DEVICE|Active comparator: blinded continuous glucose monitoring|
219639203|NCT02743936|DEVICE|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
219639204|NCT02743936|DEVICE|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
219639205|NCT05862350|OTHER|aromatherapy inhalation with lavender essential oil|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
219639206|NCT05862350|OTHER|aromatherapy inhalation with coconut essential oil.|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
219639207|NCT00850408|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
219639208|NCT03425084|DRUG|Morphine|The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
219639209|NCT06682104|BEHAVIORAL|Individual intensive short term psychodynamic therapy|ISTDP aims to help patients explore and process unconscious emotions, particularly those linked to past trauma or unresolved conflicts, that may be contributing to their physical symptoms. Patients are guided to identify and express repressed feelings such as anger, grief, or fear. The therapist actively engages the patient in a focused and intensive manner, helping them to recognize emotional defenses, break through resistance, and experience these emotions directly in the therapeutic setting.
219639210|NCT04694989|DRUG|CKD-386|QD, PO
219639211|NCT04694989|DRUG|D013, D326, D337|QD, PO
219639212|NCT03435536|OTHER|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
218954770|NCT05205473|PROCEDURE|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
218954771|NCT05205473|PROCEDURE|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
219057555|NCT02343458|DRUG|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
219057556|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
219057557|NCT02934139|OTHER|Placebo|Matched placebo
219639213|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
218954772|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
218954773|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
218954774|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
218954775|NCT06009185|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
218954776|NCT00455832|PROCEDURE|peginterferon alpha and ribavirin|sperm collection
218954777|NCT03250364|DEVICE|Multilayer bandage|See arm/group descriptions
218954778|NCT03250364|DEVICE|Double compression bandage|See arm/group descriptions
218954779|NCT03250364|DEVICE|Cohesive bandage|See arm/group descriptions
218954780|NCT03250364|DEVICE|Adhesive compression bandage|See arm/group descriptions
218954781|NCT03250364|DEVICE|Kinesiotaping bandage|See arm/group descriptions
218954782|NCT03250364|OTHER|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
218954783|NCT03250364|OTHER|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
218954784|NCT03250364|BEHAVIORAL|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
218954785|NCT05288907|DRUG|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
219057558|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
219057559|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
219057560|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
219057561|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
219057562|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
219057563|NCT06177340|DEVICE|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
219639214|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete four full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary
218954786|NCT05606003|BEHAVIORAL|Multi-Level Multi-Component Intervention (MLI)|The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
219639215|NCT06667479|OTHER|Control Group (CO)|Participants will be encouraged to maintain their current diet and exercise across the duration of the 4 week intervention. Participants will still be subjected to the pre- and post-intervention data collection session.
219639216|NCT00478777|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
219639217|NCT00478777|DRUG|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
219639218|NCT03334643|DIETARY_SUPPLEMENT|Fiber mix|Participants will test white bread or fiber mix over a span of 2 weeks. During each testing block, each food will be tested twice over two consecutive days. There are 4 testing blocks in total (one for white bread and three for fiber mix).
219639219|NCT01614717|DEVICE|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
219057564|NCT04315389|DEVICE|(1) Mobile Assistant Balance Robot|MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.
219057565|NCT04315389|DEVICE|(2) Transfer Assistive Cobot|TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
219057566|NCT01323699|BEHAVIORAL|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
219639220|NCT04293419|DRUG|Durvalumab (MEDI4736)|6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.
219639221|NCT00183053|DEVICE|BedEx Patient Occupancy Monitoring System|
219639222|NCT04345237|DIETARY_SUPPLEMENT|dietary supplement consumption|"Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training"
219639223|NCT06684886|OTHER|Ankle Brachial Index|"Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer."
219639224|NCT00876655|DRUG|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
219639225|NCT00876655|DRUG|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
219639226|NCT01070368|OTHER|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
219057567|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
219057568|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
219057569|NCT05750381|OTHER|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
219057570|NCT05750381|OTHER|Placebo balm|Placebo balm formulation for topical applications.
219057571|NCT00672477|DRUG|Methylnaltrexone|
219057572|NCT00672477|DRUG|Placebo|
219057573|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
219057574|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
219207116|NCT04644029|DRUG|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
218954787|NCT05606003|BEHAVIORAL|Community Just-In-Time Adaptive Intervention (Community JITAI)|This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
218954788|NCT00306111|DRUG|pegfilgrastim|Single dose (6mg) one day after chemotherapy
218954789|NCT01804829|BIOLOGICAL|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
218954790|NCT05207800|OTHER|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
219057575|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
219057576|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
219057577|NCT03808506|DIAGNOSTIC_TEST|Fecal calprotectin|Stool test to look at baseline burden of inflammation
219057578|NCT06525883|OTHER|No intervation|No intervention was made to the groups
219057579|NCT00381394|DRUG|sitamaquine|
218954791|NCT01543581|DRUG|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
218954792|NCT01543581|DRUG|Placebo|
218954793|NCT00158132|DRUG|Propranolol|Propranolol 100mg/day in 3 divided doses
218954794|NCT00158132|DRUG|Amantadine|Amantadine 100mg three times daily
218954795|NCT00158132|DRUG|Placebo|Placebo pills
219057580|NCT00612612|DRUG|obatoclax mesylate|Given IV
219057581|NCT00612612|DRUG|fludarabine phosphate|Given IV
219057582|NCT00612612|BIOLOGICAL|rituximab|Given IV
219057583|NCT00612612|OTHER|laboratory biomarker analysis|Correlative study
219057584|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
219057585|NCT00884481|OTHER|Natalizumab|Participants treated with Tysabri
219057586|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
219057587|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
219057588|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
218954796|NCT02405338|BIOLOGICAL|WT1/PRAME vaccination|
218954797|NCT02212600|OTHER|Observational|observational cohort of proximal humerus fractures
219057589|NCT04268017|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
219057590|NCT00272701|DRUG|Esomeprazole|
219057591|NCT00272701|DRUG|Other PPI marketed in Sweden|
219057592|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
219057593|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
219057594|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
219057595|NCT02866682|DRUG|Tacrolimus|Generic
219057596|NCT04552782|BEHAVIORAL|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
218954798|NCT04203277|OTHER|IVY|a combination of practice education and quality improvement interventions
219057597|NCT04552782|BEHAVIORAL|PTSD CBM|Trains approach or avoidance responses to trauma cues.
219057598|NCT04552782|BEHAVIORAL|Alcohol Sham|Will not train approach or avoidance responses.
219057599|NCT04552782|BEHAVIORAL|PTSD Sham|Will not train approach or avoidance responses.
219057600|NCT03207412|BIOLOGICAL|hAECs|human amniotic epithelial cells
219057601|NCT03207412|PROCEDURE|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
219057602|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
219057603|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
219057604|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
219207117|NCT04644029|DRUG|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
219207118|NCT04644029|DRUG|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
218954799|NCT01723644|OTHER|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
219057605|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
219057606|NCT04418882|OTHER|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
219057607|NCT00201006|BEHAVIORAL|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
219057608|NCT00201006|BEHAVIORAL|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
219057609|NCT00201006|OTHER|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
219057610|NCT03975348|DEVICE|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
219057611|NCT03975348|DEVICE|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
219057612|NCT03975348|DEVICE|Facemask|Oxygen therapy through a conventional facemask
219057613|NCT03556657|OTHER|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
219057614|NCT00101855|PROCEDURE|An evidence based tailored web site|
219057615|NCT00470951|PROCEDURE|open rectal resection|open rectal resection
219057616|NCT00470951|PROCEDURE|laparoscopic rectal resection|laparoscopic assisted rectal resection
219057617|NCT04271930|BEHAVIORAL|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
219057618|NCT04271930|BEHAVIORAL|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
219057619|NCT01490177|DRUG|Food proteins|Oral ingestion of Food proteins
219057620|NCT04156308|OTHER|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
219057621|NCT04156308|OTHER|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
219057622|NCT01750268|BEHAVIORAL|Medical Management Counseling|Brief alcohol and medication counseling
219057623|NCT01750268|DRUG|Topiramate|Experimental medication
219207119|NCT04644029|DRUG|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
219207120|NCT05783934|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
219057624|NCT01750268|DRUG|Placebo|Placebo comparator
219057625|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
219057626|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
219057627|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
219057628|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
218954800|NCT01723644|OTHER|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
218954801|NCT01467687|DRUG|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
218954802|NCT02191215|DRUG|Nevirapine (Viramune®)|
218954803|NCT03310307|DRUG|Vit D|50,000 IU
218954804|NCT03310307|OTHER|Placebo|
218954805|NCT04592484|BIOLOGICAL|CDK-002|CDK-002 administered intratumorally
218954806|NCT02104388|DRUG|SJP-0035 Ophthalmic Solution|
218954807|NCT02104388|DRUG|Vehicle of SJP-0035 Ophthalmic Solution|
218954808|NCT04803123|DRUG|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
218954809|NCT00564538|DRUG|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
218954810|NCT00564538|DRUG|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
218954811|NCT00721253|DEVICE|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
219057629|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
219057630|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
219207121|NCT05040841|BEHAVIORAL|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
219639227|NCT00806897|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
218954812|NCT00721253|DEVICE|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
218954813|NCT00721253|DEVICE|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
218954814|NCT05329571|BEHAVIORAL|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
218954815|NCT05329571|BEHAVIORAL|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
218954816|NCT05329571|BEHAVIORAL|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
219057631|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
219057632|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
219639228|NCT04339153|BEHAVIORAL|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
219639229|NCT02168257|DEVICE|RAM Cannula|
219639230|NCT02168257|DEVICE|Binasal Prong CPAP|
219639231|NCT04576520|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
218954817|NCT00129012|PROCEDURE|Tomotherapy|
218954818|NCT04270903|DEVICE|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
218954819|NCT00102492|DRUG|GW679769|
218954820|NCT04249726|PROCEDURE|Direct composite resin restoration|A direct composite resin restoration will be provided intracoronally without cuspal coverage.
218954821|NCT04249726|PROCEDURE|Direct composite resin restoration followed by full coverage metal ceramic crown|A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
218954822|NCT02888418|BIOLOGICAL|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
218954823|NCT02888418|BIOLOGICAL|placebo|
218954824|NCT03039621|DRUG|Ergoferon|For oral use.
218954825|NCT03039621|DRUG|Placebo|For oral use.
219639232|NCT04576520|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
219639233|NCT00308191|DRUG|Formoterol Fumarate|
219639234|NCT00308191|DRUG|Tiotropium Bromide|
218954826|NCT05722886|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
218954827|NCT05722886|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
219639235|NCT02406001|DEVICE|Tigran PTG|Open Flap Debridement
218954828|NCT05722886|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
218954829|NCT05722886|DRUG|Trastuzumab in combination with pertuzumab|"The initial loading dose of trastuzumab is 8 mg/kg body weight followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days.~The initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight.~Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
218954830|NCT05722886|DRUG|Vemurafenib in combination with cobimetinib|"Patients will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
219057633|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
219057634|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
219057635|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
219057636|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
219207122|NCT05040841|BEHAVIORAL|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
219207123|NCT05040841|BEHAVIORAL|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
219207124|NCT05040841|BEHAVIORAL|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
219207125|NCT05040841|BEHAVIORAL|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
219639236|NCT02406001|PROCEDURE|Surgical intervention|Open Flap Debridement
219639237|NCT05005195|RADIATION|Low dose abdominal computed tomography scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
219639238|NCT00144521|DRUG|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
219639239|NCT00144521|DRUG|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
219639240|NCT00144521|DRUG|MTX|8mg/week(p.o.) for 24 weeks
219639241|NCT00144521|DRUG|MTX placebo|0mg/week(p.o.) for 24 weeks
219639242|NCT06224816|DEVICE|Custom 3D mask (3DM) application in neonate|Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.
219639243|NCT06224816|DEVICE|Traditional mask (TM) application in neonate|Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.
219639244|NCT06032195|DRUG|Custodiol-N|heart will preserved in and will be treated with Custodiol-N solution
219639245|NCT06032195|DRUG|Custodiol|heart will preserved in and will be treated with Custodiol solution
219639246|NCT04854512|DRUG|Metformin DR|Delay-Release Metformin
219639247|NCT04854512|DRUG|Metformin IR|Immediate Release Metformin
219057637|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
219057638|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
219057639|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
219057640|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
218954831|NCT05722886|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
218954832|NCT00400608|DRUG|ADVAIR HFA|
218954833|NCT00400608|DRUG|ADVAIR DISKUS|
219639248|NCT04854512|DRUG|Metformin DR Placebo|Metformin DR Placebo
218954834|NCT04615455|DRUG|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
219639249|NCT04854512|DRUG|Metformin IR placebo|Metformin IR placebo
219639250|NCT00713947|DRUG|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
219639251|NCT00713947|DRUG|Pantoprazole|6 months at 20 mg
219639252|NCT00713947|DRUG|Placebo Formula 515|26 weeks, one tablet per day
218954835|NCT04615455|DRUG|Cryostor CS10|CryoStor® CS10 freeze medium
218954836|NCT00636701|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
218954837|NCT00002931|BIOLOGICAL|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
218954838|NCT00002931|DRUG|carboplatin|AUC=7, daily X 3
218954839|NCT00002931|DRUG|etoposide|20 mg/kg by 2 hours infusion daily X 3
218954840|NCT00002931|DRUG|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
219057641|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
219057642|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
219057643|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
219639253|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
218954841|NCT00002931|DRUG|paclitaxel|425 mg/m2 as 24 hour continuous infusion
218954842|NCT00002931|PROCEDURE|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
218954843|NCT00002931|PROCEDURE|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
218954844|NCT01535300|PROCEDURE|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
218954845|NCT00215670|DRUG|pegaptanib sodium (Macugen)|
218954846|NCT01954147|DRUG|GLP-1|GLP-1 therapy
218954847|NCT01954147|BIOLOGICAL|SC|Stem cell infusion
218954848|NCT01954147|OTHER|Standard Medical Treatment|Standard Medical Treatment
218954849|NCT05435040|DEVICE|proprioceptive knee brace|the patient will perform the tests with the knee brace
218954850|NCT05435040|DEVICE|No knee brace|the patient will perform the tests without the knee brace
218954851|NCT04351061|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
218954852|NCT01879579|OTHER|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
218954853|NCT02716896|RADIATION|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
219057644|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
219057645|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
219057646|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
219057647|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
219639254|NCT02553499|BIOLOGICAL|MK-1248|IV infusion
219639255|NCT02553499|BIOLOGICAL|pembrolizumab|IV infusion
219639256|NCT06684132|OTHER|Inspiratory muscle training|The H-IMT will be performed in seven sets of three-minute cycles consisting of two minutes of training followed by one minute of rest in the training workload. Each session will consist of 14 minutes of loading and seven minutes of rest for a total of 21 minutes.
219639257|NCT06684132|OTHER|Exercise|Stretching exercises for pectoral muscles, neck muscles and back muscles, strengthening exercises for upper extremity and back muscles and posture exercises will be applied.
219639258|NCT05376449|BEHAVIORAL|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
218954854|NCT02716896|PROCEDURE|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
218954855|NCT02086279|DRUG|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
218954856|NCT02806193|PROCEDURE|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
218954857|NCT03583203|DEVICE|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
218954858|NCT03431103|BEHAVIORAL|Exercise|12 week home exercise program
218954859|NCT05908318|BEHAVIORAL|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
218954860|NCT05583669|DRUG|DS-2325a|Subcutaneous injection (starting dose 300 mg)
218954861|NCT05583669|DRUG|Placebo|Subcutaneous injection
218954862|NCT05806879|OTHER|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
218954863|NCT03609151|PROCEDURE|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
218954864|NCT03609151|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
218954865|NCT04211571|DEVICE|Theranova 400 dialyzer|Hemodialysis using Theranova 400 dialyzer
218954866|NCT04211571|DEVICE|High-flux dialyzer|Hemodialysis using high-flux dialyzer
218954867|NCT00993161|DEVICE|Motriplate|Number of contact couples
218954868|NCT00993161|DEVICE|Motriplate|Number of contact couples
218954869|NCT00970866|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
219639259|NCT04538781|DEVICE|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
219639260|NCT06388954|DEVICE|True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)|"Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve.~Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side eﬀect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold."
219639261|NCT06388954|DEVICE|Sham Trancutaneous auricular Vagus Nerve Stimulation|Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation. The active electrodes will be attached to the left cymba conchae. The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
219639262|NCT03136640|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
219639263|NCT04803344|BEHAVIORAL|Expressive Writing tecnique|Expressive Writing (EW), is a simple, potentially inexpensive, therapeutic intervention which involves writing daily for 15-20 min over 3-4 consecutive days. EW can be completed at home without the need for facilitation, a specialist therapist or a dedicated facility.
219639264|NCT04803344|BEHAVIORAL|Neutral Writing|Participants were asked to write on neutral objects or events.
219639265|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - baseline|Baseline laboratory values will be obtained
219639266|NCT05538234|OTHER|Medical information 12 hours before organ harvesting|"* average hourly diuresis~* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)~* Furosemide administration (YES/NO)~* Mannitol administration (YES/NO)~* administration of anti-diuretic hormone (YES/NO)~* administration of vasopressors (YES/NO)~* polyuria \>3ml/kg/h (YES/NO)~* nephrotoxic agents during hospitalization (YES/NO)"
219639267|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 12 hours after reperfusion|Laboratory values will be obtained 12 hours after reperfusion
219639268|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 48 hours after reperfusion|Laboratory values will be obtained 48 hours after reperfusion
218954870|NCT00970866|DIETARY_SUPPLEMENT|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
218954871|NCT00970866|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
218954872|NCT01949337|DRUG|enzalutamide|Enzalutamide 160 mg daily, orally
219639269|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 7 days after reperfusion|Laboratory values will be obtained 7 days after reperfusion
219639270|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 90 days after reperfusion|Laboratory values will be obtained 90 days after reperfusion
219639271|NCT05538234|OTHER|Medical information during organ harvesting/transplantation|"Medical information during organ harvesting/transplantation~* hypotension MAP 65 Torr \> 5 minutes (YES/NO)~* vasopressor support (YES/NO, duration in minutes)"
219639272|NCT05538234|PROCEDURE|Organ harvesting|Organ harvesting for transplant
219639273|NCT05538234|PROCEDURE|Organ transplantation|Transplantation of the harvested organ
219639274|NCT06272318|OTHER|Blood Pressure Cuff, EKG, PPG|A blood pressure cuff, an EKG, and a PPG will be utilized to collect subject vitals.
219639275|NCT00078767|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
219639276|NCT00078767|DRUG|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
219639277|NCT00078767|DRUG|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
219639278|NCT02282631|BEHAVIORAL|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
219639279|NCT05749978|BEHAVIORAL|Asana adjustment|Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
219639280|NCT03603145|PROCEDURE|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
219639281|NCT00665860|DIETARY_SUPPLEMENT|Placebo|Three pills per day for two years
219639282|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
219639283|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
219639284|NCT01783028|BEHAVIORAL|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
219639285|NCT06526143|BEHAVIORAL|M2VA Pain Care Pathway (M2VAPCP)|M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.
218954873|NCT01949337|DRUG|abiraterone|abiraterone 1000 mg daily, orally
218954874|NCT01949337|DRUG|prednisone|prednisone 5 mg twice daily, orally
218954875|NCT02122601|DRUG|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
218954876|NCT02519855|BIOLOGICAL|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
218954877|NCT02519855|BIOLOGICAL|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
218954878|NCT02519855|BIOLOGICAL|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
218954879|NCT03034291|DIETARY_SUPPLEMENT|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
218954880|NCT03034291|DIETARY_SUPPLEMENT|White chocolate|
219639286|NCT06526143|BEHAVIORAL|Implementation Facilitation|"Implementation facilitation teams consisting of internal and external facilitators will conduct activities for two purposes:~1. to build working relationships within the pain and addiction care pathways to achieve the shared goal of implementing high-quality M2VAPCP; and~2. to promote constructive, problem-solving oriented communication based on indicators of M2VAPCP implementation progress.~Activities will include Virtual Site Visits, all-side facilitation team meetings, local facilitation team meetings, M2VAPCP consultation groups, learning collaboratives, case identification reports and audit and feedback."
219639287|NCT06409598|OTHER|Non-immersive virtual reality home-based exercise.|This intervention aims include some exercises in the form of games to facilitate and improve the upper limb functions and static balance from sitting and standing positions among chronic stroke survivors.
219639288|NCT01469130|DRUG|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
219639289|NCT05269446|PROCEDURE|percutaneous coronary intervention (PCI)|A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
218954881|NCT00008255|DRUG|INS316|
218954882|NCT00008255|OTHER|sputum cytology|
218954883|NCT06114459|DRUG|Sodium Chloride|Post surgery disinfection
218954884|NCT06458335|BEHAVIORAL|Cognitive-Behavioral Therapy for Perceived Social Isolation|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use
218954885|NCT06458335|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a health lifestyle
218954886|NCT05718999|DIAGNOSTIC_TEST|Not intervention|Not having intervention is an observational study
218954887|NCT04378452|BEHAVIORAL|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
218954888|NCT02037581|BEHAVIORAL|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
218954889|NCT02037581|BEHAVIORAL|Standard Care|Standard care as being offered by private psychiatrists
218954890|NCT05577455|DRUG|Medical prescription before ovulation|Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
218954891|NCT05577455|DRUG|Medical prescription after ovulation|Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
218954892|NCT04360135|DRUG|Acetaminophen|Preemptive acetaminophen the day before surgery
218954893|NCT04360135|DRUG|Placebo|Preemptive placebo the day before surgery
218954894|NCT02397499|DRUG|LIPO-202|
218954895|NCT02397499|DRUG|Placebo|
218954896|NCT02027805|BIOLOGICAL|T-Guard|
218954897|NCT03061747|DEVICE|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
218954898|NCT03930563|DIETARY_SUPPLEMENT|Pre-beetroot juice supplementation|Before administering beetroot juice to subjects.
218954899|NCT03930563|DIETARY_SUPPLEMENT|Post-beetroot juice supplementation|After administering beetroot juice to subjects.
218954900|NCT00238940|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
218954901|NCT04611672|DIAGNOSTIC_TEST|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
218954902|NCT04611672|DIAGNOSTIC_TEST|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
218954903|NCT03873857|DRUG|Venetoclax|tablet;oral
218954904|NCT01655966|DRUG|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
218954905|NCT01655966|DRUG|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
218954906|NCT01481441|DRUG|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
218954907|NCT02415842|OTHER|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
218954908|NCT06451731|BEHAVIORAL|PHOLEXSEM|Phonological, Lexical, and Semantic training
218954909|NCT06451731|BEHAVIORAL|PACE|See arm description
219639290|NCT05269446|DEVICE|total body PET/CT scan|all participants will receive a total-body PET/CT scan (uExplorer) after enrolment
219639291|NCT05269446|PROCEDURE|Coronary Angiography (CAG)|A procedure that uses X-ray imaging to visualize coronary arteries.
219639292|NCT05269446|DRUG|TSPO injection|Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
219639293|NCT02313168|OTHER|observation, inspection|
218954910|NCT06064994|BEHAVIORAL|Mindfulness meditation|"The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~1. Being mindful of breathing (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of thought (5 minutes).~4. Being mindful of sounds (5 minutes).~5. Being mindful of taste (5 minutes)~6. Full meditation"
219207126|NCT06490783|OTHER|Noninvasive wearable devices (smartwatch and heart rate monitor band)|"Each enrolled subject will be equipped with noninvasive wearable devices (smartwatch and heart rate monitor band) to monitor physiological parameters and emotional states related to anxiety and stress. Each subject will be required to wear the smartwatch on his or her wrist for the duration of the study, about 3-6 months; while the heart rate monitor band will be worn for about 10 minutes a day. At the same time, a mobile application, RESILIENT, will be developed and implemented to serve as the main interface for self-assessment data entry and for feedback and recommendations.~The psycho-physical condition of each subject will be monitored by the app through customized and contextualized mental exercises based on daily activities. This approach will test the effectiveness of the proposed architecture in reducing unhealthy habits and promoting health and wellness recommendations"
219207127|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
219207128|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
219207129|NCT06224439|PROCEDURE|hyperbaric spinal anesthesia|0.5% hyperbaric Bupivacain hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
219207130|NCT06283147|BEHAVIORAL|Risk assessment and Management Programme - Knee Osteoarthritis|"(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management."
219207131|NCT03771001|OTHER|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
219207132|NCT06368310|DEVICE|INBRAIN Graphene Cortical Interface|Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.
219207133|NCT03620058|BIOLOGICAL|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
218954911|NCT00003830|PROCEDURE|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
218954912|NCT00003830|PROCEDURE|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
219207134|NCT03620058|BIOLOGICAL|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
219207135|NCT03713554|PROCEDURE|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
219207136|NCT06284876|DRUG|Ilaprazole|Ilaprazole 10 mg
219207137|NCT06284876|DRUG|Lansoprazole|Lansoprazole 15 mg
219207138|NCT06284876|DRUG|Ilaprazole Placebo|Placebo of Ilaprazole 10 mg
218954913|NCT01840059|DEVICE|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
219207139|NCT06284876|DRUG|Lansoprazole Placebo|Placebo of Lansoprazole 15 mg
219207140|NCT06165380|DRUG|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
219207141|NCT05282043|OTHER|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
219207142|NCT00113360|DRUG|RAD001|Starting dose of 5 or 10 mg by mouth daily.
218954914|NCT06514196|DEVICE|Hintermann Series H3 Total Ankle Replacement System|The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
218954915|NCT04179409|DRUG|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
218954916|NCT04179409|DRUG|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
218954917|NCT04179409|DRUG|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
218954918|NCT03329183|DRUG|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
218954919|NCT05595759|OTHER|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
218954920|NCT05595759|OTHER|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
218954921|NCT05593549|DRUG|Trehalose|Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
218954922|NCT05593549|DRUG|Placebo|Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
219057648|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
218954923|NCT03416062|DRUG|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
218954924|NCT03416062|DRUG|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
218954925|NCT03550859|DRUG|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
218954926|NCT03550859|DRUG|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
218954927|NCT06171932|DRUG|Methylprednisolone,|No intervention required
219057649|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
219057650|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
219057651|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
219057652|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
219057653|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
219057654|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
219057655|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
219057656|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
219057657|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
219057658|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
219057659|NCT00456092|DRUG|Apremilast|Capsules for oral administration
219057660|NCT00456092|DRUG|Placebo|Capsules for oral administration
219057661|NCT00295672|DRUG|Vinorelbine|
219057662|NCT00191061|DRUG|duloxetine hydrochloride|
219057663|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
219057664|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
219057665|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
219057666|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
219207143|NCT00113360|DRUG|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
218954928|NCT00821444|DRUG|ziprasidone|40 mg capsule, single dose x 3
218954929|NCT00821444|DRUG|B16 Fasted|40 mg tablet, single dose X 3
218954930|NCT00821444|DRUG|B16 Fed|40 mg tablet, single dose X 3
218954931|NCT04385329|OTHER|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
218954932|NCT04385329|OTHER|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
219057667|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
219207144|NCT04173442|DRUG|dupilumab|Dupilumab cohort
219207145|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
218954933|NCT01467635|DEVICE|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
219639294|NCT04266834|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."
219639295|NCT05033717|OTHER|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
218954934|NCT02407145|OTHER|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
218954935|NCT00603590|DRUG|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
218954936|NCT00603590|DRUG|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
218954937|NCT02819778|PROCEDURE|usual care|
218954938|NCT02819778|PROCEDURE|S100B|
218954939|NCT05765773|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
218954940|NCT04519606|PROCEDURE|Optimal lung compliance during OLV|Stepwise increase of tidal volume from 4 ml/kg PBW to 7 ml/kg PBW during OLV to determine the optimal tidal volume at the level the the pressure-volume loop reaches upper refection point where the peak airway pressure at or just below 30 cmH2O
218954941|NCT03815045|PROCEDURE|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
218954942|NCT03815045|PROCEDURE|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
218954943|NCT03254303|OTHER|Difficulty of catheterization in group 60 s|
218954944|NCT03254303|OTHER|Difficulty of catheterization in group 90 s|
218954945|NCT03254303|OTHER|Difficulty of catheterization in group 120 s|
218954946|NCT00782431|BIOLOGICAL|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
218954947|NCT00782431|BIOLOGICAL|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
218954948|NCT05061680|DEVICE|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
218954949|NCT05985564|OTHER|imaging diagnosis|no intervention
218954950|NCT01634256|DIETARY_SUPPLEMENT|Placebo|Placebo(3.0g/day)
218954951|NCT01634256|DIETARY_SUPPLEMENT|Fermented turmeric|Fermented turmeric(3.0g/day)
219057668|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
219207146|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
219207147|NCT04967118|BEHAVIORAL|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
219207148|NCT04967118|BEHAVIORAL|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
219639296|NCT05033717|OTHER|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
219639297|NCT01603849|RADIATION|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
218954952|NCT04729400|DEVICE|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
218954953|NCT04729400|OTHER|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
218954954|NCT04729400|PROCEDURE|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
218954955|NCT04729400|PROCEDURE|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
219207149|NCT04967118|DRUG|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
218954956|NCT06213675|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
218954957|NCT06213675|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
219057669|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
218954958|NCT02523469|BIOLOGICAL|ALT-803|
218954959|NCT02523469|BIOLOGICAL|Nivolumab|
218954960|NCT03699475|BIOLOGICAL|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
219057670|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
219057671|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
219057672|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
219057673|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
219057674|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219057675|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219057676|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219057677|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219057678|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219639298|NCT04404764|DRUG|Nusinersen Injectable Product|The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
219639299|NCT01091506|OTHER|Placebo|Placebo once a day for 12 weeks
219639300|NCT01091506|OTHER|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
218954961|NCT03699475|DRUG|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
218954962|NCT03699475|DRUG|Cyclophosphamide|GVHD prophylaxis
218954963|NCT03699475|PROCEDURE|haplo-HSCT|treatment for disease
218954964|NCT05198375|DIAGNOSTIC_TEST|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
219639301|NCT05000671|DRUG|STC314 injection or Placebo(rate=58.3 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
218954965|NCT02788877|DRUG|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
218954966|NCT03725254|PROCEDURE|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
218954967|NCT03725254|RADIATION|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
218954968|NCT00539760|DRUG|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
218954969|NCT00539760|DRUG|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
219057679|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
219057680|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
219057681|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
219057682|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
219057683|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
219057684|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
218954970|NCT06506370|OTHER|nonsurgical periodontal treatment|The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
218954971|NCT06505967|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
218954972|NCT06505967|OTHER|Placebo|Rice flour
218954973|NCT03920904|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
218954974|NCT00762593|DEVICE|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
218954975|NCT00762593|DEVICE|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
218954976|NCT01440543|PROCEDURE|Water immersion insertion AND CO2 insufflation|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
218954977|NCT01440543|PROCEDURE|Water immersion insertion|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection"
219057685|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
219057686|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
219057687|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
219057688|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
219057689|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
219057690|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
219057691|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
219057692|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
219057693|NCT00000415|PROCEDURE|Physical activity|
219057694|NCT00000415|DRUG|Calcium supplement|
219639302|NCT05000671|DRUG|STC314 injection or Placebo(rate=87.5 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
219639303|NCT06106412|DRUG|Ionomycin SIGMA|Oocytes will be activated with Ionomycin SIGMA
219639304|NCT06106412|DRUG|A23187|Oocytes will be activated with A23187
219639305|NCT04437290|DRUG|investigational radiotracer [18F]MK6240|Brain PET scan
219639306|NCT03660332|PROCEDURE|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
219639307|NCT02641626|PROCEDURE|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
218954978|NCT01440543|PROCEDURE|CO2 insufflation|\- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
218954979|NCT03932006|DRUG|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
218954980|NCT03932006|DRUG|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
219057695|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
219057696|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
219057697|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
219057698|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
219057699|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
219057700|NCT05479175|DRUG|Ibuprofen|Ibuprofen
219057701|NCT05479175|DEVICE|Diode laser|Diode laser
219057702|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
219057703|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
219057704|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
219057705|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
219057706|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
219057707|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
219057708|NCT00145834|BEHAVIORAL|community based trial|
219057709|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
219057710|NCT00563797|DRUG|Placebo|Placebo pill
219057711|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
219057712|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
219057713|NCT00007800|BEHAVIORAL|Motivational Interviewing|
219057714|NCT02411721|BEHAVIORAL|Animal Assisted Intervention|"1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
219057715|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
219057716|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
219057717|NCT00497120|DRUG|acetazolamide|
219057718|NCT00497120|DRUG|placebo|
218954981|NCT03932006|DRUG|Imrecoxib|Imrecoxib 0.1g twice a day,orally
218954982|NCT04405232|OTHER|Non-interventional|Observational study
219057719|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
218954983|NCT00410709|DRUG|NatrOVA Creme Rinse (1%)|
218954984|NCT03444532|BEHAVIORAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
218954985|NCT00237510|DRUG|terazosin|
218954986|NCT05974423|DRUG|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
218954987|NCT05974423|DRUG|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
218954988|NCT03190044|DIETARY_SUPPLEMENT|PACR|Daily assumption of PACR for a 3-month period
218954989|NCT03190044|DIETARY_SUPPLEMENT|Placebo|Daily assumption of placebo
218954990|NCT00158821|DRUG|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
218954991|NCT00158821|DRUG|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
218954992|NCT00158821|DRUG|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
219057720|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
219207150|NCT01308684|DRUG|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
219207151|NCT01308684|DRUG|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
219639308|NCT02641626|PROCEDURE|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
219639309|NCT01126814|DRUG|Imatinib (Gleevec)|
218954993|NCT00158821|DRUG|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
218954994|NCT03874312|DIAGNOSTIC_TEST|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
219207152|NCT06441487|BEHAVIORAL|Mobile Health Decision Support|Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™- Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who select FIT, as well as subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.
219057721|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
219057722|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
219057723|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
219057724|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
219057725|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
219639310|NCT05808426|DEVICE|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
219639311|NCT02467062|DEVICE|MRI|MRI measurement to evualuate for 4D blood flow pattern
219639312|NCT02589626|DRUG|empagliflozin 10mg|
219639313|NCT02589626|DRUG|empagliflozin 25 mg|
219639314|NCT02589626|DRUG|Placebo|For blinding purposes
218954995|NCT01917877|DRUG|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
219639315|NCT00567658|DRUG|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
219639316|NCT05175911|OTHER|golden hour : an initial standardized stabilization|"This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm."
219639317|NCT00892151|DEVICE|GLUCOFACTS® Deluxe|Diabetes Data Management Software
219639318|NCT03217383|DEVICE|MATRx plus|The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
219639319|NCT02799667|DEVICE|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
219639320|NCT02799667|DEVICE|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
219639321|NCT01155440|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
218954996|NCT01917877|DRUG|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
218954997|NCT02217774|DEVICE|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
218954998|NCT04781920|OTHER|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
218954999|NCT04693143|OTHER|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
218955000|NCT00942071|BIOLOGICAL|MVA-NP+M1|1\. Intradermal injection at 5 x 10\^7 pfu at day 0
218955001|NCT00942071|BIOLOGICAL|MVA-NP+M1|2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
219057726|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
219057727|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
219057728|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
219057729|NCT02710630|DRUG|Dabigatran etexilate capsule|
219639322|NCT01155440|PROCEDURE|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
219639323|NCT04075682|OTHER|Inserts with efficacy messages|Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
219639324|NCT04075682|OTHER|Pictorial warnings on packs|Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
219639325|NCT03820635|DIAGNOSTIC_TEST|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
219639326|NCT05091541|DRUG|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
219639327|NCT00282399|DRUG|Subcutaneous Decitabine|
218955002|NCT00942071|BIOLOGICAL|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
218955003|NCT00338897|DRUG|SR123781A|
218955004|NCT05413577|BEHAVIORAL|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
218955005|NCT01035450|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
218955006|NCT01035450|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
218955007|NCT02225613|OTHER|Usual protocol|
218955008|NCT02225613|OTHER|Spa protocol|
218955009|NCT00734760|BEHAVIORAL|education|face-to-face education and counseling intervention
218955010|NCT01411553|OTHER|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
218955011|NCT04615169|BEHAVIORAL|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
218955012|NCT04490330|OTHER|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
218955013|NCT01111929|DRUG|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
218955014|NCT02706223|OTHER|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
218955015|NCT02706223|OTHER|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
218955016|NCT03213314|DIAGNOSTIC_TEST|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
218955017|NCT05547971|RADIATION|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
218955018|NCT01514786|BEHAVIORAL|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
219639328|NCT03046667|DIETARY_SUPPLEMENT|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
218955019|NCT05602896|OTHER|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
218955020|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
218955021|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
218955022|NCT01047098|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
219639329|NCT03046667|DIETARY_SUPPLEMENT|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
219639330|NCT06161467|DEVICE|Ultrasound devices|Safe , no radiation
219639331|NCT06270264|DEVICE|the Nociception level index monitoring|Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
219639332|NCT03627026|OTHER|Blood samples will be collected at different time points:|"* Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
218955023|NCT00613067|DRUG|escitalopram|"* Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs"
219057730|NCT00365859|DRUG|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
219639333|NCT05778968|PROCEDURE|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
219639334|NCT05778968|PROCEDURE|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
218955024|NCT05634447|DRUG|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
219057731|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
219057732|NCT02232529|DRUG|MIN-101|
219057733|NCT02232529|DRUG|Placebo|
219057734|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
219057735|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
219057736|NCT00036166|DRUG|FK463|
218955025|NCT00694538|DEVICE|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
218955026|NCT04713527|DIAGNOSTIC_TEST|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
218955027|NCT04713527|DRUG|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
218955028|NCT03739242|DIETARY_SUPPLEMENT|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
219639335|NCT05778968|PROCEDURE|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
219639336|NCT06475755|DRUG|Immunochemotherapy combined with antiangiogenic|neoadjuvant： Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
219639337|NCT06475755|DRUG|Immunochemotherapy|neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
219639338|NCT01533324|DRUG|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
219639339|NCT01983696|OTHER|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
219639340|NCT04478721|DRUG|Temocillin|The intervention of experimental arm will be Intravenous administration of temocillin.
219639341|NCT04478721|DRUG|Meropenem|The intervention of comparator arm will be intravenous administration of meropenem.
219639342|NCT00983203|OTHER|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
219639343|NCT00983203|OTHER|Soothe XP Lubricant Eye Drops|1 drop OU
219639344|NCT01522001|BEHAVIORAL|Shared Care model|"* First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge."
219639345|NCT02177916|OTHER|Education|
219639346|NCT04292912|DRUG|GSK2798745|GSK2798745 will be administered.
218955029|NCT03739242|OTHER|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
218955030|NCT01029301|DEVICE|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
219057737|NCT04284423|DIAGNOSTIC_TEST|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
219057738|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
219057739|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
219057740|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
219057741|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
219057742|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
219057743|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
219057744|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
219057745|NCT03200392|DEVICE|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
219057746|NCT03200392|DEVICE|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
219057747|NCT03200392|PROCEDURE|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
219057748|NCT04067141|DEVICE|somofilcon A|Contact Lens
219057749|NCT04067141|DEVICE|nelfilcon A|Contact Lens
218955031|NCT06280586|OTHER|Multidisciplinary intervention|"* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró."
218955032|NCT02755532|DRUG|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
218955033|NCT02755532|DRUG|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
219639347|NCT00730860|PROCEDURE|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
219639348|NCT00730860|PROCEDURE|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
219639349|NCT01141946|PROCEDURE|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
219639350|NCT01141946|PROCEDURE|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
218955034|NCT00966784|OTHER|Dietary Fibers|
219057750|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
219057751|NCT01717235|DRUG|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
219057752|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
219057753|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
219057754|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
219639351|NCT06371495|DRUG|rosuvastatin|"Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset."
219639352|NCT02379702|OTHER|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
219057755|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
219639353|NCT03981484|BIOLOGICAL|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
219639354|NCT03981484|BIOLOGICAL|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
219639355|NCT04279470|DRUG|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
219639356|NCT00555464|DRUG|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
219639357|NCT00555464|DRUG|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
219639358|NCT05410275|DRUG|Rivaroxaban|Experimental group Each patient will receive successively over 3 distinct periods the 3 doses of rivaroxaban to be evaluated, i.e., 5 mg, 10 mg, and 15 mg as a single daily dose (once daily over 3 days for each dose).
219639359|NCT05043025|OTHER|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
219639360|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablets
219639361|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablet
219057756|NCT01038921|DRUG|Placebo|Placebo
219057757|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
219639362|NCT04115592|OTHER|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
219639363|NCT04115592|OTHER|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
219639364|NCT04115592|OTHER|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
218955035|NCT04139200|BEHAVIORAL|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
218955036|NCT04139200|BEHAVIORAL|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
218955037|NCT01876433|DRUG|Mirabegron|
218955038|NCT01876433|DRUG|Placebo|
218955039|NCT04215003|DRUG|A|"Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles."
218955040|NCT04215003|DRUG|B|Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.
218955041|NCT04215003|DRUG|CL4|SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
218955042|NCT03848156|OTHER|biopsy|Biopsy of nasal polyp for RNA sequencing
218955043|NCT00786851|DRUG|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
218955044|NCT01752036|RADIATION|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
218955045|NCT04820127|BEHAVIORAL|personalized care preceded by a standardized assessment|"* personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
218955046|NCT00704665|DRUG|Relaxin|10 ug/kg/day or 25 ug/kg/day
218955047|NCT00704665|DRUG|Relaxin|Placebo
218955048|NCT02696187|BEHAVIORAL|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
218955049|NCT01877733|OTHER|Maximal strength training|
219057758|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
219057759|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
219057760|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
219639365|NCT04115592|OTHER|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
218955050|NCT05692973|BEHAVIORAL|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
218955051|NCT05692973|BEHAVIORAL|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
219057761|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
219057762|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
219057763|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
219057764|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
219057765|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
219057766|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
218955052|NCT01857557|OTHER|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
219207153|NCT06441487|BEHAVIORAL|Usual care|The study team will send subjects a prompt to visit the mobile health decision support tool (mPATH™-Cloud). Subjects with a mobile phone (as determined by their electronic health record) will receive a link to mPATH-Cloud by text. Subjects with a mailing address, but no mobile phone number in the EHR, will receive a letter inviting them to access mPATH-Cloud via URL code. Within mPATH-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT.
219207154|NCT01086163|DRUG|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
218955053|NCT02274701|OTHER|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
218955054|NCT05299788|OTHER|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
218955055|NCT05299788|OTHER|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
219057767|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
219057768|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
218955056|NCT00054171|DRUG|aminolevulinic acid hydrochloride|
219207155|NCT00739908|DRUG|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
219057769|NCT01224262|BIOLOGICAL|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
219057770|NCT01224262|BIOLOGICAL|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
219207156|NCT00739908|DRUG|Placebo|Six capsules administered three times a day for six weeks.
219207157|NCT01334489|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
219207158|NCT05088421|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
219207159|NCT05088421|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
219207160|NCT04921488|DEVICE|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
219207161|NCT01969916|DRUG|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
219207162|NCT00495677|DRUG|PF-00232798|Solution, 20 mg. once daily, 10 days
218955057|NCT06000176|DEVICE|Optical coherence tomography angiography|diagnostic test OCTA macula and ONH
218955058|NCT00570479|DRUG|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
218955059|NCT04805320|PROCEDURE|Dental Extraction|Extraction
218955060|NCT05354804|DIAGNOSTIC_TEST|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
218955061|NCT05354804|DIAGNOSTIC_TEST|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
219057771|NCT01224262|BIOLOGICAL|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
219057772|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
219057773|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
219057774|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
219057775|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
219057776|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
219057777|NCT03495336|OTHER|coffee abstention phase|no coffee consumption for 2 weeks
218955062|NCT02573038|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
218955063|NCT05386628|OTHER|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises"
219057778|NCT03495336|OTHER|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
219057779|NCT03495336|OTHER|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
219207163|NCT00495677|DRUG|PF-00232798|Solution, 150 mg. once daily, 10 days
219639366|NCT05200182|DEVICE|Neurofeedback with functional near infra-red spectroscopy|"the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
219057780|NCT02323919|BEHAVIORAL|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
219057781|NCT02323919|BEHAVIORAL|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
219057782|NCT02323919|BEHAVIORAL|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
219057783|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
219057784|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
219057785|NCT05163860|OTHER|Survey|Participants will complete an online survey.
219057786|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
219057787|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
219057788|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
219057789|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
219057790|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
219057791|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
219057792|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
219057793|NCT01480700|OTHER|Nutritional study|subjects consume 2 eggs per day during 4 months
219057794|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
219057795|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
219057796|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
219057797|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
219057798|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
219057799|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
219207164|NCT00495677|DRUG|PF-00232798|Solution, 5 mg. once daily, 10 days
219207165|NCT00495677|DRUG|PF-00232798|Solution, 40 mg. once daily, 10 days
219207166|NCT00495677|DRUG|PF-00232798|Solution, 300 mg. once daily, 10 days
219207167|NCT00495677|DRUG|PF-00232798|Solution, 400 mg. once daily, 10 days
219207168|NCT02020694|DRUG|Vitamin D|
219207169|NCT02020694|DRUG|Placebo (for vitamin D)|
219639367|NCT05200182|DEVICE|Sham Neurofeedback|the participants will receive the same instruction but will be shown a random signal
219639368|NCT05200182|OTHER|oral microbiota collection|an examination and oral swab for oral microbiota analysis will be performed by a dentist
219639369|NCT05200182|OTHER|Questionnaires|questionnaires for pre-intervention behavioral characterization
219639370|NCT05200182|DEVICE|resting-state fMRI|characterize the brain function of volunteers by resting-state fMRI
218955064|NCT05386628|OTHER|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
218955065|NCT05386628|OTHER|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
218955066|NCT06020729|OTHER|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
219057800|NCT04087057|OTHER|Interview|Participate in interview
219057801|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
219057802|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
219057803|NCT03678948|DEVICE|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
219057804|NCT03678948|DEVICE|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
219057805|NCT04598516|DIAGNOSTIC_TEST|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
219057806|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
219057807|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
219057808|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
219057809|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
219057810|NCT00659269|DRUG|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
219057811|NCT01158222|DRUG|sunitinib malate|Given orally
219057812|NCT00783536|DRUG|Etanercept + Methotrexate|
219057813|NCT00783536|DRUG|DMARDS|
219057814|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
219057815|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
219057816|NCT06035926|OTHER|questionnaire|questionnaire
219057817|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
219207170|NCT06037252|DRUG|Tirzepatide|Administered SC
219207171|NCT06037252|DRUG|Placebo|Administered SC
218955067|NCT06020729|OTHER|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
218955068|NCT03645018|DIAGNOSTIC_TEST|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
218955069|NCT01188174|DRUG|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
219057818|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
219057819|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
218955070|NCT03721445|DEVICE|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
219207172|NCT06510608|DIAGNOSTIC_TEST|Biochemical analysis of saliva sample|It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
219207173|NCT01476241|PROCEDURE|PEG tube placement|Percutaneous endoscopic gastrostomy
219207174|NCT05036837|DRUG|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
219207175|NCT02559349|OTHER|Stool Collection|
219207176|NCT06295341|DRUG|Recombinant human growth hormone (only for children with growth hormone deficiency)|6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
219207177|NCT05816265|DRUG|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
218955071|NCT05055401|PROCEDURE|Direct Laryngoscopy|The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
218955072|NCT05055401|PROCEDURE|Laryngeal Mask Airways|The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
218955073|NCT05055401|PROCEDURE|Video Laryngoscopy|The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
218955074|NCT05303701|DRUG|GV1001 Placebo|0.9% normal saline
218955075|NCT05303701|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
218955076|NCT00045942|DRUG|Itraconazole|Itraconazole was commercially available.
218955077|NCT00045942|DRUG|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
218955078|NCT04779736|BEHAVIORAL|A set of implementation strategies to reduce sexual stigma|The set of implementation strategies was finalized based on formative interviews and consultation with an advisory board. This included an in-person workshop for skills development, environmental restructuring through a website of information resources for healthcare consumers and HCWs, and supportive coaching components (i.e., coaching calls, an optional email listserve) and quality improvement meetings with two clinics to encourage and respond to the implementation of recommended practices.
218955079|NCT05814276|BEHAVIORAL|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
218955080|NCT01488474|PROCEDURE|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
218955081|NCT04951167|DRUG|Norepinephrine|in the form of infusion
218955082|NCT04951167|DRUG|Norepinephrine|in the form of bolus
218955083|NCT00159497|DEVICE|porous coated Trilogy®|THA
218955084|NCT00159497|DEVICE|Trilogy Calcicoat®|THA
218955085|NCT06482242|BEHAVIORAL|My Best Alaska Life|MBAL's combination of digital innovation, inclusive content, and youth-driven design positions it as a leading-edge intervention in the field of sexual health, with the potential to significantly impact the lives of Y/YA in AK and beyond. The open-access digital website enhances the reach and engagement of MBAL, particularly among adolescents who may prefer to seek information and support online in a private, self-paced setting. By allowing youth to fill out this tool at their own pace and return to their home page as they want to reflect/change answers, they can update it as their lives change. Additionally, MBAL incorporates interactive elements (question types of open response, ranking, scales, drag/drop; journaling prompts \& space) and personalized features (ex. avatars of common AK animals designed by Y/YA), allowing users to tailor their life planning experience according to their individual needs and preferences and return to their answers.
218955086|NCT06504745|OTHER|Peer education|experimental group
218955087|NCT06504745|OTHER|control group|instruction training
218955088|NCT02762851|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
218955089|NCT02762851|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
218955090|NCT05946434|OTHER|Kinesio Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
218955091|NCT05946434|OTHER|Rigid Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
218955092|NCT01967368|DRUG|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
218955093|NCT01967368|DRUG|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
218955094|NCT04847089|DEVICE|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
218955095|NCT03315052|DRUG|Budesonide|Oral steroid with high first-pass metabolism in liver
218955096|NCT03315052|DRUG|Tacrolimus（FK506）|Calcineurin immunosuppressant
218955097|NCT03315052|DRUG|Mycophenolate Mofetil|Immunosupressant
218955098|NCT03315052|DRUG|Prednisone|Immunosuppresant
219057820|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
219057821|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
219057822|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
218955099|NCT02095132|DRUG|Adavosertib|Given PO
219057823|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
219207178|NCT05290714|BEHAVIORAL|Mentalization-Based Treatment for Children (MBT-C)|MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.
219639371|NCT05200182|DEVICE|Electro gastrogram|Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
219639372|NCT05200182|BEHAVIORAL|Emotional Stroop task|an emotional Stroop task adapted to food and body image representation
218955100|NCT02095132|DRUG|Irinotecan Hydrochloride|Given PO
219207179|NCT05290714|BEHAVIORAL|Parenting and Social Skills Group|Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
219639373|NCT06685731|OTHER|Laughter Yoga|"Laughter Yoga Intervention:~Laughter Yoga is composed of four stages: deep breathing exercises, clapping and warm-up exercises, childlike play, and laughter exercises. These stages are designed to remove barriers to laughter, enhance emotional expression through childlike play, and prepare the lungs for laughter exercises.~Before the Laughter Yoga session begins, participants will be introduced to both the practice itself and to Laughter Yoga in general. The session will then proceed according to the following structure:~Deep Breathing Exercises: Participants inhale through the nose for 4-5 seconds, hold their breath for 2-3 seconds, and exhale through the mouth, with lips pursed, for one second longer than the inhalation, while smiling or laughing. This exercise is performed for 10-15 minutes.~Clapping and Warm-Up Exercises: Participants clap with palms and fingertips touching, keeping their hands parallel. This stimulates acupressure points in the hands. To increase group energy, a"
219639374|NCT00790244|DRUG|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
219639375|NCT00790244|DRUG|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
219639376|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
219639377|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
219639378|NCT05581940|COMBINATION_PRODUCT|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.\[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
219639379|NCT04805801|DRUG|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
218955101|NCT04482985|DRUG|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
218955102|NCT06521879|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v probiotic support|Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
218955103|NCT01029405|DRUG|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
218955104|NCT01029405|DRUG|Placebo|Ointment B Vehicle applied once or twice daily
218955105|NCT00409175|DRUG|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
218955106|NCT00409175|DRUG|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
218955107|NCT06217185|DRUG|Pyrotinib|Pyrotinib 400mg qd po continuously
218955108|NCT06217185|DRUG|Trastuzumab|For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
219057824|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
219057825|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
219639380|NCT03781362|DRUG|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
219639381|NCT03781362|DRUG|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
218955109|NCT06217185|DRUG|Taxanes|Taxanes: Usual clinical dose is administered, in a 21-day cycle.
218955110|NCT06217185|DRUG|Capecitabine|Capecitabine: 650mg/m2 each time, given twice daily
218955111|NCT04041791|DRUG|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
218955112|NCT04041791|DRUG|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
218955113|NCT04041791|DRUG|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
219057826|NCT05294263|DRUG|Placebo|Matching, inactive medication
219057827|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
219057828|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
219207180|NCT01864538|DRUG|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
218955114|NCT04041791|DRUG|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
218955115|NCT04041791|OTHER|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
218955116|NCT04041791|OTHER|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
218955117|NCT04041791|DRUG|Ampicillin|Ampicillin is a penicillin-type antibiotic.
218955118|NCT06112873|OTHER|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
218955119|NCT04918056|DIAGNOSTIC_TEST|Hematological Analysis and Genetical Analysis|"Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay."
219639382|NCT00081757|DRUG|Thalidomide|
218955120|NCT01435551|OTHER|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
218955121|NCT01312623|OTHER|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
219639383|NCT03788031|OTHER|Acuity training|The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
218955122|NCT00004382|DRUG|tin mesoporphyrin|
218955123|NCT00004382|PROCEDURE|Phototherapy|
218955124|NCT05058495|OTHER|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
218955125|NCT05058495|OTHER|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
218955126|NCT06554483|OTHER|Exercise|supportive reliable exercise programs
218955127|NCT02596750|DEVICE|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
219057829|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
219057830|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
218955128|NCT02596750|DEVICE|Sham microneedle Roller|Flat roller without microneedles
218955129|NCT03492840|DRUG|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
218955130|NCT02518503|DRUG|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955131|NCT02518503|DRUG|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955132|NCT02518503|DRUG|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955133|NCT02518503|DRUG|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955134|NCT02518503|DRUG|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955135|NCT02518503|DRUG|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955136|NCT02518503|DRUG|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955137|NCT02518503|DRUG|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
219057831|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
219057832|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
219057833|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
219057834|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
219639384|NCT03788031|OTHER|Occlusion therapy|Participants will be required to patch the good eye for 20 days, 1 hour per day.
219639385|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
219639386|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
219639387|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
219207181|NCT05184088|DRUG|[18F]florbetaben|All enrolled patients will undergo \[18F\]florbetaben PET imaging.
219207182|NCT06837805|OTHER|Iowa Produce Prescription Program (I-PPP)|The I-PPP intervention offers a produce prescription in the form of $30.00 per family member in a household every month to spend on fruit and vegetables. The dollars can be used at local retail partners, which are specific to each community. A mobile app has been developed for the I-PPP intervention participants. At the beginning of each month for six months, the app asks participants to complete a nutrition education module and a corresponding short quiz. After the participant completes the module, $30.00 per family member in the house will be loaded into the app for participants to use over the next month at local retail partners to buy fresh fruits and vegetables. Participants will have 30 days from the date of distribution to spend the funds before they expire.
219639388|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
219639389|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
219057835|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
219057836|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
219057837|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
219057838|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
219639390|NCT01070212|OTHER|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
219639391|NCT01070212|OTHER|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
219639392|NCT01070212|OTHER|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
219639393|NCT01329042|DRUG|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
219639394|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner RN|Measure Urine Volume with Bladder Scanner by RN
219639395|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound APRN|Measure Urine Volume with Point of Care Ultrasound by APRN
219639396|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner APRN|Measure Urine Volume with Bladder Scanner by APRN
219639397|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound MD|Measure Urine Volume with Point of Care Ultrasound by MD
219639398|NCT03428113|OTHER|Intermittent Straight Catheterization|Measure Urine Volume with Intermittent Straight Catheterization
219639399|NCT01094470|DEVICE|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
219639400|NCT03477253|PROCEDURE|Laparoscopic cholecystectomy|The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
219639401|NCT00660933|DRUG|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
219639402|NCT00660933|DRUG|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
219639403|NCT06668415|PROCEDURE|Hydro dilation|The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.
219639404|NCT06668415|PROCEDURE|Spencer muscle energy technique|Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist
219639405|NCT06668415|PROCEDURE|Passive Stretching|The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold.
219639406|NCT01496963|OTHER|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
218955138|NCT02518503|DRUG|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
218955139|NCT02691598|DRUG|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
218955140|NCT05030961|BEHAVIORAL|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
218955141|NCT05030961|BEHAVIORAL|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
218955142|NCT01895361|DRUG|SelG1|
218955143|NCT01895361|DRUG|Placebo|
218955144|NCT00203281|DRUG|tacrolimus|
218955145|NCT00203281|DRUG|mycophenolate mofetil|
218955146|NCT00203281|DRUG|daclizumab|
218955147|NCT00203281|DRUG|intravenous immune globulin|
219057839|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
219057840|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
219057841|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
219057842|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
219057843|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
219057844|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
219057845|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
219057846|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
219057847|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
219057848|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
219057849|NCT00390390|DRUG|Lansoprazole|
219057850|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
219639407|NCT05911048|BIOLOGICAL|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)|boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
219639408|NCT05911048|BIOLOGICAL|Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)|boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
219639409|NCT01726725|DRUG|desflurane|
219639410|NCT02818985|DRUG|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
219639411|NCT02818985|DRUG|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
219057851|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
219057852|NCT01970332|PROCEDURE|Revascularization Surgery|
219639412|NCT02818985|DRUG|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
218955148|NCT00203281|PROCEDURE|plasmapheresis|
218955149|NCT02643056|DRUG|Panitumumab|IV administration every 2 weeks
218955150|NCT04485065|DRUG|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
218955151|NCT01887743|DRUG|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
218955152|NCT06311552|OTHER|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
218955153|NCT00873470|PROCEDURE|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
218955154|NCT02760043|DRUG|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
218955155|NCT02760043|OTHER|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
218955156|NCT02760043|DRUG|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
218955157|NCT00539201|DRUG|GSK706769|
219639413|NCT06641193|DEVICE|high frequency-repetitive transcranial magnetic stimulation|rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue.
219639414|NCT06641193|DEVICE|sham stimulation|The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
219639415|NCT03727152|DRUG|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
218955158|NCT05271279|BIOLOGICAL|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
218955159|NCT02447783|DIETARY_SUPPLEMENT|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
219057853|NCT01970332|OTHER|Supervised exercise therapy|
219057854|NCT01842828|OTHER|Standard care plus electronic cigarettes|
219639416|NCT05045079|PROCEDURE|Inferior Vena Caval (IVC) Occlusion maneuver|During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
219639417|NCT04198038|BEHAVIORAL|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
219639418|NCT06104761|OTHER|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
219639419|NCT06104761|OTHER|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
219639420|NCT03119675|DEVICE|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
219639421|NCT03119675|DEVICE|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
219639422|NCT03813836|DRUG|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
219639423|NCT01335074|DRUG|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
219639424|NCT01680861|DRUG|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
219639425|NCT01680861|DRUG|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
219639426|NCT01680861|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
219639427|NCT01680861|DRUG|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
218955160|NCT02447783|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
219057855|NCT01842828|BEHAVIORAL|Standard care|
219057856|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
219057857|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
219057858|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
219057859|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
219057860|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
219057861|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
219057862|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
219057863|NCT01159301|DRUG|entinostat|Given orally (PO)
218955161|NCT05053542|PROCEDURE|Enema|Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
218955162|NCT05898269|DIAGNOSTIC_TEST|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
218955163|NCT05898269|DIAGNOSTIC_TEST|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
218955164|NCT05898269|DIAGNOSTIC_TEST|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
218955165|NCT05898269|DIAGNOSTIC_TEST|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
218955166|NCT05898269|DIAGNOSTIC_TEST|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index \> 15% will be identified as being fluid responders, and the others as non-responders."
218955167|NCT04644367|OTHER|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
219639428|NCT06681961|OTHER|squatting with hip adduction (SQU-HA) group|The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
219639429|NCT02375893|OTHER|No intervention|Collecting blood and feces samples
218955168|NCT04644367|OTHER|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
218955169|NCT01498094|PROCEDURE|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
218955170|NCT01498094|OTHER|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
218955171|NCT01209832|DRUG|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
219057864|NCT01159301|DRUG|sorafenib tosylate|Given PO
219057865|NCT01159301|OTHER|pharmacological study|Correlative studies
219057866|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
219057867|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
219057868|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
219639430|NCT02375893|OTHER|Healthy subject|Collecting blood and feces samples
219057869|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
219639431|NCT03403829|DRUG|Gemcitabine|Gemcitabine maintenance chemotherapy
219639432|NCT03403829|RADIATION|standard chemoradiotherapy|standard chemoradiotherapy
219639433|NCT00062881|DRUG|Intrathecal Mafosfamide|
219639434|NCT01366235|DRUG|chloroquine phosphate 1000 mg|1000 mg, 1day
219639435|NCT03694964|DRUG|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
219639436|NCT03694964|DRUG|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
219639437|NCT04339985|DRUG|ATx201|Topical
219639438|NCT04339985|DRUG|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
219639439|NCT05684575|OTHER|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
219639440|NCT06622928|DIAGNOSTIC_TEST|Echocardiogram|"Echocardiographic Assessments:~Pre-Hemodialysis Echocardiography:~Before each hemodialysis session, echocardiograms will be performed to evaluate cardiac function and gather baseline data on ventriculo-arterial coupling (VAC) parameters. This will include recording three apical echocardiographic views (4-chamber, 2-chamber, and 3-chamber) by a trained sonographer.~Post-Hemodialysis Echocardiography:~Following the completion of the hemodialysis session, echocardiographic assessments will be repeated to measure changes in VAC parameters and other relevant cardiac metrics."
218955172|NCT01209832|DRUG|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
218955173|NCT01268579|DRUG|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
218955174|NCT00197067|BIOLOGICAL|RTS,S/AS02D and RTS,S/AS02A|
218955175|NCT00761150|DRUG|ABT-712|ABT-712 extended-release tablet
218955176|NCT00761150|DRUG|Placebo|Placebo tablet
218955177|NCT03843710|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
218955178|NCT00479921|BIOLOGICAL|Trivalent influenza subunit vaccine|
218955179|NCT02424214|OTHER|Artificial Oocyte activation|
218955180|NCT02424214|DRUG|Ca Ionophore|
218955181|NCT02424214|DRUG|Strontium Chloride|
218955182|NCT01267695|DRUG|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
218955183|NCT01267695|PROCEDURE|conventional surgery|All the patients should receive elective surgery with R0 resection.
218955184|NCT02753244|OTHER|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
218955185|NCT02753244|OTHER|iPad Apps|Commercially available iPad game applications
218955186|NCT02692651|DRUG|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
218955187|NCT02692651|DRUG|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
218955188|NCT02184351|DRUG|Roxanes's clotrimazole troches|
218955189|NCT02184351|DRUG|Mycelex® troches|
218955190|NCT03744143|PROCEDURE|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
218955191|NCT03744143|PROCEDURE|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
218955192|NCT03744143|PROCEDURE|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
218955193|NCT01245361|DRUG|Infliximab|Infliximab 3 mg/kg wk 0,2,6
218955194|NCT01245361|DRUG|sodium chloride|Group II : Placebo wk 0,2,6
218955195|NCT02166372|OTHER|Observation of natural course of Diabetes Mellitus Type 2|
218955196|NCT01381146|BEHAVIORAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
218955197|NCT01381146|BEHAVIORAL|TAU|have access to other jail programs and services
218955198|NCT03002376|DRUG|REGN2810|REGN2810 treatment
218955199|NCT01548144|DRUG|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
218955200|NCT01548144|DRUG|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
218955201|NCT01548144|DRUG|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
218955202|NCT02480712|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
218955203|NCT00907660|BEHAVIORAL|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
218955204|NCT00907660|DIETARY_SUPPLEMENT|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
218955205|NCT01192243|DRUG|Gefitinib|250mg qd po d3-16
218955206|NCT01192243|DRUG|Pemetrexed|500mg/m2 venous infusion,D1,q3w
218955207|NCT01192243|DRUG|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
218955208|NCT00733889|DRUG|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
218955209|NCT00068133|GENETIC|Plasmid based Gene Transfer product-VLTS-589|
218955210|NCT06450951|DIAGNOSTIC_TEST|Urinary EDC metabolite testing|Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.
218955211|NCT06450951|BEHAVIORAL|Educational curriculum|A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.
218955212|NCT00885001|PROCEDURE|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
218955213|NCT00353028|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
218955214|NCT00353028|DRUG|Placebo|Placebo
218955215|NCT03566836|DEVICE|Garmin Smart Watch|Garmin Smart Watch
218955216|NCT03566836|DEVICE|Garmin Chest Band|Garmin Chest Band
218955217|NCT05018936|DRUG|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
218955218|NCT06322290|DIAGNOSTIC_TEST|assessment of pathogens in blood specimens|Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
218955219|NCT05457894|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
218955220|NCT05457894|BIOLOGICAL|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
218955221|NCT06150144|DRUG|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
218955222|NCT06150144|OTHER|SURGERY|Total excision of the lesion
218955223|NCT05463198|DEVICE|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
218955224|NCT02385227|OTHER|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
218955225|NCT02385227|OTHER|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
218955226|NCT02385227|OTHER|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
218955227|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
218955228|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
218955229|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
218955230|NCT02385227|OTHER|Nicotine product cessation C|Nicotine cessation
219057870|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
219057871|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
218955231|NCT03304496|DRUG|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
218955232|NCT03304496|DRUG|Saline Solution|Previously described.
218955233|NCT05993975|DRUG|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
218955234|NCT05993975|DRUG|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
218955235|NCT01254955|BIOLOGICAL|H1N1 vaccine Pandemrix|
218955236|NCT05967897|DIETARY_SUPPLEMENT|Blueberries|22 g freeze-dried blueberry powder mixed with water
218955237|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
218955238|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
218955239|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
218955240|NCT02239120|DRUG|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
218955241|NCT02239120|DRUG|placebo to ASA|placebo to comparator drug
219057872|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
219057873|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
219057874|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
219639441|NCT06078774|BEHAVIORAL|Virtual Health Coach|"Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management."
218955242|NCT02239120|DRUG|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
219639442|NCT04028895|DIAGNOSTIC_TEST|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
218955243|NCT02239120|DRUG|placebo to dabigatran etexilate|placebo
218955244|NCT02239120|DRUG|ASA 100 mg|active comparator drug
218955245|NCT02239120|DRUG|dabigatran etexilate|active drug
218955246|NCT01925989|BIOLOGICAL|LY2605541|Administered SQ
218955247|NCT01925989|BIOLOGICAL|Insulin Glargine|Administered SQ
218955248|NCT01724619|DRUG|[F-18] fluorinated dihydrotestosterone (FDHT)|
218955249|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
218955250|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
218955251|NCT01489241|PROCEDURE|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
218955252|NCT01535976|DRUG|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
218955253|NCT01535976|DRUG|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
218955254|NCT01235871|DRUG|SB1578|JAK2 Inhibitor
218955255|NCT01235871|DRUG|Placebo|Control arm
219639443|NCT06683963|DEVICE|Rebee|Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
219639444|NCT03055481|OTHER|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
218955256|NCT01268371|DEVICE|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
218955257|NCT01268371|DEVICE|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
218955258|NCT06032897|OTHER|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
218955259|NCT05473585|OTHER|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
218955260|NCT05473585|OTHER|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
218955261|NCT05473585|OTHER|Study e-cigarette|E-cigarette provided by study
219057875|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
219057876|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
218955262|NCT03513081|BEHAVIORAL|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
218955263|NCT04909476|PROCEDURE|Endotracheal intubation|Airways management in COVID 19 patients pneumonia
218955264|NCT06228911|DRUG|steroid (triamcinolone)|triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
218955265|NCT03281993|OTHER|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
218955266|NCT01997385|PROCEDURE|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
219057877|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
219057878|NCT01490060|DRUG|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
218955267|NCT01997385|PROCEDURE|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
218955268|NCT05072470|DEVICE|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
218955269|NCT05072470|DEVICE|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
218955270|NCT04935645|BEHAVIORAL|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
218955271|NCT05988502|OTHER|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
218955272|NCT00100334|DRUG|PPI-1019 (APAN)|
218955273|NCT04725357|DRUG|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
218955274|NCT04725357|PROCEDURE|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
218955275|NCT04725357|PROCEDURE|arthroscopic labral repair|participant will have their standard surgical procedure done
219207183|NCT06837805|BEHAVIORAL|Produce Your Path Behavioral Nutrition Intervention (PYP)|The PYP Intervention is a six-month virtual behavioral intervention grounded in Self Determination Theory. The intervention aims to improve participants' competence, autonomy, and sense of relatedness through educational videos, recipes, and supplemental resources. Each monthly module contains several short videos, totaling around 15 minutes in length. The module topics include goal-setting, planning meals, preparing fruits and vegetables, reading nutrition labels, budgeting for healthier eating, and making healthier food swaps. The videos are tailored to represent a variety of cultures, ethnicities, and backgrounds, with diverse actors and recipes. Upon completion of each monthly module, a short quiz is administered to participants to measure self-efficacy related to the topic and prompt goal-setting. To further increase social support, an optional Facebook Group component allows participants to post questions, share goals and recipes, and answer prompts from the research team.
219639445|NCT03055481|OTHER|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
219639446|NCT03804424|DRUG|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
218955276|NCT00219895|DRUG|Ibuprofen|
218955277|NCT01104532|DRUG|ASP1941|oral tablet
218955278|NCT01104532|DRUG|sitagliptin|oral tablet
219639447|NCT03804424|DEVICE|PET/MR|-All PET imaging will be performed as PET/MR or PET/CT
218955279|NCT01117909|OTHER|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
218955280|NCT01117909|OTHER|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
218955281|NCT02219802|PROCEDURE|Treatment according arm|
218955282|NCT03920540|COMBINATION_PRODUCT|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
218955283|NCT03920540|COMBINATION_PRODUCT|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
218955284|NCT03723603|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
219639448|NCT03804424|PROCEDURE|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
219639449|NCT03804424|PROCEDURE|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
219639450|NCT03804424|PROCEDURE|Urine sample|-Cohort 1 only
219639451|NCT03804424|PROCEDURE|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
219639452|NCT03804424|PROCEDURE|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
219639453|NCT03804424|DEVICE|PET/CT|-All PET imaging will be performed as PET/MR or PET/CT
219639454|NCT05448417|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
219057879|NCT01490060|DRUG|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
219057880|NCT01490060|DRUG|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
218955285|NCT00088036|DRUG|Olanzapine|
219057881|NCT01490060|DRUG|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
219057882|NCT01490060|DRUG|Doxorubicin|25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
219057883|NCT01490060|DRUG|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
219057884|NCT01490060|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
219057885|NCT01490060|DRUG|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
219057886|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
219057887|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
219057888|NCT01877421|DRUG|2 mg KSL-W|
219057889|NCT01877421|DRUG|4 mg KSL-W|
219057890|NCT01877421|DRUG|6 mg KSL-W|
219057891|NCT01877421|DRUG|10 mg KSL-W|
219057892|NCT01877421|DRUG|20 mg KSL-W|
219057893|NCT01877421|DRUG|30 mg KSL-W|
219057894|NCT01877421|DRUG|50 mg KSL-W|
219057895|NCT01877421|DRUG|75 mg KSL-W|
219057896|NCT01877421|DRUG|100 mg KSL-W|
219639455|NCT05448417|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
219639456|NCT04791319|DRUG|Placebo|Placebo will be administered subcutaneously.
219639457|NCT04791319|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
219639458|NCT04791319|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
218955286|NCT00046800|DRUG|OSI-211 (Liposomal Lurtotecan)|
218955287|NCT05449015|DRUG|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
218955288|NCT03796845|OTHER|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
218955289|NCT02284425|DRUG|REGN1193|
218955290|NCT02284425|DRUG|Placebo|
218955291|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
218955292|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
218955293|NCT00684047|PROCEDURE|Manual Compression|Manual Compression. Primary Part (II)
218955294|NCT00316108|DEVICE|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
218955295|NCT05244980|DRUG|TDM-105795|TDM-105795 topical solution
218955296|NCT05244980|DRUG|Placebo|Placebo for TDM-105795 topical solution
218955297|NCT05484687|DRUG|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
218955298|NCT04882969|DEVICE|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
218955299|NCT03493932|DRUG|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
218955300|NCT03493932|DRUG|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
218955301|NCT01863589|DRUG|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
218955302|NCT01143740|DRUG|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
218955303|NCT02591771|DRUG|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
218955304|NCT03415776|PROCEDURE|Hemodialysis|Renal replacement therapy
218955305|NCT03455790|DIAGNOSTIC_TEST|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
218955306|NCT01128764|BEHAVIORAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
219207184|NCT06065501|BEHAVIORAL|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
218955307|NCT01128764|BEHAVIORAL|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
218955308|NCT04695613|DRUG|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
219639459|NCT04796506|OTHER|Progressive Resistance Training (PRT)|PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by \>24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).
219639460|NCT04796506|OTHER|Delayed Exercise Training (DE)|PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.
219639461|NCT04796506|OTHER|Endurance Training (ET)|Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
219057897|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
219639462|NCT00006471|DRUG|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
219057898|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
219639463|NCT02982174|DEVICE|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
219639464|NCT02982174|DEVICE|DRI OCT Triton|Image acquisition of the posterior surface of the eye
219639465|NCT03407157|DIETARY_SUPPLEMENT|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
219639466|NCT03407157|OTHER|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
219639467|NCT06685666|OTHER|traditional warm-up method specific to handball|The traditional warm-up program specific to handball consists of 6 basic sections: static stretching, aerobic work, dynamic mobility exercises, passes and crosses, shooting on goal and shooting according to position, and lasts 17 minutes in total.
218955309|NCT04695613|DRUG|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
218955310|NCT03970408|PROCEDURE|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
218955311|NCT00045981|DRUG|ALT-711|
218955312|NCT04908943|BEHAVIORAL|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
218955313|NCT05532696|DRUG|ABT-101|Patients will receive ABT-101 by oral administration on a 28-day cycle
218955314|NCT04456153|DRUG|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
218955315|NCT04456153|DRUG|Placebo Group|Continued standard of care therapy together with matching placebo
218955316|NCT00212017|DRUG|voglibose|
218955317|NCT00212017|BEHAVIORAL|diet and exercise therapy|
219057899|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
219207185|NCT06065501|BEHAVIORAL|Usual care|Nurses provide routine education and consultation
219207186|NCT04963088|DRUG|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
219207187|NCT04963088|DRUG|Anlotinib|oral administration daily d1-d14, q3w;
219207188|NCT04963088|DRUG|Oxaliplatin|30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
218955318|NCT04814238|PROCEDURE|Aortic Root Surgery|First time, isolated, minimally invasive (mini-sternotomy, RALT) aortic root or aorta surgery
218955319|NCT04064008|DEVICE|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
218955320|NCT02642588|DIETARY_SUPPLEMENT|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
218955321|NCT02370576|OTHER|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
218955322|NCT05613712|OTHER|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
218955323|NCT05613712|OTHER|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
218955324|NCT01120067|BEHAVIORAL|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
218955325|NCT01120067|BEHAVIORAL|Treatment as Usual|Treatment as Usual.
218955326|NCT00388427|DRUG|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
218955327|NCT00388427|DRUG|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
219639468|NCT06685666|OTHER|elastic band exercises added to the traditional warm-up|The experimental group will be given elastic band exercises for 6 weeks after the static and dynamic exercises in the traditional warm-up and then continue with the warm-up with the ball. The exercise program was planned progressively. The exercises will be done in the first 3 weeks, 2 sets of 10 repetitions with a light resistance band. Then the exercises will be done in 3 sets of 10 repetitions with a medium resistance band. There are 8 band exercises in total.This exercise; Flexion and Extension Exercise in Diagonal Pattern, Internal and external rotation with the arm next to the body and the elbow in 90 degrees flexion, Internal and external rotation with the arm in 90 degrees abduction and the elbow in 90 degrees flexion, Scaption Exercise, Rowing, Biceps and Triceps (elbow flexion and extansion exercise), Wrist Flexors and Extensors (wrist flexion and extansion exercise).
219639469|NCT03702075|OTHER|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
219639470|NCT02499653|BEHAVIORAL|Psychological Intervention|
219639471|NCT02499653|BEHAVIORAL|Videos|
219639472|NCT01451970|OTHER|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
218955328|NCT04465201|DEVICE|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
218955329|NCT05003271|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
218955330|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
218955331|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
218955332|NCT05262348|DEVICE|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
218955333|NCT05262348|DEVICE|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
218955334|NCT06080724|DRUG|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
219639473|NCT01211457|DRUG|sapacitabine and decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
219639474|NCT01211457|DRUG|sapacitabine and venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
219639475|NCT03115138|OTHER|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
218955335|NCT00401388|DRUG|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
218955336|NCT00401388|OTHER|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
218955337|NCT00401388|OTHER|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
218955338|NCT00401388|OTHER|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
218955339|NCT03936452|DRUG|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
218955340|NCT05444998|DRUG|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
218955341|NCT04857229|DEVICE|Histolog Scanner|Confocal Microscope
219057900|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
219057901|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
219057902|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
219057903|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
219057904|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
219057905|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
219057906|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
219057907|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
219057908|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
219057909|NCT02755493|BEHAVIORAL|Sleep deprivation|
219057910|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
219057911|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
218955342|NCT00266877|DRUG|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
218955343|NCT05451927|DIETARY_SUPPLEMENT|Phaseolus Vulgaris|Weight loss
219057912|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
219057913|NCT04627727|OTHER|low FODMAP diet|low FODMAP diet
219057914|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
219057915|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
219057916|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
219057917|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
219057918|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
219057919|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
219057920|NCT05798507|DRUG|Avutometinib|Given PO
219057921|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219057922|NCT05798507|DRUG|Defactinib|Given PO
218955344|NCT05451927|DIETARY_SUPPLEMENT|Placebo|Placebo
219639476|NCT06967285|BEHAVIORAL|Prone ventilation|Cerebral Blood Flow Monitoring Before and After Prone Ventilation in Patients with ARDS.Cerebral blood flow,intracranial pressure,and systemic hemodynamic monitoring were performed at the following time points:before prone positioning(T0),1 hour after prone ventilation(T1),12 hours after prone ventilation(T2),1 hour after returning to the supine position(T3),and 7 days after returning to the supine position(T4).
219639477|NCT03192670|DEVICE|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
219639478|NCT01194128|BEHAVIORAL|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
218955345|NCT02508298|PROCEDURE|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
218955346|NCT02508298|DRUG|Indocyanine Green Retention test|As decribed in arm descriptions
218955347|NCT02508298|DEVICE|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
218955348|NCT02508298|DEVICE|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
219057923|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
219057924|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
219057925|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
219057926|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
219057927|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
219057928|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
219057929|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
219057930|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
219057931|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219057932|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
219057933|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219057934|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
219639479|NCT01194128|BEHAVIORAL|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
218955349|NCT05945862|BEHAVIORAL|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
218955350|NCT02387476|DEVICE|FRESCA mask first night|FRESCA nasal mask first night
219057935|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
219057936|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
219057937|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
219057938|NCT05547464|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
219057939|NCT05547464|BIOLOGICAL|BNT164b1|Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
219057940|NCT05547464|OTHER|Placebo|Placebo
219057941|NCT00548782|OTHER|Paleolithic diet|diet
219057942|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
219057943|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
219057944|NCT00908960|DRUG|Enoxaparin|
219057945|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
219057946|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
218955351|NCT02387476|DEVICE|CPAP Mask first night|CPAP Nasal Mask first night
218955352|NCT05258370|OTHER|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
218955353|NCT05258370|OTHER|Cardiac echography|12 months after patient enrollment
218955354|NCT01311635|DRUG|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
218955355|NCT01311635|DRUG|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
218955356|NCT01311635|DRUG|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
218955357|NCT00830076|DRUG|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
218955358|NCT00830076|DRUG|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
218955359|NCT00830076|DRUG|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
218955360|NCT00830076|DRUG|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
218955361|NCT05908058|OTHER|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
218955362|NCT04339842|OTHER|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
218955363|NCT03720392|DRUG|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
218955364|NCT03720392|DRUG|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
218955365|NCT01910077|DRUG|Tacrobell capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
218955366|NCT01910077|DRUG|Prograf capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
219057947|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
219057948|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4\. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5\. Upon completion of the scan, will be released without any restrictions."
219057949|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
219057950|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
219057951|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
219057952|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
219057953|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
219207189|NCT04963088|DRUG|Capecitabine|1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
218955367|NCT02097017|DRUG|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
218955368|NCT02097017|OTHER|placebo comparator|
218955369|NCT00002975|DRUG|aminolevulinic acid|
218955370|NCT01453387|DRUG|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
218955371|NCT01453387|DRUG|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
218955372|NCT01802918|DRUG|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
218955373|NCT01802918|DRUG|Placebo|Visually matching GSK2838232
218955374|NCT01802918|DRUG|Ritonavir|100mg tablets once daily for 12 days
218955375|NCT02202330|OTHER|Video Arm|"1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
218955376|NCT01677390|DRUG|SGN-75|1-2 mg/kg IV every 21 days
219057954|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
219057955|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
219639480|NCT06278363|OTHER|Sexual Nursing care|"The Sexual Nursing Care approach is a specialized intervention for stroke patients and partners, addressing sexual health needs. It includes personalized counseling sessions with trained nurses, assessing dysfunctions and medical history. Active partner involvement fosters intimacy and understanding. Both receive sexual education covering anatomy, physiology, and post-stroke changes. Recommendations for activities like Kegel exercises are provided. Structured outpatient sessions occur, lasting 45 minutes, facilitated by a nurse. Pre- and post-treatment assessments are conducted to identify contraindications. Emerging issues during treatment are promptly communicated for management. Sexual Nursing Care aims to holistically address post-stroke sexual health and relational needs, improving awareness and communication.~Coaching and Counselling can be provided also via telemedicine."
219639481|NCT06278363|OTHER|Standard Nursing Care|Group 2 patients receive standard nursing care without structured interventions for sexual dysfunctions. Management relies on clinical case and routine care procedures. No specific sexual sphere interventions are provided. Any emerging issues needing diagnostic investigation are reported to the specialist. Both groups are assessed quantitatively for counseling effects on sexual and relational aspects and qualitatively for psychorelational changes and mood impact on couple's quality of life.
219639482|NCT00484562|DEVICE|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
219639483|NCT00484562|DEVICE|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
219639484|NCT00484562|DEVICE|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
219639485|NCT00484562|DEVICE|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
219639486|NCT06621615|BIOLOGICAL|CVL006 Injection|CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
219639487|NCT05403814|OTHER|observational screening procedure (no intervention)|observational screening procedure (no intervention)
219639488|NCT05882838|OTHER|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
218955377|NCT01677390|DRUG|everolimus|10 mg PO daily
218955378|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
219057956|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
219057957|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
219057958|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
219057959|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
219057960|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
219057961|NCT01611571|DRUG|Risedronate|weekly risedronate
219057962|NCT01611571|DRUG|Teriparatide|daily teriparatide
219057963|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
219057964|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
218955379|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
218955380|NCT03985878|DRUG|Eteplirsen|Eteplirsen IV infusion once weekly.
219057965|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
219057966|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
219639489|NCT03279549|PROCEDURE|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
219057967|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
219057968|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
219057969|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
219057970|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
219057971|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
219639490|NCT03279549|PROCEDURE|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
219057972|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
219639491|NCT03279549|PROCEDURE|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
219057973|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
219057974|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
219057975|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
219057976|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
219057977|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
219057978|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
219057979|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
219639492|NCT03279549|PROCEDURE|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
219057980|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
219057981|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
219057982|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
219057983|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
219057984|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
219057985|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
219057986|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
219057987|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
219057988|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
219057989|NCT05867394|OTHER|Stress ball|Stress ball squeeze
219057990|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
218955381|NCT01821573|DRUG|botulinum toxin type A|"Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)"
218955382|NCT01821573|DRUG|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points"
218955383|NCT02176720|DRUG|FDOPA PET|\[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
218955384|NCT05843227|OTHER|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
218955385|NCT05301712|DRUG|Naloxone hydrochloride 5.0mg/5ml|"* Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg"
218955386|NCT05301712|DRUG|Sodium Chloride 45mg/5ml|"* Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml"
218955387|NCT03403842|DEVICE|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
218955388|NCT03403842|DEVICE|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
218955389|NCT03403842|DRUG|PCA Morphine|Administration of endovenous morphine with a PCA
218955390|NCT03603327|DRUG|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
218955391|NCT05911282|DRUG|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
218955392|NCT05911282|OTHER|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
218955393|NCT00729846|DRUG|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
218955394|NCT00729846|DEVICE|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
218955395|NCT00729846|DEVICE|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
218955396|NCT03817450|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
218955397|NCT05436340|DEVICE|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
219057991|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
219057992|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
218955398|NCT05436340|DEVICE|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
218955399|NCT01165736|DRUG|PF-05186462|single intravenous infusion of 100 microgram
218955400|NCT01165736|DRUG|PF-05186462|single oral administration of 100 microgram
218955401|NCT01165736|DRUG|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
218955402|NCT01165736|DRUG|PF-05089771|single oral administration of 100 microgram PF-05089771
218955403|NCT01165736|DRUG|PF-05150122|single intravenous administration of 100 microgram PF-05150122
218955404|NCT01165736|DRUG|PF-05150122|single oral administration of 100 microgram PF-05150122
218955405|NCT01165736|DRUG|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
218955406|NCT01165736|DRUG|PF-05241328|single oral administration 100 microgram PF-05241328
218955407|NCT04503915|PROCEDURE|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
219057993|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
219057994|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
219057995|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
219057996|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
219057997|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
219057998|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
219057999|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
218955408|NCT05683431|BEHAVIORAL|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
218955409|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
218955410|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
218955411|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
218955412|NCT00624702|DRUG|Placebo|
219639493|NCT03808324|DIAGNOSTIC_TEST|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
219058000|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
219058001|NCT03732248|DRUG|Placebo|Inert drug
219639494|NCT05775003|DIETARY_SUPPLEMENT|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
219639495|NCT04497870|DRUG|Peppermint oil|Administration of peppermint oil at one of two daily doses.
219639496|NCT04733937|OTHER|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
219639497|NCT04733937|OTHER|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
218955413|NCT05353803|OTHER|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
218955414|NCT06206070|BEHAVIORAL|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
218955415|NCT05767801|PROCEDURE|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
218955416|NCT02699788|DEVICE|Multifunction Cardiogram|
218955417|NCT01070147|OTHER|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
218955418|NCT04711746|BIOLOGICAL|blood sample|Blood sample withdrawal in order to perform DNA sequencing
218955419|NCT04667143|DRUG|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
218955420|NCT00214604|DRUG|Rosuvastatin|10mg
218955421|NCT00214604|DRUG|rosuvastatin|20mg
218955422|NCT00214604|DRUG|pravastatin|40mg
218955423|NCT01850927|PROCEDURE|Remote ischaemic preconditioning|
218955424|NCT01850927|PROCEDURE|Control|
218955425|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
219058002|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
219058003|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
219058004|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
219058005|NCT00733824|DRUG|AMD3100|
219058006|NCT00733824|DRUG|G-CSF|
219058007|NCT00733824|PROCEDURE|Apheresis|
219639498|NCT00224939|DRUG|Potassium Chloride|
219639499|NCT01686464|DRUG|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
218955426|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
219058008|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
219058009|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
219058010|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
219058011|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
219639500|NCT01686464|DEVICE|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
219639501|NCT04729829|BEHAVIORAL|Social and behaviour change communication|Each SBC treatment community will receive nutrition content and learning through savings groups. The group members will participate in skill-building activities that promote five key behaviours about fish nutrition and household decision making on fish consumption as part of facilitated discussions, interactive learning sessions, and a video-based facilitated dialogue. Increased fish consumption through SBC mass attendance events through marketing of fish vendors, interactive learning, and edu-tainment competitions promoting fish consumption. SBC will raise awareness of the benefits of eating fish as part of a balanced diet, with a particular focus on pregnant and lactating mothers, and children under 5 years of age.
219058012|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
219058013|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
219058014|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
219058015|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
219639502|NCT04729829|OTHER|Fish aggregating device|This is a moored line attached to buoys in coastal waters that attracts oceanic fish to it, to make it easier for small-scale fishers to catch them using their existing gear and boats. This FAD will work to increase the catch rate and hence, the availability of fish for sale in upland community markets.
219639503|NCT00220610|DEVICE|Transcranial magnetic stimulation|
219639504|NCT02449798|DEVICE|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
219639505|NCT02209519|DRUG|Metronidazole (male partner)|500 mg PO BID for 7 days
219639506|NCT02209519|OTHER|Placeob (male partner)|matching placebo capsules PO BID for 7 days
219639507|NCT01985932|DEVICE|MRI|
219639508|NCT00276887|BEHAVIORAL|Cognitive Behavior Therapy|
218955427|NCT00720018|DRUG|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
219639509|NCT00276887|BEHAVIORAL|Psychiatric Consultation Letter|
219639510|NCT02401048|DRUG|Ibrutinib|
219639511|NCT02401048|DRUG|MEDI4736|
219639512|NCT05622474|DRUG|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
219639513|NCT05622474|DRUG|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
219639514|NCT05622474|RADIATION|IMRT|Radical radiation: Intensity-modulated radiotherapy
218955428|NCT05268211|DIAGNOSTIC_TEST|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
218955429|NCT03472443|OTHER|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
219207190|NCT06418217|PROCEDURE|Exercise and Patient Education|"Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises."
218955430|NCT04387643|DIETARY_SUPPLEMENT|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
219207191|NCT05870254|OTHER|ExeRVIEM Program|Virtual exercise based program
219058016|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
219207192|NCT05870254|OTHER|Usual center program|Usual center cares
219639515|NCT06060951|DIAGNOSTIC_TEST|Estimated intraperitoneal pressure|"The following anthropometric measurements are required:~1. Height: measured standing with shoes off~2. Weight: dry weight should be used~3. The distance from the decubitus plane to the mid-axillary line was measured~4. Waist circumference: measured with a tape measure wrapped above the iliac crests around the level of the umbilicus.~The estimated IPP will be assessed using different equations."
218955431|NCT04828473|DEVICE|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~* It is not an implant~* It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
219058017|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
219207193|NCT05442489|DEVICE|GORE Excluder Thoracoabdominal Branch Endoprosthesis|TEVAR
219207194|NCT04740541|OTHER|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
219207195|NCT05785754|DRUG|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
219207196|NCT05785754|DRUG|Pembrolizumab|Pembrolizumab injection
219207197|NCT05785754|DRUG|Doxorubicin|1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma
219207198|NCT05785754|DRUG|Tebentafusp|1b SOC Cohort 2: Tebentafusp combination in uveal melanoma
219639516|NCT05094869|BEHAVIORAL|Use of mobile health application|The APP would regularly send messages including the medication reminder, health education knowledge, etc.
219639517|NCT05094869|BEHAVIORAL|Online interaction|The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
219639518|NCT05094869|BEHAVIORAL|Self follow-up reminders|The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
218955432|NCT01739855|DRUG|Calciferol, calcium carbonate|
218955433|NCT03621345|PROCEDURE|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
219207199|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
219207200|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
219207201|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
219207202|NCT05504135|DIAGNOSTIC_TEST|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
219207203|NCT04838717|DRUG|BPG|intramuscular injection of 2.4 million units
219207204|NCT04838717|DRUG|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
219207205|NCT06467136|BEHAVIORAL|Sound production treatment|Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
219207206|NCT06467136|BEHAVIORAL|Motor Imagery Practice|Practice of target items using motor imagery during home practice
219207207|NCT01606488|DRUG|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
219207208|NCT01606488|OTHER|no intervention|
219207209|NCT05975554|DRUG|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
219207210|NCT05975554|PROCEDURE|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
219639519|NCT05094869|BEHAVIORAL|Intelligent follow-up reminders|The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
219639520|NCT03644394|DEVICE|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
218955434|NCT03621345|OTHER|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
218955435|NCT00260611|DRUG|Oxaliplatin|
218955436|NCT00260611|DRUG|Taxotere|
218955437|NCT04484168|PROCEDURE|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
218955438|NCT04484168|PROCEDURE|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
218955439|NCT03501771|OTHER|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
218955440|NCT00191087|DRUG|Duloxetine|
218955441|NCT04932187|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
219058018|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
219058019|NCT03032926|BEHAVIORAL|Open Trial|Behavioral Intervention
219058020|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
219058021|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
219058022|NCT02811198|OTHER|No intervention|
219058023|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
219058024|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
219058025|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
219058026|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
219058027|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
219207211|NCT06203990|BEHAVIORAL|Barre exercise|Group barre exercise class
218955442|NCT05261776|OTHER|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
218955443|NCT05261776|OTHER|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
218955444|NCT00204243|DRUG|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
219207212|NCT06289504|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously once weekly.
219207213|NCT06289504|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
219207214|NCT06289504|DRUG|Atorvastatin|Atorvastatin will be administered as a single dose orally 2 times during the study.
219207215|NCT06289504|DRUG|Warfarin|Warfarin will be administered as a single dose orally 2 times during the study.
219207216|NCT02632305|DRUG|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
218955445|NCT00204243|DRUG|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
218955446|NCT00278915|DRUG|Fulvestrant|Participants will receive intramuscular injection of fulvestrant as stated in arm description.
218955447|NCT01273285|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
218955448|NCT02026570|BEHAVIORAL|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
218955449|NCT02026570|BEHAVIORAL|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
218955450|NCT06236191|DEVICE|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
218955451|NCT06236191|DRUG|Melatonin|Melatonin
218955452|NCT03478488|DRUG|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
218955453|NCT03478488|DRUG|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
218955454|NCT00381576|BEHAVIORAL|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
219639521|NCT04634591|PROCEDURE|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
219058028|NCT04181710|PROCEDURE|Kidney transplant|Organ preserved in preservation solution
219058029|NCT00004327|DRUG|octreotide|
219058030|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
219058031|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
219058032|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
219058033|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
219058034|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
219058035|NCT00271336|DRUG|Pentoxifylline|
219058036|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
219058037|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
219058038|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
219058039|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
219058040|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
219058041|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
219058042|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
219058043|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
219058044|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
219058045|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
219058046|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
219058047|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
219058048|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
219058049|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
219639522|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
219639523|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
219639524|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
218955455|NCT04592952|DRUG|Calcitonin Gene-Related Peptide|Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
218955456|NCT04592952|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
219639525|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
219639526|NCT04087720|BIOLOGICAL|Pegloticase|intravenous (IV) infusion
219639527|NCT00650013|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
219639528|NCT00650013|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
218955457|NCT04900740|DEVICE|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
219058050|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
219058051|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
219058052|NCT03333746|DRUG|Lenalidomide|Given PO
219058053|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
219058054|NCT03333746|OTHER|Pharmacological Study|Correlative studies
219058055|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
219058056|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
219058057|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
219058058|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
219058059|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
219058060|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
219058061|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
219058062|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
219058063|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
219639529|NCT05707026|OTHER|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
218955458|NCT04900740|DEVICE|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
218955459|NCT02520089|PROCEDURE|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
218955460|NCT02520089|PROCEDURE|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
218955461|NCT01337102|PROCEDURE|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
218955462|NCT01337102|PROCEDURE|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
218955463|NCT02499445|DRUG|Remifentanil|administering remifentanil for anesthesia maintenance
218955464|NCT02499445|DRUG|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
219058064|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
219058065|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
219058066|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
219058067|NCT02311049|RADIATION|Hypofractionation|
219058068|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
219058069|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
219058070|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
219058071|NCT02279810|BEHAVIORAL|survey|Survey
219058072|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
219058073|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
219058074|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
219058075|NCT02510157|DRUG|Dexamethasone|active comparator
219058076|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
219058077|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
219058078|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
219058079|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
218955465|NCT02499445|DRUG|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
219207217|NCT02885714|PROCEDURE|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
219639530|NCT05707026|OTHER|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
219639531|NCT01521390|DRUG|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
219639532|NCT01521390|DRUG|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
218955466|NCT02499445|DRUG|propofol|administering propofol for anesthesia maintenance
218955467|NCT02499445|DRUG|sufentanil|administering sufentanil for anesthesia maintenance
218955468|NCT04242667|BEHAVIORAL|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
219058080|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
219058081|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
219058082|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
218955469|NCT04242667|BEHAVIORAL|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
218955470|NCT03068091|DEVICE|Chest CT|Inspiration and expiration chest CT
218955471|NCT03068091|DIAGNOSTIC_TEST|Pulmonary Function Testing|Measure lung function
218955472|NCT03931135|DRUG|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
219639533|NCT01521390|DRUG|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
219639534|NCT01521390|DRUG|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
219639535|NCT01521390|DRUG|Placebo|Placebo, no active ingredient
219639536|NCT02148757|PROCEDURE|Doppler Ultrasound|
219639537|NCT05507385|BEHAVIORAL|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
219639538|NCT05507385|BEHAVIORAL|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
219639539|NCT05499754|OTHER|pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL|a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
219639540|NCT05356949|BEHAVIORAL|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
219639541|NCT05263050|DRUG|Cabozantinib|Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
219639542|NCT05263050|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle
218955473|NCT03234140|GENETIC|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
218955474|NCT03234140|GENETIC|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
218955475|NCT05990595|DIETARY_SUPPLEMENT|Adlay with white rice|We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.
218955476|NCT05990595|DIETARY_SUPPLEMENT|white rice|white rice
218955477|NCT05232409|BIOLOGICAL|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
218955478|NCT05232409|COMBINATION_PRODUCT|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
218955479|NCT05195060|DRUG|casirivimab with imdevimab|Monoclonal antibody
218955480|NCT05195060|DRUG|sotrovimab|Monoclonal antibody
218955481|NCT05195060|DRUG|molnupiravir|antiviral agent
218955482|NCT02081248|OTHER|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
218955483|NCT02081248|OTHER|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
218955484|NCT01439815|DRUG|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
218955485|NCT01439815|DRUG|Saline Nasal Spray|two sprays in each nostril once daily
218955486|NCT04125251|BEHAVIORAL|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
219058083|NCT03119103|DEVICE|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
219639543|NCT05404477|DEVICE|TransAeris System|The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.
219639544|NCT01376986|BEHAVIORAL|physical, psychological and social activation|
219639545|NCT04263441|BEHAVIORAL|NICE Intervention|Subjects enrolled in the intervention arm will be offered assistance in enrolling in healthcare coverage and provided assistance on where they can go for care immediately. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review.
219639546|NCT02246543|DIETARY_SUPPLEMENT|Control|Water, Toast \& Egg (Yolk only) + 0.1g 13C Octanoic Acid
219639547|NCT02246543|DIETARY_SUPPLEMENT|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
219639548|NCT02246543|DIETARY_SUPPLEMENT|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
219639549|NCT02246543|DIETARY_SUPPLEMENT|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
218955487|NCT03353740|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
218955488|NCT02970240|PROCEDURE|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
218955489|NCT03160313|BEHAVIORAL|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
218955490|NCT03160313|BEHAVIORAL|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
218955491|NCT02846220|BEHAVIORAL|Overcoming Immunity to Change health coaching|
218955492|NCT05616481|PROCEDURE|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
219058084|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
219058085|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
219058086|NCT06414109|BEHAVIORAL|BREATHE-Migraine|"The BREATHE-Migraine intervention was adapted from the research-supported curriculum, Learning to BREATHE (Broderick, 2021), based on qualitative feedback from adolescents with migraine, their parents, and pediatric headache providers. BREATHE-Migraine includes experiential and didactic exercises designed to address emotion regulation and the stress of living with frequent migraine."
219207218|NCT02885714|PROCEDURE|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
219639550|NCT02246543|DIETARY_SUPPLEMENT|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
219639551|NCT05896891|DIAGNOSTIC_TEST|esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal|During routine EGD, biopsy, blood and buccal saliva samples will be withdraw and stored at San Raffaele Hospital
219639552|NCT05956470|BEHAVIORAL|Meditation and breathing program : Sudarshan Kriya Yoga (SKY)|The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
219639553|NCT05956470|BEHAVIORAL|Stress management education|This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
219639554|NCT03706430|DEVICE|Pulse CO-Oximeter sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
219639555|NCT05362396|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
219639556|NCT03107884|DRUG|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
218955493|NCT05616481|PROCEDURE|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
218955494|NCT00553722|DRUG|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
218955495|NCT00553722|DRUG|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
219058087|NCT04278417|BIOLOGICAL|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
219207219|NCT04430075|DEVICE|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
219207220|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
219207221|NCT06418178|DRUG|Midomafetamine|One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)
219207222|NCT06418178|BEHAVIORAL|Psychotherapy|Standardized psychotherapy performed by therapy team
219639557|NCT03107884|DRUG|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
219639558|NCT03107884|DRUG|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
218955496|NCT03460509|DRUG|Sugammadex|Dose-response
219639559|NCT03107884|DRUG|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
219639560|NCT02398903|OTHER|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
219639561|NCT02398903|OTHER|DXA and impedancemetry|Body composition by DXA and impedancemetry
219639562|NCT00520533|BIOLOGICAL|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st \& 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
219639563|NCT00520533|DRUG|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
219639564|NCT02239133|DEVICE|ProVATE vaginal pessary|
219639565|NCT02397122|BIOLOGICAL|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
219639566|NCT02397122|PROCEDURE|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
219639567|NCT02397122|PROCEDURE|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
219639568|NCT05831644|DRUG|C21|C21 is an angiotensin II type 2 receptor agonist (ATRAG)
218955497|NCT02133300|OTHER|electrical stimulation|
218955498|NCT03753581|DEVICE|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
218955499|NCT03753581|DEVICE|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
219639569|NCT05694884|DRUG|Placebo|Placebo Comparator
219639570|NCT05694884|DRUG|ASLAN004|ASLAN004
219639571|NCT05193916|DRUG|chiglitazar sodium tablets|the drugs will be given orally once a day
218955500|NCT00075192|DRUG|CP-675,206 and leuprolide acetate and bicalutamide|
218955501|NCT00075192|DRUG|leuprolide acetate and bicalutamide|
218955502|NCT04363190|DIAGNOSTIC_TEST|Cytogenetic analysis|"1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
219058088|NCT04278417|PROCEDURE|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
219639572|NCT05193916|DRUG|Placebo|no active drug contained
219639573|NCT04448834|DRUG|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
219639574|NCT03453034|DRUG|TQ-B3233|QD or BID in different stage of this research
219058089|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
219058090|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
219058091|NCT06969027|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
219058092|NCT06969027|DRUG|Pemetrexed injection|Pemetrexed (500 mg/m2 IV, D1)
219639575|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
219639576|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
219639577|NCT02165189|DRUG|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram (\[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
219639578|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
219639579|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
219639580|NCT01004640|GENETIC|DNA analysis|
219639581|NCT01004640|GENETIC|Southern blotting|
219639582|NCT01004640|GENETIC|cytogenetic analysis|Correlative studies
219639583|NCT01004640|GENETIC|polymerase chain reaction|
219639584|NCT06623617|BEHAVIORAL|Three-dimensional breathing training|Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
219639585|NCT06623617|BEHAVIORAL|control group：Health education|Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
219639586|NCT00598312|DRUG|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
219639587|NCT05379283|DRUG|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
219639588|NCT05379283|OTHER|control|one arm will be pretreated with topical lidocaine, the other arm will not
219639589|NCT01839214|DRUG|VB-201 160mg|
219639590|NCT01839214|DRUG|Placebo|
218955503|NCT04939506|BEHAVIORAL|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
218955504|NCT01484288|DEVICE|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
218955505|NCT05673174|DIAGNOSTIC_TEST|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
218955506|NCT02232880|DRUG|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
218955507|NCT02232880|DRUG|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
218955508|NCT03610529|DEVICE|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
218955509|NCT03610529|DEVICE|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
218955510|NCT02337231|DIETARY_SUPPLEMENT|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
218955511|NCT01666847|PROCEDURE|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
218955512|NCT06449274|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
218955513|NCT06449274|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
218955514|NCT04564638|DRUG|Corticosteroid|
219639591|NCT00625417|PROCEDURE|breast biopsy|
219639592|NCT00625417|PROCEDURE|histopathologic examination|
219058093|NCT06969027|DRUG|Platinum|Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)
219058094|NCT06969027|DRUG|Paclitaxel|Paclitaxel (175 mg/m2 IV, D1)
219058095|NCT00628602|DEVICE|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
219639593|NCT00625417|PROCEDURE|light-scattering spectroscopy|
219639594|NCT00625417|PROCEDURE|therapeutic conventional surgery|
219639595|NCT05615363|DRUG|OPC 131461 10mg group|OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
219639596|NCT05615363|DRUG|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
219639597|NCT05615363|DRUG|OPC 131461 2mg group|OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
219639598|NCT05615363|DRUG|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
219639599|NCT05615363|DRUG|Placebo|Placebo tablet，once-daily oral administration for 14 days
219639600|NCT00000672|DRUG|Didanosine|
218955515|NCT04070976|RADIATION|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
218955516|NCT04070976|RADIATION|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
218955517|NCT06133712|DRUG|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
218955518|NCT06133712|DRUG|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/ml) plus to 1 ml lidocaine (1%) using a 25 G needle.
218955519|NCT06133712|DRUG|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
218955520|NCT04377347|OTHER|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
218955521|NCT02545543|BIOLOGICAL|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
218955522|NCT02545543|BIOLOGICAL|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
218955523|NCT01331421|DRUG|exemestane|25 mg tablet
218955524|NCT05787990|DIAGNOSTIC_TEST|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
218955525|NCT05401396|OTHER|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
218955526|NCT03320525|DIETARY_SUPPLEMENT|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
219207223|NCT06953128|PROCEDURE|Spinal Anesthesia|Participants will receive subarachnoid (spinal) anesthesia with 15-20 mg of isobaric bupivacaine 0.5% and 100 μg of intrathecal morphine. Clonidine (1 μg/kg) may be added at the discretion of the anesthesiologist. Sedation will be achieved with intravenous midazolam (up to 5 mg), fentanyl (up to 100 μg), and/or target-controlled infusion of propofol. Patients will remain spontaneously breathing throughout the procedure and receive supplemental oxygen via nasal cannula.
219639601|NCT06343415|OTHER|GAIT-assisted training|"GAIT duration starts when walking is started. The participant will walk as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Speed starts at 1 km/h and is adjusted accordingly.~The body weight support (BWS) is kept between 60-100% of total body weight. The BWS is adjusted so the knee flexion in the stance phase does not exceed 10 degrees. The guidance force is kept at 100% and symmetric in all sessions."
218955527|NCT02829944|DRUG|Ropivacaine|
218955528|NCT02829944|DRUG|Ketorolac|
218955529|NCT02829944|DRUG|Placebo|
218955530|NCT06966128|DEVICE|transcranial Direct Current Stimulation|Stimulation intensity: Variable (between 1 mA and 2 mA), Electrode placement: Dorsolateral prefrontal cortex, Duration: 10 minutes
218955531|NCT05397704|DEVICE|brain pulse oximeter|brain oxygen monitoring during hypoxia
218955532|NCT03826784|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
218955533|NCT03297411|PROCEDURE|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
218955534|NCT03297411|PROCEDURE|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
218955535|NCT03297411|PROCEDURE|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
218955536|NCT03297411|PROCEDURE|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
218955537|NCT02105753|DEVICE|1210nm Diode Laser treatments|
219639602|NCT06343415|OTHER|STEP-assisted training|"STEP duration starts when stepping and elevation are started. The participant will step as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Step cadence starts at 40 steps/minute and cadence is adjusted accordingly.~The leg loading starts a 5 kg and is, if possible, increased to a maximum of 40% of total body weight while adjusting knee extension to ≤10 degrees flexion in stance. The guidance force is kept at 100% and symmetric in all sessions."
219639603|NCT05779683|DEVICE|Caretaker Device placement|placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
219639604|NCT06045676|DEVICE|ECG|ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
219639605|NCT06577883|DIAGNOSTIC_TEST|Chest X-ray Tomosynthesis|An imaging device that uses X-rays projected from multiple angles to reconstruct a three-dimensional images of the chest
219639606|NCT02378428|DRUG|MIBG|
219639607|NCT05377307|GENETIC|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
219639608|NCT03625648|DRUG|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
219639609|NCT03625648|DRUG|Placebo|placebo
219639610|NCT04073888|PROCEDURE|Semen collection|Semen collection for seminogram and spermocytogram
218955538|NCT05053451|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.
218955539|NCT00711568|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
218955540|NCT00711568|PROCEDURE|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
218955541|NCT00711568|DEVICE|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
218955542|NCT06153979|BIOLOGICAL|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
218955543|NCT03389048|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
218955544|NCT03389048|DIAGNOSTIC_TEST|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
219058096|NCT01973985|OTHER|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
219058097|NCT01973985|OTHER|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
219639611|NCT00842023|DRUG|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
219639612|NCT00842023|DRUG|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
219639613|NCT06575972|DIETARY_SUPPLEMENT|JoyRise Recovery Powder|JoyRise Recovery Powder is a dietary supplement that contains Dihydromyricetin (DHM) and other natural ingredients. It is designed to mitigate the aftereffects of alcohol consumption. Participants will mix one serving in 8-12 oz of water and consume it the morning after alcohol consumption.
219639614|NCT06575972|DIETARY_SUPPLEMENT|Placebo|A placebo solution that is visually and tastefully similar to JoyRise Recovery Powder but contains no active ingredients. It will be mixed in 8-12 oz of water and consumed the morning after alcohol consumption.
219639615|NCT01726270|DRUG|tamsulosin|0.4 mg
219639616|NCT01323387|DEVICE|Interbody Fusion|allograft spacer + anterior plate
219639617|NCT01609647|DRUG|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
219639618|NCT01609647|DRUG|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
218955545|NCT03133962|OTHER|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
219058098|NCT01973985|PROCEDURE|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
219058099|NCT01973985|PROCEDURE|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
219058100|NCT00850031|DEVICE|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
219058101|NCT03422120|OTHER|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
219639619|NCT06664970|DRUG|Azacitidine or Ruxolitinib combined with Selinexor|"1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count\>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant."
218955546|NCT05420753|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
218955547|NCT00911001|BEHAVIORAL|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
218955548|NCT06385067|DEVICE|Biolimus Coated Coronary Artery Balloon Dilation Catheter|Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
218955549|NCT03195400|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
218955550|NCT03195400|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
218955551|NCT03195400|DIAGNOSTIC_TEST|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
218955552|NCT03195400|DIAGNOSTIC_TEST|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
218955553|NCT01071018|DRUG|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
219058102|NCT02166983|OTHER|computer-assisted cognitive training|Complete Lumosity cognitive exercises
219058103|NCT02166983|OTHER|cognitive intervention|Complete Active Journaling cognitive exercises
219058104|NCT02166983|PROCEDURE|mind-body intervention procedure|Complete relaxation exercises
219058105|NCT02166983|OTHER|memory intervention|Complete compensatory strategies
219058106|NCT02166983|OTHER|questionnaire administration|Ancillary studies
218955554|NCT01071018|DRUG|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
218955555|NCT00171470|DRUG|Tegaserod|
219207224|NCT06953128|PROCEDURE|General Anesthesia|Participants will undergo general anesthesia induced with intravenous propofol (1.5-2.5 mg/kg) or etomidate (0.2-0.3 mg/kg), remifentanil (0.2-0.4 μg/kg/min), and rocuronium (0.6 mg/kg), followed by endotracheal intubation and controlled mechanical ventilation. Maintenance will include continuous remifentanil infusion and inhaled sevoflurane. Ventilation parameters will follow a protective strategy (tidal volume 6-8 mL/kg predicted body weight and PEEP of 5 cmH₂O).
219207225|NCT06953661|PROCEDURE|Stellate ganglion block|Patients will receive a SGB
219639620|NCT02502812|DRUG|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
219639621|NCT02502812|DRUG|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
218955556|NCT03350269|OTHER|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
218955557|NCT06613893|DRUG|TIVA|Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
219058107|NCT03342664|DEVICE|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
219058108|NCT03342664|OTHER|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
219058109|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
219058110|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
219058111|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
218955558|NCT06613893|DRUG|Inhalational anesthesia|Anesthesia will be maintained with inhaled isoflurane, Iso-MAC from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
219639622|NCT02502812|DRUG|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
219639623|NCT04288687|DRUG|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
219207226|NCT06953661|PROCEDURE|Sham injection of saline|Patients will receive a subcutaneous sham injection of saline
219207227|NCT06953661|DRUG|Ropivacaine|The SGB group will receive ropivacaine 0.5% 10ml
219639624|NCT00996151|DRUG|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
219639625|NCT00131950|OTHER|physiologic testing|
219639626|NCT00131950|OTHER|study of socioeconomic and demographic variables|
219639627|NCT00131950|PROCEDURE|breast imaging study|
219639628|NCT00131950|PROCEDURE|study of high risk factors|
218955559|NCT06994351|DEVICE|Electroacupuncture|"The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 10-minute maintenance in prone and supine position respectively.~The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA).~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
219207228|NCT06953661|DRUG|Normal saline|The control group will receive normal saline in the sham injection.
219639629|NCT02165280|BEHAVIORAL|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
219639630|NCT06455293|DRUG|Psilocybin|"Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring"
219639631|NCT06575491|DEVICE|Ultrasound-guided supraclavicular approach|Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
219639632|NCT06575491|DEVICE|Ultrasound-guided infraclavicular approach|Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
219639633|NCT00582608|DRUG|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
219639634|NCT00582608|DRUG|8H9|administration of 50mg/1.73m\^2 of unlabeled 8H9.
219639635|NCT03714074|DEVICE|PEEK implant abutment|Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
219639636|NCT03714074|DEVICE|Zirconia abutment|Imolants will be restored with zirconia abutments and a PEEK superstructure
219639637|NCT06736444|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
219639638|NCT06736444|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
219639639|NCT06736444|BEHAVIORAL|Attention Control|Attention Control is comprised of 4 weekly 20-minute check-ins with a study therapists regarding the daily monitoring and mood/functioning. Referrals for additional services will be provided as needed.
219639640|NCT03745976|PROCEDURE|questionnaire and Xray for all patients|questionnaire and Xray for all patients
219639641|NCT02756130|DRUG|Birinapant|Given IV
219639642|NCT02756130|DRUG|Carboplatin|Given IV
219639643|NCT02756130|OTHER|Laboratory Biomarker Analysis|Correlative studies
219639644|NCT02756130|OTHER|Pharmacological Study|Correlative studies
219639645|NCT06747364|OTHER|Alcohol (Ethanol)|Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.
219639646|NCT03691311|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Two injections on days 1 and 8 previous to surgery breast cancer excision
219639647|NCT05142969|OTHER|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
219639648|NCT01397877|DRUG|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
219639649|NCT05389566|DIAGNOSTIC_TEST|Quantative Sensory Testing|Evaluation of small fiber neuropathy
219639650|NCT05389566|DIAGNOSTIC_TEST|NCStat-DPN-Check|Evaluation of large fiber neuropathy
219639651|NCT05389566|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
219639652|NCT05389566|DIAGNOSTIC_TEST|Computerized dynamic posturography|Evaluation of dynamic postural control
219639653|NCT05389566|DIAGNOSTIC_TEST|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
219639654|NCT05389566|DIAGNOSTIC_TEST|Accelerometer|Evaluation of gait pattern
219639655|NCT05389566|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
219639656|NCT05389566|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
219639657|NCT05389566|DIAGNOSTIC_TEST|Force Plate Platform|Evaluation of balance while standing still
219639658|NCT06181084|DRUG|LY3410738|Administered orally.
219639659|NCT06181084|DRUG|Esomeprazole|Administered orally.
219639660|NCT00404001|DRUG|MD-0727|
219639661|NCT02313207|DIETARY_SUPPLEMENT|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
219639662|NCT02171234|DRUG|Placebo|
219639663|NCT02171234|DRUG|BIA 2-093|
218955560|NCT06994351|DEVICE|Sham electroacupuncture|"The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral Anmian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 30 seconds, the electric current will be turned down.~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
218955561|NCT06995794|OTHER|kinesio tape|Kinesio tape a therapeutic tape that's applied strategically to the body to provide lessen pain, reduce swelling, improve performance.
218955562|NCT06995794|OTHER|knee strap|knee strap is used to support the tibial tuberosity which lessen the pain and enhance performance of the knee
218955563|NCT06994273|DRUG|Fentanyl|Patients received fentanyl as a 1 μg/kg bolus over 10 min, followed by a 1-5 μg/kg/hr intravenous infusion after 10-15 minutes.
218955564|NCT06994273|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a 1 μg/kg bolus over 10 min, followed by a 0.2-0.7 μg/kg/hr intravenous infusion after 10-15 minutes.
218955565|NCT06994689|DIAGNOSTIC_TEST|Perimetry and ShearWave measurement of the quadriceps muscle before and after a pulmonary rehabilitation (PR) programme|"Patients will undergo a pulmonary rehabilitation (PR) programme.~On day 1, perimetry and ShearWave measurements of the quadriceps muscle will be provided. Supplementary assessments of quadriceps thickness, quadriceps strength with a handheld dynamometry, lean body mass (bioelectrical impedance), constant work-rate endurance test and HAD questionnaire will also be provided on day 1.~The same measurements and questionnaire will be provided on the last day of the patient in the PR programme."
218955566|NCT04267224|DRUG|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
218955567|NCT03802058|DRUG|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
218955568|NCT03802058|DRUG|Carboplatin|Carboplatin AUC=2 for Injection weekly
219207229|NCT04947475|BEHAVIORAL|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
218955569|NCT03802058|RADIATION|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
219207230|NCT05895552|DRUG|RTA 901|Administered as specified in the treatment arm.
219207231|NCT05895552|DRUG|RTA 901-Matching Placebo|Administered as specified in the treatment arm.
218955570|NCT03418103|DEVICE|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
218955571|NCT05406193|OTHER|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
219207232|NCT06951438|DIAGNOSTIC_TEST|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas
219207233|NCT02629497|DIETARY_SUPPLEMENT|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
219639664|NCT02036073|DRUG|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
219639665|NCT00048386|BIOLOGICAL|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
218955572|NCT00205907|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
219639666|NCT02819973|OTHER|Educational Video1|
218955573|NCT01395784|DRUG|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
219639667|NCT02819973|OTHER|Educational Video 2|
219639668|NCT02819973|OTHER|Usual Care 3|
219639669|NCT03767153|DEVICE|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
218955574|NCT00877097|DRUG|Klodronate and Kliogest|
218955575|NCT00877097|PROCEDURE|Placebo+ Kliogest|
218955576|NCT00877097|DRUG|Bonefos|
218955577|NCT04268823|DRUG|QBW251|Capsule 300mg
219058112|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
219058113|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
219058114|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
219058115|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
219058116|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
219058117|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
219058118|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
219058119|NCT00112203|DRUG|Itopride|
219058120|NCT00006095|DRUG|irinotecan hydrochloride|
219058121|NCT00006095|DRUG|vincristine sulfate|
219058122|NCT05638373|OTHER|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
219058123|NCT05638373|OTHER|Nanohybrid resin composite|A conventional resin composite with multiple shades
218955578|NCT04268823|DRUG|Placebo|Capsule 300mg
218955579|NCT02815826|OTHER|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
218955580|NCT02815826|OTHER|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
218955581|NCT00336583|DRUG|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
218955582|NCT00399672|DRUG|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
219058124|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
219058125|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
219058126|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
219058127|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
219058128|NCT01331694|DRUG|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
219639670|NCT05914597|OTHER|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
218955583|NCT00399672|DRUG|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
219058129|NCT01331694|DRUG|tiotropium|patients initiating treatment with tiotropium
219058130|NCT01331694|DRUG|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
219639671|NCT03012997|OTHER|Fraction of inspired oxygen 40%|
218955584|NCT01091727|DRUG|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
219639672|NCT03012997|OTHER|Fraction of inspired oxygen 100%|
219639673|NCT04977427|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
219639674|NCT04977427|DRUG|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
218955585|NCT05939011|BEHAVIORAL|Well-formulated Ketogenic Diet|1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
218955586|NCT00053781|DRUG|perifosine|
218955587|NCT02099669|OTHER|Red Blood Cell Transfusions|
219058131|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
219058132|NCT01856816|OTHER|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
219058133|NCT01856816|OTHER|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
219639675|NCT04201574|DRUG|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
218955588|NCT03106766|DRUG|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
218955589|NCT03106766|DRUG|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
218955590|NCT02048982|BEHAVIORAL|Guideline|Physicians will receive information on the Choosing Wisely Guideline
218955591|NCT02048982|BEHAVIORAL|Cost|Physicians will receive cost information.
218955592|NCT02048982|BEHAVIORAL|Victim|Physicians will receive information on an identifiable victim.
219639676|NCT04201574|DRUG|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
218955593|NCT03467009|BEHAVIORAL|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
218955594|NCT03467009|OTHER|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
218955595|NCT03467009|BEHAVIORAL|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
219058134|NCT01856816|OTHER|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
219058135|NCT00178191|OTHER|Bladder diary|3-day bladder diary
219058136|NCT00178191|OTHER|Questionnaires|Incontinence Quality of Life questionnaires
219207234|NCT02629497|DIETARY_SUPPLEMENT|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
219639677|NCT04201574|DRUG|Vehicle|Vehicle Ophthalmic Solution
219639678|NCT01610882|DEVICE|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
219639679|NCT01610882|DEVICE|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
219639680|NCT01013272|DRUG|Entecavir|Entecavir 0.5mg orally daily
219639681|NCT01013272|DRUG|Lamivudine|Lamivudine 100mg orally, daily
218955596|NCT03726567|PROCEDURE|Bariatric surgery|Roux-en-Y surgery
218955597|NCT04438070|DIAGNOSTIC_TEST|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
218955598|NCT05761184|DIAGNOSTIC_TEST|Serum collection for proteomic analysis|Serum collection for proteomic analysis
218955599|NCT01698281|DRUG|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
218955600|NCT01698281|DRUG|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
218955601|NCT01698281|DRUG|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
218955602|NCT00936429|BIOLOGICAL|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
218955603|NCT00936429|BIOLOGICAL|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
218955604|NCT00910247|DRUG|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
219058137|NCT00178191|PROCEDURE|Urodynamics|Urodynamics
219058138|NCT00178191|OTHER|Pad weight|Pad weight
219058139|NCT05321394|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
219058140|NCT05321394|DRUG|Tixagevimab Cilgavimab|"2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)"
219058141|NCT05321394|DRUG|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
219058142|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
219058143|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
219639682|NCT05596929|DIAGNOSTIC_TEST|Artificial intelligence|After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
219058144|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
219058145|NCT00983580|DRUG|Aspirin|Given PO
219058146|NCT00983580|DRUG|Eflornithine|Given PO
219058147|NCT00983580|OTHER|Laboratory Biomarker Analysis|Correlative study
219058148|NCT00983580|OTHER|Placebo|Given PO
219058149|NCT00983580|OTHER|Telephone-Based Intervention|Ancillary studies
219058150|NCT05321862|DRUG|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
219058151|NCT02582099|DRUG|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
219058152|NCT02582099|DRUG|Normal saline nasal irrigation|Nasal wash with normal saline solution
218955605|NCT01283854|BEHAVIORAL|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
218955606|NCT06179433|PROCEDURE|Root canal treatment|Two-visit root canal treatment will be performed.
218955607|NCT06179433|PROCEDURE|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
218955608|NCT04048811|DRUG|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
218955609|NCT04048811|DRUG|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
218955610|NCT04048811|DRUG|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
218955611|NCT02853630|DRUG|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
218955612|NCT02853630|DRUG|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
218955613|NCT01593462|PROCEDURE|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
218955614|NCT01593462|PROCEDURE|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
218955615|NCT01593462|BEHAVIORAL|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
218955616|NCT04144218|DRUG|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
219058153|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
219058154|NCT02269462|DRUG|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
219058155|NCT02269462|DRUG|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
219207235|NCT05869149|BEHAVIORAL|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
218955617|NCT04144218|DRUG|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
218955618|NCT05598827|OTHER|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
218955619|NCT05906238|BEHAVIORAL|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
218955620|NCT05906238|BEHAVIORAL|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
218955621|NCT00349427|DRUG|Rosiglitazone 4 mg|
218955622|NCT03386253|DEVICE|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
218955623|NCT03386253|DEVICE|sham tDCS|sham tDCS session given for same length of time as active
218955624|NCT00008554|DRUG|Abacavir sulfate|
218955625|NCT00008554|DRUG|Nelfinavir mesylate|
218955626|NCT00008554|DRUG|Lamivudine|
218955627|NCT00008554|DRUG|GW433908|
218955628|NCT02783846|OTHER|normal saline|receive equal volume of normal saline
218955629|NCT02783846|DRUG|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
218955630|NCT02783846|DRUG|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
218955631|NCT03196700|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
218955632|NCT06319612|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
218955633|NCT06319612|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218955634|NCT06319612|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.
218955635|NCT06319612|PROCEDURE|Placebo injection|Normal saline is used. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218955636|NCT03331510|OTHER|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
218955637|NCT05249166|OTHER|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
218955638|NCT05249166|OTHER|Control|control group
218955639|NCT01124630|DRUG|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
218955640|NCT01124630|DRUG|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
218955641|NCT00976508|DRUG|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
218955642|NCT00976508|DRUG|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
218955643|NCT04862195|DEVICE|Attune™|Software as a medical device
218955644|NCT04862195|DEVICE|Cerena™|Software as a medical device
218955645|NCT05112276|OTHER|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
218955646|NCT04173364|DRUG|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
218955647|NCT04173364|DRUG|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
218955648|NCT01661088|DRUG|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
218955649|NCT01661088|RADIATION|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
218955650|NCT01661088|PROCEDURE|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
218955651|NCT00376818|BEHAVIORAL|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
218955652|NCT00376818|OTHER|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
218955653|NCT00376818|OTHER|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
218955654|NCT00376818|OTHER|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
218955655|NCT00376818|BEHAVIORAL|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
218955656|NCT00376818|PROCEDURE|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
219058156|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
219207236|NCT05743387|OTHER|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
219207237|NCT05743387|OTHER|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
219639683|NCT06192862|BEHAVIORAL|Assessment of screening intention and Transtheoretical Model stages for CRC screening|"Screening Intentions will be measured by asking the subject, How much do you agree or disagree: I am intending to have colon cancer screening within the next 6 months. Subjects who strongly disagrees or somewhat disagrees are considered not having screening intention. Subjects who somewhat agrees or strongly agrees are considered having screening intention. For subjects who has screening intention, they will be asked if they have plan to arrange a consultation with primary care physician to collect FIT kits in next 3 months."
219639684|NCT03813680|OTHER|Passive Vertebral Mobilization|Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
218955657|NCT03377088|OTHER|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
219207238|NCT01046825|DRUG|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
219207239|NCT01046825|DRUG|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
219639685|NCT03813680|OTHER|PNF exercise|The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
219639686|NCT03813680|OTHER|Routine Physiotherapy|Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
219639687|NCT05663073|DRUG|Irbesartan/Amlodipine FDC|Irbesartan/Amlodipine FDC
219639688|NCT05663073|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine
219639689|NCT05663073|DRUG|Amlodipine|Co-administration of Irbesartan and Amlodipine
219639690|NCT04304430|DRUG|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
219639691|NCT04304430|DRUG|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
219639692|NCT01965366|BEHAVIORAL|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
219639693|NCT01965366|DRUG|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
219639694|NCT05424848|OTHER|Ultasonographic measurement|Ultrasonographic measurements of the patients will be evaluated by Dr. Merve Damla Korkmaz. Patients will be positioned in a semi-dark room with the knees fully flexed. Ultrasonographic measurements will be made to evaluate the femoral cartilage thickness of both knees, with images taken from the suprapatellar axillary position. Images of the intercondylar area, lateral and medial femoral condyles of the right and left knees will be taken and the measurements will be made from these areas, 3 measurements will be taken from each knee and the average of these measurements will be taken.
219639695|NCT04340037|PROCEDURE|percutaneous nephrolithotomy|percutaneous surgery using nephroscope
218955658|NCT03377088|OTHER|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
218955659|NCT01198158|BIOLOGICAL|Bevacizumab|Given IV
218955660|NCT01198158|DRUG|Everolimus|Given PO
218955661|NCT01198158|OTHER|Laboratory Biomarker Analysis|Correlative studies
218955662|NCT01198158|OTHER|Pharmacological Study|Correlative studies
219639696|NCT00982332|DRUG|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
219639697|NCT00982332|DRUG|isotonic sodium chloride solution (placebo)|4 ml intramuscular
219639698|NCT00315133|PROCEDURE|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
219639699|NCT03204994|DRUG|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
219639700|NCT03271190|BEHAVIORAL|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
219639701|NCT03271190|BEHAVIORAL|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
218955663|NCT04149392|DEVICE|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
218955664|NCT05809739|DEVICE|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
218955665|NCT04817527|DRUG|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
218955666|NCT00082927|DRUG|ibandronate sodium|
218955667|NCT01479218|DEVICE|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
218955668|NCT01205581|BIOLOGICAL|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
218955669|NCT01205581|BIOLOGICAL|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
218955670|NCT05170568|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
219639702|NCT04861727|OTHER|MRPA procedure|The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
219639703|NCT04861727|OTHER|Pharmaceutical intervention|The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
219639704|NCT03007082|DEVICE|Revive SE intracranial thrombectomy device|"1. Intra-arterial mechanical thrombectomy with Revive SE；~2. According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
219639705|NCT04163120|OTHER|Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)|The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
219639706|NCT03258294|DRUG|Melatonin(Circadin®)|
219639707|NCT03258294|DRUG|Placebo Oral Tablet|
219639708|NCT04769089|PROCEDURE|Treatment with Pulse Dye Laser|Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
219058157|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
219058158|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
219058159|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
219639709|NCT04769089|PROCEDURE|Treatment with CO2 Laser|CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
219639710|NCT04769089|PROCEDURE|Treatment with combination of pulse dye laser and CO2 laser.|Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
219639711|NCT04769089|OTHER|Control|One area will be randomized to receive no laser treatment.
219639712|NCT04832594|OTHER|AI selection for supplemental breast MRI|An AI tool will generate scores used to determine eligibility. Women randomized to MRI will be examined in an MRI scanner.
219058160|NCT05705622|OTHER|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
219058161|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
219639713|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System|Infrared thermal camera
219639714|NCT04968080|DEVICE|Welch Allyn SureTemp Plus 690|Oral thermometer
219058162|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
219058163|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
219058164|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
219639715|NCT04968080|DEVICE|Welch Allyn ThermoScan PRO 6000|Ear thermometer
219639716|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer|Forehead temperature gun
219639717|NCT02073929|DRUG|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
219639718|NCT02073929|DRUG|placebo|Placebo s.c. daily for 26 weeks
219639719|NCT06577480|OTHER|No intervention|No intervention
219639720|NCT04892329|OTHER|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
218955671|NCT01879527|DRUG|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
218955672|NCT01879527|DRUG|Sugar pill|containing placebo
218955673|NCT03007108|OTHER|blood withdrawal|
218955674|NCT02840084|DEVICE|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
218955675|NCT02278471|DRUG|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
218955676|NCT02669277|DRUG|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
218955677|NCT02669277|DRUG|standard IVIG product|to compare efficacy and safety with the minipool IVIG
218955678|NCT02177487|DRUG|Telmisartan/hydrochlorothiazide|
218955679|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
218955680|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
218955681|NCT02187874|PROCEDURE|delayed umbilical cord occlusion|
218955682|NCT02187874|PROCEDURE|early umbilical cord occlusion|
218955683|NCT02187874|DRUG|Oxytocin|
219058165|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
219058166|NCT02199418|DRUG|Paclitaxel|
219058167|NCT02199418|DRUG|Cisplatin|
218955684|NCT00664027|DRUG|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
218955685|NCT01191879|OTHER|Blood test|Blood test
218955686|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
218955687|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
218955688|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
219058168|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
219639721|NCT04528940|DIAGNOSTIC_TEST|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
218955689|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
218955690|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
218955691|NCT03468543|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
218955692|NCT02142010|DRUG|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
218955693|NCT00671359|DRUG|TR-701 600mg|TR-701 600mg
218955694|NCT04934631|OTHER|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
218955695|NCT04934631|OTHER|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
219058169|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
219639722|NCT01736644|DEVICE|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
219639723|NCT01736644|DEVICE|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
219639724|NCT01710579|PROCEDURE|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
218955696|NCT01063712|DEVICE|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
219639725|NCT01710579|PROCEDURE|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
218955697|NCT04834765|OTHER|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
218955698|NCT04834765|OTHER|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
218955699|NCT04834765|OTHER|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
218955700|NCT00677703|OTHER|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
218955701|NCT01186497|DRUG|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
218955702|NCT01186497|DRUG|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
218955703|NCT01186497|DRUG|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
218955704|NCT01186497|DRUG|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
218955705|NCT01186497|DRUG|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
218955706|NCT01759134|OTHER|Post discharge formula|Babies will be given either materna sensitive or similac neosure
219058170|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1\) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
219058171|NCT01652716|DRUG|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
219058172|NCT01652716|DRUG|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
219058173|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
219639726|NCT01710579|PROCEDURE|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
219639727|NCT02802787|OTHER|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
219058174|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219058175|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219639728|NCT02989038|OTHER|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
219639729|NCT02989038|OTHER|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
219639730|NCT02989038|OTHER|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
218955707|NCT04814901|PROCEDURE|Curing small and medium sized oronasal fistula|"* Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures."
218955708|NCT01208831|DRUG|LDE225|
218955709|NCT00978432|DRUG|RAD001|10 mg/day for Part 1 of the trial
218955710|NCT00978432|DRUG|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
218955711|NCT00978432|DRUG|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
218955712|NCT04618770|DEVICE|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
218955713|NCT02732717|OTHER|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
218955714|NCT05202132|DIAGNOSTIC_TEST|Questionnaire|A 3 item validated questionnaire assessing masticatory function
218955715|NCT05202132|DIAGNOSTIC_TEST|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
218955716|NCT00470665|DRUG|Rapamune|
218955717|NCT01596543|OTHER|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
218955718|NCT05933070|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
218955719|NCT03682575|OTHER|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
218955720|NCT05472454|OTHER|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
218955721|NCT01171508|DEVICE|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
218955722|NCT01171508|DEVICE|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
218955723|NCT01171508|DEVICE|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
218955724|NCT01171508|PROCEDURE|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
218955725|NCT01171508|OTHER|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
218955726|NCT01171508|OTHER|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
219058176|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219058177|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
219058178|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
219058179|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
219058180|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
219058181|NCT02143570|DRUG|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
219207240|NCT01046825|DRUG|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
219207241|NCT05864612|BEHAVIORAL|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
219639731|NCT05056259|DEVICE|18F-FDG PET/CT|"The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data."
219639732|NCT05027659|OTHER|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
218955727|NCT01171508|OTHER|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
218955728|NCT05033002|BEHAVIORAL|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
218955729|NCT03937544|BIOLOGICAL|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
218955730|NCT03937544|DRUG|Cyclophosphamide|Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
218955731|NCT03937544|DRUG|Fludarabine|Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
218955732|NCT06526975|OTHER|Gamification exercise through a videogame|Different exercises will be performed through a videogame.
218955733|NCT04251676|OTHER|Observational study|Observational study
218955734|NCT06631937|OTHER|Human Milk Oligosaccharides|Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
218955735|NCT06631937|OTHER|Placebo|An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
218955736|NCT02739633|DRUG|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
218955737|NCT02739633|DRUG|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
219058182|NCT02143570|PROCEDURE|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
219058183|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
218955738|NCT00571584|DRUG|activated recombinant human factor VII|
218955739|NCT02642744|OTHER|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
218955740|NCT03253562|DRUG|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
218955741|NCT03253562|DRUG|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
219058184|NCT02316717|OTHER|Placebo|Matched placebo
219058185|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
219058186|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
219207242|NCT05598151|DRUG|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
219207243|NCT03304418|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
219058187|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
219058188|NCT02499393|DRUG|Magnesium Sulfate|intravenous infusion of magnesium sulphate
219058189|NCT00676442|DRUG|PN400|naproxen/esomeprazole
219366222|NCT04635865|DEVICE|3D-printed patient-specific plate|"We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder."
219639733|NCT03319732|DRUG|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
218955742|NCT02160002|PROCEDURE|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
218955743|NCT02160002|PROCEDURE|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
218955744|NCT00246571|DRUG|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
218955745|NCT00246571|DRUG|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
218955746|NCT04587180|PROCEDURE|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
218955747|NCT05747547|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
218955748|NCT05747547|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
219058190|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
219058191|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
219058192|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
219058193|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
219058194|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
219207244|NCT03304418|RADIATION|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
219058195|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
219058196|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
219058197|NCT03982329|PROCEDURE|physical therapy|
219058198|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
219058199|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
219058200|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
219058201|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
219058202|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
219058203|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
219058204|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
219207245|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
218955749|NCT05747547|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
218955750|NCT05747547|DIAGNOSTIC_TEST|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
219058205|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
219058206|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
219058207|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
219639734|NCT01019759|PROCEDURE|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
219639735|NCT01006187|DRUG|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
219639736|NCT01006187|DRUG|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
219639737|NCT01006187|OTHER|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
219639738|NCT01006187|OTHER|Distraction|By means of self-selected reading material or video
219639739|NCT02092545|OTHER|Ketogenic diet|
219639740|NCT01102868|DEVICE|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
219639741|NCT01102868|DEVICE|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
219639742|NCT02075931|OTHER|Physical activity feedback with group meetings|Physical activity feedback
219639743|NCT02075931|OTHER|Control|No intervention
219639744|NCT06170476|DRUG|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
219639745|NCT06170476|DRUG|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
219639746|NCT06170476|DRUG|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
219639747|NCT06170476|DRUG|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
219639748|NCT05334693|BIOLOGICAL|Expanded haploidentical NK cells|Two doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
219639749|NCT03855527|DRUG|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
219639750|NCT03855527|DRUG|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
218955751|NCT05747547|DIAGNOSTIC_TEST|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
218955752|NCT01549769|DRUG|Bardoxolone Methyl|Oral, once daily
218955753|NCT04896229|OTHER|Talk STEM Familia Treatment Condition|This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
218955754|NCT06628765|DEVICE|8.6 Fr single-use fURS (XFGC-FU-660RC)|Comparative device
219058208|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
219058209|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
219058210|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
219639751|NCT03855527|PROCEDURE|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
219639752|NCT02948660|DRUG|Zolpidem Tartrate Tablets|All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
219639753|NCT05445362|DEVICE|Diode laser disinfection|\- Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.
219639754|NCT05445362|DEVICE|Diode Laser bio-stimulation.|"\- The diode laser bio-stimulation with Wiser Diode Laser, Irradiation of the periapical area from the labial mucosal surface, day after day day on-day off for one week, two sessions will be applied at the same day with two hours interval, first session immediately after filing (blood induction), with flat top hand piece , diameter 1cm at a distance between 0 and 105 cm, at 1 watt power for 50s with CW continues mode in order to obtain the 5 J/cm2 fluence."
218955755|NCT06628765|DEVICE|6.3 Fr single-use fURS (Hugemed, HU30S)|Device being tested
218955756|NCT06191549|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|"Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training"
218955757|NCT02855554|OTHER|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
218955758|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
218955759|NCT05562934|BIOLOGICAL|XXB750 drug|SC injection
218955760|NCT05562934|OTHER|Placebo|SC injection
218955761|NCT04418661|DRUG|Vociprotafib|Pharmaceutical form: Varies Route of administration: Varies
218955762|NCT04418661|DRUG|Pembrolizumab|Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
218955763|NCT04418661|DRUG|Adagrasib|Pharmaceutical form:Sterile Tablet Route of administration: Oral
218955764|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218955765|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218955766|NCT05583227|OTHER|Placebo|Placebo subcutaneous injection
218955767|NCT05219799|DRUG|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
218955768|NCT05219799|DRUG|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
219639755|NCT05445362|DRUG|Triple antibiotic paste disinfection|-The root canals will be copiously and slowly irrigated with 20 ml of 1.5% (17) sodium hypochlorite (NaOCl) solution for 5 minutes alternatively with 20 ml of 17% ethylene diamine tetra acetic acid (E.D.T.A) solution for 5 minutes with intermediated rinse of distilled water with paper point dryness in between irrigations. The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline . The doxycycline capsule content will be evacuated in a sterile mortar; a tablet of metronidazole and a tablet of ciprofloxacin will be crushed and ground into homogenous powder in the same mortar using a pestle. Saline drops will be added and mixed using the pestle until a creamy paste achieved . The canals Will be dried with paper points and medicated with triple antibiotic paste; the access cavity will be sealed with intermediate restorative material (I.R.M) .
218955769|NCT05219799|DRUG|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
218955770|NCT05219799|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
218955771|NCT01563562|DRUG|Bardoxolone Methyl|Oral, Single dose
218955772|NCT02192333|PROCEDURE|Management of Therapy Complications|Receive survivorship care
218955773|NCT02192333|OTHER|Quality-of-Life Assessment|Ancillary studies
218955774|NCT02192333|OTHER|Questionnaire Administration|Ancillary studies
218955775|NCT02192333|BEHAVIORAL|Telephone-Based Intervention|Receive phone-based booster intervention
218955776|NCT05795998|OTHER|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
218955777|NCT04248621|DRUG|Leuprorelin|LHRH agonist
218955778|NCT04248621|DRUG|Goserelin|LHRH agonist
218955779|NCT04248621|DRUG|Triptorelin|LHRH agonist
218955780|NCT04248621|DRUG|Degarelix|LHRH antagonist
218955781|NCT04248621|DRUG|Bicalutamide|Antiandrogen
218955782|NCT04248621|DRUG|Flutamide|Antiandrogen
218955783|NCT04248621|DRUG|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
218955784|NCT00983008|BEHAVIORAL|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
218955785|NCT03838094|BIOLOGICAL|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
218955786|NCT03838094|BIOLOGICAL|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
219639756|NCT05445362|PROCEDURE|"revascularization using the standard method Blood Clot"|"\- The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin ."
219639757|NCT00767455|DEVICE|HP828-101|21 day patches
219639758|NCT00430573|DRUG|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
219639759|NCT00430573|DRUG|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
218955787|NCT00159822|DRUG|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
218955788|NCT02935751|OTHER|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
218955789|NCT05411575|DRUG|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
218955790|NCT05411575|OTHER|Placebo|Placebo continuous intravenous infusion for 7 days
218955791|NCT03702244|DIAGNOSTIC_TEST|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
218955792|NCT01643785|DRUG|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
218955793|NCT03541915|DRUG|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
218955794|NCT03541915|DRUG|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
219058211|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
219058212|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
219058213|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
219058214|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
219058215|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
219058216|NCT02812667|DRUG|Nivolumab + Plinabulin|
219058217|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
219639760|NCT04301869|DRUG|Antibiotics|Oral versus intravenous therapy
219639761|NCT00454376|OTHER|questionnaire administration|
219639762|NCT00454376|PROCEDURE|quality-of-life assessment|
219639763|NCT06576492|OTHER|RV4986A lotion|"* Application between Month -0.5 and Month 0 (before hair transplant): once a day on the entire scalp~* From 4 days after hair transplant and until Visit 4 (Month 0,5 post transplant): once a day on the recipient area~* Between Month 0.5 and Month 12: once a day on the entire scalp"
219639764|NCT06576492|OTHER|RD0057H shampoo|"* Application between Month -0.5 and Month 0 (before hair transplant): at usual frequency when required on the entire scalp~* From 2nd day after hair transplant and until the 7th day after hair transplant: application on the recipient area with a spray containing mixture of water and shampoo. For the rest of the head application with the same modalities than before hair transplant~* From the 8th day after hair transplant to the 15th day: application with a sponge on the recipient area~* From the 16th day after hair transplant and for the next 12th months: application with the same modalities than before hair transplant"
218955795|NCT04825353|PROCEDURE|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
218955796|NCT04825353|PROCEDURE|Standard PCNL|patient undergo SPCNL
218955797|NCT00713310|DRUG|Asacol 400 mg|"High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
218955798|NCT00713310|DRUG|Asacol 400 mg|"Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
219058218|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
219058219|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
218955799|NCT00875134|OTHER|Verbal prompt|Patient hears a voice recording
218955800|NCT00875134|OTHER|Skin Stimulus|Patient receives either a skin stimulus
218955801|NCT01149954|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
218955802|NCT02307253|DEVICE|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
218955803|NCT05566483|BEHAVIORAL|Exercise|exercise protocol
218955804|NCT02225054|DRUG|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
218955805|NCT02225054|DRUG|Ropivacaine|15 ml 0.5%
218955806|NCT02225054|DRUG|Normal Saline|1 mL 0.9%
219058220|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
219058221|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
219058222|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
219058223|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
219058224|NCT00131781|BEHAVIORAL|Cognitive Therapy|
219639765|NCT05914662|DRUG|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
219639766|NCT03046589|DRUG|DP13|dose escalation
219639767|NCT03046589|DRUG|placebo|control to dose-escalation
219639768|NCT03972189|DRUG|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
219639769|NCT00433589|DRUG|anthracycline-based|
219639770|NCT00433589|DRUG|docetaxel and capecitabine|
219639771|NCT00433589|DRUG|tamoxifen|
218955807|NCT01100476|DEVICE|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
218955808|NCT05145738|BEHAVIORAL|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
218955809|NCT05145738|BEHAVIORAL|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
218955810|NCT00628043|DRUG|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
218955811|NCT00628043|DRUG|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
218955812|NCT00590928|DRUG|esomeprazole|40mg once daily
218955813|NCT00590928|DRUG|ranitidine|50mg every h hours
218955814|NCT00275821|DRUG|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
219639772|NCT00433589|DRUG|Letrozole|
219639773|NCT00031629|DRUG|Docetaxel|Given IV
219639774|NCT00031629|BIOLOGICAL|Filgrastim|Given SC
219639775|NCT00031629|DRUG|Gemcitabine Hydrochloride|Given IV
219639776|NCT00031629|BIOLOGICAL|Pegfilgrastim|Given IV
219639777|NCT00613964|DRUG|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
219639778|NCT00613964|DRUG|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
219639779|NCT03010800|DEVICE|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
219639780|NCT03010800|DEVICE|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
219639781|NCT04559100|RADIATION|chest radiography|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
219639782|NCT04559100|RADIATION|thoracic computed tomography scan|6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
219639783|NCT04559100|DIAGNOSTIC_TEST|spirometry|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
219639784|NCT04559100|DIAGNOSTIC_TEST|Diffusing capacity of carbon monoxide|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
219639785|NCT04559100|DIAGNOSTIC_TEST|6 minute walk test|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
219639786|NCT04559100|DIAGNOSTIC_TEST|saint george respiratory questionnaire|6 and 12 months after hospital discharge.
219639787|NCT01040637|DRUG|TD-1211|Dose level 1
219639788|NCT01040637|DRUG|TD-1211|Dose level 2
219639789|NCT01040637|DRUG|TD-1211|Dose level 3
219207246|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
219207247|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
219207248|NCT06638372|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
219207249|NCT05933551|OTHER|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
219639790|NCT01040637|DRUG|TD-1211|Dose Level 4
219639791|NCT01040637|DRUG|TD-1211|Ascending doses
219639792|NCT01040637|DRUG|TD-1211|Ascending doses
219639793|NCT01040637|DRUG|TD-1211|Ascending doses
219639794|NCT01040637|DRUG|TD-1211|Ascending doses
219639795|NCT01040637|DRUG|TD-1211|Ascending doses
219639796|NCT01040637|DRUG|Placebo|Ascending doses
218955815|NCT00275821|DRUG|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
219639797|NCT05107609|BEHAVIORAL|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
219639798|NCT04463251|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
218955816|NCT00275821|DRUG|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
219639799|NCT04463251|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
218955817|NCT00329901|BIOLOGICAL|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
218955818|NCT00329901|BIOLOGICAL|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
218955819|NCT00329901|BIOLOGICAL|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
218955820|NCT00884767|DRUG|FOLFOX regimen|
218955821|NCT00884767|DRUG|fluorouracil|
218955822|NCT00884767|DRUG|leucovorin calcium|
218955823|NCT00884767|DRUG|oxaliplatin|
218955824|NCT00884767|GENETIC|gene expression analysis|
218955825|NCT00884767|GENETIC|protein expression analysis|
218955826|NCT00884767|GENETIC|proteomic profiling|
218955827|NCT00884767|OTHER|laboratory biomarker analysis|
218955828|NCT00884767|OTHER|pharmacogenomic studies|
218955829|NCT04169971|OTHER|Music|Played through headphones during the operation under spinal anaesthesia
218955830|NCT00228982|DRUG|Ceftobiprole medocaril|
218955831|NCT00228982|DRUG|Vancomycin|
219207250|NCT05154201|DRUG|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
219207251|NCT05143619|OTHER|Survey Administration|Complete surveys
219639800|NCT05619354|OTHER|Survey study|Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
219639801|NCT02698527|DRUG|Non-Buffered Lidocaine|Active comparator
219639802|NCT02698527|DRUG|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
218955832|NCT02890108|DIETARY_SUPPLEMENT|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
218955833|NCT02890108|DIETARY_SUPPLEMENT|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
219058225|NCT00131781|BEHAVIORAL|Supportive Therapy|
219058226|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
219058227|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
219058228|NCT00059904|BIOLOGICAL|aldesleukin|
219058229|NCT00059904|BIOLOGICAL|rituximab|
219058230|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
219058231|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
219058232|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
219058233|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
219639803|NCT00072280|BIOLOGICAL|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose \< 1yr 0.025 mg/kg \> or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
219639804|NCT00072280|DRUG|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
219639805|NCT00072280|DRUG|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
219639806|NCT00072280|DRUG|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
219639807|NCT00072280|DRUG|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
219639808|NCT00072280|PROCEDURE|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
219639809|NCT00072280|BIOLOGICAL|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
219639810|NCT00072280|BIOLOGICAL|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
218955834|NCT00585598|OTHER|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
218955835|NCT00992589|DRUG|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
218955836|NCT00992589|DRUG|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
218955837|NCT00992589|DRUG|Placebo|Matching placebo capsules once daily in the morning.
218955838|NCT01561196|PROCEDURE|arterial catheterisation|arterial catheterisation in Arterial Radialis
218955839|NCT01886027|BEHAVIORAL|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
218955840|NCT01886027|BEHAVIORAL|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
218955841|NCT03772002|DIAGNOSTIC_TEST|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
218955842|NCT02142387|OTHER|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
218955843|NCT00643084|PROCEDURE|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
218955844|NCT00643084|PROCEDURE|standard bowel preparation|standard bowel preparation
218955845|NCT04164693|DRUG|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
219207252|NCT05512910|DRUG|Minocycline|200 mg minocycline orally or via feeding tube, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable.
219207253|NCT05993689|OTHER|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
219207254|NCT05993689|OTHER|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
219639811|NCT00020865|DRUG|cefepime hydrochloride|
219639812|NCT00020865|DRUG|levofloxacin|
218955846|NCT04164693|OTHER|non anticoagulant therapy group|no anticoagulant was used after operation.
219639813|NCT03763929|DRUG|Trans-Sodium Crocetinate|In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
219639814|NCT03763929|OTHER|Placebo|The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
219639815|NCT05101889|DIETARY_SUPPLEMENT|Oral Impact®|3 ready-to-drink bottles/day
218955847|NCT01848782|BEHAVIORAL|interpretation of the abstract of the systematic review|
219639816|NCT03194880|DEVICE|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~1. User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~2. The laboratory component: For each test we will evaluate:~   * The percentage of assays completed~  * The percentage of assays incomplete (i.e. invalid result on two attempts)~  * Reasons for incomplete assays, e.g.~     * The sample could not be delivered to the strip or cartridge correctly~    * Invalid control~    * Results could not be interpreted~    * Others"
218955848|NCT03526380|BEHAVIORAL|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
219639817|NCT02642120|DEVICE|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
218955849|NCT01542424|DRUG|biphasic insulin aspart 30|Prescribed at the discretion of the physician
218955850|NCT01542424|DRUG|insulin detemir|Prescribed at the discretion of the physician
218955851|NCT03640780|OTHER|observation|The surgical ages and other information between two groups were compared.
218955852|NCT06493292|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
218955853|NCT00299468|BEHAVIORAL|Patient Activation Measure Intervention Package|
218955854|NCT01376440|OTHER|household water treatment|household water treatment with 1.25% sodium hypochlorite
218955855|NCT03857347|OTHER|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
218955856|NCT02513147|DRUG|Dolutegravir|
218955857|NCT02513147|DRUG|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
218955858|NCT02513147|DRUG|2 NRTI|
218955859|NCT02513147|DRUG|2 NRTI|
218955860|NCT02823639|PROCEDURE|Transcranial direct current stimulation|
218955861|NCT01446614|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
218955862|NCT03691740|DEVICE|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
218955863|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955864|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
218955865|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955866|NCT04552678|BEHAVIORAL|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
219058234|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
219058235|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
219058236|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
219058237|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
219058238|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
219058239|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
219639818|NCT02767466|PROCEDURE|Physical therapy and robotic assisted gait training|
219639819|NCT05335980|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
219639820|NCT01686126|DRUG|Levonorgestrel|Intrauterine device
219639821|NCT01686126|DRUG|Metformin|oral medication
219639822|NCT05020665|DRUG|Entospletinib|400 mg, Orally as tablets
219639823|NCT05020665|DRUG|Placebo|Orally as tablets
219639824|NCT05020665|DRUG|Cytarabine|Continuous infusion
219639825|NCT05020665|DRUG|Anthracycline|Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
219639826|NCT01725022|OTHER|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
219639827|NCT03384030|OTHER|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
219639828|NCT01172925|DRUG|Tiotropium|Inhaler
219639829|NCT01172925|DRUG|Placebo|Inhaler
219639830|NCT06577701|DRUG|traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
219639831|NCT06577701|DRUG|non traditional Chinese medicine (non-TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
218955867|NCT04552678|BEHAVIORAL|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955868|NCT04552678|BEHAVIORAL|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
218955869|NCT04552678|BEHAVIORAL|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955870|NCT04552678|BEHAVIORAL|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
218955871|NCT04552678|BEHAVIORAL|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955872|NCT04552678|BEHAVIORAL|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
218955873|NCT04552678|BEHAVIORAL|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955874|NCT04552678|BEHAVIORAL|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
219058240|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
219058241|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
219058242|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
219639832|NCT03811548|DRUG|Janagliflozin 25mg|Tablets, Oral, 25 mg, Tablets, Oral, 50 mg
219639833|NCT03811548|DRUG|Janagliflozin 50mg|Tablets, Oral, 25 mg, Once daily, 52 weeks
219639834|NCT03811548|DRUG|Placebo/Janagliflozin|Tablets, Oral, 25 mg, Once daily, 52 weeks
219639835|NCT04756973|BEHAVIORAL|Behavioral weight loss program|A 12 week small group weight loss program delivered via teleconference video technology
219058243|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
219058244|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
219058245|NCT02584309|DRUG|Dexrazoxane|
219058246|NCT02584309|DRUG|Doxorubicin|
219058247|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
219058248|NCT00546143|DRUG|Omalizumab|
219058249|NCT00546143|DRUG|Omalizumab|
219058250|NCT00546143|DRUG|Omalizumab|
219058251|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
219639836|NCT03297645|BEHAVIORAL|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
219639837|NCT03297645|BEHAVIORAL|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
218955875|NCT04552678|BEHAVIORAL|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955876|NCT04552678|BEHAVIORAL|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
218955877|NCT04552678|BEHAVIORAL|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
218955878|NCT04552678|BEHAVIORAL|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
218955879|NCT04772742|DRUG|Placebo|Placebo - solution for infusion
218955880|NCT04772742|DRUG|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
218955881|NCT00761748|DEVICE|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
218955882|NCT00761748|DEVICE|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
218955883|NCT05704985|BIOLOGICAL|DK210 (EGFR)|Solution for SC administration
218955884|NCT05704985|RADIATION|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
218955885|NCT05704985|BIOLOGICAL|Immune checkpoint blockers|IV administration of approved PD1 blocker
218955886|NCT05704985|DRUG|Chemotherapy|Single agent or combination of not more than two
218955887|NCT03722290|DRUG|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
218955888|NCT05036811|OTHER|data collection|data collection
218955889|NCT04822584|DRUG|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
219058252|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
219639838|NCT03297645|BEHAVIORAL|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
219639839|NCT03297645|BEHAVIORAL|Informational mail|Family will be mailed publicly available asthma information every 3 months.
219639840|NCT06576245|DEVICE|Quantum Molecular Resonance (QMR) Therapy|Quantum Molecular Resonance (QMR) therapy will be administered using the RexonEye® device (Resono Ophthalmic, Trieste, Italy). The device delivers low-intensity, high-frequency electrical waves ranging from 4-64 MHz through specialized contact electrodes. Participants will receive 4 QMR treatment sessions over 6 weeks. Each session lasts for 20 minutes, with a 30-second alternation between the eyes. The goal of QMR therapy is to stimulate cellular regeneration and improve tear production by targeting the lacrimal gland.
219639841|NCT06576245|DEVICE|Intense Pulsed Light (IPL) Therapy|Intense Pulsed Light (IPL) therapy will be performed using the OptiLIGHT® device (Lumenis Be Ltd., Yokneam, Israel). IPL treatment involves the application of high-intensity, non-coherent, polychromatic light within the 500 to 1200 nm wavelength spectrum. Participants will receive 3 IPL sessions over 6 weeks, with sessions targeting the periocular area and upper eyelids to improve meibomian gland function. Each session includes the application of 50 light pulses to the periocular area and upper eyelids using specified parameters (e.g., fluence 14 J/cm² for the periocular area, fluence 11 J/cm² for the upper eyelids).
218955890|NCT04822584|DRUG|Placebo|Placebo once a day orally for 36 weeks
218955891|NCT01695278|BEHAVIORAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
219058253|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
219058254|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
219058255|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
218955892|NCT06485115|DEVICE|Digital Telerehabilitation (Euleria Home)|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
218955893|NCT06485115|OTHER|Conventional therapy|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
218955894|NCT02402842|DRUG|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
219058256|NCT01813500|OTHER|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
219058257|NCT01640158|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
219058258|NCT01640158|OTHER|Commercially available computerized training|Commercially available computerized training, up to 65 hours
219058259|NCT03289962|DRUG|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
219058260|NCT03289962|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
219058261|NCT05453474|GENETIC|Whole genome amplification|DNA is amplified by whole genome amplification
219058262|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
219058263|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
219058264|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
219058265|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
219058266|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
219639842|NCT06576245|DRUG|Tear Substitute Treatment (Supportive Therapy)|"All participants will also receive supportive therapy with tear substitutes throughout the study period. This includes:~Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone): Applied 3 times per day.~VisuXL gel® (Cross-linked Carboxymethyl Cellulose with Coenzyme Q10): Applied once a day.~Artelac® Nighttime Gel (0.24% Sodium Hyaluronate with Carbomer): Applied before sleeping. These tear substitutes are intended to provide symptomatic relief and support tear film stability during the treatment period."
219639843|NCT04397497|DRUG|Mavrilimumab|human monoclonal antibody targeting GM-CSF receptor-alpha
219639844|NCT04397497|DRUG|Placebo|matching volume of diluent
219639845|NCT04771598|OTHER|Breathing exercise with the phone application|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home."
219639846|NCT04771598|OTHER|Breathing exercise|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week"
219639847|NCT00022698|DRUG|Capecitabine|
219639848|NCT00022698|DRUG|Irinotecan|
219639849|NCT02504827|DRUG|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
219058267|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
219058268|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
219058269|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
219058270|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
219058271|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
219058272|NCT01612546|OTHER|Pharmacological studies|Correlative studies
218955895|NCT03500185|OTHER|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
218955896|NCT03500185|OTHER|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
218955897|NCT04957433|DIAGNOSTIC_TEST|Blood Specimen|Blood and Sputum Specimen Samples
218955898|NCT01856764|DRUG|0.5% Roflumilast Cream|Roflumilast 0.5% cream
218955899|NCT01856764|DRUG|Vehicle Cream|Roflumilast formulation vehicle
218955900|NCT04089215|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
218955901|NCT03516903|DRUG|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
218955902|NCT03516903|DRUG|Placebo|Placebo-LDE (Lipid nanoemulsion)
218955903|NCT03516903|DRUG|Folic Acid|Folic acid pill
219058273|NCT00208377|DEVICE|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
219639850|NCT06308692|DIAGNOSTIC_TEST|ARES PCR|"Real time PCR assays will be used for the identification of infecting microorganisms and the drug resistance they carry that allow their identification, such as KPC, VIM, IMP, NDM, Acinetobacter OXA, Oxa48, MCR.~The validation of the method will be carried out in 100 (based on availability in Tropica Biobank) clinical samples: blood n=50 (positive, as for the negatives reference will be made to those already provided in the GENRES study) and rectal swabs ( positive n=40 and negative n=10) provided by the DITM. Sensitivity and specificity will be analyzed. As a reference for positivity and negativity data, reference will be made to routine diagnostic data obtained through standard operating procedures at the DITM laboratories."
219639851|NCT05248373|BIOLOGICAL|Gam-COVID-Vac|two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus
218955904|NCT01376531|PROCEDURE|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
218955905|NCT02724670|RADIATION|IGRT|MR-based IGRT
218955906|NCT01136200|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
218955907|NCT03673735|DRUG|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
218955908|NCT03673735|RADIATION|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
218955909|NCT03673735|DRUG|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
218955910|NCT03673735|DRUG|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
218955911|NCT05292144|DEVICE|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
218955912|NCT05438901|BIOLOGICAL|leech therapy|effects of medicinal leeches
218955913|NCT00184574|DRUG|biphasic insulin aspart|
218955914|NCT00184574|DRUG|metformin|
218955915|NCT00466687|BIOLOGICAL|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
219058274|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
219639852|NCT05248373|OTHER|Placebo|solution with same composition as for vaccine formulation except rAds
219639853|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
219639854|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
219639855|NCT01055691|DRUG|Metformin|metformin IR tablet 850 mg Oral Single dose
219639856|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
219639857|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
219639858|NCT01055691|DRUG|Metformin|metformin IR tablet 1000 mg Oral Single dose
219639859|NCT01267565|OTHER|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
218955916|NCT00466687|DRUG|erlotinib hydrochloride|150mg PO qd
218955917|NCT00466687|GENETIC|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
218955918|NCT00466687|GENETIC|gene expression analysis|gene expression analysis
218955919|NCT00466687|OTHER|immunologic technique|immunologic technique
218955920|NCT00466687|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
218955921|NCT00466687|PROCEDURE|biopsy|biopsy
218955922|NCT02963961|BEHAVIORAL|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
218955923|NCT05841121|DRUG|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
218955924|NCT01331018|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow harvest
218955925|NCT01331018|BIOLOGICAL|Filgrastim|Given SC
218955926|NCT01331018|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
218955927|NCT01331018|OTHER|Laboratory Biomarker Analysis|Correlative studies
218955928|NCT01331018|PROCEDURE|Leukapheresis|Undergo leukapheresis
219058275|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
219058276|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
218955929|NCT01331018|DRUG|Methylprednisolone|Given IV
218955930|NCT01331018|DRUG|Plerixafor|Given SC
218955931|NCT01331018|DRUG|Prednisone|Given PO
218955932|NCT02383225|BEHAVIORAL|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
219058277|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
219058278|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
219058279|NCT05703529|BEHAVIORAL|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
219058280|NCT05703529|OTHER|Usual Care|Usual Care means treating as usual, including a regular home visit.
219058281|NCT01947504|BEHAVIORAL|education and support intervention|
219058282|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
219058283|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
219058284|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
219058285|NCT01745029|DEVICE|Motilis-3D-transit|
219058286|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
219639860|NCT02965729|BEHAVIORAL|Family-based weight management|"The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format."
219639861|NCT02965729|BEHAVIORAL|Pedometer|In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
219639862|NCT02965729|BEHAVIORAL|Individualized step goals|In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
218955933|NCT02383225|BEHAVIORAL|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
218955934|NCT02383225|BEHAVIORAL|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
218955935|NCT01594151|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
218955936|NCT04025476|DRUG|Steroids|IV and oral steroids
218955937|NCT01680237|BEHAVIORAL|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
218955938|NCT01680237|BEHAVIORAL|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
219058287|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
219058288|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
219058289|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
219058290|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
219058291|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
219058292|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
219058293|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
219058294|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
219058295|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
219058296|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
218955939|NCT01992978|PROCEDURE|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
219639863|NCT00322231|BIOLOGICAL|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
219639864|NCT00322231|BIOLOGICAL|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
218955940|NCT01992978|PROCEDURE|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
218955941|NCT00238602|PROCEDURE|Stereotactic radiosurgery|
218955942|NCT03152006|OTHER|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
219058297|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
219058298|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
219058299|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
219058300|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
219639865|NCT00245089|BIOLOGICAL|dactinomycin|
219639866|NCT00245089|DRUG|cyclophosphamide|
219639867|NCT00245089|DRUG|vincristine sulfate|
219639868|NCT05053620|DEVICE|Calculation of the arcuate intrasomal incisions|All patients participating in the study will undergo femtosecond laser treatment for the correction of astigmatism through arcuate intrastromal incisions with the Catalys laser (Johnson \& Johnson, USA, CE marked). The calculation of intrastromal arcuate incisions will be carried out using the following nomogram indicated on the laser: 9.0 mm optical zone and symmetrical incisions of 50 degrees for 0.50D, 55 degrees for 0.75D, 60 degrees for 1.00D and 65 degrees for 1.25D of corneal astigmatism. After the incisions, conventional cataract surgery will be performed using the Centurion phacoemulsifier equipment (Alcon, USA, with CE marking) in the ZCB00 monofocal intraocular lens (IOL) implant (Johnson \& Johnson, USA, with CE marking). All patients will be treated according to standard clinical practice.
219639869|NCT01343680|DRUG|Heparin|5ml 10 units/ml IV heparin 3 times per week
218955943|NCT02842905|OTHER|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
218955944|NCT02842905|OTHER|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
218955945|NCT05719727|DIAGNOSTIC_TEST|colonoscopy|lower colonoscopy
218955946|NCT00103350|DRUG|TG100-115|
218955947|NCT05719987|OTHER|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
218955948|NCT05719987|OTHER|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
218955949|NCT01271790|DRUG|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
219058301|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
218955950|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
218955951|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
218955952|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
218955953|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg QD
218955954|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
219207255|NCT01957332|PROCEDURE|Molecular imaging|On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
219639870|NCT01343680|DRUG|Normal saline|10ml normal saline IV weekly
219639871|NCT03019601|BEHAVIORAL|Group Education|Structured group education on family planning facilitated by Peer Champions
219639872|NCT00568230|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
219639873|NCT02425124|BEHAVIORAL|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
219639874|NCT03145454|DEVICE|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
219639875|NCT03145454|DEVICE|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
218955955|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
218955956|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
219639876|NCT03145454|DEVICE|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
219639877|NCT03145454|DEVICE|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
219639878|NCT03145454|DEVICE|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
219058302|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
219058303|NCT02928328|DRUG|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
219058304|NCT02928328|DRUG|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
219058305|NCT02928328|DRUG|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
219058306|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
219058307|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
219058308|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
219058309|NCT02927691|DEVICE|EMST|
219058310|NCT02927691|BEHAVIORAL|smTAP|
219058311|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
219058312|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
219058313|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
219639879|NCT02569151|DEVICE|HBP & CBP measurement using systo 130 mmHg|
219639880|NCT01726907|DEVICE|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
219639881|NCT01726907|DEVICE|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson \& Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
218955957|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
218955958|NCT01271790|DRUG|GS-9451 placebo|placebo matching GS-9451 tablet QD
219058314|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
219639882|NCT00725361|DRUG|Ambrisentan|
219639883|NCT00998647|DEVICE|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
219639884|NCT00819845|DRUG|carvedilol|carvedilol vs ramipril
219639885|NCT00819845|DRUG|ramipril|carvedilol vs ramipril
219058315|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
219058316|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
219058319|NCT07023679|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
218955959|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
218955960|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
218955961|NCT03967691|DRUG|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
218955962|NCT03967691|DRUG|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
218955963|NCT03639571|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
218955964|NCT03639571|OTHER|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
219639886|NCT01732640|DRUG|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
218955965|NCT03333668|DRUG|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
219639887|NCT01732640|DRUG|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
218955966|NCT03333668|DRUG|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
218955967|NCT03333668|DRUG|Placebo|Vitamin C (10mg) tablet
218955968|NCT01076127|BEHAVIORAL|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
218955969|NCT01076127|BEHAVIORAL|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
218955970|NCT00741429|DRUG|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
219058320|NCT07023679|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
219058321|NCT07029347|DEVICE|Strength of the dominant and non-dominant hip muscles using hydraulic pusj pull dynamometer|fleksor, ekstensor, abductor, adductor, internal rotasi, eksternal rotasi
219058322|NCT07029347|DEVICE|Static balance parameters using stabilometry|Center of Pressure (COP) range sway, velocity sway, dan weight distribution
219058323|NCT07032961|OTHER|Collect epidemiological, diagnostic, and follow-up data after MCG examination.|MCG System: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
219639888|NCT01732640|DRUG|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
219058324|NCT07040332|OTHER||No intervention
219058325|NCT07042763|PROCEDURE|Cutaneous Suture|Subciliary incision followed by closure using skin sutures only. The skin was closed with 5-0 nylon using subdermal interrupted sutures. No closure of the periosteal plane was performed.
219058326|NCT07042763|PROCEDURE|Periosteal Suture|Subciliary incision followed by closure of both the periosteum and skin layers. The periosteum was closed with absorbable 4-0 Vicryl sutures, and the skin was closed with 5-0 nylon using subdermal sutures.
218955971|NCT00741429|DRUG|Comparator|Subjects previously treated with other anti-diabetic medications
218955972|NCT01698710|DRUG|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
218955973|NCT00998777|PROCEDURE|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
218955974|NCT02830438|DEVICE|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
218955975|NCT00105053|BIOLOGICAL|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
218955976|NCT01710410|DEVICE|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
218955977|NCT01710410|DEVICE|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
218955978|NCT04745273|DRUG|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
219639889|NCT01732640|DRUG|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
219639890|NCT01732640|RADIATION|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
219639891|NCT02240940|DEVICE|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
218955979|NCT04745273|OTHER|Salin solution|Salin solution 2ml (iv) will administer to participants
218955980|NCT00785616|OTHER|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
218955981|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
218955982|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
218955983|NCT05334810|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
218955984|NCT03346707|DEVICE|10.5 Tesla|10.5Tesla MR scan
219058327|NCT07046520|BEHAVIORAL|High intensity interval training|HIIT protocol was performed three times per week over a 10-week period, totaling 30 sessions. HIIT sessions included: (1) a standardized warm-up of five minutes of continuous jogging at 50%MAS, followed by five minutes of dynamic mobility and activation drills such as high-knee skips, high-knee running, and butt kicks. (2) a HIIT training session, consisted of four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery and (3) a cool-down of five minutes of static stretching.
219207256|NCT01957332|PROCEDURE|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
219207257|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
219207258|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
219366223|NCT04635865|DEVICE|Conventional commercial reconstruction plate|Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.\[
219207259|NCT06643715|DEVICE|PANDA PLUS|Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
218955985|NCT04381988|DRUG|Hydroxychloroquine|400mg daily
218955986|NCT04381988|OTHER|Placebo|400mg daily
219207260|NCT06644183|DRUG|Roginolisib|Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
218955987|NCT04381988|RADIATION|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
218955988|NCT02837484|OTHER|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
218955989|NCT06253221|DRUG|Mavacamten|Specified dose on specified days
218955990|NCT06253221|DRUG|Placebo|Specified dose on specified days
219207261|NCT06644183|DRUG|Venetoclax|B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
219207262|NCT06644183|DRUG|Rituximab|Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
219207263|NCT06643208|DRUG|TACE-HAIC, Envafolimab and Lenvatinib|TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
219207264|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
219207265|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
219207266|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
219207267|NCT04580771|DRUG|Cisplatin|Given IV
219207268|NCT04580771|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
219207269|NCT04580771|RADIATION|Radiation Therapy|Undergo radiation therapy
219207270|NCT00050063|BIOLOGICAL|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
219639892|NCT01832792|OTHER|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
219639893|NCT01832792|OTHER|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
219639894|NCT01832792|OTHER|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
219639895|NCT01037179|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
219639896|NCT02275455|BEHAVIORAL|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
219639897|NCT04182308|OTHER|dissection|Dissection of lisfranc ligament from 30 aldult Vietnamese cadavers's foot
219639898|NCT05342623|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
219639899|NCT05342623|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
219639900|NCT04574908|DEVICE|ViSi device|Mobile patient monitoring system for vital signs.
218955991|NCT03097354|OTHER|no intervention/observational survey study design|no intervention/observational survey study design
218955992|NCT02272387|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|
218955993|NCT02272387|OTHER|Placebo|
218955994|NCT03976869|DRUG|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
218955995|NCT00928122|DEVICE|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
218955996|NCT00928122|DEVICE|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
219207273|NCT06091267|DRUG|IV Decitabine|The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
219207274|NCT06091267|DRUG|Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
219207275|NCT06091267|DRUG|only Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
219207276|NCT02320370|DEVICE|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
219207277|NCT03124017|OTHER|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
219207278|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
219207279|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
219639901|NCT03964675|DEVICE|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
219207280|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
218955997|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
218955998|NCT00928122|DEVICE|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
218955999|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
218956000|NCT00575835|DIETARY_SUPPLEMENT|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
218956001|NCT00575835|DIETARY_SUPPLEMENT|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
219058328|NCT07042685|DRUG|Fruquintinib Combined With Chemotherapy|The intervention in this trial involves administering a combination of 5FU-based chemotherapy and fruquintinib to patients with locally advanced unresectable or metastatic colorectal cancer. Patients receive either the FOLFIRI or mFOLFOX6 regimen, both of which include 5-fluorouracil (5FU), leucovorin (LV), and either irinotecan (FOLFIRI) or oxaliplatin (mFOLFOX6). Fruquintinib is given orally once daily for 21 days in each 28-day cycle. The initial dose of fruquintinib is 4 mg daily for the first three patients to assess safety; if no dose-limiting toxicities are observed, the dose is increased to 5 mg daily for subsequent participants. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal. After six months, patients with stable disease or better transition to a maintenance phase with 5FU and fruquintinib alone.
219058329|NCT07047872|PROCEDURE|Computer-Aided Diagnosis|Undergo CAD development for patient-specific external breast prosthesis model
219058330|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo measurements for external breast prosthesis
219058331|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo fitting for 3D-printed external breast prosthesis
219058332|NCT07047872|PROCEDURE|Prosthetics Intervention|Receive 3D-printed external breast prosthesis
219058333|NCT07047872|OTHER|Questionnaire Administration|Ancillary studies
219639902|NCT02752061|OTHER|Potlako intervention|"Multicomponent intervention including:~* provider training on early detection and diagnostic approaches to cancer~* patient education on importance of obtaining timely cancer diagnosis~* provision of a patient navigator to facilitate diagnosis and entry into care~* provision of transportation support to vulnerable patients"
219639903|NCT00877487|DRUG|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
219639904|NCT00877487|DRUG|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
219639905|NCT05362877|DEVICE|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
219639906|NCT05362877|DEVICE|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
218956002|NCT00782587|DRUG|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
218956003|NCT01716871|DEVICE|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
218956004|NCT01716871|DEVICE|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
218956005|NCT01107379|DEVICE|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
218956006|NCT04559529|DRUG|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
218956007|NCT04559529|DRUG|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
218956008|NCT00609362|DRUG|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
218956009|NCT00609362|DRUG|Placebo pill|One encapsulated placebo pill a day for 14 weeks
219207281|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
219207282|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
219639907|NCT05362877|OTHER|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
219639908|NCT04846283|PROCEDURE|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
219639909|NCT01289860|DIETARY_SUPPLEMENT|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
219639910|NCT01289860|DIETARY_SUPPLEMENT|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
219639911|NCT03070002|BIOLOGICAL|Denosumab|Given SC
218956010|NCT01733797|DEVICE|Wooden spatula|Lollipop sticks placed between incisors
218956011|NCT01733797|DEVICE|Therabite|Hand held device placed in mouth that exercises the jaw
218956012|NCT02967380|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
218956013|NCT02967380|DRUG|Gadobenate Dimeglumine|Given IV
219058334|NCT07047131|BIOLOGICAL|GTO® (fully resorbable bone substitute)|Collagenated heterologous cortico-cancellous porcine bone mix + thermogelling copolymer with collagen (GTO®, OsteoBiol®, Tecnoss®)
219058335|NCT07047131|BIOLOGICAL|Apatos® (partially resorbable bone substitute)|Porcine cortical bone granules (Apatos Cortical®, OsteoBiol®, Tecnoss®) stabilized with TSV Gel®, a thermogelling copolymer with collagen.
219207283|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
219207284|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
218956014|NCT02967380|DRUG|Gadobutrol|Given IV
219639912|NCT03070002|OTHER|Laboratory Biomarker Analysis|Correlative studies
219639913|NCT00151242|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
219639914|NCT00151242|DRUG|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
219639915|NCT00151242|DRUG|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
219639916|NCT00151242|DRUG|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
218956015|NCT02967380|RADIATION|Gadopentetate Dimeglumine|Given IV
218956016|NCT03553030|DEVICE|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
219058336|NCT06722586|DRUG|Sirolimus|Sirolimus two pills (1mg) per day
219058337|NCT06722586|DRUG|Placebo|Placebo two pills per day
219058338|NCT07041814|DRUG|Oral estradiol valerate|Progynova is an oral hormone replacement therapy containing the active ingredient estradiol valerate, a synthetic ester of 17β-estradiol that, upon ingestion, is rapidly converted to bioidentical estradiol. Each film-coated tablet delivers either 1 mg or 2 mg of estradiol valerate, with inactive excipients including lactose monohydrate, maize starch, povidone, magnesium stearate, and hypromellose. In terms of pharmacokinetics, oral estradiol valerate undergoes first-pass metabolism in the liver, yielding a peak serum estradiol concentration within 4-8 hours of dosing and a biological half-life of approximately 20 hours. Progynova tablets are supplied in blister packs of 28 tablets, with recommended storage at room temperature (15-30 °C), protected from moisture and direct sunlight.
219207285|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
219207286|NCT00624442|DRUG|Placebo|IV infusion for 2 hours
219207287|NCT00624442|DRUG|Placebo|IV infusion for 24 hours
219639917|NCT00151242|DRUG|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
219639918|NCT00016432|DRUG|exemestane|25 mg for 5 years
219639919|NCT00016432|DRUG|Placebo|Placebo
219639920|NCT05072249|DRUG|Naloxone|Take Home Naloxone for reversing opioid overdose
219639921|NCT04384042|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
219639922|NCT05664152|BIOLOGICAL|MG1111|BARYCELA inj.
219639923|NCT05972486|DEVICE|Muse-S™ headband system|Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.
218956017|NCT01009281|DRUG|AIN457|
218956018|NCT01278654|BEHAVIORAL|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
218956019|NCT05861180|DEVICE|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
218956020|NCT01981369|DRUG|Dexmedetomidine|Intravenous sedation with dexmedetomidine
218956021|NCT01981369|DRUG|Propofol|Intravenous sedation with propofol
218956022|NCT01981369|PROCEDURE|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
218956023|NCT05472701|BEHAVIORAL|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
218956024|NCT05472701|BEHAVIORAL|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
219207288|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
219207289|NCT00624442|DRUG|Placebo|IV infusion for 72 hours
219207290|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
219207291|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
218956025|NCT05472701|BEHAVIORAL|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
218956026|NCT05472701|BEHAVIORAL|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
218956027|NCT05472701|BEHAVIORAL|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
218956028|NCT05472701|BEHAVIORAL|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
218956029|NCT02128360|DRUG|Letrozole, Gonadotropins|
218956030|NCT02128360|DRUG|Gonadotropins|
218956031|NCT01920035|DEVICE|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
219639924|NCT04266327|RADIATION|3D-printing Template-assisted CT-guided I-125 Seed Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seed implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume;Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc.Regular follow-up was conducted after treatment.
218956032|NCT01153776|PROCEDURE|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
218956033|NCT05049720|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
218956034|NCT00548405|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
218956035|NCT00548405|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
218956036|NCT00548405|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
218956037|NCT03102190|DRUG|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
218956038|NCT05200741|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
218956039|NCT05200741|BIOLOGICAL|Matching placebo|Solution for Intranasal Spray
218956040|NCT00195845|DRUG|Galantamine|
218956041|NCT00195845|DRUG|Placebos|
218956042|NCT05304091|OTHER|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
218956043|NCT05664854|DEVICE|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
218956044|NCT02985931|OTHER|Diagnostic imaging scans of SPECT and MRI|
218956045|NCT06094985|GENETIC|DNA exome sequencing of tumor and blood|A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
218956046|NCT03473080|BEHAVIORAL|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
218956047|NCT04048161|DRUG|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
218956048|NCT04048161|DRUG|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
218956049|NCT00421447|DRUG|Anastrozole|Group of women with breast cancer
219639925|NCT00889876|DRUG|Metformin group|2000 mg/day for one year
219639926|NCT00889876|BEHAVIORAL|Exercise|3 times/week with a personal coach for one year. Endurance training.
218956050|NCT04332809|PROCEDURE|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
218956051|NCT04332809|PROCEDURE|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
218956052|NCT06335147|DRUG|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
218956053|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
219058339|NCT07041814|DRUG|Transdermal 17β estradiol|Oestrogel® is a transdermal hormone replacement therapy containing 17β-estradiol in a hydroalcoholic gel formulation designed for topical application. Each pump actuation delivers 0.75 mg of estradiol in a 1.25 g dose of gel, which is formulated with excipients including ethanol, propylene glycol, carbomer, sodium hydroxide, and purified water to ensure consistent hormone release and skin penetration. Upon application to intact skin-typically the forearm or thigh-the gel allows for direct systemic absorption of estradiol, bypassing first-pass hepatic metabolism. Peak serum estradiol levels are generally reached within 6-12 hours post-application, with a half-life of approximately 10-20 hours, resulting in more physiological, steady- steady-state estradiol exposure compared to oral formulations. The gel is supplied in multi-dose pump bottles (150 g), each providing up to 120 actuations.
219639927|NCT02754427|BEHAVIORAL|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
218956054|NCT05207137|BEHAVIORAL|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
219639928|NCT02754427|BEHAVIORAL|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
218956055|NCT04985396|DRUG|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
218956056|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
219639929|NCT03512444|DEVICE|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
218956057|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
218956058|NCT02702245|OTHER|Placebo Comparator: Control|75 g pure glucose.
219058340|NCT07048769|DRUG|Lidocaine|10cc of 1% lidocaine buffered with 1cc 8.4% sodium bicarbonate, injected at 4 and 8 o'clock paracervical positions.
219058341|NCT07048769|PROCEDURE|Sham paracervical block|A capped needle is pressed at 4 and 8 o'clock positions to mimic lidocaine block without injection.
219058342|NCT07044804|DEVICE|Active Group (Active Anodal tDCS to the left IFG or Cathodal tDCS to the left IFG)|Participants in the active tDCS group (Anodal tDCS or Cathodal tDCS) will receive stimulation set at 1 mA (milliampere), with a duration of 20 minutes per session. The stimulation will be administered in five consecutive sessions per day, five days a week, for two weeks, totaling 10 sessions, while participants will also undergo logopedic treatment for 20 minutes. The training protocol will consist of 10 minutes of training in motor planning and programming abilities and 10 minutes of training on the lexical, morphosyntactic, and functional aspects of language and communication.
219058343|NCT07044804|DEVICE|Sham Group|For the sham condition, the same electrode placement will be used as in the anodal tDCS condition, but the current will be applied for 30 s and will be ramped down without the participant's awareness. Stimulation intensity will be set at 1 mA; the duration of stimulation will be 20 min and will be held five consecutive daily session per week for two weeks, for a total of 10 sessions. During the tDCS sessions participant will sit in a comfortable chair and a language training will be administered
219058344|NCT07051525|DRUG|Early antibiotic cessation alert|For all patients, antibiotics will be commenced at onset of fever. For those in the intervention arm an alert will fire in the electronic medical record once a patient is afebrile for 48-96 hours and clinically stable.
219639930|NCT06085469|BEHAVIORAL|Temporal Adaptation Approach|the temporal adaptation: It includes giving importance to the use of time, choosing meaningful activities, adjusting the time used during these activities and improving it. Such adaptation serves to improve an individual's quality of life, health, and occupational participation.
219639931|NCT00199238|DRUG|Rupatadine Fumarate|
219639932|NCT04781608|BEHAVIORAL|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
218956059|NCT00300079|DRUG|brinzolamide 1.0%|
218956060|NCT04024384|DRUG|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
218956061|NCT05636488|OTHER|No intervention|There is no intervention group in this study
218956062|NCT00644644|OTHER|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
218956063|NCT05421403|PROCEDURE|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
219058345|NCT07051616|BEHAVIORAL|Child laughter video|1 hour after the chemotherapy treatment was started, the video monitor was placed at a height where the patient could see comfortably while lying down and the video, which was checked and prepared beforehand, was turned on full screen. The appropriate volume was adjusted and the patient was allowed to watch the video for 10 minutes without any other intervention. The video was then stopped and the etagere was removed from in front of the patient. Chemotherapy was continued. At the 2nd hour of chemotherapy, the disinfected etagere and computer were placed in a position where the patient could see them comfortably and the 2nd video was started and the patient was allowed to watch the video for 10 minutes.
219058346|NCT07051278|DEVICE|Method Comparison|Quantifying the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for ctBil and FHbF in heparinized capillary whole blood samples in capillary measuring mode (C65).
219058347|NCT07051876|DEVICE|Mouthguard and Physiotherapy|The mouthguard and physiotherapy group will receive a custom-fitted mouthguard along with a physiotherapy program. The home-based physiotherapy exercises will include posture improvement routines, relaxation techniques, and targeted therapy for the muscles of the head, neck, and shoulders. These sessions will be performed daily at home for a duration of six weeks. Each participant will sign a consent form approved by the Ethics Committee of Saint Joseph University.
219058348|NCT07051876|DEVICE|Mouthguard Only|The mouthguard only group will receive a custom-fitted mouthguard, which will be fabricated by a qualified dentist. The mouthguard will be worn during sleep for 6 weeks. Participants will be instructed to clean the mouthguard daily and to store it in a cool, dry place.
219058349|NCT07052227|DEVICE|Delfi blood flow restriction cuff|Leg press exercise with Delfi blood flow restriction cuff
219639933|NCT05908721|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
219639934|NCT05577208|DEVICE|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
219639935|NCT03973879|BIOLOGICAL|PVSRIPO|Oncolytic polio/rhinovirus recombinant
219639936|NCT03973879|DRUG|Atezolizumab|Antibody
219639937|NCT00712543|DRUG|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
219639938|NCT00712543|DRUG|liquid lactulose|Liquid to be taken as prescribed.
219639939|NCT06363370|DRUG|Human interferon α1b Inhalation Solution|Participants will receive Human interferon α1b Inhalation Solution
219639940|NCT06363370|DRUG|Inhalation Solution Placebo|Participants will receive Inhalation Solution Placebo
219639941|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
219639942|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
219639943|NCT05953688|DRUG|ESK-001|Oral tablet
219639944|NCT05198037|DEVICE|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
219639945|NCT06238687|BIOLOGICAL|STRO-002|STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
219639946|NCT02083432|BEHAVIORAL|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
219639947|NCT00235885|DRUG|adalimumab|
218956064|NCT05421403|BEHAVIORAL|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
218956065|NCT04417426|OTHER|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
218956066|NCT05258669|BIOLOGICAL|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
218956067|NCT00625703|DRUG|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
219639948|NCT04043533|BEHAVIORAL|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
218956068|NCT01693302|OTHER|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
218956069|NCT06271174|DRUG|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
218956070|NCT06271174|DRUG|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~\- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
218956071|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
218956072|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
219639949|NCT01134445|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
219639950|NCT01496378|BEHAVIORAL|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
219639951|NCT04790461|OTHER|Pre-post test|Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
219639952|NCT04790461|BEHAVIORAL|face-to-face training + PMR exercise|4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
219639953|NCT04790461|BEHAVIORAL|mobile health education + PMR exercise|To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
219639954|NCT04790461|BEHAVIORAL|face-to-face and mobile health education + PMR exercise|4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
219639955|NCT02702388|DRUG|Lenvatinib|Lenvatinib capsule.
219639956|NCT02702388|DRUG|Lenvatinib matching placebo|Lenvatinib matching placebo capsule.
218956073|NCT04698330|DRUG|Berberine|0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
218956074|NCT04698330|DRUG|Inulin|0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
219058350|NCT07052227|DEVICE|Fitcuffs|Leg press exercise with Fitcuff blood flow restriction cuff
219058351|NCT07052227|OTHER|Control|Leg press exercise with no blood flow restriction cuff
219058352|NCT07051369|DIAGNOSTIC_TEST|Portal Hypertension diagnostics|his study aims to determine the frequency of portal hypertension among patients with cirrhotic liver using ultrasound.A cross-sectional study will be conducted at Sheikh Zaid Medical College and Hospital, Rahim Yar Khan,
219639957|NCT03686228|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
219639958|NCT03686228|DRUG|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
219639959|NCT04496193|PROCEDURE|Quadratus Lumborum block|Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
219639960|NCT06558383|OTHER|augmented posterior oblique sling activation|activation of posterior oblique sling for 18 sessions, three sessions per week for six weeks
219639961|NCT06558383|OTHER|selected physical therapy program|selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics and stabilization exercises
219639962|NCT02729051|DRUG|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
219639963|NCT02729051|DRUG|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
219639964|NCT02729051|DRUG|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
219639965|NCT02729051|DRUG|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
219639966|NCT02729051|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
219639967|NCT06128928|BEHAVIORAL|REDES|Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
219639968|NCT06128928|BEHAVIORAL|Control|Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.
219639969|NCT03439761|DRUG|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
219639970|NCT02128373|PROCEDURE|Usual care|Health care provided by physician, physician's nurse, and social worker
219639971|NCT02128373|OTHER|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
219639972|NCT02128373|OTHER|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
218956075|NCT04698330|DRUG|Berberine placebo tablets|0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
218956076|NCT04698330|DRUG|Inulin placebo tablets|0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
218956077|NCT06570824|DEVICE|active TMS|Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
218956078|NCT06570824|DEVICE|sham TMS|Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
218956079|NCT05518877|DRUG|Ketamine|Administration of Ketamine
218956080|NCT06017466|DIAGNOSTIC_TEST|Visual Vertigo Analogue Scale (VVAS)|The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
218956081|NCT01710371|DRUG|18F-AV-133|296 MBq (8 mCi)
218956082|NCT01710371|DRUG|10% Arginine Hydrochloride-R-Gene 10|
219058353|NCT07051603|DRUG|SAL0140|In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
219058354|NCT07051603|DRUG|SAL0140 placebo|In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
219058355|NCT07052643|OTHER|Image and data collection|Evaluation of the photographs by four independent raters
219058356|NCT07052253|DRUG|TT-00420 (tinengotinib)|oral
219058357|NCT07052253|DRUG|AK104|intravenous
219058358|NCT07052253|DRUG|AK112|intravenous
219058359|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Capsule|Participants received 1.7 grams of instant coffee in the form of three capsules. 200 mL of plain water was provided to participants to swallow the three capsules.
219058360|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Beverage|Dissolved 1.7 grams of instant coffee in 200 mL of hot water to make a coffee beverage.
219058361|NCT07051889|PROCEDURE|Lower Trapezius Tendon Transfer|This procedure is performed arthroscopically. The lower trapezius tendon is harvested from the back of the shoulder blade. A donor tendon is then used to extend the lower trapezius tendon so that it can reach the top of the arm bone. The tendon graft is then attached to the top of the arm bone, while the other end remains attached to the lower trapezius tendon itself. Any additional concomitant procedures (e.g. debridement, biceps release…etc.) may be performed as well.
219058362|NCT07051889|PROCEDURE|Partial Rotator Cuff Repair|This procedure is performed arthroscopically. The massive rotator cuff tear will be repaired by securing the loose tendon ends to the bone with suture anchors. The surgeon may also conduct a debridement of the area to remove any broken-down cartilage and tissues. Finally, the biceps tendon in will be further inspected for any damage or inflammatory changes, and the tendon may be released at the discretion of the surgeon (known as a biceps tenodesis or tenotomy depending on technique).
219639973|NCT02128373|OTHER|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
219639974|NCT02128373|OTHER|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
219639975|NCT02128373|OTHER|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
218956083|NCT06216470|DRUG|VIR-3434|VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
218956084|NCT00065559|DRUG|celecoxib|
218956085|NCT01071811|BEHAVIORAL|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
218956086|NCT03734705|BEHAVIORAL|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
219058363|NCT07052487|PROCEDURE|Post-Isometric Relaxation (PIR)|A manual physiotherapy technique applied to the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of transcutaneous electrical nerve stimulation (TENS) and moist heat (hot-pack), followed by three cycles per muscle group of: a 10-second isometric contraction against the therapist's counterforce, 5-second relaxation, and 30-second passive stretch. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
219058364|NCT07052487|PROCEDURE|Simple Stretching Exercises (SSE)|A set of four static stretches targeting the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of TENS and hot-pack application, followed by ten repetitions of each stretch held for 10 seconds. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
219058365|NCT07052019|DEVICE|Virtual Reality Distraction|Children wear virtual reality glasses during restorative dental treatment to reduce pain and anxiety.
219207292|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
219639976|NCT00530127|DRUG|placebo|Same dose and frequency as treatment
218956087|NCT03734705|OTHER|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
218956088|NCT06284174|DRUG|Povidone-iodine solution; chlorhexidine gluconate|Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
218956089|NCT06798675|DRUG|nC-001|solid dosage form single dose
218956090|NCT06798675|DRUG|Placebo|Placebo
218956091|NCT03264079|DRUG|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
218956092|NCT03264079|DRUG|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
219639977|NCT00530127|DRUG|deferiprone|100 mg/mL
219639978|NCT00530127|DRUG|deferiprone|100 mg/mL
219639979|NCT00530127|DRUG|placebo|Same dosage and frequency as study drug
219639980|NCT00530127|DRUG|deferiprone|100 mg/mL
219639981|NCT04674280|PROCEDURE|aHSCT|Autologous haematopoietic stem cell transplantation
219639982|NCT05127876|DRUG|Ondansetron 4 MG|Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
219639983|NCT05127876|DRUG|Ondansetron 8mg|Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
218956093|NCT06158581|BEHAVIORAL|The Emotion Awareness and Skills Enhancement Program|"EASE is a cutting-edge program created by researchers at the University of Alabama and the University of Pittsburgh in collaboration with autistic individuals, caregivers of autistic youth, and therapists. The overarching goal of the program is to support autistic clients who want to work on emotion regulation. EASE is unique because it targets emotional distress in autistic youth and adults, instead of targeting the core symptoms of autism (i.e., it is not a social skills intervention).~The program is a 16-session, mindfulness-based intervention. Each session is 1:1 for 45 minutes to one hour. While the program is designed for individual intervention, caregivers are also invited to play an active role on the care team."
218956094|NCT06158581|BEHAVIORAL|The Unified Protocol|"UP is a thoroughly-studied, manualized intervention created by researchers at the University of Miami in conjunction with researchers at Boston University. The program was designed to be customizable to meet the needs of people with a variety of diagnoses, allowing more individuals to access emotion regulation resources. The protocol also has different modules to accommodate different developmental levels (UP-Children, UP-Adolescent, UP-Adult). The overall goal of UP is to help clients identify emotions and build new strategies to cope with stressful life situations and distressing emotions.~The protocol is flexible, with each session is about 45 to 60 minutes and the number of sessions varying between 12 - 21 sessions. For the current study, the treatment will take place over 16 sessions. The intervention is cognitive behavioral therapy (CBT) based but also includes hints of mindfulness-based intervention strategies."
218956095|NCT04489901|OTHER|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
218956096|NCT01946906|DRUG|Rifaximin|
218956097|NCT00119093|PROCEDURE|Laboratory and clinical monitoring regimens|
218956098|NCT03849391|DIETARY_SUPPLEMENT|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
218956099|NCT03849391|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
219058366|NCT07052019|BEHAVIORAL|Tell-Show-Do Technique|Conventional behavioral technique where the dentist tells, shows, and then performs the procedure to reduce anxiety and build cooperation.
219058367|NCT06797518|DRUG|Iptacopan|LNP023 oral capsule 200 mg b.i.d
219058368|NCT07051447|OTHER|PKRxHD|The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).
219058369|NCT07051447|PROCEDURE|Dialysis|Standard of care dialysis.
219058370|NCT07052383|BIOLOGICAL|DIT309 cell injection|3+3 dose escalation design： Dose Level 1: 4.0×10\^6/kg CAR+ T cells；Dose Level 2: 1.0×10\^7/kg CAR+ T cells；Dose Level 3: 2.0×10\^7/kg CAR+ T cells.
219058371|NCT07052617|DEVICE|Continuos renal replacement therapy|Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h
219058372|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with water|Participants will receive single-dose TQ as 10 mg/kg taken with water and a low-fat meal (3 plain cracker biscuits; 2% fat). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
219058373|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with fat|Single-dose TQ as 10 mg/kg taken with 250 mL chocolate flavoured milk (9% fat) and a low-fat meal (3 plain cracker biscuits). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
219058374|NCT06575712|BEHAVIORAL|Step Up|A hybrid in-person and mHealth (mobile health) coping skills training and activity coaching intervention.
219639984|NCT05127876|DRUG|EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution|Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
219639985|NCT05127876|OTHER|10 mL normal saline|10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
219639986|NCT00802984|DEVICE|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
219639987|NCT03231202|PROCEDURE|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
219639988|NCT03687684|DRUG|TAK-831|TAK-831 Tablets.
219639989|NCT03687684|DRUG|Placebo|TAK-831 Matching Placebo Tablets.
219639990|NCT05386017|OTHER|Anthropometric measurements and sociodemographic and health data collection|"Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression"
219639991|NCT05018923|DRUG|Rabeprazole|20mg bid
219639992|NCT05018923|DRUG|Bismuth potassium citrate|0.6g bid
219639993|NCT05018923|DRUG|Metronidazole|0.4g qid
219639994|NCT05018923|DRUG|Doxycycline|0.1g bid
219639995|NCT05018923|DRUG|Tetracycline|0.5g qid
219639996|NCT03682861|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
218956100|NCT01456767|DIETARY_SUPPLEMENT|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
218956101|NCT01789918|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
218956102|NCT04221243|DEVICE|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
218956103|NCT04221243|DEVICE|Conventional Band and Loop|metal space maintainer
218956104|NCT00098982|DRUG|bortezomib|
218956105|NCT00098982|DRUG|fluorouracil|
218956106|NCT00098982|DRUG|leucovorin calcium|
218956107|NCT00098982|DRUG|oxaliplatin|
218956108|NCT02484625|OTHER|Potato chips|Commercially available potato chips, 180 kcal
218956109|NCT02484625|OTHER|Greek yogurt|Commercially available Greek yogurt, 180 kcal
218956110|NCT02484625|OTHER|Cookies|Commercially available cookies, 180 kcal
218956111|NCT02484625|OTHER|Cheese|Commercially available cheese, 180 kcal
218956112|NCT02484625|OTHER|Milk|Commercially available milk, 180 kcal
218956113|NCT00659477|DRUG|insulin glargine|once daily
218956114|NCT05331027|DRUG|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
218956115|NCT05331027|DRUG|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
218956116|NCT06364930|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab QD for 60 months.
218956117|NCT06364930|DRUG|Placebo 10mg Tab|Placebo 10mg Tab QD for 60 months.
218956118|NCT02582684|DRUG|Dolutegravir|Participants were prescribed 50 mg of DTG orally daily
218956119|NCT02582684|DRUG|Lamivudine|Participants were prescribed 300 mg of 3TC orally daily.
218956120|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
218956121|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt|daily intake of low fat yogurt for 8 weeks
218956122|NCT06454188|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day.
218956123|NCT06454188|DRUG|Placebo|15mg tablet once per day.
218956124|NCT04315974|DRUG|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
218956125|NCT04315974|PROCEDURE|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
219058375|NCT06575712|OTHER|Usual Care Plus (UC+)|Usual medical care plus videos delivering educational content via an app.
218956126|NCT02078973|DRUG|15 mg tolvaptan|15 mg pr day for 1 day
218956127|NCT02078973|DRUG|30 mg tolvaptan|30 mg pr day for 1 day
218956128|NCT02078973|DRUG|45 mg tolvaptan|45 mg pr day for 1 day
218956129|NCT02078973|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
218956130|NCT04783623|PROCEDURE|Surgical endometrioma excision|We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
218956131|NCT00327808|DRUG|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
218956132|NCT00327808|DRUG|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
218956133|NCT04486209|DEVICE|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
218956134|NCT02548728|DRUG|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
218956135|NCT02548728|DRUG|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
218956136|NCT05638672|DRUG|Huashi Baidu Granule|Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
218956137|NCT05638672|DRUG|Monapiravir|Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
218956138|NCT06189781|DRUG|Ropivacaine injection|The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.
218956139|NCT06189781|DRUG|Bupivacaine, lidocaine, ropivacaine|The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
218956140|NCT04664738|BIOLOGICAL|10% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
218956141|NCT04664738|DRUG|TISSEEL|Fibrin sealant made from pooled human plasma
218956142|NCT04664738|BIOLOGICAL|20% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
219058376|NCT05481021|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
218956143|NCT05116254|COMBINATION_PRODUCT|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
218956144|NCT05116254|COMBINATION_PRODUCT|AZD1390 + durvlaumab + radiotherapy|AZD1390 combined with durvalumab and preoperative radiotherapy
218956145|NCT06468748|DRUG|Semaglutide|During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
219058377|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
219058378|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
219058379|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
218956146|NCT06267313|BEHAVIORAL|Attention Bias Modification|Training attention away from threat
218956147|NCT06267313|BEHAVIORAL|Attention Control Training|Training attention control
218956148|NCT06267313|BEHAVIORAL|Neutral training|Attention training with Neutral stimuli
218956149|NCT01431300|DRUG|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
218956150|NCT00031967|DRUG|therapeutic melatonin|
218956151|NCT00031967|RADIATION|radiation therapy|
218956152|NCT05976828|DRUG|IBRX-042|"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
218956153|NCT05775367|DEVICE|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
218956154|NCT00755703|BIOLOGICAL|Pandemic Influenza Vaccine|Undetermined
218956155|NCT00755703|BIOLOGICAL|Placebo|
218956156|NCT02912637|OTHER|Hyperpolarized Xenon MRI|MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
219639997|NCT03682861|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
219639998|NCT00823147|BEHAVIORAL|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
219639999|NCT05620498|DRUG|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
219640000|NCT05620498|DRUG|tislelizumab+GEMOX|tislelizumab+GEMOX
219640001|NCT05034198|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
219640002|NCT05034198|BEHAVIORAL|Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
218956157|NCT05464888|BEHAVIORAL|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
218956158|NCT05464888|BEHAVIORAL|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
218956159|NCT05464888|BEHAVIORAL|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
219058380|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
219058381|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
219058382|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
218956160|NCT06054269|BIOLOGICAL|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
218956161|NCT06054269|BIOLOGICAL|FluQuadri|0.5 mL intramuscular dose of FluQuadri
218956162|NCT05788016|BEHAVIORAL|opioid taper|The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
218956163|NCT02498171|DRUG|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
218956164|NCT02498171|DRUG|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
219058383|NCT00099697|DRUG|DHEA|
219058384|NCT00804297|DRUG|Octreotide (drug)|
219058385|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
219058386|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
219058387|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
219207293|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
218956165|NCT00745355|BEHAVIORAL|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
218956166|NCT05582928|DEVICE|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
218956167|NCT00670943|OTHER|Platelet function testing|
218956168|NCT01911910|BEHAVIORAL|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
218956169|NCT04914013|OTHER|no intervention|no intervention
218956170|NCT02653118|BIOLOGICAL|V503|
218956171|NCT02653118|BIOLOGICAL|GARDASIL|
218956172|NCT04898647|OTHER|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
218956173|NCT04898647|BIOLOGICAL|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
218956174|NCT04898647|PROCEDURE|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
218956175|NCT02720172|BEHAVIORAL|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
218956176|NCT02720172|OTHER|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
218956177|NCT06140537|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg orally daily
218956178|NCT06140537|DRUG|Placebo|Placebo one tablet orally daily
219058388|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
219058389|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
219058390|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
219058391|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
219058392|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
219058393|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
219058394|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
219058395|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
219640003|NCT05034198|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
218956179|NCT04660838|OTHER|ACB intervention|Stopping and/or switching ACB medication to an alternative
218956180|NCT03034239|DIETARY_SUPPLEMENT|Protein supplementation|\+ insect protein
218956181|NCT03034239|OTHER|Resistance training|Resistance exercise
218956182|NCT02328378|PROCEDURE|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
218956183|NCT00899392|OTHER|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
218956184|NCT02200198|OTHER|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
219058396|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
219058397|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
219640004|NCT02118727|DRUG|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
219058398|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
219058399|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
219058400|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
219207294|NCT03462485|OTHER|Golf|Eight weeks of twice-daily golf training
218956185|NCT02200198|OTHER|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
218956186|NCT02200198|OTHER|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
218956187|NCT02067975|DRUG|Tryptophan|
218956188|NCT02067975|DRUG|Placebo|
218956189|NCT03877640|DEVICE|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
218956190|NCT01718340|DRUG|Metformin|metformin tablet 500mg three time per day
218956191|NCT06172985|OTHER|No intervention|Due to observational study
218956192|NCT05938049|DEVICE|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
218956193|NCT04185597|OTHER|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
218956194|NCT04185597|OTHER|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
218956195|NCT04185597|OTHER|Control|Current Standard of Practice
218956196|NCT00266058|DRUG|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
218956197|NCT00678756|DRUG|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
218956198|NCT00678756|RADIATION|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
218956199|NCT03248349|DRUG|Pharmacokinetics|"* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
219058401|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
219058402|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
219058403|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
218956200|NCT00866229|DRUG|Rosuvastatin|10 mg per day for 12 weeks
218956201|NCT00866229|DRUG|Simvastatin|20 mg per day
218956202|NCT06238102|OTHER|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
218956203|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
218956204|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
218956205|NCT02258776|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1/day for 12 weeks.
219058404|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
219058405|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
219058406|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
219058407|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
219058408|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
219058409|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
219058410|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
219207295|NCT00167765|DRUG|Abciximab|
218956206|NCT04850508|DEVICE|Mapping and ablation with the Advisor HD Grid catheter|"After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.~If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed."
218956207|NCT02621840|BEHAVIORAL|Mandatory On-Site Pre-Admission Testing|
219207296|NCT04263610|DRUG|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
219640005|NCT02118727|DRUG|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
218956208|NCT01640431|OTHER|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
218956209|NCT03896893|OTHER|Skin antisepsis|1% aqueous chlorhexidine gluconate
219058411|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
219058412|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
219640006|NCT00577980|DRUG|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
219640007|NCT01497912|DRUG|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
218956210|NCT03896893|OTHER|Emollient|Aquaphor skin cream
218956211|NCT04332588|DRUG|[18F]FMISO PET/MRI imaging|\[18F\]FMISO PET/MRI imaging
218956212|NCT01261780|DEVICE|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
219058413|NCT02162628|DEVICE|Exair Prolapse Repair System|
219058414|NCT02162628|PROCEDURE|Total Native Tissue Repair|
219640008|NCT01497912|DRUG|Placebo|Placebo tablet once daily for 8 weeks
219640009|NCT05010252|BEHAVIORAL|Cycled light Experimental|The preliminary plan of this study is to carry out empirical evidence and expert advice to confirm precise lighting and develop care intervention strategies for preterm infants based on evidence. It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies born 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
219640010|NCT02737943|DRUG|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
218956213|NCT01261780|DRUG|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
218956214|NCT01870323|BEHAVIORAL|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
218956215|NCT01870323|BEHAVIORAL|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
218956216|NCT01534858|DEVICE|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
218956217|NCT03977740|OTHER|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
218956218|NCT03977740|OTHER|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
218956219|NCT01239732|DRUG|Paclitaxel|175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
218956220|NCT01239732|DRUG|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
218956221|NCT01239732|DRUG|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
218956222|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
218956223|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
218956224|NCT06393556|OTHER|Virtual reality experience|An immersive VR experience, delivered using a VR head-mounted display, of the real-world environment at the hospital, featuring the pre-operative admission suite, pre-anesthetic bay, operating theatre, postoperative recovery room, and medical staff.
218956225|NCT02241889|DEVICE|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
219058415|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
219058416|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
219058417|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
219058418|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
219058419|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
219058420|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
219058421|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
219058422|NCT00002408|DRUG|Crofelemer|
219640011|NCT02737943|DRUG|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
219058423|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
219058424|NCT00548821|DRUG|Cisplatin|
219058425|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219058426|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
219058427|NCT00038493|DRUG|Temozolomide and SCH66336|
219058428|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
219058429|NCT02823925|DRUG|Pamidronate or Zoledronate|
219058430|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
219058431|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
219058432|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
219058433|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
219640012|NCT03533361|DRUG|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
219640013|NCT00164528|BEHAVIORAL|Positive Behavior Support|
219640014|NCT05515211|DIAGNOSTIC_TEST|Foot length|Foot length will be measured from the midpoint of the heel to the longest toe.
219640015|NCT00449137|DRUG|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
219640016|NCT00449137|DRUG|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
219640017|NCT00449137|DRUG|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
219640018|NCT00449137|OTHER|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
218956226|NCT02241889|DEVICE|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
218956227|NCT01318005|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
219058434|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
219058435|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
219058436|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
219058437|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
219058438|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
219058439|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
219058440|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
219058441|NCT02359292|DRUG|Placebo pMDI|
219058442|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
219058443|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
219058444|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
219058445|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
219058446|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
219058447|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
219058448|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
219058449|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
219640019|NCT00449137|GENETIC|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
218956228|NCT01318005|DRUG|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
218956229|NCT01318005|DRUG|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
218956230|NCT03021161|DRUG|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
218956231|NCT03021161|OTHER|Placebo Oral Capsule|Capsule containing no probiotic
218956232|NCT05320809|BIOLOGICAL|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
218956233|NCT05596383|DIETARY_SUPPLEMENT|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
218956234|NCT05596383|DIETARY_SUPPLEMENT|Placebo|Placebo
219058450|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
219058451|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
219640020|NCT00449137|PROCEDURE|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
219640021|NCT01045577|DRUG|Masitinib|6 mg/kg/day
219640022|NCT01045577|DRUG|Masitinib|3 mg/kg/day
219640023|NCT01045577|DRUG|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
219640024|NCT05903105|OTHER|Questionnaires|Patients fill in a questionnaire
219640025|NCT06302153|PROCEDURE|Progressive Loading Exercises|At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.
219640026|NCT04088695|OTHER|Video through a web page|Participants will see a video about blood donation.
219640027|NCT04088695|OTHER|Informative text|Participants will see a brief text about blood donation.
219640028|NCT02519998|OTHER|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
219640029|NCT04740827|DRUG|Atogepant 60 mg|Atogepant tablets.
219640030|NCT04740827|DRUG|Placebo|Atogepant matching placebo tablets.
219640031|NCT05728827|OTHER|Blood flow restriction training + Anti-gravity treadmill|Blood flow restriction training is administered via straps applied to the proximal limb with the possibility to adjust the applied occlusion pressure in order to prevent venous return leaving the arterial flow partially free. The consequent blood pooling causes a reduction in tissue saturation with oxidative stress and an increased growth factors secretion. The intervention will be applied while walking/running on the anti-gravity treadmill.
219640032|NCT05728827|OTHER|Anti-gravity treadmill|The intervention will be applied walking/running on the anti-gravity treadmill.
219640033|NCT06651827|DIAGNOSTIC_TEST|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment. The effectiveness of the treatment was assessed at baseline, 30 minutes, 1 week, and 1 month post-treatment using the Visual Analog Scale (VAS) and Yeaple Probe scores.
218956235|NCT04478344|OTHER|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
218956236|NCT03127332|OTHER|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
218956237|NCT04284462|OTHER|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
219640034|NCT02147158|DRUG|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
219640035|NCT02147158|DRUG|Placebo|Matching placebo tablet.
219640036|NCT00831298|OTHER|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
218956238|NCT00646932|DRUG|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
218956239|NCT00646932|DRUG|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
219640037|NCT06664996|RADIATION|stereotactic body radiation therapy (SBRT)|SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions.
218956240|NCT00646932|DRUG|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
218956241|NCT00646932|DRUG|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
218956242|NCT00307008|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection
218956243|NCT00933413|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
218956244|NCT00274092|DRUG|tiotropium inhalation capsules (18 mcg once daily)|
218956245|NCT00274092|DRUG|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
218956246|NCT04052802|OTHER|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
218956247|NCT00705744|DRUG|Lactic acid (Dermacyd Femina)|
218956248|NCT00319072|BEHAVIORAL|TalkToYourDoc(sm) hormone therapy module|
218956249|NCT00663247|DEVICE|Mesalazine|3 grams daily for 3 months
218956250|NCT00663247|DRUG|Placebo|3 grams daily for 3 months
218956251|NCT00002167|DRUG|Tin ethyl etiopurpurin|
218956252|NCT05631678|DRUG|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
218956253|NCT05631678|DRUG|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
219640038|NCT06664996|DRUG|Sintilimab (approved)|patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).
219640039|NCT02063945|DRUG|Methylphenidate|As stated in arm/group
219640040|NCT02063945|DRUG|Risperidone|As stated in arm/group
219640041|NCT03425396|DRUG|Omadacycline tablets|Oral Omadacycline
219640042|NCT03425396|DRUG|Nitrofurantoin capsules|Oral Nitrofurantoin
219640043|NCT01441765|DRUG|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
219640044|NCT01441765|BIOLOGICAL|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
219640045|NCT00065754|DRUG|placebo|
219640046|NCT00301353|DRUG|Isoflavones-enriched foods|
219640047|NCT02428309|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
219640048|NCT02112383|BEHAVIORAL|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
219640049|NCT02112383|BEHAVIORAL|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
219640050|NCT02380833|BEHAVIORAL|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
218956254|NCT05207345|OTHER|Interventional programme|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
219640051|NCT02380833|BEHAVIORAL|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
218956255|NCT05207345|OTHER|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
218956256|NCT02249247|DRUG|Low dose of BIIL 284 BS tablets|
219640052|NCT02380833|BEHAVIORAL|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
218956257|NCT02249247|DRUG|Medium dose of BIIL 284 BS tablets|
219640053|NCT02380833|BEHAVIORAL|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
218956258|NCT02249247|DRUG|High dose of BIIL 284 BS tablets|
218956259|NCT02249247|DRUG|Placebo|
218956260|NCT05235503|DRUG|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
218956261|NCT05235503|DRUG|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
218956262|NCT00082472|DRUG|Doxorubicin HCl Inhalation Solution|
218956263|NCT00082472|DRUG|Docetaxel|
218956264|NCT00082472|DRUG|Cisplatin|
218956265|NCT02048241|BEHAVIORAL|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
218956266|NCT02048241|OTHER|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
219058452|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
219058453|NCT02464969|DRUG|Apixaban|Tablet or Solution
219640054|NCT05931341|DIETARY_SUPPLEMENT|Rosemary extract|Softgel capsule including rosemary extract
219640055|NCT00003571|GENETIC|mutation analysis|
219640056|NCT00003571|GENETIC|tumor replication error analysis|
219640057|NCT02274012|DRUG|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
219640058|NCT02274012|DRUG|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
219640059|NCT06577064|PROCEDURE|Sacral erector spinae plane block|30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side
219640060|NCT02893033|DEVICE|repetitive transcranial magnetic stimulation|rTMS
219640061|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 1.5 mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
218956267|NCT02048241|DRUG|Intuniv|Weekly administration of medication in doses as per protocol
218956268|NCT04045509|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
218956269|NCT04045509|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
219640062|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 3.0mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
219640063|NCT04520997|DEVICE|Restylane Defyne|Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
218956270|NCT04045509|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
218956271|NCT04690439|DEVICE|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
219058454|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
219058455|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
219058456|NCT01591746|DRUG|Botulinum Toxin Type A|
219058457|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
219058458|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
219058459|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
219058460|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
219058461|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
219058462|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
219058463|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
219058464|NCT05234944|BEHAVIORAL|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
219058465|NCT02877706|OTHER|no specific intervention|
219058466|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
219058467|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
219058468|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
219640064|NCT04520997|DEVICE|Restylane Defyne|Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
219640065|NCT06024798|DIAGNOSTIC_TEST|Photon-Counting-Computed-Tomography|Initial and follow up (after 4 weeks) PCCT acquisition of the affected area of the lower extremity. Image acquisition will be performed on the PCCT
219640066|NCT03439592|DIAGNOSTIC_TEST|collection of fecal material|in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
219640067|NCT02981082|DRUG|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
218956272|NCT04690439|PROCEDURE|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
218956273|NCT01685333|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
218956274|NCT00402233|DRUG|Pramipexole|
218956275|NCT00402233|DRUG|Placebo|
218956276|NCT02483767|DRUG|goserelin|Gonadotropin-Releasing Hormone Agonist
219058469|NCT02399085|DRUG|Tafasitamab|12 mg/kg
219058470|NCT02399085|DRUG|Lenalidomide|25 mg
219058471|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
219058472|NCT02176733|DRUG|cyclosporine|
219058473|NCT01485861|DRUG|Abiraterone|Orally once daily
219058474|NCT01485861|DRUG|Apitolisib|Orally once daily
219058475|NCT01485861|DRUG|Ipatasertib|Orally once daily
219058476|NCT01485861|DRUG|Placebo|Orally once daily
219058477|NCT01485861|DRUG|Prednisone|Orally bid
219058478|NCT01485861|DRUG|Prednisolone|Orally bid
219058479|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
219058480|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
219058481|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
219058482|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
219058483|NCT00434096|DRUG|placebo|oral administration once daily
219640068|NCT02981082|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
219640069|NCT03689374|DRUG|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
218956277|NCT02483767|DRUG|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
218956278|NCT03105466|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
218956279|NCT03105466|DEVICE|Acellular Porcine Cornea|
218956280|NCT03105466|DRUG|Tacrolimus eye drops|
219640070|NCT03689374|DRUG|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
219640071|NCT03689374|DRUG|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
219640072|NCT04710784|BEHAVIORAL|Sexual health information|We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
219640073|NCT04710784|BEHAVIORAL|I-TEST branded HIVST package|The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.
219640074|NCT04710784|OTHER|Follow-up testing and clinic assessments|Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
219640075|NCT01023945|DRUG|ASP1941|oral
219640076|NCT01023945|DRUG|Placebo|oral
219640077|NCT05367973|DEVICE|IVR Dose 1|Estradiol 80 ug/day + progesterone 4 mg/day
219640078|NCT05367973|DEVICE|IVR Dose 2|Estradiol 160 ug/day + progesterone 8 mg/day
218956281|NCT03105466|DRUG|Tobradex eyedrops|
219058484|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
219640079|NCT03098654|DIAGNOSTIC_TEST|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
219640080|NCT03098654|BEHAVIORAL|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
219640081|NCT03098654|DRUG|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
219640082|NCT01961154|DRUG|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
219640083|NCT02805660|DRUG|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
219640084|NCT02805660|DRUG|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
219640085|NCT02805660|DRUG|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
219640086|NCT02805660|DRUG|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
218956282|NCT04440423|DRUG|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
218956283|NCT04440423|DRUG|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
218956284|NCT00456144|DRUG|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
218956285|NCT03220698|DEVICE|Tracheal ultrasonography|Tracheal ultrasonography
218956286|NCT02819908|DRUG|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
218956287|NCT02819908|DRUG|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
218956288|NCT04658940|DEVICE|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
219640087|NCT02805660|DRUG|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
218956289|NCT05270447|OTHER|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
219640088|NCT05892276|BEHAVIORAL|Trauma Memory Reactivation|Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
219640089|NCT05892276|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Broad-Spectrum Oil|300mg CBD broad-spectrum oil.
218956290|NCT05270447|BEHAVIORAL|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
219058485|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
219058486|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
219058487|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
218956291|NCT03579602|DRUG|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
219058488|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
219058489|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
219058490|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
219058491|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
219058492|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
219058493|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
219058494|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
218956292|NCT03579602|DEVICE|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
219058495|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
219207297|NCT04263610|DRUG|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
219640090|NCT05892276|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
219640091|NCT03647579|DRUG|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
219640092|NCT03647579|DRUG|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
219058496|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
219058497|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
219058498|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
219058499|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
219058500|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
219058501|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
219058502|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
219058503|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
219640093|NCT06445751|BEHAVIORAL|"Step Up for STEM and Health Careers (Step Up) game"|"Step Up for STEM and Health Careers (Step Up) game is an interactive, digital resource to help high school students understand the importance of diversity in STEM and health careers, attain STEM/health career self-efficacy, and help them create an inclusive learning environment for others."
219640094|NCT06445751|BEHAVIORAL|Educational PowerPoint Presentation on Diversity in STEM Careers|An educational PowerPoint on Diversity in STEM careers to increase adolescents' STEM/health career self-efficacy, and help them create an inclusive learning environment for others.
219058504|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
219058505|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
219058506|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
219058507|NCT00491790|OTHER|Sterile water|Sterile water
219058508|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
219640095|NCT02556073|OTHER|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
219640096|NCT02556073|DRUG|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
219640097|NCT02048098|DRUG|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
219640098|NCT02048098|DRUG|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
219640099|NCT01762202|DRUG|Cyclophosphamide|
218956293|NCT03839043|BEHAVIORAL|Brief behavioral intervention|"Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
219058509|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
219640100|NCT01762202|DRUG|Fludarabine|
219640101|NCT01762202|DRUG|Ofatumumab|
219640102|NCT02705300|DRUG|Irinotecan 165 mg/m2 iv|Max. 4 months
219640103|NCT02705300|DRUG|Oxaliplatin 85 mg/m2 iv|Max. 4 months
219640104|NCT02705300|DRUG|Calcium folinate 200 mg/m2 iv|Max. 6 months
219058510|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
219058511|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
219640105|NCT02705300|DRUG|5-fluorouracil 3200 mg/m2|Max. 6 months
219058512|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
219058513|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
219058514|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
219058515|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
219058516|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
219058517|NCT00764348|OTHER|no treatment|
219058518|NCT02005341|DEVICE|nanOSS|
219058519|NCT02005341|DEVICE|Autograft|
219058520|NCT02477384|PROCEDURE|8mm-TIPS|
219058521|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
219640106|NCT02705300|DIETARY_SUPPLEMENT|Tocotrienol|Max. 2 years or at the discretion of the investigator
219640107|NCT02705300|DRUG|Placebo|Max. 2 years or at the discretion of the investigator
219640108|NCT03685253|DRUG|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
219640109|NCT03685253|DRUG|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
219640110|NCT02923453|DIETARY_SUPPLEMENT|CNT 2000 American ginseng extract|
219640111|NCT02923453|DIETARY_SUPPLEMENT|Placebo|
219640112|NCT04138953|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
219058522|NCT02477384|DRUG|Propranolol|
219058523|NCT02477384|DEVICE|8mm ePTFE-covered stent|
219058524|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
219207298|NCT04263610|DRUG|Tildrakizumab|Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
219207299|NCT00127387|DRUG|Enbrel|
219640113|NCT04138953|OTHER|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS)
219640114|NCT01955278|DEVICE|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
219640115|NCT01955278|OTHER|Conventional definitive end colostomy|
219640116|NCT02660957|BEHAVIORAL|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
219640117|NCT02660957|OTHER|placebo comparator|suggest a healthy life style as a placebo comparator
219640118|NCT02921932|DIETARY_SUPPLEMENT|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
219640119|NCT02921932|OTHER|Cognitive Training, Memory Card Game|Preoperative memory card game
219640120|NCT02921932|DEVICE|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
219640121|NCT06920940|OTHER|Ketogenic Therapy|During the keto therapy (16 weeks), the youth will participate in a strict ketogenic diet, with adjustments made as necessary from weekly dietitian coaching sessions.
219640122|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
219640123|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
219640124|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
219640125|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
218956294|NCT03839043|OTHER|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
218956295|NCT03317301|DRUG|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
218956296|NCT03317301|DRUG|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
218956297|NCT00252044|DRUG|Pergolide|
218956298|NCT04851093|DRUG|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
218956299|NCT04851093|DRUG|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
218956300|NCT01922401|OTHER|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
218956301|NCT03508791|OTHER|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
218956302|NCT03508791|OTHER|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
218956303|NCT03508791|OTHER|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
218956304|NCT01873469|RADIATION|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
219207300|NCT03618758|DRUG|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
219207301|NCT03618758|DRUG|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
219640126|NCT04552990|DRUG|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
219640127|NCT04552990|PROCEDURE|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
219640128|NCT04552990|PROCEDURE|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
219640129|NCT04552990|OTHER|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
219640130|NCT05276375|DRUG|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
219640131|NCT06926387|DRUG|YHP2407|Test drug: YHP2407, Comparator: YHR2502
219640132|NCT06926387|DRUG|YHR2502|Test drug: YHP2407, Comparator: YHR2502
219207302|NCT03568409|DEVICE|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
219207303|NCT03568409|OTHER|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
219367286|NCT01893749|BEHAVIORAL|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
218956305|NCT02518464|DRUG|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
219640133|NCT05025176|DEVICE|Non invasive arterial pressure monitoring|Non invasive arterial pressure monitoring
219640134|NCT05565833|BEHAVIORAL|SHUTi OASIS|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
218956306|NCT04738305|OTHER|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
218956307|NCT01789931|DEVICE|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
218956308|NCT06297252|DIAGNOSTIC_TEST|standardized clinical psychiatric evaluations|"The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire"
218956309|NCT06297252|DIAGNOSTIC_TEST|self-administered psychiatric questionnaire assessments|"* EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)"
218956310|NCT06297252|OTHER|blood sampling|"A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA"
218956311|NCT05425316|BEHAVIORAL|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
218956312|NCT05425316|BEHAVIORAL|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
218956313|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
218956314|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
218956315|NCT05425316|BEHAVIORAL|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
218956316|NCT02472509|DRUG|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
218956317|NCT02905396|DEVICE|Spinal cord stimulation|implantation of spinal cord stimulator
218956318|NCT06129513|BEHAVIORAL|Bilateral resistance exercise|A bout of bilateral resistance exercise consisting of barbell back squat, leg leg press and leg extension
219640135|NCT05565833|OTHER|Patient Education|An educational website containing information on insomnia
219640136|NCT00006160|BEHAVIORAL|home based worker|
219640137|NCT02727946|OTHER|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
219640138|NCT01314872|DRUG|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
219640139|NCT01314872|DRUG|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
218956319|NCT06129513|DIETARY_SUPPLEMENT|Whey protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
218956320|NCT06129513|DIETARY_SUPPLEMENT|Plant-blend protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from plant-blend protein isolate
218956321|NCT00819793|DEVICE|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
218956322|NCT04232709|OTHER|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
218956323|NCT01711060|DRUG|oxytocin|
218956324|NCT01711060|PROCEDURE|balloon catheter|
219640140|NCT01314872|DRUG|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
219640141|NCT01314872|DRUG|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
219640142|NCT03286556|DRUG|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
219640143|NCT03286556|DRUG|Treatment as Usual (TAU)|Antibiotics and steroids
219640144|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
219640145|NCT04537936|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
218956325|NCT04610697|BEHAVIORAL|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
218956326|NCT04610697|BEHAVIORAL|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
218956327|NCT03894176|OTHER|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
218956328|NCT03848871|DRUG|Enstilar|Enstilar foam applied to affected area once daily
218956329|NCT06103331|OTHER|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
219058525|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
219058526|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
219640146|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
219640147|NCT04537936|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
219640148|NCT06667388|DIAGNOSTIC_TEST|Group A|each participant of this groups will receive 4 weeks of FWT and 4 weeks of BWT (the training order of A group will FWT and BWT), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
219640149|NCT06667388|COMBINATION_PRODUCT|Grojup B|each participant of B group will receive 4 weeks of BWT and 4 weeks of FWT (the training order of group B will be BWT and FWT, opposite to group A), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
219640150|NCT01582633|BIOLOGICAL|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose."
219640151|NCT05640726|DRUG|PD-1|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
219640152|NCT05640726|RADIATION|SCRT|Radiotherapy dose: 5×5 Gy
219640153|NCT05640726|DRUG|Bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
219640154|NCT05640726|DRUG|Oxaliplatin|Participants will receive Oxaliplatin，85mg/m2，day1
219640155|NCT05640726|DRUG|Calcium folinate|Participants will receive calcium folinate ，400mg/m2，day1
219640156|NCT05640726|DRUG|5-fluorouracil|Participants will receive 5-fluorouracil ，400mg/m2，day1
219058527|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
219058528|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
218956330|NCT00591110|BEHAVIORAL|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
218956331|NCT00591110|BEHAVIORAL|Social-contact control|Participants receive an engaging informational session on a non-health related topic
218956332|NCT02299973|PROCEDURE|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
218956333|NCT02299973|PROCEDURE|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
218956334|NCT00480948|BEHAVIORAL|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
218956335|NCT00480948|DIETARY_SUPPLEMENT|Control|Standard vegetable oil based infant formula
218956336|NCT00184171|DRUG|Budesonide|Budesonide 9 mg
218956337|NCT00184171|DRUG|Bismuth|Bismuth mixture
218956338|NCT00184171|DRUG|Fiber|Fiber for control
219058529|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
219207304|NCT02757898|DRUG|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
219207305|NCT06632158|BEHAVIORAL|MindBoba|MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.
219207306|NCT06632158|BEHAVIORAL|Mindshift CBT|MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help participants learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of their anxiety.
219207307|NCT02994667|DEVICE|Permanent Pacemaker Placement|
219640157|NCT03671109|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
218956339|NCT01603524|OTHER|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
218956340|NCT01603524|BEHAVIORAL|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
218956341|NCT04334538|DIETARY_SUPPLEMENT|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
218956342|NCT04334538|DIETARY_SUPPLEMENT|oat RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
218956343|NCT05292300|DIETARY_SUPPLEMENT|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
219058530|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
219058531|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
219058532|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
219058533|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
219058534|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
219058535|NCT00529828|PROCEDURE|Consumption of CLA enriched food|
219058536|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
219058537|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
219058538|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
219058539|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
219207308|NCT02401711|BEHAVIORAL|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
219640158|NCT03671109|DRUG|Placebo Oral Tablet|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
218956344|NCT05292300|BEHAVIORAL|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
218956345|NCT01181401|DRUG|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
219058540|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
219058541|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
219207309|NCT02401711|BEHAVIORAL|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
219207310|NCT02401711|BEHAVIORAL|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
219367287|NCT06076629|OTHER|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
219640159|NCT05877690|DRUG|Bupivacaine 0.5% Injectable Solution|Patient will be received the drug intrathecal
219640160|NCT05877690|DRUG|Prilocaine Hydrochloride 2% Injection|Patient will be received the drug intrathecal
219640161|NCT04188015|BIOLOGICAL|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
219640162|NCT04188015|BIOLOGICAL|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
219640163|NCT04188015|OTHER|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
219640164|NCT04645901|DRUG|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
219640165|NCT04645901|DRUG|Placebo|Oral tablets of placebo with matching several doses
219640166|NCT04532619|BEHAVIORAL|Fathering Through Change|Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
219640167|NCT01993901|OTHER|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
219640168|NCT05280457|DRUG|nivolumab-GX-188E-GX-I7|"* Nivolumab 3 mg/kg IV administered every 2 weeks~* GX-188E 2 mg IM at Weeks 1, 2, 4, 7, 10, 13, and 19~* GX-I7 1200 μg/kg or the recommended dose of the introductory safety cohort is administered at weeks 2, 10, and 18"
219640169|NCT01976650|DRUG|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
218956346|NCT01181401|DRUG|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
218956347|NCT01181401|RADIATION|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
218956348|NCT05703633|OTHER|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
219058542|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
219058543|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
219058544|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
219058545|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
219058546|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
219367288|NCT06076629|OTHER|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
218956349|NCT00572221|BEHAVIORAL|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
218956350|NCT00572221|BEHAVIORAL|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
218956351|NCT01574742|DRUG|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
218956352|NCT04334018|DEVICE|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
218956353|NCT04334018|DEVICE|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
218956354|NCT04058171|DIAGNOSTIC_TEST|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
218956355|NCT02940002|DRUG|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
218956356|NCT02940002|DRUG|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
219058547|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
219058548|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
219058549|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
219058550|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
219058551|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
219207311|NCT05175794|DIAGNOSTIC_TEST|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
219207312|NCT04993677|DRUG|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
219207313|NCT04993677|DRUG|pembrolizumab (KEYTRUDA®)|Given by IV; schedule is cohort-specific.
219640170|NCT02460250|PROCEDURE|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
219640171|NCT06803121|OTHER|Traditional treatment|Traditional exercises for scoliosis include breathing exercises, posture training, spinal flexibility exercises, stretching exercises for the involved muscles (especially for the concave side of the curve), and general strengthening exercises for the main muscle groups of trunk, pelvis, and shoulder girdle muscles (especially for the convex side of the curve).
218956357|NCT02940002|DRUG|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
218956358|NCT04022161|DRUG|Nitrogen Gas for Inhalation|See arm description
218956359|NCT04022161|OTHER|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
218956360|NCT04022161|DRUG|Nitric Oxide|See arm description
218956361|NCT06398405|OTHER|Epigallocatechin-3-gallate|Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
219207314|NCT04993677|DRUG|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
219207315|NCT04993677|DRUG|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
219640172|NCT06803121|OTHER|Core stability exercises|The CS training program includes local muscle stability training (transverses abdominis, multifidus, and diaphragm), global muscle stability training (oblique abdominal muscles, psoas major, quadratus lumborum, and pelvic floor muscles), global muscle mobility training (rectus abdominis, back extensors, and hamstring muscles), and strength training of the core muscles through the thoracolumbar fascia by maintaining the neutral spine position. Diaphragmatic breathing technique will be used during exercises.
219640173|NCT05062707|PROCEDURE|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
219640174|NCT06179017|OTHER|Experimental group:Intervention Group|Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
219640175|NCT06179017|OTHER|Control group:best medical treatment|Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
219640176|NCT00453531|PROCEDURE|Limb Ischemia|
219367289|NCT06021249|PROCEDURE|Traditional ventilation strategies|"1. Tidal volume：10ml/kg predicted body weight（PBW）；~2. 0 cm H2O positive end expiratory pressure（PEEP）；~3. negative pressure extubation"
219640177|NCT00453531|DRUG|Acetylcholine|
219640178|NCT03976167|DEVICE|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
219640179|NCT03976167|DEVICE|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
219640180|NCT00006617|DRUG|Abacavir sulfate|
219640181|NCT00006617|DRUG|Amprenavir|
219640182|NCT00006617|DRUG|Lamivudine|
219640183|NCT00006617|DRUG|Zidovudine|
219640184|NCT06623747|BEHAVIORAL|Diet|15 kcal per kg fat-free mass
219640185|NCT06623747|BEHAVIORAL|Diet|45 kcal per kg fat-free mass
219640186|NCT02118649|BEHAVIORAL|Game|
219640187|NCT03490838|DRUG|177Lu-PSMA-R2|radio-ligand therapy
219640188|NCT05906550|DIAGNOSTIC_TEST|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
218956362|NCT02162576|DEVICE|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
218956363|NCT02593045|BIOLOGICAL|IPH4102|
219640189|NCT05906550|DIAGNOSTIC_TEST|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
219640190|NCT05097534|OTHER|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
219640191|NCT05097534|OTHER|Standard of Care|Standard of Care for patients with type 2 diabetes
219640192|NCT06204315|RADIATION|Stereotactic Radiosurgery|Given by RTx
219640193|NCT05242458|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
219640194|NCT02087826|OTHER|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
219640195|NCT02087826|DRUG|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
219640196|NCT05789888|GENETIC|MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.|As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.
219640197|NCT05789888|GENETIC|SCD gene variability in obesity and normal body weight patients.|As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.
219640198|NCT05789888|OTHER|Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.|As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
219640199|NCT03060174|OTHER|monitoring and non-medical prophylaxis of delirium|
219640200|NCT05287919|OTHER|Patients received the standard physical therapy (SPT) programme (passive mobilization) twice a day.|All participants have received standard physical therapy (SPT) sessions based on a passive range of motion mobilization protocol for the lower limbs. It consisted of a bilateral series of 10 repetitions of hip flexion, knee flexion and extension, and ankle flexion and extension. The procedure was performed twice a day: a morning (between 8am - 12pm) and an afternoon session (between 2pm - 6pm).
219207316|NCT05817370|BEHAVIORAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
219207317|NCT03462147|DEVICE|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
219207318|NCT04899778|DRUG|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
219207319|NCT05799053|DRUG|Small intestinal release peppermint oil|Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.
219207320|NCT05799053|DRUG|Peppermint sweets|Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.
219640201|NCT05287919|OTHER|Patients received the low-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands). The low-frequency protocol consisted of 100 Hz and 400 ms width pulses, delivered in trains of 5 s ON (ramp-up time: 1 s, plateau: 3 s, ramp-down time: 1 s) and 10 s OFF. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
219058552|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
219058553|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
219058554|NCT01807273|OTHER|Walking test|
219058555|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
219058556|NCT03167294|DEVICE|AquaBeam System|Aquablation
219058557|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
219058558|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
219207321|NCT05799053|DRUG|Placebo|Capsule containing microcrystalline cellulose
219207322|NCT06798467|OTHER|Endodontic sealer|endodontic sealer is a material used in root canal therapy to fill the microscopic spaces between the root canal filling material (typically gutta-percha) and the walls of the root canal. Its primary function is to create a tight seal that prevents the ingress of bacteria and fluids into the root canal system, helping to prevent reinfection and promoting the healing of periapical tissues. Endodontic sealers also help to ensure that the root canal filling reaches all parts of the canal, especially in complex or irregularly shaped anatomies.
219207323|NCT06798467|OTHER|post obturation pain|Unpleasant sensation of any degree of pain after root canal treatment.
219207324|NCT00149591|PROCEDURE|coronary balloon-angioplasty with stenting|
219058559|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
219640202|NCT05287919|OTHER|Patients received the medium-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands).The medium-frequency protocol had similar parameters, but a carrier frequency of 2500 Hz and burst frequency of 100 Hz. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
219640203|NCT01435018|DRUG|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade \>= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade \>= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
219640204|NCT01435018|DRUG|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
219640205|NCT01435018|DRUG|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
218956364|NCT03403387|DIETARY_SUPPLEMENT|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
218956365|NCT03403387|OTHER|Placebo|Avicel (cellulose) and bentonite powder
218956366|NCT04510636|DRUG|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219058560|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
219058561|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
219058562|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
219058563|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
219058564|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
219058565|NCT03619733|OTHER|no intervention|this is an observational study. no intervention is planned
219058566|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
218956367|NCT04510636|DRUG|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
218956368|NCT01574001|BEHAVIORAL|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
219207325|NCT06242366|BEHAVIORAL|Intervention group|"Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management."
219207326|NCT05513742|DRUG|CTX-009|IV infusion administered on day 1 and 15 of every 28-day cycle
219207327|NCT00003222|BIOLOGICAL|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
218956369|NCT01574001|BEHAVIORAL|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
218956370|NCT01574001|BEHAVIORAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
218956371|NCT05054842|DRUG|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
218956372|NCT05054842|DRUG|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
218956373|NCT01251471|DRUG|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
218956374|NCT04686045|OTHER|observational study|observational study
218956375|NCT04396054|DEVICE|Lag Screws|Method of internal fixation
219058567|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
219640206|NCT01435018|DRUG|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
219640207|NCT06502795|OTHER|Protected Range Quadriceps Strengthening group|"Warm-up: Start with 5 minutes of stationary biking. Then, proceed with two sets of 30-second dynamic stretches targeting the quadriceps, hamstrings, calf muscles, and adductors, followed by static stretching for the abductors.~Strengthening: Complete 3 sets of 8-12 repetitions for each exercise, aiming for a perceived effort level on the Borg scale between 60% and 80%. Increase the load by 2%-10% when the patient can perform 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~For the Leg Extension Machine, maintain a range of motion between 90 to 45 degrees. During Squats and Bulgarian Squats, aim for a range of motion between 0 to 45 degrees."
218956376|NCT04396054|DEVICE|double Y-shaped plates|Method of internal fixation
218956377|NCT05807061|BEHAVIORAL|EmBARK|The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
218956378|NCT05807061|BEHAVIORAL|Popular guidance|The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
219207328|NCT00003222|BIOLOGICAL|gp100 antigen|
218956379|NCT05807061|BEHAVIORAL|Practice first|Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
218956380|NCT02433158|DRUG|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
218956381|NCT02417948|OTHER|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
218956382|NCT02417948|OTHER|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
218956383|NCT04872530|DIETARY_SUPPLEMENT|Pea-protein concentrate|Pea-protein concentrate
219058568|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
219058569|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
219207329|NCT00003222|BIOLOGICAL|incomplete Freund's adjuvant|
218956384|NCT04872530|DIETARY_SUPPLEMENT|Fava-bean protein concentrate|Fava-bean protein concentrate
219207330|NCT00003222|BIOLOGICAL|sargramostim|
219207331|NCT00003222|BIOLOGICAL|tetanus peptide melanoma vaccine|
219207332|NCT00003222|BIOLOGICAL|tyrosinase peptide|
219207333|NCT03898596|DIAGNOSTIC_TEST|ECG|An ECG collects superficial readings of heart activity
219207334|NCT04736485|DRUG|perioperative treatment|FLOT + Spartalizumab
218956385|NCT04872530|DIETARY_SUPPLEMENT|Chickpea protein concentrate|Chickpea protein concentrate
218956386|NCT04872530|DIETARY_SUPPLEMENT|Red lentil protein concentrate|Red lentil protein concentrate
219207335|NCT06564909|DRUG|L-Carnitine|L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)
219207336|NCT06564909|DRUG|The standard care for the management of myocardial infarction post PCI|include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
219207337|NCT06561009|DRUG|Anti-BAFFR CART|Anti-BAFFR CART
219207338|NCT05072093|BEHAVIORAL|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
219367290|NCT06021249|PROCEDURE|Traditional lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. Ventilator-controlled recruitment manoeuvre；~4. CPAP；~5. negative pressure extubation"
218956387|NCT04872530|DIETARY_SUPPLEMENT|Non-essential amino acid blend|Non-essential amino acid blend
218956388|NCT04872530|DIETARY_SUPPLEMENT|Whey protein concentrate|Whey protein concentrate
218956389|NCT05393258|RADIATION|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
218956390|NCT03579901|DEVICE|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
218956391|NCT04817852|OTHER|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
218956392|NCT05302661|BEHAVIORAL|re-education|Contact patients by phone or wechat and guide them
218956393|NCT04592263|OTHER|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
218956394|NCT04148872|OTHER|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
218956395|NCT04148872|DRUG|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
219058570|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
219058571|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
219058572|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
219058573|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
219058574|NCT02708745|BEHAVIORAL|Intervention Survey|
219058575|NCT02708745|BEHAVIORAL|Placebo Survey|
219058576|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
219058577|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
219058578|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
219058579|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
219058580|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
219058581|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
219058582|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
219058583|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
218956396|NCT04148872|OTHER|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
219058584|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
219207339|NCT05072093|DRUG|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
218956397|NCT02069340|DRUG|zoledronic acid|Given IV
219058585|NCT06530316|DRUG|RET Inhibitor|RET inhibitors for neoadjuvant treatment
219058586|NCT06530316|PROCEDURE|Surgery|Operable patients receive surgery after neoadjuvant therapy
219058587|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
219058588|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
218956398|NCT02069340|OTHER|pharmacological study|Correlative studies
218956399|NCT04093063|OTHER|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
218956400|NCT04721067|DEVICE|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
219207340|NCT05072093|DRUG|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
219207341|NCT05072093|DRUG|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
219207342|NCT06466330|DEVICE|microparticles|inert microparticles
219207343|NCT06466330|PROCEDURE|embolization|Injection of inert microparticles in neovessels using a microcatheter
219207344|NCT06466330|PROCEDURE|sham embolization|injection of saline solution
219207345|NCT05877898|BEHAVIORAL|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
219207346|NCT05877898|BEHAVIORAL|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
219207347|NCT06160102|OTHER|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
219207348|NCT06552091|OTHER|self-hypnosis sessions|3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
219207349|NCT06648135|PROCEDURE|Immediate implants with bone grafts|Immediate implants with bone grafts
219640208|NCT06502795|OTHER|Patient-Guided Range Quadriceps Strengthening group|"Warm-up: 5 minutes of stationary biking. Next, perform two sets of 30-second stretches for the quadriceps, hamstrings, calf muscles, adductors and abductors hip.~Strengthening: Patients will complete 3 sets of 8 to 12 repetitions for each exercise, aiming for a perceived effort level of 60% to 80% on the Borg scale. Load will be increased by 2% to 10% when patients can complete 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~Quadriceps strengthening will be performed at the patient's maximum range guided by symptoms, with pain intensity capped at 5 points on the NPRS. The patient-guided range will be adjusted based on pain intensity, comfort, and patient response, using a shared decision-making approach. The goal is to maintain exercises at the maximum possible range of motion.~For the Leg Extension Machine, Squats, and Bulgarian Squats, the range of motion will be guided by the patient's pain tolerance."
219640209|NCT02926586|DRUG|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
219640210|NCT02926586|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
218956401|NCT04721067|BEHAVIORAL|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
218956402|NCT05575921|DIAGNOSTIC_TEST|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
218956403|NCT04612608|PROCEDURE|upright bed|moving the bed into an upright position
218956404|NCT04434170|DRUG|Sacubitril-Valsartan|outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
218956405|NCT02233478|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice alone
218956406|NCT02233478|DIETARY_SUPPLEMENT|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
218956407|NCT02233478|DIETARY_SUPPLEMENT|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
218956408|NCT03972891|OTHER|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques"
218956409|NCT01346995|OTHER|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
218956410|NCT01346995|OTHER|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
218956411|NCT02622997|OTHER|Cervico-vaginal self-sample taken with first flocked swab|Cervico-vaginal self-sample taken with first flocked swab
218956412|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a second flocked swab|Cervico-vaginal self-sample taken with a second flocked swab
218956413|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a HerSwab device|Cervico-vaginal self-sample taken with a HerSwab device
218956414|NCT03351101|DEVICE|Senofilcon C|Senofilcon C Contact Lens
218956415|NCT03351101|DEVICE|Samfilcon A|Samfilcon A Contact Lens
218956416|NCT00423787|BIOLOGICAL|Ragweed MATA MPL|"4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml"
219058589|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
219058590|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
219058591|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
219058592|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
219058593|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
219058594|NCT03830671|DRUG|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
219058595|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
219058596|NCT04719585|DRUG|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
219058597|NCT02211989|DRUG|BI 14332 CL|
219058598|NCT02211989|DRUG|Placebo|
219058599|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
219058600|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
219058601|NCT02540239|DRUG|2L PEG|
219058602|NCT02540239|DRUG|2L PEG+simethicone|
219058603|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
219058604|NCT02533882|BEHAVIORAL|Movement to Music|
219058605|NCT02533882|BEHAVIORAL|Adapted Yoga|
219058606|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
219207350|NCT06648135|PROCEDURE|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
219207351|NCT05327270|DRUG|Nivolumab|Given by IT
219207352|NCT03510104|DRUG|MRX-2843|MRX-2843 capsules
219207353|NCT05386615|DEVICE|Body System - Functional|MR-Guided Focused Ultrasound
219207354|NCT06549296|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
219207355|NCT03725670|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 transduction units/ml which carry a normal ARSA gene
219207356|NCT03553810|DRUG|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
219207357|NCT03553810|DRUG|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
219207358|NCT05089084|DRUG|Plozasiran|ARO-APOC3 injection
219640211|NCT06684366|DRUG|Statins (atorvastatin or simvastatin)|A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone
219640212|NCT00137007|DRUG|Azithromycin|
219640213|NCT00137007|DRUG|Ampicillin/sulbactam|
219058607|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
219058608|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
219058609|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
219207359|NCT05089084|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219058610|NCT00411307|DRUG|OROS hydromorphone HCI|
219058611|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
219207360|NCT06598371|DRUG|Cyclophosphamide|Given by IV
219207361|NCT06598371|DRUG|Fludarabine|Given by IV
219640214|NCT02534077|DIETARY_SUPPLEMENT|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
219640215|NCT02534077|DRUG|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
218956417|NCT06134531|DRUG|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
218956418|NCT01947907|DRUG|ACP-001|Once weekly subcutaneous injection
218956419|NCT01947907|DRUG|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
218956420|NCT00604214|DRUG|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
218956421|NCT00604214|DRUG|Placebo|0.9% sodium chloride, intravenous, 96 hours
218956422|NCT04355611|OTHER|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
218956423|NCT05780151|OTHER|Methodological intervention|All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
218956424|NCT05780151|DRUG|Toujeo|All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
218956425|NCT05844709|OTHER|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
218956426|NCT05841901|DRUG|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
218956427|NCT05841901|DRUG|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
219058612|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
219058613|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
219058614|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
219058615|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
219207362|NCT06598371|DRUG|KSQ-004EX|Given by IV
218956428|NCT05553067|GENETIC|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
218956429|NCT01908920|OTHER|Osteopathic manipulative treatment|
218956430|NCT01908920|OTHER|SHAM|
218956431|NCT01908920|OTHER|CONTROL|
218956432|NCT05376943|DRUG|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
218956433|NCT05588557|DRUG|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
219058616|NCT05239091|DRUG|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
219058617|NCT05239091|DRUG|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
219058618|NCT04076228|DRUG|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
219058619|NCT01385059|DRUG|axitinib|Given PO
219058620|NCT01385059|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
219058621|NCT01385059|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219058622|NCT01385059|OTHER|laboratory biomarker analysis|Correlative studies
219058623|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
219058624|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
219058625|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
219058626|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
219058627|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
219058628|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
219207363|NCT06598371|DRUG|Interleukin-2|Given by IV
219367291|NCT06021249|PROCEDURE|Innovative lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. positive pressure extubation；~4. postoperative breathing training"
219058629|NCT03056690|DRUG|ASP0819|Oral capsule
219058630|NCT03056690|DRUG|Placebo|Oral capsule
219058631|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
218956434|NCT05588557|DRUG|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
219640216|NCT02534077|DRUG|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
219640217|NCT00272207|DRUG|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
219058632|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
219640218|NCT02177903|DEVICE|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
219640219|NCT06090903|PROCEDURE|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
219640220|NCT06090903|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219640221|NCT06090903|OTHER|Medical Chart Review|Review Medical Chart
219640222|NCT00769067|DRUG|Erlotinib|Continuous oral dosing at 150 mg daily.
219640223|NCT00769067|DRUG|PF-00299804|Continuous oral dosing at 45mg daily
219640224|NCT06292598|OTHER|Blood sample|Sample taken to test plasma permeability markers
219640225|NCT06292598|OTHER|Stool sample|Sample taken to test microbial diversity and composition
219640226|NCT06292598|OTHER|CSF sample|Sample taken to test orexin level
219640227|NCT02114944|DEVICE|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
219640228|NCT02114944|DEVICE|CPAP|Patient treated, as per attending physician's decision, with CPAP
219640229|NCT02114944|DEVICE|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
219640230|NCT02114944|DEVICE|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
219058633|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
219640231|NCT06584422|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
219640232|NCT06584422|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
219640233|NCT03073577|DRUG|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
219640234|NCT04810494|DRUG|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
219640235|NCT04810494|DRUG|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
219640236|NCT04069832|BEHAVIORAL|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
219058634|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
219058635|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
219058636|NCT03895853|OTHER|Best Practice|Receive standard of care
219058637|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
219367292|NCT06021249|PROCEDURE|Lung-protective ventilation|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；"
219640237|NCT05319873|DRUG|Carboplatin|Given IV
219640238|NCT05319873|DRUG|Docetaxel|Given IV
219640239|NCT05319873|DRUG|Fulvestrant|Given SC
219640240|NCT05319873|BIOLOGICAL|Pertuzumab|Given IV
219640241|NCT05319873|OTHER|Quality-of-Life Assessment|Ancillary Studies
219640242|NCT05319873|DRUG|Ribociclib|Given PO
219640243|NCT05319873|BIOLOGICAL|Trastuzumab|Given IV
218956435|NCT06504693|DIAGNOSTIC_TEST|CBC|diagnostic tests for iron status
218956436|NCT02894008|DRUG|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
218956437|NCT05625503|DRUG|Verapamil|All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.
218956438|NCT05625503|DRUG|Nicardipine|Calcium channel blocker
218956439|NCT03564730|PROCEDURE|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
219640244|NCT05319873|DRUG|Tucatinib|Given PO
218956440|NCT03564730|PROCEDURE|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
218956441|NCT02439528|GENETIC|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
219058638|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
219058639|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
219640245|NCT03806855|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
219640246|NCT03806933|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
219640247|NCT06124950|BEHAVIORAL|Gender-transformative intervention|"A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention.~Five 60-minutes intervention sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 5 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) before oocyte retrieval; and (4) 2 weeks after the embryo transfer; and (5) 28-30 days after the embryo transfer.~The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality."
219640248|NCT02490046|DIETARY_SUPPLEMENT|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
219640249|NCT04108468|DRUG|Golimumab|Simponi
219640250|NCT04108468|DRUG|Methotrexate|Methotrexate
219640251|NCT03316014|OTHER|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
218956442|NCT02764424|DEVICE|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
218956443|NCT04883411|DEVICE|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
218956444|NCT02016547|PROCEDURE|abciximab IV and thrombectomy|
218956445|NCT02016547|DRUG|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
219640252|NCT05197608|OTHER|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
219640253|NCT05197608|OTHER|Tailored list of resources|Control group will be provided a tailored list of resources
219640254|NCT03625466|DRUG|LUM/IVA|FDC tablets or granules for oral administration.
219640255|NCT03625466|DRUG|LUM/IVA|FDC granules for oral administration.
219640256|NCT03625466|DRUG|Placebo|Placebo matched to LUM/IVA for oral administration.
218956446|NCT05060523|DRUG|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
219058640|NCT05215574|DRUG|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
219640257|NCT01957436|DRUG|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
219640258|NCT01957436|RADIATION|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
219640259|NCT01957436|OTHER|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
219640260|NCT01957436|DRUG|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
219640261|NCT02841670|DEVICE|InFo - Instant Focus (c) lens implantation|
219640262|NCT04082572|BIOLOGICAL|Pembrolizumab|Given IV
219640263|NCT04662281|DRUG|Placebo|LX9211 matching-placebo, tablets will be administered orally.
219640264|NCT04662281|DRUG|LX9211|LX9211, 200 mg, tablets will be administered orally.
219640265|NCT03427099|BEHAVIORAL|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
219640266|NCT03427099|BEHAVIORAL|Control group|usual care
219640267|NCT05908032|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
219640268|NCT05908032|BIOLOGICAL|Placebo|Placebo
219640269|NCT00082446|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
219640270|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.
219640271|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.
219640272|NCT00082446|OTHER|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
219640273|NCT00082446|OTHER|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
218956447|NCT05060523|DRUG|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
218956448|NCT05060523|OTHER|Placebo|Placebo of Midodrine
218956449|NCT02374047|DRUG|CAT-2054|
218956450|NCT02374047|DRUG|Placebo|
219058641|NCT05215574|DRUG|NGM831 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."
219640274|NCT06217237|DIAGNOSTIC_TEST|AD FDT DBL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
219640275|NCT02708537|BIOLOGICAL|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
219640276|NCT02469688|DRUG|ASP4070|intramuscular or intradermal
219640277|NCT02469688|DRUG|Placebo|intramuscular or intradermal
219640278|NCT01421628|OTHER|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
219640279|NCT02819752|DRUG|Pembrolizumab|Pembrolizumab
218956451|NCT02374047|DRUG|CAT-2054-C|
219640280|NCT02819752|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
219640281|NCT02819752|DRUG|Chemotherapy|Chemotherapy - Standard Treatment
219640282|NCT06462352|DEVICE|Navicam SB capsule|Exploration of the small bowel by Navicam SB endoscopic capsule.
218956452|NCT02374047|DRUG|Atorvastatin|
218956453|NCT05298878|OTHER|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
219058642|NCT05215574|DRUG|NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."
219058643|NCT05383170|DRUG|CyPep-1|Intratumoral injection
219058644|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
219640283|NCT06462352|DEVICE|Pillcam SB3|Exploration of the small bowel by Pillcam SB3 endoscopic capsule.
218956454|NCT06326307|BEHAVIORAL|Tell Show and Do Guidance|In this technique, the dentist tells explains the procedure using the Tell show and do method.
218956455|NCT06326307|BEHAVIORAL|Puppet Guidance|In this technique, the dentist using the puppet to explains the procedure.
218956456|NCT03697174|OTHER|200 ppb ozone group|The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
219640284|NCT04950270|BIOLOGICAL|Blood copeptin monitoring|Blood copeptin monitoring during the first 6 days of ICU stay with PRES
219640285|NCT04950270|OTHER|phone interview|Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
219640286|NCT02718989|DEVICE|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219640287|NCT02718989|DEVICE|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219640288|NCT02718989|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219640289|NCT05902273|DIAGNOSTIC_TEST|hemodynamic monitoring|Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
218956457|NCT03697174|OTHER|0 ppb ozone group|The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
218956458|NCT02342093|DRUG|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
218956459|NCT02342093|DRUG|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
218956460|NCT01985854|DRUG|Propofol|
219058645|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
219058646|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
219058647|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
218956461|NCT01985854|DRUG|Desflurane|
218956462|NCT02368301|DRUG|Elotuzumab in combination with Lenalidomide and Dexamethasone|Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
218956463|NCT06273371|OTHER|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
218956464|NCT05634356|BEHAVIORAL|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
218956465|NCT00879944|OTHER|Blood pressure|Blood pressure will be measured once while patient is seated
218956466|NCT00879944|OTHER|Height|Height will be measured in centimeters at the time of enrollment
218956467|NCT00879944|OTHER|Weight|Weight will be measured in kilograms at enrollment
218956468|NCT00879944|OTHER|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
218956469|NCT00879944|OTHER|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
218956470|NCT01911338|DEVICE|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
218956471|NCT01911338|DEVICE|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
218956472|NCT03076229|BEHAVIORAL|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
219058648|NCT01852890|RADIATION|Radiation therapy|
219058649|NCT04231630|OTHER|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
219058650|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
219058651|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
219058652|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
218956473|NCT06354556|DRUG|HRS-1893 tablet|HRS-1893 tablet single dose
218956474|NCT06354556|DRUG|Verapamil tablet|Verapamil tablet 80 mg tid
218956475|NCT04864860|DIETARY_SUPPLEMENT|brown seaweed (ecklonia cava)|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
218956476|NCT04867031|DIETARY_SUPPLEMENT|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.
219640290|NCT05902273|DIAGNOSTIC_TEST|resistive index|We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
218956477|NCT04867031|DIETARY_SUPPLEMENT|Fish|One portion of cod (approx. 130g), providing \~140µg of iodine.
218956478|NCT04867031|DIETARY_SUPPLEMENT|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
218956479|NCT05886985|DRUG|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
218956480|NCT00130442|DRUG|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
219640291|NCT05902273|DIAGNOSTIC_TEST|Pleth variability index|During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
218956481|NCT00130442|DRUG|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
218956482|NCT02197455|DRUG|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
218956483|NCT00814333|DRUG|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
218956484|NCT00814333|DRUG|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
218956485|NCT00627614|OTHER|breast imaging study|"1\. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
218956486|NCT02233946|BEHAVIORAL|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
218956487|NCT04412993|OTHER|withdraw blood samples|withdraw blood sample from gorup O donors
218956488|NCT03325660|OTHER|whole body vibration|pelvic floor exercises
218956489|NCT03127800|DRUG|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
218956490|NCT00002779|DRUG|fludarabine phosphate|
218956491|NCT00002779|DRUG|octreotide acetate|
218956492|NCT05148520|BEHAVIORAL|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~\- arrange for follow-up."
218956493|NCT05843383|DRUG|Ciprofol|Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
218956494|NCT05843383|DRUG|Propofol|Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil
218956495|NCT02531243|BEHAVIORAL|CALMS|Family Therapy; Multi-user Biofeedback Videogames
219058653|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
219058654|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
219640292|NCT05225844|DRUG|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
218956496|NCT01283243|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
219640293|NCT05225844|DRUG|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
218956497|NCT06295978|DIAGNOSTIC_TEST|Biochemical marker assays|DOSAGE BIOMARKERS
218956498|NCT01407003|DRUG|LIK066|Participants will receive a single or multiple doses of LIK066
218956499|NCT01407003|DRUG|Placebo|Participants will receive a single or multiple doses of a matching placebo
218956500|NCT01047969|DRUG|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
218956501|NCT01047969|PROCEDURE|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
218956502|NCT06400771|DRUG|DNP007|DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
218956503|NCT00894374|DRUG|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
218956504|NCT00894374|DRUG|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
218956505|NCT00726141|BEHAVIORAL|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
219058655|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
218956506|NCT06520540|DRUG|HDM1002 100 mg QD 12weeks|Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
219058656|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
219058657|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
219640294|NCT01058993|DRUG|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
219640295|NCT00809471|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
219640296|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
219058658|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
219058659|NCT02809495|OTHER|use of app in smartphone|
219640297|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
219640298|NCT02967328|OTHER|RP% Measurement by FCM as a Diagnostic Test for ITP|
218956507|NCT06520540|DRUG|HDM1002 200 mg QD 12weeks|Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
219058660|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
218956508|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 2W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
218956509|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 3W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
219058661|NCT02543346|DRUG|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
218956510|NCT06520540|DEVICE|Placebo|Placebo
218956511|NCT02927067|DRUG|Maribavir|Participants will receive 400 mg of maribavir BID orally.
218956512|NCT02927067|DRUG|Valganciclovir|Participants will receive valganciclovir tablets orally.
219058662|NCT02543346|OTHER|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
219058663|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
219058664|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
219058665|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219058666|NCT01767116|DRUG|Ribavirin|Capsule
219058667|NCT01767116|DRUG|Placebo for ribavirin|Capsule
219058668|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
219058669|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
219640299|NCT02993328|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
219640300|NCT02993328|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
219640301|NCT00849511|DRUG|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
219640302|NCT00831311|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
218956513|NCT02927067|OTHER|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
218956514|NCT01695668|DRUG|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
218956515|NCT01695668|DRUG|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
218956516|NCT04552262|DRUG|BAY2327949|Single dose of 90 mg BAY2327949
218956517|NCT04552262|DRUG|Placebo|Single dose of placebo to BAY 2327949
219058670|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
219640303|NCT00831311|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
219640304|NCT05856383|DRUG|Inetetamab Combined With Pyrotinib and Vinorelbine|Inetetamab Combined With Pyrotinib and Vinorelbine
219640305|NCT03620123|DRUG|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
219640306|NCT03620123|DRUG|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
219640307|NCT05557643|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
218956518|NCT04581447|DRUG|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
219058671|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
219058672|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
219058673|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
219058674|NCT03732287|DEVICE|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
219058675|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
219058676|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
219058677|NCT04015193|PROCEDURE|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
219058678|NCT01242527|DRUG|placebo|4 capsules (1g) daily for 12 weeks
219640308|NCT05557643|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
219640309|NCT05231772|DRUG|Saccharomyces Boulardii Probiotic Supplement|Probiotic yeast
219640310|NCT05231772|DRUG|Placebo|Placebo
219640311|NCT01713114|OTHER|Acute measures of satiety and food intake at next meal|
219640312|NCT02180139|DEVICE|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
219640313|NCT01172223|DRUG|Myocet (Non-pegylated liposomal doxorubicin (NPLD))|60 mg/m\^2 i.v. day 1 q3 weeks
219640314|NCT01172223|DRUG|Paclitaxel|175 mg/m\^2 i.v. day 1 q3 weeks
219640315|NCT01172223|DRUG|Lapatinib (GW572016, Tykerb)|750-1500 mg/d orally daily until the day of the definitive surgery
219640316|NCT04845919|DRUG|5-Aminolevulinic Acid|"SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System."
219640317|NCT06056960|OTHER|Tailored Physical Activity|"The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem."
219640318|NCT04713254|DRUG|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
219640319|NCT04713254|OTHER|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
219640320|NCT04713254|OTHER|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
219640321|NCT04713254|OTHER|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
219640322|NCT06565026|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
218956519|NCT04581447|OTHER|Standard Care|Standard Care
219058679|NCT01242527|DRUG|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
219058680|NCT01242527|DRUG|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
219640323|NCT04996602|DRUG|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
219640324|NCT01868438|DRUG|Pyronaridine-artesunate granules|
219640325|NCT01868438|DRUG|Pyronaridine-artesunate tablets|
219640326|NCT05667116|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
218956520|NCT04581447|DIETARY_SUPPLEMENT|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
218956521|NCT05154968|DRUG|Sodium chloride|Administered SC infusion.
218956522|NCT05154968|DRUG|Citrate buffer|Administered SC infusion.
218956523|NCT05154968|DRUG|Mannitol|Administered SC infusion.
218956524|NCT05154968|DEVICE|Prefilled Autoinjector|Used to administer the drug through SC infusion.
219058681|NCT01242527|DRUG|omefas|4 capsules (1g)daily for 12 weeks
219058682|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
219058683|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
219058684|NCT04345848|DRUG|Enoxaparin|Two different doses of anticoagulation
219640327|NCT03260244|PROCEDURE|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
218956525|NCT03540498|DIETARY_SUPPLEMENT|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
219640328|NCT06665867|OTHER|Video consultation|Participants will have their follow-up consultation with the physician via video. The consultation takes place via the participant's/parent's own device.
219640329|NCT06665867|OTHER|Face-to-face consultation|The follow-up consultation with the physician will take place at the hospital.
219640330|NCT05076032|DRUG|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
219640331|NCT05076032|DRUG|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
219640332|NCT00801203|DRUG|IRCT|Up to two administrations of the IRCT during a single cough testing session
219640333|NCT06259903|DRUG|MD-18|Subcutaneous Administration of MD-18 in Healthy Subjects.
219640334|NCT03526536|DRUG|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
219640335|NCT03403296|GENETIC|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
219640336|NCT02364323|BEHAVIORAL|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
219640337|NCT02364323|OTHER|Normal usual care|General education on diabetes and diabetic complications
219640338|NCT02729363|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
219640339|NCT02729363|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
219640340|NCT02735525|DEVICE|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
219640341|NCT04286581|DEVICE|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
219640342|NCT04286581|DEVICE|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
219640343|NCT03932175|BEHAVIORAL|Intervention group|Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
219640344|NCT03528369|DRUG|CGS-200-1|CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
219640345|NCT03528369|DRUG|CGS-200-5|CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
219640346|NCT03528369|DRUG|CGS-200 Vehicle|CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
219640347|NCT00004875|DRUG|enoxaparin|
218956526|NCT03540498|DIETARY_SUPPLEMENT|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
218956527|NCT05834855|DRUG|Rituximab|Treatment with rituximab
218956528|NCT02677727|OTHER|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
218956529|NCT03643614|PROCEDURE|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
218956530|NCT04146298|DRUG|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
219640348|NCT00004875|DRUG|heparin|
219640349|NCT01872598|DRUG|Masitinib|
219640350|NCT01872598|DRUG|Placebo|
219640351|NCT01872598|DRUG|Standard of care|stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
219640352|NCT01159366|PROCEDURE|percutaneous coronary intervention|early timing
219640353|NCT06666374|BEHAVIORAL|OHL program|This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding. The program comprised seven steps designed to guide patients through key aspects of oral health care, enabling them to progressively build their skills and confidence. These steps included personalized education on oral health, hands-on practice of proper oral hygiene techniques, self-assessment exercises, and strategies for overcoming barriers to good oral health.
218956531|NCT04146298|DRUG|Fludarabine|Fludarabine will be administered prior to cell infusion.
219640354|NCT06666374|BEHAVIORAL|Traditional program|Program primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
219640355|NCT00757458|DRUG|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
218956532|NCT04146298|BIOLOGICAL|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
219640356|NCT00757458|OTHER|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
219640357|NCT00757458|OTHER|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
219640358|NCT00757458|OTHER|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
219640359|NCT00697086|DRUG|Dronedarone (SR33589)|
219640360|NCT00697086|DRUG|Placebo|
219640361|NCT06666868|BEHAVIORAL|Sustained CARD|This group is using CARD for the 2nd year in a row in participating pharmacies as the vaccination delivery framework (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter vaccination season).
219640362|NCT06666868|BEHAVIORAL|First-time CARD|CARD is being used for the 1st time in participating pharmacies as the vaccination delivery framework (2024-2025 fall/winter vaccination season).
219640363|NCT03555565|DRUG|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
219640364|NCT04804748|OTHER|No intervention|no intervention
218956533|NCT04146298|DRUG|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
218956534|NCT01921088|OTHER|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
218956535|NCT01921088|BEHAVIORAL|Ambulatory Training|Subjects are provided with an ambulatory training.
218956536|NCT01727700|DRUG|Aripiprazole|Once-daily, tablet
218956537|NCT01727700|DRUG|Placebo|
218956538|NCT00320723|DRUG|bupropion, transdermal nicotine patch|
218956539|NCT01780532|PROCEDURE|Photoacoustic Imaging (PAI)|Standard of Care
218956540|NCT01631656|DRUG|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
218956541|NCT01631656|DEVICE|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
218956542|NCT04551391|OTHER|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
218956543|NCT00212940|BEHAVIORAL|Supportive Therapy for Adherence to ART (behavior)|
218956544|NCT02404532|DEVICE|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
218956545|NCT01757691|DRUG|Fingolimod 0.5mg/daily|
218956546|NCT01757691|DRUG|Placebo|
218956547|NCT03923478|DRUG|ABI-M201|Active Treatment
218956548|NCT03923478|DRUG|Placebo|Control Treatment
218956549|NCT04518202|DRUG|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
218956550|NCT04518202|DRUG|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
218956551|NCT01706679|DRUG|ATX-101 (10 mg/ml)|
218956552|NCT01706679|DRUG|ATX-101 (20 mg/ml)|
218956553|NCT01706679|DRUG|Moxifloxacin (400 mg)|
218956554|NCT01706679|DRUG|Placebo vehicle (PBS)|
218956555|NCT03603366|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
219058685|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
219640365|NCT00394836|DRUG|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
219640366|NCT00394836|DRUG|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
219640367|NCT02593526|DRUG|Bumetanide|Diuretic
219640368|NCT02593526|OTHER|Cool Dialysate|Cool dialysate (35°C)
219640369|NCT00977704|DEVICE|Restylane and Perlane|
219640370|NCT06967883|DIAGNOSTIC_TEST|Ultrasonographic assessment of Cervical Multifidus and Longus Colli Muscle Thickness, Postural Balance and Limit of Stability using the balance platform,Cervical Flexion and Extension Strength|"Intervention Description~Participants in both groups will undergo ultrasonographic measurement of cervical multifidus and longus colli muscle thickness. Postural sway, Limits of Stability (LOS), and a 6-direction balance test (ABC-6) will be assessed using the HUR SmartBalance BTG4 platform under stable and unstable conditions with eyes open and closed. Functional balance will be evaluated with the Berg Balance Scale (BBS), Timed Up and Go (TUG) Test, and Single-Leg Stance Test. Isometric cervical flexion and extension strength will be measured bilaterally using a hand-held dynamometer. Ankylosing Spondylitis patients will additionally complete BASFI, BASMI, BASDAI, and ASQoL questionnaires."
219640371|NCT06968130|BEHAVIORAL|routine hemodialysis|Patients will receive routine hemodialysis without any additional intervention. The same scales will be administered at baseline and during two follow-ups one week apart.
219640372|NCT06968130|BEHAVIORAL|Breathing Exercise|Patients will perform deep breathing exercises guided by the researcher: 1 minute normal breathing, 3 minutes chest breathing, 3 minutes diaphragmatic breathing, 2 minutes pursed-lip breathing, and 1 minute normal breathing. Exercises will be conducted for 10 minutes before and after hemodialysis, repeated in two follow-up sessions one week apart, with post-session scale completion.
219640373|NCT06968130|DEVICE|Virtual Reality|After completing the initial scales, patients will watch a 20-minute nature simulation via virtual reality glasses before and after hemodialysis. This will be repeated in two follow-up sessions one week apart, followed by scale administration.
218956556|NCT02484859|DRUG|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
218956557|NCT02484859|DRUG|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
218956558|NCT02484859|DRUG|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
218956559|NCT02054481|DRUG|BI 655066|Medium dose
218956560|NCT02054481|DRUG|BI 655066|High dose
218956561|NCT02054481|DRUG|Ustekinumab|
219640374|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group require norepinephrine (\>5 drops/hour of 4 mg/50 mL) to maintain MAP ≥ 65 mmHg.
218956562|NCT02054481|DRUG|BI 655066|Low dose
219640375|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group maintain MAP ≥ 65 mmHg without norepinephrine infusion.
218956563|NCT01273376|DRUG|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
218956564|NCT05323565|DRUG|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
218956565|NCT04356365|OTHER|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
218956566|NCT02933580|DRUG|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
218956567|NCT02933580|OTHER|Placebo|Participants will receive matching placebo tablets on Day 1.
218956568|NCT00731432|DRUG|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
218956569|NCT00731432|DRUG|Placebo Patch|Identical in shape and texture to treatment patch
218956570|NCT05930704|DRUG|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
218956571|NCT05930704|DRUG|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
218956572|NCT04213573|DRUG|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
218956573|NCT04213573|DRUG|MI Varnish|topical fluoride varnish with calcium and phosphate
218956574|NCT00882973|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
218956575|NCT03351985|DEVICE|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
218956576|NCT01612728|OTHER|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
218956577|NCT01612728|DRUG|Women with Arthralgia|
218956578|NCT03911310|DIAGNOSTIC_TEST|[18F]PSMA-11|\[18F\]PSMA-11 PET/CT
218956579|NCT03911310|DIAGNOSTIC_TEST|[68Ga]PSMA-11|\[68Ga\]PSMA-11 PET/CT
218956580|NCT02140632|PROCEDURE|Local methylprednisolone acetate and lidnocaine injection|
218956581|NCT02140632|DEVICE|wrist splinting|
218956582|NCT00844168|DRUG|sorafenib tosylate|Given orally
218956583|NCT00844168|OTHER|laboratory biomarker analysis|Correlative studies
218956584|NCT06309615|OTHER|Standard of Care|To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,
219640376|NCT06968910|DEVICE|CANNEFF® SUP rectal suppositories|CANNEFF® SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients
218956585|NCT00773383|DRUG|RG1507|iv 9mg/kg weekly
218956586|NCT00773383|DRUG|erlotinib [Tarceva]|150mg oral daily
218956587|NCT03548090|OTHER|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
218956588|NCT03548090|OTHER|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
218956589|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
218956590|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
219640377|NCT06967363|PROCEDURE|Nerve Block|"The nerve block intervention in this study involves the targeted administration of anesthetic agents and corticosteroids to specific nerves or nerve roots to alleviate pain associated with low back pain. This procedure is performed under imaging guidance (e.g., fluoroscopy or ultrasound) to ensure precise delivery of the medication to the affected nerve. It aims to temporarily block the transmission of pain signals from the affected area to the brain, providing relief and allowing for a better assessment of the underlying pain mechanism. The nerve block is distinguished from other interventions in this study by its localized approach, focusing on pain modulation through direct neural targeting, rather than systemic pain management methods. The procedure may be used either as a standalone treatment or in conjunction with other therapies (e.g., physical therapy, medications) based on the patient's individual needs and response to treatment."
219640378|NCT06967363|PROCEDURE|endoscopic spinal disecetomy|"The Endoscopic Lumbar Discectomy is a minimally invasive surgical procedure designed to treat symptomatic lumbar disc herniations by removing the protruding or damaged disc material that is pressing on the nerve roots. This intervention is distinguished by the use of endoscopic technology, which allows for a smaller incision, real-time visualization of the affected area via an endoscope, and the removal of herniated disc tissue with minimal disruption to surrounding structures. Unlike traditional open discectomy, which requires larger incisions and muscle dissection, endoscopic discectomy involves the use of a small tubular retractor and specialized instruments, leading to reduced blood loss, shorter recovery times, and less postoperative pain.~This procedure is typically performed under local anesthesia, and the patient is often able to go home the same day. It is specifically designed for patients with lumbar disc herniations who have not responded to conservative way."
219058686|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
219058687|NCT04834011|RADIATION|3D CT angiography|
219058688|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
219640379|NCT06967363|DRUG|Medication|The treatment of lumbar pain typically involves a multimodal approach combining medications based on the specific type of pain and patient needs. NSAIDs, acetaminophen, and muscle relaxants are often first-line treatments for nociceptive pain, while opioids and anticonvulsants like pregabalin are used for more severe or neuropathic pain. The choice of medication is guided by the severity of the pain, its underlying causes, and the patient's response to treatment. Each class of medication has its strengths and limitations, and the decision to use them must take into account factors like patient safety, the risk of side effects, and long-term efficacy.
218956591|NCT03548090|OTHER|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
219058689|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
219058690|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
219058691|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
219058692|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
219058693|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
219058694|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
219058695|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
219058696|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
219058697|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
219058698|NCT04584567|DRUG|Doxycyclin|daily (100mg)
219058699|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
219058700|NCT01403103|PROCEDURE|biopsy|Correlative studies
219058701|NCT01403103|GENETIC|protein expression analysis|Correlative studies
219058702|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
218956592|NCT03548090|OTHER|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
219640380|NCT06967363|BEHAVIORAL|Psychotherapy|"Cognitive Behavioral Therapy (CBT): This structured, goal-oriented therapy focuses on identifying and changing negative thought patterns, cognitive distortions, and maladaptive behaviors associated with chronic pain. CBT equips patients with coping strategies to reframe thoughts, reduce pain-related anxiety, and enhance emotional regulation, thereby improving overall function and quality of life. CBT can include techniques such as cognitive restructuring, relaxation training, and behavioral activation.~Acceptance and Commitment Therapy (ACT): ACT encourages individuals to accept pain and distressing emotions rather than avoiding them. It emphasizes mindfulness, acceptance, and values-based living, helping patients focus on behaviors that align with their values, despite ongoing pain."
219640381|NCT06966895|DEVICE|a parent-child collaboration game app|This application is utilized throughout the entire behavioral process of a museum visit; it serves as an auxiliary tool to facilitate the parent-child groups\&#39; experience in the museum in a more targeted manner.
219640382|NCT06966895|OTHER|traditional text-based panels group|A traditional museum visitor\&#39;s manual, containing knowledge of similar content to that in the game.
219640383|NCT06968754|OTHER|Intervention Group|Pharmaceutical care will be provided by a clinical pharmacist in addition to conventional care. This includes assessment and resolution of drug therapy problems (DTPs) related to indication, effectiveness, safety, and compliance. Infection control interventions involve: patient education for early AV fistula use, topical antimicrobials at the catheter exit site (e.g., Mupirocin), antiseptic/antibiotic lock solutions to prevent bloodstream infections, and antimicrobial selection based on culture sensitivity. Patients will receive ongoing follow-up and support throughout the study period.
219640384|NCT06967506|DEVICE|Blowing exercise group|Maximum effort exhalation exercises using the AirOFitPRO will be performed three times daily. Each session will be conducted for a minimum duration of five minutes, with 30-second intervals between each effort.
219640385|NCT03364465|OTHER|change of ventilatory settings|change of tidal volume during one-lung ventilation
219640386|NCT04000425|COMBINATION_PRODUCT|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
219640387|NCT03267082|OTHER|Laparoscopic management of perforated appendicitis|"1. Insertion of Ports~2. Exposure of the Appendix~3. peritoneal toilet and aspiration of pus after abdominal exposure~4. Isolation of Mesoappendicular Artery~5. Clipping and Dividing of the Artery~6. Application of 3 x Endoloops~7. Division of the Appendix~8. Retrieval of the Appendix in an Endobag"
219640388|NCT00140244|DRUG|r-metHuLeptin|
219640389|NCT00140244|DRUG|Placebo|
219640390|NCT01975142|DRUG|Trastuzumab - Emtansine|
219640391|NCT04932655|DRUG|simufilam|Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
219640392|NCT04866758|OTHER|Survey|All data gathered will be quantitative in nature. In addition to participant completed surveys, additional demographic, and diagnosis/treatment related information will be collected from the patient's electronic medical record via Health Data Compass. Subsequent data collected as part of the patient's standard psychosocial and cancer related care (i.e., health outcomes, future utilization of UCCC psychosocial services) will also be gathered. This subsequent data collection will not include further participation, but continued access to the patient's medical record. Protected health information collected for this project will include dates (e.g., birth dates, date of diagnosis, date since last treatment, death dates) and participant zip codes. No other identifiable data will be collected. A separate survey emailed to the participant at the end of the study will collect information regarding the participant's completion status of the survey.
219640393|NCT03409289|DEVICE|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
219640394|NCT01665157|DIETARY_SUPPLEMENT|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy."
219640395|NCT01665157|OTHER|Self-controlled diet|Self-controlled low residue diet.
219640396|NCT01665157|DRUG|2L PEG-ELS|Normal volume of PEG-ELS
219640397|NCT01665157|DRUG|low volume 1.5L PEG-ELS|Low volume PEG-ELS
219640398|NCT02425878|DRUG|Ulipristal Acetate|
219640399|NCT02425878|DRUG|Placebo|
219640400|NCT01289639|DRUG|fenofibrate|micronized fenofibrate 200 mg 1 po qd
219640401|NCT01289639|DRUG|pioglitazone|pioglitazone 30 mg po qd
219640402|NCT01289639|DRUG|placebo|placebo 1 capsule po qd
219640403|NCT00347139|DRUG|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
219640404|NCT00347139|DRUG|Salmeterol 50mcg|Salmeterol 50mcg
219640405|NCT06099522|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
219640406|NCT05804422|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
219640407|NCT05804422|DIETARY_SUPPLEMENT|Placebo|Placebo
219640408|NCT02780713|DRUG|AZD9496 (Reference)|AZD9496 (Reference)
218956593|NCT03548090|OTHER|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
219640409|NCT02780713|DRUG|AZD9496 Variant A|AZD9496 Variant A.
219640410|NCT02780713|DRUG|AZD9496 Variant B|AZD9496 Variant B
218956594|NCT03548090|OTHER|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
218956595|NCT03384693|DRUG|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
218956596|NCT02935374|DRUG|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
218956597|NCT02935374|DRUG|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
219058703|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
219058704|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
219058705|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
219058706|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
219058707|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
219058708|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
219058709|NCT01132079|DRUG|cream treatment|
219058710|NCT01182077|DRUG|ASP015K|Oral
219058711|NCT01182077|DRUG|Midazolam|Oral
219058712|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
219058713|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
219058714|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
219640411|NCT02780713|DRUG|AZD9496 Variant C|AZD9496 Variant C
219640412|NCT02780713|DRUG|AZD9496 Variant D|AZD9496 Variant D
219640413|NCT01910584|PROCEDURE|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
219640414|NCT05126394|PROCEDURE|ultrasound guided serratus anterior plane block|the patients receive local anesthetic (20 ml of Bupivacaine 0.25 %), injected superficial to the serratus muscle under ultrasound guidance.
219640415|NCT00842920|DRUG|Simvastatin 60 mg|60 mg once daily
219058715|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
219058716|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
219640416|NCT00842920|DRUG|Placebo|one tablet once daily
219640417|NCT00842920|DRUG|Simvastatin 20 mg|20 mg once daily
219640418|NCT03106363|DRUG|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
219640419|NCT03106363|DRUG|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
219640420|NCT03106363|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
219640421|NCT03106363|DRUG|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
219640422|NCT00162188|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
219640423|NCT01267461|OTHER|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
219640424|NCT00905593|DRUG|Nilotinib|
219640425|NCT02454465|OTHER|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
219640426|NCT04786340|DRUG|Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution|WST-057
219640427|NCT04786340|DRUG|Placebo: WST-057 4mL topical solution|Placebo
219640428|NCT03072589|DRUG|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
219207364|NCT03766126|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg."
219640429|NCT05325190|DRUG|Granisetron Transdermal Patch System|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
219640430|NCT06968416|OTHER|Standard cleanser，standard moisturizer，standard sunscreen，Investigational serum|"Products Application and Usage Instruction~1. Mode of application: T-3W \~ T0~   Frequency:~   AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: No any other skincare or facial make up products are used except provide products~2. Mode of application: T0 \~ T12W~Frequency:~AM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer + standard sunscreen PM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer~Caution: No any other skincare or facial make up products are used except provide products~Usage Instruction： Use serum \[FLA #774715 21\] 8-10 drops (0.3ml) on cleansed face and eye skin 2 times a day (AM \& PM)."
219640431|NCT06967025|PROCEDURE|Ischemic Postconditioning|Ischemic Postconditioning will consist of 4 cycles of 2-minute cycles of balloon inflation (occlusion) followed by 2 minutes of deflation (reperfusion), and will be initiated immediately upon successful recanalization (eTICI 2b-3) using low pressure balloon in situ of the location of thrombus.
218956598|NCT02935374|DRUG|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
218956599|NCT05024318|DRUG|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
218956600|NCT05024318|RADIATION|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
218956601|NCT05024318|PROCEDURE|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
219640432|NCT06967025|PROCEDURE|Endovascular Thrombectomy|Thrombectomy alone.
219640433|NCT05704348|PROCEDURE|Sleeve gastrectomy with gastropexy|Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
219640434|NCT05704348|PROCEDURE|Sleeve gastrectomy without gastropexy|Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
219640435|NCT05323448|DEVICE|Control Group|During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
218956602|NCT00851760|PROCEDURE|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
219058717|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
219058718|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
219058719|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
219207365|NCT06559462|OTHER|Focus Group|Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.
218956603|NCT00851760|PROCEDURE|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
218956604|NCT06353230|PROCEDURE|injection 5% phenol in almond oil|Group A were given 5% phenol in almond oil
218956605|NCT06353230|PROCEDURE|injection 15% hypertonic saline|Group B were given hypertonic saline
218956606|NCT06353230|PROCEDURE|injection 50% dextrose water|group C were given 50% dextrose water
218956607|NCT05828771|PROCEDURE|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
218956608|NCT00637871|DRUG|Casodex|150mg once daily
218956609|NCT00637871|DRUG|Tamoxifen|
218956610|NCT05973396|OTHER|Physical Fatiguing Task only|Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
219640436|NCT05323448|DEVICE|ARISTA|"During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~* 5g for 5 to 8 instrumented vertebra~* 10g fo 9 or more instrumented vertebra"
219207366|NCT06559462|OTHER|Discrete Choice|Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
219207367|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
219207368|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
219207369|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
219207370|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
219207371|NCT05579626|DRUG|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
219207372|NCT05579626|DRUG|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
219640437|NCT02254967|DRUG|Fidaxomicin|oral tablets administered in an extended pulsed regimen
219640438|NCT02254967|DRUG|Vancomycin|oral capsule
219640439|NCT01765348|BEHAVIORAL|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
219640440|NCT01765348|BEHAVIORAL|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
219640441|NCT02225860|BEHAVIORAL|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
219640442|NCT00117104|DRUG|Aranesp®|
218956611|NCT05973396|OTHER|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
219207373|NCT05118919|BIOLOGICAL|BGP-014|Oral capsule containing lyophilised Lactobacillus reuteri
219207374|NCT05118919|BIOLOGICAL|Placebo|Oral capsule
219207375|NCT04757753|DEVICE|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
219640443|NCT04726072|BEHAVIORAL|Kundalini Yoga|Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
218956612|NCT05436366|DEVICE|Soleus loading response in able-bodied participants|Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
219207376|NCT04757753|DEVICE|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
219207377|NCT06965218|DIAGNOSTIC_TEST|Trans thoracic echo doppler|Aortic valve sclerosis severity study be transthoracic echo doppler
219207378|NCT06964971|DRUG|Luspatercept|The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).
219207379|NCT06964971|DRUG|Luspatercept combine with Deferasirox|"The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).~For patient with platelet counts \< 50×10⁹/L:~Deferasirox dosage: 8-10 mg/kg/day, orally.~For platelet counts ≥ 50×10⁹/L:~Deferasirox dosage: 20 mg/kg/day, orally. Discontinue deferasirox if serum ferritin drops below 500 μg/L."
219207380|NCT06965647|BEHAVIORAL|Partner-Conducted Fetal Heart Sound Measurement|Expectant fathers in the intervention group were trained in basic Leopold maneuvers and fetal heart sound measurement using a Doppler device. Under the supervision of a midwife, fathers located the fetus's back, applied gel, and measured the heart sound during prenatal visits at 28-32 and 33-38 weeks of gestation.
219207381|NCT06965062|PROCEDURE|Deep cervical lymph node to venous bypass (DCLNV-BP)|Participants will under bilateral deep cervical lymph node to venous bypass procedure under general anaesthesia.
219207382|NCT06965127|DEVICE|NNP-LE|Networked NeuroProsthesis - Lower Extremity Configuration (NNP-LE) measuring physiologic command signals and delivering neural stimulation to intramuscular and nerve cuff electrodes for trunk and leg muscle assistance.
219207383|NCT06965673|BEHAVIORAL|Visual exploration training|Visual exploration of natural scenes guided by closed-loop auditory biofeedback through eye-tracking
219640444|NCT04726072|BEHAVIORAL|Psychoeducation|Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
219640445|NCT04954001|DRUG|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
219640446|NCT02857946|DRUG|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
219207384|NCT06965673|BEHAVIORAL|Standard neuropsychological rehabilitation|Standard rehabilitation delivered at the IRCCS San Camillo hospital
219640447|NCT02857946|DRUG|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
219640448|NCT02022384|OTHER|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
219640449|NCT01597414|DRUG|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
219640450|NCT01597414|DRUG|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
219640451|NCT03131414|OTHER|Diet|Dietary intake
219640452|NCT03131414|OTHER|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
219640453|NCT05225870|GENETIC|immunohistochemical staining|sections from colorectal carcinoma will be immunohistochemically stained by anti-Cortactin antobody.
219640454|NCT04850352|DIETARY_SUPPLEMENT|Heukcha Extracts|Experimental group: Heukcha Extracts
219640455|NCT04850352|DIETARY_SUPPLEMENT|Placebo|Placebo group
219640456|NCT04679350|DRUG|hzVSF-v13|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
219640457|NCT04679350|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
219640458|NCT02453035|DEVICE|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
219640459|NCT04426721|DRUG|Ozone|10 cc of oxygen-ozone
219640460|NCT04426721|DRUG|Hyaluronic Acid|Sinovial forte 32 mg\\2ml
219640461|NCT03807479|DRUG|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
219640462|NCT05338502|DRUG|Selpercatinib|Administered orally.
219640463|NCT05338502|DRUG|Ranitidine|Administered orally.
219640464|NCT05338502|DRUG|Omeprazole|Administered orally.
219640465|NCT06578286|DRUG|ARX788|ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
219640466|NCT05105542|DRUG|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
219640467|NCT05105542|DEVICE|PET Scan|PET scanner with high sensitivity and resolution available for human brain imaging
219640468|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes without atherosclerosis|patients diagnosed as type 2 diabetes without atherosclerosis
219640469|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes with atherosclerosis|patients diagnosed as type 2 diabetes with atherosclerosis
219207385|NCT06966310|OTHER|Prone position|depending on tolerance, the objective is to spend as much time as possible, up to 16h and beyond, in prone position per period of 24 hours. For each session the patients will be encouraged to stay as long as possible in the prone position (i.e. ideally 4-8 hours each session).
219640470|NCT04424706|DIAGNOSTIC_TEST|people without type 2 diabetes or atherosclerosis|normal people without type 2 diabetes or atherosclerosis
219640471|NCT06640257|DRUG|SHR-1314 injection|SHR-1314 injection
219640472|NCT06640257|DRUG|Placebo|Placebo
219640473|NCT04046510|DRUG|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
219640474|NCT03024957|DRUG|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
219640475|NCT03024957|DRUG|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
219640476|NCT03024957|DRUG|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
219640477|NCT02218099|DRUG|ASP8232|Oral
219640478|NCT02218099|DRUG|Placebo|Oral
219640479|NCT02655991|BEHAVIORAL|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
219640480|NCT02655991|BEHAVIORAL|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
219640481|NCT03575793|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
219640482|NCT03575793|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
219640483|NCT03575793|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
219640484|NCT04594369|DRUG|Brensocatib 10 mg|Oral tablet.
219640485|NCT04594369|DRUG|Brensocatib 25 mg|Oral tablet.
219640486|NCT04594369|DRUG|Placebo|Brensocatib-matching oral tablet.
219640487|NCT03137940|DEVICE|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
219640488|NCT03137940|DEVICE|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
219640489|NCT01250873|DRUG|LY2216684|po administration
219640490|NCT01250873|DRUG|Sertraline|po administration
219640491|NCT04342637|OTHER|Practice details|Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
219640492|NCT03687333|DRUG|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
219640493|NCT01983033|BEHAVIORAL|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
219640494|NCT01983033|BEHAVIORAL|treatment as usual|12 weeks of no intervention other than treatment as usual
219640495|NCT05094674|DIAGNOSTIC_TEST|Breath Sample analysis|The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
219640496|NCT04036435|DRUG|BMS-986165|Specified dose on specified days
219640497|NCT06261125|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.
219640498|NCT06261125|DRUG|Adebrelimab|All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.
219640499|NCT06261125|DRUG|Lenvatinib|All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
219640500|NCT02278939|BEHAVIORAL|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
219640501|NCT02669836|PROCEDURE|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
219640502|NCT02669836|PROCEDURE|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
219640503|NCT06630364|DRUG|ketamine|Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane
219640504|NCT06630364|DRUG|fentanyl|Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
218956613|NCT05436366|DEVICE|Soleus loading response in participants with hemiparesis|Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
218956614|NCT04247685|DEVICE|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
218956615|NCT04247685|DEVICE|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
219058720|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
219058721|NCT04007536|OTHER|No Intervention|No Intervention
219640505|NCT05169918|OTHER|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~* Stage 1; Isolation and facilitation of target muscles~* Stage 2; Trunk stabilization training with increased load under static conditions~* Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~* Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
219058722|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
219058723|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
219640506|NCT05169918|OTHER|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
219640507|NCT05007743|DEVICE|Transcutaneous vagus nerve stimulation|"Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.~Device: Easy Tens+ device (body clock, London, UK)"
219640508|NCT02088671|DRUG|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
219640509|NCT02088671|DEVICE|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
219640510|NCT02088671|OTHER|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
219640511|NCT02088671|OTHER|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
218956616|NCT04236388|DIETARY_SUPPLEMENT|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
219058724|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
219058725|NCT03884972|DRUG|Trabectedin|Given IV
219058726|NCT03884972|DRUG|Venetoclax|Given PO
219058727|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
218956617|NCT04236388|DIETARY_SUPPLEMENT|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
218956618|NCT02605044|DRUG|Masitinib (AB1010)|
218956619|NCT02605044|DRUG|FOLFIRI|
218956620|NCT04208581|DRUG|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
218956621|NCT04208581|DRUG|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
218956622|NCT05906511|DRUG|Dronabinol 5 MG|Dronabinol 5 mg
218956623|NCT05906511|DRUG|Dronabinol 10 MG|Dronabinol 10mg
218956624|NCT05906511|DRUG|2mg Purified THC in an ethanolic solution|2mg Purified THC in an ethanolic solution
218956625|NCT05906511|DRUG|4mg Purified THC in an ethanolic solution|4mg Purified THC in an ethanolic solution
218956626|NCT05906511|DRUG|Placebo|Oral placebo and/or vaporized saline
218956627|NCT00023192|DRUG|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
218956628|NCT00790257|DEVICE|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
219640512|NCT03428672|PROCEDURE|total hip arthroplasty|Bone samples from Hip fracture were collected from the femoral head which has been replaced
219640513|NCT03462394|OTHER|Current Script|This is the version of the phone call script currently used at NYU Langone Health.
219640514|NCT03462394|OTHER|Alternate Script Iterations|Intervention includes various iterations of the phone call script (different wording or script structure).
219640515|NCT03996174|OTHER|Interview|Interview bases on the use of an interview guide, during one hour maximum
219640516|NCT06100263|OTHER|Individualized exercise program|guided exercise program for 12 weeks
219640517|NCT06100263|OTHER|Control Arm|American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
219640518|NCT04296825|DIETARY_SUPPLEMENT|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
219058728|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
219640519|NCT04296825|DIETARY_SUPPLEMENT|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
219640520|NCT04296825|DIETARY_SUPPLEMENT|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
219640521|NCT04296825|DIETARY_SUPPLEMENT|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
219640522|NCT02149446|DEVICE|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
219640523|NCT06364501|DRUG|KH801|KH801 is an injection solution
219640524|NCT06682390|BEHAVIORAL|Hypocaloric anti-inflammatory diet|The anti-inflammatory hypocaloric diet combines the exclusion of pro- inflammatory constituents and inclusion of anti-inflammatory nutrients. Excluded food items will be refined carbohydrates, soda and alcoholic beverages, ultra- processed foods, smoked foods, fatty foods, packaged foods, canned products, preservatives, emulsifiers, and sauces. Reduce or eliminate red/processed meats. Included food items will be a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., turmeric, ginger, garlic, black pepper, rosemary, cardamon, cinnamon), green tea, fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be encouraged. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Participants will also be asked to reduce their kcal by 500/day and walk for 1 gr 3x per week.
218956629|NCT04115930|DEVICE|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
219058729|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
219058730|NCT02233049|DRUG|Erlotinib|
219058731|NCT02233049|DRUG|Everolimus|
219058732|NCT02233049|DRUG|Dasatinib|
218956630|NCT01071226|DEVICE|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
219058733|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
219640525|NCT01663090|DRUG|Ferumoxytol|
219640526|NCT04128254|DRUG|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
219640527|NCT04443075|DEVICE|faecal sample collector|The frontline medical workers mainly exposed under the stress of fighting against 2019-nCoV
219640528|NCT04094987|DEVICE|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
219640529|NCT02745613|OTHER|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
219640530|NCT04544488|PROCEDURE|Recording of expulsive efforts by connection of a pressure sensor to the women's bladder probe|"Using a pressure probe connected to a Foley Catheter, intra bladder pressure wille be registered during the whole duration of expulsive phase.~The device will be inserted into women's bladder using usual guidelines for insertion of Foley catheter"
219640531|NCT06642207|DIAGNOSTIC_TEST|CBC|to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor
219640532|NCT01909193|BEHAVIORAL|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
219640533|NCT01909193|BEHAVIORAL|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
219640534|NCT01793961|OTHER|electroretinogram|
219640535|NCT01793961|OTHER|contrast sensitivity tests|
219640536|NCT06683261|BIOLOGICAL|Omalizumab|biological prescribed as add-on treatment as part of the standard of care
219640537|NCT06683261|BIOLOGICAL|Dupilumab|biological prescribed as add-on treatment as part of the standard of care
219640538|NCT06683261|BIOLOGICAL|Mepolizumab 100 mg|biological prescribed as add-on treatment as part of the standard of care
218956631|NCT01071226|DEVICE|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
219058734|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
219058735|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
219058736|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
219640539|NCT02111577|BIOLOGICAL|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
219640540|NCT02111577|BIOLOGICAL|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
219640541|NCT05783297|BEHAVIORAL|Treatment Text (TXTXT)|This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
219640542|NCT05783297|BEHAVIORAL|Standard of Care|Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
219640543|NCT04979780|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using US Optum De-Identified EHR data.
219640544|NCT04979780|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
219640545|NCT04979780|DRUG|Direct Oral Anticoagulants (DOAC)|Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
219640546|NCT03745729|DRUG|allopurinol sustained-release capsules|allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
219640547|NCT03745729|DRUG|placebo capsules|placebo sustained-release capsules, once a day, one pill at a time
218956632|NCT01071226|OTHER|HSCT|Peripheral Blood Stem Cell Transplant
218956633|NCT04555473|PROCEDURE|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~1. Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~2. Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
218956634|NCT01094912|DRUG|opioids|
219640548|NCT05342389|DRUG|Camrelizumab|a PD-1 antibody
219640549|NCT05342389|DRUG|Apatinib Mesylate|an oral tyrosine kinase inhibitor
218956635|NCT05527327|DEVICE|traxi® Panniculus Retractor|This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
218956636|NCT05465473|OTHER|Distalization|Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
219058737|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
219058738|NCT05632809|DRUG|NKTR-255|Given by IV (vein)
219058739|NCT05632809|DRUG|Durvalumab|Given by IV (vein)
219058740|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
219058741|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
219058742|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
219058743|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
219058744|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
219058745|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
219058746|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
219058747|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
219058748|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
219640550|NCT04136704|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
219640551|NCT05801289|DRUG|Quetiapine|Giving the drug to group Q
219640552|NCT06093165|RADIATION|Re-irradiation|20Gy on 10 fractions
219640553|NCT02880280|DRUG|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
219640554|NCT02880280|DRUG|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
219640555|NCT03832517|DRUG|Single intravenous doses of RC-01|Intravenous single escalating doses of RC-01
219640556|NCT03832517|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match RC-01
219640557|NCT03832517|DRUG|Multiple intravenous doses of RC-01|Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days
219640558|NCT03832517|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
219640559|NCT05838365|DEVICE|Zirconia implant|(Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
218956637|NCT02367222|OTHER|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
218956638|NCT02367222|OTHER|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
218956639|NCT03140696|DIETARY_SUPPLEMENT|Egg Alone|A chicken egg will be offered for 2 days
218956640|NCT03140696|DIETARY_SUPPLEMENT|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
218956641|NCT03140696|DIETARY_SUPPLEMENT|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
218956642|NCT00012519|DRUG|indinavir sulfate|
218956643|NCT00012519|DRUG|ritonavir|
218956644|NCT02919969|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
218956645|NCT05344703|DEVICE|Y Balance Plus Visual Perturbations|Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.
218956646|NCT05344703|DIAGNOSTIC_TEST|Y balance|Subjects will perform Y-balance without any interventional strategies.
218956647|NCT01713764|BEHAVIORAL|Low Carbohydrate Diet|
218956648|NCT01713764|BEHAVIORAL|American Diabetes Association Diet|
218956649|NCT01713764|BEHAVIORAL|Mindfulness and Positive Affect Skills|
218956650|NCT03621475|DEVICE|Novel restraint|Use of a novel arm restraint
218956651|NCT06492850|GENETIC|FT-002|Intraocular injection of a single dose
218956652|NCT01842633|DRUG|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
218956653|NCT01842633|DRUG|Ibuprofen|Caplets containing 200 mg of ibuprofen
218956654|NCT01842633|OTHER|Placebo|Matching placebo caplets
219058749|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
219058750|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
219058751|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
218956655|NCT05420350|DRUG|Lamotrigine and Bupropion|Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
218956656|NCT05420350|DRUG|Placebo|Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
218956657|NCT02138799|DRUG|enzalutamide|oral
218956658|NCT02138799|DRUG|rifampin|oral
218956659|NCT00197158|BIOLOGICAL|Hepatitis B vaccine|
218956660|NCT05173545|DRUG|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
218956661|NCT02316275|OTHER|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
218956662|NCT02316275|OTHER|Standard post-operative activity restriction|
218956663|NCT01864226|DRUG|RO5545965|Multiple ascending doses
218956664|NCT01864226|DRUG|placebo|Multiple ascending doses
218956665|NCT00559494|DRUG|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
218956666|NCT00559494|DRUG|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
218956667|NCT00559494|PROCEDURE|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
218956668|NCT00559494|PROCEDURE|SCPP control|maintenance of Mean arterial pressure of \>65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
218956669|NCT04877925|DEVICE|standard chest tubes|2 standard postoperative chest tube used
218956670|NCT04877925|DEVICE|coaxial chest tube|1 postoperative smart drain coaxial tube
219058752|NCT01072201|DRUG|Fluoride|Brush twice daily
219058753|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
219058754|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
219058755|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
218956671|NCT00178503|DRUG|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
218956672|NCT00178503|DRUG|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
218956673|NCT00178503|OTHER|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
218956674|NCT02185742|BEHAVIORAL|Strength Based Case Management|
218956675|NCT03584529|DRUG|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
219058756|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
219058757|NCT03641352|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
219058758|NCT03641352|DRUG|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
219058759|NCT00581958|OTHER|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
219058760|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
218956676|NCT01095094|DRUG|ritonavir|Given orally
218956677|NCT01095094|DRUG|lopinavir|Given orally
218956678|NCT04569071|DEVICE|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
218956679|NCT03860558|OTHER|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
218956680|NCT03860558|OTHER|No Intervention|Participants will not undergo an intervention.
218956681|NCT05124301|BEHAVIORAL|Perceptual learning|Reaching task with visual feedback offset from target finger position.
218956682|NCT05124301|BEHAVIORAL|Control|Reaching task with unmanipulated feedback.
218956683|NCT05347147|DRUG|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
219058761|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
219058762|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
219058763|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
219058764|NCT03822728|DIAGNOSTIC_TEST|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
219058765|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
219058766|NCT05927233|DRUG|Saline|30 ml Normal saline
219058767|NCT00003380|DRUG|etoposide|
219058768|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
219058769|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
219058770|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
219207386|NCT06965075|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
219367293|NCT06021249|PROCEDURE|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
219640560|NCT03921840|BEHAVIORAL|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps \& minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
218956684|NCT05347147|DRUG|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
219058771|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
219058772|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
219058773|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
219058774|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
219058775|NCT00304785|DRUG|latanoprost 0.005%|
219058776|NCT00304785|DRUG|Fotil|
219058777|NCT00304785|DRUG|placebo|
219058778|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
219058779|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
219058780|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219058781|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219058782|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
219058783|NCT00169637|DRUG|rhGH|
219058784|NCT03612037|DIETARY_SUPPLEMENT|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
219058785|NCT03612037|DIETARY_SUPPLEMENT|Cellulose|600mg/day oral dose of placebo cellulose
219058786|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
219058787|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
219058788|NCT01978184|DRUG|gemcitabine|
219058789|NCT01978184|DRUG|abraxane|
219058790|NCT01978184|DRUG|hydroxychloroquine|
219058791|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
218956685|NCT03129256|DRUG|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
218956686|NCT00280111|BIOLOGICAL|116E AGMK|Single dose of 116E 10\^5 FFu
218956687|NCT00280111|DRUG|I321|Single dose of I321 10\^5 FFu
219058792|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
219058793|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
218956688|NCT00280111|DRUG|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
218956689|NCT02093351|DRUG|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
218956690|NCT02093351|DRUG|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
218956691|NCT02093351|DRUG|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
218956692|NCT02093351|DRUG|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
218956693|NCT02093351|PROCEDURE|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
218956694|NCT04628533|BEHAVIORAL|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
218956695|NCT04628533|BEHAVIORAL|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
218956696|NCT04942457|BEHAVIORAL|Fasting|Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
218956697|NCT03146598|OTHER|No intervention as it is a observational study|No intervention as it is a observational study
218956698|NCT04360655|PROCEDURE|bronchoscopic microwave intervention|bronchoscopic microwave intervention
218956699|NCT04360655|DRUG|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
218956700|NCT05326724|DEVICE|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
218956701|NCT04748588|DRUG|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
219058794|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
219640561|NCT03921840|OTHER|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
218956702|NCT04161339|DRUG|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
218956703|NCT04161339|DRUG|Placebo oral tablet|Amido pills/daily for 8 weeks
219640562|NCT02042950|DRUG|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
218956704|NCT06229314|DEVICE|Inspiratory muscle training|In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
219058795|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
219058796|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
219058797|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
219058798|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
219640563|NCT01756781|DRUG|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
219640564|NCT01756781|DRUG|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
219640565|NCT01756781|DRUG|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
219640566|NCT01756781|DRUG|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
219640567|NCT02935179|DIETARY_SUPPLEMENT|White sweet potato diet|The diet were supplied 516 kcal daily
219640568|NCT06588751|OTHER|Scalp block|After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
219640569|NCT00305708|BIOLOGICAL|anti-thymocyte globulin|
219640570|NCT00305708|DRUG|busulfan|
219640571|NCT00305708|DRUG|fludarabine phosphate|
219640572|NCT00305708|PROCEDURE|allogeneic bone marrow transplantation|
219640573|NCT00305708|PROCEDURE|peripheral blood stem cell transplantation|
219640574|NCT00305708|PROCEDURE|umbilical cord blood transplantation|
219640575|NCT00305708|RADIATION|radiation therapy|
218956705|NCT01510288|DRUG|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
218956706|NCT03346356|BEHAVIORAL|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
218956707|NCT04493515|DRUG|Oral Oxytocin|Administration of oxytocin orally (24 IU)
218956708|NCT04493515|DRUG|Oral Placebo|Administration of placebo orally (24 IU)
218956709|NCT02858297|DRUG|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
218956710|NCT02858297|DRUG|triamcinolone acetonide|Topical corticosteroid
218956711|NCT01193296|DRUG|Vildagliptin|
218956712|NCT01193296|DRUG|Sitagliptin|
218956713|NCT05764070|DEVICE|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
219058799|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
219058800|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
219058801|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
219640576|NCT01940887|DRUG|E10030|
219640577|NCT01940887|DRUG|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
219640578|NCT01940887|DRUG|E10030 sham injection|Pressure on the eye with a syringe with no needle
219640579|NCT00749307|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|
219640580|NCT00749307|DIETARY_SUPPLEMENT|Placebo|
219640581|NCT01906307|DRUG|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
219640582|NCT04807205|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the Elite IQ device
219640583|NCT05278546|DRUG|ILB2109|ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219640584|NCT00644410|BIOLOGICAL|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
219640585|NCT00644410|BIOLOGICAL|Saline|12 injection with 0.2 ml saline
219640586|NCT04523038|DIAGNOSTIC_TEST|S-Albumin|Preoperative serum albumin levels
219640587|NCT05982236|OTHER|Questionnaire|Questionnaire on WEPI software (secure data), with link sent by e-mail to patients included in the study, including PCOSQOL, HADS, FACT G7 et ASEX scores.
219640588|NCT04914884|DIAGNOSTIC_TEST|intraocular fluid detection|This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
219640589|NCT03169075|BEHAVIORAL|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
219640590|NCT03169075|BEHAVIORAL|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
219640591|NCT04427475|DRUG|pabolizumab|100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
219640592|NCT04427475|DRUG|nafulizumab|nafulizumab
219640593|NCT06676475|DRUG|MgSO4|2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).
219640594|NCT06676475|DRUG|BOTOX-A|2ml of BTX
218956714|NCT05764070|DEVICE|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
218956715|NCT04872270|PROCEDURE|Total Shoulder Arthroplasty|Participant will have total shoulder replacement
218956716|NCT04872270|DRUG|Caffeine Pill|2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
218956717|NCT04872270|DRUG|Percocet 10Mg-325Mg Tablet|given postoperatively as standard post-op pain management
219640595|NCT06676475|DRUG|Saline (NaCl 0,9 %) (placebo)|2 ml of saline
219640596|NCT02216656|DRUG|Placebo|Oral administration
219640597|NCT02216656|DRUG|KHK7580 low dose|Oral administration
219640598|NCT02216656|DRUG|KHK7580 middle dose|Oral administration
219640599|NCT02216656|DRUG|KHK7580 high dose|Oral administration
219640600|NCT02216656|DRUG|KRN1493|Oral administration
219640601|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
219640602|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
219640603|NCT02429778|BEHAVIORAL|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
219640604|NCT02429778|BEHAVIORAL|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
219640605|NCT06610578|DIAGNOSTIC_TEST|fundus imaging|Fundus photography, OCT or OCTA
218956718|NCT04872270|DRUG|Zofran 4Mg Tablet|given postoperatively as standard post-op management
218956719|NCT04333043|DIAGNOSTIC_TEST|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
219058802|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
219640606|NCT01663285|DRUG|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
219640607|NCT03521115|BEHAVIORAL|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
219640608|NCT02475265|DRUG|estradiol 0.045 mg/levonorgestrel 0.015mg|
219640609|NCT04570865|DRUG|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
219640610|NCT04570865|DEVICE|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
219640611|NCT05906563|DRUG|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
219058803|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
219640612|NCT05906563|DRUG|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
219640613|NCT05906563|DRUG|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
219640614|NCT05906563|PROCEDURE|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
219640615|NCT04792801|RADIATION|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
219640616|NCT04927130|DIAGNOSTIC_TEST|ARNA Breast|A specific DNA fragments and globulins will be detected in blood plasma.
219640617|NCT00714012|OTHER|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
219640618|NCT01470625|OTHER|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
219640619|NCT06125938|PROCEDURE|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
219640620|NCT06125938|PROCEDURE|Autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
219640621|NCT00784303|DRUG|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
219058804|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
219058805|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
219058806|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
219058807|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
219058808|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
219058809|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
219058810|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
219058811|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
218956720|NCT05925387|OTHER|CANAP Education|The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
218956721|NCT03249688|OTHER|Regular health advice|Routine healthy lifestyle counseling
218956722|NCT03249688|BEHAVIORAL|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
218956723|NCT03249688|DIETARY_SUPPLEMENT|Medical food|Medical food product (Fortasyn Connect)
218956724|NCT03590431|DIETARY_SUPPLEMENT|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
219058812|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
219058813|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
219058814|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
219640622|NCT00784303|DRUG|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
218956725|NCT03590431|DIETARY_SUPPLEMENT|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
218956726|NCT03590431|DIETARY_SUPPLEMENT|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
218956727|NCT04614051|BIOLOGICAL|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
218956728|NCT05915039|OTHER|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
218956729|NCT03721679|BIOLOGICAL|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
218956730|NCT02446743|BIOLOGICAL|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
218956731|NCT03718299|DRUG|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
218956732|NCT00006487|DRUG|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
218956733|NCT00006487|DRUG|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
218956734|NCT00006487|DRUG|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
219058815|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
219640623|NCT06667518|DEVICE|Neuromuscular Activity Assessment|"K-Pull dynamometer is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions.~K-Myo (non-invasive EMG sensor) is an assessment tool used to detect muscle activation and tracking patient's improvement."
219640624|NCT06668519|OTHER|Magnetoencephalography|Magnetoencephalography
219640625|NCT05256459|OTHER|Long term follow-up|No extra intervention.
219640626|NCT01468259|DRUG|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
219640627|NCT04128306|BEHAVIORAL|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 milliampere (mA), in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
219640628|NCT04128306|PROCEDURE|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~* Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~* Posterior parietal cortex~* Associative somesthetic areas"
219058816|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
219058817|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
219058818|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
219058819|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
219058820|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
219058821|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
219058822|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
219058823|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
219058824|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
219058825|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
219640629|NCT04128306|OTHER|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
219640630|NCT04128306|OTHER|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
218956735|NCT00006487|RADIATION|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
218956736|NCT01787344|DRUG|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
218956737|NCT01787344|DRUG|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
218956738|NCT02810678|OTHER|Latent Tuberculosis Infection program evaluation & diagnosis|
218956739|NCT03671278|OTHER|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
218956740|NCT02895997|OTHER|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
218956741|NCT03044639|DRUG|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
219058826|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
219058827|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
219640631|NCT04128306|OTHER|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
218956742|NCT03517488|BIOLOGICAL|XmAb20717|Monoclonal bispecific antibody
218956743|NCT03989726|PROCEDURE|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
218956744|NCT02329366|OTHER|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
219058828|NCT01328002|DRUG|Placebo|matching placebo tablets daily
219058829|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
219058830|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
219058831|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
219058832|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
219058833|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
218956745|NCT03555838|OTHER|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
218956746|NCT03555838|OTHER|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
218956747|NCT05037188|BIOLOGICAL|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
219640632|NCT04128306|OTHER|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
218956748|NCT05037188|BIOLOGICAL|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
218956749|NCT05037188|BIOLOGICAL|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
218956750|NCT05037188|OTHER|Placebo injection|Placebo injection
218956751|NCT05300373|DIAGNOSTIC_TEST|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
218956752|NCT00221312|DRUG|Fosamax|
219058834|NCT00349492|DRUG|IP|irinotecan+cisplatin
219058835|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
219058836|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
219058837|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
219058838|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
219058839|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
219058840|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
219058841|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
219640633|NCT04128306|OTHER|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
219640634|NCT04128306|OTHER|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
219640635|NCT04128306|OTHER|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
219640636|NCT04128306|OTHER|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
219640637|NCT00819559|RADIATION|PCRT|Preoperative chemoradiotherapy
219640638|NCT01202942|OTHER|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
218956753|NCT01453192|DRUG|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
219640639|NCT04501640|DRUG|mirabegron|Oral adminstration
218956754|NCT01408329|DEVICE|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
218956755|NCT01407731|GENETIC|protein expression analysis|
218956756|NCT01407731|GENETIC|western blotting|
219640640|NCT04053712|DRUG|Glucagon|GlucaGen(R), Novo Nordisk, DK
218956757|NCT01407731|OTHER|laboratory biomarker analysis|
219058842|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
219058843|NCT02780349|DEVICE|WIRION|Embolic Protection System
219640641|NCT04053712|DEVICE|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
218956758|NCT02632903|DRUG|Zoledronic acid|
218956759|NCT04535167|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
218956760|NCT04535167|DRUG|Placebo|Placebo will be formulated for intravenous delivery
218956761|NCT03329781|DIETARY_SUPPLEMENT|BCM-95|Consuming 1 capsule of BCM-95 per day.
218956762|NCT03329781|DIETARY_SUPPLEMENT|Placebo|Consuming 1 placebo capsule per day
218956763|NCT04733443|DEVICE|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
219058844|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
218956764|NCT04733443|DEVICE|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
219058845|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
219640642|NCT03749967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
219640643|NCT05961072|DEVICE|Vibrotactile sensory feedback device|"The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground."
219640644|NCT04765150|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
219640645|NCT04765150|OTHER|Electronic Health Record Review|Medical charts are reviewed
219640646|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
219640647|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
218956765|NCT00882219|DEVICE|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
218956766|NCT03458793|BEHAVIORAL|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
218956767|NCT06017102|DEVICE|wired magnetic assisted capsule endoscopy|once
218956768|NCT06017102|DEVICE|esophagogastroduodenoscopy|once
218956769|NCT03272269|DRUG|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
218956770|NCT03272269|OTHER|Placebo|Solvent: alum hydroxide
218956771|NCT05285748|BEHAVIORAL|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
218956772|NCT05285748|BEHAVIORAL|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
218956773|NCT06001385|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
218956774|NCT06001385|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
218956775|NCT06001385|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
218956776|NCT06001385|DRUG|Post-Transplant Cyclophosphamide|"Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant."
218956777|NCT06001385|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
218956778|NCT06001385|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
219058846|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
219640648|NCT06667050|DRUG|Chemotherapy plus sintilimab and bevacizumab|"Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles."
219640649|NCT03870308|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
219058847|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
219058848|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
219058849|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
219058850|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
219207387|NCT06965270|BEHAVIORAL|Standardized clinical intervention|"This manualized intervention consists of 8 sessions of evidence-based treatments for substance abuse and mental health problems.~Session 1: Introduction, Psychoeducation, Assessment and Safety: Introduces what the patient's clinical assessment suggests about strengths and needs.~Session 2: Relaxation, Mindfulness and cognitive distortions in CBT. Session 3: Getting started in Cognitive Restructuring (CR): thought challenge and action plan.~Session 4: Craving management practice: includes challenging and replacing thoughts that lead to drug and alcohol use.~Session 5: CR practice exercises and motivation: introduction to risk behaviors and triggers for drug and alcohol use. Relapse prevention.~Session 6: Assertiveness and refusal techniques. Session 7: Problem solving, practice and reinforcement: CR skills, relaxation and relapse prevention applied in current circumstances.~Session 8: Care plan and end of program."
219640650|NCT05183308|DRUG|Clodronic Acid|Osteoporotic fracture treated with surgical and medical therapy
218956779|NCT06001385|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
218956780|NCT06001385|OTHER|Patient Reported Outcomes|Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
218956781|NCT06001385|DRUG|Melphalan|Given IV pre transplant as part of conditioning regimen
218956782|NCT06001385|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
218956783|NCT06001385|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
219640651|NCT05817747|OTHER|Dialogue support tool|The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
218956784|NCT06160284|DRUG|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
218956785|NCT06831942|BEHAVIORAL|ASSIP-OA|"ASSIP-OA + TAU~* First session. Narrative interview focusing on the background of the suicidal crisis. The patient receives a psychoeducational text to read and comment on as homework.~* Second session. Video playback. The patient and therapist watch the video recording from session 1 together, periodically pausing the video to comment and add information.~* Third session. Compilation of a written case conceptualization of the individual's vulnerability and triggering events that preceded the suicidal crisis.~* Fourth session. An optional extra session to further train safety strategies.~* Fifth session (optional). Includes one or two close relatives or other support person(s), chosen by the participant. The session focus on how safety measures learned in in ASSIP-OA can be translated into everyday life.~* Standardized letters. therapists will send standardized letters every third month during the first year and biannually during the second year."
218956786|NCT06831942|OTHER|Treatment as Usual (TAU)|Antidepressant medication, alone or in combination with other types of psychoactive drugs (sedatives/antipsychotics/hypnotics/mood stabilizers) constitute the cornerstone of treatment for suicidal older adults. Persons with serious depression or treatment-resistant depression may be offered electroconvulsive therapy (ECT). Some persons may receive supportive/therapeutic contacts with mental health professionals (nurses/social workers/psychologists) but no psychosocial interventions designed specifically for suicidal older adults are offered as part of ordinary treatment at the participating clinics.
218956787|NCT05822531|BEHAVIORAL|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
219058851|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
219058852|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
219058853|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
219058854|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
219058855|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
219058856|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
219058857|NCT05739500|OTHER||no intervention, just observation
219058858|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
219207388|NCT06965270|BEHAVIORAL|Internet/App intervention|"Using an already developed Internet/App platform (MeMind), patients will have access to the same therapeutic components as in the standardized intervention arm, arranged in sessions by modules.~Components will be released weekly and reminded via push notifications. Patients will also receive two counseling calls at weeks 1 and 8 to help with technical issues and review problems with the program modules."
219640652|NCT03116555|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
219640653|NCT03116555|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC
219640654|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) with metatarsal pads|A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath
219058859|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
219207389|NCT06965270|BEHAVIORAL|Treatment as usual|Patient will recieve the usual intervention provided by the Health system
219640655|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) without metatarsal pads|A pair of prefabricated foot orthoses only
219640656|NCT04661241|OTHER|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
219640657|NCT04661241|OTHER|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
219640658|NCT04259658|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous metastases will be treated with calcium electroporation.
219640659|NCT02960035|DRUG|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
219640660|NCT02960035|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
218956788|NCT06369064|OTHER|CVVHD Dialysis parameters|Patients will receive a CVVHD dialysis with a dose of 25ml/kg/h dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate
218956789|NCT06369064|OTHER|CVVHDF Dialysis parameters|Patients will receive a CVVHDF dialysis with a dose of 25ml/kg/h dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine
218956790|NCT06101628|OTHER|Gel nail application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
218956791|NCT05265052|DRUG|3D1002 (50 mg)(Phase IIa)|1 tablet of 3D1002 per oral dose
218956792|NCT05265052|DRUG|3D1002 (100 mg)(Phase IIa)|2 tablets of 3D1002 per oral dose
218956793|NCT05265052|DRUG|3D1002 (150 mg)(Phase IIa)|3 tablets of 3D1002 per oral dose
218956794|NCT05265052|DRUG|3D1002 monotherapy (Phase IIb)|3D1002 is administered at recommended dose with mimic OxyContin tablets.
218956795|NCT05265052|DRUG|OxyContin monotherapy (Phase IIb)|OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
218956796|NCT05265052|DRUG|3D1002 + OxyContin (Phase IIb)|3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
218956797|NCT04972630|BEHAVIORAL|Pal-Care|"Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies."
218956798|NCT04972630|BEHAVIORAL|Control-Usual Care|"The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
219058860|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
219058861|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
219058862|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
219058863|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
219058864|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
219058865|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
219058866|NCT03362515|DRUG|Furosemide|furosemide
219058867|NCT03362515|DRUG|Placebo|placebo
219058868|NCT05889858|OTHER|Data collection|Data collection
219058869|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
219058870|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
219058871|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
219058872|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
219058873|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
219058874|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
219058875|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
219058876|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
219058877|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
219207390|NCT01313559|DRUG|Pasireotide|Given IM
219207391|NCT01313559|DRUG|Everolimus|Given PO
218956799|NCT02446652|DRUG|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
218956800|NCT02446652|DRUG|Placebo|Placebo (orally) starting 1 week before the first day of the QT
218956801|NCT02446652|DRUG|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
219207392|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
219207393|NCT04899739|DIAGNOSTIC_TEST|Echoendoscopy|Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
219207394|NCT02514915|RADIATION|Stereotactic Radiosurgery|Radiation therapy
219640661|NCT02960035|DRUG|placebo|
218956802|NCT02446652|DRUG|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
218956803|NCT06131762|OTHER|Active release technique|This include active release technique for 4 weeks
218956804|NCT06131762|OTHER|Positional release technique|This include positional release technique for 4 weeks
218956805|NCT03452475|DRUG|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
219058878|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
219058879|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
219058880|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
219058881|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
219058882|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
219058883|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
219058884|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
219640662|NCT01623635|DRUG|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
218956806|NCT03452475|DRUG|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
218956807|NCT03452475|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
218956808|NCT02785289|DEVICE|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
218956809|NCT00075270|DRUG|Paclitaxel|Active Comparator
218956810|NCT00075270|DRUG|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
218956811|NCT02814331|DEVICE|multimodal high-resolution EEG-NIRS|
218956812|NCT03800303|BEHAVIORAL|Family-based treatment|2-week family-based treatment
218956813|NCT01646294|DRUG|YM178 modified release (OCAS)|oral
218956814|NCT01646294|DRUG|YM178 immediate release (IR)|oral
218956815|NCT04841200|DRUG|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
218956816|NCT04841200|DRUG|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
218956817|NCT06394687|DIETARY_SUPPLEMENT|Milk Protein Concentrate|Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.
218956818|NCT06394687|DIETARY_SUPPLEMENT|Micellar Casein Isolate|Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.
219058885|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
219058886|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
219058887|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
219058888|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
219058889|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
219058890|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
219058891|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
219058892|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
219058893|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
219058894|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
219058895|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
219058896|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
219058897|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
219058898|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
219058899|NCT03436472|DRUG|placebo|normal saline infusion
219058900|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
219207395|NCT06966102|DRUG|Lidocaine group|25ml of lidocaine hydrochloride 2% will be added to 25 ml of standard saline 0.9% solution in a 50ml syringe to be infused via a syringe pump. The resultant concentration will be 10mg/ml. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
219207396|NCT06966102|DRUG|Magnesium group|a 50ml syringe will be filled with magnesium sulfate solution (100mg/ml) to be infused via a syringe pump. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
218956819|NCT01070797|BIOLOGICAL|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
218956820|NCT05115994|DEVICE|Continous positive airway pressure|
218956821|NCT05868148|DEVICE|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
218956822|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956823|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956824|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956825|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956826|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956827|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
218956828|NCT01905215|DRUG|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
219058901|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
219058902|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
219058903|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
219058904|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
219058905|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
219058906|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
219207397|NCT06966102|DRUG|Control group|a 50ml syringe will be filled with a standard saline 0.9% solution to be infused via a syringe pump. Each patient will receive 0.2ml/kg/h
219367294|NCT06021249|PROCEDURE|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
219640663|NCT01623635|DRUG|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
219640664|NCT02229279|DEVICE|Teleconsulting|
218956829|NCT03461679|PROCEDURE|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
218956830|NCT03461679|PROCEDURE|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
218956831|NCT03518749|OTHER|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
218956832|NCT03518749|OTHER|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
218956833|NCT03518749|BEHAVIORAL|Cognitive control training|cognitive control training with the PASAT
219058907|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
219058908|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
219058909|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
219058910|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
219058911|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
219058912|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
219058913|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
219058914|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
219058915|NCT03049059|DRUG|4% hydroquinone cream|
219058916|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
218956834|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
218956835|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
218956836|NCT03469570|DEVICE|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
218956837|NCT02666963|DRUG|RTA 901 Capsules, 10 or 40 mg|
219640665|NCT01404754|DRUG|Lactose (inactive placebo)|Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
219367295|NCT06021249|PROCEDURE|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
219058917|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
219058918|NCT06573320|OTHER|physical exercise|physical exercise
219640666|NCT01404754|DRUG|midomafetamine HCl|120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
219058919|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
219640667|NCT00527033|DRUG|YM178|Oral
218956838|NCT02666963|DRUG|Placebo|
219058920|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
219058921|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
219058922|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
219058923|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
219058924|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
219640668|NCT00527033|DRUG|Placebo|Oral
219640669|NCT01981954|DRUG|Solifenacin succinate|Oral suspension
219640670|NCT03655470|BEHAVIORAL|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
218956839|NCT04653246|DRUG|Isatuximab|Via IV at predetermined dosage and predetermined days during each cycle
218956840|NCT04653246|DRUG|Lenalidomide|Oral, predetermined dosage and predetermined days during each cycle
218956841|NCT04653246|DRUG|Bortezomib Injection|SQ Oral, predetermined dosage and predetermined days during each cycle
219058925|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
219367296|NCT04343651|DRUG|Placebo|Placebo
219367297|NCT04343651|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
218956842|NCT04653246|DRUG|Dexamethasone|IV or Oral predetermined dosage and predetermined days during each cycle
218956843|NCT06450041|DRUG|Universal Donor (UD) TGFβi NK Cells|Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
219367298|NCT02987855|PROCEDURE|Lipoaspiration|Closed syringe harvesting subdermal fat
219367299|NCT02987855|PROCEDURE|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
219640671|NCT03655470|BEHAVIORAL|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
219640672|NCT00971607|DRUG|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
219640673|NCT00971607|DRUG|Oxygen (placebo)|Control will receive oxygen only.
218956844|NCT06450041|DRUG|Temozolomide|Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
219640674|NCT06304285|OTHER|Acupuncture treatment|Acupuncture was performed according to the corresponding acupoint of the patient
218956845|NCT06450041|DRUG|Irinotecan|50mg/m2/dose IV daily on days 1-5 of each cycle
219058926|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
219058927|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
219058928|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
219058929|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
219058930|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
219058931|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
219058932|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
219058933|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
219058934|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
219058935|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
219058936|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
219207398|NCT06823661|DEVICE|transcutaneous electrical nerve stimulation (TENS)|"A TENS 3000-unit, which is FDA and health Canada approved (Licence No.: 95655) and operated by a small 9V block battery will be used. Potential participants will receive a detailed written explanation of the TES protocol and a brief demonstration of how it works, including the feeling produced by the skin stimulator. Patient-specific TES thresholds will be determined after informed written consent for study participation is obtained. Surface electrode pads will be placed on the ventral surface of the forearm, and 1-Hz pulses will be gradually administered with an increase in current. Patients will be asked to report when they first feel the stimulation and when it becomes annoying. The milliamp current associated with these two levels of stimulation will be recorded on the participant's baseline data collection form. The annoying thresholds for all study participants will be used to deliver stimuli in response to respiratory depression in the PACU."
219207399|NCT02656706|DRUG|Ipilumumab|
219207400|NCT02656706|DRUG|Nivolumab|
219207401|NCT05546567|DIETARY_SUPPLEMENT|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
219207402|NCT05237908|DEVICE|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
219207403|NCT05192057|DEVICE|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
219207404|NCT06462027|DRUG|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
218956846|NCT06450041|DRUG|Dinutuximab|17.5mg/m2/dose IV daily on days 2-5 of each cycle
218956847|NCT06450041|DRUG|GM-CSF|250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
219207405|NCT06462027|DRUG|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
219640675|NCT06304285|OTHER|Sham acupuncture treatment|The needle only touches the patient's skin and does not penetrate the skin
219640676|NCT02272907|OTHER|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
218956848|NCT03667170|BIOLOGICAL|KN035|subcutaneous injection
218956849|NCT02392871|RADIATION|Palliative radiotherapy|
218956850|NCT02392871|DRUG|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
219058937|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
219058938|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
219207406|NCT06462027|OTHER|Saline|Control subjects will receive 500mL of normal saline intravenously.
219367300|NCT02987855|PROCEDURE|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
218956851|NCT05564195|DIAGNOSTIC_TEST|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
219640677|NCT06624007|OTHER|pediatric Nursing Excellence (PNE) model|The intervention group will apply pediatric Nursing Excellence (PNE) model included 28 Likert-type questions to assess nurses' general excellence level regarding the care of children undergoing orthopedic surgeries grouped under five main categories including engagement, values, principles, care delivery and continuous improvement.
218956853|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
218956854|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
219058939|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
219058940|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
219058941|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
219058942|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
219058943|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
219058944|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
219058945|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
219058946|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
219058947|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
219058948|NCT01626976|DRUG|Placebo|Solution, single dose
219058949|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
219058950|NCT01626976|DRUG|Placebo|suspension, single dose
219058951|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
219058952|NCT01626976|DRUG|Placebo|suspension, single dose
219058953|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
219058954|NCT01626976|DRUG|Placebo|suspension, single dose
218956855|NCT06831058|DRUG|efgartigimod|intravenous efgartigimod weekly with monitoring of ADAMTS13 activity for 8 weeks, followed by an observational period of 8 weeks or until treatment failure.
219058955|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
219058956|NCT01626976|DRUG|Placebo|suspension, single dose
219058957|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
219058958|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
219058959|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
219058960|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
219058961|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
218956856|NCT04656275|DRUG|BI 1323495|BI 1323495
218956857|NCT04656275|DRUG|Placebo|Placebo
219058962|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
219058963|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
219058964|NCT01632579|DRUG|LY3023703|Administered orally
219058965|NCT01632579|DRUG|Placebo|Administered orally
219058966|NCT01632579|DRUG|Celecoxib|Administered orally
219058967|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
219058968|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
219058969|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
219058970|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
219058971|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
219058972|NCT00175474|PROCEDURE|knee surgery|
219058973|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
219058974|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
219058975|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
219058976|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
219058977|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
219058978|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
218956858|NCT04221204|DRUG|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
218956859|NCT06101641|OTHER|Shellac nail polish application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
219640678|NCT06682715|DIETARY_SUPPLEMENT|whey protein|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
218956860|NCT02339376|DEVICE|Low-frequency repetitive transcranial magnetic stimulation|
218956861|NCT02339376|DEVICE|High-frequency repetitive transcranial magnetic stimulation|
218956862|NCT02339376|DEVICE|Sham repetitive transcranial magnetic stimulation|
218956863|NCT00811889|OTHER|Placebo|Placebo
218956864|NCT00811889|DRUG|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
218956865|NCT04827667|DIAGNOSTIC_TEST|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
218956866|NCT00300742|DRUG|Topiramate|Topiramate up to 300 mg per day.
218956867|NCT03390842|DRUG|TRC101|Oral suspension
218956868|NCT03390842|DRUG|Placebo|Oral suspension
218956869|NCT03947476|DEVICE|thoracic band|Thoracic band fixation
218956870|NCT05600621|BEHAVIORAL|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
218956871|NCT05600621|BEHAVIORAL|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
219058979|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
219058980|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
219058981|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
218956872|NCT05600621|BEHAVIORAL|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
219058982|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
219058983|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
219640679|NCT06682715|DIETARY_SUPPLEMENT|maltodextrin|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
219058984|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
219058985|NCT01187589|DEVICE|Pulsehaler|
219058986|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
219058987|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
219207407|NCT03725332|BEHAVIORAL|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
218956873|NCT05600621|BEHAVIORAL|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
219640680|NCT06682715|BEHAVIORAL|nutrition education|Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
219640681|NCT01403688|PROCEDURE|RPFNA|"1. Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~2. Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~3. Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
218956874|NCT05600621|OTHER|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
218956875|NCT01699347|DRUG|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
218956876|NCT01351675|DRUG|Placebo|Oral, once daily
219058988|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
218956877|NCT01351675|DRUG|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
219058989|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
219640682|NCT03865615|DRUG|Oxytocin|intranasal oxytocin 40IU/mL
219640683|NCT03865615|DRUG|Placebo|Placebo
219058990|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
219207408|NCT03725332|BEHAVIORAL|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
219640684|NCT06685471|DIAGNOSTIC_TEST|Screeing test|Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance Regarding Heel-Prick during Newborn Blood Screening Test
219640685|NCT06200311|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)
219640686|NCT06200311|DRUG|Pharmacological rhythm management|1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
218956878|NCT01860729|DRUG|Anacetrapib|
218956879|NCT01860729|DRUG|Placebo|
218956880|NCT03481179|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
218956881|NCT03481179|OTHER|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
218956882|NCT01129024|DRUG|Lusutrombopag|tablet
219058991|NCT02678546|OTHER|Other|case review of diagnosed disease
219058992|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
219207409|NCT04783441|DEVICE|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
219058993|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
218956883|NCT04039100|OTHER|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
219058994|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
219058995|NCT01606982|DRUG|MDV3100|oral
219058996|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
218956884|NCT02631993|RADIATION|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
218956885|NCT05754840|DRUG|MPL-001|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
218956886|NCT05754840|DRUG|MPL-005|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
219058997|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
219058998|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
218956887|NCT05754840|DRUG|MPL-009|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
219058999|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
219059000|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
219059001|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
219059002|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
219059003|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
219059004|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
219059005|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
219059006|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
219059007|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
219059008|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
218956888|NCT05418309|DRUG|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
219059009|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
219059010|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
218956889|NCT01871480|DRUG|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
218956890|NCT01871480|DRUG|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
218956891|NCT04042246|BEHAVIORAL|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
219059011|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
219059012|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
219059013|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
219207410|NCT04783441|DEVICE|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
219207411|NCT06277960|DEVICE|percutaneous intramyocardial septal radiofrequency ablation system|The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.
219207412|NCT05035108|BIOLOGICAL|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 48-72 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 4-6h.
219640687|NCT04723628|BEHAVIORAL|Intervention group (telephone counseling)|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
219640688|NCT00887783|DRUG|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
219640689|NCT00887783|RADIATION|66 Gy/33F|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
219640690|NCT00887783|RADIATION|60 Gy/30F|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
218956892|NCT01239719|DRUG|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
218956893|NCT01239719|DRUG|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
219207413|NCT05086393|DRUG|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
219207414|NCT05086393|DRUG|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
219207415|NCT06559774|BEHAVIORAL|Hastiin Bidziil|Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact
218956894|NCT03348436|PROCEDURE|radiofrequency ablation|
218956895|NCT01394640|BIOLOGICAL|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
218956896|NCT03997292|DRUG|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
218956897|NCT03997292|DRUG|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
218956898|NCT00382642|DRUG|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
218956899|NCT00382642|DRUG|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
219207416|NCT06559774|OTHER|Control condition - vehicle maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
219207417|NCT06461078|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
219640691|NCT05517109|OTHER|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
219640692|NCT04335409|DIAGNOSTIC_TEST|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
219640693|NCT04335409|OTHER|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
219640694|NCT05420298|OTHER|cervical mobilization|All participants will receive only single session of cervical mobilization
219640695|NCT05420298|OTHER|cervical manipulation|All participants will receive only single session of cervical manipulation
219640696|NCT04349462|DIAGNOSTIC_TEST|VideoFlurosocopy Swallow Study|VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
218956900|NCT01115192|PROCEDURE|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
218956901|NCT01115192|PROCEDURE|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
218956902|NCT06414785|OTHER|analysis of samples of periprosthetic capsules taken during breast implant change procedure|characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment
218956903|NCT06449937|PROCEDURE|Radical local Surgery|Radical local resection of liver metastases ( hepatectomy, ablation )
218956904|NCT06449937|DRUG|Systemic therapy|Chemotherapy, targeted drug therapy, immunotherapy treatment.
218956905|NCT06449937|OTHER|Interventional therapy|Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
218956906|NCT03442868|DEVICE|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
218956907|NCT05228379|PROCEDURE|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
218956908|NCT01261468|DEVICE|Active SCS|SCS IPG activated
218956909|NCT01261468|DEVICE|Deactivated|SCS IPG deactivated
219059014|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
219059015|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
219059016|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
219059017|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
219059018|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
219640697|NCT04349462|DIAGNOSTIC_TEST|Water Sip Test|The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
219059019|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
219640698|NCT04793529|DRUG|Cholecalciferol|Cholecalciferol injection
219640699|NCT03063086|DRUG|QVM149 150/50/80 μg o.d.|A
219640700|NCT03063086|DRUG|QVM149 150/50/160 μg o.d.|B
219640701|NCT03063086|DRUG|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
218956910|NCT02228616|DRUG|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
218956911|NCT02228616|DRUG|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
218956912|NCT02228616|DRUG|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
218956913|NCT05864456|DEVICE|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
218956914|NCT04173598|BEHAVIORAL|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
218956915|NCT04173598|BEHAVIORAL|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
218956916|NCT03254615|BEHAVIORAL|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
219207419|NCT04091126|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as intravenous infusion.
219640702|NCT05283343|DEVICE|SP-1P|A subject undergoes corneal thickness measurement with pachymeter.
218956917|NCT05973149|DRUG|QLH12016|according to the scheme description
218956918|NCT02266953|BEHAVIORAL|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
218956919|NCT02266953|BEHAVIORAL|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
218956920|NCT04656899|BEHAVIORAL|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
219640703|NCT02222350|DRUG|10mg DS-8500a tablet|
219059020|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
219640704|NCT02222350|DRUG|75mg DS-8500a tablet|
219640705|NCT02222350|DRUG|placebo|
219640706|NCT02070016|DEVICE|Transcranial Magnetic Stimulation|
218956921|NCT00231556|DRUG|topiramate|
219059021|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
219207420|NCT04091126|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
219640707|NCT00489086|DRUG|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
219640708|NCT04590586|DRUG|Standard of care|Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
219640709|NCT04590586|DRUG|Apremilast|Apremilast administered orally as a tablet.
218956922|NCT04372056|BEHAVIORAL|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
218956923|NCT01072565|OTHER|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
218956924|NCT01072565|OTHER|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
218956925|NCT00000477|DRUG|lovastatin|
218956926|NCT02011139|BEHAVIORAL|Cognitive-behavioral group therapy|
218956927|NCT04145843|PROCEDURE|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
218956928|NCT00838864|DRUG|ceftrioxone|500 mg iv q12h for 3 days
218956929|NCT00838864|DRUG|ceftrioxone|500 mg q12h for 7 days
218956930|NCT02828215|DEVICE|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
219059022|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219059023|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219059024|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
219059025|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
219059026|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
219059027|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
219059028|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
219059029|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
219059030|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
219059031|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
219059032|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
219059033|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
219059034|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
219207421|NCT04091126|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
219207422|NCT04091126|DRUG|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
219207423|NCT06186869|BEHAVIORAL|Aerobic Exercise and diet intervention|subjects randomized and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform moderate-intensity aerobic exercises
219207424|NCT06186869|BEHAVIORAL|Hiit and diet intervention|subjects randomised and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform high-intensity interval exercises in the gym
219207425|NCT06186869|BEHAVIORAL|Diet|subjects randomised and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet
218956931|NCT06024512|DEVICE|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
218956932|NCT03513848|DEVICE|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
218956933|NCT03513848|DEVICE|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
219059035|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
219059036|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
219059037|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
219059038|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
219059039|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
219059040|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
219059041|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
219059042|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
219059043|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
219059044|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
219059045|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
219059046|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
219059047|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
219059048|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
219059049|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
219059050|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
219059051|NCT01713777|DRUG|"Lamotrigine Generic A"|
219207426|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
219640710|NCT04590586|DRUG|Apremilast placebo|Matching apremilast placebo administered orally as a tablet.
219640711|NCT04590586|DRUG|Lanadelumab|Lanadelumab administered as an intravenous (IV) infusion.
218956934|NCT01453582|DRUG|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
219059052|NCT01713777|DRUG|"Lamotrigine generic B"|
219059053|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
219059054|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
219059055|NCT00928148|DRUG|Placebo|Once daily for 7 days
219059056|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
219059057|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
218956935|NCT01453582|DRUG|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
219059058|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
219059059|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
218956936|NCT04095585|GENETIC|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
218956937|NCT00686634|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth once daily
218956938|NCT00672113|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
218956939|NCT00672113|DRUG|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
219059060|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
219059061|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
219059062|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
219059063|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
219059064|NCT04198610|PROCEDURE|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
219059065|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
219059066|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
219207427|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
219207428|NCT04370509|DRUG|Axitinib (VEGF-TKI)|Given PO
219207429|NCT04370509|PROCEDURE|Cytoreductive Nephrectomy (CN)|Undergo CN
219207430|NCT04370509|PROCEDURE|Metastasectomy (MET)|Undergo MET
218956940|NCT05179551|PROCEDURE|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
219207431|NCT04370509|BIOLOGICAL|Pembrolizumab|Given IV
219207432|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
219207433|NCT02612454|DRUG|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
219207434|NCT06476717|PROCEDURE|Biopsy|Kidney allograft biopsy
219207435|NCT06476717|DIAGNOSTIC_TEST|Blood Biomarkers - cfDNA|dd-cfDNA
219207436|NCT06476717|DRUG|Antirejection therapy|Patients will receive standard antirejection therapy according to center protocol.
219640712|NCT04590586|DRUG|Lanadelumab placebo|Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
218956941|NCT00335270|DRUG|fos-amprenavir calcium, ritonavir|
218956942|NCT00335270|DRUG|abacavir/lamivudine as Epzicom|
218956943|NCT00799773|DRUG|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
219059067|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
219059068|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
219059069|NCT04446663|DRUG|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
219059070|NCT04446663|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
219059071|NCT04446663|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
219059072|NCT04446663|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
219059073|NCT00039767|DRUG|Lepirudin|
219059074|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
219059075|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
219059076|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
219059077|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
219059078|NCT02770391|PROCEDURE|Radical prostatectomy|
219059079|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
219059080|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
219059081|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
219059082|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
219059083|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
218956944|NCT00799773|PROCEDURE|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
218956945|NCT00799773|DRUG|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
218956946|NCT02361580|OTHER|Diary|Subject keeps diary of recovery
218956947|NCT06003179|DRUG|Cyclophosphamide|Conditioning chemo at different doses
218956948|NCT06003179|RADIATION|TLI|radiation given with conditioning chemo
218956949|NCT06003179|DRUG|Fludarabine|Fludarabine given as part of standard treatment
218956950|NCT03303027|DEVICE|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
218956951|NCT03303027|DEVICE|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
218956952|NCT01439698|DEVICE|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
218956953|NCT00924781|DRUG|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
218956954|NCT00924781|DRUG|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
218956955|NCT00924781|DRUG|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
218956956|NCT03819907|COMBINATION_PRODUCT|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
219059084|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
218956957|NCT03819907|COMBINATION_PRODUCT|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
219640713|NCT04590586|DRUG|Zilucoplan|Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
218956958|NCT02042820|OTHER|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
218956959|NCT01385228|DRUG|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
218956960|NCT01385228|DRUG|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
219640714|NCT04590586|DRUG|Zilucoplan placebo|Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
219640715|NCT03470155|PROCEDURE|mitral valve repair|operative reconstruction
218956961|NCT01385228|DRUG|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
218956962|NCT01385228|DRUG|Prednisone|5mg Prednisone given twice daily days 1-21.
218956963|NCT01385228|DRUG|Pegfilgrastim|
218956964|NCT00069888|DRUG|Docetaxel|
218956965|NCT00937885|BEHAVIORAL|Implementation of reminiscence|
218956966|NCT01642810|BEHAVIORAL|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
218956967|NCT01642810|OTHER|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
218956968|NCT00708201|DRUG|Alvimopan|
218956969|NCT00708201|DRUG|Placebo|
218956970|NCT01294527|DEVICE|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
218956971|NCT00558129|DEVICE|X-STOP®|Surgical implantation of X-STOP IPD device
218956972|NCT00558129|PROCEDURE|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
218956973|NCT06032481|PROCEDURE|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
218956974|NCT01653132|DRUG|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
218956975|NCT01653132|DRUG|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
218956976|NCT03865797|OTHER|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
218956977|NCT03865797|OTHER|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
218956978|NCT03828370|BEHAVIORAL|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
218956979|NCT03828370|BEHAVIORAL|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
218956980|NCT01125787|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
218956981|NCT04690062|DRUG|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
219640716|NCT01893281|DRUG|Topical Testosterone Solution|Administered topically to axillae.
219640717|NCT05130710|PROCEDURE|staging laparoscopy|All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
219640718|NCT05879523|DRUG|HRS-1893|subcutaneous, single dose, multiple doses
219640719|NCT05879523|DRUG|Placebo|subcutaneous, single dose, multiple doses
219640720|NCT04931823|DRUG|CPO-100|Docetaxel albumin-bound
218956982|NCT01663077|DRUG|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
218956983|NCT01076894|PROCEDURE|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
218956984|NCT01076894|PROCEDURE|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
218956985|NCT02101814|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery)|
218956986|NCT03231020|OTHER|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
218956987|NCT03016676|OTHER|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
218956988|NCT03016676|OTHER|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
218956989|NCT03986073|DRUG|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
219059085|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
219059086|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
219059087|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
219059088|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
219059089|NCT03813615|BEHAVIORAL|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
219059090|NCT03813615|BEHAVIORAL|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
219640721|NCT06539624|GENETIC|EXG110 injection|EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
218956990|NCT03986073|DRUG|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
218956991|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
218956992|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
218956993|NCT03986073|DRUG|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
218956994|NCT03986073|DRUG|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
219059091|NCT05226650|OTHER|Regular meal pattern|6 meals every day
219059092|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
219059093|NCT05755373|OTHER|No treatment given|No treatment given
219059094|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
219640722|NCT06251635|DRUG|Olanzapine 2.5Mg Oral Tablet|"Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg"
219640723|NCT06251635|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.
219640724|NCT06251635|DRUG|Insulin Lispro 100 UNT/ML|At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.
218956995|NCT03633760|DRUG|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
218956996|NCT03633760|DRUG|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
218956997|NCT04335201|DRUG|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
218956998|NCT04127812|BEHAVIORAL|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
218956999|NCT00041587|DRUG|IL13-PE38QQR|
218957000|NCT00041587|PROCEDURE|targeted fusion protein therapy|
218957001|NCT00041587|PROCEDURE|surgery|
218957002|NCT05214846|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
219059095|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
219059096|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
219059097|NCT06534294|OTHER|standard care|standard medical care no other treatment
219059098|NCT02386202|OTHER|No intervention|No interventions
219059099|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
219207437|NCT04503265|DRUG|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
219640725|NCT06251635|DRUG|Saline|At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
219640726|NCT04512534|DRUG|PD-1 antibody+ HDAC inhibitor|"Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~* Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~* Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator."
218957003|NCT03518476|BEHAVIORAL|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
218957004|NCT03518476|OTHER|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
218957005|NCT00503945|DEVICE|Nasal continuous positive airway pressure (nCPAP)|
218957006|NCT01830400|DRUG|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
218957007|NCT03032770|DEVICE|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
218957008|NCT04240353|OTHER|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
218957009|NCT03800472|DRUG|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
218957010|NCT03800472|DRUG|Placebo|Placebo tablets
218957011|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
218957012|NCT03800472|DRUG|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
218957013|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
218957014|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
218957015|NCT03800472|DRUG|Placebo|Placebo optimized tablets
218957016|NCT06092060|DIETARY_SUPPLEMENT|the group GS (probiotic)|The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24
218957017|NCT06092060|DIETARY_SUPPLEMENT|the group GP (placebo)|The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.
218957018|NCT03253471|DRUG|AL-611|AL-611 tablets
218957019|NCT03253471|DRUG|Placebo|Placebo to Match AL-611
218957020|NCT02677324|DRUG|ABT199|Oral BCL-2 antagonist
218957021|NCT02323360|RADIATION|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
219059100|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
219059101|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
219059102|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
219059103|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
219059104|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
219059105|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
219059106|NCT06986707|OTHER|Strain counterstrain technique|"Group A: Conventional treatment will be given for 45 minutes (repeated 2 sets in each session)~* 1 day per week~* 4 weeks protocol"
219059107|NCT06986707|OTHER|Graston technique|"GROUP B: Conventional treatment will be given for 45 minutes Before starting procedure, brisk walking or stretching is done for 4- 5 minutes~* Applying heat for 3-4 minutes to warm the area~* 40 seconds on right side~* 40 seconds on left side~* 1 day per week~* 4 weeks protocol After treatment, apply Ice for 2 minutes"
219059108|NCT02610699|OTHER|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
219059109|NCT02610699|OTHER|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
219059110|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
219207438|NCT04503265|DRUG|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
219640727|NCT04450524|BEHAVIORAL|Hypnosis|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
218957022|NCT02323360|PROCEDURE|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
218957023|NCT01221844|DIETARY_SUPPLEMENT|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
218957024|NCT01221844|DRUG|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
218957025|NCT00461331|DRUG|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
218957026|NCT00461331|DRUG|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
218957027|NCT04016740|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
218957028|NCT04016740|DRUG|Ketamine|Intraoperative infusion
218957029|NCT04016740|DRUG|Remifentanil|Intraoperative infusion
218957030|NCT04016740|DRUG|Dexmedetomidine|Intraoperative infusion
218957031|NCT04016740|DRUG|Rocuronium|Intraoperative intermittent bolus
218957032|NCT04016740|DRUG|Propofol|Intraoperative infusion
218957033|NCT04016740|DRUG|Sevoflurane|Intraoperative inhaled as needed
219059111|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
219059112|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
219059113|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
219059114|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
219059115|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
219059116|NCT06884501|BEHAVIORAL|Latin dance, MIND diet, and Strength training|This will be a 6 month remote-delivered BAILAMOS™ dance program, MIND diet and strength training intervention.
219059117|NCT06884501|BEHAVIORAL|Latin dance and MIND Diet|This will be a 6 month remote-delivered BAILAMOS™ dance and MIND diet program.
219059118|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
219059119|NCT00568308|DRUG|placebo|matched placebo
219640728|NCT04450524|BEHAVIORAL|Food inhibition training|Training the associations between foods and motor inhibition using a GO-NO-GO computer task.
219640729|NCT04450524|BEHAVIORAL|Control|A simple GO-NO-GO task
219059120|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
219059121|NCT07042256|RADIATION|Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses|Low-field MR-informed adaptive marker-less SBRT
219059122|NCT06889740|OTHER|NMNH|Reduced Nicotinamide Mononucleotide
219640730|NCT05847738|BEHAVIORAL|Pain assessment|Pain was assesd postoperatively in both groups at time intervals
219640731|NCT05628038|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
219640732|NCT05628038|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
218957034|NCT04016740|DRUG|Dexmedetomidine|Post-operative infusion
218957035|NCT04016740|DRUG|Propofol|Post-operative infusion
218957036|NCT04016740|DEVICE|EEG monitoring|Perioperative monitoring
218957037|NCT05860010|DRUG|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
218957038|NCT05860010|DRUG|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
218957039|NCT05860010|DRUG|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
218957040|NCT03312751|DRUG|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
218957041|NCT00241501|DRUG|Esomeprazole (Nexium)|
218957042|NCT03490981|OTHER|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
218957043|NCT03490981|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
218957044|NCT04929665|PROCEDURE|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
218957045|NCT03108781|DRUG|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
218957046|NCT03108781|DRUG|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
218957047|NCT02324543|DRUG|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
218957048|NCT02324543|DRUG|Taxotere|IV on days 4 and 11 of a 21 day cycle
218957049|NCT02324543|DRUG|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
218957050|NCT02324543|DRUG|Cisplatin|IV on days 4 and 11 of a 21 day cycle
219640733|NCT05628038|DRUG|5FU|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
219640734|NCT05628038|DRUG|folinic acid|400 mg/m2 q2w
219640735|NCT05628038|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
218957051|NCT02324543|DRUG|Irinotecan|IV on days 4 and 11 of a 21 day cycle
218957052|NCT00282464|DRUG|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
218957053|NCT00282464|DRUG|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
218957054|NCT03748043|DRUG|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
218957055|NCT03748043|DRUG|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
218957056|NCT05578027|PROCEDURE|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
218957057|NCT00475423|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
219059123|NCT06889740|OTHER|Placebo|Starch powder
219059124|NCT07045883|DRUG|Vitamin D Supplementation+ standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. In the vitamin D-deficient group, participants will receive standard treatment plus oral vitamin D3 supplementation (800 IU daily for 4 weeks), whereas the vitamin D normal group will receive standard treatment alone
219059125|NCT07045883|OTHER|standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. The vitamin D normal group will receive standard treatment alone
219059126|NCT06743750|DIAGNOSTIC_TEST|RT-PCR in different respiratory tract samples|RT-PCR on saliva, orrobuccal swab and nasal swab will be performed. Nasopharyngeal swab will be performed independently of the study as standard of care.
219059127|NCT07051499|DRUG|TAP Block Group|Bilateral ultrasound-guided TAP block with 0.25% levobupivacaine and 75 mcg clonidine per side, plus standard intraoperative intravenous analgesia (ketorolac, tramadol, ondansetron).
219059128|NCT07052175|BEHAVIORAL|Standard Multidisciplinary Treatment|Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.
219059129|NCT07052175|BEHAVIORAL|Digital Monitoring Tool|In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.
219059130|NCT07051265|BEHAVIORAL|Transcutaneous Electrical Nerve Stimulation (TENS)|Participants received TENS therapy at two specific acupoints - Hegu (LI4) and Lieque (LU7). Surface electrodes were placed over the acupoints, and stimulation was delivered using a standard TENS device.
219059131|NCT07051265|BEHAVIORAL|Acupressure|The acupressure group placed the acupoint patches on the Hegu and Lieque points on both hands and pressed each acupoint with the index finger and thumb for 1 minute, 3 times a day, each time for about 4 minutes.
219059132|NCT07051382|DIAGNOSTIC_TEST|Transcranial Sonographic Examination (Cranial Ultrasound)|"No evidence of intracranial abnormalities such as intraventricular hemorrhage, germinal matrix hemorrhage, periventricular leukomalacia, hydrocephalus, or infarction.~Brain structures were assessed to be age-appropriate for gestational development."
219059133|NCT07051395|DIAGNOSTIC_TEST|Road Traffic Accidents Patient|Coagulation Profiles And Injury Severity In Road Traffic Accidents Patients at Dera Ismail Khan
219059134|NCT07052123|DEVICE|MultiSense® Non-Invasive Hemodynamic Monitoring Device|The MultiSense® device is a wireless, non-invasive monitoring system designed to continuously measure blood pressure, microcirculation, central body temperature, and detect arrhythmias in ICU patients. It aims to reduce risks associated with invasive monitoring, improve patient comfort and mobility, and decrease alarm fatigue through intelligent alert algorithms.
219059135|NCT07051629|BIOLOGICAL|SIF001|SIF001 intravenous infusion every two weeks
219059136|NCT07051629|DRUG|Placebo|Placebo
219059137|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
219059138|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
219059139|NCT07051941|OTHER|Validation of a satisfaction questionnaire for robotic surgeon|"The primary endpoint is to validate a questionnaire to assess user satisfaction among expert surgeons utilizing various surgical robotic systems, including - but not limited to - the Da Vinci®, Hugo™ RAS, Versius®, and Toumai® platforms.~Based on these domains, an initial pool of items was generated; items were formulated as Likert-scale questions (5-point) and grouped into thematic sections.~The validation of the Questionnaire will be developed with a 2-step process.~1. Test for Content Validity and Face Validity: a pilot test will be performed with 5-10 surgeons from FPG to ensure content and face validity, item comprehension, and usability.~2. Validation from external users:"
219207439|NCT05247424|DRUG|Unfractionated heparin|Unfractionated heparin at dose of 100 IU /kg body weight
218957058|NCT00916214|OTHER|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
219207440|NCT06112847|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219640736|NCT05628038|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
218957059|NCT04700033|DEVICE|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
219640737|NCT05628038|DRUG|Raltitrexed|2 mg/m² q2w and 3 mg/m² q3w
219640738|NCT05628038|DRUG|Cetuximab|400 mg/m² q2w
219640739|NCT05628038|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
219207441|NCT06112847|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219207442|NCT06112847|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219640740|NCT05628038|RADIATION|Radiation|"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
219640741|NCT03512717|DEVICE|Potenfill|Maximum: 22ml
219640742|NCT03512717|DEVICE|Powerfill|Maximum: 22ml
219640743|NCT04844034|DIETARY_SUPPLEMENT|High-EPA multinutrient supplement.|"Three capsules with the largest meal of the day providing:~* 1,125 mg EPA~* 441 mg DHA~* 330 mg Magnesium~* 7.5 mg a-tocopherol"
219059140|NCT06898749|OTHER|canine mediation|"Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction.~The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist).~The canine educator will be a state-certified professional educator with a specialization in animal mediation.~The dog used is trained by the educator, with two types of learning being worked on: emotions and commands on cue."
219059141|NCT06898749|OTHER|standard psychomotor therapy|standard sessions of psychomotor therapy
219059142|NCT07051460|OTHER|Baseline Condition (No Stimuli)|Participants underwent baseline evaluation using the Vertical Maddox Test with no auditory or oral proprioceptive stimulation. This phase was used to confirm the absence of spontaneous visual pseudo-scotomas and served as an internal control condition for each participant.
219207443|NCT06112847|OTHER|Electronic Health Record Review|Ancillary studies
219207444|NCT06112847|BIOLOGICAL|Epcoritamab|Given SC
219207445|NCT06112847|DRUG|Lenalidomide|Given PO
219207446|NCT06112847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219207447|NCT06112847|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219207448|NCT03560908|DRUG|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
219207449|NCT06467019|OTHER|Informative Session|The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.
219207450|NCT01135433|DRUG|ipragliflozin|oral
219207451|NCT01135433|DRUG|Placebo|oral
218957060|NCT04700033|DEVICE|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
218957061|NCT04700033|DEVICE|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
218957062|NCT00287170|DRUG|Delayed Release 6MP or Calcitriol vs. Purinethol|
219207452|NCT01135433|DRUG|metformin|oral
219207453|NCT06827249|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, on the basis of conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, nebulized inhalation using air compression or oxygen-driven methods is administered on days 1, 3, and 5, once a day.
219640744|NCT04844034|OTHER|Placebo|"Three capsules with the largest meal of the day providing:~* 3,060 mg sunflower seed oil~* 60 mg lecithin~* 300 mg glyceryl monostearate~* 465 mg EPA/DHA (18%/12% respectively for blinding)"
218957063|NCT05111275|OTHER|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
218957064|NCT01348009|DRUG|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
218957065|NCT00088998|BIOLOGICAL|bevacizumab|
218957066|NCT00088998|DRUG|capecitabine|
218957067|NCT00088998|DRUG|docetaxel|
218957068|NCT01492543|DRUG|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
219640745|NCT02218736|DRUG|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
219640746|NCT02218736|DRUG|placebo|oral dosing of 10 mg placebo daily for 8 weeks
218957069|NCT03473418|DRUG|Ketoconazole|Ketoconazole as a topical vaginal gel
219640747|NCT03341442|PROCEDURE|No hip precautions|No hip precautions practiced after THA surgery
219640748|NCT03374696|BEHAVIORAL|SAFETY|
219640749|NCT03374696|BEHAVIORAL|Standard education|
219640750|NCT03778918|OTHER|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
219640751|NCT03778918|OTHER|IBS or Normal Control|blood based biomarker compared normal control with IBD
219640752|NCT00761670|DRUG|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
218957070|NCT03473418|DRUG|Terconazole|Terconazole 80 mg as a topical vaginal cream
218957071|NCT04309123|DEVICE|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
218957072|NCT03831685|OTHER|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
218957073|NCT04224545|DRUG|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
218957074|NCT04224545|DRUG|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
219207454|NCT06827249|DRUG|Recombinant Human Interferon α2b|Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg, based on the conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, will be administered via nebulized inhalation using air compression or oxygen-driven methods from day 1 to day 5, twice daily.
219207455|NCT06841406|DRUG|budesonide|During an 8-week treatment period, patients will receive 9 mg of Budesonide daily, administered orally in enteric-coated capsules. Following this period, participants will undergo a gradual dose reduction to minimize the risk of adrenal insufficiency: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
219207456|NCT06841406|DRUG|Mannitol|During an 8-week treatment period, patients will receive 9 mg of Mannitol daily, administered orally in enteric-coated capsules as placebo control. Following this period, participants will undergo a gradual dose reduction as is the case in the experimental group: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
219207457|NCT06988020|DEVICE|MRI|Whole body MRI including ZTE sequences
219207458|NCT06836453|DEVICE|Sweat stimulation and secretion quantification|"First session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then bubble test. b. right arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then evaporimetry.~Second session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then bubble test. b. Right arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then evaporimetry."
219640753|NCT02370628|PROCEDURE|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~* Step 1: facet block~* Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
219640754|NCT02370628|PROCEDURE|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
219640755|NCT06260111|DEVICE|Photobiomodulation|"Photobiomodulation will be used in sessions of approximately 5 to 10 minutes each. An InGaIP diode laser will be used with the following parameters: wavelength of 660 nm, output power of 40 mW, and an energy density of 4 J/cm2 measured at the end of the fiber optic with 0.04 cm2 of section area. The laser will be applied at 10 points in each oral region, with an exposure time of 4 s per point, using 0.16 J of energy per point.~The protocol was based on previous studies."
219640756|NCT06260111|OTHER|Usual care|Usual care for oral mucositis includes education, cryotherapy, and mouth hygiene.
219640757|NCT04026828|GENETIC|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
219640758|NCT04767997|DIETARY_SUPPLEMENT|Probiotic formulation|Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.
219640759|NCT04767997|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take a placebo capsule daily.
219640760|NCT05407870|DRUG|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
218957075|NCT00167466|DEVICE|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
218957076|NCT00167466|DEVICE|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
218957077|NCT02127060|DRUG|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
218957078|NCT02127060|DRUG|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
218957079|NCT05956184|DEVICE|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
218957080|NCT01954420|BEHAVIORAL|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
218957081|NCT01954420|OTHER|Attention Control|Standard care + Cancer education
218957082|NCT02633852|DRUG|Aflibercept|
218957083|NCT00879931|DRUG|Methylprednisolone|Methylprednisolone
218957084|NCT00879931|DRUG|Placebo|Placebo (NaCl 0.9%)
218957085|NCT06135194|DRUG|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
218957086|NCT00719797|BIOLOGICAL|bevacizumab|Given IV
218957087|NCT00719797|DRUG|fluorouracil|Given IV
218957088|NCT00719797|DRUG|irinotecan hydrochloride|Given IV
218957089|NCT00719797|DRUG|leucovorin calcium|Given IV
218957090|NCT00719797|DRUG|oxaliplatin|Given IV
218957091|NCT00046891|DRUG|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
218957092|NCT00046891|OTHER|Placebo|Patients will take 1 tablet BID
218957093|NCT06143605|PROCEDURE|salvage treatment|salvage radical surgery or endoscopic resection
218957094|NCT00002988|DRUG|carmustine|
218957095|NCT00002988|DRUG|irinotecan hydrochloride|
218957096|NCT03252600|DRUG|Cyclophosphamide|Given IV
218957097|NCT03252600|DRUG|Dexamethasone|Given IV
218957098|NCT03252600|BIOLOGICAL|Elotuzumab|Given IV
219059143|NCT07051460|OTHER|Auditory Stimulation only|Participants received bilateral auditory stimulation consisting of 500 Hz tones (500 ms duration, 50 dB) delivered through wireless headphones, without any accompanying oral stimuli. This condition was used to assess the isolated effect of sound on visual perception using the Vertical Maddox Test.
219059144|NCT07051460|OTHER|Auditory and Oral Proprioceptive Stimulation (OPS)|Participants received simultaneous auditory and oral proprioceptive stimuli while undergoing the Vertical Maddox Test. - Auditory: 500 Hz tones (500 ms, 50 dB) via headphones. - Oral Proprioceptive Stimuli (OPS): included Combined Oral Stimuli (e.g., tongue and lip self-administered positions) and Dental Stimuli (mechanical pressure or traction on central incisors using a calibrated probe). This condition aimed to assess whether OPS could modulate or eliminate sound-induced visual pseudo-scotomas.
219059145|NCT07051460|OTHER|Oral Proprioceptive Stimulation Only (OPS)|Participants received oral proprioceptive stimuli alone, without auditory input, during the Vertical Maddox Test. - Combined Oral Stimuli (COS): self-administered tongue/lip positions. - Dental Stimuli (DS): applied by the operator to central incisors. This condition was used to evaluate the independent effect of OPS on visual perception.
219059146|NCT06576297|OTHER|Inspiratory Muscle Training (IMT)|IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.
219059147|NCT06576297|OTHER|Standard of Care|Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
219640761|NCT05407870|DRUG|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
219640762|NCT03879525|OTHER|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
219640763|NCT03879525|OTHER|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
219059148|NCT06830096|DRUG|10 mg glipizide ingestion|A single dose of 10 mg glipizide will be ingested
219059149|NCT05274022|OTHER|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
218957099|NCT03252600|OTHER|Laboratory Biomarker Analysis|Correlative studies
218957100|NCT03252600|DRUG|Lenalidomide|Given PO
218957101|NCT03252600|OTHER|Pharmacological Study|Correlative studies
218957102|NCT04349293|PROCEDURE|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
218957103|NCT04349293|PROCEDURE|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
218957104|NCT04378985|DEVICE|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
218957105|NCT01198379|DRUG|aspirin|aspirin 100 mg qd for 3 years
218957106|NCT01198379|DRUG|Placebo|
218957107|NCT02496676|DIETARY_SUPPLEMENT|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
218957108|NCT02496676|OTHER|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
218957109|NCT02496676|DRUG|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
218957110|NCT02265601|OTHER|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
218957111|NCT02265601|OTHER|standard care|paper/pencil living will form
218957112|NCT05444140|BEHAVIORAL|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
218957113|NCT00756925|DRUG|Acthrel|1 ug/kg, i.v., 1 minute
218957114|NCT00006157|DRUG|Desipramine|
218957115|NCT00006157|BEHAVIORAL|Cognitive Behavioral Treatment|
218957116|NCT06195761|PROCEDURE|computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide
218957117|NCT06195761|PROCEDURE|free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
218957118|NCT02666703|DEVICE|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
219059150|NCT05274022|OTHER|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
219059151|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
219059152|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
219059153|NCT06786130|OTHER|observational study|This is an observational study in which participants complete PRO questionnaires via a web platform. No medical intervention or medication is involved.
219059154|NCT03522142|DRUG|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
219059155|NCT03522142|DRUG|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
219059156|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 4.1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219059157|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 4.1 Usage|Participants will use their Radicle Revive Active Study Product 1.1 as directed for a period of 6 weeks.
219059158|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
219059159|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
219059160|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
219059161|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
219059162|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
219059163|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load|"Diagnostic Test: Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.~Other Names:~Bloodwork for HgbA1c, lipid profile, creatinine, albumin and vitamin D levels. Body measurements: Ht. Wt, BMI, waist and hip measurements for waist/hip ratio. Measurements of systolic and diastolic blood pressure and heart rate"
219059164|NCT06911619|DIETARY_SUPPLEMENT|Dietary management|The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month. Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)
219059165|NCT06911619|OTHER|No dietary management|The patient will be followed up by his reference hepatologist every 3 months. Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.
219059166|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
219059167|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
219059168|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
219059169|NCT06922604|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219640764|NCT05481125|DEVICE|Clareon IOL|Alcon Clareon Aspheric Hydrophobic Acrylic IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
218957119|NCT02666703|DRUG|Methylprednisolone|
218957120|NCT06329089|PROCEDURE|Reoperative Sentinel Lymph Node Biopsy|Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
218957121|NCT04009083|DEVICE|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
218957122|NCT04009083|OTHER|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
218957123|NCT01653028|DRUG|Alisertib|Given PO
218957124|NCT01653028|OTHER|Laboratory Biomarker Analysis|Correlative studies
218957125|NCT05715671|DRUG|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
218957126|NCT03507114|BEHAVIORAL|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
218957127|NCT05297435|DIAGNOSTIC_TEST|Questionnaires|Questionnaire study
218957128|NCT01795820|DRUG|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
218957129|NCT01795820|DRUG|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
218957130|NCT01967498|DRUG|Montelukast|
218957131|NCT00319319|DRUG|Mecamylamine hydrochloride (Inversine)|
219059170|NCT06922604|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219059171|NCT06922604|BIOLOGICAL|Glofitamab|Given IV
219059172|NCT06922604|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219059173|NCT06922604|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
219059174|NCT06922604|BIOLOGICAL|Obinutuzumab|Given IV
219059175|NCT06922604|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219059176|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
219059177|NCT06935435|OTHER|Pink Beans|Pink beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
218957132|NCT04672252|DRUG|CBD Oral Disintegrating Tablet (ODT)|Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
218957133|NCT04672252|OTHER|Placebo ODT|"Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine."
218957134|NCT02927912|RADIATION|Electron Beam Therapy|Undergo IOERT boost
218957135|NCT02927912|PROCEDURE|Lumpectomy|Undergo lumpectomy
218957136|NCT02927912|OTHER|Quality-of-Life Assessment|Ancillary studies
218957137|NCT02927912|OTHER|Questionnaire Administration|Ancillary studies
218957138|NCT02927912|RADIATION|Radiation Therapy|Undergo whole breast radiation therapy
218957139|NCT02927912|PROCEDURE|Reconstructive Surgery|Undergo oncoplastic reconstruction
219059178|NCT06935435|OTHER|Great Northern Beans|Great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
219059179|NCT06935435|OTHER|Five-Bean Mixture|Five-bean mixture made of pinto, kidney, black, pink, and great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
219059180|NCT06938672|DEVICE|Placebo Transcranial Direct Current Stimulation (tDCS)|Placebo Transcranial direct current stimulation (tDCS): Participants will experience a 20-minute session of placebo tDCS on two consecutive days.
219059181|NCT06938672|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Active transcranial direct current stimulation (tDCS). Participants will experience a 20-minute session of active tDCS (1.2 mA) on two consecutive days.
219059182|NCT04560504|OTHER|Control Group|Leisure activities
218957140|NCT02391805|DRUG|Entecavir|Entecavir will be administered as per local labeling.
218957141|NCT02391805|DRUG|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
218957142|NCT02391805|DRUG|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
218957143|NCT02391805|DRUG|Tenofovir|Tenofovir will be administered as per local labeling.
219059183|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
219059184|NCT06940219|PROCEDURE|Delayed Sequence Induction|Delayed Sequence Induction - fractional dosing of Ketamin and Midazolam until a dissociative status is achieved. Dosing should follow the clinical effect. - start of preoxygenation with Bag-Valve-Mask Device or NIV when dissociative status is achieved for at least 3 minutes. - after completion of preoxygenation: neuromuscular blockade with Rocuronium - after application of Rocuronium: Intubation via standard of care. - should apnoea occur during preoxygenation, the continuation of ventilation via Bag-Valve-Mask or NIV is recommended, but not mandatory.
218957144|NCT03751735|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
218957145|NCT04391569|DRUG|Ganaxolone|Ganaxolone will be administered.
218957146|NCT04391569|DRUG|Placebo|Placebo will be administered.
219059185|NCT06940219|PROCEDURE|Modified Rapid Sequence Induction|Modified Rapid Sequence Induction - Preoxygenation FiO2 100% with Bag-Valve-Mask-Device or NIV for at least 3 Minutes. - After completion of Preoxygeniation: application of Midazolam, Ketamin and Rocuronium. - The dosing of medication is determined in advance by the operating physician. - Ventilation via Bag-Valve-Mask-device or NIV after application of rocuronium is allowed. - After application of medication: Intubation via standard of care.
219059186|NCT06947135|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
219059187|NCT06947135|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
219059188|NCT06954337|OTHER|Usual practice pattern (UPP)|Patient follows usual practice pattern for routine care
218957147|NCT03025035|DRUG|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
218957148|NCT03025035|DRUG|Olaparib|Olaparib administered orally twice a day
218957149|NCT05911243|PROCEDURE|Acupressure Therapy|Undergo auricular acupressure
218957150|NCT05911243|OTHER|Best Practice|Receive usual care
218957151|NCT05911243|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218957152|NCT05911243|OTHER|Questionnaire Administration|Ancillary studies
218957153|NCT04463797|OTHER|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
218957154|NCT04463797|OTHER|Stretching and strengthening|whole-body stretching and upper extremity strengthening
218957155|NCT01952808|BEHAVIORAL|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
218957156|NCT01952808|BEHAVIORAL|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
218957157|NCT00935155|PROCEDURE|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
218957158|NCT00935155|PROCEDURE|exercises|Coordination, mobilizing, endurance, strength
218957159|NCT03647189|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser
218957160|NCT00305929|DRUG|Treatment with Tookad VTP|
218957161|NCT00305929|DRUG|Treatment with Tookad VTP|Tookad 2 mg/kg
218957162|NCT00305929|DRUG|Treatment with Tookad VTP|2 mg/kg
218957163|NCT01431638|DRUG|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
218957164|NCT00536393|DRUG|Doxorubicin|
219059189|NCT06954337|OTHER|Experimental: Enhanced Telehealth (ET)|Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications
219059190|NCT03657641|BIOLOGICAL|Pembrolizumab|Given IV
218957165|NCT00536393|DRUG|Doxorubicin pegylated|
218957166|NCT04253054|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
218957167|NCT04253054|OTHER|Aging related health problems|Aging related health problems
218957168|NCT03603171|DIAGNOSTIC_TEST|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
218957169|NCT03603171|DIAGNOSTIC_TEST|R-PAct|A Rasch-built Pompe-specific activity scale.
218957170|NCT03603171|DIAGNOSTIC_TEST|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
218957171|NCT03603171|DIAGNOSTIC_TEST|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
218957172|NCT03603171|DIAGNOSTIC_TEST|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
218957173|NCT03603171|DIAGNOSTIC_TEST|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
218957174|NCT03603171|DIAGNOSTIC_TEST|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
218957175|NCT03603171|DIAGNOSTIC_TEST|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
218957176|NCT03603171|DIAGNOSTIC_TEST|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
218957177|NCT03603171|DIAGNOSTIC_TEST|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
219059191|NCT03657641|DRUG|Regorafenib|Given PO
219059192|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
219640765|NCT05481125|DEVICE|Clareon Toric IOL|Clareon Toric Aspheric Hydrophobic Acrylic Toric IOL for the visual correction of aphakia with pre-existing corneal astigmatism in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
219059193|NCT05582941|OTHER|No intervention will be performed.|No intervention will be performed.
219059194|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
219059195|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
219059196|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
219059197|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
219640766|NCT05481125|DEVICE|Eyhance IOL|TECNIS Eyhance IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
219640767|NCT05481125|DEVICE|Eyhance Toric IOL|TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
219640768|NCT05481125|PROCEDURE|Phacoemulsification surgery|Cataract removal by routine small incision phacoemulsification surgery
219059198|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
219059199|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
219059200|NCT03946943|DRUG|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
219059201|NCT03946943|DRUG|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
219059202|NCT03946943|PROCEDURE|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
219059203|NCT03946943|PROCEDURE|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
219059204|NCT04691869|DEVICE|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
219059205|NCT04194190|DRUG|Individual Patient TCR-Transduced PBL|
219059206|NCT03435393|PROCEDURE|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
219640769|NCT02244463|DRUG|MLN0128|
219640770|NCT03138031|PROCEDURE|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
219640771|NCT05017896|DIAGNOSTIC_TEST|Normal CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is normal.
219640772|NCT05017896|DIAGNOSTIC_TEST|Low CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is low.
219640773|NCT06439381|DRUG|300mg/600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
219640774|NCT01769508|DRUG|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
219640775|NCT01769508|DRUG|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
219640776|NCT01769508|DRUG|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
219640777|NCT01769508|RADIATION|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
219640778|NCT06685458|OTHER|Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling|This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.
219640779|NCT02940418|BIOLOGICAL|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
219059207|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
219059208|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
219059209|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
219059210|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
219059211|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
219059212|NCT04536636|DRUG|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
219059213|NCT04536636|DRUG|Control-No drug|Patients received usual medical care with no DHA
219640780|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia|The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
219640781|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia + biweekly support|Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
218957178|NCT03603171|DIAGNOSTIC_TEST|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference \> 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
218957179|NCT03603171|DIAGNOSTIC_TEST|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
218957180|NCT03603171|DIAGNOSTIC_TEST|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
218957181|NCT03603171|DIAGNOSTIC_TEST|Quick motor function test|Assessment of proximal motor function.
219640782|NCT03770962|BEHAVIORAL|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
218957182|NCT03603171|DIAGNOSTIC_TEST|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
218957183|NCT03603171|DIAGNOSTIC_TEST|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
219059214|NCT03151265|DEVICE|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
219059215|NCT03339076|DEVICE|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
219640783|NCT01298869|BIOLOGICAL|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
219640784|NCT05799612|DRUG|Paclitaxel|Given by IV (vein)
219640785|NCT05799612|BIOLOGICAL|mRNA plus Lysate-loaded Dendritic Cell Vaccine|Given by IV (vein)
219640786|NCT05799612|DRUG|PEGYLATED-INTERFERON ALPHA-2A|Given by IV (vein)
219059216|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
219059217|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
219059218|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
219640787|NCT05799612|DRUG|Filgrastim|Given by IV (vein)
219640788|NCT05571124|BEHAVIORAL|Therapeutic Exercise Intervention|Participants will perform stretching and mobility exercises in short bouts of time.
219640789|NCT06365710|OTHER|Telerehabilitation|Telerehabilitation program
219640790|NCT06365710|OTHER|Traditional physiotherapy|Guided rehabilitation program with physiotherapist appointments
219640791|NCT06068881|DRUG|Tazverik (Tazemetostat)|Oral Tablet
219640792|NCT00595738|OTHER|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
218957184|NCT03603171|DIAGNOSTIC_TEST|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
218957185|NCT03603171|DIAGNOSTIC_TEST|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
218957186|NCT03603171|DIAGNOSTIC_TEST|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
218957187|NCT00108108|DRUG|HCD122|
218957188|NCT00168792|DRUG|Tenecteplase|
218957189|NCT00168792|PROCEDURE|PCI|
219059219|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
219059220|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
219059221|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
219059222|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
219059223|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
219059224|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
219059225|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
219640793|NCT04490603|BEHAVIORAL|Virtual reality experience|Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
219640794|NCT01598090|BIOLOGICAL|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
219640795|NCT01598090|BIOLOGICAL|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
219640796|NCT01598090|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
219640797|NCT01598090|DRUG|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
219640798|NCT03615144|DRUG|Melphalan|Melphalan 70 mg/m2/day x 2
219640799|NCT03615144|DRUG|Thiotepa|Thiotepa 7.5 mg/kg/day x 2
219640800|NCT03615144|DRUG|Clofarabine|Clofarabine 20-30 mg/m2/day x 5
218957190|NCT03543488|DIAGNOSTIC_TEST|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
219640801|NCT03615144|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 5
219640802|NCT03615144|DRUG|Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)|antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
219640803|NCT03615144|PROCEDURE|CliniMACS reagents|Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
219640804|NCT00000260|DRUG|Nitrous oxide|
218957191|NCT04967040|PROCEDURE|medial plantar artery flap|Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
218957192|NCT04967040|PROCEDURE|Distally based sural artery flap|Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
218957193|NCT02227940|DRUG|Ceritinib|Given PO
219059226|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
219059227|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
219059228|NCT00004867|PROCEDURE|conventional surgery|
219059229|NCT00004867|PROCEDURE|positron emission tomography|
219059230|NCT00004867|PROCEDURE|radionuclide imaging|
219059231|NCT00004867|RADIATION|fludeoxyglucose F 18|
219059232|NCT00004867|DRUG|chemotherapy|
219059233|NCT00004867|RADIATION|Radiotherapy|
219640805|NCT06665750|BEHAVIORAL|Exercise|A progressive upper extremity neuromuscular exercise program was performed face to face with the researcher physiotherapist for the study group. The exercise program was applied for approximately 20 minutes, 2 days a week for 6 weeks, on the same days of the week, before the participants' tennis training. The exercise content and number of repetitions in the training program changed every 2 weeks with increasing difficulty.
218957194|NCT02227940|DRUG|Cisplatin|Given IV
219059234|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
219059235|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
219207465|NCT05811078|BEHAVIORAL|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
218957195|NCT02227940|DRUG|Gemcitabine Hydrochloride|Given IV
218957196|NCT02227940|OTHER|Laboratory Biomarker Analysis|Correlative studies
219059236|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
219059237|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
219059238|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
219059239|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
219059240|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
219059241|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
219059242|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
219059243|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
219059244|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
219640806|NCT06668337|DRUG|Normal Saline (Placebo)|Participants in the control group receive a continuous intravenous infusion of normal saline, which serves as an inert placebo with no pharmacological effect. This intervention mimics the administration of the active treatments, allowing for direct comparison with the ephedrine groups to assess the effectiveness of the drug in preventing maternal hypotension during spinal anesthesia.
219640807|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
219059245|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
219640808|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
219640809|NCT02358109|BEHAVIORAL|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
219640810|NCT04548115|BEHAVIORAL|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
218957197|NCT02227940|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
218957198|NCT02227940|OTHER|Pharmacological Study|Correlative studies
218957199|NCT05824507|DIAGNOSTIC_TEST|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
218957200|NCT03338413|BEHAVIORAL|Goal Management Training|9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
218957201|NCT03338413|BEHAVIORAL|Computerized Cognitive Training|9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
218957202|NCT03706651|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
218957203|NCT03409887|PROCEDURE|Intraorifice barrier of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
218957204|NCT03409887|PROCEDURE|Base of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
218957205|NCT03409887|PROCEDURE|Direct composite restoration|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
218957206|NCT00288743|DRUG|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
218957207|NCT01643980|DRUG|Vaginal micronized progesterone|200 mg vaginal route per day
219059246|NCT01696630|DRUG|Xenon|
218957208|NCT01643980|DEVICE|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
218957209|NCT00686998|DRUG|AZD2624|Oral Suspension
218957210|NCT00686998|DRUG|Olanzapine|PO BID
218957211|NCT00686998|DRUG|Placebo|
219059247|NCT01696630|DRUG|Desflurane|
219059248|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
219059249|NCT05634681|RADIATION|Standard plan|One treatment plan
219059250|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
219059251|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
219207466|NCT06825195|OTHER|isokinetic muscle strength measurement|Wrist isokinetic eccentric flexor and extensor peak Torque and fatigue will be measured at the angular velocity of 180°/s
218957212|NCT02653261|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
218957213|NCT02653261|DRUG|Placebo|An equal volume of saline
218957214|NCT01066676|DRUG|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
218957215|NCT01066676|DRUG|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
218957216|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
218957217|NCT06480760|DRUG|Carnosine|Food ingredient (supplement)
218957218|NCT06013215|OTHER|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
218957219|NCT06823479|DRUG|Nivolumab|3 mg/kg
218957220|NCT06823479|DRUG|Ipilumimab|1 mg/kg
218957221|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
218957222|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
218957223|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
218957224|NCT03189056|DIAGNOSTIC_TEST|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
218957225|NCT03189056|BIOLOGICAL|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
218957226|NCT03189056|PROCEDURE|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
218957227|NCT06982495|DEVICE|NCKU-NG system|Nasogastric tube insertion with a novel nasogastric tube assisted placement system (NCKU-NG system)
218957228|NCT06982495|OTHER|Conventional blind insertion|Conventional blind insertion following standard external measurement methods (eg. Nose-Earlobe-Xiphoid + 10 cm)
218957229|NCT06984107|DEVICE|MRONJ resection plus PN+HA|Surgical management will be performed by reflecting a full-thick flap to expose the entire affected area, followed by removal of necrotic bone until a vital, unaffected bony margin will be obtained. After bone resection, the PN+HA (Regenfast®) will be applied on the residual bone surface. Wound management will be done via primary closure.
218957230|NCT04445792|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
218957231|NCT04445792|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
218957232|NCT06987864|BIOLOGICAL|eculizumab|Intravenous infusion of BCD-148 every 2 weeks
218957233|NCT05671809|OTHER|NCRT with surgery, or NCT with surgery, or surgery|The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
218957234|NCT06995027|PROCEDURE|BBAP and RAA pacing|Bachmann's bundle area pacing and conventional pacing in the right atrial appendage during regular pacemaker implantation procedures are applied for acute electrocardiogram and echocardiogram testings.
218957235|NCT06993727|OTHER|Blood sampling|For the analysis of the autoimmune endocrine disease related antibodies (Ab) before the start of the immunotherapy, a blood sample will be collected aligned with the first visit with the treating gastro-enterologist/oncologist/pneumologist for analysis of: anti-thyroglobulin Ab (aTg), anti-thyroperoxidase Ab (aTPO), TSH receptor antibodies (TRAb), pituitary Ab, adrenal Ab, and anti-glutamic acid decarboxylase (GAD) Ab.
219059252|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
218957236|NCT06995768|OTHER|Sweat patch|Wear sweat patch during regular team sports practice session
219059253|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
219059254|NCT00173667|DRUG|Nifedipine 30 mg GITS|
219640811|NCT04548115|BEHAVIORAL|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
218957237|NCT06993701|BEHAVIORAL|Vimala Massage Training for Fathers|Fathers will receive Vimala massage training and apply it regularly to their babies at home.
218957238|NCT06993701|OTHER|Control Intervention|babies in the control group will not receive any intervention
218957239|NCT06993701|BEHAVIORAL|Vimala Massage Training for Mothers|Mothers will receive Vimala massage training and apply it regularly to their babies at home.
218957240|NCT06995664|PROCEDURE|radiotherapy|External Beam Radiotherapy - hypofractionated, short radiotherapy regime of 30Gy in 5 fractions (6Gy per fraction) delivered on alternate days over 2 weeks
218957241|NCT06995222|DIAGNOSTIC_TEST|renal resistive index with Doppler ultrasound|"Renal resistive index uses doppler ultrasonography which assesses blood flow velocity in the renal arteries. The Renal Resistive Index (RI) is calculated by substracting diastolic velocity from systolic velocity then dividing result by systolic velocity~Where:~Systolic velocity is the peak velocity of the blood flow during the systolic phase of the cardiac cycle.~Diastolic velocity is the velocity of blood flow during the diastolic phase."
218957242|NCT06995443|OTHER|Photobiomodulation|12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)
219207467|NCT06825195|OTHER|Minimum pinch force measurement|the minimum fingertip pinch force required to hold a constant weight will be measured
219640812|NCT04548115|BEHAVIORAL|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
219640813|NCT04548115|BEHAVIORAL|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
219640814|NCT04548115|BEHAVIORAL|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
219640815|NCT04455477|DRUG|Nesiritide|The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.
218957243|NCT06993532|OTHER|Validity and Reliability|The TASD questionnaire, the Thumb Disability Examination (TDX) questionnaire, the Visual Analogue Scale (VAS) for pain, as well as hand grip and pinch strength measurements using the Jamar® Hydraulic Hand Dynamometer and Jamar Hydraulic Pinch Gauge Dynamometer were employed to assess thumb function and muscle strength. The questionnaires were administered twice, with a 7-day interval, during which no medical or rehabilitation intervention was made that could alter the clinical condition of the patients.
219059255|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
219640816|NCT02587598|DRUG|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
219640817|NCT02587598|DRUG|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
219640818|NCT02587598|DRUG|Azacitidine|Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
219640819|NCT02587598|DRUG|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
219059256|NCT06452459|OTHER|No interventinon|No intervention is anticipated. This is an observational study.
219059257|NCT05361473|DEVICE|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
219059258|NCT05361473|PROCEDURE|Traditional evaluation|Traditional way of evaluation
219059259|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
219059260|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
219059261|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
219059262|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
219059263|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
219059264|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
219059265|NCT02486224|DIETARY_SUPPLEMENT|Kona Deep|Subjects will receive Kona Deep post exercise
219059266|NCT02486224|DIETARY_SUPPLEMENT|Spring Water|Subjects will receive Spring Water post exercise
219059267|NCT02486224|DIETARY_SUPPLEMENT|Sports Drink|Subjects will receive Sports Drink post exercise
219059268|NCT00673049|DRUG|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
219059269|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
219059270|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
219059271|NCT02241226|BEHAVIORAL|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
219059272|NCT05266911|BEHAVIORAL|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
219640820|NCT05437861|BEHAVIORAL|Brief Intervention|A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
219640821|NCT05326828|DEVICE|CONFIRM Rx implantable cardiac rhythm monitor (Abbott)|Implantation of CONFIRM Rx ICM
219640822|NCT05326828|DIAGNOSTIC_TEST|Systematic etiologic work-up for underlying causes of MINOCA|Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
218957244|NCT06995599|PROCEDURE|Thoracic Duct Ligation (TDL)|Following the minimally invasive right-sided lung cancer resection, during mediastinal lymph node dissection, the posterior aspect of the azygos vein is identified. The mediastinal pleura is then longitudinally incised along the medial border of the azygos vein and posterior to the esophagus. Between the azygos vein and aorta, the thoracic duct is meticulously localized as a milky-white translucent structure measuring 2-3 mm in diameter. A 5-mm segment of the duct is carefully mobilized and double-clamped with vascular clips under direct thoracoscopic visualization. The surgical field is thoroughly inspected to confirm the absence of chylous leakage, and the procedure is concluded after standard closure and confirmation of hemostasis.
219059273|NCT05266911|BEHAVIORAL|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
219059274|NCT05680025|BEHAVIORAL|Physical exercise intervention|"The intervention group will have access to training videos through social networks (WhatsApp and YouTube) and infographics. The mobile phone of each of the participants will allow send dates of workshops, link for videos, messages reminding to perform exercise routines.~The training plan will be designed so the participants will achieve being physically active at the end of 6 months of intervention. Training will be planned to gradually, through 3 levels, increase the duration and intensity of exercises; they will have an important component of aerobic exercises and others for muscular strength. Each level of training will last two months; at each level the participants will be given 4 specific trainings and will be asked to perform two per week at level 1 and 2; and at the 3 level, 3 trainings per week.~The strategy for promoting physical exercise is based on the social cognitive theory, in which the bases of the transtheoretical model are found."
219059275|NCT05680025|BEHAVIORAL|Workshops|Six workshops to promote the performance of physical activity. The workshops will be held with groups of 15 participants. During them, the work will be to promote motivation to perform physical exercise, sharing information about the health benefits, benefits for control of the disease, together creating planning of measurable, realistic goals; reinforcing behavior when the desired advances are made, monitoring progress (using a monthly self-report of exercise performed). The participants will be motivated and congratulated each time for goals reached, self-sufficiency will be reinforced as well as greater evaluation of the advantages of performing exercise against the barriers or negative aspects perceived by the participants. These activities will be performed according to the level of exercise performed by the individuals (stage of change).
219059276|NCT03421925|PROCEDURE|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
219059277|NCT05522803|DEVICE|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
219059278|NCT05522803|DEVICE|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
219059279|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
219059280|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
219059281|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
219059282|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
219059283|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
219059284|NCT02569697|OTHER|HEC Placebo gel|
219059285|NCT02569697|OTHER|Placebo Intravaginal Ring|
219059286|NCT02569697|OTHER|Placebo Vaginal Film|
219059287|NCT02569697|OTHER|Placebo Vaginal Insert|
219059288|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
219059289|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
219059290|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
219059291|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
219059292|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
219059293|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
219059294|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
219059295|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
219059296|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
219059297|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
219059298|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
219059299|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
219059300|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
219059301|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
219059302|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
219059303|NCT01511952|OTHER|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
219059304|NCT01511952|OTHER|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
219059305|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
219059306|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
219640823|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10\^5 CAR-20/19-T cells/kg"
219640824|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)"
218957245|NCT06988592|DRUG|GemCis plus PD-1/PD-L1 inhibitor|"Gemcitabine: 1000 mg/m², intravenous infusion, on Day 1 and Day 8 Cisplatin: 25 mg/m², intravenous infusion, on Day 1 and Day 8 PD-1/PD-L1 inhibitor: An approved agent (e.g., Pembrolizumab, Nivolumab, Atezolizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.~Each treatment cycle lasts 21 days, continuing until disease progression, unacceptable toxicity, or patient/physician decision to discontinue."
219640825|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)"
219640826|NCT04049383|BIOLOGICAL|CAR-20/19-T cells|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated."
218957246|NCT06995040|DIAGNOSTIC_TEST|Cerebral MRI without contrast agent injection|Cerebral MRI at inclusion or after
218957247|NCT06995040|GENETIC|saliva sample|Saliva sample for DNA analysis at inclusion or send to their home.
218957248|NCT06995040|OTHER|Questionnaires|Quality of life and cognitive questionnaires at inclusion
218957249|NCT06995560|DEVICE|Active Transcranial Electrical Stimulation|Active tES delivered using the Soterix Medical MXN-33 HD-tES stimulator. Stimulation is applied via high definition electrodes targeting either the left DLPFC or L-aINS at intensities up to 1.9 mA. Stimulation is performed for up to 45 minutes during task execution. Participants perform the ROBoT-r task during stimulation.
218957250|NCT06995560|DEVICE|Sham Transcranial Electrical Stimulation|Sham tES using the same Soterix Medical MXN-33 HD-tES stimulator and electrode placements. Stimulation ramps up and down over 20 seconds to mimic sensation but provides no continuous current. Participants perform the ROBoT-R task under sham conditions.
218957251|NCT06995157|BIOLOGICAL|Offering HPV vaccine|During regular cervical cancer prevention visit with the gynecologist, HPV vaccine will be offered to participants 35 years or younger.
218957252|NCT06994039|PROCEDURE|EUS-lePPG|EUS-PPG measured in left lateral decubitus position
218957253|NCT06995287|DRUG|Xeomin|One injection will be performed via hysteroscopy under local anesthesia.
218957254|NCT06995287|DRUG|Placebo|One injection will be performed via hysteroscopy under local anesthesia.
218957255|NCT02320903|DEVICE|VillageWhere App|
218957256|NCT03074942|DRUG|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
218957257|NCT06087003|DRUG|Basiliximab Injection|As an induction treatment for kidney transplantation
218957258|NCT06087003|DRUG|rabbit ATG|As an induction treatment for kidney transplantation
218957259|NCT06961669|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）.
218957260|NCT00991068|DRUG|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
219059307|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
219059308|NCT04028375|OTHER|No intervention|No intervention
219059309|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
218957261|NCT00036374|DRUG|Infliximab|
218957262|NCT03673410|PROCEDURE|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
218957263|NCT03673410|PROCEDURE|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
218957264|NCT04350346|DRUG|Motilitone|"1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
218957265|NCT04350346|DRUG|Gasmotin|"1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
218957266|NCT03841838|OTHER|Energy drink|Two 12 oz bottles of commercially available energy drink
218957267|NCT03841838|OTHER|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
218957268|NCT02113839|PROCEDURE|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
219059310|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
219059311|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
218957269|NCT02113839|PROCEDURE|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
219640827|NCT05015998|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
219640828|NCT04144582|DRUG|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
219640829|NCT03244631|PROCEDURE|Lumbar Plexus BLock|Peripheral nerve block
219640830|NCT03244631|PROCEDURE|Pericapsular injection|Injection around the area undergoing surgery
219640831|NCT04912440|DEVICE|MSE-ERCP|No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
219640832|NCT02764957|DIETARY_SUPPLEMENT|green coffee extract|
219640833|NCT02764957|DIETARY_SUPPLEMENT|placebo|
219640834|NCT03253289|DRUG|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
219640835|NCT04709692|DRUG|(+)-SJ000557733 (SJ733)|Anti-Malarial
219640836|NCT04062162|BEHAVIORAL|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
219640837|NCT00623740|DRUG|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
219640838|NCT00623740|DRUG|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
219640839|NCT00974467|BEHAVIORAL|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
219640840|NCT00974467|OTHER|Control|Usual hospital care provided.
218957270|NCT02113839|PROCEDURE|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
218957271|NCT02113839|PROCEDURE|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
218957272|NCT00780390|OTHER|Autonomic Function Assessment|
218957273|NCT05736484|BEHAVIORAL|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
218957274|NCT03838315|OTHER|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
218957275|NCT03838315|OTHER|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
218957276|NCT03493815|PROCEDURE|Transabdominal Ultrasound Guided IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
219640841|NCT00004465|DRUG|SYNSORB Pk|
218957277|NCT03493815|PROCEDURE|Traditional Blind IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
218957278|NCT05521880|DRUG|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
219059312|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
219640842|NCT00004465|DRUG|Placebo|
219640843|NCT03880968|DRUG|tapering or discontinuation of etanercept|Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
219640844|NCT03636204|BIOLOGICAL|AL001|Active dose of AL001
219640845|NCT03636204|OTHER|Placebo|Saline solution administered as a single infusion as palcebo.
219640846|NCT00399646|DEVICE|Metricath Gemini System|
219640847|NCT05526846|BEHAVIORAL|Plant-based diet education|"Participants will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy."
219640848|NCT06654830|PROCEDURE|RATT|Robotic-assisted thoracoscopic thymectomy (RATT) will be performed using Da Vinci Robotic Surgical Systems.
219640849|NCT06654830|PROCEDURE|VATT|Video-assisted thoracoscopic thymectomy (VATT) was performed using traditional thoracoscopic systems.
219640850|NCT03386396|DIETARY_SUPPLEMENT|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
219640851|NCT03386396|DIETARY_SUPPLEMENT|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
219207468|NCT06611293|DIAGNOSTIC_TEST|Breath test|"Participants will perform breath testing in Primary care followed by Secondary care on Day 1. At each location, participants will be asked to perform three breath tests (15 minutes apart). The environmental air will also be sampled.~This entire process will be repeated in the reverse order (i.e. breath testing in Secondary care followed by Primary care on Day 2).~Participants will be asked to maintain a clear fluid diet for a minimum of six hours prior to breath collection on both Day 1 and Day 2 of sampling."
219207469|NCT06788405|OTHER|hand hygiene theoretical training with a hand hygiene virtual reality simulation application|After giving 360 hours of hand hygiene theoretical training to the participants in the experimental group, a hand hygiene virtual reality simulation application will be performed.
219207470|NCT06788405|OTHER|hand hygiene theoretical training|Participants in the control group will receive only 360 hours of hand hygiene theoretical training. Participants in this group will not be given hand hygiene virtual reality simulation application.
219207471|NCT06781905|OTHER|Assessments of neuropsychiatric, neurocognitive and psychosocial alterations|Assessments will be conducted over two consecutive days. The first day will focus on the evaluation of neuropsychiatric and neurocognitive alterations. A comprehensive assessment involving various tools (clinical examination, individual interview, psychometric tests, standardized scales) will be carried out by a psychiatrist, a neuropsychologist, and a neurologist. The second day will be dedicated to psychosocial assessments by a team of social psychologists using a comprehensive qualitative and quantitative approach to quality of life. Quality of life will be understood as a subjective appreciation of the individual's place in their existence and three main dimensions will be explored: daily life management, social relationships, and self-image and self-esteem. The collected data will be subjected to a reflexive thematic analysis. The qualitative exploration of quality of life will be complemented by a quantitative assessment using a standardized tool (EORTC QLQ LC13).
219207472|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
219207473|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
219207474|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
219207475|NCT06988579|OTHER|AI|An integrated AI-human collaborative workflow for lung cancer screening interpretation
219640852|NCT06665958|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
219640853|NCT00280358|DRUG|Fluticasone Propionate|
219640854|NCT00280358|DRUG|Formoterol Fumarate|
219640855|NCT03976687|DRUG|EYP001a|Oral tablets
219640856|NCT03989206|DRUG|Nemolizumab|Nemolizumab
219640857|NCT05495152|DRUG|Sintilimab|Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
219640858|NCT02726906|BEHAVIORAL|Moderate-aerobic walking|
219640859|NCT02726906|RADIATION|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
219640860|NCT02726906|BEHAVIORAL|Healthy living education|
219640861|NCT02726906|DEVICE|Physical activity monitor|Wrist device that will track daily physical activity
219640862|NCT05522205|OTHER|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
219640863|NCT00355147|BEHAVIORAL|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
219640864|NCT00355147|BEHAVIORAL|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
219640865|NCT00355147|OTHER|Attention Control Group|Received Phone Calls from Staff to Control for Attention
219640866|NCT06594133|DRUG|Antibiotic Treatment|"For lung transplant recipients with Nocardia infection, the treatment regimen could include:~Sulfamethoxazole/Trimethoprim (Bactrim): 800 mg/160 mg orally or intravenously twice daily for at least 6 months.~Imipenem: 500 mg intravenously every 6 hours for severe cases. Monitoring: Regular monitoring of blood levels of the drug to avoid toxicity and adjust doses accordingly."
219640867|NCT01118260|PROCEDURE|total intravenous anaesthesia|propofol and remifentanil
218957279|NCT01109160|DRUG|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
218957280|NCT04599153|OTHER|Ventriculoperitoneal shunt opening pressure setting|The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.
218957281|NCT02621684|OTHER|Community Health Activities Model Program for Seniors (CHAMPS)|"* Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took"
218957282|NCT02621684|OTHER|Lifetime Total Physical Activity Questionnaire|"* Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
218957283|NCT02621684|OTHER|Expanded Prostate Cancer Index Composite (EPIC)|"* Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function"
218957284|NCT02621684|OTHER|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
219059313|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
219059314|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
219059315|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
219059316|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
219059317|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
219059318|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
219640868|NCT01118260|PROCEDURE|spinal anaesthesia|bupivacaine and fentanyl
219059319|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
219207476|NCT03124277|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
219640869|NCT02348346|OTHER|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
219640870|NCT05038722|OTHER|Platelet transfusion|Transfusion of platelet concentrates according to routine practice.
219640871|NCT02015416|BIOLOGICAL|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
219640872|NCT06966661|BEHAVIORAL|Peer Support Intervention|In addition to all components of Standard Health Education, participants join biweekly, small-group meetings (6-8 peers) facilitated by trained upper-year student mentors who guide goal-setting, experience sharing, and mutual accountability. A moderated online chat forum provides daily encouragement, peer-to-peer Q\&A, and group reminders, distinguishing this arm by its structured social support network.
218957285|NCT02621684|OTHER|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
219059320|NCT03574792|DRUG|Gabapentin|Given PO
219059321|NCT03574792|DRUG|Methadone|Given PO
219059322|NCT03574792|DRUG|Oxycodone|Given PO
219059323|NCT03574792|OTHER|Quality-of-Life Assessment|Ancillary studies
219059324|NCT03574792|OTHER|Questionnaire Administration|Ancillary studies
219059325|NCT03574792|DRUG|Venlafaxine|Given PO
218957286|NCT02621684|OTHER|Questionnaire regarding behavior/lifestyle changes since diagnosis|
218957287|NCT02621684|OTHER|12 week Walking Program|
219059326|NCT03574792|DRUG|Venlafaxine Hydrochloride Extended Release|Given PO
219059327|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
219059328|NCT06077396|PROCEDURE|radial artery cannulation|radial artery cannulation
219059329|NCT02595203|DRUG|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
219207477|NCT03124277|OTHER|Control Group|Best local diet
219207478|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
219207479|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide|Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
219207480|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
219207481|NCT06991712|DIETARY_SUPPLEMENT|Nicotinic Acid|Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
218957288|NCT02621684|OTHER|12 week Resistance Training Program|
218957289|NCT00972933|DRUG|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
218957290|NCT03684239|BEHAVIORAL|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
219059330|NCT02595203|DRUG|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
218957291|NCT03684239|OTHER|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
218957292|NCT00354003|BEHAVIORAL|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
218957293|NCT00852332|DIETARY_SUPPLEMENT|Curcumin|
218957294|NCT00852332|DRUG|Taxotere|
219059331|NCT01868581|DRUG|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
218957295|NCT00923988|OTHER|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
218957296|NCT03914846|PROCEDURE|Ultrasound|Undergo ultrasound with elastography
218957297|NCT06530186|DEVICE|LiviWell Postcoital Vaginal Insert|subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
218957298|NCT02585570|DRUG|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
218957299|NCT05398081|DRUG|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
219059332|NCT01868581|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
219059333|NCT06432712|DRUG|Dexamethasone 4mg|2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
219059334|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
218957300|NCT05398081|DRUG|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
218957301|NCT03970889|DEVICE|Klue|Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
219059335|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
219059336|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
219059337|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
219059338|NCT01519713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
219059339|NCT04269928|PROCEDURE|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
219059340|NCT01413451|DRUG|Amatuximab (MORab-009)|
219059341|NCT01335243|PROCEDURE|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
219059342|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
219059343|NCT01813799|DRUG|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
219059344|NCT01813799|DRUG|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
219059345|NCT01813799|DRUG|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
219059346|NCT01813799|DRUG|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
219059347|NCT01348451|DEVICE|surgical implantation|human spinal cord stem cell implantation in ALS patients
219059348|NCT00121771|BIOLOGICAL|FP9 CS|
219059349|NCT00121771|BIOLOGICAL|MVA CS|
219059350|NCT04820673|DRUG|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
219059351|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
218957302|NCT01099709|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
218957303|NCT01099709|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
218957304|NCT06284629|DEVICE|Neptune|Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.
218957305|NCT06284629|OTHER|Standard clinical care|Treatment and management according to standard clinical care
219640873|NCT06966661|BEHAVIORAL|Peer Support and eHealth Intervention|This arm integrates the full Peer Support Intervention with a custom mobile/web application that delivers weekly, interactive modules on nutrition, exercise, and mental health; offers in-app self-monitoring tools for weight, dietary intake, and mood; and hosts monthly live Q\&A webinars with clinical nutritionists and mental health professionals. The combination of real-time peer interaction and scalable digital content differentiates it as a multifaceted, blended-delivery intervention.
218957306|NCT00002455|BIOLOGICAL|Corynebacterium granulosum P40|
218957307|NCT00002455|PROCEDURE|adjuvant therapy|
219059352|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
219059353|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
219059354|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
219059355|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
219059356|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
219059357|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
218957308|NCT03636698|OTHER|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
218957309|NCT02996643|DEVICE|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
219059358|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
219059359|NCT00453765|DRUG|placebo|placebo
219059360|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
218957310|NCT02095496|DEVICE|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
219059361|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
219059362|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
219207482|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
218957311|NCT02095496|DEVICE|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
218957312|NCT06678633|DEVICE|T-Control® (experimental)|Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.
218957313|NCT06678633|DEVICE|Folysil® (control)|Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
218957314|NCT00266851|DRUG|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
218957315|NCT00266851|DRUG|Placebo|Matching placebo
218957316|NCT03521804|DEVICE|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
218957317|NCT05762770|PROCEDURE|PICSI|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
218957318|NCT02428127|DIETARY_SUPPLEMENT|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
218957319|NCT02428127|DIETARY_SUPPLEMENT|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
219059363|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
219640874|NCT02717416|DEVICE|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
218957320|NCT02428127|OTHER|Water|lukewarm water
219059364|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
219207483|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
218957321|NCT02060448|BEHAVIORAL|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
218957322|NCT02060448|BEHAVIORAL|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
218957323|NCT02346578|DRUG|Enzalutamide|
218957324|NCT02346578|DRUG|Flutamide|
218957325|NCT03956069|BIOLOGICAL|blood sample|for patient and its parents
218957326|NCT03956069|GENETIC|genome sequencing|whole genome sequencing
218957327|NCT05377073|OTHER|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
218957328|NCT05377073|OTHER|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
218957329|NCT02218476|DRUG|CoQ10|
218957330|NCT02218476|DRUG|Placebo|
219059365|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
218957331|NCT03616223|DRUG|FX-322|Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
219207484|NCT06587568|BEHAVIORAL|Mobile chat messaging|A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.
219207485|NCT06587568|BEHAVIORAL|Screening, brief intervention and referral to treatment|Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
219059366|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
219059367|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
219207486|NCT06997432|PROCEDURE|Double-blind placebo-controlled oral challenge test (DBPCFC)|Group 1. To evaluate MTD, DBPCFC will be done with peach with skin and/or peach juice as described. The patient will remain under observation for at least 2 hours.
219207487|NCT06997432|OTHER|Dietary intervention|Group 2. Patients will take for one year, MTD of fresh peach or peach juice with a frequency of 3 times/week.
219207488|NCT06997328|OTHER|Implementation of the '5 Rs to Rescue'|Quality improvement intervention increases surveillance for patients at risk of 'failure to rescue' after surgery
218957332|NCT03616223|DRUG|Placebo|Intratympanic injection
219207489|NCT06997211|BEHAVIORAL|EFT|The EFT session will be conducted mutually with the practitioner. The average duration of the session is planned to be 40-45 minutes.
218957333|NCT06307860|DEVICE|pulsed field ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
218957334|NCT06307860|PROCEDURE|radiofrequency ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
218957335|NCT05849285|OTHER|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
218957336|NCT01122394|BEHAVIORAL|TI|Tailored intervention based on the transtheoretical model
219207490|NCT06996457|DEVICE|VR|The use of a virtual reality (VR) headset to present videos with nature imagery and natural sounds (music)
219207491|NCT06996522|PROCEDURE|underwater endoscopic mucosal resection|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by UEMR
219207492|NCT06996522|PROCEDURE|Hot snare polypectomy|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by HSP
219207493|NCT06996340|OTHER|White noise group|The woman who was taken to the gynecological table for invirto fertilization will be made to listen to white noise (rain and waterfall sound) with a Bluetooth headset at a range of 75-85 decibels during the procedure. Because, it covers all sound ranges that people can hear within the range of 75-85 decibels (Cho and Hwang, 2021; Lin et al, 2018).
219207494|NCT06996340|OTHER|routine care|routine care
219207495|NCT06997055|DRUG|Ustekinumab 45 mg|biosimilar
219207496|NCT06997055|DRUG|Ustekinumab 90 mg|biosimilar
218957337|NCT01122394|BEHAVIORAL|AP|Attention placebo
218957338|NCT02970370|OTHER|no intervention|
218957339|NCT03787979|OTHER|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
218957340|NCT03787979|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
218957341|NCT00039871|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
218957342|NCT00039871|DRUG|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
219059368|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
219059369|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
218957343|NCT04638504|OTHER|ultrasonography|vascular and adipose tissue measurement by ultrasonography
218957344|NCT03751774|BEHAVIORAL|MAMAACT|Post graduate training and health education materials
219207497|NCT06996704|DRUG|AK0610 Injection solution|Active Substance: AK0610 Pharmaceutical Form: Injection solution Route of Administration: Intramuscular injection or intravenous injection.
219207498|NCT06996704|DRUG|Placebo|Active Substance: Placebo Pharmaceutical Form: Injection Route of Administration: Intramuscular injection or intravenous injection
219207499|NCT06996717|DRUG|ESA|anemia management algorithm will successfully increase the number of patients in the target hemoglobin range
219207500|NCT06996171|DRUG|Magnesium glycinate|Tab Magnesium glycinate 500mg will be given to one group for treatment of primary insomnia
219207501|NCT06996171|DRUG|Melatonin|Tab Melatonin 10mg will be given to the other group for treatment of primary insomnia
219640875|NCT02717416|DEVICE|hemoclip or electrical coagulation|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
219640876|NCT06968065|PROCEDURE|Ultrasound-guided serratus anterior plane block and serratus-intercostal interfascial plane block with bupivacaine|Participants will receive an ultrasound-guided serratus anterior plane (SAP) block using 30 mL of 0.25% bupivacaine combined with a serratus-intercostal interfascial plane (SIP) block using 10 mL of 0.25% bupivacaine. Both blocks will be administered after surgery but before emergence from anesthesia. This combination targets multiple interfascial planes to enhance postoperative analgesia in patients undergoing minimally invasive cardiac surgery (MICS).
219207502|NCT06997783|OTHER|warm up|"1. Standard Warm-Up (SWU):~   This condition will involve a typical judo-specific warm-up protocol lasting approximately 25 minutes.~2. Moderate-Load PAPE Warm-Up (80% of 6RM):~   This experimental warm-up condition will consist of the same initial exercises as the SWU, followed by the addition of a moderate-load squat-based PAPE protocol.~3. Maximal-Load PAPE Warm-Up (100% of 1RM):~This condition will also begin with the same general and judo-specific exercises as the SWU, followed by a high-intensity PAPE protocol: 1-2 sets of a single repetition of back squats at 100% of the participant's 1-repetition maximum (1RM)."
218957345|NCT00736177|PROCEDURE|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
218957346|NCT00736177|PROCEDURE|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
218957347|NCT01251627|DRUG|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
219640877|NCT06968065|PROCEDURE|Local wound infiltration with bupivacaine|Participants will receive local wound infiltration with 40 mL of 0.25% bupivacaine applied to the surgical and drain sites following surgery. This approach represents a standard method for managing postoperative pain in MICS patients and serves as the active comparator.
219640878|NCT03798301|BIOLOGICAL|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
219640879|NCT00964990|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
219640880|NCT00964990|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
218957348|NCT02153476|DRUG|2.0mg of ALG-1001|
219059370|NCT06635239|OTHER|Co-creation and assessment|"1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)"
219059371|NCT03103282|DEVICE|PuraStat®|Synthetic haemostatic material
219059372|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
219059373|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
219059374|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
219059375|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
219059376|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
219059377|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
219059378|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
219059379|NCT04789421|DEVICE|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
218957349|NCT02153476|DRUG|Balanced Salt Solution|
218957350|NCT00008827|BEHAVIORAL|Behavioral weight loss|
218957351|NCT03198039|BEHAVIORAL|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
219640881|NCT06967116|PROCEDURE|Procedure Steps|The data of the study were collected with the 'Patient Identification Form' and 'Meatal Pressure Injury Daily Monitoring Form'.
218957352|NCT02920853|BEHAVIORAL|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
219640882|NCT00225225|DRUG|Rosiglitazone|
219640883|NCT00225225|BEHAVIORAL|dietary recommendation for weight maintenance|
219640884|NCT05889364|DIAGNOSTIC_TEST|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
219640885|NCT03156608|DEVICE|Novii ECG/EKG System|External fetal heart rate monitoring
219640886|NCT03156608|DEVICE|External fetal heart rate monitoring|External fetal heart rate monitoring
219640887|NCT06666959|DRUG|Anesthesia Agent|intravenous anesthetic and inhalation anesthetic
219640888|NCT02990585|OTHER|Back school|
219640889|NCT02798289|DEVICE|Oculeve Intranasal Neurostimulator|Neurostimulation device
219640890|NCT02912260|DRUG|MGL-3196|
219640891|NCT02912260|DRUG|Placebo|
219640892|NCT02303223|DRUG|Propofol|
219640893|NCT02688062|BIOLOGICAL|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
219640894|NCT02688062|PROCEDURE|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
219640895|NCT01298726|OTHER|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
219640896|NCT01298726|OTHER|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
219640897|NCT03240068|DRUG|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
219640898|NCT03240068|DRUG|Saline|Normal saline will be used as the placebo comparator.
219640899|NCT02304731|OTHER|Physical Exercise|Incremental running
218957353|NCT02920853|BEHAVIORAL|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
218957354|NCT02708082|DEVICE|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
218957355|NCT03027479|OTHER|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
218957356|NCT05818111|DRUG|steroid|triamcinolone 40mg 4cc
218957357|NCT05818111|DRUG|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
219640900|NCT03138837|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
219640901|NCT05051280|PROCEDURE|cone-beam computed tomography fusion image|Left Atrial Appendage Occlusion Under Cone-beam Computed Tomography Fusion Image Guidance
219640902|NCT02420080|DRUG|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
219640903|NCT00827216|DRUG|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
219640904|NCT00827216|DRUG|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
219640905|NCT05423496|DIAGNOSTIC_TEST|KidneyCare|Using KidneyCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
219640906|NCT05423496|DRUG|steroid|optimization of steroids
219640907|NCT05423496|DRUG|MMF|optimization of MMF
218957358|NCT05818111|DRUG|Normal saline 2cc|normal saline 2cc
218957359|NCT05818111|DRUG|normal saline 12cc|normal saline 12cc
218957360|NCT06324916|RADIATION|Xray|X rays for ankle to see distal fibular remenant
219059380|NCT04789421|DEVICE|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
219059381|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
218957361|NCT02399436|BEHAVIORAL|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:~* Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~* The installation of new filtered water fountains outfitted with water-filling stations;~* The distribution of re-usable water bottles to students at participating schools; and~* A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
218957362|NCT02399436|BEHAVIORAL|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
218957363|NCT01444677|DRUG|MB12066|MB12066 300mg
218957364|NCT01444677|DRUG|MB12066|MB12066 400mg
218957365|NCT01444677|DRUG|MB12066|MB12066 100mg
218957366|NCT01444677|DRUG|MB12066|MB12066 200mg
219640908|NCT03408301|PROCEDURE|Tourniquet deflation|Tourniquet deflation
219640909|NCT00646815|DRUG|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
219640910|NCT04221256|DRUG|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
219640911|NCT04221256|BEHAVIORAL|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
219640912|NCT04221256|DRUG|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
219640913|NCT06491875|BEHAVIORAL|Digital Storytelling (DST)|The DST activity emphasized the use of multimedia to bring the stories to life. At the beginning of the workshop, interactive circles were formed for informative interactions. Children with autism and typically developing children were asked to prepare a short video reflecting a personal experience from their own lives. The children's habits and interests were identified and they were made to work on preparing materials such as pictures, photographs, handicrafts, dough toys, etc. to be uploaded to the computer program. It was explained that they could also choose from ready-made photos in the video editing/editing program for their stories, and that they could make short audio recordings if they wished. Digital stories are usually prepared as videos that combine audio, video, and video clips to tell a story. The DST study was conducted for 16 hours over two months. During the DST, the mothers who wanted to participate and watch also participated in the study.
219640914|NCT06491875|BEHAVIORAL|Sensory Integration Therapy (SIT)|Sensory integration training for children with ASD was conducted 2 days per week for 2 months. Taking into account the results of the Dunn Sensory Profile Scale, sensory approach strategies were determined for children with ASD, taking into account low and high neurological thresholds and hyper- and hyposensitive responses in the auditory, visual, tactile, vestibular and kinesthetic sensory systems. Sensory-motor activities with deep pressure and proprioceptive stimuli were used for children sensitive to tactile stimuli, and activities with linear and slow vestibular stimuli and resistive movement were used for children with kinesthetic sensitivity. In the intervention, swings, ball pools, ramps, rotation, and fast motion inputs were used in swing for children with hypersensitivity to motion, and sensory materials with different textures, play dough, and some other sensory materials were used for children with hypersensitivity to tactile sensory system.
219640915|NCT01707108|DEVICE|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
218957367|NCT01444677|DRUG|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
218957368|NCT04308798|PROCEDURE|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
218957369|NCT05171725|DIAGNOSTIC_TEST|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
218957370|NCT05171725|DIAGNOSTIC_TEST|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
218957371|NCT05171725|DIAGNOSTIC_TEST|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
218957372|NCT05171725|DIAGNOSTIC_TEST|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
218957373|NCT05171725|DIAGNOSTIC_TEST|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
218957374|NCT03767803|OTHER|Non-interventional study|This is an observational, non-interventional study.
218957375|NCT04131218|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
218957376|NCT05796336|DEVICE|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
218957377|NCT01264627|BEHAVIORAL|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
219640916|NCT00020644|DRUG|gemcitabine hydrochloride|
219640917|NCT02749994|DRUG|Rosuvastatin|
219640918|NCT02749994|DRUG|Ezetimibe|
219640919|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
219640920|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
219640921|NCT00542906|OTHER|localization|localization of the several types of somatosensory stimuli
219640922|NCT04164043|BEHAVIORAL|Wellness Recovery Program|12-week community-based recreation therapy
219640923|NCT06296550|OTHER|Dulce Digital Text Messaging Intervention|"Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading."
219640924|NCT06296550|OTHER|CGM Device|Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
219640925|NCT04736277|OTHER|Preoperative HbA1c|Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
219640926|NCT00680602|BEHAVIORAL|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
219640927|NCT00680602|DRUG|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
218957378|NCT01264627|BEHAVIORAL|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
218957379|NCT01555957|DRUG|intravenous lipid|intravenous given daily for 6 weeks
218957380|NCT05607836|DEVICE|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
218957381|NCT05607836|DEVICE|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
218957382|NCT04686487|PROCEDURE|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
218957383|NCT04577339|PROCEDURE|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
218957384|NCT00718081|DRUG|Oral sufentanil|Oral dosage of sufentanil
218957385|NCT00718081|DRUG|Placebo|Oral dosage of placebo
218957386|NCT05791370|DIETARY_SUPPLEMENT|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
219640928|NCT06285851|DIETARY_SUPPLEMENT|FeSC|Supplement
219640929|NCT00970541|DIETARY_SUPPLEMENT|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
218957387|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
218957388|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
219640930|NCT00970541|DIETARY_SUPPLEMENT|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
219640931|NCT04242290|DIAGNOSTIC_TEST|Lateral radiography|The lordosis angles were measured on the lateral cervical graphs of all patients.
219640932|NCT06424171|DIAGNOSTIC_TEST|Cardiac and brain magnetic resonance imaging.|Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.
218957389|NCT02809261|DRUG|Normal Saline|Normal saline is safe for perineural injection.
218957390|NCT02809261|DRUG|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
218957391|NCT03778775|DIAGNOSTIC_TEST|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
218957392|NCT01422967|BEHAVIORAL|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
219640933|NCT05320705|DRUG|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
219640934|NCT01651520|DRUG|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
219640935|NCT00650325|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
219640936|NCT00650325|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fasting
219640937|NCT06049186|BEHAVIORAL|CRD|During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
219207503|NCT05663723|DEVICE|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
219640938|NCT06049186|DRUG|Metformin|After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
219640939|NCT03606304|BEHAVIORAL|Problem-solving therapy|See previous
219640940|NCT00098137|DRUG|Olmesartan|
219640941|NCT02329379|DRUG|Levothyroxine|
219640942|NCT01014364|DRUG|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
219640943|NCT01014364|DRUG|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
219640944|NCT04644705|DRUG|Niclosamide|Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
219640945|NCT04644705|DRUG|Placebo|placebo to the interventional drug
219640946|NCT03691051|DRUG|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
219640947|NCT04610567|DRUG|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
219640948|NCT04610567|DRUG|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
219640949|NCT04610567|DRUG|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
219640950|NCT05331755|DRUG|Dupilumab|start medication in cohort
219640951|NCT04588870|DEVICE|Pre operative computer based cochlear implant surgical simulation|Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
219640952|NCT02060058|DRUG|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
219640953|NCT01672710|DRUG|plain crystalline niacin, exercise, sauna|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
218957393|NCT02394145|DRUG|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
218957394|NCT02394145|DRUG|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
218957395|NCT03833947|DRUG|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
218957396|NCT03833947|DRUG|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
218957397|NCT04589715|OTHER|electroacupuncture|the same as described in experimental arm.
219640954|NCT04404517|DRUG|Adalimumab|Monoclonal antibody used in IBD treatment
219640955|NCT02737254|DRUG|Oxytocin|40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children \>40kg administer 24IU.
219640956|NCT02737254|DRUG|Placebo|NaCl 0,9 % nasal spray.
219640957|NCT02737254|OTHER|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
219640958|NCT02737254|OTHER|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
218957398|NCT04589715|OTHER|sham electroacupuncture|the same as described in sham comparator.
218957399|NCT00357032|DRUG|belinostat|Given IV
219640959|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
218957400|NCT00357032|OTHER|laboratory biomarker analysis|Correlative studies
219640960|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
218957401|NCT01397825|DRUG|Alisertib (MLN8237)|Alisertib (MLN8237) enteric coated tablet (ECT).
219640961|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
219640962|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
219640963|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
218957402|NCT01397825|DRUG|Rituximab|Rituximab IV infusion.
218957403|NCT01397825|DRUG|Vincristine|Vincristine IV Infusion.
218957404|NCT01931670|OTHER|placebo|
218957405|NCT01931670|DRUG|Elagolix|
218957406|NCT06127537|BEHAVIORAL|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual."
219640964|NCT05786469|DRUG|Veltassa Oral Powder Product|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
218957407|NCT01323842|PROCEDURE|EDTU|bedside ultrasound imaging by the treating emergency physician
218957408|NCT00278239|PROCEDURE|cognitive assessment|
218957409|NCT00278239|PROCEDURE|psychosocial assessment and care|
218957410|NCT00278239|PROCEDURE|quality-of-life assessment|
219207504|NCT05663723|DEVICE|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
218957411|NCT00815516|DRUG|micafungin|Administered by intravenous infusion
218957412|NCT00815516|DRUG|amphotericin B deoxycholate|Administered by intravenous infusion
218957413|NCT01541345|DEVICE|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
218957414|NCT01541345|DRUG|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
218957415|NCT01541345|PROCEDURE|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
218957416|NCT03686644|PROCEDURE|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
218957417|NCT03686644|PROCEDURE|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
218957418|NCT04863209|OTHER|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
219640965|NCT05786469|OTHER|Placebo|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
218957419|NCT04863209|OTHER|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
218957420|NCT03671473|DEVICE|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
218957421|NCT00244842|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
218957422|NCT00244842|DRUG|Placebo|Placebo
218957423|NCT00607932|BEHAVIORAL|behavioral dietary intervention|
218957424|NCT00607932|DIETARY_SUPPLEMENT|Brassica vegetable|
219640966|NCT06253715|DRUG|Isoniazid|Once daily weight-based dose
219640967|NCT06253715|DRUG|Rifampin|Once daily weight-based dose
219640968|NCT06253715|DRUG|Pyrazinamide|Once daily weight-based dose
219640969|NCT06253715|DRUG|Ethambutol|Once daily weight-based dose
219640970|NCT06253715|DRUG|Rifapentine|Once daily weight-based dose
218957425|NCT00607932|DRUG|indole-3-carbinol|follow up at 2,4,6 months post baseline.
218957426|NCT00607932|OTHER|counseling intervention|2, 4, 6 months post baseline
218957427|NCT00607932|OTHER|medical chart review|2,4,6 months post baseline
219059382|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
219059383|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
218957428|NCT00607932|OTHER|questionnaire administration|
219059384|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
219059385|NCT02832895|OTHER|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
219059386|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
219640971|NCT06253715|DRUG|Moxifloxacin|Once daily weight-based dose
219640972|NCT04959240|DRUG|Velmanase Alfa|
219640973|NCT06160492|DRUG|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
219640974|NCT04999163|DEVICE|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
218957429|NCT00607932|PROCEDURE|adjuvant therapy|
218957430|NCT01736657|DEVICE|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
218957431|NCT02415855|DRUG|Dabigatran|
218957432|NCT04309747|PROCEDURE|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
218957433|NCT04524338|DEVICE|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
218957434|NCT02326311|DRUG|imatinib|Tyrosin kinase inhibitor
218957435|NCT02326311|DRUG|nilotinib|Tyrosin kinase inhibitor
218957436|NCT02326311|DRUG|dasatinib|Tyrosin kinase inhibitor
218957437|NCT01049477|OTHER|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
218957438|NCT01049477|OTHER|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
218957439|NCT00947050|OTHER|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
218957440|NCT00099645|DRUG|Mifepristone|
218957441|NCT06198140|OTHER|myofascial release and quick icing|In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
219059387|NCT06534801|DRUG|Oxycodone will be administered intravenously in the group 1|Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
219059388|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
219207505|NCT05663723|DEVICE|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
219207506|NCT06997224|OTHER|triflow application|After we have exhaled, we will try to hold the balls up as long as possible by pulling them inward with all our strength. After repeating this five times, we will turn them over.
219207507|NCT06996613|PROCEDURE|Upper endoscopy|It's a diagnostic endoscope to show the cause of upper Git bleeding
219207508|NCT06997822|BEHAVIORAL|LINE Bot-Based Remote Care Combined with In-Person Post-ICU Clinic|"Participants in this group will receive the I-CARE intervention, which includes two components: (1) a LINE Bot-based remote care system providing scheduled health education, functional assessments, and reminders tailored to ICU survivors, and (2) structured in-person visits to a post-ICU recovery clinic, where multidisciplinary professionals provide follow-up assessments and individualized rehabilitation guidance. The LINE Bot also features an interactive module (Thanks to Nurses) that allows patients to send messages, images, or audio clips to their ICU care team, with optional reciprocal feedback. The intervention will be delivered for up to 6 months following hospital discharge."
219640975|NCT05457036|DEVICE|Spry Belt|The Spry Belt is a device worn around the hips which delivers gentle energy to the lower back. The level of energy is controlled by an internal microprocessor (computer) so that it is safe and comfortable. The energy is at a level that may or may not be perceptible to the user. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via Bluetooth Low Energy (BLE)) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
219640976|NCT05457036|DEVICE|Sham Spry Belt|The Sham Spry Belt is a device worn around the hips which does not deliver gentle energy to the lower back. The device instead provides a clicking noise similar to a motor. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via BLE) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
219059389|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
219640977|NCT06822699|DEVICE|Leg elevation|leg will be raised 30 degrees after spinal anesthesia using standardized pillow
219640978|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
219640979|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
219059390|NCT05367453|OTHER|lactase tablet|lactase tablet
219059391|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
219640980|NCT03459885|DEVICE|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
219059392|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
219059393|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
219059394|NCT05228613|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
219059395|NCT05228613|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
219059396|NCT06137547|DEVICE|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
218957442|NCT06198140|OTHER|myofascial release|In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
218957443|NCT06024733|DRUG|Sevoflurane|patient recieve propofol for induction and sevoflurane for maintenance
218957444|NCT06024733|DRUG|Target Controlled Infusion|target controlled infusion of propofol
218957445|NCT06024733|DRUG|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
218957446|NCT04198818|DRUG|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
218957447|NCT06321627|RADIATION|Radiation therapy as curative treatment|Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
219059397|NCT04007952|PROCEDURE|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
219059398|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
219059399|NCT00003545|DRUG|nelarabine|
219059400|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
219059401|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
219059402|NCT00097591|DRUG|Prasugrel|Administered orally
219059403|NCT00097591|DRUG|Clopidogrel|Administered orally
219059404|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
219059405|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
219059406|NCT03318575|DEVICE|autoRIC|Automated Remote Ischemic Conditioning
219059407|NCT03318575|DEVICE|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
219059408|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
219059409|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
219059410|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
219059411|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
219059412|NCT02798848|DEVICE|Tablet computer|iPad
219059413|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
219059414|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
219059415|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
219059416|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
219059417|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
219059418|NCT02841423|PROCEDURE|neuropsychological test battery|
219059419|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
219059420|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
219640981|NCT06372379|OTHER|no intervention|no intervention
219207509|NCT06997809|OTHER|pathway care|"Group for whom the test results will be used to determine the management strategy. If one of the tests performed before randomization is positive an algological consultation before surgery will be performed with an adapted treatment. Then surgical treatment as planned.~If all tests are negative, surgical treatment is performed. The dedicated algology consultation must be done with an experienced practitioner different from the one who will perform the surgery. A rapid algological treatment circuit must be put in place to maintain the surgery date set.~Group without using the results of test for associated pain components. Standard surgical treatment as planned through dedicated staff on endometriosis treatment."
219207510|NCT06997731|PROCEDURE|Non -surgical treatment and oral hygiene instruction|Scaling and root planing which involves mechanical removal of sup-gingival calculus and necrotic cementum. Tis will be associated with oral hygiene instruction in the form of twice daily brushing for 2 minutes.
219207511|NCT06997731|DRUG|Application of minocycline and hyaluronic acid gel.|application of minocycline and Gengigel® topical gel twice weekly for 3-week 1cc for each.
219207512|NCT06997731|DRUG|local application of placebo gel|The placebo gel will be applied in the periodontal pocket twice weekly for 3-week 1cc for each.
219207513|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）|The 4-hour group treatment session lasts 4 hours (±15 minutes). In the HBAL mode of the combined bioartificial liver device QH-1A, blood is initially filtered to separate the plasma, which is then pumped into a bioreactor. In this study, this bioreactor is uniquely filled with immortalized mesenchymal stem cells (PT-MSCs) optimized for blood purification. These cells are cultured to adhere to the outer surface of hollow fibers within the bioreactor, creating a stable and efficient living interface that continuously secretes bioactive factors such as exosomes.After passing through the bioreactor, the plasma is re-filtered and then returned to the patient's circulation via a dedicated pump.
219207514|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）|After the three subjects in the 4-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 6-hour group.The 6-hour group treatment session lasts 6 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
219207515|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours）|After the three subjects in the 6-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 8-hour group. The 8-hour group treatment session lasts 8 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
219207516|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（Multiple-treatment）|Subjects in the multiple-treatment group will receive 2-3 sessions of bioartificial liver treatment; the number of sessions will be determined by the investigators based on the subjects' clinical needs. The treatment duration for each session will be set as the maximum tolerable period, as confirmed by the Safety Evaluation Committee based on 28-day safety observations from the 4-hour, 6-hour, and 8-hour groups. Each treatment session is administered following the procedure applied to patients in the group with the optimal tolerability duration.
219207517|NCT06997302|OTHER|Nutritional Supplement|Dietary nutrition guidance.
219640982|NCT06373718|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
219640983|NCT05261477|BEHAVIORAL|Bilingual Brain Injury Education and outpatient Navigation for Hispanic families|1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
219640984|NCT06437028|OTHER|Dual-layer perinatal tissue allograft|The dual-layer perinatal tissue allograft is an amnion - amnion allograft
219640985|NCT06437028|OTHER|Three-layer fenestrated perinatal tissue allograft|The three-layer fenestrated perinatal tissue allograft is an amnion - chorion - amnion allograft
219640986|NCT06437028|OTHER|Standard of care|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
219640987|NCT06156254|BEHAVIORAL|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
219640988|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
219640989|NCT06240585|OTHER|presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume|presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
219640990|NCT03774524|DRUG|Misoprostol|400 μg of sublingual misoprostol
219640991|NCT03774524|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
219640992|NCT03774524|DRUG|placebo to misoprostol|placebo tablets to misoprostol subligual
219640993|NCT03774524|DRUG|placebo to TA|110 ml saline iv
219640994|NCT03866083|DRUG|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
219640995|NCT03866083|DRUG|Standard Medical Treatment|Standard Medical Treatment
219640996|NCT01328145|DRUG|Acetylsalicylic acid|500 mg /day
218957448|NCT01463332|DRUG|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
218957449|NCT01463332|DRUG|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
218957450|NCT01463332|DRUG|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
219059421|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
219059422|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
219059423|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
219059424|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
219059425|NCT02406144|DRUG|MLN9708|
219059426|NCT02406144|DRUG|Lenalidomide|
219059427|NCT02406144|DRUG|Dexamethasone|
219640997|NCT01190410|DRUG|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
219059428|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
219059429|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
219640998|NCT01190410|DRUG|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
219640999|NCT01399047|DRUG|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
219641000|NCT01399047|DRUG|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
219641001|NCT06620731|DRUG|FCN-437c capsule|Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
219059430|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
219059431|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
219059432|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
219059433|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
219059434|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
218957451|NCT00518245|DRUG|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
218957452|NCT00766441|DRUG|Sitagliptin|tablet, 100mg, once daily, 4 weeks
218957453|NCT00766441|DRUG|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
218957454|NCT02551627|DIETARY_SUPPLEMENT|Test Product|MMN fortified beverage powder.
218957455|NCT02551627|DIETARY_SUPPLEMENT|Control|Isocaloric beverage powder without micronutrient fortification.
218957456|NCT06432868|DIETARY_SUPPLEMENT|Solarplast (R)|Daily supplementation for 28 days prior to heavy resistance exercise.
218957457|NCT06432868|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 28 days prior to heavy resistance exercise.
219059435|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
219059436|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
219059437|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
219059438|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
219059439|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
219059440|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
219059441|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
219059442|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
219059443|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
219059444|NCT02585739|GENETIC|blood sample|
218957458|NCT01285687|DEVICE|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
218957459|NCT01285947|DEVICE|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
218957460|NCT01285947|OTHER|Needle Application|30-gauge needle insertion into skin
218957461|NCT01285947|DEVICE|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
218957462|NCT01285947|DEVICE|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
218957463|NCT05222243|DRUG|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
218957464|NCT05222243|DRUG|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
218957465|NCT05222243|DRUG|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
218957466|NCT05983887|OTHER|Therapeutic Climbing|The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
218957467|NCT03142061|PROCEDURE|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
218957468|NCT00003101|BIOLOGICAL|filgrastim|
218957469|NCT00003101|DRUG|busulfan|
218957470|NCT00003101|DRUG|lomustine|
219059445|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
219059446|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
219059447|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
219059448|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
219059449|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
219059450|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
219207518|NCT06997679|DIAGNOSTIC_TEST|Patients receiving CPM|Group A was treated with Continuous Passive Motion for 30-45 minutes for 2 sessions per day for 8 weeks. CPM can be initiated in the immediate post-operative period, typically within 24-48 hours after surgery. Range of motion will be 0-90 degrees of flexion, with a gradual increase in range over time. Speed is 1-2 cycles per minute. Therapist will Monitor patients for pain and discomfort during CPM, and adjust the protocol as needed. Therapist will Monitor patients range of motion and adjust the CPM protocol to ensure optimal progress. Therapist will monitor patients' knee functions and adjusts the CMP protocol to ensure optimal progress
218957471|NCT00003101|DRUG|procarbazine hydrochloride|
218957472|NCT00003101|DRUG|thiotepa|
218957473|NCT00003101|DRUG|vincristine sulfate|
218957474|NCT00003101|PROCEDURE|autologous bone marrow transplantation|
218957475|NCT00003101|PROCEDURE|peripheral blood stem cell transplantation|
218957476|NCT05346432|DIETARY_SUPPLEMENT|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
218957477|NCT04920227|PROCEDURE|phacoemulsification;|Group A: class combined with phacoemulsification
218957478|NCT00943553|DRUG|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)
218957479|NCT00943553|DRUG|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
218957480|NCT02723578|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
218957481|NCT02723578|DRUG|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
218957482|NCT02653885|OTHER|Red red cell distribution width|Results from hemogram
218957483|NCT04810572|DIETARY_SUPPLEMENT|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
218957484|NCT04810572|DIETARY_SUPPLEMENT|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
219641002|NCT04827966|OTHER|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
218957485|NCT02388282|DEVICE|diaphragm ecography|recording of diaphragm ecography
218957486|NCT03574324|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
218957487|NCT03574324|DRUG|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
218957488|NCT01649479|BIOLOGICAL|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
218957489|NCT01649479|BIOLOGICAL|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII"
219641003|NCT04827966|OTHER|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
219641004|NCT04827966|OTHER|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
219641005|NCT04827966|OTHER|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
219641006|NCT04827966|OTHER|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
219641007|NCT04831697|BEHAVIORAL|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
219641008|NCT04831697|BEHAVIORAL|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
219641009|NCT00995046|DRUG|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
219641010|NCT00995046|DRUG|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
219641011|NCT02046005|BEHAVIORAL|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
219641012|NCT02046005|BEHAVIORAL|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
219641013|NCT02046005|BEHAVIORAL|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
219641014|NCT05895890|GENETIC|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
219641015|NCT04699201|PROCEDURE|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
219641016|NCT04699201|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
219641017|NCT04699201|DIAGNOSTIC_TEST|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
219641018|NCT05604222|DRUG|Mirabegron 50 MG|Medication to treat overactive bladder
219641019|NCT05604222|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
219641020|NCT05271318|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
219641021|NCT05271318|BIOLOGICAL|pembrolizumab|pembrolizumab, a monoclonal antibody binding PD-1
219641022|NCT05271318|DRUG|pegylated liposomal doxorubicin|Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
219059451|NCT06573398|COMBINATION_PRODUCT|SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin|Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
219059452|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
219641023|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
218957490|NCT01649479|OTHER|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
219641024|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
219641025|NCT01483274|BIOLOGICAL|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
218957491|NCT05157919|BEHAVIORAL|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
218957492|NCT03687905|DRUG|Chloroquine|group1 received chloroquine .
218957493|NCT03687905|DRUG|Hydroxychloroquine|Group 2 received hydroxychloroquine
218957494|NCT01992159|DRUG|Romosozumab|Administered by subcutaneous injection
218957495|NCT01992159|DRUG|Placebo|Administered by subcutaneous injection
218957496|NCT00354185|DRUG|tanespimycin|Given IV
219641026|NCT05822141|DIETARY_SUPPLEMENT|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
219641027|NCT05822141|DIETARY_SUPPLEMENT|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
219641028|NCT05011266|DRUG|Buprenorphine/naloxone|5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
219641029|NCT05011266|DRUG|Placebo|placebo sub-lingual tablet daily
219641030|NCT06520982|DRUG|Norepinephrine|Infused intra-arterially in a dose-response fashion
219641031|NCT06520982|DRUG|Isoproterenol|Infused intra-arterially in a dose-response fashion
219641032|NCT06520982|DRUG|Acetylcholine|Infused intra-arterially in a dose-response fashion
219641033|NCT06520982|DRUG|Nitroprusside|Infused intra-arterially in a dose-response fashion
219641034|NCT06520982|DRUG|Estrogen|Infused intra-arterially
219641035|NCT00032136|DRUG|exemestane|
219641036|NCT00032136|DRUG|tamoxifen citrate|
218957497|NCT00354185|DRUG|belinostat|Given IV
218957498|NCT00354185|OTHER|laboratory biomarker analysis|Correlative studies
218957499|NCT00354185|OTHER|pharmacological study|Correlative studies
218957500|NCT06260527|DRUG|ARTS-011|Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
218957501|NCT06260527|DRUG|Placebo|Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
218957502|NCT03088462|OTHER|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
218957503|NCT03088462|BEHAVIORAL|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
218957504|NCT03088462|BEHAVIORAL|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
218957505|NCT03023046|DRUG|Cyclophosphamide|Given IV
218957506|NCT03023046|DRUG|Dasatinib|Given PO
218957507|NCT03023046|DRUG|Doxorubicin|Given IV
219059453|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
219059454|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
219059455|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
219059456|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
219059457|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
219059458|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
219059459|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
218957508|NCT03023046|DRUG|Etoposide|Given IV
219641037|NCT00032136|PROCEDURE|adjuvant therapy|
218957509|NCT03023046|DRUG|Imatinib Mesylate|Given PO
218957510|NCT03023046|OTHER|Laboratory Biomarker Analysis|Correlative studies
219641038|NCT05136339|BEHAVIORAL|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
219641039|NCT00251303|DRUG|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
219641040|NCT00251303|DRUG|Placebo|Capsules matched active drug in appearance.
219641041|NCT01092819|OTHER|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
219641042|NCT02511067|DRUG|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
219641043|NCT02511067|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
219641044|NCT06189859|PROCEDURE|endoscopic submucosal dissection using SPRAY COAG mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
219641045|NCT06189859|PROCEDURE|endoscopic submucosal dissection using Precisect mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
219641046|NCT00504725|DRUG|Ketamine|Interventional
219641047|NCT00504725|DRUG|0.9% saline|placebo
219641048|NCT05311839|OTHER|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
219641049|NCT05311839|OTHER|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
219641050|NCT02064504|DRUG|GSK961081|Dry white to off white powder
218957511|NCT03023046|DRUG|Prednisone|Given PO
218957512|NCT03023046|BIOLOGICAL|Rituximab|Given IV
218957513|NCT03023046|DRUG|Vincristine Sulfate|Given IV
218957514|NCT03299179|DEVICE|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
218957515|NCT03299179|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
218957516|NCT03299179|BIOLOGICAL|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
218957517|NCT03299179|DEVICE|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
218957518|NCT03299179|DEVICE|Body temperature|Measuring body temperature before and after MRI-scan
218957519|NCT03299179|OTHER|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
218957520|NCT03299179|DIAGNOSTIC_TEST|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
218957521|NCT03473028|PROCEDURE|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer
218957522|NCT03473028|PROCEDURE|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
219059460|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
219641051|NCT02064504|DRUG|Fluticasone furoate|Dry white powder
219641052|NCT04019613|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
219641053|NCT01527656|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
219641054|NCT01713010|OTHER|Predictive indexes of weaning from mechanical ventilation|
219641055|NCT02990936|OTHER|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
219641056|NCT02497040|DRUG|Levobupivacaine|local injection
219641057|NCT02497040|DRUG|Bupivacaine|local injection
219641058|NCT02497040|DRUG|placebo|local injection
219641059|NCT03551769|DRUG|tricaprilin|Tricaprilin formulated as AC-SD-01
219641060|NCT03551769|OTHER|standard meal|standard meal
219641061|NCT03551769|OTHER|high-fat meal|high-fat meal
219641062|NCT03551769|OTHER|overnight fast|fasting for at least 9 hours
219641063|NCT06525805|OTHER|Long Abstract|"The intervention and control group will be provided with a structured abstract of the review by Soderberg et al., entitled Percutaneous nephrolithotomy vs. retrograde intrarenal surgery for renal stones. This review was published once in the Cochrane Database of Systematic Reviews and once in the journal BJU International. The length of the abstract differs significantly depending on the journal.~The participants assigned to this study arm will be presented with the longer version published in the Cochrane Database, comprising 771 words (PMID: 37955353)."
219641064|NCT06525805|OTHER|Short Abstract|The participants assigned to this study arm will be presented with the shorter version published in BJU International, comprising 277 words (PMID: 37942649).
219641065|NCT00956592|DEVICE|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
219641066|NCT00956592|DEVICE|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
219641067|NCT00287872|DRUG|bortezomib|
219641068|NCT00287872|DRUG|thalidomide|
218957523|NCT01849081|DEVICE|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
219059461|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
218957524|NCT01849081|BEHAVIORAL|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
218957525|NCT04440371|COMBINATION_PRODUCT|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
218957526|NCT04440371|COMBINATION_PRODUCT|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
219641069|NCT01089764|BEHAVIORAL|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
219641070|NCT02171338|OTHER|PCT-level|PCT-level is available to the treating doctor.
219641071|NCT02171338|BEHAVIORAL|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
219641072|NCT05200013|BIOLOGICAL|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
219641073|NCT05212662|DRUG|TTI-0102|"The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102."
219641074|NCT05212662|DRUG|Placebo|Placebo comparator supplied in vials identical to the active intervention, TTI-0102
218957527|NCT01600742|DRUG|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
218957528|NCT01600742|DRUG|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
218957529|NCT00434395|DRUG|MOA-728|
218957530|NCT03103815|DRUG|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
218957531|NCT03641885|BEHAVIORAL|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
218957532|NCT03641885|BEHAVIORAL|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
218957533|NCT03641885|BEHAVIORAL|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
218957534|NCT06181279|PROCEDURE|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
218957535|NCT06181279|PROCEDURE|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
218957536|NCT06515509|PROCEDURE|immediate implant placement with or without loading|immediate implant placement with or without loading
218957537|NCT02425072|DEVICE|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
219059462|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
219059463|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
219059464|NCT02972697|RADIATION|11C-acetate ligand|
219059465|NCT02972697|RADIATION|FDG ligand|
219059466|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
219059467|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
219059468|NCT05924828|OTHER|no intervention|no intervention
219059469|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
218957538|NCT01713387|DRUG|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
218957539|NCT04921098|PROCEDURE|Diode Laser Cyclophotocoagulation|A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
218957540|NCT05592522|OTHER|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
218957541|NCT05592522|OTHER|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
218957542|NCT05592522|OTHER|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
218957543|NCT00531674|DIETARY_SUPPLEMENT|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
218957544|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
218957545|NCT00531674|DIETARY_SUPPLEMENT|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
218957546|NCT00531674|DIETARY_SUPPLEMENT|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
218957547|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
218957548|NCT00531674|DIETARY_SUPPLEMENT|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
219059470|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
219059471|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
219059472|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
219059473|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
219059474|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
219059475|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
219059476|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
219059477|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
219059478|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
219059479|NCT00506935|DRUG|GVG|5 grams GVG
219059480|NCT00506935|DRUG|placebo|placebo
219059481|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
218957549|NCT05105022|DRUG|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
218957550|NCT04961970|DRUG|oxaliplatin , fluorouracil, and leucovorin|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
218957551|NCT04961970|DRUG|gemcitabine and cisplatin|administration of gemcitabine and cisplatin via vein
218957552|NCT00929812|DRUG|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
218957553|NCT00929812|DRUG|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
218957554|NCT02812303|OTHER|Centralized support for population health management activities|
218957555|NCT06489379|DEVICE|high flow nasal cannula|humidified and heated oxygen
218957556|NCT06489379|OTHER|standard oxygen|oxygen delivery through Venturi mask
218957557|NCT03663738|BEHAVIORAL|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
218957558|NCT02599948|OTHER|no intervention|
219059482|NCT00550784|BIOLOGICAL|filgrastim|
219059483|NCT00550784|DRUG|cisplatin|
219059484|NCT00550784|DRUG|cyclophosphamide|
219641075|NCT03793673|BEHAVIORAL|CoYoT1 Care|Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
218957559|NCT05857423|OTHER|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
218957560|NCT04455984|OTHER|Date collection|Retrospective data analysis
218957561|NCT01545843|BEHAVIORAL|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
219059485|NCT00550784|DRUG|melphalan|
219059486|NCT00550784|DRUG|paclitaxel|
219059487|NCT00550784|DRUG|topotecan hydrochloride|
219059488|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
219059489|NCT00550784|GENETIC|gene expression analysis|
219059490|NCT00550784|OTHER|immunohistochemistry staining method|
219059491|NCT00550784|OTHER|pharmacological study|
219059492|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
219641076|NCT03793673|OTHER|Standard Care|"Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.~NOTE: Per COVID-19 hospital policies, current clinic appointments consist of telehealth appointments."
219641077|NCT05103280|OTHER|Assistive tennis shoes|Assistive shoes include carbon-fiber and spring loaded shoes.
219641078|NCT06277882|BIOLOGICAL|HAVRIX|intramuscular injections
219641079|NCT01542723|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
219641080|NCT00160706|BIOLOGICAL|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
219641081|NCT03214380|DRUG|LY900014|Administered SC
219641082|NCT03214380|DRUG|Insulin Lispro|Administered SC
219641083|NCT03214380|DRUG|Insulin Glargine|Administered SC
219641084|NCT03214380|DRUG|Insulin Degludec|Administered SC
219641085|NCT03214380|DRUG|Metformin|Administered orally.
219641086|NCT03214380|DRUG|SGLT2 inhibitor|Administered orally.
219207519|NCT06997679|COMBINATION_PRODUCT|Patients receiving intermittent compression|Group B was treated with Intermittent Compression Therapy for 30-45 minutes for 2 sessions (morning and evening) per day for 8 weeks. Therapist stand beside the patient .IC therapy initiated in the immediate post-operative period, typically within 24-48 hours after surgery .Pressure of device between 30-40 mmHg and Cycle time is 10-30 seconds inflation, 10-30 seconds deflation. Therapist will Monitor patients for pain and discomfort during IC therapy, and adjust the protocol as needed. Therapist will Monitor patients' swelling and edema, and adjust the IC therapy protocol to ensure optimal progress. Therapist will Monitor patients' knees functions and adjust the IC therapy protocol to ensure optimal progress.
219641087|NCT01554865|DIETARY_SUPPLEMENT|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
219641088|NCT01554865|BEHAVIORAL|Conventional diet counseling|
219641089|NCT04836026|DEVICE|HF20™|HF20™ will be used for CRRT
219641090|NCT02402257|BEHAVIORAL|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
219641091|NCT03438604|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
219641092|NCT02053142|DRUG|Acyclovir|Single dose of acyclovir 200mg was given for pk study
219641093|NCT02053142|DRUG|Placebo|
218957562|NCT01545843|DRUG|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
218957563|NCT04243421|DEVICE|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
218957564|NCT03607643|DRUG|Cannabidiol|"* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
219059493|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
219059494|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
219059495|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
219059496|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
219059497|NCT00000597|DRUG|antilymphocyte serum|
219059498|NCT00000597|DRUG|nandrolone|
219059499|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
219641094|NCT02644629|DRUG|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
219641095|NCT02644629|DRUG|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
219641096|NCT02644629|DRUG|Ketamine (2st phase)|Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
218957565|NCT03607643|DRUG|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
218957566|NCT03607643|DRUG|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
218957567|NCT03607643|DRUG|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
218957568|NCT03607643|DRUG|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
219059500|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
219059501|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
219059502|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
219641097|NCT03329170|BEHAVIORAL|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
218957569|NCT03607643|DRUG|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
218957570|NCT03607643|DRUG|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
218957571|NCT03607643|DRUG|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
218957572|NCT03607643|DRUG|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
218957573|NCT05420363|OTHER|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
218957574|NCT05420363|OTHER|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
218957575|NCT03628261|DEVICE|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
218957576|NCT03628261|OTHER|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
218957577|NCT01741012|DRUG|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
218957578|NCT01575288|DRUG|Placebo|100g maltose 1/day
218957579|NCT01575288|DRUG|High-dose trehalose|100g 1/day
219059503|NCT02530619|DRUG|Alisertib|Given PO
219059504|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
218957580|NCT03571282|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
218957581|NCT00083096|DRUG|lonafarnib|
218957582|NCT00083096|DRUG|temozolomide|
218957583|NCT00306332|PROCEDURE|T-cell and B-cell depletion|
218957584|NCT03789617|BIOLOGICAL|EBViNT Cell|"1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL~2. Administration: Inject intravenously over 30 minutes~3. Dosing schedule: Single dose"
218957585|NCT02749526|DRUG|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
218957586|NCT02749526|DRUG|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
219059505|NCT02530619|OTHER|Pharmacological Study|Correlative studies
219059506|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
219059507|NCT00259753|DRUG|Bevasiranib|
219059508|NCT02747940|DRUG|flunarizine and/or pregabalin|
219059509|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
218957587|NCT02749526|DRUG|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
219059510|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
219059511|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
219059512|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
219207520|NCT06499506|PROCEDURE|Below knee amputation|trans tibial amputation one hand breadth below tibial tuberosity
219207521|NCT06322433|DIAGNOSTIC_TEST|no drugs used for this study|tomographic, angiographic and clinical follow up
219207522|NCT03201939|DRUG|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
219207523|NCT03201939|OTHER|Placebo Oral Tablet|Comparator placebo (control arm)
219207524|NCT06996119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219207525|NCT06996119|DRUG|Busulfan|Given IV
219207526|NCT06996119|PROCEDURE|Computed Tomography|Undergo chest CT
219207527|NCT06996119|DRUG|Cyclophosphamide|Given IV
219207528|NCT06996119|PROCEDURE|Echocardiography Test|Undergo ECHO
219207529|NCT06996119|BIOLOGICAL|Emapalumab|Given IV
219207530|NCT06996119|DRUG|Fludarabine|Given IV
219641098|NCT06221592|DEVICE|defocus spectacle lenses|To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
218957588|NCT02749526|DRUG|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
218957589|NCT01249118|DRUG|GDC-0973 IV Infusion|IV infusion.
218957590|NCT01249118|DRUG|GDC-0973 Oral Capsules|Oral dose.
219059513|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
219059514|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
219059515|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
219207531|NCT06996119|PROCEDURE|Hematopoietic Cell Transplantation|Given infusion
219207532|NCT06996119|DRUG|Melphalan|Given IV
219207533|NCT06996119|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219207534|NCT06996119|DRUG|Mycophenolate Mofetil|Given IV or PO
219207535|NCT06996119|OTHER|Questionnaire Administration|Ancillary studies
219207536|NCT06996119|DRUG|Tacrolimus|Given IV or PO
219207537|NCT06996899|OTHER|Health Improvement Profile (HIP)|"The Health Improvement Profile (HIP) is a comprehensive physical assessment conducted by a trained clinician which aims to link evidence based interventions for flagged abnormal health parameters. There are 27 health parameters assessed such as weight, Body Mass Index (BMI), blood pressure, blood glucose, cholesterol levels, and waist circumference, alongside questions on lifestyle factors like smoking, diet, and physical activity, as well as medication use and its side effects.~Client participant will collaborate with their clinician in developing an individualised Health Improvement Profile which identifies suitable health behaviours interventions to improve physical health.~Health behaviours may be associated with diet, exercise, sleep, hygiene (including oral care) and mindfulness."
219207538|NCT06996899|OTHER|Clinician Health Improvement Profile user training|Clinician/staff participants will receive Health Improvement Profile user training on how to conduct the comprehensive physical assessments for 27 health parameters and how to link the evidence based actions to develop an individualised Health Improvement Profile for clients admitted to inpatient service. Training includes online videos simulating assessments and completing the Health Improvement Profile and face to face workshops.
219207539|NCT06017115|DEVICE|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
219207540|NCT06619847|DRUG|VX-993|Tablets for oral administration.
219207541|NCT06619847|DRUG|HB/APAP|Capsules for oral administration.
218957591|NCT00541463|DRUG|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
218957592|NCT00541463|DRUG|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
218957593|NCT05565885|OTHER|Sampling|4 blood sampling per patient and an additional one in case of relapse
218957594|NCT00880685|DRUG|Memantine|10-30mg, daily for 8 weeks
218957595|NCT02902796|DEVICE|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
219059516|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
219059517|NCT00110240|DRUG|vildagliptin|
219059518|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
219059519|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
219059520|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
218957596|NCT04564118|DRUG|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
219207542|NCT06619847|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
219207543|NCT06619847|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
219207544|NCT06869512|BEHAVIORAL|SUCCESS|6 group-based sessions with 25 minutes of didactic content, 25 minutes of facilitated support group, and 10 minutes of group physical activity
219207545|NCT01089101|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219207546|NCT01089101|DRUG|Selumetinib|Given PO
219207547|NCT06832332|BEHAVIORAL|alternative birthing positions|In this stage, students will be given a simulated breech birth with alternative birth positions as opposed to the traditional position in the second stage of labor.
219207548|NCT06062420|DRUG|Dostarlimab|Dostarlimab will be administered.
218957597|NCT05819684|DRUG|SHR-4602 for injection|be administered via intravenous (IV) infusion
218957598|NCT04211805|DRUG|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
218957599|NCT04211805|DRUG|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
218957600|NCT01665612|DEVICE|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
218957601|NCT05776797|PROCEDURE|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
218957602|NCT05776797|DRUG|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
218957603|NCT05380999|DIAGNOSTIC_TEST|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
218957604|NCT03566069|DRUG|Intranasal Oxytocin|32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
218957605|NCT03566069|OTHER|Intranasal Placebo|32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol.
218957606|NCT05631288|GENETIC|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
218957607|NCT00119873|BIOLOGICAL|VRC-HIVADV014-00-VP|
218957608|NCT03361579|OTHER|Education|c.p. intervention description
218957609|NCT03578770|DEVICE|Hot Axios stent|Hot Axios stent
218957610|NCT04243109|DRUG|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
218957611|NCT03915522|PROCEDURE|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
219059521|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
219059522|NCT00189085|DRUG|simvastatin and ezetimibe|
219059523|NCT04459611|BIOLOGICAL|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
219059524|NCT04459611|DRUG|pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
219059525|NCT04459611|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
219641099|NCT00905281|OTHER|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
218957612|NCT03915522|PROCEDURE|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
218957613|NCT00891111|BEHAVIORAL|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
218957614|NCT00891111|BEHAVIORAL|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
218957615|NCT00001115|DRUG|Acyclovir|
218957616|NCT03319290|GENETIC|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
218957617|NCT00133393|DRUG|Pentoxifylline|
219059526|NCT04459611|DRUG|albumin-bound paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
219059527|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
219059528|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
219059529|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
219059530|NCT00334659|DRUG|apricitabine|
219059531|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
218957618|NCT00997438|DIETARY_SUPPLEMENT|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
218957619|NCT05513131|DRUG|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7 Homoharringtonine 2mg/d d1\~d7
218957620|NCT00526877|DRUG|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
218957621|NCT01236118|DRUG|LY2439821|Administered subcutaneously
218957622|NCT02133521|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
218957623|NCT02133521|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
218957624|NCT01094639|PROCEDURE|Scaling root planing|Deep gum cleaning with local anesthesia
218957625|NCT01094639|PROCEDURE|Supragingival Prophylaxis|Plaque removal
218957626|NCT00095238|DRUG|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
218957627|NCT00095238|DRUG|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
218957628|NCT00421291|BEHAVIORAL|Education|
218957629|NCT00075673|DRUG|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
218957630|NCT00075673|DRUG|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
218957631|NCT04476823|OTHER|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
218957632|NCT00586729|DEVICE|Vashe|Antimicrobial irrigant
218957633|NCT00586729|DRUG|Mafenide acetate|Antimicrobial solution
218957634|NCT02643758|DEVICE|Bifocal soft contact lenses|
218957635|NCT02827565|OTHER|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
219059532|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
219059533|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
219059534|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
219059535|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
219059536|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
219059537|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
219207549|NCT06062420|DRUG|Belrestotug|Belrestotug will be administered.
219207550|NCT06062420|DRUG|Nelistotug|Nelistotug will be administered.
219059538|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
219059539|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
219059540|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
219059541|NCT00204191|DRUG|tacrolimus|
219059542|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
219059543|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
219207551|NCT06062420|DRUG|GSK4381562|GSK4381562 will be administered.
219207552|NCT07015749|DRUG|Placebo|Participants with asthma will receive Placebo at the corresponding dose and dosing interval.
219207553|NCT07015749|DRUG|IBI3002|Participants with asthma will receive IBI3002 at the corresponding dose and dosing interval.
219641100|NCT00905281|OTHER|Standard care|No specific intervention
218957636|NCT04393298|DRUG|ginisortamab|Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
218957637|NCT04393298|DRUG|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
218957638|NCT04393298|DRUG|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
218957639|NCT02311582|BIOLOGICAL|MK-3475|Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
219059544|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
219641101|NCT00563810|DRUG|MYO-029|
219641102|NCT04537117|OTHER|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
219641103|NCT01672749|DEVICE|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
219641104|NCT01672749|DEVICE|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
219641105|NCT00100113|DRUG|GBR 12909|
219641106|NCT03863171|DIAGNOSTIC_TEST|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
219641107|NCT03863171|DIAGNOSTIC_TEST|Fundus fluorescein angiography|Fundus fluorescein angiography test
219641108|NCT03076788|OTHER|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~* Standard 12 lead ECG~* Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
219641109|NCT06968481|DRUG|Oxytocin|Sublingual oxytocin 1000 IU, 3000 IU or 6000 IU
219641110|NCT06968481|DRUG|Oxytocin|Intramuscular oxytocin 10 IU
219641111|NCT06210035|BEHAVIORAL|Belly-focus meditation|Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
219641112|NCT06210035|BEHAVIORAL|Belly-focus meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
219641113|NCT01163851|BIOLOGICAL|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
219641114|NCT01163851|BIOLOGICAL|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
218957640|NCT02311582|DEVICE|MRI-guided laser ablation|MLA is a minimally invasive laser surgery, which employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of the tumor mass where it delivers hyperthermic ablation from the core to the rim.
218957641|NCT03703570|DRUG|KW-6356|Oral administration
219059545|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
219059546|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
219059547|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
219059548|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
219059549|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
219641115|NCT06968819|OTHER|Non-immersive virtual reality|Non-immersive virtual reality-based robot-assisted intervention includes balance and coordination training, muscle strengthening exercises as well as cognitive stimulation activities on an interactive treadmill, stabilometric platform and robot-assisted upper limb rehabilitation device. In addition, the experimental group takes part in group sessions featuring active and isometric exercises or motor coordination training.
219641116|NCT06968819|OTHER|Standard physical therapy|Participants receive standard physical therapy, which includes individual sessions focused on muscle strengthening, balance training, stretching, suspension therapy, and treadmill exercises. In addition, they take part in group sessions featuring active, isometric exercises or motor coordination training.
219641117|NCT06968169|BEHAVIORAL|Supportive learning|All interventions are manipulations to the stimuli that the child hears with the goal of discovering which manipulations support verbal learning.
219641118|NCT06968169|BEHAVIORAL|Cascades|The intervention is a manipulation of word instruction with the goal of discovering whether weaker word learning results in cascading effects on semantic category memory and sentence comprehension.
219207554|NCT06756321|BIOLOGICAL|anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells|"Each subject will be infused with single dose. A classic 3+3 dose escalation will be employed.~anti-CD19-CAR T-cells~Dose level 1：1x10\^5 CAR T cells/kg, Dose level 2：3x10\^5 CAR T cells/kg, Dose level 3：1x10\^6 CAR T cells/kg~anti-CD30-CAR T-cells~Dose level 1：3x10\^6 CAR T cells/kg, Dose level 2：6x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg~anti-CD20/CD30-CAR T-cells~Dose level 1：1x10\^6 CAR T cells/kg, Dose level 2：3x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg"
219641119|NCT06968923|BEHAVIORAL|in person treatment|The group undergoes a 5-week treatment, twice a week, for a total of 10 rehabilitation sessions. Each session lasts approximately 60 minutes. The treatment follows standard in-person clinical practice.
219641120|NCT06968923|BEHAVIORAL|Telerehabilitation|The group undergoes a 5-week treatment, with 2 hours per week, for a total of 10 hours at home. Each session lasts approximately 20 minutes. The treatment consists of a sequence of exercises performed using the Euleria Home® device, a medical software that enables the delivery of personalized exercise therapy programs designed by a healthcare professional.
219641121|NCT02028767|DRUG|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
219641122|NCT02028767|DRUG|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
219641123|NCT02028767|DRUG|Metformin 500 mg|Metformin 500 mg tablet
219641124|NCT02028767|DRUG|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
219641125|NCT03192306|DRUG|Merlin|glycolic acid/ethanol solution
219641126|NCT03192306|DRUG|Ethanol|Ethanol solution
218957642|NCT03703570|DRUG|Placebo|Oral administration
218957643|NCT04691284|OTHER|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
218957644|NCT04670224|OTHER|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
218957645|NCT04670224|OTHER|Intravenous anesthesia without QLB|only intravenous anesthesia
219641127|NCT00447824|PROCEDURE|Introduction of better conditions during blood sampling|
219641128|NCT02566382|PROCEDURE|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
219641129|NCT06379646|OTHER|YTS109|Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.
219641130|NCT05147402|DRUG|midomafetamine|100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
219641131|NCT06965153|DRUG|Dual NRT|Dual nicotine replacement therapy
218957646|NCT04601831|RADIATION|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
218957647|NCT01053936|DRUG|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
218957648|NCT05966337|PROCEDURE|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
218957649|NCT05966337|PROCEDURE|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
218957650|NCT05966337|PROCEDURE|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
218957651|NCT00475475|BEHAVIORAL|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
218957652|NCT00475475|BEHAVIORAL|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
218957653|NCT00475475|BEHAVIORAL|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
218957654|NCT04678206|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
218957655|NCT04678206|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
218957656|NCT04425044|OTHER|Other|No Intervention
218957657|NCT00005665|DRUG|interferon alpha|
219641132|NCT06965153|BEHAVIORAL|PeerTTS|Peer recovery coach delivered tobacco cessation coaching
218957658|NCT00723203|DRUG|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
218957659|NCT00723203|GENETIC|gene expression analysis|Day 1 and day 28 samples
218957660|NCT00723203|GENETIC|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
218957661|NCT00723203|OTHER|laboratory biomarker analysis|Day 1 and day 28 samples
218957662|NCT00002083|DRUG|Peptide T|
219641133|NCT05629221|OTHER|TreC Diabete App|Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
219641134|NCT06621095|DRUG|anlotinib + benmelstobart + nab-paclitaxel + gemcitabine|"1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
219641135|NCT06621095|DRUG|nab-paclitaxel + gemcitabine|"1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
219641136|NCT06474988|OTHER|Skin tests|Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests
219641137|NCT03436693|DRUG|Canagliflozin|Canagliflozin 100mg orally once daily
219641138|NCT03436693|DRUG|Placebo|Placebo orally once daily
218957663|NCT02125643|DRUG|Caffeine|
218957664|NCT02125643|OTHER|Flour|Flour will be administered as the placebo.
219207555|NCT06756321|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
219207556|NCT06756321|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
218957665|NCT05888571|PROCEDURE|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
218957666|NCT05888571|PROCEDURE|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
218957667|NCT02049671|DRUG|Growth Hormone Therapy|
218957668|NCT04099771|DRUG|Ketamine|Ketamine infusion
218957669|NCT01589627|DEVICE|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
218957670|NCT01894815|DRUG|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
218957671|NCT01894815|DEVICE|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
218957672|NCT01894815|OTHER|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
218957673|NCT05503121|DIAGNOSTIC_TEST|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
218957674|NCT01721577|DRUG|AXL1717|IGF-1 receptor inhibitor
219207557|NCT05836675|OTHER|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
218957675|NCT04936464|DEVICE|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
218957676|NCT04936464|DEVICE|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
218957677|NCT05805358|DRUG|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
218957678|NCT05242861|RADIATION|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
218957679|NCT03487679|OTHER|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
218957680|NCT02590302|OTHER|Implementation Phase|"Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
218957681|NCT04526990|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
218957682|NCT04526990|BIOLOGICAL|Placebo|Intramuscular administration
219059550|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
219059551|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
219059552|NCT02504645|DRUG|IPP-201101|
219641139|NCT04798729|DEVICE|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
219641140|NCT04798729|DEVICE|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
219641141|NCT04905472|DEVICE|Vestibular prosthesis/implant|The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
218957683|NCT05152316|OTHER|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
218957684|NCT04087928|DEVICE|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
218957685|NCT04087928|DEVICE|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
218957686|NCT00981942|DRUG|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
219207558|NCT07013929|DEVICE|Renal nerve stimulation|Renal nerve stimulation will be performed prior to and post renal denervation.
219207559|NCT06625970|DRUG|Darolutamide|Pharmaceutical form: 300 mg tablets Administration route: oral (PO) Posology: 600 mg twice daily (BID)
218957687|NCT06152471|DRUG|SPC-flakes|Aktive drug
218957688|NCT06152471|DRUG|Salovum|Active drug
218957689|NCT06152471|DRUG|Placebo|Placebo drugs
218957690|NCT02602678|PROCEDURE|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
218957691|NCT02602678|PROCEDURE|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
218957692|NCT01108289|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
219059553|NCT02504645|DRUG|Placebo|
219059554|NCT02504645|OTHER|Standard of Care|
219059555|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
218957693|NCT02524977|BEHAVIORAL|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
218957694|NCT02524977|BEHAVIORAL|Educational Intervention Only|Educational conference series
219207560|NCT06625970|RADIATION|Stereotactic Body RadioTherapy (SBRT)|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~At study entry, each investigational site will be asked to choose one regimen (normo-fractionation or moderate hypo-fractionation) which will be applied for all patients included by the investigational site in the study.~SBRT, experimental treatment, will be used as a boost in Arms C \& D. The placement of 3 to 4 fiducial markers for stereotactic boost is mandatory.~SBRT will be applied only on Prostate: 2 times 10 Gy delivered to the prostate with a gap of one week between each SBRT fraction."
219059556|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
219059557|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
219059558|NCT00710333|DRUG|placebo|placebo
219059559|NCT02445079|OTHER|This is an observational study only|Observational study only
219059560|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
219207561|NCT06625970|DRUG|ADT (Standard of Care)|"Androgen Deprivation Therapy (ADT)~The ADT treatment will be chosen at the investigator's discretion, and will be administered according to local standard procedures for up to 2 years.~Patients who may have received ADT prior joining the study should have started the ADT treatment within a maximum of 6 weeks before randomization. Otherwise ADT will be started on Day 1 (or 14 days at the latest after the randomization)."
219207562|NCT06625970|RADIATION|radiotherapy|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~Arm A and Arm B:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46-54 Gy and prostate 78 Gy (39 fractions over 8 weeks).~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions; prostate 60 Gy delivered concomitantly in 20 fractions over 4 weeks.~Arm C and Arm D:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46 Gy in 23 fractions over 4.5 weeks.~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions over 4 weeks."
219207563|NCT05707351|BIOLOGICAL|Adynovate|Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
219641142|NCT04905472|DEVICE|Vestibular Implant Stimulation|VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
218957695|NCT03550651|OTHER|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
218957696|NCT03550651|OTHER|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
218957697|NCT03550651|OTHER|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
218957698|NCT03550651|OTHER|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
218957699|NCT03550651|OTHER|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
219059561|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
219059562|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
219059563|NCT05029648|OTHER|Cohort|Cohort
219059564|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
219059565|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
219059566|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
219059567|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
219059568|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
218957700|NCT04062500|OTHER|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
218957701|NCT01903525|DRUG|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
218957702|NCT01903525|DRUG|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
219059569|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
219059570|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
219059571|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
219059572|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
219059573|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
219059574|NCT00165724|DRUG|Donepezil Hydrochloride|
219059575|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
219059576|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
219059577|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
219059578|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
219059579|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219059580|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219059581|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219207564|NCT06867900|DIETARY_SUPPLEMENT|Bifidobacterium Longum ES1|Oral administration of Bifidobacterium Longum ES1 for three months.
219641143|NCT02173522|DEVICE|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
219641144|NCT00522639|OTHER|18F-deoxyglucose (FDG)|contrast medium
219641145|NCT06181734|DRUG|Ivosidenib|inhibitor of mutant IDH1
219641146|NCT06665503|DIETARY_SUPPLEMENT|Zinc Supplement, probiotic|received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
218957703|NCT00304369|DRUG|Metronidazole|
218957704|NCT00117065|DRUG|Aranesp®|
218957705|NCT00107926|DRUG|Licarbazepine|
218957706|NCT00107926|DRUG|Placebo|
218957707|NCT04698265|BIOLOGICAL|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
218957708|NCT00633620|DEVICE|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
218957709|NCT05965297|DEVICE|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
218957710|NCT05965297|DEVICE|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
218957711|NCT02856893|DRUG|Osimertinib|Osimertinib 60 or 40 mg daily until progression
218957712|NCT02856893|DRUG|Gefitinib|Gefitinib 250mg daily until progression
218957713|NCT00048087|DRUG|ZD1839|250 mg by mouth daily each day for 4 weeks.
218957714|NCT00048087|DRUG|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
218957715|NCT00955227|DIETARY_SUPPLEMENT|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
219059582|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219059583|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219207565|NCT06693648|DRUG|AMZ001 Diclofenac gel|Diclofenac gel applied once daily
219207566|NCT06693648|DRUG|Placebo gel|Matching placebo gel applied once daily
219641147|NCT00654875|DRUG|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
219641148|NCT00654875|DRUG|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
219641149|NCT04967885|BEHAVIORAL|Ecological Momentary Implementation Intentions Intervention (EMI-II)|To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
219641150|NCT04019340|OTHER|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
218957716|NCT00955227|DRUG|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
218957717|NCT00963677|PROCEDURE|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
218957718|NCT03446144|DRUG|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
218957719|NCT03446144|DRUG|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
219641151|NCT03850730|DRUG|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
219641152|NCT00096616|DRUG|Combivent® CFC MDI|
219641153|NCT00096616|DRUG|Albuterol HFA MDI|
218957720|NCT01568307|DRUG|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
218957721|NCT01717144|BEHAVIORAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
218957722|NCT02782078|BIOLOGICAL|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
218957723|NCT01361854|DEVICE|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
218957724|NCT05561010|DRUG|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
218957725|NCT05561010|DRUG|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
218957726|NCT02879396|BEHAVIORAL|PA4LE Program|"1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
218957727|NCT06345196|BEHAVIORAL|motivational interview|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
218957728|NCT01732653|OTHER|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
218957729|NCT01732653|OTHER|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
218957730|NCT02311101|DRUG|Mitomycin C|Given intravesically
218957731|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
218957732|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
219059584|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
219059585|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
219059586|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
219059587|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
219059588|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
219059589|NCT02256111|DRUG|Enzalutamide|
219059590|NCT02256111|DRUG|Androgen deprivation therapy|
219059591|NCT02256111|BEHAVIORAL|Supervised exercise training|
219059592|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
219059593|NCT06238505|OTHER|biodex|application will be made with biodex device
219059594|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
219059595|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
219641154|NCT01235026|DIETARY_SUPPLEMENT|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10\^10 CFU/g), twice a day, for 6 weeks."
219641155|NCT01235026|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin, twice a day for 6 weeks.
219641156|NCT00011258|DRUG|Paraoxonase|
219641157|NCT05594836|BEHAVIORAL|Infant Calming Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
219641158|NCT00886743|DRUG|oprelvekin|injection, 50 mg/kg, once daily
218957733|NCT02106923|DRUG|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
218957734|NCT02106923|DRUG|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
218957735|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
219059596|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
219207567|NCT04712903|DRUG|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
219059597|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
219059598|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
219207568|NCT04712903|DRUG|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
219641159|NCT05217641|BIOLOGICAL|BG505 MD39.3 mRNA|Administered by IM injection
219641160|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 mRNA|Administered by IM injection
219641161|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 CD4KO mRNA|Administered by IM injection
219641162|NCT00626821|DEVICE|SenSura|Real life assessment of SenSura
219641163|NCT01800643|OTHER|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
219641164|NCT06287632|DEVICE|Recruitment/ITP-CPAP (Intervention A)|Participant will receive a recruitment maneuver followed by CPAP set to the level of end-expiratory esophageal pressure (measured during atmospheric pressure breathing). The intervention will last for 20 minutes.
218957736|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
218957737|NCT03485495|DRUG|Divaza|Oral administration.
218957738|NCT03485495|DRUG|Placebo|Oral administration.
218957739|NCT05824520|OTHER|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
218957740|NCT05824520|OTHER|OMT|Optimal medical therapy alone
219641165|NCT06287632|DEVICE|Standard CPAP (Intervention B)|Participant will receive their home CPAP (if on CPAP at home) or CPAP at 8-10 cmH20 (if not on CPAP at home or no known diagnosis of OSA). The intervention will last for 20 minutes.
218957741|NCT05977361|PROCEDURE|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
219059599|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
219059600|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
219059601|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
219059602|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
219059603|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
219059604|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
219059605|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
219059606|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
219207569|NCT04712903|DRUG|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
219207570|NCT04712903|DRUG|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
219641166|NCT06287632|DEVICE|Atmospheric Pressure|Participant will breathe at atmosphere pressure (no CPAP) with supplemental oxygen as needed per clinical guidance.
219641167|NCT02632409|BIOLOGICAL|Nivolumab|
219641168|NCT02632409|OTHER|Placebo|
219641169|NCT06261983|PROCEDURE|Sentinel node biopsy guided by magnetic probe|Sentinel nodes exeresis guided by magnetic probe after injection submucosally and peritumorally of super-para-magnetic contrast. Standard neck dissection (levels I-II) were carry out after sentinel node biopsy
219641170|NCT00604097|BEHAVIORAL|Attachment-Based Family Therapy|12-16 week family-based therapy
219641171|NCT00604097|BEHAVIORAL|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
219641172|NCT06094283|DRUG|YCT-529|Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
219641173|NCT06094283|DRUG|YCT-529 Placebo|YCT-529 Placebo
218957742|NCT05977361|PROCEDURE|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
218957743|NCT02088242|DRUG|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
218957744|NCT02088242|DRUG|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
218957745|NCT01629199|DRUG|rhEGF(recombinant human Epidermal Growth Factor)|
218957746|NCT01629199|DRUG|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
219059607|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
219059608|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
219059609|NCT04177693|DRUG|Letrozole|5 mg for 5 days
219059610|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
219059611|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
219207571|NCT07022769|BEHAVIORAL|LLM-facilitated cognitive debiasing aid|"As part of the intervention, patients first respond to a series of questions about their beliefs regarding their symptoms (e.g., What's usually behind these symptoms?), with responses transcribed verbatim via tablet. These responses are input into a Large Language Model (LLM), which generates a brief, supportive summary of the patient's beliefs, shared back with the patient to encourage self-awareness and reflection. Patients are then invited to consider prompts such as, What emotions or circumstances might be influencing your thinking? with their reflections again transcribed. The LLM analyzes these reflections to identify potential signs of emotional distress or maladaptive beliefs, and this output is again provided to the patient. The LLM summary of identified maladaptive beliefs is then also shown to the clinician ahead of the consultation to support more tailored, empathetic communication."
219207572|NCT03741140|DIAGNOSTIC_TEST|Motivation tests|Motivation tests will characterize elementary deficits of motivation
219641174|NCT02644863|DRUG|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
219641175|NCT02644863|BIOLOGICAL|DC-CIK|Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
219641176|NCT02644863|DRUG|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
219641177|NCT04040231|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
219641178|NCT04040231|DRUG|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
219641179|NCT04040231|BIOLOGICAL|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
219641180|NCT03609931|PROCEDURE|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
219641181|NCT03118362|DRUG|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
219641182|NCT03118362|DRUG|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
218957747|NCT01028690|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
218957748|NCT01028690|DIETARY_SUPPLEMENT|Placebo|placebo
218957749|NCT01864356|DRUG|NT100|
218957750|NCT01864356|DRUG|Placebo|
218957751|NCT00736515|DRUG|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
218957752|NCT00736515|DRUG|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
219059612|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
219059613|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
219059614|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
219059615|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
219641183|NCT01397396|PROCEDURE|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max
219059616|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
219059617|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
219059618|NCT05826821|DRUG|Pirfenidone|Intervention drug
219641184|NCT00049166|DRUG|erlotinib hydrochloride|Given orally
219641185|NCT00049166|DRUG|cisplatin|Given IV
219641186|NCT00049166|RADIATION|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
219059619|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
219641187|NCT00049166|OTHER|laboratory biomarker analysis|Correlative studies
219641188|NCT06663202|PROCEDURE|Fiber retention osseous resective surgery|"At the buccal and lingual sides, paramarginal or intrasulcular incisions will be made based on probing pocket depth values and the width of keratinised tissues.~Thinned palatal flap technique will be performed on the palatal side. Bone remodelling will be carefully made using manual or rotary instruments in order to reshape positive attached fibres/bony architecture utilising the FibReORS technique, great attention will be made to distinguish between inflammatory granulation tissue and connective tissue fibres attached to root cementum by means of periodontal probe. Flaps will be positioned at the level of the alveolar crest without tension."
219641189|NCT06663202|PROCEDURE|Papilla preservation flap|Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used. Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.
219641190|NCT06663202|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
219641191|NCT03173690|OTHER|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
219641192|NCT03173690|OTHER|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
219641193|NCT00226785|DRUG|Dexmedetomidine|
219641194|NCT06043960|OTHER|Humac Norm İsokinetic Machine|Tecno Body Prokin Isokinetic Balance System CSMI (CYBEX) Humac Norm Isokinetic Testing and Exercise System Romberg Test Mini Mental Test (MMSE) Fugl-Meyer Assessment of the lower limb
219641195|NCT03903094|OTHER|Non-Interventional|Overview of anticholinergic burden, rather than to evaluate specific drugs
219641196|NCT03377504|BEHAVIORAL|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
219641197|NCT03377504|BEHAVIORAL|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
219641198|NCT01461317|DRUG|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
219641199|NCT00641290|DEVICE|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
219641200|NCT05083936|DRUG|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
219641201|NCT00151190|BEHAVIORAL|Education for diabetes self-management|
219641202|NCT06682377|PROCEDURE|Radiofrequency ablation alone|No touch RFA with dual switching monopolar + bipolar mode
219641203|NCT03269721|BEHAVIORAL|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
219641204|NCT03269721|PROCEDURE|Spirometry|Pre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
219059620|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
219059621|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
219207573|NCT06688786|DRUG|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy|Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
219207574|NCT06870513|PROCEDURE|Antegrade Cerebral Perfusion via Axillary Artery|In antegrade cerebral perfusion (ACP), patients underwent cannulation of the right axillary artery using an interposition Dacron graft (7 mm) connected to a cardiopulmonary bypass (CPB) circuit. During surgery, ACP delivered oxygenated blood flow directly into the brain arteries to maintain cerebral protection during the period of deep hypothermic circulatory arrest (DHCA), enabling the surgical team to perform the distal aortic anastomosis safely.
218957753|NCT04264052|DIAGNOSTIC_TEST|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
218957754|NCT04074239|OTHER|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
218957755|NCT04875247|DEVICE|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
218957756|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
218957757|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
219207575|NCT06870513|PROCEDURE|Retrograde Cerebral Perfusion via Superior Vena Cava|In retrograde cerebral perfusion (RCP), cannulation of the superior vena cava (SVC) was performed to deliver blood flow in reverse direction during deep hypothermic circulatory arrest (DHCA). This method aimed to provide cerebral protection by supporting cerebral metabolism during the surgical repair of acute Type A aortic dissection.
219641205|NCT03269721|PROCEDURE|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
218957758|NCT03479645|BEHAVIORAL|Serial text messages and mailed FIT kit|"1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message"
218957759|NCT03103061|DRUG|Lexiscan|Coronary vasodilator
218957760|NCT02270437|DRUG|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
218957761|NCT00231374|PROCEDURE|Myelogram|
218957762|NCT03549351|OTHER|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
218957763|NCT03988413|DRUG|25mg|SYHA1402 25mg or Placebo 25mg
218957764|NCT03988413|DRUG|50mg|SYHA1402 50mg or Placebo 50mg
218957765|NCT03988413|DRUG|100mg|SYHA1402 100mg or Placebo 100mg
218957766|NCT03988413|DRUG|200mg|SYHA1402 200mg or Placebo 200mg
218957767|NCT03988413|DRUG|400mg|SYHA1402 400mg or Placebo 400mg
218957768|NCT03988413|DRUG|800mg|SYHA1402 800mg or Placebo 800mg
219059622|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
219059623|NCT01569334|BIOLOGICAL|blood samples|
219059624|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
219059625|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
219059626|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
219059627|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
219059628|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
219059629|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
219641206|NCT03269721|PROCEDURE|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
219641207|NCT03269721|DIAGNOSTIC_TEST|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
219641208|NCT03269721|PROCEDURE|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
219641209|NCT03269721|BIOLOGICAL|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
219059630|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
219059631|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
219059632|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
218957769|NCT04743518|OTHER|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
218957770|NCT04743518|OTHER|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
218957771|NCT01325792|DEVICE|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
218957772|NCT01915628|DEVICE|BioMatrix Flex|Percutaneous coronary intervention
218957773|NCT00924625|OTHER|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
218957774|NCT00924625|OTHER|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
218957775|NCT01056380|DRUG|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
219207576|NCT06873919|OTHER|Geriatric assessment|The tertiary hospital's geriatrics department is implementing a one-year mobile team composed of a geriatrician and a nurse to conduct geriatric assessments (Anamnesis and heteroanamnesis - Clinical examination - Medication review - Proposed management plan provided to the general practionner, who independently decides which recommendations to implement) in three nursing homes. This non-randomized pilot project aims to establish a new standard of care for residents selected by their primary care physician. The project is accompanied by a clinical study designed to assess the feasibility, effectiveness, and acceptability of this intervention. Prospectively collected data will also help define key indicators for a future large-scale study focusing on cost-effectiveness.
219207577|NCT07022782|OTHER|A nutritional intervention based on the principles of Mediterranean diet|The patients will consume meals three times (i.e., breakfast, lunch and dinner) per day for 90 days (i.e., three months) that are based on the principles of Mediterranean diet.
219207578|NCT06698003|DRUG|Mogamulizumab|Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
219207579|NCT07026994|DRUG|Colchicine 0.5mg|Oral colchicine 0.5mg once per day combined with standard treatment
219641210|NCT03269721|BEHAVIORAL|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
219207580|NCT07026994|DRUG|Matching placebo|Oral matching placebo once per day combined with standard treatment
219641211|NCT03269721|PROCEDURE|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
218957776|NCT01056380|DRUG|Placebo|Tablet, twice daily with food for 5 days
218957777|NCT02203084|OTHER|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
218957778|NCT00235001|DRUG|trandolapril/verapamil|180/2 mg QD
218957779|NCT05465720|BEHAVIORAL|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
218957780|NCT01655108|DRUG|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
218957781|NCT01655108|DRUG|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
218957782|NCT03439527|OTHER|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
219207581|NCT07030426|DRUG|Vaginal Estrogen - Twice Weekly|Twice weekly for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime .
219207582|NCT07030426|DRUG|Vaginal Estrogen - Daily|Daily for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime.
219207583|NCT06710106|DIETARY_SUPPLEMENT|Prebiotic + hypocaloric diet|Study participants will add prebiotic formula in a natural yogurt every day to be consumed within a hypocaloric diet.
219207584|NCT06710106|DIETARY_SUPPLEMENT|Placebo + hypocaloric diet|Study participants will add placebo formula in a natural yogurt every day to be consumed within a hypocaloric diet.
219207585|NCT07035626|DRUG|Spermidine|As a member of the polyamine family, spermidine is a trivalent cationic compound found in eukaryotic cells. It interacts with polyanions such as nucleic acids, proteins, and ATP through electrostatic binding, thereby maintaining genomic DNA stability, regulating gene transcription and translation, and modulating autophagy, apoptosis, oxidative stress, angiogenesis, and intercellular communication. Spermidine is indispensable for cell division and proliferation.
219207586|NCT07035626|DRUG|Spermidine simulants|Patients in control group were treated with Spermidine simulants, and its use method and use time are the same as intervention group.
219207587|NCT06715163|DIETARY_SUPPLEMENT|Dose 1 (42mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Lowest dose of DAO administered in this study
219207588|NCT06715163|DIETARY_SUPPLEMENT|Placebo|Contains the same excipients as the DAO tablets but without the diamino oxidase content
219641212|NCT05194891|DIAGNOSTIC_TEST|Specular Microscopy|Phacoemulsification
219641213|NCT05187286|DRUG|Apixaban|Administered as directed by treating physician
219641214|NCT05426486|DRUG|ARX788|HER2 antibody-drug conjugate
219641215|NCT05426486|DRUG|Pyrotinib maleate|EGFR/HER2 dual inhibitor
219641216|NCT05426486|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
218957783|NCT03901456|BEHAVIORAL|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
218957784|NCT03901456|BEHAVIORAL|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
218957785|NCT03724747|DRUG|BAY2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
218957786|NCT03724747|DRUG|Darolutamide(BAY1841788)|600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
218957787|NCT05043285|BIOLOGICAL|SCTV01C|intramuscular injection
218957788|NCT05043285|OTHER|Placebo|Intramuscular injection
218957789|NCT04608942|DEVICE|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
218957790|NCT04608942|PROCEDURE|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
218957791|NCT03119207|BEHAVIORAL|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
218957792|NCT05912426|BEHAVIORAL|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
218957793|NCT01079702|DRUG|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
218957794|NCT01079702|DRUG|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
218957795|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
219641217|NCT05426486|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
219641218|NCT05426486|DRUG|Docetaxel|Cytotoxic chemotherapy
218957796|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
218957797|NCT02937220|PROCEDURE|monolithic zirconia crown|New crown material used as final restoration for dental implants
218957798|NCT02937220|PROCEDURE|metal ceramic crown|Conventional crown material used as final restoration for dental implants
218957799|NCT01334827|OTHER|high volume gel|4 mL HEC
218957800|NCT01334827|OTHER|low volume gel|2 mL HEC
218957801|NCT01334827|OTHER|vaginal film|"1 x 2 intravaginal quick-dissolving film"
218957802|NCT01136278|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
218957803|NCT01136278|DRUG|Clonidine|150 μg per os
218957804|NCT01136278|DRUG|placebo|capsules identical to MDMA or clonidine
218957805|NCT01988285|OTHER|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
218957806|NCT01988285|OTHER|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
218957807|NCT03037645|DRUG|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
219641219|NCT05426486|DRUG|Carboplatin|Cytotoxic chemotherapy
218957808|NCT00773838|DRUG|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
218957809|NCT00773838|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
218957810|NCT00773838|DRUG|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
218957811|NCT02091505|DRUG|Ranibizumab|
218957812|NCT02139059|PROCEDURE|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
218957813|NCT02139059|PROCEDURE|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
218957814|NCT05780268|BIOLOGICAL|LY3819253|LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
218957815|NCT05780268|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
218957816|NCT05780268|BIOLOGICAL|Remdesivir|Antiviral agent
218957817|NCT01116856|OTHER|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
219641220|NCT05121714|DRUG|Caffeine|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
219641221|NCT05121714|DRUG|ABX464|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
219641222|NCT05121714|DRUG|Fluvoxamine|his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
219641223|NCT04257123|DEVICE|Gelesis100|Participants will administer Gelesis100 before lunch and dinner meals.
219641224|NCT04257123|OTHER|Placebo|Participants will administer a placebo before lunch and dinner meals.
219641225|NCT05017311|DRUG|Escitalopram|All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
219641226|NCT05017311|DRUG|Brexpiprazole|Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
219207589|NCT06715163|DIETARY_SUPPLEMENT|Dose 2 (84mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Medium dose of DAO administered in this study
219207590|NCT06715163|DIETARY_SUPPLEMENT|Dose 3 (210mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Highest dose of DAO administered in this study
219207591|NCT06713538|OTHER|Equine assisted therapy|The intervention will last for 12 sessions, with two 1.5-hour sessions per week. The program is offered to patients in addition to their usual daily schedule. These 12 sessions will be organized as follows:
219207592|NCT06713538|OTHER|Physical activity|The subjects will independently carry out 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of moderate-intensity physical activity. The endurance activity should be performed according to the patient's capabilities and fatigue levels.
219207593|NCT06713928|OTHER|Oral hygiene with dog therapy|The DAT session is divided into two phases: a pre-sitting phase in which the patient could interact with the dog, touching, caressing and playing with him, under the supervision of the dog-trainer. This phase lasted about 15 minutes. The second phase was a during-sitting phase in which the dog was in the chair, next to the patient, during the entire oral hygiene procedure, under the supervision of the dog-trainer.
219641227|NCT01914471|BEHAVIORAL|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
219641228|NCT00829140|DRUG|Placebo|
219641229|NCT00829140|DRUG|Lorcaserin 10mg BID|
219641230|NCT04114201|PROCEDURE|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
219641231|NCT04114201|PROCEDURE|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
219641232|NCT02374710|PROCEDURE|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
219641233|NCT02374710|PROCEDURE|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
219641234|NCT05996341|DEVICE|blood flow restriction|12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
219641235|NCT06667258|DEVICE|Ear ECG/PPG sensors|Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear
219207594|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered six times daily|The motor threshold of 100% intensity, a TBS stimulus train for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 6 treatments per day, 50 min apart, a total of 10800 pulses/day, continuous stimulation for 5 days.
218957818|NCT05153889|OTHER|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
218957819|NCT05153889|OTHER|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
219059633|NCT05109910|PROCEDURE|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
219207595|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered 10 times daily|The motor threshold of 100% intensity, a TBS stimulus train stimulation for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 10 treatments per day, intervals of 50 min, a total of 18000 pulses/day, continuous stimulation for 5 days.
219207596|NCT06881030|PROCEDURE|Sham|The appearance of the sham stimulation coil was consistent with that of the real stimulation coil, which could simulate the touch and sound of the scalp caused by the real stimulation. The treatment frequency, location, intensity and time of the sham stimulation group were the same as those of the real stimulation group.
219207597|NCT06881589|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
219207598|NCT06881225|OTHER|Using DCE-MRI, fMRI, and DSI, establish a longitudinal brain functional and structural imaging database for three groups of nasopharyngeal carcinoma patients before and 18 months after radiotherapy.|"1. Resting-state fMRI:~   Use the Gradient Echo Echo Planar Imaging (GRE-EPI) sequence with the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, flip angle (FA) = 90°, slice thickness = 3.0 mm, slice spacing = 0.8 mm, field of view (FOV) = 240 mm × 240 mm, matrix = 128 × 128, in-plane resolution = 64 × 64, 39 axial slices scanned, 240 dynamic scans.~2. DSI:~   Use diffusion-sensitive imaging (DSI) with 64 diffusion directions, b-values of 0 and 1000 s/mm², TR = 3000 ms, TE = 64 ms, number of excitations (NEX) = 1, matrix = 112 × 112, FOV = 224 mm × 224 mm, slice thickness = 2 mm, no spacing between slices, full brain coverage, and 75 slices scanned.~3. Three-dimensional brain structural MRI:~Sagittal data acquisition is performed with the following parameters: TR = 8.16 ms, TE = 3.18 ms, inversion time (TI) = 800 ms, flip angle (FA) = 8°, matrix = 256 × 256, FOV = 256 mm × 256 mm, voxel size = 1 mm × 1 mm × 1 mm, and 176 slices scanned."
219207599|NCT07039890|DRUG|Empagliflozin + Linagliptin filmcoated tablets|Empagliflozin + Linagliptin 10 mg/5 mg filmcoated tablets
219207600|NCT07039890|DRUG|Glyxambi film-coated tablets|Glyxambi 10 mg/5 mg film-coated tablets
219641236|NCT02667964|OTHER|spiroergometry|Spiroergometry on a bicycle ergometer
219641237|NCT04016779|DRUG|Placebo|Placebo will be administered once daily
219641238|NCT04016779|DRUG|SPN-812|SPN-812 will be administered once daily and compared to Placebo
218957820|NCT02812888|DRUG|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
219641239|NCT00910208|DEVICE|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
219641240|NCT00910208|DRUG|morphine|Intravenous morphine
219641241|NCT01624779|DRUG|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1\&2
218957821|NCT03608761|DRUG|Rebamipide|rebamipide 2%
218957822|NCT03608761|BIOLOGICAL|autologous serum|AS for 3 months
218957823|NCT03608761|OTHER|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
218957824|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
219059634|NCT03571061|PROCEDURE|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
219059635|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
219059636|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
219059637|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
219059638|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
219059639|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
219207601|NCT07039435|OTHER|Alternative Frequency Mapping|Patients will have their speech processors programmed with four maps, three of which use a higher low-frequency cutoff than the default map (313 Hz, 438 Hz, 563 Hz, compared to the default map that has a low-frequency cutoff of 188 Hz).
219207602|NCT07037810|DEVICE|iBolus|MDI+ FreeStyle Libre 2 +iBolus
219641242|NCT05875779|BEHAVIORAL|Peer-led vaccine education intervention|"The intervention will be delivered face-to-face by a trained peer-educator and will consist of one session of 10-20 minutes.~Peer vaccine educators will receive written vaccine materials for distribution. These materials will present content that accurately represents the risks and benefits of vaccination.~Responsibilities of the vaccine educators will be to: provide motivational interviewing with patients, provide vaccine counseling, address questions and concerns regarding available vaccines, brief clinical provider on hesitant patients and areas of their vaccine-related concerns, and provide follow-up with participants at day 30, day 60 and day 90 for additional engagement."
219207603|NCT07037810|OTHER|Carb counting|MDI+FreeStyle Libre 2+ Carbcounting
219641243|NCT02295020|DRUG|Standard treatment only|Standard treatment such as NSAIDs and injections
218957825|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
218957826|NCT01135563|DRUG|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
219059640|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
219059641|NCT03296189|DRUG|Placebos|10 mls normal saline
219059642|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
219059643|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
219059644|NCT06533124|DEVICE|The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.|In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
219059645|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
219059646|NCT02639884|DEVICE|SedLine EEG|
219207604|NCT07038681|OTHER|Mediterranean Diet Intervention Group|In the same way as the control group, the intervention group receives standard nutritional care from the hospital nutritionist, since all the pregnant women have at least one of the following risk factors: obesity, diabetes or hypertension, nutritional - standard-care procedure in the Portuguese National Health System.
219207605|NCT07038681|OTHER|Control Group (Standard Hospital Dietary Care)|The control group will receive standard care from the nutritionist in the hospital.
219641244|NCT02295020|DEVICE|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
219641245|NCT01511874|DRUG|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
219641246|NCT03776110|DRUG|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
219641247|NCT03776110|DRUG|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
219641248|NCT05279235|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
219641249|NCT05279235|DRUG|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
219641250|NCT05279235|DRUG|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
219641251|NCT05279235|DRUG|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
219059647|NCT02639884|DEVICE|RRa monitoring|
219059648|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
219059649|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
219059650|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
219059651|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
219641252|NCT03551717|OTHER|Optical Coherence Tomography angiography|At the inclusion visit for all patients and at M3 only for 50 patients.
219641253|NCT03551717|OTHER|Fundus|At the inclusion visit for all patients and at M3 only for 50 patients.
219641254|NCT03551717|OTHER|cardiac ultrasound scan|Only for 50 patients, 3 months after the initial cardiovascular event
219641255|NCT01144039|DRUG|LG-group|
219641256|NCT01144039|DRUG|HG-group|
219641257|NCT01144039|DRUG|Placebo-group|
219641258|NCT04721119|PROCEDURE|Local Infiltration Anesthetic|For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.
219641259|NCT04721119|PROCEDURE|Local Infiltration Anesthetic + Adductor Canal Block|For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
219641260|NCT04725318|OTHER|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
219641261|NCT06969118|PROCEDURE|Minimalism Transcatheter LAAC Group|Patients will undergo transcatheter LAAC under local anesthesia, guided by DSA and TTE, using the WATCHMAN FLX system. The release criteria (PASS: Position, Anchor, Size, Seal) will be confirmed through DSA and TTE.
219641262|NCT06969118|PROCEDURE|Standard Transcatheter LAAC Group|Patients will undergo LAAC under general anesthesia, guided by TEE, using the WATCHMAN FLX system, following the steps outlined in the product manual.
218957827|NCT00124839|DRUG|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
218957828|NCT00494767|DRUG|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
218957829|NCT00494767|DRUG|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
218957830|NCT00494767|DRUG|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
218957831|NCT00494767|DRUG|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
218957832|NCT02502006|DRUG|Celecoxib|
218957833|NCT02502006|DRUG|Naproxen|
218957834|NCT02502006|DRUG|Placebo|
218957835|NCT01456975|PROCEDURE|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
219641263|NCT00001016|DRUG|Trimetrexate glucuronate|
219641264|NCT00001016|DRUG|Leucovorin calcium|
219641265|NCT02828124|BIOLOGICAL|BMS-986183|specified dose on specified days
219641266|NCT02828124|BIOLOGICAL|Nivolumab|specified dose on specified days
219641267|NCT05942014|BEHAVIORAL|dental anxiety|Evaluate dental anxiety in children and its relation with screen time exposure
219641268|NCT06968273|BEHAVIORAL|Combined respiratory physiotherapy and cardiovascular-strength training program|20-session supervised hospital-based program including respiratory physiotherapy, aerobic training (guided by Borg scale and HR monitoring), and strength training using progressive loads (based on 1RM). Duration: 4 weeks (5 sessions/week).
219641269|NCT06966973|OTHER|Polysomnograpy|All successive patients who underwent polysomnography
219641270|NCT06968832|BEHAVIORAL|Massed Prolonged Exposure Therapy (M-PE)|Massed Prolonged Exposure (M-PE) is a trauma-focused, evidence-based behavioral intervention for posttraumatic stress disorder (PTSD). It is delivered over a compressed timeline (e.g., 10 sessions over 2-4 weeks) as opposed to weekly sessions over 3-4 months. This format has been shown to accelerate PTSD symptom reduction and reduce treatment dropout. In this study, M-PE will be delivered concurrently with an Intensive Outpatient Program (IOP) for substance use disorder (SUD) at Gateway Community Services. Sessions will be led by trained clinicians using a standardized PE protocol, with treatment including imaginal exposure, in vivo exposure, and processing.
219641271|NCT06968832|BEHAVIORAL|Standard outpatient SUD care|"Patients randomized to usual care will receive standard intensive outpatient SUD treatment.~* Resilience group (weekly)~* Peer support~* Individual therapy from a variety of modalities"
219641272|NCT02079467|PROCEDURE|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
219641273|NCT02079467|PROCEDURE|Standard rehabilitation|Standard care range of motion restrictions will remain in place
219641274|NCT00620360|DIETARY_SUPPLEMENT|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
218957836|NCT00023127|PROCEDURE|Integrated Pest Management|
218957837|NCT00134420|DRUG|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
218957838|NCT00134420|PROCEDURE|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
218957839|NCT00134420|PROCEDURE|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
218957840|NCT00134420|PROCEDURE|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
218957841|NCT00573287|DRUG|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
218957842|NCT00573287|DRUG|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
218957843|NCT02206178|DRUG|N-acetylcysteine combination with acetaminophen|
218957844|NCT02206178|DRUG|Placebo|
219641275|NCT00620360|DIETARY_SUPPLEMENT|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
219641276|NCT00759460|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
218957845|NCT04944862|BIOLOGICAL|CDX-0159|administered intravenously
219641277|NCT00759460|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
219641278|NCT06618391|DRUG|Envafolimab|Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
219641279|NCT06618391|DRUG|Recombinant human endostatin|Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
219641280|NCT06618391|DRUG|recombinant human adenovirus type 5|Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
219641281|NCT05280366|DEVICE|Streamline Surgical System|Completion of the Streamline Surgical System procedure
219641282|NCT05280366|DEVICE|iStent Inject W|Implantation of competitor device
218957846|NCT04944862|DRUG|Normal saline|administered intravenously
218957847|NCT01890720|DEVICE|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
218957848|NCT01890720|OTHER|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
219641283|NCT03631914|PROCEDURE|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
218957849|NCT01311869|DIETARY_SUPPLEMENT|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
218957850|NCT01311869|DIETARY_SUPPLEMENT|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
219059652|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
219059653|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
218957851|NCT06454266|DRUG|ORM regimen|"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"
219059654|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
219059655|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
219059656|NCT02652728|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
219059657|NCT00145431|DRUG|torcetrapib/atorvastatin|
219059658|NCT00145431|DRUG|atorvastatin|
219059659|NCT00145431|DRUG|fenofibrate|
219059660|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
219059661|NCT01465334|DRUG|Ofatumumab|
219059662|NCT01465334|DRUG|High-Dose Methylprednisolone|
219059663|NCT01465334|DRUG|Alemtuzumab|
219059664|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
219059665|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
219059666|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
219059667|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
219059668|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
219641284|NCT01925066|DRUG|Vancomycin|
218957852|NCT03320694|DRUG|Metformin|metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
218957853|NCT03320694|DRUG|Insulin|The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
219059669|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
219059670|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
219059671|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
219059672|NCT01831089|DRUG|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
219059673|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
219059674|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
219059675|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
219059676|NCT00725166|OTHER|Skeletal muscle aging|"W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
219207606|NCT06688071|DIAGNOSTIC_TEST|Single Group Assignment|68Ga-DOTA/NOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga/18F-FAPI, and undergo PET/CT imaging within the specificed time.
218957854|NCT04097782|BEHAVIORAL|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
218957855|NCT03562767|BEHAVIORAL|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
218957856|NCT03562767|BEHAVIORAL|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
218957857|NCT03562767|BEHAVIORAL|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
218957858|NCT04371302|DIAGNOSTIC_TEST|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
218957859|NCT01230125|DRUG|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
218957860|NCT01230125|DRUG|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
218957861|NCT01589770|OTHER|cardiac Magnetic Resonance imaging|
218957862|NCT00226629|PROCEDURE|Endovascular vs Open Repair|
218957863|NCT00936091|DRUG|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
218957864|NCT00936091|DRUG|Placebo|125 children received placebo capsules
218957865|NCT04080271|DEVICE|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
218957866|NCT00736047|BIOLOGICAL|NIC002|
218957867|NCT00736047|BIOLOGICAL|Placebo|
218957868|NCT04388371|DRUG|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
218957869|NCT00814216|DRUG|QAV680|
219059677|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
219059678|NCT01058200|DEVICE|iCup|new vacuum extractor: sterile disposable plastic cup
218957870|NCT00814216|DRUG|Matching placebo for QAV680|
218957871|NCT00814216|DRUG|Fluticasone Propionate|
218957872|NCT02956902|OTHER|Clinician supported smartphone application intervention|
218957873|NCT05389852|DRUG|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
219207607|NCT07038811|DEVICE|Tät®II|"The Tät®II app offers a treatment program for women with urge or mixed urinary incontinence. The program includes information on the pelvic floor, urinary incontinence, and factors affecting incontinence; a bladder training program; a pelvic floor muscle training program; and incontinence-related psychoeducation. The app also contains helpful functions, the ability to create reminders, visualization of each training level, a statistics function regarding the number of exercises performed, and feedback on changes in the level of bother due to urinary incontinence during treatment.~The Tät®II app is available for download on Google Play and the App Store. Users need a one-time code to access the app, which is provided by the research team after they are included in the study. The app is self-instructive and can be used anywhere; no formal education is necessary. There is no option to communicate through the app."
219207608|NCT07039695|PROCEDURE|Volar buttress plate|Patients will be treated by a volar buttress plate.
219059679|NCT01058200|DEVICE|reference cup|reference cup of the obstetrical ward: metallic cup
219059680|NCT00422539|DRUG|70% trichloroacetic acid|
219059681|NCT00664144|DRUG|Rasburicase (SR29142)|
219207609|NCT07039695|PROCEDURE|Herbert screw|Patients will be treated by Herbert screw.
219059682|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
218957874|NCT02535780|PROCEDURE|Transcranial magnetic stimulation|TMS
218957875|NCT02535780|PROCEDURE|Transcranial direct current stimulation|tDCS
218957876|NCT00997113|DRUG|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
218957877|NCT00997113|DRUG|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
218957878|NCT00045721|DRUG|O6-benzylguanine|
218957879|NCT00045721|DRUG|polifeprosan 20 with carmustine implant|
218957880|NCT00045721|PROCEDURE|adjuvant therapy|
218957881|NCT00045721|PROCEDURE|conventional surgery|
218957882|NCT00045721|PROCEDURE|neoadjuvant therapy|
218957883|NCT02593136|DIETARY_SUPPLEMENT|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
218957884|NCT02593136|OTHER|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
218957885|NCT01658813|DRUG|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
219059683|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
219059684|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
219059685|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
219059686|NCT03522662|DRUG|GSK1070806|Single 10mg/kg infusion on Day 0
219059687|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
219059688|NCT06266221|DRUG|Oral Placebo|Oral placebo
219059689|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
219059690|NCT06266221|DRUG|IV Placebo|IV placebo
219641285|NCT02069912|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
219641286|NCT01092039|DIETARY_SUPPLEMENT|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
219059691|NCT02185352|DRUG|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
219059692|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
219059693|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
219059694|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
219059695|NCT01547572|PROCEDURE|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
219059696|NCT01547572|PROCEDURE|The control group will receive a leaflet only|The control group will receive a leaflet only
219059697|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
219059698|NCT01952912|PROCEDURE|PkEP|
219059699|NCT01952912|PROCEDURE|OP|
219059700|NCT03401970|BEHAVIORAL|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
219059701|NCT03401970|BEHAVIORAL|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
219059702|NCT03401970|BEHAVIORAL|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
219059703|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
219059704|NCT05954897|DRUG|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
219059705|NCT01597687|PROCEDURE|Blood collection|1 blood sample will be collected from each subject.
219059706|NCT01597687|OTHER|Data collection|Quality of Life and HE questionnaires.
219059707|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
219641287|NCT01092039|DIETARY_SUPPLEMENT|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
219641288|NCT01488422|BEHAVIORAL|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
219641289|NCT06438523|PROCEDURE|PULPOTOMY OF MATURE PERMENANT TEETH|Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp
218957886|NCT02948218|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
218957887|NCT02937974|DRUG|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
218957888|NCT02937974|DRUG|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
218957889|NCT06119958|DRUG|DWC202313|Experimental Drug 1
218957890|NCT06119958|DRUG|DWC202314|Experimental Drug 2
218957891|NCT00482352|OTHER|laboratory biomarker analysis|Correlative studies
218957892|NCT00938886|DRUG|Naltrexone|Daily 50 mg naltrexone
218957893|NCT00938886|DRUG|Placebo|Matched naltrexone placebo
218957894|NCT02907190|OTHER|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
218957895|NCT02907190|OTHER|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
218957896|NCT03415386|DRUG|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
218957897|NCT05324488|OTHER|No intervention|In this registry no intervention is carried out
219059708|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
219059709|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
219059710|NCT05515055|OTHER|Blood test|1 blood sample extra to standard of care is taken
219059711|NCT01625793|DRUG|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
219059712|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
219059713|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
219059714|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
219059715|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
219059716|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
219059717|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
219059718|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
218957898|NCT04365101|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
218957899|NCT00353860|DEVICE|SOLEX 300i Stem Cell Selection|
218957900|NCT02461472|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
218957901|NCT01315821|DRUG|Saccharomyces boulardii|5 million units/day for 3 months
218957902|NCT01315821|DRUG|Placebo|Placebo for 3 months
218957903|NCT03269162|DRUG|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
218957904|NCT03269162|DRUG|Docetaxel|75mg/m2,ivgtt 30mins, d1
218957905|NCT03269162|DRUG|Pemetrexed|500mg/m2, ivgtt 30mins, d1
218957906|NCT03269162|DRUG|Cisplatin|75mg/m2, ivgtt \>2h, d1
218957907|NCT04774458|PROCEDURE|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
218957908|NCT00537901|RADIATION|First-Line Bevacizumab and Chemotherapy|Chemotherapy
218957909|NCT00537901|DRUG|Bevacizumab|Chemotherapy
218957910|NCT02094768|DIETARY_SUPPLEMENT|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
218957911|NCT02094768|DIETARY_SUPPLEMENT|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
218957912|NCT02972476|DRUG|Budesonide & formoterol fumarate and Aclidinium bromide|
218957913|NCT02972476|DRUG|Fluticasone 500 & salmeterol and Aclidinium bromide|
218957914|NCT02972476|DRUG|Fluticasone 250 & salmeterol and Aclidinium bromide|
219059719|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
218957915|NCT02972476|DRUG|Aclidinium bromide & formoterol fumarate|
218957916|NCT05245448|DRUG|Tetrandrine|Administered orally
218957917|NCT05245448|DRUG|Placebo|Administered orally
218957918|NCT03786627|OTHER|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
218957919|NCT03786627|OTHER|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
218957920|NCT05125185|OTHER|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
218957921|NCT00061282|DRUG|Clotrimazole|One retention enema, administered nightly
218957922|NCT05694143|OTHER|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education."
218957923|NCT05694143|OTHER|No Intervention|They will have their regular curriculums and normal physical activity routine
219059720|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
219059721|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
218957924|NCT03320876|DRUG|filgotinib|one filgotinib oral tablet once daily.
219059722|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
219059723|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
219059724|NCT02897544|BEHAVIORAL|Individualized Manualized Health Education Intervention|
219059725|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
219059726|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
219059727|NCT01699594|DRUG|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
219059728|NCT01699594|DRUG|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
219059729|NCT02114892|DRUG|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
218957925|NCT03557996|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush
219059730|NCT02114892|DRUG|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
219059731|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
219059732|NCT00418392|PROCEDURE|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
219059733|NCT00418392|PROCEDURE|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
219059734|NCT06387563|PROCEDURE|Abdominal activation using pressure biofeedback|"PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
219207610|NCT07040072|COMBINATION_PRODUCT|Stapokibart and Finotonlimab|"Receive the combination of Stapokibart and Finotonlimab in cycles 1-3, and maintain treatment with Finotonlimab in subsequent cycles.~Stapokibart, 600mg for the first cycle, 300mg for the second and third cycles, administered subcutaneously every 3 weeks, for a total of 3 doses of Stapokibart; Finotonlimab 200mg, administered intravenously every 3 weeks until confirmed disease progression occurs according to the RECIST 1.1 imaging criteria (if the researcher determines that the subject can benefit from continuing PD-1 drug treatment, and the subject can tolerate the study treatment and agree, PD-1 drug can be continued and recorded in the study records), unacceptable toxic side effects, initiation of new anti-tumor treatment, withdrawal from the study or death (whichever occurs first), or reaching a maximum treatment period of 2 years."
218957926|NCT03557996|DRUG|Sodium Fluoride Varnish|NaF will be applied with a brush
218957927|NCT01962168|DEVICE|Evolution® Biliary Stent - Uncovered|Commercially available device
218957928|NCT03377140|DIETARY_SUPPLEMENT|Hesperidin|2 capsuls
218957929|NCT03377140|OTHER|control|2 capsuls
219641290|NCT06966999|PROCEDURE|Botulinum Toxin Type A Injection [Botox]|for patients \>12 years presenting with large-angle esotropia (\>50 PD), primary surgical intervention was recommended as the preferred approach to minimize failure and recurrence risk. Conversely, for patients ≤12 years, BTXA injection was maintained as the first-line treatment regardless of the deviation angle.
219641291|NCT06499610|DRUG|Irinotecan Hydrochloride Liposome Injection|At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
218957930|NCT02674854|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
219059735|NCT06387563|PROCEDURE|Abdominal activation using SEMG biofeedback|"SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
219059736|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
219059737|NCT00277264|DRUG|Tiotropium (Spiriva®)|
219059738|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
219059739|NCT04078282|BEHAVIORAL|Intervention group|see above
219641292|NCT03909750|PROCEDURE|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
219641293|NCT03909750|PROCEDURE|AD-cSVF|Isolation of AD-cSVF
219641294|NCT03909750|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
219641295|NCT03093649|OTHER|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
219641296|NCT03093649|OTHER|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
218957931|NCT02674854|DRUG|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
218957932|NCT02674854|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
218957933|NCT02901756|DIETARY_SUPPLEMENT|Antemig|Participants were instructed to take one tablet every morning for three months.
219641297|NCT01376921|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
219641298|NCT00256854|DRUG|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
219641299|NCT00256854|DRUG|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
218957934|NCT04919447|PROCEDURE|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
218957935|NCT01030601|DRUG|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
218957936|NCT04121624|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
218957937|NCT00913692|DRUG|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
218957938|NCT00913692|DRUG|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
218957939|NCT02102503|BEHAVIORAL|Standard Treatment|
218957940|NCT02102503|BEHAVIORAL|MI and Medication review|
219641300|NCT00256854|DRUG|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
218957941|NCT01552733|DEVICE|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
218957942|NCT01552733|OTHER|Standard of care|Rehabilitation Therapy
218957943|NCT00899080|GENETIC|gene expression analysis|
218957944|NCT00899080|GENETIC|reverse transcriptase-polymerase chain reaction|
219059740|NCT02769091|DRUG|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
219059741|NCT02769091|DRUG|Placebo|
219059742|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
219059743|NCT01787526|DRUG|ferric carboxymaltose|1 g intravenously per infusion
219059744|NCT01787526|DRUG|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
219059745|NCT03175653|OTHER|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
219059746|NCT03175653|OTHER|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
219059747|NCT03149094|BEHAVIORAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
219059748|NCT03149094|BEHAVIORAL|CBSM-SMI control|this group will receive the LifeSum app.
219059749|NCT05916508|DRUG|0.454% stannous fluoride|Brush two times daily
219059750|NCT05916508|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
219059751|NCT05916508|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
218957945|NCT00899080|OTHER|immunoenzyme technique|
219059752|NCT04992260|BIOLOGICAL|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
219641301|NCT00256854|DRUG|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
219641302|NCT00256854|DRUG|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
218957946|NCT00899080|OTHER|laboratory biomarker analysis|
219059753|NCT04992260|BIOLOGICAL|Controlled vaccine|The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
219059754|NCT02574975|DRUG|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
218957947|NCT00899080|OTHER|platelet aggregation test|
218957948|NCT00573729|OTHER|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
218957949|NCT00573729|OTHER|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
218957950|NCT04456231|DRUG|Plenvu|Patients will receive Plenvu for preparation of endoscopy
218957951|NCT02973633|DEVICE|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
218957952|NCT02973633|DRUG|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
218957953|NCT01043042|OTHER|No interventions will be used in this study|No interventions will be used in this study
218957954|NCT05399576|DRUG|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
218957955|NCT05399576|DRUG|Saline|intracoronary of 4ml saline
219059755|NCT02574975|DRUG|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
219059756|NCT02574975|DRUG|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
219059757|NCT02574975|DEVICE|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
219059758|NCT02574975|DRUG|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
219059759|NCT02302729|DIETARY_SUPPLEMENT|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
219059760|NCT02302729|BEHAVIORAL|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
219059761|NCT02302729|DIETARY_SUPPLEMENT|Placebo|Riboflavin Vitamin B2
219059762|NCT04080973|DIAGNOSTIC_TEST|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
218957956|NCT03095547|DRUG|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
219641303|NCT00256854|DRUG|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
219641304|NCT00256854|DRUG|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
218957957|NCT03095547|DRUG|Posaconazole|Pharmacokinetic assessment AUC 0-tau
219641305|NCT00256854|DRUG|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
219641306|NCT01307137|BEHAVIORAL|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~* Weight management success is defined as a loss of at least 5% of the weight since enrollment~* Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
219641307|NCT01307137|BEHAVIORAL|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
218957958|NCT03095547|DRUG|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
219641308|NCT02353442|OTHER|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
218957959|NCT03095547|DRUG|F901318|Pharmacokinetic assessment AUC 0-tau
218957960|NCT03095547|DRUG|Tacrolimus|Pharmacokinetic assessment AUC 0-t
218957961|NCT04241679|DEVICE|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
218957962|NCT05765981|DRUG|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
219059763|NCT04080973|DIAGNOSTIC_TEST|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
219059764|NCT02116465|DRUG|Levodopa Carbidopa immediate release tablets|oral administration
219059765|NCT01734668|DEVICE|In Vitro Diagnostic device to aid in diagnosis|
219059766|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
219059767|NCT03497325|DRUG|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
219059768|NCT03497325|DRUG|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
218957963|NCT02112955|BEHAVIORAL|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
218957964|NCT02112955|BEHAVIORAL|Usual care|Usual care such as hospital-based or community-based health education or services.
218957965|NCT02889562|DRUG|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
219059769|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
219059770|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
219059771|NCT02084953|DRUG|BMS-791325|
219059772|NCT02084953|DRUG|Moxifloxacin|
219059773|NCT02084953|DRUG|Placebo matching BMS-791325|
219059774|NCT04601155|DEVICE|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
219207611|NCT07038213|GENETIC|glycation genes|glycation genes
219207612|NCT07038213|DIAGNOSTIC_TEST|beta 2 microglobulin|b2m
219641309|NCT02353442|OTHER|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
218957966|NCT02889562|DRUG|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
218957967|NCT00358072|BEHAVIORAL|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
218957968|NCT01943474|DEVICE|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
218957969|NCT01943474|DEVICE|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
219641310|NCT02353442|OTHER|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
219641311|NCT02353442|OTHER|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
218957970|NCT02246712|DRUG|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
218957971|NCT02246712|OTHER|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
218957972|NCT02246712|OTHER|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
218957973|NCT02246712|GENETIC|CYP2B6 genotype|The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
218957974|NCT04128787|DRUG|AG881 Formulation 1|AG881 uncoated tablets
218957975|NCT04128787|DRUG|AG881 Formulation 2|AG881 film-coated tablets
218957976|NCT04128787|DRUG|Omeprazole|Omeprazole capsules
218957977|NCT00865488|BIOLOGICAL|ADHEXIL|Adhesions prevention
218957978|NCT05409378|DEVICE|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
218957979|NCT01470989|DRUG|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
218957980|NCT01470989|DRUG|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
218957981|NCT03346798|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
219641312|NCT02353442|OTHER|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
218957982|NCT03346798|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
218957983|NCT03346798|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
218957984|NCT00969280|DEVICE|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
218957985|NCT00969280|DEVICE|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
218957986|NCT04288544|DIETARY_SUPPLEMENT|Microalgae|Open, monocentric intervention study in crossover design
219641313|NCT02353442|OTHER|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
219641314|NCT03613909|DEVICE|CP950 OTE Sound processor|CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
218957987|NCT04288544|DIETARY_SUPPLEMENT|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
219641315|NCT06586788|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on a caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
218957988|NCT04288544|DIETARY_SUPPLEMENT|sea fish|Open, monocentric intervention study in crossover design
218957989|NCT04935450|DIAGNOSTIC_TEST|Bronchoalveolar lavage|Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis
218957990|NCT03627390|DRUG|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
218957991|NCT03627390|DRUG|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
218957992|NCT00314483|DRUG|Mesenchymal Stem Cell Infusion|
218957993|NCT04441762|DRUG|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
218957994|NCT04441762|DRUG|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
218957995|NCT05871515|DEVICE|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
218957996|NCT06364293|OTHER|Observational design does not include interventional behavior.|Observational design does not include interventional behavior.
218957997|NCT04469491|DRUG|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
218957998|NCT04469491|DRUG|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
218957999|NCT01809977|PROCEDURE|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
218958000|NCT01809977|PROCEDURE|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
218958001|NCT05346445|DRUG|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
218958002|NCT05346445|DRUG|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
218958003|NCT02119676|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
218958004|NCT02119676|DRUG|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
218958005|NCT02119676|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
218958006|NCT04764266|DIAGNOSTIC_TEST|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
218958007|NCT03046914|GENETIC|HLA-B*5801 test|Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
218958008|NCT00719433|DEVICE|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
218958009|NCT00719433|OTHER|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
218958010|NCT04153214|BEHAVIORAL|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
218958011|NCT03969966|OTHER|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
218958012|NCT03849755|DEVICE|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
218958013|NCT04705844|DRUG|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
218958014|NCT04705844|DRUG|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
218958015|NCT03947554|DIETARY_SUPPLEMENT|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
218958016|NCT03947554|DIETARY_SUPPLEMENT|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
218958017|NCT03947554|DIETARY_SUPPLEMENT|Placebo|800 mg excipient
218958018|NCT03115281|DEVICE|PCI|PCI
218958019|NCT00340574|DRUG|AMA1-C1/Alhydrogel + CpG 7909|
218958020|NCT02216812|DRUG|500 mg vitamin c, 1 pill per day for 6 weeks|
218958021|NCT02216812|DRUG|1 placebo pill for 6 weeks|
218958022|NCT01447212|DRUG|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
218958023|NCT01447212|DRUG|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
218958024|NCT01447212|DRUG|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
218958025|NCT01447212|DRUG|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
218958026|NCT00266864|DRUG|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
218958027|NCT01832168|PROCEDURE|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
218958028|NCT01832168|OTHER|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
218958029|NCT01832168|OTHER|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
218958030|NCT06553859|OTHER|No intervention conducts.|The type and method of breast reconstruction with sillicon implants and ADM implanting is now the standard treatment of breast cancer in korea. no any specific intervention has occurred during the surgery.
218958031|NCT02050126|DEVICE|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
218958032|NCT03303482|BEHAVIORAL|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
218958033|NCT01077154|DRUG|Placebo|Administered subcutaneously for up to 5 years
218958034|NCT01077154|DRUG|Denosumab|Administered subcutaneously for up to 5 years
218958035|NCT04067583|OTHER|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
218958036|NCT05167110|DIETARY_SUPPLEMENT|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
218958037|NCT05167110|DIETARY_SUPPLEMENT|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
218958038|NCT01580748|DRUG|Roflumilast|500 microgram once daily for 16 weeks
218958039|NCT00070733|DRUG|testosterone enanthate|
218958040|NCT00070733|DRUG|duastride|
218958041|NCT05144334|DRUG|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
218958042|NCT05024214|DRUG|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
218958043|NCT05024214|DRUG|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
218958044|NCT04944056|OTHER|conventional physiotherapy|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
218958045|NCT04944056|OTHER|compression mobilization|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
219641316|NCT06586788|DIAGNOSTIC_TEST|Integrated PCP Diagnosis and Eye-tracking Biomarker|A Classification and Regression Tree (CART) Analysis, based on recursive partitioning, was used to determine which combination of variables (EE Hub PCP diagnosis, diagnostic certainty, composite biomarker, and biomarker frequency \[sum of all individual biomarkers (0-6) that exceeded the 95% specificity threshold for each child\]) best predicted reference standard autism diagnosis.
219641317|NCT03514485|BEHAVIORAL|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
219641318|NCT03514485|BEHAVIORAL|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
218958046|NCT02174588|DRUG|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
218958047|NCT02174588|DRUG|propofol|propofol are used for sedation drug
218958048|NCT01216371|DRUG|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
218958049|NCT01216371|DRUG|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
219641319|NCT03514485|BEHAVIORAL|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~1. Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~2. Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~3. Asthma education for school staff/personnel at the start of each school year.~4. School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
219641320|NCT03895606|OTHER|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
218958050|NCT05340127|DEVICE|CEREBO®|Usability Study
219059775|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
219059776|NCT00162851|DRUG|alemtuzumab|
219059777|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
219059778|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
219059779|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
219059780|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
219059781|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
219059782|NCT01598480|DRUG|Flamazine|Silver sulfadiazine cream
219059783|NCT01598480|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
219059784|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
219059785|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
219059786|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
219641321|NCT00993343|DRUG|Sirolimus/tacrolimus|Standard GVHD prophylaxis
219641322|NCT00993343|DRUG|cyclosporine/methotrexate|Standard GVHD prophylaxis
219641323|NCT01041846|DRUG|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
219641324|NCT03200730|BEHAVIORAL|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
219641325|NCT05885035|DRUG|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
219641326|NCT01614782|DRUG|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
218958051|NCT01419444|BEHAVIORAL|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
218958052|NCT03579654|BIOLOGICAL|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
218958053|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
218958054|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
218958055|NCT00027222|PROCEDURE|retinal ablation|
218958056|NCT06432088|DEVICE|Extended Magnetic Grasper Device|The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.
218958057|NCT00533793|PROCEDURE|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
218958058|NCT06994728|DEVICE|Left STN-DBS on, right STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
218958059|NCT06994728|DEVICE|Right STN-DBS on, left STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
218958060|NCT06326489|DEVICE|Switching to the Medtronic 780G insulin pump|Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
218958061|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
218958062|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
218958063|NCT01074905|DRUG|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
218958064|NCT01074905|DRUG|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
219641327|NCT01614782|OTHER|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
219059787|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
219059788|NCT00003945|DRUG|cisplatin|
219059789|NCT00003945|DRUG|topotecan hydrochloride|
219059790|NCT00585754|DRUG|Guanfacine|1.5mg BID
219059791|NCT00585754|DRUG|Placebo|placebo
219059792|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
219059793|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
219059794|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
219059795|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
219059796|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
219641328|NCT05667831|OTHER|Alginate silver silver ion dressing|Alginate silver silver ion dressing is a soft, comfortable wound dressing with a high mannuronic acid content. Gels on contact with wound exudate or blood, creating a moist wound environment for optimal wound healing. Silver ions protect the dressing from a range of microorganisms.
219641329|NCT00791661|DRUG|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
219641330|NCT00791661|DRUG|Placebo|Matching placebo to MK-1006 in a single oral dose
219641331|NCT02354755|DEVICE|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
218958065|NCT01074905|DRUG|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
218958066|NCT01848197|DRUG|paclitaxel|
218958067|NCT03529812|BEHAVIORAL|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
218958068|NCT01322308|DRUG|pioglitazone|30 mg tablet QD (taken once daily)
218958069|NCT01322308|DRUG|placebo|tablet taken once a day
218958070|NCT01481129|DRUG|Akt Inhibitor MK2206|Given PO
218958071|NCT01481129|OTHER|Laboratory Biomarker Analysis|Correlative studies
218958072|NCT01481129|OTHER|Pharmacological Study|Correlative studies
218958073|NCT03983148|BEHAVIORAL|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
219207613|NCT07038850|OTHER|Multimodal nurse training about nurse driven sedation-analgesia protocol|"The training program for nursing staff in the use of the sedation-analgesia protocol includes 3 stages:~1. Initial training: e-learning module to be validated~2. Feedback session: sessions in small groups of 5 to 6 participants, led by a nurse trainer, allowing interprofessional transmission (questions/answers and critical analyzes of sedation collection sheets).~3. Bedside rehearsal: individual practice of the sedation-analgesia protocol at the patient's bedside under the supervision of a doctor or nurse trainer."
218958074|NCT03983148|BEHAVIORAL|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
219059797|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
219059798|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
219059799|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
219059800|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
219059801|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
219207614|NCT07040020|PROCEDURE|Underwater ESD (U-ESD)|Underwater ESD (U-ESD): after filling the lumen with saline and sucking all the air, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out
219207615|NCT07040020|OTHER|Conventional ESD (C-ESD)|Conventional ESD (C-ESD): under CO2 insufflation, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out.
219207616|NCT06875076|DRUG|Ivonescimab Combined With Chemotherapy|ivonescimab 20mg/kg combined with pemetrexed 500mg/m²/gemcitabine 1000mg/m²/vinorelbine 25mg/m² every 21 days for 4 cycles followed by a maintenance phase (ivonescimab monotherapy 20mg/kg every 21 days until disease progression, intolerance, or up to 2 years)
219641332|NCT05332990|DIAGNOSTIC_TEST|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
218958075|NCT06202092|DEVICE|Phonophoresis|Ultrasound using honey as a media over the knee joint
219059802|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
219207617|NCT07039409|BEHAVIORAL|Acupressure|Patients will receive three 1-hour sessions of training at home within 3 days by Community Psychiatric Nurse (CPN), who was trained by an experienced TCM practitioner. They will learn acupressure. After the training, they will be assessed by the CPN to ensure that they are able to identify the acupoint based on reports of a sensation of obtaining 'Qi' when using the Point Locator device. They will then apply constant pressure for approximately 1 minute on each acupoint using the Acupen, as indicated by a marking in red by themselves. To ensure treatment compliance, the participants will apply this intervention once per day for 10 days. During the 10-day intervention period, and the patient should sign in on WhatsApp every day. If the patient is unable to use WhatsApp, the print edition of diary will be provided and supervision will be performed by short message and home visit during the 1st day, 5th day and 10th day of the intervention period.
219207618|NCT07038837|OTHER|"Synchronised arm (intervention)"|Vaccines received together with CPS
219207619|NCT07039019|DRUG|Corticosteroid|Patients take 40 mg of prednisone daily for 4 weeks to help reduce inflammation.
219207620|NCT07039019|OTHER|No Corticosteroid|Patients do not take corticosteroid.
218958076|NCT06202092|DEVICE|Ultrasound|ultrasound using gel as a media over the knee joint
218958077|NCT06202092|PROCEDURE|conventional physiotherapy|TENS, Strengthening, and stretching exercises
218958078|NCT03050775|DEVICE|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
219641333|NCT03775863|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma
219641334|NCT00831714|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
219641335|NCT00831714|DRUG|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
219059803|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
219207621|NCT06884865|BIOLOGICAL|Enekinragene Inzadenovec (PCRX-201)|Enekinragene Inzadenovec (PCRX-201) injection
219207622|NCT06884865|BIOLOGICAL|Placebo|Placebo injection
218958079|NCT03050775|DEVICE|Standard Ventilator Circuit|no active heat and humidification during anesthesia
219059804|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
219059805|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
219059806|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
219059807|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
219059808|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
219059809|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
219059810|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
219059811|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
219059812|NCT02139163|OTHER|Cohort Study|
219059813|NCT00141960|DRUG|Famotidine|
219059814|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
219059815|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
219059816|NCT01795001|OTHER|No intervention|
219059817|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
219059818|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
219059819|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
219059820|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
219059821|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
219059822|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
219059823|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
219059824|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
218958080|NCT05882643|OTHER|moderate to deep neuromuscular blockade|"* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)~* Rocuronium (intravenous, 1.0 mg/kg at induction period)"
218958081|NCT05882643|OTHER|shallow to minimal neuromuscular blockade|"* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg at induction period)"
218958082|NCT04085367|DRUG|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
218958083|NCT04085367|DRUG|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
219641336|NCT03369834|DEVICE|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
218958084|NCT03455959|PROCEDURE|Bronchoscopy/BAL|Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
218958085|NCT03455959|PROCEDURE|Airway Brushing|After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
218958086|NCT00733850|DRUG|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
218958087|NCT00733850|DRUG|Gemcitabine|Intravenous repeating dose
218958088|NCT01245517|OTHER|Education|Dietary Phosphorus Education Program
218958089|NCT05502536|OTHER|Traditional rehabilitation programs with Individualized fairytales class|In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
218958090|NCT02383030|DRUG|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
218958091|NCT01425216|DRUG|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
218958092|NCT03084627|BEHAVIORAL|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
218958093|NCT06332638|DRUG|Tegoprazan 12.5mg|Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
219059825|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
219059826|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
219059827|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
219059828|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
219641337|NCT03369834|DEVICE|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
219059829|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
219059830|NCT00614939|DRUG|Placebo|Placebo
218958094|NCT06332638|DRUG|Tegoprazan 25mg|Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
218958095|NCT06332638|DRUG|Famotidine 20mg|Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
218958096|NCT06287606|DRUG|CTP0302-A|Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
218958097|NCT06287606|DRUG|CTP0302-B|Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
218958098|NCT06287606|DRUG|Conventional OST|Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
218958099|NCT04949919|OTHER|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
218958100|NCT05719142|OTHER|Picture exposure|Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
218958101|NCT01528423|PROCEDURE|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
218958102|NCT02821143|OTHER|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
218958103|NCT02821143|OTHER|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
218958104|NCT02981576|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
218958105|NCT05175118|DEVICE|Minimal invasive surgical fixation of distal radius Fractures|Fixation of distal radius Fractures by minimal invasive technique
218958106|NCT03789409|DIETARY_SUPPLEMENT|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
219059831|NCT03901248|OTHER|No Intervention|Observational study
219059832|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
219059833|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
219059834|NCT00000463|DRUG|lovastatin|
219059835|NCT00000463|DRUG|cholestyramine|
219059836|NCT00000463|DRUG|warfarin|
219059837|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
219059838|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
219059839|NCT00003863|GENETIC|comparative genomic hybridization|
219059840|NCT00003863|GENETIC|cytogenetic analysis|
219059841|NCT00003863|GENETIC|fluorescence in situ hybridization|
219059842|NCT00003863|GENETIC|gene rearrangement analysis|
219059843|NCT03650205|DRUG|Ivabradine|Ivabradine capsule
219059844|NCT03650205|DRUG|Placebo|Placebo oral capsule.
219059845|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
219059846|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
219059847|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
219059848|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
219059849|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
219059850|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
219059851|NCT00501605|DRUG|AZD2171|
219059852|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
219059853|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
219059854|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
219059855|NCT05898399|DRUG|Niraparib|Niraparib will be given orally.
219059856|NCT01144104|BEHAVIORAL|Public Service Announcement|
219059857|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
219059858|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
219059859|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
219059860|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
219059861|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
219059862|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
219059863|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
218958107|NCT06433362|DRUG|CMOEP|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
218958108|NCT03874481|OTHER|Observation|follow up regularly for MACE
219641338|NCT03369834|DEVICE|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
219641339|NCT03369834|DEVICE|Sham|LED device off.
218958109|NCT02262312|OTHER|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
219059864|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
219059865|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
219059866|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
219641340|NCT06617819|DEVICE|CR prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
219641341|NCT06617819|DEVICE|PS prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
219641342|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
219641343|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
219641344|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
219641345|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
219641346|NCT05453279|COMBINATION_PRODUCT|Delcetravir dry powder inhaler|Placebo dry powder inhaler
218958110|NCT03274999|DEVICE|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
219059867|NCT00485875|DRUG|Atomoxetine Hydrochloride|
219059868|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
219059869|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
219641347|NCT03944759|PROCEDURE|serratus anterior plan block|serratus anterior plan block
219641348|NCT05501015|OTHER|Ice chips|Consuming small amounts of ice chips with supervision
219641349|NCT00783315|BEHAVIORAL|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
219641350|NCT00783315|BEHAVIORAL|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
219641351|NCT00783315|BEHAVIORAL|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
219641352|NCT00679289|DRUG|HDI|20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
219641353|NCT00679289|DRUG|KW2871|5 mg/m\^2 IV every 2 weeks until disease progression
218958111|NCT01097876|DRUG|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
218958112|NCT01097876|DRUG|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
218958113|NCT03624530|DRUG|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
219641354|NCT00679289|DRUG|KW2871|10 mg/m\^2 IV every 2 weeks until disease progression
219641355|NCT00679289|DRUG|KW2871|20 mg/m\^2 IV every 2 weeks until disease progression
218958114|NCT06468384|PROCEDURE|thoracic erector spinae plane (ESP) block|The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
218958115|NCT02749123|DRUG|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
218958116|NCT02749123|DRUG|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
218958117|NCT02749123|DRUG|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
219059870|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
219059871|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
219059872|NCT02928341|OTHER|Improved water supply|
219059873|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
219059874|NCT00151359|DEVICE|SoleSensor|
219059875|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
219059876|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
219059877|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
219059878|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
219059879|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
219641356|NCT06647992|BEHAVIORAL|Nurse Navigation Program|"It is planned to provide Cervical Cancer Education and Counseling to women in the experimental group about cervical cancer. Training and counseling is planned to be implemented face to face. An information booklet will be given to the experimental group. After 30 and 60 days after the training and counseling given to the experimental and control groups, it was planned to provide online (WhatApp) training and counseling to the patients in the experimental group:~Participants will be given a contact number that they can reach during the day when they want to receive counseling about HPV-DNA or Pap smear. Interviews will be scheduled between 08.00-20.00.~Individuals who are not screened will receive a reminder message by phone on the 45th and 75th day. Transtheoretical Model In the study, interventions will be planned for the experimental group according to the stages of the transtheoretical model.~The researcher will conduct motivational interviews with the individuals."
219641357|NCT00493662|DRUG|Polyethylene Glycol 400 0.4%|
219641358|NCT00493662|DRUG|Propylene Glycol 0.3%|
219641359|NCT00493662|DRUG|0.15% sodium Hyaluronate|
219641360|NCT00493662|DRUG|sodium chloride|
219641361|NCT00493662|DRUG|sodium phosphate monobasic|
219059880|NCT03269591|DRUG|diclofenac tablets|drugs
219059881|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
219059882|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
219059883|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
219059884|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
218958118|NCT02898571|DIETARY_SUPPLEMENT|Placebo|Placebo comparitor
219059885|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
218958119|NCT02898571|DIETARY_SUPPLEMENT|Vitamin C|Active treatment
218958120|NCT02898571|DIETARY_SUPPLEMENT|epicatechin|Active treatment
218958121|NCT04438564|OTHER|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
219059886|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
219059887|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
219641362|NCT05210465|OTHER|speckle tracking mode of the stress ECHO test with dobutamine|speckle tracking mode of the stress ECHO test with dobutamine
218958122|NCT02097927|BEHAVIORAL|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
218958123|NCT01752712|DRUG|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
218958124|NCT01752712|DRUG|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
218958125|NCT05200494|PROCEDURE|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
219641363|NCT01785225|DEVICE|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
219641364|NCT01839617|DIETARY_SUPPLEMENT|Early parenteral nutrition|
218958126|NCT00375869|DRUG|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
218958127|NCT00375869|DRUG|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
218958128|NCT02440412|OTHER|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
218958129|NCT02440412|OTHER|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
218958130|NCT03495544|DIAGNOSTIC_TEST|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
218958131|NCT00003854|OTHER|immunohistochemistry staining method|
219059888|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
219059889|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
219059890|NCT00079105|DRUG|cyclophosphamide|Treatment
219059891|NCT00079105|DRUG|etoposide|Treatment
219059892|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
219059893|NCT00079105|DRUG|prednisolone|Treatment
219059894|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
219059895|NCT00079105|DRUG|vinblastine sulfate|Treatment
219059896|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
219059897|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
219059898|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
219059899|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
219059900|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
219059901|NCT00127959|DRUG|tenofovir|
219059902|NCT00127959|DRUG|emtricitabine|
219059903|NCT00127959|DRUG|zidovudine|
219059904|NCT00127959|DRUG|efavirenz|
219059905|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
219059906|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
219641365|NCT01839617|DIETARY_SUPPLEMENT|Late parenteral nutrition|
219641366|NCT03580109|OTHER|Immediate spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
219641367|NCT03580109|OTHER|Late spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
218958132|NCT00003854|PROCEDURE|lymphangiography|
218958133|NCT00003854|PROCEDURE|sentinel lymph node biopsy|
218958134|NCT00003854|PROCEDURE|therapeutic conventional surgery|
218958135|NCT00003854|RADIATION|whole breast irradiation|
218958136|NCT04475809|PROCEDURE|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
218958137|NCT04475809|PROCEDURE|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
218958138|NCT04475809|PROCEDURE|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
218958139|NCT04475809|PROCEDURE|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
218958140|NCT05954104|DRUG|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
219059907|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
219059908|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
219059909|NCT02212821|DRUG|Erythromycin|
219059910|NCT02212821|DRUG|Placebo|physiological saline
219059911|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
219059912|NCT04796831|DRUG|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
219641368|NCT01690728|BEHAVIORAL|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
219641369|NCT06407661|OTHER|"Disaster Nursing course/education"|"In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level."
219641370|NCT03699462|DRUG|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
219641371|NCT03699462|DRUG|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
219641372|NCT03931473|OTHER|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
219641373|NCT00937040|DRUG|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
219059913|NCT04796831|DRUG|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
219059914|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
219641374|NCT00937040|DRUG|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
218958141|NCT06164210|BEHAVIORAL|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
218958142|NCT03484260|DRUG|Testosterone Product|Men used testosterone product following prescription
219059915|NCT04618055|DEVICE|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
219059916|NCT04618055|DEVICE|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
218958143|NCT06079528|DEVICE|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
218958144|NCT06079528|OTHER|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
218958145|NCT06079528|OTHER|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
219059917|NCT03709537|BEHAVIORAL|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
219207623|NCT06882863|BEHAVIORAL|Motivational interviewing|"This intervention consists of a single nurse-led motivational interview aimed at reducing sedentary behavior in patients with severe COPD. The session, conducted in the patient's home, lasts approximately 60 minutes and focuses on identifying personal barriers, exploring motivation, and setting small, realistic goals to reduce sedentary time.~Unlike traditional pulmonary rehabilitation, this intervention does not involve structured exercise but instead uses motivational interviewing (MI) techniques to encourage gradual behavior change in daily routines. Before the intervention, patients wear an accelerometer for seven days to objectively measure baseline sedentary time. The study assesses feasibility, patient engagement, and adherence to determine whether the approach is suitable for a larger randomized controlled trial (RCT)."
219059918|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
219059919|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
219059920|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
219207624|NCT06883513|OTHER|Osteopathic Manipulative Therapy Long-COVID protocol|"1. Rib Raising~2. Suboccipital Release~3. Thoracic Inlet Release~4. Miller Pump~5. Pedal Pump~6. Suboccipital Release~7. Cranial Sequence of Sinus Effleurage followed by indirect force within vault hold"
219207625|NCT06883513|OTHER|Osteopathic Manipulative Therapy NOT Long-COVID treatment protocol|"1. Bilateral Trapezius Direct Myofascial Release~2. Still's technique of the First rib Bilaterally:~3. Hamstring Muscle Energy"
219207626|NCT06719063|OTHER|Multisensory Virtual Reality|"The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion occurs through the simultaneous stimulation of four of the five senses.~Session duration: 45 minutes, with 15 minutes dedicated to the protocol administration. The remaining 30 minutes will be used to welcome the patient, explain the content of the session, and review the session's outcome, particularly to assess tolerance (Simulator Sickness Questionnaire (SSQ) completed at the start of each week after the first VirtySens® session). The sessions will take place in the morning to prevent the session from being disrupted by fatigue related to the rehabilitation day."
219207627|NCT06808009|DRUG|Lactulose|Syp lactulose
219207628|NCT06808009|DRUG|Rifaximin|Rifaximin
219207629|NCT06808009|OTHER|Standard Medical treatment|Standard Medical treatment
219059921|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
219059922|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
219207630|NCT06706544|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
219207631|NCT06706544|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
219207632|NCT07039747|DRUG|treatment with DIELEN® Protect|treatment with DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
219207633|NCT07039747|DRUG|treatment with placebo of DIELEN® Protect|treatment with placebo of DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
219059923|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
219059924|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
219059925|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
219059926|NCT01971346|DRUG|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
219207634|NCT07038590|OTHER|exergame program with virtual reality|Participants who attend a patient association will add to their usual therapies or virtual exercise program to be developed 2 days a week for 3 months.
218958146|NCT06079528|OTHER|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
218958147|NCT04325984|DRUG|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
218958148|NCT06381271|PROCEDURE|Transcatheter aortic valve replacement|A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
218958149|NCT00507468|PROCEDURE|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
218958150|NCT04776044|DRUG|ATR-002|150mg tablets for oral intake
218958151|NCT04776044|DRUG|Placebo|matching tablets for oral intake
218958152|NCT00849888|BIOLOGICAL|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
218958153|NCT00849888|OTHER|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
218958154|NCT01843478|OTHER|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
219059927|NCT03735862|BIOLOGICAL|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
219059928|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
219059929|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
219059930|NCT01725568|DEVICE|BioMonitor|Implantable cardiac monitor
219059931|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
219059932|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
219059933|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
219641375|NCT00937040|DRUG|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
219641376|NCT00937040|DRUG|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
219641377|NCT00638443|DRUG|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
219641378|NCT00638443|DRUG|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
219207635|NCT07038590|OTHER|usual treatment patient association|Common therapies in patient associations: memory workshops, relaxation, and occupational therapy
219641379|NCT05526807|DRUG|Ursodeoxycholic acid|Oral
219641380|NCT03078179|DIETARY_SUPPLEMENT|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
218958155|NCT01843478|OTHER|Usual Care|
218958156|NCT02744001|OTHER|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
218958157|NCT06465212|DEVICE|TopCon Maestro 2 OCT|Ophthalmic Coherence Tomography
218958158|NCT04250311|DRUG|MMH-407|MMH-407: For oral use.
218958159|NCT04250311|DRUG|Placebo|Placebo: For oral use.
218958160|NCT05945680|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
219059934|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
219059935|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
219059936|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
219207636|NCT03734809|DRUG|Pembrolizumab|200mg every 3 weeks infusion
219207637|NCT06880458|OTHER|Oral health education|The participants will receive oral health education from multiple different sources, including the Know Your OQ website (https://www.knowyouroq.com/).
218958161|NCT05945680|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
218958162|NCT02309619|PROCEDURE|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
219059937|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
218958163|NCT03387644|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
219059938|NCT03553628|OTHER|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
219059939|NCT03553628|OTHER|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
219059940|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
219059941|NCT02333916|OTHER|overfeeding + exercise pre-training|
219059942|NCT02333916|BEHAVIORAL|fitness training|
219059943|NCT02333916|OTHER|overfeeding + exercise post-training|
219059944|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
219059945|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
219059946|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
219059947|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
219059948|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
219059949|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
219059950|NCT04231435|DRUG|Fedratinib|Oral
219207638|NCT06888596|BEHAVIORAL|Exercise|Exercise using cycle ergometer
219641381|NCT03078179|DIETARY_SUPPLEMENT|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
219641382|NCT01125670|DRUG|YM150|oral
219641383|NCT05550987|OTHER|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy|The Vibramoov device (Techno Concept, France) will be used in the rehabilitation program. Before starting the training session, each subject will undergo a diagnosis in order to qualify for the use of Functional Proprioceptive Vibration. Before starting the therapy, pads are placed on the patient's body to fix the vibrating modules in the places to be treated (lower limbs, left upper limb or right upper limb). Then the vibrating modules are attached to the supports. The therapy carried out with the use of the Vibramoov device consists in the targeted and individualized stimulation of the nervous system, as in the course of natural movements of the upper or lower limbs with the use of visual biofeedback. Therapy with the use of the Vibramoov device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
218958164|NCT03387644|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
219059951|NCT04231435|DRUG|Digoxin|Oral
219059952|NCT04231435|DRUG|Rosuvastatin|Oral
219059953|NCT04231435|DRUG|Metformin|Oral
219059954|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
219059955|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
219059956|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
219059957|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
219059958|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
219059959|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
219059960|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
219059961|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
218958165|NCT06287567|DRUG|Lusutrombopag Oral Tablet|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
218958166|NCT01667510|DIETARY_SUPPLEMENT|Cardio Mato|Soft gel capsule for oral use
219641384|NCT05550987|OTHER|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy|The Ekso GT ™ exoskeleton (Ekso Bionics, Inc. Richmond, CA, USA) used in the rehabilitation program has been approved by the Food and Drug Administration (FDA). Before starting the training session, each subject will undergo a thorough diagnosis to individually adjust the bionic skeleton. After entering the patient's data into the device's software, the physiotherapist selects the optimal training parameters. As the patient progresses during the training unit, the therapist will update the exoskeleton settings on an ongoing basis, so that the training is best suited to the current capabilities of the subject. Therapy with the use of the exoskeleton device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
218958167|NCT01667510|DIETARY_SUPPLEMENT|Placebo|Soft gel capsule without test material
218958168|NCT01211431|DRUG|Reference|Intrathécale morphine is used for post-cesarean pain control
218958169|NCT01211431|DRUG|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
218958170|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
218958171|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
219641385|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.|The RoboGait stationary robot (Bama technologist, Turkey) will be used in the rehabilitation program. Before starting the training session, each subject will undergo detailed diagnostics in order to individually adjust the orthoses. The next step will be to put on a vest and inguinal straps on a wheelchair or standing, and then lift it up with the device, then attach it to the Robogait orthoses. After entering the patient's data into the software of the device, the physiotherapist selects the optimal training parameters. During the session, biofeedback is also displayed informing the patient and the therapist about the patient's activity level in the transfer phase and the support during walking for both lower limbs. Therapy with the use of the RoboGait device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
218958172|NCT00149448|BEHAVIORAL|TB Contact Priority Model|
218958173|NCT01206387|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
218958174|NCT01206387|DRUG|placebo comparator|Placebo administered to affected area twice a day for 28 days
219641386|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy|The Zebris FDM-T treadmill will be used in the rehabilitation program for gait analysis. Before each session, patients will be equipped with a harness for safety reasons. The need for a handrail will be assessed prior to each session and patients will be encouraged to support their hands as little as possible. Before starting the training session, each subject will undergo a thorough diagnosis in order to individually adjust the training parameters. Therapy with the use of the Zebris FDM-T treadmill will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
218958175|NCT00706849|DRUG|mipomersen sodium|200 mg /mL
218958176|NCT00706849|DRUG|placebo|1 mL matching placebo
218958177|NCT00235170|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
218958178|NCT02873585|DEVICE|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
218958179|NCT02873585|DEVICE|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
218958180|NCT01611454|DEVICE|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
218958181|NCT01611454|DEVICE|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
218958182|NCT00821067|DIETARY_SUPPLEMENT|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
218958183|NCT00821067|DIETARY_SUPPLEMENT|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
218958184|NCT03269552|DRUG|Carfilzomib|Given IV
218958185|NCT03269552|OTHER|Laboratory Biomarker Analysis|Correlative studies
218958186|NCT03269552|BIOLOGICAL|Rituximab|Given IV
218958187|NCT01343225|DRUG|atripla|once a day
218958188|NCT01343225|DRUG|darunavir ritonavir raltegravir|as directed
218958189|NCT00208546|DRUG|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
218958190|NCT00208546|DRUG|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
219059962|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
219059963|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
219059964|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
219641387|NCT05550987|OTHER|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy|The Pablo (Tyromotion) device will be used in the rehabilitation program. Before the start of the training session, each subject will undergo detailed diagnostics assessing the range of mobility in the shoulder, radiocarpal (frontal and sagittal plane), elbow (sagittal plane), and explosive strength of the cylindrical, pinch and lateral and three-point grip. The Force Control Index will also be designated. The next stage will be training on the Pablo device using visual and auditory biofeedback. The physiotherapist selects the optimal training parameters (type of pad, type of game, level of the game). Each training session will be stored in the software and recorded in the patient's medical records. Therapy with the use of the Pablo device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
219641388|NCT05550987|OTHER|Control Group|In control Group the rehabilitation program will be carried out for a period of 4 weeks. In each of the studied groups, the rehabilitation program will include conventional physiotherapy sessions performed 5 times a week, consisting of 50 minutes a day of individual physiotherapy and 50 minutes a day of standing upright.
219641389|NCT02573558|DRUG|Dexmedetomidine|
219641390|NCT02573558|DRUG|Propofol|
219641391|NCT06388707|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: max. three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.
219059965|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
219641392|NCT06969378|DEVICE|Pulsed field ablation using a pentaspline ablation catheter|After conclusion of AT ablation, transseptal or transbaffle puncture will be performed under fluoroscopic and intracardiac echocardiography guidance to access the left atrium (LA) or pulmonary venous atrium (PVA) if not already done so. PFA will be performed using a pentaspline catheter (Farawave, Boston Scientific) and a steerable sheath to achieve PVI of all veins draining to the LA/PVA with entrance and exit block confirmed at each vein. In patients where PFA is unable to achieve PVI, touch-up RFA will be performed. Programmed atrial stimulation will be performed to investigate for inducible atrial tachycardias. An implantable loop recorder will be placed at the conclusion of the procedure.
219059966|NCT01507428|DRUG|Carboplatin|Given IV
219059967|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219059968|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
219059969|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
219059970|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
219059971|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
219059972|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
219059973|NCT01507428|DRUG|Paclitaxel|Given IV
219059974|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219059975|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
219059976|NCT01306617|DRUG|ABT-450|tablets
219059977|NCT01306617|DRUG|ABT-333|tablets
219059978|NCT01306617|DRUG|ribavirin|tablets
219059979|NCT01306617|DRUG|ritonavir|capsules
219207639|NCT06888999|OTHER|In vitro exposure to workplace by VR plus CAU|During the VR-session, guided by the psychotherapist, participants are virtually exposed to their workplace using VR glasses. Based on the experience of the participants during the vitual visit to their workplace, the psychotherapist can adjust the therapy. In addition Care As Usual is provided (see description active comparator).
218958191|NCT01405066|BEHAVIORAL|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
218958192|NCT01405066|BEHAVIORAL|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
218958193|NCT00981773|DRUG|Maraviroc|Maraviroc 150 mg bid
218958194|NCT00981773|DRUG|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
218958195|NCT00920907|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
218958196|NCT01176942|DIETARY_SUPPLEMENT|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
219059980|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
219059981|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
219059982|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
219059983|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
219059984|NCT02114970|OTHER|Randomized- paper consent|
219059985|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
219059986|NCT02114970|OTHER|Focus Group- paper and tablet consent|
219059987|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
219059988|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
219059989|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
219059990|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
219059991|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
219059992|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
219059993|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
219207640|NCT06888999|OTHER|CAU: Psychotherapy focused on return to work|Psychotherapy focused on return to work, provided by a psychotherapist specialized in counseling cabin crew.
219207641|NCT06887933|DRUG|Niraparib|Niraparib will be administered.
219641393|NCT06968780|PROCEDURE|Buccal Fat Pad|BFP has a long successful history in oral surgery for its use in closure of Oroantral communication and taking advantage of the fact that it contains progenitor stem cells showing similar phenotype with (ASC) adipose-derived stem cells characteristics, which can similarly differentiate into the chondrogenic, adipogenic, or osteogenic lineage. Making them an invaluable reservoir for tissue engineering.
219641394|NCT06968780|PROCEDURE|Palatal Rotation Scarf Graft|This technique uses tissue from the palatal area, which has a rich blood supply placed around the neck of the zygomatic implant aiming to protect the mucosal tissues buccal to the exteriorized implants from capillary compression and subsequent soft tissue recession. The palatal rotation scarf graft has been proven to provide a robust, resilient soft tissue flap with good potential for long-term stability and esthetic outcomes around implants.
218958197|NCT06491667|DIAGNOSTIC_TEST|CBC|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
218958198|NCT06491667|DIAGNOSTIC_TEST|C-reactive protein|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
218958199|NCT00356837|PROCEDURE|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
218958200|NCT02616601|DRUG|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
219641395|NCT06967493|BEHAVIORAL|Amazonian Dance|"Dance intervention consists of 24 Amazonian Dance, 2 times/week, lasting 1 hour, over a period of 12 weeks. Classes will be taught by qualified dance professionals with experience teaching PwPD and will take place in a specific practice room (air-conditioned, spacious, and leveled), with adequate facilities, floors, chairs, bars, mirrors, and sound system.~Classes will be divided into 4 parts. The part 1 (10-15 min.) consists of welcoming students, warm-up exercises, and body awareness activities. In the Part 2 (10-15 min.) Weight transfer activities, static and dynamic balance, motor coordination, strengthening of lower and upper limbs will be carried out. The part 3 (25-30 min.) will be based on the Amazonian Lundum and Carimbó dances. In the part 4 (5-10 min.), the final part of the class, the calm down activity will be carried out, with breathing, stretching and relaxation activities."
218958201|NCT02616601|DRUG|Carac® (Fluorouracil) Cream|Topical cream, brand product.
218958202|NCT02616601|DRUG|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
218958203|NCT02186301|DRUG|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
218958204|NCT02186301|DRUG|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
219059994|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
219059995|NCT00999349|DRUG|Placebo|
219059996|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
219059997|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
219059998|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
218958205|NCT05341388|DIAGNOSTIC_TEST|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
218958206|NCT05341388|DIAGNOSTIC_TEST|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
218958207|NCT05341388|OTHER|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
218958208|NCT05341388|DIAGNOSTIC_TEST|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
218958209|NCT05506137|DRUG|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
218958210|NCT05506137|OTHER|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
218958211|NCT04445974|BEHAVIORAL|Expand your horizons: More than my skin|'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
219059999|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
219060000|NCT03403634|DRUG|Celecoxib|Given PO
219060001|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
219060002|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
219060003|NCT03403634|DRUG|Rintatolimod|Given IV
218958212|NCT04445974|BEHAVIORAL|Creative writing activities|In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
218958213|NCT00371761|BIOLOGICAL|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
218958214|NCT00371761|DRUG|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
218958215|NCT04512339|DRUG|Dupilumab|Dupilumab injections (blinded labels)
218958216|NCT04512339|DRUG|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
218958217|NCT01490723|DRUG|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
219060004|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
219060005|NCT07042464|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises three times weekly for 12 weeks
219060006|NCT06820697|BEHAVIORAL|Low HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
219060007|NCT06820697|BEHAVIORAL|High HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
219060008|NCT07051824|DIETARY_SUPPLEMENT|Probiotic and Prebiotic|"This synbiotic intervention aims to minimize postoperative gastrointestinal symptoms in sleeve gastrectomy patients. The 5 g sachet contains:~* Partially hydrolyzed guar gum (PHGG; 4.9 g): Clinically shown to reduce diarrhea and improve stool consistency,~* Lactobacillus rhamnosus GG (LGG; 1×10⁹ CFU): Evidence-based for alleviating abdominal pain and bloating,~* Maltodextrin (0.1 g): Excipient for stability.~Administered daily in yogurt for 12 weeks post-surgery, this combination directly targets:~① Diarrhea and constipation (via PHGG's soluble fiber),~② Abdominal pain and bloating (via LGG's anti-inflammatory effects),~③ Overall GI symptom burden.~\*\*Distinctive features vs. other studies:~* Symptom-specific formulation: PHGG (high-dose fiber) + LGG (symptom-targeted probiotic) synergy,~* Surgical context: Optimized for rapid gastric transit post-sleeve gastrectomy,~* Delivery innovation: Yogurt matrix protects probiotics against surgical gut pH changes."
219060009|NCT07052058|BIOLOGICAL|Tocilizumab|Single infusion tocilizumab, 8 mg/kg, diluted in 100 mL of normal saline
219060010|NCT07052058|DRUG|Normal Saline (0.9% NaCl)|Placebo, same volume as intervention
219060011|NCT07051759|PROCEDURE|Back contouring surgery|Back rolls are assessed, and the type of surgery is determined according to grade of back rolls.
219641396|NCT06967493|BEHAVIORAL|Nordic Walking|The Nordic walking protocol consists of 3 moments: warm-up (10min), main part (40min) and final part (10min). At the beginning of the activity, a joint warm-up is performed and free walking, without poles, at a comfortable speed. Then, in the main part of the class, the participants performed an individual and daily training that is inserted in their general training cycle, elaborated from the specific and individual functional capacity, measured from the application of the 6-minute walk test. In the final part, return to calm and stretching.
219641397|NCT06967831|PROCEDURE|skin biopsy|Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.
218958218|NCT01490723|DRUG|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
218958219|NCT01490723|PROCEDURE|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
218958220|NCT01490723|DRUG|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
218958221|NCT01490723|DRUG|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
219060012|NCT07051811|PROCEDURE|Intravascular Ultrasound Ablation Therapy|"The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves.~Standardized medication regimen."
219060013|NCT07051811|PROCEDURE|Renal Artery Angiography|Only undergo renal artery angiography. Standardized medication regimen.
219060014|NCT07051681|OTHER|Individualized Medical Nutrition Therapy|Pregnant women with GDM received individualized nutrition therapy during pregnancy. No intervention was applied to the control group.
219641398|NCT06967831|OTHER|generation of iPSCs|Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.
219641399|NCT06967831|DIAGNOSTIC_TEST|blood drawing|Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.
219641400|NCT06967831|DRUG|off-label compassionate drug use|In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.
218958222|NCT01490723|DRUG|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
218958223|NCT01490723|DRUG|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
219641401|NCT06390514|OTHER|vibrating floor|activities with vibrating floor
219641402|NCT06390514|OTHER|No vibrating floor|activities without vibrating floor
219641403|NCT03033927|DIAGNOSTIC_TEST|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
219641404|NCT05336188|DEVICE|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
218958224|NCT01490723|DRUG|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
218958225|NCT01490723|DRUG|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
218958226|NCT01490723|DRUG|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
218958227|NCT01490723|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
218958228|NCT01490723|PROCEDURE|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
218958229|NCT03560739|COMBINATION_PRODUCT|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
218958230|NCT03560739|COMBINATION_PRODUCT|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
219060015|NCT07052110|OTHER|Digital storytelling|DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.
219060016|NCT07052357|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
219060017|NCT07052448|DRUG|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
219641405|NCT06679049|PROCEDURE|micromotion intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw
218958231|NCT03361176|DRUG|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
218958232|NCT03361176|COMBINATION_PRODUCT|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
219060018|NCT07051720|DEVICE|Bilateral implantation of CT ASPHINA 409M|Patients will be implanted with CT ASPHINA 409M during catarct surgery. The CT Asphina 409M has been commercially available for several years and is widely used in clinical practice. Designed with aberration-neutral optical properties, it could improve contrast sensitivity and visual quality. This monofocal aspheric IOL features four-point plate haptics and a one-piece design made from hydrophilic acrylic material with hydrophobic surface properties. It also has an overall diameter of 11 mm and a 6 mm optical diameter. The lens has a sharp posterior optic edge to minimize posterior capsule opacification. It is ideally suited as a comparative referent lens to new EDOF IOLs.
219641406|NCT06679049|PROCEDURE|standard intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
219641407|NCT05074121|DRUG|N-acetylcysteine|N-acetylcysteine
219641408|NCT05074121|OTHER|Placebo|Placebo
219641409|NCT04398238|COMBINATION_PRODUCT|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
219641410|NCT00056238|DRUG|NC-758 (Anti amyloidotic [Aß] agent)|
219641411|NCT00002172|BIOLOGICAL|HIV-1 Immunogen|
219641412|NCT01721096|DEVICE|XIENCE PRIME - Long Length (LL)|Long Length
219641413|NCT01721096|DEVICE|XIENCE PRIME - Core Size|Core Size
219641414|NCT01864551|DRUG|Lamotrigine|
219641415|NCT01864551|DRUG|Olanzapine|
218958233|NCT02496507|OTHER|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
218958234|NCT05347004|DRUG|BI 425809|BI 425809
218958235|NCT05949944|DRUG|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
218958236|NCT01656174|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
218958237|NCT04389970|BEHAVIORAL|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
218958238|NCT06265480|OTHER|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
218958239|NCT03123185|DRUG|Placebo|Tablet and solution formulation
218958240|NCT03123185|DRUG|BI 705564 (Test)|Fed state
218958241|NCT03123185|DRUG|BI 705564 (Reference)|Fasting state
218958242|NCT00179244|DRUG|Rispridone (drug) and Bupropion ER (drug)|
218958243|NCT03102840|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
218958244|NCT03102840|DIAGNOSTIC_TEST|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
218958245|NCT06074601|DIAGNOSTIC_TEST|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
219060019|NCT07051720|DEVICE|Bilateral implantation of TECNIS Eyhance ICB00|Patients will be implanted with TECNIS Eyhance ICB00 during catarct surgery. TECNIS Eyhance ICB00 is a one-piece, posterior chamber lens with an overall diameter of 13.0 mm and an optic diameter of 6.0 mm. The lens has a spherical posterior surface and a modified aspheric anterior surface that offers a smooth and continuous change in power from the periphery to the center of the lens, without a demarcation zone.
219060020|NCT07051720|DEVICE|Bilateral implantation of AcrySof® IQ Vivity®|Patients will be implanted with AcrySof® IQ Vivity® during catarct surgery. The AcrySof® IQ Vivity® is a single-piece, hydrophobic acrylic IOL that utilizes non-diffractive wavefront-shaping technology (X-wave™) on its anterior surface to achieve an extended range of vision. Its aspheric anterior surface features a 2.2 mm central zone composed of two smooth transition elements: the first forms a slightly elevated plateau (\~1 µm) that stretches the wavefront, while the second shifts the wavefront to create a negative extended focal range. Together, these elements could create advanced and delayed wavefronts resulting in a continuous extended focal range instead of multiple focal points, while optimizing light transmission. This UV-absorbing and blue light filtering foldable IOL has a refractive index of 1.55 at 35 °C, an optic diameter of 6 mm and an overall length of 13 mm. The lens is available in spherical powers ranging from +10.0 to +30.0 diopters.
219366224|NCT03043833|BEHAVIORAL|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~* Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~* Lesson 2 presents different strategies to generate realistic cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~* Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
219641416|NCT06051266|DEVICE|Dynamic navigation|Dynamic navigation eliminates the need for a laboratory fabrication process and allows for direct visualisation of the operative area during implant placement. Moreover, it can avoid interfering with water cooling. Navigation-assisted surgery makes it possible to modify the implant system, length, diameter or position in real time, both in the perioperative period and during surgery.
219641417|NCT06051266|DEVICE|Static template|In most clinical situations, a static template can be used to assist in guiding the placement of implants precisely. The static guide has some limitations in that it requires additional fabrication time, has insufficient cooling in the surgical field and is not suitable for simultaneous grafting procedures.
219641418|NCT01528982|BEHAVIORAL|Mindfulness|Subjects receive mindfulness training
219641419|NCT01528982|BEHAVIORAL|Cognition|Subject receive cognitive training
219641420|NCT06023381|OTHER|Sliding sign|"All women had Transabdominal Ultra-sonography using SAMSUNG WS80 elite ultrasound machine during the preoperative examination, using the real-time Transabdominal pelvic features (the relative motion between the maternal abdominal and uterine wall).~The patient was asked to breathe deeply, accentuating her respiratory movements and the sonographer recorded a video clip in a mid-sagittal plane lateral to umbilicus focus on the infra-umbilical space, to determine whether the structure glided freely in relation to adjacent structures. To be considered as sliding, the structures had to glide easily, one against the other (positive sliding sign); no motion of the structure in question signaled a negative sliding sign."
219641421|NCT05268783|PROCEDURE|EORTC QLQ-C30|Quality of life questionnaire that has to be completed every 6 months
218958246|NCT00000203|DRUG|Buprenorphine|
218958247|NCT03818984|BEHAVIORAL|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
218958248|NCT03067831|BIOLOGICAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
218958249|NCT02684318|DRUG|PM01183 + olaparib|
219207642|NCT06725784|DEVICE|ReHandyBot|"The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.~The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions."
219207643|NCT04878445|PROCEDURE|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
218958250|NCT04341753|OTHER|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~\- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
218958251|NCT06341803|DEVICE|Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100|MagproX 100 and Axilium Cobot with Localite camera
218958252|NCT05057910|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
218958253|NCT03289364|DEVICE|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
219207644|NCT06715553|BEHAVIORAL|BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education)|"Six types of intervention will be done on the patients as follows:~* Psychoeducational intervention program~* Art therapy program~* Bibliotherapy program~* Nutrition program~* Sport activity~* Ping Pong activity"
218958254|NCT04968054|DRUG|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
219207645|NCT06736353|DRUG|Beta Blocker Therapy or No Therapy (Control)|Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
219060021|NCT07051720|DEVICE|Bilateral implantation of LuxSmart™|Patients will be implanted with LuxSmart™ during catarct surgery. The LuxSmart™ intraocular lens is a single-piece, acrylic hydrophobic and aspheric IOL with an overall diameter of 11 mm, an optical diameter of 6 mm, and a 4-point fixation haptic design. This non-diffractive IOL utilizes a technology known as Pure Refractive Optics (PRO), incorporating a 2.0 mm central EDOF zone that combines fourth- and sixth-order spherical aberrations of opposite signs designed to improve perceived depth of focus. The paracentral region, on the other hand, is a transition zone meant to gradually decrease the optic vergence from the center to the monofocal periphery. It has also a 360° continuous square edge on the posterior surface to prevent epithelial lens cells migration and posterior capsule opacification.
219060022|NCT07051720|DEVICE|Bilateral implantation of Eyecryl SERT|Patients will be implanted with Eyecryl SERT during catarct surgery. EyeCryl-SERT (Biotech) is a new advanced monofocal, single-piece hydrophobic IOL with an aspheric surface, continuous vision from distance to intermediate, spectacle independence for intermediate vision, an extended range of vision: \>1.75 D at spectacle plane with visual acuity 0.2 LogMAR or better, an intermediate vision up to 57 cm and a design for fast neural adaptation.
219207646|NCT06736353|DRUG|RAAS blocker Therapy or No therapy (Control)|RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
219207647|NCT06736353|DRUG|Statin Therapy or No Therapy (Control)|Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
219207648|NCT06736353|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
219207649|NCT06736353|DRUG|Dual Antiplatelet Therapy or No Therapy (Control)|Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
219641422|NCT05268783|PROCEDURE|EORTC QLQ-GI.NET21|Quality of life questionnaire that has to be completed every 6 months
219641423|NCT05268783|PROCEDURE|Satisfaction survey|Questionnaire regarding satisfaction of care that has to be completed on Day 1.
219641424|NCT04684537|PROCEDURE|Extracorporeal shockwave therapy (ESWT)|The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.
219641425|NCT04684537|PROCEDURE|Ultrasound-guided piriformis steroid injection|all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.
219641426|NCT01355575|DRUG|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
219641427|NCT01213732|OTHER|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
219641428|NCT05087316|DEVICE|biomimetic oral appliance therapy (BOAT)|BOAT appliance is designed to correct maxillo-mandibular underdevelopment in both children and adults (Singh and Lipka, 2009). However, adults will only use for this study. Typically, a BOAT appliance consists of 6 patented, anterior 3-D Axial Springs™, a midline actuator (such as omega loops or screws), posterior occlusal rests, and a round labial bow (Figure 1). Patients will be trained on activation of the screw
219641429|NCT05087316|DEVICE|Standard hospital treatment|Use of CPAP and similar methods
219641430|NCT02208713|BIOLOGICAL|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
218958255|NCT04968054|DRUG|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
218958256|NCT03047681|DIAGNOSTIC_TEST|venous blood withdrawl|patients will be asked for a venous blood sample
218958257|NCT03247803|DEVICE|air-Q® SP|air-Q SP placement for airway maintenance,
218958258|NCT03247803|DEVICE|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
219060023|NCT07051720|DEVICE|Bilateral implantation of RayOne EMV|Patients will be implanted with RayOne EMV during catarct surgery. RayOne EMV (Rayner) is a new EDOF lens that has recently emerged in the market. It is a truly non-diffractive, single-piece hydrophilic IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses. RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration. Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis, elongating the focal range from far into intermediate with up to 1.5 D of depth of focus (per lens on the spectacle plane).
218958259|NCT01455467|DEVICE|One iStent|Implantation of one iStent in conjunction with cataract surgery
218958260|NCT01455467|DEVICE|Two iStent|Implantation of two iStent in conjunction with cataract surgery
218958261|NCT00841373|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
218958262|NCT00841373|PROCEDURE|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
218958263|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc combined|Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
218958264|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc on separate days|Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
218958265|NCT00470158|DIETARY_SUPPLEMENT|iron|Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
219060024|NCT07052396|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
219060025|NCT07051421|PROCEDURE|EARLY WARNING SCORE|In the RECO-EWS scoring system we designed; 0-7 low risk, 7-10 medium risk, ≥10 high risk, postoperative stay findings of high-risk patients and, if necessary, new cut-off values are determined for each parameter in the scoring system according to the analysis results.
219060026|NCT07051564|BIOLOGICAL|CNK-UT009 cell injection|CNK-UT009 cell injection
219060027|NCT07051694|DEVICE|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
218958266|NCT00470158|DIETARY_SUPPLEMENT|Zinc|Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
218958267|NCT00470158|DIETARY_SUPPLEMENT|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
218958268|NCT03772860|OTHER|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
219641431|NCT06578013|OTHER|acupressure ice massage|"* It will be used for participants in group (A), 2 cm diameter circular ice pieces will be placed inside plastic bags and covered with a thin gauze to prevent moisture transmission and direct ice contact with the skin to apply ice massage.~* Ice massage will carried out rotationally each 1 minute (30 seconds clockwise and 30 seconds counterclockwise) on L14 point for 10 minutes and on SP6 point for another 10 minutes."
218958269|NCT03772860|OTHER|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
218958270|NCT03772860|OTHER|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
219060028|NCT07051694|DEVICE|sham-taVNS|sham transcutaneous auricular vagus nerve stimulation
219060029|NCT07051213|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing using Illumina short read sequencing
219060030|NCT07051213|DIAGNOSTIC_TEST|Whole genome Sequencing|Whole genome sequencing using Illumina short read sequencing
219060031|NCT07051343|OTHER|designed artificial intelligence Chatbot education about electronic fetal monitoring|effect of using designed artificial intelligence Chatbot about electronic fetal monitoring on maternity nursing students' performance
219060032|NCT07051343|OTHER|traditional teaching method|the traditional learning method (online meeting).
218958271|NCT03772860|OTHER|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
218958272|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
218958273|NCT04179890|DRUG|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
218958274|NCT04179890|DRUG|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
218958275|NCT04179890|DRUG|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
218958276|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|As first line therapy.
218958277|NCT04179890|DRUG|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
218958278|NCT02520128|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
218958279|NCT06063707|OTHER|Taking peripheral blood|Taking peripheral blood of no more than 3ml
218958280|NCT02129218|OTHER|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
218958281|NCT02129218|OTHER|laboratory biomarker analysis|Correlative studies
219060033|NCT07051512|DRUG|dexmedetomidine 4μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 4μg)
219060034|NCT07051512|DRUG|dexmedetomidine 8 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 8 μg)
219060035|NCT07051512|DRUG|dexmedetomidine 10 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 10 μg).
219060036|NCT07051200|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and RCOs for individuals recently discharged from an acute care psychiatric facility.
219060037|NCT07052136|DRUG|Levetiracetam|Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
219060038|NCT07052136|DRUG|Valproic acid|Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
219060039|NCT05069831|DRUG|Abrocitinib|Abrocitinib daily for 4 months
219060040|NCT03586479|BEHAVIORAL|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
219060041|NCT05089656|GENETIC|OAV101|Gene therapy
219641432|NCT06578013|OTHER|pelvic rocking exercises|"* Pelvic rocking exercise will be used for all participants in both groups (A \& B).~* Each participant will be encouraged to lie down on her back on matrix with a pillow under head then bend her knees and keep her foot flat on the floor and place one hand under curve of her back and the other hand on the top of. her abdomen then tighten buttocks and abdominal muscles simultaneously. After that each participant will be encouraged to inhale and hold (1-2-3-4) then exhale and hold 4-3-2-1 then relax muscles and feel her back flat on the underneath hand. Finally, each participant will be encouraged to repeat the last two steps about 10 times each session.~* The exercise will be repeated for 15times/ session, 3 times /week, for 3 successive menstrual cycles."
219641433|NCT02454816|DEVICE|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
218958282|NCT02129218|BEHAVIORAL|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
219060042|NCT05089656|PROCEDURE|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
218958283|NCT02129218|BEHAVIORAL|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
218958284|NCT02129218|BEHAVIORAL|Low glycemic load|
218958285|NCT02129218|BEHAVIORAL|Medium Glycemic Load|
218958286|NCT06423729|DRUG|Nicorandil 10 MG|Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
218958287|NCT03396393|DRUG|Dihydroartemisinin tablet|DHA tablet
218958288|NCT03396393|DRUG|Placebo tablet|Placebo tablet
218958289|NCT06318962|BEHAVIORAL|Aviva|Digital phone app for BCBT
218958290|NCT00005863|BIOLOGICAL|filgrastim|
219060043|NCT00126048|DRUG|Atorvastatin|40mg tablet
219060044|NCT00126048|DRUG|Placebo|Placebo tablet
219060045|NCT01076400|DRUG|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
218958291|NCT00005863|DRUG|cytarabine|
218958292|NCT00005863|DRUG|daunorubicin hydrochloride|
218958293|NCT00005863|DRUG|etoposide|
218958294|NCT00005863|DRUG|fludarabine phosphate|
218958295|NCT00005863|DRUG|tretinoin|
218958296|NCT04489160|DRUG|C1 Inhibitor, Human|6000 IU C1-INH
218958297|NCT04489160|DRUG|Placebo|0.9% saline
218958298|NCT03950037|DRUG|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
218958299|NCT00674167|DRUG|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
218958300|NCT00674167|DRUG|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
218958301|NCT00674167|DRUG|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
218958302|NCT00127595|DRUG|gemcitabine, oxaliplatin|
218958303|NCT01788176|DRUG|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
219060046|NCT01076400|DRUG|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
219060047|NCT01076400|DRUG|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
219060048|NCT01076400|DRUG|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
219060049|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
219060050|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
219060051|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
219060052|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
219060053|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
219060054|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
219060055|NCT03299140|BEHAVIORAL|Family Focused Therapy|
219060056|NCT01197222|DEVICE|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
218958304|NCT01788176|DRUG|Placebo|one single intravenous infusion of 100ml of saline.
219060057|NCT05265468|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
219060058|NCT05265468|OTHER|Lewit Group|Isometric muscular exercise acompained with stretching technique
219060059|NCT05265468|OTHER|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
219641434|NCT02454816|DEVICE|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
219641435|NCT02986542|PROCEDURE|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
219060060|NCT05265468|OTHER|Placebo Group|No pain positioning of participants
219060061|NCT04844164|DRUG|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
219060062|NCT04331366|DEVICE|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
219060063|NCT05827367|DEVICE|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
219060064|NCT05827367|OTHER|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
219060065|NCT05827367|OTHER|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
219060066|NCT05103761|OTHER|Study diet|A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
219060067|NCT05103761|OTHER|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
219207650|NCT06735677|BEHAVIORAL|sexual health education|These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
218958305|NCT05563480|DRUG|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
218958306|NCT05563480|DRUG|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
218958307|NCT05563480|DRUG|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
219060068|NCT03019536|DRUG|LY3303560 - IV|Administered IV
219060069|NCT03019536|DRUG|Placebo - IV|Administered IV
219060070|NCT03019536|DRUG|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
219060071|NCT03019536|DRUG|Flortaucipir F18|Administered IV during the PET scan performed during the study.
218958308|NCT03505671|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
218958309|NCT03505671|OTHER|Best Practice|Receive usual care
218958310|NCT03505671|OTHER|Quality-of-Life Assessment|Ancillary studies
219641436|NCT04037475|DEVICE|photodynamic therapy herpes labialis|Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
218958311|NCT03505671|OTHER|Questionnaire Administration|Ancillary studies
218958312|NCT02125474|RADIATION|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
219641437|NCT03053791|PROCEDURE|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
219060072|NCT04634201|DIETARY_SUPPLEMENT|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
219060073|NCT04634201|DIETARY_SUPPLEMENT|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
219641438|NCT03053791|DEVICE|Implantation of a Deep brain stimulation system|Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.
219641439|NCT05577013|OTHER|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
219641440|NCT05577013|OTHER|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
219060074|NCT00647920|BIOLOGICAL|adalimumab|40 mg adalimumab sc, every other week
219060075|NCT00647920|BIOLOGICAL|placebo|placebo sc, every other week
218958313|NCT01142518|DRUG|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
218958314|NCT05004454|DIETARY_SUPPLEMENT|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
218958315|NCT05004454|DIETARY_SUPPLEMENT|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
218958316|NCT02038829|DRUG|Placebo|Placebo
218958317|NCT02038829|DRUG|SUN101 3 mcg|SUN-101 3 mcg bid
218958318|NCT02038829|DRUG|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
218958319|NCT02038829|DRUG|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
218958320|NCT02038829|DRUG|SUN-101 50 mcg|SUN-101 50 mcg bid
218958321|NCT02038829|DRUG|Aclidinium|Aclidinium 400 mcg bid
218958322|NCT04916782|OTHER|Quality of life Questionnaire|Quality of life questionnaire
218958323|NCT02705027|DEVICE|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
218958324|NCT06415734|DEVICE|rTMS|LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
218958325|NCT02579928|DRUG|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
218958326|NCT02579928|DRUG|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
218958327|NCT02172066|BEHAVIORAL|Narrative Exposure Therapy (NET)|
218958328|NCT03659786|OTHER|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
218958329|NCT03654027|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
218958330|NCT03654027|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
218958331|NCT00000434|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
218958332|NCT05076591|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
219060076|NCT01973127|OTHER|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
219060077|NCT01973127|OTHER|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
219060078|NCT05738395|DIAGNOSTIC_TEST|Questions|Questions
218958333|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
218958334|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
218958335|NCT04808284|DEVICE|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
219641441|NCT03113942|DRUG|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
219641442|NCT02308072|DRUG|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
218958336|NCT02328911|DEVICE|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
218958337|NCT02328911|DEVICE|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
218958338|NCT06097013|OTHER|Routine clinical rehabilitation|Routine clinical rehabilitation
218958339|NCT02352922|DRUG|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
218958340|NCT02352922|DRUG|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
218958341|NCT02752971|DRUG|Bupivacaine|
218958342|NCT02752971|DRUG|Sodium diclofenac|
219060079|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
219060080|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
219207651|NCT06779383|OTHER|pilates mat exercises|The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.
219641443|NCT02308072|DRUG|Cisplatin|35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
219641444|NCT02308072|RADIATION|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
219641445|NCT03179020|OTHER|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
219641446|NCT03179020|OTHER|Usual care|Management of the potential donor according usual care.
219641447|NCT02294396|DRUG|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
219641448|NCT02294396|DRUG|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
219641449|NCT02294396|DRUG|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
218958343|NCT02869061|PROCEDURE|Liposuction|
218958344|NCT02869061|PROCEDURE|Transurethral bladder neck resection.|
218958345|NCT02869061|BIOLOGICAL|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
218958346|NCT02869061|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
218958347|NCT04561427|OTHER|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
219060081|NCT01043874|DRUG|Nilotinib|400 mg BID
219060082|NCT02818738|DRUG|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
219060083|NCT02818738|OTHER|Placebo|matching verum
219060084|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
219060085|NCT03894449|COMBINATION_PRODUCT|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
219641450|NCT02294396|DRUG|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
218958348|NCT05109052|DRUG|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
218958349|NCT00638807|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
218958350|NCT00638807|OTHER|Placebo|Matched oral placebo for 6 weeks
218958351|NCT04833829|BEHAVIORAL|CHIMES Intervention|"There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings."
218958352|NCT04833829|BEHAVIORAL|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
218958353|NCT03754972|DIAGNOSTIC_TEST|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
218958354|NCT04811196|DRUG|Selinexor|Selinexor
218958355|NCT05161754|PROCEDURE|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
218958356|NCT06251479|BEHAVIORAL|behavioral 1|verbal and non verbal tasks
218958357|NCT06251479|BEHAVIORAL|behavioral 2|verbal and non verbal tasks with other partecipants
219060086|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
219060087|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
219060088|NCT03223298|DRUG|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
219641451|NCT02294396|DRUG|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
218958358|NCT06251479|DEVICE|neuromodulation 1|registration with neurophysiological tecniques during verbal and non verbal tasks
218958359|NCT06251479|DEVICE|neuromodulation 2|registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
218958360|NCT00437970|DRUG|Pioglitazone|15mg of Pioglitazone taken orally twice a day
218958361|NCT00437970|DRUG|Metformin|500 mg of Metformin taken orally twice a day
218958362|NCT03621618|DIAGNOSTIC_TEST|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
218958363|NCT03621618|DIAGNOSTIC_TEST|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
218958364|NCT02916238|DRUG|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
218958365|NCT02916238|BEHAVIORAL|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
219060089|NCT03223298|DRUG|0.9% Sodium Chloride Injection|1cc syringe
219641452|NCT00449358|PROCEDURE|apply methyl-ALA cream|
218958366|NCT03422627|DRUG|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
218958367|NCT01393028|OTHER|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
218958368|NCT01393028|OTHER|Standard care|Standard care according to international guidelines
219060090|NCT01653431|DEVICE|Transcranial direct current stimulation|
219060091|NCT04134663|DRUG|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
219060092|NCT04134663|DRUG|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
219060093|NCT04134663|DRUG|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
219060094|NCT00182689|DRUG|sorafenib tosylate|Given orally
219060095|NCT06074094|DRUG|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
219060096|NCT01405391|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
219060097|NCT00123227|DRUG|Rosiglitazone|
219207652|NCT06541834|DEVICE|Retinal imaging|Data of retinal imaging were acquired using Spectralis (Heidelberg, Germany) and California (Optos, UK).
219641453|NCT03243669|DIAGNOSTIC_TEST|High-definition|High-definition colonoscopy
219641454|NCT03243669|DIAGNOSTIC_TEST|Virtual chromoendoscopy|Virtual chromoendoscopy
219641455|NCT03243669|DIAGNOSTIC_TEST|Standard|Standard colonoscopy
219641456|NCT01479569|PROCEDURE|Pericardiocentesis|
219641457|NCT02164331|BEHAVIORAL|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
219641458|NCT05902299|DRUG|Antibiotic|Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
218958369|NCT05946980|OTHER|Multi-component hand hygiene intervention in primary health care facilities|"Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination."
219207653|NCT05846789|DRUG|SOC Chemotherapy|SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
218958370|NCT04895189|OTHER|No intervention|There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.
218958371|NCT05480696|DIETARY_SUPPLEMENT|Fructo-oligosaccharide enriched inulin supplement|Experiment
219060098|NCT03422003|RADIATION|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
219060099|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
219060100|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
219060101|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
219641459|NCT04559438|OTHER|Rotary Neoniti GPS file|Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
219641460|NCT04559438|OTHER|Manual stainless steel K-files|Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
218958372|NCT05480696|OTHER|Maltodextrin|Placebo.
219060102|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
219207654|NCT05846789|DRUG|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
219207655|NCT06738667|OTHER|Acupuncture|Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19). Participants will lie supine, and the skin will be sterilized. Sterile stainless-steel needles (0.25 mm diameter, 40 mm length) will be inserted using a guide device and a self-adhesive pad. Needles will be manipulated for at least 10 seconds to induce Deqi. Participants will receive 30 minutes of acupuncture for twelve sessions (3 per week for 4 weeks).
219641461|NCT03125538|OTHER|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
219641462|NCT03125538|OTHER|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
219641463|NCT02659280|OTHER|Adjunct Therapy|"Store and Forward Tele-heath"
219641464|NCT02659280|OTHER|Standard of Care|Standard of Care Outpatient Physical Therapy
219060103|NCT04054583|OTHER|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
219060104|NCT02579642|DRUG|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
219060105|NCT02579642|DRUG|Placebo|Normal saline administered with usual induction drugs for ECT
219060106|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
219060107|NCT01337089|DRUG|Nabiximols|
219207656|NCT06738667|OTHER|Sham treatment|The Park Sham device will be used for the sham acupuncture group. To maintain blinding, the acupuncture ritual will be identical in both groups, with the following exceptions: patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
219641465|NCT06685406|DIAGNOSTIC_TEST|Thorathic fluid content measurement by cardiometry|Thorathic fluid content measurement by using cardiometry
219641466|NCT02524743|DRUG|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
219641467|NCT02524743|DRUG|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
219641468|NCT02524743|OTHER|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
219641469|NCT02154503|DEVICE|topical 5% Minoxidil (Microneedling)|
219641470|NCT02120833|DEVICE|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
219641471|NCT02120833|DRUG|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
219641472|NCT01386398|DRUG|bortezomib|
219641473|NCT01386398|DRUG|vorinostat|
219641474|NCT01386398|OTHER|laboratory biomarker analysis|
219641475|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Pocket)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted pocket creation.~The device creates an intrastromal corneal pocket of 8-mm diameter and a depth of nearly 80% of the corneal thickness at the thinnest location with a superior tunnel incision at 90° of 5-mm width."
219641476|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Tunnel)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted tunnel creation.~The device creates an intrastromal tunnel with a depth of nearly 80% of the corneal thickness at the site of implantation. The tunnel inner and outer diameters are at 5 and 6 mm from the corneal center, respectively with the incision located at the steepest keratometry axis."
219641477|NCT03050853|BEHAVIORAL|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
219641478|NCT04764981|OTHER|Essence oils|Consists in olfactory training using essence oils
219641479|NCT02438826|DRUG|Galcanezumab 300 mg|Administered SC
218958373|NCT06638879|DRUG|Tacrolimus|Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
218958374|NCT05851326|DEVICE|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
218958375|NCT05851326|DEVICE|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
218958376|NCT04896645|DEVICE|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
218958377|NCT03691324|OTHER|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
218958378|NCT06526468|DEVICE|Artificial Intelligence|AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
218958379|NCT01676597|DRUG|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
218958380|NCT01676597|DRUG|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
218958381|NCT06536608|OTHER|Massage|"The Oketani Method is based upon practical breastfeeding theory, but is original in its practice. Oketani breast massage improves breastmilk secretion, can prevent and treat problems such as mastitis. In addition, the massage is painless, allowing your body to relax and breathe, something very much appreciated by mothers.~The Oketani breast massage consists of massaging and milking the base of the breasts. These delicate glands are massaged as well as protected."
218958382|NCT05373940|DEVICE|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
218958383|NCT05373940|DEVICE|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
219641480|NCT02438826|DRUG|Placebo|Administered SC
219641481|NCT01088672|PROCEDURE|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
219641482|NCT03831464|DRUG|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
219641483|NCT03831464|DRUG|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
219641484|NCT02830113|PROCEDURE|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
219641485|NCT05026437|OTHER|Cardiac surgery score and APACHE II scoring|Cardiac surgery score and APACHE II will calculated on the first postoperative day.
219641486|NCT02614742|DRUG|SFX-01|An intervention releasing sulforaphane.
219641487|NCT02614742|DRUG|Placebo|Placebo otherwise identical to Active product
219641488|NCT03282721|PROCEDURE|precise location of commissure|
219641489|NCT00526357|DRUG|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
219641490|NCT03036865|DRUG|BOS161721|Single dose administered IV or SC
219641491|NCT03036865|DRUG|Placebo|Single dose administered IV or SC
219641492|NCT04523103|BEHAVIORAL|Artificial Assisted Activation|Artificial assisted activation represents an effective technique to rescue the fertilization failure.
219641493|NCT05898984|DRUG|Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI|"CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[200 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve)."
219641494|NCT05898984|DRUG|Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI|with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
219641495|NCT05898984|DRUG|Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)|pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
219641496|NCT06685315|OTHER|Participants fill out the questionnaire|Participants fill out the questionnaire
219641497|NCT03502070|DRUG|Placebo|One dose (4 capsules) of placebo
218958385|NCT03919188|PROCEDURE|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
218958386|NCT03919188|PROCEDURE|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
218958387|NCT00528554|PROCEDURE|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
218958388|NCT00528554|PROCEDURE|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
219060108|NCT05601479|DRUG|Acetyl-L-carnitine|At the beginning of the first chemotherapy of the oxaliplatin regimen, Acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks. If subjects discontinue oxaliplatin-containing chemotherapy for various reasons (e.g., allergy to oxaliplatin), they will continue taking acetyl-L-carnitine until 24 weeks (unless acetyl-L-carnitine intolerance or other conditions interfere with medication).
219060109|NCT02341716|PROCEDURE|WA|Walk advice with Nordic Poles and best medical treatment
219060110|NCT02341716|PROCEDURE|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
219060111|NCT02341716|PROCEDURE|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
219641498|NCT03502070|DEVICE|Tobi Podhaler|The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
218958389|NCT02819232|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
218958390|NCT05638919|DRUG|Oral Antiviral|Nirmatrelvir plus ritonavir or molnupiravir
218958391|NCT00000496|DRUG|aspirin|
219060112|NCT01311830|BEHAVIORAL|Telephone Counseling|
219060113|NCT01311830|BEHAVIORAL|Written Materials|
219641499|NCT03468413|DRUG|CP1050 or Placebo|Randomised, double-blinded, placebo-controlled
219641500|NCT05712629|OTHER|Bread and vla dadiah|Consumption bread and vla dadiah to pregnant women 1 Pieces a day during 12 weeks.
219641501|NCT05712629|OTHER|Bread and vla without dadiah|Consumption bread and vla without dadiah to pregnant women 1 Pieces a day during 12 weeks.
218958392|NCT00000496|DRUG|dipyridamole|
218958393|NCT03526588|BIOLOGICAL|Autologous umbilical cord blood|6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
219060114|NCT03574129|BEHAVIORAL|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
219641502|NCT03466203|BIOLOGICAL|LLF580|LLF580 300mg
219641503|NCT03466203|DRUG|Placebo|Placebo to LLF580
219641504|NCT03417089|PROCEDURE|Falciform ligament suspension|routine of falciform ligament suspension during Mini gastric bypass
219641505|NCT03417089|PROCEDURE|no suspension|working without of falciform ligament suspension during Mini gastric bypass
219641506|NCT04525014|DRUG|RRx-001|RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
218958394|NCT01797406|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
219060115|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
218958395|NCT01797406|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
218958396|NCT00946140|PROCEDURE|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
219060116|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
219060117|NCT06168708|PROCEDURE|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
219060118|NCT06168708|DRUG|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
219060119|NCT06168708|DRUG|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
219060120|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
219060121|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
219641507|NCT04525014|DRUG|Temozolomide|100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle
219641508|NCT04525014|DRUG|Irinotecan|90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
219641509|NCT03361969|DRUG|Estetrol|estetrol formulated in tablets
219641510|NCT03361969|DRUG|Placebo Oral Tablet|placebo tablets
219641511|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
218958397|NCT01012648|DRUG|Fluid resuscitation|Volume resuscitation
218958398|NCT01012648|DRUG|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
219060122|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
219060123|NCT04890340|DIAGNOSTIC_TEST|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
219060124|NCT04959045|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
219060125|NCT04514315|PROCEDURE|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
219641512|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
219641513|NCT06330246|DIETARY_SUPPLEMENT|Colonization with Oxalobacter formigenes|Ingestion of live Oxalobacter formigenes
218958399|NCT05293392|BEHAVIORAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
218958400|NCT05293392|BEHAVIORAL|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
219365243|NCT00217919|BEHAVIORAL|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
219641514|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
218958401|NCT03284918|DIETARY_SUPPLEMENT|Plant stanol ester|
219060126|NCT04514315|PROCEDURE|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
219060127|NCT06373094|DRUG|Donepezil Dihydroxynaphthalate for Injection|HHT201 will be injected into the muscle of gluteus.
219060128|NCT01627249|DRUG|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
219060129|NCT01627249|DRUG|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
219060130|NCT01627249|DRUG|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
219060131|NCT05884060|OTHER|No intervention|No interventions
219060132|NCT00736242|BIOLOGICAL|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
219060133|NCT00736242|DRUG|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
219060134|NCT04981587|PROCEDURE|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
219641515|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
218958402|NCT03284918|DIETARY_SUPPLEMENT|Placebo|
218958403|NCT00735189|OTHER|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
218958404|NCT00735189|OTHER|usual care|patient receives usual anticoagulation care from their regular primary care physician
218958405|NCT04933643|OTHER||
218958406|NCT01868919|BEHAVIORAL|Positive Parenting Program|Level 3 or 4 of Triple P
218958407|NCT05806489|OTHER|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
218958408|NCT05806489|OTHER|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
218958409|NCT01843647|DRUG|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
219060135|NCT04981587|OTHER|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
219060136|NCT00648232|BEHAVIORAL|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
219060137|NCT00648232|BEHAVIORAL|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
219060138|NCT00648232|BEHAVIORAL|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
219207657|NCT06739876|BEHAVIORAL|Wearable device-based intervention (with motivational support via social media)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.
219207658|NCT06739876|BEHAVIORAL|Wearable device-based intervention (without support)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.
219207659|NCT06737289|PROCEDURE|Surgical Guide|Placing extralarge implats for rahabilitation atrophic maxilla
219207660|NCT06737549|DRUG|Nerver growth factor (NGF) injection|The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
219207661|NCT06737549|DRUG|Placebo injection|Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
219207662|NCT06737549|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of patient can tolerate, targeting a current strength of 3.0mA, for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
219365244|NCT04316169|DRUG|Abemaciclib|150 mg b.i.d
219365245|NCT04316169|DRUG|Hydroxychloroquine 200 mg|Dose level: 200 mg b.i.d.
219641516|NCT02622412|OTHER|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
218958410|NCT01843647|DRUG|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
218958411|NCT05195138|BEHAVIORAL|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
218958412|NCT05195138|BEHAVIORAL|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
218958413|NCT04896450|PROCEDURE|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
218958414|NCT04896450|DEVICE|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
218958415|NCT02475824|DRUG|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
218958416|NCT02475824|DRUG|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
218958417|NCT02475824|DRUG|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
218958418|NCT02475824|DRUG|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
218958419|NCT00934648|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
218958420|NCT00934648|DRUG|methotrexate|10-25mg weekly
219365246|NCT04316169|DRUG|Faslodex|Cohort B will receive Faslodex.
219365247|NCT04316169|DRUG|Anastrazole|Cohort A will receive anastrazole or letrozole.
218958421|NCT02689102|DEVICE|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
218958422|NCT01482390|DRUG|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
218958423|NCT01482390|DRUG|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
218958424|NCT01482390|DRUG|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
218958425|NCT01482390|DRUG|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
218958426|NCT01482390|DRUG|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
218958427|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
219641517|NCT02622412|OTHER|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
219641518|NCT06666686|DEVICE|Active noise control headphone|This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
218958428|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
218958429|NCT03131401|DIAGNOSTIC_TEST|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
218958430|NCT04399746|DRUG|Ivermectin|6mg once daily in day 0,1,7 and 8
218958431|NCT04399746|DRUG|Azithromycin|500mg once daily for 4 days
218958432|NCT04399746|DRUG|Cholecalciferol|400 IU twice daily for 30 days
218958433|NCT05885308|BEHAVIORAL|Otago|Group training is compared with training performed at participants' homes, using an online film
218958434|NCT03748615|DEVICE|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
218958435|NCT03454009|BEHAVIORAL|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
218958436|NCT05448820|DRUG|YH001|Anti-CTLA4 antibody
218958437|NCT05448820|DRUG|Envafolimab|Anti-PD-L1 antibody
218958438|NCT05448820|DRUG|Doxorubicin|Anthracycline
218958439|NCT00000481|BEHAVIORAL|diet, fat-restricted|
219060139|NCT00648232|BEHAVIORAL|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
219060140|NCT05674695|DRUG|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
219641519|NCT06666686|DEVICE|Passive noise control headphone|This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
219641520|NCT03939780|DIAGNOSTIC_TEST|[F18]RO-948|Single radiotracer IV injection with subsequent emission scan
219641521|NCT03939780|DIAGNOSTIC_TEST|[F18]MK-6240|Single radiotracer IV injection with subsequent emission scan
219641522|NCT03939780|DIAGNOSTIC_TEST|[F18]AV1451|Single radiotracer IV injection with subsequent emission scan
219641523|NCT02805179|RADIATION|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
219641524|NCT02805179|DRUG|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m\^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m\^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
219641525|NCT02836379|OTHER|No intervention|No intervention
219641526|NCT02748135|DRUG|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
218958440|NCT04954248|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
219060141|NCT04181554|OTHER|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
219060142|NCT05740462|BEHAVIORAL|Recipes consumption|Participants will eat two recipes a day for 17 weeks
219060143|NCT05740462|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
219060144|NCT01443962|OTHER|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
219060145|NCT01443962|OTHER|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
219365248|NCT04316169|DRUG|Letrozole|Cohort A will receive anastrazole or letrozole.
219365249|NCT04316169|DRUG|Hydroxychloroquine 400 mg|Dose level: 400 mg. b.i.d.
219365250|NCT04316169|DRUG|Hydroxychloroquine 600 mg|Dose level: 600 mg b.i.d.
219641527|NCT02748135|DRUG|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
219641528|NCT02748135|DRUG|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
219641529|NCT02748135|DRUG|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
219641530|NCT01921790|BIOLOGICAL|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
219641531|NCT01921790|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
219641532|NCT01921790|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
219641533|NCT01921790|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
219641534|NCT01921790|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
219641535|NCT06056687|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha Lipoic Acid 600 MG Oral Tablet once daily
219641536|NCT06056687|OTHER|Placebo Tablet|Placebo Tablet once daily
219060146|NCT01346657|DRUG|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
219060147|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
218958441|NCT04239430|DIAGNOSTIC_TEST|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
218958442|NCT01915329|DEVICE|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
218958443|NCT01915329|DEVICE|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
218958444|NCT05265780|PROCEDURE|kinesiotape|an elastic adhesive tape
218958445|NCT05265780|PROCEDURE|sham taping|a sham taping without the tension
218958446|NCT01993836|DRUG|Total intravenous anesthesia with propofol|
218958447|NCT01993836|DRUG|General anesthesia with isoflurane|
218958448|NCT04707547|BIOLOGICAL|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
218958449|NCT04707547|PROCEDURE|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
218958450|NCT02612831|PROCEDURE|Early bariatric surgery|
218958451|NCT02612831|PROCEDURE|Delayed bariatric surgery|
218958452|NCT02195687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
218958453|NCT02195687|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
218958454|NCT02263170|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
218958455|NCT02263170|OTHER|US (ultra sound)|Assessment of the sphincter morphology
218958456|NCT02263170|OTHER|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
219060148|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement + Whey Protein Hydrolysate|Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
219641537|NCT02380261|OTHER|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
219641538|NCT06071143|BIOLOGICAL|KDSTEM Inj.|"1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)"
219641539|NCT00595517|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
218958457|NCT02263170|OTHER|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
218958458|NCT01753778|DEVICE|Cryo-Touch III Device|Treatment with Cryo-Touch III
218958459|NCT02155803|DRUG|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
218958460|NCT00479583|DRUG|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
218958461|NCT00479583|DRUG|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
218958462|NCT01197001|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan low dose
218958463|NCT01197001|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
218958464|NCT02755792|BEHAVIORAL|Calligraphy Training|
218958465|NCT02755792|BEHAVIORAL|iPad Training|
218958466|NCT04515862|OTHER|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
219060149|NCT06478147|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate + still water|Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
219641540|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 1|Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
218958467|NCT03539809|DIETARY_SUPPLEMENT|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
218958468|NCT05279404|OTHER|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
218958469|NCT02288377|DRUG|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
218958470|NCT02288377|DRUG|Placebo|
218958471|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
218958472|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
218958473|NCT03372889|BEHAVIORAL|Patient educaiton materials - Print based|Print (paper) based materials
218958474|NCT03372889|BEHAVIORAL|Patient educaiton materials - Media based|Media (electronic) based materials
219365251|NCT01214044|DRUG|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
219365252|NCT02471157|OTHER|Observation|
219365253|NCT01450176|DRUG|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
219365254|NCT01450176|DRUG|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
218958475|NCT02217072|BEHAVIORAL|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
218958476|NCT02217072|BEHAVIORAL|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
218958477|NCT04156516|BEHAVIORAL|HEART|sexual health intervention
218958478|NCT04156516|BEHAVIORAL|HealthyMinds|Growth mindsets of personality and mental health
218958479|NCT03224780|DIAGNOSTIC_TEST|maternal serum creatine kinase|Biochemical marker
218958480|NCT03224780|DIAGNOSTIC_TEST|3D Doppler ultrasound|Doppler for placental vessels
218958481|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
218958482|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
218958483|NCT00002967|DRUG|cyclophosphamide|
218958484|NCT00002967|DRUG|doxorubicin hydrochloride|
218958485|NCT00002967|DRUG|octreotide pamoate|
218958486|NCT00002967|DRUG|tamoxifen citrate|
218958487|NCT04369924|BEHAVIORAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
218958488|NCT04369924|BEHAVIORAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
218958489|NCT05818605|BEHAVIORAL|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
218958490|NCT05254054|OTHER|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
218958491|NCT05254054|OTHER|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
218958492|NCT01398878|BEHAVIORAL|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
218958493|NCT02359175|DRUG|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
218958494|NCT02359175|DRUG|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
218958495|NCT02359175|DRUG|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
219060150|NCT05064969|BEHAVIORAL|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
219207663|NCT06737549|DEVICE|Acupuncture intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are connected to an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) without closed circuit, with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
218958496|NCT02359175|DRUG|Oral Paracetamol|Paracetamol to be given orally
218958497|NCT02359175|DRUG|Oral NSAID|NSAID to be given orally
218958498|NCT02359175|DRUG|Oral opioids|Opioids to be given orally
218958499|NCT02359175|DRUG|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
218958500|NCT00976118|DRUG|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
218958501|NCT00976118|DRUG|placebo|matching placebo to masitinib
218958502|NCT02844686|OTHER|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
218958503|NCT02712814|DRUG|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
218958504|NCT02712814|PROCEDURE|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
218958505|NCT02712814|PROCEDURE|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
218958506|NCT05543434|DRUG|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
218958507|NCT03255070|DRUG|ARX788|An antibody drug conjugate
218958508|NCT02582762|DRUG|Nail gel|apply nail gel on affected nails twice daily for 2 months
218958509|NCT02273609|DRUG|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
218958510|NCT00375947|OTHER|Hand Exercise|
218958511|NCT00375947|OTHER|sham hand cream|placebo intervention
218958512|NCT00003184|BIOLOGICAL|BCG vaccine|
218958513|NCT00003184|BIOLOGICAL|CD80 breast cancer vaccine|
218958514|NCT00003184|BIOLOGICAL|sargramostim|
219207664|NCT06741241|BEHAVIORAL|eHealth Promotora|Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
219641541|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 2|Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
219641542|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 3|Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
219641543|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 4|Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
219641544|NCT00426296|DRUG|atazanavir (Reyataz)|
219641545|NCT00426296|DRUG|ritonavir (Norvir)|
219641546|NCT00005891|DRUG|cyclophosphamide|
218958515|NCT02258984|DEVICE|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
218958516|NCT06179368|DIAGNOSTIC_TEST|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
218958517|NCT06179368|DIAGNOSTIC_TEST|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
218958518|NCT02554279|DRUG|menotropin|
218958519|NCT02554279|DRUG|recombinant FSH|
218958520|NCT01680133|OTHER|Hyperinsulinemic euglycemic clamp|
219641547|NCT00005891|PROCEDURE|Allogeneic Bone Marrow Transplantation|
219641548|NCT04563910|OTHER|young mania rating scale|questionnaires to the patients and their family after their written consent
219641549|NCT00305084|DRUG|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
219641550|NCT00305084|DRUG|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
219641551|NCT06419842|OTHER|hypnosis|the patient benefits from a dedicated nurse consultation. During this consultation, the nurse will explain the highlights of the hospitalization, the procedure and anticipate the hypnosis technique to be used. The technique chosen during the consultation will be applied during the test. The nurse is positioned at the head of the patient and with physical contact.
218958521|NCT00812487|DRUG|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
218958522|NCT00812487|DRUG|Subcutaneous insulin|4 injections of insulin/day
218958523|NCT04695587|DIAGNOSTIC_TEST|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
219365255|NCT03104842|DRUG|Isatuximab|Antibody Intravenous
219365256|NCT03104842|DRUG|Carfilzomib|Intravenous
218958524|NCT04695587|DIAGNOSTIC_TEST|MSNA|MSNA in subacute phase and 12 months after the acute episode
218958525|NCT04695587|DIAGNOSTIC_TEST|ABPM|ABPM in subacute phase and 12 months after the acute episode
218958526|NCT04695587|DIAGNOSTIC_TEST|ECHO|ECHO in subacute phase and 12 months after the acute episode
218958527|NCT04695587|DIAGNOSTIC_TEST|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
218958528|NCT04695587|DIAGNOSTIC_TEST|CMR|CMR in 12 months after the acute episode
218958529|NCT00882401|DRUG|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
218958530|NCT00882401|DRUG|Placebo|Matching placebo at same dose schedule as ergocalciferol
219365257|NCT03104842|DRUG|Lenalidomide|Capsel
219207665|NCT06741241|BEHAVIORAL|eHealth Healthy Nutrition|Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
219207666|NCT06040359|OTHER|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
218958531|NCT02207660|DRUG|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
218958532|NCT02360605|BEHAVIORAL|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
219060151|NCT01737112|DRUG|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
219060152|NCT01130766|PROCEDURE|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
219060153|NCT01509573|BEHAVIORAL|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
219060154|NCT01390012|DRUG|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
219060155|NCT01390012|DRUG|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
219641552|NCT06419842|OTHER|comfort|the patient benefits from a nurse consultation. Non-medicinal techniques are not offered. During the infusion test, the nurse will be positioned at the patient's head allowing proximity but without oral or physical intervention.
219060156|NCT06395350|DEVICE|Spire Health Monitor|Use of Health Monitor is Assessed
219207667|NCT06040359|OTHER|Usual care|Usual perinatal care
219207668|NCT05321784|OTHER|Dermoscopy|Take digital dermoscopy images (DDI)
219207669|NCT05321784|OTHER|Digital Photography|Take smartphone clinical images (SCI)
219207670|NCT05321784|PROCEDURE|Self-Skin Examination|Perform self-skin exam (SSE)
219207671|NCT05321784|DEVICE|Skin Examination with Sklip|Apply Sklip System
219207672|NCT05321784|PROCEDURE|Skin Examination|Undergo in-person full body skin examination (FBSE)
219207673|NCT05321784|OTHER|Survey Administration|Ancillary studies
219207674|NCT05480098|DRUG|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
219641553|NCT04468308|OTHER|Questionnaire|Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
219641554|NCT06530251|DRUG|AK112|Following a predefined dose and date.
219641555|NCT06530251|DRUG|Cadonilimab|Following a predefined dose and date.
219641556|NCT06530251|DRUG|AK127|Following a predefined dose and date.
219641557|NCT06530251|DRUG|AK130|Following a predefined dose and date.
219641558|NCT06530251|DRUG|Sintilimab Injection|Following the local label direction.
218958533|NCT02360605|BEHAVIORAL|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
218958534|NCT02360605|BEHAVIORAL|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
218958535|NCT01364675|DRUG|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
218958536|NCT01364675|DRUG|Placebo tablet|Identical Placebo Tablet
218958537|NCT05039827|OTHER|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
218958538|NCT05039827|OTHER|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
218958539|NCT00121407|DRUG|Visudyne for injection|
218958540|NCT02146144|PROCEDURE|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made"
218958541|NCT03291301|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
218958542|NCT03291301|OTHER|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
218958543|NCT02222025|OTHER|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
218958544|NCT03630276|DIAGNOSTIC_TEST|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
218958545|NCT03209453|OTHER|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
218958546|NCT01230775|DRUG|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
219060157|NCT00966940|DRUG|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
219060158|NCT00966940|DRUG|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
219060159|NCT05168774|DRUG|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
219060160|NCT06191926|DIAGNOSTIC_TEST|ultrasound|Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer
219060161|NCT03719872|DIAGNOSTIC_TEST|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
219365258|NCT03104842|DRUG|Dexamethasone|Capsel
219641559|NCT06530251|DRUG|Bevacizumab biosimilar|Following the local label direction.
219641560|NCT01962077|PROCEDURE|MedCem MTA pulpotomies in primary teeth.|
218958547|NCT01230775|DRUG|Placebo|"Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
218958548|NCT04791527|BEHAVIORAL|Mind-body therapy|Online yoga, meditation, behavior change tips, and nutrition tips
219060162|NCT03719872|DIAGNOSTIC_TEST|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
219060163|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
219641561|NCT06499454|DIAGNOSTIC_TEST|Ruby ROSE evaluation|Creation and digitization of ROSE slides produced using Ruby's instrument from bronchoscopic biopsy samples
219641562|NCT04105218|BEHAVIORAL|Exercise|Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
219641563|NCT03570411|DIAGNOSTIC_TEST|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
219641564|NCT06487000|DRUG|EC-18|oral administration, QD
219641565|NCT06487000|DRUG|Placebo EC-18|oral administration, QD
219641566|NCT03770039|DRUG|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
219641567|NCT03770039|DRUG|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
219641568|NCT03770039|DRUG|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
219641569|NCT04102748|PROCEDURE|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
219641570|NCT00297180|DRUG|GW869682|
219641571|NCT02258373|DEVICE|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
219641572|NCT02258373|DEVICE|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
218958549|NCT04171427|OTHER|Lithium liposome|Cosmetic product
218958550|NCT04171427|OTHER|Placebo|Cosmetic product vehicle
219060164|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
219060165|NCT04661995|DEVICE|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
219207675|NCT06887140|DIAGNOSTIC_TEST|Echocardiography|"* First echocardiography: within 24 hours after study enrollment,~* Second echocardiography: 48-72 hours after the initial echocardiography.~* The recorded echocardiographic parameters include:~  * Morphological and Functional Parameters~ * Mitral Valve Flow Parameters~ * Tissue Doppler Echocardiography Parameters~ * STE Parameters for Left Ventricle Assessment~ * STE Parameters for Right Ventricle Assessment"
219641573|NCT02650258|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
219641574|NCT00926848|BEHAVIORAL|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
219641575|NCT00714857|DRUG|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
219641576|NCT01694290|OTHER|Chemical Cold Pack|
219641577|NCT05481385|BEHAVIORAL|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
218958551|NCT06326970|DIAGNOSTIC_TEST|99mTc-FAPI SPECT imaging|99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
218958552|NCT03742648|OTHER|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
218958553|NCT01995045|DRUG|Triamcinolone|Retrobulbar anesthesia
218958554|NCT01995045|DRUG|Bupivicaine Hydrochloride|Retrobulbar anesthesia
218958555|NCT00590837|DRUG|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
219060166|NCT05625906|OTHER|Multi-media experiential training programme|"1. Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~2. A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~3. Writing a reflective journal after the role play with standardised patients"
219060167|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
219060168|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
219060169|NCT06459609|DIETARY_SUPPLEMENT|protein supplementation|Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
219060170|NCT00258986|PROCEDURE|Living donornephrectomy|
219060171|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
219060172|NCT05905185|DRUG|Placebo|50mg of Placebo
219060173|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
219641578|NCT05481385|BEHAVIORAL|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
219641579|NCT05481385|BEHAVIORAL|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
219641580|NCT01167881|DRUG|BI 10773|Medium dose once daily
219641581|NCT01167881|DRUG|Glimepiride|1-4 mg once daily
219641582|NCT01167881|DRUG|Placebo|Placebo matching BI 10773
218958556|NCT06305871|PROCEDURE|Ablation therapy|Ablative treatment of hyperthyroidism
218958557|NCT01179035|OTHER|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
219060174|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
219060175|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
219060176|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
219207676|NCT06793176|DIAGNOSTIC_TEST|Video capture|A 20-second video capture of head-neck movements at high frame rates is conducted for all participants to obtain high-resolution images. The captured videos are analyzed using an algorithm based on Vibraimage technology to infer whether the participants have depression.
219365259|NCT03839108|OTHER|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
219641583|NCT01167881|DRUG|Placebo|Placebo matching Glimepiride
219641584|NCT06618690|OTHER|Exercise program|"A supervised training plan will be carried out for 12 weeks with a frequency of 3 sessions per week with a duration of 60 minutes, an ideal estimate according to the meta-analysis of Montaño-Rojas et al. The first two weeks the group exercises will be performed to familiarize the participants with the exercises and then each participant will perform them at home with a review every two weeks to assess the increase of the load.~The exercises and loads included in this treatment plan have been designed and modified based on previous clinical trials. The training plan will work upper limbs, lower limbs and trunk. All sessions begin with a general warm-up, which will be previously instructed to the participants, in which the heart rate will be increased (see Multimedia Appendix 1). After a two-minute break, the specific block of each session will begin (see Table 1 and Multimedia Appendix 1). All exercises will be performed with dumbbells, elastic bands and a ball."
219641585|NCT01435460|DRUG|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
219060177|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
218958558|NCT01179035|OTHER|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
218958559|NCT05419427|DRUG|Denosumab|Denosumab 60 MG/ML
218958560|NCT05419427|DRUG|Denosumab-Ref|Denosumab 60 MG/ML
218958561|NCT01802970|DRUG|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
218958562|NCT06142227|OTHER|Reading a Pictorial Storybook|The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
218958563|NCT00290407|DRUG|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
219060178|NCT03196648|OTHER|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
218958564|NCT00290407|DIETARY_SUPPLEMENT|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
218958565|NCT00121797|PROCEDURE|urine culture|
218958566|NCT00121797|DRUG|antibiotics according to culture|
218958567|NCT01933789|BEHAVIORAL|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
218958568|NCT00145678|BEHAVIORAL|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
218958569|NCT00145678|BEHAVIORAL|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
218958570|NCT00597844|OTHER|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
218958571|NCT00597844|OTHER|undergo voice evaluation and fMRI prior|in approximately one month and six months
218958572|NCT01888887|OTHER|Cetaphil Daily Facial Cleanser|
218958573|NCT00020332|DRUG|alvocidib|
218958574|NCT00020332|DRUG|docetaxel|
218958575|NCT01499862|DEVICE|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
218958576|NCT05095493|DIETARY_SUPPLEMENT|Zinc Acetate|50 mg tablet
218958577|NCT05095493|DIETARY_SUPPLEMENT|Placebo|Zinc Acetate matched placebo tablet
219060179|NCT03196648|OTHER|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
218958578|NCT04447872|PROCEDURE|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
218958579|NCT02710643|DRUG|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
218958580|NCT04441866|DIAGNOSTIC_TEST|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
218958581|NCT04441866|DIAGNOSTIC_TEST|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
218958582|NCT00050687|DRUG|Gallium maltolate|
219060180|NCT03196648|OTHER|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
219060181|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
219060182|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
219060183|NCT03434717|OTHER|Care as usual|Patients will get care as usual
218958583|NCT03539796|PROCEDURE|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
219641586|NCT01435460|DRUG|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
218958584|NCT03539796|PROCEDURE|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
218958585|NCT03539796|PROCEDURE|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
219641587|NCT04751955|DRUG|Olinvacimab added to Capecitabine|Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
219641588|NCT01706939|RADIATION|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy
219641589|NCT01706939|RADIATION|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy
218958586|NCT02391896|DEVICE|Dual energy and tomosynthesis xray|
218958587|NCT01117792|DEVICE|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
219641590|NCT01706939|DRUG|Carboplatin|Day 1, every 7 days ( + 2 days)
219641591|NCT01139957|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
219641592|NCT01139957|OTHER|Quality-of-Life Assessment|Ancillary studies
219641593|NCT01139957|OTHER|Questionnaire Administration|Ancillary studies
219641594|NCT01139957|PROCEDURE|Study of High Risk Factors|Ancillary studies
219641595|NCT03595514|OTHER|Single injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
219641596|NCT03595514|OTHER|Double injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
219641597|NCT03595514|DRUG|lidocaine, bupivacaine, epinephrine, dexamethasone|lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
219641598|NCT05346081|DEVICE|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
219641599|NCT00853645|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) System|
219641600|NCT04047836|OTHER|Low Nicotine E-Liquid|Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
219641601|NCT04047836|OTHER|Medium or High Nicotine E-Liquid|Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
219641602|NCT01046903|DRUG|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
219641603|NCT02404636|OTHER|Interview|Brief structured interview
219641604|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
219641605|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
218958588|NCT02217540|OTHER|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
218958589|NCT02217540|OTHER|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
218958590|NCT02964403|DRUG|Cox-2|
218958591|NCT02964403|DRUG|Indomethacin|
218958592|NCT01856283|DRUG|Nilotinib 300mg BID|Nilotinib
218958593|NCT06171490|OTHER|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
218958594|NCT06171490|OTHER|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
218958595|NCT06171490|OTHER|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
219060184|NCT02044510|DRUG|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
219060185|NCT02044510|DRUG|Placebo|Matched placebo capsules to the intervention arm
219060186|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
219641606|NCT03300349|OTHER|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
219641607|NCT03300349|OTHER|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
219641608|NCT02131285|OTHER|Sensory training|
219641609|NCT02868190|DEVICE|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
219641610|NCT03621306|DEVICE|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
219641611|NCT01328977|BEHAVIORAL|education|teaching
219641612|NCT02674958|DRUG|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
219641613|NCT05893251|OTHER|Manual therapy|"Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching"
219641614|NCT05893251|OTHER|Postural exercises|The treatment plan includes active postural exercises for the cervical spine.
218958596|NCT06171490|OTHER|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
219060187|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
219060188|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
219060189|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
219641615|NCT01130259|DRUG|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
219641616|NCT06212700|BEHAVIORAL|Preoperative Exercise|Aerobic (HIIT) Endurance Respiratory Muscle Strength Education
219641617|NCT06212700|BEHAVIORAL|Postoperative Exercise|Aerobic Muscle Strength Walking Program Education
219641618|NCT06212700|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
218958597|NCT00470912|DRUG|sunscreen RV 2547C|
218958598|NCT04656483|OTHER|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
218958599|NCT04656483|OTHER|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
218958600|NCT01640093|DRUG|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
218958601|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
218958602|NCT01640093|DRUG|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
218958603|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
219060190|NCT02009618|DRUG|placebo|
219060191|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
219060192|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
219060193|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
219060194|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
219060195|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
219060196|NCT06155981|OTHER|Coke Zero|Coca-Cola Zero Sugar drink will be given.
219641619|NCT06212700|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
219060197|NCT06155981|OTHER|Coke|Coca-Cola drink will be given.
219641620|NCT06212700|BEHAVIORAL|Preoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
219641621|NCT06212700|BEHAVIORAL|Postoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
219641622|NCT06212700|OTHER|Preoperative Nursing|Comorbidities Managing pain Wound care Complications Surgical education ERAS
219641623|NCT06212700|OTHER|Postoperative Nursing|Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education
219641624|NCT06212700|OTHER|Preoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
219641625|NCT06212700|OTHER|Postoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
219641626|NCT06212700|OTHER|Usual Care|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
219641627|NCT03163498|OTHER|No intervantion. It´s a Cross-Sectional Study|No intervential
219641628|NCT01981941|DRUG|Gabapentin enacarbil|Oral
219641629|NCT04839523|DEVICE|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
219641630|NCT04839523|DEVICE|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
219641631|NCT06667778|DEVICE|Osseodesification densah burs|"Drill no. VT1525 (2mm) of densah burs will be used first in counter clockwise (in the osteotomy site).~Then drill no. VT2535 (3mm) of densah burs will be used in counter clockwise to put 3.5mm implant diameter."
219641632|NCT06667778|DEVICE|Microdent|"No. 1 Microdent expander will be placed and screwed slowely (to avoid heat generation) into the osteotomy site till reaching the full desired length.~N0. 2 microdent expander will be placed and screwed into the osteotomy site as the same step.~Then no. 3 Microdent expander will be inserted for placing 3.5mm implant diameter"
219641633|NCT06299878|DIAGNOSTIC_TEST|Gut microbiota analysis|Patients with resectable stage IIIB-D melanoma will have a lymph node core biopsy to confirm metastatic lesions, following standard procedures. Additionally, a portion of the tumor tissue will be preserved for biomarker analysis. Participants will then be instructed to submit fecal samples and complete a dietary questionnaire before receiving three doses of PD1 monotherapy, in accordance with the center\&#39;s routine practice, typically spanning 6-10 weeks. Between weeks 10 and 12, a radiological assessment of the response will be conducted. Following this, participants will undergo regional lymphadenectomy, and the pathological response will be evaluated. After surgery, patients will be placed on adjuvant therapy for 12 months as per routine practice of the center . Subsequently, they will be monitored for five years, adhering to the institution\&#39;s standard follow-up protocol.
219641634|NCT03847753|OTHER|Organic Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641635|NCT03847753|OTHER|Substance Use Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641636|NCT03847753|OTHER|Schizophrenia Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
218958604|NCT05086068|DEVICE|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
218958605|NCT00277641|DRUG|Lamotrigine|25 mg or 100 mg
218958606|NCT00277641|DRUG|placebo|identical tablets to study drug
219207677|NCT06756412|PROCEDURE|Temporomandibular Joint Arthrocentesis|The symptomatic temporomandibular joint (TMJ), either right or left, will be anesthetized using an auriculotemporal nerve block and intracapsular anesthesia. The arthrocentesis procedure will be performed using the double-puncture technique. A 21-gauge needle will be inserted into the posterior region of the joint capsule, targeting the upper joint compartment at a point located 10 mm anterior to the tragus. A second 21-gauge needle will be introduced into the anterior region of the joint capsule, also targeting the upper compartment, at a point located 20 mm anterior to the tragus. The upper joint compartment will then be irrigated with a minimum of 200 mL of saline solution through one of the needles.
218958607|NCT06147973|BEHAVIORAL|Acceptance-based Treatment (ABT)|Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
218958608|NCT06147973|BEHAVIORAL|Health Education (HE) Comparison|Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
218958609|NCT01277081|DRUG|Paracetamol hot drink|Hot drink containing paracetamol
218958610|NCT01277081|DRUG|Paracetamol tablets|Paracetamol tablets
218958611|NCT01772511|BEHAVIORAL|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
218958612|NCT02330328|OTHER|No Telemetry Monitoring|
219060198|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
219060199|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
219060200|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
219207678|NCT06756412|PROCEDURE|Self Exercise Following Arthrocentesis|Following the arthrocentesis procedure described for the other study group, patients will undergo a standardized exercise regimen based on established literature. The regimen includes two sets of movements. The first set involves freely opening the jaw, shifting it right, left, and forward, and repeating these movements while applying finger resistance-closing the mouth against the pressure or forcing the jaw open with the fingers. Each movement will last 10 seconds and be performed 10 times daily. The second set aims to improve the mandibular condyle-articular disc relationship. Patients will open their mouth as wide as possible, advance their lower jaw fully, and close their teeth in an edge-to-edge position. These movements will be performed three times daily for 5 minutes after meals.
219207679|NCT06736184|DRUG|Sodium Zirconium Cyclosilicate (SZC)|5g/meal\*3meals/day
219207680|NCT06735118|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy
219207681|NCT06735430|DRUG|Ciprofol|Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
219207682|NCT06735430|DRUG|Propofol|Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
219207683|NCT07039851|OTHER|Experimental|"Each session in the experimental group includes four phases:~1. Warm-up (10 min): Students engage in ice-breakers and movement activities to relax and prepare mentally and physically.~2. Games \& Activities (30 min): Drama and game-based tasks related to nature and recycling promote experiential learning and teamwork.~3. Improvisation (30 min): Students take part in role-plays and skits (e.g., acting as a tree or a recycled item) to build empathy and deepen their connection to environmental themes.~4. Evaluation (20 min): Students reflect on their learning, share feelings, and receive feedback. Facilitators summarize key points and reinforce the session's goals."
219641637|NCT03847753|OTHER|Mood disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641638|NCT03847753|OTHER|Neurotic disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
218958613|NCT02330328|DEVICE|Telemetry Monitoring|
218958614|NCT01178996|BIOLOGICAL|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
219641639|NCT03847753|OTHER|Eating Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641640|NCT03847753|OTHER|Personality Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641641|NCT03847753|OTHER|Intellectual Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
218958615|NCT01178996|DRUG|Ribavirin|Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
218958616|NCT01178996|BIOLOGICAL|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
218958617|NCT01178996|DRUG|Placebo|Placebo
218958618|NCT04259892|BIOLOGICAL|2019-nCoV PCR|Nasopharyngeal swabs
218958619|NCT03579030|DRUG|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
218958620|NCT03579030|DRUG|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
218958621|NCT01687556|OTHER|topical EGCG application on acne|two times application of topical EGCG on acne lesion
218958622|NCT03253419|OTHER|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
219060201|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
219060202|NCT02453789|DRUG|Placebo|
219060203|NCT02998242|DRUG|Apatinib|
219060204|NCT02998242|RADIATION|SBRT to symptomatic bony metastatic bony site(s)|
219060205|NCT05020483|DRUG|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
219060206|NCT05020483|DRUG|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
219207684|NCT06808061|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum KABP-51
219060207|NCT00581945|DRUG|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
219641642|NCT03847753|OTHER|Developmental Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
218958623|NCT05811533|OTHER|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
218958624|NCT05811533|OTHER|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
219207685|NCT06808061|DIETARY_SUPPLEMENT|Placebo|maltodextrin
219207686|NCT06892431|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome Injection 20mg/m2, or 16mg/m2, intravenous drip, Q4W.
219207687|NCT06892431|DRUG|JMT101 injection|JMT101 Injection 6 mg/kg, intravenous drip,
218958625|NCT00740051|DRUG|Linagliptin|5mg once daily
218958626|NCT00740051|DRUG|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
219060208|NCT00581945|DRUG|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
219641643|NCT03847753|OTHER|Behavioral Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
219641644|NCT05051553|DRUG|Fedratinib|Specified dose on specified days
218958627|NCT00740051|DRUG|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
219060209|NCT06388577|OTHER|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
218958628|NCT04995796|OTHER|Surveys for Research Purposes|"VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
218958629|NCT00164229|BEHAVIORAL|math|
218958630|NCT00164229|BEHAVIORAL|behavior regulation|
219207688|NCT06892431|DRUG|Capecitabine|The dosage of capecitabine is 1000 mg/m2, taken orally twice daily, administered on D1-14 (Days 1-14) of each cycle, with every 3 weeks as one cycle (Q3W);
219207689|NCT06892431|DRUG|Docetaxel injection|The dosage of docetaxel is 75 mg/m2, administered via intravenous drip on D1 of each cycle, Q3W.
219641645|NCT00800774|PROCEDURE|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
219207690|NCT06892431|DRUG|Gemcitabine hydrochloride for injection|The dosage of gemcitabine is 1000 mg/m2, administered via intravenous drip on D1 and D8 (Day 1 and Day 8) of each cycle, Q3W;
219207691|NCT06891404|OTHER|Nurse-Led Health Belief Model-Based Education|"Topic of the Training:~Importance of Genital Hygiene Behaviors Definition of Urinary Tract Infection (UTI) Complications that may arise if left untreated Effects on daily life Proper toilet hygiene Selection and cleaning of underwear Menstrual hygiene Importance of sexual hygiene Common Misconceptions About Genital Hygiene Behaviors"
219207692|NCT06890429|BIOLOGICAL|RSV/Flu-01E|Participants will receive single intranasal injection of RSV/Flu-01E vaccine in 0.5 ml, containing 8.4 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the F antigen of respiratory syncytial virus
219207693|NCT06890429|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer solution in 0.5 ml
219207694|NCT06739863|OTHER|healthcare waste management|"To evaluate and compare the healthcare waste management practices in primary and secondary hospital Mianwali.~Focuses on assessing the current methods of waste disposal, segregation, treatment, and overall management in healthcare settings at two different levels of care: primary and secondary hospitals."
219207695|NCT06893874|OTHER|Preventive migraine treatment|Participants will be observed while receiving treatment-as-usual for their migraine by their treating physician
218958631|NCT00274924|BIOLOGICAL|filgrastim|Given subcutaneously or intravenous bolus.
219641646|NCT05454761|BEHAVIORAL|Group-based Lifestyle Medicine Program|Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
219641647|NCT02674308|DRUG|Vedolizumab|
219641648|NCT02674308|OTHER|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
219641649|NCT03831360|BEHAVIORAL|Yoga|Hatha yoga for depressed adolescents
219641650|NCT03831360|BEHAVIORAL|Group CBT|Group cognitive behavioral therapy for depressed adolescents
219641651|NCT03925233|DRUG|Trastuzumab|Trastuzumab Injection
219641652|NCT03925233|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride Injection
219641653|NCT03925233|DRUG|Epirubicin hydrochloride|Epirubicin hydrochloride injection
218958632|NCT00274924|BIOLOGICAL|rituximab|Given IV
218958633|NCT00274924|DRUG|carboplatin|Given IV
218958634|NCT00274924|DRUG|cyclophosphamide|Given IV
218958635|NCT00274924|DRUG|doxorubicin hydrochloride|Given IV
218958636|NCT00274924|DRUG|etoposide|Given IV
218958637|NCT00274924|DRUG|ifosfamide|Given IV
218958638|NCT00274924|DRUG|prednisone|Taken orally
218958639|NCT00274924|DRUG|vincristine|Given IV
218958640|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 6 g/day|dark chocolate 6 g/day
218958641|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 25 g/day|dark chocolate 25 g/day
218958642|NCT04739865|DRUG|Psilocybin|Open label
218958643|NCT06166030|DIETARY_SUPPLEMENT|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
218958644|NCT00522964|BEHAVIORAL|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
218958645|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
218958646|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
218958647|NCT01966432|BEHAVIORAL|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
218958648|NCT01966432|BEHAVIORAL|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
218958649|NCT05884632|RADIATION|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
219641654|NCT03925233|DRUG|Fluorouracil|Fluorouracil injection
219641655|NCT03925233|DRUG|Paclitaxel|Paclitaxel injection
219641656|NCT03925233|DRUG|Gemcitabine|Gemcitabine injection
219641657|NCT03925233|DRUG|Cisplatin|Cisplatin injection
219641658|NCT03925233|DRUG|Recombinant Human Endostatin|Recombinant Human Endostatin Injection
219641659|NCT03925233|DRUG|Pirarubicin hydrochloride|Pirarubicin hydrochloride injection
219641660|NCT03925233|DRUG|Pyrrolidine|Pyrrolidine tablets
219641661|NCT03925233|DRUG|Ixabepilone|Ixapilone Injection
219641662|NCT03925233|DRUG|Tamoxifen citrate|Tamoxifen citrate tablets
219641663|NCT03925233|DRUG|Vinorelbine tartrate|Vinorelbine tartrate injection
219641664|NCT03925233|DRUG|Carboplatin|Carboplatin injection
219641665|NCT03925233|DRUG|Methotrexate|Methotrexate injection
219641666|NCT03925233|DRUG|Eribulin mesylate|Eribulin mesylate injection
219641667|NCT03925233|DRUG|Toremifene citrate|Toremifene citrate tablets
219641668|NCT03925233|DRUG|Anastrozole|Anastrozole tablets
219641669|NCT03925233|DRUG|Letrozole|Letrozole tablets
219641670|NCT03925233|DRUG|Exemestane|Exemestane tablets
218958650|NCT01295931|DRUG|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
218958651|NCT01295931|PROCEDURE|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
218958652|NCT00181623|DRUG|Recombinant Human Prolactin|
218958653|NCT05319093|DRUG|Ozanimod|Three-months, longitudinal observational period
218958654|NCT02676128|BEHAVIORAL|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
219641671|NCT03925233|DRUG|Fulvestrant|Fulvestrant injection
219641672|NCT03925233|DRUG|Olaparib|Olapani pill
219641673|NCT03925233|DRUG|Bevacizumab|Bevacizumab injection
219641674|NCT03925233|DRUG|Apatinib mesylate|Apatinib mesylate tablets
219641675|NCT03925233|DRUG|Pattozumab|Pattozumab injection
218958655|NCT02676128|BEHAVIORAL|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
218958656|NCT01116479|OTHER|Blood transfusion|Blood transfusion with packed erythrocytes
218958657|NCT04323605|OTHER|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
218958658|NCT00400114|DRUG|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
218958659|NCT00400114|DRUG|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
218958660|NCT00400114|PROCEDURE|Radiation|Radiation 50 Gy (weeks 4-9)
218958661|NCT00400114|PROCEDURE|Surgery|Esophagectomy
219060210|NCT06182865|DRUG|Ga-68 Dolacga Injection|Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
218958662|NCT00400114|DRUG|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
219060211|NCT05772793|DEVICE|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
219060212|NCT01169870|DRUG|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
219207696|NCT06888648|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
218958663|NCT02531100|DEVICE|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
219641676|NCT03925233|DRUG|Capecitabine|Capecitabine tablets
219641677|NCT03925233|DRUG|Ear particles|Ear particles
219641678|NCT03925233|DRUG|Aidi Injection|Aidi Injection
219641679|NCT03925233|DRUG|Cyclophosphamide|Cyclophosphamide injection
219641680|NCT04678232|BEHAVIORAL|Positive Processes and Transition to Health (PATH)|See arm/group description for details regarding this intervention
219641681|NCT00004494|DRUG|vasoactive intestinal peptide|
219641682|NCT05529875|DRUG|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
219641683|NCT05529875|DRUG|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
218958664|NCT02531100|OTHER|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
218958665|NCT01673282|DRUG|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
218958666|NCT03158792|DRUG|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
218958667|NCT03158792|DRUG|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
218958668|NCT02393586|DRUG|Faropenem|Single oral dose
218958669|NCT02393586|DRUG|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
218958670|NCT02393586|DRUG|Rifampicin|Single oral dose
218958671|NCT03446261|DRUG|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
218958672|NCT03446261|DRUG|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
218958673|NCT02735889|OTHER|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
218958674|NCT02735889|OTHER|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
218958675|NCT02735889|OTHER|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
218958676|NCT03935399|DRUG|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
218958677|NCT03935399|DRUG|Saline|1.5 ml preservative free saline for intramuscular injection
219060213|NCT01169870|DRUG|Paclitaxel|
219060214|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
219060215|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
219060216|NCT03749551|DIAGNOSTIC_TEST|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
219060217|NCT03152747|DEVICE|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
219060218|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
219060219|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
219060220|NCT04576169|PROCEDURE|Arthroscopic Debridement|Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
218958678|NCT01358279|PROCEDURE|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
218958679|NCT01813045|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
218958680|NCT01813045|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
219060221|NCT04576169|PROCEDURE|Placebo surgery|Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
219060222|NCT04576169|PROCEDURE|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
219060223|NCT04576169|PROCEDURE|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
219060224|NCT02387021|PROCEDURE|Continuous femoral nerve block|
219060225|NCT02387021|PROCEDURE|Continuous adductor canal block|
219060226|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
219641684|NCT06659094|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"Using a WeChat mini-program, we offer personalized OCD SC-ICBT remote services. Training is customized based on individual assessments, focusing on psychological education and homework to simulate CBT therapy. If a patient's YBOCS score drop from baseline isn't 25% after four therapist sessions (one week of theory, two sessions/week), they get three more weeks of online guidance.~The program includes four structured lessons over six weeks:~Lesson 1: Psychological Health Education on OCD and related disorders. Lesson 2: ERP theory, exposure item lists, and related info. Lesson 3: Daily ERP practice for about an hour, followed by two weeks of therapist guidance.~Lesson 4: Retrospection and relapse prevention."
219641685|NCT06659094|OTHER|Cognitive Behavioral Group Therapy (CBGT)|The CBGT group will receive cognitive-behavioral group therapy for 6 weeks, twice a week, each session lasting 2 hours, at the Shanghai Mental Health Center. The CBGT program follows a structured process for treating OCD. During the prep phase, therapists assess patients for 50 minutes, collect data, and set CBGT groundwork. In Session 1, families join to understand CBGT, with goals reinforced and OCD education provided. Session 2 reviews homework and develops ERP strategies. Session 3 initiates ERP practice. Sessions 4-11 continue homework review and group ERP practice. The final session involves families in a review, discussing challenges, celebrating achievements, and focusing on relapse prevention.
219641686|NCT06659094|DRUG|conventional medical treatment (TAU)|Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
219641687|NCT02275260|DEVICE|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
219641688|NCT02275260|DEVICE|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
219641689|NCT02275260|OTHER|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
219641690|NCT06684340|PROCEDURE|Exposure to major abdominal surgery|This study is a retrospective cohort study. The 'exposure' situation is based on historical records and observation, and no active intervention has been conducted on the study subjects to change their exposure status.
218958681|NCT01813045|RADIATION|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
219641691|NCT06622798|OTHER|Non-interventional|Non-interventional
218958682|NCT05778643|BEHAVIORAL|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
218958683|NCT01373307|BEHAVIORAL|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
219060227|NCT02387021|DRUG|Ropivacaine 0.2%|
219060228|NCT02387021|DRUG|Saline|
219060229|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
219060230|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
219060231|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
218958684|NCT04824716|PROCEDURE|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
218958685|NCT04824716|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
218958686|NCT01112683|DRUG|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
218958687|NCT01112683|DRUG|Placebo|These are identically-looking pills to those in the Memantine Arm.
218958688|NCT01931709|RADIATION|fludeoxyglucose F 18|Undergo FDG PET
218958689|NCT01931709|DEVICE|positron emission tomography|Undergo FDG PET
219060232|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
218958690|NCT01931709|DEVICE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219060233|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
219207697|NCT06888648|DRUG|mFOLFIRINOX Treatment Regimen|continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks
218958691|NCT01931709|OTHER|laboratory biomarker analysis|Correlative studies
218958692|NCT01007682|OTHER|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
218958693|NCT03232125|DRUG|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
219641692|NCT03388645|BIOLOGICAL|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
219641693|NCT03388645|BIOLOGICAL|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
219641694|NCT05504798|OTHER|Selected physical therapy program|Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
219641695|NCT05504798|PROCEDURE|Interrupted serial casting|Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
219641696|NCT05504798|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
219641697|NCT06683287|DEVICE|red light and distant image screen|red light plus distant image screen, children use these two devices at the same time
219641698|NCT06683287|DEVICE|red light|children use red light for 3 minutes each time, twice a day
219641699|NCT06683287|DEVICE|distant image screen|Children in this group were asked to use this device for ≥1 hour/day
219641700|NCT04366297|DEVICE|Intravenous access|obtaining intravascular access using a standard intravenous cannula
218958694|NCT03232125|DRUG|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
218958695|NCT03003299|DEVICE|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
218958696|NCT03363425|DRUG|Lidocaine Iv|Lidocaine Iv
218958697|NCT03363425|DRUG|Dexmedetomidine|dexmedetomidine iv
218958698|NCT03363425|DRUG|Normal saline|placebo
218958699|NCT04304547|DRUG|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet"
218958700|NCT04304547|DRUG|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once"
218958701|NCT04304547|DRUG|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet"
218958702|NCT06506305|DRUG|FB1001|Intravitreal (IVT) injection
218958703|NCT01323920|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 IV
218958704|NCT01323920|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
218958705|NCT01323920|DRUG|Methotrexate|Methotrexate 15 mg/m\^2 IV
218958706|NCT02915874|BEHAVIORAL|Acceptance and Commitment Therapy|
218958707|NCT00001965|DRUG|Cyclosporine A|
219060234|NCT05430516|OTHER|No intervention|No intervention
219060235|NCT01075321|DRUG|everolimus|Given orally
219641701|NCT04366297|DEVICE|Intraosseous access|obtaining intravascular access using a ready intravenous NIO needle set
219641702|NCT00001353|DRUG|Genetically Marked Syngeneic T Lymphocytes|
219641703|NCT06015295|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin)|Given by Injection
219641704|NCT06015295|DIAGNOSTIC_TEST|Pet Scan|Scans
218958708|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958709|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958710|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
218958711|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958712|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
218958713|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958714|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
218958715|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958716|NCT00677053|DRUG|Placebo|Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
218958717|NCT04730414|DRUG|Full-spectrum hemp (0.018% THC)|Topical Application
218958718|NCT04422795|DEVICE|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
218958719|NCT04422795|DEVICE|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
219641705|NCT02396277|PROCEDURE|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
219641706|NCT06968000|DEVICE|EOX Anion-Enriched Hospital Room|Participants are assigned to hospital rooms equipped with an operational EOX device, which actively regenerates air and releases bioavailable anions through cold atmospheric plasma. Exposure lasts for 96 hours postoperatively. The intervention aims to enhance postoperative recovery by modulating oxidative stress, improving mitochondrial function, and promoting sleep quality.
219641707|NCT06567405|PROCEDURE|mechanical periodontal treatment|Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.
219641708|NCT06567405|DEVICE|Derma pen with topical ascorbic Acid|local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
219641709|NCT05988983|OTHER|Availability of OTC contraceptive pill|Over the counter contraceptive pill
219641710|NCT04167033|DRUG|Hormone replacement therapy:effect on ventricular repolarization|Hormone replacement therapy and QTc measurement
219641711|NCT04167033|DIAGNOSTIC_TEST|ECG|QTc measurement
219641712|NCT04215211|DIAGNOSTIC_TEST|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
218958720|NCT04422795|DRUG|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
218958721|NCT05224011|DEVICE|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
218958722|NCT04999254|OTHER|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
219060236|NCT01075321|DRUG|lenalidomide|Given orally
219060237|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
219641713|NCT03000998|BEHAVIORAL|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
219641714|NCT03000998|BEHAVIORAL|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
219641715|NCT00482677|DRUG|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
219060238|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
219060239|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
219060240|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
219060241|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
219060242|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
219060243|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
218958723|NCT04999254|OTHER|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
218958724|NCT00216866|DRUG|Dalteparin|
218958725|NCT00216866|DRUG|Warfarin|
218958726|NCT03865576|DIAGNOSTIC_TEST|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
218958727|NCT00268580|BEHAVIORAL|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
218958728|NCT00141570|DRUG|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
218958729|NCT04019587|DIAGNOSTIC_TEST|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
218958730|NCT00150644|DRUG|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
218958731|NCT00150644|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
218958732|NCT00150644|DRUG|Placebo|Placebo Tablet, oral Daily for 12 weeks
218958733|NCT01213667|DRUG|Ranibizumab|upload (three monthly injections), re-treatment as needed
218958734|NCT00600145|DRUG|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
219641716|NCT00482677|GENETIC|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
218958735|NCT00600145|OTHER|Placebo|Placebo
218958736|NCT04903821|DRUG|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
219641717|NCT00482677|PROCEDURE|quality-of-life assessment|prior to randomization until end of study
218958737|NCT01718912|DRUG|metronidazole-nystatin oral rinse|
218958738|NCT05255185|PROCEDURE|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
218958739|NCT04231981|DRUG|Retifanlimab|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
218958740|NCT01701518|DRUG|Ozurdex|biodegradable 0.7mg dexamethasone implant
219641718|NCT00482677|RADIATION|Radiation|Short course radiotherapy
219641719|NCT03554395|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
219641720|NCT03554395|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
219641721|NCT02992977|BIOLOGICAL|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
219641722|NCT04192071|OTHER|virtual technology - high interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
219641723|NCT04192071|OTHER|virtual technology - low interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.
219641724|NCT04192071|OTHER|non-colorectal cancer related module|Participants engage with web-based content not related to colorectal cancer or nutrition.
219641725|NCT06291038|DIETARY_SUPPLEMENT|• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks|treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
219641726|NCT06291038|DIETARY_SUPPLEMENT|• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.|treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
219641727|NCT06612762|DIETARY_SUPPLEMENT|The daily ingestion of capsules containing naringenin|Following surgical intervention, patients will be administered two capsules (equivalent to 500 mg) daily for a period of 14 days. Subsequently, patients will ingest the maintenance dose of 250 mg per day until the 90th day post-surgery.
218958741|NCT06200025|OTHER|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
218958742|NCT06200025|OTHER|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
218958743|NCT03177629|DRUG|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
218958744|NCT00476801|DEVICE|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
218958745|NCT05979545|DIAGNOSTIC_TEST|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
219060244|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
219060245|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
219641728|NCT06612762|DIETARY_SUPPLEMENT|Placebo|The daily ingestion of capsules containing placebo
219641729|NCT04097262|OTHER|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
218958746|NCT06396182|OTHER|group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).|"group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
218958747|NCT03872414|BEHAVIORAL|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
218958748|NCT03872414|BEHAVIORAL|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
218958749|NCT05117957|DRUG|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
218958750|NCT02685475|DRUG|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
218958751|NCT01705782|BIOLOGICAL|E. coli endotoxin, US standard|
218958752|NCT03033147|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
218958753|NCT03033147|DRUG|Oral placebo|placebo 30 minutes before root canal treatment
219060246|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
219060247|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
219060248|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
219060249|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
219060250|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
219060251|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
219060252|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
219060253|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
219060254|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
219060255|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
219060256|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
219060257|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
219207698|NCT06888648|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
219207699|NCT06742268|OTHER|Single vision spectacles|Other interventions for myopia treatment, except for glasses, will not be provided.
219207700|NCT06741839|PROCEDURE|Confocal laser endomicroscopy guided pleural biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined based on the results of chest CT/ ultrasound. The benign and malignant states of pleural lesions were explored by nCLE and image records were collected. Then, the biopsy tissues were collected under the guidance of nCLE.
219207701|NCT06741839|PROCEDURE|Plerual biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined according to the results of chest CT/ ultrasound, and random pathological biopsy was performed, and biopsy tissues were collected by biopsy forceps.
219641730|NCT04097262|OTHER|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
219060258|NCT01914432|DRUG|YH16410|
219060259|NCT01914432|DRUG|Rosuvastatin|
219060260|NCT01914432|DRUG|Telmisartan|
219060261|NCT01914432|DRUG|YH16410 placebo|
219060262|NCT01914432|DRUG|Rosuvastatin placebo|
219060263|NCT01914432|DRUG|Telmisartan placebo|
219060264|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
219060265|NCT05027191|DRUG|Desflurane|Desflurane
219060266|NCT05027191|DRUG|Sevoflurane|Sevoflurane
219641731|NCT05313568|OTHER|static stretching|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
219641732|NCT05313568|OTHER|self massage|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
219641733|NCT05313568|OTHER|Manual Stimulation|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
219641734|NCT00392938|DRUG|antiandrogen therapy|
219641735|NCT00392938|DRUG|docetaxel|
219641736|NCT00392938|DIAGNOSTIC_TEST|C-11 acetate PET scan|
219641737|NCT00392938|DIAGNOSTIC_TEST|F-18 FDG PET scan|
219641738|NCT00392938|DIAGNOSTIC_TEST|Tc-99m bone scan|
219641739|NCT00392938|DIAGNOSTIC_TEST|CT scan of the chest, abdomen and pelvis|
219641740|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws
218958754|NCT04144491|DIETARY_SUPPLEMENT|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
218958755|NCT04144491|DIETARY_SUPPLEMENT|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
219060267|NCT06635460|OTHER|Motivational interviewing|This programme has been developed from the literature and structured according to expert opinion. It will consist of a total of 8 online sessions. The duration of the motivational interviewing sessions will be limited to 30-45 minutes, in line with the literature.
219060268|NCT06635460|OTHER|Social media-based patient monitoring|Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
219641741|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
219641742|NCT06669949|OTHER|no intervention|No interventions are involved in this observational study.
218958756|NCT01230203|PROCEDURE|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
218958757|NCT04357691|BEHAVIORAL|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
219060269|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
219060270|NCT05578404|DRUG|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
218958758|NCT04357691|BEHAVIORAL|AI-led training|Participants will perform an AI-led training for 4 weeks
218958759|NCT03491189|DEVICE|Lag screw fixation|surgical fixation
219060271|NCT05578404|DRUG|Placebo|matching placebo to Vit D
219060272|NCT00030550|DRUG|thalidomide|
219060273|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
219060274|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
219060275|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
219060276|NCT01800877|DRUG|Vasopressors|
219060277|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
219060278|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
219060279|NCT00935103|BEHAVIORAL|Psychoeducation|
219060280|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
219060281|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
219060282|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
219207702|NCT06729983|PROCEDURE|Prophylactic Conjoint Tendon Lengthening|During a standard reverse shoulder arthroplasty procedure, the conjoint tendon will be incised and lengthened prophylactically
218958760|NCT03491189|DEVICE|Helical blade fixation|surgical fixation
218958761|NCT06325930|DRUG|[14C]-HU6|\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
218958762|NCT06520969|OTHER|Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
218958763|NCT00570232|DRUG|Erlotinib|150 mg per day by mouth for 12 months
218958764|NCT06402253|BEHAVIORAL|Music composition / edition|"Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch."
218958765|NCT06402253|BEHAVIORAL|Photography composition / edition|"Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch."
218958766|NCT03460600|OTHER|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
218958767|NCT05838989|DEVICE|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
219060283|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
218958768|NCT05838989|OTHER|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
219060284|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
219060285|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
219060286|NCT06372730|OTHER|Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)|All patients will undergo a V/Q SPECT/CT scan at inclusion.
218958769|NCT05838989|OTHER|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
219060287|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
219060288|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
219060289|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
219207703|NCT06729983|PROCEDURE|Standard Reverse Shoulder Arthroplasty|A standard reverse shoulder arthroplasty procedure will be performed
219207704|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
219207705|NCT05543083|BEHAVIORAL|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
218958770|NCT05959642|DEVICE|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
218958771|NCT05959642|DEVICE|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
218958772|NCT02708303|OTHER|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
218958773|NCT01585584|DRUG|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
218958774|NCT00527488|DRUG|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
218958775|NCT00527488|DRUG|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
218958776|NCT00527488|DRUG|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
218958777|NCT00527488|DRUG|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
218958778|NCT01958827|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
218958779|NCT06273800|PROCEDURE|Blood sample|Collection of serum sample at the day of start of neo adjuvant treatment
218958780|NCT02848443|DRUG|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
218958781|NCT02848443|DRUG|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
218958782|NCT02848443|DRUG|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
219060290|NCT05219201|DEVICE|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
219060291|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
219060292|NCT05307224|DEVICE|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
219060293|NCT01243450|DRUG|Tretinoin|Treatment of acne
218958783|NCT02848443|DRUG|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
219060294|NCT01243450|DRUG|placebo|treatment of acne
219207706|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
218958784|NCT03874260|DRUG|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
218958785|NCT05059899|BEHAVIORAL|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
218958786|NCT03492008|OTHER|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
218958787|NCT03492008|OTHER|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
218958788|NCT03492008|OTHER|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
218958789|NCT00004393|DRUG|risperidone|
219641743|NCT05021874|OTHER|Four different physiotherapy treatment|Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.
219060295|NCT06101693|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
218958790|NCT05202470|OTHER|TE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
218958791|NCT05202470|OTHER|CE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
218958792|NCT02372214|PROCEDURE|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
218958793|NCT00280670|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
218958794|NCT03036800|DRUG|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
219060296|NCT04880551|RADIATION|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
219060297|NCT02176889|DIETARY_SUPPLEMENT|Lactospore|Bacillus coagulans MTCC 5856
219060298|NCT02176889|OTHER|Placebo|
219060299|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
219641744|NCT01399463|DEVICE|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
219641745|NCT01399463|DEVICE|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
219641746|NCT06147596|OTHER|Head impact exposure|The cohort is exposed to naturalistic head impacts (heading) during voluntary participation in a soccer match. All participants are regular soccer players and are therefore not exposed to excessive head impacts compared to their regular exposure.
219641747|NCT04737252|BEHAVIORAL|Sage (formerly known as COMPASS)|Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
219641748|NCT05658263|DIETARY_SUPPLEMENT|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
219641749|NCT05658263|DIETARY_SUPPLEMENT|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
219641750|NCT05886140|DRUG|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
218958795|NCT03036800|OTHER|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
219641751|NCT06139198|BEHAVIORAL|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
219641752|NCT06727565|DRUG|Domvanalimab|Administered intravenously
219641753|NCT06727565|DRUG|Zimberelimab|Administered intravenously
219641754|NCT06727565|DRUG|Paclitaxel|Administered intravenously
219641755|NCT06727565|DRUG|Carboplatin|Administered intravenously
219641756|NCT06735911|OTHER|Spa therapy|Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
218958796|NCT00035867|DRUG|TLK199 HCl Liposomes for Injection|
218958797|NCT02511964|BEHAVIORAL|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
218958798|NCT02511964|BEHAVIORAL|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
218958799|NCT05996991|OTHER|Positive expectation speech regarding spinal manipulative therapy|Patients will watch a short video with positive expectations regarding spinal manipulative therapy.
218958800|NCT05996991|OTHER|Neutral expectation speech regarding spinal manipulative therapy|Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.
218958801|NCT05996991|OTHER|Negative expectation speech regarding spinal manipulative therapy|Patients will watch a short video with negative expectations regarding spinal manipulative therapy.
218958802|NCT05996991|PROCEDURE|Spinal Manipulative Therapy|One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
218958803|NCT05985980|DIAGNOSTIC_TEST|Exercise Treadmill Test (ETT)|The study population consists of premenopausal women who applied to the outpatient clinic with chest pain. ETT is ordered as a routine diagnostic workup. Two ETTs are performed on each participant. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
218958804|NCT06292299|DEVICE|Pneumowave|Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring data
218958805|NCT05758441|BEHAVIORAL|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
218958806|NCT05758441|BEHAVIORAL|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
218958807|NCT06297785|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
218958808|NCT05117671|OTHER|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
218958809|NCT03460015|DRUG|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
218958810|NCT03460015|DRUG|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
218958811|NCT03447977|OTHER|cervical|cervical spine manual therapy
218958812|NCT03447977|OTHER|thoracic|thoracic spine manual therapy
218958813|NCT03447977|OTHER|exercises|exercises for pain
219060300|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
219060301|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
219641757|NCT02894944|BIOLOGICAL|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
218958814|NCT04382677|BEHAVIORAL|Promoting First Relationships ®|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
218958815|NCT04382677|OTHER|Resource & Referral|This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
219641758|NCT05872269|DRUG|Saroglitazar|4 Mg Oral Tablet
219060302|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
219060303|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
219060304|NCT00592995|DRUG|Creatine monohydrate|10 to 30 grams daily
219060305|NCT00592995|DRUG|Placebo|10 to 30 grams daily
219060306|NCT02013765|DRUG|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
219060307|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
219060308|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
219060309|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
219060310|NCT06475157|OTHER|No intervention|No intervention is applied.
219060311|NCT04023695|DRUG|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
219060312|NCT04023695|DRUG|Corticosteroid with normal saline|Trigger finger injection
219060313|NCT00583726|BEHAVIORAL|motivational interviewing|telephone counseling
219060314|NCT00583726|BEHAVIORAL|written materials only|dietary guidance materials and pedometers
219060315|NCT02011438|BEHAVIORAL|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
218958816|NCT05419999|DEVICE|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
218958817|NCT05419999|OTHER|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
218958818|NCT05419999|BEHAVIORAL|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
218958819|NCT05005793|DRUG|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
218958820|NCT05005793|DRUG|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
219060316|NCT02216331|DRUG|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
219060317|NCT02216331|DRUG|rifapentine|
219060318|NCT02216331|DRUG|rifampicin|
219641759|NCT04152837|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
219641760|NCT01416493|DRUG|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
219641761|NCT02214329|DEVICE|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
219641762|NCT02214329|OTHER|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
219060319|NCT00002026|DRUG|Acyclovir|
219060320|NCT05043337|BEHAVIORAL|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
219060321|NCT05043337|BEHAVIORAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
219207707|NCT05543083|BEHAVIORAL|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
219207708|NCT03876951|DIAGNOSTIC_TEST|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
218958821|NCT05744258|DEVICE|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
218958822|NCT06967064|DRUG|lidocaine cream|Group U receives 1 mL of lidocaine cream extracted using a syringe and evenly applied across the entire posterior surface of the LMA cuff by carefully spreading the cream to ensure uniform coverage, while Group N receives 1 mL of lidocaine cream also extracted using a syringe but applied without ensuring even distribution, resulting in a patchy or non-uniform application.
219060322|NCT05043337|BEHAVIORAL|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
219060323|NCT02491320|OTHER|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
219060324|NCT02491320|DRUG|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
219060325|NCT03039673|DRUG|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
219060326|NCT03039673|DRUG|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
219060327|NCT03039673|DRUG|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
219060328|NCT01134900|OTHER|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
219060329|NCT03408158|PROCEDURE|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
219060330|NCT03197220|OTHER|fish|300 gr/week fish
219060331|NCT03197220|OTHER|walnut|18 walnut per week
219060332|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
219060333|NCT00575588|DRUG|Metformin|open-label metformin
219060334|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
219060335|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
219060336|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
219060337|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
219060338|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
219060339|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
219060340|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
219060341|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
219060342|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
218958823|NCT06967064|OTHER|Placebo|No lidocaine cream will be applied to the LMA
218958824|NCT05387915|RADIATION|Radiation Therapy|Undergo reduced dose radiation therapy
218958825|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
218958826|NCT01702636|DRUG|Tranexamic Acid|
218958827|NCT01702636|DRUG|Placebo|
218958828|NCT01848041|DRUG|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
218958829|NCT01848041|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
219060343|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
219060344|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
219060345|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
219060346|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
219060347|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
219060348|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
219060349|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
219060350|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
219207709|NCT05650320|DRUG|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
219207710|NCT05650320|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
219641763|NCT00684320|BEHAVIORAL|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
218958830|NCT00540618|DRUG|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
218958831|NCT00540618|OTHER|Placebo|
218958832|NCT00540618|DRUG|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
218958833|NCT00540618|DRUG|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
218958834|NCT06436664|OTHER|Tooth brushing|Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
218958835|NCT01464905|BIOLOGICAL|NU100|0.25 mg SQ, every other day for 12 months
218958836|NCT01464905|BIOLOGICAL|Placebo|1 mL SQ, every other day for 4 months
218958837|NCT01464905|BIOLOGICAL|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
218958838|NCT00871507|DRUG|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
219060351|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
218958839|NCT00871507|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
219060352|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
219060353|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
219060354|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
219060355|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
219060356|NCT05604729|DRUG|Placebo|Saline solution
219060357|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
219060358|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
219207711|NCT05650320|OTHER|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
219207712|NCT04079517|DRUG|Tamoxifen|A registered SERM drug, Tamoxifen.
219207713|NCT04952129|DRUG|Selenomethionine|Seleno-amino acid
219207714|NCT04952129|DRUG|Methylselenocysteine|Seleno-amino acid
219641764|NCT00684320|BEHAVIORAL|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
219641765|NCT02607774|DRUG|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
219641766|NCT02607774|DRUG|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
218958840|NCT00871507|DRUG|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
218958841|NCT00871507|DRUG|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
218958842|NCT00893620|DEVICE|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
218958843|NCT04879979|BEHAVIORAL|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
218958844|NCT02417493|BEHAVIORAL|Simulation of epinephrine self-injection|
219060359|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
219060360|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
219060361|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
218958845|NCT06969521|BEHAVIORAL|Visual acoustic biofeedback: ORDER|In visual-acoustic biofeedback treatment, elements of traditional articulation treatment are used, including auditory models, verbal descriptions of correct articulator placement, cues for repetitive motor practice via images and diagrams of the vocal tract as visual aids. These strategies are supplemented with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum (Sona-Match module of PENTAX Sona- Speech software). Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak on the visual display.
218958846|NCT06969521|BEHAVIORAL|Perception Training: ORDER|Description: Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program (Gorilla). Stimuli are organized into three separate tasks. In tasks 1 and 3, which train category goodness judgment, participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels. In task 2, participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline, but they will recei
218958847|NCT01689116|DRUG|Bardoxolone Methyl 20mg|Oral
218958848|NCT01689116|DRUG|Bardoxolone Methyl 80mg|Oral
218958849|NCT01689116|DRUG|Bardoxolone Methyl Placebo|Oral
218958850|NCT01689116|DRUG|Moxifloxacin 400mg|Oral
218958851|NCT01689116|DRUG|Moxifloxacin Placebo|Oral
218958852|NCT05671133|DIAGNOSTIC_TEST|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
218958853|NCT03090321|BEHAVIORAL|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
218958854|NCT03090321|BEHAVIORAL|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
218958855|NCT03090321|BEHAVIORAL|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
218958856|NCT03090321|BEHAVIORAL|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
218958857|NCT04782531|OTHER|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
218958858|NCT04782531|OTHER|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
218958859|NCT06256159|OTHER|12 MSWS questionnaire|The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
218958860|NCT06486077|DIETARY_SUPPLEMENT|Power Line Program|Power Line program consisting of 4 nutritional supplements: a meal replacement shake, a vegetable based green drink, a vascular health product, and a pre-meal fiber supplement
218958861|NCT05737225|DEVICE|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
218958862|NCT05821517|DEVICE|Helmet virtual reality.|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
218958863|NCT05821517|DRUG|Administration of METHOXYFLURANE|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
218958864|NCT05821517|DRUG|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
218958865|NCT00505492|DRUG|Carboplatin|AUC 5 by vein once every 28 Days
218958866|NCT00505492|DRUG|Cisplatin|40 mg/m\^2 by vein (IV) Weekly Over 4 Hours
218958867|NCT00505492|DRUG|Paclitaxel|135 mg/m\^2 by vein (IV) Once Every 28 Days
218958868|NCT01006603|DRUG|Saxagliptin|5 mg, oral tablet, once daily
218958869|NCT01006603|DRUG|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
218958870|NCT06995365|OTHER|Risk Prediction Model|This study analyzes retrospective electronic health record (EHR) data from older adults to refine and validate a predictive model for other conditions in future studies.
218958871|NCT06994429|DIAGNOSTIC_TEST|MRI Techniques for Graft Function Assessment|"\### Intervention Description~The intervention in this study is the use of advanced MRI techniques for assessing liver transplant graft function. It includes:~* \*\*Diffusion Weighted Imaging (DWI):\*\* To evaluate tissue integrity and detect early graft dysfunction.~* \*\*Dynamic Contrast-Enhanced MRI (DCE-MRI):\*\* To assess vascular complications and blood flow in the graft.~* \*\*Blood Oxygenation Level-Dependent (BOLD) MRI:\*\* To monitor oxygenation levels, indicative of graft health.~These MRI methods provide a non-invasive, comprehensive assessment of liver graft function, distinguishing this intervention from traditional invasive methods like biopsy."
218958872|NCT06994546|DEVICE|ArtiBest ® Intra articular Injection|single intra articular injection of 3 ml (one syringe) per knee joint. Each syringe contains 20 mg/mL sodium hyaluronate.
218958873|NCT06993818|OTHER|Gingival Crevicular Fluid|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
219060362|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
219060363|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
218958874|NCT06993818|DIAGNOSTIC_TEST|Serum Asprosin|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
218958875|NCT06471140|OTHER|magnetic resonance imaging (MRI)|MRI performed three times during pregnancy and 6 months postpartum
218958876|NCT06518512|DEVICE|Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system|"AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit"
218958877|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
218958878|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
218958879|NCT06876506|DIAGNOSTIC_TEST|Venepuncture|Whole blood flow cytometry analysis of T-/B-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4
218958880|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
219060364|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
219060365|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
219060366|NCT01771003|DEVICE|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
219060367|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
219060368|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
219060369|NCT01854827|DRUG|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
219060370|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
219060371|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
219060372|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
219060373|NCT02688634|DRUG|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
219060374|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
219060375|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
219060376|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
219641767|NCT03813082|BEHAVIORAL|Prolonged wakefulness|40 hours of prolonged wakefulness
218958881|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
218958882|NCT06897163|DEVICE|Specialized Absorbent Intestinal Tampon|The specialized absorbent intestinal tampon is designed to be self-inserted by participants with ileostomies. It aims to collect ileostomy output and improve the quality of life by reducing complications associated with traditional stoma bags. The study will test different tampon designs and coatings to find the most suitable one for insertion and retention. Participants will be observed and interviewed during the insertion process, and their feedback on discomfort or pain will be collected using a numerical rating scale (NRS). Stool samples will be collected before and after tampon use for microbiota analysis.
219060377|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
219060378|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
219060379|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
219060380|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
219060381|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
219060382|NCT05709730|DIAGNOSTIC_TEST|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
219641768|NCT00226460|DRUG|Fetal porcine cells, Neurocell-PD|
219641769|NCT03260829|DRUG|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
219641770|NCT00101166|BIOLOGICAL|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
219641771|NCT03674320|DRUG|Testosterone Enanthate|Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
219641772|NCT03674320|DRUG|Placebo|Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
218958883|NCT06899074|DIETARY_SUPPLEMENT|Omega 3 Polyunsaturated Fats|Omega-3 PUFA dietary supplement daily for 12 weeks. The intervention is 1 teaspoon of liquid omega-3 containing oil profile 40% EPA / 60% DHA.
218958884|NCT06899074|OTHER|Matching Placebo|The placebo is a matched 1 teaspoon liquid of coconut oil, consisting mainly of saturated fatty acids and lacking omega-3 fatty acids.
218958885|NCT01067547|DRUG|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
218958886|NCT01067547|DRUG|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
218958887|NCT04514302|DRUG|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
218958888|NCT04514302|DRUG|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
218958889|NCT01275339|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
218958890|NCT01275339|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
218958891|NCT02478398|BIOLOGICAL|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
218958892|NCT02478398|BIOLOGICAL|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
218958893|NCT02478398|DRUG|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
218958894|NCT02478398|DRUG|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
218958895|NCT02478398|DRUG|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
218958896|NCT02478398|DRUG|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
218958897|NCT02478398|DRUG|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
218958898|NCT00321061|DRUG|VRC-HIVDNA016-00, VRC-HIVADV014-00|
218958899|NCT01348971|DIETARY_SUPPLEMENT|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
219060383|NCT02571452|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
219060384|NCT02571452|BEHAVIORAL|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
218958900|NCT01348971|OTHER|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
218958901|NCT03254368|DRUG|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
218958902|NCT03254368|DRUG|Placebo|Placebo has the same excipients and appearance as ZGN-1061
218958903|NCT06214494|OTHER|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
218958904|NCT06214494|OTHER|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
218958905|NCT01816841|PROCEDURE|fluorescence imaging|Undergo DVFE
218958906|NCT01816841|PROCEDURE|biopsy|Undergo scalpel biopsy
218958907|NCT01816841|PROCEDURE|examination|Undergo COE
219060385|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
219060386|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
219641773|NCT04671498|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219641774|NCT04671498|PROCEDURE|Droplet-BC Test|Undergo Droplet-BC Test
218958908|NCT01816841|PROCEDURE|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
218958909|NCT01196039|DRUG|MEMP1972A|Intravenous repeating dose
218958910|NCT01196039|DRUG|placebo|Intravenous repeating dose
218958911|NCT01689909|DRUG|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
218958912|NCT01689909|DRUG|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
218958913|NCT03722043|BEHAVIORAL|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
219207715|NCT05993650|OTHER|Inspiratuar Muscle Training Group|Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks
218958914|NCT02568982|OTHER|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
218958915|NCT02179775|DRUG|propranolol|
218958916|NCT02179775|DRUG|Quince's oxymel|
218958917|NCT02179775|DRUG|placebo|
218958918|NCT04969003|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
218958919|NCT00209508|DRUG|GPI 1485|
218958920|NCT04585152|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
218958921|NCT02405936|PROCEDURE|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
218958922|NCT03110939|OTHER|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
218958923|NCT05911425|DRUG|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
219060387|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
219060388|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
219060389|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
219060390|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
219060391|NCT01714219|PROCEDURE|Posterior reconstruction|
219060392|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
219060393|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
219641775|NCT04671498|OTHER|Electronic Health Record Review|Medical records are reviewed
219641776|NCT00686829|DRUG|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
218958924|NCT05245396|DRUG|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
219641777|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
218958925|NCT05245396|DRUG|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
218958926|NCT05245396|DRUG|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
218958927|NCT05245396|DRUG|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
218958928|NCT05245396|DRUG|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
218958929|NCT05245396|DRUG|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
218958930|NCT05245396|DRUG|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
218958931|NCT05245396|DRUG|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
219060394|NCT02268773|DRUG|Asasantin®|
219060395|NCT02268773|DRUG|Acetylsalicylic acid low dose|
219060396|NCT02268773|DRUG|Acetylsalicylic acid high dose|
219060397|NCT03807362|DRUG|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
219060398|NCT03888573|OTHER|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
219060399|NCT00749151|BEHAVIORAL|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
219060400|NCT02816671|DEVICE|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
219060401|NCT01828242|BEHAVIORAL|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
218958932|NCT05245396|DRUG|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
218958933|NCT05245396|DRUG|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
218958934|NCT00964080|DRUG|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
219060402|NCT01828242|OTHER|Control group following conventional approach|Control group following conventional approach
219060403|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
219207716|NCT05993650|OTHER|Thoracic Expansion Exercise Group|"Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
219207717|NCT01028963|DRUG|Placebo|Placebo capsules once daily
219207718|NCT01028963|DRUG|pioglitazone|pioglitazone 30 mg tablet once daily
219207719|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
219207720|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group D)
219207721|NCT06821594|DRUG|Furosemide|Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks
219207722|NCT05025826|OTHER|Phycocare|Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
219207723|NCT05025826|OTHER|Placebo|Placebo every day during 9 months (except days of chemotherapy = no Placebo)
219207724|NCT06852105|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
219207725|NCT06852105|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
219207726|NCT05328401|DEVICE|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
219207727|NCT05328401|DEVICE|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
219207728|NCT02446405|DRUG|Enzalutamide|
219207729|NCT02446405|DRUG|NSAA|
219207730|NCT02446405|DRUG|LHRHA or Surgical Castration|
219207731|NCT06837038|DEVICE|rhythmic auditory stimulation|The intervention group was treated with a gait rhythm device under the supervision of the researchers. The complete gait training was conducted once a day for 15 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
219207732|NCT06837038|DEVICE|No rhythm stimulation|The control group received gait training without rhythmic auditory stimulation under the supervision of the researchers. The complete gait training was conducted once a day for 15 to 20 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
219207733|NCT06749418|DRUG|Eplerenone|Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
219641778|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
219641779|NCT04161404|DRUG|Metformin (Glucophage) 1000mg|Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
218958935|NCT03111069|PROCEDURE|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
218958936|NCT03111069|DRUG|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
218958937|NCT03111069|RADIATION|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
219060404|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
219060405|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
219207734|NCT06750796|BEHAVIORAL|The Half Swaddling Application|Half swaddling application in term babies
219207735|NCT06750835|PROCEDURE|SPSIP block|Serratus posterior superior intercostal plane block
219207736|NCT06750835|PROCEDURE|SAP block|Serratus anterior plane block
219207737|NCT06750835|PROCEDURE|Paravertebral block|"* The block will be administered under ultrasound guidance at the T2-T5 levels.~* A total of 15 mL of 0.25% bupivacaine will be injected into the paravertebral space on the side of the surgery."
219207738|NCT06750718|DEVICE|Virtual Reality (VR)|Oculus Quest 2 (OQ2) advanced 256 GB all-in-one virtual reality headset, Wi-Fi will be used.
219207739|NCT06750718|OTHER|Comprehensive Sensorimotor Training|An exercise program consisting of Cervical JPSM, Cervical movement sense, and Oculomotor control exercises.
218958938|NCT01121731|DRUG|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
218958939|NCT01121731|DRUG|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
218958940|NCT01121731|DRUG|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
218958941|NCT02853227|OTHER|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
218958942|NCT04678479|DRUG|Ganaxolone|ganaxolone
218958943|NCT00993876|DRUG|citalopram|20 to 30 mg per day for 4 weeks
218958944|NCT00993876|DRUG|reboxetine|4 to 8 mg per day for 4 weeks
218958945|NCT00993876|BEHAVIORAL|interpersonal psychotherapy|
219060406|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
219060407|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
219060408|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
219060409|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
219060410|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
219060411|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
219060412|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
219060413|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
219641780|NCT03314532|PROCEDURE|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
218958946|NCT04650061|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
218958947|NCT04650061|DEVICE|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
218958948|NCT00293488|DRUG|polyamine analogue PG11047|
218958949|NCT02577432|DRUG|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
218958950|NCT02577432|DRUG|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
218958951|NCT02577432|DRUG|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
218958952|NCT02577432|DRUG|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
218958953|NCT01166243|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
218958954|NCT01166243|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
218958955|NCT04079569|BEHAVIORAL|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
218958956|NCT04079569|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
218958957|NCT04581135|OTHER|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
219060414|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
219060415|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
219060416|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
218958958|NCT00056056|DRUG|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
219207740|NCT06748313|OTHER|Mango Pickle (Water-Based)|The ingredients used in Mango Pickle (Water-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Mashed garlic, Mustard oil, Vinegar, and Water. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
219207741|NCT06748313|OTHER|Mango Pickle (Oil Based)|The ingredients used in Mango Pickle (Oil-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Vinegar, Mashed garlic, and Mustard oil. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
218958959|NCT00056056|DRUG|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
219641781|NCT03955913|OTHER|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
218958960|NCT00056056|PROCEDURE|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
218958961|NCT03668418|DRUG|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958962|NCT03668418|DRUG|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958963|NCT03668418|DRUG|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958964|NCT03668418|DRUG|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958965|NCT03668418|DRUG|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958966|NCT03668418|DRUG|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
219060417|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
219060418|NCT02660944|DRUG|RSLV-132|RNase-Fc fusion protein
219060419|NCT02660944|DRUG|Placebo|Saline placebo
219060420|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
219060421|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
219060422|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
219060423|NCT04143347|OTHER|No Intervention|
219060424|NCT03450551|DEVICE|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
219060425|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
219060426|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
219060427|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
219060428|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
219060429|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
219060430|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
219060431|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
219060432|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
219641782|NCT04679311|BIOLOGICAL|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
219641783|NCT04679311|OTHER|Normal Saline|Subjects will be treated with normal saline 500 cc
219641784|NCT00322270|DRUG|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
218958967|NCT03668418|DRUG|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958968|NCT03668418|DRUG|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958969|NCT03668418|DRUG|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
218958970|NCT00202176|DRUG|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
218958971|NCT05577468|DRUG|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
218958972|NCT00008866|BIOLOGICAL|Tetanus Toxoid Vaccine|
218958973|NCT00008866|DRUG|Hydroxyurea|
218958974|NCT00008866|DRUG|Didanosine|
218958975|NCT03752411|OTHER|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
218958976|NCT03752411|OTHER|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
218958977|NCT00284492|PROCEDURE|Traditional chinese medicine type acupuncture|10 acupuncture sessions
218958978|NCT00284492|BEHAVIORAL|Self Care|Lifestyle advice on diet, physical activity
219060433|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
219060434|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
219060435|NCT02782481|DRUG|ND0612|
219060436|NCT02782481|DRUG|Placebo|
219060437|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
219060438|NCT01603550|OTHER|Energy Restriction|Energy Restriction
219060439|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
218958979|NCT03207919|BEHAVIORAL|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
218958980|NCT05121493|OTHER|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
218958981|NCT05121493|OTHER|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
218958982|NCT02410785|DEVICE|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
218958983|NCT02410785|OTHER|Placebo|Placebo tablet
219060440|NCT06202885|DRUG|Immunotherapy|Immunotherapy
219060441|NCT02059148|DRUG|LY2835219|Administered orally.
219060442|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
219060443|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
219060444|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
219060445|NCT03639155|DRUG|vadadustat test tablets|oral tablet
219060446|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
218958984|NCT00957593|DRUG|Oxytocin|Continuation of oxytocin once in active labor
218958985|NCT00957593|DRUG|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
218958986|NCT05669313|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
218958987|NCT00263939|BEHAVIORAL|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
218958988|NCT02328469|DRUG|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
218958989|NCT02328469|DRUG|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
218958990|NCT02328469|OTHER|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
218958991|NCT02328469|DRUG|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
218958992|NCT03964337|DRUG|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
218958993|NCT03964337|PROCEDURE|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
219060447|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
219060448|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
219060449|NCT01645709|DRUG|Verapamil|
219060450|NCT01645709|DRUG|Placebo|
219060451|NCT02157558|DRUG|Fexofenadine|All subjects will receive 180 mg fexofenadine
219060452|NCT02157558|DRUG|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
219060453|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
219060454|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
219060455|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
219060456|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
219060457|NCT03290716|OTHER|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
219207742|NCT06748313|OTHER|Carrot Pickle (Water-Based)|The ingredients used in Carrot Pickle (Water-Based) are Carrots, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
219207743|NCT06748313|OTHER|Radish Pickle (Water-Based)|The ingredients used in Radish Pickle (Water-Based) are Radish, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
219207744|NCT06748313|OTHER|Onion Pickle (Water-Based)|The ingredients used in Onion Pickle (Water-Based) are Onion, Vinegar, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 3-4 days, and it will be ready to use.
218958994|NCT03875170|OTHER|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
219207745|NCT06748313|OTHER|Lemon & Chili Pickle (Water-Based)|The ingredients used in Lemon \& Chili Pickle (Water-Based) are Lemon, Green Chili, Turmeric, Vinegar, water, and salt. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
218958995|NCT03875170|OTHER|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
218958996|NCT01546129|DEVICE|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
218958997|NCT01551446|DRUG|Bardoxolone Methyl|Oral, once daily
218958998|NCT06126731|DRUG|Enzalutamide 40mg|Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
218958999|NCT06126731|DRUG|Amoxicillin 500mg|"Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder"
219060458|NCT03290716|OTHER|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
219060459|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
219060460|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
219060461|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
219060462|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
219060463|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
219060464|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
219060465|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
219060466|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
219060467|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
219060468|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
219060469|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
219060470|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
219060471|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
219060472|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
219060473|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
219060474|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
219641785|NCT05807698|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
218959000|NCT06126731|DRUG|Metronidazole 400mg|"Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other"
219641786|NCT02985645|PROCEDURE|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
218959001|NCT06126731|DRUG|Vancomycin 125mg|"Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass"
218959002|NCT06126731|DRUG|Ciprofloxacin 500g|"White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side"
218959003|NCT04249830|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
218959004|NCT04249830|DEVICE|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
218959005|NCT03160859|OTHER|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
218959006|NCT03160859|DEVICE|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
218959007|NCT02915120|PROCEDURE|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
218959008|NCT02915120|PROCEDURE|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
219060475|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
219060476|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
219060477|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
219060478|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
219060479|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
219060480|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
219060481|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
219060482|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
219060483|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
219060484|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
219060485|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
219060486|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
219060487|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
219060488|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
219060489|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
219060490|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
219060491|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
219060492|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
219060493|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
219060494|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
219641787|NCT02985645|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
218959009|NCT06361797|OTHER|Rotator cuff repair augmented with whole bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.
218959010|NCT06361797|OTHER|Rotator cuff repair augmented with concentrated bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. This volume will be concentrated and, at the end of the procedure, the concentrate will be injected back into the joint space.
218959011|NCT05617209|OTHER|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
218959012|NCT05658575|DRUG|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
218959013|NCT05658575|OTHER|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
218959014|NCT02522871|DEVICE|OCS™ Liver System|
219060495|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
219060496|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
219207746|NCT06647342|DRUG|Bleomycin|In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
219207747|NCT06805279|PROCEDURE|Axillary Vein Cannulation|"This study aims to evaluate the potential advantages of using the hockey stick ultrasonography probe for axillary vein cannulation and determine whether this probe enhances axillary vein imaging, accelerates the central vein cannulation procedure and reduces the rate of complications compared to the linear probe"
219207748|NCT06819527|OTHER|Medication reconciliation service|Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.
219207749|NCT06820320|DRUG|oral iohexol|Upon diagnosing chylous ascites, patients received oral iohexol treatment, a critical intervention in our therapeutic armamentarium. The initial oral dose was standardized to ensure a balance between efficacy and patient safety. In the event of a less than optimal response or significant drainage within the first 24 hours, a second identical dose of Iohexol was considered to maintain therapeutic concentration levels in the body.
218959015|NCT02522871|OTHER|Control|
218959016|NCT04138979|DRUG|cyclophosphamide|First use of chemotherapy after breast cancer
218959017|NCT05179174|GENETIC|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
218959018|NCT00377130|OTHER|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
218959019|NCT02620371|PROCEDURE|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
218959020|NCT05062395|PROCEDURE|Computed Tomography|Undergo FDG PET CT
218959021|NCT05062395|OTHER|Fludeoxyglucose F-18|Undergo FDG PET CT
218959022|NCT05062395|OTHER|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
219060497|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
219207750|NCT06820320|PROCEDURE|Lymphangiography and Embolization|"When conservative methods fall short in resolving chylous ascites, our protocol advances to precise interventional treatments. The escalation begins with ultrasound-guided lymphangiography. Through unilateral or bilateral inguinal lymph node access, iodized oil contrast is infused via a 9 ml/hour micro-pump, meticulously monitored by fluoroscopic imaging at 3-5 minutes intervals.~Following precise localization of the leakage site, embolization is performed with a sequence of carefully calibrated steps. The process entails cone-beam CT scanning and 3D reconstruction for a clear depiction of the leak, followed by direct needle access to the lymphatic rupture under DSA guidance. A fine guidewire is inserted above the rupture, which facilitates the delivery of an embolizing mixture of iodized oil and NBCA glue. This is done with the utmost precision to prevent any spillage, ensuring the embolization's success and marking the conclusion of the procedure."
218959023|NCT05062395|PROCEDURE|Positron Emission Tomography|Undergo FDG PET CT
218959024|NCT03195296|OTHER|No intervention|No intervention related to the study is foreseen
219060498|NCT00002684|DRUG|cisplatin|
219060499|NCT00002684|DRUG|ifosfamide|
219060500|NCT00002684|DRUG|paclitaxel|
219060501|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
219060502|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
218959025|NCT04330105|DEVICE|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
218959026|NCT00509262|DRUG|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
219641788|NCT01217476|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
218959027|NCT00509262|DRUG|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
218959028|NCT00509262|DRUG|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
218959029|NCT00509262|DRUG|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
219060503|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
219060504|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
219060505|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
219060506|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
219060507|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
219060508|NCT00780091|OTHER|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
219060509|NCT00780091|OTHER|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
219060510|NCT00352729|DEVICE|ACell dressing|dressing
219060511|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
219060512|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
219060513|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
219060514|NCT01260233|OTHER|Smoking cessation program|"Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
219060515|NCT01070810|DRUG|D5W|Dextrose 5%
219060516|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
219060517|NCT04498936|DRUG|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
219060518|NCT04498936|DRUG|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
219060519|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
219060520|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
219060521|NCT01032967|PROCEDURE|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
219060522|NCT01032967|RADIATION|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
218959030|NCT02218177|DRUG|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
218959031|NCT02218177|DRUG|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
218959032|NCT02218177|PROCEDURE|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
219060523|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
219060524|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
219060525|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
219060526|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
219060527|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
219060528|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
219207751|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
219366225|NCT05461638|PROCEDURE|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
219060529|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
219060530|NCT00378417|BIOLOGICAL|7-valent pneumococcal-CRM197 conjugate vaccine|
219060531|NCT00378417|BIOLOGICAL|7-valent pneumococcal-OMPC conjugate vaccine|
219060532|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
219060533|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
219641789|NCT01577953|DRUG|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
218959033|NCT00691119|BEHAVIORAL|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
218959034|NCT00691119|OTHER|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
218959035|NCT05034666|BEHAVIORAL|Before the education program|Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
218959036|NCT05034666|BEHAVIORAL|After the education program|After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
219060534|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
219060535|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
219060536|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
219060537|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
219060538|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
218959037|NCT03511898|DRUG|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
218959038|NCT03511898|DRUG|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
218959039|NCT03511898|DRUG|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
218959040|NCT02569827|DRUG|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
218959041|NCT02569827|DRUG|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
218959042|NCT02569827|DRUG|Placebo|Placebo Q6H for 5 days
218959043|NCT02569827|DRUG|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
219060539|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
219060540|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
219060541|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
219060542|NCT04240821|DRUG|Theophylline ER|Oral theophylline
219060543|NCT06435871|BEHAVIORAL|Expanded Prostate Cancer Index Composite and Decision Regret Scale|This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
219060544|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
219060545|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
219060546|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
218959044|NCT00294281|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
218959045|NCT00129909|DRUG|fixed dose combination therapy|
218959046|NCT00725842|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
218959047|NCT00725842|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
218959048|NCT04661254|OTHER|Lymphapheresis|\- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
218959049|NCT01044329|DRUG|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
219641790|NCT01577953|DRUG|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
219060547|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
219060548|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
219060549|NCT02012374|BEHAVIORAL|Intensive Language Action Therapy|
219060550|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
219060551|NCT04897516|DRUG|Short regimen of benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
218959050|NCT01044329|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
218959051|NCT00201162|DIETARY_SUPPLEMENT|Soy|Dietary supplement of isolated soy protein containing isoflavones
218959052|NCT00201162|DIETARY_SUPPLEMENT|Placebo|dietary supplement casein placebo
218959053|NCT02556164|PROCEDURE|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
218959054|NCT02556164|OTHER|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
218959055|NCT01853618|DRUG|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
218959056|NCT01853618|PROCEDURE|RFA|Performed on Day 36
219060552|NCT04897516|DRUG|Short treatment with benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
219060553|NCT04897516|DRUG|Standard treatment with benznidazole|Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
218959057|NCT01853618|PROCEDURE|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
218959058|NCT01853618|PROCEDURE|Cryoablation|Performed on Day 36
218959059|NCT04951739|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
218959060|NCT00558571|DRUG|BI 10773 low dose|
218959061|NCT00558571|DRUG|placebo to BI 10773|
218959062|NCT00558571|DRUG|BI 10773 medium dose|
218959063|NCT00558571|DRUG|BI 10773 high dose|
218959064|NCT03380936|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
218959065|NCT03380936|OTHER|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
218959066|NCT00801671|PROCEDURE|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
218959067|NCT00065364|BEHAVIORAL|Newborn Individualized Developmental Care Assessment Program|
218959068|NCT03029637|DEVICE|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
218959069|NCT03029637|DEVICE|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
219060554|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
219060555|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
219060556|NCT00032292|DRUG|Visilizumab|
219060557|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
219060558|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
219060559|NCT01899976|DEVICE|X-Suit NIR Covered Biliary Stent|
219060560|NCT03373591|DRUG|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
219060561|NCT03373591|DRUG|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
219366226|NCT05461638|PROCEDURE|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
218959070|NCT04860908|OTHER|no intervention, observation only|no intervention, observation only
218959071|NCT00471614|DRUG|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
218959072|NCT00947505|DEVICE|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
218959073|NCT00947505|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
218959074|NCT02492737|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
218959075|NCT03858439|OTHER|Dietary|Low sodium, low protein dietary recommendation
218959076|NCT01517971|OTHER|laboratory biomarker analysis|Correlative studies
218959077|NCT02325843|OTHER|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
218959078|NCT06046352|PROCEDURE|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
218959079|NCT04457388|OTHER|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
218959080|NCT01247805|DRUG|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
218959081|NCT01247805|DRUG|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
218959082|NCT01247805|DRUG|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
218959083|NCT03487601|OTHER|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
218959084|NCT03487601|OTHER|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
218959085|NCT02858700|BIOLOGICAL|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
218959086|NCT01715129|DRUG|Triptorelin Pamoate 11.25mg|
218959087|NCT00712556|RADIATION|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
218959088|NCT02044328|DRUG|Icotinib|Icotinib is administered 125 mg three times per day.
218959089|NCT02588001|DRUG|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
218959090|NCT06156124|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
218959091|NCT06116240|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
218959092|NCT06116240|DRUG|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
219207752|NCT06816173|DRUG|Propofol group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer propofol intravenously at a dose of 2.0 mg/kg.~Maintenance phase: Infuse propofol (4-12 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
218959093|NCT06116240|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
218959094|NCT06116240|DRUG|Cisplatin injection|Cisplatin is a chemotherapy drug.
218959095|NCT04613401|OTHER|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
218959096|NCT02793622|DRUG|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
219207753|NCT06816173|DRUG|Remimazolam group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer remimazolam intravenously at a dose of 0.45-0.55 mg/kg.~Maintenance phase: Infuse remimazolam (1-3 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
219207754|NCT06673342|BEHAVIORAL|Nutritional Counseling|Nutritional counseling based on Stephan's Curve. The Stephan's curve is a diagram that shows how the acidity of the oral cavity changes with consumption of food, specifically with added sugar. A laminated Stephan's curve will be used to show the drop of pH (acidity) based on the subject's reported daily consumption of food and snacks. Recommendations will be provided on a balanced diet according to the American Dental Association guidelines and recommendations on reducing the frequency of snacking.
219207755|NCT06757179|DIETARY_SUPPLEMENT|Elysium Naso Gola|"Elysium Naso Gola Supplement is a dietary supplement designed to soothe the upper respiratory tract, providing a range of benefits thanks to the properties of its natural ingredients. Its anti-inflammatory, antibacterial, antifungal, antiviral, antioxidant, and prebiotic activities suggest a comprehensive product for supporting respiratory health.~Mullein promotes the functionality of the respiratory mucous membranes. Thyme supports nasal and throat well-being, aids in the fluidity of bronchial secretions, and has antioxidant properties."
219207756|NCT06757179|OTHER|Placebo|Placebo
219207757|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
218959097|NCT02793622|DRUG|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
218959098|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
218959099|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
219207758|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
219641791|NCT03764397|BEHAVIORAL|Prehabilitation for behavioural change|The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
219641792|NCT02953847|DRUG|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
219641793|NCT02953847|DRUG|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
219641794|NCT02953847|DRUG|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
219641795|NCT06152874|OTHER|consumption of glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
219641796|NCT06152874|OTHER|consumption of glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
219641797|NCT06152874|OTHER|consumption of Bread A and oral processing|bread made with 95% durum wheat fine semolina (\< 400 micrometer) + 5% of gluten + 1.2% of yeast + 1% of salt + 59%of water) (portion corresponding to 50 g available carbohydrates) + 250 mL water
219641798|NCT06152874|OTHER|consumption of Bread B and oral processing|bread made with 80% durum wheat fine semolina (\< 400micrometer) + 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
219641799|NCT06152874|OTHER|consumption of Bread C and oral processing|bread made with 80% durum wheat coarse semolina (\> 500micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
219641800|NCT03033602|BEHAVIORAL|written exposure therapy|five sessions of writing about traumatic experience.
219641801|NCT03033602|BEHAVIORAL|CPT, cognitive only|12 sessions of cognitive therapy related to traumatic experience.
219641802|NCT00680485|DRUG|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
219641803|NCT03738813|DEVICE|Gloreha Aria|Device offers specific programs that help patients to move arm, wrist and fingers
218959100|NCT03556488|DIAGNOSTIC_TEST|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
218959101|NCT02821663|BEHAVIORAL|vocal intervention|10 x 60 min. sessions of vocal intervention
218959102|NCT04138966|DEVICE|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
218959103|NCT04138966|DEVICE|Skin Conductance|Measures skin conductance as a surrogate to nociception
218959104|NCT01146860|DRUG|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
218959105|NCT01146860|DRUG|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
218959106|NCT04705740|OTHER|ERCP|ERCPs performed annually by an endoscopist
218959107|NCT04260932|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
218959108|NCT01650129|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
219641804|NCT03738813|OTHER|Usual care|Conventional occupational therapy
219641805|NCT03131973|DRUG|BMS-986195|Specified dose on specified days
219641806|NCT03131973|DRUG|Methotrexate|Specified dose on specified days
219641807|NCT03131973|DRUG|Leucovorin|Specified dose on specified days
219641808|NCT03131973|DRUG|Caffeine|Specified dose on specified days
219641809|NCT03131973|DRUG|Montelukast|Specified dose on specified days
219641810|NCT03131973|DRUG|Flurbiprofen|Specified dose on specified days
219641811|NCT03131973|DRUG|Omeprazole|Specified dose on specified days
219641812|NCT03131973|DRUG|Midazolam|Specified dose on specified days
219641813|NCT03131973|DRUG|Digoxin|Specified dose on specified days
219641814|NCT03131973|DRUG|Pravastatin|Specified dose on specified days
219641815|NCT04445714|DRUG|dapagliflozin and saxagliptin|Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
219641816|NCT03582982|BEHAVIORAL|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
219641817|NCT01612689|DEVICE|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
219641818|NCT00536159|OTHER|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
219641819|NCT00536159|OTHER|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
219641820|NCT05891223|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
219641821|NCT05891223|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219641822|NCT05891223|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application."
219641823|NCT05891223|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219641824|NCT05891223|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
218959109|NCT01650129|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
218959110|NCT05349253|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
218959111|NCT05349253|DIETARY_SUPPLEMENT|Placebo|One intake in total
218959112|NCT00151203|DRUG|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
218959113|NCT00728143|DIETARY_SUPPLEMENT|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
218959114|NCT02916121|DIETARY_SUPPLEMENT|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
218959115|NCT02916121|OTHER|Placebo|placebo
218959116|NCT03015480|BEHAVIORAL|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
218959117|NCT02721186|DRUG|MDA with DHAp and SLD Primaquine|
218959118|NCT02306031|DRUG|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
218959119|NCT02306031|DRUG|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
218959120|NCT01555385|DIETARY_SUPPLEMENT|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
218959121|NCT04572516|DRUG|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
218959122|NCT04572516|DRUG|BTX A Injection|In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
219060562|NCT03735550|DEVICE|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
219060563|NCT01172548|DRUG|imatinib mesylate|
218959123|NCT01092832|DRUG|voriconazole|"Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
219641825|NCT05891223|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219641826|NCT05891223|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
219641827|NCT05891223|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
219641828|NCT02527252|OTHER|Craniosacral therapy|
219641829|NCT02527252|OTHER|Classic Massage|
219641830|NCT01436877|DEVICE|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
219641831|NCT02480374|BIOLOGICAL|IMNN-001|
218959124|NCT01341392|DRUG|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
218959125|NCT01341392|DRUG|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
218959126|NCT01341392|DRUG|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
218959127|NCT00722371|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
218959128|NCT00722371|DRUG|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
218959129|NCT00722371|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
218959130|NCT00722371|DRUG|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
219060564|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
219060565|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
219060566|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
219060567|NCT02749903|DRUG|enzalutamide|oral
219060568|NCT04266457|OTHER|No Intervention|No Intervention
219060569|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
219060570|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
219060571|NCT06142201|DRUG|JT001|oral administration
219060572|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
219060573|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
219060574|NCT02041429|DRUG|Ruxolitinib|
219060575|NCT02041429|DRUG|Paclitaxel|
219060576|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
219060577|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
219060578|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
219060579|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
219060580|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
219060581|NCT00861341|DRUG|Aspirin|81 mg
219060582|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
219060583|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
219207759|NCT06860087|DIETARY_SUPPLEMENT|Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 200 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
219207760|NCT06860087|DIETARY_SUPPLEMENT|Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 400 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
219207761|NCT05460520|BEHAVIORAL|VOR Readaptation|"The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment."
219641832|NCT05747573|DRUG|GB1211|Hard tablet or capsules for oral use
219641833|NCT01684943|OTHER|Multiplex pharmacokinetic profiling|
219641834|NCT01684943|OTHER|Continuous insulin monitoring|
218959131|NCT00722371|DRUG|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
219060584|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
219060585|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
219060586|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
219060587|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
219060588|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
219060589|NCT03933293|DRUG|Statins|Lipid-lowering therapies
219641835|NCT00379444|BEHAVIORAL|Standard intervention (counseling + self-help written materials)|counseling
218959132|NCT02299518|DRUG|mitoxantrone hydrochloride|Given IV
218959133|NCT02299518|DRUG|etoposide|Given IV and PO
218959134|NCT02299518|DRUG|cytarabine|Given IV
219060590|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
218959135|NCT02299518|DRUG|selinexor|Given PO
218959136|NCT02299518|OTHER|laboratory biomarker analysis|Correlative studies
219641836|NCT00379444|BEHAVIORAL|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
219641837|NCT02320773|DRUG|Betmiga®|Oral
219641838|NCT02511392|PROCEDURE|rTMS-1Hz|
219641839|NCT02511392|PROCEDURE|rTMS-10 Hz|
218959137|NCT02299518|OTHER|pharmacological study|Correlative studies
218959138|NCT00225927|PROCEDURE|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
218959139|NCT02257671|DRUG|Oral contraceptive|Neovletta
218959140|NCT03139942|DEVICE|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
218959141|NCT00133978|OTHER|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
218959142|NCT00133978|OTHER|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
218959143|NCT00133978|OTHER|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
218959144|NCT00133978|OTHER|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
218959145|NCT04668612|DEVICE|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
218959146|NCT04668612|DEVICE|Standard bolus|Standard boluses for all meals
218959147|NCT00298753|PROCEDURE|fluid restriction for 14 days (15ml fluid per kg weight)|
218959148|NCT06492343|OTHER|fMRI based neurofeedback|participants will receive neurofeedback from their brain in order to modify their own brain function
218959149|NCT04223492|DIAGNOSTIC_TEST|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
219060591|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
219060592|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
219060593|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
219060594|NCT01835782|DRUG|L-Serine|
219060656|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
219641956|NCT06683872|PROCEDURE|surgical myectomy|Our procedure was performed via a right infra-axillary incision (4-5 cm), enter the thoracic cavity through the third intercostal space lateral to the pectoralis major muscle. Generally, neither rib resection nor division of the pectoralis major muscle were required. The intervention utilized femoral-femoral cardiopulmonary bypass (CPB). The aorta was clamped using a Glauber clamp (CardioVision MICAortic Clamp, Cardiomedical GmbH). Myocardial protection was achieved with antegrade Del Nido cardioplegia. After inducing of cardiac asystole, a transverse incision was made in the aorta and the aorta incision was suspended to enhance visualization. A mesh retractor (FEHLING INSTRUMENTS, Karlstein, Germany) was placed in the aortic sinus to protect the aortic leaflets. The extent of the septal myectomy, determined based on preoperative TEE, started 5 mm below the midpoint of the right coronary cusp. It extended counterclockwise towards the anterior commissure of the mitral valve a
219641957|NCT04113655|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
219641958|NCT04113655|BIOLOGICAL|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
219641959|NCT04113655|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
219641960|NCT02989246|OTHER|Ventilator protocol|Open loop ventilator management by a computer based protocol
219641961|NCT02989246|DEVICE|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
219641962|NCT02610543|DRUG|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
219641963|NCT02610543|DRUG|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
219641964|NCT03429933|DRUG|BMS-986278|Specified dose on specified days
219641965|NCT03429933|OTHER|Placebo|Specified dose on specified days
219641966|NCT01477996|PROCEDURE|27-gauge|27-gauge needle for IVT
219641967|NCT01477996|PROCEDURE|30-gauge|30-gauge needle for IVT
219641968|NCT00287196|RADIATION|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
219641969|NCT00613691|DRUG|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
219641970|NCT04126902|OTHER|interleukin-6, presepsin and pentraxin-3|measurements and compare
219641971|NCT02649244|BEHAVIORAL|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
219060657|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
219641972|NCT03233529|DRUG|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
219641973|NCT03233529|DRUG|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
219641974|NCT06684509|DRUG|Atrovastain|atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
219641976|NCT04166344|BEHAVIORAL|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online \& offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
219641977|NCT05194761|DRUG|Normal saline|Using normal saline nebulization in neonates postextubation
219641978|NCT01177293|DRUG|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
219641979|NCT01177293|DRUG|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
219060658|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
219641980|NCT01003483|DRUG|orlistat|Tablet,120mg,three times a day,three months
219641981|NCT03858361|DEVICE|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
219060659|NCT02758236|OTHER|No Intervention|No Intervention
219060660|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
219641982|NCT00052130|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
219060661|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
219641983|NCT00633815|OTHER|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
219641984|NCT00633815|OTHER|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
219641985|NCT00574470|DRUG|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
219641986|NCT05418582|DRUG|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
219641987|NCT05418582|DRUG|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
219641988|NCT03614468|OTHER|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
219641989|NCT03614468|OTHER|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
219641990|NCT01355016|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
219641991|NCT01883050|DEVICE|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
219641992|NCT03917316|OTHER|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
219641993|NCT00751049|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
219060662|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
219060663|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
219641994|NCT00751049|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
219641995|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
219641996|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
219641997|NCT01694069|DRUG|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
219060664|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
219060665|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
219060666|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
219060667|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
219060668|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
219641998|NCT01491204|DRUG|Paclitaxel+HM30181|oral, 3times for 4weeks
219641999|NCT00981669|BIOLOGICAL|rotavirus vaccine|3 doses with 6 weeks interval
219642000|NCT00981669|BIOLOGICAL|placebo|3 doses with 6 weeks interval
219642001|NCT01623401|DRUG|TR-701 FA|TR-701 FA 200 mg once daily
219642002|NCT01702480|DRUG|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
219642003|NCT01702480|DRUG|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
219642004|NCT05902091|BEHAVIORAL|Neurophysiology-based intervention|
219642005|NCT01038401|PROCEDURE|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
219642006|NCT01038401|BIOLOGICAL|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
219642007|NCT03719248|DEVICE|thoracic epidural|high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
219642008|NCT03088163|DEVICE|Diffusion weighted magnetic resonance imaging|The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
219642009|NCT00648622|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
219642010|NCT00648622|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
219060669|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
219060670|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
219642011|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.
219060671|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
219060672|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
219060673|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
219060674|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
219060675|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
219060676|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
219060677|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
219060678|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
219060679|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
219060680|NCT00233025|DRUG|Duloxetine|
219642012|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.
219060681|NCT00233025|DRUG|Placebo|
219060682|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
219060683|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
219060684|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
219060685|NCT00090012|DRUG|Olanzapine|
219060686|NCT00090012|DRUG|Quetiapine|
219060687|NCT00228449|DRUG|peginesatide|
219060688|NCT04095858|DRUG|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
219060689|NCT04095858|DRUG|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
219060690|NCT04095858|DRUG|Methotrexate|IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
219060691|NCT04095858|DRUG|Tacrolimus|Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
219060692|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
219060693|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
219060694|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
219060695|NCT01343706|DRUG|Placebo|Solution for oral administration
219060696|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
219060697|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
219060698|NCT01343706|DRUG|BI 409306|solution for oral administration
219060699|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
219060700|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
219060701|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
219060702|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
219100250|NCT00000230|DRUG|Buprenorphine|
219223669|NCT07014059|DRUG|Autologous Serum 20%|The collection of autologous serum in a closed blood processing system for ocular use
219060703|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
219642013|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)|This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
219060704|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
219642014|NCT04194762|OTHER|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
219642015|NCT05482373|DIETARY_SUPPLEMENT|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
219642016|NCT05482373|DIETARY_SUPPLEMENT|Placebo|The capsules intake will last for a total of 4 months.
219642017|NCT06068829|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
219642018|NCT06068829|DRUG|Rituximab(RTX)|RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
219642019|NCT02339324|DRUG|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
219642020|NCT02590575|DEVICE|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"1. With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
219642021|NCT02297178|PROCEDURE|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
219642022|NCT02297178|PROCEDURE|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
219642023|NCT02807571|PROCEDURE|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
219642024|NCT03305861|PROCEDURE|ThuLEP|Thulium laser enucleation of prostate
219642025|NCT03305861|PROCEDURE|Green LEP|Greenlight laser enucleation of prostate
219642026|NCT01905553|DRUG|SSP-004184SS|Disodium salt
219642027|NCT01233960|DRUG|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
219642028|NCT02240927|DRUG|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
219642029|NCT02240927|DRUG|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
219642030|NCT02240927|DRUG|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
219642031|NCT02240927|DRUG|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
219642032|NCT05118776|DRUG|ASC40 tablets|ASC40 tablets administered orally once daily
219642033|NCT05118776|DRUG|Placebo tablets|Placebo administered orally once daily.
219642034|NCT05118776|DRUG|Bevacizumab|Bevacizumab once every 2 weeks, intravenous drip.
219642035|NCT05632198|OTHER|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
219642036|NCT02951221|DRUG|BIIB074 Treatment A|Lower dose RCF fasted
219642037|NCT02951221|DRUG|BIIB074 Treatment B|Lower dose DCF fasted
219642038|NCT02951221|DRUG|BIIB074 Treatment C|Higher dose DCF fasted
219642039|NCT02951221|DRUG|BIIB074 Treatment D|Higher dose DCF fed
219642040|NCT03879980|DRUG|Bilateral QL block|Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
219642041|NCT03879980|DRUG|Non-QL block|Only received fentanyl IV during surgery.
219642042|NCT03459898|DEVICE|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
219642043|NCT04181047|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Psychotherapy.
219642044|NCT04181047|OTHER|Usual care|Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
219642045|NCT02538289|BEHAVIORAL|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
219642046|NCT02586519|DEVICE|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
219642047|NCT04453072|OTHER|Interview|Participate in interviews
219642048|NCT04453072|OTHER|Media Intervention|Receive iPhone with W8Loss2Go app
219642049|NCT04453072|OTHER|Questionnaire Administration|Complete questionnaires
219642050|NCT04453072|OTHER|Scale Device|Receive body scale and food scale
219642051|NCT04453072|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
219642052|NCT04453072|OTHER|Text Message|Receive text message
219642053|NCT04885179|OTHER|no intervention|No interventions are involved in this observational study.
219642054|NCT00655707|BIOLOGICAL|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
219642055|NCT01083888|DRUG|roxadustat|oral
219642056|NCT03138252|DRUG|Oxytocin|
219642057|NCT06622356|OTHER|MRI with Eovist|The study was retrospective and did not design an intervention
219642058|NCT01767506|OTHER|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
219642059|NCT01767506|OTHER|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
219642060|NCT00076752|DRUG|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m\^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
219642061|NCT00076752|DRUG|cyclophosphamide|Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
219642062|NCT00076752|BIOLOGICAL|Rituxan (rituximab)|Priming regimen: 375 mg/m\^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m\^2 intravenous infusion, day -7.
219642063|NCT00076752|BIOLOGICAL|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC \>500 microliters.
219642064|NCT00076752|DRUG|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
219642065|NCT00076752|OTHER|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
218985174|NCT03016806|DRUG|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
218985175|NCT03016806|DRUG|Melphalan|140 mg/m2
218985176|NCT05711849|BIOLOGICAL|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
218985177|NCT05711849|PROCEDURE|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
218985178|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 6 weeks.|
218985179|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 5 weeks.|
218985180|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
218985181|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
218985182|NCT05706701|OTHER|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
218959329|NCT03008564|OTHER|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~* Age~* Gender~* Weight~* Height~* BMI~* Distance of ASIS to base of patella~* Distance of Point A to base of patella~* Distance of Point B to base of patella~* Distance of apex of femoral triangle to base of patella"
218959330|NCT00533091|BIOLOGICAL|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
218959331|NCT00533091|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
218959332|NCT05666115|DIETARY_SUPPLEMENT|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
219642066|NCT00076752|OTHER|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
219642067|NCT00076752|PROCEDURE|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
219060705|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
219060706|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
219060707|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
219060708|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
219060709|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
219060710|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
219642068|NCT00076752|DRUG|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
219642069|NCT00076752|DRUG|Mesna|Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
219642070|NCT03854370|OTHER|Baby shampoo|baby shampoo will be used to prepare the surgical site prior to incision
219642071|NCT03854370|OTHER|Betadine|Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
219060711|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
219060712|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
219060713|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
219060714|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
219060715|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
219642072|NCT03854370|OTHER|Peridex|Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
219060716|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
219060717|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
219060718|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
219060719|NCT02376413|RADIATION|Radiation therapy|
219060720|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
219642073|NCT03854370|OTHER|TechniCare|TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
219642074|NCT03152331|BEHAVIORAL|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
219642075|NCT00452673|DRUG|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
219642076|NCT00452673|DRUG|Capecitabine|Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
219642077|NCT04071548|OTHER|HIIT Exercise|"HIIT exercise bike protocol~* 3 minute warm up~* Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~* 10x60 second Recovery period~* 5 minute cool-down"
219642078|NCT06545773|PROCEDURE|Root Canal Treatment with ProTaper Next Nickel-Titanium File (PTN)|ProTaper Next (Dentsply Sirona) is a rotational system made of a nickel-titanium alloy called M-Wire. It has a rectangular cross-sectional design; thus, only two sides touch the root canal. Five files are available: X1 17/. 04, X2 25/.06, X3 30/. 07, X4 40/.06, and X5 50/.06. This file aggressively removes the coronal dentine of root canals due to its large taper. PTN nickel-titanium systemis used in root canal treatments to debride and shape the root canals.
219642079|NCT06545773|PROCEDURE|Root Canal Treatment withTruNatomy Nickel-Titanium File (TN)|TruNatomy (Dentsply Sirona) is a heat-treated nickel-titanium system that consists of an orifice modifier, glide path, and shaping files. The TruNatomy Small, Prime, and Medium files have sizes of 20/.04, 26/.04, and 35/.04, respectively. It has a rectangular cross-section and a regressive taper. Its slim design allows for a conservative preparation of root canals and the preservation of the coronal dentine. TN nickel-titanium system is used in root canal treatments to debride and shape the root canals.
219642080|NCT02656290|DEVICE|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
219100251|NCT05125393|PROCEDURE|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
219642081|NCT04259203|BEHAVIORAL|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
219642082|NCT04638881|DRUG|Magnesium sulfate|Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
219642083|NCT04638881|DRUG|Normal Saline|Placebo. Bolus and infusion administered similarly under general anesthesia.
219642084|NCT05504486|DRUG|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
219642085|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
219642086|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
219642087|NCT05195918|COMBINATION_PRODUCT|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
219642088|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
219642089|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
219642090|NCT05195918|COMBINATION_PRODUCT|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
219642091|NCT05554536|PROCEDURE|PEEP titration trial|PEEP trial, starting from clinical PEEP 16 cmH2O and ending at PEEP 6 cmH2O. The PEEP trial will be stopped for haemodynamic instability (defined as arterial pressure \< 80 mmHg and /or heart rate \> 150 bpm) or desaturation (defined as SpO2 \< 92%).
218959333|NCT05666115|OTHER|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
219642092|NCT06494332|OTHER|Exercise and stretching programe|It consists in: a serie of mobility exercises, which were used as warp-up; the mobility of the elbow, forearm, wrist and fingers of both upper limbs was worked on; and, exercises were performed to strengthen the muscles of both forearms.
219642093|NCT01608087|DRUG|BI 695502|BI 695502 single i.v. infusion
219642094|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
219642095|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
219642096|NCT02877394|DEVICE|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
218959334|NCT02927405|DRUG|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
218959335|NCT02927405|PROCEDURE|TAP Block|a procedure done anesthetize the anterior abdominal wall
218959336|NCT04632914|OTHER|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
218959337|NCT04632914|OTHER|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
218959338|NCT00769327|DRUG|imatinib mesylate|
218959339|NCT00769327|DRUG|nilotinib|
218959340|NCT00769327|GENETIC|cytogenetic analysis|
218959341|NCT00769327|GENETIC|fluorescence in situ hybridization|
219642097|NCT02877394|DEVICE|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
218959342|NCT00769327|GENETIC|microarray analysis|
219642098|NCT02760212|DEVICE|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
219642099|NCT02760212|OTHER|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
219642100|NCT02410421|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
219642101|NCT04984863|DEVICE|Magnetically controlled capsule endoscopy|Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
219642102|NCT02603068|DRUG|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
219642103|NCT04958681|OTHER|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
219642104|NCT00348595|DRUG|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
219642105|NCT05213013|OTHER|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
219642106|NCT05475587|OTHER|Routine care|Both two groups received the same routine care.
219642107|NCT05427760|DRUG|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
219642108|NCT01323153|DRUG|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
219642109|NCT01323153|DRUG|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
219642110|NCT00459004|DRUG|rimonabant (SR141716)|
218959343|NCT00769327|GENETIC|mutation analysis|
218959344|NCT00769327|GENETIC|polymerase chain reaction|
218959345|NCT00769327|GENETIC|polymorphism analysis|
218959346|NCT00769327|OTHER|laboratory biomarker analysis|
218959347|NCT03024580|DRUG|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
218959348|NCT03024580|DRUG|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
218959349|NCT03024580|DRUG|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
218959350|NCT03024580|DRUG|Exemestane 25 MG|Exemestane 25 mg PO daily
218959351|NCT03024580|DRUG|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
218959352|NCT03024580|DRUG|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
218959353|NCT04537780|OTHER|Placebo|Placebo tabled every day
218959354|NCT04537780|DRUG|Montelukast|Montelukast 10 mg daily at bed time.
219642111|NCT04875988|PROCEDURE|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
219642112|NCT04875988|PROCEDURE|Traditional|ultrasound will not be used in the traditional IV placement group
219642113|NCT05906173|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
219642114|NCT04898283|BIOLOGICAL|10,000 MG01 +10,000 T521|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
218959355|NCT01380938|DRUG|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
218959356|NCT00965328|PROCEDURE|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
218959357|NCT00965328|PROCEDURE|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
218959358|NCT03705936|DEVICE|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
218959359|NCT05604183|PROCEDURE|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
218959360|NCT05604183|PROCEDURE|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
218959361|NCT05604183|DIAGNOSTIC_TEST|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
218959362|NCT01150474|DRUG|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
218959363|NCT01150474|DRUG|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
218959364|NCT01423604|DRUG|Capecitabine|Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
218959365|NCT01423604|DRUG|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
218959366|NCT01423604|DRUG|Placebo|Placebo matching ruxolitinib
218959367|NCT05343468|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
218959368|NCT00000931|BEHAVIORAL|Behavioral intervention|
218959369|NCT00000931|BEHAVIORAL|Risk-reduction counseling|
218959370|NCT00424255|DRUG|Lapatinib|Dual ErbB1/2 inhibitor
218959371|NCT00424255|RADIATION|Chemoradiation|Radiation plus platinum based chemotherapy
218959372|NCT00424255|OTHER|Placebo|Placebo
218959373|NCT03737071|BEHAVIORAL|Low Carbohydrate Diet|Ketogenic dietary intervention
218959374|NCT03737071|BEHAVIORAL|Simple Calorie Restriction Diet|Simple calorie restriction dietary intervention
218959375|NCT03766282|DEVICE|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
218959376|NCT00357929|PROCEDURE|Permissive hypercarbia|
218959377|NCT00002805|BIOLOGICAL|filgrastim|
218959378|NCT00002805|DRUG|cladribine|
218959379|NCT00002805|DRUG|cytarabine|
218959380|NCT00002805|DRUG|etoposide|
218959381|NCT00002805|DRUG|methotrexate|
218959382|NCT00002805|DRUG|mitoxantrone hydrochloride|
218959383|NCT00002805|DRUG|therapeutic hydrocortisone|
218959384|NCT00002805|PROCEDURE|allogeneic bone marrow transplantation|
218959385|NCT00002805|PROCEDURE|autologous bone marrow transplantation|
218959386|NCT00002805|PROCEDURE|peripheral blood stem cell transplantation|
218959387|NCT00002805|RADIATION|low-LET cobalt-60 gamma ray therapy|
218959388|NCT00002805|RADIATION|low-LET electron therapy|
218959389|NCT00002805|RADIATION|low-LET photon therapy|
218959390|NCT00374205|DRUG|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
218959391|NCT00374205|DRUG|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
218959392|NCT04738318|DRUG|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
218959393|NCT04738318|DRUG|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
218959394|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
218959395|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
218959396|NCT01226121|BIOLOGICAL|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
218985183|NCT05706701|OTHER|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
218985184|NCT05706701|OTHER|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
218959397|NCT04781660|DEVICE|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
219642115|NCT04898283|BIOLOGICAL|30,000 MG01 +10,000 T521|Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
219642116|NCT04898283|OTHER|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients
219642117|NCT06968546|DRUG|Intranasal Sufentanil|After randomization, the children will receive intranasal Sufentanil .
219060721|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
219642118|NCT06968546|DRUG|Intranasal Ketamine (IN)|After randomization, chidren will receive intranasal Ketamine
219642119|NCT06968455|OTHER|parabens|endocrine disruptors
219642120|NCT06966635|DRUG|Sodium Bicarbonate Oral Capsule|On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time
219642121|NCT06966635|DRUG|Potassium Citrate Tablets|On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time
219642122|NCT06966635|DRUG|uric-acid-lowering drug|The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.
219642123|NCT06968767|OTHER|bioflx crown|"(Group A: Preformed Biofix Crown - Assigned Intervention)~Crown Selection \& Tooth Preparation:~Measure the mesiodistal width using calipers to select an appropriately sized crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach. If crimping is necessary, use Howe's pliers.~Perform 1-1.5 mm occlusal reduction using a tapered diamond bur.~Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation:~Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup:~Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
219642124|NCT06968767|OTHER|zirconia crown|"Group B: Preformed Zirconia Crown - Assigned Intervention)~Crown Selection:~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the one that closely matches the mesiodistal width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation:~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur.~Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish.~Perform a 1-2 mm subgingival preparation in passively placed fissure bur.~Crown Placement \& Passive Fit Check:~Place the selected crown on the prepared tooth.~Cementation of the Crown:~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure seating."
219642125|NCT06966739|OTHER|MSOT of musculature|All measurements using multispectral optoacustic tomography (MSOT) are performed on the paraspinal muscles as well as the trapezius, rectus abdominus and the proximal and distal limb muscles in a right vs. left comparison (leg proximal: quadriceps and ischiocrural muscle, leg distal triceps surae muscle, tibialis anterior muscle; arm proximal: M. biceps, distal: forearm flexors).
219642126|NCT03322761|COMBINATION_PRODUCT|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
219642127|NCT03322761|BEHAVIORAL|Educational program|Informations regarding health benefits of physical activity and exercise.
219642128|NCT05707468|DRUG|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
219642129|NCT05707468|RADIATION|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
218959398|NCT03888638|PROCEDURE|Hepatectomy|Removal of a part of the liver because of tumor
218959399|NCT04513821|DRUG|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
218959400|NCT01830777|DRUG|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
218959401|NCT01830777|DRUG|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
218959402|NCT01830777|DRUG|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
219642130|NCT01942486|DEVICE|Investigational Coating|
219642131|NCT04616638|BEHAVIORAL|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
219642132|NCT04616638|BEHAVIORAL|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
219642133|NCT03909061|BEHAVIORAL|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
219642134|NCT04490044|OTHER|Under & Over rehabilitation tool|Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
219642135|NCT02048826|DEVICE|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
219642136|NCT02048826|DEVICE|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
219642137|NCT04379531|DIAGNOSTIC_TEST|Low-dose Chest CT|Patients referred by the primary care physician with suspected pneumonia.
219642138|NCT05991336|GENETIC|Gene therapy|Autologous edited hematopoietic stem cell transplantation
219642139|NCT00113854|DRUG|Mannitol|
219642140|NCT06618820|DRUG|Tranexamic acid|One dose consists of three 650 milligram (mg) capsules, to be taken orally.
219642141|NCT06618820|DRUG|Placebo|One dose consists of three microcrystalline cellulose capsules.
219642142|NCT00002251|DRUG|Ganciclovir|
219642143|NCT05845762|DRUG|Obinutuzumab Injection|1000mg intravenous injection
219642144|NCT00966004|DRUG|YM178|oral
219642145|NCT00966004|DRUG|Placebo|oral
219642146|NCT00966004|DRUG|tolterodine|oral
218959403|NCT01830777|DRUG|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
218959404|NCT06067659|OTHER|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
219642147|NCT02610335|OTHER|Control group (C)|"* kyphosis reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
219642148|NCT02610335|OTHER|Test group|"* spinal mobility reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
219642149|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
219642150|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
219642151|NCT00060203|DRUG|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
219642152|NCT04370756|DIETARY_SUPPLEMENT|Beetroot Juice|Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
218985185|NCT05706701|OTHER|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
219642153|NCT04370756|OTHER|Exercise Training|Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
219642154|NCT04176315|OTHER|Conventional Home-based Rehabilitation Plan|Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
219642155|NCT04176315|DEVICE|ReHub Home-based Rehabilitation Plan|"Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
219642156|NCT01985607|DIETARY_SUPPLEMENT|new extensively hydrolysed formula|
219642157|NCT01985607|DIETARY_SUPPLEMENT|Extensively hydrolysed formula|
219642158|NCT01011465|DRUG|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
219642159|NCT01011465|DRUG|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
219642160|NCT01011465|BEHAVIORAL|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
219642161|NCT01011465|BEHAVIORAL|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
219642162|NCT03937921|DRUG|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
219642163|NCT03927521|PROCEDURE|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
219642164|NCT00800592|DRUG|sildenafil|10 mg sildenafil bolus
219642165|NCT06682026|OTHER|listening to music or chatting|"Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups."
219642166|NCT00068367|DRUG|erlotinib hydrochloride|150 mg per day, daily until disease progression
219642167|NCT04024540|DIETARY_SUPPLEMENT|isocaloric dietary restriction|Very low caloric diet
219642168|NCT04024540|PROCEDURE|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
219642169|NCT04610112|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
219642170|NCT02584595|DEVICE|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
219642171|NCT03010150|PROCEDURE|Biospecimen Collection|Provide blood samples
219642172|NCT03010150|OTHER|Questionnaire Administration|Ancillary studies
219642173|NCT04698538|BEHAVIORAL|JASPER|JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
219642174|NCT03597750|DEVICE|Repose®|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors"
219642175|NCT06668701|DEVICE|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at children and adolescents with depression, healthy children and adolescents and parents. The project focuses on education, prevention, support and destigmatisation through the transfer of evidence-based knowledge."
219642176|NCT04115917|DEVICE|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
219642177|NCT04115917|DEVICE|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
219642178|NCT04409808|DEVICE|IRIS|prototype IRIS vitrectomy device.
219642179|NCT00723008|DEVICE|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
218959405|NCT06067659|OTHER|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
218959406|NCT06067659|OTHER|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
218959407|NCT00311480|BIOLOGICAL|Influenza vaccine surface antigen adjuvanted with MF59|
218959408|NCT03271294|DEVICE|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
219060722|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
219060723|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
219060724|NCT00560833|DRUG|esmirtazapine|
219642180|NCT02484781|OTHER|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
219642181|NCT02879617|DRUG|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
219642182|NCT05534386|BEHAVIORAL|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
219642183|NCT05534386|BEHAVIORAL|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
218959409|NCT00739271|OTHER|Early feeding|
218959410|NCT00739271|OTHER|late feeding after bowel sounds return|Traditional method
218959411|NCT03503890|DRUG|rovalpituzumab tesirine|intravenous
219060725|NCT00560833|DRUG|Placebo|
219060726|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
219060727|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
219060728|NCT04159831|DRUG|Placebo|normal saline
219060729|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
219642184|NCT05534386|BEHAVIORAL|First stage control intervention|A set of skill-based pamphlets will be given.
219642185|NCT05534386|BEHAVIORAL|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
219642186|NCT06123221|PROCEDURE|Osseodensification with Versah system|Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol
219642187|NCT06123221|PROCEDURE|Lateral window|A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
219642188|NCT01928602|BEHAVIORAL|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
219642189|NCT01928602|BEHAVIORAL|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
219642190|NCT02089308|DRUG|Test treatment : V0116 transdermal patch|
219642191|NCT02089308|DRUG|Reference treatment : Nicotine transdermal patch|
219642192|NCT04678154|DRUG|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
218959412|NCT04112589|DRUG|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
218959413|NCT04112589|DRUG|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
218959414|NCT04112589|DRUG|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
218959415|NCT04112589|DRUG|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
218959416|NCT04112589|DRUG|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
218959417|NCT04597060|DEVICE|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
218959418|NCT04597060|OTHER|corticosteroid injection|corticosteroid injection using TA 10mg/ml
218959419|NCT02290431|DRUG|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
218959420|NCT02290431|DRUG|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).
218959421|NCT02290431|DRUG|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)
218959422|NCT02556476|PROCEDURE|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
218959423|NCT02556476|PROCEDURE|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
218959424|NCT02556476|PROCEDURE|renal replacement therapy|the procedures used to treat acute kidney injury
219060730|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
219060731|NCT05676411|DRUG|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
219060732|NCT05676411|PROCEDURE|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
219642193|NCT04678154|DRUG|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
219642194|NCT06665451|OTHER|Non coated dental implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by non coated immediate implant .
219642195|NCT06665451|OTHER|Erythropoietin gel coated implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by immediate implant coated by erythropoietin gel.
219642196|NCT05334342|DIETARY_SUPPLEMENT|Low-GI Diet|Participants will be given a low glycemic index diet
219642197|NCT05334342|DIETARY_SUPPLEMENT|High-GI Diet|Participants will be given a high glycemic index diet
219642198|NCT01014988|DRUG|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
219642199|NCT00882778|DRUG|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
219642200|NCT03604393|BEHAVIORAL|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
219642201|NCT06682611|DRUG|SYHA1813|In accordance with the protocol
219642202|NCT06682611|DRUG|SG001|In accordance with the protocol
219642203|NCT06682611|DRUG|HB1801|In accordance with the protocol
219642204|NCT06682611|DRUG|Carboplatin|In accordance with the protocol
219642205|NCT06682611|DRUG|Cisplatin|In accordance with the protocol
219642206|NCT06682611|DRUG|Paclitaxel|In accordance with the protocol
219642207|NCT06682611|DRUG|Etoposide|In accordance with the protocol
219642208|NCT06682611|DRUG|Everolimus|In accordance with the protocol
219642209|NCT06682611|DRUG|Regorafenib|In accordance with the protocol
219642210|NCT02880878|PROCEDURE|Early Surgical Hematoma Evacuation|Early Minimally Invasive Parafascicular Surgery (MIPS)
219642211|NCT05631093|DRUG|ART|Standard of care ART, per approved product list, taken orally
219642212|NCT05631093|DRUG|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
219642213|NCT00986128|DRUG|topiramate|100 mg tablet twice daily for 3 weeks
219642214|NCT00986128|DRUG|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
218959425|NCT02556476|PROCEDURE|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
218959426|NCT00432601|BEHAVIORAL|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
218959427|NCT04308811|BIOLOGICAL|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
218959428|NCT04308811|COMBINATION_PRODUCT|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
218959429|NCT04308811|DEVICE|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
219060733|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
219060734|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
219060735|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
219060736|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
219642215|NCT01683266|DRUG|HOE901-U300 (Insulin glargine new formulation)|
219642216|NCT01683266|DRUG|Lantus (Insulin glargine)|
219642217|NCT03766165|BEHAVIORAL|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
219642218|NCT03766165|BEHAVIORAL|Control|Participants will receive job announcements only.
219642219|NCT06532812|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
219642220|NCT06532812|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219642221|NCT06532812|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219642222|NCT06532812|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
219642223|NCT06532812|DRUG|Pembrolizumab|Intravenous (IV) infusion
219642224|NCT06220981|OTHER|Endovascular treatment|
219642225|NCT04001218|DRUG|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
219642226|NCT04001218|DRUG|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
218959430|NCT03528395|OTHER|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
218959431|NCT03528395|OTHER|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
218959432|NCT00821327|DRUG|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2\. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3\. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
218959433|NCT03986762|DRUG|Clavulanic Acid|\~10 days of Clavulanic Acid
218959434|NCT03122301|DRUG|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
219060737|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
219060738|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
219060739|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
219060740|NCT05436574|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
219060741|NCT02798198|OTHER|T2DM|T2DM without DKD
219642227|NCT00000818|DRUG|Zidovudine|
219642228|NCT00756236|DRUG|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
219642229|NCT00756236|DRUG|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
219642230|NCT00756236|DRUG|P-Group|0.9%NaCl dispensed in 60ml \& 5ml syringes
219642231|NCT00210197|PROCEDURE|Blood collection (pre and postoperative): plasma coagulation parameters|
219642232|NCT05269173|DRUG|Flos gossypii flavonoids tablet|The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
218959435|NCT03122301|DRUG|Saline|sham injection with saline
218959436|NCT03960021|RADIATION|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
218959437|NCT02555280|DEVICE|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
219060742|NCT02206529|BEHAVIORAL|Social Network Engagement+Std Treatment|
219060743|NCT02206529|BEHAVIORAL|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
219642233|NCT00200174|DRUG|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
219642234|NCT00200174|DRUG|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
219642235|NCT02102620|DRUG|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
219642236|NCT02102620|DRUG|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
219642237|NCT01337492|DRUG|Nexavar|400 mg of Sorafenib
219642238|NCT06294366|DEVICE|Bipolar Bowa device|Bipolar Bowa device used in prostatic resection and enucleation
219642239|NCT06284057|PROCEDURE|Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte|Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.
219060744|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
219642240|NCT01867710|DRUG|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
219642241|NCT01867710|DRUG|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
218959438|NCT02555280|PROCEDURE|Decompression|Decompression alone
218959439|NCT03924271|DIAGNOSTIC_TEST|Iron deficiency testing|Blood sample for complete iron status
219642242|NCT01867710|DRUG|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
219642243|NCT01867710|DRUG|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
219642244|NCT01867710|DRUG|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
219642245|NCT06160895|DRUG|TQ-A3334 tablets|TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
219642246|NCT06160895|DRUG|TQ-A3334 placebo tablets|TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
219642247|NCT05712213|PROCEDURE|Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.
219642248|NCT05712213|PROCEDURE|Standard intraperitoneal onlay mesh repair (sIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
219642249|NCT01062113|DRUG|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
219642250|NCT01062113|DRUG|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
219642251|NCT01062113|DRUG|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
219642252|NCT03098238|BIOLOGICAL|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
219642253|NCT06598202|DRUG|exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).
219642254|NCT06598202|DRUG|a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes placebo
219642255|NCT02671084|DRUG|sevoflurane|compare effect of sevoflurane when administered before PCI
219642256|NCT05832502|DRUG|GBS6|The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).
218959440|NCT01281527|DRUG|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
218959441|NCT04983953|DEVICE|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
219642257|NCT05832502|DRUG|Placebo|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
219642258|NCT02675621|OTHER|Phenolic Beverage|
218959442|NCT01171833|DRUG|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
218959443|NCT01171833|DRUG|Desflurane|6.0 vol% prefilled in a corrugated circuit.
219642259|NCT02727790|DEVICE|Stimulator|
218959444|NCT01171833|DRUG|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
218959445|NCT04983303|OTHER|TICK-B group|These interventions will distract the child during venipuncture
218959446|NCT03559426|DRUG|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
218959447|NCT03559426|DRUG|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
218959448|NCT00459979|DRUG|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
218959449|NCT00459979|PROCEDURE|conventional surgery|nephrectomy
218959450|NCT02820701|PROCEDURE|OMT|Osteopathic Manipulative Treatment to low back region
218959451|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
219642260|NCT04270409|DRUG|Isatuximab SAR650984|Pharmaceutical for: Solution for infusion Route of administration: Intravenous
219642261|NCT04270409|DRUG|Lenalidomide|Pharmaceutical form: Capsules Route of administration: Oral
219642262|NCT04270409|DRUG|Dexamethasone|Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
219642263|NCT04270409|DRUG|Montelukast or equivalent|Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
219642264|NCT04270409|DRUG|Acetaminophen|AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
219642265|NCT04270409|DRUG|Diphenhydramine or equivalent|AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
219642266|NCT04270409|DRUG|Methylprednisolone or equivalent|AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
219642267|NCT06666985|DRUG|ITM + Usual Care|The participants allocated to this group will receive ITM (Intrathecal Morphine) in addition to usual care with opioid-based PCA(Patient-Controlled Analgesia). ITM consists of an intrathecal injection of 300 micrograms (0.3mg) of preservative-free morphine.Usual care involves postoperative analgesia with opioid-based PCA without postoperative continuous infusion of opioids. No other drugs other than opioids are allowed in the PCA.
219642268|NCT06666985|DRUG|Sham ITM + Usual Care|The sham ITM mimics the ITM procedure, but the dura is not breached.
219642269|NCT00595985|DRUG|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219642270|NCT05193344|DEVICE|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
219642271|NCT05193344|OTHER|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
219642272|NCT03999827|OTHER|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
219642273|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations BID
219642274|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
219642275|NCT01471340|DRUG|Mometasone Furoate MDI 100 mcg|two inhalations BID
219642276|NCT01471340|DRUG|Mometasone Furoate MDI 200 mcg|two inhalations BID
218959452|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
218959453|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
219642277|NCT01471340|DRUG|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
219642278|NCT01471340|DRUG|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
219642279|NCT03662191|DRUG|Tafamidis|bioavailability study
219642280|NCT01319474|OTHER|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
219642281|NCT06093048|PROCEDURE|Endoscopic retrograde cholangiopancreatography|saftey and outcome in patients older than 65 years old
219642282|NCT00059891|PROCEDURE|conventional surgery|
219642283|NCT00059891|PROCEDURE|management of therapy complications|
219642284|NCT02261948|DRUG|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
219642285|NCT02261948|DRUG|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
219642286|NCT03481101|DEVICE|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
219642287|NCT00526669|DRUG|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
219642288|NCT01782625|OTHER|NO exercise at depth|Subjects will NOT exercise while at depth
219642289|NCT01782625|OTHER|exercise at depth|Subjects will exercise while at depth
219642290|NCT00544323|DEVICE|oral implant|
218959454|NCT00219544|DRUG|Placebo|Placebo
218959455|NCT04456010|OTHER|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
219642291|NCT05975034|DIETARY_SUPPLEMENT|Probiotic|Probiotic taken daily for 12 weeks.
219060745|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
219642292|NCT05975034|DIETARY_SUPPLEMENT|Placebo|Placebo taken daily for 12 weeks.
219642293|NCT04259424|DEVICE|Aerobic Exercise + Duck Duck Punch|"Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session."
219642294|NCT05162625|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|Topical moxifloxacin 0,5% 01 drop every 3 hours
219642295|NCT05162625|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]|Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
219642296|NCT02300038|DRUG|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
219642297|NCT02300038|DIETARY_SUPPLEMENT|NaCl|perineuromally administration of NaCL
219642298|NCT01176149|BEHAVIORAL|SMBG plus intensive education|
219642299|NCT03499899|DRUG|LAG525|LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
219642300|NCT03499899|DRUG|PDR001|Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
219642301|NCT03499899|DRUG|Carboplatin|Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
219642302|NCT04647799|DEVICE|smartphone|Samsung A 71
219642303|NCT02033967|PROCEDURE|vasodilator induced hypovolemia|
219642304|NCT00905892|DIETARY_SUPPLEMENT|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
219642305|NCT01382472|DRUG|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
219642306|NCT01382472|DRUG|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
219642307|NCT00247650|DRUG|Zoledronic Acid; Letrozole|
219642308|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
219642309|NCT00166309|DRUG|FEIBA and NovoSeven|
219642310|NCT03408509|BEHAVIORAL|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
219642311|NCT03406585|DRUG|ProTrans: Allogeneic transplantation with WJMSCs|The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
219642312|NCT03406585|DRUG|Placebos|Placebo treatment
219642313|NCT06664385|OTHER|concurrent physical exercise|It consists of a periodization which consists of three moments adapted to the patient's needs distributed in 6 weeks and increasing the intensity gradually.
219642314|NCT06166407|OTHER|no intervention|no intervention
219642315|NCT00055653|BIOLOGICAL|anti-thymocyte globulin|
219642316|NCT00055653|BIOLOGICAL|filgrastim|
219642317|NCT00055653|DRUG|busulfan|
219642318|NCT00055653|DRUG|cyclophosphamide|
219642319|NCT00055653|DRUG|cyclosporine|
219642320|NCT00055653|DRUG|fludarabine phosphate|
219642321|NCT00055653|DRUG|melphalan|
219642322|NCT00055653|DRUG|methylprednisolone|
219642323|NCT00055653|PROCEDURE|umbilical cord blood transplantation|
219642324|NCT00055653|RADIATION|radiation therapy|
219642325|NCT06666595|PROCEDURE|Titanium dental implant (Conical SPI, Vitronix, Italy), Medical device that interfaces with the jawbone to support a dental prosthesis.|Placement of titanium dental implant to retain and support Kennedy class 1 removable partial denture (RPD).The implant fuses with the bone through a process called osseointegration.
219642326|NCT05887258|DRUG|Opioid free anesthesia|It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.
219642327|NCT05887258|DRUG|Opioid based Anesthesia|administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
218985186|NCT05827952|BEHAVIORAL|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
219060746|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
219060747|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
219642328|NCT03154463|PROCEDURE|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
219642329|NCT03154463|PROCEDURE|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
219642330|NCT06398496|BEHAVIORAL|Aerobic Exercise|Aerobic exercise intervention will involve multiple exercise sessions completed (unsupervised) by participants. Exercise programs will be given to participants, matched to their current level of fitness as determined via a maximal cardiorespiratory fitness test, and will be adjusted via progressive overload every 1-2 weeks by an exercise and sports science professional.
219642331|NCT01983943|DIETARY_SUPPLEMENT|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
219642332|NCT01983943|DIETARY_SUPPLEMENT|Placebo|A 40mg placebo will be taken once per day for 6 months.
219642333|NCT01983943|BEHAVIORAL|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
219642334|NCT01983943|DEVICE|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
219686089|NCT04420728|COMBINATION_PRODUCT|Early auto-mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
219686090|NCT04420728|COMBINATION_PRODUCT|Delayed auto mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
219642335|NCT03341143|DRUG|Fecal Microbiota Transplant with Pembrolizumab|"FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
219642336|NCT06233916|DRUG|[14C] D-1553|\[14C\] D-1553 (approximately 400 mg/80 μCi)
219642337|NCT01951612|BEHAVIORAL|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
219642338|NCT01951612|BEHAVIORAL|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
219060748|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
219642339|NCT00685724|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
219642340|NCT00685724|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
219642341|NCT05779033|BEHAVIORAL|scapular stabilization exercises|scapular stabilization exercises 3 times per week for 4 weeks.
219642342|NCT05779033|DEVICE|ultrasound|Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes
219642343|NCT05779033|OTHER|Kinesio Tape|"Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms)."
219642344|NCT06432075|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
219642345|NCT04024111|BEHAVIORAL|KONTAKT(c)|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes facilitated by two health professionals with experience of running groups for autistic children
219642346|NCT04024111|OTHER|Art group|Art program, a manualized Art group delivered in a social format, has been designed for children on the Autism Spectrum delivered by health professionals with experience of running social groups for Autistic children. The Art program's participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes.
219642347|NCT05529615|PROCEDURE|detection of ctDNA|the ctDNA will be detected during the treatment and served as the andomization basis
219642348|NCT03655093|OTHER|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
219642349|NCT01082211|RADIATION|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
219642350|NCT06684145|OTHER|Kinesiotape application|Kinesiotape application will be performed by a certified researcher using 5cm x 5cm kinesiotape material. The standing patient, prepared in terms of clothing and skin, will be asked to lean forward. While adhering the tape to the right paravertebral region, the lower end of the tape will be adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. The patient, still leaning forward, will be then asked to make a slight rotation to the left; in this position, the tape will be adhered upwards on the paravertebral muscles without any tension. For the left paravertebral region, the procedure will be reversed as compared to the right, ensuring that the tape was not stretched at all.
219642351|NCT06684145|OTHER|Exercise|Patients will be given a 30-day home exercise program. This consists of passive lumbar flexion (single and double leg stretching), hamstring stretching, pelvic tilt, half sit-up, bridge, straight leg raises, and hip and back extensor strengthening exercises.
219686091|NCT06347367|OTHER|Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)|Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
219060749|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
219060750|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
219060751|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
219060752|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
219060753|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
219642352|NCT06682195|DRUG|Neoadjuvant chemotherapy combined with Toripalimab|"1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment."
219642353|NCT06665412|DRUG|Radotinib Hydrochloride|200mg BID, every day up to 12months
219642354|NCT03834766|DRUG|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
219642355|NCT03834766|DRUG|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
219642356|NCT03702010|DEVICE|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
219642357|NCT03702010|DEVICE|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
219642358|NCT04623034|DRUG|Ademetionine|
219642359|NCT00059696|PROCEDURE|Constraint-Induced Movement Therapy|
219642360|NCT05713396|DRUG|Quinapril|Per os
219642361|NCT05713396|DRUG|Losartan|Per os
219642362|NCT05713396|DRUG|Quinapril + Losartan|Per os
219642363|NCT03753919|DRUG|Durvalumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
219642364|NCT03753919|DRUG|Tremelimumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
219642365|NCT06682819|DIAGNOSTIC_TEST|Optical coherent tomography|We compare the metabolomics profile of healthy patients based on the OCT appearance of the optic disc and RNFL
219642366|NCT00002641|BIOLOGICAL|filgrastim|
219642367|NCT00002641|DRUG|doxorubicin hydrochloride|
219642368|NCT00002641|DRUG|ifosfamide|
219642369|NCT00002641|DRUG|isolated perfusion|
219642370|NCT00002641|PROCEDURE|adjuvant therapy|
219642371|NCT00002641|PROCEDURE|conventional surgery|
219642372|NCT00002641|RADIATION|radiation therapy|
219642373|NCT05851313|COMBINATION_PRODUCT|Vitamin-D|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
219642374|NCT05127213|PROCEDURE|Intragastric balloon system|Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract
219642375|NCT05127213|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
219642376|NCT02866149|BIOLOGICAL|Blood sampling|Up to 5 blood samplings can be performed at different time points
219642377|NCT02866149|PROCEDURE|Tumor sampling|One tumor sampling can be performed, if applicable
219642378|NCT02866149|OTHER|Stool sampling|Up to 5 blood samplings can be performed at different time points
219642379|NCT03933618|DRUG|Anastrozole 1mg|
219060754|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
219642380|NCT03933618|DRUG|Clomiphene Citrate 25mg|
219642381|NCT03933618|DRUG|Placebo - Cap|
219642382|NCT01080118|DEVICE|Airtraq|Subjects were taught with the Airtraq video laryngoscope
219642383|NCT01080118|OTHER|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
219642384|NCT05283902|BIOLOGICAL|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
219642385|NCT00510913|DRUG|tacrolimus|
219642386|NCT06683690|PROCEDURE|Measurement of TGF- β1 in leprosy patients|Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
219642387|NCT01744379|DRUG|Lesinurad|
219642388|NCT01744379|DRUG|Placebo|
219642389|NCT01604980|DIETARY_SUPPLEMENT|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
219642390|NCT00312260|DRUG|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
219642391|NCT00312260|DRUG|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
219642392|NCT02740868|DRUG|Xenon-129 and Perfluoropropane (19F)|Xenon gas and perfluoropropane to be inhaled by research participants
219642393|NCT02740868|DEVICE|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
219060755|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
219642394|NCT02740868|DEVICE|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
219642395|NCT03572816|DEVICE|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
219642396|NCT03046316|OTHER|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
219642397|NCT02658955|PROCEDURE|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
219642398|NCT02721810|BEHAVIORAL|Consideration of 3-month functional prognosis|
219642399|NCT05971238|OTHER|Indoor vs. outdoor scenes|Light conditions in indoor (artificial light) and outdoor (daylight) settings
219642400|NCT06215989|DRUG|Colchicine Pill|Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
219642401|NCT06215989|DRUG|Placebo|Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
219642402|NCT06662461|PROCEDURE|ultrasound guided Greater occipital nerve block|"Patients will be positioned in a prone position with their neck slightly flexed.~The trapezius , semispinalis, obliqus capitis muscles will be revealed on short-axis view.~A 25- or 21 gauge is used, with puncture point 1-1.5 cm away from the ultrasound probe.~Under the guidance of the ultrasound, GOB will performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
219642403|NCT06662461|PROCEDURE|Ultrasound guided Stellate ganglion block|"Patients are positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment the C7 level is confirmed. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus collis muscle are revealed on this short-axis view.~A 25- or 21 gauge is used and the puncture point is 1-1.5 cm away from the ultrasound probe The tip of the needle reach the surface of the longus collis muscle and the 5 o'clock position of the carotid artery. Under the guidance of the ultrasound, SGB is performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
219642404|NCT03394898|OTHER|body mass index, eating behaviour|The patients' weights and heights will be measured and the body mass index will be calculated from the measured values.Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
219642405|NCT05160246|OTHER|kinesiology tape|The tape will be fixed without any tension 10 cm below the origin of the rectus femoris muscle. Then 35-50% tension will be applied to the band and descended to the patella. After this point, the Y-shaped band will be terminated to wrap the patella medially and laterally without any tension.
219642406|NCT05160246|OTHER|Placebo tape|The tape will attach to the rectus femoris without any tension.
219642407|NCT01946958|BEHAVIORAL|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
219642408|NCT01946958|OTHER|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
219642409|NCT04310605|BEHAVIORAL|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
218959456|NCT00505882|DRUG|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
218959457|NCT00505882|DRUG|Glargine|
218959458|NCT00505882|DRUG|Lispro|
218959459|NCT00505882|DRUG|Aspart|
218959460|NCT02655393|DIETARY_SUPPLEMENT|Mitopure|
218959461|NCT00625573|DRUG|Abraxane|100mg/m2 every week X's 3
219642410|NCT04310605|BEHAVIORAL|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
219642411|NCT04782453|BEHAVIORAL|ToQuit, a technology delivered tobacco cessation intervention|"The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~* Psychoeducation about consequences of tobacco use and benefits of quitting;~* goal setting;~* managing goals and self-monitoring of behavior;~* avoidance strategies;~* self-awareness and reflection messages;~* social and pharmacological support, and help-seeking;~* identifying and managing cravings;~* relapse prevention strategies."
219642412|NCT04782453|BEHAVIORAL|Tobacco quitting helplines|Participants from the control group will be sent the details of other functional tobacco helplines in India.
219642413|NCT03998644|OTHER||
219642414|NCT04286789|DRUG|Low dose ORTD-1|Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
219642415|NCT04286789|DRUG|Low dose vehicle control|Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
219642416|NCT04286789|DRUG|High dose ORTD-1|Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
219642417|NCT04286789|DRUG|High dose vehicle control|Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
218959462|NCT03920072|DRUG|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
219642418|NCT03492814|PROCEDURE|partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
219642419|NCT03492814|PROCEDURE|total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
219642420|NCT04287725|DEVICE|exercise + photobiomodulation therapy|Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
219642421|NCT06620536|DEVICE|Electrical stimulation|Electrical stimulation of peripheral nerves for the recovery of hand function in tetraplegic patients of fundamental importance in improving quality of life.
219642422|NCT06084819|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75mg/m2/day, days 1 to 7).~2. Cytarabine (75-100mg/m2 q12h, days 1 to 5).~3. Aclacinomycin(20mg/day, days 1,3,5).~4. Chidamide(30mg/day , days 1,4,8,11).~5. Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~6. Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
219642423|NCT06084819|DRUG|Best-Available Therapy(BAT) Regimen|"1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5)."
219642424|NCT02980419|BEHAVIORAL|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
219642425|NCT06967103|DRUG|QL1706|bispecific antibody targeting PD-1 and CLTA-4
218959463|NCT05130944|BEHAVIORAL|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
218959464|NCT05130944|BEHAVIORAL|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
218959465|NCT00056498|DRUG|Placebo|Placebo capsule daily for 16 weeks
218959466|NCT00056498|DRUG|Risperdal|Risperdal 4 mg per day for 16 weeks
218959467|NCT03385083|BEHAVIORAL|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
218959468|NCT03385083|BEHAVIORAL|Step count monitoring without consultation|Subject counseled on step counts at initial visit
218959469|NCT03385083|DEVICE|Fitbit tracker|Fitbit tracker given to participant
219642426|NCT06967103|DRUG|Nab-PE|Nab-paclitaxel+Epirubicin
219642427|NCT01146379|OTHER|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
219642428|NCT00222365|DRUG|Arnica montana, 5 CH|
219642429|NCT00222365|DRUG|Bryonia alba, 5 CH|
219642430|NCT00222365|DRUG|Hypericum perforatum, 5 CH|
219642431|NCT00222365|DRUG|Ruta graveolens, 3 DH|
219642432|NCT06560229|OTHER|Grocery gift card|Monthly $100 grocery gift cards for 12 months
219642433|NCT03637140|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
219642434|NCT03637140|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
219642435|NCT04079192|DEVICE|Biolimus A9 Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
219642436|NCT04079192|DEVICE|SeQuent Please Paclitaxel Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
219642437|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A supplements
219642438|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
219642439|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
219642440|NCT02394340|DRUG|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
218959470|NCT05760118|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
219642441|NCT02394340|DRUG|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
219642442|NCT04169048|BEHAVIORAL|Group training for mothers with Borderline Personality Disorder|The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
219642443|NCT06665230|DRUG|MK-6552|Oral administration
219642444|NCT06665230|DRUG|Modafinil|Oral administration
219642445|NCT01183208|DRUG|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
219642446|NCT01183208|DRUG|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
219642447|NCT01183208|DRUG|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
219642448|NCT01183208|DRUG|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
219642449|NCT01183208|DRUG|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
219642450|NCT01590121|OTHER|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
219642451|NCT01590121|OTHER|Questionnaire|Flight by aeroplane (previous)
219642452|NCT03589638|DEVICE|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
219642453|NCT03589638|DEVICE|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
219642454|NCT03589638|DEVICE|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
219642455|NCT01010295|DRUG|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
218959471|NCT05371171|PROCEDURE|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
219642456|NCT06967428|COMBINATION_PRODUCT|Combined metabolic modulator|This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to support energy metabolism.
219642457|NCT06967428|DIETARY_SUPPLEMENT|Rice Protein Powder with Vitamin C|Rice Protein Powder (39g) with Vitamin C (1g) daily
219642458|NCT04457102|DEVICE|MANIV|mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac
219642459|NCT04457102|OTHER|Spontaneous DIBH|performed on Varian® Halcyon LINAC and Infinity Elekta® linac
219223670|NCT07014293|OTHER|Enhanced Usual Care|Participants will receive a singleevaluation with a site social worker along with a list of mental health, social or community resources . This most closely resembles the real-world care available to survivors on an outpatient basis, however, we call this enhanced usual care since proactive identification and referral of posttreatment survivors is not routinely done.
219642460|NCT03957603|DIETARY_SUPPLEMENT|Enteral Nutrition Suspension (TFP-DM)|Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
219642461|NCT03957603|BEHAVIORAL|Medical Nutrition Therpay|Individualized dietary and lifestyle intervention
219642462|NCT01873456|OTHER|multifactorial nutritional intervention|
219642463|NCT05503602|OTHER|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
219642464|NCT05503602|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
219642465|NCT05503602|OTHER|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
219642466|NCT02004886|DRUG|MK-0893|10 mg and 100 mg tablets
219642467|NCT02004886|DRUG|Metformin|500 mg metformin tablets
219642468|NCT02004886|DRUG|Placebo|Placebo tablets matching MK-0893
219642469|NCT02004886|DRUG|Placebo|Placebo tablets matching metformin
219642470|NCT03474016|DIAGNOSTIC_TEST|Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction|Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
218959472|NCT05371171|PROCEDURE|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
218959473|NCT00423748|DRUG|ambrisentan|
218959474|NCT06302738|DIAGNOSTIC_TEST|polysomnography|patients will undergo a home sleep study to evaluate the presence of sleep disorders
218959475|NCT01007253|DRUG|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
218959476|NCT01007253|DRUG|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
219060756|NCT05360524|PROCEDURE|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
219060757|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
219642471|NCT00733239|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
219642472|NCT03265821|PROCEDURE|Healing after treatment|
219642473|NCT04150484|OTHER|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
219642474|NCT06437821|DIAGNOSTIC_TEST|Petrissage|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
219642475|NCT06437821|OTHER|Graston Technique|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
219642476|NCT01876784|DRUG|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
219642477|NCT01876784|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219642478|NCT03425578|DIETARY_SUPPLEMENT|MSG|150 mg/kg body mass monosodium glutamate (MSG).
219642479|NCT03425578|DIETARY_SUPPLEMENT|CHO|75g CHO (i.e. dextrose)
219642480|NCT03425578|DIETARY_SUPPLEMENT|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
219642481|NCT03425578|DIETARY_SUPPLEMENT|Placebo B|A non-caloric placebo composed of flavoured water.
219642482|NCT03605862|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
219060758|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
219060759|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
219060760|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
219060761|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
219642483|NCT03605862|DRUG|Placebo|Placebo administered orally twice daily for five days
219642484|NCT05239494|DEVICE|DT1 Sphere Contact Lenses|Devices: Dailies Total 1 Sphere Contact Lenses
219642485|NCT03891862|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219642486|NCT03891862|DRUG|Placebo oral capsule|non-active dosage form
219642487|NCT01194531|DEVICE|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
219642488|NCT00818467|OTHER|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
219642489|NCT00818467|OTHER|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
218959477|NCT01007253|DRUG|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
218959478|NCT01007253|DRUG|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
218959479|NCT00576212|BEHAVIORAL|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
218959480|NCT02689687|BEHAVIORAL|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
218959481|NCT02689687|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
219060762|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
219060763|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
219642490|NCT03250767|DEVICE|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
219642491|NCT03322774|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
218959482|NCT02689687|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
218959483|NCT02689687|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
218959484|NCT03932968|PROCEDURE|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
218959485|NCT00084461|DRUG|romidepsin|Given IV
218959486|NCT00084461|OTHER|laboratory biomarker analysis|Correlative studies
219060764|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
219060765|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
219060766|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
219060767|NCT01912248|OTHER|strength training|strength training, lower limb.
219642492|NCT03322774|BEHAVIORAL|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
219642493|NCT03322774|BEHAVIORAL|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
219642494|NCT01531530|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
219060768|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
219060769|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
219642495|NCT01531530|OTHER|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
219642496|NCT02370589|BIOLOGICAL|Base Dose EBOV GP Vaccine|
219642497|NCT02370589|BIOLOGICAL|2x Base Dose EBOV GP Vaccine|
219642498|NCT02370589|BIOLOGICAL|4x Base Dose EBOV GP Vaccine|
219642499|NCT02370589|BIOLOGICAL|8x Base Dose EBOV GP Vaccine|
218959487|NCT03492775|DRUG|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
218959488|NCT03492775|DRUG|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
218959489|NCT01575886|OTHER|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
218959490|NCT00814801|DRUG|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
219642500|NCT02370589|BIOLOGICAL|Placebo|
219642501|NCT02370589|BIOLOGICAL|Matrix-M Adjuvant|
219642502|NCT01053962|DRUG|SP-304 0.3 mg|SP-304 0.3 mg
219642503|NCT01053962|DRUG|SP-304 1.0 mg|SP-304 1.0 mg
219642504|NCT01053962|DRUG|SP-304 3.0 mg|SP-304 3.0 mg
219642505|NCT01053962|DRUG|SP-304 9.0 mg|SP-304 9.0 mg
219642506|NCT01053962|DRUG|Placebo|Placebo
219060770|NCT00424905|DRUG|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
219642507|NCT05763394|OTHER|Polarized workout program|Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.
219642508|NCT05763394|OTHER|High intensity workout program|High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
219642509|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
219642510|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
219642511|NCT03928262|BIOLOGICAL|Benralizumab|Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
219642512|NCT02772874|OTHER|No intervention|No intervention
219642513|NCT04303026|DRUG|Zoledronic Acid|5mg IV infusion
219642514|NCT04303026|DRUG|Saline 0.9%|Placebo Group. Saline 0.9% 100 ml infusion
219642515|NCT03247465|OTHER|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
219642516|NCT03269617|DIETARY_SUPPLEMENT|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
219642517|NCT03269617|OTHER|Placebo Control|Placebo control capsule consisting of rice maltodextrin
219642518|NCT02012842|OTHER|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
219642519|NCT02966678|PROCEDURE|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
219642520|NCT01329809|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
219642521|NCT03360409|PROCEDURE|ACD|Undertake anterior cervical discectomy without fusion
219642522|NCT03360409|PROCEDURE|ACDF|anterior cervical discectomy with fusion
219642523|NCT03360409|PROCEDURE|ACDA|anterior cervical discectomy with arthroplasty
219642524|NCT05785585|DIETARY_SUPPLEMENT|Methylcobalamin|Treatment with Methylcobalamin during 12 weeks
219642525|NCT05785585|DIETARY_SUPPLEMENT|Cyanocobalamin group|Treatment with Cyanocobalamin during 12 weeks
219642526|NCT05785585|DIETARY_SUPPLEMENT|Control group|Treatment with microcrystalline cellulose during 12 weeks
219642527|NCT04871061|PROCEDURE|PENG Block|Pericapsular Nerve Group Block
219642528|NCT04871061|DRUG|Conventional opioid analgesia (Fentanyl)|standardised intravenous opioid
219642529|NCT02648893|OTHER|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
219642530|NCT02648893|OTHER|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
219642531|NCT01747889|DEVICE|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
219642532|NCT03212092|DIETARY_SUPPLEMENT|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
218959491|NCT00814801|DRUG|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
219642533|NCT03212092|DIETARY_SUPPLEMENT|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
218959492|NCT00814801|DRUG|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
218959493|NCT00586664|DRUG|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
218959494|NCT00586664|DRUG|placebo comparator|sterile ophthalmic solution
218959495|NCT00586664|DRUG|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
218985187|NCT03641404|DRUG|L-ergothioneine|Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.
218985188|NCT03641404|DRUG|Placebo|Placebo. Study control (99% microcrystalline cellulose, 1% magnesium stearate)
218985189|NCT01734863|RADIATION|External Beam Radiotherapy|
218985190|NCT06129422|DRUG|NMK89|Route of administration: intravenous infusion
218985191|NCT03019185|DRUG|Placebo Oral Capsule|Capsule containing an inert placebo
219642534|NCT03431025|DEVICE|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
219642535|NCT02657057|DEVICE|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
219642536|NCT02657057|DEVICE|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
219642537|NCT05104216|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
219642538|NCT03898479|DRUG|CTP-543|Twice daily dosing
219642539|NCT02410798|DEVICE|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
219642540|NCT03740555|DRUG|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
219642541|NCT03740555|DRUG|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose, matching placebo
219642542|NCT03740555|DRUG|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg
219642543|NCT03740555|DRUG|Placebo multiple ascending doses|Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
219642544|NCT05122910|BEHAVIORAL|Stress Management and Resilience Training - Moral Resilience (SMART-MR) program|All participants will attend an initial 2.5 hour workshop and a 1-hour follow-up workshop. The workshop will include general resilience strategies with a focus on the moral/ethical dimensions of clinical practice to offer participants specific skills to address ethical challenges. In addition to the workshops, there will be follow-up supplemental resources.
219642545|NCT01858779|BEHAVIORAL|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
219642546|NCT01858779|DEVICE|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
219642547|NCT00004638|PROCEDURE|pathogenesis study|
219642548|NCT06648174|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear."
219642549|NCT06648174|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.
219642550|NCT06648174|OTHER|Blood glucose meters (BGM)|Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.
219642551|NCT03835624|DIAGNOSTIC_TEST|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
219642552|NCT06681948|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
219642553|NCT06681948|DIETARY_SUPPLEMENT|placebo|placebo
219642554|NCT03884517|DRUG|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
219642555|NCT01894100|DEVICE|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
219642556|NCT05236738|DRUG|Atazanavir|Specified dose on specified days
219642557|NCT05236738|DRUG|Cobicistat|Specified dose on specified days
219642558|NCT05236738|DRUG|Atazanavir/Cobicistat Mini-tablet|Specified dose on specified days
219642559|NCT00000743|DRUG|Alvircept sudotox|
219642560|NCT00000743|DRUG|Zidovudine|
219642561|NCT06044350|DRUG|BAT4406F Injection|Intravenous infusion; Dosage:500mg/time
219642562|NCT06044350|DRUG|BAT4406F Placebos|Intravenous infusion; Dosage:500mg/time
219642563|NCT03857386|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance
218985192|NCT03019185|DRUG|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
219642564|NCT03857386|PROCEDURE|Control group|Local infiltration anesthesia performed during the operation
219642565|NCT01094301|DEVICE|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
219642566|NCT06459414|OTHER|: Oropharyngeal Administration Of Colostrum|Preterm less than 34 weeks gestation will receive Oropharyngeal Colostrum for 3 days ( the first group) and for 10 days( the second group)
219642567|NCT05754762|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the etomidate injection
219642568|NCT02357160|BEHAVIORAL|Artwork|Prints by local artists that are hung on the walls of patient rooms.
219642569|NCT05283980|DRUG|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
218985193|NCT05578326|DRUG|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
218985194|NCT05578326|DRUG|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
218985195|NCT05880862|BEHAVIORAL|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
218985196|NCT05880862|DRUG|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
218985197|NCT05880862|DRUG|Trospium Chloride|A 12-week course of Trospium XL -extended release, 60mg once daily.
219060771|NCT00836875|DRUG|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
219060772|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
219060773|NCT00273403|BEHAVIORAL|Access to Care Services|
219642570|NCT05700175|DIAGNOSTIC_TEST|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA\_MFS\_signature).~The obtained TAA\_MFS\_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
219642571|NCT04218656|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
219642572|NCT02235077|DRUG|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
219642573|NCT02235077|DRUG|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
219642574|NCT01232686|OTHER|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
219642575|NCT06044636|OTHER|Digi-physical breastfeeding support|"* Breastfeeding support after birth is provided via chat~* Extended home visits by a pediatric nurse after discharge from the maternity ward~* Extra support from a lactation counselor when needed after discharge until one year after childbirth"
219642576|NCT01455532|DRUG|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219642577|NCT01455532|DRUG|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219642578|NCT01455532|DRUG|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219642579|NCT01455532|DRUG|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219642580|NCT01455532|DRUG|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
219642581|NCT05476250|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
219642582|NCT00004642|DRUG|SDZ MSL-109|
219642583|NCT04674917|OTHER|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
219642584|NCT04674917|OTHER|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
219642585|NCT04674917|OTHER|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
219060774|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
219060775|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
219642586|NCT01209585|OTHER|Blood samples|Subjects will have visits on Days 1, 30 and 120.
219642587|NCT01209585|OTHER|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
219642588|NCT01209585|OTHER|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
219642589|NCT04013672|DRUG|Pembrolizumab|200 mg IV every 3 weeks
219642590|NCT04013672|DRUG|SurVaxM|500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
219060776|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
219060777|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
219060778|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
219060779|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
219642591|NCT04013672|DRUG|Sargramostim|100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
219642592|NCT04013672|DRUG|Montanide ISA 51|1 ml per dose dosed every two weeks for 4 doses and then every 3 months
219642593|NCT02078440|DRUG|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
219642594|NCT06744582|OTHER|VO2 max|The aim of this study is to generate data on the estimation of natural variation in VO2 max changes before and after surgery using seismocardiography.
219642595|NCT06383910|BEHAVIORAL|Square Stepping Exercise|The exercise is performed on a thin exercise mat divided into 40 small squares. Participants are shown specific step patterns on this mat and are instructed to repeat the same step pattern until the end of the exercise mat. Once a pattern is completed on the exercise mat, its mirror-image pattern is also performed. The basic pattern is repeated 3-5 times, followed by the same number of repetitions for the mirror-image pattern. However, if participants struggle with the pattern, it is repeated until they learn it. Individuals execute the demonstrated pattern on the exercise mat and return to the beginning of the mat after completing it.
219642596|NCT01157104|DRUG|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
219642597|NCT01157104|DRUG|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
219642598|NCT01157104|DRUG|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
219642599|NCT01157104|DRUG|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
219642600|NCT00586820|DRUG|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
219642601|NCT00586820|DRUG|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
219642602|NCT03198312|DEVICE|CathiportTM|fully implanted
219642603|NCT03198312|DEVICE|Implant Port|fully implanted
219642604|NCT01976429|OTHER|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
219642605|NCT01976429|OTHER|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
219642606|NCT01976429|OTHER|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
219642607|NCT03887442|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
219642608|NCT03887442|DRUG|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
219642609|NCT00385047|BIOLOGICAL|Group A FMP2.1/AS01B|
219642610|NCT00385047|BIOLOGICAL|Group B FMP2.1/AS02A|
219642611|NCT03773029|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 capsules)
219642612|NCT03773029|OTHER|placebo|2 capsules of placebo
219642613|NCT01283451|BEHAVIORAL|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
219642614|NCT03620305|OTHER|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
219642615|NCT03616574|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
219642616|NCT03616574|DRUG|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
219642617|NCT01868022|DRUG|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
219642618|NCT01868022|DRUG|paclitaxel|paclitaxel will be from commercial stock.
219642619|NCT01868022|DRUG|carboplatin|carboplatin will be from commercial stock.
219642620|NCT01868022|DRUG|docetaxel|docetaxel will be from commercial stock.
219060780|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
219642621|NCT01868022|DRUG|pemetrexed|pemetrexed will be from commercial stock
219642622|NCT01868022|DRUG|cisplatin|cisplatin will be from commercial stock
219686092|NCT06347367|OTHER|Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)|İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
218959496|NCT02751931|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight \>=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became \>=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
218959497|NCT02677311|PROCEDURE|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
218959498|NCT02677311|PROCEDURE|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
219642623|NCT01628198|DEVICE|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
219642624|NCT01991509|BIOLOGICAL|LBR-101 IV|LBR-101 Administered Intravenously
219642625|NCT01991509|BIOLOGICAL|LBR-101 SC|LBR-101 Administered Subcutaneously
219642626|NCT02792543|DEVICE|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
219642627|NCT02792543|DRUG|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
219642628|NCT02693028|DRUG|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
219642629|NCT02693028|DRUG|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
219642630|NCT02693028|DRUG|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
219642631|NCT02693028|DRUG|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
219642632|NCT02693028|DRUG|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
219642633|NCT06401473|BEHAVIORAL|Ipsilateral Scratch Task|Patients scratch the skin within the relevant cervical dermatome, ipsilateral to the injection site
219642634|NCT06401473|BEHAVIORAL|Motor Distraction Task|Patients scratch the skin of the shoulder/neck contralateral to the injection site
218959499|NCT01037088|DRUG|Mild dose cannabis|3.53% THC by weight
218959500|NCT01037088|DRUG|Low dose cannabis|1.29% THC by weight
218959501|NCT01037088|DRUG|Cannabis|0.00% THC by weight
218959502|NCT01042782|DRUG|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
218959503|NCT00355277|DRUG|Amitriptyline|
218959504|NCT02002585|PROCEDURE|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
219642635|NCT04450277|PROCEDURE|Emergency surgery|Emergency surgery vs conservative management
219642636|NCT02429661|BEHAVIORAL|Peer support groups|
219642637|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
219642638|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
219642639|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
219642640|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
218959505|NCT03734484|DIAGNOSTIC_TEST|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
218959506|NCT04183751|OTHER|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
219642641|NCT06406907|OTHER|Control Group|"The subjects of this group will perform squat exercise 6 days a week but without BFR. Pneumatic cuff will be wrapped around the thigh of the subjects but it would not be inflated.~Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
218959507|NCT04647890|DRUG|FT011|Two x 100mg capsules once daily for 12 weeks
219642642|NCT03636971|DRUG|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
219642643|NCT03636971|DRUG|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
219642644|NCT03636971|DRUG|Placebos|single shot injection of saline, same volume
218959508|NCT04647890|DRUG|FT011|Two x 200mg capsules once daily for 12 weeks
219642645|NCT03324347|PROCEDURE|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
219642646|NCT00541411|DRUG|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
219642647|NCT06416891|DRUG|bupivacaine 0.25%|SCPB using 10 ml of bupivacaine 0.25%
219642648|NCT06416891|DRUG|dexamethasone 2 mg in bupivacaine 0.25%|SCPB using dexamethasone 2 mg in 10 ml of bupivacaine 0.25%
219642649|NCT06240273|DIETARY_SUPPLEMENT|Corn silk powder|Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.
219642650|NCT03759015|BEHAVIORAL|Health education|All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
219642651|NCT05566704|DEVICE|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
218959509|NCT04647890|DRUG|Placebo|Two placebo capsules once daily for 12 weeks
219060781|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
219060782|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
219060783|NCT06661980|OTHER|Placebo|Normal Saline IV.
219060784|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
219060785|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
219060786|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
219642652|NCT06479967|OTHER|The VR glasses group|"The Virtual Reality glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon"
219642653|NCT06479967|OTHER|the music group|The music group listened to classical piano \&#34;The Best of Chopin.\&#34; After the music group took a 1-minute break from listening to music, and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10.
219686093|NCT05922644|DEVICE|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
219686094|NCT05922644|OTHER|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
219686095|NCT02420535|BEHAVIORAL|Immediately Receive Tool|
219686096|NCT02420535|BEHAVIORAL|One Month Delay|
219686097|NCT01447407|BIOLOGICAL|NDV-3 vaccine with alum IM|One dose administered IM
219686098|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum IM|One dose administered IM
218959510|NCT05582954|BEHAVIORAL|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
218959511|NCT05582954|BEHAVIORAL|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
219686099|NCT01447407|BIOLOGICAL|Placebo with alum IM|One dose administered ID
219060787|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
219060788|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
219060789|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
218959512|NCT06579391|DIETARY_SUPPLEMENT|Essential amino acids|Twice daily consumption for two weeks before and one week after surgery.
218959513|NCT06579391|DIETARY_SUPPLEMENT|Alanine|Twice daily consumption for two weeks before and one week after surgery.
218959514|NCT06246279|BEHAVIORAL|Adaptation to Adolescence and Type 1 Diabetes Management Training Program|The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
218959515|NCT02414503|DRUG|8IU intranasal oxytocin|
218959516|NCT02414503|DRUG|24IU intranasal oxytocin|
218959517|NCT02414503|DRUG|Placebo|
218959518|NCT02414503|DEVICE|OptiNose Breath Powered Bi|
218959519|NCT00025805|DRUG|G-CSF|
218959520|NCT00958490|OTHER|Walking program|4 week physical activity walking program
219060790|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
219060791|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
219060792|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
219642654|NCT03953495|BEHAVIORAL|Better Together|The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
219642655|NCT05607680|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
219642656|NCT05607680|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219642657|NCT03892382|DEVICE|rTMS|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
219642658|NCT03799692|DRUG|Chemotherapy|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15."
219642659|NCT01659593|OTHER|procog|3 to 5 people group program
218959521|NCT01731184|DRUG|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
218959522|NCT05557318|DEVICE|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
218959523|NCT05557318|DEVICE|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
218959524|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
218959525|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
218959526|NCT02866851|OTHER|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
218959527|NCT05337033|DRUG|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
218959528|NCT02785237|DEVICE|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
218959529|NCT02785237|DEVICE|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
218959530|NCT03787043|DRUG|FDC(MP-513 10mg/Metformin XR 750mg)|
218959531|NCT05048069|DRUG|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
219060793|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
219642660|NCT01659593|OTHER|Placebo|
219686100|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum ID|One dose administered ID
219642661|NCT05550454|DEVICE|Automatic Mechanical Ventilation|"Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 \~ 1,000 ml"
219642662|NCT05550454|DEVICE|Manual Ventilation|Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
219642663|NCT03491046|DEVICE|PET scan|low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
219642664|NCT03491046|DEVICE|MRI scan|standard of care MRI
219642665|NCT02122887|BEHAVIORAL|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
219642666|NCT05175664|OTHER|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
219642667|NCT05175664|OTHER|Short-term study|No intervention. Investigations: blood samples and pupillometry.
219642668|NCT05175664|OTHER|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
219642669|NCT04321174|DRUG|Lopinavir/ritonavir|The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
219642670|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
219642671|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
219642672|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
219642673|NCT01809301|DRUG|Niaspan|
219642674|NCT01809301|DRUG|TRIA-662|
219642675|NCT06946914|DRUG|Misoprostol|administration of 100mg of misoprostol to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.
219642676|NCT00880854|DRUG|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
219642677|NCT04383938|DRUG|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
219642678|NCT04181515|DRUG|Placebo oral tablet|placebo stressor
219642679|NCT04181515|DRUG|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
219642680|NCT04181515|DEVICE|sham rTMS|sham rTMS (inactive coil)
219642681|NCT04181515|DEVICE|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
219642682|NCT05164640|OTHER|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
219642683|NCT00972816|BIOLOGICAL|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
219642684|NCT05839652|DRUG|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
219642685|NCT03916367|RADIATION|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
219642686|NCT02615015|OTHER|Blood draw|
219642687|NCT02533557|DEVICE|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
218959532|NCT01967381|DRUG|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
219642688|NCT02533557|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
219642689|NCT02958358|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
219642690|NCT02358525|BEHAVIORAL|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
218959533|NCT04278274|PROCEDURE|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
219060794|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
219642691|NCT00801281|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
219642692|NCT00801281|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
218959534|NCT04278274|PROCEDURE|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
218959535|NCT03907839|OTHER|clinical trials|examined two type of training on cognitive parameters for COPD patients
218959536|NCT00004190|DRUG|gemcitabine hydrochloride|
218959537|NCT00004190|DRUG|oxaliplatin|
218959538|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
218959539|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 2|High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
218959540|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 1|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
219060795|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
219060796|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
219642693|NCT00801281|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
219642694|NCT00801281|DRUG|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
219642695|NCT00801281|DRUG|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
219642696|NCT00801281|DRUG|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
219642697|NCT00878566|OTHER|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
219642698|NCT00878566|OTHER|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
219642699|NCT03147079|BEHAVIORAL|Lifestyle intervention|
219642700|NCT05713669|BEHAVIORAL|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
219642701|NCT05713669|BEHAVIORAL|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
219642702|NCT03490461|DRUG|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
218959541|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 2|Addition of a 3rd dose, TBD depending on outcome of Part A
218959542|NCT05599776|OTHER|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
219060797|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
219060798|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
219642703|NCT05233748|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
218959543|NCT02555241|BEHAVIORAL|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
218959544|NCT02555241|BEHAVIORAL|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
219060799|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
219060800|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
219060801|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
219642704|NCT01105078|PROCEDURE|Flow rate|Different flow rate during cardiopulmonary bypass
219642705|NCT06010693|DRUG|Daridorexant|Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
219642706|NCT06010693|DRUG|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
219642707|NCT00811811|BEHAVIORAL|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
219642708|NCT00811811|BEHAVIORAL|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
219642709|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
219642710|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270/single RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
218959545|NCT02555241|BEHAVIORAL|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
218959546|NCT01015001|PROCEDURE|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
218959547|NCT01015001|PROCEDURE|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
219642711|NCT06086145|OTHER|No intervention|No intervention
219642712|NCT03448575|OTHER|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
219642713|NCT03448575|OTHER|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
219642714|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
219642715|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 0.25 mg/kg
219642716|NCT04183153|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
219642717|NCT04677751|DEVICE|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
219642718|NCT06667349|DRUG|Ticagrelor|Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
219642719|NCT06395506|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
219642720|NCT01953601|DRUG|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
219642721|NCT01953601|DRUG|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
219642722|NCT01953601|OTHER|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
219642723|NCT03473639|DRUG|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
219642724|NCT03473639|DRUG|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
219642725|NCT06667492|DEVICE|Traction Dynamometry|K-Pull dynamometer (Model MP.09.02.FN, Kinvent, Montpellier, France) is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions. This instrument will be used to evaluate isometric activity (maximum and average torque values) of the hip and knee flexors and extensors at specific joint angles.
218959548|NCT01015001|PROCEDURE|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
218959549|NCT05024643|PROCEDURE|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
218959550|NCT00817479|DRUG|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
218959551|NCT00817479|DRUG|Placebo|Placebo saline
218959552|NCT04319679|DEVICE|Extracorporeal shockwave therapy|6 times during 2 weeks
218959553|NCT04319679|DEVICE|Sham therapy|6 times during 2 weeks
218959554|NCT02276573|BIOLOGICAL|buccal cavity sample|
219060802|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
219060803|NCT07052539|OTHER|High protein and sodium meal|Meal with 1g/kg protein content and 3900mg sodium
218959555|NCT03767595|DEVICE|ProACT Adjustable Continence Therapy for Men|The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
218959556|NCT02005289|BIOLOGICAL|MOR00208|Given by IV infusion
218959557|NCT02005289|DRUG|lenalidomide|Given PO
218959558|NCT02005289|OTHER|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
218959559|NCT05652348|OTHER|Establishment of organoid cultures and in vitro sensitivity testing|Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.
218959560|NCT05539703|OTHER|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
219642726|NCT02837939|DRUG|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month"
219642727|NCT02837939|DRUG|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~* 3 doses in first week: day 1,3,5~* 2 doses in week 2: day 8 , 11~* 1 dose in week 3 and 4 : day 15, 22~* 1 dose once a month up to 6 month"
219642728|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
219642729|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
219642730|NCT02230696|DRUG|Placebo nasal spray|Placebo nasal spray
219642731|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
219642732|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
219642733|NCT03005275|OTHER|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
219642734|NCT03005275|OTHER|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
219642735|NCT03425409|DEVICE|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
219642736|NCT03425409|DEVICE|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
219642737|NCT05441111|BEHAVIORAL|Common Elements Toolbox|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities"
219642738|NCT05441111|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
219642739|NCT05441111|BEHAVIORAL|Guided self-help|"Participants in the guided self-help condition are assigned an eCoach who provides emotional support as well as who promote adherence to the intervention"
219642740|NCT06191328|DRUG|Chiglitazar sodium|In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
219642741|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
219642742|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension Placebo|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
219642743|NCT00270153|DRUG|enalapril|5mg enalapril daily for 6 months
219642744|NCT00270153|DRUG|Placebo|5mg enalapril-matching placebo daily for 6 months
219642745|NCT05800197|DRUG|Tamoxifen 20mg|Selective estrogen receptor modulator
219642746|NCT05800197|DRUG|Anastrozole 1mg|Aromatase Inhibitor
219642747|NCT05800197|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
219642748|NCT05800197|DRUG|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
219642749|NCT05800197|DRUG|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
219642750|NCT05241405|DIETARY_SUPPLEMENT|QISENG|2 capsules/day for 8 weeks.
219642751|NCT05241405|DIETARY_SUPPLEMENT|PLACEBO|2 capsules/day for 8 weeks.
219642752|NCT01450826|DRUG|aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
219642753|NCT01450826|DRUG|ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
219642754|NCT02223650|DEVICE|Overminus treatment|2.50D overminus spectacles
218959561|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
219642755|NCT02223650|DEVICE|Non-overminus treatment|spectacles without overminus or no spectacles
219642756|NCT01671072|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
219642757|NCT01671072|DRUG|Normal Saline|Sodium chloride 0.9%, 3.5ml
218959562|NCT04808999|DRUG|Pembrolizumab Injection|200 mg IV infusion
218959563|NCT06242197|OTHER|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
219642758|NCT02883075|OTHER|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
219642759|NCT02883075|OTHER|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
219642760|NCT02883075|OTHER|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
219642761|NCT05499260|DRUG|CB03-154|CB03-154 tablet once daily.
219642762|NCT05499260|DRUG|Placebo|Placebo tablet once daily.
219642763|NCT04457375|DIAGNOSTIC_TEST|TDC|measurements
219642764|NCT00665587|PROCEDURE|Cox-MAZE III|Maze procedure according to standards of the department
219642765|NCT00245076|BEHAVIORAL|smoking cessation intervention|
219642766|NCT00245076|OTHER|internet-based intervention|
219642767|NCT04587791|DRUG|400mg Cannabidiol|Participants will receive 400mg
219642768|NCT04587791|DRUG|800mg Cannabidiol|Participants will receive 800mg
219642769|NCT04587791|DRUG|1200mg Cannabidiol|Participants will receive 1200mg
219642770|NCT04587791|DRUG|Saline|Participants will receive saline
219642771|NCT06968572|DRUG|HSK41959|Oral administration, QD
219642772|NCT06967909|BEHAVIORAL|Tai Chi training|Participants will receive 24 weeks of Tai Chi training. For the first 12 weeks, they will receive 3 instructor-led Tai Chi training sessions per week, and practice 2 Tai Chi sessions by themselves. In the next 12 weeks, they will receive 1 instructor-led Tai Chi session and self-practice 2 Tai Chi sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified instructors. Each 1-hour training session consists of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors are required to attend a training session that ensure all of them to deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training session will be delivered in group. The group size is 25-30 persons.
219642773|NCT06967909|PROCEDURE|Acupuncture|Participants in the acupuncture group will receive 30 acupuncture treatment sessions, each last for 1 hour. Acupuncture will be performed every 2 days within one week, followed by a 3-day break, i.e., twice a week for the first 12 weeks; then it will be performed once every two weeks for the next 12 weeks. In total 30 sessions during 24 weeks treatment period. All acupuncture sessions will be administered by registered Traditional Chinese Medicine practitioners in Hong Kong with at least three years of clinical experience.
219642774|NCT03991299|DRUG|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
219642776|NCT01351792|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
219642777|NCT01351792|DRUG|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
219642778|NCT01916681|DEVICE|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
219642779|NCT01916681|DRUG|Misoprostol Alone|Misoprostol will be used alone to induce the patient
219642780|NCT01916681|DEVICE|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
219642781|NCT01916681|DEVICE|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
219642782|NCT04080024|DRUG|SN132D|Novel manganese-based macromolecular MRI contrast agent
219642783|NCT05668585|DRUG|CFT1946|Specified oral dose on specified day
219642784|NCT05668585|DRUG|Trametinib|Specified oral dose on specified day
219642785|NCT05668585|DRUG|Cetuximab|Specified intravenous dose on specified day
219642786|NCT00163761|DRUG|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
219642787|NCT00163761|DRUG|gemcitabine, vinorelbine, filgastrim|Drug
219642788|NCT02821338|DRUG|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
219642789|NCT06968260|OTHER|Education Type|Machine Guidance group will receive education from a software, while the Instructor Guidance Group will receive education from a human instructor.
219642790|NCT02476812|BEHAVIORAL|Positive Piggy Bank|Already noted.
219642791|NCT02014493|PROCEDURE|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
219642792|NCT02014493|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
219642793|NCT00495209|OTHER|Qigong|EQT daily for 5 consecutive days prior to surgery.
219642794|NCT05537779|DEVICE|CT examination|Administration of contrast medium using the power injector
218959564|NCT04030026|DRUG|NAL ER|Participants received NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID.
218959565|NCT04030026|DRUG|Placebo|Participants received Placebo tablet (matching NAL ER ).
218959566|NCT00933777|DRUG|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
218959567|NCT02207946|DRUG|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
218959568|NCT02207946|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
218959569|NCT06031389|DRUG|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
218959570|NCT06031389|DRUG|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
219060804|NCT07052500|DIETARY_SUPPLEMENT|Seed Cycling|Daily consumption of 1 tablespoon each of flax and pumpkin seeds during the follicular phase and 1 tablespoon each of sunflower and sesame seeds during the luteal phase
219060805|NCT07051174|DIAGNOSTIC_TEST|MIMS|This study is an extension follow up study conducted in continuation of the prior MIMS® study (see: STUDY ID: MMS EEU-1), in which the long-term (i.e., 28, 36, 42 months) clinical outcomes of Minimally Invasive Micro Sclerostomy System \[MIMS® System\] \[CE Marked device\] are evaluated.
219060806|NCT07052422|DRUG|Venetoclax (VEN)|Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.
219060807|NCT07052422|DRUG|Decitabine (DAC)|"Decitabine (DAC) was administered at 20mg/m2/day on days~-10 to -8."
219642795|NCT06522087|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
219642796|NCT00792974|BEHAVIORAL|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
219060808|NCT07052422|DRUG|Busulfan (Bu)|"Busulfan (Bu) was administered at 3.2 mg/kg/day on days~-5 to -4."
219060809|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.
219060810|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.
219060811|NCT06765863|DIETARY_SUPPLEMENT|Human Milk Fortifier|"Human milk fortifier added to expressed human milk (mother's own milk or pasteurized donor human milk) per feed per manufacturer's instructions for a minimum of 21 days (in-facility provision only)~* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
219060812|NCT06765863|OTHER|Volume targets|"* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
219060813|NCT06618352|OTHER|Simulated indoor overheating exposure|Young adults exposed to a multi-day extreme heat event
219060814|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
219642797|NCT04189939|OTHER|clinical assessments|"Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):"
219642798|NCT03728426|DRUG|Letermovir|"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."
219686101|NCT02671851|DRUG|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
219686102|NCT02671851|DRUG|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
218959571|NCT03175055|DEVICE|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
218959572|NCT02776202|DRUG|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
218959573|NCT03507530|OTHER|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
218959574|NCT00523367|PROCEDURE|24 hour pH testing|24 hour pH testing will be used to screen patients
218959575|NCT00811642|DRUG|Posaconazole|400mg BID oral suspension for 12 weeks
218959576|NCT01278927|BEHAVIORAL|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
218959577|NCT01278927|BEHAVIORAL|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
218959578|NCT01278927|BEHAVIORAL|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
218959579|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
218959580|NCT05394493|DRUG|avelumab|as provided in real world setting
219642799|NCT06608563|PROCEDURE|Fissure sealant without adhesive system (NO BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~5. Lightcuring: The material will be lightcured for 20 seconds."
219060815|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
219642800|NCT06608563|PROCEDURE|Fissure sealant with adhesive system (BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Adhesive system application: the adhesive system (Futurabond, VOCO) single dose capsule will be applied over the surface to be sealed for 5 seconds using a microbrush. The adhesive system will be air thin dried and lightcured for 10s before sealant placement.~5. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~6. Lightcuring: The material will be lightcured for 20 seconds."
219642801|NCT06685341|DRUG|YZJ-1139|YZJ-1139
219642802|NCT06685341|DRUG|Placebo|Oral tablet
218959581|NCT05394493|DRUG|axitinib|as provided in real world settings
219060816|NCT00756509|DRUG|Nilotinib|800 mg/d orally
219060817|NCT06405230|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
219060818|NCT06405230|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219642803|NCT06685341|DRUG|Zolpidem|Oral tablet
219642804|NCT01881334|BIOLOGICAL|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
219060819|NCT06405230|DRUG|Pemetrexed+ (carboplatin or cisplatin)|PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
219642805|NCT02064270|DEVICE|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
219642806|NCT02064270|DEVICE|Standard postsurgical dressings|Use of Standard postsurgical dressings
219642807|NCT02176863|BIOLOGICAL|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
219642808|NCT02176863|DRUG|Placebo|Normal saline solution
219642809|NCT00860535|OTHER|Comparator: Biomarker evaluation|"Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a \~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day \[qd\]), dasatinib (recommended dose 70 mg twice a day \[bid\]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I."
219642810|NCT00484835|PROCEDURE|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
219642811|NCT02989376|PROCEDURE|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
219642812|NCT03024762|PROCEDURE|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
218959582|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
218959583|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
218959584|NCT02642549|BEHAVIORAL|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
218959585|NCT03037723|OTHER|CT simulation|
219060820|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
219060821|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
219060822|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
219060823|NCT06939816|DRUG|Vonafexor low dose|Oral tablets
219060824|NCT06939816|DRUG|Vonafexor high dose|Oral tablets
219060825|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
219642813|NCT00005807|DRUG|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
219642814|NCT06335693|OTHER|Radiotherapy|The patients after radical prostatectomy with high-risk pathological factors will receive adjuvant hypofractionated radiation therapy in 15 fractions.
219642815|NCT01949844|DRUG|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
219642816|NCT01949844|DRUG|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
219642817|NCT01949844|DEVICE|Myocardial perfusion MRI|
219642818|NCT00231114|DEVICE|Alair System|Treatment of airways with the Alair System
219642819|NCT00231114|DEVICE|Alair System|Sham treatment of airways with the Alair System
219642820|NCT04792593|BIOLOGICAL|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
219642821|NCT03748810|DRUG|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 3 years
219642822|NCT03748810|DRUG|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 3 years
219642823|NCT04436562|DRUG|[14C]-Poziotinib|Single oral administration of 8 mg (as the hydrocholoride salt) of \[14C\]-poziotinib
219642824|NCT00419848|DRUG|Doxycycline|Cap 100mg- 100mg/daily
219642825|NCT00419848|DRUG|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
219642826|NCT04470544|DRUG|Camostat Mesilate|Given PO
219642827|NCT04470544|OTHER|Standard of Care|At Investigator discretion
219642828|NCT03592667|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
219642829|NCT03592667|DRUG|Placebo - Cap|One per day before breakfast during 12 weeks.
219642830|NCT05340933|OTHER|Voice registration|Voice registration
219642831|NCT03721692|DEVICE|RIC|The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
219642832|NCT06683027|BEHAVIORAL|Nonattachment for Post Traumatic Stress|"This study seeks to cultivate nonattachment specifically for the alleviation of symptoms of post-traumatic stress. This is an 8-week online intervention where, following a Qualrics-hosted pre-screen, users are directed to www.npts.online to use as they wish. Users are then solicited to re-take quantitative assessments, and a subset of 10 (target number) will be recruited for a qualitative interview regarding their experience of the intervention.~A final prompt for assessment re-takes will follow at 3 months post-intervention to determine longitudinal efficacy."
219642833|NCT00823069|DEVICE|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
219642834|NCT00712881|DRUG|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
219642835|NCT00712881|DRUG|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
219642836|NCT00712881|DRUG|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
219642837|NCT00712881|DRUG|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
219642838|NCT00712881|DRUG|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
219642839|NCT05296668|DEVICE|Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)|(group C) to receive a cuffed ETT for airway management.
219642840|NCT05296668|DEVICE|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
219642841|NCT04483817|DEVICE|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
219642842|NCT04483817|DEVICE|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
219642843|NCT02027597|OTHER|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
219642844|NCT02027597|OTHER|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
219642845|NCT02027597|OTHER|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
219642846|NCT06682351|DRUG|Metformin|16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
219642847|NCT06682351|DRUG|GLP-1A|16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
218959586|NCT00176189|DEVICE|All ceramic FPDs|
218959587|NCT05667415|DRUG|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
218959588|NCT05667415|DRUG|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
218959589|NCT06086015|DEVICE|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
218959590|NCT03635411|DIETARY_SUPPLEMENT|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
218959591|NCT03635411|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Basis supplement.
219642848|NCT06682351|DIETARY_SUPPLEMENT|MED|16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
219642849|NCT02931084|OTHER|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
219642850|NCT02931084|PROCEDURE|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
219642851|NCT02609620|DEVICE|Peristaltic Feeding Tube|
219642852|NCT02609620|DEVICE|ConvaTec Levin Duodenal Tube|
219642853|NCT01194999|DEVICE|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
219642854|NCT02135185|OTHER|custom work endurance|Experimental: Rehabilitation effort
219642855|NCT02135185|BEHAVIORAL|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
219642856|NCT05262907|DEVICE|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
219642857|NCT05262907|DEVICE|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
219642858|NCT04437875|BIOLOGICAL|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
219642859|NCT06200415|DRUG|Glucosamine Sulfate|Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
219642860|NCT06200415|DRUG|Ginger Oil|Ginger (Zingiber officinale Roscoe) has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities.
219642861|NCT00325481|DRUG|FluMist|
219642862|NCT01514058|PROCEDURE|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
219642863|NCT01514058|PROCEDURE|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
219642864|NCT00230854|DRUG|EMZ702|
219642865|NCT01703247|PROCEDURE|Pulmonary vein isolation|
219642866|NCT01703247|PROCEDURE|Ganglionated plexi ablation|
219642867|NCT01703247|PROCEDURE|Linear Lesion Ablation|
219642868|NCT00186979|DRUG|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
219642869|NCT04290208|DRUG|Acetaminophen|IV Acetaminophen
219642870|NCT04290208|DRUG|Acetaminophen|Acetaminophen liquid syrup
219060826|NCT05102890|OTHER|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
219642871|NCT04290208|DRUG|Placebos|Flavored, non-medicated (placebo) liquid syrup
219642872|NCT04290208|DRUG|Placebos|IV salt solution (non-medicated)
219642873|NCT04102254|PROCEDURE|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
219642874|NCT00826254|DRUG|Vitamin K|180 micrograms vitamin K daily
219642875|NCT00826254|DRUG|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
219642876|NCT03268200|OTHER|segmental reexamination|segmental reexamination during colonoscopy
219642877|NCT04719052|OTHER|Diet and behavioural intervention|Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
219642878|NCT04719052|OTHER|Diet and behavioural intervention|Control group will receive a specific diet designed following the characteristics of Low fat Diet.
219642879|NCT02844842|BIOLOGICAL|Allergovac Poliplus|
219642880|NCT06648200|DRUG|JS004|Specified dose on specified days.
219642881|NCT06648200|DRUG|Toripalimab|Specified dose on specified days.
219642882|NCT06648200|DRUG|Etoposide|Specified dose on specified days.
219642883|NCT06648200|DRUG|Platinum|Specified dose on specified days.
219642884|NCT01404156|DRUG|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1\) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2\) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
219686103|NCT00268983|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
219686104|NCT00268983|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
219686105|NCT06203470|DRUG|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
219686106|NCT06203470|DRUG|Tacrolimus|topical Calcineurin inhibitor
219642885|NCT01404156|OTHER|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1\. Dose specifications:~1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
219642886|NCT06668688|DEVICE|"ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de)"|"The web-based information platform for educational professionals ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. The website is intended to provide low-threshold information about depression and mental health in the school context."
219642887|NCT06289478|DRUG|Topical tranexamic acid administration|Tranexamic acid will be topically administered in intervention groups
219642888|NCT02666378|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
219642889|NCT02666378|OTHER|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
219642890|NCT03208478|PROCEDURE|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
219642891|NCT03208478|PROCEDURE|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
219642892|NCT03208478|DEVICE|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
219642893|NCT05835011|DRUG|Decitabine/Cedazuridine|Oral FDC tablets administration
219642894|NCT05835011|DRUG|Magrolimab|IV administration
219642895|NCT05839197|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
219642896|NCT05839197|DRUG|Camrelizumab plus Apatinib|"Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC."
219642897|NCT03834974|BEHAVIORAL|Sun Safety Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
219642898|NCT03834974|BEHAVIORAL|Digital Health Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
219642899|NCT04675918|PROCEDURE|Cardiac arrest|Definition of characteristics of cardiac arrest and resuscitation as well as post-resuscitational care and follow up.
219642900|NCT01055275|DEVICE|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
219642901|NCT02737085|BIOLOGICAL|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
219642902|NCT02482948|DEVICE|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
219060827|NCT03059108|PROCEDURE|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
219060828|NCT03059108|PROCEDURE|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
219642903|NCT02482948|DRUG|Collagenase|Study agent to be applied daily to the wound.
219060829|NCT01918995|DRUG|Regadenoson|Intravenous (IV)
219060830|NCT01918995|DRUG|Placebo|Intravenous (IV)
219060831|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
219060832|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
219060833|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
219060834|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
219060835|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
219642904|NCT01859117|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
219642905|NCT01859117|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 cells administered on Study Days 1 and 8
219642906|NCT01859117|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
219642907|NCT01859117|BIOLOGICAL|100 x 10^6 cells|100 x 10\^6 cells administered on Study Days 1 and 8
219642908|NCT02698657|DRUG|ASP5094|Intravenous (IV)
219642909|NCT02698657|DRUG|Placebo|Intravenous (IV)
219642910|NCT04080843|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
219642911|NCT04080843|DRUG|Capecitabine|Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
219642912|NCT04080843|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2,D1
219642913|NCT00823043|DRUG|timolol hemihydrate|timolol hemihydrate 0.5% solution
219642914|NCT00823043|DRUG|timolol maleate|timolol maleate in sorbate
219642915|NCT04091412|DRUG|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
219642916|NCT05094635|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
219642917|NCT01913535|DRUG|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
219642918|NCT01913535|DRUG|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
219642919|NCT02976753|DRUG|efmoroctocog alfa|extended half-life factor VIII product
219642920|NCT02976753|DRUG|Factor VIII|conventional factor VIII product
219642921|NCT02410434|OTHER|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
219642922|NCT03383835|DIETARY_SUPPLEMENT|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
219642923|NCT00217893|BEHAVIORAL|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
219642924|NCT00217893|BEHAVIORAL|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
219642925|NCT00217893|BEHAVIORAL|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
219060836|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
219642926|NCT00217893|BEHAVIORAL|Usual education program|Participants will receive the usual education about ETS.
219642927|NCT04270071|DRUG|Yangxin Shengmai|Yangxin Shengmai Granules
219642928|NCT04270071|DRUG|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
219060837|NCT03787368|DRUG|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
219060838|NCT03787368|DRUG|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
219060839|NCT02256501|BIOLOGICAL|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
219060840|NCT00434720|DEVICE|GlideScope Specific Stylet|
219642929|NCT04270071|DRUG|nitroglycerin tablets|Be used when angina attack
219642930|NCT01316211|DEVICE|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
219060841|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
219060842|NCT00812292|DRUG|TMC278|
219060843|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
219642931|NCT01316211|PROCEDURE|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
219642932|NCT03032328|DIETARY_SUPPLEMENT|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
219642933|NCT01513265|OTHER|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
219642934|NCT05032495|OTHER|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
219642935|NCT05032495|OTHER|Focus group|To answer any questions and discuss topics covered in the standard presentation.
218959592|NCT01302132|DRUG|ASP1941|Oral solution
219642936|NCT03999736|DEVICE|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
219642937|NCT03878836|OTHER|Routine assessments|Routine assessments, no specific intervention
219642938|NCT01185184|DRUG|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
219642939|NCT03444948|DEVICE|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
218959593|NCT02830984|PROCEDURE|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
218959594|NCT02830984|PROCEDURE|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
218959595|NCT00383773|PROCEDURE|Retinal endo vascular surgery|
218959596|NCT02954042|DEVICE|Pelvital probe|Pelvital probe
218959597|NCT02954042|DEVICE|Placebo Probe|Placebo Probe
218959598|NCT04252521|DRUG|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
219060844|NCT03136068|DRUG|Placebo|Trans-abdominal injection
219060845|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
219060846|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
218959599|NCT04252521|DRUG|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
218959600|NCT04252521|DRUG|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
218959601|NCT06400875|DEVICE|InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)|weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and compression therapy
218959602|NCT01633593|DRUG|Donepezil|5 mg PO a day, during 2 weeks
218959603|NCT03961477|OTHER|Interferential therapy|Exercise therapy
218959604|NCT05201456|DEVICE|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
218959605|NCT03754725|DRUG|Deferiprone pill|1000 mg of deferiprone (oral) BID (15 mg/Kg)
218959606|NCT03754725|DRUG|placebo|patients will receive placebo orally
218959607|NCT03754725|BEHAVIORAL|Montreal Cognitive Assessment|Neurocognitive assessment, lower score indicates lower cognitive level
218959608|NCT02242591|DRUG|Ropivacaine 7,5 mg/ml|
218959609|NCT02242591|DRUG|Saline|
218959610|NCT02179138|DRUG|TFV 1% gel|
219060847|NCT00432380|BIOLOGICAL|Placebo|oral dose
219060848|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
219060849|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
219642940|NCT03444948|PROCEDURE|EUS|Standard intervention
219642941|NCT03990194|DRUG|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
219642942|NCT03922217|BEHAVIORAL|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
219642943|NCT05080114|PROCEDURE|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
219642944|NCT05080114|PROCEDURE|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
218959611|NCT03773003|DIETARY_SUPPLEMENT|Probiotics|"The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus"
219060850|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
219060851|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
219642945|NCT01594190|BEHAVIORAL|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
219642946|NCT01594190|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
219642947|NCT03229928|DEVICE|MOCHA|"* MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants)."
219642948|NCT04779528|PROCEDURE|Fiberoptic intubation in supine position.|"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
219642949|NCT04779528|PROCEDURE|Fiberoptic intubation in lateral position.|"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
219642950|NCT06662474|OTHER|1. cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks
219060852|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
219060853|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
219060854|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
219060855|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
219060856|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
219060857|NCT02365051|BEHAVIORAL|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
219060858|NCT01698060|BIOLOGICAL|ND1.1|
219060859|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
219060860|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
219060861|NCT02239718|PROCEDURE|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
219642951|NCT06662474|OTHER|2. psychoeducation and cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total)
219642952|NCT06662474|OTHER|3. no intervention|maintaines their lifestyle up until their inclusion in the study without following additional measures
219686107|NCT02147613|OTHER|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
219686108|NCT02147613|OTHER|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
219060862|NCT02239718|PROCEDURE|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
219060863|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
219060864|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
218959612|NCT03773003|DIETARY_SUPPLEMENT|Placebo|Identically looking to verum, containing corn starch.
218959613|NCT00007059|DRUG|mycophenolate mofetil|
218959614|NCT06712875|DRUG|Trametinib and Nivolumab|Trametinib combined with nivolumab (Cohort A)
218959615|NCT06712875|DRUG|Dabrafenib, trametinib, nivolumab|Dabrafenib + trametinib combined with nivolumab (Cohort B)
218959616|NCT03403335|BEHAVIORAL|Mindfulness Based Practices for Health Care Professionals in Training|Eight weekly sessions including didactic lecture, discussion, homework, gentle yoga, and meditation and mindfulness exercises
219642953|NCT02880774|OTHER|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
219642954|NCT02880774|OTHER|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
219642955|NCT01524939|DRUG|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
219642956|NCT00589134|DIETARY_SUPPLEMENT|Gatorade Endurance Formula|carbohydrate electrolyte beverage
219642957|NCT00589134|OTHER|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
219642958|NCT00543517|DRUG|MK0767|
219642959|NCT00611949|OTHER|Geranium oil|2 applications of topical oil per week for 2 weeks
219642960|NCT03452384|OTHER|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
219642961|NCT04980820|OTHER|No mask|The participant is asked to wear no mask for 10 minutes.
219642962|NCT04980820|DEVICE|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
219642963|NCT04980820|DEVICE|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
219642964|NCT03557931|DRUG|ASP4345|oral administration
219642965|NCT03557931|DRUG|placebo|oral administration
219642966|NCT03557931|DRUG|risperidone|oral or depot administration
219642967|NCT03557931|DRUG|quetiapine|oral administration
219642968|NCT03557931|DRUG|olanzapine|Oral or depot administration
219642969|NCT03557931|DRUG|ziprasidone|Oral or depot administration
219642970|NCT03557931|DRUG|aripiprazole|Oral or depot administration
219642971|NCT03557931|DRUG|brexpiprazole|Oral administration
219642972|NCT03557931|DRUG|paliperidone|Oral or depot administration
218959617|NCT05555940|DEVICE|Transcranial magnetic stimulation|The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
219642973|NCT03557931|DRUG|lurasidone|Oral administration
219642974|NCT04259931|DIAGNOSTIC_TEST|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
219642975|NCT06038344|BEHAVIORAL|Gluten-free food guide teaching|Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
219642976|NCT00737204|DRUG|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
219642977|NCT00737204|DRUG|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
219642978|NCT00239746|DRUG|Ibuprofen|200mg taken orally daily for 6-12 weeks
218959618|NCT04476589|DIAGNOSTIC_TEST|Functional MRI|measurement of functional brain networks
218959619|NCT02965287|OTHER|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
218959620|NCT02361346|DRUG|MT-3724 Phase 1|Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
218959621|NCT02361346|DRUG|MT-3724 Phase 2|Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
219642979|NCT00239746|DRUG|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
219642980|NCT05192590|OTHER|Educational Materials and Chronic Disease Management Test (CDMT)|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the CDMT technology. These materials are comprised of a PowerPoint presentation.~Intervention 1 participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it during the second round of case simulations."
219642981|NCT06969326|DRUG|Use of topical estradiol|The investigators will conduct a double blinded randomized control pilot trial. Participants will be randomized in 1:1 fashion to either receive no treatment or receive 2g of estradiol cream, placed after clearing the vaginal vault of any blood and discharge, at the conclusion of the surgery.
219642982|NCT06969326|OTHER|No intervention|This arm will not receive estradiol or other cream
219642983|NCT05888389|PROCEDURE|Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia|Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.
218959622|NCT01161030|DIETARY_SUPPLEMENT|Almonds|
218959623|NCT05771064|BEHAVIORAL|Gentle Moves|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
218959624|NCT03593460|DRUG|Synthetic PreImplantation Factor|peptide
218959625|NCT06111547|DRUG|TAK-279|TAK-279 oral tablet.
218959626|NCT06111547|DRUG|Placebo|TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
218959627|NCT01465685|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
218959628|NCT01465685|DRUG|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
218959629|NCT01465685|DRUG|Placebo|capsules identical to MDMA or methylphenidate
218959630|NCT06983015|PROCEDURE|sticky bone|extraction socket will be augmented using a sticky bone.
219642984|NCT05888389|PROCEDURE|General Anesthesia|Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
219642985|NCT04662866|DRUG|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
219642986|NCT02829723|DRUG|BLZ945|"BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days."
219642987|NCT02829723|DRUG|PDR001|PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
218959631|NCT06983015|PROCEDURE|xenograft mixed with cross-linked hyaluronic acid|Socket will be augmented with a mixture of xenograft and cross linked hyaluronic acid.
218959632|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
218959633|NCT06984900|OTHER|Group Aerobic Exercise Session|"The Aerobic Exercise Program is designed to improve mood and reduce stress among university students through structured, moderate-intensity aerobic activities.~Session Structure: Participants engage in moderate-intensity aerobic exercises such as treadmill walking or running, tailored to individual fitness levels, ensuring accessibility and inclusivity. Each session consists of a 10-minute warm-up, 30 minutes of aerobic exercise, and a 5-minute cool-down.~This intervention incorporates a dual assessment approach using the Profile of Mood States (POMS) and the Perceived Stress Scale (PSS) to evaluate mood and stress levels both before and after exercise. Participants complete these assessments multiple times, allowing for a nuanced understanding of how aerobic exercise influences mood and stress over time."
218959634|NCT06986278|DEVICE|tDCS|Stimulation will be applied at an intensity of 2 mA for 20 minutes, with an average ramp-up and ramp-down rate of 0.1 mA/s, using rectangular electrodes of 35 cm² (resulting in a current density of 0.06 mA/cm²) covered with sponges moistened with 0.9% saline solution. A Sooma tDCS™ direct current stimulator (Sooma Oy Ltd, Helsinki, Finland), certified for clinical use, will be used. The anode will be placed over the Cz stimulation site, and the cathode will be placed on the right shoulder. The electrode will be secured to the participant's head using a neoprene cap (Neuroelectrics, Barcelona, Spain) and to the shoulder with a crepe bandage.
218959635|NCT06986278|DEVICE|shamtDCS|The sham tDCS group will use the same device and electrode placement as the active stimulation group. The protocol will consist of a 10-second ramp-up to 1 mA, followed by a 7-second ramp-down to 0.3 mA, which will be maintained for 19 minutes and 40 seconds, and a final 3-second ramp-down to 0 mA. This sham stimulation method is integrated into the Sooma stimulator.
218959636|NCT06985186|DRUG|Ultra-Long GnRH Agonists + Letrozole|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. Upon initiation of the GnRH agonist, patients will also receive 2.5mg of Letrozole every 12h for 60 days. The start of therapy will be during the menstrual phase of the cycle.
219642988|NCT02989649|DRUG|Alogliptin|Alogliptin tablets
219642989|NCT02989649|DRUG|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
219642990|NCT02989649|DRUG|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
219642991|NCT00003779|BIOLOGICAL|Connaught|Compare two strains of BCG
219642992|NCT00003779|BIOLOGICAL|Tice|Compare two strains of BCG
219642993|NCT01677884|DRUG|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
219642994|NCT01677884|DRUG|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
219642995|NCT01677884|DRUG|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
219642996|NCT03257852|DRUG|ASP5094|intravenously administration
218959637|NCT06985186|DRUG|Ultra-Long GnRH Agonists|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. The first injection of GnRH agonist will be administered during the menstrual phase of the cycle.
218959638|NCT06984939|DEVICE|Grasp|Participants assigned to the intervention group will be instructed to squeeze the Grasp ball at regular intervals of approximately every 1-2 seconds. This action will activate a melody played through a speaker connected to the iPad, accompanied by a dynamic wavy line displayed on the screen. Participants will begin squeezing the Grasp ball at least 10 seconds prior to the start of the procedure and will continue until the procedure is completed.
219642997|NCT03257852|DRUG|Placebo|intravenously administration
219642998|NCT03257852|OTHER|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
219642999|NCT03840759|OTHER|inpatient geriatric consultation team|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
219643000|NCT00006251|RADIATION|total-body irradiation|Undergo TBI
219643001|NCT00006251|DRUG|fludarabine phosphate|Given IV
219643002|NCT00006251|DRUG|cyclosporine|Given PO
219643003|NCT00006251|DRUG|mycophenolate mofetil|Given PO
218959639|NCT06979687|PROCEDURE|knotless barbed suture closure of the hysterotomy at caesarean section|Use of Medtronic V-loc 180 suture (VL) for a 2 layer closure of the caesarean hysterotomy rather than the standard 2 layer closure using the 910 polyglactin suture (SS).
219643004|NCT00006251|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
219643005|NCT00006251|BIOLOGICAL|donor lymphocytes|Undergo DLI
219643006|NCT00006251|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
219643007|NCT00006251|OTHER|laboratory biomarker analysis|Correlative studies
219643008|NCT04861285|DEVICE|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
219643009|NCT04861285|DEVICE|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
219643010|NCT04861285|DEVICE|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
219643011|NCT03432793|DRUG|TD-9855|oral tablet, QD
219643012|NCT03432793|DRUG|Fluvoxamine|oral tablet, QD
219643013|NCT03432793|DRUG|Itraconazole|oral tablet solution, QD
219643014|NCT03432793|DRUG|Caffeine|oral solution, single dose
219643015|NCT04216693|DRUG|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
219643016|NCT04216693|OTHER|Placebo|The control group will receive the digoxin-like placebo treatment.
219643017|NCT04052386|BEHAVIORAL|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
219643018|NCT02894125|OTHER|SPA Therapy|
218959640|NCT06979687|PROCEDURE|Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)|Standard 2 layer closure using the 910 polyglactin suture (SS)
219643019|NCT05150808|OTHER|IRS insecticide: Vectron T500|public health insecticide
218959641|NCT06820307|DRUG|Suzetrigine|Tablets for Oral Administration.
218959642|NCT06820307|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
218959643|NCT06820307|DRUG|NGM/EE|Combination Tablets for Oral Administration.
218959644|NCT05533125|DRUG|Rituximab|Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
218959645|NCT05533125|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously with usual premedication
218959646|NCT06986291|DIAGNOSTIC_TEST|Imaging and biomarkers|MR imaging of the heart, ECG and TTE measurements, blood sample
218959647|NCT06585930|BIOLOGICAL|Blood sample|Additional 8.1 ml blood sample
218959648|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid composite block|This refers to restorations fabricated from nano-ceramic hybrid composite blocks via chairside CAD/CAM workflow and cemented to permanent molars affected by MIH (molar-incisor hypomineralization).
218959649|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid ceramic block|This refers to restorations fabricated from polymer-infiltrated hybrid ceramic blocks using a digital workflow, then cemented to MIH-affected permanent molars.
218959650|NCT06990425|PROCEDURE|Groin closure with PDS suture|Closure of the groin will be performed with PDS suture
218959651|NCT06990425|PROCEDURE|Groin closure suture material|Closure of the groin will be performed with Vicryl suture
219643020|NCT04335981|DEVICE|FT-CC and Swallow Exercises|Once daily treatment with FT Plus with investigational connectivity software and standard of care swallow exercises.
219643021|NCT04335981|OTHER|Swallow Exercises|Standard of care swallow exercises.
219643022|NCT01813214|DRUG|Vemurafenib|
219643023|NCT01813214|DRUG|Cobimetinib|
219643024|NCT04090138|DIETARY_SUPPLEMENT|Setria performance blend|Oral capsules
218959652|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
218959653|NCT06994312|DRUG|Nafamostat Mesylate|Anticoagulation with Nafamostat Mesylate for SIC Patients Undergoing Hemofiltration
218959654|NCT06994312|DRUG|sodium citrate|Anticoagulation with Sodium Citrate for SIC Patients Undergoing Hemofiltration
218959655|NCT06994247|BEHAVIORAL|Motivational Telephone Call|This intervention consists of a single, personalized motivational telephone call delivered by a medical doctor, one month after initiation of CPAP treatment, uniquely timed to address early barriers and enhance self-efficacy. Unlike standard care or automated follow-ups, it offers tailored support based on patient experience, making it a low-cost yet targeted behavioral strategy to improve adherence. Content of the telephone call includes inquiry about patient's experience with CPAP therapy, identification of barriers to regular use, education on the health benefits of consistent CPAP usage, and personalized motivational messages aimed at increasing compliance.
218985198|NCT04252066|DRUG|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
219643025|NCT04090138|DIETARY_SUPPLEMENT|Placebo|Oral capsules
219643026|NCT05929196|DIAGNOSTIC_TEST|In vitro full blood diagnostic test.|Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
219643027|NCT00370318|BIOLOGICAL|10 valent pneumococcal conjugate vaccine|
219643028|NCT00370318|BIOLOGICAL|Infanrix Hexa|
219643029|NCT00370318|BIOLOGICAL|Rotarix|
219643030|NCT00370318|DRUG|Paracetamol|
219643031|NCT04711174|BEHAVIORAL|LMA removal|the timing when conducting LMA removal
219643032|NCT01608243|BIOLOGICAL|SLIT tablets of house dust mite allergen extracts|10 dosing days
219643033|NCT01608243|BIOLOGICAL|Matching placebo|10 dosing days
219643034|NCT03228524|DRUG|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
218959656|NCT06995417|OTHER|Smoking counseling|"The investigator, upon enrollment, will initiate a standardized strategy from clinical practice: the investigator will conduct brief counseling (minimal advice) using the administration of of a questionnaire that will include, in addition to questions about current and past, the administration of the Fagerstrom test to measure physical dependence on nicotine and questions to investigate intention to quit smoking (Mondor test)"
218959657|NCT06994741|OTHER|Quantitative movement analysis|During their reeducation, patient can go through an quantitative movement analysis. Inside a movement laboratory, we observe their gait with 5 passageways.
218959658|NCT06993961|DEVICE|Ultrasound|Ultrasound (US) measurement of optic nerve sheath diameter (ONSD) was performed.
218959659|NCT06995092|OTHER|Music therapy|Patient will receive a 15-minute RAS session immediately before patient standard physiotherapy session. The RAS session will consist of metronome beats matched to your walking cadence. After completing the RAS sessions, patient will continue with the standard rehabilitation program as usual.
218959660|NCT06995092|OTHER|Standard physiotherapy program|Patient will receive the standard physiotherapy program without the RAS pre-gait training. Therapy will include sessions aimed at improving balance and gait, conducted for 15 minutes during each session. Assessments will be conducted at baseline, after completing the therapy, and during two follow-up evaluations.
218959661|NCT06995105|PROCEDURE|TACE|The first day of TACE treatment is the first day (D1). TACE is started on D1. Subsequent TACE is arranged by the investigator based on a comprehensive assessment of the patient's physical condition, disease progression, adverse reactions, etc. The total number of TACEs shall not exceed 4 times, with at least 4 weeks between each two times.
218959662|NCT06995105|DRUG|Sintilimab combined with Bevacizumab|Sintilimab (200 mg) combined with bevacizumab (Dayoutong injection, 15 mg/kg), intravenous infusion, once every 3 weeks, until the patient is intolerant or the tumor progresses
219060865|NCT02751281|PROCEDURE|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
219060866|NCT02751281|PROCEDURE|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
219643035|NCT03228524|BEHAVIORAL|Therapeutic exercise|Standard physiotherapy
219643036|NCT03228524|DRUG|Placebo Oral Tablet|Placebo
219643037|NCT00746824|DRUG|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
218959663|NCT06995105|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
218959664|NCT06994221|DIAGNOSTIC_TEST|18F FAPI-42 PET/CT scan|During the hospital stay, participants will receive an 18F FAPI-42 PET/CT scan. 18F FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for fibrosis imaging. PET/CT will be performed using the ultra-high-resolution digital PET/CT uEXPLORER (United Imaging, Shanghai, China)
218959665|NCT06994780|PROCEDURE|dynamic compliance guided PEEP titration|In order to find the individualized optimal PEEP value, PEEP will be increased at 2-minute intervals with a maximum peak pressure of 45 cmH2O and a driving pressure of 15 cmH2O. Recruitment will be performed. When the target is reached, the PEEP value will be adjusted to the value at which the highest dynamic compliance is achieved by decreasing it.
218959666|NCT06994650|DRUG|HRS9531|HRS9531 will be administered by Subcutaneous injection
218959667|NCT06994650|DRUG|Placebo|Matching Placebo will be administered by Subcutaneous injection
218959668|NCT06688331|BIOLOGICAL|ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)|regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)
219060867|NCT04777565|OTHER|Robotic surgery|Cochlear implant surgery with HEARO procedure
219060868|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
219060869|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
219643038|NCT04178707|DEVICE|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
219643039|NCT01773161|PROCEDURE|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
219643040|NCT00306358|DRUG|Vitamin B12 (Cyanocobalamin)|
219643041|NCT00000238|DRUG|Buprenorphine|
219643042|NCT02140216|BIOLOGICAL|No blood transfusion|No blood transfusion
219643043|NCT02140216|BIOLOGICAL|Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
219643044|NCT02140216|BIOLOGICAL|Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
218959669|NCT06688331|BIOLOGICAL|Anti-CD20 (rituximab)|rituximab
219643045|NCT02078895|DRUG|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
219643046|NCT04010903|DIAGNOSTIC_TEST|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
219643047|NCT06201975|OTHER|Thyme honey|Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
219643048|NCT02199353|OTHER|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
219643049|NCT02199353|OTHER|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
219643050|NCT06614998|DRUG|Patients diagnosed with HLH-94 should be treated as soon as possible|For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
219643051|NCT04804267|DRUG|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
219643052|NCT04804267|DRUG|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
219643053|NCT04804267|DRUG|Placebo|Drug: Placebo orally once daily
219643054|NCT02289508|DEVICE|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
219643055|NCT02289508|DEVICE|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
219643056|NCT06591884|DRUG|Tacrolimus modified-release|0.08% tacrolimus nanoencapsulated aqueous solution spray
218959670|NCT06688331|OTHER|Placebo|intrevenous 0,9% NaCl
218959671|NCT06688331|OTHER|Treg sham|intrevenous 0,9% NaCl
218959672|NCT06689696|DEVICE|miLens system|The miLens system consists of the miLens contact lens made of soft, biocompatible materials, the miLens imaging system, and miLens analysis software.
218959673|NCT02586883|OTHER|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
218959674|NCT06629558|DRUG|Silver Nitrate|bronchoscopic lung volume reduction in management of localized emphysema
218959675|NCT06629558|DRUG|Nano-silver nitrate|bronchoscopic lung volume reduction in management of localized emphysema
218959676|NCT06629558|DEVICE|Bronchoscopic lung volume reduction|bronchoscopic lung volume reduction in management of localized emphysema
218959677|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
218959678|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218959679|NCT06049355|OTHER|Educational Intervention|Receive educational materials
218959680|NCT06218264|DIETARY_SUPPLEMENT|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
218959681|NCT06878235|OTHER|Assessment of the functional status|assessment of their functional status using the French version of the PLSFRS scale during a routine multidisciplinary assessment every 3-6 months for all patients with motor neurone disease, as recommended by the FILSLAN network
218959682|NCT01406405|PROCEDURE|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
218959683|NCT06710717|BIOLOGICAL|CD19 CAR-T cells|Study participant will be given single infusion of autologous CD19 CAR-T cells following lymphodepletion chemotherapy
218959684|NCT02104739|DRUG|Exenatide|Single subcutaneous injection (10 mcg)
218959685|NCT02104739|DRUG|Saxagliptin|Single dose orally (5 mg)
218959686|NCT02104739|DRUG|Exenatide extended-release (ER)|Subcutaneous injection (2mg) weekly for 6 weeks
218959687|NCT02104739|OTHER|Placebo|Placebo tablets and Placebo (normal saline) injections
218959688|NCT05218954|DIAGNOSTIC_TEST|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
218959689|NCT06747130|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
218959690|NCT06747130|DRUG|Montelukast Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
218985199|NCT03665454|DRUG|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
219643057|NCT06591884|DRUG|tacrolimus ointment 0.1%|0.1% free tacrolimus commercial ointment
219643058|NCT00171938|DRUG|imatinib mesylate|
219643059|NCT06643364|OTHER|Vision Training Program|Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.
219643060|NCT06643364|OTHER|Routine Training Program|All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
219643061|NCT04603482|BEHAVIORAL|Resourcefulness training|Resourcefulness training is a cognitive behavioral intervention that consists of teaching and reinforcing personal (self-help) and social (help-seeking) strategies to overcome adversity.
219643062|NCT04603482|BEHAVIORAL|Biofeedback|Biofeedback training combines teaching slow, deep, paced breathing with real-time tracking to increase an individual's heart rate variability and ultimately improve self-regulation.
219643063|NCT04603482|BEHAVIORAL|Attention Control|Participants randomly assigned to this intervention will receive suggested Diversional Activities, presented in an audiovisual format.
218959691|NCT06842316|OTHER|1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)|Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.
218959692|NCT04211233|DEVICE|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
218959693|NCT04211233|OTHER|Control arm|Standard Treatment based on Brain Trauma Foundation
218959694|NCT06880367|BEHAVIORAL|The intervention is an audio-proprio-phonatory training|The audio-proprio-phonatory training involves engaging in group workshops and performing exercise sessions independently, following the guidance provided by the specialist, over a duration of five weeks
218959695|NCT06880367|DIAGNOSTIC_TEST|high-density electroencephalogram (HD-EEG)|HD-EEG examination with 256 channels distributed throughout the skull that record resting brain connectivity(10 min).
218959696|NCT05903469|OTHER|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
218959697|NCT06900426|OTHER|10 PEEP|Using 10cmH2O PEEP during anesthetic induction monitored by EIT.
218959698|NCT06900426|OTHER|ZEEP|No PEEP
218959699|NCT06900426|OTHER|5PEEP|Using 5cmH2O PEEP
219643064|NCT05232604|OTHER|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
219643065|NCT05232604|OTHER|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
219643066|NCT03500913|DRUG|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
218959700|NCT06309355|DRUG|YR001 ointment|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
218959701|NCT06309355|OTHER|Placebo|The intervention is Placebo on a range of body surface area for multiple topical administration
218959702|NCT04227301|OTHER|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
218959703|NCT05772702|DEVICE|Closed-loop tACS|Individual alpha tACS
218959704|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
218959705|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
218959706|NCT02048293|DRUG|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
218959707|NCT02048293|DRUG|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
219643067|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
219643068|NCT04125914|BEHAVIORAL|Behavioral Dietary Intervention|Record food intake
219643069|NCT04125914|OTHER|E-mail|Receive e-mails
219643070|NCT04125914|BEHAVIORAL|Exercise Intervention|Undergo exercise
219643071|NCT04125914|OTHER|Health Promotion and Education|Receive text messages
219643072|NCT04125914|OTHER|Internet-Based Intervention|Join Facebook page
219643073|NCT04125914|OTHER|Questionnaire Administration|Ancillary studies
219643074|NCT04125914|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
218959708|NCT02048293|DRUG|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
218959709|NCT05463367|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
219643075|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Oral Tablet|Oral cyanocobalamin supplement administered as a 1000 mcg tablet taken once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
219643076|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Sublingual Tablet|Sublingual cyanocobalamin supplement administered as a 1000 mcg tablet placed under the tongue once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
219643077|NCT06966856|OTHER|Proton Pump Inhibitor therapy only|This group will continue their standard PPI therapy without receiving any vitamin B12 supplementation, serving as a control group for the comparison of B12 correction efficacy.
219643078|NCT06452836|OTHER|Green color exposure|Patients will wear green colored glasses before and during the surgery.
219643079|NCT06452836|OTHER|Red color exposure|Patients will wear red colored glasses before and during the surgery.
219643080|NCT06452836|OTHER|Blue color exposure|Patients will wear blue colored glasses before and during the surgery.
219643081|NCT06452836|OTHER|control|Patients will wear translucent glasses before and during the surgery.
219643082|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
219643083|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
218959710|NCT05463367|DRUG|Naproxen 500 Mg|Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
218959711|NCT05463367|DRUG|Opioids|Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
218959712|NCT04081896|OTHER|Exercise|"Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do \>20 repetitions. If they are able to reach \>10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy."
218959713|NCT02071147|OTHER|No Clinical Follow up|
218959714|NCT02071147|OTHER|Quality of Life questionnaire|
218959715|NCT02071147|OTHER|Patient satisfaction Questionnaire|Conducted at Research clinic.
218959716|NCT04199936|DEVICE|Electrical Muscle stimulation|Electrical muscle stimulation
218959717|NCT04376177|DIAGNOSTIC_TEST|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
218959718|NCT04376177|DIAGNOSTIC_TEST|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
218959719|NCT04376177|DIAGNOSTIC_TEST|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
218959720|NCT04376177|DIAGNOSTIC_TEST|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
218959721|NCT04376177|DIAGNOSTIC_TEST|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
218959722|NCT04376177|DIAGNOSTIC_TEST|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
219643084|NCT01054196|DRUG|lenalidomide|daily dose dependent on dose-escalation schedule
219643085|NCT01054196|DRUG|melphalan|100 mg/m2 given Days -2 and -1
219643086|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
218959723|NCT04376177|DIAGNOSTIC_TEST|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
218959724|NCT05591742|DIETARY_SUPPLEMENT|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
218959725|NCT05591742|OTHER|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
218959726|NCT04095832|PROCEDURE|Epidural anesthesia|Epidural anesthesia using standardized technique
218959727|NCT02269748|PROCEDURE|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
218959728|NCT02269748|PROCEDURE|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
218959729|NCT02269748|DRUG|Analgesic Therapy|Ibuprofen 600 mg TID
218959730|NCT06243224|OTHER|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
219643087|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
219643088|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
219643089|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
219643090|NCT04276857|DEVICE|Irreversible electroporation (NanoKnife® )|IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
219643091|NCT00179673|DRUG|Lenalidomide|
219643092|NCT03686943|OTHER|Family pharmacy|Observation of the family pharmacy in elderly group
218959731|NCT06243224|OTHER|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
218959732|NCT03387150|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
218959733|NCT03387150|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
218959734|NCT01158508|PROCEDURE|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
218959735|NCT02680899|BEHAVIORAL|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
218959736|NCT02667327|DRUG|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
218959737|NCT02667327|OTHER|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
218959738|NCT04522531|OTHER|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
218959739|NCT06143553|DRUG|Paclitaxel Polymeric Micelles for Injection|Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
218959740|NCT06143553|DRUG|Eribulin Mesilate injection|Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
218959741|NCT06143553|DRUG|Capecitabine Tablets|Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
218959742|NCT06143553|DRUG|Gemcitabine Hydrochloride for Injection|Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
219060870|NCT01134874|BEHAVIORAL|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
219643093|NCT03445741|OTHER|Supervised treadmill group (%70 VO2 max) (group 1)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
218959743|NCT06143553|DRUG|Vinorelbine Tartrate Injection|Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
218959744|NCT06143553|DRUG|Paclitaxel (albumin-bound)|Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
218959745|NCT06094127|DEVICE|Endovascular aortic treatment|Use of ZTA to treat diseases in the descending thoracic aorta, such as thoracic aortic aneurysm and penetrating aortic ulcer.
219060871|NCT01134874|BEHAVIORAL|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
219686109|NCT01756989|DRUG|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
219686110|NCT05618314|DRUG|AT-527|single dose AT-527
218959746|NCT02937272|DRUG|LY3200882|Administered orally
218959747|NCT02937272|DRUG|LY3300054|Administered intravenously
218959748|NCT02937272|DRUG|Gemcitabine|Administered intravenously
218959749|NCT02937272|DRUG|nab-Paclitaxel|Administered intravenously
218959750|NCT02937272|DRUG|Cisplatin|Administered intravenously
218959751|NCT02937272|RADIATION|Intensity Modulated Radiotherapy|
219643094|NCT03445741|OTHER|Supervised treadmill group (%50 VO2 max) (group 2)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
219643095|NCT03445741|DEVICE|ECE PEDO pedometer group (%50 VO2 max) (group 3)|Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
219643096|NCT00492648|PROCEDURE|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
219643097|NCT06967571|PROCEDURE|Jejunal Pouch reconstruction.|The JP will be fashioned with a standard length of 12 cm using two 60 mm staple lines, the esophago-pouch anastomosis will be performed with a circular mechanical 25 mm stapling device, and finally the staple entrance on the pouch will be closed with two layers of running sutures in Vicryl 3/0
219643098|NCT06968871|PROCEDURE|Modified Pap test|For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
219643099|NCT01547442|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
219643100|NCT03943069|PROCEDURE|Thoracoscopic bullectomy alone|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
219643101|NCT03943069|PROCEDURE|Thoracoscopic bullectomy with pleurodesis|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
219643102|NCT00282113|DIETARY_SUPPLEMENT|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
219643103|NCT00282113|DIETARY_SUPPLEMENT|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
219643104|NCT00282113|OTHER|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
219643105|NCT01204684|BIOLOGICAL|autologous tumor lysate-pulsed DC vaccination|
219643106|NCT01204684|BIOLOGICAL|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
219643107|NCT01204684|BIOLOGICAL|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
218959752|NCT05039853|BEHAVIORAL|Brief cognitive task-based intervention|Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation +/- Boosters
218959753|NCT05039853|BEHAVIORAL|Placebo activity|Listening to a pod-cast on a smart-device for approximately 15 minutes.
218959754|NCT05929079|DRUG|Retatrutide|Administered SC
218959755|NCT05929079|DRUG|Placebo|Administered SC
219643108|NCT02949843|DRUG|Chemotherapy|Receive other treatment
219643109|NCT02949843|BIOLOGICAL|Immunotherapy|Receive other treatment
219643110|NCT02949843|OTHER|Laboratory Biomarker Analysis|Correlative studies
219643111|NCT02949843|BIOLOGICAL|Nivolumab|Given IV
219643112|NCT02949843|BIOLOGICAL|Pembrolizumab|Given IV
218959756|NCT03609398|BIOLOGICAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
218959757|NCT06331845|DRUG|Gemcitabine|1000 mg/m2 on Days 1 and 8
218959758|NCT06331845|DRUG|Cisplatin|a total of 80-100 mg/m2 for d1-3
218959759|NCT06331845|DRUG|Paclitaxel protein-bound|260 mg/m2 on Day 1
218959760|NCT06331845|DRUG|Capecitabine|a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
219643113|NCT02949843|DRUG|Targeted Molecular Therapy|Receive drug targeting secondary mutation
219643114|NCT02949843|DRUG|Tyrosine Kinase Inhibitor|Given PO
219643115|NCT00421018|DRUG|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
219643116|NCT05845021|COMBINATION_PRODUCT|Surgeon-Initiated Bone Health Referral Pathway|Described in arm description
219643117|NCT06363110|DRUG|Vericiguat (Verquvo, BAY1021189)|Follow clinical practice/administration
219643118|NCT05069402|DIETARY_SUPPLEMENT|Immunonutrition|diet with immunonutrients
219643119|NCT05069402|DIETARY_SUPPLEMENT|High-protein|Oral nutrition with high-protein content
218959761|NCT06331845|DRUG|Tislelizumab|200 mg on Day 1
218959762|NCT00435500|DRUG|Fluoride varnish|
218959763|NCT03901703|OTHER|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
218959764|NCT00334074|DRUG|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
218959765|NCT02637128|DRUG|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
218959766|NCT02637128|DRUG|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
218959767|NCT01362595|DRUG|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
218959768|NCT00067912|DRUG|Duloxetine Hydrochloride|
218959769|NCT00067912|DRUG|Venlafaxine Extended Release|
218959770|NCT03620825|OTHER|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
218959771|NCT03620825|DRUG|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
219643120|NCT05069402|DIETARY_SUPPLEMENT|Standard ONS|Oral nutrition with standard ingredients
219643121|NCT01366703|DEVICE|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
219643122|NCT01363245|BEHAVIORAL|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
219643123|NCT01363245|BEHAVIORAL|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
219643124|NCT05932589|OTHER|EEG and Auditory and Visual Evoked Potentials (AEP and VEP)|Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
219643125|NCT05932589|OTHER|Clinical assessment|Established clinical measures for RTT will be collected for RTT participants
219643126|NCT05890989|DIAGNOSTIC_TEST|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
219643127|NCT05346315|OTHER|RDN Medical Nutrition Therapy|The RDNs will provide bi-monthly nutrition care, counseling, and dietary recommendations for a 6-month intervention, delivered either in-person or via telehealth, to the grocery store patrons during the study intervention. The RDN will provided care to the participant based upon the participant's unique dietary and nutritional needs. The RDN will provide nutrition recommendations and create meal plans via NutriStyle for the participants to follow. The meal plans will be uploaded into the grocery store's E-commerce shopping platform, which the participant can utilize to purchase foods that are needed to follow the RDNs nutrition recommendations for an individual person.
219643128|NCT01927003|PROCEDURE|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
219643129|NCT06597448|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD)|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The intervention consists of 9- 2hr sessions, the first half involves teaching and practice of CBT skills (cognitive restructuring, thinking errors, problem solving etc) followed by one hour of unstructured discussion around topics relevant to participants with Postpartum Depression (PPD) (sleep, supports, transitions, etc). Each group will be delivered by one randomly selected PHN and one randomly selected peer using our intervention manual.
219643130|NCT04937933|DRUG|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
219060872|NCT01134874|BEHAVIORAL|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
219060873|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
219060874|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
219060875|NCT04474184|OTHER|Survey Administration|Ancillary studies
219060876|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
219643131|NCT04937933|DRUG|Saline solution|saline solution
219643132|NCT04028869|DRUG|Glycyrrhizic acid preparation|To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
219643133|NCT02594904|DRUG|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
219643134|NCT05927740|DIAGNOSTIC_TEST|Optic coherence tomography|Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
219643135|NCT03189667|DEVICE|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon."
219643136|NCT03189667|DEVICE|Plain balloon angioplasty|"Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon."
219686111|NCT05618314|DRUG|AT-527|Single dose of AT-527 pre- and post-dialysis
219686112|NCT05618314|DRUG|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
219686113|NCT00002223|DRUG|Indinavir sulfate|
219686114|NCT00002223|DRUG|Ritonavir|
219686115|NCT01586234|PROCEDURE|DSAEK with graft shaping and smoothing|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
219686116|NCT01586234|PROCEDURE|Standard DSAEK|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
219060877|NCT03257982|PROCEDURE|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
219686117|NCT01854749|DRUG|S1 combined with cisplatin|
219686118|NCT03618446|OTHER|The presence of a pelvic fracture|
219643137|NCT03189667|DEVICE|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion."
219643138|NCT04974281|COMBINATION_PRODUCT|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
219643139|NCT05277636|DRUG|3,4-methylenedioxymethamphetamine|A dose of 125 mg racemic MDMA will be administered.
219643140|NCT05277636|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 125 mg enantiomeric S-MDMA will be administered.
218959772|NCT02469038|DEVICE|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
219643141|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (125 mg)|A dose of 125 mg enantiomeric R-MDMA will be administered.
219643142|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (250 mg)|A dose of 250 mg enantiomeric R-MDMA will be administered.
219643143|NCT05277636|OTHER|Placebo|Placebo (Mannitol)
219643144|NCT03912649|DEVICE|RemovAid|The RemovAid device is used for removal
219643145|NCT03788408|BEHAVIORAL|Intensive Psychotherapy and case management for refugee trauma|CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
219643146|NCT03503643|DEVICE|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
218959773|NCT02469038|DEVICE|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
218985200|NCT03665454|DRUG|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
219643147|NCT02180295|BIOLOGICAL|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
219643148|NCT02180295|BIOLOGICAL|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
219643149|NCT02180295|BIOLOGICAL|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
219643150|NCT06239571|BEHAVIORAL|Resilient Families (R-FAM)|Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
219643151|NCT02521051|DRUG|Alectinib|
219643152|NCT02521051|DRUG|Bevacizumab|
219643153|NCT06414395|DRUG|Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection|The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
219643154|NCT06414395|OTHER|C group: Patients received saline infusion over 10 minutes|the group will receive normal saline infusion over 10 minutes.
219643155|NCT06685393|PROCEDURE|Platelet rich plasma (PRP)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (PRP) at test side only at baseline,3ed, 6th week.
219686119|NCT04924634|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
219686120|NCT00155714|DRUG|type-5 phosphodiesterase Inhibitor (Sildenafil)|
219686121|NCT01061541|BIOLOGICAL|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
219686122|NCT01061541|BIOLOGICAL|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
219686123|NCT01061541|BIOLOGICAL|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
219686124|NCT01061541|BIOLOGICAL|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
219686125|NCT01061541|BIOLOGICAL|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
219686126|NCT00972959|DRUG|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
219686127|NCT00972959|DRUG|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
219686128|NCT00972959|DRUG|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
219686129|NCT02365935|PROCEDURE|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
219686130|NCT02365935|PROCEDURE|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
219686131|NCT02365935|DRUG|Cisplatin|
219686132|NCT02365935|DRUG|Paclitaxel|
219686133|NCT06175286|OTHER|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
219686134|NCT03135314|DIETARY_SUPPLEMENT|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
219686135|NCT03135314|DIETARY_SUPPLEMENT|placebo|7 days of placebo intake
219686136|NCT03022591|OTHER|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
219686137|NCT02917174|BEHAVIORAL|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
219686138|NCT02917174|BEHAVIORAL|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
219686139|NCT01098084|DRUG|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
219643156|NCT06685393|PROCEDURE|INJECTABLE PLATELET RICH FIBRIN(I-PRF)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (I-PRF) at test side only at baseline,3ed, 6th week.
219643157|NCT05561322|OTHER|Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver|Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.
218959774|NCT02448680|BIOLOGICAL|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
218959775|NCT01357200|OTHER|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
218959776|NCT02206243|DRUG|Embozene Microspheres|Intraarterial application
218959777|NCT05427955|PROCEDURE|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
218959778|NCT05427955|PROCEDURE|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
218959779|NCT05715879|DIAGNOSTIC_TEST|covid infection|patients with covid infection which was proved with positive test
218959780|NCT05715879|BIOLOGICAL|admission to hispital|patients with sever covid disease, who was admitted in hospital
218959781|NCT03663153|OTHER|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
218959782|NCT03663153|OTHER|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
218959783|NCT02825407|DIETARY_SUPPLEMENT|Oral physiology|
218959784|NCT01234818|DEVICE|Mirena (LNG-IUS)|* General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
218959785|NCT00636987|DEVICE|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
218959786|NCT00355901|DRUG|Visilizumab (Nuvion®; HuM291)|
218959787|NCT03524079|DRUG|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
218959788|NCT01251146|DRUG|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
218959789|NCT01251146|DRUG|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
219060878|NCT01244048|DIETARY_SUPPLEMENT|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
219060879|NCT00264615|DRUG|lamotrigine extended-release|
219060880|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
219060881|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
219643158|NCT05561322|OTHER|Magnetic Resonance Imaging of the lumbar spine|Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
219686140|NCT04511897|DRUG|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
219060882|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
219060883|NCT01772433|DIETARY_SUPPLEMENT|Olive oil|Phonophoresis with Olive oil for 10 day, daily
219060884|NCT01772433|DRUG|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
219643159|NCT05667363|COMBINATION_PRODUCT|Digital Intervention|Digital therapeutics are consist of a smartphone app and an intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
219643160|NCT01082263|DRUG|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
219643161|NCT06446115|DEVICE|Virtual Reality|Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.
219643162|NCT06446115|OTHER|Preferred activity|Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.
219643163|NCT06446115|OTHER|Questionnaires|Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.
219643164|NCT03086928|OTHER|lava ultimate|resin nano ceramic material
219643165|NCT03086928|OTHER|E.max cad|Lithium disilicate glass ceramic
219643166|NCT01303406|DRUG|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
219643167|NCT01303406|DRUG|Placebo|
219643168|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|phase 3 tablets
219643169|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|registration tablets
219643170|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment C)|registration tablets
219643171|NCT05236777|DRUG|Natalizumab|Administered as specified in the treatment arm.
219643172|NCT00039351|DRUG|cyclophosphamide|
219643173|NCT00039351|DRUG|prednisone|
219643174|NCT00039351|DRUG|vincristine sulfate|
219643175|NCT00039351|RADIATION|radiation therapy|
219643176|NCT04002245|PROCEDURE|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
219643177|NCT03953053|DEVICE|Femtosecond Laser Assissted Cataract Surgery|During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
219643178|NCT00162045|DRUG|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
219643179|NCT05804019|BEHAVIORAL|Nutritional and physical interventions|The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
219643180|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
219643181|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
219643182|NCT04435977|DRUG|Cabozantinib 60 MG|"• The assigned dose for study treatment is 60 mg qd. Two dose reductions will be permitted (Table 2):~* 60 mg qd to 40 mg qd (level 1)~* 40 mg qd to 20 mg qd (level 2)"
219686141|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
218959790|NCT04730167|OTHER|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
218959791|NCT01739400|DRUG|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
218959792|NCT00414427|PROCEDURE|Intraarticular steroids|
218959793|NCT06519110|DRUG|Neratinib tablets|In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
218959794|NCT04965909|OTHER|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
218959795|NCT02876640|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218959796|NCT02876640|DRUG|Retinoid 9cUAB30|Given PO
218959797|NCT02876640|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection surgery
218959798|NCT01216995|BIOLOGICAL|Dose A|ADRC Dose A
218959799|NCT01216995|BIOLOGICAL|Placebo|Placebo Comparator
218959800|NCT01810965|PROCEDURE|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
218959801|NCT01402895|OTHER|Exercise|Transversus abdominus exercise
218959802|NCT01402895|OTHER|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
218959803|NCT04997590|BIOLOGICAL|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
218959804|NCT04997590|DRUG|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
219643183|NCT04563533|BIOLOGICAL|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
219643184|NCT04563533|BIOLOGICAL|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
218959805|NCT01630785|DEVICE|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
219060885|NCT00919243|DRUG|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
219643185|NCT04563533|BIOLOGICAL|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
219643186|NCT04563533|BIOLOGICAL|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
219643187|NCT02482714|BEHAVIORAL|Physical activity.|Have subject do moderate physical activity.
219643188|NCT01101945|DRUG|dutogliptin|400 mg QD
219643189|NCT05207657|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
219060886|NCT00919243|DRUG|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
219060887|NCT04367168|DRUG|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
219060888|NCT04367168|DRUG|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
219060889|NCT03239379|DRUG|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
219060890|NCT03239379|DRUG|Placebo|Normal Saline
219643190|NCT04872894|OTHER|Observational study. No intervention is performed|Descriptive study in participants with clinical and biochemical suspicion of FHH. Comparison between genotype-negative and genotype-positive participants with clinical and biochemical suspicion of FHH.
219643191|NCT06610981|DEVICE|Laser acupuncture|Laser acupuncture will be used in this study with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks
219643192|NCT06610981|OTHER|traditional physical therapy|exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks
219643193|NCT06610981|DEVICE|Sham laser acupuncture|Participants will receive laser acupuncture while the device is turned off.
219643194|NCT03852628|DRUG|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
219643195|NCT03852628|DRUG|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
219643196|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
219643197|NCT04948463|DRUG|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
219643198|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
219643199|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
219643200|NCT04948463|DRUG|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
218959806|NCT01643603|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
218959807|NCT01643603|OTHER|laboratory biomarker analysis|Correlative studies
218959808|NCT05196399|DRUG|Aprocitentan (Formulation A)|A single oral dose of 25 mg.
218959809|NCT05196399|DRUG|Aprocitentan (Formulation B)|A single oral dose of 25 mg.
218959810|NCT05992571|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
219060891|NCT00393926|DEVICE|TheraDrive Assistive Device|
219060892|NCT00393926|PROCEDURE|Rote Therapy versus Fun Therapy|
219060893|NCT03711981|PROCEDURE|TAP Block|
219060894|NCT00814372|DRUG|MBX-102|capsule
219060895|NCT00814372|DRUG|Placebo|matching placebo
219060896|NCT00814372|DRUG|Actos|over-encapsulated to match MBX-102 and placebo
219060897|NCT00814372|DRUG|Metformin|greater than or equal to 1500 mg/kg day
219060898|NCT01220011|PROCEDURE|Fetoscopic laser surgery|Fetoscopic laser surgery
219060899|NCT05385016|BEHAVIORAL|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
219643201|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
219643202|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
219643203|NCT04948463|DRUG|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
219643204|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
219643205|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
219643206|NCT04948463|DRUG|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
219060900|NCT05385016|BEHAVIORAL|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
219060901|NCT02627677|DRUG|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
219060902|NCT02627677|DRUG|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
219060903|NCT02627677|DRUG|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
219643207|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
219643208|NCT03500783|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
219643209|NCT03500783|OTHER|Standard CPB|Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
219686142|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
219686143|NCT04590118|DRUG|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
219686144|NCT04590118|DRUG|Placebo|Single intravenous infusion of 1 ml/kg placebo
219686145|NCT02733718|DEVICE|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
219686146|NCT04159467|OTHER|Pelvic Floor Muscle Training|4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
219686147|NCT02884102|GENETIC|genetic sequencing|
219686148|NCT04398940|DRUG|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
219686149|NCT03920085|DEVICE|OneTouch Verio|OneTouch Verio Blood Glucose Monitoring System.
219686150|NCT03920085|DEVICE|OneTouch Select Plus|OneTouch Select Plus Blood Glucose Monitoring System.
219686151|NCT03920085|DEVICE|OneTouch Ultra|OneTouch Ultra Blood Glucose Monitoring System.
219686152|NCT00178737|BEHAVIORAL|Electronic reminder message|
219686153|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
219686154|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
219686155|NCT03461198|DEVICE|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
219686156|NCT02432339|DRUG|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
219686157|NCT02432339|DRUG|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
219686158|NCT03921736|DRUG|Perindopril|4 mg/day p.o. for 12 months
219686159|NCT03921736|DRUG|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
219686160|NCT03921736|DRUG|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
219686161|NCT06958796|DRUG|Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months|The interventional arm will receive Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months as (150 mg/kg) for 3 consecutive months (Days 0, 28 and 56 +/- 3 days). The non-interventional arm will not receive any intervention.
219686162|NCT06198920|PROCEDURE|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
219686163|NCT05017272|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
219686164|NCT03607799|BEHAVIORAL|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
219686165|NCT03607799|BEHAVIORAL|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
219686166|NCT05711095|DIETARY_SUPPLEMENT|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
219686167|NCT05711095|DIETARY_SUPPLEMENT|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
219686168|NCT05711095|DIETARY_SUPPLEMENT|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
219686169|NCT05179746|DEVICE|Implants are decontaminated with electrolytic cleaning|Implants are decontaminated with electrolytic cleaning
219686170|NCT05179746|DEVICE|Implants are decontaminated without electrolytic cleaning|Implants are decontaminated without electrolytic cleaning
219686171|NCT03191851|DEVICE|standard device|paracentesis using standard
219686172|NCT03191851|DEVICE|Melody Device|paracentesis using Melody Device
219686173|NCT03191851|DEVICE|Melody Device with Pump|paracentesis using Melody Device with Pump
219060904|NCT04247854|DIETARY_SUPPLEMENT|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
219060905|NCT04247854|OTHER|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
219060906|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
219060907|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
219060908|NCT02007486|OTHER|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
219060909|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
219060910|NCT03041415|BEHAVIORAL|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
219060911|NCT03041415|BEHAVIORAL|ALED + Our Voice PA Program|"* 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
219060912|NCT00137332|DRUG|GAP-486 (ZP-123)|
219060913|NCT00137332|DRUG|0.9% Sodium Chloride, USP|
219060914|NCT03818373|PROCEDURE|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
219060915|NCT00389714|DEVICE|dental restoration|
218959811|NCT05992571|DIETARY_SUPPLEMENT|β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
218959812|NCT02990156|DEVICE|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
218959813|NCT02990156|DEVICE|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
218959814|NCT01507454|DRUG|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
218959815|NCT03298776|DEVICE|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
218959816|NCT03298776|DIAGNOSTIC_TEST|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
218959817|NCT03722199|DIETARY_SUPPLEMENT|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
218959818|NCT03722199|OTHER|Placebo|single intake of capsules with a placebo
218959819|NCT03028350|DRUG|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
218959820|NCT03028350|DRUG|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
218959821|NCT03718182|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D3 daily oral supplement
218959822|NCT05386823|DRUG|HF1K16|HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
218959823|NCT05386823|DRUG|Placebo|Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
218959824|NCT05468385|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
218959825|NCT05468385|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
218959826|NCT05660980|DRUG|Once daily CAB tablet + RPV tablet|Tablet
218959827|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
218959828|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
219060916|NCT03269032|OTHER|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
219060917|NCT03269032|OTHER|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
219060918|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
219060919|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
219060920|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
219643210|NCT05645640|COMBINATION_PRODUCT|Village doctor-led tailored health management|"Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life."
219643211|NCT02855372|PROCEDURE|Lung transplantation|
219643212|NCT06030232|DEVICE|Therasphere|Transarterial radioembolization
219643213|NCT06628037|BIOLOGICAL|SN514-066b|Enzyme debrider
219643214|NCT00544401|OTHER|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
219643215|NCT01073813|DRUG|Minocycline|100mg twice daily
219643216|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
219643217|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
219643218|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
218959829|NCT05002153|OTHER|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
218959830|NCT05002153|OTHER|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
218959831|NCT00599781|GENETIC|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
218959832|NCT02519387|DRUG|Buprenorphine Transdermal Patch|
219643219|NCT01964144|DRUG|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
219643220|NCT05119322|DIAGNOSTIC_TEST|GlutenDetect home urine test|GFD compliance self-asessment using a home rapid test for GIP detection in urine.
219643221|NCT06721559|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
219643222|NCT06721559|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
219643223|NCT05039814|OTHER|postoperative acute kidney injury|patients suffered postoperative acute kidney injury
219643224|NCT05039814|OTHER|none postoperative acute kidney injury|patients did not suffered postoperative acute kidney injury
219643225|NCT00352222|DEVICE|stent implantation|
219643226|NCT04858061|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
219643227|NCT04858061|BEHAVIORAL|Treatment-as-usual|Pharmacotherapy and psychotherapy
219643228|NCT06784895|BEHAVIORAL|Women only Cardiac Rehab program|"This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.~This group orientation prior to starting CR will allow additional time for enhanced story telling among patients, provide a more detailed description of what to expect in CR, and allow additional time to address participant concerns or worries prior to starting CR. Women-specific education content will be provided monthly in addition to the standard weekly mini-teaches. This education content will be developed and delivered by experience health care professionals that are experts in women's health."
219643229|NCT06784895|BEHAVIORAL|Standard of Care (mixed-sex) rehab program|This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.
219643230|NCT05280444|DRUG|Idarubicin Hydrochloride for Injection|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
219643231|NCT00556933|DRUG|rabbit anti-thymocyte globulin - single dose|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
219643232|NCT00556933|DRUG|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
219643233|NCT00556933|DRUG|rabbit anti-thymocyte globulin - 4 doses|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
219643234|NCT00556933|DRUG|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
219643235|NCT00556933|DRUG|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
219643236|NCT00755599|PROCEDURE|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
219643237|NCT00755599|PROCEDURE|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
219643238|NCT03364400|DRUG|VT1021|Peptide
219643239|NCT00005777|PROCEDURE|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (\>52 mm Hg)
219643240|NCT00005777|PROCEDURE|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)
219643241|NCT00005777|DRUG|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
219643242|NCT00005777|DRUG|Placebo|The infants in the placebo groups received equal volumes of saline.
219643243|NCT06346444|OTHER|Diagnostic test and behavioral|Questionnaires (CGI, RSBQ) and Outcome measurements (Neuroscope, EEG, Brain MRI, Bone densitometry, X-ray of thoracic and lumbosacral spine Blood biomarkers-RNA, proteins, other metabolites-)
219643244|NCT02523976|DRUG|Dasatinib|Second-generation tyrosine kinase inhibitor
219643245|NCT02523976|DRUG|prednisone|
219643246|NCT02523976|DRUG|cyclophosphamide|
219643247|NCT02523976|DRUG|daunorubicin|
219643248|NCT02523976|DRUG|vincristine|
219643249|NCT02523976|DRUG|cytarabine|
219643250|NCT02523976|DRUG|mercaptopurine|
219643251|NCT02523976|DRUG|methotrexate|
219643252|NCT02523976|DRUG|dexamethasone|
219643253|NCT02523976|DRUG|mitoxantrone|
219643254|NCT02523976|DRUG|etoposide|
218959833|NCT02777749|DRUG|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
219060921|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
219643255|NCT02523976|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219643256|NCT02523976|PROCEDURE|autologous hematopoietic stem cell transplantation|
219643257|NCT00445497|DRUG|amoxicillin-clavulanate potassium|
219643258|NCT00445497|DRUG|ciprofloxacin|
219643259|NCT00445497|PROCEDURE|psychosocial assessment and care|
219643260|NCT00445497|PROCEDURE|quality-of-life assessment|
219643261|NCT01668173|DRUG|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
219643262|NCT01174706|BEHAVIORAL|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
219643263|NCT01240577|DRUG|IPdR|
219643264|NCT02300662|DEVICE|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
219643265|NCT02300662|OTHER|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
219643266|NCT00944086|OTHER|Recruitment Manoeuvre|Recruitment Manoeuvre
219643267|NCT00746564|DEVICE|SJM Confirm|All patients in this study will receive the SJM Confirm device.
219643268|NCT06235021|OTHER|Saffron|"Saffron powder (purchased from Moayeri Copmany2 in Oman, prepared from the stigma of Crocus sativus L.).~Total of 10 mg of saffron powder will be added to 100 ml of distilled water. Then, it will be incubated on a shaker for 24 h. The material will be passed through several layers of muslin cloth. The extracts will then be poured into a round bottom balloon and placed in the freezer at a temperature of -80°C. After freezing, the extracts were placed in a freeze-dryer.~In vacuum, the solvent will be removed and saffron powder will be obtained. After preparing the initial concentration, serial dilution with ratios of one-half and one-third will be performed in sterile vials and one-half of the final concentration will be discarded.~After the preparation of extract, the 0.2% saffron mouthwash will be prepared by mixing the following ingredients: 1. propylene glycol (5 g) 2. saffron extract (0.2 g) 3. polysorbate 80 (1.8 g) 4. sodium benzoate (0.2 g) 5. water (91 g)."
219643269|NCT06235021|OTHER|chlorhexidine mouthwash|commercial product of 0.2% chlorhexidine mouthwash.
218959834|NCT06052098|DEVICE|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
218959835|NCT06052098|DEVICE|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
218959836|NCT05198700|DIETARY_SUPPLEMENT|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
218959837|NCT05198700|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
218959838|NCT01850602|DRUG|PA21|
218959839|NCT01850602|DRUG|Sevelamer hydrochloride|
218959840|NCT01108978|DRUG|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
218959841|NCT01108978|DRUG|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
218959842|NCT00612898|DRUG|apricitabine|800mg BID apricitabine orally for 48 weeks
218959843|NCT00612898|DRUG|lamivudine|150mg BID lamivudine orally for 48 weeks
218959844|NCT06438627|DRUG|TPC combined with Apatinib and Camrelizumab|Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
218959845|NCT06438627|DRUG|GP Combined With Camrelizumab|Gemcitabine, Cisplatin regimen Combined With Camrelizumab
218959846|NCT03771547|DIAGNOSTIC_TEST|ERCP|
218959847|NCT01857310|DIETARY_SUPPLEMENT|5 mg folic acid and 30 mg elemental zinc|
218959848|NCT01857310|DRUG|Placebo Comparator: Placebo|
218959849|NCT03573102|DRUG|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
218959850|NCT03573102|DRUG|ACE inhibitor|ACE inhibitor once daily
218959851|NCT01041378|DRUG|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
218959852|NCT05606653|OTHER|Measurement of critical airway closing pressure|Measurement of critical airway closing pressure
218959853|NCT05606653|OTHER|Respiratory function tests|CO2 response test
218959854|NCT05606653|OTHER|pharyngometry|measure of the pharyngometry
218959855|NCT05752266|DIETARY_SUPPLEMENT|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
218959856|NCT05752266|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
219060922|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
219643270|NCT06578598|DEVICE|Igelplus|Intubation with Igelplus laryngeal mask
218959857|NCT02873520|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
219686174|NCT01635829|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
218959858|NCT02873520|BIOLOGICAL|Precision Cell Immunotherapy|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
218959859|NCT04118582|OTHER|Body composition and resting metabolic rate analisys|
218959860|NCT00407290|DRUG|neostigmine|
218959861|NCT03926546|BEHAVIORAL|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
218959862|NCT01275547|DRUG|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
218959863|NCT01275547|DRUG|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
218959864|NCT01252303|BEHAVIORAL|Nutrisystem|Nutrisystem meal replacements for 12 weeks
218959865|NCT06136988|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
218959866|NCT06136988|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
218959867|NCT06136988|DRUG|Cisplatin for injection|Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
218959868|NCT06136988|DRUG|Paclitaxel|Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
218959869|NCT06136988|RADIATION|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
219060923|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
219060924|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
219643271|NCT03318497|DRUG|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
219643272|NCT03318497|PROCEDURE|Computed Tomography|Undergo PET/CT
219643273|NCT03318497|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219643274|NCT03318497|OTHER|Laboratory Biomarker Analysis|Correlative studies
219643275|NCT03059745|PROCEDURE|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
219643276|NCT00077298|BIOLOGICAL|cetuximab|Given IV
219643277|NCT00077298|BIOLOGICAL|bevacizumab|Given IV
219643278|NCT00077298|DRUG|irinotecan hydrochloride|Given IV
219643279|NCT00077298|OTHER|laboratory biomarker analysis|Correlative studies
219643280|NCT04836962|DRUG|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
219643281|NCT04836962|DRUG|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
219643282|NCT00907491|DEVICE|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
219643283|NCT02921880|OTHER|Cardiac Rehabilitation|
219643284|NCT03732482|DRUG|Temozolomide capsules|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
219643285|NCT03732482|DEVICE|radiotherapy|Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
219643286|NCT02842580|DRUG|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
219643287|NCT02842580|DRUG|acide folinique|200 mg/m² if Elvorine
218959870|NCT01759888|DRUG|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
218959871|NCT03508427|OTHER|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
219643288|NCT02842580|DRUG|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
218959872|NCT04016584|BEHAVIORAL|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
219643289|NCT02842580|DRUG|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
219643290|NCT02842580|DRUG|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
219643291|NCT02842580|DRUG|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
219643292|NCT05972408|PROCEDURE|percutaneous nephrlolithotomy|Endoscopic removal of renal stones
219643293|NCT05972408|GENETIC|VDR gene, CASR gene|checking possible mutations of VDR and CASR genes
219643294|NCT00669565|DRUG|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
219643295|NCT01827267|DRUG|neratinib|
219643296|NCT01827267|DRUG|temsirolimus|
219643297|NCT03321851|DEVICE|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
219643298|NCT06218537|DIAGNOSTIC_TEST|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
219643299|NCT06218537|DIAGNOSTIC_TEST|Control group|Contains only sodium bicarbonate.
219643300|NCT04222998|OTHER|Home-based growth charts|The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
219643301|NCT04222998|OTHER|Home visits for baseline surveys|Households will be visited for baseline surveys.
219643302|NCT04222998|OTHER|Home visits for end line surveys|Households will be revisited after 1 year of grace-period for baseline end line surveys.
219643303|NCT04222998|OTHER|Measurement of child's height-for-age and weight-for-age|The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
219643304|NCT04896398|DEVICE|ESWT|In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
219643305|NCT04901247|BEHAVIORAL|media refreshment|20µL of culture medium is aspirated using Eppendorf PCR tips, and freshly, overnight equilibrated 20µL global total LP will be added to the same well
219643306|NCT04901247|BEHAVIORAL|embryo grading|embryo grading should be done prior to media refreshment
219643307|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
219643308|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
219643309|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
219643310|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
219643311|NCT01432301|DRUG|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
219643312|NCT00406263|PROCEDURE|Scheimpflug crystalline lens photographs|scheimpflug photographs
218959873|NCT01358071|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
219643313|NCT05533008|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg as a bolus injection
219643314|NCT05533008|OTHER|Placebo|IV Placebo as a bolus injection
218959874|NCT01358071|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
218959875|NCT01358071|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
218959876|NCT03398278|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
218959877|NCT03398278|DRUG|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
219643315|NCT01408316|DRUG|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
219643316|NCT02882217|DRUG|XC8 (histamine glutarimide)|
219643317|NCT02882217|DRUG|Placebo|
219643318|NCT02119455|DEVICE|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
219643319|NCT02439814|DRUG|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
219643320|NCT02439814|OTHER|Placebo|Inactive comparator
219643321|NCT03860402|OTHER|Temperature|temperature of drug
219643322|NCT03418233|DRUG|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
219643323|NCT03418233|DRUG|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
219643324|NCT00134706|DRUG|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
219643325|NCT00134706|DRUG|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
219643326|NCT06572306|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.
218959878|NCT02757950|BIOLOGICAL|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
219643327|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
219643328|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
218959879|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
218959880|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
218959881|NCT01337271|PROCEDURE|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
219060925|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
219686175|NCT01635829|DRUG|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
219686176|NCT01635829|DRUG|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
219686177|NCT00611585|DEVICE|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
219060926|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
219060927|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
219060928|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
219060929|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
219060930|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
219060931|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
219686178|NCT00248469|BEHAVIORAL|In-school Sexual Health Education|
219643329|NCT02400554|BEHAVIORAL|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, \& women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership \& personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion \& synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal \& leadership goals \& experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD \& obesity prevention. Includes: digital storytelling training to create a story related to ATOD \& obesity prevention \& an individual MI booster session to revise their personal \& community leadership goals.~Month 12: Share digital stories \& community event experiences \& undergo a ceremony to transition to health leaders within their communities."
219643330|NCT04813575|OTHER|Cryo lung biopsies|Bronchoscopic lung biopsy utilizing the cryo technique
219643331|NCT04152070|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
219643332|NCT06111859|DIAGNOSTIC_TEST|Ultrasound based Elastography and fat quantification|Correlation of ultrasound-based elastography and fat quantification on liver biopsy
219643333|NCT05580627|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
219643334|NCT05580627|OTHER|Live Modality (control)|For this evaluation, the live modality is considered the control group.
219643335|NCT00537576|BIOLOGICAL|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days
219643336|NCT00537576|BIOLOGICAL|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
219643337|NCT00537576|BIOLOGICAL|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
218959882|NCT01337271|PROCEDURE|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
218959883|NCT06325475|PROCEDURE|labor with neuraxial labor analgesia|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
219060932|NCT06634563|OTHER|mindfulness meditation|the patients will receive mindfulness meditation in the form of Attention-focusing technique (body scan, directing attention throughout the body in a relaxed, supine state) guided by audiotapes. Relaxing every part of the body by guided audiotape from head to toes and Sitting meditation (systematically directing attention to breath) guided by audiotapes. Relaxing deep rhythmic breathing with concentration on every breath.
219060933|NCT06634563|OTHER|cognitive behavioral training|Training sessions will include three cognitive training tasks each of them target a particular core cognitive capability and are grouped into three categories by target domain: memory (working memory), attention (selective attention), and problem solving (logical reasoning) through these games (organic order and fuse clues for logical reasoning training, lost in migration, trouble brewing, assist ants and train of thought for attention training and memory match and memory match one drive for working memory training).
219643338|NCT00537576|OTHER|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
219643339|NCT00537576|OTHER|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
219643340|NCT00537576|OTHER|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
219643341|NCT03222089|DRUG|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
219643342|NCT03222089|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
219643343|NCT03222089|DRUG|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
219643344|NCT03222089|DRUG|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
219643345|NCT03222089|DRUG|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
219643346|NCT03222089|DRUG|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
219643347|NCT01741766|OTHER|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
219643348|NCT06129435|BEHAVIORAL|Visuospatial Task (VST)|Participants randomized to the VST condition will play a visuospatial game (i.e., Tetris). Participants will be given two minutes to practice Tetris and then will be instructed to play for 15 minutes without stopping.
219686179|NCT00248469|BEHAVIORAL|Youth-friendly health services|
219686180|NCT00248469|BEHAVIORAL|Youth condom promotion & distribution|
219686181|NCT00248469|BEHAVIORAL|Community activities related to adolescent sexual health|
219686182|NCT03079167|DRUG|Epoetin Alfa|
219686183|NCT03079167|DRUG|Normal saline|
219686184|NCT00321906|DRUG|azathioprine|azathioprine 2mg/kg
219686185|NCT00321906|DRUG|sirolimus|sirolimus 2-4mg daily
218959884|NCT06325475|PROCEDURE|labour without noroaxial labor analgesia|"Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen."
219686186|NCT00516685|BIOLOGICAL|Recombinant Human rEGF-P64K/Montanide Vaccine|
219686187|NCT01018914|DRUG|Prograf|oral
219686188|NCT01018914|DRUG|Advagraf|oral
219686189|NCT01018914|DRUG|Myfortic|oral
219686190|NCT04380870|DIETARY_SUPPLEMENT|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
219643349|NCT06129435|BEHAVIORAL|Word Association Task (WAT)|Participants randomized to the WAT condition will play a word association game. Research staff members will read from a list of 300 words, not associated with trauma, to the participant. The participant will verbally respond to each word out loud with the first word that comes to their mind. This word association task will continue for 15 minutes or until all 300 words are read, whichever occurs first.
219643350|NCT06533956|OTHER|10-week gait training program combined with simultaneous blood flow restriction (BFR).|The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
219643351|NCT05401500|BIOLOGICAL|blood sample|blood sampling
219643352|NCT05154019|BEHAVIORAL|Managing Minds at Work Online Training|"The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them."
218959885|NCT00494845|BEHAVIORAL|Mindfulness|8-week mindfulness program will be compared to an education control group.
218959886|NCT00494845|BEHAVIORAL|Control: Health Education Class|8-week education program
218959887|NCT01527266|DIETARY_SUPPLEMENT|Carbohydrate drink|sucrose beverage
218959888|NCT01527266|DIETARY_SUPPLEMENT|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
218959889|NCT03191578|DRUG|RUTI®|Administration of RUTI®
218959890|NCT03191578|DRUG|Placebo|Administration of placebo
218959891|NCT00307879|DRUG|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
218959892|NCT00307879|PROCEDURE|collection of mobilized peripheral blood stem cells|
218959893|NCT00307879|PROCEDURE|Intracoronary infusion of mobilized cells|
218959894|NCT05025540|DIAGNOSTIC_TEST|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
219060934|NCT06635421|OTHER|Model of care delivery for long-acting injectable ART|This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
219060935|NCT05237622|DEVICE|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
219060936|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
219060937|NCT03788889|DRUG|Ketamine|Ketamine infusion
218959895|NCT04052724|BEHAVIORAL|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
218959896|NCT05894122|DIAGNOSTIC_TEST|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
218959897|NCT03053765|OTHER|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
218959898|NCT04757428|PROCEDURE|Endocrown|Endocrown
218959899|NCT03318718|DRUG|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
218959900|NCT03318718|DIAGNOSTIC_TEST|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
218959901|NCT03318718|DIAGNOSTIC_TEST|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
218959902|NCT01778179|DRUG|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~\- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
219643353|NCT06363773|RADIATION|Stereotactic Radiotherapy|"Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between.~Patients enrolled in the study would not have received this stereotactic radiotherapy outside the study, that is why this procedure is additional (compared to Standard of care) and considered as burdensome (as this is radiation). Before performing the stereotactic radiotherapy, patients will do a radiotherapy CT scanner (no injected) in order to prepare precisely the radiotherapy (treatment plan)."
219643354|NCT04326946|DEVICE|Alfapump|alfapump implementation
219643355|NCT00535717|PROCEDURE|uttarbasti (per urethral administration of medicated oil )|
219643356|NCT02573415|PROCEDURE|Uterus Transplant|transplant of a deceased donor uterus.
219643357|NCT04159454|DEVICE|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate \~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
219643358|NCT06675526|BEHAVIORAL|Detour|"Detour is a mobile game designed to assist youth with smoking cessation. First, Detour targets stimuli devaluation using a gamified go/no-go training. Second, the researchers aimed to reduce delay discounting in two ways; 1) players can replace neutral images in the go/no-go training with positive images from their own lives related to their future self; 2) players can set and monitor personal goals via the game, to promote future-self priming. Third, participants join a social shell comprising Instagram and TikTok content to provide psychoeducation about quitting smoking and to interact with fellow players who quit simultaneously. Finally, the timing and content of in-game messaging is personalized to each participant based on information provided in an ecological momentary assessment component and a stop plan filled out during the week before the quit attempt."
219643359|NCT06675526|BEHAVIORAL|Self-help brochure|The brochure provides guidelines to independently design a stop-plan including questions about seeking support from others, strategies to fight cravings, and setting rewards for milestones after quitting. Participants will be encouraged to complete this stop-plan in week 0 of the intervention, so the week before quit day. Additionally, the brochure includes psychoeducational information that is valuable when planning to quit smoking.
219643360|NCT01421160|DRUG|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
219643361|NCT00001344|DRUG|dextromethorphan|
219643362|NCT01268930|PROCEDURE|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
219643363|NCT01268930|PROCEDURE|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
219643364|NCT03129945|DRUG|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
219643365|NCT03129945|DRUG|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
219643366|NCT06389045|OTHER|Procedural Sedation|Profopol Sedation in Endoscopic Ultrasonography
219643367|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
218959903|NCT01778179|PROCEDURE|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
219643368|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
219643369|NCT03082157|BEHAVIORAL|Mighty Men Intervention|African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.
219643370|NCT05397392|OTHER|guideline recommended routine treatment|
219643371|NCT03183089|DRUG|Rohto Dry-Aid®|
218959904|NCT02220127|RADIATION|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
218959905|NCT02220127|RADIATION|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
218959906|NCT02497976|BIOLOGICAL|Certolizumab pegol|400 mg
218959907|NCT02497976|DRUG|Placebo|Normal saline
218959908|NCT05143359|DIAGNOSTIC_TEST|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
218959909|NCT05143359|DIAGNOSTIC_TEST|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
218959910|NCT04801316|BEHAVIORAL|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
218959911|NCT04801316|BEHAVIORAL|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
218959912|NCT00170963|DRUG|valsartan/amlodipine|
218959913|NCT00745225|DRUG|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
218959914|NCT00745225|DRUG|placebo comparator|1 capsule daily, 96 weeks.
218959915|NCT01911637|DRUG|VBY-036|Study drug VBY-036
218959916|NCT01911637|DRUG|Placebo|Placebo
219060938|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
219643372|NCT03183089|DRUG|Systane® Ultra|
218959917|NCT03013127|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
219643373|NCT06398067|BEHAVIORAL|Vietnamese Self-Help Plus (vSH+)|vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
219643374|NCT06398067|OTHER|'Doing What Matters in Times of Stress' (DWM) Guide|An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
219643375|NCT02953444|OTHER|Thirty-Second Mindfulness Practice|
219643376|NCT02953444|OTHER|Three-Minute Mindfulness Practice|
219643377|NCT05736640|DRUG|Denosumab|
219643378|NCT05736640|DRUG|Placebo|
219643379|NCT03424772|DIAGNOSTIC_TEST|Whole genome sequencing|WGS will be performed for the trio
219643380|NCT00986921|DRUG|mifepristone 200 mg|mifepristone would be given the day before the procedure
219643381|NCT00986921|DEVICE|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
219643382|NCT05353855|OTHER|No intervention|No intervention
219643383|NCT02660281|RADIATION|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
219643384|NCT02660281|DRUG|Fludarabine|Fludarabine
219643385|NCT02660281|DRUG|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
219643386|NCT02660281|DRUG|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
219643387|NCT02660281|DRUG|Busulfan|Busulfan
219643388|NCT02660281|DRUG|Melphalan|Melphalan
219643389|NCT02660281|PROCEDURE|Stem Cell Infusion|Stem cell infusion
218959918|NCT05610085|DRUG|Levetiracetam Injection|Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
218959919|NCT05610085|DRUG|Phenobarbital Sodium Injection|Standard of care for neonatal seizures
219060939|NCT03788889|DRUG|Lorazepam|Standard of Care
218959920|NCT04049227|DRUG|Abemaciclib|Given PO
218959921|NCT04049227|DRUG|Letrozole|Given PO
219643390|NCT02660281|DRUG|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
219643391|NCT02660281|DRUG|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
219643392|NCT02660281|DRUG|Thiotepa|Thiotepa
219643393|NCT00813813|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
219643394|NCT06234748|RADIATION|Radiation|"Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume\_2 wks+ MTV3\_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV\_2 wks + MTV3\_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
219643395|NCT06234748|DRUG|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
219643396|NCT01528826|DRUG|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
219643397|NCT02017795|OTHER|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
218959922|NCT04049227|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
219060940|NCT03788889|DRUG|Placebo A|Placebo injection
219060941|NCT03788889|DRUG|Placebo B|Placebo infusion
219060942|NCT02032901|DRUG|Daclatasvir|
219060943|NCT02032901|DRUG|Sofosbuvir|
219060944|NCT00444158|DRUG|MOA-728|
219643398|NCT02017795|OTHER|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
219643399|NCT03371017|DRUG|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
219643400|NCT03371017|DRUG|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
219643401|NCT03371017|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
219643402|NCT03371017|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
219643403|NCT03371017|DRUG|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
219643404|NCT00419484|DRUG|pioglitazone|
219643405|NCT01167114|DRUG|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
219643406|NCT01220388|DIETARY_SUPPLEMENT|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
219643407|NCT01220388|DIETARY_SUPPLEMENT|placebo|placebo, 3 times a day, orally, during meals
219643408|NCT01720654|BEHAVIORAL|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
219643409|NCT00003427|DRUG|irinotecan hydrochloride|
219643410|NCT00003427|DRUG|oxaliplatin|
218959923|NCT05871983|DEVICE|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
219643411|NCT00250627|DRUG|Saredutant succinate (SR48968C)|
219643412|NCT00833482|DRUG|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
219643413|NCT00833482|DRUG|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
219643414|NCT00833482|DRUG|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
219643415|NCT01710189|DRUG|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
219643416|NCT01128998|DRUG|Sorafenib|"1. Name: Sorafenib~2. Dosage form: 200 mg / Tablet~3. Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
219643417|NCT01128998|DRUG|S-1|"1. Name:S-1~2. Dosage form: 20 mg or 25 mg / Capsule~3. Dosing schedule: 20-40 mg/m2 bid,po, 14 days on \& 7 days off"
219643418|NCT05866744|OTHER|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
219643419|NCT05866744|OTHER|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
219643420|NCT05866744|OTHER|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
219643421|NCT04412343|BEHAVIORAL|Virtual Group Intervention|Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.
219643422|NCT04412343|BEHAVIORAL|Personal Exercise Intervention|Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
219643423|NCT05956132|OTHER|retrospective study|data collection from clinical history and medical records
219643424|NCT06665087|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
219643425|NCT06665087|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
219643426|NCT06665087|DRUG|PD-1 antibody|Sintilimab
218959924|NCT06231836|DEVICE|High flow nasal cannula (HFNO)|O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
218959925|NCT06231836|DEVICE|nasal cannula|O2 is administered by nasal cannula at 6L/min
219643427|NCT06665087|DRUG|Chemotherapy (Fluorouracil)|5-Fluorouracil or capecitabine
219643428|NCT06665087|DRUG|Chemotherapy (Raltitrexed)|Raltitrexed
219643429|NCT06665087|DRUG|Chemotherapy (Oxaliplatin)|Oxaliplatin
219060945|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
219060946|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
219060947|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
219643430|NCT06665087|DRUG|Chemotherapy (CPT-11)|Irinotecan
219643431|NCT06665087|DRUG|Targeted Therapy (anti-VEGF)|anti-VEGF antibody
219643432|NCT06665087|DRUG|Targeted Therapy (anti-EGFR)|anti-EGFR antibody
219643433|NCT05711056|BEHAVIORAL|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~* Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~* Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
219643434|NCT04153149|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
219643435|NCT04153149|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection.
219643436|NCT02779764|DRUG|roxadustat|Oral
219643437|NCT01392027|PROCEDURE|Blood Draw|Blood draw for research specimens only
219643438|NCT02876991|PROCEDURE|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
219643439|NCT02778074|BEHAVIORAL|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
219643440|NCT02778074|BEHAVIORAL|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
219643441|NCT04229329|COMBINATION_PRODUCT|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
219643442|NCT04229329|COMBINATION_PRODUCT|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
219643443|NCT04454684|DRUG|Midomafetamine|Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.
219643444|NCT04454684|BEHAVIORAL|Non-directive therapy|Non-directive therapy will be conducted during Experimental Sessions.
219643445|NCT04454684|BEHAVIORAL|Therapy|Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
219643446|NCT06684808|OTHER|Fitness|The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements.
219643447|NCT06684808|OTHER|Creative|The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.
219643448|NCT06684808|OTHER|Combined|The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.
219643449|NCT06684808|OTHER|Control|Regular physical activity at school during the weeks.
219643450|NCT06209970|DRUG|HA35|All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
219643451|NCT04173975|DEVICE|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
219223671|NCT07014293|OTHER|SMART3RP-Lymphoma|The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.
219643452|NCT04538547|RADIATION|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
219643453|NCT04538547|RADIATION|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
219643454|NCT06079177|DEVICE|Ultrasound|LUS using B-lines Caval-Aorta index using ultrasound
219643455|NCT00481598|PROCEDURE|magnet resonance spectroscopy|magnet resonance spectroscopy
219643456|NCT06684197|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.
219643457|NCT06684197|DRUG|Placebo|Saline will be used instead of dexmedetomidine
219223672|NCT07012759|OTHER|biomarkers|pleural effusion biomarkers in lung adenocarcinoma
219643458|NCT05861492|OTHER|Fatigue Differential Diagnosis Aid|The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
219643459|NCT00621868|DRUG|ipragliflozin|Oral
219643460|NCT00621868|DRUG|Placebo|Oral
219643461|NCT02231138|DRUG|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
219643462|NCT05402969|PROCEDURE|Transimedance Matrix measurements|TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes
219643463|NCT05402969|PROCEDURE|Depth sounding and spectroscopy|Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.
219643464|NCT05402969|PROCEDURE|Cone Beam Computer Tomography|CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
219643465|NCT01062542|PROCEDURE|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
219643466|NCT00487006|OTHER|Serum Lab testing|Serum Lab testing
219643467|NCT05742009|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
219643468|NCT05742009|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
219643469|NCT05742009|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
219643470|NCT03764878|DIAGNOSTIC_TEST|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
219643471|NCT03489707|BEHAVIORAL|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
219643472|NCT03489707|BEHAVIORAL|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
219643473|NCT02587507|OTHER|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
219643474|NCT02587507|OTHER|Water|Individuals will consume the HFHC meal with 500mL of water.
219643475|NCT02587507|OTHER|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
219643476|NCT01817582|DRUG|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
219643477|NCT01817582|DRUG|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
219643478|NCT01817582|DRUG|Soothe® Lubricant Eye Drops|
219207768|NCT06717295|OTHER|DiNanoTrack: Therapeutic Response Monitoring Blood Test|"Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance."
219643479|NCT06094660|PROCEDURE|Diagnostic genicular nerve block|Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.
219643480|NCT06094660|PROCEDURE|Genicular nerve block with Radiofrequency Ablation (RFA)|"Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds."
219643481|NCT06094660|PROCEDURE|Genicular nerve block with Phenol 6%|"Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary."
219643482|NCT06576440|DRUG|Ghrelin|Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.
219643483|NCT06576440|DRUG|Saline|Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.
219643484|NCT01092091|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
219643485|NCT06057662|OTHER|personalized comprehensive diabetes support|personalized comprehensive diabetes support
219643486|NCT02358096|DRUG|ASP8232|oral capsule
219643487|NCT02358096|DRUG|Placebo|oral capsule
219643488|NCT05432154|DEVICE|Film forming silicone gel (7-0940)|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
219643489|NCT04233047|DRUG|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
219643490|NCT01489215|BEHAVIORAL|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
219643491|NCT01489215|BEHAVIORAL|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
219643492|NCT04744233|OTHER|Orange juice|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed were: freshly squeezed (FS), commercially available low pasteurized juice (LP) and juices treated by high-pressure processing (HPP) and by pulsed electric fields (PEF). All participants consumed the LP and the HPP orange juices. Six subjects consumed PEF-orange juice and other six consumed the FS-orange juice.
219643493|NCT04630691|PROCEDURE|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
219643494|NCT06769256|DRUG|rhTNK-tPA, 4-8 mg|Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.
219643495|NCT06769256|DRUG|Tirofiban|Intracoronary influsion of Tirofiban (10 µg/kg) , and then administered intravenously at 0.075-0.15 µg/kg.min for 36 h or longer
219643496|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
219643497|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
219643498|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
219643499|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
219643500|NCT04237103|DRUG|Methotrexate|oral capsules taken once a week
219643501|NCT04237103|DRUG|Placebos|Administered identically to the experimental group
219643502|NCT00170625|DRUG|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
219643503|NCT04514445|OTHER|Observational|
219643504|NCT00685204|DRUG|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
219643505|NCT05305885|DRUG|Pemetrexed|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
219223673|NCT07014215|DRUG|Sintilimab combined with Bevacizumab and tafolecimab|Patients who met the inclusion criteria were treated with sintilimab(200mg Q3W) combined with Bevacizumab(7.5mg/kg Q3W) and tafolecimab(600mg Q6W) until disease progression or intolerable adverse reactions or death(up to 24 months)
219643506|NCT05305885|RADIATION|Radiotherapy|Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
219643507|NCT01600456|BEHAVIORAL|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
219643508|NCT01600456|OTHER|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
219643509|NCT04604392|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
219643510|NCT01733290|DRUG|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
219223674|NCT07012447|DRUG|Venetoclax|Orally by mouth
219643511|NCT01733290|DRUG|Normal saline instillation|Normal saline instillation
219643512|NCT02842710|DEVICE|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
219643513|NCT03617770|BEHAVIORAL|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
219643514|NCT03617770|BEHAVIORAL|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
219643515|NCT03563352|OTHER|Interview|Attend an interview
219643516|NCT03563352|OTHER|Survey Administration|Ancillary studies
219643517|NCT03475862|DRUG|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
219643518|NCT03475862|DRUG|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
219643519|NCT03475862|DRUG|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
219643520|NCT03475862|OTHER|Placebo|Matching placebos for PTI-821 and oxycodone IR
219643521|NCT03475862|DRUG|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
219643522|NCT00792792|DEVICE|Modulated Imaging|Modulated Imaging Spectroscopy
219643523|NCT04921826|OTHER|online survey|online survey
219643524|NCT03963232|DRUG|Galcanezumab|Administered SC
219643525|NCT03963232|DRUG|Placebo|Administered SC
219060948|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
219643526|NCT05510570|GENETIC|The research does not require interventions|We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmental language disorder) children.
219643527|NCT05806632|OTHER|Prognostic model|Risk assessment and risk stratification
219643528|NCT00356135|DRUG|prasugrel 10 mg|10 mg tablet taken orally
219643529|NCT00356135|DRUG|clopidogrel|75 mg tablet taken orally
219643530|NCT00356135|DRUG|prasugrel placebo|oral, as blinding mechanism.
219643531|NCT00356135|DRUG|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
219643532|NCT00356135|DRUG|clopidogrel placebo|oral, as blinding mechanism
219643533|NCT04965311|BIOLOGICAL|Botulinum Toxin Type A|Given via endoscopic injection into intraduodenal sphincter of Oddi segment
219643534|NCT04143854|DRUG|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
219643535|NCT04143854|DRUG|Placebo|Intramuscular injection; normal saline
219643536|NCT02898428|DEVICE|Continuous glucose monitoring (CGM)|
219643537|NCT03138759|DRUG|Pexidartinib|Orally, on Day 2
219643538|NCT03138759|DRUG|Probenecid|Orally, on Day 2
219643539|NCT03512210|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
219643540|NCT03512210|OTHER|Minimal Monitoring (MINMON) Strategy|"MINMON Strategy:~1. No pre-treatment HCV genotyping~2. Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~3. No scheduled on-treatment laboratory monitoring or clinic visits~4. Remote contact with participants at week 4 and week 22"
219643541|NCT02586038|DRUG|MLN9708|
219643542|NCT02586038|DRUG|Dexamethasone|
219643543|NCT02586038|DRUG|Cyclophosphamide|
219643544|NCT02586038|DRUG|Thalidomide|
219060949|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
219060950|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
219223675|NCT07012447|DRUG|Azacitidine|Subcutaneous injection
219223676|NCT07012447|DRUG|Cytarabine|Intravenous infusion
219643545|NCT04638764|OTHER|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
219643546|NCT04638764|OTHER|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
219643547|NCT04638764|OTHER|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
219643548|NCT04725955|OTHER|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
219643549|NCT01547260|DRUG|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
219643550|NCT01547260|DRUG|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
219643551|NCT04649840|DIAGNOSTIC_TEST|Humoral and cellular immunity|Humoral (IgG) and cellular (antigen-specific cells) immunity
219643552|NCT04199169|BIOLOGICAL|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
219643553|NCT04199169|BIOLOGICAL|Normal Saline Placebo|0.9% Saline
219643554|NCT03660774|OTHER|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
219643555|NCT01590069|BIOLOGICAL|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
219643556|NCT01590069|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219643557|NCT03285867|PROCEDURE|TACE|transcatheter arterial chemoembolization
219643558|NCT03642964|DRUG|CTC-501|pramipexole IR, given with ondansetron
219643559|NCT02169141|OTHER|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
219643560|NCT03070769|PROCEDURE|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
219643561|NCT02589236|DRUG|Cavosonstat|GSNOR inhibitor
219643562|NCT02589236|DRUG|Placebo|Control sample with only capsule excipients and fillers
219643563|NCT03760367|OTHER|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
219643564|NCT03760367|OTHER|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
219643565|NCT06492265|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
219643566|NCT06492265|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
219643567|NCT05678244|DRUG|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
219643568|NCT05678244|DRUG|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
219643569|NCT05299944|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in opioid consumption, opioid craving, pain, peripheral markers of inflammation, and anxiety, as well as changes in sleep, AEA, and cognition.
219643570|NCT05299944|DRUG|Placebo|Placebo arm
219643571|NCT00811317|DEVICE|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
219643572|NCT01803503|DRUG|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
219643573|NCT01803503|DRUG|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
219643574|NCT04809857|OTHER|Exercise|
218959926|NCT06424665|DRUG|FZ-AD005|Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
218959927|NCT00584740|DRUG|AIN457|10 mg/kg
219643575|NCT06035081|DRUG|Prednisolone|see arm description
219643576|NCT06035081|OTHER|Placebo|Placebo similar to prednisolone
219643577|NCT03928756|BEHAVIORAL|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
219643578|NCT03928756|BEHAVIORAL|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
219643579|NCT03928756|BEHAVIORAL|No Push Notifications|Participants will not receive a push notification.
219643580|NCT03806699|BIOLOGICAL|Placebo|Sterile normal saline
219643581|NCT03806699|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
219643582|NCT00115245|DRUG|Telbivudine (LdT)|
219643583|NCT00115245|DRUG|Adefovir Dipivoxil|
219643584|NCT05830981|OTHER|Educational intervention|3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
219643585|NCT00378508|DRUG|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
219643586|NCT00378508|DRUG|Placebo Arm|
219643587|NCT00006485|DRUG|alvocidib|
219643588|NCT00006485|DRUG|irinotecan hydrochloride|
219643589|NCT04289207|DRUG|Romiplostim and danazol|Treatment with romiplostim and danazol
219643590|NCT04827628|DIETARY_SUPPLEMENT|Oryza Sativa Extract|The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.
219643591|NCT04827628|DIETARY_SUPPLEMENT|Control|citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal
219643592|NCT05697237|DRUG|Carrelizumab|Carrelizumab 200mg/3 weeks
219643593|NCT05697237|DRUG|Solfantinib|Solfantinib 300mg/d
219643594|NCT04563871|DRUG|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
219643595|NCT04960683|DEVICE|Lokomat training|"Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~* 5 sessions of 45 minutes a week, each session includes:~* 5 minutes of stretching exercise~* 20 minutes of strengthening exercise~* 10 minutes of balance exercise~* 10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~* 5 sessions of 45 minutes of conventional therapy (same as above) per week~* 5 sessions of 45 minutes on Lokomat per week"
218959928|NCT00584740|DRUG|Placebo|Matching placebo to AIN457
218959929|NCT05305417|PROCEDURE|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
219643596|NCT02014233|DIETARY_SUPPLEMENT|Omega-3|
219643597|NCT02014233|DIETARY_SUPPLEMENT|Olive oil|
219643598|NCT00950040|BEHAVIORAL|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
219643599|NCT00950040|BEHAVIORAL|General health education|The intervention will consist of information about several general health behaviors.
219643600|NCT00559624|DRUG|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
219643601|NCT02393924|OTHER|No intervention|
219643602|NCT02478034|OTHER|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
219643603|NCT05454969|BEHAVIORAL|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
219643604|NCT05454969|BEHAVIORAL|Control|Patients will receive standard of care.
219643605|NCT06392139|BEHAVIORAL|Specific Therapy Program for Personality Disorders|The program was founded in 1999; since then, it has provided a wide range of different treatment interventions (outpatient, inpatient and day care). The interventions are psychoanalytically oriented and specifically for patients with Borderline Personality Disorder. Most of them are in the form of group psychoanalytic psychotherapy. The program consists of two steps: 1) an initial reception outpatient clinic where patients are followed after the referral to the Program, for a period of 6-8 months. This first step consists of monthly psychodynamically oriented sessions, monthly psychiatric appointments and application of psychological assessment instruments. The intervention focuses on crisis management and construction of the treatment plan for every patient. 2) The second step consists of long-term psychodynamic psychotherapy interventions, in combination with psychiatric treatment when it is is needed.
219643606|NCT06392139|OTHER|Treatment As Usual (TAU) Group|"The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital.~Treatment As Usual (TAU) The TAU includes the psychiatric management, consultation and pharmacotherapy if needed in the two Specific Outpatient Clinics for BPD patients. TAU provides one thirty minutes session per month. In case of crisis management patients contact their psychiatrist during the working hours, or after that they leave a message on the telephone answering machine and if needed make a visit in the Emergency Department of the Hospital on Duty."
219643607|NCT03540004|DEVICE|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
219643608|NCT01556568|DRUG|MEK162|
219643609|NCT06620601|DIAGNOSTIC_TEST|Portable Polysomnography|Research assistants set up the portable polysomnography (Prodigy) for the overnight sleep study.
219643610|NCT06620601|DEVICE|Treatment|Based on the decision aid, patient preference, and CADTH recommendations, the sleep physicians will recommend the participant to use Auto-CPAP or MAD for six months.
219643611|NCT06620601|OTHER|Questionnaires|Participants will complete eleven questionnaires: Stop-Bang, Insomnia severity index, Epworth sleepiness score (ESS), quality of life (FOSQ-10), Beck Depression Inventory (BDI), Chalder Fatigue Scale (CFQ), primary care post-traumatic stress disorder (PTSD) scale (PC-PTSD-5), Asthma control questionnaire (ACQ), OHIP-14, and Participant demographics. The RA will help the participants complete the questionnaires (\~one and a half hours in total).
219643612|NCT01665820|DEVICE|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
219643613|NCT05524818|DIAGNOSTIC_TEST|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
219643614|NCT03326349|OTHER|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
219643615|NCT03326349|OTHER|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
218959930|NCT05305417|PROCEDURE|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
218959931|NCT02973607|PROCEDURE|Nephrectomy|This is observational in design.
218959932|NCT03657303|DEVICE|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
218959933|NCT02299778|DIETARY_SUPPLEMENT|13C6-p-aminobenzoic acid|
219643616|NCT04967547|OTHER|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
219643617|NCT04967547|OTHER|Education|Education on renal replacement therapy and dialysis
219643618|NCT06485440|DRUG|Dysport 300 UNT Injection|300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
219643619|NCT06648057|DRUG|lenvatinib plus pembrolizumab|"* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens)."
219643620|NCT03940274|BEHAVIORAL|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
219643621|NCT01764789|OTHER|questionnaire administration|Ancillary studies
219643622|NCT01764789|PROCEDURE|quality-of-life assessment|Patients will participate in a quality life assessment.
219643623|NCT01764789|PROCEDURE|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
219643624|NCT01764789|BEHAVIORAL|behavioral intervention|Participate in multi-component biobehavioral intervention
219643625|NCT01764789|OTHER|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
219643626|NCT01764789|OTHER|educational intervention|Participate in multi-component biobehavioral intervention
219643627|NCT01607229|OTHER|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
219643628|NCT04384861|BEHAVIORAL|Mayo Clinic SMART program (Stress Management and Resilience Training)|The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
219643629|NCT04760041|DRUG|Midazolam nebulized|midazolam nebulized
219643630|NCT04760041|DRUG|Midazolam oral solution|midazolam given oral
219643631|NCT01585324|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
219643632|NCT01585324|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
219643633|NCT05780970|OTHER|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
219643634|NCT01037517|DRUG|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
219643635|NCT01037517|OTHER|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
219643636|NCT04669873|RADIATION|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
219643637|NCT04669873|RADIATION|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
219643638|NCT04669873|RADIATION|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
219643639|NCT05262309|DRUG|Pamrevlumab|"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."
219643640|NCT05013151|DIETARY_SUPPLEMENT|Dates|Consumption of 6 dates a days until 41 weeks of gestation
219643641|NCT05013151|DIETARY_SUPPLEMENT|Castor oil|One time consumption of 60 CC Castor oil
219643642|NCT05156372|OTHER|High Intensity Interval Training|Participants will perform high-intensity aerobic and resistance exercise
219643643|NCT06619314|DRUG|MK-1084|Oral Tablet
219643644|NCT06619314|DRUG|PPI|Oral Capsule
219643645|NCT03784209|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
219643646|NCT02461706|DRUG|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
219643647|NCT02461706|OTHER|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
219643648|NCT03659175|OTHER|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
219643649|NCT05830136|DRUG|sodium bicarbonate Ringer's solution|Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
219643650|NCT03430479|DRUG|Cohort A|Radiation + Nivolumab + hormone therapy
219643651|NCT04815265|DRUG|Remimazolam|Remimazolam is used for sedation
219643652|NCT04815265|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation
219643653|NCT05318092|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
219643654|NCT01914146|OTHER|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
219643655|NCT01914146|OTHER|No Insulin|Study session will occur prior to initiation of insulin therapy.
219643656|NCT03303573|DRUG|recombinant human erythropoietin|Subcutaneous rhEPO injection
219643657|NCT06666166|DRUG|SHR-A1811 & Apartinib|SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
219643658|NCT00048802|DRUG|Lithium|
219643659|NCT00048802|DRUG|Olanzapine|
219643660|NCT00048802|DRUG|Divalproex|
219643661|NCT00048802|DRUG|Risperidone|
219643662|NCT00048802|DRUG|Quetiapine|
219643663|NCT00048802|DRUG|Ziprasidone|
219643664|NCT00048802|DRUG|Aripriprazole|
219643665|NCT04796623|DRUG|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
219643666|NCT04796623|DRUG|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
219643667|NCT03638999|DRUG|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
219643668|NCT03638999|DRUG|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
219643669|NCT03917472|DRUG|Brolucizumab|Intravitreal injection
219643670|NCT03917472|DRUG|Aflibercept|Intravitreal injection
219643671|NCT03075345|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
219643672|NCT03075345|BEHAVIORAL|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
219643673|NCT04434469|DRUG|RO7297089|RO7297089 will be given via intravenous (IV) infusion
219643674|NCT03788434|DRUG|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
219643675|NCT03788434|DRUG|Placebo|Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
219643676|NCT02991729|OTHER|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
219643677|NCT02991729|OTHER|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
219643678|NCT05225298|BEHAVIORAL|Offering SARS-CoV-2 test|A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
219643679|NCT06263998|DRUG|NCP112|NCP112 topical ophthalmic solution
219643680|NCT06263998|DRUG|NCP112 Placebo|Placebo comparator
219643681|NCT05234879|OTHER|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
219643682|NCT01037595|DRUG|turmeric|turmeric 500 md tid orally for 8 weeks
219643683|NCT01037595|DRUG|placebo|placebo 3 time orally for 8 weeks
219643684|NCT01037595|DRUG|turmeric|500 mg tid orally for 8 weeks
219643685|NCT02753387|DRUG|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
219643686|NCT02753387|DEVICE|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
219643687|NCT05167370|DRUG|Amifostine|Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
219643688|NCT03812770|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
219643689|NCT03812770|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219643690|NCT03812770|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
219643691|NCT00570544|DRUG|tiotropium|18ug capsule daily for 30 days
219643692|NCT06257342|PROCEDURE|6 minutes walk|A 6 minutes walk test
219643693|NCT05923242|BEHAVIORAL|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
219643694|NCT02935504|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
219643695|NCT02935504|BEHAVIORAL|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
219643696|NCT00415116|DRUG|carboplatin|
219643697|NCT00415116|DRUG|docetaxel|
219643698|NCT00415116|DRUG|lenalidomide|
219643699|NCT04887090|DEVICE|Acupuncture and Drug Compound Technology|Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.
219643700|NCT04887090|OTHER|Routine perioperative management|Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.
219643701|NCT02180984|DEVICE|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
219643702|NCT00869284|DRUG|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
219643703|NCT00869284|PROCEDURE|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
219643704|NCT06440330|DEVICE|continuous glucose monitoring|continuous glucose monitoring will be used during the first 14 days post-transplantation
219643705|NCT01070095|OTHER|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
218959934|NCT04688879|PROCEDURE|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
218959935|NCT00930982|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
219643706|NCT01740271|DRUG|Epirubicin|
219643707|NCT02428049|RADIATION|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
218959936|NCT00930982|DRUG|Placebo|Inhalation of matching placebo twice a day
218959937|NCT02272543|DIETARY_SUPPLEMENT|Fish surimi peptide|
218959938|NCT04637906|DIETARY_SUPPLEMENT|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
218959939|NCT00034749|DRUG|Risperidone|
218959940|NCT04230564|DRUG|azacitidine|Patients taking azacitidine
218959941|NCT04230564|DRUG|venetoclax|patients taking venetoclax
218959942|NCT04230564|DRUG|glasdegib|patients taking glasdegib
218959943|NCT06290973|PROCEDURE|surgery of varicose veins|including ablation with radiofrequency, phlebectomy and saphenectomy.
219060951|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
219643708|NCT02796352|DRUG|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
219643709|NCT00489775|DRUG|Duloxetine|
219643710|NCT00489775|DRUG|Paroxetine|
218959944|NCT02288143|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm."
219643711|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
219643712|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
219643713|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
219643714|NCT06347055|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Continuous theta burst rTMS
219643715|NCT06649136|DRUG|Methotrexate|comparison between oral and subcutaneous methotrexate dosis of 25mg
219643716|NCT01828541|BEHAVIORAL|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
219643717|NCT01828541|OTHER|Standard of Care|
219643718|NCT04062032|DRUG|Aspirin 81 mg|ASA 81mg taken daily
219643719|NCT04062032|DRUG|Aspirin 325mg|ASA 325mg taken daily
219643720|NCT02429388|DRUG|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
219643721|NCT04826887|OTHER|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
219643722|NCT04826887|OTHER|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
219643723|NCT03831412|BEHAVIORAL|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
219643724|NCT03831412|BEHAVIORAL|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
219643725|NCT04676958|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
219643726|NCT04676958|DIETARY_SUPPLEMENT|Micro-crystalline cellulose|Micro-crystalline cellulose
219643727|NCT05838339|BEHAVIORAL|Healthy Sleep Intervention|The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
218959945|NCT02616471|DIETARY_SUPPLEMENT|High-fat cheese|
218959946|NCT02616471|DIETARY_SUPPLEMENT|Low-fat cheese|
218959947|NCT02616471|DIETARY_SUPPLEMENT|No-cheese/carbohydrate|
218959948|NCT02224118|DRUG|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
219643728|NCT06622772|DEVICE|Valsalva assist device|A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.
219643729|NCT06622772|OTHER|standard Valsalva manoeuvre|The Valsalva manoeuvre is carried out without any device.
219643730|NCT04450784|OTHER|collection of the clinical and biological characteristics of secondary AMLs in children|to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
219643731|NCT00124202|BEHAVIORAL|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
219643732|NCT05796284|BEHAVIORAL|Breast pressure relief intervention at the end of pregnancy|When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
219643733|NCT05796284|OTHER|Routine care|Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
219643734|NCT03638284|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
219643735|NCT04283682|BEHAVIORAL|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
219643736|NCT01192529|DIETARY_SUPPLEMENT|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
219643737|NCT01192529|DIETARY_SUPPLEMENT|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
219643738|NCT04083469|BEHAVIORAL|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
218959949|NCT02224118|DRUG|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
219643739|NCT04083469|BEHAVIORAL|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
219643740|NCT04083469|BEHAVIORAL|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
219643741|NCT03761758|DEVICE|Spectacle lenses|Spectacle lenses with clear central apertures
218959950|NCT02224118|DRUG|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
218959951|NCT02224118|DRUG|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
218959952|NCT02224118|DRUG|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
218959953|NCT04281953|DIAGNOSTIC_TEST|High frequency audiometry|Simple hearing test
218959954|NCT04281953|OTHER|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
218959955|NCT04281953|OTHER|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
218959956|NCT04281953|OTHER|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
218959957|NCT03282331|PROCEDURE|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
219223677|NCT07014254|DRUG|177Lu-CTR-FAPI nuclide-targeted therapy|Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle
219643742|NCT06618716|BIOLOGICAL|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|Intravenous administration of endotoxin (0.8 ng/kg body weight)
218959958|NCT03282331|PROCEDURE|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
219643743|NCT06618716|OTHER|Placcebo|Placebo injection of 0.9% NaCl
218959959|NCT03282331|PROCEDURE|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
218959960|NCT02067052|PROCEDURE|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
218959961|NCT02067052|PROCEDURE|Surgery|Vulvectomy \& lymphadenectomy
219643744|NCT01306318|DRUG|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
219643745|NCT01306318|DRUG|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
218959962|NCT03217981|OTHER|Sepsis protocol|Adherence to the sepsis protocol
219060952|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
219060953|NCT05004623|DEVICE|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
219060954|NCT03263377|DIETARY_SUPPLEMENT|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
219060955|NCT01320410|DRUG|ISM®|
219643746|NCT06648018|BEHAVIORAL|Nutritional information|Written nutritional information about food with high content of iron.
219643747|NCT06648018|DIETARY_SUPPLEMENT|Iron-succinate|100 mg of Iron-succinate per day.
219643748|NCT01928342|DRUG|Coenzyme A|Coenzyme A 400mg per day
219643749|NCT01928342|DRUG|Placebo|Capsule without coenzyme A.
219643750|NCT05785013|DIETARY_SUPPLEMENT|Zinc|Zinc Supplementation
219643751|NCT02140528|BIOLOGICAL|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
219643752|NCT02140528|BIOLOGICAL|Placebo|
219643753|NCT03309657|DRUG|Ceftolozane/tazobactam|This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
219643754|NCT01470651|DRUG|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
219643755|NCT01470651|DRUG|Sugar Pill|Inactive pill, matched to look like active medication
219643756|NCT01936181|DRUG|Remicade (infliximab)|
219643757|NCT01936181|DRUG|SB2 (proposed biosimilar to infliximab)|
219643758|NCT05700916|DRUG|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
219643759|NCT05700916|DIETARY_SUPPLEMENT|Dairy Powder|Effects of dairy control powder
219643760|NCT04962724|DRUG|Radiolabelled Xevinapant 200 mg (Oral Solution)|\[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.
219643761|NCT04962724|DRUG|Radiolabelled Xevinapant 100 μg (IV Solution)|100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].
219643762|NCT04962724|DRUG|Xevinapant 200 mg (Oral Solution)|Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
219643763|NCT00664859|DRUG|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
219643764|NCT02620241|OTHER|sitting position|
219643765|NCT03777813|DRUG|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
219643766|NCT03777813|COMBINATION_PRODUCT|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
219643767|NCT06621433|OTHER|T-PRF with CAF|Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.
219643768|NCT06621433|OTHER|SECTG with CAF|Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.
219643769|NCT03911986|DEVICE|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
219643770|NCT01950559|OTHER|Oral food challenge|Oral food challenge to determine allergy to soy
219643771|NCT01943851|DRUG|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
219643772|NCT00900757|DRUG|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
219643773|NCT00832442|DRUG|Beta blocker|as determined by individual study
219643774|NCT00832442|OTHER|Placebo|in addition to usual care
219643775|NCT04982692|DRUG|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
218959963|NCT05678049|DIAGNOSTIC_TEST|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
218959964|NCT03860883|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
218959965|NCT03860883|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
219643776|NCT04982692|DRUG|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
219643777|NCT01567566|OTHER|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
219643778|NCT00039494|DRUG|erlotinib hydrochloride|Given orally
219643779|NCT00039494|RADIATION|3-dimensional conformal radiation therapy|
219643780|NCT00039494|DRUG|temozolomide|Given orally
219643781|NCT05969366|PROCEDURE|Total hip arthroplasty|
219643782|NCT04766489|PROCEDURE|Complete Decongtestive Therapy|Patients will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise, for 5 days a week and for a mean of 20 sessions. Each session will be of 1 hour duration for compressive therapies(Short stretch bandages will be left on for 23 hours a day), 30 minutes of manual lymphatic drainage, and decongestive exercises 3 times a day for 15 minutes each time.
219643783|NCT00748189|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
218959966|NCT02873403|DEVICE|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
218959967|NCT02873403|DEVICE|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
218959968|NCT03915860|DRUG|Trifarotene|Topical Cream
218959969|NCT02195011|DEVICE|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
218959970|NCT02195011|DRUG|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
218959971|NCT02194608|DEVICE|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
218959972|NCT02551250|DEVICE|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
218959973|NCT02551250|DEVICE|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
218959974|NCT00617643|DRUG|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
218959975|NCT00617643|DRUG|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
218959976|NCT01609478|DRUG|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
218959977|NCT01609478|DRUG|placebo|placebo delivered via Concept 1 inhaler
218959978|NCT01609478|DRUG|mometasone furoate|via Twisthaler inhaler
218959979|NCT06239623|DRUG|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
218959980|NCT01975987|DEVICE|Bonfils fiberscope|
218959981|NCT01067443|DRUG|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
219060956|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
219643784|NCT00748189|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
218959982|NCT01067443|DRUG|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
219643785|NCT02784626|DRUG|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
219643786|NCT02784626|DRUG|Propofol|Intraoperative sedation using propofol
219643787|NCT01287091|DRUG|GDC-0980|Oral tablet dose
218959983|NCT01067443|DRUG|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
218959984|NCT02309866|GENETIC|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
218959985|NCT02474225|DRUG|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
219060957|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
219060958|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
219060959|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
219060960|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
219223678|NCT07015619|OTHER|Task Specific Balance Training|Group A participants will undergo Task Specific Balance Training. It is a rehabilitation approach that focus on improving balance by practicing specific balance related tasks.
218959986|NCT03042273|DIETARY_SUPPLEMENT|High Strength Cranberry|Softgel capsule
218959987|NCT03042273|DIETARY_SUPPLEMENT|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
218959988|NCT02953158|OTHER|Haas Avocado|Hypocaloric weight loss diet
218959989|NCT02953158|BEHAVIORAL|Dietary Counseling|Dietary Counseling
218959990|NCT02236481|DRUG|Anakinra|
218959991|NCT02236481|DRUG|TNF alpha inhibitors|
218959992|NCT02102360|DEVICE|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
218959993|NCT02102360|DEVICE|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
218959994|NCT01450111|DRUG|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
218959995|NCT01450111|DRUG|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
218959996|NCT01450111|DRUG|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
218959997|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
218959998|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
219060961|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
219060962|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
219643788|NCT01287091|DRUG|GDC-0980|Oral capsule dose
219643789|NCT01287091|DRUG|GDC-0980|Oral tablet dose in fed state
219643790|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fasting state
219643791|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fed state
219643792|NCT01287091|DRUG|GDC-0980|Oral tablet in a fasting state
219643793|NCT01287091|DRUG|rabeprazole|Oral repeating dose
219643794|NCT00058968|DRUG|Duloxetine hydrochloride|
219643795|NCT00058968|DRUG|placebo|
219643796|NCT04105946|DRUG|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
219643797|NCT04105946|DRUG|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
219643798|NCT03320850|DRUG|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
219643799|NCT03320850|DRUG|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
219643800|NCT06344533|DRUG|JMKX003142 Injection|JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
219643801|NCT06344533|DRUG|Placebo|Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
219643802|NCT01335880|BEHAVIORAL|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
219643803|NCT01335880|BEHAVIORAL|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
219643804|NCT00616980|BIOLOGICAL|CD34-positive cells|
219643805|NCT00616980|BIOLOGICAL|CD34-positive cells|
219643806|NCT00616980|BIOLOGICAL|Saline and 5% autologous plasma|
219643807|NCT02742116|GENETIC|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
219643808|NCT00546117|DRUG|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
219643809|NCT00546117|DRUG|placebo|Placebo Solutab in 15 and 30 mg dosages.
219643810|NCT00079586|DRUG|Heparin|Unfractionated Heparin per institutional practice
219643811|NCT00079586|DRUG|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
219643812|NCT01424514|DRUG|SB-705498|12mg intra nasal
219643813|NCT01424514|DRUG|Placebo|Placebo intra nasal
219643814|NCT06624241|PROCEDURE|Lipo-Curcumin gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.
219643815|NCT06624241|PROCEDURE|Lipo gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.
219643816|NCT06624241|PROCEDURE|Discharged Gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.
219643817|NCT06624241|PROCEDURE|SRP alone|The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
219643818|NCT02638675|BEHAVIORAL|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
219643819|NCT02638675|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
219643820|NCT02638675|BEHAVIORAL|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
219643821|NCT04178642|DRUG|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
219060963|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
219060964|NCT04419636|DRUG|Lu AG06466|capsules, orally
219643822|NCT04178642|PROCEDURE|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
219643823|NCT02670733|PROCEDURE|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
219643824|NCT06207149|BEHAVIORAL|ASISTIR|This will be a 24 hour advocacy program focused on adult disability services.
219643825|NCT00373009|BEHAVIORAL|Traditional Army training|As usual training for Soldiers
219643826|NCT00373009|BEHAVIORAL|Core stabilization exercise only|Core stabilization exercise
219643827|NCT00373009|BEHAVIORAL|Psychosocial education class only|Psychosocial education class
219643828|NCT00373009|BEHAVIORAL|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
219643829|NCT02653170|OTHER|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services."
219643830|NCT02653170|OTHER|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~1. Contact list of care team members.~2. Access to hospital patient portal.~3. Stroke education materials, resources, and guidelines.~4. Access to Michigan 2-1-1 services.~5. Medication information and adherence tools.~6. Patient and Caregiver support networks."
219643831|NCT01439022|BEHAVIORAL|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
219643832|NCT01439022|BEHAVIORAL|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
219643833|NCT02147522|BEHAVIORAL|Self-care management|AHH behavioral intervention is provided by promotoras
219643834|NCT06648577|PROCEDURE|Ultrasound imaging|The participants are scanned with an ultrasound scanner
219643835|NCT06623851|OTHER|Intraoral scanner|"* The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages"
219643836|NCT06623851|OTHER|Alginate impression|Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
219643837|NCT06130891|OTHER|Cognitive sensory motor relearning|"Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
218959999|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
218960000|NCT02487823|DRUG|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
218960001|NCT03859206|OTHER|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
218960002|NCT06008834|PROCEDURE|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
218960003|NCT04431427|DEVICE|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
218960004|NCT04431427|DEVICE|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
219643838|NCT06130891|OTHER|Sensory motor relearning|"Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
219643839|NCT06130891|OTHER|Motor Relearning|"Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
219643840|NCT04409535|OTHER|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
219643841|NCT05901350|DRUG|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
219643842|NCT05588869|OTHER|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
219643843|NCT05039567|BEHAVIORAL|optimal heart team protocol|Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.
219643844|NCT01968356|DRUG|3M CHG/IPA Prep Colorless|Apply topically.
219643845|NCT01968356|DRUG|3M CHG/IPA Prep Tint|Apply topically.
219643846|NCT01968356|DRUG|ChloraPrep|Apply topically.
219643847|NCT01968356|DRUG|Saline|Apply topically.
219643848|NCT03133091|DRUG|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
219643849|NCT03133091|DRUG|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
219643850|NCT04775498|BEHAVIORAL|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
219643851|NCT04775498|BEHAVIORAL|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
219643852|NCT01619540|OTHER|Valsalva maneuver|
219643853|NCT05021016|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
219643854|NCT01132248|DRUG|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
219643855|NCT01132248|DRUG|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
219643856|NCT06180369|OTHER|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissur Sealent application
218960005|NCT00883844|DRUG|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
219643857|NCT06180369|OTHER|BeutiSealant (Shofu, Kyoto, Japonya)|Fissur Sealent application
218960006|NCT00883844|DRUG|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
218960007|NCT03911219|OTHER|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
218960008|NCT05526209|PROCEDURE|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
218960009|NCT00272727|BEHAVIORAL|Dialog tool for caregivers|
219223679|NCT07015619|OTHER|Task-oriented Basketball Training|Group B participants will undergo Task-oriented Basketball Training. It is a rehabilitation approach that focuses on balance, coordination and gross motor skills through specific basketball related tasks.
219223680|NCT07012564|DIETARY_SUPPLEMENT|Vitamin C|1000 mg oral vitamin C tablet taken daily from one day before surgery to postoperative day 7.
218960010|NCT00741962|DIETARY_SUPPLEMENT|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
218960011|NCT00741962|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
219223681|NCT07012564|OTHER|Placebo|Identical-appearing oral tablet taken on the same schedule as the vitamin C group.
219643858|NCT00187681|DRUG|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
219643859|NCT00312832|DRUG|switching; dose reduction|
219643860|NCT04720911|BEHAVIORAL|In-person TASCS|In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
219643861|NCT04720911|BEHAVIORAL|Telehealth TASCS|Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
219643862|NCT04720911|BEHAVIORAL|Self-administered TASCS|Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.
219643863|NCT04720911|BEHAVIORAL|Follow-up care|Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
219643864|NCT05406115|DRUG|AMG 786|Oral tablet
219643865|NCT05406115|OTHER|Placebo|Oral tablet
219643866|NCT05620732|BIOLOGICAL|Claudin18.2 CAR-T cells|patients treated with Claudin18.2 CAR-T cells
219643867|NCT04444193|DRUG|Durvalumab|Anti-PD-L1 Monoclonal Antibody
219643868|NCT04444193|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
219643869|NCT00090220|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
219643870|NCT00090220|BIOLOGICAL|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
219643871|NCT00941863|DRUG|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
219643872|NCT00941863|DRUG|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
219643873|NCT00941863|DRUG|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
219643874|NCT00941863|DRUG|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
219643875|NCT00941863|DRUG|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
219643876|NCT01167673|DIETARY_SUPPLEMENT|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
219643877|NCT01167673|DIETARY_SUPPLEMENT|Placebo|placebo
219643878|NCT04080557|OTHER|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
219643879|NCT00537316|BIOLOGICAL|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
218960012|NCT01419067|PROCEDURE|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
218960013|NCT01419067|DEVICE|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
218960014|NCT01419067|DRUG|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
218960015|NCT01419067|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
219643880|NCT00537316|DRUG|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
219643881|NCT00537316|DRUG|Placebo to Azathioprine|Placebo to AZA tablet orally every day
219643882|NCT00537316|DRUG|Placebo infusion|Placebo to IFX intravenous (IV) infusion
219643883|NCT04579835|OTHER|External Cephalic Version|External Cephalic Version Twin A
219643884|NCT05113979|DEVICE|AccuraSee IOPCL with +3.0D add|The IOPCL (intraocular pseudophakic contact lens) consists of a 4.5mm diameter optic. All subjects will receive a +3.0 power regardless of diopter power based on IOL Master. This IOPCL will be coupled to a Bausch and Lomb Model LI61SE or LI61AO intraocular lens to correct residual refractive errors after cataract surgery.
219643885|NCT04561557|BIOLOGICAL|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.
219643886|NCT04561557|DRUG|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
219643887|NCT06685367|DEVICE|Acura AKI|When the AI algorithm (Acura AKI) identifies a high-risk AKI patient, nephrologists and ICU pharmacists will receive an alert message. Upon receiving the alert, they will review the patient's electronic health record and make treatment suggestions based on AKI bundle care protocols. They will also coordinate with the patient's primary care team to ensure that the recommendations are implemented
219643888|NCT00697125|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
219643889|NCT00697125|BIOLOGICAL|HBV-MPL vaccine (208129)|
219643890|NCT00697125|BIOLOGICAL|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
219643891|NCT00643825|DRUG|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
219643892|NCT00643825|DRUG|Temozolomide|Observation till Progression then rechallenging with TMZ
219643893|NCT06665490|OTHER|CLn Body Wash|All enrolled patients will self-administer at home the commercially available study product (CLn Body Wash) containing 0.006% NaOCl body wash in a sealed, child-safe pump dispenser to use daily for 8 weeks by wetting the body thoroughly with showering, lathering the study product on the body with special attention to affected areas, leaving on the skin for 2 minutes, and rinsing off with warm water.
219643894|NCT06074796|BEHAVIORAL|No intervention.|"No intervention. This is a retrospective study. Data will have been collected in routine consultations as part of the transition process for transgender patients.~Description of the collected informations : gender of destination, BMI, siblings, children, moral, previous hormone therapy, when the project was born, change of marital status desired or carried out, ALD status, psychiatric assessment, desire for future care for the transition course. Desire to preserve erectile function, parenthood desire, couple projections, type of couple, cryopreservation desired, done or not, desire of pregnancy, ultrasound count of antral follicles, initial hormone assays and tests : BMD, pelvic ultrasound? Data relating to stimulation and ovarian puncture and sperm collection."
219643895|NCT03821714|DRUG|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
219643896|NCT03821714|DRUG|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
219643897|NCT03453879|OTHER|no intervention|No intervention - only observation of teams delivering acute obstetric care
219643898|NCT02274870|DRUG|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
219643899|NCT02274870|DRUG|Bupivacaine HCl|Administered via CFNB
219643900|NCT03149133|OTHER|Heavy hypertrophy training|Training with 75-80 % of 1-RM
219643901|NCT03149133|OTHER|Light hypertrophy training|Training with 35-50 % of 1-RM
219643902|NCT00078975|DRUG|gemcitabine hydrochloride|
219643903|NCT00078975|DRUG|triapine|
219643904|NCT05950737|PROCEDURE|Sentinel node biopsy|All patients have undergone completion neck dissection following SNB in the process of standardization.
219643905|NCT04180137|PROCEDURE|Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins|"Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm."
219643906|NCT04180137|DRUG|Pharmacotherapy|After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
219643907|NCT06684756|PROCEDURE|Retrograde intrarenal surgery|Flexible optic devices and lasers fragment kidney stones during this operation. In this surgery, an ureteral access sheath is recommended to be used.
219643908|NCT04121156|DEVICE|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
219643909|NCT04121156|DEVICE|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
219643910|NCT01310088|BEHAVIORAL|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
219643911|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
219643912|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
219643913|NCT01864109|DRUG|Cyclophosphamide|
219643914|NCT01864109|DEVICE|Doxorubicin|
219643915|NCT01864109|DRUG|Vincristine|
219643916|NCT01864109|DRUG|Ifosfamide|
219643917|NCT01864109|DRUG|Etoposide|
219643918|NCT01864109|PROCEDURE|Surgery|
219643919|NCT01864109|RADIATION|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
219643920|NCT01864109|DRUG|Temozolomide|
219643921|NCT01864109|DRUG|Irinotecan|
219643922|NCT01864109|DRUG|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
219643923|NCT01864109|DRUG|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
219643924|NCT01864109|DRUG|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
219643925|NCT03119753|DEVICE|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
219643926|NCT03119753|DEVICE|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
219643927|NCT05449587|OTHER|MRI and PRO|MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
219643928|NCT04486053|OTHER|Screening|The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
219643929|NCT01609543|DRUG|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
219643930|NCT05578716|DIETARY_SUPPLEMENT|Partially hydrolysed formula|Partially hydrolysed formula
219643931|NCT06277323|BEHAVIORAL|Monthly report card intervention|The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
219643932|NCT06277323|BEHAVIORAL|Storyboard intervention|The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
219643933|NCT04116658|BIOLOGICAL|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
219643934|NCT03807219|DIETARY_SUPPLEMENT|Magnox Comfort|Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
219643935|NCT03807219|OTHER|Placebo|placebo
219643936|NCT00111319|DRUG|bortezomib|
219643937|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
218960016|NCT04395508|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
219643938|NCT01472016|DRUG|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
219643939|NCT01472016|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
218960017|NCT05632289|OTHER|osteopathic manipulative therapy|osteopathic manipulative therapy : manuel therapy
219643940|NCT01472016|DRUG|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
219643941|NCT01472016|DRUG|erlotinib|Erlotinib will be taken orally daily.
219643942|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
219643943|NCT06683833|DRUG|Egyptian MTA|"* Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
219643944|NCT06683833|DRUG|Biodentine|"* Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
219223682|NCT07009782|PROCEDURE|QIP block|The Quadroiliac Plane (QIP) block is a novel ultrasound-guided fascial plane block. In this study, it will be performed postoperatively under spinal anesthesia in the prone position. A low-frequency convex transducer will be used to visualize the quadratus lumborum muscle at its attachment to the inner iliac crest. Using an in-plane technique with a 22G x 100 mm needle, 40 mL of 0.25% bupivacaine will be injected into the fascial plane beneath the quadratus lumborum muscle. The block will be performed unilaterally on the surgical side. The aim is to provide postoperative analgesia in patients undergoing femur fracture surgery.
218960018|NCT05632289|OTHER|sham osteopathic manipulative therapy|placebo of osteopathic treatment
219643945|NCT06683833|DRUG|Calcium Hydroxide (Ca(OH)2)|"* Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
219643946|NCT00004235|DRUG|docetaxel|
219643947|NCT00004235|DRUG|irinotecan hydrochloride|
219643948|NCT00899171|GENETIC|DNA analysis|
219643949|NCT00899171|GENETIC|DNA methylation analysis|
219643950|NCT00899171|GENETIC|RNA analysis|
219643951|NCT00899171|GENETIC|gene expression analysis|
219643952|NCT00899171|GENETIC|reverse transcriptase-polymerase chain reaction|
219643953|NCT00899171|OTHER|laboratory biomarker analysis|
219643954|NCT03452488|DRUG|BIO101|Oral capsules
219643955|NCT03452488|DRUG|Placebo|Oral capsules
219643956|NCT00653770|BIOLOGICAL|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)
219643957|NCT00653770|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)
219643958|NCT01065870|DRUG|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
219643959|NCT01065870|DRUG|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
219643960|NCT05484440|OTHER|Psychological|
219643961|NCT06684067|BEHAVIORAL|Patient navigation|Participants will receive online educational material, hospital site navigation guidance and direct contact with the patient navigator, in addition to standard instructions on the colonoscopy procedure.
219643962|NCT06122012|DRUG|HSK16149 20mg BID|HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
219643963|NCT01671995|PROCEDURE|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
219643964|NCT01671995|PROCEDURE|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
219643965|NCT00565643|DEVICE|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
219643966|NCT00565643|DEVICE|Placebo|Routine abdominal closure without placement of adhesion barrier
218960019|NCT00715416|DEVICE|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
219643967|NCT06355258|DRUG|Troxerutin|Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
219643968|NCT06355258|DRUG|Placebo|Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
219643969|NCT06355258|DRUG|placebo + low molecular weight heparin|2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
218960020|NCT00715416|PROCEDURE|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
218960021|NCT05425576|DRUG|OT-101|OT-101 in combination of pembrolizumab
218960022|NCT01766193|PROCEDURE|vaginal delivery|
218960023|NCT01766193|PROCEDURE|forceps extraction|vaginal delivery by forceps extraction
218960024|NCT01766193|PROCEDURE|vacuum extraction|vaginal delivery by vacuum extraction
218960025|NCT01766193|PROCEDURE|cesarean section|
219643970|NCT06355258|DRUG|troxerutin + low molecular weight heparin|2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
219643971|NCT00003416|BIOLOGICAL|filgrastim|
219643972|NCT00003416|BIOLOGICAL|recombinant interferon alfa|
219643973|NCT00003416|DRUG|dexamethasone|
219643974|NCT00003416|DRUG|melphalan|
219643975|NCT00003416|PROCEDURE|peripheral blood stem cell transplantation|
219643976|NCT01782417|BEHAVIORAL|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
219643977|NCT02691819|DEVICE|single stent and embedded balloon angioplasty|
219643978|NCT02775149|OTHER|Collection of saliva samples|Collection of saliva samples
219643979|NCT02775149|OTHER|Visual detection of BEWE-index|Visual detection of BEWE-index
219643980|NCT02196688|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
218960026|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
219643981|NCT02196688|DRUG|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
219643982|NCT03024203|BEHAVIORAL|Cognitive Remediation - Executive Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
219643983|NCT03024203|BEHAVIORAL|Cognitive Remediation - Perceptual Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
219643984|NCT01137110|OTHER|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
219643985|NCT01137110|OTHER|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
219643986|NCT03374501|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
219643987|NCT03374501|DIETARY_SUPPLEMENT|Soft drink|Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
219643988|NCT02960165|BEHAVIORAL|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
219643989|NCT02960165|BEHAVIORAL|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
219643990|NCT06249347|PROCEDURE|PROMISED|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Roof linear ablation: linear ablation in the left atria roof; Anterior septal linear ablation: linear ablation in the anterior septal linear which coursed from the middle of the right superior and inferior pulmonary veins or the middle of the right superior pulmonary vein to the mitral valve annulus; Mitral isthmus linear ablation: linear ablation in the mitral isthmus; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
219643991|NCT06249347|PROCEDURE|CPVI and LAAC|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
219643992|NCT06249347|DEVICE|Radiofrequency ablation catheter|Device： Radiofrequency ablation catheter
219643993|NCT06249347|DEVICE|left atrial appendage occlusion device|Device： left atrial appendage occlusion device
219643994|NCT02793674|DEVICE|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
219643995|NCT02793674|DEVICE|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
219643996|NCT05177536|DRUG|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
219643997|NCT01858116|DRUG|[68Ga]ABY-025|Intravenous injection followed by PET imaging
219207769|NCT06746727|BEHAVIORAL|Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE)|This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).
219207770|NCT06747741|PROCEDURE|PNF stretching(Contract relax with agonist contraction)|1.Passively dorsiflex the patient's foot then ask to perform active planterflexion against resistance and hold for 7-10 sec then ask patient to perform dorsiflexion to the maximum available range.
219643998|NCT05536024|DIAGNOSTIC_TEST|Prediction of glioma grading and molecular subtype|Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
219643999|NCT06246123|OTHER|Non-interventional|No intervention will be administered.
219644000|NCT06069349|OTHER|Early Rehabilitation|Early Rehabilitation for patients after cardiac surgery
219644001|NCT06069349|OTHER|usual treatment|Patients are not allowed to exercise Early Rehabilitation
219644002|NCT05353244|DEVICE|PrTMS|Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
219207771|NCT06747741|PROCEDURE|Conventional physical therapy|"Static Stretching:(Seated Calf Stretch With a Resistance Band)~1. Sit on the floor with your legs extended.~2. Loop a resistance band around one foot, holding both sides of it with your hands.~3. Gently pull your toes toward your shin until you feel the stretch in your calf.Repeat on the other side.~Isometric Calf Raise:~1. Stand with feet shoulder-width apart and arms at sides.~2. Engage your abs for stability and roll up onto the balls of your feet, lifting both heels off the floor.~3. Hold for 5 seconds, then return to the starting position. Frequency : 5 reps with 5-7Sec hold,3 days per week for 4 weeks (alternatively)"
219644003|NCT05353244|DEVICE|Sham|Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
219644004|NCT06967870|OTHER|Osteopathic intervention|"Researcher will use osteopathic techniques on cranial area includes light touch.~Home based exercises will be show on cases and demand to do exercise regularly"
219644005|NCT06967870|OTHER|Home based exercise education|Home based exercises will be show on cases and demand to do exercise regularly.
219644006|NCT04975750|BEHAVIORAL|Problem solving intervention|The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
219644007|NCT04975750|BEHAVIORAL|Care as usual|The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
219644008|NCT06457412|OTHER|Intervention group for the treatment of childhood obesity|Intervention for children aged 6 to 12 years with childhood obesity (with a BMI greater than the 99th percentile), fostering motivation and encouraging changes toward healthy lifestyle habits to achieve greater adherence and to improve health. The program comprises 9 educational sessions designed by specialized professionals (code of Spanish register: 2007144741729) to be conducted in a health center. The sessions will be held every 15 days, with a duration of 90 minutes for a group of 10 children and another group of 10 family members and/or caregivers. Professionals from different disciplines (paediatricians, psychologists, nurses and nutritionists), will meet with groups of pediatric patients and in another group with their family members or primary caregivers.
219644009|NCT02470065|DRUG|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
218960027|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
219644010|NCT02470065|PROCEDURE|Immediate surgery|anatomical resection and systematic lymph node dissection
219644011|NCT03476408|OTHER|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
219644012|NCT06666881|OTHER|HIIT only|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times a week and total 24-36 times.
219644013|NCT06666881|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times in a week and total 24-36 times. And do the recording of physical activities at home.
219644014|NCT01871181|PROCEDURE|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
219644015|NCT01871181|PROCEDURE|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
219644016|NCT06487221|DRUG|Avutometinib|3.2mg orally
219644017|NCT06487221|DRUG|Defactinib|200 mg orally
219644018|NCT04264390|BEHAVIORAL|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
219644019|NCT00330343|DRUG|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
219644020|NCT06052423|DRUG|HS-20093|HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
219644021|NCT01595464|BEHAVIORAL|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
219644022|NCT02251145|DRUG|Tipranavir low dose|
219644023|NCT02251145|DRUG|Tipranavir high dose|
219644024|NCT02251145|DRUG|Ritonavir low dose|
219644025|NCT02251145|DRUG|Ritonavir high dose|
219644026|NCT02251145|DRUG|Tenofovir disoproxil fumarate|
219644027|NCT00281632|DRUG|GW786034|800 mg GW786034 administered orally on a daily basis.
218960028|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
218960029|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
218960030|NCT03383731|PROCEDURE|Group 1|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
219223683|NCT03816163|DRUG|zolbetuximab|Administered as an intravenous infusion.
219223684|NCT03816163|DRUG|nab-paclitaxel|Administered as an intravenous infusion
219644028|NCT01542437|DRUG|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
219644029|NCT05827042|DRUG|Intravenous thrombolysis|Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
219644030|NCT05827042|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy
219644031|NCT05728606|PROCEDURE|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
219644032|NCT04510506|DEVICE|Artificial Pancreas (AP)|The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
219644033|NCT06307756|OTHER|Music group|"Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
219644034|NCT03996356|OTHER|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
219644035|NCT03990571|DRUG|Avelumab|Given IV
219644036|NCT03990571|DRUG|Axitinib|Given PO
219644037|NCT05657197|BEHAVIORAL|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
219644038|NCT05657197|OTHER|Usual care|Usual care, including general advice concerning chronic fatigue.
219644039|NCT03562611|DRUG|Nalbuphine|Nalbuphine administration during surgery
219644040|NCT03562611|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
219644041|NCT03562611|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
219644042|NCT01945970|OTHER|Black tea extract|Black tea extract
219644043|NCT01945970|OTHER|Positive control|Positive control
219644044|NCT01945970|OTHER|Placebo|Placebo
219644045|NCT03830684|DRUG|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
219644046|NCT03830684|DRUG|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
219644047|NCT03830684|DRUG|blank control 0mg|6 placebo per time, three times a day
219644048|NCT04850261|DRUG|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
219644049|NCT04850261|DRUG|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
219644050|NCT02587585|BEHAVIORAL|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
219644051|NCT02587585|BEHAVIORAL|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
219644052|NCT00782184|DRUG|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
219644053|NCT00782184|DRUG|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
219644054|NCT00782184|DRUG|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
219644055|NCT00447031|DRUG|intravitreal bevacizumab and triamcinolone acetonide|
219644056|NCT02406079|PROCEDURE|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
219644057|NCT01173731|DRUG|AFQ056|
219644058|NCT03614078|DRUG|PRCL-02|Oral tablets
219644059|NCT03614078|DRUG|Placebo|Oral tablets
219644060|NCT01369108|DEVICE|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
219644061|NCT01369108|DEVICE|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
219644062|NCT00260312|BIOLOGICAL|Inactivated Polio Vaccine given at an accelerated schedule|
218960031|NCT03383731|PROCEDURE|Group 2|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
219644063|NCT00399412|DEVICE|subcutaneous ICD|
219644064|NCT06648538|DEVICE|Phonix Care|Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
219644065|NCT04282317|OTHER|MRI scan|MRI scan
219644066|NCT00295035|DRUG|CELECOXIB|
219644067|NCT00295035|DRUG|CURCUMIN|
219644068|NCT04748458|DEVICE|Conical tapered stem|Implantation of conical tapered stem
219644069|NCT04894149|OTHER|Physiotherapy|Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
219644070|NCT02698202|DEVICE|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
219644071|NCT06624306|PROCEDURE|Prone PNL|Prone PNL
219644072|NCT06624306|PROCEDURE|Prone-flexed PNL|Prone-flexed PNL
219644073|NCT04143594|DRUG|Oral Lenacapavir|Tablets administered without regard to food
219644074|NCT04143594|DRUG|F/TAF|Tablets administered without regard to food
219644075|NCT04143594|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
219644076|NCT04143594|DRUG|TAF|Tablets administered without regard to food
219644077|NCT04143594|DRUG|BIC|Tablets administered without regard to food
219644078|NCT04143594|DRUG|B/F/TAF|Tablets administered without regard to food
219644079|NCT00940966|DIETARY_SUPPLEMENT|standard ADA diet|standard ADA diet
219644080|NCT00940966|DIETARY_SUPPLEMENT|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
219644081|NCT00940966|DIETARY_SUPPLEMENT|low glycemic diet|restricted ketogenic diet
219644082|NCT00285116|PROCEDURE|Clinical examination and radiological evaluation|
219644083|NCT01050010|OTHER|MRI|dedicated extremity MRI
219644084|NCT04867993|DRUG|Amikacin|15 mg/kg/36h
219644085|NCT03706885|DRUG|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
219644086|NCT06041308|OTHER|valve|bioprothetic valve versus mechanical valve
219644087|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum italicum infusion.
219644088|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum arenarium|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum arenarium infusion.
219644089|NCT06617221|BIOLOGICAL|Composite graft plug|after tooth extraction the socket was grafted with a composite graft plug
219644090|NCT06617221|BIOLOGICAL|Allograft|after tooth extraction the socket was grafted with allograft
219644091|NCT03415789|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
219644092|NCT03415789|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
219644093|NCT03415789|DIAGNOSTIC_TEST|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
219644094|NCT03415789|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
219644095|NCT04007068|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET/CT baseline, month 1, month 4, month 10, than every 6 months
219644096|NCT05051267|OTHER|Non-Pharmacological Methods|All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
219644097|NCT03852368|OTHER|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
219644098|NCT01909323|OTHER|maltitol 85% / FOS15%|
219644099|NCT01909323|OTHER|maltitol alone|
219644100|NCT01909323|OTHER|maltitol 68% / FOS 32%|
219644101|NCT01909323|OTHER|maltitol 50% / FOS 50%|
219644102|NCT01909323|OTHER|FOS alone|
219644103|NCT01909323|OTHER|Placebo|
219644104|NCT06519643|BEHAVIORAL|career planning application|"Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app."
219644105|NCT06390774|DRUG|SSGJ-705|anti-PD-1 and anti-HER2 bispecific antibody
219644106|NCT05337540|DEVICE|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
218960032|NCT05687604|BEHAVIORAL|multiple behavior change therapy|goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
219644107|NCT05337540|DEVICE|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
219644108|NCT05512806|DRUG|AZD5462|Participants will receive AZD5462 orally.
219644109|NCT05955326|DRUG|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
219644110|NCT05955326|OTHER|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
219644111|NCT03665545|DRUG|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
219644112|NCT03665545|DRUG|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
218960033|NCT03768297|PROCEDURE|dual zone concept|immediate implant with bone fill till soft tissue level
219644113|NCT03411174|RADIATION|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
219644114|NCT05986838|DEVICE|aser puncture|laser puncture (3 sessions per week)
219644115|NCT05986838|DEVICE|ultraviolet radiatio|ultraviolet radiation (3 sessions per week)
219644116|NCT05986838|DRUG|Metformin|for 3 months
219644117|NCT02426905|DRUG|trientine dihydrochloride|A retrospective review of patients' medical records
219644118|NCT03775902|DRUG|Placebo|placebo tablet
219644119|NCT03775902|DRUG|Nicorandil|20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
219644120|NCT01691495|DRUG|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
219644121|NCT04348864|DIAGNOSTIC_TEST|COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 as detected by rapid antigen test or LAMP/PCR-based molecular test taken from nasopharyngeal swab samples in the recent past.
218960034|NCT04693026|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
219644122|NCT04348864|OTHER|Telemedicine|Imaging of the test using the software application COVIDscanDX and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).
219644123|NCT03220295|DRUG|Single Dose of VU319|Single dose of VU319
219644124|NCT03220295|DRUG|Single Dose Placebo|Single dose of placebo
219644125|NCT03220295|OTHER|Fed State|drug is given 30 minutes after a high fat breakfast
218960035|NCT04693026|DRUG|Baricitinib|Baricitinib oral tablet form
219207772|NCT06746454|OTHER|Video Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included a landing error scoring system, knee position error sense, and frontal plane projection angle. After the pre-test measurements, 2 training packages with special instructions were performed for the video instructed training (VIT) group. The special instruction for the VIT group included a previously prepared video of a successful vertical jump landing task. This video was shown to the VIT group. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
219644126|NCT03220295|OTHER|Fasted State|drug is given after an overnight fast
219644127|NCT03220295|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
219644128|NCT03220295|DRUG|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
219644129|NCT02685358|BEHAVIORAL|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
219644130|NCT02685358|BEHAVIORAL|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
218960036|NCT04693026|DRUG|Tocilizumab|Tocilizumab IV Infusion
218960037|NCT01139424|DEVICE|endoscopic suturing|endoscopic suturing of the anastomotic leak
218960038|NCT02219113|PROCEDURE|Arthroscopic surgery|
218960039|NCT02219113|PROCEDURE|Liposuction|
218960040|NCT02219113|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
218960041|NCT02219113|OTHER|Intraarticular administration of autologous ADRC|
219644131|NCT00065936|DRUG|Naltrexone hydrochloride|
219644132|NCT00065936|PROCEDURE|Transcutaneous sensory nerve stimulation|
218960042|NCT00000495|BEHAVIORAL|diet, reducing|
218960043|NCT00000495|BEHAVIORAL|diet, sodium-restricted|
218960044|NCT00000495|BEHAVIORAL|alcohol restriction|
218960045|NCT00000495|BEHAVIORAL|exercise|
218960046|NCT02065115|OTHER|Cryotherapy (ice pack)|
219223685|NCT03816163|DRUG|gemcitabine|Administered as an intravenous infusion
219223686|NCT03936478|RADIATION|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
219644133|NCT03994133|OTHER|Measurement of the hydration state by bio-impedance spectroscopy|"* The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~* The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~* The measurement will be done in pre-dialytic"
219644134|NCT04722510|DEVICE|repeated transcranial magnetic stimulation|Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, \> 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
219644135|NCT01490879|DRUG|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
219644136|NCT01490879|DRUG|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
219644137|NCT01490879|DRUG|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
219644138|NCT01490879|DRUG|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
219644139|NCT05794984|OTHER|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
219644140|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a photon-counting detector CT (PCD-CT)|Cardiac CTA will be performed on a dual-source photon-counting CT
219644141|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a regular CT with Energy-Integrating Detector (EID-CT)|Cardiac CTA was performed on a dual-source CT with regular energy-integrating detector (EID-CT)
219644142|NCT00764036|DRUG|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
219644143|NCT03328871|DEVICE|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
219644144|NCT03328871|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
219644145|NCT03328871|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
219644146|NCT04293029|DRUG|SHR0302|SHR0302
219644147|NCT04715542|DRUG|Stibium metallicum praeparatum 6x|Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
218960047|NCT03923322|DRUG|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
218960048|NCT03923322|OTHER|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
218960049|NCT06636266|OTHER|Survey using a questionnaire.|This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
218960050|NCT06630819|OTHER|1.8 ml of 4% Articaine|Buccal infiltration of 1.8 ml of 4% Articaine
218960051|NCT06630819|OTHER|3.6 ml of 4% Articaine|Buccal infiltration of 3.6 ml of 4% Articaine.
218960052|NCT04966741|DRUG|Setmelanotide|SC injection once daily.
218960053|NCT04726397|RADIATION|Reduced margin adaptive radiotherapy|Reduced (5 mm) clinical target volume margin with weekly contrast-enhanced adaptive radiation on the MR-Linac treatment machine
218960054|NCT01784393|RADIATION|chemoradiation|
218960055|NCT05340907|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
218960056|NCT00276913|DRUG|STA-5312|
218960057|NCT06595030|DEVICE|Active Lighting Intervention|The TLI will allow researchers to use a light source that will control how the circadian system is stimulated and provide the participants with options as to how the light treatment will be delivered.
218960058|NCT06595030|DEVICE|Control Lighting Intervention|The TLI will allow researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
218960059|NCT05161039|DEVICE|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
218960060|NCT05161039|DEVICE|POBA|Plain balloon angioplasty device
219644148|NCT04715542|DRUG|Placebo|Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
218960061|NCT05662462|DEVICE|DEXCOM G7 PRO Continuous Glucose Monitor|Participants in the intervention arm will be provided with DEXCOM® G7 PRO CGM sensors and transmitters. The Dexcom G7 CGM system is accurate and safe in pregnant individuals with diabetes. Participants will be taught how to place and remove CGM sensors by a trained research nurse, and will be given sensors to change themselves at home every 10 days. Of note, the DEXCOM® G7 PRO can be applied as a patch on the abdomen, arm, or upper buttocks, is well-tolerated in pregnancy, and does not require calibration. Our mHealth app will allow for wireless synchronization with the CGM sensor so that data are seamlessly reported back to the healthcare team.
219644149|NCT02602132|PROCEDURE|Clamping|To clamp before the removal of short-term indwelling urethral catheters
219644150|NCT00417716|DRUG|Intravitreal Bevacizumab|
219644151|NCT05370586|OTHER|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
219644152|NCT05370586|OTHER|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
219644153|NCT00474201|DRUG|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
219644154|NCT00474201|DRUG|Gemfibrozil|Control arm (no intervention used in this arm)
219644155|NCT05265923|DRUG|CM310|IL-4Rα monoclonal antibody
219644156|NCT05265923|OTHER|Placebo|Placebo
219644157|NCT04804670|DEVICE|Power device A|Oral hygiene regimen completed daily
219644158|NCT04804670|DEVICE|Power device B|Oral hygiene regimen completed daily
219644159|NCT04804670|DEVICE|Routine Oral Hygiene|Oral hygiene regimen completed daily
219644160|NCT02784613|DRUG|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
219644161|NCT05819086|BEHAVIORAL|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
219644162|NCT05819086|BEHAVIORAL|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
219644163|NCT03670446|OTHER|Pharmacists' intervention|"1. Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~2. Establish a medical record and remind their follow-up by message, phone every 2 weeks.~3. Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
219060965|NCT03502343|DRUG|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
219060966|NCT05570526|DIETARY_SUPPLEMENT|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
219060967|NCT05570526|OTHER|Placebo|Placebo tablet once daily.
219644164|NCT05808868|OTHER|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
219644165|NCT02851589|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
219060968|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
219060969|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
219644166|NCT00355563|DEVICE|PAS-Port Automated Proximal Anastomosis System|
219644167|NCT05410405|PROCEDURE|implant site preparation|piezoelectric bone surgery osseodensification drills
219644168|NCT02570412|DRUG|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
219644169|NCT05063357|DRUG|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
219644170|NCT05063357|DEVICE|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
219644171|NCT05421702|PROCEDURE|laparoscopic conventional colectomy|Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
218960062|NCT05662462|DEVICE|Patient mHealth app linked to a provider dashboard|The mHealth app is based on our team's prototype intervention developed at our study site. The mHealth app provides diverse functions, including education, reminders, care goals, care pathway recommendations, CGM data and PROs reporting and monitoring, messaging and video conferencing, and a calendar function. Content is based on clinical guidelines for diabetes in pregnancy. Participants will be directed to appropriate resources and online learning to help them navigate the app and its resources. PROs in the mHealth app will be embedded to address health and social needs, and rule-based algorithms will provide tailored care goals, show care pathways, and establish the frequency of elicited PROs.
218960063|NCT05662462|BEHAVIORAL|Care team coaching for medical and social needs (HUB)|"Participants will be screened at enrollment and throughout the intervention for social needs using a survey adapted from validated instruments, such as the Accountable Health Communities Health-Related Social Needs Screening Tool. The care team will refer participants with affirmative responses to the HUB through the provider dashboard to address social needs (e.g., food insecurity, housing, employment). HUB community health workers will perform comprehensive social needs assessments and connect participants to community resources through care pathways, a defined action plan addressing patient needs which is recorded and tracked."
218960064|NCT05662462|DEVICE|Provider dashboard|The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
218960065|NCT04331197|DRUG|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
218960066|NCT04331197|DRUG|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
218960067|NCT06576739|PROCEDURE|Spinal Manipulation|Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
219060970|NCT02423473|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
219060971|NCT02423473|PROCEDURE|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
219060972|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
219060973|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
219060974|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
219060975|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
219060976|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
219060977|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
219060978|NCT02799433|BEHAVIORAL|Usual services|Control condition
219644172|NCT05421702|PROCEDURE|laparoscopic complete mesocolic excision|Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
219644173|NCT01826578|PROCEDURE|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
219644174|NCT02983188|DRUG|Berberine|Berberine tablets, 0.3g every time, two times daily
219644175|NCT02983188|DRUG|Placebos|Placebo tablets, 0.3g every time, two times daily
219644176|NCT02983188|DRUG|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
219644177|NCT01415713|DRUG|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
219644178|NCT01665625|PROCEDURE|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
219644179|NCT03568370|OTHER|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
219644180|NCT02107859|DRUG|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
219644181|NCT00977314|DEVICE|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
219644182|NCT00977314|DEVICE|SoundBite|
219644183|NCT00977314|DEVICE|SoundBite Hearing System|
219644184|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 2 months|
219644185|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 6 months|
219644186|NCT01548911|DRUG|gemtuzumab ozogamicin|Given IV
219644187|NCT01548911|OTHER|laboratory biomarker analysis|Correlative studies
219644188|NCT03297918|BEHAVIORAL|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
219644189|NCT01658124|DRUG|Tranexamic Acid|
219644190|NCT01658124|DRUG|Placebo|
219644191|NCT01752881|BIOLOGICAL|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
219644192|NCT01752881|BIOLOGICAL|AdimFlu-S|
219644193|NCT03557216|DIAGNOSTIC_TEST|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
219644194|NCT03557216|DIAGNOSTIC_TEST|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
219060979|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
219644195|NCT03557216|DIAGNOSTIC_TEST|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
219644196|NCT01343277|DRUG|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
219644197|NCT01343277|DRUG|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
219644198|NCT04190511|DIETARY_SUPPLEMENT|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
219644199|NCT04190511|DIETARY_SUPPLEMENT|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
219644200|NCT03264924|BEHAVIORAL|IPAIR|Motivational interview training
219644201|NCT02344251|DEVICE|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
219644202|NCT02344251|DEVICE|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
219644203|NCT04982354|DRUG|CPX-351|For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
218960068|NCT03486145|DIETARY_SUPPLEMENT|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
218960069|NCT03486145|DIETARY_SUPPLEMENT|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
218960070|NCT04732897|PROCEDURE|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
218960071|NCT02783469|GENETIC|Identification of genetic causes of diabetic neuropathic pain|
218960072|NCT04517955|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
219644204|NCT04982354|DRUG|Midostaurin|The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
219644205|NCT04982354|DRUG|Busulfan|0.8 mg/kg/dose every six hours x 12 doses administered intravenously
219644206|NCT04982354|DRUG|Melphalan|70 mg/m2/day x 2 doses administered intravenously
219644207|NCT04982354|DRUG|Fludarabine|25 mg/m2/day x 5 doses administered intravenously
219644208|NCT04982354|BIOLOGICAL|CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor|Allogeneic stem cell transplant infused intravenously
219644209|NCT02078453|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
219644210|NCT04588051|DRUG|Cabozantinib|60mg daily
219644211|NCT02901119|DIETARY_SUPPLEMENT|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
219644212|NCT06060990|OTHER|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
219644213|NCT06969352|DRUG|Vorasidenib|"Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older:~* For patients weighing at least 40 kg: 40 mg, orally, once daily.~* For patients weighing less than 40 kg: 20 mg, orally, once daily."
218960073|NCT00247221|BEHAVIORAL|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
218960074|NCT00247221|BEHAVIORAL|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
218960075|NCT02048280|PROCEDURE|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
218960076|NCT02048280|OTHER|NAVA level|Increase NAVA level every 3 minutes
218960077|NCT02171559|DRUG|Enoxaparin prefilled syringes|
218960078|NCT02171559|DRUG|Dabigatran etexilate capsules|
218960079|NCT01965886|PROCEDURE|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
218960080|NCT01965886|PROCEDURE|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
219060980|NCT05739747|OTHER|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~* Patient registration.~* Complete medical history.~* Gendolcat scale (including the Spanish version of the SF-12 scale).~* Spanish version of the catastrophizing scale."
219060981|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
219060982|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
219060983|NCT05739747|OTHER|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
219644214|NCT01926613|BEHAVIORAL|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
219644215|NCT01926613|BEHAVIORAL|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
219644216|NCT05545514|DRUG|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
219644217|NCT06513013|PROCEDURE|transversus abdominis plane (TAP) block in cesarean section|.an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.
218960081|NCT01552707|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
218960082|NCT01552707|PROCEDURE|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
218960083|NCT04894214|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
218960084|NCT04894214|OTHER|Recording of hemodynamic monitoring|Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
218960085|NCT04894214|OTHER|Recording of respiratory monitoring|Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
218960086|NCT05294120|DEVICE|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
218960087|NCT05294120|RADIATION|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
219644218|NCT06513013|DRUG|Magnesium sulfate|25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 250 mg of MgSO4) to keep the total volume the same in both group
219644219|NCT06513013|DRUG|Neostigmine|"25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 500 mcg neostigmine.~A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered. Following the affirmation of a hypoechoic region on the USG image, the study solutions will be injected as per group allocation. Postoperatively,both groups of patients received an injection of paracetamol 1gm intravenously every 8th hourly as a part of multimodal analgesia and the patients will be evaluated for pain, nausea or vomiting in the post anaesthesia care unit at time 0 (time of completion of TAP block), 2, 4, 6,12 and 24 h by an investigator blinded to the group assignment. Whenever the NRS \>4, Nalbuphine 0.1 mg/kg IV will be administered as a rescue analgesic."
219644220|NCT02838914|PROCEDURE|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
219644221|NCT02308423|RADIATION|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
219644222|NCT06419543|DRUG|Remimazolam|Observe the incidence of paradoxical reactions after the first induction.
219644223|NCT01654120|DRUG|Liraglutide|SC, 1.8mg,QD, six months to one year
219644224|NCT01654120|DRUG|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
219060984|NCT05739747|OTHER|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
219644225|NCT00135512|DRUG|bupropion hydrochloride|Study drug
219644226|NCT05938660|OTHER|acupressure at Sanyinjiao point|When pressing Sanyinjiao point, the subject should be in a comfortable sitting position. Press the acupoints with the thumb until the subject feels soreness, then press and knead in a circle according to the strength acceptable to the subject. Press and knead once a second, and rest for 1 second every 5 seconds are one cycle, the speed is 10 cycles/minute, and it lasts for five minutes.
219644227|NCT06612242|PROCEDURE|early tracheostomy (less than 7 days from intubation)|Early tracheostomy (less than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
219644228|NCT06612242|PROCEDURE|Late tracheostomy (more than 7 days from intubation)|Late tracheostomy (more than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
219644229|NCT01098760|DRUG|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
219644230|NCT06621745|BEHAVIORAL|Gratitude Intervention App|The GIA app, an iOS application designed for this study, is based on effective gratitude interventions and tailored for youth. Access required a unique login. It features five exercises: a journal, photo book, imagine exercise, speech exercise, and meditation. The journal encourages daily entries. The photo book involves uploading photos of things users are grateful for, promoting mindfulness. The imagine exercise reflects on gratitude, while the speech exercise records users' gratitude. The meditation exercise enhances well-being. During the three-week study, daily notifications prompted exercise completion. The app, green and white with a flower-heart icon, offers email support for technical issues.
219644231|NCT06254001|DRUG|Bupropion|Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy
219644232|NCT06254001|DRUG|Nicotine replacement therapy (Nicotine patches)|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
219644233|NCT00045370|BIOLOGICAL|recombinant interferon alfa|
219060985|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
219060986|NCT01194115|DRUG|placebo|placebo representing standard of care
219060987|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
219060988|NCT03931577|DIAGNOSTIC_TEST|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
219060989|NCT03931577|PROCEDURE|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
219060990|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
219060991|NCT00052065|DRUG|TLK286|
219644234|NCT00045370|DRUG|temsirolimus|
219644235|NCT04092946|DEVICE|Digital intervention|"Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions."
219644236|NCT00137475|PROCEDURE|Intensity-Modulated Radiation Therapy|
219644237|NCT04266587|BIOLOGICAL|Blood sampling|blood sampling is done on healthy volunteers
219644238|NCT02526420|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
219644239|NCT03846154|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance /.) If needed, legal assistance"
219644240|NCT04793490|PROCEDURE|Sphenopalatine ganglion block|Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone
219644241|NCT04793490|DRUG|paracetamol|patients will receive paracetamol 1 g thrice daily intravenously
219644242|NCT01803217|OTHER|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
219644243|NCT06651112|DRUG|Antipsychotic drugs|Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
219644244|NCT03601312|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.
219644245|NCT03601312|BEHAVIORAL|OC-Go|OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
219644246|NCT03150511|DRUG|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
218960088|NCT05959603|DRUG|Vancomycin|Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
218960089|NCT02953509|DRUG|Magrolimab|Administered intravenously
218960090|NCT02953509|DRUG|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
218960091|NCT02953509|DRUG|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
219644247|NCT04984369|DRUG|HLX208|HLX208 450mg bid po OR 600mg bid po OR 900mg bid po
219644248|NCT04984369|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500 mg/m2 IV Q2W
219644249|NCT04590911|BEHAVIORAL|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
219644250|NCT03156179|DIAGNOSTIC_TEST|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
219644251|NCT06920303|DEVICE|transcranial colour coded duplex|transcranial colour coded duplex is good non invasive tool in detect velocity and obstructions of intracranial arteries
219644252|NCT00001460|BEHAVIORAL|inpatient evaluation and management|
219644253|NCT01989325|DRUG|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
219223687|NCT05861258|DRUG|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
219644254|NCT01989325|DRUG|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
219644255|NCT01989325|DRUG|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
219644256|NCT01989325|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
219644257|NCT02964208|DEVICE|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
218960092|NCT02953509|DRUG|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
218960093|NCT02953509|DRUG|Allopurinol|Administered orally during Cycle 1
218960094|NCT06312670|DRUG|EPI-7386|600 mg orally administered twice daily
218960095|NCT06312670|DRUG|Enzalutamide|160 mg administered orally once daily, with or without food
218960096|NCT06312670|DRUG|Androgen Deprivation Therapy (ADT)|LHRH agonist/antagonist or orchiectomy
218960097|NCT06033976|PROCEDURE|Endoscopic submucosal dissection (ESD)|Endoscopic injection of fluid into the gastrointestinal submucosal space followed by endoscopic knife dissection around and under the lesion so as to remove the lesion specimen in one piece with lesion free resection margins.
219644258|NCT06680687|BEHAVIORAL|Educational Program (video, information booklet, Survivorship Card)|"Caregivers will be invited to attend an educational group session. Each session will be organized weekly to monthly. A maximum of ten caregivers can be present at a session.~First a video will be displayed in which healthcare providers explain medical aspects of survivorship. Caregivers of survivors and young adult survivors discuss experiences after completing cancer treatment in the video.~Secondly, the present healthcare provider will hand over an information booklet 'Life after childhood cancer' to the caregivers. The booklet covers similar topics as presented in the video.~Lastly, a Survivorship Card will be shared with the caregivers. The card contains a record of the patient's cancer and treatment history and the expected follow-up appointment schedule. The survivor and family take one card home and a duplicate copy of the card remains in the medical file."
219644259|NCT06680687|BEHAVIORAL|Follow-Up Program (form and healthcare provider training)|"Healthcare providers will attend a training session of approximately 90 minutes, in which investigators will discuss the same topics as covered in the educational group session supported by PowerPoint slides.~A Follow-Up Form will be introduced to be used by healthcare providers in the outpatient follow-up clinic. The form will include questions referring to symptoms specific for certain late effects. Specific questions will be included per subcategory: hematological malignancies, solid tumors or central nervous system (CNS) tumors."
219644260|NCT04996316|OTHER|Electronic Health Record Review|Health record reviewed
219644261|NCT04996316|OTHER|Interview|Participate in interview
219644262|NCT04996316|OTHER|Media Intervention|Use MammoScreen
219644263|NCT04996316|OTHER|Survey Administration|Complete survey
219644264|NCT04996316|OTHER|Training and Education|Undergo training
219644265|NCT02526979|DRUG|mirabegron|oral
219644266|NCT06686680|DEVICE|extracorporeal shockwave therapy (ESWT)|Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.
219644267|NCT06686680|DEVICE|Sham Comparator|All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
218960098|NCT05944328|OTHER|systematic and structured review of patient pharmacotherapeutic treatment plans|"The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient."
219060992|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
219060993|NCT03669003|BIOLOGICAL|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
219060994|NCT03669003|PROCEDURE|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
219060995|NCT02505932|PROCEDURE|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
219060996|NCT02505932|PROCEDURE|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
219060997|NCT04564833|DRUG|Low Dose RBT-1|intravenous administration
219060998|NCT04564833|DRUG|High Dose RBT-1|intravenous administration
219060999|NCT04564833|DRUG|Placebo|intravenous administration
219061000|NCT02672904|DEVICE|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
219061001|NCT02672904|DEVICE|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
219061002|NCT01664845|DRUG|metformin|metformin 500mg tid
219061003|NCT01664845|DRUG|pegylated-IFN|pegasys 180 mcg qw
219061004|NCT01664845|DRUG|ribavirin|ribavirin 800-1200 mg qd according to BW
219061005|NCT00836823|DRUG|Alfuzosin|Alfuzosin 10mg once daily for 12 months
218960099|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
218960100|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
218960101|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
219644268|NCT05486533|OTHER|Acupressure|The experimental group will start with LI4 points and continue P6 and LI11 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
219644269|NCT05665075|DRUG|QN-023a|NK cell therapy
219644270|NCT05665075|DRUG|Cyclophosphamid|Lympho-conditioning Agent
219644271|NCT05665075|DRUG|Fludarabine|Lympho-conditioning Agent
219644272|NCT05665075|DRUG|Cytarabine|Lympho-conditioning Agent
219644273|NCT05665075|DRUG|VP-16|Lympho-conditioning Agent
219644274|NCT06316193|OTHER|Diary|The diary is the tool through which the experiences and experiences of the parents of infants admitted to Neonatal Pathology and included in the study and the health care personnel who decide to participate will be collected and analyzed. This tool is given to the parents of infants included in the study in the first few days of the infant's stay (by the third day after admission), subject to the parents' written consent, accompanied by a brief letter of introduction to the diary itself, written by the nurses on the ward. This tool has been part of current clinical practice since January 2023.
219644275|NCT06879717|DRUG|roginolisib|tablet, 40mg tablet strength
219644276|NCT06879717|DRUG|Dostarlimab|500 mg administered as IV infusion
219644277|NCT06879717|DRUG|Docetaxel|75 mg/m2 administered over 1 hour as IV infusion
219644278|NCT05193071|DRUG|Aspirin 100mg; Clopidogrel 300mg|Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization
219644279|NCT00671528|DRUG|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
218960102|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
218960103|NCT00000843|DRUG|Adefovir dipivoxil|
218960104|NCT00484185|DRUG|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
219644280|NCT00671528|DRUG|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
219644281|NCT00671528|DRUG|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
219644282|NCT06720584|BEHAVIORAL|Health coach-led, online support program for people living with lupus|"The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.~Program Session Structure (\~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.~Associated Materials: Notebook, expert videos available."
219644283|NCT06729554|OTHER|Education & Care in RARE|Education \& Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education \& Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program.
219644284|NCT04172259|DRUG|Doxorubicin liposome|PLD
219644285|NCT04172259|DRUG|Cyclophosphamide|CTX
219644286|NCT04172259|DRUG|Trastuzumab|H
219644287|NCT04172259|DRUG|Docetaxel|DOC
219644288|NCT04172259|DRUG|Epirubicin|EPI
219644289|NCT04172259|DRUG|Pertuzumab|P
219644290|NCT04172259|DRUG|Paclitaxel|paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
219644291|NCT04172259|DRUG|Paclitaxel-albumin|albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
219644292|NCT06730594|DIETARY_SUPPLEMENT|VL-BK-02 (25 billion CFU/Capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
219644293|NCT06730594|DIETARY_SUPPLEMENT|Placebo (Microcrystalline Cellulose - 375 mg/capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
219644294|NCT02913274|DEVICE|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
219644295|NCT02913274|DEVICE|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
219644296|NCT02913274|DEVICE|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
219644297|NCT06737432|OTHER|RKP Monitoring Software|Use of RKP alerting and monitoring software.
219644298|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Plasty|Surgical technique involving partial removal of the cyst wall to decompress the nerve root, followed by plasty of the nerve root sleeve to restore nerve function and prevent recurrence.
219644299|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Reinforcement and Reconstruction:|Advanced surgical technique combining partial cyst wall removal with additional reinforcement and reconstruction of the nerve root sleeve to provide enhanced support and reduce the risk of cyst recurrence.
219644300|NCT06756984|PROCEDURE|Autologous Fat/Muscle with Fibrin Glue Microscopic Cyst Filling|Minimally invasive surgical technique where autologous fat or muscle tissue is used to fill the cyst cavity, and fibrin glue is applied to seal the defect, aiming to obliterate the cyst and prevent cerebrospinal fluid leakage.
219644301|NCT05390242|DIAGNOSTIC_TEST|Radiographic study|Candidates undergo a radiographic study (Orthopantomography and Implant periapical radiography)
219644302|NCT00602459|DRUG|Cyclophosphamide|Given IV
219644303|NCT00602459|DRUG|Fludarabine Phosphate|Given IV or PO
219644304|NCT00602459|OTHER|Laboratory Biomarker Analysis|Correlative studies
219644305|NCT00602459|DRUG|Lenalidomide|Given PO
218960105|NCT03952390|OTHER|control|
219644306|NCT00602459|BIOLOGICAL|Rituximab|Given IV
219644307|NCT06343467|DEVICE|Generic Volar Locking Plate|Application of a generic volar locking plate is done in the generic implant arm compared to the other commonly used implants by surgeons in the conventional implant arm.
218960106|NCT03952390|OTHER|sepsis|
219644308|NCT06343467|DEVICE|Conventional Volar Locking Plate|Application of a conventional, brand name volar locking plate is done in the conventional implant arm compared to the generic implant arm.
219644309|NCT05314127|DRUG|Tazarotene 0.1% Gel,Top|once daily topical application at night with a cotton tipped applicator on every lesion
219644310|NCT05314127|DRUG|Imiquimod|Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
219644311|NCT05314127|DRUG|Fluorouracil Cream|5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
219644312|NCT05314127|DRUG|Petrolatum|applied once daily at night
219644313|NCT04057482|DRUG|D|treatment of BV with dequalinium chloride vaginal tablets
219644314|NCT00688662|PROCEDURE|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
219644315|NCT00688662|PROCEDURE|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
219644316|NCT01295827|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
219644317|NCT01883726|DEVICE|Grayson's presurgical nasoalveolar molding|Grayson NAM
219644318|NCT01883726|DEVICE|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
219644319|NCT06809777|DRUG|Topical 25% podophyllin|25% podophyllin applied topically once weekly for 4 weeks
218960107|NCT06299371|DRUG|Adebrelimab|Adebrelimab IV
219644320|NCT06809777|PROCEDURE|Cryotherapy|cryotherapy of 10 sec freeze cycle applied twice weekly for 4 weeks
219644321|NCT00264745|BEHAVIORAL|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
219644322|NCT00264745|BEHAVIORAL|Attention Control|Minimal intervention beyond initial hospital visit.
218960108|NCT06299371|DRUG|paclitaxel for injection (albumin bound)|paclitaxel for injection (albumin bound) IV
218960109|NCT06299371|DRUG|Cisplatin or Carboplatin|Cisplatin or Carboplatin IV
218960110|NCT00933218|DIETARY_SUPPLEMENT|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
218960111|NCT00933218|DIETARY_SUPPLEMENT|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
219644323|NCT01743560|DRUG|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
219644324|NCT01743560|DRUG|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
219644325|NCT03226769|DEVICE|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
219644326|NCT03226769|DEVICE|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
219644327|NCT01130441|BEHAVIORAL|psychotherapy|short problem-solving skills therapy intervention
219644328|NCT02640677|BIOLOGICAL|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
219644329|NCT02203227|DIETARY_SUPPLEMENT|Placebo|
219644330|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
219644331|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
219644332|NCT02203227|DIETARY_SUPPLEMENT|MaQxan|
219644333|NCT01516008|DRUG|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
219644334|NCT01516008|DRUG|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
219644335|NCT01516008|DRUG|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
219644336|NCT05704998|OTHER|Physiotherapy|Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
219644337|NCT04801680|DEVICE|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
219644338|NCT04393480|OTHER|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
219644339|NCT04393480|OTHER|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
219644340|NCT06458582|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
219644341|NCT04463420|DRUG|PHR160 Spray|One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
219644342|NCT04463420|DRUG|Placebo|participants will receive a placebo spray every hour. This process will continue for 10 days.
219644343|NCT04463420|DRUG|Standard treatment|: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
219644344|NCT04287231|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
218960112|NCT00170924|DRUG|Valsartan|
218960113|NCT00812760|DRUG|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
219644345|NCT02036840|DRUG|Antibiotic|
219644346|NCT05284591|BIOLOGICAL|Daratumumab|intravenous or subcutaneous
219644347|NCT02932527|BEHAVIORAL|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
218960114|NCT03216928|DIAGNOSTIC_TEST|Blood test|
218960115|NCT03430453|PROCEDURE|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
218960116|NCT05530629|DEVICE|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
219061006|NCT06063629|PROCEDURE|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
219061007|NCT06063629|PROCEDURE|No drain|No drain will be inserted into patients allocated to this group
219644348|NCT02932527|PROCEDURE|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
219644349|NCT02932527|PROCEDURE|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
219644350|NCT03960489|DRUG|Roxadustat|Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
219644351|NCT06683430|DIETARY_SUPPLEMENT|High Potassium, Low Sodium Diet|Daily intake of 3500 mg K and 1500 mg Na for 14 days.
219644352|NCT06683430|DIETARY_SUPPLEMENT|Standard Diet|Daily intake of 1700 mg K and 2000 mg Na for 14 days.
219644353|NCT00004647|DRUG|mexiletine|
219644354|NCT03699280|OTHER|Virtual Reality|Oculus Go VR device
219644355|NCT03270852|DEVICE|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
219644356|NCT03270852|OTHER|No Enhanced reality|Identical rehabilitation without enhanced reality
219644357|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to others
219644358|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to self
219644359|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform self-kindness meditation
219644360|NCT03319342|BEHAVIORAL|Behavioral Intervention|Keep track of daily activities
219644361|NCT03319342|OTHER|Questionnaire Administration|Ancillary studies
219644362|NCT06137131|BEHAVIORAL|Straw phonation in air|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
219644363|NCT06137131|BEHAVIORAL|straw phonation in water|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
219644364|NCT06137131|BEHAVIORAL|/u/ phonation|/u/ phonation without a straw, control condition
219644365|NCT02715362|DRUG|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
219644366|NCT02497443|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
219644367|NCT01253005|BEHAVIORAL|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
219644368|NCT02551770|PROCEDURE|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
219644369|NCT02551770|PROCEDURE|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
219644370|NCT02551770|DEVICE|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
219644371|NCT01927549|PROCEDURE|Immediate multivessel PCI|
219644372|NCT01927549|PROCEDURE|Culprit Lesion only PCI|
218960117|NCT05530629|DEVICE|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
218960118|NCT00746200|PROCEDURE|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
218960119|NCT00746200|PROCEDURE|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
218960120|NCT02566408|OTHER|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
218960121|NCT02566408|OTHER|Survey Questions|Complete survey
218960122|NCT06053710|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
218960123|NCT04770077|OTHER|Intubation on manikin|Training of medical student to focus on manikin vocal cord before intubation
218960124|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
218960125|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
218960126|NCT00545285|PROCEDURE|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
218960127|NCT05260281|DEVICE|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
218960128|NCT01799382|OTHER|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
218960129|NCT01799382|DEVICE|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
218960130|NCT00239525|DEVICE|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
219644373|NCT05172440|DRUG|tislelizumab combined with axitinib|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
219644374|NCT06937060|BIOLOGICAL|semaglutide|Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
219644375|NCT04328129|PROCEDURE|Human biological samples|"* Blood sample~* Nasopharyngeal swab."
219644376|NCT06947460|DRUG|CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219644377|NCT03721263|BIOLOGICAL|ASLAN004|Single Dose
219644378|NCT02531477|DRUG|propofol|intracarotid propofol as an anesthetic agent
219644379|NCT04089904|DRUG|Pembrolizumab Injection|Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
219644380|NCT04320693|DRUG|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
219644381|NCT06434805|OTHER|sex workers and sexual minorities education workshop|The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
219644382|NCT03287362|BEHAVIORAL|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
219644383|NCT03287362|BEHAVIORAL|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
219644384|NCT03287362|BEHAVIORAL|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
219644385|NCT02843776|OTHER|Questionnaires completion|
219644386|NCT00321698|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
219644387|NCT00321698|DRUG|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
219644388|NCT05270395|BEHAVIORAL|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
218960131|NCT00239525|DRUG|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
219223688|NCT07012824|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief, one-time intervention that teaches individuals to notice warning signs of an impending crisis (e.g., suicidal crisis) and provide them with skills to help reduce suicide risk.
219644389|NCT05258279|DRUG|Pembrolizumab|IV infusion Q3W
219644390|NCT05258279|DRUG|Lenvatinib|Oral capsule once daily
219644391|NCT05258279|DRUG|Carboplatin|IV infusion Q3W
219644392|NCT05258279|DRUG|Pemetrexed|IV infusion Q3W
219644393|NCT05844020|BEHAVIORAL|Educational materials|Trauma-informed intimate partner violence screening, brief interventions, and referrals to treatment by providers
219644394|NCT04691986|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
219644395|NCT04691986|OTHER|Placebo|Placebo pills contain micro cellulose powder.
219644396|NCT03725761|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
219644397|NCT00071656|BEHAVIORAL|Psychosocial (behavioral) Intervention|
219644398|NCT02809105|DRUG|linaclotide|Oral administration once daily
219644399|NCT02809105|DRUG|Placebo|Oral administration once daily
219644400|NCT05177926|DRUG|antiviral prophylaxis with Tenofovir Alafenamide Fumarate|All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
219644401|NCT06209398|BIOLOGICAL|Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )|Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
219644402|NCT06209398|BIOLOGICAL|Recombinant Hepatitis B Vaccine|Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
219644403|NCT06209398|BIOLOGICAL|Group A meningococcal polysaccharide vaccine|This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
219644404|NCT03622398|PROCEDURE|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
219644405|NCT03622398|PROCEDURE|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
219644406|NCT01351480|BIOLOGICAL|abatacept|Abatacept administered SC weekly at 125 mg dose
219644407|NCT06666777|BEHAVIORAL|Intervention focused on intersubjective prelinguistic and socio-communicative skills|"The intervention consists of 8 45-minute, weekly sessions over two months. These sessions may take place in various settings, such as free play, snack time, or structured activities. The speech therapist will use these settings to help parents observe intersubjective and social-communicative behaviors, providing guidance and strategies to support them.~The following topics will be addressed: Attention; Multisensory Stimulation and Integration: Sensitivity and Responsiveness; Communicative Codes and Preference/Discrimination; Gestures; Intentionality and Communicative Styles.~These topics are not structured into rigid levels for each session. Instead, several topics may be addressed within the same session and revisited across multiple sessions. This flexibility allows the speech therapist to adapt the intervention based on observations, interactions with the child, and discussions with the parent."
219644408|NCT06666777|BEHAVIORAL|Standard speech therapy intervention|The standard speech therapy intervention, as typically conducted in rehabilitation centers, consists of 8 weekly sessions, each lasting 45 minutes, over a two-month period (same as the experimental intervention). During these sessions, the therapist may provide various stimulations aimed at enhancing the child's vocalization, verbal comprehension, and speech production. While the therapist may offer guidance to parents on how to continue these stimulations in daily routines, they will not be directly involved in the sessions unless strictly necessary.
219644409|NCT00199797|DRUG|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
219644410|NCT00199797|DRUG|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
219644411|NCT00199797|DRUG|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
219644412|NCT00199797|DRUG|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
219061008|NCT01998373|BEHAVIORAL|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
219061009|NCT00709163|DRUG|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
219061010|NCT00709163|DRUG|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
219061011|NCT02855060|DEVICE|Pelvic Binder|
219061012|NCT01686711|DRUG|AD-4833 15 mg|
219061013|NCT01686711|DRUG|AD-4833 30 mg|
219061014|NCT01686711|DRUG|Placebo|
219061015|NCT03826277|OTHER|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
219061016|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
219061017|NCT04563858|DIAGNOSTIC_TEST|Validation|Assessment of Polish version of the 4AT
219061018|NCT02525133|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
219061019|NCT02525133|OTHER|Placebo|Plain collagen implant (vehicle)
219061020|NCT04073043|BEHAVIORAL|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
219223689|NCT07012824|BEHAVIORAL|Couples-based Crisis Response Planning|This intervention expands on traditional CRP by integrating the intimate partner into the intervention. Among service members, intimate partners are the group most likely to be told about suicidal thoughts prior to a suicide attempt.
219644413|NCT01684098|DRUG|Tc 99m EC20|
219644414|NCT03429751|DRUG|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
219061021|NCT03876067|DRUG|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
219644415|NCT03429751|DRUG|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
219644416|NCT05789784|OTHER|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
219061022|NCT03876067|DRUG|Cardioplegic Solutions|in which in which only cold blood cardioplegia
219061023|NCT02199457|DEVICE|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
219061024|NCT02199457|DEVICE|SVSS and reference devices|Body temperature taken with infrared thermometer
219644417|NCT05789784|OTHER|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
219644418|NCT01103453|BEHAVIORAL|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
219644419|NCT03677323|DEVICE|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
219644420|NCT03677323|DRUG|Droleptan|Venous administration of 1.25 mg of Droleptan
219644421|NCT03677323|DRUG|Propofol|Venous administration of 20 mg of Propofol
219644422|NCT03677323|DRUG|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
219644423|NCT02121015|BEHAVIORAL|Share|
219644424|NCT02121015|BEHAVIORAL|Self-Directed|
219644425|NCT06619925|BEHAVIORAL|after-school extended sports service|Impact of voluntary participation in different types (e.g. outdoor physical activities, indoor physical activities, ball games, calisthenics, etc.), intensity and duration of after-school extended physical education services on children\&#39;s myopia and other physical and psychological well-being
219644426|NCT06619925|BEHAVIORAL|non-after school extended sports service|Students in the same grade as the exposure group but participating in after-school non-physical education extended services (e.g., homework help, static activities such as calligraphy, chess, etc.) served as a control group, aiming to maximise the control of the influence of potential factors other than physical activity on the results of the study.
219061025|NCT02199457|DEVICE|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
219061026|NCT02199457|DEVICE|SVSS and reference devices|Measurement of respiration rate
219061027|NCT05331352|BEHAVIORAL|Semi-structured interviews|Interview
219061028|NCT05331352|BEHAVIORAL|Projective methode|Rorschach + thematic aperception test
219061029|NCT05331352|BEHAVIORAL|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
219061030|NCT01258114|OTHER|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
219644427|NCT02338297|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
219644428|NCT02338297|DRUG|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
219644429|NCT02338297|DRUG|PVA|Occlude arterioportal shunts(APS) with PVA
219061031|NCT01258114|OTHER|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
219061032|NCT03358225|PROCEDURE|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
219061033|NCT03358225|PROCEDURE|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
219061034|NCT03358225|PROCEDURE|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
219644430|NCT06649422|DRUG|Blinatumomab|The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
219644431|NCT03356119|DEVICE|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
219686191|NCT01449292|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
219061035|NCT04265755|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
219061036|NCT04779801|BEHAVIORAL|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
219061037|NCT02624973|DRUG|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
219061038|NCT02624973|DRUG|Neoadjuvant letrozole (postmenopausal women)|
219061039|NCT02624973|DRUG|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
219061040|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide|
219644432|NCT02556619|BEHAVIORAL|Early Palliative Care/Symptom Control|"1. Establish palliative care goals~   1. Determination of Medical Power of Attorney~  2. Discuss/plan code status/advance directives~  3. Document palliative care goals~2. Symptom Assessment and Control~   1. Pain-treatment with opioid and non-opioid medications~  2. Itching-H2 blockers, steroids~  3. Nutrition-appetite stimulated with Megace, review low sodium diet~  4. Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~  5. Nausea- treated with anti-emetics~  6. Jaundice and Body Image- counselling regarding symptoms~3. End-of-Life Care~   1. Discuss religious preferences~  2. Assess for distress- ensure interaction with Cancer Resource Center~  3. Hospice- charity Hospice options for select patients."
219644433|NCT06618495|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.
219644434|NCT01843114|DEVICE|FDOCT|Measurement of retinal blood velocities
219644435|NCT01843114|OTHER|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
219644436|NCT00771251|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
219644437|NCT00771251|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
219644438|NCT05970588|BEHAVIORAL|Standing Promotion Intervention|Participants will be provided with a standing desk converter to set on top of their existing desk for 4 weeks.
219644439|NCT01892111|OTHER|Structured exercise program.|
219644440|NCT02925715|PROCEDURE|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
219644441|NCT05773651|OTHER|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
219644442|NCT01004224|DRUG|BGJ398|
219061041|NCT02624973|DRUG|Neoadjuvant docetaxel|
219061042|NCT02624973|DRUG|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
219061043|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
219061044|NCT02624973|DRUG|Neoadjuvant olaparib|
219061045|NCT02624973|DRUG|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
219061046|NCT02624973|PROCEDURE|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
219061047|NCT02624973|RADIATION|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
219061048|NCT02624973|DRUG|Adjuvant trastuzumab|
219061049|NCT02624973|DRUG|Adjuvant letrozole (postmenopausal women)|
219061050|NCT02624973|DRUG|Adjuvant tamoxifen + goserelin (premenopausal women)|
219644443|NCT04432090|DRUG|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
219644444|NCT04432090|DRUG|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
219644445|NCT04432090|OTHER|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
219061051|NCT02624973|DRUG|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
219061052|NCT02624973|DRUG|Adjuvant Epirubicin+ Cyclophosphamide|
219061053|NCT04659980|DEVICE|hilotherapy|continuous cooling of hands and feet at a constant temperature
219061054|NCT04659980|DEVICE|frozen gloves|cooling of hands and feet using frozen gloves
219061055|NCT05794269|OTHER|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
219061056|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
219061057|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
219061058|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
219061059|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
219061060|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
219061061|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
219061062|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
219644446|NCT04250350|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
219644447|NCT03926390|DIETARY_SUPPLEMENT|Bovine colostrum|bovine colostrum for first 2 weeks
219644448|NCT00772824|DIETARY_SUPPLEMENT|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
219644449|NCT00772824|DIETARY_SUPPLEMENT|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
219644450|NCT02358785|DEVICE|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
219644451|NCT06356974|DRUG|Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)|Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
219644452|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
219644453|NCT03737708|DRUG|tacrolimus|Administered orally
219644454|NCT03737708|DRUG|methotrexate|Administered orally
219644455|NCT03737708|BIOLOGICAL|adalimumab|Administered as subcutaneous injection
219644456|NCT03737708|BIOLOGICAL|tocilizumab|Administered by intravenous injection
219644457|NCT03737708|BIOLOGICAL|abatacept|Administered by intravenous injection
219644458|NCT04502147|PROCEDURE|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
219644459|NCT00546676|DRUG|Telithromycin|
218960132|NCT05860101|OTHER|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
218960133|NCT06300593|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
218960134|NCT06300593|DIAGNOSTIC_TEST|Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
218960135|NCT04284150|DRUG|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
218960136|NCT01791556|OTHER|HIV-1 viral load testing|
218960137|NCT05278637|DRUG|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
218960138|NCT05278637|DRUG|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
218960139|NCT01205178|DRUG|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
218960140|NCT01205178|DRUG|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
219644460|NCT05839847|DEVICE|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
218960141|NCT01205178|DRUG|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
218960142|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
218960143|NCT00645788|DRUG|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
219061063|NCT04014660|DIETARY_SUPPLEMENT|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
219061064|NCT04014660|DIETARY_SUPPLEMENT|Placebo|The placebo supplement consists of corn starch only.
219644461|NCT05839847|DEVICE|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
219644462|NCT05555615|DRUG|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
219644463|NCT06405347|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
219644464|NCT04606485|OTHER|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
219644465|NCT04707703|DRUG|Isavuconazonium Injection [Cresemba]|Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
219644466|NCT04707703|DRUG|Placebo|Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
219644467|NCT05924815|DRUG|Aficamten|Oral Tablet
218960144|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
219644468|NCT05924815|DRUG|Aficamten-matching Placebo|Oral Tablet
219644469|NCT05924815|DRUG|Moxifloxacin|Oral Tablet
219644470|NCT01098656|DRUG|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
219644471|NCT02195622|DEVICE|Lumenis VersaCut Morcellator|
219644472|NCT02195622|DEVICE|Wolf Piranha Morcellator|
219644473|NCT03190668|DRUG|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
219644474|NCT03190668|DRUG|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
219644475|NCT03190668|DEVICE|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
219644476|NCT03190668|DEVICE|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
219644477|NCT00743730|OTHER|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
219644478|NCT00743730|OTHER|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
219644479|NCT00743730|OTHER|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
219644480|NCT02836236|DRUG|TAF|TAF 25 mg tablet administered orally once daily
219644481|NCT02836236|DRUG|TDF|TDF 300 mg tablet administered orally once daily
219644482|NCT02836236|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
219644483|NCT02836236|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
219644484|NCT04569422|DRUG|Benoxyl|reduce pain
219644485|NCT04546529|DEVICE|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
219644486|NCT04546529|DEVICE|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
219644487|NCT02222363|DRUG|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
219644488|NCT05601622|PROCEDURE|Fluid loading|Intravenous administration of 10ml/kg of crystalloids over 10 minutes
219644489|NCT05601622|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiographic measurement of stroke volume index
219644490|NCT05601622|DIAGNOSTIC_TEST|PVI, RPVI|Continuous measurement of pleth variability index and Rainbow pleth variability index
219644491|NCT05601622|PROCEDURE|Tidal volume change|Changing tidal volume for mechanical ventilation as 6, 8, 10 ml/kg
219644492|NCT05068778|BEHAVIORAL|Artificial Intelligence Application|AI application through smart phone
219644493|NCT03136341|DRUG|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
219644494|NCT03136341|OTHER|Placebo|Dosing will be determined at each study visit based upon muscles involved
219644495|NCT05716256|DRUG|Ulinastatin|The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
219644496|NCT05716256|PROCEDURE|TOF monitoring|The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
218960145|NCT00645788|DRUG|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
219061065|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
218960146|NCT03149848|DRUG|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
218960147|NCT03149848|DRUG|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
218960148|NCT01244490|DRUG|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
218960149|NCT01244490|DRUG|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
219644497|NCT04097795|OTHER|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
219644498|NCT04288921|DIAGNOSTIC_TEST|Swab|Swab samples for diagnostic test
219644499|NCT02287285|DRUG|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
219644500|NCT03337945|DRUG|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
219644501|NCT03482297|DEVICE|automated abdominal binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.
219644502|NCT03482297|DEVICE|Sham binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
219644503|NCT03482297|DRUG|Placebo|Oral placebo will be given three times a day on the baseline day (placebo)
219644504|NCT03482297|DRUG|Midodrine|A midodrine pill 10mg will be given three times a day on the standard of care study day
219644505|NCT02790359|OTHER|Air|Group of patients who would receive air insufflation
218960150|NCT01244490|DRUG|Placebo Comparator|Placebo
218960151|NCT00862108|DRUG|Methylphenidate|mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
218960152|NCT00133731|DRUG|Otamixaban (XRP0673)|
218960153|NCT00133731|DRUG|Unfractionated Heparin|
218960154|NCT00133731|PROCEDURE|Percutaneous Coronary Intervention|
218960155|NCT04786509|DIAGNOSTIC_TEST|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
218960156|NCT01486810|DRUG|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
219061066|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
219644506|NCT02790359|OTHER|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
218960157|NCT01486810|BEHAVIORAL|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
219061067|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
219644507|NCT00522535|PROCEDURE|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
219644508|NCT00522535|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
219644509|NCT05142150|OTHER|Questionaire|"Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying."
219644510|NCT04738097|DRUG|Ticagrelor 90mg|ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
219644511|NCT04738097|DRUG|Clopidogrel 75 mg|ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
219644512|NCT00784238|DRUG|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
218960158|NCT00474682|DRUG|Micronized dispersible ferric pyrophosphate|
218960159|NCT02165176|DRUG|Oral cannabis|
218960160|NCT00983697|PROCEDURE|therapeutic conventional surgery|
218960161|NCT00983697|RADIATION|fludeoxyglucose F 18|
219061068|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
219644513|NCT01047826|PROCEDURE|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
219644514|NCT01047826|PROCEDURE|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
218960162|NCT00971620|BIOLOGICAL|Botulinum toxin type A|Given as an intralesional injection.
218960163|NCT00971620|OTHER|Placebo|Given as an intralesional injection
218960164|NCT04564885|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
218960165|NCT04564885|DEVICE|Mobi-C Cervical Disc|surgery
218960166|NCT04715334|DEVICE|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
218960167|NCT00824070|DRUG|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
218960168|NCT00824070|DRUG|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
218960169|NCT00824070|DRUG|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
218960170|NCT01951859|OTHER|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
218960171|NCT01216605|DRUG|Syntocinon 24 IU|
218960172|NCT01216605|DRUG|Placebo|
219644515|NCT03693612|DRUG|feladilimab|feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
219644516|NCT03693612|DRUG|Tremelimumab|Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
219644517|NCT03693612|DRUG|Docetaxel|Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
219644518|NCT03693612|DRUG|Paclitaxel|Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
219644519|NCT03693612|DRUG|Cetuximab|Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
219644520|NCT00166543|DRUG|TAS-108|
219644521|NCT05900869|OTHER|FSFI|Female Sexual Function Index questionnaire
219644522|NCT05900869|OTHER|BES|Body Esteem Scale questionnaire
219644523|NCT02872974|OTHER|GDM|Exposure to GDM during fetal life
219644524|NCT04376944|OTHER|Survey|questionnaire on their symptoms and their exposures
219644525|NCT02241083|DRUG|Dopamine|
219644526|NCT02241083|DRUG|Norepinephrine|
219644527|NCT02241083|OTHER|no medication|
219644528|NCT02422966|DRUG|Paracetamol|
219644529|NCT02422966|DRUG|Ibuprofen|
219644530|NCT00102375|DRUG|Topotecan|
219644531|NCT02219581|DRUG|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
219644532|NCT02219581|DRUG|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
219644533|NCT02219581|DRUG|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain"
219644534|NCT02219581|DRUG|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
218960173|NCT03128151|BEHAVIORAL|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
218960174|NCT01173887|DRUG|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
218960175|NCT01173887|BIOLOGICAL|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
218960176|NCT03489954|OTHER|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
218960177|NCT00812695|DEVICE|CPAP|Gold standard treatment for Obstructive sleep apnea
218960178|NCT03206905|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
218960179|NCT03206905|BEHAVIORAL|Diet and Exercise|nutritional/exercise counseling
219644535|NCT01261572|DRUG|degarelix|periodic injection
219644536|NCT05622058|DRUG|ALRN-6924|ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
219644537|NCT05622058|DRUG|TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)|TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
219644538|NCT03146689|DRUG|Topical NSAID|Applied four times daily
219644539|NCT03146689|DRUG|Topical Capsaicin|Applied four times daily
218960180|NCT06146998|OTHER|3D health education model|explanation combined with 3D health education model
218960181|NCT06146998|OTHER|Verbal explanation|Regular explanation
218960182|NCT06165627|DEVICE|Lehfilcon A toric contact lenses|Commercially available soft contact lenses worn as indicated
218960183|NCT06165627|DEVICE|Comfilcon A toric contact lenses|Commercially available soft contact lenses) worn as indicated
218960184|NCT06165627|DEVICE|CLEAR CARE|Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
218960185|NCT02095314|BIOLOGICAL|Pentavalen|Batch 5010613
218960186|NCT06052215|BEHAVIORAL|Online Information Cards Education|Providing family planning education to women through online information cards
219644540|NCT03554863|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
218960187|NCT03304444|DRUG|Bupivacaine|bupivacaine hydrochloride used in TAP block
218960188|NCT03304444|DRUG|liposomal bupivacaine|liposomal bupivacaine used in TAP block
218960189|NCT00327470|DRUG|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
219644541|NCT03554863|DEVICE|Facial Mask|Preoxygenation with facial mask
219644542|NCT01154296|BEHAVIORAL|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
219644543|NCT02464475|OTHER|osteopathic manipulative treatment|
219644544|NCT02464475|OTHER|sham osteopathic treatment|
218960190|NCT02362568|PROCEDURE|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
219644545|NCT04518098|OTHER|Strength and balance exercise|The exercise program consists of muscle strengthening and balance training exercises that progress in difficulty. After completion of the baseline assessment and randomization, IG participants will receive orientation and learn the exercise routines (in the Cancer Rehabilitation Clinic within the Faculty of Rehabilitation Medicine at the University of Alberta). The duration of training is 3 months (40-50 minutes per scheduled session, three times a week) at home, with a minimum of one live group session supervised by the CEP, a minimum of one independent home session supported by the Active Living module of the HEAL-ME application; (the third session can be a live session or independent session at the participant's discretion).
219644546|NCT01793480|DRUG|Methadone|
219644547|NCT06317714|OTHER|questionnaires|"o Quality of life questionnaires EORTC QLQC-30 and EQ-5D-5L~° questionnaires NCI- PRO-CTCAE"
219644548|NCT02759055|OTHER|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
219644549|NCT04594226|PROCEDURE|EA combined with medication|"Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session."
219644550|NCT04594226|DRUG|Medication|The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
219644551|NCT06623812|OTHER|Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake|Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
219644552|NCT01865201|DRUG|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
219644553|NCT01865201|OTHER|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
219644554|NCT00109681|DRUG|Iloprost Inhalation Solution (Ventavis)|
218960191|NCT02581943|DRUG|Carboplatin|Given IV
218960192|NCT02581943|OTHER|Laboratory Biomarker Analysis|Correlative studies
218960193|NCT02581943|DRUG|Paclitaxel|Given IV
218960194|NCT02581943|BIOLOGICAL|Pembrolizumab|Given IV
219223690|NCT07014241|OTHER|Family psychoeducation|The study intervention, tagged SPARKED (Supportive Program for Advancing Recovery, Knowledge, and Empowerment in Depression), is a co-designed family-based psychoeducational intervention for individuals with MDD and their family members or caregivers. The intervention will cover structured modules to enhance participants' understanding of MDD and its treatment, coping strategies, and self-efficacy skills. It will also focus on recognising early signs of relapse and empowering participants to engage actively in treatment decision-making.
219644555|NCT02877095|DRUG|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
219644556|NCT02327338|DEVICE|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
219644557|NCT02327338|DRUG|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
219644558|NCT06616675|DRUG|Darifenacin|Anticholinergic drug therapy for OAB treatment - Darifenacin, 15mg/day
219644559|NCT06616675|DEVICE|Neuromodulation - Sacral nerve stimulation|Neurodyn Portable TENS FES neuromuscular stimulation device in an outpatient clinic. Two self-adhesive electrodes (5x9cm) were used, positioned one in each gluteal region, below the iliac spine to apply low-frequency biphasic current with 10 Hz. Pulse duration of 0.5 milliseconds was applied for 40 minutes with continuous stimulation, 3 times a week, for 20 sessions.
219644560|NCT01785511|RADIATION|UVA Radiation|UVA radiation exposure for 20 minutes
219644561|NCT03914261|DRUG|Risankizumab|Tablet
219644562|NCT05444725|OTHER|Stage of Decision Making|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
219686192|NCT01449292|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
219223691|NCT07012161|DRUG|Colecalciferol (Vitamin D3) 50000 UI|Participants will received vit d upto 6 months
219223692|NCT04506567|DRUG|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
218960195|NCT02581943|OTHER|Quality-of-Life Assessment|Ancillary studies
218960196|NCT02758405|DRUG|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
218960197|NCT02758405|DRUG|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
218960198|NCT02758405|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
218960199|NCT02115126|BIOLOGICAL|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
218960200|NCT02115126|BIOLOGICAL|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
218960201|NCT03274375|DRUG|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
218960202|NCT03274375|DRUG|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"
218960203|NCT01415089|BEHAVIORAL|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
218960204|NCT03021564|OTHER|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
218960205|NCT01987947|DRUG|Placebo|Two administrations by subcutaneous injection
218960206|NCT01987947|DRUG|Quilizumab|Two administrations by subcutaneous injection
219644563|NCT05444725|OTHER|Choice framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
218960207|NCT03374618|OTHER|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
219223693|NCT04506567|DIAGNOSTIC_TEST|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
219644564|NCT05444725|OTHER|Opportunity Framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
219644565|NCT05313022|BIOLOGICAL|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
219644566|NCT05313022|OTHER|Placebo|Normal saline solution
219644567|NCT02807012|OTHER|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access."
219644568|NCT00545246|DRUG|aflibercept (AVE0005)|intravenous infusion
219644569|NCT00545246|DRUG|docetaxel|intravenous infusion
219644570|NCT02153671|BIOLOGICAL|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
219644571|NCT02153671|BIOLOGICAL|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
219644572|NCT05481528|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
219644573|NCT05481528|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant
219644574|NCT05481528|DRUG|Placebo|Single oral dose of placebo
219644575|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
219644576|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area in Gunter 1610. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete three full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary.
219686193|NCT05833126|DRUG|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
219223694|NCT04506567|DRUG|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
219644577|NCT03992170|DRUG|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
219644578|NCT06459349|OTHER|exteroceptive and proprioceptive sensory stimulation training|Patients in this group will receive intervention exteroceptive and proprioceptive sensory stimulation for 50 minutes per session, 03 times a week, for 06 weeks
218960208|NCT03920384|BEHAVIORAL|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
219644579|NCT06459349|OTHER|sensorimotor therapy group|Patients will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks
219644580|NCT02070731|DEVICE|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
219644581|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
219644582|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
218960209|NCT03920384|BEHAVIORAL|Active control arm|Standard psychological therapy for psychosis without new therapy components
218960210|NCT04136756|DRUG|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
218960211|NCT04136756|DRUG|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
218960212|NCT04136756|DRUG|Rituximab|Rituximab administered intravenously at specified dose on specified days
218960213|NCT04136756|DRUG|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
218960214|NCT03444077|DIAGNOSTIC_TEST|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.
218960215|NCT03444077|DIAGNOSTIC_TEST|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
219223695|NCT06697106|DRUG|Nonsteroidal anti-inflammatory drugs|Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
219644583|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
219644584|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
219644585|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (highest dose)
219644586|NCT01322594|OTHER|Placebo|Placebo single IV dose
219644587|NCT04070690|PROCEDURE|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
219644588|NCT00063791|DRUG|Bortezomib|
219644589|NCT05742139|OTHER|Non intervention|Non intervention
218960216|NCT03444077|OTHER|STTTOPPP the bleeding|"* Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
218960217|NCT03444077|OTHER|Regular Care|Regular local pre-hospital care.
218960218|NCT00453388|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
218960219|NCT00453388|DRUG|Cyclophosphamide|Given IV
218960220|NCT00453388|DRUG|Cyclosporine|Given IV or PO
218960221|NCT00453388|DRUG|Fludarabine Phosphate|Given IV
218960222|NCT00453388|OTHER|Laboratory Biomarker Analysis|Correlative studies
218960223|NCT00453388|DRUG|Mycophenolate Mofetil|Given PO
218960224|NCT00453388|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
218960225|NCT00453388|RADIATION|Total-Body Irradiation|Undergo TBI
219223696|NCT06697106|DRUG|Placebo|Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
219644590|NCT03743103|DRUG|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
219644591|NCT03743103|DRUG|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
219644592|NCT05454384|OTHER|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
219644593|NCT05218356|DRUG|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
219644594|NCT05218356|DIAGNOSTIC_TEST|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
219223697|NCT06628167|BEHAVIORAL|Transportation|Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
219644595|NCT05218356|DIAGNOSTIC_TEST|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
219644596|NCT05218356|DIAGNOSTIC_TEST|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
219644597|NCT05218356|DIAGNOSTIC_TEST|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
219644598|NCT05218356|OTHER|NEWS-2 score|assessment of the participant by the NEWS-2 score.
219644599|NCT05218356|OTHER|WHO score|assessment of the participant by the score of the World Health Organization.
219644600|NCT05218356|OTHER|Physical examination|evaluation by the principal investigator or assistant physician
219644601|NCT05218356|OTHER|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
219644602|NCT06181292|BIOLOGICAL|PHH-1V81|booster of PHH-1V81
219644603|NCT06181292|BIOLOGICAL|Comirnaty Omicron XBB1.5|booster of Comirnaty Omicron XBB1.5
219644604|NCT02794701|OTHER|People with silicosis|
219644605|NCT04274504|DIAGNOSTIC_TEST|Osteopontin|Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
218960226|NCT00745615|DRUG|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
219644606|NCT03692325|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
219644607|NCT00002104|DRUG|Thalidomide|
219644608|NCT03961386|BEHAVIORAL|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
219644609|NCT03961386|BEHAVIORAL|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
219644610|NCT03087422|BEHAVIORAL|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
219644611|NCT04456868|BEHAVIORAL|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
219644612|NCT04456868|BEHAVIORAL|walking test|8-Meter walking test will be done for gait parameter assessment
219644613|NCT04456868|BEHAVIORAL|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
219061069|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
219644614|NCT04456868|PROCEDURE|Position emission tomography|Position emission tomography will be done for
219644615|NCT06620718|PROCEDURE|coronectomy|The inferior alveolar nerve and buccal nerve were blocked with maxicaine anaesthetic solution (articaine hydrochloride 40 mg, epinephrine hydrochloride 0.006 mg). Incisions were applied uniformly across all patients, and a triangular flap technique was employed. After elevating the flap and exposing the bone, the bone overlying the crown of the tooth was removed using a bone round bur to fully visualize the tooth\&#39;s crown. Once the crown was fully exposed, the crown preparation was initiated at the enamel-dentin junction using a fissure bur. The crown preparation was completed without leaving any sharp edges, and the crown was extracted. Then, the exposed pulp was washed with sterile serum without any further intervention. The surgical area was sutured using 5/0 silk. Analgesic (25 mg of dexketoprofen trometamol twice a day) and antibiotic (125 mg clavulanic acid, 875 mg amoxicilin twice a day) drugs were described.
219644616|NCT06623513|DRUG|Parecoxib Sodium|Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.
219644617|NCT06623513|DRUG|Indomethacin suppository|Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
219644618|NCT01202370|DRUG|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
219644619|NCT00922467|DRUG|NaCl 9/00|Same volume as in the esmolol group
219644620|NCT00922467|DRUG|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
219644621|NCT01099501|DIETARY_SUPPLEMENT|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
219644622|NCT01099501|DIETARY_SUPPLEMENT|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
219644623|NCT01099501|DIETARY_SUPPLEMENT|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
218960227|NCT00745615|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
218960228|NCT00907062|DIETARY_SUPPLEMENT|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
218960229|NCT03405636|DEVICE|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
219061070|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
219223698|NCT06628167|BEHAVIORAL|Scheduling|Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
219223699|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
219644624|NCT06317142|DRUG|Acipimox 250 mg Oral Capsule|A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.
219644625|NCT02668809|OTHER|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
219644626|NCT02668809|OTHER|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
219061071|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
219061072|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
219644627|NCT02668809|OTHER|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
219644628|NCT02668809|OTHER|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
219644629|NCT02668809|OTHER|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
219644630|NCT02668809|OTHER|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
219644631|NCT02668809|OTHER|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
219644632|NCT02668809|OTHER|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
219644633|NCT03586674|DRUG|Lipanthyl|Tablet
219644634|NCT03586674|DRUG|Ursogal|suspension
219644635|NCT00496275|DRUG|Zactima (ZD6474)|
219644636|NCT00496275|DRUG|Vinorelbine plus cisplatin|
219644637|NCT00496275|DRUG|Gemcitabine plus cisplatin|
219644638|NCT06620887|OTHER|Evaluate the impact of HEMAGO program on maternal morbidity and mortality in sickle cell disease patients during their pregnancies.|"HEMAGO pregnancy monitoring is a joint consultation program between the sickle cell disease hematologist and an obstetrician. This program was implemented in April 2016 at the Croix-Rousse maternity Hospital. This program offers close, complete and personalized pregnancy monitoring for each patient with major sickle cell syndrome.~These are follow-up consultations once a month until 24 weeks then every 15 days until delivery. At each consultation, doctors evaluate a general and obstetric clinical examination. The team establishes a precise schedule adapted to each patient for pregnancy monitoring : monthly blood tests, monthly ultrasounds with maternal and fetal Doppler, adaptation of basic treatment, transfusion exchange program according to eligibility criteria, and organization of childbirth."
219644639|NCT01413789|DRUG|Dermatix|1 application of Dermatix
219644640|NCT01413789|DRUG|Kelocote|1 application of Kelocote
219644641|NCT01413789|DRUG|BAP scar gel|1 application of BAP scar gel
219644642|NCT01413789|DRUG|Alhydran|1 application of Alhydran
219644643|NCT01413789|DRUG|Bap Scar Care T|1 application of BAP Scar Care T
219644644|NCT01413789|DRUG|Bap Scar Care S|1 Application of Bap Scar Care S
219644645|NCT01413789|DRUG|Mepiform|1 application of Mepiform
219644646|NCT01413789|DRUG|Scar Ban Elastic|1 application of Scar Ban Elastic
219644647|NCT00562289|DRUG|aspirin|during the follow up
219644648|NCT00562289|DRUG|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
219644649|NCT00562289|DEVICE|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
219644650|NCT00970632|DRUG|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
219644651|NCT00970632|DRUG|Placebo tablet|Placebo tablet po QD for 12 weeks
219644652|NCT00970632|DRUG|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
219644653|NCT00970632|DRUG|Placebo capsule|Placebo capsule po QD for 12 weeks
219061073|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
219061074|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
219644654|NCT03811327|BEHAVIORAL|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
219644655|NCT05545631|OTHER|no intervention|no intervention in this study
219644656|NCT02817516|DRUG|TAK-828|TAK-828 solution.
219644657|NCT02817516|DRUG|Placebo|TAK-828 placebo-matching solution.
219686194|NCT00132288|BEHAVIORAL|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
219686195|NCT00132288|BEHAVIORAL|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
219061075|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
219061076|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
219686196|NCT02056418|DIETARY_SUPPLEMENT|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
219644658|NCT02168374|OTHER|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
219644659|NCT06642155|BEHAVIORAL|RESPONSIBLEPLAY© MTM-Based Intervention|Participants in this group will receive a theory-based intervention using the Multi-theory Model (MTM) of health behavior change. The intervention includes participatory dialogue, behavioral confidence-building, and strategies to modify the physical and social environments. It also incorporates emotional transformation and practice for change. Sessions will be delivered in-person over three weeks, focusing on promoting responsible gambling behaviors.
219644660|NCT06642155|BEHAVIORAL|Knowledge-Based Intervention|Participants in this group will receive a knowledge-based intervention that provides information on gambling risks and responsible gambling strategies. The intervention consists of lectures and reading materials delivered in-person over three weeks. It focuses on raising awareness of gambling risks but does not include the behavioral change strategies used in the MTM-based intervention.
219644661|NCT04002999|DEVICE|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, \[24\] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
219644662|NCT04002999|DEVICE|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
219644663|NCT04002999|DEVICE|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
219644664|NCT01433068|DEVICE|NBTXR3|One intratumor implantation by injection
219644665|NCT06052202|BEHAVIORAL|CRC mHealth|Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
219644666|NCT06052202|BEHAVIORAL|Control|Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
219644667|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention
219644668|NCT06967467|BEHAVIORAL|Survey|Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use
219644669|NCT06967467|BEHAVIORAL|Ethnographic observation|Observations designed to identify communication and contextual barriers to the implementation of RENEW
219644670|NCT06967467|BEHAVIORAL|Survey|Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention
219644671|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention
219644672|NCT06966609|PROCEDURE|Control Group|Conventional Physical Therapy ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars. Duration of session is 45 min.
219686197|NCT02056418|DRUG|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
219686198|NCT05986981|DRUG|Vaccine|"Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects)."
219061077|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
219061078|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
219061079|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
219061080|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
219644673|NCT06966609|PROCEDURE|Experimental Group|Conventional Physical Therapy and Cuevas Medek Exercises ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars.Along with conventional physical therapy, experimental group participants will get Cuevas Medek Exercises that includes antigravity exercises, specefic types of stretchings and balancing exercises. Types of exercises that will be performed on the patient out of 100 exercises,will depend on the patient's need that is affecting his or her gross motor proficiency.Total duration of session is 90 min.
219644674|NCT06969157|PROCEDURE|Surgery|Minor or major surgeries were performed depending upon the primary diagnosis. Major surgery was defined as one done under general anesthesia while minor was one done under local anesthesia.
219644675|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal and parietal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session for one time with EEG monitoring conducted before and after electrical stimulation.
219644676|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
219686199|NCT02773095|OTHER|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
219686200|NCT04977141|OTHER|Decisional Conflict Scale|Decisional Conflict Scale
219686201|NCT03703778|PROCEDURE|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
219686202|NCT03703778|DRUG|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
218960230|NCT05765656|BEHAVIORAL|GP - pharmacist collaboration and pharmacist motivational interviewing|"1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
218960231|NCT02554851|DRUG|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
218960232|NCT02554851|OTHER|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
218960233|NCT04932070|DIETARY_SUPPLEMENT|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
218960234|NCT02481427|PROCEDURE|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
219061081|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
219061082|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
219061083|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
219061084|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
219223700|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
219686203|NCT03703778|DRUG|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
219686204|NCT00234026|DRUG|gemcitabine hydrochloride|
219686205|NCT00289094|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
219686206|NCT00289094|DEVICE|Total knee replacement|Fixed Cruciate Retaining Knee System
219686207|NCT02835859|OTHER|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
219644677|NCT06966908|OTHER|Facilitate the referral of in-hospital chronic hepatitis B patients and provide treatment and follow-up in the infectious disease department.|After visiting the hospital, high-risk HBV patients are prescribed HBsAg testing by their primary physician. If HBsAg positivity is detected in patients from non-infectious disease departments, their lab reports will include a reminder to visit the Hepatitis B Health Clinic. Some primary physicians may also request an infectious disease consultation or recommend patient referral. Additionally, within two weeks, the Hepatitis B Specialist Assistant will contact the patients by phone to provide referral recommendations. Once referred to the Hepatitis B Health Clinic, physicians will conduct health education, complete liver function and virological assessments, and develop individualized treatment and follow-up plans.
219644678|NCT03652220|BEHAVIORAL|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
219644679|NCT03652220|OTHER|Minimal treatment|Drug continuation under medical supervision
219644680|NCT03652220|OTHER|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
219644681|NCT02055989|RADIATION|Dose-escalated radiotherapy level 1|
219644682|NCT02055989|RADIATION|Sequential dose-escalated radiotherapy level 2|
219644683|NCT04298814|OTHER|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
219644684|NCT06333067|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219644685|NCT01905202|DRUG|Secretrol|
219644686|NCT04304235|DEVICE|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
219644687|NCT04304235|OTHER|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
219644688|NCT04377425|DIAGNOSTIC_TEST|COVID-19 swap test PCR|COVID-19 swap test PCR performed according to hospital standard operating procedures
219644689|NCT04240717|BEHAVIORAL|Patient Decision Aid|The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
218960235|NCT02481427|PROCEDURE|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
218960236|NCT02909803|OTHER|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
218960237|NCT02909803|OTHER|White Bread|Participants will consume white bread on at least two different test days
218960238|NCT03787563|DRUG|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
218960239|NCT03787563|DRUG|Placebo Tea|Similar looking inert placebo tea.
219061085|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
219061086|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
219644690|NCT00155272|DRUG|Thalidomide|
219644691|NCT04400864|OTHER|Dietary intervention|dietary counseling based on the principals pf the dietary intervention group.
219644692|NCT02234830|DEVICE|Exoseal closure device|Closure device for femoral artery access closure
219644693|NCT02234830|DEVICE|Angioseal closure device|Closure device for femoral artery access closure
219644694|NCT04122703|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
219644695|NCT04122703|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
219644696|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold ® coffee|"Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~\- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
219644697|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold DECAF® coffee|"Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
219644698|NCT03813901|OTHER|Samalochana Counselling|Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
219644699|NCT03813901|OTHER|Wait list control|Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
219644700|NCT06665893|DEVICE|Digi-physical treatment tool|A support tool named Evira will be used to provide behavioral treatment. Through daily weightings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored.
219644701|NCT02907528|BIOLOGICAL|Bone|Furcation defect regenerated with bone graft material
219644702|NCT02907528|BIOLOGICAL|EMD|Furcation defect regenerated with EMD
219644703|NCT02202993|DRUG|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
219644704|NCT04251793|OTHER|Observation|Soft tissue implant measurements and radiographs
219644705|NCT04429555|DRUG|Ibudilast|50 mg (5 x 10 mg capsules) twice daily for 7 days
219644706|NCT04429555|DRUG|Placebo|0 mg (5 matching capsules) twice daily for 7 days
219644707|NCT04541108|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
219644708|NCT04541108|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
219644709|NCT04541108|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
219644710|NCT04541108|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
218960240|NCT05646472|DIAGNOSTIC_TEST|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
218960241|NCT04856865|BIOLOGICAL|Low dose ADP101|Active powder formulation
218960242|NCT04856865|BIOLOGICAL|High dose ADP101|Active powder formulation.
219644711|NCT04711928|BEHAVIORAL|Physical activity and sedentary behaviour|Athletes with a high physical activity and a low or high sedentary time
219644712|NCT04447001|BEHAVIORAL|Tai-chi prime (TCP)|TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
219644713|NCT02657213|DEVICE|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
219644714|NCT02657213|DEVICE|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
219644715|NCT02401490|DRUG|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
219644716|NCT02401490|DRUG|Placebo|
218960243|NCT04856865|BIOLOGICAL|Pooled Placebo|Placebo powder
219644717|NCT00277303|DRUG|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
219644718|NCT04558606|DEVICE|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
219644719|NCT04558606|DEVICE|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
219644720|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
218960244|NCT02982785|BEHAVIORAL|Standard post-operative rehabilitation|
218960245|NCT01163032|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
218960246|NCT01163032|DRUG|Placebo|Placebo capsules, PO daily for 6 months
219061087|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
219061088|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
219061089|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
219061090|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
219061091|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
219061092|NCT02306915|DRUG|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
219644721|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
219644722|NCT00425061|OTHER|placebo|placebo
219686208|NCT02835859|OTHER|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
219686209|NCT03450577|PROCEDURE|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
219686210|NCT03733366|OTHER|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
219061093|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
219644723|NCT02793401|DEVICE|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
219644724|NCT02793401|DEVICE|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
219644725|NCT02793401|DEVICE|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
219644726|NCT02793401|DEVICE|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
219644727|NCT02793401|OTHER|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
219644728|NCT02793401|OTHER|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
219644729|NCT06136182|PROCEDURE|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
219644730|NCT00093418|DRUG|tipifarnib|Given orally
219644731|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification and autotransplantation of anterior lens capsule|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification with autotransplantation of anterior lens capsule.
219644732|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification alone.
218960247|NCT00728767|OTHER|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
218960248|NCT00728767|OTHER|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
219061094|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
219644733|NCT06084949|DEVICE|Nordic walking or inspiratory muscle training|Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
219644734|NCT00491309|BEHAVIORAL|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
219644735|NCT03927261|DRUG|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
219644736|NCT01337466|RADIATION|[124I]FIAU|This is a single dose study of 2 mCi \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
219644737|NCT05329363|DIAGNOSTIC_TEST|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
219644738|NCT05329363|OTHER|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
218960249|NCT04119154|DIAGNOSTIC_TEST|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
218960250|NCT00766961|PROCEDURE|Trans-catheter arterial embolization|Trans-catheter arterial embolization
219061095|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
218960251|NCT00766961|PROCEDURE|Surgery|Surgery
218960252|NCT01464723|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
218960253|NCT03127787|DIAGNOSTIC_TEST|CMV Assay|Molecular diagnostic test to detect CMV
218960254|NCT02306499|PROCEDURE|ICSI|Intracytoplasmic Sperm Injection
218960255|NCT06243627|OTHER|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
219061096|NCT00221936|BEHAVIORAL|Self-administration or nurse administered medication|
219061097|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
219061098|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
218960256|NCT06243627|OTHER|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
218960257|NCT06243627|OTHER|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
219061099|NCT02881281|OTHER|educational program for Development of problem-solving skills|
219061100|NCT02881281|OTHER|no education program|no education program
219644739|NCT03730467|BEHAVIORAL|Phone call to the patient|Phone call to the patient
219644740|NCT02137850|DRUG|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
219644741|NCT01402843|DRUG|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
219644742|NCT05764616|PROCEDURE|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
219061101|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
219061102|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
219061103|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
219644743|NCT05764616|PROCEDURE|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
218960258|NCT06243627|OTHER|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
218960259|NCT06288373|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
218960260|NCT06288373|DRUG|Cisplatin|Cisplatin：75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
218960261|NCT06288373|DRUG|Nab paclitaxel|Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
218960262|NCT06288373|PROCEDURE|Radical surgery|Radical surgery
218960263|NCT06288373|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
218960264|NCT06288373|DRUG|Cisplatin|Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
218960265|NCT02750215|DRUG|Capmatinib (INC280)|treatment with Capmatinib (INC280)
218960266|NCT04599179|DEVICE|self-expandable metal stent|self-expandable metal stent endoscopic positioning
218960267|NCT01700868|OTHER|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
218960268|NCT01700868|OTHER|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
218960269|NCT03248700|OTHER|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
219644744|NCT05764616|PROCEDURE|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
218960270|NCT02192840|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
218960271|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
218960272|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
218960273|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
218960274|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
219061104|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
219061105|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
219061106|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
219061107|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
219061108|NCT00701389|DRUG|sumatriptan placebo|single oral dose
219061109|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
219061110|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
219223701|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
219061111|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
219223702|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
218960275|NCT01307020|DRUG|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
218960276|NCT01307020|DRUG|Placebo|Placebo, oral film-coated table, once
218960277|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
218960278|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
218960279|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
218960280|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
218960281|NCT00000750|DRUG|Zidovudine|
218960282|NCT02380690|BEHAVIORAL|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
218960283|NCT04673279|DIAGNOSTIC_TEST|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
219061112|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
219061113|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
219061114|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
219223703|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
219644745|NCT06684912|OTHER|High-intensity interval exercise|The number of bouts of exercise-recovery for each participant was tailored to achieve the desired EE. For example, a participant with a peak oxygen uptake (V̇O2) peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
219644746|NCT06684912|OTHER|Moderate continuous exercise|Energy expenditure of exercise conditions (HIIE and MICE) were matched for energy expenditure. A participant with a V̇O2 peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
219644747|NCT04533412|BEHAVIORAL|Self-management barrier support|For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.
219644748|NCT04533412|BEHAVIORAL|Basic COPD Education|"The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician."
219644749|NCT02655510|DRUG|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
219644750|NCT00890708|DRUG|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
219644751|NCT02582450|OTHER|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
219644752|NCT05182814|DIETARY_SUPPLEMENT|Placebo drink|Blank
219644753|NCT05182814|DIETARY_SUPPLEMENT|Collagen Juice Drink|Testing product
219644754|NCT05087810|BEHAVIORAL|Psychological stress induction|Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.
219644755|NCT05087810|OTHER|Accelerated oral hydration|Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
219644756|NCT03300635|OTHER|Mental distress and relaxation test|
219644757|NCT03300635|OTHER|Glucose tolerance test|
219644758|NCT03300635|OTHER|Exercise test|
219644759|NCT01808079|OTHER|Laboratory Biomarker Analysis|Correlative studies
219644760|NCT02355821|DRUG|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
219644761|NCT02355821|DRUG|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
219644762|NCT03386643|DRUG|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
219644763|NCT03386643|DRUG|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
219644764|NCT05109884|DIAGNOSTIC_TEST|PSMA PET Scan|\[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
218960284|NCT03343418|DRUG|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
218960285|NCT03343418|DRUG|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
219223704|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
219223705|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
219644765|NCT05109884|DIAGNOSTIC_TEST|FDHT PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
219644766|NCT04030390|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
219644767|NCT04030390|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
218960286|NCT02553668|DRUG|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
218960287|NCT02553668|DEVICE|Facemask|
218960288|NCT04413227|DRUG|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
218960289|NCT04045418|DEVICE|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
218960290|NCT00727532|DRUG|Sorafenib|400mg by mouth twice daily for 28 consecutive days
219644768|NCT05616507|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
219644769|NCT01372488|PROCEDURE|Suture self removal|Suture self removal
219644770|NCT01372488|PROCEDURE|Suture removal by family doctor or clinic|As above
219686211|NCT04361422|DRUG|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
219686212|NCT01209403|DRUG|Glucose-infusion|Continuous iv infusion of glucose
219223706|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
219644771|NCT03380078|BEHAVIORAL|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
219644772|NCT03380078|BEHAVIORAL|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
219644773|NCT03380078|BEHAVIORAL|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
219644774|NCT03380078|BEHAVIORAL|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
219644775|NCT03380078|BEHAVIORAL|Team-Enhanced Teams Leadership Institute (TLI)|TLI-2 enhances TLI training by (a) including additional team members important to EBI implementation (e.g., supervisors, support staff) and (b) including the team in the development of an implementation plan using a team charter process. TLI-2 includes 5 components : 1. Assessment: The Implementation Climate Scale (ICS) will be completed by team members, providers, and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training for the implementation team in implementation climate and development of an implementation plan. 3. Coaching: Bi-monthly, brief (15-30 min) coaching calls keep the team on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up: At month 4, team members attend a 2-hour booster session . 5. Graduation: TLI-2 programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
218960291|NCT00829933|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
219207773|NCT06746454|OTHER|Verbal Combined Focus Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included landing error scoring system, knee position error sense, and frontal plane projection angle. After the pretest measurements, 2 training packages with specific instructions were performed for the CSE group. The special instruction given to the CSE group consisted of the following sentence, which included the both internal and external focus of attention; focus on how hard you push yourself off the ground and how fast you straighten your knees during this push-off. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
219686213|NCT01209403|DRUG|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
219207774|NCT06747494|PROCEDURE|General Anesthesia|Participants will receive a one-time general anesthesia dose during the total joint arthroplasty procedure as per standard of care.
219207775|NCT06747494|PROCEDURE|Spinal Anesthesia|Participants will receive a one-time spinal anesthesia dose during the total joint arthroplasty procedure as per standard of care.
219207776|NCT02817659|DRUG|Glucagon|Glucagon infusion
218960292|NCT00829933|DRUG|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
218960293|NCT02311218|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
218960294|NCT02311218|DIETARY_SUPPLEMENT|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
218960295|NCT02338336|DRUG|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
218960296|NCT02338336|DRUG|Placebo|Matching placebo liquid for topic administration.
218960297|NCT03473457|BIOLOGICAL|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
218960298|NCT00534261|DRUG|Interferon beta-1a|IM injection
218960299|NCT01986933|DRUG|nemolizumab (CIM331)|
218960300|NCT01986933|OTHER|Placebo|
219223707|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
219207777|NCT06759311|OTHER|ART|The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin
219644776|NCT03631615|DRUG|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
219644777|NCT04884360|DRUG|Olaparib|Olaparib tablets 300 mg oral twice daily
219644778|NCT04884360|OTHER|Matching placebo|Matching placebo tablets taken orally at a dose of 300 mg twice daily
219644779|NCT03871946|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.
219644780|NCT00879346|DRUG|AZD8931|160mg oral single dose (4 x 40mg tablets)
219644781|NCT03014895|DRUG|Placebo|Intravenous infusion
219644782|NCT03014895|DRUG|E3112|Intravenous infusion
219644783|NCT00968981|DRUG|GDC-0449|Daily oral repeating dose
219644784|NCT00968981|DRUG|GDC-0449|Three times weekly oral repeating dose
219644785|NCT00968981|DRUG|GDC-0449|Once weekly oral repeating dose
219644786|NCT05875025|OTHER|Placebo formulated with HFA-152a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
219644787|NCT05875025|OTHER|Placebo formulated with HFA-134a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
219644788|NCT06665334|DRUG|Huaier granule|Oral administration, 10g per dose (1 bag), 3 times a day, recommended for at least 6 months.
219644789|NCT02149758|DRUG|Etoricoxib|
219644790|NCT05147922|BEHAVIORAL|Booster Training with the Neonatal Resuscitation Quality Improvement Cart|The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
219644791|NCT06683443|BEHAVIORAL|Robotic Joy for All™ pet|Patients will be provided with the robotic pet within 48 hours of admission and have access to the pets throughout their hospitalization to provide comfort and engagement.
219644792|NCT04988906|DEVICE|Zoll Accuvent Ventilation Monitor|Provides real-time ventilation quality monitoring (rate and volume)
219644793|NCT00119691|DRUG|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
218960301|NCT03119701|DRUG|Interferon Beta-1A|Lyophilisate for solution for injection.
218960302|NCT03119701|DRUG|Placebo|Lyophilisate for solution for injection as placebo.
218960303|NCT02421003|PROCEDURE|heart surgery|
218960304|NCT01952470|DRUG|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
218960305|NCT01952470|DRUG|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
218960306|NCT02300727|DRUG|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
218960307|NCT02300727|DRUG|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
218960308|NCT02300727|DRUG|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
218960309|NCT02019901|OTHER|Nurse-led clinic|
219061115|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
219061116|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
219061117|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
219061118|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
219644794|NCT03669055|OTHER|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
219644795|NCT05286255|BIOLOGICAL|Allogeneic Mesenchymal Stromal Cells|Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment
219644796|NCT05131464|DRUG|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
219644797|NCT01489254|DRUG|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
219644798|NCT01489254|DRUG|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
219644799|NCT01489254|DRUG|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
219644800|NCT04073433|DRUG|Midomafetamine HCl|120 mg midomafetamine HCl
219644801|NCT04073433|BEHAVIORAL|Therapy|Non-directive therapy conducted during MDMA-assisted therapy session
219644802|NCT06229288|DRUG|Amoxicillin|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).~Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)"
219644803|NCT06229288|DRUG|Amoxicillin/clavulanate|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)"
219644804|NCT03199807|BIOLOGICAL|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4-6 doses.
219644805|NCT03199807|RADIATION|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F \* 10F
219644806|NCT04199078|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
219644807|NCT02968693|DEVICE|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
219644808|NCT02968693|DEVICE|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
219644809|NCT02968693|DRUG|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
219644810|NCT06683716|OTHER|Training in presence of the instructor|The instructor gives the trainee instructions for the examination while he/she is present in the examination room.
219644811|NCT06683716|OTHER|Telemedically training by an instructor|The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses
219644812|NCT04290910|BEHAVIORAL|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
219644813|NCT05778435|DEVICE|wireless fetal monitoring system|The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
219644814|NCT00507819|DRUG|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
219644815|NCT00507819|DRUG|Placebo|One placebo capsule will be taken by mouth three times-a-day.
219644816|NCT05508035|DRUG|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
219686214|NCT04001010|DRUG|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
219686215|NCT04001010|DRUG|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
218985201|NCT06203171|OTHER|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
219644817|NCT05508035|DRUG|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
219644818|NCT04684459|BIOLOGICAL|Dual-targeting HER2 and PD-L1 CAR-T cells|HER2-positive solid tumor serosal cavity infusion
219644819|NCT05161975|DIETARY_SUPPLEMENT|Vitamin K2|Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
219644820|NCT01187771|PROCEDURE|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
219644821|NCT01187771|PROCEDURE|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
219644822|NCT06682507|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219644823|NCT00965978|DRUG|ONO-5920 / YM529|oral
219644824|NCT06666478|OTHER|Exercise protocol at workspace|"The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work."
219644825|NCT02222311|OTHER|Blood Samples|
219644826|NCT06666023|DEVICE|Device|Use of the device in groups to test its ability to diagnose infections.
219644827|NCT05830734|OTHER|injection of freshly collected adipose cells|"A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested."
219644828|NCT05830734|PROCEDURE|Bascoms Cleft lift procedure|The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
219644829|NCT01254318|OTHER|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
219644830|NCT02780141|DRUG|roxadustat|Oral
219644831|NCT05833113|DEVICE|Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively"
219644832|NCT05833113|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively"
219686216|NCT00871234|DRUG|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
219686217|NCT02288104|DEVICE|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
219686218|NCT00970905|DRUG|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
218985202|NCT03260881|DRUG|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
219644833|NCT05311436|BEHAVIORAL|Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children|"Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation.~Adolescent girls: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for 6 months. Iron and folic acid (200 mg ferrous fumarate and 400 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month.~Children \<2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety.~Intensive WASH counselling: Intensive WASH counseling will be provided to separate group of child participants twice a month for 6 months.~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 2 months."
219644834|NCT00952796|DRUG|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
219644835|NCT00952796|DRUG|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
219644836|NCT04079413|DRUG|GP40071|GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
219644837|NCT04079413|DRUG|NovoRapid® Penfill®|NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
219644838|NCT06622902|OTHER|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
219644839|NCT06622902|OTHER|change flow from 2 to 6 LPM. Follow TcCO2 for 3h|change flow from 2 to 6 LPM. Follow TcCO2 for 3h
219644841|NCT03805984|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
219644842|NCT03805984|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
219644843|NCT03805984|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
219644844|NCT02877810|OTHER|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
219644845|NCT02877810|OTHER|Telephone|Consultations will be given over telephone.
219644846|NCT00737295|PROCEDURE|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
218960310|NCT02392832|BIOLOGICAL|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
219644847|NCT06051838|PROCEDURE|surgery|if the patients is TD positive, we recommond careful surgery and pathological examination.
219644848|NCT02058784|DRUG|pracinostat|
219644849|NCT02119689|OTHER|Diabetic Patients|measuring CD34 cell function in relation to diabetic retinopathy status
219644850|NCT02119689|OTHER|Healthy Controls|measuring CD34 cell function
219644851|NCT04013360|OTHER|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
219644852|NCT04013360|OTHER|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
219644853|NCT02952092|DRUG|roxadustat|Oral
219644854|NCT02952092|DRUG|Darbepoetin alfa|Intravenous
219644855|NCT05449301|OTHER|Rhythmic Auditory Stimulation|The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.
219644856|NCT05449301|OTHER|Treadmill Training|participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
218960311|NCT00663442|DRUG|OROS methylphenidate|18, 36, 54 mg
218960312|NCT04220853|DIAGNOSTIC_TEST|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
219644857|NCT05449301|OTHER|Unilateral Step Training|Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
219644858|NCT03628339|DRUG|Midazolam|Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.
219644859|NCT03628339|DRUG|Tepotinib|Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.
219061119|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
219644860|NCT01172496|DRUG|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
219644861|NCT02846116|OTHER|Prosthetic crown|
219061120|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
219061121|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
219061122|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
219061123|NCT06175494|BIOLOGICAL|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
219061124|NCT06175494|BIOLOGICAL|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
218960313|NCT04220853|DIAGNOSTIC_TEST|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
218960314|NCT05175053|OTHER|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
218960315|NCT05175053|OTHER|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
218960316|NCT04824027|PROCEDURE|Harmonic motion imaging|Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
218960317|NCT04813627|PROCEDURE|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every 3 months for 21 months
218960318|NCT00333346|DRUG|Administration of tramadol intravenously|
218960319|NCT06391190|DRUG|Albumin-Bound Paclitaxel, cisplatin, Sintilimab|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
218960320|NCT02996032|OTHER|Vascular and Pulmonary Ultrasound|
218960321|NCT04176042|BEHAVIORAL|Track 1|Intervention + Follow-up
218960322|NCT04176042|BEHAVIORAL|Track 2|Wait list + Intervention
218960323|NCT03643471|DEVICE|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
218960324|NCT03347578|DIAGNOSTIC_TEST|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
218960325|NCT06221527|PROCEDURE|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
218960326|NCT04244812|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
218960327|NCT04244812|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
218960328|NCT00675207|DRUG|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
218960329|NCT00675207|DRUG|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
218960330|NCT00675207|DRUG|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
218960331|NCT03999151|BEHAVIORAL|Exercise and Diet|Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
218960332|NCT06194851|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each bCBCT session.
218960333|NCT06194851|DRUG|Saline nasal spray|Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.
218960334|NCT06194851|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized bCBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
218960335|NCT05164666|BIOLOGICAL|TAK-103|TAK-103 intravenous infusion
218960336|NCT04029480|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
219644862|NCT02117908|DEVICE|RESMED AUTOSET S9|Continuous positive pressure during surgery
219644863|NCT00644176|DRUG|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
219644864|NCT00644176|OTHER|placebo|placebo
218960337|NCT04029480|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
218960338|NCT04029480|DRUG|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
218960339|NCT04029480|DRUG|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
219644865|NCT00644176|DRUG|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
219644866|NCT00644176|OTHER|placebo|placebo
219644867|NCT04611191|OTHER|Team Sports|The intervention involves team sports in sports clubs in local municipalities
219644868|NCT04611191|OTHER|Control|The intervention involves a control condition with participants continuing their normal way of living
219644869|NCT04590508|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule and taken orally.
219644870|NCT04590508|OTHER|Placebo|The placebo will be administered in a capsule and taken orally.
219644871|NCT02804139|OTHER|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
219644872|NCT02804139|OTHER|Standard Care|Standard Care after C-section with no additional physical therapy.
219644873|NCT06968715|DIETARY_SUPPLEMENT|Experimental 1: low-breath hydrogen|Hydrogen-rich water (1.0 L/day)
219644874|NCT06968715|DIETARY_SUPPLEMENT|Experimental 2: high-breath hydrogen|Hydrogen-rich water (1.0 L/day)
219644875|NCT06968715|DIETARY_SUPPLEMENT|Experimental 3: low-breath hydrogen|Placebo water (1.0 L/day)
219644876|NCT06968715|DIETARY_SUPPLEMENT|Experimental 4: high-breath hydrogen|Placebo water (1.0 L/day)
219644877|NCT01532843|DRUG|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
219644878|NCT05461521|OTHER|Family members of patients admitted to the ICU|"At inclusion:~* Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~* Venous blood sampling at 350 relatives~* Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~  3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~  6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
219644879|NCT05461521|OTHER|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
218960340|NCT04029480|BIOLOGICAL|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
218960341|NCT04029480|DRUG|Metformin|Participants will receive stable dose of background metformin.
218960342|NCT05112991|DRUG|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
218960343|NCT05112991|DRUG|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
219644880|NCT05461521|OTHER|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
219644881|NCT00804102|DEVICE|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
219644882|NCT00804102|DEVICE|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
219644883|NCT04447352|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
219644884|NCT04447352|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
219644885|NCT04447352|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
218960344|NCT03944187|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
218960345|NCT05957211|DRUG|0.09% cyclosporine A ophthalmic solution|Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
218960346|NCT03916315|BEHAVIORAL|Transdiagnostic Treatment|"The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each."
218960347|NCT00697944|DRUG|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
219061125|NCT06175494|BIOLOGICAL|Placebo|boost with saline
219061126|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
219061127|NCT04478097|DRUG|CKD-333 Tab.|1T
219644886|NCT04447352|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
219644887|NCT04447352|DRUG|Cisplatin|intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
219644888|NCT05622318|DRUG|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
219644889|NCT05622318|DRUG|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level \[IV:PO ratio = 1:4\]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
219644890|NCT05622318|DRUG|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
219644891|NCT05622318|DRUG|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
219686219|NCT00970905|DRUG|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
218960348|NCT02528539|OTHER|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
219644892|NCT05511532|OTHER|Orthopaedic treatment|"Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken."
219644893|NCT03975556|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
219644894|NCT03975556|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
219644895|NCT01558856|PROCEDURE|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
219644896|NCT01558856|PROCEDURE|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
219644897|NCT00972556|DRUG|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
219644898|NCT00972556|DRUG|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
219644899|NCT01760967|DRUG|Dexmedetomidine|intervention to administer dexmedetomidine or not
219644900|NCT01388244|OTHER|Screening|Screening by risk factor assessment (FRAX) followed by DXA
219644901|NCT01388244|OTHER|Control|Observation by use of register data
219644902|NCT01891565|BEHAVIORAL|Feedback|
219644903|NCT03340220|DRUG|XPF-008|Capsule filled with XEN1101
219644904|NCT03340220|DRUG|Microcrystalline Cellulose|Placebo capsule
219644905|NCT03340220|DRUG|XPF-010|Capsule filled with XEN1101
219644906|NCT03340220|DRUG|Itraconazole 400mg|Oral
219644907|NCT03796416|DRUG|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
219644908|NCT02091596|DRUG|PluroGel N|Study Drug
219644909|NCT02091596|DRUG|PluroGel|PluroGel Vehicle Placebo Comparator
219644910|NCT03705650|DIAGNOSTIC_TEST|Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
219644911|NCT03016481|BEHAVIORAL|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
218960349|NCT01693588|OTHER|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
218960350|NCT01881490|DEVICE|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
218985203|NCT03260881|DRUG|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
219644912|NCT03016481|BEHAVIORAL|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
219644913|NCT04432714|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
219644914|NCT04432714|DRUG|Rituximab|Rituximab 375 mg/m2，IV, d0
219644915|NCT04432714|DRUG|Etoposide|Etoposide 50 mg/m2/day CI24h d1-d4
219644916|NCT04432714|DRUG|Doxorubicin|Doxorubicin 10 mg/m2/day CI24h d1-d4
219644917|NCT04432714|DRUG|Vincristine|Vincristine 0.4mg/m2/day CI24h d1-d4
219644918|NCT04432714|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2/day IV d5
219644919|NCT04432714|DRUG|Prednisone|Prednisone 60 mg/m2/bid oral or IV d1-d5
219644920|NCT04157114|DRUG|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
219644921|NCT04157114|DRUG|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
219644922|NCT04157114|BEHAVIORAL|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
219644923|NCT01345981|DRUG|Lidocaine|dosage 20 mg and 40 mg
219644924|NCT01232881|PROCEDURE|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
219644925|NCT01232881|PROCEDURE|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
219644926|NCT02175134|OTHER|Blood and Ascites ELISPOT|
219644927|NCT06078358|OTHER|Resistance exercise training|Traditional linear periodization resistance training.
219644928|NCT04530058|DRUG|Metformin|Metformin 500 mg twice a day, administered orally or via gastric tube.
219644929|NCT04530058|DRUG|Placebos|Placebo twice a day, administered orally or via gastric tube.
219644930|NCT01628796|OTHER|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
219644931|NCT03701841|DRUG|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
219644932|NCT02050919|DRUG|Epirubicin Hydrochloride|Given IV
219644933|NCT02050919|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219644934|NCT02050919|DRUG|Ifosfamide|Given IV
219644935|NCT02050919|OTHER|Laboratory Biomarker Analysis|Correlative studies
219644936|NCT02050919|DRUG|Sorafenib Tosylate|Given PO
219644937|NCT02050919|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219644938|NCT01435096|DRUG|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
219644939|NCT06062602|DRUG|TAK-676|Intratumoral microdose injection by the CIVO device.
219644940|NCT06062602|DRUG|Carboplatin|Intratumoral microdose injection by the CIVO device.
219644941|NCT06062602|DRUG|5-FU|Intratumoral microdose injection by the CIVO device.
219644942|NCT06062602|DRUG|Paclitaxel|Intratumoral microdose injection by the CIVO device.
219644943|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin|Intratumoral microdose injection by the CIVO device.
219644944|NCT06062602|COMBINATION_PRODUCT|Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
219644945|NCT06062602|COMBINATION_PRODUCT|Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
219644946|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
219061128|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
219644947|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
219644948|NCT02691936|DEVICE|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
219644949|NCT02691936|DRUG|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
219644950|NCT06631521|DRUG|Darolutamide|600 mg (two 300 mg tablets) taken orally twice daily.
219644951|NCT06631521|DRUG|Relugolix|A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
219644952|NCT06631521|PROCEDURE|Radical Prostatectomy|Performed at least 48 hours and within 2 weeks after the completion of neoadjuvant therapy.
219644953|NCT00921102|DRUG|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
219644954|NCT00921102|DRUG|Morphine|200 µg of a 200 µg/ml solution, intrathecally
219644955|NCT00921102|DRUG|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
219644956|NCT00921102|DRUG|Atropine|"100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine"
219644957|NCT03024684|DRUG|Atorvastatin|Atorvastatin 10mg daily
219644958|NCT03024684|DRUG|Placebo Oral Tablet|Placebo one tablet daily
219644959|NCT06092827|BEHAVIORAL|Non weight-bearing physical activity program|12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
219644960|NCT01878084|OTHER|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
219644961|NCT01878084|OTHER|empty extraction socket|Extraction socket will be left empty
219644962|NCT00749684|BIOLOGICAL|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
219644963|NCT03376308|DIAGNOSTIC_TEST|Pain Score|"Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe"
219644964|NCT03376308|DIAGNOSTIC_TEST|Withdrawal movement score|"Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response."
219644965|NCT03376308|DIAGNOSTIC_TEST|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
219644966|NCT05970549|DEVICE|IRRAflow® Active Fluid Exchange System|"All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.~Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise."
219644967|NCT05970549|DEVICE|Traditional extraventricular drain|The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
219686220|NCT00687908|DRUG|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
219686221|NCT00687908|DRUG|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
219686222|NCT03380377|DRUG|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
219644968|NCT05970549|PROCEDURE|Non-contrast head CTs|Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.
219644969|NCT01620775|OTHER|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
219644970|NCT01620775|OTHER|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
219644971|NCT02647970|BEHAVIORAL|PUFA-Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
219644972|NCT02647970|BEHAVIORAL|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
219644973|NCT04000542|OTHER|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
219644974|NCT02039518|DRUG|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
219644975|NCT02039518|OTHER|observation group|observation group
219644976|NCT04725942|DRUG|Oral Posaconazole tablets|Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.
219644977|NCT02103959|DRUG|CMX-2043|Slow bolus IV administration of CMX-2043
219644978|NCT02103959|DRUG|Placebo comparator|Slow bolus IV administration of PBS
219644979|NCT02993952|DEVICE|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
219644980|NCT02993952|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
219644981|NCT04888442|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219061129|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
219644982|NCT00372606|BEHAVIORAL|Online MiDieta Diet and Weight Management Program for Hispanics|
219644983|NCT02643849|DEVICE|The Spanner Temporary Prostatic Stent|
219644984|NCT01645878|BEHAVIORAL|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
219644985|NCT01645878|BEHAVIORAL|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
219644986|NCT01645878|BEHAVIORAL|routin breast feeding education|
219644987|NCT06293989|DRUG|Diazepam 5mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
219644988|NCT06293989|DRUG|Diazepam 10 mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
219644989|NCT06293989|DRUG|Placebo|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
219061130|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
219061131|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
219061132|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
219061133|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
219061134|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
219644990|NCT02556294|BEHAVIORAL|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
219644991|NCT02556294|BEHAVIORAL|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
218960351|NCT03464370|OTHER|Measure of emotional stressors|"For the Epileptic Group~* Rapid interrogation, completing the clinical data~* A scale of impact of the precipitating factors of crises~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A measure of the perception of emotions using film clips~* A scale of measurement of perceived stress~* The transfer of psychiatric scales~For the healthy volunteers group :~* A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A scale of measurement of perceived stress~* A measure of the perception of emotions using film clips~* A rapid neuropsychological assessment"
219644992|NCT01913431|DRUG|Baracle Tab.®|
218960352|NCT02206581|DEVICE|Hydration Monitor|
218960353|NCT06051045|DRUG|Bulevirtide|Hepcludex, 2 mg daily subcutaneous injection
218960354|NCT05483998|DRUG|TLC-2716|TLC-2716
218960355|NCT05483998|OTHER|Placebo|Placebo to match
218960356|NCT01766661|PROCEDURE|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
218960357|NCT01766661|PROCEDURE|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
218960358|NCT01766661|PROCEDURE|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
218960359|NCT01931072|BEHAVIORAL|High-intensity interval training|Interval training 3 times a week for 8 weeks
218960360|NCT01931072|BEHAVIORAL|Moderate training|Moderate training 3 times a week for 8 weeks
219061135|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
219644993|NCT01913431|DRUG|Baraclude Tab.®|
219644994|NCT02544425|DRUG|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
219644995|NCT02544425|DRUG|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
219644996|NCT02544425|DRUG|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
219644997|NCT02544425|DRUG|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
219644998|NCT02544425|DRUG|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
219644999|NCT02544425|DRUG|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
218960361|NCT00782795|DRUG|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
218960362|NCT00782795|DRUG|Placebo|
218960363|NCT04480424|BIOLOGICAL|GAMUNEX-C|Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
218960364|NCT04480424|DRUG|Standard Medical Treatment|SMT per local policies or guidelines.
218960365|NCT06573866|BEHAVIORAL|Preventive Participatory workplace intervention|The Participatory Workplace Intervention (PPWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles or changes and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. In a subsequent meeting, the implementation of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
218960366|NCT00004407|DRUG|immune globulin|
218960367|NCT05800730|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
218960368|NCT05800730|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
218960369|NCT05800730|OTHER|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
219061136|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
219061137|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
219061138|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
219061139|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
219645000|NCT02892422|DRUG|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
219645001|NCT05521334|DEVICE|micropulse transscleral cyclophotocoagulation|glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
219645002|NCT04058535|BIOLOGICAL|Eylea|Aflibercept
219645003|NCT04058535|BIOLOGICAL|ALT-L9|Aflibercept biosimilar
219645004|NCT03676296|DRUG|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
219645005|NCT03676296|DRUG|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
219645006|NCT01064258|DEVICE|CPAP|CPAP at 4 cm H2O
219645007|NCT01064258|DEVICE|autoCPAP|autoCPAP working between 4 and 15 cm H2O
219645008|NCT05081700|DRUG|All patients in the study will be treated with ocrelizumab|300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
219645009|NCT05890352|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood
219645010|NCT05890352|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
219645011|NCT05890352|DRUG|Lenalidomide|Given PO
219645012|NCT05890352|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219645013|NCT05890352|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219645014|NCT05890352|OTHER|Quality-of-Life Assessment|Ancillary studies
219645015|NCT05890352|OTHER|Questionnaire Administration|Ancillary studies
219645016|NCT05890352|BIOLOGICAL|Tafasitamab|Given IV
219061140|NCT00618657|DRUG|Carboplatin|Given IV
219061141|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219061142|NCT00618657|DRUG|bevacizumab|Given IV
219645017|NCT05890352|DRUG|Tazemetostat|Given PO
219645018|NCT05890352|DRUG|Zanubrutinib|Given PO
219645019|NCT01023256|DRUG|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
219645020|NCT01023256|DRUG|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
219645021|NCT01023256|DRUG|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
219645022|NCT00032188|BIOLOGICAL|aldesleukin|Given subcutaneously
219061143|NCT00618657|DRUG|trastuzumab|Given IV
219061144|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
219061145|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
219061146|NCT03890341|DRUG|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
219061147|NCT03890341|DRUG|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
219061148|NCT03890341|DRUG|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
219645023|NCT00032188|DRUG|bryostatin 1|Given IV
219645024|NCT00032188|OTHER|laboratory biomarker analysis|Correlative studies
219645025|NCT03200756|BEHAVIORAL|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
219645026|NCT03200756|BEHAVIORAL|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
219645027|NCT03155178|DRUG|3M CHG/IPA Prep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
219645028|NCT03155178|DRUG|ChloraPrep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
219645029|NCT03065088|BEHAVIORAL|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
219645030|NCT03065088|BEHAVIORAL|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
219645031|NCT03065088|BEHAVIORAL|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
219645032|NCT04018456|OTHER|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
219061149|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
219645033|NCT04018456|OTHER|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
219645034|NCT03241628|DEVICE|Dressing Glove|Viscose dressing glove
219645035|NCT03089697|BIOLOGICAL|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
219645036|NCT03089697|OTHER|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
219645037|NCT01077609|DRUG|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
219645038|NCT01077609|DRUG|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
218960370|NCT05800730|OTHER|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
218960371|NCT05763485|PROCEDURE|Anti reflux mucosal ablation (ARMA)|"In patients fulfilling the inclusion criteria and being randomized for ARMA, the procedure using argon plasma coagulation involves two semicircular ablations of the mucosa of the EGJ in a butterfly shape of a width of 2 cm. The approximate duration of the procedure is 30min.~Follow includes objective evaluation of reflux disease by reflux questionnaires, esophagogastroduodenoscopy, esophageal manometry, pH metry."
218960372|NCT05763485|PROCEDURE|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, the procedure involves esophagogastroduodenoscopy with the same set of movements and duration as the ARMA procedure without the actual ablation.
218960373|NCT01729585|PROCEDURE|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
218960374|NCT03646240|DRUG|ABI-009|For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
218960375|NCT02782923|DEVICE|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
218960376|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
218960377|NCT03333538|OTHER|Placebo|Placebo vaccination
219645039|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
219645040|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
218960378|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
218960379|NCT03333538|BIOLOGICAL|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
219207778|NCT06759311|OTHER|Brix 3000|Brix 3000 gel will be applied to the caries lesion using a spoon excavator\*\* leaving gel according to the manufacturer's instructions. After 2 minutes, the gel will turn from translucent green colour to cloudy after the gel removal.
219207779|NCT06759311|OTHER|Carie Move|Carie-Move gel will be applied to the caries lesion according to the manufacturer's instructions at second visit in the same child. After 30 second the gel will be removed.
218960380|NCT05907538|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
218960381|NCT05907538|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
218960382|NCT05907538|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
218960383|NCT02828501|PROCEDURE|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
219645045|NCT01729000|OTHER|Gloves|All staff must wear gloves for subjects that are in the experimental group.
219645046|NCT03207542|DRUG|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
219645047|NCT04346901|DRUG|Thiamazol|All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
219645048|NCT03785912|BEHAVIORAL|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
219645049|NCT00834639|DRUG|divalproex sodium|delayed-release 500 mg tablet
219645050|NCT00834639|DRUG|Depakote®|delayed-release 500 mg tablet
219645051|NCT01406145|DRUG|ASP0777|oral tablet
219645052|NCT01406145|DRUG|Placebo|oral tablet
219645053|NCT01136889|OTHER|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
219645054|NCT01609439|DRUG|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
219645055|NCT01609439|DRUG|Placebo|Placebo
219645056|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
219645057|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
218960384|NCT03975140|PROCEDURE|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
219645058|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
219645059|NCT03750669|DRUG|AG regimen|Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
219207780|NCT06759311|OTHER|Smart Bur|Removal of carious dentin will be carried out employing smart bur II mounted on a low-speed handpiece without water spray. Caries removal will be proceeded until the smart bur II becomes dull after repeated contact with healthy dentin (21) (figure 3)
219645060|NCT03750669|DRUG|mFolfirinox|Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
218960385|NCT03975140|PROCEDURE|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
218960386|NCT03765879|OTHER|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of an avatar receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
218960387|NCT03765879|OTHER|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of an avatar receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
219207781|NCT02817958|DRUG|Chemotherapy TIP|Paclitaxel, ifosfamide, and cisplatin
219207782|NCT06759090|DRUG|Metronomic capecitabine|Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;
219207783|NCT06759090|DRUG|Camrelizumab|Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;
219645061|NCT02697526|OTHER|Terumo|
219645062|NCT02697526|OTHER|Tensoplast|
219645063|NCT03382834|DRUG|Tamoxifen|20 mg orally
219645064|NCT03382834|DRUG|Vorinostat|400 mg orally
219645065|NCT03382834|DRUG|Antiretroviral drugs|Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
219645066|NCT02387957|DRUG|Fovista®|
219645067|NCT02387957|DRUG|bevacizumab|
219645068|NCT02387957|DRUG|ranibizumab|
219645069|NCT02387957|DRUG|aflibercept|
219645070|NCT04150796|PROCEDURE|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
219645071|NCT05510115|DRUG|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
219645072|NCT05510115|DRUG|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
219645073|NCT02034981|DRUG|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~* 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~* 165 mg/m² twice daily for ALCL patients aged from 1 to 17."
219645074|NCT06346821|DEVICE|Optune® (Tumor Treating Fields)|TTFields at 200 kHz to the brain using the Optune® System
219645075|NCT06253390|BEHAVIORAL|Metacognitive training|Metacognitive training therapy
219645076|NCT06253390|BEHAVIORAL|control|management technique as usual
219645077|NCT01259349|PROCEDURE|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
219645078|NCT01259349|PROCEDURE|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
219645079|NCT03546036|DEVICE|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
219645080|NCT03546036|DEVICE|Control plastic chain blanket|A blanket with light plastic chains
219645081|NCT03613649|DRUG|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
219645082|NCT03613649|DRUG|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
219645083|NCT03613649|OTHER|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
219645084|NCT05882305|BIOLOGICAL|Autologous monocyte-derived DCs pulsed withEBV-associated antigen|Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
218960388|NCT00538343|DRUG|berubicin hydrochloride (RTA 744)|
218960389|NCT04683042|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
218960390|NCT04683042|OTHER|PT only|Routine PT therapy only
218960391|NCT04701164|DRUG|ANX005|Solution for intravenous infusion
219207784|NCT06759090|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.
219645085|NCT00299897|DRUG|SP01A|
219645086|NCT06447597|DRUG|B007|B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
219645087|NCT06447597|DRUG|Placebo|B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
219686223|NCT00910845|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
219686224|NCT00910845|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
219686225|NCT02600923|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
218960392|NCT04701164|DRUG|Placebo|Solution for intravenous infusion
218960393|NCT05455619|DRUG|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
218960395|NCT06080737|OTHER|quality of life questionnaire|telephone interview to assess mortality and quality of life in the population included in a trial
219207785|NCT06789354|OTHER|Questionnaire and Physical Exam|All assessments were carried out face-to-face with the same physiotherapist.
219207786|NCT06763601|PROCEDURE|SSMP, Isometric exercise, eccentric exercise, heavy slow resistance , functional program|In this group the patients will be given symptom modification procedure in the first phase followed by isometric exercises in second phase, eccentrics and HSR in third phase and functional program in fourth phase
219645088|NCT05335395|BEHAVIORAL|SUNRISE radio campaign|"The SUNRISE radio campaign will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life.~The SUNRISE campaign will follow DMI's established intervention approach with:~1. 60-second radio spots, tailored to increase awareness, knowledge, motivation, skills and opportunity regarding the target behaviours, will include scripted dramas and modelling of responsive parent-child interactions. Each spot will be broadcast 10 times a day for a week; the content of the spots will be changed on a weekly basis. This weekly cycle will continue for three years.~2. Long format 60-minute programmes broadcast 2-3 times a week, incorporating longer dramas, real life testimonials and practical 'how to' advice, with space for listeners to call in, express opinions and uncertainties and ask questions."
219645089|NCT06684392|OTHER|Inspiratory muscle training|Subjects will train only inspiratory muscle strength if they do not achieve VP or definitive disconnection of MV, and, when they already achieve these VP or definitive disconnection, the new EMI regimen that combines strength and resistance training will begin to be applied. Inspiratory muscle training guideline (EMI). On the day that, according to the EMI guideline, the Pimax evaluation corresponds, the training time will be replaced by the evaluation to avoid overloading the subjects with ventilatory work, training them only once a day.
219645090|NCT03937440|DRUG|Deep neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
219645091|NCT03937440|DRUG|Moderate neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
219645092|NCT03132064|PROCEDURE|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
219645093|NCT01334671|DRUG|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
219645094|NCT00093587|BIOLOGICAL|anti-thymocyte globulin|
219645095|NCT00093587|DRUG|busulfan|
219645096|NCT00093587|DRUG|cyclophosphamide|
219645097|NCT00093587|DRUG|cyclosporine|
219645098|NCT00093587|PROCEDURE|allogeneic bone marrow transplantation|
219645099|NCT00093587|PROCEDURE|peripheral blood stem cell transplantation|
219645100|NCT00093587|RADIATION|radiation therapy|
218960396|NCT06574464|OTHER|BIG SCORE|"The trauma BIG score is used to predict posttraumatic injury severity and mortality. It was originally designed for the pediatric population. The score is calculated using the Base Deficit (BD), International Normalized Ratio (INR), and Glasgow Coma Scale (GCS) score on admission using the following formula:~BIG score = (admission BD) + (2.5 × INR) + (15 - GCS)."
218960397|NCT06574464|OTHER|Glasgow coma scale|The Glasgow Coma Scale is a neurological assessment tool used to evaluate the level of consciousness of a patient. It assesses three items: eye-opening (spontaneous, 4 points; to verbal stimuli, 3 points; to pain stimuli, 2 points; no response, 1 point); verbal responses (oriented, 5 points; confused but coherent speech, 4 points; inappropriate words, 3 points; incomprehensible speech, 2 points; no response, 1 point); and motor responses (obeys commands, 6 points; localizes pain, 5 points; withdraws from pain, 4 points; flexes in response to pain, 3 points; extends in response to pain, 2 points; no response, 1 point). The total GCS score is obtained by summing the scores for the three items, and it ranges from 3 to 15.
219645101|NCT00675428|DRUG|BG00002 (natalizumab)|
219645102|NCT02064842|DRUG|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
219645103|NCT02064842|DRUG|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
219645104|NCT02064842|DRUG|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
219645105|NCT02064842|DRUG|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV \[80 mg/mL strength\]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
219645106|NCT04144348|BIOLOGICAL|mRNA-1653|Sterile liquid for injection
219645107|NCT04144348|BIOLOGICAL|Placebo|Sterile liquid for injection
219645108|NCT00120562|PROCEDURE|Gastric Bypass Surgery|
219645109|NCT00319592|BIOLOGICAL|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
219645110|NCT00319592|BIOLOGICAL|JE-VAX® vaccine|1.0 mL, subcutaneously
218960398|NCT06574464|OTHER|Revised Trauma Score|The Revised Trauma Score (RTS) is a physiological scoring system used to assess the severity of a traumatic injury. It considers three key parameters, Glasgow Coma Scale (GCS), Systolic Blood Pressure (SBP), and Respiratory Rate (RR), with a total score of 12 points. The study team retrospectively computed the RTS on admission by retrieving the GCS score, SBP, and RR per minute from the hospital's automated systems and archives.
218960399|NCT06574464|OTHER|Injury Severity Score|The Injury Severity Score (ISS) is an anatomical scoring system used to assess the severity of injuries sustained by trauma patients. It provides a numerical value based on the anatomical regions of the body affected by trauma and the severity of those injuries. The ISS is calculated by dividing the body into six regions: the head/neck, face, chest, abdomen/pelvis, extremities, and external. Each region is assigned a score ranging from 1 to 6, with 1 indicating minor injury and 6 indicating severe injury. The highest score from each region is squared and then the scores are summed to calculate the overall ISS.
219645111|NCT06205901|DEVICE|PET-CT, MRI|whole body MRI and PET-CT for cancer patients with distant metastasis
219645112|NCT03244540|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
219645113|NCT03244540|PROCEDURE|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
219645114|NCT03244540|DEVICE|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
219645115|NCT03244540|DRUG|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
219645116|NCT03244540|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
219645117|NCT03244540|PROCEDURE|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
219645118|NCT03244540|PROCEDURE|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
219645119|NCT03244540|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
219645120|NCT03244540|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
219645121|NCT03244540|DRUG|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
219645122|NCT01707355|BEHAVIORAL|intervention - poster|
219645123|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645124|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645125|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645126|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645127|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645128|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645129|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
219645130|NCT01512446|DRUG|Alendronate|70 mg per week
219645131|NCT01512446|DRUG|Placebo|1 pill per week
219645132|NCT01297439|PROCEDURE|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
219645133|NCT01297439|PROCEDURE|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
219645134|NCT06668532|DEVICE|Digital toolkit|Access to the Flourish app and instruction to use at least twice a week for 6 weeks.
219645135|NCT06668532|OTHER|National mental health resources|Access to national mental health resources from Mental Health America, which can be found here: https://mhanational.org/ten-tools. Participants will receive one resource each week for 6 weeks and each time, will be asked to reflect on how the information can be applied to their own lives.
218960400|NCT06571760|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
218960401|NCT05016180|DRUG|Ropivacaine|Before the induction of anesthesia, ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
218960402|NCT00140465|DRUG|Clopidogrel|after PCI
218960403|NCT00140465|DRUG|Clopidogrel|after PCI
218960404|NCT02418156|DEVICE|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
218960405|NCT03368118|DRUG|ABX464|All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
219207787|NCT06763601|PROCEDURE|MWM,Isometric exercise, eccentric exercise, heavy slow resistance , functional program|in this mobilization with movement in first phase will be given followed by isometrics, eccentrics and heavy slow resistance exercise and finally the functional program
219645136|NCT05938829|OTHER|Ultrasound following the SMFM guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.
219645137|NCT05938829|OTHER|Ultrasound following the ISUOG guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
219645138|NCT05655910|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
219645139|NCT03808597|OTHER|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
219645140|NCT05450003|DEVICE|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
219645141|NCT01500187|DEVICE|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
219645142|NCT01500187|DEVICE|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
219645143|NCT05499221|DEVICE|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
219645144|NCT02385838|BEHAVIORAL|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
219645145|NCT02385838|BEHAVIORAL|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
219645146|NCT02385838|BEHAVIORAL|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
219645147|NCT02385838|BEHAVIORAL|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
219645148|NCT01551264|DEVICE|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
219645149|NCT01992653|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
219645150|NCT01992653|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
219645151|NCT01992653|DRUG|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
219207788|NCT06763601|PROCEDURE|sham mobilization|Sham mobilization followed by isometrics, eccentric training and heavy resistance training and finally the functional program .
219645152|NCT01992653|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
219645153|NCT01992653|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
219645154|NCT01992653|DRUG|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
219645155|NCT01992653|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
219645156|NCT05764538|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
219645157|NCT05016141|BEHAVIORAL|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
219645158|NCT00356356|DRUG|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
219645159|NCT05326347|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
219645160|NCT05849883|DRUG|Omeprazole 20 mg Capsules|Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
219645161|NCT02001844|DEVICE|Trial Foot Orthoses (FOs)|"Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
219645162|NCT02001844|DEVICE|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
219645163|NCT00798343|BIOLOGICAL|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
219645164|NCT00798343|BIOLOGICAL|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
219645165|NCT04310709|DRUG|Regorafenib/Nivolumab|Combination of regorafenib and nivolumab
219645166|NCT03127735|DRUG|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
219645167|NCT00288600|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin
219645168|NCT00288600|DRUG|Normal saline solution|Normal saline solution 10 ml/Kg
218960406|NCT03970746|BIOLOGICAL|PDC*lung01|PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
218960407|NCT03970746|DRUG|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
218960408|NCT03970746|DRUG|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
218960409|NCT05985824|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
218960410|NCT05505227|BEHAVIORAL|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
219207789|NCT06885463|PROCEDURE|platelets rich plasma combined with PDO threads|"1. Injections of platelets-rich plasma in the Anterior Vaginal Wall.~2. PDO thread placement in the paraurethral, lateral urethrovaginal, and suburethral areas"
219207790|NCT05545280|DRUG|Neostigmine with glycopyrrolate|Administration by intravenous infusion
219207791|NCT05545280|DRUG|Sugammadex|Administration by intravenous infusion
219645169|NCT05727566|OTHER|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
219645170|NCT03600194|DEVICE|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
219645171|NCT03600194|DEVICE|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
219061150|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
219645172|NCT03600194|DEVICE|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
219645173|NCT03600194|DEVICE|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
219645174|NCT04365504|DIAGNOSTIC_TEST|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
219645175|NCT06618079|DRUG|HUC2-565-A, HUC2-565-A and HUC2-565-B|Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.
219645176|NCT06618079|DRUG|HUC2-565-B, HUC2-565-A and HUC2-565-B|Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
219645177|NCT02913404|PROCEDURE|ACL Reconstruction|standard surgical procedure
219645178|NCT02913404|PROCEDURE|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
219645179|NCT01585662|PROCEDURE|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
219645180|NCT04110561|DEVICE|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
219645181|NCT01582178|PROCEDURE|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
219645182|NCT01582178|PROCEDURE|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
219645183|NCT04439214|BIOLOGICAL|Nivolumab|Given IV
219207792|NCT06760988|DIETARY_SUPPLEMENT|CL22205|Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days
219207793|NCT06760988|OTHER|Placebo|Mode: Oral, once daily after breakfast Duration: 135 days
219645184|NCT06362993|OTHER|Bundling|Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.
219645185|NCT06362993|OTHER|MEGH|Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
219645186|NCT00657488|DRUG|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
219645187|NCT02611271|OTHER|Monitoring of antibiotic drug removal|No study specific intervention will be performed
219645188|NCT05405361|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
219645189|NCT05405361|OTHER|Placebo|Intravenous administration of placebo
219207794|NCT06715501|DRUG|Cadonilimab|Cadonilimab is a PD-1/CTLA-4 bispecific antibody. The drug is administered at a fixed dose of 10mg/kg, intravenously (i.v.), on day 1, every 3 weeks (q3w), until disease progression or intolerable toxicity occurs, with a maximum treatment duration of 1 year.
219645190|NCT00771017|BIOLOGICAL|GVAX prostate cancer vaccine|Given intradermally
219645191|NCT00771017|DRUG|bicalutamide|Given orally
219061151|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
219061152|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
219061153|NCT01762761|DRUG|eltrombopag|TPO-R agonist
219061154|NCT01762761|DRUG|placebo|placebo
219061155|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
219061156|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
219645192|NCT00771017|DRUG|goserelin|Given intramuscularly
219645193|NCT00771017|DRUG|leuprolide acetate|Given intramuscularly
218960411|NCT05505227|BEHAVIORAL|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
218960412|NCT02405104|DRUG|chlorzoxazone|ATC-code: M03BB03
218960413|NCT02405104|DRUG|Placebo|Placebo
218960414|NCT02405104|PROCEDURE|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
218960415|NCT02405104|PROCEDURE|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
219061157|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
219061158|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
219061159|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
219061160|NCT01793857|OTHER|Data collection|Paper questionnaire
219645194|NCT00327028|DRUG|Diphenine|
219645195|NCT06882577|OTHER|observational only- no intervention|observational only- no intervention
219645196|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
219645197|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
219645198|NCT01483729|DRUG|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
218960416|NCT03818633|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
218960417|NCT01445626|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
218960418|NCT00000375|DRUG|Nortriptyline-lithium (NOR-Li)|
218960419|NCT00000375|PROCEDURE|Bilateral electroconvulsive therapy (ECT)|
218960420|NCT00000375|DRUG|Continuation therapy|
218960421|NCT00000375|BEHAVIORAL|Continuation ECT|
219061161|NCT06425393|DIAGNOSTIC_TEST|Urea beath test (UBT)|H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
219061162|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
219061163|NCT00120393|DRUG|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
219061164|NCT00120393|DRUG|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
219645199|NCT01483729|DRUG|ritonavir|Test Formulation 1, single oral dose
219645200|NCT01483729|DRUG|ritonavir|Test Formulation 2, single oral dose
219645201|NCT01483729|DRUG|ritonavir|Reference Formulation, single oral dose
219645202|NCT06667570|PROCEDURE|SALFOAM 3%|"* Drug: Polidocanol 3%~* Device: Lidstop®"
219645203|NCT06667570|PROCEDURE|Control Group|"* Drug: Polidocanol 3%~* Device: Standard compression with dental roll and elastic stockings"
219645204|NCT06729450|DEVICE|DispersinB Acne Cleanser|DispersinB Acne Cleanser, strength: 80 ug/g, topical gel
219645205|NCT06296927|OTHER|Emotional Freedom Technique|The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
219645206|NCT02166736|DEVICE|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
219645207|NCT02166736|DEVICE|FFR|Intervention guided by Fractional Flow Reserve
219645208|NCT06627309|DRUG|Dara IV|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
219645209|NCT06627309|DRUG|Bortezomib (drug)|Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
219645210|NCT06627309|DRUG|Dexamethasone|Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
219645211|NCT06627309|DRUG|Cyclophosphamide (CTX)|Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
219645212|NCT06627309|DRUG|Dara SC|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
219645213|NCT03530605|DEVICE|Optune TTF device|portable device which produces electrical fields
219645214|NCT06405828|BEHAVIORAL|ACCESS Supportive Care|"ACCESS Supportive Care includes:~1. Coaching sessions: 6 one-hour weekly Community Navigator led supportive and early palliative care health coaching sessions. Sessions will be hybrid (in-person or virtual) per participant preference.~2. Monthly check-in: Monthly check-ins (\~5-10 minutes) about their supportive care and social determinants of health needs over 16 weeks.~3. Scheduling of outpatient supportive oncology appointment if interested.~4. Community linkage: Warm hand offs and connection to community resources to enhance access to support groups, educational workshops, and healthy lifestyle services."
219645215|NCT06405828|BEHAVIORAL|Phone sessions|6 weekly phone sessions, approximately 10 minutes in length each, to review breast cancer and supportive and palliative care resources in NYC and online. The 6 weekly phone sessions will include the topics discussed in the intervention arm but will be informational in nature. The phone sessions will be followed by monthly check-ins (\~5 minutes) to review and answer questions about the resources for the duration of 16 weeks.
219645216|NCT06826807|OTHER|Regular monitoring with transient elastography|MASLD patients were received their liver fat and fibrosis status regularly using transient elastography
219645217|NCT04180852|OTHER|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
219645218|NCT04986410|DIAGNOSTIC_TEST|CCTA, CT-MPI, CT-FFR, SPECT-MPI|Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
219645219|NCT06258720|DRUG|Lu AF82422|Lu AF82422 solution for intravenous infusion
219645220|NCT04811092|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
219645221|NCT04811092|OTHER|Placebo|Placebo
219645222|NCT06767306|RADIATION|Stereotactic Body Radiotherapy (extracranial) concurrent with immunotherapy|A minimum SBRT biologically effective dose (BED) of 48Gy10 to all sites of extracranial metastatic disease should be administered between cycle 1 and cycle 3 of standard of care immunotherapy.
218960422|NCT03171428|PROCEDURE|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
218960423|NCT03991546|BEHAVIORAL|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
218960424|NCT00993044|DRUG|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
218960425|NCT00993044|DRUG|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
219061165|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
219061166|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
219061167|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
219061168|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
219061169|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
219645223|NCT06767306|DRUG|Immunotherapy alone|All patients will receive standard of care 1st line immunotherapy as decided by the treating clinician and in accordance with the current listing on the Australian Register of Therapeutic Goods (ARTG) or applicable international regulatory agency.
219645224|NCT00796952|BEHAVIORAL|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
219645225|NCT00796952|BEHAVIORAL|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
219645226|NCT00796952|BEHAVIORAL|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
219645227|NCT06532864|BEHAVIORAL|Practice Mawangdui Guiding Technique|Nursing staff with experience in teaching Mawangdui Daoyin Exercise conducted the operation instruction on different floors. A feasibility assessment of the older adults was carried out by the nursing staff at the end of the teaching, and only after passing this assessment could the experimental part begin. The treatment group participated in five Mawangdui Daoyin Exercise sessions per week, each lasting approximately 45 minutes, and the exercises continued for 12 weeks.
219645228|NCT01466504|PROCEDURE|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
219645229|NCT05887440|BEHAVIORAL|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
219645230|NCT03296644|DEVICE|Class II correction using PowerScope2|
219645231|NCT03296644|DEVICE|Class II correction using Forsus|
219645232|NCT05581784|OTHER|Pain neuroscience education|"PNE sessions will be led by an experienced physical therapist certified in PNE in 35-minute face-to-face group sessions. Here elements of the neurophysiology of pain are addressed, as well as the different psychosocial dimensions that influence it. The distribution of themes will be carried out as follows:~Week One: Coping with Pain. Week 2: Pain and Cognition Week 3: Your security system Week 4: Altered Alarm System (extra sensitive). Week 5: The defense system is in distress. Week 6: Fatigue, anxiety, and stress Week 7: Current Models of Treatment Week 8: Achievements and goals Week 9: Pain emphasis and differentiation This group remains with pharmacological treatment and the usual guidelines given by the doctor."
219645233|NCT05581784|OTHER|Conventional management or Usual care|This group will only have pharmacological treatment and the usual guidelines given by the doctor. Without educational intervention.
219645234|NCT00004237|DRUG|cyclophosphamide|
219645235|NCT00004237|DRUG|doxorubicin hydrochloride|
219645236|NCT00004237|DRUG|epirubicin hydrochloride|
219645237|NCT00004237|DRUG|mitoxantrone hydrochloride|
219645238|NCT00004237|DRUG|vinorelbine tartrate|
219645239|NCT00004237|PROCEDURE|conventional surgery|
219645240|NCT00004237|RADIATION|radiation therapy|
219645241|NCT06529445|DRUG|High Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
219645242|NCT06529445|DRUG|Median Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
219645243|NCT06529445|DRUG|Low Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
219645244|NCT03556501|DIAGNOSTIC_TEST|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
219645245|NCT03200314|OTHER|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
219645246|NCT04808063|PROCEDURE|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
219645247|NCT06576141|OTHER|Kaleidoscope|The participation of patients in this group in the study will take approximately 15-20 minutes.
219645248|NCT06576141|OTHER|Virtual Reality|The participation of patients in this group in the study will take approximately 15-20 minutes.
219645249|NCT06576141|OTHER|control|The participation of patients in this group in the study will take approximately 5-10 minutes.
219645250|NCT02695550|DRUG|CT-707|
219645251|NCT06461299|DRUG|Seysara Oral Product|"Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four."
219645252|NCT03565159|BIOLOGICAL|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
219645253|NCT03565159|OTHER|Sodium Chloride 0.9%|Placebo
219645254|NCT04589936|PROCEDURE|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
219645255|NCT04993638|DEVICE|hip arthroplasty|Hip prosthesis surgery
219645256|NCT04553471|RADIATION|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
219645257|NCT04553471|PROCEDURE|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
219645258|NCT05917834|BIOLOGICAL|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
219645259|NCT04399135|DIAGNOSTIC_TEST|Orthopantomogram X-ray view|taking an X-ray to determine bone loss level and attachment loss level for periodontitis classification
219061170|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
219645260|NCT04399135|DIAGNOSTIC_TEST|Endo-Ice|Included teeth will be dried with 4x4 gauze then tested with a cold test using Endo-Ice.
219645261|NCT04399135|DIAGNOSTIC_TEST|Electric Pulp Tester (EPT)|Included teeth will be dried with 4x4 gauze then tested with an Electric test using electric pulp tester (EPT).
219645262|NCT04155229|OTHER|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
219645263|NCT03048292|OTHER|Acute Endovascular Stroke Treatment|
219645264|NCT06028685|DEVICE|Acupoint stimulation|The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.
219645265|NCT06028685|DEVICE|Acupoint stimulation(placebo)|The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
219645266|NCT02236845|DEVICE|Lacrima Medical Device and sham comparator|
219645267|NCT00940823|DEVICE|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
219645268|NCT00940823|DEVICE|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
218960426|NCT00993044|DRUG|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
218960427|NCT00993044|DRUG|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
218960428|NCT04609475|PROCEDURE|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
218960429|NCT04609475|PROCEDURE|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
218960430|NCT06422754|DEVICE|Becure GmbH|Becure Balance System
218960431|NCT04134351|OTHER|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
218960432|NCT03228199|OTHER|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
218960433|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
218960434|NCT04768998|OTHER|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
218960435|NCT05408065|DRUG|Triamcinolone Hexacetonide and hyaluronic acid|infiltration under fluoroscopy
218960436|NCT05408065|DRUG|Triamcinolone Hexacetonide|infiltration under fluoroscopy
218960437|NCT04008381|BIOLOGICAL|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
219061171|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
219061172|NCT03749226|DRUG|Aztreonam lysine|nebulization
219061173|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
219223708|NCT07029035|BIOLOGICAL|İnjectable platelet-rich fibrin|Repeated application of I-PRF to the periodontal pockets in the test sites was performed twice: once immediately following scaling and root planing (SRP), and once at the third week.
219645269|NCT02194712|OTHER|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
219645270|NCT03211780|DEVICE|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
219645271|NCT01681680|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
219645272|NCT00323791|DRUG|gemcitabine hydrochloride|
219645273|NCT00323791|DRUG|imatinib mesylate|
219645274|NCT00323791|GENETIC|gene expression analysis|
219645275|NCT00323791|GENETIC|protein expression analysis|
219645276|NCT00323791|OTHER|immunohistochemistry staining method|
219645277|NCT00323791|OTHER|laboratory biomarker analysis|
219645278|NCT05484856|BIOLOGICAL|Autologous adipose tissue derived stromal cells|autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
219645279|NCT05504538|PROCEDURE|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
219645280|NCT05504538|DEVICE|Tight rope|Adjustable button device from Arthrex Naples USA
218960438|NCT00161421|DRUG|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
219061174|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
219061175|NCT03089424|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
219061176|NCT03089424|DEVICE|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
219645281|NCT05669131|OTHER|Motor imagery training|Participants imagine themselves through their own eyes performing submaximal elbow flexion contractions.
219645282|NCT02482480|OTHER|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
219645283|NCT02482480|OTHER|Control|Dietary and general recommendations
219645284|NCT05152758|DEVICE|PARx|Prescription Physical Activity Programming Application
219645285|NCT05139212|PROCEDURE|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
219645286|NCT05342077|BEHAVIORAL|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
219645287|NCT05342077|BEHAVIORAL|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
219645288|NCT04302454|RADIATION|Radiotherapy|Radiotherapy
219645289|NCT04302454|DRUG|Leuprorelin|Hormonal therapy
219645290|NCT06265649|OTHER|NOM|Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if \>4cm, restoring a regular diet
219645291|NCT06621368|OTHER|Exercise|the RT program will consist of eight exercises for different body segments, namely: vertical bench press, horizontal leg press, low row, leg extension, scott curl, leg curl, triceps pulley and seated calf raise. Every 12 weeks of training, the program will be restructured with changes in the order in which the exercises are performed, the number of sets, the number of repetitions or the training system in an attempt to avoid a supposed adaptive plateau. The protocols in each stage will follow the recommendations for prescribing RT for the elderly, aiming at improving strength and hypertrophy, namely: a combination of single-joint and multi-joint exercises (free weights and machines), slow or moderate execution speed (ratio 1:2 for concentric and eccentric muscle actions, respectively), one to three sets of multiple repetitions, 8-12 RM or 10-15 RM, with recovery intervals between sets of one to two minutes, and a training frequency of two to three weekly sessions, on alternate days.
219645292|NCT06621368|OTHER|Control-no treatment|Participants will maintain their daily activities.
219645293|NCT06622564|DRUG|Before CPB Tranexamic Acid|Tranexamic acid 1 to 10 g (10 to 100 mL) administered intravenously as per standard care at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB).
218960439|NCT00161421|DRUG|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
218960440|NCT00161421|DRUG|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
218960441|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
218960442|NCT01576887|DRUG|Bardoxolone Methyl 20 mg|Oral, once daily
218960443|NCT01576887|DRUG|Placebo|Oral, once daily
219061177|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
219061178|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
219207795|NCT06715501|RADIATION|radiotherapy|GTV is defined as visible lesions (GTVp: primary lesion; GTVn: metastatic lymph nodes), CTVp is defined as 3cm above and below the primary lesion, with 0.5cm outward expansion around the periphery, and CTVn is defined as 0.5cm outward expansion of GTVn; PTVp is an outward expansion of 0.5cm for CTVp, and PTVn is an outward expansion of 0.5cm for CTVn. Radiotherapy dose: DT50.4Gy/28f, once daily, 5 times a week
219645294|NCT06622564|DRUG|After CPB Tranexamic Acid|Tranexamic acid 5 g (50 mL) administered after heparin reversal (i.e., after CPB).
219645295|NCT06622564|DRUG|Before CPB Placebo|Placebo (10 to 100 mL saline) administered intravenously at the induction of anesthesia as a bolus and/or continuous infusion.
219645296|NCT06622564|DRUG|After CPB Placebo|Placebo (50 mL saline) administered after heparin reversal.
219645297|NCT04948541|COMBINATION_PRODUCT|osa treatment|different treatments can be included
219645298|NCT04948541|OTHER|no treatment|no treatment was undergone
219645299|NCT06435325|BEHAVIORAL|Precision diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
219645300|NCT06435325|BEHAVIORAL|Control diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
219645301|NCT03196661|BIOLOGICAL|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
219645302|NCT01862263|DRUG|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
219645303|NCT01862263|DRUG|Insulin|Long- acting human insulin analog indicated to improve glycemic control
219645304|NCT01862263|DRUG|Placebo|Matching placebo of vildagliptin
219645305|NCT04194320|PROCEDURE|Ultrasound (US) guided supraclavicular brachial plexus block|Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
219645306|NCT04622514|OTHER|Village doctor-led telemedicine integrated care|1\. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
219645307|NCT04622514|OTHER|Enhanced usual care|1\. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
219061179|NCT02317575|BIOLOGICAL|LY900014|Administered SC
219061180|NCT02317575|BIOLOGICAL|Insulin Lispro|Administered SC
219645308|NCT06174298|DRUG|Granulocyte Colony-Stimulating Factor (Filgrastim)|"Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
219645309|NCT06174298|OTHER|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
219645310|NCT02068781|DIETARY_SUPPLEMENT|Low-sodium diet|50 mmol NaCl per 24h
219645311|NCT02068781|DIETARY_SUPPLEMENT|High-sodium diet|250 mmol NaCl per 24h
219686226|NCT02600923|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
219207796|NCT06715501|DRUG|carboplatin, paclitaxel|Induction chemotherapy: carboplatin 5AUC，q3w; Paclitaxel 135mg/m2,q3w. Simultaneous chemotherapy: 2AUC/W，total 5w; Paclitaxel 50mg/m2/w，total 5w
219207797|NCT06745687|DRUG|CM336|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1 and cycle2. Then patients will be given 160mg every 2 weeks from cycle 3 to cycle 6. The dosing interval is adjusted according to the evaluation of efficacy every 6 cycles from cycle 7 to cycle 24.
219686227|NCT01590901|DRUG|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
219686228|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
219686229|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
219686230|NCT04865029|OTHER|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
219645312|NCT02618837|PROCEDURE|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~* Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~* Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel\* daily for at least 12 months~  * If subject is \>75 years old or \<60 kg, daily dose of prasugrel should be 5mg"
219645313|NCT02618837|PROCEDURE|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
219061181|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
219061182|NCT00130884|DRUG|levosimendan|
219061183|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
219061184|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
219061185|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
219645314|NCT05128630|DRUG|Durvalumab|Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
219645315|NCT03902717|PROCEDURE|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
219645316|NCT05738551|OTHER|stress ball|Applicable to group 1
219645317|NCT05738551|OTHER|chewing gum|Applicable to group 2
219645318|NCT03717051|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
219645319|NCT03717051|BEHAVIORAL|Medication counseling|Medication counseling
219686231|NCT04865029|DRUG|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
219686232|NCT04865029|DRUG|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
219061186|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
219061187|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
219061188|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
219061189|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
219061190|NCT02326402|DEVICE|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
219061191|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
219061192|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
219061193|NCT03346668|DRUG|Topical gabapentin|topical gabapentin 6% solution
219061194|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
219061195|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
219061196|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
219061197|NCT04421144|PROCEDURE|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
219061198|NCT01857544|DRUG|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
219061199|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
219061200|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
219061201|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
219061202|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
219061203|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
219061204|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
219061205|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
219061206|NCT01231698|OTHER|control|standard treatment without strict heart rate control
219645320|NCT02416648|BEHAVIORAL|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
219645321|NCT04378959|DRUG|Lidocaine patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
219645322|NCT04378959|DRUG|Placebo patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
219645323|NCT00928941|BEHAVIORAL|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
219645324|NCT00928941|BEHAVIORAL|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
219645325|NCT05735990|DEVICE|Intraocular lens|Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
219645326|NCT03711149|OTHER|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
219645327|NCT00784550|DRUG|Tiotropium Bromide|Long-acting muscarinic antagonist
219645328|NCT00784550|DRUG|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
219645329|NCT04796883|DEVICE|Hanita Glaucoma shunt Ver.3.2|The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
219645330|NCT05705115|DRUG|Ringer acetate|Ringer acetate 5 ml/kg.
219645331|NCT05705115|OTHER|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
218960444|NCT04725006|DEVICE|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
219645332|NCT02425761|PROCEDURE|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
219645333|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
219645334|NCT04822636|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
219645335|NCT05987553|OTHER|e-learning program|All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.
219645336|NCT05608369|DRUG|Cisplatin|Cisplatin100 mg/m2 every 3 weeks or 40 mg/m2 weekly
219645337|NCT05608369|RADIATION|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
218960445|NCT00734747|DEVICE|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
218960446|NCT05560646|DRUG|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
218960447|NCT05560646|DRUG|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
218960448|NCT06985992|PROCEDURE|Group morphine|Group Morphine: Spinal anesthesia will be applied to patients who will undergo caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml saline
218960449|NCT06985992|PROCEDURE|Group morfin+dexamethasone|Group morfin+dexamethasone: Spinal anesthesia will be applied to patients who will undergo a caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml (2 mg) dexamethasone
219061207|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
219645338|NCT05608369|DRUG|Vorinostat|Pre-treatment; 300 mg every other day and ends with the dose closest to the last fraction of radiation (total of 8 weeks)
219645339|NCT03582800|DRUG|STS|"M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~* Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~* Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation."
219645340|NCT03665675|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
219061208|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
219645341|NCT03665675|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given intravenously
219645342|NCT04270864|DRUG|Ipilimumab|20mg (4mL) IT
219645343|NCT04270864|DRUG|Nivolumab|360mg IV then 480mg IV
219645344|NCT04270864|DRUG|Tilsotolimod|8 mg (2mL) IT
219061209|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
219061210|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
219061211|NCT00042328|DRUG|Valacyclovir|
219645345|NCT05094765|BIOLOGICAL|FMT|Fecal Microbiota Transplantation
218960450|NCT06986096|BEHAVIORAL|Aerobic-strength training and nutritional counseling|The intervention consists of a structured program that includes aerobic-strength training (1h training, 3 times per week) conducted by professional trainers combined with nutritional counseling.
219645346|NCT00688701|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219645347|NCT00688701|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219061212|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
219061213|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
219061214|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
219061215|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
219061216|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
219061217|NCT03594448|PROCEDURE|Specimen Collection|Undergo collection of blood samples
219645348|NCT00688701|DEVICE|Pen auto-injector|
219645349|NCT00029536|BIOLOGICAL|Progesterone Lozenges|200mg Progesterone Lozenges
218960451|NCT06986096|BEHAVIORAL|Cognitive training and stretching.|The intervention consists of a structured program that includes cognitive training combined with stretching training (90mins training, 2x per week).
218960452|NCT06184737|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
218960453|NCT06184737|BEHAVIORAL|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
218960454|NCT04070911|OTHER|WATER|ORAL WATER
218960455|NCT04070911|OTHER|ICE APPLICATION|ICE APPLICATION
219061218|NCT03594448|PROCEDURE|Serial Liquid Biopsy|Undergo serial liquid biopsy
219061219|NCT00309998|BIOLOGICAL|bevacizumab|
219061220|NCT00309998|DRUG|vinorelbine tartrate|
219645350|NCT00029536|OTHER|Matched Placebo Lozenges|Matched Placebo Lozenges
218960456|NCT06985459|DEVICE|PIP extension deficit treated with an exercise RMF orthosis|The RM orthoses will be worn between 6-12 hours per day during functional use.
219207798|NCT06748885|DEVICE|Mpact 3D Metal Monolith|THA with Mpact 3D Metal Monolith
219207799|NCT06758453|OTHER|Dietary Challenge|Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.
219645351|NCT00095641|DRUG|capecitabine|
219645352|NCT00095641|PROCEDURE|adjuvant therapy|
219645353|NCT00095641|PROCEDURE|chemotherapy|
219645354|NCT03892577|DRUG|Precision oncology including targeted therapy and immunotherapy|Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
219645355|NCT04183738|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
219645356|NCT04183738|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
219645357|NCT04183738|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
219645358|NCT04183738|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
219686233|NCT03948152|OTHER|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
219645359|NCT06032052|DRUG|Single drug chemotherapy plus immunotherapy|The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
219061221|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
219061222|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
219061223|NCT01717573|PROCEDURE|Deferred stenting|
219061224|NCT01717573|PROCEDURE|Conventional treatment|
219645360|NCT03410407|OTHER|Observation of CNS involvement|AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
219061225|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
219061226|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
219061227|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
219061228|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
219061229|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
219645361|NCT04596709|DIETARY_SUPPLEMENT|Vitalose|dissolved in water
219645362|NCT04596709|DIETARY_SUPPLEMENT|isomaltulose|dissolved in water
219645363|NCT04596709|DIETARY_SUPPLEMENT|sucrose|dissolved in water
219645364|NCT04596709|DIETARY_SUPPLEMENT|glucose|dissolved in water
218960457|NCT06985459|DEVICE|PIP extension deficit treated with a placebo RMF orthosis|"The placebo orthosis has the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
218960458|NCT06985459|DEVICE|PIP flexion deficits treated with a placebo RMF orthosis|"The placebo orthosis have the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
219061230|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
219061231|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
219061232|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
219061233|NCT00343187|DRUG|Vehicle Control|
219061234|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
219061235|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
219061236|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
219207800|NCT06759337|BEHAVIORAL|Stress Ball Group|Participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete.
219207801|NCT06759337|BEHAVIORAL|Hand-Holding Group|The researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves.
219645365|NCT00283855|BEHAVIORAL|Online Self-Management|Online Self-Management
219645366|NCT06640985|DEVICE|EDX110 wound dressing system|EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
219645367|NCT00102648|DRUG|Lonafarnib|Given PO
219645368|NCT00102648|DRUG|Temozolomide|Given PO
219645369|NCT06623825|DEVICE|teleconsultation by Augmented Reality smart glasses|The device operated on Android 9.0 and it connected to 5G connection with a bandwidth speed 30-mbps delivering a very low latency. The device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. Physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. The features facilitate healthcare providers at SRRSH and medical personnel in the HAG2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient.
219645370|NCT06623825|DEVICE|teleconsultation by two-way radio connection.|adhering to the standard conventional triage process without the AR tool, only using a two-way radio connection.
219645371|NCT01168908|DRUG|Sildenafil|20mg tablet three times daily
219645372|NCT00418366|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
219645373|NCT00166257|DEVICE|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
219645374|NCT00166257|DRUG|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
218960459|NCT06985459|DEVICE|PIP flexion deficits treated with an exercise RME orthosis|The dedicated orthosis wearing time is 6-12 hours per day during functional use.
218960460|NCT06984848|COMBINATION_PRODUCT|Oral7® mouth spray contains Natural Enzymes (Lactoperoxidase, Glucose Oxidase, Lactoferrin, Lysozyme), Calcium, Xylitol, Aloe Vera, Natural peppermint.|This study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia
219061237|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
219061238|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
219207802|NCT06749743|DIAGNOSTIC_TEST|FASTER RCNN|train artificial intelligence models ( FASTER RCNN, YOLOY ) to detect dental caries , then test their accuracy
219207803|NCT06744361|DRUG|esketamine hydrochloride|Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
219207804|NCT06744361|DRUG|propofol|Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol
219207805|NCT06763900|DEVICE|Skeletal anchorage and intermaxillary elastic assisted maxillary protraction|maxillary protraction with corticotomy-assisted different miniplate and intermaxillary elastic applications after growth spurt in patients with skeletal Class III malocclusion
219645375|NCT01393509|DRUG|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
219645376|NCT05018767|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219645377|NCT06341543|DIAGNOSTIC_TEST|Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).|The QF-CMV will be performed in all participants.
219645378|NCT06341543|OTHER|Communication of the result of the QF-CMV to the clinician in charge|"The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge."
219645379|NCT01765777|PROCEDURE|Osteopathic Manipulative Medicine|
219645380|NCT01765777|PROCEDURE|Phototherapy|
219645381|NCT03653351|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
219645382|NCT03653351|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
219645383|NCT03150654|DEVICE|Laser pan-retinal photocoagulation|Green laser photocoagulator
219645384|NCT05533957|OTHER|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
219645385|NCT05034861|DEVICE|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
219645386|NCT05034861|DIAGNOSTIC_TEST|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
219645387|NCT01106677|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
219645388|NCT01106677|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
219645389|NCT01106677|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
219645390|NCT01106677|DRUG|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
219645391|NCT02567734|PROCEDURE|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
219645392|NCT04248140|OTHER|radio frequency electromagnetic field|Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
219645393|NCT03122743|PROCEDURE|Biospecimen Collection|Undergo collection of serum samples
219645394|NCT03122743|OTHER|Laboratory Biomarker Analysis|Correlative studies
219645395|NCT03122743|OTHER|Questionnaire Administration|Ancillary studies
219645396|NCT03937908|DRUG|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
219645397|NCT03937908|DRUG|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
219645398|NCT05740189|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
218960461|NCT06987344|OTHER|Field-based closed kinetic chain exercise with progressively increased time under tension|This intervention is uniquely characterized by the integration of field-based closed kinetic chain (CKC) exercises with a systematically increased eccentric time under tension (TUT), specifically tailored for university-level soccer players. Unlike conventional strength training protocols, which are often gym-based and rely on traditional resistance machines or free weights, this program emphasizes functional, sport-specific movement patterns performed on the field, enhancing ecological validity and transfer to soccer performance.
218960462|NCT06987344|OTHER|Regular soccer training routines|Trained three times a week: two days were dedicated to functional and tactical on-field training, while the third day was reserved for a two-hour gym session focused on flexibility, muscular strength, and endurance development.
218960463|NCT06242743|OTHER|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
218960464|NCT06242743|OTHER|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
219645399|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
219645400|NCT05919472|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
218960465|NCT03344523|DRUG|Iron protein succinylate oral solution|Iron protein succinylate oral solution
218960466|NCT03344523|OTHER|standard treatment|standard treatment
218960467|NCT01397097|DRUG|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
218960468|NCT01397097|DRUG|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
218960469|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
218960470|NCT06990152|OTHER|MCTs and fiber|Water-soluble powder containing medium-chain triglycerides, soluble and unsoluble fiber.
218960471|NCT06990152|OTHER|Placebo powder|Water-soluble powder containing no medium-chain triglycerides and no fiber.
218960472|NCT06993376|PROCEDURE|PENG block|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
218960473|NCT06993376|PROCEDURE|ESPB|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
219645401|NCT05919472|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
219645402|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
218960474|NCT06989567|DRUG|L-citrulline|This intervention uses intravenous L-citrulline as an acute treatment for vaso-occlusive crisis (VOC) in sickle cell disease, administered as a 50 mg/kg IV bolus followed by a 9 mg/kg/hr continuous infusion. Unlike other studies that evaluate oral citrulline or chronic VOC prevention, this study focuses on real-time symptom resolution in the emergency department setting by targeting impaired nitric oxide production and vasoconstriction. The selected dosing regimen was optimized in prior studies to achieve a therapeutic plasma concentration associated with improved pain scores and reduced opioid use, distinguishing it mechanistically and clinically from other interventions.
218960475|NCT06989567|OTHER|Placebo|Placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline
218960476|NCT06598527|RADIATION|Stereotactic body radiotherapy (SBRT)|"Radiation source: 6MV photon linear gas pedal is used. Position immobilization: supine position, hands up, vacuum bag or styrofoam immobilization.~Radiotherapy plan design: 4DCT positioning, radiotherapy plan design at 20% respiratory time-phase CT, isocentric irradiation, IMRT or VMAT design.~Definition of target area:~Gross tumor volume (GTV) includes the primary tumor in the lung, excluding lymph nodes. Internal target volume (ITV); Internal target volume (ITV) is formed by the fusion of 10 respiratory phases of GTV; Planning target volume (PTV) is formed by expanding the ITV by 0.5 cm in all directions."
218960477|NCT06598527|DRUG|Tislelizumab|PD-L1 inhibitor
218960478|NCT06598527|DRUG|Chemotherapy|platinum-based double-agent chemotherapy
218960479|NCT06862648|DEVICE|Acoustic Stimulation Therapy Device|The SUI-100 Device is a non-invasive device designed for the treatment of stress urinary incontinence (SUI) in females.
219645403|NCT05919472|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
219645404|NCT02416128|DRUG|Euphrasia|1 drop in the treated eye QID X 10 days
219645405|NCT02416128|DRUG|Prednisolone acetate|1 drop in the treated eye QID X 10 days
219645406|NCT05753267|DRUG|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
219645407|NCT05753267|DRUG|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
219061239|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
219061240|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
219061241|NCT00003326|DRUG|paclitaxel|
219223709|NCT07029035|OTHER|Sterile saline (0.9%)|Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material.
219645408|NCT01969786|OTHER|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
219645409|NCT06665880|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for DRE.
219645410|NCT03875092|BIOLOGICAL|Pembrolizumab|IV infusion
219645411|NCT03875092|DRUG|Paclitaxel|IV infusion
219645412|NCT03875092|DRUG|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
219645413|NCT03875092|DRUG|Saline placebo for pembrolizumab|IV infusion
218960480|NCT06862648|DEVICE|Sham Acoustic Stimulation Therapy Device|The sham intervention uses the same device setup with sham procedures.
218960481|NCT03757390|DRUG|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
218960482|NCT03757390|DRUG|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
218960483|NCT06995586|DIETARY_SUPPLEMENT|Vitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose|This is a randomized and controlled trial with an intervention group that will be administered orally daily in addition to the Optimal Medical Therapy (OMT), namely 1000 mg Vitamin C, 840 mg EPO/DHA, 2130 mg Lignin \& 720 mg Lactulose and a control group that will receive only the OMT.
218960484|NCT06993558|PROCEDURE|Poly-L-Lactic Acid (Sculptra) injection|1 to 2 sessions at intervals of 4 to 6 weeks are planned with PLLA (Sculptra®, Galderma Laboratories). PLLA will be injected into the face or neck region using a blunt cannula. For reconstitution, 7 ml of saline solution and 1 ml of 1 % lidocaine will be used. 5 minutes of massaging for 5 times a day are recommended.
219645414|NCT03205761|DRUG|Olaparib|Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
219645415|NCT04420585|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
219645416|NCT01513109|BIOLOGICAL|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
219645417|NCT06430502|BIOLOGICAL|Tumor Treatment Vaccine; PD-1/L1 inhibitors|Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
219645418|NCT02444364|DRUG|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
219645419|NCT00065637|DRUG|Teriparatide|Synthetic human parathyroid hormone
218960485|NCT06993558|PROCEDURE|Calcium Hydroxyapatite|For CaHA treatment (Radiesse®, Merz Pharma; HarmonyCa®, Allergan), 1 session is planned. The face (cheeks, jawline) or neck will be augmented using a blunt cannula, either diluted (Radiesse® 1:0.2 - 1:2) or undiluted (HarmonyCA®) depending on the product and the region being treated.
218960486|NCT06993558|PROCEDURE|Radiofrequency Microneedling|For RFMN treatment (Genius®, Lutronic Medical Systems), 1 to 3 sessions at intervals of 6 to 8 weeks are planned. Prior to treatment, subjects were given topical anesthesia (23% lidocaine, 3.5% tetracaine) under occlusion for at least 1.5 hours. The face will be treated with an RFMN system, using parameters adjusted for each anatomical location. Each region received three passes with 50 - 70 % overlap, starting with the longest needle setting. A minimum total energy of 1000 J will be aimed. Treatment will be performed using forced cooled air (Cryo6, Zimmer Aesthe cDivision).
218960487|NCT06994481|DIAGNOSTIC_TEST|optic nerve sheet diameter measurement|Both groups will undergo bilateral optic nerve sheath diameter measurement with ultrasonography after induction, after airway manipulations, and before awakening.
218960488|NCT06994169|DRUG|Glofitamab|Glofitamab received for DLBCL in Early Phase Access
218960489|NCT06995547|DEVICE|implant overdenture|Each patient will be receive two dental implants for overdenture fixation
218985204|NCT06474286|DRUG|Prucalopride 1 MG|The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
219223710|NCT07028632|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
219645420|NCT00065637|DRUG|Placebo teriparatide|Placebo injections
219645421|NCT00641576|DEVICE|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
219645422|NCT02756780|OTHER|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
219645423|NCT04277650|OTHER|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
219645424|NCT01374932|DEVICE|CPAP|Continuous positive airways pressure (CPAP)
219645425|NCT06232057|OTHER|Virtual Reality|Women in the intervention group will be given a pre-test (STAI) before cesarean. Then, they will be shown a relaxing video (video with nature views accompanied by nature sounds) through virtual reality glasses for a maximum of 20 minutes. After a cesarean, women's anxiety levels (STAI) will be evaluated within the first 4 hours postoperatively. Pain levels (VAS) will be assessed postoperatively at the 2nd, 4th, and 6th hours.
219645426|NCT02163226|RADIATION|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
219645427|NCT02163226|RADIATION|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
219645428|NCT02163226|BEHAVIORAL|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
219645429|NCT04114357|DRUG|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
219645430|NCT05435625|PROCEDURE|FCO2|Fractional Carbon dioxide laser
219645431|NCT05435625|PROCEDURE|FRF|Fractional Microneedling Radiofrequency
219645432|NCT00477750|DRUG|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
219686234|NCT03948152|OTHER|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
218960490|NCT06995274|BIOLOGICAL|Umbilical Cord Blood Infusion (Autologous and Allogeneic)|"The intervention consists of three intravenous infusions of umbilical cord blood (UCB) in a pediatric patient diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder (ASD). The first infusion uses autologous UCB stored at a certified cord blood bank. The second and third infusions use allogeneic UCB units selected from a hospital-based donor cord blood bank. Donor units are matched at a minimum of 3 out of 6 HLA loci (HLA-A, B, DRB1) and contain ≥ 3×10⁷ total nucleated cells per kilogram of body weight.~Each infusion is administered intravenously via peripheral vein at the Cell Therapy Center of CHA Bundang Medical Center. Prior to each infusion, the participant receives premedication with intravenous chlorpheniramine maleate (0.6 mL/10 kg) to reduce the risk of allergic reactions. For allogeneic infusions, oral cyclosporine (0.07 mL/kg twice daily) is administered for 7 days (3 days before, day of, and 3 days after infusion) to minimize immune-mediated reactions"
218960491|NCT06994845|DRUG|iptacopan|Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd
218960492|NCT04657107|DRUG|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
218960493|NCT04657107|OTHER|normal saline|Saline group: pregnant women received saline, intravenous drip
218960494|NCT04657107|DRUG|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
218960495|NCT04461509|DRUG|18F-PSMA|"Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer"
218960496|NCT06709716|DRUG|Quadratus Lumborum Block (QLB)|Pre-operative quadratus lumborum block with liposomal bupivacaine
218960497|NCT06709716|DRUG|Quadratus lumborum block|Pre-operative quadratus lumborum block with saline
218960498|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of 0.25% bupivacaine at each incision site
218960499|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of saline at each incision site.
218960500|NCT04932798|DIAGNOSTIC_TEST|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
218960501|NCT04932798|DIAGNOSTIC_TEST|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
218960502|NCT04932798|DIAGNOSTIC_TEST|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
219061242|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
219061243|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
219061244|NCT00643955|OTHER|muscle strength|muscle strength
219645433|NCT00477750|DRUG|melphalan|"Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression"
219645434|NCT00477750|DRUG|prednisone|60mg/m\^2, orally days 1-4 every 28 days until progression
219645435|NCT01048060|PROCEDURE|Bone marrow specimen banking|
219645436|NCT04958148|DIETARY_SUPPLEMENT|Salt pills|Subjects will supplement salt pills with meals.
219645437|NCT04958148|DIETARY_SUPPLEMENT|Placebo pills|Subjects will supplement placebo pills with meals.
219645438|NCT05491525|DRUG|Vibegron|Participants will be administered Vibegron orally, once daily (QD)
219645439|NCT06618508|PROCEDURE|Manual debridement|Traditional technique which consists of scraping off the irregular epithelium to allow a new layer to form.
219645440|NCT06618508|PROCEDURE|Phototherapeutic keratectomy|New technique which has been increasingly used and which consists of a 193nm excimer laser that breaks molecular bonds between cells on the epithelial surface.
219645441|NCT05277142|OTHER|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
219645442|NCT05277142|DEVICE|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
219645443|NCT03558152|DRUG|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
219645444|NCT03558152|DRUG|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
219645445|NCT03558152|DRUG|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
219645446|NCT03558152|DRUG|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
219645447|NCT03018496|DIETARY_SUPPLEMENT|Beta-Hydroxy-Beta-Methylbutyrate|
219645448|NCT03018496|OTHER|Placebo|
219645449|NCT01335217|PROCEDURE|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
219645450|NCT06621901|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
219645451|NCT06621901|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
219645452|NCT06682585|OTHER|Individualised dietary intervention|"* Energy Intake: Caloric needs will be calculated based on the patient's age, weight, and activity level, taking into account the potential impact of corticosteroid therapy on energy expenditure.~* Protein Intake: Protein requirements will be met through a balanced diet, aiming to optimize muscle protein synthesis.~* Calcium and Vitamin D Intake: Adequate intake of these nutrients will be emphasized to support bone health and prevent osteoporosis.~* Fluid Intake: Fluid intake will be monitored to prevent dehydration and constipation.~* Carbohydrate Intake: A low-glycemic index diet will be recommended to manage blood glucose levels and insulin resistance, especially in patients on corticosteroid therapy.~* Sodium Intake: Sodium intake will be restricted to minimize fluid retention and hypertension."
219645453|NCT00136136|PROCEDURE|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
219645454|NCT03513809|DEVICE|Thoracic electrical impedance tomography|Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
219645455|NCT05678868|PROCEDURE|MitraClip procedure|MitraClip is surgical procedure to repair the mitral valve in your heart. During the procedure, the doctor will access the mitral valve using a thin tube (called a catheter) that is guided through a vein in your leg to reach your heart. A small implanted clip is attached to the mitral valve to reduce the leaking across the valve and to reduce symptoms and stress on the heart.
219645456|NCT01214369|PROCEDURE|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
219645457|NCT00476268|DRUG|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
219645458|NCT00476268|DRUG|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
219645459|NCT00476268|DRUG|Formoterol powder 12 µg/unit dose|2 inhalations bid
219645460|NCT00177853|DRUG|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
219645461|NCT00177853|DRUG|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
219645462|NCT00177853|PROCEDURE|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
219645463|NCT03247153|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart using ultrasound
219645464|NCT03109353|DRUG|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
219645465|NCT02661269|DEVICE|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
219645466|NCT02661269|DEVICE|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
219645467|NCT00601172|DRUG|Casopitant|Experimental NK-1 receptor antagonist
219645468|NCT00601172|DRUG|Dexamethasone|Standard antiemetics
219645469|NCT00601172|DRUG|Placebo|Placebo to match IV casopitant
219645470|NCT00601172|DRUG|Ondansetron|Standard antiemetics
219645471|NCT02383368|DRUG|ASP4132|oral
219645472|NCT05437874|DRUG|Natural Water|"355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
219686235|NCT03281941|OTHER|Inhaled capsaicin cough challenge|
219686236|NCT04990115|OTHER|root canal shaping|root canal treatment
219645473|NCT04158674|DRUG|Levosimendan|Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
219645474|NCT04158674|DRUG|Cernevit|mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
219645475|NCT05330364|DRUG|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
219645476|NCT05330364|DRUG|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
219645477|NCT06665139|DIAGNOSTIC_TEST|muscle thickness|Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.
219645478|NCT06559865|BEHAVIORAL|Breathing exercises|as per group description
219645479|NCT03030989|DRUG|Chlorhexidine Gluconate 2% Wipe|
219645480|NCT03030989|DRUG|Placebo Wipe|
219645481|NCT01826890|OTHER|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
219645482|NCT02872610|BEHAVIORAL|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
219645483|NCT00090701|DRUG|AG2037|
219645484|NCT03862794|BEHAVIORAL|new social norm feedback letter with bar chart|letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
219645485|NCT03862794|BEHAVIORAL|standard social norm feedback letter|social norm feedback letter used as standard practice, without specific information about the prescribing percentile
218960503|NCT06715280|DRUG|Riociguat (Adempas)|Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period
218960504|NCT06711952|DIAGNOSTIC_TEST|Subjective Cognitive Decline-Questionnaire (SCD-Q)|The SCD-Q is an established instrument to quantify self-perceived cognitive decline. In addition to the self-perceived cognitive complaints, a 24 items questionnaire of informants is part of SCD-Q. The self-reported SCD-Q will be included in the standard health questionnaire that all patients of the memory clinic of the LMU Department of Psychiatry and Psychotherapy are required to complete before the examination date. The health questionnaire will be sent per mail. All routine clinical procedures will remain unchanged.
218960505|NCT06711952|DIAGNOSTIC_TEST|Cognitive Failure Questionnaire (CFQ)|The Cognitive Failure Questionnaire (CFQ) is a questionnaire for measuring self-reported subjective failures in cognition, memory and motor functions in everyday life. The German CFQ consists of 32 items related to everyday possibilities of error, whose frequency in the last six months is to be estimated by means of a five-point rating scale.
219645486|NCT05681468|OTHER|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
219645487|NCT05681468|OTHER|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
218960506|NCT06711952|DIAGNOSTIC_TEST|biomarkers|"Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer.~Only available clinical and biomarker data will be used (Routine cerebrospinal fluid biomarkers, routine imaging biomarkers)."
218960507|NCT06711952|DIAGNOSTIC_TEST|Cognitive Tests|"The investigators plan to examine the patients´ visuospatial performance on site with a digital clock-drawing test, which has been validated in large community-based studies.~The Functional Activities Questionnaire (FAQ) shall be filled out by an informant. FAQ is a reliable and valid measure of activities of daily living. The results of the routine neuropsychological tests (Consortium to Establish a Registry for AD, Mini-Mental-State Examination) will be used in the analysis."
219645488|NCT05681468|OTHER|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
219645489|NCT00123617|PROCEDURE|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
219645490|NCT02706886|DRUG|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
219645491|NCT02706886|DRUG|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
219645492|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
219645493|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
219645494|NCT04653337|COMBINATION_PRODUCT|Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
218960508|NCT06781333|BIOLOGICAL|hMSC|Participants will come in person to receive one intravenous infusion of approximately 25 million cells up to 20 minutes.
218960509|NCT04537377|GENETIC|VTX-801|"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."
219645495|NCT02083055|DRUG|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
218960510|NCT01909453|DRUG|LGX818|LGX818- Orally 100 mg and 50 mg capsules
219645496|NCT02083055|DRUG|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
219645497|NCT05269875|OTHER|ACP|The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
219645498|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.
219645499|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.
219645500|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.
218960511|NCT01909453|DRUG|MEK162|MEK162- Orally 15 mg tablets
219645501|NCT01115920|DRUG|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
218960512|NCT01909453|DRUG|vemurafenib|Tablets in bottles or blisters 240 mg
218960513|NCT06926114|DEVICE|Microlearning intervention|thirteen students will be included into the microlearning group will receive sequential daily learning units over ten days, . Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
218960514|NCT06926114|DEVICE|Traditional block-format module group|eleven students will be inclued into the self block module group will engage in a comprehensive two-day self-learning module. Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
218960515|NCT06801847|BEHAVIORAL|Socialization|Socialization lasting from 30-60 minutes each session
218960516|NCT06801847|BEHAVIORAL|Walking|Twice weekly walking (30 minutes)
218960517|NCT06801847|BEHAVIORAL|Moderate Exercise|Twice weekly moderate exercise (30 minutes)
218960518|NCT06524453|BEHAVIORAL|Wheelchair accessible exercise program|"1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes"
218960519|NCT06908174|DIAGNOSTIC_TEST|ADOS-2|The subjects in case group will receive the ADOS-2 assessment to confirm their diagnosis.
219645502|NCT01669174|DRUG|Placebo|
218960521|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
218960522|NCT05941832|DEVICE|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
218960523|NCT06919068|DIAGNOSTIC_TEST|Colon capsule endoscopy|PillCam Colon 2
218960524|NCT01382147|DRUG|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
218960525|NCT02151136|DRUG|24% sucrose|
218960526|NCT02151136|DRUG|Sterile water|
219645503|NCT01669174|DRUG|BYM338|BYM338
219645504|NCT04353167|OTHER|observational evaluation|Patients will be evaluated only observationally without intervention
219645505|NCT04582929|DRUG|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
219645506|NCT05537441|BEHAVIORAL|Text messaging|Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
218960527|NCT02151136|OTHER|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
219061245|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
219061246|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
219061247|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
219061248|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
219645507|NCT03274141|OTHER|Non-Interventional|Non-Interventional
219645508|NCT03697759|OTHER|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
219645509|NCT05528107|PROCEDURE|Lap IPOM plus|Participants will undergo Lap IPOM plus repair according to the assigned treatment arm.
219645510|NCT05528107|PROCEDURE|eTEP|Participants will undergo eTEP repair according to the assigned treatment arm.
219645511|NCT01264237|DRUG|Etoricoxib|90mg Tablet QD at 10:00a.m.
219645512|NCT01264237|DRUG|Placebo|One tablet QD at 10:00a.m.
219645513|NCT06621147|PROCEDURE|Surgery|Surgery
219645514|NCT04164251|OTHER|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
219645515|NCT02849860|DRUG|IDP-121 Lotion|Lotion
219645516|NCT02819180|BIOLOGICAL|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
219645517|NCT04310397|DRUG|Dabrafenib|Given PO
218960528|NCT05829200|DEVICE|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
218960529|NCT05587348|BEHAVIORAL|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
218960530|NCT05587348|BEHAVIORAL|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
218960531|NCT05008211|OTHER|Information-Motivation-Behavioral skills (IMB) model-based intervention|A six-week programme
219061249|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
219645518|NCT04310397|BIOLOGICAL|Spartalizumab|Given IV
219645519|NCT04310397|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219645520|NCT04310397|DRUG|Trametinib|Given PO
219645521|NCT01641497|RADIATION|3D conformational radiation|25 \* 1.8 Gy in 5 weeks (=45 Gy)
219645522|NCT01641497|RADIATION|IMRT|25 \* 1.8 Gy in 5 weeks (=45 Gy)
218960532|NCT05008211|OTHER|Control - usual care|he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
218960533|NCT05288777|DRUG|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
218960534|NCT05288777|DRUG|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
218960535|NCT05288777|RADIATION|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
218960536|NCT05288777|RADIATION|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
218960537|NCT05384275|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
218960538|NCT03845374|DEVICE|Hyper-CL™ lens|Use of the Hyper-CL™
218960539|NCT00234403|DRUG|gefitinib and fulvestrant|
218960540|NCT04399031|DRUG|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
219061250|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
219645523|NCT03397329|DRUG|AG-348 Sequence A|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
219645524|NCT03397329|DRUG|AG-348 Sequence B|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
219645525|NCT00985998|DRUG|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12\~18 weeks)."
219645526|NCT05595564|DEVICE|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
219645527|NCT05012904|BEHAVIORAL|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
219645528|NCT04231929|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved."
219645529|NCT01383629|BEHAVIORAL|Counselling|Preoperative counselling
219645530|NCT00723255|BIOLOGICAL|bevacizumab|Given IV
219645531|NCT00723255|DRUG|temsirolimus|Given IV
219645532|NCT00614523|DRUG|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
219645533|NCT00614523|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
219645534|NCT01249924|DEVICE|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
219645535|NCT01249924|DEVICE|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
219645536|NCT00776113|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
219645537|NCT03635905|DRUG|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
219645538|NCT03635905|DRUG|Placebo|Methylcellulose placebo capsule
219645539|NCT06342219|BEHAVIORAL|Neurofeedback Mindfulness|The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.
219645540|NCT06342219|BEHAVIORAL|Attention Task|The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
219645541|NCT02000336|DRUG|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
219645542|NCT02000336|DRUG|Placebo|
219645543|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
218960541|NCT04798495|OTHER|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
218960542|NCT02092272|BEHAVIORAL|instructional exercise video source|instructional exercise video source
218960543|NCT00596856|BEHAVIORAL|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
218960544|NCT01702831|DRUG|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
218960545|NCT01702831|DRUG|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
219686237|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
218960546|NCT01702831|DRUG|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
218960547|NCT01998815|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass surgery|
219061251|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
219061252|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
219686238|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
219686239|NCT04504110|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
219686240|NCT02590991|OTHER|Prebiotics|To study the long term effect of supplementation in early life
219686241|NCT02590991|OTHER|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
219686242|NCT01836562|BIOLOGICAL|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
219686243|NCT00128661|BIOLOGICAL|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
219686244|NCT00128661|BIOLOGICAL|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
219645544|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
219645545|NCT05565001|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
219645546|NCT03310801|PROCEDURE|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
219645547|NCT04220749|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
219645548|NCT04220749|PROCEDURE|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
219645549|NCT02130804|DRUG|Salsalate (4 g/day)|Given orally twice daily
219645550|NCT02130804|DRUG|Placebo (4 g/day)|Given orally twice daily
219645551|NCT03224416|OTHER|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
219645552|NCT03224416|OTHER|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
219645553|NCT03224416|OTHER|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
219645554|NCT05743101|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
219645555|NCT05743101|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
219645556|NCT02339350|DRUG|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
219645557|NCT02339350|DRUG|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
219645558|NCT05038501|OTHER|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
219645559|NCT00318500|DRUG|ERB-041|
219645560|NCT01084200|DRUG|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
219645561|NCT01084200|DRUG|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
218960548|NCT01460589|PROCEDURE|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
219061253|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
219645562|NCT01084200|DRUG|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
219061254|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
219061255|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
219061256|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
219645563|NCT06623175|DEVICE|Acupuncture needles|See arm description
219645564|NCT05514587|BEHAVIORAL|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
219645565|NCT06428552|DEVICE|Mobile Application|Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
219645566|NCT03966924|DEVICE|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
219645567|NCT05887570|BEHAVIORAL|Educational intervention|intervention through extra education, modules, instruction on models
219645568|NCT05887570|OTHER|Control - Regular Instruction|participants receive usual training
219645569|NCT05603195|DRUG|REGN7508 (IV)|Administered sequential, ascending single intravenous (IV) dose
219645570|NCT05603195|DRUG|REGN7508 (SC)|Administered sequential, ascending single subcutaneous (SC) dose
219645571|NCT05603195|DRUG|Matching Placebo (IV)|Administered sequential, ascending single intravenous (IV) dose
219645572|NCT05603195|DRUG|Matching Placebo (SC)|Administered sequential, ascending single subcutaneous (SC) dose
218960549|NCT00884377|DRUG|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
218960550|NCT00884377|DEVICE|ThermoMed|ThermoMed heat treatment device, one treatment
218960551|NCT03768973|PROCEDURE|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
218960552|NCT01070758|DRUG|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
219645573|NCT04184362|DEVICE|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
219645574|NCT05115422|BEHAVIORAL|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
219645575|NCT05630521|BEHAVIORAL|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
219645576|NCT01300338|DEVICE|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
219645577|NCT01300338|DEVICE|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
219645578|NCT04001894|DRUG|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
219645579|NCT04001894|DRUG|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
219645580|NCT04888429|DRUG|Camrelizumab|Patients received camrelizumab 200 mg every 3 weeks
219645581|NCT04888429|DRUG|Famitinib|Patients received Famitinib 20 mg once per day
219645582|NCT05856994|DRUG|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
219645583|NCT01506765|DRUG|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
219645584|NCT05031650|PROCEDURE|openCPAP|Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
219645585|NCT05031650|PROCEDURE|standardCPAP|Randomized to : Standard level CPAP between 6-8 cmH2O pressure
219645586|NCT06621134|OTHER|AI Chatbot|Participants will be required to provide consent for randomization when they first access our system. Users can ask questions covered by the question bank, as well as specific questions not covered by the bank, through an AI chatbox. The aim is to understand the significant difference between using AI chatbots and telephone hotlines to assist parents, as well as the effectiveness of AI chatbots compared to telephone hotlines.
219645587|NCT06621134|OTHER|Telephone hotline|Participants will be asked to consent to randomization on their first access to our system. Users ask questions covered by the question bank and specific questions not covered by the question through a telephone hotline.
219645588|NCT04694950|PROCEDURE|Usual care|Intravenous morphine according to clinician´s discretion.
219645589|NCT02461524|DEVICE|Endurant Evo AAA Stent Graft System|
219645590|NCT02461524|PROCEDURE|Endovascular aneurysm repair (EVAR)|
219645591|NCT02071862|DRUG|CB-839|CB-839 monotherapy
219645592|NCT02071862|DRUG|Pac-CB|CB-839 in combination with standard dose paclitaxel
218960553|NCT01887340|DRUG|Carboplatin|"\- carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)"
218960554|NCT01887340|DRUG|Etoposide|100 mg/m2 D1 to D5
218960555|NCT01887340|DRUG|Cisplatin|20 mg/m2 de D1 to D5
218960556|NCT03613480|OTHER|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
218960557|NCT01135823|PROCEDURE|Patient survey|
218960558|NCT03939156|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
219645593|NCT02071862|DRUG|CBE|CB-839 in combination with standard dose everolimus
219645594|NCT02071862|DRUG|CB-Erl|CB-839 in combination with standard dose erlotnib
219645595|NCT02071862|DRUG|CBD|CB-839 in combination with standard dose docetaxel
218960559|NCT02003365|DRUG|FX006 10 mg|Extended-release formulation
218960560|NCT02003365|DRUG|FX006 40 mg|Extended-release formulation
218960561|NCT02003365|DRUG|TCA IR 40 mg|Immediate-release formulation
218960562|NCT05199740|OTHER|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
218960563|NCT04908657|DRUG|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
218960564|NCT05787288|BIOLOGICAL|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
218960565|NCT03293797|BEHAVIORAL|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
219645596|NCT02071862|DRUG|CB-Cabo|CB-839 in combination with standard dose cabozantinib
218960566|NCT05859256|OTHER|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
218960567|NCT05859256|OTHER|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
219645597|NCT06597565|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.
219645598|NCT06597565|DRUG|ACR-368|ACR-368 is an experimental drug.
219645599|NCT01470781|BEHAVIORAL|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
219645600|NCT01470781|BEHAVIORAL|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
219645601|NCT00878150|BEHAVIORAL|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
218960568|NCT01834118|PROCEDURE|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
219645602|NCT00878150|BEHAVIORAL|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
219645603|NCT00765895|DRUG|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
219645604|NCT00765895|DRUG|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
219645605|NCT00478010|OTHER|counseling intervention|
219645606|NCT00478010|OTHER|study of socioeconomic and demographic variables|
218960569|NCT04064788|OTHER|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
219645607|NCT00478010|PROCEDURE|psychosocial assessment and care|
218960570|NCT04064788|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
219645608|NCT00478010|PROCEDURE|quality-of-life assessment|
219645609|NCT01171781|DRUG|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
218960571|NCT04064788|OTHER|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
218960572|NCT03152032|BEHAVIORAL|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
219645610|NCT01171781|DRUG|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
219645611|NCT06010238|DEVICE|Short term variation|Short term variation in computer software analysis
219645612|NCT06010238|DEVICE|Visual interpretation|Visual interpretation of cardiotocography
219645613|NCT03360006|DRUG|ABBV-744|Tablet, oral
219645614|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
219645615|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
219645616|NCT05885295|DIAGNOSTIC_TEST|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
219645617|NCT05817487|BEHAVIORAL|high-intensity interval training (HIIT)|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
219645618|NCT05817487|BEHAVIORAL|crossover point(COP) exercise training|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
219645619|NCT04055376|DEVICE|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
219645620|NCT04055376|DEVICE|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
219645621|NCT03272659|DRUG|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
219645622|NCT06485349|DIETARY_SUPPLEMENT|Olive Leaf Extract (OLE)|Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.
219645623|NCT06485349|OTHER|Placebo|100mg microcrystalline cellulose
219645624|NCT03706859|PROCEDURE|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
219645625|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
219645626|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
219645627|NCT02123615|DRUG|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
219645628|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
219645629|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
219645630|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
219645631|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
219645632|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
219645633|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
218960573|NCT04354961|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
218960574|NCT03829774|DEVICE|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
218960575|NCT03829774|DRUG|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
218960576|NCT02622334|DRUG|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
218960577|NCT02622334|DRUG|Placebo|Matching placebo formulation will be administered in Part A.
219645634|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
219645635|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
219645636|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
219645637|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
219645638|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
219645639|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
219645640|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
219645641|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
219645642|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
219645643|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
218960578|NCT02622334|DRUG|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
218960579|NCT01533129|DRUG|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
218960580|NCT01533129|DRUG|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
218960581|NCT00572143|OTHER|ca coli follow-up by GP|patients randomized to follow up by GP
218960582|NCT03249389|BIOLOGICAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
218960583|NCT03490162|DRUG|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
218960584|NCT03490162|OTHER|Placebo|Placebo
218960585|NCT06458426|DEVICE|shock-absorbing prosthesis|the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
218960586|NCT04232306|DRUG|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
218960587|NCT04232306|DRUG|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
218960588|NCT03729687|COMBINATION_PRODUCT|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
218960589|NCT01459848|BEHAVIORAL|block play|30 minutes of block play
218960590|NCT01459848|BEHAVIORAL|baby dvd|30 minutes of dvd viewing
218960591|NCT00057122|DRUG|Isoniazid|300mg
219061257|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
219645644|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
219061258|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
219061259|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
219061260|NCT02073968|DRUG|Carboplatin|Given IV
219645645|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
219645646|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
219645647|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
219645648|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
218960592|NCT00057122|DRUG|Rifapentine|Rifapentine 900 mg
218960593|NCT00057122|DRUG|Rifampin|Rifampin 600 mg
218960594|NCT06281301|OTHER|education tool|Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.
218960595|NCT06281301|OTHER|no additional information|Survey will be administered without reviewing the single sided card
218960596|NCT05275660|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
218960597|NCT05275660|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
218960598|NCT00566644|DEVICE|levonorgestrel-releasing intrauterine system|
218960599|NCT00566644|OTHER|questionnaire administration|
218960600|NCT00566644|PROCEDURE|observation|
218960601|NCT03735173|PROCEDURE|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
218960602|NCT03735173|PROCEDURE|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
218960603|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
218960604|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
218960605|NCT04985188|DIAGNOSTIC_TEST|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
219061261|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
219061262|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
219061263|NCT02073968|DRUG|Paclitaxel|Given IV
219645649|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
219645650|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
219645651|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
219645652|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
219645653|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
219645654|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
219645655|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
219645656|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
219645657|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
219645658|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
219645659|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
219645660|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
219645661|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
219645662|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
219645663|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
219645664|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
219645665|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
218960606|NCT00321724|DRUG|cediranib maleate|Given orally
218960607|NCT00321724|OTHER|laboratory biomarker analysis|Correlative studies
218960608|NCT05969327|DRUG|Vitamin D|oral supplementation of two different doses
219645666|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
219645667|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
219645668|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
219645669|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
219645670|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
219645671|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
219645672|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
219645673|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
219645674|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
219645675|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
219645676|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
219645677|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
219645678|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
219645679|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
219645680|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
219645681|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
218960609|NCT05637658|OTHER|Exercise|aerobic exercise
218960610|NCT03150485|DEVICE|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
218960611|NCT02097537|DRUG|Methacholine Chloride (SK-1211)|
218960612|NCT02779712|PROCEDURE|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
219645682|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
219645683|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
219645684|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
219645685|NCT02085616|BEHAVIORAL|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
219645686|NCT02085616|BEHAVIORAL|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
219645687|NCT00672386|DRUG|JNJ16269110|5 mg twice daily for 12 weeks
219645688|NCT00672386|DRUG|JNJ16269110|10 mg twice daily for 12 weeks
219645689|NCT00672386|DRUG|JNJ16269110|15 mg twice daily for 12 weeks
219645690|NCT00672386|DRUG|Placebo|twice daily for 12 weeks
219645691|NCT00672386|DRUG|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
218960613|NCT02779712|PROCEDURE|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
219645692|NCT00672386|OTHER|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
219645693|NCT04766957|DEVICE|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
219645694|NCT01389570|PROCEDURE|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
219645695|NCT01940315|BIOLOGICAL|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
219645696|NCT01940315|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
219645697|NCT00868491|DRUG|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
219645698|NCT00868491|RADIATION|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
219645699|NCT00868491|DRUG|cetuximab, cisplatin|"* cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
219645700|NCT05759429|OTHER|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
219645701|NCT05759429|OTHER|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
219645702|NCT03358589|DIAGNOSTIC_TEST|FDG-PET/CT|Scans
219645703|NCT02128425|DRUG|FOLFOXIRI|"irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients"
219645704|NCT02128425|DRUG|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
219645705|NCT03343717|OTHER|Rehabilitation|physical therapy exercise
219645706|NCT03343717|OTHER|Chest physical therapy|chest physical therapy exercise
219645707|NCT04458025|OTHER|Standard rehabilitation program|Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
219645708|NCT04458025|OTHER|Early rehabilitation program|Early rehabilitation program will start 2 weeks
219645709|NCT00492596|DEVICE|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
219645710|NCT00492596|PROCEDURE|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
219645711|NCT05961410|DRUG|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
219645712|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
219645713|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
219645714|NCT02062710|DRUG|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
219645715|NCT02062710|DRUG|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
219645716|NCT02062710|DRUG|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
219645717|NCT02062710|DRUG|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
219645718|NCT04481191|BIOLOGICAL|RotaTeq (V260)|Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
219645719|NCT04481191|BIOLOGICAL|IPV|0.5 mL dose IPV (Sabin strain based), administered via IM injection
219645720|NCT05754580|RADIATION|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
219645721|NCT05754580|RADIATION|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
219645722|NCT01950104|OTHER|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
219645723|NCT01950104|OTHER|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
219645724|NCT00297531|DEVICE|PerioWave|
219645725|NCT00297531|PROCEDURE|Scaling and Root Planing|
219645726|NCT04955665|PROCEDURE|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
219645727|NCT04955665|PROCEDURE|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
219645728|NCT01702194|DRUG|TD-1211 IV [C14]|
219645729|NCT01702194|DRUG|TD-1211 PO [C14]|
219645730|NCT03091881|DRUG|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
219645731|NCT03091881|DRUG|Placebos|Placebos will be given 10 min before spinal block
219645732|NCT04376086|PROCEDURE|Epidural anesthesia|Segmental epidural analgesia
219645733|NCT04376086|PROCEDURE|general anesthesia|general anesthesia
218960614|NCT04019418|DIETARY_SUPPLEMENT|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
219645734|NCT03048123|PROCEDURE|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
219645735|NCT03048123|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
219645736|NCT03048123|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
218960615|NCT04019418|OTHER|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
218960616|NCT04019418|OTHER|Rest|30 minutes laying on a bed
218960617|NCT04019418|OTHER|Water|A drink containing 300ml of water
218960618|NCT02857361|DRUG|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
219645737|NCT03048123|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
219645738|NCT01670734|DRUG|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
219645739|NCT00996411|DRUG|Salvinorin A|This is an initial dose ranging study
218960619|NCT00957385|DRUG|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
218960620|NCT03269461|DEVICE|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
218960621|NCT03887403|BEHAVIORAL|Multimodal Intervention|
218960622|NCT03887403|OTHER|Usual care|
218960623|NCT00255801|DRUG|Targretin® (bexarotene)|
218960624|NCT00255801|DRUG|pegylated liposomal doxorubicin hydrochloride|
218960625|NCT01836224|DRUG|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
218960626|NCT01836224|DRUG|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
218960627|NCT00130273|BEHAVIORAL|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
218960628|NCT00130273|BEHAVIORAL|Standard care|Participants will receive standard of care for 12 months.
219645740|NCT02487771|DRUG|DHA|600 mg DHA capsule
218960629|NCT01394718|DRUG|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
218960630|NCT01394718|OTHER|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
218960631|NCT02642874|DRUG|Methocarbamol|Methocarbamol twice daily
218960632|NCT02642874|DRUG|Calcium Carbonate|Calcium carbonate twice daily
218960633|NCT05625620|DEVICE|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
218960634|NCT05625620|DEVICE|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
218960635|NCT00344240|BEHAVIORAL|Functional circuit training with lifestyle behavior|
218960636|NCT03593434|DRUG|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
218960637|NCT01452009|DRUG|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
218960638|NCT01452009|DRUG|TRAVATAN®|TRAVATAN® administered one drop once daily
218960639|NCT06325904|PROCEDURE|Uniportal VATS|"* single port video-assisted thoracoscopic surgery in the 5th intercostal space~* performed under general anesthesia.~* pleural fluid/pus was drained~* pleural adhesions was removed"
218960640|NCT06325904|PROCEDURE|Tube thoracostomy|"* Chest tube is inserted in 5th mid-axillary line~* performed under local anaesthesia"
219645741|NCT02487771|DRUG|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
219645742|NCT02043951|DEVICE|Lutonix Drug Coated Balloon Catheter|
219645743|NCT02002533|BEHAVIORAL|Brief Behavioral Therapy|Undergo BBT intervention
219645744|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo BBT intervention
219645745|NCT02002533|OTHER|Educational Intervention|Undergo HEAL
218960641|NCT04620395|DIAGNOSTIC_TEST|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
218960642|NCT05277961|RADIATION|Ultraviolet radiation|UV6 tubes
218960643|NCT01889940|BEHAVIORAL|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
218960644|NCT04078178|DIETARY_SUPPLEMENT|Niagen|Nicotinamide Riboside
218960645|NCT04078178|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo
218960646|NCT05957055|BEHAVIORAL|parental training in behavior management|Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.
218960647|NCT05957055|DRUG|Lisdexamfetamine|Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
218960648|NCT05957055|DRUG|Methylphenidate|Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
218960649|NCT06210282|DIAGNOSTIC_TEST|Focused lung ultrasound (FLUS)|We will use a 14-zone scanning approach. Each hemithorax is divided into anterior, lateral, and posterior surfaces. The anterior and lateral surfaces on each hemithorax are divided into an upper and lower quadrant. The posterior surfaces on each hemithorax are divided into an upper, middle, and lower quadrant. Each quadrant represents a scanning zone. Each scanning zone should be assessed using FLUS. The participating general practitioners use point-of-care ultrasound on a weekly basis before trial commencement and will use the ultrasonography device already available to them.
219645746|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo HEAL
219645747|NCT00451295|DRUG|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
219645748|NCT00451295|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
219645749|NCT00241124|DRUG|valsartan|
219645750|NCT00241124|DRUG|lisinopril|
218960650|NCT06210282|OTHER|Usual Care|Participants assigned to the control group will receive the GP's usual care of adults (≥ 18 years) presenting with symptoms of an acute LRTI where the GP suspects CAP. Usual care will be used as a pragmatic comparator to reflect the current standard examinations and care of these patients in general practices in Denmark. Usual care is recommended to follow applicable guidelines from the Danish Society of General Practitioners (DSAM) and Lægehåndbogen \[The Doctor's Handbook\].
218985205|NCT03355365|BIOLOGICAL|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
218985206|NCT03355365|OTHER|Intrathecal saline injection|Placebo
218985207|NCT06961214|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
218985208|NCT06961214|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered
219061264|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
219645751|NCT02351908|DRUG|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
219645752|NCT02351908|DRUG|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
219645753|NCT02351908|DRUG|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
219645754|NCT04319081|DRUG|PCSK9 inhibitor|Patients are included after PCSK9 inhibitors prescription , at the first dispensation
219645755|NCT03710070|DEVICE|Amplatzer vascular plug 4|See above
219645756|NCT03710070|OTHER|Sham Control|Angiography of the IMA without occlusion
219645757|NCT02362776|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
219645758|NCT05984264|DRUG|lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
219645759|NCT02312453|PROCEDURE|Posterior approach|We adopted the technique as described by Hebbard et al.
219645760|NCT04574934|OTHER|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
219645761|NCT00101036|DRUG|lapatinib ditosylate|Given PO
219645762|NCT00101036|OTHER|laboratory biomarker analysis|Correlative studies
219645763|NCT06017817|DEVICE|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
219061265|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219061266|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
219061267|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
219061268|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
219061269|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
219061270|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
219061271|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
219061272|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
219061273|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
219061274|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
219061275|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
219061276|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
219645764|NCT06017817|PROCEDURE|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
219645765|NCT06017817|PROCEDURE|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
219645766|NCT06017817|PROCEDURE|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
219645767|NCT04761549|PROCEDURE|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
219645768|NCT02823392|OTHER|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 \< 95%).
219645769|NCT03675295|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
219645770|NCT03675295|DRUG|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
219645771|NCT06667895|OTHER|respiratory gated taVNS|Electrical stimulation will be delivered in bursts during expiration
219645772|NCT06667895|OTHER|random burst stimulation|Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle
219645773|NCT06667895|OTHER|continuous stimulation|Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.
219645774|NCT06667895|OTHER|Sham stimulation|Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
219061277|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
219061278|NCT01384539|DRUG|Cholecalciferol|
219061279|NCT01384539|DRUG|Calcitriol|
219061280|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
219061281|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
219061282|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
219061283|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
219061284|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
219061285|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
219061286|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
219061287|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
219061288|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
219061289|NCT05831852|OTHER|no intervention|no intervention
219061290|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
219061291|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
219061292|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
219061293|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
219645775|NCT01539395|OTHER|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
219645776|NCT00722566|DRUG|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
219645777|NCT00722566|DRUG|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
219645778|NCT04621526|DRUG|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
219645779|NCT04621526|DRUG|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
219645780|NCT06619145|DRUG|Low dose Oliceridine|Low dose Oliceridine
219645781|NCT06619145|DRUG|High dose Oliceridine|High dose Oliceridine
219645782|NCT06649188|DEVICE|Magnesium Sulphate Iontophoresis|"Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity."
219645783|NCT06649188|OTHER|traditional physical therapy program|Deep friction massage, stretching and pressure therapy.
219645784|NCT04533243|DRUG|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
219645785|NCT04533243|DRUG|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
219645786|NCT03863704|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
219645787|NCT05136144|DRUG|SM-020|Topical Akt Inhibitor SM-020 Gel
219645788|NCT03469180|OTHER|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
219645789|NCT03469180|OTHER|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
219645790|NCT01570569|DRUG|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
219645791|NCT01570569|DRUG|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
219645792|NCT01570569|DRUG|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
219645793|NCT01570569|DRUG|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
219645794|NCT01570569|DRUG|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
219645795|NCT01570569|DRUG|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
219645796|NCT04875026|DRUG|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
219645797|NCT04875026|DEVICE|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
219645798|NCT04076423|DRUG|Dual Therapy|DTG + 3TC
219645799|NCT04076423|DRUG|Triple therapy|BIC / FTC / TAF
218985209|NCT04121923|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
219645800|NCT01859052|OTHER|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
219645801|NCT01859052|OTHER|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
219645802|NCT01859052|OTHER|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
219645803|NCT00854919|DRUG|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
219645804|NCT00854919|BEHAVIORAL|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
219645805|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
219645806|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
219645807|NCT00340106|BEHAVIORAL|Counseling|
219645808|NCT03504306|OTHER|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
219645809|NCT05967923|RADIATION|Shock wave therapy|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
219645810|NCT05967923|RADIATION|Low level lazer therapy|Patients in this group will receive low level lazer therapy three times a week week for four weeks in addition to routine physical therapy program.
219645811|NCT05967923|OTHER|Routine physical therapy program|Patients in this group will receive only routine physical therapy program three times a week for four weeks.
219645812|NCT06730737|OTHER|Video preventive education|Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
219645813|NCT04885400|BEHAVIORAL|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
219645814|NCT04984278|DRUG|Nabiximols|oromucosal spray
219645815|NCT04984278|DRUG|Placebo|oromucosal spray
219645816|NCT06523543|PROCEDURE|Inclusion (Visit 1 - Week 7-16)|Extraction of cervico-vaginal sampling
219645817|NCT06523543|DIAGNOSTIC_TEST|Second semester of pregnancy (Visit 2 - Week 20-24)|Ultrasound examination (determination of chromosomal sex)
218960651|NCT05300152|PROCEDURE|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days \& subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
218960652|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Fibronectin Antibody|"1. Deparaffinization/Rehydration~   * Slides heated in an oven at 65C for 1 hour.~  * De-paraffinization~2. Antigen Retrieval~   * Immersion of slides into staining dish containing Antigen Retrieval Solution.~  * Placing the staining dish into rice cooker.~  * When turned to warm, unplug cooker~  * Allow to cool down for 20 min~3. Staining~   * Wash slides with TBST for 5 min on a shaker.~  * Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~  * Block slides with blocking solution for 1 hour.~  * Dilute primary antibody in blocking buffer~  * Apply primary antibody to each section and incubate overnight in humidified chamber~  * Wash slides three times with TBST"
218960653|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
218960654|NCT04617795|DEVICE|Omnipod 5 Automated Insulin Delivery System|"The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers."
218960655|NCT00472459|PROCEDURE|Photodynamic therapy with Metvix 160 mg/g cream|
218960656|NCT03442764|DRUG|mavacamten|MYK-461
218960657|NCT03442764|DRUG|Placebo|Placebo
218960658|NCT02746367|OTHER|Diagnostic test (LDT)|Proteomic assay
218960659|NCT03271229|BIOLOGICAL|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
218960660|NCT03271229|BIOLOGICAL|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
218985210|NCT03875365|PROCEDURE|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
218985211|NCT03258931|DRUG|Crenolanib|Crenolanib will be administered orally
218985212|NCT03258931|DRUG|Midostaurin|Midostaurin will be administered orally
218985213|NCT03258931|DRUG|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
219645818|NCT06523543|DIAGNOSTIC_TEST|Third semester of pregnancy (Visit 3- Week 34)|Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
219645819|NCT04305925|DEVICE|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
219645820|NCT05806996|DRUG|Magnesium|Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
218985214|NCT03258931|DRUG|Duanorubicin|90 mg/m2 IV
219645821|NCT05806996|DRUG|Placebo|Equivalent volume of normal saline
219645822|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
219645823|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
219645824|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
219645825|NCT03225755|DRUG|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
219645826|NCT03750513|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
219645827|NCT03750513|OTHER|Quality-of-Life Assessment|Ancillary studies
219645828|NCT03750513|OTHER|Questionnaire Administration|Ancillary studies
219645829|NCT06965556|OTHER|Medical Humanities-based Patient Education Strategy|Medical Humanities-based Patient Education with Comic-based Medical Education Materials for Breast Cancer Patients during Perioperative Hospitalization Stage
219645830|NCT04185428|BEHAVIORAL|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
219645831|NCT06183307|DIETARY_SUPPLEMENT|Nattokinase|Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months
219645832|NCT06183307|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.
219645833|NCT05195684|OTHER|imaginal probe|trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
219645834|NCT05675904|PROCEDURE|Colon oncological resection|Scheduled colon cancer surgery
219645835|NCT03697512|DRUG|Ibrutinib|capsules for oral intake in a dosage of 560 mg (four capsules) daily
219645836|NCT03697512|DRUG|Rituximab|Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.
219645837|NCT04512196|DRUG|Superoxidized Water|Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
219645838|NCT04512196|DRUG|Normal Saline|Normal saline contains 0.9% sodium chloride.
219645839|NCT03683927|COMBINATION_PRODUCT|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
219645840|NCT03683927|OTHER|Sterile water|The placebo group will receive sterile water 4 times a week
218960661|NCT06710964|OTHER|The Ten Item Personality Inventory|"The Ten Item Personality Inventory (TIPI) is a brief self-report measure of the Big Five personality dimensions, which will provide the mock basis for the self-dehumanization induction. Participants will indicate responses on 7-point Likert scale ranging from 1 (disagree strongly) to 7 (agree strongly).~Building off previously validated tasks participants will be told that the TIPI measure provided certain information about their personalities (and therefore expectations for their future). To establish credibility, participants will receive accurate feedback surrounding their reported levels of extraversion (high, medium, low). Participants will be randomly assigned to receive one of the following pre-written, feedback scripts as additional implications about their extraversion scores in relationship to future social expectations."
218960662|NCT06710964|OTHER|Mechanistic Self-Dehumanization Condition|"Future Mechanistic Self-Dehumanization Script: Based on your responses, you're the type who will feel at times that you're just a number in the system. The day-to-day pattern of going to work and fulfilling responsibilities will seem repetitive, like you are a mechanical device just going through the motions. You might find that relationships feel distant or lack the warmth you seek, making it challenging to form deeper connections. Over time, each day will blend into the next, which will likely lead to you operating on autopilot, existing among humans."
218985215|NCT01705730|DRUG|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
218985216|NCT05875428|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
218985217|NCT05344365|DRUG|Iloperidone|oral tablet
218985218|NCT04217330|BEHAVIORAL|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
218985219|NCT04217330|BEHAVIORAL|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
219645841|NCT00546065|DRUG|esomeprazole treatment|concomitant esomeprazole treatment
219645842|NCT01749709|BEHAVIORAL|Music listening|
219645843|NCT01749709|BEHAVIORAL|Audiobook listening|
219645844|NCT06967077|OTHER|Virtual reality head set.|Tennis game exercise using virtual reality head set
219645845|NCT06968858|DIAGNOSTIC_TEST|NIMBLE test|Non-invasive assessment of ISR with the NIMBLE System (Microwave Interferometry)
219645846|NCT05579197|DEVICE|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~* The Optogait system; for a markerless gait analysis;~* The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
219645847|NCT01482065|DEVICE|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI\> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
218985220|NCT01570088|DIETARY_SUPPLEMENT|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
218985221|NCT01570088|DIETARY_SUPPLEMENT|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
218985222|NCT01570088|OTHER|Placebo|Placebo contains no folic acids
218985223|NCT00705289|BIOLOGICAL|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
218985224|NCT04167982|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
218985225|NCT04167982|DRUG|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
218985226|NCT04167982|DRUG|Oral low-dose isotretinoin|low-dose isotretinoin
218985227|NCT02721160|OTHER|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
219645848|NCT05590416|DRUG|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
219645849|NCT04884113|DEVICE|Motorized Spiral enteroscopy|Small-bowel enteroscopy for diagnosis and intervention
219645850|NCT02942381|DRUG|Hydroxychloroquine Sulfate|200mg Bid (eGFR\>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
219645851|NCT02942381|DRUG|Placebo|
219645852|NCT04321369|DIAGNOSTIC_TEST|Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals|This is an operational project. Patients will collect a sample from the tongue, nasal cavity and MT and then clinicians will collect a NP sample from the nostril corresponding to each participant's dominant hand.
219645853|NCT06011395|DEVICE|Smartwatch|Activity tracker (step count, calories burned), heart rate monitor
219645854|NCT06011395|DEVICE|Imperial Healthy Hearts app|Digital cardiac rehabilitation smartphone application. Represents smart watch data and source of educational materials for cardiac rehabilitiation programme.
219645855|NCT05320783|OTHER|music|Classical music pre-selected was started to the patients with individual comfortable volume.
219645856|NCT05320783|OTHER|control|music player was not started.
218960663|NCT06710964|OTHER|Debrief|Debrief: Those in the self-dehumanized condition will receive a brief rehumanization intervention to undo the effects of the self-dehumanized condition. This intervention will involve a reminder that the condition was fabricated and will involve reading quotes involving general themes of humanness. The participants will then share with the experimenter how they connect to their humanness. The experimenter will document responses and encourage engagement in humanizing activities following the study visit. Findings from these qualitative responses will inform a rehumanization intervention in another study.
218960664|NCT06710964|OTHER|Control Condition|"Future Control Script: Based on your responses, you're the type who will have a very normal life. You will wake up, go to your job during the weekdays, and complete all necessary tasks. On the weekends you will spend time doing fulfilling activities. Relationships will have natural ups and down, but overall, you will feel satisfied by your connectedness to others. Though some days may feel monotonous, you will feel relaxed knowing you belong."
218960665|NCT06710964|DIAGNOSTIC_TEST|Clinical Interview|Clinical Interview. Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
218960666|NCT06710964|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
218960667|NCT06710964|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled Ethylenediaminetetraacetic Acid (EDTA) tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
218960668|NCT04916002|DRUG|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
219645857|NCT02158468|DEVICE|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
219645858|NCT02158468|DEVICE|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
219645859|NCT01337713|OTHER|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
219645860|NCT01337713|OTHER|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
219645861|NCT06147947|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG."
219645862|NCT01405417|PROCEDURE|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
219645863|NCT00000861|DRUG|Indinavir sulfate|
218960669|NCT04916002|DRUG|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
218960670|NCT06324708|DIAGNOSTIC_TEST|DXA|Patients will undergo a femoral and lumbar DXA
218960671|NCT02395016|DRUG|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
218960672|NCT02395016|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
218960673|NCT02395016|OTHER|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
218960674|NCT04094051|DRUG|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
218960675|NCT06168695|DEVICE|removable anterior expansion screw|"For the upper and lower arches, precise and profound alginate impressions were obtained and plaster study models were created. The removable appliance was constructed using acrylic resin with bilateral occlusal coverage for posterior teeth. The removable appliance was inserted in the patient's mouth and the patient was recalled after 24 hours to check the appliance fit.~Patient was recalled every four weeks until the dental cross-bite was corrected."
218960676|NCT06168695|DIAGNOSTIC_TEST|Speech and language evaluation|"speech evaluation was done by a Phoniatrician and all children were subjected to the Protocol of speech evaluation before expansion screw appliance insertion and after complete correction of anterior crossbite using an articulation test, intelligibility test, and spectrographic analysis.~* Articulation test: Five speech sounds were chosen to be studied /s/, /s /, /z/, /z/, /∫ /. The consonants were tested in the initial, medial, and final word positions.~* Speech intelligibility test : The general intelligibility score was calculated using Speech intelligibility in context: 5 -point scale:~* Spectrographic analysis: Using the computerized speech lab, the child was seated in an upright position \& allowed to talk freely \& repeated syllables were said to him/her."
218960677|NCT06168695|OTHER|Oral Health Related Quality of Life (OHRQoL) Assessment|The Child Perceptions Questionnaire (CPQ 8-10) in Brazilian version was used to gauge how the anterior cross bite affected the children's OHRQoL. It has twenty-five items total, broken down into four health domains (subscales): five questions each about oral symptoms (OS), five questions about functional limitations (FL), five questions about emotional wellbeing (EW), and ten questions about social well-being (SW). The responses never (0), once/twice (1), occasionally (2), often (3), and every day/almost every day (4) are provided for each question on an ordinal scale. The sum of the scores for all questions is used to calculate the scores for each subscale. The CPQ 8-10 was used to assess the OHRQoL before appliance insertion and after complete correction of anterior crossbite.
218960678|NCT02024282|DEVICE|Use of C-reactive protein (CRP) point of care test|
218960679|NCT02024282|OTHER|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
218960680|NCT02024282|DEVICE|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
218960681|NCT04551729|BEHAVIORAL|Lifestyle advice for liberal fluid intake|Lifestyle advice for liberal fluid intake for 3 months
218960682|NCT01547780|DRUG|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
218960683|NCT03038685|BEHAVIORAL|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
218985228|NCT04755790|DEVICE|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
219645864|NCT02860975|OTHER|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
219645865|NCT05204160|BIOLOGICAL|Pembrolizumab|Given IV
219645866|NCT03933644|DEVICE|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
219645867|NCT03933644|DEVICE|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
219645868|NCT02848365|DEVICE|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
218960684|NCT02195414|DEVICE|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
218960685|NCT01418560|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
218960686|NCT02140476|DEVICE|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
218960687|NCT02140476|PROCEDURE|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
218960688|NCT00814879|DRUG|Raltegravir|400 mg BID
218960689|NCT00814879|DRUG|Atazanavir|300 mg BID
218960690|NCT00814879|OTHER|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
218960691|NCT00463073|DRUG|Cetuximab|
218960692|NCT00463073|DRUG|Bevacizumab|
218960693|NCT00463073|DRUG|Irinotecan|
218960694|NCT04541251|DRUG|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
218960695|NCT04174014|PROCEDURE|Recruitment manoeuvre|PEEP increment and decrement
218960696|NCT05340647|PROCEDURE|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
218960697|NCT05340647|PROCEDURE|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
218960698|NCT05340647|PROCEDURE|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
218960699|NCT00647218|DRUG|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
218960700|NCT00647218|DRUG|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
218960701|NCT00647218|PROCEDURE|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
218960702|NCT00647218|RADIATION|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
218960703|NCT00647218|DRUG|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
218960704|NCT06142526|DEVICE|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
219645869|NCT03358771|OTHER|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
219645870|NCT03358771|OTHER|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
219645871|NCT02161484|PROCEDURE|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
219645872|NCT02161484|PROCEDURE|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
218960705|NCT00360152|PROCEDURE|Fine needle aspiration biopsy (FNAB)|
218960706|NCT00360152|PROCEDURE|Sentinel Lymph Node Biopsy|
218960707|NCT01461057|DRUG|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
218960708|NCT01461057|DRUG|Cisplatin|80 mg/m2 on Day 1 of each cycle
218960709|NCT01461057|DRUG|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
218960710|NCT01461057|DRUG|Pertuzumab|840 mg once every three weeks
218960711|NCT01461057|DRUG|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
218960712|NCT01908738|DRUG|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
218960713|NCT01908738|DRUG|10%lidocaine spray|
219645873|NCT02161484|DRUG|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
219645874|NCT02161484|DRUG|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
218960714|NCT01288976|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
218960715|NCT01288976|DRUG|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
218960716|NCT01288976|PROCEDURE|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
218960717|NCT03137576|PROCEDURE|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
218960718|NCT03137576|PROCEDURE|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
218960719|NCT02800954|BIOLOGICAL|blood samples|
218960720|NCT02800954|BIOLOGICAL|Bone marow samples|
218960721|NCT05249777|DRUG|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
218960722|NCT05249777|DRUG|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
218960723|NCT01867073|OTHER|Biomarker|
218960724|NCT01520831|DRUG|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
219645875|NCT02259192|DEVICE|MED-EL Maestro Cochlear Implant|cochlear implant
218960725|NCT01520831|DRUG|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
218960726|NCT01520831|DRUG|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
218960727|NCT01520831|DRUG|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
218960728|NCT06506071|DIAGNOSTIC_TEST|Spectral CT|Myocardial tissue characterization with Spectral CT
218960729|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
218960730|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
218960731|NCT01554631|DRUG|Acarbose (Glucobay ODT, BAYG5421)|
218960732|NCT01554631|DRUG|Acarbose (Glucobay, BAYG5421)|
218960733|NCT01276197|OTHER|Story-Telling DVD|DVD will contain both informational and story-telling components.
218960734|NCT01276197|OTHER|Non-Storytelling DVD|DVD will contain only informational component.
218960735|NCT02176824|BEHAVIORAL|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
219645876|NCT01054274|DEVICE|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
219645877|NCT01054274|DEVICE|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
218960736|NCT02176824|BEHAVIORAL|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
218960737|NCT02176824|OTHER|Treatment as usual|
218960738|NCT00558376|DRUG|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
218960739|NCT00558376|DRUG|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
218960740|NCT00171678|DRUG|Diclofenac Topical Sodium Gel 1%|
218960741|NCT01966692|DRUG|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
218960742|NCT01966692|DRUG|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
218960743|NCT01966692|DRUG|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
218960744|NCT01966692|DRUG|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation."
218960745|NCT01742676|DRUG|ADVAGRAF|oral
218960746|NCT01742676|DRUG|PROGRAF|oral
218960747|NCT00649311|DRUG|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
218960748|NCT00649311|DRUG|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
218960749|NCT05891964|DRUG|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
219645878|NCT01895270|DRUG|Isradipine|Isradipine extended release formulation
219645879|NCT01895270|DRUG|Placebo|Placebo will consist of microcrystalline cellulose.
219645880|NCT00657033|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
218960750|NCT00478881|DRUG|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
218960751|NCT00478881|DRUG|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
218960752|NCT05368272|OTHER|Processed electroencephalography|Acquisition of raw EEG data from processed EEG monitor. Analysis of data acquired for prespecified bandwidth properties
218960753|NCT05368272|OTHER|Postoperative delirium assessment|Twice daily assessment for the incidence of postoperative delirium using validated tool (questionnaire)
218960754|NCT04387760|DRUG|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
218960755|NCT04387760|DRUG|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
218960756|NCT04387760|OTHER|Routine care for COVID-19 patients|Supportive care according to local guidelines
218960757|NCT00737464|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
218960758|NCT02457273|DRUG|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
218960759|NCT04520893|PROCEDURE|ventilator setting vcv with pause|ventilator setting vcv with pause
218960760|NCT04520893|PROCEDURE|ventilator setting vcv|ventilator setting vcv without pause
218960761|NCT04520893|PROCEDURE|ventilator setting pcv-vg|ventilator setting with pcv-vg
218960762|NCT01487473|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
218960763|NCT02090868|OTHER|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
218960764|NCT05262725|BEHAVIORAL|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
218960765|NCT03261180|OTHER|Best Practice|Receive regular diet
218960766|NCT03261180|OTHER|Laboratory Biomarker Analysis|Correlative studies
218960767|NCT03261180|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive Nestle Impact AR
218960768|NCT04054063|DRUG|HSK3486+ etomidate|
218960769|NCT03022227|OTHER|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
218960770|NCT02834377|OTHER|Treatment algorithm targeting individual cardiac output|
219061294|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
219061295|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
218960771|NCT04505397|DRUG|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
218960772|NCT04505397|DRUG|Placebo|Sugar pill manufactured to mimic SKL24741
218960773|NCT00244166|DRUG|prednisolone|
219061296|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
219061297|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
218960774|NCT00872027|DRUG|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
218960775|NCT00872027|DRUG|Placebo|Placebo pills for 8 weeks
218960776|NCT06259201|DEVICE|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
218960777|NCT04733378|PROCEDURE|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
218960778|NCT03079180|OTHER|Strength training at 80% 1RM|Detailed in Arms section's
218960779|NCT03079180|OTHER|Strength training at 55% 1RM|Detailed in Arms section's
218960780|NCT04432337|PROCEDURE|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
218960781|NCT01046370|BEHAVIORAL|Amygdala Retraining Program|Mind-body intervention.
219061298|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
219061299|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
219061300|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
219061301|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
219061302|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
219645881|NCT00657033|DRUG|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
219645882|NCT04756193|DIAGNOSTIC_TEST|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
219645883|NCT04236661|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
218960782|NCT00193388|DRUG|Topotecan|
218960783|NCT02156531|BEHAVIORAL|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
218960784|NCT02156531|BEHAVIORAL|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
218960785|NCT00225303|DRUG|TMC125|
218960786|NCT05260970|PROCEDURE|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
218960787|NCT02188342|BEHAVIORAL|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
218960788|NCT05113342|DRUG|Descartes-25|allogeneic Mesenchymal Stem Cell product.
218960789|NCT06226467|BEHAVIORAL|Neurobehavioral Affective Control Training|"The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control."
218960790|NCT04110262|OTHER|High dietary sodium intake|Fourteen day feeding period of high dietary sodium (3400 mg/day)
219061303|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
219061304|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
219061305|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
219061306|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
219061307|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
219645884|NCT06664905|OTHER|Resistance Exercise|10 Repetition Maximum (RM)
219645885|NCT06664905|OTHER|Placebo|No exercise
219645886|NCT05399862|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17648 probiotic|Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
219645887|NCT05399862|OTHER|Placebo|Placebo capsule with no microbial cell preparation
219645888|NCT04609774|OTHER|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
219645889|NCT04164173|DEVICE|EzPAP|Patient will receive 10 min EzPAP 4 times daily
219645890|NCT04164173|DEVICE|Metaneb|Patient will receive 10 min Metaneb 4 times daily
219645891|NCT04164173|DEVICE|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
219645892|NCT03822663|DIETARY_SUPPLEMENT|Caffeine supplementation|The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
219645893|NCT03822663|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
219645894|NCT05926973|OTHER|Enhanced cardiac arrest bundle|"* Delivering shocks with the LUCAS mechanical CPR device running~* After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~* Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator."
218960791|NCT04110262|OTHER|Low dietary sodium intake|Fourteen day feeding period of low dietary sodium (2300 mg/day)
218960792|NCT05410392|BEHAVIORAL|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
218960793|NCT05410392|BEHAVIORAL|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
218960794|NCT05410392|BEHAVIORAL|Health education|Provision of general information about a variety of topics
218960795|NCT05837819|DEVICE|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
218960796|NCT05837819|DEVICE|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
218960797|NCT05086939|DRUG|Autologous MSCs|Intra-articular injection 40 million/4 ml.
218960798|NCT05086939|DRUG|Allogenic MSCs|Intra-articular injection 40 million/4 ml.
218960799|NCT05086939|DRUG|Hyaluronic Acid|Intra-articular injection 60mg / 3 ml .
218960800|NCT03410823|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
218960801|NCT03410823|DIETARY_SUPPLEMENT|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
218960802|NCT03410823|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
218960803|NCT05249192|DEVICE|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
218960804|NCT05249192|DEVICE|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
218960805|NCT03988543|BEHAVIORAL|Patient Self-management|Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
218960806|NCT05725096|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies according to CCTA results
218960807|NCT05725096|OTHER|Traditional cardiovascular risk stratification|Intervention strategies according to traditional cardiovascular risk stratification based on Chinese guidelines for lipid management (2023)
218960808|NCT06449963|BEHAVIORAL|Health Belief Model Education|"Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress."
218960809|NCT03569293|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
218960810|NCT03569293|DRUG|Upadacitinib|Tablets taken orally once a day
218960811|NCT05803603|BEHAVIORAL|Stipend and Social Work Supports|Same as arm description
219645895|NCT02103192|OTHER|Anti-Oxidant Drink|
219645896|NCT04685772|DRUG|Methylprednisolone|"The Methylprednisolone dose pack (Medrol Dose Pack) is pre-packaged with dosing instructions. This dose pack is tapered over 7 days and administration will be the following for all patients:~Day 1 (total 24 milligrams (mg)) - 8mg before breakfast, 4mg after lunch and dinner, and 8mg at bedtime Day 2 (total 20mg) - 4mg before breakfast, after lunch and dinner, and 8mg at bedtime Day 3 (total 16mg) - 4mg before breakfast, lunch, dinner, and at bedtime Day 4 (total 12mg) - 4mg before breakfast, after lunch, and at bedtime Day 5 (total 8mg) - 4mg before breakfast and at bedtime Day 6 (total 4mg) - 4mg before breakfast Day 7 (total 0mg) - Completed"
219645897|NCT05231746|BIOLOGICAL|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
219645898|NCT02651155|DRUG|Lubiprostone|Lubiprostone capsules
219645899|NCT02651155|DRUG|Placebo|Lubiprostone placebo-matching capsules
219645900|NCT01046058|DRUG|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
219645901|NCT03123835|PROCEDURE|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
219645902|NCT00976820|BIOLOGICAL|GSK2340274A|Two intramuscular injections
219061308|NCT01579344|DRUG|Radioiodine therapy|Radioiodine therapy with NaI131
219061309|NCT03758898|OTHER|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
219061310|NCT03758898|OTHER|Group 2|Only mobilization was applied twice a day, 8 times in total.
219061311|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
218960812|NCT05198609|PROCEDURE|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
219061312|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
219645903|NCT00976820|BIOLOGICAL|GSK2340273A|Two intramuscular injections
219645904|NCT06572748|OTHER|10-week programme|"1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments."
218960813|NCT05198609|DRUG|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
218960814|NCT05198609|DRUG|Apatinib|Apatinib was administered orally 250mg once per day
218960815|NCT05128929|DRUG|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
218960816|NCT05128929|DRUG|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
218960817|NCT06275490|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
218960818|NCT06275490|BIOLOGICAL|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
218960819|NCT02480907|BEHAVIORAL|Workshop Group|Workshop support group
218960820|NCT02480907|BEHAVIORAL|Internet-based support group|Internet based support group with E-mail coaching
218960821|NCT02742246|BEHAVIORAL|Individual clinician-provided CBT|Individual clinician-provided CBT
218960822|NCT02742246|BEHAVIORAL|CBT4CBT|CBT computer program assisted therapy
218960823|NCT00809029|OTHER|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
218960824|NCT04173208|OTHER|Fecal microbial transplant|Fecal microbial transplant
218960825|NCT04173208|OTHER|Placebo|Placebo
218960826|NCT05675605|DRUG|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
219061313|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
219061314|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
219061315|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
219061316|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
219061317|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
219061318|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
219061319|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
219645905|NCT02233296|DRUG|Lasmiditan|2 discrete doses separated by 6 days.
219645906|NCT03741751|DEVICE|rTMS|Participants will receive either active or sham bilateral rTMS over the dorsolateral prefrontal cortex (DLPFC) for 12.5 min per side.
219645907|NCT03741751|BEHAVIORAL|Computerized cognitive training|All participants will receive computerized cognitive training for 40 min after each rTMS session.
218960827|NCT06207578|PROCEDURE|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
218960828|NCT06207578|PROCEDURE|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
218960829|NCT00464243|DRUG|volinanserin|oral administration
218960830|NCT00464243|DRUG|placebo|oral administration
218960831|NCT06387537|PROCEDURE|Conventional physical therapy|Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.
218960832|NCT06387537|PROCEDURE|Scapular mobilization.|Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
218960833|NCT03081221|DIAGNOSTIC_TEST|USG|
219645908|NCT06110754|BEHAVIORAL|I-STRONG for SCD|I-STRONG for SCD is a group-based, multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training. The intervention includes 16 sessions that occur over 8 weeks. Adolescents attend every session and parents attend 6 of the 16 sessions.
219645909|NCT05377554|DRUG|Bevonescein|Bevonescein will be infused during the pre-operative period.
219645910|NCT05377554|OTHER|Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay|Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
219645911|NCT05377554|OTHER|Intra-operative Visualization using White Light Reflectance (WLR)|Intra-operative real time nerve visualization will be undertaken using WLR.
219645912|NCT01098500|DRUG|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
219686245|NCT01614015|BEHAVIORAL|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
218960834|NCT04338984|DRUG|General anesthetic|Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
218960835|NCT04338984|DRUG|Ropivacaine 0.5% Injectable Solution|"Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%."
218960836|NCT01695200|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
218960837|NCT06532799|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
218960838|NCT06532799|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
218960839|NCT06532799|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
218960840|NCT06532799|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
219061320|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
219207806|NCT06764914|OTHER|integrative and complementary medicine|Treatment with integrative and complementary methods for both, inpatients and outpatients, includes conventional therapy, integrative methods and ordinal therapy/MBM, which are individually designed for each patient. Similar to a shedule, with therapy units from the following areas: hydrotherapy/thermotherapy, exercise therapy, physiotherapy, nutritional therapy and bodywork therapy, supplemented as required by phytotherapeutic and other therapies, such as acupuncture, neural therapy and cupping. After inpatient treatment, patients can receive up to 10 additional outpatient treatments at our TCM outpatient clinic. There is also a 10-week programme for day patients. This focuses on ordinal therapy to achieve sustainable, balanced lifestyle changes. This includes classic acupuncture and drainage techniques such as Gua Sha (connective tissue massage in TCM) or cupping, as well as neural therapy, electro-acupuncture and others. Daily medical visits and self-care advice are also included.
218960841|NCT06532799|DRUG|Pembrolizumab|Intravenous (IV) infusion
218960842|NCT05997680|BEHAVIORAL|Parent-child yoga|The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
218960843|NCT05959746|OTHER|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
219207807|NCT05198297|DEVICE|Hydrus Microstent|Minimally invasive glaucoma surgery device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
219207808|NCT05198297|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
218960844|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
218960845|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
218960846|NCT04377490|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
218960847|NCT04377490|BIOLOGICAL|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
218960848|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
218960849|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
218960850|NCT05968508|DRUG|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
218960851|NCT05113394|DRUG|HDM sublingual Immunotherapy|HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
219645913|NCT01698242|BEHAVIORAL|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
219645914|NCT01698242|BEHAVIORAL|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
219645915|NCT02157649|DRUG|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
219645916|NCT02157649|DRUG|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
219645917|NCT02157649|DRUG|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
219645918|NCT04072393|PROCEDURE|Home-based cardiac rehabilitation|-Patients will be evaluated by the clinical team at The Heart Care Institute (HCI). They will receive a heart rate monitor, blood pressure monitor, and weight scale that they will take home with them. They will receive training on how to use the heart rate monitor and blood pressure monitor. They will receive training on how to record their exercises and weights in the teleHeart application by an exercise physiologist from HCI. Within 6 weeks of completion of standard of care radiation therapy or cytotoxic chemotherapy (whichever is last), they will be prescribed a course of home-based CR by a cardiologist at HCI and be instructed on the regimen by an exercise physiologist from HCI.
219645919|NCT06684795|DRUG|FG001 prior to surgery|Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
219645920|NCT03722758|DEVICE|Spectrum TPH3|tooth restoration with two different restorative materials
219645921|NCT03722758|DEVICE|Riva LC|tooth restoration with two different restorative materials
219645922|NCT03261674|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
219645923|NCT03261674|BEHAVIORAL|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
219645924|NCT03159234|RADIATION|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
218960852|NCT05113394|DRUG|Placebo|Placebo sublingual therapy
218960853|NCT03553836|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
218960854|NCT03553836|OTHER|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
219645925|NCT03159234|RADIATION|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
219645926|NCT03159234|RADIATION|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
219645927|NCT06411535|BEHAVIORAL|Full-mouth ultrasonic debridement plus Nutritional counseling|After diagnosis of gingivitis, patients will receive a nutritional counseling focused on ultra-processed foods entails educating individuals about the nutritional content and potential health implications of highly processed food products. They will undergo a session of full-mouth ultrasonic debridement and reinforcment of dietary counseling. Between consecutive time points, patients will receive motivational emails.
218960855|NCT06642935|DEVICE|Totally implantable cochlear Implant|Totally implantable cochlear Implant
219207809|NCT06773221|DRUG|Chiglitazar 64mg|Chiglitazar 64mg, oral, qd, for 72 weeks
219207810|NCT06773221|DRUG|Placebo|Placebo, oral, qd, for 72 weeks
218960856|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
218960857|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
218960858|NCT03220438|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
218960859|NCT04062123|DRUG|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
218960860|NCT04062123|DRUG|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
218960861|NCT04062123|DRUG|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
219645928|NCT06411535|OTHER|Full-mouth ultrasonic debridement|After diagnosis of gingivitis, patients will receive a session of full mouth ultrasonic debridement
219645929|NCT04158895|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219645930|NCT05500638|BEHAVIORAL|Virtual Reality|At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
219645931|NCT04126915|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
219645932|NCT00576160|BEHAVIORAL|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
219645933|NCT03285568|DRUG|Palbociclib|Observe patients receiving palbociclib for dose adjustment and lab monitoring
219645934|NCT05919225|PROCEDURE|Risk stratification before decision-making about patient hospitalization or discharge|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
219645935|NCT00623935|DRUG|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
218960862|NCT04062123|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
218960863|NCT04062123|DRUG|Placebo|Crystalloid IV solution will be infused, with no active drug.
218960864|NCT05737771|DRUG|DWC202213|DWC202213
218960865|NCT05737771|DRUG|DWJ1563|DWJ1563
219645936|NCT00623935|DRUG|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
219645937|NCT00623935|RADIATION|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
218960866|NCT05737771|DRUG|DWP16001|DWP16001
219645938|NCT00623935|PROCEDURE|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
219645939|NCT06665152|DEVICE|ProTaper File System|A rotary file system
219645940|NCT06665152|DEVICE|WaveOne File System|A reciprocating file system
219645941|NCT01571999|DRUG|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
219645942|NCT01571999|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
218960867|NCT05475340|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
218960868|NCT00000832|BIOLOGICAL|MF59|
218960869|NCT00000832|BIOLOGICAL|rgp120/HIV-1 SF-2|
219645943|NCT01665885|DEVICE|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
219645944|NCT01665885|DEVICE|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
219645945|NCT03986788|OTHER|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
219645946|NCT05036577|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
219645947|NCT05036577|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
219645948|NCT05036577|DRUG|Methotrexate (MTX)|high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
219645949|NCT05036577|DRUG|Dexamethasone|Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
219645950|NCT05342051|OTHER|balneotherapy|immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.
219645951|NCT05318248|DRUG|Clonidin|0,15mg Clonidin orally versus placebo pill
219645952|NCT05318248|DRUG|Placebo|placebo pill
219645953|NCT06685523|PROCEDURE|Subgingival debridement|To be applied 1 times (0. days)
219645954|NCT06685523|PROCEDURE|Er:YAG laser decontamination|To be applied 3 times
218960870|NCT01687621|PROCEDURE|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
218985229|NCT05459272|DIETARY_SUPPLEMENT|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
219645955|NCT06685523|PROCEDURE|Diyot laser decontamination|To be applied 3 times
219645956|NCT05069025|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
219645957|NCT05069025|OTHER|no-music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
219645958|NCT04878484|BIOLOGICAL|TCRT-ESO-A2|TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1.
219645959|NCT01354743|DRUG|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
219645960|NCT01354743|DEVICE|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
219645961|NCT02845960|BEHAVIORAL|rapid recovery|rapid recovery
219645962|NCT03718481|OTHER|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training \[1\]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
219645963|NCT03308591|DRUG|NACT|Platin based chemotherapy
219645964|NCT03308591|PROCEDURE|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
219645965|NCT03308591|DRUG|Adjuvant chemotherapy|Platin based chemotherapy
219645966|NCT02056457|BEHAVIORAL|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
219645967|NCT02056457|BEHAVIORAL|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
219645968|NCT00747474|DRUG|Lipotecan|Lipotecan IV day 1, 8, 15
219645969|NCT05170100|BEHAVIORAL|NUIG OAB App|An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
219645970|NCT00694252|DRUG|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
219645971|NCT04025411|DEVICE|Intensive Visual Simulation 3 (IVS3) device|"Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand."
219645972|NCT04025411|DEVICE|traditional Mirror Therapy (TM)|Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
219645973|NCT04025411|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
219645974|NCT04008771|DEVICE|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
219645975|NCT01814293|DEVICE|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
219645976|NCT01675570|DRUG|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
219645977|NCT01675570|DRUG|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
219645978|NCT00890084|DRUG|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
219645979|NCT04726644|PROCEDURE|hernia repair|different methods for hernia repair
218960871|NCT06479395|OTHER|Pediatric Endurance and Limb Strengthening (PEDALS) program|Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
218960872|NCT06479395|OTHER|Task-Oriented Training (TOT)|The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
218960873|NCT02017600|DRUG|ND-420|ND-420 50 mg/m2 on day1
218960874|NCT02017600|PROCEDURE|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
218960875|NCT02017600|DRUG|Cisplatin|cisplatin 70 mg/m2 on day1
218960876|NCT02017600|DRUG|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
218960877|NCT05944224|DRUG|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
218960878|NCT05944224|DRUG|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
218960879|NCT03976245|DRUG|Etanercept|injection
218960880|NCT03976245|DRUG|tofacitinib|tablet
218960881|NCT04482478|DIETARY_SUPPLEMENT|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
218960882|NCT04482478|OTHER|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
218960883|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
218960884|NCT01706692|BIOLOGICAL|Adalimumab|all dosages, frequencies and durations prescribed
218960885|NCT01706692|BIOLOGICAL|Etanercept|all dosages, frequencies and durations prescribed
218960886|NCT01706692|BIOLOGICAL|Infliximab|all dosages, frequencies and durations prescribed
218960887|NCT01706692|BIOLOGICAL|Ustekinumab|all dosages, frequencies and durations prescribed
218960888|NCT01706692|DRUG|Cyclosporine A|all dosages, frequencies and durations prescribed
218960889|NCT01706692|DRUG|Fumaric acids|all dosages, frequencies and durations prescribed
218960890|NCT01706692|DRUG|Methotrexate|all dosages, frequencies and durations prescribed
218960891|NCT01706692|DRUG|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
218985230|NCT05459272|OTHER|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
218985231|NCT02601027|PROCEDURE|Transversus Abdominis Plane (TAP) block|
219061321|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
219061322|NCT01736852|DEVICE|CRB|Labor induction using the CRB
219061323|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
219645980|NCT04306744|DEVICE|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
219061324|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
219061325|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
219645981|NCT04306744|DEVICE|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
219645982|NCT00619567|BEHAVIORAL|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
219645983|NCT05959096|DRUG|LY3437943|Administered SC
218960892|NCT05806775|BEHAVIORAL|Low-load resistance training with blood flow restriction|A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
218960893|NCT01554696|DRUG|peficitinib|oral
218960894|NCT01554696|DRUG|Placebo|oral
218960895|NCT01554696|DRUG|methotrexate|oral
218960896|NCT06546969|DRUG|Gemcitabine|1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
218960897|NCT06546969|DRUG|Cisplatin|25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
218960898|NCT06546969|DRUG|Durvalumab|1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
219061326|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
219645984|NCT05959096|DRUG|LY3437943|Administered IV
219645985|NCT01647516|DRUG|Ozanimod|Ozanimod capsules by mouth daily.
219645986|NCT01647516|DRUG|Placebo|
218960899|NCT06546969|RADIATION|Spatially Fractionated RT|Administered to 1 measurable lesion on cycle 2-day 1
219061327|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
219061328|NCT02235766|OTHER|Echocardiographic assessment|
219061329|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
219645987|NCT04028427|BEHAVIORAL|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston \& Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
219645988|NCT04028427|BEHAVIORAL|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
219645989|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
218960900|NCT06546969|DEVICE|Deep Hyperthermia|Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1
218960901|NCT05372536|OTHER|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
219645990|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
219645991|NCT03177031|DEVICE|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
219645992|NCT03177031|DEVICE|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
219645993|NCT02630329|PROCEDURE|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
219645994|NCT02630329|PROCEDURE|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
219645995|NCT01323595|DRUG|Celecoxib|Celecoxib 200mg PO BID x 6 days
219645996|NCT01323595|DRUG|Sugar Pill|Sugar pill PO BID x 6 days
218960902|NCT05843396|BEHAVIORAL|Neonatal Massage|caregivers providing therapeutic touch techniques on their neonate
218960903|NCT02397564|DEVICE|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
218960904|NCT06481176|BEHAVIORAL|12-Week RLS Exercise Program|"Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week"
218960905|NCT05676593|DEVICE|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
218960906|NCT05676593|OTHER|Therapeutic education|Therapeutic education
218960907|NCT00075439|DRUG|gefitinib|Given orally
218960908|NCT00075439|OTHER|laboratory biomarker analysis|Correlative studies
218960909|NCT03584373|DRUG|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
218960910|NCT03584373|DRUG|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
218960911|NCT03584373|DRUG|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
218960912|NCT01487577|DRUG|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
218960913|NCT04618887|PROCEDURE|pallidotomy|deep brain nuclei lesion of GPi
218960914|NCT04618887|PROCEDURE|deep brain stimulation|deep brain stimulation of GPi
218985232|NCT02601027|DEVICE|Nimbus Infusion Pump IV Administration|
218985233|NCT02601027|DRUG|Bupivacaine infusion|
218985234|NCT02601027|DRUG|Acetominophen|
218985235|NCT02601027|DRUG|Hydromorphone|
218985236|NCT02601027|DRUG|Oxycodone|
218985237|NCT02601027|DRUG|Ondansetron|
218985238|NCT03532841|DRUG|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
218985239|NCT03532841|DRUG|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
218985240|NCT05490407|DRUG|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
218985241|NCT01744873|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
218985242|NCT01744873|DRUG|Bisoprolol|10 mg tablet once a day
218985243|NCT00495365|DRUG|Epoetin alfa|
219645997|NCT03592537|DRUG|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
219645998|NCT03592537|DRUG|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
219645999|NCT03592537|DRUG|Bupivacaine Hydrochloride|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
219646000|NCT06277635|DRUG|Silymarin|Silymarin is randomly assigned to the participants for 12 weeks during study.
219646001|NCT06277635|DRUG|Placebo|Placebo is randomly assigned to the participants for 12 weeks during study.
219646002|NCT00482404|BEHAVIORAL|Romantic kissing|
219646003|NCT01760486|BEHAVIORAL|Shape Up Rhode Island|
219646004|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Professional Coach + Incentives|
218960915|NCT00634270|DRUG|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
218960916|NCT06289621|BEHAVIORAL|False Safety Behavioral Elimination Treatment (FSET)|5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
218960917|NCT06289621|BEHAVIORAL|Enhanced Standard Care|Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
218960918|NCT01415193|PROCEDURE|Selective Tibial Nerve block|Use of selective pain block.
218960919|NCT01415193|PROCEDURE|Sciatic Nerve Block|Use of Sciatic Nerve Block
218960920|NCT00805376|DRUG|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
218960921|NCT00805376|PROCEDURE|Tumor Removal|Surgical Tumor Resection
218960922|NCT00673270|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
218960923|NCT00673270|DRUG|Hydrocortisone|50 mg of intravenous hydrocortisone
218960924|NCT00673270|DRUG|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
218960925|NCT00673270|DRUG|Placebo of Hydrocortisone|2 ml of isotonic saline solution
218960926|NCT05476484|DRUG|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
218960927|NCT04903379|OTHER|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
218960928|NCT05765227|DEVICE|Lehfilcon A multifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
218960929|NCT05765227|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
218960930|NCT05765227|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
218960931|NCT00662532|DRUG|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
219646005|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Peer Coach + Incentives|
218960932|NCT02280083|DRUG|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
218960933|NCT02280083|DRUG|placebo|placebo
218960934|NCT04999774|DIAGNOSTIC_TEST|Different diagnostic tests|Each SAC will be tested with all tests
218960935|NCT05314985|OTHER|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
218960936|NCT00367770|DRUG|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
218960937|NCT01595945|PROCEDURE|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
218960938|NCT01595945|BEHAVIORAL|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
218960939|NCT05338398|DEVICE|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
218960940|NCT05338398|DRUG|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
218960941|NCT00416897|DRUG|chemotherapy|
218960942|NCT00416897|DRUG|dexamethasone|
218960943|NCT00416897|PROCEDURE|plasmapheresis|
219061330|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
219061331|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
219646006|NCT02588716|DRUG|Terlipressin|Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
219646007|NCT02588716|DRUG|normal saline|Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
219646008|NCT05670041|BEHAVIORAL|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
219646009|NCT02331550|PROCEDURE|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
219646010|NCT02331550|PROCEDURE|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
219646011|NCT04671381|BEHAVIORAL|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
219646012|NCT04671381|DEVICE|Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation|Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.
219646013|NCT04671381|BEHAVIORAL|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
219646014|NCT04671381|DEVICE|Provision of Over-the-Counter Hearing Aids|Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
219646015|NCT06149650|DEVICE|Shockwave Medical IVL System|Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
219646016|NCT03193801|DEVICE|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
219646017|NCT00387140|DRUG|MK2295|
219646018|NCT00831974|DRUG|masitinib (AB1010)|3 mg/kg/day
219646019|NCT00831974|DRUG|masitinib (AB1010)|6 mg/kg/day
219646020|NCT03993574|OTHER|Self- management program|"The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks"
219646021|NCT03993574|OTHER|Standard care|"All stroke patients being discharged from the acute hospital receive the following care:~1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~2. A stroke clinic appointment that is set to occur 90-days post discharge.~3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~4. Information on local support groups.~5. Referrals to start physical, occupational or speech therapy, if recommended by their physician."
219646022|NCT01098201|DRUG|Certolizumab|Subcutaneous administration on a monthly basis for six months
219646023|NCT02350686|DRUG|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
219646024|NCT02350686|DRUG|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
218960944|NCT02771587|DIETARY_SUPPLEMENT|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
218960945|NCT02771587|DIETARY_SUPPLEMENT|Alcohol|Multiple oral dose of alcohol
219646025|NCT00874835|DEVICE|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
219646026|NCT05524896|DEVICE|ElucidVivo|Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
219646027|NCT06647719|OTHER|Educational Videos|Subjects in the experimental group will be provided with 3 links to videos to be watched after CTR surgery. These videos will be available through YouTube, Twitter, Facebook, Instagram, TikTok, or MyChart. Videos will be available to watch multiple times at the subjects choice.
219646028|NCT05123664|OTHER|Capsule|1 cap daily at same time of the day with or without food for 4 weeks
219646029|NCT02437500|BIOLOGICAL|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
219646030|NCT02209142|OTHER|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
219646031|NCT02209142|OTHER|psychometric data collection|
219646032|NCT04513080|BEHAVIORAL|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
219646033|NCT04513080|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
219646034|NCT04513080|BEHAVIORAL|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
219646035|NCT04513080|BEHAVIORAL|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
218960946|NCT02771587|DIETARY_SUPPLEMENT|Energy drink|Multiple oral dose of energy drink
218960947|NCT02771587|DIETARY_SUPPLEMENT|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
218960948|NCT01155479|DRUG|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
218960949|NCT01155479|DRUG|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
218960950|NCT01155479|DRUG|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
218960951|NCT01155479|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
218960952|NCT01155479|DRUG|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
218960953|NCT01155479|DRUG|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
218960954|NCT03018665|DRUG|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
218960955|NCT03018665|DRUG|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
218960956|NCT03018665|DRUG|Metformin|oral，0.85g，twice a day in three months
218960957|NCT04676555|DRUG|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
218960958|NCT04676555|DRUG|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
218960959|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
218960960|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
219646036|NCT04016922|OTHER|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
218960961|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
218960962|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
218960963|NCT01566760|DRUG|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
218960964|NCT01197443|BEHAVIORAL|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
218960965|NCT01197443|BEHAVIORAL|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
218960966|NCT02779387|DRUG|Goserelin Acetate|
218960967|NCT00095927|DRUG|Amifostine|Given subcutaneously
219646037|NCT05246059|OTHER|Olfactory Training|Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
219646038|NCT02584127|BEHAVIORAL|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
219646039|NCT02584127|BEHAVIORAL|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
219646040|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
219646041|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
219646042|NCT05484349|DRUG|Tizanidine Hydrochloride Placebo|Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
219646043|NCT04323306|DRUG|MMV688533|Investigational medicinal product
219646044|NCT01946893|BEHAVIORAL|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
218960968|NCT00095927|DRUG|Carboplatin|Given IV
218960969|NCT00095927|DRUG|Paclitaxel|Given IV
218960970|NCT00095927|RADIATION|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
218960971|NCT06356701|DIETARY_SUPPLEMENT|Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)|"Medication for Research :~* Spirulina Bifidobacterium Capsules~* Fish Oil Grape Seed Blueberry Soft Capsules;~* Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin)~  * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin)~ * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion"
219061332|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
218960972|NCT02910375|OTHER|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
219646045|NCT01946893|BEHAVIORAL|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
219646046|NCT00707278|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
219646047|NCT00707278|DRUG|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
219646048|NCT00707278|DRUG|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
219646049|NCT05129137|DRUG|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
219646050|NCT05129137|DRUG|paracetamol 500 mg X2|paracetamol 500 mg X2
219646051|NCT05129137|DRUG|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
219646052|NCT03367546|PROCEDURE|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
219646053|NCT01684982|DEVICE|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
219646054|NCT01684982|DEVICE|sirolimus eluting stent|control arm of a comparison between drug eluting stents
219646055|NCT04429204|PROCEDURE|Biospecimen Collection|Undergo collection of tissue
219646056|NCT04429204|PROCEDURE|Cryosurgery|Undergo cryoablation
219646057|NCT06621550|OTHER|High Intensity Interval Training|Participants will receive a single session of HIIT, which last for 19 minutes in duration. During the HIIT session, participants will complete 2 minutes stretching warm-up exercise, followed by a video of exercises which will be projected on the screen to facilitate the participants to follow. The exercise in the video involves various combinations of aerobic and core resistance exercise such as squat jump, jump lunge, push up, burpee, mountain climber etc. The exercise involved bodyweight or minimal basic equipment only, the workout to rest ratio is 45 secs: 15 secs. Participants' heart rate will be kept surveillance and to maintain their respective heart rate attained 85% of aged predicted maximal heart rate during the workout period.
219061333|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
219061334|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
219646058|NCT01104246|DRUG|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
219646059|NCT05093530|DRUG|Neumifil|Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
219061335|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
219061336|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
219646060|NCT05093530|DRUG|Placebo|Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
219646061|NCT03374930|PROCEDURE|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
219646062|NCT06648941|PROCEDURE|Muscle release|supraspinatus muscle release
219646063|NCT05877417|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
219646064|NCT05877417|DEVICE|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
219646065|NCT05877417|OTHER|Exercise|Participants will exercise
219646066|NCT06623916|DEVICE|Endometrial Cancer Survivors|strain sonoelastograghy method has not been studied before in endometrial cancer as a prognostic factor. we compared well known pathologic prognostic factors with elastographic methods.
219646067|NCT02317835|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
219646068|NCT06619548|OTHER|Auricular magnet with a magnetic strength of 1800 Gauss|Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.
219646069|NCT06619548|OTHER|Auricular magnet with no magnetic strength|Auricular magnets with no magnetic strength are used as placebo control.
219646070|NCT04979195|OTHER|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
218960973|NCT02910375|OTHER|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
219646071|NCT04979195|OTHER|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
219646072|NCT01894659|OTHER|24% oral sucrose|
219646073|NCT01894659|OTHER|30% oral glucose|
219646074|NCT05747898|PROCEDURE|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
219646075|NCT05747898|PROCEDURE|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
219646076|NCT01497964|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
219646077|NCT06027918|PROCEDURE|Infraclavicular brachial plexus block|In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
219646078|NCT00750139|DRUG|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
219646079|NCT00750139|DRUG|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
219646080|NCT00750139|DRUG|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
219646081|NCT00750139|DRUG|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
219646082|NCT00186836|BIOLOGICAL|Engerix-B and Twinrix|
219646083|NCT00429936|DRUG|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
218960974|NCT00955383|DRUG|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
218960975|NCT00955383|DRUG|Placebo|Matching placebo
218960976|NCT05673564|PROCEDURE|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
218960977|NCT06119022|PROCEDURE|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
218960978|NCT06119022|OTHER|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
218960979|NCT01216267|DRUG|Lansoprazole|lansoprazole 30 mg HS x 7 days
218960980|NCT01216267|DRUG|lansoprazole|lanzoprazole 30 mg HS for 7 days
218960981|NCT00998764|DRUG|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
219646084|NCT06287164|OTHER|Data collection|Data collection on heart failure therapy and follow up
219646085|NCT00002059|DRUG|Inosine pranobex|
219646086|NCT01375972|DRUG|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
219646087|NCT01375972|DRUG|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
219646088|NCT04535869|DRUG|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
218960982|NCT02103543|OTHER|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
218960983|NCT02103543|PROCEDURE|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
218960984|NCT02103543|DRUG|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
218960985|NCT03583242|DRUG|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
218960986|NCT03583242|DRUG|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
218960987|NCT03477929|DRUG|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
219646089|NCT03191461|DIAGNOSTIC_TEST|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
219646090|NCT01167933|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
219646091|NCT01259804|DIETARY_SUPPLEMENT|Peanut oral immunotherapy|Daily doses of peanut flour
219646092|NCT01886209|DRUG|Prednisone|
219646093|NCT01886209|DRUG|VX-509|
219646094|NCT01886209|DRUG|Methylprednisolone|
219646095|NCT03045432|OTHER|video-teaching|By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
219646096|NCT03045432|OTHER|oral-teaching|The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
219646097|NCT03045432|OTHER|regular rehabilitation program|Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
219646098|NCT04205331|DEVICE|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
219646099|NCT06522698|DEVICE|Smart Pill Bottle|Patients in the intervention group will have their opioid medication consumption monitored through a smart pill bottle that records medication usage and streamlines the data into an online platform accessible by the medical staff. This group will also fill out surveys delivered through the smart pill bottle's online platform.
219646100|NCT03641326|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
219646101|NCT03641326|DEVICE|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
218960988|NCT03477929|DRUG|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
218960989|NCT01633437|DRUG|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
218960990|NCT01633437|OTHER|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
218960991|NCT01360775|BEHAVIORAL|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
218960992|NCT02022774|DRUG|Fimasartan|Fimasartan 60 \~ 120 mg/po take one tablet once a day
218960993|NCT04761627|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
218960994|NCT04761627|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
218960995|NCT04626466|OTHER|Biological investigations|(complete blood count, platelet count, renal function evaluation)
218960996|NCT01214174|DRUG|IBI-10090|
218960997|NCT00005566|BEHAVIORAL|Desperation Scale|
218960998|NCT03689933|DEVICE|Root analog implant|a custom made root analogue implant made from milled titanium
218960999|NCT00458497|DEVICE|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
218961000|NCT00458497|DEVICE|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
218961001|NCT03588247|PROCEDURE|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
218961002|NCT05204875|RADIATION|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
218961003|NCT03551080|BIOLOGICAL|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
218961004|NCT03551080|BIOLOGICAL|Placebo|Saline administered intravenously
218961005|NCT03342300|DRUG|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
218961006|NCT03342300|DRUG|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
218961007|NCT02929784|DEVICE|Intervention|Device: neuroConn\_CE\_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
218961008|NCT02929784|DEVICE|Sham|no meaningful stimulation will be given.
218961009|NCT00689091|DEVICE|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
218961010|NCT00689091|DEVICE|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
218961011|NCT00521911|BEHAVIORAL|Cognitive Behavioural Therapy|
218961012|NCT01634178|DRUG|Apremilast|Tablet for oral administration
218961013|NCT02625883|OTHER|Interview|Interview by validated Quality-of-life-questionnaire
218961014|NCT00124397|DRUG|Atorvastatin|
218961015|NCT04628832|BEHAVIORAL|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
218961016|NCT04628832|BEHAVIORAL|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
218961017|NCT04628832|BEHAVIORAL|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
218961018|NCT02259790|DRUG|Telmisartan/amlodipine fixed-dose combination tablet|
218961019|NCT02259790|DRUG|Telmisartan|
218961020|NCT02259790|DRUG|Amlodipine|
218961021|NCT00290979|DRUG|insulin glulisine|
218961022|NCT05629104|OTHER|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
218961023|NCT00991952|DRUG|alvocidib|Given IV
219646102|NCT01529788|DRUG|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
218961024|NCT00991952|DRUG|irinotecan hydrochloride|Given IV
218961025|NCT00991952|OTHER|laboratory biomarker analysis|Correlative studies
218961026|NCT01704898|DRUG|Efavirenz 600 Test-Stocrin 600 Reference|
218961027|NCT01704898|DRUG|Stocrin 600 Reference-Efavirenz 600 Test|
218961028|NCT06331676|PROCEDURE|Tissue collection|Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
218961029|NCT06331676|OTHER|Data collection|Questionnaire on menstrual health and history of hormone treatments for the research purpose
218961030|NCT05502640|OTHER|Education model|Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
218961031|NCT05502640|OTHER|Routine Education model|In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
218961032|NCT00021671|DRUG|Erythromycin|
218961033|NCT00021671|DRUG|Nevirapine|
219061337|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
219061338|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
219061339|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
219061340|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
219061341|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
219061342|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
219207811|NCT06779253|DRUG|pimicotinib capsules|the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration
219646103|NCT01529788|DRUG|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
219646104|NCT01872065|DRUG|ARC-520|
219646105|NCT01872065|DRUG|Placebo|
219646106|NCT01017523|BEHAVIORAL|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
218961034|NCT00021671|DRUG|Ampicillin sodium|
218961035|NCT00021671|DRUG|Metronidazole|
218961036|NCT02240147|BEHAVIORAL|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
218961037|NCT01740843|DEVICE|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
218961038|NCT05920902|OTHER|routine therapy of acute ischemia stroke|Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
218961039|NCT03742440|BIOLOGICAL|GrafixPL PRIME|GrafixPL PRIME
218961040|NCT00597337|BEHAVIORAL|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
218961041|NCT01168960|BEHAVIORAL|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
218961042|NCT05479773|DEVICE|Standard NIV mask|The hospital standered NIV mask
218961043|NCT05479773|DEVICE|Lumena NIV mask|aerosol-reducing mask
218961044|NCT02416310|DEVICE|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
218961045|NCT00350454|DEVICE|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
218961046|NCT00350454|DEVICE|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
219061343|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
219061344|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
219646107|NCT01017523|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
219646108|NCT02211482|DRUG|dolutegravir, lamivudine|single arm
219646109|NCT01758731|DRUG|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
219646110|NCT01758731|DRUG|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
219646111|NCT01758731|RADIATION|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
219646112|NCT04280744|OTHER|Music therapy|Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
219646113|NCT02615431|OTHER|MitraClip Intervention|
219646114|NCT04505072|BEHAVIORAL|PR-ESSENCE|Manual-based training of mutual problem-solving
219646115|NCT04505072|BEHAVIORAL|Treatment as usual|General support in daily structure and activities that is given to all youth staying at the treatment homes
219646116|NCT02173678|DRUG|COMBIVENT® HFA-MDI|
219646117|NCT02173678|DRUG|COMBIVENT® CFC-MDI|
219646118|NCT02173678|DRUG|Placebo HFA-MDI|
219646119|NCT05274854|BEHAVIORAL|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
219646120|NCT05274854|BEHAVIORAL|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
219646121|NCT06685627|OTHER|Open water wetsuited swimming.|All swimmers used their own well-fitting wetsuits (5 mm maximum thickness in accordance with World Triathlon guidelines7) and were free to supplement additional neoprene hats, gloves and booties as desired. A safety paramedic attended all swims. Swim distance was self-determined
218961047|NCT00350454|DEVICE|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
218961048|NCT00582816|DEVICE|Clinimacs Cell Separation System|Depletion of T-cells
218961049|NCT00582816|DRUG|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
218961050|NCT00582816|OTHER|DLI|NK Cell selected DLI
218961051|NCT00055224|DEVICE|Threat of shock|During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
218961052|NCT01231854|DRUG|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
218961053|NCT01231854|DRUG|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
218961054|NCT03448055|DIETARY_SUPPLEMENT|Immunocal|cysteine-rich whey protein isolate
218961055|NCT02832583|DEVICE|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
219646122|NCT06668727|DRUG|HepB mAb19|"The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD."
219646123|NCT06530680|BEHAVIORAL|Hippotherapy|Two 1-hour sessions of hippotherapy for eight weeks.
219646124|NCT06188455|DRUG|Fluzoparib Capsules|Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
218961056|NCT00458874|BEHAVIORAL|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
218961057|NCT02598570|DRUG|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
218961058|NCT03520244|BEHAVIORAL|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
219207812|NCT06756594|DRUG|Dexmedetomidine-Propofol|efficacy of sedation with Dexmedetomidine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
219646125|NCT06188455|DRUG|Apatinib Mesylate Tablets|Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
219646126|NCT02731937|DEVICE|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
219646127|NCT05263856|DEVICE|laser acupuncture|The parameter setting of 810nm wavelength laser acupuncture device in 1) ear were irradiated with a 4mm probe, adjusted to Nogier A frequency for acute treatment, and the pulsed mode was irradiated with an emission frequency of 200mW for 10seconds, each acupoint provided 1 joule of energy with total of 12joules,and 2) myofascial trigger point were irradiated with a 10mm probe, adjusted to Nogier C frequency for muscle treatment, and the pulsed mode was irradiated with an emission frequency of 500mW for 20 seconds, each acupoint provided 5 joule of energy with total of 50 joules, providing a total of 62 joules of one intervention session.
219646128|NCT03207464|DRUG|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
219646129|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
219646130|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
219646131|NCT01868698|OTHER|high-voltage electrical stimulation|
219646132|NCT01868698|OTHER|Kinesiotherapy|
219646133|NCT01868698|OTHER|shortwave diathermy|
219646134|NCT06925464|DRUG|CD7 CAR-T cells infusion|Approximately 3-5 days prior to CD7 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219646135|NCT06904807|DRUG|LIFE-001|Single dose of LIFE-001 between 10mg and 300mg administered subcutaneously
219646136|NCT06904807|DRUG|Placebo|Single dose of placebo comparator administered subcutaneously
219646137|NCT06904807|DRUG|LIFE-001|Four doses of LIFE-001 between 50mg and 300mg administered subcutaneously seven days apart
219646138|NCT06904807|DRUG|Placebo|Four doses of placebo comparator administered subcutaneously seven days apart
219646139|NCT04754958|DEVICE|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
219646140|NCT06841419|PROCEDURE|surgical reconstruction of a soft tissue defects by a pedicled flap|harvesting of a fasciocutaneous flap from the anterolateral aspect of thigh based on a perforators from the descending branch of lateral femoral circumflex artery to reconstruct a neighboring soft tissue defect.
219646141|NCT05608291|DRUG|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
219646142|NCT05608291|DRUG|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
218961059|NCT04584697|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
218961060|NCT04584697|DRUG|Placebo|Diluent solution
218961061|NCT04080687|DEVICE|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
218961062|NCT02004639|RADIATION|Masticators sparing techniques|
218961063|NCT02004639|OTHER|electro-acupunture treatment|electro-acupunture treatment and sham-EA
218961064|NCT02607566|BEHAVIORAL|Yoga|
219207813|NCT06756594|DRUG|Ketamine-Propofol|efficacy of sedation with Ketamine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
219646143|NCT05608291|DRUG|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
219646144|NCT05608291|DRUG|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
219646145|NCT04829617|BEHAVIORAL|PP-MI Intervention|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
218961065|NCT02607566|BEHAVIORAL|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
218961066|NCT01673750|OTHER|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
218961067|NCT01082822|BIOLOGICAL|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
218961068|NCT01302015|BIOLOGICAL|RNL-Vascostem®|
218961069|NCT04584307|DRUG|Elotuzumab|Elotuzumab 10-20mg/kg
218961070|NCT04584307|DRUG|Pomalidomide|Pomalidomide 2mg
218961071|NCT04635670|DIETARY_SUPPLEMENT|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
218961072|NCT04635670|DIETARY_SUPPLEMENT|Placebo|Soluble powder for oral use twice daily.
219646146|NCT04829617|BEHAVIORAL|MI-alone Intervention|The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
219646147|NCT03692975|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
219646148|NCT03692975|OTHER|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
219646149|NCT03692975|OTHER|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
219646150|NCT03692975|DEVICE|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
219646151|NCT01397786|DRUG|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
219646152|NCT03509428|BEHAVIORAL|SRETP|SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
219646153|NCT03509428|BEHAVIORAL|Psychological support|Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
219646154|NCT04649736|OTHER|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
219646155|NCT00811785|DRUG|Copper Histidine|Daily subcutaneous injections for three years
219646156|NCT05848492|DRUG|Fluconazole|Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
219646157|NCT05848492|DRUG|Saline|0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
219646158|NCT03681990|DRUG|3M CHG/IPA Prep|Apply topically to intact skin
219646159|NCT06107270|DEVICE|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
219646160|NCT06107270|DEVICE|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
219646161|NCT06107270|DEVICE|infra red radiation|(R 125, 250watt, Philips)
218961073|NCT06108986|OTHER|tabata training|this include tabata training thrice a week for six weeks
219646162|NCT06107270|OTHER|post isometric relaxation|sustained contraction followed by relaxation
219646163|NCT03126162|PROCEDURE|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
219646164|NCT03126162|PROCEDURE|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
219646165|NCT01310556|OTHER|ogtt for patients with coronary artery disease|75 g OGTT
219646166|NCT04682262|PROCEDURE|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
219646167|NCT05382195|OTHER|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
218961074|NCT06108986|OTHER|plyometric training|this include plyometric training thrice a week for six weeks
218961075|NCT05222490|DEVICE|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
218961076|NCT05222490|DEVICE|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
218961077|NCT05796778|PROCEDURE|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
218961078|NCT05796778|PROCEDURE|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
219061345|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
219646168|NCT06619223|DIAGNOSTIC_TEST|Duplex Ultrasound|The primary intervention in this study is the use of ankle Doppler waveform assessment for post-revascularisation surveillance in patients with Peripheral Arterial Disease (PAD). This technique utilises continuous-wave Doppler (CWD) and pulsed-wave Doppler (PWD) to assess the blood flow in the key ankle arteries, including the dorsalis pedis artery (DPA) and posterior tibial artery (PTA).
219646169|NCT05497232|PROCEDURE|simultaneous pancreas-kidney transplantation|"Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases."
219646170|NCT01226498|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
219646171|NCT00384748|BEHAVIORAL|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
219646172|NCT00384748|BEHAVIORAL|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
219646173|NCT00384748|BEHAVIORAL|Usual care|Routine VA care.
219646174|NCT00757965|GENETIC|polymorphism analysis|
219646175|NCT00757965|OTHER|laboratory biomarker analysis|
219646176|NCT00757965|OTHER|questionnaire administration|
219646177|NCT00991471|BEHAVIORAL|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
219061346|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
219646178|NCT00991471|BEHAVIORAL|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
219646179|NCT02005692|DEVICE|DynaSense sensor|
219646180|NCT01892709|DRUG|Hydromorphone|
219646181|NCT02091375|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219646182|NCT02091375|DRUG|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219646183|NCT06166537|OTHER|Graduated compression stockings|Graduated compression stockings are standard care (control)
219646184|NCT06166537|OTHER|No Graduated compression stockings|No Graduated compression stockings is the intervention
219646185|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
219646186|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
219646187|NCT00731718|DEVICE|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
219061347|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
219646188|NCT05542628|OTHER|No intervention included|No intervention included
219646189|NCT03625765|DEVICE|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
219646190|NCT01741792|DRUG|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
219646191|NCT06394466|OTHER|Non Applicable|Non Applicable
219646192|NCT03268759|OTHER|fMRI|Observation of neural markers of reward processing
219061348|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
219061349|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
219061350|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
219061351|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
219061352|NCT05491733|DRUG|APX001|Low-load oral tablet
219061353|NCT05491733|DRUG|APX001A|High-load oral tablet
219646193|NCT04499300|OTHER|Data collection from medical files|Data collection from medical files
219646194|NCT04349059|OTHER|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
219646195|NCT04349059|OTHER|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
219646196|NCT00555126|DEVICE|Forced Air Warming|Warming after Randomization
219646197|NCT00555126|DEVICE|Warming with endovascular catheter + forced air warming|Warming after Randomization
219646198|NCT05863507|DIETARY_SUPPLEMENT|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
219646199|NCT05863507|DIETARY_SUPPLEMENT|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
219646200|NCT00112528|BIOLOGICAL|bevacizumab|
219646201|NCT00112528|DRUG|gemcitabine hydrochloride|
219646202|NCT00112528|DRUG|oxaliplatin|
219646203|NCT06576960|DRUG|Nano silver fluoride varnish and tri calcium phosphate varnish|Fluoride varnishes
219646204|NCT02918474|OTHER|Decision Aid|Use decision making tool
219646205|NCT02918474|OTHER|Questionnaire Administration|Ancillary studies
219646206|NCT03511040|DEVICE|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
219646207|NCT01949012|OTHER|Capnography|Capnography waveform and capnometry readings
219646208|NCT01719913|OTHER|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
219646209|NCT01719913|OTHER|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
219646210|NCT02901743|OTHER|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
219646211|NCT01883817|DRUG|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
219646212|NCT01883817|DRUG|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
219646213|NCT04336319|BIOLOGICAL|Fecal Microbial Transplantation|"1. At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~2. FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline)."
219646214|NCT05325489|DRUG|Nebulized Budesonide|use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
219061354|NCT02449824|OTHER|magnetic resonance imaging|early MRI
219061355|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
219061356|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
219061357|NCT01650389|BIOLOGICAL|MVA85A|
219061358|NCT01650389|BIOLOGICAL|Candin|
219646215|NCT05325489|DRUG|Intranasal Budesonide Spray|nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
219646216|NCT04560972|DRUG|Atezolizumab|Given IV
219646217|NCT04560972|DRUG|Carboplatin|Given IV
219646218|NCT04560972|DRUG|Etoposide|Given IV
219646219|NCT04560972|DRUG|Protein Phosphatase 2A Inhibitor LB-100|Given IV
219646220|NCT03108768|DEVICE|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
219646221|NCT03108768|DEVICE|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
219646222|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
219646223|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~1. a mobile-enabled website,~2. diet and physical activity tracking apps and physical activity tracker~3. tailored self-monitoring feedback~4. caregiver podcasts~5. animated videos for adolescent patients~6. social support via social media."
219646224|NCT05189301|DIAGNOSTIC_TEST|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
219646225|NCT05189301|DIAGNOSTIC_TEST|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
219646226|NCT02735512|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
219646227|NCT02735512|OTHER|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
219646228|NCT02263391|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
219061359|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
219061360|NCT00948831|BIOLOGICAL|Osteocel Plus|biologic
219061361|NCT04498650|DRUG|PQ912|PQ912 50 mg tablets and 150 mg tablets
219646229|NCT02263391|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
219646230|NCT04736446|DEVICE|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
219646231|NCT04736446|DEVICE|Face mask ventilation|Use of a face mask to deliver ventilations
219646232|NCT01188824|DRUG|Cilostazol|100 mg, bid p.o.
219646233|NCT01188824|OTHER|placebo|1 tablet, bid
219646234|NCT03417232|PROCEDURE|CAF|The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
219646235|NCT06648070|PROCEDURE|Neuromuscular reeducation technique|"5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds."
219646236|NCT06648070|PROCEDURE|Post Facilitation Stretch|3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
219646237|NCT04507256|COMBINATION_PRODUCT|AZD7442|Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
219646238|NCT04507256|OTHER|Placebo|Participants randomised to placebo will receive the same volume of solution as participants on active treatment.
219646239|NCT06244056|PROCEDURE|Stellate Ganglion Block|A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
219646240|NCT06247007|PROCEDURE|Electroacupuncture|LI-4, LI-11, GV-14, GV-20 acupuncture points were needled bilaterally.
219646241|NCT00631410|DRUG|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
218961079|NCT01884727|DIETARY_SUPPLEMENT|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
218961080|NCT01884727|DIETARY_SUPPLEMENT|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
218961081|NCT06041776|DRUG|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
219061362|NCT04498650|DRUG|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
219061363|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
219061364|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
219061365|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
219061366|NCT01420796|OTHER|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
219061367|NCT01420796|OTHER|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
219061368|NCT01420796|OTHER|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
219061369|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
219061370|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
219061371|NCT02233712|BIOLOGICAL|G17DT|
219061372|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
219061373|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
219061374|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
219061375|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
219061376|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
219061377|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
219061378|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
219061379|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
219061380|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
219061381|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
219061382|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
219061383|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
219646242|NCT00631410|DRUG|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
219061384|NCT01700946|DRUG|dexamethasone|given intravenously or orally
219061385|NCT01700946|DRUG|vincristine sulfate|given intravenously
219061386|NCT01700946|BIOLOGICAL|rituximab|given intravenously
219061387|NCT01700946|DRUG|clofarabine|given intravenously
219061388|NCT01700946|DRUG|cyclophosphamide|given intravenously
219646243|NCT02413385|BEHAVIORAL|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
219646244|NCT00316615|BIOLOGICAL|influenza vaccine|
219646245|NCT04762485|BIOLOGICAL|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5-10)x10\^6 CD7 CAR-T cells/kg
219646246|NCT00504699|PROCEDURE|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
219061389|NCT01700946|DRUG|etoposide|given intravenously
219061390|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
219061391|NCT01700946|DRUG|pegaspargase|given intravenously
219061392|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
219061393|NCT01700946|DRUG|mercaptopurine|given orally
219061394|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
219061395|NCT01700946|DRUG|mitoxantrone|given intravenously
219061396|NCT01700946|DRUG|teniposide|given intravenously
219061397|NCT01700946|DRUG|vinblastine|given intravenously
219061398|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
219061399|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
219061400|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
219061401|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
219646247|NCT02233101|DRUG|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
219646248|NCT02233101|DRUG|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
219646249|NCT04633629|OTHER|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
219646250|NCT03330262|DEVICE|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
219646251|NCT06093646|BEHAVIORAL|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
219646252|NCT05098912|OTHER|Manual acupuncture|Manual acupuncture using filiform needle
219646253|NCT05098912|OTHER|Thread embedding acupuncture|Thread Embedding acupuncture using Polydioxanone thread
219646254|NCT02980341|DRUG|Patritumab Deruxtecan|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
219646255|NCT01844180|DRUG|ONO-2952|
219646256|NCT01844180|DRUG|ONO-2952 Matching Placebo|
219646257|NCT04424082|OTHER|Removal of dead space filter|Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
219646258|NCT01354665|BIOLOGICAL|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
219646259|NCT02997644|BEHAVIORAL|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
219646260|NCT02997644|BEHAVIORAL|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
219646261|NCT05987904|DEVICE|LynxPatch|Measurements with the LynxPatch device are conducted.
219646262|NCT02375594|OTHER|Exercise in park equipment|
219646263|NCT00215696|GENETIC|BioBypass®|
219646264|NCT04567368|DIAGNOSTIC_TEST|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
219646265|NCT03134846|DRUG|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
219646266|NCT06623864|OTHER|meaningful activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
219646267|NCT06623864|OTHER|other activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
219646268|NCT05245916|DRUG|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
219646269|NCT05245916|DRUG|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
219646270|NCT05245916|DRUG|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
219646271|NCT00616616|PROCEDURE|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
219646272|NCT02247596|DRUG|Resveratrol|1g tds 2 weeks
218961082|NCT06041776|DRUG|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
218961083|NCT02029599|DRUG|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
218961084|NCT02029599|DRUG|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
218961085|NCT02029599|DRUG|Methotrexate|7.5-15mg per week，All patients should be used
218961086|NCT02029599|DRUG|Acetaminophen tablets|Oral,0.5g, 1\~2 times a day, when vas=10
218961087|NCT03063671|DRUG|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
218961088|NCT06097780|GENETIC|NestaCell®|Human Dental Pulp Stem Cells (hDPSCs).
218961089|NCT00768469|DRUG|Neratinib|Administered orally, continuous, once daily.
218961090|NCT00768469|DRUG|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
219061402|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
218961091|NCT03706898|DRUG|Elpida®|Elpida® capsules, 20mg
218961092|NCT03706898|DRUG|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
218961093|NCT03706898|DRUG|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
218961094|NCT03706898|DRUG|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
218961095|NCT01725412|DIETARY_SUPPLEMENT|Thiamine 300mg PO once daily|
218961096|NCT01725412|DIETARY_SUPPLEMENT|placebo|
219646273|NCT02247596|DRUG|Placebo|Sugar pill 1g tds for 2 weeks
219646274|NCT05771896|DRUG|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (\>56 days between cycles). Any participant requiring dose interruption \>28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
219646275|NCT05771896|DRUG|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption \>28 consecutive days (\>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
218961097|NCT03835728|DRUG|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
218961098|NCT03835728|DRUG|Saline|This will be the matching placebo used in the study.
218961099|NCT03487978|DIAGNOSTIC_TEST|resting-state functional MRI|"1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not."
218961100|NCT04918901|COMBINATION_PRODUCT|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
218961101|NCT06159101|DRUG|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
218961102|NCT06159101|DRUG|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
218961103|NCT06159101|DRUG|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
218961104|NCT06159101|DRUG|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
218961105|NCT03490279|DIETARY_SUPPLEMENT|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
218961106|NCT03490279|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
219061403|NCT04592367|PROCEDURE|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
219061404|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
219061405|NCT05013892|DRUG|Memantine|Capsule, taken orally
219061406|NCT00001402|DEVICE|PET scan|
219061407|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
219061408|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
219061409|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
219061410|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
219061411|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
218961107|NCT00234910|DRUG|Tenofovir DF|TDF 300mg QD for 72 wks
218961108|NCT00234910|DRUG|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
218961109|NCT04942197|OTHER|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
218961110|NCT06035770|OTHER|Mental Health First Aid (educational training program)|"The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors."
218961111|NCT06139692|DRUG|Dexmedetomidine|Patients receive perioperative sedation with dexmedetomidine
218961112|NCT06139692|DRUG|Midazolam|Patients receive perioperative sedation with midazolam
218961113|NCT04808700|OTHER|Follow-up of Episealer implant|Follow-up and radiographic evaluation in patients who received an Episealer implant
219061412|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
219646276|NCT05447819|PROCEDURE|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
219646277|NCT03886519|PROCEDURE|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
219646278|NCT03886519|PROCEDURE|Trabut|Trichiasis surgery using the Trabut procedure
219646279|NCT03216590|DEVICE|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
219646280|NCT03875274|DRUG|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
218961114|NCT04500756|DRUG|Metformin|Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
218961115|NCT04500756|OTHER|Placebo|One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
219646281|NCT03875274|DRUG|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
219646282|NCT03316469|DRUG|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
219646283|NCT03316469|DIAGNOSTIC_TEST|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
219646284|NCT04964544|COMBINATION_PRODUCT|5 mg rosuvastatin calcium with a Web App (combination product)|The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
219646285|NCT06419686|OTHER|Placebo (saline)|Intravenous saline during experimental days.
219646286|NCT06419686|DRUG|GIP|Intravenous GIP administration during experimental days.
218961116|NCT04276363|BEHAVIORAL|Thrive Professional Learning plus ParentCorps|led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
218961117|NCT04276363|BEHAVIORAL|Thrive Professional Learning only|Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
218961118|NCT04276363|BEHAVIORAL|Inspire Professional Learning|Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
218961119|NCT03952299|DRUG|Oxybutynin Transdermal Patch|Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
218961120|NCT03952299|DRUG|Oral Oxybutynin|Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
218961121|NCT04607798|DEVICE|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
218961122|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
219646287|NCT06419686|DRUG|Alanine|Intravenous alanine administration during experimental days.
218961123|NCT04769999|BEHAVIORAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
218961124|NCT00459056|DRUG|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
219646288|NCT06419686|DRUG|GIP + alanine|Intravenous administration of GIP and alanine during experimental days.
219646289|NCT01613222|DEVICE|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
219646290|NCT01550081|OTHER|Rate of perceived exertion|Exercise intensity controlled by Borg scale
219646291|NCT01550081|OTHER|Heart rate monitor|Exercise intensity controlled by heart rate monitors
219646292|NCT02205008|PROCEDURE|surgery|Total or subtotal gastrectomy with D2
219646293|NCT02205008|DRUG|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
219646294|NCT02205008|DRUG|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
218961125|NCT00459056|DRUG|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
218961126|NCT02562690|OTHER|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
218961127|NCT01964456|OTHER|Joint perception task|
218961128|NCT01964456|BEHAVIORAL|Body Shape Questionnaire|
218961129|NCT01964456|OTHER|Measure of the heart rate|
219061413|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
219061414|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
219646295|NCT01348308|DRUG|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
219646296|NCT01348308|DRUG|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
219646297|NCT01328106|DRUG|GSK1120212|Repeating oral dose
219646298|NCT04109287|DEVICE|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
219646299|NCT03696108|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID
219646300|NCT03696108|DRUG|Placebo|Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
218961130|NCT05939778|BIOLOGICAL|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1\. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2\. 7 subjects were included in the second step."
218961131|NCT00941577|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
218961132|NCT00941577|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
218961133|NCT03596632|DRUG|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
218961134|NCT05357729|DEVICE|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
218961135|NCT02100709|DEVICE|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
218961136|NCT00000128|DEVICE|Bifocal Spectacle Lenses|
218961137|NCT04493840|DRUG|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
218961138|NCT04493840|DRUG|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
218961139|NCT01456377|DRUG|predinose oral|1 mg for kg for 3 wekees
218961140|NCT01456377|DRUG|placebo group|use a oral placebo
218961141|NCT00712062|DRUG|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
218961142|NCT05955976|OTHER|BIOPSY|biopsy
218961143|NCT04303923|PROCEDURE|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
218961144|NCT02447705|DRUG|telbivudine|telbivudine replace Lamivudine
218961145|NCT01504061|OTHER|Mederma N&I|Topical gel applied three times a day for eight weeks.
218961146|NCT01504061|OTHER|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
218961147|NCT03410264|BEHAVIORAL|CR-EXP|See arm/group descriptions
218961148|NCT03410264|BEHAVIORAL|EXP-CR|See arm/group descriptions
218961149|NCT03410264|BEHAVIORAL|Stress Management|See arm/group descriptions
218961150|NCT03189381|RADIATION|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
218961151|NCT03189381|RADIATION|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
218961152|NCT03761797|DRUG|TRADIANCE® Combination Tablets AP|Fixed dose combination
218961153|NCT03761797|DRUG|TRADIANCE® Combination Tablets BP|Fixed dose combination
218961154|NCT00251004|DRUG|Everolimus|oral, bis in diem/twice a day (bid)
218961155|NCT00251004|DRUG|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
218961156|NCT00251004|DRUG|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
218961157|NCT00251004|DRUG|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
218961158|NCT00251004|DRUG|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
218961159|NCT05742386|BEHAVIORAL|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
218961160|NCT05742386|BEHAVIORAL|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
219061415|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
219646301|NCT04692480|BEHAVIORAL|Breastfeeding Video Education|"Video entitled Breastfeeding in the First Hour, It's in Your Hands"
219646302|NCT04692480|BEHAVIORAL|Breastfeeding PDF education|PDF of standard breastfeeding education handouts
219061416|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
219061417|NCT02308202|DRUG|doxazosin|
219061418|NCT02308202|DRUG|Perindopril|
218961161|NCT04873271|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
219061419|NCT02308202|DRUG|Placebo|
219061420|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
219061421|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
219061422|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
219061423|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
218961162|NCT03239691|DRUG|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
218961163|NCT03239691|DRUG|Placebo|Matching placebo available as matching capsules for oral administration
218961164|NCT02071927|DRUG|CB-839|Single-agent CB-839
218961165|NCT02071927|DRUG|CB-Aza|CB-839 in combination with standard dose azacitidine
219061424|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
219061425|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
219061426|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
219061427|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
219061428|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
219061429|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
219061430|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
218961166|NCT02312427|DRUG|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
219061431|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
219061432|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
219061433|NCT02958644|DIETARY_SUPPLEMENT|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
219061434|NCT02958644|DIETARY_SUPPLEMENT|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
219061435|NCT02534974|DEVICE|NOSTEN|
219061436|NCT00418171|DRUG|Ziprasidone|
219061437|NCT00418171|DRUG|Olanzapine|
219061438|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
219061439|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
218961167|NCT02312427|DRUG|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
218961168|NCT02312427|DRUG|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
218961169|NCT03301974|PROCEDURE|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
218961170|NCT03301974|PROCEDURE|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
219061440|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
219061441|NCT05378711|DRUG|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
219061442|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
219061443|NCT02801045|BEHAVIORAL|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects."
218961171|NCT03301974|PROCEDURE|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
218961172|NCT02573701|DRUG|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
219646303|NCT02319174|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
219646304|NCT02196376|OTHER|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
219646305|NCT02196376|OTHER|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
219646306|NCT02196376|OTHER|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
219646307|NCT02196376|BEHAVIORAL|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
219646308|NCT00704444|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets
219646309|NCT00704444|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
218961173|NCT02573701|BEHAVIORAL|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
218961174|NCT02573701|DRUG|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
218961175|NCT00914303|DRUG|AZD3241|Oral Tablet, Repeated Administration
218961176|NCT00914303|DRUG|Placebo Tablet|Oral Tablet. Repeated Administration
218961177|NCT04080076|DRUG|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
218961178|NCT04080076|DRUG|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
218961179|NCT02188043|BEHAVIORAL|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
218961180|NCT03804073|RADIATION|standard treatment|3000 cGy in 10 daily fractions
218961181|NCT03804073|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
219061444|NCT03321981|DRUG|Zenocutuzumab|full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
219061445|NCT03321981|DRUG|Trastuzumab|humanised IgG1 monoclonal antibody
218961182|NCT04880330|DEVICE|Cryo-Auriculotherapy|1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
218961183|NCT04880330|DEVICE|Sham comparator|1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
218961184|NCT04549974|OTHER|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
218961185|NCT00954252|DRUG|CHF 5074|1x, oral capsule, single dose
218961186|NCT00954252|DRUG|placebo|placebo, oral capsule, single dose
218961187|NCT00954252|DRUG|CHF 5074|2x, oral capsule, single dose
218961188|NCT00954252|DRUG|CHF 5074|4x, oral capsule, single dose
218961189|NCT00954252|DRUG|CHF 5074|8x, oral capsule, single dose
218961190|NCT00954252|DRUG|CHF 5074|16x, oral capsule, single dose
219646310|NCT05748392|DEVICE|Wound and per-wound assessments While using Device|3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
219646311|NCT04798989|DRUG|CY6463|CY6463 Oral Tablet
219646312|NCT04798989|DRUG|Placebo|Placebo Oral Tablet
219646313|NCT05219292|OTHER|Active music therapy|"Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~* Its use is simple,~* It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~* The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns."
219646314|NCT05219292|OTHER|Questionnaires|"We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand."
218961191|NCT00954252|DRUG|CHF 5074|24x, oral capsule, single dose
218961192|NCT01797172|PROCEDURE|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
218961193|NCT01797172|PROCEDURE|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
218961194|NCT02345746|DRUG|Oxaliplatin|infusion over 12 hours via HAI
218961195|NCT02345746|DRUG|Folinic Acid|as a 2-hour infusion via HAI on day 2
218961196|NCT02345746|DRUG|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
218961197|NCT00256282|DRUG|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
218961198|NCT00256282|DRUG|Docetaxel|40mg/m2 IV over 1 hour every 14 days
218961199|NCT00256282|DRUG|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
218961200|NCT01874990|DIETARY_SUPPLEMENT|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
218961201|NCT01874990|DIETARY_SUPPLEMENT|low-salt diet|
218961202|NCT00328978|DRUG|Quetiapine|
218961203|NCT06421818|DRUG|Baitouweng Tang|Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
218961204|NCT06421818|OTHER|Placebo|The same volume and color as Baitouweng Decoction.
218961205|NCT01723696|DIETARY_SUPPLEMENT|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
218961206|NCT01723696|DIETARY_SUPPLEMENT|Placebo tablet+prenatal vitamin|
218961207|NCT00579085|DRUG|Ketamine|IV Ketamine .35mg/kg times ten days.
218961208|NCT00579085|OTHER|IV NSS|Placebo inactive ingredients
218961209|NCT00579085|OTHER|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
218961210|NCT03291418|DRUG|ATB-346 OR Placebo|Comparison of gastrointestinal effects
218961211|NCT03291418|DRUG|Naproxen sodium|Comparison of gastrointestinal effects
218961212|NCT04219462|DEVICE|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
219061446|NCT03321981|DRUG|Vinorelbine|antineoplastic drug of vinca alkaloid family
219061447|NCT03321981|DRUG|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
219061448|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
219061449|NCT03424876|DRUG|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
219061450|NCT03424876|DRUG|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
219061451|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
219061452|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
219061453|NCT04519229|BEHAVIORAL|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
219061454|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
219061455|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
219061456|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
219061457|NCT00817089|DRUG|Placebo Oral Tablet|Placebo pill
219061458|NCT00817089|DRUG|Naltrexone|50 mg of naltrexone prior to challenge session
219061459|NCT01592708|OTHER|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
219646315|NCT05120466|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
219646316|NCT05120466|BEHAVIORAL|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
219646317|NCT00528060|DRUG|Atazanavir|2pills/day
219646318|NCT00528060|DRUG|Ritonavir|1 pill/day
219646319|NCT00528060|DRUG|Tenofovir/emtricitabine|1 pill/day
219646320|NCT02861326|DEVICE|Gracey Curettes|
219646321|NCT00003134|DRUG|irinotecan hydrochloride|
219646322|NCT04033341|DRUG|LY3214996|Administered orally
219646323|NCT04033341|DRUG|[14C]-LY3214996|Administered orally
219646324|NCT05082558|OTHER|No intervention, as this was retrospective study.|No intervention performed. Participants were entolled retrospectively and medical records were accessed for data.
219646325|NCT04217837|DEVICE|Transcranial Magnetic Stimulator|Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
219646326|NCT01008956|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
219646327|NCT04760509|OTHER|In this study, the short-term follow-up of patients with neural tube defects in the neonatal intensive care unit will be evaluated retrospectively.|there is no intervention. It is retrospective study.
219646328|NCT00880061|DRUG|IL13-PE38QQR|
219646329|NCT00330109|PROCEDURE|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
219646330|NCT00330109|PROCEDURE|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
219646331|NCT00330109|PROCEDURE|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
219646332|NCT03855020|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
219646333|NCT01051544|DRUG|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
219646334|NCT01051544|DRUG|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
219646335|NCT05697029|DRUG|Tetrandrine|tetrandrine TID for 28 days
219646336|NCT03608657|DRUG|Apremilast|Apremilast
219646337|NCT02372929|PROCEDURE|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
219646338|NCT03632629|OTHER|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
219646339|NCT04042766|PROCEDURE|laser vaginal treatment|Er:YAG laser
219646340|NCT04811612|DIAGNOSTIC_TEST|Warmed heel stick|One heel will be warmed before sampling with the other heel will not be warmed
219646341|NCT05565040|PROCEDURE|Circumcision in concealed penis|comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
219646342|NCT06644469|DEVICE|Dynatronics VF5 Model vibration platform|The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.
219646343|NCT06644469|DEVICE|Placebo Dynatronics VF5 Model vibration platform|Placebo intensity with vertical vibration of 0.2 mm
219646344|NCT05209126|DIETARY_SUPPLEMENT|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
219646345|NCT03655912|DEVICE|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
219646346|NCT03655912|DEVICE|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
219646347|NCT03655912|DEVICE|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
219646348|NCT01128101|DRUG|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
219646349|NCT02619110|OTHER|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
219646350|NCT02619110|OTHER|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
219646351|NCT02449317|OTHER|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr"
219646352|NCT02449317|OTHER|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
219646353|NCT01748617|OTHER|Controlled diet|1 week of controlled diet
219646354|NCT06111196|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection|100mg/4ml;single dose;intravenous injection
219646355|NCT06111196|DRUG|Pembrolizumab injection|100mg/4ml;single dose;intravenous injection
219646356|NCT00196066|DEVICE|Peripheral Vessel Stenting|
219646357|NCT03805217|DEVICE|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
219646358|NCT04629781|DRUG|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
219646359|NCT06616714|OTHER|Observtional Study|Observtional Study
219646360|NCT03596281|DRUG|Pembrolizumab|200mg Q3W IV
219646361|NCT03596281|DRUG|Bevacizumab|400 or 300 mg Q3W IV
219646362|NCT03596281|DRUG|pegylated liposomal doxorubicin (PLD)|15 or 20 or 30 mg/m² Q3W IV
219646363|NCT06653608|DRUG|Nano-reinforced calcium hydroxide medicament|Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)
219646364|NCT06653608|DRUG|Calcium hydroxide without nanoparicles|Group B ( Calcium hydroxide medicament without nanoparticles)
219646365|NCT06570343|DRUG|Fentanyl-Morphine|Intrathecal injection of bupivacaine, fentanyl and morphine
219646366|NCT06570343|DRUG|Morphine|Intrathecal injection of bupivacaine and morphine
219646367|NCT01623843|PROCEDURE|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
219646368|NCT01623843|PROCEDURE|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
219646369|NCT01899742|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
219646370|NCT01899742|DRUG|Tiotropium 18 mcg|Inhalation Powder
219646371|NCT05845905|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.
219646372|NCT05845905|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
219646373|NCT02662764|DRUG|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
219646374|NCT05398952|DIAGNOSTIC_TEST|Laboratory investigations|Laboratory investigations correlated with symptoms and imaging results
219646375|NCT02852200|OTHER|SEGAm|
219646376|NCT06411600|DRUG|Encorafenib|Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
219646377|NCT06411600|DRUG|Cetuximab|Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
219646378|NCT06411600|DRUG|Bevacizumab|Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
219646379|NCT06043778|BEHAVIORAL|Community care for People with Schizophrenia in India (COPSI)|This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
219061460|NCT01990053|BEHAVIORAL|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
219646380|NCT06043778|BEHAVIORAL|mindLAMP Mobile Application|Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
219061461|NCT01785602|DRUG|QAW039|Capsules
219061462|NCT01785602|DRUG|Placebo|Capsules
219646381|NCT00089778|DRUG|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
219646382|NCT00089778|DRUG|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
219646383|NCT00089778|OTHER|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
219646384|NCT06523881|PROCEDURE|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.
219646385|NCT06523881|PROCEDURE|Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)|Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
219646386|NCT00372710|DRUG|Zoledronic acid|
219646387|NCT05307016|DIAGNOSTIC_TEST|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
219646388|NCT05787535|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
219646389|NCT05787535|BIOLOGICAL|HRYZ-T101 TCR-T Cell|On day 1, the TCR-T cells will be administered one time.
219646390|NCT06623708|DEVICE|SMARTCLOTH|The intervention consists of using SMARTCLOTH. This device makes it possible to monitor dietary intake throughout the day and record it in a database that, through a website, allows to track it. SMARTCLOTH is a digital tablecloth consisting of a scale, several buttons and a screen. The device allows weighing the food to be consumed and recording its nutritional value (macronutrients in grams, macronutrient servings and kilocalories). The latter is achieved because SMARTCLOTH allows the patient to select to which food group the food being weighed belongs, increasing the accuracy of the nutritional estimation.
219646391|NCT01783600|DEVICE|NanoCross .014 balloon catheter|
219646392|NCT04660500|OTHER|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
219646393|NCT06452199|DIETARY_SUPPLEMENT|B. infantis|1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.
219646394|NCT06452199|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
219646395|NCT04123106|PROCEDURE|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
219646396|NCT04123106|PROCEDURE|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
219646397|NCT02195310|DEVICE|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
219646398|NCT02195310|DEVICE|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
219646399|NCT06313086|DRUG|DP303c|intravenous injection
219646400|NCT06313086|DRUG|trastuzumab emtansine|intravenous injection
219061463|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
219061464|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219061465|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219061466|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
219061467|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
219061468|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
219061469|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
219061470|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
219061471|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
219061472|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
219061473|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
219646401|NCT02141568|OTHER|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
219646402|NCT02493010|DEVICE|Arousal-based biofeedback system|
219646403|NCT02830958|DEVICE|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
219646404|NCT02830958|OTHER|No intervention|No intervention. Uses of an ordinary tape
219646405|NCT04843124|DEVICE|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
218961213|NCT04219462|DEVICE|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
218961214|NCT03462290|DRUG|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
218961215|NCT03462290|DRUG|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
218961216|NCT01141777|DIETARY_SUPPLEMENT|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
218961217|NCT01141777|DIETARY_SUPPLEMENT|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
218961218|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
218961219|NCT01167985|DEVICE|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
218961220|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
218961221|NCT05599919|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
218961222|NCT02021656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
218961223|NCT05772988|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine
218961224|NCT05772988|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
219646406|NCT04843124|OTHER|Traditional hearing aid|Traditional hearing aid
219646407|NCT02723903|DRUG|Deanxit|we use Deanxit for the patient with anxiety
218961225|NCT04325555|DRUG|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
218961226|NCT02843737|OTHER|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
218961227|NCT05026190|DIAGNOSTIC_TEST|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
218961228|NCT05669248|DIAGNOSTIC_TEST|mid covid-19 patients|Collect the patient's whole blood for testing
218961229|NCT05055245|OTHER|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
219061474|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
219646408|NCT02723903|DRUG|Prozac|we use Prozac for the patient with depression
219646409|NCT02723903|PROCEDURE|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
219646410|NCT04613661|OTHER|Australian Spasticity Assessment Scale|Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
219646411|NCT06149065|DRUG|Testosterone|Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
219061475|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
219061476|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
219061477|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
219061478|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
219061479|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
219061480|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
219061481|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
219061482|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
219061483|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
219061484|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
219061485|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
219061486|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
219061487|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
219646412|NCT05905666|BEHAVIORAL|health education and counseling|In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
219646413|NCT06031935|BEHAVIORAL|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
219646414|NCT01191775|DRUG|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
219061488|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
219061489|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
219061490|NCT01384435|DRUG|KPS-0373|
219646415|NCT01154088|BIOLOGICAL|Mencevax ACWY|One dose, Subcutaneous injection
219646416|NCT01154088|BIOLOGICAL|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
219646417|NCT02937142|BEHAVIORAL|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
219646418|NCT02937142|OTHER|Treatment as usual|Education on ADHD, and ADHD medication if indicated
219646419|NCT00534885|BIOLOGICAL|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
219646420|NCT00534885|BIOLOGICAL|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
219061491|NCT01384435|DRUG|KPS-0373|
219061492|NCT01384435|DRUG|KPS-0373|
219061493|NCT01384435|DRUG|KPS-0373|
219061494|NCT01384435|DRUG|Placebo|
219061495|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
219061496|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
219061497|NCT01867034|OTHER|Bare Metal Stent|
219061498|NCT04534842|DRUG|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
219061499|NCT04534842|DRUG|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
219646421|NCT00534885|BIOLOGICAL|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
219646422|NCT00534885|BIOLOGICAL|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
219061500|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
219646423|NCT01122407|DRUG|L-NMMA|L-NMMA 250 ug/Kg/min
219061501|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
219061502|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
219646424|NCT01122407|DRUG|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
219646425|NCT06617871|PROCEDURE|Mechanical Alignment (MA)|Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.
219646426|NCT06617871|PROCEDURE|Kinematic Alignment (KA) Interventions:|Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
219646427|NCT06617182|DRUG|Thalidomide|Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
219646428|NCT06617182|DRUG|Glutamine|In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
219646429|NCT06617182|DRUG|Thalidomide+Glutamine|Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.
219646430|NCT02491372|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
219646431|NCT04128722|DRUG|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
218961230|NCT01990144|DRUG|Bendamustine+Rituximab|"Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
218961231|NCT01574833|DEVICE|pulsed electromagnetic field|PEMF treatment
219061503|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
219061504|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1\) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
219061505|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
219061506|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
219646432|NCT05178641|DEVICE|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
219646433|NCT05178641|OTHER|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
219646434|NCT04042350|OTHER|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
219646435|NCT06141616|OTHER|Asthma Rehabilitation Program|The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.
219646436|NCT00811824|BEHAVIORAL|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
219646437|NCT05022524|DIETARY_SUPPLEMENT|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
218961232|NCT01574833|DEVICE|sham|sham treatment
218961233|NCT01198171|OTHER|Laboratory Biomarker Analysis|Correlative studies
218961234|NCT01198171|OTHER|Study of Socioeconomic and Demographic Variables|
218961235|NCT04215133|OTHER|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
218961236|NCT00019110|BIOLOGICAL|human papillomavirus 16 E7 peptide|
218961237|NCT00019110|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
219646438|NCT03367052|PROCEDURE|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
219646439|NCT03367052|PROCEDURE|Hybrid|The hybrid method will be used in one group of patients.
219646440|NCT01869699|DRUG|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
219646441|NCT01869699|DRUG|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
219646442|NCT01475851|DRUG|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
219646443|NCT05400070|DRUG|Neoadjuvant therapy 1|Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
219646444|NCT05161520|PROCEDURE|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
219646445|NCT05161520|PROCEDURE|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
219646446|NCT01576276|RADIATION|Integrated MR-PET scan|Integrated MR-PET scan using \[11C\]diprenorphine
219646447|NCT01576276|DRUG|Ketorolac|3 administrations of ketorolac over course of study
219646448|NCT01867294|DRUG|Doxycycline|Given PO
219646449|NCT01867294|PROCEDURE|Management of Therapy Complications|Moisturizer given topically
219646450|NCT01867294|OTHER|Placebo|Given topically
219646451|NCT01867294|OTHER|Questionnaire Administration|Ancillary studies
219646452|NCT01867294|DRUG|Spironolactone|Given topically
219646453|NCT01867294|DRUG|Sunscreen|Given topically
219646454|NCT01867294|DRUG|Therapeutic Hydrocortisone|Given topically
219646455|NCT01993589|DRUG|comparison of pain relievers during curattage|
218961238|NCT05740995|DRUG|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
218961239|NCT00596362|DRUG|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
218961240|NCT00207571|BEHAVIORAL|Computer|
219646456|NCT01993589|DRUG|comparison of pain relievers|
219646457|NCT01993589|DRUG|comparison of pain relievers during curattage|
219646458|NCT01993589|DRUG|comparison of pain relievers during curattage|
219646459|NCT01993589|DRUG|comparison of pain relievers during curattage|
219646460|NCT06648083|OTHER|Food autonomy|Determine the age of acquisition of full oral feeding in extremely premature infants hospitalised in a neonatal unit where that applies a strategy of specific and individualized stimulation of orality.
219646461|NCT04255732|DEVICE|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
219646462|NCT04255732|DEVICE|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
219646463|NCT03521297|DRUG|Probiotic|UDCA combined probiotic
219646464|NCT03521297|DIETARY_SUPPLEMENT|Placebo|UDCA combined placebo
219646465|NCT06261060|DRUG|Sirolimus|Given by PO
219646466|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
218961241|NCT03562871|BIOLOGICAL|IO102|test immunotherapy
218961242|NCT03562871|BIOLOGICAL|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
219646467|NCT02447497|OTHER|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
219646468|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
219646469|NCT02447497|OTHER|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
219646470|NCT05797415|PROCEDURE|Sentinel Lymph Node Biopsy|"* Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
219646471|NCT06645353|DEVICE|MSOT Multispectral Optoacoustic Tomography|MSOT Multispectral Optoacoustic Tomography, single-wavelength, HbT, Hb, HbO2, collagen and mSO2 (700-1.100 nm wavelength range, in 10 nm increments) in the tibialis anterior and flexor hallucis brevis, at multiple time-points before, during and after interventional LER Lower Extremity Revascularization .
219646472|NCT04642677|OTHER|healthcare provider's recommended communication with sympathy and printed paper|"Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation."
219646473|NCT01653860|BEHAVIORAL|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
219061507|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
219061508|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
219646474|NCT01653860|BEHAVIORAL|Ordinary group treatment|group treatment 8 weeks (16 hours)
219646475|NCT02873572|BEHAVIORAL|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
219646476|NCT02873572|BEHAVIORAL|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~* psychiatric assesment and~* registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
219646477|NCT02017912|BIOLOGICAL|Nurown MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
219646478|NCT02017912|BIOLOGICAL|Placebo|Excipient administration by combined intramuscular and intrathecal administration
219646479|NCT02231281|DRUG|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
219646480|NCT02231281|PROCEDURE|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
219646481|NCT06622681|OTHER|No intervention|No intervention
219646482|NCT02289781|DEVICE|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
219646483|NCT05292417|RADIATION|hypofractionation Radiotherapy|Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
219646484|NCT05292417|DRUG|sintilimab|200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
219646485|NCT05292417|DRUG|GM-CSF|200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
219646486|NCT05292417|DRUG|Fruquintinib|Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
219646487|NCT05015621|DRUG|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
219646488|NCT05015621|DRUG|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
219646489|NCT03285503|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
219646490|NCT05811052|OTHER|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
219646491|NCT05811052|OTHER|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
218961243|NCT03562871|DRUG|Carboplatin (Carboplatin Kabi)|chemotherapy
218961244|NCT03562871|DRUG|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
218961245|NCT02043379|DRUG|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
218961246|NCT02043379|OTHER|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
218961247|NCT04604691|DRUG|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
218961248|NCT06536231|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
218961249|NCT03504930|OTHER|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
218961250|NCT02266043|DEVICE|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
218961251|NCT04153071|DEVICE|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
218961252|NCT00259675|DRUG|carboplatin/gemcitabine, carboplatin/taxol|
218961253|NCT02457585|DRUG|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
219646492|NCT00307632|DRUG|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
219646493|NCT04706806|DIETARY_SUPPLEMENT|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
219646494|NCT04706806|DIETARY_SUPPLEMENT|vinegar pill|one pill taken daily
219646495|NCT05587868|BIOLOGICAL|COVID-19 Vaccine|Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
219646496|NCT01022294|DRUG|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
219646497|NCT01022294|DRUG|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
219646498|NCT04553640|OTHER|Group A/Intervention Curriculum|Virtual patient cases and feedback
219646499|NCT04553640|OTHER|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
219646500|NCT01301781|DRUG|BLI801|BLI801 laxative - oral solution
219646501|NCT01301781|DRUG|Placebo|BLI801 placebo - oral solution
219646502|NCT03105986|DRUG|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
219646503|NCT03105986|DRUG|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
219646504|NCT04085224|DRUG|Somatropin|LG Somatropin
219646505|NCT00732758|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
218961254|NCT05530876|OTHER|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
218961255|NCT00744458|OTHER|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
218961256|NCT00744458|OTHER|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
218961257|NCT00744458|OTHER|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
218961258|NCT02037152|BEHAVIORAL|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
218961259|NCT04600011|OTHER|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
218961260|NCT04600011|OTHER|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
218961261|NCT03798899|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
218961262|NCT03798899|DRUG|Normal Saline|Placebo
218961263|NCT02874768|DRUG|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
219646506|NCT00732758|DIETARY_SUPPLEMENT|Placebo Tablet|Placebo Tablet once daily for 6 months
219646507|NCT02453217|BEHAVIORAL|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
219646508|NCT02453217|OTHER|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
219646509|NCT02918435|BEHAVIORAL|WE CARE|The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
219646510|NCT03373058|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.
219646511|NCT03373058|PROCEDURE|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
219646512|NCT03373058|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
219646513|NCT02553785|DEVICE|Revivent TC|
219646514|NCT02205905|DRUG|14C PER977|Open-label, single dose
219061509|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
219061510|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
219646515|NCT03228316|PROCEDURE|superior hypogastric plexus block|nerve plexus block
219646516|NCT03228316|RADIATION|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
219646517|NCT02900417|DRUG|Sitagliptin|All the patients will receive sitagliptin 100mg daily
219646518|NCT05214586|PROCEDURE|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
219646519|NCT01844206|DRUG|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
219646520|NCT01844206|DRUG|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
219646521|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
219646522|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
219646523|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
219646524|NCT05085106|DRUG|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
219646525|NCT05085106|DRUG|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
219646526|NCT02991716|OTHER|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
219646527|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
219646528|NCT03408249|DIAGNOSTIC_TEST|IBDoc calprotectin test|Patients are asked to perform a single IBDoc calprotectin home test.
219207814|NCT06750211|OTHER|METs|"* Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* Muscle energy technique protocol: The individual was in a position of supine. The therapist was at the edge of bed, near the participants head. the therapist positioned the joint at the point of beginning range of motion resistance when performing a given movement. When the therapist felt restriction, positioned the cervical spine in that region and apply the resistive force. Patient was instructed to contract isometrically for five seconds without exceeding the therapist force. thereafter, therapist counterforce gradually reduced and patient was asked to relaxed. Therapist move the joint into new point of barrier and same protocol repeated three times.~Patient came thrice per week for a total of 4 weeks."
219646529|NCT03408249|OTHER|questionnaire|Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
219646530|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
219646531|NCT02673268|PROCEDURE|Mastectomy|
219646532|NCT02673268|DEVICE|Da Vinci Robot Xi|
219646533|NCT02271399|DRUG|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
219646534|NCT02271399|DRUG|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
219646535|NCT04722029|BIOLOGICAL|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
219646536|NCT03845491|DEVICE|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
219646537|NCT06679569|DRUG|rocuronium 0.2 mg/kg/hr continuous infusion|To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.
219061511|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
219646538|NCT06679569|DRUG|rocuronium 0.6 mg/kg/hr continuous infusion|To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
219646539|NCT03406559|OTHER|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
219646540|NCT01590043|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
219646541|NCT04670952|OTHER|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
219646542|NCT04670952|OTHER|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
219646543|NCT02322658|DRUG|Eszopiclone Tablets 3 mg|
219646544|NCT01680159|DRUG|TA-650|
219646545|NCT06683313|COMBINATION_PRODUCT|combination femoral nerve and popliteal sciatica block|Combination of femoral nerve and popliteal sciatica block performed after knee surgery
219061512|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
219061513|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
219061514|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
219646546|NCT06683313|COMBINATION_PRODUCT|combination adductor canal and IPACK block|Combination of adductor canal and IPACK block performed after knee surgery
219646547|NCT03633305|DRUG|Hypnotics|Medication used 1 to 7 nights/week for 6 to 8 weeks.
219646548|NCT03633305|BEHAVIORAL|Online CBT|Internet self-help program for insomnia with 6 cores.
218961264|NCT02874768|DRUG|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
218961265|NCT00282347|DRUG|Rituximab|Rituximab was provided as a sterile solution for injection.
219646549|NCT03633305|BEHAVIORAL|Face-to-face CBT|Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
218961266|NCT00282347|DRUG|Placebo|Placebo was provided as a sterile solution for injection.
218961267|NCT00282347|DRUG|Mycophenolate mofetil|
218961268|NCT00282347|DRUG|Methylprednisolone|
218961269|NCT00282347|DRUG|Diphenhydramine|
218961270|NCT00282347|DRUG|Acetaminophen|
218961271|NCT00282347|DRUG|Prednisone|
218961272|NCT05388123|DRUG|Low dose vemurafenib plus rituximab|Vemurafenib 240 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
218961273|NCT00356122|DRUG|Docetaxel|70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
218961274|NCT00356122|DRUG|Oxaliplatin|100 mg/m\^2 administered IV on Day 1 for Cycles 1-6
218961275|NCT00356122|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
218961276|NCT04386824|OTHER|Erectil dysfunction|A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
218961277|NCT00491556|PROCEDURE|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
218961278|NCT00491556|PROCEDURE|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
218961279|NCT00990457|BEHAVIORAL|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.~The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
218961280|NCT03488758|OTHER|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
218961281|NCT03488758|OTHER|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
219061515|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
219061516|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
219061517|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
219061518|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
219061519|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
219061520|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
219061521|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
219061522|NCT00602303|DRUG|Torsemide|
219061523|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
219061524|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
219646550|NCT02200536|OTHER|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
219646551|NCT02200536|OTHER|Infant oral health pamphlet|Infant oral health pamphlet
219646552|NCT04936802|DEVICE|Transcatheter tricuspid valve repair system (Trialign)|To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation
219646553|NCT00380289|DRUG|Thiazide and beta blocker|
219646554|NCT06682767|DIETARY_SUPPLEMENT|FMD1 (LNT22-017-1)|FMD is a plant-based ketogenic diet that provides essential nutrients while maintaining hypo-caloric content. FMD is administered cyclically with 3-5 consecutive days of the diet followed by resumption of normal eating.
219646555|NCT00061867|DRUG|pegylated liposomal doxorubicin hydrochloride|
219061525|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
219061526|NCT00536367|OTHER|No intervention - observational study only|
219061527|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
219061528|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
219061529|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
219646556|NCT00061867|PROCEDURE|hyperthermia treatment|
218961282|NCT06072209|BEHAVIORAL|Behavioral Activation|\- instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
218961283|NCT06072209|BEHAVIORAL|Mindfulness and Gratitude|\- instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
218961284|NCT06072209|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
218961285|NCT06994910|OTHER|Maitland mobilization techniques|Participants with temporomandibular joint dysfunction received Maitland mobilization techniques applied to the TMJ over a defined treatment period. Outcomes were assessed at baseline (pre-intervention) and after completion of the intervention (post-intervention)
218961286|NCT06995534|OTHER|splint|static wrist-hand splint + education on activity modification and positioning in daily life
218961287|NCT06995534|OTHER|Exercise Therapy|Home-based Exercise Therapy + Education on activity modification and positioning in daily life
218961288|NCT06993519|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
218961289|NCT06993649|BEHAVIORAL|Experimental High Reality Simulator|The process steps including normal labour skills will be shown on d1= High Reality simulator (full-size, computer-based, time-setting, expressions of pain from the mother, performed with a female robotic simulator, Noelle S575 Mother and Newborn simulator), d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) and d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the labour scenario) will be done to each student in the group respectively.
218961290|NCT06993649|BEHAVIORAL|Experimental Medium Reality Simulator|The process steps including normal labour skills will be shown on d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) will be done to each student in the group respectively.
218961291|NCT06993649|BEHAVIORAL|Experimental Simulated Woman|Then, the process steps including normal labour skills will be shown d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the scenario of labour by the midwifery student) will be done to each student in the group respectively.
218961292|NCT06994624|OTHER|Nutritional intervention|A plant-based diet
218961293|NCT06994403|DIETARY_SUPPLEMENT|Durum wheat pasta enriched with carob flour|Participants will consume 68 g of durum wheat pasta enriched with carob flour (231 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
218961294|NCT06994403|DIETARY_SUPPLEMENT|Standard durum wheat pasta|Participants will consume 63 g of standard durum wheat pasta (221 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
218961295|NCT06994403|DIETARY_SUPPLEMENT|White bread reference meal|Participants will consume 84 g of white bread (225 kcal), providing 50 g of available carbohydrates. The bread will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
218961296|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 IM on Days 1, 8, 15, and 22."
218961297|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 IM on Days 1, 8, 15, and 22."
218961298|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive high dose of KSHN001034 IM on Days 1, 8, 15, and 22."
218961299|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 SC on Days 1, 8, 15, and 22."
218961300|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 SC on Days 1, 8, 15, and 22."
219646557|NCT01148303|DRUG|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
219061530|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
219061531|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
219061532|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
219061533|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
219646558|NCT01148303|DRUG|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
219646559|NCT01148303|DRUG|Placebo|Placebo
219646560|NCT03745690|PROCEDURE|Image-Guided Surgery|Undergo near-infrared image guided surgical resection
219646561|NCT03745690|DRUG|Indocyanine Green Drug|Given IV
219646562|NCT02388815|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
219646563|NCT05909878|DEVICE|Virtual Reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
218961301|NCT06995482|DRUG|Fulvestrant|"Reference Product: Faslodex® (Fulvestrant), 5 mL pre-filled syringe containing 250 mg/5 mL of fulvestrant, administered as two 5 mL injections (total 500 mg) via intramuscular (IM) injection. Marketed by AstraZeneca.~• 2 subjects will receive 500 mg Fulvestrant IM on Days 1 and 15."
218961302|NCT06995248|BEHAVIORAL|Laughter Yoga|Laughter yoga sessions are a behavioral intervention regularly conducted to help participants reduce stress, build social connections, and enhance overall well-being.
218961303|NCT06994234|BEHAVIORAL|In-Place Slow Jogging|ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes.
218961304|NCT06993987|OTHER|Descriptive analysis|The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.
218961305|NCT06993883|DRUG|Venetoclax|observational study for the result of venetoclax use combined with chemotherapy in AML patients in Sohag governorate
218961306|NCT06994585|DRUG|Drinklear|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
218961307|NCT06994585|DRUG|Niflec|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
218961308|NCT06995404|PROCEDURE|TAP Block Group|Patients in the TAP group will receive a bilateral Transversus Abdominis Plane (TAP) block under ultrasound guidance prior to surgery after general anaesthesia, with the local anesthetic administered between the internal oblique and transversus abdominis muscles. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
218961309|NCT06995404|PROCEDURE|M-TAPA Block group|Patients in the M-TAPA group will receive a bilateral Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA) under ultrasound guidance prior to surgery after general anaesthesia. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
218961310|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (with strategy)|Participants will learn to play a complex online game using specific guidance or strategy.
219061534|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
219061535|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
219646564|NCT05909878|OTHER|Standard Protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
218961311|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (without strategy)|Participants will learn to play a complex online game without specific guidance or strategy.
218961312|NCT06994702|DEVICE|MRI without mask|MRI in position of cerebral radiotherapy treatment without mask
218961313|NCT06994702|DEVICE|MRI with mask 1|MRI in position of cerebral radiotherapy treatment with mask 1
218961314|NCT06994702|DEVICE|MRI with mask 2|MRI in position of cerebral radiotherapy treatment with mask 2
219061536|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
219061537|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
219061538|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
219061539|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
219061540|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
219061541|NCT05458349|DEVICE|acellular dermis|
218961315|NCT06995079|PROCEDURE|Postoperative pain assessment of patients who underwent block|Postoperative pain assessment of patients who underwent block
218961316|NCT06993779|OTHER|Deep learning system for prognostication prediction in upper tract urothelial carcinoma|develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.
219061542|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
219646565|NCT00310752|DEVICE|DermaStream(tm) application and Streaming of Saline|
219646566|NCT02179970|DRUG|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
218961317|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|doxycycline gel exhibits bacteriostatic activity against prevalent periodontal pathogens
218961318|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|the formulation of doxycycline and incorprating it with PLGA nano-particles will increase the absorption rate in gingival sulcus
218961319|NCT06994455|PROCEDURE|scaling and root planing|control group in the study
218961320|NCT06994637|OTHER|Liquid Hourglass|The liquid hourglass to be used in the study is made of high-quality plastic material, approximately 14 cm long. It contains colored liquid gel. When the hourglass is turned, the colored liquid gel inside flows downwards in the form of bubbles, drop by drop. It is suitable for use by all age groups of children. The visual and moving nature of the liquid hourglass may distract the child during the blood collection process.
218961321|NCT06994637|OTHER|Spiky Ball|The spiky ball to be used in the study is a ball made of sturdy environmentally friendly plastic, approximately 6 cm in size. This ball has a hard body with thorns on it and provides tactile stimulation by pricking the child's fingers. The pressure applied by the thorns on the balls to the hand can reduce pain, muscle tension and stress by stimulating the nerve endings more quickly. It is suitable for use by children over the age of two. The tactile stimulation on the spiky ball can distract the child during the blood collection process.
218961322|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB).|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
219061543|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
219061544|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
219061545|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
219061546|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
219061547|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
219061548|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
219061549|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
219061550|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
219061551|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
219061552|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
219061553|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
219061554|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
219061555|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
219061556|NCT00249145|DRUG|risperidone|
219223711|NCT07022106|OTHER|Myofascial Release Therapy (MRT) Group|"Myofascial Release Therapy (MRT) involves hands-on palpation to detect fascial restrictions, followed by 60-90 seconds of sustained pressure to release tension. In the supine position, the target areas include the superficial fascia, transversalis fascia, and extraperitoneal fascia, while in the prone position, the focus shifts to the thoracolumbar fascia and the erector spinae complex. This technique aims to restore mobility and reduce restrictions within the fascial system.~Frequency: Each patient will recieve a single session at their most painful day from this intervention."
219646567|NCT00005889|DRUG|alanine|
219646568|NCT00005889|DRUG|amino acids|
219646569|NCT00005889|DRUG|glucagon|
219646570|NCT00005889|DRUG|glucose|
219646571|NCT00005889|DRUG|glutamine|
219646572|NCT00005889|DRUG|glycerol|
219646573|NCT00005889|DRUG|insulin|
219646574|NCT00005889|DRUG|leucine|
219646575|NCT00005889|DRUG|lipids|
219646576|NCT00005889|DRUG|urea|
219646577|NCT04676451|DEVICE|Femto-AK|Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
219646578|NCT00168272|DEVICE|Transcranial Magnetic Stimulation|
219646579|NCT04225429|DRUG|Tazemetostat|800mg/dose taken orally twice every day.
219646580|NCT06120569|DEVICE|Soleus ms exercise|Soleus muscle exercise before and after eating by half an hour
219646581|NCT03204929|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
219646582|NCT01252563|DRUG|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
219646583|NCT03025139|OTHER|Educational Intervention|Attend survivorship education
219646584|NCT03025139|OTHER|Laboratory Biomarker Analysis|Correlative studies
219646585|NCT03025139|PROCEDURE|Meditation Therapy|Attend mindfulness meditation
219646586|NCT03025139|OTHER|Questionnaire Administration|Ancillary studies
219646587|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 3 μg/kg
219646588|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 5 μg/kg
219646589|NCT02537002|DRUG|Placebo|A single intravenous dose of matched placebo
219646590|NCT06028802|DIAGNOSTIC_TEST|CT Clock Tool measurement|Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
219646591|NCT02497963|PROCEDURE|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
219646592|NCT02497963|PROCEDURE|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
219646593|NCT02825758|DIETARY_SUPPLEMENT|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
219646594|NCT02223936|OTHER|group exposed|Assessment by Brunet Lezine scale
219646595|NCT02223936|OTHER|Control|Not exposed group
219646596|NCT04293913|BEHAVIORAL|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
219646597|NCT04701229|GENETIC|somatic cytogenetic and genetic characterization|investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
219646598|NCT01246869|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
219646599|NCT01246869|DRUG|1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole|Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia
219646600|NCT01246869|DRUG|[15O]water|Brain scan with imaging tracer used for measuring tumor blood flow/perfusion
219646601|NCT01246869|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Brain scan to assess tumor size and tumor blood flow/perfusion
219646602|NCT03429244|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET-MRI|Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
219646603|NCT06429345|DRUG|Coenzyme Q10 100 Milligrams Oral Capsule|Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
219646604|NCT06429345|DRUG|Placebo|placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
219646605|NCT03627338|DIAGNOSTIC_TEST|questionaire, interview|questionaire, interview
219646606|NCT04502225|OTHER|Tilt|Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
218961323|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB)|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
218961324|NCT03640520|OTHER|FACETS: Pediatric Resuscitation|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
219646607|NCT04502225|OTHER|Elevated trunk|Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
219646608|NCT04502225|OTHER|Tilt - In home|Tilt of the whole bed so that the head is elevated by 8 inches overnight.
219646609|NCT04502225|OTHER|Elevated Trunk - In home|Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
219646610|NCT01062243|BEHAVIORAL|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
219646611|NCT05573477|DRUG|ATB-1011|Oral tablet
219646612|NCT05573477|DRUG|ATB-1012|Oral tablet
219646613|NCT05573477|DRUG|ATB-1013|Oral tablet
219646614|NCT05573477|DRUG|ATB-1011 placebo|Placebo matched to ATB-1011
219646615|NCT05573477|DRUG|ATB-1012 placebo|Placebo matched to ATB-1012
219646616|NCT05573477|DRUG|ATB-1013 placebo|Placebo matched to ATB-1013
218961325|NCT03640520|OTHER|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
218961326|NCT05542745|DEVICE|palatal and buccal retraction|comparison
218961327|NCT01094561|DRUG|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
218961328|NCT01094561|PROCEDURE|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
218961329|NCT01094561|PROCEDURE|Secretin-Enhanced Endoscopic Ultrasound|
218961330|NCT05953090|DEVICE|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
218961331|NCT00139867|DRUG|PARCOPA|
218961332|NCT06556654|DEVICE|TRBR Device|The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
218961333|NCT06786494|OTHER|Tart Cherry Juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of tart cherry juice at approximately 1 hour before bedtime for 4 weeks.
218961334|NCT06786494|OTHER|Placebo juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of placebo juice at approximately 1 hour before bedtime for 4 weeks.
218961335|NCT05519644|OTHER|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
218961336|NCT05519644|OTHER|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
218961337|NCT05519644|OTHER|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
218961338|NCT05519644|OTHER|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
218961339|NCT05519644|OTHER|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
218961340|NCT05519644|BEHAVIORAL|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
219646617|NCT02716831|BEHAVIORAL|Nutritional Counseling & Acceptance-based Therapy|
219646618|NCT02716831|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|
218961341|NCT05519644|OTHER|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
219646619|NCT04167631|RADIATION|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
219646620|NCT01279122|DEVICE|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
219646621|NCT03404726|DRUG|BAY2402234|BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
219646622|NCT00004422|DRUG|immune globulin|
219646623|NCT03134534|PROCEDURE|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
219646624|NCT03134534|PROCEDURE|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
219646625|NCT01609634|OTHER|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
219646626|NCT01609634|OTHER|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
219646627|NCT01609634|OTHER|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
219646628|NCT04675957|OTHER|cardiac rehabilitation|stationary or ambulatory cardiac rehabilitation
219646629|NCT01863316|DEVICE|I gel|
219646630|NCT01863316|DEVICE|LMA Supreme|
219646631|NCT00658775|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
218961342|NCT05519644|OTHER|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
218961343|NCT05519644|OTHER|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
218961344|NCT05519644|OTHER|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
218961345|NCT05519644|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
218961346|NCT05519644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
218961347|NCT05519644|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
218961348|NCT05680727|PROCEDURE|transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
218961349|NCT06820450|OTHER|Blood test|A blood test (2 x 5 ml dry tubes) will be taken to analyze steroid profiles
218961350|NCT06820450|OTHER|urine sample|a 20 ml urine sample will be taken to analyze steroid profiles
218961351|NCT06820450|OTHER|vaginal sample|to characterize the microbiota.
218961352|NCT06909019|BEHAVIORAL|Control (QR) Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
218961353|NCT06909019|BEHAVIORAL|Low Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Low Climate Impact labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
218961354|NCT06909019|BEHAVIORAL|High Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
218961355|NCT06909019|BEHAVIORAL|Traffic Light Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
218961356|NCT06909019|BEHAVIORAL|Climate Grade Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
218961357|NCT04268498|DRUG|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
218961358|NCT04268498|DRUG|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
219646632|NCT00658775|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
219646633|NCT04025775|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data."
219061557|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
219646634|NCT04025775|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
218961359|NCT04268498|DRUG|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
218961360|NCT04268498|DRUG|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
218961361|NCT04268498|DRUG|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
218961362|NCT04268498|DRUG|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
218961363|NCT04268498|DRUG|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
218961364|NCT04268498|DRUG|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
218961365|NCT04268498|BIOLOGICAL|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
218961366|NCT06268730|OTHER|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
218961367|NCT03856775|DEVICE|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
218961368|NCT04166227|PROCEDURE|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
218961369|NCT04166227|PROCEDURE|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
218961370|NCT06939894|BEHAVIORAL|Drama activities|iintervention group will paticipate drrama activities aabout pain assessment of a patient.
218961371|NCT04854642|DRUG|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
218961372|NCT01372982|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
218961373|NCT01918722|DRUG|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
218961374|NCT01918722|DRUG|placebo|placebo herbal medicine, one dose,bid, for 10 days
218961375|NCT01918722|DRUG|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
218961376|NCT03794960|BIOLOGICAL|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
219646635|NCT04091100|PROCEDURE|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
219061558|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
219646636|NCT04091100|PROCEDURE|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
219646637|NCT02368743|DRUG|mesalazine|
219646638|NCT00588211|BEHAVIORAL|Interviews|45-minute individual interviews after the conclusion of their dental appointment
219646639|NCT00588211|BEHAVIORAL|focus group|A focus group of the preliminary cancer-related risk perception item pool.
219646640|NCT00588211|BEHAVIORAL|Survey|Quantitative item analysis of the final item pool.
219646641|NCT00588211|BEHAVIORAL|Survey|A second confirmatory factor analysis.
219646642|NCT00387010|DRUG|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
219646643|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
218961377|NCT03794960|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
218961378|NCT05320627|DRUG|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
218961379|NCT05611177|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
218961380|NCT00119600|DRUG|AMG 114|
218961381|NCT05500066|DEVICE|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
218961382|NCT03249220|DEVICE|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
218961383|NCT03688425|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
218961384|NCT03688425|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
218961385|NCT05523518|DEVICE|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
218961386|NCT05523518|DEVICE|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
218961387|NCT04644445|DIETARY_SUPPLEMENT|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
218961388|NCT04759027|OTHER|subacromial distance measurement|distance between acromion and humerus
218961389|NCT05091203|DRUG|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
218961390|NCT06240507|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
218961391|NCT06240507|PROCEDURE|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
218961392|NCT01596673|DRUG|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
218961393|NCT01596673|DRUG|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
218961394|NCT02430506|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
218961395|NCT02430506|BIOLOGICAL|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
218961396|NCT03213353|DRUG|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
218961397|NCT03213353|DRUG|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
218961398|NCT01915264|DRUG|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
218961399|NCT02048189|DRUG|LEVEMIR|
218961400|NCT02048189|DRUG|APIDRA|
218961401|NCT00562627|DRUG|ropivacaine|intraoperative and 1. postoperative day
218961402|NCT00562627|DRUG|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
218961403|NCT00562627|DRUG|ketorolac|intraoperative and 1. postoperative day
218961404|NCT00562627|DRUG|morphine|intraoperative
218961405|NCT00562627|DRUG|fentanyl|continuous postoperatively
218961406|NCT00562627|DRUG|bupivacaine|continuous postoperatively
218961407|NCT01139840|DIETARY_SUPPLEMENT|vitamin D2|Study Supplement
218961408|NCT01139840|DIETARY_SUPPLEMENT|vitamin D3|Study Supplement
218961409|NCT01994499|DEVICE|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
218961410|NCT01994499|DRUG|Medical drainage|Medical pleural drainage
218961411|NCT00625742|BEHAVIORAL|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
219061559|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
219061560|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
218961412|NCT00625742|BEHAVIORAL|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
218961413|NCT00625742|DRUG|Melatonin|20 mg by mouth (PO) Daily
218961414|NCT00625742|DIETARY_SUPPLEMENT|Juven|90 calories of Juven, twice a day.
218961415|NCT00625742|DRUG|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
218961416|NCT00625742|DRUG|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
218961417|NCT03264170|DIAGNOSTIC_TEST|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
218961418|NCT00333892|PROCEDURE|leukapheresis|pack of cells as per protocol
218961419|NCT01709578|DRUG|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
218961420|NCT01709578|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
218961421|NCT01709578|DRUG|hydroxychloroquine|Dispensed according to the local practice.
218961422|NCT01709578|DRUG|methotrexate|Dispensed according to the local practice.
219061561|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
219646644|NCT00949819|OTHER|Active surveillance|Serial, long term data collection and active surveillance
218961423|NCT01709578|DRUG|sulfasalazine|Dispensed according to the local practice.
218961424|NCT01709578|DRUG|leflunomide|Dispensed according to the local practice.
218961425|NCT04050371|DRUG|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
218961426|NCT01107418|DRUG|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
218961427|NCT01107418|DRUG|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
218961428|NCT01107418|DRUG|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
218961429|NCT01107418|DRUG|RO5185426|960 mg orally twice daily, from day 22 onward
218961430|NCT01107418|DRUG|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
218961431|NCT00597701|DRUG|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
218961432|NCT00597701|DRUG|Placebo|Placebo
218961433|NCT00597701|DRUG|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
218961434|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (\~140 mg tablet)
219646645|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
219646646|NCT06036810|OTHER|Shared Medical Decision Tool|standard of care
219646647|NCT06036810|BEHAVIORAL|Engaging Patients in Decision Making|standard of care
219646648|NCT06036810|BEHAVIORAL|Literacy Spanish Language|standard of care
219646649|NCT06683625|DIAGNOSTIC_TEST|6K Max Effort Erg Test|"6K Max Effort Erg Test, involves participants completing a 6000-meter rowing distance on an ergometer as quickly as possible. This test is designed to measure peak endurance and performance under controlled conditions and will serve as a primary assessment of each athlete's physical output and adaptive capacity."
219646650|NCT00789256|DRUG|Melphalan|Melphalan: 2mg orally, once daily
219646651|NCT00789256|DRUG|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
219646652|NCT00789256|DRUG|Melphalan and bortezomib|
219646653|NCT01453478|DRUG|GSK1325756|CXCR2 antagonist
219646654|NCT06478433|DEVICE|Munatoril Aerosol Combo|"Munatoril® Aerosol Combo is a Medical Device that contains:~5 ml single-dose vials of sterile, 3% hypertonic, near-neutral pH bromine-iodine saline solution, based on Cervia integral sea salt, salso-bromo-iodine saline mother water from the Cervia Thermal Baths and hyaluronic acid with high molecular weight.~Lavonase® syringe with blue nebulizer valve (microsol), 10 ml, Medical Device for the administration of solutions in nebulized form within the nasal cavities and nasopharynx."
219646655|NCT06478433|DEVICE|Iperclenny|Hypertonic and Isotonic solution present on market in italy.
219646656|NCT00191347|DRUG|pemetrexed|
219646657|NCT00191347|DRUG|gemcitabine|
219646658|NCT05306314|DIETARY_SUPPLEMENT|TREATAPROST|oral administration before meals 30 minutes
219646659|NCT04529785|PROCEDURE|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
219646660|NCT04529785|PROCEDURE|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
219646661|NCT02808728|DRUG|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
219646662|NCT02808728|DRUG|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
219646663|NCT00431028|DEVICE|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
219646664|NCT02468154|DEVICE|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
219646665|NCT02468154|OTHER|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
219646666|NCT04074681|BEHAVIORAL|Gambling Internet-based Protocol|Gambling Internet-based protocol is a multimedia interactive and self-help program for problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
219646667|NCT02646540|DRUG|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
219646668|NCT02646540|DRUG|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
219646669|NCT02646540|DRUG|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
219646670|NCT00058929|DRUG|treprostinil sodium|
219061562|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
219061563|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
219061564|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
219646671|NCT03992027|BEHAVIORAL|CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis|CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
219646672|NCT03992027|BEHAVIORAL|Waitlist Control|Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
219646673|NCT03998384|PROCEDURE|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
219061565|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
219061566|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
219061567|NCT02455908|DRUG|Proleukin®|
219061568|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
219061569|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
219061570|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
219061571|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
219061572|NCT00755586|PROCEDURE|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
218961435|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (\~275 mg tablet)
219061573|NCT00755586|PROCEDURE|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
219061574|NCT00755586|PROCEDURE|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
219061575|NCT05690958|OTHER|Survey|Filling in a survey
219061576|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
219061577|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
219061578|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
219061579|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
219646674|NCT03998384|PROCEDURE|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
219646675|NCT02686463|PROCEDURE|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
219646676|NCT02686463|PROCEDURE|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
218961436|NCT01258270|PROCEDURE|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
218961437|NCT01258270|PROCEDURE|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
219646677|NCT01829100|BEHAVIORAL|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
219646678|NCT02841280|DRUG|Chlorthalidone|This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
219646679|NCT02841280|DRUG|Placebo|This is a forced-titration study and placebo will be increased if goal BP is not achieved.
219646680|NCT02246179|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
219646681|NCT02246179|DRUG|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
218961438|NCT03406923|OTHER|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
219061580|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
219646682|NCT02246179|DRUG|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
219646683|NCT00077142|DRUG|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
219646684|NCT05322889|DRUG|Telmisartan tablets|12 weeks treatment
219646685|NCT05277051|DRUG|GSK4381562|GSK4381562 will be administered.
219646686|NCT05277051|DRUG|Dostarlimab|Dostarlimab will be administered.
218961439|NCT01314612|BEHAVIORAL|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
218961440|NCT01030627|DEVICE|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
218961441|NCT02749669|OTHER|Qualitative research|Semi-structured Interviews
218961442|NCT00902161|DRUG|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
218961443|NCT00902161|DRUG|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
218961444|NCT00902161|DRUG|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
218961445|NCT00988325|DRUG|Tamiflu|oral repeating dose
218961446|NCT00937781|GENETIC|RNA analysis|
218961447|NCT00937781|GENETIC|gene expression analysis|
218961448|NCT00937781|GENETIC|microarray analysis|
218961449|NCT00937781|GENETIC|polymerase chain reaction|
218961450|NCT00937781|OTHER|immunohistochemistry staining method|
218961451|NCT00937781|OTHER|laboratory biomarker analysis|
219061581|NCT01085318|DRUG|Rebif|44 mcg tiw
219061582|NCT01224041|DRUG|Tacrolimus|oral
219061583|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
219061584|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
219646687|NCT05277051|DRUG|Belrestotug|Belrestotug will be administered.
219646688|NCT05277051|DRUG|Nelistotug|Nelistotug will be administered.
219646689|NCT05277051|DRUG|GSK5764227|GSK5764227 will be administered.
218961452|NCT00301821|BIOLOGICAL|epratuzumab|
219061585|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
219061586|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
219061587|NCT01267123|PROCEDURE|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
219061588|NCT01267123|PROCEDURE|Standard care|The patient will be placed in the standard horizontal position
219646690|NCT03448731|DRUG|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
219646691|NCT02449382|PROCEDURE|continuous venovenous hemofiltration|If the serum sodium concentration \>150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
219646692|NCT02449382|DRUG|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
219646693|NCT03550755|BIOLOGICAL|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
219646694|NCT02754271|OTHER|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
219646695|NCT00002837|BIOLOGICAL|Filgrastim (G-CSF)|
219646696|NCT00002837|DRUG|Cyclophosphamide|
219646697|NCT00002837|DRUG|Doxorubicin Hydrochloride|
219646698|NCT00002837|DRUG|Paclitaxel|
219646699|NCT00002837|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
219646700|NCT04538833|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
219646701|NCT04538833|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
218961453|NCT00301821|BIOLOGICAL|rituximab|
218961454|NCT00301821|DRUG|cyclophosphamide|
218961455|NCT00301821|DRUG|doxorubicin hydrochloride|
218961456|NCT00301821|DRUG|prednisone|
218961457|NCT00301821|DRUG|vincristine sulfate|
218961458|NCT03206957|DIAGNOSTIC_TEST|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
219646702|NCT02026791|DEVICE|I-gel|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
218961459|NCT03206957|DIAGNOSTIC_TEST|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
219061589|NCT04064281|OTHER|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
219061590|NCT04064281|OTHER|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
219646703|NCT02026791|DEVICE|Supreme-LMA|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
219646704|NCT01869205|DEVICE|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
219646705|NCT06665360|OTHER|The high speed bur was used to mill the cancellous cortical bone of the lamina|The high speed bur was used to mill the cancellous cortical bone of the lamina
219646706|NCT06242392|GENETIC|homologous recombination deficiency|Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
219646707|NCT02298062|DRUG|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
219646708|NCT02298062|DRUG|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
218961460|NCT03206957|DIAGNOSTIC_TEST|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
218961461|NCT03206957|DIAGNOSTIC_TEST|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
218961462|NCT03206957|DIAGNOSTIC_TEST|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
218961463|NCT00195871|DRUG|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
218961464|NCT00195871|PROCEDURE|hematopoietic stem cell allograft|conventional procedures
218961465|NCT00892918|DRUG|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
218961466|NCT05503316|OTHER|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
218961467|NCT05503316|OTHER|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
218961468|NCT03758326|OTHER|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
219646709|NCT06663540|OTHER|Exercise & Abacus|"Features two main interventions: physical exercise sessions and abacus training activities.~Physical Exercise Sessions aim to enhance fitness and cognitive function through activities like aerobic exercises and team sports. Research indicates that regular physical activity can improve memory, attention, and problem-solving skills essential for academic success.~Abacus Training Activities focus on developing mathematical skills and cognitive abilities. Children learn to manipulate the abacus for calculations, which enhances numerical understanding and memory retention, positively impacting academic performance.~The program's innovative dual approach suggests that integrating physical and cognitive training can lead to greater improvements in academic performance and emotional resilience than either intervention alone."
219646710|NCT06436950|DEVICE|transcutaneous electrical phrenic nerve stimulation (TEPNS)|TEPNS is conducted twice a day for consecutive 5 days. Electrodes are applied to bilateral neck skin which phrenic nerve runs underneath.
219646711|NCT02727777|DRUG|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
219646712|NCT02727777|OTHER|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
219646713|NCT05152966|DEVICE|Ablation|Ablation using the FARAPULSE™ Cardiac Ablation System Plus
219646714|NCT00005944|DRUG|chemotherapy|
219646715|NCT00005944|DRUG|fluorouracil|
219646716|NCT00005944|DRUG|leucovorin calcium|
219646717|NCT00005944|DRUG|mitomycin C|
219646718|NCT00005944|PROCEDURE|conventional surgery|
219646719|NCT00005944|PROCEDURE|laparoscopic surgery|
219646720|NCT05052372|DRUG|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
219646721|NCT02787421|DEVICE|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
219646722|NCT03925038|BEHAVIORAL|Augmented Care: Electronic Media Dashboard|A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
219646723|NCT03925038|BEHAVIORAL|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
219646724|NCT03732352|OTHER|Fludeoxyglucose F-18|Given IV
219646725|NCT03732352|DRUG|Osimertinib|Given PO
219646726|NCT03732352|PROCEDURE|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
219646727|NCT01794182|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
219646728|NCT01794182|DRUG|Placebo|Administered as specified in the treatment arm.
219646729|NCT03005327|DRUG|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
218961469|NCT02935543|BIOLOGICAL|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
218961470|NCT02670343|DRUG|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
218961471|NCT01837771|DEVICE|Diaphragmatic stimulation|
218961472|NCT00494065|OTHER|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
218961473|NCT00494065|OTHER|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
218961474|NCT03718325|DEVICE|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
218961475|NCT03718325|DEVICE|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
218961476|NCT02931591|DRUG|Metformin|Metformin is administered as an oral solution
218961477|NCT02931591|DRUG|Growth Hormone|Growth Hormone- no specific band
218961478|NCT02931591|DRUG|Placebo|
218961479|NCT04545359|BEHAVIORAL|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
219646730|NCT01377740|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219646731|NCT02626130|PROCEDURE|Cryosurgery|Undergo cryoablation
219646732|NCT02626130|OTHER|Laboratory Biomarker Analysis|Correlative studies
219646733|NCT02626130|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219646734|NCT02626130|BIOLOGICAL|Tremelimumab|Given IV
219646735|NCT03718520|OTHER|no intervention, this is a purely observational study|No intervention
219646736|NCT06411730|DRUG|BMS-986368|Specified dose on specified days
219646737|NCT01987739|DRUG|200 mg almorexant|
219646738|NCT01987739|DRUG|400 mg almorexant|
219646739|NCT01987739|DRUG|1000 mg almorexant|
219646740|NCT01987739|DRUG|20 mg zolpidem|
219646741|NCT01987739|DRUG|40 mg zolpidem|
219646742|NCT01987739|DRUG|placebo|
219646743|NCT04683692|DEVICE|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
219646744|NCT04683692|OTHER|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
219646745|NCT04523272|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219646746|NCT04523272|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
219646747|NCT04523272|DRUG|Sunitinib|A multi-target receptor tyrosine kinase inhibitor.
219646748|NCT05076669|OTHER|stoma follow-up|delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites
219646749|NCT05076669|OTHER|standard of care|routine management of stoma
218961480|NCT04545359|BEHAVIORAL|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
219646750|NCT03359668|DIAGNOSTIC_TEST|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
219646751|NCT01510795|DRUG|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
219646752|NCT06257927|BEHAVIORAL|Tuko Pamoja|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
219646753|NCT05933174|OTHER|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
219646754|NCT05933174|OTHER|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
219646755|NCT00915876|DRUG|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
218961481|NCT02514317|PROCEDURE|percutaneous treatment|
218961482|NCT02514317|DEVICE|Ultrasound|
218961483|NCT03858478|DRUG|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
218961484|NCT00002567|BIOLOGICAL|filgrastim|
218961485|NCT00002567|DRUG|etoposide|
219646756|NCT00915876|DRUG|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
219646757|NCT04619329|DEVICE|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
219646758|NCT04619329|PROCEDURE|Surgical Resection|Surgical Resection of HCC
218961486|NCT00002567|PROCEDURE|peripheral blood stem cell transplantation|
218961487|NCT00002567|RADIATION|low-LET electron therapy|
219061591|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
219646759|NCT06665529|OTHER|28-day mortality prediction by ICU staff and mortality scores|28-day mortality prediction by ICU staff (three senior physicians and ICU nurse) and mortality scores (APACHE 2, MPM 2 and MODS).
219646760|NCT06684548|PROCEDURE|Hip/shoulder width ratio|the effect of hip/shoulder-width ratio on sensory blockade level in patients undergoing intrathecal anesthesia for subumbilical herniorrhaphy
219646761|NCT03902184|BIOLOGICAL|IPH4102|Patients will receive a flat dose of 750mg
219646762|NCT05303298|DEVICE|Anti-reflux oesophageal stent|Fully covered self-expanding metal stent with anti-reflux mechanism
219646763|NCT05303298|DEVICE|Conventional oesophageal stent|Fully covered self-expanding metal stent without an anti-reflux mechanism
219646764|NCT01923298|DRUG|Estradiol|
219646765|NCT04880798|DIAGNOSTIC_TEST|124I PET/CT|The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
219646766|NCT03008265|OTHER|Postoperative fascial dehiscence|
219646767|NCT02572076|DEVICE|Motus Cleansing System|
219646768|NCT05209776|BIOLOGICAL|Peripheral immunological assessment on venous blood|Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
218961488|NCT00002567|RADIATION|low-LET photon therapy|
218961489|NCT03454321|OTHER|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
218961490|NCT04877223|OTHER|No intervention|No intervention
218961491|NCT04040868|DEVICE|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
218961492|NCT04040868|DEVICE|Freehand|conventional fluoroscopy-assisted
219061592|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
219061593|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
219061594|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
219061595|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
219061596|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
218961493|NCT00623116|DRUG|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
218961494|NCT01314911|DRUG|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
218961495|NCT01314911|DRUG|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
218961496|NCT06115031|DRUG|Remimazolam|General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
218961497|NCT06115031|DRUG|Propofol|General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
218961498|NCT01565837|DRUG|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
218961499|NCT01565837|RADIATION|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
218961500|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
219061597|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
219061598|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
219061599|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
219061600|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
219061601|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
219061602|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
219061603|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
219646769|NCT05209776|BIOLOGICAL|Immunological assessment carried out on intracardiac material|Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
219646770|NCT05016401|DEVICE|KONTACT PERIO LEVEL (KPL)|The Kontact™ Perio Level is an implant with a transgingival neck that facilitates one-step surgery.
219061604|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
219061605|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
219061606|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
219061607|NCT06669013|DRUG|dinutuximab beta|Chemotherapy + Immunotherapy (dinutuximab beta)
219646771|NCT01068067|OTHER|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
219646772|NCT01068067|DRUG|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
219646773|NCT00883467|PROCEDURE|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
219646774|NCT00883467|PROCEDURE|no preconditioning|no preconditioning
219646775|NCT04525768|DIAGNOSTIC_TEST|JAK2 mutation test|Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
219646776|NCT02591901|DRUG|Uro vaxom|Prevention of recurrent symptomatic lower urinary tract infections
219646777|NCT02591901|OTHER|Placebo comparator|Placebo comparator
219646778|NCT04287946|DEVICE|Ablation|Ablation of a single-side of the greater splanchnic nerve
218961501|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
218961502|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
218961503|NCT04473625|OTHER|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
218961504|NCT00141583|DRUG|Enalapril 20 mg bd|
218961505|NCT00141583|DRUG|Candesartan 8 mg bd|
218961506|NCT02369562|PROCEDURE|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
218961507|NCT01843595|BEHAVIORAL|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
218961508|NCT00460369|DRUG|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
218961509|NCT00460369|DRUG|artemether-lumefantrine|"tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight"
219061608|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
218961510|NCT00460369|DRUG|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
218961511|NCT04540939|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
218961512|NCT04540939|BEHAVIORAL|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
218961513|NCT02763761|DRUG|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
218961514|NCT02763761|DRUG|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
218961515|NCT03905473|BEHAVIORAL|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
219061609|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
218961516|NCT01128751|PROCEDURE|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
218961517|NCT01128751|PROCEDURE|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
218961518|NCT01128751|PROCEDURE|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
218961519|NCT01981759|DRUG|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
219061610|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
219061611|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
219061612|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
219061613|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
219646779|NCT06840587|BEHAVIORAL|Connect-Home ADRD|Connect-Home ADRD will introduce new structure and processes to support SNF staff delivery of transitional care for transitions to home, assisted living, or long-term care, and post-discharge transitional care by the Dementia Caregiving Specialist.
219646780|NCT00186966|DRUG|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
219646781|NCT00186966|DRUG|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
219646782|NCT00186966|PROCEDURE|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
219646783|NCT00186966|RADIATION|Total body irradiation|See Detailed Description section for details of treatment interventions.
219646784|NCT01280032|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
219646785|NCT06249737|BEHAVIORAL|Training|Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.
218961520|NCT01981759|OTHER|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
218961521|NCT01981759|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
218961522|NCT03810144|GENETIC|Vectra MBDA Test|Vectra Guided versus Usual Care
218961523|NCT04138888|DRUG|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
219061614|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
219061615|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
219061616|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
219061617|NCT06866054|DRUG|SPSIPB block|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
219061618|NCT06866054|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219646786|NCT00052052|DRUG|interferon-gamma 1b|200 mcg, SQ, 3x per week
219646787|NCT04304482|DRUG|ANAVEX2-73 oral liquid|Liquid oral solution
219646788|NCT04304482|DRUG|Placebo oral liquid|Liquid oral solution
219646789|NCT01986127|DRUG|Adalimumab|single intralesional administration during endoscopy process
219646790|NCT01986127|DRUG|placebo|single intralesional administration during endoscopy
219646791|NCT04119076|OTHER|Classroom-based physical activity|
219646792|NCT04119076|OTHER|Control Group|
219646793|NCT06682676|DEVICE|Nasal ventilation function test and cold and dry air nasal provocation test|The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.
219646794|NCT02496091|DEVICE|ATLANTIS Abutment|
218961524|NCT04138888|DRUG|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
218961525|NCT01541202|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
218961526|NCT01541202|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
219061619|NCT03977844|OTHER|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
219061620|NCT03977844|OTHER|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
219061621|NCT03977844|OTHER|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
219061622|NCT03977844|OTHER|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
219061623|NCT04832763|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219061624|NCT04832763|OTHER|Medical Chart Review|Review of medical charts
219061625|NCT04832763|OTHER|Physical Performance Testing|Undergo physical function testing
219061626|NCT04832763|OTHER|Quality-of-Life Assessment|Ancillary studies
219061627|NCT04832763|OTHER|Questionnaire Administration|Complete questionnaire
219061628|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
219061629|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
219061630|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
219061631|NCT05317936|DRUG|Pirtobrutinib|Given by PO
219061632|NCT05317936|DRUG|Venetoclax|GIven by PO
219061633|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
219061634|NCT05350449|BEHAVIORAL|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
219061635|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
219646795|NCT03951974|BEHAVIORAL|Social Emotion Regulation Strategy Development|Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
219646796|NCT03951974|BEHAVIORAL|Control|Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
219646797|NCT06058520|DRUG|Fecal Microbiota - lyophilized|Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
219646798|NCT06058520|DRUG|Placebo drug|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
219061636|NCT05115162|OTHER|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
219061637|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
219646799|NCT04183582|BEHAVIORAL|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
219646800|NCT06186427|DIAGNOSTIC_TEST|68Ga-DOTA-GPFAPI-04 PET/CT|The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
219646801|NCT03174873|PROCEDURE|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
219646802|NCT06621160|OTHER|Observation|After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.
219646803|NCT06459050|OTHER|Dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by the dominant limb.
219646804|NCT06459050|OTHER|Non-dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by non-dominant limb.
219646805|NCT05908123|BEHAVIORAL|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
219646806|NCT06685614|DEVICE|orthodontic bracket bonding|compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
219646807|NCT06061523|DRUG|Sotorasib|Oral Tablet
219646808|NCT04275921|DIAGNOSTIC_TEST|MRI scan|MRI analysis using TWIST and HASTE
219646809|NCT04275921|DIAGNOSTIC_TEST|4D MRI|4D MRI alongside 4D CT in lung cancer
219646810|NCT06674655|BEHAVIORAL|Motor Imagery Plus Therapeutic Exercise|This group will perform three days of lumbo-pelvic motor control exercise intervention along with a motor imagery intervention program during active breaks between exercises.
219646811|NCT06674655|BEHAVIORAL|Therapeutic Exercise|This group will perform a lumbo-pelvic motor control exercise program for three consecutive days.
219646812|NCT06674655|BEHAVIORAL|Minimal intervention|This group will carry out a therapeutic counseling and minimal education intervention during a one-day intervention.
218961527|NCT05868018|BEHAVIORAL|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
219646813|NCT00922506|DRUG|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
219646814|NCT04540159|DIAGNOSTIC_TEST|Flow-cytometric analysis|Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
219646815|NCT02272842|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 in a multivitamin paste.
219646816|NCT05769400|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
218961528|NCT06145607|DRUG|ABBV-CLS-7262|ABBV-CLS-7262
218961529|NCT03937700|DEVICE|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
219646817|NCT03687398|DIAGNOSTIC_TEST|genetic testing with nanoclonal technique|endometrial sampling
219646818|NCT05832905|BEHAVIORAL|Mobile and Wearable-assisted Case Management|The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
219646819|NCT05590897|PROCEDURE|Teeth Brushing|All 52 participants were instructed through a lecture on how to perform toothbrushing with a fluoridated toothpaste (Colgate T®) and dental flossing three times per day after meals for 30 days. The Bass technique was taught, by which the bristles should be positioned at an approximate angle of 45º to the gingival pocket on both the free and proximal faces, with the performance of short, slightly circular vibrating movements.
219061638|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
219061639|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
219061640|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
219061641|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
219061642|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
219646820|NCT05590897|PROCEDURE|Dental Flossing|All 52 participants were instructed to floss, 3 times a day after meals for 30 days.
219646821|NCT05590897|PROCEDURE|Tongue Scraping|Tongue scraping was performed by the same operator for all participants. Posteroanterior movements were performed with the scraper on the dorsum of the tongue, followed by the cleaning of the scraper with gauze. The procedure was performed ten times on each participant to standardize mechanical removal.
219646822|NCT05590897|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|"One session of aPDT was performed. The annatto photosensitizer was mixed at a concentration of 20% (Fórmula e Ação®, Brazil) in spray form, applied with a sufficient quantity to coat the middle third of the dorsum of the tongue (five sprays) and left for two minutes for incubation. The excess was removed with an aspirator. \|The surface of the tongue remained moist with the photosensitizer itself without the use of water. Six points were irradiated with a distance of 1 cm between points, considering the spread of the light and effectiveness of aPDT. The device was previously calibrated at a wavelength of 395-480 nm. Light was irradiated to ensure a beam area of 2 cm in diameter per point. Energy was 9.6 J and exposure time was 20 seconds per point."
219646823|NCT04339647|BEHAVIORAL|The SIMS programme|The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
219646824|NCT00138398|BIOLOGICAL|Commercial TriValent Split Influenza Virus|
219646825|NCT02255305|BIOLOGICAL|FMT|Patients in the FMT group will receive \~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
219646826|NCT02255305|DRUG|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
219646827|NCT00172601|PROCEDURE|mobilization|
219646828|NCT06069076|DIAGNOSTIC_TEST|cathepsin S and chromogranin A|Diagnostic value of serum Cathepsin S and Chromogranin A
219646829|NCT02330367|DRUG|AC0010|"Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D."
219646830|NCT05033262|OTHER|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
219646831|NCT00569673|BIOLOGICAL|filgrastim|
219646832|NCT00569673|BIOLOGICAL|pegfilgrastim|
219646833|NCT00569673|DRUG|docetaxel|
219646834|NCT00569673|DRUG|trabectedin|
219646835|NCT00334529|DRUG|Oseltamivir|
218961530|NCT01764035|BEHAVIORAL|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
219061643|NCT02177344|DRUG|Placebo|
219646836|NCT05002673|DEVICE|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
219646837|NCT06137573|DRUG|[14C]TNP-2198|600mg suspension containing 150μCi of \[14C\] TNP-2198
219646838|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) present|Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.
219646839|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) absent|Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.
219646840|NCT02050217|PROCEDURE|Neurally Adjusted Ventilatory Assist|
219646841|NCT06240702|OTHER|Telerehabilitation Group|Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
219061644|NCT05710523|BEHAVIORAL|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
219646842|NCT03193112|DRUG|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
219646843|NCT01812317|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
219646844|NCT01812317|PROCEDURE|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
219646845|NCT02238912|DRUG|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
219646846|NCT04068012|OTHER|Ventilator protocol|open loop ventilator management by a computer based protocol
219061645|NCT05710523|OTHER|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
219061646|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
219646847|NCT03518619|BEHAVIORAL|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
219646848|NCT00589381|DRUG|fenretinide lipid matrix|
219646849|NCT04016038|OTHER|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
219646850|NCT01493284|DEVICE|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
219646851|NCT01640379|BEHAVIORAL|Technology Enhanced Community Health Nursing|"* Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~* Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)"
219646852|NCT00325156|BIOLOGICAL|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
219646853|NCT05792332|OTHER|Telemonitoring|Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
219646854|NCT05792332|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
219646855|NCT03449654|DRUG|Liraglutide|Liraglutid
219646856|NCT03449654|DRUG|Placebo (for liraglutide)|Placebo (for liraglutide)
219646857|NCT05045027|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
219646858|NCT05045027|PROCEDURE|Diagnostic Imaging|Undergo multinuclear metabolic imaging
218961531|NCT01764035|BEHAVIORAL|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
219061647|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
219061648|NCT05507268|OTHER|no intervention|no intervention
219646859|NCT05045027|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219646860|NCT05507476|DRUG|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
219646861|NCT05507476|DRUG|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
219646862|NCT05970276|DEVICE|Deep Sleep (N3) Enhancement with TES|As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When slow wave sleep is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes.
219646863|NCT02117921|BEHAVIORAL|One-on-one interview and educational sessions. Reading material for educational series provided.|A one-on-one interview with the patient and the principal investigator and group educational sessions.
219646864|NCT05144308|PROCEDURE|Images of the operated eye (s)|Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
219646865|NCT02114450|BEHAVIORAL|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
219646866|NCT02114450|BEHAVIORAL|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
219646867|NCT00296946|DRUG|ipratropium bromide (drug)|
219646868|NCT06668038|OTHER|Multidisciplinary and multicenter validation of re-irradiation with curative intent|"Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM.~In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM."
218961532|NCT00403403|DRUG|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
219646869|NCT05698979|DRUG|BOTOX INJECTION|"The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2)."
219646870|NCT03507764|OTHER|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
219646871|NCT05685264|DRUG|Ponsegromab|Participants will receive one subcutaneous injection
219646872|NCT05685264|DRUG|Ponsegromab|Participants will receive four subcutaneous injections
219646873|NCT01960270|DEVICE|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
219646874|NCT02433821|OTHER|Pilates|
219646875|NCT03395184|DRUG|PF-06651600 Placebo|12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
219646876|NCT03395184|DRUG|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
219646877|NCT03395184|DRUG|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
219646878|NCT03395184|DRUG|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
219646879|NCT06045403|BEHAVIORAL|Issuing health risk warning for a heat or cold|Whenever a health risk warning for a heat or cold is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
219646880|NCT06045403|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
219646881|NCT06045403|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
219646882|NCT06045403|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and electrocardiography (ECG).
219646883|NCT04729179|DRUG|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
219646884|NCT04729179|DRUG|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
219646885|NCT02522156|BEHAVIORAL|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
219646886|NCT02522156|BEHAVIORAL|Control|Neutral guided imagery scenarios making no reference to smoking.
219646887|NCT05452499|OTHER|Pain neuroscience education and therapeutic exercise|Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
219646888|NCT02779699|DRUG|AL2846|AL2846 p.o. qd
219646889|NCT06301607|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219646890|NCT06301607|DEVICE|Nasogastric Tube|The group is given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219646891|NCT06301607|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219646892|NCT01290978|DRUG|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
219646893|NCT01290978|DRUG|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
219646894|NCT04182269|OTHER|Measurement of functional exercise capacity|The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
219646895|NCT05496959|DRUG|Lutetium Lu-177 PNT2002|Given IV
219646896|NCT05496959|OTHER|Quality-of-Life Assessment|Ancillary studies
219646897|NCT05496959|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219646898|NCT06315881|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral mucosa sample collection
219646899|NCT06315881|DRUG|Cigarette|Smoke usual brand cigarette
219061649|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
219646900|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN R/S ONP
219646901|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN \> 99% S ONP
219646902|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high R/S ONP
219646903|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high FBN \> 99% ONP
219646904|NCT06315881|DRUG|Smokeless Tobacco|Insert ST
219646905|NCT06315881|OTHER|Survey Administration|Ancillary studies
219646906|NCT06315881|OTHER|Text Message-Based Navigation Intervention|Receive text with a link to daily diary surveys
218961533|NCT00403403|DRUG|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
218961534|NCT00403403|DRUG|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
218961535|NCT04357366|DRUG|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
218961536|NCT04006119|BIOLOGICAL|Ad-RTS-hIL-12|"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"
219061650|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
219061651|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
219061652|NCT03047447|BEHAVIORAL|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
219061653|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
219061654|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
219061655|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
219061656|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
219646907|NCT06796036|OTHER|Combat Medic Decision-Making with and without artificial intelligence assistance|Participants will complete 10 simulated Tactical Combat Casualty Care (TCCC) scenarios, with 5 scenarios conducted using AI assistance (GPT-4) and 5 without AI. In AI-assisted scenarios, participants will use GPT-4 to query and optimize ventilator settings based on patient data, while non-AI scenarios rely solely on their clinical judgment.
219646908|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
218961537|NCT04006119|DRUG|Veledimex|20mg/day 15 oral daily doses of veledimex
218961538|NCT04006119|DRUG|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
218961539|NCT02718001|DEVICE|Edwards EVOQUE Eos Mitral Valve Replacement System|Replacement of the mitral valve through a transcatheter approach
218961540|NCT06590324|DRUG|Apabetalone|100-mg capsule, twice daily oral administration with meals
218961541|NCT06055985|OTHER|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
218961542|NCT06055985|DRUG|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
218961543|NCT04850313|DEVICE|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
218961544|NCT03688009|BEHAVIORAL|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
218961545|NCT03688009|BEHAVIORAL|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
218961546|NCT03418623|DRUG|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
219061657|NCT04790253|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
219646909|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
219646910|NCT05523479|BEHAVIORAL|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
219646911|NCT05523479|BEHAVIORAL|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
219646912|NCT05523479|BEHAVIORAL|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
219646913|NCT05523479|OTHER|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
219646914|NCT05523479|OTHER|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
219646915|NCT06483048|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
219646916|NCT06483048|DRUG|Bendamustine|Given IV
219646917|NCT06483048|PROCEDURE|Biospecimen Collection|Undergo blood and possible ascites sample collection
219646918|NCT06483048|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219646919|NCT06483048|DRUG|Cyclophosphamide|Given IV
219646920|NCT06483048|PROCEDURE|Echocardiography|Undergo ECHO
219646921|NCT06483048|PROCEDURE|Leukapheresis|Undergo leukapheresis
219646922|NCT06483048|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219646923|NCT06483048|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219646924|NCT06483048|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218961547|NCT03418623|OTHER|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
218961548|NCT02528175|DEVICE|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
218961549|NCT02528175|RADIATION|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
218961550|NCT02528175|DRUG|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
218961551|NCT04469426|OTHER|Interactive online informational and peer support app|The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
218961552|NCT05541068|DEVICE|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
218961553|NCT05550649|PROCEDURE|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
218961554|NCT03306706|DIETARY_SUPPLEMENT|Whole pea muffins|2 muffins containing whole peas
218961555|NCT03306706|DIETARY_SUPPLEMENT|Split pea muffins|2 muffins containing split peas
219061658|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
219061659|NCT02607579|DRUG|Exparel|
219061660|NCT02607579|DRUG|Ropivacaine|
219061661|NCT06326801|OTHER|Resistive Diaphragmatic breathing exercise|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
219061662|NCT06326801|OTHER|Diaphragmatic breathing exercise|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
219061663|NCT06326801|OTHER|Conventional stroke physiotherapy|Conventional stroke physiotherapy
219061664|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
219061665|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
219646925|NCT00264069|DRUG|antipsychotic|as prescribed
219646926|NCT00264069|DRUG|antidepressants|as prescribed
219646927|NCT03945370|DIETARY_SUPPLEMENT|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
219646928|NCT03945370|DIETARY_SUPPLEMENT|Placebo drink|Oral placebo drink
219646929|NCT03527810|PROCEDURE|Sleeve Gastrectomy Without Interrogation of Hiatus|Weight-loss procedure to reduce the stomach.
219646930|NCT03527810|PROCEDURE|Sleeve Gastrectomy With Interrogation of Hiatus|Weight-loss procedure to reduce the stomach with hiatal repair.
219646931|NCT01953874|DEVICE|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
219646932|NCT01953874|DRUG|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
219646933|NCT03339726|DRUG|New Formulation Phenylephrine HCl|2 doses of one tablet 12 hours apart
219646934|NCT03339726|DRUG|Marketed Phenylephrine HCl|4 doses of one capsule 4 hours apart
219646935|NCT03339726|DRUG|Placebo|4 doses of placebo capsule and tablet taken 4 hours apart
219646936|NCT01275755|DRUG|Placebo|
219646937|NCT01275755|DRUG|ADL5945 0.25 mg|
219686246|NCT01614015|BEHAVIORAL|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
219646938|NCT05288595|DEVICE|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
219646939|NCT02010281|DEVICE|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
219646940|NCT00006398|DRUG|Timolol Maleate|
219646941|NCT00006398|DRUG|Placebo|
219646942|NCT01885702|BIOLOGICAL|DC vaccination|DC vaccination
219646943|NCT05592015|DRUG|Ruxolitinib|Given PO
219646944|NCT05892939|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
219646945|NCT05892939|DRUG|intranasal Placebo|Administration of intranasal Placebo
219646946|NCT04624490|DRUG|Hyperpolarized Xe129|During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
218961556|NCT03306706|DIETARY_SUPPLEMENT|Wheat muffins|2 muffins containing wheat
218961557|NCT03203278|BEHAVIORAL|Web-based exercise programme|Aerobic, resistance and balance exercises
218961558|NCT00738192|DRUG|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
218961559|NCT00738192|DRUG|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
218961560|NCT00738192|DRUG|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
218961561|NCT05589090|BEHAVIORAL|Super Skills for Life program|Children in the experimental group received eight sessions of the Super Skills for Life protocol. The intervention was implemented using a structured manual for the therapist and a workbook for the children \[Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández\]. The intervention was administered via an online virtual platform for eight weeks, with each session lasting approximately one hour.
218961562|NCT04386915|DRUG|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
218961563|NCT04386915|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
218961564|NCT00174239|DRUG|cabergoline|
218961565|NCT00174239|DRUG|controlled-release levodopa / carbidopa|
218961566|NCT05930587|OTHER|Cold water immersion|Cold water immersion (15 degree celsius, 20 minutes)
219061666|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
219061667|NCT00206648|DRUG|Betaferon/Betaseron|Betaseron 250 µg SC every other day
219646947|NCT00979589|DRUG|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
219646948|NCT00979589|DRUG|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
219646949|NCT04792840|DRUG|Femara Pill|study effect on bone
219646950|NCT03754634|DRUG|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
218961567|NCT03988959|PROCEDURE|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
218961568|NCT01382511|DRUG|Simvastatine|80 mg
218961569|NCT01277042|BIOLOGICAL|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
218961570|NCT01277042|BIOLOGICAL|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
218961571|NCT04856670|PROCEDURE|Cataract surgery|Cataract surgery- Manual or femtosecond laser assisted
218961572|NCT00588952|DRUG|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
219061668|NCT00206648|DRUG|Betaferon/Betaseron|Avonex 30 µg IM once per week
219061669|NCT02959060|DRUG|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
219061670|NCT02959060|DRUG|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
219061671|NCT00359112|DRUG|metformin|
219061672|NCT00359112|DRUG|sulphonylurea|
219061673|NCT00359112|DRUG|Avandamet|
219061674|NCT04372966|DEVICE|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
219061675|NCT06025955|PROCEDURE|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
219061676|NCT06025955|PROCEDURE|open flap debridement|flap surgery will be done
219061677|NCT02794493|DRUG|Traditional Chinese Medicine Formula LC09|
219061678|NCT02794493|OTHER|Placebo|
219646951|NCT03871738|OTHER|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
219646952|NCT00196339|DRUG|Cyproterone acetate 5|Cyproterone acetate 5 mg
219646953|NCT00196339|DRUG|Placebo|Matching placebo
219646954|NCT00196339|DRUG|Cyproterone acetate 15|Cyproterone acetate 15 mg
219646955|NCT00196339|DRUG|Cyproterone acetate 25|Cyproterone acetate 25 mg
219646956|NCT03048695|BEHAVIORAL|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
219646957|NCT04136977|DEVICE|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
219646958|NCT01318590|DRUG|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
219646959|NCT01318590|OTHER|EUS procedure|EUS procedure without any drug injection
218961573|NCT06138054|BEHAVIORAL|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
218961574|NCT06138054|BEHAVIORAL|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
219646960|NCT06252051|DRUG|Trivalent Influenza Vaccine|We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
219646961|NCT02210247|DRUG|EXPAREL|
218961575|NCT05733403|DRUG|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
218961576|NCT05733403|DRUG|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
218961577|NCT03072771|DRUG|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
218961578|NCT03072771|PROCEDURE|Autologous stem cell transplant|-Standard of care
219207815|NCT06750211|OTHER|MCTE along with METs|"▪ Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* After it was treated with motor control therapeutic exercises together with muscle energy technique. Motor control therapeutic exercises included cranio-cervical flexor exercises, cranio-cervical extensor exercises, co contraction of flexor and extensor and synergy exercise for strengthening deep neck flexor. Exercises were performed in three sets with 10 repetitions with an approximate duration of 10 to 20 minutes. They were advised to perform at home once in a day, five times in a week for a duration of 4 weeks.~All exercises were performed three times per week for total of 4 weeks."
219646962|NCT01621451|DRUG|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
219646963|NCT01621451|DRUG|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
218961579|NCT03072771|DRUG|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
218961580|NCT03072771|DRUG|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
219207816|NCT05652673|DRUG|nivolumab|Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
219646964|NCT05791630|OTHER|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
219646965|NCT02161237|DRUG|Advagraf®|oral
219646966|NCT05113888|DRUG|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
219207817|NCT06898385|BIOLOGICAL|IX001 TCR-T injection|IX001 TCR-T injection will be administered intravenously after lymphodepletion.
219207818|NCT06898385|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219646967|NCT05113888|DRUG|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
219646968|NCT05113888|DRUG|Placebo|take orally before meals, 1 bag each time, 3 times a day.
219646969|NCT01865669|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
219646970|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 1|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
219646971|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 1|Preparation of PRP Concentrate via sterile Terumo-Harvest System
219646972|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 2|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
219646973|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 2|Preparation of PRP Concentrate via sterile Terumo-Harvest System
219646974|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 2|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
219646975|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 3|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
219646976|NCT04238143|DRUG|Sterile Normal Saline (IV Solution)|Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
219646977|NCT03452046|OTHER|IVC diametres|
219646978|NCT05431023|DRUG|Lactoferrin|Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
219646979|NCT05431023|DRUG|Pneumonia treatment|Antibiotics for pneumonia
219646980|NCT05264792|OTHER|Enhanced Implementation Support|"This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines."
219646981|NCT05264792|OTHER|Routine Implementation Support|This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
219646982|NCT03133273|OTHER|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
219646983|NCT02416531|DRUG|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
219646984|NCT02416531|RADIATION|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
219646985|NCT02416531|RADIATION|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
218961581|NCT03072771|DRUG|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
218961582|NCT03072771|DRUG|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
219646986|NCT03541954|OTHER|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
219646987|NCT03541954|OTHER|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
219646988|NCT03541954|OTHER|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
219646989|NCT03541954|OTHER|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
219646990|NCT03350061|DEVICE|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
219646991|NCT01088880|DRUG|Canakinumab|
219646992|NCT00636194|DEVICE|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
219646993|NCT00636194|DEVICE|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
219646994|NCT03470012|DEVICE|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
218961583|NCT03072771|PROCEDURE|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
218961584|NCT01445054|DRUG|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
218961585|NCT06177574|DRUG|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
219207819|NCT06898385|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219207820|NCT06830902|DEVICE|Regular Double J stent|Regular Double J stent
219207821|NCT06830902|DEVICE|Comfi J stent|Comfi J stent
219207822|NCT06828211|DIETARY_SUPPLEMENT|Trans-resveratrol extract from Polygonum Cuspidatum|Trans-resveratrol extract from Polygonum Cuspidatum
219207823|NCT06828211|OTHER|Placebo|Placebo
218961586|NCT03914508|BEHAVIORAL|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
219061679|NCT00796718|RADIATION|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
219646995|NCT02449135|PROCEDURE|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
219646996|NCT05144789|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
219646997|NCT05144789|DEVICE|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
219646998|NCT05144789|DEVICE|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219646999|NCT05482464|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
219647000|NCT03808350|PROCEDURE|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
219647001|NCT03808350|OTHER|Placebo/Control|Family members will not be invited to remain in the ICU room
219647002|NCT04412200|DEVICE|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
219647003|NCT01537874|BEHAVIORAL|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
219647004|NCT01537874|BEHAVIORAL|Usual best practices|Standard care delivered using informational materials
219647005|NCT04599725|DRUG|medical abortion|medical abortion
219647006|NCT05462223|COMBINATION_PRODUCT|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~1. VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~2. VRS Light Fiber~3. VRS Light Source"
219647007|NCT06033430|OTHER|True dry needling|Prior to the procedure, participants will be given a detailed explanation of the dry needling technique. Afterward, the specific area will be thoroughly cleaned using an alcohol pad. In the true dry needling group, along with routine physiotherapy, a sterile filiform acupuncture needle, measuring 2 cm in length and designed for single-use, will be inserted at a 15-degree angle relative to the skin's surface, directly into the scar tissue. Once inserted, the needle will be gently rotated to aid in separating tissue adhesions along the path of the scar. Routine physiotherapy includes the application of kinesiology taping, in addition to a 20-minute session of infrared therapy positioned 30 cm away from the scar tissue. A total of six treatment sessions will be administered to the patients, with three sessions per week scheduled over a two-week period.
219061680|NCT00796718|DRUG|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
219061681|NCT03266588|DRUG|Rimegepant|75 mg oral tablet
219061682|NCT04785404|PROCEDURE|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
219061683|NCT06373822|DIAGNOSTIC_TEST|Circulating-mirna|A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
219061684|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
219061685|NCT00244244|DRUG|arimoclomol|
219061686|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
219061687|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
219647008|NCT06033430|OTHER|Sham dry needling|The sham group participants will be positioned in a similar manner to those in the experimental group, with a minor exception. Instead of inserting the 2-cm single-use sterile filiform acupuncture needle into the scar tissue, it will be superficially inserted at a point further away from the scar tissue and removed after 20 minutes. Moreover, routine physiotherapy administered to the participants in the sham group will be identical to that of the experimental group, ensuring consistency between the two groups.
219647009|NCT06682936|PROCEDURE|ambulatory chest drain and talc pleurodesis|a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
219647010|NCT04187625|BIOLOGICAL|endothelial progenitor cell|Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
219647011|NCT03715972|DRUG|Hydroxyurea|info included in arm group
219647012|NCT03715972|DRUG|Acetazolamide|Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
219647013|NCT01745224|DEVICE|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
219647014|NCT01745224|DEVICE|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
219647015|NCT02056366|DRUG|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
219647016|NCT04015921|OTHER|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
218961587|NCT01852357|OTHER|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
218961588|NCT01852357|OTHER|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
219061688|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
219647017|NCT01826136|DEVICE|Acapella device|
219647018|NCT05876624|OTHER|Blood Pressure measurement|Blood Pressure measurement
219647019|NCT06490380|DRUG|PARPi|Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
219647020|NCT00441376|DRUG|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
219647021|NCT00246272|DRUG|risperidone|
219647022|NCT02621489|DRUG|Bydureon|2 mg Once Weekly
218961589|NCT01823510|DRUG|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
218961590|NCT01823510|DRUG|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
218961591|NCT03503851|DEVICE|MitraClip implantation|Device to approximate the mitral valve leaflets
218961592|NCT00112398|PROCEDURE|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
218961593|NCT02392533|OTHER|Education|Education
218961594|NCT02607644|DEVICE|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
218961595|NCT02607644|DEVICE|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
218961596|NCT03544788|DEVICE|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
218961597|NCT02379845|DEVICE|NBTXR3|One intratumor implantation by injection
218961598|NCT02379845|DEVICE|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
219061689|NCT01073618|DRUG|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
218961599|NCT03054090|OTHER|Quality Improvement Support|Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
218961600|NCT03230201|PROCEDURE|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
218961601|NCT00611871|DRUG|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
218961602|NCT00611871|DRUG|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
218961603|NCT01257360|DRUG|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
218961604|NCT01257360|RADIATION|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
218961605|NCT01511666|DEVICE|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
218961606|NCT01511666|OTHER|Standard care|Standard care as per recent guidelines will be provided.
218961607|NCT01455376|DRUG|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
218961608|NCT00959374|DEVICE|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
218961609|NCT00959374|DEVICE|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
218961610|NCT06156475|PROCEDURE|Proprioception exercises|Patients trained for proprioception exercises.
218961611|NCT06156475|PROCEDURE|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
218961612|NCT06156475|PROCEDURE|Wand Exercise|Patients were educated with wand exercises.
218961613|NCT01840839|DEVICE|brain stimulation|
218961614|NCT01840839|DEVICE|Sham Stimulation|
219061690|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
219061691|NCT02812810|DEVICE|active rTMS|
219061692|NCT02812810|DEVICE|sham rTMS|
219647023|NCT02621489|DRUG|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
219647024|NCT02621489|DRUG|Metformin|Metformin 1g BID
219647025|NCT00278122|BIOLOGICAL|sargramostim|
219647026|NCT00278122|DRUG|paclitaxel|
219647027|NCT05046379|OTHER|Lipidomics|Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.
219647028|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
219647029|NCT00650117|DRUG|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
219647030|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
219647031|NCT00650117|DRUG|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
219647032|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
219647033|NCT00650117|DRUG|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
219647034|NCT04833270|OTHER|KM non-pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
219647035|NCT04833270|OTHER|Pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
219647036|NCT01246349|BEHAVIORAL|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
219647037|NCT01246349|BEHAVIORAL|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
219647038|NCT02000700|DRUG|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
219647039|NCT02000700|DRUG|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
219647040|NCT02000700|DRUG|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
218961615|NCT00859261|PROCEDURE|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
219647041|NCT02000700|DRUG|Placebo|One matching placebo tablet orally administered at baseline phase.
219061693|NCT01144312|DRUG|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
219647042|NCT04025437|PROCEDURE|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
219647043|NCT04025437|RADIATION|Neoadjuvant radiotherapy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
219061694|NCT01834365|OTHER|Structured education|Formatted education about hypertension
219061695|NCT01834365|OTHER|Checklist|
219061696|NCT01834365|OTHER|Without structure education with checklist|
219061697|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
219647044|NCT00024037|PROCEDURE|management of therapy complications|
219647045|NCT01772745|PROCEDURE|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
219647046|NCT01772745|PROCEDURE|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
219647047|NCT01579045|DEVICE|senofilcon A|bilateral daily use soft contact lens
219647048|NCT01579045|DEVICE|etafilcon A|bilateral daily use soft contact lens
219647049|NCT01579045|DEVICE|nelfilcon A|bilateral daily use soft contact lens
219647050|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lens
219647051|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lenses
219647052|NCT01566942|DRUG|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
219647053|NCT01566942|DRUG|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
219647054|NCT04673747|PROCEDURE|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
219647055|NCT04673747|PROCEDURE|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
219647056|NCT01472653|DRUG|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
219647057|NCT01472653|RADIATION|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
219647058|NCT01472653|DRUG|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
219647059|NCT05637047|PROCEDURE|pulsed radiofrequency|ultrasound-guided intramuscular and interfascial pulsed radiofrequency ablation
219647060|NCT05637047|PROCEDURE|Dry needling|ultrasound-guided intramuscular and interfascial dry needling
219647061|NCT05613998|OTHER|GPR Group|"6-week treatment using the GPR method. 1 weekly session (45 min) with frog on the ground and sitting postures + daily home self-postures (10 min)"
219647062|NCT05613998|OTHER|Aerobic Exercice Group|6-week nonspecific aerobic exercise treatment. Participants will take a daily walk (20 min)
219647063|NCT00438243|DRUG|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
219647064|NCT00438243|DRUG|Refresh Plus|1 drop in the affected eye twice daily
219647065|NCT03552224|PROCEDURE|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
219647066|NCT03500458|BEHAVIORAL|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
219686247|NCT02126215|PROCEDURE|MRI CO2 and O2 stress testing|Pre and post operatively
219686248|NCT02211378|OTHER|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
218961616|NCT00859261|PROCEDURE|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
218961617|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
219647067|NCT04934189|BEHAVIORAL|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists \[PI and Co-I\] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
219647068|NCT05551546|BEHAVIORAL|Functional Medicine Health Coaching for Elimination Diet for Elimination Diet|"All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection."
219647069|NCT05551546|BEHAVIORAL|Self-guided Elimination Diet|"The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study."
219647070|NCT00745238|OTHER|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
218961618|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
218961619|NCT03350984|DRUG|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
219061698|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
219061699|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
219647071|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
219647072|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
219647073|NCT05530200|RADIATION|Hypofractionated radiotherapy|24Gy/8Gy/3f
219061700|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
219061701|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
219061702|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
219647074|NCT05530200|DRUG|PD-L1 inhibitor|q3w
219647075|NCT05530200|DRUG|GM-CSF|200μg, D1-D7
219647076|NCT05530200|DRUG|IL-2|at a dose of 2 million IU, D8-D14
219647077|NCT01532336|DRUG|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
219647078|NCT01532336|DRUG|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
219647079|NCT04326296|DRUG|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
219647080|NCT05911828|DRUG|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
219647081|NCT05911828|DRUG|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
219061703|NCT02912533|DRUG|JR-131|
219061704|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
219647082|NCT03911661|OTHER|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
219647083|NCT03911661|OTHER|Usual care|Historical management of warfarin by patient's usual care providers
219647084|NCT02781753|BIOLOGICAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
219647085|NCT02781753|BIOLOGICAL|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
219061705|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
219061706|NCT06043921|OTHER|No intervention|There is no intervention associated with this observational study.
219647086|NCT02726438|DRUG|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
219647087|NCT00880581|DRUG|PF-3512676|18 mg injection
219647088|NCT00880581|RADIATION|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
219647089|NCT06006494|OTHER|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
219647090|NCT06006494|OTHER|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
219647091|NCT06006494|OTHER|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
219647092|NCT00735137|DEVICE|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
219647093|NCT00564837|PROCEDURE|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
219647094|NCT00564837|PROCEDURE|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
219647095|NCT03780465|DRUG|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
219647096|NCT03780465|DRUG|NOX66 (A)|Idronoxil formulated in suppository base A
219647097|NCT03780465|DRUG|NOX66 (B)|Idronoxil formulated in suppository base B
219647098|NCT06483243|DRUG|Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG|At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
218961620|NCT03350984|DRUG|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
218961621|NCT01203254|DRUG|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
219061707|NCT02677545|DRUG|Ticagrelor|
219061708|NCT02677545|DRUG|Clopidogrel|
219061709|NCT02677545|DRUG|Aspirin|
218961622|NCT01203254|DRUG|Placebo|Placebo tablet: 3 times daily 2 tablets
218961623|NCT00015938|BIOLOGICAL|filgrastim|
218961624|NCT00015938|DRUG|docetaxel|
218961625|NCT00015938|DRUG|vinorelbine|
218961626|NCT00642473|DRUG|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
218961627|NCT00642473|DRUG|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
218961628|NCT00642473|OTHER|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
218961629|NCT04195126|DEVICE|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
219061710|NCT01229345|DRUG|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
219061711|NCT00949247|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
219647099|NCT02558621|DEVICE|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
219647100|NCT04512599|OTHER|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
219686249|NCT02211378|OTHER|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
219686250|NCT01518569|DRUG|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
219686251|NCT01518569|DRUG|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
219686252|NCT00954265|DRUG|10000 IU urinary HCG|ovulation triggering
219686253|NCT00954265|DRUG|250 mcg recombinant HCG|ovulation triggering
219686254|NCT03758157|DIAGNOSTIC_TEST|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
219686255|NCT03758157|DIAGNOSTIC_TEST|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
219061712|NCT00949247|BIOLOGICAL|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
219061713|NCT00949247|DRUG|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
219061714|NCT00949247|DRUG|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
218961630|NCT04459767|DRUG|Vupanorsen|80 mg subcutaneous injection
218961631|NCT04459767|DRUG|Placebo|Subcutaneous injection
218961632|NCT03849027|DRUG|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
218961633|NCT03849027|DRUG|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
218961634|NCT02262052|OTHER|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
218961635|NCT06514443|OTHER|survey|survey exploring barriers and faciltiators for physical activity
218961636|NCT00048711|DRUG|N-acetylgalactosamine 4-sulfatase|
218961637|NCT04451642|PROCEDURE|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
218961638|NCT05817279|DIAGNOSTIC_TEST|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
218961639|NCT03700879|RADIATION|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
218961640|NCT01221103|DRUG|Combination of dexamethasone, ofatumumab and bendamustine|"* Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
218961641|NCT01146210|OTHER|laboratory biomarker analysis|Correlative studies
218961642|NCT01175837|OTHER|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
218961643|NCT01175837|OTHER|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
218961644|NCT01175837|OTHER|laboratory biomarker analysis|Correlative studies
218961645|NCT01563146|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
218961646|NCT02284178|OTHER|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
218961647|NCT02284178|OTHER|Usual Care|Oral suction with suction swab every 4 hours
218961648|NCT01680549|DRUG|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
219061715|NCT00949247|OTHER|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
219061716|NCT02199847|DRUG|Pharmaton® Caplets|
219061717|NCT02199847|DRUG|Placebo|
218961649|NCT00569829|BEHAVIORAL|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
218961650|NCT00242983|PROCEDURE|quality-of-life assessment|
218961651|NCT03256188|BEHAVIORAL|Active classroom|30 minutes of moderate-to-vigorous physical activity
218961652|NCT03238846|OTHER|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
218961653|NCT03238846|OTHER|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
218961654|NCT05868720|DRUG|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
218961655|NCT04396496|DRUG|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
218961656|NCT02906969|OTHER|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
218961657|NCT02906969|OTHER|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
218961658|NCT02162641|PROCEDURE|Sentinel lymph node biopsy|
218961659|NCT00827580|DRUG|Eniluracil|
218961660|NCT04289350|DIAGNOSTIC_TEST|fetal heart rate variability|An observational study. No intervention
219686256|NCT03292185|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
219647101|NCT06333574|OTHER|Family weight self-measurement and remote follow-up management based on wechat.|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
219647102|NCT06333574|OTHER|Routine care|The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
219647103|NCT02170896|DRUG|BIBR 1048 MS Capsule A|
219647104|NCT02170896|DRUG|BIBR 1048 MS Capsule B|
219647105|NCT02170896|DRUG|BIBR 1048 MS Capsule C|
219647106|NCT02170896|DRUG|BIBR 1048 MS Capsule D|
219647107|NCT02170896|DRUG|BIBR 1048 MS tartaric acid solution|
219647108|NCT02170896|DRUG|Pantoprazole|
219647109|NCT04763655|DIAGNOSTIC_TEST|clinical and neuropsychological testing|Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
218961661|NCT02609698|DEVICE|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
218961662|NCT02609698|DRUG|3 months DAPT|
218961663|NCT02609698|DRUG|6 months DAPT|
219061718|NCT06257147|BEHAVIORAL|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
219061719|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
219647110|NCT00508287|DRUG|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
219647111|NCT00508287|DRUG|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
219647112|NCT00508287|DRUG|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
219647113|NCT03357575|BIOLOGICAL|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
218961664|NCT00132561|DRUG|Sulfadoxine/pyrimethamine and artesunate|
218961665|NCT04132882|DRUG|Sodium Thiosulfate (STS)|
218961666|NCT03486717|DEVICE|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
218961667|NCT01483690|DRUG|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
218961668|NCT01483690|DRUG|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
218961669|NCT01483690|DRUG|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
218961670|NCT01483690|DRUG|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
219061720|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
218961671|NCT01483690|DRUG|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
218961672|NCT01483690|DRUG|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
218961673|NCT01483690|DRUG|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
219061721|NCT02671487|BEHAVIORAL|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
219061722|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
219647114|NCT03357575|BIOLOGICAL|Hyaluronic Acid|inject hyaluronic acid
219647115|NCT02312869|OTHER|No intervention|not applicable, observational study
219647116|NCT01286168|DEVICE|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
219647117|NCT01286168|DEVICE|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
219686257|NCT03292185|DRUG|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
219686258|NCT03292185|DRUG|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
219647118|NCT01286168|PROCEDURE|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
218961674|NCT03092804|PROCEDURE|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
218961675|NCT03589014|DRUG|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
218961676|NCT04534465|DRUG|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
218961677|NCT04534465|DRUG|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
218961678|NCT02301585|PROCEDURE|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
218961679|NCT02301585|PROCEDURE|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
218961680|NCT02524093|BEHAVIORAL|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
218961681|NCT02524093|OTHER|treatment as usual|
218961682|NCT04633460|DIETARY_SUPPLEMENT|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
218961683|NCT04633460|DIETARY_SUPPLEMENT|placebo drink|KE free placebo drink
218961684|NCT05755165|BEHAVIORAL|Depression|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
218961685|NCT05755165|BEHAVIORAL|Depression, adjusted|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
218961686|NCT05755165|BEHAVIORAL|Control|\~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
219647119|NCT01286168|DEVICE|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
219647120|NCT06617910|RADIATION|SBRT by Cyberknife|The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife.
218961687|NCT01516528|PROCEDURE|Spirometry|Assessment of lung function by spirometry
219061723|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
219647121|NCT02870816|PROCEDURE|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
219647122|NCT02870816|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
219647123|NCT02870816|PROCEDURE|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
218961688|NCT06505629|BEHAVIORAL|the online Paired Emotion Reading Intervention (PERI)|In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
218961689|NCT06505629|BEHAVIORAL|the online Paired General Reading Intervention (PGRI)|Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
219647124|NCT02542241|DRUG|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
219647125|NCT02542241|DRUG|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
219061724|NCT02246998|DRUG|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
219061725|NCT02246998|DRUG|TVD|200/300 mg FDC tablet administered orally once daily with food
219061726|NCT02246998|DRUG|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
219061727|NCT02246998|DRUG|RTV|100 mg tablet administered orally once daily with food
219061728|NCT02246998|DRUG|ATV|300 mg capsule administered orally once daily with food
219647126|NCT02548000|OTHER|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
219647127|NCT02548000|OTHER|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
219647128|NCT01763723|DEVICE|IPL-home use device|A light based home use device for hair removal
219647129|NCT04598451|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
219647130|NCT04598451|OTHER|Placebo|Subcutaneous injection of placebo
219647131|NCT04598451|DRUG|prednisone|Oral prednisone tablets
219647132|NCT03764228|BIOLOGICAL|hAECs|Human amniotic epithelial cells（hAECs）
218961690|NCT05791981|BEHAVIORAL|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
218961691|NCT05791981|BEHAVIORAL|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
218961692|NCT05791981|DEVICE|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
218961693|NCT01515540|DRUG|lidocaine|5% lidoderm patch
218961694|NCT01515540|DRUG|placebo|placebo
218961695|NCT03251677|PROCEDURE|Surgical procedure, Hysterectomy|Surgical removal of the uterus
218961696|NCT06253689|DEVICE|Defecation Posture Modification Device|Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
219061729|NCT02246998|DRUG|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
219061730|NCT02246998|DRUG|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
219061731|NCT05881044|OTHER|Psychiatric interview|"1. Psychiatric interview which include personal identification, present history, past history and family history~2. Complete physical and Neurological Examination.~3. Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~4. Symptom checklist 90(SCL 90)~5. Quality of life questionnaire.~6. Hamilton Depression scale.~7. Hamilton Anxiety scale.~8. Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
219061732|NCT00856401|DRUG|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
219061733|NCT00004179|BIOLOGICAL|rituximab|
219061734|NCT00004179|DRUG|CHOP regimen|
219647133|NCT04317924|DEVICE|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
219647134|NCT04317924|OTHER|Standard of care|Standard of care after air leak post lung resection
219647135|NCT01311518|DRUG|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
219647136|NCT01311518|DRUG|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
219647137|NCT03338543|DEVICE|PENS|percutaneous electrical nerve stimulation
219647138|NCT03338543|DEVICE|TENS|transcutaneous electrical nerve stimulation
218961697|NCT06069648|BEHAVIORAL|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
218961698|NCT06069648|BEHAVIORAL|a leaftlet|a leaflet containing information about healthy lifestyles
219061735|NCT00004179|DRUG|cyclophosphamide|
219061736|NCT00004179|DRUG|doxorubicin hydrochloride|
219061737|NCT00004179|DRUG|prednisone|
219061738|NCT00004179|DRUG|vincristine sulfate|
219061739|NCT01343082|DRUG|DE-111 ophthalmic solution|
219061740|NCT04997174|DRUG|Celecoxib|Patients in ERAS group received celecoxib
219061741|NCT01075074|PROCEDURE|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
219061742|NCT01054729|DRUG|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
219647139|NCT01976468|OTHER|SCC metastasis|occurrence of SCC metastasis
219647140|NCT05383092|OTHER|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
219647141|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
219647142|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
219647143|NCT01237249|DRUG|Melphalan|
219647144|NCT01237249|DRUG|Prednisone|
219647145|NCT01237249|DRUG|Velcade|
219647146|NCT01237249|DRUG|Revlimid|
219647147|NCT01237249|DRUG|Dexamethasone|
219061743|NCT01054729|DRUG|Placebo|Placebo to match sofosbuvir administered orally once daily
219061744|NCT01054729|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
219061745|NCT01054729|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
219061746|NCT05978882|PROCEDURE|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
219647148|NCT01029171|BEHAVIORAL|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
219647149|NCT01029171|BEHAVIORAL|control; usual care|Usual care as prescribed by geriatrician.
219647150|NCT03651687|OTHER||
219061747|NCT00873795|DRUG|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
219061748|NCT03464227|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
219061749|NCT03464227|OTHER|Placebo|"* Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use"
219061750|NCT03753438|PROCEDURE|Intragstric Ballooning|Intragstric Ballooning will be put.
219061751|NCT05785780|BEHAVIORAL|Targeted CRC Screening Toolkit|Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
219207824|NCT06776978|DEVICE|Active treatment|Participants receive anodic tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). A constant current of 2 mA is applied for 20 minutes per session. The stimulation targets the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
219647151|NCT00369200|DRUG|AFP464|Given IV
219647152|NCT00369200|OTHER|laboratory biomarker analysis|Correlative study
219647153|NCT00369200|OTHER|pharmacological study|Correlative study
219647154|NCT03121924|PROCEDURE|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
219647155|NCT00421824|DRUG|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
219647156|NCT00421824|DRUG|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
219647157|NCT03535194|DRUG|Mirikizumab|Administered SC
219647158|NCT03535194|DRUG|Placebo|Administered SC
219647159|NCT03535194|DRUG|Secukinumab|Administered SC
219647160|NCT02091960|DRUG|Enzalutamide|Capsules for oral administration
219647161|NCT02091960|DRUG|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
218961699|NCT06069648|BEHAVIORAL|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
218961700|NCT04251156|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
218961701|NCT04251156|DRUG|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
218961702|NCT01453660|OTHER|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
219647162|NCT00382590|DRUG|5-Azacytidine|75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.
219647163|NCT00382590|DRUG|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
219647164|NCT00382590|DRUG|Valproic Acid (VPA)|50 mg/m\^2 orally daily days 1-7.
219647165|NCT03460405|BIOLOGICAL|Vi-DT Vaccine|1 dose of Vi-DT Vaccine
219647166|NCT03460405|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Vi Polysaccharide Vaccine
219647167|NCT03460405|BIOLOGICAL|IPV Vaccine|1 dose of IPV Vaccine
219647168|NCT06666842|BEHAVIORAL|Noom Weight|Participants assigned to Noom Weight will be provided access to the app-based program for 16 weeks. This program offers access to self-monitoring features, psychoeducational articles, one-on-one coaching from health experts, and group support. The app includes a robust database of foods, allowing users to track their energy intake. Self-monitoring via the app enables users to review and monitor behavior and weight change patterns. Daily articles review principles of behavior change, nutrition, exercise, etc.
219647169|NCT06666842|BEHAVIORAL|Educational Control|Participants assigned to the educational control will receive 16 brief (5-10 minute read) weekly newsletters outlining information on developing and maintaining a healthy diet and lifestyle adapted from the 2015-2020 Department of Health and Human Services (HHS) and Department of Agriculture (USDA) Dietary Guidelines for Americans. Newsletters include detailed information on topics such as nutrition fundamentals (e.g., calorie limits; healthy eating), food groups and dietary guidelines (e.g., importance of vegetables, fruits, and grains), and tips for habit change (e.g., reducing added sugar and saturated fats). Each week includes prompts for individuals to try new strategies (e.g., make a conscious decision about everything you eat; try to eat at your calorie budget).
219647170|NCT01579084|DRUG|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
219647171|NCT01579084|DRUG|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
219647172|NCT01579084|DRUG|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
219647173|NCT01579084|DRUG|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
219647174|NCT03992989|DEVICE|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
219647175|NCT03992989|DEVICE|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
219647176|NCT04923581|BEHAVIORAL|Oral Health Behavioral Interventions|The study will use a factorial design to evaluate the efficacy of three distinct intervention components: Motivational interviewing, storytelling videos and oral health promotion messages, in enhancing mothers' brushing of their preschool children's teeth using fluoridated toothpaste.
219647177|NCT03375671|DRUG|Ketalar|single administration of 5 mg/kg, IM
219647178|NCT03375671|DRUG|Midazolam injection|single administration of 5 mg, IM
219647179|NCT03375671|DRUG|Haloperidol|single administration of 5 mg, IM
219647180|NCT05756803|DEVICE|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
218961703|NCT01453660|OTHER|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
218961704|NCT04300920|DRUG|N-acetyl cysteine|600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
218961705|NCT04300920|DRUG|Placebo|Matching oral placebo tablet three times daily for 24 months.
218961706|NCT01041495|DRUG|cyclobenzaprine ER (AMRIX)|active drug
218961707|NCT01041495|DRUG|placebo|matching placebo for cyclobenzaprine ER (AMRIX)
218961708|NCT02882074|DRUG|Human albumin|human albumin 5% during surgery
218961709|NCT02882074|DRUG|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
218961710|NCT03905109|DRUG|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
218961711|NCT03905109|DRUG|Placebo|In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
218961712|NCT05048082|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
219647181|NCT03727126|PROCEDURE|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
219647182|NCT03727126|PROCEDURE|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
218961713|NCT05048082|PROCEDURE|Tumor resection surgery|Standard of care surgical removal of cancerous lung lesion
218961714|NCT01479985|OTHER|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
219647183|NCT03104062|DIAGNOSTIC_TEST|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
219647184|NCT03104062|DIAGNOSTIC_TEST|Platelet Aggregability|Obtained using Multiplate Analyzer
219647185|NCT03104062|DIAGNOSTIC_TEST|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
218961715|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
218961716|NCT02538861|DIAGNOSTIC_TEST|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
218961717|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
218961718|NCT00155870|BEHAVIORAL|questionnaires|
218961719|NCT03838783|DRUG|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
218961720|NCT01562067|DEVICE|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
218961721|NCT05171829|OTHER|Track U|Track U diary
219647186|NCT05222152|DRUG|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
219647187|NCT05222152|DRUG|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
219647188|NCT01847781|BIOLOGICAL|Prevenar13|
219647189|NCT06141122|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
219647190|NCT06011356|DEVICE|Smartwatch|Activity tracker (step count, calories burned), measures heart rate, heart variability and other physiological variables.
219647191|NCT04333407|DRUG|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
219647192|NCT04333407|DRUG|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
219647193|NCT04333407|DRUG|Rivaroxaban 2.5 MG|"* If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~* If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
219647194|NCT04333407|DRUG|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
219647195|NCT04333407|DRUG|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
219647196|NCT06582407|OTHER|Mathematical Prediction of unforseen patient reorientation|The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
219647197|NCT03603470|OTHER|EOS imagery|Whole body EOS imaging in seated and standing position
219647198|NCT02682823|DEVICE|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
219647199|NCT02682823|DRUG|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
219647200|NCT06237413|DRUG|ZG2001 Tosilate Tablets|ZG2001 will be administered orally once or twice daily in a continuous regimen
219647201|NCT06622213|OTHER|mucoadhesive film with Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
219647202|NCT06622213|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Apply ¼ inch on ulcer 3 times per day (after meals)
219647203|NCT06622213|OTHER|mucoadhesive film without Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
219647204|NCT05021458|OTHER|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
219647205|NCT05021458|OTHER|SNAG|: Ten patients will be treated with SNAGs
219647206|NCT06622473|DEVICE|hand dexterity assessement|Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
219647207|NCT03066245|BIOLOGICAL|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
219647208|NCT06193811|DRUG|Avenciguat (BI 685509) (intended commercial formulation (iCF))|Avenciguat (BI 685509) (intended commercial formulation (iCF))
219647209|NCT06193811|DRUG|Avenciguat (BI 685509) (trial formulation 2 (TF2))|Avenciguat (BI 685509) (trial formulation 2 (TF2))
219647210|NCT06193811|DRUG|esomeprazole|esomeprazole (Nexium mups)
219647211|NCT01938430|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
219647212|NCT01938430|DRUG|RBV|RBV tablets administered orally in a divided daily dose
218961722|NCT03665857|BEHAVIORAL|a multicomponent intervention|"1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
219647213|NCT00462592|DRUG|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.
219647214|NCT00462592|DRUG|montelukast|montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
219647215|NCT00462592|OTHER|placebo|placebo
218961723|NCT00950261|RADIATION|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
218961724|NCT02296879|GENETIC|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
219647216|NCT06366516|DIAGNOSTIC_TEST|Methylation Test|"Participants who aged 25-65 years with high-risk HPV infection are recruited.To start with,cervical exfoliated cells are collected, coded (according to the actual enrollment sequence), and stored in the pathology department where methylation testing is performed.In addition,patients will underwent colposcopy and biopsy.~Patients are followed up by cytology, high-risk HPV and methylation tests at 6 and 12 months after enrollment.Cervical conization and hysterectomy will be taken if necessary according to histopathological results. The clinical endpoint is reached when CIN2+ is confirmed by histopathological result."
219647217|NCT05120518|OTHER|Collection of post mortem tissue donation|Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
219647218|NCT06665282|DEVICE|Pulsed high intensity laser therapy|"The study employs a BTL-6000 high-intensity laser therapy (12 W) to apply high intensity laser therapy to deep tissues. high intensity laser therapy therapy uses powerful beams (\>500 mw) to penetrate deeper, delivering high multi-directional energy in a short time. Pulsed laser therapy, a form of high intensity laser therapy therapy, enhances cell metabolism without disrupting it.~High-intensity laser therapy is a safe treatment method consisting of three phases. The first phase involves fast scanning around the wrist, hand, and fingers, with fluencies set at 510, 610, and 710mJ/cm2. The second phase involves holding the handpiece vertically to 90° on 10 fixed points around the metacarpophalangeal and interphalangeal joints, each radiated for 15 seconds, and a total dose of 1500 J. The third phase is the same but at a slower rate, with a total energy of 300 J."
218961725|NCT00931346|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
218961726|NCT00931346|DRUG|Placebo|Placebo
218961727|NCT05836779|DRUG|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
218961728|NCT02718950|DRUG|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
218961729|NCT00208182|DRUG|Risperidone|
219647219|NCT06665282|DEVICE|sham pulsed high intensity laser therapy|Patients in the control group will receive sham high-intensity laser therapy, where all parameters will be set up without switching on the start button and high intensity laser therapy machine is switched on with a visible light beam only
219686259|NCT01488552|DRUG|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
218961730|NCT05606146|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
219647220|NCT06665282|OTHER|Routine physical therapy program|All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
219647221|NCT04026893|PROCEDURE|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
219647222|NCT03692793|OTHER|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
219647223|NCT03755869|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
219647224|NCT01287949|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
219061752|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
219647225|NCT00979875|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
219647226|NCT00979875|DRUG|Insulin lispro|
219647227|NCT00979875|DRUG|Insulin glulisine|
219647228|NCT00979875|DRUG|Insulin aspart|
219647229|NCT04519320|DIAGNOSTIC_TEST|Pulmonary function testing|"D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan~* Pulmonary function testing (PFT)~* 6-minute walk test (6MWT)~* MOS SF-36 Questionnaire~* HADS scale~* Ventilatory polygraphy~M6: D0 + 6 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~M12: D0 + 12 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan (If anomaly found at M3)~* PFT~* Pulmonary Exercise Stress Test~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO \<LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale"
219647230|NCT06281210|PROCEDURE|Omission of surgical treatment|Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
219647231|NCT03644485|DRUG|Tacrolimus immediate-release formulation|oral
219647232|NCT03644485|DRUG|Tacrolimus prolonged-release formulation|oral
219647233|NCT03644485|DRUG|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
219647234|NCT03644485|DRUG|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
219647235|NCT03644485|DRUG|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
219647236|NCT02606006|BEHAVIORAL|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
219647237|NCT02606006|BEHAVIORAL|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
219647238|NCT00000161|DRUG|Aspirin|
219647239|NCT00000161|DRUG|Beta-Carotene|
219647240|NCT00000161|DRUG|Vitamin C|
219647241|NCT00000161|DRUG|Vitamin E|
219647242|NCT03251261|DEVICE|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
219647243|NCT06503783|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
219647244|NCT02738879|DRUG|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
219647245|NCT02738879|DRUG|Placebo to sitagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
219647246|NCT02738879|DRUG|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
219647247|NCT02738879|DRUG|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
219647248|NCT02738879|DRUG|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
219647249|NCT03184194|DRUG|nivolumab-daratumumab|nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
219647250|NCT03184194|DRUG|nivolumab-daratumumab with low-dose cyclophosphamide|nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
219061753|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
219061754|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
219061755|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
219647251|NCT01438294|OTHER|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
219647252|NCT01438294|OTHER|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
218961731|NCT05448976|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
218961732|NCT02644200|DEVICE|Gelatin tannate|
218961733|NCT04710277|OTHER|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
218961734|NCT04710277|OTHER|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
218961735|NCT02157207|DIETARY_SUPPLEMENT|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
218961736|NCT02157207|OTHER|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
218961737|NCT05867342|DRUG|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
218961738|NCT05867342|DRUG|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
219061756|NCT03270761|OTHER||
219061757|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
219061758|NCT00058890|DRUG|Placebo|
219647253|NCT01302444|DRUG|Tadalafil|Tadalafil 40mg for 12 weeks
219647254|NCT01302444|DRUG|Placebo|Placebo for 12 weeks
219647255|NCT06620029|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.
219686260|NCT01488552|DRUG|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
219061759|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
219061760|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
219061761|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
218961739|NCT05867342|DRUG|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
218961740|NCT03600688|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair
218961741|NCT00470184|DRUG|capecitabine|Oral
218961742|NCT00470184|DRUG|oxaliplatin|IV
218961743|NCT00470184|GENETIC|gene expression analysis|Correlative Study
218961744|NCT00470184|GENETIC|microarray analysis|Correlative Study
218961745|NCT00470184|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative Study
218961746|NCT00470184|PROCEDURE|adjuvant therapy|Metastatic growth control
218961747|NCT00470184|PROCEDURE|biopsy|Examination of tissue type
218961748|NCT00470184|PROCEDURE|conventional surgery|Tissue removal
218961749|NCT00470184|PROCEDURE|neoadjuvant therapy|Tumor shrinkage
218961750|NCT00470184|PROCEDURE|quality-of-life assessment|Correlative Study
218961751|NCT00470184|RADIATION|radiation therapy|Undergoing radiation therapy
219061762|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
219061763|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
219061764|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
219061765|NCT02773979|OTHER|Placebo|Placebo
219061766|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
219061767|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
219061768|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
219061769|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
219061770|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
219061771|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
219061772|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
219061773|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
219061774|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
219061775|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
219061776|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
219647256|NCT06620029|DRUG|Paclitaxel (Taxol)|Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
219647257|NCT01346189|BEHAVIORAL|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
219647258|NCT05715489|PROCEDURE|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
219647259|NCT05715489|PROCEDURE|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
219647260|NCT04241744|DRUG|Vancomycin 125 MG po BID|prevention to develop CDI during hospitalization
219647261|NCT04188431|DRUG|Dexamethasone|Is usually commercialized as dexamethasone phosphate as solution for injection
219647262|NCT04188431|DRUG|Sodium chloride|prepared in the same intravenous volume to mimic experimental arm
219647263|NCT00205868|DEVICE|Precision Spinal Cord Stimulation System|Stimulation on throughout study
219647264|NCT00020046|DRUG|docetaxel|
218961752|NCT05953714|OTHER|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
218961753|NCT05271708|DRUG|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
218961754|NCT05271708|DRUG|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
218961755|NCT01410552|DEVICE|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
219061777|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
219061778|NCT02647658|BEHAVIORAL|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
219061779|NCT02647658|BEHAVIORAL|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
219061780|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
219061781|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
219061782|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
219061783|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
219061784|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
219061785|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
219647265|NCT00020046|DRUG|thalidomide|
219061786|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
219061787|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
219061788|NCT02239458|DRUG|Saxagliptin|
219647266|NCT05024240|DIAGNOSTIC_TEST|Stabilometry|Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
219061789|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
219061790|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
219061791|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
219061792|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
219061793|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
219647267|NCT05024240|DIAGNOSTIC_TEST|Stroop test|There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
219647268|NCT05024240|DIAGNOSTIC_TEST|Backward counting test|In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
218961756|NCT04387825|DRUG|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
218961757|NCT02483533|DRUG|LIPO-202|
218961758|NCT02483533|DRUG|Placebo|
218961759|NCT03452527|BIOLOGICAL|ICON-1|ICON-1 0.6 mg by intravitreal injection
218961760|NCT03452527|BIOLOGICAL|aflibercept|aflibercept 2 mg by intravitreal injection
218961761|NCT02684487|DRUG|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
218961762|NCT02684487|DRUG|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
218961763|NCT04756180|DRUG|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
218961764|NCT05155462|OTHER|One or two phone call|Phone call to collect patient data
218961765|NCT05084729|DEVICE|Imagio OA/US|Imagio optoacoustic
218961766|NCT03255330|DRUG|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
218961767|NCT03255330|DRUG|Metamizol|Standardized treatment
218961768|NCT03255330|DRUG|Tramadol|Standardized treatment
218961769|NCT01782001|DIETARY_SUPPLEMENT|vitamin A|vitamin A with placebo
218961770|NCT01782001|DIETARY_SUPPLEMENT|vitamin A and zinc|combination of vitamin A and zinc supplements
218961771|NCT04200040|BIOLOGICAL|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
218961772|NCT04200040|DRUG|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
218961773|NCT00002681|BIOLOGICAL|aldesleukin|
218961774|NCT00002681|BIOLOGICAL|daclizumab|
218961775|NCT03625271|DEVICE|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
218961776|NCT05023824|DRUG|alpha-blocker or 5-ARI withdrawal|Withdrawal of either alpha-blocker or 5-ARI
218961777|NCT05023824|DRUG|Maintenance of alpha-blocker and 5-ARI|Maintenance of alpha-blocker and 5-ARI
218961778|NCT01686802|DRUG|oral morphine|
218961779|NCT01686802|DRUG|Ibuprofen|
218961780|NCT01537107|DRUG|vismodegib|Given PO
218961781|NCT01537107|DRUG|sirolimus|Given PO
218961782|NCT01537107|PROCEDURE|positron emission tomography|Correlative studies
218961783|NCT01537107|PROCEDURE|computed tomography|Correlative studies
218961784|NCT01537107|OTHER|pharmacological study|Correlative studies
218961785|NCT01537107|OTHER|laboratory biomarker analysis|Correlative studies
218961786|NCT01537107|RADIATION|fludeoxyglucose F 18|Correlative studies
218961787|NCT04195737|PROCEDURE|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
218961788|NCT04195737|PROCEDURE|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
218961789|NCT00121173|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
218961790|NCT02585128|OTHER|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
218961791|NCT02585128|OTHER|MMSE (Mini Mental State Examination)|
218961792|NCT02585128|OTHER|Barthel index|
219061794|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
219647269|NCT03572725|PROCEDURE|Gas tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
219647270|NCT03572725|PROCEDURE|Air tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
219647271|NCT01197625|BIOLOGICAL|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
219647272|NCT06484348|BEHAVIORAL|Monitoring of eating behaviors|Overall eating behaviors will be assessed from pictures of consumed food and drinks taken by the participants with their smartphones. A complete assessment of eating habits will be carried out daily for 4 days. For each photo, the participants will indicate the reasons why they ate by completing analogical scales (hunger, craving, sleepiness, stress, negative emotion) and an open question (other reason). These data will be used to determine the reason and timing of food intake and the number of calories ingested for each food category. Eating behaviors specifically related to sugar intake will be monitored using the FREESTYLE PRO® sensor. This small device is used routinely for diabetes care and is placed on the back of the arm. The system is designed to measure glucose levels in the interstitial fluid every 15 minutes for up to 14 days. The recorded data can be downloaded by an investigator using the FREESTYLE LIBRE PRO® reader.
219647273|NCT06484348|BEHAVIORAL|Monitoring of sleep/wake rhythm|"The sleep-wake rhythm will be measured continuously during the 5 days, both subjectively (sleep diary) and objectively, using the GT9X LINK ACTIGRAPH."
219647274|NCT06484348|BEHAVIORAL|Measure of nocturnal sleep parameters|The quality and quantity of the participants' sleep will be recorded using the SOMFIT® device. This non-invasive portable device will allow the determination of sleep architecture as well as sleep EEG microstructure.
219647275|NCT06484348|BEHAVIORAL|Measure of sleepiness|Sleepiness will be assessed by the Karolinska Sleepiness Scale (KSS) at the initiation of food intake and 30 min and 2 hours afterwards, and by analysis of EEG activity recorded by the SOMFIT® over a time window surrounding food intake. Indeed, participants will also be asked to wear the device as much as possible during the day when they are at home in order to explore sleepiness markers during wakefulness.
219647276|NCT01730534|DRUG|Dapagliflozin 10 mg|Oral dose (od)
219647277|NCT01730534|DRUG|Placebo tablet|Oral dose (od)
219647278|NCT02554058|DEVICE|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
219647279|NCT04540341|OTHER|Mulligan mobilization|Mulligan mobilization technique will be apply.
218961793|NCT02585128|OTHER|HADS (Hospital Anxiety and Depression Scale)|
218961794|NCT02585128|OTHER|MNA-SF (Mini Nutritional Assessment - Short Form)|
218961795|NCT02585128|DEVICE|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
218961796|NCT02585128|OTHER|CIRS (Cumulative Illness Rating Scale)|
218961797|NCT01677312|PROCEDURE|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
218961798|NCT01677312|PROCEDURE|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
218961799|NCT04746872|DIAGNOSTIC_TEST|Alinity m HR HPV|A qualitative in vitro test that amplifies and detects HR HPV DNA in cervical tissue samples.
218961800|NCT01792570|DRUG|RPV + DRV/r|Switch to dual HAART
218961801|NCT01792570|DRUG|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
218961802|NCT05628688|DIAGNOSTIC_TEST|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
219061795|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
218961803|NCT02301611|DRUG|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
218961804|NCT02301611|DRUG|Placebo|
218961805|NCT00860977|DRUG|valacyclovir|oral valacyclovir 500mg twice daily
218961806|NCT00860977|DRUG|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
218961807|NCT03256890|BEHAVIORAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
219061796|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
219061797|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
219061798|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
219207825|NCT06776978|DEVICE|Sham Stimulation|Participants receive sham tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). No therapeutic current is applied during the 20-minute session. The electrode placement mimics the active condition, targeting the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. Sham tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
219061799|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
219061800|NCT02378142|DRUG|Pazopanib|
219647280|NCT04540341|OTHER|Core stabilization|Core stabilization technique will be apply.
219647281|NCT04540341|OTHER|Conventional therapy|Conventional therapy exercise will be apply.
219647282|NCT05622682|OTHER|Observational only: Serology and flow cytometry for ALL cohort participants|Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
219647283|NCT05622682|OTHER|Observational only: Infection rates|Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.
219647284|NCT04369131|DEVICE|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
219647285|NCT03355157|DRUG|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
218961808|NCT03256890|OTHER|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
218961809|NCT03923985|DIETARY_SUPPLEMENT|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
218961810|NCT05373771|OTHER|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
218961811|NCT04291001|DEVICE|ENG implant|This is an FDA-approved contraceptive device
218961812|NCT04291001|DRUG|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
218961813|NCT00065130|DRUG|human insulin|
218961814|NCT00065130|DRUG|insulin NPH|
218961815|NCT00065130|DRUG|insulin aspart|
219647286|NCT04151160|DIAGNOSTIC_TEST|Point of care ultrasound measurements|i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
219647287|NCT04053140|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
219647288|NCT04053140|DEVICE|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
219647289|NCT04053140|DRUG|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
219647290|NCT04053140|DRUG|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
219647291|NCT04053140|DRUG|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
219647292|NCT04782895|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
219647293|NCT04782895|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
219647294|NCT06322095|DRUG|PD-1|Previous PD-1
218961816|NCT06497036|DRUG|GP404141|subcutaneous injection
218961817|NCT06497036|DRUG|Nplate|subcutaneous injection
218961818|NCT00876798|DRUG|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
218961819|NCT00876798|DRUG|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
218961820|NCT00174291|DRUG|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
218961821|NCT02970201|OTHER|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
218961822|NCT04044027|BEHAVIORAL|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
218961823|NCT02313454|DEVICE|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
218961824|NCT01417182|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
218961825|NCT04676971|DRUG|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
218961826|NCT04676971|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
218961827|NCT00412490|BEHAVIORAL|Questionnaire|Written survey at 1 Month \& 6 Months post surgery.
218961828|NCT00412490|BEHAVIORAL|Interview|One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
218961829|NCT02744937|DRUG|Aspirin|aspirin is continued by its regular dosing
219647295|NCT06322095|DRUG|MET inhibitor|Previous MET inhibitor
219647296|NCT06322095|DRUG|ALK inhibitor|Previous ALK inhibitor
219647297|NCT06322095|DRUG|BRAF Inhibito|Previous BRAF inhibitor
219647298|NCT06322095|DRUG|EGFR Monoclonal antibody|Previous EGFR Monoclonal antibody
219647299|NCT06322095|DRUG|GH21|Oral, 15mg BIW or 6mg QD
219647300|NCT06322095|DRUG|MEK Inhibitor|Previous MEK Inhibitor
219647301|NCT04814550|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
219647302|NCT01895608|BEHAVIORAL|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
219647303|NCT01895608|BEHAVIORAL|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
219647304|NCT01895608|BEHAVIORAL|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
219647305|NCT01895608|BEHAVIORAL|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
219647306|NCT03505593|DEVICE|ENVUE System|The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
219647307|NCT05855174|DIETARY_SUPPLEMENT|Whey protein|Weight protein provided in a shake with carbohydrate and water
219647308|NCT06434220|DIAGNOSTIC_TEST|Baseline model|Model prediction of patient disposition including feature importance scores driving prediction.
219647309|NCT06434220|DIAGNOSTIC_TEST|Fairness-aware model|Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
219647310|NCT02611570|OTHER|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
219647311|NCT01619137|DRUG|water and soap|water and soap for 6-8 hours per day.
219647312|NCT01619137|DRUG|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
219647313|NCT02184585|DRUG|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
218961830|NCT00260078|DRUG|Atazanavir|200 mg to 400 mg orally daily
218961831|NCT00260078|DRUG|Darunavir|300 mg or 600 mg orally twice daily
219207826|NCT06776237|DIAGNOSTIC_TEST|PoCUS|Participants after getting recruited will be asked for an ultrasonography of the neck. It will take around 30 minutes. At home, participants will be asked to wear a portable sleep study device overnight, to perform home sleep study. Although these devices are noninvasive and safe, they are not routinely used as a standard of care in the pregnant patient population.
219207827|NCT06775353|DRUG|Dexamethasone eyedrop|Infants who developed stages of pretreatment-requiring severe ROP were usually given one eyedrop of dexamethasone daily until the ROP changes regressed.
219647314|NCT02184585|DRUG|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
219647315|NCT02184585|DRUG|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
219647316|NCT06004856|DRUG|Orelabrutinib|Orelabrutinib once daily (QD)
219647317|NCT06004856|DRUG|Placebo|Placebo once daily (QD)
219647318|NCT05290909|OTHER|The protocol of blended and problem-based learning|The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.
219647319|NCT05290909|OTHER|The traditional problem-oriented teaching model|The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
218961832|NCT00260078|DRUG|Efavirenz|Dosage dependent on participant
218961833|NCT00260078|DRUG|Nevirapine|Dosage dependent on participant
218961834|NCT00260078|DRUG|Ritonavir|50 mg or 100 mg orally twice daily
218961835|NCT00260078|DRUG|Tenofovir disoproxil fumarate|300 mg orally daily
218961836|NCT00260078|PROCEDURE|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
218961837|NCT04738929|OTHER|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
218961838|NCT03116347|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
218961839|NCT03116347|BIOLOGICAL|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
218961840|NCT03116347|BIOLOGICAL|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
218961841|NCT06222359|DEVICE|COMPASS|Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
218961842|NCT04679545|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
218961843|NCT04679545|DRUG|Placebo|An inactive compound.
219647320|NCT00877409|DRUG|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
219647321|NCT00877409|DRUG|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
219647322|NCT02833844|DRUG|Evolocumab|Dose of subcutaneous evolocumab QM
219647323|NCT02833844|DRUG|Placebo|Dose of matching placebo QM
219647324|NCT00065104|DRUG|DHEA|
219647325|NCT06386068|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for chronic Whiplash-Associated Disorder (WAD). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants' lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
219647326|NCT02704572|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection.
218961844|NCT00476047|COMBINATION_PRODUCT|Tositumomab and Iodine I 131 Tositumomab|Give IV
219647327|NCT03369067|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
219647328|NCT03369067|DEVICE|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
219647329|NCT03369067|DEVICE|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
219647330|NCT06498622|DRUG|Donafenib + Envafolimab|"Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI"
219647331|NCT02952846|OTHER|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
219647332|NCT02312596|DEVICE|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
219647333|NCT02312596|OTHER|Usual and Customary Practice|Usual and customary care for non-healing wounds
219647334|NCT04828265|BIOLOGICAL|Aldafermin|Single dose of aldafermin
219647335|NCT05451550|PROCEDURE|Brachial plexus block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
219647336|NCT05451550|PROCEDURE|General anesthesia|General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
219647337|NCT05451550|PROCEDURE|Suprascapular nerve block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
219647338|NCT06665295|BEHAVIORAL|THRIVE-CAR-T|The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
219647339|NCT01245543|DRUG|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
219647340|NCT01245543|DRUG|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
219647341|NCT06499233|DRUG|Trimethoprim/Sulfamethoxazole|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
218961845|NCT03170232|DRUG|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
218961846|NCT03170232|DRUG|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
219647342|NCT02377479|DRUG|Clomiphene|Taken for controlled ovarian hyperstimulation.
219647343|NCT02377479|DRUG|Letrozole|Taken for controlled ovarian hyperstimulation
219647344|NCT05132712|DRUG|Losartan Potassium|ACE inhibitor
219647345|NCT05132712|DRUG|multi-vitamins|placebo drug
219647346|NCT03963050|OTHER|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
219647347|NCT03963050|OTHER|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
219647348|NCT03963050|OTHER|Control|NO changes in lifestyle
219647349|NCT01692249|OTHER|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
219647350|NCT05824052|OTHER|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
219647351|NCT02197286|DRUG|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
219647352|NCT02197286|DRUG|Placebo|Daily dose of a single gelatin placebo capsule.
219647353|NCT03768011|COMBINATION_PRODUCT|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
219647354|NCT00558662|DEVICE|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
219647355|NCT00558662|DEVICE|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
219647356|NCT06499168|DRUG|neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery|"In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy."
218961847|NCT03170232|DEVICE|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
218961848|NCT03170232|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
219647357|NCT01070667|DRUG|Dronedarone|400mg orally once per day for 3 months
219647358|NCT01070667|DRUG|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
219647359|NCT02541669|DRUG|TAK-491|TAK-491 tablets
219647360|NCT02541669|DRUG|TAK-491 placebo|TAK-491 placebo-matching tablets
219647361|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS|Real multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 20 minutes.
219647362|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Sham multifocal tDCS|Sham multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 30 seconds.
219647363|NCT06668610|BEHAVIORAL|Cognitive treatment|During the two cycles, all participants will undergo traditional cognitive stimulation therapy, involving paper-and-pencil exercise and computerised activity on several cognitive domains including memory, attention, and executive functions (duration 30-40 minutes) .
219647364|NCT04086212|DRUG|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
219647365|NCT04086212|DRUG|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
218961849|NCT02355600|OTHER|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
219647366|NCT03580434|DEVICE|V-STRUT|Minimally invasive implantation of V-STRUT
219647367|NCT02284659|DEVICE|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
219647368|NCT02284659|DEVICE|FES- Sham|
219647369|NCT06668675|OTHER|A serious game known as the 'Happy Heart' will be used as the intervention.|"The serious game known as 'Happy Heart' is a mobile game used for educational purpose in addition to entertainment. It focuses on healthy habits for the heart and is aimed at improving knowledge on diet and physical activity among school-going adolescents.~The game is developed in collaboration with the game development team from the School of Informatics, University of Skövde and the health team from Kathmandu Medical College, Nepal."
219647370|NCT04558775|OTHER|Observational|no intervention
219647371|NCT01138358|OTHER|medical chart review|
219647372|NCT01138358|OTHER|study of socioeconomic and demographic variables|
219647373|NCT01138358|OTHER|survey administration|
219647374|NCT01138358|PROCEDURE|quality-of-life assessment|
219647375|NCT06622603|DRUG|Febuxostat|The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
219647376|NCT04651049|DRUG|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
219647377|NCT04651049|DEVICE||
219647378|NCT00124007|BIOLOGICAL|VRC-HIVADV014-00-VP|
219647379|NCT00124007|BIOLOGICAL|VRC-HIVDNA016-00-VP|
219647380|NCT04433715|DIAGNOSTIC_TEST|ICIQ-SF|All participants completed ICIQ-SF,
219647381|NCT04433715|DIAGNOSTIC_TEST|UDI-6|All participants completed UDI-6
219647382|NCT04433715|DIAGNOSTIC_TEST|IIQ-7|All participants completed IIQ-7
219647383|NCT02737631|DEVICE|"Chameleon Personal Lubricant"|
219647384|NCT05172869|PROCEDURE|Suprainguinal Performed FICB|Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
219647385|NCT05172869|PROCEDURE|Infrainguinal Performed FICB|Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
219647386|NCT02191722|BEHAVIORAL|reading comics booklet|
219647387|NCT03912714|PROCEDURE|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (\>20).
219647388|NCT03912714|PROCEDURE|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
219647389|NCT00752258|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
219647390|NCT06648616|OTHER|EBT|Elastic Band Resistance Training
218961850|NCT06028100|PROCEDURE|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
218961851|NCT02730897|PROCEDURE|Central/Peripheral|Central versus peripheral location of the primary tumor
218961852|NCT02931266|DEVICE|PASS MIS®|Posterior mini-invasive osteosynthesis
219647391|NCT01118624|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
219647392|NCT01118624|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
219647393|NCT01118624|DIETARY_SUPPLEMENT|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
219647394|NCT00690196|BEHAVIORAL|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
219647395|NCT00690196|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
219647396|NCT06621342|BIOLOGICAL|PRP Experimental|All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
219647397|NCT04799548|DRUG|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
219647398|NCT04799548|DRUG|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
218961853|NCT03498001|DRUG|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
219061801|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
219061802|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
219061803|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
219061804|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
219061805|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
219647399|NCT05053048|DEVICE|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
219647400|NCT00902343|PROCEDURE|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
219647401|NCT00902343|PROCEDURE|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
219647402|NCT01783639|PROCEDURE|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
219647403|NCT05591612|BEHAVIORAL|Salt replacement seasoning (50% salt and 50% MSG) mix|Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.
219647404|NCT05591612|BEHAVIORAL|Salt replacement seasoning (70% salt and 30% MSG) mix|Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.
219647405|NCT05591612|BEHAVIORAL|NaCl (sodium chloride/table salt)|Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
219647406|NCT05267925|DIETARY_SUPPLEMENT|CuraLin|"CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour"
219647407|NCT02774122|DEVICE|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
219647408|NCT02774122|DEVICE|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
219647409|NCT03748576|BEHAVIORAL|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
219647410|NCT00396552|DEVICE|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
219647411|NCT00396552|DEVICE|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
218961854|NCT03498001|PROCEDURE|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
218961855|NCT03498001|OTHER|Follow up by phone|at 2 and 4 mois
219647412|NCT06431399|DRUG|JLP-2004 qd|Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
219647413|NCT03149289|DRUG|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
219647414|NCT05990348|OTHER|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
219686261|NCT01488552|DRUG|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
219686262|NCT01488552|GENETIC|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
219686263|NCT01488552|DRUG|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
219686264|NCT01488552|DRUG|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
219686265|NCT00642226|PROCEDURE|Grid Laser|ETDRS Grid Laser
219686266|NCT00642226|PROCEDURE|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
219647415|NCT06418477|DRUG|Dara-CyBorD|"Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis."
219647416|NCT00101075|DRUG|Capecitabine|
219647417|NCT00101075|DRUG|Oxaliplatin|
219647418|NCT02658734|DRUG|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
218961856|NCT02656212|DRUG|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
219647419|NCT05409313|BEHAVIORAL|EBP training|The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
219647420|NCT05409313|BEHAVIORAL|SDM training|A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
219647421|NCT00459706|DEVICE|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
219647422|NCT00459706|DEVICE|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
219647423|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
219647424|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
219647425|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
219647426|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
219647427|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
219647428|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
219647429|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
219647430|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
219647431|NCT00074997|OTHER|Placebo|Single intravenous infusion of placebo.
219647432|NCT00074997|GENETIC|OZ1|Single intravenous infusion of OZ1.
219647433|NCT00074997|GENETIC|CD34+ cells|Autologous CD34+ cells.
219647434|NCT01385488|BEHAVIORAL|self-monitor arm volume|bioelectrical impedance
219647435|NCT01880086|DRUG|Clomiphene citrate|
219647436|NCT01880086|DRUG|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
218961857|NCT02656212|DRUG|Placebo|Placebo pill, taken orally, one pill/day in the morning
218961858|NCT00586326|DEVICE|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
219647437|NCT01068886|PROCEDURE|External pancreatic stent|stent through pancreatic anastomosis
219647438|NCT02458768|DRUG|IVF-M HP Inj.|
219647439|NCT02458768|DRUG|Menopur® Inj.|
219647440|NCT04901351|PROCEDURE|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
219647441|NCT06093737|BEHAVIORAL|COPE: Communities Organizing for Power through Empathy|A three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
219647442|NCT04756570|OTHER|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
218961859|NCT01546064|DEVICE|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
219061806|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
219647443|NCT04756570|OTHER|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
219207828|NCT06776276|BEHAVIORAL|Tai Chi exercises|Tai-chi (TC) is a kind of CAM Qigong exercises, is a type of classic Chinese martial arts. It entails deliberate, slow-motion physical movements that are done alongside inward concentration, awareness of breathing, and the inherent power or energy in the body. It promotes general purposes of health and spirituality. It is generally accessible and offered to older people in public places.
219207829|NCT06776328|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of children and adolescents with suicidal thoughts/behavior.
219207830|NCT06776835|DIAGNOSTIC_TEST|Analysis of relative quantitative of small non-coding RNAs|Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs
219647444|NCT04756570|OTHER|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
219647445|NCT04724629|BIOLOGICAL|Ixekizumab|80 mg of IL-17 inhibitor
219647446|NCT04724629|BIOLOGICAL|Aldesleukin|1.5 million IU (low-dose) of IL-2
219647447|NCT04724629|DRUG|Colchicine|0.5 mg of indirect IL-6 inhibitor
219647448|NCT04724629|DRUG|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
219647449|NCT03843632|BIOLOGICAL|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
219647450|NCT05929729|DRUG|Ferric derisomaltose|Refer to arm/group descriptions
219647451|NCT05929729|DRUG|NovaFerrum|Refer to arm/group descriptions
219647452|NCT00055770|DRUG|erlotinib hydrochloride|Given orally
219647453|NCT00055770|DRUG|docetaxel|Given IV
219647454|NCT00055770|OTHER|laboratory biomarker analysis|Correlative studies
219647455|NCT00055770|OTHER|pharmacological study|Correlative studies
219647456|NCT00774553|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
219647457|NCT00774553|DRUG|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
219647458|NCT03403751|DRUG|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
219647459|NCT03403751|DRUG|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
219647460|NCT01820572|DRUG|Belatacept|
219647461|NCT01820572|DRUG|Tacrolimus|
219647462|NCT01820572|DRUG|Cyclosporine|
219647463|NCT00266643|DRUG|duloxetine hydrochloride|
219647464|NCT02411058|BEHAVIORAL|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
219647465|NCT02411058|BEHAVIORAL|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
219647466|NCT00896181|DRUG|docetaxel|Given IV
219647467|NCT00896181|DRUG|cisplatin|Given IV
219647468|NCT00896181|DRUG|carboplatin|Given IV
219647469|NCT00896181|DRUG|fluorouracil|Given IV
219647470|NCT00896181|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
219647471|NCT00896181|RADIATION|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
219647472|NCT05761210|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
219647473|NCT06622343|DRUG|Antivenom Serum|Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.
219647474|NCT06622343|PROCEDURE|Wound Debridement|Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.
219647475|NCT00351741|DEVICE|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
219647476|NCT00351741|DEVICE|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
219647477|NCT05036668|BIOLOGICAL|Cryptosporidium parvum oocysts (ABO809)|ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1
219647478|NCT01539551|OTHER|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
219647479|NCT05108142|OTHER|Dietary intervention|fresh, hot pasta and re-heated pasta
219647480|NCT02947256|PROCEDURE|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
219647481|NCT02947256|PROCEDURE|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
219647482|NCT06620978|PROCEDURE|Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..|"Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..~Operative hysteroscopy without anesthesia using normal Saline as medium with different pressure according to the arm allocated. The procedure is done for endometrial polyp removal, retained products of conception removal, intrauterine adhesyolisis and intrauterine device removal."
219647483|NCT06620978|PROCEDURE|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium in High pressure.|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium at high pressure.
219647484|NCT04586634|DEVICE|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
219647485|NCT00871442|OTHER|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
219647486|NCT00871442|OTHER|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
219647487|NCT00871442|DRUG|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
219647488|NCT01739218|DRUG|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
219647489|NCT01739218|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
219647490|NCT01739218|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
219647491|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
219647492|NCT00778284|DRUG|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
218961860|NCT01546064|DEVICE|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
218961861|NCT02968589|BEHAVIORAL|Training|
218961862|NCT03889171|BEHAVIORAL|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
218961863|NCT06111391|DEVICE|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
218961864|NCT02122731|DRUG|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
218961865|NCT02908867|OTHER|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
218961866|NCT01439347|DRUG|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
218961867|NCT01439347|DRUG|Vincristine Sulfate Injection (VSI)|1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
218961868|NCT02054871|PROCEDURE|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
218961869|NCT00284076|DRUG|L-arginine|
218961870|NCT04161300|OTHER|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
218961871|NCT04161300|OTHER|Control Group (CG)|The CG did not receive any intervention.
219061807|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
219061808|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
219647493|NCT02710253|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219647494|NCT02710253|OTHER|Laboratory Biomarker Analysis|Correlative studies
219647495|NCT02710253|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219647496|NCT01118793|DRUG|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
219647497|NCT03381079|PROCEDURE|Posterior scleral reinforcement|Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.
219647498|NCT03048318|PROCEDURE|Arterial Flushing|
219647499|NCT03048318|PROCEDURE|Portal Flushing|
219647500|NCT02589990|BEHAVIORAL|Strength training|see arm description
219647501|NCT04455191|PROCEDURE|Thawing Embryos in Advance|Thaw Embryos one day in Advance
219647502|NCT04455191|PROCEDURE|Thawing Embryos on the Day of Transfer|Thaw Embryos on the morning of transfer day.
219647503|NCT06219824|DRUG|premixed Bio-ceramic MTA|pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber
219647504|NCT06219824|DRUG|Conventional MTA|pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
219647505|NCT05314842|DRUG|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
219647506|NCT05314842|DRUG|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
219647507|NCT02952131|PROCEDURE|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
219647508|NCT02952131|PROCEDURE|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
219647509|NCT02952131|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
218961872|NCT04161300|OTHER|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
219647510|NCT06038461|DRUG|Surufatinib Combined With Temozolomide and S-1|"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"
219647511|NCT03064100|OTHER|Observational Study|Exclusion from the study
218961873|NCT02972762|DRUG|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
218961874|NCT00739492|BEHAVIORAL|financial incentives|financial incentives based on attaining weight loss goals
218961875|NCT01525121|OTHER|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
218961876|NCT00882700|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
218961877|NCT00882700|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
218961878|NCT03494777|BEHAVIORAL|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.
218961879|NCT03494777|BEHAVIORAL|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
218961880|NCT03494777|BEHAVIORAL|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.
218961881|NCT03494777|BEHAVIORAL|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
219061809|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
219061810|NCT00406029|DRUG|Preladenant|1 mg BID capsules
219061811|NCT00406029|DRUG|Preladenant|2 mg BID capsules
219061812|NCT00406029|DRUG|Preladenant|5 mg BID capsules
219061813|NCT00406029|DRUG|Preladenant|10 mg BID capsules
219061814|NCT00406029|DRUG|Placebo|BID capsules
218961882|NCT03494777|BEHAVIORAL|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
218961883|NCT05337930|DEVICE|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
218961884|NCT05854927|DIAGNOSTIC_TEST|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
218961885|NCT02879240|OTHER|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
218961886|NCT02879240|OTHER|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
218961887|NCT03931668|DRUG|TPN-672|single dose of TPN-672 maleate tablet
219647512|NCT06181305|DRUG|estradiol valerate and letrozole|hormone replacement therapy by estradiol valerate plus letrozole incorporation .
219061815|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
219061816|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
219061817|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
219061818|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
219061819|NCT00058305|DRUG|bryostatin 1|Given IV
219061820|NCT00058305|DRUG|vincristine sulfate|Given IV
219647513|NCT06181305|DRUG|letrozole 2,5 mg tablet|mild ovarian stimulation
219647514|NCT02963428|BEHAVIORAL|Enhanced Care|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
219647515|NCT04848779|DRUG|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
219647516|NCT03195725|OTHER|Review of notes|No intervention will occur
219647517|NCT05110846|DRUG|Placebo|Placebo
219647518|NCT05110846|DRUG|CT-868|CT-868
219647519|NCT02408289|DIETARY_SUPPLEMENT|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
219647520|NCT02408289|DIETARY_SUPPLEMENT|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
219647521|NCT02408289|DIETARY_SUPPLEMENT|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
219647522|NCT02408289|DIETARY_SUPPLEMENT|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
219647523|NCT01931956|DEVICE|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
219647524|NCT03283293|RADIATION|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
219647525|NCT02076503|PROCEDURE|PET-MR 18f-FACBC|
219647526|NCT02076503|PROCEDURE|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
218961888|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
219647527|NCT00868725|OTHER|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
219647528|NCT02847494|DRUG|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
219647529|NCT02847494|DRUG|Dexamethasone|dexamethasone 10mg intramuscular injection
219647530|NCT02847494|DRUG|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
219061821|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
219061822|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
219061823|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
219061824|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
219061825|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
219207831|NCT06775548|OTHER|Aerobic Exercises + Vitamin E|"For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals.~The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike"
219647531|NCT01901653|DRUG|Rovalpituzumab tesirine (SC16LD6.5)|
219647532|NCT06898580|OTHER|sacral massage with tennis ball|When the cervical dilatation in labor is 5-6 cm, 7-8 cm and 9-10 cm, the woman will be asked to mark the intensity of the pain she feels on the VAS scale before starting the procedure. Then, the researcher explains sacral massage to the pregnant woman. While performing this application, the researcher will apply pressure to the sacral area with a tennis ball in a circular motion so that the patient can feel but not feel pain. The application will be applied to the pregnant woman for a total of 3 contractions. 30 minutes after each procedure, the woman will be asked to mark the intensity of the pain she feels on the VAS scale and mark the Birth Comfort Scale. The research will end when a total of 70 experimental groups and 70 control groups are reached.
219647533|NCT06760572|DEVICE|Airway insertion|Tube will be inserted into the trachea to make airway data measurements.
219647534|NCT04272944|DRUG|10 mg/kg Q2W|10 mg/kg MSB2311 every two weeks
219647535|NCT04272944|DRUG|20 mg/kg Q3W|20 mg/kg MSB2311 every three weeks.
219647536|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
219647537|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
219647538|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
219647539|NCT02091986|OTHER|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
219647540|NCT03002948|OTHER|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score"
219647541|NCT00751504|DRUG|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
219647542|NCT03792100|DRUG|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
219647543|NCT03792100|DRUG|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
219647544|NCT01017133|RADIATION|fludeoxyglucose F 18|Given IV
219647545|NCT01017133|RADIATION|Fluorine F 18 EF5|Given IV
219647546|NCT01017133|PROCEDURE|Positron emission tomography|Undergo scan
219647547|NCT02270047|DIETARY_SUPPLEMENT|Orange nectar|Orange nectar
218961889|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
218961890|NCT00655460|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
219061826|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
219061827|NCT01799174|PROCEDURE|Placebo|
219061828|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
219061829|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
219061830|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
218961891|NCT02775201|PROCEDURE|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
219061831|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
219061832|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
219061833|NCT00426478|DRUG|Amlodipine (5mg)|
219647548|NCT02270047|DIETARY_SUPPLEMENT|Orange Nectar with fibre|
219647549|NCT02027987|DRUG|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
219647550|NCT00323570|DRUG|activated recombinant human factor VII|
219647551|NCT01357070|DIETARY_SUPPLEMENT|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
219647552|NCT01357070|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
219647553|NCT06452849|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
219647554|NCT04350437|DRUG|induction of labor|Giving drugs to facilitate uterine contractions and fasten the process of delivery
219647555|NCT04616573|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
219647556|NCT04616573|DEVICE|iStent inject|Trabecular meshwork implantation
219647557|NCT06574945|DRUG|intravenous injection of propofol only|Propofol was administered intravenously 2 mg/kg
218961892|NCT02775201|PROCEDURE|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
218961893|NCT06256627|DRUG|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
218961894|NCT02793193|DIETARY_SUPPLEMENT|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
219061834|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
219647558|NCT06574945|DRUG|intravenous injection of propofol +esketamine|intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol
219647559|NCT02537431|BIOLOGICAL|burosumab|solution for subcutaneous injection
219647560|NCT03148860|DRUG|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
219647561|NCT03148860|DRUG|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
219647562|NCT03148860|OTHER|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
219647563|NCT04881227|DEVICE|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
219647564|NCT04881227|OTHER|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
219647565|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
219647566|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
219647567|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
219647568|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,2 application)
219647569|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
219647570|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
219647571|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
219061835|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
219647572|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,8 application)
219647573|NCT01738503|DRUG|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
219647574|NCT01738503|DRUG|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
219647575|NCT03887026|DRUG|Norketotifen|Norketotifen oral capsule
219647576|NCT03887026|DRUG|Placebo|Placebo oral capsule
219647577|NCT00919373|PROCEDURE|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
219647578|NCT00919373|PROCEDURE|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
219647579|NCT00919373|PROCEDURE|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
219647580|NCT00794040|DRUG|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
219647581|NCT00794040|DRUG|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
219647582|NCT00392743|PROCEDURE|pet/spect scan|
219647583|NCT00836381|DRUG|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
219647584|NCT00836381|DRUG|Placebo|Identical Placebo once daily
219647585|NCT02375308|BEHAVIORAL|HDT|20 sessions, individual psychotherapy
219647586|NCT02375308|BEHAVIORAL|ACDT|20 sessions, individual psychotherapy
219647587|NCT06669884|OTHER|Cardiodynamicsgram (CDG)|Cardiodynamicsgram (CDG) technique
219647588|NCT06372587|OTHER|genetically encoded engineered proteins|using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
219647589|NCT06685354|DRUG|hepatic arterial infusion of recombinant human type 5 adenovirus|Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
219647590|NCT01340027|DRUG|Mirabegron|oral
219647591|NCT01340027|DRUG|Solifenacin succinate|oral
219647592|NCT01340027|DRUG|Placebo|oral
219647593|NCT04448457|DRUG|Sufentanil Sublingual Tablet|15 mcg with lockout interval of 20 min
219647594|NCT04448457|DRUG|Oxycodone oral tablet and oxycodone extended-release oral tablet|Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
219647595|NCT04687072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
219647596|NCT04687072|OTHER|Placebo PH20 SC|Subcutaneous injection with placebo PH20 SC
218961895|NCT02793193|DIETARY_SUPPLEMENT|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
218961896|NCT02793193|DRUG|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
219647597|NCT00335569|DRUG|hCG-IBSA|
219647598|NCT02348801|BEHAVIORAL|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of \~90 min duration 15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and, after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
219647599|NCT02348801|BEHAVIORAL|Healthy lifestyle|Diabetes support and education
219647600|NCT06666920|RADIATION|laser irradiation|Immediately after applying the bleaching agent, the gel on the left upper and lower hemiarches (teeth 21-25 and 31-35) was irradiated using an Er,Cr:YSGG laser (2780 nm). Specifically, an Er,Cr:YSGG solid-state laser device (Waterlase MD Turbo, BIOLASE, Irvine, CA, USA) equipped with a Z-type glass tip (MZ8) measuring 800 μm in diameter and 6 mm in length was used. This tip was attached to the laser system's gold handpiece. The laser parameters for the treatment included an average output power of 1.25 W, a pulse duration of 700 μs (S-mode), and a pulse repetition rate of 10 Hz, without water or air flow, according to a previous study. Each tooth received two 15-s irradiation intervals, one for each 20-min session (totaling 30 s), while maintaining the laser handpiece approximately 2.5 cm from the tooth surface, perpendicular to the enamel. The gel was irradiated using a scanning mode, with the handpiece moved slowly in both horizontal and vertical directions at a speed of 2 mm/s.
219647601|NCT02094976|DEVICE|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
219647602|NCT02094976|DEVICE|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
218961897|NCT02793193|DIETARY_SUPPLEMENT|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
218961898|NCT00272753|DRUG|budesonide/formoterol Turbuhaler|
218961899|NCT00272753|DRUG|formoterol Turbuhaler|
218961900|NCT00272753|DRUG|salbutamol|
218961901|NCT04330196|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participant ingests 75g of glucose
219647603|NCT02094976|DEVICE|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
219647604|NCT01990131|OTHER|Cognitive Anxiety Sensitivity Treatment|
219647605|NCT01990131|OTHER|Physical Health Education Training|
219647606|NCT06003374|DEVICE|Ultrasound|"At international protocol U/S examination is performed from an anterior approach, with the transducer in a sagittal plane parallel to the femoral neck. The patients are positioned supine with the hips in neutral position. Also a coronal view is performed from the lateral approach. Establish a new protocol in the MSK unit to perform hip US,~* adductor view: flexion, abduction and lateral rotation of the hip joint with viewing the hip via adductor muscle group.~* gluteal view: posterior approach of the hip joint via gluteal region with the patient lying on the contralateral examined hip.~Psoas and thigh views: US examination of psoas and quadriceps muscles to exclude the presence of absecess .~-finally US guided aspiration under complete a septic condition."
219647607|NCT03181269|OTHER|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
219061836|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
219061837|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
219647608|NCT03181269|OTHER|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
219647609|NCT06668129|BEHAVIORAL|Back care intervention program|"The back care intervention consists of:~1. Nine oral presentations. Include Programa Suma't programme developed by the Provincial Council of Majorca.~2. Multisubject Teaching Unit.~3. Information campaign widespread by the school (i.e. posters, triptychs, school website, social networks, etc.)~4. The Back Care Day at school."
219647610|NCT06682260|DRUG|Nitroglycerin (NTG)|Infusion of intravenous nitroglycerin beginning at 2 microgram/kg/min (2 ml/hour) and titrated with the aim of a MAP reduction of 20-30%. Infusion rate will not be increased after the first 30 minutes and is limited to 0.1 µg/kg/min to 5 µg/kg/min.
219647611|NCT01883180|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
219647612|NCT03242876|OTHER|Control|Control will be 109 g white bread to be consumed together with 200 mL water
219647613|NCT03242876|OTHER|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
219647614|NCT02782065|OTHER|Not an interventional study|
219647615|NCT01490073|DRUG|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
219647616|NCT01490073|DRUG|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
219647617|NCT01662791|DRUG|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
219647618|NCT02130089|BEHAVIORAL|Intensive Tailored Education|
219647619|NCT03404947|DIETARY_SUPPLEMENT|Ethanol|For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
218961902|NCT04330196|DIAGNOSTIC_TEST|Ingestion of placebo|Participant ingests 700mg of aspartame
218961903|NCT02552615|OTHER|body awareness therapy|
219061838|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
219061839|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
219061840|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
218961904|NCT02552615|OTHER|core stabilization exercises|
218961905|NCT02552615|OTHER|traditional exercises|
219061841|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
219061842|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
219061843|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
219061844|NCT00389324|BIOLOGICAL|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
219647620|NCT02074098|DEVICE|Macintosh laryngoscope|Direct Laryngoscope
219647621|NCT02074098|DEVICE|Glidescope|Videolaryngoscope-1
219647622|NCT02074098|DEVICE|Airwayscope|Videolaryngoscope-2
219647623|NCT00037947|PROCEDURE|Hearing in Multiple Sclerosis|
219647624|NCT02807298|DRUG|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
219647625|NCT02807298|DRUG|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
219647626|NCT02807298|DRUG|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
218961906|NCT01859585|DRUG|Parecoxib|Parecoxib 40 mg intravenous
218961907|NCT01859585|DRUG|Ketorolac|Ketorolac 30 mg intravenous
219647627|NCT04778943|OTHER|Surgery(OLIF and MIS-TLIF)|oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
219647628|NCT04482998|OTHER|No intervention - retrospective study|No intervention - retrospective study
218961908|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
218961909|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
218961910|NCT02992561|BEHAVIORAL|FORNET (adapted version)|
218961911|NCT03925168|BEHAVIORAL|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
218961912|NCT06556966|DRUG|LY03020|LY03020 for one single dose
218961913|NCT06556966|DRUG|Placebo|Placebo for one single dose
219647629|NCT02396420|DEVICE|Embosphere Microspheres|
219647630|NCT01273623|DEVICE|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
219647631|NCT02714088|OTHER|Novel high-intensity interval training|
219647632|NCT00519428|DRUG|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
219647633|NCT00519428|DRUG|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
219647634|NCT00519428|DRUG|escitalopram + bupropion|same dosing schedule as for monotherapy
219647635|NCT02949193|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
219647636|NCT02949193|DRUG|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
219647637|NCT01598233|DEVICE|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
219647638|NCT04064411|COMBINATION_PRODUCT|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
219647639|NCT04064411|COMBINATION_PRODUCT|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
219647640|NCT06664697|DEVICE|Cochlear Implantation with Robotic-Assisted Insertion System|The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
219647641|NCT02663102|OTHER|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
219647642|NCT00533702|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
219647643|NCT00533702|DRUG|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
219647644|NCT05494008|PROCEDURE|Korean herbal medicine treatment|Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
219647645|NCT05494008|PROCEDURE|Non-Korean herbal medicine treatment|acupuncture, pharmacoacupuncture, cupping, chuna
219647646|NCT02057484|DRUG|Tacrolimus|oral
219647647|NCT06665243|BEHAVIORAL|Technology-enhanced horticultural activities|The indoor technology-enhanced horticultural activities will be delivered to people with dementia and their family caregivers through a smart grower. The smart grower is a hydroponic indoor grower that creates a controllable environment with auto optimization for growing healthy plants, fresh vegetables, herbs, and fruits. A mobile app will be connected to the grower for controlling the growing environment (e.g., lighting, watering), tracking the progress of the plants, and guiding the older people with dementia and their family caregivers in conducting the horticultural activities. The program will consist of eight face-to-face (F-T-F) horticultural activity training sessions for groups of 6-8 participants. The indoor program contains various horticultural, cognitive, and multisensory stimulation activities, such as asking PWD and family caregivers to record the sense of touch and odor when caring for the plants and to observe the various changes in the plants using the smart grower.
219647648|NCT00811902|DRUG|Nerispirdine|tablet, oral administration
219647649|NCT00811902|DRUG|placebo|tablet, oral administration
219647650|NCT01919684|DRUG|LGD-6972|
218961914|NCT04885439|BEHAVIORAL|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
218961915|NCT01016899|RADIATION|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
218961916|NCT01108276|DEVICE|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
218961917|NCT00902395|DRUG|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
219061845|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
219647651|NCT01919684|DRUG|Placebo (Captisol®)|
219647652|NCT06662487|BEHAVIORAL|Resistance Training|Participants in the experimental group will perform free weight resistance training sessions focused on push, pull, and leg movement patterns. The program will last for 10 weeks, progressively increasing in load and intensity. The intervention will be designed to improve the participants' physical strength and observe how these changes affect their cognitive performance.
219647653|NCT03069599|PROCEDURE|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
219647654|NCT01182597|DRUG|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
219647655|NCT01182597|DRUG|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
219647656|NCT02342197|DRUG|Decapeptyl|half the dose of Gn agonist
219647657|NCT03224611|DEVICE|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
219061846|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
219061847|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
219061848|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
219647658|NCT03215511|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
219647659|NCT05629611|DEVICE|Vi-Sealer|using Reusable device, Vi-Sealer
219647660|NCT05629611|DEVICE|Ligasure|using Ligasure
219647661|NCT05629611|DEVICE|Other AHD|Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
219647662|NCT00286780|DRUG|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
219647663|NCT05296044|DRUG|JT-003|Subjects take the investigational products once a day for 24 weeks.
218961918|NCT00902395|BEHAVIORAL|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
218961919|NCT00902395|DRUG|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
218961920|NCT03265392|OTHER|Bread|Serving of wheat bread providing 50 g of carbohydrates
218961921|NCT03265392|OTHER|Water|250 mL of water
219061849|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
219061850|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
219061851|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
219647664|NCT05296044|DRUG|JT-003 Placebo|Subjects take the investigational products once a day for 24 weeks.
219647665|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
219647666|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
219647667|NCT01881204|DIETARY_SUPPLEMENT|Control|Cookies without Hesperidin or Calcilock added.
219647668|NCT06601569|DIAGNOSTIC_TEST|balance and range of motion|"* Spinal alignment and range of motion measure scale (SAROMM): is a measure of spinal alignment and range of motion using standard physical therapy techniques scored on a 5-point ordinal score of 0 (normal alignment and range with active correction) to4 (severe ﬁxed deformity) (Bartlett ey al., 2005)~* Modified Ashworth scale (MAS): is a measure of muscle motion and scoring the perceived resistance to movement on a scale of 1 (no increase in tone) to 5 (rigid in ﬂexion or extension) (Clopton et al., 2005).~* Early clinical assessment of balance (ECAB) scale: Is a 13-item test that estimates postural stability for children with CP across all levels of functional ability (Jeffries etal., 2016).~* Functional strength assessment scale: Therapists completed a functional strength assessment (FSA) to obtain an estimate of strength for major muscle groups including the neck and trunk ﬂexors and extensors, and hip extensors, knee extensors, and shoulder ﬂexors bilaterally."
219647669|NCT03088046|DRUG|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
219647670|NCT05173168|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts
219647671|NCT03053063|DRUG|SEL|Tablets administered orally once daily
218961922|NCT03265392|OTHER|Lemon juice|250 mL of lemon juice
218961923|NCT03265392|OTHER|Tea|250 mL of tea
218961924|NCT03265392|OTHER|Peas|20 peas
218961925|NCT01563822|BIOLOGICAL|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
218961926|NCT03929718|DRUG|Spironolactone|receive spironolactone treatment after CTI ablation
219647672|NCT03053063|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
219647673|NCT03053063|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
218961927|NCT03929718|DRUG|No Spironolactone|no spironolactone treatment
218961928|NCT04605263|DEVICE|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
218961929|NCT04605263|PROCEDURE|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
218961930|NCT02519673|DEVICE|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
218961931|NCT03425227|OTHER|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
219647674|NCT03743324|PROCEDURE|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
219647675|NCT03743324|PROCEDURE|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
219647676|NCT03743324|RADIATION|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
219647677|NCT02578121|DRUG|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
219647678|NCT02578121|DRUG|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
218961932|NCT01227148|OTHER|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
218961933|NCT01227148|OTHER|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
218961934|NCT03333733|BEHAVIORAL|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
218961935|NCT03299114|OTHER|Whirlpool|
218961936|NCT04722835|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage (BAL)|"1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~5. Blood draw~6. Medical Health and Symptom Questionnaires~7. Physical Exam by study doctor to determine suitability and safety for participation."
218961937|NCT04068896|BIOLOGICAL|NGM120 30mg|NGM120 30mg Subcutaneous Injection
218961938|NCT04068896|BIOLOGICAL|NGM120 100mg|NGM120 100mg Subcutaneous Injection
218961939|NCT04068896|BIOLOGICAL|NGM120 30mg with Gemcitabine and Abraxane|NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
218961940|NCT04068896|BIOLOGICAL|NGM120 100mg with Gemcitabine and Abraxane|NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
218961941|NCT04068896|BIOLOGICAL|NGM120 100mg Q3W|NGM120 100mg Subcutaneous Injection every 3 weeks
218961942|NCT04068896|OTHER|Placebo|Placebo
219647679|NCT02578121|DRUG|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
219647680|NCT04391738|OTHER|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
219647681|NCT03477747|DEVICE|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
219647682|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
218961943|NCT06371508|BEHAVIORAL|Education based on breast cancer and breast examination|Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
218961944|NCT01461161|DRUG|bardoxolone methyl|oral, single dose
219647683|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
219647684|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
219647685|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
219647686|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
219647687|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
219647688|NCT02341495|DRUG|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
218961945|NCT06779136|DRUG|Placebo|Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
219647689|NCT02341495|DRUG|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
219647690|NCT02341495|DRUG|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
219647691|NCT04374162|PROCEDURE|PEEP|different PEEP set on the anesthetic machine
219647692|NCT03633162|OTHER||
219647693|NCT02151734|DRUG|KALOMIN™ Tab.|
219647694|NCT02151734|DRUG|Umckamin syrup|
219647695|NCT04311749|GENETIC|Expanded panel cell free DNA testing (non-invasive prenatal testing)|Maternal blood sampling
218961946|NCT01655186|DRUG|Bardoxolone Methyl|
218961947|NCT01655186|DRUG|Placebo|
218961948|NCT05674552|DRUG|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
218961949|NCT06455995|BEHAVIORAL|DEPTH|All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.
219061852|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
219061853|NCT04020510|DRUG|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
219647696|NCT04311749|GENETIC|Placental biopsy|Post-delivery placental sampling
219647697|NCT04311749|GENETIC|Umbilical cord blood|Post-delivery umbilical cord blood sampling
219647698|NCT03183713|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
219647699|NCT03183713|BEHAVIORAL|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
219647700|NCT00199706|DRUG|7.2% NaCl in 6% hydroxyethyl starch solution|
219647701|NCT01970475|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in pre-filled syringe
219647702|NCT01970475|BIOLOGICAL|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
219647703|NCT03587883|OTHER|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
219647704|NCT03587883|OTHER|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
219647705|NCT03587883|OTHER|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
219647706|NCT03587883|OTHER|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
219647707|NCT05154500|OTHER|Iron biofortified potato|A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.
218961950|NCT06455995|BEHAVIORAL|DEPTH-Morning|Morning will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
218961951|NCT06455995|BEHAVIORAL|DEPTH-Evening|Evening will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
218961952|NCT02935400|DRUG|Hemin|Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
219061854|NCT05046938|BEHAVIORAL|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
219061855|NCT02250404|OTHER|cytology specimen collection procedure|Correlative studies
219061856|NCT02250404|OTHER|laboratory biomarker analysis|Correlative studies
219061857|NCT04815603|DRUG|BGE-117|Active Treatment
219061858|NCT04815603|OTHER|Placebo|Placebo
219647708|NCT05154500|OTHER|Zinc biofortified potato|A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
219647709|NCT01000220|DRUG|Omeprazole|
219647710|NCT01000220|DRUG|Placebo|
219647711|NCT00536627|BIOLOGICAL|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
219647712|NCT00570427|BEHAVIORAL|Problem Solving Therapy (PST)|Counseling
219647713|NCT00570427|BEHAVIORAL|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
219647714|NCT02824601|DEVICE|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
219647715|NCT02824601|DRUG|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
219647716|NCT03828552|OTHER|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
219647717|NCT04174183|DEVICE|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
219647718|NCT04285424|BIOLOGICAL|Fecal Microbiota Transplantation|The fecal collection produced from a single healthy donor, unrelated to the patients
219647719|NCT01188876|DRUG|carboplatin|Given intravenously on Day 1 of each 28-day cycle
219647720|NCT01188876|DRUG|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
219647721|NCT01188876|DRUG|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
219647722|NCT01188876|DRUG|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
219647723|NCT02224027|DEVICE|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
219647724|NCT02224027|DEVICE|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
218961953|NCT04034953|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
218961954|NCT04034953|DIAGNOSTIC_TEST|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
218961955|NCT04034953|DIAGNOSTIC_TEST|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
219647725|NCT02224027|DEVICE|i-gel|In i-gel group, i-gel is inserted by novices.
218961956|NCT04444830|DRUG|Sprix|Intranasal Ketorolac - used as directed for an appropriate, previously established indication
218961957|NCT02283177|DRUG|crenolanib|
218961958|NCT02283177|DRUG|cytarabine|
218961959|NCT02283177|DRUG|daunorubicin|
219647726|NCT05663645|BEHAVIORAL|Health insurance educational guide|The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
219647727|NCT00941499|DRUG|HAI Oxaliplatin|140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
219647728|NCT00941499|DRUG|5-FU|900-1750 mg/m\^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
219647729|NCT00941499|DRUG|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
219647730|NCT00941499|DRUG|Cetuximab|Loading dose of 250-500mg/m\^2 and Maintenance dose of 125-250 mg/m\^2 by vein on Day 1 of 21 day cycle.
219647731|NCT00941499|DRUG|Leucovorin|200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
219647732|NCT00941499|DRUG|5-FU|300-400 mg/m\^2 bolus + 600-1000 mg/m\^2 infusion over 22 hours on Days 1-2 of each cycle.
219647733|NCT00941499|DRUG|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
219647734|NCT00206687|BIOLOGICAL|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
219647735|NCT00206687|PROCEDURE|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
218961960|NCT02283177|DRUG|idarubicin|
219061859|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
219061860|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
219061861|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
219647736|NCT03861299|PROCEDURE|Awake craniotomy|Awake craniotomy
219647737|NCT03861299|PROCEDURE|Craniotomy under general anesthesia|Craniotomy under general anesthesia
219647738|NCT01985087|RADIATION|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
219647739|NCT01985087|DRUG|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
219647740|NCT06468800|DEVICE|TRACMOTION|Patients already scheduled for ESD will undergo an ESD procedure with the aid of the Tracmotion device
219647741|NCT03008863|OTHER|Education|
219647742|NCT04628390|DEVICE|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
219647743|NCT04628390|OTHER|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
219647744|NCT06815783|DEVICE|Ultrasound guidance|Use of ultrasound in group 2
219647745|NCT06815783|DEVICE|Fluoroscopy guided|Conventional techniques for implanting LBBAP lead
219647746|NCT04940754|PROCEDURE|osteosynthesis|Closed reduction, internal fixation
218961961|NCT04152980|DRUG|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
219647747|NCT04021537|DEVICE|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
219647748|NCT01840150|PROCEDURE|breath test|Undergo NA-NOSE breath test
219647749|NCT01840150|OTHER|laboratory biomarker analysis|Correlative studies
219647750|NCT05692531|BEHAVIORAL|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
219647751|NCT04115995|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
219647752|NCT04693377|PROCEDURE|Cryosurgery|Undergo cryoablation
219647753|NCT04693377|OTHER|Quality-of-Life Assessment|Ancillary studies
219647754|NCT04693377|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
219647755|NCT01740752|BEHAVIORAL|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
219647756|NCT01740752|BEHAVIORAL|CBT|"weekly manualized higher dose of individual CBT"
219647757|NCT06059261|DRUG|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
219647758|NCT06253637|DRUG|Daratumumab plus chemotherapy according to the national treatment program|"Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8."
219647759|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
219647760|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
219647761|NCT03467061|OTHER|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
219647762|NCT03144271|DRUG|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
219647763|NCT03144271|DRUG|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
219647764|NCT03014297|DRUG|everolimus|everolimus
219647765|NCT03014297|DRUG|fosbretabulin|fosbretabulin
219647766|NCT01514838|DRUG|ASP1941|oral
219647767|NCT01514838|DRUG|acarbose|oral
219647768|NCT01514838|DRUG|Placebo|oral, used only during placebo run-in period
219647769|NCT04875728|DRUG|Cefazolin|Given IV
219647770|NCT04875728|PROCEDURE|Resection|Undergo standard of care surgical resection
219647771|NCT04905602|DRUG|SHR-1905/placebo|"Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose"
219647772|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
219647773|NCT03114527|DRUG|Everolimus|mTOR inhibitor
219647774|NCT02718170|PROCEDURE|Buried Intramedullary K-wire Fixation|
219647775|NCT02718170|PROCEDURE|Plate and Screw Fixation|
219647776|NCT05521529|OTHER|no intervention, as this is an observational study|no intervention
219647777|NCT06847438|BEHAVIORAL|Optimized version of the EPIC-HF Checklist|The EPIC-HF checklist is a 1-page patient activation tool that contains approved and guideline-recommended medications and target doses for HFrEF. The EPIC-HF checklist allows patients to see recommended doses and categories of GDMT, which they can compare to their current medications and dosing. The EPIC-HF checklist has been refined and updated to include GDMT prescription and has been optimized for delivery through electronic medical record (EMR) systems. The checklist is being used as a patient activation/ discussion tool only and data entered on the checklist will not be collected for purposes of this study.
219647778|NCT06847438|BEHAVIORAL|Clinician-facing Decision Support|Information regarding GDMT (including target doses and medications) analogous to what is contained in the checklist will be provided to clinicians in intervention clinics. This information will be visible at the time of the encounter.
219647779|NCT06847438|BEHAVIORAL|Standard of Care|Patients of clinics that are not implementing EPIC-HF checklist will not have the checklist available to them through the electronic medical record (EMR).
219647780|NCT02686866|DEVICE|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
219647781|NCT02686866|DEVICE|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
219647782|NCT02686866|DEVICE|hand grip strength|
219647783|NCT04773184|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
219647784|NCT04773184|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
219647785|NCT04773184|PROCEDURE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
219647786|NCT04773184|PROCEDURE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
219647787|NCT04773184|PROCEDURE|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
219647788|NCT04773184|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
219647789|NCT04773184|OTHER|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
219647790|NCT05129293|BEHAVIORAL|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
219647791|NCT05129293|BEHAVIORAL|Educational|Psychoeducation
219647792|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
219647793|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac)|MRI without contrast
219647794|NCT03805451|BEHAVIORAL|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
219647795|NCT04908904|DIETARY_SUPPLEMENT|Cafestol|Capsule with 12 mg cafestol
219647796|NCT04908904|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
219647797|NCT00621595|DIETARY_SUPPLEMENT|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
219647798|NCT06797297|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
219647799|NCT06797297|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal anti-PD1 antibody
219647800|NCT05782270|DRUG|Warfarin|dual antiplatelet therapy combined with warfarin
219647801|NCT05782270|DRUG|DAPT|Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
219647802|NCT05782270|OTHER|CE+CABG|Coronary endarterectomy combined with coronary artery bypass grafting
219647803|NCT06037161|PROCEDURE|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
219647804|NCT06666660|DIETARY_SUPPLEMENT|Multivitamin/Mineral supplements|Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.
219647805|NCT06666660|OTHER|Placebo|Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.
219647806|NCT05044936|DRUG|Cannabidiol Oil|"The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive."
219647807|NCT05044936|OTHER|Resistance Exercise|Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
219647808|NCT01073228|DRUG|EVP-6124|
219647809|NCT01073228|DRUG|Placebo|
219647810|NCT00854425|DRUG|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
219647811|NCT05489991|BIOLOGICAL|TmPSMA-02|Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
219647812|NCT00828724|DRUG|Lorcaserin 10mg|
219647813|NCT05592561|OTHER|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (\~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was \~10 min.
219647814|NCT01275651|OTHER|laboratory biomarker analysis|Correlative studies
219647815|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
219647816|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
219647817|NCT01210196|PROCEDURE|MRI|Cardiac MRI after 12 and 24 months.
219647818|NCT00908791|DRUG|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
219647819|NCT03716843|OTHER|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
218961962|NCT00990275|OTHER|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
218961963|NCT05504772|GENETIC|Whole Genome Sequencing|Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
218961964|NCT05504772|GENETIC|RNA seq|Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
218961965|NCT05504772|GENETIC|DNA Methylation|Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
218961966|NCT05504772|GENETIC|Targeted Panel Sequencing|"Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type"
218961967|NCT05504772|GENETIC|High Throughput Sequencing (in vitro)|High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
218961968|NCT05504772|GENETIC|Patient Derived Xenograft (PDX)(in vivo)|In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
219647820|NCT06441032|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
219647821|NCT03192995|DRUG|lorcaserin|lorcaserin 20 mg tablet
219647822|NCT03192995|DRUG|Placebo Oral Tablet|placebo 20 mg. tablet
219647823|NCT03192995|BEHAVIORAL|Substance use counseling|Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
219647824|NCT03192995|BEHAVIORAL|ACASI|Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
219647825|NCT03192995|DIAGNOSTIC_TEST|Cocaine metabolites|Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
219647826|NCT03192995|BEHAVIORAL|Ecological Momentary Assessment (EMA)|EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
219647827|NCT03192995|BEHAVIORAL|Balloon Analogue Risk Task (BART)|BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
219647828|NCT03192995|BEHAVIORAL|Qualitative Exit Interview|The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
219647829|NCT03506568|DEVICE|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
219647830|NCT01768975|DRUG|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
219647831|NCT01768975|OTHER|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
219647832|NCT04630249|BEHAVIORAL|Listening to Women and Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
219647833|NCT05165199|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
219647834|NCT04476342|DEVICE|minimal invasive cardiopulmonary bypass (MICPB) system|The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
219647835|NCT00492882|DRUG|usual administration of exogenous recombinant FSH|
219647836|NCT02893553|DRUG|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
219647837|NCT02893553|DRUG|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
219647838|NCT02893553|DRUG|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
219647839|NCT02893553|OTHER|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
219647840|NCT01596153|DIETARY_SUPPLEMENT|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
219647841|NCT01443091|OTHER|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
219647842|NCT01443091|OTHER|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
219647843|NCT04175782|PROCEDURE|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
219647844|NCT01899716|OTHER|Exercise|
219647845|NCT03578016|OTHER|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
219647846|NCT03578016|OTHER|Treatment as Usual|TAU consists of clinical assessment and treatment.
218961969|NCT05504772|OTHER|Liquid Biopsy|Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
218961970|NCT01101191|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
218961971|NCT01101191|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
218961972|NCT04926454|DRUG|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
218961973|NCT04803682|BEHAVIORAL|Preventive Intervention|Participate in ASPIRE and mentorship program
218961974|NCT04803682|BEHAVIORAL|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
218961975|NCT06271473|PROCEDURE|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
218961976|NCT01891045|BEHAVIORAL|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
219647847|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
219647848|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
219647849|NCT02900495|DEVICE|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
219647850|NCT00083941|BIOLOGICAL|TroVax|1ml intramuscular injection
219061862|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
219061863|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
219207832|NCT06775548|OTHER|Resistance Exercises + Vitamin E|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
219647851|NCT00083941|BIOLOGICAL|Interleukin-2|Intravenous IL-2
219647852|NCT03043157|DRUG|rocuronium|intravenous rocuronium infusion
219647853|NCT05809258|PROCEDURE|Supraclavicular block|brachial plexus nerve block by supraclavicular route
219647854|NCT05809258|PROCEDURE|Axillary block|brachial plexus nerve block by axillary route
219647855|NCT01373112|PROCEDURE|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
219647856|NCT01373112|PROCEDURE|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
219647857|NCT03097055|PROCEDURE|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
219647858|NCT03097055|PROCEDURE|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
219647859|NCT06514755|PROCEDURE|GNA followed by GAE|Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.
219647860|NCT06514755|PROCEDURE|GAE alone|Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
218961977|NCT01891045|BEHAVIORAL|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
218961978|NCT02009384|DRUG|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
218961979|NCT02530047|GENETIC|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."
218961980|NCT02530047|BEHAVIORAL|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
218961981|NCT03442400|DEVICE|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
218961982|NCT00407680|DRUG|Intensive therapy Valsartan,Fluvastatin|
219061864|NCT00649012|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
219061865|NCT00649012|DRUG|Actos® Tablets 45 mg|45mg, single dose fed
219061866|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
219061867|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
219061868|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
219061869|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
219647861|NCT02889250|DEVICE|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
219061870|NCT00795600|DRUG|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
219647862|NCT02579343|DEVICE|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
219647863|NCT02579343|DRUG|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
219647864|NCT01671150|DRUG|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
219647865|NCT00035295|DRUG|MK0869, aprepitant|
219647866|NCT00035295|DRUG|Comparator: placebo|
219647867|NCT03364517|OTHER|Predictor score of the imminence of a childbirth (SPIA)|The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
219647868|NCT00381238|DRUG|rosiglitazone|Extended Release Tablets
219647869|NCT03410212|DRUG|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
219647870|NCT03410212|BEHAVIORAL|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
219647871|NCT02968667|BEHAVIORAL|Empowerment|6 weeks of empowerment program and supported face to face discussion
219647872|NCT02806544|DRUG|Tamoxifen|Tamoxifen 20mg by mouth daily
219647873|NCT00061373|DRUG|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
219647874|NCT00061373|DRUG|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
219647875|NCT00061373|DRUG|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
219647876|NCT00002701|DRUG|busulfan|
219647877|NCT00002701|DRUG|cyclophosphamide|
219647878|NCT00002701|DRUG|cytarabine|
219647879|NCT00002701|DRUG|etoposide|
219647880|NCT00002701|DRUG|idarubicin|
219647881|NCT00002701|DRUG|mercaptopurine|
219647882|NCT00002701|DRUG|methotrexate|
219647883|NCT00002701|DRUG|mitoxantrone hydrochloride|
219647884|NCT00002701|DRUG|thioguanine|
219647885|NCT00002701|DRUG|tretinoin|
219647886|NCT00002701|PROCEDURE|allogeneic bone marrow transplantation|
219647887|NCT00002701|PROCEDURE|autologous bone marrow transplantation|
219647888|NCT00002701|RADIATION|radiation therapy|
219647889|NCT05027048|DRUG|Calcium chloride|See arm description above
219647890|NCT05027048|DRUG|Saline placebo|see arm description above
219647891|NCT02068170|DRUG|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
219647892|NCT04973059|DEVICE|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
219647893|NCT04973059|DEVICE|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
219061871|NCT00795600|DRUG|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
219061872|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
219061873|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
219061874|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
219647894|NCT02086448|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
219647895|NCT02086448|DEVICE|sham-CPAP|
219647896|NCT02086448|OTHER|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
219647897|NCT00560287|DEVICE|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
219647898|NCT00560287|DEVICE|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
219647899|NCT01758107|OTHER|Withdraw cyclosporine|
219647900|NCT00344591|BEHAVIORAL|Structured Ecosystems Therapy (SET)|
219647901|NCT00344591|BEHAVIORAL|Individually tailored intervention|
219647902|NCT00843037|DRUG|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
219647903|NCT06162845|BEHAVIORAL|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
219647904|NCT06162845|BEHAVIORAL|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
219647905|NCT03879057|DRUG|Surufatinib/humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
219647906|NCT04112160|DRUG|Ketorolac|IM injection of either normal saline or Ketorolac
219647907|NCT04112160|DRUG|normal saline|normal saline
219647908|NCT01895348|DRUG|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
219647909|NCT01895348|DRUG|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
219647910|NCT01895348|DRUG|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
219647911|NCT03055468|BEHAVIORAL|Peer support|Peer support and antidepressant medications
219647912|NCT04889196|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
219647913|NCT04889196|DEVICE|hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
219647914|NCT02982616|DIETARY_SUPPLEMENT|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
219647915|NCT02982616|BEHAVIORAL|Positive emotion|Positive emotion induced by facial expressions and classic music.
219647916|NCT02982616|DIETARY_SUPPLEMENT|saline|saline
219647917|NCT02982616|BEHAVIORAL|neutral emotion|Neutral emotion induced by facial expressions and classic music.
219647918|NCT04977362|OTHER|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
219061875|NCT04218019|DEVICE|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
219061876|NCT04890002|DEVICE|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
219061877|NCT04890002|DEVICE|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
219647919|NCT04977362|OTHER|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
219647920|NCT06621056|OTHER|not applicable for observational research|This is an observational research and has no intervention
219647921|NCT01883947|PROCEDURE|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
219647922|NCT01883947|OTHER|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
219647923|NCT00642109|PROCEDURE|midurethral sling procedure|quality of life, voiding dysfunction
219061878|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
219061879|NCT01973790|DRUG|Z-338|100mg TID
219061880|NCT03649022|DEVICE|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
219061881|NCT01775891|DRUG|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
219647924|NCT05192408|BEHAVIORAL|Multi-component intervention|"Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
219647925|NCT05192408|OTHER|Usual Care|Patient Education Materials
219647926|NCT06372418|OTHER|Breastfeeding peer support intervention|In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, care givers will receive a homebased individualized face to face support provided by breastfeeding peer supporters and phone call support upto 7 weeks post hospital discharge.
219647927|NCT06372418|OTHER|Standard Care|Caregivers will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines.
219647928|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
219647929|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
219647930|NCT03153267|DRUG|Controls without a history of lyme disease.|No intervention.
219647931|NCT00923663|DRUG|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
219647932|NCT01825083|DRUG|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
219647933|NCT01825083|DRUG|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
219647934|NCT00509379|DRUG|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
219647935|NCT00509379|DRUG|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
219647936|NCT01871402|DRUG|000-0551 Lotion|
219647937|NCT01871402|DRUG|Vehicle Lotion|
219647938|NCT04685668|BEHAVIORAL|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
219647939|NCT05500482|BIOLOGICAL|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
219647940|NCT04012281|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
219647941|NCT04594941|DRUG|Flurpiridaz (18F) Injection|All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
219647942|NCT04399603|OTHER|no intervention-mechanistic study|no intervention-mechanistic study
219647943|NCT00600990|DRUG|GW597599|
219647944|NCT06467994|OTHER|Cashew oral immunotherapy|Cashew Flour (boiled/ roasted) that is prepared under food manufacturing regulations
219647945|NCT06467994|OTHER|Placebo oral immunotherapy|Placebo oral immunotherapy consists of corn flour with food colouring that has similar appearance, taste and smell to the active product
219647946|NCT02679989|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
219647947|NCT02679989|BEHAVIORAL|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
219647948|NCT03790449|BEHAVIORAL|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
219647949|NCT03790449|BEHAVIORAL|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
219647950|NCT00571571|BEHAVIORAL|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
219647951|NCT00571571|BEHAVIORAL|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
219647952|NCT00179205|DRUG|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
219647953|NCT00179205|DRUG|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
219647954|NCT05646966|OTHER|one time testing|
219647955|NCT02794792|DRUG|Ipragliflozin L-proline|Oral
219061882|NCT01775891|DRUG|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
219061883|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
219061884|NCT00114374|DRUG|Escitalopram|
218961983|NCT00718237|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
219647956|NCT02794792|DRUG|Metformin|Oral
219647957|NCT02794792|DRUG|Placebo|Oral
219647958|NCT01654718|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
219647959|NCT01654718|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
219647960|NCT05691335|PROCEDURE|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
219647961|NCT05691335|PROCEDURE|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
219647962|NCT05691335|PROCEDURE|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
218961984|NCT00718237|BIOLOGICAL|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
218961985|NCT06165770|PROCEDURE|laparoscopy|Conservative or surgery treatment for cornual pregnancies
218961986|NCT04739176|OTHER|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
218961987|NCT00804037|PROCEDURE|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
219061885|NCT00389662|DEVICE|"Wearing the Nike Free shoe"|
219061886|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
219647963|NCT02424630|DEVICE|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
219647964|NCT02424630|DEVICE|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
219647965|NCT02424630|DRUG|Placebo|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
219647966|NCT02424630|DRUG|Ropivacaine|All the regional blocks in this study were performed using 10mL ropivacaine.
219647967|NCT02703272|DRUG|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
219647968|NCT02703272|DRUG|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
219647969|NCT02703272|DRUG|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
219647970|NCT02703272|DRUG|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
219647971|NCT02703272|DRUG|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
218961988|NCT02678598|DRUG|Micafungin|Intravenous
218961989|NCT02315443|DRUG|Nerinetide (NA-1)|
219061887|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
219061888|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
219061889|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
219061890|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
218961990|NCT02315443|DRUG|Placebo|
218961991|NCT03538574|BEHAVIORAL|CBT-I|CBT-I is a behavioral treatment for insomnia
218961992|NCT03538574|BEHAVIORAL|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
218961993|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
219647972|NCT02703272|DRUG|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
219647973|NCT02703272|DRUG|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
219647974|NCT02703272|DRUG|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
219647975|NCT02637895|DRUG|Placebo|Placebo pill matching Vortioxetine.
219647976|NCT02637895|DRUG|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
219647977|NCT05415605|DEVICE|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
219647978|NCT05768750|OTHER|Rehabilitation|X
219647979|NCT05896527|DRUG|DC-806|DC-806 was supplied as tablets to be administered orally.
219647980|NCT05896527|OTHER|Placebo|Matching placebo was supplied as tablets to be administered orally.
219647981|NCT02666196|DRUG|DAA-I|
219647982|NCT02666196|DRUG|Placebo|
219647983|NCT03085238|DEVICE|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
219647984|NCT06621797|DIETARY_SUPPLEMENT|Intervention 1: Dietary Supplement - Caffeine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) taken orally 45 minutes before performance testing. No additional interventions will be administered.
219647985|NCT06621797|DIETARY_SUPPLEMENT|Intervention 2: Dietary Supplement - Caffeine + L-Theanine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) along with L-theanine in a 1:2 ratio taken orally 45 minutes before performance testing.
218961994|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
218961995|NCT05942209|DIAGNOSTIC_TEST|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
218961996|NCT05384977|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
218961997|NCT02694718|DRUG|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
219061891|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
219061892|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
218961998|NCT02694718|DRUG|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
218961999|NCT02925793|DRUG|DS107|
219061893|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
219647986|NCT06621797|BEHAVIORAL|Intervention 3: Dietary Supplement - Caffeine Supplement + Diaphragmatic Breathing Exercises|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) 45 minutes before performance testing, followed by a 10-minute session of diaphragmatic breathing exercises.
219647987|NCT03926364|OTHER|Patients with referred pain|The project does not affect treatment or does not offer any intervention.
219647988|NCT06622369|OTHER|Virtual Reality-Game group|Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use
219647989|NCT06622369|OTHER|Virtual Reality-Cartoon-video group|Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
219647990|NCT06412185|BIOLOGICAL|CM383|CM383 Injection
219647991|NCT06412185|OTHER|Placebo|Placebo
219647992|NCT03789578|DRUG|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
219647993|NCT03789578|DRUG|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
218962000|NCT02925793|OTHER|Vehicle cream|
218962001|NCT00879879|DRUG|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
219647994|NCT03789578|DRUG|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
219647995|NCT06683040|DRUG|Oxacom|Lyophilisate for solution for intravenous administration, 6.3 mg
219647996|NCT06683040|DRUG|Placebo|0.9% sodium chloride
219647997|NCT00800605|BIOLOGICAL|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
219647998|NCT00800605|BIOLOGICAL|Placebo: Phosphate-buffered saline|Single intramuscular injection
219647999|NCT05862883|DRUG|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
219648000|NCT05862883|OTHER|Control group|Taking basic therapy without Rutan
219648001|NCT01279174|OTHER|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
219648002|NCT00005601|BIOLOGICAL|rituximab|
219648003|NCT00005601|DRUG|cisplatin|
218962002|NCT02581839|DRUG|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
218962003|NCT02581839|DEVICE|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
218962004|NCT02581839|DRUG|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
218962005|NCT02581839|DRUG|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
219648004|NCT00005601|DRUG|cytarabine|
219648005|NCT00005601|DRUG|dexamethasone|
219648006|NCT00005601|DRUG|sargramostim|
219648007|NCT00005836|DRUG|oxaliplatin|
218962006|NCT03020446|DEVICE|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
218962007|NCT00868179|DRUG|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
218962008|NCT03824509|OTHER|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
218962009|NCT00667446|DRUG|Leuprolide Acetate 3 Month Depot|
218962010|NCT03889483|DEVICE|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
218962011|NCT05428982|PROCEDURE|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
219648008|NCT06388616|DRUG|Balcinrenone|50 mg, Immediate release capsule to be taken orally.
219648009|NCT01925235|PROCEDURE|remote ischemic preconditioning|
219648010|NCT03781583|DEVICE|SmartHMD version 1|First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.
219648011|NCT03781583|DEVICE|SmartHMD version 2|Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.
219648012|NCT03781583|DEVICE|SmartHMD version 3|Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.
219648013|NCT03781583|DEVICE|SmartHMD version 4|Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
219648014|NCT03724903|PROCEDURE|Ductal lavage|The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
218962012|NCT02655146|DRUG|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
218962013|NCT02655146|DRUG|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
218962014|NCT02655146|DRUG|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
218962015|NCT02655146|DRUG|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
219061894|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
219061895|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
219648015|NCT03724903|DRUG|Corticosteroid therapy|Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
219648016|NCT01248052|DRUG|LY2979165|administered orally
219648017|NCT01248052|DRUG|Placebo|administered orally
219648018|NCT05862337|DRUG|Anlotinib hydrochloride capsules, Penpulimab injection|"Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1)."
219648019|NCT05862337|DRUG|Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo|placebo control, no active substance.
219648020|NCT05474170|OTHER|AHA resuscitation sequence|Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations
219648021|NCT05474170|OTHER|ERC resuscitation sequence|Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
219648022|NCT03884699|PROCEDURE|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
219648023|NCT00943956|DRUG|bicalutamide|
219648024|NCT00943956|DRUG|everolimus|
219648025|NCT00943956|DRUG|leuprolide acetate|
219648026|NCT00943956|RADIATION|external beam radiation therapy|
219648027|NCT04399109|DEVICE|TCC-COVID mHealth solution|Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.
219648028|NCT04150211|DIETARY_SUPPLEMENT|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
219648029|NCT02222545|BIOLOGICAL|OMS721|
219648030|NCT03187847|DEVICE|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
219648031|NCT04954794|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219648032|NCT04954794|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
219648033|NCT00761280|DRUG|trabedersen|
219648034|NCT00761280|DRUG|temozolomide|
219648035|NCT00761280|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
219648036|NCT00761280|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
219648037|NCT00761280|DRUG|carmustine|
219648038|NCT00761280|DRUG|lomustine|
218962016|NCT00746408|OTHER|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
218962017|NCT03505931|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
218962018|NCT01343901|DRUG|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
218962019|NCT05523687|DRUG|[14C]-PC14586|Single, oral dose of \[14C\]-PC14586
218962020|NCT05249335|DRUG|OST|The subject will receive Orafang for colonoscopy
218962021|NCT05249335|DRUG|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
218962022|NCT01536275|OTHER|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
219648039|NCT04639102|OTHER|PATH Intervention|"Patients will receive an enhanced level of care and service:~1. Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~2. Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~3. Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care."
219648040|NCT06402448|DIAGNOSTIC_TEST|muscle pain , joint pain and nerve pain.|to discover the percentage of each tissue that causing pain even it is muscle, joint or nerve in patients with spinal disorders.
219648041|NCT04121065|PROCEDURE|Blood withdrawal|Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
219648042|NCT03875482|DRUG|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
219648043|NCT03875482|DRUG|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
219648044|NCT00949403|DRUG|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
219648045|NCT01275508|DRUG|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
219648046|NCT06684015|DRUG|İNTRATECHAL MORPHİNE GROUP|Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications
219648047|NCT06684015|PROCEDURE|Erector Spinae Plane Block|Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
219648048|NCT02890485|DEVICE|Dry Needling|Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
218962023|NCT05860374|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
218962024|NCT04110600|OTHER|Coffee effect on early gastric motility|this group 100ml coffee after two hours
218962025|NCT04110600|OTHER|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
218962026|NCT00004644|DRUG|acyclovir|
218962027|NCT04351776|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
218962028|NCT04351776|OTHER|VR-Distraction|Participants will be instructed to use one of three applications
218962029|NCT04351776|OTHER|360 Video|Participants will be instructed which video to view
218962030|NCT02510755|OTHER|MRI|
218962031|NCT05447221|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
219648049|NCT02890485|DEVICE|Sham Dry Needling|"The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled."
218962032|NCT02392715|DEVICE|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
218962033|NCT02392715|DEVICE|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
218962034|NCT04551339|DIETARY_SUPPLEMENT|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
219061896|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
219061897|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
219061898|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
218962035|NCT04551339|DIETARY_SUPPLEMENT|Multivitamin with 11mg of zinc|One tab taken daily for three months
218962036|NCT00003395|DRUG|arsenic trioxide|
218962037|NCT04652739|DRUG|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
219061899|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
219061900|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
219648050|NCT02890485|OTHER|Physical Therapy|Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
219648051|NCT03121196|OTHER|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
219648052|NCT06575088|OTHER|Standard tourniquet pressure (250 mmHg)|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
219648053|NCT06575088|OTHER|Limb occlusion pressure|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
219061901|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
219061902|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219061903|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219061904|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219061905|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
219061906|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
219061907|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
219648054|NCT06575088|OTHER|Cotton Pad|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
219648055|NCT06575088|OTHER|Elastic stockinette|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
219648056|NCT06623123|DEVICE|Oto Smartphone Application (Oto Health Ltd)|The smartphone application delivers personalized tinnitus therapy combining evidence-based CBT with mindfulness, patient education as well as physical therapy such as stretches and exercises. There are additional sounds available to listen to from the sound library. There will be a structured programme that the participants can work through however they are encouraged to personalise their own therapy.
219648057|NCT06623123|BEHAVIORAL|Tinnitus Retraining Therapy (TRT)|Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.
219648058|NCT04797741|OTHER|IDEA3 Intervention|Delivery of IDEA3 intervention, a 12-hour online sexual assault resistance intervention for college women.
218962038|NCT04652739|DRUG|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
218962039|NCT03486275|DEVICE|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
218962040|NCT03486275|DEVICE|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
218962041|NCT01432210|OTHER|Post-prandial Feeding Study|
218962042|NCT01063777|OTHER|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
218962043|NCT01063777|OTHER|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
218962044|NCT03229460|OTHER|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
218962045|NCT03229460|DEVICE|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
219061908|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
219648059|NCT01570972|BEHAVIORAL|Group Cognitive Behavioral Therapy|weekly
218962046|NCT03229460|DEVICE|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
219061909|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
219061910|NCT05409924|DRUG|ATR-258|Single Ascending Dose
219061911|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
219061912|NCT05409924|DRUG|ATR-258|Repeat Dose
219061913|NCT03125668|BEHAVIORAL|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
219061914|NCT03125668|BEHAVIORAL|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
219648060|NCT01570972|BEHAVIORAL|Multifamily Group Psychoeducation|twice monthly
219648061|NCT02878564|DRUG|Praziquantel|40 mg/kg, PO (orally administered tablets)
219648062|NCT06684171|PROCEDURE|Echocardiographic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under guidance of fully echocardiography but any fluoroscopy in the entire process.
219648063|NCT06684171|PROCEDURE|Fluoroscopic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under combined guidance of echocardiography and fluoroscopy in the entire process.
219648064|NCT02338219|OTHER|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
219648065|NCT02338219|OTHER|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
219648066|NCT04392128|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
219648067|NCT04392128|DRUG|Azithromycin 250 MG Oral Capsule|Azithromycin is amacrolide antibiotic.
219648068|NCT04392128|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
219648069|NCT04392128|DRUG|Placebo oral capsule|Placebo of Azithromycin capsules.
219648070|NCT02045862|DRUG|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
219648071|NCT02045862|DRUG|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
219648072|NCT02045862|DRUG|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
219648073|NCT02045862|DRUG|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
219648074|NCT06665711|PROCEDURE|3% Hypertonic Saline|In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
219648075|NCT06665711|PROCEDURE|Intervention: Salbutamol (Ventolin)|In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
219648076|NCT03156842|DRUG|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
218962047|NCT00264862|PROCEDURE|DynaCT|
218962048|NCT03680469|BEHAVIORAL|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
218962049|NCT03680469|BEHAVIORAL|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
218962050|NCT05982067|OTHER|mindfulness-based phsycial exercise intervention|The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.
218962051|NCT05982067|OTHER|health education|The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
218962052|NCT02551952|DEVICE|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
219061915|NCT03125668|BEHAVIORAL|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
219648077|NCT03156842|DRUG|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
219648078|NCT03156842|DRUG|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
219061916|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
219648079|NCT01813253|DRUG|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
219648080|NCT01813253|DRUG|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
219648081|NCT03857451|DIAGNOSTIC_TEST|Clinical gait analysis|Three dimensional gait analysis consisting of joint kinematics, kinetics and dynamic EMG data will be introduced into the diagnostic scheme
219648082|NCT01432912|BEHAVIORAL|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
219061917|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
219061918|NCT03251846|DEVICE|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
219061919|NCT05491473|DEVICE|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
219648083|NCT03721055|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
219648084|NCT03164564|DRUG|Oral CAB|CAB 30 mg tablet
219648085|NCT03164564|DRUG|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
219648086|NCT03164564|DRUG|Placebo for oral CAB|Placebo tablets
219648087|NCT03164564|DRUG|Placebo for oral TDF/FTC|Placebo tablets
219648088|NCT03164564|DRUG|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
219648089|NCT03164564|DRUG|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
219648090|NCT04722744|PROCEDURE|screwmented metal frameworks|Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
219648091|NCT04139512|PROCEDURE|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
219648092|NCT04139512|PROCEDURE|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
219648093|NCT06059430|OTHER|no intervention|no intervention
219648094|NCT06337916|BEHAVIORAL|Cervical Stabilization Exercise|The cervical stabilization exercise group will receive cervical stabilization exercises 1 session a day, 3 days a week for 6 weeks. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
219648095|NCT06337916|BEHAVIORAL|Cervical Standard Exercise Group|The patients in cervical standard exercise group will receive conventional cervical exercise for 6 weeks, 3 days a week, 1 session a day. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
219648096|NCT05045781|DRUG|Eptinezumab|single iv infusion
219061920|NCT02736084|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
219061921|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
219061922|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
219207833|NCT06775548|OTHER|Aerobic Exercises + Vitamin D|For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals. The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike
219648097|NCT02449304|DEVICE|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
219648098|NCT04324346|DRUG|FEC75 (or EC90) x 6|Type of Chemotherapy
219648099|NCT04324346|DRUG|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
219648100|NCT04324346|DRUG|Paclitaxel|Type of Chemotherapy
219648101|NCT02691013|DRUG|Ramelteon|
219648102|NCT02691013|DRUG|Placebo|
219648103|NCT05193617|DRUG|GP+Penpulimab+Anlotinib|GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
219648104|NCT05193617|DRUG|GP+Penpulimab|GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
219648105|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
219648106|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
219061923|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
219061924|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
219061925|NCT02543359|BEHAVIORAL|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
219061926|NCT02543359|BEHAVIORAL|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
219061927|NCT02543359|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
219061928|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
219061929|NCT01248650|DRUG|nalfurafine hydrochloride|
219061930|NCT00650468|DRUG|tacrolimus|Oral
219061931|NCT00650468|DRUG|CellCept|IV or Oral
219061932|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
219648107|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
219648108|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
219648109|NCT04550975|OTHER|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
219648110|NCT01363752|DRUG|Advagraf|oral
219648111|NCT01363752|DRUG|Mycophenolate Mofetil|oral
218962053|NCT01897376|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
218962054|NCT01897376|PROCEDURE|vertical skin incision|vertical skin incision at time of cesarean section
218962055|NCT03895762|DRUG|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
218962056|NCT03219463|DIETARY_SUPPLEMENT|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
218962057|NCT01500343|DRUG|Saccharomyces boulardii|1 gram per day, during 3 months
218962058|NCT03839927|OTHER|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
218962059|NCT03954327|DRUG|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
218962060|NCT03954327|DRUG|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
219061933|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
219061934|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
219061935|NCT03249623|DEVICE|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
219061936|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
219061937|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
219061938|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
219648112|NCT01363752|DRUG|Sirolimus|oral
219648113|NCT01363752|DRUG|Corticosteroids|i.v. and oral
219648114|NCT05169437|DRUG|Niraparib|Eligible participants will receive daily dosing of Niraparib.
218962061|NCT03954327|DRUG|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
219648115|NCT04130542|BIOLOGICAL|LVGN6051|IV infusion once every 3 weeks (Q3W).
219648116|NCT04130542|BIOLOGICAL|KEYTRUDA® (pembrolizumab)|IV infusion once every 3 weeks (Q3W).
219648117|NCT06017752|BEHAVIORAL|STAC Teacher Module|"The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
219648118|NCT03539770|PROCEDURE|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
219648119|NCT02357706|DEVICE|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
219648120|NCT02357706|DEVICE|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
219648121|NCT03544099|DRUG|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
219648122|NCT05248256|OTHER|Evidence-based radiation dose limitation to the vertebral bone marrow|The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
219648123|NCT02111785|DRUG|Dexamethasone|Treatment with a short course of oral dexamethasone
219648124|NCT02111785|PROCEDURE|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
219648125|NCT04193956|OTHER|Standard-of-care procedures|Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
219648126|NCT04193956|OTHER|Study procedures|Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
218962062|NCT00829985|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
218962063|NCT00829985|BIOLOGICAL|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
218962064|NCT04112498|DRUG|relatlimab|Specified dose on Specified days
218962065|NCT04112498|DRUG|nivolumab|Specified dose on Specified days
218962066|NCT04112498|DRUG|rHuPH20|Specified dose on Specified days
218962067|NCT03631797|PROCEDURE|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
218962068|NCT06416995|DIAGNOSTIC_TEST|first trimester serum diagnostic test|First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
218962069|NCT06254222|OTHER|No intervention|No intervention
218962070|NCT01115582|DRUG|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
218962071|NCT00810927|PROCEDURE|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
218962072|NCT00810927|PROCEDURE|Laser Doppler flowmetry|Measurement of choroidal blood flow
218962073|NCT00810927|PROCEDURE|Measurement of intraocular pressure|
218962074|NCT05776602|DIAGNOSTIC_TEST|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
219061939|NCT05719974|OTHER|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
219061940|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
219061941|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
219061942|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
219648127|NCT01844661|BIOLOGICAL|CELYVIR|
219648128|NCT03790228|DRUG|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
219648129|NCT04743193|OTHER|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
219648130|NCT04743193|OTHER|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
219648131|NCT00682370|DRUG|saline solution|intravenous infusion, single dose
219648132|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
219648133|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
219648134|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
219648135|NCT02976779|DRUG|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
219648136|NCT02976779|DRUG|OWC Control Cream|Topical Cream without active ingredients
218962075|NCT05089071|DEVICE|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
218962076|NCT03324581|DRUG|OPC-64005|OPC-64005 film coated tablets
218962077|NCT03324581|DRUG|Atomoxetine|Atomoxetine gelatin capsules
218962078|NCT03324581|DRUG|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
218962079|NCT03924466|DRUG|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
218962080|NCT00442884|BEHAVIORAL|Trier Social Stress Test (TSST)|
218962081|NCT05106790|BEHAVIORAL|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
218962082|NCT05106790|BEHAVIORAL|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
218962083|NCT05106790|BEHAVIORAL|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
219061943|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
219061944|NCT04612361|OTHER|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
219061945|NCT05712291|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
219061946|NCT05712291|DEVICE|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
219061947|NCT05712291|PROCEDURE|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
219061948|NCT02602301|DRUG|Oxytocin|different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
219061949|NCT02026700|DEVICE|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
219061950|NCT00089440|DRUG|Aripiprazole|
219061951|NCT02667158|OTHER|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
219061952|NCT02169687|DEVICE|HIFU|High Intensity focalized Ultrasounds
219061953|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
219061954|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
219061955|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
219061956|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
219061957|NCT06635993|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\&#39;s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
219061958|NCT06634667|DRUG|third-generation EGFR-TKI combined with anlotinib|third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
219061959|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
219061960|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
219061961|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
219061962|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
219061963|NCT01709019|BIOLOGICAL|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
219061964|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
219061965|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
219061966|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
218962084|NCT03575481|DIAGNOSTIC_TEST|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
218962085|NCT06400927|OTHER|HF-guided VA|VA guided recommendation
218962086|NCT06400927|OTHER|Standard-of-care|Standard-of-care
218962087|NCT03498664|DEVICE|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
218962088|NCT03498664|DEVICE|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
218962089|NCT00706069|DRUG|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
218962090|NCT00706069|DRUG|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
218962091|NCT01203176|PROCEDURE|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
219648137|NCT05243485|DIAGNOSTIC_TEST|PreHEART|"The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes."
219648138|NCT06620679|BIOLOGICAL|Lipopolysaccharide (LPS)|Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight
219648139|NCT06620679|OTHER|Placebo|Normal saline, single i.v. bolus, in equal volume to intervention
219648140|NCT05587829|OTHER|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
219648141|NCT05587829|OTHER|basic breathing technique|Deep Breathing for 15 minutes
219648142|NCT03199482|DRUG|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
219648143|NCT03199482|DRUG|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
219648144|NCT00904865|PROCEDURE|SPA cholecystectomy|SPA cholecystectomy
219648145|NCT00904865|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
219648146|NCT01607060|DRUG|Lactulone|Patients will receive lactulone to daily laxation
219648147|NCT00786331|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
219648148|NCT00786331|DRUG|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
219648149|NCT02360631|DRUG|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
219648150|NCT02360631|DRUG|Placebo|Health education counseling will be provided to all participants.
219648151|NCT05035667|OTHER|Questionnaire Administration|Complete questionnaires
219061967|NCT02843568|OTHER|Laboratory Biomarker Analysis|Correlative studies
219061968|NCT02843568|RADIATION|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
219061969|NCT02843568|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
219061970|NCT02843568|PROCEDURE|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
219648152|NCT05631691|BEHAVIORAL|Support for Students exposed to Trauma Program|Support for students exposed to trauma program (SSET) is a school-based intervention program for students who have been exposed to traumatic events and exhibit signs of post-traumatic stress disorder (PTSD). (Jaycox, Langley, \& Dean, 2009; Jaycox, Langley, Stein et al., 2009). SSET is specifically designed for school teachers, school counsellors, and other non-clinical staff. SSET program is a series of 10 structured lessons designed to reduce post-traumatic and depressive symptoms and improve functioning in school children exposed to traumatic events. it includes psycho-education, relaxation, cognitive restructuring, social problems solving and behavioral exposure.
219648153|NCT04704492|DRUG|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
219648154|NCT00857168|DRUG|Testosterone MD-Lotion|
219648155|NCT01955772|DRUG|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
219061971|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
219061972|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
219061973|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
219061974|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
219061975|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
219648156|NCT06664840|OTHER|MDR diet assessment|Participants will record their dietary intake on the MyRareDiet (MRD) app and nutrient content will be assessed to validate MRD compared to a traditional interviewer assessed 24 hour recall.
219648157|NCT06664840|OTHER|24 hour recall|A trained nutritionist will conduct a telephone multi-pass 24 hour diet recall on 3 randomized nonconsecutive days. The dietary intake will be analyzed using NDSR and metabolic pro and nutrient intake will be compared to the nutrient intake assessed with the MRD app.
219648158|NCT02689869|DRUG|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
219648159|NCT02689869|DRUG|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
219648160|NCT03166540|OTHER|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
219648161|NCT03166540|OTHER|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
219648162|NCT01341340|DEVICE|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
219648163|NCT01075646|DRUG|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
219648164|NCT01075646|DRUG|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
219648165|NCT04117672|DIETARY_SUPPLEMENT|Salovum|Active egg yolk powder
219648166|NCT04117672|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Normal egg yolk powder
219648167|NCT05186246|DRUG|Combination cream|Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
219648168|NCT05186246|DRUG|Placebo cream|Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
219648169|NCT02002312|DRUG|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
219648170|NCT00416130|DRUG|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
219648171|NCT00330330|DRUG|ISIS 113715|
219648172|NCT02064322|DEVICE|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
219648173|NCT02228239|DRUG|Esketamine|Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
219648174|NCT02228239|DRUG|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
219648175|NCT02228239|DRUG|Placebo (Matched to Esketamine)|Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
219648176|NCT02228239|DRUG|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
219648177|NCT02048566|DEVICE|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
219648178|NCT02048566|DEVICE|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
219648179|NCT02048566|OTHER|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
219648180|NCT02048566|OTHER|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
219648181|NCT04624958|DRUG|Zanubrutinib and Rituximab|Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
219648182|NCT04624958|DRUG|R-DHAOx|Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
219648183|NCT04624958|DRUG|Zanubrutinib Maintenance|Zanubrutinb 160mg PO BID.
219648184|NCT01520558|BIOLOGICAL|CNDO-109-AANK Cells|Single dose, infusion
219648185|NCT04410016|OTHER|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
219648186|NCT01676896|BEHAVIORAL|Asthma in-school class|
219648187|NCT01676896|BEHAVIORAL|Asthma Day Camp|
219648188|NCT01676896|BEHAVIORAL|Health Promotion in-school class|
219648189|NCT05705882|OTHER|Malnutrition|For the diagnosis of malnutrition, the investigators adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
219648190|NCT02256982|DRUG|Gemcitabine|
219648191|NCT02256982|DRUG|Cisplatin|
219648192|NCT02256982|PROCEDURE|Surgery|Surgical Resection and Lymphadenectomy
219648193|NCT02256982|RADIATION|Radiation|Radiation Therapy
219648194|NCT01775982|OTHER|Psychiatric evaluation|"This evaluation is carried out in several stages:~* Assessment of cognitive functioning;~* Interview with a relative;~* Interview with caregivers;~* Evaluation of the presence of delirium according to DSM-IV criteria;~* Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~* Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
219648195|NCT01775982|OTHER|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
219648196|NCT01735344|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
219648197|NCT01735344|DRUG|Lisinopril|40 mg tablet once a day
218962092|NCT06387433|BEHAVIORAL|mobile app use|The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
218962093|NCT04340427|DRUG|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
218962094|NCT03783702|DRUG|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
218962095|NCT03783702|DRUG|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
218962096|NCT03783702|DRUG|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
218962097|NCT01727778|BIOLOGICAL|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
218962098|NCT04473482|BEHAVIORAL|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
218962099|NCT04411862|DIETARY_SUPPLEMENT|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
219648198|NCT00639444|DIETARY_SUPPLEMENT|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
219648199|NCT01943968|OTHER|Blood test|
219648200|NCT01120080|BEHAVIORAL|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
219648201|NCT01120080|BEHAVIORAL|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
219648202|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
218962100|NCT04411862|BEHAVIORAL|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
219061976|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
219061977|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
218962101|NCT03239028|BEHAVIORAL|Observational|
218962102|NCT06516367|OTHER|Ain Shams University Screening Tool for Malnutrition, Sarcopenia, and Cachexia (ASUST-MSC)|25 items dichotomous questionnaire
218962103|NCT03007069|OTHER|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
218962104|NCT03007069|OTHER|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
219648203|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
219648204|NCT00672581|DRUG|ZD4054|10mg, Oral tablet, single dose
219648205|NCT01072435|DEVICE|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
219648206|NCT01072435|DEVICE|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
219648207|NCT06097624|OTHER|synchronized tele-exercise|All evaluations and exercise interventions will be performed by via Google Meet, a video-conferencing application. The participation link will be sent to the individual by the researcher before each session. In case of any technological disruption, the session will be postponed to the nearest available time by phone. All interventions will be run by a blinded researcher.
219648208|NCT03194750|OTHER|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of \< 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
219648209|NCT03194750|OTHER|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
219648210|NCT05380544|DEVICE|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
219648211|NCT03395470|DRUG|PXL770|MAD
219648212|NCT03395470|DRUG|Placebo|MAD
219648213|NCT03395470|DRUG|Rosuvastatin|DDI
219648214|NCT03142542|DRUG|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
219648215|NCT03142542|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
218962105|NCT05573412|OTHER|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
218962106|NCT00469261|DRUG|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
218962107|NCT00469261|DRUG|Current medical therapy for AMI|Current medical therapy for AMI
219648216|NCT00893165|BEHAVIORAL|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
219648217|NCT00405522|DRUG|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
219648218|NCT00405522|DRUG|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
219648219|NCT04201158|DIAGNOSTIC_TEST|Exercise Capacity|Modified Shuttle Walk Test
219648220|NCT05174858|DEVICE|Hemostatic dressing ETIK COLLAGENE|The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
219648221|NCT05174858|OTHER|Comparator|The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
219648222|NCT03275675|DRUG|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
219648223|NCT00797628|BEHAVIORAL|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
219648224|NCT00797628|BEHAVIORAL|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
219648225|NCT00775840|DRUG|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
219648226|NCT00775840|DRUG|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
218962108|NCT01662414|DIETARY_SUPPLEMENT|Whey protein|1 sachect (10 g) 2times/ day
218962109|NCT01662414|DIETARY_SUPPLEMENT|Soy protein|1 sachect (10g) 2times/day
218962110|NCT03099070|BEHAVIORAL|Stress|Trier Social Stress Test
218962111|NCT03099070|OTHER|Fasting|12-hour fasting prior to study visit
218962112|NCT02793843|DRUG|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
218962113|NCT02793843|DRUG|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
218962114|NCT02793843|OTHER|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
218962115|NCT01120834|DRUG|azacytidine|"* Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
218962116|NCT01120834|DRUG|vorinostat|"* Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
218962117|NCT02547883|DRUG|Cessation of statin|The intervention evaluated is the cessation of statin
218962118|NCT01030367|DRUG|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
218962119|NCT05352776|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
218962120|NCT04231591|DIAGNOSTIC_TEST|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
218962121|NCT05346367|RADIATION|SRT|SRT
218962122|NCT05346367|RADIATION|fSRT|fSRT
218962123|NCT00769483|DRUG|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
219648227|NCT03231540|DIETARY_SUPPLEMENT|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
219648228|NCT05153200|DRUG|Upadacitinib|15 mg po daily
219648229|NCT05153200|DRUG|Adalimumab|40 mg sc every other week
219648230|NCT05013879|DEVICE|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
219648231|NCT00630175|DRUG|zolpidem-MR (modified release)|
219648232|NCT00630175|DRUG|zolpidem (SL800750)|
219648233|NCT00630175|DRUG|placebo|
219648234|NCT01469832|BIOLOGICAL|MA09-hRPE|"* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
219648235|NCT06339411|DRUG|Cerebrolysin|Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
219648236|NCT03408470|DRUG|TD-1473 oral capsule|(Intervention description included in arm description)
219648237|NCT03408470|DRUG|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
219648238|NCT03408470|DRUG|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
219648239|NCT05482321|DRUG|Definity Suspension for Injection|"* DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided)."
219648240|NCT03676114|DRUG|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
219648241|NCT03676114|DRUG|Normal saline|Same volume of normal saline will be administrated
219648242|NCT00003764|DRUG|cyclophosphamide|
219648243|NCT00003764|DRUG|fludarabine phosphate|
219648244|NCT04202913|BEHAVIORAL|Coaching|Child will receive 1:1 coaching with health coach.
219648245|NCT01044290|OTHER|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
219648246|NCT01044290|OTHER|Attention Control|Subjects listened to a non-guided relaxation CD
219648247|NCT04874233|DRUG|HU6|HU6 is active study drug
219648248|NCT04874233|DRUG|Placebo|Non-active study drug N = 20
219648249|NCT01901354|OTHER|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
219648250|NCT01901354|OTHER|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
219648251|NCT06158659|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
219648252|NCT06158659|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
218962124|NCT00769483|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
218962125|NCT00769483|DRUG|Erlotinib|100 mg by mouth daily.
219648253|NCT06158659|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
219648254|NCT00759785|DRUG|dalotuzumab (MK0646)|Single intravenous infusion
219648255|NCT00720512|BIOLOGICAL|bevacizumab|Given IV
219648256|NCT00720512|DRUG|fluorouracil|Given IV
219648257|NCT00720512|DRUG|irinotecan hydrochloride|Given IV
219648258|NCT00720512|DRUG|leucovorin calcium|Given IV
219648259|NCT00720512|DRUG|oxaliplatin|Given IV
219648260|NCT05127850|BEHAVIORAL|Consultation audio recording app|Smartphone or tablet mobile application which allows for voice recording
219648261|NCT03256058|PROCEDURE|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
219648262|NCT03256058|PROCEDURE|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
219648263|NCT03268824|DEVICE|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
219648264|NCT03268824|DEVICE|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
219648265|NCT03268824|OTHER|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
218962126|NCT00001282|DRUG|Zidovudine (AZT) & Interleukin-2 (IL2)|
218962127|NCT00003171|DRUG|bryostatin 1|
218962128|NCT01113476|DRUG|Nab-paclitaxel|Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
218962129|NCT01113476|DRUG|Bevacizumab|Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
218962130|NCT01113476|DRUG|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
219648266|NCT02589249|DIETARY_SUPPLEMENT|AyuFlex|Active product
219648267|NCT02589249|DIETARY_SUPPLEMENT|Placebo|Placebo
219648268|NCT00559403|BEHAVIORAL|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
219648269|NCT00559403|BEHAVIORAL|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
219648270|NCT02220179|BEHAVIORAL|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
219648271|NCT02465879|OTHER|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
219648272|NCT05182359|OTHER|SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
219648273|NCT01460654|DRUG|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
219648274|NCT01460654|DRUG|Alendronate|Alendronate (Fosamax) 70mg every week.
219648275|NCT01460654|DRUG|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
219648276|NCT01460654|DRUG|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
219648277|NCT00875199|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
219648278|NCT00875199|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
219648279|NCT00046852|BIOLOGICAL|filgrastim|
219648280|NCT00046852|BIOLOGICAL|pneumococcal polyvalent vaccine|
219648281|NCT00046852|BIOLOGICAL|therapeutic autologous lymphocytes|
219648282|NCT00046852|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
218962131|NCT03455764|DRUG|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
218962132|NCT03455764|DRUG|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
218962133|NCT03455764|DRUG|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
218962134|NCT02528266|DEVICE|Nerve Capping Device|
218962135|NCT05946655|DRUG|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
218962136|NCT03699384|DRUG|Azacitidine|AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
218962137|NCT03699384|DRUG|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
218962138|NCT05697978|DEVICE|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
218962139|NCT05649202|OTHER|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
219648283|NCT00046852|DRUG|carmustine|
218962140|NCT05649202|OTHER|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
218962141|NCT04204785|BEHAVIORAL|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
218962142|NCT01437800|DRUG|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
218962143|NCT02707159|DRUG|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
218962144|NCT01211587|DRUG|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
219648284|NCT00046852|DRUG|cyclophosphamide|
219648285|NCT00046852|DRUG|melphalan|
219648286|NCT00046852|PROCEDURE|bone marrow ablation with stem cell support|
219648287|NCT00046852|PROCEDURE|peripheral blood stem cell transplantation|
219648288|NCT01967706|OTHER|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
219648289|NCT01967706|OTHER|mCC|Single use of subject's own menthol cigarette (mCC)
219648290|NCT01967706|OTHER|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
219648291|NCT02777970|DRUG|Tramadol Hydrochloride/Dexketoprofen Trometamol|
219648292|NCT02777970|DRUG|Tramadol Hydrochloride/Paracetamol|
219648293|NCT02777970|DRUG|Placebo|
219648294|NCT02347891|DRUG|Belimumab|Randomized phase: Week 0 - Week 40
219648295|NCT02347891|DRUG|Placebo|Randomized phase: Week 0 - Week 40
219648296|NCT00538044|DRUG|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
219648297|NCT01685489|DRUG|Docetaxel, PSK®|
219648298|NCT01685489|DRUG|Docetaxel, Placebo|
219648299|NCT02319967|BEHAVIORAL|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
219648300|NCT02319967|BEHAVIORAL|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
219648301|NCT00000864|DRUG|Abacavir sulfate|
219648302|NCT00000864|DRUG|Zidovudine|
219648303|NCT00463762|DRUG|CP-75385-02 Cefoperazone/sulbactam|
219648304|NCT02728583|DIETARY_SUPPLEMENT|Margarine enriched with plant sterols and fish oil|
219648305|NCT02728583|DIETARY_SUPPLEMENT|Placebo margarine|
219648306|NCT06178731|DEVICE|rTMS|3 min rTMS delivery with iTBS to the left DLPFC
219648307|NCT06178731|OTHER|Virtual Reality|2-15 min VR viewing, 15 min descriptive and imaginal recounting
219648308|NCT05698472|OTHER|questionnaire|"Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly."
219648309|NCT03310658|DEVICE|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
219648310|NCT02155517|DRUG|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
219648311|NCT02155517|DRUG|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
219648312|NCT03308136|PROCEDURE|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1\) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
219648313|NCT03308136|PROCEDURE|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2\) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.
219648314|NCT03308136|DRUG|1% Lidocaine|1% Lidocaine
219648315|NCT06618560|DEVICE|Enamel Matrix Derivative application|After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.
218962145|NCT01211587|DRUG|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
219648316|NCT06618560|DEVICE|Hyaluronic Acid (HA)|After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.
219648317|NCT06618560|PROCEDURE|Control|Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
218962146|NCT02948101|BIOLOGICAL|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
218962147|NCT02948101|DRUG|Cyclophosphamide|Given PO
218962148|NCT02948101|OTHER|Laboratory Biomarker Analysis|Correlative studies
218962149|NCT01179997|DEVICE|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
219061978|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
219061979|NCT02313142|BEHAVIORAL|Leg exercises|
219061980|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
219648318|NCT05002894|OTHER|Pilates exercises|Pilates exercises for flexibility and stability
219648319|NCT05002894|DIETARY_SUPPLEMENT|medical standard care for fatigue|supplements and medical care
219648320|NCT05668143|BEHAVIORAL|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
219648321|NCT04913350|OTHER|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
219648322|NCT04913350|DEVICE|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
219648323|NCT01071486|DRUG|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
219648324|NCT03028857|DRUG|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
218962150|NCT01179997|DEVICE|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
218962151|NCT01859104|BEHAVIORAL|Use of smartphone app|
218962152|NCT00004727|DRUG|aspirin|
218962153|NCT00004727|DRUG|ticlopidine|
218962154|NCT03754192|RADIATION|perfusion Computed Tomography|Will be carried before liver surgery
218962155|NCT06642246|BEHAVIORAL|Intervention|During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
219648325|NCT03028857|DRUG|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
219648326|NCT05555225|OTHER|Methylome|Epigenetic study : analysis of DNA methylation
219648327|NCT00122122|BEHAVIORAL|Enhanced Pharmacy Care|
219648328|NCT02952625|OTHER|Imaging|Single arm Imaging (PET/MR) study
219648329|NCT00549913|BIOLOGICAL|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
219648330|NCT00549913|PROCEDURE|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
219648331|NCT06528535|OTHER|Health promotion intervention|Health promotion activities on nutrition with distribution of baskets of fresh fruits and vegetables
219648332|NCT00343785|DRUG|cyclophosphamide|Given IV
219648333|NCT00343785|BIOLOGICAL|anti-thymocyte globulin|Given IV
219648334|NCT00343785|DRUG|cyclosporine|Given IV or PO
219648335|NCT00343785|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
219648336|NCT00343785|DRUG|methotrexate|Given IV
219648337|NCT00343785|GENETIC|DNA analysis|Correlative studies
219061981|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
219061982|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
219648338|NCT00343785|OTHER|flow cytometry|Correlative studies
219648339|NCT00343785|GENETIC|polymorphism analysis|Correlative studies
219648340|NCT00343785|OTHER|laboratory biomarker analysis|Correlative studies
219648341|NCT03598920|DEVICE|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
219648342|NCT03598920|OTHER|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
219648343|NCT04636385|OTHER|Observational study no intervention|No intervention
219648344|NCT03937401|DRUG|Oxytocin|Oxytocin infusion during MRI-HIFU treatment
219648345|NCT01305889|BEHAVIORAL|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
219648346|NCT01305889|DRUG|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
219648347|NCT06451289|DIAGNOSTIC_TEST|Head computered tomography|Retrospective data collecting from medical records
219648348|NCT02085668|DEVICE|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
219648349|NCT03783130|BIOLOGICAL|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
219061983|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
219061984|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
219648350|NCT03783130|OTHER|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
219648351|NCT05657600|BEHAVIORAL|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
219648352|NCT05657600|OTHER|Video-based yoga|Video-based yoga
219648353|NCT05657600|OTHER|Face-to-face yoga|Face-to-face yoga
219648354|NCT05657600|OTHER|physical exercise|physical exercise
218962156|NCT04954170|DIAGNOSTIC_TEST|IRRTM|IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
218962157|NCT04954170|DIAGNOSTIC_TEST|the lift-off test|The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
218962158|NCT04954170|DIAGNOSTIC_TEST|the belly-press test|The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
218962159|NCT04954170|DIAGNOSTIC_TEST|the IRLS test|IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
218962160|NCT04954170|DIAGNOSTIC_TEST|the bear-hug test|The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
218962161|NCT04954170|DIAGNOSTIC_TEST|IRRT 0°|IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
218962162|NCT04954170|DIAGNOSTIC_TEST|Diagnostic arthroscopy|At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
218962163|NCT00474656|DEVICE|High-frequency oscillation|
218962164|NCT00474656|DEVICE|Conventional lung-open mechanical ventilation|
219061985|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
219061986|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
219061987|NCT06247176|BEHAVIORAL|Sensory Habituation Protocol|"The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated.~At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation.~VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video.~Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit."
219648355|NCT00655733|DRUG|HMPL-004|HMPL-004 1200 mg/d
219648356|NCT00655733|DRUG|Placebo|Placebo 1200 mg/d
219648357|NCT03440307|BEHAVIORAL|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
219648358|NCT03440307|BEHAVIORAL|Email Only|Participants received health and fitness education.
219648359|NCT03070340|DIAGNOSTIC_TEST|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
219648360|NCT03070340|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
219648361|NCT01881880|DEVICE|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
219648362|NCT00662662|BEHAVIORAL|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
219648363|NCT04446195|BEHAVIORAL|Individualized Intervention|In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index \> 25 kg / m2, age \> 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
219648364|NCT05567432|PROCEDURE|thyroidectomy|use diathermy or ligasure for homeostatic during thyroidectomy
219648365|NCT02847143|DRUG|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
219648366|NCT02847143|DEVICE|fMRI|FMRI during emotional image visualization
219648367|NCT02847143|BEHAVIORAL|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
219648368|NCT02847143|BEHAVIORAL|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
218962165|NCT06066801|PROCEDURE|Bedside blind bone biopsy procedure|It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
218962166|NCT03227341|OTHER|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
218962167|NCT00806507|PROCEDURE|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
219648369|NCT04873453|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
219648370|NCT04873453|DRUG|Placebo|Placebo arm
219648371|NCT06618768|DIETARY_SUPPLEMENT|Consumption of an aronia-mixture to prevent Urinary Tract Infections in female patients|The present pilot study will assess the feasibility of methods and procedures to be used in a larger study and contribute to establish power calculations required to conduct a randomised clinical trial which will examine whether consumption of 1 dL aronia-mixture/day for six months will reduce prevalence of symptomativ UTi episodes among adult women with a recent history of uncomplicated, recurrent UTIs.
219648372|NCT03410472|BEHAVIORAL|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
219648373|NCT01226368|OTHER|Biological Sample collection|Cervix cells
219648374|NCT06647563|BIOLOGICAL|Toripalimab|Specified dose on specified days
219648375|NCT06647563|BIOLOGICAL|Cetuximab|Specified dose on specified days
219648376|NCT06647563|DRUG|Albumin-Bound Paclitaxel|Specified dose on specified days
219648377|NCT06647563|DRUG|Carboplatin|Specified dose on specified days
219648378|NCT06647563|DRUG|Cisplatin|Specified dose on specified days
219648379|NCT06647563|RADIATION|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
219648380|NCT06647563|RADIATION|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
219061988|NCT04011150|DEVICE|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
219648381|NCT06647563|RADIATION|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
219648382|NCT02236806|DRUG|Bisoprolol|5 mg daily
219648383|NCT02236806|DRUG|Ramipril|5 mg daily
219648384|NCT02236806|DRUG|Placebo|1 capsule daily
219648385|NCT03242187|PROCEDURE|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
218962168|NCT00806507|PROCEDURE|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
218962169|NCT00539097|DIETARY_SUPPLEMENT|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
218962170|NCT06283927|PROCEDURE|Re-resection|Resection of the recurrent tumor
219648386|NCT03242187|PROCEDURE|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
219648387|NCT02122770|DRUG|MLN4924|MLN4924 intravenous solution.
219648388|NCT02122770|DRUG|Fluconazole|Fluconazole tablets.
219648389|NCT02122770|DRUG|Itraconazole|Itraconazole oral solution.
219648390|NCT02122770|DRUG|Docetaxel|Docetaxel intravenous solution.
219648391|NCT02122770|DRUG|Carboplatin|Carboplatin intravenous solution.
219648392|NCT02122770|DRUG|Paclitaxel|Paclitaxel intravenous solution.
219648393|NCT06312111|BEHAVIORAL|recommendation to increase physical activity|education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
219648394|NCT06443398|OTHER|There is no intervention in the study|There is no intervention in the study
219648395|NCT00036491|DRUG|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
219648396|NCT01734538|DIETARY_SUPPLEMENT|Omega-3 Complete|
218962171|NCT06283927|DRUG|Temozolomide|Re-challenge Temozolomide chemotherapy
219648397|NCT01734538|DIETARY_SUPPLEMENT|Placebo capsule|
219648398|NCT00132938|DRUG|telithromycin|
219648399|NCT02396017|DEVICE|Capsule endoscopy|Endoscopic device
219648400|NCT02396017|DRUG|Polyethylene Glycol|Bowel purgative
218962172|NCT06283927|DRUG|Lomustine|Second line chemotherapy with Lomustine
218962173|NCT06283927|RADIATION|Re-irradiation|Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
218962174|NCT06283927|PROCEDURE|Experimental therapy|Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
218962175|NCT06283927|OTHER|Best supportive care|Best supportive care, focused on alleviating symptoms
218962176|NCT05968365|DEVICE|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
218962177|NCT01247181|OTHER|Mobile phone text message|Weekly message with motivational content
218962178|NCT01247181|OTHER|Usual care|Usual care provided at clinic
218962179|NCT05287542|OTHER|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
218962180|NCT05287542|OTHER|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
218962181|NCT05409820|PROCEDURE|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
219223712|NCT07022106|OTHER|Kinesiotape (KT) Group|"Kinesio Taping (KT) Intervention~Description:~Participants will receive a standardized 3-tape sensory modulation technique using Kinesiotape, applied to the abdomen and sacrum to target fascial tension and visceral pain in primary dysmenorrhea.~Procedure:~Abdominal Application (Two Tapes, 0% Stretch):~Horizontal Tape: Placed between the iliac crests (lower abdomen) to reduce fascial tension.~Vertical Tape: Applied from the navel to the pubic symphysis to modulate visceral pain signaling.~Sacral Application (One Tape, 15-25% Stretch):~Horizontal Tape: Anchored across the S2-S4 vertebrae (at PSIS level) to activate the pain-gating mechanism via cutaneous-visceral reflexes.~Frequency/Duration:~Each participant will receive a single session at their most painful day from this intervention"
219648401|NCT00688935|BIOLOGICAL|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
219648402|NCT04342741|DEVICE|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
219648403|NCT03647735|OTHER|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
218962182|NCT01076075|DRUG|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
218962183|NCT01076075|DRUG|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
218962184|NCT01076075|DRUG|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
218962185|NCT01076075|DRUG|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
218962186|NCT01076075|DRUG|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
218962187|NCT01076075|DRUG|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
218962188|NCT01076075|DRUG|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
219648404|NCT04247464|PROCEDURE|Fasting|Food intake restriction
219648405|NCT04586218|BEHAVIORAL|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure \> 65mmHg
219648406|NCT04586218|BEHAVIORAL|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
219648407|NCT02965196|DRUG|IV Dexamethasone Therapy|
219648408|NCT02965196|OTHER|IV Normal Saline (NaCl 0.9%)|
219648409|NCT03108599|OTHER|Enhanced Cab|The enhanced cab intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep program.
219648410|NCT03108599|BEHAVIORAL|Fit4Sleep|The behavioral sleep program includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The behavioral sleep program includes an optional body weight management component. The intervention arm will receive the behavioral sleep program in combination with the enhanced cab intervention.
219648411|NCT06078449|DEVICE|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of \>20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves \& to reduce friction.
218962189|NCT02116478|PROCEDURE|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
218962190|NCT03769103|DRUG|Osimertinib|Daily oral osimertinib
218962191|NCT03769103|RADIATION|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
219648412|NCT06078449|DRUG|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
219648413|NCT01577849|DRUG|Vitamin D3|administration of Vitamin D3 24,000 IU
219648414|NCT01577849|DRUG|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
219648415|NCT04448132|BIOLOGICAL|IPV-Al|adjuvanted reduced dose inactivated polio vaccine
219648416|NCT04036305|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
219648417|NCT04036305|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
219648418|NCT04036305|DRUG|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
218962192|NCT02106039|PROCEDURE|intensive monitoring|
218962193|NCT00553865|DRUG|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
218962194|NCT01860573|DRUG|Amino acids|
219648419|NCT06617728|PROCEDURE|Intervention 1: Regional Analgesia|Regional analgesia techniques like epidural or peripheral nerve blocks.
219648420|NCT06617728|DRUG|Intervention 2: Intravenous (IV) Analgesia|IV medications used for pain control, including opioids and non-opioid analgesics.
218962195|NCT03680430|RADIATION|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
218962196|NCT02586285|DRUG|S-Adenosyl Methionine|500mg-1000mg,iv,qd
218962197|NCT05404360|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
218962198|NCT05404360|DEVICE|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
218962199|NCT04285580|DRUG|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
218962200|NCT04285580|DRUG|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
218962201|NCT05352490|DIAGNOSTIC_TEST|calculate LUS score|calculate LUS score
218962202|NCT01736384|PROCEDURE|Gastric bypass or cholecystectomy|
218962203|NCT00076024|DRUG|Placebo|5 mg twice daily \[bid\] continuous dosing
218962204|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
218962205|NCT00076024|DRUG|AG-013736 (axitinib)|5mg twice daily \[bid\] continuous dosing
218962206|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
218962207|NCT04333771|DRUG|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
218962208|NCT04333771|DRUG|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
218962209|NCT00848575|DEVICE|Flexible Endoscope|
218962210|NCT03912896|BEHAVIORAL|Taekwondo|Children will participate in a 7-week taekwondo program.
219648421|NCT05073328|OTHER|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
219648422|NCT02638571|OTHER|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
219648423|NCT05390528|DRUG|HLX301|HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
219648424|NCT05642260|OTHER|fall prevention programe|Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
219648425|NCT06265701|BEHAVIORAL|Derailment-Focused Reflective Journaling|Experimental group aimed at decreasing anxiety symptoms
219648426|NCT06265701|OTHER|Everyday Tasks Reflective Journaling|Control group
219648427|NCT04933916|DRUG|EMB-001|Combination product metyrapone and oxazepam
219648428|NCT06311435|DIAGNOSTIC_TEST|RNA Biomarker Blood Test|Blood will be collected into a PaxGene Blood tube for processing by sponsor
219648429|NCT05248113|DEVICE|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
219648430|NCT03990935|OTHER|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
219648431|NCT00727844|DRUG|Immediate Start Linezolid|
218962211|NCT01179893|BIOLOGICAL|IVIG|Intravenous immunoglobulin
218962212|NCT01179893|PROCEDURE|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
218962213|NCT03012516|BEHAVIORAL|PAP-treatment by physiotherapist|
218962214|NCT03012516|BEHAVIORAL|Ordinary PAP-treatment at the health care center|
218962215|NCT01173861|BEHAVIORAL|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
219648432|NCT00727844|DRUG|Delayed Start Linezolid|
219207834|NCT06775548|OTHER|Resistance Exercises + Vitamin D|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
219207835|NCT06769139|OTHER|Red blood cell exchange|Red blood cell exchange manual exchange and automatized exchange
219207836|NCT06768190|BEHAVIORAL|WhatsApp as usual|Pregnant women and their partners are instructed to use WhatsApp as normal for six weeks.
219207837|NCT06768190|BEHAVIORAL|WhatsApp-based psycho-socio-educational intervention (WeLove)|The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.
219648433|NCT06619340|DRUG|Exparel|20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.
218962216|NCT00000762|BIOLOGICAL|rgp120/HIV-1MN|
218962217|NCT00000762|BIOLOGICAL|rgp120/HIV-1 SF-2|
218962218|NCT00000762|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
218962219|NCT06157060|DIAGNOSTIC_TEST|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
218962220|NCT05375747|DRUG|Remimazolam|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
218962221|NCT05375747|DRUG|Propofol|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
218962222|NCT03989167|OTHER|Clinical decision support|Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
218962223|NCT01695148|DIETARY_SUPPLEMENT|β-Carotene Biofortified Maize Flour|
218962224|NCT01695148|DIETARY_SUPPLEMENT|White Maize Flour|
218962225|NCT02366598|OTHER|Hemp shake|Hemp protein shake
218962226|NCT02366598|OTHER|Soybean shake|Soybean protein shake
218962227|NCT02366598|OTHER|Control|Non-protein shake
218962228|NCT00454831|DEVICE|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
218962229|NCT02318576|OTHER|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
218962230|NCT05458726|DRUG|Osimertinib|Osimertinib or chemotherapy
219207838|NCT06767410|OTHER|Multidomain Intervention|The intervention is distinguished by its multidomain approach combining cognitive, social, and musical activities through choir participation, targeting holistic cognitive and emotional benefits, unlike active controls (general activities) and passive controls (no activities).
219207839|NCT06767410|OTHER|General activities|Participants will carry out a series of physical, manual and/or intellectual activities (e.g., horticulture, physical activities, theatre, learning programs etc.) but not musical activities
219223713|NCT06700083|DRUG|SHR-6934 injection|SHR-6934 injection
219223714|NCT06700083|DRUG|SHR-6934 placebo|SHR-6934 placebo
219648434|NCT01905501|DRUG|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
219648435|NCT01905501|DRUG|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
218962231|NCT02172170|DRUG|BI 10773 single rising dose|
218962232|NCT02172170|DRUG|Placebo|
218962233|NCT01178255|DRUG|homeopathic q-potencies|individualised homeopathic medicines
218962234|NCT01178255|DRUG|Placebo|placebo
218962235|NCT01178255|OTHER|homeopathic case history taking type I|one special homeopathic technique for case history taking
218962236|NCT01178255|OTHER|homeopathic case history type II|another type of homeopathic case history taking
218962237|NCT01483586|DRUG|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
218962238|NCT01483586|DRUG|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
218962239|NCT06274905|DRUG|EMLA|EMLA cream
218962240|NCT06274905|DRUG|Ethyl chloride|Ethyl chloride
218962241|NCT06274905|DRUG|Aqueous cream BP|Aqueous cream
218962242|NCT05682248|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
218962243|NCT05682248|DEVICE|Sham Transcranial magnetic stimulation|Sham Transcranial magnetic stimulation
218962244|NCT04682873|DRUG|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
218962245|NCT04682873|DRUG|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
218962246|NCT04946461|DRUG|Dexamfetamine Sulfate 5 Mg Oral Tablet|The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
218962247|NCT04946461|DRUG|Lisdexamfetamine Dimesylate|The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
218962248|NCT04946461|BIOLOGICAL|blood samples|The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
218962249|NCT00660556|DEVICE|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
218962250|NCT06168760|DIAGNOSTIC_TEST|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
218962251|NCT00582283|DRUG|I124-NM404|I-124-NM404
218962252|NCT00381251|DRUG|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
218962253|NCT02547714|DRUG|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
218962254|NCT00474838|DRUG|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
218962255|NCT00474838|DRUG|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
218962256|NCT03311620|PROCEDURE|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
218962257|NCT03512015|OTHER|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
218962258|NCT03512015|OTHER|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
218962259|NCT00752024|DEVICE|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
218962260|NCT00752024|DRUG|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
218962261|NCT04280146|BEHAVIORAL|daily energy intake|Investigate daily energy intake according to eating rate and food processing
218962262|NCT04944628|DIETARY_SUPPLEMENT|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
218962263|NCT04815746|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
218962264|NCT04815746|BEHAVIORAL|Standard Education|Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
218962265|NCT04920318|COMBINATION_PRODUCT|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
218962266|NCT04920318|COMBINATION_PRODUCT|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
218962267|NCT03269110|DIAGNOSTIC_TEST|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
218962268|NCT05782465|PROCEDURE|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
219648436|NCT04944810|PROCEDURE|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
219648437|NCT04944810|PROCEDURE|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
219061989|NCT04011150|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
219061990|NCT04011150|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
219061991|NCT05961202|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg qd
219061992|NCT05961202|DRUG|Prednisolone|Prednisolone 20mg qd
218962269|NCT05782465|PROCEDURE|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
218962270|NCT05782465|DIAGNOSTIC_TEST|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
218962271|NCT05558267|DIETARY_SUPPLEMENT|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
219648438|NCT04944810|PROCEDURE|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
219648439|NCT04944810|PROCEDURE|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
219648440|NCT04944810|PROCEDURE|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
219648441|NCT05261334|PROCEDURE|contour augmentation|early implant placement with contour bone augmentation
219648442|NCT05212324|PROCEDURE|widening of first web space|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
219648443|NCT00373958|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
218962272|NCT05558267|DIETARY_SUPPLEMENT|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
219648444|NCT00373958|BIOLOGICAL|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
219648445|NCT02743390|BIOLOGICAL|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
218962273|NCT05152862|PROCEDURE|Laser|Retinal laser photocoagulation
219648446|NCT02743390|OTHER|Saline|Saline for 2 hours (250mL)
218962274|NCT05152862|PROCEDURE|Anti VEGF|Anti-VEGF intravitreous injection
218962275|NCT06157398|OTHER|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
218962276|NCT06846385|BIOLOGICAL|Placebo|A single dose was administered
218962277|NCT06846385|BIOLOGICAL|MG-K10 Humanized Monoclonal Antibody Injection|MG-K10 Humanized Monoclonal Antibody Injection
218962278|NCT04370899|OTHER|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
219061993|NCT04452461|DRUG|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
219061994|NCT04452461|DRUG|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
219061995|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
219061996|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
219061997|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
219648447|NCT00525941|DRUG|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
218962279|NCT05283928|DEVICE|OsseoDensification (OD) protocol|Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
219648448|NCT02691429|OTHER|Acai dye 10%|dye to be used during chromovitrectomy in humans
218962280|NCT05283928|DEVICE|standard drilling (SD) protocol (NobelReplace® Conical)|osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
219061998|NCT06538532|OTHER|Zamzam water|Zamzam water
219061999|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
219062000|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
219062001|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
219062002|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
219062003|NCT06636097|DEVICE|Full arch|design
219648449|NCT01196689|DRUG|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
219648450|NCT06621992|OTHER|Skills to Enhance Positivity|
219648451|NCT06621992|OTHER|Treatment as Usual|Participants received treatment as usual
219648452|NCT06366139|PROCEDURE|Radiofrequency thermocoagulation of the trigeminal ganglion|The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.
219648453|NCT06366139|PROCEDURE|Maxillary/Mandibular nerve pulsed radiofrequency|The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
218962281|NCT03544775|PROCEDURE|Isolated General Anesthesia|No nerve block identified through physician billing codes
218962282|NCT03544775|PROCEDURE|Peripheral Nerve Block|Nerve block identified through physician billing codes
218962283|NCT04911426|BEHAVIORAL|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
219062004|NCT06635512|OTHER|The Effect of Stress Ball Application After Transurethral Resection of the Prostate on Patients' Recovery Quality and Hospital Discharge Time|The effect of the stress ball applied after surgery on patients' recovery quality will be evaluated.
219062005|NCT06635265|DEVICE|Target Stimulation (HGN, AC, GG, Strap muscles)|Simulation of a combination of: HGN, AC, GG or strap muscles
219062006|NCT06635174|OTHER|Dextrose|we are using 2ml of 50% dextrose
219062007|NCT06635174|OTHER|normal water|patient will receive 2ml of normal water
219062008|NCT00851214|DEVICE|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
219062009|NCT04504045|DRUG|Metformin|500 mg tablet
219062010|NCT04504045|DRUG|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
219062011|NCT04504045|DRUG|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
219062012|NCT04504045|DRUG|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
219062013|NCT04504045|DRUG|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
219062014|NCT04504045|DRUG|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
219062015|NCT04504045|DRUG|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
219062016|NCT00023829|DRUG|bicalutamide|
219062017|NCT00023829|DRUG|flutamide|
219062018|NCT00023829|DRUG|releasing hormone agonist therapy|
219062019|NCT00023829|PROCEDURE|adjuvant therapy|
219062020|NCT00023829|RADIATION|radiation therapy|
219062021|NCT01720095|DRUG|Niaspan|
219648454|NCT05798013|BEHAVIORAL|Digital health management|The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
219648455|NCT03421145|DEVICE|3M™ Oral Rinse|The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
219648456|NCT03421145|OTHER|Vehicle Control Oral Rinse|The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
219648457|NCT03421145|DEVICE|PerioShield™ Oral Health Rinse|PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
219648458|NCT03421145|OTHER|Water|Purified bottled water containing no active ingredients.
219648459|NCT02773212|DRUG|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
219648460|NCT02773212|BEHAVIORAL|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
219648461|NCT02773212|DRUG|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
219648462|NCT06619873|DRUG|HRS-8080|"Medication regimen A~Drug:~600mg, Old process tablets，NPO~Medication regimen B~Drug:~600mg, New process tablets，NPO~Medication regimen C~Drug:~600mg, New process tablets，PC.，low-fat diet~Medication regimen D~Drug:~600mg, New process tablets，PC.，high-fat diet"
219648463|NCT00271011|DRUG|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
218962284|NCT06272669|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
218962285|NCT06272669|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
218962286|NCT00743782|DRUG|Synthetic Human Parathyroid Hormone 1-34|
218962287|NCT03981822|COMBINATION_PRODUCT|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
218962288|NCT03981822|COMBINATION_PRODUCT|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
218962289|NCT06460493|DRUG|Ensifentrine 3 mg twice daily|All subjects will receive ensifentrine.
218962290|NCT05595369|DRUG|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
218962291|NCT05595369|DRUG|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
218962292|NCT05595369|DRUG|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
219648464|NCT00271011|DRUG|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
219648465|NCT00271011|DRUG|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2.
219648466|NCT05853549|DEVICE|optical surface monitoring system|An optical surface monitoring system (OSMS) could achieve continuous monitoring of patient position through a nonradiographic and noninvasive technology, which has been widely applied to many sites of radiation therapy, including breast, intracranial, head and neck, abdomen, and extremities
218962293|NCT06475118|OTHER|Dynamometry measurement, myokine dosing, sarcopenia calculation|Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index
219062022|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
219062023|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
219062024|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
219062025|NCT03858075|DRUG|BLU-782|oral capsules
219062026|NCT03858075|DRUG|Placebo|oral capsules
219062027|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
219223715|NCT06698861|DRUG|PEG-MetHuG-CSF|Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2
219648467|NCT03319264|OTHER|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
219648468|NCT03319264|OTHER|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
219648469|NCT03319264|RADIATION|DXA measurement|DXA measurement will be performed to assess patient's body composition
219648470|NCT03319264|OTHER|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
219648471|NCT03319264|BEHAVIORAL|Life habits Questionnaire|Life habits Questionnaire
219648472|NCT02105246|BEHAVIORAL|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
219648473|NCT02105246|BEHAVIORAL|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
219648474|NCT03001349|PROCEDURE|Computed Tomography|Undergo PET/CT
219648475|NCT03001349|DRUG|Gallium Ga 68-Edotreotide|Given IV
219648476|NCT03001349|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219648477|NCT05525988|PROCEDURE|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
219648478|NCT00520481|DRUG|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
219648479|NCT04896346|OTHER|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
219648480|NCT04896346|OTHER|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
218962294|NCT01852370|BIOLOGICAL|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
218962295|NCT05355402|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
218962296|NCT05355402|DRUG|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
218962297|NCT06273540|DRUG|STP7 (mavoglurant) or Placebo|"STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline."
218962298|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
218962299|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
218962300|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
218962301|NCT05627661|DEVICE|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
218962302|NCT04166149|DIAGNOSTIC_TEST|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
218962303|NCT03987373|OTHER|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
218962304|NCT00309660|DRUG|Rosiglitazone|
219062028|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
219062029|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
219062030|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
219062031|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
219648481|NCT05905653|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
219062032|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
219062033|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
219062034|NCT00027430|DRUG|TheraDerm|
219062035|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
219223716|NCT06698861|DRUG|Neulasta (Amgen)|Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
219648482|NCT00589758|DIAGNOSTIC_TEST|Echocardiography|2D and 3D echocardiography
219648483|NCT00589758|OTHER|Biomarker evaluation|Blood and urine collected
219648484|NCT03942068|DRUG|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
219648485|NCT03942068|DRUG|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
219648486|NCT04829032|PROCEDURE|Hartmann's procedure|Hartmann's procedure
218962305|NCT06321029|BEHAVIORAL|Diabetes Tune-Up Group|The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
218962306|NCT03558412|COMBINATION_PRODUCT|CODOX-M/IVAC|Given ivgtt
218962307|NCT03558412|DRUG|Decitabine|Given ivgtt
218962308|NCT04307745|OTHER|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
218962309|NCT02651714|DRUG|Tradipitant|
218962310|NCT02651714|DRUG|Placebo|
218962311|NCT05853627|BEHAVIORAL|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
218962312|NCT05853627|DRUG|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
218962313|NCT01622127|DEVICE|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
218962314|NCT01976078|DRUG|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
218962315|NCT05988697|DRUG|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
218962316|NCT05272215|PROCEDURE|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
218962317|NCT05272215|PROCEDURE|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
218962318|NCT01920009|BEHAVIORAL|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
218962319|NCT05929066|DRUG|Retatrutide|Administered SC
218962320|NCT05929066|DRUG|Placebo|Administered SC
218962321|NCT02779465|DRUG|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
218962322|NCT01850264|DEVICE|Application of quadripolar / bipolar LV electrodes|
218962323|NCT01389518|DRUG|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
218962324|NCT01389518|DRUG|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
218962325|NCT00978107|BIOLOGICAL|MVA-FCU1, flucytosine|"1. TG4023: single IT injection; possibility to re-administer once,~   * Percutaneous IT injections, under radiological or ultrasound imaging guidance~  * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~  * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~   * Dose and dosing schedule:~     * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~    * Duration: 2 weeks.~  * Possible routes of administration:~     * PO: 500 mg tablets, qid~    * IV: 1% 250 mL vials, 45-minute infusions."
218962326|NCT02987660|PROCEDURE|Topography Guided LASIK|Corneal surgery for refractive error correction
218962327|NCT02987660|PROCEDURE|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
218962328|NCT02987660|DEVICE|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
218962329|NCT02987660|DEVICE|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
218962330|NCT06267430|BEHAVIORAL|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
219062036|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
219648487|NCT04441957|DEVICE|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
219648488|NCT06666101|DIETARY_SUPPLEMENT|Long chain polyunsaturated Omega-3|2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d
219648489|NCT06666101|DIETARY_SUPPLEMENT|Placebo|Olive oil
219648490|NCT06665854|BEHAVIORAL|Rhythmic Song Group|The rhythmic song group will first click on the start button on the mobile application. When starting the application to stimulate the baby, a bell will ring, and the baby movements will be coded as present/absent via the mobile application; then they will sing a rhythmic song and recode the baby movements as present/absent via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
218962331|NCT03624400|BEHAVIORAL|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
218962332|NCT03624400|BEHAVIORAL|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
218962333|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
218962334|NCT01933711|DRUG|rituximab|
218962335|NCT05341934|OTHER|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine …; The CS referring to soft drinks will be the words Coca-Cola, Fanta… and Filling CS referring to vegetables and fruits will be: Apple, Banana…In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
218962336|NCT04168697|BEHAVIORAL|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
218962337|NCT01087242|DRUG|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
218962338|NCT02789878|DRUG|Goserelin|Androgen Deprivation Therapy
218962339|NCT02789878|DRUG|Prednisone|Corticosteroid
218962340|NCT02789878|DRUG|Abiraterone|CYP17 inhibitor
218962341|NCT02789878|DRUG|Apalutamide|Androgen-receptor antagonist
219648491|NCT06665854|BEHAVIORAL|Rhythmic Instrument Group|The Rhythmic Instrument Group will first click on the start button on the mobile application. Then, they will ring a bell to start the application to warn the baby, and they will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
218962342|NCT00715000|PROCEDURE|Oral rehydration therapy|oral rehydration solution
218962343|NCT00715000|PROCEDURE|classical hydration via intravenous infusion|intravenous infusion
218962344|NCT04634838|DEVICE|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
218962345|NCT06255834|DRUG|IPG11406|"IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets"
218962346|NCT03284437|BEHAVIORAL|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
218962347|NCT06256120|DIAGNOSTIC_TEST|Restrictive|3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
218962348|NCT06256120|DIAGNOSTIC_TEST|Liberal|7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
218962349|NCT03707184|PROCEDURE|Computed Tomography|Undergo PET/CT scan
218962350|NCT03707184|DRUG|Fluciclovine F18|Given IV
218962351|NCT03707184|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
218962352|NCT05602649|DRUG|Cannabis|Cannabis will be orally ingested
218962353|NCT05602649|DRUG|Placebo|Placebo will be orally ingested
219648492|NCT06665854|BEHAVIORAL|Control Group|"Control Group will first code Start via the mobile application. Then, a bell will ring to warn the baby, they will code the baby's movements as present/absent via the mobile application again and will only rest. When the application is over, all pregnant women will code Finish via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week."
218962354|NCT06206213|BEHAVIORAL|Assessment of two different locomotion types.|Exposure to virtual environment by the HMD in two different locomotion styles.
219648493|NCT05709951|OTHER|Functional Exercises|The patients were requested to perform these functional exercises for 4 days per week three times for 20 min (8 weeks).
218962355|NCT05267665|BEHAVIORAL|Brief Family Intervention (BFI)|A 2-session psychoeducational and skills-based family intervention.
219648494|NCT05709951|OTHER|Core Stability Exercises|The patients were requested to perform 4 core strengthening exercises for 4 days per week three times for 20 min (8 weeks)
219648495|NCT04257032|DRUG|Rosuvastatin|Tablet
219648496|NCT04257032|DRUG|Rosuvastatin + BI 1323495|Tablets
219648497|NCT04257032|DRUG|Dabigatran etexilate|Capsule
219648498|NCT04257032|DRUG|Dabigatran etexilate + BI 1323495|Capsule and tablets
219648499|NCT03560726|BEHAVIORAL|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
219648500|NCT04406584|PROCEDURE|Injection into olfactory cleft|Already stated above.
219648501|NCT01558440|DIETARY_SUPPLEMENT|Infant Formula|A diet that is being fed to the young infants.
219648502|NCT01558440|DIETARY_SUPPLEMENT|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
218962356|NCT04704154|DRUG|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
218962357|NCT04704154|DRUG|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
219648503|NCT01558440|DIETARY_SUPPLEMENT|Diluted F-100|300 ml of water is added to 1000 ml of f-100
219062037|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
219062038|NCT02091999|DRUG|enfortumab vedotin|intravenous (IV) infusion
219062039|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
219062040|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
219062041|NCT01061749|OTHER|Pharmacological Study|Correlative studies
219648504|NCT00957268|DRUG|Alogliptin|Alogliptin tablets
219648505|NCT06078267|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
219648506|NCT05236374|OTHER|Beef protein|Animal protein source
219648507|NCT02393807|DRUG|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
219648508|NCT02393807|DRUG|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
219648509|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
219648510|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
219648511|NCT03626363|BEHAVIORAL|Stress Management|An eight week stress reduction course.
219648512|NCT01443338|DRUG|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
219648513|NCT01443338|DRUG|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
219648514|NCT03901833|BEHAVIORAL|Telemedicine Support|Telemedicine intervention
219648515|NCT03901833|OTHER|Standard of Care|Standard of Care
219648516|NCT03368885|OTHER|Maternal dietary diversity|Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
219648517|NCT03368885|OTHER|Diet diversity in complementary feeding|Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
218962358|NCT06631209|DEVICE|Transcranial Magnetic Stimulation (TMS)|Specifically, Continual Theta Burst Stimulation
218962359|NCT06631209|OTHER|Sham|Sham TMS
218962360|NCT03419221|PROCEDURE|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
218962361|NCT03419221|OTHER|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
218962362|NCT06172465|OTHER|EOIP|Ultrasound guided External oblique intercostal block will be performed bilaterally.
218962363|NCT06172465|OTHER|OSTAP|Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
219062042|NCT01061749|DRUG|Selumetinib|Given PO
219062043|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
219648518|NCT03368885|OTHER|Exclusive Breast Feeding|Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
219648519|NCT03368885|OTHER|Community mobilization|Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
219648520|NCT03368885|OTHER|Capacity Building|Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
219648521|NCT03368885|OTHER|Use of existing platforms VHSND|Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
219648522|NCT03368885|OTHER|Strategic use of data|Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
219648523|NCT04500483|DIAGNOSTIC_TEST|indirect calorimetry|measurement of resting energy expenditure using indirect calorimetry
219648524|NCT05971511|OTHER|Questionnaire|Questionnaire
219648525|NCT01893060|DRUG|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
219648526|NCT01893060|DRUG|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
218962364|NCT01303887|DRUG|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
218962365|NCT01303887|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
218962366|NCT01303887|DRUG|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
218962367|NCT01303887|DRUG|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
218962368|NCT01303887|DRUG|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
218962369|NCT05327959|DEVICE|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
218962370|NCT03306810|OTHER|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
218962371|NCT01949454|DRUG|Fluorometholone 0.1% ophthalmic solution|
218962372|NCT01949454|OTHER|Artificial tears (Placebo)|Artificial tears (Placebo)
218962373|NCT04845373|OTHER|Mediterranean diet|Diet intervention:Mediterranean diet
218962374|NCT04845373|OTHER|Control diet: Low fat diet|Low fat diet
218962375|NCT02068456|DRUG|Roflumilast|
218962376|NCT01057771|BEHAVIORAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
218962377|NCT01057771|BEHAVIORAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
218962378|NCT04251715|DRUG|Dexamethasone|Given intraarterially via HAI pump
218962379|NCT04251715|DRUG|Floxuridine|Given intraarterially via HAI pump
219062044|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
219648527|NCT01893060|DRUG|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
219648528|NCT01893060|OTHER|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
219648529|NCT01746420|DRUG|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
219648530|NCT01746420|DRUG|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
218962380|NCT04251715|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
218962381|NCT04251715|DRUG|Irinotecan|Given IV
218962382|NCT04251715|DRUG|Leucovorin|Given IV
218962383|NCT04251715|DRUG|Oxaliplatin|Given IV
218962384|NCT04251715|OTHER|Quality-of-Life Assessment|Ancillary studies
218962385|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
218962386|NCT03586518|DIAGNOSTIC_TEST|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
218962387|NCT03586518|DIAGNOSTIC_TEST|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
218962388|NCT03586518|PROCEDURE|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
218962389|NCT03586518|DIAGNOSTIC_TEST|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
219062045|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
219062046|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
219062047|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
219062048|NCT01131481|DEVICE|Intraocular lens|
219062049|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
219062050|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
219062051|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
219062052|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
219062053|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
218962390|NCT03586518|DIAGNOSTIC_TEST|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
218962391|NCT01583920|RADIATION|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
218962392|NCT02978560|DIAGNOSTIC_TEST|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
219648531|NCT04245540|DIETARY_SUPPLEMENT|Pau d' Arco|Encapsulated herbal Pau d' Arco.
218962393|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
218962394|NCT05394129|DIAGNOSTIC_TEST|SurePath™|In the liquid-based cytology, a fine-needle aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
218962395|NCT05882071|DRUG|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
219062054|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
219062055|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
219062056|NCT00024518|DRUG|30,000 units hrINF-alpha|
218962396|NCT06109285|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
218962397|NCT03223753|OTHER|Educational Intervention|Receive educational handouts about to physical activity
218962398|NCT03223753|OTHER|Internet-Based Intervention|Access limited version of device app/website
218962399|NCT03223753|OTHER|Internet-Based Intervention|Access full version of interactive reward-based device app/website
218962400|NCT03223753|OTHER|Laboratory Biomarker Analysis|Correlative studies
218962401|NCT03223753|DEVICE|Medical Device Usage and Evaluation|Wear physical activity tracking device
218962402|NCT03223753|OTHER|Quality-of-Life Assessment|Ancillary studies
218962403|NCT03223753|OTHER|Questionnaire Administration|Ancillary studies
219062057|NCT00024518|DRUG|5,000 hrINF-alpha|
219062058|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
219062059|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
219648532|NCT04410120|OTHER|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
219648533|NCT05261724|DIAGNOSTIC_TEST|MRI|In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
219648534|NCT05872867|BIOLOGICAL|WM-A1-3389|Anti-IGSF1 (Immunoglobulin superfamily member 1)
219648535|NCT05872867|BIOLOGICAL|Pembrolizumab|Anti-PD-1(Programmed cell death protein 1)
219648536|NCT00517140|PROCEDURE|Repeat Caesaen section|
219648537|NCT00517140|PROCEDURE|vaginal delivery|
219648538|NCT06903559|DRUG|Roxadustat|Intervention Description: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for the treatment of anemia associated with chronic kidney disease in patients on dialysis, based on hemoglobin levels.
219648539|NCT06903559|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
219648540|NCT06487338|OTHER|Low-level laser therapy|Is a form of medicine that applies low-level (low-power) lasers that relieve pain.The effects appear to be limited to a specified set of wavelengths
219648541|NCT06487338|OTHER|Shock wave Therapy|is a non-invasive treatment that stimulates the body's natural healing process. It can relieve pain and promote healing of injured tendons, ligaments, and other soft tissues
219648542|NCT00489905|DRUG|Zolderonic acid (Zometa)|
219648543|NCT01945853|DEVICE|7 Tesla MRI|
219648544|NCT02600845|DEVICE|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
219648545|NCT04837508|DRUG|MRG002|Administrated intravenously
219648546|NCT05941143|OTHER|mindfulness-based intervention|8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
219648547|NCT06287827|PROCEDURE|Simplified protocol|"MUAC-based dosing:~* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets Ready to use Therapeutic Food (RUTF)/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
219648548|NCT06287827|PROCEDURE|Standard protocol|"Weight-based dosing~* SAM: Mid-upper-arm circumference (MUAC) \<115mm or Weight-Height/length Z Score \<-3 or mild or moderate bipedal oedema: 150-185 kcal/kg/day is offered using RUTF until the patient passes to MAM and then the dose is reduced to 100 -130 kcal/kg/day using RUTF until recovery.~* MAM: MUAC 115-\<125mm or Weight-Height/length Z Score \<-2: 100-130 kcal/kg/day is offered using RUTF until recovery."
219648549|NCT06489327|DRUG|melatonin (Circadin ®) 0.2 mg/kg|Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
219648550|NCT06489327|DRUG|melatonin (Circadin ®) 0.4 mg/kg|Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
219648551|NCT06489327|DRUG|placebo group|Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
219648552|NCT03845582|DRUG|ALK-001 oral capsule|Daily administration for 24 months
219648553|NCT03845582|DRUG|Placebo oral capsule|Daily administration for 24 months
219648554|NCT00352092|DRUG|calcineurin inhibitor|
219648555|NCT00352092|DRUG|sirolimus|
219648556|NCT00352092|DRUG|mycophenolate mofetil|
219648557|NCT05897086|DRUG|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
218962404|NCT03066973|BEHAVIORAL|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
218962405|NCT01840995|PROCEDURE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
218962406|NCT05651568|OTHER|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
219648558|NCT04084834|OTHER|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
219648559|NCT02409563|DRUG|Budesonide nasal spray (100 mcg bid)|
219648560|NCT02409563|DRUG|Budesonide nasal spray (50 mcg bid|
219062060|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
219062061|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
219062062|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
219062063|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
219648561|NCT02529124|DIETARY_SUPPLEMENT|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
219648562|NCT02529124|DIETARY_SUPPLEMENT|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
219648563|NCT02529124|BEHAVIORAL|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
218962407|NCT05651568|OTHER|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
219648564|NCT02531776|DEVICE|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson \& Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
219648565|NCT04416867|DEVICE|splint and home exercise|Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
219648566|NCT04416867|DEVICE|RESWT|RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
219648567|NCT04416867|DEVICE|physical therapy|20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
218962408|NCT02331160|BEHAVIORAL|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
218962409|NCT06298604|DEVICE|EUS-guided standard fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.
218962410|NCT06298604|DEVICE|EUS-guided motorized fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
218962411|NCT01993095|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
218962412|NCT01993095|BEHAVIORAL|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
218962413|NCT02398279|DIETARY_SUPPLEMENT|L-Arginine|Experimental supplement
219062064|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
219062065|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
219062066|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
219648568|NCT01080469|DRUG|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
219648569|NCT06668662|DEVICE|Endoactivator|Endoactivator is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
219648570|NCT06668662|DEVICE|Conventional irrigation|Conventional irrigation is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
218962414|NCT02398279|OTHER|Placebo|Placebo capsules in the same color and shape with the experimental supplement
218962415|NCT00084591|DRUG|capecitabine|
218962416|NCT00084591|PROCEDURE|conventional surgery|
218962417|NCT00084591|PROCEDURE|neoadjuvant therapy|
218962418|NCT00084591|RADIATION|radiation therapy|
218962419|NCT01633580|DRUG|corifollitropin alfa|long acting FSH
218962420|NCT04809636|OTHER|This is not an interventional study|While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes
218962421|NCT05440149|RADIATION|No PMRT for mastectomy / No regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
219062067|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
219648571|NCT03145961|DRUG|Pembrolizumab|200mg intravenous infusion
219648572|NCT06022276|DRUG|Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
219648573|NCT02289547|DRUG|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
219648574|NCT06929624|DRUG|SHR-A1912 Injection|SHR-A1912 injection.
219648575|NCT06929624|DRUG|Rituximab Injection|Rituximab injection.
219062068|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
219062069|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
219062070|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
219062071|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
219062072|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
219062073|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
219062074|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
219062075|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
219062076|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
219062077|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
219062078|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
219648576|NCT06929624|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine hydrochloride for injection.
219648577|NCT06929624|DRUG|Oxaliplatin Injection|Oxaliplatin injection.
219648578|NCT06922747|OTHER|Group exercising|Weekly, supervised exercise sessions in groups
219648579|NCT06922747|OTHER|Somatic tracking|A psychological intervention aiming to learn the brain to reinterpret pain signals.
219648580|NCT06922747|OTHER|General activity recommendaitons|General recommendaitons for physical activity and healthy lifestyle
219648581|NCT04195620|OTHER|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
219648582|NCT04195620|OTHER|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
219648583|NCT03726294|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
219648584|NCT01904292|DRUG|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
219062079|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
219062080|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
219062081|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
219062082|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
219648585|NCT03096678|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
219648586|NCT03546426|DRUG|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
219648587|NCT03546426|BIOLOGICAL|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
218962422|NCT05440149|RADIATION|PMRT for mastectomy / WBI + Regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
218962423|NCT03780400|BEHAVIORAL|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
218962424|NCT03571477|DEVICE|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
218962425|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
218962426|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
218962427|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
218962428|NCT01653782|BEHAVIORAL|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
218962429|NCT01653782|BEHAVIORAL|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
218962430|NCT01653782|BEHAVIORAL|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
218962431|NCT05124418|DIAGNOSTIC_TEST|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
218962432|NCT01142128|DRUG|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
218962433|NCT01142128|DRUG|Placebo to Nexium|one capsule per day for one month
218962434|NCT01142128|DRUG|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
218962435|NCT01142128|DRUG|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
218962436|NCT00611039|DRUG|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
218962437|NCT00611039|DRUG|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
219062083|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
219062084|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
219062085|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
219062086|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
219062087|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
219648588|NCT03546426|DRUG|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
219648589|NCT03139006|DEVICE|Dual-layer spectral detector CT|A dual energy CT approach
219648590|NCT04413552|DRUG|INDV-2000|INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
219648591|NCT04413552|DRUG|Placebo|Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
219648592|NCT06772987|DEVICE|Accelerated rTMS treatment|1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.
219648593|NCT02070627|DRUG|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
219648594|NCT02070627|DEVICE|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
219648595|NCT05711186|OTHER|Structured SDM|The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR
219648596|NCT05711186|OTHER|Usual Care|Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
219648597|NCT03675165|BEHAVIORAL|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
219648598|NCT04693832|DEVICE|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
219648599|NCT06576388|DRUG|EXG001-307 injection|Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
219648600|NCT01993953|OTHER|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
219648601|NCT01993953|OTHER|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
219648602|NCT01993953|OTHER|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
219648603|NCT05237102|PROCEDURE|Cerebrospinal fluid shunt|"The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）"
219648604|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
219648605|NCT06507839|OTHER|Placebo|Matching placebo
219648606|NCT06943937|DRUG|YTS109 cell injection|Subjects will receive YTS109 Cell Injection(1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.
219648607|NCT06939335|DEVICE|Disposable PEEP Valve set at 5 cm H20.|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 and a 22 mm disposable PEEP Valve set at 5 cm H20.
219648608|NCT06939335|DEVICE|Controle|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 without a disposable PEEP Valve.
219648609|NCT01442311|OTHER|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
219648610|NCT01442311|OTHER|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
219648611|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
219648612|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
219648613|NCT00251082|DRUG|Placebo|Placebo
219648614|NCT02700373|DRUG|PDC-APB|
219648615|NCT02700373|DRUG|Placebo|
219648616|NCT06433622|DIAGNOSTIC_TEST|Repeat Thromboelastography with Platelet Mapping|Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
219648617|NCT03277469|DEVICE|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
219648618|NCT03277469|RADIATION|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
219062088|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
219062089|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
219062090|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
219062091|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
219062092|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
219062093|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
219062094|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
219062095|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
219207840|NCT06779240|OTHER|Quality of life questionnaires|The clinical protocols at our institute involve the regular and continuous evaluation of the quality of life in patients undergoing treatment and monitoring for scoliosis and other vertebral deformities. To this end, the SRS-22 (Scoliosis Research Society) questionnaire and the ODI (Oswestry Disability Index) questionnaire are employed, along with other measures such as the COMI (Core Outcome Measure Index) and ISYQoL (Italian Spine Youth Quality of Life) and administrated to every patients
219207841|NCT06778681|OTHER|Cheer|"During voluntary muscle contraction subjects will be cheered with verbal encouragement (push, push, push) and clapping."
219207842|NCT06778746|OTHER|no interventions|No interventions, this is an observational study
219648619|NCT03277469|DEVICE|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
219648620|NCT05711485|OTHER|Whole blood transfusion|Whole blood is sourced from the Zambia National Blood Transfusion Service.
219648621|NCT04852679|DRUG|Lanreotide autogel|Administered as deep subcutaneous (SC) injections
219648622|NCT04183413|OTHER|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
219648623|NCT04183413|OTHER|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
219648624|NCT00795080|PROCEDURE|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
219648625|NCT03466606|BEHAVIORAL|pre-habilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
219648626|NCT06453928|DEVICE|Hybrid Closed Loop Insulin Pump System|Patients will be started on an automated insulin delivery system.
219648627|NCT04604444|BEHAVIORAL|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
219648628|NCT01294696|DRUG|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
219062096|NCT02520635|DRUG|supra-early TEMODAL® chemotherapy|
219062097|NCT02520635|DRUG|standard TEMODAL® chemotherapy|
219062098|NCT02520635|RADIATION|Radiotherapy 60Gy|
219062099|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
219062100|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
219062101|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
219207843|NCT06778902|DRUG|azacytidine|Azacytidine: 75mg/m2, d1-d5
219207844|NCT06778902|DRUG|R-GemOx|Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
219207845|NCT06779539|DRUG|Ensartinib|Ensartinib 225 mg oral once daily 12 weeks
219223717|NCT07033962|COMBINATION_PRODUCT|"Fractional CO2 laser and topical fluconazole microemulsion"|four sessions of fractional CO2 at 3weeks interval with a laser device (multixel, Daeshin enterprise co., LTD. (D.S.E) 105, 271, digital -ro, Guro-gu, Seoul, Koreaa) at a pulse energy of 140 mJ, a density of 150 spots/ cm2 and a depth of 1 cm combined with twice daily topical fluconazole microemulsion.
219223718|NCT07033962|COMBINATION_PRODUCT|"Urea 40% and topical fluconazole microemulsion"|urea 40% paste under occlusion once daily over 4 weeks followed by topical fluconazole microemulsion twice daily for 8 weeks.
219223719|NCT07033455|DRUG|HRS-1893|Single dose of HRS-1893 orally administered
219648629|NCT03689907|OTHER|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
219648630|NCT04323618|DEVICE|Breathe Well|
219062102|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
219062103|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
219648631|NCT06366087|DRUG|Atropine Sulfate Ophthalmic Solution USP, 1%|Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
219062104|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
219062105|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
219062106|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
219062107|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
219223720|NCT07032363|OTHER|Core Implementation Strategies|"* Task Sharing/Revise Professional Roles~* Distribute educational materials/Dynamic Training/Address Stigma~* Clinician Implementation Team Meetings~* Partner with CoCT DoH~* Champion~* Audit and Feedback~* Stage Scale Up/Tailoring"
219648632|NCT06366087|DRUG|Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)|Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
219648633|NCT03474744|DRUG|Copanlisib|Solution for IV infusion
219648634|NCT03474744|DRUG|Rituximab|Solution for IV infusion
219223721|NCT07032363|OTHER|Enhanced Implementation Strategies|"* Train the trainer~* Ongoing supervision and consultation"
218962438|NCT03174899|RADIATION|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
218962439|NCT02598336|DEVICE|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
218962440|NCT02598336|DEVICE|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
218962441|NCT06268145|DRUG|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
219648635|NCT01515462|GENETIC|TLT003|TLT003 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
219648636|NCT06793527|DRUG|Celiac Plexus Block|During general anesthesia, a celiac plexus block will be performed intraoperatively (20 ml of 0.5% ropivacaine). The patient will not feel discomfort due to general anesthesia.
219648637|NCT06793527|DRUG|ESP block|Before the procedure, a block of the erector spinae (ESP) compartment will be performed with approximately 20 ml of 0.25% ropivacaine at the Th4 level. The patient will be informed about the possibility of short-term discomfort if the block is performed before full induction of anesthesia.
219648638|NCT06793527|DRUG|Lidacaine|Instead of a regional block, an intravenous infusion of lidocaine will be used.
219648639|NCT06248359|DRUG|L-Arginine hydrochloride|Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
219648640|NCT05810506|OTHER|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
219648641|NCT00860249|BEHAVIORAL|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
219648642|NCT00860249|BEHAVIORAL|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
219648643|NCT03817957|DRUG|Polyglucoferron|intravenous administration
219648644|NCT03817957|DRUG|Ferric carboxymaltose|intravenous administration
219648645|NCT03817957|DRUG|Ferrous Sulfate|oral administration
219648646|NCT04935801|BIOLOGICAL|LD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
218962442|NCT05478954|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
218962443|NCT05478954|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
219062108|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
219062109|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
219062110|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
219062111|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
219062112|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
219062113|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
219062114|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
219062115|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
219062116|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
219062117|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
219062118|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
219062119|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
219648647|NCT04935801|BIOLOGICAL|LD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
219648648|NCT04935801|BIOLOGICAL|HD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
219648649|NCT04935801|BIOLOGICAL|HD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
219648650|NCT00432796|DRUG|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
219648651|NCT00432796|OTHER|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
219062120|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
219062121|NCT04287933|DEVICE|Drain insertion|insertion of a drain
219648652|NCT03574142|DRUG|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
219648653|NCT04481581|OTHER|Electronic Alerts|When FiO2 remains =\>0.4 and SpO2 =\>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
219648654|NCT06078748|BEHAVIORAL|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
219648655|NCT06078748|BEHAVIORAL|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
219648656|NCT06078748|BEHAVIORAL|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
219648657|NCT06078748|BEHAVIORAL|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
219648658|NCT03614260|DEVICE|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
219648659|NCT03614260|PROCEDURE|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
219648660|NCT01714843|DRUG|linaclotide|oral
219648661|NCT01714843|DRUG|placebo|oral
218962444|NCT03000127|DRUG|AndroGel 1 % Topical Gel|testosterone gel
218962445|NCT03000127|DRUG|Placebos|Placebo gel
218962446|NCT05977725|DIAGNOSTIC_TEST|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
218962447|NCT04643171|DEVICE|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
218962448|NCT04643171|DEVICE|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
218962449|NCT00393640|PROCEDURE|Early and regular breast milk expression|Breast pump given to be used on regular intervals
218962450|NCT01618812|PROCEDURE|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
218962451|NCT04782960|DRUG|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
218962452|NCT04782960|DRUG|Placebo|0.9 saline
218962453|NCT00579007|BEHAVIORAL|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
218962454|NCT00442468|OTHER|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
218962455|NCT04728672|OTHER|Kinesio Tape|Kinesio Tape
218962456|NCT04728672|OTHER|Micropore Tape|Micropore Tape
218962457|NCT03199339|DRUG|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
218962458|NCT03199339|DRUG|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
218962459|NCT00613197|DRUG|Epanova|4g/day in divided doses
218962460|NCT04568343|DEVICE|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
218962461|NCT03551353|OTHER|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
218962462|NCT03551353|OTHER|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
218962463|NCT04300374|OTHER|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
218962464|NCT02571400|OTHER|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics \>90 days post-surgery
218962465|NCT00926588|DRUG|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
218962466|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
219062122|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
219062123|NCT03789422|DRUG|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
219062124|NCT03789422|DRUG|Levocetirizine only|levocetirizine 20 mg/day
219062125|NCT04994626|DRUG|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
219062126|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
219062127|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
219062128|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
219207846|NCT06779422|BEHAVIORAL|Pai.ACT|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors (see NCT06086951). The contents of Pai.ACT is underpinned by: (i) the core principles of Focused ACT, (ii) our validated Focused ACT protocol used in our ongoing Focused ACT trial (see NCT05803252), and (iii) our validated ACT protocols, established since 2019, that address psychological challenges specific to the Chinese parenting context (e.g., affiliate stigma, internalisation of external criticism, self-blame) through a 4-to-6 week of ACT.
219648662|NCT06645782|BEHAVIORAL|Virtual, Group CF-CBT|Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
219648663|NCT06189729|BEHAVIORAL|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
219648664|NCT06189729|BEHAVIORAL|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
219648665|NCT00174967|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
219648666|NCT00174967|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
219648667|NCT00174967|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
219648668|NCT00174967|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
219648669|NCT06234592|DRUG|Angiotensin II|Angiotensin II infusion
219648670|NCT06234592|DRUG|Vasopressin|Vasopressin infusion
219648671|NCT06234592|DRUG|Norepinephrine|Standard care vasopressor therapy, norepinephrine infusion
219648672|NCT03625635|OTHER|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
219648673|NCT04250532|OTHER|Drowning|Measurement of pulse oximetry, after lifeguard immersion during their morning training
218962467|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
219062129|NCT04616651|BEHAVIORAL|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
219062130|NCT04616651|BEHAVIORAL|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
219648674|NCT02004821|DIETARY_SUPPLEMENT|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
218962468|NCT02866487|PROCEDURE|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
218962469|NCT04494022|DIAGNOSTIC_TEST|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
219062131|NCT04616651|BEHAVIORAL|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
219062132|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
219062133|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
219062134|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
219062135|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
219062136|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
219062137|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
219062138|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
219062139|NCT02817789|DRUG|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
219062140|NCT02817789|DRUG|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
219062141|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
219648675|NCT06046625|OTHER|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
219648676|NCT02539966|DEVICE|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
219648677|NCT02938403|BEHAVIORAL|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
219648678|NCT02938403|BEHAVIORAL|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
219648679|NCT06054061|BEHAVIORAL|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
219648680|NCT06054061|BEHAVIORAL|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
219648681|NCT03382301|DRUG|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
219648682|NCT03382301|DRUG|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
219648683|NCT05073029|OTHER|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
219062142|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
219062143|NCT02905526|OTHER|Mobile phone app|Mobile phone app
219062144|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
219062145|NCT04986657|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
219062146|NCT03604250|DIETARY_SUPPLEMENT|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
219207847|NCT06779422|OTHER|Positive parenting advice|Positive parenting advice is recommended by the Child Assessment Services under the Department of Health, and videoconferencing session(s) led by another experienced counsellor for content revision. No access to AI chatbot/ACT modules will be granted.
219207848|NCT06760702|DRUG|AUR109 200mg|AUR109 200mg (once daily)
219207849|NCT06760702|DRUG|AUR109 300mg|AUR109 300mg once daily
219207850|NCT06760702|DRUG|AUR109 400mg|AUR109 400mg once daily
219207851|NCT06768970|DIETARY_SUPPLEMENT|CARDIO® salmon oil|CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.
219207852|NCT06772688|PROCEDURE|orthognathic surgery|Maxillary repositioning and fixation with custom made plate
219648684|NCT05073029|DIETARY_SUPPLEMENT|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
219648685|NCT05073029|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
219648686|NCT02947204|OTHER|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
219648687|NCT02947204|OTHER|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
219648688|NCT02066818|DRUG|Lidocaine/tetracaine patch|
219648689|NCT02066818|DRUG|1% lidocaine|
219648690|NCT01668524|DRUG|ATS907|Single dose of each of three increasing concentrations
219648691|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219648692|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
218962470|NCT02326545|BEHAVIORAL|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
219648693|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
218962471|NCT02326545|BEHAVIORAL|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
218962472|NCT02803515|BIOLOGICAL|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
218962473|NCT00000253|DRUG|10% N2O|
218962474|NCT00000253|DRUG|20% N2O|
218962475|NCT00000253|DRUG|30% N2O|
218962476|NCT00000253|DRUG|40% N2O|
218962477|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
218962478|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
218962479|NCT04375475|DIETARY_SUPPLEMENT|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
218962480|NCT03809793|OTHER|Exercise Program|12-week walking based intervention (3 sessions per week)
218962481|NCT03809793|DIAGNOSTIC_TEST|DXA|Participants will undergo an assessment of body composition (DXA)
218962482|NCT03809793|DIAGNOSTIC_TEST|MRI|used to measure fat stored in the liver
219062147|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
219062148|NCT01897584|OTHER|inverse IE|in only one group changes of I:E ratio would be applied
219062149|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
219062150|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
219062151|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
219062152|NCT00487201|PROCEDURE|plastic stent placement|
219062153|NCT03727204|PROCEDURE|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
219062154|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 250 Mcg|
219062155|NCT00877448|BIOLOGICAL|Multimeric-001 250 Mcg|
219062156|NCT00877448|BIOLOGICAL|Phosphate Buffered saline|
219062157|NCT00877448|BIOLOGICAL|Adjuvanted PBS|
219062158|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 500 Mcg|
219062159|NCT00877448|BIOLOGICAL|Multimeric-001 500 Mcg|
219062160|NCT00877448|BIOLOGICAL|Multimeric-001 125 Mcg|
219062161|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
219648694|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219648695|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219648696|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
219648697|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
219648698|NCT05295979|DRUG|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
219648699|NCT05295979|DRUG|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
219648700|NCT04615806|DRUG|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
219648701|NCT02641886|DRUG|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
219648702|NCT02641886|OTHER|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
219648703|NCT02481271|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
219648704|NCT02481271|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
219648705|NCT01882881|OTHER|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
219648706|NCT01882881|OTHER|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).
218962483|NCT03809793|DIAGNOSTIC_TEST|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
218962484|NCT03809793|DIAGNOSTIC_TEST|VO2 Max|Assessment of maximum aerobic capacity.
218962485|NCT03809793|DIAGNOSTIC_TEST|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
218962486|NCT03809793|PROCEDURE|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
218962487|NCT03809793|DRUG|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
218962488|NCT05791903|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
218962489|NCT02385188|DRUG|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
218962490|NCT02385188|DRUG|paracetamol|
218962491|NCT02385188|DRUG|lidocaine in Vaseline ointment|
218962492|NCT00571376|OTHER|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
219648707|NCT01882881|OTHER|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
218962493|NCT05998928|DRUG|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"
218962494|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
218962495|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
218962496|NCT00336180|BEHAVIORAL|HealthWise South Africa curriculum|18 classroom lessons
218962497|NCT04148677|DIETARY_SUPPLEMENT|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
218962498|NCT00315354|OTHER|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
218962499|NCT00315354|OTHER|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
218962500|NCT00315354|OTHER|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
218962501|NCT03577171|DRUG|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
218962502|NCT03577171|DRUG|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
218962503|NCT03577171|DRUG|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
219648708|NCT01882881|OTHER|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
219648709|NCT06618131|OTHER|Exercise|Exercise program with virtual reality applications for lower extremities
219648710|NCT03117894|DRUG|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
219648711|NCT03117894|DRUG|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
219648712|NCT03117894|DRUG|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
219648713|NCT03117894|DRUG|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
219648714|NCT03117894|DRUG|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
219648715|NCT03117894|DRUG|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
219648716|NCT03117894|DRUG|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
219648717|NCT03117894|DRUG|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
218962504|NCT03823378|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
219648718|NCT02716493|BEHAVIORAL|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
219648719|NCT00997217|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
218962505|NCT03823378|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
218962506|NCT03823378|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
218962507|NCT03823378|DRUG|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
219648720|NCT00154804|DRUG|Paclitaxel, Cisplatin,Surgery, CCRT|
219648721|NCT04568954|DIAGNOSTIC_TEST|Truenat TB platform/TB assays|"Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life."
219648722|NCT00687843|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
219648723|NCT00687843|DRUG|Krestin (PSK)|3 g, PO from day 1 to day 336
219648724|NCT06086210|OTHER|Low-level laser therapy|Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.
219648725|NCT06086210|OTHER|Sham|Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
219648726|NCT06793943|DRUG|Zasocitinib|Zasocitinib tablets specified doses on specified days.
219648727|NCT06793943|DRUG|COC|COC tablets (containing LNG and EE) specified doses on specified days.
219648728|NCT06793943|DRUG|Metformin|Metformin tablets specified doses on specified days.
219648729|NCT06793943|DRUG|Digoxin|Digoxin tablets specified doses on specified days.
219648730|NCT06793943|DRUG|Esomeprazole|Esomeprazole capsules specified doses on specified days.
219648731|NCT04947228|DEVICE|trackPAD|TrackPAD is a smartphone app to provide PAD-specific support for SET
219207853|NCT06781866|OTHER|Massage|A relaxation type of massage will be used as the main massage intervention in this study. This technique is designed to promote deep relaxation, reduce stress, and enhance overall well-being. It is characterized by the use of five primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage (long, gliding strokes), petrissage (kneading and squeezing), tapotement (rhythmic tapping), friction (deep, circular rubbing), and vibration or shaking movements (Table 1). In addition to these, the technique also incorporates rhythmic movements and deep light pressure to enhance relaxation and alleviate tension. It is designed to promote relaxation, increase blood circulation, relieve muscle tension, improve flexibility and promote relaxation and reduce pain. The total duration of the Relaxation massage is 45 minutes.
219648732|NCT00030667|DRUG|imatinib mesylate|Given orally
219648733|NCT00030667|OTHER|laboratory biomarker analysis|Correlative studies
219648734|NCT00030667|OTHER|pharmacological study|Correlative studies
219648735|NCT03892174|OTHER|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
219648736|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
219648737|NCT06821347|DRUG|NanO2TM|Intravenous NanO2 0.17ml/kg (three doses given over 4.5 hours)
219648738|NCT06821347|OTHER|Sodium Chloride 0.9% Intravenous|Placebo
219648739|NCT01689246|DRUG|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
219648740|NCT01689246|DRUG|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
219648741|NCT01689246|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
219648742|NCT02197832|PROCEDURE|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
219648743|NCT02197832|PROCEDURE|control procedure|Using pipelle catheter without entering the uterine cavity.
219648744|NCT02197832|DEVICE|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
219648745|NCT00503958|GENETIC|DNA methylation analysis|
219648746|NCT00503958|GENETIC|DNA stability analysis|
219648747|NCT00503958|GENETIC|gene expression analysis|
219648748|NCT00503958|OTHER|epidemiologic study|
219648749|NCT00503958|OTHER|study of socioeconomic and demographic variables|
219648750|NCT00503958|PROCEDURE|biopsy|
219648751|NCT00503958|PROCEDURE|evaluation of cancer risk factors|
219648752|NCT00503958|PROCEDURE|study of high risk factors|
219648753|NCT06008197|DRUG|Finerenone|Oral finerenone
219648754|NCT06008197|DRUG|Placebo|Matching oral placebo
219648755|NCT03495674|BEHAVIORAL|Exercise Intervention|Complete cycling classes
218962508|NCT01278303|DEVICE|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
218962509|NCT05442775|DRUG|Reldesemtiv|Oral tablet
218962510|NCT05443360|DIETARY_SUPPLEMENT|DENSITY™ (Amorphous calcium carbonate, ACC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
218962511|NCT05443360|DIETARY_SUPPLEMENT|Crystalized calcium carbonate (CCC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
218962512|NCT02337348|OTHER|Optical coherence tomography|Preintervention imaging
218962513|NCT02337348|RADIATION|Coronary angiography|Conventional coronary intervention
218962514|NCT01020539|DRUG|Fludarabine|Conditioning Regimen
218962515|NCT01020539|DRUG|Busulfan|Conditioning Regimen
218962516|NCT01020539|DRUG|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
218962517|NCT01020539|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
218962518|NCT01020539|DRUG|Anti-Thymocyte Globulin|Unrelated Donors only
218962519|NCT01020539|DRUG|Isotretinoin|JMML patients only
218962520|NCT04163822|OTHER|no intervention|no intervention, only observation
218962521|NCT02001025|DEVICE|Absorb scaffold|
218962522|NCT02001025|DEVICE|Xience stent|
218962523|NCT04849325|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
218962524|NCT04849325|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
219648756|NCT03495674|OTHER|Informational Intervention|Receive information about exercise guidelines
219648757|NCT03495674|DEVICE|Monitoring Device|Wear Fitbit
219648758|NCT03495674|OTHER|Questionnaire Administration|Complete questionnaire
219648759|NCT05033730|DEVICE|Flow Controlled Ventilation|Mechanically ventilated using Flow Controlled Ventilation (FCV)
219648760|NCT00217776|BEHAVIORAL|Open Airways Educational Intervention|
219648761|NCT00217776|BEHAVIORAL|Peer Asthma Action Educational Intervention|
219648762|NCT06358846|BEHAVIORAL|Self-care behavior to promote foot care through educational guidance among individual with diabetes|Apart from physician consultation, individuals will received structured training of how to care their foot to avoid ulcer and inflammation.
219648763|NCT05528198|DRUG|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
219648764|NCT05528198|DRUG|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
219648765|NCT05528198|DRUG|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
219648766|NCT03946683|RADIATION|Cyberknife for Early Stage Breast Cancer|Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
219648767|NCT06620575|PROCEDURE|Atrial fibrillation ablation|Persistent atrial fibrillation ablation
219648768|NCT00369070|BIOLOGICAL|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
219648769|NCT00369070|DRUG|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
219648770|NCT00369070|DRUG|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
219648771|NCT00369070|DRUG|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
219062162|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
219062163|NCT00984841|OTHER|Tailored letter|
219062164|NCT03673436|PROCEDURE|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
219062165|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
219062166|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
219062167|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
219648772|NCT02530411|DRUG|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
219648773|NCT02530411|DRUG|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
219648774|NCT02031640|DRUG|Beclomethasone dipropionate|
219648775|NCT02031640|DRUG|Placebo|
219648776|NCT02031640|DRUG|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
219648777|NCT05409001|DIAGNOSTIC_TEST|tomography pan scan|This is a retrospective chart review
219648778|NCT02395640|DRUG|Epirubicin|50mg/m2 ivgtt d1
219648779|NCT02395640|DRUG|Oxaliplatin|
219648780|NCT02395640|DRUG|Capecitabine|1000mg/m2 po d1-14
219062168|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
219062169|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
219062170|NCT04111497|DRUG|Glasdegib|Given PO
219062171|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
219062172|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
219062173|NCT03321019|DRUG|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
219062174|NCT03321019|DEVICE|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
219062175|NCT03321019|OTHER|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
219062176|NCT03321019|PROCEDURE|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
219062177|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
219648781|NCT04514640|BEHAVIORAL|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
219648782|NCT06416410|DRUG|JAB-21822|JAB-21822 administered orally as a tablet
219648783|NCT06416410|DRUG|Tislelizumab|Tislelizumab administered as an intravenous (IV) infusion
219648784|NCT06416410|DRUG|JAB-3312|JAB-3312 administered orally as a tablet or capsule
219648785|NCT06416410|DRUG|Pemetrexed|Pemetrexed administered as an intravenous (IV) infusion
219648786|NCT06416410|DRUG|Carboplatin|Carboplatin administered as an intravenous (IV) infusion
219648787|NCT05212688|OTHER|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 \& GV24 midline.
219648788|NCT05212688|OTHER|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
219062178|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
219648789|NCT00635453|BEHAVIORAL|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
218962525|NCT02537795|DEVICE|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
218962526|NCT02537795|PROCEDURE|anterior capsulotomy|
218962527|NCT00058539|DRUG|rhuMAb 2C4 (pertuzumab)|
218962528|NCT05976438|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
218962529|NCT05976438|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
218962530|NCT03190369|DEVICE|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
218962531|NCT03190369|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
219207854|NCT06781866|OTHER|Sham (No Treatment)|The Sham massage (PLA) will be used as a control session, without applying the deeper techniques that characterize the Relaxation massage in order to eliminate the influence of the human touch sensation on the participant's skin. This massage consisted only of superficial oil application movements over the entire body, without any added pressure or deep muscle manipulation. Oil was used to facilitate smooth gliding, mimicking the sensation of a full massage, but without the intensity or techniques aimed at muscle tissue relaxation. The total duration of the sham massage is 45 minutes.
219207855|NCT06781463|OTHER|Registry (N/A)|This study is a registry, thus no research intervention is being directly tested.
219648790|NCT06090409|OTHER|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
218962532|NCT04455360|OTHER|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
218962533|NCT04385927|BEHAVIORAL|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
218962534|NCT05386485|OTHER|None intervation|Observational Study
219062179|NCT04090307|BEHAVIORAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
219207856|NCT06782022|DRUG|5-Fluoro-Uracil|"Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached."
219648791|NCT01654653|DRUG|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
219648792|NCT01654653|DRUG|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
219648793|NCT02940093|OTHER|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
218962535|NCT04991428|OTHER|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
218962536|NCT01631019|BEHAVIORAL|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
218962537|NCT01631019|BEHAVIORAL|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
218962538|NCT02963831|BIOLOGICAL|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
219062180|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
219062181|NCT03259035|DRUG|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
219062182|NCT03259035|DRUG|Capox|4 cycles of q3weekly CAPOX
219648794|NCT05356533|BEHAVIORAL|Drinking to Cope CBT skills|Young adults who drink to cope with negative affect will receive 8 web-based modules with cognitive behavioral skills
219648795|NCT03785613|DRUG|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
219648796|NCT03785613|DRUG|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
218962539|NCT02963831|DRUG|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
218962540|NCT02963831|DRUG|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
218962541|NCT05036720|BEHAVIORAL|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
218962542|NCT05036720|BEHAVIORAL|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
218962543|NCT01943708|DEVICE|SPAP|Novel Auto-algorithm for Auto-CPAP device
218962544|NCT01943708|DEVICE|CPAP|Standard CPAP therapy
218962545|NCT02382250|BEHAVIORAL|Survey|Survey will be given to all participants
219648797|NCT03785613|DRUG|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
219648798|NCT03785613|DRUG|Matching placebo patch to T1|Placebo patch to T1.
219648799|NCT03785613|DRUG|Matching placebo patch to T2|Placebo patch to T2.
219648800|NCT03785613|DRUG|Matching placebo patch to R|Placebo patch to R.
219648801|NCT03595813|PROCEDURE|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
219648802|NCT03595813|PROCEDURE|Biopsy collection|Optional biopsy collection at baseline and progression
219648803|NCT02898324|OTHER|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
219648804|NCT01192113|DRUG|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
219648805|NCT01192113|DRUG|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
219648806|NCT01192113|DRUG|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
219648807|NCT01254838|BIOLOGICAL|HLA-A02 restricted HIG2|
219062183|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
219062184|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
219648808|NCT03195023|DRUG|Lisinopril|
219648809|NCT03195023|DRUG|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
219648810|NCT01279070|BEHAVIORAL|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
219648811|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
219648812|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
219648813|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
219648814|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
219648815|NCT05115188|DIETARY_SUPPLEMENT|Dex4/ dextrose|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
219648816|NCT05115188|DIETARY_SUPPLEMENT|Glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
219648817|NCT06002529|OTHER|HFR|patient received HFR treatment
218962546|NCT03315091|DRUG|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
219648818|NCT05139303|DEVICE|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: \> 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI \>5 events/hour with OSA associates symptoms.
219648819|NCT05535075|DEVICE|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg\*h/L
219648820|NCT05535075|DRUG|Vancomycin|Vancomycin treatment
218962547|NCT03315091|DRUG|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
218962548|NCT04224883|PROCEDURE|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
219062185|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
219062186|NCT04543929|BEHAVIORAL|exercise|partially supervised and home-based exercise activity
219062187|NCT01304836|DRUG|Advagraf|oral
219062188|NCT01304836|DRUG|Mycophenolate Mofetil|oral
219648821|NCT02754687|DRUG|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
219648822|NCT02754687|DRUG|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
219648823|NCT03013907|BEHAVIORAL|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
219648824|NCT03013907|BEHAVIORAL|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
219648825|NCT06436898|DEVICE|Combined overground gait exoskeleton and FES applied to lower limb|Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.
219648826|NCT06436898|DEVICE|Overground gait exoskeleton|Gait rehabilitation for persons with stroke, with an overground exoskeleton.
219062189|NCT01304836|DRUG|Simulect|IV
219062190|NCT01304836|DRUG|Corticosteroids|IV \& oral
219648827|NCT03723161|DEVICE|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
219648828|NCT02938988|PROCEDURE|Antimicrobial photodynamic therapy|Described in arm/group
219648829|NCT02938988|PROCEDURE|Scaling and root planning|Described in arm/group
219648830|NCT02938988|DEVICE|red laser|658nm; 0.1W; 2229J/cm², 10s per point
219648831|NCT02938988|DRUG|methylene blue dye|
219648832|NCT04865601|OTHER|resectomy of the colon|The patient scheduled for colon resectomy are included in the study
219648833|NCT06668857|DIAGNOSTIC_TEST|video-oculography|All participants will receive quantitative oculomotor and pupillomotor measurements using two different video-oculography devices. Thereby both pursuit eye movements, saccades and pupillary responses to light will be assessed. In addition, there will be a quantitative assessment of the angular vestibulo-ocular reflex (aVOR) by use of video-head-impulse testing and a hearing test.
219648834|NCT02895113|DRUG|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
219648835|NCT02895113|OTHER|Placebo|Patients in this arm will be treated with placebo
219648836|NCT03764826|DEVICE|CAABT|The sound generators with CAABT will be used 15 min each session, three times a day
219648837|NCT03764826|DEVICE|TMT|The sound generators with TMT will be used 15 min each session, three times a day
219648838|NCT04613141|DEVICE|WalkingTall-PD|Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
219648839|NCT04613141|OTHER|Mobility-plus|Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
219648840|NCT00154778|DRUG|Taxol, UFT,Leucovorin|
219648841|NCT03645746|DRUG|REGN5069|REGN5069 will be administered by IV infusion or SC injection
219648842|NCT03645746|DRUG|Placebo|Placebo-matching REGN5069
219648843|NCT06243367|OTHER|Placebo drink|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
219648844|NCT06243367|DIETARY_SUPPLEMENT|Carbohydrate|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
219648845|NCT04603768|OTHER|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
218962549|NCT04224883|PROCEDURE|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
218962550|NCT04224883|PROCEDURE|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
218962551|NCT01606254|DRUG|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
218962552|NCT04766372|OTHER|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
218962553|NCT04543409|BIOLOGICAL|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
218962554|NCT04543409|BIOLOGICAL|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
218962555|NCT03977454|PROCEDURE|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
218962556|NCT03977454|PROCEDURE|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1\. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
218962557|NCT03977454|DRUG|Ropivacaine|60 ml 0.2% ropivacaine
218962558|NCT03977454|DRUG|Dex|10 mg DEX/ 80 mg MPA
218962559|NCT02147912|OTHER|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
218962560|NCT05584371|DIETARY_SUPPLEMENT|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
218962561|NCT00477581|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
219648846|NCT04603768|OTHER|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
219648847|NCT04603768|OTHER|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
219648848|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at high intensity (HI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 85% of the one-repetition maximum per exercise (high load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
219648849|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate-high intensity (MHI-bands)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
219648850|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate intensity (MI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 65-70% of the one-repetition maximum per exercise (moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
218962562|NCT00477581|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
218962563|NCT02563132|PROCEDURE|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
218962564|NCT02093026|DRUG|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
218962565|NCT02093026|DRUG|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
218962566|NCT02093026|DRUG|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
219062191|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
219062192|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
218962567|NCT02093026|DRUG|Folic Acid|Participants will receive folic acid \>= 5 mg/week or equivalent.
218962568|NCT03493659|BEHAVIORAL|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
218962569|NCT03493659|BEHAVIORAL|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
218962570|NCT03493659|BEHAVIORAL|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
218962571|NCT06143111|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
218962572|NCT06143111|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
218962573|NCT04365257|DRUG|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
218962574|NCT04365257|OTHER|Standard of care|Participants in this arm will receive standard of care.
219062193|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
219062194|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
219062195|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
219062196|NCT04182425|OTHER|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
219062197|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
219648851|NCT06618469|BEHAVIORAL|Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic tubes equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase)
219648852|NCT06618469|BEHAVIORAL|Water-based resistance training program at moderate intensity (WMI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
219648853|NCT03734146|BEHAVIORAL|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
219648854|NCT03734146|BEHAVIORAL|Resistance Exercise|180 minutes of resistance exercise per week
218962575|NCT00518973|DRUG|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
218962576|NCT00518973|DRUG|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
218962577|NCT04744038|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
218962578|NCT06329843|DEVICE|Picterus Jaundice Pro (JP)|"Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw)."
218962579|NCT02218983|DEVICE|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
218962580|NCT02218983|OTHER|Usual care|
218962581|NCT05953376|DRUG|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
218962582|NCT00501579|DRUG|Difluprednate|
218962583|NCT00501579|DRUG|Prednisolone Acetate|
218962584|NCT02129777|DRUG|Namilumab|Namilumab subcutaneous injection
218962585|NCT02129777|DRUG|Placebo|Placebo subcutaneous injection
218962586|NCT00415454|GENETIC|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
218962587|NCT01001299|DRUG|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
218962588|NCT01001299|DRUG|RO5185426|960 mg orally twice daily
218962589|NCT01754909|DRUG|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
218962590|NCT01754909|DRUG|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
218962591|NCT04081233|PROCEDURE|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
218962592|NCT04081233|PROCEDURE|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
218962593|NCT00822809|DRUG|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
218962594|NCT00822809|DRUG|Prednisolone|25 mg premedication
219062198|NCT04413604|OTHER|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
219648855|NCT03734146|BEHAVIORAL|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
219648856|NCT02089958|PROCEDURE|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
219648857|NCT05988463|DRUG|Artesunate Oral Product|Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
219648858|NCT04114331|OTHER|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
219648859|NCT00514644|OTHER|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
219648860|NCT00514644|OTHER|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
219648861|NCT06356844|DIETARY_SUPPLEMENT|Resolvin supplement|Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
219648862|NCT05730244|DRUG|Cassia alata extract|1 ml Cassia alata extract
219648863|NCT05730244|DRUG|Placebo|1 ml placebo solution
219648864|NCT00031681|DRUG|7-hydroxystaurosporine|Given IV
219648865|NCT00031681|DRUG|irinotecan hydrochloride|Given IV
219648866|NCT00031681|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219648867|NCT00402558|DRUG|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
219648868|NCT00402558|DRUG|Busulfan|130 mg/m\^2 By Vein Over 3 Hours x 4 Days
219648869|NCT00402558|DRUG|Fludarabine|40 mg/m\^2 By Vein Over 30 Minutes x 4 Days
219648870|NCT00402558|PROCEDURE|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
219648871|NCT00402558|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 x 109/L for 3 consecutive days.
219648872|NCT00402558|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
219648873|NCT00402558|DRUG|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
219648874|NCT00402558|DRUG|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
219062199|NCT04481347|DEVICE|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
219648875|NCT01687465|PROCEDURE|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
219648876|NCT01687465|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
219648877|NCT03683693|DIAGNOSTIC_TEST|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT \< 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT \< 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
219648878|NCT01220765|DEVICE|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 \> 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
219648879|NCT00395941|DRUG|Pioglitazone|
219648880|NCT00395941|DRUG|Acitretin|Acitretin
219648881|NCT02989779|DRUG|NK1 Antagonist|
219648882|NCT02989779|DRUG|Placebo Oral Capsule|
219648883|NCT05367284|DRUG|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
219648884|NCT02822573|DRUG|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
219648885|NCT02822573|DRUG|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
219062200|NCT04481347|OTHER|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
219062201|NCT04481347|DEVICE|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
219648886|NCT04971148|OTHER|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
219648887|NCT04971148|OTHER|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
219207857|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular in children with OBPP with deficiency of Shoulder External Rotation|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve in children with OBPP presented with deficiency of Shoulder External Rotation.
219648888|NCT04971148|OTHER|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
219648889|NCT04971148|OTHER|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set 2 times of patient peak tidal inspiratory flow
219648890|NCT02275780|DRUG|Doravirine|Doravirine 100 mg tablet administered p.o. q.d.
219648891|NCT02275780|DRUG|Darunavir|Darunavir 800 mg tablet administered p.o. q.d.
218962595|NCT01784627|BEHAVIORAL|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
218962596|NCT01565499|DRUG|Nab-paclitaxel|
218962597|NCT00977808|DEVICE|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
218962598|NCT00977808|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
218962599|NCT06169228|DEVICE|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
218962600|NCT02004392|DRUG|EVP-6124|
219648892|NCT02275780|DRUG|Ritonavir|Ritonavir 100 mg tablet administered p.o. q.d.
219648893|NCT02275780|DRUG|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
219648894|NCT03960866|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
219648895|NCT03960866|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
219648896|NCT05465265|BEHAVIORAL|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
218962601|NCT00781508|DRUG|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
218962602|NCT00781508|OTHER|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
218962603|NCT01923168|DRUG|alpelisib|BYL719 + Letrozole
218962604|NCT01923168|DRUG|buparlisib|BKM120 + Letrozole
218962605|NCT01923168|DRUG|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
218962606|NCT03418571|BIOLOGICAL|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
219648897|NCT02855359|DRUG|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
219648898|NCT02855359|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
218962607|NCT03418571|OTHER|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
219648899|NCT02855359|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
219648900|NCT02855359|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
218962608|NCT04325399|OTHER|Volitional help sheet|
219062202|NCT03895060|DEVICE|autogenous ring blockls with GBR covered by collagen membrane|"* A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
219062203|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
219062204|NCT05759598|OTHER|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
219062205|NCT05759598|OTHER|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
219062206|NCT00899223|OTHER|biologic sample preservation procedure|
219062207|NCT03067441|DRUG|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
219062208|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
219062209|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
219062210|NCT00723177|DRUG|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
219062211|NCT00723177|DRUG|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
219648901|NCT02855359|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
219648902|NCT02855359|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
218962609|NCT06418464|DEVICE|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
218962610|NCT00847639|DRUG|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
219062212|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
219062213|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
219207858|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve|Just to assess clinical outcomes after Neurotization of spinal accessory nerve to Supra-Scapular Nerve in patients with deficiency of Shoulder External Rotation
218962611|NCT02376829|DEVICE|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
218962612|NCT00006367|BIOLOGICAL|filgrastim|
219648926|NCT01864876|BIOLOGICAL|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
219648927|NCT01864876|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
219648928|NCT01864876|BIOLOGICAL|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
219648929|NCT05901012|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
219648930|NCT05901012|DRUG|Placebo|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
219648931|NCT04403503|DRUG|Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
219648932|NCT04403503|DRUG|Cyanoacrylate, Isobutyl|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
219648933|NCT02190032|DEVICE|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
219648934|NCT02190032|DEVICE|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
219648935|NCT04430842|DRUG|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
219648936|NCT05531578|DEVICE|INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)|Transfemoral implantation of the INOVARE® transcatheter valve
219648937|NCT01864915|DRUG|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
219648938|NCT01864915|PROCEDURE|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
219648939|NCT00738881|DRUG|Erlotinib Hydrochloride|Given PO
219648940|NCT00738881|DRUG|Pemetrexed Disodium|Given IV
219648941|NCT06365008|DRUG|Sintilimab+irinotecan+leucovorin folinate+fluorouracil|sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
219648942|NCT04212208|DEVICE|IV cannulation|IV cannulation in the preoperative period
219648943|NCT00348790|DRUG|vatalanib|
219648944|NCT06410703|DRUG|CAN1012|CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
219648945|NCT04303533|DEVICE|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
219648946|NCT00387751|BIOLOGICAL|Bevacizumab|Given IV
219648947|NCT00387751|OTHER|Laboratory Biomarker Analysis|Correlative studies
219648948|NCT00387751|OTHER|Pharmacological Study|Correlative studies
219648949|NCT00387751|DRUG|Sorafenib Tosylate|Given orally
219648950|NCT02733354|DEVICE|watch viedo|
219648951|NCT03081559|BEHAVIORAL|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
218962613|NCT00006367|DRUG|busulfan|
219648952|NCT06646159|BEHAVIORAL|REThink Intervention|"At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention."
219648953|NCT02809859|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
219648954|NCT05735314|OTHER|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
218962614|NCT00006367|DRUG|cytarabine|
218962615|NCT00006367|DRUG|idarubicin|
218962616|NCT00006367|PROCEDURE|peripheral blood stem cell transplantation|
219648955|NCT05735314|OTHER|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
219648956|NCT06022614|DRUG|Use Bupivacaine 0.25% Injectable Solution|Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.
218962617|NCT05846477|DEVICE|MySpine|patient specific guide for screw positioning
218962618|NCT03348787|BEHAVIORAL|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
218962619|NCT03614767|DIAGNOSTIC_TEST|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
218962620|NCT05110547|BIOLOGICAL|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
218962621|NCT05644847|OTHER|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
219207859|NCT06847347|BEHAVIORAL|More Than Words®|More Than Words® (MTW) is a 13-week parent-implemented program designed to enhance communication, play development, and parent-child interaction for children under 4 years of age who have autism or social communication challenges. MTW is delivered by speech-language pathologists (SLPs) certified by The Hanen Centre, a global not-for-profit organization based in Toronto. MTW is delivered virtually in this trial. The program an orientation session, an individual pre-program consultation appointment, 8 x 2½ hour group training sessions (with 6-8 parents per group), and 3 individual video feedback sessions. During video feedback, the parent demonstrates use of communication facilitation strategies with their child, while the SLP records the interactions. The parent and SLP then review the videos together, analyze use of the strategies and how the child responded, and formulate plans to foster development of new skills.
219207860|NCT06839326|BIOLOGICAL|Autologous Conditioned Serum, Genesis Biyomedikal, Sanakin®-Acrs produce|Arthrocentesis and 1ml ACS injection will be performed twice in total, two weeks apart.
219648957|NCT06022614|DRUG|Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine|Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
219648958|NCT06051123|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day.
219648959|NCT06051123|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
219648960|NCT02032381|OTHER|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
219648961|NCT06424990|OTHER|balance training with TENS|children will receive Biodex balance training with TENS for 30 minutes a day, 5 days per week for 4 weeks
219648962|NCT06424990|OTHER|Balance training with placebo TENS|children will receive Biodex balance training with placebo TENS for the same period.
219648963|NCT03074435|DEVICE|Indoor residual sprayings|Houses will be spayed with this formulation containing Pyrimiphos methyl.
219648964|NCT03074435|DEVICE|Larvicide|Larval breeding sites will be treated with larvicide
219648965|NCT03074435|BEHAVIORAL|BCC|
219648966|NCT03074435|BIOLOGICAL|Ivermectin|
219648967|NCT04586738|PROCEDURE|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
219648968|NCT04305249|DRUG|ATG-017|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
219648969|NCT04305249|DRUG|ATG-017+Nivolumab|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
219648970|NCT04712019|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric at 125mmHg of continuous negative pressure on a closed surgical incision
219648971|NCT04712019|DEVICE|Standard Silver-containing Dressing|A standard silver-containing dressing applied to a closed surgical incision
219648972|NCT06577519|DRUG|Vicagrel|Vicagrel loading followed by Maintenance dose
219648973|NCT06577519|DRUG|Clopidogrel|Clopidogrel loading followed by Maintenance dose
219648974|NCT01646021|DRUG|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
219648975|NCT01646021|DRUG|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
219648976|NCT05888441|OTHER|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
219648977|NCT04521621|BIOLOGICAL|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
219648978|NCT04521621|DRUG|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
219648979|NCT01282164|PROCEDURE|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
219648980|NCT01282164|PROCEDURE|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
219648981|NCT06540664|OTHER|Auricular Acupuncture needles|Auricular Acupuncture needles 5 days in 2 weeks
219648982|NCT06540664|OTHER|Sham Auricular Acupuncture needles|Sham Auricular Acupuncture needles 5 days in 2 weeks
219648983|NCT00485043|BEHAVIORAL|Modified T'ai Chi: T'ai Chi for Arthritis|
219648984|NCT04525079|DRUG|CT-P59|CT-P59 will be administered
219648985|NCT04525079|DRUG|Placebo|Placebo-matching CT-P59
219648986|NCT01663779|PROCEDURE|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
219648987|NCT01663779|PROCEDURE|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
219648988|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.1%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
219648989|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|IVW-1001 Ophthalmic Eyelid Wipe 0.2%
219648990|NCT06400459|DRUG|IVW-1001 Placebo|IVW-1001 Placebo
219648991|NCT00438100|DRUG|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
219207861|NCT06839326|BIOLOGICAL|Platelet Rich Plasma|Arthrocentesis and 1ml PRP injection will be performed twice in total, two weeks apart.
219207862|NCT06839326|OTHER|Control Group/ Only Arthrocentesis|Arthrocentesis will be performed twice in total, two weeks apart.
219207863|NCT06772727|DRUG|Lidocaine|After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)
219648992|NCT00438100|DRUG|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
219648993|NCT03140332|OTHER|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
219648994|NCT06618742|PROCEDURE|Cryotherapy|Focal cryoballoon ablation, 1-3 treatments with an interval of 1-3 weeks
219648995|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
219648996|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
219648997|NCT02316899|DRUG|linaclotide|Oral administration once daily
219648998|NCT02316899|DRUG|Placebo|Oral administration once daily
219648999|NCT03108170|OTHER|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
219649000|NCT03108170|OTHER|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
219649001|NCT03108170|OTHER|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
219649002|NCT01570270|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
219649003|NCT02581475|PROCEDURE|Extending withdrawal time in the proximal colon|
219649004|NCT02581475|PROCEDURE|Segmental examination twice of the proximal colon|
219649005|NCT03450785|OTHER|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
218962622|NCT05644847|PROCEDURE|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
218962623|NCT01255787|DRUG|Vortioxetine|Vortioxetine tablets
218962624|NCT01255787|DRUG|Placebo|Vortioxetine placebo-matching tablets
218962625|NCT04443751|DRUG|SHR-1702|SHR-1702 monotherapy, administered IV
218962626|NCT01866553|DRUG|Nilotinib|300 mg capsule BID oral use
218962627|NCT01866553|DRUG|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
218962628|NCT01261832|DRUG|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
218962629|NCT03085277|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
218962630|NCT03085277|DIETARY_SUPPLEMENT|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
218962631|NCT03249493|OTHER|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL"
218962632|NCT03381157|OTHER|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
218962633|NCT05695664|DRUG|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
219062214|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
219207864|NCT06772727|DRUG|Fentanyl|After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).
219207865|NCT06772727|DRUG|Propofol|After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously
219207866|NCT06772727|DRUG|Succinyl choline|After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.
219207867|NCT06748300|BEHAVIORAL|web- based education|breastfeeding education
219207868|NCT06774157|OTHER|A session combining motor imagery and listening to low frequency sounds|Prospective study of the efficacy of the Allyane procedure after knee sprain
219207869|NCT06774157|OTHER|Standard management - Control group|Active extension (e.g. by lateral raising of the quadriceps, strengthening of the quadriceps) quadriceps)
219207870|NCT06774157|OTHER|Standard management - Control group|Flexor inhibition (e.g. massage, hamstring stretching)
219649006|NCT04001387|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
219649007|NCT03585153|OTHER|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
219649008|NCT05845567|DRUG|Givinostat|ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
219207871|NCT06774157|OTHER|Standard management - Control group|Active flexion (e.g. strengthening the flexors)
219649009|NCT05845567|DRUG|Clarithromycin|Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
219649010|NCT06098872|DRUG|Trametinib tablet|Drug is supplied in 2mg and 0.5 mg tablets
219649011|NCT00226668|DRUG|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
219649012|NCT00226668|DRUG|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
219649013|NCT03861312|BEHAVIORAL|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
219649014|NCT03861312|BEHAVIORAL|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
219649015|NCT01757912|PROCEDURE|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
219649016|NCT04424212|BEHAVIORAL|Intervention group CoronaCope|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
219649017|NCT06420934|OTHER|Drying procedure after surgical handwashing|Participants will dry their hands with one surgical towel
219649018|NCT00725608|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
219649019|NCT00004087|BIOLOGICAL|filgrastim|as prescribed by physician
219649020|NCT00004087|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
218962634|NCT05695664|DRUG|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
218962635|NCT03642093|COMBINATION_PRODUCT|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
218962636|NCT03642093|BEHAVIORAL|Physical Activity Intervention|Walking and Inspiratory Muscle Training
218962637|NCT03549403|BEHAVIORAL|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
219062215|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
219062216|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
219649021|NCT00004087|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
219649022|NCT00004087|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
219649023|NCT00004087|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
219649024|NCT06622915|DEVICE|Tissue Doppler imaging and Conventional Echocardiography|non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum
218962638|NCT03742908|DRUG|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
218962639|NCT05041530|DEVICE|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
218962640|NCT01733927|DEVICE|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
218962641|NCT03221075|OTHER|Registry|There is no intervention.
218962642|NCT03582644|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
219649025|NCT04775901|OTHER|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
219649026|NCT04775901|DEVICE|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
219649027|NCT04558567|DRUG|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
219649028|NCT04697004|DEVICE|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
219649029|NCT04697004|DEVICE|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
219649030|NCT06623539|DRUG|Pemafibrate high dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, two tablets per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 2 tablets 1 or 0.4 mg for 1 tablet 1 can be substituted.
219649031|NCT06623539|DRUG|Pemafibrate low dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, one tablet per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 1 tablets 1 can be substituted.
219649032|NCT06623539|DRUG|Fenofibrate|Fenofibrate 53.3 mg tablets shall be administered orally once daily, one tablet per dose, after breakfast. Thereafter, the dose may be carefully increased to two tablets per dose at the physician\&amp;#39;s discretion.
219649033|NCT05965635|OTHER|Ixodus scapularis nymphs|Tick challenge
219649034|NCT04402996|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
219649035|NCT04402996|OTHER|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
219649036|NCT03409107|DRUG|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
219649037|NCT03409107|DRUG|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
219649038|NCT03409107|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
218962643|NCT05837143|BIOLOGICAL|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
219062217|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
219062218|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
219062219|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
219062220|NCT01465893|DRUG|Vitamin D|vitamin D ,50000 unit /week
219062221|NCT01465893|DRUG|Vitamin D withheld|do not receive anything
218962644|NCT00857402|DIETARY_SUPPLEMENT|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
218962645|NCT00857402|DIETARY_SUPPLEMENT|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
218962646|NCT00965510|BEHAVIORAL|care coordination|patients receive care coordination to improve their type II diabetes
218962647|NCT03882008|DRUG|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
218962648|NCT05658536|BEHAVIORAL|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
218962649|NCT03156361|DRUG|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
218962650|NCT03156361|DRUG|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
218962651|NCT00848003|DRUG|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
219649039|NCT00247078|BIOLOGICAL|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
219649040|NCT00247078|BIOLOGICAL|Placebo|
219649041|NCT05010512|DEVICE|Delefilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
219649042|NCT05010512|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
219649043|NCT04842188|PROCEDURE|L-PRF with aPDT|surgical open flap debridement followed by L-PRF with aPDT
219649044|NCT04842188|PROCEDURE|L-PRF|surgical open flap debridement followed by L-PRF alone
219649045|NCT00169715|PROCEDURE|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
219649046|NCT00675168|RADIATION|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
219649047|NCT00422344|DRUG|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
219649048|NCT04417192|DRUG|Olaparib|Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
219649049|NCT04417192|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
219649050|NCT01846481|DRUG|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
219649051|NCT01846481|DRUG|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
219649052|NCT01846481|DRUG|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
219649053|NCT01846481|DRUG|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
219649054|NCT03359486|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
219649055|NCT03359486|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
219649056|NCT00866086|OTHER|questionnaire administration|
219649057|NCT00866086|PROCEDURE|computed tomography|
219649058|NCT00866086|RADIATION|radiation therapy treatment planning/simulation|
219649059|NCT01885286|PROCEDURE|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
219649060|NCT05234086|COMBINATION_PRODUCT|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
219649061|NCT05234086|PROCEDURE|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
219649062|NCT00136435|DRUG|prednisone|Induction Phase: Given orally on days 1-28
219649063|NCT00136435|DRUG|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
219062222|NCT05319327|OTHER|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
219649064|NCT00136435|DRUG|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
219649065|NCT00136435|DRUG|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
219649066|NCT00136435|DRUG|asparaginase|Induction: Given into the muscle on day 5
219649067|NCT00136435|DRUG|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
219649068|NCT00136435|RADIATION|cranial radiation|Given in 10 daily treatments during CNS therapy phase
219649069|NCT00136435|DRUG|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
219649070|NCT00136435|DRUG|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
219649071|NCT00136435|DRUG|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
219649072|NCT00136435|DRUG|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
219649073|NCT00136435|DRUG|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
219649074|NCT00864825|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
219649075|NCT06002139|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
219649076|NCT06002139|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~* Two hours of kinesiotherapy (120 minutes, including gait training).~* Thirty minutes of ergotherapy.~* Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
219649077|NCT06621303|BIOLOGICAL|Diabetic foot ulcer treatment|The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.
219649078|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
219649079|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
219649080|NCT04724902|OTHER|Elastic bandage compression|The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
219649081|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
219649082|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
219649083|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
219649084|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
219649085|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
219649086|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
219649087|NCT00567385|DRUG|somatropin|
219649088|NCT04430231|OTHER|Wait list time|
219649089|NCT00312065|DEVICE|Application of reflective heat shield to thermistor probe|
219649090|NCT00828074|DRUG|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
218962652|NCT00848003|DRUG|Placebo|Strawberry flavored yogurt
218962653|NCT02506569|DEVICE|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
218962654|NCT02506569|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
219062223|NCT05319327|OTHER|Control|General counseling to adhere to a healthy Mediterranean diet
219062224|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
219062225|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
219062226|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
219062227|NCT00931177|OTHER|weight|weight and dehydration scores
219062228|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
219062229|NCT06535126|DRUG|CanProFem-AK|Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
219062230|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
218962655|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
218962656|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
219062231|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
219062232|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
219062233|NCT00043446|DRUG|intravenous T900607-sodium|
218962657|NCT02875925|OTHER|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
218962658|NCT01411930|DRUG|Intramuscular olanzapine, aripiprazole|"1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
218962659|NCT01411930|DRUG|Intramuscular aripiprazole, olanzapine|"1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
218962660|NCT05509946|DRUG|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
218962661|NCT05509946|DRUG|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
218962662|NCT05509946|DRUG|Placebo|Placebo
219649091|NCT00828074|DRUG|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
219649092|NCT02512081|OTHER|No intervention applied|No intervention applied
219649093|NCT06682312|DEVICE|Non-invasive blood pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
219649094|NCT00224146|DRUG|oxybutynin transdermal delivery system (Oxytrol(r))|
219649095|NCT05221268|OTHER|Level walking exercise|treadmill exercise with 0 inclination
218962663|NCT02499458|OTHER|None- observational study|
219062234|NCT06341218|OTHER|Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management|"The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed."
219062235|NCT02332486|DRUG|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
219062236|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
219062237|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
219649096|NCT05221268|OTHER|Downhill exercise|treadmill exercise with -20 inclination
219649097|NCT03747068|DRUG|Anti-TNF Drug|
219649098|NCT03219359|PROCEDURE|Autologous stem cell transplant|Hematopoietic stem cell transplantation
219649099|NCT03219359|DRUG|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
219649100|NCT03219359|DRUG|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
218962664|NCT04447612|DRUG|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
218962665|NCT04447612|DRUG|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
218962666|NCT04447612|DRUG|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
218962667|NCT02200783|DEVICE|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
218962668|NCT02200783|DEVICE|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
218962669|NCT02200783|DEVICE|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
218962670|NCT03500471|PROCEDURE|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
219062238|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
219649101|NCT03219359|DRUG|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
219649102|NCT03219359|DRUG|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
219649103|NCT03219359|DRUG|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
219649104|NCT05225675|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
219649105|NCT05225675|OTHER|Placebo|Intravenous administration of placebo
219649106|NCT05784974|DRUG|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
219649107|NCT01011166|DRUG|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
219649108|NCT01011166|DRUG|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
219649109|NCT01011166|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
219649110|NCT01011166|DRUG|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
219649111|NCT01264666|DIETARY_SUPPLEMENT|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
219649112|NCT01264666|DIETARY_SUPPLEMENT|Chinese Meijiao liquor|
218962671|NCT03500471|PROCEDURE|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
218962672|NCT05153473|DEVICE|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
218962673|NCT00176722|OTHER|table tilt|One group randomized to table tilt. One group will be flat.
218962674|NCT01796496|OTHER|Manipulative Therapy Techniques|"* Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
218962675|NCT01796496|OTHER|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
219062239|NCT02921412|DEVICE|fanfilcon A|contact lens
219062240|NCT00534729|DRUG|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
219062241|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
219062242|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
219062243|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-5 minutes|
219062244|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-1 minute|
219649113|NCT01264666|DIETARY_SUPPLEMENT|Water control|
219649114|NCT04987099|DIETARY_SUPPLEMENT|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
219649115|NCT04987099|DIETARY_SUPPLEMENT|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
219649116|NCT00858299|DRUG|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
219649117|NCT05481593|BEHAVIORAL|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
219062245|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
219649118|NCT05481593|BEHAVIORAL|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
219649119|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
219649120|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
219649121|NCT00258349|DRUG|vorinostat|Given orally
219649122|NCT00258349|DRUG|trastuzumab|Given IV
219649123|NCT01028638|OTHER|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
219649124|NCT01152359|BEHAVIORAL|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
219649125|NCT01152359|BEHAVIORAL|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
219649126|NCT01914575|DEVICE|Mapping with the Acutus Medical System followed by Ablation|
219649127|NCT03089671|OTHER|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
219649128|NCT03089671|OTHER|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
219649129|NCT03419598|PROCEDURE|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
219649130|NCT03419598|DEVICE|Personalised subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
219649131|NCT03419598|DEVICE|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
219649132|NCT04205409|BIOLOGICAL|Nivolumab|Given IV
219649133|NCT02945397|BEHAVIORAL|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
219649134|NCT02945397|BEHAVIORAL|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
219649135|NCT03179293|DRUG|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
219649136|NCT03179293|DRUG|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
219649137|NCT02474589|DRUG|tecovirimat|Study is based on Animal Regulatory Rule
219649138|NCT02474589|OTHER|Placebo|Does not apply
219649139|NCT06619262|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
218962676|NCT05407610|PROCEDURE|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
218962677|NCT05407610|PROCEDURE|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
218962678|NCT05407610|PROCEDURE|Sham procedure|Sham procedure with placing of needles subcutaneously.
218962679|NCT00014027|DRUG|Docosahexaenoic acid (DHA)|
219062246|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
219062247|NCT06336070|BEHAVIORAL|HIIT program (8 weeks)|Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
219062248|NCT06336070|BEHAVIORAL|MPI program (8 weeks)|Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
219062249|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
219649140|NCT06619262|DEVICE|Neuromuscular and Muscular Electrical Stimulation|Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
219649141|NCT06619262|OTHER|Exercise program|Specific exercise program for patients with lower extremity hemiparesis after stroke
219649142|NCT01740128|DEVICE|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
219649143|NCT01740128|OTHER|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
219649144|NCT06631482|DEVICE|Maintain HPI < 85|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
219649145|NCT06631482|DRUG|Maintain MAP>=73|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
219649146|NCT02999529|OTHER|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
219649147|NCT04388904|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
219649148|NCT05685862|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
219649149|NCT04108494|PROCEDURE|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
219649150|NCT06385691|OTHER|myDIET software tool|"The tool is based on self-questionnaires completed by the patient. They are mainly filled in using visual analogue scales (from 0-10) or grades of symptoms/toxicities (Grades 0 to 4), based on the CTCAE V5. These scales will cover the following themes: food intake, weight changes, digestive symptoms, taste disorders, pain and fatigue. The system will be able to monitor data changes and the response given will be adapted according to the severity of symptoms:~* No signs of seriousness: general prevention or treatment documents/advice: toxicity management, nutritional advices targeted on symptoms, on digestive problems, on appropriate physical activity.~* Presence of signs of seriousness: action to be taken and alert to the coordinating nurse, oncologist or dietician.~In case of an alert, the coordinating nurse will call the patient back and either manage the symptom, schedule a nutritional consultation to initiate nutritional management, or refer the patient to the oncologist."
219649151|NCT06623604|BEHAVIORAL|Experimental: Physical activity program|"In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity."
219649152|NCT00809640|BEHAVIORAL|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
219649153|NCT06471946|DRUG|Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT|"Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9"
219649154|NCT01223469|DEVICE|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
219649155|NCT03455010|OTHER|Increased load|Participants walk with 120% body weight achieved with a weight vest
218962680|NCT00014027|DRUG|Eicosapentaenoic acid|
219649156|NCT03455010|OTHER|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
219649157|NCT01692210|DRUG|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
218962681|NCT06386731|OTHER|Intermittent Phototherapy|2-hour phototherapy application in the intervention group
218962682|NCT01902251|DRUG|Enzalutamide tablet|Oral
218962683|NCT01902251|DRUG|Enzalutamide capsule|Oral
218962684|NCT03519386|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
218962685|NCT03519386|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
218962686|NCT03474315|DIAGNOSTIC_TEST|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
218962687|NCT01215864|DRUG|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2"
218962688|NCT04341662|BEHAVIORAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
219649158|NCT06621381|BEHAVIORAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
218962689|NCT04341662|BEHAVIORAL|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
219649159|NCT02719912|DEVICE|mitral valve replacement|transcatheter mitral valve replacement
219649160|NCT03664310|OTHER|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
219649161|NCT03664310|OTHER|Control|Physical health control
219686267|NCT01261390|BEHAVIORAL|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
218962690|NCT05659966|BEHAVIORAL|Plant-based diet|Participants will receive a behavioral intervention on a plant-based diet in partnership with a local restaurant.
218962691|NCT05659966|OTHER|Voucher only|Participants will receive vouchers to a local restaurant. Participants will not attend nutrition classes but will receive a class at the end of the 12-week study.
218962692|NCT00704080|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
218962693|NCT00704080|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
218962694|NCT00485147|PROCEDURE|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
218962695|NCT06533137|OTHER|Neutral ginger-flavored drink described as energizing, hypoglycemic, caffeine-based drink|"It is a neutral ginger-flavored drink with no energizing properties, although it was presented as particularly energizing, hypoglycemic, caffeine-based, and designed to reduce fatigue and improve performance."
218962696|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger flavoured drink described as an energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance.
219649162|NCT03254212|DEVICE|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to \> 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to \< 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
219649163|NCT06298695|BEHAVIORAL|Individual Schema Therapy|"Schema therapy focuses on adapting maladaptive schemas (i.e., core representations of oneself, others or the world) and dysfunctional personality traits, while also incorporating exposure therapy. It consists of a maximum of 40 sessions within one year."
219649164|NCT06298695|OTHER|TAU|Treatment As Usual according to the Dutch Multidisciplinary Guidelines Anxiety Disorders and the Dutch Quality Standard for Anxiety Disorders. TAU often consists of a continuation of Cognitive Behavioral Therapy (CBT) and (different) medications, sometimes in a more treatment-intensive format. There are no restrictions to TAU, except that it may not be schema therapy. The actual content of TAU will be tracked.
219649165|NCT02012738|BEHAVIORAL|FORNET|"8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook"
219649166|NCT02012738|BEHAVIORAL|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
219649167|NCT02012738|OTHER|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
219649168|NCT02012738|OTHER|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
219649169|NCT05186038|DIAGNOSTIC_TEST|iVYCHECK GIP Urine|To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).
219649170|NCT05186038|DIAGNOSTIC_TEST|CeliacDetect|To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
219649171|NCT03470558|OTHER|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
219649172|NCT01944618|DRUG|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
219649173|NCT04902313|BEHAVIORAL|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
219649174|NCT00236158|DEVICE|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
219649175|NCT04933084|BEHAVIORAL|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
219649176|NCT01684579|BEHAVIORAL|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
219649177|NCT01684579|BEHAVIORAL|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
219649178|NCT01684579|BEHAVIORAL|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
218962697|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger-flavored beverage bescribed as a mineral salt-based drink
218962698|NCT03101267|DRUG|ASP4070|Intradermal vaccination at 2-week intervals
218962699|NCT03101267|DRUG|Placebo|Intradermal vaccination at 2-week intervals
218962700|NCT06247683|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
218962701|NCT04414514|DRUG|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
218962702|NCT02470715|GENETIC|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
218962703|NCT03763565|BIOLOGICAL|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
218962704|NCT03763565|OTHER|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
218962705|NCT05027360|DRUG|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
218962706|NCT02854475|PROCEDURE|Venous blood collection|weekly within two weeks
219649179|NCT04113408|OTHER|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
219649180|NCT05839106|DRUG|PM1032 injection|Subjects will receive PM1032 by intravenous administration.
219649181|NCT00189306|DRUG|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
219649182|NCT02658006|PROCEDURE|Cardiac surgery|All cardiac surgery procedures
219649183|NCT00001111|DRUG|Nevirapine|
219649184|NCT00001111|DRUG|Zidovudine|
219649185|NCT06072677|BEHAVIORAL|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
219649186|NCT01735968|DRUG|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
218962707|NCT02854475|PROCEDURE|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
218962708|NCT04178369|OTHER|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
218962709|NCT04178369|OTHER|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
218962710|NCT06020638|DEVICE|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
218962711|NCT06020638|DEVICE|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
219649187|NCT04982068|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
219649188|NCT04982068|BIOLOGICAL|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
219649189|NCT04982068|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
219649190|NCT04982068|OTHER|Placebo|Normal saline solution
219649191|NCT01048112|BIOLOGICAL|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
219649192|NCT02434172|OTHER|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
219649193|NCT02160522|DEVICE|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
218962712|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
218962713|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
218962714|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
218962715|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
218962716|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
218962717|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
218962718|NCT01222403|BIOLOGICAL|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
218962719|NCT01222403|BIOLOGICAL|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
218962720|NCT06082271|DEVICE|Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)|Anti-inflammatory and regenerative effect, 5 mg/ml
218962721|NCT06082271|DRUG|Cortisone|DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
218962722|NCT02063971|OTHER|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
218962723|NCT02064075|DRUG|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
218962724|NCT02064075|DRUG|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
219649194|NCT03640481|DRUG|Belumosudil (KD025)|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
219649195|NCT02835950|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
219649196|NCT06511323|DIAGNOSTIC_TEST|dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases|at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
219207872|NCT06744634|OTHER|Romania group|The questionnaire which was prepared by researchers will be performed by older adults from Romania. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
219207873|NCT06744634|OTHER|Turkey Group|The questionnaire which was prepared by researchers will be performed by older adults from Turkey The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
219207874|NCT06744634|OTHER|Croatia Group|The questionnaire which was prepared by researchers will be performed by older adults from Croatia. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
219649197|NCT06646510|OTHER|traditional exercises|strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand
219649198|NCT06646510|OTHER|sensory electrical stimulation|The stimulated muscles included the flexor carpi radialis (FCR), extensor carpi radialis (ECR), and flexor carpi ulnaris (FCU). Rectangular surface electrodes (Ag/AgCl; 50mm \_ 50mm size) were attached on the motor point of each muscle, i.e., at four fingerbreadths from biceps tendon of FCR, at two fingerbreadths distal from lateral epicondyle for the ECR, at two fingerbreadths volar to ulna at the junction of the upper and middle thirds of the forearm for FCU.14 Portable stimulators will use with the following stimulation settings: constant current (0.2 mA step), 100 Hz stimulation frequency, biphasic pulse, and 300 \_s pulsewidth.
218962725|NCT00910468|PROCEDURE|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
218962726|NCT01362751|OTHER|No intervention|This study is an observational cohort study \> no interventions
218962727|NCT01125501|DIETARY_SUPPLEMENT|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
218962728|NCT02398227|BEHAVIORAL|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
218962729|NCT02398227|BEHAVIORAL|PCT|Present Centered Therapy for PTSD
219649199|NCT05470621|BEHAVIORAL|PlayOn! playground curriculum|A staff and student training to implement a playground curriculum in after-school and recess settings
219649200|NCT00311519|DRUG|Hylenex|
219649201|NCT01329718|OTHER|Blood Sample|Blood sample collection
219649202|NCT02004899|DRUG|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
218962730|NCT02262182|OTHER|KP group|
218962731|NCT02262182|OTHER|KM group|
218962732|NCT03709641|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
218962733|NCT04779931|BEHAVIORAL|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
218962734|NCT00618839|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
218962735|NCT00618839|PROCEDURE|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
218962736|NCT05917769|OTHER|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
219062250|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
219062251|NCT01528228|DEVICE|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
219062252|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
219062253|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
219062254|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
219062255|NCT02579993|PROCEDURE|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
219062256|NCT02579993|PROCEDURE|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
219062257|NCT05198232|BEHAVIORAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
219207875|NCT06741501|PROCEDURE|"C Single Flap Plasty Reconstruction"|"1\. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed. 3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux."
219649203|NCT03395717|DEVICE|Exoskeleton-Assisted Gait Training|
219649204|NCT01250132|OTHER|Biological and behavioral explorations|"Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
219649205|NCT06579937|DRUG|Esketamine hydrochloride|During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
219649206|NCT06579937|DRUG|normal saline|During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
219649207|NCT03081806|DRUG|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
219649208|NCT00311636|DRUG|cyclophosphamide|
219649209|NCT00311636|DRUG|docetaxel|
219649210|NCT00311636|DRUG|doxorubicin hydrochloride|
219649211|NCT00311636|DRUG|epirubicin hydrochloride|
219649212|NCT00311636|DRUG|fluorouracil|
219649213|NCT00311636|DRUG|methotrexate|
219649214|NCT00311636|DRUG|paclitaxel|
219649215|NCT00311636|DRUG|triptorelin|
219649216|NCT00311636|PROCEDURE|adjuvant therapy|
219649217|NCT05492487|DRUG|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
219649218|NCT05492487|DRUG|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
219649219|NCT03944369|OTHER|KB109|KB109 is a novel glycan
219649220|NCT03944369|OTHER|No intervention|No intervention
219649221|NCT00535847|DRUG|Telaprevir|Tablet
219649222|NCT00535847|DRUG|Ribavirin|Tablet
219649223|NCT00535847|DRUG|Pegylated interferon alfa 2a|Solution for Injection
219649224|NCT05454540|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
219649225|NCT04569968|OTHER|Expiratory muscle training|For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
219649226|NCT04911335|COMBINATION_PRODUCT|Faringel plus and oral hygiene|The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
219649227|NCT03375879|DEVICE|Bandage contact lens|Bandage contact lens
219649228|NCT01726387|BEHAVIORAL|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
219649229|NCT01726387|BEHAVIORAL|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
219649230|NCT04887636|OTHER||
219649231|NCT06315478|DRUG|Omeprazole 20 MG Oral Tablet|standard triple therapy for 14 days Bid for each drug
219649232|NCT06315478|DRUG|Amoxicillin 500Mg Tab|Quadruple regimen for 14 days Bid for each drug
219649233|NCT06315478|DRUG|Clarithromycin 500Mg Tab|Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
219649234|NCT01552915|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
219649235|NCT01552915|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
219649236|NCT01552915|DRUG|Placebo|Daily oral dosing in the AM for 8 weeks
219649237|NCT00005072|BIOLOGICAL|Leuvectin|1000 ug of Leuvectin injected intratumorally
219649238|NCT02370667|OTHER|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
219649239|NCT02370667|OTHER|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
219649240|NCT02370667|OTHER|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
219649241|NCT01983072|DIETARY_SUPPLEMENT|Infant formula|
219649242|NCT01983072|OTHER|Breastfeeding|Breastfeeding
219649243|NCT01902758|DRUG|ambrisentan and theophylline|
219649244|NCT01902758|DRUG|placebo|placebo for comparison group
219649245|NCT02987517|OTHER|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
219649246|NCT02987517|OTHER|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
218962737|NCT05917769|OTHER|Postural correction exercises|"* Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
218962738|NCT04598789|OTHER|no intervention|no intervention, observational study
218962739|NCT02747654|GENETIC|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
218962740|NCT00663949|DRUG|Captopril|25 mg captopril tablet q8h
218962741|NCT00663949|DRUG|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
218962742|NCT01028378|DEVICE|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
219649247|NCT02987517|OTHER|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
219649248|NCT02346110|DRUG|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
218962743|NCT04783675|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
218962744|NCT05158647|OTHER|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
218962745|NCT05158647|DRUG|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
218962746|NCT05165589|DEVICE|ActiveInsights accelerometer device|Accelerometer device
218985244|NCT06463405|OTHER|Splinted|The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
219649249|NCT02346110|DRUG|Dexamethasone|4 mg
219649250|NCT02346110|OTHER|Sodium chloride|1 mL of sodium chloride solution as placebo
219649251|NCT02457832|BEHAVIORAL|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
219649252|NCT02457832|BEHAVIORAL|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
219649253|NCT02831985|PROCEDURE|general practice follow-up|Post-surgery follow-up by general practitioner
219649254|NCT02831985|PROCEDURE|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
219649255|NCT05026047|OTHER|HPV self-sampling|HPV self-sampling in HIV-positive women
219649256|NCT05725265|DEVICE|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
218985245|NCT05251766|DRUG|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
219207876|NCT06741501|PROCEDURE|Normal Reconstruction|1\. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.
219649257|NCT05725265|DEVICE|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
219649258|NCT05884424|BEHAVIORAL|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
219649259|NCT04339803|OTHER|rehabilitation intervention|we use lower limb mirror therapy after stroke for two weeks
219649260|NCT02129790|BEHAVIORAL|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
219649261|NCT06268405|GENETIC|Liquid Biopsy|Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
219649262|NCT06268405|DEVICE|Positron Emission Mammography (PEM)|PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
219649263|NCT04221620|DEVICE|Zengar Electroencephalogram (EEG) Neurofeedback device|Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
219649264|NCT03694444|DRUG|AMY-101|C3 complement inhibitor
219649265|NCT03694444|OTHER|Water for injection|Placebo
219649266|NCT03482076|DIAGNOSTIC_TEST|transferrin receptor concentration|Sandwich radio-imunoassay
219649267|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
219062258|NCT05198232|BEHAVIORAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
219649268|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
219649269|NCT00423189|DRUG|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
219649270|NCT00423189|DRUG|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
219649271|NCT01671566|BEHAVIORAL|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
219649272|NCT02546791|DRUG|Dasatinib|
219649273|NCT02028403|DRUG|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
219649274|NCT02028403|DRUG|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
218962747|NCT04673123|OTHER|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
218962748|NCT04673123|OTHER|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
218962749|NCT05623865|OTHER|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
218962750|NCT05623865|OTHER|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
218962751|NCT02642939|DRUG|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
218962752|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
219062259|NCT02073045|OTHER|educational intervention|Receive educational handouts
219062260|NCT02073045|OTHER|lymphedema survey|Ancillary studies
219649275|NCT01818206|OTHER|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
219649276|NCT03170466|BEHAVIORAL|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
219649277|NCT01459718|DRUG|Deferasirox|20-40 mg/kg/day orally, once daily
219649278|NCT01459718|DRUG|Deferoxamine (DFO)|40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
218962753|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
218962754|NCT00701623|DRUG|folder water|patients will receive the application of folder water directly on the injured area
218962755|NCT06258473|COMBINATION_PRODUCT|Multicomponent decentralized care|"1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
218962756|NCT06258473|COMBINATION_PRODUCT|mHealth|Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
218962757|NCT01086839|DRUG|sodium chloride 6%|"* one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days"
218962758|NCT01086839|DRUG|sodium chloride 0,9%|"* one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days"
219649279|NCT01040936|DRUG|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
219649280|NCT01040936|DRUG|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
219649281|NCT00691899|DRUG|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
219649282|NCT00691899|DRUG|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
219649283|NCT04690725|DRUG|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
219649284|NCT05353972|DRUG|IMG-007 or placebo|intravenously administered
219649285|NCT02938624|DRUG|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
219649286|NCT02938624|DRUG|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
218962759|NCT05587465|DEVICE|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
218962760|NCT01262352|DRUG|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
218962761|NCT01262352|DRUG|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
218962762|NCT02153879|DRUG|Fenofibrate|fenofibrate 145/day for 12 weeks
218962763|NCT02153879|DRUG|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
218962764|NCT02792621|DIETARY_SUPPLEMENT|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
218962765|NCT02792621|DIETARY_SUPPLEMENT|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
218962766|NCT00645710|DRUG|gemcitabine hydrochloride|Given IV
218962767|NCT00645710|DRUG|floxuridine|Given via hepatic arterial infusion
218962768|NCT00645710|GENETIC|proteomic profiling|Correlative studies
218962769|NCT00645710|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
218962770|NCT00645710|OTHER|liquid chromatography|Correlative studies
219649287|NCT02938624|DRUG|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
219649288|NCT02938624|DRUG|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
219649289|NCT02938624|PROCEDURE|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
219649290|NCT03840551|OTHER|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
219649291|NCT06463418|DEVICE|Ekoskeleton (Intervention)|Exoskeleton walking three times per week for 12 weeks.
219649292|NCT06463418|OTHER|Relaxation (Comparator)|Relaxation three times per week for 12 weeks.
219649293|NCT01258075|DRUG|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
218962771|NCT00645710|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
218962772|NCT00645710|OTHER|laboratory biomarker analysis|Correlative studies
218962773|NCT00645710|OTHER|mass spectrometry|Correlative studies
218962774|NCT00645710|OTHER|pharmacological study|Correlative studies
218962775|NCT05664698|BEHAVIORAL|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri \& Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
218962776|NCT01185834|DEVICE|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
218985246|NCT05251766|DRUG|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
218985247|NCT02609828|DRUG|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
218985248|NCT01227759|DRUG|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
219649294|NCT01258075|DRUG|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
219649295|NCT01200732|DRUG|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
219649296|NCT02413242|OTHER|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
219649297|NCT01899807|DEVICE|OssDsign AB|
219649298|NCT03367559|BIOLOGICAL|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
219649299|NCT03897114|DIETARY_SUPPLEMENT|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
219649300|NCT03897114|DIETARY_SUPPLEMENT|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
219649301|NCT00651534|DRUG|Ronacaleret|
219649302|NCT00051441|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|
219649303|NCT01023841|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
219649304|NCT01023841|DRUG|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
219649305|NCT04568525|DIAGNOSTIC_TEST|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
219649306|NCT03347344|DRUG|Riluzole|50 mg will be administered (per os) twice a day
219649307|NCT03347344|DRUG|Placebo|50 mg will be administered (per os) twice a day
219649308|NCT01591551|DRUG|Natalizumab (Tysabri)|300 mg IV every 4 weeks
218962777|NCT01063933|DRUG|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
218962778|NCT03989739|DEVICE|Da Vinci|
218962779|NCT02235727|DRUG|GBR 900|
218962780|NCT02235727|DRUG|Placebo|
218962781|NCT02420782|DRUG|ASP6282|oral
218962782|NCT02420782|DRUG|Itraconazole|oral
218962783|NCT02420782|DRUG|Pilocarpine|oral
218962784|NCT02420782|DRUG|Placebo|oral
218962785|NCT02420782|DRUG|Midazolam|oral
218962786|NCT04572360|OTHER|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
218962787|NCT04572360|OTHER|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
218962788|NCT00373061|DRUG|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
218962789|NCT02618356|DRUG|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
218962790|NCT01450904|PROCEDURE|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
218962791|NCT01450904|PROCEDURE|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
218962792|NCT01450904|PROCEDURE|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
218962793|NCT04615585|OTHER|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
218962794|NCT04615585|PROCEDURE|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
218962795|NCT03812627|OTHER|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
218962796|NCT03812627|OTHER|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
218962797|NCT01325220|DRUG|arbaclofen|5 mg bid
218962798|NCT01325220|DRUG|arbaclofen|10 mg bid
218962799|NCT01325220|DRUG|arbaclofen|10 mg tid
218962800|NCT01325220|DRUG|Placebo|tid
218962801|NCT03754231|OTHER|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
218962802|NCT03754231|OTHER|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
219649309|NCT03518970|OTHER|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
219649310|NCT04647656|DEVICE|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
219649311|NCT04647656|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
219649312|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
219649313|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
219649314|NCT00916968|DEVICE|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
219649315|NCT00916968|DEVICE|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
219649316|NCT03488849|DEVICE|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
219649317|NCT03488849|OTHER|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
219649318|NCT02444975|DIETARY_SUPPLEMENT|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
219649319|NCT02444975|OTHER|Coaching program|Coaching program to support increased water intake
219649320|NCT02444975|OTHER|No intervention|No intervention
219649321|NCT06545630|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
219649322|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
219649323|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
219649324|NCT06511362|PROCEDURE|Functional stabilization training|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
219649325|NCT06511362|PROCEDURE|perturbation exercises|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
219649326|NCT04944303|DRUG|Sugammadex|Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
219649327|NCT04944303|DRUG|Normal saline|Equal doseage of normal saline was injected to reverse the NMB.
219649328|NCT05267990|DIAGNOSTIC_TEST|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
219649329|NCT01618019|DIETARY_SUPPLEMENT|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
218962803|NCT00130351|DEVICE|formoterol|
218962804|NCT03091972|PROCEDURE|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
219649330|NCT01618019|DIETARY_SUPPLEMENT|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
219649331|NCT03380104|DEVICE|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
219649332|NCT03380104|BEHAVIORAL|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
219649333|NCT04823793|DIAGNOSTIC_TEST|Stool DNA methylation detection|Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
218962805|NCT03091972|PROCEDURE|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
218962806|NCT03091972|PROCEDURE|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
219062261|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
219062262|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
218962807|NCT00344890|PROCEDURE|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
218962808|NCT01092065|DRUG|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
218962809|NCT01092065|DRUG|Placebo|hard gelatin capsule to be taken bid for six weeks
218962810|NCT04459429|DEVICE|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
218962811|NCT00540371|OTHER|Port wine stain Birthmark|Port wine stain Birthmark
218962812|NCT01975831|DRUG|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
218962813|NCT01975831|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
218962814|NCT05546853|DRUG|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
218962815|NCT05546853|DRUG|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
218962816|NCT05546853|DRUG|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
218962817|NCT05546853|DRUG|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
218962818|NCT05546853|DRUG|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
219062263|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
219062264|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
219062265|NCT03877367|OTHER|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
219062266|NCT02747342|DRUG|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
218962819|NCT00107952|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
218962820|NCT00107952|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
218962821|NCT01216007|DRUG|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
218962822|NCT01216007|DRUG|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
218962823|NCT04074876|DEVICE|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension"
218962824|NCT02702596|OTHER|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
218962825|NCT02702596|BEHAVIORAL|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
218962826|NCT02702596|BEHAVIORAL|Standard Education|The the use of a pamphlet to educate people about depression.
218962827|NCT01401959|DRUG|Eribulin|1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
218962828|NCT01401959|DRUG|Trastuzumab|6 mg/kg IV Day 1 every 21 days
218962829|NCT01456910|BEHAVIORAL|Resistance Training Program|Frequency, volume, repetitions, load, interval
219649334|NCT01612637|BEHAVIORAL|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
218962830|NCT05811650|BEHAVIORAL|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
219649335|NCT01612637|BEHAVIORAL|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
219649336|NCT05236894|BEHAVIORAL|Cigarette Smoking|Smoke preferred brand of cigarette
219649337|NCT05236894|DRUG|Nicotine Oral Pouch|Given lower dose nicotine pouch
219649338|NCT05236894|DRUG|Nicotine Oral Pouch|Given higher dose nicotine pouch
219649339|NCT05236894|OTHER|Questionnaire Administration|Ancillary studies
219649340|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
218962831|NCT00887744|DEVICE|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
218962832|NCT05896579|BEHAVIORAL|Exercise training|Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
218962833|NCT02879149|DEVICE|AUGMENT® Bone Graft|AUGMENT® Bone Graft
218962834|NCT02879149|PROCEDURE|Standard of Care|Autologous Bone Graft
218962835|NCT00600054|BIOLOGICAL|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
218962836|NCT05888012|DEVICE|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
219649341|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
219649342|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
219649343|NCT04289909|OTHER|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
219649344|NCT06492733|DEVICE|FastWire System - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
218962837|NCT05888012|DEVICE|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
218962838|NCT02051816|DEVICE|Video Laryngoscopy|
218962839|NCT02051816|DEVICE|Apneic Oxygenation|
218962840|NCT02051816|DEVICE|Direct Laryngoscopy|
218962841|NCT02051816|DEVICE|No Apneic Oxygenation|
218962842|NCT03120988|BIOLOGICAL|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
218962843|NCT00042029|DRUG|MK0869, aprepitant|
218962844|NCT00042029|DRUG|Comparator: placebo|
218962845|NCT01097798|DRUG|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
218962846|NCT01097798|DRUG|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
218962847|NCT04647487|DRUG|LY3484356|Administered orally.
218962848|NCT03277833|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
218962849|NCT03277833|DIETARY_SUPPLEMENT|Placebo|Placebo, parallel design
218962850|NCT02951676|PROCEDURE|Extraction|Extraction of impacted third molar teeth
218962851|NCT00101829|DRUG|Rituximab|1000 mg intravenous infusion
218962852|NCT04365062|DEVICE|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
218962853|NCT04365062|DEVICE|Excimer laser and plain balloon|Excimer laser and plain balloon
218962854|NCT04365062|DEVICE|plain balloon and drug coated balloon|plain balloon and drug coated balloon
218962855|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
218962856|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
218962857|NCT06194019|DEVICE|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
218962858|NCT04604847|DIAGNOSTIC_TEST|blood test|blood test to explore BDNF level
218962859|NCT01412918|DEVICE|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
218962860|NCT02837081|OTHER|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
219649345|NCT02463344|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
219649346|NCT02783729|DRUG|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
219649347|NCT02783729|DRUG|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
219649348|NCT02783729|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
219649349|NCT02783729|DRUG|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
219649350|NCT02783729|DRUG|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
219649351|NCT02693171|DRUG|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
218962861|NCT02837081|OTHER|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
218962862|NCT02251522|DEVICE|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
218962863|NCT02251522|DEVICE|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
218962864|NCT05658523|BIOLOGICAL|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
218962865|NCT05658523|BIOLOGICAL|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
218962866|NCT03905447|DRUG|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
218962867|NCT03905447|DRUG|Standard of Care|Standard of Care antifungal medication
218962868|NCT02982278|BEHAVIORAL|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
219062267|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
219062268|NCT02532218|DRUG|ARI-3037MO|Lipid lowering treatment Statins
219062269|NCT04289753|BEHAVIORAL|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
219062270|NCT04289753|BEHAVIORAL|Brief clinician education|Clinicians will be invited to view brief education material.
219649352|NCT06666803|OTHER|FNB sampling|A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.
219649353|NCT06666803|BIOLOGICAL|blood sampling|A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.
219649354|NCT03830957|DRUG|Ivabradine|7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg
219649355|NCT03830957|DRUG|Metoprolol|5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
218962869|NCT00997542|DRUG|Allopurinol|
218962870|NCT00997542|DRUG|Placebo|
218962871|NCT04426760|PROCEDURE|Transcervical resection of fibroids|Transcervical resection of fibroids
218962872|NCT04426760|PROCEDURE|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
218962873|NCT03763227|DRUG|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
218962874|NCT03763227|DRUG|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
218962875|NCT02274038|DRUG|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
219649356|NCT01421186|DRUG|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
219649357|NCT01421186|DRUG|MOR03087|MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
219649358|NCT01421186|DRUG|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
219649359|NCT01421186|DRUG|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
219649360|NCT01421186|DRUG|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
218962876|NCT02274038|DRUG|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
218962877|NCT02274038|DRUG|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
218962878|NCT03704701|DIAGNOSTIC_TEST|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
218962879|NCT05475782|PROCEDURE|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
218962880|NCT05475782|PROCEDURE|ESWL|ESWL+ERCP
218962881|NCT02596282|PROCEDURE|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
218962882|NCT00321893|DRUG|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
218962883|NCT00321893|OTHER|Placebo|Inhaled placebo twice daily for one year.
218962884|NCT02070471|DRUG|Placebo|Placebo
218962885|NCT02070471|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
218962886|NCT02070471|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
218962887|NCT02070471|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
218962888|NCT01212133|DRUG|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
218962889|NCT01306877|DEVICE|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
218962890|NCT01306877|DEVICE|Endosurgery Proximate PPH03 Stapling Set|Surgical device
218962891|NCT00209651|DRUG|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
218962892|NCT00209651|DRUG|TS-1|80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
218962893|NCT03302520|DEVICE|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
218962894|NCT03302520|DEVICE|PEEK cage|PEEK cage
218962895|NCT00116792|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
218962896|NCT05265377|DEVICE|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
218962897|NCT04631991|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
218962898|NCT03702296|OTHER|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
218962899|NCT03684252|BEHAVIORAL|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
218962900|NCT03684252|OTHER|Treatment as Usual|Participants' will receive treatment as usual.
218962901|NCT00422318|DRUG|Benzbromarone (drug)|
218962902|NCT05635188|PROCEDURE|Intestinal ostomy confection|Surgical procedure for fecal diverting
218962903|NCT04330820|DRUG|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
218985249|NCT01227759|DRUG|Placebo|Placebo containing no active ingredient
219649361|NCT03261726|DEVICE|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
219649362|NCT06662526|DRUG|Trace lithium dose plus treatment as usual|Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years
219649363|NCT06662526|DRUG|Placebo pill plus treatment as usual|Patients will receive a placebo pill plus treatment as usual by their clinical providers
219649364|NCT01866657|DRUG|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
219649365|NCT01866657|OTHER|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
219649366|NCT01866657|OTHER|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
219649367|NCT01866657|OTHER|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
219649368|NCT01866657|DRUG|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
219649369|NCT01866657|BIOLOGICAL|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
219649370|NCT01866657|DRUG|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
219649371|NCT03366766|BIOLOGICAL|Nivolumab|Given IV
219649372|NCT03366766|DRUG|Cisplatin|Given IV
219649373|NCT03366766|DRUG|Pemetrexed Disodium|Given IV
219649374|NCT03366766|DRUG|Gemcitabine Hydrochloride|Given IV
219649375|NCT00621166|DRUG|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
219649376|NCT04528212|DRUG|Glimepiride Tablets|Glimepiride (4 mg) per Day
219649377|NCT04528212|DRUG|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
219649378|NCT04528212|DRUG|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
219649379|NCT05522322|OTHER|COPD scoring ststems in ICU|SAPS \& APACH scoring systems in COPD ICU pts
219649380|NCT01185743|DRUG|olanzapine|olanzapine 10mg od + placebo od
219649381|NCT01185743|DRUG|ziprasidone|ziprasidone 40mg td
218962904|NCT04853303|DEVICE|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
219649382|NCT01185743|DRUG|placebo|placebo td
219649383|NCT06621836|DRUG|ICPB H|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side"
219649384|NCT06621836|DRUG|ICPB - L|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group L will receive 10 ml 0.125% bupivacaine. The technique will be repeated on the opposite side"
219649385|NCT03107689|OTHER|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
219649386|NCT01095900|PROCEDURE|conservative lateral internal sphincterotomy|
219649387|NCT01095900|PROCEDURE|Intra-sphincteric Botulinum-toxin injection|
219649388|NCT03634995|DRUG|BMS-986256|Specified dose on specified days
219649389|NCT03634995|OTHER|Placebo|Specified dose on specified days
219649390|NCT03374592|RADIATION|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
219649391|NCT03374592|RADIATION|Conventional Radiotherapy|Conventional radiotherapy technique
219649392|NCT06269380|PROCEDURE|Esophagogastroduodenoscopy|During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
219649393|NCT06269380|PROCEDURE|Endoscopic biopsy sampling|The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
218962905|NCT02943252|DRUG|Apatinib|apatinib 500 mg in tablet once daily
218962906|NCT02943252|DRUG|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
219649394|NCT04360174|DRUG|OTX-TIC|OTX-TIC implant is injection in the anterior chamber of the eye
219649395|NCT02979912|BIOLOGICAL|Platelet Lysate|Eye drops of Platelet Lysate
219649396|NCT04088279|DIAGNOSTIC_TEST|MRI|Oxygen enhanced and fourier decomposition MRI
219649397|NCT02288091|DRUG|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
219649398|NCT00676312|DRUG|PTH134|
219207877|NCT06888791|PROCEDURE|US-guided Hydro Dissection|All procedures are performed under sterile conditions. The patient is seated in a sitting position with the physician behind the patient, the shoulder joint and the surrounding area is cleaned extensively with 10% povidone iodine. The probe is placed in the posterior lateral region of the shoulder, below the level of the scapular spine. The posterior labrum is observed as a triangular hyperechoic structure extending from the glenoid to the humeral head. A 22 G spinal needle is inserted approximately 1 cm medial to the probe along the axis of the spina scapula and 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline is slowly injected into the joint in a total of 20 mL into the glenohumeral region. For suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
219649399|NCT04081025|OTHER|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
219649400|NCT06480721|OTHER|Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan|"Patients in the investigational arm will undergo the extra FET-PET scan, with use of the O-(2-~¹⁸F-fluoroethyl)-L-tyrosine (¹⁸F-FET) tracer. FET-PET scanning will be performed according to the joint European Association of Nuclear Medicine (EANM)/European Association of Neuro-Oncology (EANO)/Response Assessment in Neuro-oncology (RANO) guidelines. In most patients, a static scan (20-40 minutes post-injection) will performed. If the logistics of the research site allow for a dynamic scan (0-60 minutes post-injection), this will be performed. Interpretation will be done by an experienced nuclear medicine physician from the local center according to current European guidelines. Central review will be performed by a panel of nuclear medicine physicians from the study team. Clinical management is based on the index MRI and this additional \[¹⁸F\] FET PET scan."
219649401|NCT06666634|DRUG|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
219649402|NCT03451097|RADIATION|echocardiography|cardiac ultrasound
219649403|NCT00214149|RADIATION|brachytherapy|breast brachytherapy to 34 Gy
219649404|NCT00552981|PROCEDURE|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
219649405|NCT00552981|PROCEDURE|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
219649406|NCT01961895|PROCEDURE|Continuous lumbar plexus (LP) block analgesia|
219649407|NCT01961895|DRUG|Intravenous patient-controlled analgesia|
219649408|NCT03973918|DRUG|Encorafenib|450mg QD 28 day cycle
219649409|NCT03973918|DRUG|Binimetinib|45mg BID 28 day cycle
219649410|NCT03973918|BIOLOGICAL|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
219649411|NCT03973918|BIOLOGICAL|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
219649412|NCT04351373|DRUG|Fluorescein Sodium|Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.
219649413|NCT04351373|DEVICE|YELLOW560 filter|Integrated fluorescence module serves to make fluorescent areas visible to assist in visualizing tumor during the resection.
219649414|NCT03376451|OTHER|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
219649415|NCT03876366|OTHER|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
219649416|NCT03876366|OTHER|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
219062271|NCT01646476|DEVICE|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
219649417|NCT01075230|PROCEDURE|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
219649418|NCT01629810|DEVICE|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
219649419|NCT05685134|DEVICE|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
219649420|NCT05685134|DEVICE|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
219649421|NCT02683057|OTHER|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
219649422|NCT05855590|DRUG|Tranexamic acid|10mg/kg intravenous single dose
219649423|NCT05855590|OTHER|0.9% isotonic saline solution|100 ml intravenous single dose
219649424|NCT02683252|OTHER|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
219649425|NCT03338803|DRUG|Linagliptin|drug
219649426|NCT03887507|OTHER|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
219649427|NCT03887507|OTHER|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
219649428|NCT05970770|DEVICE|Hypotension Prediction Index|in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index \>85
219649429|NCT05970770|DRUG|Norepinephrine|Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
219649430|NCT05755607|PROCEDURE|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
218962907|NCT01958112|DRUG|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
219649431|NCT05755607|PROCEDURE|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
219649432|NCT06387706|OTHER|Gamified web-based pain management Program|"Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform."
219649433|NCT02856724|DRUG|PGE2|10 mg PGE2 vaginal ovul(Propess)
219649434|NCT04255680|DIAGNOSTIC_TEST|Buccal Swabs and Blood Draws|Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
219649435|NCT05870956|DRUG|Nintedanib|Nintedanib
219649436|NCT02006797|OTHER|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
219649437|NCT05798741|PROCEDURE|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
219649438|NCT01148160|DRUG|voriconazole|intravenous, oral administration
219649439|NCT02683395|DRUG|PLX51107|
219649440|NCT02880865|BIOLOGICAL|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
219649441|NCT02880865|BIOLOGICAL|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
219649442|NCT06333275|BIOLOGICAL|Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles|"First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative"
218962908|NCT01958112|DRUG|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
218962909|NCT00600860|OTHER|No interventions|Only registration of clinical practice
218962910|NCT03052933|DRUG|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
218962911|NCT03052933|DRUG|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
218962912|NCT00939952|DRUG|ertapenem|500 mg IV once
218985250|NCT02098967|DRUG|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
219649443|NCT05982483|PROCEDURE|Erector Spinae plane block using 20 ml of bupivicaine 0.25%|"Utilizing the in line approach, a 22 gauge 3.5 spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane."
219649444|NCT05982483|DRUG|Usual care|Analgesia as dictated by the treating emergency physician
219649445|NCT06166745|DEVICE|Sensi-IP toothpaste|Brushing daily with the Sensi-IP toothpaste for 14 days for dentinal hypersensitivity.
219649446|NCT06166745|DEVICE|Sodium Fluoride Toothpaste|Brushing daily with the Sodium Fluoride toothpaste for 14 days for dentinal hypersensitivity.
219649447|NCT03724877|DRUG|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
219649448|NCT03724877|DRUG|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
219649449|NCT01446237|OTHER|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
219649450|NCT06684236|OTHER|transcutaneous electrical stimulation|electrical stimulation is given through electrodes attached to the skin
219649451|NCT06684236|OTHER|electrodes attachment|electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
218962913|NCT01781169|DIETARY_SUPPLEMENT|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
218962914|NCT02138526|DRUG|pazopanib|pazopanib 800mg OD without food
218962915|NCT02138526|OTHER|continental breakfast|pazopanib 600mg OD with food
218962916|NCT02732743|DIETARY_SUPPLEMENT|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
218962917|NCT05635058|OTHER|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
219062272|NCT01646476|DEVICE|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
219062273|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
219649452|NCT06666153|BIOLOGICAL|EBV immunological agent|"27 participants with will be enrolled in the study and divided into three groups, including EBV-LPD (Adults group), EBV-LPD (Children group) and PTLD (Adults group） each with 9 people.The participants will be divided into three different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^5, the medium dose is 2.0×10\^6 and the high dose is 5.0×10\^6 for children and low dose is 5.0×10\^6, the medium dose is 2.0×10\^7 and the high dose is 5.0×10\^7 for adults. Only one dose will be administered to each participant with EBV immunological agent combined with Toripalimab 240mg."
219649453|NCT04737798|OTHER|oil pulling with coconut oil|using oil pulling therapy with coconut oil
219649454|NCT04737798|OTHER|oil pulling with sesame oil|using oil pulling therapy with sesame oil
219649455|NCT00611845|DRUG|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
219649456|NCT04535531|DRUG|SB206 10.3% berdazimer|Topically once daily
219649457|NCT04535531|DRUG|vehicle gel|Topically once daily
219649458|NCT04724343|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
219649459|NCT04724343|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
218962918|NCT00999921|DRUG|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
218962919|NCT00999921|DRUG|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
218962920|NCT01326559|DRUG|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
219649460|NCT04724343|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
219649461|NCT04724343|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
219649462|NCT06500065|PROCEDURE|Computed Tomography|Undergo dPET/CT
219649463|NCT06500065|RADIATION|Gallium Ga 68-HA-DOTA-TATE|Given IV
219649464|NCT06500065|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
219649465|NCT04203992|BEHAVIORAL|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
219649466|NCT04203992|BEHAVIORAL|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
218962921|NCT04315935|DRUG|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
218962922|NCT04315935|DRUG|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
219649467|NCT01190267|DRUG|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
219649468|NCT06339164|OTHER|skills and learning quality in breech delivery|evaluation of different skill retention and learning quality after different learning methods
219649469|NCT00630721|OTHER|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
219649470|NCT00591617|OTHER|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
219649471|NCT01056198|DRUG|Santyl|2 mm Santyl applied once daily.
219649472|NCT01056198|PROCEDURE|Control|Daily gauze and optional sharp debridement
219649473|NCT06618456|BEHAVIORAL|VR dive (with Hypnosis)|Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.
219649474|NCT06618456|BEHAVIORAL|VR dive (without Hypnosis)|Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.
219649475|NCT06618456|BEHAVIORAL|Height exposure|The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
219649476|NCT00742508|DRUG|SK&F-105517-D 10 mg capsule|1 capsule once a day
219649477|NCT00742508|DRUG|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
218962923|NCT00060398|BIOLOGICAL|epoetin alfa|
218962924|NCT00060398|DRUG|dexamethasone|
218962925|NCT03494348|DEVICE|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
218962926|NCT03608423|DEVICE|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
219649478|NCT00742508|DRUG|SK&F-105517-D 20 mg capsule|1 capsule once a day
219649479|NCT00742508|DRUG|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
219649480|NCT00742508|DRUG|Carvedilol-IR 10 mg tablet|1 tablet twice a day
218962927|NCT02376283|DRUG|Prasugrel|
218962928|NCT02376283|DRUG|Clopidogrel|
218962929|NCT02376283|DRUG|ticagrelor|
218962930|NCT00989573|DRUG|Placebo|oral administration of placebo once-daily for 8 weeks
219062274|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
219649481|NCT01952119|OTHER|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
219649482|NCT03481374|DIAGNOSTIC_TEST|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities"
219649483|NCT04017832|DRUG|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
219649484|NCT04017832|DRUG|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
219649485|NCT04017832|DRUG|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
219062275|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
219062276|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
219649486|NCT04017832|DRUG|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
219649487|NCT03633149|BEHAVIORAL|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
219649488|NCT03633149|BEHAVIORAL|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
218962931|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
218962932|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
218962933|NCT00450775|DRUG|Dermatix Q|Dermatix Q applied twice daily
218962934|NCT00610584|PROCEDURE|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
218962935|NCT00610584|PROCEDURE|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
219062277|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
219062278|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
219062279|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
219062280|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
219062281|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
219062282|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
219062283|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
219062284|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
219062285|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
219062286|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
219062287|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
219062288|NCT02546752|OTHER|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
219062289|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
219062290|NCT01573702|DRUG|Erlotinib|150mg once daily
219062291|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
219062292|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
219649489|NCT03633149|BEHAVIORAL|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
219649490|NCT06620783|BEHAVIORAL|exercise|Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
219649491|NCT06620783|BEHAVIORAL|yoga|The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
219649492|NCT06620783|BEHAVIORAL|active self-care|The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
219649493|NCT06667934|DRUG|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
219649494|NCT06667934|DRUG|Methalazine suppository was given rectally once a day|Methalazine suppository was given rectally once a day
219062293|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
219062294|NCT01398605|OTHER|Exercise training|Different dose of exercise training
219649495|NCT06668766|DEVICE|10-cm Single Lumen Mildine|Arm Description: The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.
219686268|NCT01261390|DEVICE|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
218962936|NCT00610584|DRUG|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
218962937|NCT03800082|BEHAVIORAL|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
218962938|NCT05074173|BEHAVIORAL|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
218962939|NCT03548571|BIOLOGICAL|Dendritic cell immunization|Intradermal injection
218962940|NCT03548571|DRUG|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
218962941|NCT01933815|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
218962942|NCT01933815|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
218962943|NCT01712321|DRUG|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
218962944|NCT01712321|DRUG|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
218962945|NCT03193125|DIETARY_SUPPLEMENT|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
218962946|NCT03193125|DIETARY_SUPPLEMENT|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
218962947|NCT00046111|DRUG|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
218962948|NCT05068895|OTHER|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
218962949|NCT04617535|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
218962950|NCT05628961|DRUG|HOPO 14-1|HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
218962951|NCT00995865|BIOLOGICAL|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL
218962952|NCT00995865|BIOLOGICAL|Placebo|NaCl Injectable 0.9%
219062295|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
219062296|NCT00759109|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
219062297|NCT00759109|OTHER|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
219062298|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
219062299|NCT00538161|OTHER|Ventilation strategy|
219062300|NCT01827904|DEVICE|Transcranial ExAblate|
218962953|NCT04798807|DIAGNOSTIC_TEST|Nutritional screening|
218962954|NCT05997472|DIAGNOSTIC_TEST|evaluation af mobility and balance|evaluation af mobility and balance Timed Up and Go Test Berg Balance Scale
218962955|NCT04926727|OTHER|Survey|Observational study
218962956|NCT01456273|PROCEDURE|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
218962957|NCT01456273|PROCEDURE|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
218962958|NCT04689438|DIAGNOSTIC_TEST|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
218962959|NCT00439465|BIOLOGICAL|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
218962960|NCT00000523|BEHAVIORAL|exercise|
218962961|NCT04426903|OTHER|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
218962962|NCT04426903|OTHER|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
218962963|NCT05080660|DRUG|LY3526318|Administered orally.
218962964|NCT05080660|DRUG|Placebo|Administered orally.
219649496|NCT06668766|DEVICE|4.78 cm Long Peripheral Intravenous Catheter|The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
219649497|NCT06684600|DRUG|Dalpiciclib + Pyrotinib|Dalpiciclib Isethionate tablets, 125mg, oral administration on days 1 to 21, followed by a 7-day drug holiday, every 4 weeks; Pyrotinib Maleate tablets, 320mg, oral administration once daily on days 1 to 28, every 4 weeks; Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, or the investigator determines that the subject should discontinue study treatment.
219649498|NCT03376256|DEVICE|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
219649499|NCT02229175|DRUG|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
219649500|NCT02229175|DEVICE|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
219649501|NCT05019846|DRUG|Triptorelin Embonate|single administration before SRT starting
219649502|NCT05019846|DRUG|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
219649503|NCT02046395|DRUG|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
219649504|NCT06724900|BIOLOGICAL|KB304|Genetically modified herpes simplex type 1 virus
219649505|NCT06724900|DRUG|0.9% Normal Saline (NS)|Placebo
219649506|NCT04010929|PROCEDURE|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
219649507|NCT04010929|PROCEDURE|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
219649508|NCT00963027|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
219649509|NCT00963027|DRUG|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
219649510|NCT00355576|DRUG|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
219649511|NCT00355576|DRUG|Creatine|10 g BID for either study arm
219649512|NCT00355576|DRUG|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
219649513|NCT05250102|DEVICE|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
219649514|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
219649515|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
219649516|NCT04971200|DRUG|Tildrakizumab|2 100mg subcutaneous injections Q4W
219649517|NCT06914999|PROCEDURE|Computed Tomography|Undergo PET/CT
219649518|NCT06914999|OTHER|Fludeoxyglucose F-18|Given F-18 FDG
219649519|NCT06914999|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
219649520|NCT06914999|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219649521|NCT06914999|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219649522|NCT06914999|DRUG|Sodium Fluoride F-18|Given IV
219649523|NCT02100670|DRUG|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
218962965|NCT02602977|OTHER|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
219062301|NCT01827904|DEVICE|Sham Transcranial ExAblate|
219649524|NCT02100670|DRUG|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
219649525|NCT02100670|DRUG|3% menthol|To be applied four times daily for 10 days.
219649526|NCT02100670|DRUG|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
219649527|NCT04096638|DRUG|SB 11285|SB 11285 2mg lyophilized powder for IV infusion
219649528|NCT04096638|DRUG|Atezolizumab|1680 mg every 4 weeks
219649529|NCT06934174|BEHAVIORAL|WeSafe (myPlan Thailand: Friends and Family)|WeSafe, a Web-Based App (myPlan Thailand) is a culturally tailored web-based app designed to empower and support friends and family of IPV survivors. It gathers key data on survivors' demographics, relationship status, living situation, and children's ages to personalize the safety support plan. The app delivers comprehensive IPV information through text, videos, images, and illustrations, addressing culturally specific issues. It guides users in setting priorities through pairwise comparisons and includes a risk assessment tool adapted from Danger Assessment (DA)-Thailand. Based on the inputs, myPlan Thailand provides a tailored plan with supportive strategies, communication scripts, advocacy tips, self-care resources, and child safety strategies, enhancing overall safety and well-being.
219062302|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
219649530|NCT06934174|BEHAVIORAL|DV learning|Control group. The control condition will be the publicly-available Thai-language DV learning launched in 2019.49 This app screens users for Domestic violence (physical, psychological, and sexual violence), and provides information about 6 modules include 1. Understanding situation of domestic violence 2. Key principles of helping survivors 3. Guideline for helping survivors 4. Case management and working with multi professionals 5. Legal Proceedings and Justice System Processes for Domestic Violence and Intimate Partner Violence Cases 6. Selfcare for providers. This platform put the knowledge from understanding the basic situation through practical intervention for providers and other people who are interested in. It is optional to get the certificate if participants have 80% pass rate on quizzes.
219649531|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
219649532|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
219649533|NCT03634033|BEHAVIORAL|MiCAP with IF (Main Study)|"Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
219649534|NCT03634033|BEHAVIORAL|MiCAP with IF and EF (Main Study)|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
219649535|NCT03634033|BEHAVIORAL|MiCAP with IF and Caregiver Engagement (Administrative Supplement)|A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
219649536|NCT06516094|DRUG|Celecoxib+Pregabalin+Vitamin B fixed dose|One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
219649537|NCT06516094|DRUG|Celecoxib + Vitamin B fixed dose|One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
219649538|NCT06516094|DRUG|Pregabalin + Vitamin B fixed dose|One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
219649539|NCT06397365|OTHER|medical hypnosis|"The first hypnosis session (V2) consists of a safe place suggestion. Through this type of suggestions, patients will safely experience the dissociative state, and will be given tools (recordings of sessions) to perform self-hypnosis at home between the visits. The suggestions will help the patient to visualize an imaginary place where they feel well and safe, a protective place to rest. In this first session, CPAP treatment will be introduced during hypnosis, with specific suggestions relating to the use of this treatment.~The second session (V3) The second session will also use the safe place. We will adapt the suggestions according to the experience reported by the patient on the day of the visit. During this session, we'll focus on changes in the patient's perception of the CPAP machine.~Patients will also be given the recording of each session to perform self-hypnosis at home between the visits."
219649540|NCT05434182|PROCEDURE|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
219649541|NCT05434182|PROCEDURE|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
219649542|NCT05342636|BIOLOGICAL|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
219649543|NCT05342636|BIOLOGICAL|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
219649544|NCT05342636|BIOLOGICAL|MK-4830|800 mg administered via IV infusion Q3W
219649545|NCT05342636|DRUG|Lenvatinib|20 mg administered via oral capsules each day
219649546|NCT05342636|DRUG|Irinotecan|180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
219062303|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
219062304|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
219649547|NCT05342636|DRUG|Paclitaxel|80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
219649548|NCT05461677|DEVICE|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
219649549|NCT05461677|DEVICE|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
219062305|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
219062306|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
219062307|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
219062308|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
219649550|NCT05461677|OTHER|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
219649551|NCT04501406|DRUG|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
219649552|NCT04501406|OTHER|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
219649553|NCT00815815|BEHAVIORAL|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
219649554|NCT00318851|DEVICE|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
219649555|NCT05092295|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
219649556|NCT05092295|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
219649557|NCT02326116|OTHER|Trachael Preparation Education|
219649558|NCT01296542|DRUG|Moxifloxacin Ophthalmic|
218962966|NCT02602977|OTHER|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
218962967|NCT02602977|BIOLOGICAL|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
219649559|NCT01296542|DRUG|Besifloxacin Ophthalmic|
219649560|NCT03243344|DEVICE|Surgiflo|using device during the endonasal surgery.
219649561|NCT03243344|DEVICE|Floseal|using device during the endonasal surgery.
219649562|NCT03243344|DEVICE|Algosteril|using device during the endonasal surgery.
219649563|NCT01045083|DRUG|RO4917523|Oral single dose
219649564|NCT01045083|DRUG|escitalopram|Oral single dose
219649565|NCT01045083|DRUG|methylphenidate|Oral single dose
218962968|NCT00002065|DRUG|Disulfiram|
219649566|NCT01045083|DRUG|placebo|Oral single dose
219649567|NCT01649648|BIOLOGICAL|Autologous cord blood|Baby's own umbilical cord blood
219649568|NCT01668953|OTHER|Platelet Rich Plasma (PRP) Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
219649569|NCT01668953|OTHER|Whole Blood Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
219649570|NCT01668953|OTHER|Dry Needle Fenestration|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
219649571|NCT01668953|OTHER|Sham Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
219649572|NCT05451433|DRUG|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
219649573|NCT05451433|DRUG|Placebo|Placebo capsule twice a day
219649574|NCT02819245|PROCEDURE|posterior correction and fusion|
219649575|NCT02134002|DRUG|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
219649576|NCT02134002|DRUG|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
219649577|NCT03931317|DRUG|Latanoprostene bunod 0.024% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
219649578|NCT03931317|DRUG|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
219649579|NCT01643733|DEVICE|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
219649580|NCT02804906|BEHAVIORAL|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
219649581|NCT02804906|BEHAVIORAL|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
219649582|NCT01267084|DRUG|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
219649583|NCT01267084|DRUG|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
218962969|NCT06003569|BEHAVIORAL|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
218962970|NCT06003569|BEHAVIORAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
218962971|NCT02148146|DRUG|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
218962972|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
218962973|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
218962974|NCT04533685|BEHAVIORAL|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
218962975|NCT04533685|BEHAVIORAL|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
218962976|NCT01608854|OTHER|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
218962977|NCT04221230|DRUG|NMRA-335140|Active Drug
218962978|NCT04221230|DRUG|Placebo|Placebo
219223722|NCT07034404|BEHAVIORAL|Digital Adapted Physical Activity|"The digital Adapted Physical Activity (APA) program will be delivered via a digital platform and participants will be guided by an APA teacher to meet the WHO recommendations (i.e. 150 minutes of moderate intensity aerobic PA per week and muscle-strengthening activities that involve all major muscle groups twice weekly).~Participants will benefit from 10 visits with the APA teacher: an initial assessment to define personalized goals and familiarize participants with the digital platform, eight sessions to monitor progress and adapt the exercise program, and a final evaluation aimed at assessing outcomes and encouraging long-term adherence to physical activity. Daily physical activity will be objectively monitored using a Withings connected watch to provide feedback and track metrics such as step count."
219649584|NCT01267084|DRUG|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
219649585|NCT01944670|DEVICE|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
219649586|NCT05850390|OTHER|Respiratory-Responsive Vocal Biomarker application|"A smartphone app that allows participants to receive a respiratory-responsive vocal biomarker (RRVB) score by recording a 6-second held ahh vowel elicitation. The applications returns the RRVB score which has previously been validated to correspond to the likelihood that the user's voice is similar to those of people diagnosed with asthma. This study will examine if the RRVB scores correlate with respiratory function and symptoms in asthma patients."
219649587|NCT05194995|DRUG|JAB-21822|JAB-21822 administered orally as a tablet.
219649588|NCT05194995|DRUG|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
219649589|NCT00289406|DRUG|S-amlodipine gentisate|
219649590|NCT00289406|DRUG|Amlodipine besylate|
218962979|NCT00371007|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
218962980|NCT00371007|DRUG|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
218962981|NCT02774733|DEVICE|spirometer;Intraocular pressure;Color doppler imaging|
218962982|NCT03615508|DRUG|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
218962983|NCT04841226|DEVICE|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
218962984|NCT02022176|OTHER|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
218962985|NCT02022176|OTHER|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
218962986|NCT02022176|OTHER|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
219649591|NCT01167556|BEHAVIORAL|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
219649592|NCT00743288|DRUG|Melphalan|Same as above
218962987|NCT01871064|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
218962988|NCT04898621|DIETARY_SUPPLEMENT|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
218962989|NCT04898621|DIETARY_SUPPLEMENT|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
218962990|NCT03687970|OTHER|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
218962991|NCT03687970|OTHER|Hospital Anxiety and Depression Scale|"* 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
218962992|NCT03687970|OTHER|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
218962993|NCT03687970|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
218962994|NCT03687970|PROCEDURE|Quantitative sensory testing|"* Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
218962995|NCT03687970|PROCEDURE|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
218962996|NCT03687970|OTHER|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
218962997|NCT01377285|DRUG|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
218962998|NCT01377285|DRUG|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
218962999|NCT01377285|DRUG|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
218963000|NCT04174040|BEHAVIORAL|Gross's Process of Emotion Regulation Model Interventions|"Interventions were based on Gross's Process Model which include the basis concepts of cognitive-behavioral therapy and carried on with five semi-structured sessions. Cognitive-behavioral theories accept the existence of a thought process (attention-perception-interpretation) that appears in the mind about the event just before the anger emerges. Therefore, anger studies with cognitive-behavioral approach generally proceed with the steps of gaining awareness about this concealed thought, identifying behavioral response and avoidance attitudes and thus regulating emotion. It consists of five 90-minute group sessions structured in this context. While being an accredited cognitive behavioral therapist, investigator have qualified to manage these approach.~The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
218963001|NCT04174040|BEHAVIORAL|Musical Rhythm Interventions|"This musical group rhythm intervention was continued with 90 minute long five sessions. The students participated in the practice together with a music expert and lead researcher. The lead researcher took on the role of observer in these sessions. Each session was continued with warming, improvisation and targeted semi-structured rhythm practices aiming anger regulation. The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
218985251|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
219223723|NCT07034404|BEHAVIORAL|Control (Standard treatment)|Participants will receive standard care and advice on physical activity (based on the recommendations of the World Health Organization, WHO, and the European Alliance of Associations for Rheumatology, EULAR) through a document provided to them.
219649593|NCT00743288|DRUG|Panobinostat|
219649594|NCT03443765|DIAGNOSTIC_TEST|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
219649595|NCT03443765|DIAGNOSTIC_TEST|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
219649596|NCT03290534|DEVICE|CivaSheet|implanting CivaSheet for localized radiation dose delivery
219649597|NCT04565210|OTHER|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
219062309|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
219062310|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
219649598|NCT04565210|OTHER|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
219062311|NCT02582905|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
219062312|NCT02582905|DIETARY_SUPPLEMENT|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
219062313|NCT02582905|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
219649599|NCT02983149|DEVICE|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
219649600|NCT02983149|DEVICE|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
219649601|NCT02983149|DEVICE|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
219649602|NCT00026442|DRUG|capecitabine|
219649603|NCT04338269|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
219649604|NCT04338269|DRUG|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
218963002|NCT04174040|BEHAVIORAL|Musical Rhythm Integrated Gross's Emotion Regulation Process Interventions|"The students participated in the practice together with a music expert and lead researcher. The lead researcher ensured the integration of rhythm applications into the Process Model through cognitive-behavioral semi-structured interventions. Five semi-structured 90-minute group sessions were performed. The effectiveness of the experiment was evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
218963003|NCT01964131|DRUG|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
218963004|NCT01964131|DRUG|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
218963005|NCT03166878|BIOLOGICAL|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
219062314|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
219649605|NCT00217074|OTHER|acupuncture|
219649606|NCT02562638|OTHER|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
219649607|NCT06580613|OTHER|New model of Hypertension Management|Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
219062315|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
219062316|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
219649608|NCT06580613|OTHER|Control|Hypertension Management as usual
219062317|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
219062318|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
219649609|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
219649610|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
219649611|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
219649612|NCT01942044|DEVICE|Promus element, Xience prime, and Nobori|
219649613|NCT02076737|DEVICE|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
219649614|NCT02715700|DRUG|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
219649615|NCT02715700|DRUG|Doravirine|Doravirine 100 mg oral tablet once per day.
219649616|NCT02263248|DRUG|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
219062319|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
219649617|NCT02263248|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
219062320|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
219649618|NCT02263248|DRUG|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
219649619|NCT06356480|BIOLOGICAL|1% Acetic acid dressing|1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
219649620|NCT04752761|BEHAVIORAL|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
219649621|NCT03014128|OTHER|Clinical examination and data processing of questionnaires|xy
219649622|NCT04857814|DEVICE|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
219649623|NCT02730377|DRUG|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649624|NCT02730377|DRUG|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649625|NCT02730377|DRUG|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649626|NCT02730377|DRUG|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649627|NCT02730377|DRUG|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649628|NCT02730377|DRUG|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649629|NCT02730377|DRUG|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
219649630|NCT02128347|OTHER|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
218963006|NCT03070444|DEVICE|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
218963007|NCT03070444|DEVICE|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
218963008|NCT03070444|DEVICE|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
218963009|NCT03070444|PROCEDURE|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
218963010|NCT03070444|OTHER|Questionnaire|A questionnaire is completed at the follow-up visits.
218963011|NCT05012761|DRUG|SR419 capsules|Ascending single and multiple doses of SR419 orally
218963012|NCT05012761|DRUG|Placebo|Ascending single and multiple doses of placebo orally
218963013|NCT06557525|BEHAVIORAL|Neurofeedback|Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
218963014|NCT01373489|BEHAVIORAL|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
218963015|NCT00174330|DRUG|atorvastatin|
218963016|NCT00174330|DRUG|amlodipine|
218963017|NCT02112006|PROCEDURE|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
218963018|NCT02112006|PROCEDURE|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
218963019|NCT04444349|DRUG|Coenzyme Q10|Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
218963020|NCT04444349|DIETARY_SUPPLEMENT|Standard Medical Therapy|Patients only received standard medical therapy without CoQ10.
218963021|NCT05647096|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber
218963022|NCT06433570|GENETIC|multiplex PCR|Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
218963023|NCT04088656|OTHER|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
219649631|NCT06263270|BIOLOGICAL|CYT-108, a recombinant protease inhibitor|"CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the bait region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA."
219649632|NCT06263270|OTHER|Phosphate Buffered Saline (PBS)|Phosphate Buffered Saline (PBS)
219649633|NCT00860041|BEHAVIORAL|pain questionnaires|
219649634|NCT01069237|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
219649635|NCT01069237|DEVICE|Clear Care|Lens Care Solution for contact lenses
219649636|NCT01055405|DRUG|Sildenafil|Sildenafil 20mg TID orally
219649637|NCT01055405|OTHER|Placebo|Placebo TID orally
218963024|NCT05191979|OTHER|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
218963025|NCT05780606|OTHER|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
218963026|NCT04591860|DEVICE|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
218963027|NCT06004908|DEVICE|MRI|a type of scan that uses strong magnetic field sand radio waves to produce detailed images of the inside of the body
218963028|NCT01425775|DRUG|vitamin D 25(OH)D|2000IU/day for 12 months
218963029|NCT01425775|OTHER|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
218963030|NCT05272085|PROCEDURE|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
218963031|NCT05272085|PROCEDURE|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
218963032|NCT00188331|BEHAVIORAL|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
218963033|NCT03838965|DEVICE|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
218963034|NCT01850433|BEHAVIORAL|Internet based CBT for body dysmorphic disorder|
218963035|NCT06233760|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
218963036|NCT06233760|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
218963037|NCT06233760|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
218963038|NCT06233760|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
218963039|NCT06233760|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
218963040|NCT06233760|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
218963041|NCT06233760|OTHER|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
218963042|NCT06233760|OTHER|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
218963043|NCT05405127|OTHER|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
218963044|NCT05405127|OTHER|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
219649638|NCT05563012|DRUG|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
219649639|NCT00302484|DRUG|Zoledronate|
219649640|NCT00697541|DRUG|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
219649641|NCT00697541|DRUG|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
219649642|NCT00697541|DRUG|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
219649643|NCT00697541|DRUG|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
219649644|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the participant will be able to troubleshoot any technical difficulties and ask any questions about the material being taught in the intervention."
218963045|NCT02306733|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
218963046|NCT02306733|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
218963047|NCT05125887|OTHER|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
218963048|NCT01383668|DRUG|sirolimus|Given PO
218963049|NCT01383668|DRUG|gold sodium thiomalate|Given IM
218963050|NCT01383668|OTHER|pharmacological study|Correlative studies
218963051|NCT01383668|GENETIC|RNA analysis|Correlative studies
218963052|NCT01383668|GENETIC|polymerase chain reaction|Correlative studies
218963053|NCT02582255|BIOLOGICAL|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
218963054|NCT01744912|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
218963055|NCT01744912|DRUG|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
218963056|NCT06523192|OTHER|Questionnaires|No intervention
218963057|NCT03268148|DEVICE|LaserPen|low level laser is used before heel-lancing for newborn screening
219062321|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
219062322|NCT02138318|OTHER|High definition (HD) endoscopy|
219062323|NCT02138318|OTHER|chromoendoscopy|
219062324|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
219062325|NCT00472914|DEVICE|portable surface electromyography|
218963058|NCT00375375|DRUG|Lactulose|
218963059|NCT01409759|PROCEDURE|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
218963060|NCT00847171|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
218963061|NCT00847171|BIOLOGICAL|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
218963062|NCT00847171|DRUG|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
218963063|NCT00847171|OTHER|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
218963064|NCT00847171|OTHER|immunoenzyme technique|
218963065|NCT00847171|OTHER|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
218963066|NCT00847171|OTHER|laboratory biomarker analysis|
218963067|NCT00847171|OTHER|pharmacological study|
218963068|NCT00847171|PROCEDURE|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
219062326|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
219062327|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
219062328|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
219062329|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
218963069|NCT04285099|DEVICE|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
218963070|NCT04285099|DEVICE|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
218963071|NCT05578157|DIAGNOSTIC_TEST|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
218963072|NCT02895633|OTHER|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
218963073|NCT02895633|OTHER|CT scan|With injection of Iomeron 400
218963074|NCT02895633|OTHER|MRI|With injection of gadolinium (Multihance)
218963075|NCT04369170|DEVICE|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
218963076|NCT04369170|DEVICE|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
218963077|NCT00436930|BIOLOGICAL|autologous tumor cell vaccine|Given subcutaneously
218963078|NCT00436930|BIOLOGICAL|sargramostim|Given subcutaneously
218963079|NCT00436930|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously
218963080|NCT02029339|DEVICE|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
218963081|NCT02029339|DEVICE|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
218963082|NCT02269826|DEVICE|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
218963083|NCT02269826|DEVICE|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
218963084|NCT06040879|PROCEDURE|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
218963085|NCT02417844|DRUG|tamsulosin (Astellas)|
218963086|NCT02417844|DRUG|Tamsulosin HCL|
218963087|NCT00728078|DRUG|thalidomide|thalidomide 50mg tid for 6 months
218963088|NCT01785095|DRUG|FSH (Follicle Stimulating Hormone)|
218963089|NCT01155219|DRUG|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
219686269|NCT01261390|DEVICE|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
218963090|NCT01155219|DRUG|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
218963091|NCT03124238|OTHER|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
218963092|NCT05838235|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
218963093|NCT02922595|DEVICE|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
218963094|NCT02922595|DEVICE|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
218963095|NCT00048451|DRUG|paricalcitol|
218963096|NCT05921318|COMBINATION_PRODUCT|Beijing protocol|"For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
218963097|NCT05612022|PROCEDURE|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
219062330|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
219062331|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
219062332|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
219649645|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention without phone coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week."
219649646|NCT05809024|DRUG|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
219649647|NCT03180658|PROCEDURE|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
219649648|NCT03180658|PROCEDURE|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
219649649|NCT04463056|BIOLOGICAL|Elizaria®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
219649650|NCT04463056|BIOLOGICAL|Soliris®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
219649651|NCT03198832|PROCEDURE|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
219649652|NCT03796442|DEVICE|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
219649653|NCT03796442|DEVICE|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
219649654|NCT05487287|DEVICE|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~1. Finger extension~2. Wrist extension~3. Finger separation~4. Finger clamp"
219649655|NCT04995653|DRUG|Vancomycin Pre-Treatment|Four times daily dosing with Vancomycin
219649656|NCT04995653|DRUG|Vancomycin Placebo|Four times daily dosing with Vancomycin Placebo
219649657|NCT04995653|DRUG|SER-155|Once daily dosing with SER-155
219649658|NCT04995653|DRUG|SER-155 Placebo|Once daily dosing with SER-155 placebo
219649659|NCT04519788|DRUG|AT-301B|Nasal Spray
219649660|NCT04519788|DRUG|AT-301A|Nasal Spray
219649661|NCT00535782|DRUG|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
218963098|NCT05612022|PROCEDURE|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
218963099|NCT05748080|OTHER|Eating apples|the eating of 2 apples a day for a period of 6 weeks
218963100|NCT04004130|OTHER|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
219649662|NCT00535782|DRUG|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
219649663|NCT00535782|DRUG|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
218963101|NCT06382805|OTHER|Physiotherapy program|The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
218963102|NCT06382805|OTHER|Kinesio Tape|The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
219649664|NCT05679531|OTHER|intervention|After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes.
219649665|NCT03359330|OTHER|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
219649666|NCT05561907|PROCEDURE|Surgical gastrojejunostomy (SGJ)|Laparoscopic gastrojejunostomy
219649667|NCT05561907|PROCEDURE|Endoscopic gastrojejunostomy (EGJ)|Endoscopic ultrasound (EUS) guided gastrojejunostomy
219649668|NCT06282224|DEVICE|Performing endoscopic transnasal skull base surgery with AR-integrated endoscope|To explore how to use augmented reality technology (AR) to highlight important anatomical structures in the neuroendoscopic field of view, optimize the endoscopic surgical field of view, make up for the shortage of simple endoscopic field of view, make it easier for surgeons to distinguish deep anatomical structures, and reduce the intraoperative and postoperative complications of transnasal endoscopic surgery.
219649669|NCT04830384|DEVICE|Fully Active|7 subjects will be dispensed active treatment devices with light and music fully functional
219649670|NCT04830384|DEVICE|LLLT Only|7 subjects will be dispensed active treatment devices with only light functional
219649671|NCT04830384|DEVICE|Music Only|7 subjects will be dispensed placebo comparator devices with only music functional
219649672|NCT04830384|DEVICE|Placebo|7 subjects will be dispensed placebo or sham devices with no light or music functional
219649673|NCT04623879|DRUG|Lumacaftor, Ivacaftor Drug Combination|
219649674|NCT04306159|PROCEDURE|Subcostal TAP|Subcostal transversus abdominis plane block
219649675|NCT04306159|PROCEDURE|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
219649676|NCT04306159|OTHER|General anesthesia|Traditional general anesthesia management
219649677|NCT02856607|OTHER|determine the prognosis of threated patients according to the clinical care pathway.|
219649678|NCT00401713|PROCEDURE|Transplantation of autologous RPE|RPE cell suspension
219649679|NCT00401713|PROCEDURE|Translocation of autologous RPE and Choroid|RPE patch
219649680|NCT02327403|DRUG|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
219649681|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
219649682|NCT04510246|BEHAVIORAL|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
219649683|NCT00880230|DEVICE|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
219649684|NCT04318522|DEVICE|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
219649685|NCT02394496|DRUG|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
219649686|NCT02394496|DRUG|Lapatinib|1500mg (TBD) O.S. qd
219649687|NCT02394496|DRUG|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
218963103|NCT06382805|OTHER|High Intensity Laser therapy|High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
218963104|NCT05753033|DRUG|SR750 tablet|Ascending single and multiple doses of SR750 orally
218963105|NCT05753033|DRUG|Placebo|Ascending single and multiple doses of placebo orally
218963106|NCT00730444|DRUG|Iobenguane I 123 Injection|1-10 mCi administered intravenously
218963107|NCT00719264|DRUG|RAD001(everolimus)|10 mg qd
219062333|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
219649688|NCT02394496|DRUG|Placebo Lapatinib|1500mg (TBD) O.S. qd
219649689|NCT00863473|PROCEDURE|Surgical treatment with LCP|
219649690|NCT04310631|DRUG|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
219649691|NCT04562831|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
219649692|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
219649693|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
219649694|NCT03494062|BEHAVIORAL|Exercise|Home-based exercise training
219649695|NCT05285995|OTHER|Music Intervention|Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.
219649696|NCT05285995|OTHER|The animation intervention|Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
218963108|NCT00719264|DRUG|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
218963109|NCT00719264|DRUG|bevacizumab|10 mg/kg every 2 weeks
218963110|NCT01568801|BEHAVIORAL|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
218963111|NCT03375229|OTHER|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
218963112|NCT03375229|DEVICE|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
218963113|NCT00003409|DRUG|motexafin gadolinium|
218963114|NCT00003409|RADIATION|radiation therapy|
218963115|NCT00531986|DRUG|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
218963116|NCT00531986|DRUG|HAART|Patients will continued their current HAART
218963117|NCT03034200|DRUG|ONC201|625mg ONC201 will be given on two consecutive days each week
219649697|NCT00220324|DRUG|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
219649698|NCT03641625|DEVICE|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained \> 70% (absolute measurement) and \> baseline throughout the entire procedure.
219649699|NCT02729038|DRUG|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
219649700|NCT02458339|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
219649701|NCT02458339|DRUG|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
219649702|NCT06018896|DRUG|Ascorbate|For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
219649703|NCT02002039|DRUG|Erythropoietin|500 units /kg /day every other day for 5 doses
219649704|NCT02630225|BEHAVIORAL|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
218963118|NCT06518694|DRUG|Βeta-Blockers discontinued (with tapering)|"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."
218963119|NCT01084447|DEVICE|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
218963120|NCT01084447|DEVICE|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
218963121|NCT02895009|DEVICE|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
218963122|NCT02895009|DEVICE|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
218963123|NCT05293509|DRUG|Fludarabine|40 mg/m2/day i.v.- by vein
218963124|NCT05293509|DRUG|Dexamethasone|25 mg/m2/day i.v.-by vein
218963125|NCT05293509|DRUG|Cyclophosphamide|100 mg/m2 IV-by vein
218963126|NCT05293509|DRUG|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
218963127|NCT05293509|DRUG|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
219649705|NCT02630225|OTHER|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling"
219649706|NCT02630225|BEHAVIORAL|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
218963128|NCT05293509|DRUG|Busulfan|110 mg/m2 i.v-by vein
218963129|NCT05293509|DRUG|Cyclophosphamide (Cy)|by vein
218963130|NCT05293509|DRUG|Tacrolimus (or cyclosporine)|by vein
218963131|NCT05293509|DRUG|Mycophenolate mofetil (MMF)|given by PO
218963132|NCT05293509|DRUG|Rabbit ATG|by vein
218963133|NCT05423249|DRUG|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
218963134|NCT05423249|DRUG|Prenatal|Oral prenatal vitamin once daily for both groups
218963135|NCT05423249|DRUG|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
218963136|NCT05423249|DRUG|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
218963137|NCT05423249|DRUG|Placebo|Oral placebo pill once daily
218963138|NCT01871103|PROCEDURE|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
218963139|NCT03464565|DEVICE|Penumbra System|Penumbra System
218963140|NCT03148119|DRUG|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
218963141|NCT03148119|DEVICE|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
218963142|NCT02454231|BIOLOGICAL|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
218963143|NCT02454231|BIOLOGICAL|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
218963144|NCT05245279|DIAGNOSTIC_TEST|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
219649707|NCT02630225|OTHER|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
219649708|NCT00451893|PROCEDURE|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
219649709|NCT00451893|PROCEDURE|Lichtenstein operation with a light-weight mesh|Johnson\&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
219649710|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
219649711|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
219649712|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
219649713|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
219649714|NCT06375746|OTHER|Personalized video|After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
219649715|NCT05489263|OTHER|No intervention|No intervention
219649716|NCT00851916|RADIATION|CyberKnife Radiosurgery|CyberKnife Radiosurgery
219649717|NCT01915667|DRUG|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
219649718|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
219649719|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
219649720|NCT01921192|DRUG|Folic Acid, vit B6 and B12|
219649721|NCT01921192|DRUG|Placebo|
219649722|NCT06014619|PROCEDURE|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
219649723|NCT06014619|PROCEDURE|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
219649724|NCT03562286|PROCEDURE|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
219649725|NCT04253639|OTHER|Questionnaires|"Patients must fill questionnaires to collect socio-demographics, aetiology and characteristics of pain, efficacy and tolerance regarding the TENS.~Study sites must fill questionnaires to collect information regarding the type of pain management centre, the characteristics of the clinician, the characteristics of the TENS prescribed."
219649726|NCT02683655|DRUG|Apatinib|Apatinib 500mg qd p.o.
219649727|NCT02683655|DRUG|Apatinib|Apatinib 750mg qd p.o.
219649728|NCT03829618|DRUG|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
219649729|NCT03829618|DRUG|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
219649730|NCT03829618|DRUG|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
218963145|NCT05245279|DIAGNOSTIC_TEST|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
219649731|NCT01906021|PROCEDURE|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
219649732|NCT01906021|PROCEDURE|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
219649733|NCT01129349|DRUG|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
218963146|NCT00035347|DRUG|IV azithromycin|500 mg once daily
218963147|NCT00035347|DRUG|ceftriaxone|1 gram once daily for 2 to 5 days
218963148|NCT00035347|DRUG|oral azithromycin|2 x 250 mg once daily
218963149|NCT00035347|DRUG|IV levofloxacin|500 mg once daily
218963150|NCT00035347|DRUG|oral levofloxacin|500 mg once daily
218963151|NCT05260346|DIETARY_SUPPLEMENT|Cranberry juice|composition: Water, cranberry juice concentrate
218963152|NCT05260346|DIETARY_SUPPLEMENT|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
219649734|NCT06621888|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
219649735|NCT06194747|OTHER|Quality improvement bundle|(1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams
219649736|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles with central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.
219649737|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles without central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.
218963153|NCT01509690|OTHER|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
218963154|NCT03794882|COMBINATION_PRODUCT|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
218963155|NCT03794882|PROCEDURE|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
218963156|NCT03400982|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone densitometry and measurement of body composition
218963157|NCT00897338|OTHER|flow cytometry|laboratory analysis
218963158|NCT00897338|OTHER|fluorescence activated cell sorting|laboratory analysis
218963159|NCT00897338|OTHER|immunohistochemistry staining method|laboratory analysis
218963160|NCT00897338|OTHER|immunologic technique|laboratory analysis
219062334|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
219062335|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
219062336|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
219649738|NCT06440356|OTHER|laser therapy|low level laser therapy applied
219649739|NCT06472531|DRUG|INR101|• 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
219649740|NCT06472531|DRUG|INR101|"* 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT"
219649741|NCT06470035|DEVICE|Active VeNS Device|Battery powered non-invasive neurostimulation device
219649742|NCT06470035|DEVICE|Sham VeNS Device|Placebo comparator sham device (no active stimulation)
219649743|NCT02853669|PROCEDURE|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
219649744|NCT02853669|PROCEDURE|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
218963161|NCT00897338|OTHER|biomarker analysis|laboratory analysis
218963162|NCT00064298|DIETARY_SUPPLEMENT|fruit and vegetable extracts|Given orally
218963163|NCT00064298|DIETARY_SUPPLEMENT|placebo|Given orally
218963164|NCT03286127|OTHER|specialized palliative care|specialized palliative care provided in different settings
218963165|NCT04439565|GENETIC|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
218963166|NCT05043376|DRUG|Standard of care|Standard COVID-19 care as per the hospital guidelines
218963167|NCT05043376|DIETARY_SUPPLEMENT|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
218963168|NCT03016143|BIOLOGICAL|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
218963169|NCT03016143|BIOLOGICAL|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
218963170|NCT06047184|DRUG|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
218963171|NCT06047184|DRUG|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
219062337|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
219062338|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
219062339|NCT02803710|OTHER|Microbiological study|
219062340|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
219062341|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
219062342|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
219062343|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
219062344|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
219062345|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
219062346|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
219062347|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
219649745|NCT04738617|BEHAVIORAL|Inter and intra-individual variation in acute responses to two different warm-up types|Comparison of the acute effects of two different warm-up protocols on subsequent performance.
219649746|NCT04998279|DRUG|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
219649747|NCT04998279|OTHER|placebo|mock test without injection of G-CSF
219649748|NCT01054300|DRUG|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
219649749|NCT01054300|DRUG|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
219649750|NCT01054300|DRUG|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
219649751|NCT01054300|DRUG|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
219649752|NCT01054300|DRUG|Placebo|Placebo to ertugliflozin administered as a single dose
219649753|NCT04749654|OTHER|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
219649754|NCT04749654|OTHER|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
219649755|NCT04749654|OTHER|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
219649756|NCT01241877|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin
218963172|NCT06047184|DRUG|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
218963173|NCT00466492|PROCEDURE|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
218963174|NCT03614975|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
219649757|NCT01241877|DIETARY_SUPPLEMENT|placebo|placebo
219649758|NCT00962975|DRUG|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
219649759|NCT00308087|DRUG|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
219649760|NCT00308087|DRUG|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
219649761|NCT01000532|DEVICE|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
219649762|NCT01000532|DEVICE|Pacemaker therapy|Pacemaker therapy
219649763|NCT01000532|DEVICE|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
219649764|NCT02977611|DRUG|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
219649765|NCT01321138|PROCEDURE|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
219649766|NCT01321138|PROCEDURE|PCA morphine|Postoperative analgesia with self-administration iv morphine
219649767|NCT03700333|DRUG|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
219649768|NCT03700333|DRUG|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
219649769|NCT00177307|DRUG|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
219649770|NCT00177307|DRUG|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
219649771|NCT00177307|DRUG|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
218963175|NCT03614975|BIOLOGICAL|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
218963176|NCT00450385|DRUG|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
218963177|NCT00450385|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
218963178|NCT00450385|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
218963179|NCT00450385|DRUG|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
218963180|NCT00450385|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
219649772|NCT03845361|PROCEDURE|Radial artery cannulation|Radial artery cannulation
219649773|NCT06621693|DEVICE|Transcutaneous electrical diaphragmatic stimulation intervention|It will be applied on diaphragm, 30 min per session ,3 days/week for 4 weeks at a stimulation frequency of 30 Hz, pulse width of 400 μs, the intensity was gradually increased until visible muscle contraction was observed.
219649774|NCT06621693|OTHER|traditional physiotherapy program|The participants will receive traditional physiotherapy ( postural drainage, percussion , diaphragmatic breathing, phase 1 cardiac Rehabilitation and balance training ) three times per week for 4 weeks
219649775|NCT00200109|DEVICE|Occipital Nerve Stimulation|Each group had a different plan
219649776|NCT00895128|DRUG|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
219649777|NCT00895128|DRUG|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
219649778|NCT00622661|OTHER|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
219649779|NCT00622661|OTHER|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
218963181|NCT04042935|DRUG|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
218963182|NCT04066764|DRUG|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
218963183|NCT04066764|DRUG|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
218963184|NCT04066764|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
218963185|NCT01569464|DRUG|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
218963186|NCT01569464|OTHER|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
218963187|NCT03551925|BEHAVIORAL|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
218963188|NCT03551925|BEHAVIORAL|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
218963189|NCT00227071|BEHAVIORAL|exercise|
218963190|NCT00296608|DRUG|fluorouracil|
218963191|NCT00296608|DRUG|leucovorin calcium|
218963192|NCT00296608|PROCEDURE|conventional surgery|
218963193|NCT00296608|RADIATION|radiation therapy|
218963194|NCT03687164|OTHER|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
218963195|NCT05956210|DEVICE|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
219649780|NCT00279617|DRUG|levetiracetam|open label levetricetam
219649781|NCT01878812|BIOLOGICAL|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
219649782|NCT02523924|DRUG|18F-DCFPyL|18F-DCFPyL PET/CT
219649783|NCT02677038|DRUG|Olaparib|Given PO
219649784|NCT03671564|DRUG|Milademetan|Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
219649785|NCT06647602|DRUG|Euthyrox (levothyroxine)|Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
219649786|NCT06647602|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
219649787|NCT02078375|DIETARY_SUPPLEMENT|Protein|whey protein plus casein protein
218963196|NCT04983212|OTHER|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
218963197|NCT02468011|OTHER|vibration|vibration will be applied at 35 Hz
218963198|NCT00419679|PROCEDURE|x-ray diffraction of human hair|
218963199|NCT04144465|DRUG|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
218963200|NCT04144465|DRUG|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
218963201|NCT04600310|DEVICE|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
218963202|NCT04600310|DEVICE|No Intervention|Conventional skin preparation technique
218963203|NCT00629278|BIOLOGICAL|trastuzumab|
218963204|NCT00629278|DRUG|aromatase inhibition therapy|
218963205|NCT00629278|DRUG|cyclophosphamide|
218963206|NCT00629278|DRUG|docetaxel|
218963207|NCT00629278|DRUG|doxorubicin hydrochloride|
218963208|NCT00629278|DRUG|epirubicin hydrochloride|
218963209|NCT00629278|DRUG|fluorouracil|
218963210|NCT00629278|DRUG|paclitaxel|
218963211|NCT00629278|DRUG|releasing hormone agonist therapy|
218963212|NCT00629278|DRUG|tamoxifen citrate|
219649788|NCT02078375|DIETARY_SUPPLEMENT|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
219649789|NCT02078375|OTHER|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
219649790|NCT04294706|DIETARY_SUPPLEMENT|Hemp arm|Hemp oil
219649791|NCT06411951|OTHER|Participation in the INTUK care offer at Klinik Zugersee|Person-centered treatment and care tailored to the individual patients needs by a team consisting of a senior physician, a nurse, social workers and peers.
219649792|NCT05502744|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
219649793|NCT03590535|DIAGNOSTIC_TEST|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
219649794|NCT03590535|DIAGNOSTIC_TEST|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
219649795|NCT01176695|DRUG|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
219649796|NCT01176695|DRUG|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
219649797|NCT05913635|BEHAVIORAL|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
219649798|NCT05913635|BEHAVIORAL|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
219649799|NCT06621706|DEVICE|Gastric ultrasonography|"Women will be requested to fast 2 hours for clear drinks, 6 hours for a light meal, and 8 hours for a meal high in fried or fatty content prior to their next antenatal clinic visit.~On the day of assessment, fasting and dietary compliance will be confirmed individually with each woman and Gastric ultrasonography will be performed after sex and eight hours of fasting food.~Women will be first scanned in a semi-recumbent (45 degrees head up) supine position, followed by a semi-recumbent (45 degrees head up) right lateral position (RLP). In both positions the gastric antrum will be identified in the sagittal plane with its internal anatomical landmarks identified, i.e. the left lobe of the liver anteriorly and the abdominal aorta posteriorly."
219649800|NCT00655148|BIOLOGICAL|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
219649801|NCT00655148|BIOLOGICAL|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
219649802|NCT03775122|DEVICE|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
219649803|NCT03347734|BEHAVIORAL|Eye exercises group|"* 20 times hot water, 20 times cold water washing face in the morning and evening.~* Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~* 20 blinks~* Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
219649804|NCT03347734|BEHAVIORAL|Convergence exercise group|"* Close eyes for 15 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 20 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Blink for 5 s,~* Close eyes for 5 s."
218963213|NCT00629278|PROCEDURE|adjuvant therapy|
218963214|NCT00629278|RADIATION|radiation therapy|
218963215|NCT02962843|BEHAVIORAL|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
218963216|NCT04948931|OTHER|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
218963217|NCT04948931|OTHER|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
218963218|NCT04948931|OTHER|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
218963219|NCT04839575|DRUG|Latiglutenase|Administered orally (daily)
218963220|NCT04839575|DRUG|Placebo|Administered orally (daily)
218963221|NCT01286831|DRUG|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
218963222|NCT03739788|DRUG|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
218963223|NCT04445116|DEVICE|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
218963224|NCT04726098|DRUG|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
218963225|NCT04726098|DRUG|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
218963226|NCT02539615|DEVICE|ForeCYTE Breast Aspirator|
218963227|NCT03458598|PROCEDURE|Rectus sheath block|Rectus sheath block under ultrasound
218963228|NCT03458598|PROCEDURE|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
219649805|NCT03347734|BEHAVIORAL|Oculomotor Exercise Group (OMEG)|"* The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~* The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~* The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~* The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
219649806|NCT02779335|OTHER|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
218963229|NCT03458598|DRUG|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
218963230|NCT03458598|PROCEDURE|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
218963231|NCT02831907|PROCEDURE|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
218963232|NCT02178683|DRUG|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
218963233|NCT04028661|DEVICE|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
218963234|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 30 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
218963235|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 100 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
218963236|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 300 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
218963237|NCT05471076|OTHER|Placebo|Administered via injection as a split dose into the deltoid muscle (both left and right).
218963238|NCT05471076|BIOLOGICAL|BG505|A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
218963239|NCT03407339|OTHER|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
218963240|NCT04473573|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
218963241|NCT03539224|DRUG|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
218963242|NCT03539224|DRUG|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
218963243|NCT01721980|DRUG|GLPG0974|
218963244|NCT01721980|DRUG|Placebo|
218963245|NCT01376557|DRUG|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
218963246|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
218963247|NCT01376557|DRUG|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
218963248|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
218963249|NCT01376557|DRUG|Placebo|Subjects will receive placebo once daily.
218963250|NCT02940106|DEVICE|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
218963251|NCT02940106|DEVICE|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
218963252|NCT01390220|DRUG|USL261|
218963253|NCT01390220|DRUG|Placebo|
218963254|NCT01466543|DRUG|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
218963255|NCT01466543|DRUG|Placebo|Placebo
218963256|NCT01989260|DEVICE|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
218963257|NCT06299423|DEVICE|Howdy Senior® device|Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
218963258|NCT02045303|DEVICE|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
218963259|NCT02045303|DEVICE|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
218963260|NCT03063203|DRUG|Decitabine|"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
218963261|NCT03063203|PROCEDURE|Bone marrow biopsy/aspirate|"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
218963262|NCT03063203|PROCEDURE|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
219062348|NCT01583972|DIETARY_SUPPLEMENT|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
218963263|NCT03063203|PROCEDURE|Skin biopsy|"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
218963264|NCT03063203|PROCEDURE|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
218963265|NCT00555139|DRUG|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
218963266|NCT00555139|DRUG|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
218963267|NCT00555139|DRUG|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
218963268|NCT00555139|DRUG|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
218963269|NCT00026611|BIOLOGICAL|Dryvax vaccine|
218963270|NCT02318108|OTHER|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
218963271|NCT02318108|OTHER|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
218963272|NCT05517460|OTHER|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
218963273|NCT05517460|OTHER|health education|health education for self-care and medication adherence
218963274|NCT04946227|DRUG|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
218963275|NCT03448081|DRUG|SNA-120|SNA-120 (0.5%) active ointment
218963276|NCT03448081|DRUG|Placebo|Vehicle Ointment
218963277|NCT03448081|DRUG|Calcipotriene|Calcipotriene ointment (0.005%)
218963278|NCT01856023|DRUG|High Dose Interleukin-2|
218963279|NCT01856023|DRUG|Ipilimumab|
218963280|NCT00755911|BIOLOGICAL|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
218963281|NCT00755911|DEVICE|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
218963282|NCT04082039|OTHER|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
218963283|NCT04082039|OTHER|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
219686270|NCT01261390|DEVICE|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
218963284|NCT04132375|DRUG|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
218963285|NCT04132375|DRUG|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
218963286|NCT00796354|DRUG|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
218963287|NCT00796354|DRUG|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
218963288|NCT00829283|BEHAVIORAL|Behavioral Weight Loss|weekly individual sessions for 6 months
218963289|NCT00829283|BEHAVIORAL|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
218963290|NCT00829283|DRUG|Placebo|One pill daily
218963291|NCT00829283|DRUG|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
218963292|NCT01411072|DRUG|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
218963293|NCT01411072|DRUG|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
218963294|NCT05186428|OTHER|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
218963295|NCT05186428|OTHER|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
218963296|NCT05958693|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
218963297|NCT05958693|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
218963298|NCT00453960|DIETARY_SUPPLEMENT|Genivis|54 mg/day daily for 6 months
218963299|NCT00453960|DRUG|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
218963300|NCT00453960|OTHER|placebo|tablets daily for 6 months
219649807|NCT06648369|OTHER|MAX-ICH care bundle|The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.
219649808|NCT06648369|OTHER|Standard of care|The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
219649809|NCT03698838|DEVICE|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
219649810|NCT01505738|OTHER|bacterial samples|bacterial samples taken
218963301|NCT00536861|DRUG|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
219649811|NCT00515359|PROCEDURE|Intermittent Propofol Sedation|Intermittent versus continuous dosage
219649812|NCT00515359|PROCEDURE|Continuous Propofol Sedation|intermittent vs continuous dosage
219649813|NCT03270475|OTHER|exercise training|subjects complete 4-5 weeks of training
219649814|NCT06623552|OTHER|Neck Pain and Disability Scale (NPDS)|"The Turkish version of the Neck Pain and Disability Scale (NPDS), developed by Wheeler et al., was used for individuals with neck pain. The severity of neck pain is evaluated on a 5-point Likert scale; where 0 indicates no pain and 4 indicates very severe pain. The score is higher in those with upper extremity symptoms.The cut-off value of this scale was set to 15 to detect disability-related neck pain.The cut-off value is mandatory to evaluate a patient or a particular group of patients for clinically significant neck pain by distinguishing it from insignificant pain"
219649815|NCT06623552|OTHER|Fonseca Anamnestic Index (FAI)|It is a questionnaire consisting of 10 questions, including pain during the period, parafunctional habits, movement restriction, clicking, malocclusion, emotional stress.In this study, clinical signs relevant to each severity category of Fonseca's anamnestic index were used to detect the frequency of symptoms and to characterize the symptoms and clinical findings of TMD.The Turkish version of Fonseca's Anamnestic Index (FAI) questionnaire was used to assess the symptom severity.
219649816|NCT06623552|OTHER|Evaluation of Jaw Functional Limitation|The Jaw Functional Limitation Scale (JFLS) was developed as an 8-item scale for general functional limitation in the jaw. In the light of the obtained items and supporting psychometric data, it has been expanded and re-developed to include the verbal and non-verbal communication limitations that occur in a 20-item tool16 JFLS-20 is a tool with three structure contents (chewing, vertical mobility of jaw state and emotional and verbal statement) to evaluate functional state.Difficulty performing a determined task is graded from 0 (without limitation) to 10 (severe limitation). Higher scores are a more serious sign of functional limitation.
219649817|NCT06620692|DRUG|5% GM-XANTHO [GM-XAN003]|5% GM-XANTHO \[GM-XAN003\]
219649818|NCT06620692|DRUG|Placebo|The placebo
219649819|NCT03042169|DRUG|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
219649820|NCT03042169|PROCEDURE|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
219649821|NCT03042169|DRUG|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
219686271|NCT00873717|OTHER|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
219686272|NCT00873717|OTHER|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
219686273|NCT00873717|OTHER|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
218963302|NCT01039012|OTHER|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
218963303|NCT01039012|OTHER|Standard Care|Participant follow the standard care recommended by their physician.
219062349|NCT01583972|DIETARY_SUPPLEMENT|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
218963304|NCT05965648|BEHAVIORAL|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
218963305|NCT02923544|PROCEDURE|YUMI manipulator|
219649822|NCT06622395|DIAGNOSTIC_TEST|Remote diagnosys|Remote Diagnostic Arm (Teleconsultation): First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability). Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction.
219649823|NCT02916394|RADIATION|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
219649824|NCT00904202|DRUG|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
219062350|NCT03876327|PROCEDURE|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
219062351|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
219649825|NCT00904202|DRUG|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
218963306|NCT04573647|DRUG|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
219649826|NCT00904202|DRUG|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
219649827|NCT00904202|DRUG|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
219649828|NCT00904202|DRUG|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
219649829|NCT00904202|DRUG|Gabapentin 1800 mg/day + Lidoderm patch|
219649830|NCT02892604|DEVICE|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
219649831|NCT04747067|DEVICE|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
218963307|NCT06057740|BEHAVIORAL|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig \& Levin, 2017).
219062352|NCT06223646|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
219062353|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
219062354|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
219062355|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
219062356|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
218963308|NCT06057740|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
219062357|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
219062358|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
219062359|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
218963309|NCT04718103|BIOLOGICAL|GSK3511294|GSK3511294 was administered using a pre-filled syringe.
219649832|NCT05997823|OTHER|kinesiotape|The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension
219649833|NCT05997823|OTHER|home exercises|home exercises
219649834|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
219649835|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
218963310|NCT04718103|BIOLOGICAL|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
219649836|NCT01489124|DRUG|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
219649837|NCT00591058|DRUG|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
219649838|NCT06622551|DIETARY_SUPPLEMENT|Iron-folic acid supplement|The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.
219649839|NCT05007041|BIOLOGICAL|FLUAD® Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
219649840|NCT05007041|BIOLOGICAL|Fluzone® High-Dose Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
219649841|NCT05007041|BIOLOGICAL|SHINGRIX®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
219649842|NCT00443664|DEVICE|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
218963311|NCT05982431|OTHER|Traditional physical therapy program|60-minutes exercise program, three times a week on alternate days for 12 successive weeks
218963312|NCT05982431|OTHER|Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
218963313|NCT05982431|OTHER|placebo Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
218963314|NCT04387383|DEVICE|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
218963315|NCT04387383|DEVICE|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
219062360|NCT02384603|OTHER|Global postural reeducation|
219062361|NCT02384603|OTHER|Segmental muscle stretching exercises|
219649843|NCT05540041|OTHER|Bubble breathing play therapy group|The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.
219649844|NCT05540041|OTHER|Tell-show-do play therapy group|The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.
219649845|NCT05540041|OTHER|No intervention|Routine nursing care
219649846|NCT05899075|OTHER|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
219649847|NCT05899075|OTHER|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
219649848|NCT03896711|BEHAVIORAL|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
219686274|NCT04906226|BEHAVIORAL|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
219686275|NCT01715948|DEVICE|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
218963316|NCT04167956|DEVICE|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
218963317|NCT00825851|DRUG|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
218963318|NCT00825851|DRUG|Placebo patch|
218963319|NCT00825851|BEHAVIORAL|Smoking cessation|
218963320|NCT00825851|BEHAVIORAL|Continuous smoking|subjects smoke 20 cigarettes per day
218963321|NCT02756065|OTHER|no intervention|no intervention is used
218963322|NCT01016704|BEHAVIORAL|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
219062362|NCT02384603|OTHER|Cognitive behavioral therapy|
219062363|NCT03943810|OTHER|No intervention|There is no intervention
219062364|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
219062365|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
219062366|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
219062367|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
219062368|NCT00228527|DRUG|Esomeprazole (Nexium)|
219649849|NCT03896711|OTHER|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
219062369|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
219062370|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
219649850|NCT01266785|DRUG|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
219649851|NCT04889157|DRUG|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
219649852|NCT04889157|DRUG|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
219062371|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
219062372|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
219062373|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
219649853|NCT03873415|DRUG|BMS-986165|Oral administration
219649854|NCT05720026|DRUG|SYSA1901|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
219649855|NCT05720026|DRUG|Pertuzumab|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
219649856|NCT05720026|DRUG|Trastuzumab|loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
219649857|NCT05720026|DRUG|Docetaxel|75 mg/m\^2 IV, q3w/cycle, total 4cycle
219062374|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
219062375|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
219062376|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
219062377|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
219062378|NCT00000252|DRUG|0% N2O|
219062379|NCT00000252|DRUG|10% N2O|
219649858|NCT01546168|DEVICE|esophageal deviation with IDE device|esophageal deviation during AF ablation
219649859|NCT04258540|BEHAVIORAL|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
219649860|NCT04258540|BEHAVIORAL|yoga course|yoga course
219649861|NCT02850016|DRUG|3BNC117|Intravenous Infusion of 3BNC117
219649862|NCT02850016|DRUG|Romidepsin|Intravenous Infusion of Romidepsin
219649863|NCT02034396|PROCEDURE|Blood Draw|One blood draw at enrollment
219649864|NCT05919914|OTHER|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
219649865|NCT05919914|OTHER|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
219649866|NCT02946814|DRUG|essential oils|
219062380|NCT00000252|DRUG|20% N2O|
219062381|NCT00000252|DRUG|30% N2O|
219062382|NCT00000252|DRUG|40% N2O|
219062383|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
219062384|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
219062385|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
219062386|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
219649867|NCT02946814|DRUG|essential oils without mouthwash|
219649868|NCT02946814|DRUG|sterile water|
219649869|NCT05959408|PROCEDURE|Collection of throat swab|Introduction of a cotton swab for self-collection
219649870|NCT05959408|PROCEDURE|Collection of anal swab|Introduction of a cotton swab for self-collection
219649871|NCT05959408|PROCEDURE|Collection of first void urine|first void urine collected on urine pot
219649872|NCT00157911|DRUG|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
219649873|NCT00157911|DRUG|Comparator: simvastatin / Duration of Treatment: 12 weeks|
219649874|NCT02954653|BIOLOGICAL|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
219649875|NCT02954653|DRUG|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
219649876|NCT02954653|DRUG|Daunorubicin|60-90 mg/m2 daily for 3 days
219649877|NCT02954653|DRUG|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
219649878|NCT02954653|DRUG|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
219649879|NCT05308784|OTHER|Cellworks Singula and Ventura reports|Personalized drug match reports based on patients' genomic aberration.
219649880|NCT01032421|PROCEDURE|IVF procedure|
219649881|NCT04875390|OTHER|Erector spina plane block|After the surgery is completed, intraoperative Erector spina plane block will be performed
219649882|NCT04875390|OTHER|local infiltration|After the surgery is completed, intraoperative local infiltration will be performed
219649883|NCT02211690|DRUG|dolutegravir 50 mg (one tablet daily)|
219649884|NCT02211690|DRUG|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
218963323|NCT00322153|DRUG|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
218963324|NCT00322153|DRUG|Placebo|Matching placebo oral administration once daily.
218963325|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
218963326|NCT00136604|BIOLOGICAL|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
218963327|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
218963328|NCT00136604|BIOLOGICAL|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
218963329|NCT02829983|DRUG|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
218963330|NCT02829983|DRUG|Placebo|Use of placebo tablets twice a day for 3 days.
219649885|NCT00711828|DRUG|Bortezomib|Given IV
219649886|NCT00711828|BIOLOGICAL|Rituximab|Given IV
219649887|NCT00711828|DRUG|Cyclophosphamide|Given PO
218963331|NCT02829983|OTHER|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
218963332|NCT06477809|DEVICE|ARIA Glasses ( Augmented Reality in Audio )|ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
218963333|NCT01879540|BIOLOGICAL|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
218963334|NCT03004248|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular Injection
218963335|NCT01309893|DEVICE|Investigational Lens|Lenses worn on a daily wear basis for one week
218963336|NCT01309893|DEVICE|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
218963337|NCT06312969|BEHAVIORAL|Video game based training|"Type of intervention: Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games~Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
219649888|NCT00711828|DRUG|Dexamethasone|Given PO
219649889|NCT00711828|OTHER|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
219649890|NCT00711828|OTHER|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
219649891|NCT01825174|BEHAVIORAL|Ball games program|twice a week different ball games 90min
219649892|NCT01825174|BEHAVIORAL|Nutrition counseling|9 units of 90min each of nutrition counseling
219649893|NCT06260267|DRUG|Microbiota suspension|Microbiota suspension
219649894|NCT06260267|DRUG|Microbiota capsule|Microbiota capsule
219649895|NCT06260267|DRUG|Placebo suspension|Placebo suspension
219649896|NCT06260267|DRUG|Placebo capsule|Placebo capsule
219649897|NCT04218292|DEVICE|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
219649898|NCT01890226|BEHAVIORAL|Mobile Personal Health Record App.|
219649899|NCT00278226|BEHAVIORAL|smoking cessation intervention|
219649900|NCT00278226|OTHER|educational intervention|
219649901|NCT02286648|DRUG|Formocresol|pulpotomy with formocresol
219649902|NCT02286648|DRUG|Mineral Trioxide Aggregate|pulpotomy with MTA
219649903|NCT05551520|DEVICE|Normative|ImPACT will be administered at baseline testing
219649904|NCT05551520|DEVICE|Reliability|ImPACT will be administered again within 60 days of baseline test
219649905|NCT01659346|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
219649906|NCT01659346|DRUG|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
219649907|NCT03826810|RADIATION|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
219649908|NCT03826810|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
219649909|NCT03407703|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|HCV treatment
219649910|NCT00483210|DRUG|Fenofibrate|
219649911|NCT05028413|BEHAVIORAL|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
219649912|NCT00994695|BIOLOGICAL|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
219649913|NCT03912818|DRUG|Carboplatin|Given IV
219649914|NCT03912818|DRUG|Cisplatin|Given IV
219649915|NCT03912818|PROCEDURE|Cystectomy|Undergo cystectomy
219649916|NCT03912818|DRUG|Doxorubicin|Given IV
219649917|NCT03912818|BIOLOGICAL|Durvalumab|Given IV
219649918|NCT03912818|DRUG|Gemcitabine|Given IV
219649919|NCT03912818|DRUG|Methotrexate|Given IV
219649920|NCT03912818|DRUG|Vinblastine|Given IV
219649921|NCT00006066|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
219649922|NCT00006066|BIOLOGICAL|Diphtheria and Tetanus Toxoids Adsorbed|
219649923|NCT00006066|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|
219649924|NCT00006066|DRUG|Bacteriophage phi X 174|
219649925|NCT00006066|DRUG|Aldesleukin|
219649926|NCT06621225|DEVICE|Artificial Intelligence|Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
219649927|NCT06621225|DEVICE|Mucosal Exposure Device|The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
218963338|NCT00001860|DRUG|Sandostatin LAR Depot versus transsphenoidal surgery|
219649928|NCT04398186|DIAGNOSTIC_TEST|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
219649929|NCT00715728|DEVICE|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
218963339|NCT02798614|DEVICE|10-day cast|Removal of plaster cast fixation 10 days after reduction
218985252|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
218985253|NCT02164214|DRUG|etanercept Treatment|
219062387|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
219649930|NCT00715728|DEVICE|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
219649931|NCT05876793|DRUG|Remimazolam tosilate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
219649932|NCT01930344|DEVICE|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
219649933|NCT01930344|DEVICE|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
219062388|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
219649934|NCT03841539|BEHAVIORAL|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
219649935|NCT03841539|DIETARY_SUPPLEMENT|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
219649936|NCT03841539|BEHAVIORAL|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
219649937|NCT03541330|OTHER|semi-directive interview|semi-structured interview conducted by a clinical psychologist
219649938|NCT02526875|DRUG|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
219062389|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
219062390|NCT00001100|DRUG|ganciclovir|
219062391|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
219062392|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
219062393|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
219062394|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
219062395|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
219649939|NCT02387775|DEVICE|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
219649940|NCT01200459|BEHAVIORAL|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
219649941|NCT01206413|DIETARY_SUPPLEMENT|Low glycemic index diet|
219649942|NCT01206413|DIETARY_SUPPLEMENT|High glycemic index diet|
219649943|NCT01206413|OTHER|Home-based exercise intervention|
219649944|NCT01206413|OTHER|Non-exercisers|
219649945|NCT06057493|OTHER|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
219649946|NCT03589963|BEHAVIORAL|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
219649947|NCT06254508|BEHAVIORAL|Online program that includes exercise guided by the FITT-VP principle and dietary advice|"1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance."
219649948|NCT06254508|BEHAVIORAL|Conventional in-clinic nutrition and exercise advice and self-control|Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
219649949|NCT00556634|DRUG|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
219649950|NCT05021289|BEHAVIORAL|guided imagery|guided imagery
219649951|NCT06355089|DIETARY_SUPPLEMENT|Placebo Comparator|Low-protein milk product
219649952|NCT06355089|DIETARY_SUPPLEMENT|Whey protein hydrolysate milk product|Milk product with whey protein hydrolysate
219649953|NCT06355089|DIETARY_SUPPLEMENT|Postbiotic and whey protein hydrolysate milk product|Milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
219649954|NCT01252862|DEVICE|iStent|Implantation of two iStents through a small temporal clear corneal incision
219649955|NCT01500213|DRUG|Rolapitant|200 mg PO
219649956|NCT01500213|DRUG|Granisetron|10 mcg/kg IV
219649957|NCT01500213|DRUG|Dexamethasone|20 mg PO and 8 mg PO
219649958|NCT01500213|DRUG|Placebo|(4 X 0 mg capsules) o mg PO
219649959|NCT02468128|DRUG|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
219649960|NCT02468128|DRUG|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
219649961|NCT03667417|OTHER|Questionnaires|standardized data collection and 10-year prospective follow-up
219649962|NCT02172586|DRUG|Telmisartan|
219649963|NCT02172586|DRUG|Losartan|
219649964|NCT02172586|DRUG|Hydrochlorothiazide|
219649965|NCT06726837|OTHER|Postoperative pain - 6th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 6th hour.
219649966|NCT06726837|OTHER|Postoperative pain - 24th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 24th hour.
219649967|NCT06726837|OTHER|Postoperative pain - 48th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 48th hour.
219649968|NCT06726837|OTHER|Postoperative pain - 72nd hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 72nd hour.
219649969|NCT06726837|OTHER|Postoperative pain - 7 day|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 7 day.
219686276|NCT01715948|DEVICE|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
219686277|NCT00625456|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
219649970|NCT05274542|OTHER|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
219686278|NCT00643019|BEHAVIORAL|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
218985254|NCT03187275|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
218985255|NCT03187275|OTHER|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
219686279|NCT00643019|OTHER|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
219686280|NCT04928456|OTHER|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
219686281|NCT01693913|BEHAVIORAL|cognitive behavioral exercise and nutrition over|
219686282|NCT01693913|BEHAVIORAL|nutrition and exercise education|
219686283|NCT05609396|BEHAVIORAL|Behaviorally enhanced reminder letter|Behavioral interventions to increase FIT-based colorectal cancer screening uptake
219686284|NCT05861414|BEHAVIORAL|EWM-T|"This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials."
219686285|NCT02411240|DEVICE|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
219686286|NCT00624000|DRUG|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
219686287|NCT00646373|OTHER|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
219686288|NCT01005576|DRUG|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
219686289|NCT05231343|PROCEDURE|Dual Mini-fragment Plating|Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.
219686290|NCT05231343|PROCEDURE|Single Precontoured Plating|Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
219686291|NCT00089518|DRUG|Valsartan|
219686292|NCT00055120|DRUG|Emtricitabine/tenofovir disoproxil fumarate|
219686293|NCT00055120|DRUG|Lopinavir/ritonavir|
219686294|NCT00055120|DRUG|Stavudine|
219686295|NCT03468725|DRUG|XPF-008|Capsule filled with XEN1101
219686296|NCT03468725|DRUG|Microcrystalline Cellulose|Placebo capsule
219686297|NCT06072118|DRUG|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
219686298|NCT02721056|RADIATION|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
219686299|NCT04749095|DRUG|Erector spinae plane block|bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
219686300|NCT04749095|DRUG|sham subcutaneous infiltration|bilateral ESP block will be injected with 20 ml of normal saline
219686301|NCT00469222|PROCEDURE|hypofractionated external beam|
219686302|NCT02492893|OTHER|Hatha yoga|
219649971|NCT05274542|OTHER|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
219649972|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
219649973|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
219649974|NCT00460707|DRUG|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
219649975|NCT00460707|DRUG|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
219649976|NCT00460707|DRUG|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
219649977|NCT00460707|DRUG|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
219649978|NCT00460707|DRUG|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
219649979|NCT01447875|OTHER|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
219649980|NCT01447875|DRUG|propofol or mexmedetomidine|
218963340|NCT05047627|BEHAVIORAL|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
218963341|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
218963342|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
218963343|NCT00591578|DRUG|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
218963344|NCT01644370|DRUG|HAART|as per Thai HIV Treatment guidelines
219649981|NCT03098056|OTHER|PROG2|"Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food"
218963345|NCT00791232|DRUG|extended-release (ER) OROS paliperidone|
218963346|NCT02632838|DEVICE|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
218963347|NCT03712254|DRUG|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
218963348|NCT02859818|OTHER|therapeutic education program|
218963349|NCT02352584|BIOLOGICAL|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
218963350|NCT02352584|BIOLOGICAL|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
218963351|NCT02352584|BIOLOGICAL|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
218963352|NCT03631355|DRUG|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
218985256|NCT01286233|DRUG|Metformin|
218985257|NCT01286233|DRUG|Placebo|
219649982|NCT02097797|OTHER|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
219062396|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
219062397|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
219062398|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
219062399|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
219649983|NCT02097797|OTHER|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
219649984|NCT00250536|DRUG|nandrolone decanoate|
219649985|NCT00250536|BEHAVIORAL|resistance exercise training|
218963353|NCT06133738|OTHER|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
218963354|NCT06133738|OTHER|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
218963355|NCT06133738|OTHER|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
218963356|NCT03143491|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
218963357|NCT01165567|DRUG|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
218963358|NCT02810340|BIOLOGICAL|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
218963359|NCT02810340|BIOLOGICAL|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
218963360|NCT02810340|BIOLOGICAL|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
218963361|NCT04652180|PROCEDURE|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
218963362|NCT05879510|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
218963363|NCT05930366|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
218963364|NCT05930366|PROCEDURE|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
218963365|NCT03468569|OTHER|Functional Movement Screen|
218963366|NCT04063527|DRUG|adjuvant chemotherapy|combination of paclitaxel and carboplatin
218963367|NCT03900962|OTHER|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
218963368|NCT03900962|OTHER|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
218963369|NCT05880823|DEVICE|Synergy cervical disc system|motion preservation disc
218963370|NCT02261025|DRUG|acetylsalicylic acid|75-100mg,per day
219062400|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
219062401|NCT01344460|DRUG|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
219062402|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
219062403|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
219062404|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
219062405|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
219649986|NCT01733043|DRUG|Dexmedetomidine|
219649987|NCT01733043|DRUG|Placebo|
218963371|NCT04077476|BEHAVIORAL|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
218963372|NCT04077476|BEHAVIORAL|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
218963373|NCT01983150|BEHAVIORAL|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
218963374|NCT01983150|BEHAVIORAL|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
218963375|NCT00122733|DRUG|loxapine|
218963376|NCT03945175|DRUG|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
218963377|NCT03945175|DRUG|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
218963378|NCT00951782|DEVICE|High frequency TMS|deep TMS HADD coil
218963379|NCT00951782|DEVICE|Sham TMS|sham deep TMS HADD coil
218963380|NCT00951782|DEVICE|Low frequency TMS|Deep TMS - HADD coil
218963381|NCT03230669|OTHER|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
218963382|NCT00688207|DRUG|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
218963383|NCT04252833|DRUG|CT-044|CT-044 HCl is a reactive species decomposition accelerant
219062406|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
219062407|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
219062408|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
219649988|NCT06730243|PROCEDURE|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"
219649989|NCT06730243|PROCEDURE|Standard Robot-Assisted Radical Prostatectomy|Standard Robot-Assisted Radical Prostatectomy
219649990|NCT06730243|PROCEDURE|Laparoscopic Radical Prostatectomy|Laparoscopic Radical Prostatectomy
219649991|NCT03197870|DRUG|AKB-9778|Subcutaneous AKB-9778 15mg
219649992|NCT03197870|DRUG|Placebo|Subcutaneous Placebo
218963384|NCT02088515|DRUG|Nedaplatin|
218963385|NCT02088515|DRUG|Cisplatin|
218963386|NCT02088515|DRUG|Docetaxel|
218963387|NCT03917433|BEHAVIORAL|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
219062409|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
219062410|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
219062411|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
219062412|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
219062413|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
219649993|NCT05737017|DEVICE|ClearCoajet|The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.
219649994|NCT00313365|PROCEDURE|Surgical Lavage (Arthrotomy)|
219649995|NCT00313365|PROCEDURE|Arthrocentesis (Serial needle aspiration)|
219649996|NCT03294291|PROCEDURE|Quadratus lumborum block|Postoperative pain procedure
219649997|NCT03294291|PROCEDURE|Caudal block|Postoperative pain procedure
218963388|NCT03917433|BEHAVIORAL|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
219649998|NCT00807391|PROCEDURE|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
219649999|NCT03725774|OTHER|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
219650000|NCT05304689|DIAGNOSTIC_TEST|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
219650001|NCT01570634|DRUG|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
218963389|NCT03917433|BEHAVIORAL|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
218963390|NCT03716570|DRUG|BIIB054|Administered as specified in the treatment arm.
218963391|NCT03716570|DRUG|Placebo|Administered as specified in the treatment arm.
218963392|NCT00870233|BEHAVIORAL|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
219650002|NCT01542034|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
219650003|NCT01542034|DRUG|Placebo|Phosphate buffered saline placebo for injection
219650004|NCT05020418|OTHER|Chart Review|Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
219650005|NCT06342583|OTHER|Advanced social relations training with technical device|15 participants from the experimental group will undergo a first part in which they will be guided through social stories to construct an appropriate conversation repertoire. In the first phase the participants will see 8 social stories with scenes from everyday life and after learning the correct mode of interaction and communication they will be asked to interact in the group by playing the roles previously seen in the social stories. These will be shown on a technological device. Participants will have the opportunity to choose the correct mode of interaction by selecting it directly on the technological device. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media. Slides will be shown to explain risks and correct use and the operator will show on the technological device (Smartphone) all the practical steps to be taken (e.g. privacy settings).
219650006|NCT06342583|OTHER|Advanced social relations training without technical device|15 participants from the control group will undergo a first part in which they will be guided through social stories to build an appropriate conversation repertoire. In the first phase, the participants will see eight social stories illustrating scenes from everyday life and, after learning the correct modes of interaction and communication, they will be invited to interact in the group by playing the roles previously seen in the social stories. These will be shown in traditional mode (flashcards). Participants will have the opportunity to choose the correct mode of interaction by touching the card showing the appropriate mode. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media (facebook, instagram, TikTok, Whatsapp, YouTube). The trainer will show images on paper related to risks and correct use of social media.
218963393|NCT00825773|DEVICE|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
218963394|NCT05999942|DRUG|Liposomal Amikacin for Inhalation|Administered via the Pari LC STAR™ nebulizer.
218963395|NCT03221764|DRUG|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
218963396|NCT03221764|DEVICE|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
218963397|NCT00349271|PROCEDURE|Stem cell|Stem cell
218963398|NCT00349271|DRUG|Filgrastime (G-CSF)|Filgrastime (G-CSF)
218963399|NCT00349271|DRUG|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
218963400|NCT01768247|DRUG|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
218963401|NCT02686190|OTHER|Luxtherapy|
218963402|NCT00378079|OTHER|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
218963403|NCT00378079|DRUG|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
218963404|NCT00378079|DRUG|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
218963405|NCT02902679|DRUG|BMS-986177|
218963406|NCT02778360|DEVICE|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
218963407|NCT02778360|DRUG|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
218963408|NCT03654430|OTHER|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
218963409|NCT01795066|DEVICE|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
218963410|NCT01449695|BEHAVIORAL|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
219062414|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
219062415|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
219062416|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
219650007|NCT02612610|DRUG|Gefapixant|Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
219650008|NCT02612610|DRUG|Placebo (for gefapixant)|
219650009|NCT05801900|DRUG|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
219650010|NCT05801900|DRUG|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
219650011|NCT01801280|DRUG|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
219650012|NCT01801280|DRUG|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
219650013|NCT01801280|DRUG|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
219650014|NCT02149823|DRUG|Syntocinon 24 Intranasal Units (IU)|
219650015|NCT02149823|DRUG|Syntocinon 40 Intranasal Units (IU)|
219650016|NCT02149823|DRUG|Intranasal Placebo|
218963411|NCT01449695|BEHAVIORAL|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
218963412|NCT01449695|BEHAVIORAL|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
218963413|NCT04178356|OTHER|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
218963414|NCT04178356|OTHER|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
218963415|NCT01609101|DEVICE|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
218963416|NCT01609101|DEVICE|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
218963417|NCT01609101|DEVICE|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
218963418|NCT01609101|DEVICE|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
218963419|NCT01609101|DEVICE|King Vision® videolaryngoscope|King Vision® videolaryngoscope
218963420|NCT01609101|DEVICE|Venner® videolaryngoscope|Venner® videolaryngoscope
218963421|NCT01609101|DEVICE|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
218963422|NCT05038176|BEHAVIORAL|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
218963423|NCT03109847|DRUG|Metformin Hydrochloride|Given Orally
218963424|NCT03109847|OTHER|Radioactive Iodine|Undergo radioactive iodine treatment
218963425|NCT03109847|OTHER|Placebo|Given orally
218963426|NCT01233687|DRUG|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
218963427|NCT00846170|DRUG|co-biotic|give probiotic 2 t/day
219650017|NCT00176644|DRUG|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
219650018|NCT02456389|OTHER|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
218963428|NCT00846170|DRUG|placebo 2T/day|cross over of patients from study arm to placebo arm
218963429|NCT00876603|PROCEDURE|ACDF|Anterior cervical decompression and fusion
218963430|NCT00876603|PROCEDURE|Cervical laminoplasty|Cervical laminoplasty
219650019|NCT02456389|OTHER|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
219650020|NCT02456389|OTHER|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
219650021|NCT02456389|OTHER|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
219650022|NCT02456389|OTHER|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
218963431|NCT01296243|DRUG|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
218963432|NCT04123028|OTHER|observatory|observation for 1 year period
218963433|NCT05840029|PROCEDURE|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
218963434|NCT05694000|DEVICE|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
218963435|NCT05694000|DEVICE|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
218963436|NCT00006389|DRUG|bryostatin 1|Given IV
218963437|NCT00006389|DRUG|cisplatin|Given IV
218963438|NCT00006389|OTHER|laboratory biomarker analysis|Correlative studies
219062417|NCT01081977|PROCEDURE|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
219062418|NCT01081977|PROCEDURE|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
219062419|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
219650023|NCT02456389|OTHER|Standard postoperative care|Routine postoperative care, as medically indicated
219650024|NCT05384002|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)
219650025|NCT06014697|DIAGNOSTIC_TEST|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
219650026|NCT06014697|OTHER|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
219650027|NCT04261413|DRUG|RS-0139|RS-0139 will be administered for the indication of solid tumors.
219650028|NCT03400709|DRUG|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
219650029|NCT03400709|DRUG|Placebo Oral Tablet|Placebo treatment
219650030|NCT05127304|DEVICE|Trelegy Ellipta|Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol
219650031|NCT05127304|DEVICE|Stiolto Respimat|Stiolto Respimat with Tiotropium Bromide/Olodaterol
219650032|NCT05127304|DRUG|Furoate/Umeclidinium/Vilanterol|Furoate/Umeclidinium/Vilanterol
218963439|NCT03977428|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
218963440|NCT01210287|DRUG|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
218963441|NCT05451342|DIAGNOSTIC_TEST|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
218963442|NCT03037268|DEVICE|Lytro Plenoptic Camera and 28D lens|"* visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader"
218963443|NCT03891160|OTHER|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
218963444|NCT04694456|OTHER|cytokines dosage|Mesure of cytokines concentration in serum
219062420|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
219062421|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
219062422|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
219650033|NCT05127304|DRUG|Tiotropium Bromide/Olodaterol|Tiotropium Bromide/Olodaterol
218963445|NCT04694456|PROCEDURE|test of walk|patient must walk during 6 minutes on a flat surface
218963446|NCT04694456|PROCEDURE|Manual muscular test|test performed to evaluate the patient muscular weakness
218963447|NCT04694456|PROCEDURE|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
218963448|NCT03114059|DIAGNOSTIC_TEST|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
218963449|NCT00169884|BEHAVIORAL|cognitive-behavioural therapy|
218963450|NCT04466228|DEVICE|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
218963451|NCT02728778|DRUG|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
218963452|NCT02728778|PROCEDURE|Acupuncture|Application of acupuncture into the forehead
218963453|NCT04862858|OTHER|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
218963454|NCT06104371|DEVICE|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
218963455|NCT05038904|DRUG|Acalabrutinib|100 mg oral capsule
219650034|NCT03583060|BEHAVIORAL|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
219650035|NCT02310425|DRUG|S. boulardii|50 mg/kg twice daily
219650036|NCT02310425|DRUG|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
219650037|NCT03858725|DRUG|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
218963456|NCT04545203|OTHER|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
218963457|NCT02845518|PROCEDURE|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
218963458|NCT04177238|DIETARY_SUPPLEMENT|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
218963459|NCT01771575|OTHER|Placebo device|Placebo device
218963460|NCT01771575|DEVICE|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
218963461|NCT03949491|PROCEDURE|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
218963462|NCT01253330|OTHER|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
218963463|NCT00224627|PROCEDURE|Capsule GIVEN IMAGING LTD|
218963464|NCT02770469|BEHAVIORAL|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
218963465|NCT02770469|BEHAVIORAL|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
218963466|NCT03069118|BEHAVIORAL|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
219650038|NCT03858725|DRUG|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
219650039|NCT00301301|DRUG|Gemcitabine|
219650040|NCT00301301|DRUG|Cisplatinum|
219650041|NCT00301301|DRUG|Rituximab|
219650042|NCT05274841|OTHER|Support of relatives|Screening of the support needs of relatives
219650043|NCT05600270|DEVICE|Angled guidewire|Cannulation of the common bile duct using an angled-tip guidewire during ERCP
219650044|NCT05600270|DEVICE|Straight guidewire|Cannulation of the common bile duct using an straight-tip guidewire during ERCP
219650045|NCT03777332|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
218963467|NCT03069118|BEHAVIORAL|Control - Resource List|Tailored list of resources.
218963468|NCT04590079|DEVICE|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
219062423|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
219062424|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
219062425|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
219062426|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
219650046|NCT02126267|PROCEDURE|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
219650047|NCT02126267|PROCEDURE|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
219650048|NCT02126267|DRUG|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
219650049|NCT02126267|DRUG|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
219650050|NCT02126267|DRUG|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
219650051|NCT06684730|PROCEDURE|Hand Function Assessment Scales|The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.
219650052|NCT06684730|OTHER|Prosthesis Satisfaction Scale|The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.
219650053|NCT06684730|OTHER|Quality of Life Scale|5Q-5D-5L will be used as quality of life scale.
219650054|NCT06684730|PROCEDURE|Kinematic Analysis|Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.
219650055|NCT06684730|PROCEDURE|Parkour Completion Time|A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.
219650056|NCT06684730|PROCEDURE|Fatigue Scale|A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.
219650057|NCT02891434|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
219650058|NCT02891434|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
219650059|NCT02891434|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
219650060|NCT04021121|DRUG|LZD|LZD 1200 mg daily
219650061|NCT04021121|DRUG|High dose RIF|RIF 35 mg/kg/day
219650062|NCT04021121|DRUG|Standard dose RIF|RIF 10 mg/kg/day
219650063|NCT00901017|DEVICE|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
219650064|NCT00901017|DEVICE|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
218963469|NCT02959164|DRUG|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
218963470|NCT02959164|DRUG|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
218963471|NCT00004017|PROCEDURE|conventional surgery|
218963472|NCT00004017|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
219062427|NCT00411021|PROCEDURE|Pipelle (Endometrial Sampling)|
219062428|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
219062429|NCT02116322|DEVICE|Expect 19 G Flex needle|
219650065|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
219650066|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
219650067|NCT05660005|OTHER|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
219650068|NCT05660005|OTHER|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
219650069|NCT05660005|OTHER|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
219650070|NCT05542706|OTHER|Accompanying caregivers by paramedical team|At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
219650071|NCT00832845|BEHAVIORAL|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
219650072|NCT00832845|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
219650073|NCT06444269|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
218963473|NCT03015883|RADIATION|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219650074|NCT06444269|DRUG|microbubble CEUS Contrast Enhanced Ultrasound (CEUS)|Microbubble Contrast non-FDA approved for route of administration
219650075|NCT01665222|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
219650076|NCT02315495|DRUG|Saxagliptin|
219650077|NCT02315495|DRUG|Acarbose|
219650078|NCT00978250|DRUG|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
218963474|NCT02524964|DRUG|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
218963475|NCT02524964|OTHER|control|equivalent volume of sodium chloride solution
218963476|NCT04538196|OTHER|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
218963477|NCT01522586|DRUG|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
218963478|NCT01522586|DRUG|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
218963479|NCT03360786|OTHER|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
218963480|NCT03360786|OTHER|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
218963481|NCT01771185|PROCEDURE|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
218963482|NCT01771185|DRUG|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
218963483|NCT03096015|BEHAVIORAL|Intensive Comprehensive Aphasia Program|
218963484|NCT00002585|DRUG|pyrazoloacridine|
218963485|NCT01440062|DRUG|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
218963486|NCT01440062|DRUG|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
218963487|NCT04867434|DRUG|RZL-012|small synthetic molecule for submental fat reduction
219650079|NCT01323010|DRUG|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (\> 15 to 20 kg), 1500 mcg (\> 20 to 25 kg) and 1800 mcg (\> 25 kg).
219650080|NCT01323010|DRUG|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (\> 25 kg)
219650081|NCT03826628|DRUG|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
219650082|NCT03826628|DRUG|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
219650083|NCT00987870|DRUG|BFH772|
219650084|NCT00987870|DRUG|Placebo|
219650085|NCT00987870|DRUG|BFH772|
219650086|NCT00987870|DRUG|Placebo|
219650087|NCT00987870|DRUG|calcipotriol/betamethasone|
218963488|NCT04867434|DRUG|Placebo|Placebo
218963489|NCT01445886|DRUG|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
218963490|NCT01445886|DRUG|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
218963491|NCT03858465|DRUG|Ephedrine|intravenous 25 mg of ephedrine
218963492|NCT03858465|DRUG|Phenylephrine|intravenous 0,3 mg of phenylephrine
219062430|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
219062431|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
219062432|NCT03890302|DRUG|FB704A|Administered by IV infusion
219062433|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
218963493|NCT01872234|DEVICE|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
218963494|NCT02385136|DRUG|Temozolomide|
218963495|NCT04956770|PROCEDURE|Implantation surgery|"The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
218963496|NCT05029973|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
219062434|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
219650088|NCT01330394|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
219650089|NCT02357095|PROCEDURE|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
219650090|NCT01134679|BEHAVIORAL|Multi-disciplinary disease management approach|Follow up with phone calls
219650091|NCT05335447|DRUG|GLPG3667 capsule|On Day 1, participants will receive a single oral dose of GLPG3667
219650092|NCT05335447|DRUG|[14C]-GLPG3667 solution for infusion|On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
219650093|NCT05335447|DRUG|[14C]-GLPG3667 capsule|On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
218963497|NCT05029973|DRUG|Sintilimab|200mg IV d1,Q3W
218963498|NCT05029973|DRUG|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
218963499|NCT00079131|BIOLOGICAL|oblimersen sodium|Given IV
218963500|NCT00079131|OTHER|pharmacological study|Correlative studies
218963501|NCT00079131|OTHER|laboratory biomarker analysis|Correlative studies
218963502|NCT05366673|OTHER|massage|Perform a 10-minute back massage every day for a week
218963503|NCT06077708|DIETARY_SUPPLEMENT|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
218963504|NCT06077708|OTHER|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
218963505|NCT02704910|BEHAVIORAL|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
218963506|NCT05295797|BEHAVIORAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
218963507|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
219650094|NCT03538977|PROCEDURE|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
219650095|NCT03538977|PROCEDURE|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
219650096|NCT06668298|DRUG|Oliceridine|The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
219650097|NCT06668298|DRUG|Sulfentanil|The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
219650098|NCT04064970|BEHAVIORAL|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
219650099|NCT02222233|DRUG|BI 671800 HEA delayed release (enteric coated) tablet|
219650100|NCT02222233|DRUG|BI 671800 HEA solution|
219650101|NCT02222233|DRUG|BI 671800 HEA particulate|
219650102|NCT05174949|DEVICE|Transcranial direct current stimulation (high-definition)|"Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham"
219650103|NCT02951533|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
219650104|NCT02951533|DRUG|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
219650105|NCT03141229|BEHAVIORAL|Mindfulness based stress reduction|
219650106|NCT02029989|DEVICE|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
219650107|NCT02029989|DEVICE|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
218963508|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
218963509|NCT04671173|DEVICE|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
219062435|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
219062436|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
219062437|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
219062438|NCT01751022|DEVICE|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
219062439|NCT03860896|DRUG|GB004|GB0004 high dose
219062440|NCT03860896|DRUG|Placebo|Placebo
219062441|NCT03860896|DRUG|GB004|GB004 low dose
219062442|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
219062443|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
219062444|NCT02479984|DEVICE|Laparoscopic ultrasound|
219062445|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
219062446|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
219650108|NCT02029989|DEVICE|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
219650109|NCT02029989|DEVICE|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
219650110|NCT02029989|DEVICE|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
219650111|NCT02029989|BEHAVIORAL|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
219650112|NCT05306782|DEVICE|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
219650113|NCT05306782|BEHAVIORAL|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
219650114|NCT03101826|BEHAVIORAL|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
219650115|NCT04537910|DRUG|LY3819253|Administered SC.
219650116|NCT04537910|DRUG|Placebo|Administered SC.
219650117|NCT03581734|BIOLOGICAL|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
219650118|NCT03581734|BIOLOGICAL|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
218963510|NCT03500679|BIOLOGICAL|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
218963511|NCT03500679|BIOLOGICAL|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
218963512|NCT03473938|DEVICE|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
218963513|NCT00404703|DRUG|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
218963514|NCT00404703|DRUG|Platinum-based chemotherapy|As prescribed
218963515|NCT03300518|DRUG|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
218963516|NCT03300518|DRUG|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
218963517|NCT03300518|DRUG|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
218963518|NCT03300518|DRUG|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
218963519|NCT04073329|OTHER|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with \> 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
218963520|NCT01962922|DRUG|LCP-Tacro|once-daily extended release tablet
218963521|NCT01962922|DRUG|Tacrolimus -IR|twice daily capsules
218963522|NCT04128332|RADIATION|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
218963523|NCT03368573|DEVICE|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
218963524|NCT04319822|OTHER|blood sample and muscular biopsy|blood sample and muscular biopsy
219062447|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
218963525|NCT01759485|DRUG|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
219062448|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
219650119|NCT03091036|OTHER|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
219650120|NCT01528397|PROCEDURE|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
219650121|NCT06630078|DEVICE|Wevosys acoustic analysis|Recording of voice signal of subjects enrolled
218963526|NCT01759485|DRUG|placebo|
219650122|NCT06619301|DRUG|Insulin glargine|Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
219650123|NCT06619301|DRUG|insulin NPH|Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
219650124|NCT01623037|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
219650125|NCT02782299|OTHER|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
219650126|NCT05686161|BIOLOGICAL|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
219650127|NCT05686161|BIOLOGICAL|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
219650128|NCT05686161|BIOLOGICAL|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
218963527|NCT04658173|DRUG|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
218963528|NCT04658173|DRUG|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
218963529|NCT00391261|DRUG|Metformin|open-label, flexible dosing
218963530|NCT04923165|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
219650129|NCT01203826|BIOLOGICAL|Asfotase Alfa|
219650130|NCT04198285|PROCEDURE|Retrograde bladder filling|The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
219650131|NCT02071810|DRUG|BIA 9-1067|
219650132|NCT02071810|DRUG|Placebo|
219650133|NCT04473820|DRUG|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
219650134|NCT04473820|DRUG|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
219650135|NCT04576065|OTHER|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
219650136|NCT03344575|PROCEDURE|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
219650137|NCT03344575|PROCEDURE|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
219650138|NCT00968058|PROCEDURE|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
219650139|NCT06643416|DRUG|Timolol 0.5% eye drops and betamethasone valerate 0.1% cream|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
219650140|NCT06643416|DRUG|Betamethasone valerate 0.1% cream|The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
218963531|NCT04923165|DIAGNOSTIC_TEST|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
218963532|NCT04923165|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
218963533|NCT04923165|DIAGNOSTIC_TEST|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
218963534|NCT02882373|DIETARY_SUPPLEMENT|Arginine|Given PO
218963535|NCT02882373|DRUG|Placebo|Given PO
218963536|NCT01418027|OTHER|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
218963537|NCT01418027|OTHER|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
218963538|NCT01616134|OTHER|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
218963539|NCT01616134|OTHER|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
218963540|NCT00013195|BEHAVIORAL|Telephone Care|
219650141|NCT00091637|DRUG|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
218963541|NCT03913325|OTHER|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
219650142|NCT00091637|DRUG|Placebo infusion|bolus infusion over a 10 minute period once
219650143|NCT02788370|DEVICE|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
219650144|NCT02788370|OTHER|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)"
219650145|NCT04761406|DIETARY_SUPPLEMENT|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
219650146|NCT04761406|DIETARY_SUPPLEMENT|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
219650147|NCT06618781|PROCEDURE|Sedation|Preoperatively, 2 mg intravenous midazolam was administered to the patients. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and when the Vizel analog score was \>4, intravenous 0.1-1 mcg/kg remifentanil was administered.
219650148|NCT06618781|PROCEDURE|Sedation + Quadratus Lumborum Block|Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \>4.
219650149|NCT01513811|DRUG|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
219650150|NCT01513811|DRUG|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
219650151|NCT01513811|DRUG|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
219650152|NCT00718484|DRUG|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
219650153|NCT00718484|DRUG|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
219650154|NCT02491801|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
219650155|NCT02630849|PROCEDURE|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
219650156|NCT02630849|PROCEDURE|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
219650157|NCT05336292|BEHAVIORAL|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
219650158|NCT05336292|BEHAVIORAL|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
219650159|NCT05336292|BEHAVIORAL|Control Group|This group does not do any intervention
218963542|NCT03913325|OTHER|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
218963543|NCT06473987|OTHER|Personalized cognitive-sensorimotor VR/AR training|Thinking task integrated walking and balance training program
218963544|NCT06473987|OTHER|Traditional dual-task training|Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training
219650160|NCT03099694|PROCEDURE|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
219650161|NCT03099694|PROCEDURE|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
219650162|NCT05691959|DRUG|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
219650163|NCT05691959|DRUG|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
219650164|NCT03832790|OTHER|observation|observation
218963545|NCT06473987|OTHER|Standard of Care|Standard walking and balance training
219062449|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
219062450|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
218963546|NCT03098771|PROCEDURE|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
218963547|NCT03098771|DRUG|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
219207878|NCT06888791|PROCEDURE|Fluoroscopy-guided Hydro Dissection|The patient is placed on the scope table in supine position and the shoulder joint is cleaned with 10% povidone iodine. The acromioclavicular joint and the glenohumeral joint are visualized using C-arm fluoroscopy with anteroposterior view. The acromioclavicular joint is marked as the entry point to the shoulder joint. After the skin and subcutaneous tissue is anesthetized with 1 cc 2% lidocaine with a 27 G needle, a 22 G spinal needle is inserted through the acromioclavicular joint and the needle is directed towards the glenohumeral joint. With 1 ml of contrast medium, the localization of the needle is confirmed. After appropriate spread of contrast agent, 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline are administered into the joint in a total of 20 mL. For US-guided suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
219207879|NCT06738199|DIETARY_SUPPLEMENT|dietary iron supplementation|This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).
219207880|NCT06890832|DRUG|50 mg cabazitaxel|50 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
219207881|NCT06890832|DRUG|100 mg cabazitaxel|100 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
219207882|NCT06890832|DRUG|200 mg cabazitaxel|200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6
219207883|NCT06887114|OTHER|Experimental Group (Mulligan Mobilization + Conventional Therapy)|Mulligan Sustained Natural Apophyseal Glides (SNAGs) applied to the lumbar spine, combined with conventional rehabilitation exercises (neuromuscular training, stretching, strengthening, and balance exercises).
219650165|NCT05994911|BEHAVIORAL|Mindfulness Training|"The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness."
219650166|NCT06771622|DRUG|HCB101|QW
219650167|NCT06771622|DRUG|Trastuzumab|8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;
219650168|NCT06771622|DRUG|Pertuzumab|840 mg IV on Day 1, cycled every 21 days;
218963548|NCT00254774|DRUG|quetiapine fumarate or valproate|
219650169|NCT06771622|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1, cycled every 21 days
219650170|NCT06771622|DRUG|Capecitabine|1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days
219650171|NCT06771622|DRUG|Ramucirumab|8 mg/kg IV on Days 1 and 15, Cycled every 28 days
219062451|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
219207884|NCT06887114|OTHER|(Conventional Therapy Only)|Neuromuscular training, stretching, strengthening, balance exercises, and gait training performed without Mulligan mobilization.
219207885|NCT06809647|DEVICE|Glaucoma surgery|This is an implant-free, minimally invasive glaucoma surgery
219650172|NCT06771622|DRUG|Paclitaxel|80 mg/m2 IV on Days 1, 8, and 15, Cycled every 28 days
219650173|NCT06771622|DRUG|Bevacizumab|5 mg/kg IV on Day 1, Repeat every 2 weeks; or 7.5 mg/kg IV on Day 1, Repeat every 3 weeks.
219650174|NCT06771622|DRUG|Cetuximab|400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly; or 500 mg/m2 IV over 2 hours on Day 1 every 2 weeks;
219650175|NCT06771622|DRUG|Irinotecan|180 mg/m2 IV over 30-90 minutes on Day 1 every 2 weeks
219650176|NCT06771622|DRUG|Leucovorin|400 mg/m2 IV on Day 1 every 2 weeks
219062452|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
219650177|NCT06771622|DRUG|5-FU|400 mg/ m2 IV bolus on Day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks
219650178|NCT06771622|DRUG|Toripalimab|240 mg/kg IV on Day 1 Cycled every 21 days
219650179|NCT06771622|DRUG|Albumin-bound paclitaxel|125 mg/m2 IV on day 1 and Day 8 Cycled every 21 days
219650180|NCT06771622|DRUG|Pembrolizumab|200 mg IV day 1; given every 21 days
219650181|NCT06771622|DRUG|Gemcitabine|1000 mg/m2 IV days 1 and 8
219650182|NCT06595446|PROCEDURE|Early Stent removal|Ureteral JJ stents removed 5-7 days after radical cystectomy and ileal conduit formation
218963549|NCT05641675|DIAGNOSTIC_TEST|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
218963550|NCT02319356|DIETARY_SUPPLEMENT|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
218963551|NCT02319356|DIETARY_SUPPLEMENT|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
219062453|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
219062454|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
219062455|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
219650183|NCT06595446|PROCEDURE|Late Stent removal|Ureteral JJ stents removed 4-6 weeks after radical cystectomy and ileal conduit formation
219650184|NCT03424902|DIAGNOSTIC_TEST|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
219650185|NCT04507919|DRUG|Dabrafenib|150 mg
219650186|NCT04507919|DRUG|Trametininb|2.0 mg
219650187|NCT06159556|OTHER|Peanut intake|Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
219650188|NCT06330792|OTHER|bio-mechanical awareness|Biomechanical awareness advices for physiotherapists during session: consist of group of awareness advices and McKenzie extension part method exercises to help physiotherapist working in correct position and consume his energy.
219650189|NCT06330792|OTHER|core stability exercises|Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area
219650190|NCT00471718|DRUG|ABT-751|"Phase I:~Cohort \| Number of Patients \|Dose (mg) ABT-751 (BID)~* -1 \| 3-6 \|100 mg BID~* 1 \| 3-6 \|125 mg BID~* 2 \| 3-6 \|150 mg BID~* 3 \| 3-6 \|175 mg BID~* 4 \| 3-6 \|200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
219650191|NCT04699513|DEVICE|Mechanical Ventilation Mode (airway pressure release ventilation )|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
219650192|NCT05731037|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
219650193|NCT05566834|DRUG|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
219650194|NCT03287284|DEVICE|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
219650195|NCT03287284|BEHAVIORAL|Resistance Training|Resistance Training
219650196|NCT03287284|DEVICE|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
219062456|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
219650197|NCT02971475|PROCEDURE|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
219650198|NCT02971475|PROCEDURE|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
219650199|NCT02971475|DRUG|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
219650200|NCT02224820|BIOLOGICAL|IdeS|Doses are administered in ascending doses
219650201|NCT06523075|OTHER|Tumor Necrosis Factor|This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.
219650202|NCT06523075|OTHER|Interleukin-1β|This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.
219650203|NCT06523075|OTHER|Interleukin-12|This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.
219650204|NCT06523075|OTHER|Interleukin-18|This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.
219650205|NCT06523075|OTHER|Complement C3|This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.
219650206|NCT06523075|OTHER|Complement C5|This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.
219650207|NCT01117675|OTHER|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
219650208|NCT01117675|OTHER|Standard of Care|Standard of Care
219650209|NCT05546346|DEVICE|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
219650210|NCT03069261|DEVICE|Indocyanine green angiography|
219650211|NCT03867487|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
219650212|NCT03867487|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
219650213|NCT02958280|BEHAVIORAL|Fit&Sober App|Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
219650214|NCT02958280|BEHAVIORAL|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
219650215|NCT02438605|DEVICE|Nellix|
219650216|NCT02591095|DRUG|ABT-263|
219650217|NCT04323033|DEVICE|PERS stent|"PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1)."
219650218|NCT04323033|DEVICE|NEPTUN C stent|Neptun C is balloon-expanding cobalt-chromium stent.
219650219|NCT05516524|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
219650220|NCT05516524|DIAGNOSTIC_TEST|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
219650221|NCT05674123|PROCEDURE|Colonoscopy|Undergo colonoscopy
219650222|NCT05674123|PROCEDURE|Endoscopic Ultrasound|Undergo rectal endoscopic ultrasound
218963552|NCT05730816|DRUG|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
218963553|NCT05730816|DRUG|Normal Saline|Intravenous infusion of normal saline.
218963554|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
218963555|NCT00989690|DRUG|docetaxel|
218963556|NCT00989690|DRUG|erlotinib hydrochloride|
218963557|NCT00989690|DRUG|pemetrexed disodium|
218963558|NCT00989690|GENETIC|fluorescence in situ hybridization|
218963559|NCT00989690|GENETIC|mutation analysis|
218963560|NCT00989690|GENETIC|proteomic profiling|
218963561|NCT00989690|OTHER|immunohistochemistry staining method|
218963562|NCT00989690|OTHER|laboratory biomarker analysis|
218963563|NCT00989690|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
219650223|NCT05674123|OTHER|Medical Chart Review|Ancillary studies
219650224|NCT05674123|OTHER|Medical Device Usage and Evaluation|Undergo resection with the Flex Robotic System
219650225|NCT05674123|PROCEDURE|Resection|Undergo resection with the Flex Robotic System
219650226|NCT01662921|DRUG|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
219650227|NCT01662921|DRUG|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
218963564|NCT00989690|PROCEDURE|breath test|
218963565|NCT02891616|DRUG|fludeoxyglucose F 18|
218963566|NCT02891616|DEVICE|Positron emission tomography-computed tomography|
218963567|NCT02891616|DRUG|18F-fluorothymidine|
219650228|NCT01662921|DRUG|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
219650229|NCT05703880|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.
219650230|NCT02269410|DIETARY_SUPPLEMENT|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
219650231|NCT02269410|DIETARY_SUPPLEMENT|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
219650232|NCT02269410|DIETARY_SUPPLEMENT|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
219650233|NCT02269410|DIETARY_SUPPLEMENT|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
219650234|NCT03634436|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
218963568|NCT02891616|DEVICE|Positron emission tomography-magnetic resonance imaging|
218963569|NCT00451139|DRUG|artemether/lumefantrine|
218963570|NCT00451139|DRUG|quinine|
218963571|NCT00451139|DRUG|atovaquone/proguanil|
218963572|NCT03224546|BEHAVIORAL|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
218963573|NCT01041729|DRUG|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
218963574|NCT01041729|DRUG|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
219062457|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
219062458|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
219650235|NCT03634436|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
219650236|NCT01850147|DRUG|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
219650237|NCT00438737|BIOLOGICAL|bevacizumab|
218963575|NCT00644748|DRUG|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
219650238|NCT00438737|BIOLOGICAL|cetuximab|
218963576|NCT02780323|DRUG|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
218963577|NCT02780323|DRUG|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
218963578|NCT02780323|DRUG|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
218963579|NCT02780323|DRUG|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
218963580|NCT03088215|DEVICE|shock-waves|Application of shock-waves (radial and focused)
218963581|NCT03268473|OTHER|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
218963582|NCT03268473|OTHER|Control|Control: Non-surgical periodontal therapy in Periodontitis
218963583|NCT04673084|DEVICE|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
219062459|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
219062460|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
219650239|NCT00438737|DRUG|fluorouracil|
219650240|NCT00438737|DRUG|leucovorin calcium|
219650241|NCT00438737|DRUG|oxaliplatin|
219650242|NCT00438737|PROCEDURE|adjuvant therapy|
219650243|NCT00438737|PROCEDURE|conventional surgery|
219650244|NCT00438737|PROCEDURE|neoadjuvant therapy|
219650245|NCT04696354|DIAGNOSTIC_TEST|IVUS|Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
219650246|NCT04696354|OTHER|Continued Compression Therapy/Stockings|Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
219650247|NCT04647396|OTHER|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"|"Implementation of the KDIGO bundle for at least 12 hours~1. discontinuation of all nephrotoxic drugs when possible~2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions"
219650248|NCT03734302|DRUG|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
219650249|NCT06604689|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
219650250|NCT01081444|DEVICE|rTMS|effective and active cortical magnetic stimulations
219650251|NCT01081444|DEVICE|Placebo rTMS|non active cortical magnetic stimulation
219650252|NCT00381732|DRUG|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
219650253|NCT00381732|DRUG|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
219650254|NCT06619808|PROCEDURE|Hyperbaric oxygen therapy|Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
219650255|NCT03565042|PROCEDURE|Arthroscopy|Arthroscopy of swollen joint (ankle/knee)
219650256|NCT05140629|OTHER|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
219650257|NCT05140629|OTHER|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
219650258|NCT06256692|OTHER|Pulse oximeter|No real intervention, but all study participants will have an additional pulse oximeter attached, to measure oxygen saturation.
219650259|NCT05352672|DRUG|Fianlimab|Intravenous (IV) infusion
219650260|NCT05352672|DRUG|Cemiplimab|IV infusion
219650261|NCT05352672|DRUG|Pembrolizumab|IV infusion
219650262|NCT05352672|DRUG|Placebo|IV infusion
219650263|NCT06648356|OTHER|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) is applied during an isometric contraction. The NMES uses a symmetrical biphasic rectangular pulse (50Hz frequency and 300 µs phase width) delivered through an Enraf Nonius TensMed S82 electrostimulator. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, yet painless, contraction level. During the intervention, one researcher maintains the stretch position while another researcher controls the current intensity and monitors the timing of both stretching and contractions.
219650264|NCT06648356|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
219650265|NCT04684628|DRUG|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
219650266|NCT06585527|BIOLOGICAL|TS-2021|The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.
219650267|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood sample collection|Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
219650268|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
219650269|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
219650270|NCT06348433|OTHER|Ketogenic diet|Ketogenic diet is a formula diet with high fat, low carbohydrate, proper amount of protein and other nutrients.
219650271|NCT04982211|DRUG|Propranolol|Oral propranolol hydrochloride capsules, dosed per participant weight
219650272|NCT04982211|DRUG|Placebo|Oral placebo capsules, dosed per participant weight
219650273|NCT06451562|DRUG|Lidocaine|a local anesthetic drug of the amino amide type
219650274|NCT00502892|DRUG|Topotecan|0.5 mg/m\^2 IV Daily x 3 Days
219650275|NCT00502892|DRUG|Ifosfamide|1.8 grams/m\^2 IV Over 1 Hour x 5 Days
219650276|NCT00502892|DRUG|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days \[for patients \> 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days\]
218963584|NCT05806671|DRUG|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
218963585|NCT05806671|DRUG|Pyrotinib|Pyrotinib 320mg/day orally continuously
218963586|NCT05806671|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
218963587|NCT04594954|DIETARY_SUPPLEMENT|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
218963588|NCT04594954|OTHER|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure."
218963589|NCT04594954|OTHER|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
219650277|NCT00965341|DRUG|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
219650278|NCT00965341|DRUG|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
219650279|NCT02807506|DEVICE|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
219650280|NCT02807506|OTHER|Survey|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
219650281|NCT03548142|BEHAVIORAL|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
219650282|NCT04778462|DEVICE|extracorporeal shock wave and conventional treament|"Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
219650283|NCT04778462|DEVICE|high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points|"will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression"
219650284|NCT04778462|OTHER|conventional treatment for myofascial pain trigger point|"Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
219650285|NCT02898727|OTHER|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
219650286|NCT02925182|DEVICE|Er,Cr:YSGG Laser|
219650287|NCT06667791|OTHER|Computer guided sodium hyaluronate injections|Patients will be treated with Computer guided sodium hyaluronate injections in superior TMJ space
218963590|NCT00775385|DRUG|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
218963591|NCT00775385|DRUG|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
218963592|NCT00238537|DRUG|Alteplase t-PA|
218963593|NCT04432220|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
218963594|NCT04140136|DIETARY_SUPPLEMENT|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
218963595|NCT04140136|DIETARY_SUPPLEMENT|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
218963596|NCT02730208|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
218963597|NCT02730208|DRUG|Ivacaftor|IVA 150 mg tablet.
218963598|NCT02730208|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
218963599|NCT02730208|DRUG|Placebo|Placebo matched to IVA tablet.
218963600|NCT01206673|OTHER|Blood sampling|One blood sampling is required for the research
218963601|NCT02890290|DIETARY_SUPPLEMENT|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
218963602|NCT02890290|DIETARY_SUPPLEMENT|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
218963603|NCT02978131|OTHER|Histopathological study|
218963604|NCT02978131|OTHER|Molecular study (Polymerase chain reaction)|
218963605|NCT00245219|BEHAVIORAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
218963606|NCT00245219|BEHAVIORAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
218963607|NCT04641520|OTHER|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
218963608|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
218963609|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
218963610|NCT01687374|DRUG|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
218963611|NCT01687374|DRUG|Placebo|Saline injection daily for 8 weeks.
218963612|NCT00510952|DRUG|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
218963613|NCT00510952|DRUG|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
218963614|NCT03918668|BEHAVIORAL|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
218963615|NCT03551262|DEVICE|OTSC|Positioning of OTSC in bleeding peptic ulcer
218963616|NCT03551262|DEVICE|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
218963617|NCT03457233|DRUG|Gonadotropins|1\) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
219062461|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
219062462|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
219062463|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
219062464|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
219062465|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
219207886|NCT06809153|BEHAVIORAL|Putting Children First|An online parenting intervention for families experiencing high inter-parental conflict during divorce or separation. Children in these families are at greater risk of adverse health outcomes such as mental illness, substance use, and social adjustment problems. Putting Children First will include evidence-based parent training and employ motivational interviewing to increase engagement, will promote parallel parenting to help parents minimize conflict, thereby mitigating negative health outcomes in their children.
219650288|NCT06667791|OTHER|conventional sodiumhyaluronate injections|Patients will be treated with conventional sodium hyaluronate injections in superior TMJ space
219650289|NCT00960986|DRUG|Duloxetine hydrochloride|po, QD
219650290|NCT06407557|BEHAVIORAL|Accelerometer|Use of prompts to enable activity in older adults.
219650291|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
218963618|NCT03457233|DRUG|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
218963619|NCT03457233|DRUG|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
218963620|NCT03457233|DRUG|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
218963621|NCT00048893|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10\^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
218963622|NCT00048893|BIOLOGICAL|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10\^8 pfu x 1 dose subcutaneously.
218963623|NCT00048893|BIOLOGICAL|filgrastim|5 mcg/kg/day subcutaneously
218963624|NCT00048893|BIOLOGICAL|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
218963625|NCT00048893|DRUG|cyclophosphamide|"First induction chemotherapy: 2700 mg/m\^2 per cycle (900 mg/m\^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m\^2 per cycle (600 mg/m\^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m\^2 per cycle (600 mg/m\^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4)."
218963626|NCT00048893|DRUG|doxorubicin hydrochloride|60 mg/m\^2 per cycle (60 mg/m\^2 slow intravenous push day 1).
218963627|NCT00048893|DRUG|fludarabine phosphate|120 mg/m\^2 (30 mg/m\^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
218963628|NCT00048893|DRUG|paclitaxel|160 mg/m\^2 per cycle (53.3 mg/m\^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
219650292|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
219650293|NCT03097367|DIAGNOSTIC_TEST|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at \<2 cm below SMSP, and Level -2: bladder neck at \>2 cm below SMSP.
219650294|NCT00003829|DRUG|cyclophosphamide|
219650295|NCT00003829|DRUG|fludarabine phosphate|
219650296|NCT01077739|DRUG|fluorouracil (5FU)|standard FOLFOX regimen
219650297|NCT01077739|DRUG|leucovorin|standard FOLFOX regimen
219650298|NCT01077739|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
219062466|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
219062467|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219062468|NCT05932290|DRUG|Standard of care|Standard of care
218963629|NCT00048893|DRUG|Mesna|"Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.~3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)"
219650299|NCT01077739|DRUG|capecitabine [Xeloda]|standard XELOX regimen
219650300|NCT01077739|DRUG|oxaliplatin|standard XELOX or FOLFOX regimen
219650301|NCT04864340|DEVICE|CE marked medical device|Tetanic stimulation
219650302|NCT04864340|DEVICE|Algometer|Pressure stimulation
219650303|NCT04864340|PROCEDURE|Comparator|Non-nociceptive procedure (fine touch)
219650304|NCT01766752|DEVICE|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
219650305|NCT00539149|DRUG|Amoxycillin|50 mg/kg/day twice daily
219650306|NCT00539149|DRUG|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
219650307|NCT06276777|PROCEDURE|Tooth varnish (PRG Barrier Coat from Shofu)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
219650308|NCT06276777|PROCEDURE|Tooth varnish (Clinpro white varnish 3M)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
219650309|NCT05523193|OTHER|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
218963630|NCT02717845|DEVICE|Ellipse|diagnostic CT scan imaging
218963631|NCT02717845|DEVICE|Tomofix|diagnostic CT scan imaging
218963632|NCT02691962|DEVICE|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
218963633|NCT06330688|PROCEDURE|percutaneous cholecystostomy|PC is a minimally invasive, nonsurgical, image-guided intervention that aims to drain and decompress the gallbladder by placing a pigtail catheter through the abdominal wall into the gallbladder lumen.
218963634|NCT05806684|OTHER|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
218963635|NCT02325856|DEVICE|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
218963636|NCT02325856|BEHAVIORAL|Clinical judgement|
218963637|NCT01604109|DRUG|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
218963638|NCT01604109|DRUG|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
219062469|NCT01850004|DRUG|Dasatinib|
219062470|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
219062471|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
219062472|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
219062473|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
219062474|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
219062475|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
219062476|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
219062477|NCT06321718|PROCEDURE|PENG + LFCN block versus S-FICB|1\. Group (A) will receive PENG + LFCN block:
219062478|NCT00738842|DRUG|AZD6140|Oral tablets taken bid for 5 days
219062479|NCT00738842|DRUG|Placebo to match AZD6140|Oral tablets taken bid for 5 days
219062480|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
219062481|NCT01946711|DRUG|Budesonide|Inhalation
219062482|NCT01946711|DRUG|Budesonide|Nasal spray
219062483|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
219062484|NCT02398097|BIOLOGICAL|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
219062485|NCT02398097|BIOLOGICAL|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
219062486|NCT02398097|BIOLOGICAL|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
219062487|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
219062488|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
219062489|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
219062490|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
219062491|NCT03773744|DRUG|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
219062492|NCT03773744|DRUG|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
219062493|NCT03773744|DRUG|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
219062494|NCT03773744|DRUG|Cyclophosphamide|low-dose chemotherapy
219062495|NCT06300008|DRUG|cetylated fatty acid|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
219062496|NCT06300008|DRUG|Placebo|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
219062497|NCT01198080|BIOLOGICAL|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
219062498|NCT03859323|DRUG|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
219062499|NCT03859323|OTHER|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
219062500|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
219062501|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
219062502|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
219062503|NCT00822510|BEHAVIORAL|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
219062504|NCT00822510|BEHAVIORAL|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
219062505|NCT06081660|BEHAVIORAL|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
219207887|NCT06841549|OTHER|FAPI|FAPI is a new method to find the myocardial fibrosis under some conditions, like myocardial infarction or cardiac myopathy.
219650310|NCT03229447|BEHAVIORAL|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
219650311|NCT03229447|BEHAVIORAL|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
219062506|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
219062507|NCT05424419|PROCEDURE|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
219207888|NCT06779877|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
219207889|NCT06779877|DIAGNOSTIC_TEST|The optic nerve sheath diameter measurement method by ultrasonography|The optic nerve sheath diameter measurement method by ultrasonography-Determine intracranial pressure.
219207890|NCT06844708|BIOLOGICAL|CMTS0929|China Microbiota Transplantation System 0929 (CMTS0929) is defined as suspension from washed microbiota.
219650312|NCT05189327|OTHER|No intervention|Non-interventional study
219650313|NCT00110227|BEHAVIORAL|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
219650314|NCT00110227|BEHAVIORAL|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
219650315|NCT06450054|DIAGNOSTIC_TEST|Aerobic Exercise in diabetic post-stroke patients|The experimental group's members will use the treadmill for a five-minute warm-up and cool-down. Over 12 weeks, they will attend three 40-minute weekly sessions in groups of two to four. They will then perform aerobic exercise for thirty minutes at a heart rate reserve of 60% to 80%. Those with a low exercise tolerance will first be given small workouts lasting at least ten minutes, interspersed with rest periods until they can perform 30 minutes of exercise. They will progress to longer, continuous workouts punctuated by shorter rest periods as their tolerance to exercise grows. The degree of treadmill training intensity will be adjusted step-by-step according to each person's tolerance, heart rate, blood pressure responses, and perceived effort rate. If they exercise beyond their cardiovascular conditioning zone, participants will be instructed to raise their treadmill speed until they achieve it
219062508|NCT05577429|OTHER|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
219062509|NCT05577429|OTHER|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
219062510|NCT05577429|OTHER|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
219062511|NCT01404312|DRUG|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
219062512|NCT01404312|DRUG|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
219207891|NCT06746038|DEVICE|Extended Wear Hearing Aid|Extended wear hearing aid means that the device is worn 24 hours per day, 7 days a week for months at a time. However, this study will only fit devices on participants for one testing session lasting 2 hours.
219650316|NCT06450054|OTHER|Aerobic Exercise in Non diabetic post-stroke patients|Group B will be managed aerobic exercise in non-diabetic post-stroke patients. Participants in the control group will walk outside comfortably while maintaining a heart rate reserve of less than 40%. They will be instructed to reduce their pace until their training zone reaches ≤40% if their heart rate reserve exceeds 40%. If the efficacy is demonstrated, participants in the control group will receive the experimental intervention
219650317|NCT04464720|BEHAVIORAL|Cooking Ventilation Intervention|An educational video presentation for the families regarding the importance of ventilation use during and after cooking, and strategies for improving the ventilation during cooking, has been created by Dr. Holm, with input from Youth Research Assistants (YRAs) The youth involvement will help to ensure that the information is presented in a way that will resonate with the local community and will also provide the youth with exposure to developing health education tools. The educational video will be shown to families at the time of the intervention visit and they will receive printed reminder materials of what they have learned.
219650318|NCT04116827|DRUG|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
219650319|NCT02389569|PROCEDURE|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
219650320|NCT02389569|PROCEDURE|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
219650321|NCT02511314|DEVICE|TENA Identifi|TENA Identifi
219650322|NCT00342563|DRUG|mecamylamine|mecamylamine 10mg/day
219650323|NCT00342563|DRUG|Placebo|Placebo
219650324|NCT04818606|OTHER|Mindfulness Oriented Recovery Enhancement|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings.
219650325|NCT05537792|DEVICE|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
218963639|NCT02104973|BEHAVIORAL|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
218963640|NCT00138411|DRUG|Ciprofloxacin 500 mg|
218963641|NCT00138411|DRUG|ETI-204 (Anthim)|
218963642|NCT06336161|DRUG|Fentanyl|to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
218963643|NCT00867477|PROCEDURE|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
218963644|NCT00867477|BEHAVIORAL|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
218963645|NCT00867477|PROCEDURE|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
218963646|NCT05650528|DRUG|QG101-23-0 capsules|Single and Multiple Dose for oral
218963647|NCT05650528|DRUG|Placebo|Single and Multiple Dose for oral
218963648|NCT03624829|OTHER|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
219062513|NCT01404312|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
219062514|NCT00584688|DRUG|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
219650326|NCT06629298|OTHER|5Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 5 Hz."
219062515|NCT04477980|OTHER|Disease outcome (mortality)|Mortality rate between the two groups
218963649|NCT02793128|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
218963650|NCT03469674|RADIATION|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
218963651|NCT03469674|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
218963652|NCT03469674|OTHER|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
219650327|NCT06629298|OTHER|2 Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 2 Hz."
219650328|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
219650329|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
219650330|NCT04913727|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging before the procedure|CMR image acquisition with previously mentioned analysis
219650331|NCT04913727|PROCEDURE|Transcatheter mitral edge-to-edge repair.|Included patients will undergo Transcatheter mitral edge-to-edge repair.
219650332|NCT06329960|OTHER|Ultrasound-guided injection combined with needle release|Ultrasound-guided PIT using D5W HD for dorsal scapular nerve combined with needle release of major and minor rhomboideus
219650333|NCT05123092|OTHER|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
219650334|NCT05123092|OTHER|Intrathecal Morphine injection|Injecting intrathecal morphine
219650335|NCT03150992|DIETARY_SUPPLEMENT|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars \& sweeteners.
219650336|NCT01376466|OTHER|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
219650337|NCT06509750|OTHER|Carob-meal|A meal with carob-beverage
219650338|NCT06509750|OTHER|Non-carob-meal|A meal with orange-beverage
219650339|NCT00319384|DEVICE|Ultrafiltration therapy|
219650340|NCT00033202|DRUG|Gimatecan® (ST-1481)|
218963653|NCT02340273|DEVICE|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
218963654|NCT02340273|DEVICE|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
218963655|NCT00320359|DRUG|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
218963656|NCT00320359|DRUG|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
218963657|NCT02355977|DRUG|minocycline|Periocline dental ointment
218963658|NCT02355977|PROCEDURE|surface and root planning|surface and root planning
218963659|NCT00677430|BEHAVIORAL|Questionnaire|A brief questionnaire packet will be completed.
218963660|NCT00677430|PROCEDURE|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
218963661|NCT01652300|BEHAVIORAL|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
218963662|NCT01652300|BEHAVIORAL|no education|women in the control group received no education
218963663|NCT04483687|DRUG|Filgotinib|Tablets administered orally once daily
218963664|NCT04483687|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
219062516|NCT05704959|DIAGNOSTIC_TEST|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
219062517|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
218963665|NCT05963893|BEHAVIORAL|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
218963666|NCT02850133|OTHER|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
218963667|NCT00785967|BIOLOGICAL|Various vaccines|VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
218963668|NCT02359851|BIOLOGICAL|Pembrolizumab|Given IV
218963669|NCT02359851|OTHER|Laboratory Biomarker Analysis|Correlative studies
219650341|NCT04614038|DIAGNOSTIC_TEST|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
219650342|NCT01636154|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
219650343|NCT01636154|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
219650344|NCT01636154|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
219650345|NCT03763461|DEVICE|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
219650346|NCT03763461|DEVICE|Oxygen Mask|Application of oxygen during conscious sedation
219650347|NCT01522287|BEHAVIORAL|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
219650348|NCT03677336|DRUG|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
219650349|NCT03677336|DRUG|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
219650350|NCT03677336|DRUG|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
219650351|NCT03677336|DRUG|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
218963670|NCT04533477|PROCEDURE|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
218963671|NCT04533477|PROCEDURE|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
218963672|NCT04029532|DEVICE|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
218963673|NCT04029532|DEVICE|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
218963674|NCT04029532|DEVICE|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
218963675|NCT04029532|BEHAVIORAL|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
218963676|NCT04029532|BEHAVIORAL|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
218963677|NCT04029532|BEHAVIORAL|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
218963678|NCT04029532|BEHAVIORAL|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
218963679|NCT04993222|DRUG|Amphotericin B liposome for injection|IV infusion
218963680|NCT04993222|DRUG|AmBisome®|IV infusion
218963681|NCT04075370|OTHER|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
218963682|NCT01888003|DRUG|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
218963683|NCT01888003|DRUG|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
218963684|NCT01888003|OTHER|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
218963685|NCT06424418|DEVICE|Robotic Scope Cleaner|The device is used to clean the scope when it visualization becomes obstructed during a surgical procedure.
218963686|NCT00215579|DRUG|Depot Risperidone Microsphere (Consta)|
219650352|NCT03955081|DEVICE|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
219650353|NCT01751334|DEVICE|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
219650354|NCT01751334|DEVICE|total knee arthroplasty|Fixed Total Knee Arthroplasty
219650355|NCT00954512|DRUG|Carboplatin|
219650356|NCT00954512|DRUG|Epirubicin|
219650357|NCT00954512|BIOLOGICAL|Trastuzumab|
219650358|NCT00954512|DRUG|Everolimus|
219650359|NCT00954512|DRUG|Gemcitabine|
219650360|NCT00954512|BIOLOGICAL|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
219650361|NCT00954512|BIOLOGICAL|Cetuximab|
219650362|NCT00954512|DRUG|Paclitaxel|
219650363|NCT00954512|DRUG|Cisplatin|
219650364|NCT00954512|DRUG|5-FU|
219650365|NCT00954512|DRUG|Erlotinib|
219650366|NCT00954512|DRUG|Irinotecan|
219650367|NCT00954512|DRUG|Folinic Acid|
219650368|NCT03531528|OTHER|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
219650369|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
219650370|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
218963687|NCT06518889|PROCEDURE|Selective Dorsal Rhizotomy|Selective Dorsal Rhizotomy (SDR) is an irreversible neurosurgical procedure where 50-70% of the sensory nerve roots are cut at the spinal level. The procedure is used to reduce lower limb spasticity permanently and is augmented by intensive rehabilitation for at least two years after surgery to optimise outcomes.
218963688|NCT03385161|PROCEDURE|Botulinum toxin A|
219062518|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
219650371|NCT05073341|OTHER|Nurse-led family intervention|Nurse-led family intervention having three components first is infarmation about the patient's condition and guidance will be given to solve there queries and the emotional support will be given to the primary caregivers of CLD patient's admitted in HDU
219650372|NCT06334653|OTHER|exercise|acute exercise bout
219650373|NCT04398485|DRUG|ION251|ION251 administered by IV infusion
219650374|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
218963689|NCT03385161|PROCEDURE|Ethanol|
218963690|NCT00055471|DRUG|ZD4054 10 mg|1 x 10 mg oral tablets once daily
218963691|NCT00055471|DRUG|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
218963692|NCT00055471|DRUG|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
218963693|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
218963694|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
218963695|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
218963696|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
219062519|NCT00354705|BEHAVIORAL|Questionnaire|Two questionnaires taking 30 minutes to complete.
218963697|NCT01935310|DRUG|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
218963698|NCT03190356|DEVICE|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
218963699|NCT01854944|DRUG|Brexpiprazole 1mg to 4mg|
218963700|NCT00127621|PROCEDURE|early tracheotomy|
218963701|NCT00127621|PROCEDURE|prolonged endotracheal intubation|
218963702|NCT02285556|BEHAVIORAL|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
218963703|NCT02285556|BEHAVIORAL|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
219062520|NCT00880932|BEHAVIORAL|Electronic Alert|
219062521|NCT05684016|OTHER|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
219062522|NCT05684016|OTHER|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
219062523|NCT05684016|OTHER|EDSS|Extended Disability Status Score
219650375|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
219650376|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
219650377|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
219650378|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
219650379|NCT01794793|DRUG|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
219650380|NCT01794793|DRUG|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
219650381|NCT01794793|DRUG|Pasireotide LAR|Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
219650382|NCT03495154|DEVICE|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
219650383|NCT05599139|BEHAVIORAL|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
219650384|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
219650385|NCT05685732|OTHER|placebo|matching placebo
219650386|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
219650387|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
219650388|NCT05244044|OTHER|Pulmonary rehabilitation in primary care|Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
219650389|NCT04973540|DEVICE|Iron Bioresorbable Scaffold System (IBS Angel)|Subjects in this arm will be implanted with IBS Angel.
219650390|NCT05397171|DRUG|AZD8853|Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
219650391|NCT05397171|DRUG|Zirconium-89 crefmirlimab berdoxam|CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
219650392|NCT05354102|DRUG|BMC128|A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
219650393|NCT05354102|DRUG|Nivolumab|A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
219650394|NCT00900549|DEVICE|CRT on|12 months
219650395|NCT00900549|DEVICE|CRT off|12-month
219650396|NCT06914986|PROCEDURE|Performed flexible and navigable suction ureteral access sheath combined with needle perc|Patients are performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
219650397|NCT06914986|PROCEDURE|PCNL|Patients were performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
219650398|NCT06915012|DEVICE|Tesla BioHealing(R) Biophoton Generators|Biophoton generators have been reported to reduce severe chronic pain significantly. This is to determine its efficacy.
218963704|NCT02285556|RADIATION|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
218963705|NCT02285556|RADIATION|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
218963706|NCT03742089|DEVICE|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
218963707|NCT06546930|BEHAVIORAL|DREAM intervention|"Virtual Peer Groups (VPGs)~Participants will have multiple opportunities to attend a VPG on a specific topic during their 12-month participation period. The VPG topics will include the following:~* Diabetes technology - basics or advanced use (audience-dependent)~* Family relationships and diabetes~* Diabetes in real life - school, work, social gatherings, travel~* Wellbeing and support when living with diabetes~* Working with your diabetes care team - who to call for what~* Eating and activity - what's different with T1D?~In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies."
218963708|NCT03983278|OTHER|School Model|Free delivery of glasses at the school within two weeks after screening
219062524|NCT05684016|OTHER|Physical Examination|Physical Examination
219062525|NCT00711685|PROCEDURE|coronary artery bypass grafting via midline sternotomy|
219062526|NCT04419493|DRUG|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
219062527|NCT04419493|DRUG|Alteplase (from current manufacturing process)|Alteplase, TPA-02
219062528|NCT04419493|DRUG|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
219062529|NCT00524134|DRUG|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
219062530|NCT01283789|DRUG|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
219062531|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
219062532|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
219062533|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
219062534|NCT00587873|DRUG|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
219062535|NCT00587873|DRUG|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
219650399|NCT02720263|DRUG|ASP4345|Oral
219650400|NCT02720263|DRUG|Matching Placebo|Oral
219062536|NCT00587873|DRUG|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
219062537|NCT00053833|DRUG|irinotecan|
219650405|NCT06667635|DIAGNOSTIC_TEST|Artificial intelligence|Artificial intelligence (AI) tools developed through the training of large amounts of image data can assist with the analysis and interpretation of neuroimaging data of cerebral small vascular disease（CSVD）.
219650406|NCT02955095|DEVICE|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
219650407|NCT06173037|DRUG|RC88|2.0 mg/kg Q3W IV
219650408|NCT02234596|DRUG|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
219650409|NCT05629494|DRUG|Ibuprofen 400 mg, TID|Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
219062538|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
219062539|NCT05556408|DRUG|Succinylcholine|1.5mg/kg was given intravenously
219062540|NCT06201182|DRUG|FMT via rectal enema|50 grams of FMT via rectal enema
219062541|NCT06201182|DRUG|FMT capsules|FMT capsules given twice daily for 2 consecutive days
219062542|NCT06201182|DRUG|Placebo via rectal enema|Placebo via rectal enema
219062543|NCT06201182|DRUG|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
219062544|NCT00270543|DRUG|Taxotere, Fluorouracil, Leucovorin|
219062545|NCT03399734|DRUG|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
219650410|NCT05629494|DIAGNOSTIC_TEST|PSA test|PSA test will be repeated in 6 weeks
219650411|NCT05206955|DRUG|Tadalafil|10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
219650412|NCT05206955|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
219650413|NCT06951425|DRUG|TH-CART-027|3+3 dose escalation design: Dose Level 1: 0.3×10\^6 CAR+ T cells /kg; Dose Level 2: 1.0×10\^6 CAR+ T cells /kg; Dose Level 3: 3.0×10\^6 CAR+ T cells /kg
218963709|NCT03983278|OTHER|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
218963710|NCT03983278|OTHER|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
218963711|NCT04110067|OTHER|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
218963712|NCT01449643|DEVICE|Threshold|
218963713|NCT01449643|DEVICE|Sham Threshold|
219062546|NCT03399734|DRUG|Perampanel|Single 4-mg dose of perampanel fine granules
219062547|NCT05820724|DIAGNOSTIC_TEST|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
219062548|NCT05820724|OTHER|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
219062549|NCT05820724|DRUG|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
219062550|NCT00005854|DRUG|cyclophosphamide|
219650414|NCT05203848|PROCEDURE|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
219650415|NCT05203848|OTHER|Control group|Control group
219650416|NCT05630040|DEVICE|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
219650417|NCT05630040|DEVICE|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
219650418|NCT05633992|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
218963714|NCT02101112|DRUG|Apixaban|
218963715|NCT05505994|DRUG|DWP16001|DWP16001 A mg tablet
218963716|NCT05505994|DRUG|Dapagliflozin|Dapagliflozin tablet
218963717|NCT05505994|DRUG|DWP16001 Placebo|DWP16001 Placebo tablet
218963718|NCT05505994|DRUG|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
218963719|NCT00004904|BIOLOGICAL|anti-thymocyte globulin|
218963720|NCT00004904|BIOLOGICAL|filgrastim|
218963721|NCT00004904|DRUG|cladribine|
218963722|NCT00004904|DRUG|cyclophosphamide|
218963723|NCT00004904|DRUG|etoposide|
219062551|NCT00005854|DRUG|cyclosporine|
219062552|NCT00005854|DRUG|methotrexate|
219062553|NCT00005854|PROCEDURE|allogeneic bone marrow transplantation|
219062554|NCT00005854|PROCEDURE|in vitro-treated bone marrow transplantation|
219062555|NCT00005854|RADIATION|radiation therapy|
219062556|NCT05637463|OTHER|No intervention|no intervention was made
219062557|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
219062558|NCT03794089|BEHAVIORAL|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
219062559|NCT03794089|BEHAVIORAL|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
219062560|NCT00404339|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
219062561|NCT00404339|BIOLOGICAL|tetanus toxoid helper peptide|
219062562|NCT00404339|PROCEDURE|adjuvant therapy|
219650419|NCT05633992|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
219650420|NCT04801147|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
219650421|NCT05310318|PROCEDURE|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
219650422|NCT03060967|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
219650423|NCT05582044|OTHER|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
219650424|NCT05582044|OTHER|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
219650425|NCT05582044|OTHER|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
219650426|NCT05903924|DRUG|Tradipitant|Oral Capsule
219650427|NCT05903924|DRUG|Placebo|Oral Capsule
219650428|NCT06331871|PROCEDURE|Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.|Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.
219650429|NCT06331871|PROCEDURE|Manual physiotherapy protocol based on available evidence.|Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
219650430|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
219650431|NCT06162169|DRUG|JAB-21822|JAB-21822 was administered orally
219650432|NCT06162169|DRUG|Itraconazole|Itraconazole was administered orally
218963724|NCT00004904|DRUG|methylprednisolone|
218963725|NCT00004904|DRUG|tacrolimus|
218963726|NCT00004904|PROCEDURE|allogeneic bone marrow transplantation|
218963727|NCT00004904|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
218963728|NCT01683773|BIOLOGICAL|AERAS-402|Intramuscular needle injection 1x10\^11 vp
219062563|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
219062564|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
219062565|NCT02279758|DRUG|Metformin|
219650433|NCT06162169|DRUG|Omeprazole|Omeprazole was administered orally
218963729|NCT01683773|BIOLOGICAL|MVA85A|Intradermal needle injection 1x10\^8 pfu
218963730|NCT01150331|DRUG|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
218963731|NCT01150331|DRUG|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
218963732|NCT04124718|GENETIC|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
218963733|NCT01724320|DRUG|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
219062566|NCT02357212|PROCEDURE|coronary angiography|invasive procedure performed to determine coronary anatomy
218963734|NCT05088655|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
218963735|NCT04864210|DRUG|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
218963736|NCT04864210|DRUG|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
219062567|NCT02357212|PROCEDURE|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
219062568|NCT03574168|BIOLOGICAL|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
219062569|NCT01184066|BEHAVIORAL|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
219650434|NCT06162169|DRUG|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
219650435|NCT06162169|DRUG|Rifampicin|Rifampicin was administered orally
219650436|NCT05494684|OTHER|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
219650437|NCT02988362|DRUG|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
219650438|NCT02988362|DRUG|Candesartan 16mg and Amlodipine 10mg|
219650439|NCT05175196|DIAGNOSTIC_TEST|CandyCollect|The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.
219650440|NCT05175196|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice."
219650441|NCT05486104|DRUG|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
219650442|NCT05486104|DRUG|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
219650443|NCT00465803|DRUG|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
218963737|NCT04340063|DEVICE|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
218963738|NCT04340063|DEVICE|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
218963739|NCT06278415|OTHER|Physiological based cord clamping|see Arm Description
218963740|NCT06278415|OTHER|Differed cord clamping|see Arm Description
218963741|NCT06975982|OTHER|No intervention|No intervention
218963742|NCT06574412|DRUG|cardonilizumab combined with renvastinib|Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \&lt;60kg, 8mg, once a day, orally, for 4 cycles Weight \&gt;60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \&lt;60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \&gt; 60kg, 12mg, once a day, orally, a total of 8 cycles.
218963743|NCT06575933|DRUG|MK-1084|Oral administration
218963744|NCT06575933|DRUG|Midazolam|Oral administration
218963745|NCT06575933|DRUG|Digoxin|Oral administration
218963746|NCT04577027|DRUG|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
218963747|NCT04577027|DEVICE|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
218963748|NCT04577027|DEVICE|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
218963749|NCT04577027|OTHER|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
218963750|NCT04577027|OTHER|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
218963751|NCT04577027|OTHER|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
218963752|NCT01598571|DRUG|Fostamatinib|Fostamatinib 50 mg tablet
218963753|NCT01598571|DRUG|Fostamatinib|Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
218963754|NCT04438733|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
218963755|NCT04438733|DRUG|reference-anastrozole tablet (Arimidex)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
218963756|NCT03413267|OTHER|Custard|Food matrix: custard (liquid emulsion)
218963757|NCT03413267|OTHER|Flan|Food matrix: flan (soft gel)
218963758|NCT03413267|OTHER|Sponge cake|Food matrix: sponge cake (porous and spongy)
218963759|NCT03413267|OTHER|Biscuit|Food matrix: biscuit (thick and crunchy)
218963760|NCT04488211|OTHER|Survey|The IVM survey will be structured as a series of open questions and multiple-choice questions.
219650444|NCT00465803|DRUG|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
219650445|NCT00465803|DRUG|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
219650446|NCT06668233|RADIATION|CT|CT Brain
219650447|NCT06668233|RADIATION|CT scan|Neuroimaging in case with delayed development , focal neurological symptoms or seziures
218963761|NCT02789722|OTHER|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
218963762|NCT02789722|OTHER|Placebo|Take 3 capsules, 3 times daily for 28 days.
218963763|NCT05481450|DIETARY_SUPPLEMENT|Nutritears®|Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
218963764|NCT05481450|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule (Total capsule weight ≈670 mg)
218963765|NCT05923619|PROCEDURE|Total pulpotomy|Total pulpotomy procedures explained in arm descriptions.
218963766|NCT05923619|PROCEDURE|Root canal treatment|Root canal treatment procedures explained in arm descriptions.
219650448|NCT05887843|DRUG|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
219650449|NCT05887843|DRUG|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
219062570|NCT01184066|BEHAVIORAL|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
219062571|NCT00129987|BEHAVIORAL|Self management education|
219650450|NCT05887843|DRUG|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
219650451|NCT03185715|BEHAVIORAL|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
219650452|NCT06622980|OTHER|Education|"The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice."
219650453|NCT00180492|DEVICE|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
219650454|NCT05098119|DRUG|Sintilimab, Nab-paclitaxel, Carboplatin|Neoadjuvant Therapy
219650455|NCT05098119|PROCEDURE|Surgical resection|Standard of care
219650456|NCT05098119|DRUG|Sintilimab|Adjuvant Therapy
219650457|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 1)|1 week of consecutively consuming oral placebo (1 time/day)
219650458|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 1)|1 week of consecutively consuming oral probiotics (1 time/day)
219650459|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 2)|1 week of consecutively consuming oral placebo (1 time/day)
219650460|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 2)|1 week of consecutively consuming oral probiotics (1 time/day)
219650461|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 3)|1 week of consecutively consuming oral placebo (1 time/day)
219650462|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 3)|1 week of consecutively consuming oral probiotics (1 time/day)
219650463|NCT06064825|OTHER|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
219650464|NCT04838756|OTHER|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
218963767|NCT01718795|DEVICE|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
218963768|NCT06102746|DRUG|Sintilimab，Surufatinib|Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
218963769|NCT01857583|DRUG|15mg DU-176b|
219062572|NCT02684422|OTHER|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
219062573|NCT03721380|BEHAVIORAL|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
219062574|NCT01017406|DEVICE|PSU heel cushion and plantar fascia specific stretching exercise|"* Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day"
219207892|NCT05990062|DEVICE|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
218963770|NCT01857583|DRUG|30mg DU-176b|
218963771|NCT01857583|DRUG|Fondaparinux|
218963772|NCT06640335|OTHER|Co-ingestion|Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.
219650465|NCT04838756|OTHER|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
219650466|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
219650467|NCT06061185|DEVICE|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
219650468|NCT02454010|BIOLOGICAL|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
219650469|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
219650470|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
219650471|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
219650472|NCT04659707|DRUG|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
219650473|NCT06391541|PROCEDURE|modified thoracolumbar interfacial plan block (mTLIP)|Injecting local anesthetic at L3 vertebral level between the longisimus and iliocostalis muscles within the erector spinae muscles.
219650474|NCT06391541|PROCEDURE|Intertransverse process block (ITP)|injection of local anesthetic on the superior costotransverse ligament between the transverse process and the pleura.
219650475|NCT04775342|DEVICE|smartphone|modern technology
219650476|NCT02988440|DRUG|PDR001|PDR001 will be administered intravenously
219650477|NCT02988440|DRUG|Sorafenib|Sorafenib is formulated as a tablet.
219650478|NCT05269420|PROCEDURE|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
219650479|NCT06219291|OTHER|Observational|Observation of the natural course of the disease
219650480|NCT04722367|BEHAVIORAL|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
219650481|NCT03868748|DIETARY_SUPPLEMENT|Beta-arbutin|Beta-arbutin capsules
219650482|NCT03868748|OTHER|Placebo|Placebo capsules containing non-medicinal ingredients
219650483|NCT05341336|PROCEDURE|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
219650484|NCT03580408|DRUG|Nivolumab|240 mg
219650485|NCT03580408|DRUG|Vinblastin|6mg/m²
218963773|NCT06640335|OTHER|0 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.
218963774|NCT06640335|OTHER|5 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.
218963775|NCT06640335|OTHER|10 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
218963776|NCT06640335|OTHER|15 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
218963777|NCT06640335|OTHER|20 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 20 minutes, then consume 300 g of mashed potatoes.
219062575|NCT01735539|DIETARY_SUPPLEMENT|15g EAA bolus|Oral; in aqueous solution
219062576|NCT01735539|DIETARY_SUPPLEMENT|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
219650486|NCT03290755|BEHAVIORAL|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
219650487|NCT03322865|DRUG|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
219650488|NCT00670293|RADIATION|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
219650489|NCT00670293|DRUG|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
219650490|NCT00670293|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
219062577|NCT01735539|DIETARY_SUPPLEMENT|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
219062578|NCT05234294|OTHER|Survey|We will investigate symptoms through monthly surveys.
219062579|NCT00033254|RADIATION|radiation therapy|Undergo conventional radiation therapy
219062580|NCT00033254|DRUG|thalidomide|Given orally
219062581|NCT00033254|PROCEDURE|quality-of-life assessment|Ancillary studies
219062582|NCT06467045|OTHER|Pediatric patients who received sedation for magnetic resonance imaging|Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
219062583|NCT03114254|DRUG|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
219650491|NCT04387734|DRUG|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
219650492|NCT04387734|DRUG|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
219650493|NCT03378414|PROCEDURE|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
218963778|NCT06640335|OTHER|Spinach only / 10 min preload|Subjects consume 200 g baby round spinach WITHOUT canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
218963779|NCT06640335|OTHER|Canola oil only / 10 min preload|Subjects consume 20 g of canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
218963780|NCT03971513|PROCEDURE|Trans abdominal plane|"Trans abdominal plane block is performed with ultra sound guidance.~1. \- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~2. \- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
219650494|NCT03378414|PROCEDURE|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
219650495|NCT03378414|BIOLOGICAL|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
219650496|NCT06444308|OTHER|CommCare with Mobile Clinical Decision Support (CDS) Application|For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
219650497|NCT06444308|OTHER|Remote Supervision by Physicians|teleconsultation with a supervising physician
219650498|NCT06444308|OTHER|CommCare Application without CDS|The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
219650499|NCT05486117|DRUG|Delgocitinib|Cream for topical application 20 mg/g
218963781|NCT01510457|DRUG|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
218963782|NCT01510457|DRUG|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
218963783|NCT02824861|BEHAVIORAL|Bemobile|
218963784|NCT00134537|DEVICE|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
218963785|NCT00134537|DEVICE|Conservative Care|Medication, exercise and spinal injections
218963786|NCT04163679|PROCEDURE|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
218963787|NCT01187719|DRUG|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
219650500|NCT05099614|COMBINATION_PRODUCT|Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system|1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
219650501|NCT05670223|OTHER|Fit&Strong Exercise Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
219650502|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
218963788|NCT04235465|OTHER|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
218963789|NCT00458536|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
219650503|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
219650504|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
219650505|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
219650506|NCT00102141|DRUG|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
219650507|NCT04916743|OTHER|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
219650508|NCT06322953|DRUG|Direct-Acting Oral Anticoagulants (used as per local standard practice)|Direct-acting oral anticoagulants to be prescribed as per local standard practice at either 1 or 4 weeks.
219650509|NCT02142361|DEVICE|enfilcon A|Silicone hydrogel toric lenses.
219650510|NCT05346211|DIETARY_SUPPLEMENT|Curcumin|Curcumin Supplementation
219650511|NCT05117554|DRUG|casdatifan|Capsule
219650512|NCT05117554|DRUG|Placebo|Capsule
219650513|NCT05117554|DRUG|Midazolam|Syrup solution
219650514|NCT04932824|BIOLOGICAL|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
219650516|NCT06453876|DEVICE|Ultrasound assisted Thrombolysis|Please see Arms
219650517|NCT06453876|DEVICE|Percutaneous Embolectomy|Please see arms
219650518|NCT06453876|DRUG|Heparin|Active comparator
219650519|NCT05727787|RADIATION|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
219650520|NCT04517851|BIOLOGICAL|Elotuzumab|Given IV
219650521|NCT04517851|OTHER|Questionnaire Administration|Ancillary studies
219650522|NCT02610829|DIETARY_SUPPLEMENT|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
219650523|NCT00514826|OTHER|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
219650524|NCT03792529|OTHER|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
218963790|NCT00458536|DRUG|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
218963791|NCT01676363|DRUG|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
219062584|NCT02609243|BEHAVIORAL|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
219650525|NCT05800587|DRUG|Carboplatin|Standard of care chemotherapy regimen
219650526|NCT05800587|DRUG|Pemetrexed|Standard of care chemotherapy regimen
219650527|NCT05800587|DRUG|Paclitaxel|Standard of care chemotherapy regimen
219062585|NCT03137511|OTHER|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
219062586|NCT01577706|DRUG|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
219650528|NCT05800587|DRUG|Nab paclitaxel|Standard of care chemotherapy regimen
219650529|NCT05800587|DRUG|Docetaxel|Standard of care chemotherapy regimen
218963792|NCT06003998|DRUG|Irinotecan|2 weekly IP irinotecan (max 12 cycles), dose 75 mg flat dose
218963793|NCT06003998|DRUG|FOLFOX regimen|FOLFOX-4 regimens consist of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1 followed by 1600 mg/m2 5-FU as a 46-h infusion
218963794|NCT06003998|DRUG|Bevacizumab|Bevacizumab according to standard of care
218963795|NCT02811354|DRUG|AZD9291|oral administration as a single daily dose of 80 mg
219062587|NCT01577706|DRUG|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
219062588|NCT01577706|OTHER|Placebo|Placebo, gel-capsule, single-dose, 1-day
218963796|NCT00538525|DRUG|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
218963797|NCT05117632|DRUG|ALTO-100 PO tablet|one tablet twice daily
219062589|NCT03405987|DIAGNOSTIC_TEST|Strain analysis by CMR|Strain analysis by CMR will be performed
219062590|NCT00737087|DEVICE|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
219062591|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
219062592|NCT01156753|DRUG|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
219650530|NCT05800587|DRUG|Gemcitabine|Standard of care chemotherapy regimen
219650531|NCT05800587|DRUG|Etoposide|Standard of care chemotherapy regimen
219650532|NCT05800587|DRUG|Irinotecan|Standard of care chemotherapy regimen
219650533|NCT05800587|DRUG|Topotecan|Standard of care chemotherapy regimen
219650534|NCT05800587|DRUG|Lurbinectedin|Standard of care chemotherapy regimen
219650535|NCT06649396|DIAGNOSTIC_TEST|Dried Blood Spot|Comparing analysis results between dried blood spot and plasma
219650536|NCT06649396|DIAGNOSTIC_TEST|Analysis on plasma|Analysis on plasma
219650537|NCT04829110|OTHER|ETOH|Participants will consume Vodka
219650538|NCT04829110|OTHER|Sucrose|Participants will consume sucrose in solution with water
219650539|NCT06405789|OTHER|yoga practice|The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
219650540|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as an observer rather directly taught.
219650541|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
219650542|NCT06066697|BEHAVIORAL|SOVA Ambassador|"The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments."
219650543|NCT06066697|BEHAVIORAL|Self-Reflection|Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
219650544|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
218963798|NCT06333756|OTHER|Cross education|Cross education training of the biceps brachii (12 rep./set, 3sets, 60%MVIC,180°/s, eccentric contraction)
219650545|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219650546|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219650547|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219650548|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219650549|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
218963799|NCT04894916|OTHER|My Diabetes Care Mobile (MDC-m)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
218963800|NCT05821634|BEHAVIORAL|Personalized intervention condition: Cognitive behavioral therapy skills|An 11-session cognitive behavioral therapy (CBT) skills based intervention will be delivered to participants randomized to the personalized intervention. Influential constructs will be identified using the person specific digital phenotyping model, targeted using CBT skills, and tracked across sessions.
219650550|NCT02616965|DRUG|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
219650551|NCT02616965|DRUG|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
219650552|NCT04233346|DRUG|Ponatinib 30mg OD|Ponatinib 30mg OD
219650553|NCT04233346|DRUG|Ponatinib 45mg OD|Ponatinib 45mg OD
219650554|NCT05234593|DIETARY_SUPPLEMENT|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
218963801|NCT05821634|BEHAVIORAL|Therapeutic control condition: Cognitive behavioral therapy skills|Participants randomized to this condition will receive an 11-session CBT skills based treatment targeting a non-personalized construct selected from the person-specific digital phenotyping model.
218963802|NCT05821634|BEHAVIORAL|Tracking control condition: Supportive counseling|Participants randomized to this condition will receive 11 supportive counseling sessions that are non-directive in nature (providing support and validation for non-acute weekly stressors). Participants will continue digital phenotyping, controlling for the effect of counseling and digital phenotyping.
219207893|NCT06762574|OTHER|Low Level Laser Therapy|Low Level Laser Therapy sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low intensity light therapy. The effect is photochemical not thermal. The light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors and triggers chemical changes.
219650555|NCT06621355|OTHER|Physical fitness test: Progressive intervalic test|"An incremental interval test of 4\&#39; of work for 1\&#39; of rest will be performed at an individual intensity below the aerobic threshold. At the end of the rest minute, the load shall be increased slightly. In order to be as adjusted and individualised as possible, the subjective physical condition level stated by the patient during the sociodemographic data collection shall be taken as a reference for the establishment of the initial load, being a value of power (W) in cycle ergometer and speed (km/h) in treadmill. Never less than 50W or 6 km/h, respectively.~The minimum incremental values will be 25W or 0.5km/h until you are unable to complete a full interval. An incomplete interval shall also be recorded and analysed.~During the one minute rest period, as will have been well emphasised during the explanation of the test, no part of the body may be moved at all, so at the end of the 4 minutes of work, the evaluator will count down for the patient to get ready and remain stil"
219650556|NCT05234125|BEHAVIORAL|Better|It is a nonpharmacologic sleep intervention to improve maternal glucose metabolism in African American Pregnant Women (AAPW). Sleep BETTER is composed of sleep hygiene practices and cognitive-behavioral principles.
219650557|NCT05234125|BEHAVIORAL|Birth Prep|The intervention involves training about pregnancy-related issues, and follow up
219650558|NCT06422312|DEVICE|Cystoscopy with RedPine flexible disposable cystoscope|Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.
219650559|NCT06422312|DEVICE|Cystoscopy with standard of care flexible reusable scope|Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
218963803|NCT02776267|DEVICE|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
219207894|NCT06762574|OTHER|Placebo Low Level Laser Therapy|Placebo Low Level Laser Therapy:turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect.
219650560|NCT05536895|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
219650561|NCT05536895|DIAGNOSTIC_TEST|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
219650562|NCT06145698|DEVICE|Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device|Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
219650563|NCT02441270|DRUG|Cyclophosphamide|
219062593|NCT01156753|DRUG|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
219062594|NCT05147818|OTHER|CBC ,renal function tests , fundus Examination|Laboratory investigations
219062595|NCT00999479|DRUG|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
219062596|NCT00999479|DRUG|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
219062597|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
219062598|NCT00547560|DRUG|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
219650564|NCT02441270|RADIATION|Stereotactic body radiotherapy|
219650565|NCT05224960|BIOLOGICAL|UC-MSCs|3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
219650566|NCT05224960|BIOLOGICAL|Placebo(solution without UC-MSCs)|3 doses of placebo intravenously at day 1, day 8, day 15.
219650567|NCT02889198|BEHAVIORAL|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
219650568|NCT02111746|DRUG|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
219650569|NCT02111746|DRUG|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
219650570|NCT02111746|DRUG|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
219650571|NCT06292585|PROCEDURE|MMA embolization plus medical therapy|Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment. Patients will receive the best conservative treatment recommended by the guidelines after MMA, and conservative treatment will be the same in both groups
219650572|NCT06292585|DRUG|Medical therapy alone|Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
219062599|NCT03796455|DIETARY_SUPPLEMENT|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
219650573|NCT01618851|RADIATION|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
219650574|NCT02203851|DRUG|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
219650575|NCT04390672|DEVICE|SUPRAFLEX Cruz|Percutaneous Coronary Intervention for multivessel disease
219062600|NCT03796455|OTHER|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
219650576|NCT04390672|DEVICE|SYNERGY|Percutaneous Coronary Intervention for multivessel disease
219650577|NCT03164473|DRUG|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
219650578|NCT03164473|DRUG|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
219650579|NCT03164473|DRUG|Placebo-rituximab|4 infusions for 18 months
219650580|NCT03164473|DRUG|Placebo-azathioprine|oral tablets for 24 months
219650581|NCT00331513|DRUG|vorinostat|Given orally
219650582|NCT00331513|DRUG|idarubicin|Given IV
219650583|NCT00331513|OTHER|laboratory biomarker analysis|Correlative studies
219650584|NCT00331513|OTHER|pharmacological study|Correlative studies
219650585|NCT01701297|DRUG|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
219650586|NCT01701297|DRUG|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
219650587|NCT01701297|DRUG|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
219650588|NCT00046917|DRUG|alvocidib|Given IV
219650589|NCT00046917|DRUG|irinotecan hydrochloride|Given IV
219650590|NCT00046917|DRUG|cisplatin|Given IV
219650591|NCT04439305|DRUG|Dasatinib|Given PO
219062601|NCT03185975|BEHAVIORAL|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
219062602|NCT03185975|BEHAVIORAL|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
219062603|NCT00326235|DRUG|Buspirone|
219062604|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
219062605|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
219650592|NCT06179732|COMBINATION_PRODUCT|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
219650593|NCT06179732|BEHAVIORAL|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
219062606|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
219062607|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
219062608|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
219062609|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
219062610|NCT02230657|PROCEDURE|Same day discharge|
219062611|NCT02230657|PROCEDURE|Next day discharge|
219650594|NCT06179732|DIAGNOSTIC_TEST|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
219650595|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
219650596|NCT05654090|DRUG|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
219650597|NCT03523143|OTHER|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
219650598|NCT03523143|OTHER|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
219650599|NCT01624857|DRUG|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
219650600|NCT01624857|DRUG|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
219650601|NCT00005768|DRUG|Estrogen|
219650602|NCT00326781|DRUG|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
218963804|NCT06566521|PROCEDURE|thoracic paravertebral block|After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
219062612|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
219062613|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
219650603|NCT00326781|DRUG|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
219062614|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
219650604|NCT03250481|DRUG|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
219650605|NCT00402532|DRUG|Everolimus|Initial dosage 2 x 0.75 mg/d
219650606|NCT00402532|DRUG|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
219650607|NCT04045132|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
219650608|NCT04045132|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
219650609|NCT05288387|PROCEDURE|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
219650610|NCT00327743|DRUG|larotaxel|IV infusion on Day 1 of a 21-day cycle
219650611|NCT00327743|DRUG|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
219650612|NCT02768441|DRUG|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
219650613|NCT05210101|DRUG|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
219207895|NCT06225297|COMBINATION_PRODUCT|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
219650614|NCT04169672|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
219650615|NCT04169672|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
219650616|NCT00192101|DRUG|gemcitabine|
219650617|NCT00192101|DRUG|cisplatin|
219650618|NCT00606840|BEHAVIORAL|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
219650619|NCT00606840|BEHAVIORAL|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
219650620|NCT02189655|PROCEDURE|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
219650621|NCT05160038|DEVICE|Embodied virtual reality|An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
219650622|NCT04489849|DRUG|Apixaban 2.5 MG|apixaban 2.5mg BID for 3 months in experimental group
219650623|NCT04489849|OTHER|Active Control|Medication other than anticoagulation
219650624|NCT04264117|PROCEDURE|FlexAbility (Mesh-like irrigated tip catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
219650625|NCT04264117|PROCEDURE|TactiCath (Contract force monitoring catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. contact force \>10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
219650626|NCT00393263|DRUG|pimecrolimus and clobetasol|
219650627|NCT00393263|DRUG|clobetasol 0.05% cream|twice daily for three months
218963805|NCT04397887|PROCEDURE|micro-surgical varicocelectomy|Sub-inguinal micro-surgical varicocelectomy
218963806|NCT06987773|DRUG|RLF-OD032 100 mg/mL oral suspension|Sapropterin dihydrochloride
218963807|NCT06987773|DRUG|Kuvan 100 MG Powder for Oral Solution|Sapropterin dihydrochloride
218963808|NCT06986460|DEVICE|MagPro X100/R30 stimulator, Cool-B70 coil|1Hz rTMS delivered to the right DLPFC
218963809|NCT06816836|PROCEDURE|Bed Side ultrasound guided muscle mass estimation of lower extremity|Bed Side ultrasound guided muscle mass estimation of psoas major, rectus femoris, vastus intermedius and tibialis anterior.
218963810|NCT06589778|DRUG|SHR-A2102|SHR-A2102: injection, 80mg/ bottle, intravenous drip
218963811|NCT06589778|DRUG|Adebelimab (SHR-1316)|Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
218963812|NCT06589778|DRUG|SHR-8068|SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
219207896|NCT06890195|PROCEDURE|dialysate cooling|patients will be subjected to individualized cool dialysate (dialysate temperature 0.5 °C lower than core body temperature)
219650628|NCT05096260|BEHAVIORAL|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
219650629|NCT01632150|BIOLOGICAL|Elotuzumab|Powder for solution, 400-mg vials, for infusion
219650630|NCT01632150|BIOLOGICAL|Thalidomide|50-mg capsules administered orally
219650631|NCT01632150|BIOLOGICAL|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
218963813|NCT06666504|OTHER|Combined Retrospective and Prospective Data Analysis|Collection of both retrospective and prospective data all ready available for participant
218963814|NCT06993857|OTHER|Neuromuscular taping applied with no tension|Neuromuscular taping applied with no tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
218963815|NCT06993857|OTHER|Neuromuscular taping applied with distal-to-proximal tension|Neuromuscular taping applied with distal-to-proximal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
218963816|NCT06993857|OTHER|Neuromuscular taping applied with proximal-to-distal tension|Neuromuscular taping applied with proximal-to-distal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
218963817|NCT06994533|PROCEDURE|methods on bone reconstrucion after chest wall tumor resection|Selecting appropriate implants for chest wall bone reconstruction
218963818|NCT06993571|DEVICE|Active-tACS|30 seconds of closed-loop tACS at 2-4 mA, with 6 alternating phase alignments and 1-3 repetitions. Phase alignment is adjusted to the patient's tremor frequency and rhythm in real time. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
219650632|NCT01632150|BIOLOGICAL|Cyclophosphamide|50-mg tablets administered orally
219650633|NCT03203408|DEVICE|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
219650634|NCT03203408|DEVICE|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
219650635|NCT04288141|OTHER|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
219650636|NCT05171244|BEHAVIORAL|virtual reality training|training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care
219650637|NCT05171244|BEHAVIORAL|usual care|usual program of interventions in usual care
219650638|NCT00900640|PROCEDURE|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
219650639|NCT00219570|DRUG|clindamycin|
219650640|NCT00219570|DRUG|nadifloxacin|
218963819|NCT06993571|DEVICE|Sham-tACS|30 seconds of tACS at 0 mA and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The sham protocol begins with a 3-second ramp-up and ends with a 3-second ramp-down.
219650641|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (RhinAdvil(R))
219650642|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (BI product)
219650643|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (BI product)
219650644|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
219650645|NCT06620900|OTHER|Integrated Model of Care|The Integrated Model of Care was developed and piloted by the study team provide support for individuals seeking care in an interdisciplinary intensive outpatient program for mild traumatic brain injury to receive support for co-occurring substance use-related needs.
219650646|NCT02607852|DEVICE|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
219650647|NCT01552148|OTHER|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
219650648|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
219650649|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
219650650|NCT04142320|DEVICE|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
219650651|NCT04142320|DEVICE|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
219650652|NCT04142320|DEVICE|sham rTMS|Delivers placebo magnetic stimulation
219650653|NCT04516382|DRUG|PTG-300|Active drug
218963820|NCT06993571|DEVICE|Unlocked-tACS|30 seconds of open-loop tACS at 2-4 mA, with no phase alignments and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
218963821|NCT06993506|DRUG|SKB264 Monotherapy or Combination Therapy|The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.
219062615|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
219062616|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
219062617|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
219062618|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
219062619|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
219207897|NCT06890195|PROCEDURE|standard dialysate temperature|patients will be subjected to standard dialysate temperature (dialysate temperature of 37 °C).
219207898|NCT06881017|DRUG|Trastuzumab|iv，d1
219207899|NCT06881017|DRUG|Adebrelimab|iv，d1，q3w
219650654|NCT02143791|PROCEDURE|Burst and Tonic stimulation|
219207900|NCT06881017|DRUG|Apatinib|po，qd，d1-21，q3w
219650655|NCT06623760|DEVICE|Desk and chair adaptation interventions|Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
219650656|NCT06620991|DRUG|Phentolamine|A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml
219650657|NCT06620991|DRUG|Esmolol|A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml
219650658|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
219650659|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
219650660|NCT04890977|BEHAVIORAL|Talking Story|A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
219650661|NCT04477044|OTHER|Study Group|GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
219650662|NCT04308980|DIETARY_SUPPLEMENT|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
219650663|NCT04308980|BEHAVIORAL|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
219650664|NCT00401544|DRUG|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
219650665|NCT00401544|DRUG|IV iron dextran|Administered by intravenous (IV) injection.
219650666|NCT00276185|DRUG|Time delay treatment of botulinum toxin|
219650667|NCT02564445|BEHAVIORAL|Gamification|All participants will be entered with their teammate into a game that includes points and levels
218963822|NCT06994390|DEVICE|tDCS|This group will receive single-phase direct current with an intensity of 2 mA up. Electrodes with a size of 35cm² (5 x 7 centimeters) will be used. Electrodes will be placed on the scalp, fixed with elastic bands, and immersed in 10 to 12 mL of saline solution.
218963823|NCT06994390|DEVICE|sham intervention|The device displays will be identical across active and sham groups, and to ensure blinding, an active current will be applied for 30 seconds at the beginning and end of the sham stimulation to mimic the sensation of the current ramp experienced in active stimulation. Stimulations of less than 3 minutes of tDCS do not induce cortical excitability effects, according to Nitsche and Paulus (2000), being safely inactive for the expected results.
218963824|NCT06994572|DRUG|CT-01|Investigational small-molecule degrader targeting transcription factors in HCC. Used as monotherapy or with everolimus in dose-escalation/expansion settings. Specific to protocol CT-01-CD-1.
218963825|NCT06994572|DRUG|EVEROLIMUS|Approved mTOR inhibitor used in combination with CT-01 for HCC in this study. Evaluated for safety, tolerability, and PK/PD in CT-01-CD-1 protocol.
218963826|NCT06994520|OTHER|Cannabidiol (CBD)|5%CBD cream
218963827|NCT06994520|DRUG|Triamcinolone (TAC) 0.1% cream|comparator
218963828|NCT06993948|DEVICE|Transthoracic echocardiography|Transthoracic echocardiography (TTE) was carried out. The assessment of left ventricular ejection fraction (LVEF) relied primarily on two-dimensional echocardiography using visual estimation.
218963829|NCT01591850|DRUG|RO5093151|Single oral dose
218963830|NCT01591850|DRUG|atazanavir|Multiple oral doses
218963831|NCT01591850|DRUG|ketoconazole|Multiple oral doses
218963832|NCT01591850|DRUG|rifampicin|Multiple oral doses
218963833|NCT01591850|DRUG|ritonavir|Multiple oral doses
218963834|NCT02516267|DEVICE|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG
218963835|NCT06056765|DEVICE|"Minilith, Storz, Swiss"|shock waves
218963836|NCT03757013|DRUG|Apremilast|Apremilast
218963837|NCT02386670|OTHER|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
219207901|NCT06881017|DRUG|S-1|po，bid，d1-14，q3w
219207902|NCT06881017|DRUG|Capecitabine|po，bid，d1-14
219207903|NCT06881017|DRUG|Oxaliplatin|iv，d1，q3w
219207904|NCT06881017|DRUG|zolbetuximab|iv，d1
219650668|NCT02564445|BEHAVIORAL|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
219650669|NCT02564445|BEHAVIORAL|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
218963838|NCT02386670|OTHER|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
218963839|NCT06685588|DRUG|5-FU (fluorouracil)|Topical 5-FU (fluorouracil) pretreatment prior to dovonex
218963840|NCT06685588|DRUG|Calcipotriol|Calcipotriol pre-treatment prior to PDT
218963841|NCT06682247|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
219207905|NCT06881017|DRUG|SHR-A1811|iv，d1 ，q3w
219207906|NCT06881017|DRUG|SHR-A1904|iv，d1 ，q3w
219207907|NCT06881017|DRUG|SHR-1701|iv，d1 ，q3w
219207908|NCT06750068|OTHER|3D printed space maintainer|Digitally fabricated #d printed space maintainer
219207909|NCT06750068|OTHER|Conventional space maintainer|Stainless steel space maintains
219650670|NCT02564445|BEHAVIORAL|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
219650671|NCT00598611|DRUG|desloratadine|singel dose, oral, 20 mg
219650672|NCT00598611|DRUG|desloratadine|single dose, oral, 5 mg
219650673|NCT01429064|DRUG|ODM-201|ODM-201 administered orally daily
219650674|NCT02787018|DRUG|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
218963842|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).
218963843|NCT06683703|DRUG|Utidelone|Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
218963844|NCT06683703|DRUG|Utidelone combined with Bevacizumab|In the combination group, the dose of Utidelone was determined according to the safety run-in period, 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3W.
218963845|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The dose of Utidelone was 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3w.
218963846|NCT06684873|DRUG|AK112 Injection|AK112 injection plus chemotherapy was administered to all eligible patients
218963847|NCT06684522|DRUG|Upadacitinib 15 MG|Upadacitinib 15mg daily
218963848|NCT05952271|OTHER|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
218963849|NCT06708377|OTHER|dry needling of masseter|"Experimental group included Dry needling of masseter muscle for 30 second to 2 minutes into the trigger point.~Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day."
218963850|NCT06708377|OTHER|myofascial massage therapy on masseter muscle|Control group included Myofascial massage - sliding and kneading, for 30 minutes per session/3x per week. Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day
218963851|NCT06878495|OTHER|Discontinuation of 5-ASA|Discontinuation of 5-ASA from the time of study enrollment.
219062620|NCT02577705|BEHAVIORAL|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
219650675|NCT02787018|DRUG|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
219650676|NCT02787018|DRUG|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
219650677|NCT06057714|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
219650678|NCT02847923|OTHER|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
218963852|NCT06717334|DIAGNOSTIC_TEST|Low Dose CT imaging|at baseline and at Year 1.
218963853|NCT06717334|OTHER|blood draws|at baseline and at Year 1.
218963854|NCT06717334|OTHER|screening questionnaire|at baseline and at 1 year after registration.
218963855|NCT03670836|DEVICE|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
219062621|NCT02577705|BEHAVIORAL|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
219062622|NCT02577705|BEHAVIORAL|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
219207910|NCT06833749|DRUG|KBP-336|KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
219207911|NCT06833749|DRUG|Placebo|Placebo to match KBP-336
219207912|NCT06849154|BEHAVIORAL|REAL™ SEL Intervention Group|A structured intervention using virtual reality (VR) components to improve emotional regulation in early adolescents
219650679|NCT02847923|OTHER|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
219650680|NCT02847923|OTHER|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
219062623|NCT04497441|OTHER|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
219062624|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
219062625|NCT04558957|DEVICE|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
219062626|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
219062627|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
219062628|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
219062629|NCT01384344|OTHER|observational|Observation during a physical exercise
218963856|NCT03670836|DRUG|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
219650681|NCT02847923|OTHER|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
219650682|NCT06550011|DRUG|ABI-110 Low Dose|Low dose. lower than the safety factor of 10 as recommended by the FDA
219062630|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
219062631|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
218963857|NCT03287635|DRUG|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
219650683|NCT06550011|DRUG|ABI-110 Medium Dose|Medium dose
219650684|NCT06550011|DRUG|ABI-110 High Dose|High Dose
219650685|NCT03078296|OTHER|survey respondents|all survey participants will be asked to complete a questionnaire
219650686|NCT06112158|BEHAVIORAL|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support"
218963858|NCT00396032|DRUG|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
218963859|NCT00396032|DRUG|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
219062632|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
219062633|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
219062634|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
219062635|NCT00005619|GENETIC|polymerase chain reaction|
219062636|NCT00005619|OTHER|flow cytometry|
219062637|NCT00005619|OTHER|immunohistochemistry staining method|
219062638|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
219062639|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
219062640|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
219062641|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
219650687|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
219686303|NCT05398406|OTHER|TAP Block group|TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
218963860|NCT06921356|BEHAVIORAL|Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention|Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.
218963861|NCT06921356|BEHAVIORAL|Self-Shopping DASH diet advice|Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.
218963862|NCT06894992|DRUG|Tegoprazan|Tegoprazan 50 mg tab PO OD in 2 weeks
218963863|NCT06894992|DRUG|Lansoprazole|Lansoprazole 30 mg tab PO OD in 2 weeks
218963864|NCT06730750|DRUG|BMS-986490|Specified dose on specified days.
218963865|NCT06730750|DRUG|Bevacizumab|Specified dose on specified days.
218963866|NCT01598363|DRUG|Digoxin|Oral, Day 1 and Day 10
218963867|NCT01598363|DRUG|Rosuvastatin|Oral, Day 1 and Day 10
218963868|NCT06770517|BEHAVIORAL|Exposure therapy|The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.
218963869|NCT06770517|BEHAVIORAL|Usual Care|The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.
218963870|NCT04981834|OTHER|Quality-of-Life Assessment|Ancillary studies
218963871|NCT04981834|OTHER|Questionnaire Administration|Ancillary studies
218963872|NCT04981834|PROCEDURE|Radical Prostatectomy|Undergo RARP
218963873|NCT04981834|PROCEDURE|Vesicopexy|Undergo vesicopexy
218963874|NCT06871124|DEVICE|transcranial electrical stimulation|Anodal transcranial electrical stimulation (A-tES) is a widely used and well tolerated non-invasive electrical stimulation paradigm that promotes adaptive neuroplasticity and may prevent or reduce pathological sequela following brain injury. It has been used in a wide variety of neurologic and psychiatric disorders for cognitive and motor rehabilitation.
218963875|NCT06871124|DEVICE|Sham Comparator|Sham comparator consist of A-tES in the beginning and end of stimulation block but no stimulation during the actual stimulation period.
218963876|NCT05423912|BEHAVIORAL|Keeping on Course Program|MCI dyads engaging in the testing aim of the Keeping on Course Program take part in group meetings lasting 90 to 120 minutes over the course of 6 virtual meetings. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be invited to take part in a virtual, semi-structured 30-60 minute qualitative interview focused on their experiences in and perceptions of the intervention.
218963877|NCT04914416|DIETARY_SUPPLEMENT|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
218963878|NCT04914416|DIETARY_SUPPLEMENT|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
218963879|NCT04914416|DIETARY_SUPPLEMENT|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
219650688|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
219650689|NCT06667102|BEHAVIORAL|Strategic and Interactive Signing Instruction|SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.
219650690|NCT03575299|BIOLOGICAL|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
219650691|NCT03575299|OTHER|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
219650692|NCT03575299|DRUG|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
219650693|NCT00642096|DRUG|Metoprolol Succinate|
219650694|NCT00642096|DRUG|Hydrochlorothiazide|
219650695|NCT06604962|PROCEDURE|IMES using IEP|First group (n=12) received IMES using inverse electrode placement. The needle electrode inserted into the paraspinal region was connected to the active or cathode pole of the electrical stimulator. The reference or anode pole of the electrical stimulator was connected to the electrode that was inserted into the MTrP area of the UT muscle. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation
219650696|NCT06604962|PROCEDURE|IMES using CEP|Second group (n=12) underwent IMES with conventional electrode placement. In this group, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. Needle electrodes were connected using alligator clip connectors. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation.
219650697|NCT06604962|OTHER|Sham-IMES|Third group (n=12) received sham-IMES. Similar to the experimental intervention groups, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. However, the delivered IMES was very minimal intensity
219650698|NCT04735692|OTHER|Full mouth or quadrant SRP|Full mouth or quadrant SRP
219650699|NCT04754438|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy
219650700|NCT04754438|BEHAVIORAL|Mental Health Coaching|Electronically delivered mental health coaching
219650701|NCT01354392|DRUG|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
219650702|NCT03007290|OTHER|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
219650703|NCT06522555|DRUG|polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide|"Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
219650704|NCT06522555|DRUG|zanubrutinib, rituximab and lenalidomide|"Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
219686304|NCT05398406|OTHER|Paravertebral block group|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
218963880|NCT04914416|DIETARY_SUPPLEMENT|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
218963881|NCT04914416|DIETARY_SUPPLEMENT|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
218963882|NCT04914416|DIETARY_SUPPLEMENT|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
218963883|NCT04914416|DIETARY_SUPPLEMENT|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
218963884|NCT04914416|DIETARY_SUPPLEMENT|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
218963885|NCT04914416|DIETARY_SUPPLEMENT|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
218963886|NCT04914416|DIETARY_SUPPLEMENT|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
218963887|NCT04914416|DIETARY_SUPPLEMENT|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
218963888|NCT04914416|DIETARY_SUPPLEMENT|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
219650705|NCT01178879|BEHAVIORAL|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
219650706|NCT00981045|DRUG|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
219650707|NCT00981045|DRUG|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
219650708|NCT05129475|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
219650709|NCT05129475|DRUG|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
219650710|NCT04181983|OTHER|Personalized exercise program|Home-based personalized exercise program using a smart phone app
219650711|NCT04181983|OTHER|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
219650712|NCT05702242|PROCEDURE|IUD removal with no visible strings|Removal with either alligator forceps or MVA
219650713|NCT05702242|DEVICE|Alligator forceps|IUD removal with alligator forceps
219650714|NCT05702242|DEVICE|Manual Vacuum Aspirator|IUD removal with MVA
219650715|NCT00135798|DRUG|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued."
219650716|NCT04186806|DEVICE|3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray|20 ml bottle
219650717|NCT04186806|DEVICE|Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray|44.3 ml bottle
219650718|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
219650719|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
219650720|NCT05274581|OTHER|A new type of ultrasound course|All participants will receive the educational intervention. The educations intervention consists of three teaching seminars over three months, a curriculum of 10 point-of-care ultrasound applications, an online learning platform providing educational support before, during and after the teaching sessions.
219650721|NCT00286923|DRUG|Topiramate|
219650722|NCT03819595|OTHER|Supervised exercise|a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
218963889|NCT04914416|DIETARY_SUPPLEMENT|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
218963890|NCT04914416|DIETARY_SUPPLEMENT|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
218963891|NCT04914416|DIETARY_SUPPLEMENT|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
218963892|NCT04914416|DIETARY_SUPPLEMENT|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
218963893|NCT04914416|DIETARY_SUPPLEMENT|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
218963894|NCT05629637|BEHAVIORAL|Mindfulness-Based Resilience Training (MBRT)|MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
218963895|NCT06938945|BEHAVIORAL|Digitized patient-reported outcomes|Patients fill out the PRO scale regularly online through a specific cell phone program or website, which intelligently analyzes the patient's physical condition, gives symptom management recommendations (which are based on clinical guidelines and expert consensus, and are updated monthly by oncology clinical experts during the study period), and sends alerts to clinical caregivers when the scale scores are abnormal.
218963896|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
218963897|NCT01561027|DRUG|CNV1014802|Administered as specified in treatment arm.
218963898|NCT01561027|DRUG|Placebo|Administered as specified in treatment arm
218963899|NCT05523323|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
218963900|NCT05523323|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
218963901|NCT05523323|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
218963902|NCT00494598|DRUG|Sufentanil|200 mcg intra-arterial one time bolus
219650723|NCT03819595|OTHER|Personalized Program PVS|"a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record."
219650724|NCT02609100|PROCEDURE|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
219650725|NCT02609100|PROCEDURE|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
219650726|NCT02609100|DEVICE|1.0 X 2.5 cm 'pill' containing a camera|
218963903|NCT03435640|DRUG|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
218963904|NCT03435640|DRUG|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
218963905|NCT03435640|DRUG|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
218963906|NCT04648501|OTHER|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
218963907|NCT03882775|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
218963908|NCT03882775|DRUG|Heparin|heparin with or without gpi during emergency PCI.
218963909|NCT03676985|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
218963910|NCT03676985|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
218963911|NCT03676985|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
219650727|NCT02339116|DRUG|fluoruracil|
218963912|NCT06319352|DEVICE|Active UroShield|Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.
219062642|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
219062643|NCT03354000|BEHAVIORAL|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
219650728|NCT02339116|DRUG|Oxaliplatin|
219650729|NCT02339116|DRUG|Irinotecan|
219650730|NCT02339116|DRUG|Bevacizumab|
219650731|NCT00702442|DRUG|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
219650732|NCT00702442|DRUG|Saline solution|Saline solution administrated i.v 30 min prior surgery
219650733|NCT03703011|DEVICE|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
219650734|NCT05860439|PROCEDURE|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
219650735|NCT04739722|DIAGNOSTIC_TEST|ColoSense|"ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals."
219650736|NCT01917812|DEVICE|Digital Activity Tracker|
218963913|NCT06319352|DEVICE|Sham UroShield|Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.
219650737|NCT01917812|OTHER|Smart Text Messaging|
219650738|NCT06622174|RADIATION|Pulse radiotherapy|Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
219650739|NCT06523907|OTHER|Intervention Basic Nursing skills|Evaluating the effectiveness of the education program in improving paramedics' knowledge of essential nursing care principles, such as hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
219650740|NCT06523907|OTHER|Control Present Knowledge about basic nursing skill|Assess the current and baseline knowledge status of the participants about the hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
219650741|NCT01185509|DRUG|trastuzumab|
219650742|NCT01185509|DRUG|vinorelbine|
219650743|NCT03687372|DRUG|A-101|hydrogen peroxide topical solution 45%
219650744|NCT03687372|OTHER|vehicle|vehicle as a topical solution
219650745|NCT04884425|DEVICE|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
219650746|NCT03380702|PROCEDURE|whitening photoactivation gel|35 subjects in active comparator group
219650747|NCT03380702|PROCEDURE|placebo|35 subjects in placebo comparator group
219650748|NCT05028075|BEHAVIORAL|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
219650749|NCT01932736|OTHER|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
219650750|NCT06426862|OTHER|Otago Exercise Program|"Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing"
219650751|NCT06426862|OTHER|Control Group|Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
219650752|NCT04790162|BEHAVIORAL|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
219650753|NCT04403646|DIETARY_SUPPLEMENT|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
219650754|NCT04403646|OTHER|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
219650755|NCT00878969|DRUG|valsartan (ARB)|
219650756|NCT00878969|DRUG|ramipril (ACE inhibitor)|
219650757|NCT00878969|DRUG|Placebo|
218963914|NCT05012787|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
218963915|NCT05012787|BIOLOGICAL|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
218963916|NCT05012787|OTHER|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
218963917|NCT01927302|BEHAVIORAL|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
219062644|NCT03354000|BEHAVIORAL|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
219062645|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
219650758|NCT02350946|DRUG|Oxytocin|
219650759|NCT02350946|DRUG|Placebo|
219650760|NCT05831839|DEVICE|RehaCom|computerized cognitive training
219650761|NCT03640975|OTHER|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
219650762|NCT02120820|BEHAVIORAL|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
219650763|NCT02120820|BEHAVIORAL|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
219650764|NCT02120820|OTHER|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
219650765|NCT02120820|BEHAVIORAL|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
219686305|NCT05398406|OTHER|Erector spinae block group|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
218963918|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
218963919|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
218963920|NCT01927302|BEHAVIORAL|No Treatment|No treatment will be administered.
219062646|NCT05942508|DRUG|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
219062647|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
219062648|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
219062649|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
219062650|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
219062651|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
219062652|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
219062653|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
219062654|NCT03499158|OTHER|nerve conduction study|nerve conduction study
219062655|NCT01902017|DRUG|Ketotifen|5 mg PO bid
219062656|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
219062657|NCT01518205|DEVICE|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
219062658|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
219650766|NCT05977075|OTHER|ApisMela protocol|The activities and games proposed by this protocol are offered in a sequence characterized by increasing complexity. The same function is stimulated with varied tasks because the repetitiveness of the same task negatively affects skill generalization. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Language plays a crucial role, participants are encouraged to use speech as a tool for attention regulation and cognitive processing. It's divided into 20 sessions: a weekly group meeting of one hour and thirty.
219650767|NCT05977075|OTHER|"Unstuck and on Target protocol"|The protocol teaches people to be more flexible, skillful in planning and goal-oriented. It is useful for moving more easily from one topic to another and from one task to another, considering new ideas or another person's point of view, generalizing skills learned across contexts so that teachers, parents and therapists can focus more on educational aspects and less on behavioral management. It is divided into 20 sessions: a weekly group meeting of one hour and thirty minutes. A homework sheet is provided for each session to consolidate the skill learned and generalize it outside the work setting. Parents have an active role in performing the task.
219650768|NCT02083185|DRUG|Relugolix|Relugolix tablets
219062659|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
219062660|NCT01982916|DRUG|AGR tablet|
219062661|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
219062662|NCT01982916|DRUG|Active Comparator|
219062663|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
219062664|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
219062665|NCT02613481|DRUG|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
219062666|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
219062667|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
219062668|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
219062669|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
219207913|NCT06769555|DRUG|CM-336 BCMA/CD3 bispecific antibody|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
219207914|NCT06832995|DRUG|IV morphine administered during the PACU stay|IV morphine administered during the PACU stay
219207915|NCT06844123|PROCEDURE|Robot-assisted keratoplasty|Feasibility pilot interventional study. Monocentric, one arm. Microsurgical robot will be used to perform penetrating keratoplasty. During the procedure, the corneal sutures will be performed using symani surgical system, that is a microsurgical robot controlled by a surgeon
219650769|NCT02083185|DRUG|Leuprorelin|Leuprorelin subcutaneous injection
219650770|NCT01609309|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
219650771|NCT01609309|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
219650772|NCT02952989|DRUG|SGN-2FF|SGN-2FF oral daily dosing.
219650773|NCT02952989|DRUG|pembrolizumab|200 mg every 3 weeks by IV infusion
219650774|NCT04018040|OTHER|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
219650775|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
219650776|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
219650777|NCT00380081|DRUG|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
219650778|NCT03867149|OTHER|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
219650779|NCT03867149|OTHER|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
219650780|NCT01815606|PROCEDURE|biopsy with 19 gauge needle|biopsy with 19 gauge needle
219650781|NCT01815606|PROCEDURE|biopsy with 25 gauge needle|biopsy with 25 gauge needle
218963921|NCT03354975|BEHAVIORAL|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
218963922|NCT03354975|BEHAVIORAL|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
218963923|NCT03593941|OTHER|Standard Diet|Participants will consume the standard diet provided in care home
218963924|NCT00792077|DRUG|Lenalidomide|5 mg daily for 56 days.
218963925|NCT02857595|BEHAVIORAL|Online Behavioral Weight Loss program|
218963926|NCT02857595|BEHAVIORAL|Weight Loss Nomogram|
218963927|NCT02857595|BEHAVIORAL|Bite Counter|
218963928|NCT05437835|DRUG|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
218963929|NCT04835467|DEVICE|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
218963930|NCT02075970|DRUG|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
219650782|NCT02026817|DRUG|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
219650783|NCT02026817|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
219650784|NCT02026817|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
219650785|NCT03054064|DEVICE|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
219650786|NCT06439628|DRUG|Rimegepant|patients take rimegepant to treat migraine attack as needed
219650787|NCT03787303|DRUG|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
219650788|NCT01471717|DRUG|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
219650789|NCT01471717|DRUG|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
219650790|NCT01471717|DRUG|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
219650791|NCT01471717|DRUG|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
218963931|NCT02075970|DRUG|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
218963932|NCT04927000|DRUG|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
218963933|NCT02016339|BEHAVIORAL|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
218963934|NCT02016339|BEHAVIORAL|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
219062670|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
219650792|NCT01471717|DRUG|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
219650793|NCT01471717|DRUG|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
219650794|NCT04895813|BEHAVIORAL|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
219650795|NCT05870449|DEVICE|tunneled PICC|Tunneled PICC is a type of PICC catheterization technique that involves establishing a subcutaneous tunnel to keep the outlet of the catheter away from the puncture site
219650796|NCT05870449|DEVICE|routine PICC|Peripherally inserted central venous catheterization is a technique that involves inserting PICC through the peripheral vein and infusing drugs into the central vein through a catheter.
219650797|NCT00431665|DRUG|NG-monomethyl-L-Arginine (L-NMMA)|
219650798|NCT00431665|DRUG|triglycerides (Intralipid 20%)|
219650799|NCT00431665|DRUG|heparin|
219650800|NCT00431665|DRUG|somatostatin|
219650801|NCT00431665|DRUG|insulin|
218963935|NCT03083860|DEVICE|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
218963936|NCT01225536|DRUG|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
218963937|NCT04389814|DIAGNOSTIC_TEST|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
218963938|NCT01948310|DRUG|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
218963939|NCT01948310|BEHAVIORAL|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
218963940|NCT01948310|DRUG|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
218963941|NCT03442387|OTHER|Frame of numerical information|Each group received only one frame of information.
218963942|NCT06084728|DIAGNOSTIC_TEST|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
218963943|NCT03226873|BEHAVIORAL|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
219650802|NCT00431665|DRUG|glucose|
219650803|NCT00431665|DRUG|inulin|
219650804|NCT00431665|DRUG|paraamino hippurate (PAH)|
219650805|NCT01384019|DEVICE|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
218963944|NCT05912452|OTHER|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
218963945|NCT05912452|OTHER|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
218963946|NCT05912452|OTHER|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
219650806|NCT01384019|PROCEDURE|c-PCI|conventional PCI without Guard wire
219650807|NCT02824536|DRUG|3BNC117|Intravenous Infusion of 3BNC117
219650808|NCT02824536|DRUG|10-1074|Intravenous Infusion of 10-1074
219650809|NCT02824536|DRUG|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
219650810|NCT01772186|DEVICE|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
219650811|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
219650812|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
219650813|NCT04587349|OTHER|Physiotherapy|Physiotherapy 2-years-long (3/week)
219650814|NCT02851056|BIOLOGICAL|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered."
219650815|NCT02851056|PROCEDURE|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
219650816|NCT02851056|BIOLOGICAL|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
219650817|NCT02851056|DRUG|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
219650818|NCT02619396|PROCEDURE|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
219650819|NCT02619396|PROCEDURE|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
219650820|NCT02619396|PROCEDURE|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
219650821|NCT02619396|PROCEDURE|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
219650822|NCT04489381|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
219650823|NCT04489381|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
219650824|NCT04489381|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
219650825|NCT01751581|BEHAVIORAL|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
219650826|NCT01751581|BEHAVIORAL|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
219650827|NCT05143008|BEHAVIORAL|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
218963947|NCT03277521|OTHER|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
218963948|NCT03929484|DEVICE|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
218963949|NCT00775944|BEHAVIORAL|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
218963950|NCT00775944|BEHAVIORAL|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
218963951|NCT00775944|DRUG|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
218963952|NCT00674778|PROCEDURE|Any percutaneous cardiovascular procedure|
218963953|NCT00920829|DRUG|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
219650828|NCT00760370|DRUG|Zoledronic Acid|4 mg intravenous (iv), one treatment
219650829|NCT03567512|BEHAVIORAL|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
219650830|NCT03567512|BEHAVIORAL|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes)."
219650831|NCT03343249|BEHAVIORAL|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
218963954|NCT00920829|DRUG|Placebo|placebo
218963955|NCT05793437|BEHAVIORAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
218963956|NCT05793437|BEHAVIORAL|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
218963957|NCT04533880|DEVICE|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
218963958|NCT04533880|DEVICE|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
218963959|NCT04533880|OTHER|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
218963960|NCT05684731|BIOLOGICAL|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
218963961|NCT05684731|DRUG|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
218963962|NCT03375827|OTHER|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
219062671|NCT05140278|DRUG|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
218963963|NCT03665415|BEHAVIORAL|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
218963964|NCT04082832|DRUG|Cu(II)ATSM|oral suspension
219062672|NCT05140278|DRUG|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
219650832|NCT03202537|DRUG|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
219650833|NCT00525902|DRUG|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
219650834|NCT02180997|DRUG|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
219650835|NCT02180997|DRUG|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
219650836|NCT02180997|DRUG|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
219650837|NCT00985959|DRUG|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
219650838|NCT00985959|DRUG|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
219650839|NCT00985959|DRUG|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
219650840|NCT00985959|DRUG|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
219650841|NCT00985959|DRUG|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
219062673|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
219062674|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
219062675|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
219062676|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
219650842|NCT00383175|OTHER|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
219650843|NCT01590732|DRUG|Carboplatin|Given IV
219650844|NCT01590732|DRUG|Etoposide|Given IV
219062677|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
219062678|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
219650845|NCT01590732|DRUG|Ifosfamide|Given IV
219650846|NCT01590732|DRUG|Romidepsin|Given IV
218963965|NCT04082832|DRUG|Placebos|oral suspension
218963966|NCT02394678|DEVICE|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
219062679|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
219062680|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
219062681|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
219062682|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
219062683|NCT02065466|DRUG|nab-paclitaxel|
219650847|NCT00392470|BIOLOGICAL|cetuximab|
219650848|NCT00392470|DRUG|irinotecan hydrochloride|
219650849|NCT00392470|PROCEDURE|conventional surgery|
219650850|NCT00392470|PROCEDURE|neoadjuvant therapy|
219650851|NCT00392470|RADIATION|3-dimensional conformal radiation therapy|
219650852|NCT00392470|RADIATION|intensity-modulated radiation therapy|
219650853|NCT04756128|DRUG|Colchicine 0.6 mg|"Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)"
219207916|NCT06930092|PROCEDURE|Physiology-and imaging-guided PCI|"The criteria for performing revascularization are as follows~1. Lesions with ≥50% diameter stenosis and FFR ≤ 0.80, or lesions with severe stenosis (\>90%)~2. In vessels meeting the above criteria, IVUS findings consistent with either:~   * Minimum lumen area (MLA) ≤ 3 mm²~  * 3 mm² \< MLA ≤ 4 mm² and plaque burden \>70%~For all target vessels and lesions identified for intervention, optimal revascularization should be pursued. The criteria for optimal revascularization are as follows, and operators are encouraged to achieve them:~1. Post-PCI FFR \> 0.86 in all treated vessels is recommended, with a minimum threshold of post-PCI FFR \> 0.80 to achieve functional complete revascularization.~2. Post-PCI ΔFFR (defined as \[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05 is recommended.~3. On IVUS, achieving a minimum stent area (MSA) \> 5.5 mm² and MSA/average reference lumen \> 80% is recommended."
219650854|NCT04756128|DRUG|Naltrexone|"Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension."
219650855|NCT04373798|DIAGNOSTIC_TEST|C-reactive protein|Measurement of CRP value from blood sample taken at covid19 check point (baseline).
219207917|NCT06930092|DRUG|Optimal medical treatment|All study participants will receive guideline-directed medical therapy. Even for patients assigned to the optimal medical therapy group, revascularization may be performed during follow-up if clinically indicated. If such a decision is made prior to the primary endpoint assessment, a gadolinium-enhanced cardiac MRI will be performed at the time of consideration to reassess myocardial viability.
219650856|NCT03851146|BIOLOGICAL|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
218963967|NCT04974918|PROCEDURE|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.|A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
219207918|NCT06504966|DRUG|MAB-22|Single subcutaneous dose of 60 mg
219207919|NCT06504966|DRUG|Prolia®|Single subcutaneous dose of 60 mg
219207920|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
219207921|NCT06892366|BEHAVIORAL|Home-Based Aerobic Exercise Program|Aerobic Exercise (AE) Group This intervention consists of a home-based aerobic exercise program emphasizing moderate-intensity walking, tailored to 40-60% of peak VO2 or Borg Scale 4-6 for those on beta blockers. Distinctive features include real-time session supervision via video conferencing and heart rate monitoring with a smart wristband. This approach ensures remote guidance, personalized intensity, and participant safety throughout the 8-week program.
219207922|NCT06892366|BEHAVIORAL|Home-Based Aerobic and Resistance Exercise (ARE) Group|Participants engaged in a combined home-based aerobic and resistance exercise program. Aerobic sessions followed the same protocol as the AE group (3 days/week). Resistance training was performed 2 additional days per week using elastic resistance bands set at 40-50% of one-repetition maximum (1RM). Resistance exercises targeted major muscle groups, with each session consisting of 3 sets of 10 repetitions, and 1-3 minutes of rest between sets. All sessions were monitored and supervised remotely.
219650857|NCT02744482|DRUG|risedronate|risedrante tablet (75 mg)
219650858|NCT02744482|DRUG|placebo|risedrante placebo tablet (75 mg)
219650859|NCT02858180|DRUG|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
219650860|NCT00526331|DEVICE|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
218963968|NCT05654441|BIOLOGICAL|Influenza vaccine|0.5 mL single-dose injection
218963969|NCT05654441|BIOLOGICAL|Placebo|0.5 mL single-dose injection with no therapeutic effect
218963970|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
218963971|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
218963972|NCT05592834|BEHAVIORAL|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
219062684|NCT02065466|DRUG|Temozolomide|
219062685|NCT02065466|DRUG|Bevacizumab|
219062686|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
219062687|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
219062688|NCT01263743|BEHAVIORAL|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
219062689|NCT01263743|BEHAVIORAL|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
219650861|NCT00526331|DEVICE|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
219650862|NCT05600062|DRUG|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
219650863|NCT05600062|DRUG|Placebo|Placebo capsule
219650864|NCT03229148|PROCEDURE|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
219650865|NCT03229148|PROCEDURE|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
219650866|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
219650867|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
219650868|NCT01866267|DRUG|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
219650869|NCT06242418|DRUG|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
219650870|NCT06242418|DRUG|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
219650871|NCT00669552|PROCEDURE|Percutaneous coronary intervention|PCI previously electively scheduled.
219650872|NCT00574249|BIOLOGICAL|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
219650873|NCT00574249|DRUG|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
219650874|NCT00574249|DRUG|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
219650875|NCT04305106|DRUG|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
219650876|NCT04305106|OTHER|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
219650877|NCT04305106|OTHER|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
219650878|NCT04940520|BIOLOGICAL|Drug recommended by the Brazilian Society of Dermatology|Using a drug recommended by the Brazilian Society of Dermatology, twice a day.
219650879|NCT04940520|COMBINATION_PRODUCT|Alpha bisabolol product and laser|Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.
219650880|NCT04940520|BIOLOGICAL|Alpha bisabolol product|Using alpha bisabolol-based product twice a day
219650881|NCT00392522|DRUG|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
219650882|NCT02604355|OTHER|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
219650883|NCT02604355|DRUG|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
219650884|NCT03684824|DRUG|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
219650885|NCT03684824|DRUG|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
219650886|NCT01330056|PROCEDURE|FOPS|"* Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group."
219650887|NCT01330056|RADIATION|CRT|"* Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
219650888|NCT03084068|OTHER|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
219650889|NCT03084068|OTHER|Placebo|Open rotator cuff surgery with standard suture repair
219650890|NCT02999724|DRUG|Gabapentin|Gabapentin 300-600 mg 1 hour preop
219650891|NCT02999724|OTHER|placebo|placebo capsule(s) 1 hour preop
219062690|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
219650892|NCT02470819|GENETIC|Genetic profiling|genetic profiling
219650893|NCT05280899|OTHER|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
219650894|NCT05280899|OTHER|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
219650895|NCT01036659|DRUG|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
219650896|NCT03079037|DEVICE|Stimulation|Traditional deep brain stimulation
219650897|NCT04850573|OTHER|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
219650898|NCT02827435|DRUG|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
219650899|NCT05921149|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
219650900|NCT05921149|DRUG|Carboplatin|Given IV
219650901|NCT05921149|DRUG|Paclitaxel|Given IV
219650902|NCT05921149|DIETARY_SUPPLEMENT|Standard diet|Normal diet
219650903|NCT05109637|DEVICE|Konectom NMD Application|Administered as specified in the treatment arm.
219650904|NCT04855214|OTHER|Qualitative Analysis|Mixed methods analysis of the user's experience with upper limb prosthetics.
219650905|NCT01629290|DEVICE|Enamel Pro|Varnish treatment containing 5% NaF
219650906|NCT01629290|DEVICE|Duraphat|Varnish treatment containing 5% NaF
219650907|NCT01629290|DEVICE|Vanish|Varnish treatment containing 5% NaF
219650908|NCT01629290|DEVICE|Placebo|Bland varnish containing no NaF
218963973|NCT05592834|BEHAVIORAL|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
218963974|NCT05592834|OTHER|Control|This group will receive neither the PD nor the PFT interventions but care as usual
218963975|NCT00443612|DRUG|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
218963976|NCT00443612|DRUG|Irbesartan|Administration of irbesartan 150 mg/day
219062691|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
219650909|NCT02219789|DRUG|Alisertib|Given PO
218963977|NCT06385990|DRUG|UTD1|UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
218963978|NCT03824028|DEVICE|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
219062692|NCT01921348|DEVICE|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
219062693|NCT01921348|DEVICE|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
219062694|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
219062695|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
219062696|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
219062697|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
219062698|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
219650910|NCT02219789|DRUG|Fulvestrant|Given IM
219650911|NCT02219789|OTHER|Laboratory Biomarker Analysis|Correlative studies
219650912|NCT05969964|BEHAVIORAL|Avoid second resection after initial complete resection|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
219650913|NCT01295463|OTHER|questionnaire administration|
219650914|NCT01295463|OTHER|study of socioeconomic and demographic variables|
219650915|NCT01295463|PROCEDURE|assessment of therapy complications|
219650916|NCT01295463|PROCEDURE|fertility assessment and management|
219650917|NCT01295463|PROCEDURE|psychosocial assessment and care|
219650918|NCT01295463|PROCEDURE|quality-of-life assessment|
219650919|NCT02538887|DEVICE|Radio Frequency Surgical Detection|
219650920|NCT02047656|DRUG|LFF269|LFF269 capsules twice daily (b.i.d)
219650921|NCT02047656|DRUG|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
219650922|NCT01123941|BIOLOGICAL|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
219650923|NCT01123941|BIOLOGICAL|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
219650924|NCT01463592|BIOLOGICAL|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
219650925|NCT01463592|DRUG|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
219650926|NCT01463592|BIOLOGICAL|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
219650927|NCT03337581|DRUG|Dexmedetomidine|see arms
219650928|NCT04601103|DRUG|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
219650929|NCT04601103|DRUG|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
219650930|NCT04601103|DRUG|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
219650931|NCT04601103|DEVICE|Anti-plaque|Rinse prevents bacterial adherence to teeth
219650932|NCT06619288|DRUG|B/F/TAF|Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
219650933|NCT06619288|DRUG|TDF+3TC+EFV|Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
219650934|NCT06619288|DRUG|DTG/3TC|Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
219650935|NCT01044511|BEHAVIORAL|Home visits|home visits by specialist nurse 2 times and 1 phonecall
219650936|NCT01044511|BEHAVIORAL|standard|hotline
219650937|NCT05497388|OTHER|Serious Game|using Serious Game for HCV education
218963979|NCT01607268|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
218963980|NCT02005328|DEVICE|Tested product : DC161-DP0291|Application of product in the mouth twice daily
219650938|NCT06318052|DEVICE|The FemTouch delivery system|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology
219650939|NCT06318052|DRUG|Gynomunal gel treatment|hormone/free, vaginal moisturizing gel for women with vaginal dryness
219650940|NCT01729052|DEVICE|Acupuncture|
219650941|NCT06011161|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
219650942|NCT04295057|OTHER|Non-intervention|Non-intervention
219650943|NCT05230004|DEVICE|iFIT prosthesis|An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
219650944|NCT02349919|DRUG|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
219650945|NCT02349919|DRUG|Placebo|Placebo twice daily for 4 weeks
219650946|NCT01802736|BEHAVIORAL|Motivational intervention counselling plus SPP|
218963981|NCT02005328|DEVICE|Tested product : DC161-DP0292|Application of product in the mouth twice daily
218963982|NCT02005328|DEVICE|Tested product : DC161-DP0293|Application of product in the mouth twice daily
218963983|NCT02005328|DEVICE|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
219062699|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
219062700|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
219062701|NCT01177111|OTHER|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
219062702|NCT01177111|OTHER|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
219062703|NCT00793416|DEVICE|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
219062704|NCT06149260|DRUG|Semaglutide Pen Injector|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
219650947|NCT03099213|DRUG|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
219650948|NCT03489018|BIOLOGICAL|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
219650949|NCT03489018|BIOLOGICAL|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
219650950|NCT06604143|BEHAVIORAL|Quality Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training focuses on specific aspects of finger movement, and participants will receive feedback related to their playing. They will wear a wrist brace for support, and their hand and arm positions will be monitored to ensure proper technique.
219650951|NCT06604143|BEHAVIORAL|Goal Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training emphasizes learning to play and producing music. Feedback will be provided on various aspects of performance such as speed and accuracy, but specific details about finger movement or technique will not be given. The use of a wrist brace and monitoring of hand and arm positions will be consistent with standard practice.
218963984|NCT02849665|OTHER|Kangaroo Position|
218963985|NCT04830644|DRUG|Iguratimod|Iguratimod orally twice a day
219650952|NCT02212990|OTHER|Acetaminophen Arm|Blinded Therapy
219650953|NCT02212990|OTHER|Placebo Arm|Blinded Therapy
219650954|NCT02212990|OTHER|Ibuprofen Arm|Open Label Therapy
219650955|NCT04197102|DRUG|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
219650956|NCT04197102|OTHER|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
219650957|NCT04197102|OTHER|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
219650958|NCT00381043|DRUG|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
219650959|NCT06442098|BEHAVIORAL|CAMP SMART Literacy Summer Camp|Multimodal approach to reading intervention
219650960|NCT05625945|BEHAVIORAL|Physical activity monitoring|Physical activity patterns will be measured using the activPAL3 micro monitor
219650961|NCT04065451|DRUG|Epinephrine|Epinephrine in the submucosal injection fluid
219650962|NCT01222754|DRUG|Lenalidomide|"1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
219650963|NCT01222754|RADIATION|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
219650964|NCT03266458|PROCEDURE|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
219650965|NCT06126835|DRUG|Ozanimod|Women with UC exposed to ozanimod during pregnancy
219650966|NCT06126835|DRUG|Conventional therapy|Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
219650967|NCT06126835|DRUG|Advanced therapy|Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
219650968|NCT01978470|DEVICE|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
219650969|NCT02585817|DEVICE|Remote CIED Management|Information Technology
218963986|NCT04830644|DRUG|Placebo|Placebo orally twice a day
218963987|NCT04867239|OTHER|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
218963988|NCT04768985|DRUG|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
219650970|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
219650971|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
219650972|NCT02501954|DRUG|Cisplatin|Given IV
219650973|NCT02501954|DRUG|Carboplatin|Given IV
219650974|NCT02501954|DRUG|Paclitaxel|Given IV
219650975|NCT02501954|RADIATION|Radiation Therapy|Undergo Radiation Therapy
219650976|NCT01683851|DEVICE|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
219650977|NCT05263765|PROCEDURE|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
219650978|NCT05062824|BEHAVIORAL|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. \[Parental FFQ portal\]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age \[Clinician Portal\]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component \[Parent's Portal\].
218963989|NCT04768985|DRUG|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
218963990|NCT01955980|DRUG|Budesonide|Inhalation
218963991|NCT01955980|DRUG|Budesonide|Nasal Spray
218963992|NCT04259554|DEVICE|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
218963993|NCT02530567|PROCEDURE|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
218963994|NCT04177927|DEVICE|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
218963995|NCT04177927|DEVICE|Rutine monitoring|peripheric Oxygen saturation is monitored.
218963996|NCT02477267|DRUG|SL spray|
218963997|NCT02477267|DRUG|SL film|
218963998|NCT01037322|DRUG|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
218963999|NCT01037322|DRUG|placebo in drops|olive oil containing no drug given in drops twice daily
218964000|NCT02793011|DRUG|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
218964001|NCT02793011|DRUG|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
219650979|NCT04611737|BEHAVIORAL|Interviewing|Self-Determination Theory within motivational interviewing
219650980|NCT02097251|DRUG|UX003|Open Label
219650981|NCT06368895|PROCEDURE|Fecal microbiota transplantation delivery through colonoscopy|Patients will receive 4 L of macrogol and salts solution the afternoon before FMT and remain fasting the night before the scheduled treatment. During colonoscopy, about 350 mL of donor fecal preparation will be infused in the cecum.
219650982|NCT06368895|DRUG|Fecal microbiota transplantation delivery through oral capsules|Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).
219650983|NCT03178240|BEHAVIORAL|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
219650984|NCT04697420|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
219650985|NCT04697420|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
218964002|NCT04535765|OTHER|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
218964003|NCT04535765|OTHER|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
218964004|NCT01711879|DRUG|Aflibercept|Details covered in arm description
218964005|NCT05692167|DRUG|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
218964006|NCT05692167|DRUG|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
218964007|NCT04426201|DRUG|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
218964008|NCT04426201|DRUG|Placebo|Same number, volume and frequency of IM administration of saline
218964009|NCT04542538|OTHER|No intervention, observational study|
218964010|NCT00503438|DEVICE|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
218964011|NCT04160481|DIETARY_SUPPLEMENT|FruitFlow|300mg tomato extract
218964012|NCT04160481|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219207923|NCT05838924|OTHER|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
219650986|NCT02874079|OTHER|Blood sample and cotton skin swabs|
219650987|NCT01508052|DEVICE|sequential compression device|applying sequential compression device during the surgery
218964013|NCT05768971|OTHER|Mild diet|
218964014|NCT05768971|OTHER|Provocative diet|
218964015|NCT03071198|PROCEDURE|TME|"1. Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~2. At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
219650988|NCT01508052|DEVICE|elastic stockings|applying elastic stockings during the surgery
219650989|NCT05104801|DRUG|sitravatinib|sitravatinib 100mg QD PO
219650990|NCT05104801|DRUG|tislelizumab|tislelizumab 200mg Q3W IV
219650991|NCT03992573|PROCEDURE|CGF application|CGF application into post-operative soft tissue and bone defects
219650992|NCT06668753|DRUG|Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab|SGLT-2 inhibitors
219650993|NCT04713592|DRUG|Placebo for Risankizumab|Subcutaneous (SC) Injection
219650994|NCT04713592|DRUG|Risankizumab|Subcutaneous (SC) Injection
218964016|NCT03071198|RADIATION|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
218964017|NCT03071198|DRUG|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
218964018|NCT03071198|DRUG|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
218964019|NCT03658707|OTHER|questionnaire|Shoulder questionnaire
218964020|NCT03892473|OTHER|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
218964021|NCT03892473|OTHER|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
219650995|NCT03781258|DRUG|Warfarin|Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
219650996|NCT05050734|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)|Behavioral treatment for persistent tic disorders.
218964022|NCT01231308|PROCEDURE|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
218964023|NCT01231308|BEHAVIORAL|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
218964024|NCT02464917|DEVICE|Device: simple facemask to administer supplemental oxygen|
218964025|NCT02343133|BIOLOGICAL|HemaMax|
218964026|NCT02343133|DRUG|Placebo|
218964027|NCT05035641|DRUG|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
218964028|NCT05035641|DRUG|Placebo|Orally, 3 times per week
218964029|NCT00234390|DRUG|Pulmicort (budesonide) pMDI|
218964030|NCT02783677|PROCEDURE|Percutaneous balloon angioplasty|
218964031|NCT02147028|RADIATION|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
218964032|NCT02147028|RADIATION|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
218964033|NCT05910177|DRUG|Karelizumab combined with etoposide and cisplatin|Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
218964034|NCT03718871|BEHAVIORAL|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
218964035|NCT02239224|BIOLOGICAL|Placebo|Concentrate for solution for infusion
218964036|NCT02239224|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
218964037|NCT05730634|DRUG|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
218964038|NCT01512056|DRUG|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
218964039|NCT03031236|BEHAVIORAL|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
218964040|NCT00073073|DRUG|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
218964041|NCT00073073|DIETARY_SUPPLEMENT|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
219062705|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
219650997|NCT00321880|PROCEDURE|therapeutic touch|administration of healing touch in 30 minute sessions
219650998|NCT01310634|BEHAVIORAL|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
219650999|NCT06376565|OTHER|Best Practice|Receive standard care
219651000|NCT06376565|OTHER|Communication Intervention|Complete clinic EHR interventions
219651001|NCT06376565|OTHER|Communication Intervention|Receive scheduling reminders
219651002|NCT06376565|OTHER|Communication Intervention|Receive reminders and pending EHR orders
219651003|NCT06376565|OTHER|Interview|Complete interview
219651004|NCT06376565|OTHER|Interview|Ancillary studies
218964042|NCT00073073|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 400 international units PO every day x 2 years
218964043|NCT00101712|DRUG|vildagliptin|
218964044|NCT00101712|DRUG|Vildagliptin Placebo|
218964045|NCT05291026|OTHER|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
218964046|NCT03183778|DRUG|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
218964047|NCT03183778|DIETARY_SUPPLEMENT|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
218964048|NCT05337436|BIOLOGICAL|Lymphatic drainage|Biological determination in plasma:
218964049|NCT05337436|BIOLOGICAL|Total and ionized magnesium|Total and ionized magnesium
218964050|NCT05337436|BIOLOGICAL|Total and ionized calcium|Total and ionized calcium
218964051|NCT01466179|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
218964052|NCT02248415|OTHER|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
218964053|NCT02248415|OTHER|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
218964054|NCT02248415|OTHER|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
218964055|NCT02248415|OTHER|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
218964056|NCT02248415|OTHER|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
218964057|NCT02248415|OTHER|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
218964058|NCT01640626|OTHER|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
218964059|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
218964060|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
218964061|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
218964062|NCT02921360|DRUG|acetylsalicylic acid|
219651005|NCT03277053|DEVICE|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
219651006|NCT03277053|OTHER|Control.|Patient receive an ipad with no application.
219651007|NCT05709353|BEHAVIORAL|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist."
218964063|NCT05559333|PROCEDURE|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
218964064|NCT03489551|DRUG|Haldol|
218964065|NCT00143117|DRUG|UK-390,957|
218964066|NCT05793515|DIAGNOSTIC_TEST|whole genome sequencing|Whole genome sequencing will be performed in patients whose test was negative for the targeted resequencing and/or clinical exome sequencing.
218964067|NCT01465061|BEHAVIORAL|Online support group|Joining online support group
218964068|NCT03310710|DEVICE|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
218964069|NCT02448186|BEHAVIORAL|ESTEEM|10-session cognitive behavioral treatment
218964070|NCT00054717|DRUG|Tipranavir|
218964071|NCT00054717|DRUG|Ritonavir(r)|
218964072|NCT00054717|DRUG|Comparator Protease Inhibitor (CPI)|
218964073|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
218964074|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
218964075|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
218964076|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
218964077|NCT06535919|BEHAVIORAL|Treatment as Usual|Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
218964078|NCT03370614|OTHER|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
218964079|NCT03370614|OTHER|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
218964080|NCT04350866|BEHAVIORAL|Expert Recommendations for Implementing Change bundle of strategies|"* Develop a formal implementation blueprint/checklist~* Conduct educational meetings~* Develop and distribute educational materials~* Organize implementation meetings~* Facilitation~* Increase demand with marketing to patients~* Promote adaptability"
218964081|NCT04350866|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|"An adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) that is focused on behavioral components stimulus control and sleep restriction (the four rules):~1. Reduce time awake in bed.~2. Don't go to bed unless ready for sleep.~3. Don't stay in bed unless asleep.~4. Get up and out of bed at the same time everyday.~Delivered weekly to bi-weekly over 4-6 sessions, with each session typically 30 minutes or less, consistent with other interventions delivered in PCMHI."
219651008|NCT05709353|DRUG|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
219651009|NCT05709353|DRUG|Niacin|Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
219651010|NCT03492398|DRUG|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
218964082|NCT05114538|BEHAVIORAL|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
218964083|NCT05088863|OTHER|flaxseed|40g of flaxseed per day
218964084|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
219651011|NCT06618482|PROCEDURE|Kinesiotaping|Low back kinesiotaping
219651012|NCT06618482|PROCEDURE|Kinesiotaping|Transversus abdominis kinesiotaping
219651013|NCT03782298|DEVICE|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|"PEEK Suture Anchors, which include:~* SPYROMITE™ 2.0 PK Suture Anchor with Needles~* DYNOMITE™ 2.0 PK Suture Anchor with Needles~* RAPTORMITE™ 3.0 Suture Anchor with Needles~* FOOTPRINT™ Ultra PK SL Suture Anchor"
219651014|NCT00852215|DEVICE|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
218964085|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
218964086|NCT04423939|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
218964087|NCT06207617|PROCEDURE|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
219207924|NCT05838924|OTHER|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
219207925|NCT00349830|PROCEDURE|blood draw|
219207926|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
219651015|NCT00852215|DEVICE|Vision stent|Stenting with VISION coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
219651016|NCT05213884|DRUG|Camrelizumab|200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.
219651017|NCT05213884|DRUG|Concurrent cisplatin chemotherapy|cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
219651018|NCT05213884|RADIATION|Intensity-modulated radiotherapy (IMRT)|70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
219651019|NCT03118141|PROCEDURE|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
219651020|NCT03118141|PROCEDURE|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
219651021|NCT03118141|PROCEDURE|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
219651022|NCT05665166|GENETIC|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
219651023|NCT06623929|DRUG|Etofenamat|E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
219651024|NCT06623929|DRUG|Diclofenac|Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
219651025|NCT05100368|OTHER|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
219651026|NCT05658055|DRUG|Vonoprazan|Potassium-competitive acid blocker
219651027|NCT05658055|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219651028|NCT05658055|DRUG|probiotics|Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
219651029|NCT06488209|DRUG|LAD191|LAD191 SC injection.
219651030|NCT06488209|OTHER|Placebo|Matching placebo SC injection.
219651031|NCT00785434|DRUG|escitalopram|Dose ranging up to 50mg
219651032|NCT01382225|DRUG|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
219651033|NCT01382225|OTHER|Vehicle|Inactive ingredients used as run-in and placebo comparator
219651034|NCT03530813|OTHER|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
219651035|NCT03530813|OTHER|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
219651036|NCT04159649|DRUG|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
219651037|NCT04159649|DRUG|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
219651038|NCT04159649|PROCEDURE|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
219651039|NCT00697736|PROCEDURE|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
219651040|NCT03273725|OTHER|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
219651041|NCT01498224|DEVICE|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
219651042|NCT01498224|PROCEDURE|Sutures|
219651043|NCT05731869|OTHER|epicondylitis band|An off-the-shelf lateral epicondylitis tape in S-M-L dimensions was used distal to the lateral epicondylitis.
219651044|NCT05731869|OTHER|wrist orhosis|Wrist orthosis of the shelf was used in sizes S-M-L, covering the hand and wrist.
219651045|NCT05463237|DIAGNOSTIC_TEST|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
219651046|NCT05463237|DIAGNOSTIC_TEST|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
219651047|NCT05517824|PROCEDURE|microinsulated needle radiofrequency|A single treatment using a microinsulated needle radiofrequency device
219651048|NCT04859153|DIAGNOSTIC_TEST|central nerve sensory, motor control and various muscle mechanical characteristic and sport-related fitness test|To explore the sports performance of the adolescent sprinters, including analyzing the correlations between the results and central nerve sensory, and also between motor control and various muscle mechanical characteristic and sport-related fitness factor.
219651049|NCT02511054|DRUG|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
218964088|NCT06207617|PROCEDURE|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
219207927|NCT06035276|OTHER|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
219651050|NCT02511054|DRUG|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
219651051|NCT02511054|BIOLOGICAL|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
219651052|NCT00604942|PROCEDURE|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
219651053|NCT00604942|PROCEDURE|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
219651054|NCT00604942|DRUG|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
219651055|NCT00604942|DRUG|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
219651056|NCT01852201|DEVICE|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
219651057|NCT01063270|DRUG|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
219651058|NCT01063270|PROCEDURE|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
219651059|NCT04174664|DIAGNOSTIC_TEST|1-minute sit to stand test|Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.
219651060|NCT06018298|OTHER|Treatment as usual (TAU)|the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
219651061|NCT00342381|DRUG|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
219651062|NCT00342381|DRUG|Placebo|Single dose placebo treatment
219651063|NCT03657524|OTHER|echocardiography|Speckle tracking echocardiography
219651064|NCT02513498|DRUG|Ixazomib Citrate|Given PO
219651065|NCT02513498|OTHER|Laboratory Biomarker Analysis|Correlative studies
219651066|NCT02513498|OTHER|Quality-of-Life Assessment|Ancillary studies
219651067|NCT02513498|OTHER|Questionnaire Administration|Ancillary studies
219651068|NCT00760695|DRUG|dronabinol|tablets, twice daily, for 4 weeks
219651069|NCT00760695|DRUG|placebo|tablets, twice daily, for 4 weeks
219651070|NCT06101017|DIAGNOSTIC_TEST|Optical Coherence Tomography|Non-invasive imaging test that use light waves to take cross-section pictures of the eye.
219651071|NCT06148428|PROCEDURE|Laser in situ keratomileusis (LASIK)|"Patients were planned to undergo laser in situ keratomileusis. Local anesthesia was achieved by preservative-free oxybuprocaine hydrochloride 0.4% drops (a commonly used topical anesthetic due to its effectiveness in alleviating pain and ocular surface discomfort during the procedure). During surgery, the lights of the operating room were dimmed as much as possible and the surgeons spoke to the patients in a calm voice and explained what was happening. They also reassured the patients that the surgery was going as planned and would be over soon.~For patients undergoing (Microkeratome) MK-LASIK, a Moria 2 Microkeratome (Moria SA, Antony, France) was used to create the flap. For patients undergoing Femtosecond LASIK (FS-LASIK), the Allegretto Wave Light FS-200 femtosecond Laser (Alcon labs, Fort Worth, TX, USA) was used for flap creation.~Laser ablation was performed using WaveLight EX500 Excimer Laser (Alcon labs, Fort Worth, TX, USA) with a planned post-operative emmetropia."
219651072|NCT06481111|DRUG|supplementary treatment with vitamin D|observational design
219651073|NCT02409745|PROCEDURE|endometrial scratch|local injury to the endometrium by Pipelle
219651074|NCT01171703|DEVICE|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
219651075|NCT01171703|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
219651076|NCT02770404|DRUG|Nafithromycin|100, 200, or 400 mg of nafithromycin
219651077|NCT02770404|DRUG|Placebo|IV matching placebo
219651078|NCT03922737|PROCEDURE|In-person office visit|Post-operative visit to occur in-person with provider
219651079|NCT03922737|PROCEDURE|Teleheath visit|Post-operative visit to occur via telehealth software platform with provider
219651080|NCT06038058|DRUG|BRY812 for injection|BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
219651081|NCT00737347|BEHAVIORAL|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
219651082|NCT05710991|BEHAVIORAL|Sleep Hygiene Workshop|Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise
219651083|NCT05710991|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia Workshop|The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
219062706|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
219062707|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
219651084|NCT06664047|PROCEDURE|OTT ACLR|Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.
219651085|NCT06664047|PROCEDURE|ACLR LET|Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
219651086|NCT00494052|BEHAVIORAL|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
219651087|NCT00494052|BEHAVIORAL|Physician Education Session|A physician education session will be included in the program.
219651088|NCT03951064|DEVICE|Esophageal balloon|All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed \>30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
219062708|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
219062709|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
219651089|NCT03951064|PROCEDURE|Intervention Spontaneous Breathing Trial (SBT) and Extubation|Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
218964089|NCT03844477|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
219651090|NCT03951064|PROCEDURE|Control Spontaneous Breathing Trial and Extubation|Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
219651091|NCT03951064|PROCEDURE|Intervention Weaning after Tracheostomy|Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial only with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
219651092|NCT03951064|PROCEDURE|Control Weaning after Tracheostomy|The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
219651093|NCT00746707|DEVICE|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
219651094|NCT00746707|PROCEDURE|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
219651095|NCT01198288|OTHER|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
219651096|NCT01198288|OTHER|Standard Care|As describe in the standard care arm
218964090|NCT03844477|PROCEDURE|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
218964091|NCT02285283|DRUG|Itraconazole|
218964092|NCT02285283|DRUG|Placebo|
218964093|NCT06080048|DRUG|SOR102|SOR102 capsules
219651097|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
218964094|NCT06080048|DRUG|Placebo|Matching placebo capsules
218964095|NCT05349682|DIAGNOSTIC_TEST|dynamic contrast enhanced MRI|An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
218964096|NCT05349682|PROCEDURE|geniculate artery embolization|The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
218964097|NCT05749432|DRUG|Hemay181|Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
218964098|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - emotion regulation skills training|"Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions."
219062710|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
219062711|NCT03326999|DRUG|Saline|Saline as placebo comparator
219062712|NCT00681317|DRUG|AZD6280|oral
219651098|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
219651099|NCT02046083|DRUG|arachid|
219651100|NCT06620796|DRUG|Arm 1|Ivonescimab combined with Cadonilimab plus EC
219651101|NCT06620796|DRUG|second-line group|AK112+AK104+paclitaxel
219651102|NCT00464516|DRUG|placebo|once daily for 14 days orally
219651103|NCT00464516|DRUG|Estetrol|once daily for 14 days orally
219651104|NCT05372055|OTHER|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
219651105|NCT02166411|PROCEDURE|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
219686306|NCT04432883|DEVICE|Active Comparator: Experimental: Active cathodal tDCS + language training|"Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment."
219651106|NCT02166411|PROCEDURE|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
219651107|NCT04210388|DRUG|AZD5718 tablet, Formulation A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
219651108|NCT04210388|DRUG|AZD5718 tablet, Formulation B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
219651109|NCT04210388|DRUG|AZD5718 tablet, Formulation C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
219651110|NCT04210388|DRUG|AZD5718 tablet, Formulation D|Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
219651111|NCT04210388|DRUG|AZD5718 film-coated tablet, Reference treatment|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
219651112|NCT03005223|DRUG|Co-administration of DWC20155/DWC20156|
218964099|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - interpersonal effectiveness skills training|Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
218964100|NCT04626310|BEHAVIORAL|Interpersonal psychotherapy|Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
218964101|NCT06311877|DIETARY_SUPPLEMENT|mBerry|mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.
218964102|NCT06311877|OTHER|No intervention|The control group will not received intervention.
218964103|NCT02278341|DRUG|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
218964104|NCT02278341|DRUG|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
218964105|NCT02278341|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
218964106|NCT02278341|DRUG|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
219651113|NCT03005223|DRUG|DWC20163|
219651114|NCT06373393|OTHER|STABILISE|"STABILISE technique: Stent assisted balloon induced intimal disruption and relamination in aortic dissection repair"
219651115|NCT01300299|RADIATION|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (\> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
219651116|NCT02294175|DEVICE|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
219651117|NCT02294175|PROCEDURE|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
219651118|NCT04316442|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
219651119|NCT02548351|DRUG|Obeticholic Acid|
219651120|NCT02548351|DRUG|Placebo|
219651121|NCT06142877|BEHAVIORAL|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
219651122|NCT01718834|BIOLOGICAL|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
219651123|NCT01718834|BIOLOGICAL|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
219651124|NCT01945437|DRUG|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
219651125|NCT00792688|DRUG|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
218964107|NCT05851105|BIOLOGICAL|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
218964108|NCT02604017|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
218964109|NCT00740246|DRUG|VIT-45|15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously
218964110|NCT00740246|DRUG|Placebo|for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously
218964111|NCT02906384|RADIATION|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
218964112|NCT04578080|DEVICE|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
218964113|NCT06521450|PROCEDURE|anti incontinence surgery|anti incontinence surgery with prolapse surgery will be performed simultaneously
218964114|NCT04297657|OTHER|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
218964115|NCT03682809|DRUG|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
219062713|NCT03032120|DIETARY_SUPPLEMENT|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
219062714|NCT03032120|DIETARY_SUPPLEMENT|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
219062715|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
219062716|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
219062717|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
219062718|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
219207928|NCT06035276|OTHER|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
219207929|NCT06833060|DEVICE|Selective Laser Trabeculoplasty|Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty
219207930|NCT06826716|DIETARY_SUPPLEMENT|Fenugreek (Trigonella foenum graecum)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
219207931|NCT06826716|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
219651126|NCT00792688|DRUG|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
218964116|NCT01060345|DRUG|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
219651127|NCT00792688|DRUG|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
219686307|NCT04432883|BEHAVIORAL|Sham Comparator: Placebo cathodal tDCS + Speech and language|Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
218964117|NCT02545231|DRUG|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
218964118|NCT02545231|DRUG|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
218964119|NCT02545231|DRUG|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
218964120|NCT05602311|DRUG|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
218964121|NCT00366340|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
218964122|NCT00366340|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
218964123|NCT04699253|DEVICE|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
219207932|NCT06762782|DRUG|Postoperative adjuvant lenvatinib|Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.
219207933|NCT06762782|OTHER|Supportive care measures|Adjuvant treatments such as antiviral, TACE, HAIC, radiotherapy, and systemic antitumor therapy can be used
219686308|NCT00407342|DRUG|Alefacept (drug)|alefaceptgiven iv
219651128|NCT05040607|OTHER|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~-Retrospective data of pulmonary function, respiratory muscle function, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device using tapered flow resistive loading and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength."
219651129|NCT05040607|OTHER|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle function, exercise capacity, physical fitness, and activities of daily living (ADL).
219651130|NCT01921712|DRUG|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
219651131|NCT01921712|DRUG|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
219651132|NCT01921712|DRUG|Active comparator|Randomized single dose of inhaled active comparator product
219651133|NCT06860984|DRUG|Duloxetine|Duloxetine, a non-opioid neuromodulator, has been widely used to manage neuropathic pain. It possesses dual central and peripheral analgesic properties
219651134|NCT06860984|OTHER|Placebo capsule|Placebo will have the same look and appearance of active comparator
219651135|NCT05655286|DRUG|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
219651136|NCT05655286|BEHAVIORAL|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
219651137|NCT05655286|BEHAVIORAL|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
219651138|NCT01247051|PROCEDURE|Precoating|preoperative filling of heart lung machine with patients blood
219651139|NCT01247051|PROCEDURE|Standard priming|preoperative filling of heart lung machine with colloids
219207934|NCT06855927|OTHER|Guided Imagery|Guided imagery is a potential healing technique that aims to help individuals mentally visualize positive physical and psychological states.
219651140|NCT00125242|BEHAVIORAL|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
219651141|NCT00606554|DEVICE|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
219651142|NCT00606554|BEHAVIORAL|Standard of Care weaning|Evidence-based standard of care weaning process.
219651143|NCT01664949|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
219651144|NCT01664949|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
219651145|NCT04654754|DEVICE|high-flow high humidity oxygen device with tracheostomy adapter|This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
219651146|NCT02496351|DEVICE|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
219651147|NCT00618943|BEHAVIORAL|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
219651148|NCT00991757|DRUG|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
219651149|NCT02683278|BEHAVIORAL|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
219651150|NCT02683278|BEHAVIORAL|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
219651151|NCT02683278|OTHER|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
219651152|NCT04104217|BEHAVIORAL|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
219686309|NCT00407342|PROCEDURE|Narrowband UVB phototherapy|
218964124|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
218964125|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
218964126|NCT01464983|DRUG|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
218964127|NCT01464983|DRUG|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
219651153|NCT04104217|BEHAVIORAL|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
219651154|NCT05577169|BEHAVIORAL|Mind-body skills|The purpose of mind-body medicine is to use conscious thoughts and actions to positively impact autonomic responses from the brain as well as coping mechanisms for life's stresses. Examples of mind-body skills include deep breathing exercises, meditation, drawing, guided imagery, journaling, affirmations, and biofeedback.
219651155|NCT05577169|BEHAVIORAL|Diabetes education|When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.
219651156|NCT00003407|DRUG|amifostine trihydrate|
219651157|NCT00003407|DRUG|cytarabine|
219651158|NCT00003407|DRUG|mitoxantrone hydrochloride|
219651159|NCT05220462|DRUG|Remimazolam|As per Remimazolam arm
219651160|NCT05220462|DRUG|Midazolam|As per Midazolam arm
219651161|NCT04447391|OTHER|Combined exercise program|Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet
219651162|NCT04447391|OTHER|Control|300 kcal deficit diet only
219651163|NCT03003494|DRUG|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
219651164|NCT02414360|OTHER|Shortened Format|Shortened format of a systematic review
219651165|NCT02414360|OTHER|Full Length|Full length systematic review
219651166|NCT04831827|OTHER|IVR Reminder|Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
219651167|NCT04831827|OTHER|Phone call from research team|Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
219651168|NCT04831827|OTHER|EHR Portal message|Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
219651169|NCT03804229|DRUG|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
219651170|NCT03804229|DRUG|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
219651171|NCT04687943|COMBINATION_PRODUCT|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
219651172|NCT01911481|OTHER|hydration|
219651173|NCT06260423|PROCEDURE|Experienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
219651174|NCT06260423|PROCEDURE|Unexperienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
219651175|NCT06260423|PROCEDURE|Experienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
219651176|NCT06260423|PROCEDURE|Unexperienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
219651177|NCT04898764|DRUG|Mometasone Furoate|Mometasone furoate nasal spray suspension, 50µg/actuation
219651178|NCT00099684|DRUG|Ezetimibe|
219651179|NCT01131143|BEHAVIORAL|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
219651180|NCT01131143|BEHAVIORAL|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
219651181|NCT06682884|DRUG|Lorlatinib 100 mg|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
219651182|NCT03107364|OTHER|Hospital stay|Collection of hospital lengths of stay and readmissions
219651183|NCT05231733|BIOLOGICAL|SPX-101|Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
218964128|NCT01464983|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
219207935|NCT06939088|DRUG|Tirzepatide|Once weekly injections s.c. with tirzepatide (Mounjaro(R))
219651184|NCT04991077|BIOLOGICAL|analyse of angiogenic, vasoactive and VEGF systems|the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
218964129|NCT01242397|DEVICE|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
219651185|NCT05969977|DRUG|PPI-1011|PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.
219651186|NCT05969977|DRUG|Placebo|Placebo
218964130|NCT00354900|DRUG|Aprotinin|
219651187|NCT05238025|BIOLOGICAL|MVA-BN-RSV vaccine|One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
219651188|NCT05238025|BIOLOGICAL|Tris Buffered Saline (TBS)|One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
219651189|NCT01559350|PROCEDURE|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
219651190|NCT01559350|PROCEDURE|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
219651191|NCT03040804|RADIATION|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
219651192|NCT04546139|OTHER|footwork|six-point footwork
219651193|NCT01902810|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization
219651194|NCT01902810|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization
219651195|NCT04331977|DEVICE|Maxillary Expansion|2 appliances to expand the maxillary arch
219651196|NCT03628131|DRUG|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
219651197|NCT03628131|DRUG|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
219651198|NCT03628131|DRUG|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
219651199|NCT03628131|DRUG|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
219651200|NCT01265576|DRUG|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
219651201|NCT01265576|DRUG|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
219651202|NCT01265576|DRUG|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
219651203|NCT01730027|DRUG|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
218964131|NCT03152422|DIAGNOSTIC_TEST|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
219651204|NCT01730027|DRUG|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
219651205|NCT01730027|DRUG|montelukast|montelukast for 12 weeks
219651206|NCT02776891|DRUG|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
219651207|NCT02038855|BEHAVIORAL|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
219651208|NCT03651427|DRUG|Estradiol|Induced hypogonadism and re-institution of CSHT
219651209|NCT00003762|DRUG|docetaxel|
219651210|NCT00003762|DRUG|gemcitabine hydrochloride|
219651211|NCT00738790|RADIATION|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
219651212|NCT00738790|RADIATION|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
219686310|NCT01129245|DRUG|Celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
219686311|NCT01129245|DRUG|Placebo|Placebo identical to celecoxib
218964132|NCT01110070|DEVICE|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
218964133|NCT01110070|DEVICE|ChonDux|single use device
218964134|NCT00132106|DRUG|phentolamine|
218964135|NCT00489190|DRUG|Insulin Glulisine|
218964136|NCT03671590|DRUG|TG-1701|Oral daily dose
218964137|NCT03671590|DRUG|Umbralisib|Oral Daily Dose
218964138|NCT03671590|BIOLOGICAL|Ublituximab|IV infusion
218964139|NCT02034136|DIETARY_SUPPLEMENT|Ginsenoside|3.0 g/ d for 28 days
218964140|NCT02034136|DIETARY_SUPPLEMENT|Dietary fiber fill|3g/day, 28days
218964141|NCT03792984|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
218964142|NCT03792984|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
219651213|NCT03814720|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF\_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.
219651214|NCT05721872|COMBINATION_PRODUCT|D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)|"After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients."
219651215|NCT05721872|DRUG|FOLFOX/FOLFIRI regimen|"FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks"
219651216|NCT01257763|DEVICE|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
219651217|NCT01257763|DEVICE|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
219651218|NCT01107808|DRUG|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
219651219|NCT01107808|DRUG|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
219651220|NCT03418584|DEVICE|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
219651221|NCT03891043|DIETARY_SUPPLEMENT|Selenium|A 100 micrograms of Selenium was given to be taken twice a day.
218964143|NCT03792984|DRUG|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
218964144|NCT03792984|DRUG|Placebo|PO for 8 weeks.
218964145|NCT01232218|OTHER|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
218964146|NCT01232218|OTHER|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
218964147|NCT05413278|BEHAVIORAL|Behavioral|Patient education, information and empowerment
218964148|NCT00057681|DRUG|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
218964149|NCT00057681|DRUG|Valproate|Titrated until blood level is 111 to 125 ug/mL
218964150|NCT00057681|DRUG|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
218964151|NCT01315236|DRUG|Liposomal amikacin for inhalation (LAI)|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
218964152|NCT01315236|DRUG|placebo|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
218964153|NCT05216601|BIOLOGICAL|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
218964154|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
218964155|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
218964156|NCT00377975|DRUG|Ephedrine|
218964157|NCT00377975|DRUG|Pioglitazone|
219207936|NCT06939088|DRUG|Placebo|Once weekly injections s.c. with placebo (BD Posiflush)
218964158|NCT00377975|DRUG|Caffeine|
218964159|NCT00696475|DRUG|Diazoxide choline|
218964160|NCT00696475|DRUG|Diazoxide choline|
218964161|NCT00696475|DRUG|Diazoxide choline|
218964162|NCT00696475|DRUG|Placebo|
219651222|NCT03891043|OTHER|Placebo|Placebo pill of 100 micrograms of starch was given to be taken twice a day.
219686312|NCT06015971|DIETARY_SUPPLEMENT|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
219686313|NCT06015971|DIETARY_SUPPLEMENT|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
219651223|NCT01193465|DEVICE|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
219651224|NCT01193465|DEVICE|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
219651225|NCT01193465|DEVICE|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
219651226|NCT01193465|DEVICE|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
219651227|NCT02401516|DEVICE|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
219651228|NCT02062073|DRUG|Abametapir Lotion 0.74% w/w|
219651229|NCT02062073|OTHER|0.1% sodium lauryl sulfate|
218964163|NCT00240474|DRUG|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
218964164|NCT00240474|DRUG|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
218964165|NCT05999539|DEVICE|Transtibial prosthesis|A transtibial prosthesis to be used for at least one year.
218964166|NCT02483052|DEVICE|RejuvenAir|RejuvenAir
218964167|NCT05065775|DEVICE|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
218964168|NCT03115580|DEVICE|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
218964169|NCT03115580|DEVICE|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
218964170|NCT02069418|RADIATION|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
218964171|NCT02069418|RADIATION|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
218964172|NCT04873128|GENETIC|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
218964173|NCT00814125|DRUG|Anastrozole (Arimidex)|1mg, orally, once daily
218964174|NCT00814125|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
218964175|NCT00814125|DRUG|Nolvadex placebo|
219651230|NCT02062073|OTHER|saline 0.9%|
218964176|NCT00814125|DRUG|Arimidex placebo|
218964177|NCT05829187|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
218964178|NCT05829187|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
218964179|NCT05829187|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
218964180|NCT05829187|DRUG|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
218964181|NCT02628665|DRUG|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
218964182|NCT02628665|DEVICE|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
218964183|NCT02669238|DEVICE|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
219651231|NCT02062073|OTHER|Vehicle Lotion|
219651232|NCT06422104|DEVICE|Repetitive transcranial magnetic stimulation|10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
219651233|NCT02957435|DRUG|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
219651234|NCT03197324|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
219651235|NCT03197324|DRUG|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
219651236|NCT03308435|DIAGNOSTIC_TEST|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
219686314|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
219686315|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
219686316|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
219686317|NCT04513171|DRUG|Norditropin®|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
219686318|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
219686319|NCT04513171|DRUG|Norditropin|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
219686320|NCT00977613|BEHAVIORAL|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
219686321|NCT03644420|DIAGNOSTIC_TEST|Clinical evaluation|Functional scores for the pathological joint will be determined
219651237|NCT03308435|DIAGNOSTIC_TEST|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
219651238|NCT03308435|DIAGNOSTIC_TEST|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
219651239|NCT03308435|DIAGNOSTIC_TEST|Cardiological assessment|ECG, echocardiography
219651240|NCT01959763|BEHAVIORAL|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
219651241|NCT01630863|PROCEDURE|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
219651242|NCT05641285|DEVICE|The OtoSight Middle Ear Scope|The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
219651243|NCT01510600|GENETIC|DNA analysis|
219651244|NCT01510600|GENETIC|polymerase chain reaction|
219651245|NCT01510600|OTHER|laboratory biomarker analysis|
219651246|NCT01510600|OTHER|medical chart review|
219651247|NCT02232828|PROCEDURE|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
219651248|NCT02232828|PROCEDURE|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
219651249|NCT00877071|DRUG|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
219651250|NCT00927511|DRUG|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
219651251|NCT06620393|DRUG|Dexmedetomidine|DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
219651252|NCT06620393|DRUG|Placebo|NaCl 0.9% 100ml
219651253|NCT06354361|BEHAVIORAL|Trauma-Informed Goal Management Training (TI-GMT)|"Trauma Informed-Goal Management Training (TI-GMT) is a modified version of Goal Management Training (GMT), a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours. TI-GMT enhances the standard GMT protocol with the addition of several trauma-informed adaptations and content that is sensitive and specific to public safety personnel with PTSD.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
219651254|NCT06354361|BEHAVIORAL|Goal Management Training (GMT)|"Goal Management Training (GMT) is a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
219651255|NCT01984892|DRUG|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
219651256|NCT04158882|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219686322|NCT03644420|DIAGNOSTIC_TEST|Radiology|
219651257|NCT06621940|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
219651258|NCT06621940|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
219651259|NCT05120531|OTHER|Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia|Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
219651260|NCT05407974|PROCEDURE|pleurectomy|"All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax \& surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months."
219651261|NCT03886779|DRUG|Bromfenac|0.7 MG/ML \[Prolensa\]
219651262|NCT03886779|DRUG|Nepafenac|3 MG/ML \[Ilevro\]
219651263|NCT02964754|DEVICE|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
219651264|NCT02964754|PROCEDURE|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
219651265|NCT04827082|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
219651266|NCT04973631|GENETIC|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
219651267|NCT03568682|BEHAVIORAL|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
219651268|NCT02156895|DRUG|Axitinib|based on Axitinib approval
219686323|NCT03644420|DIAGNOSTIC_TEST|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
219686324|NCT03644420|DIAGNOSTIC_TEST|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
219686325|NCT01497067|DEVICE|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
219686326|NCT03130933|PROCEDURE|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
219686327|NCT03130933|DRUG|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
219686328|NCT03130933|OTHER|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
219686329|NCT01406314|DRUG|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
219686330|NCT03574077|BEHAVIORAL|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
219686331|NCT03574077|BEHAVIORAL|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
219686332|NCT03574077|BEHAVIORAL|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
219686333|NCT03574077|BEHAVIORAL|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
218964184|NCT02669238|DRUG|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
218964185|NCT06477328|PROCEDURE|Telemedicine|Video calls were made with the telemedicine group.
218964186|NCT04639037|DEVICE|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
218964187|NCT04639037|DEVICE|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
218964188|NCT00521001|DRUG|everolimus|
218964189|NCT00521001|DRUG|temozolomide|
218964190|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
218964191|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
218964192|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
218964193|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
218964194|NCT02821910|DRUG|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
218964195|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
218964196|NCT00287079|DRUG|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
218964197|NCT00287079|OTHER|No Treatment|No treatment for 96 weeks
218964198|NCT02822547|DRUG|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
218964199|NCT02380820|DEVICE|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
218964200|NCT02380820|DEVICE|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
218964201|NCT04218123|DRUG|Venlafaxine|Daily oral intake 37.5 mg
218964202|NCT04218123|DRUG|Placebo oral tablet|Daily oral intake
218964203|NCT05832021|PROCEDURE|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
218964204|NCT05832021|PROCEDURE|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
218964205|NCT03590197|DRUG|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
218964206|NCT03590197|OTHER|Placebo|Placebo with Valproate
219651269|NCT05994521|PROCEDURE|ERCP alone|"ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed"
218964207|NCT00508768|DRUG|Oral SCIO-469 capsule|
218964208|NCT03613597|DRUG|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
218964209|NCT03613597|DRUG|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
218964210|NCT01082640|DRUG|Febuxostat|Febuxostat capsules
218964211|NCT01082640|DRUG|Placebo|Febuxostat placebo-matching capsules
218964212|NCT03636711|OTHER|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
218964213|NCT02671162|DRUG|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
218964214|NCT02671162|DRUG|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
218964215|NCT00413478|DRUG|5-Azacytidine|Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
218964216|NCT00776685|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
218964217|NCT00156572|PROCEDURE|Sodium supplementation|
218964218|NCT00156572|PROCEDURE|Fluid restriction|
218964219|NCT00162721|DRUG|doxorubicin, ifosfamide, cisplatin|
218964220|NCT03598634|PROCEDURE|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
218964221|NCT03598634|PROCEDURE|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
218964222|NCT04577352|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
218964223|NCT04577352|DRUG|Placebo|Placebo will be administered per schedule specified in the arm.
218964224|NCT01830075|BEHAVIORAL|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
218964225|NCT03734744|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
218964226|NCT05196178|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
218964227|NCT00669760|OTHER|non-interventional study|does not apply
218964228|NCT05493618|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
218964229|NCT05493618|DRUG|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
218964230|NCT05493618|DRUG|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
218964231|NCT03701321|DRUG|Bortezomib|Given SC
218964232|NCT03701321|BIOLOGICAL|Daratumumab|Given IV
218964233|NCT03701321|DRUG|Dexamethasone|Given PO
218964234|NCT03701321|DRUG|Venetoclax|Given PO
218964235|NCT04335422|DEVICE|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
218964236|NCT04335422|BEHAVIORAL|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
218964237|NCT00198796|BIOLOGICAL|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
218964238|NCT04349085|DEVICE|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
219062719|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
219062720|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
219062721|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
219062722|NCT03963895|DRUG|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
219062723|NCT03963895|DRUG|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
219062724|NCT03963895|DRUG|placebo|placebo administered on Day 1 as a single intravenous infusion
219651270|NCT05994521|PROCEDURE|ERCP +ProEUS-GE|ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
219651271|NCT05723328|BEHAVIORAL|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
219651272|NCT04531254|BEHAVIORAL|Wearing a face mask at all times|Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
219651273|NCT03805373|OTHER|Diet Assessment Survey|Participants will complete 2 different diet assessment tools separated by at least 1 week.
219651274|NCT03476174|DRUG|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
219686334|NCT03574077|BEHAVIORAL|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
219686335|NCT01167348|PROCEDURE|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
219686336|NCT03919123|OTHER|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
219686337|NCT01535313|DEVICE|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
219686338|NCT05826210|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
219686339|NCT03742986|DRUG|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
219062725|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
219651275|NCT03476174|DRUG|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
219651276|NCT06272136|DEVICE|Clinical Demo 2.0|During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
219651277|NCT03410082|DEVICE|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
219651278|NCT03410082|DIAGNOSTIC_TEST|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
219651279|NCT01056991|OTHER|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
219651280|NCT01056991|OTHER|warming blanket|
219062726|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
219062727|NCT00871481|DRUG|cyclophosphamide|Given IV
219651281|NCT05972291|DIETARY_SUPPLEMENT|Oral Glutamine|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
219651282|NCT05972291|OTHER|Control Arm|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
219651283|NCT05984173|DRUG|Vitamin E application|patients received vitamin E inside the socket after extraction
219651284|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
219651285|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
219651286|NCT03953027|OTHER|Survey Administration|Ancillary studies
219651287|NCT06337786|DEVICE|Digital app RB4.1|Standard care and the digital app RB4.1
219062728|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
219062729|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
219062730|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
219062731|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
219062732|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
219062733|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
219651288|NCT06337786|OTHER|Control arm|Standard care alone
219651289|NCT06065007|OTHER|No intervention|This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
219651290|NCT05878925|OTHER|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
219651291|NCT05878925|OTHER|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
219686340|NCT03742986|DRUG|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
219686341|NCT03742986|DRUG|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
219686342|NCT03742986|DRUG|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
219686343|NCT03742986|DRUG|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
219686344|NCT03742986|DRUG|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
219686345|NCT03742986|DRUG|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
219686346|NCT04346199|DRUG|Acalabrutinib|Acalabrutinib- administered orally
219686347|NCT05105191|DIAGNOSTIC_TEST|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
219686348|NCT00262652|DRUG|sodium pyruvate|
219686349|NCT03812900|DRUG|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
219651292|NCT06280066|OTHER|Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers|The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
219651293|NCT03605771|OTHER|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
219651294|NCT04220814|RADIATION|MRI|MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done
219651295|NCT04220814|OTHER|Electrophysiology|Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
219651296|NCT06346847|DIETARY_SUPPLEMENT|Postbiotic|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
219651297|NCT06346847|DIETARY_SUPPLEMENT|Placebo|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
219651298|NCT05201144|DRUG|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
219651299|NCT05201144|OTHER|Placebo|Equal volume of placebo
218964239|NCT04349085|DEVICE|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
218964240|NCT01623986|DEVICE|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
218964241|NCT01623986|DEVICE|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
218964242|NCT05333783|BEHAVIORAL|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
218964243|NCT05895799|OTHER|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
218964244|NCT03431311|BIOLOGICAL|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
218964245|NCT05369260|OTHER|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
219651300|NCT04104412|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2\*10\^7
219062734|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
219062735|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
219062736|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
219062737|NCT02999555|PROCEDURE|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
219062738|NCT00370162|DRUG|lactoserum|
219062739|NCT03221582|DRUG|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
219651301|NCT01109628|DIETARY_SUPPLEMENT|Protein drink|Twice a day during 6 months
219651302|NCT01109628|DIETARY_SUPPLEMENT|Placebo drink|Twice a day during 6 months
219651303|NCT03337360|DIETARY_SUPPLEMENT|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
219651304|NCT03337360|OTHER|Placebo|Inactive ingredients, placebo
219651305|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
218964246|NCT05369260|OTHER|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
219651306|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
219651307|NCT04797949|DRUG|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
218964247|NCT04026581|BEHAVIORAL|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
219062740|NCT01858662|PROCEDURE|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
219062741|NCT01858662|DRUG|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
219651308|NCT05470283|DRUG|OBX-115|Given by IV
219651309|NCT05470283|DRUG|Acetazolamide|Given by PO
219651310|NCT05470283|DRUG|Cyclophosphamide|Given by IV
219651311|NCT05470283|DRUG|Furosemide|Given by IV
219062742|NCT01858662|DRUG|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
219062743|NCT01858662|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
219062744|NCT01858662|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
219062745|NCT01858662|DRUG|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
219207937|NCT06946654|PROCEDURE|Geriatric Assessment|This is a study held in all patients undergoing allogenic hematopoietic stem cell transplantation. Pre-transplant assessment: (1)Patients-related assessment: (a) Age; (b) Functional status (BADL score; IADL score; KPS score; ECOG PS score); (c) Comorbidities (HCT-CI score); (d) Nutritional Status (Body weight; BMI; NRS-2002; MNA-SF; MUST); (e) Psychological Status (SF36-MCS; GDS; PHQ-9; GAD-7); (f) Cognitive Function (MMSE; BMOC); (g) Social Support Level (MOS-SSS; MSPSS); (h) Total Number of Medications Used. (2) Disease-Related Factors Assessment: Primary Disease Diagnosis; ELN Risk Stratification (assessed only for AML patients); Disease Status. (3) Donor-Related Factors Assessment: Donor Age; Donor Sex; Donor-Recipient Blood Type Compatibility; Donor Type; DSA. (4) Treatment-Related Factors Assessment: Conditioning Regimen; GVHD Prophylaxis Regimen; Graft Type.
219651312|NCT05470283|DRUG|Mesna|Given by IV
219651313|NCT05470283|DRUG|Fludarabine Phosphate|Given by IV
219651314|NCT05669352|DRUG|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
219651315|NCT05669352|DRUG|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
219651316|NCT04161079|DEVICE|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
219651317|NCT06158568|OTHER|Percutaneous Electrical Nerve Stimulation|Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
219651318|NCT06158568|OTHER|Placebo Percutaneous Electrical Nerve Stimulation|Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
219062746|NCT02484794|BEHAVIORAL|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
219651319|NCT06158568|OTHER|Exercise|Application of three weeks of progressive exercises targeting the shoulder musculature
219651320|NCT05527847|BEHAVIORAL|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
219651321|NCT05527847|BEHAVIORAL|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
219651322|NCT05872100|BEHAVIORAL|MINDFULNESS BASED APPLICATION|"* The effectiveness of mindfulness practices in the field of health~* Breathing exercise~* Discussing and sharing about exercise~* Introduction of informal and formal mindfulness practices~* Communication exercise with conscious awareness~* Sounds and thoughts meditation~* The concept of compassion~* Biological foundations of compassion~* Self-compassion~* Barriers to compassion~* Coping with compelling emotions~* Coping with the intensity of compassion~* Compassionate mindfulness attitudes~* Admission stages and improving acceptance~* Compassion Meditation~* Courtesy Meditation~* My partner activity~* Body Scan~* Mindfulness Sitting Meditation~* Receiving feedback on the development of mindfulness skills and the content of the training program~* Integration of conscious awareness exercises in daily life for the future"
219651323|NCT02013570|DRUG|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
218964248|NCT04026581|BEHAVIORAL|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
218964249|NCT02783885|DRUG|immunotherapy|
219651324|NCT03572400|DRUG|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
219651325|NCT03572400|DRUG|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
218964250|NCT04870736|PROCEDURE|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
219062747|NCT02484794|BEHAVIORAL|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
219062748|NCT06360835|PROCEDURE|total hip arthroplasty|
219062749|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
219062750|NCT00005776|DRUG|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
219062751|NCT00005776|DRUG|Placebo|100% Oxygen
219062752|NCT00475059|DRUG|cimetidine arrow|patients who received cimétidine
219651326|NCT04253405|DEVICE|High Flow Nasal Catheter|"HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2"
218964251|NCT04870736|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
218964252|NCT04900168|DEVICE|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
218964253|NCT00847119|BIOLOGICAL|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
219062753|NCT01248884|BIOLOGICAL|Infanrix hexa™|3 doses, intramuscular into left thigh
219062754|NCT01248884|BIOLOGICAL|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
219062755|NCT01248884|BIOLOGICAL|GSK217744|3 doses, intramuscular into left thigh
219062756|NCT06507267|OTHER|Pain and Clinical Reflections in Pelvic Congestion Syndrome|Pain and Clinical Reflections in Pelvic Congestion Syndrome
219062757|NCT03074422|PROCEDURE|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
219062758|NCT03110289|OTHER|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
219062759|NCT03110289|OTHER|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
219062760|NCT02511431|DRUG|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
219651327|NCT04253405|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
219651328|NCT00623597|DRUG|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
219651329|NCT00623597|DRUG|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
219651330|NCT01157000|DRUG|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
219651331|NCT03309826|DEVICE|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
218964254|NCT00847119|DRUG|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
218964255|NCT00847119|RADIATION|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
218964256|NCT00400790|DRUG|propofol|Propofol used as the primary anaesthetic agent
218964257|NCT00400790|DRUG|desflurane|Desflurane used as the primary anaesthetic
218964258|NCT05461807|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
218964259|NCT05461807|DRUG|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
219062761|NCT02511431|DRUG|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
219062762|NCT02511431|OTHER|Placebo|Placebo
219062763|NCT05996354|DEVICE|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
219062764|NCT03713762|DRUG|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
219651332|NCT03309826|DEVICE|Nasal Dilator Strip|Nightly use of nasal dilator strip
219651333|NCT02515994|DEVICE|senofilcon C|Investigational contact lens
219651334|NCT02515994|DEVICE|comfilcon A|Marketed Monthly Replacement Lens (Control)
219651335|NCT02642003|DRUG|Granulocyte Colony Stimulating Factor|
218964260|NCT01082380|DRUG|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
218964261|NCT02011893|DEVICE|Tonic Stimulation|Prodigy Neurostimulation System with associated components
218964262|NCT02011893|DEVICE|Burst Stimulation|Prodigy Neurostimulation System with associated components
219062765|NCT03713762|DRUG|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
219062766|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
219062767|NCT04479618|DEVICE|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
219651336|NCT04943302|DRUG|Bendamustine Hydrochloride|To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
219651337|NCT04943302|DRUG|Isatuximab|To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
219651338|NCT06284395|DRUG|Bortezomib|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
219062768|NCT04479618|DEVICE|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
219651339|NCT03161002|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219651340|NCT03132870|OTHER|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
219651341|NCT03653949|OTHER|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
219651342|NCT03653949|OTHER|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
219651343|NCT05392439|DEVICE|taVNS|transcutaneous auricular vagal nerve stimulation
219651344|NCT05392439|DEVICE|sham-taVNS|transcutaneous stimulation at the elbow area
219651345|NCT03203226|OTHER|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
219651346|NCT05548998|OTHER|General anesthesia with low fresh gas flow|General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia
219651347|NCT05548998|OTHER|General anesthesia with high fresh gas flow|General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia
219062769|NCT04479618|DEVICE|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
218964263|NCT04488107|DRUG|FCN-437c|\- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
218964264|NCT04488107|DRUG|Letrozole 2.5mg|"* Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
218964265|NCT05990998|DRUG|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
218964266|NCT00229918|DRUG|triamcinolone acetonide|
218964267|NCT01496768|DIETARY_SUPPLEMENT|Leucine|7,2 g/day during 3 months
219651348|NCT05548998|DIAGNOSTIC_TEST|Mini mental state examination|6 category and 30-point test to inquire patient's cognitive function
219651349|NCT05548998|DIAGNOSTIC_TEST|Visual Analogue Scale|The patient's self-reported pain intensity according to a visual scale between 0 and 100
219651350|NCT03051516|OTHER|Laboratory Biomarker Analysis|Correlative studies
219651351|NCT03051516|OTHER|Placebo Administration|Given IM
219651352|NCT03051516|OTHER|Questionnaire Administration|Ancillary studies
219651353|NCT03051516|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219651354|NCT05262712|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
219651355|NCT05262712|OTHER|Placebo Control|Devices mounted, no stimulation
219651356|NCT05605639|DRUG|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
219651357|NCT05605639|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
219651358|NCT03621540|DEVICE|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
219651359|NCT03621540|DEVICE|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
219651360|NCT03621540|BEHAVIORAL|Adaptive working memory training|Adaptive spatial n-back training.
219651361|NCT04156945|BEHAVIORAL|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
219651362|NCT04156945|DIAGNOSTIC_TEST|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
218964268|NCT01496768|DIETARY_SUPPLEMENT|Alanine|7,2 g/day during 3 months
218964269|NCT03409068|PROCEDURE|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
218964270|NCT03409068|PROCEDURE|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
218964271|NCT06256757|PROCEDURE|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
218964272|NCT03541876|OTHER|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
218964273|NCT06130007|DRUG|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
218964274|NCT01875003|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
218964275|NCT01875003|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
218964276|NCT01875003|DRUG|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
219651363|NCT00204503|DRUG|Depakote ER|
219651364|NCT00888602|DIETARY_SUPPLEMENT|3.4 g psyllium|3.4 g psyllium served with meal
219651365|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium served with a meal
219651366|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium
219651367|NCT00888602|OTHER|Meal|meal
219651368|NCT04106362|BIOLOGICAL|Cetuximab|Given IV
219651369|NCT04106362|DRUG|Cisplatin|Given IV
219651370|NCT04106362|OTHER|Quality-of-Life Assessment|Ancillary studies
219651371|NCT04106362|OTHER|Questionnaire Administration|Ancillary studies
219651372|NCT04106362|RADIATION|Radiation Therapy|Undergo radiation therapy
219651373|NCT02232854|BEHAVIORAL|Depression training/supervision program|"The intervention will be composed of:~* Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~* After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~* Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~* Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
219651374|NCT04587739|COMBINATION_PRODUCT|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
219651375|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
219651376|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
219651377|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
219651378|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
219651379|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
219651380|NCT05976308|DRUG|Bushen Huatan Decoction|The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
218964277|NCT04733612|OTHER|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
218964278|NCT05368532|OTHER|Temperature|The temperature will be reduced for approximately one hour.
218964279|NCT03211962|OTHER|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
219651381|NCT05976308|DRUG|Placebo|The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
219651382|NCT06133946|GENETIC|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
218964280|NCT03157960|OTHER|Blueberry drink|Participant receive blueberry drink
218964281|NCT03157960|OTHER|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
219062770|NCT05843942|OTHER|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
219062771|NCT04984044|DIETARY_SUPPLEMENT|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
218964282|NCT03157960|OTHER|Soft beverage|Participant receive a soft beverage drink
218964283|NCT03157960|OTHER|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
219651383|NCT04511195|DIETARY_SUPPLEMENT|Standardized extract of Sphaeralcea angustifolia|Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin
219651384|NCT04511195|DRUG|Diclofenac Sodium Gel|Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
219651385|NCT01272141|DRUG|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
219651386|NCT00572052|DEVICE|NovoFine® needle 6 mm|
218964284|NCT03157960|OTHER|Fructose|Participant receive a drink containing fructose
218964285|NCT03157960|OTHER|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
218964286|NCT01019811|PROCEDURE|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
218964287|NCT01289782|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
218964288|NCT01289782|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
218964289|NCT01289782|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
218964290|NCT01289782|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
218964291|NCT04433143|DRUG|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
219062772|NCT04984044|DIETARY_SUPPLEMENT|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
219062773|NCT00146952|DEVICE|Vibrotactile feedback|
219651387|NCT00572052|DEVICE|Ultra-Fine needle 12.7 mm|
219651388|NCT01819753|PROCEDURE|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
219651389|NCT05574803|DEVICE|Active-tDCS|Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.
218964292|NCT01241240|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
218964293|NCT01241240|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
218964294|NCT01410539|DEVICE|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
219062774|NCT01060228|DRUG|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
219062775|NCT01060228|DRUG|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
219062776|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
219651390|NCT05574803|DEVICE|Sham-tDCS|Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
219651391|NCT05571202|PROCEDURE|General anesthesia plus local infiltration|The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.
218964295|NCT01410539|DRUG|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
219651392|NCT05571202|PROCEDURE|Spinal anesthesia|The eligible patients underwent anorectal surgery under spinal anesthesia alone.
219651393|NCT04543721|DEVICE|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
219651394|NCT01131884|DRUG|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
219651395|NCT01131884|DRUG|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
219651396|NCT02935582|DRUG|Enstilar® aerosol foam|Treatment according to local labelling
219651397|NCT02935582|DRUG|Other topical|Treatment according to local practise
218964296|NCT01386905|DEVICE|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
218964297|NCT04884776|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
218964298|NCT04884776|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
218964299|NCT02913040|OTHER|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
218964300|NCT02913040|OTHER|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
218964301|NCT04499599|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
219651398|NCT05024981|BEHAVIORAL|Videographic feedback|Twice a week during his classic re-education sessions, the patient will be filmed for 1 minute. After transferring the video to a tablet, he will watch the video once and decide what he wants to correct. During the second viewing, he will analyse his walk, the therapist being present to provide additional information. Finally, the patient will apply his analysis while being filmed and will compare the possible differences between the 2 videos. Depending on the time available, the patient may have to repeat the recordings, analyses and exercises.
219651399|NCT05024981|BEHAVIORAL|Classic reeducation|The patient will benefit twice a day for 30 minutes from re-education sessions.
219651400|NCT02537834|DRUG|Tofogliflozin|
219651401|NCT02537834|DRUG|GLP-1 analogue|
219651402|NCT05556564|DRUG|observational study|No intervention, observational study
218964302|NCT04499599|OTHER|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
218964303|NCT04499599|OTHER|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
219062777|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
219062778|NCT02811029|BEHAVIORAL|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
219062779|NCT05191576|OTHER|Children's sleep habits questionnaire (CSHQ)|"1. Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~2. DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~3. DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~   SDQ).is used to screen emotional and behavioral problems in children.~4. SDQ is used to screen emotional and behavioral problems in children."
219062780|NCT02334800|DRUG|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
219651403|NCT03350308|OTHER|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
219651404|NCT02758444|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
219651405|NCT02758444|DIETARY_SUPPLEMENT|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
219651406|NCT02758444|DIETARY_SUPPLEMENT|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
219651407|NCT02758444|DIETARY_SUPPLEMENT|MNP without Zn|Same as above except MNP will not contain Zn
219651408|NCT02339155|BIOLOGICAL|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
219651409|NCT02339155|BIOLOGICAL|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
219651410|NCT02339155|DRUG|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
218964304|NCT06488547|OTHER|Diaphragmatic breathing (DF)|Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
219207938|NCT02911064|BEHAVIORAL|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
219207939|NCT06191848|DRUG|Tirzepatide|Participants will receive tirzepatide subcutaneously
219651411|NCT00162149|DRUG|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
219651412|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
219651413|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
219207940|NCT06191848|DRUG|Placebo|Participants will receive placebo subcutaneously
219207941|NCT01675440|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
219207942|NCT05062291|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
219651414|NCT00162149|DRUG|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
219651415|NCT00842075|DRUG|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
219651416|NCT01214252|DEVICE|Permacol Surgical Implant|Permacol Surgical Implant
219651417|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
219651418|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
219651419|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
219651420|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
219651421|NCT02057913|DRUG|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
219651422|NCT02703506|OTHER|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
219651423|NCT02703506|OTHER|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
218964305|NCT06488547|OTHER|Progressive Muscle Relaxation (PMR)|"Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation."
218964306|NCT05078918|OTHER|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
218964307|NCT05078918|OTHER|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
218964308|NCT04076527|DRUG|UDCA|Routine data is collected for UDCA therapy.
218964309|NCT04076527|DRUG|Ocaliva|Routine data is collected for OCA therapy.
219651424|NCT03250585|DIAGNOSTIC_TEST|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
219651425|NCT03250585|DIAGNOSTIC_TEST|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
219651426|NCT02954185|OTHER|WellClub|
219651427|NCT02954185|BEHAVIORAL|Standard Therapy|
219651428|NCT01827878|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
218964310|NCT00715169|DRUG|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
218964311|NCT00715169|OTHER|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
218964312|NCT02597634|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
219062781|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
219651429|NCT01827878|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
219651430|NCT04062071|OTHER|no intervention|no intervention
219651431|NCT00360815|BEHAVIORAL|Insulin|
219651432|NCT04927871|BEHAVIORAL|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
219651433|NCT04927871|BEHAVIORAL|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
219651434|NCT04927871|BEHAVIORAL|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
219651435|NCT04927871|BEHAVIORAL|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
218964313|NCT02597634|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
218964314|NCT01218282|BEHAVIORAL|Home exercise training|20-30 min/day for at least 4 days/week
218964315|NCT01218282|BEHAVIORAL|NO Exercise Training|No intervention
218964316|NCT01025154|DRUG|Clofarabine|Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
218964317|NCT01025154|DRUG|Idarubicin|Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
219062782|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
219207943|NCT06562673|DRUG|intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)|After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
219207944|NCT05795153|DRUG|LOU064|One film-coated tablet (25 mg) was to be taken in the morning and evening, respectively, with a 12-hour interval at approximately the same time everyday.
219651436|NCT02176083|BEHAVIORAL|Text message management prompts|
219651437|NCT02036671|DEVICE|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
219207945|NCT05731856|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.
219651438|NCT02817698|DRUG|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
219651439|NCT02957045|PROCEDURE|Cough pressure measurement|
218964318|NCT01025154|DRUG|Cytarabine|Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
218964319|NCT06115668|OTHER|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
218964320|NCT06115668|OTHER|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
218964321|NCT02040285|DRUG|Bisacodyl & PEG-CS|"the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
218964322|NCT02040285|DRUG|Iopamidol|"the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet"
218964323|NCT01262209|DEVICE|portable CCTV|This is a small handheld mini screen intended to improve reading.
218964324|NCT01262209|DEVICE|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
219207946|NCT00207480|BEHAVIORAL|Brief, motivational interviewing intervention|
219651440|NCT02957045|DEVICE|Pcough|
219651441|NCT04616105|DRUG|REGN6490|Single dose of REGN6490
219651442|NCT04616105|DRUG|Placebo|Placebo matching single dose of REGN6490
219651443|NCT04327661|DRUG|Tradipitant|Oral Capsule
219651444|NCT04327661|DRUG|Placebo|Oral Capsule
219651445|NCT03950141|DRUG|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
219651446|NCT02320682|DEVICE|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
219651447|NCT02671825|DRUG|PUR0200|PUR0200 dry powder inhalation
219651448|NCT02671825|DRUG|Reference Product|Dry Powder Inhalation Reference Product
218964325|NCT01262209|DEVICE|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
218964326|NCT03239665|BEHAVIORAL|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
218964327|NCT03239665|BEHAVIORAL|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
218964328|NCT03812432|DEVICE|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
218964329|NCT00772083|BEHAVIORAL|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
218964330|NCT00772083|BEHAVIORAL|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
218964331|NCT01406925|DRUG|Placebo control|Placebo cream
218964332|NCT01406925|DRUG|NRL001 cream|Cream for single-dose intra-anal application
218964333|NCT03436810|PROCEDURE|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
218964334|NCT03436810|PROCEDURE|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
218964335|NCT03436810|PROCEDURE|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
218964336|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
218964337|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
218964338|NCT00797342|DRUG|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
218964339|NCT05682573|DIAGNOSTIC_TEST|hospitalized patient|Collect the patient's whole blood for testing
219062783|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
219062784|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
219062785|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
219651449|NCT02454374|PROCEDURE|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
219651450|NCT02454374|PROCEDURE|Routine Physiotherapy Care|Routine Physiotherapy Care
219651451|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
219651452|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
218964340|NCT04033523|BEHAVIORAL|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
218964341|NCT05370456|DEVICE|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
218964342|NCT05370456|PROCEDURE|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
218964343|NCT03251664|DIETARY_SUPPLEMENT|Food groups consumed|
218964344|NCT00542451|DRUG|Paclitaxel|Every week for 12 weeks
218964345|NCT00542451|DRUG|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
218964346|NCT03046173|OTHER|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
218964347|NCT03046173|OTHER|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
218964348|NCT05225337|OTHER|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
218964349|NCT05225337|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
218964350|NCT05082610|DRUG|HMBD-002|IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
218964351|NCT05082610|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
218964352|NCT01582854|DRUG|Actovegin|Actovegin solution for infusion and Actovegin tablets
219651453|NCT02498509|DRUG|CKD-342|treatment for 4 weeks after randomization
219651454|NCT02498509|DRUG|Mometasone furoate|treatment for 4 weeks after randomization
219651455|NCT02498509|DRUG|Levocabastine HCL|treatment for 4 weeks after randomization
219651456|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
219651457|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
219686350|NCT05449171|OTHER|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
218964353|NCT01582854|DRUG|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
218964354|NCT06177808|DEVICE|Wolverine cutting balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
219207947|NCT06791564|DEVICE|AVELI|Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
219207948|NCT05180539|BEHAVIORAL|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
219686351|NCT06140433|DEVICE|VSC-MEDlib|VSC-MEDlib will be used for post-processing
219686352|NCT04132037|OTHER|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
218964355|NCT06177808|DEVICE|Non-compliant balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
218964356|NCT05992324|DEVICE|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
218964357|NCT04214249|PROCEDURE|Biospecimen Collection|Undergo collection of blood
218964358|NCT04214249|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218964359|NCT04214249|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218964360|NCT04214249|PROCEDURE|Computed Tomography|Undergo CT
218964361|NCT04214249|DRUG|Cytarabine|Given via continuous IV infusion
218964362|NCT04214249|DRUG|Daunorubicin Hydrochloride|Given IV
218964363|NCT04214249|PROCEDURE|Echocardiography Test|Undergo ECHO
218964364|NCT04214249|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
218964365|NCT04214249|DRUG|Idarubicin Hydrochloride|Given IV
218964366|NCT04214249|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218964367|NCT04214249|BIOLOGICAL|Pembrolizumab|Given IV
218964368|NCT04214249|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
218964369|NCT06047548|DRUG|Tirzepatide|Administered SC
218964370|NCT06047548|DRUG|Placebo|Administered SC
218964371|NCT06138145|OTHER|Video|Different videos were shown for the generic and appeal groups. No videos were shown to the control or ink-pen incentive groups
218964372|NCT06138145|BEHAVIORAL|Survey|Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
218964373|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
218964374|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
218964375|NCT05488756|OTHER|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
219207949|NCT05180539|BEHAVIORAL|Control Condition|Two-session in person group discussions focusing on college health behaviors
219207950|NCT05220501|DIAGNOSTIC_TEST|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
219207951|NCT05220501|DIAGNOSTIC_TEST|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
219207952|NCT03779984|DEVICE|Red Rubber Catheter|Experimental group will be intubated with red rubber catheter guidance
219207953|NCT03779984|DEVICE|Standard nasal tracheal Intubation|Control group will be intubated with standard nasal tracheal tube without guidance
219207954|NCT05990790|DRUG|Desflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
219062786|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
219651458|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
219651459|NCT06851663|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
219651460|NCT06851663|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
219651461|NCT06851663|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
219651462|NCT06851663|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
219651463|NCT05919849|BEHAVIORAL|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
219651464|NCT05919849|OTHER|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
218964376|NCT05488756|OTHER|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
218964377|NCT05488756|OTHER|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
219651465|NCT06272760|OTHER|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
219651466|NCT05756231|BEHAVIORAL|SIHT-16|a pencil-paper assessment tool.
219651467|NCT06146010|OTHER|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
219651468|NCT00419601|DRUG|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
219651469|NCT00419601|DRUG|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
219651470|NCT04927377|BEHAVIORAL|AI4DM|Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor
219686353|NCT03805737|OTHER|Amulez and sunlight|Amulez and sun exposure for 2 hours
219207955|NCT05990790|DRUG|Sevoflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
219686354|NCT03805737|OTHER|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
219686355|NCT03227718|BEHAVIORAL|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
219686356|NCT03159598|DEVICE|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
219686357|NCT03159598|DEVICE|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
219686358|NCT03159598|OTHER|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
219686359|NCT06560684|DRUG|Oral F/TDF Pills|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.
219651471|NCT04927377|BEHAVIORAL|Attention-control|Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.
219651472|NCT01617772|DRUG|Atorvastatin|Atorvastatin 20 mg
219651473|NCT01617772|DRUG|L-Carnitine|1000mg L-carnitine
219651474|NCT01617772|DRUG|Placebo|Identically looking placebo
219651475|NCT06157164|OTHER|UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)|Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
218964378|NCT02652767|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
218964379|NCT02652767|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
219651476|NCT05622071|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
219651477|NCT05674916|DIAGNOSTIC_TEST|Point-of-care ultrasound-driven diagnostic pathway|Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
218964380|NCT03906188|OTHER|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
218964381|NCT02889276|OTHER|Functional Resistance Training|Supervised group-based Functional Resistance Training
218964382|NCT02889276|BEHAVIORAL|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
218964383|NCT02399007|DEVICE|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
218964384|NCT02399007|DEVICE|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
218964385|NCT06002685|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
218964386|NCT06002685|OTHER|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
219062787|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
219062788|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
219062789|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
219651478|NCT02659514|DRUG|Poziotinib|8 mg oral tablets, administered QD.
219651479|NCT04869319|BEHAVIORAL|MyChart message|Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
219651480|NCT03823079|DRUG|rhTPO|rhTPO 300u/kg, subcutaneous injection, qd
219651481|NCT03823079|DRUG|irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
219651482|NCT03823079|DRUG|Raltitrexed|3mg/m2 q3w
219651483|NCT03823079|RADIATION|radiotherapy|in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
219651484|NCT03823079|DRUG|rhIL-11|rhIL-11 50ug/kg, subcutaneous injection, qd
219686360|NCT06560684|DRUG|TFV rectal douche|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
219686361|NCT05895045|BEHAVIORAL|Yoga|Restorative Vinyasa Yoga
219686362|NCT05341973|BEHAVIORAL|Education|Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
219651485|NCT03387228|OTHER|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
219651486|NCT03387228|OTHER|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
219651487|NCT05249322|OTHER|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~* An usual in-hospital consult of about 1h30 with paramedical and medical consult."
219651488|NCT06667323|OTHER|Integrated health service delivery for very young adolescent girls|The proposed HPV-VISION intervention will aim to increase girl-centered access to HPV vaccination and other VYA services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health post level.
219651489|NCT03264781|DRUG|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
219651490|NCT02684409|DRUG|PROT-CL-NP101-015.01|
219651491|NCT00003913|BIOLOGICAL|anti-thymocyte globulin|
219651492|NCT00003913|BIOLOGICAL|filgrastim|
219651493|NCT00003913|DRUG|busulfan|
219651494|NCT00003913|DRUG|cyclophosphamide|
219651495|NCT00003913|DRUG|methylprednisolone|
218964387|NCT00527670|PROCEDURE|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
218964388|NCT00527670|PROCEDURE|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
218964389|NCT00419809|DRUG|SB-681323 oral tablets|
218964390|NCT04148729|DRUG|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally. 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.
218964391|NCT04148729|DRUG|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
219651496|NCT00003913|PROCEDURE|umbilical cord blood transplantation|
219651497|NCT00003913|RADIATION|radiation therapy|
219651498|NCT04892212|DRUG|Sirolimus|The daily dose of sirolimus is divided twice.
219651499|NCT00984139|BIOLOGICAL|Engerix™-B Kinder|Intramuscular, one dose.
219651500|NCT05333939|DIETARY_SUPPLEMENT|Moringa leaf powder|capsule ingestion
219651501|NCT05333939|OTHER|Placebo|capsule ingestion
219651502|NCT03991013|DRUG|Dolutegravir 50 mg|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
219651503|NCT03991013|DRUG|Placebo|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
219651504|NCT00108485|DRUG|Extended release niacin|Extended release niacin 1500-2000mg once daily
218964392|NCT03367247|BEHAVIORAL|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
218964393|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
218964394|NCT04059367|DRUG|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
218964395|NCT04059367|DRUG|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
218964396|NCT00752596|DRUG|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
218964397|NCT02039440|OTHER|Blood draw|One-time blood draw
219062790|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
219062791|NCT03704818|DRUG|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
219062792|NCT03704818|DRUG|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
219062793|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
219062794|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
219062795|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
219062796|NCT02828111|DRUG|Patidegib|
219062797|NCT02828111|DRUG|Vehicle gel|
219062798|NCT00965224|BIOLOGICAL|dendritic cell vaccination (active specific immunotherapy)|
219062799|NCT02289131|PROCEDURE|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
219651505|NCT00108485|OTHER|Placebo|Placebo tablets
219651506|NCT03067688|DRUG|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
219651507|NCT03067688|DRUG|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
219651508|NCT03067688|DRUG|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
219651509|NCT00978939|OTHER|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
219651510|NCT00978939|OTHER|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
219651511|NCT04336449|DRUG|Eptinezumab|Eptinezumab - single intravenous infusion
219651512|NCT04336449|DRUG|Placebo|Placebo - single intravenous infusion
219651513|NCT05131087|DEVICE|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
219651514|NCT03442478|OTHER|2D/3D Tomosynthesis|
219651515|NCT01701193|DRUG|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
219651516|NCT01701193|DRUG|Physiologic saline|Placebo
219651517|NCT05735262|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
219651518|NCT05735262|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
219651519|NCT02062944|DRUG|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
219651520|NCT02956369|DIETARY_SUPPLEMENT|Control|Control granulates (maize starch and long-chain fatty acids) with powder
219651521|NCT02956369|DIETARY_SUPPLEMENT|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
219651522|NCT00278148|DRUG|carboplatin|AUC2 weekly x 3 weeks
218964398|NCT03872011|DRUG|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
218964399|NCT03872011|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
218964400|NCT03877081|BIOLOGICAL|Probiotics|Administration of oral probiotics with 2 doses a day
218964401|NCT03877081|OTHER|Placebo|Administration of oral placebo with 2 doses a day
218964402|NCT02565927|DEVICE|Traditional airway stent|process airway stenting
218964403|NCT02565927|DRUG|Iodine-125 seeds|process intraluminal brachytherapy
218964404|NCT01025765|DRUG|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
219062800|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
219062801|NCT01184014|DRUG|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
219062802|NCT01184014|DRUG|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
219651523|NCT00278148|DRUG|Erlotinib|Daily
219651524|NCT00278148|DRUG|paclitaxel|50mg/m2/weekly x 3 weeks
219651525|NCT00278148|PROCEDURE|conventional surgery|conventional surgery
219651526|NCT00278148|RADIATION|radiation therapy|150 cGy bid
219651527|NCT02181322|DRUG|Meloxicam - low dose|
219651528|NCT02181322|DRUG|Meloxicam - medium dose|
219651529|NCT02181322|DRUG|Meloxicam - high dose|
218964405|NCT01025765|DRUG|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
219651530|NCT05846399|DRUG|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
219651531|NCT05846399|DRUG|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
218964406|NCT01025765|DRUG|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
218964407|NCT03932097|BEHAVIORAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
218964408|NCT03932097|OTHER|Active Control Materials|NIAAA materials on underage drinking for parents
218964409|NCT02631356|DRUG|Ringer's lactate solution|
218964410|NCT02631356|DRUG|Succinylated gelatin|
218964411|NCT06136442|DRUG|Atogepant|atogepant in real life in Italy
218964412|NCT02576769|OTHER|No intervention|
218964413|NCT04651101|DIAGNOSTIC_TEST|coronary angiography|extent of coronary artery disease in invasive coronary angiography
219651532|NCT05846399|DRUG|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
219651533|NCT05846399|OTHER|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
219651534|NCT05846399|PROCEDURE|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
219651535|NCT00245297|DRUG|Kogenate FS, reconstituted in a suspension of liposomes|
219651536|NCT03873909|OTHER|Fruit Smoothie|Fruit Smoothie with 150-200 g mamey sapote fruit
219651537|NCT03873909|OTHER|Matrix-Free Shake|Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
219651538|NCT06275711|BEHAVIORAL|Therapeutic communication methods|Drawing pictures, story completion, breathing and relaxation exercises
219651539|NCT05386277|DEVICE|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
219651540|NCT00420277|DRUG|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
219651541|NCT00420277|DRUG|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
219651542|NCT06619795|DEVICE|Anodal tDCS|In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
219651543|NCT06619795|DEVICE|Sham tDCS|In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
219651544|NCT05331768|COMBINATION_PRODUCT|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
219651545|NCT00043030|PROCEDURE|psychosocial assessment and care|
219651546|NCT03813186|DRUG|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
219651547|NCT03813186|DRUG|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
219651548|NCT00095186|DRUG|Recombinant Human Lactoferrin|
219651549|NCT03998163|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
219651550|NCT02467257|DIETARY_SUPPLEMENT|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
219651551|NCT03824886|OTHER|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
219651552|NCT01088243|DRUG|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
219651553|NCT01088243|DRUG|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
219651554|NCT00716352|BEHAVIORAL|Educational intervention programme|
219651555|NCT06622200|BEHAVIORAL|Mindfulness-based Intervention|"In the present research, the standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study.~Participants in the experimental group completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing and delivering MBIs."
219651556|NCT03721042|DEVICE|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
219651557|NCT02119832|DEVICE|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
219651558|NCT00638742|DRUG|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
219651559|NCT02340442|OTHER|Obstetrical care parameters|
219651560|NCT02340442|OTHER|DVA measurements|
219062803|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
219651561|NCT02340442|OTHER|Fundus photographs|
219651562|NCT02763332|OTHER|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
219062804|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
219651563|NCT02763332|OTHER|Global trunk group (GTG)|This bandage was placed globally along the back
219062805|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
219651564|NCT00483106|DRUG|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
219062806|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
219062807|NCT00016289|BIOLOGICAL|recombinant interleukin-12|Given intraperitoneally
219651565|NCT00483106|DRUG|Placebo|taken orally twice a day for 7 consecutive days
219062808|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
219651566|NCT06288399|OTHER|No treatment given|No treatment given
219651567|NCT00028899|DRUG|asparaginase|
219651568|NCT00028899|DRUG|cytarabine|
219651569|NCT00028899|DRUG|gemtuzumab ozogamicin|
219651570|NCT00028899|DRUG|mitoxantrone hydrochloride|
219651571|NCT05672407|DRUG|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
219651572|NCT05672407|DRUG|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
219651573|NCT04341831|DRUG|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
219651574|NCT01041976|BEHAVIORAL|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
219651575|NCT01041976|BEHAVIORAL|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
219651576|NCT03814512|BEHAVIORAL|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
219651577|NCT03679338|DEVICE|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
219651578|NCT01437917|OTHER|20% amylose bread|20% amylose bread
219651579|NCT01437917|DIETARY_SUPPLEMENT|10% amylose bread|10% amylose bread
218964414|NCT06154681|OTHER|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
218964415|NCT05019976|RADIATION|Radiation - Dose Level 0|"Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14"
219062809|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
219651580|NCT01437917|DIETARY_SUPPLEMENT|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
219651581|NCT03186534|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
219651582|NCT03186534|BEHAVIORAL|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
219651583|NCT02062424|OTHER|DIPI|
219651584|NCT02231879|DRUG|Plerixafor|Twice daily low dose injection for 14 months.
219651585|NCT02231879|DRUG|G-CSF|Twice daily low dose injection for 14 months.
219651586|NCT05203549|PROCEDURE|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
219651587|NCT04653753|DEVICE|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
219651588|NCT03165760|PROCEDURE|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
218964416|NCT05019976|RADIATION|Radiation - Dose Level 1|"Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10"
219062810|NCT05110885|OTHER|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
219062811|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
219062812|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
219062813|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
219062814|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
219651589|NCT03667872|PROCEDURE|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
219651590|NCT02587572|BIOLOGICAL|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
219651591|NCT06623838|DIAGNOSTIC_TEST|Evolutionarily informed case conceptualization|Case conceptualization of personality functioning of a few transcripts of initial sessions and report of psychometric measures of patients diagnosed with personality disorder.
219651592|NCT03269084|OTHER|No intervention. DIPP is an observational study.|
219651593|NCT01949441|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
219651594|NCT01949441|BIOLOGICAL|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
219651595|NCT04167124|BEHAVIORAL|multi-sensor lifestyle intervention|
219651596|NCT03573219|RADIATION|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
219651597|NCT03714854|DEVICE|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
218964417|NCT05019976|RADIATION|Radiation - Dose Level 2|"Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7"
218964418|NCT05019976|RADIATION|Radiation - Dose Level 3|"Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5"
218964419|NCT05019976|RADIATION|Radiation - Dose Level 4|"Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3"
218964420|NCT01642407|DRUG|Sildenafil|Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
218964421|NCT02881333|GENETIC|Blood samples|
218964422|NCT02723318|BEHAVIORAL|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
218964423|NCT02723318|BEHAVIORAL|Access to Referrals to Social Services|
218964424|NCT04877873|BEHAVIORAL|Gait analysis pre- and post- surgery|None (observational)
218964425|NCT00721903|PROCEDURE|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
219062815|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
219651598|NCT00522704|OTHER|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
219651599|NCT00750412|BEHAVIORAL|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
219651600|NCT04228757|DIETARY_SUPPLEMENT|phytoestrogen herbal blend|phytoestrogen herbal blend
219651601|NCT04228757|OTHER|Placebo|Tablet without active ingredients
219651602|NCT06505135|BIOLOGICAL|Stem-cell treatment|"In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe."
218964426|NCT00721903|PROCEDURE|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
218964427|NCT00017485|DRUG|HPPH|
218964428|NCT03533686|DEVICE|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
218964429|NCT03533686|DEVICE|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
218964430|NCT02523612|PROCEDURE|Biopsy|
218964431|NCT02523612|PROCEDURE|Blood sample|
218964432|NCT01585012|DEVICE|Cervical cap (Focus Touch™ Conception System)|Cervical cap
218964433|NCT00245583|DRUG|Topiramate|minimum does of 50mg/day
219062816|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
219062817|NCT00916877|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
219062818|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
219062819|NCT03815071|DRUG|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
219062820|NCT03813329|DIETARY_SUPPLEMENT|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
218964434|NCT00245583|DRUG|Placebo|matching tablet
218964435|NCT00205400|PROCEDURE|medical care delivery model|
218964436|NCT03657966|BIOLOGICAL|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
218964437|NCT03657966|DRUG|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
218964438|NCT02587247|DRUG|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
218964439|NCT03316183|OTHER|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
218964440|NCT03419975|DRUG|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
218964441|NCT03419975|DRUG|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
219651603|NCT06505135|OTHER|Standard care|Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
219651604|NCT05909813|BEHAVIORAL|Individualized Piano Keyboard Instruction|"During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson."
219651605|NCT01210495|DRUG|Axitinib (AG-013736)|Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
219651606|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
219651607|NCT01210495|DRUG|Placebo|Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
219651608|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
219651609|NCT04504266|BEHAVIORAL|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
219651610|NCT00065650|DRUG|Vedic Medicine|
219651611|NCT00065650|BEHAVIORAL|Vedic Medicine|
219651612|NCT00751257|DRUG|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
219651613|NCT00751257|DRUG|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
219651614|NCT00648934|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
219651615|NCT00648934|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
219651616|NCT02189018|OTHER|Active Exercise|Active exercise on a treadmill
219651617|NCT02189018|OTHER|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
218964442|NCT01652911|DEVICE|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
219651618|NCT02189018|OTHER|Weight loss and active exercise|Weight loss and active exercise on a treadmill
219651619|NCT02189018|OTHER|Ad lib activity at home|Ad lib activity at home
219651620|NCT06602349|DRUG|Lidocaine 10 MG/ML|administration of lidocaine in posterior perineal block infiltration
219651621|NCT06602349|DRUG|Saline|administration of salin solution in posterior perineal block infiltration
219651622|NCT00228319|DIETARY_SUPPLEMENT|Oral Ascorbic Acid|4 grams per day for 12 months
219651623|NCT00228319|DRUG|Paclitaxel|Six cycles
219651624|NCT00228319|DRUG|Carboplatin|Six cycles
219651625|NCT00228319|DRUG|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
219651626|NCT00228319|DIETARY_SUPPLEMENT|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
219651627|NCT00228319|DIETARY_SUPPLEMENT|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
219651628|NCT02712021|OTHER|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
219651629|NCT02712021|OTHER|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
219651630|NCT03502018|DRUG|Bupivacaine liposome|A long-acting liposomal bupivacaine
219651631|NCT03502018|DRUG|Saline|Saline injection used as control
219651632|NCT00454818|GENETIC|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
219651633|NCT00454818|PROCEDURE|Placebo Infusion|Saline; epicardial coronary artery infusion
219651634|NCT00454818|GENETIC|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
219651635|NCT01791946|PROCEDURE|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
219651636|NCT01791946|PROCEDURE|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
219651637|NCT06620822|DRUG|IBI363|IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.
218964443|NCT03190642|DRUG|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
219651638|NCT06620822|DRUG|LM-108+Sintilimab|LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.
219651639|NCT06620822|DRUG|IBI310+Sintilimab|The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.
219651640|NCT06620822|DRUG|Sintilimab|Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
218964444|NCT00676221|DRUG|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
218964445|NCT01046760|BEHAVIORAL|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
218964446|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
218964447|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
219651641|NCT03784118|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
219651642|NCT03784118|DIAGNOSTIC_TEST|perfusion index|measurement of perfusion index immediately after arterial catheterization until surgery end, in arterial catheterization site and contralateral site.
219651643|NCT04324736|OTHER|no interventional study|no interventional study
219651644|NCT06726902|DEVICE|GBT and SI with erythritol powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy~   * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system.~  * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only."
219651645|NCT06726902|OTHER|GBT and SI with glycine powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder.~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
218964448|NCT02609997|DRUG|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
218964449|NCT02609997|DEVICE|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
218964450|NCT02609997|DRUG|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
218964451|NCT00005093|DRUG|gemcitabine hydrochloride|
218964452|NCT00005093|DRUG|tacedinaline|
218964453|NCT02545595|DRUG|Sugammadex 1 mg/kg|
218964454|NCT02545595|DRUG|Sugammadex 2 mg/kg|
219062821|NCT03813329|DIETARY_SUPPLEMENT|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
219062822|NCT03813329|DIETARY_SUPPLEMENT|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
219062823|NCT02844946|BEHAVIORAL|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
218964455|NCT02545595|DRUG|Sugammadex 4 mg/kg|
219062824|NCT01060761|BEHAVIORAL|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
219062825|NCT02873611|DEVICE|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
219062826|NCT02873611|PROCEDURE|genicular ablation procedure|
219062827|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
219062828|NCT00462384|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
219062829|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
219651646|NCT06726902|OTHER|GBT and SI with trehalose powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
219651647|NCT06726902|OTHER|SRP and SI|conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed
219651648|NCT00766285|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
218964456|NCT06352333|PROCEDURE|supraclavicular ultrasound guided brachial plexus block|two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
219651649|NCT00766285|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
219651650|NCT04151485|BEHAVIORAL|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
218964457|NCT02414139|DRUG|Capmatinib|"Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food."
218964458|NCT01087697|DEVICE|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
218964459|NCT05325710|BEHAVIORAL|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
218964460|NCT03291171|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
218964461|NCT04036643|RADIATION|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
218964462|NCT00457964|DRUG|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
219062830|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
219062831|NCT02897843|DEVICE|sham tDCS|sham tDCS
219651651|NCT04151485|BEHAVIORAL|Fertility Support Program|see Arm Description
219651652|NCT01914211|DRUG|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
219651653|NCT01914211|PROCEDURE|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)
219651654|NCT04631328|OTHER|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
219651655|NCT03639805|OTHER|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
219651656|NCT03639805|OTHER|standard care of vaso-occlusive crises|administration of standard care only
219651657|NCT00215371|DRUG|Formoterol Fumarate|
219651658|NCT06649474|BIOLOGICAL|assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy|assess the serum HMGB1 concentrations
218964463|NCT02797054|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
218964464|NCT02797054|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
218964465|NCT02797054|BEHAVIORAL|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
219062832|NCT00742703|OTHER|Mineralized water|
219062833|NCT00742703|OTHER|Low mineralized water|
219062834|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
219062835|NCT02765932|PROCEDURE|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
219651659|NCT06263881|DRUG|Raphamin|Tablet for oral use.
219651660|NCT06263881|DRUG|Placebo|Tablet for oral use.
219651661|NCT01695330|DRUG|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
219651662|NCT03259672|DRUG|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
219651663|NCT03259672|DRUG|Desflurane|Desflurane was used as a maintenance anesthetic agent.
219651664|NCT00767039|DRUG|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
219651665|NCT00767039|DRUG|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
219651666|NCT00772122|DRUG|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
219651667|NCT00772122|DRUG|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
219651668|NCT04502238|OTHER|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
219651669|NCT01826370|DRUG|Linagliptin|tablet
219651670|NCT01332279|DRUG|everolimus|Given PO
219651671|NCT01332279|DRUG|erlotinib hydrochloride|Given PO
219651672|NCT01332279|PROCEDURE|biopsy|Correlative studies
219651673|NCT01332279|OTHER|laboratory biomarker analysis|Correlative studies
219651674|NCT01332279|OTHER|immunohistochemistry staining method|Correlative studies
218964466|NCT04644783|DIAGNOSTIC_TEST|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
218964467|NCT02717377|BEHAVIORAL|physical activity|
218964468|NCT00602745|DRUG|S-1|oral administration
218964469|NCT00602745|DRUG|5-Fluorouracil|intravenous bolus
218964470|NCT05546801|OTHER|questionnaire|questionnaire on postnatal development
218964471|NCT01363414|DRUG|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
218964472|NCT01363414|DRUG|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
219062836|NCT02765932|PROCEDURE|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
219062837|NCT06580808|OTHER|Fontan Training Group|The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
219062838|NCT05391282|OTHER|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
219062839|NCT01168817|DRUG|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
219651675|NCT01332279|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
218964473|NCT01747018|BIOLOGICAL|Platelet-rich Plasma|
218964474|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
218964475|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
218964476|NCT02172053|OTHER|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
218964477|NCT02172053|OTHER|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
219651676|NCT01332279|OTHER|pharmacological study|Correlative studies
219651677|NCT01332279|RADIATION|external beam radiation therapy|Undergo EBRT
219651678|NCT01332279|GENETIC|microarray analysis|Correlative studies
218964478|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
218964479|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
218964480|NCT01017575|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
218964481|NCT01017575|DRUG|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
218964482|NCT01017575|DRUG|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
219651679|NCT04939675|DRUG|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
219651680|NCT04939675|DRUG|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
219651681|NCT04939675|DRUG|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
219651682|NCT01575275|DRUG|aminolevulinic acid|Given PO
219651683|NCT01575275|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219651684|NCT06622018|PROCEDURE|Seashell Nanoparticles and Gluma Desensitizer|Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
219062840|NCT01168817|DRUG|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
219651685|NCT04416737|DRUG|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
219651686|NCT03332628|DEVICE|Microneedle patch|Each patch contains 50 microneedles.
219651687|NCT01821209|PROCEDURE|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
219651688|NCT01472757|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
219651689|NCT01472757|DRUG|Placebo|Placebo delivered via a new dry powder inhaler
219651690|NCT06614296|PROCEDURE|Crenel Lateral Interbody Fusion|The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.
219651691|NCT06614296|PROCEDURE|Crenel lateral interbody fusion plus second stage surgery|The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
219651692|NCT06253741|PROCEDURE|PARAVERTEBRAL BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes
219686363|NCT06158035|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219686364|NCT06158035|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
219686365|NCT05288322|PROCEDURE|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
218964483|NCT01949285|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
218964484|NCT06438146|DRUG|Liraglutide|"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"
219062841|NCT01168817|DRUG|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
219062842|NCT05695859|DRUG|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
219062843|NCT03647514|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
219062844|NCT03647514|DRUG|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
219062845|NCT01056224|DRUG|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
218964485|NCT05445934|DRUG|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
218964486|NCT05445934|DRUG|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
218964487|NCT04401644|DIAGNOSTIC_TEST|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
218964488|NCT02854410|DIETARY_SUPPLEMENT|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
218964489|NCT02854410|DIETARY_SUPPLEMENT|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
218964490|NCT05344638|DRUG|AGS (Experimental)|tid
218964491|NCT05344638|DRUG|AGU (Active Comparator)|tid
219062846|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
219062847|NCT01705457|DRUG|placebo|
219651693|NCT06253741|PROCEDURE|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
219651694|NCT06253741|PROCEDURE|PLACEBO|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
219062848|NCT02501304|DEVICE|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
219651695|NCT03157739|BEHAVIORAL|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
219651696|NCT03768024|DRUG|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
219651697|NCT03768024|DRUG|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
219651698|NCT03768024|DRUG|Matching placebo|Matching placebo
219062849|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
219207956|NCT05990790|DRUG|Propofol|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
219651699|NCT02833935|BEHAVIORAL|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
219062850|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
219651700|NCT01194635|GENETIC|fluorescence in situ hybridization|
219651701|NCT01194635|GENETIC|gene expression analysis|
219651702|NCT01194635|GENETIC|polymerase chain reaction|
219651703|NCT01194635|GENETIC|protein analysis|
219651704|NCT01194635|GENETIC|protein expression analysis|
219651705|NCT01194635|OTHER|enzyme-linked immunosorbent assay|
218964492|NCT04586361|COMBINATION_PRODUCT|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
218964493|NCT04586361|COMBINATION_PRODUCT|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
219651706|NCT01194635|OTHER|immunohistochemistry staining method|
219651707|NCT01194635|OTHER|laboratory biomarker analysis|
219651708|NCT04007224|DRUG|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
219651709|NCT04007224|BIOLOGICAL|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
218964494|NCT04586361|OTHER|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
219062851|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
219207957|NCT02566889|DRUG|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
218964495|NCT06265779|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
218964496|NCT06265779|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
218964497|NCT06265779|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
218964498|NCT06278220|DEVICE|placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam )|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo pentacam and topolyzer examination to asses corneal high order aberrations before LASIK procedure.~Patients will be assigned to undergo LASIK. Follow up pentacam and topolyzer examination will be done 3 months after LASIK."
218964499|NCT04485429|DRUG|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
218964500|NCT04485429|DRUG|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
218964501|NCT01476644|OTHER|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
218964502|NCT01476644|OTHER|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
218964503|NCT01476644|OTHER|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
218964504|NCT02399618|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
218964505|NCT02922491|DIETARY_SUPPLEMENT|vitamin E|daily intake of vitamin E
219062852|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
219062853|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
219062854|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
219062855|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
219062856|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
219062857|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
218964506|NCT02922491|DIETARY_SUPPLEMENT|starch|daily intake of starch (control)
218964507|NCT01486485|DRUG|heparinized saline priming group|
219062858|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
219062859|NCT04036916|OTHER|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
219062860|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
219062861|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
219651710|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
219686366|NCT02989402|DRUG|Rivastigmine|15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
219651711|NCT02266290|PROCEDURE|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
219651712|NCT02266290|DEVICE|Sport tex® kinesiotape|
219651713|NCT02266290|DEVICE|Pretape Cramer®|
219651714|NCT02062996|DRUG|Oxymetazoline|
219651715|NCT02941796|DRUG|HCP1105|
219651716|NCT02941796|DRUG|HCP0918|
219651717|NCT02941796|DRUG|HCP0816|
219651718|NCT00070018|BIOLOGICAL|rituximab|250 mg/m\^2, as part of Zevalin regimen
218964508|NCT01486485|DRUG|nafamostat infusion after heparinized saline priming|
218964509|NCT00238511|DRUG|SPM 927|
218964510|NCT00095628|DRUG|ispinesib|Given IV
218964511|NCT00095628|OTHER|laboratory biomarker analysis|Correlative studies
218964512|NCT00095628|OTHER|pharmacological study|Correlative studies
218964513|NCT03777735|PROCEDURE|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
218964514|NCT04373668|BEHAVIORAL|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
218964515|NCT04373668|BEHAVIORAL|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
218964516|NCT04373668|BEHAVIORAL|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
218964517|NCT02201511|DRUG|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
219651719|NCT00070018|DRUG|Cyclophosphamide|750 mg/m\^2
218964518|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
218964519|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
218964520|NCT02201511|DRUG|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
218964521|NCT04271280|OTHER|Non-interventional|This is a non-interventional study.
218964522|NCT03555773|PROCEDURE|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
218964523|NCT03231982|DRUG|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
218964524|NCT03231982|DRUG|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
218964525|NCT00423696|BIOLOGICAL|bevacizumab|
218964526|NCT00423696|DRUG|capecitabine|
218964527|NCT00423696|DRUG|fluorouracil|
219651720|NCT00070018|DRUG|doxorubicin hydrochloride|50 mg/m\^2
218964528|NCT00423696|DRUG|irinotecan hydrochloride|
218964529|NCT00423696|DRUG|leucovorin calcium|
218964530|NCT02962154|RADIATION|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
218964531|NCT02962154|OTHER|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
219651721|NCT00070018|DRUG|prednisone|100 mg
218964532|NCT02962154|OTHER|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
219651722|NCT00070018|DRUG|vincristine sulfate|1.4 mg/m\^2
219651723|NCT00070018|RADIATION|radiation therapy|4000-5000 cGy total
219651724|NCT00070018|BIOLOGICAL|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
219651725|NCT00070018|BIOLOGICAL|Indium-111 ibritumomab tiuxetan|5 mCi
219651726|NCT01094652|DIETARY_SUPPLEMENT|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
219651727|NCT01094652|DIETARY_SUPPLEMENT|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
219651728|NCT02961062|DRUG|SAF312|
219651729|NCT02961062|DRUG|Placebo|
219651730|NCT03861871|DRUG|Fenfluramine Hydrochloride|Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
219651731|NCT02086825|DRUG|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
219651732|NCT02086825|DRUG|Lactulose|20g dose titrated
219651733|NCT02400866|DRUG|Olanzapine|
219651734|NCT02939716|OTHER|Rhubarb|300gm rhubarb
219651735|NCT02939716|OTHER|Bread|2 slices bread
219651736|NCT02939716|OTHER|Lettuce|300g lettuce
219651737|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
219651738|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
219651739|NCT00570349|DRUG|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
219651740|NCT00371644|BEHAVIORAL|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
219651741|NCT00371644|BEHAVIORAL|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
219651742|NCT02543892|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
218964533|NCT02962154|OTHER|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
218964534|NCT02962154|OTHER|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
218964535|NCT02962154|OTHER|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
218964536|NCT02962154|OTHER|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
218964537|NCT03276819|PROCEDURE|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
218964538|NCT03276819|BEHAVIORAL|Psychological and Sociological evaluation|Cohort B ....
218964539|NCT03276819|BEHAVIORAL|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
218964540|NCT03276819|BEHAVIORAL|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
219062862|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
218964541|NCT02765776|OTHER|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
218964542|NCT00190515|DRUG|5FU+l-leucovorin|5FU+l-leucovorin
218964543|NCT00190515|DRUG|UFT+Leucovorin|UFT+Leucovorin
218964544|NCT06404424|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
218964545|NCT06404424|DEVICE|Efferon CT|"Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
218964546|NCT01846520|OTHER|educational intervention|Receive FCPCI home education sessions
219062863|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
219062864|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
219062865|NCT00188526|DEVICE|lung biopsy|
219062866|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
219651743|NCT02543892|BIOLOGICAL|Placebo|Normal Saline
218964547|NCT01846520|BEHAVIORAL|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
219062867|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
219062868|NCT06280300|OTHER|health services intervention|Health services intervention
219062869|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
219651744|NCT06731426|BEHAVIORAL|CBM-TAF|CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.
218964548|NCT01846520|PROCEDURE|quality-of-life assessment|Ancillary studies
218964549|NCT01846520|OTHER|questionnaire administration|Ancillary studies
219062870|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
219062871|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
219651745|NCT06731426|BEHAVIORAL|CBM-SMP|CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
219651746|NCT00598546|BEHAVIORAL|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
219651747|NCT00821223|PROCEDURE|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
219651748|NCT00821223|PROCEDURE|manual small incision surgery|
219651749|NCT00821223|PROCEDURE|phacoemulsification|cataract surgery
219651750|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
219651751|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
219651752|NCT00785213|DRUG|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
218964550|NCT05000333|OTHER|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
218964551|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
219651753|NCT01656278|PROCEDURE|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)"
219651754|NCT01656278|OTHER|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2"
219651755|NCT01777568|DRUG|30% oxygen|Inspired oxygen will be maintained at 30%.
219651756|NCT01777568|DRUG|80% oxygen|Inspired oxygen will be maintained at 30%.
219651757|NCT03579628|DRUG|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
219651758|NCT05008393|DRUG|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
219651759|NCT05008393|DRUG|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
218964552|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
218964553|NCT02982512|DRUG|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
218964554|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 10 mg IV every 8 weeks
218964555|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 5mg IV every 8 weeks
218964556|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
218964557|NCT00744471|BIOLOGICAL|Placebo|Placebo to match tanezumab IV every 8 weeks
218964558|NCT01775462|DRUG|EDI200|3 or 10 mg/kg of EDI200
218964559|NCT02786524|BEHAVIORAL|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
218964560|NCT05596396|BEHAVIORAL|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
218964561|NCT05596396|BEHAVIORAL|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
218964562|NCT03978715|OTHER|No intervention-retrospective study|This is a retrospective study. No intervention
219651760|NCT05008393|DRUG|Placebo|Patients will receive placebo daily for 10 days.
218964563|NCT02034422|DIETARY_SUPPLEMENT|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
218964564|NCT02034422|OTHER|Exercise rehabilitation|8 weeks of exercise rehabilitation
218964565|NCT01511185|DRUG|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
218964566|NCT01511185|DRUG|placebo|A single dose administered subcutaneously in random order
219062872|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
219651761|NCT00103493|BEHAVIORAL|Motivational interviewing|
219651762|NCT00103493|BEHAVIORAL|Targeted DVD-based educational program|
219651763|NCT03760328|DEVICE|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
218964567|NCT02577783|DRUG|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
218964568|NCT02577783|DRUG|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
218964569|NCT04552730|DRUG|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
218964570|NCT01525173|DRUG|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
218964571|NCT01525173|DRUG|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
219651764|NCT00844480|DRUG|zoledronic acid|zoledronic acid, 5mg, iv
219651765|NCT00844480|DRUG|placebo|iv
219651766|NCT06730880|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (abbreviated PCR) is a laboratory technique for rapidly producing (amplifying) millions to billions of copies of a specific segment of DNA, which can then be studied in greater detail.
219651767|NCT03907930|PROCEDURE|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
219651768|NCT02490748|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
219651769|NCT02490748|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
218964572|NCT01525173|DRUG|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
218964573|NCT01525173|DRUG|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
219062873|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
219651770|NCT01028248|DRUG|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
219651771|NCT02951039|DRUG|Edoxaban|Prescribed according to approved label
219651772|NCT05563402|DEVICE|Atalante|Atalante Gait training: Using the Atalante System (self-reliant walking system), participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute).
219651773|NCT01734252|DRUG|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
219062874|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
219062875|NCT00931021|DRUG|Nicotine Patch|21 mg
219651774|NCT04636294|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
219651775|NCT03449394|OTHER|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
219651776|NCT01259375|DRUG|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
219651777|NCT00008775|DEVICE|Pressure support ventilation|
219651778|NCT03124121|DRUG|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
219651779|NCT03334318|OTHER|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
218964574|NCT03706222|DRUG|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
218964575|NCT04706416|DIETARY_SUPPLEMENT|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
218964576|NCT04706416|OTHER|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
219062876|NCT03827629|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
219062877|NCT03827629|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
219062878|NCT03827629|DRUG|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
219062879|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
219062880|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
219062881|NCT03835377|OTHER|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
219062882|NCT03835377|OTHER|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
219062883|NCT01517451|RADIATION|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
219651780|NCT03334318|OTHER|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
218964577|NCT01733849|OTHER|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
218964578|NCT01733849|OTHER|Data collection|Log books
219062884|NCT01517451|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
219062885|NCT02961140|OTHER|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
219062886|NCT02961140|OTHER|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
219062887|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
218964579|NCT04478331|BEHAVIORAL|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
218964580|NCT05294536|DRUG|Liraglutide injection,RD12014|single dose, s.c. injection
218964581|NCT05294536|DRUG|Liraglutide injection,Victoza|single dose, s.c. injection
218964582|NCT05091502|DIAGNOSTIC_TEST|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
218964583|NCT03455049|OTHER|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
218964584|NCT00425633|DRUG|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
218964585|NCT04385407|DRUG|Sofosbuvir + Simeprevir + Ribavirin|
218964586|NCT06207565|PROCEDURE|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
218964587|NCT06207565|PROCEDURE|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
219062888|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
219207958|NCT06952166|BEHAVIORAL|Qigong (Baduanjin)|Participants will receive 24 sessions of Baduanjin training over 12 weeks (2 sessions per week). Each session will last for 60 minutes. Baduanjin consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. The training will be delivered by an instructor after training by the project team.
219651781|NCT03334318|OTHER|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651782|NCT03334318|OTHER|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651783|NCT03334318|OTHER|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651784|NCT03334318|OTHER|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651785|NCT03334318|OTHER|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651786|NCT03334318|OTHER|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651787|NCT03334318|OTHER|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
219651788|NCT03334318|DRUG|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
219651789|NCT03334318|DRUG|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
218964588|NCT00249158|DRUG|Risperidone|
218964589|NCT03014492|DEVICE|Q Collar|Collar designed to mitigate slosh in the brain
218964590|NCT06403631|OTHER|observational|Data will be gathered longitudinally from participants newly diagnosed with multiple sclerosis. Participants will fill in online questionnaires measuring flow, mindfulness, positive mental health, anxiety and depression. The questionnaires, including both scaled and open-ended questions, will be proposed at the project start (T1) and 6 months later (T2).
219062889|NCT06395597|DIAGNOSTIC_TEST|Nine Hole Peg Test|3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
219062890|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
219651790|NCT02311556|DEVICE|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
219651791|NCT05009407|BIOLOGICAL|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
219651792|NCT02832141|PROCEDURE|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
219062891|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
219062892|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
219651793|NCT02832141|PROCEDURE|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
219686367|NCT04891302|DRUG|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
219686368|NCT04891302|DRUG|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
219686369|NCT00045799|DRUG|Omeprazole sodium bicarbonate immediate release PWD/FS|
219686370|NCT00045799|DRUG|Cimetidine IV|
218964591|NCT05261451|OTHER|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
218964592|NCT01736332|DRUG|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
219651794|NCT04808232|BEHAVIORAL|progressive muscle relaxation exercise|"We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body."
218964593|NCT01736332|OTHER|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
218964594|NCT04891731|DRUG|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
218964595|NCT02903212|BIOLOGICAL|Autologous apoptotic cells injection|cells injection
218964596|NCT01539317|DRUG|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
218964597|NCT01539317|DRUG|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
218964598|NCT04350398|OTHER|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
218964599|NCT04350398|OTHER|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
218964600|NCT01423149|DRUG|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
218964601|NCT01776385|OTHER|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
218964602|NCT01776385|OTHER|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
218964603|NCT01616082|BEHAVIORAL|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
218964604|NCT01616082|DRUG|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
219062893|NCT03535818|PROCEDURE|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
219651795|NCT05827575|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
219651796|NCT00508937|OTHER|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
219651797|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
219651798|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
219651799|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
219651800|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
219651801|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
219651802|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
219651803|NCT00914706|OTHER|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
219651804|NCT00478699|DRUG|Docetaxel/Cisplatin control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
219651805|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
219651806|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
219651807|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
219651808|NCT04060199|DRUG|Viltolarsen|IV infusion
219651809|NCT04060199|DRUG|Placebo|IV infusion
219651810|NCT01005888|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
219651811|NCT01005888|DRUG|Placebo (saline)|
219651812|NCT04993599|DEVICE|Social robot interaction|The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
219651813|NCT00044707|DRUG|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
219651814|NCT02371564|DEVICE|High flow humidified oxygen|
219651815|NCT02371564|DEVICE|Standard flow humidified oxygen|
219651816|NCT04308915|BEHAVIORAL|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
219651817|NCT04115410|DRUG|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
219651818|NCT04115410|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
219651819|NCT03669718|BIOLOGICAL|ISA101b|Every 3 weeks for a total of 3 times
219651820|NCT03669718|DRUG|Cemiplimab|Every 3 weeks for up to 24 months
219651821|NCT03669718|OTHER|Placebo|Every 3 weeks for a total of 3 times
219651822|NCT00669019|DRUG|saracatinib|
219651823|NCT02947906|OTHER|No intervention|No intervention
219651824|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
219651825|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
219651826|NCT05166720|BEHAVIORAL|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
219651827|NCT02846870|OTHER|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
219651828|NCT02846870|OTHER|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
219651829|NCT01864213|DRUG|Ametop cream|
218964605|NCT04705363|BEHAVIORAL|High Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used high dialectal variation that will guide participants through the interaction.
219651830|NCT00581542|DRUG|moxifloxacin|1-2 drops three times a day for 8-10 days.
219651831|NCT00581542|DRUG|polytrim|1-2 drops four times a day for 8-10 days.
219651832|NCT04341350|DRUG|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
219651833|NCT04341350|DRUG|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
219651834|NCT06552962|DEVICE|Whole body vibration|The aim of this study is to reveal the effect of exercises performed with WBV on the myofascial tissue of the lumbar region and the tone of superficial back muscles, as well as to investigate the effects on pain, function, muscle strength, balance, proprioception and endurance parameters, compared to the exercise-only group.
219651835|NCT06552962|BEHAVIORAL|lumbar stabilization exercises|The control group will undergo lumbar stabilization exercises twice a week for 6 weeks.
219651836|NCT03783403|DRUG|CC-95251|Specified dose on specified days
219651837|NCT03783403|DRUG|Rituximab|Specified dose on specified days
219651838|NCT03783403|DRUG|Cetuximab|Specified dose on specified days
219651839|NCT00656851|DRUG|Pioglitazone|30mg/day for 16 weeks
219651840|NCT00656851|BEHAVIORAL|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
219651841|NCT01391195|DEVICE|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
219651842|NCT00041106|DRUG|gemcitabine hydrochloride|Given IV
219651843|NCT00041106|DRUG|cisplatin|Given IV
219651844|NCT00041106|DRUG|gefitinib|Given PO
219651845|NCT00041106|OTHER|laboratory biomarker analysis|Correlative studies
219651846|NCT02348151|OTHER|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
219651847|NCT02348151|OTHER|Corridor|The volunteers will perform the shuttle walk test on the corridor
219651848|NCT06601322|OTHER|Pacemaker Interrogation and Electrocardiogram (ECG):|Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
219651849|NCT06601322|OTHER|Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR|Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
218964606|NCT04705363|BEHAVIORAL|Low Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used low dialectal variation that will guide participants through the interaction.
218964607|NCT04705363|BEHAVIORAL|Non-Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used no dialectal variation that will guide participants through the interaction.
218964608|NCT04705363|BEHAVIORAL|Text-only|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide participants through the interaction. No voice will accompany the photos or text.
218964609|NCT00976573|BIOLOGICAL|bevacizumab|Given IV
218964610|NCT00976573|DRUG|carboplatin|Given IV
218964611|NCT00976573|DRUG|everolimus|Given orally
218964612|NCT00976573|DRUG|paclitaxel|Given IV
218964613|NCT02847468|OTHER|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
218964614|NCT02847468|OTHER|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
218964615|NCT04322214|DRUG|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
218964616|NCT04322214|DRUG|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
218964617|NCT04322214|DRUG|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
218964618|NCT02370771|PROCEDURE|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
218964619|NCT02370771|DEVICE|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
219651850|NCT06601322|OTHER|Continuous pacemaker telemetry (CPT)|CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
219651851|NCT05667974|BIOLOGICAL|PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried|PIKA rabies vaccine
219651852|NCT05667974|BIOLOGICAL|Chirorab|Active Comparator
219651853|NCT03234517|DRUG|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
218964620|NCT02285660|PROCEDURE|4D PET-CT Scan|
218964621|NCT02285660|OTHER|No intervention|
218964622|NCT02531334|DIETARY_SUPPLEMENT|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
218964623|NCT02117427|BIOLOGICAL|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
218964624|NCT02054468|DRUG|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
218964625|NCT02054468|DRUG|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
219062894|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
219062895|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
219062896|NCT00700687|DRUG|PA32540|aspirin/omeprazole
218964626|NCT02054468|DRUG|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
218964627|NCT02054468|DRUG|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
218964628|NCT02054468|DRUG|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
218964629|NCT02054468|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
218964630|NCT02054468|DRUG|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
218964631|NCT02054468|DRUG|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
218964632|NCT02054468|DRUG|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
218964633|NCT01603238|DRUG|[14C]-LC15-0444|A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
218964634|NCT03638843|PROCEDURE|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
218964635|NCT03052543|DEVICE|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
218964636|NCT03843242|DEVICE|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
219062897|NCT00700687|DRUG|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
218964637|NCT03843242|DEVICE|Pacemaker with VpS® algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
219062898|NCT00700687|DRUG|aspirin and [NSAID]|aspirin and \[NSAID\]
219651854|NCT03234517|DRUG|Vaginal Probiotic|Vaginal Probiotic
219651855|NCT01058616|DRUG|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
218964638|NCT03843242|DEVICE|Pacemaker with IRSplus algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
218964639|NCT02788162|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
218964640|NCT04401527|DRUG|Sodium Nitrite|Continuous intravenous infusion of Sodium Nitrite Injection
218964641|NCT04401527|DRUG|Normal Saline|Continuous intravenous infusion of Normal Saline
218964642|NCT02125604|DRUG|dimethyl fumarate|capsules administered according to the prevailing product label
218964643|NCT04756674|OTHER|No intervetion will be used|No intervention will be used
218964644|NCT01876810|DRUG|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
218964645|NCT01876810|DRUG|Placebo|One lactose pill twice a day for two weeks.
218964646|NCT00548587|DRUG|E5555|
218964647|NCT00548587|DRUG|Placebo|
218964648|NCT04768907|DRUG|MaaT013|
218964649|NCT05733065|OTHER|saliva sample|Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.
218964650|NCT05733065|OTHER|questionnaire|Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
218964651|NCT02277613|BIOLOGICAL|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
218964652|NCT02277613|OTHER|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
218964653|NCT03816501|OTHER|music|The preference of the patients will be listened to preoperatively through the headphones
218964654|NCT03816501|OTHER|no music|the patients will not be listened
218964655|NCT04412161|PROCEDURE|Liver transplantation|Living donor liver transplantation
218964656|NCT02096874|DRUG|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
218964657|NCT02621710|OTHER|Questionnaire 3 months post-operatively|
218964658|NCT06006533|OTHER|taping|Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
218964659|NCT06006533|OTHER|massage|Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
218964660|NCT00248066|DRUG|RESTEN-MP|
218964661|NCT05025228|DRUG|Paracetamol|Paracetamol given orally or intravenously
219651856|NCT03841968|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
219651857|NCT03841968|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
219651858|NCT06012955|DEVICE|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
218964662|NCT05402410|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
218964663|NCT01030783|DRUG|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
218964664|NCT01030783|DRUG|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
218964665|NCT02966886|PROCEDURE|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version."
218964666|NCT02966886|PROCEDURE|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
219651859|NCT02094222|DRUG|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
219651860|NCT06452745|PROCEDURE|Colonoscopy|Colonoscopy performed as a regular practice during colorectal cancer screening.
219651861|NCT06452745|OTHER|Urine and FOBT collection|After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
219651862|NCT05960448|OTHER|Transcutaneous Spinal Cord Stimulation (TSCS)|This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
219651863|NCT05960448|OTHER|Sham Transcutaneous Spinal Cord Stimulation|This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
219651864|NCT01838434|DRUG|lenalidomide|given PO
218964667|NCT02966886|PROCEDURE|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
218964668|NCT04631484|DRUG|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
218964669|NCT04631484|DRUG|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
218964670|NCT06420466|BEHAVIORAL|Time-restricted Feeding|Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
218964671|NCT02789579|DRUG|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
218964672|NCT02789579|DRUG|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
218964673|NCT02789579|DRUG|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
218964674|NCT06666049|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric Ultrasound
218964675|NCT06995313|BEHAVIORAL|Biofeedback training|This is an audio-luminous stimulation on the micro perimeter that teaches the brain to use a different fixation locus on the retinal other than the fovea and develops visual attention to the surrounding retinal areas. 20 minutes exercises for stimulation are performed on the micro perimeter, once a week, for 5 weeks.
219651865|NCT01838434|DRUG|idelalisib|given PO
219651866|NCT03147859|BIOLOGICAL|Vedolizumab (brand name Entyvio)|IV infusion
219651867|NCT01454154|DRUG|Glyburide|Administered as specified in the Treatment Arm.
219651868|NCT01454154|DRUG|Placebo|Administered as specified in the Treatment Arm.
219651869|NCT04368039|DEVICE|Normobaric Oxygen|40% FiO2 for 4 weeks
219651870|NCT04368039|DEVICE|Placebo|21% FiO2 for 4 weeks
219651871|NCT03411980|DRUG|Vilaprisan (BAY1002670)|Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
219651872|NCT01639404|PROCEDURE|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
219651873|NCT01639404|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
219651874|NCT02291601|DRUG|Chlorhexidine Gluconate|comparison with other CHG products
218964676|NCT06995209|DIETARY_SUPPLEMENT|Placebo|20 g, \~74 Kcal, 97% flavored maltodextrin, similar in color, flavor, taste, and energy as PWS
218964677|NCT06995209|DIETARY_SUPPLEMENT|Pre-workout Supplement|20 g, \~73 Kcal, 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate, and 5 g branched chained amino acid (BCAA)
218964678|NCT05824741|BEHAVIORAL|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
218964679|NCT06277791|DRUG|Adebrelimab|Adebrelimab：20mg/kg, ivdrip, D1，Q3W
218964680|NCT06622070|DRUG|SPY002-072|Experimental
218964681|NCT06622070|OTHER|Placebo|Placebo
219062899|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
219062900|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
219062901|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
219651875|NCT02291601|OTHER|Vehicle|Excipients of CHG product only.
219651876|NCT02291601|DRUG|DynaHex-2|2% CHG solution
219651877|NCT03137901|DEVICE|Capstesia|Picture of the arterial waveform taken with a smartphone
219651878|NCT01712867|OTHER|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
219651879|NCT01712867|OTHER|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
219686371|NCT00765856|DRUG|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
219686372|NCT01715233|DRUG|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
219686373|NCT01715233|DRUG|Leucovorin|Leucovorin 400mg/m2 on Day 1
219651880|NCT06666894|OTHER|Intermittent fasting|subjects consumed 100 % of their energy needs in an 8-h period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. The remaining 16 h per 24-h period made up the fasting period. Subjects in the ND group consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. all patients will be subjected to 30 minutes mild aerobic exercise on treadmill.
219651881|NCT06666894|OTHER|Dietary approach to stop hypertension (DASH)|The USDA's 2015-2020 Dietary Guidelines for Americans recommend a healthy eating pattern, including a variety of vegetables, fruits, whole grains, fat-free dairy, protein, and oils. Limit saturated fats, trans fats, added sugars, and sodium to less than 10% daily calories, 10% saturated fat daily calories, and 2,300 mg sodium per day.
219651882|NCT03809767|DRUG|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
219651883|NCT00196729|DRUG|Thyrogen + Radioiodine (131I)|
219651884|NCT04755413|OTHER|Medical/Behavioral therapy|"* Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~* Overweight/Obese: Advise calorie reduction, dietician consultation.~* Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~* High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~  b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~  d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of \<55mg/dl in diabetes~* Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~* Diabetes management: HbA1c goal 6.5%"
219651885|NCT04755413|OTHER|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
219651886|NCT04755413|OTHER|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
219651887|NCT05262088|OTHER|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
219651888|NCT04995250|OTHER|corrective exercise training for knee|All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
219651889|NCT02704520|DIAGNOSTIC_TEST|High resolution MRI scan|MRI reporting of tumour but not mrTRG in the control arm = standard of care
219651890|NCT02704520|DIAGNOSTIC_TEST|mrTRG assessment|Watch and wait offered for good responders Consider further treatment for poor responders
219651891|NCT02688998|DEVICE|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
219651892|NCT01457586|BIOLOGICAL|Blood transfusion|Blood transfusion in perioperative period.
218964682|NCT04996498|DRUG|Oxytocin|intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
218964683|NCT04996498|OTHER|sterile bacteriostatic water ampule|a placebo drug similar in shape to oxytocin ampules
218964684|NCT06893185|OTHER|Dry cupping therapy|Dry cupping therapy will perform on the skin areas containing the EX-B2, A-shi, and GB21 acupuncture points every 3 days for 2 weeks.
219651893|NCT01457586|BIOLOGICAL|No blood transfusion|No transfusion in the perioperative period.
219651894|NCT00536549|DEVICE|Guardian RT|
219651895|NCT00536549|BEHAVIORAL|Education about the self monitoring blood glucose|
219651896|NCT04278651|DRUG|Ferumoxytol|510mg infusion x 2 doses 3-8 days apart
219651897|NCT04278651|DRUG|Ferrous Sulfate|325mg oral twice daily
219651898|NCT01931943|DRUG|selatinib ditosilate tablets|
219651899|NCT03360851|DIAGNOSTIC_TEST|low-dose CT|see arm/group description
219651900|NCT03360851|DIAGNOSTIC_TEST|PoC-PCR|see arm/group description
219651901|NCT00000753|DRUG|Atevirdine mesylate|
218964685|NCT06893185|OTHER|Electroacupuncture|Electroacupuncture therapy will be performed five times a week for 2 weeks. The acupoints are the Huatuojiaji (EX-B2), A-shi, and Jianjing (GB21).
219651902|NCT00000753|DRUG|Zidovudine|
218964686|NCT06118892|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
218964687|NCT06742710|DRUG|Liraglutide and metformin|Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
218964688|NCT06742710|DRUG|Metformin|Metformin 1500 mg/day until pregnancy
218964689|NCT05329584|DEVICE|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
218964690|NCT06748170|OTHER|ChatGPT|OpenAI's ChatGPT language model with chat interface.
218964691|NCT06754917|BEHAVIORAL|Face-Forward-Web|This is a self-administered web-based mind-body intervention that consists of 5 30-minute video sessions disseminating tailored relaxation, mindfulness, and cognitive-behavioral skills for COP. Ultimately, the Face-Forward-Web program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive coping behaviors.
219062902|NCT06535217|PROCEDURE|Liver transplantation|Liver transplantation
219651903|NCT00000753|DRUG|Zalcitabine|
219651904|NCT00000753|DRUG|Didanosine|
219651905|NCT00347919|DRUG|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
219651906|NCT00347919|DRUG|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
219651907|NCT00347919|DRUG|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
219651908|NCT00347919|DRUG|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
219686374|NCT01715233|DRUG|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
219686375|NCT01715233|DRUG|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
218964692|NCT06809894|PROCEDURE|Application of an action protocol for the management of delirium through the use of non-pharmacological interventions|The interventions carried out stand out for being non-pharmacological, this avoiding the use of drugs and polypharmacy in elderly patients, avoiding the appearance of clinical complications derived from the side effects that the use of these substances can lead to in the patient. In addition, it also encourages the education of health professionals and nurses' families or caregivers in the management of delirium.
218964693|NCT06809894|OTHER|Tradicional management of delirium|The use of the pharmacological treatment and the mechanical patients restrain were de base of the traditional treatment in deliriums patient in the University hospital of Igualada, because of the less knowledge of the professionals and non-existence protocol of non-pharmacological interventions to management the delirium.
218964694|NCT04840030|BEHAVIORAL|Multimodal intervention (MM-int)|"1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
218964695|NCT00323869|DRUG|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
218964696|NCT00323869|DRUG|Gemcitabine|Nucleoside analog
218964697|NCT00323869|DRUG|Carboplatin|Alkylating agent
218964698|NCT00000506|DRUG|fenfluramine|
218964699|NCT00000506|DRUG|phentermine|
218964700|NCT06577870|PROCEDURE|Hospitalization in intensive care or continuing care unit|Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
218964701|NCT00921245|DRUG|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
218964702|NCT05331248|BEHAVIORAL|Leaders in Action: Household Treatment|The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.
218964703|NCT05331248|BEHAVIORAL|Leaders in Action: Group Treatment|The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.
219062903|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
219651909|NCT01597375|DRUG|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
219651910|NCT01597375|DRUG|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
219651911|NCT03379753|OTHER|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
219651912|NCT01999998|RADIATION|Radiotherapy|
219651913|NCT01549561|BEHAVIORAL|Parent Training|16 weeks of parent training led by a trained group facilitator
219062904|NCT01999504|OTHER|PAL-2|meal
219062905|NCT01999504|OTHER|TFH-1|Meal
219062906|NCT01999504|OTHER|Reference|Meal
219062907|NCT00034762|DRUG|risperidone|
219062908|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
219062909|NCT02209324|DRUG|ASP2151|
219062910|NCT04679467|DIETARY_SUPPLEMENT|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
219062911|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
219651914|NCT01549561|BEHAVIORAL|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
219651915|NCT05001516|DRUG|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
219651916|NCT00155766|BIOLOGICAL|HPV16 E7 peptide-pulsed autologous DCs|
219651917|NCT01258062|DRUG|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
219651918|NCT01258062|DRUG|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
219651919|NCT05665972|OTHER|Mandala coloring|Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
219651920|NCT02059668|BIOLOGICAL|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
219651921|NCT02235051|BEHAVIORAL|exercise intervention|Undergo Curves exercise program
219651922|NCT02235051|OTHER|laboratory biomarker analysis|Correlative studies
219651923|NCT02235051|OTHER|questionnaire administration|Ancillary studies
219651924|NCT02235051|OTHER|quality-of-life assessment|Ancillary studies
219651925|NCT06618170|DIAGNOSTIC_TEST|Tissue surface analysis with the device|Usage of the device to analyse the presence or absence of tumoral membrane marker at the surface of the removed tumoral specimen
219651926|NCT06328816|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
219651927|NCT06328816|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
219651928|NCT04819503|DRUG|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
219651929|NCT04819503|DEVICE|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
219651930|NCT05284708|DEVICE|Atalante|Powered Exoskeleton
219651931|NCT01032239|DRUG|intrathecal baclofen|ITB test, implant, 6 months follow-up
219651932|NCT03173742|DRUG|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651933|NCT03173742|DRUG|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651934|NCT03173742|DRUG|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651935|NCT03173742|DRUG|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651936|NCT03173742|DRUG|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651937|NCT03173742|DRUG|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
219651938|NCT04688528|RADIATION|Dose de-escalation and / or Volume de-escalation|The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
219651939|NCT04159428|DIAGNOSTIC_TEST|HHIE-S survey score|"First, the patient will fill in the French translation of the HHIE-S questionnaire in the observation book.~* Secondly, he will perform the audiometry in silence test: for the tonal test in silence, we will test the frequencies 500, 1000, 2000 and 4000 hertz in each ear with pure tone sound. For the vocal in silence test, we will use the dissyllabic lists of words (Fournier's lists) at the intensities of 20, 30, 40, 50 and 60 decibels. This test will be in free-field conditions testing both ears.~* Thirdly, he will perform the speech in noise audiometry test that consists in repeating sentences pronounced at an equal intensity (60 decibels) while the intensity of the noise is increasing. This test will be in free-field conditions testing both ears."
219651940|NCT00383695|BIOLOGICAL|cetuximab|
219651941|NCT00383695|DRUG|capecitabine|
219651942|NCT00383695|DRUG|oxaliplatin|
219651943|NCT00383695|PROCEDURE|adjuvant therapy|
219651944|NCT00383695|PROCEDURE|conventional surgery|
219651945|NCT00383695|PROCEDURE|neoadjuvant therapy|
219651946|NCT00383695|RADIATION|radiation therapy|
219651947|NCT02118142|DIETARY_SUPPLEMENT|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
219651948|NCT02118142|DIETARY_SUPPLEMENT|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
219651949|NCT02226705|PROCEDURE|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
219651950|NCT01040195|DRUG|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
219651951|NCT01040195|DRUG|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
219651952|NCT02738255|DEVICE|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
218964704|NCT07052344|OTHER|Preload condition|Participants will consume a fixed compulsory preload meal of Campbell's Tomato soup (\~300 grams) 30 minutes after the baseline assessments. Fifteen minutes after consuming the preload meal, participants will receive the ad libitum test meal, consisting of a pre-weighed serving of Stouffer's Macaroni and Cheese (\~700 g).The pre-load condition will be completed at only one of two visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. Duration for the pre-load condition visit will be up to 6 hours
219651953|NCT00002038|DRUG|Fluconazole|
219651954|NCT00582504|BIOLOGICAL|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
218964705|NCT07052344|OTHER|Ad-libitum control condition|Participants will only consume the ad libitum test meal, which consists of a pre-weighted serving of Stouffer's Macaroni and Cheese (\~700 g). The ad-libitum meal will be consumed at both visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. The ad-libitum control condition visit will take up to 2 hours.
218964706|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
219207959|NCT06952166|BEHAVIORAL|Mindfulness-based intervention|Participants will receive mindfulness-based intervention with the same duration and frequency as qigong group. The intervention incorporates psychoeducation on mindfulness and stress management and group-based mindfulness practice about breathing, awareness of body sensations, thoughts, stretching, and walking. All the mindfulness practices are based on publicly accessible audio recordings. The training will be delivered by an instructor after training by the project team.
219651955|NCT00624195|DRUG|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
219651956|NCT06622447|DIETARY_SUPPLEMENT|βGluCnCs intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
219651957|NCT06622447|DIETARY_SUPPLEMENT|Placebo intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
219651958|NCT01576445|PROCEDURE|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
219651959|NCT01576445|PROCEDURE|medial parapatellar approach|medial parapatellar approach
219651960|NCT00602498|DRUG|Clarithromycin|
219651961|NCT06164847|BEHAVIORAL|AERO Program|HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
219651962|NCT06164847|OTHER|Standard Care|home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
219686376|NCT02198846|DEVICE|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
219686377|NCT02198846|DRUG|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
219686378|NCT06309667|DRUG|PG-102(MG12)|GLP-1 and GLP-2 fusion protein
218964712|NCT06034002|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
218964713|NCT06034002|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
218964714|NCT02502162|DRUG|LDN|
218964715|NCT02502162|DRUG|Placebo|Sugar pill
218964716|NCT07117708|OTHER|Early Surgical Consent|Surgical consent for possible cesarean delivery will be completed upon arrival to labor and delivery before induction of labor begins
218964717|NCT07117708|OTHER|Surgical Consent if Clinically Indicated|Surgical consent for possible cesarean delivery will be completed if it appears clinically indicated during a participant's induction of labor.
218964718|NCT06362226|DRUG|Steroid/Antibiotic (Maxitrol)|Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
218964719|NCT06362226|DRUG|5-FU/Kenalog|Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
218964720|NCT07126912|DEVICE|Alcarisa (hyaluronic acid filler)|A single injection of Alcarisa filler with a maximum dose of 2 to 4 cc , was administered in the zygomaticomalar area, and if deemed appropriate by the physician, also in the anteromedial cheek and submalar areas on each side of the face.
219651963|NCT01567345|DEVICE|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
219651964|NCT01567345|DEVICE|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
219651965|NCT05989074|DEVICE|ALLEGRA TAVI System TF|Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital
219651966|NCT05989074|DEVICE|Ballon-expandable valve system|Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
219651967|NCT05498103|DRUG|Methazolamide 25 MG|25 mg tablets
219651968|NCT05498103|DRUG|Methazolamide 50 MG|50 mg tablets
219651969|NCT01940900|DRUG|E10030|
219651970|NCT01940900|DRUG|ranibizumab|
219651971|NCT01940900|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
218964721|NCT06934161|PROCEDURE|dynamic computer-guided Corticotomy|corticotomy cuts were made guided by a dynamic navigation system, ensuring accuracy and reducing the risk of injuries
218964722|NCT06934161|PROCEDURE|static computer-guided Corticotomy|corticotomy cuts were made guided by a static system (using reticulated surgical template), ensuring accuracy and reducing the risk of injuries
218964723|NCT06934161|DIAGNOSTIC_TEST|smartphone-based thermography|a Mini2 Infrared Smartphone Camera (Hangzhou HIKMICRO Sensing Technology Co., China) was initially calibrated with the surrounding ambient temperature. The calibration phase was essential as it enabled the device's algorithm to have a reference point based on the surrounding conditions and eliminate any bias caused by varying environmental temperatures. Then, pre-operative temperatures of attached gingiva and alveolar mucosa surfaces were recorded. The measurements were registered by distinguishing, for both arches, the temperature corresponding to soft tissues from incisor region (from central incisor to homolateral canine), premolar region (first and second premolars), and molar region (first and second molars).
218964724|NCT01683019|DEVICE|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
218964725|NCT01683019|DEVICE|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
218964726|NCT01343927|BEHAVIORAL|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
218964727|NCT01343927|BEHAVIORAL|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
218964728|NCT01343927|BEHAVIORAL|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
218964729|NCT04604158|BEHAVIORAL|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
218964730|NCT06275607|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
219062912|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
219062913|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
219062914|NCT05799495|DRUG|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
219062915|NCT05799495|DRUG|Placebo|Placebo
219062916|NCT06299501|PROCEDURE|Routine questions|The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
219062917|NCT06299501|PROCEDURE|Questions on evidence based indication|The group of nurses will receive training and supervision and will ask questions on evidence based indication
219062918|NCT06299501|PROCEDURE|Treatment as usual|The group of nurses will ask questions when suspecting ongoing violence in the family
219062919|NCT03105362|DIETARY_SUPPLEMENT|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
219062920|NCT02038738|DRUG|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
219651972|NCT00161642|DRUG|CMD-193|
219651973|NCT00744549|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
219651974|NCT00744549|DRUG|Placebo|Twice a day with meals.
219651975|NCT03098498|PROCEDURE|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
219651976|NCT02835651|DIETARY_SUPPLEMENT|Palmitic acid|Experimental products are enriched with C16:0
219651977|NCT02835651|DIETARY_SUPPLEMENT|Stearic acid|Experimental products are enriched with C18:0
219651978|NCT03839290|PROCEDURE|Early neonatal cheiloplasty|
218964731|NCT06275607|BEHAVIORAL|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
219062921|NCT06477445|DEVICE|Visual feedback balance training system|Using an visual feedback balance training system to provide a dynamic balance training platform for patients to perform balance training based on visual feedback.
219062922|NCT06477445|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
219651979|NCT00483197|DEVICE|VentrAssistTM Left Ventricular Assist Device|
219651980|NCT00654992|DRUG|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
219651981|NCT00654992|DRUG|Normal Saline|300 IU/kg of normal saline intravenously before surgery
219651982|NCT02481401|BEHAVIORAL|Intensive Individual Intervention Program|
219651983|NCT02481401|BEHAVIORAL|Peer-To-Peer Program Intervention|
219651984|NCT02225366|BIOLOGICAL|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
219062923|NCT06477445|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
219651985|NCT02225366|OTHER|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
219651986|NCT06202664|PROCEDURE|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
219651987|NCT06202664|DRUG|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
219651988|NCT01292694|DRUG|Losartan|Oral, single-dose, 50 mg tablet
219651989|NCT01292694|DRUG|Captopril|Oral, single-dose, 50 mg tablet
219651990|NCT01292694|DRUG|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
218964732|NCT01570920|BEHAVIORAL|physical training|walking many times a week
218964733|NCT05732220|BEHAVIORAL|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
218964734|NCT05732220|BEHAVIORAL|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
218964735|NCT05732220|BEHAVIORAL|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
218964736|NCT01645904|BEHAVIORAL|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
219651991|NCT01512069|BEHAVIORAL|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
219651992|NCT01512069|BEHAVIORAL|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
219651993|NCT03475199|DEVICE|FabLife|"* A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility."
219651994|NCT02012465|BIOLOGICAL|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~* Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~* The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
219686379|NCT06309667|OTHER|Placebo|Placebo drug of PG-102(MG12)
219686380|NCT05970965|PROCEDURE|Biological sampling|\- Saliva and blood sampling
219686381|NCT04786691|OTHER|Addition of half and half to coffee|1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
218964737|NCT01645904|BEHAVIORAL|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
218964738|NCT01645904|BEHAVIORAL|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
218964739|NCT01645904|BEHAVIORAL|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
218964740|NCT01015053|PROCEDURE|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
219062924|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
218964741|NCT01015053|PROCEDURE|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
218964742|NCT02373878|BEHAVIORAL|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
218964743|NCT02373878|BEHAVIORAL|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
219062925|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
218964744|NCT05640804|DRUG|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
219651995|NCT06622811|OTHER|Students' Knowledge about Virtual Reality Questionnaire|"Part I: Personal Characteristics of Nursing Students:~It covers; age and gender.~Part II: Students' Knowledge about Virtual Reality Questionnaire:~This part will used to assess students' knowledge related to virtual reality that includes a definition of virtual reality, history of virtual reality, advantages and disadvantages of virtual reality on nursing education and equipment used for virtual reality and the effect virtual reality on future of education~Scoring system:~Respondents' answers will be scored (0) for incorrect answers, and (1) for correct answers. The overall items scores will be summed up and categorized according to the total percentages of unsatisfactory (\<60%) and satisfactory (≥60%)."
219651996|NCT06622811|OTHER|California Critical Thinking Disposition Inventory (CCTDI)|"It will consist of 24 items classify into 7 dimensions grouped as follows; truth-seeking (3 items); open-mindedness (4 items); analyticity (3 items); systematicity (4 items); critical thinking self-confidence (4 items); inquisitiveness (3 items); and cognitive maturity (3 items).~Scoring system:~Students asked to respond to all items with six points Likert scale as follows; strongly disagree = 1, disagree= 2, neutral = 3, sometimes agree = 4, agree = 5, and strongly agree= 6. The overall items scores will be summed up and categorized according to the total percentages of satisfactory critical thinking (≥75%) and unsatisfactory critical thinking (\<75%)."
219651997|NCT02426749|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
219651998|NCT02426749|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
219651999|NCT01797081|BIOLOGICAL|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
219652000|NCT01797081|BIOLOGICAL|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
218964745|NCT05640804|DRUG|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
219652001|NCT01797081|OTHER|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
219652002|NCT03762928|DRUG|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
219652003|NCT03762928|DRUG|midazolam|single administration of midazolam 2 mg oral solution
219652004|NCT03762928|DRUG|efavirenz|single administration of efavirenz 50 mg capsule
219652005|NCT04868851|BEHAVIORAL|Here for Health Only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
218964746|NCT03457688|DIETARY_SUPPLEMENT|prebiotic inulin-type fructans|
218964747|NCT03457688|DIETARY_SUPPLEMENT|placebo maltodextrin|
218964748|NCT05533723|PROCEDURE|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
218964749|NCT05533723|PROCEDURE|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
218964750|NCT00950287|DEVICE|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
218964751|NCT04629885|DRUG|Oxytocin 400 IU vaginal gel|
218964752|NCT04629885|DRUG|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
218964753|NCT05415683|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
218964754|NCT00032097|DRUG|motexafin gadolinium|
218964755|NCT00032097|RADIATION|radiation therapy|
218964756|NCT05023798|DEVICE|ATD (device test)|Medical device test (no intervention)
218964757|NCT04832087|DRUG|Teduglutide|Standard of care Teduglutide dosing
218964758|NCT00543855|DRUG|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
219652006|NCT04868851|BEHAVIORAL|mHealth technology assisted exercise counselling|Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
219652007|NCT03480191|DRUG|Daptomycin|Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
219652008|NCT05077176|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
219652009|NCT05077176|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
219652010|NCT03624062|DRUG|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
219652011|NCT02767492|DEVICE|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
219652012|NCT02767492|DRUG|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
219652013|NCT01177709|DRUG|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
218964759|NCT00543855|DRUG|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
218964760|NCT00543855|DRUG|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
218964761|NCT00543855|DRUG|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
218964762|NCT02732522|DRUG|Sublingual misoprostol|
218964763|NCT02732522|DRUG|Vaginal misoprostol|
218964764|NCT01459939|DIETARY_SUPPLEMENT|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
218964765|NCT01459939|DIETARY_SUPPLEMENT|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
218964766|NCT00967928|DRUG|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
219062926|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
219062927|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
219652014|NCT00796705|DRUG|Adalimumab|40 mg injection of adalimumab administered subcutaneously
219652015|NCT00796705|DRUG|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
219652016|NCT00796705|DRUG|Etanercept|50 mg dimeric fusion protein administered subcutaneously
219652017|NCT00831545|DRUG|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
218964767|NCT00967928|DRUG|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
218964768|NCT00967928|RADIATION|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
218964769|NCT04727281|OTHER|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
218964770|NCT00386971|DIETARY_SUPPLEMENT|L-carnitine|3 grams daily in liquid form by mouth
218964771|NCT00386971|OTHER|placebo|1 oz sweet tasting liquid daily by mouth
219652018|NCT06666790|DEVICE|Scan with elastic scattering spectroscopy device to assess risk of malignancy|Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
219652019|NCT02251106|DEVICE|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
219652020|NCT05565443|DEVICE|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
219652021|NCT02375555|DRUG|Lenalidomide|
219652022|NCT02375555|DRUG|Elotuzumab|
219652023|NCT02375555|DRUG|Bortezomib|
219652024|NCT02375555|DRUG|Dexamethasone|
219652025|NCT02375555|PROCEDURE|Stem Cell Mobilization|
219652026|NCT02267772|DRUG|IV Acetaminophen|IV Acetaminophen
219652027|NCT02267772|DRUG|IV Morphine|IV Morphine
219652028|NCT05253716|OTHER|ONS|Immunonutritional supplement
219652029|NCT04926103|OTHER|Fecal Microbiota transplant (FMT)|Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
219652030|NCT03111472|OTHER|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
218964772|NCT04969796|OTHER|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
218964773|NCT02974101|OTHER|registration of AdaptiveStim|
218964774|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
218964775|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
219652031|NCT03809468|OTHER|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
219652032|NCT05030909|BEHAVIORAL|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
219652033|NCT06712966|OTHER|EngageRx_SMBP|Patients in the EngageRx\_SMBP arm will be automatically registered in the CareSimple system and mailed a device they can use at home. They may also choose to install a smartphone application from CareSimple that will provide reminders about measuring their BP. The clinician will then manage the patient's hypertension according to the standard of care. The SMBP measurements from CareSimple will be available through EngageRx for them to use, and they will receive a weekly staff message to check EngageRx if there are new SMBP measurements for them to review. The clinician will also be able to indicate when they would like to stop using the CareSimple system.
219652034|NCT02141815|DIETARY_SUPPLEMENT|Arabinoxylan-oligosaccharides|
219652035|NCT02141815|DIETARY_SUPPLEMENT|Maltodextrine|
219652036|NCT03404349|BEHAVIORAL|Mindfulness for Adolescence Course|There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
219652037|NCT04805580|PROCEDURE|unilateral intrathecal block|Quadratus lunborum block
219652038|NCT03065959|DRUG|reldesemtiv|oral
219652039|NCT03065959|DRUG|Placebo|oral
219652040|NCT01565369|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
219652041|NCT03136458|PROCEDURE|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
219652042|NCT03136458|DRUG|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
219652043|NCT00224458|DRUG|Truvada|
219652044|NCT00224458|DRUG|efavirenz|
219652045|NCT06505915|DIETARY_SUPPLEMENT|Pre op Carbohydrate drink|Lemon flavoured clear carbohydrate drink
219652046|NCT06505915|OTHER|Clear fluid as per sip til send policy|clear fluid such as water
219652047|NCT06563544|DEVICE|FCV|90 minutes of FCV
219686382|NCT04786691|OTHER|Addition of non-dairy creamer to coffee|1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
219686383|NCT04786691|OTHER|Black|No Creamer
219686384|NCT03801642|DRUG|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
219686385|NCT03801642|OTHER|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
219652048|NCT05928559|OTHER|OMRON BF511 Body Composition Monitor|The OMRON BF511 Body Composition Monitor is a digital scale and participants' body compositions will be evaluated with this device. The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test and the maximum oxygen consumption levels will be calculated with the help of the formula with the data obtained from this test. The trunk extensor muscle endurance of the participants will be evaluated with the Biering-Sorensen Test and the trunk flexor endurance will be evaluated with the Kraus-Weber Test. Participants' M. Quadriceps, M. Hamstring, M. Biceps Brachii and M. Triceps Brachii muscle strengths will be evaluated with MicroFET® 2 hand dynamometer.
219652049|NCT06886048|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
218964776|NCT02723253|RADIATION|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
218964777|NCT02723253|DRUG|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
218964778|NCT04491097|DEVICE|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
218964779|NCT04491097|DEVICE|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
218964780|NCT05054244|OTHER|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
218964781|NCT05054244|PROCEDURE|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
218964782|NCT02284971|BIOLOGICAL|CDX1127|
218964783|NCT02284971|RADIATION|SBRT|
218964784|NCT03565471|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography.
218964785|NCT03565471|DIAGNOSTIC_TEST|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
218964786|NCT03565471|DIAGNOSTIC_TEST|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
218964787|NCT03565471|DIAGNOSTIC_TEST|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
218964788|NCT04509739|BEHAVIORAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
218964789|NCT05537090|DRUG|BV100|Rifabutin for Infusion
218964790|NCT05537090|DRUG|Midazolam|Syrup for oral administration
218964791|NCT06432634|OTHER|Standard care|The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.
219062928|NCT01198600|DEVICE|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
219062929|NCT01198600|DEVICE|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
219062930|NCT01198600|DEVICE|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
219062931|NCT03694548|BEHAVIORAL|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
219062932|NCT03694548|BEHAVIORAL|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
219062933|NCT02256475|DRUG|NBI-98854|
219652050|NCT01996410|DEVICE|Acupuncture|
219652051|NCT00154232|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219652052|NCT06076018|DRUG|Group morphine|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
219652053|NCT06076018|OTHER|Group placebo|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
219652054|NCT06124755|DEVICE|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
219652055|NCT06124755|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
218964792|NCT06432634|OTHER|Comprehensive pulmonary rehabilitation programs|"1. Warm-up and cool-down exercises: stretching various muscle groups for a duration of 15 to 20 minutes and a slow 3-minute walk~2. Aerobic training: using a lower-limb cycle ergometer for a duration of 30 to 40 minutes. Initiated warm-up at 0 wattages for 5 minutes. Incrementally increased wattages within 5-10 minutes until reaching the 40-80% heart rate reserve or 4 to 6 of modified Borg scale for at least 20 minutes. Concludes with a 5-minute cool-down period at 10 wattages.~3. The resistance training involves both upper and lower limbs:~（1） Upper Limb Resistance Training: Shoulder lift, abduction, and horizontal abduction exercises are performed. Each exercise is repeated for three sessions comprising 10 repetitions each. A 0.5-2 kg dumbbell is utilized for resistance.~（2） Lower Limb Resistance Training: Sit-to-stand exercises are performed. Each session consists of three sets of 10 repetitions."
218964793|NCT05887375|DRUG|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
219062934|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
219652056|NCT05380284|OTHER|Senior Driving Simulation Training|The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
219652057|NCT05380284|OTHER|Waiting list control|The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.
219652058|NCT05545384|DRUG|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
219652059|NCT05545384|DRUG|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
219652060|NCT05545384|DRUG|Standard of care|Patients in this group will be treated according to standard care
219652061|NCT05238870|OTHER|Interviews for the needs analysis. No intervention.|To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
219652062|NCT05161208|DRUG|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
219652063|NCT05161208|DRUG|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
219652064|NCT04907643|DEVICE|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
218964794|NCT05887375|DRUG|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
218964795|NCT05887375|DRUG|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
219062935|NCT06530953|BEHAVIORAL|Patient Navigator Model|The patient navigator model is an evidence-based intervention to improve access to healthcare services.
219207960|NCT06952166|BEHAVIORAL|Physical exercise|Participants of the physical exercise group will receive training of a series of low-to-moderate intensity physical activities for the same duration and frequency as qigong group. The physical activities include stretching, flexibility exercise, balance exercise, and aerobic exercise. The training will be delivered by an instructor after training by the project team.
219207961|NCT06500572|OTHER|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
219207962|NCT06500572|OTHER|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
219652065|NCT00940680|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
219652066|NCT00940680|DRUG|Losartan|losartan 100mg q.d.
219652067|NCT02559791|BIOLOGICAL|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
219652068|NCT02559791|DRUG|Placebo|Matching placebo once monthly for 2 months
219207963|NCT06500572|OTHER|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
219652069|NCT02973113|BIOLOGICAL|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
219652070|NCT02973113|BIOLOGICAL|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
219652071|NCT06617247|DRUG|Intervention1: Cannabidiol|Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
219652072|NCT06617247|DRUG|Intervention 2: Placebo|In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (
219652073|NCT06808074|DRUG|Inhaled amikacin|Dosage of amikacin: 20 mg/kg based on ideal body weight, with a maximal dose of 2 g, once daily for 3 consecutive days.
219652074|NCT06808074|DRUG|Placebo|The equivalent volume of saline solution (0.9% sodium chloride \[NaCl\]) will be administered once daily for three consecutive days
219652075|NCT01744184|DRUG|Entonox|Entonox arm
219652076|NCT01744184|DRUG|Midazolam|up to 5mg midazolam as appropriate
218964796|NCT05887375|DRUG|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
218964797|NCT06358131|DEVICE|Endoscopy|upper and lower endoscopy
218964798|NCT04444895|DRUG|Lanadelumab|Lanadelumab SC injection
218964799|NCT05085288|DEVICE|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
218964800|NCT05085288|OTHER|Turning population every two hours|The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
218964801|NCT02395510|DRUG|Vortioxetine|Vortioxetine 5-20mg
218964802|NCT00749580|DRUG|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
218964803|NCT04732169|DRUG|Active study drug ( oral CBD)|CBD in single dose syringes
218964804|NCT04732169|DRUG|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
218964805|NCT00000656|DRUG|Zidovudine|
218964806|NCT00000656|DRUG|Didanosine|
218964807|NCT02725853|DEVICE|tDCS|Application of 1.5 mA tDCS for 30 minutes
218964808|NCT02725853|DEVICE|sham tDCS|Application of sham tDCS for 30 minutes
218964809|NCT02725853|BEHAVIORAL|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
218964810|NCT02725853|BEHAVIORAL|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
218964811|NCT05417243|OTHER|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
218964812|NCT01670318|DEVICE|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
218964813|NCT04758910|DEVICE|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
219652077|NCT06857825|BEHAVIORAL|Implementation of Infection Control Link Nurses (ICLNs)|"Infection Control Link Nurses (ICLNs) are clinical nurses, working in direct nursing care, with an interest and expertise on infection control practice. They work with constant and direct support by the IPC hospital team, and they are required to follow a training course with numerous scheduled meetings about IPC-related issues.~They will be selected via spontaneous application or identified by their Head Nurses. All ICLNs activities are to be completed during working hours, they still maintain their clinical nursing role, but in addition they implement and translate IPC-measures into clinical practice by observing, monitoring and analyzing data on compliance with hand hygiene, compliance with standard and isolation precautions, healthcare-associated infections and other IPC-related issues"
219652078|NCT06896630|DRUG|Tenofovir Disoproxil Fumarate (TDF)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
219652079|NCT04542421|DIAGNOSTIC_TEST|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
219652080|NCT02336360|DRUG|Flortaucipir F18|No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
219652081|NCT02339480|OTHER|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
219652082|NCT05301179|OTHER|Protein quantity and quality|Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
218964814|NCT04758910|DEVICE|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
218964815|NCT05830903|BEHAVIORAL|VR-assisted occupational training|VR-assisted occupational training
219652083|NCT06327087|OTHER|No intervention|Observational study in the late follicular and mid-luteal phase
219652084|NCT03586505|DEVICE|Light exposure|"The 6 lights used randomly are :~* 482nm =standard blue light illumination,~* 650nm,~* 675nm,~* 700nm,~* 750nm~* 800nm"
218964816|NCT00272428|BEHAVIORAL|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
218964817|NCT02929173|OTHER|Allceram|Pressed E-max coping veneered with E-max veneering system
218964818|NCT02929173|OTHER|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
218964819|NCT04152031|OTHER|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
218964820|NCT02119169|DEVICE|Pigtail catheter|pigtail catheter for pleural drainage
218964821|NCT02587039|PROCEDURE|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
218964822|NCT02587039|BEHAVIORAL|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
219652085|NCT00141245|DRUG|Pregabalin|
218964823|NCT05281952|PROCEDURE|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
219062936|NCT02046434|DRUG|Glycerol Phenylbutyrate|
219062937|NCT02950493|OTHER|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
219062938|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
219062939|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
219652086|NCT02754674|PROCEDURE|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
219652087|NCT06668844|PROCEDURE|Endoscopic direct Draf IIa|Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy
219652088|NCT06668844|PROCEDURE|Endoscopic angled Draf IIa|Group BFrontal sinusotomy using angled endoscopeand instruments
219652089|NCT01095978|DRUG|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
218964824|NCT05281952|PROCEDURE|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
218964825|NCT00182871|DRUG|testosterone|
218964826|NCT05041946|DRUG|Methylphenidate|Given PO
218964827|NCT05041946|OTHER|Placebo (Sugar Pill)|Given PO
218964828|NCT01941043|DRUG|CERC-301|
218964829|NCT01941043|OTHER|Placebo|
218964830|NCT05201742|OTHER|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
218964831|NCT05201742|OTHER|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
218964832|NCT02588937|DRUG|EntecaBell ODT. 0.5mg|
218964833|NCT02588937|DRUG|Baraclude Tab. 0.5mg|
218964834|NCT02556827|OTHER|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
218964835|NCT02556827|DEVICE|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
218964836|NCT02556827|DEVICE|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
219062940|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
219207964|NCT05858879|OTHER|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
219652090|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
219652091|NCT02135107|DRUG|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
219652092|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
219652093|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
219652094|NCT05523011|DRUG|Exosome ointment|100 µg MSC exosomes/g ointment
219652095|NCT06323746|DEVICE|Denneroll cervical traction orthodontic|The duration of each session will start at approximately three minutes and increase by one minute per session until reaching the goal of 20 minutes per session. The intervention will be repeated three times per week for 10 weeks in the supervised setting.
219652096|NCT01846429|DRUG|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
218964837|NCT02556827|DEVICE|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
219652097|NCT00489229|DRUG|Rosiglitazone|
219652098|NCT00489229|DRUG|Ramipril|
219652099|NCT00808639|DRUG|Methotrexate|intravenously 30mg/m2 over 30 minutes
219652100|NCT00808639|DRUG|Doxorubicin|intravenously 30mg/ms over 15 minutes
219652101|NCT00808639|DRUG|vinblastine|intravenously 3mg/m2 over 30 minutes
219652102|NCT00808639|DRUG|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
219652103|NCT00808639|DRUG|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
219652104|NCT02266472|DRUG|metformin|single dose of metformin given as tablets
219652105|NCT02266472|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
219652106|NCT02266472|DRUG|empagliflozin|single dose of empagliflozin given as tablet
219652107|NCT06667986|OTHER|artificial intelligence models (YOLO and Mask-RCNN)|machine learning model will used to detect secondary caries around restorations by comparing the results with digital bitewing radiography
219652108|NCT00432224|PROCEDURE|photodynamic therapy|
219652109|NCT01585753|DRUG|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
219652110|NCT01585753|DRUG|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
219652111|NCT01585753|DRUG|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
219652112|NCT00409968|PROCEDURE|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
219652113|NCT00288067|DRUG|fenretinide|Given PO
219652114|NCT00288067|DRUG|rituximab|Given IV
219652115|NCT06414824|DEVICE|Intermittently Scanned Continuous Glucose Monitoring|FreeStyle Libre, 4 weeks
219652116|NCT06414824|DEVICE|Standard Blood Glucose Monitoring|Standard blood glucose monitoring with glucose meters
219652117|NCT04635124|BEHAVIORAL|Dog visit|An visitor visits the participant with a dog
218964838|NCT04014023|DRUG|DWP16001|DWP16001 tablets
218964839|NCT04014023|DRUG|Placebo|DWP16001 placebo-matching tablets
218964840|NCT00905827|BEHAVIORAL|CAMS|Collaborative assessment management in suicidality
218964841|NCT04467931|DRUG|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
219207965|NCT04518943|BEHAVIORAL|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
219652118|NCT04635124|BEHAVIORAL|Encourage to engage in activity|In each visit the visitor invites the participant to engage in an activitty
219652119|NCT06204471|DEVICE|Helite hip protector|hip protector
219652120|NCT06204471|DEVICE|Wolk hip protector|Hip protectdor
219652121|NCT04894552|PROCEDURE|Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma|Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
219652122|NCT04737395|DEVICE|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
219652123|NCT04025931|DRUG|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
219652124|NCT04779580|PROCEDURE|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
219652125|NCT04779580|PROCEDURE|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
218964842|NCT04467931|DRUG|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
219062941|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
219652126|NCT04497376|PROCEDURE|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
219652127|NCT04497376|PROCEDURE|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
219652128|NCT05040672|BEHAVIORAL|questionare online application|questionare online application
219652129|NCT03055494|BIOLOGICAL|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
219652130|NCT03055494|BIOLOGICAL|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
218964843|NCT04467931|DRUG|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
218964844|NCT04467931|DRUG|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
218964845|NCT06086691|OTHER|Strength Training with Caffeine|"The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
218964846|NCT06086691|OTHER|Endurance Training with Caffeine|"The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
218964847|NCT00509392|DEVICE|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
218964848|NCT00509392|DEVICE|Endovenous Laser|laser catheter
218964849|NCT02857179|PROCEDURE|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
219062942|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
219062943|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
219062944|NCT00900484|OTHER|biologic sample preservation procedure|
219062945|NCT00900484|OTHER|immunohistochemistry staining method|
219062946|NCT00900484|OTHER|laboratory biomarker analysis|
219062947|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
219062948|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
219062949|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
219062950|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
219062951|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
219652131|NCT00662428|OTHER|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
219652132|NCT00662428|OTHER|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
219652133|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
219652134|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
219652135|NCT04692324|OTHER|Survey Administration|Ancillary studies
219652136|NCT05732116|OTHER|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
219652137|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
219652138|NCT03383081|BIOLOGICAL|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
219062952|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
219062953|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
219062954|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
219062955|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
219062956|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
219062957|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
219062958|NCT01723891|DRUG|Surfolase capsule|
219062959|NCT01723891|DRUG|HT-002-01|
219062960|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
219062961|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
219062962|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
219062963|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
219652139|NCT03383081|BIOLOGICAL|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
219652140|NCT03383081|PROCEDURE|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
219652141|NCT04867967|BEHAVIORAL|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
219652142|NCT04867967|BEHAVIORAL|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
219652143|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
219652144|NCT06315517|OTHER|Conventional lactose-free cow's milk|"Participants will receive conventional lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
218964850|NCT04119310|OTHER|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
218964851|NCT04119310|OTHER|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
219062964|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
219652145|NCT06315517|OTHER|Nonconventional (A2) cow's milk|"Participants will receive nonconventional (A2) cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
219652146|NCT06315517|OTHER|Nonconventional (A2) lactose-free cow's milk|"Participants will receive nonconventional (A2) lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
219652147|NCT05961930|BEHAVIORAL|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
219652148|NCT05399043|OTHER|Multidisciplinary Conventional Neuromotor Rehabilitation|Patients will receive conventional treatment consisting of two daily one-hour session (4 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
219652149|NCT05399043|DEVICE|Technology-based Rehabilitation|"According to their individualized rehabilitation project, patients will undergo RAT or non-immersive VR-based rehabilitation.~RAT will consist of three times a week one-hour session (4 weeks) and will be conducted by the implementation of an exoskeleton device for the upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™).~VR-based rehabilitation will consist of one daily one-hour session (4 weeks) and will be conducted by the implementation of a single non-immersive VR device among the Riablo™ (Corehab, Italy), the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), the Walker View™ (TechnoBody SRL, Italy).~Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants."
219652150|NCT05897827|BEHAVIORAL|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
219652151|NCT05897827|BEHAVIORAL|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
219652152|NCT05342753|DEVICE|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
219652153|NCT05999318|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219062965|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
219062966|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
219062967|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
219207966|NCT02734069|DRUG|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
219207967|NCT06797180|DEVICE|Virtual Reality Education for Dementia Caregivers|This group will receive 100 minutes of BPSD foundational education followed by 100 minutes of VR-based training focused on managing BPSD.
219207968|NCT04300127|DRUG|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
219652154|NCT05999318|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
219652155|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 5.5-minute \[all but 5 participants\] or 3-minute \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] argon activation (2000 psi starting at 100% power but decreased to keep return gas flow temperature warmer than -100C) followed by a 30-second helium defrost. For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
219652156|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
219652157|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 1 cycle of 5.5 minutes \[all but 5 participants\] or 3 minutes \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] of argon and 30 seconds of helium. However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
219652158|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
219652159|NCT05441033|OTHER|Fetal Heart Sounds (FHS) Listening Intervention|Pregnant women and their partners listened to fetal heart sounds (also referred to as angel sounds) for 20 minutes before bedtime on three consecutive nights using a fetal heart rate monitoring device. The intervention aimed to enhance prenatal attachment and reduce anxiety by increasing awareness of the fetus through auditory stimulation.
218964852|NCT03619343|PROCEDURE|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
218964853|NCT04038931|OTHER|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
218964854|NCT02210273|DEVICE|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
218964855|NCT02210273|DEVICE|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
218964856|NCT00372203|PROCEDURE|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
219062968|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
219062969|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
219062970|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
218964857|NCT03004222|DRUG|Bupivacaine|20 ml of 0.5% Bupivacaine
218964858|NCT03004222|DRUG|Placebos|
218964859|NCT05465746|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
218964860|NCT05465746|DIAGNOSTIC_TEST|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
218964861|NCT02330484|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
218964862|NCT02330484|BEHAVIORAL|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
218964863|NCT05574166|DRUG|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
218964864|NCT05574166|DRUG|Placebo|Placebo for SP-8356 powder
219652160|NCT05441033|OTHER|Guided Imagery Technique (GIT) Intervention|Pregnant women and their partners listened to guided imagery audio recordings for 20 minutes before bedtime on three consecutive nights. The recordings were developed to support bonding with the baby, reduce anxiety, and improve sleep quality. The intervention was delivered via audio files prepared by the research team based on structured imagery scripts.
219652161|NCT05199662|DRUG|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
219652162|NCT05199662|DRUG|Placebo|Placebo matching IV TNK
219652163|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Bangladesh|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
219652164|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Uganda|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
219652165|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in India|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
218964865|NCT03670927|OTHER|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
218964866|NCT04951440|DRUG|Nitrate ketone oxazine|Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
218964867|NCT02266914|DEVICE|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
218964868|NCT00428662|DEVICE|drug eluting nonpolymeric nanoporous stent|
219652166|NCT02548559|DRUG|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
219652167|NCT02548559|DRUG|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
219652168|NCT02548559|DRUG|Placebo|Placebo solution.
219652169|NCT04190368|OTHER|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
219652170|NCT04190368|OTHER|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
219652171|NCT06796335|OTHER|RIGht|The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.
219652172|NCT00197002|BIOLOGICAL|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
219652173|NCT00197002|BIOLOGICAL|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
219652174|NCT02017717|BIOLOGICAL|Nivolumab|specified dose on specified days
219652175|NCT02017717|BIOLOGICAL|Bevacizumab|specified dose on specified days
219652176|NCT02017717|BIOLOGICAL|Ipilimumab|specified dose on specified days
219652177|NCT05635227|DRUG|Dexamethasone phosphate|See description of arms
219652178|NCT05635227|DRUG|Isotonic sodium chloride (0.9%)|See description of arms
218964869|NCT04689815|DRUG|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
218964870|NCT05241483|DIAGNOSTIC_TEST|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
218964871|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
218964872|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
218964873|NCT04342273|DRUG|Placebo|Placebo will be administered once daily at Day 1 through Day 7
218964874|NCT04342273|DRUG|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
218964875|NCT05959200|DEVICE|Serafilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
219652179|NCT05635227|DRUG|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
219652180|NCT05635227|DRUG|Placebo capsule|capsule identical to capsule containing olanzapine
219652181|NCT05635227|PROCEDURE|Flow-targeted hemodynamic management|See description of arms
218964876|NCT05959200|DEVICE|Senofilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
218964877|NCT05959200|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
219652182|NCT05635227|PROCEDURE|Pressure-targeted hemodynamic management|See description of arms
219652183|NCT05635227|PROCEDURE|Low tidal-volume ventilation|See description of arms
219652184|NCT05635227|PROCEDURE|No ventilation|See description of arms
219652185|NCT05687747|DRUG|Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI|68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.
219652186|NCT05956886|BEHAVIORAL|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
219652187|NCT06847906|OTHER|Iteratively designed (new) clinical decision support tool for virtual visits|The new, iteratively designed clinical decision support tool includes the traditional CDS along with links to supportive tipsheets, which include one for providers on how to add an order for patients to upload vitals in their electronic health record, and one that walks patients through how to upload vitals on their own.
219652188|NCT06847906|OTHER|Traditional clinical decision support tool|The traditional CDS tool is the usual care intervention, and does not include links to tipsheets to support virtual patient care.
219652189|NCT05940402|DRUG|Emraclidine|Oral tablets
219652190|NCT05371496|DRUG|Semaglutide|3.0 mg/ml (titrated to 2.4 mg) subcutaneous once weekly for 12 months
219652191|NCT05371496|DRUG|Placebo|Matched placebo with no active drug once weekly for 12 months
219652192|NCT05371496|BEHAVIORAL|Counselling on healthy lifestyle intervention|All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.
219652193|NCT03527264|DRUG|Nivolumab induction|2 doses Nivolumab 240mg IV
219652194|NCT03527264|DRUG|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
219652195|NCT03527264|RADIATION|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
219652196|NCT03527264|DRUG|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
219652197|NCT03527264|DRUG|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
219652198|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
219652199|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
219652200|NCT06072430|DRUG|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
219652201|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
219652202|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
218964878|NCT02906904|OTHER|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
218964879|NCT02906904|OTHER|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
218964880|NCT03954041|DRUG|BIIB093|Administered as specified in the treatment arm.
219652203|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
219652204|NCT05962164|BEHAVIORAL|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
219652205|NCT05962164|BEHAVIORAL|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
218964881|NCT03954041|DRUG|Placebo|Administered as specified in the treatment arm.
218964882|NCT06110572|DRUG|Carboplatin|Given by IV
218964883|NCT06110572|BIOLOGICAL|Atezolizumab|Given by IV
218964884|NCT06110572|DRUG|Etoposide|Given by IV
218964885|NCT06110572|RADIATION|Total Body Irradiation|Undergo Total Body Irradiation
218964886|NCT06110572|RADIATION|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
218964887|NCT06110572|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
219652206|NCT04236414|DRUG|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
218964888|NCT04210778|BEHAVIORAL|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
219652207|NCT05684055|DRUG|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
219652208|NCT05684055|OTHER|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
219652209|NCT02984566|DEVICE|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
219652210|NCT06579755|BIOLOGICAL|TDV|TDV SC injection.
219652211|NCT06579755|OTHER|Placebo|Placebo SC injection.
219652212|NCT03848663|BEHAVIORAL|Traditional Remapping|Shifting text outside of scotoma
219652213|NCT03848663|BEHAVIORAL|Personalized Remapping|Shifting text based on individual letter-based perimetry
218964889|NCT04210778|BEHAVIORAL|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
218964890|NCT05446636|DEVICE|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
219062971|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
219062972|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
219652214|NCT04367857|OTHER|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
219652215|NCT04367857|BEHAVIORAL|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
218964891|NCT06343389|DIAGNOSTIC_TEST|serum creatinine|to detect patients with Acute kidney injury
218964892|NCT03054454|PROCEDURE|Podiatry|Podiatry treatments and care from the multidisciplinary team.
218964893|NCT04204122|DRUG|Vigamox|-FDA approved medication
218964894|NCT04204122|DRUG|Placebo|-The placebo is artificial tear drops
218964895|NCT03024879|DRUG|Erythromycin|
218964896|NCT03024879|DRUG|Saline|
218964897|NCT04958772|BIOLOGICAL|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
219062973|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
219062974|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
219062975|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
218964898|NCT04958772|BIOLOGICAL|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
218964899|NCT02090075|DRUG|apixaban|5 po or 2.5 po bid.
218964900|NCT02090075|DRUG|warfarin|
218964901|NCT00144131|DRUG|Aranesp®|
219062976|NCT00206063|DRUG|EXANTA|
218964902|NCT05324722|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
218964903|NCT05324722|OTHER|cross body stretch|crossbody stretch performed by an individual
218964904|NCT05926414|DRUG|Enavogliflozin|treated with Envlo tab. 0.3mg
218964905|NCT05926414|DRUG|Enavogliflozin|Envlomet SR Tablet 0.3/1,000mg
219062977|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
219652216|NCT04488419|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
219652217|NCT04488419|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
219652218|NCT05380687|DIAGNOSTIC_TEST|Inspiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
219652219|NCT05380687|DIAGNOSTIC_TEST|Expiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
219652220|NCT05380687|DIAGNOSTIC_TEST|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
219652221|NCT05380687|OTHER|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
218964906|NCT02218255|DEVICE|Eeva™ results|
219062978|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
219652222|NCT05380687|OTHER|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
219652223|NCT05380687|OTHER|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
219652224|NCT04642430|DRUG|Apixaban|Refer to Apixaban group
219652225|NCT04642430|DRUG|Rivaroxaban|Refer to Rivaroxaban group
219652226|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
219652227|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
219652228|NCT04652908|BIOLOGICAL|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
219652229|NCT04652908|OTHER|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
219652230|NCT02999230|OTHER|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
219652231|NCT02999230|OTHER|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
219652232|NCT02999230|OTHER|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
219652233|NCT02999230|OTHER|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
219062979|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
219652234|NCT00177281|DRUG|S CKD602|
219062980|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
219062981|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
219062982|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
219062983|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
219062984|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
218964907|NCT02600065|OTHER|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
218964908|NCT02837068|DEVICE|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
219652235|NCT05199194|DRUG|Tenecteplase|Intravenous thrombolysis with tenecteplase 0.25mg/kg
219652236|NCT05199194|DRUG|Placebo|Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
219652237|NCT06467656|OTHER|Individualized, periodized endurance training for ultra-endurance triathlon.|Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
219652238|NCT06467656|OTHER|Time-Aligned Control|Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
219652239|NCT06620263|OTHER|Pre-education period (PreEd)|No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
219652240|NCT06620263|OTHER|Post-education period (PostEd)|In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
219652241|NCT00663897|DRUG|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
218964909|NCT02837068|DEVICE|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
218964910|NCT05857943|DEVICE|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
218964911|NCT02547324|RADIATION|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
218964912|NCT02547324|RADIATION|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
218964913|NCT06278662|OTHER|video directly observed therapy (vDOT)|The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.
218964914|NCT04837092|DRUG|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
219652242|NCT00663897|DRUG|mosapride|mosapride, 5 mg, thrice daily for 14 days
219652243|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
218964915|NCT03868124|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
219062985|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
219062986|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
219062987|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
219062988|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
219652244|NCT05930886|OTHER|Focus Group|Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
219652245|NCT06320457|OTHER|Brief case management intervention|"The brief case management intervention aims to support patients during the difficult phase of involuntary hospitalisation and reduce the impact of this short-term event on their long-term recovery process. The intervention starts during the hospital stay, at the latest one week after admission, and lasts for a maximum of one month after discharge. The intervention consists of five sessions, the order of which may vary according to the specific needs of the patient:~1. Personal account of involuntary hospitalisation and its consequences~2. Presentation of the personal recovery model and the tools to promote it and prevent coercion~3. Introduction to the personal recovery plan~4. Network meeting and discussion on dignity of risk~5. Personal recovery plan"
218964916|NCT03868124|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
218964917|NCT03622528|RADIATION|Chest CT scan|Standard dose chest CT scan
218964918|NCT05620108|PROCEDURE|Endotracheal Intubation at TOFC=1|Intubation using a video laryngoscopy will be performed after train-of-four (TOFC) stimulation indicates neuromuscular blockade
218964919|NCT05620108|PROCEDURE|Endotracheal Intubation 2 minutes after rocuronium administration|Intubation using a video laryngoscopy will be performed 2 minutes after administration of rocuronium at 0.6 mg/kg (usual current clinical routine)
219062989|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
219062990|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
219062991|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
219062992|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
219062993|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
218964920|NCT04106908|BIOLOGICAL|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
218964921|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.
218964922|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.
218964923|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.
218964924|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
218964925|NCT03958383|BIOLOGICAL|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
218964926|NCT03958383|RADIATION|Radiation Therapy|Palliative radiation therapy
219652246|NCT03976336|DIETARY_SUPPLEMENT|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
219652247|NCT03976336|OTHER|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
219652248|NCT05488509|DRUG|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
218964927|NCT03958383|BIOLOGICAL|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
218964928|NCT03958383|BIOLOGICAL|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
218964929|NCT05802173|DRUG|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
218964930|NCT05802173|DRUG|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
218964931|NCT05802173|DRUG|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
218964932|NCT04602689|DRUG|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
218964933|NCT01165333|DRUG|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800"
218964934|NCT01165333|DRUG|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
218964935|NCT01165333|RADIATION|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
218964936|NCT01165333|BIOLOGICAL|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
218964937|NCT01165333|BIOLOGICAL|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
218964938|NCT01165333|BIOLOGICAL|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
218964939|NCT05099393|DIETARY_SUPPLEMENT|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
218964940|NCT01632917|DRUG|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
218964941|NCT01632917|DRUG|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
218964942|NCT04120285|BEHAVIORAL|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
218964943|NCT03861923|OTHER|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
219652249|NCT05488509|DRUG|Placebo|Participants will inhale vapor from a placebo product.
218964944|NCT03861923|OTHER|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
218964945|NCT03861923|OTHER|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
218964946|NCT04795427|DRUG|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
218964947|NCT04795427|OTHER|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
218964948|NCT05192122|OTHER|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
218964949|NCT03920618|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
218964950|NCT03920618|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
218964951|NCT03920618|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
218964952|NCT05534087|DRUG|mFOLFIRINOX-FOLFIRI intensified chemotherapy|"(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2"
219652250|NCT06838416|DRUG|Finerenone|Treatment will continue for 48 weeks.
219652251|NCT06480227|DEVICE|Solyx Single-incision Sling|Minimally invasive mesh device placed to treat stress urinary incontinence.
219652252|NCT06480227|DEVICE|Bulkamid Transurethral Bulking Agent|Minimally invasive bulking agent injections used to bulk up the tissue surrounding the urethra to treat stress urinary incontinence. Up to 2 treatments within 12 months are allowed
219062994|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
219062995|NCT04102501|DRUG|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
219062996|NCT04102501|DRUG|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
219062997|NCT01427712|DRUG|Pancrelipase|
219652253|NCT06485427|PROCEDURE|Selective Intra-arterial Cooling Infusion (IA-SCI)|"Pre-recanalization: During the procedure, the micro-catheter is advanced over a micro-guide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4 ℃) is infused intro into the ischemic territory at a rate of 10 mL/min via the micro-catheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~Post-recanalization: After recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL/min for 10 min, repeated twice with a 10-minute interval between infusions."
219652254|NCT05276726|DRUG|JAB 21822|Administered orally
219652255|NCT05756894|DEVICE|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
219652256|NCT05756894|OTHER|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
219652257|NCT05299333|OTHER|Exercise|High repetition muscle endurance and strengthening exercises Walking
219652258|NCT04330664|DRUG|MRTX849|KRAS G12C Inhibitor
219652259|NCT04330664|DRUG|TNO155|SHP2 Inhibitor
219652260|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
219652261|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
219652262|NCT00005005|DRUG|PTH|
219652263|NCT00005005|DRUG|Alendronate|
219652264|NCT06275074|PROCEDURE|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
219652265|NCT06275074|OTHER|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
219652266|NCT05553223|BEHAVIORAL|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
219652267|NCT06003023|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
219652268|NCT06003023|BEHAVIORAL|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
219652269|NCT06003023|BEHAVIORAL|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
219652270|NCT06003023|BEHAVIORAL|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
219062998|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
219652271|NCT04483284|DRUG|TACE combined with Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
219652272|NCT04483284|PROCEDURE|TACE plus Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
219652273|NCT06372899|OTHER|E-cigarettes|Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. They will be provided with an e-cigarette device and nicotine pods.
219652274|NCT06372899|OTHER|Oral nicotine pouches|Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks. They will be provided with nicotine pouches.
219652275|NCT01190059|DRUG|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
219062999|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
219063000|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
219063001|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
219063002|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
219063003|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
219652276|NCT05573672|COMBINATION_PRODUCT|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
219652277|NCT03570372|BEHAVIORAL|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
219652278|NCT03570372|BEHAVIORAL|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
218964953|NCT05534087|DRUG|FOLFOX or CAPOX adjuvant chemotherapy|"1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14"
218964954|NCT06053463|DEVICE|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
218964955|NCT06262464|BEHAVIORAL|Prevention|A cognitive-behavioural prevention programme.
218964956|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 1|self-amplifying mRNA vaccine
218964957|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 2|self-amplifying mRNA vaccine
218964958|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 3|self-amplifying mRNA vaccine
218964959|NCT06028347|BIOLOGICAL|Placebo|Saline for injection
218964960|NCT05228184|DRUG|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
218964961|NCT05228184|DRUG|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
218964962|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
218964963|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
218964964|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
218964965|NCT06581796|OTHER|pepsinogen-1|association between pepsinogen 1 serum level with hyperemesis gravidarum
218964966|NCT04953052|DRUG|Imatinib Mesylate|An isotonic sterile solution of imatinib.
218964967|NCT04953052|DRUG|Placebo|An isotonic sterile solution
218964968|NCT06427759|PROCEDURE|arm aesthetic surgery|liposuction of arms brachioplasty of arms
218964969|NCT02974309|BEHAVIORAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
218964970|NCT02974309|BEHAVIORAL|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
218964971|NCT01135108|DRUG|Placebo|Placebo IV Infusion
218964972|NCT01135108|DRUG|KAI-1678|KAI-1678 IV Infusion
218964973|NCT06533527|DRUG|Semaglutide|GLP1 medication
219063004|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
219063005|NCT00148057|BEHAVIORAL|Low-fat diet|
219063006|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
218964974|NCT06533527|DRUG|Tirzepatide|GLP1/GIP medication
218964975|NCT06533527|DRUG|Liraglutide|GLP1 medication
218964976|NCT06533527|DRUG|Dulaglutide|GLP1 Medication
218964977|NCT03073967|DRUG|Pritelivir|100 mg oral tablets
218964978|NCT03073967|DRUG|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
218964979|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
218964980|NCT06544057|BEHAVIORAL|CBT-MI|CBT-MI combines elements from Cognitive Behavioural Therapy and Motivational Interviewing in treating nicotine addiction, delivered remotely via Zoom by trained 'layperson coaches'
219652279|NCT05957445|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
219652280|NCT05957445|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
219652281|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
219652282|NCT05613868|DRUG|TPN-101|100 mg/ day up to 400mg/day of TPN-101
219652283|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
219652284|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
219652285|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
219652286|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
219652287|NCT05957354|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
219652288|NCT05957354|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
219652289|NCT05711381|DRUG|HM15912|Singe subcutaneous administration of HM15912 0.5 mg/kg
218964981|NCT05499650|BEHAVIORAL|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
218964982|NCT06048718|DRUG|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
219063007|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
219652290|NCT05868226|DRUG|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
219652291|NCT05868226|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
219652292|NCT05868226|DRUG|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
219652293|NCT05868226|DRUG|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
219652294|NCT05651022|DRUG|Decoy20|Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
219652295|NCT05651022|DRUG|Tislelizumab|Tislelizumab is a PD-1 inhibitor.
218964983|NCT06559540|RADIATION|Hypofractionated radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
218964984|NCT06559540|RADIATION|Ultra-hypofractionated breast/chest wall and regional nodal radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
218964985|NCT04902326|BEHAVIORAL|Automated educational text messages|"During the first two weeks, participants receive a series of educational messages delivered via text message. These messages welcome participants to the study, set expectations for the next 12 months, and establish a general level of knowledge among all participants on prediabetes, the Diabetes Prevention Program (DPP), and metformin.~For the next 11.5 months, participants receive three automated text messages per week that provide evidence-based educational content about prediabetes and tips on prevention. Additionally, participants receive monthly messages reminding them about their health insurance plan's coverage of the DPP at no cost and coverage of metformin as a low co-pay medication, and monthly messages providing feedback on their participation in the DPP and use of metformin in the previous calendar month. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months."
218964986|NCT04902326|BEHAVIORAL|Autonomy-supportive automated educational text messages|Participants receive the same text messages as in the automated educational text message intervention, but the thrice weekly messages have been modified, where applicable, to support the participant's autonomy, in accordance with principles of Self-Determination Theory. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months.
218964987|NCT04902326|BEHAVIORAL|Financial incentives|Participants in this arm have the opportunity to earn a financial incentive ranging from $50 to $250 per month for taking an evidence-based action to prevent T2DM (i.e., engagement in a DPP or fill of a metformin prescription) in the previous month.
218964988|NCT04902326|BEHAVIORAL|Tailored text messages|Participants receive twice-weekly tailored text messages that link evidence-based actions to prevent T2DM to the participant's self-identified top values, roles, and strengths. Text messages are also tailored, when possible, to participants' self-reported importance of taking action to try to prevent T2DM (i.e., participating in the DPP or taking metformin), confidence in being able to take such preventive action, and past preventive actions taken.
218964989|NCT02810353|DEVICE|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
219652296|NCT04335487|BEHAVIORAL|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
219652297|NCT04335487|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
219652298|NCT02228304|DRUG|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
219652299|NCT02228304|DRUG|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
219652300|NCT05519332|PROCEDURE|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
219652301|NCT00800813|BEHAVIORAL|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
219652302|NCT04393064|DEVICE|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera \& light source \& video recording system will be used. Procedure will be done without anesthesia~."
219652303|NCT05627310|OTHER|Diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by external dataset.
219652304|NCT00079300|DRUG|imiquimod|
219652305|NCT00079300|PROCEDURE|conventional surgery|
219652306|NCT00072540|DRUG|celecoxib|
219652307|NCT00072540|PROCEDURE|anti-cytokine therapy|
219652308|NCT00072540|PROCEDURE|antiangiogenesis therapy|
219652309|NCT00072540|PROCEDURE|biological therapy|
219652310|NCT00072540|PROCEDURE|cancer prevention intervention|
219652311|NCT00072540|PROCEDURE|chemoprevention of cancer|
219652312|NCT00072540|PROCEDURE|enzyme inhibitor therapy|
219652313|NCT00072540|PROCEDURE|growth factor antagonist therapy|
219063008|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
219652314|NCT06431685|RADIATION|Whole Brain Low Dose Radiotherapy|Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).
219652315|NCT06431685|DRUG|Pemetrexed|Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total
219652316|NCT06431685|DRUG|Sintilimab|PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total
219652317|NCT06431685|DRUG|Chemotherapy|Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
219652318|NCT04401761|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
219652319|NCT04401761|DRUG|Acetylsalicylic acid|75 - 100 mg once daily at the discretion of the investigator
219652320|NCT04743583|DEVICE|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
219652321|NCT03873441|OTHER|Computer Games-Aided Balance Training Protocol|"1\) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities."
219652322|NCT03873441|OTHER|Conventional Balance Training Protocol|"The following is a summary of the conventional physical therapy balance training protocol:~1. Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~2. Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~3. Weight transfer exercises with multi-directional reach outs and~4. Stepping exercises in different directions on variety of surfaces."
219652323|NCT02535234|DEVICE|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
219652324|NCT02535234|DEVICE|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
219652325|NCT02407132|BEHAVIORAL|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
219652326|NCT02407132|BEHAVIORAL|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
219652327|NCT03617861|DRUG|Human Secretin|Injected once over one minute
218964990|NCT02810353|DEVICE|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
218964991|NCT04057989|DRUG|ketamine|
218964992|NCT05211687|OTHER|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~1. Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~2. Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~3. Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
218964993|NCT02698995|DRUG|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
218964994|NCT02698995|DRUG|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
218964995|NCT02698995|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
218964996|NCT02698995|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
218964997|NCT02698995|DRUG|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
219063009|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
218964998|NCT01117051|DRUG|placebo|placebo
218964999|NCT01117051|DRUG|prucalopride|1 or 2 mg prucalopride once daily before breakfast
218965000|NCT04758000|DRUG|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
219063010|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
219063011|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
219063012|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
219652328|NCT03617861|DRUG|Placebo|Injected once over one minute
219652329|NCT01031745|BEHAVIORAL|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
219652330|NCT01031745|OTHER|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
219652331|NCT03790618|DRUG|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
219652332|NCT03790618|DRUG|methamphetamine|Please see above.
219652333|NCT03384784|DRUG|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
219652334|NCT03384784|DRUG|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
219652335|NCT01849068|DRUG|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
218965001|NCT05596123|BEHAVIORAL|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
218965002|NCT05596123|BEHAVIORAL|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
218965003|NCT05835973|OTHER|Sleep activity|"Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
218965004|NCT05835973|OTHER|Questionnaires|"The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit."
218965005|NCT02755688|PROCEDURE|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
219063013|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
219652336|NCT01849068|DRUG|Placebo|Placebo for 12 weeks
219652337|NCT06457360|DRUG|tranexamic acid|Application of sterile gauze after extraction for hemostasis
219652338|NCT06457360|DRUG|Ankaferd Blood Stopper|Application of sterile gauze after extraction for hemostasis
219652339|NCT06457360|DRUG|Chitosan|Application of sterile gauze after extraction for hemostasis
219652340|NCT02210286|DIETARY_SUPPLEMENT|Magtein|
219652341|NCT04606992|PROCEDURE|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
219652342|NCT01668966|DRUG|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
219652343|NCT01712893|DRUG|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
218965006|NCT02755688|PROCEDURE|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
219652344|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
219652345|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
219652346|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
219652347|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
219652348|NCT02909881|BEHAVIORAL|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
219652349|NCT05008809|DRUG|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
219652350|NCT05008809|DRUG|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
219652351|NCT05008809|DRUG|FOLFIRI|Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.
219652352|NCT05008809|DRUG|CAPOX|Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
219652353|NCT02322450|DRUG|QGC001|
219652354|NCT02322450|DRUG|Placebo|
218965007|NCT02911207|BEHAVIORAL|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
218965008|NCT03535571|DIETARY_SUPPLEMENT|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
218965009|NCT03447197|PROCEDURE|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
218965010|NCT04643470|DRUG|Zanubrutinib|Administered as specified in the treatment arm
218965011|NCT04643470|DRUG|Placebo|Placebo to match zanubrutinib
218965012|NCT05244642|DRUG|Penpulimab|A humanized monoclonal immunoglobulin.
218965013|NCT05244642|DRUG|Investigator's choice of Chemotherapy|Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
218965014|NCT05847712|OTHER|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
218965015|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
219652355|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
219652356|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
219652357|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
219652358|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
219652359|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
219652360|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
219652361|NCT00361166|DRUG|ACP-103|
219652362|NCT00348426|DRUG|Botulinum AntiToxin|
219652363|NCT00348426|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
219652364|NCT00348426|PROCEDURE|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
219652365|NCT03427268|DRUG|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
218965016|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil monotherapy
219652366|NCT02491125|DIETARY_SUPPLEMENT|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
219652367|NCT02491125|DIETARY_SUPPLEMENT|Placebo|12 weeks daily intake of 15g of maltodextrin
218965017|NCT05163873|PROCEDURE|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
219652368|NCT03702491|DRUG|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
219652369|NCT03702491|DRUG|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
219652370|NCT00998348|BEHAVIORAL|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
219652371|NCT02226926|DRUG|Aggrenox|
219652372|NCT02226926|DRUG|Persantin Retard|
219652373|NCT02226926|DRUG|Acetylsalicylic acid|
219652374|NCT01542905|DIETARY_SUPPLEMENT|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
219652375|NCT01542905|OTHER|Placebo|Placebo Capsule (1g/day) for 8 Weeks
219652376|NCT03864666|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
219652377|NCT03864666|DRUG|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
219652378|NCT03955965|OTHER|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
219652379|NCT03541434|DIAGNOSTIC_TEST|Complete Blood Count|White blood cell subgroups count
219652380|NCT03541434|DIAGNOSTIC_TEST|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
219652381|NCT03541434|PROCEDURE|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
219652382|NCT01813734|DRUG|Ponatinib|28 day cycle
219652383|NCT03357900|DEVICE|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
219652384|NCT00939406|DEVICE|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
218965018|NCT01087866|DRUG|Metformin|
218965019|NCT01087866|DRUG|Insulin|
218965020|NCT00005934|DRUG|5-Azacytidine|
218965021|NCT01894412|BIOLOGICAL|Etanercept (Enbrel)|
218965022|NCT01894412|BIOLOGICAL|HD203|
219652385|NCT05588999|PROCEDURE|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
219652386|NCT05588999|COMBINATION_PRODUCT|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
219652387|NCT00533052|BEHAVIORAL|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
219652388|NCT02160028|OTHER|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
219652389|NCT02160028|OTHER|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
219652390|NCT00345878|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
218965023|NCT02661711|DRUG|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
218965024|NCT00550056|BEHAVIORAL|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
219652391|NCT00345878|BIOLOGICAL|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
218965025|NCT00550056|BEHAVIORAL|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
218965026|NCT05956379|OTHER|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
219652392|NCT03391232|BIOLOGICAL|PolyPEPI1018 CRC Vaccine|Colorectal Cancer Vaccine
219652393|NCT00552032|DRUG|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
218965027|NCT02808572|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
219652394|NCT00552032|DRUG|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
219652395|NCT02384109|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
218965028|NCT02808572|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
218965029|NCT02808572|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
218965030|NCT06338605|OTHER|no intervention, observational study of AKI under CDK4/6 inhibitor treatment|no intervention
219652396|NCT02384109|OTHER|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
218965031|NCT03355664|DRUG|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
219652397|NCT05390723|BEHAVIORAL|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
219063014|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
219063015|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
219063016|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
218965032|NCT03355664|DRUG|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
218965033|NCT03597217|DRUG|PF-05221304|3, 10, 50 mg
218965034|NCT03597217|DRUG|PF-05221304|50 mg multiple dose
218965035|NCT03597217|DRUG|Placebo|Placebo
219063017|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
218965036|NCT06057155|DIAGNOSTIC_TEST|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
218965037|NCT03280927|DRUG|Jublia®|Jublia® topical solution
218965038|NCT03745430|DRUG|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
218965039|NCT04763876|DRUG|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
218965040|NCT04763876|DRUG|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
219063018|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
219063019|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
219063020|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
219063021|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
219063022|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
219063023|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
219652398|NCT01796314|BEHAVIORAL|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~1. Knowledge of the disease~2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~3. Crisis situations. Prevention of caregiver's exhaustion~4. Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
219652399|NCT02519816|OTHER|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
219652400|NCT02719834|DRUG|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
219652401|NCT02719834|OTHER|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
219652402|NCT01402505|PROCEDURE|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
219652403|NCT05393934|OTHER|High dense nutrients formula|High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
219652404|NCT05393934|OTHER|Pediatric Nutrition Care (PNC)|Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
218965041|NCT03662243|BEHAVIORAL|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
219063024|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
219063025|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
219652405|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly"
219652406|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly"
218965042|NCT06497231|OTHER|Beautifil II LS|Beautifil II LS is a low shrinkage bioactive giomer resin composite.
218965043|NCT06497231|OTHER|Nanohybrid resin composite material|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
218965044|NCT00276042|DRUG|Faropenem Medoxomil|
218965045|NCT00084773|BIOLOGICAL|cetuximab|
218965046|NCT00084773|DRUG|fluorouracil|
218965047|NCT00084773|PROCEDURE|neoadjuvant therapy|
218965048|NCT00084773|RADIATION|radiation therapy|
218965049|NCT05276648|DIAGNOSTIC_TEST|CAM ICU test|CAM ICU for delirium
218965050|NCT05276648|DIAGNOSTIC_TEST|MOCA test|MOCA for cognitif disfonction
218965051|NCT05276648|DIAGNOSTIC_TEST|brief pain test|BRİEF PAİN for chronic pain
218965052|NCT05276648|DIAGNOSTIC_TEST|VAS scale|VAS scale for acute pain
218965053|NCT00218101|DRUG|Buprenorphine|
218965054|NCT02392845|DRUG|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
218965055|NCT01337687|DRUG|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
218965056|NCT01337687|DRUG|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
218965057|NCT02577276|DEVICE|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
218965058|NCT04784104|DRUG|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
218965059|NCT04784104|DRUG|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
218965060|NCT04784104|DRUG|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
218965061|NCT04784104|PROCEDURE|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
218965062|NCT04784104|PROCEDURE|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
218965063|NCT02389075|PROCEDURE|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
218965064|NCT02389075|PROCEDURE|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
218965065|NCT01158664|DEVICE|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
218965066|NCT01158664|DEVICE|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
218965067|NCT05345041|BEHAVIORAL|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
218965068|NCT05345041|BEHAVIORAL|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
219063026|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
219063027|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
219652407|NCT06712186|DRUG|Dexmedetomidine Group / Group D|In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.
218965069|NCT01751802|DRUG|Ecopipam|Antagonist of the dopamine D1 receptor
218965070|NCT01751802|DRUG|Placebo|Placebo for Ecopipam
218965071|NCT01617148|DRUG|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
218965072|NCT06278233|DEVICE|Transcranial direct current stimulation|TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
218965073|NCT03186885|BEHAVIORAL|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
219063028|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
219063029|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
219063030|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
219652408|NCT06712186|OTHER|Normal Saline (Placebo)|The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
219652409|NCT05551689|DRUG|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
219652410|NCT05551689|DEVICE|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
219652411|NCT00223730|DRUG|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
219652412|NCT00223730|DRUG|Placebo|
219652413|NCT04010864|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
219652414|NCT03566056|OTHER|Complications to Whipples procedure|Patients undergoing the Whipple procedure often tend to have a lot of complications. This study aims to investigate what complications these patients experience
219652415|NCT01844973|DRUG|M518101|Proper quantity twice a day
219063031|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
219652416|NCT01844973|DRUG|Vehicle|Proper quantity twice a day
219652417|NCT01123772|DRUG|INO-8875|eye drops for 14 days in one eye
219652418|NCT01123772|OTHER|Placebo control|Matched placebo
219652419|NCT00002030|DRUG|Pentamidine isethionate|
219652420|NCT06347445|OTHER|There is no intervention.|There is no intervention.
219652421|NCT01643798|PROCEDURE|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
219652422|NCT01643798|PROCEDURE|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
219652423|NCT00507351|BEHAVIORAL|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
219652424|NCT00148655|DEVICE|Decision Board|Decision board that explains the risks and benefits of treatment options
219652425|NCT02144636|DIETARY_SUPPLEMENT|herbalife protein shake|
219652426|NCT06471855|DEVICE|Multidisciplinary Conventional and Technology-based Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
218965074|NCT03186885|BEHAVIORAL|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
219652427|NCT06471855|OTHER|Multidisciplinary Conventional Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
218965075|NCT03186885|BEHAVIORAL|Control|Participants receive standard of care
219652428|NCT06838871|BEHAVIORAL|Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|"ADIM aims to enhance trunk stability by selectively activating the transversus abdominis. Participants begin in a supine position and practice drawing in their abdomen toward the spine while maintaining a stable trunk and pelvis. A therapist provides verbal instructions and manual guidance to ensure proper muscle activation.~IMT is performed using the Threshold RMT device (IMT, GH INNOTEK, Busan, South Korea). Participants wear a nose clip and start with 30% of Maximal Inspiratory Pressure (MIP), gradually increasing by 10% per week to reach 60% MIP by the final week. Each session consists of five sets of 10-15 repetitions, with a one-minute rest between sets."
219652429|NCT06838871|BEHAVIORAL|Sham Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|Sham IMT with ADIM training performs the same ADIM protocol as the IMT with ADIM training but undergoes IMT with minimal resistance (0 cmH₂O) to prevent actual muscle strengthening. This design ensures that the effects observed can be attributed to IMT rather than ADIM.
218965076|NCT04111952|DEVICE|CO2 laser|A single session of CO2 vaginal laser treatment
219063032|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
219652430|NCT05045391|DIAGNOSTIC_TEST|Aspergillus IgG detection|Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
219652431|NCT05597917|DRUG|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
219652432|NCT05597917|BIOLOGICAL|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.
219652433|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
219652434|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
219652435|NCT04516343|DEVICE|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
218965077|NCT04111952|DEVICE|Sham laser|A single session of sham laser treatment.
218965078|NCT05115890|OTHER|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
219652436|NCT05565781|DEVICE|ECG smartwatch|Testing ECG smartwatch to detect AF or potential signs of AF
219652437|NCT05565781|DEVICE|Insertable Cardiac Monitor (ICM)|Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)
219652438|NCT05565781|DEVICE|External ECG Monitoring|Regular cardiac monitor for diagnosis of AF
218965079|NCT00405327|BIOLOGICAL|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
218965080|NCT00405327|OTHER|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
219652439|NCT03991923|DEVICE|XVIVO heart preservation devices|The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
218965081|NCT00589784|DRUG|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
218965082|NCT02901639|OTHER|counseling|
219063033|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
219652440|NCT03991923|DEVICE|Standard ICSS|Cold static preservation using standard preservation solution
219652441|NCT04178824|BEHAVIORAL|Discount Intervention|15% or 30% discount on fruits and vegetables
219652442|NCT06330311|OTHER|Physiotherapy|Evidence-based multimodal physiotherapy treatment based on learning and motor control
219652443|NCT05651438|OTHER|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
219652444|NCT02179606|DEVICE|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
219652445|NCT02179606|DEVICE|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
219652446|NCT02928783|BEHAVIORAL|Home-based cardiac rehabilitation|
219652447|NCT06188442|DRUG|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
219652448|NCT06188442|DRUG|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
219652449|NCT01014897|DEVICE|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
219652450|NCT05542797|DRUG|Duphastone|dydrogesterone hormone
219652451|NCT03611231|DRUG|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
219652452|NCT05848882|DEVICE|Elastodontic Device|Removable device that embraces two dental archs
218965083|NCT03127956|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
218965084|NCT05447962|BEHAVIORAL|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
218965085|NCT05447962|BEHAVIORAL|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
218965086|NCT01960387|DRUG|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
218965087|NCT01960387|DRUG|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
218965088|NCT04245462|OTHER|No intervention|Cross-sectional
218965089|NCT02758977|PROCEDURE|ALPPS|For detailed information please refer to description of experimental arm
218965090|NCT02758977|PROCEDURE|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
218965091|NCT00423670|DRUG|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
218965092|NCT00423670|DRUG|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
218965093|NCT00423670|DRUG|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
219063034|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
219063035|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
219063036|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
219063037|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
219063038|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
219652453|NCT03794661|DEVICE|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
219652454|NCT04810247|BEHAVIORAL|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
219063039|NCT04433767|DRUG|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
219063040|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
219063041|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
219652455|NCT04094272|DIAGNOSTIC_TEST|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
219652456|NCT04773652|DIAGNOSTIC_TEST|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
219652457|NCT01995175|PROCEDURE|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
219652458|NCT01995175|PROCEDURE|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
219652459|NCT01995175|OTHER|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
219652460|NCT06042361|BEHAVIORAL|Smokefree Implementation Framework and Toolkit|"Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities."
219652461|NCT01877551|DRUG|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
219652462|NCT01877551|OTHER|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
219652463|NCT04932746|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
219652464|NCT04932746|DRUG|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
219652465|NCT02472743|DEVICE|Custom-built phototherapy lamp|Described in the arm description
219652466|NCT00984061|DRUG|colchicine|0.6mg tablet administered at 9am on Day 1
218965094|NCT00423670|DRUG|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
218965095|NCT00286611|PROCEDURE|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
218965096|NCT01071473|OTHER|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
218965097|NCT01861171|DIETARY_SUPPLEMENT|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
219652467|NCT00984061|DRUG|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
219652468|NCT00984061|DRUG|colchicine|0.6 mg tablet administered at 9am on Day 29
219652469|NCT02262598|DRUG|Telmisartan|
218965098|NCT05637671|DRUG|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
219652470|NCT02262598|DRUG|Hydrochlorthiazide (HCTZ)|
219652471|NCT02262598|DRUG|Telmisartan/HCTZ fixed dose|
219652472|NCT04853342|DRUG|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
219652473|NCT04853342|DRUG|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
219652474|NCT06388863|DRUG|Healthy donor-derived FMT capsule|Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
219652475|NCT06388863|DRUG|Placebo capsule|Capsules whose appearance and smell are identical as FMT capsules but contain milk powder
219652476|NCT05525585|DIETARY_SUPPLEMENT|Early HMF|Mom's milk or donor milk will be fortified between postnatal day 4 and 7
219652477|NCT05525585|DIETARY_SUPPLEMENT|Delayed HMF|Mom's milk or donor milk will be fortified between postnatal day 10 and 14
219652478|NCT05838742|DRUG|GSK3858279|GSK3858279 will be administered.
219652479|NCT05838742|DRUG|Placebo|Placebo will be administered.
219652480|NCT05896553|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
219652481|NCT05896553|DRUG|intranasal Placebo|Administration of intranasal Placebo
219652482|NCT06653465|DRUG|Acetaminophen|Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
219652483|NCT06653465|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment.
219652484|NCT02697890|DEVICE|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
219652485|NCT02697890|DEVICE|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
219652486|NCT06652438|DRUG|Revumenib|day 1- 28 per cycle
219652487|NCT06652438|DRUG|Placebo|day 1- 28 per cycle
219652488|NCT05935007|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
219652489|NCT04695262|PROCEDURE|EUS-FNB|Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB)
219652490|NCT04236518|BEHAVIORAL|Diets with either predominantly animal protein sources.|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
219652491|NCT04236518|BEHAVIORAL|Diets with predominantly plant protein sources|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
218965099|NCT05637671|DRUG|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
219652492|NCT05803213|OTHER|Virtual Reality 360 interactive video|Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students
219652493|NCT05803213|OTHER|Traditional mini-lecture|Clinical scenario described according to the script as a mini-lecture to the medical students
218965100|NCT03901118|DRUG|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
218965101|NCT03901118|DRUG|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
218965102|NCT03901118|DRUG|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
219063042|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
219652495|NCT03348475|BEHAVIORAL|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
219652496|NCT01380717|DRUG|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
219652497|NCT01380717|DRUG|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
219652498|NCT03828110|DEVICE|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
219652499|NCT03828110|PROCEDURE|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
218965103|NCT04942353|BEHAVIORAL|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
218965104|NCT04942353|BEHAVIORAL|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
218965105|NCT05832827|DRUG|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
218965106|NCT05832827|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
218965107|NCT05832827|DRUG|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
218965108|NCT05832827|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
218965109|NCT05151601|DIETARY_SUPPLEMENT|Experimental|2 x sachets per day
218965110|NCT05151601|OTHER|Placebo|2 x sachets per day
218965111|NCT00002576|DRUG|cyclophosphamide|
218965112|NCT00002576|DRUG|doxorubicin hydrochloride|
218965113|NCT00002576|DRUG|mitoxantrone hydrochloride|
218965114|NCT00002576|DRUG|prednisolone|
218965115|NCT00002576|DRUG|vincristine sulfate|
218965116|NCT01905111|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
218965117|NCT02886156|DEVICE|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
219063043|NCT03702829|DRUG|Inotersen|Open Label Study
219063044|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
219063045|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
219652500|NCT05245721|DRUG|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
219652501|NCT05245721|DRUG|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
219652502|NCT03928808|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
219652503|NCT00455559|DRUG|Perifosine|
219652504|NCT00455559|DRUG|Imatinib Mesylate|
218965118|NCT02886156|DIETARY_SUPPLEMENT|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
218965119|NCT04622982|OTHER|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
218965120|NCT00450112|DEVICE|Gel-200|Single Intra-articular Injection
218965121|NCT01451268|DRUG|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
218965122|NCT01451268|DRUG|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
218965123|NCT03444987|GENETIC|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method"
218965124|NCT00276081|DRUG|Gabapentin, Estrogen and placebo administration|
218965125|NCT03433027|DRUG|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
218965126|NCT04399174|DEVICE|US|
218965127|NCT01384643|DRUG|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
219652505|NCT05923775|PROCEDURE|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
219063046|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5\. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
219063047|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
219063048|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
219063049|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
219063050|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
219063051|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
219063052|NCT03498534|DRUG|Isoniazid 300 MG|\+ TST test will receive isoniazid 300MG Tab for 6 months
219063053|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
219063054|NCT04976920|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
219063055|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
219063056|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
219063057|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
219063058|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
219063059|NCT05427669|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
219652506|NCT06608875|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
219652507|NCT06608875|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
219652508|NCT06608875|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
219652509|NCT01504607|PROCEDURE|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
219063060|NCT05427669|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
219652510|NCT00006007|DRUG|gemcitabine hydrochloride|
219652511|NCT00006007|DRUG|pemetrexed disodium|
219652512|NCT01628653|DEVICE|U-SMART|4-weeks' training
219652513|NCT05390151|PROCEDURE|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
219652514|NCT05390151|PROCEDURE|RAF|current golden standard in transsphincteric fistula surgery
219652515|NCT03352193|DIETARY_SUPPLEMENT|Wheat spaghetti|Wheat oral immunotherapy
219652516|NCT04560283|DRUG|Vaginal gel HYALOGYN®|Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
219652517|NCT04560283|BEHAVIORAL|Expectant management|Expectant management for 12 consecutive weeks
219652518|NCT05365646|DEVICE|Hearing aids equipped with motion sensing abilities|Participants will wear hearing aids that will assess their movement, and fall risk.
219652519|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
219652520|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
219652521|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
219652522|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
219652523|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
219652524|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
219652525|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
219652526|NCT01240980|DRUG|Placebo|Solution, Oral, 0 mg, once daily, 1 day
219652527|NCT01240980|DRUG|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
219652528|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
219652529|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
219652530|NCT01240980|DRUG|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
219652531|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
219652532|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
219652533|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
219652534|NCT00268567|DRUG|leflunomide combined with prednisone|
219652535|NCT02092480|BEHAVIORAL|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
219652536|NCT00742872|DRUG|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
219652537|NCT00742872|DRUG|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
219652538|NCT06439966|DRUG|ABBV-787|Intravenous (IV) Infusion
219652539|NCT06215924|OTHER|Reverse Kegel exercise|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
219652540|NCT06215924|OTHER|Postisometric Relaxation Technique|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
219652541|NCT02455258|OTHER|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
219652542|NCT02455258|OTHER|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
219652546|NCT06619158|PROCEDURE|Crown modification|Zirconia glaze removal and polish after crown removal to reduce roughness and prohibit plaque adhesion
219063061|NCT01450358|OTHER|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
219063062|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
219063063|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
219063064|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
219652547|NCT05296954|PROCEDURE|high resolution cartography|High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
219652548|NCT06621108|OTHER|Focus group session|Participants will take part in a focus group, which includes sharing their experience of the four-week feeling tone mindfulness course in an online group session. The focus group session will be led by trained moderator, and attended by several other course participants who completed the four-week feeling tone mindfulness course. The session will be audio-recorded as the research team will analyze the qualitative feedback offered by participants.
219652549|NCT06666751|PROCEDURE|Cataract plus Microstent surgery|Both the Hydrus microstent and iStent Inject W are used in combination with cataract surgery, in order to help lower intraocular pressure for patients with open-angle glaucoma. The microstent is a small flexible device that is inserted into the eye during cataract surgery in order to improve the outflow of fluid from the eye.
219652550|NCT02075528|DRUG|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
219652551|NCT01021761|DRUG|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
219652552|NCT01021761|DRUG|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
218965128|NCT02433327|OTHER|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
219063065|NCT03806829|OTHER|Water|250 ml
219063066|NCT03806829|OTHER|Red Wine|250 ml
219063067|NCT03806829|OTHER|Green Tea|250 ml
219063068|NCT03806829|OTHER|Orange Juice|250 ml
219063069|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
219063070|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
219652553|NCT01021761|DRUG|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
218965129|NCT02433327|OTHER|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
219063071|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
219063072|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
219652554|NCT00614120|DRUG|liraglutide|0.6 mg/day, s.c. (under the skin) injection
219652555|NCT00614120|DRUG|placebo|Glimepiride placebo, capsules
219652556|NCT00614120|DRUG|liraglutide|1.2 mg/day, s.c. (under the skin) injection
219652557|NCT00614120|DRUG|liraglutide|1.8 mg/day, s.c. (under the skin) injection
219652558|NCT00614120|DRUG|glimepiride|Capsules, 4.0 mg/day
219652559|NCT00614120|DRUG|metformin|Tablets, 1.5-2.0 g/day
219652560|NCT00614120|DRUG|placebo|Liraglutide placebo, s.c. (under the skin) injection
219652561|NCT04197674|OTHER|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
219652562|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
219652563|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
219652564|NCT02353494|DRUG|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
219652565|NCT03030144|OTHER|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
219652566|NCT03825835|DRUG|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
219652567|NCT03825835|DRUG|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
219652568|NCT03578458|OTHER|subjects will install a mobile app for use|novel mobile application
218965130|NCT00573196|RADIATION|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
218965131|NCT04428775|DRUG|ALZT-OP1a (cromolyn)|"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"
218965132|NCT06314620|DRUG|Heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
218965133|NCT06314620|OTHER|Without heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
218965134|NCT05041517|BEHAVIORAL|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
219063073|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
219063074|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
218965135|NCT04729946|DEVICE|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
219652569|NCT05069142|OTHER|Rehabilitation|Pre- and post-operative exercise and education.
218965136|NCT06207435|BEHAVIORAL|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
218965137|NCT00750880|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
219652570|NCT05026099|OTHER|Boxing training|Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment
218965138|NCT05428293|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
218965139|NCT05428293|DRUG|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
218965140|NCT05428293|DRUG|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
219063075|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
219063076|NCT00782613|DRUG|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
219063077|NCT00782613|DRUG|Placebo|Placebo in a cream formulation
219063078|NCT01746823|DRUG|Cyclosporins|
219063079|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
219652571|NCT05026099|OTHER|Task Oriented Training|Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
218965141|NCT05456919|OTHER|SFQ28 Questionnaire|SFQ28 Questionnaire
218965142|NCT05950958|OTHER|Multimodal therapy for prevention of delirium|Multimodal therapy for prevention of delirium
218965143|NCT03360825|DEVICE|TetraGraph|The TetraGraph is a dedicated neuromuscular stimulator / recorder intended to evoke, record, and analyze muscle action potentials during surgical procedures
218965144|NCT04883957|DRUG|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
218965145|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
218965146|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, IM
218965147|NCT02687178|DRUG|Canrenone 50 vs canrenone 100 mg|
218965148|NCT00455910|DRUG|Thalidomide|
218965149|NCT04638192|DEVICE|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
218965150|NCT03964844|OTHER|No intervention|No intervention
218965151|NCT02964507|DRUG|GSK525762|GSK525762 will be administered.
218965152|NCT02964507|DRUG|Placebo|Placebo will be administered.
219652572|NCT03289598|BEHAVIORAL|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
218965153|NCT02964507|DRUG|Fulvestrant|Fulvestrant will be administered.
218965154|NCT05450978|DRUG|Lamotrigine|Anti-seizure concentrations
218965155|NCT05450978|DRUG|Levetiracetam|Anti-seizure concentrations
218965156|NCT05450978|DRUG|Oxcarbazepine|Anti-seizure concentrations
218965157|NCT05979779|DRUG|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
218965158|NCT05979779|OTHER|Placebo|Placebo
218965159|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
218965160|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
218965161|NCT03874494|DRUG|Brexpiprazole|Brexpiprazole 2-4 mg/day
218965162|NCT03874494|DRUG|Aripiprazole|Aripiprazole 10-20 mg/day
218965163|NCT02610569|DEVICE|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
218965164|NCT02610569|DEVICE|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
218965165|NCT06490445|DRUG|Medical Cannabis|Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
218965166|NCT06490445|DRUG|Placebo|Placebo administered using Fixed-dose Syqe Inhaler.
218965167|NCT03392324|DEVICE|PRIMA|Implantation of PRIMA device
218965168|NCT04781530|DEVICE|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
218965169|NCT05788796|BEHAVIORAL|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
218965170|NCT05832476|OTHER|No intervention|No intervention
218965171|NCT04955860|OTHER|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
219652573|NCT06620497|PROCEDURE|stress free implant bar|SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
219652574|NCT06620497|PROCEDURE|milled bar|bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
219652575|NCT01968707|DRUG|ChloraPrep Hi-Lite Orange|Apply topically.
219652576|NCT01968707|DRUG|Normal saline|Apply topically.
219652577|NCT01968707|DRUG|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
219652578|NCT01968707|DRUG|3M CHG/IPA Prep Tint 26-mL|Apply topically
219652579|NCT06664320|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
219652580|NCT06664320|DRUG|hydroxyethyl starch (HES 130/0.6)|hydroxyethyl starch (HES 130/0.6)
219652581|NCT00916344|DEVICE|EVIA Pacemaker|patient has standard indication for pacemaker therapy
219652582|NCT04736927|DRUG|GLPG3667|From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
219652583|NCT04736927|DRUG|Midazolam|On Day 1 and Day 7 as liquid formulation, orally in fed state.
218965172|NCT02699216|DEVICE|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
219652584|NCT02395237|DRUG|: Amaryl® M IR 2/1000|
219652585|NCT05912231|RADIATION|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
219652586|NCT05912231|RADIATION|Accelerated Photon Radiation Therapy (XRT)|per protocol
219652587|NCT02946073|DRUG|buprenorphine|
219652588|NCT02946073|OTHER|Placebo|
219652589|NCT03663465|OTHER|Hawthorn|Hawthorn tablet
219652590|NCT03663465|DRUG|SGAs|SGAs tablet
219652591|NCT03544931|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
218965173|NCT00943943|DRUG|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
218965174|NCT00943943|DRUG|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
218965175|NCT00943943|DRUG|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
218965176|NCT01847911|OTHER|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
218965177|NCT01847911|OTHER|instructor training|a pre-validated OSCE neonatal resuscitation program
218965178|NCT00097851|DRUG|docetaxel|
218965179|NCT00097851|DRUG|PI-88|
218965180|NCT02918981|BEHAVIORAL|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
218965181|NCT02918981|DIETARY_SUPPLEMENT|14 g Whey protein|
218965182|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine|
218965183|NCT02918981|DIETARY_SUPPLEMENT|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
218965184|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
218965185|NCT02918981|OTHER|Water control|
218965186|NCT01326325|DRUG|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
218965187|NCT01326325|DRUG|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
218965188|NCT01484938|DEVICE|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
218965189|NCT00003950|DRUG|cyclosporine|
218965190|NCT00003950|DRUG|CPT-11|
219652592|NCT03544931|DEVICE|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
218965191|NCT03869827|OTHER|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
219652593|NCT03936465|DRUG|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
218965192|NCT04783142|OTHER|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
219063080|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
219063081|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
219652594|NCT03936465|DRUG|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
219652595|NCT03096769|OTHER|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
219652596|NCT04495504|DRUG|Ropivacaine|Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
218965193|NCT04783142|OTHER|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
218965194|NCT05868889|DRUG|Trabectedin and PLD|The main treatment observed in this study is trabectedin in combination with PLD in elderly patients with platinum-sensitive relapsed ovarian cancer, according to the SmPC.
218965195|NCT04043780|DEVICE|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
218965196|NCT04043780|DEVICE|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
218965197|NCT01657929|BIOLOGICAL|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
218965198|NCT01657929|BIOLOGICAL|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
218965199|NCT01657929|BIOLOGICAL|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
218965200|NCT01657929|BIOLOGICAL|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
218965201|NCT05638477|BEHAVIORAL|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
218965202|NCT03857152|DIAGNOSTIC_TEST|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
218965203|NCT01580371|DRUG|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
218965204|NCT02942576|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
218965205|NCT02942576|DRUG|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
219652597|NCT02529904|BIOLOGICAL|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
219652598|NCT02454712|DRUG|PF614|PF614 is an oxycodone prodrug
219652599|NCT02454712|DRUG|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
219652600|NCT02454712|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
218965206|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
218965207|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
218965208|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
218965209|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
218965210|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
219652601|NCT03891472|DRUG|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
218965211|NCT01631955|DRUG|Ciprobay|Ciprobay (250mg, bid, oral)
218965212|NCT01403233|DIETARY_SUPPLEMENT|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
218965213|NCT01403233|DIETARY_SUPPLEMENT|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
218965214|NCT01403233|DIETARY_SUPPLEMENT|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
218965215|NCT03373799|OTHER|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
218965216|NCT03373799|OTHER|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
219652602|NCT01679067|PROCEDURE|colonoscopy with endoscopic biopsies|
218965217|NCT06301243|OTHER|Inactivity|Low physical activity level prior to the exercise intervention.
218965218|NCT00192686|PROCEDURE|culture a.m. Kamme-Lindberg|
218965219|NCT04188171|PROCEDURE|Polidocanol foam sclerotherapy|"* Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
219207969|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
219652603|NCT04376125|OTHER|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
219652604|NCT02614222|DEVICE|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
218965220|NCT04503291|PROCEDURE|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
218965221|NCT00938964|DRUG|Lidocaine|Lidocaine versus placebo infusion for 48 hours
218965222|NCT00938964|DRUG|Placebo|Lidocaine versus placebo infusion for 48 hours
218965223|NCT02139800|PROCEDURE|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
218965224|NCT02139800|PROCEDURE|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
218965225|NCT05656989|OTHER|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
218965226|NCT05751616|OTHER|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
219652605|NCT05342922|PROCEDURE|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
219652606|NCT05342922|PROCEDURE|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
219652607|NCT05803096|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
219652608|NCT05803096|OTHER|Oxygen|Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
219652609|NCT01655849|DRUG|z160|
219652610|NCT01655849|DRUG|Placebo|
219652611|NCT04865549|PROCEDURE|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
219652612|NCT04211532|OTHER|Surgery|Surgical risk is calculated according to the surgery performed.
219652613|NCT03602391|BEHAVIORAL|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
219063082|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
219063083|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
219063084|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
219063085|NCT01024387|DRUG|AMG 479|
219652614|NCT04448067|BEHAVIORAL|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
219652615|NCT04448067|BEHAVIORAL|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
219652616|NCT00227630|DRUG|cisplatin|
219063086|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
219063087|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
219063088|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
219063089|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
219063090|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
219063091|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
219063092|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
219063093|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
219063094|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
219063095|NCT02408614|DEVICE|Treadmill|
219063096|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
219652617|NCT00227630|DRUG|pemetrexed disodium|
219652618|NCT00227630|PROCEDURE|adjuvant therapy|
219652619|NCT00227630|PROCEDURE|conventional surgery|
219652620|NCT00227630|PROCEDURE|neoadjuvant therapy|
219652621|NCT00227630|RADIATION|radiation therapy|
218965227|NCT05751616|OTHER|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
218965228|NCT02986880|DRUG|Botulinum toxin A|
218965229|NCT02986880|PROCEDURE|Placebo|Injection of sodium chloride (NaCl) 9/1000
218965230|NCT00842452|DRUG|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
218965231|NCT00842452|OTHER|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
218965232|NCT02526329|BIOLOGICAL|donor regulatory T lymphocytes|Given IV
218965233|NCT02526329|OTHER|laboratory biomarker analysis|Correlative studies
219063097|NCT01681693|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
219063098|NCT06432127|DRUG|Placebo|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
219063099|NCT06432127|DRUG|Bupivacaine|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using 0.5% Bupivacaine 3 mL
219063100|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
219207970|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
219652622|NCT06124248|BEHAVIORAL|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention."
219652623|NCT01588457|DRUG|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
219652624|NCT01588457|DRUG|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
219652625|NCT01588457|DRUG|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
219652626|NCT01588457|DRUG|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
218965234|NCT05977478|DEVICE|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
219652627|NCT03205735|DIAGNOSTIC_TEST|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
219652628|NCT06213896|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
219652629|NCT06213896|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
219652630|NCT06213896|DEVICE|EyeCheckup v2.0|Screening for existence of eye diseases
219652631|NCT00536224|BEHAVIORAL|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
219652632|NCT00536224|BEHAVIORAL|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
219652633|NCT00293124|DRUG|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
219652634|NCT06506019|DRUG|Psilocybin|25 mg psilocybin
219652635|NCT06506019|DEVICE|Functional MRI|The fMRI involving resting state measures and a facial affect task will be conducted one-day and one-month after the dosing session.
219652636|NCT02721524|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
219652637|NCT02527759|BEHAVIORAL|Survey|
218965235|NCT05578001|DRUG|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
218965236|NCT03420027|OTHER|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
218965237|NCT03784287|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
218965238|NCT02586402|DRUG|pegol-Sihematide|
218965239|NCT02586402|DRUG|Epoetin Alfa|
218965240|NCT01513369|DRUG|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
218965241|NCT01513369|DRUG|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
219207971|NCT05774704|DRUG|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
218965242|NCT04697381|BIOLOGICAL|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
219207972|NCT05774704|DRUG|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
218965243|NCT04697381|BIOLOGICAL|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
218965244|NCT04697381|BIOLOGICAL|somatropin - adult cohort|somatropin 0.084 mg/kg/week
218965245|NCT01227564|BIOLOGICAL|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
219207973|NCT03928041|DEVICE|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
219652638|NCT04690790|PROCEDURE|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
219652639|NCT00022243|DRUG|batabulin sodium|
219652640|NCT03555864|DEVICE|infrared transluminescent device|use of infra red for venous access for second intravenous access
219652641|NCT05803070|DRUG|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
219652642|NCT05803070|DRUG|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
219652643|NCT02012933|DRUG|3,4-diaminopyridine|10mg tablets for up to 100mg per day
219652644|NCT06622382|PROCEDURE|Bariatric endoscopic antral myotomy|A mucosal incision is performed using a triangle-tip knife J at the level of the incisura along the level of the greater curvature. Submucosal tunneling is then performed and stopped immediately proximal to the pylorus. Two parallel lines of partial thickness myotomy are then performed from the distal to proximal antrum using the same endoscopic knife. The myotomy is stopped approximately 2 cm distal to the mucosal incision site. Finally, the mucosal incision is closed using endoclips after haemostasis is confirmed.
219652645|NCT00559780|BEHAVIORAL|Resistance training|12 weeks of resistance training (3/week)
219652646|NCT00559780|BEHAVIORAL|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
218965246|NCT01227564|BIOLOGICAL|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
218965247|NCT01227564|OTHER|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
218965248|NCT04616742|DRUG|[14C]SHR6390|Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
218965249|NCT02687659|DEVICE|TEMIS system|Wearing TEMIS system over the day during one week
218965250|NCT01057901|DRUG|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
218965251|NCT01057901|DRUG|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
218965252|NCT00230477|DRUG|Hepsera|
218965253|NCT00230477|DRUG|Hepsera and lamivudine|
218965254|NCT02799979|DEVICE|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
218965255|NCT00890188|DRUG|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
218965256|NCT02096575|OTHER|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
218965257|NCT03825471|PROCEDURE|electrotherapy|Cranial electrotherapy stimulation
219063101|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
219063102|NCT00911365|BIOLOGICAL|normal saline|saline
219652647|NCT00559780|BEHAVIORAL|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
219652648|NCT04789291|DRUG|BI 1595043|Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
219652649|NCT05288894|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
219652650|NCT05015140|OTHER|musıc therapy|calm music with nature sounds set by the music therapist
219652651|NCT03249246|OTHER|No intervention|
219652652|NCT02673801|OTHER|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
218965258|NCT03825471|DRUG|Opioid Anesthetics|consumption of opioids during general anesthesia
218965259|NCT03825471|PROCEDURE|colon cancer surgery|laparoscopic colon cancer surgery
218965260|NCT05463627|DRUG|Metformin|All participants among the three groups were treated with metformin
218965261|NCT02862600|DRUG|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
218965262|NCT02862600|DEVICE|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
218965263|NCT05193357|DEVICE|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
218965264|NCT05990621|BIOLOGICAL|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
218965265|NCT05501262|DEVICE|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
219063103|NCT02384148|OTHER|Circadian rhythm measurement|
219063104|NCT02384148|PROCEDURE|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
219063105|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
219063106|NCT04777682|PROCEDURE|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
219652653|NCT05146986|DEVICE|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
219652654|NCT03729570|OTHER|ePrEP|Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
219652655|NCT04908215|DRUG|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
219652656|NCT04908215|DRUG|Vehicle Cream|topical cream base for dermal application containing no active agent
219652657|NCT02985606|OTHER|Caffeine powder -60|
219652658|NCT02985606|OTHER|Caffeine powder -30|
219652659|NCT02985606|OTHER|Caffeine powder 0|
219652660|NCT02985606|OTHER|Placebo powder -60|
219652661|NCT02985606|OTHER|Placebo powder -30|
219652662|NCT02985606|OTHER|Placebo powder 0|
219652663|NCT00805870|DRUG|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
219652664|NCT00805870|DRUG|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
219652665|NCT02289287|BEHAVIORAL|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
219652666|NCT02289287|BEHAVIORAL|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
219652667|NCT06016569|DIAGNOSTIC_TEST|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
219652668|NCT06016569|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
218965266|NCT05501262|PROCEDURE|Nerve block|Ultrasound and fluoroscopic guided nerve block.
218965267|NCT04859114|BEHAVIORAL|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
219652669|NCT06016569|PROCEDURE|LDCT|LDCT scan will be performed.
219652670|NCT06016569|DIAGNOSTIC_TEST|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
218965268|NCT04859114|BEHAVIORAL|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
219652671|NCT06016569|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed.
218965269|NCT02503345|DRUG|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
218965270|NCT02503345|DRUG|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
218965271|NCT02503345|DRUG|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
218965272|NCT02503345|DRUG|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
219063107|NCT04251468|DEVICE|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
219652672|NCT05107791|DRUG|Stulln Eyedrops|Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
219652673|NCT05107791|DRUG|Thera Tears|The eyedrops will be used in the identical manner as Stulln eyedrops.
219652674|NCT01647191|BEHAVIORAL|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
219652675|NCT01647191|BEHAVIORAL|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
219652676|NCT03499457|DRUG|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
219652677|NCT02407457|DEVICE|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
219652678|NCT02407457|DEVICE|FDA Approved EVAR AAA Graft Systems|
219652679|NCT02035748|DRUG|Ocriplasmin|0.5 mg/0.2 mL solution for injection
219652680|NCT06098703|BEHAVIORAL|CARD (Comfort Ask Relax Distract)|CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
219652681|NCT01647984|DIETARY_SUPPLEMENT|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
219652682|NCT01647984|DIETARY_SUPPLEMENT|placebo|
219652683|NCT01156649|DEVICE|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
219652684|NCT01156649|DEVICE|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
219652685|NCT04346212|DIAGNOSTIC_TEST|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
219652686|NCT01778699|DIETARY_SUPPLEMENT|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
219652687|NCT04662788|DRUG|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
219652688|NCT02707315|DRUG|Gemcitabine|
219652689|NCT02707315|RADIATION|Stereotactic Radiosurgery|
219652690|NCT05448287|BEHAVIORAL|Health and family planning|Promotion of health and family planning behaviors
219652691|NCT05448287|BEHAVIORAL|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
219652692|NCT05448287|BEHAVIORAL|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
219652693|NCT05448287|BEHAVIORAL|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
219652694|NCT03249597|DIAGNOSTIC_TEST|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
219652695|NCT06477068|COMBINATION_PRODUCT|Mobile medical reminder application|"Experimental group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department, in addition to being supported through the telemedicine medication reminder app on smartphones.~Control group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department."
219652696|NCT01112410|OTHER|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
219652697|NCT01112410|OTHER|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
218965273|NCT03809923|DRUG|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
218965274|NCT03809923|DRUG|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
218965275|NCT03809923|DRUG|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
218965276|NCT03809923|DRUG|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
218965277|NCT02906462|OTHER|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
218965278|NCT02906462|OTHER|Usual practices|the centres applies their usual practices
218965279|NCT04223648|DRUG|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
219063108|NCT04251468|DEVICE|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
219652698|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
219652699|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
219063109|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
219652700|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
219652701|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
219652702|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
219652703|NCT01168310|DRUG|Formoterol Fumarate|Inhalation Solution
219652704|NCT01168310|DRUG|Placebo|Inhalation Solution
219652705|NCT01759810|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
219652706|NCT01759810|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
219652707|NCT05410041|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.
219652708|NCT06620341|BEHAVIORAL|drug education|"* Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably."
218965280|NCT03826576|BEHAVIORAL|Multicomponent intervention|"The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants"
218965281|NCT03245229|DRUG|Aprocitentan|Capsule for oral administration
218965282|NCT03245229|DRUG|Rosuvastatin|Tablet for oral administration
218965283|NCT02378025|BEHAVIORAL|Yoga Group|A 10-week yoga course designed to treat pain.
219063110|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
219652709|NCT04399408|DEVICE|Obstetrics Ultrasound (non invasive)|Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
218965284|NCT02378025|BEHAVIORAL|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
218965285|NCT03750422|DEVICE|Picoway|1064/532nm picosecond laser
219652710|NCT04329091|DRUG|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
219652711|NCT01886742|DRUG|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
219652712|NCT01886742|DRUG|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
219652713|NCT03257878|OTHER|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
219063111|NCT00099983|DRUG|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
219652714|NCT00273468|DRUG|Granisetron|
219652715|NCT01058486|BEHAVIORAL|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
218965286|NCT03750422|OTHER|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
218965287|NCT03750422|OTHER|Aquasonic|clear ultrasound gel
218965288|NCT04291378|RADIATION|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
218965289|NCT05151627|PROCEDURE|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
218965290|NCT05151627|DEVICE|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
219063112|NCT00099983|DRUG|Placebo|Placebo
219063113|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
219063114|NCT03352115|DRUG|Placebos|Placebo syrup
219063115|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
218965291|NCT02495103|DRUG|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
219652716|NCT00516191|DRUG|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
219652717|NCT00356902|PROCEDURE|titration of oxygen during resuscitation|
219652718|NCT00533689|PROCEDURE|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
219652719|NCT03722953|OTHER|Control|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
219652720|NCT03722953|OTHER|Aerobic Exercise|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
219652721|NCT02484651|DRUG|Sugammadex|Reversal of deep neuromuscular block
219652722|NCT02484651|DRUG|Rocuronium|Maintenance of deep neuromuscular block
219652723|NCT04637581|BEHAVIORAL|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
219652724|NCT03596606|PROCEDURE|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
219652725|NCT03596606|PROCEDURE|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
219652726|NCT00569647|DEVICE|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
219652727|NCT00569647|DEVICE|Placebo|no use of device
218965292|NCT02495103|DRUG|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
218965293|NCT02495103|DRUG|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
218965294|NCT04186091|PROCEDURE|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
219207974|NCT02932618|BIOLOGICAL|Vonicog alfa|Lyophilized powder and solvent to prepare solution for injection.
219652728|NCT04614610|DRUG|Lidocaine Iv|Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
219652729|NCT04614610|DRUG|Placebo|Dextrose 5% 100mL over 10 minutes
219652730|NCT03668847|DRUG|DM-CHOC-PEN|DM-CHOC-PEN administration by IV infusion
219652731|NCT05476627|DIAGNOSTIC_TEST|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
219652732|NCT00200876|PROCEDURE|Hypertonic saline|To elicit pain
219652733|NCT00200876|PROCEDURE|Isotonic saline|Non-painful control
219652734|NCT00250874|DRUG|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
219652735|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IP
219652736|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IV
219652737|NCT02280746|OTHER|Gluten challenge|Intervention will be continued for at least 6 months
219652738|NCT02857244|DRUG|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
219652739|NCT02857244|DRUG|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
219652740|NCT02857244|DRUG|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil \& duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
219652741|NCT04500964|DEVICE|TAVR|Trancatheter aortic valve replacement
218965295|NCT02187770|DEVICE|IMED-4|Non invasive recording electrode used to assess lung fluid
218965296|NCT00633867|DEVICE|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
218965297|NCT00633867|DEVICE|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
219207975|NCT02932618|BIOLOGICAL|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
218965298|NCT04452929|DRUG|Erenumab|Subcutaneous injection of 140 mg erenumab.
218965299|NCT04452929|DRUG|Placebo|Subcutaneous injection of saline placebo.
218965300|NCT04452929|DRUG|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
218965301|NCT04452929|DRUG|Cilostazol|Oral intake of 200 mg cilostazol.
218965302|NCT01654796|DEVICE|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
218965303|NCT01654796|DEVICE|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
219063116|NCT00359450|DRUG|BMS-275183 (oral taxane)|
219063117|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
219063118|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
219063119|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
219652742|NCT06682182|DRUG|Tislelizumab+SOX|"OX: S-1 dosing based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-\<1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 6 cycles.~Tislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg/m² in 3500ml normal saline, at 43°C for 60 minutes."
219652743|NCT01263782|DRUG|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
219652744|NCT01263782|DRUG|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
219652745|NCT01263782|DRUG|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
219652746|NCT01263782|DRUG|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
219652747|NCT06482294|DRUG|Salbutamol|One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
219652748|NCT06482294|DRUG|Fluticason either Beclometasone or Budesonide|One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
219652749|NCT04381689|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Teratect Prefilled Syringe Inj. 0.5mL
219652750|NCT04381689|BIOLOGICAL|Fluarix Tetra Pre-filled Syringe|Fluarix Tetra Pre-filled Syringe 0.5mL
219652751|NCT01154348|DRUG|S-707106|Tablet, taken once daily with morning meal
219652752|NCT01154348|DRUG|Placebo|Placebo tablet, taken once daily with morning meal
219652753|NCT01154348|DRUG|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
219652754|NCT01154348|DRUG|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
219652755|NCT05768230|DRUG|levosimendan|Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
219652756|NCT05768230|DRUG|5% glucose injection|5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
219652757|NCT02381730|DRUG|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
218965304|NCT04971330|DIAGNOSTIC_TEST|Access HCV|"All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
219652758|NCT04742712|DEVICE|CoronaCheck Device|All participants breath normally into the device for up to 6 minutes
219652759|NCT01864369|BEHAVIORAL|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
219652760|NCT04545567|DEVICE|RocketAP|Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal
219652761|NCT04545567|DEVICE|USS Virginia|Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
219652762|NCT01877967|DIETARY_SUPPLEMENT|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
219652763|NCT01877967|DIETARY_SUPPLEMENT|placebo|
219652764|NCT03979807|DRUG|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
219652765|NCT03979807|DRUG|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
219652766|NCT04060277|DRUG|Letermovir|Given as SOC
218965305|NCT01497145|DRUG|KRN321|
218965306|NCT00649415|DRUG|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
218965307|NCT00649415|DRUG|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
218965308|NCT04610164|DRUG|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
219652767|NCT04060277|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219652768|NCT04060277|OTHER|Placebo Administration|Given IM
219652769|NCT05279976|OTHER|Visualized Education|The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
218965309|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation
219652770|NCT05279976|OTHER|Distraction|Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
219652771|NCT05874427|PROCEDURE|Multimedia informed consent|A standard consent form on paper to explain the procedure, with an additional video to explain the procedure and risks.
219652772|NCT05874427|PROCEDURE|Standard informed consent|A standard consent form, written on paper, used to explain a procedure to a patient face-to-face by a physician.
219652773|NCT01177631|PROCEDURE|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
218965310|NCT03486704|BEHAVIORAL|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
218965311|NCT03486704|BEHAVIORAL|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
218965312|NCT03486704|BEHAVIORAL|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
218965313|NCT03486704|BEHAVIORAL|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
219207976|NCT06173466|DRUG|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
219207977|NCT06173466|DRUG|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
219652774|NCT02644720|PROCEDURE|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
219652775|NCT02644720|PROCEDURE|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
219652776|NCT02644720|DRUG|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
219652777|NCT02644720|DEVICE|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
219652778|NCT02644720|DEVICE|monofocal intraocular lens (IOL) (Tecnis ZCB)|
219652779|NCT05379270|OTHER|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
219652780|NCT05304793|OTHER|Best Practice|Receive usual management of dyspnea
219652781|NCT05304793|BEHAVIORAL|Cognitive Behavior Therapy|Receive TAB treatment
219652782|NCT05304793|OTHER|Questionnaire Administration|Ancillary studies
219652783|NCT04056845|DEVICE|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
219652784|NCT04056845|OTHER|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
219652785|NCT04570527|PROCEDURE|PCI|percutaneous coronary intervention
219652786|NCT05351879|BIOLOGICAL|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
219652787|NCT05128890|PROCEDURE|Resection techniques for pancreatic and liver tumors|to compare open versus minimally invasive pancreatic resection techniques and analyze the different outcome variables from the clinical standpoint
219652788|NCT01826565|PROCEDURE|Rotational technique|90 degree rotation
219652789|NCT02329067|OTHER|walnuts|consumption of 43 g walnuts per day
219652790|NCT02419612|DRUG|Saxagliptin|
219652791|NCT02419612|DRUG|Dapagliflozin|
219652792|NCT02419612|DRUG|Glimepiride|
219652793|NCT02419612|OTHER|Placebo|
219652794|NCT01033955|DRUG|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
219652795|NCT01033955|DRUG|Placebo|identical appearing encapsulated placebo.
219652796|NCT04210908|OTHER|Visual biofeedback|Patient will observe the descent of the fetal head as they push during contractions
219652797|NCT01740908|OTHER|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
219652798|NCT02827019|OTHER|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
219652799|NCT06482684|DRUG|KTE-X19|See description of treatment arms
219652800|NCT06482684|DRUG|Ibrutinib|See description of treatment arms
219652801|NCT04411979|OTHER|treatment-as-usual plus aerobic walking|aerobic walking
219652802|NCT06664138|DRUG|Remimazolam|Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
219652803|NCT06664138|DRUG|Etomidate|Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
219652804|NCT06666933|BEHAVIORAL|Time restricted eating|TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks
219652805|NCT06666933|DRUG|Metformin|Taking metformin 1g bid po only for 6 weeks as control
219652806|NCT03083561|DRUG|LY3337641|Administered orally.
219652807|NCT03083561|DRUG|Placebo|Administered orally.
219652808|NCT00474045|DRUG|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
219652809|NCT00474045|DRUG|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
219652810|NCT00474045|DRUG|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
218965314|NCT03486704|BEHAVIORAL|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
218965315|NCT04276454|DEVICE|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
218965316|NCT00745576|DRUG|SAM-531|
218965317|NCT02599805|DEVICE|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
218965318|NCT05590221|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
218965319|NCT05590221|DRUG|Fludarabine|Administered according to package insert
218965320|NCT05590221|DRUG|Cyclophosphamide|Administered according to package insert
219652811|NCT01754961|DRUG|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
219652812|NCT01754961|DRUG|Placebo|Placebo given orally on Day 1
218965321|NCT02663583|BEHAVIORAL|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
218965322|NCT02663583|BEHAVIORAL|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
219652813|NCT02009397|DRUG|Ipilimumab|
219652814|NCT02009397|DRUG|GM-CSF|
219652815|NCT02175082|OTHER|Cycling at Forced rate|
219652816|NCT02175082|OTHER|Cycling at self-selected rate|
219652817|NCT01312168|DEVICE|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
219652818|NCT01312168|DEVICE|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure \<3 cmH2O, daily use at sleep, six months
219652819|NCT05221346|DIETARY_SUPPLEMENT|Plant food supplement|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
219652820|NCT05221346|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
219652821|NCT05839782|PROCEDURE|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
219652822|NCT05839782|PROCEDURE|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
219652823|NCT05204173|DRUG|sintilimab, paclitaxel and S-1|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
219652824|NCT03280082|OTHER|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
218965323|NCT02663583|BEHAVIORAL|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
218965324|NCT03785743|PROCEDURE|TLPD Surgery|TLPD
218965325|NCT03785743|PROCEDURE|OPD Surgery|OPD
218965326|NCT04735718|DEVICE|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
218965327|NCT04327479|DIAGNOSTIC_TEST|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
218965328|NCT01692873|PROCEDURE|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
218965329|NCT01309308|PROCEDURE|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
218965330|NCT01309308|OTHER|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
218965331|NCT03714737|BIOLOGICAL|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
218965332|NCT03714737|BIOLOGICAL|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
218965333|NCT03714737|BIOLOGICAL|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
218965334|NCT03810404|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
218965335|NCT03810404|DIETARY_SUPPLEMENT|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
218965336|NCT04235803|OTHER|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
218965337|NCT01432509|OTHER|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~* Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and \< 1,26 g/l) or fasting blood glucose ≥ 1 g/l and \< 1,10 g/l with HbA1c ≥ 6,5%.~* First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~* Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~* End of study phone call"
218965338|NCT04496310|PROCEDURE|Telemedicine|Telemedicine versus usual care (face to face visit)
218965339|NCT00938223|BIOLOGICAL|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
219063120|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
219063121|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
219063122|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
219063123|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
219652825|NCT03280082|OTHER|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
218965340|NCT06138288|BEHAVIORAL|acupressure|The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
218965341|NCT03551483|DEVICE|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
218965342|NCT03551483|DEVICE|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
218965343|NCT00411931|DRUG|Multihance|0.5M administered as a single injection
218965344|NCT00002398|DRUG|Levocarnitine|
218965345|NCT00002398|DRUG|Adefovir dipivoxil|
218965346|NCT03304639|BIOLOGICAL|Pembrolizumab|Given IV
218965347|NCT03304639|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218965348|NCT00003173|BIOLOGICAL|filgrastim|
218965349|NCT00003173|DRUG|thiotepa|
218965350|NCT00003173|PROCEDURE|autologous bone marrow transplantation|
218965351|NCT00003173|PROCEDURE|peripheral blood stem cell transplantation|
218965352|NCT01854931|BEHAVIORAL|Tai Ji Quan|single aim intervention
218965353|NCT03759288|DRUG|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
218965354|NCT03759288|DRUG|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
218965355|NCT03759288|DRUG|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
218965356|NCT03759288|DRUG|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
218965357|NCT00371501|DRUG|Rosuvastatin|10mg/day
218965358|NCT00371501|DRUG|placebo|one tablet/day
218965359|NCT00371501|DRUG|aspirin|80mg/day
218965360|NCT00371501|DRUG|placebo|placebo
218965361|NCT05462041|OTHER|DBD Donor Heart Transplantation|A technique of donor heart procurement.
218965362|NCT05462041|DEVICE|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
218965363|NCT02772679|BIOLOGICAL|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
218965364|NCT03811275|BEHAVIORAL|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
218965365|NCT03811275|BEHAVIORAL|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
218965366|NCT04898205|OTHER|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
218965367|NCT04898205|OTHER|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
218965368|NCT04898205|OTHER|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
218965369|NCT03266198|OTHER|No intervention|No intervention
218965370|NCT01214148|DEVICE|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
218965371|NCT02975583|DRUG|Vorapaxar|2.08 mg oral tablet daily
218965372|NCT02975583|DRUG|Placebos|Placebo oral tablet daily
219652826|NCT02987374|BIOLOGICAL|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
219652827|NCT02278120|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
219652828|NCT02278120|DRUG|Tamoxifen|Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)
219652829|NCT02278120|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
219652830|NCT02278120|DRUG|Anastrozole|Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
219652831|NCT02278120|DRUG|Goserelin|Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle
219652832|NCT02278120|DRUG|Placebo|Placebo (hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
219652833|NCT03545594|OTHER|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
219652834|NCT03545594|OTHER|Control|Usual follow-up in the municipality
219652835|NCT02441127|DEVICE|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
219652836|NCT02441127|PROCEDURE|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
219652837|NCT00287989|DRUG|Carboplatin|
218965373|NCT04101201|DIETARY_SUPPLEMENT|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
218965374|NCT04101201|OTHER|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
218965375|NCT05547022|PROCEDURE|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
218965376|NCT03934814|DRUG|TJ011133|TJ011133 will be administered weekly.
218965377|NCT03934814|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
218965378|NCT03934814|DRUG|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
218965379|NCT04964284|BIOLOGICAL|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
218965380|NCT04964284|RADIATION|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
218965381|NCT02648321|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
218965382|NCT02648321|BEHAVIORAL|Health Education|General education about healthy lifestyle and diet.
218965383|NCT03125291|BEHAVIORAL|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
218965384|NCT01818960|PROCEDURE|IRA-PCI|IRA only PCI at the time of Primary PCI
218965385|NCT01818960|PROCEDURE|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
218965386|NCT01574079|OTHER|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
218965387|NCT01574079|OTHER|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
218965388|NCT02865343|DEVICE|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
218965389|NCT02865343|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
218965390|NCT00924417|BEHAVIORAL|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
219652838|NCT00287989|DRUG|erlotinib hydrochloride|150mg
219652839|NCT00287989|DRUG|Paclitaxel|200mg/m2
219652840|NCT00287989|DRUG|erlotinib hydrochloride|1500mg
219652841|NCT00254176|DIETARY_SUPPLEMENT|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
219652842|NCT00254176|DIETARY_SUPPLEMENT|Placebo - added premasol|Premasol 121 mg per kg per day
219652843|NCT00920127|DIETARY_SUPPLEMENT|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
219652844|NCT00006280|DRUG|Tobramycin for Inhalation|
219652845|NCT02262689|DRUG|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
219652846|NCT02262689|DRUG|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
219652847|NCT01966068|OTHER|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
219652848|NCT01486901|DRUG|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
219652849|NCT05071040|BEHAVIORAL|Home-based physical activity|Participants will follow a strength exercise program
219652850|NCT06173635|DEVICE|Maxi Move 5|4 comparative devices will be used to evaluate the MM5 device
219652851|NCT05781516|DRUG|Prednisolone|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
219652852|NCT05781516|DRUG|Baricitinib|Oral Baricitinib 2mg daily for 12 months.
219652853|NCT06667024|DRUG|Hyperbaric bupivacaine|Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
219652854|NCT06667024|DRUG|Dexmedetomidine and Hyperbaric bupivacaine|Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
219652855|NCT02009124|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
219652856|NCT05793450|DRUG|IBI362|2.0mg, SC, single dose
219652857|NCT05303766|DEVICE|Radio-frequency ablation|Radiofrequency thermocoagulation of the genicular nerves
219652858|NCT05303766|DRUG|Intra-articular steroids|Intra-articular steroids for Knee osteoarthritis
218965391|NCT00924417|BEHAVIORAL|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
219063124|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
219652859|NCT05303766|DEVICE|Pulsed Radio-frequency|Intraarticular Pulsed Radiofrequency of the knee
219063125|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
219063126|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
219063127|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
219063128|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
219063129|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
219063130|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
219063131|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
219063132|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
219063133|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
219063134|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
219063135|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
219063136|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
219063137|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
219063138|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
219063139|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
219063140|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
219063141|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
219063142|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
219063143|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
219063144|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
219652860|NCT04430764|PROCEDURE|non-surgical periodontal treatment|Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
219652861|NCT00207558|DRUG|folic acid|
219652862|NCT00020943|BIOLOGICAL|filgrastim|5 ug/kg subQ daily day 4 until ANC \>10,000 (or ANC\> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
219652863|NCT00020943|BIOLOGICAL|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5
219652864|NCT00020943|DRUG|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
219652865|NCT00020943|DRUG|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
219652866|NCT00020943|DRUG|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
219652867|NCT00020943|DRUG|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1\& 2
219652868|NCT00020943|DRUG|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
219652869|NCT00020943|DRUG|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
219652870|NCT00020943|DRUG|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
219652871|NCT00020943|DRUG|prednisone|100 mg/sq m PO Days 3-7, Tx 1 \& 2
219652872|NCT00020943|DRUG|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 \& 2
219652873|NCT00020943|PROCEDURE|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
219652874|NCT01151202|DRUG|AG NPP709syrup|
219652875|NCT00004406|DRUG|human parathyroid hormone|
219652876|NCT01187498|BEHAVIORAL|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
219652877|NCT01187498|DRUG|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
219652878|NCT00041977|DRUG|doxycycline hyclate 20 mg twice daily|
219652879|NCT05043597|PROCEDURE|Thrombus aspiration|Thrombus aspiration
219652880|NCT01720498|DRUG|remifentanil|The effect site concentration of remifentanil
219652881|NCT01717482|DRUG|Metformin|
219652882|NCT01717482|OTHER|Placebo Comparator|Standard of Care Observation
219652883|NCT04794374|OTHER|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
219652884|NCT00191282|DRUG|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
219652885|NCT00191282|DRUG|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%
219652886|NCT00191282|DRUG|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
219652887|NCT00191282|DRUG|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
219652888|NCT00191282|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
219652889|NCT01736774|OTHER|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
219652890|NCT01736774|OTHER|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
219652891|NCT00102531|DRUG|Cisplatin liposomal|
219652892|NCT02628457|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
219652893|NCT02429024|DEVICE|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
219652894|NCT02429024|DEVICE|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
219652895|NCT05468242|DRUG|Neoadjuvant chemo-immunotherapy|The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
219652896|NCT05468242|DRUG|Bevacizumab|The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
219652897|NCT05468242|RADIATION|Radiotherapy|Definitive radiotherapy to the thoracic lesions.
219652898|NCT05468242|DRUG|Tislelizumab|Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
219652899|NCT06163742|DEVICE|Product X|The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
219652900|NCT06163742|DEVICE|Standard-of-Care|The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
219652901|NCT03494400|OTHER|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
219652902|NCT03494400|OTHER|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
219652903|NCT03004170|BEHAVIORAL|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
219652904|NCT03004170|BEHAVIORAL|Telephone-Administered Coping Effectiveness Training|
219652905|NCT06370871|DRUG|Brigimadlin|Brigimadlin
219652906|NCT06370871|DRUG|Ezabenlimab|Ezabenlimab
219652907|NCT06370871|DRUG|Gemcitabine|Solution for infusion
219652908|NCT06370871|DRUG|Docetaxel|Solution for infusion
219652909|NCT05462132|DRUG|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
219652910|NCT02288078|OTHER|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
219652911|NCT02288078|OTHER|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
219652912|NCT02288078|OTHER|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
219652913|NCT02288078|OTHER|Clinical findings|"* Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis"
219652914|NCT02288078|OTHER|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
219652915|NCT02288078|OTHER|Coagulation and fibrinolysis system|international normalized ratio (INR)
219652916|NCT02288078|OTHER|Urinalysis|Proteinuria (qualitative)
219652917|NCT02288078|OTHER|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
219652918|NCT02288078|OTHER|Adverse event|CTCAE ver.4.0
219652919|NCT02288078|OTHER|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
219652920|NCT02288078|OTHER|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
219652921|NCT02288078|OTHER|Brain MRI|If any symptom of brain metastasis is suspected
219652922|NCT02288078|DRUG|Dexamethasone|Capsule filled with dexamethasone and lactose
219652923|NCT02288078|DRUG|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
219652924|NCT02288078|DRUG|Placebo|Capsule filled with lactose
219652925|NCT02288078|DRUG|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
219652926|NCT02694354|DRUG|BI 685509|
219652927|NCT02694354|DRUG|Placebo|
219652928|NCT04756154|DRUG|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
219652929|NCT04756154|DRUG|Normal saline|Apply topically to the inguinal region for 2 minutes
219652930|NCT05599087|BIOLOGICAL|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
219652931|NCT00596128|BEHAVIORAL|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
219652932|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
219652933|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
219652934|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
219652935|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
219652936|NCT05028127|DRUG|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
219652937|NCT02345460|DRUG|Irinotecan Hydrochloride|Given IV
219652938|NCT02345460|DRUG|Oxaliplatin|Given IV
219652939|NCT02345460|DRUG|Leucovorin Calcium|Given IV
219652940|NCT02345460|DRUG|Fluorouracil|Given IV
219652941|NCT02345460|OTHER|Laboratory Biomarker Analysis|Correlative studies
219652942|NCT00639574|DRUG|Néfopam|"There are two groups :~* a group N : néfopam~* a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
219652943|NCT00454220|OTHER|Placebo|33 patients to placebo + 131-I arm
219652944|NCT00454220|DRUG|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
219652945|NCT00454220|DRUG|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
219652946|NCT02562222|PROCEDURE|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652947|NCT02562222|PROCEDURE|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652948|NCT02562222|PROCEDURE|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652949|NCT02562222|PROCEDURE|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652950|NCT02562222|PROCEDURE|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652951|NCT02562222|PROCEDURE|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219207978|NCT06579807|BEHAVIORAL|Exercise training|The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
219207979|NCT01805219|OTHER|GPS and accelerometer recording (s) during exercises|
219207980|NCT02324790|DEVICE|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
219207981|NCT05661955|DRUG|BGB-A445|administered intravenously
219207982|NCT05661955|DRUG|Tislelizumab|administered intravenously
219652952|NCT02562222|PROCEDURE|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
219652953|NCT04973371|DIAGNOSTIC_TEST|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® \[Cepheid, Sunnyvale, CA\] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
219652954|NCT00525811|OTHER|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
219652955|NCT00525811|OTHER|patient information|Information on acute low back pain, information on depression
219652956|NCT01790828|DRUG|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
219652957|NCT02101931|DRUG|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
219652958|NCT06463392|OTHER|No Intervention: Observational Cohort|No intervention is scheduled for this observational study.
219652959|NCT04271319|DEVICE|BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device|"Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
219652960|NCT04271319|DEVICE|Sham PRO-SPORT Ultra® Device|"Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications."
219652961|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652962|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652963|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652964|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652965|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652966|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
219652967|NCT04567927|OTHER|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
219652968|NCT04015076|DRUG|Inzomelid|Active Drug
219652969|NCT04015076|DRUG|Placebo|Placebo to Match
219652970|NCT00468754|DEVICE|Insulin pumps|
219652971|NCT03721835|DEVICE|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
219652972|NCT04198584|BEHAVIORAL|VC-CBCS|A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
219652973|NCT06408064|OTHER|Music therapy|Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.
219063145|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
219063146|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
219063147|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
219063148|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
218965392|NCT06324929|BEHAVIORAL|CARRII Native Rapid Pilot Testing|The candidates that will be tested are: 1) Telephone-administered 30 day timeline follow-back of drinking, sex, and contraception, administered by phone at enrollment and monthly, which should increase awareness of AEP risk and motivation for alcohol and contraception behavior change, 2) Mailed pregnancy tests sent monthly to raise consciousness of pregnancy risk and to detect a new pregnancy early, which should increase motivation for contraception behavior change, 3) Automated, personalized digital safer sex and drink counting/reduction skills training, to improve drinking self-management skills and self-efficacy for drinking reduction and contraception use, 4) Fully automated text messages prompting usage of safer sex and drink reduction skills, which should increase self-efficacy for behavior change, and 5) access to an anonymized Community Message Board of Native women to discuss challenges in behavior change, which should increase perceived social support.
218965393|NCT00028275|DRUG|Gamma Interferon 1b|
218965394|NCT04071587|DEVICE|Brain Computer Interface training|Training with RecoveriX system.
218965395|NCT04071587|BEHAVIORAL|Control|Standard physiotherapy and occupational therapy according to clinical routines.
218965396|NCT03391531|PROCEDURE|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
218965402|NCT05128500|PROCEDURE|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
218965403|NCT03640559|DRUG|Seroguard|
218965404|NCT03640559|DRUG|Placebos|
218965405|NCT01436162|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
218965406|NCT01436162|DRUG|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
218965407|NCT04157556|OTHER|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705."
218965408|NCT05270161|PROCEDURE|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
218965409|NCT05270161|PROCEDURE|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
218965410|NCT05270161|PROCEDURE|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
218965411|NCT05270161|PROCEDURE|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
218965412|NCT00805233|DRUG|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
218965413|NCT00805233|DRUG|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
219652974|NCT02744027|OTHER|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
219652975|NCT02744027|OTHER|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
219652976|NCT02744027|OTHER|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
219652977|NCT01726036|DEVICE|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
219652978|NCT01726036|DEVICE|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
218965414|NCT01825954|DEVICE|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
218965415|NCT01467245|PROCEDURE|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
219063149|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
219652979|NCT00779532|DRUG|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
219652980|NCT00779532|DRUG|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
219652981|NCT00779532|DRUG|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
219652982|NCT00779532|DRUG|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
219652983|NCT02763397|DEVICE|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
219652984|NCT02763397|DEVICE|DBS|DBS will be switched off
219652985|NCT05519059|DRUG|Pelareorep|Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
219652986|NCT05341206|DRUG|Herbal gargle|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
219063150|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
219652987|NCT05341206|OTHER|Normal saline|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
219652988|NCT02343445|DRUG|P-1037|P-1037 is a novel ENaC inhibitor
219652989|NCT02343445|DRUG|Hypertonic Saline|4.2% saline solution
219652990|NCT02343445|DRUG|Saline|0.17% saline solution
219652991|NCT01190358|DIETARY_SUPPLEMENT|Placebo|Sugar pill containing maltodextrin.
219652992|NCT01190358|DIETARY_SUPPLEMENT|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
219652993|NCT02057029|BEHAVIORAL|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
218965416|NCT01467245|PROCEDURE|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
218965417|NCT05362578|DEVICE|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
219652994|NCT06605989|PROCEDURE|Nasotracheal intubation|For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.
219652995|NCT05743062|BEHAVIORAL|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
219652996|NCT05743062|OTHER|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
219652997|NCT01390428|DRUG|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
219652998|NCT02800915|OTHER|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
219652999|NCT06062199|PROCEDURE|Training in the A-DIVA scale and its failure prediction score|Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
218965418|NCT05362578|DEVICE|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
218965419|NCT05364021|DRUG|LP352|LP352 administered three times daily, orally or through G-tube
218965420|NCT05364021|DRUG|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
219063151|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
219653000|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
219653001|NCT06100770|DEVICE|Aveir AR Leadless Pacemaker|This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.
219653002|NCT06100770|DEVICE|Single-chamber atrial transvenous pacemaker|This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study
219653003|NCT05348837|PROCEDURE|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
219653004|NCT00462176|PROCEDURE|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
219653005|NCT00462176|OTHER|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
219653006|NCT05863520|BEHAVIORAL|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
219653007|NCT05863520|BEHAVIORAL|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
219653008|NCT04381195|DIAGNOSTIC_TEST|REALS Development|Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.
218965421|NCT01931085|DRUG|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
218965422|NCT02747979|OTHER|hemodialysis only|hemodialysis treatment only
218965423|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
218965424|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
218965425|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in enhanced standard care
218965426|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in psychological intervention
218965427|NCT06080139|BEHAVIORAL|Refugee parenting education in a participatory community|"Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas."
218965428|NCT01742247|OTHER|Physiogel|Application of moisturizer on laser-treated area
218965429|NCT01742247|OTHER|Moisturizer|Application of moisturizer on laser-treated area
219653009|NCT04381195|DIAGNOSTIC_TEST|REALS Testing|A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
219653010|NCT04281784|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
219653011|NCT05998161|BEHAVIORAL|reviga|Participants will receive access to the digital health intervention reviga in addition to TAU.
219653020|NCT04322539|DRUG|Fruquintinib|Oral VEGFR inhibitor
218965430|NCT02283151|DIETARY_SUPPLEMENT|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
218965431|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
219063152|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
219063153|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
219063154|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
219063155|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
219063156|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
218965432|NCT03456609|DRUG|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
219063157|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
219063158|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
219063159|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
219063160|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
219063161|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
219063162|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
219653021|NCT04322539|DRUG|Placebo|Placebo capsule
219653022|NCT06052748|DRUG|AD-223A|PO, Once daily(QD), 8weeks
219653023|NCT06052748|DRUG|AD-223B|PO, Once daily(QD), 8weeks
219653024|NCT06052748|DRUG|AD-223C|PO, Once daily(QD), 8weeks
219653025|NCT06052748|DRUG|AD-223A Placebo|PO, Once daily(QD), 8weeks
219653026|NCT06052748|DRUG|AD-223B Placebo|PO, Once daily(QD), 8weeks
219653027|NCT06052748|DRUG|AD-223C Placebo|PO, Once daily(QD), 8weeks
219653028|NCT05899491|PROCEDURE|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
219653029|NCT05899491|PROCEDURE|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
219653030|NCT03203928|BEHAVIORAL|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
219653031|NCT00743938|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
219653032|NCT00743938|DRUG|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
219653033|NCT01702532|DRUG|Nicotine|Comparison of different dosage forms of nicotine
219653034|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for banking
219653035|NCT05770531|PROCEDURE|Computed Tomography|Undergo CT
219653036|NCT05770531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219653037|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
219653038|NCT05770531|BIOLOGICAL|Sacituzumab Govitecan|Given by IV
219063163|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
219063164|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
219653039|NCT04030260|DRUG|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
219653040|NCT04030260|RADIATION|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
219653041|NCT04549376|DRUG|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
219653042|NCT04549376|DRUG|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
219653043|NCT04549376|DRUG|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
219653044|NCT04549376|DRUG|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
219653045|NCT04549376|DRUG|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
219653046|NCT04549376|OTHER|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
218965433|NCT03456609|DRUG|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
218965434|NCT00657826|DEVICE|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
218965435|NCT00247533|PROCEDURE|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
219063165|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
219063166|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
219063167|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
219653047|NCT04549376|OTHER|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
219653048|NCT05103436|OTHER|TENS|Electrical nerve stimulation
219653049|NCT03751436|DRUG|Enzalutamide|Given PO
219653050|NCT03751436|DRUG|Venetoclax|Given PO
219653051|NCT05258799|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
219653052|NCT04222842|DRUG|CM082|Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
219653053|NCT06537076|DRUG|AR1005|AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
219653054|NCT06537076|DRUG|Placebo|Matching placebo for AR1005 to be administered BID for 20 weeks
219653055|NCT06537076|DRUG|Rivastigmine 3 mg|3mg Rivastigmine will be administered BID for both active and placebo groups
219653056|NCT02533102|DRUG|E7050|100 mg tablet administered orally
219653057|NCT01846221|DRUG|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
218965436|NCT05049733|DRUG|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
218965437|NCT05049733|DRUG|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
218965438|NCT05049733|DRUG|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
219653058|NCT01846221|DRUG|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
219653059|NCT02920541|DRUG|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
219653060|NCT02967913|PROCEDURE|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
218965439|NCT05049733|DRUG|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
218965440|NCT04604509|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
218965441|NCT04604509|DRUG|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
218965442|NCT04604509|OTHER|Questionnaire Administration|Ancillary studies
218965443|NCT04604509|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
218965444|NCT04604509|DRUG|Varenicline|Given PO
219653061|NCT01609166|DRUG|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
219653062|NCT01609166|DRUG|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
219653063|NCT06649526|OTHER|endotracheal intubation with videolaryngoscope|The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
219653064|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
219653065|NCT01639066|DRUG|Entecavir|Entecavir 1 mg daily Oral
219653066|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
219653067|NCT06309420|DEVICE|Cryogenic treatment of warts (Pixie CO2)|Treatment of common and plantar warts by cryotherapy treatment.
219653068|NCT06309420|DEVICE|Cryogenic treatment of warts (Wortie®)|Treatment of common and plantar warts by cryotherapy treatment.
219653069|NCT06620081|OTHER|Performance Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
219653070|NCT06620081|OTHER|Functional Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
219653071|NCT02712762|OTHER|Cross-sectional study|
219653072|NCT04146675|DEVICE|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
219653073|NCT04146675|DEVICE|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
219653074|NCT04326868|DRUG|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
218985258|NCT04776109|PROCEDURE|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
219063168|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
219653075|NCT03652233|DRUG|Nivolumab|Given by vein every 14 days for up to 12 months
219653076|NCT03652233|DRUG|Afatinib|Taken by mouth daily for up to 12 months
219653077|NCT02879994|OTHER|Laboratory Biomarker Analysis|Correlative studies
219653078|NCT02879994|BIOLOGICAL|Pembrolizumab|Given IV
219653079|NCT02741791|DRUG|AXS-05|AXS-05 taken daily for 6 weeks.
219653080|NCT02741791|DRUG|Bupropion|Buproprion taken daily for 6 weeks.
219653081|NCT02750605|DEVICE|DEB|Intervention with drug eluting balloon.
219653082|NCT02750605|DEVICE|POBA|Intervention with old technology as comparison
219653083|NCT04132089|BEHAVIORAL|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
219653084|NCT04096898|DEVICE|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
219653085|NCT06077149|BIOLOGICAL|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
219653086|NCT03568032|DIAGNOSTIC_TEST|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
219653087|NCT03568032|DIAGNOSTIC_TEST|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
219653088|NCT03568032|DIAGNOSTIC_TEST|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
219653089|NCT03568032|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Cognitive assessment
219653090|NCT03568032|OTHER|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
219653091|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
219653092|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
219653093|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
219653094|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
219653095|NCT05387460|DIAGNOSTIC_TEST|radiomics|Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
219653096|NCT00372723|DRUG|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
219653097|NCT04564469|DRUG|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration \&( F - 15)protocol in which furosemide is administered 15 min before tracer administration
219653098|NCT02101372|BEHAVIORAL|treatment as usual|case management
219653099|NCT02101372|BEHAVIORAL|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
219653100|NCT01097421|DRUG|Pramipexole Extended Release|
219653101|NCT06523023|BEHAVIORAL|An integrated online program|Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
219063169|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
219063170|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
219063171|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
219063172|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
219063173|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
219063174|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
219653102|NCT00122538|DRUG|Efavirenz (EFV)|
219653103|NCT00122538|DRUG|Lamivudine (3TC)|
219653104|NCT00122538|DRUG|Didanosine (ddI)|
219653105|NCT01013844|BEHAVIORAL|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
219653106|NCT02018172|DRUG|somatropin|
219653107|NCT05212701|DRUG|Reparixin|The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
219653108|NCT05212701|DRUG|Placebo|The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
219653109|NCT02685501|OTHER|no intervention|
219653110|NCT02381301|BIOLOGICAL|Venous blood sampling prior to CCTA.|
219653111|NCT02634268|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
219653112|NCT05102825|DIAGNOSTIC_TEST|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
219653113|NCT03479359|BEHAVIORAL|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
219653114|NCT05523232|OTHER|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
219653115|NCT05523232|OTHER|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
219653116|NCT00740909|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
218965445|NCT05545163|DEVICE|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
218965446|NCT00655941|BEHAVIORAL|Dietary instruction|Weekly instruction by dieticians
218965447|NCT00655941|OTHER|Exercise|Supervised exercise in groups
218965448|NCT01419262|DRUG|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
218965449|NCT01419262|DRUG|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
219653117|NCT01608815|BIOLOGICAL|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
219653118|NCT01820507|DEVICE|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
219653119|NCT01820507|DEVICE|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
219653120|NCT05526378|BEHAVIORAL|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
219653121|NCT00368693|DEVICE|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
219653122|NCT00410020|BEHAVIORAL|Alpha-linolenic enriched diet|
219653123|NCT01619644|DRUG|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
219653124|NCT01619644|DRUG|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
219653125|NCT04282291|PROCEDURE|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
219653126|NCT04282291|DRUG|Morphine|The continuous (basal) dose
219653127|NCT04282291|DEVICE|PCA CADD Smith Medical pumps|perfusion
219653128|NCT02340260|BEHAVIORAL|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
219653129|NCT02340260|BEHAVIORAL|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
219653130|NCT06622460|OTHER|Hand Dexterity Assessment|to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
219653131|NCT00522691|PROCEDURE|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
219063175|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
219063176|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
219063177|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
219063178|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
219653132|NCT01945801|DRUG|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
218965450|NCT05745194|BEHAVIORAL|Promotion of adherence to the MedDiet|"Participants will be followed in six individual nutrition consultations with a duration of 30 to 60 minutes. The consultations will be focused on promoting the adherence to the MedDiet.~The nutritional intervention will be personalized to each individual ad libitum, without calories or macronutrients restriction and without the goal to promote weight change. The intervention will begin with an initial assessment of the dietary patterns of the participants in which the nutritionist will identify potential behavioural changes to promote adjustments in dietary habits and therefore adherence to the MedDiet.~The intervention will promote positive recommendations (behaviours recommended to follow) and negative recommendations (behaviours recommended to reduce or eliminate) (26), using the strategy and MedDiet definition proposed by Estruch et al. in the Primary Prevention of Cardiovascular Disease with a Mediterranean Diet study (3).~The participants will also maintain MDD TAU."
219653133|NCT01945801|OTHER|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
218965451|NCT06491329|OTHER|high-intensity interval training|high-intensity interval training ： 40-50 minutes, patients engage in power cycling with intervals of high-intensity exercise at 75%-100% of VO2peak for 30s-1min, followed by 30s-1min of passive recovery, totaling 15-25 cycles.
218965452|NCT06491329|OTHER|moderate-intensity interval training|40-50 minutes, involves power cycling with 8 minutes of moderate-intensity exercise at 40%-60% of VO2peak followed by 2 minutes of passive recovery, totaling 4 cycles.
218965453|NCT00033852|PROCEDURE|Massage Therapy|
218965454|NCT00474981|BEHAVIORAL|IMNCI|Implementation of IMNCI in the intervention sites
218965455|NCT01564446|OTHER|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
218965456|NCT01697098|DRUG|Dexamethasone 24 hours|
218965457|NCT01697098|DRUG|Dexamethasone 12|
218965458|NCT02211638|DRUG|Candesartan Cilexetil|Candesartan Cilexetil tablet
218965459|NCT03237195|OTHER|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
218965460|NCT04029155|DEVICE|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
218965461|NCT01260961|DIETARY_SUPPLEMENT|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
218965462|NCT01260961|DIETARY_SUPPLEMENT|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
218965463|NCT06207981|DRUG|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)"
218965464|NCT06207981|DRUG|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
218965465|NCT06207981|RADIATION|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
218965466|NCT00859027|DRUG|risedronate|35 mg/week by mouth
218965467|NCT00859027|DRUG|Placebo risedronate oral tablet|One tablet by mouth every week as directed
218965468|NCT04041700|DEVICE|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
218965469|NCT02775903|DRUG|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
218965470|NCT02775903|BIOLOGICAL|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
218985259|NCT05821400|OTHER|observational study|observational study
219653134|NCT01945801|DRUG|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
219653135|NCT03246165|PROCEDURE|Cardiac surgery|Coronary bypass, heart valve replacement
219653136|NCT02417922|OTHER|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
219653137|NCT02417922|OTHER|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
219653138|NCT05149352|BEHAVIORAL|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
219207983|NCT05880004|BEHAVIORAL|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
219207984|NCT03699163|DIAGNOSTIC_TEST|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
219207985|NCT06446492|OTHER|ViDEO explaining study|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
219207986|NCT06446492|OTHER|Usual Care|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
219653139|NCT05149352|BEHAVIORAL|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
219653140|NCT03275259|DEVICE|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
218965471|NCT03173534|DEVICE|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
218965472|NCT03173534|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
218965473|NCT05611125|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
218965474|NCT06404346|DIAGNOSTIC_TEST|High Velocity Thrust|Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
219653141|NCT03540303|DRUG|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
219653142|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
218965475|NCT06404346|OTHER|Bowen therapy|participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
218965476|NCT00188799|PROCEDURE|daily Xray volume imaging for planning radiotherapy|
219207987|NCT06570616|DEVICE|CPAP (fixed mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
219207988|NCT06570616|DEVICE|APAP (automatic mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
219207989|NCT04140487|DRUG|Azacitidine|Given IV
219207990|NCT04140487|DRUG|Gilteritinib|Given PO
219207991|NCT04140487|DRUG|Venetoclax|Given PO
219207992|NCT03705793|DRUG|Mometasone Furoate Nasal Irrigation|Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
219207993|NCT03705793|DRUG|Mometasone Nasal Spray|Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
219207994|NCT04090541|OTHER|Rigid Tape|Non-Elastic Tape
219653143|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
219653144|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
219653145|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
219653146|NCT06478849|OTHER|QUESTIONNAIRES|QUESTINNAIRES / WEBINARS
219653147|NCT04446845|DRUG|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
219653148|NCT04446845|DRUG|Conventional Stimulation (Elonva+rFSH) in follicular phase|From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
219653149|NCT02895308|BEHAVIORAL|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
219653150|NCT02895308|BEHAVIORAL|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
219207995|NCT04090541|OTHER|Kinesiology Tape|Tape can be elongate only one direction
219207996|NCT04090541|OTHER|Biomechanical Tape|Tape can be elongate only two direction
219207997|NCT02719574|DRUG|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
219207998|NCT02719574|DRUG|Azacitidine|azacitidine will be administered per site's standard of care
219207999|NCT02719574|DRUG|Cytarabine|low-dose cytarabine will be administered per site's standard of care
219208000|NCT01443260|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
219208001|NCT03027128|BIOLOGICAL|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
219208002|NCT06137976|PROCEDURE|Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)|Placement of tube through the nose or mouth into the stomach for gastric decompression
218965477|NCT01284673|OTHER|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
218965478|NCT04588532|DRUG|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
218965479|NCT04588532|DRUG|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
218965480|NCT04588532|DRUG|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
218965481|NCT04588532|DRUG|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
218965482|NCT03868982|DEVICE|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
219208003|NCT06336967|BEHAVIORAL|GUIDE|The GUIDE App is a wellbeing app designed for first responders and veterans that uses small group support, a learning management system, drivers of behavior change, and an anonymous member experience safeguarded by a leader in identity and login privacy, Okta (okta.com). It includes three main features: 1) Community, 2) Wisdom, and 3) Daily Practice. The Community feature connects app users with an online community of like folks, allowing for human support, encouragement, accountability and coaching. Online communities are moderated by GUIDE employees. The Wisdom feature includes tools and interactive media for personal growth. The Daily Practice feature includes simple, daily routines to maintain mental and emotional wellness.
219208004|NCT06261814|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
219208005|NCT06261814|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219653151|NCT06424600|OTHER|Gingival Index|The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.
219653152|NCT02049840|DEVICE|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
218965483|NCT02861378|DRUG|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
218965484|NCT02861378|DRUG|Water|Injection of 1ml of physiologic saline water at injection site
218965485|NCT04104542|BEHAVIORAL|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
218965486|NCT04104542|BEHAVIORAL|Healthy Lifestyle|Diet and Exercise
218965487|NCT07129798|PROCEDURE|ILM flap with no endotamponade technique|Standard 3-port pars plana vitrectomy will be performed under either local anesthesia or general anesthesia. After core vitrectomy, posterior vitreous detachment induction will be done using vitrectomy cutter suction with the staining of intravitreal triamcinolone if necessary. This is followed by staining of the ILM with ILM blue dye. A half-moon shaped temporal ILM flap will be created, bridging the MH, using an end-gripping intraocular forceps. The posterior pole would be filled with perfluorocarbon (PFC) liquid and cohesive viscoelastic will be injected under the PFC to stabilize the ILM flap over the MH. Removal of PFC and search for peripheral retinal breaks will be done before removal of vitrectomy trocars and closure of sclerotomies wounds. Surgery will be combined with cataract removal (phacoemulsification) with intraocular lens implantation if patients have visually significant cataract. No specific post-operative posture will be required.
218965488|NCT03255447|DEVICE|Immunoadsorption|Fresenius Globaffin
218965489|NCT06575036|DRUG|Sugammadex|The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
218965490|NCT01815203|DRUG|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
218965491|NCT01815203|DRUG|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
218965492|NCT04571515|DRUG|MR-107A-01|Oral tablet
218965493|NCT04571515|DRUG|Placebo|Oral tablet
218965494|NCT06994078|DRUG|68Ga-NOTA-Nectin-4 antibody fragment|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed urothelial carcinoma, breast cancer, lung carcinoma and other malignant tumors with high Nectin-4 expression and healthy volunteers, using specific positron imaging agents targeting Nectin-4 (taking \[68Ga\]Ga-NOTA-Nectin-4 antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
219208006|NCT06261814|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
219653153|NCT05645419|BEHAVIORAL|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
219653154|NCT05207618|DIETARY_SUPPLEMENT|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
219208007|NCT06261814|OTHER|Medical Chart Review|Ancillary studies
219208008|NCT06547931|OTHER|Data collection and analysis|Retrospective collection of clinical and laboratory data relating to the definition of the nature of neutropenia
219208009|NCT03094052|DRUG|Neratinib|Given orally (PO)
219208010|NCT03094052|BIOLOGICAL|Trastuzumab|Given Intravenously (IV)
219208011|NCT03094052|DRUG|Loperamide|Given PO
219208012|NCT03094052|DRUG|Crofelemer|Given PO
219208013|NCT03094052|DRUG|Diphenoxylate/Atropine|Allowed for participants experiencing refractory diarrhea
218965495|NCT06676631|BIOLOGICAL|NK 010 or NK042|NK010 is an allogeneic non-genetically modified NK cell infusion. NKX010 will be administered at a dose of 2.5 × 109 NK cells, 5.0 × 109 NK cells and 7.5 × 109 NK cells by a dose-escalation design and administered IV. N042 is an allogeneic genetic modification of NK cell. NKX042 will be administered at a dose of 6 × 108 NKR positive NK cells, 1.2 × 109 NKR positive NK cells and 2.4 × 109 NKR positive NK cells by a dose-escalation design and administered IV.
218965496|NCT06676631|DRUG|Rituximab|RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
218965497|NCT05140382|DRUG|AZD4573|AZD4573 will be given intravenously
219653155|NCT00813670|DRUG|XPF-001|Single oral dose, or 6 days of repeated oral doses.
219653156|NCT03714646|DIETARY_SUPPLEMENT|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
219653157|NCT03714646|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before the CID
219653158|NCT03714646|DIETARY_SUPPLEMENT|beta gluten|12 g beta gluten there day before the CID
219653159|NCT05896722|OTHER|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
219653160|NCT05896722|OTHER|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
219653161|NCT05896722|OTHER|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
219653162|NCT05896722|OTHER|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
219653163|NCT05896722|OTHER|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
219653164|NCT00175032|DRUG|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
219653165|NCT00175032|DRUG|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
218965498|NCT06612424|DRUG|ANTERİOR QUADRATUS LUMBORUM BLOCK|In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 20 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
218965499|NCT06612424|DRUG|İNTRATECHAL MORPHİNE GROUP|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
219208014|NCT05567068|DRUG|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
219208015|NCT05567068|DRUG|Mesalamine|Mesalamine
219653166|NCT02662400|BIOLOGICAL|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
219653167|NCT04495816|DRUG|Omega-3 Fatty Acid Supplement|Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
219653168|NCT04495816|DRUG|Placebo/Control|Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
219653169|NCT05399017|DEVICE|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
219653170|NCT00428051|OTHER|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
219653171|NCT03889470|DRUG|NTG 1 MG/ML Injectable Solution|administered after sheath placement
219653172|NCT06269016|OTHER|expremental pre and post test|effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
219653173|NCT02052596|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
219653174|NCT02052596|BIOLOGICAL|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
219653175|NCT00558896|DRUG|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
219653176|NCT00558896|DRUG|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
219653177|NCT05964517|OTHER|Fascial Distortion Model|Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
219653178|NCT06119334|BEHAVIORAL|Online intervention|Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
219653179|NCT00150124|DRUG|MTZ+LT4|
219653180|NCT00150124|DRUG|Methimazole|
219653181|NCT00705718|DEVICE|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
219653182|NCT03509870|BIOLOGICAL|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
219653183|NCT00182728|PROCEDURE|surgery|conventional
219653184|NCT00182728|PROCEDURE|therapy|neoadjuvant
218965500|NCT07010770|OTHER|Web-Based Training (WBT)|A self-paced online training course that includes video demonstrations, self-guided modules, and clinical materials/resources.
219653185|NCT00182728|RADIATION|radiation therapy|intraoperative radiation therapy
219653186|NCT06649461|PROCEDURE|ozone injections|Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).
219653187|NCT06649461|OTHER|Splint|hand splint for night
219653188|NCT01881997|DRUG|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
219653189|NCT01881997|DRUG|Normal Saline|IM normal saline
219653190|NCT02402634|OTHER|Mechanical ventilatory lung care|
219653191|NCT06041425|DRUG|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
218965501|NCT07010770|OTHER|Work Sample Review (WR)|Four months of weekly hour-long consultation that will include trainer-led reviews of work samples, focusing on the Impact Statement and Stuck Point Log.
219653192|NCT06041425|DRUG|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
219653193|NCT00463216|BEHAVIORAL|A multidisciplinary diagnostic evaluation|
219653194|NCT02161003|PROCEDURE|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
219653195|NCT02161003|PROCEDURE|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
218965502|NCT07010770|OTHER|Step down to fidelity self-monitoring|"After four months, and for participants who are classified as meeting early fidelity, for the next two months, therapists in self-monitored fidelity will no longer attend group consultation. Instead, they will assess their own fidelity through self-report surveys."
218965503|NCT07010770|OTHER|Step up to session audio review|"After four months, and for participants who are classified as meeting fidelity in progress, for the next two months, therapists will have their session audio recordings reviewed and rated for fidelity."
218965504|NCT07010770|OTHER|Standard Consultation (SC)|Four months of weekly hour-long group consultation
218965505|NCT07010770|OTHER|Standard Training (ST)|2-day instructor-led CPT workshop.
218965506|NCT07010770|OTHER|Continue in Standard Consultation|After four months, therapists will continue to attend weekly hour-long group consultation for another two months.
218965507|NCT00911742|DRUG|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
218965508|NCT00911742|DRUG|Zytram|1 Zytram 200 mg tablet as a single dose
218965509|NCT06683755|DRUG|Nivolumab|Given by IV
218965510|NCT06683755|DRUG|Relatlimab|Given by IV
218965511|NCT06683755|DRUG|Ipilimumab|Given by IV
219653196|NCT06137703|DRUG|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
219653197|NCT06137703|DRUG|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
219653198|NCT06137703|DRUG|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
219653199|NCT06137703|DRUG|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
218965512|NCT06684444|BEHAVIORAL|firefighter Sleep Health Coaching Intervention (ffSHC)|This multi-component intervention is based on principles of cognitive behavioral therapy for insomnia. It includes telephone-based sleep health coaching to individuals, targeted training and sleep health education to fire service leaders, agency-level sleep health promotion, and facilitation strategies to internal facilitators.
219653200|NCT02550392|BEHAVIORAL|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
219653201|NCT02160847|BEHAVIORAL|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
219653202|NCT01971762|BEHAVIORAL|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
219653203|NCT01971762|BEHAVIORAL|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
219653204|NCT05473689|DEVICE|Continuous positive airway pressure (CPAP) therapy|Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
219653205|NCT02594189|OTHER|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
219653206|NCT06620094|OTHER|diabetes education videos|In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
219653207|NCT03837119|OTHER|pregnancy outcome|descriptive statistics of variables
219653208|NCT04649918|OTHER|pulmonary rehabilitation|COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
219653209|NCT06166043|BEHAVIORAL|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
219653210|NCT03059706|DEVICE|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
219653211|NCT03059706|OTHER|saline|intra-articular injection of saline after arthroscopic surgery
219653212|NCT00108342|DRUG|Nicotine gum - 2 mg and 4 mg|
219653213|NCT00108342|DRUG|Nicotine lozenges - 2 mg and 4 mg|
219653214|NCT00108342|DRUG|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
219653215|NCT00108342|OTHER|Computer learning|
219653216|NCT01527487|DRUG|Eribulin|1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
219653217|NCT01527487|DRUG|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
219653218|NCT01527487|DRUG|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
219653219|NCT05631522|OTHER|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
218965513|NCT06684444|BEHAVIORAL|Control (Minimally Enhanced Usual Care)|The control arm is minimally enhanced usual care. Usual care interventions for sleep disturbance include any health or wellness interventions administered by the agency on the topic of sleep, including occupational health intervention, employee assistance programs, education, signage, and webinars. The type and dose of care will be assessed at each timepoint. Minimal enhancement is a referral to the agency's Employee Assistance Program and will address the ethical problem in the control condition of identifying but not treating a sleep disturbance.
218965514|NCT06682325|OTHER|Multi-drug interaction|The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.
218965515|NCT06682052|OTHER|anti-stress ball|The women will be given a round, silicone, medium-sized and medium-hard anti-stress ball, and they will be told how to use the stress ball, and they will be asked to squeeze the anti-stress ball throughout the examination, allowing the patients to rest occasionally as they wish. The women will be told to count to 3 as they squeeze the anti-stress ball, then to relax the stress ball and repeat this process.
218965516|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
218965517|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
218965518|NCT06689800|BEHAVIORAL|Let's Get REAL|Family health communication tool
218965519|NCT04067440|DIAGNOSTIC_TEST|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
218965520|NCT06684717|BEHAVIORAL|Educational video intervention|A 3-minute educational video mainly about the benefits of Continuous positive airway pressure therapy in OSA patients. The video starts with basic knowledge about OSA and how it affects human health. What is a CPAP machine and how does it works? It was developed from consensus among expert opinions of Neurobehavioral specialists and sleep physicians.
218965521|NCT07024797|DRUG|ABBV-932|Oral Capsule
218965522|NCT07024797|DRUG|Placebo for ABBV-932|Oral Capsule
218965523|NCT06696183|DRUG|Gilteritinib (GILT)|80 mg
219653220|NCT01070836|DRUG|natalizumab|Administered as specified in the treatment arm
219653221|NCT02255136|OTHER|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
219653222|NCT02255136|OTHER|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
219653223|NCT02283736|OTHER|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
219653224|NCT02283736|OTHER|Talc powder|Tablet containing talc powder
219653225|NCT02283736|PROCEDURE|Periodontal treatment|Scaling and root planning
219653226|NCT02400567|DRUG|Fluorouracile|
219653227|NCT02400567|DRUG|Epirubicin|
219653228|NCT02400567|DRUG|Cyclophosphamide|
219653229|NCT02400567|DRUG|Letrozole|
219653230|NCT02400567|DRUG|Palbociclib|
219653231|NCT02326922|DEVICE|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
219653232|NCT06620913|OTHER|Description of clinical, immunological and tumor features of patients harboring CV2 Abs|This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
219653236|NCT03181503|DRUG|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
219653237|NCT03181503|DRUG|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
219653238|NCT04673656|DIETARY_SUPPLEMENT|BKR-017|Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
218965524|NCT06696183|DRUG|Venetoclax (VEN)|400 mg
218965525|NCT06696183|DRUG|Azacitidine (AZA)|75 mg/m²
218965526|NCT06994117|DRUG|Mezigdomide|Mezigdomide
218965527|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
218965528|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
218965529|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
218965530|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
218965531|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
218965532|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
218965533|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
218965534|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
218965535|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
218965536|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
218965537|NCT04526899|BIOLOGICAL|BNT111|IV injection
218965538|NCT04526899|BIOLOGICAL|Cemiplimab|IV infusion
218965539|NCT06683950|DRUG|Aflibercept 8mg|"Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing."
218965540|NCT06878391|PROCEDURE|Preemptive ultrasound-guided interscalene brachial plexus block and suprascapular nerve block and axillary nerve block|Preemptive ultrasound-guided interscalene brachial plexus block using ropivacaine, and suprascapular nerve block and axillary nerve block using ropivacaine or saline. Low fixed dose patient controlled analgesia (PCA) were done in the two group.
219063179|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
219063180|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
219063181|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
219063182|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
219063183|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
219063184|NCT02605590|DRUG|AIR DNase|
219063185|NCT02605590|DRUG|Placebo|
219063186|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
219063187|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
219653239|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
219653240|NCT06620315|COMBINATION_PRODUCT|RBM|Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability
219653241|NCT06620315|COMBINATION_PRODUCT|sand blasted implant|sand blasted implant
219653242|NCT01523015|OTHER|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
219653243|NCT01523015|PROCEDURE|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
219653244|NCT06021756|DRUG|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
219653245|NCT01491750|BEHAVIORAL|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
219653246|NCT01491750|BEHAVIORAL|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
219653247|NCT02300350|DRUG|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
219653248|NCT02300350|DRUG|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
219653249|NCT02300350|DRUG|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
219653250|NCT02036658|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
218965541|NCT06708039|OTHER|Mobile Instant Messaging Application based Self-management and Exercise Programme (SMEP)for Older Adults with Chronic Knee Pain.|The Mobile Instant Messaging Application based self-management and exercise programme (SMEP) consists of 10 short videos of self-management on chronic knee pain in older adults (5-10 minutes/video), 10 short videos of exercise interventions (5-10 minutes/video) and group discussions (10-20 minutes/session) with each video/session focusing on different content. A WhatsApp group that includes all participants in the intervention group will be created to deliver the three components of the program twice a week for five weeks. At the end of each session, they will be given the power point slides from the self-management video in Pdf format and an e-pamphlet of the exercise video. A total of 30-40 minutes will be allocated for each session to allow for socialization between the participants and researcher and also for a question and answer session.
218965542|NCT06707051|DRUG|Tranexamic Acid|Group A received Trannexamic Acid 500mg three times a day for 5 days
219063188|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
219063189|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
219653251|NCT02036658|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
219653252|NCT03785899|DEVICE|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
219653253|NCT03785899|DEVICE|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
219653254|NCT03785899|DEVICE|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
219653255|NCT03785899|DEVICE|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
219653256|NCT00640653|BEHAVIORAL|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
219063190|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
219063191|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
219063192|NCT00499369|DRUG|leucovorin calcium|Given IV
219063193|NCT00499369|DRUG|fluorouracil|Given IV
219653257|NCT00640653|BEHAVIORAL|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
219653258|NCT00640653|BEHAVIORAL|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
219063194|NCT00499369|BIOLOGICAL|cetuximab|Given IV
219063195|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
219653259|NCT00640653|BEHAVIORAL|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
219653260|NCT00640653|BEHAVIORAL|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
219653261|NCT00001783|DRUG|0-15 Water|
219653262|NCT02277158|DRUG|Chemoradiotherapy|S-1 CCRT
219653263|NCT05984693|BEHAVIORAL|Video Assisted Instruction|Video Assisted Instruction
219653264|NCT01729533|OTHER|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
219653265|NCT01729533|OTHER|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
219653266|NCT04695951|DIETARY_SUPPLEMENT|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
219653267|NCT04695951|OTHER|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
219653268|NCT00291772|DRUG|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
219653269|NCT04723563|DRUG|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
219653270|NCT04723563|DRUG|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
219653271|NCT04380012|DRUG|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
219653272|NCT04380012|DRUG|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
218965543|NCT06707051|DRUG|Calcium dobesilate (Doxium)|Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
218965544|NCT05501366|DIETARY_SUPPLEMENT|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) \& 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
218965545|NCT05501366|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
218965546|NCT05501366|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
218965547|NCT05501366|OTHER|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
218965548|NCT05501366|OTHER|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
219063196|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
219063197|NCT00296101|BEHAVIORAL|Physical Activity|
219063198|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
219653273|NCT03843424|BEHAVIORAL|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
219653274|NCT03843424|BEHAVIORAL|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
219653275|NCT04276610|BEHAVIORAL|Low Vision Reading Rehabilitation|Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
219653276|NCT03295123|OTHER|phone interview with the mother|it's a telephone survey about children's health
219653277|NCT02865590|DEVICE|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
219653278|NCT02865590|DEVICE|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
219653279|NCT02505334|DRUG|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
219653280|NCT02433041|DRUG|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
219653281|NCT02433041|DRUG|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
219653282|NCT02433041|DRUG|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
219653283|NCT02433041|DRUG|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
219653284|NCT05110521|BEHAVIORAL|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
218965549|NCT05501366|OTHER|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day
218965550|NCT05501366|RADIATION|DXA|Lean Body Mass will be assessed once via DXA
218965551|NCT05501366|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
219063199|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
219063200|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
219653285|NCT05110521|BEHAVIORAL|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
219653286|NCT01835275|BEHAVIORAL|Enhanced Audio|
219653287|NCT01835275|BEHAVIORAL|Audio|
218965552|NCT06704646|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
218965553|NCT06656195|OTHER|glueus maximus strengthening|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
219063201|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
219063202|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
219063203|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
219063204|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
219653288|NCT03409900|OTHER|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
219653289|NCT03409900|OTHER|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
219653290|NCT06494306|BEHAVIORAL|European Test of Olfactory Capabilities (ETOC)|Investigators will collect the ETOC score in patient of both arms
219653291|NCT06494306|BEHAVIORAL|Standardized Hedonicity Test|To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))
219653292|NCT06494306|BEHAVIORAL|Questionnaires|Patients with PTSD will have the following questionnaires : PTSD Checklist for Diagnostic and Statistical Manual (DSM)-V (PCL-5), Peri-trauma Dissociation Experience Questionnaire (PDEQ), Patient Health Questionnaire-9 (PHQ9), Snaith-Hamilton Pleasure Scale (SHAPS), Childhood Trauma Questionnaire (CTQ) and Apathy Evaluation Scale (AES)
219653293|NCT06494306|BEHAVIORAL|Odor / trauma association questionnaire|Patients with PTSD will have Odor / trauma association questionnaire
219653294|NCT03199612|DRUG|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
219653295|NCT03199612|DRUG|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
219653296|NCT00154401|DRUG|liraglutide|
219653297|NCT05228925|OTHER|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
219653298|NCT02284763|OTHER|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
218965554|NCT06656195|OTHER|hamstring stretching group|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
218965555|NCT06715696|DEVICE|"HANBIO Gauze (Sterilized, 1% Collagen)"|"After tissue resection in a standard procedure for gynecological surgery, direct application of HANBIO Gauze to cover the bleeding site/area which identified during dissection."
218965556|NCT05401019|DRUG|Pramipexole|Oral medication, once a day during 16 weeks
218965557|NCT05401019|DRUG|Risperidone|Oral medication, once a day during 16 weeks
218965558|NCT01711372|DEVICE|Groundskeeper game for controls|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
218965559|NCT01711372|DEVICE|Groundskeeper game for ADHD|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
219653299|NCT00667186|OTHER|Targeted Screening|Selection method for screening is based on risk
219653300|NCT00667186|OTHER|Routine Screening|Selection method for screening is not based on risk
219653301|NCT06339216|DRUG|Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)|"Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes."
219653302|NCT05359510|PROCEDURE|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
219653303|NCT05468749|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
219653304|NCT03644836|DRUG|Amino Acids|Sweet taste cocoa flavored drink
219653305|NCT03644836|DRUG|Placebos|Sweet taste cocoa flavored drink
219653306|NCT02747849|DEVICE|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
219653307|NCT06238661|DIAGNOSTIC_TEST|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
218965560|NCT06912685|OTHER|Technology Enhanced Implementation Package|The Technology Enhanced Implementation Package for SafeCare delivery consists of protocol adaptations, evidence-informed guidelines, and digital health resources to improve SafeCare outcomes related to reach, quality, and equity.
218965561|NCT06912685|OTHER|SafeCare|SafeCare is an evidence-based home visiting parenting program with three modules focused on child health, home safety, and parent-child relationships. SafeCare sessions typically occur weekly over 18 weeks.
218965562|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
218965563|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
218965564|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
219653308|NCT05702411|OTHER|Air Stacking Technique|Air Stacking lung reexpansion technique after aspiration with expiratory pause in a closed system.
219653309|NCT05702411|OTHER|No Air Stacking Technique|Aspiration technique in a closed system of aspiration with an expiratory pause of 10 seconds.
218965565|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
218965566|NCT00071578|BEHAVIORAL|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
218965567|NCT00071578|BEHAVIORAL|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
219653310|NCT03542591|OTHER|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
219653311|NCT03685292|BEHAVIORAL|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
218965568|NCT02102971|PROCEDURE|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
218965569|NCT02158260|BEHAVIORAL|Position changing|
218965570|NCT01250288|OTHER|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
218965571|NCT01607840|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
218965572|NCT02294773|PROCEDURE|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
218965573|NCT02294773|DRUG|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
218965574|NCT02294773|DRUG|Letrozole|Patient is to take letrozole during cycle days 3-7.
218965575|NCT05932784|DEVICE|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
218965576|NCT03052764|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
218965577|NCT03052764|DRUG|Placebo (saline)|Placebo (saline) injection into the bladder.
218965578|NCT05828095|BIOLOGICAL|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
218965579|NCT05828095|BIOLOGICAL|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
218965580|NCT02199860|DRUG|SD I|
218965581|NCT02199860|DRUG|SD II|
218965582|NCT02199860|DRUG|Placebo|
218965583|NCT03206073|DRUG|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
218965584|NCT03206073|DRUG|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
218965585|NCT03206073|BIOLOGICAL|Pexa-Vec|3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
218965586|NCT03206073|BIOLOGICAL|Pexa-Vec|1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
218965587|NCT03332771|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
218965588|NCT03332771|DRUG|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
218965589|NCT03332771|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
218965590|NCT03332771|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
218965591|NCT03332771|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
218965592|NCT00096954|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
218965593|NCT00096954|DRUG|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
218965594|NCT02414659|PROCEDURE|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
219653312|NCT03685292|DRUG|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
219653313|NCT03685292|DEVICE|Behavioral Division|This study is relative to minimal contact control (MCC).
219653314|NCT04754620|OTHER|real time online video visit|Participants have received an online visit by a smartphone application
219653315|NCT01319240|DRUG|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
219653316|NCT01319240|DRUG|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
219653317|NCT01319240|DRUG|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
219653318|NCT03724266|DRUG|Chitosan|chitosan will be used as intracanal medication
219653319|NCT03724266|DRUG|Calcium Hydroxide|intracanal medication
218965595|NCT02460445|PROCEDURE|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
219653320|NCT00081731|DRUG|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
219653321|NCT00081731|PROCEDURE|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
219653322|NCT06288269|OTHER|Severity of Stroke and 1 year survival|Evaluated from NIHSS and clinical outcome 1 year survival death
219653323|NCT02841566|OTHER|questionnaire|
219653324|NCT02182466|DEVICE|Colon capsule endoscopy|
218965596|NCT02460445|DRUG|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
218965597|NCT02460445|DRUG|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
218965598|NCT02855073|BIOLOGICAL|ReJoinTM|adipose derived mesenchymal progeinitor cells
218965599|NCT02855073|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Injection
218965600|NCT00654121|DRUG|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
218965601|NCT04176497|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
218965602|NCT06084689|DRUG|Ezabenlimab + BI907828|A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.
218965603|NCT04347096|BEHAVIORAL|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
218965604|NCT04347096|BEHAVIORAL|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
218965605|NCT05621460|OTHER|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
218965606|NCT05621460|OTHER|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
218965607|NCT05621460|OTHER|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
218965608|NCT02435329|OTHER|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
218965609|NCT04478123|DRUG|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
218965610|NCT02643329|DRUG|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
218965611|NCT02643329|DRUG|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
218965612|NCT00463203|DRUG|Bevacizumab|10 mg/kg every 2 weeks
218965613|NCT00463203|DRUG|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
219063205|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
218965614|NCT02496962|DRUG|Atorvastatin|atorvastatin were taken daily for 5 days
218965615|NCT02496962|DRUG|placebo|placebo were taken daily for 5 days
218965616|NCT06706596|OTHER|Screening for TB symptoms|Individuals will be screened for cough, blood in sputum, fever, weight loss, night sweats and chills lasting for \>2 weeks
219063206|NCT04902105|DRUG|ecopipam HCL|oral tablets
219063207|NCT04902105|DRUG|Mefenamic acid|oral capsules
219653325|NCT01135069|DRUG|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
219653326|NCT01135069|DRUG|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
219653327|NCT01135069|DRUG|placebo microsphere gel|treatment of acne vulgaris
219653328|NCT00829816|DRUG|Dimebon|
219653329|NCT00829816|DRUG|Placebo|
219653330|NCT02096068|DRUG|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
219653331|NCT02096068|DRUG|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
219653332|NCT05240469|DEVICE|Automated sperm selection software|"The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters."
218965617|NCT06706596|DIAGNOSTIC_TEST|Chest X-ray|Chest X-ray will be performed to diagnose or exclude TB
218965618|NCT02026960|DEVICE|RNA extraction and amplification from biopsy specimens|
218965619|NCT06166602|DRUG|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
219063208|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
219063209|NCT01802411|DRUG|EXPAREL 266 mg|
219063210|NCT01802411|DRUG|Placebo|
218965620|NCT04314154|OTHER|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
219653333|NCT03860714|DIAGNOSTIC_TEST|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
219653334|NCT03451110|DRUG|lemborexant|oral tablet
219653335|NCT03451110|DRUG|Loestrin|oral tablet
219653336|NCT03451110|DRUG|famotidine|oral tablet
219063211|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
219063212|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
219063213|NCT00389935|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
219653337|NCT03451110|DRUG|fluconazole|oral tablet
219653338|NCT02948010|DEVICE|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device
219653339|NCT02948010|DEVICE|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
219653340|NCT02948010|DEVICE|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
219653341|NCT02948010|DEVICE|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
219653342|NCT02948010|DEVICE|CPAP with comfort feature A|CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
219653343|NCT02948010|DEVICE|CPAP with comfort feature B|CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
219653344|NCT02948010|DEVICE|CPAP with no comfort feature|CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
219653345|NCT02948010|DEVICE|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
219653346|NCT02948010|DEVICE|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
219653347|NCT03625310|DRUG|Sodium Fluoride|
219653348|NCT03625310|DRUG|Sodium Fluoride with TCP|
219653349|NCT03625310|DRUG|Sodium Fluoride with CXP|
219653350|NCT03625310|DRUG|Sodium Fluoride with CPP-ACP|
219653351|NCT04462523|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
219653352|NCT04462523|DRUG|Topical Prednisolone|Standard of care topical drop treatment
219653353|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
219653354|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
219063214|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
219063215|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
219063216|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
219653355|NCT00134641|DRUG|gemcitabine|
219653356|NCT00134641|DRUG|vinorelbine|
219653357|NCT00110916|DRUG|Intra-articular metHuIL-1ra (anakinra)|anakinra
219653358|NCT00110916|DRUG|placebo|placebo
219653359|NCT02947542|DEVICE|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
219653360|NCT02947542|DEVICE|Standard catheter|Coronary angiography will be performed using a standard catheter.
219653361|NCT03654105|DRUG|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
219653362|NCT03654105|DRUG|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
219653363|NCT03654105|OTHER|Diet Modification and Physical Activity Increase|"It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results."
219653364|NCT03654105|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
219653365|NCT03654105|DIAGNOSTIC_TEST|spirometry with CO test|spirometry with CO test
219653366|NCT03654105|OTHER|anthropometic data collection|anthropometic data collection
219653367|NCT03654105|OTHER|blood test|blood test to assess the metabolic and inflammatory profile
219653368|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
219653369|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
219653370|NCT06154161|DIETARY_SUPPLEMENT|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
219653371|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
219653372|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
219653373|NCT02979080|OTHER|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
219653374|NCT06148675|OTHER|No Intervention|No intervention,data collection
219653375|NCT05181254|BEHAVIORAL|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
219653376|NCT05440435|DIAGNOSTIC_TEST|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
219653377|NCT03188068|DRUG|Sirolimus|Oral administration
219653378|NCT03188068|DRUG|Prednisolone|Oral administered with sirolimus
219653379|NCT06668272|BEHAVIORAL|Small Changes program|"Participants will be asked to track their compliance with their Small Changes diet plan using a simple checklist record . Participants will be asked to follow their diet plan every day. They are encouraged to create a diet plan that is as close to their current diet as possible. Meal options include make-from-scratch recipes, quick grab-and-go options,and restaurant options. There may be some time involved in learning the recipes and the routine of their new diet. It also may alter their grocery spending and habits somewhat"
219653380|NCT06668272|BEHAVIORAL|Standard behavioral therapy for weight loss|Participants will be provided guidance on cutting and counting calories, setting goals, reading labels, and portion sizes.
219653381|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
219653382|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
218965621|NCT04822649|DIAGNOSTIC_TEST|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
218965622|NCT04999982|OTHER|Screening|Parent-report screening for remediable, unmet social needs.
218965623|NCT04999982|OTHER|Resource Packet|"Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted."
218965624|NCT04999982|OTHER|Resource Navigation|Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.
219653383|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
219653384|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
219653385|NCT04989634|BEHAVIORAL|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
219653386|NCT04989634|BEHAVIORAL|Standard care|Standard prenatal education on diet, nutrition and physical activity
219653387|NCT03584464|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
219653388|NCT01841450|DEVICE|iStent|Implantation of one iStent in conjunction with cataract surgery
219653389|NCT01841450|PROCEDURE|Cataract surgery|Cataract surgery alone
219653390|NCT01292421|BIOLOGICAL|hepatitis B antigen peptide|Given PO
219063217|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
219063218|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
219063219|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
219653391|NCT01292421|OTHER|placebo|Given orally (PO)
219653392|NCT01292421|OTHER|immunoenzyme technique|Correlative studies
219653393|NCT00732979|PROCEDURE|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
219653394|NCT00732979|PROCEDURE|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
218965625|NCT04999982|OTHER|Care as usual|Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
218965626|NCT03581786|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
218965627|NCT03581786|DRUG|Placebos|placebo combine with chemotherapy
218965628|NCT01083927|PROCEDURE|Rotational Narrow Strip Conjunctival Graft|Surgical technique
218965629|NCT01083927|PROCEDURE|Full Conjunctival Graft|Surgical technique
218965630|NCT05718050|DIAGNOSTIC_TEST|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
218965631|NCT06517108|PROCEDURE|Chuna therapy|"The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
218965632|NCT06517108|PROCEDURE|Physical therapy|"The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
218965633|NCT00572897|DRUG|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
218965634|NCT01347307|RADIATION|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
218965635|NCT01347307|RADIATION|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
218965636|NCT06707870|OTHER|Cervical retraction exercise|"Neck retraction exercises are performed on patients either in sitting or standing in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range (3 seconds hold)of 10 repetitions in each session at sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
218965637|NCT06707870|OTHER|Facet oscillatory mobilization|"Facet joint oscillatory mobilization on the cervical spine C2-C7(6 to 10 repetitions in each session) in the sitting position.~Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
218965638|NCT06790290|BIOLOGICAL|Formulation B|IVT PCV-25
218965639|NCT06790290|BIOLOGICAL|Formulation C|IVT PCV-25
218965640|NCT06790290|BIOLOGICAL|Formulation D|IVT PCV-25
218965641|NCT06790290|BIOLOGICAL|Prevnar20|20 valent pneumococcal conjugate vaccine
219063220|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
218965642|NCT00446589|DRUG|ibandronate|iv 1mg ibandronate monthly for one year
218965643|NCT00446589|DRUG|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
218965644|NCT01339026|DRUG|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
218965645|NCT01339026|DRUG|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
219653395|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
219653396|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
218965646|NCT02069288|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
219063221|NCT02756624|DRUG|AC-170 0.24%|
219063222|NCT02756624|DRUG|AC-170 Vehicle|
219063223|NCT05783180|DRUG|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
219063224|NCT05783180|DRUG|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
219063225|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
219653397|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
219653398|NCT03336268|BEHAVIORAL|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
219653399|NCT03871816|OTHER|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
219653400|NCT04442269|DRUG|dupilumab|Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
219653401|NCT04442269|DRUG|Placebo|Matching placebo
219653402|NCT05409079|DEVICE|Abilitech Assist|The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
219653403|NCT06619938|BEHAVIORAL|Mindfulness With Biofeedback|The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.
219653404|NCT06619938|BEHAVIORAL|Mindfulness Without Biofeedback|The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
219653405|NCT03279796|BIOLOGICAL|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
219653406|NCT03279796|DRUG|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
219653407|NCT03369028|OTHER|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
219653408|NCT06514053|PROCEDURE|Full pulpotomy|A full pulpotomy will be performed by removing the entire roof of the pulp chamber and the remaining pulp tissue will be covered by Biodentine.
219653409|NCT06514053|PROCEDURE|Root canal treatment|The regular procedure of root canal treatment will be performed on teeth with irreversible pulpitis
219653410|NCT00140270|BEHAVIORAL|PEP program|
219653411|NCT04144036|BIOLOGICAL|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
219653412|NCT04144036|DRUG|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
219653413|NCT04144036|DRUG|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
219653414|NCT04144036|DRUG|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
219653415|NCT02293759|PROCEDURE|HoLEP|Holmium laser enucleation of the prsotate
219653416|NCT02293759|PROCEDURE|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
218965647|NCT02069288|DRUG|Placebo|1 tablet of placebo per os
218965648|NCT03252184|DEVICE|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
219653417|NCT01793688|DRUG|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
219653418|NCT01753661|BEHAVIORAL|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
219653419|NCT01753661|BEHAVIORAL|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
219653420|NCT01753661|BEHAVIORAL|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
219653421|NCT05156762|PROCEDURE|Bariatric surgery|Patients randomized to the bariatric surgery study arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass - this decision would be a joint decision made between the study participant and the bariatric surgeon after consideration of the patient's overall goals with weight loss and discussion of the risks and benefits of each procedure.
219653422|NCT05156762|BEHAVIORAL|Medical weight loss|Study participants randomized to the medical weight loss study arm will have consultations with nutritionists, dieticians, and endocrinologists, and will make dietary and lifestyle changes in an effort to lower their BMI to ≤ 40 kg/m2. Patients may also be placed on pharmacotherapy to assist with weight loss.
219653423|NCT05156762|OTHER|Patient research surveys|Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.
219653424|NCT05156762|PROCEDURE|Total joint arthroplasty (TJA)|Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.
218965649|NCT03252184|DEVICE|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
218965650|NCT03252184|DEVICE|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
218965651|NCT04823416|PROCEDURE|Resection|Left hemicolectomy
218965652|NCT04823416|PROCEDURE|Stoma|Colostomy
218965653|NCT03470974|BEHAVIORAL|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
218965654|NCT01530347|DEVICE|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
218965655|NCT00606944|BEHAVIORAL|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
218965656|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
218965657|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
219208016|NCT06513507|DIETARY_SUPPLEMENT|Cannabigerol (CBG)|The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
218965658|NCT02808091|RADIATION|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
219208017|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
219653425|NCT05156762|OTHER|Usual standard of care|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics. They will be urged to make an appointment or to seek any other interventions they choose to help lower their BMI, but no appointments will be made for them. A follow up visit in 6 months and 1 year will be made for them in the arthroplasty clinic to reassess their progress. Referral information will again be provided at 6 months if no progress has been made."
218965659|NCT05561179|PROCEDURE|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
219063226|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
219063227|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
219063228|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
219063229|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
219063230|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
218965660|NCT05561179|PROCEDURE|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
218965661|NCT01557894|OTHER|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
218965662|NCT05266274|DRUG|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
218965663|NCT01386112|DRUG|EUR-1100|Active oral medication
218965664|NCT01386112|DRUG|placebo|matching placebo
219063231|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
219063232|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
219063233|NCT00452101|DRUG|Aquamin F|
219063234|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
219063235|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
219063236|NCT03864614|DRUG|SAGE-217|SAGE-217
219063237|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
219063238|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
219063239|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
219063240|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
219063241|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
219063242|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
219063243|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
219063244|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
219063245|NCT04120506|DRUG|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
219063246|NCT03347500|OTHER|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
219653426|NCT00510016|DRUG|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
219653427|NCT02255318|DEVICE|Taurolock|
219653428|NCT02255318|DRUG|Placebo|
219063247|NCT04576208|DRUG|TAK-788|TAK-788 capsules
219653429|NCT03762863|DEVICE|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
219653430|NCT01433445|DRUG|panobinostat|Given 3 times a week, every other week in 28-day cycles.
219063248|NCT04576208|DRUG|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
219063249|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
219063250|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
219063251|NCT03119766|DRUG|Kolofort|Oral administration
219063252|NCT03119766|DRUG|Placebo|Oral administration
219063253|NCT02754635|OTHER|Induction of labour|Induction of labour
219063254|NCT02754635|OTHER|Expectant management|Expectant management
219063255|NCT02562755|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
219653431|NCT01433445|DRUG|ruxolitinib|Given twice daily in 28-day cycles.
219653432|NCT03785509|DRUG|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
219653433|NCT05097092|PROCEDURE|Orthopedic immobilization|Orthopedic immobilization will be performed with a sling and swathe.
219653434|NCT05097092|OTHER|Unilateral resistance training|Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
219653435|NCT05097092|OTHER|Bilateral resistance training|Bilateral resistance training will be performed by both arms in both groups during Phase 2.
219653436|NCT04917458|DRUG|Cholecalciferol 4000 IU Oral Capsule, Liquid Filled|-Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
219063256|NCT02562755|DRUG|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
219063257|NCT02034578|DRUG|Apixaban|
219063258|NCT06264440|DRUG|BIIB122|Administered as specified in the treatment arm.
219063259|NCT06264440|DRUG|Rabeprazole|Administered as specified in the treatment arm.
219063260|NCT05377398|BEHAVIORAL|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
219063261|NCT05377398|BEHAVIORAL|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
219653437|NCT04917458|DRUG|Placebo|Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
219653438|NCT01775358|DRUG|ALRN-5281 0.015 mg/kg|
219653439|NCT01775358|DRUG|ALRN-5281 0.05 mg/kg|
219653440|NCT01775358|DRUG|ALRN-5281 0.15 mg/kg|
219653441|NCT01775358|DRUG|Placebo 0.015 mg/kg|
219653442|NCT01775358|DRUG|Placebo 0.05mg/kg|
219653443|NCT01775358|DRUG|Placebo 0.15mg/kg|
219653444|NCT04972968|DRUG|ABBV-154|Subcutaneous Injection
219653445|NCT04972968|DRUG|Placebo|Subcutaneous Injection
219653446|NCT04972968|DRUG|Glucocorticoid|Oral Tablet
219653447|NCT06452147|OTHER|Nerve block+standard anesthesia|"1. Receive nerve block as soon as possible after randomization;~2. Ultrasound-guided nerve block is recommended, with the iliacfascia block recommended as the blocking site;~3. It is recommended to use 1.33% bupivacaine liposome (long-acting), and the maximum dose should not exceed 133mg; or regular local anesthetic (bupivacaine or ropivacaine, etc.) with electronic analgesic pumping infusion; or multiple single injections of regular local anesthetics should be used to maintain the continuity of nerve block effect."
219653448|NCT06452147|DRUG|Intravenous lidocaine+standard anesthesia|"1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward.~2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded."
219653449|NCT06452147|DRUG|Bupivacaine liposome|1.33% bupivacaine liposome
219653450|NCT06452147|DEVICE|Ultrasound-guided nerve block|Ultrasound-guided nerve block
219653451|NCT01698879|DRUG|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m\^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m\^2, SC, days 0 to 7. GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
219653452|NCT01788189|DRUG|Lenalidomide|
219653453|NCT02622763|BIOLOGICAL|Tolerogenic Dendritic Cells|Intralesional administration
219653454|NCT06154395|PROCEDURE|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
219653455|NCT06154395|PROCEDURE|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
219653456|NCT06154395|PROCEDURE|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
219653457|NCT03421314|DIETARY_SUPPLEMENT|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
219653458|NCT06056882|OTHER|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
219653459|NCT06622707|OTHER|kinesio taping|Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.
219653460|NCT06622707|OTHER|Routine clinical care|As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
219653461|NCT06618937|OTHER|Treatment medication withdrawal strategy|The study aims to compare early biomarkers-guided versus conventional unguided drugs withdrawal strategy.
218965665|NCT04827121|PROCEDURE|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
218965666|NCT04827121|PROCEDURE|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
219063262|NCT05377398|BEHAVIORAL|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
218965667|NCT06083935|DRUG|Daflon|Daflon; two film coated tablets 500 mg daily
218965668|NCT06083935|DRUG|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
218965669|NCT06083935|DRUG|Metformin|Glucophage ® 500 tablets twice daily
218965670|NCT00964132|DRUG|NRX194204|Once Daily, Oral
218965671|NCT04123665|DRUG|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
218965672|NCT04123665|DRUG|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
219653462|NCT02550600|PROCEDURE|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P\_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P\_peak - PEEP) ≤15 cm H2O and P\_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
219653463|NCT02550600|PROCEDURE|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
219653464|NCT02433925|DIETARY_SUPPLEMENT|Resveratrol|
219653465|NCT02433925|DIETARY_SUPPLEMENT|Placebo|
219653466|NCT06494410|PROCEDURE|High versus Low Fraction of Inspired Oxygen|to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
218965673|NCT02237911|OTHER|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
218965674|NCT02237911|OTHER|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
218965675|NCT03015545|DEVICE|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
218965676|NCT03015545|DEVICE|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
218965677|NCT03015545|DEVICE|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
218965678|NCT03015545|DEVICE|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
218965679|NCT02809326|BEHAVIORAL|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
218965680|NCT02809326|BEHAVIORAL|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
218965681|NCT02809326|BEHAVIORAL|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
219063263|NCT05377398|BEHAVIORAL|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
218965682|NCT01938872|PROCEDURE|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
218965683|NCT04960410|COMBINATION_PRODUCT|Types and exposure of different air pollutants|Types and exposure of different air pollutants in COPD patients' living and working environment
218965684|NCT00053365|DRUG|irofulven|Given IV
218965685|NCT03708185|DIETARY_SUPPLEMENT|Beta-alanine|N/A: see arm description
218965686|NCT03708185|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
218965687|NCT01583543|DRUG|Olaparib|400mg PO BID Continuous
218965688|NCT01546012|DEVICE|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
219063264|NCT04711564|OTHER|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
219653467|NCT05408871|DRUG|adnectin 18F-BMS-986192 Head and Neck Cancer|Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
218965689|NCT01546012|DEVICE|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
218965690|NCT05755737|DRUG|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
218965691|NCT05755737|DRUG|Placebo|Matching placebo identical in appearance.
218965692|NCT02493582|BIOLOGICAL|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
218965693|NCT02493582|DRUG|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
218965694|NCT05241431|DRUG|SGLT2 inhibitor|10 mg orally once daily in addition to standard medical treatment.
218965695|NCT05241431|DRUG|Placebo|Placebo tablets similar to active treatment.
218965696|NCT02260531|DRUG|Cabozantinib|
218965697|NCT02260531|DRUG|Trastuzumab|
219208018|NCT03844152|DIETARY_SUPPLEMENT|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
219063265|NCT04711564|OTHER|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
219063266|NCT01822860|DRUG|Chlorthalidone 12.5 mg|
218965698|NCT00543491|DRUG|MK0767|
218965699|NCT03234777|BEHAVIORAL|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
218965700|NCT03234777|BEHAVIORAL|Regular video|Developed by CDC
218965701|NCT00958789|DEVICE|Triathlon TS Knee System|Total knee replacement for revision cases
218965702|NCT02584699|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
218965703|NCT00295828|OTHER|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
218965704|NCT00295828|PROCEDURE|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
218965705|NCT05509790|DRUG|LY3484356|Administered orally.
218965706|NCT00253500|BIOLOGICAL|pegfilgrastim|6 mg in a syringe
218965707|NCT00253500|DRUG|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
218965708|NCT00253500|PROCEDURE|conventional surgery|to remove small piece of cancer
218965709|NCT04741698|DRUG|Propranolol|Propranolol 2mg IV
219063267|NCT01822860|DRUG|Hydrochlorothiazide 25 mg|
219063268|NCT01822860|DRUG|Placebo|
219063269|NCT03419169|DEVICE|Light load BFR resistance training|A novel training light load resistance training modality.
219063270|NCT03419169|PROCEDURE|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
219063271|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
218965710|NCT01242059|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
218965711|NCT01242059|OTHER|yellow pea fiber|Served in a tomato soup
218965712|NCT01242059|DIETARY_SUPPLEMENT|Control|Served in a tomato soup
218965713|NCT05515172|OTHER|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
218965714|NCT04233463|DIETARY_SUPPLEMENT|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
218965715|NCT04233463|DRUG|Budesonide|Standard treatment for mild Crohn Disease patients
218965716|NCT04680676|DRUG|BI 730357|BI 730357
218965717|NCT04680676|DRUG|Placebo|Placebo
218965718|NCT01409395|DRUG|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
218965719|NCT01409395|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
218965720|NCT00356733|DRUG|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
219653468|NCT05408871|DRUG|adnectin 18F-BMS-986192 Brain Metastases|Brain Metastases: Recruited patients will undergo standard clinical MRI within 2 weeks prior to PET, including T1 weighted pre- and post-gadolinium spin-echo and gradient-echo imaging, diffusion weighted imaging, susceptibility weighted imaging (2D SWI), T2 weighted imaging, 3D FLAIR, and combined DCE and dynamic susceptibility contrast (DSC) perfusion (DCE perfusion will be performed first, DSC perfusion will utilize T2 spin echo images). DCE perfusion will be processed on syngo Tissue 4D software (Siemens). DSC perfusion will be processed with syngo MR Perfusion Engine (Siemens). Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
219653469|NCT05981261|OTHER|inducement of experimental pain|Inducement of experimental pain
219653470|NCT05005585|PROCEDURE|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
219653471|NCT00270270|DRUG|epoetin alfa|
219653472|NCT04373811|DIAGNOSTIC_TEST|Lung ultrasound|"Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded."
219653473|NCT04373811|DIAGNOSTIC_TEST|Muscle ultrasound|"Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe."
219653474|NCT01344993|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
219653475|NCT05757427|DEVICE|Wavelia #2|Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
219653476|NCT04009668|DRUG|adalimumab|Adalimumab will be dosed based on weight
219653477|NCT03103373|DEVICE|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
219653478|NCT03103373|DEVICE|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
219653479|NCT06522282|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
219653480|NCT06522282|COMBINATION_PRODUCT|Standard stroke unit|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
219653481|NCT03573531|OTHER|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
219653482|NCT00847769|OTHER|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
219653483|NCT00847769|OTHER|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
219653484|NCT00847769|OTHER|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
218965721|NCT06139796|DRUG|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
218965722|NCT00488280|BEHAVIORAL|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
218965723|NCT03703050|DRUG|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
218965724|NCT03703050|DRUG|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
219208019|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
219653485|NCT06126029|DRUG|Metformin 500 Mg extended release Oral Tablet|34 patients of experimental group will get metformin 500mg extended release oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
219653486|NCT06126029|DRUG|Placebo oral tablet|34 patients of placebo group will get placebo oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
219653487|NCT06569173|DEVICE|LaiKai anti-reflux ureteral stent|Ureteral stents are serving to support the ureter and facilitate urine drainage with an anti-reflux valve.
219653488|NCT06569173|DEVICE|LaiKai Ureteral Stent|Ureteral stents are serving to support the ureter and facilitate urine drainage.
219653489|NCT04427163|GENETIC|Blood sample analysis|Nucleic acids sequencing, presence of proteins and metabolites.
219653490|NCT04427163|OTHER|Health status|Health status will be examined by a physician and subject will complete a health status questionnaire.
219653491|NCT04427163|OTHER|Race and ethnicity|Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
219653492|NCT06647667|OTHER|HIITS|"Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.~session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve"
219653493|NCT06647667|OTHER|MICT|"Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.~Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down"
219653494|NCT05146544|OTHER|Heart Rate Recording|During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
218965725|NCT05343000|BEHAVIORAL|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
218965726|NCT04931212|PROCEDURE|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
218965727|NCT05945745|DRUG|Chemotherapy|different treatments based on the molecular analysis
218965728|NCT05008185|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
218965729|NCT05008185|PROCEDURE|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
218965730|NCT06313008|DRUG|Empagliflozin 10 MG|eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
219653495|NCT05935163|PROCEDURE|Conventional therapy for hamstring tightness|Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.
219653496|NCT05935163|PROCEDURE|Bowen Technique|"Bowen Technique:~1. The patient will assume a full prone-lying position on the plinth.~2. Sequence of short gentle moves will be applied over hamstrings. Firstly, the thumbs will be placed on top of the hamstrings muscle and the tightness is assessed.~3. Then, the muscle will be hooked by the thumbs from its lateral edge. Then, gentle pressure will be applied to the point of resistance to challenge the muscle in medial direction, as the thumbs will be flattened in medial direction, the muscle will pluck under the thumbs.~4. First with the thumbs, then will be followed by the fingers. Often, the hands are placed with a distance of inch of space between the thumbs and fingers so that the hands performed the technique on the muscle easily.~5. The whole procedure will be repeated again. The treatment time for each session will be 20 minutes for each side."
219653497|NCT05935163|PROCEDURE|Dynamic Soft Tissue Mobilization (DSTM):|"1. To access the hamstring muscle group, the subject will be asked to attain prone position and deep longitudinal strokes will be applied to the entire muscle group. Once the specific area of hamstring muscle tightness will be located, the remaining treatment will be limited to this target area.~2. To execute the dynamic intervention, the subject will be requested to move in the supine position with the hip and knee flexed to 90 degree.~3. Deep longitudinal strokes will be applied in a distal to proximal direction to the area of hamstring tightness and the leg will be passively moved to knee extension. Five strokes will be applied and 20 seconds of shaking is performed at the completion of this technique.~4. This treatment will be given for 20 minutes on each side."
219653498|NCT03344692|DRUG|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
219653499|NCT03344692|OTHER|Placebo|prefilled pen containing 1 ml of solution without Praluent
219653500|NCT00581347|OTHER|outreach services|Tracking/reminder/recall/home visit strategy.
219653501|NCT06262945|DIAGNOSTIC_TEST|Diagnoses|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
219653502|NCT06262945|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
218965731|NCT06313008|DRUG|Vildagliptin 50 MG|eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
218965732|NCT06537609|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol)."
218965733|NCT06537609|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole."
218965734|NCT06537609|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed."
219208020|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
219653503|NCT06262945|BIOLOGICAL|platelet rich fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
219653504|NCT06262945|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
219653505|NCT06262945|DEVICE|low laser therapy, bicure laser|There are studies in the literature that low-energy lasers have positive effects on the biological and biochemical processes of wound healing. Acceleration of local circulation, increase in cell proliferation and collagen synthesis are among the various effects of laser application. B Cure Dental Pro Laser application will be applied to the patient for the first 3 days. Low dose laser application will be applied to the angulus area, covering the surgical area for 8 minutes. Before this laser procedure, the patient will be asked to fill out a pain scale. This pain scale and the number of analgesics used will be monitored for 3 days.
219653506|NCT06262945|DRUG|Analgesic|Analgesics are prescribed for the patients.
219653507|NCT03186274|BEHAVIORAL|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
219653508|NCT03186274|BEHAVIORAL|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
219653509|NCT03430401|BEHAVIORAL|Perceptual-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
219653510|NCT03430401|BEHAVIORAL|Semantic-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
219653511|NCT03430401|BEHAVIORAL|Cognitive stimulation|The frequency, duration and the number of sessions will be consistent with the experimental interventions.
219653512|NCT03391544|PROCEDURE|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
219653513|NCT06622746|PROCEDURE|Endoscopic Hand Suturing|Endoscopic Hand Suturing is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
219653514|NCT03579186|DEVICE|OKS|Optokinetic stimulation
219653515|NCT06342622|DIAGNOSTIC_TEST|Using routine clinical data and machine learning models.|This study used clinical data and machine learning model to screen young-onset colorectal cancer.
219653516|NCT04641663|DIETARY_SUPPLEMENT|Multi-target Dietary Supplement (MTDS)|"The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components."
219653517|NCT04183140|PROCEDURE|primary percutaneous coronary intervention|primary percutaneous coronary intervention via transulnar or transradial access
219653518|NCT05688033|RADIATION|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
219653519|NCT05680051|DEVICE|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
219653520|NCT05680051|DEVICE|Drug-eluting stent|Drug eluting stent was used in the control group
219653521|NCT05622877|DRUG|Qushi Formula|Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
219653522|NCT05622877|DRUG|Zhu's Wenban Formula|Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome
219653523|NCT05622877|DRUG|placebo|The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
219653524|NCT05622877|OTHER|Basic treatment|Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
219653525|NCT03349554|OTHER|body-scan meditation|15 minutes audio-guided body-scan meditation
219653526|NCT03349554|DIAGNOSTIC_TEST|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
219653527|NCT05393115|OTHER|Square wave breathing|difference in time to failure from the two breathing modes
219653528|NCT04054973|DRUG|L-arginine|6000mg of L-arginine daily for 14 days
219653529|NCT04054973|DRUG|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
218965735|NCT06537609|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses"
218965736|NCT06537609|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
218965737|NCT03335917|OTHER|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
218965738|NCT03335917|OTHER|Exercise|Graded cycling exercise to volitional fatigue
218965739|NCT00427960|BEHAVIORAL|Dietary advice|
218965740|NCT00427960|DRUG|rosuvastatin|rosuvastatin 5 mg
218965741|NCT00427960|DRUG|atorvastatin|atorvastatin 10 mg
219653530|NCT03109665|DIAGNOSTIC_TEST|SD-OCT Angiography|SD-OCT Angiography
218965742|NCT04804020|PROCEDURE|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
218965743|NCT04804020|PROCEDURE|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
218965744|NCT04804020|PROCEDURE|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
219208021|NCT04310449|PROCEDURE|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
219653531|NCT03109665|DIAGNOSTIC_TEST|SD-OCT|SD-OCT
219653532|NCT05896462|OTHER|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
219653533|NCT04648982|OTHER|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
219653534|NCT00070382|DRUG|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
219653535|NCT00070382|DRUG|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
219653536|NCT00790231|DEVICE|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
219653537|NCT03628989|BEHAVIORAL|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
219653538|NCT02855229|DRUG|Methylphenidate|cross-over, single-dose intervention
219653539|NCT04092673|DRUG|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
219653540|NCT04092673|DRUG|Sotorasib|Recommended dosage: 960 mg orally once daily
219653541|NCT04092673|DRUG|Fulvestrant|500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
219653542|NCT04092673|DRUG|Abemaciclib|Dose in combination with fulvestrant: 150 mg twice daily
219653543|NCT04092673|DRUG|Trastuzumab|600 mg every 3 weeks
219653544|NCT06506643|DRUG|Zinc-64 Aspartate|KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).
219653545|NCT03931772|BEHAVIORAL|Automated Self-Hypnosis|Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
219653546|NCT05115227|BEHAVIORAL|Education|The team will educate the patient about low back pain and how this can be self-managed.
219653547|NCT05115227|BEHAVIORAL|Exercise|The team will advice the patient to conduct relevant exercises and to stay physical active.
219653548|NCT03128320|DRUG|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
219653549|NCT03128320|DRUG|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
219653550|NCT03128320|DRUG|Placebo|Single dose of placebo given in the fasted state
219653551|NCT06144320|OTHER|Acupuncture|Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
219653552|NCT00129727|DRUG|Paclitaxel|Given intravenously
219653553|NCT00129727|DRUG|Carboplatin|Given intravenously
219653554|NCT00129727|DRUG|Bevacizumab|Given intravenously
219653555|NCT02814227|DEVICE|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
219653556|NCT06083727|OTHER|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
219653557|NCT03589976|DRUG|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
219653558|NCT03589976|OTHER|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
219653559|NCT04483492|DRUG|Caffeine citrate|diaphragm contractility after administration
219653560|NCT01833624|DIETARY_SUPPLEMENT|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
219653561|NCT01833624|DIETARY_SUPPLEMENT|Sondalis® HP|
219653562|NCT01780402|BEHAVIORAL|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
219653563|NCT05854303|BEHAVIORAL|Opioid cessation|opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
219653564|NCT05854303|OTHER|No opioid cessation|Subjects will not stop taking opioids
219653565|NCT06624098|PROCEDURE|Early TIPS|TIPS was performed within 72 hours after the endoscopic hemostasis.
219653566|NCT00346047|DRUG|Placebo|Corresponding placebo is applied for 12weeks
219653567|NCT00346047|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
219653568|NCT06558747|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.
219653569|NCT06558747|PROCEDURE|Cementation|Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
219653570|NCT02900105|DRUG|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
219653571|NCT03815591|DEVICE|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
219653572|NCT06295627|OTHER|There were no interventions in retrospective analysis|A retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. A single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.
219653573|NCT02133794|DEVICE|Tomosynthesis|
219653574|NCT00847782|PROCEDURE|Blood draw|1 day
219653575|NCT01862939|DRUG|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
219653576|NCT01862939|DRUG|placebo|placebo to match part 2 DS-7309
219653577|NCT03794102|OTHER|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
219653578|NCT03794102|OTHER|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
219653579|NCT02718690|DEVICE|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219653580|NCT02718690|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
219653581|NCT03755843|DIAGNOSTIC_TEST|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
219653582|NCT01328899|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
219653583|NCT03060343|BIOLOGICAL|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10\^5 cells/kg, Dose Level Two: 1.0×10\^6 cells/kg, Dose Level Three: 1.0×10\^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
219653584|NCT02368379|OTHER|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
219653585|NCT02368379|OTHER|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
219653586|NCT00468442|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
219653587|NCT00468442|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
219653588|NCT00468442|BIOLOGICAL|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
219653589|NCT00468442|BIOLOGICAL|Rituximab|Depletes transient B-cells
219653590|NCT00468442|DRUG|Sirolimus|Maintenance immunosuppressive therapy
219653591|NCT03454828|DIETARY_SUPPLEMENT|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
219653592|NCT03454828|DIETARY_SUPPLEMENT|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
219653593|NCT01312233|OTHER|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
219653594|NCT01312233|OTHER|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
219653595|NCT01312233|OTHER|Shared Care|Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
219653596|NCT04662528|DRUG|Placebo|4 x 1g capsules/day
219653597|NCT04662528|DRUG|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
219653598|NCT06064838|DIETARY_SUPPLEMENT|Flavonoids|1 capsule every 12h for 90 days
218965745|NCT03935620|BEHAVIORAL|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
218965746|NCT01564771|OTHER|Non Intervention|This Is A Non Interventional Study
219208022|NCT04310449|PROCEDURE|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
219653599|NCT06602427|OTHER|Shoulder proprioception measurement using isokinetic dynamometer|A Cybex brand isokinetic dynamometer \[Cybex NORM®, Humac, CA, USA\] was used for shoulder proprioception assessment. Active Joint Position Sensation (AJPS) was evaluated to examine proprioception. AJPS was measured in the sitting position. The target angle was 30° external and 30° internal rotation. The participant was positioned with the elbow in 90° flexion and the wrist in the neutral position. The dynamometer was fixed at 0° to ensure the same starting position for each participant during trials and evaluations. Before starting the test, 3 trials were performed and then the participants were asked to find the target angle 3 times. The amount of error between the target angle and the angle found by the participant was used to describe the accuracy of the AJPS. The arithmetic mean of the result of the 3 tests was recorded for use.
219653600|NCT01601327|DRUG|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
219653601|NCT01601327|DRUG|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
219653602|NCT01601327|DRUG|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
219653603|NCT00774527|DRUG|Cyclophosphamide-fludarabine-anti thymocyte globulin|"* Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
219653604|NCT06124027|DEVICE|Monitoring tcPCO2 and mitoPO2|Monitoring tcPCO2 using SenTec and mitoPO2 using COMET
219653605|NCT03062527|OTHER|Dietary Intervention: Low vs. moderate glycemic index|
219653606|NCT00163982|DRUG|Norfloxacin|
219653607|NCT01875627|DIETARY_SUPPLEMENT|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
219653608|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate and Konjac Noodles|
219653609|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate noodles|
219653610|NCT01003704|PROCEDURE|Lower extremity amputation|
219653611|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
219653612|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
219653613|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
219653614|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
219653615|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.
219653616|NCT05737576|DRUG|HR011408 injection; NovoRapid®|NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
219653617|NCT06621680|DRUG|Multivitamins|All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
219653618|NCT06621680|OTHER|Connective tissue massage|Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
219653619|NCT02580669|OTHER|Neuropsychological assessment|A neuropsychological assessment is done
219653620|NCT02580669|OTHER|Neurologic consultation|A neurologic consultation is done
219653621|NCT02580669|OTHER|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
219653622|NCT00001044|BIOLOGICAL|Aluminum hydroxide|
219653623|NCT00001044|BIOLOGICAL|QS-21|
219653624|NCT00001044|BIOLOGICAL|rgp120/HIV-1MN|
219653625|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
219653626|NCT00721344|DRUG|Moxifloxacin|Tablets 400mg
219653627|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
219653628|NCT00721344|DRUG|Placebo|Placebo cartridges
219653629|NCT01562301|DRUG|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
219653630|NCT01562301|DRUG|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
219653631|NCT01562301|DRUG|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"
219653632|NCT01562301|BEHAVIORAL|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
219653633|NCT03465501|RADIATION|Brachytherapy|Brachytherapy
218965747|NCT01011023|OTHER|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
219653634|NCT01486472|DRUG|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
218965748|NCT00842764|PROCEDURE|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
218965749|NCT03282565|OTHER|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
218965750|NCT03282565|OTHER|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
218965751|NCT03282565|OTHER|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
218965752|NCT04403490|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
218965753|NCT04403490|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
218965754|NCT04163718|DRUG|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
218965755|NCT02983396|DEVICE|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
218965756|NCT04565184|DRUG|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
218965757|NCT04565184|DRUG|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
218965758|NCT02131532|BEHAVIORAL|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
218965759|NCT00270829|DRUG|nesiritide|Drug given intrarenally or placebo
218965760|NCT02594540|DEVICE|Mechanical Peripheral Stimulation (GONDOLA)|
218965761|NCT06229782|DIAGNOSTIC_TEST|Orbital Doppler ultrasonography|During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
218965762|NCT06229782|DIAGNOSTIC_TEST|Transcranial Doppler ultrasonography|"During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used."
218965763|NCT06229782|DIAGNOSTIC_TEST|Computed Tomography Angiography|Cranial Computed Tomography Angiography
218965764|NCT05049369|DEVICE|Polysomnography|Polysomnography is performed one time overnight
218965765|NCT00146107|BEHAVIORAL|Diet|10 percent weight loss through diet and behavioral modification
218965766|NCT00146107|OTHER|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
218965767|NCT00146107|OTHER|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
218965768|NCT00562744|OTHER|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
219208023|NCT00124735|DRUG|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
219208024|NCT00124735|DRUG|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
219653635|NCT02557204|PROCEDURE|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
218965769|NCT02410733|BIOLOGICAL|Lipo-MERIT|vaccination
218965770|NCT01264016|DEVICE|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
218965771|NCT03504579|OTHER|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
218965772|NCT00911378|PROCEDURE|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
219653636|NCT02557204|PROCEDURE|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
219653637|NCT02557204|PROCEDURE|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
219653638|NCT02557204|PROCEDURE|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
219653639|NCT01687569|OTHER|Control Cracker Snack|Base cracker snack
219653640|NCT01687569|OTHER|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
219653641|NCT01687569|OTHER|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
219653642|NCT00514904|BIOLOGICAL|Nimenrix|Single dose, intramuscular injection
219653643|NCT00514904|BIOLOGICAL|Mencevax|Single dose, subcutaneous injection
219653644|NCT04441840|DIETARY_SUPPLEMENT|Active Probiotic Culture|Both conditions matched in appearance and serving size
218965773|NCT00911378|PROCEDURE|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
219063272|NCT03873649|OTHER|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
219063273|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
219063274|NCT01045447|DRUG|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
219063275|NCT01045447|DRUG|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219063276|NCT03157986|OTHER|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
219063277|NCT03157986|OTHER|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
219063278|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
219653645|NCT04441840|DIETARY_SUPPLEMENT|Inactive Probiotic Culture|Both conditions matched in appearance and serving size
219653646|NCT06620484|DEVICE|Musculoskeletal Ultrasound with elastography|Musculoskeletal Ultrasound with elastography
219653647|NCT03820219|DEVICE|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
219653648|NCT03820219|OTHER|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
219653649|NCT03430895|DRUG|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
219063279|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
219653650|NCT04186702|PROCEDURE|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
219653651|NCT06649513|DIAGNOSTIC_TEST|eye drops (Tropicamid)|Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
219653652|NCT03837366|BEHAVIORAL|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
219653653|NCT04570852|OTHER|LiDCO|"We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,"
219653654|NCT01759849|OTHER|Allergen|Allergen extract is administered by inhalation.
219653655|NCT06622837|PROCEDURE|implant overdenture|With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.
219653656|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
219653657|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
218965774|NCT04665193|DIAGNOSTIC_TEST|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
218965775|NCT02182648|DRUG|etomidate|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction"
218965776|NCT02182648|DRUG|propofol|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction"
219653658|NCT06617156|OTHER|RSBI Value Evaluation|"Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance."
219653659|NCT01317797|DRUG|namilumab (MT203)|administered three times, subcutaneous in the abdomen
219653660|NCT01317797|DRUG|Placebo|administered three times, subcutaneous in the abdomen
219653661|NCT00182598|PROCEDURE|computer-based psychoeducational intervention|
219653662|NCT00182598|PROCEDURE|community-based substance abuse counseling|
219653663|NCT06158997|DEVICE|EyePeace|EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.
219653664|NCT06158997|DEVICE|Heated Eye Mask|Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
219653665|NCT00260598|PROCEDURE|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
219653666|NCT06620354|DRUG|Selumetinib|Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)
219653667|NCT03597009|DRUG|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
219653668|NCT03597009|DRUG|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
219653669|NCT05803447|OTHER|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
219653670|NCT05803447|DIAGNOSTIC_TEST|biochemical parameters|"The concentrations of the following parameters were determined from the:~* blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~* plasma: metabolites of the oxidative stress"
219653671|NCT05803447|DIAGNOSTIC_TEST|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
219653672|NCT01550705|DRUG|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
218965777|NCT02182648|DRUG|sevoflurane|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance"
218965778|NCT03128645|DEVICE|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
218965779|NCT02801344|DIETARY_SUPPLEMENT|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
219208025|NCT00630487|DRUG|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
219653673|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
219653674|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
219653675|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
218965780|NCT02801344|DIETARY_SUPPLEMENT|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
218965781|NCT02801344|DIETARY_SUPPLEMENT|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
218965782|NCT02801344|OTHER|Controlled-diet|the diet containing 0.8 g protein /kg/day
218965783|NCT00079534|BEHAVIORAL|Non-local/distant healing or prayer|
218965784|NCT00246688|DRUG|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
218965785|NCT02359162|DRUG|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
218965786|NCT02359162|DRUG|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
218965787|NCT02359162|DRUG|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
218965788|NCT02359162|DRUG|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
218965789|NCT02359162|DRUG|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
219653676|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
219653677|NCT01430780|DRUG|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
219653678|NCT01430780|DRUG|control group|placebo
219653679|NCT06624280|PROCEDURE|single-event multilevel surgery|surgical orthopedic approach where multiple deformities are corrected in one solution, often involving both lower limbs, to improve walking performance
219653680|NCT01594892|RADIATION|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
219653681|NCT01007331|BEHAVIORAL|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10\^10 colony forming units pr day of probiotics
219653682|NCT06590389|OTHER|mandala activity|A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
219653683|NCT00006357|DRUG|imatinib mesylate|
219653684|NCT03026530|PROCEDURE|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
219653685|NCT03026530|PROCEDURE|Laparoscopic bariatric surgery|
219653686|NCT03026530|DEVICE|Ventilator|
218965790|NCT02359162|DRUG|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
218965791|NCT02359162|DRUG|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
218965792|NCT02359162|DRUG|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
218965793|NCT02359162|RADIATION|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
219653687|NCT00138073|DEVICE|Web-based waveform interpretation guide|Use of an educational website.
219653688|NCT05759624|DRUG|rhGH|Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
219653689|NCT01239212|DRUG|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
219653690|NCT06090643|OTHER|Best Practice|Receive CRC screening usual care
219653691|NCT06090643|OTHER|Consultation|Receive consultation with clinic staff
219653692|NCT06090643|OTHER|Educational Intervention|Receive education and training on CRC screening
219653693|NCT06090643|OTHER|Electronic Health Record Review|Ancillary studies
219653694|NCT06090643|OTHER|Fecal Immunochemical Test|Receive FIT kit with culturally tailored instructions
219653695|NCT06090643|BEHAVIORAL|Feedback|Receive feedback on CRC screening
219653696|NCT06090643|BEHAVIORAL|Health Education|Receive CRC screening recommendations
219653697|NCT06090643|OTHER|Support Education Activity|Utilize clinical decision support tool
219653698|NCT06090643|OTHER|Text Message-Based Navigation Intervention|Receive text message reminders
218965794|NCT00417482|DRUG|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
218965795|NCT04551144|DRUG|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
218965796|NCT04551144|DRUG|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
218965797|NCT05402020|DRUG|Tiotropium (Tio)|Tiotropium (Tio)
218965798|NCT05402020|DRUG|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
218965799|NCT05402020|DRUG|Olodaterol (Olo)|Olodaterol (Olo)
218965800|NCT05402020|DRUG|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
218965801|NCT05199727|DEVICE|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
218965802|NCT05199727|DRUG|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
218965803|NCT06400979|DEVICE|Elequil aromatab|Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
219653699|NCT03370575|DRUG|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
219653700|NCT03370575|DRUG|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
219653701|NCT05662059|DEVICE|RAVANS|Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation
219653702|NCT05662059|DEVICE|RAVANS-sham|RAVANS sham device
219653703|NCT02750475|DRUG|Sunscreen Sport Lotion (BAY987516)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
219653704|NCT02750475|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
219653705|NCT01746498|PROCEDURE|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
219653706|NCT01746498|PROCEDURE|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
219653707|NCT01746498|PROCEDURE|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
219653708|NCT06395298|OTHER|Experimental group PIOMI|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI
219653709|NCT06395298|OTHER|Control group NIDCAP|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
219653710|NCT03411694|OTHER|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
219653711|NCT05977127|BIOLOGICAL|Comirnaty|Administration of Comirnaty vaccine
219653712|NCT05484076|OTHER|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
219653713|NCT03108404|OTHER|Validation of a diagnostic test|Validation of a diagnostic test
219653714|NCT02211963|DRUG|BI 44847|
219653715|NCT02211963|DRUG|Placebo|
219653716|NCT02010658|OTHER|Cognitive Aid|
219653717|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on deepLive™ LC-OCT device|Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
219653718|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on skin biopsy|Control Arm: Standard management with an initial diagnosis based on skin biopsy
219653719|NCT02744664|PROCEDURE|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
218965804|NCT03403270|OTHER|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
218965805|NCT05440071|DEVICE|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
219653720|NCT02744664|DRUG|Icotinib|After Cryotherapy, subjects begin Icotinib administration
219653721|NCT05613608|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
218965806|NCT05812079|DIAGNOSTIC_TEST|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
218965807|NCT05901792|OTHER|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
219653722|NCT05613608|DRUG|Placebo|Placebo arm.
219653723|NCT00519233|DRUG|AGS-1C4D4|IV
219653724|NCT00507078|PROCEDURE|Surgical treatment for OSA|
219653725|NCT06646328|PROCEDURE|Central venous access|Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
219653726|NCT06646328|DEVICE|Pump-assisted circuit|The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
219653727|NCT06646328|DRUG|Heparin sodium|Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
219653728|NCT06646328|OTHER|Regional citrate anticoagulation|Regional citrate anticoagulation will be used in the other arm with an initial dose of 3 mmol/L and with a calcium reinfusion solution at an initial dose of 2 mmol/L, with adaptation of both infusions to the patient ionic calcium levels.
219653729|NCT06646328|PROCEDURE|Blood and ultrafiltrate samples|"Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein."
219653730|NCT05484154|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
219653731|NCT05484154|OTHER|Placebo|Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
219653732|NCT04756583|OTHER|Notification system|Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
219653733|NCT00790998|DRUG|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
219653734|NCT00790998|DRUG|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
219208026|NCT00630487|DRUG|Somatropin|Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
219653735|NCT00773578|DEVICE|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
219653736|NCT00773578|DEVICE|Measurement of biomarkers of nasal inflammation|Nasal lavage
219653737|NCT00444041|DRUG|Bevacizumab|neoadjuvant therapy prior to elective surgery
219653738|NCT03909113|DIETARY_SUPPLEMENT|amino acid based formula|amino acid based formula
219653739|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Tablet|1.5 grams/day
219653740|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Placebo|2 tablets
219653741|NCT02520882|DRUG|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
219653742|NCT02520882|DEVICE|PET/CT|
219653743|NCT06621082|DRUG|Selumetinib|After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
219653744|NCT03148457|DRUG|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
219653745|NCT03148457|DRUG|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
219653746|NCT06174376|DEVICE|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
219653747|NCT00375050|DRUG|Riluzole|
219653748|NCT00375050|DRUG|Placebo|placebo
219653749|NCT00847392|PROCEDURE|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
219653750|NCT03250091|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
219653751|NCT03250091|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
219653752|NCT03250091|PROCEDURE|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
219653753|NCT03250091|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
219653754|NCT00478114|DRUG|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
219653755|NCT06429215|DEVICE|Multi-component Intervention (MC-I): VR Cognitive training and Psychoeducation on health and lifestyle|"In a period of 5 consecutive weeks, participants will receive:~* an interactive immersive virtual reality cognitive training for 30 minutes, 3 days per week. It consists in different tasks implemented in virtual real-like scenarios of daily living situations that target the following cognitive processes: long-term associative memory, relational binding, spatial pattern separation and pattern completion;~* an interactive immersive virtual reality health and lifestyle education program for 30 minutes, 1 day per week. It consists in 360° videos aimed at advancing awareness and knowledge of the various health conditions associated with an increased risk of cognitive decline and dementia and helping participants to develop a healthier lifestyle."
219653756|NCT06429215|DEVICE|Cognitive-only intervention (CO-I): VR Cognitive training (+ Psychoeducation active control)|"In a period of 5 consecutive weeks, participants will receive:~* the interactive immersive virtual reality cognitive training as described in the MC-I condition, for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for 30 minutes, 1 day per week."
219653757|NCT06429215|DEVICE|Active control intervention (AC-I): VR Cognitive active control + Psychoeducation active control|"In a period of 5 consecutive weeks, participants will receive:~* an active control of the immersive virtual reality cognitive training (participants will be requested to virtually carry out daily actions, in the same setting as those performed in cognitive immersive VR training, but they will follow prearranged instructions requiring very low cognitive demands) for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for about 30 minutes, 1 day per week."
219653758|NCT04824391|BIOLOGICAL|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
219653759|NCT04824391|BIOLOGICAL|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
219653760|NCT04824391|OTHER|Placebo|Two IM applications on Days 1 and 28
219653761|NCT03211923|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
219653762|NCT01845168|OTHER|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
219653763|NCT01845168|DEVICE|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
219653764|NCT01845168|DEVICE|Computer-alert|
219653765|NCT06618248|COMBINATION_PRODUCT|Sirolimus coated balloon angioplasty|This study involves the use of a Sirolimus-Coated Balloon (SCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The SCB is coated with sirolimus, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
219653766|NCT06618248|COMBINATION_PRODUCT|Paclitaxel coated balloon angioplasty|This study involves the use of a Paclitaxel-Coated Balloon (PCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The PCB is coated with paclitaxel, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
219653767|NCT06598384|DRUG|Venetoclax combined with Azacytidine|"Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5."
219653768|NCT01560533|BEHAVIORAL|Interviews|Interviews will be done with patients
219653769|NCT02152553|DRUG|Hydrocortisone|
219653770|NCT02152553|DRUG|Placebo|
219653771|NCT04323865|DIAGNOSTIC_TEST|fetal heart rate variability|No direct intervention, as the study is observational.
219653772|NCT03445234|DIETARY_SUPPLEMENT|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
219653773|NCT03445234|DIETARY_SUPPLEMENT|Placebo|Placebo powder
219653774|NCT03445234|DIETARY_SUPPLEMENT|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
219653775|NCT03445234|DIETARY_SUPPLEMENT|No banana|water only
219653776|NCT01834716|BEHAVIORAL|Aerobic vs. Non-Aerobic exercise|
219653777|NCT03211143|DRUG|CKD-381|Test drug: CKD-381
219653778|NCT03211143|DRUG|Nexium|Reference drug: Nexium
219653779|NCT05072964|DEVICE|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
219653780|NCT05250687|PROCEDURE|MR- High intensity focused ultrasound|The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
219653781|NCT05250687|RADIATION|External beam radiotherapy|Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
219653782|NCT03081143|DRUG|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
219653783|NCT03081143|DRUG|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
219653784|NCT03081143|DRUG|Paclitaxel|80 mg/m2 on day 1, 8, 15
219653785|NCT03690973|DRUG|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
219653786|NCT03690973|DEVICE|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
219653787|NCT03690973|DEVICE|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
219653788|NCT03690973|DRUG|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
219653789|NCT05461456|DRUG|Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)|"Intervention:~The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.~Comment:~The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation."
219208027|NCT04910438|OTHER|STIs screening and care|"* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~* Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
219208028|NCT03958019|OTHER|RESTORE II Program|Detailed in arm description
219653790|NCT02042300|DEVICE|XIENCE Xpedition/Alpine/Sierra|
219653791|NCT05636007|DEVICE|Huawei Watch|pulse rate variability measured by a smartwatch
219653792|NCT06622733|BEHAVIORAL|Questionnaire|Attitude towards the concept of CS on demand
219653793|NCT04787796|DEVICE|a 28-channel ECG (MECG) system|To test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms.
219653794|NCT04010747|BEHAVIORAL|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
219653795|NCT04010747|BEHAVIORAL|Mental Health Services Consultation and Waitlist|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
219653796|NCT03635385|PROCEDURE|Apheresis technics|Blood draw will be performed for anti bodies dosages
219653797|NCT04412187|DIAGNOSTIC_TEST|[18F]-GE-180 PET|serial \[18F\]-GE-180 PET imaging to assess microglia activation
219653798|NCT04412187|DIAGNOSTIC_TEST|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
219653799|NCT04412187|DIAGNOSTIC_TEST|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
219208029|NCT00327561|PROCEDURE|Intensive periodontal therapy|
219208030|NCT00327561|PROCEDURE|Community based periodontal therapy|
219653800|NCT06246487|BEHAVIORAL|Occupational Therapy Intervention|Children randomized to the intervention condition will receive a sensory enriched intervention 2x's per week, 60-minutes per session, for 16 weeks. The intervention will follow a codified protocol developed by Dr. Bodison that is theoretically grounded in neurodevelopmental research. The interveners will be occupational therapists who will be trained by Dr. Bodison to deliver the codified, intervention protocol to provide a personally customized set of therapeutically guided environmental interactions. Because, at its core, the intervention emphasizes playful interaction with a sensory enriched environment, the intervention room will be equipped with swings, scooter boards, climbing equipment, bolsters, and large carpeted barrels. Within this setting, using the codified manual of intervention developed by Dr. Bodison, the intervener will structure activities to provide tactile and proprioceptive input to address the child's individualized areas of need.
219653801|NCT05299398|DRUG|Trazodone|Trazodone capsule once daily
219653802|NCT05299398|DRUG|Placebo|Placebo capsule once daily
219653803|NCT03197467|DRUG|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
219063280|NCT05372445|BEHAVIORAL|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
219208031|NCT02261506|OTHER|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
219653804|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|6 IU single dose
219653805|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|IN-OXT 6 IU three times a day for 2 weeks
218965808|NCT05901792|OTHER|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
219653806|NCT04789148|DRUG|Placebo|Intranasal placebo three times a day for 2 weeks
219653807|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|24 IU single dose
219653808|NCT04789148|DRUG|Placebo|placebo single dose
219653809|NCT02224781|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219653810|NCT02224781|PROCEDURE|Computed Tomography|Undergo CT
219653811|NCT02224781|DRUG|Dabrafenib Mesylate|Given PO
219653812|NCT02224781|PROCEDURE|Echocardiography Test|Undergo ECHO
219653813|NCT02224781|BIOLOGICAL|Ipilimumab|Given IV
219653814|NCT02224781|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219653815|NCT02224781|BIOLOGICAL|Nivolumab|Given IV
218965809|NCT02545140|OTHER|No intervention|
219208032|NCT02261506|OTHER|14 days of adequate antibiotic treatment durations|
219653816|NCT02224781|OTHER|Quality-of-Life Assessment|Ancillary studies
219653817|NCT02224781|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219653818|NCT06229132|BEHAVIORAL|LGBTQ-affirmative CBT for transgender individuals|The intervention addresses unique stressors encountered by transgender individuals due to discrimination and lack of adequate and affirming healthcare resources.
219653819|NCT03666533|OTHER|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
219208033|NCT01440933|DRUG|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
219653820|NCT03666533|OTHER|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
219653821|NCT02159495|DRUG|cyclophosphamide|Given IV
219653822|NCT02159495|BIOLOGICAL|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
219653823|NCT02159495|OTHER|laboratory biomarker analysis|Correlative studies
219653824|NCT02159495|BIOLOGICAL|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
219653825|NCT02159495|DRUG|Fludarabine Phosphate|Given IV
219653826|NCT05892432|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
219653827|NCT05892432|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
219653828|NCT05892432|DRUG|Placebo|A medically inert placebo medication will be taken for 8 weeks.
219653829|NCT06326190|DRUG|Local standard of Care|According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.
219653830|NCT06326190|DRUG|177Lu-DOTATATE|Intravenous injection of 177Lu-DOTATATE
219653831|NCT04602026|OTHER|Best Practice|Receive standard of care
219653832|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
219653833|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
219653834|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
219653835|NCT05565586|DIETARY_SUPPLEMENT|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
219653836|NCT05565586|DIETARY_SUPPLEMENT|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
219653837|NCT00626236|DRUG|SPN-810|1.67mg capsule taken TID
219653838|NCT00626236|DRUG|SPN-810|3.33mg capsule taken TID
219653839|NCT00626236|DRUG|SPN-810|5mg capsule taken TID
219653840|NCT00626236|DRUG|SPN-810|6.67 mg capsule taken TID
219653841|NCT06008171|OTHER|Patient Decision Aid|A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
219653842|NCT04283292|DRUG|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
219653843|NCT04283292|DRUG|Placebo|Placebo cream that is applied once topically
219653844|NCT00077441|DRUG|bortezomib|Given IV
219653845|NCT00077441|OTHER|laboratory biomarker analysis|Correlative studies
219653846|NCT06612099|OTHER|Aerobic Exercise|Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
219653847|NCT06612099|OTHER|Mat Pilates Exercise|Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
219653848|NCT03978247|DIAGNOSTIC_TEST|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
219653849|NCT06374277|OTHER|Med AAAction intervention|The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
219653850|NCT03050541|DRUG|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
219653851|NCT03050541|DRUG|Placebo|
219653852|NCT02104349|BEHAVIORAL|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
218965810|NCT05468138|DRUG|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
218965811|NCT05468138|DRUG|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
218965812|NCT05468138|OTHER|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
218965813|NCT05468138|DRUG|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
218965814|NCT04706117|DEVICE|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
218965815|NCT04536831|DRUG|Vitamin D|Vitamin D will be given to group A selected by Lottery method
218965816|NCT04536831|DRUG|Normal saline|Vitamin D will be given to group B slected by Lottery method
218965817|NCT02428985|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
218965818|NCT01526122|DRUG|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
218965819|NCT01526122|DRUG|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
218965820|NCT03739840|DRUG|Padsevonil|Padsevonil in different dosages.
218965821|NCT03739840|DRUG|Placebo|Placebo will be provided matching padsevonil.
218965822|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
219653853|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
219653854|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
219653855|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
219653856|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
219653857|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
219653858|NCT06052137|DEVICE|Active TBS-DLPFC|"Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
219653859|NCT06052137|DEVICE|TBS-DMPFC|"Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
219653860|NCT03596671|DEVICE|RENOVA iStim™ System|Tibial implantable neuromodulation device
219653861|NCT03548961|DRUG|FOLFOX regimen|FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
219653862|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
219653863|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
219653864|NCT02544295|BEHAVIORAL|Clinical interview|
219653865|NCT02544295|BEHAVIORAL|Virtual reality task|
219653866|NCT04291326|DIAGNOSTIC_TEST|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
219653867|NCT03606694|DRUG|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
219653868|NCT03606694|DRUG|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
219653869|NCT02824016|BIOLOGICAL|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
218965823|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
218965824|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
218965825|NCT01545453|DRUG|placebo|subcutaneous dose every 4 weeks
218965826|NCT03411915|BIOLOGICAL|XmAb18087|monoclonal bispecific antibody
219653870|NCT02824016|RADIATION|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
219653871|NCT04991363|PROCEDURE|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
219653872|NCT00088959|DRUG|erlotinib hydrochloride|Given orally
219653873|NCT00088959|DRUG|celecoxib|Given orally
219653874|NCT00088959|OTHER|laboratory biomarker analysis|Correlative studies
219653875|NCT05450926|PROCEDURE|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
219653876|NCT01825356|PROCEDURE|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
219653877|NCT01825356|PROCEDURE|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
219653878|NCT03219151|DEVICE|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
219653879|NCT03219151|OTHER|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
219653880|NCT01333358|DRUG|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
219653881|NCT02915536|OTHER|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
219653882|NCT02872857|DRUG|Placebo|Placebo will match drug capsules.
219653883|NCT02872857|DRUG|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
219653884|NCT02872857|DRUG|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
219653885|NCT05108740|DRUG|everolimus|Self-administered as a daily dose of 10mg orally
219653886|NCT03443310|PROCEDURE|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
219653887|NCT04142164|OTHER|MacInfo presentation|Presentation about intravitreal drug injection
219653888|NCT04142164|OTHER|Placebo presentation|Placebo presentation
219653889|NCT02663752|PROCEDURE|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
219653890|NCT02663752|DRUG|Deferasirox|Patients are already on commercial deferasirox before entering the study.
219653891|NCT01779167|DRUG|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)
219653892|NCT01779167|DRUG|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.
219653893|NCT01779167|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
219653894|NCT04392167|DEVICE|a/LCI-OCT imaging probe|a/LCI and OCT imaging measurements of several locations in the esophagus
219653895|NCT04392167|PROCEDURE|esophageal biopsy|biopsies of esophageal tissue imaged by a/LCI-OCT probe
219653896|NCT06010420|DEVICE|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
219653897|NCT01644526|DEVICE|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
219653898|NCT01652326|DRUG|Diazepam|
219653899|NCT06095635|OTHER|Placebo Protocol|ingestion of 500 mg of starch following 30 minutes of exercise (treadmill)
219653900|NCT06095635|OTHER|Protocol Beet|ingestion of 500 mg of beet extect following 30 minutes of exercise (treadmill)
219653901|NCT06095635|OTHER|Protocol Resveratrol|ingestion of 500 mg of resveratrol following 30 minutes of exercise (treadmill)
219653902|NCT06095635|OTHER|Protocol Beet and Resveratrol|ingestion 500 mg of beet extect and 500 mg of resveratrol following 30 minutes of exercise (treadmill)
219653903|NCT02395263|DRUG|Yuxintine|
219208034|NCT01440933|DRUG|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
219653904|NCT00955045|DRUG|istradefylline|
219653905|NCT04585399|BEHAVIORAL|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
219653906|NCT01071239|DEVICE|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
219653907|NCT01071239|DRUG|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
219653908|NCT01071239|DRUG|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
219208035|NCT01461759|DRUG|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
219653909|NCT01071239|DRUG|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
219653910|NCT01071239|DRUG|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
219653911|NCT02428803|OTHER|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
219653912|NCT05821790|OTHER|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
219653913|NCT03251794|DIAGNOSTIC_TEST|three dimensional ultrasound|evaluation of the suprarenal glands
219653914|NCT03251794|DIAGNOSTIC_TEST|color Doppler|Doppler evaluation of the suprarenal artery
219653915|NCT04518969|DEVICE|CytoSorb|"CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
219653916|NCT05057117|DEVICE|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
219208036|NCT01461759|DRUG|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
219653917|NCT05057117|DRUG|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
219653918|NCT05734950|OTHER|Translational study|Non-interventional, translational study
219653919|NCT05391581|OTHER|GIPR antagonist / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
219653920|NCT05391581|OTHER|GLP-2R antagonist / study tool|Selective antagonist of the GLP-2R, GLP-2(3-33)
219653921|NCT05391581|OTHER|Placebo|Saline
219653922|NCT06731738|DRUG|Gadoteric acid|A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.
219653923|NCT06731738|DRUG|Mangafodipir trisodium injection|Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
219653924|NCT01831323|DIETARY_SUPPLEMENT|VSL#3|VSL#3
219653925|NCT01831323|DRUG|Rifaximin|Rifaximin
219653926|NCT01831323|DRUG|Mesalazine|Mesalazine
219653927|NCT01831323|DIETARY_SUPPLEMENT|Psyllium|psyllium
219653928|NCT05597579|DIAGNOSTIC_TEST|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
219653929|NCT02165475|BEHAVIORAL|Biofeedback|
219653930|NCT02165475|DRUG|Loperamide|
219653931|NCT02165475|DRUG|Stool bulking agent (stericulia or isphagula husk)|
219653932|NCT02165475|OTHER|Combination of biofeedback and medical treatment|
219653933|NCT04063657|PROCEDURE|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
219653934|NCT04063657|PROCEDURE|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
219653935|NCT04382144|DRUG|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
219653936|NCT03336723|DEVICE|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
219653937|NCT06454916|DEVICE|Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
219653938|NCT05452733|BEHAVIORAL|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
219653939|NCT06528795|OTHER|Scenario-based high-reality hybrid simulation method|"Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario."
219653940|NCT03408444|DEVICE|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
219653941|NCT03408444|DEVICE|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
219653942|NCT03408444|DEVICE|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
219653943|NCT03408444|DEVICE|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
219653944|NCT04984681|BEHAVIORAL|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
218965827|NCT02245204|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
219653945|NCT04984681|OTHER|Usual Care|The control condition will continue receiving usual care or standard of care.
219653946|NCT00960349|DRUG|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
219653947|NCT00960349|DRUG|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
218965828|NCT00147420|DRUG|Zhi Byed 11|
218965829|NCT03560830|OTHER|2 submaximal exercise stress tests|
219063281|NCT05372445|BEHAVIORAL|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
219063282|NCT01659918|DRUG|Montelukast|
219063283|NCT01659918|DRUG|Singulair|
219063284|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
219208037|NCT01646450|DRUG|Icotinib|Icotinib: 125mg, oral administration, three times per day.
219653948|NCT00960349|DRUG|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
219653949|NCT00960349|DRUG|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
219653950|NCT00960349|DRUG|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
219653951|NCT03141775|OTHER|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
219653952|NCT00357136|BEHAVIORAL|password usage|
219653953|NCT03447600|BEHAVIORAL|Alternate Day Fasting|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
219653954|NCT03447600|BEHAVIORAL|Continuous dietary restriction|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
219653955|NCT00001736|DRUG|Cysteamine|
219653956|NCT02267213|DRUG|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
219653957|NCT00957749|DRUG|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
219653958|NCT00568256|BEHAVIORAL|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
219653959|NCT01823172|PROCEDURE|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
219653960|NCT04628078|OTHER|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
219653961|NCT01279564|DEVICE|ETview TVT endotracheal tube|intubation
219653962|NCT01279564|DEVICE|Endotracheal tube|Intubation
219653963|NCT00287391|DRUG|Rabeprazole|
219653964|NCT01473394|DRUG|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
219653965|NCT01473394|DRUG|Vilazodone|Vilazodone was supplied as tablets.
219653966|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
219653967|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
219653968|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
219653969|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
219653970|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
219653971|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
219653972|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
219653973|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
219653974|NCT00782691|OTHER|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
219653975|NCT03057223|DEVICE|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
218965830|NCT03531034|OTHER|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
218965831|NCT01828515|DRUG|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
218965832|NCT01828515|DRUG|Placebo|
218965833|NCT01828515|DRUG|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
218965834|NCT01646060|DEVICE|CM-1500|Blood Volume Monitor
218965835|NCT01095471|BIOLOGICAL|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
218965836|NCT02593201|DRUG|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
218965837|NCT02593201|DRUG|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
218965838|NCT05993182|DRUG|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
218965839|NCT05993182|DRUG|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
218965840|NCT05993182|DRUG|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
218965841|NCT04246255|DRUG|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
219653976|NCT06215755|DRUG|VRG50635|"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."
219653977|NCT01538992|DEVICE|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
219653978|NCT03769597|DRUG|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
219653979|NCT02732405|DRUG|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
219653980|NCT00546455|DRUG|Fenretinide|200 mg/day
219653981|NCT00546455|DRUG|Placebo|2 capsules/day
219653982|NCT00032422|PROCEDURE|Acupuncture|
219653983|NCT05795205|BEHAVIORAL|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
219653984|NCT05795205|BEHAVIORAL|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
218965842|NCT04246255|DRUG|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
218965843|NCT02992080|OTHER|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
219653985|NCT05795205|BEHAVIORAL|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
219653986|NCT04577534|DRUG|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
219653987|NCT02018978|BEHAVIORAL|Comprehensive Triaged HIV Prevention (CTHP)|"1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
219653988|NCT01482962|DRUG|Alisertib|Alisertib enteric coated tablets
218965844|NCT04309071|OTHER|Dietary intervention|Salivary insulin responses to a standardized mixed meal
218965845|NCT03970213|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
218965846|NCT03970213|DRUG|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
219653989|NCT01482962|DRUG|Pralatrexate|Pralatrexate IV infusion
219653990|NCT01482962|DRUG|Gemcitabine|Gemcitabine IV infusion
219653991|NCT01482962|DRUG|Romidepsin|Romidepsin IV infusion
219653992|NCT04393220|DRUG|Bevacizumab Injection|15mg/kg (Q3W)
218965847|NCT00961766|DRUG|BG00010 (Neublastin)|Single dose, weight-based IV administration
219063285|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
219063286|NCT06535685|DRUG|Romiplostim|Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
219653993|NCT04393220|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
219653994|NCT05759520|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
219653995|NCT05759520|BIOLOGICAL|Prevenar 13|the 2-month-old control group received the active control vaccine
219653996|NCT04357912|BEHAVIORAL|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
218965848|NCT00961766|DRUG|Placebo|Single dose IV matched placebo
218965849|NCT01058265|OTHER|Integrative|Integrative Medicine medical evaluation.
218965850|NCT01058265|OTHER|Standard|Standard general medical evaluation.
218965851|NCT01511393|OTHER|No treatment given|None. Non-interventional study.
218965852|NCT04601922|OTHER|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
218965853|NCT02594332|DRUG|Mepolizumab|100 mg SC every 4 weeks for 13 injections
218965854|NCT02594332|DRUG|Placebo|
219063287|NCT02181530|OTHER|No Intervention|No treatment (intervention) is being administered as part of this study.
219208038|NCT04347733|DRUG|Triamcinolone Acetonide 40mg/mL|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
219653997|NCT04357912|BEHAVIORAL|Standard of Care Group|Participants will receive standard of care exercise education.
219653998|NCT01583075|PROCEDURE|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
219653999|NCT01583075|PROCEDURE|single ring pulmonary vein ablation|single ring pulmonary vein ablation
219654000|NCT03219606|OTHER|Organized education course of Modified Rodnan Skin Scoring|"1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
219654001|NCT01798407|DEVICE|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
219654002|NCT01798407|OTHER|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
219654003|NCT06299904|BEHAVIORAL|Modified Air-pulse Stimulation|Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)
218965855|NCT05802875|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
219208039|NCT04347733|DRUG|Hyaluronidase Injection|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
219208040|NCT02972788|DRUG|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
219654004|NCT06299904|BEHAVIORAL|Conventional air-pulse stimulation|The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
219654005|NCT01325116|BEHAVIORAL|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
219654006|NCT03111199|OTHER|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
219654007|NCT03111199|OTHER|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
219654008|NCT03111199|OTHER|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
219654009|NCT03111199|OTHER|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
219654010|NCT04892628|OTHER|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
219654011|NCT04892628|OTHER|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
219654012|NCT02174913|DEVICE|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
219654013|NCT02174913|DRUG|Target controlled infusion of propofol|TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
219654014|NCT02174913|DRUG|Fentanyl|Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
219654015|NCT02174913|DRUG|Atracurium|Atracurium 0.6 mg/kg is used for endotracheal intubation
219654016|NCT00897962|OTHER|Healthy Controls|One blood draw (2 teaspoons)
219654017|NCT00897962|OTHER|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
219654018|NCT00897962|OTHER|Non-cancer medical illness|One blood draw (2 teaspoons)
219208041|NCT02972788|OTHER|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
219208042|NCT03778541|DRUG|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
219654019|NCT02564640|DEVICE|videolaryngoscope|patients intubated by using the videolaryngoscope
219654020|NCT02564640|DEVICE|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
219654021|NCT02678585|DRUG|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
219208043|NCT03778541|RADIATION|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
219208044|NCT01921075|OTHER|normal dietary behavior|normal dietary behavior during examination days
219208045|NCT01921075|OTHER|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
219208046|NCT02996136|DEVICE|Flu Symptoms|Flu Symptoms
219208047|NCT02254720|DRUG|BEA 2180 BR solution for infusion|
219208048|NCT02254720|DRUG|Placebo|Intravenous infusion
219208049|NCT02254720|DRUG|BEA 2180 BR solution for inhalation|
219208050|NCT02254720|DEVICE|Respimat®|
219654022|NCT02678585|DRUG|Lidocaine|53 patients received intravenous regional lidocaine
219654023|NCT04891211|DIETARY_SUPPLEMENT|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
219654024|NCT05642624|DRUG|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
219654025|NCT03932149|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
219654026|NCT03932149|DEVICE|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
219654027|NCT04815499|DIETARY_SUPPLEMENT|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
219654028|NCT04815499|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
219654029|NCT06623500|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
219654030|NCT06623500|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
218965856|NCT05802875|BEHAVIORAL|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
219654031|NCT06293118|DEVICE|Ischemic conditioning group|The ischemic conditioning protocol will consist of a period of 12 weeks (24 sessions) with a frequency of 2 weekly sessions lasting between 15 and 20 minutes each. Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) with customized ischemia programs, partially restricting blood flow through special pressure cuffs that are internally valved, providing greater comfort and safety for these patients who typically have stiffness in the affected limb and localized muscle pain. In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
219654032|NCT06293118|DEVICE|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer
219654033|NCT02378415|DRUG|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
219654034|NCT02378415|DRUG|Placebo|Normal Saline Infusion
219654035|NCT03023111|DRUG|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
218965857|NCT02897765|BIOLOGICAL|NEO-PV-01|Personal cancer vaccine
219654036|NCT03023111|DRUG|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
219654037|NCT03023111|DRUG|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
219654038|NCT06620211|PROCEDURE|promontofixation, prolapse cure|Patient who underwent surgery to place the Sacromesh® medical device (promontofixation) for a prolapse cure, between 2009 and 2018
219654039|NCT00497978|DIETARY_SUPPLEMENT|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
219654040|NCT00497978|DIETARY_SUPPLEMENT|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
219654041|NCT06622577|DIETARY_SUPPLEMENT|Cysteine|Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
219654042|NCT04669951|OTHER|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
219654043|NCT05562765|OTHER|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
219654044|NCT02632240|OTHER|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
219654045|NCT03260517|DEVICE|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
219654046|NCT04855617|DRUG|Ocrelizumab|"Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion"
219654047|NCT02333721|PROCEDURE|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
219654048|NCT02333721|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
219654049|NCT05051605|BIOLOGICAL|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
219654052|NCT04794205|DRUG|Low Dose Beta-Caryophyllene|5 mg BCP
219654053|NCT04794205|DRUG|Medium Dose Beta-Caryophyllene|30 mg BCP
219654054|NCT04794205|DRUG|High Dose Beta-Caryophyllene|150 mg BCP
219654055|NCT04794205|DRUG|Placebo|Placebo drug.
219654056|NCT02115074|DRUG|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219654057|NCT02115074|DRUG|Celebrex|"Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219654058|NCT01729520|OTHER|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
219654059|NCT04106089|BEHAVIORAL|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
219654060|NCT00741091|DEVICE|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
219654061|NCT00741091|DEVICE|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
219654062|NCT03085992|DRUG|FOLFOXIRI plus Bevacizumab|"* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
219654063|NCT03085992|OTHER|Chemoradiotherapy plus Bevacizumab|"* FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
219654064|NCT00449943|PROCEDURE|Computed Tomographic Angiography|CT scan
219654065|NCT00449943|PROCEDURE|Myocardial Perfusion Imaging Scan|SPECT
219654066|NCT01801358|DRUG|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
219654067|NCT01801358|DRUG|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
219654068|NCT04303936|DEVICE|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
219654069|NCT03122613|DIETARY_SUPPLEMENT|Curcumin|3g of Curcumin per day
219654070|NCT03122613|DRUG|Placebo|3g of Curcumin Placebo per day
219654071|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
219654072|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
219654073|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
219654074|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
219654075|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
219654076|NCT01985438|PROCEDURE|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
219654077|NCT01985438|PROCEDURE|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
219654078|NCT00292110|DRUG|Methadone|100 mg/day orally
219654079|NCT00292110|BEHAVIORAL|Contingency Management|Incentives given for cocaine abstinence
219654080|NCT00292110|DRUG|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
219654081|NCT00292110|BEHAVIORAL|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
219654082|NCT04147624|DRUG|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
219654083|NCT04147624|OTHER|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
219654084|NCT01967641|DRUG|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
219654085|NCT06648902|DRUG|meldonium|500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6
219654086|NCT00723190|DRUG|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
218965858|NCT02897765|BIOLOGICAL|Nivolumab|monoclonal antibody against PD1
218965859|NCT02897765|OTHER|Adjuvant|immune adjuvant
218965860|NCT05633004|DEVICE|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
219654087|NCT04660318|DEVICE|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
219654088|NCT04660318|DEVICE|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
219654089|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
219654090|NCT04042922|DEVICE|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
219654091|NCT04042922|DEVICE|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
219654092|NCT06615713|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
219654093|NCT04930042|DRUG|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
219654094|NCT04930042|DRUG|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
219654095|NCT00001656|DRUG|Olanzapine|tablet; 5-20mg/day; 8 weeks
219654096|NCT00001656|DRUG|Clozapine|tablet; 12.5-900mg/day; 8 weeks
219654097|NCT06079307|OTHER|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
219654098|NCT06079307|OTHER|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
219654099|NCT00000207|DRUG|Buprenorphine|
219654100|NCT05451615|DRUG|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
219654101|NCT05451615|DRUG|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
219654102|NCT02585271|DEVICE|Transanal decompression tube|22 Fr transanal decompression tube
219654103|NCT02585271|DEVICE|Stent|self-expandable colorectal nitinol alloys stent
219654104|NCT06730971|PROCEDURE|Total thyroidectomy|Post operative specimen after total thyroidectomy
219654105|NCT06730971|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
218965861|NCT05344885|BEHAVIORAL|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.
218965862|NCT05344885|BEHAVIORAL|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
219654106|NCT03141983|DRUG|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
219654107|NCT03141983|DRUG|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
219654108|NCT03839771|DRUG|AG-120|250mg tablets
219654109|NCT03839771|DRUG|Placebo for AG-120|250mg tablets
219654110|NCT03839771|DRUG|AG-221|100mg tablets
219654111|NCT03839771|DRUG|Placebo for AG-221|100mg tablets
219654112|NCT00673725|DRUG|Locobase® REPAIR|emollient
218965863|NCT05220800|DRUG|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
218965864|NCT05220800|DRUG|Placebo|Isoton saline infusion
218965865|NCT02343081|DRUG|Temozolomide|
218965866|NCT02343081|DRUG|Temozolomide|
218965867|NCT00729287|DIETARY_SUPPLEMENT|selenium|Given orally
218965868|NCT00729287|OTHER|placebo|Given orally
219654113|NCT00391157|DRUG|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
219654114|NCT06054243|BEHAVIORAL|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
218965869|NCT00952627|DIETARY_SUPPLEMENT|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
219654115|NCT06054243|BEHAVIORAL|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
219654116|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation|Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. No adjunctive therapies were applied in this group.
219654117|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and chlorhexidine irrigation|The participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were irrigated with 0.2% chlorhexidine digluconate solution for 1 minute.
219654118|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and ozone application|The participants in the mechanical instrumentation with ozone (MO) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, gaseous ozone was applied to the peri-implant pockets using an ozone-generating device and a specialized glass fiber probe. The ozone gas was delivered to four sites (mesial, distal, buccal, and lingual) for 15 seconds per site, resulting in a total application time of 1 minute per implant. The device operated at a power of 3 watts and 80% oxygen concentration, as recommended by the manufacturer.
219654119|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and air abrasion|The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were treated with glycine powder-based air abrasion using an air-abrasion device (AIR-FLOW® handy 3.0 PERIO HANDPIECE, EMS, Nyon, Switzerland) and a flexible Perio-Flow® nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant.
219654120|NCT06730568|PROCEDURE|Air abrasion monotherapy|The participants in the glycine powder air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion. Local anesthesia was applied before the procedure. The peri-implant pockets were instrumented with an air-abrasion device using glycine powder and a flexible nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant. .
218965870|NCT00952627|DIETARY_SUPPLEMENT|Placebo|
218965871|NCT02613949|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
219208051|NCT06307743|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
218965872|NCT04173234|OTHER|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
218965873|NCT04173234|OTHER|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
218965874|NCT02169284|DRUG|Erlotinib Hydrochloride|Given PO
218965875|NCT02169284|OTHER|Laboratory Biomarker Analysis|Correlative studies
218965876|NCT02169284|OTHER|Pharmacological Study|Correlative studies
218965877|NCT02169284|OTHER|Placebo|Given PO
218965878|NCT02169284|OTHER|Quality-of-Life Assessment|Ancillary studies
218965879|NCT02169284|PROCEDURE|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
218965880|NCT06568783|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
218965881|NCT02738632|DRUG|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
218965882|NCT02738632|DRUG|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
218965883|NCT02738632|DRUG|Placebo for Hydrochlorothiazide|
218965884|NCT06195683|DRUG|Serplulimab|Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
218965885|NCT03048916|OTHER|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
219654121|NCT06496022|DIAGNOSTIC_TEST|Frail scale|FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).
219654122|NCT06496022|DIAGNOSTIC_TEST|Barthel scale|The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.
219654123|NCT06496022|DIAGNOSTIC_TEST|SARC-F|The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).
219654124|NCT06496022|DIAGNOSTIC_TEST|FRAX|FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72
219654125|NCT06496022|DIAGNOSTIC_TEST|Mini-Cog scale|The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).
219654126|NCT06496022|DIAGNOSTIC_TEST|dynamometry|carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
219654127|NCT05285722|BEHAVIORAL|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
219654128|NCT04318639|COMBINATION_PRODUCT|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
219654129|NCT00745511|DRUG|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
219654130|NCT00745511|DRUG|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
219654131|NCT03672448|OTHER|Naturalistic observation|Naturalistic observation
219654132|NCT06477835|BIOLOGICAL|SIM0718 Injection|Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
219654133|NCT05137535|OTHER|Questionnaire|Family-based questionnaire
219654134|NCT01549041|DRUG|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
219654135|NCT01549041|DRUG|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
219654136|NCT00063479|DRUG|Zoledronic Acid|
219654137|NCT03247764|OTHER||observational study
219654138|NCT02521779|OTHER|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
218965886|NCT03048916|OTHER|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
218965887|NCT00984568|BIOLOGICAL|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
218965888|NCT00984568|DRUG|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
218965889|NCT00984568|DRUG|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
218965890|NCT00984568|DRUG|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
218965891|NCT02415257|DRUG|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
218965892|NCT04482712|DRUG|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
218965893|NCT04482712|DRUG|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
219063288|NCT00826891|DRUG|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
219063289|NCT00374530|DRUG|PGE2|
219654139|NCT02521779|OTHER|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
219654140|NCT02521779|OTHER|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
219654141|NCT02521779|OTHER|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
219654142|NCT00210600|DRUG|PROCRIT (Epoetin alfa)|
219654143|NCT00324142|DRUG|Oral tinidazole|
219654144|NCT00597506|DRUG|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
219654145|NCT00597506|DRUG|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
219654146|NCT04211974|DIAGNOSTIC_TEST|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
219654147|NCT00100191|PROCEDURE|uterine artery embolization|
219654148|NCT00100191|PROCEDURE|hysterectomy|
219654149|NCT01270386|DRUG|apatinib|Apatinib 750 mg p.o. once daily
219654150|NCT01270386|DRUG|placebo|placebo p.o. once daily
219654151|NCT01931241|DRUG|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
218965894|NCT01843088|DRUG|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
219654152|NCT02938949|DRUG|alirocumab|
219654153|NCT02938949|DRUG|placebo|
219654154|NCT01368107|DRUG|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
219654155|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
219654156|NCT01368107|DRUG|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
219654157|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
219654158|NCT03266692|BIOLOGICAL|ACTR087|Autologous T cell product
219654159|NCT03266692|BIOLOGICAL|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
219654160|NCT00201240|BIOLOGICAL|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
219654161|NCT01870674|DRUG|YH12852|
219654162|NCT01870674|DRUG|Prucalopride|
219654163|NCT01870674|DRUG|Placebo|
219654164|NCT01241617|DEVICE|Duet TRS|Endo GIA stapler with integrated Duet TRS
219654165|NCT01241617|DEVICE|Endo GIA|Endo GIA stapler with Single Use Loading Units
219208052|NCT00355888|DRUG|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
219654166|NCT00909714|DEVICE|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
219654167|NCT00909714|DEVICE|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
219654168|NCT02356510|PROCEDURE|Primary PCI|
219654169|NCT04912219|DEVICE|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
219654170|NCT00027677|DRUG|halofuginone hydrobromide|
219654171|NCT00006994|DIETARY_SUPPLEMENT|glutamine|20 cc three times daily for 60 days
219654172|NCT00006994|RADIATION|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
219654173|NCT00006994|DRUG|l-glutamine placebo|20 cc three times daily for 60 days
219654174|NCT00941694|BEHAVIORAL|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
219654175|NCT00941694|BEHAVIORAL|placebo group|3 phone calls not related to asthma self-management
219654176|NCT03077659|DRUG|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
219654177|NCT04940715|OTHER|Passive joint mobilization|Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (\>50% of maximum therapist strength), according to patient's irritability and severity.
219654178|NCT04940715|OTHER|Mobilization with movement|Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
218965895|NCT01843088|DRUG|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
218965896|NCT04857970|OTHER|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
218965897|NCT04857970|OTHER|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
219654179|NCT03069456|DEVICE|BIS|
219654180|NCT03069456|DEVICE|ADMS|
219654181|NCT01537978|OTHER|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
219654182|NCT04353388|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
219654183|NCT00874328|DRUG|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
219654184|NCT00874328|DRUG|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
219654185|NCT00874328|DRUG|TS-1 (S-1)|TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
219654186|NCT00038896|DRUG|Venlafaxine ER|
219654187|NCT03437876|OTHER|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
219654188|NCT00986986|DRUG|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
219654189|NCT01917357|BIOLOGICAL|Quinvaxem in Uniject|
219654190|NCT01917357|BIOLOGICAL|Quinvaxem in single dose vials|
219654191|NCT06658886|OTHER|No intervention|No intervention
219654192|NCT03404258|OTHER|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
219654193|NCT04886206|BIOLOGICAL|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
219654194|NCT05867693|DIETARY_SUPPLEMENT|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
219654195|NCT05867693|DIETARY_SUPPLEMENT|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
219654196|NCT04610450|DEVICE|HEARO|Robotic system for otological procedures
219654197|NCT04610450|DEVICE|OTOPLAN|Otological surgical planning software
219654198|NCT04686786|DRUG|CVL-865|Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
219654199|NCT01526876|DRUG|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
219654200|NCT00563160|DRUG|gemcitabine, carboplatin|
219654201|NCT00563160|PROCEDURE|surgery|
219654202|NCT04263480|DRUG|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
219654203|NCT04263480|DRUG|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
219654204|NCT03413956|PROCEDURE|Surgeries|Surgeries
219654205|NCT01942356|PROCEDURE|TIVA - Hypotension|"Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1. Give 200 mL Fluid Bolus~2. If not successful, give ephedrine 5 mg bolus~3. Repeat from 1.) if even is not resolved after 3.)"
218965898|NCT01316354|OTHER|Bread types|Bread with 50 g available carbohydrate
218965899|NCT05059587|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
218965900|NCT05059587|DRUG|BOTOX|Botox will be injected into the Glabellar line.
219063290|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
219063291|NCT05006170|DRUG|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
219063292|NCT05006170|DRUG|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
219654206|NCT01942356|PROCEDURE|TIVA - Hypertension|"Defined as: SBP \> 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered"
218965901|NCT01284582|BIOLOGICAL|ATH03|4 vaccinations
218965902|NCT06324760|DIETARY_SUPPLEMENT|Alpha-lipoic acid combined with B vitamins|The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system
219654207|NCT01942356|PROCEDURE|TIVA - Bradycardia|"Defined as: Heart rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
219654208|NCT01942356|PROCEDURE|TIVA - Tachycardia|"Defined as: Heart Rate \> 90 beats/min~1. If associated with normal NIBP (MAP \> 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~2. If associated with hypertension (SAB \> 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
219654209|NCT01942356|PROCEDURE|INH - Hypotension|"Defined as: MAP \< 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. give a 200 ml fluid bolus (crystalloid).~2. If not successful, give ephedrine 5 mg bolus.~3. If not successful decrease volatile by 0.1 MAC.~4. Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
219654210|NCT01942356|PROCEDURE|INH - Hypertension|"Defined as: SBP \> 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. increase Sevoflurane by 0.1 MAC~2. If not successful after 3 minutes (SBP \>130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~3. If still not successful (SBP \>130% of baseline), Labetolol 5mg IV will be administered."
219654211|NCT01942356|PROCEDURE|INH - Bradycardia|"Defined as: Heart Rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
219654212|NCT01942356|PROCEDURE|INH - Tachycardia|"Defined as: Heart rate \> 90 beats/min~1. if associated with normal NIBP (MAP \> 70% of baseline and SBP \<130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~2. If associated with hypertension (SBP \>130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~3. If associated with hypotension (MAP \< 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
219654213|NCT06353126|PROCEDURE|DEB-TACE|"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."
219654214|NCT04010526|COMBINATION_PRODUCT|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
219654215|NCT04010526|OTHER|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
219654216|NCT04050124|DEVICE|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
218965903|NCT05893355|BEHAVIORAL|Acupressure group|"Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
219063293|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
219063294|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
219063295|NCT00332748|DRUG|Oral Taxane|
219654217|NCT04050124|DEVICE|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
219654218|NCT04271839|COMBINATION_PRODUCT|fluticasone/formoterol k-haler (medium strength)|2 inhalations every 12 hours
219654219|NCT04271839|COMBINATION_PRODUCT|Standard of care (ICs/LABA high strength)|Depend of the ICs/LABA combination
219654220|NCT04281901|DRUG|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
219654221|NCT04281901|DRUG|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
219654222|NCT01551719|BEHAVIORAL|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
219654223|NCT03119623|DRUG|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
218965904|NCT00185068|DRUG|Olmesartan medoxomil|
218965905|NCT00185068|DRUG|Olmesartan medoxomil/hydrochlorothiazide|
219063296|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
219063297|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
218965906|NCT00185068|DRUG|Hydrochlorothiazide|
219654224|NCT03119623|DRUG|Enalapril|enalapril 5mg, titrated up to 10mg po BID
219654225|NCT04669964|PROCEDURE|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
219654226|NCT05163821|DIAGNOSTIC_TEST|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
219654227|NCT05163821|DIAGNOSTIC_TEST|ACE-III Somali Translation|Cognitive screen for dementia
219654228|NCT05168878|BEHAVIORAL|30-second BeSMART video|30 second video focused on education about child gun deaths and responsible gun storage
218965907|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
218965908|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
218965909|NCT00072631|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
219654229|NCT05168878|BEHAVIORAL|3-minute BeSMART video|3-minute video focused on education about child gun deaths and responsible gun storage
219654230|NCT01633008|BEHAVIORAL|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
219654231|NCT01577615|BEHAVIORAL|Patterned Experience|"* The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age."
219654232|NCT01914159|DRUG|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
219654233|NCT06413056|DRUG|Micafungin|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
219654234|NCT06413056|DRUG|Amphotericin B|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
219654235|NCT00802061|BEHAVIORAL|Sleeping position in glaucoma patient|
219654236|NCT01907061|DRUG|N-acetylcysteine|drug will be administered via IV,NG
219654237|NCT01907061|DRUG|Placebo|placebo or NAC will be given
219654238|NCT03183934|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
219654239|NCT02396303|DRUG|Carbetocin|
219654240|NCT04476121|PROCEDURE|PRF application|PRF application into post-operative wound.
219654241|NCT04476121|DRUG|Nipas application|Nipas application into post-operative wound.
219654242|NCT03576534|OTHER|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
219654243|NCT03688958|DRUG|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
219654244|NCT03688958|DRUG|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
219654245|NCT03688958|DRUG|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
219654246|NCT03688958|DRUG|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
218965910|NCT05439642|OTHER|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
218965911|NCT02932683|DEVICE|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
218965912|NCT03439059|BEHAVIORAL|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
219063298|NCT03859843|COMBINATION_PRODUCT|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
219654247|NCT01537068|DRUG|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
219654248|NCT01537068|DRUG|Placebo|Matching placebo pills
219654249|NCT02574702|PROCEDURE|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
219654250|NCT04512313|DRUG|Rocuronium 0,3mg/kg|Rocuronium 0,3mg/kg at induction
219654251|NCT04512313|DRUG|Rocuronium 0,9mg/kg|Rocuronium 0,9mg/kg at induction
219654252|NCT01664832|DEVICE|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
219654253|NCT05002517|DRUG|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
218965913|NCT05318482|BEHAVIORAL|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
218965914|NCT05318482|OTHER|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
218965915|NCT03647332|PROCEDURE|Cooled RFA treatment|cooled radiofrequency ablation
219654254|NCT05002517|DRUG|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
219654255|NCT00483704|DRUG|Telcagepant 140 mg|Telcagepant 140 mg tablets
219654256|NCT00483704|DRUG|Talcagepant 280 mg|Telcagepant 280 mg tablets
219654257|NCT00483704|DRUG|Placebo|Placebo tablets
218965916|NCT03647332|DRUG|Steroid Drug|steroid injection
219208053|NCT00367653|DRUG|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
219654258|NCT02589353|DRUG|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
219654259|NCT01948583|DRUG|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
219654260|NCT03968250|BEHAVIORAL|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
219654261|NCT03407183|PROCEDURE|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
219654262|NCT01647919|DIETARY_SUPPLEMENT|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
219654263|NCT01647919|DIETARY_SUPPLEMENT|Placebo|4 capsules of placebo identical to cogniVida™ once a day
219654264|NCT04392388|BIOLOGICAL|Non applicable|to collect data from questionnaires and to collect serological samples
219654265|NCT01157650|OTHER|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
218965917|NCT03886662|DRUG|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
219063299|NCT03859843|OTHER|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
219063300|NCT03859843|OTHER|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
219208054|NCT00367653|DRUG|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
219208055|NCT05222646|DRUG|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
219208056|NCT00047190|DRUG|tipifarnib|Given PO
219654266|NCT06498466|OTHER|myofascial release|Myofascial release therapy (MRT) is a manual therapy technique that involves gradual stretching by a therapist or the individual, acting on the muscles and surrounding fascia. Its effects include increasing joint range of motion and mobility of soft tissues, eliminating imbalances in muscle tone, reducing muscle pain, reducing stress on joints, and increasing neuromuscular efficiency.
219654267|NCT02815124|OTHER|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
219654268|NCT02815124|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
219654269|NCT02147951|DRUG|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
219654270|NCT06648551|DIAGNOSTIC_TEST|CONUT|It is a scale that uses albumin, lymphocytes, and cholesterol for the diagnosis of malnutrition
219654271|NCT00501124|DRUG|Clevudine|
219654272|NCT00501124|BIOLOGICAL|Purified hepatitis B surface antigen|
219654273|NCT01630408|DRUG|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
219654274|NCT00005046|DRUG|chemotherapy|
219654275|NCT00005046|DRUG|paclitaxel|
219654276|NCT01772849|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
219654277|NCT05814536|DRUG|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
219654278|NCT00827749|DEVICE|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
219654279|NCT01981343|DIETARY_SUPPLEMENT|A-F Betafood|
219654280|NCT01981343|OTHER|Placebo|
219654281|NCT06583447|BEHAVIORAL|Calorie-restricted diet (CRD)|"Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week."
219654282|NCT06583447|BEHAVIORAL|Time-restricted eating (TRE)|Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
219654283|NCT05926752|DEVICE|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
219654284|NCT05926752|OTHER|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
219654285|NCT06375096|OTHER|evaluate bone mineral density|observation effect of graves' in bone mineral density in children
218965918|NCT05544370|BEHAVIORAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
219654286|NCT04466761|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
219654287|NCT04466761|OTHER|Placebo Comparator|Placebo (cellulose powder).
219654288|NCT02032862|DRUG|Sage extract, 3400 mg , DER 1:17|
219063301|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
219654289|NCT00819780|DRUG|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
219654290|NCT00819780|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
219654291|NCT00819780|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
219654292|NCT05141916|PROCEDURE|Endoscopic Retrograde Cholagiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
219654293|NCT04364113|OTHER|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
219654294|NCT04364113|OTHER|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
219063302|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
219654295|NCT04364113|OTHER|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
219654296|NCT04364113|DRUG|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
219654297|NCT04364113|DRUG|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
219654298|NCT02517242|DEVICE|Pens Device|
219654299|NCT02517242|DEVICE|Syringe|
219654300|NCT02517242|OTHER|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
219654301|NCT03596723|DRUG|KPI-121 1%|eye drops
219654302|NCT03596723|DRUG|Prednisolone acetate|eye drops
219654303|NCT03326128|DRUG|Bupropion Hydrochloride|Antidepressant that is also effective in smoking cessation
219654304|NCT00150800|DRUG|Brivaracetam|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral"
219654305|NCT00865917|DRUG|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
219654306|NCT00865917|DRUG|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
219063303|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
219654307|NCT00865917|DRUG|Placebo|matching appearance
219654308|NCT02389790|DRUG|MT-1303|
219654309|NCT05838443|OTHER|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
219654310|NCT05838443|OTHER|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
219654311|NCT05838443|OTHER|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
219654312|NCT06099132|DIAGNOSTIC_TEST|Electromyographic measurements|HD and bipolar EMG were assessed from gastrocnemius medialis (GM), soleus (SO) and tibialis anterior (TA) at seated position, ankle at 0°, during isometric submaximal effort and maximal effort, knee flexed (90°) and knee extended (0°)
219654313|NCT06895252|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
219654314|NCT06895252|OTHER|Anti inflammatory diet|The modified diet plan will be given to each study participant
219654315|NCT06895252|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
219654316|NCT06895252|OTHER|Sham diet|Dietary counselling alone
219654317|NCT03090724|DRUG|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
219654318|NCT05644821|OTHER|complex intervention|"The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4\) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist."
219654319|NCT05644821|OTHER|current clinical practice|current clinical practice
219654320|NCT04450407|DRUG|LY3209590|Administered SC
219654321|NCT04450407|DRUG|Insulin Degludec|Administered SC
219063304|NCT02516618|DRUG|Fasinumab|
219063305|NCT02516618|DRUG|Placebo|
219063306|NCT04489446|DRUG|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
219208057|NCT00047190|OTHER|laboratory biomarker analysis|Correlative studies
218965919|NCT05544370|BEHAVIORAL|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
218965920|NCT03800810|DRUG|Hyaluronic Acid|
219654322|NCT01258179|OTHER|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
219654323|NCT04028622|OTHER|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
219654324|NCT06767748|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
219654325|NCT06767748|DRUG|insulin degludec|insulin degludec s.c.,once-daily，treat-to-target dose
219654326|NCT03378297|DRUG|Metformin|Metformin tablets 850 mg x 2 orally
219654327|NCT03378297|DRUG|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
219654328|NCT03378297|DRUG|Olaparib|Olaparib capsules 300 mg x 2 orally
219654329|NCT03378297|DRUG|Letrozole|Letrozol tablets 2.5 mg x 1 orally
219654330|NCT05916859|OTHER|Group 2 PDT (10 s)|\- Conventional endodontic treatment associated with PDT (10 s)
219654331|NCT05916859|OTHER|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
219654332|NCT05916859|OTHER|Group 1. Placebo|Conventional endodontic treatment
219654333|NCT06618261|DIETARY_SUPPLEMENT|Caffeine + Resistance exercise|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
219654334|NCT06618261|DIETARY_SUPPLEMENT|Placebo + Resistance exercise|Acute placeb intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
219654335|NCT04483375|BIOLOGICAL|SCTA01|recombinant humanized anti-SARS-CoV-2 monoclonal antibody
218965921|NCT03800810|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
219063307|NCT04489446|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
219063308|NCT03525353|OTHER|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
219208058|NCT01534546|DRUG|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
219208059|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
219654336|NCT04483375|OTHER|Placebo|Placebo
219654337|NCT06903585|DRUG|Naproxen (Proxen S)|Naproxen will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be taken as an initial dose of 500mg then as 250mg every 8 hours for a total of 5 days.
219654338|NCT06903585|DRUG|Placebo|Placebo will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be given every 8 hours for a total of 5 days.
218965922|NCT03800810|BIOLOGICAL|Recombinant Human Somatropin|
218965923|NCT03802695|BIOLOGICAL|OrcaGraft (Orca-Q)|engineered donor allograft
218965924|NCT04843059|OTHER|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
218965925|NCT03281460|DEVICE|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
219063309|NCT02980367|OTHER|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
219208060|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
219654339|NCT06903585|DRUG|Esomeprazole 20mg once daily|Esomeprazole will be given to all subjects as 20mg once daily starting from the day they start palliative radiotherapy and for a total of 5 days.
219654340|NCT05659979|OTHER|Comprehensive geriatric assessment|A detailed comprehensive geriatric assessment will be given to all the participants randomized to this group, including the administration of multidimensional prognostic index (MPI), a tool derived from the CGA and consisting of eight different domains.
219654341|NCT01574638|DRUG|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
219654342|NCT03943264|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
219654343|NCT03087097|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
219654344|NCT03185754|PROCEDURE|Sublobar resection|Sublobar resection
219654345|NCT03185754|PROCEDURE|lobectomy|lobectomy
219654346|NCT06903923|DRUG|GLP-1 receptor agonist|Participants prescribed a GLP-1 receptor agonist (semaglutide) by their physician will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
219654347|NCT06903923|BEHAVIORAL|Lifestyle Management|Participants receiving usual lifestyle interventions will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
219654348|NCT04190498|DIAGNOSTIC_TEST|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
219654349|NCT05705154|BEHAVIORAL|Psychology interventions|"Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~* Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~* Identifying the connections between body and mind to address anxiety and breathlessness~* Coping skills for managing anxiety using principles from narrative therapy and mindfulness~* Online materials to improve self-efficacy with home practice~* Social connection with other CYP for peer support, and resource sharing~* Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
219654350|NCT01712165|DIETARY_SUPPLEMENT|ANMUM Materna|
219654351|NCT01712165|DIETARY_SUPPLEMENT|Control (milk powder)|
219654352|NCT02683382|DEVICE|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
219654353|NCT00923182|DRUG|alemtuzumab|
219654354|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
219654355|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
218965926|NCT03281460|PROCEDURE|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
219654356|NCT01921244|OTHER|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
219654357|NCT02188472|DRUG|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
219654358|NCT02188472|DRUG|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
219654359|NCT02188472|DRUG|Placebo|Placebo: 2 tablets should be taken twice daily
219654360|NCT01748422|DRUG|Qutenza|Transdermal patch
219654361|NCT03784144|DIAGNOSTIC_TEST|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
219654362|NCT05001295|PROCEDURE|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
219654363|NCT02089334|DRUG|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
218965927|NCT05185115|DRUG|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
218965928|NCT05185115|OTHER|no oxygen therapy|No oxygen therapy during hospitalization
218965929|NCT06293300|DRUG|BoNT A|Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
218965930|NCT06063772|DRUG|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
218965931|NCT06063772|DRUG|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
219654364|NCT02613039|DRUG|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
219208061|NCT03875313|DRUG|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
218965932|NCT04920799|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
218965933|NCT04920799|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
218965934|NCT03583073|BEHAVIORAL|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
218965935|NCT03583073|BEHAVIORAL|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
218965936|NCT03690453|DRUG|Ivermectin|single dose of Ivermectin
219654365|NCT03177434|DRUG|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
219654366|NCT03177434|DRUG|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
219654367|NCT05546216|OTHER|Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients|The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
219654368|NCT01179841|BEHAVIORAL|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
219654369|NCT01179841|BEHAVIORAL|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
219654370|NCT01179841|BEHAVIORAL|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
219654371|NCT02215863|BIOLOGICAL|Fluad and Prevenar13|
219654372|NCT02215863|BIOLOGICAL|Fluad|
219208062|NCT03875313|DRUG|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
219654373|NCT02215863|BIOLOGICAL|Prevenar13|
219654374|NCT01604863|DRUG|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
219654375|NCT01604863|DRUG|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
219654376|NCT01604863|DRUG|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
219654377|NCT02510105|DEVICE|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
219654378|NCT02510105|DEVICE|CT scan|
219654379|NCT02510105|DEVICE|Servo-i|
219654380|NCT02510105|DEVICE|- Intubation|
219654381|NCT02510105|DEVICE|Ventilation ( with an ICU conventional ventilator)|
219654382|NCT05108077|BIOLOGICAL|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
218965937|NCT04555226|PROCEDURE|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
218965938|NCT04555226|RADIATION|Standard chemoradiation±pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
219654383|NCT05108077|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
219654384|NCT01355198|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
219063310|NCT02980367|PROCEDURE|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
219654385|NCT01355198|DIETARY_SUPPLEMENT|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
219654386|NCT06620705|DEVICE|Left bundle branch area pacing|Pacing of the left bundle branch area using a transvenous pacemaker lead
219654387|NCT06620705|DEVICE|Biventricular pacing|Pacing of the right and left ventricle using transvenous pacemaker leads
219654388|NCT01993498|PROCEDURE|blood sampling|blood samples collection
219654389|NCT06621927|OTHER|Diet|The Ideal Food Pyramid, which has not been applied before, is used to observe disease activities and especially changes in intestinal microbiota in rheumatoid arthritis.
219654390|NCT06621927|OTHER|Control (Standard treatment)|We chose a control group to show the effect of the intervention we would apply to the diet group and did not apply any intervention to the control group.
219654391|NCT00792376|DRUG|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
219654392|NCT00792376|DRUG|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
219654393|NCT02584894|DEVICE|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
219654394|NCT02584894|DEVICE|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
219654395|NCT02584894|BEHAVIORAL|psychoneurological assessment|psychoneurological assessment
219654396|NCT02584894|DEVICE|conductivity meter|electrodermal conductance measure
219654397|NCT02584894|DEVICE|electrocardiogram|heart rate measure
219654398|NCT00791362|OTHER|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
219654399|NCT05720494|DRUG|JZP441|Oral study drug administered for up to 4 weeks
219654400|NCT05720494|DRUG|Placebo|Oral placebo administered for up to 4 weeks
219654401|NCT06514716|PROCEDURE|Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI)|Participants will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). This combination aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
219654402|NCT06514716|PROCEDURE|Geniculate Artery Embolization alone (GAE alone)|Participants will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This procedure aims to serve as a control to evaluate the effectiveness and safety of GAE with IACI in comparison.
219654403|NCT06050655|DEVICE|Lingual aligners|orthodontic treatment with lingual aligners
219654404|NCT02402023|BEHAVIORAL|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
219654405|NCT02402023|BEHAVIORAL|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
218985260|NCT06271122|OTHER|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
219208063|NCT04121546|BEHAVIORAL|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
219654406|NCT04507802|DEVICE|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
219654407|NCT03425266|OTHER|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
219654408|NCT04490642|OTHER|Questionnaire|Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
219654409|NCT05157542|DRUG|Durvalumab|Day 1 and 22, 1500mg
219654410|NCT05157542|DRUG|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
219654411|NCT05157542|RADIATION|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
219208064|NCT05825066|DRUG|Nab paclitaxel|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
219654412|NCT02832375|DRUG|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
219654413|NCT02832375|DRUG|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
219654414|NCT00356252|DRUG|mixed carotenoids|
219654415|NCT06628752|DEVICE|Deep brain stimulation|Stimulation through a device implanted bilaterally into deep brain structures.
219654416|NCT03817411|DRUG|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
219654417|NCT03817411|DRUG|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
219654418|NCT03817411|DRUG|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
219654419|NCT03817411|DRUG|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
219654420|NCT05311228|DRUG|Azithromycin Powder|Azithromicyn intravena for 14 days
219654421|NCT00201461|DEVICE|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
219654422|NCT00201461|DRUG|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
219654423|NCT05407428|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients
219654424|NCT06350461|OTHER|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.
219654425|NCT06350461|OTHER|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
219654426|NCT03385044|PROCEDURE|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
219654427|NCT03385044|PROCEDURE|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
219654428|NCT02486640|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
219654429|NCT02486640|DEVICE|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
219654430|NCT06620224|DEVICE|Virtual Reality|we only use single group in this study, before the acupuncture treatment, let the participant wear the virtual reality to realize the course of the acupuncture treatment
219654431|NCT02247635|BEHAVIORAL|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
219654432|NCT00084318|BIOLOGICAL|cetuximab|400 mg/m\^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m\^2 intravenously over 60 minutes in weeks 2 through 7.
219654433|NCT00084318|DRUG|cisplatin|30 mg/m\^2 intravenously infused over over 60 minutes in weeks 2 through 7.
219654434|NCT00084318|DRUG|docetaxel|15 mg/m\^2 intravenously infused over 30 minutes in weeks 2 through 7.
219654435|NCT00084318|RADIATION|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
219654436|NCT06575179|DRUG|Dexmedetomidine low-dose|The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
219654437|NCT06575179|DRUG|normal Saline|The control group received volume-matched 0.9% saline infusions at identical rates.
219654438|NCT06575179|DRUG|Dexmedetomidine high-dose|The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
219654439|NCT02290236|DEVICE|Pulseoximetry|Peripheral saturation will be recorded continuously
219654440|NCT00754208|DRUG|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
219654441|NCT04477590|DRUG|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
219654442|NCT04627532|DRUG|PF-07304814|Participants will receive PF-07304814
219654443|NCT04627532|DRUG|Placebo|Participants will recieve placebo
219654444|NCT03064854|DRUG|PDR001|Powder for solution for infusion
219654445|NCT03064854|DRUG|Cisplatin|Intravenous infusion
219654446|NCT03064854|DRUG|Gemcitabine|Intravenous infusion
219654447|NCT03064854|DRUG|Pemetrexed|Intravenous infusion
219654448|NCT03064854|DRUG|Carboplatin|Intravenous infusion
219654449|NCT03064854|DRUG|Paclitaxel|Intravenous infusion
219654450|NCT03064854|DRUG|Canakinumab|Subcutaneous injection
219654451|NCT06667154|DRUG|Low-dose nivolumab combined with platinum-based doublet chemotherapy|Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
219654452|NCT01113645|PROCEDURE|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
219208065|NCT05825066|DRUG|Gemcitabine|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
219654453|NCT03577977|DRUG|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
218965939|NCT04555226|RADIATION|Chemoradiation± pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
218965940|NCT04967612|OTHER|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
218965941|NCT01367119|DRUG|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
218965942|NCT01367119|DRUG|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
218965943|NCT00645684|PROCEDURE|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
218965944|NCT05515666|DIAGNOSTIC_TEST|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
218965945|NCT04570722|OTHER|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
219063311|NCT00857324|DRUG|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
219063312|NCT06457542|OTHER|Active Release Technique|Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.
219208066|NCT05825066|OTHER|Radiological Assessments|CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
219208067|NCT05825066|DRUG|mFOLFIRINOX|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
219208068|NCT05038215|BEHAVIORAL|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
219654454|NCT02893176|DRUG|macitentan|
219654455|NCT02893176|DRUG|placebo (for macitentan)|
219654456|NCT03756727|DRUG|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
219654457|NCT03756727|DRUG|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
219654458|NCT02884557|OTHER|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
219208069|NCT05038215|PROCEDURE|Routine Care|The control group will receive routine care
219654459|NCT02339129|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
219654460|NCT02339129|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
219654461|NCT00754520|DEVICE|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
219654462|NCT00754520|DEVICE|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
218965946|NCT06030310|OTHER|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
218965947|NCT05860335|DRUG|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
219208070|NCT06416085|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
219208071|NCT04697784|DEVICE|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
219654463|NCT01645891|DEVICE|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
219654464|NCT01645891|DEVICE|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
219654465|NCT00000592|PROCEDURE|blood transfusion|
219654466|NCT00212472|DRUG|Factor VIII concentrates|To be determined at the discretion of the investigator.
219654467|NCT00212472|OTHER|Low-dose treatment|50 FVIII u/kg three times a week.
219654468|NCT00212472|OTHER|High-dose treatment|200 FVIII u/kg per day.
219654469|NCT06590025|BEHAVIORAL|INtegral Cognitive REMediation program|This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.
219654470|NCT06590025|BEHAVIORAL|Psychoeducation for depression|Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
219654471|NCT03140072|DRUG|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
219654472|NCT03140072|DRUG|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
218965948|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
219208072|NCT06951750|OTHER|Reflexology|The participants will receive two minutes of specific reflexology on each point of the uterus, pituitary, and solar plexus in the form of rotational pressures. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
219208073|NCT06951750|OTHER|placebo reflexology|The participants will receive rotational pressures on a neutral point on the lateral side of the heel (placebo point) for six minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
219208074|NCT06951750|OTHER|general foot massage|The participants will receive a general massage on each foot for four minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
219208075|NCT04285671|BIOLOGICAL|Necitumumab|Given IV
219654473|NCT06621043|DRUG|NTI164|Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
219654474|NCT04982458|DIAGNOSTIC_TEST|68Ga-FAPI|68Ga-FAPI injection is a radiopharmaceutical used for positron emission tomography (PET) diagnosis. This product is used for PET, qualitative and localized diagnosis and evaluation of abnormal expression of fibroblast-activated protein in focus-associated fibroblasts.
219654475|NCT03301740|OTHER|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
219654476|NCT03301740|OTHER|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
219654477|NCT03707119|OTHER|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
219654478|NCT05496413|DEVICE|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
219654479|NCT00687349|BEHAVIORAL|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
219654480|NCT01869621|DRUG|Metformin|6 days treatment with metformin to steady-state
219654481|NCT01852552|DEVICE|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
219654482|NCT01852552|PROCEDURE|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
219654483|NCT01037127|DRUG|GSK1120212|Daily oral dosing
219654484|NCT05740176|DEVICE|Anterior Cervical Discectomy and Fusion|Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
219654485|NCT03440762|BEHAVIORAL|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
218965949|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
218965950|NCT04088604|DRUG|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
218965951|NCT02238171|DRUG|Atrovent® inhalets|
218965952|NCT06043284|DEVICE|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
219654486|NCT02622373|DEVICE|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
219654487|NCT03071731|DRUG|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
219654488|NCT03071731|DRUG|Placebos|Administration of a nebulized placebo before the administration of a functional test
219654489|NCT00826592|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
219654490|NCT05610384|DRUG|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
218965953|NCT04455243|DRUG|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
218965954|NCT04455243|DRUG|Placebo|Matching placebo administered in the same schedule and volume as NAC
218965955|NCT03315182|BIOLOGICAL|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
219208076|NCT04285671|DRUG|Osimertinib|Given PO
218965956|NCT01578564|DRUG|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
218965957|NCT00560378|DRUG|Tacrolimus ointment 0.1%|Topical
218965958|NCT02480985|OTHER|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)"
219654491|NCT05610384|DRUG|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
219654492|NCT00962364|BIOLOGICAL|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
219654493|NCT00274079|DRUG|SPIRIVA|
219654494|NCT00334633|DRUG|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
219208077|NCT04285671|OTHER|Quality-of-Life Assessment|Ancillary studies
219654495|NCT03484936|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
219654496|NCT03484936|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
219654497|NCT05930028|DRUG|Fimasartan|Subjects take the investigational products once a day for 8 weeks.
219654498|NCT05930028|DRUG|Ezetimibe/Atorvastatin|Subjects take the investigational products once a day for 8 weeks.
219654499|NCT05930028|DRUG|Fimasartan Placebo|Subjects take the investigational products once a day for 8 weeks.
219654500|NCT05930028|DRUG|Ezetimibe/Atorvastatin Placebo|Subjects take the investigational products once a day for 8 weeks.
219654501|NCT06448533|OTHER|No intervention|No intervention
219654502|NCT05871398|DRUG|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
219654503|NCT05871398|DRUG|Placebo|Placebo
219654504|NCT06473454|OTHER|aerobic exercise and basic body awareness therapy ( exercise)|exercise
219654505|NCT02584998|OTHER|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
219208078|NCT04285671|OTHER|Questionnaire Administration|Ancillary studies
219208079|NCT04285671|BIOLOGICAL|Trastuzumab|Given IV
219208080|NCT02075554|DEVICE|CALIBER|Expandable interbody spacer
219208081|NCT02574611|DRUG|Neostigmine|
219208082|NCT02574611|DRUG|Glycopyrrolate|
219654506|NCT02584998|OTHER|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
219654507|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Nut|
219654508|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Sup|
219654509|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
218985261|NCT01936805|DRUG|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
219654510|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
219654511|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
219654512|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
219654513|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
219654514|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
219654515|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
219654516|NCT05923411|DRUG|Single dose of PF-07220060 as third tablet formulation|A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
219654517|NCT02637713|DEVICE|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
219654518|NCT02637713|PROCEDURE|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
219654519|NCT02747797|DRUG|Lucitanib|10 mg orally daily
218985262|NCT00404937|DRUG|Tobradex (Antibiotic steroid combination)|
218985263|NCT05700448|BIOLOGICAL|Sugemalimab|IV infusion
218985264|NCT05700448|DRUG|Placebo|IV infusion
218985265|NCT05700448|DRUG|Pegaspargase|Intramuscular injection
218985266|NCT05700448|DRUG|Gemcitabine|IV infusion
218985267|NCT05700448|DRUG|Oxaliplatin|IV infusion
218985268|NCT04891978|BEHAVIORAL|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
219208083|NCT02574611|OTHER|Saline (Placebo)|
219208084|NCT02574611|DEVICE|High Resolution Colonic Manometry|
219208085|NCT01316107|DRUG|ipragliflozin|oral
219208086|NCT01316107|DRUG|nateglinide|oral
219208087|NCT02446444|DRUG|Enzalutamide|
219208088|NCT02446444|DRUG|Conventional NSAA|
219208089|NCT02446444|DRUG|LHRHA|
219208090|NCT02446444|RADIATION|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
219654520|NCT01537627|OTHER|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
219654521|NCT01537627|OTHER|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
219654522|NCT01461720|OTHER|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
219654523|NCT01461720|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
218965959|NCT04360863|OTHER|Telephone survey|Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
218965960|NCT02794740|DRUG|X0002|External Spray
218965961|NCT02794740|DRUG|Placebo|External Spray
219208091|NCT06324981|BEHAVIORAL|Generic text messages|The same unidirectional text message will be sent each week for 9 weeks.
219063313|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
219063314|NCT01893242|DRUG|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
219063315|NCT01893242|DRUG|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
219063316|NCT00116805|DRUG|TDF|300 mg tablet administered orally once daily
219063317|NCT00116805|DRUG|ADV|10 mg tablet administered orally once daily
219063318|NCT00116805|DRUG|TDF placebo|Tablet administered orally once daily
219654524|NCT02191176|DRUG|Dextromethorphan syrup - low dose|
219654525|NCT02191176|DRUG|Dextromethorphan syrup - high dose|
219654526|NCT02191176|DRUG|Placebo|
219654527|NCT03273465|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
219654528|NCT00215527|DRUG|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
218965962|NCT05464173|DRUG|Chidamide|10-30mg biw
218965963|NCT05464173|DRUG|Abemaciclib|150mg or 100mg bid
218965964|NCT05464173|DRUG|endocrinotherapy（doctor's choice）|According to the drug insert
218965965|NCT00884533|DRUG|Rosi XR|Rosi XR
218965966|NCT00884533|OTHER|Placebo|Placebo
218965967|NCT00884533|DRUG|Moxifloxacin|400mg single dose
218965968|NCT06013982|BEHAVIORAL|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video"
218965969|NCT03180684|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
218965970|NCT03180684|DRUG|Imiquimod 5% Cream|Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
219063319|NCT00116805|DRUG|ADV placebo|Tablet administered orally once daily
219208092|NCT06324981|BEHAVIORAL|Interactive AI chatbot text messaging|Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.
218965971|NCT03180684|DEVICE|CELLECTRA™ 2000|IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
218965972|NCT06051448|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|This program teaches the four pillars of resilience (stress management, goal setting, cognitive restructuring, and benefit-finding) in a one-on-one training program consisting of four 20-30 minute sessions occurring once weekly.
218965973|NCT06051448|BEHAVIORAL|Clinical-focused narrative (CFN)|This program consists of questions posed to adults with primary mitochondrial disease at regular mitochondrial medicine center visits. Specific topics will be discussed at each session. This consists four 20-30 minute sessions occurring once weekly.
218965974|NCT06524895|OTHER|Medical Reiki|Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
219063320|NCT00116805|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
219063321|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
219654529|NCT06906679|DEVICE|Experimental Group|"The EG will follow 20 sessions of robot-assisted therapy for the upper limb. Exercises will be performed using a handpiece to support the weight of the upper limb during therapy and to assist (or resist) movements according to the patient's needs. These modalities are presented to the patient through visual and motor feedback (force feedback).~The exercises will focus on rehabilitating upper limb performance, for example:~Elbow: flexion-extension; Shoulder: horizontal adduction/abduction, flexion-extension.~The software includes serious games for:~* Motor control (both movement control and force control);~* Coordination;~* Cognitive training;~* Simulation of daily activities. The exercises will be defined by specialized personnel based on the patient's characteristics. Each rehabilitation session lasts 45 minutes, including 5 minutes for device setup, 20 minutes for the right upper limb and 20 minutes for the left upper limb."
219654530|NCT06906679|OTHER|control group|The CG will last 20 sessions (3 days/week) of conventional rehabilitative treatment without the use of technological devices for the upper limb. Each session will last 45 minutes. The motor exercises will focus on upper limb rehabilitation and will be performed with a therapist who will personalize the treatment based on the patient's characteristics and needs. Specifically, the upper limb treatment will include exercises for mobility (shoulder, elbow, wrist, and hand), coordination, and manual dexterity.
219654531|NCT03247491|BEHAVIORAL|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
219654532|NCT02464891|DRUG|CCX168|
219654533|NCT01173055|DRUG|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
219654534|NCT01173055|DRUG|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
219654535|NCT05467618|PROCEDURE|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
219654536|NCT00126100|DRUG|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
219654537|NCT00126100|OTHER|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
219654538|NCT06618833|OTHER|Collection of medical data|Collection of medical data focused on the history of atrial fibrillation by the principal investigator
219654539|NCT06618833|BEHAVIORAL|Collection of global health elements|Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient
219654540|NCT06618833|BEHAVIORAL|PROMIS global questionnaire|"The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense"
219654541|NCT06618833|BEHAVIORAL|Collection of sociological data|Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
219654542|NCT06621628|OTHER|stretching, strengthening exercises and active exercises|Bioptron light therapy device, resisted exercises and stretching exercises
219654543|NCT02351193|OTHER|transvaginal Ultrasound|
218965975|NCT06524895|OTHER|Sham Reiki|Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
218965976|NCT02675231|DRUG|Abemaciclib|Administered Orally
218965977|NCT02675231|DRUG|Trastuzumab|Administered IV
218965978|NCT02675231|DRUG|Fulvestrant|Administered IM
218965979|NCT02675231|DRUG|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
218965980|NCT05133492|DEVICE|Endovascular Aneurysm Stabilization Treatment (EAST)|Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.
218965981|NCT05279079|DIAGNOSTIC_TEST|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
218965982|NCT05351294|OTHER|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
218965983|NCT05351294|COMBINATION_PRODUCT|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
218965984|NCT06144840|DRUG|Dersimelagon|MT-7117
218965985|NCT06144840|DRUG|Placebo|Placebo
218965986|NCT05585320|DRUG|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
219208093|NCT06324981|BEHAVIORAL|Proactive pharmacist support|Pharmacists that will proactively facilitate effective engagement with patients.
219654544|NCT06906588|DEVICE|Experimental|The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one upper limb BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system.. Each participant will perform a total of 16+/-3 treatment sessions with a frequency of 4 times a week for 4 consecutive weeks. During the first session, the device should be adjusted according to the patient's bilateral size and suspension angle. The selection of personalized exercises will be based on each patient's motor skills and the difficulty can be gradually increased during the treatment period. These modalities are shown to the patient with visual and motor feedback (force feedback). The duration of the single rehabilitation treatment is 45 minutes, of which 5 minutes are used for setting up the device, 10 minutes for assembly/disassembly, 10 minutes for unilateral treatment with the affected upper limb and 20 minutes for bilateral treatment.
219654545|NCT06906588|OTHER|Control|The control group (GC), in addition to the standard routine rehabilitation treatment, will follow 45 minutes of conventional rehabilitation of the upper limbs without the use of technological devices. Each participant will perform a total of 16+/-3 conventional upper limb treatment sessions with a frequency of 4 times a week for 4 weeks. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient. Specifically, the treatment of the upper limb will be characterized by motor exercises (shoulder, elbow, wrist and hand), coordination and manual dexterity. Each session will consist of passive, active-assisted and active exercises.
219654546|NCT04250233|DEVICE|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
219654547|NCT04325698|DRUG|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
219654548|NCT04325698|DRUG|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
219654549|NCT04325698|DRUG|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
219654550|NCT04325698|DRUG|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
219654551|NCT04253782|OTHER|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
219654552|NCT01063920|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
219654553|NCT01063920|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
219654554|NCT05425043|BIOLOGICAL|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
219654555|NCT00481260|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
219654556|NCT03890627|DEVICE|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
218965987|NCT05585320|DRUG|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2"
218965988|NCT05585320|DRUG|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2"
219063322|NCT04256551|OTHER|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
219654557|NCT00962091|DRUG|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
219063323|NCT04256551|OTHER|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
219063324|NCT04256551|OTHER|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
219063325|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
219208094|NCT04900675|OTHER|Bright light intervention|Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
219654558|NCT02939027|DEVICE|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
219654559|NCT02939027|DEVICE|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
219654560|NCT00504491|DRUG|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
219654561|NCT06371729|PROCEDURE|DEEP mapping|"The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
219654562|NCT06371729|PROCEDURE|Activation Mapping|"VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
218965989|NCT05585320|DRUG|IMM-1-104 + dabrafenib (Treatment Group D)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with twice daily oral dose of dabrafenib until treatment discontinuation criteria are met. Dabrafenib will be administered at a dose of 150mg daily (75mg twice daily).
218965990|NCT05585320|DRUG|IMM-1-104 + pembrolizumab (Treatment Group E)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of pembrolizumab in sequence or concurrently depending on the enrolled cohort (two sub cohorts) until treatment discontinuation criteria are met. Pembrolizumab will be administered at a dose of 400mg.
218965991|NCT05014490|DRUG|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
218965992|NCT05014490|DRUG|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
218965993|NCT06647420|BEHAVIORAL|Sedative Music|The participants will come twice in person and listen to 9 minutes of sedative music.
218965994|NCT06647420|BEHAVIORAL|Stimulative Music|The participants will come twice in person and listen to 9 minutes of stimulative music.
218965995|NCT05734430|GENETIC|Genetic profiling|Whole exome sequencing
218965996|NCT05734430|OTHER|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
218965997|NCT05587673|DRUG|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
219654563|NCT03491631|DRUG|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
219654564|NCT03491631|DRUG|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
219063326|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
219208095|NCT04900675|OTHER|Reddish placebo light|Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
219208096|NCT01318694|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
219654565|NCT06559384|OTHER|Interviews|semi-structured individual interviews
219654566|NCT01690910|DEVICE|Rifton Gait Trainer|
219654567|NCT01690910|DEVICE|Front Wheeled Walker|
219654568|NCT04875312|DEVICE|Ultrasound cavitation in group A|"Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
219654569|NCT04875312|DEVICE|Electro acupuncture in group B|"Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
218965998|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
218965999|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
218966000|NCT04677413|RADIATION|Ultrafractionated radiotherapy for rectal cancer|To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
218966001|NCT02495233|DRUG|Gilteritinib|oral
218966002|NCT02495233|DRUG|Erlotinib|oral
218966003|NCT04232553|DRUG|Mirikizumab|Administered IV
218966004|NCT04232553|DRUG|Mirikizumab|Administered SC
218966005|NCT05078138|DRUG|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
218966006|NCT05915182|COMBINATION_PRODUCT|Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler|Participants with moderate to severe Chronic Obstructive Pulmonary Disease
219208097|NCT01318694|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
219654570|NCT00003910|DRUG|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
219654571|NCT00003910|DRUG|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
219654572|NCT00003910|DRUG|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
219654573|NCT01979471|OTHER|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
219654574|NCT02953106|DRUG|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
219654575|NCT02953106|DRUG|Placebos|Placebo nasal spray
219654576|NCT02253771|DEVICE|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
219654577|NCT02253771|DEVICE|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
219654578|NCT01446276|DIETARY_SUPPLEMENT|Resveratrol|500 mg 3 times daily for six month
219654579|NCT01446276|OTHER|Placebo|1 placebo tablet 3 times daily for six month
219654580|NCT01501773|BIOLOGICAL|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
219654581|NCT03144843|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
218966007|NCT03880461|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention
218966008|NCT04847622|DRUG|Remdesivir|treated with Remdesivir
218966009|NCT06416670|OTHER|Skilled nursing facility care at home|Skilled nursing facility care at home delivers a range of advanced rehabilitation services in patients' homes, enabling care at home despite requiring intensive rehabilitative care. Our approach blends personalized, high-level professional care with innovative technology applications to ensure adequate rehabilitation.
218966010|NCT03828318|OTHER|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
218966011|NCT01875224|DRUG|Belatacept|
218966012|NCT01875224|DRUG|Tacrolimus|Standard administration of tacrolimus
218966013|NCT01873703|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi)
218966014|NCT01873703|DRUG|Placebo|Placebo
218966015|NCT01873703|DRUG|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
218966016|NCT00672204|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
218966017|NCT00672204|DRUG|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
218966018|NCT00672204|DRUG|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
218966019|NCT00672204|DRUG|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
219208098|NCT01318694|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
219654582|NCT03144843|DRUG|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
219654583|NCT03191864|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
219654584|NCT03191864|DRUG|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
219654585|NCT06619054|DRUG|KP-001|Oral single dose 50mg.
219654586|NCT02650947|DIETARY_SUPPLEMENT|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
219654587|NCT02650947|DIETARY_SUPPLEMENT|Placebo|Consumption of empty capsule everyday for 4 weeks
219654588|NCT00688311|DIETARY_SUPPLEMENT|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).
219654589|NCT00688311|DIETARY_SUPPLEMENT|Placebo|Placebo
218966020|NCT03325751|DIAGNOSTIC_TEST|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
218966021|NCT02848053|OTHER|no intervention|
218966022|NCT00210860|DRUG|topiramate|
218966023|NCT01503112|OTHER|No intervention, observational study|
218966024|NCT04134403|DRUG|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
218966025|NCT01295268|OTHER|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
218966026|NCT01295268|OTHER|Inert oil|A specified amount of inert oil will be applied daily to area.
218966027|NCT01973530|PROCEDURE|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
219654590|NCT05738876|PROCEDURE|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
219654591|NCT01765829|DRUG|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
219654592|NCT01765829|DRUG|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
219654593|NCT04687020|DRUG|Viltolarsen|Received during weekly intravenous infusions
219654594|NCT03962231|OTHER|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
219654595|NCT03962231|OTHER|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
219654596|NCT00583882|OTHER|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
219654597|NCT03399903|DRUG|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
219654598|NCT01389479|BIOLOGICAL|Fluviral™|Intramuscular, single dose
219654599|NCT01389479|BIOLOGICAL|Fluzone®|Intramuscular, single dose
219654600|NCT02405975|OTHER|SCRIPT|An online tool designed to train doctors in all areas of prescribing
218966028|NCT01973530|PROCEDURE|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
218966029|NCT04722653|DRUG|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
218966030|NCT04722653|DRUG|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
219063327|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
218966031|NCT06391801|BEHAVIORAL|Neuroathletic training|Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
219654601|NCT05708677|BIOLOGICAL|EB-101|This is non-interventional and follows patients treated with EB-101
219654602|NCT02342548|DRUG|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
219654603|NCT01047332|DEVICE|Partially Covered Wallstent|Partially covered wallstent
219654604|NCT01047332|DEVICE|Uncovered Wallstent|Uncovered wallstent
219654605|NCT01471509|OTHER|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
219654606|NCT00291161|BEHAVIORAL|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
219654607|NCT06902532|BEHAVIORAL|coconut oil pulling with clove oil|Participants will swish 10 mL of coconut oil mixed with 2 drops of clove oil once daily for 4 weeks. This intervention is designed to assess its antimicrobial efficacy in reducing Streptococcus mutans levels in children and improving oral hygiene.
219654608|NCT06902532|BEHAVIORAL|coconut oil pulling|Participants will swish 10 mL of pure coconut oil once daily for 4 weeks. This intervention aims to evaluate the effectiveness of coconut oil alone in reducing Streptococcus mutans levels and its potential role in maintaining oral health.
219654609|NCT06902532|DRUG|Fluoride Mouthwash|Participants will rinse with 10 mL of fluoride mouthwash three times daily for 4 weeks. This intervention serves as the active comparator, as fluoride mouthwash is a well-established method for reducing Streptococcus mutans levels and preventing dental caries.
219654610|NCT04727034|DRUG|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
219654611|NCT04727034|DRUG|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
219654612|NCT03702712|BEHAVIORAL|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
219654613|NCT03702712|BEHAVIORAL|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
219654614|NCT03702712|BEHAVIORAL|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
219654615|NCT00203944|BEHAVIORAL|Behavioral, Development|
218966032|NCT06391801|BEHAVIORAL|Traditional movement therapy in outpatient rehabilitation|Traditional movement therapy in outpatient rehabilitation
219654616|NCT00082017|DRUG|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days."
219654617|NCT00703794|DEVICE|The AXIUM Progressive Coil System|Embolization of aneurysm
219654618|NCT02286570|DEVICE|Glidescope|videolaryngoscope used for endotracheal intubation
219654619|NCT02286570|DEVICE|Airtraq|videolaryngoscope used for endotracheal intubation
219654620|NCT02286570|DEVICE|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
219654621|NCT04229602|DRUG|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
219654622|NCT04229602|DRUG|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
219654623|NCT03970148|PROCEDURE|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
219654624|NCT01399489|BEHAVIORAL|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
219654625|NCT04889599|DRUG|BH009 (Docetaxel injection)|75mg/m2
219654626|NCT04889599|DRUG|Docetaxel injection|75mg/m2
219654627|NCT05863793|OTHER|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
219654628|NCT05863793|OTHER|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
219654629|NCT05404633|DEVICE|Ergogycle prototype testing for acceptability|The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
219654630|NCT02417961|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
219654631|NCT02624128|DRUG|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
219654632|NCT02624128|DRUG|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
219654633|NCT02624128|DRUG|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
219654634|NCT03765853|OTHER|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
219063328|NCT03506516|DIETARY_SUPPLEMENT|Mixing alcohol|Alcoholic beverages, different types
219063329|NCT03506516|DIETARY_SUPPLEMENT|Single type alcohol|Alcoholic beverages, different types
219063330|NCT04431323|BEHAVIORAL|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
219063331|NCT01760954|DRUG|Elagolix|Elagolix tablets administered orally
219063332|NCT03320070|DRUG|Acthar Gel|Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
219063333|NCT03320070|DRUG|Placebo|Placebo gel for SC injection
219063334|NCT01479660|OTHER|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
219063335|NCT01479660|DRUG|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
219063336|NCT04898335|DEVICE|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
219654635|NCT05645328|OTHER|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
218966033|NCT05684939|BEHAVIORAL|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
218966034|NCT03862040|DRUG|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
218966035|NCT03862040|DRUG|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
218966036|NCT04118933|DRUG|JS001|JS001 240mg, Q3W
219063337|NCT00709969|DRUG|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
219654636|NCT03843645|PROCEDURE|general anesthesia|surgical procedure under general anesthesia
219654637|NCT03843645|PROCEDURE|regional anesthesia|surgical procedure under regional anesthesia
219654638|NCT04796350|DEVICE|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
219654639|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
219654640|NCT06539949|BEHAVIORAL|Rapid Planning Method (RPM)|RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
219654641|NCT06539949|BEHAVIORAL|Journaling|Subjects will be keeping a weekly to-do list.
219654642|NCT05354427|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
219654643|NCT05397210|DEVICE|Infinity-Lock Button System|Infinity-Lock Button System
219654644|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
219654645|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
219654646|NCT00642603|DRUG|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
219654647|NCT00642603|DRUG|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
219654648|NCT00642603|DRUG|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
219654649|NCT06148337|DIETARY_SUPPLEMENT|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
218966037|NCT04094077|DRUG|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
218966038|NCT06324669|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
218966039|NCT06324669|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
219063338|NCT02559674|BIOLOGICAL|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
219063339|NCT02559674|BIOLOGICAL|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
219063340|NCT02559674|BIOLOGICAL|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
218966040|NCT01407042|PROCEDURE|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
218966041|NCT03764488|DRUG|Tofersen|Administered as specified in the treatment arm.
218966042|NCT03764488|DRUG|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
218966043|NCT04025710|DEVICE|BIOMONITOR III and BIOMONITOR IIIm|"* Insertion of BIOMONITOR III or BIOMONITOR IIIm~* three scheduled in-office follow-ups~* 48-hour Holter ECG"
219063341|NCT04433169|DRUG|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
219063342|NCT04433169|DRUG|VEGFR inhibitor|VEGFR inhibitor
219063343|NCT04433169|DRUG|Chemotherapy|chemotherapy
219063344|NCT00457262|PROCEDURE|soy consumption|
219063345|NCT00122018|DRUG|N-acetylcysteine|
219063346|NCT00122018|DRUG|fenoldopam|
219654650|NCT06148337|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
219654651|NCT04871308|DRUG|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
219654652|NCT04871308|DRUG|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
219654653|NCT05195398|DEVICE|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
219654654|NCT05195398|DEVICE|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
219654655|NCT04851613|DRUG|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
219654656|NCT04851613|DRUG|Afuresertib/placebo|afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
219654657|NCT05172258|PROCEDURE|Biopsy Procedure|Undergo biopsy
218966044|NCT03695874|OTHER|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
219063347|NCT04608474|DRUG|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
219654658|NCT05172258|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219654659|NCT05172258|PROCEDURE|Computed Tomography|Undergo CT
218966045|NCT03695874|OTHER|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
219654660|NCT05172258|DRUG|Ipatasertib|Given PO
219654661|NCT05172258|BIOLOGICAL|Pembrolizumab|Given IV
218966046|NCT02431247|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
218966047|NCT02431247|DRUG|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
218966048|NCT02431247|DRUG|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
219063348|NCT04608474|DRUG|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
219063349|NCT00392561|DIETARY_SUPPLEMENT|Selenium|200 ug Selenium daily
219063350|NCT00392561|DIETARY_SUPPLEMENT|vitamin E|100 mg Vitamin E daily
219063351|NCT02001480|DEVICE|12 lead Holter|12 lead Holter measurements will be performed for 7 days
219654662|NCT06417775|DRUG|Ubrogepant|Oral Tablets
219654663|NCT06417775|DRUG|Placebo for Ubrogepant|Oral Tablets
219654664|NCT05619653|DRUG|Prednisolone|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
219654665|NCT05619653|DRUG|Losartan|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
219208099|NCT01318694|DRUG|ALV Placebo|ALV placebo soft gel capsules administered orally
219208100|NCT04959669|OTHER|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
219208101|NCT00004361|DRUG|calcium gluconate|
219208102|NCT00004361|DRUG|sodium citrate|
219654666|NCT04057352|DEVICE|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
219654667|NCT02823821|OTHER|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
219654668|NCT02823821|OTHER|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
219654669|NCT06625320|DRUG|RMC-6236|Oral Tablets
219654670|NCT06625320|DRUG|Gemcitabine|intravenous (IV) infusion
219654671|NCT06625320|DRUG|nab-paclitaxel|IV infusion
219063352|NCT02001480|DEVICE|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
219208103|NCT03820544|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
219208104|NCT03820544|OTHER|Standard of care|Undergo standard of care surgical resection
219654672|NCT06625320|DRUG|Irinotecan|IV infusion
219654673|NCT06625320|DRUG|Liposomal irinotecan|IV infusion
219654674|NCT06625320|DRUG|5-fluorouracil|IV infusion
219654675|NCT06625320|DRUG|leucovorin|IV infusion
219654676|NCT06625320|DRUG|Oxaliplatin|IV infusion
219654677|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
219654678|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
219654679|NCT00819208|BEHAVIORAL|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
219654680|NCT00819208|OTHER|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
219654681|NCT00819208|OTHER|educational intervention|Once at the beginning of the program
219654682|NCT00819208|OTHER|laboratory biomarker analysis|Every 12 months
218966049|NCT02431247|DRUG|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
218966050|NCT02431247|DRUG|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
218966051|NCT02431247|DRUG|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
218966052|NCT02091674|DEVICE|Hyaluronic acid|Injected gel
218966053|NCT03174249|BEHAVIORAL|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
218966054|NCT01765660|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
218966055|NCT01765660|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
218966056|NCT04448054|OTHER|MRI|"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* \+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
218966057|NCT00769665|OTHER|Systane Ultra|Re-wetting ocular eye drop
218966058|NCT00769665|OTHER|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
218966059|NCT06276985|DEVICE|low intensity pulsed ultrasound and iPRF|iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
218966060|NCT03029130|DEVICE|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
218966061|NCT05942859|DIAGNOSTIC_TEST|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
218966062|NCT01690338|DRUG|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
218966063|NCT01690338|DRUG|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
218966064|NCT01690338|DRUG|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
218966065|NCT03711227|DIAGNOSTIC_TEST|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
218966066|NCT01113047|DRUG|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
218966067|NCT06423989|COMBINATION_PRODUCT|IVIG|treatment of subfertility
218966068|NCT01562873|DRUG|Ruxolitinib|
218966069|NCT02855515|PROCEDURE|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
218966070|NCT00291733|DRUG|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
218966071|NCT00291733|DRUG|Placebo|Placebo tabl
218966072|NCT01369485|DEVICE|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
219654683|NCT00819208|OTHER|questionnaire administration|Every 6 months
219654684|NCT00819208|OTHER|study of socioeconomic and demographic variables|Every 6 months
219654685|NCT00819208|PROCEDURE|fatigue assessment and management|Every 6 months
218966073|NCT01369485|DEVICE|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
218966074|NCT00416728|DRUG|Aliskiren|
218966075|NCT00416728|DRUG|Valsartan|
218966076|NCT02048579|BEHAVIORAL|Behavior Therapy + Motivational Interviewing|
218966077|NCT03280043|PROCEDURE|Hematoma|Hematoma requiring return to operating room.
218966078|NCT05312047|PROCEDURE|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
218966079|NCT00071266|DRUG|Niacin Extended Release and Lovastatin Tablets|
218966080|NCT04950114|DRUG|GFB-887|GFB-887 is a potent, small molecule inhibitor of TRPC5.
218966081|NCT01358773|OTHER|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
219208105|NCT05682144|BIOLOGICAL|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
219654686|NCT00819208|PROCEDURE|quality-of-life assessment|Every 6 months
219654687|NCT00819208|OTHER|Educational Intervention|For Arm 2 just once at beginning of program.
219654688|NCT00819208|OTHER|Fitness testing|Objective fitness testing for both arms
219654689|NCT06300450|BEHAVIORAL|Computer Alert|On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
219654690|NCT05729282|DRUG|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
219654691|NCT05729282|DRUG|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
219654692|NCT05729282|DRUG|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
218966082|NCT03696927|DEVICE|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
219654693|NCT05729282|DEVICE|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
219654694|NCT05729282|DRUG|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
219654695|NCT04759274|DEVICE|Diuretic Tuner|Mobile device application for diuretic dose titration
219654696|NCT05814016|DRUG|Danavorexton|Danavorexton IV infusion.
219654697|NCT05814016|DRUG|Placebo|Placebo matching danavorexton IV infusion.
219654698|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer without cycloplegia|Objective refraction without cycloplegia
219654699|NCT06524115|OTHER|Distance visual acuity check using objective refraction without cycloplegia|Distance visual acuity is checked, using objective refraction without cycloplegia
218966083|NCT01858636|DEVICE|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
218966084|NCT01765803|DRUG|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
218966085|NCT00746447|DRUG|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
218966086|NCT00746447|DRUG|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
218966087|NCT00746447|DRUG|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
218966088|NCT05480774|DRUG|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
218966089|NCT05480774|DRUG|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
218966090|NCT02646202|PROCEDURE|Sclerotherapy|Injection of varices
218966091|NCT02646202|PROCEDURE|Band ligation|endoscopic banding of varices
218966092|NCT02646202|PROCEDURE|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
218966093|NCT04230720|DRUG|Systane Complete|1 drop 4 times a day for 14 days
218966094|NCT03523000|OTHER|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
218966095|NCT03523000|DRUG|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
219654700|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer with cycloplegia|Objective refraction with cycloplegia
219654701|NCT06524115|OTHER|Distance visual acuity check using objective refraction with cycloplegia|Distance visual acuity is checked, using objective refraction with cycloplegia
219654702|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
219654703|NCT06079970|DEVICE|Neelde Based Confocal Laser Endomicroscopy|Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
219654704|NCT06079970|PROCEDURE|Conventional diagnostic bronchoscopy|Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
219654705|NCT05155163|BEHAVIORAL|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
219654706|NCT00006113|BIOLOGICAL|MART-1 antigen|
219208106|NCT05630508|BEHAVIORAL|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
219654707|NCT00006113|BIOLOGICAL|aldesleukin|
219654708|NCT00006113|BIOLOGICAL|gp100 antigen|
219654709|NCT00006113|BIOLOGICAL|recombinant CD40-ligand|
218966096|NCT03523000|DRUG|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
218966097|NCT03523000|DRUG|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
219208107|NCT05630508|OTHER|Sham|Receiving standard care, LIVEN educational material and access to the application
219208108|NCT04625023|OTHER|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
219208109|NCT03011671|DRUG|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
219654710|NCT00006113|BIOLOGICAL|recombinant interferon gamma|
219654711|NCT00006113|BIOLOGICAL|recombinant interleukin-4|
219654712|NCT00006113|BIOLOGICAL|sargramostim|
219654713|NCT00006113|BIOLOGICAL|therapeutic autologous dendritic cells|
219654714|NCT00006113|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219654715|NCT00006113|BIOLOGICAL|tyrosinase peptide|
219654716|NCT00006113|RADIATION|Candida albicans skin test reagent|
219654717|NCT05402033|BEHAVIORAL|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
219654718|NCT05845996|DRUG|SAR441344|Solution for intravenous/subcutaneous injection
219654719|NCT05845996|DRUG|placebo|Solution for intravenous/subcutaneous injection
219654720|NCT05845996|BIOLOGICAL|Keyhole limpet hemocyanin|Subcutaneous Lyophilized powder for reconstitution
219654721|NCT04056884|BEHAVIORAL|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
219654722|NCT04057898|DRUG|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
219654723|NCT04057898|DRUG|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
219654724|NCT06633224|PROCEDURE|Blood Specimen Collection|Blood samples will be obtained throughout the course of the study
219654725|NCT06633224|OTHER|Stool Specimen Collection|Stool samples will be obtained throughout the course of the study
219654726|NCT06633224|OTHER|Quality of Life (QOL) Questionnaires|Surveys will be given throughout the course of the study.
219654727|NCT06369415|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)|"Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour"
219654728|NCT01827969|PROCEDURE|ablathermy focused ultrasound|ablathermy focused ultrasound
218966098|NCT03523000|DEVICE|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
218966099|NCT03000270|DEVICE|Impella unloading prior to PPCI|Impella unloading prior to PPCI
219654729|NCT04655508|DRUG|Seretide|"For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~\- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
219654730|NCT04655508|DRUG|Placebo|For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
219654731|NCT06226844|DEVICE|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
219654732|NCT06470282|DRUG|Enfortumab Vedotin|Given intravenously (IV)
219654733|NCT06470282|BIOLOGICAL|Pembrolizumab|Given IV
219654734|NCT06470282|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Undergo standard of care, IMRT
219654735|NCT06470282|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
219654736|NCT06470282|PROCEDURE|Cystoscopy (CS)|Undergo cystoscopy
219654737|NCT06470282|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
219654738|NCT06470282|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
218966100|NCT02958384|BIOLOGICAL|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
218985269|NCT04891978|BEHAVIORAL|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
219208110|NCT03011671|DRUG|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
219208111|NCT05572970|DRUG|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
219208112|NCT05572970|DRUG|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
219654739|NCT06470282|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET Scan, may be combined with CT (PET/CT)
219654740|NCT02389244|DRUG|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
219654741|NCT02389244|DRUG|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
219654742|NCT06372015|OTHER|Nutritional Approach|Nutritional Approach
219654743|NCT06372015|OTHER|Surgery Approach|Bariatric surgery
219654744|NCT05502770|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
219654745|NCT05502770|OTHER|Physical development and General Health|Physical development and General health examination
219654746|NCT05502770|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
219654747|NCT06286748|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
219654748|NCT06286748|OTHER|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
219654749|NCT05934253|DRUG|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
219654750|NCT02559856|DRUG|Apixaban|
219654751|NCT02559856|DRUG|Rivaroxaban|
219654752|NCT03547362|DIETARY_SUPPLEMENT|Casein|See arm description
219654753|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 1|See arm description
218966101|NCT04246736|BEHAVIORAL|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
218966102|NCT03709329|DEVICE|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
218966103|NCT03709329|DEVICE|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
218966104|NCT01085500|BEHAVIORAL|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
219208113|NCT06152809|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
219208114|NCT06152809|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.
219654754|NCT03547362|DIETARY_SUPPLEMENT|Whey protein|See arm description
219654755|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 2|See arm description
219654756|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 3|See arm description
219654757|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 4|See arm description
219654758|NCT05709444|DRUG|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
219654759|NCT05709444|DRUG|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
219654760|NCT04743804|BIOLOGICAL|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
219654761|NCT04743804|OTHER|Placebo|Matching placebo
218966105|NCT01085500|PROCEDURE|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
218966106|NCT06516601|OTHER|no intervention|observational study, the patients received corticosteroids according to the physician on duty
218966107|NCT00480974|OTHER|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
218966108|NCT04812080|DEVICE|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
219208115|NCT06152809|DRUG|Venetoclax|Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
219654762|NCT04743804|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
219654763|NCT00715104|BIOLOGICAL|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
219654764|NCT00715104|BIOLOGICAL|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
219654765|NCT04721704|DRUG|Clarithromycin+ Amoxicillin + Omeprazole|In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
219654766|NCT04721704|DRUG|Metronidazole +Amoxicillin + Omeprazole|Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
219654767|NCT05709119|DIAGNOSTIC_TEST|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
219654768|NCT05373992|BEHAVIORAL|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
219654769|NCT05373992|BEHAVIORAL|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
219654770|NCT05373992|BEHAVIORAL|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
219654771|NCT05373992|BEHAVIORAL|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
219654772|NCT01455246|DRUG|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of \> 30 ml/min and \< 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
219654773|NCT01455246|DRUG|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
219654774|NCT00427206|DRUG|acetaminophen (4g/day)|
219654775|NCT00427206|DRUG|placebo|
219654776|NCT02059434|DRUG|LAS190792 Dose 1|
219654777|NCT02059434|DRUG|LAS190792 Dose 2|
218966109|NCT06309407|DEVICE|Hand Dosimeters|Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
218966110|NCT06309407|DEVICE|Standard Practice|Participants only wore standard chest dosimeters
218966111|NCT01807832|OTHER|capsaicin challenge|
219654778|NCT02059434|DRUG|LAS190792 Dose 3|
219654779|NCT02059434|DRUG|LAS190792 Dose 4|
219654780|NCT02059434|DRUG|LAS190792 Dose 5|
219654781|NCT02059434|DRUG|LAS190792 Dose 6|
219654782|NCT02059434|DRUG|LAS190792 Dose 1 (Part 2)|
219654783|NCT02059434|DRUG|LAS190792 Dose 2 (Part 2)|
219654784|NCT02059434|DRUG|Tiotropium 18 μg|
219654785|NCT02059434|DRUG|Indacaterol 150 μg|
219654786|NCT02059434|DRUG|Placebo|
219654787|NCT03958214|BEHAVIORAL|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
219654788|NCT03958214|BEHAVIORAL|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
218966112|NCT05320302|DRUG|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
218966113|NCT04410770|BEHAVIORAL|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
218966114|NCT04661969|PROCEDURE|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
218966115|NCT00468039|DRUG|vildagliptin + metformin|
218966116|NCT05550610|BEHAVIORAL|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
218966117|NCT02851186|DEVICE|Acupuncture|
218966118|NCT02851186|DEVICE|Sham acupuncture|
218966119|NCT01480128|PROCEDURE|Single-port|Single-port laparoscopic colon resection
218966120|NCT01480128|PROCEDURE|Multi-port|Multi-port laparoscopic colon resection
218966121|NCT05242523|OTHER|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
218966122|NCT05242523|OTHER|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
218966123|NCT00939757|DRUG|mirabegron|oral tablet
219654789|NCT04965441|PROCEDURE|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness\<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
219654790|NCT05575037|DRUG|Dupilumab|8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
219654791|NCT01877356|PROCEDURE|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
219654792|NCT01877356|PROCEDURE|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
218966124|NCT06275581|DEVICE|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
218966125|NCT06275581|DEVICE|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
218966126|NCT05927324|BEHAVIORAL|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
218966127|NCT03461510|PROCEDURE|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
218966128|NCT03461510|PROCEDURE|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
218966129|NCT00296803|DRUG|clopidogrel|
218966130|NCT05357547|DRUG|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
218966131|NCT05357547|DRUG|Placebo comparator|Lactose-sucrose tablets in opaque capsule
218966132|NCT02818491|DRUG|Placebo|Normal saline 0.9% in 2 mls
218966133|NCT02818491|DRUG|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
218966134|NCT02818491|DRUG|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
219654793|NCT02956447|DRUG|Kisspeptin 112-121|0.313 ug/kg - 2 ug/kg IV or SC
219654794|NCT02956447|DRUG|GnRH|0.075 ug/kg IV
218966135|NCT02818491|DRUG|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
218966136|NCT02818491|DRUG|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
219654795|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
219654796|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
219654797|NCT02634034|DRUG|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
219654798|NCT02634034|DRUG|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
219654799|NCT02634034|DRUG|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
219654800|NCT00771264|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
219654801|NCT06189391|DRUG|MK-1045|IV infusion
219654802|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
218966137|NCT02818491|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
218966138|NCT06025929|OTHER|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
218966139|NCT06025929|OTHER|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
218985270|NCT04891978|BEHAVIORAL|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
218985271|NCT04912193|DRUG|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
218985272|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from F. Vesiculosus|4 g daily
218985273|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from U. Pinnatifida|4 g daily
218985274|NCT01597960|OTHER|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
219654803|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
219654804|NCT01004406|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
219654805|NCT01004406|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
219654806|NCT04355806|DRUG|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
219654807|NCT04355806|BIOLOGICAL|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
219654808|NCT03211442|RADIATION|Radiotherapy|Breast cancer patients treated with radiotherapy
219654809|NCT03393429|OTHER|DAVID assisted training|DAVID device assisted training under supervision
219654810|NCT03393429|OTHER|training recommendation|"training recommendation to stay active"
219654811|NCT06637423|DRUG|Sacituzumab tirumotecan|Intravesical administration
219654812|NCT06637423|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
219654813|NCT06637423|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
219654814|NCT00631085|DRUG|gamma tocopherol|Maxi Gamma softgels 1200mg QD
218966140|NCT06025929|OTHER|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
218966141|NCT02761291|DRUG|Gemcitabine|Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
218966142|NCT02761291|DRUG|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
219654815|NCT02928770|DEVICE|Nastent|Use of the device while at home and in the sleep lab
219654816|NCT00403741|BEHAVIORAL|motivational interviewing|
219654817|NCT01738841|BIOLOGICAL|Priorix-Tetra™|Single dose, subcutaneous injection
219654818|NCT01738841|OTHER|Safety data collection|Recording of adverse events, using diary cards
219654819|NCT05936541|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium Bifidum PRL2010|Probiotic supplement
219654820|NCT05936541|OTHER|Control group|No probiotic supplementation
219654821|NCT00929474|DEVICE|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
219654822|NCT00929474|DEVICE|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
219654823|NCT03201874|BEHAVIORAL|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
219654824|NCT03201874|BEHAVIORAL|Education|Education about sickle cell disease to increase disease knowledge
219654825|NCT03248518|BEHAVIORAL|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
219654826|NCT03248518|BEHAVIORAL|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
219654827|NCT03248518|BEHAVIORAL|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
218966143|NCT02761291|DRUG|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
219654828|NCT04857918|BEHAVIORAL|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
219654829|NCT04857918|BEHAVIORAL|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
219654830|NCT00436098|BEHAVIORAL|Motorpedagogic exercise|physical training
219654831|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
219654832|NCT04205461|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
218966144|NCT01604759|DEVICE|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
218966145|NCT06110520|DEVICE|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
219654833|NCT02428374|DRUG|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
219654834|NCT02428374|DRUG|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
219654835|NCT02428374|DRUG|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
219654836|NCT02428374|DRUG|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
219654837|NCT03440294|DIAGNOSTIC_TEST|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
219654838|NCT03440294|DIAGNOSTIC_TEST|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
219654839|NCT01100216|OTHER|Nicotine Lozenge|4 mg for 12 days
219654840|NCT01100216|OTHER|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
219654841|NCT01100216|OTHER|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
219654842|NCT01100216|OTHER|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
219654843|NCT01651338|PROCEDURE|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
219654844|NCT01831505|DRUG|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
219654845|NCT02427438|OTHER|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
219654846|NCT02427438|OTHER|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
219654847|NCT05104879|OTHER|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
219654848|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
219654849|NCT02907593|DRUG|Budesonide in Calfactant|Budesonide in Calfactant
219654850|NCT00104065|DRUG|CG53135-05, velafermin|
219654851|NCT04139837|BEHAVIORAL|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
218966146|NCT06110520|DEVICE|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
219654852|NCT03941197|BEHAVIORAL|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
218966147|NCT02732080|DEVICE|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
218966148|NCT02732080|DEVICE|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
218966149|NCT04639115|DRUG|Ozanimod|Ozanimod
218966150|NCT04720261|DRUG|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
218966151|NCT02942589|OTHER|Meal portion size|
218966152|NCT04616027|DRUG|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
219654853|NCT02071602|DRUG|CD-NP|Randomized 1:1:1
219654854|NCT04405284|OTHER|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
219654855|NCT05963828|BEHAVIORAL|Post-hospital management based on WeChat applet|The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.
218966153|NCT03020290|DEVICE|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
218966154|NCT06134609|BEHAVIORAL|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
218966155|NCT00468767|DRUG|Vernakalant Injection 20 mg/mL|
218966156|NCT01195077|OTHER|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
218966157|NCT04290390|DRUG|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
218966158|NCT04290390|DRUG|Rifampin|CYP3A inducer
219654856|NCT05963828|BEHAVIORAL|Routine post-hospital follow-up management|The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
219654857|NCT00322361|BIOLOGICAL|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
219654858|NCT00322361|BIOLOGICAL|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
219654859|NCT05442606|OTHER|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
219654860|NCT05442606|OTHER|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
218966159|NCT04290390|DRUG|Itraconazole|CYP3A inhibitor
218966160|NCT00318227|PROCEDURE|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
218966161|NCT04490031|DRUG|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
218966162|NCT01987531|OTHER|left ventricular epicardial pacing lead|
218966163|NCT01400685|DRUG|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
218966164|NCT01400685|DRUG|Bendamustine|90 mg/m\^2 IV days 1-2 of each cycle for 6 cycles
218966165|NCT01400685|DRUG|Rituximab|375 mg/m\^2 IV day 1 (cycle 1), 500 mg/m\^2 day 1 (cycles 2-6)
218966166|NCT03737851|DRUG|elezanumab|solution for infusion
218966167|NCT03737851|DRUG|placebo|solution for infusion
218966168|NCT05658666|BEHAVIORAL|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
219654861|NCT05442606|OTHER|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
219654862|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
219654863|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
219654864|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
218966169|NCT04173793|DRUG|AK102|Administered by subcutaneous injection
218966170|NCT04173793|DRUG|Placebo|Administered by subcutaneous injection
218966171|NCT04173793|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
218966172|NCT05675982|OTHER|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
218985275|NCT03543150|DRUG|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
218985276|NCT04526431|DRUG|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
218985277|NCT04099147|OTHER|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
218985278|NCT02898883|BEHAVIORAL|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
218985279|NCT02000479|OTHER|training|
219654865|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
219654866|NCT04896437|PROCEDURE|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
219654867|NCT04508114|BEHAVIORAL|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
219654868|NCT04618471|DEVICE|Boston Scientific WaveWriter SCS System|WaveWriter SCS Programming
219654869|NCT03859180|BEHAVIORAL|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
219654870|NCT01080729|DRUG|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
219654871|NCT03954717|BEHAVIORAL|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
219654872|NCT01752634|DRUG|Secukinumab (AIN457)|Secukinumab (AIN457)
219654873|NCT01752634|DRUG|Placebo|Placebo PFS for s.c. administration.
219654874|NCT00727987|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
219654875|NCT00727987|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
219654876|NCT00727987|DRUG|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
219654877|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
219654878|NCT06104449|DRUG|Opevesostat|Tablets to be taken orally.
219654879|NCT06104449|DRUG|Dexamethasone|Tablets to be taken orally.
219654880|NCT06104449|DRUG|Fludrocortisone acetate|Tablet to be taken orally.
219654881|NCT06104449|DRUG|Hydrocortisone|Tablets to be taken orally as a recue medication.
219654882|NCT06474078|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
219654883|NCT06101940|DIAGNOSTIC_TEST|MRI scan|Brain MRI scan to evaluate the integrity of the nervous system; lower limb muscle MRI scan to evaluate fat infiltration in skeletal muscles of the lower limb
219654884|NCT06101940|DIAGNOSTIC_TEST|Electrocardiography|Standard 12-lead electrocardiography or Holter monitoring performed to assess cardiac conduction abnormalities and arrhythmias in patients with DM1.
219654885|NCT06101940|DIAGNOSTIC_TEST|Pulmonary function test|Comprehensive pulmonary function testing including spirometry to assess respiratory muscle weakness and restrictive lung disease in DM1 patients.
218966173|NCT02125773|BEHAVIORAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
218966174|NCT04113031|BEHAVIORAL|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
219654886|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
219654887|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
219654888|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
219654889|NCT06487403|RADIATION|Standard of care external beam radiotherapy (single integrated boost)|70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
219654890|NCT06487403|RADIATION|Standard of care external beam radiotherapy (two-phase treatment)|70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
219654891|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
219654892|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
218966175|NCT04534803|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
218966176|NCT04534803|OTHER|Placebo|.1 nL of diluent (saline) given intradermally at baseline
219654893|NCT05482880|OTHER|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~\*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
219654894|NCT06660407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219654895|NCT06660407|PROCEDURE|Computed Tomography|Undergo CT
219654896|NCT06660407|OTHER|Immunotherapy|Given immunotherapy
219654897|NCT06660407|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
219654898|NCT06660407|RADIATION|Spatially-fractionated Radiation Therapy|Undergo grid radiation therapy
219654899|NCT06961370|DRUG|RO7669330|RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
219654900|NCT06961370|DRUG|Syfovre™|Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
219654901|NCT06961370|DRUG|Izervay™|Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
219654902|NCT06831461|RADIATION|Proton Beam Therapy|Patients randomized to the experimental arm will be treated with proton beam therapy.
219654903|NCT06831461|RADIATION|Photon Radiotherapy|Patients randomized to standard arm will be treated with photon therapy.
219654904|NCT06912555|OTHER|Diet|The nutritional plan will be initially based on a protein intake of 1.3 to 1.5 g per kilogram of body weight. From this, the total daily calorie intake is calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Protein distribution will be approximately 40% at breakfast and lunch, and 60% at dinner. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never provide less than 1200 kcal per day to ensure that the minimum nutritional requirements are met.
219654905|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 1.3 to 1.5 g per kilogram of body weight. Based on this protein amount, the total daily caloric intake will be determined, allocating 30% of the calories to fat consumption. The remaining calories will be assigned to carbohydrates, proportional to the protein intake. Protein distribution will be approximately 85% during breakfast and lunch and 15% at dinner. The caloric restriction will be moderate, with a 30% reduction in total energy expenditure calculated individually, resulting in an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
219654906|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 0.8 g per kilogram of body weight. From this protein amount, the total daily calorie intake will be calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
219654907|NCT06910423|BEHAVIORAL|Psychosocial intervention|Culturally relevant psychosocial intervention for people with insomnia
219654908|NCT06503159|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR) Program|The study intervention is a 9-week MBSR intervention once per week in-person or remotely (via an NIH approved remote platform used in compliance with policy, including HRPP Policy 303). The MBSR will be delivered to groups of 8-12 participants. Only the vaping adolescents will receive MBSR training.
219654909|NCT02338167|PROCEDURE|Blood sampling|A blood sample will be taken during a routine blood draw
219654910|NCT06359652|DEVICE|Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)|We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
219654911|NCT06387498|PROCEDURE|Testicular tissue biopsy and cryopreservation|Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.
219654912|NCT06182332|OTHER|Electronic Health Record Review|Undergo medical record review
219654913|NCT06182332|OTHER|Internet-Based Intervention|Use AI algorithm
219654914|NCT06377098|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
219654915|NCT06377098|DRUG|Placebo Oral Tablet|Placebo table given orally every eight hours up to three times while mother is in labor
219654916|NCT04431895|DRUG|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
219654917|NCT05409131|DEVICE|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
218966177|NCT03930160|OTHER|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
218966178|NCT06256198|OTHER|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
219654918|NCT04783220|BEHAVIORAL|Comprehensive structured parent intervention|"1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app"
219654919|NCT06109571|DEVICE|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
219654920|NCT05564403|DRUG|Binimetinib|Given PO
219654921|NCT05564403|PROCEDURE|Biopsy Procedure|Undergo biopsy
219654922|NCT05564403|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219654923|NCT05564403|PROCEDURE|Bone Scan|Undergo bone scan
219654924|NCT05564403|PROCEDURE|Computed Tomography|Undergo CT
218966179|NCT04426578|DRUG|Perhexiline|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
218966180|NCT04426578|OTHER|Placebo|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
218966181|NCT00937391|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
218966182|NCT00184873|BEHAVIORAL|Health Counseling|
219654925|NCT05564403|PROCEDURE|Echocardiography Test|Undergo ECHO
219654926|NCT05564403|DRUG|Fluorouracil|Given IV
219654927|NCT05564403|DRUG|Leucovorin Calcium|Given IV
219654928|NCT05564403|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219654929|NCT05564403|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219654930|NCT05564403|DRUG|Oxaliplatin|Given IV
219654931|NCT03891784|DRUG|Abemaciclib|Given PO
219654932|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
219654933|NCT01315041|DRUG|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
219654934|NCT01315041|DRUG|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
219654935|NCT02672332|DRUG|SB204 4%|Once daily
219654936|NCT02672332|DRUG|Vehicle Gel|Placebo comparator
219654937|NCT01451164|DRUG|OPC-34712|orally administered once daily
219654938|NCT01451164|DRUG|OPC-34712|orally administered once daily
219654939|NCT01451164|DRUG|OPC-34712|orally administered once daily
219654940|NCT01451164|DRUG|Placebo|orally administered once daily
219654941|NCT00297050|DRUG|Peramivir|
219654942|NCT05250531|BEHAVIORAL|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
219654943|NCT06229548|DRUG|SYH2053|subcutaneous injection
219654944|NCT06229548|DRUG|Placebo|subcutaneous injection
219654945|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D2|Ergocalciferol vitamin D2
219654946|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol vitamin D2
219654947|NCT02686242|PROCEDURE|spinal anesthesia|bupivacaine injected by spinal puncture
219654948|NCT02686242|PROCEDURE|general anesthesia|general anesthesia with intubation
219654949|NCT02027662|DRUG|Osvaren Granules|
219654950|NCT02027662|DRUG|Osvaren film-coated tablets|
219654951|NCT01308112|DIETARY_SUPPLEMENT|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
219654952|NCT06511570|DRUG|sabirnetug (ACU193)|sabirnetug by intravenous infusion
219654953|NCT06511570|COMBINATION_PRODUCT|Sabirnetug + rHuPH20|sabirnetug + rHuPH20 by subcutaneous injection
219654954|NCT04599933|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
219654955|NCT04599933|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
219654956|NCT01424046|DRUG|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
218966183|NCT04425824|DRUG|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
219654957|NCT01424046|DRUG|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
219654958|NCT05366985|PROCEDURE|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
219654959|NCT01289756|DRUG|Clomiphene|clomiphene once 100 mg oral
219654960|NCT01289756|DRUG|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
219654961|NCT01289756|DRUG|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
219654962|NCT05098067|DRUG|Capsaicin Topical Cream|5g 0.075% applied once
219654963|NCT05098067|DRUG|Metoclopramide|10mg IV once
219654964|NCT05098067|DRUG|Ondansetron|8mg IV once if needed
219654965|NCT05098067|DRUG|Lactated Ringers, Intravenous|1000cc once
219654966|NCT02411604|DRUG|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
219654967|NCT00072436|DRUG|gemcitabine hydrochloride|Given IV
219654968|NCT00072436|DRUG|alvocidib|Given IV
219654969|NCT00072436|OTHER|pharmacological study|Correlative studies
219654970|NCT00497848|BEHAVIORAL|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
219654971|NCT00497848|OTHER|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
219654972|NCT04281316|DEVICE|Nasal High Flow installation|"Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface"
219654973|NCT04281316|DEVICE|Non Invasive Ventilation|Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.
219654974|NCT04281316|OTHER|Training session|The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital
218966184|NCT01668927|DRUG|Proton Pump Inhibitor|
218966185|NCT01668927|DRUG|Bismuth|
219654975|NCT04281316|OTHER|Education session|Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
219654976|NCT03722940|DRUG|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
219654977|NCT03722940|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
219654978|NCT01503398|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
219654979|NCT04731025|DRUG|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
219654980|NCT04731025|OTHER|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
219654981|NCT00050817|DRUG|clopidogrel (SR25990)|
219654982|NCT05507827|DRUG|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
218966186|NCT01668927|DRUG|Metronidazole|
218966187|NCT01668927|DRUG|Tetracycline|
218966188|NCT01668927|DRUG|Furazolidone|
218966189|NCT01668927|DRUG|Amoxicillin|
218966190|NCT02884843|DEVICE|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
219654983|NCT05507827|DRUG|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
219654984|NCT03652649|OTHER|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
219654985|NCT06647875|BEHAVIORAL|Complementary Feeding Education|"This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet."
219654986|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
219654987|NCT00336388|DEVICE|Paracheck Device|
219654988|NCT00619164|DRUG|E5555|E5555, 50 mg (tablet), taken orally, once a day.
219654989|NCT00619164|DRUG|E5555|E5555, 100 mg (tablet), taken orally, once a day.
219654990|NCT00619164|DRUG|E5555|E5555, 200 mg (tablet), taken orally, once a day.
219654991|NCT00619164|DRUG|Placebo|Placebo tablet taken orally, once a day.
219654992|NCT02608008|DEVICE|Data analysis|data parameters Analysis
219654993|NCT05675514|OTHER|Myofascial Release Therapy|The increasing number of basketball players also increases the risk of sports-related injuries. Basketball has the highest injury risk of all sports because the game is so powerful and fast moving. Myofascial release therapy; ıt is a form of manual therapy applied on the muscle fascia complex to restore optimal length, reduce pain and improve functions. It is known to be effective in providing rapid relief of pain and tissue sensitivity. By restoring the length and health of the restricted connective tissue with the myofascial release therapy, it aims to relieve pressure on pain sensitive structures such as nerves and blood vessels, as well as improves sports performance.
219654994|NCT03182634|DRUG|Fulvestrant|
219654995|NCT03182634|DRUG|Neratinib|
219654996|NCT03182634|DRUG|AZD5363|
219654997|NCT03182634|DRUG|Olaparib|
219654998|NCT03182634|DRUG|AZD6738|
219654999|NCT00865267|DRUG|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
219655000|NCT00574223|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
219655001|NCT00574223|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
219655002|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
219655003|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
219655004|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
218966191|NCT02884843|DEVICE|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
218966192|NCT03613610|RADIATION|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
218966193|NCT03824067|DIAGNOSTIC_TEST|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
218966194|NCT03824067|DIAGNOSTIC_TEST|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
218966195|NCT05834413|DRUG|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
218966196|NCT05834413|DRUG|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
218966197|NCT00295971|BIOLOGICAL|anti-thymocyte globulin|
218966198|NCT00295971|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218966199|NCT00295971|DRUG|fludarabine phosphate|
218966200|NCT00295971|DRUG|thiotepa|
218966201|NCT00295971|PROCEDURE|allogeneic bone marrow transplantation|
218966202|NCT00295971|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218966203|NCT00295971|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
218966204|NCT00295971|RADIATION|total-body irradiation|
218966205|NCT03702686|DEVICE|FEEDBACK System|Smart Nipple Shield and Monitor Unit
219063353|NCT06170008|DEVICE|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
219063354|NCT06170008|DEVICE|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
219655005|NCT04182438|DIETARY_SUPPLEMENT|Low potassium content vegetables|use low-potassium content vegetables
219655006|NCT05083052|OTHER|Propolis 15%|oothpaste formulation with 15% propolis.
219655007|NCT05083052|OTHER|Propolis 10%|Toothpaste formulation with 10% propolis.
219655008|NCT05083052|OTHER|Placebo|Formulation of toothpaste without active ingredient.
219655009|NCT03346304|OTHER|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
219655010|NCT02204358|PROCEDURE|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
219655011|NCT01027897|DRUG|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
218966206|NCT02547285|OTHER|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
218966207|NCT02169193|RADIATION|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
218966208|NCT06115837|PROCEDURE|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
218966209|NCT06002243|DIAGNOSTIC_TEST|SPLASH echocardiography screening|Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
218966210|NCT02323932|BEHAVIORAL|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
218966211|NCT03317132|BEHAVIORAL|IPS|One year of IPS Support
219655012|NCT06730828|COMBINATION_PRODUCT|The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)|Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
219655013|NCT03870529|DRUG|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
219655014|NCT03870529|PROCEDURE|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
219655015|NCT05562141|BIOLOGICAL|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
219655016|NCT02045732|BIOLOGICAL|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
219655017|NCT02045732|BIOLOGICAL|Placebo|Bi-Weekly Subcutaneous Injections X 6
219655018|NCT02045732|BIOLOGICAL|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
219655019|NCT02045732|BIOLOGICAL|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
219655020|NCT02265757|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
219655021|NCT02265757|BEHAVIORAL|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
219655022|NCT02265757|BEHAVIORAL|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
219655023|NCT02265757|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
219655024|NCT02265757|BEHAVIORAL|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
219655025|NCT05914389|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
219655026|NCT05914389|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
219655027|NCT05914389|DRUG|Anti-PD-L1 Monoclonal Antibody|The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
219655028|NCT05914389|DRUG|Clostridium butyricum|Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
219655029|NCT05914389|PROCEDURE|Colectomy|The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
219655030|NCT00473824|BIOLOGICAL|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
218966212|NCT04623385|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
218966213|NCT04623385|DRUG|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
218966214|NCT05223335|DRUG|Clopidogrel|75 mg/day
218966215|NCT05223335|DRUG|Prasugrel|60 mg bolus then 10 mg daily
218966216|NCT05223335|DRUG|Tricagrelor|180 mg bolus then 90 mg twice daily
219655031|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|280 mg three times daily for four weeks
218966217|NCT05621915|DRUG|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
219655032|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|420 mg three times daily for four weeks
218966218|NCT04853381|OTHER|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
218966219|NCT04853381|OTHER|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
218966220|NCT04853381|OTHER|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
218966221|NCT04853381|OTHER|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
218966222|NCT03779360|DRUG|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
218966223|NCT03779360|DRUG|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
218966224|NCT03779360|DRUG|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
218966225|NCT03779360|DRUG|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
218966226|NCT03779360|OTHER|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
219655033|NCT00755950|OTHER|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
219655034|NCT02795468|PROCEDURE|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
219655035|NCT02560623|PROCEDURE|Biopsy|Undergo biopsy
219655036|NCT02560623|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219655037|NCT02560623|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
219655038|NCT02560623|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
219655039|NCT05230745|DEVICE|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
219655040|NCT06850116|PROCEDURE|Retzius-sparing robot-assisted radical prostatectomy|Retzius-sparing robot-assisted radical prostatectomy
219655041|NCT05737121|DRUG|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
219655042|NCT05737121|DRUG|Placebo|Inactive placebo for VNX001
219655043|NCT05737121|DRUG|Lidocaine|Alkalinized lidocaine hydrochloride
219655044|NCT05737121|DRUG|Heparin|Alkalinized heparin sodium
219655045|NCT06096779|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
219655046|NCT06096779|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
219655047|NCT01412697|BEHAVIORAL|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
219655048|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
219655049|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
219655050|NCT05014815|DRUG|Ociperlimab|900 mg intravenously (IV) once every 3 weeks (Q3W)
219655051|NCT05014815|DRUG|Tislelizumab|200 mg IV Q3W
219655052|NCT05014815|DRUG|Carboplatin|Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
218966227|NCT03552458|DRUG|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
218966228|NCT03552458|DRUG|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
218966229|NCT02312921|OTHER|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
219655053|NCT05014815|DRUG|Paclitaxel|75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
219655054|NCT05014815|DRUG|Nab paclitaxel|100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
219655055|NCT05014815|DRUG|Cisplatin|75 mg/m², administered intravenously on Day 1 of each 21-day cycle
219655056|NCT05014815|DRUG|Pemetrexed|500 mg/m² administered intravenously on Day 1 of each 21-day cycle
219655057|NCT05014815|DRUG|Placebo|Administered intravenously Q3W to match ociperlimab
219655058|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
219655059|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
218966230|NCT02958189|BEHAVIORAL|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
219655060|NCT04247880|BEHAVIORAL|Mentoring program|Apprentice-level female construction workers will be assigned to a mentor who has gone through a rigorous mentorship training. Participants will be asked to meet with a mentor at least 4 times/year in person to discuss the challenges of being a female in construction, learn coping mechanisms, and otherwise discuss the unique challenges of the job environment.
219655061|NCT00568997|DRUG|Pimecrolimus|Pimecrolimus 1% cream
219655062|NCT06020612|OTHER|Assessment by dermatopathologists|Histological assessment of the cSCCs by eight dermatopathologists.
219655063|NCT05617716|RADIATION|Conventional external beam radiation therapy dose (EBRT)|Participants will undergo 8 Gray in 1 fraction of EBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
219655064|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy standard dose|Participants will undergo 24 Gray in 2 fractions of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
219655065|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy high dose|Participants will undergo 19 Gray in 1 fraction of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
219655066|NCT05962177|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
219655067|NCT05962177|OTHER|Blood withdrawal|Blood withdrawal
218966231|NCT02958189|BEHAVIORAL|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
218966232|NCT01520454|DRUG|Saline|IV saline at 0.83 mL/kg/hr for six hours
218966233|NCT01520454|DRUG|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
218966234|NCT01520454|DIETARY_SUPPLEMENT|Water|Water by mouth
218966235|NCT01520454|DIETARY_SUPPLEMENT|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
218966236|NCT01520454|DRUG|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
219655068|NCT05962177|OTHER|Neuropsychological tests|Neuropsychological tests
219655069|NCT06303167|PROCEDURE|Biopsy Procedure|Undergo biopsy
219655070|NCT06303167|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219655071|NCT06303167|PROCEDURE|Echocardiography Test|Undergo ECHO
219655072|NCT06303167|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218985280|NCT01417442|GENETIC|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
218985281|NCT05738954|OTHER|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
219655073|NCT06303167|DRUG|Osimertinib|Given PO
219655074|NCT06303167|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219655075|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
219655076|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
219655077|NCT00532272|DRUG|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
219655078|NCT01276691|DRUG|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
219655079|NCT06619119|OTHER|Excape room simulation|"Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time."
219655080|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)|
219655081|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)+Tremelimumab|
219655082|NCT02453282|DRUG|Paclitaxel + Carboplatin|Chemotherapy Agents
219655083|NCT02453282|DRUG|Gemcitabine + Cisplatin|Chemotherapy Agents
219655084|NCT02453282|DRUG|Gemcitabine + Carboplatin|Chemotherapy Agents
219655085|NCT02453282|DRUG|Pemetrexed + Cisplatin|Chemotherapy Agents
219655086|NCT02453282|DRUG|Pemetrexed + Carboplatin|Chemotherapy Agents
219655087|NCT02453282|BIOLOGICAL|Tremelimumab|
219655088|NCT00376272|DRUG|Valsartan|
219655089|NCT00376272|DRUG|Placebo|
219655090|NCT03410732|BIOLOGICAL|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
219655091|NCT03410732|PROCEDURE|radical surgery only|Only radical surgery is given to the control group
219655092|NCT01160835|PROCEDURE|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
219655093|NCT06338657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218966237|NCT01351246|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
219063355|NCT06170008|DEVICE|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
219655094|NCT06338657|PROCEDURE|Computed Tomography|Undergo CT scan
219655095|NCT06338657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219655096|NCT06338657|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
219655097|NCT06338657|PROCEDURE|Tumor Resection|Undergo surgical resection
219655098|NCT05227703|DRUG|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
219655099|NCT05227703|DRUG|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
219655100|NCT05227703|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
219655101|NCT03813784|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
219655102|NCT03813784|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
219655103|NCT03813784|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
219655104|NCT03813784|DRUG|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
219655105|NCT06559137|DRUG|Ropivacaine 0.2% Injectable Solution|Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
219655106|NCT05341947|BIOLOGICAL|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
219655107|NCT06283992|OTHER|Digital Navigation|1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
219655108|NCT06037460|DRUG|Tocilizumab treatment|"* 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24"
219655109|NCT06037460|OTHER|questionnaires|HAQ, SF-36, FACIT-Fatigue score
219655110|NCT06037460|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
219655111|NCT06037460|PROCEDURE|18FDG PET scan|PETVAS calculation (to be performed between W0 and W8) (optional).
219655112|NCT04983667|DIETARY_SUPPLEMENT|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
219655113|NCT05889585|OTHER|quality of life questionnaire|EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
219655114|NCT03364764|DRUG|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
219655115|NCT00850304|DRUG|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
219655116|NCT00850304|DRUG|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
218966238|NCT04292392|OTHER|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
218966239|NCT04292392|OTHER|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
218966240|NCT04292392|OTHER|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
218966241|NCT01851915|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
218966242|NCT01851915|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
218966243|NCT05554523|DEVICE|Photoacoustic imaging|Photoacoustic imaging
218966244|NCT00392821|DRUG|Sorafenib|Sorafenib
218966245|NCT00392821|DRUG|RAD001|RAD001
219063356|NCT02496013|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
219655117|NCT01661933|BIOLOGICAL|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
219655118|NCT01661933|BIOLOGICAL|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
219655119|NCT02545361|DRUG|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
219655120|NCT06605222|DRUG|SHR-7787 injection|Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
219655121|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix|The 25g MCT-based nutrient mix will be consumed two hours after breakfast.
219655122|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix + cofactors|The 25g MCT-based nutrient mix + cofactors will be consumed two hours after breakfast.
219655123|NCT06511206|DIETARY_SUPPLEMENT|non-ketogenic control|The non-ketogenic control will be consumed two hours after breakfast.
219655124|NCT01120249|DRUG|everolimus|Given orally
219655125|NCT01120249|OTHER|placebo|Given orally
219655126|NCT01520142|DRUG|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
219655127|NCT01520142|DRUG|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
219655128|NCT01447446|DRUG|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
219655129|NCT01447446|DRUG|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
219655130|NCT01447446|DRUG|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
219655131|NCT01447446|DRUG|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
219655132|NCT01447446|DRUG|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
219655133|NCT03530787|OTHER|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
219655134|NCT03530787|OTHER|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
218966246|NCT04411524|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
219063357|NCT03676062|OTHER|exercise|All exercises programs applied three sessions per week, totally six week.
219063358|NCT05659290|DRUG|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
219655135|NCT05774795|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
218966247|NCT04411524|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
218966248|NCT04411524|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
218966249|NCT04411524|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
218966250|NCT01338142|OTHER|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
219063359|NCT05659290|DRUG|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
219655136|NCT05774795|PROCEDURE|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
219655137|NCT02961322|OTHER|lobo-isthmectomy assisted robot|
219655138|NCT02262000|RADIATION|Image Guided Stereotactic Ablative Radiotherapy|
218966251|NCT01338142|OTHER|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
218966252|NCT02812355|DRUG|Heparin|
219655139|NCT02750007|DRUG|HS-20004|
218966253|NCT02449720|DRUG|Ropivacaine|Intraperitoneal instillation and infusion
218966254|NCT02449720|DRUG|0.9% Saline|Intraperitoneal instillation and infusion
218966255|NCT01253707|DRUG|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
218966256|NCT01753739|DRUG|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
218966257|NCT01753739|DRUG|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
219063360|NCT02487563|DRUG|Decitabine|Decitabine
219063361|NCT02487563|DRUG|rhTPO|rhTPO
219063362|NCT02487563|OTHER|Conventional Treatment|immunoglobulin, glucocorticoid etc
219655140|NCT05704335|OTHER|Questionnaire administration|A trained physician will administer a structured questionnaire
219655141|NCT00705458|PROCEDURE|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
219655142|NCT00705458|PROCEDURE|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
219655143|NCT01230424|DRUG|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
219655144|NCT01230424|DRUG|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
219655145|NCT01128218|DRUG|Tumor fluorescence|"Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2"
219655146|NCT05449535|DRUG|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
218966258|NCT00881478|OTHER|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
219655147|NCT05449535|DRUG|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
219655148|NCT05449535|DRUG|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
218966259|NCT00881478|OTHER|Nutrition counseling|Nutrition counseling with registered dietician
218966260|NCT02653404|OTHER|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
218966261|NCT01157156|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
218966262|NCT04572555|OTHER|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
218966263|NCT01232205|DIETARY_SUPPLEMENT|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
218966264|NCT01232205|DIETARY_SUPPLEMENT|Control|supplementation with milk
218966265|NCT02945787|BEHAVIORAL|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
218966266|NCT02945787|BEHAVIORAL|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
218966267|NCT03411837|BIOLOGICAL|Dupilumab|Biologic (monoclonal antibody)
218966268|NCT06324227|OTHER|multimodal music therapy|music therapy
218966269|NCT06324227|OTHER|no intervention|no intervention
219063363|NCT00317772|DRUG|Topotecan|"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
219063364|NCT00317772|DRUG|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
219063365|NCT03102398|DRUG|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
219063366|NCT02359669|BEHAVIORAL|StimuLearn Intervention|"* StimuLearn apps~* Cognitive questionnaires"
219063367|NCT02359669|BEHAVIORAL|Without StimuLearn intervention|Cognitive Questionnaires
219063368|NCT01886547|OTHER|Prostate health screening|
219063369|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
219063370|NCT05924919|PROCEDURE|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
219063371|NCT05924919|PROCEDURE|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
219063372|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
219655149|NCT06623045|OTHER|Pelvic floor muscle training intervention|"The training program consisted of 12 weeks of PFM exercises, 3 times per week, with each session lasting between 10 and 15 minutes. The program followed different stages through the weeks: (1) proprioception of pelvic floor muscles activation and integration with diaphragmatic breathing, (2) stabilization and strengthening of the pelvic floor musculature through progressive overloading, and (3) transference of these exercises to FFT practice. During the 12 weeks, short contractions (2) were combined with longer ones (5 to 10), carrying out the progressive overload by increasing the number of contractions, the duration of the contraction, or by evolving the execution position towards more upright postures and sporting movements."
219655150|NCT02813005|PROCEDURE|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
219655151|NCT02813005|PROCEDURE|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
219655152|NCT06317844|BEHAVIORAL|Behavioral Writing Intervention|This behavioral intervention will require participants to write about certain aspects of their lives.
219655153|NCT06521255|DRUG|Tafasitamab|Tafasitmab was infused intravenously
218966270|NCT03194490|OTHER|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
219655154|NCT06521255|DRUG|Lenalidomide|Lenalidomide orally
219655155|NCT06521255|DRUG|Gemcitabine|Gemcitabine was infused intravenously
219655156|NCT06521255|DRUG|Oxaliplatin|Oxaliplatin was infused intravenously
219655157|NCT06521255|DRUG|Rituximab|Rituximab was infused intravenously.
219655158|NCT03536949|DRUG|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
219655159|NCT03536949|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
219655160|NCT00435435|DRUG|Disulfiram|
219655161|NCT00435435|DRUG|Acamprosate|
219655162|NCT00435435|DRUG|Naltexone|
218966271|NCT03194490|OTHER|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
219063373|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
219063374|NCT04081207|BEHAVIORAL|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
219063375|NCT06137391|PROCEDURE|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
219655163|NCT01425970|DRUG|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
219655164|NCT01425970|DRUG|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
219655165|NCT01425970|DRUG|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
219655166|NCT01425970|DRUG|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
219655167|NCT01425970|BIOLOGICAL|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
219655168|NCT01425970|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
219655169|NCT01425970|DRUG|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
219655170|NCT01425970|DRUG|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
219655171|NCT04058106|PROCEDURE|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
219655172|NCT06648109|DEVICE|Electric Blanket|Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
219655173|NCT04888715|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
219655174|NCT04888715|DRUG|Pirfenidone|Pirfenidone
219655175|NCT04888715|DRUG|Nintedanib|Nintedanib
219655176|NCT01721915|DRUG|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
219655177|NCT01721915|DRUG|Placebo|
219655178|NCT02901275|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
219655179|NCT05471570|DEVICE|tDCS stimulation|The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
219655180|NCT03441607|DRUG|mHACMb|Active ingredient
219655181|NCT03441607|OTHER|placebo|inactive ingredient
219655182|NCT02063178|BEHAVIORAL|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
219655183|NCT02063178|BEHAVIORAL|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
219655184|NCT02063178|BEHAVIORAL|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
219655185|NCT02063178|BEHAVIORAL|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
219655186|NCT02063178|BEHAVIORAL|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
219655187|NCT02063178|BEHAVIORAL|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
218966272|NCT00477074|PROCEDURE|bronchoalveolar lavage, blood analysis|
218966273|NCT05165745|BEHAVIORAL|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
218966274|NCT03833518|OTHER|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
218966275|NCT03833518|OTHER|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
218966276|NCT03833518|OTHER|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
218966277|NCT04279288|DEVICE|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
218966278|NCT03793868|DRUG|Perampanel|Oral tablet
218966279|NCT03793868|OTHER|Placebo|Placebo (not drug)
218966280|NCT03348384|RADIATION|[C-11]|Radiolabel
218966281|NCT03348384|DRUG|NOP-1A|Tracer
218966282|NCT03303703|OTHER|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
218966283|NCT03347708|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
218966284|NCT03347708|DRUG|Saline Solution|Sodium Chloride Solution
218966285|NCT03347708|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
219063376|NCT02233829|DRUG|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
219655188|NCT02063178|BEHAVIORAL|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
219655189|NCT02063178|BEHAVIORAL|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
218966286|NCT03094039|PROCEDURE|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
218966287|NCT03094039|PROCEDURE|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
218966288|NCT02707809|DRUG|Dexmedetomidine|Dexmedetomidine infusion
219063377|NCT02233829|RADIATION|Brain Dopamine Receptor|The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
219063378|NCT02048943|DRUG|dovitinib lactate|Given PO
219063379|NCT02048943|DRUG|gemcitabine hydrochloride|Given IV
219063380|NCT02048943|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219063381|NCT02048943|OTHER|pharmacological study|Correlative studies
219063382|NCT02048943|OTHER|laboratory biomarker analysis|Correlative studies
219063383|NCT05615467|DRUG|LY3556050|Administered orally.
219063384|NCT05615467|DRUG|Metformin|Administered orally.
219655190|NCT02063178|BEHAVIORAL|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
219655191|NCT02063178|BEHAVIORAL|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
219655192|NCT02063178|BEHAVIORAL|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
219655193|NCT02718183|OTHER|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
219655194|NCT02718183|OTHER|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
219655195|NCT06463483|DEVICE|Medtronic 780G System|Automated insulin delivery using Medtronic 780G system
219655196|NCT06463483|DEVICE|Continuous Glucose Monitoring|Usual care with continuous glucose monitoring
219655197|NCT02657577|OTHER|There is no intervention|There is no intervention
219655198|NCT03149120|BIOLOGICAL|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
219655199|NCT03149120|DRUG|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
219655200|NCT01440140|OTHER|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
219655201|NCT01440140|OTHER|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
219655202|NCT03265548|DEVICE|Video Laryngoscope|The use of video laryngoscopy
219655203|NCT00250458|DRUG|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
219655204|NCT00250458|DRUG|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
219655205|NCT01103102|DRUG|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
219655206|NCT01103102|DRUG|Placebo|Placebo
218966289|NCT03062410|OTHER|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
218966290|NCT04245371|DRUG|Lidocaine 1.8%|Topical Patch
218966291|NCT04245371|DRUG|Placebo|Matching Placebo Patch
218966292|NCT01397812|DEVICE|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
218966293|NCT01397812|DEVICE|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
218966294|NCT06187675|BEHAVIORAL|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
218966295|NCT03724175|DRUG|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
218966296|NCT04192370|DRUG|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
218966297|NCT00946400|OTHER|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
218966298|NCT00946400|OTHER|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
218966299|NCT04184258|BIOLOGICAL|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
219655207|NCT05573490|DEVICE|Cognitive Training|Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
219655208|NCT05573490|BEHAVIORAL|Tai Chi- Qi Gong|Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
219655209|NCT05573490|DEVICE|Brain Games|Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
218966300|NCT04184258|OTHER|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
218966301|NCT01834859|BEHAVIORAL|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
219655210|NCT05573490|BEHAVIORAL|Stretching|Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
219655211|NCT01756105|DRUG|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
219655212|NCT01756105|DRUG|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
219655213|NCT05666128|DRUG|HD-6277|HD-6277 100mg
219655214|NCT05666128|DRUG|HD-6277|HD-6277 50mg
219655215|NCT05666128|DRUG|Placebo|Placebo
219655216|NCT05213793|DIAGNOSTIC_TEST|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
219655217|NCT00735293|DEVICE|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
219655218|NCT03051698|DRUG|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
219655219|NCT03051698|OTHER|Saline|0.9% NaCl
219655220|NCT03051698|DRUG|Antibiotics|vancomycin, ciprofloxacin, metronidazole
219655221|NCT01972451|PROCEDURE|Colonoscopy with enhanced dye|
219655222|NCT02563262|OTHER|body angles measurements during weightlessness|
219655223|NCT01255462|BIOLOGICAL|LFG316|
219655224|NCT01255462|BIOLOGICAL|LFG316|
219655225|NCT01255462|BIOLOGICAL|LFG316|
219655226|NCT01255462|BIOLOGICAL|LFG316|
219655227|NCT05814692|DIAGNOSTIC_TEST|blood and urine samples|blood and urine samples
219655228|NCT06618404|OTHER|No intervention - cross-sectional cohort analysis|Observational
219655229|NCT01238718|DRUG|Lidocaine|lidocaine 1.5 mg/kg intravenously
219655230|NCT01238718|DRUG|Placebo|normal saline
219655231|NCT05659511|DIAGNOSTIC_TEST|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
219655232|NCT02273271|OTHER|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
219655233|NCT01892085|BEHAVIORAL|Early initiation|Initiation of breast milk expression \<1 hour following delivery.
219655234|NCT01892085|BEHAVIORAL|Intermediate expression|Initiation of milk expression 1-\<3 hours following delivery.
219655235|NCT01892085|BEHAVIORAL|Late initiation|Initiation of milk expression \>3-6 hours following delivery.
219655236|NCT05205148|DEVICE|Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz|Patients treated with ultrathin coronary stents (namely stents with strut thickness \< 70 um) for specific coronary disease scenarios: unprotected left main stenosis; Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm); Chronic total coronary occlusion; In-stent restenosis
219655237|NCT02212548|DEVICE|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
219655238|NCT04801472|OTHER|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
219655239|NCT05074446|OTHER|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information."
218966302|NCT01834859|BEHAVIORAL|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
218966303|NCT02828527|OTHER|Observational|
218966304|NCT06307431|BIOLOGICAL|Intismeran autogene|IM injection
218966305|NCT06307431|BIOLOGICAL|Pembrolizumab|IV infusion
218966306|NCT06307431|BIOLOGICAL|Placebo|IM injection
219063385|NCT05615467|DRUG|Iohexol|Administered IV.
219063386|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
218966307|NCT02600754|BEHAVIORAL|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
218966308|NCT02600754|BEHAVIORAL|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
218966309|NCT05032859|DRUG|tapinarof cream, 1%|applied topically once daily
218966310|NCT05032859|DRUG|vehicle cream|applied topically once daily
218966311|NCT05694052|BEHAVIORAL|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
218966312|NCT01535664|OTHER|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"
218966313|NCT02787070|DRUG|PQ supervised|
218966314|NCT02787070|DRUG|PQ unsupervised|
219063387|NCT00774735|DRUG|GSK1349572|30 mg given in combination with lopinavir/ritonavir
219063388|NCT00774735|DRUG|GSK1349572|30 mg in combination with darunavir/ritonavir
219063389|NCT00151801|DRUG|estroprogestins|
219063390|NCT00151801|DRUG|interferon-beta 1a|
219063391|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
219655240|NCT05276622|OTHER|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
219655241|NCT05276622|OTHER|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
219655242|NCT05276622|OTHER|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
219655243|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 1
218966315|NCT00700076|DRUG|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
218966316|NCT00700076|DRUG|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
219063392|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
219063393|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
219063394|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
219655244|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 2
219655245|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 3
219655246|NCT01367496|DRUG|IV Methylnaltrexone (MNTX)|
219655247|NCT02425722|DRUG|ASP0456|oral
219655248|NCT02425722|DRUG|Placebo|oral
219655249|NCT05919095|DRUG|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
219655250|NCT00645125|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
219655251|NCT00645125|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
219655252|NCT00274313|DRUG|552-02|
219655253|NCT03619759|DRUG|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
219655254|NCT05168163|BIOLOGICAL|Atezolizumab|Given IV
219655255|NCT05168163|DRUG|Cabozantinib|Given PO
219655256|NCT05168163|DRUG|Lenvatinib|Given PO
219655257|NCT01255410|BIOLOGICAL|10^6 PFU rHMPV-Pa vaccine|Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally
219655258|NCT01255410|BIOLOGICAL|10^5 PFU rHMPV-Pa vaccine|Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally
219655259|NCT01255410|BIOLOGICAL|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
219655260|NCT05783024|OTHER|Data collection|retrospective data collection
219655261|NCT03989934|BEHAVIORAL|The Mind in Action|Mindfulness program for adolescents
219655262|NCT03989934|BEHAVIORAL|Healthy Topics|Health education program for adolescents
218966317|NCT01586273|DEVICE|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
218966318|NCT01931202|DRUG|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
218966319|NCT01931202|DRUG|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
218966320|NCT03272984|PROCEDURE|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
218966321|NCT03272984|PROCEDURE|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
219063395|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
219063396|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
219063397|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
219063398|NCT01786356|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
219063399|NCT01786356|OTHER|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
219063400|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
219063401|NCT01732393|DRUG|Placebo|
219655263|NCT03308318|PROCEDURE|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
219655264|NCT06619002|PROCEDURE|Sentinel lymph node sampling|video analysis
219655265|NCT02440321|BEHAVIORAL|Parent-child interactive program|
219655266|NCT02440321|OTHER|written materials|
218966322|NCT02153710|BEHAVIORAL|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
219655267|NCT05583279|BEHAVIORAL|Dialetical Behavioral Therapy for Adolescents|DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
218966323|NCT02153710|BEHAVIORAL|Phonomotor Therapy|Experimental therapy.
218966324|NCT00983398|DRUG|Carboplatin|Given IA
218966325|NCT00983398|DRUG|Mannitol|Given IA
218966326|NCT00983398|DRUG|Melphalan|Given IA
218966327|NCT00983398|OTHER|Quality-of-Life Assessment|Ancillary studies
218966328|NCT00983398|OTHER|Questionnaire Administration|Ancillary studies
218966329|NCT00983398|DRUG|Sodium Thiosulfate|Given IV
218966330|NCT05333081|OTHER|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
218966331|NCT05748665|DRUG|Remimazolam besylate|Using remimazolam for induction of general anesthesia
218966332|NCT05748665|DRUG|etomidate|Using etomidate for induction of general anesthesia
218966333|NCT05022875|DEVICE|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
218966334|NCT05022875|DEVICE|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
218966335|NCT00193193|DRUG|Paclitaxel|
218966336|NCT00193193|DRUG|Estramustine|
218966337|NCT00193193|DRUG|Carboplatin|
218966338|NCT05538819|DRUG|Glimepiride|Glimepiride 1-4 mg/day
218966339|NCT06725901|DEVICE|Web-Based Application|The intervention involves the DIAGEN-IA platform, a diagnostic support tool designed to identify pediatric neurological diseases with a genetic basis. Using a Bayesian network model and integrating ontologies such as ORDO, HPO, and HOOM, DIAGEN-IA links phenotypic data entered by physicians to suggested diagnoses and tests. Pediatric neurologists will be trained to use the platform during a 12-month intervention. DIAGEN-IA allows clinicians to input clinical and diagnostic data, generating differential diagnoses and recommended tests, with results exportable in PDF for integration into medical records. Platform usage will be tracked, including login frequency, time spent, and evaluations performed.
218966340|NCT03893916|PROCEDURE|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
218966341|NCT06738173|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
219063402|NCT01772992|BEHAVIORAL|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
219063403|NCT02800707|OTHER|Sucralose|Sweetner
219063404|NCT02800707|OTHER|Stevia|Sweetner
219063405|NCT05934344|OTHER|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
219063406|NCT01834820|DRUG|Epinephrine and Dexamethasone|
219655268|NCT03047096|DRUG|hyaluronic acid|intra-Articular injection
218966342|NCT00385190|DRUG|HCV-796|
219063407|NCT01834820|DRUG|Hypertonic Saline|
219063408|NCT01834820|DRUG|Normal Saline|
219655269|NCT03047096|DRUG|hyaluronic acid and corticosteroids|intra-Articular injection
219655270|NCT04972370|OTHER|Patients with Unilateral Cleft Lip with or without Cleft Palate|2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
219655271|NCT02089100|RADIATION|stereotactic body radiation therapy|
219655272|NCT02089100|RADIATION|Systemic treatment|
219655273|NCT06295887|OTHER|Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation|Simulation program using VR or simulator that mimics patient's desaturation
219655274|NCT05220059|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
219655275|NCT05220059|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219655276|NCT01622270|OTHER|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
219655277|NCT02636101|DRUG|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
219655278|NCT05236101|BEHAVIORAL|survey research|Children with dental treatment were asked to draw pictures.
219655279|NCT02034812|OTHER|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
219655280|NCT01629823|DEVICE|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
219655281|NCT04112095|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
219655282|NCT00239213|DRUG|catechin extracts (health food)|
219655283|NCT05914038|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
219655284|NCT03740321|DEVICE|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
219655285|NCT05615805|OTHER|OSDI questionnaire|Ocular Surface Disease Index
219655286|NCT05615805|OTHER|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
219655287|NCT05742893|DIAGNOSTIC_TEST|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
219655288|NCT04066296|DRUG|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
219655289|NCT02609724|OTHER|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
219655290|NCT02609724|OTHER|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
219655291|NCT02609724|OTHER|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
219655292|NCT02609724|OTHER|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
219655293|NCT02609724|OTHER|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
219655294|NCT02609724|OTHER|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
219655295|NCT06363032|DIAGNOSTIC_TEST|elastography|When routine renal ultrasound is arranged, patients will be invited to receive elastography at the same time.
219655296|NCT00709007|BEHAVIORAL|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
219655297|NCT00709007|BEHAVIORAL|SAT|Participants take their HIV medications by themselves.
219063409|NCT00354354|DRUG|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
219063410|NCT01407185|OTHER|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
219655298|NCT04872556|DEVICE|Laser acupuncture device|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
219655299|NCT04872556|DEVICE|Pseudo-laser acupuncture|The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
219655300|NCT03957811|OTHER|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
219655301|NCT03767556|PROCEDURE|Inspiratory muscle training|Powerbreathe® K5
219655302|NCT00674856|DRUG|naproxcinod|750mg
219655303|NCT06153316|OTHER|School shooting incident|The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
219655304|NCT01139099|BEHAVIORAL|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
219655305|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
219655306|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
219655307|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
219655308|NCT03024528|BEHAVIORAL|CPOT assessment|Polish version of Critical care pain observation tool validation.
219655309|NCT04982978|BEHAVIORAL|PMT Threat Appraisal|"The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university."
219655310|NCT04982978|BEHAVIORAL|General Nutrition and Lifestyle|The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
219063411|NCT00164801|DRUG|Baclofen, Diltiazem|
219063412|NCT01126593|DRUG|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
219063413|NCT01126593|DRUG|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
219655311|NCT06720077|OTHER|Acupressure|"It will be applied for the experimental group only. Before starting the first treatment session, the participants will be instructed briefly about the nature of the treatment to gain their confidence and cooperation. Each participant in this group will be asked to lie in supine position and the acupressure will be applied by using the therapist's fingers on the following acupoints (san jio 6/ spleen 15/ stomach 25/ joining vally  intestine 4) 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week for 6 weeks."
219655312|NCT06720077|OTHER|Diaphragmatic breathing exercises|A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
219063414|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
218966343|NCT06746441|DRUG|Psilocybin|"Psilocybin is a naturally occurring serotonergic psychedelic compound found in Psilocybe mushrooms. It is metabolized in the body into its active form, psilocin, which has a high affinity for serotonin 5-HT2A receptors. This enables psilocin to bypass the default serotonin pathway, producing antidepressant effects.~For this study:~Psilocybin will be administered orally in a dose of 5-6 grams per session. Each participant in the Psilocybin and Psilocybin-assisted CBT arms will receive two sessions spaced six weeks apart.~The therapy will be conducted in a controlled hospital setting with medical monitoring during the session to ensure safety until the hallucination phase subsides.~Psilocybin will be added to routine antidepressant medication."
218966344|NCT06746441|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Cognitive Behavioral Therapy (CBT) is a structured, time-limited psychotherapy aimed at alleviating symptoms of depression. It involves addressing negative thoughts and behavioral patterns through the following steps:~Identifying troubling life situations. Recognizing thoughts, emotions, and beliefs about those situations. Identifying negative or inaccurate thinking patterns. Restructuring those thoughts into positive and realistic perspectives.~In this study:~CBT will consist of 8-10 structured sessions, each lasting approximately 90 minutes.~Participants will attend therapy sessions twice weekly over a six-week period. The intervention will be delivered by trained psychotherapists in a controlled hospital setting.~Routine antidepressant medications will be continued alongside CBT."
218966345|NCT04430205|PROCEDURE|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
219655313|NCT06720077|OTHER|General bowel care advise|All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
219655314|NCT03207074|DIAGNOSTIC_TEST|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
218966346|NCT07136870|DEVICE|Medical tape|The purpose of this exploratory study is to assess the adhesion to skin properties of test material samples over 24 hours to establish the peel-off measurement method at the new Essity study site. As the performance and safety of the tapes, WAFs and post-OPs in its intended use are not tested in the current study it is not considered a medical device study according to EU medical device regulation (MDR) 2017/745
218966347|NCT06916286|DEVICE|K-Lock|Surgical drain securement with a novel sutureless K-LOCK device
218966348|NCT06916286|OTHER|Suture|Surgical drain securement with traditional suture-based methods
218966349|NCT07140718|BEHAVIORAL|Fundamental Adaptive Skills Training|The FAST intervention will be approximately 60 minutes in duration. The video component of FAST, animated using the Vyond software, will be presented via computer or projector. Pause points and brief interactive exercises will be added throughout the presentation to promote engagement and ensure comprehension of FAST material. The treatment will be sectioned into thirds: a physical health section focused on sleep hygiene and physical activity, an anxiety sensitivity section dispelling common AS myths, and a social health section. Each section will contain brief psychoeducation focused on dispelling common myths or promoting adaptive skills use.
219063415|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
219063416|NCT04088097|BEHAVIORAL|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
219063417|NCT04088097|OTHER|Control Condition|Educational and informational materials on adolescent health and nutrition.
219063418|NCT02067247|DEVICE|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
219063419|NCT03057119|BEHAVIORAL|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
219063420|NCT03057119|BEHAVIORAL|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
219063421|NCT03057119|BEHAVIORAL|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
219063422|NCT03057119|BEHAVIORAL|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
219063423|NCT03057119|BEHAVIORAL|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
219063424|NCT00373789|DRUG|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
218966350|NCT07140718|BEHAVIORAL|Relaxation and Mindfulness Training|The RMT intervention will be primarily psychoeducational and focused on explaining relaxation methods used in various psychological treatments such as progressive muscle relaxation, guided imagery, and mindfulness-focused breathing exercises. Interactive relaxation and mindfulness exercises and brief discussions following each relaxation component will be included to control for time spent on interactive exercises in the FAST condition. The intervention will take approximately 60 minutes. Tailored to control for the effects of general education, practice exercises, and time spent on the FAST intervention, RMT will be a stronger control in comparison to a waitlist or repeated contact condition. Like the FAST intervention, this program will also be digitalized to allow for ease-of-administration.
219655315|NCT03216148|DIAGNOSTIC_TEST|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
219655316|NCT00937248|DEVICE|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
219655317|NCT00937248|DEVICE|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
219655318|NCT02232152|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219655319|NCT02232152|DRUG|fluorouracil|Given IV
219655320|NCT02232152|OTHER|pharmacological study|Correlative studies
218966351|NCT06934577|OTHER|Standard optometric examination|Participants will see the optometrist at the Federally Qualified Health Center. The guidelines define usual care as: an in-person comprehensive eye examination with assessment of patient history, visual acuity, pupil examination, ocular motility and alignment, intraocular pressure, and biomicroscopy with additional tests, as appropriate. A glasses prescription will be given to the participant if needed. Participants will complete surveys at baseline before their eye exam and 6 weeks after the eye exam.
218966352|NCT06934577|OTHER|Technology enhanced eye disease detection protocol|Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (no disease detected) or an in-depth appointment with the optometrist (disease detected). During the first visit, participants receive care navigation support to purchase low-cost glasses from an on-line retailer. When participants return for the optometrist exam, glasses will be fit. Participants will receive care navigation support to attend any recommended specialty follow-up appointments.
218966353|NCT04161456|DRUG|Apremilast|Apremilast twice daily 30 mg
218966354|NCT05368077|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy is a standard surgical procedure for pediatric OSA treatment, which involves removal of hypertrophied tonsils and adenoids.
218966355|NCT03668366|DRUG|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
218966356|NCT04376879|OTHER|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
218966357|NCT04108442|BEHAVIORAL|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
218966358|NCT04108442|BEHAVIORAL|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
219063425|NCT00373789|DRUG|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
219655321|NCT02232152|OTHER|laboratory biomarker analysis|Correlative studies
219655322|NCT01675375|DEVICE|Eye Shield|one application following refractive surgery
219655323|NCT05040620|DRUG|Olive Oil Topical Oil|the effect of olive oil local application in decreasing orthodontic alighment phase
219655324|NCT06030830|BEHAVIORAL|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
219063426|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
219063427|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
219063428|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
219063429|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
219655325|NCT05409430|DEVICE|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
219655326|NCT00324389|DRUG|Interferon alpha|
219655327|NCT00191425|DRUG|Teriparatide|
219655328|NCT00191425|DRUG|Raloxifene|
219655329|NCT01683422|RADIATION|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
219655330|NCT01683422|RADIATION|Proton Radiation|
219655331|NCT00061022|DRUG|NXY-059|
219655332|NCT03203460|BEHAVIORAL|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
219655333|NCT02110030|DEVICE|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
219655334|NCT02110030|DEVICE|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
219655335|NCT02370030|DIETARY_SUPPLEMENT|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
219655336|NCT02672007|DEVICE|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
219655337|NCT05031637|BEHAVIORAL|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
219655338|NCT05031637|BEHAVIORAL|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
219655339|NCT05890430|BIOLOGICAL|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
219655340|NCT04809948|BIOLOGICAL|viral vector vaccine|AstraZeneca vaccine
219655341|NCT05949541|DRUG|Everolimus 10 mg|Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
219655342|NCT05949541|DRUG|CDK4/6 Inhibitor SHR6390|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
218966359|NCT01885871|DEVICE|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
218966360|NCT00721123|DRUG|Tocilizumab|Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
218966361|NCT00246896|BEHAVIORAL|care management|
218966362|NCT05753527|BEHAVIORAL|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
219655343|NCT05949541|DRUG|Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
219655344|NCT04660708|BEHAVIORAL|manual physical therapy|Previously described in the arm description
219655345|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
219655346|NCT01393132|DRUG|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
219655347|NCT01393132|DRUG|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
219655348|NCT04217005|DEVICE|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
219655349|NCT04150302|OTHER|Exploratory interviews|Exploratory interviews to generate an interview guide
219655350|NCT04150302|OTHER|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
219655351|NCT04150302|OTHER|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
219655352|NCT04150302|OTHER|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
219655353|NCT04150302|OTHER|Psychometric validation|Psychometric properties study
219655354|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
219655355|NCT06482177|DRUG|Cyclosporine ophthalmic solution|Cyclosporine BID in the study eye
219655356|NCT02003963|BEHAVIORAL|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
219655357|NCT04800614|DRUG|sitravatinib|100 mg sitravatinib on Day 1 of each of 3 periods
219655358|NCT04294433|BIOLOGICAL|Infanrix-hexa, Twinrix-Junior|Vaccines administrated according to product monographs' recommendations
219655359|NCT01658449|OTHER|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
219655360|NCT01658449|OTHER|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
218966363|NCT04398251|DRUG|Febuxostat 40mg Tab|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
218966364|NCT04398251|BEHAVIORAL|Non-drug control group|All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
218966365|NCT00877201|DRUG|CDR2|
218966366|NCT04215588|DEVICE|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
218966367|NCT04215588|DEVICE|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
219063430|NCT05966441|DIETARY_SUPPLEMENT|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
219655361|NCT06264674|DRUG|CHF5993 200/6/12.5 μg pMDI HFA-152a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
219655362|NCT06264674|DRUG|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
218966368|NCT06016192|BEHAVIORAL|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
219063431|NCT05966441|DRUG|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
219655363|NCT02706171|RADIATION|CyberKnife|
219655364|NCT01794598|BEHAVIORAL|Receiving educational material of depression care|The educational material provides patients about depression management
219655365|NCT01110668|DRUG|Nilotinib|
219655366|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
219655367|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
219655368|NCT04748848|DRUG|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
219655369|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
218966369|NCT06667765|DRUG|RPT1G|Dose formulation- Oral capsule
218966370|NCT06667765|DRUG|Placebo|Dose formulation- Oral capsule
218966371|NCT03213600|DEVICE|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
218966372|NCT00168402|DRUG|Botulinum Toxin Type A|
218966373|NCT00415376|DRUG|levetiracetam|
218966374|NCT00415376|PROCEDURE|quality-of-life assessment|
218966375|NCT00791310|DRUG|Flucis|FDG injected i.v
218966376|NCT01279473|DRUG|Nilotinib|
219655370|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
219655371|NCT00392496|DRUG|sunitinib malate|Given orally
219655372|NCT04064255|OTHER|Practical Body Image (session 1 - 7)|Practical body image therapy
219655373|NCT04064255|OTHER|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
219655374|NCT00055510|DRUG|BO-653|
219655375|NCT04315844|DEVICE|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
218966377|NCT03007407|DRUG|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
218966378|NCT03007407|DRUG|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
218966379|NCT03960931|OTHER|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
218966380|NCT03960931|OTHER|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
219655376|NCT00003394|DRUG|carboplatin|
219655377|NCT00003394|DRUG|endocrine-modulating drug therapy|
219655378|NCT00003394|DRUG|estramustine phosphate sodium|
219655379|NCT00003394|DRUG|goserelin acetate|
219655380|NCT00003394|DRUG|leuprolide acetate|
219655381|NCT00003394|DRUG|paclitaxel|
219655382|NCT03442699|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
219655383|NCT05995951|DEVICE|Deep Bran Stimulation (DBS)|Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)
219655384|NCT05995951|DEVICE|Sham-stimulation|Deep brain stimulation (DBS) surgery - Sham stimulation
219655385|NCT04079166|BIOLOGICAL|SCIB1 or iSCIB1+ DNA vaccine|"Participants receive up to 11 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment."
219655386|NCT05461898|OTHER|Inpatient Rehabilitation|Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.
219655387|NCT05461898|OTHER|Inspiratory muscle training|Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
218966381|NCT03960931|OTHER|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
218966382|NCT00850161|DRUG|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
218966383|NCT00850161|DRUG|Nasulin™|100 IU(2 puffs in each nostril)
219655388|NCT05121168|DRUG|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
219655389|NCT05121168|DRUG|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
219655390|NCT06257017|DRUG|gemcitabine|1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
219655391|NCT06257017|DRUG|Cisplatin|70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
218966384|NCT00364754|DRUG|Tesmilifene (YMB 1002)|
218966385|NCT05805488|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
218966386|NCT05805488|DIETARY_SUPPLEMENT|TCI904 sachet|consume 1 sachet per day
219655392|NCT03486678|DRUG|SHR-1210+GEMOX|28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
219655393|NCT05109832|DRUG|14C-IMP4297|14C marked IMP4297
219655394|NCT03589326|DRUG|Ponatinib|Ponatinib Tablets.
219655395|NCT03589326|DRUG|Imatinib|Imatinib Tablets.
219655396|NCT03589326|DRUG|Vincristine|Vincristine IV injection.
218966387|NCT00090051|DRUG|Rituximab|Intravenous repeating dose
219655397|NCT03589326|DRUG|Dexamethasone|Dexamethasone Tablets.
219655398|NCT03589326|DRUG|Cytarabine|Cytarabine IV infusion.
218966388|NCT00090051|DRUG|Fludarabine Phosphate|Intravenous repeating dose
219655399|NCT03589326|DRUG|Methotrexate|Methotrexate IV infusion.
219208116|NCT06189807|BEHAVIORAL|Decision aid|Enrolled participants will be sent the novel educational decision aid about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment, study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
218966389|NCT00090051|DRUG|Cyclophosphamide|Intravenous repeating dose
219655400|NCT03589326|DRUG|Prednisone|Prednisone Tablets.
218966390|NCT00198926|BEHAVIORAL|covert v overt nutrition labeling|
218966391|NCT00198926|BEHAVIORAL|varying meal nutrition manipulation|
218966392|NCT02186431|DEVICE|senofilcon A|
218966393|NCT03696173|OTHER|Non-Interventional|Non-Interventional
218966394|NCT03696173|OTHER|Non-Interventional|Non-Interventional
218966395|NCT04450888|OTHER|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
218966396|NCT03754673|DEVICE|MRI|MRI pulmonary with no contrast administration
218966397|NCT05419986|GENETIC|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
219063432|NCT04344067|DEVICE|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
219063433|NCT05222919|DIETARY_SUPPLEMENT|Bare performance supplement|dietary supplement
219063434|NCT05222919|DIETARY_SUPPLEMENT|Placebo|Placebo
219063435|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
219063436|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
219063437|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
219655401|NCT01727544|PROCEDURE|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
219655402|NCT06660745|OTHER|telenursing-based family empowerment program|"The intervention was conducted in two sections. The first part included a one-day educational workshop conducted through Skype for the child and their caregiver and was planned to introduce the members of the intervention group to each other and provide information on how to deliver and receive the content. In the second part of the intervention, the content was prepared based on a scheduled plan. It was in the form of a 5-10-minute audio file, video, or educational text and was uploaded on the SendBig website. Once the upload is complete, a link is provided to the user. The link was sent to the phone numbers of children with cystic fibrosis and their caregivers so that they could watch the weekly content over three months. Once it was confirmed that the link had been received (acknowledged in the Cystic Fibrosis Companions group) and the content had been viewed, remote follow-ups were scheduled twice a week, on Sundays and Tuesdays between 6:00 PM and 8:00 PM, using Skype messenger."
218966398|NCT02961673|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
218966399|NCT02961673|BIOLOGICAL|Botox Inj|Clostridium botulinum type A
218966400|NCT05356078|DRUG|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
218966401|NCT06033053|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
218966402|NCT01055522|DRUG|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
218966403|NCT01055522|DRUG|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
218966404|NCT01055522|DRUG|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
218966405|NCT04343820|PROCEDURE|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
218966406|NCT02330965|PROCEDURE|Blood Draw|Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
219655403|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
219655404|NCT00955981|DRUG|RDEA594|Uricosuric agent for the treatment of gout
219655405|NCT00955981|DRUG|Placebo|Matching placebo
219655406|NCT02290600|DEVICE|Continuous Glucose Monitor|CGM sensor calibration individualization
219655407|NCT05805085|DEVICE|Lens A|Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
219655408|NCT05805085|DEVICE|Lens B|Silicone Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
219655409|NCT04108949|BEHAVIORAL|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
219655410|NCT04108949|BEHAVIORAL|Treatment as usual|See description included in arm/Group description.
219655411|NCT06136598|DRUG|Opevesostat|Tablets to be taken orally.
219655412|NCT06136598|DRUG|Dexamethasone|Tablets to be taken orally
219655413|NCT06136598|DRUG|Fludrocortisone|Tablets to be taken orally.
219655414|NCT06136598|DRUG|Hydrocortisone|Tablet to be taken orally as a rescue medication.
219655415|NCT03046901|DRUG|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
219655416|NCT05451784|DRUG|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."
219655417|NCT01702675|DRUG|ACH15 50 mg|ACH15 50mg capsule
219655418|NCT01702675|DRUG|ACH15 250 mg|ACH15 250mg capsule
219655419|NCT01702675|DRUG|ACH15 500mg|ACH15 500 mg capsule
219655420|NCT01702675|DRUG|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
219655421|NCT01702675|DRUG|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
219655422|NCT01702675|DRUG|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
219655423|NCT01702675|DRUG|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
219655424|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
219655425|NCT01702675|DRUG|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
219655426|NCT01702675|DRUG|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
219655427|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
219655428|NCT04921527|DRUG|chiauranib|50mg orally once daily
219655429|NCT04921527|DRUG|Placebo|50mg orally once daily
219655430|NCT04921527|DRUG|Paclitaxel|at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
219655431|NCT02847182|BIOLOGICAL|Cord Blood Infusion|
219655432|NCT02847182|BIOLOGICAL|Placebo|
219655433|NCT06906536|OTHER|Acute Intermittent Hypoxia (AIH)|4 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
219655434|NCT02345889|DEVICE|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
218966407|NCT02330965|PROCEDURE|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
218966408|NCT06557070|OTHER|The Emotional Freedom Technique|Emotional freedom technique (EFT) is a method to help manage emotions and troubling thoughts and lower stress and anxiety. EFT is applying by tapping. To do EFT, you tap your fingertips on certain points on your hand, head, and torso which are used in acupuncture.
218966409|NCT04177355|BIOLOGICAL|BG505 SOSIP.664 gp140|Administered by IM injection
219655435|NCT02345889|DEVICE|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
219655436|NCT02345889|DEVICE|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
219655437|NCT02345889|DEVICE|Standard Colonoscopy|Current standard of care colonoscopy
219655438|NCT06328244|BEHAVIORAL|Simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
219655439|NCT00756392|PROCEDURE|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
219655440|NCT05908435|BEHAVIORAL|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
219655441|NCT06153186|DRUG|Flunarizine Hydrochloride|Flunarizine tablet
219655442|NCT03398512|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
219655443|NCT03398512|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
219655444|NCT03398512|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
219655445|NCT03333902|PROCEDURE|QLB|QLB, quadratus lumborum block.
219655446|NCT03333902|PROCEDURE|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
219655447|NCT03335423|DRUG|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
219655448|NCT03335423|DRUG|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
219655449|NCT03335423|DRUG|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
219655450|NCT03335423|DRUG|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
219655451|NCT00456508|DRUG|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
219655452|NCT05922319|OTHER|Computerized cognitive training with different training doses|The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
218966410|NCT04177355|BIOLOGICAL|Placebo|Administered by IM injection
218966411|NCT04177355|BIOLOGICAL|3M-052-AF|Administered by IM injection
218966412|NCT04177355|BIOLOGICAL|CpG 1018|Administered by IM injection
218966413|NCT04177355|BIOLOGICAL|GLA-LSQ|Administered by IM injection
218966414|NCT04177355|BIOLOGICAL|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
218966415|NCT04177355|BIOLOGICAL|Trimer 4571|Administered by IM injection
218966416|NCT05922046|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
218966417|NCT06457919|DRUG|Tinengotinib|Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
219063438|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
219063439|NCT01151670|DRUG|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
219063440|NCT01151670|DRUG|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
218966418|NCT06457919|DRUG|abiraterone acetate with prednisone|Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
218966419|NCT06457919|DRUG|Enzalutamide|Enzalutamide 160 mg PO QD
218966420|NCT05152875|OTHER|biological|fungal colonization by weekly cultures
219063441|NCT03876041|DRUG|solumedrol|intravenous solution for injection
219063442|NCT03876041|DRUG|Dexamethasone phosphate|intravenous solution for injection
219063443|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
219063444|NCT00693992|OTHER|Placebo|Given PO
219063445|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
219655453|NCT06623318|DEVICE|Remote therapeutic monitoring device|IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.
219655454|NCT05994118|OTHER|NaCl 0.9% (normal saline)|Subcutaneous normal saline injection
219655455|NCT05994118|OTHER|Magnetized Normal Saline|Magnetized Normal Saline
219655456|NCT02021136|DEVICE|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
219655457|NCT02021136|OTHER|Control|Usual antalgic treatment + physical exercises recommendations
219655458|NCT03126006|PROCEDURE|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
219655459|NCT03126006|OTHER|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
219655460|NCT02757937|BEHAVIORAL|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
219655461|NCT02757937|OTHER|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
218966421|NCT06796998|BIOLOGICAL|Epcoritamab|"Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 0.16 mg~* Cycle 1, Day 8: 0.8 mg~* Cycle 1, Day 15: 3 mg~* Cycle 1, Day 22: 48 mg~* Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg~* Cycles 4 to 9, Days 1 and 15: 48 mg~* Cycles 10 to 12; Day 1: 48 mg"
218985282|NCT02211040|BEHAVIORAL|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
219063446|NCT00693992|DRUG|Sunitinib Malate|Given PO
219063447|NCT03786601|OTHER|Observation|The participants were assigned to different groups according to the results of HPV detection.
219063448|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
219063449|NCT04634487|OTHER|No intervention|No intervention
219063450|NCT01637012|PROCEDURE|Implantation|index angioplasty with ALEX stent implatation
219655462|NCT01829178|DRUG|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
219655463|NCT01829178|DRUG|Placebo|placebo tablets: 420 mg in 3 divided dose
219655464|NCT01829178|DRUG|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
219655465|NCT00743015|DRUG|BI 44370 TA tablet|
219655466|NCT02225327|BIOLOGICAL|Fluad alone|Fluad
219655467|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the different arms|Fluad and Prodiax
219655468|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the same arm|Fluad and Prodiax
219655469|NCT02225327|BIOLOGICAL|PPV23 alone|Prodiax
219655470|NCT04206176|DRUG|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
219655471|NCT04216589|DRUG|Semaglutide|Administered subcutaneously
219655472|NCT04080674|OTHER|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
219655473|NCT04530591|OTHER|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
219655474|NCT04530591|OTHER|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
219655475|NCT03187067|DEVICE|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
219655476|NCT02326298|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
219655477|NCT02326298|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
219655478|NCT01768845|GENETIC|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
218966422|NCT03003117|BEHAVIORAL|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
218966423|NCT03003117|BEHAVIORAL|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
219655479|NCT00855205|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
219655480|NCT02008747|DRUG|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
219655481|NCT04751773|BEHAVIORAL|Exercise training|Perioperative exercise training
219655482|NCT00312481|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
219655483|NCT00312481|DRUG|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
219655484|NCT00534079|DRUG|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
218966424|NCT06736847|PROCEDURE|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer
218966425|NCT04986579|DEVICE|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
218966426|NCT04986579|DRUG|Eribulin|Intravenous Infusion
218966427|NCT04986579|DRUG|Sacituzumab govitecan|Intravenous Infusion
218966428|NCT04986579|DRUG|Trastuzumab deruxtecan|Intravenous Infusion
218985283|NCT01457573|DRUG|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
218985284|NCT01457573|DRUG|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
219655485|NCT00534079|DRUG|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
219655486|NCT01908933|DEVICE|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
219655487|NCT01730651|RADIATION|Tomotherapy|"IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
219655488|NCT03399682|DIAGNOSTIC_TEST|cystography|observationnal study
219655489|NCT01563367|DRUG|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
219655490|NCT01563367|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
219655491|NCT04948034|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
219655492|NCT04948034|DRUG|Fruquintinib|Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.
219655493|NCT04948034|DRUG|Tislelizumab|Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
219655494|NCT02410083|DRUG|Clopirin 1|
219655495|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 1|
219655496|NCT02410083|DRUG|Clopirin 2|
219655497|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 2|
219655498|NCT00659698|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
219655499|NCT05311566|COMBINATION_PRODUCT|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
219655500|NCT01725932|BEHAVIORAL|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
219655501|NCT00633776|DRUG|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
219655502|NCT03521817|OTHER|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
219655503|NCT03521817|OTHER|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
219655504|NCT03066856|OTHER|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products."
219655505|NCT03153982|DRUG|Ruxolitinib|Given orally
219655506|NCT05740683|DIAGNOSTIC_TEST|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
219655507|NCT06084715|OTHER|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
219655508|NCT01848743|DRUG|Tenofovir|
219655509|NCT01848743|DRUG|lamivudine|
219655510|NCT06910917|BEHAVIORAL|Roy Adaptation-Based Nursing Interventions|"After the research groups were formed, a six-session interview program was created for the participants in the experimental group. Individual goals were set for the participants in the experimental group by combining the evaluations of the areas related to the psychosocial adaptation brought by the disease (physiological, self-concept, role function, interdependence) and the stimuli that would disrupt the adaptation (focus, affecting and possible) and nursing interventions were determined in line with these goals.~applied. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. It was applied to the participants as standard."
219655511|NCT03264378|BEHAVIORAL|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
219655512|NCT00634686|DIETARY_SUPPLEMENT|DHA/EPA|1.2 gram capsule daily for 6 months
219655513|NCT00634686|DIETARY_SUPPLEMENT|Placebo capsule|daily for 6 months
219655514|NCT00634686|DIETARY_SUPPLEMENT|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
219655515|NCT06531798|DRUG|Breztri Aerosphere|Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
219655516|NCT04113421|DIAGNOSTIC_TEST|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
218966429|NCT05834296|BIOLOGICAL|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
218966430|NCT05834296|DRUG|Placebo|Saline
219655517|NCT06203210|DRUG|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
219655518|NCT06203210|DRUG|Topotecan|Topotecan will be administered per local SoC.
219655519|NCT06203210|DRUG|Amrubicin|Amrubicin will be administered per local SoC.
219655520|NCT06203210|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SoC
218985285|NCT02332668|BIOLOGICAL|Pembrolizumab|IV infusion
219655521|NCT06829615|DEVICE|Shen.AI|Contactless measurement of heart rate, heart rate variability, breathing rate, and blood pressure using Shen.AI software and reference methods.
219655522|NCT06964087|DRUG|OPT101|Subcutaneous injection.
219655523|NCT06964087|OTHER|OPT101 Placebo to Match (PTM)|5% Dextrose (w/v)
218985286|NCT05962346|DEVICE|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
219655524|NCT06519071|OTHER|Tryptophan Intake|Each hourly meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 Resting Energy Expenditure and adequate protein (at 1.5 g.kg.d), to maintain a metabolic steady state. The liquid shake contains protein-free powder orange-flavored drink crystals, corn oil, and water.
218985287|NCT05962346|DEVICE|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
219063451|NCT01176539|DEVICE|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
219655525|NCT05390944|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
219655526|NCT05390944|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
219655527|NCT06789666|BEHAVIORAL|ARTCan App|"The ARTCan App is an art therapy technology application program. The application can be accessed via the web (via computer, phone, or on a device such as an iPad). With the use of the application, participants complete weekly sessions that culminate in an art piece. Note that participants are not required to have expertise in drawing; developing art skills or assessing the quality of art pieces is not the focus of the ARTCan program.~Subjects will upload a photo of the art they created to this application to show proof of completion of art therapy. They will also answer questions specific to the art therapy theme for the week."
219655528|NCT06493578|DRUG|VYN201 Gel|VYN201 Gel is a topical formulation applied as a thin layer to affected areas.
219655529|NCT06493578|DRUG|Vehicle Gel|Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
219655530|NCT04762602|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
219655531|NCT04533698|OTHER|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
219655532|NCT04533698|OTHER|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
218966431|NCT06259084|DEVICE|Seedchrony|The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
218966432|NCT06395688|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one|AEF0117 soft capsules of 1mg
218966433|NCT06395688|DRUG|Placebo|Placebo soft capsules (identical to active compound)
218966434|NCT00397943|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
218966435|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
218966436|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
218966437|NCT00397943|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
218966438|NCT00205829|DEVICE|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
218966439|NCT03718975|DEVICE|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
218966440|NCT03718975|DEVICE|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
219063452|NCT01713218|DRUG|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
219063453|NCT01713218|DRUG|Vismodegib|150 mg capsule, oral, once daily
219063454|NCT01713218|PROCEDURE|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
219655533|NCT06032143|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
219063455|NCT05519839|DRUG|qNIV Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
219063456|NCT05519839|DRUG|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
219063457|NCT05519839|DRUG|CIC Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
219063458|NCT05519839|OTHER|Placebo Comparator|Intramuscular (deltoid) injection of placebo given on Day 70.
219063459|NCT05519839|DRUG|SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
219655534|NCT06032143|BEHAVIORAL|Control environmental education|Participants in the control group will receive access to environmental exposures other than phthalates.
219655535|NCT06032143|BEHAVIORAL|Phthalate conversation|Participants in the intervention groups will be asked to engage in conversations about phthalates between doulas/pregnant individuals.
219655536|NCT06032143|BEHAVIORAL|Environmental exposures conversation|Participants in the intervention groups will be asked to engage in conversations about environmental exposures (other than phthalates) between doulas/pregnant individuals.
219655537|NCT05965063|DIETARY_SUPPLEMENT|Bifidobacterium M-16V|Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.
219655538|NCT05965063|OTHER|allergy food avoidance|strict avoidance of the specific allergenic food
219655539|NCT06091904|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
219655540|NCT06091904|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
219655541|NCT04240886|DRUG|fosmanogepix|IV and oral fosmanogepix
219655542|NCT03740139|OTHER|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
219655543|NCT02459847|BEHAVIORAL|Mindfulness Training|
219655544|NCT02459847|BEHAVIORAL|Sonographic Biofeedback|
219655545|NCT02459847|OTHER|Standard Care|
219655546|NCT01632904|DRUG|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
219655547|NCT01632904|DRUG|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
219655548|NCT01632904|DRUG|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
218966441|NCT06574165|BEHAVIORAL|Moderate Intensity Continuous Training|6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
219655549|NCT01632904|DRUG|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
218966442|NCT00216554|DRUG|risperidone|
218966443|NCT04521777|BEHAVIORAL|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
218966444|NCT04521777|OTHER|Physical Performance Testing|Complete a physical function test
218966445|NCT04521777|OTHER|Questionnaire Administration|Ancillary studies
218966446|NCT02314208|DRUG|Xenbilox|
218966447|NCT02314208|DIETARY_SUPPLEMENT|Resveratrol|
218966448|NCT02314208|DRUG|Tahor|
218966449|NCT05933395|DRUG|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
218966450|NCT05933395|DRUG|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
218966451|NCT05933395|DRUG|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
218966452|NCT05933395|DRUG|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
218966453|NCT05933395|DRUG|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
218966454|NCT05815524|OTHER|Physical activity training|training on treadmill
218966455|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
218966456|NCT06218069|DRUG|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
218966457|NCT06218069|RADIATION|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
218966458|NCT06218069|DRUG|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
218966459|NCT05255653|DRUG|Olaparib|300 mg twice daily for one year
219063460|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
218966460|NCT05255653|RADIATION|Pelvic external beam radiotherapy|45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
218966461|NCT05255653|DRUG|Chemotherapy|Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
218966462|NCT05255653|DRUG|Durvalumab|1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
218966463|NCT05255653|DRUG|Medroxyprogesterone Acetate|Oral medroxyprogesterone acetate for two years
218966464|NCT05255653|DRUG|Megestrol Acetate|Oral medroxyprogesterone acetate for two years
219655550|NCT01942317|OTHER|Balneotherapy|
219655551|NCT03163056|BEHAVIORAL|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
219655552|NCT03163056|BEHAVIORAL|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
219655553|NCT03163056|BEHAVIORAL|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
219655554|NCT06462469|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
219655555|NCT01232621|OTHER|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
219655556|NCT02398370|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
219655557|NCT01074723|DIETARY_SUPPLEMENT|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
218966465|NCT05255653|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
218966466|NCT05255653|OTHER|Observation|No adjuvant therapy
219063461|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
219063462|NCT01277965|OTHER|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
219655558|NCT05853211|COMBINATION_PRODUCT|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
219655559|NCT03071679|DRUG|Omiganan|Omignan 1%, 2.5%
219063463|NCT01277965|OTHER|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
219063464|NCT01277965|OTHER|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
218966467|NCT01896479|DRUG|Cabozantinib (XL184) 140 mg|
218966468|NCT01896479|DRUG|Cabozantinib (XL184) 60 mg|
218966469|NCT01896479|DRUG|Placebo tablet|
219063465|NCT01277965|OTHER|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
219063466|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change
219063467|NCT00353704|DRUG|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
219063468|NCT00353704|DRUG|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
219063469|NCT00353704|DRUG|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
219063470|NCT04495374|DRUG|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
219063471|NCT04495374|OTHER|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
219063472|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
218966470|NCT01896479|DRUG|Placebo capsule|
218966471|NCT00433511|BIOLOGICAL|Bevacizumab|Given IV
218966472|NCT00433511|DRUG|Cyclophosphamide|Given IV
219063473|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
219063474|NCT02042482|DIETARY_SUPPLEMENT|Coenzyme Q10U, L-carnitine|
219063475|NCT02052349|DRUG|ABT-333|Dose of ABT-333
219655560|NCT03071679|DRUG|Imiquimod|Imiquimod 15mg
219655561|NCT03071679|DRUG|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
219655562|NCT03071679|DRUG|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
219655563|NCT03071679|DRUG|Placebo|Vehicle
219655564|NCT00516802|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219655565|NCT00516802|DRUG|dacarbazine|intravenous injection over at least 20 minutes
219655566|NCT01250171|BIOLOGICAL|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
219655567|NCT01250171|BIOLOGICAL|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
219655568|NCT01250171|BIOLOGICAL|Placebo|The placebo solution for infusion contained 5% glucose.
219655569|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
219655570|NCT01196936|DRUG|Placebo|1 tablet daily
219655571|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
219655572|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
219655573|NCT01196936|OTHER|pharmacological study|Correlative Studies
219655574|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
219655575|NCT01196936|GENETIC|protein expression analysis|correlative studies
219655576|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
219655577|NCT01196936|OTHER|questionnaire administration|Ancillary studies
219655578|NCT01196936|PROCEDURE|Fine needle aspiration|
219655579|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
219655580|NCT06254898|BEHAVIORAL|Child life standard of care|Standard preparation and support provided to the participant by a Certified Child Life Specialist.
218966473|NCT00433511|DRUG|Doxorubicin Hydrochloride|Given IV
219655581|NCT06254898|BEHAVIORAL|Child life standard of care + incentives provided with conditional agreement.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.
219655582|NCT06254898|BEHAVIORAL|Child life standard of care + incentive provided unconditionally.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
219063476|NCT03116919|OTHER|Potato|Participants will be given an extra serving of potato a day
219063477|NCT03116919|OTHER|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
219063478|NCT02907333|BEHAVIORAL|Advice to use condoms|
219063479|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
219655583|NCT06581432|DRUG|Zongertinib|Zongertinib
219655584|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
219655585|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
219655586|NCT05596318|DEVICE|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
219655587|NCT05596318|DEVICE|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
219655588|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
219655589|NCT05317754|BEHAVIORAL|Mindful breathing|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
218966474|NCT00433511|OTHER|Laboratory Biomarker Analysis|Correlative studies
218966475|NCT00433511|DRUG|Paclitaxel|Given IV
218966476|NCT00433511|OTHER|Placebo Administration|Given IV
219063480|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
218966477|NCT00433511|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
218966478|NCT06293924|DIAGNOSTIC_TEST|Pericardiocentesis|"Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
218966479|NCT06293924|DIAGNOSTIC_TEST|Pericardiotomy|"During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
219063481|NCT06046313|DRUG|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
219063482|NCT06046313|DRUG|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
219063483|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
219655590|NCT05317754|BEHAVIORAL|Prostrations, according to Tibetan Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
219655591|NCT05317754|BEHAVIORAL|The Koan Mu, according to Zen Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
219655592|NCT05317754|BEHAVIORAL|The mirror exercise, according to Toltec tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
219655593|NCT05608772|PROCEDURE|revision surgery|revision procedure after failed sleeve gastrectomy
219655594|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
219655595|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
218966480|NCT06293924|DIAGNOSTIC_TEST|Cytofluorometry and Gene expression analysis|"A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules."
218966481|NCT04874038|DRUG|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
218966482|NCT04874038|DRUG|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
218966483|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
218966484|NCT02232191|BIOLOGICAL|Pneumovax-23|
218966485|NCT06183502|BEHAVIORAL|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer not to take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
218966486|NCT06183502|PROCEDURE|HIV and STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
218966487|NCT06183502|BEHAVIORAL|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
219063484|NCT05934045|BIOLOGICAL|RNAseq|there is no intervention done.
219063485|NCT00111657|BIOLOGICAL|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
219655596|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
219655597|NCT04159727|OTHER|stool and blood analysis|High throughput sequencing and quantitative PCR
219655598|NCT04977388|DRUG|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
219655599|NCT04977388|OTHER|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
219655600|NCT00962949|DRUG|Angiotensin II|Angiotensin II infusion for 1 hour
218966488|NCT05607797|OTHER|Epidemiological study|Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
218966489|NCT04090723|BEHAVIORAL|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
218966490|NCT05432297|BEHAVIORAL|Preventive physical exercise|Daily physical activity depending on daily condition
218966491|NCT03240731|BIOLOGICAL|bone marrow transplant|haploidentical bone marrow transplant
218966492|NCT04474132|DEVICE|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
218966493|NCT05481437|DRUG|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
218966494|NCT05346250|BEHAVIORAL|Non-exercise control|12 month lifestyle education
218966495|NCT05346250|BEHAVIORAL|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
219063486|NCT01054820|DRUG|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
219063487|NCT01154166|DRUG|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
219063488|NCT01154166|DRUG|Placebo|Placebo
219063489|NCT05477355|BEHAVIORAL|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
219063490|NCT05440526|PROCEDURE|Herbst Group|"Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
219063491|NCT05440526|DEVICE|TFBC Group|"TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
219063492|NCT05360979|DRUG|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
219063493|NCT01725646|DRUG|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
219063494|NCT01725646|DRUG|Placebo|Subjects in placebo group will take this drug
219655601|NCT03155906|OTHER|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
219655602|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
218966496|NCT05346250|BEHAVIORAL|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
218966497|NCT04912011|DRUG|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
218966498|NCT04912011|DRUG|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
218966499|NCT03139604|DRUG|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
218966500|NCT03139604|DRUG|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
218966501|NCT03139604|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
219655603|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
219655604|NCT06909955|OTHER|Exercise|"Relaxation Exercises (Progressive Muscle Relaxation Exercises):~Progressive muscle relaxation exercises, one of the relaxation techniques, will be used in this study. Participants will be instructed to sit in a comfortable position on a chair during the exercises. Clear and precise instructions will be provided to ensure proper execution. The exercise program will be conducted for 8 weeks, 3 days a week, for 30 minutes, under the supervision of an expert physiotherapist."
219655605|NCT06085560|BEHAVIORAL|Usual Care Message|Usual care is provided by the FQHC for the screening option chosen.
219655606|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Standard Message|Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
218966502|NCT03139604|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
219063495|NCT00954369|DRUG|[F-18]W372|"The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
219655607|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Culturally-Targeted Message|Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
219655608|NCT04936048|BEHAVIORAL|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
219655609|NCT04936048|BEHAVIORAL|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
219655610|NCT04557124|BEHAVIORAL|USS|social cognitive training
219655611|NCT04557124|BEHAVIORAL|MovingForward|problem solving training
219655612|NCT05996003|DRUG|NS-089/NCNP-02|"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
219063496|NCT04074642|PROCEDURE|Neurosurgery|adenoma removal
219655613|NCT06802094|OTHER|Single-session balance intervention in virtual reality|Single-session balance intervention (30 minutes) in a virtual reality environment, the Gait Real-time analysis Interactive Lab (GRAIL) or the Computer Assisted Rehabilitation Environment (CAREN) in children with and without Developmental Coordination Disorder (Motek Medical, The Netherlands).
219655614|NCT00646945|DRUG|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
219655615|NCT00646945|DRUG|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
219655616|NCT06103864|DRUG|Dato-DXd|Provided in 100mg vials. IV infusion. Experimental drug.
219655617|NCT06103864|DRUG|Durvalumab|Provided in 500mg vials. IV infusion. Experimental drug.
219655618|NCT06103864|DRUG|Paclitaxel|IV infusion. Active comparator.
219655619|NCT06103864|DRUG|Nab-paclitaxel|IV infusion. Active comparator.
219655620|NCT06103864|DRUG|Gemcitabine|IV infusion. Active comparator.
219655621|NCT06103864|DRUG|Carboplatin|IV infusion. Active comparator.
219655622|NCT06103864|DRUG|Pembrolizumab|IV infusion. Active comparator.
218966503|NCT05669482|DRUG|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
219063497|NCT00446316|DRUG|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
219655623|NCT05234983|BEHAVIORAL|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
219655624|NCT04242147|DRUG|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
219655625|NCT05745714|DRUG|Ruxolitinib|oral
219655626|NCT05745714|DRUG|Venetoclax|oral
218966504|NCT06635395|OTHER|Scale validity and reliability|The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
218966505|NCT05977439|DEVICE|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
218966506|NCT05977439|DEVICE|fNIRS-EEG-TMS|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
219655627|NCT05745714|DRUG|Dexamethasone|oral/intravenous
219655628|NCT05745714|DRUG|Cyclophosphamide|intravenous
219655629|NCT05745714|DRUG|Cytarabine|intravenous
219655630|NCT05745714|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
219655631|NCT06557785|BIOLOGICAL|CH505M5 N197D mRNA-gp160|To be administered intramuscularly as a split dose
219655632|NCT06557785|BIOLOGICAL|CH505 TF mRNA-gp160|To be administered intramuscularly as a split dose
219655633|NCT06022120|BEHAVIORAL|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
219655634|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
219655635|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
218966507|NCT05977439|DEVICE|fNIRS-EEG-rTMS Interleaved with CBT|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
218966508|NCT03322891|OTHER|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
218966509|NCT03322891|OTHER|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
218966510|NCT06003712|BEHAVIORAL|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
218966511|NCT05912413|OTHER|there is no intervention|there is no intervention
218966512|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
218966513|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
218966514|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
218966515|NCT05693805|BEHAVIORAL|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
218966516|NCT05693805|BEHAVIORAL|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
218966517|NCT06121466|DRUG|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
218966518|NCT05007717|BEHAVIORAL|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
219063498|NCT00446316|DRUG|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
219063499|NCT05382780|OTHER|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
219655636|NCT05455450|OTHER|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
219655637|NCT05455450|OTHER|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
219655638|NCT05794178|BEHAVIORAL|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
219655639|NCT05794178|BEHAVIORAL|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
219655640|NCT05794178|BEHAVIORAL|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more \[40%\], sit less \[40%\], inspirational quotes \[20%\])
219655641|NCT05794178|BEHAVIORAL|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
219655642|NCT04823130|DRUG|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219655643|NCT06599502|DRUG|AZD0022|AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
219655644|NCT06599502|DRUG|Cetuximab|Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands
219655645|NCT05264389|DEVICE|Poly-Tape Devices|Poly-Tape Devices, 10mm Poly-Tape or 5mm Infinity-Lock Tape, for Medial Patellofemoral Ligament (MPFL) Reconstruction
219655646|NCT06546618|BEHAVIORAL|pictorial warning and no flavor|LCC Package with pictorial warning and no flavor
219655647|NCT06546618|BEHAVIORAL|pictorial warning and 'sweet' flavor|LCC Package with pictorial warning and 'sweet' flavor
219063500|NCT05382780|OTHER|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
219063501|NCT05382780|OTHER|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
219655648|NCT06546618|BEHAVIORAL|text-only warning and no flavor|LCC Package with text-only warning and no flavor
219655649|NCT06546618|BEHAVIORAL|text-only warning and 'sweet' flavor|LCC Package with text-only warning and 'sweet' flavor
219655650|NCT06802263|DIAGNOSTIC_TEST|at-home quantitative urine b-hCG test|"Cases will begin performing urine and serum hCG testing 24 hours after the initial hCG level. Urine hCG testing will be performed on the first morning urine at home and participants will limit water for at least 8 hours before testing. Serum hCG testing will occur at a UCHealth laboratory before 10 am and within 2 hours of the urine test to allow for the comparison of the values. Both urine and serum hCG testing will then occur daily x 7 days, or until a medical or surgical intervention is indicated. If serum testing is indicated on a weekend, patients will present to the UCH Infusion Center.~Non-pregnant controls will test the first morning urine at home and undergo serum hCG testing in a UCHealth lab on the 4th and 6th day of the menstrual cycle. All urine hCG values will be recorded in the Mira home kit and evaluated in comparison to serum hCG levels."
219655651|NCT06374290|DRUG|Naltrexone (Vivitrol)|At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
218966519|NCT06495424|DRUG|Capsaicin 8%|Repeat applications every 12 weeks in patients with PDPN of the feet.
218966520|NCT06387030|BIOLOGICAL|Blood sampling|3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
218966521|NCT06387030|BIOLOGICAL|Esophageal biopsies|4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
218966522|NCT06387030|BIOLOGICAL|Unstimulated saliva sampling|A esophageal brushing will be done during digestive endoscopy.
218966523|NCT06387030|BIOLOGICAL|Urine sampling|A urine sample will be collected during hospitalization for digestive endoscopy.
218966524|NCT06387030|BIOLOGICAL|Stool sampling|A stool sample will be collected during hospitalization for digestive endoscopy.
218966525|NCT03436563|BIOLOGICAL|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
219063502|NCT04020770|OTHER|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
219655652|NCT06374290|DRUG|Bupropion|Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
219655653|NCT06533462|DIETARY_SUPPLEMENT|Multiallergen powder|OIT multiallergen powder.
219655654|NCT06474923|BEHAVIORAL|Face image and voice audio|Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.
219655655|NCT03315455|DRUG|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
218966526|NCT05488483|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
218966527|NCT06070441|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
218966528|NCT06070441|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
218966529|NCT06070441|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
218966530|NCT06042257|DRUG|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
218966531|NCT06042257|DRUG|Placebo|Matching placebo capsule
219655656|NCT03711058|DRUG|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
219655657|NCT03711058|DRUG|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
219655658|NCT03991091|DRUG|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
219655659|NCT03991091|DRUG|continuation of oxytocin administration|continuation of oxytocin administration
219655660|NCT06521554|DRUG|NVL-330|Oral Tablet of NVL-330
219655661|NCT05343481|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
219655662|NCT05343481|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
219655663|NCT05343481|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
219655664|NCT05441514|DRUG|Cobimetinib|Given PO
219655665|NCT05441514|DRUG|Enasidenib Mesylate|Given PO
219655666|NCT03513770|OTHER|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
219655667|NCT03513770|DRUG|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
219655668|NCT03513770|DRUG|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
219655669|NCT06291415|DRUG|HMPL-523|Syk inhibitor
219655670|NCT05507931|DIETARY_SUPPLEMENT|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
219655671|NCT05507931|DIETARY_SUPPLEMENT|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
219655672|NCT06246357|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
219655673|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
219655674|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
219655675|NCT06021223|OTHER|Placebo|140ml of placebo to be consumed daily for 2 weeks
219655676|NCT06131749|OTHER|No intervention|No intervention, observational cohort study
219655677|NCT06474767|BEHAVIORAL|P-CGS (Pediatric Collaborative Goal Setting)|Electronic questionnaire sent to participants ahead of a pediatric primary care well child visit, assessing goals for themselves and the child's health with prompt to share with providers during visit
219655678|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
219655679|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
219655680|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
219655681|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
219655682|NCT06511193|DRUG|Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
219655683|NCT05685602|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
219655684|NCT05685602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219655685|NCT05685602|PROCEDURE|Computed Tomography|Undergo a CT scan
219655686|NCT05685602|BIOLOGICAL|Emavusertib|Given PO
219655687|NCT05685602|DRUG|Gemcitabine Hydrochloride|Given IV
219655688|NCT05685602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219655689|NCT05685602|DRUG|Nab-paclitaxel|Given IV
219655690|NCT05685602|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
219655691|NCT05685602|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219655692|NCT06378268|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
219655693|NCT06378268|DRUG|Cetrorelix 0.25 mg|Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
219655694|NCT04847466|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
219655695|NCT04847466|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
218966532|NCT04902053|DIAGNOSTIC_TEST|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
218966533|NCT04449991|PROCEDURE|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI \> 3
218966534|NCT05785429|DRUG|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
218966535|NCT05785429|DRUG|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
219655696|NCT04847466|BIOLOGICAL|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
219655697|NCT05713253|DEVICE|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
218966536|NCT06583239|OTHER|Engagement Navigator Service (ENS)|ENS will be a centralized service, staffed by dedicated professional to (1) receive and organize referrals, (2) complete ongoing specialized training in engagement science and evidence-based strategies, (3) provide unbiased support when participants' and/or families' relationships with a CSC program are poor, (4) re-engage participants in CSC or actively connect them with other services if preferred, and (5) continue contact with those who refuse treatment in case they reconsider.
218966537|NCT03844607|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
218966538|NCT03844607|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
218966539|NCT02806973|DRUG|Nasal Glucagon|Administered intranasally.
218966540|NCT02629484|OTHER|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
218966541|NCT04540575|BEHAVIORAL|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
218966542|NCT04540575|BEHAVIORAL|Mother Provides MOM|Mother receives standard Rush NICU lactation care
218966543|NCT02840240|DRUG|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
218966544|NCT02840240|DRUG|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
218966545|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
218966546|NCT03606044|DEVICE|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
219655698|NCT06394999|DRUG|Mifepristone 50 mg|Once-weekly oral mifepristone 50 mg
219655699|NCT06122779|DRUG|BMS-986435|Specified dose on specified days
219655700|NCT06122779|OTHER|Placebo|Specified dose on specified days
219655701|NCT06351566|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
219655702|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
219655703|NCT06351566|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
219655704|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo, 10g per day.
219655705|NCT05880680|DEVICE|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
218966547|NCT04223583|DRUG|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
218966548|NCT03900442|DRUG|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
218985288|NCT05962346|DEVICE|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
218985289|NCT03285984|OTHER|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
218985290|NCT03285984|OTHER|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
218985291|NCT03285984|OTHER|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
218966549|NCT05940311|PROCEDURE|Blood sampling in addition to the blood normally required for their clinical management|Patients will undergo blood sampling in addition to the blood normally required for their clinical management. The study aims to collect 50 blood samples (one to 4) from 20 patients undergoing treatment in the adjuvant or advanced (metastatic) setting, as per standard of care. The first blood sample (T1) will be carried out immediately before the treatment, the subsequent blood samples (T2-T4) will coincide with the periodic radiographic re-evaluations, typically at months 3 and 6 (M3 and M6, T2 and T3), and at progression/recurrence, if and when recorded.
218966550|NCT05940311|PROCEDURE|Blood plasma and circulating tumor DNA (ctDNA)|Blood drawing by venepuncture (elbow) in K2EDTA vacutainers to obtain blood plasma.The patients will otherwise receive the most appropriate treatment for their condition. The following data will be collected and pseudo-anonymised: demographic data (age and gender), histopathology including primary and metastatic sites, BRAF status, medical imaging, previous therapies assigned if any
218966551|NCT00585559|DRUG|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
219655706|NCT06512623|DEVICE|Hemoadsoprtion|The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge is standardized at 250 ml/min.
218966552|NCT00585559|DRUG|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
218966553|NCT00585559|DRUG|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
218966554|NCT00585559|DRUG|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
218966555|NCT00585559|DRUG|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
218966556|NCT04349514|OTHER|Natural history|Longitudinal observation of neuroimaging, clinical, and blood markers.
218966557|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
218966558|NCT06191380|BEHAVIORAL|PACE-MS|A single bout of cycling.
218966559|NCT01953640|OTHER|Laboratory Biomarker Analysis|Correlative studies
218966560|NCT01953640|OTHER|Quality-of-Life Assessment|Ancillary studies
218966561|NCT04418440|DIETARY_SUPPLEMENT|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
218966562|NCT04803877|DRUG|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
218966563|NCT04803877|DRUG|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
218966564|NCT04803877|DRUG|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
218966565|NCT06219941|DRUG|AZD0901|Antibody-drug conjugate/Biologic
218966566|NCT06219941|DRUG|5-Fluorouracil|Chemotherapy agents
218966567|NCT06219941|DRUG|Leucovorin|Chemotherapy agents
218966568|NCT06219941|DRUG|l-leucovorin|Chemotherapy agents
219063503|NCT00996996|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
219655707|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
219655708|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
219655709|NCT00001029|DRUG|Zidovudine|
219655710|NCT00001029|DRUG|Zalcitabine|
219655711|NCT00001029|DRUG|Didanosine|
219655712|NCT02170467|OTHER|assessment of the intestinal permeability|
218966569|NCT06219941|DRUG|Irinotecan|Chemotherapy agents
218966570|NCT06219941|DRUG|Nanoliposomal Irinotecan|Chemotherapy agents
218966571|NCT06219941|DRUG|Gemcitabine|Chemotherapy agents
218966572|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
218966573|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary motor cortex|It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
218966574|NCT06262425|DEVICE|sham repetitive Transcranial Magnetic Stimulation|It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
218966575|NCT06079190|DRUG|GSK4527226|GSK4527226 will be administered.
218966576|NCT06079190|OTHER|Placebo|Placebo will be administered.
218966577|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
219655713|NCT01903681|DRUG|Circadin 2 mg|First arm lower dose
218966578|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
218966579|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
218966580|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
218966581|NCT06833359|OTHER|Observation|The Cervical Disability Index will be taught individually online through the Google questionnaire.
218966582|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
218966583|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
219063504|NCT00534196|RADIATION|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
219063505|NCT06529679|BEHAVIORAL|Split-belt Training|Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.
219063506|NCT06529679|BEHAVIORAL|Tied-Belt Training|Walking on a split-belt treadmill in which the speed of both belts is the same.
219655714|NCT01903681|DRUG|Circadin 10 mg|Second arm higher dose
219655715|NCT04051099|PROCEDURE|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
219655716|NCT04051099|DRUG|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
219655717|NCT04051099|PROCEDURE|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
219655718|NCT04051099|PROCEDURE|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
219655719|NCT05390463|OTHER|PERformance guided Fracture Rehablitation Method (PERFoRM) protocol.|A structured rehabilitation protocol for surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures).
219655720|NCT05710094|DRUG|SoftOx Biofilm Eradicator (Groups 1 to 7)|SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
219655721|NCT05710094|DEVICE|Sterile isotonic saline (Groups 1 to 4)|Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
219655722|NCT01911780|DRUG|placebo|placebo matching amlodipine capsule
219655723|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
219655724|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
219655725|NCT01911780|DRUG|amlodipine|capsule
219655726|NCT05303402|BIOLOGICAL|PHH-1V|COVID-19 Vaccine HIPRA, 40 mcg/dose
219655727|NCT05337917|PROCEDURE|Surgical of the digital nerve|All patients (cases and controls) were subject to surgical repair of digital nerve injury.
219655728|NCT02673294|OTHER|balance virtual rehabilitation|
219655729|NCT01337323|DRUG|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
219655730|NCT05196113|BEHAVIORAL|sipIT|Participants receive education and digital tools to monitor their fluid intake and just-in-time text messages to remind them when they have lapsed in regular fluid intake.
219655731|NCT05399732|DRUG|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
219655732|NCT05399732|DRUG|Cyclosporine|Cyclosporine was administered at a 3-5 mg/(kd/d) and maintained at a 100-200 ng/ml trough plasma concentration.
219063507|NCT03774186|DEVICE|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
219655733|NCT05692635|DIAGNOSTIC_TEST|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
219655734|NCT05692635|OTHER|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
219655735|NCT05692635|OTHER|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
219655736|NCT05692635|DRUG|Gadolinium|Given intravenously
219655737|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
219655738|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
218966584|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
218966585|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
219063508|NCT03774186|DEVICE|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
219063509|NCT02327026|PROCEDURE|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
219655739|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
219655740|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
219655741|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
219655742|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
219655743|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
219655744|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
219655745|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
219655746|NCT04527003|DRUG|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
219655747|NCT04527003|DRUG|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
219655748|NCT04527003|OTHER|Placebo|a substance or treatment which is designed to have no therapeutic value
219655749|NCT06271837|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
219655750|NCT06271837|DRUG|Bevacizumab|Bevacizumab by intravenous infusion
219655751|NCT04795193|PROCEDURE|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
219655752|NCT04795193|PROCEDURE|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
219655753|NCT03140956|DRUG|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
219655754|NCT02496104|BEHAVIORAL|Package n°1 of the APIB|
219655755|NCT05667649|BIOLOGICAL|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
219655756|NCT06365047|DEVICE|8% Arginine toothpaste|Investigative
219655757|NCT06365047|DRUG|1000 ppm F toothpaste|Control
219655758|NCT03902522|DRUG|PRO 140|2 injections of PRO 140 (2 X 2 mL/inj.) Subjects who were previously enrolled and receiving 350 mg dose had the option to move to the 700mg dose for the remainder of the trial.
219655759|NCT05336396|OTHER|BMI|Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
219655760|NCT05054361|DIAGNOSTIC_TEST|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
219655761|NCT05054361|DIAGNOSTIC_TEST|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
219655762|NCT05054361|DIAGNOSTIC_TEST|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
218966586|NCT05417737|OTHER|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
218966587|NCT06328361|PROCEDURE|Nonoperative surveillance|Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
219655763|NCT05054361|PROCEDURE|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
219655764|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
219655765|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
219655766|NCT02996552|PROCEDURE|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
219655767|NCT02996552|PROCEDURE|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
219655768|NCT00181350|DEVICE|Relocatable fixation system|
219655769|NCT02375490|BEHAVIORAL|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
219655770|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
219655771|NCT01920737|DRUG|Vincristine|
219655772|NCT01920737|DRUG|Prednisone|
219655773|NCT01920737|DRUG|PEG-Asparaginase|
218966591|NCT02379338|DRUG|[18F]Fluortriopride|All subjects will receive a \[18F\]Fluortriopride PET/CT scan
218966592|NCT05507008|DIETARY_SUPPLEMENT|Kenetik Ketone Drink|BHB supplementation
219063510|NCT02327026|PROCEDURE|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
219063511|NCT05873114|DIAGNOSTIC_TEST|Mobilization|Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
219655774|NCT01920737|DRUG|Methotrexate|
219655775|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
219655776|NCT01920737|DRUG|Cyclophosphamide|
219655777|NCT01920737|DRUG|Cytarabine|
219655778|NCT01920737|DRUG|Leucovorin|
219655779|NCT01920737|DRUG|Dexamethasone|
219655780|NCT01920737|OTHER|Blood draw|
218966593|NCT06347159|DRUG|EDG-7500|Liquid suspension formulation of EDG-7500
219655781|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
219655782|NCT02899559|BEHAVIORAL|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
219655783|NCT03606538|DRUG|Midomafetamine HCl|80 mg midomafetamine HCl
218966594|NCT06347159|DRUG|EDG-7500|Solid oral formulation of EDG-7500
218966595|NCT06403514|OTHER|Psychological Skills Training (PST)|PST will include self-talk, imagery, goal-setting and arousal regulation (Biofeedback)
218966596|NCT06462547|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
218966597|NCT06848088|DRUG|Fianlimab+cemiplimab|No study drug administered in this observational study.
218966598|NCT01165632|PROCEDURE|biopsy|Correlative studies
218966599|NCT01165632|PROCEDURE|computed tomography|Undergo computed tomography
218966600|NCT01165632|PROCEDURE|therapeutic conventional surgery|Undergo stereotactic craniotomy
218966601|NCT01165632|RADIATION|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
218966602|NCT01165632|RADIATION|radiation therapy|Undergo radiation therapy
218966603|NCT01165632|PROCEDURE|magnetic resonance imaging|Undergo magnetic resonance imaging
218966604|NCT01165632|PROCEDURE|positron emission tomography|Undergo positron emission tomography
219655784|NCT06463652|PROCEDURE|Cervical cerclage|Cervical cerclage using the McDonald technique under anaesthesia.
219655785|NCT06463652|DRUG|Vaginal progesterone|Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
219655786|NCT06621212|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day 1, every 4 weeks
219655787|NCT06621212|DRUG|Cytarabine|Cytarabine (100 mg/m\^2 ) on day 1-7, every 4 weeks
219655788|NCT06621212|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-8, every 4 weeks
219655789|NCT02836964|DEVICE|Crown placement|Dental implant
219063512|NCT05873114|DIAGNOSTIC_TEST|Muscle Energy Technique (MET)|Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
219063513|NCT02738567|PROCEDURE|patients undergoing surgery or medical procedure|
219655790|NCT05353582|DRUG|Preoperative systematic therapy|6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.
219655791|NCT05353582|PROCEDURE|CRS+HIPEC|CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.
219655792|NCT05353582|DRUG|Postoperative chemotherapy|6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
218966605|NCT01165632|DRUG|fluorine F 18 fluorodopa|Given IV
218966606|NCT04632953|OTHER|No Intervention|No Intervention
218966607|NCT06427083|DRUG|Envlo Tablet|Enavogliflozin 0.3mg
218966608|NCT06427083|DRUG|Envolomet SR Tablet|Enavogliflozin 0.3mg/Metformin1,000mg
218966609|NCT06287918|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
218966610|NCT06347107|DEVICE|Robotic subretinal tPA injection|-The insertion of a 41G subretinal needle adjacent to a subretinal hemorrhage using the stabilizing (tremor-reducing) properties of a robotic instrument in order to slowly inject tPA and evaluate whether the needle can be held in place for up tot 3 minutes.
218966611|NCT02477423|DRUG|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
218966612|NCT02477423|DRUG|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
218966613|NCT02477423|DRUG|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
219063514|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
219063515|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
219063516|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
219063517|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
219063518|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
219063519|NCT00130767|DRUG|finasteride|
219063520|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
219063521|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
219655793|NCT05353582|DRUG|Postoperative chemotherapy|12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
219655794|NCT03385304|DRUG|10% povidone-iodine (1% free iodine) in purified water|Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
218966614|NCT06101784|DRUG|Avenanthramide|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
218966615|NCT06101784|DRUG|Placebo|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
218966616|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
219063522|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
218966617|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
219063523|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
219655795|NCT03385304|DRUG|4% chlorhexidine gluconate (CHG) in purified water|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
219655796|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
219655797|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
219655798|NCT04154462|OTHER|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
218966618|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
218966619|NCT04851184|DEVICE|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
218966620|NCT04851184|BEHAVIORAL|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
218966621|NCT05336045|PROCEDURE|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
218966622|NCT03465423|PROCEDURE|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
218966623|NCT04924179|DRUG|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
218966624|NCT00625482|BIOLOGICAL|OPV|
218966625|NCT00625482|BIOLOGICAL|OPV plus BCG|
218966626|NCT00625482|BIOLOGICAL|OPV|
218966627|NCT00625482|BIOLOGICAL|OPV plus BCG|
218966628|NCT04205097|DRUG|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
218966629|NCT04205097|DRUG|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
218966630|NCT06197425|DRUG|"FOLFIRI cures"|(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
218966631|NCT06197425|DRUG|Trifluridine cures|Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
218966632|NCT06197425|BIOLOGICAL|BIOLOGICAL ASSESSMENT|blood sample ACE markers
218966633|NCT06197425|OTHER|Questionnaires|Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
218966634|NCT06197425|OTHER|Thoracic-abdomino-pelvic scan or MRI|Thoracic-abdomino-pelvic scan or MRI
218966635|NCT02962947|DRUG|Propranolol|80 mgR propranolol once daily
218966636|NCT02962947|DRUG|Placebo|placebo once daily
218966637|NCT03155360|OTHER|Non interventional study|Non interventional study
218966638|NCT03355118|OTHER|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
218966639|NCT03899688|PROCEDURE|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
218966640|NCT04374968|DEVICE|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
218966641|NCT02902978|DRUG|E6130|
218966642|NCT02902978|DRUG|Placebo|E6130 matched placebo
218966643|NCT04816201|OTHER|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
218966644|NCT01466140|OTHER|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
219655799|NCT06307691|PROCEDURE|Conventional drilling|Atraumatic extraction, followed by sequential drilling using conventional drills
218966645|NCT00797368|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
218966646|NCT00797368|OTHER|Home exercises|Home exercises
218966647|NCT05016284|OTHER|JW-100|Cosmetic CBD cream (JW-100)
218966648|NCT05016284|DRUG|Eucrisa|Topical EUCRISA®, Pfizer
218966649|NCT03986632|BEHAVIORAL|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
219655800|NCT06307691|PROCEDURE|Osseodensification drilling|Atraumatic extraction, followed by osteotomy prepared using densah bur (sequential drilling)
219655801|NCT05161455|BIOLOGICAL|platelet rich fibrin|we would like to measure the effect of PRF on soft and hard tissue healing
219655802|NCT03731559|DRUG|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
219655803|NCT03731559|DRUG|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
219655804|NCT06142942|OTHER|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
219655805|NCT05398185|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
218966650|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
219655806|NCT03238885|DIAGNOSTIC_TEST|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
219655807|NCT05477485|BEHAVIORAL|Experimental: AIMS program - patient|Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.
219655808|NCT05477485|OTHER|No Intervention/Usual care|Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
219655809|NCT06602271|DRUG|PF614 capsule|Experimental oxycodone prodrug
219655810|NCT06602271|DRUG|Placebo|Inactive medication
219655811|NCT06602271|DRUG|Oxycodone HCl 10 mg|Active comparator
219655812|NCT05983120|OTHER|Education|Educate the patients who suffer from Type 2 Diabetes Mellitus
219655813|NCT02720744|DRUG|FT218|
219655814|NCT02720744|DRUG|Placebo|
219655815|NCT06328881|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219655816|NCT06328881|DEVICE|Intermittent Oro-esophageal Tube|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
218966651|NCT02145507|DRUG|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
218966652|NCT02145507|DRUG|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
218966653|NCT01182779|RADIATION|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
218966654|NCT01182779|RADIATION|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
218966655|NCT01490970|OTHER|Database|Database
218966656|NCT05173480|OTHER|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
218966657|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
218966658|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
218966659|NCT01807702|DRUG|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
219655817|NCT06328881|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
218966660|NCT05648656|DRUG|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
218966661|NCT05648656|OTHER|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
218966662|NCT02811601|PROCEDURE|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
219655818|NCT05525442|PROCEDURE|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
219655819|NCT04612881|DRUG|fitostimoline vaginal pessaries|vaginal pessaries
219655820|NCT04612881|OTHER|standard of care|standard of care
219655821|NCT02406300|PROCEDURE|Subarachnoid Anesthesia|
219655822|NCT02406300|PROCEDURE|PNB/GA|
219655823|NCT02406300|DRUG|ropivacaine|
219655824|NCT02406300|DRUG|sevoflurane or desflurane|
219655825|NCT02406300|DRUG|bupivacaine or levobupivacaine|
219655826|NCT01021475|PROCEDURE|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
219655827|NCT01021475|DRUG|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
219655828|NCT01942499|OTHER|Community-based exercise program|
219655829|NCT03494972|DRUG|Tetracyclin ointment|During 3rd molar surgery
219655830|NCT00403650|DRUG|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
219655831|NCT04938219|OTHER|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
219655832|NCT05168332|BEHAVIORAL|patellar taping combined with isometric strength training|patellar taping combined with isometric strength training
219655833|NCT05168332|BEHAVIORAL|sham patellar taping combined with isometric strength training|sham patellar taping combined with isometric strength training
219655834|NCT01007136|DEVICE|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
219655835|NCT01007136|DEVICE|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
219655836|NCT06621069|DRUG|Bisphosphonates|Alendronate Sodium or Zoledronic acid
219655837|NCT06621069|OTHER|Control|control without BP
219655838|NCT01752153|DRUG|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
218966663|NCT03277079|DRUG|statin + ezetimibe|Combination of two drugs
218966664|NCT03277079|DRUG|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
218966665|NCT04499547|BEHAVIORAL|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
218966666|NCT06274528|DRUG|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
218966667|NCT06274528|DRUG|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
218966668|NCT06274528|DRUG|Placebo|0 mg; capsule; QD; 6 month duration
219655839|NCT01752153|DRUG|Silymarin (Legalon)|
219655840|NCT06393257|DEVICE|Oscillation and Lung Expansion|A novel airway clearance technology
219655841|NCT06393257|BEHAVIORAL|Postural drainage|A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.
219655842|NCT06393257|DRUG|Anti-infective therapy|Antibiotics were used in these patients.
219655843|NCT06393257|DRUG|Mucolytic|Mucolytics were used in these patients.
219655844|NCT04395612|DRUG|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
219655845|NCT04395612|DRUG|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
219655846|NCT05148403|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
219655847|NCT05314140|DIAGNOSTIC_TEST|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
219655848|NCT02553434|DEVICE|Pigtail catheter|Insertion of pigtail catheter
219655849|NCT06300476|GENETIC|JWK006|Subretinal administration of gene therapy vector JWK006 to one eye.
219655850|NCT01329926|PROCEDURE|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
218966669|NCT03503071|PROCEDURE|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
218985292|NCT03285984|OTHER|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
219655851|NCT03274557|PROCEDURE|RFM|
219655852|NCT03796819|PROCEDURE|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
219655853|NCT05974644|OTHER|Registry|The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.
219655854|NCT05906186|BEHAVIORAL|kiwifruit|eating two kiwifruits a day
219655855|NCT05136313|BEHAVIORAL|Time-restricted eating|16 weeks of TRE consisting of an 8-hour eating window.
219655856|NCT06462235|DRUG|Part A: ATM-AVI Single Dose, Cohorts 1-4|Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
219655857|NCT06462235|DRUG|Part B: Multiple-dose ATM-AVI, Cohorts 1-4|Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
219655858|NCT06622265|DEVICE|Electrocardiogram recording|ECG recording with investigational device
219655859|NCT02380495|OTHER|Data Collection|
219655860|NCT00881439|DRUG|Aliskiren|Oral, 300 mg, once daily, 6 months
219655861|NCT00881439|DRUG|Placebo|Matching Placebo once daily, 6 months
219655862|NCT01511718|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
219655863|NCT01511718|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
219655864|NCT01890616|DEVICE|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
219655865|NCT01696149|DEVICE|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
219655866|NCT03284138|DEVICE|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
219655867|NCT03284138|DEVICE|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
219655868|NCT05915676|DIAGNOSTIC_TEST|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
219655869|NCT00550862|DRUG|INT-747|Once a day (QD) by mouth (PO)
219655870|NCT00550862|DRUG|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
219655871|NCT00550862|DRUG|Placebo|Placebo
219655872|NCT00980174|DRUG|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
219655873|NCT00980174|OTHER|Placebo|Placebo for denosumab (SC injection every 6 months)
219655874|NCT01811836|DIETARY_SUPPLEMENT|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
219655875|NCT02335749|DEVICE|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
219655876|NCT03488225|DRUG|Cyclophosphamide|Given IV
219655877|NCT03488225|DRUG|Cytarabine|Given IT or IV
219655878|NCT03488225|DRUG|Dexamethasone|Given IV or PO
219655879|NCT03488225|DRUG|Doxorubicin Hydrochloride|Given IV
219655880|NCT03488225|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219655881|NCT03488225|OTHER|Laboratory Biomarker Analysis|Correlative studies
219655882|NCT03488225|DRUG|Leucovorin Calcium|Given IV
219655883|NCT03488225|DRUG|Mercaptopurine|Given PO
219655884|NCT03488225|DRUG|Methotrexate|Given IT, IV or PO
219655885|NCT03488225|BIOLOGICAL|Ofatumumab|Given IV
219655886|NCT03488225|DRUG|Prednisone|Given PO
219655887|NCT03488225|BIOLOGICAL|Rituximab|Given IV
219655888|NCT03488225|DRUG|Vincristine Sulfate|Given IV
219655889|NCT03774225|OTHER|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
219655890|NCT03774225|OTHER|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
219655891|NCT03774225|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
219655892|NCT05680506|PROCEDURE|Pain neuroscience education|Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.
219655893|NCT05680506|PROCEDURE|Standard Therapy|Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
219655894|NCT05714475|PROCEDURE|Pancreas surgery|"Criteria~Inclusion Criteria:~* Isolated pancreatic metastases from Colorectal cancer~* Previous surgery for colorectal cancer~* Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
219655895|NCT04105894|DEVICE|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
219655896|NCT04105894|DIAGNOSTIC_TEST|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
219655897|NCT04105894|DRUG|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
219655898|NCT00248144|DRUG|Famciclovir|
219655899|NCT05724108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219655900|NCT05724108|PROCEDURE|Computed Tomography|Undergo CT
219655901|NCT05724108|DRUG|Lutetium Lu 177 Dotatate|Given IV
219655902|NCT05724108|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219655903|NCT05724108|DRUG|Triapine|Given PO
218966670|NCT00900601|PROCEDURE|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
218966671|NCT00869427|DRUG|vitamin C|vitamin C 1g bid for 1 year
218966672|NCT00608543|DRUG|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
218966673|NCT03137030|DRUG|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
218966674|NCT03137030|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
218966675|NCT01654861|DRUG|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
218966676|NCT00095680|DRUG|SCIO-469|two 30-mg capsules three times daily
218966677|NCT00095680|DRUG|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
218966678|NCT01076816|DRUG|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
219063524|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
219063525|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
219655904|NCT01053130|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
218966679|NCT01076816|PROCEDURE|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
218966680|NCT01076816|PROCEDURE|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
218966681|NCT05859555|OTHER|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
218966682|NCT05984368|DRUG|BG136|Subjects injected with BG136 in Part 1 and Part 2
218966683|NCT05984368|DRUG|Placebo|Subjects injected with Placebo in Part 1 and Part 2
219655905|NCT01053130|BEHAVIORAL|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
219655906|NCT02303990|DRUG|Pembrolizumab|
219655907|NCT02303990|RADIATION|Radiotherapy|
219655908|NCT03102307|OTHER|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
219655909|NCT03102307|PROCEDURE|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
219655910|NCT05156645|DRUG|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
219655911|NCT05156645|DRUG|Placebo|Diluted by 0.9% normal saline
219655912|NCT04719130|OTHER|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
219655913|NCT04719130|OTHER|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
219655914|NCT01537016|DEVICE|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
219655915|NCT01537016|DEVICE|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
219655916|NCT05289024|BEHAVIORAL|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
219063526|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
219063527|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
219655917|NCT00958607|BEHAVIORAL|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
219655918|NCT00958607|BEHAVIORAL|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
219655919|NCT00627809|DRUG|Streptokinase|intracoronary infusion, 250.000 Units
219655920|NCT00627809|PROCEDURE|primary percutaneous coronary intervention|balloon catheter, stent
218966684|NCT00366015|PROCEDURE|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
218966685|NCT00366015|PROCEDURE|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
218966686|NCT02722096|DRUG|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
218966687|NCT02722096|DRUG|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
218966688|NCT05390190|DEVICE|Non ablative radiofrequency|Device
218966689|NCT03026088|DRUG|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
218966690|NCT03565965|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
218966691|NCT03565965|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
218966692|NCT05162040|DEVICE|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
218966693|NCT01536288|DRUG|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
218966694|NCT01536288|DRUG|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
218966695|NCT04949971|BEHAVIORAL|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
219063528|NCT02869217|DRUG|Cyclophosphamide|
219063529|NCT02869217|BIOLOGICAL|TBI-1301|
219063530|NCT02869217|DRUG|Fludarabine|
219063531|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
219063532|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
219655921|NCT05245734|DRUG|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
219655922|NCT02476370|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
219655923|NCT02476370|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
219655924|NCT01197170|DRUG|Anastrozole|1 mg by mouth daily of a 28 day cycle.
219655925|NCT01197170|DRUG|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
219655926|NCT01197170|DRUG|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
219655927|NCT01197170|DRUG|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
219655928|NCT01197170|DRUG|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
219655929|NCT04631107|DRUG|AD109 dose1- A|Oral administration at bedtime
219655930|NCT04631107|DRUG|AD109 dose2- B|Oral administration at bedtime
219655931|NCT04631107|DRUG|Placebo- C|Oral administration at bedtime
219655932|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
219655933|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
219655934|NCT01192035|DRUG|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count \>250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
219655935|NCT01192035|DRUG|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
219655936|NCT02621658|OTHER|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
219655937|NCT02621658|OTHER|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
219655938|NCT01797159|RADIATION|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
219655939|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
219655940|NCT02035397|DRUG|Botulinum Toxin Type A|
219655941|NCT02035397|DRUG|Saline solution|
219655942|NCT04592289|PROCEDURE|Full bowel preparation|MBP+OA
219655943|NCT04592289|PROCEDURE|Mechanical bowel preparation only|MBP
219655944|NCT04392830|DRUG|ALZ002 DS|Administered orally
218966696|NCT04174950|OTHER|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
219655945|NCT04392830|DRUG|Placebo|Administered orally
219655946|NCT00990067|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
219655947|NCT00990067|DRUG|Duloxetine|120 mg two doses 12h and 2h before MDMA
219655948|NCT00990067|DRUG|Placebo|capsules identical to MDMA or duloxetine
219655949|NCT05385224|DIAGNOSTIC_TEST|PillSense|The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
219655950|NCT01910220|DRUG|REGN1033 (SAR391786)|
219655951|NCT01910220|OTHER|placebo|
219655952|NCT01273714|PROCEDURE|thyroid resection|bilateral subtotal versus total thyroidectomy
219655953|NCT05369494|OTHER|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
219655954|NCT05547061|DRUG|Lu-177-DGUL|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
219655955|NCT05547061|DRUG|Ga-68-NGUL|Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
219655956|NCT06529172|OTHER|Resistance training|RG performed RT with an elastic band (yellow, force of 9-11 pounds when stretched twice the original length). They performed eight movements. Each movement was performed for 3-5 sets at 8 times/sets with 30 s of rest between groups. The movements included upright rows, reverse curls, standing shoulder rotations, neck-elbow extensions, elbow bends, downward lunges, standing leg lifts, side lifts and standing back kicks. All participants completed the RT movements according to the regular rhythm (1-2-1) provided by the experimenter, which ensured that all participants had similar movements completion rates.
219655957|NCT06529172|OTHER|Yijinjing|YG performed 12 movements . These movements included extending the hands upwards and slowly lowering them; extending the torso by stretching the hands straight up and bending the body to the left or right; squatting with the hands on the knees and standing up slowly; bending the body to the left or right side, extending the arms and waist; getting down on the knees, leaning forward, extending the hands forward and slowly pulling them back; bending forward, placing the hands around the knees and standing up slowly; placing the hands on the hips; and leaning back to stretch the back and waist.
219655958|NCT06529172|OTHER|Baduanjing|BG performed eight movements . These movements included holding the hands straight up, slowly bringing the hands down and turning the waist while in a standing position; bending the body to the left or right side and extending the arms; extending one hand straight up, placing the other hand on the waist, then switching arms and repeating the movement; tilting the head back and looking back while stretching the neck and back; squatting the body, swinging the head and hips from side to side and moving the spine and waist; bending the body forward, touching the hands to the toes and standing up slowly; making fists with the hands and moving the arms and shoulders; and gently bouncing the body to relax the whole body in a standing position.
219655959|NCT06529172|OTHER|Control|The CG group maintained their original lifestyle without engaging in regular exercise
219063533|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
219063534|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
219655960|NCT00551161|DRUG|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
219655961|NCT01935128|DRUG|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
219655962|NCT00096993|DRUG|Placebo|Placebo was provided as a single-use formulation for infusion.
219655963|NCT00096993|DRUG|Gemcitabine|Gemcitabine was provided as a solution for infusion.
219655964|NCT00096993|DRUG|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
219655965|NCT02658383|OTHER|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
219655966|NCT02658383|OTHER|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
219655967|NCT00772005|DRUG|armodafinil|150 mg/day armodafinil
219655968|NCT00772005|DRUG|placebo|placebo
219655969|NCT00772005|DRUG|armodafinil|200 mg/day armodafinil
219655970|NCT00772005|DRUG|armodafinil|250 mg/day armodafinil
219655971|NCT00287677|BIOLOGICAL|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
219655972|NCT00287677|BIOLOGICAL|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
219655973|NCT00287677|DRUG|HAART|HAART all over the trial
219655974|NCT03280225|OTHER|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
219655975|NCT04172922|DRUG|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
219655976|NCT01828216|DEVICE|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
219655977|NCT01828216|DEVICE|conventional polysomnography|conventional type I sleep study according to international guidelines
219655978|NCT04420819|DEVICE|Ischemic Preconditioning|The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
219655979|NCT06261541|DEVICE|ABLE Exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
219655980|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
219655981|NCT01159288|BIOLOGICAL|Dex2|"* Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~* Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~* Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
219655982|NCT05173285|DIAGNOSTIC_TEST|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
219655983|NCT05173285|BEHAVIORAL|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
219655984|NCT05173285|DIAGNOSTIC_TEST|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
219655985|NCT05173285|DIAGNOSTIC_TEST|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
219655986|NCT01375582|DRUG|B & L Soothe Lubricant Eye Drops|Eye Drop
219655987|NCT01375582|DRUG|Liposic EDO|Eye Drop
219655988|NCT01375582|DRUG|OcuFresh Eye Wash|Saline drop
219655989|NCT03330366|DIETARY_SUPPLEMENT|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
219655990|NCT03330366|DIETARY_SUPPLEMENT|Placebo|take two capsules per day
219063535|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
219063536|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
219655991|NCT02338466|DRUG|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
219655992|NCT02338466|DRUG|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
219655993|NCT02254122|DRUG|BEA 2180 BR|
219655994|NCT02254122|DRUG|Placebo|
219655995|NCT02254122|DEVICE|Respimat®|
219655996|NCT04928469|OTHER|No intervention performed|Collection of clinical and laboratory data
219655997|NCT03933722|DEVICE|Caretaker|Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
219655998|NCT01440569|DRUG|COBI|150 mg tablet administered orally with food once daily
219655999|NCT01440569|DRUG|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
219656000|NCT01440569|DRUG|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
219656001|NCT05821465|DEVICE|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
219656002|NCT05889208|DEVICE|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
219656003|NCT05389826|DEVICE|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
219656004|NCT00596726|DEVICE|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
218966697|NCT04174950|OTHER|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
219656005|NCT00382902|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
219656006|NCT04092088|DEVICE|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
219656007|NCT04092088|DEVICE|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
219656008|NCT04092088|DEVICE|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
218966698|NCT01522885|DEVICE|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
218966699|NCT01522885|PROCEDURE|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
218966700|NCT00660283|DRUG|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7\. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
218966701|NCT02917473|BEHAVIORAL|In-person counseling|"In-person counseling~Sun protection"
219063537|NCT01170780|DRUG|Saline|2 ml IV
219063538|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
219063539|NCT00865527|OTHER|Fecal occult blood test|FOBT
219656009|NCT04092088|DEVICE|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
218966702|NCT02917473|BEHAVIORAL|Written advice|Written advice
218966703|NCT02917473|BEHAVIORAL|Medical skin screening|Medical skin screening
218966704|NCT02171702|DRUG|BIBW 2992|
218966705|NCT03508271|OTHER|Non-Interventional|Non-Interventional
218966706|NCT05547152|OTHER|massages|The experimental rehabilitation protocol includes massages
218966707|NCT05547152|OTHER|motor stimulation and stretching|motor stimulation and stretching
218966708|NCT05547152|OTHER|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
218966709|NCT02744469|OTHER|No intervention (observational study)|
219063540|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
219656010|NCT01082393|DRUG|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
219656011|NCT01082393|DRUG|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
219656012|NCT01082393|DRUG|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
219656013|NCT01082393|DRUG|cold cream|4 applications (day 1, day 3, day 6 and day 10)
219656014|NCT03197740|DRUG|Donepezil patch|Treatment
219656015|NCT03197740|DRUG|aricept Tab|Comparator
219656016|NCT01412892|DRUG|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
219656017|NCT05020366|BEHAVIORAL|Promoting Health through Parent Empowerment and the Activation of Routines|Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
219656018|NCT05020366|BEHAVIORAL|Enhanced Usual Care|For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
219656019|NCT03471234|DEVICE|Angioplasty|Inspiron Drug Eluting stent implantation
219656020|NCT05477628|OTHER|Childcare Navigator|"Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record."
219656021|NCT05477628|OTHER|Lactation Consultant|"Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare."
219656022|NCT05477628|OTHER|Lactation Consultant Support and Childcare Navigator Support|This intervention is a combination of the two interventions described above.
219656023|NCT05477628|OTHER|Control Group|All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
218966710|NCT05572190|DRUG|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
218966711|NCT01133561|DRUG|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
218966712|NCT01133561|DRUG|actozone B|one tablet of vehicle without active ingredient pioglitazone
218966713|NCT02583243|BEHAVIORAL|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
218966714|NCT02583243|DRUG|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
218966715|NCT03141073|DRUG|HMS5552|BID oral administration
218966716|NCT03141073|DRUG|Placebo|BID oral administration
218985293|NCT00413244|DRUG|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
218985294|NCT00413244|DRUG|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
218985295|NCT00136123|PROCEDURE|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
218985296|NCT03821909|PROCEDURE|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
218985297|NCT00770939|DEVICE|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
218985298|NCT04474158|BEHAVIORAL|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
218985299|NCT04474158|BEHAVIORAL|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
218985300|NCT00203073|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
219656024|NCT05801419|DEVICE|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
219656025|NCT05801419|DEVICE|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
219656026|NCT05801419|DEVICE|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
219656027|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
219656028|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
219656029|NCT00288808|DEVICE|Hemosense (PT/InR point of care device)|
219656030|NCT01782560|DRUG|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
219656031|NCT01782560|DRUG|Placebo|
219656032|NCT01044758|DRUG|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
219656033|NCT01044758|DRUG|Levetiracetam 125mg|125mg twice daily (2 weeks)
219656034|NCT01044758|DRUG|Levetiracetam 250mg|250mg twice daily (2 weeks)
218966717|NCT04792515|DRUG|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
219063541|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
219656035|NCT01044758|DRUG|Placebo|placebo capsule twice daily (2 weeks)
219656036|NCT00282386|DRUG|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
219063542|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
219063543|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
219656037|NCT00282386|DRUG|Placebo/ Duration of Treatment: 156 weeks|
219656038|NCT00870610|PROCEDURE|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
219656039|NCT01009255|DRUG|GSK239512|Histamine H3 Antagonist
219656040|NCT01009255|DRUG|Placebo|Placebo to match GSK239512
219656041|NCT01072981|BIOLOGICAL|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
219656042|NCT01072981|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
219656043|NCT01072981|RADIATION|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
219656044|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
219656045|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
219656046|NCT03737279|BEHAVIORAL|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
219656047|NCT03737279|BEHAVIORAL|Routine Care|"Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy"
219656048|NCT00714584|DRUG|Naltrexone HCl.|
219656049|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
219656050|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
219656051|NCT04150705|DEVICE|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
219656052|NCT05667207|DIAGNOSTIC_TEST|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
219656053|NCT00041210|BIOLOGICAL|bleomycin sulfate|
219656054|NCT00041210|DRUG|ABVD regimen|
219656055|NCT00041210|DRUG|Stanford V regimen|
219656056|NCT00041210|DRUG|dacarbazine|
219656057|NCT00041210|DRUG|doxorubicin hydrochloride|
219656058|NCT00041210|DRUG|etoposide|
219656059|NCT00041210|DRUG|mechlorethamine hydrochloride|
219656060|NCT00041210|DRUG|prednisone|
219656061|NCT00041210|DRUG|vinblastine sulfate|
219656062|NCT00041210|DRUG|vincristine sulfate|
219656063|NCT00041210|RADIATION|radiation therapy|
219656064|NCT01065714|DRUG|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
219656065|NCT01065714|DRUG|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
219656066|NCT06435546|DIAGNOSTIC_TEST|Blood samples|Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
219656067|NCT06435546|OTHER|Adherence to anti-cancer therapies questionnaires|GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
219656068|NCT01768091|PROCEDURE|POEM|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~4. Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
219656069|NCT01768091|PROCEDURE|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
219656070|NCT02085226|OTHER|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
219656071|NCT02085226|OTHER|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
219656072|NCT01244217|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
219656073|NCT03886389|DIETARY_SUPPLEMENT|PreOP|Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
219656074|NCT06305260|DIAGNOSTIC_TEST|Lumbar Ultrasound|Investigators will utilize our ultrasound machine to complete a pre-procedural lumbar ultrasound prior to epidural placement.
219656075|NCT03502694|DRUG|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
219656076|NCT03502694|DRUG|Placebo|Participants will receive matching placebo tablets orally.
219656077|NCT01025466|DRUG|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
219656078|NCT01025466|DRUG|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
219656079|NCT05710692|DRUG|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
219656080|NCT05710692|DRUG|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
219656081|NCT02787057|DRUG|vancomycin|IP vancomycin 1g every 5 days
219656082|NCT02787057|DRUG|moxifloxacin|oral moxifloxacin 400mg QD
219656083|NCT02787057|DRUG|ceftazidime|IP ceftazidime 1g QD
219656084|NCT01260272|OTHER|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
219656085|NCT01260272|OTHER|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
219656086|NCT04774848|DEVICE|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
219656087|NCT04774848|DEVICE|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
219656088|NCT04951713|DRUG|XZP-3287 combined with clarithromycin|Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
219656089|NCT04951713|DRUG|XZP-3287 combined with rifampicin|Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
219656090|NCT02268682|OTHER|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
219656091|NCT02268682|OTHER|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
219656092|NCT06316388|PROCEDURE|vitrectomy|pars plana vitrectomy
219656093|NCT04396600|BEHAVIORAL|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
219656094|NCT06329310|DEVICE|aXess-E conduit|The aXess-E conduit is a sterile, regenerative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess-E conduit is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
219656095|NCT06370546|OTHER|Low intensity|Low intensity group: participants will be requested to perform the following exercises: 1)squat, 2) rowing, 3)deadlift and 4)bench press. All exercises will be performed with low intensity (40% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
219656096|NCT06370546|OTHER|high intensity|High intensity group: participants will be requested to perform the following exercises: 1)squat, 2)rowing, 3)deadlift and 4)bench press. All exercises will be performed with high intensity (80% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
219656097|NCT06370728|DRUG|Orforglipron|Administered orally
219656098|NCT06370728|DRUG|Carbamazepine|Administered orally
219656099|NCT00435487|DRUG|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
218966718|NCT01013298|DEVICE|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
218966719|NCT02891811|DRUG|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
218966720|NCT02891811|DRUG|Thalidomide|100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
218966721|NCT02891811|DRUG|Lenalidomide|25mg p.o. on days 1-21 of each cycle
218966722|NCT02891811|DRUG|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
218966723|NCT00154726|DRUG|Paclitaxel-HDFL|
219656100|NCT00435487|DRUG|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg \[units per kilogram\] and initial infusion of 12 U/kg/h \[units per kilogram per hour\]).
219656101|NCT02627326|PROCEDURE|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
219656102|NCT06525025|OTHER|Observational study, non intervention|Observational study, non intervention
219656103|NCT03301844|COMBINATION_PRODUCT|Blephapad Combo|"Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes."
219656104|NCT03301844|OTHER|Standard treatment|Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
219656105|NCT01198561|DEVICE|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
219656106|NCT01935856|DRUG|KHK7580|Oral administration
219656107|NCT02730767|BEHAVIORAL|partially supervised exercise intervention|
219656108|NCT04695574|PROCEDURE|Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test|Clinical evaluation methods
219656109|NCT05087966|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
219656110|NCT04703374|DRUG|CKD-382(formulation I)|1 tablet administered under fasting condition for 7days
219656111|NCT04703374|DRUG|CKD-382(formulation II)|1 tablet administered under fasting condition for 7days
219656112|NCT04703374|DRUG|D026|1 tablet administered under fasting condition for 7days
219656113|NCT02543372|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
219656114|NCT02543372|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
219656115|NCT03934723|BEHAVIORAL|Exercise|The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
219656116|NCT03495739|DRUG|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
219656117|NCT03495739|DRUG|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
219656118|NCT00993759|DRUG|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
219656119|NCT05839405|OTHER|None - Cross Sectional.|There is no intervention, this is cross-sectional only.
218966724|NCT04095273|DRUG|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
218966725|NCT04095273|DRUG|Pembrolizumab (Keytruda®)|Study drugs will be administered as scheduled
218966726|NCT02836353|DRUG|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
218966727|NCT02836353|DRUG|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
218966728|NCT01137318|BEHAVIORAL|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
218985301|NCT00203073|DRUG|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
219656120|NCT05728853|RADIATION|Assessment of body composition|Assessment of body composition using BIA and DXA
219656121|NCT05402124|DRUG|acetylsalicylic acid delayed release tablets, 81mg|acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
219656122|NCT01886586|BEHAVIORAL|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
219656123|NCT01886586|BEHAVIORAL|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
219656124|NCT01886586|OTHER|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
219656125|NCT00707876|DRUG|ferumoxytol|Dose 1 versus non-contrast MRA
219656126|NCT00707876|DRUG|ferumoxytol|Dose 2 versus non-contrast MRA
219656127|NCT00707876|DRUG|ferumoxytol|Dose 3 versus non-contrast MRA
219656128|NCT03126565|OTHER|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
219656129|NCT02105714|PROCEDURE|Stool culturing for pathogenic bacteria|
219656130|NCT02105714|PROCEDURE|Kato-Katz technique|
219656131|NCT02105714|PROCEDURE|Baermann technique|
219656132|NCT02105714|DEVICE|Mini-FLOTAC|
219656133|NCT02105714|DEVICE|Crypto/Giardia Duo Strip|
219656134|NCT02105714|PROCEDURE|Formalin-ether concentration technique|
219656135|NCT02105714|DEVICE|CCA RDT|
219656136|NCT02105714|PROCEDURE|Koga agar plate culture|
219656137|NCT02105714|PROCEDURE|Kinyoun staining|
219656138|NCT02105714|DEVICE|Multiplex PCR|
219656139|NCT02105714|PROCEDURE|Metagenomics analysis|
219656140|NCT04561024|DIAGNOSTIC_TEST|AI model|Deep Learning CNN model
219656141|NCT03193658|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
219656142|NCT03193658|DRUG|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
219656143|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
219656144|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
219656145|NCT01267201|DRUG|methylprednisolone|tablet 32 mg single dose
219656146|NCT05060146|OTHER|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
219656147|NCT04985175|BEHAVIORAL|Question prompt list|The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
219656148|NCT01338961|PROCEDURE|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
219656149|NCT00501059|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
219656150|NCT00501059|DRUG|Placebo|Placebo, taken daily
219656151|NCT05661630|OTHER|EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL|"In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended."
219656152|NCT00517894|DRUG|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
219656153|NCT06142175|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
219656154|NCT02811588|DEVICE|Non-invasive ventilation|
219656155|NCT02978859|DRUG|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
219656156|NCT02237209|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
219656157|NCT02237209|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
219656158|NCT01046032|DRUG|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
218966729|NCT03300531|BIOLOGICAL|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
218966730|NCT03300531|BIOLOGICAL|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
219063544|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
218966731|NCT03300531|DRUG|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
218966732|NCT05521724|PROCEDURE|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
219656159|NCT01046032|DRUG|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
219656160|NCT02719938|BEHAVIORAL|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
219656161|NCT01885715|DRUG|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
219656162|NCT01455181|DRUG|NPSP558|50, 75, 100 μg
219656163|NCT02041650|DRUG|Ticagrelor|
219656164|NCT04529512|DRUG|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
219656165|NCT00955968|DRUG|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
219656166|NCT00117624|DRUG|darbepoetin alfa|
219656167|NCT03456999|BIOLOGICAL|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
219656168|NCT03456999|BIOLOGICAL|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
219656169|NCT05949424|DRUG|Olaparib|Starting dose of 200mg 2dd.
219656170|NCT05949424|DRUG|Lenvatinib|Starting dose of 10mg 1dd.
219656171|NCT05949424|DRUG|Sunitinib|Starting dose of 25mg 1dd 28/42 days.
219656172|NCT05949424|DRUG|Palbociclib|Starting dose of 75mg 1dd 21/28 days.
219656173|NCT05949424|DRUG|Pazopanib|Starting dose of 200mg 1dd.
219656174|NCT05949424|DRUG|Olaparib|Starting dose of 300mg 2dd.
219656175|NCT05949424|DRUG|Lenvatinib|Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.
219656176|NCT05949424|DRUG|Sunitinib|Starting dose of 50mg 1dd 28/42 days.
219656177|NCT05949424|DRUG|Palbociclib|Starting dose of 125mg 1dd 21/28 days.
218966733|NCT03110731|BEHAVIORAL|Physical training|Physical training (2x / week) was performed for 12 weeks
218966734|NCT04008823|OTHER|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
218966735|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed High Dose|26 gram flaxseed intervention
218966736|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed Low Dose|13 grams flaxseed
218966737|NCT00089856|BIOLOGICAL|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
218966738|NCT00089856|DRUG|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
218966739|NCT02568137|BEHAVIORAL|Smart-phone based technology|
218966740|NCT04704973|BEHAVIORAL|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
218966741|NCT02900001|PROCEDURE|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
218966742|NCT02900001|PROCEDURE|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
218966743|NCT01169597|DRUG|prednisone|prednisone 12.5 mg daily po
218966744|NCT01466595|DRUG|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
218966745|NCT01685346|BEHAVIORAL|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
218985302|NCT00046878|DRUG|O6-benzylguanine|
218985303|NCT00046878|DRUG|carmustine|
218985304|NCT06403852|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) with propofol|Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
219656178|NCT05949424|DRUG|Pazopanib|Starting dose of 800mg 1dd.
219656179|NCT06712849|DEVICE|Sham Transcranial Random Noise Stimulation|Sham transcranial random noise stimulation will be applied over the primary visual cortex (area V1) with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2.0 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 40 minutes.
219656180|NCT06712849|DEVICE|High Frequency Transcranial Random Noise Stimulation|Non-invasive brain stimulation will involve the use of high-frequency transcranial random noise stimulation (100-640 Hz) to apply a 2.0 milliamp current over the primary visual cortex (area V1) for approximately 40 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
219656181|NCT03559868|DRUG|Digoxin|Participants will receive 3 mcg/Kg/day doses of oral digoxin
219656182|NCT03559868|OTHER|Placebo|Oral placebo
219656183|NCT03559868|DRUG|Digoxin|Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
219656184|NCT00876226|DRUG|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
219656185|NCT04482595|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
219656186|NCT04482595|DRUG|Placebo|Matched placebo for BIO 300 Oral Suspension
219656187|NCT03152825|PROCEDURE|PCI|percutaneous coronary intervention attempt
219656188|NCT06731686|OTHER|Retrospective study|Collection of children's datas
218966746|NCT01672229|DRUG|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
218966747|NCT01244698|DRUG|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
218966748|NCT01244698|DRUG|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
218966749|NCT01957527|DEVICE|Peripheral arterial tonometry (EndoPAT)|
218966750|NCT05160610|BEHAVIORAL|Multilevel intervention|Multilevel intervention based on AACTT theory
218966751|NCT02117414|DEVICE|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
218966752|NCT02117414|OTHER|Waiting Period Visit|Waiting period time will equate to 1 hour
219656189|NCT02201095|DEVICE|Forced air warming|
219656190|NCT02201095|DEVICE|Conduction warming mattress|
219656191|NCT05084365|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
219656192|NCT05084365|DRUG|Placebo|Placebo
219656193|NCT00430352|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
219656194|NCT05177900|DEVICE|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
219656195|NCT04511949|DIAGNOSTIC_TEST|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"* The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
219656196|NCT04383340|BEHAVIORAL|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
219656197|NCT04383340|BEHAVIORAL|Treatment as usual|Standard hospital care and parental support
219656198|NCT04947995|DEVICE|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
219656199|NCT06730516|DRUG|Latanoprost (Xalatan)|latanoprost 0.005
219656200|NCT06730516|DRUG|Brimonidine 0.2 %|Brimonidine0.2
219656201|NCT02331849|DEVICE|High resolution manometry (HRM)|High resolution manometry of the esophagus
219656202|NCT00565669|DRUG|Cyclosporin A Restasis®|
219656203|NCT00565669|DRUG|Blink tears|blink tears to be used twice a day
219656204|NCT00565669|DRUG|Systane|systane to be used twice a day
219656205|NCT04326439|DRUG|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
218966753|NCT04394182|RADIATION|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
218966754|NCT04394182|DEVICE|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
219656206|NCT04326439|DRUG|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
219656207|NCT04326439|DRUG|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
219656208|NCT04326439|DRUG|Etoposide|150 mg/m²/dose IV Days 1-5
219656209|NCT04326439|DRUG|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
219656210|NCT04326439|PROCEDURE|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
219656211|NCT04326439|DRUG|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
219656212|NCT02930525|OTHER|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
219656213|NCT02930525|OTHER|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
218966755|NCT04394182|DRUG|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
219656214|NCT02689310|OTHER|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
219656215|NCT02689310|OTHER|Standard of Care Treatment|No information available- PI left- study being withdrawn.
219656216|NCT06272045|BEHAVIORAL|ENRICH|In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.
219656217|NCT06272045|BEHAVIORAL|Usual Home Visiting|Usual home visiting without cardiovascular health promotion content
219656218|NCT04291677|OTHER|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
219656219|NCT04291677|OTHER|Without intervention musical|Control group with standard treatment without musical intervention.
219656220|NCT03643913|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
219656221|NCT03643913|PROCEDURE|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
219656222|NCT03643913|DRUG|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
219656223|NCT05603156|DRUG|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
219656224|NCT00095745|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
219656225|NCT04840420|OTHER|social prescribing|as above
219656226|NCT04840420|OTHER|usual care|as above
219656227|NCT05999617|OTHER|Rehabilitation|Conventional rehabilitation (stretching, strengthening, balance) and dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
219656228|NCT00204477|DIETARY_SUPPLEMENT|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
219656229|NCT00204477|DIETARY_SUPPLEMENT|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
219656230|NCT00632684|BEHAVIORAL|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
219656231|NCT00632684|BEHAVIORAL|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
219656232|NCT06618196|BIOLOGICAL|LR20062|DTaP-HepB-IPV-Hib vaccine
219656233|NCT06618196|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Control hexavalent vaccine
218966756|NCT04394182|DRUG|Hydroxychloroquine|200 mg/12h
218966757|NCT04394182|DRUG|Azithromycin|500 mg/24h, 3 days
218966758|NCT04394182|DRUG|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
218966759|NCT04394182|DRUG|Low molecular weight heparin|prophylactic doses
218966760|NCT04394182|DRUG|Corticosteroid injection|250mg x 3 boluses
218966761|NCT04394182|DRUG|Tocilizumab|600mg single dose
218966762|NCT03924531|BEHAVIORAL|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
218966763|NCT03924531|BEHAVIORAL|Health Promotion Program|Health Promotion Program
218966764|NCT00688727|BEHAVIORAL|CBT|CBT, up to 12 sessions.
218966765|NCT00688727|BEHAVIORAL|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
218985305|NCT05232071|DRUG|IVA337|800 mg
218985306|NCT05232071|DRUG|Placebo|Placebo to match
218985307|NCT05232071|DRUG|Empagliflozin|10 mg
218985308|NCT02264639|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
218985309|NCT00003661|BIOLOGICAL|anti-thymocyte globulin|
218985310|NCT00003661|DRUG|busulfan|
218985311|NCT00003661|DRUG|cyclosporine|
218985312|NCT00003661|DRUG|melphalan|
218985313|NCT00003661|DRUG|methylprednisolone|
218985314|NCT00003661|PROCEDURE|umbilical cord blood transplantation|
218985315|NCT00003661|RADIATION|radiation therapy|
218985316|NCT02154074|DRUG|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
218985317|NCT02154074|DRUG|Isoflurane|inhale Isoflurane 1.5MAC
218985318|NCT02154074|DRUG|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
218985319|NCT02154074|DRUG|normal saline|the same volume of saline + Isoflurane during operation
218985320|NCT03917238|RADIATION|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
219656234|NCT04543318|PROCEDURE|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
219656235|NCT04543318|PROCEDURE|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
219656236|NCT00388336|DRUG|Epoetin Alfa|
219656237|NCT01500408|DRUG|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
218966766|NCT03555435|OTHER|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
218966767|NCT03555435|BEHAVIORAL|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
218966768|NCT03555435|BEHAVIORAL|Wait|Participants in this group will wait 6 weeks.
218966769|NCT04804007|DRUG|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
218966770|NCT03961373|PROCEDURE|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
218966771|NCT03961373|PROCEDURE|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
218966772|NCT05315856|BIOLOGICAL|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
218966773|NCT02758756|OTHER|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
219063545|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
219063546|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
219063547|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
219063548|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
219063549|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
219063550|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
219063551|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
219656238|NCT01500408|DRUG|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
219656239|NCT00359736|DRUG|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
219063552|NCT01148810|DRUG|BAF312|
219063553|NCT01148810|DRUG|Placebo|
219063554|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
219063555|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
219656240|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
219656241|NCT04272606|DRUG|Saline Solution|Placebo
219656242|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
219656243|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
219656244|NCT02432391|BEHAVIORAL|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
219656245|NCT06715683|DRUG|BMS-986278 Batched method, Dose A|Specified dose on specified days
219656246|NCT06715683|DRUG|BMS-986278 Batched method, Dose B|Specified dose on specified days
219656247|NCT06715683|DRUG|BMS-986278 Continuous method|Specified dose on specified days
219656248|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
219656249|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
219656250|NCT06592755|PROCEDURE|single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection|The included patients chose to undergo single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach based on patients preference.
219656251|NCT06592755|PROCEDURE|conventional open surgery|These patients chose to undergo total thyroidectomy with central compartment neck dissection via conventional open surgery based on patients preference.
219656252|NCT02611128|OTHER|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
219656253|NCT04064021|PROCEDURE|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
219656254|NCT03061656|DRUG|Cyclophosphamide|1st HDCT
219656255|NCT03061656|DRUG|Carboplatin|1st HDCT
219656256|NCT03061656|DRUG|Etoposide|1st HDCT
218966774|NCT02758756|OTHER|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
218966775|NCT00063193|DRUG|minocycline|
218966776|NCT00063193|DRUG|creatine|
219063556|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
219063557|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
219063558|NCT02974361|DRUG|Ibuprofen|
219063559|NCT02974361|DRUG|Ibuprofen Lysine|
219063560|NCT02974361|DRUG|Ibuprofen-LDH|
219063561|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
219063562|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
219063563|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
219063564|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
219063565|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
219656257|NCT03061656|RADIATION|131I-MIBG|2nd HDCT
219656258|NCT03061656|DRUG|Thiotepa|2nd HDCT
219656259|NCT03061656|DRUG|Melphalan|2nd HDCT
219656260|NCT05428202|DRUG|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
219656261|NCT05428202|DRUG|Placebo|Placebo cream containing base without active ingredients
218966777|NCT00348244|DRUG|Ketorolac, Prednisolone Acetate|
219063566|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
219063567|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
219063568|NCT02700646|BEHAVIORAL|Developmental recommendations|
219063569|NCT02700646|BEHAVIORAL|Standard care|standard care
219063570|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
219063571|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
219063572|NCT00131794|BIOLOGICAL|BCG|
219656262|NCT02250482|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
219656263|NCT00057304|DRUG|RO 205-2349|
219656264|NCT00301496|DEVICE|Coban 2 Layer Compression System|
219656265|NCT02012790|OTHER|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
219656266|NCT02923362|PROCEDURE|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
219063573|NCT04408469|BEHAVIORAL|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
219063574|NCT04408469|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
219063575|NCT01202773|DRUG|LY2127399|Administered Subcutaneously (SC)
219063576|NCT01202773|DRUG|Placebo Q4W|Administered SC
219063577|NCT01202773|DRUG|Placebo Q2W|Administered SC
219063578|NCT04885829|DRUG|Tocilizumab Prefilled Syringe|0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
219656267|NCT02923362|DEVICE|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
219656268|NCT00097955|DRUG|aliskiren|
219656269|NCT00656487|DRUG|rimonabant|double blind, placebo controlled, single 90 mg dose
219656270|NCT00656487|DRUG|placebo|matched placebo
219656271|NCT02209805|DRUG|BIRB 796 BS, low dose|
219656272|NCT02209805|DRUG|BIRB 796 BS, high dose|
219656273|NCT02209805|DRUG|Placebo|
218966778|NCT04290780|OTHER|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
218966779|NCT02869438|DRUG|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
218966780|NCT02869438|OTHER|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
218966781|NCT03877731|PROCEDURE|isolated septal myectomy|
218966782|NCT03877731|PROCEDURE|septal myectomy + edge-to-edge mitral valve repair|
219656274|NCT05985473|OTHER|audiological measurements|audiological measurements
219656275|NCT05985473|OTHER|Objective and subjective audiological measurements|Objective and subjective audiological measurements
218966783|NCT03877731|PROCEDURE|septal myectomy + posterior leaflet sliding plasty|
219063579|NCT01895166|PROCEDURE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
219063580|NCT01895166|PROCEDURE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
219063581|NCT00620477|DRUG|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
219063582|NCT00620477|DRUG|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
219063583|NCT01279226|DEVICE|Auralevée device|Single treatment with Auralevée device.
219656276|NCT05985473|OTHER|Evaluation of the denoising methods REFINED|Evaluation of the denoising methods REFINED
219656277|NCT01254851|BEHAVIORAL|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
219656278|NCT05669898|BEHAVIORAL|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
218966784|NCT03877731|PROCEDURE|septal myectomy + secondary chordae transection|
218966785|NCT05229978|OTHER|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
219063584|NCT04171700|DRUG|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
219656279|NCT05669898|OTHER|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
219656280|NCT05669898|BEHAVIORAL|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
218966786|NCT03408002|BEHAVIORAL|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
218966787|NCT03400644|DEVICE|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
218966788|NCT00856648|DEVICE|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
219656281|NCT03293082|DEVICE|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
219656282|NCT03293082|DEVICE|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
219656283|NCT05479591|DRUG|IDegLira|Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
219656284|NCT03031574|DRUG|SUVN-D4010|Tablets
219656285|NCT00416676|DRUG|carboplatin|
219656286|NCT00416676|DRUG|cisplatin|
219656287|NCT00416676|DRUG|cyclophosphamide|
219656288|NCT00416676|DRUG|etoposide|
219656289|NCT00416676|DRUG|vincristine sulfate|
219656290|NCT00416676|PROCEDURE|adjuvant therapy|
219656291|NCT00416676|PROCEDURE|conventional surgery|
219656292|NCT00416676|PROCEDURE|neoadjuvant therapy|
219656293|NCT00416676|RADIATION|radiation therapy|
219656294|NCT04919876|DIETARY_SUPPLEMENT|fruit/vegetable supplement (FVS)|The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
219656295|NCT04919876|DIETARY_SUPPLEMENT|Placebo|The product does not contain nutrients present in the FVS.
218966789|NCT00658580|DRUG|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
218966790|NCT00658580|DRUG|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
219063585|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
219063586|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
219063587|NCT05354050|DRUG|DARE-BV1|2% Clindamycin 100 MG
219656296|NCT03424629|BIOLOGICAL|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
219656297|NCT03424629|BIOLOGICAL|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
219656298|NCT03424629|DRUG|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
219656299|NCT04231396|OTHER|Audiobooks for hearing loss App|Same as Arm 1
219656300|NCT00382395|DEVICE|SOLX Gold Shunt GMS-plus|Single use implant
219656301|NCT00382395|DEVICE|Ahmed FP7 Glaucoma Valve|Single use implant
219656302|NCT00787917|DRUG|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
219656303|NCT00787917|DRUG|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
218966791|NCT04115644|DRUG|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
219656304|NCT00787917|DRUG|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
219656305|NCT00077116|DRUG|busulfan|
219656306|NCT00077116|DRUG|cyclophosphamide|
218966792|NCT04115644|DRUG|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
218966793|NCT04115644|DRUG|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
219656307|NCT00077116|DRUG|cytarabine|
219656308|NCT00077116|DRUG|gemtuzumab ozogamicin|
219656309|NCT00077116|DRUG|idarubicin|
219656310|NCT00077116|PROCEDURE|allogeneic bone marrow transplantation|
219656311|NCT00077116|PROCEDURE|peripheral blood stem cell transplantation|
219656312|NCT00077116|RADIATION|radiation therapy|
219656313|NCT01113138|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
219656314|NCT01113138|DRUG|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
219656315|NCT06907992|DRUG|Antifungal treatment|Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)
219656316|NCT02672358|DRUG|Dabrafenib|Oral Dabrafenib 150 mg BID
219656317|NCT02672358|DRUG|Trametinib|Oral Trametinib 2 mg QD
219656318|NCT01230684|PROCEDURE|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
219656319|NCT05631106|BEHAVIORAL|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
219656320|NCT05631106|BEHAVIORAL|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
219656321|NCT05329051|BIOLOGICAL|SCTV01E|intramuscular injection
219656322|NCT05329051|BIOLOGICAL|Comirnaty|intramuscular injection
219656323|NCT01485445|DRUG|Fluticasone Furoate (200mcg unit strength)|inhalation powder
218966794|NCT01840618|DEVICE|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
218966795|NCT01033721|DRUG|Palomid 529|comparison of different dosages of drug
218966796|NCT05023876|OTHER|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
218966797|NCT05023876|OTHER|Respiratory Exercise|Respiratory Exercise
218966798|NCT01601431|DEVICE|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
218966799|NCT01601431|DEVICE|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
219656324|NCT01485445|DRUG|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
219656325|NCT05421052|OTHER|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
219656326|NCT04588727|DRUG|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
219656327|NCT04588727|DRUG|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
219656328|NCT04588727|DRUG|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
219656329|NCT04588727|DRUG|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
219656330|NCT00778102|DRUG|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
219656331|NCT00778102|DRUG|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
219656332|NCT00778102|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
219656333|NCT00778102|DRUG|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
219656334|NCT00778102|DRUG|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
219656335|NCT00778102|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
219656336|NCT00778102|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
218966800|NCT03526731|OTHER|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
218966801|NCT05958667|BEHAVIORAL|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
218966802|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
218966803|NCT06637839|BEHAVIORAL|Moderate-Intensity Locomotor Training Program|The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
218966804|NCT06637839|BEHAVIORAL|High-Intensity Locomotor Training Program|The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
218966805|NCT06637839|BEHAVIORAL|High-Step Count Locomotor Training Program|The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
218966806|NCT02660398|PROCEDURE|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
218966807|NCT05305027|BEHAVIORAL|Prompt diagnois pregnancy outcome|
218966808|NCT05613803|DRUG|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
218966809|NCT05613803|OTHER|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
218985321|NCT04759573|BEHAVIORAL|Early Vocal Contact|Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
219656337|NCT00778102|DRUG|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
219656338|NCT06912386|DEVICE|taVNS|"Intervention Name: Transauricular Vagus Nerve Stimulation (taVNS)~Intervention Description:~Participants will receive transauricular vagus nerve stimulation on the tragus. Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
219656339|NCT06912386|DEVICE|SHAM stimulation|"Intervention Name: SHAM stimulation of the earlobe. Participants will receive SHAM stimulation on the earlobe, which does not stimulate the vagus nerve.~Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Placebo stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
219656340|NCT06912321|OTHER|No Intervention: Observational Cohort|No intervention：all participants did not receive any intervention measures throughout the study
219656341|NCT06911645|OTHER|Immediate access to customized version of GPT-4|Group is given immediate access to a customized version of GPT-4 to support their diagnostic reasoning for each case.
219656342|NCT06911645|OTHER|Access to customized version of GPT-4 following use of conventional resources|Group is first encouraged to reason through diagnostic cases with the support of conventional resources. After they submit a case's answers they are then given access to a customized version of GPT-4 and have the opportunity to change their initial answers.
219656343|NCT06911151|DEVICE|innovative footwear|HDC shoe
219656344|NCT06905834|DRUG|Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC|Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.
219656345|NCT05778032|OTHER|Multidisciplinary metabolic rehabilitation program|Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks
219656346|NCT00992628|DEVICE|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
219656347|NCT00992628|DEVICE|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
219656348|NCT05368415|DRUG|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
219656349|NCT03946878|DRUG|Acalabrutinib|Given PO
219656350|NCT03946878|DRUG|Venetoclax|Given PO
219656351|NCT03244670|OTHER|Observation study only, no specific intervention|Observation study only, no specific intervention
219656352|NCT03185806|DEVICE|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
219656353|NCT06912568|DEVICE|Miniscrew insertion|four or two miniscrews insertions using computer-guided minimally-invasive and flapless approach
218966810|NCT04092569|BEHAVIORAL|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
218966811|NCT06392971|DRUG|Deep-sea fish oil|Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
218966812|NCT06392971|OTHER|Placebo|Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
219063588|NCT03238937|DEVICE|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
219656354|NCT06912568|DEVICE|Expander|In the TB group, the tooth-borne hyrax appliance was designed with bands on the maxillary first molars; in the BB4 group, the bone-borne expander was supported by 4 miniscrews inserted both in paramedian and parapalatal position of the palatal vault; in the BB2 group, the bone-borne expander was supported by 2 miniscrews inserted in the paramedian region of the palate. The same type of expansion screw and expansion protocol were used in all groups. Specifically, a 10mm hyrax click screw (Dentaurum, Bologna, Italy) was activated by 4 quarter-turns on the first day and by 3 quarter-turns per day during the active phase of treatment (0.20mm per turn, 0.6mm daily) until an 8mm screw opening was achieved.
219656355|NCT06912568|RADIATION|CBCT|"All patients underwent CBCT examinations before the application of the RME device (T0) and post-treatment, after the 6-month retention period (T1). The exposure settings were as follows: 10 mA, 90 kV, total scanning time of 15.0 seconds, effective radiation time of 4.0 seconds, voxel size of 0.2 mm, scanning area of 14 x 16.5 cm, and an effective radiation dose of approximately 524 mGy/cm2.~The CBCT images analyzed in this study were not acquired specifically for this research but were part of an ongoing prospective randomized clinical trial aimed at evaluating the skeletal and dentoalveolar effects of three different orthodontic devices. The imaging protocol was established in accordance with ethical guidelines and was approved by the relevant institutional review board."
219656356|NCT06910410|BEHAVIORAL|BodyScreen App|The BodyScreen App uses behavioural interventions along with haptic interruptions in social media app usage. The app will engage participants by sending them notifications, reminders, and activities to complete throughout the day and the week.
219656357|NCT00800306|DRUG|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
219656358|NCT00800306|DRUG|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
219656359|NCT05481229|OTHER|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
219656360|NCT00282906|DEVICE|hybrid PET-CT imaging system|15 mCi of FDG
219656361|NCT05191589|OTHER|Haptic|Trainees are randomized in this group to use the haptic device.
219656362|NCT06909916|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|The investigators will be assessing the use of weight-bearing CT and conventional CT, specifically its imaging, with RSA-like software, for analyzing fracture healing for a periprosthetic distal knee fracture.
219656363|NCT06912490|OTHER|Amniotic Fluid Proteomic Analysis Using Capillary Electrophoresis-Mass Spectrometry (CE-MS)|This intervention consists of analyzing the amniotic fluid proteome using capillary electrophoresis coupled with mass spectrometry (CE-MS). The goal is to evaluate a predefined 98-peptide signature that predicts postnatal kidney function in fetuses with bilateral congenital anomalies of the kidney and urinary tract. Unlike standard prenatal assessments based on ultrasound and fetal biochemistry, this method provides a molecular-based prognostic tool to improve decision-making regarding pregnancy management and neonatal care
219656364|NCT01328548|DRUG|Zostavax|
219656365|NCT06910735|OTHER|Control|Participants will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center
218966825|NCT01257802|DRUG|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
219656366|NCT06910735|BEHAVIORAL|Threshold financial incentive|Participants will receive the standard care with an additional financial incentive of 300 € if they successfully achieve the weight loss target corresponding to their weight at 12 months after bariatric surgery. This financial incentive will be awarded 12 months after their inclusion in the study.
219656367|NCT06910735|BEHAVIORAL|Proportional financial incentive|Participants will receive the standard care with an additional financial incentive, which will be determined based on the proportion of their actual weight loss in relation to the predefined weight loss target corresponding to their weight at 12 months after bariatric surgery. The financial incentive can be up to 300 € if the weight loss target is achieved 12 months after their inclusion in the study.
218966826|NCT01257802|DRUG|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
218966827|NCT04776239|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
218966828|NCT04776239|OTHER|Placebo|Placebo delivered via peripheral intravenous infusion
218966829|NCT05809622|BEHAVIORAL|Elbow focused rehabilitation|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
218966830|NCT05809622|BEHAVIORAL|Scapular and rotator cuff muscles strengthening|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~* Scapular stabilizer muscle + rotator cuff (RM) strengthening"
218966831|NCT06059209|DIETARY_SUPPLEMENT|Enfamil NeuroPro|FDA Infant formula
218966832|NCT06059209|DIETARY_SUPPLEMENT|Enfamil Infant|FDA Infant formula
218966833|NCT05155709|DRUG|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
218966834|NCT05155709|DRUG|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
218966835|NCT05155709|DRUG|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
218966836|NCT05468476|OTHER|No intervention|No intervention
218966837|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
218966838|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
218966839|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
219656368|NCT06910345|OTHER|A skin patch (2.1 mg melatonin) was applied to the melatonin group. The melatonin patches will be placed at 8:00 PM (on the upper chest or forearm, as determined by the patient) before going to sleep|A skin patch (2.1 mg melatonin) was applied to the melatonin group.
219656369|NCT05963451|OTHER|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
219656370|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
219656371|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
219656372|NCT05919992|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
219656373|NCT05919992|DRUG|Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
219656374|NCT05919992|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
219656375|NCT05919992|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
219656376|NCT06910085|BEHAVIORAL|kettlebell-training|15 min of body weight or kettlebell loaded strength training
219656377|NCT06911593|DIAGNOSTIC_TEST|Doppler ultrasonography|The delay time was determined as the time difference between the onset of the Doppler waveform and the R-wave on the electrocardiogram(ECG) of the USG device. The distance between the carotid and femoral arteries, where imaging was performed, was then measured. This distance was divided by the delay time to calculate the carotid-femoral pulse wave velocity(PWV) in meters per second, which was considered a measure of arterial stiffness.
219656378|NCT05766618|PROCEDURE|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~* Space closure will be done on a 17x25 stainless steel wire~* Both molars will be indirectly anchored to the miniscrew~* Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~* Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~* The First injection will be 3 weeks before extraction~* By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~* At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~* follow up every month and injection will be repeated month after month with an observational period of 5 months."
219656379|NCT04852796|OTHER|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
219656380|NCT05890690|DIAGNOSTIC_TEST|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~\- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
218966840|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
218966841|NCT05227547|OTHER|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
218966842|NCT06190353|BEHAVIORAL|An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.|An eight module self help program
218966843|NCT00004076|DRUG|mureletecan|
218966844|NCT00246779|PROCEDURE|Modified ultrafiltration|
218966845|NCT03703596|DRUG|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
218966846|NCT03703596|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
218966847|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
218966848|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
218966849|NCT03143881|BEHAVIORAL|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
218966850|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
218966851|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
218966852|NCT06322264|DIAGNOSTIC_TEST|Measurement of variation in heart rate|The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
218966853|NCT05064839|PROCEDURE|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
218966854|NCT01115803|DRUG|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
218966855|NCT01115803|DRUG|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
218966856|NCT01115803|DRUG|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
218966857|NCT02885168|DRUG|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
219656381|NCT05890690|DIAGNOSTIC_TEST|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~\- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
219656382|NCT05903053|BEHAVIORAL|Early Self-Regulation Intervention|"Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total)."
219656383|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
219656384|NCT04641260|DRUG|Fezolinetant|Oral
219656385|NCT00073983|BIOLOGICAL|filgrastim|filgrastim
219656386|NCT00073983|BIOLOGICAL|pegfilgrastim|pegfilgrastim
219656387|NCT00073983|DRUG|docetaxel|docetaxel
219656388|NCT00073983|DRUG|gemcitabine hydrochloride|gemcitabine hydrochloride
219656389|NCT00073983|GENETIC|microarray analysis|microarray analysis
219656390|NCT00073983|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219656391|NCT00073983|OTHER|pharmacokinetic study|pharmacokinetic study
219656392|NCT01896947|DIAGNOSTIC_TEST|MRI|evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
219656393|NCT05519488|BEHAVIORAL|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
219656394|NCT05519488|BEHAVIORAL|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
219656395|NCT04047134|OTHER|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
219656396|NCT04047134|OTHER|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
219656397|NCT05930795|PROCEDURE|pectopexy|pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
219656398|NCT05930795|PROCEDURE|lateral suspension|lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
218966858|NCT02885168|DEVICE|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
218966859|NCT02885168|DRUG|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
218966860|NCT02885168|BIOLOGICAL|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
218966861|NCT04489238|OTHER|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
218966862|NCT00000188|DRUG|Selegiline|
218966863|NCT03475875|DEVICE|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
218966864|NCT03475875|DEVICE|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
218966865|NCT05494320|DRUG|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
218966866|NCT02264873|DRUG|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
218966867|NCT03686826|PROCEDURE|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
218966868|NCT03536897|RADIATION|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
218966869|NCT01396330|BEHAVIORAL|stress|3 professional safe drive training courses each lasting 30 minutes
218966870|NCT00506610|DRUG|T-62|
218966871|NCT01104220|OTHER|Weight loss|Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
219656399|NCT06667882|DRUG|Alteplase Injectable Product|The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
219656400|NCT00774254|BEHAVIORAL|A|Intervention
219656401|NCT00774254|BEHAVIORAL|B|Intervention
219656402|NCT04684758|OTHER|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
219656403|NCT05569928|OTHER|Administration of deuterated compounds for kinetic study|Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
219656404|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
219656405|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
219656406|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
219656407|NCT04655092|BIOLOGICAL|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
219656408|NCT03376971|PROCEDURE|Biopsy|Undergo lung biopsy
219656409|NCT03376971|OTHER|Laboratory Biomarker Analysis|Correlative studies
219656410|NCT03800836|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
219656411|NCT03800836|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
219656412|NCT03800836|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
219656413|NCT03800836|DRUG|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of each 28 day cycle.
219656414|NCT03800836|DRUG|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
218966872|NCT01043900|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
218966873|NCT04109898|DEVICE|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
219063589|NCT02685254|BEHAVIORAL|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
219063590|NCT02685254|OTHER|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
219063591|NCT03021226|BEHAVIORAL|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
219063592|NCT03021226|BEHAVIORAL|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
219063593|NCT03021226|BEHAVIORAL|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
219656415|NCT00538512|BIOLOGICAL|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
219656416|NCT00538512|BIOLOGICAL|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
219656417|NCT00538512|OTHER|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
219656418|NCT05523947|DRUG|YH32367|"Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively."
218966874|NCT03141645|OTHER|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
218966875|NCT03141645|DRUG|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
218966876|NCT03195842|OTHER|Recordable card|
219063594|NCT01452269|BEHAVIORAL|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
219063595|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
219063596|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
219063597|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
219063598|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
219656419|NCT05698147|DRUG|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
219656420|NCT05698147|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
219656421|NCT05698147|DRUG|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
219656422|NCT06282757|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
218966877|NCT04421807|OTHER|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
218966878|NCT04421807|OTHER|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
218966879|NCT04143529|BEHAVIORAL|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
218966880|NCT04143529|BEHAVIORAL|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
218966881|NCT06415851|DRUG|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
219063599|NCT03791125|DRUG|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
219063600|NCT03791125|DRUG|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
219063601|NCT00243373|DEVICE|Barcode technology/eMAR|
219656423|NCT06282757|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
218966882|NCT04811573|DRUG|EU-sourced Otezla®|Test product
218966883|NCT04811573|DRUG|US-sourced Otezla®|Reference product 1
218966884|NCT04811573|DRUG|Japan-sourced Otezla®|Reference product 2
218966885|NCT04631302|BEHAVIORAL|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
219063602|NCT03524404|BEHAVIORAL|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
219063603|NCT03181360|DRUG|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
219063604|NCT03181360|OTHER|Control|Best standard treatment
219063605|NCT00749138|DRUG|tamoxifen|giving drug tamoxifen
219063606|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
219063607|NCT02772068|OTHER|Exercise|
219656424|NCT06583941|DIETARY_SUPPLEMENT|Low Dose Virtiva Plus|Participants will consume a low dose of Virtiva Plus (120mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (120mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
219063608|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
219656425|NCT06583941|DIETARY_SUPPLEMENT|High Dose Virtiva Plus|Participants will consume a high dose of Virtiva Plus (240mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (240mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
219656430|NCT05328180|OTHER|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
218966886|NCT04631302|BEHAVIORAL|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
218966887|NCT05120843|BEHAVIORAL|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
218966888|NCT02869984|DRUG|Ramosetron|
218966889|NCT03358537|DIETARY_SUPPLEMENT|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
219063609|NCT00736996|DRUG|Pioglitazone|30 - 45mg tablet daily for 6 months
219063610|NCT00736996|DRUG|Placebo|Matching tablet daily for 6 months
219063611|NCT00736996|BEHAVIORAL|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
219063612|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
219063613|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
219063614|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
219208117|NCT06189807|OTHER|Standard handout|Enrolled participants will be sent the standard information about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment, the participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
219656431|NCT05328180|OTHER|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
219656432|NCT02567422|DRUG|Berzosertib|Given IV
219656433|NCT02567422|DRUG|Cisplatin|Given IV
219656434|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219656435|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
219656436|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219656437|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219656438|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
219656439|NCT04356677|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
219656440|NCT04356677|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
219656441|NCT05773781|OTHER|PuraBond|Application of PuraBond to surgical field
219656442|NCT05391048|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
219656443|NCT05391048|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
219656444|NCT05488691|BEHAVIORAL|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
219656445|NCT05488691|BEHAVIORAL|TAU|treatment as usual for substance use disorders
219656446|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
219656447|NCT05994313|DIETARY_SUPPLEMENT|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
219656448|NCT05994313|DIETARY_SUPPLEMENT|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
219656449|NCT04427137|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
219656450|NCT00098202|DRUG|Low phytic acid maize|
219656451|NCT00098202|DRUG|Zinc|
219656452|NCT04497350|DEVICE|Transcranial Magnetic Stimulation|5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
219656453|NCT04497350|DEVICE|Theta Burst Stimulation|One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
219656454|NCT05490823|DEVICE|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
219656455|NCT02376296|DRUG|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
219656456|NCT02376296|OTHER|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
219656457|NCT02800941|DRUG|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
219656458|NCT01229813|DRUG|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
219656459|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
219656460|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
219656461|NCT01229813|DRUG|low dose capecitabine|capecitabine 500 mg twice daily
219656462|NCT03129113|DRUG|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
219656463|NCT03129113|DRUG|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
219656464|NCT02525302|DRUG|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
219656465|NCT05748873|DRUG|SPVN06|AAV-RdCVF-RdCVFL
219656466|NCT01110369|DIETARY_SUPPLEMENT|Protein drink|Protein drink twice a day during 6 months.
219656467|NCT01110369|OTHER|Resistance exercise training|Resistance exercise training twice per week during 6 months.
219208118|NCT05904054|BIOLOGICAL|SARS-CoV-2 DNA Vaccine (ICCOV)|The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.
218966890|NCT03358537|DIETARY_SUPPLEMENT|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
218966891|NCT01177332|OTHER|exercise|2 hours cycling exercise at 50 % of maximal power output
219656468|NCT01110369|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink twice a day during 6 months.
218966892|NCT00194675|DRUG|Dutasteride|Dutasteride 0.5 mg orally daily
218966893|NCT00194675|DRUG|Testosterone gel|Testosterone gel 7.5 g daily topical
218966894|NCT00194675|DRUG|Placebo dutasteride|placebo dutasteride orally daily
218966895|NCT00704808|PROCEDURE|Primary surgical treatment|Primary surgery for tumor resection.
219656474|NCT05015764|OTHER|Fluid Management|Removal of excess extracellular fluid using diuretics
219656475|NCT05015764|DEVICE|Reprieve Cardiovascular System|System with Fluid Management Module
219656476|NCT04523857|DRUG|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
219656477|NCT04523857|DRUG|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
219656478|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
218966896|NCT00704808|RADIATION|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
219656479|NCT06959394|OTHER|Ultrasound|Participants will receive ultrasound at 1.5 W/cm2 for 6 minutes (transmitter agent aquasonic gel) 5 sessions per week for 2 weeks.
219656480|NCT06959394|OTHER|Phonophoresis|Participants will receive ultrasound with 1.5 W/cm2, 6 min (transmitter diclofenac gel) for 5 sessions per week for 2 weeks.
219656481|NCT06959394|OTHER|Placebo|Participants will receive 0 W/cm2, 6 min ultrasound, 5 sessions per week for 2 weeks.
219656482|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
219656483|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
218966897|NCT00704808|DRUG|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
218966898|NCT01285960|DEVICE|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
218966899|NCT00433264|PROCEDURE|peritoneal dialysis|individualised
218966900|NCT02515032|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
218966901|NCT02515032|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
218966902|NCT04664244|COMBINATION_PRODUCT|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
218966903|NCT00586196|DRUG|donepezil|5 mg each day for 30 days
218966904|NCT00586196|DRUG|Placebo|Encapsulated cornstarch One capsule daily for 30 days
219656484|NCT06743191|BEHAVIORAL|Access Nourish|A total of 65 participants with hypertension and low access to high quality food will be enrolled to test the feasibility of using commercially available grocery delivery services, simultaneous to a robust behavioral intervention, to improve adherence to the DASH eating pattern. The behavioral intervention will include skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. Participants will also receive a membership to Instacart+ and weekly grocery list recommendations from a health coach. Participants will be able to complete all intervention components via smartphone. The intervention period for participants will be 4 months.
219656485|NCT05468203|DRUG|Dapagliflozin 10mg Tab|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
219656486|NCT05468203|DRUG|Placebo|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
218966905|NCT04910373|OTHER|Experimental Extensively Hydrolyzed Formula|experimental powder formula
218966906|NCT04910373|OTHER|Placebo Extensively Hydrolyzed Formula|placebo powder formula
218966907|NCT05969418|DIAGNOSTIC_TEST|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
218966908|NCT06409403|DEVICE|clinical application of robotic technique|effect of various surgical technique on clinical efficacy of TME
218966909|NCT03832075|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
218966910|NCT03832075|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
218966911|NCT03832075|DIAGNOSTIC_TEST|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
218966912|NCT03804034|DEVICE|Block of resin|
218966913|NCT03804034|DEVICE|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
218966914|NCT03690323|PROCEDURE|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
218985322|NCT04759573|BEHAVIORAL|Behavioral Observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
218985323|NCT00927602|DRUG|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
218985324|NCT01902199|BEHAVIORAL|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
218985325|NCT03295084|DRUG|Irinotecan|Dose Escalation
218985326|NCT03295084|DRUG|Capecitabine|Dose Escalation
218985327|NCT01416272|DEVICE|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
218985328|NCT04258163|DRUG|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
218985329|NCT04258163|DRUG|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
218985330|NCT04258163|DRUG|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
218985331|NCT04258163|DRUG|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
218985332|NCT04258163|DRUG|Anastrozole|1mg PO qd
218985333|NCT04258163|DRUG|Letrozole|2.5mg PO qd
218985334|NCT00913172|OTHER|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
218985335|NCT00837356|DRUG|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
218985336|NCT00837356|DRUG|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
219063615|NCT01255358|DRUG|Dexamethasone|"Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)"
219063616|NCT06636617|DRUG|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
219063617|NCT06636617|DRUG|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
219656487|NCT04917120|DEVICE|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
219656488|NCT04343274|DRUG|Tozuleristide|
219656489|NCT04983862|DRUG|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
219656490|NCT04983862|DEVICE|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
219656491|NCT06514898|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|"After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)"
219656492|NCT06514898|BIOLOGICAL|TTRNA-xALT|All participants will receive a single infusion of T-cells.
219656493|NCT06514898|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
219656494|NCT06514898|BIOLOGICAL|autologous HSCs|All participants will receive a single intravenous infusion of autologous HSCs.
219656495|NCT06514898|DRUG|Pembrolizumab|Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
219656496|NCT03385109|DEVICE|Surgery|Patients are approached surgically with the Senhance Surgical System
219656497|NCT03961854|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
219656498|NCT03961854|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
219656499|NCT05673460|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
219656500|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A1|Suspension for injection. Route of administration: IM injection
219656501|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A2|Suspension for injection. Route of administration: IM injection
219656502|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A3|Suspension for injection. Route of administration: IM injection
219656503|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B1|Suspension for injection. Route of administration: IM injection
219656504|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B2|Suspension for injection. Route of administration: IM injection
219063618|NCT06636617|DRUG|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
219063619|NCT06635018|OTHER|Resting conditions|The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
219063620|NCT06635018|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
219656505|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B3|Suspension for injection. Route of administration: IM injection
219656506|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C1|Suspension for injection. Route of administration: IM injection
219656507|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C2|Suspension for injection. Route of administration: IM injection
219656508|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C3|Suspension for injection. Route of administration: IM injection
219656509|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 1|Suspension for injection. Route of administration: IM injection
219656510|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 2|Suspension for injection. Route of administration: IM injection
219656511|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 3|Suspension for injection. Route of administration: IM injection
219656512|NCT06583031|BIOLOGICAL|Monovalent RSV Vaccine|Suspension for injection. Route of administration: IM injection
219656513|NCT05128773|DRUG|Amcenestrant|tablet, oral
219656514|NCT05128773|DRUG|Tamoxifen|tablet, oral
219656515|NCT05128773|DRUG|Amcenestrant-matching placebo|tablet, oral
219656516|NCT05128773|DRUG|Tamoxifen-matching placebo|tablet, oral
219656517|NCT04023331|DRUG|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
219656518|NCT04023331|DRUG|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
219656519|NCT06961760|DRUG|zervimesine|Zervimesine (CT1812) was shown to be safe and well tolerated in a study of healthy volunteers and in Phases 1 and 2 studies of participants with mild to moderate AD and DLB. This is an open label expanded access program designed to provide access to CT1812 and to evaluate the long-term safety of CT1812 administered once daily for 12 months in adults aged 50 to 86 who have been diagnosed with mild to moderate DLB (the targeted clinical indication for CT1812). Participants will receive 100 mg of CT1812 once daily for 360 days.
219656520|NCT05941442|DRUG|Darigabat|Oral tablets
219656521|NCT05941442|DRUG|Placebo|Oral tablets
219656522|NCT04250714|DEVICE|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
219656523|NCT06115824|DRUG|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
219656524|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
218966915|NCT03690323|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
218966916|NCT03690323|DRUG|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
218966917|NCT03690323|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
218966918|NCT04186481|DEVICE|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
219063621|NCT06635018|OTHER|Circulation constriction|The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
219656525|NCT06254326|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
219656526|NCT06254326|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Participants will receive a single infusion of autologous CD34+ HSCs
219656527|NCT06254326|BIOLOGICAL|TTRNA-xALT|Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
219656528|NCT06254326|DRUG|Td vaccine|All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
219656529|NCT04048655|DRUG|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
219656530|NCT04676412|BIOLOGICAL|Pembrolizumab|IV infusion
219656531|NCT04676412|DRUG|Lenvatinib|oral capsule
219656532|NCT04676412|DRUG|Placebo for lenvatinib|oral capsule
219656533|NCT04697056|DRUG|Imsidolimab|Humanized Monoclonal Antibody
219656534|NCT04697056|BIOLOGICAL|placebo|placebo
219656535|NCT05820087|DEVICE|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
219656536|NCT06459180|BIOLOGICAL|Sacituzumab Tirumotecan|IV infusion
219656537|NCT06459180|DRUG|Pemetrexed|IV infusion
219656538|NCT06459180|BIOLOGICAL|Tisotumab Vedotin|IV infusion
219656539|NCT06459180|DRUG|Topotecan|IV infusion
218966919|NCT01477203|DRUG|Escitalopram|2-4 weeks, 5-10mg, max 20mg
218966920|NCT03862716|DRUG|IDegLira|Dose is titrated to achieve fasting normoglycemia
218966921|NCT03862716|DRUG|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
218966922|NCT03862716|DRUG|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
219063622|NCT06635005|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219063623|NCT06635005|OTHER|Dietary Intervention|Receive the Low-EDIH dietary pattern intervention
219063624|NCT06635005|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
219063625|NCT06635005|BEHAVIORAL|Motivational Interviewing|Undergo motivational interviews
219063626|NCT06635005|OTHER|Nutritional Assessment|Participate in nutrition counseling
219063627|NCT06635005|OTHER|Questionnaire Administration|Ancillary studies
219063628|NCT06635187|DIAGNOSTIC_TEST|Speech and swallowing assessment|This is an observational study in which post-stroke patients will undergo a series of assessments tapping oral-motor and speech functions. Both behavioral and instrumental examinations will be used. Their performance will be captured via an artificial intelligence(AI)-powered mobile health application. The relation between the oral/speech-motor movements captured by the app and their performance as measured via instruments/behavioral means will be investigated.
219063629|NCT06635369|DIAGNOSTIC_TEST|Periodontal Indices|Saliva, serum and periodontal indexes were obtained from patients
219656540|NCT06459180|DRUG|Vinorelbine|IV infusion
219656541|NCT06459180|DRUG|Gemcitabine|IV infusion
219656542|NCT06459180|DRUG|Irinotecan|IV infusion
219656543|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
218966923|NCT03862716|BEHAVIORAL|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
218966924|NCT04980573|OTHER|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
218966925|NCT04980573|OTHER|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
218966926|NCT05497635|DRUG|STSA-1002 Injection|Intravenous injection
218966927|NCT05497635|DRUG|Placebo|Intravenous injection
218966928|NCT02280473|DRUG|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
219656544|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
218966929|NCT02280473|DRUG|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
218966930|NCT01469104|OTHER|3 day fast|Subjects will fast for 72 hours
218966931|NCT01469104|OTHER|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
218966932|NCT05529940|DRUG|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
219656545|NCT06645366|DEVICE|Treatment with BTL-785F|Three (3) treatment sessions will be applied to the subjects' face and neck using the BTL-785F system equipped with the BTL-785-4-4 tip on BTL-785-4 applicator, lasting from 20 to 60 minutes depending on the size of the treated area. Each treatment will be spaced 2 - 6 weeks apart, after the complete healing of scabs.
219656546|NCT03760835|DRUG|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
219656547|NCT03760835|DRUG|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
219656548|NCT05751044|DRUG|Dasatinib|Oral
219656549|NCT05751044|DRUG|Venetoclax|oral
219656550|NCT05751044|DRUG|Dexamethasone|oral/intervenous
219656551|NCT05751044|DRUG|Cyclophosphamide|intravenous
219656552|NCT05751044|DRUG|Cytarabine|intravenous
219656553|NCT05751044|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
219656554|NCT03945162|COMBINATION_PRODUCT|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
219656555|NCT05904119|DRUG|Lomustine|Oral administration of Lomustine
219656556|NCT05904119|RADIATION|Reirradiation|Given at least 6 months after the end of prior radiotherapy
219656557|NCT06193954|DEVICE|VasoStar guidewire system|The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a wire with an electromagnetic source.
219656558|NCT04064359|DRUG|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
219656559|NCT06630234|DRUG|DCC-3009|Administered orally
219656561|NCT03819296|OTHER|Best Practice|Receive standard of care
219656562|NCT03819296|OTHER|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
219656563|NCT03819296|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
219656564|NCT03819296|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
218966933|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
219656565|NCT03819296|BIOLOGICAL|Infliximab|Given intravenously (IV)
219656566|NCT03819296|OTHER|Laboratory Biomarker Analysis|Ancillary studies
219656567|NCT03819296|DRUG|Prednisone|Given orally
219656568|NCT03819296|BIOLOGICAL|Vedolizumab|Given IV
219656569|NCT05558397|DEVICE|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
219656570|NCT05558397|DRUG|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
219656571|NCT05989997|DRUG|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
219656572|NCT03260491|DRUG|HER3-DXd (FL-DP)|HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
219656573|NCT03260491|DRUG|HER3-DXd (CTM-1 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
219656574|NCT03260491|DRUG|HER3-DXd (CTM-3 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
219656575|NCT03729544|BEHAVIORAL|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
219656576|NCT04609839|OTHER|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
219656577|NCT04590872|BIOLOGICAL|Tolerogenic Dendritic Cell Vaccine|PIpepTolDCs
219656578|NCT06800248|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
218966934|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
219656579|NCT06800248|DRUG|Mebendazole 100 MG|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
219656580|NCT06800248|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
219656581|NCT06800248|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
219656582|NCT06797531|DRUG|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib will be based solely on clinical judgement.
219656583|NCT04162353|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
218966935|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
219656584|NCT05599984|DRUG|ABBV-706|Intravenous (IV) Infusion
219656585|NCT05599984|DRUG|Cisplatin|Intravenous infusion
219656586|NCT05599984|DRUG|Budigalimab|IV Infusion
219656587|NCT05599984|DRUG|Carboplatin|Intravenous infusion
219656588|NCT05204147|DRUG|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
219656589|NCT05204147|PROCEDURE|Biospecimen Collection|Correlative studies
219656590|NCT04210349|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
219656591|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
219656592|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
218966936|NCT01858311|DIETARY_SUPPLEMENT|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
218966937|NCT01858311|OTHER|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
218966938|NCT03583515|BEHAVIORAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
218966939|NCT03583515|BEHAVIORAL|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
218966940|NCT04598464|OTHER|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
219656593|NCT04089189|DRUG|IMP4297|IMP4297 100mg PO QD
219656594|NCT03312595|DEVICE|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
219656595|NCT06507618|DRUG|Tamoxifen, Letrozole, Anastrozole, or Exemestane|Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
219656596|NCT03657394|OTHER|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
219656597|NCT06522854|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
219656598|NCT06522854|DRUG|Placebo Oral Tablet|Placebo tablet given orally every eight hours up to three times while mother is in labor
219656599|NCT04439357|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219656600|NCT04765722|DRUG|Mepolizumab|Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
219656601|NCT04765722|DRUG|Normal Saline|Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
219063630|NCT06635083|OTHER|Telerehabilitation|A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
219656602|NCT06244771|DRUG|FMC-376|Oral Capsule
219656603|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
219656604|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
219656605|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
219656606|NCT05502237|DRUG|Zimberelimab|Administered intravenously
219656607|NCT05502237|DRUG|Domvanalimab|Administered intravenously
219656608|NCT05502237|DRUG|Pembrolizumab|Administered intravenously
219656609|NCT05502237|DRUG|Carboplatin|Administered intravenously
219656610|NCT05502237|DRUG|Cisplatin|Administered intravenously
218966941|NCT00749554|DEVICE|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
218966942|NCT00749554|DEVICE|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
219063631|NCT06636305|BEHAVIORAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
219063632|NCT01559402|PROCEDURE|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
219208119|NCT04782830|DEVICE|Accelerometer|A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
219656611|NCT05502237|DRUG|Paclitaxel|Administered intravenously
219656612|NCT05502237|DRUG|Nab-paclitaxel|Administered intravenously
219656613|NCT05502237|DRUG|Pemetrexed|Administered intravenously
219656614|NCT03859063|BEHAVIORAL|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
219656615|NCT03859063|BEHAVIORAL|Control|Community based follow-up as usual
219656616|NCT05991323|DRUG|Dupilumab|Injection solution; subcutaneous
219656617|NCT04537416|OTHER|No intervention|No intervention
219656618|NCT05906836|DRUG|Rosuvastatin|Administered orally.
219656619|NCT05906836|DRUG|Selpercatinib|Administered orally.
219656620|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
219656621|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
219656622|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
219656623|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
218966943|NCT06380829|OTHER|Questionnaire|Self-Care Assessment Scale for Children with CP aged 3-6 years - Parent Form (SPÇÖS-EF): A draft scale named SPÇÖS-EF was prepared by the researchers, using the literature, to determine the self-care status of children with cerebral palsy aged 3-6.
218966944|NCT01497327|DRUG|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
218966945|NCT01497327|DRUG|PSI-7977|PSI-7977 400mg QD for seven days
218966946|NCT01484054|DEVICE|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
218966947|NCT01484054|DEVICE|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
218966948|NCT05360368|DRUG|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
218966949|NCT04461249|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
218966950|NCT04461249|DRUG|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
219063633|NCT01559402|PROCEDURE|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
219063634|NCT01559402|PROCEDURE|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
219063635|NCT06634550|OTHER|Mulligan technique|The participants will receive Mulligan technique (modified SNAGs) (10 rep. / 3 sets with 5 min rest in between) for 30 minutes, 3 sessions / week in addition to lifestyle modification advice for 4 weeks.
219656624|NCT03672318|DRUG|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days."
219656625|NCT04109131|OTHER|Samples collection: Plasma|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
219656626|NCT04109131|OTHER|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
219656627|NCT04109131|OTHER|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
218966951|NCT04461249|DRUG|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
218966952|NCT04749511|BEHAVIORAL|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
218966953|NCT02163122|PROCEDURE|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
218966954|NCT02163122|OTHER|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
218966955|NCT02163122|BIOLOGICAL|Cat allergen (FelD1)|
218966956|NCT02632643|BEHAVIORAL|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
218966957|NCT01610271|DEVICE|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
218966958|NCT04968379|DRUG|Ferric carboxymaltose|Intravenous
218966959|NCT03860142|BEHAVIORAL|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
218966960|NCT03660631|BEHAVIORAL|CVRS Intervention|"1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider"
219063636|NCT06634550|OTHER|Core stability exercise|The participants will perform core stability exercises (spinus multifiduse ex, diaphragmatic strengthening ex, frontal plank, pelvic floor ex,) 3 sessions / week for 30 min each session in addition to lifestyle modification advice for 4 weeks
219063637|NCT06634550|OTHER|Lifestyle modification advice|The participants will receive lifestyle modification advice only for 4 weeks
219063638|NCT00797667|DRUG|Telcagepant 140 mg|
219063639|NCT00797667|DRUG|Telcagepant 280 mg|
219063640|NCT00797667|DRUG|140 mg telcagepant placebo|
219063641|NCT00797667|DRUG|280 mg telcagepant placebo|
219063642|NCT05085600|OTHER|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
219208120|NCT04782830|DRUG|placebo pill|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
219208121|NCT04782830|DRUG|Midodrine or atomoxetine pill|Either midodrine or atomoxetine at their regular dose.
218966961|NCT06132399|DEVICE|META QUEST 3 virtual reality glasses|The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
218966962|NCT06132399|DEVICE|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)|This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
218966963|NCT06132399|OTHER|Usual care|The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
219656628|NCT04109131|OTHER|Brain MRI|"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
219656629|NCT04109131|OTHER|Samples collection: Serum|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
219656630|NCT04281199|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219656631|NCT04281199|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219656632|NCT04281199|RADIATION|Tomotherapy|Undergo IMRT with tomotherapy
219656633|NCT04281199|RADIATION|Total-Body Irradiation|Undergo TBI
219656634|NCT04281199|RADIATION|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
219656635|NCT04728516|DRUG|Vonoprazan-based dual eradication therapy for two weeks|Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.
219656636|NCT04728516|DRUG|amoxicillin|amoxicillin
219656637|NCT04728516|DRUG|Pantoprazole|Pantoprazole
219656638|NCT04227028|BIOLOGICAL|Bevacizumab|Given IV
219656639|NCT04227028|DRUG|Brigatinib|Given PO
219656640|NCT04107038|PROCEDURE|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
219656641|NCT04107038|PROCEDURE|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
219656642|NCT04801290|PROCEDURE|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
219656643|NCT06103877|BIOLOGICAL|AZD1163|"In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1.~In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15."
219656644|NCT06103877|OTHER|Placebo|"In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1.~In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15."
219656645|NCT05691504|PROCEDURE|Biopsy Procedure|Undergo biopsy
219656646|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219656647|NCT05691504|DRUG|Cobimetinib|Given PO
219656648|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
219656649|NCT05691504|PROCEDURE|Echocardiography Test|Undergo ECHO
219656650|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219656651|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219656652|NCT05691504|DRUG|Pelcitoclax|Given IV
219656653|NCT02542293|BIOLOGICAL|Durvalumab +Tremelimumab|
219656654|NCT02542293|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
219656655|NCT02542293|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
219656656|NCT02542293|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
219656657|NCT02542293|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
219656658|NCT02542293|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
219656659|NCT06196008|OTHER|Educational Intervention|Attend telephone-based coaching sessions
219656660|NCT06196008|OTHER|Educational Intervention|Receive written educational materials on physical activity and standard preoperative care
219656661|NCT06196008|OTHER|Exercise Intervention|Receive a personalized physical activity program, set fitness goals
219656662|NCT06196008|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
219656663|NCT06196008|OTHER|Physical Performance Testing|Ancillary studies
219656664|NCT06196008|OTHER|Quality-of-Life Assessment|Ancillary studies
219656665|NCT06196008|OTHER|Questionnaire Administration|Ancillary studies
219656666|NCT03297606|DRUG|Olaparib|300mg taken twice daily
219656667|NCT03297606|DRUG|Dasatinib|100mg administered orally once daily
219656668|NCT03297606|DRUG|Nivolumab plus Ipilimumab|"* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
219656669|NCT03297606|DRUG|Axitinib|5mg orally twice daily
219656670|NCT03297606|DRUG|Bosutinib|500mg orally once daily
219656671|NCT03297606|DRUG|Crizotinib|250mg orally twice daily
219656672|NCT03297606|DRUG|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
219656673|NCT03297606|DRUG|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
219656674|NCT03297606|DRUG|Temsirolimus|25mg infused over a 30-60 minute period once a week
219656675|NCT03297606|DRUG|Erlotinib|150mg orally, once daily
219656676|NCT03297606|DRUG|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
218966964|NCT04878887|PROCEDURE|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
219656677|NCT03297606|DRUG|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
219656678|NCT03297606|DRUG|Vismodegib|150mg taken orally, once daily
219656679|NCT03297606|DRUG|Tucatinib|300mg taken orally, twice daily
219656680|NCT04044534|DRUG|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
219656681|NCT04044534|DRUG|Placebo|Subjects in this arm will receive placebo.
219656682|NCT04529850|DRUG|Drug: GC4419|GC4419 60 Minute Infusion
219656683|NCT04529850|RADIATION|Intensity-modulated radiation therapy (IMRT)|2.0 to 2.2 Gy daily over 7 weeks
219656684|NCT04529850|DRUG|Cisplatin|100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
219656685|NCT00928655|DRUG|acetazolamide|acetazolamide 250mg 1/0/2
219656686|NCT00928655|PROCEDURE|nocturnal continuous positive airway pressure|continuous positive airway pressure
219656687|NCT00928655|DRUG|placebo|placebo capsules
219656688|NCT06553729|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
219656689|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
219656690|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo.
219656691|NCT06553729|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
219656692|NCT06202625|DRUG|avatrombopag|The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
219656693|NCT06202625|DRUG|Placebo|The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
219656694|NCT04604964|OTHER|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
219656695|NCT00383682|DRUG|morphine and mexiletine|
219656696|NCT01534806|DRUG|Ketorolac|Ketorolac(0.5mg/kg) IV push
219656697|NCT01534806|DRUG|Placebo|Sodium Chloride 0.9% - 10 mL IV push
219656698|NCT03529344|DIETARY_SUPPLEMENT|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
218966965|NCT00364130|DEVICE|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
218966966|NCT00364130|DEVICE|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
218966967|NCT05751096|DEVICE|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
218966968|NCT05751096|DEVICE|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
218966969|NCT05777018|PROCEDURE|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
218966970|NCT05777018|PROCEDURE|ultrasound-guided recruitment maneuvers|"* Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
218966971|NCT04448873|DRUG|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
219656699|NCT03529344|DIETARY_SUPPLEMENT|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
219656700|NCT04577222|PROCEDURE|Technical modification during radical prostatectomy|Covering the NVB with fat
219656701|NCT02697565|BEHAVIORAL|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
219656702|NCT02697565|BEHAVIORAL|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
219656703|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
219656704|NCT05673096|BEHAVIORAL|MAU|Management as usual
219656705|NCT00919997|GENETIC|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
219656706|NCT00919997|GENETIC|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
219656707|NCT00919997|OTHER|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
219208122|NCT06435845|DRUG|Anti-(integrin beta-3) human monoclonal antibody|human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
219208123|NCT05708495|OTHER|posterior ilium mobilization|the therapist will mobilize the innominate on the affected side posteriorly
219656708|NCT00919997|OTHER|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
219656709|NCT00919997|OTHER|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
219656710|NCT00919997|PROCEDURE|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
219656711|NCT01451242|OTHER|no intervention is made|no intervention is made
219656712|NCT02553707|DRUG|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
219656713|NCT00480493|BEHAVIORAL|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
219656714|NCT05958745|BEHAVIORAL|Aerobic Exercise|Aerobic exercise training Program
219656715|NCT05958745|BEHAVIORAL|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
219656716|NCT00568360|DEVICE|Oximeter|
219656717|NCT03747302|OTHER|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
219656718|NCT03747302|OTHER|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
219656719|NCT04375501|OTHER|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
219656720|NCT04160572|BEHAVIORAL|Morning sleep schedule|sleep right after night shifts
219656721|NCT04160572|BEHAVIORAL|Evening sleep schedule|sleep before night shifts
219656722|NCT05123469|DEVICE|Electroencephalography|Simultaneous recording of electroencephalogram by conventional EEG device and the Zeto EEG device
219656723|NCT05411094|PROCEDURE|Biopsy Procedure|Undergo biopsy
219656724|NCT05411094|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
219656725|NCT05411094|PROCEDURE|Computed Tomography|Undergo CT scan
218966972|NCT02809521|OTHER|Activity Liking|
219656726|NCT05411094|BIOLOGICAL|Durvalumab|Given IV
219656727|NCT05411094|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218966973|NCT03207334|DRUG|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
219208124|NCT05708495|OTHER|strengthening and stretching exercises|the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
219208125|NCT03248492|DRUG|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
219208126|NCT03767335|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
219208127|NCT03767335|DRUG|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
219656728|NCT05411094|DRUG|Olaparib|Given PO
218966974|NCT03207334|DRUG|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
218966975|NCT03310320|DRUG|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
218966976|NCT03310320|DRUG|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
218966977|NCT05129891|DRUG|Semaglutide D|Tablet given orally
218966978|NCT05129891|DRUG|Semaglutide G|Tablet given orally
219208128|NCT03767335|DRUG|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
219208129|NCT05740241|OTHER|Elderly|A group of participants with physical activity (protocolized)
219208130|NCT03705390|DRUG|ILB®|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
219656729|NCT03769675|DEVICE|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
219656730|NCT01032070|DRUG|erlotinib|oral
219656731|NCT01032070|DRUG|etoposide|oral
219656732|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
219656733|NCT04306887|DRUG|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
219656734|NCT00738062|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219656735|NCT00738062|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219656736|NCT00426660|DRUG|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
219656737|NCT02064465|DRUG|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
219656738|NCT02064465|DRUG|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
219656739|NCT06032520|BEHAVIORAL|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
219656740|NCT00791830|DRUG|Irbesartan|Tablets, 300 mg \* 1 daily, 1 year
219656741|NCT00791830|DRUG|Placebo matching irbesartan 150 mg|Tablets, 300 mg \* 1 daily, 1 year
219656742|NCT03862768|PROCEDURE|surgery|Surgery requires at least removal of all drug-resistant lesions.
219656743|NCT03862768|DRUG|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
219656744|NCT03862768|DRUG|Imatinib escalation|Imatinib 600 MG/d
219656745|NCT03862768|DRUG|Sunitinib|Sunitinib 37.5 MG/d
219656746|NCT06731569|DEVICE|Advanced intelligence drill|"The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included."
219656747|NCT06731569|DEVICE|Traditional rotary instrument|"Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone."
219656748|NCT05763368|DIAGNOSTIC_TEST|Clinical tests and proprioception evaluation|Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
219656749|NCT06214702|DIAGNOSTIC_TEST|ELISA|ELISA estimation of PLGF, sFlt-1 and Serpin C
219656750|NCT05839184|DEVICE|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
219656751|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
218966979|NCT05129891|DRUG|Semaglutide H|Tablet given orally
219063643|NCT05085600|OTHER|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
219063644|NCT01023100|DRUG|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
219208131|NCT04832100|DRUG|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
219208132|NCT05345561|OTHER|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
219656752|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
218966980|NCT05129891|DRUG|Semaglutide I|Tablet given orally
218966981|NCT05129891|DRUG|NNC0385-0434 B|Tablet given orally
218966982|NCT05129891|DRUG|NNC0385-0434 C|Tablet given orally
218966983|NCT05129891|DRUG|NNC0385-0434 D|Tablet given orally
218966984|NCT05129891|DRUG|NNC0385-0434 E|Tablet given orally
218966985|NCT04526327|OTHER|exercise|the combination of aerobic and resistive exercise, three time a week
218966986|NCT02789332|DRUG|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
218966987|NCT02789332|DRUG|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
219063645|NCT03249038|OTHER|Measurement of external blood loss|
219063646|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
219063647|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
219656753|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
219656754|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
219656755|NCT04056000|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine, 60 minutes before exercise
219656756|NCT04056000|DIETARY_SUPPLEMENT|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
219656757|NCT04056000|BEHAVIORAL|60-minutes of steady state exercise|See intervention name
218966988|NCT02789332|DRUG|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
218966989|NCT02789332|PROCEDURE|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
218966990|NCT02789332|OTHER|Stratification|Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
218966991|NCT05281601|DRUG|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
219063648|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
219656758|NCT02645552|DRUG|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
219656759|NCT02645552|OTHER|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
219656760|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
219656761|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
219656762|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
219656763|NCT06498089|DRUG|Prednisone|This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.
219656764|NCT06498089|DRUG|Methotrexate|This drug will be used in the traditional arm. A dose of 15mg per week will be used.
218966992|NCT01145612|DRUG|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
218966993|NCT01145612|DRUG|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
218966994|NCT03810820|DEVICE|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
218966995|NCT00586846|DRUG|Cisplatin|Cisplatin 120 mg/m\^2
218966996|NCT00586846|DRUG|Doxorubicin|75mg/m\^2
219063649|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
219063650|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
219063651|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
219656765|NCT06498089|DRUG|Tocilizumab|This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).
219656766|NCT06498089|DRUG|Tofacitinib|This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).
219656767|NCT06498089|DRUG|Adalimumab|This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
219656768|NCT00199329|DRUG|ondansetron adding in PCA|
219656769|NCT04858594|OTHER|Planned Chemotherapy|standard oncologic supportive care including antibiotic prophylaxis
219656770|NCT00156039|BEHAVIORAL|Follow-up Strategy for Breast Cancer|
219656771|NCT00112255|BEHAVIORAL|Practice nurse-led partner notification|
219656772|NCT00112255|BEHAVIORAL|Referral to specialist genitourinary clinic|
219656773|NCT05055934|DRUG|SHR-1314 injection|SHR-1314 injection
219656774|NCT05055934|DRUG|placebo|placebo
219656775|NCT06380803|OTHER|A educational program|A educational program using cadaver or porcine models for robotic brest surgery
219656776|NCT00894790|DRUG|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
219656777|NCT00894790|DRUG|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
219656778|NCT03005457|BEHAVIORAL|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
219656779|NCT02555124|DRUG|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
219063652|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
218966997|NCT00586846|DRUG|Methotrexate|Methotrexate 12g/m\^2
219208133|NCT06106191|BEHAVIORAL|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
219656780|NCT02555124|DRUG|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
219656781|NCT02555124|DRUG|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
218966998|NCT00626054|DRUG|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
218966999|NCT00626054|DRUG|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
218967000|NCT01954732|DRUG|metformin hydrochloride|Given PO
218967001|NCT01954732|OTHER|pharmacological study|Correlative studies
219063653|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
219063654|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
219063655|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
219063656|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
219208134|NCT06106191|OTHER|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
219208135|NCT06106191|OTHER|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
219208136|NCT05116462|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
219208137|NCT05116462|DRUG|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
219656782|NCT02555124|DRUG|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
219656783|NCT04130048|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
219656784|NCT02073318|OTHER|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
219656785|NCT02073318|OTHER|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
219656786|NCT02240303|PROCEDURE|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
218967002|NCT00069966|BIOLOGICAL|filgrastim|
218967003|NCT00069966|BIOLOGICAL|rituximab|
218967004|NCT00069966|DRUG|cisplatin|
218967005|NCT00069966|DRUG|cytarabine|
218967006|NCT00069966|DRUG|methylprednisolone|
218967007|NCT00069966|DRUG|pixantrone dimaleate|
218967008|NCT00069966|PROCEDURE|autologous bone marrow transplantation|
218967009|NCT00069966|PROCEDURE|peripheral blood stem cell transplantation|
218967010|NCT00519298|DRUG|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
218967011|NCT00519298|OTHER|placebo|placebo
218967012|NCT00519298|DRUG|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
219063657|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
219063658|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
219063659|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
219063660|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
219063661|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
219063662|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
219063663|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
219063664|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
219063665|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
219208138|NCT05116462|DRUG|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
219208139|NCT05116462|DRUG|Sintilimab|200 mg D1 IV Q3W
219208140|NCT05116462|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
219208141|NCT05116462|DRUG|Nab paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
219656787|NCT02240303|PROCEDURE|Physical Performance|Participants in both groups will have a Physical Performance test.
219656788|NCT02240303|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
219656789|NCT02240303|PROCEDURE|Blood Sample|Participants in both groups will have blood samples taken.
219656790|NCT02766452|BEHAVIORAL|"You and your child in the recovery room DVD"|
219656791|NCT02766452|BEHAVIORAL|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
219656792|NCT05366218|BIOLOGICAL|Tafasitamab|Antibody vaccination
219656793|NCT04365478|PROCEDURE|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
219656794|NCT04365478|PROCEDURE|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
219656795|NCT04414189|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis
218967013|NCT00715923|OTHER|Modified consent form|modified consent form used
218967014|NCT00715923|OTHER|Standard consent form|standard consent form used
218967015|NCT01571024|DRUG|BKM120|BKM120 40 mg, orally, once daily.
218967016|NCT01571024|DRUG|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
218967017|NCT01328171|DRUG|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
218967018|NCT01328171|DRUG|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
218967019|NCT06011031|DEVICE|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
218967020|NCT06011031|DEVICE|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
218967021|NCT06288113|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218967022|NCT06288113|PROCEDURE|Computed Tomography|Undergo PET/CT and SPECT/CT
218967023|NCT06288113|OTHER|Gallium Ga 68 Gozetotide|Given IV
218967024|NCT06288113|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
218967025|NCT06288113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218967026|NCT06288113|OTHER|Questionnaire Administration|Ancillary studies
218967027|NCT06288113|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
218967028|NCT04408131|BIOLOGICAL|Blood sample|virological test
218967029|NCT04408131|BIOLOGICAL|Blood sample|serological test
218967030|NCT01110655|OTHER|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
219063666|NCT04802733|BIOLOGICAL|MSK-DA01|MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
219063667|NCT04802733|DEVICE|MSK-DA01 Cell Delivery Device|A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
219063668|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
219063669|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
219208142|NCT05116462|DRUG|Placebo|20 ml D1 IV Q3W
219656796|NCT01217125|DRUG|Sirolimus|plasma levels between 4 and 8
219656797|NCT01846468|DRUG|LHW090|1 mg, 12.5 mg, 100 mg capsules
218967031|NCT01110655|OTHER|Oral hypertonic saline|Oral 100mL bolus of 3% saline
219656798|NCT01846468|DRUG|Placebo|Matching placebo capsules
218967032|NCT02701920|DEVICE|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
218967033|NCT02701920|DEVICE|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
218967034|NCT02701920|DEVICE|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
219656799|NCT01432275|DEVICE|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
218967035|NCT02701920|DEVICE|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
218967036|NCT02701920|OTHER|parental feedback|Questionnaire
218967037|NCT02701920|OTHER|healthcare provider feedback|Questionnaire
218967038|NCT00410202|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
218967039|NCT00410202|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily
218967040|NCT00410202|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
218967041|NCT00410202|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
218967042|NCT00773916|DRUG|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
218967043|NCT02653027|DRUG|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
219656800|NCT01432275|DEVICE|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
219656801|NCT01432275|DEVICE|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
219656802|NCT03516006|DRUG|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
219656803|NCT03516006|DRUG|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
219656804|NCT01935700|DRUG|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
219656805|NCT03030885|DRUG|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
219656806|NCT00316407|DRUG|lapatinib (GW572016)|1000 mg po qd
219656807|NCT00316407|DRUG|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
218967044|NCT02653027|OTHER|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
218967045|NCT05314088|BEHAVIORAL|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
219656808|NCT00316407|DRUG|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
219656809|NCT04471571|OTHER|Resin infiltration and microabrasion for MIH-affected incisors|MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
219656810|NCT04471571|OTHER|Resin infiltration for MIH-affected incisors|MIH-affected incisors will be treated with resin infiltration alone
219656811|NCT06441695|DIETARY_SUPPLEMENT|xumXR extended release caffeine|proprietary capsule for extended release of caffeine
219656812|NCT06441695|DIETARY_SUPPLEMENT|immediate release caffeine|immediate release caffeine capsule
219656813|NCT05732701|OTHER|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)"
219656814|NCT05732701|OTHER|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
219656815|NCT02292186|DRUG|Revusiran (ALN-TTRSC)|
219656816|NCT05406505|DRUG|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
219656817|NCT05406505|OTHER|Placebo|patients will receive placebo and standard care.
219656818|NCT04658524|DIAGNOSTIC_TEST|Thyroid function|laboratorial thyroid tests
218967046|NCT05314088|BEHAVIORAL|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
218967047|NCT01482351|BEHAVIORAL|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
219063670|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
219656819|NCT06052540|DIETARY_SUPPLEMENT|Probiotic supplement|"* Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~* Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
219656820|NCT06052540|DIETARY_SUPPLEMENT|Placebo|"* Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~* Stick: Maltodextrin."
219656821|NCT06331195|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol.
219656822|NCT06331195|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil.
219656823|NCT06331195|DIETARY_SUPPLEMENT|Phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
219656824|NCT06331195|DIETARY_SUPPLEMENT|Krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
219656825|NCT07119229|DEVICE|Implantable Artificial Bronchus|The Implantable Artificial Bronchus (IAB) is a tapered, flexible and fenestrated polymer-based airway stent that is implanted bronchoscopically using a proprietary delivery system into diseased lungs of patients with emphysema.
219656826|NCT05020899|BEHAVIORAL|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
219656827|NCT05020899|OTHER|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
219656828|NCT05020899|OTHER|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
219656829|NCT05020899|OTHER|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
219656830|NCT04314375|DRUG|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
219656831|NCT04314375|DRUG|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
219656832|NCT04314375|DRUG|Placebo|Matching placebo once daily.
219656833|NCT00055861|BIOLOGICAL|bevacizumab|Given IV
219656834|NCT00055861|DRUG|docetaxel|Given IV
218967048|NCT01482351|BEHAVIORAL|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
218967049|NCT00107367|PROCEDURE|conventional surgery|
218967050|NCT00107367|RADIATION|intraoperative radiation therapy|
218967051|NCT00144027|BEHAVIORAL|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
218967052|NCT06197399|PROCEDURE|Detethering Surgery|Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
218967053|NCT06197399|PROCEDURE|Spinal Column Shortening Surgery|"Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols."
218967054|NCT04624438|OTHER|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
219208143|NCT06269432|DRUG|Precision Antiplatelet Therapy Trial Group|Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
219656835|NCT00055861|OTHER|laboratory biomarker analysis|Correlative studies
219656836|NCT03433313|DRUG|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
219656837|NCT03433313|DRUG|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
219656838|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
219656839|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
219656840|NCT02124759|DRUG|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
219656841|NCT02124759|DRUG|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
219656842|NCT02124759|DRUG|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
219656843|NCT02124759|OTHER|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
219656844|NCT02124759|OTHER|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
219656845|NCT00693342|BIOLOGICAL|immunological adjuvant OPT-821|Given subcutaneously
219656846|NCT00693342|BIOLOGICAL|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
219656847|NCT05014269|PROCEDURE|Phacoemulsification in eyes with corneal opacities|senile cataract extraction using lens emulsification under the slit illuimnation of the surgical microscope
219656848|NCT00006486|DRUG|carboxyamidotriazole|Given orally
219656849|NCT00006486|OTHER|placebo|Given orally
219656850|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
219656851|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
219656852|NCT05262868|DEVICE|rTMS|The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
219656853|NCT03860116|BEHAVIORAL|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
219656854|NCT03860116|BEHAVIORAL|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
219656855|NCT04907500|DEVICE|Intraocular lens|Cataract surgery
219656856|NCT03648554|DRUG|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
219656857|NCT03648554|OTHER|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
218967055|NCT04624438|OTHER|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
219656858|NCT00822575|DEVICE|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
219656859|NCT01068626|DRUG|Rosuvastatin|10 mg once daily
219656860|NCT01068626|DRUG|Placebo for rosuvastatin|once daily
219656861|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
219656862|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
218967056|NCT04624438|OTHER|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
219063671|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
219656863|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219656864|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219656865|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219656866|NCT03342131|OTHER|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
219656867|NCT01785849|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
219656868|NCT01785849|DRUG|Placebo|Administered intravenously (IV) three times per week.
218967057|NCT02521571|BEHAVIORAL|Resiliance Alliance|"The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
219656869|NCT01110213|BEHAVIORAL|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
219656870|NCT01110213|BEHAVIORAL|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
219656871|NCT05461937|BEHAVIORAL|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
219656872|NCT05461937|BEHAVIORAL|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
219656873|NCT05118061|DIAGNOSTIC_TEST|Ketone|compare diagnostic tests to reference methods
219656874|NCT05929248|DRUG|Telitacicept|160mg once a week for 48 weeks
218967058|NCT02521571|BEHAVIORAL|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
219063672|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
219656875|NCT05929248|DRUG|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
219656876|NCT05929248|DRUG|Placebo|Used once a week in combination with standard treatment
219063673|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
219208144|NCT06269432|DRUG|Traditional Antiplatelet Therapy Control Group|No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
219208145|NCT06213493|DIAGNOSTIC_TEST|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
219656877|NCT06288204|DIETARY_SUPPLEMENT|Propolis associated with Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis together, for 2 months.
219656878|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 1 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
219656879|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
219208146|NCT06730893|OTHER|SDM protocol|Card news and Videos related to general knowledge and treatment of low-risk thyroid cancer
219656880|NCT04958759|OTHER|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
219656881|NCT04958759|OTHER|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
219656882|NCT04958759|OTHER|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
219656883|NCT05452616|OTHER|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
219656884|NCT05452616|OTHER|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
219656885|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
219656886|NCT01110785|BIOLOGICAL|panitumumab|
219656887|NCT01110785|DRUG|simvastatin|
219656888|NCT01110785|OTHER|laboratory biomarker analysis|
219656889|NCT06853886|OTHER|blood sample HBV patient|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 2 dry tube per patient"
219656890|NCT06853886|OTHER|blood sample healthy volunteers|"* 3 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 2 dry tube"
218967059|NCT02474888|OTHER|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
218967060|NCT03813771|DRUG|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
218967061|NCT03813771|DRUG|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
218967062|NCT03813771|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
218967063|NCT03813771|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
218967064|NCT02761928|OTHER|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
218967065|NCT00636883|DRUG|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
218967066|NCT03954652|GENETIC|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
218967067|NCT04597918|DRUG|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
218967068|NCT00395538|DRUG|PTH 1-34|Given twice daily by subcutaneous
219656891|NCT05551273|DRUG|Selgantolimod|1.5 mg tablet
219656892|NCT05551273|DRUG|Placebo|Matching placebo tablet
219656893|NCT04340843|DRUG|Belinostat|Given IV
219656894|NCT04340843|PROCEDURE|Biopsy Procedure|Undergo biopsy
219656895|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219656896|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
219656897|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
219208147|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
219656898|NCT04340843|DRUG|Guadecitabine|Given SC
219656899|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219656900|NCT04249622|OTHER|Best Practice|Given standard of care pertuzumab-based chemotherapy
219656901|NCT04249622|OTHER|Questionnaire Administration|Ancillary studies
219656902|NCT04249622|DRUG|Rifaximin|Given PO
218967069|NCT02240173|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
218967070|NCT02240173|DRUG|Haloperidol|Conventional drug normally used for psychotic problems
218967071|NCT02752555|OTHER|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
218967072|NCT05572554|OTHER|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
218967073|NCT04299893|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
219656903|NCT06654466|DEVICE|Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.|The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
219656904|NCT03075202|DEVICE|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
219656905|NCT06620549|DIAGNOSTIC_TEST|gastric ultrasonograppy|Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (\>1,5ml/Kg) and the last option is solid food in one or both positions.
219656906|NCT00779688|DEVICE|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
219656907|NCT06977568|DRUG|Zilretta|triamcinolone acetonide, extended release injectable suspension
219656908|NCT06977568|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide, Immediate Release (TCA-IR)
219656909|NCT04250298|DIETARY_SUPPLEMENT|sucrosomial iron|oral intake of iron as sachets or capsules
219656910|NCT06241560|DRUG|BI 1015550|BI 1015550
219656911|NCT06241560|DRUG|Pirfenidone|Pirfenidone
219656912|NCT06806995|DRUG|Zidebactam-Cefepime|(1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h)
219656913|NCT06806995|DRUG|Metronidazole|(2) metronidazole 0.5 g IV alone administered over 1 h
218967074|NCT04299893|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
218967075|NCT05511701|BEHAVIORAL|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is \> 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
218967076|NCT05511701|BEHAVIORAL|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is \> 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
218967077|NCT06322329|OTHER|Dynamic MRI|Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
218967078|NCT01074047|DRUG|Azacitidine|75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
218967079|NCT01074047|DRUG|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end"
218967080|NCT06186479|DRUG|Aconite pain oil|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
218967081|NCT06186479|DRUG|Placebo|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
218967082|NCT04094103|DIETARY_SUPPLEMENT|Active strawberry powder|Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
218967083|NCT04094103|DIETARY_SUPPLEMENT|Placebo strawberry powder|Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
218967084|NCT04094103|DIETARY_SUPPLEMENT|Mixed strawberry powder|Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
219656914|NCT06806995|DRUG|FEP-ZID|(3) metronidazole 0.5 g IV over 1 h, followed by ZID-FEP 3g IV over 1 h over 3 treatment periods separated by a 48 h washout period.
219656915|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
219656916|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
219656917|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
219656918|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
219656919|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
219656920|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
219656921|NCT06981936|DRUG|Balance Tablet|Each Balance tablet contains a broad range of vitamins and trace minerals at doses designed to prevent deficiencies (including but not limited to vitamins A, B-complex, C, D, E, K, calcium, iron, zinc, magnesium, selenium, and others, per standard multivitamin composition).
219656922|NCT06981936|DRUG|Control (placebo)|The placebo is an inert pill formulated to be indistinguishable from the Balance tablet in appearance, weight, and taste.
218967085|NCT06267001|DRUG|Atezolizumab|Atezolizumab will be administered IV.
219656923|NCT06983353|DEVICE|transphyseal screw|transphyseal screw in proximal femoral physis
218967086|NCT06267001|DRUG|Tiragolumab|Tiragolumab will be administered IV.
218967087|NCT06267001|DRUG|Placebo|Placebo will be administered IV.
218967088|NCT02145702|OTHER|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
218967089|NCT02145702|PROCEDURE|Standard Care Dialysis|12 weeks of standard of care.
218967090|NCT03160196|OTHER|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
218967091|NCT03160196|OTHER|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
218967092|NCT03894592|OTHER|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
218967093|NCT02186132|DRUG|Atropine 0.6 mg|Atropine 0.6 mg intravenous
218967094|NCT02186132|DRUG|Atropine 1.2 mg|Atropine 1.2 mg intravenous
218967095|NCT04468932|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
218967096|NCT06429761|DRUG|Trastuzumab deruxtecan|IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.
219656924|NCT06811480|OTHER|Conventional Physiotherapy|"Participants in the first group underwent conventional physiotherapy interventions for 6 weeks, 5 days per week. These interventions included Ultrasound (US), Transcutaneous Electrical Nerve Stimulation (TENS), wrist joint range of motion exercises, stretching exercises, and strengthening exercises using Digiflex, Powerweb, and dumbbells. The number of repetitions and sets of the exercises was adjusted based on the patients' conditions, following a progressive approach.~US was applied to the affected wrist for a total of 30 sessions, 5 days a week, once daily, for 6 minutes at an intensity of 1.5 W/cm², using an underwater application method. TENS was administered at a frequency of 100 Hertz for 20 minutes. All participants received manual stretching exercises for wrist flexion, extension, ulnar and radial deviation, supination, and pronation. These stretches were performed by a physiotherapist, with 5 repetitions in each direction, holding the end position for 20 seconds."
219656925|NCT06811480|OTHER|Closed Kinetic Chain Exercise|Participants in the second group received a treatment protocol that included closed kinetic chain exercises (CKCE) in addition to conventional physiotherapy. CKCE exercises were performed with 15 repetitions each and involved stabilizing a ball between the hand and the wall in different arm positions, rolling it in multiple directions. Participants also performed weight-shifting exercises against a wall and on a table, holding positions for 6 seconds. Additionally, in a crawling position, they moved their unaffected arm diagonally on both a firm surface and a cushion.
219656926|NCT03604705|DRUG|APX001|APX001
219656927|NCT06453473|OTHER|TSBR|"The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to maintain moderate-intensity training, corresponding to 64-76% of the predicted maximal heart rate (Borg scale 12-14), including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling."
219656928|NCT06453473|OTHER|PerTSBR|Participants of the intervention group will receive a combination of lateral and medial tilting unannounced perturbations during stage 2 of the TSBR training. This will be provided by roll and pitch angles (tilt) balance perturbations that aim to evoke trunk and arm balance recovery responses.
219656929|NCT06657222|DRUG|TUB-030|A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
219656930|NCT06878807|BEHAVIORAL|eye movement|Participants underwent EM tasks during the first 30 seconds of the extinction phase. All participants in this group experienced identical EM conditions in terms of speed and duration.
219656931|NCT06878807|BEHAVIORAL|TMT-B|Participants performed the Trail Making Test B (TMT-B).
219656932|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
219656933|NCT06592521|DEVICE|OPTI-FREE EXPRESS MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
219656934|NCT06592521|DEVICE|OPTI-FREE PureMoist MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
219656935|NCT06592521|DEVICE|OPTI-FREE REPLENISH MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
219656936|NCT06592521|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
218967097|NCT03041012|DRUG|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
218967098|NCT03041012|DRUG|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
218967099|NCT03041012|DRUG|Antiretrovirals|Combination antiretroviral therapy
218967100|NCT01770587|BEHAVIORAL|Behavioral Insomnia Treatment|
219063674|NCT03293940|PROCEDURE|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
219063675|NCT03293940|PROCEDURE|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
219063676|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
219656937|NCT06158074|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
219656938|NCT06158074|PROCEDURE|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.Patients are administrated by antibiotics peri-operatively to prevent lead site infection.
219656939|NCT06819592|DRUG|Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride|2 grams of Ceftriaxone diluted in \>200ml of 0.9%sodium chloride are administered intravenously once following randomisation
219656940|NCT06819592|DRUG|Placebo comparator - no ceftriaxone|placebo: \>200ml 0.9% sodium chloride given as an intravenous infusion once after randomisation
219656941|NCT06816446|DEVICE|Myopia control spectacle lens|The intervention group will wear specially designed lenses that aim to slow the progression of myopia. Follow-up visits will take place at regular intervals.
219656942|NCT06816446|DEVICE|Single-vision lens|The control group will wear single vision lenses for one year. They will then switch to the myopia control lens for a further year. Follow-up visits will take place at regular intervals.
219656943|NCT04923685|OTHER|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
219656944|NCT05241847|BEHAVIORAL|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
219656945|NCT06683053|DRUG|empagliflozin|Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.
219656946|NCT05548868|DEVICE|E4W mobile app|Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
219656947|NCT05548868|BEHAVIORAL|Standard Care|Patients will receive standard dietary counselling as part of the weight management program.
219656948|NCT00323401|OTHER|Antenatal classes|3 sessions of 3 hours each
219656949|NCT05741853|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
219656950|NCT05741853|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
219656951|NCT02913014|OTHER|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
219656952|NCT01229033|PROCEDURE|Ablation|Ablation of atrial tachycardia
219656953|NCT01229033|PROCEDURE|Cardioversion|Cardioversion of atrial tachycardia
219656954|NCT02966119|DRUG|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
219656955|NCT02233920|DRUG|Ventilat® - metered dose inhaler|
218967101|NCT06575946|DIAGNOSTIC_TEST|Vestibular Hypofunction Group|Demographic information form, vestibular tests, balance tests will be used in the evaluation. The demographic information form includes demographic information (name, surname, gender, smoking, alcohol use, etc.) and clinical conditions (past illnesses and/or surgeries, medications used, whether there is a history of falls, if any, frequency, whether they are afraid of heights and uncomfortable in the dark, etc.). The patients will be diagnosed with videonystagmography (VNG) after the decision of the ENT physician, and their hypofunction levels will be recorded. Vestibular and balance tests will be applied to the patients in the clinical setting. At the end of the study, it will be examined whether there is a relationship between the degree of vestibular hypofunction and the vestibular tests applied in the clinic.
218967102|NCT04059705|BEHAVIORAL|Dual-Task Training|The ThinkFIT intervention will involve two days per week participation in simultaneous cognitive and motor training activities, facilitated by the SMARTFit Multisensory FItness System.
219063677|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
219063678|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
219656956|NCT05036057|OTHER|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
219656957|NCT02252471|BEHAVIORAL|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
218967103|NCT05606874|OTHER|Pre-heating of flowable resin composite used as a pit and fissure sealant.|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
218967104|NCT05606874|OTHER|Conventional resin fissure sealant|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
218967105|NCT00025675|DRUG|gefitinib|
218967106|NCT01069185|PROCEDURE|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
218967107|NCT01069185|PROCEDURE|Routine endotracheal suctioning|Endotracheal suctioning every two hours
218967108|NCT06247527|BEHAVIORAL|Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy|This is a brief transdiagnostic psychological intervention based on the trauma-focused cognitive behavioral therapy (TF-CBT) designed for delivery by non-specialist providers to adolescents and youth with psychological distress
218967109|NCT06247527|BEHAVIORAL|Standard of care|Any intervention, including counseling, provided as a routine intervention at the HIV clinic selected as a control clinic
219656958|NCT06097689|DEVICE|Lab Demo 1.0|"Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)."
219656959|NCT01634659|DEVICE|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
219656960|NCT01634659|DEVICE|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
219656961|NCT05189067|DRUG|Paclitaxel|i.v. 80mg/m\^2
219656962|NCT05189067|DRUG|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
219656963|NCT05189067|DRUG|Docetaxel|i.v. 100mg/m2
219656964|NCT02431806|DRUG|Placebo|Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
219656965|NCT02431806|DRUG|Levomilnacipran|Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
219656966|NCT02431806|DRUG|Fluoxetine|Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
219656967|NCT03627416|DEVICE|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
219656968|NCT06098963|DEVICE|sacral neuromodulation|sacra neuromodulator implantation outcomes
219656969|NCT01185223|DRUG|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
219656970|NCT01185223|DRUG|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
219063679|NCT02201602|DRUG|Gliclazide|
219656971|NCT06624033|OTHER|amino acids kinetics|"After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured."
219656972|NCT01342250|BIOLOGICAL|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
219656973|NCT01342250|BIOLOGICAL|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
219063680|NCT02201602|DRUG|Glibenclamide|
219656974|NCT01342250|BIOLOGICAL|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
219656975|NCT01916603|BEHAVIORAL|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
219063681|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
219063682|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
219063683|NCT02717091|DRUG|FOLFIRINOX|
219656976|NCT05619536|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
219656977|NCT05619536|DRUG|Saline placebo|Sterile normal saline for injection
219656978|NCT02691728|DRUG|LDV/SOF FDC|
219656979|NCT06007963|PROCEDURE|Treatment with impella device.|Impella percutaneous mechanical supported patients will be included after revision to support.
219656980|NCT06588400|DEVICE|AOSEPT Plus and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
219656981|NCT06588400|DEVICE|AOSEPT Plus with HydraGlyde and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
219656982|NCT06588400|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
219656983|NCT06597188|DEVICE|VitaFlow Liberty|All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty
219656984|NCT06597188|DEVICE|Commercially available surgical bioprosthetic valve|All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
219656985|NCT06988371|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and reduced nicotine content cigarettes will be the only available combustible cigarette.
219656986|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored combustible nicotine products will be the only combustible nicotine products available.
219656987|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
219656988|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
219656989|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
219656990|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
219656991|NCT04482075|OTHER|segmental stability training|SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
219656992|NCT04450134|OTHER|Lactose|Placebo: Lactose capsules
218967110|NCT05262231|BEHAVIORAL|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
218967111|NCT04881656|OTHER|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
218967112|NCT06259799|BEHAVIORAL|Smart Water Bottle|Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
218967113|NCT00285207|DRUG|placebo|5 days of 28 day cycle for 2 cycles
219063684|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
219063685|NCT04842955|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
219656993|NCT04450134|DRUG|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
219063686|NCT04842955|DEVICE|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
219063687|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
219063688|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
219063689|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
219656994|NCT04450134|DRUG|Famotidine|H2 receptor antagonist: 40 mg Famotidine
219656995|NCT04450134|OTHER|High-intensity interval training (HIIT)|6 weeks HIIT
219656996|NCT05665140|DRUG|Isatuximab|i.v. Induction Phase (Arm A and B): Induction Cycle 1 10 mg/kg D 1, 8, 15, 22, 29. Induction Cycle 2-3 10 mg/kg D 1, 15, 29 Consolidation Phase (Arm B): Consolidation Cycle 1-3 10 mg/kg D 1, 15, 29 Maintenance Phase (Arm A and B): Maintenance Cycle 1 and subsequent cycles 10 mg/kg D 1, 15, 29
219656997|NCT05665140|DRUG|Lenalidomide|hard capsule for oral use. Induction Phase (Arm A and B): Induction Cycle 1-3 25 mg D1-14, 20-35. Consolidation Phase (Arm B): Consolidation Cycle 1-3 25 mg D1-14, 20-35. Maintenance Phase (Arm A and B): Maintenance Cycle 1-2 10 mg D1-28. Maintenance Cycle 3 and subsequent cycles 15 mg D1-28 if tolerable
219656998|NCT05665140|DRUG|Bortezomib|s.c. injection. Induction Phase (Arm A and B): Induction Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32. Consolidation Phase (Arm B): Consolidation Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32
219656999|NCT05665140|DRUG|Dexamethasone|orally and i.v. Induction Phase (Arm A and B): Induction Cycle 1 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 8, 15, 22 and 29. Induction Cycles 2 and 3 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 15 and 29. Consolidation Phase (Arm B): Consolidation Cycle 1-3 20 mg p.o. on D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. on D1, 15 and 29
219657000|NCT05665140|OTHER|autologous stem cell transplant|autologous stem cell transplant
219657001|NCT06509971|DRUG|QL1706|"The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab."
219657002|NCT06729541|OTHER|Multigenetic Pharmacogenomics-Guided Treatment (MPGT)|In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
219657003|NCT04555655|DIETARY_SUPPLEMENT|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
219657004|NCT04555655|DIETARY_SUPPLEMENT|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
219657005|NCT04555655|OTHER|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
219657006|NCT06995677|DRUG|TYRA-300 60mg|Self-administered 60mg dose Oral tablet(s) given daily
219657007|NCT06995677|DRUG|TYRA-300 50mg|Self-administered 50mg dose Oral tablet(s) given daily
218967114|NCT00285207|DRUG|A007|5 days of 28 day cycle
218967115|NCT05175885|DEVICE|Ex vivo normothermic perfusion|Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
218967116|NCT05175885|DEVICE|Cold preservation|Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
219657008|NCT06995677|DRUG|TYRA-300 Dose TBD|To Be Determined Dose: Self-administered Oral tablet(s) given daily
219657009|NCT04626024|OTHER|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
219657010|NCT04626024|DRUG|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
219657011|NCT06033196|DRUG|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
219657012|NCT06033196|DRUG|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
219657013|NCT01876537|DEVICE|Hardware wound healing|
219657014|NCT01876537|DEVICE|Usual Surgery|
219657015|NCT00398437|BIOLOGICAL|trastuzumab|
219657016|NCT00398437|DRUG|chemotherapy|
219657017|NCT00398437|PROCEDURE|magnetic resonance imaging|
219657018|NCT05614180|PROCEDURE|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
219657019|NCT06948981|BIOLOGICAL|GT719 Injection|GT719 Injection
219657020|NCT01444729|DRUG|Xiapex|Xiapex administration will follow SMPC
219657021|NCT01444729|PROCEDURE|surgery|Non-pharmacological treatment
219657022|NCT02144480|BEHAVIORAL|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
219657023|NCT02144480|BEHAVIORAL|traditional training|usual care: conventional rehabilitation
219657024|NCT06994364|OTHER|Trigger point release|"Ischemic compression technique is based on the application of manual pressure to treat trigger points.~The patient was asked to lie in the supine position on the examination table. The osteopath identified the muscle through deep palpation and movement-based muscle differentiation, then applied 90 seconds of tolerable pressure to the trigger point on both sides."
219657025|NCT06994364|OTHER|Simulation of the intestinal listening technique.|The patient will be asked to lie in a supine position on the treatment table to simulate the listening technique for assessing the mobility and motility of the small intestine without influencing the final results, with the sensory hand placed below the umbilicus.
219657026|NCT03776643|DRUG|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
219657027|NCT06530706|DRUG|Esketamine|Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
218967117|NCT06809621|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
218967118|NCT06809621|DRUG|Insulin aspart|Insulin aspart will be administered subcutaneously.
218967119|NCT06809881|OTHER|olfactory testing, MRI acquisition, clinical assessment|
218967120|NCT07118592|DIETARY_SUPPLEMENT|Low Salt Diet|8 days of diet with low salt content will be given to the study participants
219657028|NCT06530706|DRUG|normal saline|Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
219657029|NCT07001657|PROCEDURE|SPSIP Block|Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.
219657030|NCT07001657|PROCEDURE|PECS II Block|Patients in this group will receive an ultrasound-guided PECS II block with 30 mL of 0.25% bupivacaine hydrochloride (20 mL between the pectoralis minor and serratus anterior muscles, and 10 mL between the pectoralis major and minor muscles), 30 minutes before breast cancer surgery.
219657031|NCT06864806|OTHER|Genetic profile|Filiation analysis between the fetus and his father
218967121|NCT07118592|DIETARY_SUPPLEMENT|High Salt Diet|8 days of diet with high salt content will be given to the study participants
218967122|NCT07118592|DIETARY_SUPPLEMENT|Saline Infusion|2 Liters of normal saline infusion (0.25 ml/kg/min over 2 hours) will be given to the study participants at the end of each study period
218967123|NCT01913587|DEVICE|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
218967124|NCT01913587|PROCEDURE|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
218967125|NCT03620656|DIAGNOSTIC_TEST|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
218967126|NCT06666569|DEVICE|Use of the test for treatment optimization|Intervention cohort, where the clinician will have information on the test results to support decision making on treatment optimization. The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up.
218967127|NCT06683547|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester.
218967128|NCT06683547|DIETARY_SUPPLEMENT|Flavour matched placebo drink (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
218967129|NCT06683547|OTHER|Resistance Exercise|\- 5 sets of 10 repetitions of leg press and 3 sets of 12 repetitions of leg extension/leg curl 'supersets' (1 set of each back to back with no rest in between sets) at 95% of their 10-RM. Between-set rest intervals for the leg exercises will be 60 seconds.
218967130|NCT06691724|OTHER|LLM-based transcription and reporting tool|"The LLM-based transcription and reporting tool works in three steps:~1. The conversation between patient and GP is transcribed to text with a speech-to-text LLM~2. The text is summarized according to the Subjective, Objective, Assessment, Plan (SOAP) rules~3. The SOAP summary is imported in the electronic health record of the GP"
218967131|NCT05063318|DRUG|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
218967132|NCT05063318|DRUG|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
218967133|NCT07017387|BEHAVIORAL|Motivational interviewing based health education|Participants will receive three sessions of face-to-face health education using motivational interviewing techniques through home visits, along with an informational brochure.
218967134|NCT07017387|BEHAVIORAL|Health education|Participants will receive one face-to-face health education session and a brochure, followed by two reminder sessions via phone.
218967135|NCT07024706|DRUG|Acalabrutinib|Acalabrutinib is an orally available cBTKi that inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
218967136|NCT07024706|DRUG|Venetoclax|Venetoclax is an orally bioavailable inhibitor of the anti-apoptotic protein BCL-2
218967137|NCT07026279|DRUG|narmafotinib ascending doses|once daily capsules
218967138|NCT07026279|DRUG|narmafotinib dose comparison|once daily capsules
218967139|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
218967140|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
218967141|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
218967142|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
218967143|NCT06699732|BEHAVIORAL|Mindful Self Compassion Therapy|"Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.~Week 8: Integration - Consolidate skills to maintain self-compassion in daily life."
218967144|NCT06878261|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
218967145|NCT06878261|OTHER|Placebo|Placebo subcutaneous injection
218967146|NCT06928298|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
218967147|NCT07136103|DRUG|ABBV-277|• Intravenous (IV) infusion
218967148|NCT07136103|DRUG|Placebo|• Intravenous (IV) infusion
219063690|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
219657032|NCT03713008|DIAGNOSTIC_TEST|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
219657033|NCT06671925|BEHAVIORAL|Strengthening COnnections to Overcome Pain (SCOOP)|Each week for 7 weeks, SCOOP intervention group participants will watch a brief video on the study website teaching a pain management or social connectedness skill and have a session with a community health worker, where they will receive support with behavioral goal-setting related to pain management and/or social connections. Participants will be screened for unmet social needs and connected to appropriate resources.
219657034|NCT06594562|DIAGNOSTIC_TEST|Telementored eFAST|Ultrasound examination guided in real-time by a remote expert for detecting free fluid.
219657035|NCT06308302|OTHER|Group A (Inspiratory Muscles Training + Aerobic Interval Training)|"Performed Inspiratory muscle training on a breather device (20), (10 inhales with maximum 3-sec hold), 3 sets with a 1-minute interval between each set, for 6 days a week along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40 minutes in 3rd week, 45-60 minutes in 4th week each session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
219657036|NCT06308302|OTHER|Group B (Expiratory Muscles Training +Aerobic Interval Training)|"Performed Expiratory muscle training along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40-45 minutes in 3rd week, 45-60 minutes in 4th week per session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
219657037|NCT04339777|DRUG|Busulfan test dose|0.8 mg/kg IV infusion over 2 hours
219657038|NCT04339777|DRUG|Fludarabine|40 mg/m2 IV infusion over 30 min once daily for 4 days
219657039|NCT04339777|DRUG|Busulfan|"AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6)."
219657040|NCT04339777|DRUG|Alemtuzumab|Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
219657041|NCT04339777|RADIATION|Total body Irradiation|200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
219657042|NCT04339777|PROCEDURE|Allogeneic HSCT|Stem cell transplant
218967149|NCT06941012|OTHER|Blood draw for the laboratory assessment|Participants' clinical histories will be reviewed at T0 (baseline) and T1 (24 months). They will also undergo a clinical assessment at T0 and T1. The assessments will be tailored based on whether the participant belongs to the PD or non-PD group, as outlined below: • MDS-UPDRS + H\&Y: Used to evaluate the neurological domain, applied to the PD group. • BERG: Used to assess balance and performance, applied to both PD and non-PD groups. • CIRS-G: Used to evaluate comorbidities, applied to both PD and non-PD groups. • PD-CRS: Used to assess cognitive function, applied to the PD group. • MMSE (temporal and spatial orientation only): Used to assess cognitive function, applied to both PD and non-PD groups. • PDQ-8: Used to evaluate quality of life, applied to the PD group. • PD-CFRS: Used for functional assessment, applied to the PD group. • GDS: Used to assess depression, applied to both PD and non-PD groups. Blood samples will be collected at T0 and T1, with 20 mL drawn per participant.
218967150|NCT05551052|DIAGNOSTIC_TEST|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
218967151|NCT00511212|DRUG|intravenous immunoglobulin|
218967152|NCT06949098|PROCEDURE|Local Tumor Resection|All enrolled patients will first undergo local tumor resection.
218967153|NCT06949098|RADIATION|Radiotherapy|"Pelvic field irradiation 45Gy in 25 fractions plus Local tumor bed boost 5.4Gy in 3 fractions.~For patients with positive surgical margins after local resection, a radiotherapy boost (pelvic field 45Gy/25 fractions + tumor bed local boost 14.4Gy/8 fractions) can be given."
218967154|NCT06949098|DRUG|Chemotherapy|Concurrent oral capecitabine 825 mg/m² twice daily with radiotherapy
218967155|NCT05498116|DRUG|Montelukast|10mg daily
218967156|NCT05498116|OTHER|Placebo|1 capsule daily
218967157|NCT07150572|PROCEDURE|surgery assisted rapid maxillary expansion|Under general anesthesia, the patients underwent a maxillary expansion procedure, during which the maxillary resistance sites were surgically released
218967158|NCT07149662|DRUG|monoclonal CD-20 antibodies|Treatment with monoclonal CD-20 antibodies 6 months before or during pregnancy
218967159|NCT07149662|DRUG|No Drug|No medication
218967160|NCT07149662|DRUG|Other treatment|Any other immune modulating treatment
218967161|NCT07149870|OTHER|Pain Management Team + Whole Health Coach (PMT-WHC)|"Whole Health Coaching (WHC) begins by completing a Personalized Health Inventory (PHI), where progress is evaluated within 8 dimensions of health and wellness. The PHI culminates in defining personal values and overall goals for health and wellness (i.e., What do you want your health for?). This is used to create goals for a Personal Health Plan. The Plan emphasizes self-management strategies to manage pain. After the Plan is developed, ongoing support is provided from the Coach through 8 coaching sessions over approximately 5 months."
219063691|NCT03916003|DRUG|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
219063692|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
219657043|NCT04339777|DRUG|Tacrolimus (Tacro)|Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
219657044|NCT04339777|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
219657045|NCT04339777|DRUG|Cyclophosphamide (Cytoxan)|Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
219657046|NCT05973019|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
219657047|NCT01277653|DEVICE|tumor maker interval shortly|tumor maker interval every 3 month
219657048|NCT03405389|PROCEDURE|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
219657049|NCT02131818|DRUG|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
219657050|NCT02131818|DRUG|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
219657051|NCT01910987|DRUG|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
219657052|NCT01910987|DRUG|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
219657053|NCT01910987|DRUG|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
219657054|NCT01910987|DRUG|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
219657055|NCT01353690|BIOLOGICAL|AMDC|Cell Treatment
219657056|NCT06662864|OTHER|Patients reported outcomes|Patients reported outcomes were collected via telephone
219657057|NCT06662864|OTHER|questionnaire global Pittsburgh Sleep Quality Index (PSQI)|Patients reported outcomes were collected via telephone
219657058|NCT04446650|DRUG|Fedratinib|Oral
219657059|NCT05260385|DRUG|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
219657060|NCT04251728|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
219657061|NCT04251728|OTHER|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
218967162|NCT07149870|OTHER|Pain Management Team-Usual Care (PMT-UC)|Pain Management Team-Usual Care (PMT-UC) involves working with VA PMTs that includes working with PMTs comply with legislation requiring each medical center to have PMTs with expertise in pain, addiction, behavioral approaches, and rehabilitation approaches. PMTs will conduct multidisciplinary intakes (at least two provider types) with biopsychosocial assessments for all new patients. Follow-up care will be determined by the PMTs based on what is clinically indicated (with recommended minimum medication management follow ups at 1- 3- and 6-months for patients making medication changes).
218967163|NCT07149519|DIETARY_SUPPLEMENT|probiotics - Lactobacillus spp|Group 1: Specific dietary guidance (low-FODMAP diet ) combined with placebo Group 2: Specific dietary guidance (low-FODMAP diet ) combined with probiotic Group 3: Control - Exclusive habitual diet After the 12-week period, we will evaluate the clinical improvement response of pelvic pain
218967164|NCT07150234|DEVICE|Acupuncture|The needles will be inserted in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
218967165|NCT07150234|DEVICE|sham acupuncture|The needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
218967166|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced)"|"Enhanced Standard of Care (Enhanced) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, and SA Starter Packs."
219063693|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
219063694|NCT04236349|GENETIC|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
219063695|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
219063696|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
219657062|NCT04251728|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
219657063|NCT05996640|OTHER|This is study does not use an intervention|This is study does not use an intervention. A survey will be used to collected data on patients' experiences and preferences about waiting list for heart surgery.
219657064|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
219657065|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
218967167|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced-Plus)"|"Enhanced Standard of Care (Enhanced-Plus) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, SA Starter Packs, and three additional intensive external facilitation components."
218967168|NCT07149337|OTHER|Oral phosphate load|Participants ingest an oral phosphate load containing 558 mg of phosphorus once.
218967169|NCT07150767|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 5.0×10\^10 viral particle (VP) ,2.0×10\^11 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
218967170|NCT07150559|PROCEDURE|Arch-Clamping Technique under Mild Hypothermia|This procedure is performed under mild hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allows bilateral antegrade cerebral perfusion (bACP) through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
218967171|NCT07150559|PROCEDURE|Arch-Clamping Technique under Moderate Hypothermia|This procedure is performed under moderate hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allow bACP through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
218967172|NCT07150559|PROCEDURE|Total Arch Replacement combined Frozen Elephant Trunk Implantation using Bilateral Antegrade Cerebral Perfusion under Moderate Hypothermic Circulatory Arrest|This procedure is performed using bACP under MHCA, which involves FET deployment in the descending aorta followed by total arch replacement with a four-branched vascular graft. Deployment of the FET and suture of distal anastomosis are completed during bACP. MHCA is terminated and distal reperfusion is initiated once the distal anastomosis is completed, and the left carotid artery is reconstructed first (after which bACP is stopped, rewarming is started and the brain is perfused bilaterally). The root or valve procedures and some concomitant operations, if indicated, are performed during the cooling phase.
218967173|NCT07149792|DIAGNOSTIC_TEST|Prescreen platform|Different biomarkers on PsO, PsA and paradoxical PsA
218967174|NCT07149792|BIOLOGICAL|biologics treatment|All psoriasis patients are receiving biologics treatment
218967175|NCT07150299|DRUG|Mavacamten in clinical routine use|Clinical observation of mavacamten use
218967176|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Negative Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
218967177|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education (Control Group)|Control group
218967178|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Positive Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
218967179|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) alone.
218967180|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training (PFMT) with medical treatment|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) with medical treatment.
219063697|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
219063698|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
219657066|NCT06720974|OTHER|AquaReBal|"The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task."
219657067|NCT04451616|DIAGNOSTIC_TEST|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
219657068|NCT04451616|DIAGNOSTIC_TEST|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
219657069|NCT04451616|DIAGNOSTIC_TEST|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
219657070|NCT04451616|DIAGNOSTIC_TEST|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
219657071|NCT04451616|DIAGNOSTIC_TEST|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
219657072|NCT04451616|DIAGNOSTIC_TEST|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
219657073|NCT03065764|DRUG|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
219063699|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
219657074|NCT04836481|OTHER|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
219657075|NCT05565144|OTHER|None, pure observational study|None, pure observational study
219657076|NCT07041008|BEHAVIORAL|Digital intervention|Individual cognitive stimulation sessions will be delivered using RehaCom software, which provides adaptive, computerised exercises targeting specific cognitive domains.
219657077|NCT07041008|BEHAVIORAL|Physical/Analogue Intervention|Individual cognitive stimulation sessions will employ structured physical materials, specifically the 'Memories from North to South©' and 'Cognitive Domains' resources, applied on an alternating basis.
219657078|NCT05701956|DRUG|Tenecteplase|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
219657079|NCT05701956|PROCEDURE|Endovascular thrombectomy|The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
219657080|NCT05538767|DRUG|Emodepside|Treatment with Emodepside 30 mg
219657081|NCT05538767|DRUG|Albendazole 400mg|Treatment with Albendazole 400 mg
219657082|NCT01789580|OTHER|Gambling moderator|
219657083|NCT05094089|DEVICE|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
219657084|NCT03619902|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
219657085|NCT02923245|OTHER|point-of-care ultrasound|
219657086|NCT06747845|DRUG|Niraparib|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle.
219657087|NCT06747845|DRUG|FOLFIRI|Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.
219657088|NCT06747845|DRUG|Ipilimumab|Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
219657089|NCT06828601|DRUG|IV Lidocaine|Participant receives IV Lidocaine during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
219657090|NCT06828601|DRUG|IV Saline|Participant receives IV Saline (placebo) during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
219657091|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
219657092|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
218967181|NCT07150936|BEHAVIORAL|stress ball application|Participants' demographic information will be collected interview using the Patient Information Form. Approximately 30 minutes before surgery, patients' systolic and diastolic blood pressure, heart rate, respiratory rate, and oxygen saturation will be measured and recorded. Pain severity will also be assessed using the VAS, and anxiety levels will be assessed using the VAS-A and Spielberger Trait Anxiety Scale. Intraoperative Period: All patients will be placed in the supine position on the operating room table. Patients in the intervention group will continue to use the stress ball for 15 minutes during the surgery, as per randomization. All patients will undergo a repeat 15-minute postoperative assessment of vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, oxygen saturation), pain with a VAS, and anxiety levels with a VAS-A. After the patients are taken to the clinic after the surgery, the same physiological measurements will repeated 10 mnt later
218967182|NCT04724395|OTHER|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
218967183|NCT04221412|DRUG|JNJ-53718678|JNJ-53718678 will be administered as directed by treating physician.
218967184|NCT06517810|DEVICE|QUELIMMUNE (SCD-PED)|QUELIMMUNE device used as part of clinical practice.
218985058|NCT06497998|DEVICE|Mechanical characterization|"The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane."
218985059|NCT02994992|DRUG|BAY 987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
219657093|NCT00362713|DRUG|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
219657094|NCT06898177|BEHAVIORAL|mCBT-AR|mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
219657095|NCT06763146|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
219657096|NCT07071558|BIOLOGICAL|RSV vaccine formulation 1 dose|Suspension for injection. Route of administration: IM injection
219657097|NCT07071558|BIOLOGICAL|RSV vaccine formulation 2 dose|Suspension for injection. Route of administration: IM injection
219657098|NCT07071558|BIOLOGICAL|RSV vaccine formulation 3 dose|Suspension for injection. Route of administration: IM injection
219657099|NCT07071558|BIOLOGICAL|RSV vaccine formulation 4 dose|Suspension for injection. Route of administration: IM injection
219657100|NCT07071558|BIOLOGICAL|RSV vaccine formulation 5 dose|Suspension for injection. Route of administration: IM injection
219657101|NCT07071558|BIOLOGICAL|RSV vaccine formulation 6 dose|Suspension for injection. Route of administration: IM injection
219657102|NCT07071558|BIOLOGICAL|RSV vaccine formulation 7 dose|Suspension for injection. Route of administration: IM injection
219657103|NCT07071558|BIOLOGICAL|RSV vaccine formulation 8 dose|Suspension for injection. Route of administration: IM injection
219657104|NCT06766851|OTHER|Procedure: TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
219063700|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
219063701|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
219657114|NCT05138276|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC
219657115|NCT05138276|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
219657116|NCT04404920|OTHER|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
219657117|NCT06561464|DEVICE|EzPAP®|EzPAP® is a portable, single-use respiratory exercise device that provides positive expiratory pressure during expiration while supporting respiration during inspiration. Its use has been increasing in recent years as an oxygenation device. It is portable, single-use, easy to use, well-tolerated, and cost-effective. EzPAP® helps increase functional capacity in the lungs and reduces atelectasis. With EzPAP®, an oxygen flow of 5-8 L/min reaches the patient as 35-42% fractionated oxygen, thus quadrupling the oxygen flow.
219657118|NCT06561464|DEVICE|Non-invasive mechanical ventilation (NIMV)|NIMV provides respiratory support during both expiration and inspiration through continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Treatment success can be monitored within the first 2 hours by the improvement in oxygenation and reduction in pCO2 levels
219657119|NCT02893982|RADIATION|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
219657120|NCT06519344|BIOLOGICAL|anti-CD20/CD30-CAR-T Cells|Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
219657121|NCT02715505|DRUG|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
219657122|NCT01963377|DEVICE|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
219657123|NCT01963377|DEVICE|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
219657124|NCT02520427|DRUG|AMG 330|0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.
219657125|NCT00655473|DRUG|Dalcetrapib (RO4607381)|600mg po daily for 24 months
218967185|NCT04945330|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
218967186|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
218967187|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
219657126|NCT00655473|DRUG|Placebo|po daily for 24 months
219657127|NCT03324516|PROCEDURE|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
218967188|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
218967189|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
218967190|NCT00032032|DRUG|carboplatin|
218967191|NCT00032032|DRUG|paclitaxel|
218967192|NCT00032032|RADIATION|radiation therapy|
218967193|NCT02546115|DEVICE|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
218967194|NCT02546115|OTHER|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
218967195|NCT01659658|DRUG|IXAZOMIB|IXAZOMIB capsules
219657128|NCT03324516|PROCEDURE|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
219657129|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219657130|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
219657131|NCT00793624|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
219657132|NCT00793624|DRUG|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
219657133|NCT00793624|DRUG|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
219657134|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
219657135|NCT02048917|DRUG|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
219657136|NCT02048917|DRUG|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
219657137|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
219657138|NCT02048917|DRUG|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
219063702|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
219063703|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
219657139|NCT02048917|DRUG|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
219657140|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
219657141|NCT02048917|DRUG|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
219657142|NCT02048917|DRUG|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
219657143|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
219657144|NCT02048917|DRUG|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
219657145|NCT02048917|DRUG|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
219657146|NCT00710684|DRUG|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
219063704|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
219657147|NCT00710684|DRUG|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
219657148|NCT00710684|DRUG|Placebo|Placebo added to existing donepezil
219657149|NCT00710684|DRUG|donepezil 5-10mg|existing donepezil treatment
219657150|NCT04778059|DRUG|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
219657151|NCT04778059|DRUG|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
219657152|NCT06433661|DRUG|Etavopivat|Participants will receive single dose of oral Etavopivat in each treatment period.
219657153|NCT05659862|BEHAVIORAL|Digitally assisted behavioral physical activity intervention|"Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward"
219657154|NCT05659862|BEHAVIORAL|Education|"Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website."
219657155|NCT02683044|PROCEDURE|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
219657156|NCT01553240|DEVICE|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
219063705|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
219063706|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
219063707|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
219657157|NCT00688233|DEVICE|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
219657158|NCT01665846|DRUG|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
219657159|NCT05843058|BEHAVIORAL|laughter yoga|The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
219657160|NCT00247169|DRUG|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
219657161|NCT06648343|OTHER|Intensive cognitive and physical training|The cognitive and physical training program consists of 25-35 minutes of cognitive training (memory, attention, visuospatial orientation) and 10-15 minutes of physical training (stretching, strength training, coordination, and aerobic exercise). Additionally, participants will be instructed to perform 30-40 minutes of aerobic exercise 3-4 times per week
219657162|NCT04909749|GENETIC|Oneome RightMEd Pharmacogenomic testing Kit|The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively
219657163|NCT01828333|OTHER|No intervention|No intervention
219657164|NCT01506154|DRUG|MRX-7EAT|Once daily application of a patch for 14 days
219063708|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
219657165|NCT01623973|OTHER|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
219657166|NCT07088653|DRUG|MicroRepair ABX mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using MicroRepair® ABX mouthwash. The formulation contains zinc-hydroxyapatite with antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.
219657167|NCT07088653|DRUG|Chlorhexidine 0.12% mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using 0.12% chlorhexidine (CHX) mouthwash. Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same SLS-free toothpaste (Biorepair®) throughout the study.
219657168|NCT04216446|BEHAVIORAL|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
219657169|NCT06623578|PROCEDURE|robotic-assisted surgery|robotic-assisted surgery via single-incision transaxillary approach
219657170|NCT06623578|PROCEDURE|Open Surgery|conventional open surgery
219657171|NCT03439540|DIETARY_SUPPLEMENT|Plantago major|Individuals receive Plantago major daily, for 12 weeks
219657172|NCT03439540|DIETARY_SUPPLEMENT|Placebo|Individuals receive placebo daily, for 12 weeks
219657173|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
219657174|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
219657175|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
219657176|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
219657177|NCT00264160|DRUG|AMN107|
218967196|NCT01659658|DRUG|Dexamethasone|Dexamethasone tablets
218967197|NCT01659658|DRUG|Melphalan|Melphalan tablets
218967198|NCT01659658|DRUG|Cyclophosphamide|Cyclophosphamide tablets
218967199|NCT01659658|DRUG|Thalidomide|Thalidomide capsules
218967200|NCT01659658|DRUG|Lenalidomide|Lenalidomide capsules
218967201|NCT06227455|PROCEDURE|Maxillary alveolar ridge augmentation|The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.
218967202|NCT00400231|DRUG|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
218967203|NCT00400231|DRUG|Study Drug: Metformin|2000mg/day
218967204|NCT00400231|DRUG|Study Drug: fenofibrate|145mg/day of fenofibrate
218967205|NCT00400231|DRUG|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
218967206|NCT02250859|DRUG|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
218967207|NCT00311662|DRUG|Tonabersat|Tablet 40mg daily for 12 weeks
218967208|NCT00311662|DRUG|Placebo|Tablet once daily for 12 weeks
218967209|NCT01847001|DRUG|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
219657178|NCT02319720|BIOLOGICAL|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
219657179|NCT02319720|BIOLOGICAL|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
219657180|NCT02319720|PROCEDURE|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
219657181|NCT01518231|PROCEDURE|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
219657182|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
219657183|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
219657184|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
219657185|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt.
219657186|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
219657187|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
219657188|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
219657189|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt
219657190|NCT05960227|DRUG|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
219657191|NCT05960227|DRUG|Placebo|250ml of saline 0,9% for 4 hours insusion.
219657192|NCT06906523|OTHER|Blood flow restriction training|The intensity of the work will be set at around 40% of the maximum intensity that can be executed in a single repetition (1RM). To reach the established intensity, weights, weighted ankle supports and rubber bands of different resistances will be used. Three sets of 8-10 repetitions will be performed with breaks of 1-2 seconds between repetitions and 2-3 minutes between sets. The intensity of the work will be established by applying the rate of perceived exertion. A blood flow restriction device will be used (Akrafit, Valencia, Spain model).
219657193|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
219657194|NCT04101929|DRUG|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
219657195|NCT04101929|DRUG|S-1 capsule|Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
219657196|NCT04101929|DRUG|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
219657197|NCT00731757|DRUG|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
219657198|NCT04395092|BIOLOGICAL|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
219657199|NCT04395092|PROCEDURE|Conditioning Regimen|"From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3."
219657200|NCT04395092|PROCEDURE|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
219657201|NCT03702114|DEVICE|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
219657202|NCT03258970|OTHER|Observational cohort study|taking vitamin supplements
219657203|NCT00108511|DRUG|Gemfibrozil|
219657204|NCT04724577|RADIATION|carbon ion radiotherapy|dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
219657205|NCT06249854|DRUG|Bojungikki-tang(BJIKT)|"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects"
219657206|NCT06249854|DRUG|Pembrolizumab|It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
219657207|NCT06237244|DIAGNOSTIC_TEST|triglyceride to glucose ratio|Ratio of triglyceride level to glucose
219657208|NCT06237244|DIAGNOSTIC_TEST|triglycerdie to HDL ratio|Ratio of triglyceride to HDL cholesterol
219657209|NCT07088666|DRUG|MicroRepair ABX mouthwash|"At baseline (T0), participants receive clinical assessments, oral hygiene instruction, and begin a 14-day home regimen with MicroRepair® ABX mouthwash, which contains zinc-hydroxyapatite microcrystals and antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). The mouthwash is used twice daily (10 mL for 30 seconds) after toothbrushing, without rinsing, and participants avoid food or drink for 1 hour. All participants use a sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.~At 1 month (T1), participants undergo professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, ultrasonic debridement with an EMS Piezon piezoelectric device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and a repeated 14-day mouthwash cycle are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
219657210|NCT07088666|DRUG|Chlorhexidine 0.2% mouthwash|"At baseline (T0), participants undergo clinical and photographic assessments, receive oral hygiene instruction, and begin a 14-day home regimen with 0.2% chlorhexidine digluconate mouthwash, used twice daily (10 mL for 30 seconds) after toothbrushing. The solution is not rinsed away, and participants avoid food or drink for 1 hour. All participants use a standardized sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®).~At 1 month (T1), participants receive professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, piezoelectric ultrasonic scaling with an EMS Piezon device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and repetition of the 14-day home regimen are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
219657211|NCT05428163|OTHER|Biological sampling|3ml of blood
218967210|NCT01847001|OTHER|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
218967211|NCT01847001|DRUG|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
219063709|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
219063710|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
219063711|NCT01961830|DRUG|ME1100 inhalation solution|
219063712|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
219063713|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
219063714|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
219063715|NCT05166018|DIAGNOSTIC_TEST|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
219063716|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
219063717|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
219063718|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
219657212|NCT05801510|BEHAVIORAL|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
219657213|NCT02863510|DEVICE|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
219657214|NCT01243502|DRUG|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
219657215|NCT01243502|DRUG|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
219657216|NCT01903785|DRUG|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
219657217|NCT01903785|DRUG|Placebo|
219657218|NCT02222597|DEVICE|infrascanner|
219657219|NCT05724628|PROCEDURE|Laparoscopic appendectomy|Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
219657220|NCT05724628|DRUG|Antibiotics (IV transitioned to oral)|"Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin"
219657221|NCT06459505|OTHER|Routine or standard Physical Therapy|Participants will undergo physical therapy to stop abnormal movement patterns and restore control over output in the developmental sequence. Therapists will provide cues to elicit basic posture and movement patterns, inhibiting aberrant patterns. The therapy aims to promote normal posture and movement patterns, incorporating the hemiplegic side for symmetry and functional use. Active usage and targeted strengthening activities will be emphasized, with motor performance practice included.
219657222|NCT06459505|OTHER|Adapted Physical Activity|For Upper extremities, Manual Ability Classification Scale (MACS) is a tool designed to support individuals with hemiplegic cerebral palsy by providing structured support through activities focusing on strength, flexibility, balance, and coordination. Participants at different MACS levels receive tailored treatments, including adaptive tools, task-specific training, assistive gadgets, and functional training. For lower extremities, the therapy will begin on stable support surfaces before progressing to more challenging surfaces such as inflatable cushions, foam pads, or balance discs, focusing on slow and controlled motions for improved body alignment and coordination.
219657223|NCT01306045|DRUG|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
219657224|NCT01306045|DRUG|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
219657225|NCT01306045|DRUG|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
219657226|NCT01306045|DRUG|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
219657227|NCT01306045|DRUG|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
219657228|NCT01306045|PROCEDURE|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
219657229|NCT04103827|OTHER|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
219657230|NCT00026429|BIOLOGICAL|denileukin diftitox|
219657231|NCT03944733|DIETARY_SUPPLEMENT|Iron|65 mg of iron (ferrous sulfate)
219657232|NCT03944733|DIETARY_SUPPLEMENT|Gelatin|600 mg gelatin
219657233|NCT04948554|BIOLOGICAL|MK-2225|Administered Subcutaneously (SC)
219657234|NCT04948554|BIOLOGICAL|Placebo|Administered SC
219657235|NCT00153127|DRUG|polyethyleneglycol3350|
219657236|NCT04907331|BIOLOGICAL|Vaxzevria|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
219657237|NCT04907331|BIOLOGICAL|Comirnaty|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
219063719|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
219063720|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
219657238|NCT05930834|BEHAVIORAL|exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
219657239|NCT02381938|BEHAVIORAL|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
219657240|NCT02381938|OTHER|Healthy Finances|6-month intervention to educate and improve financial health
219657241|NCT06043479|OTHER|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
219657242|NCT02432859|PROCEDURE|Electrical Stimulation|Direct current with sensory intensity for one hour
219657243|NCT02432859|PROCEDURE|Placebo|Direct current with zero intensity for one hour
219657244|NCT03750747|DEVICE|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing \>10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
219657245|NCT07094412|OTHER|Educational content on statin side effects|Participants will view educational content that will include written material, graphics and video. The content will explain side effects and benefits of statin medications. The content will also explain placebo and nocebo effects and how they may impact people taking statins.
219657246|NCT03863327|OTHER|No intervention|There will be no intervention as a part of this protocol.
219657247|NCT02987972|BIOLOGICAL|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
219657248|NCT02987972|BIOLOGICAL|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
219657249|NCT02987972|BIOLOGICAL|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
219657250|NCT06906458|OTHER|Paresthesia|Patients experiencing paresthesia during the interscalene nerve block
219657251|NCT06906458|OTHER|No paresthesia|Patients not experiencing paresthesia during the interscalene nerve block
219657252|NCT05679817|OTHER|Dose-graded aerobic exercises|The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes
219657253|NCT05679817|OTHER|Traditional physical rehabilitation|The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
219657254|NCT02568228|DIETARY_SUPPLEMENT|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
219657255|NCT02568228|OTHER|Lean and fatty fish|The fish group will be open labeled.
219657256|NCT02568228|DIETARY_SUPPLEMENT|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
219657257|NCT04494763|DRUG|Propanolol|Non-selective Beta-blocker
219657258|NCT04494763|OTHER|Placebo|Inactive drug
219657259|NCT06912438|OTHER|Fill out questionnaire|"After signed consent all patients will be asked to fill a series of questionnaires in print. The questionnaires administered are standardized and validated in Hebrew.~Patients will be asked to fill out:~Diagnostic Criteria for Temporomandibular Disorders (DC-TMD) questionnaire.~Patient Health Questionnaire 9 PHQ-9-HEB~Emotion Regulation Questionnaire (ERQ)~Toronto Alexithymia Scale (TAS - 20)~At each injection session, all patients will be asked to fill out the Profile of Mood States Hebrew translation (POMS-H) before and after trigger point injections."
219657260|NCT07091864|OTHER|Best Practice|Receive SOC treatment
219657261|NCT07091864|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219657262|NCT07091864|OTHER|Dietary Intervention|Attend dietary counseling sessions
218967212|NCT01847001|DRUG|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
218967213|NCT01847001|DRUG|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
218967214|NCT01847001|DRUG|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
218967215|NCT01847001|DRUG|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
218967216|NCT01847001|DRUG|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
218967217|NCT01847001|PROCEDURE|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
219657263|NCT07091864|OTHER|Glucose Measurement|Undergo intermittent glucose monitoring
219657264|NCT07091864|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219657265|NCT07091864|OTHER|Monitoring|Undergo CGM
219657266|NCT07091864|OTHER|Questionnaire Administration|Ancillary studies
219657267|NCT07091864|OTHER|Supportive Care|Receive endocrinology-guided interventions
219657268|NCT07133646|OTHER|Rib Mobilization Technique and Diaphragm Release Technique|The RMT, adapted from Henderson et al10 and Abdelaal et al,15 was carried out in 2 different participant positions: supine and seated. In the supine position, the therapist was placed next to the participant and positioned the last 4 fingertips of both hands at the rib angles. The therapist mobilized the costal angles in the postero anterior direction accompanying the participant's normal inspiration The movement was performed in 2 series of 10 respiratory cycles in each hemi thorax, with a 1-minute interval between sets.
219657269|NCT07133646|OTHER|Diaphragm Release Technique|The DRT was performed according to the protocol described by Rocha et al.13 In this protocol, the participant remains in the supine position so that the therapist is able to maintain manual contact with the bottom edge of the rib cage. During inspiration, the therapist exerts traction after the natural rib-cage movement, then deepens the manual contact and maintains the resistance exerted in the previous phase throughout exhalation. The technique was applied in 2 series of 10 deep respiratory cycles, with a 1-minute interval between the series, under the therapist's verbal command.
219657270|NCT07095270|DEVICE|Circadian OS software|Circadian OS is a software program that runs on existing iPads. It utilizes the iPad capabilities to control and deliver circadian-effective light.
219657271|NCT06910488|OTHER|Daily Living Activities Mobile Application|mobile application was used for three months
219657272|NCT06910488|OTHER|Individual interviews|"The individual's daily living activities are assessed using forms and scales that evaluate disability, functional level, and the ability to perform skill-based activities.~Factors affecting daily living activities, such as strengths and weaknesses, barriers, accessible healthcare services, and social support networks, are examined.~The client's independent, semi-dependent, and dependent daily living activities are evaluated together.~Implementation steps are created to achieve the identified goals. Barriers to achieving the goals and supporting factors are identified."
219657273|NCT06910488|OTHER|Group education|"Information is provided about the symptoms of schizophrenia and bipolar disorder, their causes, and treatment.~The early warning signs are explained, along with the importance of recognizing that they can lead to an emergency situation.~The importance of prior planning for what to do in case of an emergency is discussed. As homework, the family is asked to make this plan together.~Information is provided about the importance of daily living activities and what they entail.~Information is provided about self-care skills, healthy nutrition, movement planning, good sleep hygiene, the importance of body temperature regulation, and elimination issues.~Information is provided about communication skills. Information is given about what to pay attention to in order to establish effective communication."
219657274|NCT06910488|OTHER|Routine rehabilitation program|It includes psychiatric rehabilitation services that are part of the clinic's program.
219657279|NCT07099365|DEVICE|Orbi|Orbi is adapted from COMPASS, a web-based cognitive behavioural therapy (CBT) intervention based on the Transdiagnostic Model of Adjustment in Long-Term (physical) Conditions Model. Orbi is made up of 13 topics, each exploring a different challenge faced by individuals with a LTC(s). Orbi is a self-guided CBT programme with no therapist involvement.
218967218|NCT01847001|DRUG|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
218967219|NCT01847001|DRUG|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
218967220|NCT01847001|DRUG|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
218967221|NCT05131360|BEHAVIORAL|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
218967222|NCT05131360|BEHAVIORAL|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
219063721|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
219063722|NCT01316744|DRUG|ketamine hydrochloride|
219063723|NCT01316744|OTHER|pharmacogenomic studies|
219063724|NCT01316744|OTHER|questionnaire administration|
219063725|NCT01316744|PROCEDURE|assessment of therapy complications|
219063726|NCT01316744|PROCEDURE|quality-of-life assessment|
219063727|NCT01863017|DEVICE|tDCS|
219063728|NCT02804958|PROCEDURE|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
219063729|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
219063730|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
219063731|NCT02493361|DRUG|Pembrolizumab|
219063732|NCT02493361|DRUG|pIL-12|
219063733|NCT02334748|DRUG|canakinumab|canakinumab
219063734|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
219063735|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
219657280|NCT06908109|DEVICE|Yankauer Suction Device|The Yankauer suction device is a hollow, curved and flexible tube that has a suction tip surrounded by a bulbous head to allow effective suctioning without damaging the surrounding tissue. It has been frequently used in multiple settings that range from minor dental procedures to large surgeries. It is also frequently used in the intensive care units to suction oropharyngeal secretions and prevent aspiration. Throughout this study, and regardless of the study group (control or intervention group), the Yankauer suction device is attached to a distinct suction port and placed, at the other end, inside the oral cavity of the patient.
219657281|NCT06908109|PROCEDURE|Bronchoscopy|Flexible bronchoscopy done for the following indications: presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough. Flexible bronchoscopy (FB) is a medical procedure that has been used for more than five decades for the diagnostic evaluation and/or therapeutic intervention in a multitude of pulmonary and bronchial diseases
219657282|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
219657283|NCT06620653|OTHER|Telemonitoring|Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.
219657284|NCT06620653|OTHER|Standard Care|patients with a recent admission for heart failureare seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines with face-to-face follow up at 6 and 12 weeks.
219657285|NCT06696443|DRUG|Suzetrigine|Tablets for oral administration.
219657286|NCT04084730|RADIATION|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
219657287|NCT06395103|BIOLOGICAL|Zilovertamab vedotin|Administered via IV infusion
219657288|NCT07109609|DRUG|Topical application of 20% menthol solution in MCT oil.|To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
219657289|NCT07109609|DRUG|Topical Placebo Oil rolled onto the cheek.|To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
219657290|NCT00673751|DRUG|GLP-2|450 nmol subcutaneous
219657291|NCT00673751|DRUG|Placebo|
219657292|NCT06910215|OTHER|Elastic therapeutic taping|Elastic therapeutic taping is a non-invasive method that uses a specially designed elastic cotton tape applied directly to the skin. In this study, it is used to support pain management after open-heart surgery (CABG via sternotomy). The tape is applied near the surgical site to gently lift the skin, which may help reduce pain, improve circulation, and support healing. The application is done by a trained physiotherapist following a standardized taping protocol. The tape remains on the skin for up to 48 hours.
218967223|NCT05131360|BEHAVIORAL|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
218967224|NCT05131360|BEHAVIORAL|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
218967225|NCT05131360|BEHAVIORAL|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
218967226|NCT05131360|BEHAVIORAL|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
218967227|NCT05131360|BEHAVIORAL|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
218967228|NCT05131360|BEHAVIORAL|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
218967229|NCT04652232|OTHER|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
218985060|NCT02994992|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
218985061|NCT04754152|OTHER|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
218985062|NCT04754152|DRUG|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
218985063|NCT02650674|OTHER|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
219657293|NCT06910215|OTHER|Placebo Elastic Therapeutic Taping|In this group, the same type of elastic tape used in the therapeutic group is applied to the skin near the surgical area, but without any stretch or therapeutic technique. The tape does not provide physical support or intended therapeutic effects. It is used to help researchers understand whether any improvements are due to the taping itself or simply from receiving an intervention. The tape remains in place for up to 48 hours and is applied by trained personnel using a standardized, non-therapeutic method.
219063736|NCT01046643|DRUG|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
219657294|NCT06910215|OTHER|Therapeutic Taping on Non-Surgical Areas|In this group, elastic therapeutic tape is applied to body areas not directly related to the surgery, such as the shoulder, back, or rib area. The purpose is not to treat pain at the surgical site, but to simulate the experience of receiving a physical intervention. This approach helps researchers understand the potential impact of attention, expectation, or psychological support related to being part of a study. The tape is applied gently without therapeutic intent and stays on for up to 48 hours
219657295|NCT06912256|BEHAVIORAL|Sleep restriction|During the intervention period (i.e., 9 consecutive days), the intervention group started the sleep protocol, sleeping only the quantity of hours defined for their individual chronic partial sleep restriction (15% of the usual sleep time). The amount and quality of sleep obtained were daily monitored through actigraphy devices, and all the players filled in a sleep diary when they woke up. During this period, players performed the SSGs in two different moments (moment 1 and moment 2), interspersed by 4 days.
219657296|NCT06909851|PROCEDURE|Adductor Canal Block (ACB)|Evaluation of postoperative analgesic effectiveness of ACB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
219657297|NCT06909851|PROCEDURE|Genicular Nerve Block (GNB)|Evaluation of postoperative analgesic effectiveness of GNB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
219657298|NCT07112391|OTHER|Observational Invasive Hemodynamic Assessment|Collection and analysis of invasive hemodynamic data obtained through routine cardiac catheterization performed as part of standard care. No intervention is mandated by the study protocol.
219657299|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
219657300|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
219657301|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
219657302|NCT05305547|DRUG|S-217622|Administered as a round tablet.
219657303|NCT05305547|DRUG|Placebo|Administered as a round tablet.
219657304|NCT06940713|DEVICE|Imaging Time|"fUS:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system.~fUS-EEG:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system, performed simultaneously with an EEG examination.~The fUS examinations consist of recording brain activity for a few minutes in one of the imaging planes (Posterior Coronal, Median Coronal, Frontal Coronal, Right Para-sagittal, Right/Left Para-sagittal, 3-plane Antero-posterior Coronal) including structures involved in brain functional connectivity networks (somatosensory, auditory, visual, salience).~These fUS examinations are conducted to perform longitudinal follow-up of patients in the 5 different groups."
218967230|NCT04652232|OTHER|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
218967231|NCT02235519|DRUG|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
218967232|NCT02235519|DRUG|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
218967233|NCT02022631|OTHER|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
218967234|NCT02022631|OTHER|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
218967235|NCT00411112|PROCEDURE|blue and isotopic detection of sentinel lymph nodes|
219657305|NCT06945640|DEVICE|RUS NE|RUS NE is a surgical navigation system designed for use in robot-assisted partial nephrectomy. It reconstructs CT images into 3D models, providing visualization of tumor and vascular structures to enhance surgical precision and optimize resection planning. This system aids in reducing resection volume and improving operative outcomes by integrating anatomical insights into the surgical workflow.
219657306|NCT07146230|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD 1 on T cells and CD80 (B7.1) on immune cells.
219657307|NCT07146230|DRUG|Monalizumab|Monalizumab is a humanized mAb of the IgG4 subtype that specifically binds and inhibits Cluster of Differentiation 94 (CD94)/NK cell protein group 2 A(NKG2A).
219657308|NCT07146230|DRUG|Oleclumab|Oleclumab is a human IgG1λ mAb that selectively binds to and inhibits the ectonucleotidase activity of CD73.
219657309|NCT07146230|RADIATION|Radiotherapy|PET based dose painted radiotherapy. If these treatment techniques are not available for some reason treatment may be delivered using a sequential boost technique (2.75 Gy x 17 to the low-risk PTV followed by 2.75 Gy x 3 to the high-risk planning target volume).
219657310|NCT07071051|OTHER|Non-Interventional Study|Non-interventional study
219657311|NCT07175493|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol
219657312|NCT07176845|OTHER|Observational|This study is observational of nature: multidimensional data is collected and no interventional is imposed
219657313|NCT07176312|DRUG|Zanidatamab|Zanidatamab 1,200 mg (patients \<70 kg at baseline) or 1,600 mg (patients ≥70 kg at baseline), administered i.v. on day 1 of each 2-week cycle (Q2W)
219657314|NCT07176312|DRUG|Pembrolizumab|Pembrolizumab 400 mg, administered i.v. on day 1 of every third cycle (Q6W)
219657315|NCT07176312|DRUG|mFOLFOX|modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and 2 of each 2-week cycle (Q2W)
219657316|NCT07175168|OTHER|No medical or experimental intervention will be administered|Laboratory procedures (blood sampling for karyotyping, basic investigations such as echocardiography, thyroid function tests, abdominal ultrasound) are part of standard diagnostic assessment, not rese
219657317|NCT07174817|BEHAVIORAL|weight loss|The weight loss intervention group underwent dietary and exercise programs for three months prior to initiating IVF treatment. These interventions included consuming foods with a low glycemic index (GI), achieving a daily net energy expenditure of 500-750 kcal, and engaging in moderate-intensity exercise 3-5 times per week. After the three-month period, weight maintenance was managed according to each patient's preferences.
219657318|NCT07176624|PROCEDURE|Enteral nutrition is reduced before the prone position|Before the prone position, the gastric contents are aspirated with a syringe, and the dose of enteral nutrition reduction is determined based on the different amounts of gastric residue. If the residual volume in the stomach is less than 200ml, the enteral nutrition intake will be reduced by one third. Gastric residual volume 200-500ml: Reduce enteral nutrition by half. If the residual gastric volume is greater than 500ml: Stop enteral nutrition and consider post-pyloric feeding
219657319|NCT07174791|DEVICE|cone beam computed tomography|-Implant marginal bone height changes will be measured by cone beam radiograph after one and two years of loading
219657320|NCT07174791|DEVICE|photogrammetric scan using elite scanner (shining 3d)|implant placement accuracy will be evaluated using photogrammetric scan after implant insertion
219657321|NCT07175077|DEVICE|7t MRI|7t brain MRI followed by up to 12 months of standard of care 1.5t/3t MRI scans
219657322|NCT07176858|OTHER|brain gym exercise|specially designed physical therapy program in addition to brain gym exercises for 60 min (30 min designed P.T program and other 30 min for brain gym exercises), 3 sessions/ week for 3 successive months. eight Brain Gym exercises will be selected: Cross Crawl, Lazy 8s, Hook-ups, Brain Buttons, The Elephant, The Owl, Neck Rolls, Double Doodle
218967236|NCT06166082|DEVICE|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
218967237|NCT06166082|DEVICE|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
218967238|NCT04918576|DRUG|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
218967239|NCT04918576|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
218967240|NCT04209062|DEVICE|Medical device validation|The medical devices will both record electrical signals for comparison
218967241|NCT00849537|DRUG|Triamcinolone|Injection of intravitreal Triamcinolone
219657323|NCT07176858|OTHER|specially designed pt program|conventional physical therapy program including reinforcement of the normal motor development, reflex inhibiting patterns, postural reaction, stretching, strengthening exercises, and gait training was applied to children in the control group
219657324|NCT07175974|BEHAVIORAL|Feldenkrais Method - Awareness Through Movement (ATM)|Participants attended eight consecutive sessions of the Feldenkrais Method, each lasting 90 minutes, over 8 days (total 12 hours). Sessions focused on enhancing upper limb functionality, trunk integration, posture, coordination, body awareness, and somatic regulation through slow, mindful, guided movements.
219657325|NCT07177053|DRUG|non fluoridated hydroxyapatite tooth paste (KAREX KINDER tooth paste)|"arm 1 : hydroxyapatite tooth paste \[ HAP\] (study group): assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence~(ΔF, %) and extension of the lesion (area; mm2)."
218967242|NCT00000612|DRUG|estrogens, conjugated|
218967243|NCT00000612|BEHAVIORAL|diet, soy proteins|
218967244|NCT00000612|BEHAVIORAL|dietary supplements|
218967245|NCT05272839|DIETARY_SUPPLEMENT|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
219657326|NCT07177053|DRUG|fluoridated toothpaste (Colgate Total PROTECTION ACTIVE)|"Arm 2 :Fluoride-containing tooth paste \[1450ppm fluoride\] (control group):~assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence (ΔF, %) and extension of the lesion (area; mm2)."
219657327|NCT07175883|PROCEDURE|Redon drain|Patients in group A will have a Redon drain placed at the end of the procedure following the usual technique
219657328|NCT07177300|DRUG|PK-optimized oral hydroxyurea at MTD until 15 years of age.|Because people are different, we will measure how each participant's body absorbs and eliminates the medicine, hydroxyurea, using blood tests. This information will be used to determine the best dose for each participant (rather than using the same weight-based dose for everyone).
219657329|NCT07176221|PROCEDURE|endoscopic cardia constriction ligation|The experimental group used disposable endoscopes to perform ECCL, while the control group used traditional endoscopes to perform ECCL. ECCL involves ligating and fixing the mucosa and partial muscle layer above the dentate line under direct endoscopic visualization to create folds. Post-procedure, the ligated mucosa undergoes ischemic necrosis and heals to form scar tissue, thereby reducing the cardia diameter, increasing LES pressure, and alleviating reflux symptoms.
219657330|NCT07176234|BEHAVIORAL|Treatment|The Linking Exercise for Advancing Daily Stress (LEADS) Management intervention integrates a family-based intervention to address chronic stressors to promote behavioral skills for increasing PA in overweight AA adolescents and their parents. Based on Lazarus and Folkman's Stress and Coping Model, Family Systems, and Social Cognitive Theories, the proposed intervention integrates components that build coping skills (mindfulness, deep breathing, active coping, cognitive reframing), self-esteem (self-affirmation), and positive parenting practices (parent support, nurturance, family routines).
219657331|NCT07176234|OTHER|Health Education|Attention Control Comparator
219657332|NCT07175727|DEVICE|Pulmonary vein isolation|Pulmonary vein isolation for paroxysmal atrial fibrillation
219657333|NCT07175727|RADIATION|cerebral magnetic resonance tomography|A subset of consecutive patients of each group (n=25 of each group) receives cMRI on the day after the procedure to asses silent cerebral lesions. A control cMRI is scheduled in case of positive findings.
219657334|NCT07175727|DIAGNOSTIC_TEST|Biomarker assessment (C-reacitve Protein, troponine)|A subset of patients of each group (n=25 of each group) received blood tests to asses inflammation and troponine release.
219657335|NCT07174830|DRUG|Allisartan Isoproxil Tablets 240mg or placebo|Allisartan Isoproxil Tablets 240mg or placebo, QD
219657336|NCT07174830|DRUG|Allisartan Isoproxil Tablets 480mg or placebo|Allisartan Isoproxil Tablets 480mg or placebo, QD
219657337|NCT07174830|DRUG|Allisartan Isoproxil Tablets 720mg or placebo|Allisartan Isoproxil Tablets 720mg or placebo, QD
219657338|NCT07175337|BEHAVIORAL|Surah Maryam group|Pregnant women who came for birth were taught Surah Maryam. They were monitored throughout the labor process, and in addition to routine midwifery care, Surah Maryam was played twice during labor to provide spiritual support.
219657339|NCT07175337|BEHAVIORAL|Virgin Mary's Hand Plant Group|he pregnant woman was monitored throughout labor; in addition to routine midwifery care, she was given spiritual support by placing the Virgin Mary's Hand plant in water and watching the plant unfold, encouraging her to believe that the birth canal also opens in the same way.
219657340|NCT07176351|DRUG|Buprenorphine|Weekly or monthly extended-release subcutaneous injection
219657341|NCT07175688|DEVICE|Abdominal Ultrasound|Standard abdominal ultrasonography performed to evaluate pancreatic steatosis by comparing pancreatic echogenicity to liver and kidney tissue.
219657342|NCT07175688|DEVICE|Transient elastography|Non-invasive transient elastography used to assess hepatic steatosis and liver stiffness in patients with chronic hepatitis B.
219657343|NCT07175688|DIAGNOSTIC_TEST|Waist Circumference|The midpoint between the superior aspect of the iliac crests and the lower lateral margins of the ribs using an inelastic tape (TBW Import Ltd) that was 0.5 cm in width and 200 cm in length, according to World Health Organization (WHO) recommendations. Abdominal obesity, determined as a waist circumference of ≥94 cm in males or ≥80 cm in females according to the recommendations of the International Diabetes Federation group
218967246|NCT05272839|DIETARY_SUPPLEMENT|Control group|The control group will receive only lifestyle and dietary recommendations.
218967247|NCT05183815|OTHER|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
218967248|NCT02380144|OTHER|Fresh orange fruit and pasteurized fruit juice|
218967249|NCT01464892|BEHAVIORAL|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
218967250|NCT01464892|BEHAVIORAL|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
218967251|NCT01245920|BIOLOGICAL|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
218967252|NCT01245920|OTHER|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
218967253|NCT04960800|OTHER|Specific exercises|Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
218967254|NCT00283231|BEHAVIORAL|Paced Respiration|
218967255|NCT02421029|DRUG|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
218967256|NCT00171743|DRUG|Cyclosporine microemulsion|
218967257|NCT01135602|DRUG|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
218967258|NCT01319357|DRUG|Saxagliptin|orally 5 mg/d for 6 weeks
218967259|NCT01319357|DRUG|Placebo|orally for 6 weeks
219657344|NCT07175688|DIAGNOSTIC_TEST|Body mass index|"It was calculated by the equation dividing the weight in kilograms by height in meters squared.~BMI=〖mass〗\_kg/(〖height〗\_m\^2 )"
219657345|NCT07172386|DRUG|Toripalimab and axitinib|Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles before surgery, and followed by 17 cycles' toripalimab for adjuvant therapy.
219657346|NCT07174908|DRUG|IN10018 in combination with D-1553|IN10018 100mg QD PO and D-1553 600mg BID PO, 21days per cycle
219657347|NCT07174908|DRUG|anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed|Tislelizumab 200mg Q3W IV + Carboplatin AUC 5 mg/mL/min or Cisplatin 75mg/m² Q3W IV+ Pemetrexed 500mg/m² Q3W IV
219657348|NCT07177066|DRUG|EDG-15400|EDG-15400 is administered orally
219657349|NCT07177066|DRUG|Placebo|Placebo is administered orally
219657350|NCT07177144|OTHER|anti müllerian hormone|participants were checked for amh levels preoperatively
219657351|NCT07177144|DIAGNOSTIC_TEST|anti müllerian hormon|participants were checked for amh levels at 3 months postoperatively.
219657352|NCT07176429|DEVICE|Measurement of refractive error and amplitude of pseudoaccommodation|We will be using an assessor, masked as to which participant received what particular lens implant to determine the range of pseudoaccommodation in each eye. This will be done for each eligible eye and the 3 cohorts will be studied and compared.
219657353|NCT07174427|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
219657354|NCT07174427|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
219657355|NCT07174427|DRUG|Fludarabine|Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
219657356|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
219657357|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
219657358|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
219657359|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
219657360|NCT07176208|DRUG|Alcohol beverage|Subjects in this arm will receive placebo capsule with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
219657361|NCT07176208|DRUG|Placebo|Subjects in this arm will receive a placebo capsule with a placebo beverage in one of the assigned treatment days.
218967260|NCT05335278|DRUG|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
218967261|NCT00215683|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
218967262|NCT04356326|DRUG|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
218967263|NCT04356326|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
218967264|NCT04233034|DEVICE|HCL|Hybrid Closed Loop therapy
218967265|NCT04233034|DRUG|verapamil 120mg tablet|verapamil tablet
218967266|NCT04233034|DEVICE|non-HCL|Usual diabetes care
218967267|NCT04233034|DRUG|placebo|placebo pill manufactured to mimic verapamil 120mg tablet
218967268|NCT04493333|DRUG|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
218985064|NCT02650674|OTHER|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
218985065|NCT02650674|OTHER|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
218985066|NCT02650674|OTHER|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
218985067|NCT02650674|OTHER|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
218985068|NCT02650674|OTHER|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
218985069|NCT04234191|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
218985070|NCT04234191|DRUG|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
218985337|NCT05968339|OTHER|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
219063737|NCT01046643|DRUG|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
219063738|NCT01046643|DRUG|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
219063739|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
219063740|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
219063741|NCT01408589|DRUG|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
219063742|NCT02243787|DRUG|COVA322|
219063743|NCT02243787|OTHER|Placebo|
219063744|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
219063745|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
219063746|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
219657362|NCT07176676|OTHER|Lavanda Angustifolia essential oil|Administration of Lavender Angustifolia essential oil by inhalation in reducing nausea after abdominal, vascular, neurosurgical and gynaecological surgery under general anaesthesia during the 24-hour postoperative period.
219657363|NCT07176676|OTHER|Usual Care|Patients in the Usual Care group will follow the standard procedure, which consists of administering antiemetics if provided in therapy or reporting to the doctor with a subsequent treatment decision
219657364|NCT05769868|DRUG|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
219657365|NCT03647163|BIOLOGICAL|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
219657366|NCT03647163|BIOLOGICAL|Pembrolizumab|Pembrolizumab
219657367|NCT03647163|BIOLOGICAL|ipilimumab + nivolumab|Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg
219657368|NCT06787924|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|bovine collagen peptides
219657369|NCT06787924|DIETARY_SUPPLEMENT|Starch|Starch placebo
219657370|NCT02295059|DIETARY_SUPPLEMENT|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
219657371|NCT03254667|BIOLOGICAL|Brodalumab|Brodalumab
219657372|NCT03254667|DRUG|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
218967269|NCT04493333|COMBINATION_PRODUCT|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
218967270|NCT04855929|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
218967271|NCT04855929|DRUG|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
218967272|NCT06201416|BIOLOGICAL|SBT777101|Experimental treatment
218967273|NCT06472245|DRUG|OSE2101|OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
218967274|NCT06472245|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
218967275|NCT06472245|DEVICE|NGS HLAA2 assay|Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
218967276|NCT02135159|DRUG|TDM1|administration of the TDM1 by IV perfusion
218967277|NCT02135159|RADIATION|Brain Sequential RT|local RT
218967278|NCT05271162|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg q.d; p.o
218967279|NCT05271162|OTHER|Placebo|Placebo 1 tabl q.d; p.o
218967280|NCT06283524|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
218967281|NCT00451451|DRUG|BG00012|
218967282|NCT00451451|DRUG|Placebo|
218967283|NCT00451451|DRUG|Glatiramer Acetate|
218967284|NCT02739165|DRUG|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
218967285|NCT02739165|DRUG|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
218967286|NCT02759978|OTHER|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
218967287|NCT04878627|DRUG|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
218967288|NCT04878627|DRUG|Placebo|patients receive placebo for 3 weeks
218967289|NCT00347841|DRUG|Bimatoprost 0.03%, Latanoprost|
219657373|NCT05174286|BEHAVIORAL|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
219657374|NCT05174286|BEHAVIORAL|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
219657375|NCT02345265|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
219657376|NCT02345265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219657377|NCT02345265|DRUG|Cediranib Maleate|Given PO
219657378|NCT02345265|PROCEDURE|Computed Tomography|Undergo CT scan
219657379|NCT02345265|PROCEDURE|Echocardiography Test|Undergo echocardiogram
219657380|NCT02345265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219657381|NCT02345265|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219657382|NCT02345265|DRUG|Olaparib|Given PO
219657383|NCT02345265|OTHER|Questionnaire Administration|Ancillary studies
219657384|NCT03900832|OTHER|Without Heating|Subject will complete walking protocol without any heating procedure
219063747|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
219657385|NCT03900832|OTHER|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP \>20 mmHg), the subject will be removed from the bath even if the time is \<30 min."
219657386|NCT03900832|OTHER|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
219657387|NCT03900832|OTHER|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (\~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches \~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
219063748|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
219063749|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
219657388|NCT03900832|OTHER|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at \~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
219657389|NCT03900832|OTHER|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
219657390|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
219063750|NCT04327414|BEHAVIORAL|Intervention group|Standing desks
219063751|NCT00324623|BIOLOGICAL|Melan-A VLP vaccine, IMP321 adjuvant|
219657391|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
219657392|NCT05935735|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|4 in-person sessions; 1 individual and 3 group sessions
219063752|NCT00324623|BIOLOGICAL|adoptive immunotherapy|
219063753|NCT00324623|BIOLOGICAL|therapeutic autologous lymphocytes|
218967290|NCT04237012|DRUG|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
218967291|NCT04237012|OTHER|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
218967292|NCT01225770|DIETARY_SUPPLEMENT|green tea|Gargling three times daily for 90 days
218967293|NCT04755244|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
218967294|NCT04755244|DRUG|venetoclax|BCL-2 inhibitor
218967295|NCT04755244|DRUG|azacitidine|Hypomethylating agent (HMA)
218967296|NCT02804529|DEVICE|Veress needle|
218967297|NCT05447039|DRUG|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
218967298|NCT00084838|BIOLOGICAL|filgrastim|
218967299|NCT00084838|DRUG|cisplatin|
218967300|NCT00084838|DRUG|cyclophosphamide|
218967301|NCT00084838|DRUG|cytarabine|
218967302|NCT00084838|DRUG|dexrazoxane hydrochloride|
218967303|NCT00084838|DRUG|doxorubicin hydrochloride|
218967304|NCT00084838|DRUG|etoposide|
218967305|NCT00084838|DRUG|leucovorin calcium|
218967306|NCT00084838|DRUG|methotrexate|
218967307|NCT00084838|DRUG|temozolomide|
218967308|NCT00084838|DRUG|therapeutic hydrocortisone|
218967309|NCT00084838|DRUG|vincristine sulfate|
218967310|NCT00084838|RADIATION|radiation therapy|
218967311|NCT00084838|DRUG|Dactinomycin|
218967312|NCT01654627|DEVICE|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
218967313|NCT01654627|DEVICE|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
218967314|NCT00017238|DRUG|KRN5500|Given IV
218967315|NCT00017238|OTHER|pharmacological study|Correlative studies
218967316|NCT05785104|OTHER|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
218967317|NCT05785104|OTHER|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
218967318|NCT00558727|DRUG|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
218967319|NCT00122278|DRUG|Dexamethasone|Dexamethasone 10mg IV
218967320|NCT00122278|OTHER|Placebo|Placebo Dexamethasone 10mg IV
218967321|NCT01871857|DRUG|Hypertonic saline and epinephrine|
218967322|NCT01871857|DRUG|Normal saline and epinephrine|
218967323|NCT01872260|DRUG|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
218967324|NCT01872260|DRUG|Letrozole|Letrozole 2.5 mg/day
218967325|NCT01872260|DRUG|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
218967326|NCT03480035|PROCEDURE|lightwand intubation|intubation using lightwand
218967327|NCT02002611|DRUG|Lobeglitazone|
218967328|NCT02002611|DRUG|Warfarin|
218967329|NCT01728948|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
218967330|NCT01865084|DRUG|Tadalafil|Administered orally
218967331|NCT01865084|DRUG|Placebo|
218967332|NCT02469376|DRUG|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
218967333|NCT02289001|BEHAVIORAL|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
218985338|NCT01095055|BIOLOGICAL|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
218985339|NCT01095055|BIOLOGICAL|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
218985340|NCT06180720|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
218985341|NCT06180720|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
218985342|NCT06058702|DRUG|Delta-9-THC Very Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
218985343|NCT06058702|DRUG|Placebo|Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
218967334|NCT02619669|DRUG|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
218967335|NCT02619669|DRUG|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
218967336|NCT02653534|BEHAVIORAL|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
218967337|NCT04351997|PROCEDURE|Cord clamping|Umbilical cord clamping after delivery.
218967338|NCT00503516|DRUG|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
218967339|NCT00503516|DRUG|Placebo|1 sachet of 160 mg of placebo b.i.d.
218967340|NCT03319667|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
218967341|NCT03319667|DRUG|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous"
218967342|NCT03319667|DRUG|Lenalidomide|"Pharmaceutical form: Capsules~Route of administration: Oral"
218967343|NCT03319667|DRUG|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
219063754|NCT00324623|DRUG|cyclophosphamide|
219657393|NCT04726839|OTHER|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
219657394|NCT05072106|DRUG|Lurbinectedin|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
219657395|NCT05072106|DRUG|Bosentan|Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
219657396|NCT03839459|DRUG|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
219657397|NCT03713983|OTHER|Observational study|Observational study
219657398|NCT05400512|BEHAVIORAL|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
218967344|NCT06957080|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
218967345|NCT06957080|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
218967346|NCT03294473|BEHAVIORAL|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
218967347|NCT03294473|BEHAVIORAL|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
218967348|NCT03294473|BEHAVIORAL|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
219657399|NCT05400512|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
219657400|NCT05400512|DEVICE|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
218967349|NCT01994590|DRUG|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
218967350|NCT01994590|DRUG|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
218967351|NCT01994590|DRUG|Prednisone|5 mg by mouth twice daily.
218967352|NCT03878186|OTHER|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
218985344|NCT06058702|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes.
218985345|NCT03217630|OTHER|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
218985346|NCT06822452|PROCEDURE|radical prostatectomy|Robot-assisted
218985347|NCT06402071|DIAGNOSTIC_TEST|Ascitic fluid study|Ascitic fluid study will be obtained from all participants
218985348|NCT02688478|OTHER|Phthalate|Delivered by inhalation on day 1 of the triad
219657401|NCT06100809|BEHAVIORAL|Personalized coaching|Personalized fatigue mitigation coaching.
218985349|NCT02688478|OTHER|Filtered Air|Delivered by inhalation on day 1 of the triad
218985350|NCT02688478|OTHER|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
218985351|NCT03301805|DRUG|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."
219657402|NCT06100809|BEHAVIORAL|Nutrition handout|Nutrition handout
219657403|NCT06161025|DRUG|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
219657404|NCT06161025|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion
219657405|NCT06161025|DRUG|Paclitaxel|Paclitaxel will be administered as an IV infusion
219657406|NCT06161025|DRUG|Topotecan|Topotecan will be administered as an IV infusion
219063755|NCT00324623|DRUG|fludarabine phosphate|
219063756|NCT00439959|DRUG|GSK625433/placebo|
219063757|NCT05520905|OTHER|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
219657407|NCT06161025|DRUG|PLD|PLD will be administered as an IV infusion
219657408|NCT05077384|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
219657409|NCT04569240|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
219657410|NCT02785848|OTHER|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
219657411|NCT06432764|DRUG|AZD7798|Each participating patient will receive the study drug as specified in the study protocol.
219657412|NCT06432764|DRUG|[11C]AZ14132516|A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination
219657413|NCT04822688|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
219657414|NCT06057142|BEHAVIORAL|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
219657415|NCT06307496|OTHER|Smoking cessation intervention|Receive links to smoking cessation videos
219657416|NCT06307496|OTHER|Informational intervention|"Receive NCI's Clearing the Air booklet"
219657417|NCT03919500|DRUG|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
219657418|NCT03919500|DRUG|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
219657419|NCT00310466|BIOLOGICAL|Sublingual immunotherapy|once daily intake of sublingual drops
219657420|NCT00310466|BIOLOGICAL|Placebo|once daily intake of sublingual drops
219657421|NCT03787199|DEVICE|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
219657422|NCT03787199|OTHER|Treadmill|Bodyweight supported treadmill walking
219657423|NCT01458951|DRUG|tofacitinib|10 mg oral BID
219657424|NCT01458951|DRUG|Placebo|Placebo oral BID
219657425|NCT02269254|DEVICE|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
219657426|NCT02269254|DEVICE|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
219657427|NCT06007794|OTHER|JUMP group|patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
219657428|NCT00585013|DRUG|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
219657429|NCT03664830|DRUG|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
219657430|NCT06459570|BEHAVIORAL|Virtual reality based exercises|one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.
219657431|NCT06459570|OTHER|standard physical therapy|"Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes."
219657432|NCT00293371|DRUG|docetaxel|
219063758|NCT04880759|OTHER|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
219063759|NCT02291718|DRUG|Isovue|iodine contrast
219063760|NCT02997358|DRUG|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
219063761|NCT02997358|DRUG|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
219063762|NCT04724655|OTHER|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
219657433|NCT00293371|DRUG|prednisone|
219657434|NCT00293371|DRUG|vatalanib|
219657435|NCT02882880|DEVICE|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
219657436|NCT02963558|DEVICE|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
219657437|NCT01194934|DRUG|NOX-A12|4 mg/kg daily IV for 5 days
219657438|NCT01194934|DRUG|NOX-A12|2 mg/kg daily IV for 5 days
219657439|NCT01194934|DRUG|Filgrastim|5 µg/kg SC daily for 5 days
219657440|NCT01194934|DRUG|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
219657441|NCT06004492|BEHAVIORAL|blended learning program|blended learning program: 8 hours of workshops and four months of practical learning on technology platforms.
219657442|NCT02495194|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
219657443|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
219657444|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
219657445|NCT01087580|DRUG|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
219657446|NCT05320107|DRUG|Ketamine|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
219657447|NCT05320107|DRUG|Placebo|0.9% NaCl
219657448|NCT01573767|DRUG|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
219657449|NCT01573767|DRUG|Placebo|Placebo inhalation powder during treatment period
219657450|NCT01573767|DRUG|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
219657451|NCT00476892|PROCEDURE|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
219657452|NCT05473741|DRUG|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
219657453|NCT00013000|BEHAVIORAL|Test strategy for implementation guideline|
219657454|NCT00112021|DRUG|pramlintide acetate|
219657455|NCT04989972|DRUG|PSIL428|1 mg of psilocybin
219657456|NCT04989972|DIETARY_SUPPLEMENT|Oyster mushroom|1 mg of oyster mushroom
219657457|NCT04989972|DRUG|PSIL428|1 mg psilocybin
219657458|NCT06484335|BIOLOGICAL|VRC07-523LS|VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site
219657459|NCT06484335|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.
219657460|NCT06484335|BIOLOGICAL|ChAdOx1.tHIVconsv1|ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.
219657461|NCT06484335|BIOLOGICAL|ChAdOx1.HIVconsv62|ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.
219657462|NCT06484335|BIOLOGICAL|MVA.tHIVconsv4|MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.
219657463|NCT06484335|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.
219657464|NCT06484335|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic
219657465|NCT06484335|OTHER|Placebo|Normal saline (0.9% sodium chloride for injection) will be used as a placebo.
219657466|NCT05111392|BIOLOGICAL|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
219657467|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
219657468|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
219657469|NCT04529304|DEVICE|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
219657470|NCT01920256|OTHER|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
219657471|NCT01920256|OTHER|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
219657472|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
219657473|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
219657474|NCT01733485|DRUG|Aspirin|500 mg/8 h for 5 days
219657475|NCT01733485|DRUG|Indomethacin|25 mg/8 h for 5 days
219657476|NCT05161078|DEVICE|CARPEDIEM|CARPEDIEM treatment as per local standard of care
219657477|NCT03721588|OTHER|Clinical interviews, psychometric scales were applied.|
219657478|NCT01371877|DRUG|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
219657479|NCT01371877|DRUG|Low Dose Vitamin D3|Vitamin D 600 IU per day
219657480|NCT04482166|OTHER|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
219657481|NCT04482166|DEVICE|supraglottic airway device|supraglottic airway device
219657483|NCT00869557|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
219657484|NCT00869557|DRUG|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
219657485|NCT04498416|DIAGNOSTIC_TEST|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
219657486|NCT01625208|PROCEDURE|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
219657487|NCT01625208|PROCEDURE|Supraclavicular block|Standard supraclavicular brachial plexus block
219657488|NCT06091592|OTHER|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
219657489|NCT03246841|OTHER|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
219657490|NCT03013608|PROCEDURE|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
219657491|NCT04842799|OTHER|Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|"Participants will receive a link to the digital pre-test information. This will consist of text covering: Genetics and cancer risk; Genetics testing; What will happen if your test is positive; What will happen if your test is negative; Implications for insurance.~Where relevant, parts of the text will be linked through to additional information, such as insurance advice from the Association of British Insurers. Participants will be able to call a genetic counsellor on the hotline during weekday office hours, should they have any questions or require further information."
219657492|NCT04842799|OTHER|Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform|Participants will receive a digital message that their results are available. When they click this, they will receive digital notification of their negative (normal) result in short form. Full details will be provided in an individualised letter.
219657493|NCT06059729|DEVICE|Al-Lisaan|Al-Lisaan is a digital application for the self assessment and management of adult stutters.
219657494|NCT03218605|OTHER|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
219657495|NCT01580345|DIETARY_SUPPLEMENT|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
219657496|NCT01580345|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
219063763|NCT04724655|OTHER|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
219063764|NCT04724655|DRUG|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
219063765|NCT04724655|OTHER|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
219063766|NCT00276445|DRUG|beta-1,3-glucan|
219063767|NCT05441930|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
219063768|NCT05441930|DRUG|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
219063769|NCT00399477|DRUG|rasagiline mesylate|Azilect®
219657497|NCT00097305|BEHAVIORAL|Body-Oriented Therapy|
219657498|NCT00097305|BEHAVIORAL|Standardized Massage Therapy|
219657499|NCT05974956|OTHER|Mastitis care teaching protocol|It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
219063770|NCT00399477|DRUG|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
219657500|NCT06009809|DIAGNOSTIC_TEST|transesophageal echocardiogram|To measure mean blood velocity at the level of the right renal and superior mesenteric artery
219657501|NCT05450185|PROCEDURE|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
219657502|NCT00181649|DRUG|Recombinant human prolactin|
219657503|NCT03065036|DRUG|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
219657504|NCT01967095|DRUG|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
219657505|NCT00840593|PROCEDURE|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
219657506|NCT00840593|PROCEDURE|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
219657507|NCT02368210|DRUG|122-0551 Foam|Topical Foam
219657508|NCT02368210|DRUG|Vehicle Foam|Topical Foam
219657509|NCT00078949|BIOLOGICAL|rituximab|Given IV
219657510|NCT00078949|DRUG|cisplatin|Given IV
219657511|NCT00078949|DRUG|cytarabine|Given IV
219657512|NCT00078949|DRUG|dexamethasone|Given IV
219657513|NCT00078949|DRUG|gemcitabine hydrochloride|Given IV
218967353|NCT03878186|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
218967354|NCT05023707|BIOLOGICAL|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
218967355|NCT00261183|DRUG|Melatonin|
218967356|NCT05899062|OTHER|"Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp"|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
219063771|NCT00399477|DRUG|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
219657514|NCT04214405|PROCEDURE|fixation of tripodal zygomatic fractures|One point versus two point fixation of tripodal zygomatic fractures
219657515|NCT01290497|DRUG|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
219657516|NCT01290497|DRUG|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
219657517|NCT01290497|DRUG|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
219657518|NCT01153789|PROCEDURE|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
219063772|NCT00399477|DRUG|Rasagiline mesylate with Requip|Azilect®, Requip
219063773|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
219063774|NCT01194674|DRUG|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
219063775|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
219063776|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
219063777|NCT04327466|DEVICE|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
219657519|NCT01153789|OTHER|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
219657520|NCT01046357|DRUG|AZD7687|Single oral dose
219657521|NCT01046357|DRUG|Placebo|Single oral dose
218967357|NCT05899062|OTHER|Training and exercise practices with the telerehabilitation method.|The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 4 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
219657522|NCT00362531|DRUG|tacrolimus combined with prednisone|
219657523|NCT05477992|PROCEDURE|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
219657524|NCT05279768|BIOLOGICAL|UC-MSCs|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
219657525|NCT05279768|BIOLOGICAL|Secretomes|Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
219657526|NCT05279768|BIOLOGICAL|UC-MSCs and Secretomes|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
219657527|NCT05279768|BIOLOGICAL|Control|Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
219657528|NCT06035939|BEHAVIORAL|Voice Crisis Alert V2|The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
219657529|NCT06035939|BEHAVIORAL|Electronic educational materials|The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
219657530|NCT02510300|DRUG|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
218967358|NCT03574480|BEHAVIORAL|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
219657531|NCT02510300|DRUG|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219657532|NCT02510300|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219657533|NCT02510300|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
218967359|NCT03574480|BEHAVIORAL|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
218967360|NCT00003930|DRUG|cisplatin|
218967361|NCT00003930|DRUG|gemcitabine hydrochloride|
218967362|NCT00003930|DRUG|paclitaxel|
219657534|NCT02534519|OTHER|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
219657535|NCT06398392|DRUG|[18F]PBR111|\[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
219657536|NCT06398392|PROCEDURE|PBR111 injection|\[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq
219657537|NCT06398392|DEVICE|PET scan|Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.
218967363|NCT00003930|PROCEDURE|conventional surgery|
218967364|NCT00003930|RADIATION|radiation therapy|
218967365|NCT02769676|OTHER|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
218967366|NCT02769676|OTHER|usual care|Participants in the usual care arm will receive no additional interventions.
218967367|NCT00300118|DRUG|budesonide|9 mg
218967368|NCT00300118|DRUG|mesalazine|4.5 g
219657538|NCT06398392|RADIATION|PBR111 dosimetry|to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
219657539|NCT06558136|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219657540|NCT03758976|DIAGNOSTIC_TEST|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
219657541|NCT06342453|PROCEDURE|Art Therapy|Participate in CrA
219657542|NCT06342453|PROCEDURE|Discussion|Participate in art focus group, art-making
219657543|NCT06342453|OTHER|Media Intervention|Watch videos
219657544|NCT06342453|OTHER|Survey Administration|Ancillary studies
219657545|NCT04088708|OTHER|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
219657546|NCT04088708|OTHER|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
219657547|NCT02929251|DRUG|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
219657548|NCT02929251|DRUG|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
219657549|NCT02929251|DRUG|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
219657550|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
219657551|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
219657552|NCT04511988|OTHER|Diagnostic Test|blood sample (20 ml) and biopsy
219657553|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
219657554|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
219657555|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
219657556|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
219657557|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
219657558|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
219657559|NCT05412095|OTHER|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
219657560|NCT05412095|OTHER|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
219657561|NCT05412095|OTHER|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
219657562|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
219657563|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
219063778|NCT04327466|DEVICE|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
219063779|NCT00002872|BIOLOGICAL|bleomycin sulfate|
219657564|NCT06102044|DIETARY_SUPPLEMENT|Zinc Supplements|Dispersible zinc citrate tablets
219657565|NCT06102044|DIETARY_SUPPLEMENT|Placebo Supplements|Dispersible placebo tablets
219657566|NCT06394830|DRUG|VNX001|Intravesical administration of VNX001
219657567|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
219657568|NCT06242691|BIOLOGICAL|MK-1200|IV Infusion
218985352|NCT04920552|DEVICE|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
219063780|NCT00002872|DRUG|doxycycline|
219063781|NCT00002872|OTHER|talc|
219063782|NCT00305058|DRUG|Morphine|0.05 mg/kg Intravenous
219063783|NCT00305058|DRUG|Hydromorphone|0.0075 mg/kg intravenous
219063784|NCT02987413|BIOLOGICAL|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
219063785|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
219063786|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
219063787|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
219063788|NCT06516757|DIETARY_SUPPLEMENT|Boric Acid Suppository|Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
219063789|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
219657569|NCT06242691|DRUG|Antiemetic|One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
219657570|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
219063790|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
219657571|NCT04852770|BEHAVIORAL|Trial-Based Cognitive Therapy|TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
219063791|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
219063792|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
219063793|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
219063794|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
219063795|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
219063796|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
219063797|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
219063798|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
219063799|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
219063800|NCT03080519|PROCEDURE|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
219063801|NCT05316038|DIAGNOSTIC_TEST|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
219063802|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
219063803|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
219063804|NCT02745379|PROCEDURE|BFPSCs+ DFDBA+ PRF|
219063805|NCT02745379|PROCEDURE|DFDBA + PRF|
218967369|NCT05455762|OTHER|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
218967370|NCT01825603|DRUG|ADH-1|Given IV
218967371|NCT01825603|DRUG|Cisplatin|Given IV
219657572|NCT04852770|BEHAVIORAL|Mindfulness-Based Health Promotion|"The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line."
219657573|NCT04852770|BEHAVIORAL|Positive psychotherapy|PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
219657574|NCT06541158|OTHER|Best Practice|Receive usual care
219657575|NCT06541158|OTHER|Discussion|Participate in a CAB
219657576|NCT06541158|OTHER|Educational Intervention|Receive PAF pamphlet
219657577|NCT06541158|BEHAVIORAL|Health Promotion and Care|Receive the TRACT program
219657578|NCT06541158|OTHER|Media Intervention|Receive transportation awareness brief video
219657579|NCT06541158|OTHER|Questionnaire Administration|Ancillary studies
219657580|NCT01143064|DRUG|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
218967372|NCT01825603|DRUG|Gemcitabine Hydrochloride|Given IV
218967373|NCT01825603|OTHER|Laboratory Biomarker Analysis|Correlative studies
218967374|NCT00033072|DRUG|Selegiline|
219657581|NCT01143064|DRUG|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
219657582|NCT00323037|DRUG|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
219657583|NCT00323037|DRUG|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
219657584|NCT04933396|DIAGNOSTIC_TEST|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).
219657585|NCT05943184|BEHAVIORAL|Cognitive Behavioral Nursing Model|(1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
219657586|NCT06277271|OTHER|E-cigarette|Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
218967375|NCT06313879|OTHER|online education|Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.
218967376|NCT02517970|BEHAVIORAL|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
218985353|NCT04920552|DEVICE|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
218985354|NCT04545060|BIOLOGICAL|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
218985355|NCT04545060|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
218985356|NCT05036759|DRUG|68Ga-FAPI|intravenously injected with 68Ga-FAPI
219063806|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
219063807|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
219063808|NCT03567226|BEHAVIORAL|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise"
218967377|NCT03981302|OTHER|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
218967378|NCT03004196|DRUG|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
218967379|NCT03004196|DRUG|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
218967380|NCT03004196|OTHER|Control Group|No Probiotic toothpaste \& Chlorhexidine Mouthwash
218967381|NCT04406285|OTHER|Standard protocol Leukemia|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
218967382|NCT04406285|OTHER|Periodic Resistance Training Program Leukemia|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
218967383|NCT04406285|OTHER|Standard protocol Lymphoma|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
218967384|NCT04406285|OTHER|Periodic Resistance Training Program Lymphoma|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
218967385|NCT04768673|DRUG|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
218967386|NCT04768673|DRUG|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
219657587|NCT05265091|DRUG|KL590586 Capsule|Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
219657588|NCT03603951|DRUG|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
219657589|NCT00230022|BEHAVIORAL|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
218967387|NCT04768673|DRUG|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
218967388|NCT05821673|PROCEDURE|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
218967389|NCT05821673|PROCEDURE|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
218967390|NCT04383899|OTHER|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
218967391|NCT05350735|BEHAVIORAL|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
218967392|NCT01869725|DRUG|gallium Ga 68-edotreotide|Given IV
218967393|NCT01869725|PROCEDURE|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
218967394|NCT01869725|RADIATION|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
219657590|NCT05044949|OTHER|Probiotic|The study product is a probiotic strain
219657591|NCT05044949|OTHER|Placebo|The study product is a placebo to the probiotic strain
219657592|NCT06622967|DIAGNOSTIC_TEST|CadAI-B|"The ultrasound is performed following the usual process. If there are any lesions or areas of concern identified by the patient, a more detailed analysis is conducted on the affected area.~When a lesion is confirmed, the examiner verifies the results through the frozen image, while also securing the results displayed on CadAI-B.~The examiner uses the analysis from CadAI-B as a reference to make the final BI-RADS classification.~Static images and cine clips are captured from the most suspicious areas."
219657593|NCT05866367|DRUG|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
219657594|NCT05866367|DRUG|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
219657595|NCT02107287|RADIATION|IMRT Technique|
219657596|NCT01573416|OTHER|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
219657597|NCT01573416|OTHER|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
219657598|NCT05248334|DRUG|Ranibizumab Injection|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
218967395|NCT01869725|PROCEDURE|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
218967396|NCT01869725|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
218967397|NCT01143207|DRUG|Medroxyprogesterone acetate|Injectable hormonal contraceptive
218967398|NCT02235259|DRUG|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
218967399|NCT02235259|DRUG|Placebo|
218967400|NCT03490968|BEHAVIORAL|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
218967401|NCT03490968|BEHAVIORAL|Vascular Assessment|"Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
218967402|NCT01669564|OTHER|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
218967403|NCT01669564|OTHER|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
219657599|NCT05248334|PROCEDURE|PPV|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
219657600|NCT06473025|BEHAVIORAL|Information on Relative Nutritional Status|The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards
219657601|NCT06473025|BEHAVIORAL|Information on Returns to Child Nutrition|The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
218967404|NCT00123968|BIOLOGICAL|VRC-HIVDNA016-00-VP|1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
218967405|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
218967406|NCT00123968|BIOLOGICAL|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
218967407|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
219063809|NCT03567226|BEHAVIORAL|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
219657602|NCT03801824|OTHER|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
219657603|NCT03801824|OTHER|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
219657604|NCT05936216|BIOLOGICAL|TVI-Brain 1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
219657605|NCT01942031|BEHAVIORAL|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
219657606|NCT06197412|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
219657607|NCT00081796|DRUG|larotaxel (RPR109881, XRP9881)|
219657608|NCT00081796|DRUG|capecitabine|
219657609|NCT02026336|OTHER|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
219657610|NCT02707471|BEHAVIORAL|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
219657611|NCT02707471|BEHAVIORAL|general health education|general health education intervention that focuses on improving overall health.
219657612|NCT05680831|BIOLOGICAL|0.070 ppm ozone concentration|The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
219657613|NCT05680831|BIOLOGICAL|Clean air (0.0 ppm ozone)|Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
219657614|NCT01004601|DRUG|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
219657615|NCT01004601|DRUG|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
219657616|NCT01681316|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
219657617|NCT01681316|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
218967408|NCT04457973|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
218967409|NCT04457973|DEVICE|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
218967410|NCT01056328|DEVICE|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
218967411|NCT01056328|DEVICE|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
218967412|NCT00281073|DEVICE|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
218967413|NCT00281073|DEVICE|Intracardiac Echo|Intracardiac Echo Viewmate
219063810|NCT02106026|OTHER|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
219063811|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
219657618|NCT01681316|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
219657619|NCT03258008|DRUG|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
219657620|NCT03258008|BIOLOGICAL|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
219657621|NCT00240955|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219657622|NCT06500923|OTHER|Oral rehabilitation by means of implant-supported single unit crowns|Surgery: Implant placement; Prothetic rehabilitation: single unit crown
219657623|NCT01763138|BEHAVIORAL|oral health education|oral health education in the form of a pictorial pamphlet.
219657624|NCT01763138|BEHAVIORAL|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
219657625|NCT01199822|BIOLOGICAL|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
219657626|NCT03374670|DRUG|Zimura|Zimura in combination with Eylea
219657627|NCT03374670|DRUG|Eylea|Zimura in combination with Eylea
219063812|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
219063813|NCT00748436|DRUG|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
219657628|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
218967414|NCT00281073|DEVICE|ICE|ICE or TEE
218967415|NCT00187759|DRUG|cephalexin|
218967416|NCT02960997|DRUG|Sirolimus, 2%|
218967417|NCT02960997|DRUG|Vehicle|
219657629|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
219657630|NCT03644056|DRUG|IMC-001|Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
219657631|NCT02013856|DIETARY_SUPPLEMENT|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
219657632|NCT02013856|DIETARY_SUPPLEMENT|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
219657633|NCT02013856|DIETARY_SUPPLEMENT|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
219657634|NCT02013856|DIETARY_SUPPLEMENT|Placebo|Placebo control once daily for 28 days
219657635|NCT04996511|DEVICE|PulseOn|Postoperative HRV measurement
219657636|NCT03803228|DRUG|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
219657637|NCT03803228|DRUG|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
219657638|NCT03284645|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
219657639|NCT03284645|DRUG|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
219657640|NCT03284645|DRUG|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
219657641|NCT00204282|BEHAVIORAL|Educational presentation, group discussion, questionnaires|
219657642|NCT05362240|PROCEDURE|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
219657643|NCT05362240|PROCEDURE|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
219657644|NCT05795920|DRUG|Utidelone injection in combination with gemcitabine|Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
218967418|NCT05920928|RADIATION|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
218967419|NCT05920928|RADIATION|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
219208148|NCT04732962|DEVICE|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
219208149|NCT04732962|PROCEDURE|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
219657645|NCT04027075|BEHAVIORAL|Qlarity app users|Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
219657646|NCT00583375|DEVICE|Augment® Bone Graft|Augment® Bone Graft
219657647|NCT00583375|PROCEDURE|Standard of Care|Autologous Bone Graft
219657648|NCT05914675|DRUG|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
219657649|NCT00586287|OTHER|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
219657650|NCT00586287|OTHER|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
218967420|NCT01639586|BEHAVIORAL|respite platform|Impact of the respite platform patient care on health profit
218967421|NCT01639586|BEHAVIORAL|Day care|Impact of the day care on health profit of patient
219657651|NCT00586287|DRUG|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
219657652|NCT02772276|DRUG|MB-102-- single dose of 4 µmol/kg|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
219657653|NCT02772276|DRUG|MB-102-- single dose of 130 mg|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
219657654|NCT02772276|DRUG|MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
218967422|NCT01639586|BEHAVIORAL|No access to a respite structure|Control group without access to a respite structure
219657655|NCT02772276|DRUG|MB-102-- two doses of 130 mg 24 hours apart|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
219657656|NCT02772276|DRUG|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
219657657|NCT02772276|DEVICE|QuantumLeap|Optical Renal Function Monitor (ORFM)
219657658|NCT02772276|DEVICE|Radiance|Optical Renal Function Monitor (ORFM)
219657659|NCT02772276|DEVICE|Brilliance (1 or 2 sensors)|Optical Renal Function Monitor (ORFM)
219657660|NCT02772276|DEVICE|Brilliance (2-part sensor)|Optical Renal Function Monitor (ORFM)
219657661|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
219657662|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with an arcuate cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
219657663|NCT00109876|PROCEDURE|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
219657664|NCT00455520|DRUG|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
219657665|NCT00455520|DRUG|placebo|matching placebo twice daily for 12 weeks
219657666|NCT03059199|BEHAVIORAL|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
219657667|NCT00919906|DEVICE|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
219657668|NCT01752894|DEVICE|Angio-guided PCI with EES or BES|Angio-guided intervention
218967423|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
219657669|NCT01752894|DEVICE|OCT-guided PCI with EES or BES|OCT-guided intervention
218967424|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
218967425|NCT00218725|BEHAVIORAL|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
218967426|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
218967427|NCT01553032|DRUG|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
218967428|NCT01553032|RADIATION|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
218967429|NCT00003301|DRUG|irinotecan hydrochloride|
218967430|NCT00902733|OTHER|medical chart review|
218967431|NCT00902733|OTHER|questionnaire administration|
218967432|NCT00902733|PROCEDURE|fatigue assessment and management|
218967433|NCT00902733|PROCEDURE|psychosocial assessment and care|
219657670|NCT01752894|DEVICE|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
219657671|NCT01752894|DEVICE|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
218967434|NCT00902733|PROCEDURE|quality-of-life assessment|
218967435|NCT01218633|DRUG|saline infusion|saline infused at 30ml/hour
218967436|NCT01218633|DRUG|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
219657672|NCT01752894|DRUG|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.
219657673|NCT01752894|DRUG|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
219657674|NCT01477294|DRUG|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
219657675|NCT01477294|DRUG|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
219657676|NCT02848989|OTHER|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
219657677|NCT03138694|OTHER|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
219657678|NCT00943176|DRUG|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
219657679|NCT05548491|DRUG|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
219657680|NCT03808025|BEHAVIORAL|opioid education|see arm/group descriptions
219657681|NCT05859022|OTHER|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
219657682|NCT05859022|OTHER|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
219657683|NCT02887222|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
219063814|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~\- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~\- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
219063815|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
219063816|NCT06331221|OTHER|Muscle fatigue Protocol|Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
219063817|NCT02552836|BEHAVIORAL|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
219063818|NCT02552836|BEHAVIORAL|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
219657684|NCT03511716|DEVICE|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
219657685|NCT03448939|DRUG|S5G4T-1|Once a day topical cream
219657686|NCT03448939|DRUG|S5G4T-2|Once a day topical cream
219657687|NCT01541839|DEVICE|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
219657688|NCT04405622|DRUG|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
219657689|NCT05525234|DRUG|Thalidomide|Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
219657690|NCT05525234|DRUG|Placebo|Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
218967437|NCT01218633|DRUG|Exendin-9,39 at low dose|infused at 30pmol/kg/min
218967438|NCT01218633|DRUG|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
218967439|NCT03395054|OTHER|cervical stabilization exercises|cervical stabilization exercises
218967440|NCT03395054|OTHER|conventional exercises|conventional exercises
218967441|NCT04824365|DRUG|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
218967442|NCT04824365|OTHER|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
218967443|NCT01577654|DRUG|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
218967444|NCT01577654|DRUG|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
218967445|NCT01577654|DRUG|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
219063819|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
218967446|NCT01577654|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
218967447|NCT02193698|DRUG|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
218967448|NCT01770652|DRUG|Deferiprone|Oral iron chelator
219063820|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
219063821|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
219208150|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
219657691|NCT00040235|PROCEDURE|magnesium|
219657692|NCT03619824|DRUG|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
218967449|NCT05931588|OTHER|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
219063822|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
219063823|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
219657693|NCT03619824|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
219657694|NCT03619824|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219657695|NCT03619824|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
219657696|NCT03461016|BEHAVIORAL|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure \[is\] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
219657697|NCT01744002|OTHER|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
219657698|NCT01744002|OTHER|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
219657699|NCT02482064|OTHER|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
219657700|NCT06730802|DRUG|PCSK9 inhibitor|the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
219657701|NCT06730802|DRUG|Statin|the control group will receive standard statin therapy.
219657702|NCT03013764|BEHAVIORAL|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
219657703|NCT03013764|BEHAVIORAL|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
219657704|NCT01733459|DRUG|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
219657705|NCT01733459|DRUG|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
219657706|NCT01733459|DRUG|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
219657707|NCT01733459|DRUG|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
219657708|NCT04575259|DRUG|ANAVEX2-73|Oral capsules
219657709|NCT03039491|BIOLOGICAL|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
219657710|NCT03039491|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
219657711|NCT04093492|OTHER|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
218967450|NCT05931588|OTHER|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
218967451|NCT00010127|BIOLOGICAL|therapeutic autologous dendritic cells|
218967452|NCT03472066|OTHER|Previous conization|a group of women who have been conized,
218967453|NCT03472066|OTHER|no previous conization|group with asymptomatic patients on routine second trimester echography
218967454|NCT03463031|DRUG|GSP 301 NS|1 spray in each nostril twice daily for 14 days
218967455|NCT03463031|DRUG|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
219657712|NCT04093492|OTHER|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
219657713|NCT02317770|DRUG|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
218967456|NCT00290212|DRUG|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
218967457|NCT00290212|DRUG|Placebo capsules|
218967458|NCT04348890|DRUG|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
218967459|NCT04709939|OTHER|OPAT|Observation of patients who are discharged from the hospital on OPAT.
218967460|NCT04709939|OTHER|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
218967461|NCT02160353|DRUG|Abiraterone acetate, Prednisolone|
219063824|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
219063825|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
219063826|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
219657714|NCT02317770|DRUG|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
219657715|NCT04812340|OTHER|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
219657716|NCT04812340|OTHER|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
219657717|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
219657718|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
219657719|NCT05480865|DRUG|BBP-398|BBP-398 administered orally
219657720|NCT05480865|DRUG|sotorasib|sotorasib administered orally
219063827|NCT02288429|DRUG|colistimethate sodium|
219063828|NCT03841786|OTHER|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
219657721|NCT00140530|DEVICE|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
219657722|NCT00140530|DEVICE|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
219657723|NCT01472965|DRUG|ethanol|70% ethanol catheter lock therapy
219657724|NCT01472965|DRUG|heparin-saline placebo|heparin-saline placebo catheter lock therapy
219657725|NCT05995457|OTHER|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques"
219657726|NCT05995457|OTHER|Intramuscular injection of Haloperidol decanoate using standard techniques|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
219657727|NCT00628095|DRUG|CE-224,535|500 mg po BID
219657728|NCT00628095|DRUG|Placebo|no active ingredient
219657729|NCT06433934|DEVICE|Oxy2mask|Open design oxygen mask
219657730|NCT05234034|OTHER|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
219657731|NCT00189319|DRUG|Flecainide controlled release|
219657732|NCT01576003|DRUG|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
219657733|NCT01576003|DIETARY_SUPPLEMENT|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
219657734|NCT06721221|DEVICE|Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software|PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
219657735|NCT04352218|DEVICE|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
219657736|NCT04352218|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
219657737|NCT03235115|DEVICE|Methafilcon A IV|Contact Lens
219657738|NCT03235115|DEVICE|Ocufilcon B|Contact Lens
219657739|NCT03235115|DEVICE|Omafilcon A|Contact Lens
219657740|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
219657741|NCT02271711|OTHER|Laboratory Biomarker Analysis|Correlative studies
219657742|NCT02271711|BIOLOGICAL|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
218967462|NCT00920231|DEVICE|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
218967463|NCT00920231|DEVICE|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
219063829|NCT03841786|OTHER|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
219208151|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
219657743|NCT00848978|BEHAVIORAL|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
219657744|NCT05209711|PROCEDURE|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
218967464|NCT06552247|DIAGNOSTIC_TEST|Fundus Picture AI testing|G-Risk AI algorithm will assess the optic disc centered fundus picture and determine whether or not there is a need for referrable based on a pre-determined threshold (\>=0.73)
218967465|NCT02233062|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition Therapy|
219208152|NCT04495621|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
219208153|NCT04495621|DRUG|Cetuximab|Cetuximab solution for infusion administered weekly via intravenous infusion.
219657745|NCT05209711|PROCEDURE|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
218967466|NCT00931736|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
218967467|NCT00931736|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
218967468|NCT02316912|DRUG|ATX2417|Randomised double blind parallel group ascending dose assessment
218967469|NCT02316912|DRUG|Placebo|Randomised double blind parallel group ascending dose assessment
218967470|NCT01933217|DRUG|Methylphenidate|
218967471|NCT01933217|DRUG|Placebo|
218967472|NCT04779996|DIAGNOSTIC_TEST|Laboratory Samples|"1. After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~2. Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~3. Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
218967473|NCT04378907|OTHER|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
218967474|NCT01669096|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
218967475|NCT01377571|BIOLOGICAL|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
218967476|NCT02861131|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
218967477|NCT02861131|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
218967478|NCT00027937|BIOLOGICAL|aldesleukin|
218967479|NCT00027937|BIOLOGICAL|filgrastim|
218967480|NCT00027937|BIOLOGICAL|sargramostim|
218967481|NCT00027937|DRUG|busulfan|
218967482|NCT00027937|DRUG|cyclophosphamide|
218967483|NCT00027937|DRUG|melphalan|
218967484|NCT00027937|DRUG|paclitaxel|
218967485|NCT00027937|DRUG|thiotepa|
219208154|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
218967486|NCT00027937|PROCEDURE|bone marrow ablation with stem cell support|
218967487|NCT00027937|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
218967488|NCT01822704|DEVICE|Low intensity whole body vibration|
218967489|NCT01822704|DEVICE|High intensity whole body vibration|
218967490|NCT01822704|BEHAVIORAL|Leg exercises|
218967491|NCT00454701|DRUG|Alefacept exposure|Observational
218967492|NCT04953299|BEHAVIORAL|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
218967493|NCT04953299|BEHAVIORAL|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
218967494|NCT06386289|DEVICE|Cereglide 92|Aspiration of cerebral large vessels occlusions
218967495|NCT00004834|DRUG|imipramine|
218967496|NCT00004834|BEHAVIORAL|cognitive-behavioral therapy|
218967497|NCT01542073|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
218967498|NCT02937428|BEHAVIORAL|Look away from the needle|Participant looks away from the needle during vaccination
218967499|NCT02937428|BEHAVIORAL|Look at the needle|Participant looks at the needle during vaccination
219208155|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
219657746|NCT00771511|DRUG|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
219657747|NCT00771511|DRUG|Placebo|Only lidocaine gel will be appled to the cervix
219657748|NCT00648505|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
219657749|NCT00648505|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
219657750|NCT02933905|DRUG|Intravitreal Ranibizumab injection|
219657751|NCT00006305|PROCEDURE|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
219657752|NCT00006305|PROCEDURE|Coronary Artery Bypass|Coronary Artery Bypass
219657753|NCT00006305|DRUG|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
219657754|NCT00006305|DRUG|Insulin, sulfonylurea|Insulin, sulfonylurea
218967500|NCT05922956|OTHER|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
218967501|NCT01684020|BIOLOGICAL|ARTISS human fibrin sealant|
218967502|NCT00240695|DRUG|galantamine hydrobromide|
218967503|NCT03583164|DRUG|Olorofim|30mg oral tablets
218967504|NCT02291744|PROCEDURE|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
218967505|NCT02291744|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
218967506|NCT03507062|OTHER|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
218967507|NCT03507062|OTHER|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
218967508|NCT03507062|OTHER|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
218967509|NCT02636842|DRUG|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
218967510|NCT02822391|OTHER|observation|
218967511|NCT02164149|OTHER|Patients with primary colon cancer|CT scan two days after surgery
218967512|NCT03246620|DRUG|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
218967513|NCT03246620|DRUG|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
218967514|NCT03246620|DRUG|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
218967515|NCT02494362|OTHER|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
218967516|NCT04659239|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
219208156|NCT04932525|PROCEDURE|Biopsy|Blood and tumor samples for Genetic Profiling research
219657755|NCT00006305|DRUG|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
219657756|NCT01928797|DEVICE|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
219657757|NCT05207904|DRUG|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
219657758|NCT01569750|DRUG|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
219657759|NCT01569750|DRUG|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
219657760|NCT01569750|DRUG|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
219657761|NCT01569750|DRUG|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
219657762|NCT01569750|DRUG|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
219657763|NCT06188104|DRUG|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
219657764|NCT01350440|BIOLOGICAL|IVIG|Intravenous Immune Globulin
219657765|NCT05526222|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
219657766|NCT05220748|COMBINATION_PRODUCT|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
219657767|NCT05220748|BIOLOGICAL|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
219657768|NCT02745912|DRUG|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
219657769|NCT02745912|DRUG|Metformin|Metformin immediate-release tablet.
219657770|NCT04940416|DEVICE|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
219657771|NCT00662558|DRUG|celecoxib|200 mg capsules BID for 6 weeks
219657772|NCT00662558|DRUG|tramadol HCL|50 mg capsules QID for 6 weeks
219657773|NCT00047216|DRUG|tipifarnib|
219657774|NCT04814316|DIAGNOSTIC_TEST|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
219657775|NCT04970017|RADIATION|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
219657776|NCT06412458|BIOLOGICAL|IM83 CAR-T Cells|IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
218967517|NCT04659239|BIOLOGICAL|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
218967518|NCT02764125|DRUG|Stalevo|levodopa/carbidopa/entacapone
218967519|NCT02764125|DRUG|levodopa MR|levodopa MR/carbidopa/ODM-104
218967520|NCT02144129|OTHER|active Whole Body Electromyostimulation|
218967521|NCT02144129|OTHER|Passive WB-EMS|
218967522|NCT02144129|DEVICE|WB-EMS application|
219063830|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
219657777|NCT05136534|PROCEDURE|spinal anesthesia|subarachnoid anesthesia with 2% hyperbaric pilicaine
219657778|NCT05136534|PROCEDURE|local anesthesia|(Mepivacaine 2%) performed by the surgeon before skin incision
219657779|NCT05646758|DRUG|TQB2934 injection|TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
219657780|NCT00975858|PROCEDURE|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
219657781|NCT06285734|DIAGNOSTIC_TEST|Breath test|The concentration of methane and hydrogen in the exhaled gas of patients with Abdominal distention is measured by a breath test to determine the presence of SIBO and abnormal OCTT.
219657782|NCT03035435|OTHER|fast-track rehabilitation|
219657783|NCT03035435|OTHER|standard care rehabilitation|
218967523|NCT02606695|DEVICE|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
218967524|NCT02606695|DEVICE|NuvaMap|Clinical imaging software used to assess spinal alignment
219208157|NCT04967131|OTHER|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
219657784|NCT00329641|DRUG|carboplatin|Given IV
219657785|NCT00329641|DRUG|paclitaxel|Given IV
219657786|NCT00329641|DRUG|sorafenib tosylate|Given orally
218967525|NCT01727843|DRUG|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
218967526|NCT01727843|OTHER|placebo|applied topically to surgical site in OR.
218967527|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
218967528|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
218967529|NCT05695300|DIETARY_SUPPLEMENT|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
218967530|NCT04661020|DRUG|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
218967531|NCT03537612|DRUG|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
218967532|NCT03537612|OTHER|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
219657787|NCT04629924|DEVICE|sleeper one|anesthesic injection with sleeper one device
219657788|NCT04629924|DEVICE|conventional technis|anesthesic injection with the conventional technic
219657789|NCT01934075|BEHAVIORAL|Mental health treatment|6 sessions of individual mental health counseling.
219657790|NCT05771818|OTHER|Falls Prevention Program|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
219657791|NCT04394793|RADIATION|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
219657792|NCT03375515|DRUG|Hydromorphone|"1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
219657793|NCT03375515|DEVICE|PCA pump|"1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
219657794|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
219657795|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
219657796|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
219657797|NCT05704777|BEHAVIORAL|Exercise|A 24-weeks concurrent exercise training program
219657798|NCT05704777|OTHER|Control|Usual care
219657799|NCT02709681|OTHER|Physician standard-of-care in SCD patients|
218967533|NCT04454164|BIOLOGICAL|PRP|platelet rich plasma
218967534|NCT04454164|DRUG|Saline|serum physiologic
218967535|NCT02797015|DRUG|RPC1063|Oral capsule daily
218967536|NCT05258643|OTHER|Blood analysis|Venipuncture and collection of serum and whole blood
218967537|NCT00076973|DRUG|montelukast sodium|Duration of Treatment: 6 months
218967538|NCT00076973|DRUG|Comparator: placebo|Duration of Treatment: 6 months
218967539|NCT04213521|OTHER|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
218967540|NCT04213521|OTHER|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
218967541|NCT03600298|OTHER|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
218967542|NCT01994928|DEVICE|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
218967543|NCT01994928|DEVICE|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
219657800|NCT06730308|RADIATION|Radiotherapy|Hypofractionated radiotherapy
219657801|NCT06730308|DRUG|Concurrent chemotherapy|weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
219657802|NCT06730308|DRUG|Methylprednisolone|Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
218967544|NCT01994928|PROCEDURE|Intubation|Intubation
218967545|NCT00057954|PROCEDURE|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
218967546|NCT00057954|DRUG|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
218967547|NCT00057954|RADIATION|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
218967548|NCT00057954|PROCEDURE|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
218967549|NCT00057954|DRUG|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
218967550|NCT00057954|DRUG|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
218967551|NCT00057954|DRUG|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
218967552|NCT00559754|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
218967553|NCT00559754|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
219208158|NCT02834884|GENETIC|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
219657803|NCT02259634|BEHAVIORAL|Patient Navigation|Motivational Interviewing
218967554|NCT00559754|DRUG|Standard chemotherapy|As prescribed
218967555|NCT06219694|DEVICE|Laser Acupuncture|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
218985357|NCT04526860|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
218985358|NCT01617200|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
219657804|NCT00783224|DRUG|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
219657805|NCT00783224|DRUG|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
219657806|NCT00783224|DRUG|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
219657807|NCT00783224|DRUG|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
219063831|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
219063832|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
219063833|NCT00256789|PROCEDURE|Radiation|
219063834|NCT00256789|DRUG|Chemotherapy|
219063835|NCT06243653|DIAGNOSTIC_TEST|CMD test|Measured CFR and IMR
219657808|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
219657809|NCT01711619|DEVICE|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
219657810|NCT01711619|OTHER|Optimized Medical Management|Optimized medical management
219657811|NCT01601002|DRUG|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
219657812|NCT01325259|OTHER|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
219657813|NCT01325259|RADIATION|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of \[18F\]AV-45
219657814|NCT01325259|RADIATION|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
218967556|NCT06219694|DEVICE|Sham|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After \> 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
218967557|NCT05839483|DIAGNOSTIC_TEST|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
218967558|NCT00315146|DRUG|Pioglitazone|
218967559|NCT00315146|BEHAVIORAL|Resistance exercise training to maximize muscle power|
218967560|NCT00315146|BEHAVIORAL|Hypocaloric diet|
218967561|NCT00315146|DRUG|Placebo|
218967562|NCT04863547|OTHER|Data collection|Data collection
218967563|NCT05179850|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
218967564|NCT02334631|DRUG|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
218967565|NCT02334631|DRUG|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
218967566|NCT00415350|DRUG|Azithromycin|Azithromycin Tablet 250 mg daily
219063836|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
219208159|NCT02834884|GENETIC|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
219208160|NCT02834884|GENETIC|RP-1843 Arcagen|NGS panel
219208161|NCT02834884|GENETIC|RP-1920 BioRadon|NGS panel
219657815|NCT01325259|OTHER|MRI|Magnetic Resonance Imaging
219657816|NCT04127175|DEVICE|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
219657817|NCT02732236|OTHER|Rituximab|Cohort observation study
219657818|NCT02635542|DRUG|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
219657819|NCT02635542|DRUG|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
219657820|NCT04018807|OTHER|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
218967567|NCT00415350|OTHER|Placebo|Placebo tablet 1 daily
218967568|NCT05067673|OTHER|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
218967569|NCT05067673|OTHER|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
218967570|NCT05104554|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
219208162|NCT06295354|OTHER|No intervention, we just study 'aging'|No intervention, we just study 'aging'
219208163|NCT06315933|PROCEDURE|General anesthesia|General anesthesia including inhaled and intravenous
219208164|NCT05150145|RADIATION|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
219208165|NCT06839001|PROCEDURE|cryoablation|"Two devices can be used to perform cryoablation: Cryocare® and ProSense IceCure®:~* Cryocare® - This procedure utilizes two types of gases: argon gas for freezing and helium gas for thawing.~* ProSense IceCure® - This procedure uses extremely low temperatures generated by liquid nitrogen (LN2) to freeze and destroy the target tissue, without the need for an additional gas."
219657821|NCT04018807|BEHAVIORAL|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
219657822|NCT01277809|BEHAVIORAL|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
219657823|NCT01277809|BEHAVIORAL|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
219657824|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
219657825|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
218985359|NCT01617200|DRUG|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
218985360|NCT01617200|DRUG|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
218985361|NCT01617200|DRUG|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
218985362|NCT02509767|DRUG|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
218985363|NCT01459081|DRUG|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
218985364|NCT01459081|DRUG|Placebo|inhaled by mouth, twice daily, for 5 days
218985365|NCT03515278|PROCEDURE|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
218985366|NCT03515278|PROCEDURE|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
218985367|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
218985368|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
218985369|NCT02592122|DRUG|Salbutamol Aerosol|
218985370|NCT02592122|DRUG|No drugs|
218985371|NCT02892123|DRUG|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
218985372|NCT02892123|DRUG|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
218985373|NCT02892123|DRUG|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
219657826|NCT00588081|BEHAVIORAL|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
219657827|NCT04728555|PROCEDURE|Game about radiotherapy|A digital pedagogical game about radiotherapy
219657828|NCT02669914|DRUG|MEDI4736|
219657829|NCT05148845|BIOLOGICAL|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
219657830|NCT01857700|OTHER|Compensation for transport cost|
219657831|NCT01857700|OTHER|Compensation for lost wages|
219657832|NCT01857700|OTHER|Compensation for transport cost and lost wages|
219657833|NCT01857700|OTHER|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
219657834|NCT05940896|DRUG|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
218967571|NCT05104554|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
219657835|NCT03539185|DEVICE|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
219657836|NCT03539185|DEVICE|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
219657837|NCT00503997|DRUG|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
219657838|NCT00503997|DRUG|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
219657839|NCT06361615|OTHER|Single-Task|Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.
219657840|NCT06361615|OTHER|Dual-Task|DT training (multicomponent physical exercise + cognitive tasks)
219657841|NCT00001569|DRUG|Cisplatin|
218967572|NCT00009061|DRUG|Ritonavir|
218967573|NCT00009061|DRUG|Abacavir sulfate|
218967574|NCT00009061|DRUG|Nelfinavir mesylate|
218967575|NCT00009061|DRUG|Lamivudine|
218967576|NCT00009061|DRUG|GW433908|
219208166|NCT06839001|PROCEDURE|Breast Surgery (Lumpectomy or Mastectomy)|Surgery can be performed as lumpectomy or mastectomy and axillary surgery, preferably sentinel lymph node biopsy.
219657842|NCT00001569|DRUG|Paclitaxel|
219657843|NCT00001569|DRUG|5-FU|
219657844|NCT06071572|OTHER|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
219657845|NCT01195844|BIOLOGICAL|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
219657846|NCT03745040|DRUG|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
218967577|NCT03413943|OTHER|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
218967578|NCT00214500|DRUG|migalastat HCl|
219657847|NCT04510389|DIETARY_SUPPLEMENT|Maltodextrin|Bariatric patients with or without sarcopenia receiving maltodextrin
218967579|NCT04935437|OTHER|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
218985374|NCT02892123|DRUG|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
218985375|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
218985376|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
218985377|NCT02638701|DRUG|Infliximab|Please see protocol for details.
218985378|NCT00990405|DRUG|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
218985379|NCT02319837|DRUG|Enzalutamide|
218985380|NCT02319837|DRUG|Placebo (No longer applicable in Open Label study period)|Sugar pill to mimic enzalutamide
218985381|NCT02319837|DRUG|Leuprolide Open Label|
219657848|NCT04510389|DIETARY_SUPPLEMENT|Whey|Bariatric patients with or without sarcopenia receiving whey protein
219657849|NCT06245967|DEVICE|Frequency specific microcurrent therapy|Concussion protocol
219657850|NCT06245967|DEVICE|Sham Frequency specific microcurrent therapy|Shan concussion protocol
219657851|NCT00851773|DRUG|semaglutide|0.1 mg once weekly, s.c. injection
219657852|NCT00851773|DRUG|semaglutide|0.2 mg once weekly, s.c. injection
219657853|NCT00851773|DRUG|semaglutide|0.4 mg once weekly, s.c. injection
219657854|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
219657855|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
219657856|NCT00851773|DRUG|placebo|0.1 mg once weekly, s.c. injection
219657857|NCT00851773|DRUG|placebo|0.2 mg once weekly, s.c. injection
219657858|NCT00851773|DRUG|placebo|0.4 mg once weekly, s.c. injection
219657859|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
219657860|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
219657861|NCT05170230|DRUG|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
219657862|NCT00240825|DRUG|Ibuprofen|
219657863|NCT00240825|DRUG|Placebo|
219657864|NCT00240825|DRUG|Acetaminophen|
219657865|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
219657866|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
219657867|NCT03632226|DRUG|18F-OGA-1|
219657868|NCT05433480|DRUG|BPI-16350|BPI-16350 400 mg, orally once daily
219657869|NCT05433480|DRUG|placebo|Placebo 400 mg, orally once daily
218967580|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals \[kPa\] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity \[(m/sec)/kHz\] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
218967581|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
218967582|NCT06224543|DEVICE|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
218967583|NCT06224543|DRUG|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
219208167|NCT02944487|DRUG|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
219208168|NCT02944487|DRUG|Placebo|Matching placebo capsules
219208169|NCT06964906|PROCEDURE|HIFU|HIFU therapy is administered to the targeted breast lesion site.
219657870|NCT05433480|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
219657871|NCT05037539|DRUG|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
219657872|NCT05037539|DRUG|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
219657873|NCT02799173|BIOLOGICAL|RANKL/OPG ratio|
219657874|NCT02799173|DEVICE|bone densitometry|
219657875|NCT02799173|DEVICE|fan beam CT scan|
219657876|NCT02799173|DEVICE|Doppler ultrasound|
219657877|NCT00104468|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
219657878|NCT00081926|DRUG|Gleevec|
219657879|NCT02991014|BEHAVIORAL|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
219657880|NCT02991014|BEHAVIORAL|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
219657881|NCT02991014|BEHAVIORAL|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
219657882|NCT03217019|PROCEDURE|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
219657883|NCT03217019|PROCEDURE|Direct|catheter insertion without guidewire assist(catheter over needle)
219657884|NCT00776802|DRUG|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
219657885|NCT00776802|DRUG|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
219208170|NCT06964906|DRUG|Toripalimab|240 mg, IV infusion, Q3W
219657886|NCT02851979|OTHER|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
219063837|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
219063838|NCT05090501|BEHAVIORAL|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
219063839|NCT03424681|DRUG|Modafinil|Modafinil 300 mg by mouth daily
219657887|NCT03361436|DRUG|Eribulin Mesylate|Given IV
219657888|NCT03361436|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219657889|NCT03361436|OTHER|Laboratory Biomarker Analysis|Correlative studies
218967584|NCT03601000|DRUG|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
218967585|NCT03601000|DRUG|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
218967586|NCT00147251|DRUG|FDA approved drugs to treat blood pressure and cholesterol|
218967587|NCT04795986|PROCEDURE|HEARO Procedure|robotic access to the middle and inner ear in cochlear implantation
219063840|NCT03424681|OTHER|Placebo|Placebo
219063841|NCT04307186|DRUG|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
219063842|NCT04307186|DRUG|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
219063843|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
219063844|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
219063845|NCT02106468|DRUG|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
219063846|NCT02106468|DRUG|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
219657890|NCT03361436|OTHER|Quality-of-Life Assessment|Ancillary studies
219657891|NCT03361436|OTHER|Questionnaire Administration|Ancillary studies
219657892|NCT03361436|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219657893|NCT02733575|OTHER|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
219657894|NCT01676506|DRUG|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
218967588|NCT04804501|DEVICE|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
218967589|NCT04804501|OTHER|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
219063847|NCT02465229|PROCEDURE|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
219063848|NCT05499923|DEVICE|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
219063849|NCT04957602|OTHER|Blood collection|Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
219063850|NCT04326491|DIAGNOSTIC_TEST|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
219063851|NCT02410395|PROCEDURE|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
219063852|NCT02410395|PROCEDURE|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
219063853|NCT01175226|DRUG|BTA798|BTA798 twice daily
219063854|NCT01175226|DRUG|Placebo|Placebo twice daily
219208171|NCT06964906|DRUG|nab-Paclitaxel (nab-P)|125 mg/m2, IV infusion, QW
219208172|NCT06964906|DRUG|Epirubicin (E)|90 mg/m2, IV infusion, Q3W
219208173|NCT06964906|DRUG|Cyclophosphamide (C)|600 mg/m2, IV infusion, Q3W
219657895|NCT01676506|PROCEDURE|Ranibizumab Injection|
219657896|NCT01118988|BEHAVIORAL|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
218967590|NCT04437953|DRUG|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, … 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
218967591|NCT03149393|DRUG|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
218967592|NCT03149393|DRUG|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
218967593|NCT05732987|OTHER|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
218967594|NCT05732987|OTHER|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
218967595|NCT05732987|OTHER|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
218967596|NCT05732987|OTHER|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
218967597|NCT01629706|DEVICE|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
218967598|NCT01629706|DEVICE|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
218967599|NCT01629706|DEVICE|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
218967600|NCT01629706|DEVICE|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
218967601|NCT01629706|DEVICE|Habitual lens care|Lens care per habitual use
218967602|NCT05324176|RADIATION|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
218967603|NCT03368248|OTHER|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
218967604|NCT05536505|GENETIC|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
218967605|NCT03376048|PROCEDURE|Wound infiltration plus TAP|"1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
218967606|NCT03376048|PROCEDURE|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
218967607|NCT03376906|PROCEDURE|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
218967608|NCT03376906|PROCEDURE|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
218967609|NCT03376906|PROCEDURE|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
218967610|NCT03003156|PROCEDURE|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
218967611|NCT03003156|PROCEDURE|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
219208174|NCT06965491|DIETARY_SUPPLEMENT|Placebo Supplement|"Placebo supplement:~Oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water"
219208175|NCT06965491|DIETARY_SUPPLEMENT|Ketone ester supplement|Ketone ester supplement Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
219657897|NCT03453996|OTHER|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
219657898|NCT03453996|OTHER|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
219657899|NCT02479971|DRUG|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
219657900|NCT02479971|DRUG|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
219657901|NCT03566875|PROCEDURE|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
219657902|NCT03566875|PROCEDURE|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
219657903|NCT04620694|DEVICE|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
219657904|NCT01048970|OTHER|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
219657905|NCT01048970|DIETARY_SUPPLEMENT|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
219657906|NCT02623842|DEVICE|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
219657907|NCT02565706|BEHAVIORAL|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
219657908|NCT02565706|BEHAVIORAL|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
219657909|NCT04632056|DRUG|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
219657910|NCT00803309|DRUG|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
219657911|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
219657912|NCT00803309|DRUG|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
219657913|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
218967612|NCT00701376|OTHER|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
218967613|NCT01429038|BIOLOGICAL|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
218967614|NCT04448782|DIAGNOSTIC_TEST|Asynchronies detection|Asycnhronies detection
218967615|NCT02537574|DRUG|NTX/BUP|Daily doses
218967616|NCT02537574|DRUG|NTX/PBO-B|Daily doses
219063855|NCT02953626|BEHAVIORAL|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
219208176|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
218967617|NCT02537574|DRUG|PBO-N/PBO-B|Daily doses
218967618|NCT02663687|DRUG|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
218967619|NCT02663687|DRUG|Placebo|Subjects will receive matching placebo
218967620|NCT02663687|DRUG|SHP623|SHP623
218967621|NCT02663687|DRUG|Placebo|Placebo
218967622|NCT05774977|OTHER|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
219657914|NCT03623971|DEVICE|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
219657915|NCT02897388|OTHER|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
219657916|NCT03315611|DRUG|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
219657917|NCT03315611|OTHER|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
219657918|NCT02253732|BEHAVIORAL|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
219657919|NCT00477997|DEVICE|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
219657920|NCT06294873|DIAGNOSTIC_TEST|A screening device for the detection of colorectal and other aerodigestive tract cancers|DNA test to screen to detect colon cancer and precancerous lesions
219657921|NCT04012307|DRUG|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
219657922|NCT04012307|DRUG|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
219657923|NCT02100137|OTHER|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
219657924|NCT06510920|BEHAVIORAL|Aerobic exercise|The mixed design scheme of football and volleyball sports technology and competition will be adopted.aerobic exercise intensity will be moderate-intensity aerobic exercise load , and the intervention time was 12 weeks, 60 minutes each time, twice a week. The main preparation activities were jogging and special preparation activities (10 minutes), and the main part was technical teaching combined with competition (60 minutes).The end part is mostly jogging and stretching (10 minutes). Two subjects in each group were selected to wear Decathlon Bluetooth heart rate band, and the exercise intensity was controlled by detecting the heart rate of the subjects.
219657925|NCT03985189|DRUG|ME-401|"\[Phase 1 study (DLT evaluation)\] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~\[Roll over study\] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
219657926|NCT01395173|PROCEDURE|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
219657927|NCT01395173|PROCEDURE|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
219657928|NCT03646149|BEHAVIORAL|Housing Skills Training Group|12-session social skills training group for persons with homeless experiences and serious mental illness delivered once a week for 12 weeks
218967623|NCT05774977|OTHER|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
218967624|NCT05774977|OTHER|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
218967625|NCT05774977|OTHER|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
218967626|NCT05774977|OTHER|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
218967627|NCT05774977|OTHER|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
218967628|NCT06556264|DRUG|Dupilumab|Dupilumab 300mg every 2 weeks for 24 weeks
218967629|NCT06556264|OTHER|Placebo|Placebo 300mg every 2 weeks for 24 weeks
218967630|NCT04807478|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
219208177|NCT05719883|DEVICE|Maurora® Sirolimus Eluting Stent System|The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
219657929|NCT01551706|DIETARY_SUPPLEMENT|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
219657930|NCT01551706|OTHER|Placebo|Placebo
219657931|NCT00475878|DRUG|escitalopram|10mg escitalopram/day for 3 months
219657932|NCT00475878|DRUG|placebo|placebo capsule/day for 3 months
219657933|NCT03040505|OTHER|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
218967631|NCT02492581|DRUG|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
218985382|NCT04134052|DRUG|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
219657934|NCT04678401|RADIATION|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
219657935|NCT04678401|DRUG|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
219657936|NCT04678401|DRUG|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
219657937|NCT04678401|DRUG|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
219657938|NCT04678401|DRUG|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
219657939|NCT04678401|BIOLOGICAL|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
219657940|NCT04678401|BIOLOGICAL|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
219657941|NCT04678401|PROCEDURE|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
219657942|NCT00567697|DRUG|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
219657943|NCT00567697|DRUG|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
219657944|NCT00231283|DEVICE|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
219657945|NCT05016297|DRUG|Baricitinib|baricitinib 4mg per day
219657946|NCT05016297|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
219657947|NCT00019422|DRUG|carboplatin|
219657948|NCT00019422|DRUG|lobradimil|
219657949|NCT05956405|BEHAVIORAL|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
218967632|NCT01424202|DEVICE|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
218967633|NCT02297282|BEHAVIORAL|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
218967634|NCT03220529|DEVICE|Brillouin Ocular Scanner|
218967635|NCT05648071|DRUG|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
218967636|NCT03595774|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice
218967637|NCT00112697|DRUG|cisplatin|
218967638|NCT00112697|DRUG|docetaxel|
218967639|NCT00112697|DRUG|fluorouracil|
218967640|NCT00112697|RADIATION|radiation therapy|
218967641|NCT02891005|DEVICE|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
219208178|NCT05719883|DEVICE|APOLLO™ Intracranial Stent System|The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
219657950|NCT05956405|BEHAVIORAL|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
218967642|NCT02891005|DEVICE|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
219657951|NCT02379507|OTHER|DEC033 Study Product|Apply twice daily
219657952|NCT04952207|DRUG|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
219657953|NCT01741571|DEVICE|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
219657954|NCT04246645|OTHER|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
219657955|NCT04494594|BEHAVIORAL|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
219657956|NCT00017680|DRUG|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
219657957|NCT00017680|PROCEDURE|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
219657958|NCT01836991|PROCEDURE|surgery|
218967643|NCT02770261|DRUG|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
218967644|NCT02770261|DRUG|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
218967645|NCT02770261|DRUG|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
218967646|NCT02770261|DRUG|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
218967647|NCT02770261|DRUG|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
218967648|NCT02770261|DRUG|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
218967649|NCT01151098|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
218967650|NCT04988828|DEVICE|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
218967651|NCT06329115|OTHER|Exercise training|Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
218967652|NCT00190944|DRUG|Teriparatide|
218967653|NCT00190944|DRUG|placebo|
218967654|NCT04384588|BIOLOGICAL|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
218967655|NCT04686123|OTHER|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
218967656|NCT04686123|OTHER|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
218967657|NCT00160589|DRUG|Levocetirizine|
218967658|NCT01015144|DRUG|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
218967659|NCT03533582|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218967660|NCT03533582|DRUG|Carboplatin|Given IV
218967661|NCT03533582|DRUG|Cisplatin|Given IV
218967662|NCT03533582|DRUG|Doxorubicin|Given IV
218967663|NCT03533582|DRUG|Etoposide|Given IV
219208179|NCT06965244|DRUG|Lenalidomide|Lenalidomide with oral dose of 5 mg/day during 16 weeks associated with low-dose aspirin of 100 mg/day except for patients already receiving anticoagulant therapy
219657959|NCT00022880|DRUG|Iodine-131 Anti-B1 Antibody|
219657960|NCT01225289|DIETARY_SUPPLEMENT|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
219657961|NCT01225289|DRUG|Placebo|1 capsule per day for six months
219657962|NCT00401960|DRUG|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
219657963|NCT05679180|DEVICE|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
219657964|NCT02428894|DEVICE|LVAD|
219657965|NCT04670380|OTHER|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
218967664|NCT03533582|DRUG|Fluorouracil|Given IV
218967665|NCT03533582|DRUG|Gemcitabine|Given IV
218967666|NCT03533582|DRUG|Irinotecan|Given IV
218967667|NCT03533582|DRUG|Oxaliplatin|Given IV
218967668|NCT03533582|OTHER|Patient Observation|Undergo watchful waiting
218967669|NCT03533582|PROCEDURE|Resection|Undergo surgical resection
218967670|NCT03533582|DRUG|Sorafenib|Given PO
218967671|NCT03533582|DRUG|Vincristine Sulfate|Given IV
218967672|NCT03059433|OTHER|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
218967673|NCT05909527|BIOLOGICAL|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
218967674|NCT00926068|DRUG|HO/03/03 10µg|
218967675|NCT00926068|DRUG|Placebo|
218967676|NCT04186936|DRUG|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
218967677|NCT04186936|DRUG|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
218967678|NCT04186936|DRUG|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
218967679|NCT01593722|DRUG|Diethylcarbamazine|single dose
218967680|NCT01593722|DRUG|Ivermectin|single dose
218967681|NCT04490824|DEVICE|KELEA Excellerated Water|Water with increased kinetic activity as assessed by published methods of the PI
219208180|NCT06965244|DRUG|Methotrexate (MTX)|Methotrexate oral dose of 15 mg per week for individuals \< 80 kg, and a dose of 20mg per week for those over 80 kg, along with an equal dose of folic acid supplementation given 48 hours after each dose
219657966|NCT02649426|DEVICE|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
219657967|NCT02649426|DEVICE|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
219657968|NCT03173365|DRUG|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
219657969|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
219657970|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
218967682|NCT04490824|DEVICE|Water Without an Elevated Level of KELEA|Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
218967683|NCT01489371|OTHER|Laboratory Biomarker Analysis|Correlative studies
218967684|NCT01489371|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
218967685|NCT01489371|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
218967686|NCT01285453|DRUG|vadimezan|
218967687|NCT00434343|OTHER|Global Therapeutic Massage (GTM)|
218967688|NCT00434343|OTHER|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
218967689|NCT01148797|DRUG|Canakinumab|
218967690|NCT05141825|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
218967691|NCT01554228|OTHER|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
218967692|NCT00346944|PROCEDURE|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
218967693|NCT00116168|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
218967694|NCT00116168|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
218967695|NCT00116168|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
218967696|NCT00116168|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
218967697|NCT03110744|DRUG|Palbociclib|application on 21 consecutive days of a 28 days cycle
218967698|NCT06364306|PROCEDURE|Robotically-assisted ventral hernia repair (RVHR)|"3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes."
218985383|NCT04741607|DEVICE|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
218985384|NCT04741607|PROCEDURE|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
218985385|NCT04741607|PROCEDURE|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
218985386|NCT00003052|DRUG|doxorubicin hydrochloride|
218985387|NCT00003052|DRUG|etoposide|
218985388|NCT00003052|DRUG|ifosfamide|
218985389|NCT00003052|PROCEDURE|conventional surgery|
218985390|NCT00003052|PROCEDURE|hyperthermia treatment|
218985391|NCT00003052|RADIATION|radiation therapy|
218985392|NCT05767320|PROCEDURE|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
218985393|NCT05767320|PROCEDURE|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
218985394|NCT01790776|RADIATION|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
218985395|NCT01790776|RADIATION|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
219657971|NCT02612350|GENETIC|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
219657972|NCT01606202|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
219657973|NCT01606202|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
219657974|NCT02190409|DEVICE|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
219657975|NCT02859688|GENETIC|pyrosequencing|
219657976|NCT02859688|GENETIC|Methylome|
219657977|NCT05658640|DRUG|Trametinib|Oral
219657978|NCT05658640|DRUG|Dexamethasone|Oral/ Intravenous
219657979|NCT05658640|DRUG|Cyclophosphamide|Intravenous
219657980|NCT05658640|DRUG|Cytarabine|Intravenous
219657981|NCT05658640|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
219657982|NCT01634451|OTHER|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
219657983|NCT01634451|OTHER|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
219657984|NCT01634451|DEVICE|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
219657985|NCT06730451|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
219657986|NCT00444860|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
219657987|NCT05756361|BEHAVIORAL|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
219657988|NCT05133414|OTHER|Selective left subclavian ansae stimulation|Percutaneous, transarterial approach for target stimulation
219657989|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
219657990|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
219657991|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
219657992|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
219657993|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
219657994|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
219657995|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
219657996|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
219657997|NCT00840736|PROCEDURE|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
219657998|NCT00840736|PROCEDURE|vertical banded gastroplasty|vertical banded gastroplasty
219657999|NCT00164502|BEHAVIORAL|Community-based eight session group self-management program|
219658000|NCT02030496|PROCEDURE|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
219063856|NCT05928598|BEHAVIORAL|Survey questionnaires|Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
219063857|NCT05928598|BEHAVIORAL|Epilepsy Visit Planner|"Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record."
219063858|NCT05928598|BEHAVIORAL|Questionnaires for Providers|Providers will be asked to complete a survey after the clinic visit for the intervention group.
219658001|NCT02030496|OTHER|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
219658002|NCT00771979|DRUG|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
219658003|NCT00771979|DRUG|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
219658004|NCT06509490|DRUG|KD-025 cell injection|This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
219658005|NCT01678703|DEVICE|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
219658006|NCT01678703|DRUG|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
219063859|NCT00150631|DRUG|Candesartan|placebo controlled double blind
219063860|NCT06157931|BEHAVIORAL|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
219658007|NCT02584959|DRUG|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days
219658008|NCT02584959|DRUG|Placebo|Placebo
219658009|NCT04849585|OTHER|semi-directed entretien|semi-directed entretien
219658010|NCT04909814|BIOLOGICAL|The performance of colposcopy in vaccinated women|Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
219658011|NCT03526055|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
219658012|NCT00195494|DRUG|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
219063861|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
219063862|NCT02854540|DEVICE|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
219063863|NCT00087074|DRUG|temsirolimus|Given IV
219063864|NCT00087074|OTHER|laboratory biomarker analysis|Optional correlative studies
219063865|NCT03910127|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219063866|NCT03910127|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219063867|NCT03910127|DRUG|Anlotinib|matching placebo
219063868|NCT00438516|BEHAVIORAL|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
219063869|NCT02837341|DEVICE|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
219063870|NCT00949351|DRUG|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
219063871|NCT00754845|DRUG|letrozole|Given orally
219063872|NCT00754845|OTHER|placebo|Given orally
219063873|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
218967699|NCT06364306|PROCEDURE|Open ventral hernia repair (OVHR)|Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
219658013|NCT00195494|DRUG|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
219658014|NCT00195494|DRUG|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
219658015|NCT03252366|DEVICE|GELFOAM|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
219658016|NCT03252366|DEVICE|xenograft|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
219658017|NCT06730269|BEHAVIORAL|Face-to-Face Rehabilitation Program|The Face-to-Face Rehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group engaged in the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction. The exercises were performed three times per week over six weeks, under the direct supervision of a trained therapist. This setup ensured real-time feedback, personalized adjustments, and guidance during each session, optimizing the effectiveness of the rehabilitation process.
219658018|NCT06730269|BEHAVIORAL|Telerehabilitation Program|The Telerehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group followed the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction, performed three times per week over six weeks. The program was delivered remotely through the Fiziu platform, allowing therapists to provide virtual guidance, feedback, and monitoring during the sessions. This approach offered flexibility for families and ensured accessibility to rehabilitation services from the comfort of their homes.
219658019|NCT05023551|DRUG|DSP-0390|DSP-0390 administered orally
219658020|NCT02624622|PROCEDURE|Chlorhexidine application to cord by mother|
219658021|NCT02624622|PROCEDURE|Chlorhexidine application by CHW|
219658022|NCT00878605|DRUG|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
219658023|NCT00878605|DRUG|Placebo|Placebo control
219658024|NCT03353948|DRUG|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
219658025|NCT03353948|DRUG|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
219658026|NCT04573166|PROCEDURE|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
219658027|NCT05323747|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
218967700|NCT01763671|DRUG|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
219063874|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
219063875|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
219658028|NCT05691621|DRUG|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
219658029|NCT05326126|DEVICE|coronary physiology|To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
219658030|NCT03019003|DRUG|Oral Decitabine|DNA methyltransferase inhibitor
219658031|NCT03019003|DRUG|Durvalumab|anti-PD-L1
219658032|NCT03019003|DRUG|5' Azacitidine|DNA methyltransferase inhibitor
219658033|NCT03019003|DRUG|Tremelimumab|anti-CTLA4
219658034|NCT01133496|DRUG|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
219658035|NCT02300961|BEHAVIORAL|Cognitive rehabilitation program|
219658036|NCT05599347|DRUG|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
219658037|NCT05599347|OTHER|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
219658038|NCT06153173|DRUG|Mirdametinib|Mirdametinib is administered by mouth twice daily on a continuous schedule, with each cycle being 4 weeks. Patients are instructed to take consecutive doses separated by a minimum of 6 hours and a maximum of 14 hours.
219658039|NCT06350643|OTHER|Quit and Screen Project training|This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by the G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training.
219658040|NCT06350643|OTHER|G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training|The G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
219658041|NCT05808764|DRUG|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
219658042|NCT05211895|DRUG|Durvalumab|Durvalumab IV (Intravenous infusion)
219658043|NCT05211895|DRUG|Domvanalimab|Domvanalimab IV (Intravenous infusion)
219658044|NCT05211895|OTHER|Placebo|Placebo IV (Intravenous infusion)
219658045|NCT05245331|DEVICE|Peristeen® Transanal irrigation system with the conic catheter|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
219658046|NCT05245331|DEVICE|Standard reusable enema|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
219658047|NCT06234956|BIOLOGICAL|BIMERVAX|BIMERVAX
219658048|NCT05735184|DRUG|Ziftomenib|Oral Administration
219658049|NCT05735184|DRUG|Venetoclax|Oral Administration
219658050|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
219658051|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
219658052|NCT05735184|DRUG|Cytarabine|Intravenous Administration
219658053|NCT05735184|DRUG|Quizartinib|Oral Administration
219658054|NCT05840406|DRUG|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
218967701|NCT01763671|DRUG|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
219658055|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
219658056|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
219658057|NCT05840406|DRUG|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
219658058|NCT05840406|DRUG|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
219658059|NCT05840406|DRUG|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
219658060|NCT05844735|DRUG|SAR441566|Tablet
219658061|NCT05844735|DRUG|Placebo|Tablet
219658062|NCT05844735|DRUG|Ciprofloxacin|Tablet
219658063|NCT03910452|DRUG|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
219658064|NCT03910452|DRUG|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
219658065|NCT03910452|DRUG|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
219658066|NCT03910452|DRUG|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
219063876|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
219063877|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
219063878|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
219063879|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
219063880|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
219063881|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
219063882|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
219063883|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
219063884|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
219063885|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
219063886|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
219063887|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
219063888|NCT02278601|DEVICE|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
219658067|NCT03910452|RADIATION|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
219658068|NCT03910452|BIOLOGICAL|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
219063889|NCT02278601|DRUG|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
219063890|NCT02278601|DRUG|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
219063891|NCT00240422|DRUG|Telmisartan|
219063892|NCT00240422|DRUG|Ramipril|
219063893|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
219063894|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
219063895|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
219063896|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
219658069|NCT06484452|DEVICE|No Intervention|No Intervention
219658070|NCT04912388|OTHER|Lumbal stabilization excercises|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
219658071|NCT04912388|OTHER|Conventional exercises|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
219658072|NCT01443494|OTHER|NE|norepinephine
219658073|NCT04417140|BIOLOGICAL|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
219658074|NCT03812562|BIOLOGICAL|Nivolumab|Given IV
219658075|NCT03812562|RADIATION|Yttrium Y 90 Glass Microspheres|Given IV
219658076|NCT05481268|OTHER|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
219658077|NCT05481268|OTHER|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
219658078|NCT05481268|OTHER|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
219658079|NCT01312714|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
219658080|NCT01312714|DRUG|Placebo|3 tablets of 1000 IU daily for 26 weeks
219658081|NCT03056365|PROCEDURE|Advanced Nurse (AN)|Protocoled AN-based management of detox
219658082|NCT03056365|PROCEDURE|General Practitioner (GP)|'As usual' medical management of detox
219658083|NCT04020081|OTHER|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
219658084|NCT06443801|OTHER|THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY|"The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria."
219658085|NCT02622841|PROCEDURE|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
219658086|NCT03994614|OTHER|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
219658087|NCT01740869|BIOLOGICAL|Autologous Intrathecal Hematopoietic Stem Cells|Patients will be stimulated with granulocyte colony-stimulating factor (G-CSF) for 3 consecutive days. Bone marrow will be harvested, processed to isolate CD34+ hematopoietic stem cells and reduce red blood cells. An inoculum of 5-10 mL will then be infused intrathecally into the cerebrospinal fluid.
219658088|NCT01740869|OTHER|Observation with IDEA and CARS Scales|Participants will be observed for 6 months without active intervention. They will be evaluated using the Childhood Autism Rating Scale (CARS) and the IDEA scale at baseline, 30 days, and 180 days. After 6 months, participants may crossover to the experimental arm.
219658089|NCT06620367|PROCEDURE|conventional guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks
219658090|NCT06620367|PROCEDURE|digital guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
219658091|NCT00270283|DRUG|epoetin alfa|
219658092|NCT06080906|BIOLOGICAL|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
219658093|NCT06080906|BIOLOGICAL|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
219658094|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
219658095|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
219658096|NCT06521580|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
219658097|NCT01528657|OTHER|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
219658098|NCT01528657|OTHER|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
219658099|NCT03802565|DRUG|Tolperisone|TID
218967702|NCT01763671|DRUG|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
218967703|NCT02788474|DRUG|nintedanib|
218967704|NCT02788474|DRUG|placebo|
219063897|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
219063898|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
219063899|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
218967705|NCT04340297|DRUG|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
219063900|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
219063901|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
219063902|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
219063903|NCT02422030|DRUG|Lipitor Tab. 40mg|
219063904|NCT02422030|DRUG|Trilipix 135mg|
219063905|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
219063906|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
219063907|NCT05897216|DRUG|CKD-383|QD, PO
219063908|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
219658100|NCT03802565|DRUG|Placebo|Placebo
219658101|NCT05619406|DEVICE|Riskometer Application|The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.
219658102|NCT05619406|BEHAVIORAL|Routine Clinic Therapy|After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
219658103|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
219658104|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
219658105|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
219658106|NCT03759145|OTHER|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
219658107|NCT03759145|OTHER|usual care|participants continued their planned rehabilitation sessions
218967706|NCT04340297|DRUG|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
218967707|NCT04340297|DRUG|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
218967708|NCT02317146|DRUG|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
219063909|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
219063910|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
219063911|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
219063912|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
219658108|NCT00005604|BIOLOGICAL|recombinant interleukin-12|Given IV
219658109|NCT00005604|BIOLOGICAL|aldesleukin|Given SC
219658110|NCT00005604|OTHER|laboratory biomarker analysis|Correlative studies
219658111|NCT05477212|DIETARY_SUPPLEMENT|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
218967709|NCT01272284|DEVICE|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
218967710|NCT00117286|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
219658112|NCT06686251|DEVICE|App LuAna|Inclusion of chest x-ray images in the LuAna app to receive feedback on lung findings.
219658113|NCT07138118|BEHAVIORAL|Blood Flow Restriction + Dual Task Training|Participants will undergo lower limb resistance and gait training while wearing blood flow restriction cuffs at 40% of their individualized arterial occlusion pressure. Tasks include walking, sit-to-stand, and obstacle crossing combined with verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
219658114|NCT07138118|BEHAVIORAL|Dual Task Training Only|Participants will perform the same cognitive-motor dual task training without blood flow restriction. Tasks include forward walking, obstacle crossing, and sit-to-stand exercises with concurrent cognitive tasks such as verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
219658115|NCT06879418|OTHER|Low dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|Patients will receive 2000 shocks, 1 bar (energy flux density 0.045 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching exercises for upper trapezius.
218967711|NCT02351986|PROCEDURE|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
218967712|NCT02351986|OTHER|ice pack|
218967713|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|2.5mg po daily
218967714|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
218967715|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
218967716|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|150mg po monthly
218967717|NCT00048061|DIETARY_SUPPLEMENT|Calcium|500 mg/day
218967718|NCT00048061|DIETARY_SUPPLEMENT|Vitamin D|400 IU/day
218967719|NCT04152707|DEVICE|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
218967720|NCT05102695|DIAGNOSTIC_TEST|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
218967721|NCT03751228|DRUG|BMS-986165|Swish and expectorate after tasting
219658116|NCT06879418|OTHER|Medium dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with 4 bars (Energy flux density 0.18 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching for upper trapezius
219658117|NCT06879418|OTHER|sham shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with energy flus density 0.00 on upper trapezius trigger points plus strengthening and stretching exercise for upper trapezius.
219658118|NCT07039461|DEVICE|OptiLIGHT|three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment
219658119|NCT07044687|DRUG|Venetoclax|Oral Tablet
219658120|NCT07044687|DRUG|Azacitidine|Subcutaneous (SC) Injection
219658121|NCT07044687|DRUG|Azacitidine|Intravenous (IV) Injection
218967722|NCT03751228|DRUG|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
219658122|NCT06735664|PROCEDURE|Biopsy|Undergo ultrasound guided biopsy
219658123|NCT06735664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218967723|NCT01323946|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
218967724|NCT01206868|PROCEDURE|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
218967725|NCT01206868|PROCEDURE|Control|Standard kidney transplantation
218967726|NCT03300310|OTHER|nursing visit|nursing visit at patient home
218967727|NCT03300310|OTHER|no nursing visit|the patient take his treatment without nursing visit
218967728|NCT03871335|DIAGNOSTIC_TEST|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
218967729|NCT04005170|DRUG|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
218967730|NCT04005170|DRUG|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
218967731|NCT04005170|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
218967732|NCT00992927|PROCEDURE|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
218967733|NCT00992927|PROCEDURE|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
218967734|NCT03543618|DEVICE|Sloped|Placement of implant with sloped design
218967735|NCT03543618|DEVICE|Control|Placement of implant with conventional design
219658124|NCT06735664|PROCEDURE|Bone Marrow Biopsy|Undergo optional bone marrow biopsy
219658125|NCT06735664|PROCEDURE|Computed Tomography|Undergo CT
219658126|NCT06735664|PROCEDURE|Echocardiography|Undergo ECHO
219658127|NCT06735664|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219658128|NCT06735664|BIOLOGICAL|Odronextamab|Given IV
219658129|NCT06735664|PROCEDURE|Positron Emission Tomography|Undergo PET
219658130|NCT06735664|PROCEDURE|Ultrasound Imaging|Undergo ultrasound guided biopsy
219658131|NCT06735664|DRUG|Zanubrutinib|Given PO
219658132|NCT02742883|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
219658133|NCT04835428|DEVICE|Treatment Group: AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
219658134|NCT04835428|DEVICE|Control Group: PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
219658135|NCT05803382|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219658136|NCT05803382|PROCEDURE|Biopsy Procedure|Undergo biopsy
219658137|NCT05803382|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219658138|NCT05803382|DRUG|Capecitabine|Given PO
219658139|NCT05803382|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
219658140|NCT05803382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219063913|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
219658141|NCT05803382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219658142|NCT07059078|BEHAVIORAL|Brief Motivational Interviewing-based Alcohol Intervention|"Participants in both arms (BMAI and BMAI + MT) will receive a brief motivational interviewing-based alcohol intervention (BMAI) delivered by a pediatric clinician in the primary care setting.~BMAI is adapted from the Provider Guide: Adolescent SBIRT Using the S2BI-CRAFFT Screening Tool, grounded in the stages of change model and motivational interviewing (MI). It consists of one or more brief sessions involving structured feedback, advice, and goal setting to help adolescents recognize links between substance use and health outcomes and develop personalized change plans. The intervention is face-to-face, delivered during routine or follow-up visits, and modeled after the brief negotiated interview. The first session lasts 10-30 minutes and includes six MI-based steps. This is followed by one or more additional brief MI sessions lasting 5-15 minutes where the patient's goals are reviewed, gains or barriers are addressed, and ongoing support is provided."
219658143|NCT07059078|BEHAVIORAL|Smartphone App-delivered Mindfulness Training|"In addition to BMAI, participants in the BMAI + MT arm will receive 8 weeks of smartphone-delivered mindfulness training using the Healthy Minds Program (HMP) app.~The HMP app provides self-guided, self-paced mindfulness and meditation training designed to improve psychological well-being, reduce stress/anxiety, and enhance self-regulation. It includes podcast-style teachings and guided meditations. The app features four modules-Awareness, Insight, Connection, and Purpose-based on neuroscience research. Each module offers 27 practices (5-30 minutes each). This study focuses on the Awareness and Insight modules, which teach breath and body awareness and emotion noting to support mindfulness in daily life. Participants will be asked to use the app 5-30 minutes per day, following 4 weeks of Awareness content, then 4 weeks of Insight. After 8 weeks, they will have open access to all modules and be encouraged to explore additional practices as they find helpful during follow-up."
219658144|NCT05201066|DRUG|decitabine|Solution for intravenous infusion
219658145|NCT05201066|DRUG|spartalizumab|Solution for intravenous infusion
219658146|NCT05201066|DRUG|sabatolimab|Solution for intravenous infusion
219658147|NCT05201066|DRUG|azacitidine|Solution for subcutaneous injection or intravenous infusion
218967736|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
219063914|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
219063915|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
219063916|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
219063917|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
219063918|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
219063919|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
219658148|NCT05201066|DRUG|venetoclax|Tablet for oral administration
219658149|NCT05201066|DRUG|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
219658150|NCT07058623|PROCEDURE|Nurse-Led Telehealth Consultation|Participants receive scheduled postoperative nursing consultations delivered remotely via the HA Go mobile application, a secure, hospital-approved telehealth platform. Consultations occur approximately two weeks after total knee replacement surgery, with additional sessions arranged as clinically needed within the first month post-surgery. Each telehealth session lasts about 20 to 30 minutes and includes assessment of recovery progress, monitoring for complications, patient education, and guidance on rehabilitation exercises. Patients receive technical support to facilitate effective use of the telehealth platform. This intervention leverages virtual care technology to provide convenient, accessible nursing follow-up without requiring in-person clinic visits.
219063920|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
219063921|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
219063922|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
219063923|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
218967737|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
218967738|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
218967739|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
219658151|NCT07058623|PROCEDURE|Traditional In-Person Nursing Consultation|Participants receive scheduled postoperative nursing consultations in person at the Specialist Outpatient Department. Each consultation lasts approximately 20 to 30 minutes and includes physical assessment, monitoring for complications, patient education, and rehabilitation guidance. Follow-up visits are typically scheduled two weeks after total knee replacement surgery, with additional visits as clinically indicated. This intervention represents standard postoperative nursing care delivered face-to-face.
219658152|NCT06778863|DRUG|CLSP-1025|CLSP-1025 will be administered by IV infusion
219063924|NCT00732121|DRUG|Placebo|Placebo
219658153|NCT06917456|DEVICE|Virtual Reality Headset|Participants will use either a Meta Quest VR device, or a Pico headset. Both of these devices are standard non-medical hardware items.
219658154|NCT06901245|DRUG|Tirzepatide|Subjects will take Tirzepatide for 48 weeks
219658155|NCT04874116|BEHAVIORAL|Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging|Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
219658156|NCT04874116|BEHAVIORAL|Mobile text messaging|Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
219658157|NCT05031416|COMBINATION_PRODUCT|LTQ|The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
219658158|NCT02280616|DRUG|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
218967740|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
219658159|NCT02280616|DRUG|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
219658160|NCT02280616|DRUG|high dose budesonide suspension|placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily
218967741|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
219658161|NCT02280616|DRUG|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
219658162|NCT06483815|DIAGNOSTIC_TEST|Culture, İsolation|Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
219658163|NCT06461715|OTHER|Machine learning with artificial intelligence software program|This is a retrospective observational study using cardiac MRI, cardiac CT and x-ray fluoroscopy images to develop a 3D hybrid guidance system with the use of deep learning methods.
218967742|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
218967743|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
219063925|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
219063926|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
219658164|NCT00059605|GENETIC|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
218967744|NCT02670174|OTHER|Traditional training|
219063927|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
219063928|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
219063929|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
219658165|NCT04417972|DRUG|SHR7280|treatment
219658166|NCT04417972|DRUG|Placebo oral tablet|blank control
219658167|NCT00867828|DIETARY_SUPPLEMENT|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
219658168|NCT00867828|DIETARY_SUPPLEMENT|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
219658169|NCT00867828|DIETARY_SUPPLEMENT|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
219658170|NCT04655040|DRUG|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
219658171|NCT04655040|OTHER|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
219658172|NCT02681757|DEVICE|triple antibiotic ointment dressing|used for control group under soft cast
219658173|NCT02681757|DEVICE|Mepitel Ag|used for variable/experimental group under soft cast
218967745|NCT02670174|OTHER|Separate kinetic chain training|
218967746|NCT02670174|OTHER|Integrated kinetic chain training|
218967747|NCT03585348|OTHER|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
218967748|NCT03947203|BEHAVIORAL|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
218967749|NCT05005754|DIETARY_SUPPLEMENT|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
218967750|NCT05005754|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
219658174|NCT06730477|OTHER|observational study|Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
219658175|NCT02359799|DEVICE|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
219658176|NCT06907654|DEVICE|well-being app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
219658177|NCT06907654|BEHAVIORAL|List of well-being resources|Participants will be given a list of resources that promote well-being.
219658178|NCT04064541|OTHER|Virtual Visit|Virtual Visit
219658179|NCT06731452|BEHAVIORAL|Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance|"Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience."
219658180|NCT06910553|OTHER|Non-exposed group|Pregnant individuals with IBD who are not exposed to an IBD pharmacotherapy during pregnancy
219658181|NCT06910553|DRUG|Exposed to IBD pharmacotherapy during pregnancy|Pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy
219658182|NCT03982446|GENETIC|Mutations|
218967751|NCT02860455|DEVICE|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
218967752|NCT02860455|DEVICE|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
218967753|NCT05288699|BEHAVIORAL|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
219063930|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
219063931|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
219063932|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
219063933|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
219063934|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
219063935|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
219063936|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
219063937|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
219063938|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
219658183|NCT07111078|BIOLOGICAL|VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) Adjuvant|"FLUMOS0122-00-VP (SteMos1) is a sterile, aqueous buffered solution supplied in 3 mL single-dose glass vials containing 0.7 +/- 0.1 mL with a vaccine concentration of 1080 mcg/mL.~The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21 that is vialed at 0.6 mL/vial in 3.0 mL glass vials. 0.5 mL of ALFQ adjuvant will be mixed with the 60 or 180 mcg dose of SteMos1 during preparation in the pharmacy prior to"
219658184|NCT04506905|DRUG|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
219658185|NCT04506905|DRUG|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
218967754|NCT04354727|DRUG|APG-1252|infusion once weekly
218967755|NCT04354727|DRUG|Ruxolitinib|taken orally twice a day
218967756|NCT01926665|DRUG|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
218967757|NCT01926665|DRUG|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
218967758|NCT00773929|DRUG|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
219063939|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
219063940|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
219063941|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
219063942|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
219658186|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
219658187|NCT05319743|OTHER|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
219658188|NCT06937762|DEVICE|Intra capsular coblation tonsillotomy|Tonsils were dissected from the surface inward with the wand set at Coblate 7 setting. The wand skims the tonsil surface with continuous saline irrigation. Ablation was performed without penetrating the tonsillar capsule. Retraction of the tonsillar pillars is done to define the margins for near complete ablation. When the capsule is approached, the wand is turned down to Coblate 3 setting. Thin layer of tonsillar tissue is left to protect the capsule. Bleeding does not occur in most cases, but when it occurs, the wand was used in the Coagulate 5 setting for homeostasis
219658189|NCT06937762|DEVICE|Extracapsular cold knife dissection tonsillectomy|Begin by retracting the anterior tonsillar pillar to expose the tonsil, use a cold knife (scalpel or tonsil dissector) to make an incision along the anterior pillar near the mucosal margin of the tonsil, identify the plane between the tonsillar capsule and the underlying pharyngeal muscle, then carefully dissect the tonsil away from the surrounding tissues, following the plane to avoid trauma to the underlying structures, proceed from the superior pole of the tonsil to the inferior pole, ensuring that the entire tonsil is removed, use gauze or sponges to control minor bleeding during the procedure, for more significant bleeding, apply direct pressure or use ligatures and cold packs, achieve final hemostasis using absorbable sutures or electrocautery if needed
219658190|NCT06937762|DEVICE|Extra capsular Radiofrequency tonsillectomy|Radiofrequency bipolar forceps, connected to a radiofrequency apparatus model Ellman Surgitron 4 MHz (Ellman International, New York, USA) by which cutting and dissection with coagulation were done in the same time with minimal diffuse heating to the surrounding tissue. The power was adjusted to a power grade 40 in a bipolar mode.
219658191|NCT07143487|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219658192|NCT07143487|OTHER|Genetic Testing|Undergo genetic testing
219658193|NCT07143487|OTHER|Communication Intervention|Receive proband-mediated communication
219658194|NCT07143487|OTHER|Survey Administration|Ancillary studies
219658195|NCT07158541|PROCEDURE|tunneled coronally advanced flap with connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined withh a connective tissue graft).
219658196|NCT07158541|PROCEDURE|modified tunnel with connective tissue graft|At the recession site, the gingiva is undermined to create a tunnel, and a connective tissue graft is inserted through the sulcus into this space before advancing the flap coronally.
219658197|NCT07161102|OTHER|Reflexology|A complementary technique that involves applying pressure to reflexology points on the feet. In this study, foot reflexology will be applied in 10 sessions, twice a week, for 30 minutes, aiming to reduce anxiety symptoms.
219658198|NCT07161102|OTHER|Sham Reflexology|A simulated procedure consisting of superficial and random maneuvers on the feet, without stimulation of specific reflexology points. Ten sessions will be conducted twice a week, each lasting 30 minutes, for placebo control purposes.
218967759|NCT02549053|PROCEDURE|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
219063943|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
218967760|NCT02549053|PROCEDURE|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
218967761|NCT04094623|OTHER|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
218967762|NCT04094623|OTHER|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
218967763|NCT01272661|BEHAVIORAL|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
218967764|NCT01272661|BEHAVIORAL|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
219063944|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
219063945|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063946|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219208181|NCT05563649|BEHAVIORAL|Online Guided Self-Help-Family-based Treatment|GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
219658199|NCT07167030|BEHAVIORAL|Virtual Reality Digital Storytelling|Participants in the intervention group will receive digital storytelling modules using virtual reality (VR) headsets once a week for four weeks, starting at 28 weeks of gestation. Each module will include three topics (2-10 minutes). After each topic, there will be a rest period followed by an interactive session. The final two modules will be administered during the NST recording, and mother and baby status will be monitored. Each module, including the interactive session, will last 45-50 minutes. Participants will receive an educational brochure after the module and will be reminded via WhatsApp.
219658200|NCT07165340|COMBINATION_PRODUCT|Indocyanine Green near infrared fluorescence imaging|A total of 10 intradermal injections of 25 ug indocyanine green (ICG) in 0.1 mL saline are administered in the feet, medial ankles, lateral calves, and thigh. The total dose of ICG will not exceed 250 ug. After injection, the legs will be illuminated by the dim output of a 780 nm laser diode, and the resultant fluorescent signal emanating from ICG-laden lymph will be collected by a custom built near-infrared fluorescent lymphatic imager.
219658201|NCT07165340|DEVICE|advanced pneumatic compression|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy. Daily treatment will be prescribed for approximately 30 days.
219658202|NCT07165340|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound to measure venous reflux will be done at each visit.
219658203|NCT07165340|DEVICE|compression wrap|A compression wrap, to provide 20-40 mm Hg of pressure, will be provided for daily use between visits (approximately 30 days).
219658204|NCT07175571|PROCEDURE|Intracytoplasmic Sperm Injection (ICSI)|Mature oocytes are injected with a single frozen-thawed donor sperm cell using micromanipulation under a microscope. This fertilization method is performed shortly after oocyte retrieval. Sperm used are pre-screened and standardized for post-thaw motility and morphology. ICSI is conducted in accordance with standard embryology lab protocols. The oocyte allocation to ICSI is randomized within each participant's cycle.
219658205|NCT07175571|PROCEDURE|Conventional Insemination (IVF)|Oocytes are inseminated by co-incubation with frozen-thawed donor sperm in a culture dish for 16-18 hours. Sperm are washed and prepared according to lab protocol to ensure motility and concentration suitability. This method does not involve direct sperm injection. Oocytes are randomly assigned to this method within each participant's retrieved cohort.
219658206|NCT07174700|OTHER|Questionnaire|An online questionnaire will be used to assess the prevalence of internet addiction, gaming addiction, and porn addiction, and their relation with stress, anxiety and depression
219658207|NCT07175675|PROCEDURE|Operative treatment of surgeons choice|treatment of single finger amputation with revision amputation, local or micro-vascular flap as best befits each specific injury
219658208|NCT07175675|PROCEDURE|Semi-occlusive film|The film is placed on a cleansed wound surface. bone is shortened to the level of injury. Visible nerves, arteries and tendons are cut and allowed to retract. The film is to be changed once weekly until the wound has closed.
218967765|NCT01272661|BEHAVIORAL|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
218967766|NCT01415895|DRUG|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
218967767|NCT01415895|DRUG|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
218967768|NCT05174845|DRUG|1L PEG + ASCORBIC ACID|"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
218967769|NCT04033198|PROCEDURE|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
218967770|NCT05784961|DEVICE|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
218967771|NCT01543373|DEVICE|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
219208182|NCT05563649|BEHAVIORAL|FBT via Videoconferencing|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
219208183|NCT04665921|DRUG|SGN-STNV|Given into the vein (IV; intravenously)
219658209|NCT07176468|OTHER|Neuronavigation-guided individualized iTBS|"Participants will receive individualized iTBS for 14 consecutive days in addition to their usual medication regimen.~iTBS parameters: 50 Hz bursts every 200 ms (5 Hz), 2s on/8s off, total 600 pulses per session;6 sessions/day (3 in morning, 3 in afternoon, 3600 pulses/day); 100% RMT intensity; Neuronavigation: Brainsight system (Rogue Research, Canada)"
219658210|NCT07175714|OTHER|Methodologies to induce gait perturbations|Method 1: Obstacles deployed at the frond end side of the treadmill Method 2: Obstacles deployed on the side of the treadmill Method 3: Spit-bell treadmill to induce slip perturbations Method 4: String method
219658211|NCT07176689|DRUG|Nirogacestat|Nirogacestat oral tablet
219658212|NCT07175207|BIOLOGICAL|UCB-MNCs|UCB-MNCs will be administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
219658213|NCT07174947|DRUG|Fluoxetine (drug)|Fluoxetine: Maintain at 20mg per day, orally, until disease progression or intolerance
219658214|NCT07174947|DRUG|Placebo|Placebo: 1 placebo tablet per day for maintenance, orally.
219658215|NCT07174713|BIOLOGICAL|Biologic Therapy|Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
219658216|NCT07176390|DRUG|Tulisokibart|Subcutaneous (SC) administration
218967772|NCT01543373|DEVICE|Bare Metal Stent|Bare metal coronary stent
218967773|NCT04710420|DEVICE|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
218967774|NCT03773211|DRUG|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
218967775|NCT03773211|DRUG|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
218967776|NCT03057379|OTHER|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
218967777|NCT04314310|DRUG|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
218967778|NCT04314310|DRUG|Placebo|equal volume of normal saline
218967779|NCT00312637|PROCEDURE|Magnetic Resonance Spectroscopy|
218967780|NCT02145988|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
218967781|NCT02145988|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
218967782|NCT00005110|DRUG|Salmeterol|
218967783|NCT00005110|DRUG|Albuterol|
218967784|NCT04806958|OTHER|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
218967785|NCT00573248|DRUG|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
218967786|NCT00573248|OTHER|Placebo|Placebo Patch
219208184|NCT05902572|OTHER|No intervention|Observational data collection only.
219208185|NCT05377528|DRUG|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
219208186|NCT05377528|DRUG|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
219658217|NCT07176390|DRUG|Placebo|SC Injection
219658218|NCT07176390|DRUG|Methotrexate|Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.
219658219|NCT07175350|OTHER|PROFFIT|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire is a 30-item questionnaire that measures health-related quality of life (HRQOL) in cancer patients ; PRO-CTCAE is a short list of 43 symptoms relevant for ovarian cancer
219658220|NCT07176702|DRUG|HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy|"Drugs: HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV).~Administration: Administered every 3 weeks until disease progression, unacceptable toxicity, or withdrawal."
219658221|NCT07175025|BEHAVIORAL|Narrative Exposure Therapy (NET)|Narrative Exposure Therapy (NET) is the PTSD intervention for the treatment group.
219063947|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219658222|NCT07174960|BEHAVIORAL|Life-Skills Training Program|This study aims to assess the impact of a life-skills training program on self-efficacy in patients with substance use disorders. The program is designed to prevent relapse by equipping individuals with crucial skills for managing triggers and challenges. It focuses on developing constructive coping strategies, effective stress and craving management techniques, social competencies like assertiveness, and emotional regulation abilities including anger control. By enhancing these domains, the intervention seeks to strengthen patients' confidence in their capacity to resist substance use and make adaptive decisions, thereby reducing relapse risk.
219658223|NCT07176169|PROCEDURE|Muscle Energy Technique for Sacral torsion|"Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises,~* Clamshells~* Four Point Kneeling~* Bridging/Side Bridges~* Bird-Dog Pose~* Dead Bugs~* Dynamic Core Stability (Unstable Surfaces) For Sacral Torsions, Six MET protocols address Forward and Backward torsions on Left and Right Oblique axis using patient generated force in Prone or Side-lying positions. Left-on-Left (LOL) Forward Torsion, Right -on-Right (ROR) Forward Torsion, Right-On-Left (ROL) Backward Torsion, Left-on-Right (LOR) Backward Torsion, Bilateral Sacral Nutation, Bilateral Sacral Counternutation"
219658224|NCT07176169|PROCEDURE|Muscle Energy Technique for Innominate rotation|Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises, • Clamshells • Four Point Kneeling • Bridging/Side Bridges • Bird-Dog Pose • Dead Bugs • Dynamic Core Stability (Unstable Surfaces). Anterior Innominate Rotation and Posterior Innominate Rotation.
218967787|NCT02737046|DRUG|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
218967788|NCT02737046|DRUG|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
218967789|NCT02737046|DRUG|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
218967790|NCT02737046|DRUG|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
218967791|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
218967792|NCT00206310|DRUG|CRESTOR|
218967793|NCT06434038|DRUG|Low Dose Regular insulin|Administered intranasally at 40 IU
218967794|NCT06434038|DRUG|High Dose Regular insulin|Administered Intranasally at 80 IU
218967795|NCT06434038|OTHER|0.9% Saline|Placebo control
218967796|NCT06370325|PROCEDURE|VPOD Wireless Tens Unit|The VPOD unit will deliver NMES to participants in the Intervention Group.
218967797|NCT06370325|PROCEDURE|Physical Therapy|Physical therapy as per standard of care.
218967798|NCT06370325|DEVICE|Biodex|Used to assess strength, endurance, power, and range of motion.
218967799|NCT03415854|DRUG|Paricalcitol (Zemplar)|combination therapy
218967800|NCT05495087|DEVICE|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
218967801|NCT05495087|OTHER|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
218967802|NCT03038451|DRUG|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
218967803|NCT03260439|DRUG|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
219063948|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063949|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063950|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063951|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063952|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
219063953|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
219063954|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
219063955|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
219063956|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
219063957|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
219063958|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
219063959|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
219063960|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
219063961|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
219063962|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
219063963|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
219063964|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
218967804|NCT03260439|DRUG|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
219063965|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
219208187|NCT05377528|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
219208188|NCT04207086|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219658225|NCT07174921|PROCEDURE|Laparoscopic Lateral Suspension|Participants in this arm will undergo laparoscopic lateral suspension for post-hysterectomy vaginal cuff prolapse. The procedure involves attaching a synthetic mesh from the vaginal cuff to the lateral abdominal wall to provide support and restore normal vaginal anatomy. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
219658226|NCT07174921|PROCEDURE|Laparoscopic Sacrocolpopexy|Participants in this arm will undergo laparoscopic sacrohysteropexy for post-hysterectomy vaginal cuff prolapse. The procedure involves suspending the vaginal cuff to the sacral promontory using a synthetic mesh, restoring vaginal support. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
219208189|NCT04207086|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
219208190|NCT02879656|PROCEDURE|non-operative treatment|conservative treatment with 5 weeks cast immobilization
219658227|NCT07175948|OTHER|Standard Medical Therapy|All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (e.g., dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Treatment is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status. The goal is to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.
218967805|NCT05967143|DEVICE|SIRT|Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
218967806|NCT02017171|DRUG|Allopurinol|
218967807|NCT02017171|DRUG|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
218967808|NCT05185336|DIAGNOSTIC_TEST|ultrasound assessment|gastric volume assessment by ultrasound
218967809|NCT06004687|DRUG|acetaminophen mannitol|Intravenous acetaminophen was administered 30 minutes before anesthesia
218967810|NCT06004687|DRUG|Normal saline|Intravenous acetaminophen was administered 30 minutes before anesthesia
218967811|NCT02981355|PROCEDURE|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
219063966|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
218967812|NCT02981355|DEVICE|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
219063967|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
219063968|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
219208191|NCT02879656|PROCEDURE|operative treatment|surgery with volar locking plate with modified Henry's volar approach
219658228|NCT07175948|DRUG|Standard Medical Therapy|"All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Therapy is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.~2️⃣ Intervention 2"
219658229|NCT07176754|DRUG|Infliximab|"The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name anbaite.The dosage was administered at 5 mg/kg, dissolved in 250 mL of 0.9% sodium chloride injection, and delivered via intravenous infusion over 2 hours."
219658230|NCT07176754|DRUG|Sodium chloride injection USP, 0.9% (placebo)|Patients in the control group received 250 mL of 0.9% sodium chloride injection as a placebo, administered via intravenous infusion over 2 hours.
219658231|NCT07176494|PROCEDURE|Patients who underwent surgery under general anesthesia|Patients undergoing surgery under general anesthesia will undergo general anesthesia induction. During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia.
219658232|NCT07176494|PROCEDURE|Patients who underwent surgery under regional anesthesia|"25 cc (15 cc 0.5% bupivacaine + 5 cc 2% lidocaine + 5 cc isotonic) local anesthetic solution is prepared. 10 cc of the medication is administered into the interpectoral plane, and 15 cc into the pectoserratus plane.~During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia."
219658233|NCT07175545|DEVICE|Independent use of the Mobili® Device by patients, overseen by pharmacists|"After recruitment each participant will be subject to a type I medication review.~After allocation to the intervention group, pharmacists will provide initial training to participants, and during the course of the intervention whenever necessary (e.g. when delivering the eDosette with the therapeutic regime). Pharmacists will prepare the eDosette in the pharmacy and deliver it directly to participants with no further intervention.~Participants will receive the number of eDosettes their therapeutic regime allows, to minimize visits to the pharmacy. For the control group, pharmacists will also provide the number of DAAs the therapeutic regime allows. Upon finishing the intervention, a new type II medication review will be performed for all participants (intervention and control) and information related to their personal therapeutic regime will be provided, ensuring a safe exit of the study."
219658234|NCT07174401|DRUG|Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.|The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.
219658235|NCT07174401|DEVICE|Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.|One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.
219658236|NCT07177248|BEHAVIORAL|Family-Based 12-Week Multicomponent Program|Weekly digital materials to parents (email/WhatsApp) + three on-site sessions (\~90 min each: functional training; modified games; outdoor trekking); 12 weeks total; delivered by a Physical Education teacher; attendance and delivery logs for fidelity.
219658237|NCT07175311|DIAGNOSTIC_TEST|Multimodal imaging findings|Fundus photography, Optical Coherence Tomography, and Fluorescein Angiography will be performed 7 days after meeting the criteria for inactivation of endophthalmitis, as outlined in the MEX-ESG guidelines. These imaging tests will be repeated one month after meeting the inactivation criteria.
219658238|NCT07175909|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
219658239|NCT07177170|OTHER|Differentiated screening delivery|More flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options.
219658240|NCT07177170|OTHER|Single visit|All the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible).
219658241|NCT07175090|COMBINATION_PRODUCT|Coconut oil|The rinse is used three times a day during three weeks
219658242|NCT07175090|OTHER|Placebo|Inactive ingredients with same taste and colour
218967813|NCT04972747|OTHER|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
219658243|NCT07176013|BEHAVIORAL|Voice therapy|All patients will receive a course of voice therapy as normal.
219658244|NCT07176013|BEHAVIORAL|Meditation|Meditation at the start of each session. (each session is 30 minutes)
219658245|NCT07176013|DEVICE|Virtual Reality|TRIPP application in the Meta Quest 2 Virtual Reality Headset.
218967814|NCT04609111|DRUG|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
218967815|NCT04609111|DRUG|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
218967816|NCT00546221|BEHAVIORAL|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
219063969|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
219658246|NCT07175597|DIETARY_SUPPLEMENT|Hibiscus sabdariffa drink|A daily dose of Hibiscus sabdariffa drink that provides 9.6 mg of anthocyanins
219658247|NCT07177079|DRUG|Azacitidine|A chemotherapy drug known as a hypomethylating agent
219658248|NCT07177079|DRUG|Venetoclax|Targeted cancer therapy used to treat certain blood cancers. It specifically targets a protein called BCL-2 to trigger the self-destruction of cancer cells.
219658249|NCT07177079|DRUG|High-dose ascorbate|Administering vitamin C intravenously to achieve very high concentrations in the bloodstream. In contrast to low doses, which act as antioxidants, these pharmacological doses can function as a pro-oxidant, killing cancer cells while leaving healthy cells unharmed.
219658250|NCT07177079|DRUG|Decitabine|Azacitidine may be substituted with decitabine 20 mg/m2 daily, on days 1-5, at PI discretion in the event of toxicity/drug supply shortage.
219658251|NCT07174635|BEHAVIORAL|Intervention-telenursing|The first researcher sent an educational booklet prepared on the educational topics or the topics the patient needed to the patients in the experimental group as a message. The patient was then called by phone and informed about the educational booklet. After the main interview, the patients were called 2 more times for follow-up. The intervention group was given education on topics such as reducing pain complaints, increasing activity level, exercise, and coping with stress. The education of the intervention group lasted approximately 4 weeks.
219658252|NCT07176403|OTHER|intradialytic exercise|"50 patients will undergo Exercise training program for twelve weeks during hemodialysis session.~1. Type of exercise: aerobic exercise training sessions using a lower limb ergometer.~2. Frequency: three times per week.~3. Duration: thirty minutes per session."
219658253|NCT07176403|OTHER|control group|50 patients will not perform exercise during hemodialysis session
219658254|NCT07176078|OTHER|Osteopathic care|"Participants allocated to the osteopathic care group will receive 4 weekly consultations of person-centered osteopathic care. Each consultation will last approximately 45 minutes and consist of a careful medical history, a clinical examination, treatment, and advice (e.g. exercise, dietary, lifestyle).~The osteopathic treatment protocol could be labeled as 'custom tailored': the determination of the treatment was left to the clinical judgment of the osteopath, meaning that no predefined, standardized osteopathic protocol would be implemented. Standard osteopathic techniques (Glossary of Osteopathic Terminology) can be applied, including diagnostic techniques (e.g. observation, neurological tests, palpation, and motion testing) and therapeutic direct (e.g. high-velocity low-amplitude, muscle energy), indirect techniques (e.g. strain counter strain, balanced ligamentous tension, balanced membranous tension), or combined techniques."
219658255|NCT07176078|OTHER|Sham Osteopathic care|"For this trial, sham intervention will mimic the osteopathic care according to the touch equality assumption. Therefore, it mimics a clinical examination and treatment. The sham clinical evaluation involves a full evaluation of the position and mobility of the spine.This screening of the patient will be performed using conventional osteopathic manual tests, without any intention to make a diagnosis. Sham treatment will involve light manual contact, with the subject lying supine on the treatment table."
219658256|NCT07176078|BEHAVIORAL|Flexi-FODMAP Diet|"In addition to the real or sham osteopathic care, all participants will follow a 4-week flexi-FODMAP diet delivered online. Participants will receive structured dietary instructions via a customized online platform, based on the NHS Gentle-FODMAP diet guidelines and informed by expert input from dieticians. This modified FODMAP-gentle approach involves a targeted, less restrictive elimination of selected high-FODMAP foods."
219658257|NCT06508515|BEHAVIORAL|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|"The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation."
219658258|NCT06508515|BEHAVIORAL|RUBI in Educational Settings (RUBIES)-Team|RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
219658259|NCT05670314|DIETARY_SUPPLEMENT|Inulin Fibre supplement|20g/ day. Inulin is easily dissolvable in liquid and can be incorporated into the usual diet - by adding to water, juice, smoothies, cereal, yogurt etc.
219658260|NCT05670314|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10g/ day which can be consumed by adding to breakfast cereal/ smoothie/ yogurt or drink of choice
219658261|NCT05670314|BEHAVIORAL|Exercise|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises.
219658262|NCT06558214|DRUG|Pembrolizumab|Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
219658263|NCT06558214|DEVICE|Optune GIO®|".~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2."
219658264|NCT06558214|DEVICE|NeuroBlate®|Treatment with NeuroBlate will occur one time at the beginning of the study.
219658265|NCT06529029|DEVICE|Sigma-Stim|Right Ultra-Brief Low Amplitude Seizure Therapy at 600mA or 700mA vs Right Unilateral Ultra-Brief Standard ECT at 800mA.
219658266|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
219658267|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
219658268|NCT06095479|DEVICE|2D ultrasound scan and MRI examination|All subjects will undergo a 2D ultrasound scan and MRI examination.
219658269|NCT05337410|BEHAVIORAL|YES IDEAS|YES IDEAS is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES IDEAS curriculum empowers youth from various backgrounds to address bullying and promote positive behaviors as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting non-violence in their community.
219658270|NCT05503719|PROCEDURE|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
219658271|NCT05503719|PROCEDURE|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
219658272|NCT06298864|BEHAVIORAL|Internet-CBT|"* Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
218967817|NCT00546221|BEHAVIORAL|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
219658273|NCT06298864|BEHAVIORAL|Internet-CL|"* Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle."
219658274|NCT06370832|OTHER|IMT and exercise training group|Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
218967818|NCT00833079|DRUG|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
218967819|NCT00833079|DRUG|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
218967820|NCT00833079|DRUG|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
218967821|NCT03169751|DEVICE|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
218967822|NCT00600509|DRUG|Levetiracetam|
218967823|NCT04585139|DEVICE|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
218967824|NCT05501912|DRUG|ABM-1310|"Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level."
218967825|NCT03370289|BIOLOGICAL|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
218967826|NCT02503995|BEHAVIORAL|Physical Exercise Participation|
218967827|NCT02220998|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
218967828|NCT02220998|DRUG|SOF|SOF 400 mg tablet administered orally once daily
219208192|NCT06149156|BEHAVIORAL|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
218967829|NCT02220998|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218967830|NCT04047927|DEVICE|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
218967831|NCT01415739|OTHER|laboratory biomarker analysis|Correlative studies
218967832|NCT05034445|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
218967833|NCT05351398|DRUG|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
218967834|NCT05351398|DRUG|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
218967835|NCT02314143|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
218967836|NCT02314143|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
219658275|NCT04802447|DRUG|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
219658276|NCT04313725|DEVICE|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
219658277|NCT04313725|OTHER|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
219658278|NCT06191887|BIOLOGICAL|Autologous BAFFR-targeting CAR T Cells|Given IV
219658279|NCT06191887|DRUG|Bendamustine|Given IV
219658280|NCT06191887|PROCEDURE|Biopsy|Undergo biopsy
219658281|NCT06191887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219658282|NCT06191887|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
219658283|NCT06191887|PROCEDURE|Computed Tomography|Undergo CT scan
219658284|NCT06191887|DRUG|Cyclophosphamide|Given IV
218967837|NCT00873860|OTHER|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
218967838|NCT00873860|BIOLOGICAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
218967839|NCT00873860|BIOLOGICAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
218967840|NCT00873860|BIOLOGICAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
218967841|NCT05991921|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
218967842|NCT05991921|OTHER|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
218967843|NCT02695212|DRUG|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
218967844|NCT04344743|DEVICE|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
218967845|NCT06523517|DRUG|Eliglustat Tartrate Capsules|The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
218967846|NCT04562272|PROCEDURE|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
219063970|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
219063971|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
219063972|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
219063973|NCT01976416|DRUG|Hydroxyurea|
219658285|NCT06191887|PROCEDURE|Echocardiography|Undergo echocardiography
219658286|NCT06191887|DRUG|Fludarabine|Given IV
219658287|NCT06191887|PROCEDURE|Leukapheresis|Undergo leukapheresis
218967847|NCT02914145|DRUG|Dihydroartemisinin-piperaquine|Mass drug administration
219063974|NCT01976416|DRUG|Placebo|
219208193|NCT06149156|BEHAVIORAL|Well-being Resources|List of well-being resources that comprises of online video links and books
219658288|NCT06191887|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219658289|NCT06191887|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219658290|NCT06192992|OTHER|Peripheral heating of 2 feet|Heating of both feet
219658291|NCT06192992|OTHER|Sham|No heating
219658292|NCT04104932|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation
219658293|NCT05014841|BEHAVIORAL|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
219658294|NCT00669643|DRUG|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
219658295|NCT00669643|DRUG|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
219658296|NCT00669643|DRUG|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
219658297|NCT00669643|DRUG|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
219658298|NCT06531772|DRUG|Antitubercular Agents|Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
219658299|NCT03309696|DEVICE|sham tDCS and sham rTMS|Both combinations of tDCS and rTMS in this intervention are sham.
219658300|NCT03309696|DEVICE|sham tDCS and active rTMS|tDCS in this intervention is sham and rTMS is active
219658301|NCT03309696|DEVICE|active tDCS and active rTMS|Both combinations of tDCS and rTMS in this intervention are active
219658302|NCT03176615|DIETARY_SUPPLEMENT|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
219658303|NCT01432821|OTHER|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2"
219658304|NCT00769535|GENETIC|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR\_RFLP
219658305|NCT02849392|OTHER|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
219658306|NCT06156137|OTHER|Glucose variability|A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
219658307|NCT00850096|OTHER|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
219658308|NCT00850096|DRUG|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
219658309|NCT01323036|DIETARY_SUPPLEMENT|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
219658310|NCT01323036|DIETARY_SUPPLEMENT|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
219658311|NCT06665971|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
219658312|NCT00553982|PROCEDURE|Patellar component|Resurfacing with onlay technique
218967848|NCT02734420|DRUG|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
218967849|NCT02734420|DRUG|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
219658313|NCT00553982|PROCEDURE|No patellar component|Trimming of osteophytes when appropriate
219658314|NCT05024526|DRUG|edaravone dexborneol or edaravone|Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
219658315|NCT06294665|DRUG|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed ,the patient is placed in the supine position , the procedural leg is slightly abducted, the curvilinear low-frequency ultrasound probe will be placed over the line parallel to the inguinal ligament. It will subsequently rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration, by one of the two syringes each one has a serial number corresponding to each group.
219658316|NCT02666638|OTHER|Control Volunteers|MRI on up to a 7T scanner without contrast.
219658317|NCT02666638|OTHER|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
219658318|NCT05940077|BEHAVIORAL|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
219658319|NCT02683148|DRUG|DHEA|
218967850|NCT02734420|DEVICE|Laser|
218967851|NCT02436642|DEVICE|AVERT Plus System|
219208194|NCT04262206|DRUG|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
218967852|NCT00708071|BIOLOGICAL|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
218967853|NCT02140775|BEHAVIORAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
218967854|NCT02710500|DRUG|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
218967855|NCT00329940|DRUG|Letrozole|
218967856|NCT05540080|DEVICE|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
218967857|NCT04800666|PROCEDURE|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
218967858|NCT04800666|PROCEDURE|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
218967859|NCT04800666|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
218967860|NCT01766700|BEHAVIORAL|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
218967861|NCT01766700|BEHAVIORAL|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
218967862|NCT03580304|BEHAVIORAL|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
218967863|NCT03580304|BEHAVIORAL|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
218967864|NCT03580304|BEHAVIORAL|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
218967865|NCT06515028|PROCEDURE|Group GA|Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.
219063975|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
219063976|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
219063977|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
219063978|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
219063979|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219063980|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
219063981|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
219208195|NCT04262206|DRUG|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
219658320|NCT02683148|OTHER|FACT-67 validated survey|"* Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much."
218967866|NCT06515028|PROCEDURE|Group IB|infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
218967867|NCT01171170|DRUG|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
219658321|NCT02532114|DRUG|Enzalutamide|Given PO
219658322|NCT02532114|OTHER|Laboratory Biomarker Analysis|Correlative studies
219658323|NCT02532114|DRUG|Niclosamide|Given PO
219658324|NCT02532114|OTHER|Pharmacological Study|Correlative studies
219658325|NCT05105516|PROCEDURE|Ablation|Ablation of ectopic foci causing PVCs
219658326|NCT02507843|DRUG|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
219658327|NCT02507843|DRUG|Placebo|Placebo will be administered in placebo group monthly for 6 months.
219658328|NCT01172964|DRUG|flucytosine|Given orally
219658329|NCT01172964|OTHER|polymerase chain reaction|Correlative studies
219658330|NCT01172964|OTHER|immunohistochemistry staining method|Correlative studies
218967868|NCT01171170|DRUG|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
219658331|NCT01172964|BIOLOGICAL|gene therapy|Injected at the time of the surgery to resect the tumor
219658332|NCT01172964|OTHER|pharmacological study|Correlative studies
219658333|NCT01172964|OTHER|3-Tesla magnetic resonance imaging|Correlative studies
219658334|NCT01172964|OTHER|laboratory biomarker analysis|Correlative studies
219658335|NCT01172964|PROCEDURE|therapeutic conventional surgery|Surgery to resect the tumor
219658336|NCT01172964|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
219658337|NCT04128891|DRUG|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
219658338|NCT00053508|BIOLOGICAL|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
219658339|NCT00053508|BIOLOGICAL|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
219658340|NCT04424771|BEHAVIORAL|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
219658341|NCT02102100|DRUG|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
219658342|NCT02102100|DRUG|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
219658343|NCT04478500|DRUG|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
219658344|NCT03006263|PROCEDURE|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
218967869|NCT01795378|BIOLOGICAL|donor natural killer cell infusion|"* Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~* The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~* For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~* The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
218967870|NCT02633618|BIOLOGICAL|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
218967871|NCT02633618|BIOLOGICAL|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
218967872|NCT02041442|PROCEDURE|Electrical mapping of the urinary bladder|
218967873|NCT02669654|OTHER|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
218967874|NCT06178705|BEHAVIORAL|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
218967875|NCT02898584|OTHER|BP Track|
218967876|NCT05396703|PROCEDURE|TOETVA|Completed procedure.
218967877|NCT06070571|DRUG|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
219658345|NCT03006263|PROCEDURE|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
218967878|NCT02985970|OTHER|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
218967879|NCT00945854|OTHER|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
218967880|NCT00945854|OTHER|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
218967881|NCT04149275|DRUG|Cabozantinib|Treatment with oral Cabozantinib once daily
218967882|NCT04149275|DRUG|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
218967883|NCT04149275|DRUG|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
218967884|NCT03039972|DIAGNOSTIC_TEST|No intervention|No intervention
218967885|NCT06278610|DIAGNOSTIC_TEST|PELVIC EXENTERATION|PELVIC EXENTERATION
218967886|NCT04589312|BIOLOGICAL|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
218967887|NCT04589312|BIOLOGICAL|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
218967888|NCT01613196|OTHER|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days."
218967889|NCT04228575|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
218967890|NCT01064245|DRUG|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
218967891|NCT01064245|OTHER|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
218967892|NCT03927599|OTHER|Data Collection|Colleciton of data from medical records only
218967893|NCT01244360|DIETARY_SUPPLEMENT|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
218967894|NCT01244360|OTHER|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
219658346|NCT00962936|DRUG|CT-011|CT-011
218967895|NCT04650646|OTHER|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
218967896|NCT04650646|OTHER|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
218967897|NCT02436655|PROCEDURE|surgical aortic valve replacement|open heart aortic valve replacement
218967898|NCT04397627|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
218967899|NCT01172275|DRUG|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
218967900|NCT01172275|OTHER|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
218967901|NCT04470921|PROCEDURE|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
219658347|NCT00328094|DRUG|continuous intravenous insulin infusion|Tight glucose control versus standard of care
219658348|NCT03241433|OTHER|High intensity interval training|exercise by use of stationary cycles
219658349|NCT03241433|OTHER|Moderate intensity continuous training|exercise by use of stationary cycles
219658350|NCT03241433|OTHER|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
219658351|NCT02003989|OTHER|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
219658352|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
219658353|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
219658354|NCT01483989|OTHER|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
219658355|NCT05470855|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
219658356|NCT01142765|BIOLOGICAL|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
219658357|NCT01142765|BIOLOGICAL|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
219658358|NCT01142765|BIOLOGICAL|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
219658359|NCT01142765|BIOLOGICAL|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
219658360|NCT01142765|BIOLOGICAL|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
219658361|NCT02441751|PROCEDURE|intra-operative blood loss|surgery in the urology and orthopedics
219658362|NCT03994757|BEHAVIORAL|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
218967902|NCT02168426|PROCEDURE|Guardix|Applying 6g of guardix during abdominal surgery
218967903|NCT02168426|PROCEDURE|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
218967904|NCT01865071|PROCEDURE|loop ileostomi|
218967905|NCT03243266|DIAGNOSTIC_TEST|CBC/Diff Reference Interval|Results will not be used to manage patients
218967906|NCT01661816|BEHAVIORAL|interview|psychological, emotional, family and social parameters
219063982|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
219063983|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
219063984|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
219063985|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
219658363|NCT03994757|BEHAVIORAL|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
219658364|NCT02309723|DEVICE|Beta amyloid imaging|
218967907|NCT02325310|BIOLOGICAL|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
218967908|NCT05269251|DEVICE|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
218967909|NCT02438527|BEHAVIORAL|Chart for CPR guidance|
219063986|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
219063987|NCT00821691|DRUG|Amantadin|Amantadin caps
219063988|NCT00821691|DRUG|Placebo|Placebo caps
219063989|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
218967910|NCT05218265|DIAGNOSTIC_TEST|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
218967911|NCT00812344|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
219063990|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
219063991|NCT02369133|DRUG|Placebo|
219658365|NCT06346574|BEHAVIORAL|Experimental|Participants will receive access to health and wellness app and guide
219658366|NCT03811210|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
219658367|NCT00128804|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
219658368|NCT00006033|BIOLOGICAL|gene therapy|
219658369|NCT00006033|BIOLOGICAL|interleukin-2 gene|
219658370|NCT00006033|DRUG|methotrexate|
218967912|NCT00812344|DRUG|Ketoconazole|tablets, orally, once daily for 3 days
218967913|NCT00812344|DRUG|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
218967914|NCT01810588|DEVICE|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
218967915|NCT01810588|DRUG|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
218967916|NCT01810588|DRUG|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
219063992|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
219063993|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
219063994|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
219658371|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
219658372|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
219658373|NCT01565668|DRUG|AC220|oral
219658374|NCT03192618|PROCEDURE|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
219658375|NCT03192618|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
219658376|NCT02255552|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
219658377|NCT03613558|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
218967917|NCT01810588|DRUG|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
218967918|NCT01810588|DRUG|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
219063995|NCT00400413|PROCEDURE|fMRI|
219063996|NCT02936076|OTHER|Exercise intervention|
219658378|NCT03613558|DRUG|Placebo|saline solution
219063997|NCT02936076|OTHER|Delayed exercise intervention|
219063998|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
219063999|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
219064000|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
219064001|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
219658379|NCT02918903|PROCEDURE|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
219658380|NCT02918903|PROCEDURE|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
219658381|NCT01276522|DRUG|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
219658382|NCT01067625|DEVICE|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
219658383|NCT02222675|PROCEDURE|Sonography assisted breast surgery|
218967919|NCT01810588|RADIATION|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
218967920|NCT01810588|DRUG|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
218967921|NCT01810588|DRUG|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
218967922|NCT00730262|DRUG|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
219064002|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
219064003|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
219064004|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
219208196|NCT03567876|DRUG|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
219208197|NCT06367933|PROCEDURE|mini-invasive spine surgery|spine deformity correction using a mini-invasive technique
219658384|NCT02222675|PROCEDURE|Conventional breast surgery|
219658385|NCT00801437|DRUG|Xalacom|Xalacom 1 drop into the affected eye daily
219658386|NCT00355706|PROCEDURE|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
219208198|NCT04221035|DRUG|Vincristine|1.5 mg/m2 (max dose 2 mg)
219208199|NCT04221035|DRUG|Carboplatin|750 mg/m2
219208200|NCT04221035|DRUG|Etoposide|175 mg/m2
219208201|NCT04221035|DRUG|Vindesine|3 mg/m2/day (max dose 6 mg)
219658387|NCT01764724|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
219658388|NCT06514703|PROCEDURE|CT-Guided Genicular Nerve Ablation|This procedure involves using computed tomography (CT) imaging to guide the precise placement of a needle for the ablation of genicular nerves in the knee. The goal is to disrupt the pain signals caused by osteoarthritis, providing long-term pain relief. The intervention is performed under local anesthesia and is aimed at patients who have not responded adequately to conservative pain management strategies.
218967923|NCT06477224|OTHER|Scooter Board Activities|Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.
219064005|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
219064006|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
219208202|NCT04221035|DRUG|Dacarbazine|200 mg/m2/day
219208203|NCT04221035|DRUG|Ifosfamide|1500 mg/m2/day
219208204|NCT04221035|DRUG|Doxorubicin|30 mg/m2/dose
219208205|NCT04221035|DRUG|Busulfan|\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
219208206|NCT04221035|DRUG|Melphalan|140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
219208207|NCT04221035|DRUG|Thiotepa|300 mg/m2/day over 2 hours
219208208|NCT04221035|RADIATION|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
219208209|NCT04221035|DRUG|Dinutuximab Beta|Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
219208210|NCT04221035|DRUG|Cisplatin|80 mg/m2/24h
219208211|NCT04221035|DRUG|Temozolomide 100 MG|100 mg/m²/Day
219208212|NCT04221035|DRUG|Irinotecan|50 mg/m²/jour de J0 à J4
219658389|NCT06514703|PROCEDURE|Fluoroscopic-Guided Genicular Nerve Ablation|This procedure utilizes fluoroscopy to accurately guide the needle placement for the ablation of genicular nerves associated with osteoarthritis knee pain. The technique focuses on minimizing pain and improving functional mobility by disrupting nerve pathways that transmit pain signals. Like the CT-guided approach, it is intended for use in patients whose symptoms have not been sufficiently managed with non-invasive treatments.
219658390|NCT01313494|DRUG|Roflumilast|Roflumilast tablets
219658391|NCT01313494|DRUG|Placebo|Placebo tablets
219658392|NCT01313494|DRUG|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
219658393|NCT00111371|DRUG|Levodopa|
219658394|NCT04742166|PROCEDURE|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
219658395|NCT04288336|OTHER|Food Diary|Ancillary studies
219658396|NCT04288336|OTHER|Preventative Dietary Intervention|Follow intermittent fasting
218967924|NCT06477224|OTHER|Routine Physical Therapy|Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
218967925|NCT04650854|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
218967926|NCT05072327|PROCEDURE|Mohs surgery|Mohs surgery of eyelid
218967927|NCT05072327|PROCEDURE|cryotherapy|cryotherapy of eyelid
218967928|NCT03986515|DRUG|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
218967929|NCT05308290|OTHER|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
218967930|NCT05308290|OTHER|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
218967931|NCT02516735|DEVICE|I-scan with magnification|
218967932|NCT02516735|DEVICE|Standard endoscopy|
218967933|NCT04437368|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
218967934|NCT02025062|OTHER|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
219064007|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
219064008|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
219064009|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
219658397|NCT04288336|OTHER|Questionnaire Administration|Ancillary studies
218967935|NCT03178695|OTHER|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
219658398|NCT03906721|DRUG|Placebo|Sugar pill used to condition patients.
219658399|NCT03906721|DRUG|Oxycodone|An opioid used for analgesia.
219658400|NCT03906721|OTHER|Essential Oil|An aromatic oil used for conditioning.
219658401|NCT03165474|OTHER|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
219658402|NCT03165474|OTHER|Didactic health information|Didactic health information and resources by email and/or text
219064010|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
219064011|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
219064012|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
219064013|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
219064014|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
219064015|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
219064016|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
219658403|NCT00000710|DRUG|Didanosine|
219658404|NCT03847415|DIAGNOSTIC_TEST|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
219658405|NCT02689882|DIETARY_SUPPLEMENT|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
219658406|NCT06073275|DIETARY_SUPPLEMENT|Beetroot juice ingestion|Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
219064017|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
219064018|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
219064019|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
219064020|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
219658407|NCT06073275|DIETARY_SUPPLEMENT|Placebo ingestion|Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
219658408|NCT00956631|PROCEDURE|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
219658409|NCT05676476|DRUG|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
219658410|NCT05939791|OTHER|Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518|The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
219658411|NCT05939791|OTHER|Physical exercise|The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
219658412|NCT03994744|DRUG|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
219658413|NCT03994744|DRUG|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
219658414|NCT02970019|DRUG|K0706|Once a day administration after fast
219658415|NCT02970019|DRUG|Placebo|Once a day administration after fast
219658416|NCT03595358|DIAGNOSTIC_TEST|Ellume Home Flu Test|The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
219658417|NCT03595358|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
218967936|NCT00121888|BEHAVIORAL|Prolonged Exposure Therapy|
218967937|NCT00121888|DRUG|Paroxetine-CR|
218967938|NCT00266773|BEHAVIORAL|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
218967939|NCT04914507|DEVICE|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
218967940|NCT03181373|OTHER|Cognitive rehabilitation program|Rehabilitation
218967941|NCT04368273|DRUG|PD-1 antibody|a new treatment drug combined radical radiotherapy concurrent chemotharpy
218967942|NCT06071936|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
218967943|NCT06071936|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
218967944|NCT01247038|DEVICE|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
218967945|NCT01247038|DEVICE|Metal-on-Metal|Metal on Metal articulation
218967946|NCT01054807|DEVICE|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
218967947|NCT01054807|DEVICE|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
218967948|NCT01054807|DEVICE|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
218967949|NCT01462786|DRUG|ATX-101|2 mg/cm2 ATX-101
218967950|NCT05321160|DRUG|Esketamine|0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
218967951|NCT05321160|DRUG|Sevoflurane|4% sevoflurane for induction and 2-4% sevoflurane for maintain
218967952|NCT05453266|PROCEDURE|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
218967953|NCT05453266|PROCEDURE|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
218967954|NCT01388920|DRUG|Tesamorelin|
219064021|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
218967955|NCT01388920|DRUG|Placebo|
218967956|NCT00590629|DRUG|Niaspan|1500 mg Niaspan for 16 weeks
218967957|NCT00972855|DRUG|Bicalutamide|50 mg Tablet
218967958|NCT00972855|DRUG|Casodex®|50 mg Tablet
218967959|NCT02467335|DRUG|BMS-663068|BMS-663068
218967960|NCT00727831|DRUG|glucarpidase|
218967961|NCT00727831|DRUG|leucovorin calcium|
218967962|NCT00727831|DRUG|methotrexate|
218967963|NCT00727831|OTHER|laboratory biomarker analysis|
218967964|NCT00727831|PROCEDURE|quality-of-life assessment|
219064022|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
219658418|NCT03595358|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT\_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
218967965|NCT00727831|RADIATION|radiation therapy|
218967966|NCT01280955|DRUG|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
218967967|NCT05246904|OTHER|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
218967968|NCT04295655|OTHER|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
218967969|NCT04295655|OTHER|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
218967970|NCT04295655|OTHER|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
219064023|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
219064024|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
219064025|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
219064026|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
219064027|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
219064028|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
219064029|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
219064030|NCT06574867|DEVICE|viQtor Wearable Monitoring Device|The viQtor device is a wearable medical device designed for continuous monitoring of vital signs, including heart rate (PR), respiratory rate (RR), and blood oxygen saturation (SpO2). It is worn on the upper arm and transmits data wirelessly to a cloud-based platform. This device is being evaluated as part of the standard monitoring protocol for post-operative patients in a surgical ward setting.
219064031|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
218967971|NCT00904306|DIETARY_SUPPLEMENT|Sugar Pill|placebo oral tablet taken once per day
218967972|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|1000 ug/day chromium picolinate for 6 months
218967973|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|600 ug/day chromium picolinate
218967974|NCT01314157|OTHER|Isostretching|12 interventions (two times per week) for 45 minutes
219064032|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
219658419|NCT03595358|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
219658420|NCT03161886|DEVICE|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
218967975|NCT04105543|DRUG|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
218967976|NCT04223232|DRUG|[14C]-MD1003|single oral dose of 100mg \[14C\]-MD1003
218967977|NCT04884932|DEVICE|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
219064033|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
219208213|NCT04221035|DRUG|Cyclophosphamid|Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
219658421|NCT03219086|PROCEDURE|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
219658422|NCT03219086|DRUG|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
219658423|NCT03219086|DRUG|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
219658424|NCT05988710|DRUG|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
219658425|NCT05988710|DRUG|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
219658426|NCT05988710|DRUG|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
219658427|NCT05988710|DRUG|Buccal Placebo|Placebo for buccal administration
219658428|NCT05988710|DRUG|Oral Placebo|Placebo for oral administration
219658429|NCT05988710|DRUG|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
219658430|NCT05988710|DRUG|Buccal Buprenorphine 450mcg|buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
219658431|NCT03660124|DEVICE|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
218967978|NCT04884932|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
218967979|NCT04075110|DRUG|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
218967980|NCT04075110|DRUG|Placebo|Placebo tablet once daily
218967981|NCT00808431|BEHAVIORAL|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
218967982|NCT05027893|DRUG|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
218967983|NCT05027893|DRUG|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
219658432|NCT00160134|DRUG|SLV320|
219658433|NCT00169624|DRUG|Metformin|
219658434|NCT00169624|DRUG|Gliclazide|
219658435|NCT06238713|PROCEDURE|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
219658436|NCT06238713|PROCEDURE|Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
219658437|NCT03827902|DEVICE|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
219064034|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
219658438|NCT02424864|OTHER|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
219658439|NCT03422159|DRUG|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
219658440|NCT03422159|DRUG|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
219658441|NCT03422159|DRUG|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
218967984|NCT05027893|OTHER|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
218967985|NCT05695534|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
218967986|NCT00001431|DRUG|gemcitabine|
218967987|NCT00801918|DRUG|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
219064035|NCT02838017|DEVICE|Tissue Adhesive|
219064036|NCT02838017|DEVICE|Sterile strips|
219064037|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
219658442|NCT03422159|DRUG|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
219658443|NCT04136275|BIOLOGICAL|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
219064038|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
219064039|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
219658444|NCT01971632|DRUG|Oxycodone & naloxone combination, prolonged release|
219658445|NCT01971632|DRUG|placebo oxycodone / naloxone|
219658446|NCT06731153|DRUG|Ivarmacitinib|a selective Janus kinase 1 inhibitor
219658447|NCT06731153|DRUG|Camrelizumab (SHR-1210)|a humanised anti-programmed death-1 (anti PD-1) antibody
219658448|NCT06731153|DRUG|Eribulin|Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
219658449|NCT01759836|DRUG|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
219658450|NCT02525536|DRUG|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
218967988|NCT00801918|DRUG|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
218967989|NCT04840576|OTHER|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
218967990|NCT04840576|OTHER|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
219064040|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
219064041|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
219064042|NCT01884350|DRUG|Apixaban|
219064043|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
219064044|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
219064045|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
219064046|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
219064047|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
219064048|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
219064049|NCT00299234|DRUG|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
218967991|NCT04951232|DRUG|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
219658451|NCT02525536|DRUG|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
219658452|NCT02525536|DRUG|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
218967992|NCT04951232|OTHER|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
218967993|NCT01778777|DEVICE|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
218967994|NCT04984603|PROCEDURE|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
218967995|NCT04526301|DEVICE|Tablo Hemodialysis System|Home hemodialysis treatments \~4 times a week.
218967996|NCT04842422|DRUG|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
218967997|NCT04907461|PROCEDURE|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
218967998|NCT05731531|DEVICE|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
218967999|NCT01674634|BIOLOGICAL|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
219064050|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
219658453|NCT02077413|PROCEDURE|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
219658454|NCT02077413|PROCEDURE|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes."
219658455|NCT02077413|PROCEDURE|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
218968000|NCT04471597|DRUG|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
219658456|NCT02077413|PROCEDURE|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
219658457|NCT03848806|DRUG|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219658458|NCT03848806|DRUG|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219658459|NCT05871671|BEHAVIORAL|Pulmonary Rehabilitation|A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.
218968001|NCT04471597|DRUG|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
218968002|NCT01810211|OTHER|Horizontal Adduction Stretch and Pendulums|
218968003|NCT01810211|OTHER|Modified Sleeper Stretch and Pendulum|
218968004|NCT00935298|DRUG|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
218968005|NCT04151342|DRUG|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
218968006|NCT04151342|OTHER|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
218968007|NCT05684523|DRUG|Valerian-Hop Extract|herbal drug
218968008|NCT05684523|DRUG|Placebo|Placebo
218968009|NCT01003444|PROCEDURE|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
218968010|NCT04302818|BEHAVIORAL|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
218968011|NCT04302818|BEHAVIORAL|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
218968012|NCT01721070|DRUG|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
218968013|NCT01721070|DRUG|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
218968014|NCT02025517|OTHER|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
218968015|NCT00934258|DRUG|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
219064051|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
219064052|NCT04020120|OTHER|questionnaires|answer questionnaires
219064053|NCT02345512|DEVICE|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
219064054|NCT06205524|BIOLOGICAL|TI-0010|Sterile liquid for injection
219658460|NCT05871671|OTHER|Control|The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
219658461|NCT04982172|DRUG|Infliximab|Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
219658462|NCT04982172|DRUG|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
219658463|NCT05029804|OTHER|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
219658464|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
219658465|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
219658466|NCT01752868|DIETARY_SUPPLEMENT|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
219658467|NCT01962545|DRUG|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
219658468|NCT04499105|DRUG|Mesenchymal Stem Cell + NaCl 0,9% 2ml|Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
218968016|NCT00934258|GENETIC|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
218968017|NCT00687232|DRUG|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
218968018|NCT00687232|DRUG|Placebo|
218968019|NCT00596297|DRUG|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
218968020|NCT00596297|PROCEDURE|pars plana vitrectomy|4 weeks after baseline
218968021|NCT00355654|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
218968022|NCT00355654|BIOLOGICAL|DT3aP-HBs-IPV|0.5 mL, IM
218968023|NCT04152044|OTHER|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
218968024|NCT02204007|DEVICE|3D imaging & surrogate bone model|3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
218968025|NCT03052907|BEHAVIORAL|BSPAN|"1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
218968026|NCT02477137|DEVICE|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
218968027|NCT02341105|PROCEDURE|Catheter ablation|Pulmonary vein isolation by catheter ablation
218968028|NCT02341105|DRUG|Amiodarone|antiarrhythmic therapy using Amiodarone
218968029|NCT05345054|OTHER|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
218968030|NCT01514500|DRUG|somapacitan|Administered s.c. (subcutaneously, under the skin)
218968031|NCT01514500|DRUG|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
218968032|NCT02578771|DRUG|ZuraPrep with 70% IPA|Apply topically
218968033|NCT02578771|DRUG|ZuraPrep without 70% IPA|Apply topically. 0% IPA
218968034|NCT02578771|DRUG|ChloraPrep CHG/IPA Teal Tint|Apply topically
218968035|NCT02578771|OTHER|Normal Saline|Apply topically
218968036|NCT04722549|DIETARY_SUPPLEMENT|Placebo|Cellulose
218968037|NCT04722549|DIETARY_SUPPLEMENT|Butyrate|Sodium butyrate
218968038|NCT00766883|BEHAVIORAL|Problem Solving Education|
218968039|NCT05616806|BEHAVIORAL|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
218968040|NCT05350176|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
219658469|NCT05899647|DIAGNOSTIC_TEST|Ultraviolet Microscopic Analysis|"Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected."
219064055|NCT06205524|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219064056|NCT02018055|DRUG|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
219658470|NCT01153620|DRUG|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
219658471|NCT01153620|OTHER|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
219658472|NCT01413074|OTHER|Peritoneal Dialysis treatment|PD treatment
219658473|NCT01413074|OTHER|Hemodialysis treatment|HD treatment
219658474|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
219658475|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
218968041|NCT05350176|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
218968042|NCT00526604|BEHAVIORAL|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
218968043|NCT02671773|DRUG|Inhaled corticosteroid dose/type|
218968044|NCT05034133|DRUG|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
218968045|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
218968046|NCT03172910|DRUG|Placebo|Saline for injection
219658476|NCT05489640|OTHER|No Intervention|No Intervention will be administered in this study.
218968047|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
218968048|NCT06069726|DRUG|Atezolizumab|One dose of atezolizumab will be given prior to resection.
218968049|NCT05307705|DRUG|LOXO-783|Oral
218968050|NCT05307705|DRUG|Fulvestrant|Intramuscular
218968051|NCT05307705|DRUG|Imlunestrant|Oral
218968052|NCT05307705|DRUG|Abemaciclib|Oral
218968053|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
218968054|NCT05307705|DRUG|Paclitaxel|Intravenous
218968055|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
219658477|NCT06404840|DRUG|nimotuzumab|nimotuzumab (400 mg, iv, d1, qw)
219658478|NCT06404840|DRUG|AG chemotherapy|(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
219658479|NCT01201174|OTHER|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
219658480|NCT04167930|OTHER|electronic medical record(EMR) Data and patient survey|"1. Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~2. Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
219658481|NCT00980018|DRUG|Nilotinib|Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
218968056|NCT00538564|DRUG|tadalafil|10mg oral tablets taken 3 times a week for 2 months
218968057|NCT00538564|DRUG|placebo|Placebo tablets taken orally 3 times a week for 2 months
219064057|NCT02018055|DRUG|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
219064058|NCT05898542|PROCEDURE|Nature-based therapy|Therapy sessions conducted outdoors
219064059|NCT02171468|DRUG|Dabigatran high dose|
219064060|NCT02171468|DRUG|Dabigatran low dose|
219064061|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
219064062|NCT03861000|DRUG|BPN14770|selective compound
219064063|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
219064064|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
219064065|NCT01855009|DIETARY_SUPPLEMENT|MannaBears|Subjects will be administered 4 MannaBears daily
219064066|NCT01855009|DIETARY_SUPPLEMENT|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
219064067|NCT01855009|DIETARY_SUPPLEMENT|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
219064068|NCT01855009|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be administered 800 IU vitamin D3
219064069|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
219064070|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
219064071|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
219064072|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
219658482|NCT01621971|DRUG|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
218968058|NCT04885946|OTHER|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
218968059|NCT04885946|OTHER|Placebo|Food coloring, water, glycerol
219064073|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
219064074|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
219064075|NCT02394743|RADIATION|18FDG-PET|
219064076|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
219064077|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
219064078|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
219064079|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
219064080|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
219208214|NCT06436625|OTHER|outpatient pulmonary rehabilitation|Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
219208215|NCT05617638|BEHAVIORAL|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
219208216|NCT04599296|DEVICE|Hip brace|Hip brace
219208217|NCT06177769|DEVICE|LMA classic|Airway is secured with LMA clasic
219658483|NCT01621971|DRUG|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
219208218|NCT06177769|DEVICE|LMA Proseal|Airway is secured with LMA proseal
219658484|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
219658485|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
219208219|NCT06177769|DEVICE|I-gel|Airway is secured with I-gel
219208220|NCT06131437|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
219208221|NCT06131437|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
219658486|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
218968060|NCT02999399|OTHER|Brussel Sprouts|Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
218968061|NCT02999399|DRUG|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
218968062|NCT01199107|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
218968063|NCT01199107|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
218968064|NCT01199107|BEHAVIORAL|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
218968065|NCT04070144|DEVICE|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
218968066|NCT01927341|DRUG|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
218968067|NCT01927341|DRUG|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
218968068|NCT03250169|DRUG|Alemtuzumab|Licensed dose
219658487|NCT01474031|OTHER|Biomechanics|"* Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)"
219658488|NCT05769920|DRUG|TTHX1114(NM141) Ophthalmic Solution|Eye drop twice daily
219658489|NCT02758873|GENETIC|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
219658490|NCT02758873|GENETIC|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
219658491|NCT02758873|OTHER|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
219658492|NCT04694768|BEHAVIORAL|Rehabilitation|Rehabilitation program
219658493|NCT01821950|BEHAVIORAL|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
218968069|NCT05030324|DRUG|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
218968070|NCT05030324|DRUG|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
218968071|NCT05030324|DRUG|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
218968072|NCT00248131|DRUG|Octreotide acetate in microspheres|
218968073|NCT01397201|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
218968074|NCT01397201|DRUG|BI 54903|BI 54903
218968075|NCT01397201|DRUG|Fluticasone propionate|Fluticasone propionate
218968076|NCT05064904|DRUG|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
219064081|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
219064082|NCT04280211|OTHER|Balance Assessment|Postural stability
219658494|NCT01858623|DRUG|Losartan/hydrochlorothiazide|
219658495|NCT01858623|DRUG|Losartan|
219658496|NCT01858623|DRUG|Hydrochlorothiazide|
219064083|NCT06664281|BEHAVIORAL|SIT|sprint interval training
219064084|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
219064085|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
219064086|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
219064087|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
219208222|NCT06131437|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
219658497|NCT00087126|DRUG|topotecan hydrochloride|
219658498|NCT05096572|DEVICE|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
219658499|NCT05096572|DEVICE|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
219658500|NCT05096572|DEVICE|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
219658501|NCT00699712|DRUG|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
219658502|NCT01832818|DEVICE|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
219658503|NCT01399970|OTHER|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
219658504|NCT01399970|OTHER|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
219658505|NCT04220099|PROCEDURE|Electroconvulsive therapy(ECT)|Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
219658506|NCT01839799|DRUG|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
219658507|NCT01839799|DRUG|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
219658508|NCT01839799|DRUG|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
219658509|NCT01839799|RADIATION|Chemoradiation|
219658510|NCT00934856|DRUG|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
219658511|NCT00934856|DRUG|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
219658512|NCT00934856|DRUG|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
219658513|NCT01742715|OTHER|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
219658514|NCT01742715|OTHER|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
219658515|NCT01742715|OTHER|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
219658516|NCT05112757|OTHER|Smartphone application use|Use of a smartphone application
219658517|NCT05555316|DRUG|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
219658518|NCT03765112|DEVICE|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
219658519|NCT02184910|DRUG|pepsinogen and gastrin|
219658520|NCT06731634|DEVICE|Hand grip strength dynamometer, pinch strength dynamometer|Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer
219658521|NCT06731634|DIAGNOSTIC_TEST|Finkelstein test|Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
218968077|NCT04691401|DEVICE|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
218968078|NCT05996627|DRUG|Belumosudil|Given PO
218968079|NCT05996627|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218968080|NCT05996627|OTHER|Electronic Health Record Review|Ancillary studies
218968081|NCT05996627|DRUG|Placebo Administration|Given PO
218968082|NCT01054326|OTHER|Exercises|
218968083|NCT04648280|DRUG|Fostemsavir|fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
218968084|NCT01083485|DRUG|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
219208223|NCT01187199|DRUG|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
219658522|NCT04423575|OTHER|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
219658523|NCT04297475|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
219658524|NCT04255407|DEVICE|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
218968085|NCT01083485|DRUG|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
218968086|NCT02858011|OTHER|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
219208224|NCT01187199|DRUG|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
219208225|NCT01187199|DRUG|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
219208226|NCT01187199|DRUG|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
219064088|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
219064089|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
219658525|NCT04255407|DRUG|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
219658526|NCT06511115|OTHER|Experimental Group|"Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits."
219658527|NCT04015778|BIOLOGICAL|Nivolumab|240mg Q2W or 360mg Q3W
219658528|NCT04015778|DRUG|carboplatin|AUC 5, d1 every three weeks
219658529|NCT04015778|DRUG|nab-paclitaxel|135 mg/m2, d1, 8
219658530|NCT01256385|BIOLOGICAL|Cetuximab|Given IV
219658531|NCT01256385|OTHER|Laboratory Biomarker Analysis|Correlative studies
219658532|NCT01256385|DRUG|Temsirolimus|Given IV
219658533|NCT06308757|DIETARY_SUPPLEMENT|Very-low-calorie ketogenic diet (VLCKD) with meal replacements|The VLCKD study arm will receive an experimental diet therapy with very-low-calorie ketogenic meal replacements (VLCKD) consisting of 5 successive phases (600 - 1500 kcal/day).
219658534|NCT06308757|DIETARY_SUPPLEMENT|Mediterranean low-calorie diet (LCD)|The Control arm LCD will receive standard Mediterranean type low-calorie diet (LCD) therapy by the most recent guidelines on MAFLD/NAFLD (1200-1500 kcal/day).
219658535|NCT00135902|DRUG|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
218968087|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
218968088|NCT02858011|DIETARY_SUPPLEMENT|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
218968089|NCT02858011|OTHER|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
219658536|NCT00135902|DRUG|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
219658537|NCT06419010|PROCEDURE|Surgery with the use of L-PRF|The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes
218968090|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
218968091|NCT02026284|OTHER|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
218968092|NCT03539848|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
218968093|NCT02791399|BEHAVIORAL|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
218968094|NCT06039410|DEVICE|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
218968095|NCT01991106|BEHAVIORAL|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
218968096|NCT01991106|BEHAVIORAL|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
218968097|NCT01991106|DIETARY_SUPPLEMENT|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
218968098|NCT04603053|BEHAVIORAL|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
218968099|NCT00462631|DEVICE|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
218968100|NCT00462631|DEVICE|paclitaxel eluting stent|paclitaxel eluting stent
218968101|NCT00462631|DEVICE|bare metal stent|bare metal stent
218968102|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
218968103|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
218968104|NCT03320603|OTHER|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
219064090|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
219658538|NCT06419010|PROCEDURE|Standard surgery|The standard surgical treatment, taking place in the operating room under general anesthesia
219658539|NCT00865579|DRUG|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
219658540|NCT02364154|OTHER|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
219658541|NCT02364154|OTHER|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
219658542|NCT03268512|OTHER|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
219208227|NCT01187199|DRUG|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
219208228|NCT05356169|DRUG|with or without venetoclax|Bcl-2 inhibitor
219658543|NCT03268512|OTHER|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
219658544|NCT01807468|PROCEDURE|haploidentical stem cell transplantation and NK cell therapy|
219658545|NCT03637530|OTHER|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
219658546|NCT02020512|DRUG|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
219064091|NCT06508554|OTHER|Haptonomy|5\. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
219064092|NCT04725331|BIOLOGICAL|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.
219064093|NCT04725331|DRUG|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
219064094|NCT03358563|DRUG|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
219064095|NCT03358563|DRUG|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
219064096|NCT03358563|DRUG|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
219064097|NCT03358563|RADIATION|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
219064098|NCT06495671|DEVICE|Magnetically enhanced diffusion|Iron nanoparticle (intra-arterial) + External magnet workstation
219064099|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
219064100|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
219064101|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
219064102|NCT05556681|DEVICE|BD™ Sirolimus Drug Coated Balloon Catheter percutaneous transluminal angioplasty|The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries. Eligible patients will undergo percutaneous transluminal angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
219658547|NCT04854083|DRUG|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
219064103|NCT01873794|DEVICE|Bright white light|
219208229|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
219658548|NCT04854083|DRUG|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
219658549|NCT03023540|DRUG|PXT3003|Liquid oral solution, twice 5 mL (Dose 1) bid
219658550|NCT05754255|DEVICE|Nasal Cannula|"A nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow.~The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils."
219658551|NCT05754255|DEVICE|Nasal Positive Airway Pressure System|Positive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems.
219064104|NCT01873794|DEVICE|Dim red light|
219208230|NCT06648278|BEHAVIORAL|Patient Navigation Program|Online health tool
219658552|NCT01734915|DEVICE|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
219658553|NCT02464761|DRUG|Visudyne|
219658554|NCT06011304|DRUG|[18F]Florastamin Injection|"The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection."
219658555|NCT00835679|BIOLOGICAL|cetuximab|Given IV
219658556|NCT00835679|DRUG|dasatinib|Given orally
219658557|NCT00835679|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218968105|NCT03320603|OTHER|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
218968106|NCT02013869|DEVICE|Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas|Desflurane Dialed setting 18 % on the machine gas vaporized
218968107|NCT02013869|DEVICE|Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated|Desflurane dialed 18% on the machine gas vaporized
218968108|NCT01764425|DRUG|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
218968109|NCT06156540|OTHER|virtual reality glasses|Using virtual reality glasses, caregivers in the experimental group were shown 360-degree VR relaxing videos.
218968110|NCT04407260|DEVICE|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
218968111|NCT06045169|PROCEDURE|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
218968112|NCT06431373|DRUG|Brepocitinib PO QD|Brepocitinib PO QD
218968113|NCT06431373|DRUG|Placebo PO QD|Placebo PO QD
218968114|NCT02898155|OTHER|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
219658558|NCT00835679|OTHER|laboratory biomarker analysis|Correlative studies
218968115|NCT01598675|OTHER|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
218968116|NCT01598675|OTHER|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
218968117|NCT00471016|BEHAVIORAL|Guided intervention|
218968118|NCT05132868|OTHER|Educational video and pamphlet|The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
218968119|NCT05132868|OTHER|Traditional genetic counseling|Patients will receive traditional genetic counseling
218968120|NCT03732690|OTHER|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
218968121|NCT03732690|OTHER|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
218968122|NCT05067907|PROCEDURE|Early physiotherapy|"Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration."
218968123|NCT02969564|OTHER|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
218968124|NCT02969564|OTHER|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
218968125|NCT03607422|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
219064105|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
219064106|NCT03070522|DRUG|Placebos|Placebo
219064107|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
219658559|NCT02560324|DRUG|Ramelteon|
219658560|NCT02560324|DRUG|Placebo|
219658561|NCT04683354|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
219658562|NCT00126269|DRUG|cisplatin|
219658563|NCT00126269|DRUG|gemcitabine|
219658564|NCT06402591|DRUG|Cefazolin|cefazolin extended prophylaxis 5 days (15 doses)
219208231|NCT06648278|OTHER|Quality-of-Life (QOL) Assessment|Online surveys to assess QOL
219658565|NCT05152654|DEVICE|Tacker|metallic staples used to fix the mesh
219208232|NCT06648278|OTHER|Survey Administration|Ancillary studies
219208233|NCT05513586|DRUG|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
219208234|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
219208235|NCT04875871|RADIATION|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
219208236|NCT04875871|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
219658566|NCT06618365|DRUG|Vitamin D Deficiency|"The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each."
219658567|NCT03477994|DRUG|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
219658568|NCT03477994|DRUG|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
219658569|NCT00951834|DRUG|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
219658570|NCT00951834|DRUG|Placebo|Placebo
219658571|NCT02994758|OTHER|Personalised treatment|Treatment based on NGS or DSRT
219658572|NCT01860742|DRUG|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
219208237|NCT04875871|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
219208238|NCT04875871|DIAGNOSTIC_TEST|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
219208239|NCT04875871|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
219658573|NCT01860742|DRUG|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
219658574|NCT05745467|DRUG|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
219658575|NCT00911209|BEHAVIORAL|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
219658576|NCT01572467|GENETIC|RNA analysis|
219658577|NCT01572467|GENETIC|gene expression analysis|
219658578|NCT01572467|GENETIC|mutation analysis|
219658579|NCT01572467|GENETIC|reverse transcriptase-polymerase chain reaction|
219658580|NCT01572467|OTHER|laboratory biomarker analysis|
219658581|NCT01572467|OTHER|medical chart review|
219658582|NCT04197895|PROCEDURE|Socket preservation with APRF|Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
218968126|NCT03607422|DRUG|Upadacitinib|Tablets taken orally once a day
218968127|NCT06710951|PROCEDURE|Change of normal concentration of povidone-iodine 5% to 1%|Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.
218968128|NCT03693170|DRUG|encorafenib|300 mg administered orally once daily (QD)
218968129|NCT03693170|DRUG|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
218968130|NCT03693170|DRUG|Cetuximab|"Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
218968131|NCT03964805|OTHER|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
219658583|NCT04197895|PROCEDURE|natural healing|after atraumatic extraction , the socket will be left for natural healing after suturing
219658584|NCT00274443|DRUG|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
219658585|NCT06348121|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study had last 56 days, and each patient will make 3 visits (d0, d28, d56).
219658586|NCT05436678|DRUG|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
219658587|NCT05436678|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
218968132|NCT03964805|OTHER|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
218968133|NCT03964805|OTHER|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
218968134|NCT00634400|DRUG|Candesartan|
218968135|NCT00634400|DRUG|Placebo|
218968136|NCT03432520|GENETIC|SPK-8011|Observational long-term safety follow-up study of participants previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study
218968137|NCT03432520|GENETIC|SPK-8016|Observational long-term safety follow-up study of participants previously treated with SPK-8016 in any Spark-sponsored SPK-8016 study
218968138|NCT03402659|DRUG|neflamapimod|40 mg neflamapimod capsule
218968139|NCT03402659|OTHER|placebo|matching placebo capsule
218968140|NCT04414332|OTHER|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
218968141|NCT05419531|OTHER|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
218968142|NCT02878824|OTHER|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
218968143|NCT02878824|OTHER|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
219064108|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
219208240|NCT04875871|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
219658588|NCT05436678|DRUG|Celecoxib 200mg|Celecoxib
219658589|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
219658590|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
219658591|NCT06124586|PROCEDURE|Percutaneous transluminal angioplasty|Percutaneous transluminal angioplasty of the leg
219064109|NCT03823118|DRUG|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
219064110|NCT01865370|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
219064111|NCT01865370|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
219064112|NCT01108848|BIOLOGICAL|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
219658592|NCT01839305|OTHER|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
219658593|NCT02702141|DRUG|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
219658594|NCT04174937|DRUG|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
219658595|NCT04174937|OTHER|Placebo PA|Intervention is administered to patients in this Arm
219658596|NCT04810559|DEVICE|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
219658597|NCT04769739|OTHER|CO2|using CO2 insufflation to help insertion
219658598|NCT04769739|OTHER|Water|using water instead of traditional gas to help insertion
219658599|NCT04769739|OTHER|50% saline|using 50% saline solution instead of traditional gas to help insertion
219658600|NCT04769739|OTHER|25% saline|using 25% saline solution instead of traditional gas to help insertion
219658601|NCT01669200|OTHER|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
219658602|NCT01669200|OTHER|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
219658603|NCT01922154|DRUG|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
218968144|NCT01442038|DRUG|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
218968145|NCT01442038|DRUG|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
219208241|NCT04906096|DRUG|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
219208242|NCT02887950|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
219658604|NCT01922154|PROCEDURE|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
218968146|NCT00089284|DRUG|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
219208243|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
219658605|NCT02657070|BEHAVIORAL|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
219658606|NCT02657070|BEHAVIORAL|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
219658607|NCT02081664|BEHAVIORAL|lifestyle intervention|
219658608|NCT06977724|DRUG|ABBV-319|Intravenous (IV) Infusion
219658609|NCT06679257|DIAGNOSTIC_TEST|cell-free dNA|Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
219658610|NCT06678893|DEVICE|Acupuncture Needle on an adhesive|This study utilizes acupuncture needs on small adhesives which will be placed according to the 5NP NADA Auricular Acupuncture Protocol.
219658611|NCT06678893|DEVICE|Adhesives|For those randomized to the placebo arm, adhesives without needles will be placed according to the 5NP NADA Auricular Acupuncture Protocol placement
219658612|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
219658613|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
219658614|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
219658615|NCT03689543|DRUG|Estradiol|Estradiol patch 0.1 mg transdermal every three days for three weeks
219658616|NCT03689543|DRUG|ER Beta Agonist|Lilly Compound LY500307, a selective estrogen receptor (ER) beta agonist
219658617|NCT03689543|OTHER|Placebo|Placebo orally once daily
219658618|NCT03689543|DRUG|Provera|Provera 5 mg orally once a day for one week after completion of randomization
219658619|NCT05921578|DIAGNOSTIC_TEST|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
219658620|NCT01736605|PROCEDURE|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
218968147|NCT00089284|DRUG|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
219658621|NCT01736605|PROCEDURE|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
219658622|NCT00932451|DRUG|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
219658623|NCT01451632|DRUG|MM-121|escalating doses MM-121 IV QW
219658624|NCT01451632|DRUG|Irinotecan|180 mg/m2 IV Q2W
219658625|NCT01451632|DRUG|Cetuximab|escalating doses cetuximab IV QW
219658626|NCT05764746|DRUG|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
219658627|NCT05764746|DRUG|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
219658628|NCT05764746|DRUG|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
219658629|NCT01933178|DEVICE|Cirrus AS-OCT|
219658630|NCT05538975|OTHER|Physiotherapy Treatment|Pulmonary Rehabilitation Techniques
219658631|NCT03050047|BIOLOGICAL|BCD-100|Anti-PD1 monoclonal antibody
219658632|NCT00585715|DEVICE|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
219658633|NCT00425893|BEHAVIORAL|hand hygiene|alcohol-based hand wash
219658634|NCT00425893|OTHER|health education|Proper nutrition, etc.
219658635|NCT00425893|DEVICE|face masks|face masks
219658636|NCT04891406|OTHER|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
219658637|NCT04891406|OTHER|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
218968148|NCT00089284|DRUG|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
218968149|NCT01658618|BIOLOGICAL|HP802-247|
218968150|NCT01043146|DRUG|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
218968151|NCT01043146|DRUG|placebo|intravenous 0.9 % NaCl
218968152|NCT00215202|DRUG|Iressa (ZD1839)|
219658638|NCT04891406|OTHER|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
219658639|NCT04891406|OTHER|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
219658640|NCT04891406|OTHER|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
219658641|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
219658642|NCT05717764|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
219658643|NCT05717764|DRUG|Capecitabine|Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
219658644|NCT04080518|DRUG|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
219658645|NCT01920659|BEHAVIORAL|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
218968153|NCT03092024|OTHER|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
218968154|NCT04360590|DEVICE|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
218968155|NCT01499069|DRUG|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
219658646|NCT01920659|BEHAVIORAL|REHIT|6 weeks 3 x week (20sec intervals)
219658647|NCT04079257|OTHER|Blood collection for measurement of eculizumab peak concentrations|collection of blood
219658648|NCT06258317|PROCEDURE|fixation of conventional polypropylene mesh|"By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh."
219658649|NCT01246037|DRUG|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
219658650|NCT03969303|DEVICE|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
219658651|NCT03108872|DEVICE|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
219658652|NCT03108872|DRUG|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
219658653|NCT03363451|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
218968156|NCT05391542|OTHER|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
219208244|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
219658654|NCT06080880|DRUG|Ondansetron every 3 weeks|Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
219658655|NCT06080880|DRUG|Aprepitant|aprepitant, Po, 125mg/d, 1day' application every 3 weeks
219658656|NCT06080880|DRUG|Dexamethasone|dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
219658657|NCT06080880|DRUG|Ondansetron weekly|Ondansetron, Po, 24mg/d, 3 days' application weekly
219658658|NCT03414996|OTHER|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
219658659|NCT03227172|PROCEDURE|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
219658660|NCT01795092|OTHER|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
218968157|NCT02128828|DRUG|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
218968158|NCT02493387|OTHER|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
218968159|NCT02493387|OTHER|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
218968160|NCT02503007|DIETARY_SUPPLEMENT|Placebo|
218968161|NCT02503007|DIETARY_SUPPLEMENT|HMB-FA|
218968162|NCT04615897|PROCEDURE|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
218968163|NCT03228420|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
218968164|NCT03228420|OTHER|CMM|Conventional Medical Management
218968165|NCT02428608|BIOLOGICAL|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
218968166|NCT01841736|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218968167|NCT01841736|PROCEDURE|Computed Tomography|Undergo CT
218968168|NCT01841736|PROCEDURE|Echocardiography Test|Undergo ECHO
218968169|NCT01841736|OTHER|Laboratory Biomarker Analysis|Correlative studies
218968170|NCT01841736|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218968171|NCT01841736|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218968172|NCT01841736|DRUG|Pazopanib Hydrochloride|Given PO
218968173|NCT01841736|OTHER|Placebo Administration|Given PO
218968174|NCT01841736|OTHER|Quality-of-Life Assessment|Ancillary studies
219658661|NCT04760288|DRUG|Pralsetinib|Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
219658662|NCT04760288|DRUG|Cabozantinib|Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
219658663|NCT04760288|DRUG|Vandetanib|Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
218968175|NCT01841736|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
218968176|NCT04523948|BEHAVIORAL|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
219658664|NCT02968433|DRUG|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
219658665|NCT04291664|DRUG|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
219658666|NCT04291664|DRUG|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
219658667|NCT04291664|DRUG|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
219658668|NCT04275726|DEVICE|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
219658669|NCT04275726|DEVICE|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
219658670|NCT01293513|OTHER|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
219658671|NCT00043667|DRUG|Daclizumab|
219658672|NCT06647901|DRUG|ICG (Indocyanine Green)|Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
219658673|NCT00877149|DRUG|telbivudine/LDT600|
218968177|NCT02777736|DRUG|Methotrexate|i.v. or intrathecal CNS prophylaxis
218968178|NCT05346497|PROCEDURE|Bentall|Bentall procedure: include replacement of both aortic valve and root
218968179|NCT05346497|PROCEDURE|David|David procedure: include replacement of aortic root and aortic valvuloplasty
218968180|NCT05346497|PROCEDURE|ARR|Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
219658674|NCT06234696|OTHER|entrepreneurial intervention|The experimental group will be given psychoeducation for 4 weeks.
219658675|NCT06184113|PROCEDURE|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
219658676|NCT06184113|DIAGNOSTIC_TEST|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
219658677|NCT06184113|DIAGNOSTIC_TEST|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
219658678|NCT02079636|DRUG|Abemaciclib|Administered orally
219658679|NCT02079636|DRUG|Pemetrexed|Administered IV
219658680|NCT02079636|DRUG|Gemcitabine|Administered IV
218968181|NCT06247800|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
218968182|NCT06247800|OTHER|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
218968183|NCT03835104|DEVICE|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
218968184|NCT05859685|OTHER|Experimental|"Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
218968185|NCT05859685|OTHER|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
218968186|NCT03468985|DRUG|Cabozantinib|Given PO
218968187|NCT03468985|BIOLOGICAL|Ipilimumab|Given IV
218968188|NCT03468985|BIOLOGICAL|Nivolumab|Given IV
218968189|NCT03094988|BEHAVIORAL|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
218968190|NCT03094988|OTHER|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
218968191|NCT00535457|OTHER|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
218968192|NCT04393285|DRUG|Abemaciclib|Abemaciclib 150mg orally twice a day
219208245|NCT06732505|DRUG|[225Ac]Ac-DOTATATE|"The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.~The dose expansion phase will be divided into 3 cohorts based on Ki-67 index."
219658681|NCT02079636|DRUG|Ramucirumab|Administered IV
219658682|NCT02079636|DRUG|LY3023414|Administered orally
219658683|NCT02079636|DRUG|Pembrolizumab|Administered IV
219658684|NCT00006013|DRUG|semaxanib|
218968193|NCT04393285|DRUG|Letrozole|Letrozole 2.5mg orally once a day
218968194|NCT00080275|DRUG|Niacin Extended-Release and simvastatin Tablets|
218968195|NCT04367233|OTHER|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
218968196|NCT04367233|OTHER|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
218968197|NCT04367233|OTHER|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
218968198|NCT02718560|BEHAVIORAL|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
218968199|NCT02661451|DEVICE|SAPIEN 3 THV|
218968200|NCT02661451|BIOLOGICAL|Optimal Heart Failure Therapy|
218968201|NCT06305624|DEVICE|Connections App|mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
218968202|NCT06443944|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
218968203|NCT06443944|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
218968204|NCT05318417|DEVICE|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
218968205|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 8 days of total exposure to furosemide over the 16-day N-of-1 trial.
218968206|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
218968207|NCT06959108|DRUG|Pucotenlimab|200mg every 3 weeks (21-day cycles) for a total of 3 cycles.
218968208|NCT06959108|DRUG|MRG003|2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.
218968209|NCT04974047|DRUG|Tislelizumab|Administered intravenously as specified in the treatment arm.
218968210|NCT06789913|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
218968211|NCT06789913|DRUG|Placebo|RLY-2608 matched-placebo
218968212|NCT06431984|DIAGNOSTIC_TEST|prick test|self-sampling of capillary blood using the finger prick test method
218968213|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
219658685|NCT05593536|BEHAVIORAL|Breastfeeding Education|Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
219658686|NCT02437032|DRUG|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
219658687|NCT02437032|DRUG|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
219658688|NCT02437032|DRUG|hMG|Controlled ovarian stimulation with 150-300 UI hMG
219658689|NCT00689559|DRUG|AZD3480|AZD3480 capsules qd, oral, 22 days
219658690|NCT00689559|DRUG|Placebo|Placebo qd, 12 days
219658691|NCT00689559|DRUG|Aripiprazole|single dose on day 5
219658692|NCT00875433|DRUG|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
219658693|NCT01167049|DRUG|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
219658694|NCT04781829|DIAGNOSTIC_TEST|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
219658695|NCT05309473|DEVICE|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
219658696|NCT05309473|DEVICE|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
219658697|NCT02433067|OTHER|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
219658698|NCT02433067|OTHER|Control Group|standard oncologic care
219658699|NCT05715047|BEHAVIORAL|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
219658700|NCT05715047|BEHAVIORAL|Usual Care|Standard transplant care.
219658701|NCT06623877|DIAGNOSTIC_TEST|renal shear wave elastography|"Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups"
218968214|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
218968215|NCT03560310|DRUG|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
219658702|NCT00637806|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
219658703|NCT00637806|DRUG|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
219658704|NCT00637806|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
219658705|NCT00725101|DRUG|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
219658706|NCT02079142|BEHAVIORAL|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
219658707|NCT02079142|BEHAVIORAL|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
219658708|NCT03564080|OTHER|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
219658709|NCT01923844|DRUG|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
219658710|NCT00556205|DRUG|Sunitinib|Sunitinib orally once daily
219658711|NCT00556205|DRUG|Bevacizumab|Intravenously every 14 days
219658712|NCT06621498|PROCEDURE|Ridge preservation technique|Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
219658713|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
219658714|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, full-thickness graft harversting and socket sealing with it.
219658715|NCT03528564|DRUG|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
219658716|NCT03528564|DRUG|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
219658717|NCT03528564|DRUG|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
219658718|NCT02501083|OTHER|no intervention|The study will not include any intervention.
219658719|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
219658720|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
219658721|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
219658722|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219658723|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
219658724|NCT06594016|DRUG|Fosigotifator|Oral
219658725|NCT06592768|DRUG|Briquilimab|Subcutaneous Administration
219658726|NCT06592768|OTHER|Placebo Comparator|Subcutaneous Administration
219658727|NCT03196037|BEHAVIORAL|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
219658728|NCT06122233|BEHAVIORAL|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources."
218968216|NCT03560310|DRUG|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
218968217|NCT02549157|PROCEDURE|Pelvic Floor Muscle Training|
218968218|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
218968219|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
219658729|NCT06668922|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
219658730|NCT06991166|BEHAVIORAL|Cognitive behavioral therapy (CBT) psychotherapy group/telehealth|Type of psychotherapy. CBT focuses on identifying and changing unhelpful beliefs and behavioral patterns that lead to negative emotions (e.g., depression, anxiety, grief, shame) in order to break the emotion-thought-behavior cycle
219658731|NCT06991166|BEHAVIORAL|Interpersonal therapy (IPT) psychotherapy group/telehealth|Type of psychotherapy. IPT focuses on improving interpersonal communication and deficits, processing grief, and role transitions
219658732|NCT00877955|DRUG|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
219658733|NCT00877955|DRUG|alprazolam sublingual tablet test|0.5 mg tablet, single dose
219658734|NCT04173728|OTHER|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
219658735|NCT00189852|DEVICE|Chronic heart failure monitoring system|
219658736|NCT00189852|DEVICE|Lifestyle monitoring system|
219658737|NCT06865495|OTHER|Handwashing Hardware and Supply Provision|Households will be given a locally available handwashing facility called the Kalingalinga bucket. Intervention delivery workers will set-up the handwashing facility, and demonstrate how it works, including where to place soap on the stand. Households will also be given supplies and materials to make their own liquid soap from locally available soap products (soapy water). Discussions will also be held on HWF maintenance. This component of the intervention should take no longer than 30 minutes. Intervention delivery workers will return to households after three months (one visit) to ensure there are no issues with the handwashing station (e.g., broken stand or tap), to bring more liquid soap and to remind households how to make soapy water.
218968220|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
218968221|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
218968222|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
218968223|NCT06358651|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
218968224|NCT06358651|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
218968225|NCT06126744|BIOLOGICAL|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
218968226|NCT06430814|OTHER|No intervention|No intervention
218968227|NCT06092580|BIOLOGICAL|AWT020|Participants receiving AWT020 once every two weeks or longer at designated dose levels
219658738|NCT06865495|BEHAVIORAL|Hand Hygiene Behavioural Promotion|"The hand hygiene behavioural promotion intervention employs interactive storytelling and visual aids to promote handwashing with soap. Intervention delivery workers will act as storytellers, narrating stories about three characters with different handwashing habits.~The intervention progresses through five bi-weekly visits, with a final sixth visit 4 weeks after the fifth visit. The 30-minute visits progress through different stages: (1) identifying behaviours, (2) understanding disease risks, (3) encouraging practical solutions and (4) promoting practice. The penultimate stage of the intervention focuses on reflection and commitment, encouraging participants to assess their behaviours and pledge to adopt improved hygiene practices. The final visit allows participants to reflect on the whole intervention and covers information participants would like to revisit."
219658739|NCT05617079|OTHER|Survey|an electronic survey will be conducted
219658740|NCT06992362|DRUG|Perioperative treatment|RC48+SOX+Sindilizumab
219658741|NCT06255379|DRUG|Fuquinitinib+Tegafur Gimeracil Oteracil|Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
218968228|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
218968229|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
218968230|NCT02207465|RADIATION|Radiotherapy|
218968231|NCT02207465|DRUG|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
218968232|NCT04060862|DRUG|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
218968233|NCT04060862|DRUG|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
218968234|NCT04060862|DRUG|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
218968235|NCT04060862|DRUG|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
218968236|NCT02051413|DRUG|Venlafaxine extended release|antidepressant drug
218968237|NCT06504381|GENETIC|DB107-RRV|Given intracranially (IC) during resection and intravenously (IV) immediately following
218968238|NCT06504381|DRUG|DB107-FC|Given orally (PO)
218968239|NCT06504381|RADIATION|Radiation Therapy (RT)|Undergo RT
218968240|NCT06504381|DRUG|Temozolomide|Given PO
218968241|NCT06504381|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo standard of care MRI
218968242|NCT06504381|PROCEDURE|Surgical resection|Undergo non-investigational tumor resection
218968243|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
218968244|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
219658742|NCT00622336|DRUG|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
219658743|NCT00622336|DRUG|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
219658744|NCT01890213|BIOLOGICAL|AVX701|
218968245|NCT05274685|PROCEDURE|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
218968246|NCT03557827|DRUG|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
218968247|NCT03557827|PROCEDURE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
218968248|NCT05310188|DIAGNOSTIC_TEST|pseudocholinesterease|blood samples
218968249|NCT05542134|DIAGNOSTIC_TEST|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
218968250|NCT00185653|PROCEDURE|Autologous followed by non-myeloablative allogeneic transplantation|
218968251|NCT04282512|OTHER|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
219658745|NCT06998524|DRUG|Emicizumab|"Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W).~During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators."
218968252|NCT00928798|DRUG|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
218968253|NCT00928798|DRUG|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
218968254|NCT03416374|DRUG|Ixazomib|Ixazomib capsules
218968255|NCT03416374|DRUG|Bortezomib|Bortezomib injections
218968256|NCT03416374|DRUG|Carfilzomib|Carfilzomib intravenous infusions
218968257|NCT03416374|DRUG|Lenalidomide|Lenalidomide capsules
218968258|NCT03416374|DRUG|Dexamethasone|Dexamethasone tablets
218968259|NCT05156476|PROCEDURE|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
218968260|NCT05156476|PROCEDURE|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
218968261|NCT05156476|PROCEDURE|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
218968262|NCT01165190|OTHER|pioglitazone|
218968263|NCT01266941|DRUG|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
218968264|NCT04327310|DRUG|Meplazumab for Injection|humanized mAb against CD147
218968265|NCT04327310|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
218968266|NCT01052844|DRUG|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
218968267|NCT01052844|DRUG|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
218968268|NCT02147002|DIETARY_SUPPLEMENT|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
218968269|NCT03599401|OTHER|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
218968270|NCT03671993|PROCEDURE|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
218968271|NCT03671993|PROCEDURE|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
218968272|NCT02647840|BEHAVIORAL|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
218968273|NCT06252298|BIOLOGICAL|SCTC21C|SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
218968274|NCT01159977|BEHAVIORAL|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
219658746|NCT06998524|DRUG|von Willebrand Factor (VWF) Concentrates|Used according to local labeling or local treatment guidelines.
219658747|NCT06998524|DRUG|Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
219658748|NCT06998524|DRUG|von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
219658749|NCT06998524|DRUG|Bypassing Agents|Used according to local labeling or local treatment guidelines.
219658750|NCT04520516|DEVICE|Active VAGUSTIM device|Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
219658751|NCT04520516|DEVICE|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
219658752|NCT07003386|DRUG|Galantamine|Start within 24 hours of hospitalization, administer 5.0 mg of galantamine via intramuscular injection once daily, and continue the treatment for 10 days.
219658753|NCT07003386|DRUG|Standard treatment for acute ischemic stroke|Standard treatment for acute ischemic stroke
219208246|NCT06273579|BEHAVIORAL|Expert instruction using AI tutor script|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the instructor must deliver this command using the exact wording provided by the ICEMS.
219658754|NCT07004790|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|A non-invasive bedside diagnostic procedure used to measure cerebral blood flow velocities and pulsatility index in intracranial arteries, primarily the middle cerebral artery (MCA). The test is performed within the first 24 hours of symptom onset using standard ultrasound equipment with a 2-MHz probe. The data collected is used solely for prognostic evaluation and does not influence treatment decisions.
219658755|NCT04837547|BIOLOGICAL|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
219658756|NCT04858880|RADIATION|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
219658757|NCT01758198|BIOLOGICAL|Abatacept|
218968275|NCT01159977|BEHAVIORAL|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
218968276|NCT01159977|BEHAVIORAL|Usual practice|No protected time provided.
218968277|NCT00176527|BIOLOGICAL|recombinant interferon alfa-2b|
218968278|NCT00176527|DRUG|docetaxel|
218968279|NCT00176527|DRUG|estramustine phosphate sodium|
218968280|NCT00176527|DRUG|isotretinoin|
218968281|NCT00176527|GENETIC|polyacrylamide gel electrophoresis|
218968282|NCT00176527|GENETIC|protein expression analysis|
219658758|NCT01758198|DRUG|Placebo matching with Abatacept|
219658759|NCT01758198|DRUG|Methotrexate|
219658760|NCT06542432|GENETIC|Disclosure of integrate risk score for coronary artery disease|Participants will receive their integrated risk score for coronary disease along with an optional genetic counseling visit to discuss the results.
218968283|NCT00176527|OTHER|immunohistochemistry staining method|
218968284|NCT06081400|PROCEDURE|Cryoablation|Percutaneous imaging-guided cryoablation
218968285|NCT06081400|DRUG|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
218968286|NCT01222858|BEHAVIORAL|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
218968287|NCT01222858|BEHAVIORAL|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
218968288|NCT02005432|DRUG|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
218968289|NCT02005432|DRUG|panfotocoagulation (PASCAL)|
218968290|NCT02005432|DRUG|panfotocoagulation (PRP) single shoot (ETDRS)|
218968291|NCT02803762|DRUG|Pacritinib|400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
218968292|NCT03512990|PROCEDURE|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
219658761|NCT07006948|DIAGNOSTIC_TEST|Autism Diagnostic Observation Schedule, the 2nd edition(ADOS-2)|The toddlers diagnosed with ASD will receive the ADOS-2 evaluation to confirm the diagnosis.
219658762|NCT07006948|DIAGNOSTIC_TEST|Griffiths Developmental Scales, Chinese edition(GDS-C)|The toddlers diagnosed with ASD, GDD, LD, and typically developing will receive the GDS-C evaluation to confirm the diagnosis.
218968293|NCT05232981|PROCEDURE|Ligation of the bilateral internal iliac arteries|"opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures ."
218985396|NCT00810472|OTHER|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
218985397|NCT00810472|PROCEDURE|Penetrating keratoplasty|Corneal transplantation.
219658763|NCT07003789|BEHAVIORAL|Women-Centered HIV Prevention Program|This behavioral intervention consists of a participatory, youth-designed HIV prevention program that uses Human-Centered Design (HCD) principles and WhatsApp-based engagement. It includes information and support for HIV self-testing and PrEP, with the goal of increasing awareness, improving uptake, and reducing stigma among young women in Ghana.
218968294|NCT05232981|PROCEDURE|Shehat's technique|"The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours"
218968295|NCT01637987|PROCEDURE|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
218968296|NCT01637987|PROCEDURE|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
218968297|NCT01637987|PROCEDURE|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
218968298|NCT03111173|DEVICE|Holter Device|MyECG E3.80 Holter Recorder
218968299|NCT03115073|DRUG|Candiplus|Administration of Candiplus
218968300|NCT03115073|DRUG|Clotrimazole|Administration of Clotrimazole
218968301|NCT03189771|PROCEDURE|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
218968302|NCT00209768|DEVICE|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
218968303|NCT05234658|BIOLOGICAL|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
218968304|NCT05234658|BIOLOGICAL|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
218968305|NCT05234658|BIOLOGICAL|Skin Autograft|Skin Autograft
218968306|NCT03303014|DEVICE|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
218968307|NCT05722457|OTHER|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
218968308|NCT05722457|OTHER|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
219658764|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
218968309|NCT00721266|DRUG|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
218968310|NCT00486551|BEHAVIORAL|Anger control training|
218968311|NCT03603054|OTHER|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
218968312|NCT03603054|OTHER|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
218968313|NCT05655052|DEVICE|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
218985398|NCT03865771|BEHAVIORAL|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
218985399|NCT03865771|BEHAVIORAL|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
218985400|NCT03865771|OTHER|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
219658765|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
219658766|NCT05186974|DRUG|Carboplatin|Administered intravenously
219658767|NCT05186974|DRUG|Cisplatin|Administered intravenously
219658768|NCT07008378|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.
219658769|NCT07008378|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
219658770|NCT07008378|DRUG|Fludarabine|Fludarabine will be administered intravenously.
219658771|NCT04739813|BIOLOGICAL|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
218968314|NCT05655052|DEVICE|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
218968315|NCT04327960|DIAGNOSTIC_TEST|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
218968316|NCT02729675|OTHER|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F\&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F\&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F\&V fresh.
218985401|NCT06481839|OTHER|Starting dose of NE|Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
218985402|NCT00620347|DRUG|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
218985403|NCT02872207|DRUG|BAY 987516 (Y65-122)|5 µL in one eye
218985404|NCT02872207|DRUG|BAY 987516 (Y65-118)|5 µL in one eye
219658772|NCT04739813|DRUG|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219658773|NCT04739813|DRUG|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219658774|NCT04739813|BIOLOGICAL|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219658775|NCT04739813|DRUG|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219658776|NCT04739813|DRUG|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
219658777|NCT06870591|DEVICE|Cardiac Performance System (CPS)|CPS is a non-invasive platform for hemodynamic assessment that uses acoustic sensors and electrocardiogram electrodes.
219658778|NCT07009210|BEHAVIORAL|AI Assisted Personalized Legacy Program|AI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work.
219658779|NCT04794322|DIAGNOSTIC_TEST|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
219658780|NCT04794322|DIAGNOSTIC_TEST|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
219658781|NCT04794322|DIAGNOSTIC_TEST|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
219658782|NCT07011342|DRUG|18F-rhPSMA-7.3|Utility of 18F-rhPSMA-7.3 in the diagnosis of prostate cancer after Focal Gland Treatment (SCOUT)
218985405|NCT02872207|DRUG|Control|5 uL in other eye
218985406|NCT05191173|PROCEDURE|Cardiac Surgery|No intervention, just observation is performed.
218985407|NCT03422042|OTHER|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
218985408|NCT03422042|OTHER|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
218985409|NCT04709354|DIAGNOSTIC_TEST|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
218985410|NCT02438657|PROCEDURE|median nerve block|
218985411|NCT03264313|DEVICE|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
218985412|NCT00294801|DRUG|flex-a-new (food supplement)|
218985413|NCT03011619|BEHAVIORAL|Usual Standard of Care|medication management, group therapy, and individual therapy.
218985414|NCT03011619|BEHAVIORAL|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
218985415|NCT06462885|BEHAVIORAL|home support, hiving alone|Home support: living alone
218985416|NCT06462885|BEHAVIORAL|home support, living with others|Home support: living with others
218985417|NCT01131156|BEHAVIORAL|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
219658783|NCT06394557|PROCEDURE|In-office Dental Bleaching Conventional|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
219658784|NCT06394557|PROCEDURE|In-office Dental Bleaching Alternative|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
218968317|NCT02729675|BEHAVIORAL|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F\&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F\&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
218968318|NCT02729675|BEHAVIORAL|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
218968319|NCT05807633|DEVICE|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
218968320|NCT03819426|BEHAVIORAL|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
218968321|NCT03819426|BEHAVIORAL|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
218968322|NCT02330809|OTHER|Daily extra water intake|Amount of extra daily water intake to consume
218968323|NCT02330809|OTHER|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
218968324|NCT00316771|DRUG|P38 Inhibitor (4) 150mg|150mg po qd
218968325|NCT00316771|DRUG|P38 Inhibitor (4) 25mg|25mg po bid
218968326|NCT00316771|DRUG|P38 Inhibitor (4) 300mg|300mg po qd
219658785|NCT07008456|DRUG|APHD-012|12 g dextrose beads
219658786|NCT07008456|DRUG|APHD-002|2 g dextrose beads
218968327|NCT00316771|DRUG|P38 Inhibitor (4) 50mg|50mg po qd
218968328|NCT00316771|DRUG|P38 Inhibitor (4) 75mg|75mg po bid
218968329|NCT00316771|DRUG|Placebo|po bid
218968330|NCT02830061|OTHER|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
218968331|NCT03325699|DEVICE|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
218968332|NCT01356979|PROCEDURE|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
218968333|NCT01068652|DRUG|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
218968334|NCT01068652|DRUG|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
218968335|NCT01068652|DRUG|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
218968336|NCT01068652|DRUG|metformin|1000-2000 mg/day in combination with insulin treatment
219658787|NCT07008456|DRUG|APHP-012|12 g placebo beads
219658788|NCT07008456|DRUG|APHP-002|2 g placebo beads
219658789|NCT07005362|BEHAVIORAL|Fitbit and AI Chatbot|Participants will wear their Fitbit devices daily for 12-weeks and will receive personalized messages from the AI Chatbot every week with a new exercise recommendation based on their previous week's activity level. Additionally, they can engage with the AI Chatbot through text message for further support and education.
219658790|NCT07005362|OTHER|Routine Care|The control group will consist of patients with type 2 diabetes who meet the study's inclusion criteria but have not participated in the intervention.
219658791|NCT03964506|DRUG|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
219658792|NCT06624059|DRUG|Alectinib|"Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery."
219658793|NCT06624059|DRUG|Cisplatin|"Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery."
219658794|NCT06624059|DRUG|Carboplatin|"Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
219658795|NCT06624059|DRUG|Pemetrexed|"Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
219658796|NCT01018381|PROCEDURE|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
219658797|NCT01018381|PROCEDURE|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
219658798|NCT01018381|PROCEDURE|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
219658799|NCT01018381|PROCEDURE|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
219658800|NCT01018381|DIETARY_SUPPLEMENT|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
219658801|NCT01018381|DRUG|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
219658802|NCT07012291|DEVICE|Whole Blood Clotting Time|"Fresh whole blood samples from patients on rivaroxaban or apixaban taken at various times during the day to obtain samples from DOAC patients that represent the entire analytical range to the extent possible, as opposed to a strict trough/peak testing schedule."
219658803|NCT07012291|DEVICE|Whole Blood Clotting Time|Fresh whole blood samples, non-citrated, are drawn and loaded onto a cuvette free of any biological reagents, to obtain a whole blood clotting time value.
219658804|NCT07021248|DIETARY_SUPPLEMENT|Elan Believe|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Believe for SG addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
218968337|NCT06556758|OTHER|stripping massage + conventional therapy|Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks. Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks
219658805|NCT07021248|DIETARY_SUPPLEMENT|Elan Compass|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Compass for RYGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
218985418|NCT05024201|BEHAVIORAL|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
219658806|NCT07021248|DIETARY_SUPPLEMENT|Elan Supreme|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Supreme for OAGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
219658807|NCT05497960|BEHAVIORAL|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
219658808|NCT07021170|DIETARY_SUPPLEMENT|Elan Believe|Elan Believe is formulated specifically for patients undergoing SG and contains 18 mg of elemental zinc.
219658809|NCT07021170|DIETARY_SUPPLEMENT|Elan Compass|Elan Compass is tailored for RYGB and contains 24 mg of zinc.
219658810|NCT07021170|DIETARY_SUPPLEMENT|Elan Supreme|Designed for OAGB, provides 36 mg of zinc.
219658811|NCT07021170|DIETARY_SUPPLEMENT|Standard Multivitamins|Over-the-counter multivitamin containing 100% of the recommended daily allowance (RDA) for essential vitamins and minerals. Unlike the specialized formulations, the standard multivitamin is not designed to accommodate the altered gastrointestinal absorption characteristics of post-MBS patients.
219658812|NCT04148287|DRUG|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
219658813|NCT06596577|BEHAVIORAL|Palliative care needs information|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs
219658814|NCT06596577|BEHAVIORAL|Default consult order|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs + a choice to cancel the default palliative care consult order
219658815|NCT05410145|DRUG|D3S-001|Oral
219658816|NCT05410145|DRUG|Pembrolizumab|Intravenous
219658817|NCT05410145|DRUG|Cisplatin|Intravenous
219658818|NCT05410145|DRUG|Carboplatin|Intravenous
219658819|NCT05410145|DRUG|Pemetrexed|Intravenous
219658820|NCT05410145|DRUG|Cetuximab|Intravenous
219658821|NCT06253117|DRUG|Pirfenidone|"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"
219658822|NCT06253117|DRUG|Placebo|Placebo
219658823|NCT06694688|DIAGNOSTIC_TEST|the supine/standing postural change test|The prevalence of orthostatic hypotension will be characterized by the percentage of patients with a decrease of ≥ 20mmHg in systolic blood pressure or ≥ 10mmHg in diastolic blood pressure following the supine/standing postural change position.
219658824|NCT06631768|OTHER|Casual labor subsidy|Eligible participants will be offered a voucher that can be redeemed for a set number of days of agricultural labor from casual laborers hired by local One Acre Fund offices. Casual laborers receive standard training in line with the trainings currently offered by the organization to participating farmers.
219658825|NCT06685965|DRUG|RE03|Buccal Dexmedetomidine
219658826|NCT06685965|DRUG|Placebo|Matching Placebo
219658827|NCT06492486|RADIATION|Adaptive radiotherapy|Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
219658828|NCT03164265|BIOLOGICAL|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
219658829|NCT06874335|DRUG|BHV-1530|BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
219658830|NCT06702332|DRUG|MSD-001|MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications
219658831|NCT06702332|DRUG|Placebo Comparator|Matching Placebo
219658832|NCT06702592|BEHAVIORAL|Virtual support|Subjects will use a virtual support platform that was built for their needs.
219658833|NCT06702592|BEHAVIORAL|Patient educational material|Participants will have access to patient educational material.
219658834|NCT02144207|DEVICE|Glidescope|
219658835|NCT06704295|BEHAVIORAL|Control ad with dark gray product with tobacco flavor name|The e-cigarette ad with a dark gray product with a tobacco flavor name
219658836|NCT06704295|BEHAVIORAL|Dark gray product with strawberry flavor name|The e-cigarette ad with a dark gray product with a strawberry flavor name
219658837|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name|The e-cigarette ad with a colorful (strawberry color) product with strawberry flavor name
219658838|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name and image|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name and strawberry image
219658839|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features|The e-cigarette advertisement with colorful (strawberry color) product with strawberry flavor name, strawberry image, and strawberry flavor sensation descriptor
219658840|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features and choice claim|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name, strawberry image, strawberry flavor sensation descriptor, and flavor choice claim
219658841|NCT06709391|PROCEDURE|Fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to fusion (active treatment):~Pedicle screws are placed. Interbody cages may be used. Fluoroscopy or intraoperative computed tomography with or without intraoperative navigation is performed for correct implant positioning. Decortication is performed in the surgical area, and the cartilage in the facet joints is partially removed to allow fusion. Local bone graft is used and placed in the surgical area. Rods are placed in the screws and the fixation system is locked. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue, and skin is sutured."
219658842|NCT06709391|PROCEDURE|Non-fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to non-fusion surgery (control):~No implants are placed. No decortication is performed. The facet joints are left intact. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue and skin is sutured."
219658843|NCT07136272|DEVICE|SSAM|Embedded software featuring neural-network classifiers designed to detect and classify sleep stages (N1/N2, N3, REM, Wake), autonomic arousals, and an Arousal Index based on data (specifically instantaneous pulse rate and full-resolution flow waveforms) collected during PAP therapy.
219658844|NCT07136272|DIAGNOSTIC_TEST|Polysomnography|Polysomnography (PSG) is an overnight, in-laboratory diagnostic procedure that records multiple physiological parameters during sleep. It typically includes monitoring of brain activity (EEG), eye movements (EOG), muscle activity (EMG), heart rhythm (ECG), respiratory effort, airflow, oxygen saturation, and body position. PSG is used to evaluate sleep architecture, identify sleep stages, detect arousals, and diagnose sleep disorders such as sleep apnea. The collected data are analyzed manually by trained sleep technologists following standardized scoring criteria.
219658845|NCT07136272|DEVICE|EnsoSleep|EnsoSleep is software-only medical device intended for use by physicians to assess sleep quality and aid in the diagnosis of sleep disorders. The software analyzes physiological signals and automatically scores sleep study results, including respiratory, sleep staging, arousal and movement events. Automatically scored events and physiological signals are analyzed, displayed, and summarized for review by clinicians.
219658846|NCT06718803|BEHAVIORAL|Hypnosis|"The Evia program includes three mayor components, 1. A hypnotherapy program for the reduction of hot flashes, 2. Educational readings on hot flashes and menopausal-related topics, 3. Daily hot flash tracker.~The hypnotherapy is delivered in short, daily 10-20 minute audio recordings that involve numerous suggestions for coolness and relaxation (i.e., cool breeze, snowy mountain, deep lake) for a period of five weeks. The hypnotherapy program is based on previous randomized controlled trials for the reduction of hot flashes (Elkins et al., 2008; Elkins et al., 2013)."
218968338|NCT06556758|OTHER|Conventional therapy|conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
218985419|NCT03929510|DRUG|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
219658847|NCT06718803|OTHER|Structured Attention|Data collection of hot flash severity and frequency will mirror the hot flashes daily tracker offered by the intervention group (Evia app), and account for time and structured attention control while removing any potential therapeutic effects.
219658848|NCT06702436|OTHER|Observational Study|This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
219658849|NCT07031739|BEHAVIORAL|Resource information|Participants randomized to this arm will receive a tailored list of information about community resources.
219658850|NCT07031739|BEHAVIORAL|Community Health Worker (CHW) assistance|The CHW will meet with the participant at the baseline visit and will follow up with participants at least every other week. The CHW will also work directly with the patient's care team.
218985420|NCT03929510|DRUG|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
219208247|NCT06273579|BEHAVIORAL|AI-augmented personalized expert instruction|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the instructor will have the freedom to personalize and contextualize feedback without restriction to ICEMS wording.
218985421|NCT03929510|DRUG|PF-06651600|Oral solution 200mg
219208248|NCT03111537|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
219208249|NCT03111537|OTHER|E-Cigarette|Use of E-cigarette: multiple flavors offered.
219208250|NCT03111537|OTHER|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
218968339|NCT06007859|OTHER|section orientation|The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
218968340|NCT01997710|DEVICE|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
219658851|NCT07031739|BEHAVIORAL|Medically-tailored Meals (MTM)|MTM will consist of weekly home meal delivery. During the 3 months, participants will receive 10 medically tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly.
219658853|NCT05876767|DRUG|SAR444336|Single or repeated dose subcutaneous injection
219658854|NCT05876767|DRUG|Placebo|Single or repeated dose subcutaneous injection
219658855|NCT06729060|OTHER|Combination of Motor Imagery and Physical Performance|"For 15 minutes you will physically eliminate targets by clicking on them in the Aim Lab Trainer (Physical Performance Part).~Then, on a screen divided into 60 squares, the target will appear and disappear in a random square for 5 seconds. At the same time, the metronome will give a warning sound at each new target. The stimulus will come every five seconds and each time the stimulus comes, the target will imagine that it has disappeared. In the next 5 seconds, the stimulus will come again in a different place and he will imagine that he has destroyed it again. In the first two weeks, this will happen for 60 stimuli with 5 second intervals.~(60target\*5sec=300sec \*3=900sec/60 =15 min). In the next 2 weeks, the interval will be reduced by 1 second and in the last two weeks it will not be reduced. But the duration will always be 15 minutes (Motor Imagery Part)."
219658856|NCT06729060|OTHER|Physical Performance|For 30 minutes, they will eliminate the Aim Lab Trainer test by clicking quickly and accurately with their dominant hands. The physical performance practice to be applied both in this group and in the Motor Imagery and Physical Performance Combination Group is the same and will be applied in the same way for 8 weeks
219658857|NCT07049952|DEVICE|taVNS|Active or inactive non-invasive vagus nerve stimulation of the auricular branch of the vagus nerve paired with 2 oral feedings/day for 14d
219658858|NCT07049952|COMBINATION_PRODUCT|NAC and taVNS|NAC 100 mg/kg diluted 1:3 with sterile water (or equal volume sterile water), q6h NG 1h before a feed for 4d prior to delivering active or sham taVNS paired with 2 feeds/day for 14d with NAC (or sterile water).
219658859|NCT07049952|DEVICE|inactive taVNS|inactive transcutaneous auricular vagus nerve stimulation with 2 feeds/day x 14 days
219658860|NCT07049952|COMBINATION_PRODUCT|sterile water and inactive taVNS|Sterile water per NG tube every 6h for 4 days, then continuing with 14days of inactive taVNS paired with oral feeding
219658861|NCT06633861|DEVICE|spot-check measurement|Spot-check measurement: different Philips SpO2 sensors and Philips FAST pulse oximeter system, capnography
219658862|NCT06745804|DRUG|68Ga-R10602 injection|68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer
219658863|NCT06740071|BEHAVIORAL|somatosensory interactive pelvic floor muscle training|synchronized PFMT guidance through a combination of audio and video
219658864|NCT06740071|PROCEDURE|pelvic floor magnetic stimulation therapy|stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions
219658865|NCT06740071|BEHAVIORAL|standard pelvic floor muscle training|"traditional verbal instructions and paper-based educational materials of PFMT are given to participants.~All patients would receive PFMT under the guidance of digital rectal examination by nurses, and their pelvic floor muscle function was graded according to the Oxford Grading System (grades 0-5), ensuring the correctness of subsequent PFMT."
218968341|NCT01997710|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
219208251|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
219208252|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
219208253|NCT06647277|COMBINATION_PRODUCT|Fecal Microbiota Transplant|Fecal Microbiota Transplant
218985422|NCT00753766|OTHER|Multifactorial Intervention|
218968342|NCT04158791|PROCEDURE|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
219658866|NCT06894394|BEHAVIORAL|UP-A|The UP-A (Ehrenreich-May et al., 2018, 2020, 2022) is a transdiagnostic intervention with eight modules targeting neuroticism. It improves emotion regulation and reduces avoidance, with summaries after each module and a Parent Module (P). The intervention is a group adaptation of the Spanish version of UP-A that consists of 16 weekly sessions, each lasting 60 to 90 minutes, held in person at a Day Hospital within the Spanish public healthcare system. Due to the complexity of the setting, parent sessions are not viable. However, parents receive summaries of the modules covered with the adolescents, as well as the Parent Module (Parenting the Emotional Adolescent), to support their understanding of the treatment content.
219658867|NCT06738641|BEHAVIORAL|Pro2col Health|The Pro2col Health application is a smartphone application that provides users with health behavior guidance, personalized feedback, and assessments designed to estimate their current healthspan and biological age.
218968343|NCT03771053|DRUG|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
218968344|NCT03771053|DRUG|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
218968345|NCT06515522|OTHER|differential diagnosis|this is a retrospective observational study. no intervention has been or will be performed
218968346|NCT01880047|DRUG|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
218968347|NCT01880047|DRUG|Placebo|
218968348|NCT03210987|PROCEDURE|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
218968349|NCT03210987|PROCEDURE|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
218968350|NCT01270854|OTHER|Plasmalyte A|Intravenous fluid
218968351|NCT01270854|OTHER|Normal Saline|Intravenous fluid
219658868|NCT06738641|BEHAVIORAL|Control|The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
219658869|NCT07054489|OTHER|Beta blocker|Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.
219658870|NCT06497582|OTHER|zhan-zhuang|zhan-zhuang as a fundamental type of qigong
219658871|NCT06497582|OTHER|self-acupressure|Self-acupressure as a common type of traditional Chinese medicine therapies
219658872|NCT06482437|DRUG|NMD670|Tablets taken twice daily for 21 days
219658873|NCT06482437|DRUG|Placebo|Tablets taken twice daily for 21 days
219658874|NCT07059234|BEHAVIORAL|Non-exercise activity|The 5-week intervention to assess the effects of non-exercise activity on the activity-subjective energy association incorporates two high-intensity Ambulatory Assessment (AA) weeks at the beginning and end, with a tapered 3-week Ecological Momentary Intervention (EMI) phase in between. Momentary targeted micro interventions (JITAIs) with a Within-Person-Encouragement Design (WPED) are used to tailor the activity to the individual situation and phenotype of each participant.
218968352|NCT03343067|DRUG|elagolix|Tablets
218968353|NCT03343067|DRUG|estradiol/norethindrone acetate (E2/NETA)|Capsules
218968354|NCT02824965|DRUG|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
218968355|NCT02824965|BIOLOGICAL|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
218968356|NCT03282851|DRUG|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
218968357|NCT03282851|DRUG|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
218968358|NCT03282851|DRUG|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
218968359|NCT03704987|DIAGNOSTIC_TEST|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
218968360|NCT04489732|BIOLOGICAL|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland"
218968361|NCT04226534|OTHER|Maximal effort test|Performing a maximal effort test on the treadmill
218968362|NCT02193451|PROCEDURE|Urodynamics|Diagnostic test for urinary storage and voiding function
218968363|NCT02193451|PROCEDURE|Usual care|
218968364|NCT01243671|BIOLOGICAL|Adalimumab|
219658875|NCT07054190|DRUG|Inavolisib|Inavolisib will be administered as per the schedule specified in the arms
219658876|NCT07054190|DRUG|Ribociclib|Ribociclib will be administered as per the schedule specified in the arms
219658877|NCT07054190|DRUG|Letrozole|Letrozole will be administered as per the schedule specified in the arms
219658878|NCT06752850|DRUG|Efanesoctocog alfa|50 IU/kg once weekly, Intravenous injection
219658879|NCT03449381|DRUG|BI 907828|Film-coated tablet
218968365|NCT06145906|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
219208254|NCT06651554|BEHAVIORAL|Digital Platform Intervention|Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
219658880|NCT07058909|DEVICE|ELISIO™-HX Dialyzer|Following consent, participants will undergo a baseline hemodialysis treatment with their currently used dialyzer, the ELISIO-H™, and following the baseline visit will receive hemodialysis with the investigational device, ELISIO™-HX, three times a week for 12 weeks.
218968366|NCT06145906|PROCEDURE|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
218968367|NCT03470948|OTHER|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
218968368|NCT02175784|DRUG|ipragliflozin|oral
218968369|NCT02175784|DRUG|placebo|oral
218968370|NCT05059795|DRUG|Albumin + electrolyte solution|Type of resuscitation fluid, dose and use of inotrope
218968371|NCT05059795|DIAGNOSTIC_TEST|POCUS guided fluid resuscitation|Conventional goal directed therapy
219208255|NCT06469190|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
219208256|NCT02752685|DRUG|Pembrolizumab|
219208257|NCT02752685|DRUG|Nab-Paclitaxel|
219658881|NCT00139100|DRUG|antimicrobial agent in soap|
219658882|NCT06897839|OTHER|Air-sham|Room air for intratracheal administration
219658883|NCT06897839|DRUG|Zelpultide alfa|Reconstituted Zelpultide alfa for intratracheal administration
218968372|NCT02602392|BEHAVIORAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
218968373|NCT02602392|BEHAVIORAL|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
218968374|NCT05790174|BEHAVIORAL|"ROS chubby and healthy - a multidisciplinary family-based weight-loss treatment program"|"The weight-loss treatment program ROS is family-based and delivered by a multidisciplinary team of physicians, nurses, dieticians, and psychologists. The treatment is based on an individualized tailored plan made together with the family. The plan consists of dietary changes, more physical activity, regular weight checks, and motivational conversations. The program includes options of cooking classes, group session with a psychologist and participation in structured physical activity called ROS sports twice a week. Follow up visits are scheduled every 2-3 months at the different health care professionals."
218968375|NCT05790174|BEHAVIORAL|Overweight Clinic for Children and Adolescents|The 'Overweight Clinic for Children and Adolescents' program at the municipal Health Center is based on the family-centered, multidisciplinary protocol developed by the Children's Obesity Clinic (TCOCT) at Holbæk Hospital. The intervention is individualized, informed by medical history and a structured questionnaire-based interview to identify behavioral and lifestyle changes needed to reduce the child's degree of overweight or obesity. The program consists of individual consultations every 6-8 weeks over approximately 12-18 months, with additional follow-up appointments as needed.
218968376|NCT05790174|BEHAVIORAL|Family Nutrition Guidance|"This treatment program is based on the Danish Health Authority's recommendations for lifestyle interventions. It follows a family-centered approach tailored to the family's everyday life and habits, focusing on sustainable changes in diet and physical activity. The program provides guidance on healthy eating, physical activity, and strategies for integrating these behaviors into daily routines.~The program included the entire family and began with school-based consultations delivered by health nurses during the first three months, followed by additional sessions at the municipal Health Center when needed. Families were offered 4-6 consultations within the first six months and follow-up sessions twice a year."
219658884|NCT06795581|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
219658885|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
219658886|NCT03912428|DRUG|11C-MC1|PET radioligand for Cyclooxygenase-2 (COX-2)
219658887|NCT03912428|DRUG|Celecoxib|Cyclooxygenase-2 (COX-2) inhibitor
219658888|NCT03912428|DRUG|[11C]ER176|Radioligand for 18-kDa Translocator Protein
219658889|NCT03912428|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)/computed tomography (CT) Scan|Whole body or brain PET/CT scans
219658890|NCT06427798|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.
219658891|NCT06427798|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
219658892|NCT06427798|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
218968377|NCT05619523|BEHAVIORAL|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
218968378|NCT04965493|DRUG|Pirtobrutinib|Oral
218968379|NCT04965493|DRUG|Venetoclax|Oral
218968380|NCT04965493|DRUG|Rituximab|Intravenous (IV)
218968381|NCT04505540|OTHER|Bridge Clinic|Specialized addiction bridge clinic
218968382|NCT06399198|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
218968383|NCT04941781|DRUG|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
218968384|NCT05082532|OTHER|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
218968385|NCT05342532|DRUG|Amoxicillin|1 g
218968386|NCT05342532|DRUG|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
218968387|NCT05342532|DRUG|Clarithromycin|500 mg twice daily
218968388|NCT00330798|DRUG|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
219658893|NCT06192758|DEVICE|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
219658894|NCT06844669|DRUG|Carvedilol|6.25 mg with food
218968389|NCT00330798|OTHER|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
218968390|NCT02808871|DRUG|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
218968391|NCT02808871|DRUG|Placebo|Placebo three times daily for 52 weeks
218968392|NCT06340854|DRUG|Insulin icodec|Insulin Icodec will be administered subcutaneously.
218968393|NCT06340854|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
218968394|NCT02057393|DRUG|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
219658895|NCT06844669|DRUG|Empagliflozin|10 mg in the morning with or without food
218968395|NCT02057393|DRUG|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
219658896|NCT06439576|DRUG|Faricimab|The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
219658897|NCT06778876|OTHER|lavender sachet group|The normal procedure applied in the sleep clinic (keeping a sleep diary, sleep hygiene education) will be followed and participants will be asked to sleep with lavender sachets inside their pillows for two weeks.
219658898|NCT06778876|OTHER|control group|Participants will follow the normal procedure applied (keeping a sleep diary, sleep hygiene training) in the sleep clinic and no additional intervention will be performed.
219658899|NCT06891911|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 4-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size."
219658900|NCT06891911|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a stipend during the 4-week intervention period. They are permitted to use the stipend however they choose and will not be asked about how they spent these funds."
219658901|NCT06842173|BIOLOGICAL|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg + IB160 adjuvant (0.5mL total)
219658902|NCT06842173|BIOLOGICAL|Monovalent influenza vaccine type A (H5N8) 15 mcg|Monovalent influenza vaccine type A (H5N8) 15 mcg + IB160 adjuvant (0.5mL total)
219658903|NCT06842173|OTHER|Placebo|Phosphate buffered saline (PBS) (0.5 mL/dose).
219658904|NCT04961398|DEVICE|OCT imaging|OCT imaging on Normal Eyes without any filter and with various ND filters as per protocol
219658905|NCT07081178|DRUG|Semaglutide|Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.
219658906|NCT07083765|DRUG|Dehydrated Alcohol Injection, USP|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
219658907|NCT07083765|PROCEDURE|Sham procedure|Endovascular, renal angiography
218968396|NCT02057393|DRUG|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
218968397|NCT05164718|BEHAVIORAL|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
219064113|NCT04525391|DRUG|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
219208258|NCT06662357|BEHAVIORAL|Behavioral Treatment|"Family Connections Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
219208259|NCT04265872|DRUG|Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis|injection into a vein
219658908|NCT06929338|DIAGNOSTIC_TEST|Functional precision medicine|The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices. Treatment will not be given as part of the study.
219658909|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
219658910|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
219658911|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
219658912|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
219658913|NCT00545389|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
219658914|NCT06243783|BEHAVIORAL|Montreal Imaging Stress Test|In the Montreal Imaging Stress Test, participants are required to solve basic mathematical tasks, but the allowed reaction time is set lower than their average.
219658915|NCT06881277|BEHAVIORAL|Mobile phone based intervention|The PRIMI intervention is a 6-month smartphone-based digital health program designed to promote a healthy diet and physical activity among migrant women after pregnancy.
219658916|NCT06620965|PROCEDURE|Mulligan Mobilization Technique|NAGs (Natural Apophyseal Glides) involve passive oscillatory movements of a spinal facet joint in an anterocranial direction, performed with the patient seated. SNAGs (Sustained Natural Apophyseal Glides) maintain facet glides during active movements, aiming to reach the joint\&#39;s end range. In SNAGs, the patient actively participates, and overpressure is applied at the end of movements to enhance the range of motion. Techniques include increasing rotation, lateral flexion, flexion, and extension. These were applied by a certified physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain.
219064114|NCT02733900|PROCEDURE|femoral head removal|
219064115|NCT04058769|DEVICE|Premedication Guide|Software with guidelines recommendations for preoperative assessment
219064116|NCT05500469|DEVICE|Paul glaucoma drainage device (GDD)|Implantation of the GDD
219658917|NCT06620965|PROCEDURE|Proprioceptive Neuromuscular Facilitation (PNF) Technique|"Proprioceptive Neuromuscular Facilitation (PNF) Technique: PNF consists of four movement patterns in two diagonals:~Flexion-left rotation and extension-right rotation Flexion-right rotation and extension-left rotation 3 PNF techniques were applied.~Combined Isotonic Contractions: This technique involves concentric, eccentric, and stabilizing contractions of a muscle group (agonist). The goal is to increase active range of motion (ROM), strength, and improve control and coordination.~Dynamic Stabilization (Stabilizing Reversal): This involves applying resistance in various directions to prevent movement, aiming to enhance dynamic stability, strength, and agonist-antagonist coordination.~Hold-Relax Technique: This relaxation method involves isometric contractions against maximum resistance without movement to increase passive ROM and reduce pain. These were applied by physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain."
219658918|NCT01639547|DRUG|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
219658919|NCT03885180|DRUG|Warfarin Sodium|Extending warfarin anticoagulation
219658920|NCT02888392|OTHER|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
219658921|NCT02888392|DIETARY_SUPPLEMENT|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
219658922|NCT05210114|DEVICE|Skin Hydration Sensor|The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
219658923|NCT04056273|OTHER|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
219658924|NCT04056273|OTHER|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
219658925|NCT02180802|BEHAVIORAL|motivational interviewing|
219658926|NCT02180802|BEHAVIORAL|motivational interviewing with parental involvement|
219208260|NCT06771791|OTHER|oral provocation test|Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
219208261|NCT06772662|PROCEDURE|Tubing Direction|We are studying the procedure of placing the Cryotherapy Tubing in two different directions: up vs down
219208262|NCT06996691|PROCEDURE|Erector Spinae Plane Block (ESPB) group|30ml of 0.25% levobupivacaine for erector spinae block at level of T5
219658927|NCT02180802|BEHAVIORAL|Control group|
219658928|NCT03647774|DRUG|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
219658929|NCT02889835|DEVICE|Supreme Universal Restorative|
219658930|NCT02889835|DEVICE|Supreme Flowable Restorative|
219658931|NCT02889835|DEVICE|Bulk Fill Flowable Restorative|
219658932|NCT06912451|DEVICE|Sport custom mouthguard|This mouthguard will be made using two 3mm vinyl acetate ethylene sheets in a vacuum machine, following the recommendations for an appropriate mouthguard regarding trauma prevention and patient comfort. The patients will be monitored after 1, 3, and 6 months of using the mouthguard.
219658933|NCT06403046|DRUG|intraarticular injection|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
219658934|NCT07109739|DEVICE|POWERbreathe K5|The POWERbreathe K5 is portable, battery-powered, and commercially available. No modifications to the FDA-approved design are being made. Its use in this study is consistent with prior published human research and does not constitute a significant deviation from labeled use in terms of safety or function.
219658935|NCT07110441|DRUG|Single Dose G1090N|Subjects will receive single ascending doses of G1090N up to 1200mg.
219658936|NCT07110441|DRUG|Multiple dosing of G1090N|Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.
219208263|NCT06996691|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|30 mL of 0.25% levobupivacaine injected anteriorly to the rib and deep to the serratus anterior at level of 5 th rib
219658937|NCT07110597|OTHER|Statement communicating 1 source of uncertainty|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
219658938|NCT07110597|OTHER|Statements communicating 2 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her."
219658939|NCT07110597|OTHER|Statements communicating 3 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live."
218968398|NCT05164718|OTHER|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
219658940|NCT07110597|OTHER|Statements communicating 4 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.~Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown."
219658941|NCT07110597|OTHER|Control group|No information about uncertainty
219658942|NCT06911437|OTHER|treatment group|"Xiaoyu Zhitong Formula: 10g of long pepper, 10g of cloves, 10g of borneol, 10g of papaya, 10g of white peony, 10g of licorice, 15g of chicken blood vine, 10g psoralen, 10g of cistanche, powdered petroleum jelly, wrapped in gauze and heated and applied to the affected area.~Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks."
219658943|NCT06911437|OTHER|control group|External application of Diclofenac Diethylamine Emulgel（Manufacturer: Switzerland,Haleon CH SARL） combined with lymphatic drainage technique for treatment，Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks.
219658944|NCT07111182|DEVICE|HIVEN Medical Device|A medical device (HIVEN®) detects 5-ALA-induced fluorescence from the surgical suction and gives sound feedback to the operating surgeon indicating tumor tissue and overcoming the challenges is the contemporary FGS methods. The device is used for detecting fluorescence of flowing tissues within a transparent tube and providing auditory feedback of tissue fluorescence for neurosurgeons. There is no patient contact intended with this device.
219658948|NCT04440891|DEVICE|TMS stimulation with X-Torp task|TMS-Stimulation with X-Torp task
219658949|NCT04440891|DEVICE|TMS-Stimulation with MindMotion Go|TMS-Stimulation with MindMotion Go
219658950|NCT04440891|DEVICE|TMS-Sham with X-Torp task|TMS-Sham with X-Torp task
219658951|NCT04440891|DEVICE|TMS-Sham with MindMotion Go|TMS-Sham with MindMotion Go
219658952|NCT06910371|BEHAVIORAL|smartphone screen time reduction|Smartphone screen time has to be reduced to less-equal 2 hours per day for 3 consecutive weeks.
219658953|NCT02826668|OTHER|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
219658954|NCT07113054|DRUG|Edoxaban 60 MG [Lixiana]|Single administration of edoxaban
219658955|NCT07113054|OTHER|Edoxaban 60 MG [Lixiana] + Grapefruit Juice|Coadministration of edoxaban and grapefruit juice
218968399|NCT05748470|OTHER|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
218968400|NCT05748470|OTHER|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
218968401|NCT04337450|DRUG|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
218968402|NCT04337450|DRUG|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
218968403|NCT05826782|BIOLOGICAL|Proxeed Plus 2*1 A arm|Proxeed plus 2 x daily sachets (2\*1) three mounths
218968404|NCT05826782|BIOLOGICAL|Placebo|Placebo 2 x daily sachets (2\*1) three mounths
218968405|NCT03978481|COMBINATION_PRODUCT|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
219208264|NCT06995755|BEHAVIORAL|atlas|A theoretically-grounded, highly individualized text messaging intervention that 1) provided information on current climate-related and environmental risks (e.g., high temperatures, air quality alerts, asthma triggers etc.) that might adversely affect a user's current health conditions; 2) linked users to local zip-code matched resources to mitigate their specific risk (e.g., cooling centers, hurricane shelters); 3) implemented a full range of best practices in tailored health behavior change communications to personalize ongoing communications regarding the link between human actions and extreme weather based on the user's level of concern about and belief in climate change; and 4) provided customized actionable tips for addressing climate change to promote climate efficacy at the individual, community, and policy/advocacy level based on the user's level of motivation.
219208265|NCT01459107|PROCEDURE|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
218968412|NCT02284711|DEVICE|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
218968413|NCT02284711|DEVICE|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
219658956|NCT07116200|OTHER|Early Literacy Intervention in Kindergarten|In the kindergarten intervention, children will receive early literacy instruction through the Early Literacy Program, adapted for those using augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program enables nonverbal responses such as signs, symbol pointing, or eye-gaze, removing the need for speech. Instruction follows evidence-based practices including direct and explicit teaching, scaffolding, immediate feedback, cumulative review, practice, and subvocal rehearsal. The program targets five foundational literacy skills: phonological awareness, letter-sound correspondence, sound blending, shared reading, and understanding concepts about print. Supplementary materials such as flashcards and lotto games will also be used to reinforce learning.
219658957|NCT07116200|OTHER|Literacy Intervention in First Grade|In the first-grade intervention, students will receive literacy instruction using the Reading for All program, which is adapted for children who use augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program allows responses through nonverbal methods like signs, symbol pointing, or eye-gaze, eliminating the need for oral replies. Instruction is grounded in evidence-based practices such as direct and explicit instruction, scaffolding, immediate corrective feedback, cumulative review, practice, and subvocal rehearsal. Reading for All addresses six key literacy skills: sound blending, letter-sound correspondence, phoneme segmentation, sight word recognition, shared reading, and decoding. Additional activities (flashcards and lotto games) will be a supplement to the material.
219658958|NCT06917872|DRUG|BI 1291583|BI 1291583
219658959|NCT06917872|DRUG|erythromycin|erythromycin
219658960|NCT00602290|DRUG|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.
219658961|NCT00602290|DRUG|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
219064117|NCT03330379|DEVICE|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
218968414|NCT04685226|DRUG|ICP-723|ICP-723 is a white, round, uncoated table
218968415|NCT06513312|DRUG|Lenacapavir Injection|Administered subcutaneously
218968416|NCT06513312|DRUG|Lenacapavir Tablet|Administered orally
218968417|NCT06513312|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
218968418|NCT05323656|DRUG|Setanaxib|Oral tablets, 400 mg per tablet
218968419|NCT05323656|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
218968420|NCT05323656|DRUG|Placebo|Oral tablets
218968421|NCT05942469|BEHAVIORAL|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
218968422|NCT05323006|OTHER|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
218968423|NCT05304832|OTHER|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
219064118|NCT06462326|DRUG|Moxifloxacin Oral Tablet|400mg per tablet
219064119|NCT06462326|DRUG|Omadacycline Oral Tablet|150 mg per tablet
219064120|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
219064121|NCT02290665|OTHER|Saline enema|
219658962|NCT00602290|DRUG|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
219658963|NCT07095894|DRUG|Atropine|Daily 0.05% atropine eyedrops
219658964|NCT07095894|DEVICE|Spectacles with HAL|Spectacle lenses with highly aspherical lenslets (HAL)
219658965|NCT07095894|DRUG|Placebo Eyedrops|Daily placebo eyedrops
219658966|NCT06933329|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
219658967|NCT03175692|DIAGNOSTIC_TEST|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
219658968|NCT04824794|BIOLOGICAL|GEN3014|GEN3014 is administered by IV infusion.
219658969|NCT04824794|DRUG|Daratumumab|Daratumumab is administered by SC injections.
219658970|NCT07145918|DRUG|Emraclidine|Oral Tablets
219658971|NCT07145918|DRUG|Placebo|Oral Tablets
219658972|NCT06945952|DEVICE|diaphragmatic ultrasonography|using diaphragmatic ultrasonography to measure diaphragmatic thickening fraction and then calculate the ratio RR/DTF
219658973|NCT05194072|DRUG|Felmetatug Vedotin|Given into the vein (IV; intravenously)
219658974|NCT05194072|DRUG|Pembrolizumab|400 mg every 6 weeks, given by IV
219658975|NCT06948656|OTHER|fitting a blood glucose sensor|automatic, continuous collection by the blood glucose sensor for 14 days
219658976|NCT06948656|OTHER|food collection|14-day dietary record in a notebook for the patient
219658977|NCT06948656|OTHER|tests and questionnaires|measurement of muscle strength using a hand-held dynamometer, animal enumeration test, self-questionnaire on the frequency of consumption of the main food groups
219658978|NCT07144527|DIETARY_SUPPLEMENT|NMN, betaine, low-dose hydrogen peroxide (EGA)|Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
219658979|NCT07144527|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide (NMN)|Conventional NMN supplement.
219658980|NCT07144527|DIETARY_SUPPLEMENT|Placebo|Organoleptically matched inert control.
219658981|NCT07152548|OTHER|Task-oriented exercises and mirror therapy|Patients in this group will receive task-oriented exercises 3 sessions per week for 6 weeks.Therapy will include the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.Mirror therapy group: 3 sessions per week for 6 weeks.A mirror will be placed on the learning table, and exercises will be carried out by the patient looking into the mirror, where an unaffected limb would be placed in front of the mirror. Through looking into the mirror, the patient will assume the reflection of the unaffected limb is the affected limb. Exercises will be performed by hand opening and closing, wrist extension and flexion, squeezing, opposition, calculation, and finger flexion and extension.
219658982|NCT07152548|OTHER|Task-oriented exercises|Patients in this group received task-oriented exercises 3 sessions per week for 6 weeks.Therapy included the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.
219658983|NCT07152548|OTHER|Mirror Therapy|Mirror therapy group 3sessions per week for 6 weeks. Mirror will be placed on the learning table and exercises will be carried out by the patient looking into the mirror where an unaffected limb would be placed in front of the mirror, through looking into the mirror patient will assume the reflection of the unaffected limb as the affected limb. Exercises will be performed hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation, finger flexion and extension.
219658984|NCT07153263|PROCEDURE|Ultrasound-guided retro-SCTLB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the retro-SCTLB was performed under ultrasound guidance.
219658985|NCT07153263|PROCEDURE|Ultrasound-guided TPVB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the TPVB was performed under ultrasound guidance.
219658986|NCT07153497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219658987|NCT07153497|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219658988|NCT07153497|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219658989|NCT07153497|DRUG|Decitabine and Cedazuridine|Given PO
219658990|NCT07153497|DRUG|Olutasidenib|Given PO
219658991|NCT07153497|DRUG|Venetoclax|Given PO
219658992|NCT05652205|DRUG|Linaclotide|Capsule; oral
219658993|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
219658994|NCT07157540|BEHAVIORAL|Personalized Feedback on Cannabis Protective Behavioral Strategies, Cannabis Use, Cannabis Expenditures, and Cannabis-Related Consequences (PF)|"PF comprises the following content:~* Self-reported PBS questionnaire, personalized feedback on PBS, possibility to select strategies to start using or use more often, possibility to set a reminder to use PBS strategies.~* Short questionnaire on cannabis use (frequency/number of hours under the influence) and normative feedback on participant's cannabis use as compared to people of same age and gender in the general population and among Cann-L participants.~* Question on money spent for cannabis purchase, personalized feedback (total amount spent and corresponding number of grams of cannabis over one year), gamified gauge to picture potential yearly savings, reflection on how to use the saved money, and possibility to set a reminder for money saving objectives.~* Questionnaire on cannabis-related consequences, feedback on the level of consequences met, question about which consequence(s) participant might want to think about, and possibility to set a reminder to think about consequences."
218968424|NCT05304832|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
219658995|NCT07157540|BEHAVIORAL|Imagining the Future Using Counterfactual Thinking and Episodic Future Thinking (IMAGIN)|"Two-task intervention including:~1. Counterfactual thinking:~   * Description of a recent negative situation related to cannabis use encountered by the participant~  * Identification of a preventive strategy that would have addressed this situation~  * Writing a sentence formatted as If only +preventive strategy, then + description on how the specific past problem would have improved~  * Assessment of participant's intention and confidence in using the preventive strategy~  * Imagining a future situation using this preventive strategy~  * Possibility to set a reminder of the preventive strategy.~2. Episodic future thinking:~   * Description of a significant positive event that might occur in the short-term (3 months) and that does not involve cannabis use~  * Assessment of the importance and enjoyment of this positive event~  * Encouragement to imagine it as vividly as possible~  * Suggestion to describe the positive event in detail and to write it down~  * Possibility to set a reminder of the positive event."
219658996|NCT07157540|BEHAVIORAL|Behavioral Economics-Informed Exercises to Increase Motivation to Engage in Substance-Free Activities (SFAS)|"SFAS includes:~* A questionnaire on how participant value different aspects of their life, and feedback on valued domains.~* Two open-ended questions on short- and long-term life goals.~* A questionnaire assessing time allocation (hours per week allocated to different activities, e.g. socializing, working, etc.), and personalized feedback including the time spent using substances and recovering from their effects.~* Gamified exercise to imagine allocating time in a different way.~* List of substance-free recreational activities in the region of Lausanne, with possibility to select activities on a wish-list including internet hyperlinks.~* Possibility to set a reminder of the selected activities.~* Single-item questionnaire on stress and mood, and feedback on stress and mood level.~* Open-ended question on coping strategies currently used for stress and mood.~* List of coping strategies that can be selected.~* Possibility to set a reminder of stress/mood coping strategies."
219658997|NCT07157540|BEHAVIORAL|Information|Minimal intervention (Control Intervention), consisting of simple, text-only web pages containing information on cannabis effects and health-related risks, cannabis consumption modes, cannabis harm reduction and protective behavioral strategies, as well as hyperlinks to additional resources and online help.
218968425|NCT05366205|DIETARY_SUPPLEMENT|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
218968426|NCT05366205|BEHAVIORAL|Nutrition consultation|Nutritional treatment advice will be given
218968427|NCT05893797|DRUG|Insulin Lispro|As prescribed.
219658998|NCT07161141|DEVICE|Immersive Virtual Reality Platform to Support Birth Preparedness and Mental Wellbeing|"The VR-based intervention will be grounded in a childbirth education framework designed to enhance women's awareness of their attitudes toward childbirth, their readiness for the birthing process, and their expectations related to labor, delivery, and the postpartum period. The program aims to strengthen emotional insight and coping capacities by guiding participants to reflect on their feelings and thoughts throughout the childbirth journey. The intervention will integrate key components such as breath awareness exercises, coping techniques, and motivational messages. While participants receive structured childbirth education, they will simultaneously be supported in developing psychological preparedness through immersive and reflective experiences tailored to foster emotional resilience and self-efficacy.~The digital labyrinth will be designed both visually and functionally to facilitate immersive navigation. It will be set in an expansive virtual landscape enriched with natural elem"
219658999|NCT07164664|PROCEDURE|External Oblique Intercostal Block|Bilateral ultrasound-guided External Oblique Intercostal Block (30 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
219659000|NCT07164664|PROCEDURE|Port-Site Infiltration|Before port placement, 0.25% bupivacaine solution will be injected into the laparoscopic port insertion sites (5 mL at each port site).
219659001|NCT07164664|DRUG|ıv morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/ kg (IBW). No basal infusion will be used.
218968428|NCT05893797|DEVICE|Tempo Smart Button|Attached to the Tempo Pen
218968429|NCT05893797|DEVICE|Dexcom G6 CGM|Continuous glucose monitor
218968430|NCT05893797|DEVICE|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
218968431|NCT05942105|PROCEDURE|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
218968432|NCT02524210|DRUG|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
218968433|NCT02524210|DRUG|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
218968434|NCT02524210|DRUG|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
218968435|NCT01291433|DRUG|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
218968436|NCT01291433|DRUG|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
218968437|NCT01291433|DRUG|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
218968438|NCT01291433|DRUG|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
219659002|NCT07169214|DRUG|BT-114143 Injection at low dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at low dose. BT-114143 will be administered twice daily for three consecutive days.
219659003|NCT07169214|DRUG|BT-114143 Injection at Medium-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at Medium-dose. BT-114143 will be administered twice daily for three consecutive days.
219659004|NCT07169214|DRUG|BT-114143 Injection at High-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at High-dose. BT-114143 will be administered twice daily for three consecutive days.
219659005|NCT07169214|DRUG|control group|The ratio of subjects in the experimental group to those in the control group is 10:3, with 3 placebo - treated control subjects corresponding to each dose group. The subjects will receive placebo treatment twice a day for 3 consecutive days.
219659006|NCT07169890|OTHER|Dextrose Phonophoresis|To apply Dextrose Phonophoresis on a patient with acne vulgaris, begin by cleansing the affected skin area thoroughly with a gentle, non-comedogenic cleanser to remove any dirt or oils. Pat the skin dry with a clean towel. Prepare a dextrose gel, a 10% dextrose gel, which is then coupled with low-frequency ultrasound to facilitate deeper penetration of the dextrose
219659007|NCT07169890|OTHER|Ultrasound|the ultrasound probe is moved in a circular motion over the skin for a duration of 5 to 10 minutes per session
219659008|NCT07169890|OTHER|Dextrose Topical application|Apply a thin layer of the dextrose gel evenly across the acne-affected areas using a sterile applicator or cotton pad
219659009|NCT05934903|DEVICE|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
219659010|NCT07170267|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
219659011|NCT07170267|DRUG|Intrathecal dexmedetomidine|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.
219659012|NCT07177196|DRUG|nL-PRPH2-001|Personalized antisense oligonucleotide
219659013|NCT07174596|DEVICE|B+L Infuse spherical soft contact lenses|Test lens
219659014|NCT07174596|DEVICE|J&J ACUVUE OASYS 1-Day spherical soft contact lenses|Control lens
219659015|NCT07176637|BEHAVIORAL|A-B-C Program|"The purpose of this study is to assess the effectiveness of the 4-week A-B-C program in implementing and maintaining daily PA. We will explore outcomes for the effectiveness of the program, on (1) increasing the weekly duration of PA, and (2) reducing baseline depressive symptoms and other mental health outcomes among sedentary older adults with depressive symptoms at baseline. Specifically, we will evaluate the change in depressive symptoms, stress, and self-esteem from baseline, at the end of the 4-week intervention, and after additional 4 weeks from the end of the intervention (at follow-up). The intervention will be 4 weeks overall, with total of 8 sessions: the duration of each session will be 60 minutes each, and the frequency will be twice weekly for 4 weeks."
218968439|NCT01291433|DRUG|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
218968440|NCT01291433|DRUG|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
218968441|NCT04737057|PROCEDURE|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
218968442|NCT04737057|PROCEDURE|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
218968443|NCT01155505|DRUG|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
218968444|NCT02533791|BIOLOGICAL|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10\^10vp/1ml per dose
218968445|NCT02533791|BIOLOGICAL|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
218968446|NCT02533791|BIOLOGICAL|placebo|
218968447|NCT05208307|BIOLOGICAL|Belantamab Mafodotin|Given IV
218968448|NCT05208307|DRUG|Dexamethasone|Given PO
218968449|NCT05208307|DRUG|Pomalidomide|Given PO
218968450|NCT06260761|PROCEDURE|MIPO|minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
218968451|NCT06260761|PROCEDURE|Conventional|standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
218968452|NCT04450459|DIAGNOSTIC_TEST|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
218968453|NCT02721979|DRUG|Apalutamide|Given PO
218968454|NCT02721979|OTHER|Laboratory Biomarker Analysis|Correlative studies
218968455|NCT02721979|OTHER|Quality-of-Life Assessment|Ancillary studies
218968456|NCT02721979|OTHER|Questionnaire Administration|Ancillary studies
218968457|NCT00622076|PROCEDURE|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
218968458|NCT02347696|BEHAVIORAL|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
219659016|NCT07176637|OTHER|Physical Activity Educational Program|"The control group will serve as an sham active comparator, designed to control for group format, scheduled sessions, and social interaction. The agenda for the control group was designed to specifically function as a control to compare the A-B-C program. These participants will also attend twice-weekly 60-minute sessions over four weeks, focusing on educational content about the health benefits of physical activity and current physical activity guidelines.~The difference between the two interventions is that the control program is strictly educational, whereas the A-B-C program focuses on challenging cognitive biases that change decision making related to physical activity. To reiterate, the control program simply provides education on the effects of physical activity with physiological evidence."
219659017|NCT07175480|DRUG|Intermittent PD-1/PD-L1 ICI + VEGFR-TKI|Any PD-1/PD-L1 inhibitor or VEGFR-TKI that is commercially marketed, regulatory-approved and reimbursed under public health plans.Dose as recommended by the manufacturer.
219659018|NCT07175805|PROCEDURE|Bariatric Surgery|Patients in this arm plan to undergo gastric sleeve or gastric bypass surgery.
219659019|NCT07175805|DRUG|GLP1 receptor agonist|Patients in this arm plan to start a GLP-1 receptor agonist.
219659020|NCT07176416|DEVICE|Veritas Vision System|Veritas Vision System
219659021|NCT07177261|BEHAVIORAL|Fast Friends|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 questions with the other person that become increasingly personal in nature, e.g., When did you last cry in front of another person? By yourself?"
219659022|NCT07177261|BEHAVIORAL|Small Talk|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 impersonal questions with the other person , e.g., Do you prefer digital watches and clocks or the kind with hands? Why?"
219659023|NCT07176325|OTHER|Creatine Monohydrate|Creatine Monohydrate was dosed based on industry recommendations, with and without a loading dose
219659024|NCT07175428|DRUG|REGN7508|Administered per the protocol
219659025|NCT07175428|DRUG|REGN9933|Administered per the protocol
219659026|NCT07175428|DRUG|Apixaban|Administered per the protocol
219659027|NCT07174765|OTHER|Person-level linkage of the database looking for relationship with septic shock survival and comorbidities, previous intake of medication, and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted with septic shock to hospitals in the region will be carried out.~The overall data of patients admitted to hospitals will be analysed. The survival data of patients will be compared with their previous individual drug consumption and inhospital survival to septic shock. In addition, drug dependence and dependence on health services of survivors will be studied in comparison with their situation prior to sepsis.~The objective is to establish the Registry of Administrative Data Automatically Recorded for Septic Shock (RADAR-Septic Shock), leveraging administrative data to characterize septic shock incidence, describe patient profiles, identify population-specific healthcare needs, and provide benchmark values for performance assessment in Catalonia's public health system."
219659028|NCT07175116|DEVICE|3M™ Tegaderm™ Antimicrobial Transparent Dressing (chlorhexidine gluconate-impregnated)|Individually applied transparent dressing containing chlorhexidine gluconate (0.5-1 mg/cm²) for antimicrobial protection at the central venous catheter insertion site. The dressing maintains site visibility, reduces catheter manipulation frequency, and provides sustained release of chlorhexidine to lower colonisation and bloodstream infection risk.
219659029|NCT07175116|DEVICE|Conventional transparent polyurethane dressing|Transparent polyurethane dressing without antimicrobial impregnation, applied at the central venous catheter insertion site. This dressing allows site inspection and is widely used in standard paediatric intensive care protocols but provides no antimicrobial activity.
219659030|NCT07177157|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2000 IU of Vitamin D daily (1 pill)
219659031|NCT07175064|BEHAVIORAL|Nursing-Led Livelihood Programs|A set of community-based livelihood initiatives introduced in 2016 and facilitated by nursing faculty in partnership with local leaders. Activities included bracelet making, rag making, and liquid dishwashing. The programs aimed to provide sustainable income, build women's confidence and skills, and indirectly improve health outcomes by addressing poverty-related social determinants of health.
219659032|NCT07177014|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|Stress First Aid for Harm Reduction Workers is a 2-hour training and up to six virtual 30-minute monthly learning collaborative meetings.
219659033|NCT07176741|DIAGNOSTIC_TEST|TREM-1 expression (via immunohistochemistry) between SAH patients and controls|"this is the first study to focus on hepatocyte-specific TREM-1 expression in human liver tissue~What Distinguishes This Study Tissue-Level Focus: Unlike most studies that assess blood biomarkers or systemic inflammation, this research directly measures TREM-1 expression in liver tissue (hepatocytes), offering localized insights into disease severity and immune response.~Retrospective Biobank Utilization: Leverages a rich biobank of archival biopsies spanning 10 years, ensuring real-world data and long-term clinical follow-up-rarely combined at this scale in similar research.~Dual Purpose (Diagnostic \& Prognostic): Most biomarkers are evaluated for either diagnostic or prognostic value-this study uniquely addresses both in a single, comprehensive framework.~Therapeutic Translation Potential: TREM-1 is already a target for pharmacological inhibition (e.g., with peptide inhibitors tested safely in humans for other conditions). This positions the study for rapid clinical translation,"
219659034|NCT07176273|BEHAVIORAL|Modular Cognitive Processing Therapy|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of Contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need. Modular CPT contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need."
218968459|NCT02347696|BEHAVIORAL|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
218968460|NCT02347696|BEHAVIORAL|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1."
218968461|NCT02347696|BEHAVIORAL|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session"
218968462|NCT02347696|BEHAVIORAL|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
218968463|NCT02347696|BEHAVIORAL|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
218968464|NCT01642121|OTHER|laboratory biomarker analysis|Correlative studies
218968465|NCT03091777|DRUG|GDC-229|GDC-229 is a vaginal gel.
218968466|NCT03091777|DRUG|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
218968467|NCT03091777|DRUG|Placebo|Inactive arm of the study
219208266|NCT01459107|DRUG|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
219659035|NCT07176273|BEHAVIORAL|Modular Prolonged Exposure Therapy|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. Modular PE is comprised of the same elements of standard PE, but clinicians select and dose modules (i.e., imaginal exposure, in vivo exposure) based on individual patient need.
219659036|NCT07176273|BEHAVIORAL|Step Down Treatment|Self-managed treatment will involve receiving a self-help version of the remaining treatment materials and ongoing use of the intervention companion app (CPT Coach or PE Coach).
219659037|NCT07176273|BEHAVIORAL|Digital Interventions|The prompt will be a text message delivered through VA-approved technology (e.g., PETALS).
219659038|NCT07176273|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of progressive worksheets to examine stuck points, develop balanced beliefs, and facilitate the experience of natural emotions."
219659039|NCT07176273|BEHAVIORAL|Prolonged Exposure (PE)|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. In imaginal exposure, participants repeatedly, systematically approach their trauma memory and related thoughts and feelings. In in vivo exposure, participants repeatedly, systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma.
219659040|NCT07176650|DRUG|HLX13|Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
219659041|NCT07176650|DRUG|Yervoy|Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
219659042|NCT07176650|DRUG|OPDIVO|Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.
219659043|NCT07174778|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking prompted via text-based cues and picture-based cues to help them adhere to oral anticoagulants. Participants will also receive health education on atrial fibrillation-related stroke prevention.
219659044|NCT07174778|BEHAVIORAL|attention control|The control group will receive standard care, including routine health education from ward nurses and one post-discharge telephone follow-up. In additon, participants will receive a message from the researcher at the same time point each day, but the message will only involve daily greetings.
218968468|NCT02914821|BEHAVIORAL|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
218968469|NCT03371771|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
218968470|NCT03371771|BEHAVIORAL|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
218968471|NCT02536833|DRUG|SM04690|
218968472|NCT02536833|DRUG|Placebo|
218968473|NCT00248885|PROCEDURE|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
218968474|NCT00003567|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
218968475|NCT00003567|BIOLOGICAL|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
218968476|NCT00003567|BIOLOGICAL|therapeutic autologous lymphocytes|
219659045|NCT07175519|DEVICE|Endovascular treatment of aneurysms|Aneurysm can be treated by endovascular devices using catheters, Treatment modalities can include coils, stents, flow diverters as well as intrasaccular devices
219659046|NCT07175272|DRUG|Holy basil extract|"Holy basil extract (Ocimum sanctum) will be provided as an oral capsule formulation. Each capsule contains 300 mg of standardized holy basil extract with defined amounts of active compounds including ursolic acid (≥0.10 mg) and rosmarinic acid (≥0.50 mg). Participants will be instructed to take one capsule once daily for 28 consecutive days.~The capsules will be dispensed in blister packs, with labeling according to clinical trial regulatory requirements. Participants will be asked to record daily intake in a study diary, and compliance."
219659047|NCT07177105|PROCEDURE|Cytoreductive surgery|* Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
219659048|NCT07177105|DRUG|Immunochemotherapy|"1. Treatment phase:~   ① Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less;~   ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less;~   ③ Carboplatin Dose: administered according to the area under the curve (AUC) of 5 mg/mL/min, with infusion time controlled within 15-60 minutes.~   The above regimen will be administered every 3 weeks after surgery for a total of 4 cycles.~2. Maintenance phase:~   * Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less; ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less; The above regimen will be administered every 3 weeks. Maintenance with sintilimab will continue for up to 31 cycles, or the total duration of systemic therapy from randomization will not exceed 2 years, or until disease progression or the occurrence of unacceptable toxicity"
219659049|NCT07175662|BIOLOGICAL|NWRD08 administered by electroporation|NWRD08 delivered via IM injection + electroporation using TERESA device
219659050|NCT07175662|BIOLOGICAL|Placebo administered by electroporation|Placebo delivered via IM injection + electroporation using TERESA device
219659051|NCT07174531|PROCEDURE|Transcatheter valve in Valve implantation|Transcatheter valve-in-valve implantation for patients with degenerated aortic/mitral/tricuspid bioprosthetic valves who are at high-risk to redo surgical valve replacement.
218968477|NCT00003567|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
218968478|NCT00003567|DRUG|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
218968479|NCT00003567|DRUG|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
218968480|NCT00003567|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
218968481|NCT05381337|PROCEDURE|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
218968482|NCT05381337|PROCEDURE|coronal scalp incision|Coronal scalp incisions were used as control group.
219064122|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
219064123|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
219064124|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
219659052|NCT07177274|RADIATION|Low Level Laser Therapy|Collecting wound stiffness data using the OCT-air-jet and Myoton Pro before and after the LLLT treatment using the device's indentation system. Then the intervention is applying LLLT to the wound for 3 min. The LLLT utilized the Red Dot Laser Diode Module Class IIIA.
219659053|NCT07175740|DIETARY_SUPPLEMENT|Fasting|No meal
219659054|NCT07175740|DIETARY_SUPPLEMENT|Sucrose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g sucrose
219659055|NCT07175740|DIETARY_SUPPLEMENT|Fructose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g fructose
219659056|NCT07175740|DIETARY_SUPPLEMENT|Fat enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 15g fat
219659057|NCT07175740|DIETARY_SUPPLEMENT|Aspartame enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, aspartame (matched for taste)
219659058|NCT07175740|OTHER|Exercise session|A 60-minutes exercise session on a cycle ergometer (Corival 400, Quinton Instruments, Seattle, WA, USA) at 60% of the VO2peak (determined at a baseline visit)
219659059|NCT07175324|DEVICE|optical coherence tomography angiography|correlation between OctA and Visual field changes in Multiple Sclerosis
219659060|NCT07175324|DEVICE|Visual Field Perimetry|Correlation between OctA and Visual field changes in Multiple sclerosis
219659061|NCT07176117|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)|A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.
219659062|NCT07176117|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).
219659063|NCT07176897|DIAGNOSTIC_TEST|Normal Toric IOL implantation with digital marking|Digital marking was compared to bedside marking, but there was no change in clinical practice. The difference in the marks was measured.
219659064|NCT07177027|BEHAVIORAL|Music intervention|Participants listened to 12 relaxing music tracks introduced during prenatal childbirth classes at 36 weeks of gestation. The tracks were shared via WhatsApp to encourage regular listening during pregnancy. During labor, participants were encouraged to listen to music whenever they wished. At cervical dilations of 4 cm, 6 cm, and 8 cm, participants listened to their preferred tracks from the playlist for 20 minutes. Pain intensity was measured before and after each session using the Visual Analog Scale (VAS).
219659065|NCT07177027|BEHAVIORAL|Breathing Exercise|Participants were trained in Lamaze breathing techniques during prenatal childbirth classes. They practiced guided breathing exercises during labor at cervical dilation points of 4 cm, 6 cm, and 8 cm. Pain intensity was assessed before and after each session using the Visual Analog Scale (VAS).
218968483|NCT00922701|DRUG|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
218968484|NCT03231150|PROCEDURE|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
218968485|NCT03231150|PROCEDURE|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
218968486|NCT03231150|PROCEDURE|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
219064125|NCT04040803|DEVICE|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
219208267|NCT06995807|OTHER|EL-SHIN THERAPY|"Participants will be randomly assigned to Group A and Group B. Group A : Attend a talk on Malaysia Tourism + current coping strategies.~Group B : EL-SHIN® Therapy + current coping strategies. Duration of therapies: 2 weeks Assessments using (i) DASS-21 (ii) MHQoL (iii) SLEEP QUALITY SCALE (SQS) at baseline, after 1st week \& 2nd weeks for both groups. Assessment will be done on end of 3rd week to see effect when EL-SHIN Therapy Stopped.~Group B participants: Attend a workshop on administration of EL-SHIN® Therapy. Will reinitiate EL-SHIN Therapy on the 4th week and assess on the 8th day to see the effect."
219208268|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
219659066|NCT07175857|DEVICE|Lyv Endo app|Lyv Endo is a CE-marked Class I therapeutic digital medical device offering a patient-centered, integrative approach. Its innovation lies in its ability to deliver personalized content based on symptoms, surpassing the limits of traditional care.
219659067|NCT07175363|DRUG|An postoperative analgesic pump was used|The drugs in the analgesic pump include butorphanol, hydromorphone, tramadol, and other medications.
219659068|NCT07174895|DRUG|Intra-articular Tranexamic Acid + Suction Drainage|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure, along with a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively.
219659069|NCT07174895|DRUG|Intra-articular Tranexamic Acid|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure. No suction drain was used.
219659070|NCT07174895|DEVICE|Suction Drainage Only|Patients had a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively. No tranexamic acid was administered.
218968487|NCT06286371|PROCEDURE|Laparoscopic Endometriosis Surgery|Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
218968488|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
218968489|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
218968490|NCT00621803|DRUG|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
218968491|NCT05814601|DRUG|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
219659071|NCT07175246|DIAGNOSTIC_TEST|Polysomnography (PSG)|Polysomnography (PSG) is the gold standard, multi-parametric diagnostic test used to comprehensively assess sleep architecture and diagnose sleep disorders. This objective, overnight recording captures simultaneous physiological data channels, including electroencephalography (EEG) to stage sleep, electrooculography (EOG) to detect eye movements, electromyography (EMG) to measure muscle tone, electrocardiography (ECG) for heart rhythm, respiratory effort (via thoracic and abdominal belts), nasal airflow, and pulse oximetry for blood oxygen saturation. As the primary/secondary outcome measure, PSG will be administered to quantitatively evaluate the intervention's effect on key sleep parameters such as total sleep time (TST), sleep efficiency (SE), wake after sleep onset (WASO), latency to sleep onset, and the frequency of sleep-disordered breathing events (e.g., Apnea-Hypopnea Index, AHI) or periodic limb movements.
218968492|NCT02354482|BEHAVIORAL|Patient Communication and Care Management|"Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers"
218968493|NCT02354482|BEHAVIORAL|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment"
218968494|NCT02354482|BEHAVIORAL|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers"
218968495|NCT02354482|BEHAVIORAL|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment"
218968496|NCT02354482|BEHAVIORAL|Assessment and Teach Back|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills"
218968497|NCT02354482|OTHER|Standard of Care (Reference)|No specific Transitional Care Strategy
218968498|NCT00899509|OTHER|laboratory biomarker analysis|correlative studies
218968499|NCT02818647|PROCEDURE|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
218968500|NCT00652691|BIOLOGICAL|filgrastim|
218968501|NCT00652691|DRUG|carboplatin|
218968502|NCT00652691|DRUG|cyclophosphamide|
218968503|NCT00652691|DRUG|topotecan hydrochloride|
218968504|NCT00652691|PROCEDURE|autologous hematopoietic stem cell transplantation|
218968505|NCT00652691|PROCEDURE|peripheral blood stem cell transplantation|
218968506|NCT00004229|BIOLOGICAL|recombinant human endostatin|
218968507|NCT02764190|BEHAVIORAL|I-ACT with Check Yourself|
218968508|NCT04934280|DIAGNOSTIC_TEST|sonohysterography|saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
218968509|NCT05549427|OTHER|Ventilation|Ventilation in ICU
218968510|NCT00569751|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
218968511|NCT00236951|DRUG|iron sucrose injection USP|
218968512|NCT00236951|DRUG|stable erythropoietin therapy|
218968513|NCT02142114|DEVICE|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
219208269|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
219208270|NCT06995846|DIAGNOSTIC_TEST|Bacterial DNA Levels in Ascites|The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).
218968514|NCT01050478|DRUG|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
218968515|NCT01050478|DRUG|Benzodiazepine|Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
218968516|NCT02448342|DEVICE|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
218968517|NCT04507854|OTHER|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
218968518|NCT01022827|OTHER|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes \[about 6 minutes for each muscle and order was random\] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
219064126|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
219659072|NCT07175870|PROCEDURE|Non-cardiac surgery followed by postoperative PCI|Patients undergo the planned time-sensitive non-cardiac surgery first in a hybrid operating room, with PCI standby available in case of an intraoperative acute coronary event. If such an event occurs, immediate PCI will be performed. Additional PCI will be performed postoperatively if clinically indicated.
219659073|NCT07175870|PROCEDURE|Preoperative PCI followed by delayed non-cardiac surgery ~3 months later|Patients undergo PCI first. The planned non-cardiac surgery will then be performed approximately 3 months after PCI, in accordance with current guideline recommendations for the timing of non-cardiac surgery following PCI.
219659074|NCT07176182|DRUG|mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.~Citrus flavonoid tablets (Alvenor) : 500 mg orally three times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment)."
219659075|NCT07176182|DRUG|mFOLFOX regimen neoadjuvant therapy group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours."
219659076|NCT07176884|PROCEDURE|nurse-performed coronary catheterization|nurse-performed coronary catheterization
218968519|NCT06271499|OTHER|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
218968520|NCT06271499|OTHER|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
218968521|NCT04467996|DEVICE|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
219659077|NCT07176884|PROCEDURE|interventional cardiologist-performed coronary catheterization|interventional cardiologist-performed coronary catheterization.
218968522|NCT02252276|PROCEDURE|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
218968523|NCT02252276|PROCEDURE|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
219064127|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
219064128|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
219064129|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219064130|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
219064131|NCT02295111|DEVICE|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
219064132|NCT02295111|BEHAVIORAL|TCM health consult|Traditional Chinese Medicine Health Consult without needling
218968524|NCT01936402|BEHAVIORAL|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
219659078|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with ropivacaine|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of 0.25% ropivacaine (local anesthetic), up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
219659079|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with placebo|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia. which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of saline (placebo) up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
219659080|NCT07175701|BEHAVIORAL|Behavioral: Nutritional education and diet counselling|"All participants will be asked to visit the study site after the 10-day baseline monitoring period. They will receive a 30-minute nutrition education focusing on reducing UPF intake; and personalized counselling session based on their dietary intake observed during the baseline monitoring period.~Participants allocated to the intervention group will receive nutrition education and personalized counselling aimed at reducing ultra-processed food (UPF) intake by encouraging the substitution of UPFs with unprocessed/minimally processed foods, thereby improving overall diet quality. Participants will be educated on the definition of UPFs, how to identify them, practical strategies for reducing UPF intake, UPF-reducing recipes, and the associations between UPF intake and health outcomes. The content related to UPFs was developed based on previous studies exploring the health effects of UPF intake, while the content on diet quality was based on the 2020 Korean Dietary Reference Intakes."
219659081|NCT07175701|BEHAVIORAL|Conventional nutrition education and diet counseling|All participants will be asked to visit the study site after the 10-day baseline monitoring period. Participants in the control group will receive a conventional nutrient-based education and personalized diet counseling developed based on the 2020 Korean Dietary Reference Intakes.
219659082|NCT07175259|RADIATION|Echocardiography|Simple, bedsides, non invasive
219659083|NCT07176715|OTHER|Same-Day Colectomy|"study, they will undergo extensive education during their preoperative visit. Perioperative education includes management of perioperative medications, bowel prep and perioperative antibiotics. Perioperative education will include that of the patient and their designated caregiver.~Perioperative nursing staff will go over postoperative discharge instructions again. A custom discharge instruction sheet will be made and given to all patients upon discharge. On days 1 and 3 postoperatively, patients will receive a phone call or virtual visit from a member of the research team. Questions will be asked of patients based on a script made. Patients will then be seen in the clinic between postoperative day 5-7.~Patients' medical record will be followed for six months postoperatively to track emergency department visits, readmissions, and postoperative complications. Postoperative complications will include surgical site infection, deep surgical infection, bleeding requiring transfusion, ana"
219659084|NCT07174505|DEVICE|Mechanical Thrombectomy using the CONDA Stent Retriever|Intravenous sedation, local or general anesthesia, and anticoagulation management will be administered following the institution's standard of care to ensure subject safety and comfort. These procedures should be applied to the target population at the discretion of the investigator and in accordance with clinical guidelines. The use of CONDA is no different than that established for other CE marked stent retrievers. The use of supportive devices including, long sheaths, guide catheters with our without balloons, distal access catheters, ANA funnel catheter, microcatheters and microwires, along with the CONDA device, will be guided by operator preference and/or center established practices. Operators are required to use these devices according to their labeling and instructions for use.
219659085|NCT07176260|OTHER|Patients with pre-Capillary pulmonary hypertension|Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.
219659086|NCT07175415|DRUG|Capivasertib|Oral
219659087|NCT07175415|DRUG|Venetoclax|Oral
219659088|NCT07175415|DEVICE|Dexamethasone|oral/intravenous
219659089|NCT07175415|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
219659090|NCT07176611|OTHER|Guided imagery|Participants in this group will receive the guided imagery intervention. The guided imagery audio recording will be applied in a quiet room once during the initial session, and participants will be instructed to continue the practice at home before sleep for eight weeks.
219659091|NCT07176975|DRUG|BI 1831169|BI 1831169
219659092|NCT07176975|DRUG|nivolumab|nivolumab
219659093|NCT07174752|PROCEDURE|Non-Submerged De-Epithelialized Free Gingival Graft|The Free gingival graft will be de-epithelialized and fixed at the recipient site in a non-submerged manner to increase the keratinized mucosa
218968525|NCT01164384|DRUG|Baminercept|
218968526|NCT01304784|DRUG|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
218968527|NCT01304784|DRUG|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
218968528|NCT01304784|DRUG|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
218968529|NCT01304784|DRUG|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
218968530|NCT01304784|DRUG|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
218968531|NCT03096145|BEHAVIORAL|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
218968532|NCT03096145|BEHAVIORAL|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
218968533|NCT03096145|BEHAVIORAL|Health incentive|Smokers receive a $25 gift card if they call the quitline
219064133|NCT02295111|OTHER|Usual Care|Standard NHS care
219659094|NCT07174752|PROCEDURE|Conventional FGG|The Free gingival graft will be fixed at the recipient site to increase the keratinized mucosa
219659095|NCT07176819|BEHAVIORAL|Gait retraining|The intervention is a wearable device-assisted gait retraining program designed specifically for female runners with patellofemoral pain (PFP). Unlike conventional physiotherapy or exercise-based interventions, this program integrates real-time biofeedback through a commercially available smartwatch and its mobile application. Participants are instructed to increase their step rate by 10% above their preferred cadence. The smartwatch provides auditory metronome cues and real-time cadence feedback to ensure accurate step-rate modification.
219659096|NCT07176819|BEHAVIORAL|Education|PFP education, load management strategies, symptom-based training modifications, and strengthening exercises.
219659097|NCT07175558|OTHER|Reiki|"The patient will be explained about reiki (life energy recovery) and the application environment will be kept quiet.~Metal objects on the patient and the researcher will be removed. The researcher will wash and warm their hands. The patient's privacy will be ensured. The patient will be given a flat lying position with their arms and legs on both sides and comfortable. The patient will be asked to close their eyes. The researcher's fingers will be straight, side by side and closed, and energy will be provided to the application areas; crown chakra (top of the head), forehead chakra (top of the forehead), throat chakra (top of the throat), heart chakra (middle of the chest), solar plexus (under the chest, above the navel), sacral chakra (below the navel) and root chakra (upper back). Reiki application will be applied to the points on the 7 chakra regions for 4 minutes each, for a total of 28 minutes. The patient will be asked to open their eyes at the end of the application."
219659098|NCT07177001|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
219659099|NCT07177001|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
219659100|NCT07176039|RADIATION|High-Intensity Laser Therapy (HILT)|will be administered to active myofascial trigger points in the neck and shoulder region. The laser device used is an 808 nm gallium-aluminum-arsenide (GaAlAs) diode laser in continuous mode. Parameters: power output of 8-10 W, frequency of 2000 Hz, and application time of 60 seconds per trigger point, targeting 5-6 trigger points per session. Treatment will be delivered twice weekly for 4 consecutive weeks, totaling 8 sessions.
219659101|NCT07176039|OTHER|Extracorporeal Shockwave Therapy (ESWT)|ESWT will be applied to active myofascial trigger points using a radial shockwave device. Parameters: Energy flux density 0.1-0.2 mJ/mm², 2000 shocks per session, frequency of 2 sessions per week for 4 weeks (8 sessions).
219659102|NCT07176910|OTHER|conduct angiopuncture on perforator points|conducted angiopuncutre on patients of intervention group, and compare those patients pain scores before and after angiopuncture therapy.
219659103|NCT07176923|BIOLOGICAL|CS-121|CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 protein expression and serum triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
219659104|NCT07174843|BIOLOGICAL|CD19/CD22/BCMA CAR-T cells(BZE2204)|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of BZE2204 CAR T cells.~On day0 subjects will receive a single dose BZE2204 CAR T cells by intravenous (IV) injection."
219659105|NCT07175298|PROCEDURE|conventional opioid-based technique|Control Group: Participants will receive general anaesthesia with a conventional opioid-based technique
219659106|NCT07175298|PROCEDURE|SPSIPB Group|SPSIPB Group: Participants will receive an ultrasound-guided Serratus posterior superior intercostal plane block with 30 ml 0.25% bupivacaine per side pre-incision and general anaesthesia with opioid based fentanyl
219659107|NCT03073356|BIOLOGICAL|Infusion of 3-OHB|Increase in 3-OHB levels
219659108|NCT03073356|BIOLOGICAL|Infusion of placebo|NaCl
219659109|NCT06227715|OTHER|universal adhesive|
219659110|NCT01618461|BEHAVIORAL|Drug indication icons|Icons illustrate the purpose of each medication
219659111|NCT01618461|BEHAVIORAL|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
218968534|NCT04356170|DRUG|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
218968535|NCT04356170|DRUG|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
218968536|NCT04356170|DRUG|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
218968537|NCT00081965|PROCEDURE|acupuncture therapy|
218968538|NCT00081965|PROCEDURE|hot flashes attenuation|
218968539|NCT00081965|PROCEDURE|management of therapy complications|
218968540|NCT00079014|DRUG|triapine|Given IV
218968541|NCT00079014|DRUG|doxorubicin hydrochloride|Given IV
218968542|NCT00079014|OTHER|laboratory biomarker analysis|Correlative studies
218968543|NCT00079014|OTHER|pharmacological study|Correlative studies
218968544|NCT02068339|DRUG|Oltipraz 1 (90mg)|
218968545|NCT02068339|DRUG|Placebo|
218968546|NCT02068339|DRUG|Oltipraz 2 (120mg)|
218968547|NCT03362307|DEVICE|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
218968548|NCT03362307|DEVICE|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
218968549|NCT06468969|OTHER|Enhanced Follow-up|"Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)"
218968550|NCT01982331|BIOLOGICAL|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
218968551|NCT01982331|OTHER|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
219064134|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
219064135|NCT03129334|BEHAVIORAL|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
219659112|NCT04964583|DRUG|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
219659113|NCT04009161|PROCEDURE|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
219659114|NCT01777139|DRUG|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
218968552|NCT04646772|PROCEDURE|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
218968553|NCT03937869|DRUG|Secnidazole|One dose
218968554|NCT03551340|DIAGNOSTIC_TEST|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
218968555|NCT01469117|OTHER|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
218968556|NCT04498494|DEVICE|ECG|12-lead ECG
218968557|NCT06288789|OTHER|Social Frailty Index|Social Frailty Index will be applied twice, one week apart.
219064136|NCT02337647|OTHER|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
219064137|NCT01203189|DRUG|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
219659115|NCT05622279|PROCEDURE|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
219659116|NCT03876769|BIOLOGICAL|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
219659117|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
219659118|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
218968558|NCT03679585|OTHER|Internet-Based Intervention|Undergo Talking Pictures social media intervention
218968559|NCT03679585|OTHER|Quality-of-Life Assessment|Ancillary studies
218968560|NCT03679585|OTHER|Questionnaire Administration|Ancillary studies
218968561|NCT04145479|BEHAVIORAL|physical activity|exercise
219064138|NCT01203189|DRUG|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
219659119|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
219659120|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
219659121|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
219659122|NCT04088721|BIOLOGICAL|AD17002|LTh(αK) as immunomodulator
219659123|NCT04088721|OTHER|Formulation Buffer|Formulation buffer
219659124|NCT02502266|DRUG|Cediranib|Given PO
219659125|NCT02502266|DRUG|Cediranib Maleate|Given PO
219659126|NCT02502266|PROCEDURE|Computed Tomography|Undergo CT
219659127|NCT02502266|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219659128|NCT02502266|DRUG|Olaparib|Given PO
219659129|NCT02502266|DRUG|Paclitaxel|Given IV
219659130|NCT02502266|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219659131|NCT02502266|OTHER|Questionnaire Administration|Ancillary studies
219659132|NCT02502266|DRUG|Topotecan|Given IV
219659133|NCT02502266|DRUG|Topotecan Hydrochloride|Given IV
219659134|NCT01604317|PROCEDURE|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
219659135|NCT01604317|PROCEDURE|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
219659136|NCT02707406|OTHER|NEOX®CORD 1K|use of human tissue product wound covering
219659137|NCT02707406|OTHER|standard of care|standard wound coverings
219659138|NCT02921750|DEVICE|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
219659139|NCT02921750|DEVICE|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
219659140|NCT03298659|DIAGNOSTIC_TEST|iFR|Treatment guided by instantaneous wave-free ratio
219659141|NCT03298659|DIAGNOSTIC_TEST|CMR|Treatment guided by stress perfusion CMR
219659142|NCT04295213|OTHER|oligosaccharides|1 dose a day of oligosaccharides or placebo
219659143|NCT05201040|DEVICE|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
219659144|NCT05201040|DEVICE|Normal saline|2mL of normal saline
219659145|NCT03824821|OTHER|No intervention|No intervention
219659146|NCT03310294|DIETARY_SUPPLEMENT|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
219659147|NCT03310294|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
219659148|NCT00554541|OTHER|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
219659149|NCT03219905|DEVICE|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
218968562|NCT02914847|BEHAVIORAL|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
218968563|NCT01091337|DRUG|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~\+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
218968564|NCT01091337|DRUG|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
218968565|NCT01490788|DRUG|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
218968566|NCT01490788|DRUG|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
218968567|NCT01490788|DRUG|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
218968568|NCT00062322|DRUG|cisplatin|
218968569|NCT00062322|DRUG|irinotecan hydrochloride|
218968570|NCT00062322|PROCEDURE|conventional surgery|
219659150|NCT03219905|DEVICE|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
219659151|NCT03734900|OTHER|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
218968571|NCT00062322|PROCEDURE|neoadjuvant therapy|
218968572|NCT00062322|RADIATION|radiation therapy|
219659152|NCT03734900|BIOLOGICAL|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
219659153|NCT03734900|BIOLOGICAL|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
219659154|NCT02323737|DRUG|Irinotecan and cisplatin|
219659155|NCT02323737|DRUG|Etoposide and cisplatin|
219659156|NCT01535586|DEVICE|CPAP versus MAD|Cross over design
219659157|NCT04140916|DEVICE|Midline catheter|Peripherally inserted short intravenous catheter
219659158|NCT04140916|DEVICE|PICC-line catheter|Peripherally inserted long intravenous catheter
219659159|NCT05422768|BEHAVIORAL|Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
219659160|NCT05422768|BEHAVIORAL|Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
218968573|NCT01231230|DRUG|fluticasone|220- mcg once
218968574|NCT01231230|DRUG|placebo inhalation|placebo inhalation once
218968575|NCT01231230|DRUG|Salmeterol|50 mcg salmeterol once
218968576|NCT01231230|DRUG|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
219064139|NCT05403489|PROCEDURE|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
219064140|NCT05403489|PROCEDURE|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
219064141|NCT00765115|DRUG|LY450139|
219064142|NCT00765115|DRUG|placebo|
218968577|NCT04723758|DEVICE|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
218968578|NCT04723758|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
218968579|NCT04529473|DIETARY_SUPPLEMENT|Eubacterium hallii|Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
218968580|NCT04529473|OTHER|Placebo|Placebo capsules are identical to the active treatment
218968581|NCT05580510|DRUG|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
218968582|NCT05580510|DRUG|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
218968583|NCT06267976|DEVICE|ProSomnus RPMO2|The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
218968584|NCT05031598|OTHER|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
218968585|NCT02393690|RADIATION|Iodine I-131|Given PO
218968586|NCT02393690|OTHER|Placebo Administration|Given PO
218968587|NCT02393690|DRUG|Selumetinib|Given PO
218968588|NCT03902106|DRUG|salbutamol|subjects ingest salbutamol
218968589|NCT03902106|OTHER|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
218968590|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
218968591|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
218968592|NCT00591266|DRUG|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
218968593|NCT06304038|DRUG|Flu Vaccine|Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
218968594|NCT00686179|DRUG|AZD3480|Capsule, oral, single dose, 6 days
219659161|NCT06002256|PROCEDURE|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
219659162|NCT06002256|PROCEDURE|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
219659163|NCT03605849|DRUG|Centanafadine SR|200mg, BID, oral tablets
219659164|NCT02488590|DRUG|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
219659165|NCT02488590|DRUG|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
219659166|NCT02488590|DRUG|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
219659167|NCT02488590|DRUG|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
219659168|NCT02488590|DRUG|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
219659169|NCT05717803|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
218968595|NCT00686179|DRUG|Moxifloxacin|Capsule(encapsulated), oral, single dose
218968596|NCT00686179|DRUG|PLACEBO|Capsule, oral, single dose
218968597|NCT05771792|OTHER|ECCENTRIC EXERCISE|Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
219064143|NCT05812573|OTHER|no intervention|No intervention, only observation
219064144|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
218968598|NCT05771792|OTHER|CONVENTIONAL EXERCISES PROGRAM|The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
218968599|NCT04121416|DRUG|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
218968600|NCT04121416|DRUG|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
218968601|NCT02572193|PROCEDURE|POEM|To determine the feasibility of same-day discharge following a POEM procedure
218968602|NCT04880005|BEHAVIORAL|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
219064145|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
219659170|NCT04283474|DRUG|XG005-03|3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
219659171|NCT04283474|DRUG|Placebo|Placebo topical formulation
219659172|NCT02278692|DIETARY_SUPPLEMENT|Vitamin K|Oral vitamin K
219064146|NCT03956017|DRUG|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
219064147|NCT03956017|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
219659173|NCT02278692|OTHER|Placebo|Oral placebo tablet
219659174|NCT04616846|DIAGNOSTIC_TEST|Peripheral venous ultrasound|Screening for VTE from D7 to 42
219659175|NCT06083545|BEHAVIORAL|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
219659176|NCT04715217|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
218968603|NCT04880005|BEHAVIORAL|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
218968604|NCT04880005|BEHAVIORAL|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
218968605|NCT02935101|DRUG|Prednisolone|formulated for oral administration. encapsulated.
219064148|NCT02062502|BIOLOGICAL|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
219064149|NCT02062502|BIOLOGICAL|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
219064150|NCT02062502|BIOLOGICAL|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
219064151|NCT04411108|OTHER|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
219064152|NCT04411108|OTHER|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
219659177|NCT04787861|OTHER|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
219659178|NCT00590538|DRUG|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
219659179|NCT00590538|DRUG|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
219659180|NCT00590538|DRUG|Placebo|The placebo is given to match the active comparator for four days.
219659181|NCT00381329|BEHAVIORAL|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
219659182|NCT00381329|BEHAVIORAL|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
219659183|NCT02411981|OTHER|Autogenic drainage|
219659184|NCT03718195|OTHER|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
219659185|NCT01125813|BIOLOGICAL|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
219659186|NCT00985426|BIOLOGICAL|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
218968606|NCT02935101|DRUG|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
218968607|NCT01626638|PROCEDURE|Confocal Micro Endoscopy|
218968608|NCT03005938|PROCEDURE|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
219659187|NCT00985426|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
219659188|NCT00985426|OTHER|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
219659189|NCT05969496|DRUG|Axitinib|Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
219659190|NCT05969496|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
219659191|NCT06029933|BIOLOGICAL|Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)|Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
219659192|NCT06029933|BIOLOGICAL|High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)|Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
219659193|NCT00160225|DRUG|Daglutril|
219659194|NCT04258254|BEHAVIORAL|Multimodal|Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.
219659195|NCT04258254|BEHAVIORAL|General|The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.
219659196|NCT04258254|BEHAVIORAL|Standard of Care|The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
219659197|NCT05000203|BEHAVIORAL|Online prenatal specific education|"The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants."
219659198|NCT05000203|BEHAVIORAL|Intrapartum specific support|"At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard"
219659199|NCT05000203|BEHAVIORAL|Prenatal usual education|The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
218968609|NCT03005938|PROCEDURE|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
218968610|NCT05733377|DIAGNOSTIC_TEST|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
219064153|NCT04554862|DRUG|Magnesium sulfate|magnesium sulfate will be added to the block
219064154|NCT04554862|DRUG|Ketorolac Tromethamine|ketorolac will be added to the block
218968611|NCT05733377|DIAGNOSTIC_TEST|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
219659200|NCT05000203|BEHAVIORAL|Intrapartum usual support|A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
219659201|NCT02113995|OTHER|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
219659202|NCT03570606|DEVICE|bone graft substitute|orthopaedic or spine bony defects
219659203|NCT05350332|DEVICE|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
219659204|NCT05350332|DEVICE|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test evaluating lung function, consisting of two parts: spirometry and body plethysmography. In spirometry, participants breathe through a mouthpiece that measures airflow and volume to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants enter in an enclosed chamber where they breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing are used to calculate the volume of air that remains in the lung after expiration. A MiniBox+ device may be used. The MiniBox+ device derives total lung capacity (TLC) during tidal breathing by the analysis of gas pressures and airflows immediately preceding and immediately following airway occlusions to calculate the same measures as conventional PFT analysis.
219659205|NCT05350332|DEVICE|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed transcutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS8R Bipolar Constant Current Stimulator). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
219659206|NCT03722745|BEHAVIORAL|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
219659207|NCT03722745|BEHAVIORAL|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
219659208|NCT02895724|DRUG|Medical Oxygen|Hyperbaric oxygen therapy
219659209|NCT04605380|OTHER|Virtual reality online world|Virtual patient with open fracture inside a virtual world
219659210|NCT04829331|DEVICE|Restrata|Restrata is a sterile, single use device intended for use in local management of wounds
219659211|NCT00361920|DRUG|prednisone|
219659212|NCT03221140|DRUG|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
219659213|NCT06618430|OTHER|None (Observational Study)|None (Observational Study)
219659214|NCT01947426|DIETARY_SUPPLEMENT|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
219659215|NCT01947426|DIETARY_SUPPLEMENT|Control (milk without DHA)|mothers consuming placebo product and their neonates
219659216|NCT04363918|DEVICE|bioelectric stimulation|bioelectric stimulation
219659217|NCT05528913|DRUG|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
219659218|NCT05528913|OTHER|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
219659219|NCT03425357|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
219659220|NCT06623565|PROCEDURE|Multimodal image-guided resection|Supramarginal resection using combination of ADC MRI and FET PET
219659221|NCT02823834|DEVICE|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
219659222|NCT01149421|DRUG|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
219659223|NCT01149421|DRUG|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
219659224|NCT03160001|DRUG|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
218968612|NCT04581759|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
219064155|NCT04554862|PROCEDURE|supraclavicular block|it is done by ultrasound- guided
219064156|NCT00326508|DRUG|Daclizumab|
219659225|NCT03160001|DRUG|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
219659226|NCT03160001|DRUG|Etanercept|Etanercept 50mg weekly
219659227|NCT00707902|DRUG|chlorhexidine/lidocaine|
219659228|NCT00707902|DRUG|echinacea/sage|
219659229|NCT03588078|DRUG|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
219659230|NCT03588078|DRUG|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
219659231|NCT06514378|BIOLOGICAL|Mesenchymal stem cells|Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
219659232|NCT04108988|BEHAVIORAL|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
219659233|NCT04108988|OTHER|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
219659234|NCT03964467|DEVICE|transcranial direct current stimulation|see arm/group descriptions
219659235|NCT05900817|OTHER|antivet|A material used for micro abrasion of teeth
219659236|NCT05900817|OTHER|Oplsture|A material used for micro abrasion of teeth
219659237|NCT03570554|DRUG|Naproxen Sodium (Aleve, BAY117031)|660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
219659238|NCT03570554|DRUG|Acetaminophen ER|3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
219659239|NCT03570554|DRUG|Celecoxib|200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
219659240|NCT03570554|DRUG|Placebo|Over-encapsulation capsule, 4 days, oral (Treatment D)
219659241|NCT00176436|BEHAVIORAL|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
219659242|NCT00176436|BEHAVIORAL|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
219659243|NCT00317200|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
218968613|NCT04581759|DRUG|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
218968614|NCT01016561|RADIATION|intracavitary balloon brachytherapy|
218968615|NCT01016561|RADIATION|external beam radiation therapy|
218968616|NCT01016561|RADIATION|intensity-modulated radiation therapy|
218968617|NCT01016561|RADIATION|radiation therapy treatment planning/simulation|
218968618|NCT01016561|RADIATION|3-dimensional conformal radiation therapy|
218968619|NCT01016561|DRUG|Cisplatin|
219064157|NCT03285282|PROCEDURE|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
219659244|NCT00317200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
218968620|NCT01119560|OTHER|Cytology Specimen Collection Procedure|Correlative studies
218968621|NCT01119560|OTHER|Laboratory Biomarker Analysis|Correlative studies
218968622|NCT01119560|OTHER|Questionnaire Administration|Ancillary studies
218968623|NCT00438438|BEHAVIORAL|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
218968624|NCT01473056|DRUG|JTK-853|Tablets, twice a day for 3 days
218968625|NCT01473056|DRUG|Dose 2 JTK-853|Tablets, twice a day for 3 days
218968626|NCT01473056|DRUG|Dose 3 JTK-853|Tablets, three times a day for 3 days
218968627|NCT01473056|DRUG|Dose 4 JTK-853|Tablets, twice a day for 3 days
218968628|NCT01473056|DRUG|Placebo|Tablets, twice a day or three times a day for 3 days
218968629|NCT02250027|DRUG|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
218968630|NCT02250027|DRUG|Placebo|2 capsules at once, 3 times a day, for 7 days
218968631|NCT03497676|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
218968632|NCT03497676|DRUG|Oral Rilpivirine (RPV)|25 mg tablets administered orally
218968633|NCT03497676|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
219064158|NCT03844763|DRUG|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
219064159|NCT03844763|DRUG|CTX|CTX: 50 mg Daily untill PD or major toxicity
219064160|NCT03844763|RADIATION|RT|RT: 8 Gy single shot day 8
219064161|NCT02848508|DRUG|Metformin|
219064162|NCT00846664|PROCEDURE|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
219064163|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
219659245|NCT00328159|DRUG|Oil special 107 and MYGLIOL 810|
219659246|NCT06154642|DIAGNOSTIC_TEST|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
219659247|NCT06154642|DIAGNOSTIC_TEST|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
219659248|NCT06154642|DIAGNOSTIC_TEST|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
219659249|NCT06154642|DIAGNOSTIC_TEST|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
219659250|NCT06154642|DIAGNOSTIC_TEST|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
219659251|NCT06154642|DIAGNOSTIC_TEST|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
219659252|NCT06154642|PROCEDURE|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
219659253|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
218968634|NCT03497676|DRUG|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
218968635|NCT03497676|DRUG|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
218968636|NCT06533397|PROCEDURE|Sinus floor elevation (SFE)|Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
218968637|NCT06533397|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
218968638|NCT06533397|DIAGNOSTIC_TEST|postoperative CBCT|A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
218968639|NCT06533397|DIAGNOSTIC_TEST|bone core biopsy|At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
218968640|NCT06533397|PROCEDURE|dental implant placement|Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
218968641|NCT06533397|PROCEDURE|fixed dental prosthesis (FDP) fabrication|3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
218968642|NCT06533397|DEVICE|bone grafting|A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.
218968643|NCT04684290|PROCEDURE|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
219064164|NCT00489970|PROCEDURE|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
219064165|NCT00489970|BIOLOGICAL|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
219064166|NCT00489970|BIOLOGICAL|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
219659254|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
218968644|NCT04684290|PROCEDURE|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
218968645|NCT01226043|DRUG|Insulin Glargine|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous"
219064167|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
219064168|NCT01093794|DRUG|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
219064169|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
219659255|NCT00390442|DEVICE|continuous positive airway pressure|
219659256|NCT03008993|BEHAVIORAL|HQIS implementation|
219659257|NCT00842998|DRUG|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
219659258|NCT06292793|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
219659259|NCT06292793|BEHAVIORAL|Cyclical Sighing|A 4-minute audio recording consisting of a 1-minute introduction to cyclical sighing followed by a 3-minute cyclical sighing practice.
219659260|NCT00676572|OTHER|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
219659261|NCT02956057|DRUG|Polyethylene Glycols|
219659262|NCT02956057|DRUG|Natrium picosulfate / Magnesium citrate|
219659263|NCT02956057|DRUG|Polyethylene glycol / Ascorbic acid|
219659264|NCT00565916|DRUG|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
219659265|NCT00565916|DRUG|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
219659266|NCT00565916|DRUG|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
219659267|NCT06607835|BEHAVIORAL|Mindful- compassion|Online mindful-compassion weekly for four weeks
219659268|NCT06607835|BEHAVIORAL|Mindful-compassion and cannabis suppositories|Cannabis suppositories and online mindful-compassion for vaginal pain
219659269|NCT03415659|DRUG|HWH340 tablet|"1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
219659270|NCT02745691|OTHER|Surgery|Thoracic surgery for lung cancer
219659271|NCT02745691|OTHER|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
219659272|NCT02745691|OTHER|Targeted therapy|New targeted therapies for lung cancer
219659273|NCT02745691|OTHER|Immunotherapy|New immunotherapies for lung cancer
219659274|NCT03479593|DIAGNOSTIC_TEST|CMR and OCT in NSTEMI patients with MVD|Lesions \>50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
219659275|NCT04134065|DRUG|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration \<75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
219659276|NCT04134065|DRUG|Placebo oral capsule|the capsule contain nothing
219659277|NCT00112281|DRUG|Tilarginine Acetate Injection intravenous infusion|
219659278|NCT04053010|BIOLOGICAL|Sabin-IPV and DTaP|Sabin-IPV +DTaP at the age of 3/4/5 months old respectively
219659279|NCT04053010|BIOLOGICAL|Sabin-IPV|Sabin-IPV only at the age of 3/4/5 months old respectively
219659280|NCT04053010|BIOLOGICAL|DTaP|DTaP only at the age of 3/4/5 months old respectively
219659281|NCT02769039|OTHER|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
219659282|NCT03240224|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
219659283|NCT03240224|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
219659284|NCT02308813|OTHER|Braking and functionality|
219659285|NCT04794413|DRUG|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
219659286|NCT00693602|DRUG|Erwinase|Chemotherapy
219659287|NCT02651519|DRUG|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
219659288|NCT02651519|DRUG|saline|stellate-ganglion block with saline
219659289|NCT02322502|DRUG|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
219659290|NCT02322502|DRUG|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
219659291|NCT02322502|DRUG|propofol|intravenous injection to maintain anaesthesia
219659292|NCT06385197|DEVICE|App randomizing dosing regimen|patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.
219659293|NCT03768700|OTHER|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
219659294|NCT03125187|BIOLOGICAL|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
219659295|NCT03125187|BIOLOGICAL|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
219659296|NCT03356899|DRUG|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
219659297|NCT03356899|DRUG|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
219659298|NCT00002756|BIOLOGICAL|filgrastim|
219659299|NCT00002756|DRUG|asparaginase|
219659300|NCT00002756|DRUG|cyclophosphamide|
219659301|NCT00002756|DRUG|cytarabine|
219659302|NCT00002756|DRUG|daunorubicin hydrochloride|
219659303|NCT00002756|DRUG|etoposide|
219659304|NCT00002756|DRUG|leucovorin calcium|
219659305|NCT00002756|DRUG|mercaptopurine|
219659306|NCT00002756|DRUG|methotrexate|
219659307|NCT00002756|DRUG|prednisone|
219659308|NCT00002756|DRUG|therapeutic hydrocortisone|
219659309|NCT00002756|DRUG|vincristine sulfate|
219659310|NCT04022356|DEVICE|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
218968646|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
218968647|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
218968648|NCT01110304|OTHER|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
218968649|NCT01110304|DEVICE|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
218968650|NCT00284596|PROCEDURE|High tibial osteotomy|HTO
218968651|NCT00666874|BEHAVIORAL|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
218968652|NCT00666874|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
218968653|NCT00092690|DRUG|MK0653A, ezetimibe (+) simvastatin|
218968654|NCT00092690|DRUG|Comparator: atorvastatin|
218968655|NCT00910988|DRUG|Olanzapine|olanzapine/Zyprexa
218968656|NCT00910988|DRUG|Ziprasidone|ziprasidone/Geodon
218968657|NCT00494273|BEHAVIORAL|Cognitive Behavioral and Standard Care with Healthy Living|
218968658|NCT00400530|DRUG|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
218968659|NCT00400530|DRUG|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
218968660|NCT02701842|DEVICE|ImPACT Online/Paper Pencil Tests|
218968661|NCT02701842|DEVICE|ImPACT Online|
218968662|NCT06045650|OTHER|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
218968663|NCT06045650|OTHER|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
218968664|NCT06045650|OTHER|Neuro-economical game|A game played to assess the trust-index of participants
218968665|NCT06045650|OTHER|Childhood Trauma Questionnaire|to assess childhood trauma score
218968666|NCT06045650|OTHER|Relationships Questionnaire|to assess attachment type
219659311|NCT05100498|DEVICE|Web-based oncofertility support tool|The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
219659312|NCT06472999|PROCEDURE|Nephroprotective measures|Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
219659313|NCT04679051|BEHAVIORAL|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
218968667|NCT06045650|OTHER|demographic questionnaire|To obtain basic data on demographics
219659314|NCT04837599|DEVICE|Discovery TM of Pentax medical on/off in colonoscopy|on the monitor artificial integlligence Discovery can be switched on or off.
219659315|NCT00033657|DRUG|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
219659316|NCT00033657|DRUG|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
219659317|NCT00033657|DRUG|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
219659318|NCT00033657|PROCEDURE|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
219659319|NCT00033657|RADIATION|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
218968668|NCT01624051|OTHER|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
218968669|NCT01624051|OTHER|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
218968670|NCT05618431|OTHER|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
218968671|NCT05425589|PROCEDURE|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
219659320|NCT05143216|OTHER|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
219659321|NCT05143216|OTHER|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
219659322|NCT02698644|DRUG|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
218968672|NCT03004443|DRUG|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
218968673|NCT03004443|DRUG|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
218968674|NCT00003800|OTHER|immunohistochemistry staining method|
218968675|NCT00003800|OTHER|laboratory biomarker analysis|
218968676|NCT00003800|PROCEDURE|radionuclide imaging|
218968677|NCT00828854|DRUG|Entinostat|Entinostat 5 mg PO every week
218968678|NCT00828854|DRUG|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
218968679|NCT04176575|OTHER|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
218968680|NCT03476668|OTHER|MIRT|4-week multidisciplinary intensive rehabilitation treatment
218968681|NCT05774275|DRUG|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
218968682|NCT05774275|DRUG|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
218968683|NCT05774275|DRUG|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
218968684|NCT05774275|RADIATION|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
218968685|NCT00543738|DRUG|MK0767|
218968686|NCT00137865|GENETIC|EGEN-001 (phIL-12-005/PPC)|
218968687|NCT06087146|OTHER|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
218968688|NCT05605431|DIAGNOSTIC_TEST|Polysomnography|over nightSleep study
218968689|NCT04253912|DRUG|VBP-245|2% Povidone-Iodine Gel
218968690|NCT04253912|DRUG|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
218968691|NCT05183893|DIETARY_SUPPLEMENT|L-citrulline|5 g of L-citruline + 5 g of additives
218968692|NCT05183893|DIETARY_SUPPLEMENT|Citrulline-malate|8g of citrulline-malate + 2 g of additives
218968693|NCT05183893|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrine
218968694|NCT04630639|DEVICE|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
218968695|NCT01522729|DRUG|Fentanyl|Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
218968696|NCT01522729|DRUG|Placebo comparator|placebo \[NaCl\]
218968697|NCT00685555|BEHAVIORAL|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
218968698|NCT00685555|BEHAVIORAL|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
219659323|NCT03707366|BEHAVIORAL|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
219659324|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
218968699|NCT03188627|BIOLOGICAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
218968700|NCT01841307|DRUG|Cromolyn Sodium|
218968701|NCT02644031|PROCEDURE|mtwo rotary system|post-treatment pain after using mtwo rotary system
218968702|NCT02644031|PROCEDURE|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
218968703|NCT02644031|PROCEDURE|hand files|post-treatment pain after using hand files
219659325|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
219659326|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
218968704|NCT02103049|DRUG|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
218968705|NCT02015702|OTHER|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
218968706|NCT02015702|OTHER|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
218968707|NCT01600508|OTHER|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
219659327|NCT02945254|DEVICE|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
219659328|NCT05344690|GENETIC|SLMAP and EPO genetic polymorphism|Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
219659329|NCT02348359|DRUG|X-82|
219659330|NCT02348359|DRUG|Anti-VEGF|
218968708|NCT03425019|DEVICE|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
218968709|NCT04430829|DIAGNOSTIC_TEST|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
218968710|NCT04430829|DIAGNOSTIC_TEST|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
218968711|NCT05116358|DEVICE|Phototherapy device|The active phototherapy device will emit light
218968712|NCT00294476|DRUG|IVIG|
218968713|NCT00294476|PROCEDURE|Biological Therapy|
218968714|NCT04095390|DRUG|Pyrotinib|400 mg
218968715|NCT04095390|DRUG|SHR6390|125mg
218968716|NCT04095390|DRUG|Letrozole|2.5mg
218968717|NCT04095390|DRUG|Capecitabine|500mg
218968718|NCT05938179|DRUG|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
218968719|NCT05938179|DRUG|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
218968720|NCT05938179|DRUG|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
218968721|NCT05938179|DRUG|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
218968722|NCT02826850|PROCEDURE|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
218968723|NCT02826850|PROCEDURE|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
219064170|NCT01093794|DRUG|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
219659331|NCT02348359|DRUG|Placebo|
219659332|NCT04060459|DRUG|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
219659333|NCT00150306|DRUG|Zoloft (Sertraline)|
219659334|NCT03186859|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
219659335|NCT03186859|PROCEDURE|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
219659336|NCT02155075|DEVICE|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
219659337|NCT04826133|DRUG|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
219659338|NCT04826133|OTHER|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
219659339|NCT02631070|DRUG|Luspatercept|
219659340|NCT02631070|OTHER|Placebo|
219659341|NCT04788875|PROCEDURE|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
219659342|NCT04788875|PROCEDURE|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
219659343|NCT06731387|OTHER|Pharmaceutical technical assistants supported medication dispensation on the hospital ward|Pharmaceutical technical assistants (PTAs) visit the hospital ward for two hours in the morning or afternoon to dispense medications for admitted patients for the following day. Night nurses then complete any final additions or adjustments as needed.
219659344|NCT03146871|DRUG|Azacitidine|Given IV or SC
219659345|NCT03146871|DRUG|Decitabine|Given IV
219659346|NCT03146871|OTHER|Laboratory Biomarker Analysis|Correlative studies
219659347|NCT03146871|OTHER|Pharmacological Study|Correlative studies
219659348|NCT03146871|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219659349|NCT01417585|BEHAVIORAL|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
219659350|NCT01417585|BEHAVIORAL|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
219659351|NCT05180955|OTHER|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
219659352|NCT05180955|OTHER|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
219659353|NCT03027206|OTHER|Vibration technique|Comparison of different technique
219659354|NCT03027206|OTHER|Acceleration of expiratory flow|Comparison of different technique
219659355|NCT03514706|DIAGNOSTIC_TEST|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
219064171|NCT02740127|PROCEDURE|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
219659356|NCT03514706|DIAGNOSTIC_TEST|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
219659357|NCT05499078|DEVICE|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
219659358|NCT01329588|DRUG|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
219659359|NCT01329588|DRUG|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
219659360|NCT00432315|DRUG|Docetaxel + CDDP|"* 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel"
219659361|NCT00432315|DRUG|docetaxel + CDDP|"* 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel"
219659362|NCT00231309|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
219659363|NCT05416645|PROCEDURE|patients with GERD after LSG|patients with GERD after LSG
219659364|NCT03725501|DRUG|ALS-L1023|ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
219064172|NCT02740127|DRUG|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
219064173|NCT02740127|DRUG|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
219064174|NCT02740127|DRUG|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
219064175|NCT02740127|DRUG|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
219659365|NCT03725501|DRUG|Ranibizumab|LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
219659366|NCT03725501|OTHER|Placebo|Control group for comparison with oral administration of ALS-L1023
219659367|NCT01303640|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent
219659368|NCT01303640|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
219659369|NCT05005689|DRUG|Fluoride mouthwash (0.05%; 225ppm).|Mouthwash
219659370|NCT05005689|DRUG|Tooth Mousse Plus|Tooth Mousse
219659371|NCT04324866|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
219659372|NCT01819948|DIETARY_SUPPLEMENT|PhytoMed™|
218968724|NCT05861310|DRUG|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
218968725|NCT05861310|DRUG|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
218968726|NCT00140634|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
218968727|NCT02770833|OTHER|Fish and carbohydrats with low or high GI|
218968728|NCT02770833|OTHER|Veal and carbohydrats with low or high GI|
218968729|NCT05736510|OTHER|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
218968730|NCT05736510|OTHER|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
218968731|NCT01720212|DRUG|YM178|oral
218968732|NCT01974154|OTHER|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
219064176|NCT02740127|DRUG|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
219064177|NCT02740127|BEHAVIORAL|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
219208271|NCT06858995|OTHER|to measure the residual activity on the Totally Implantable Venous Access Port|VOI (volume of interest)TIVAP at 4 ml were drawn manually on the chamber of the TIVAP on each tomography. Blood background was determined by an VOI (volume of intesrest of Right Auricle on the right atrium. The VOIRA was automatically delineated on the CT by XXX. Standardized Uptake Value (SUV)max, SUVpeak, SUVmean were extracted from the VOIs and unilateral comparisons of superiority were performed using Wilcoxon tests. A qualitative analysis along the (TIVAP) catheter was performed: positive if an uptake was superior to the blood background and negative if any.
219208272|NCT06670274|DRUG|HC002 SAD|"Part 1 will enroll 32 participants across 4 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 4 cohorts."
219208273|NCT06670274|DRUG|HC002 MAD|"Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days"
219659373|NCT00688922|DRUG|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
219659374|NCT05495217|DEVICE|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
219659375|NCT05495217|DEVICE|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
219064178|NCT04759820|DRUG|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
219064179|NCT04759820|DRUG|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
219064180|NCT04000906|DRUG|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
219064181|NCT04000906|DRUG|Cisplatin|10.5 mg/m2
219064182|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
219064183|NCT02707055|OTHER|Placebo|Placebo
219208274|NCT06670274|DRUG|Placebo|Matching placebo will be administered across SAD and MAD
219208275|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
219208276|NCT03598998|DRUG|Pralatrexate|Given IV
219208277|NCT05585346|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
219208278|NCT05585346|DRUG|Oral vitamin B1|Oral vitamin B1 10mg, times/day
219659376|NCT04982016|OTHER|crystal therapy|Infusion of 250ml crystal solution before anesthesia induction
219659377|NCT04982016|OTHER|colloid therapy|Infusion of 250ml colloid solution before anesthesia induction
218968733|NCT01974154|OTHER|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
218968734|NCT03508531|PROCEDURE|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
218968735|NCT03508531|PROCEDURE|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
218968736|NCT03508531|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
218968737|NCT03602729|OTHER|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
218968738|NCT00453518|DEVICE|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
218968739|NCT00191646|DRUG|Gemcitabine|"1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
218968740|NCT00191646|DRUG|Paclitaxel|"175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
219659378|NCT01522235|DRUG|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
219659379|NCT01522235|OTHER|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
218968741|NCT00191646|DRUG|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
218968742|NCT01932073|DEVICE|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
218968743|NCT01501396|DRUG|Megestrol Acetate|
218968744|NCT01501396|DRUG|Mirtazapine|
218968745|NCT02666534|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
218968746|NCT02666534|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
219064184|NCT06158750|DEVICE|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
219064185|NCT03564496|DEVICE|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
219659380|NCT01522235|OTHER|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
219659381|NCT03105921|DEVICE|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
218968747|NCT02666534|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
218968748|NCT02666534|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
218968749|NCT00322101|RADIATION|total-body irradiation|Radiation
218968750|NCT00322101|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
218968751|NCT00322101|DRUG|cyclophosphamide|Given IV
218968752|NCT00322101|DRUG|mycophenolate mofetil|Given orally
218968753|NCT00322101|DRUG|busulfan|Given IV or orally
218968754|NCT00322101|DRUG|cyclosporine|Given IV or orally
218968755|NCT00322101|DRUG|fludarabine phosphate|Given IV
218968756|NCT00322101|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
218968757|NCT00322101|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
218968758|NCT00322101|OTHER|laboratory biomarker analysis|Correlative studies
218968759|NCT00322101|GENETIC|cytogenetic analysis|Correlative studies
218968760|NCT00322101|OTHER|flow cytometry|Correlative studies
218968761|NCT00322101|GENETIC|fluorescence in situ hybridization|Correlative studies
218968762|NCT00322101|OTHER|pharmacological study|Correlative studies
218968763|NCT00322101|GENETIC|polymorphism analysis|Correlative studies
218968764|NCT00322101|DRUG|tacrolimus|Given IV or orally
218968765|NCT00322101|DRUG|methotrexate|Given IV
218968766|NCT03579576|DRUG|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
218968767|NCT04142593|OTHER||
218968768|NCT00003099|DRUG|Fenretinide|Daily for 14-28 days.
218968769|NCT00003099|DRUG|Tamoxifen Citrate|Daily for 14-28 days.
218968770|NCT00003099|OTHER|Placebo|Daily for 14-28 days
218968771|NCT00723931|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
218968772|NCT04948567|OTHER|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
218968773|NCT04948567|OTHER|split-dose of PEG|purgative for bowel preparation
218968774|NCT04483323|PROCEDURE|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
218968775|NCT04483323|PROCEDURE|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
218968776|NCT00328549|DRUG|Pegylated Interferon and Ribavirin|
218968777|NCT04350606|BIOLOGICAL|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
218968778|NCT03139097|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219208279|NCT06997705|BEHAVIORAL|Optimized VMS|Building on the Systematic Medical Visits (VMS) the Optimized VMS, optimizes these services for in-school and out-of-school adolescents by expanding availability of VMS services through community and facility platforms and building capacity of health workers to provide integrated services. Also the intervention will involve demand generation activities such as community sensitization.
219659382|NCT04853108|OTHER|Remote Monitoring of COVID-19|Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
219659383|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
219659384|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
219659385|NCT02802644|DRUG|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
219659386|NCT02802644|DRUG|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
219659387|NCT05039320|DIETARY_SUPPLEMENT|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
219659388|NCT05039320|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
218968779|NCT06851195|DEVICE|lower limb neuromuscular electrical stimulation|The study adopts a quasi-experimental design with convenience sampling. Data collection will be done through structured questionnaires. Patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. The experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. The control group will only participate in pulmonary rehabilitation exercises. Based on Hill et al. (2018), neuromuscular electrical stimulation should continue for 4 to 8 weeks. Questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, Modified Medical Research Council Dyspnea Scale, Manchester COPD Fatigue Scale,
218968780|NCT06851195|BEHAVIORAL|pulmonary rehabilitation exercises|The control group will only participate in pulmonary rehabilitation exercises
218968781|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B|Intervention group will receive a nutritional formula A and, after 1-week washout period, will receive a nutritional formula B
218968782|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A|Intervention group will receive a nutritional formula B and, after 1-week washout period, will receive a nutritional formula A
219208280|NCT05794932|DIAGNOSTIC_TEST|Stress test|"Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer"
219659389|NCT02791646|BEHAVIORAL|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
219659390|NCT02791646|BEHAVIORAL|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
219659391|NCT05260216|COMBINATION_PRODUCT|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
219659392|NCT05260216|COMBINATION_PRODUCT|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
219659393|NCT00622596|OTHER|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
219659394|NCT02433899|PROCEDURE|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
219659395|NCT02433899|PROCEDURE|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
219659396|NCT02433899|DRUG|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
219659397|NCT02433899|DRUG|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
219659398|NCT02433899|DRUG|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
219659399|NCT06536088|OTHER|Walking assesment|Spatiotemporal walking assessments are performed using the Gait Analyzer app (version 0.9.95.0) on a smartphone. Participants who can walk independently without assistance walk a 25-meter path at their normal speed, with the smartphone securely attached to their body above the third lumbar vertebra using a belt. The app records gait velocity, cadence, step time, step length, and vertical center of mass for all participants.
219659400|NCT01836809|DRUG|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
219659401|NCT01836809|DRUG|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
219659402|NCT01273155|DRUG|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
219659403|NCT00360802|BEHAVIORAL|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
219659404|NCT00360802|BEHAVIORAL|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
219659405|NCT02810171|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
219659406|NCT02810171|BEHAVIORAL|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
219659407|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
219659408|NCT00336323|PROCEDURE|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
219659409|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
219659410|NCT00336323|DRUG|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
219659411|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
219659412|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
219659413|NCT03017521|DRUG|TAS-117|TAS-117 16mg, daily
219659414|NCT01438814|DRUG|metformin placebo|metformin placebo tablets 500mg
219659415|NCT01438814|DRUG|linagliptin placebo|linagliptin placebo tablets 5mg
219659416|NCT01438814|DRUG|metformin|metformin tablets 500mg
219659417|NCT01438814|DRUG|metformin|metformin tablets 500 mg
219659418|NCT01438814|DRUG|linagliptin|linagliptin tablets 5mg
219659419|NCT02548923|DRUG|Dexmedetomidine|comparison to propofol
219659420|NCT01448863|OTHER|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
219659421|NCT01488396|DRUG|0.05%cyclosporin eye drop|use twice daily for 6 months
219659422|NCT06731712|OTHER|Physical Function Exercises|Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
219659423|NCT01666210|DRUG|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
219659424|NCT01666210|DRUG|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
219659425|NCT01715519|DRUG|Treatment (Viibryd)|
219659426|NCT05307718|DRUG|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
219659427|NCT06224036|DRUG|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
219659428|NCT06224036|DRUG|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
219659429|NCT06224036|DRUG|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
219659430|NCT01935713|DRUG|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
219659431|NCT01935713|DRUG|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
219659432|NCT01935713|DRUG|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, \>2 packs per day).
219659433|NCT05846113|DIAGNOSTIC_TEST|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
219659434|NCT02495818|PROCEDURE|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
219659435|NCT02495818|PROCEDURE|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
219659436|NCT02495818|OTHER|Homemade exercises|Codman and Hughston exercises.
219659437|NCT02234336|PROCEDURE|Noncontrast echocardiography|
219659438|NCT02234336|PROCEDURE|Contrast Echocardiography|
219659439|NCT02234336|PROCEDURE|Cardiac magnetic resonance imaging|
218968783|NCT02996734|PROCEDURE|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
219659440|NCT03322436|DIAGNOSTIC_TEST|HeartLinc kit|Samples are collected and analyzed afterwards
218968784|NCT03118973|PROCEDURE|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
218968785|NCT05211284|DRUG|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of treatment (24 weeks).
219064186|NCT03564496|DEVICE|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
218968786|NCT05211284|DRUG|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of treatment (24 weeks).
218968787|NCT04992624|DRUG|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
219064187|NCT03564496|DEVICE|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
219064188|NCT04989348|PROCEDURE|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
219064189|NCT04989348|PROCEDURE|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
219659441|NCT00609713|BEHAVIORAL|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
219659442|NCT00609713|OTHER|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
219659443|NCT05559684|PROCEDURE|Erector spinae plane block|Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
219659444|NCT05559684|PROCEDURE|Transversus thoracis plane block|Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
219064190|NCT02977624|BEHAVIORAL|The Cognitive Orientation to daily Occupational Performance|
219659445|NCT04309903|OTHER|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
219659446|NCT01957943|DIETARY_SUPPLEMENT|SMOFLipid|
219659447|NCT01957943|DIETARY_SUPPLEMENT|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
219659448|NCT04015752|DIAGNOSTIC_TEST|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
219659449|NCT04116606|DRUG|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
219659450|NCT04116606|DRUG|Placebo|Matching placebo containing the same excipients
218968788|NCT04992624|DRUG|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
219659451|NCT01711775|DRUG|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
219659452|NCT03593187|DRUG|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
219659453|NCT01440387|BIOLOGICAL|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
219659454|NCT00956605|BEHAVIORAL|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
219659455|NCT02690597|OTHER|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
219659456|NCT01870297|DRUG|LY3025876|Administered SQ
219659457|NCT01870297|DRUG|Placebo|Administered SQ
219659458|NCT01870297|DRUG|Liraglutide|Administered SQ
219659459|NCT04128124|OTHER|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
218968789|NCT04992624|DRUG|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
218968790|NCT04898114|DRUG|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
218968791|NCT04898114|DRUG|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
218968792|NCT04898114|OTHER|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
218968793|NCT03593161|BEHAVIORAL|Humor therapy|Clown visits
218968794|NCT06310044|OTHER|Root canal irrigant Commiphora Myrrh 50%|Root canal irrigant
219659460|NCT04760223|BEHAVIORAL|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
219659461|NCT05855408|BIOLOGICAL|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
219208281|NCT06810453|OTHER|A 5 cc venous blood sample was obtained|A 5 cc venous blood sample was obtained just before anesthesia induction and at the end of surgery.
219659462|NCT05855408|BIOLOGICAL|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
219659463|NCT05855408|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
219659464|NCT05855408|BIOLOGICAL|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
219659465|NCT05297110|DRUG|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
219659466|NCT04328610|PROCEDURE|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
219659467|NCT00441155|DRUG|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
219659468|NCT05571423|BEHAVIORAL|Medical Play|Study subject will be engage in the medical play.
219659469|NCT05571423|BEHAVIORAL|Routine Play|Study subject will be engage in the routine play (coloring exercise).
218968795|NCT05597670|OTHER|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
218968796|NCT05597670|OTHER|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
218968797|NCT05388396|OTHER|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
218968798|NCT03911843|DRUG|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
218968799|NCT03911843|DRUG|Vitamin D supplementation|Cholecalciferol 1000 IU/die
218968800|NCT04449471|DRUG|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
218968801|NCT05456945|OTHER|acupressure application|Acupressure will be applied to the UB32 point
218968802|NCT05456945|DEVICE|Shotblocher|Shotblocher will be administered during injection
218968803|NCT02142985|DRUG|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
218968804|NCT06515249|OTHER|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
218968805|NCT01907100|DRUG|Nintedanib|triple kinase inhibitor; 200mg starting dose
218968806|NCT01907100|DRUG|Pemetrexed|backbone chemo
218968807|NCT01907100|DRUG|Cisplatin|backbone chemo
218968808|NCT01907100|DRUG|Cisplatin|backbone chemo
219659470|NCT01004458|BEHAVIORAL|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
219659471|NCT01004458|OTHER|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
219659472|NCT00464555|PROCEDURE|Islet transplant|Transplantation of pancreatic islet cells
219659473|NCT00464555|DRUG|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
218968809|NCT01907100|DRUG|Pemetrexed|backbone chemo
218968810|NCT01907100|DRUG|Placebo|Nintedanib matching placebo
218968811|NCT01048489|BEHAVIORAL|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
218968812|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks \& 9 months
218968813|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks \& 9 months
218968814|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6\&14 weeks \& 9 months
218968815|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks \& 9 months
218968816|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks \& 9 months
218968817|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6\&14 weeks \& 9 months
218968818|NCT03464695|DEVICE|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
218968819|NCT02859506|OTHER|Respiratory quotient|
218968820|NCT02859506|OTHER|Olfactory liking|
218968821|NCT02914587|DEVICE|ARTAS System|
218968822|NCT02914587|OTHER|Manual Implantation|
218968823|NCT01863810|DRUG|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
218968824|NCT01863810|DRUG|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
218968825|NCT01863810|DRUG|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
218968826|NCT01863810|DRUG|Placebo of KW21052|Oral,once a day, for 8 weeks
218968827|NCT01863810|DRUG|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
218968828|NCT01466777|PROCEDURE|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
219659474|NCT00464555|DRUG|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
219659475|NCT00464555|DRUG|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
219659476|NCT00464555|DRUG|Sirolimus|Maintenance immunosuppressive therapy
219659477|NCT00464555|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
219659478|NCT04341558|OTHER|Family supplemented patient monitoring|Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
219659479|NCT05133258|OTHER|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
219659480|NCT02926417|PROCEDURE|High Density-Electroencephalogram|
219659481|NCT04408508|DRUG|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
219659482|NCT00337779|DRUG|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
219659483|NCT00337779|DRUG|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
219659484|NCT04298034|DRUG|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
219659485|NCT01512459|DRUG|Venlafaxine|Venlafaxine MR Capsules 150 mg
219659486|NCT00542100|DEVICE|PCMRI|
219659487|NCT05849506|DEVICE|Touch® Prosthesis|The Touch® prosthesis is a medical device approved in Switzerland, which is an effective surgical treatment for advanced CMC I osteoarthritis.
219659488|NCT03107975|BIOLOGICAL|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
219659489|NCT01544192|DRUG|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
219659490|NCT01544192|DRUG|α-tocopherol|2x300 mg α-tocopherol
219659491|NCT01544192|DRUG|Placebo|control group did not receive oral neuroprotective agent
219659492|NCT01544192|DRUG|Antioxidant formula|2x1 tablet AOF
219659493|NCT03932929|DEVICE|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
219659494|NCT00570180|DRUG|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
219659495|NCT03008278|DRUG|Olaparib|Give PO
219659496|NCT03008278|BIOLOGICAL|Ramucirumab|Given IV
219659497|NCT04283526|DRUG|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
219659498|NCT04283526|DRUG|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
219659499|NCT04283526|DRUG|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
218968829|NCT01466777|PROCEDURE|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
218968830|NCT02059005|BEHAVIORAL|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
219659500|NCT04283526|DRUG|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
219659501|NCT01126866|DRUG|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
219659502|NCT05775926|OTHER|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
219659503|NCT00819572|BIOLOGICAL|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
219659504|NCT00819572|DRUG|Placebo|
219659505|NCT00513357|DRUG|Melatonin|20 mg by mouth daily for 4 Weeks
219659506|NCT00513357|DRUG|Placebo|Capsule by mouth daily for 4 Weeks
219659507|NCT02897167|GENETIC|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
219659508|NCT02897167|GENETIC|Prospective study of fresh samples|Samples of serum and cells will be drawn.
219659509|NCT01162122|BIOLOGICAL|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
218968831|NCT02059005|BEHAVIORAL|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
218968832|NCT05037968|DEVICE|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
218968833|NCT05037968|DEVICE|Trinity Elite|Procedure: Instrumented Posterolateral Lumbar Fusion
218968834|NCT06799026|DRUG|Elranatamab|Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.
218968835|NCT06799026|BIOLOGICAL|GM-CSF|Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.
218968836|NCT06799026|BIOLOGICAL|DC/MM Fusion Vaccine|Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.
218968837|NCT02650427|DRUG|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
219659510|NCT01162122|BIOLOGICAL|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
219659511|NCT02262416|DRUG|leuprolide|normal saline
219659512|NCT00088816|DRUG|cisplatin|
219659513|NCT00088816|DRUG|tegafur-gimeracil-oteracil potassium|
219659514|NCT00088816|PROCEDURE|adjuvant therapy|
219659515|NCT00088816|PROCEDURE|conventional surgery|
219659516|NCT00088816|PROCEDURE|neoadjuvant therapy|
219659517|NCT01001806|DRUG|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
219659518|NCT01001806|DRUG|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
219659519|NCT01001806|DRUG|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
219659520|NCT04460131|DIAGNOSTIC_TEST|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
219659521|NCT00753844|BIOLOGICAL|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
219659522|NCT05282589|OTHER|lumbopelvic manipulation and conventional therapy|"Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
219659523|NCT05282589|OTHER|conventional therapy|"Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
219659524|NCT00546494|DRUG|Effexor® (Venlafaxine)|
219659525|NCT04949763|OTHER|rehabilitation|Patients underwent ususal rehabilitation treatment
219659526|NCT00422422|DRUG|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5"
219659527|NCT01758718|PROCEDURE|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
219659528|NCT01635309|OTHER|Coronary CT Angiogram|pre-operative coronary CTA
219659529|NCT06073756|RADIATION|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
219659530|NCT02928601|DRUG|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
218968838|NCT06553326|DEVICE|EndoStyle|The EndoStyle system is able to transform the style of the different video-processor images.
218968839|NCT04042298|OTHER|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
218968840|NCT04042298|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
218968841|NCT04042298|OTHER|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
218968842|NCT04042298|OTHER|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
218968843|NCT05725499|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
219659531|NCT02928601|DRUG|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
219659532|NCT05721183|BEHAVIORAL|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
219659533|NCT01529294|DRUG|Iloperidone|
219659534|NCT06311526|OTHER|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
219659535|NCT00019630|DRUG|doxorubicin HCl liposome|
219659536|NCT04535128|OTHER|No intervention|No intervention
219659537|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
219659538|NCT02454868|DRUG|Remifentanil|Remifentanil for intubation without neuromuscular blockade
219659539|NCT01527708|PROCEDURE|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
219659540|NCT03313310|BEHAVIORAL|Employment Intervention|Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
219659541|NCT02453659|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
219659542|NCT02453659|BEHAVIORAL|Health Education (HE)|
219659543|NCT02453659|BEHAVIORAL|Smoking Cessation counseling|
219659544|NCT02453659|DRUG|Transdermal Nicotine Patch|
219659545|NCT05187559|OTHER|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
219659546|NCT05187559|DEVICE|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
219659547|NCT00912106|OTHER|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
219659548|NCT04786171|DIAGNOSTIC_TEST|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
219659549|NCT01756508|DRUG|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
219659550|NCT00898495|GENETIC|loss of heterozygosity analysis|
219659551|NCT00898495|GENETIC|polymerase chain reaction|
219659552|NCT00898495|GENETIC|polymorphism analysis|
219659553|NCT03029845|DRUG|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
219659554|NCT03029845|DRUG|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
219659555|NCT03029845|DRUG|Placebo|Participants will take placebo twice a day for 2 weeks
219659556|NCT05463757|DRUG|Vismodegib|Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
219659557|NCT05463757|DRUG|Sonidegib|Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
218968844|NCT05725499|DIAGNOSTIC_TEST|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
219659558|NCT06094894|OTHER|sucralose|Food additive used to replace sugar providing a sweet taste without calories.
219659559|NCT06094894|OTHER|placebo|Cornstarch without significant physiological effects
219659560|NCT02171013|DRUG|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
218968845|NCT04619225|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
218968846|NCT05749770|OTHER|blood testing|blood testing for basal hormones and markers of inflammation
218968847|NCT02142803|BIOLOGICAL|Bevacizumab|Given IV
219659561|NCT02171013|DRUG|Dabigatran polymorph I|
219659562|NCT01217385|PROCEDURE|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
219659563|NCT00090987|DRUG|imatinib mesylate|400 mg orally once a day for up to 6 months.
219659564|NCT01060878|DRUG|PYM50028|IMP
219659565|NCT01060878|DRUG|Placebo|Matching placebo comprising identical vehicle to active doses
219659566|NCT04788225|OTHER|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
219659567|NCT04788225|OTHER|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
219659568|NCT04788225|OTHER|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
219659569|NCT04788225|OTHER|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
219659570|NCT04053985|COMBINATION_PRODUCT|TAI combine lenvatinib|TAI combine lenvatinib
219659571|NCT04053985|DRUG|Lenvatinib|lenvatinib only
219659572|NCT00370981|DRUG|pagoclone|
219659573|NCT01637766|DRUG|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
219659574|NCT04441684|DIAGNOSTIC_TEST|Blood sample for serological test|"Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
219659575|NCT05998434|BEHAVIORAL|Improving Low Back Pain Through Motor Control Training|In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.
219659576|NCT06354205|DIAGNOSTIC_TEST|Sliva Procalcitonin|Sliva Procalcitonin vs Blood procalcitonin
219659577|NCT01825239|OTHER|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
219659578|NCT05213026|PROCEDURE|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
219659579|NCT03825185|PROCEDURE|Transcervical Thymectomy|Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.
219659580|NCT03825185|PROCEDURE|Transsternal Thymectomy|Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
219659581|NCT01718145|DRUG|Daclatasvir|
219659582|NCT01718145|DRUG|Asunaprevir|
219659583|NCT01718145|DRUG|Ribavirin|
219659584|NCT01718145|BIOLOGICAL|pegIFNα-2b|
219659585|NCT01718145|DRUG|Telaprevir|
219659586|NCT00757185|DRUG|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
219659587|NCT00757185|DRUG|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
219659588|NCT03370523|OTHER|No intervention is planned in our study|No intervention is planned in our study
218968848|NCT02142803|OTHER|Laboratory Biomarker Analysis|Correlative studies
218968849|NCT02142803|OTHER|Pharmacological Study|Correlative studies
218968850|NCT02142803|DRUG|Sapanisertib|Given PO
218968851|NCT01298544|PROCEDURE|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
218968852|NCT02900560|DRUG|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
219659589|NCT03794505|DRUG|Methylprednisolone Acetate|depo-medrol 40 mg
219659590|NCT03794505|DRUG|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
219659591|NCT03794505|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
219659592|NCT03463707|DRUG|BP101|Investigational product BP101, nasal spray
219659593|NCT03463707|DRUG|Placebo|Placebo to Investigational product BP101, nasal spray
218968853|NCT02900560|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
219659594|NCT03290547|DEVICE|Cutera enLighten laser|Subjects will receive laser treatments.
218968854|NCT04929379|DRUG|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
218968855|NCT04929379|OTHER|Placebo|Inactive tablets identical to fenofibrate
218968856|NCT05950503|RADIATION|Hepatic MRI|The patients will undergo hepatic MRI in pre-established timepoints
218968857|NCT06224673|DRUG|ARX788|Given IV
218968858|NCT06224673|PROCEDURE|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
218968859|NCT06224673|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218968860|NCT06224673|DRUG|Amiloride|Ophthalmologic drops given topically to participants for an eye toxicity substudy
218968861|NCT04050917|DEVICE|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
218968862|NCT04050917|DEVICE|no stimulation|The smartwatch generates no stimulation.
218968863|NCT02196571|OTHER|Structured Exercise|
218968864|NCT00657904|DRUG|Bicalutamide|150mg daily
218968865|NCT00657904|DRUG|Placebo|once daily
218968866|NCT04321096|DRUG|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
218968867|NCT04321096|DRUG|Placebo oral tablet|Placebo
218968868|NCT07119840|DRUG|Listerine Mouthwash Product|Participants in this group will receive Listerine mouthwash containing essential oils (menthol, thymol, eucalyptol, and methyl salicylate). They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
219659595|NCT03545646|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
218968869|NCT07119840|DRUG|Chlorhexidine mouthwash|Participants in this group will receive Chlorhexidine mouthwash at a concentration of 0.12%. They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
219659596|NCT02285543|DRUG|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
219659597|NCT02285543|PROCEDURE|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
219659598|NCT02285543|RADIATION|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
219659599|NCT06649123|DIAGNOSTIC_TEST|Oricol Test|Assessment of diagnostic accuracy of Oricol Sampling device for triage in patients with suspected lower gastrointestinal cancer
218968870|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
218968871|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
218968872|NCT06059547|DRUG|Placebo|Placebo (NaCl) for Visugromab (CTL-002)
218968873|NCT02718300|DRUG|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
218968874|NCT02718300|DRUG|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
218968875|NCT02718300|DRUG|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
218968876|NCT02718300|DRUG|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
218968877|NCT02718300|DRUG|Parsaclisib|"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
219064191|NCT01159938|DRUG|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
219659600|NCT04096443|BIOLOGICAL|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
219659601|NCT03067675|DEVICE|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
219659602|NCT01058759|DRUG|Enoxaparin|
219659603|NCT01058759|OTHER|No Enoxaparin|
219659604|NCT01605032|DRUG|Busulfan|Given IV
219659605|NCT01605032|DRUG|Melphalan|Given IV
219659606|NCT01605032|DRUG|Bortezomib|Given IV
219659607|NCT01605032|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
219659608|NCT01605032|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
219659609|NCT06400706|PROCEDURE|EEG guided general anesthesia|EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
219659610|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
219659611|NCT02222441|DRUG|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
219659612|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
218968878|NCT06276530|OTHER|EOS imaging for musculoskeletal disorder|The patients will have a low radiation 2D/3D biplane imaging of the rib cage, and spine before and after surgery.
218968879|NCT06276530|OTHER|Movement analysis by an optoelectronic camera.|Movement analysis by an optoelectronic camera before and after surgery.
218968880|NCT06276530|OTHER|Stabilometric measurement by strength platform|Stabilometric measurement by strength platform before and after surgery.
218968881|NCT06813690|DEVICE|Cold Therapy with Axanova Cold Hot Pearls Maxi Pack|This intervention involves the application of the Axanova Cold Hot Pearls Maxi Pack, a cooling device designed to provide targeted cold therapy. The device will be used to cool both thighs for 20-minute sessions, three times per day, following a muscle soreness protocol. The cold therapy aims to reduce inflammation, swelling, and muscle pain associated with Delayed Onset Muscle Soreness (DOMS). The intervention begins immediately after completing the muscle soreness protocol in Group A, and 24 hours later in Group B. Participants will receive cooling treatment for a total of 72 hours, with temperature and duration carefully monitored to ensure effective cooling.
219064192|NCT02126293|DRUG|Zinc Supplement|
219659613|NCT02222441|DRUG|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
219659614|NCT05582369|BEHAVIORAL|Affective Rewards Messages|Messages about the affective rewards of exercise
219659615|NCT05583500|OTHER|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
219659616|NCT01100892|DRUG|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
219659617|NCT05572177|DEVICE|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
219659618|NCT01686698|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
219659619|NCT01686698|OTHER|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
219659620|NCT04939753|DRUG|Sevoflurane|Sevoflurane administration to sedate the patient
219659621|NCT04403659|DEVICE|Telemedicine/telemonitoring (TM) suite|"The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured."
219659622|NCT03866733|OTHER|continous erector spinea block|Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
219659623|NCT03866733|DRUG|intravenous narcotics|intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
219659624|NCT01731470|BIOLOGICAL|Liposomes|Intravesical instillation of liposomes.
219659625|NCT04486469|OTHER|Physical Therapy Group|"1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
219659626|NCT01541670|DRUG|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
219659627|NCT01205074|DEVICE|13C Methacetin Breath Test|
219659628|NCT01205074|DIETARY_SUPPLEMENT|Grape fruit juice|
219659629|NCT01205074|DRUG|Non selective beta blocker - Propranolol|
219659630|NCT01205074|DIETARY_SUPPLEMENT|Ethanol|
219659631|NCT04134520|DEVICE|ProLung System|Non-invasive bioconductance measurements
219659632|NCT05365269|BEHAVIORAL|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
219659633|NCT05103839|BEHAVIORAL|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
219659634|NCT05842005|DEVICE|Mesh-reduced Sling|In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
219659635|NCT06619886|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R248Q|TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
219659636|NCT01546597|DRUG|Metformin|"* Metformin 500 mg bid on Days 1-5~* Metformin 850 mg bid on Days 6-10~* Metformin 500 mg bid on Days 11-15~* Metformin 850 mg bid on Days 16-20"
219659637|NCT01546597|DRUG|Ranolazine|"* Ranolazine 1000 mg bid on Days 11-15~* Ranolazine 1000 mg bid on Days 16-20"
219659638|NCT01592292|DRUG|Rituximab|Rituximab as per physician's discretion.
219659639|NCT01592292|DRUG|Adalimumab|Adalimumab as per physician's discretion.
219659640|NCT01592292|DRUG|Etanercept|Etanercept as per physician's discretion.
219659641|NCT01592292|DRUG|Infliximab|Infliximab as per physician's discretion.
219659642|NCT02598011|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
219659643|NCT02598011|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
219659644|NCT04738136|DRUG|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
219659645|NCT00670605|OTHER|medical chart review|
219659646|NCT00670605|OTHER|study of socioeconomic and demographic variables|
219659647|NCT01521156|OTHER|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
219659648|NCT01521156|OTHER|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
219659649|NCT02624245|OTHER|Conventional Physical Therapy|
219659650|NCT04300452|DRUG|Carbetocin|Administration of Carbetocin after placental detachment
219659651|NCT04300452|DRUG|Ergometrine Maleate|Administration of ergometrin after placental detachment
219659652|NCT04582500|DRUG|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
219659653|NCT02490462|OTHER|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
219659654|NCT02490462|OTHER|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
219659655|NCT03751800|DRUG|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
219659656|NCT00825656|DRUG|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
219659657|NCT02106416|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
218968882|NCT03836976|OTHER|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
218968883|NCT06810999|OTHER|From Fear to Purpose (Acceptance and Commitment Therapy)|The From Fear to Purpose ACT Protocol is based on Acceptance and Commitment Therapy (ACT) strategies, build around identifying and committing to personal values. The intervention will be group-based (90 minutes session).
219659658|NCT02595281|OTHER|Experimental arm|"Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy"
219659659|NCT05439616|DRUG|Cariprazine|Oral Capsules or Oral Solution
219659660|NCT05439616|DRUG|Placebo|Oral capsules or Oral Solution
219659661|NCT07027735|OTHER|Rotator Cuff Repair with Allograft Patch|Rotator cuff repairs will be augmented with use of a decellularized human placental allograft patch
219659662|NCT07027735|OTHER|Rotator Cuff Repair with No Augmentation|Standard rotator cuff repair with no augmentation
218968884|NCT06810999|OTHER|Placebo|The placebo condition consists of a group-based attentional control intervention.
218968885|NCT06605027|OTHER|Therapeutic Ketogenic Diet|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
218968886|NCT05132439|DRUG|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
218968887|NCT05132439|DRUG|placebo|Matched to active study drug
218968888|NCT01996046|OTHER|FDG PET/CT scan|\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
218968889|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
218968890|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
218968891|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
218968892|NCT03120624|OTHER|Pharmacological Study|Correlative studies
218968893|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
218968894|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
218968895|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
218968896|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
218968897|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
218968898|NCT04169347|DRUG|Oxaliplatin|2 week cycles
218968899|NCT06216015|OTHER|Exercise training|"Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each."
218968900|NCT06216015|OTHER|Continue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
218968901|NCT06216015|OTHER|Discontinue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
218968902|NCT06147037|DRUG|FPI-2053|FPI-2053 is a bispecific antibody that targets EGFR and cMET
219659663|NCT03080766|DRUG|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
219659664|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
219659665|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
219659666|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
219659667|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
219659668|NCT03715231|OTHER|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
219659669|NCT03715231|OTHER|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
218968903|NCT06147037|DRUG|[111In]-FPI-2107|"\[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
218968904|NCT06147037|DRUG|[225Ac]-FPI-2068|"\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
218968905|NCT03315910|BEHAVIORAL|Motivational Interviewing (MI)|two counseling sessions
218968906|NCT03315910|DRUG|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
218968907|NCT03315910|DRUG|Nicotine Lozenge|6 packs of NRT 2mg lozenge
218968908|NCT03315910|BEHAVIORAL|Message Framing|health communication literature and quitting messages
218968909|NCT03315910|OTHER|saliva sample|saliva samples from those reporting abstinence and analyze samples
219659670|NCT01451944|BEHAVIORAL|education|home asthma case management and education
219659671|NCT01876979|DEVICE|IMF Screws|stainless steel screws placed in bone
219659672|NCT01876979|DEVICE|Erich Arch Bars|Surgical braces wired around teeth
219659673|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
219659674|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
219659675|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
219659676|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
219659677|NCT06890637|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
219659678|NCT06890637|OTHER|Crohns Disease Exclusion Diet|The modified diet plan will be given to each study participant
219659679|NCT06890637|OTHER|Sham transplantation|Sham transplantation will involve saline infusion via colonoscopy
219659680|NCT06890637|OTHER|Sham Diet|Dietary counselling alone
219659681|NCT06890637|OTHER|Advanced therapy|Advanced therapy as standard dose and schedule
218968910|NCT07130552|DEVICE|femoral triangle block and popliteal plexus block|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for PPB
219659682|NCT06828445|BEHAVIORAL|Veggie Vouchers|"Caregivers will receive brief education about a SNAP fruit and vegetable incentive program in South Carolina during their child's pediatrician visit. Following the visit, caregivers will receive a free trial of this SNAP program to encourage first-time use. After the free trial, caregivers can continue purchasing the same fruit and vegetable boxes at a steeply discounted price using their SNAP card. Free home delivery during the free trial and for all subsequent boxes purchased at a discounted rate will be offered during the full study duration."
219659683|NCT06375616|DRUG|Nafamostat Mesylate|During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
218968911|NCT07130552|DEVICE|Femoral triangle block and distal iPACK|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for distal iPACK
218968912|NCT05079516|OTHER|Theta burst transcranial magnetic stimulation|Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
218968913|NCT05564091|DEVICE|Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device|360 degree microcatheterization and viscodilation of Schlemm's canal
219064193|NCT02126293|PROCEDURE|Repeat blood and urine tests|
219064194|NCT03914157|DEVICE|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
219659684|NCT06375616|DRUG|Unfractionated Heparin|During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
218968914|NCT05564091|PROCEDURE|Cataract surgery|Cataract surgery alone
218968915|NCT05642039|BEHAVIORAL|Mindfulness Course|Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.
219064195|NCT02638662|OTHER|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
219064196|NCT05864794|DIAGNOSTIC_TEST|MRI|MRI scan of the brain
219064197|NCT00169169|DRUG|ACVBP|
219064198|NCT00169169|DRUG|ACE|
219659685|NCT05171634|DEVICE|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
219659686|NCT05171634|DEVICE|iSCAN|Virtual colonoscopy assisted by iSCAN
218968916|NCT05642039|BEHAVIORAL|HS Educational Course|Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.
218968917|NCT06619366|OTHER|coach-guided personalized depression risk communication|see information in arm description.
218968918|NCT06619366|OTHER|depression risk information|see information in arm description.
218968919|NCT06622889|OTHER|Multidomain Intervention Program|The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.
218968920|NCT04799535|PROCEDURE|Ultrasound|Undergo breast ultrasound
219064199|NCT00169169|DRUG|rituximab|
219064200|NCT00169169|PROCEDURE|Autologous stem cell transplant|
219064201|NCT01625429|DRUG|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
219064202|NCT03214497|DEVICE|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
219064203|NCT03214497|DEVICE|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
219064204|NCT05073016|OTHER|neuromodulation|neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.
219064205|NCT05073016|OTHER|motor learning training|motor learning training requires performing a sequential training called finger taping task
219659687|NCT05308602|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
219659688|NCT05308602|BIOLOGICAL|SCTV01C|Day 28; intramuscular injection
219659689|NCT05308602|BIOLOGICAL|SCTV01C|Day 180; intramuscular injection
219659690|NCT05308602|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
219659691|NCT05308602|BIOLOGICAL|SCTV01E|Day 28; intramuscular injection
219659692|NCT05308602|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
219659693|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 0; intramuscular injection
219659694|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 28; intramuscular injection
219659695|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 180; intramuscular injection
219659696|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
219659697|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 28; intramuscular injection
219659698|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 180; intramuscular injection
219659699|NCT03366324|GENETIC|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
219659700|NCT03366324|PROCEDURE|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
219659701|NCT01786824|DRUG|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
219659702|NCT01786824|DRUG|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
219659703|NCT01786824|DRUG|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
219659704|NCT01786824|PROCEDURE|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
219659705|NCT03660475|DRUG|Naltrexone|naltrexone formulated as ophthalmic solution
219659706|NCT03660475|DRUG|Placebos|Placebo ophthalmic solution
219659707|NCT00948506|DRUG|1% topical cidofovir|1% topical cidofovir
219659708|NCT00948506|DRUG|3% topical cidofovir|3% topical cidofovir
218968921|NCT06076005|OTHER|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
218968922|NCT03098628|BIOLOGICAL|PCV Vaccine|PCV vaccination
218968923|NCT06694285|DIAGNOSTIC_TEST|Ultrasound evaluation|The subjects will constitute a cohort whose medical history, clinical, ultrasound and treatment data reported in the appropriate data collection form will be prospectively collected. Enrolled patients will undergo clinical and ultrasonographic evaluation in a manner not unlike routine clinical practice.
218968924|NCT06630039|OTHER|Scale validity and reliability|The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
218968925|NCT05541250|BIOLOGICAL|Autologous Human Schwann Cell|A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
218968926|NCT06683118|DEVICE|Rapamycin neurovascular Balloon Catheter|Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
218968927|NCT06683118|DEVICE|Conventional Balloon|Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis
218968928|NCT06884657|DRUG|mannitol|2.5 mg/kg Mannitol will be given intravenously
218968929|NCT06884657|OTHER|Saline|2.5 ml/kg saline will be given as plasebo
218968930|NCT07050368|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
218968931|NCT07050368|DRUG|Placebo|Capsule with no active ingredients
219659709|NCT00948506|DRUG|Placebo|topical placebo
219659710|NCT04445506|DRUG|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
219659711|NCT06392854|DRUG|Insulin|2 dose insulin infusion 4 hours
219659712|NCT06766656|PROCEDURE|Incision|"The pocket for the vascular port is made through a small incision in the skin in the subclavicular area. The skin incision can be made transversely or longitudinally"
219659713|NCT06861062|DRUG|Vitamin D3|Vitamin D3(cholecalciferol),1600 IU per day.
219659714|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan|yeast β-glucan, 600mg per day.
219659715|NCT06861062|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
219659716|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan placebo|yeast β-glucan placebo
219659717|NCT06860932|BEHAVIORAL|Palliative care video comprises the conversation and advance directives.|The palliative care video was done in a way that facilitates discussion and minimizes anxiety or any psychological risk/burden. The video is narrated by a young adult who opens with an empathic statement regarding the situation the young adult/adult patient finds themselves in. Then, there is a transition to contemplating what the future might hold and decisions about medical care and introducing the concept of ACP. There is acknowledgment that decision making is difficult, and that the presence of caregivers often helps. There is an explicit statement regarding values and spiritual beliefs and how that might impact decision making. The video then attempts to translate the preceding conversation into actionable medical orders using the most common three-goal framework that is based on the Physician Orders for Life Sustaining Treatment (POLST) paradigm: life-prolonging care, limited/blended care and comfort care.
219659718|NCT06860932|BEHAVIORAL|Palliative care written material|Written materials about palliative care conversation and advance directives.
219659719|NCT06864169|BIOLOGICAL|Raludotatug Deruxtecan (R-DXd)|Administered via intravenous (IV) infusion.
219659720|NCT06894368|BEHAVIORAL|UP-A|The intervention is a group adaptation of the Spanish version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018, 2020, 2022). It consists of 16 weekly 90-minute sessions held in person at a public Mental Health Center. The intervention also includes three in-person group sessions for parents, each lasting one hour, held at the beginning, middle, and end of the program. These sessions cover content from the therapist's guide, including the Parent Module (Parenting the Emotional Adolescent), and provide a space for questions and emotional support.
219659721|NCT06894914|BEHAVIORAL|24-hour Activity Counselling|"Physiotherapists will participate in the self-paced brief action planning (BAP) online training (2-4 hours long), followed by 2-3 hours of practice and feedback over the phone with an experienced BAP instructor. In addition, they will attend a 2-hour session with the research team on training around on prescribing physical activity while balancing with rest and sleep.~Once training is complete the PT can start implementing the counselling approach with the older adult patients."
219659722|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
219659723|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
219659724|NCT06741644|DRUG|Pemetrexed|IV infusion
218968932|NCT06736171|DEVICE|Robotic Exoskeleton|EksoNR, Ekso Bionics, San Rafael, CA, USA Atalante X, Wandercraft, Paris, France ReStore™, Lifeward Inc, Marlborough, MA
218968933|NCT06736171|OTHER|SOC|Standard of Care
218968934|NCT06743477|OTHER|Supergraft|This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.
218968935|NCT07056634|BEHAVIORAL|Active Nature Engagement|Participants in this group will walk at a comfortable pace for 30 minutes in an urban park, three times per week for four weeks. They will be guided to focus on their surroundings using a grounding exercise (e.g., noticing sights, sounds, and smells) and instructed not to use mobile phones or listen to music during the walk.
218968936|NCT07056634|BEHAVIORAL|Passive Nature Engagement|Participants in this group will sit quietly for 30 minutes in a designated spot within an urban park, three times per week for four weeks. They will engage in grounding exercises and draw aspects of the natural environment. Participants will be instructed not to use mobile phones or listen to music during the walk.
218968937|NCT07056634|BEHAVIORAL|Indoor Exercise|Participants will be asked to walk on a treadmill in an indoor room without windows for 30 minutes. The treadmill will be set to the speed that match the average pace in nature walk group (approximately 3 km/hr). The speed could be adjusted by the participant if needed, but kept within the range of 2.6 km/hr to 4.6 km/hr. Participants will be asked to not use their phones or listen to music.
218968938|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist/delegated staff as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
218968939|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
218968940|NCT07135843|BEHAVIORAL|Digital exercise program|KOKU is a digital adaptation of the evidence based Otago Exercise Program and Falls Management Exercise program, both designed to improve strength, balance, and reduce fall risk in older adults. KOKU includes 26 balance and strength exercises of varying difficulty. Each exercise is accompanied by written and audio instructions for safe performance and is demonstrated by a virtual trainer. Training sessions consist of three exercises suggested by the KOKU app, which participants are encouraged to perform for as many repetitions as possible until fatigue. Progression is guided by the participant's subjective assessment of effort and difficulty. Participants may choose to perform any exercise at any time, regardless of the app-suggested sequence. The KOKU app also provides reminders to exercise if no activity is detected for two days.
218968941|NCT07135843|BEHAVIORAL|Personal coaching for physical activity promotion|Personal coaching consists of three video calls conducted via the study tablet by staff trained in BCTs and motivational communication skills. Participants receive a low cost, wrist worn activity tracker during the initial home visit to support self-monitoring and provide feedback on PA behavior. The first virtual coaching session (week 2) focuses on goal setting and action planning, the second session (week 3) addresses identification and management of barriers, and the third session (week 12) serves as a booster to review and adjust activity goals for the post intervention period.
218985423|NCT01440452|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
218985424|NCT01440452|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
219659725|NCT06741644|DRUG|Carboplatin|IV infusion
219659726|NCT06741644|DRUG|Paclitaxel|IV infusion
219659727|NCT06741644|DRUG|Etoposide|IV infusion
219659728|NCT06741644|DRUG|Nab-paclitaxel|IV infusion
219659729|NCT06741644|DRUG|Oxaliplatin|IV infusion
219659730|NCT06741644|DRUG|Capecitabine|oral tablets
219659731|NCT04008940|DEVICE|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
219659732|NCT07074977|DRUG|nemolizumab|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
219659733|NCT07074977|DRUG|Placebo|Participants will receive matching placebo as SC injection.
218968942|NCT07149779|OTHER|Exercise|A total of 20 kickboxers between the ages of 20-26, healthy, and actively involved in this branch for at least 4 years participated in the study. The volunteers participating in the study were randomly divided into two groups as the study and control groups. The study group applied calisthenic strength exercises in addition to routine kickboxing technical training for 8 weeks and 3 days a week, while the control group continued only their weekly routine kickboxing training without applying any strength training. Static strength performance (grip-leg-back), dynamic strength performance (1RM bench press and 1RM barbel squat), 30-second push-ups and 30-second sit-ups tests were applied to the athletes participating in the study before and after the 8-week training.
219659734|NCT06927804|PROCEDURE|Virtual reality intervention|A virtual reality device will be used in one study arm during the implantation of the subcutaneous port.
219659735|NCT06927804|PROCEDURE|Standard Care (in control arm)|Patients in this study arm will receive standard care, without the use of VR.
219659736|NCT07132918|RADIATION|MRgART|Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
219659737|NCT07132918|RADIATION|LINAC|Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.
219659738|NCT04847453|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
219659739|NCT04847453|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219659740|NCT04847453|PROCEDURE|Computed Tomography|Undergo CT scan
219659741|NCT04847453|DRUG|Dexamethasone|Given PO
219659742|NCT04847453|PROCEDURE|Echocardiography Test|Undergo ECHO
219659743|NCT04847453|DRUG|Ixazomib Citrate|Given PO
219659744|NCT04847453|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219659745|NCT04847453|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219659746|NCT04847453|PROCEDURE|Transabdominal Ultrasound|Undergo transabdominal ultrasound
219659747|NCT04847453|DRUG|Venetoclax|Given PO
218968943|NCT07149961|DIETARY_SUPPLEMENT|Curcumin plus Piperine|A loading dose of 2 capsules (each containing 390 mg curcumin + 20 mg piperine) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized curcumin extract (390 mg) combined with piperine (20 mg), given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI). The curcumin-piperine formulation is used to enhance bioavailability and anti-inflammatory effects, aiming to improve post-MI recovery and reduce oxidative stress.
218968944|NCT07149961|OTHER|Placebo capsules|A loading dose of 2 capsules (each containing saccarum lactic) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized placebo capsule, given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
218968945|NCT07150221|DEVICE|Vivacit-E Elevated Liners|Primary total hip arthroplasty
218968946|NCT07150507|OTHER|Session 1: Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
219064206|NCT02942199|OTHER|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
218968947|NCT07150507|OTHER|Session 2: Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
218968948|NCT07150507|OTHER|Session 3: Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
219659748|NCT04847453|PROCEDURE|X-Ray Imaging|Undergo x-ray
219659749|NCT07076433|OTHER|Core Stability Exercises|Participants will engage in core stability exercises targeting the muscles of the trunk and pelvis, such as pelvic tilting, abdominal crunches, back extension, side bridges, and bird dog. These exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The intensity will be progressively increased based on individual tolerance.
219659750|NCT07076433|OTHER|Pilates:|Participants will undergo Pilates sessions that emphasize flexibility, posture, and core engagement. Pilates exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The focus will be on breathing, spinal alignment, and strengthening exercises that challenge flexibility and balance.
219659751|NCT07078877|OTHER|home based exercise|The conventional home based exercise program includes: hip and knee range of motion (ROM) exercises; stretching exercises for the hamstring, calf, and quadriceps muscles; isometric, concentric, and eccentric strengthening exercises for the quadriceps, hamstrings, and hip adductors/abductors; relaxation exercises; and walking as aerobic exercises. The program will begin with ROM, stretching, relaxation, aerobic, and isometric strengthening exercises. After one week, concentric and eccentric strengthening exercises will be added using elastic bands. The home exercise program will be performed 3 days a week, each exercise in 3 sets of 10 repetitions and 2 minutes of rest between sets. Aerobic walking at a moderate pace (as determined by the talk test: the patient can talk but not sing during exercise) for 30 minutes will be recommended. Program will continue for 12 weeks.
219659752|NCT07078877|DEVICE|Low Level Laser Therapy|Patients will receive LLLT treatment, they will be treated in a supine position with the knee flexed to 30 degrees, 5 sessions per week for 2 weeks. A total of 6 points will be treated each for 60 seconds. The treatment will be applied using the BTL SMART 4000 laser device at a wavelength of 835 nm and a dose of 10 J/point.
219659753|NCT03233204|DRUG|Olaparib|Given PO
219659754|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
219659755|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
219659756|NCT04173104|DIAGNOSTIC_TEST|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
219659757|NCT04173104|DRUG|[18F]PARPi|Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
219659758|NCT06785051|BEHAVIORAL|AI-based physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises guided by AI technology, 30 minutes of intervention, once a week, and a total of 12 weeks
219659759|NCT06785051|BEHAVIORAL|Conventional physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises, 30 minutes of intervention, once a week, and a total of 12 weeks
219659760|NCT06785051|BEHAVIORAL|Scar management|scar massage and jaw-mobilizing exercises combined with devices or depressors
219659761|NCT06751563|BEHAVIORAL|Behavioral Text Messages and Produce Box Delivery|Participants will receive a produce box delivered weekly to the participants home customized based on the participants cooking preferences and household size. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on participant goal attainment and daily responses.
219659762|NCT06751563|BEHAVIORAL|Behavioral Text Message Program and Produce Voucher|Participants will receive a weekly produce voucher redeemable at a local market vendor for fresh produce of the participant's choice. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on goal attainment and daily responses.
219659763|NCT05983198|DRUG|225Ac-PSMA-R2|PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
219659764|NCT05983198|RADIATION|68Ga-PSMA-R2|Kit for radiopharmaceutical preparation
219659765|NCT05983198|RADIATION|68Ga-PSMA-11|Kit for radiopharmaceutical preparation
219659766|NCT06665620|BEHAVIORAL|ViraBrite nudges|Each day, participants will receive prompts via smartphone notifications that encourage them to access the ViraBrite app and utilize suicide safety planning skills.
219659767|NCT07082738|DRUG|AZD6793|Oral dosage
219659768|NCT07082738|OTHER|Placebo|Oral dosage
218968949|NCT07150507|OTHER|Session 4: What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
219659769|NCT07086339|DEVICE|Implantable pulmonary stent|Implantable polymer based pulmonary stent for severe COPD/emphysema
218968950|NCT07150507|OTHER|Session 5: Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
218968951|NCT07150507|OTHER|Session 6: What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
218968952|NCT07150507|OTHER|Session 7: Relaxation|Practicing the relaxation CD with patients
218968953|NCT07150507|OTHER|Session 8: Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
219659770|NCT05401448|BIOLOGICAL|Influenza|Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
219659771|NCT05401448|BIOLOGICAL|MMR vaccines|MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
219659772|NCT05401448|OTHER|Placebo|Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
219659773|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
219659774|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
219659775|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
219659776|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
219659777|NCT06930976|DRUG|13C6-Glucose|Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion
219659778|NCT05126667|PROCEDURE|Breast-conserving surgery|Breast conserving surgery plus whole breast irradiation
219659779|NCT05126667|PROCEDURE|Mastectomy|Breast mastectomy
219659780|NCT00311064|BEHAVIORAL|physical activity|
219659781|NCT00721279|DRUG|Sifrol® (pramipexole dihydrochloride)|
218968954|NCT07150741|BEHAVIORAL|Exercise-Assisted Ergonomic Training|The program includes structured ergonomic and exercise activities designed to improve posture, reduce musculoskeletal pain, enhance sleep quality, and decrease anxiety levels among nursing students. Theoretical lectures cover ergonomics principles, postural assessment, body mechanics, and ergonomic risks in nursing. Practical sessions are delivered via video twice a week for 4 weeks, each lasting 30-40 minutes, including warm-up, stretching, strengthening, balance, and posture exercises. The intervention is supervised by an exercise specialist to ensure safety and proper technique.
218968955|NCT07149935|OTHER|Rehabilitation Training|The rehabilitation training has two parts: the exercise training at home（5 times per week, as well as the Inspiratory muscle training(once per day) including Respiratory trainer exercise and abdominal breathing training.
218985425|NCT01440452|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
219659782|NCT01482143|DRUG|AFQ056|
219659783|NCT03977753|DRUG|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
219659784|NCT03977753|DRUG|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
219659785|NCT06840483|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
219659786|NCT02680834|DEVICE|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
219659787|NCT02680834|DEVICE|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
219659788|NCT05744037|BIOLOGICAL|regimen with BTK inhibitor +Anti-CD19 CAR T cells|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
219659789|NCT00862342|DRUG|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
219659790|NCT06619678|DRUG|MK-8507|Oral administration
219659791|NCT06619678|DRUG|Islatravir|Oral administration
219659792|NCT03809377|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
219659793|NCT02222831|PROCEDURE|Day 0 denudation and time lapse culture on IVF-oocytes.|
219659794|NCT03467763|DRUG|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
219659795|NCT03467763|DRUG|Placebo oral capsule|Placebo capsule
219659796|NCT06677151|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
219659797|NCT05105828|DIAGNOSTIC_TEST|Share wave fibro scan|Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
219659798|NCT07119437|PROCEDURE|low pneumoperitoneum laparoscopy with microsurgery|Use of low pressure for pneumoperitoneum (8-10 mmHg) and mini surgical access for bariatric procedure (sleeve gastrectomy).
219659799|NCT07119437|PROCEDURE|standard laparoscopy|Standard laparoscopy (12-14 mmHg) and normal surgical access for bariatric procedures (sleeve gastrectomy).
219659800|NCT03816319|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219659801|NCT03816319|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218968956|NCT07149922|OTHER|Blood pressure was regulated within the normal target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<120 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 120-160 mmHg (\<160 mmHg and \>120 mmHg). For SBP \>160 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 120-160 mmHg, standard supportive care was provided.
218968957|NCT07149922|OTHER|Blood pressure was regulated within the elevated target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<160 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 160-180 mmHg ( ≥160 mmHg and ≤120 mmHg). For SBP \>180 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 160-180 mmHg, standard supportive care was provided.
218968958|NCT07149831|DRUG|Flotufolastat F-18 Injection|Single dose intravenous injection of Flotufolastat F-18 Injection . Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
218968959|NCT07150949|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
218968960|NCT07150949|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
218968961|NCT07150949|DRUG|Capecitabine|Xeloda
218968962|NCT07150949|DRUG|Celecoxib|celecoxib 200 mg orally twice a day
218968963|NCT07150949|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
218968964|NCT07150949|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
218968965|NCT07149649|DRUG|Magnesiocard|2.5 mmol film-coated tablets in addition to standard first line therapy
219064207|NCT05709834|OTHER|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
219659802|NCT03816319|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219659803|NCT03816319|PROCEDURE|Echocardiography Test|Undergo ECHO
219659804|NCT03816319|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219659805|NCT03816319|DRUG|UAE Inhibitor TAK-243|Given IV
219659806|NCT07102810|BEHAVIORAL|Standardized Hypnotic Susceptibility Testing|Participants will be guided through the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A), a validated group hypnosis protocol that includes standardized hypnotic inductions and suggestibility tasks.
218968966|NCT07149649|DRUG|Magnesium Diasporal|4 mmol IV formulation in addition to standard first line therapy
219659807|NCT07128199|DRUG|Cisplatin|IV infusion.
219659808|NCT07128199|DRUG|Carboplatin|IV infusion.
219659809|NCT07128199|DRUG|Pemetrexed|IV infusion.
219659810|NCT07128199|DRUG|TAS6417|Oral tablets.
219659811|NCT07128199|DRUG|Zipalertinib Matching-placebo|Oral tablets.
219659812|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
219659813|NCT07137624|BEHAVIORAL|Action Observation + Motor Imagery|Participants will watch videos showing walking actions and will be instructed to mentally simulate the movement.
219659814|NCT07137624|BEHAVIORAL|Nature Video|Participants will watch a video of nature scenes.
219659815|NCT07137598|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
219659816|NCT07137598|DRUG|Placebo|Placebo will be administered as SC injection.
219659817|NCT06940037|OTHER|Progressive Resistance Training|3 times a week
219659818|NCT06940037|OTHER|Health Education|once a week
219659819|NCT07143734|DEVICE|transcranial pulse stimulation (TPS)|The TPS/Sham-TPS therapy is administered for the first two weeks, followed by additional sessions at some week intervals.
219659820|NCT07143734|DEVICE|transcranial pulse stimulation (TPS-Sham)|Participants will undergo an identical procedure using a device that mimics the sound and sensation of active TPS but delivers no therapeutic energy pulses to the brain.
219659821|NCT07140146|DEVICE|Trehalose Powder Air-Polishing|Air-polishing procedure using trehalose-based powder (particle size \<65 µm, low abrasiveness) applied supra- and subgingivally with a professional air-polishing device in patients diagnosed with peri-implant mucositis. The intervention is combined with non-surgical debridement using manual curettes and ultrasonic scalers. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). Clinical outcomes assessed include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS). Implant surfaces are also evaluated in vitro using scanning electron microscopy (SEM) to assess any surface alterations after powder application.
219659822|NCT07140146|DEVICE|Glycine Powder Air-Polishing|Air-polishing procedure using glycine-based powder (particle size \~25 µm, amino acid composition) applied supra- and subgingivally with a professional air-polishing device in patients with peri-implant mucositis. This treatment is combined with standard non-surgical supportive peri-implant therapy involving manual and ultrasonic debridement. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). The intervention aims to reduce plaque accumulation and inflammation. Clinical parameters recorded include PI, BoP, PPD, and BS. Implant surfaces are also assessed in vitro via SEM to compare the effects of glycine versus trehalose on implant surface integrity.
218968967|NCT07149649|OTHER|Microcrystalline cellulose|Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy
218968968|NCT07149649|OTHER|Isotonic saline solution 0.9%|Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy
218968969|NCT05887648|BEHAVIORAL|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
218968970|NCT01350154|DRUG|Sildenafil|20 mg in gelatine capsules, oral, three times daily
218968971|NCT01350154|DRUG|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
218968972|NCT00729924|DRUG|Raltegravir|400mg orally every 12 hours for 7 days
218968973|NCT06199037|DRUG|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
218968974|NCT06199037|DRUG|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
218968975|NCT01638767|DRUG|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
219064208|NCT05709834|OTHER|Conventional treatment|Patients will receive conventional treatment
219064209|NCT06065072|DEVICE|Optical measurement|Optical measurements by optical biometers and an OCT
219064210|NCT03895424|DIETARY_SUPPLEMENT|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
219064211|NCT03895424|DIETARY_SUPPLEMENT|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
218968976|NCT01638767|DRUG|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
218968977|NCT02862899|DEVICE|Thermowire|
218968978|NCT01330706|DRUG|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
218968979|NCT06403670|DRUG|Dexmedetomidine|Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
218968980|NCT06403670|DRUG|Remifentanil|Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
218968981|NCT06220279|DRUG|Diclofenac|Each were monitored for pain within 24 hours
218968982|NCT02340507|OTHER|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
218968983|NCT02340507|OTHER|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
219659823|NCT07141732|BIOLOGICAL|Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System|The Elekta Xoft® Axxent® Electronic Brachytherapy (eBx®) System is a device that delivers high-dose-rate radiation. It is designed for use with Axxent applicators to treat neoplastic tumors inside or on the body surface where radiation therapy is indicated. The Axxent System and its applicators were cleared by the FDA under 510(k) submissions K050843, K072683, K090914, and K122951. The Russian Federation medical device registration certificate (No. RZN 2015/2593) was obtained on April 17, 2015.
219064212|NCT03895424|DIETARY_SUPPLEMENT|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
219064213|NCT04931511|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
218968984|NCT02486354|DRUG|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
219064214|NCT04931511|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
219064215|NCT04931511|BEHAVIORAL|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
219064216|NCT05851404|PROCEDURE|Thyroidectomy|Total thyroidectomy or lobectomy
218968985|NCT03813797|DEVICE|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
218968986|NCT03813797|DEVICE|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
218968987|NCT03126877|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
218968988|NCT03126877|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
218968989|NCT01032902|DEVICE|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
218968990|NCT03037801|DEVICE|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
218968991|NCT03208595|DIAGNOSTIC_TEST|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
218968992|NCT05936125|OTHER|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
218968993|NCT06097338|PROCEDURE|bariatric surgery (BS)|bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
218968994|NCT01904539|DRUG|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
219064217|NCT01417312|DIETARY_SUPPLEMENT|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
219064218|NCT01417312|DIETARY_SUPPLEMENT|Placebo|Daily intake of placebo capsules for 3 months
219064219|NCT00122512|DRUG|Tenofovir Disoproxil Fumarate|
219064220|NCT05496504|OTHER|Holter ECG|
219064221|NCT00299650|DRUG|cisatracurium|
219208282|NCT06810453|PROCEDURE|low-flow anesthesia|Low-flow anesthesia, also known as inhalational anesthesia method, is a type of anesthesia that is performed using a semi-closed, rebreathing system containing at least 50% fresh gas. Generally, low-flow anesthesia is used in anesthesia practices because it reduces costs, prevents environmental pollution, increases the humidity of gases, and reduces heat loss. Another important benefit of low-flow is that it requires closer monitoring of patients, which allows for early detection of complications during general anesthesia, thus improving patient safety. Concerns about low-flow anesthesia being used infrequently in the past have been addressed by the introduction of modern anesthesia workstations with sophisticated monitoring and safety features, which have made low-flow anesthesia widely used in most centers.
219659824|NCT06946680|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
219659825|NCT03200847|DRUG|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
218968995|NCT01173939|DRUG|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
219064222|NCT00299650|DRUG|Placebo|physiological serum infusion
219064223|NCT00299650|DRUG|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
219064224|NCT00989651|BIOLOGICAL|Bevacizumab|Given IV
219064225|NCT00989651|DRUG|Carboplatin|Given IV
219064226|NCT00989651|DRUG|Cisplatin|Given IP
219064227|NCT00989651|OTHER|Laboratory Biomarker Analysis|Correlative studies
219064228|NCT00989651|DRUG|Paclitaxel|Given IV or IP
219064229|NCT00989651|DRUG|Veliparib|Given PO
219064230|NCT03249922|DEVICE|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
219659826|NCT06953817|BEHAVIORAL|Kangaroo Care Intervention Group|The mother should wear a comfortable outfit that can be easily opened at the front, and attention should be given to the mother's privacy. The infant should be covered with a light blanket. While applying kangaroo care, the baby may be completely naked, or the baby may wear items such as a hat, diaper, and socks. The kangaroo care position involves placing the baby upright between the mother's breasts. The newborn's abdomen should be positioned at the level of the mother's epigastric region. While performing kangaroo care, the mother should ensure that the baby's face is visible and that the baby's head is not in extreme extension or excessive flexion. During the procedure, care should be taken to ensure that the baby can breathe comfortably while on the mother's chest. The pregnant women will be instructed to practice kangaroo care intermittently for 30 minutes.
219659827|NCT07153016|OTHER|Legal Services|Legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota.
219659828|NCT07150702|OTHER|Conventional physical therapy program|Conventional physical therapy program that includes hot packs, transcutaneous electrical nerve stimulation, ultrasound, and core stabilization exercises
219659829|NCT07150702|BEHAVIORAL|Close follow-up by a physician|Daily physician-patient meetings during the sessions
218968996|NCT01173939|DRUG|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
218968997|NCT05237297|DRUG|Ilaprazole|Ilaprazole 10mg
218968998|NCT05237297|DRUG|Naproxen|Naproxen 500mg
218968999|NCT05237297|DRUG|Aceclofenac|Aceclofenac 100mg
218969000|NCT05237297|DRUG|Celecoxib|Celecoxib 200mg
218969001|NCT03939026|GENETIC|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
218969002|NCT03939026|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
218969003|NCT03939026|DRUG|Fludarabine|Chemotherapy for lymphodepletion
218969004|NCT03939026|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
218969005|NCT03897504|PROCEDURE|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
218969006|NCT01536743|DRUG|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
218969007|NCT04833673|BEHAVIORAL|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
218969008|NCT04833673|BEHAVIORAL|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
218969009|NCT05650060|DRUG|Secukinumab|all patients with psoriasis who received secukinumab
218969010|NCT05096052|DRUG|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
218969011|NCT05096052|DRUG|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
218969012|NCT02076633|DRUG|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
218969013|NCT04703387|DIAGNOSTIC_TEST|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
218969014|NCT00091416|BIOLOGICAL|VRC-HIVADV014-00-VP|
218969015|NCT04096742|DRUG|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
218969016|NCT04096742|OTHER|Vehicle|Lotion not containing active ingredient (tretinoin)
218969017|NCT05159284|DRUG|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
219064231|NCT03821376|DRUG|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
219208283|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
219208284|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
218969018|NCT05159284|DEVICE|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
218969019|NCT05159284|DEVICE|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
218969020|NCT05159284|DEVICE|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
218969021|NCT03272230|BEHAVIORAL|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
218969022|NCT03272230|BEHAVIORAL|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
219659830|NCT07157800|OTHER|ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
219659831|NCT07157800|OTHER|exercise + ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors.~Other: exercise program stretching exercises strengthening exercises waist exercises core exercises relaxation exercises"
218969023|NCT03272230|DIAGNOSTIC_TEST|Neuropsychological assessment|STARKSTEIN APATHY SCALE (SAS) / DAS / MMSE / MADRS / EBI / MINI-SEA / FAB / HAD / MATTIS / HAYLING / STROOP / Verbal Span / Lexical verbal fluency / TMT / CDRS
218969024|NCT03272230|BEHAVIORAL|ICM_APATHY_TASKS|Apathy experimental task
218969025|NCT03272230|OTHER|MRI|T1 / T2 / rs-fMRI / MS-DWI
218969026|NCT03272230|BIOLOGICAL|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
218969027|NCT02439983|DIETARY_SUPPLEMENT|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
219659832|NCT07157566|BEHAVIORAL|Mindfulness|Structured over 8 weeks (twice weekly) with dual modules (dietary + movement), this group employs Mindfulness-Based Eating Awareness Training (MB-EAT) to improve mind-body awareness. Week 1 establishes foundational practices through mindful eating concepts and introductory yoga; Weeks 2-4 systematically train awareness of hunger/satiety cues using partner breathing techniques, postural alignment, and group-assisted stretching; Week 5 analyzes emotional eating triggers while integrating therapeutic yoga for emotional regulation; Weeks 6-7 foster body acceptance and autonomous food choices; the program concludes with closing rituals. Rooted in Mindfulness-Based Stress Reduction (MBSR), it strengthens interoceptive awareness, non-judgmental self-acceptance, and emotional management to transform dysfunctional eating patterns.
219659833|NCT07157566|BEHAVIORAL|e-Health Literacy|This 8-week program (twice weekly) aims to enhance participants' ability to access, evaluate, and apply digital health information. It progresses through sequential modules: Week 1 introduces e-Health literacy fundamentals and physical activity principles; Weeks 2-3 focus on nutritional assessment and personalized planning; Week 4 addresses sleep health; Weeks 5-7 train health information retrieval skills, including database navigation and source reliability verification; the final week hones critical appraisal capabilities. The intervention is based on the e-Health Literacy 3.0 model and cultivates three core competencies: digital navigation, information discernment, and evidence-based decision-making, enabling participants to independently navigate the digital health ecosystem.
218969028|NCT02439983|DIETARY_SUPPLEMENT|Placebo|2 capsules taken by mouth with morning and evening meals.
218969029|NCT05894226|PROCEDURE|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
218969030|NCT03082482|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials
218969031|NCT03082482|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
218969032|NCT03082482|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
218969033|NCT03082482|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
218969034|NCT03947996|OTHER|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
218969035|NCT03947996|OTHER|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
218969036|NCT05933447|DRUG|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
218969037|NCT05933447|DRUG|Moxifloxacin|Oral, Tablet, 400 mg QD
218969038|NCT05933447|DRUG|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
218969039|NCT05933447|DRUG|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
219659834|NCT07154225|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
219659835|NCT07154225|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
219659836|NCT07161427|PROCEDURE|Fu's Subcutaneous Needling therapy|Participants first assume the supine position. After routine disinfection, the Fu's subcutaneous needle is inserted parallelly into the subcutaneous loose connective tissue around the pathologically taut muscles (such as the tibialis anterior, peroneus longus, gastrocnemius, soleus, peroneus brevis, and extensor digitorum longus, etc.). After the needle is fully inserted, fix the protruding part of the hose holder onto the card slot.To minimize the participants' perception of pain, the doctor uses the index finger and ring finger to perform a smooth, gentle, and fan-shaped swinging motion in an alternating front-to-back manner.The sector angle is approximately 60°. It makes a total of round - trips 45 times within 30 seconds. The rocking motion is accompanied by Reperfusion Approach: A set of procedures consists of 20 times of rocking followed by 10 seconds of reperfusion method. Each target lesioned tense muscle requires 2 - 3 sets of the above - mentioned procedures.
219659837|NCT07161427|BEHAVIORAL|Ankle joint aids combined with exercise therapy|Participants in the combination therapy group wore ankle orthoses during their daily activities from 9:00 to 20:00 every day for a total of 2 weeks. To ensure standardization, a unified specification is selected for the ankle joint orthosis: Product number: 100159548, the 195R Super Sports Ankle Brace for Inversion/Eversion Sprains and Ligament Fixation by McDavid from the United States. During the treatment with ankle joint orthosis, complete the resistance training every day.
219659838|NCT07163026|PROCEDURE|Erector Spine Plane Block|Bilateral erector spinae plane block was performed under aseptic conditions at the T7 vertebral level using ultrasound guidance with a convex probe. An 80-mm peripheral nerve block needle was inserted 3-4 cm lateral to the midline with an in-plane approach to the fascial plane deep to the erector spinae muscle. After negative aspiration and hydrodissection with 1-3 ml of saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
218969040|NCT03095833|OTHER|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
218969041|NCT03095833|OTHER|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
218969042|NCT03095833|OTHER|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
218969043|NCT03095833|OTHER|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
218969044|NCT03095833|OTHER|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
218969045|NCT03095833|OTHER|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
218969046|NCT03095833|OTHER|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
218969047|NCT03095833|OTHER|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
218969048|NCT03095833|OTHER|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
219659839|NCT07163026|PROCEDURE|External Oblique - Intercostal Plane Block|Bilateral external oblique-intercostal plane block was performed under aseptic conditions by identifying the 6th and 7th ribs along the midclavicular line. Using ultrasound guidance with the probe placed parallel to the midclavicular line, the ribs, intercostal muscles, external oblique muscle, and pleura were visualized. A 50-mm block needle was advanced craniocaudally into the plane between the external oblique and intercostal muscles. After negative aspiration and hydrodissection with 1-3 ml saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
219659840|NCT07163481|DRUG|Sacituzumab Govitecan + Fulvestrant|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with Fulvestrant 500 mg intramuscularly into the buttock on Day 1 of 28-day cycles and Cycle 1 Day 15
219659841|NCT07163481|DRUG|Sacituzumab Govitecan + Anastrozole / Exemestane|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with One of the Two Investigator's choice of aromatase inhibitors (ICAI), orally, once daily: Anastrozole 1 mg Exemestane 25 mg
219659842|NCT07158528|PROCEDURE|coronally advanced flap with connective tissue graft|The gum at the recession site is elevated and repositioned higher, combined with a connective tissue graft.
219659843|NCT07158528|PROCEDURE|tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached, and repositioned higher, combined with a connective tissue graft.
219659844|NCT07160361|DRUG|Lenvatinib + losartan|"Patients will receive a combination of lenvatinib and losartan at the same time after surgery for treatment cycles once daily (lenvatinib and losartan).~Adjuvant therapy will be started within 2-6 weeks after surgery for a period of time to evaluate the effect of different treatment regimens on reducing tumor recurrence and improving survival.~lenvatinib: orally once daily according to standard dosing guidelines, starting postoperatively.~losartan: 50mg losartan potassium tablets orally once daily starting postoperatively."
219659845|NCT07166913|BEHAVIORAL|Toolkit|The toolkit contains information regarding enhanced stakeholder engagement strategies. The toolkit includes guidance materials, checklists, and templates/ sample materials, to increase stakeholder engagement in the research. This includes guidance on setting up a stakeholder advisory board (SAB) and ensuring literacy- and language- sensitivity of participant-/stakeholder-facing materials.
218969049|NCT03095833|OTHER|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
218969050|NCT03095833|OTHER|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
218969051|NCT05312372|DRUG|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
218969052|NCT00085709|DRUG|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
218969053|NCT00085709|OTHER|observation|No treatment given
219659846|NCT07166211|BIOLOGICAL|CM512 injection|subcutaneous injection
219659847|NCT07166211|DRUG|placebo|subcutaneous injection
218969054|NCT00085709|DRUG|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
218969055|NCT00085709|DRUG|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
218969056|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
218969057|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
218969058|NCT06377696|OTHER|Best Practice|Receive SOC
218969059|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
218969060|NCT06377696|DRUG|Metformin|Given PO
218969061|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
218969062|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
218969063|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulation. Frequency of 10 Hz|The US-guided PNM intervention will be performed with the patient in the prone position, the shoulder to be treated flexed at 90 degrees, the humerus partially supported on the table, the elbow flexed at 90 degrees, and the musculature relaxed. Needles will be inserted near the perineurium of the axillary and suprascapular nerves. Prior to needle insertion, the skin will be cleaned with isopropyl alcohol and chlorhexidine. The PNM intervention will consist of applying a compensated asymmetric biphasic current, with a rectangular positive phase and a triangular negative phase, at a frequency of 10 Hz, pulse width of 240 μs, and the maximum tolerated intensity that elicits a painless maximal muscle contraction, following this protocol: 10 stimulations of 10 seconds each, with a 10-second rest between stimulations.
218969064|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulación. Frequency of 1 Hz|Same intervention as previously described, with the only difference being that the frequency will be 1 Hz instead of 10 Hz.
218969065|NCT05716451|DEVICE|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
218969066|NCT06797401|DRUG|RBD5044|RBD5044, active drug.
218969067|NCT06797401|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
219659848|NCT07161882|OTHER|Observational Data Collection|Collection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study.
218969068|NCT05773742|DEVICE|Low-volume irrigation|Qufora IrriSedo MiniGo
219659849|NCT07169136|DRUG|GLP-1 Receptor Agonists|Weekly subcutaneous Semaglutide.
219659850|NCT07175896|BEHAVIORAL|Immediate delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
219659851|NCT07175896|BEHAVIORAL|Delayed delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
219659852|NCT07175389|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
219659853|NCT07175389|DRUG|Serplulimab|Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
219659854|NCT07177092|PROCEDURE|Surgery|① Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
219659855|NCT07177092|DRUG|Osimertinib|Dose: 80 mg orally, once daily, until disease progression or the occurrence of unacceptable toxicity. The dose should be administered at approximately the same time each day, at 24-hour intervals.
219659856|NCT07175220|DRUG|SHR2554; SHR-A2102|SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days
219659857|NCT07175220|DRUG|SHR2554; Adabelimumab|SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days
219659858|NCT07175220|DRUG|SHR2554; SHR-1701|SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days
219659859|NCT07177209|DRUG|Non-Interventional Study|As provided in real world practice
219659860|NCT07174973|OTHER|Balance training with FES|"Participants assigned to this group complete a standardized balance training program while receiving FES to the lower limb muscles. Training sessions involve standing in a safety harness and performing interactive, game-based balance tasks on a force plate that provides real-time visual feedback of body sway.~FES will be applied bilaterally to specific leg muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) using surface electrodes. Stimulation parameters (pulse width, frequency, and amplitude) are individually adjusted to produce visible yet comfortable muscle contractions that support functional standing and balance activities. Stimulation is delivered in synchrony with balance exercises to augment muscle activation during postural adjustments."
218969069|NCT05892653|DRUG|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
218969070|NCT06005142|DIETARY_SUPPLEMENT|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
218969071|NCT06005142|DIETARY_SUPPLEMENT|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
218969072|NCT06005142|DIETARY_SUPPLEMENT|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
218969073|NCT04069572|DEVICE|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
219659861|NCT07174973|OTHER|Balance training wiith combined neuromodulation (TSCS+FES)|Participants in this group complete the standardized balance training program while receiving both FES and TSCS. Training sessions take place in a safety harness and involve interactive, game-based balance exercises performed on a force plate with real-time visual feedback of body sway.FES is delivered bilaterally to lower limb muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) through surface electrodes. Stimulation parameters (pulse width, frequency, amplitude) are individualized to produce visible, comfortable contractions that facilitate muscle activation during postural tasks.TSCS is applied simultaneously via electrodes placed over the thoracolumbar spinal region to modulate spinal excitability and enhance neuromuscular control. Standardized stimulation parameters are used across participants, with adjustments made to ensure tolerance and safety.
218969074|NCT04069572|DEVICE|Sham Stimulation|Low-frequency sham of VCR stimulation
218969075|NCT03554616|OTHER|Chlorfenapyr LLIN|Dual active ingredient Long Lasting Insecticidal Net
218969076|NCT03554616|OTHER|pyriproxyfen LLIN|Dual active ingredient Long Lasting Insecticidal Net
218969077|NCT03554616|OTHER|Piperonyl butoxide LLIN|Combination insecticide and synergist Long Lasting Insecticidal Net
218969078|NCT03554616|OTHER|Standard LLIN|Standard Long Lasting Insecticidal Net with one insecticide
218969079|NCT06005974|DRUG|REC-4881|REC-4881 4mg capsules
218969080|NCT06142019|DEVICE|Controlled desaturation (hypoxemia)|Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures
218969081|NCT03646643|PROCEDURE|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
218969082|NCT03646643|PROCEDURE|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
218969083|NCT04131556|DRUG|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
218969084|NCT06470867|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
218969085|NCT06470867|BEHAVIORAL|Control training|"An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention."
218969086|NCT04481009|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
218969087|NCT04481009|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
218969088|NCT04481009|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
218969089|NCT04481009|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
218969090|NCT05498220|DRUG|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
218969091|NCT05498220|DRUG|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
218969092|NCT05498220|DRUG|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
218969093|NCT05498220|DRUG|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
218969094|NCT05498220|DRUG|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
218969095|NCT05498220|DRUG|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
218969096|NCT05498220|DRUG|GCSF|granulocyte-colony stimulating factor (GCSF )
218969097|NCT06377501|OTHER|Whole-food, plant-based diet|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
218969098|NCT05985161|DRUG|Selinexor|This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
218969099|NCT04882501|OTHER|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
218969100|NCT04882501|OTHER|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
218969101|NCT05700539|BEHAVIORAL|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
218969102|NCT06580080|BEHAVIORAL|Are You Ready? (AYR)|"AYR is a group-based entertainment education (EE) intervention designed for sexually active youth who are at risk for or involved in the juvenile justice and/or child welfare systems. AYR is delivered in one, 2.5-hour (150-minute) session with a group of between 2 to 20 youth. The session includes screening a 40-minute video, Happy Birthday, Leonard and group-based discussions led by one to two facilitators. Discussions are guided by a participant workbook with journal prompts and handouts.~The session includes two modules; each module involves screening approximately 20 minutes of Happy Birthday, Leonard followed by a 40-minute group discussion. Module 1 includes topics related to contraception, condom use (with a condom demonstration), healthy communication, and stress management. Module 2 includes topics related to condom negotiation, communication styles, and intergenerational cycles."
218969103|NCT06580080|BEHAVIORAL|Social Media Awareness Shorts (SMAS)|SMAS is a virtually delivered, individual-based health program focused on social media use awareness. Participants are directed to a learning management platform that contains a pre-recorded, facilitated program. The program involves watching several short films and independently completing several activities related to social media use. The program does not include information related to the primary outcomes for this study.
218969104|NCT06788249|DRUG|Ketamine only|The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
218969105|NCT06104527|COMBINATION_PRODUCT|Standard protein enteral nutrition with enteral tracer|Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
218969106|NCT06104527|COMBINATION_PRODUCT|High protein enteral nutrition with enteral tracer|Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
218969107|NCT00277797|DEVICE|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
218969108|NCT00277797|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
218969109|NCT03207893|BEHAVIORAL|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
218969110|NCT03207893|OTHER|Routine Care|Subject's current t2d treatment
219659862|NCT07174973|OTHER|Balance training only|Participants in this group complete the standardized balance training program without electrical stimulation. Sessions are conducted in a safety harness and consist of interactive, game-based balance exercises performed on a force plate, which provides real-time visual feedback of body sway. Tasks are designed to challenge postural control by requiring weight shifting in multiple directions, maintaining stability during perturbations, and progressively increasing task difficulty.
219659863|NCT07175636|DRUG|Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)|"QL1706 is an investigational bifunctional MabPair antibody that simultaneously targets PD-1 (IgG4) and CTLA-4 (IgG1). It is administered intravenously according to the study protocol during the neoadjuvant chemotherapy cycles. The use of QL1706 aims to enhance antitumor immunity in the pMMR/MSS rectal cancer setting, a population typically unresponsive to immune checkpoint blockade alone.~mFOLFOX6 is a standard oxaliplatin-based chemotherapy regimen composed of oxaliplatin, leucovorin, and 5-fluorouracil. It is administered in combination with QL1706 during the neoadjuvant phase as part of total neoadjuvant therapy (TNT). The regimen is modified to optimize tolerability while maintaining efficacy in locally advanced rectal cancer.~Short-course radiotherapy consists of a total dose of 25 Gy delivered in 5 fractions over one week to the pelvis. This approach is designed to rapidly downstage tumors, release tumor antigens, and prime the immune microenvironment for subsequent immunotherapy"
218969111|NCT03497078|OTHER|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
218969112|NCT06221917|OTHER|Face-to-face|FTF group are participants who will learn simple sutures physically present with the instructor in the same room.
218969113|NCT06221917|OTHER|Live-streaming|One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
218969114|NCT05991388|DRUG|Odronextamab|CD20xCD3 bispecific antibody
218969115|NCT05991388|DRUG|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
218969116|NCT05991388|DRUG|Rituximab|Modified R-ICE chemotherapy
218969117|NCT05991388|DRUG|Ifosfamide|Modified R-ICE chemotherapy
218969118|NCT05991388|DRUG|Carboplatin|Modified R-ICE chemotherapy
218969119|NCT05991388|DRUG|Etoposide|Modified R-ICE chemotherapy
218969120|NCT05991388|DRUG|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
218969121|NCT05991388|DRUG|Dexamethasone|Modified R-ICE chemotherapy
218969122|NCT05991388|BIOLOGICAL|CAR T-cells (TBC)|Modified R-ICE chemotherapy
218969123|NCT06245629|DRUG|Bortezomib-bendamustine-melphalan|The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
218969124|NCT05407844|OTHER|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
218969125|NCT04629508|DRUG|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
218969126|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
218969127|NCT03288454|DRUG|Placebo|Saline for injection
218969128|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
218969129|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
218969130|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
218969131|NCT02397668|DEVICE|CorMatrix Cor TRICUSPID ECM Valve|CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
218969132|NCT01678027|DRUG|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
218969133|NCT01678027|DRUG|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
218969134|NCT05701488|DRUG|Durvalumab|Intravenous infusion
218969135|NCT05701488|DRUG|Tremelimumab|Intravenous infusion
218969136|NCT05701488|DEVICE|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
218969137|NCT01135576|DIETARY_SUPPLEMENT|non-fortified fruit juices consumed as part of the usual diet|
218969138|NCT01135576|DIETARY_SUPPLEMENT|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
218969139|NCT05005520|DRUG|DTRI-031|Investigational drug
218969140|NCT05005520|DRUG|Placebo|Matching placebo to DTRI-031
219659864|NCT07176247|DRUG|Aztreonam-Avibactam|Antibiotic therapy with Aztreonam-Avibactam
219659865|NCT07174570|DRUG|Celecoxib|Receive by mouth (PO).
219659866|NCT07174570|BIOLOGICAL|Durvalumab|Receive intravenously (IV).
218969141|NCT03375710|DEVICE|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
218969142|NCT00396747|DRUG|Infliximab, methylprednisolone, methotrexate|
218969143|NCT00396747|DRUG|Methotrexate|
218969144|NCT00396747|DRUG|Methotrexate + Methylprednisolone|
218969145|NCT00396747|DRUG|Methotrexate + Infliximab|
218969146|NCT03051646|DRUG|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
218969147|NCT03051646|DRUG|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
218969148|NCT01973543|BIOLOGICAL|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
218969149|NCT00504985|BEHAVIORAL|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
218969150|NCT05558917|PROCEDURE|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
218969151|NCT05558917|PROCEDURE|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
218969152|NCT00788398|PROCEDURE|Saline Solution|Irrigation with Saline
219659867|NCT07174570|BIOLOGICAL|Tremelimumab|Given intravenously (IV).
219659868|NCT07174570|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219659869|NCT07174570|PROCEDURE|Computed Tomography|Undergo Computed Tomography (CT).
219659870|NCT07174570|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging (MRI).
218969153|NCT00788398|PROCEDURE|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
218969154|NCT00788398|PROCEDURE|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
218969155|NCT00788398|PROCEDURE|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
218969156|NCT00788398|PROCEDURE|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
218969157|NCT06409351|BEHAVIORAL|Intervention group|Please refer to arm descriptions
218969158|NCT00048763|DRUG|Pletal|
218969159|NCT00378586|PROCEDURE|Rectal biopsy|Rectal biopsy.
218969160|NCT00378586|PROCEDURE|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
218969161|NCT00378586|PROCEDURE|Measurement of rectal lactic acid|Equilibrium dialysis.
218969162|NCT01732731|OTHER|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
218969163|NCT04643821|DRUG|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
218969164|NCT05380310|DEVICE|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
218969165|NCT05380310|DEVICE|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
219659871|NCT07174570|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy.
219659872|NCT07174661|BEHAVIORAL|Advance Care Planning|Attend ACP appointment
219659873|NCT07174661|OTHER|Educational Intervention|Watch on-demand early ACP educational video
219659874|NCT07174661|OTHER|Electronic Health Record Review|Ancillary studies
219659875|NCT07174661|OTHER|Survey Administration|Ancillary studies
219659876|NCT07176091|DEVICE|Combined treatment of tDCS and rTMS|Bilateral pre-treatment with tDCS is carried out for 10 minutes. The current is 2 mA, and the electrodes are spaced 5 cm apart. The current gradually rises and falls in the first and last 30 seconds. Subsequently, the bilateral primary motor cortex (M1 area) of the patient is stimulated with iTBS at a frequency of 5 Hz. The magnetic field intensity is set at 80% of the resting motor threshold. Each train contains 10 pulses, and each pulse consists of 3 bidirectional pulses at 50 Hz. The interval between each train is 8 seconds. There are 60 trains per session (1800 pulses per session), and the treatment lasts for 5 days in total.
219659877|NCT07176091|DEVICE|sham-tDCS combined with real TMS|Participants received sham transcranial direct current stimulation combined with intermittent theta burst stimulation for a total of 5 days
219659878|NCT07175129|PROCEDURE|Transverse Tibial Bone Transport|Tibial tibial bone transport is a novel surgical procedure that involves the gradual movement of a bone segment in order to improve perfusion and tissue healing.
219659879|NCT07175129|DEVICE|TrueLok Elevate|This device is used to move the bone segment as a part of the tibial bone transport surgery.
219659880|NCT07174687|DRUG|Dapagliflozin|Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.
219659881|NCT07174687|OTHER|Matching Placebo|Matching oral placebo to dapagliflozin
219659882|NCT07175649|DRUG|Methylprednisolone sodium succinate|"Intravenous methylprednisolone sodium succinate will be administered at a dose of 2 mg/kg/day for 3 days, with a maximum daily dose of 160 mg (4 vials, 40 mg/vial).~It is recommended that the initial dose be administered as soon as possible after randomization."
219659883|NCT07175649|DRUG|Placebo|Matched intravenous placebo will be administered for 3 days, with a maximum daily dose of 4 vials.
219659884|NCT07175285|DRUG|Current standard of care treatment options|According to the product label
219659885|NCT07176338|DIAGNOSTIC_TEST|Blood and lens capsule samples for PK testing|Blood samples and lens capsule tissue will be collected from patients for PK testing
219659886|NCT07175012|DEVICE|ELECTROVEST|A wearable vest device that delivers airway clearance therapy through high-frequency chest wall oscillation (HFCWO) combined with surface neuromuscular electrostimulation (EEM). The session includes a 2-minute warm-up phase at 4 Hz, 16 minutes of active stimulation at 8 Hz, and a 2-minute recovery phase at 4 Hz (total duration: 20 minutes). The intervention is administered during supervised physiotherapy sessions to promote mucociliary clearance and respiratory muscle activation in patients with chronic respiratory diseases.
219659887|NCT07175012|DEVICE|The Vest® Model 105|A conventional airway clearance therapy using a commercial high-frequency chest wall oscillation (HFCWO) device (The Vest® Model 105 or AffloVest®). The session includes a 2-minute warm-up phase at 13 Hz, 16 minutes of treatment at 20 Hz, and a 2-minute cool-down at 13 Hz (total duration: 20 minutes). This intervention serves as the active comparator in the crossover trial.
219659888|NCT07176000|BEHAVIORAL|Patient Navigation|Receive tailored PN activities
219659889|NCT07176000|OTHER|Educational Intervention|Receive LCS educational handout
219659890|NCT07176000|OTHER|Best Practice|Receive enhanced usual care
219659891|NCT07176000|OTHER|Interview|Ancillary studies
219659892|NCT07176000|OTHER|Survey Administration|Ancillary studies
219659893|NCT07176000|OTHER|Electronic Health Record Review|Ancillary studies
218985426|NCT01440452|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
219659894|NCT07174479|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
219659895|NCT07174466|OTHER|Standard Referral to 211|Participants receive a standard referral to United Way 211 for assistance with social needs. 211 specialists contact referred patients, provide available service referrals, and follow up in an ad-hoc manner as per standard 211 protocols.
219659896|NCT07174466|BEHAVIORAL|e-SINCERE (Phone Support)|Participants receive a study-provided cellphone to ensure stable phone access. Using this device, participants are connected to United Way 211 specialists, who provide referral services for identified social needs. This intervention focuses on overcoming communication barriers that might otherwise prevent successful service connection.
219659897|NCT07174466|BEHAVIORAL|e-SINCERE (Digital Navigation)|Participants receive a study-provided TracFone and direct support from a trained Digital Navigator. The Digital Navigator assists participants with accessing United Way 211 services, troubleshooting barriers to phone or internet use, and reinforcing follow-through on referrals. This arm is designed to provide enhanced, structured navigation support to address digital access barriers and increase successful service connections.
219659898|NCT07177222|PROCEDURE|laparoscopic esophagocardiomyotomy|Heller myotomy, is a minimally invasive surgical procedure that involves cutting the muscle at the lower end of the esophagus to treat achalasia, a condition where this muscle (esophageal sphincter) fails to relax and hinders food passage into the stomach.
219659899|NCT07177222|PROCEDURE|open surgery|Open surgery, or traditional surgery, involves a surgeon making one large incision to directly access and view the internal organ or body part being operated on.
219659900|NCT07176130|OTHER|No Intervention: Observational Cohort|Not applicable, No intervention. Observational study.
219659901|NCT07176988|OTHER|Hierarchical method|"Participants in the hierarchical version of Conversation Training Therapy (CTTH) will receive four weekly sessions of voice therapy. This approach gradually increases the difficulty of speaking tasks-from simple sounds to full conversations-based on the participant's progress. The therapy begins with basic awareness and speech sounds (e.g., consonant-vowel pairs), then progresses through words, phrases, and sentences, culminating in natural conversation. Each level must be completed with at least 80% accuracy before proceeding to the next one.~The structure is modeled after traditional voice therapies like resonant voice and aims to help participants succeed early and reduce mental fatigue. Daily homework includes seven short (2.5-minute) practice sessions, aligned with prior research showing this is a realistic and effective amount of practice."
219659902|NCT07176988|OTHER|Non Hierarchical method|"The therapy includes four weekly sessions and several key techniques:~Clear Speech: Speaking clearly, like leaving an important voicemail.~Awareness Training: Paying attention to how the voice sounds and feels in the mouth and face.~Negative Practice: Switching between their bad voice and good therapy voice to recognize and improve differences.~Embedded Gestures: Briefly holding certain speech sounds to reduce vocal strain and boost clarity.~Prosody and Projection: Working on pitch, rhythm, and speaking louder through better technique.~Participants practice these skills throughout the day using a mobile app to track their progress and record a weekly sample. Unlike hierarchical models, components in CTT can be introduced in any order based on individual needs, making it flexible and personalized"
219659903|NCT07174934|BIOLOGICAL|application of injectable platelet-rich fibrin on the wound area .|Injectable platelet-rich fibrin will be prepared using low speed centrifugation technique, after centrifugation, the I-PRF in the upper part of the tube will be collected via an injector and will be transferred to a metal godet. It will be left for 15-20 min for polymerization of the I-PRF ,Then the polymerized I-PRF will be applied to the secondary wound of test area.
219659904|NCT07176663|DRUG|Tirzepatide|2.5 mg weekly first month and 5 mg weekly for two month
219659905|NCT07176481|BEHAVIORAL|Diné Parents Taking Action Program|A culturally adapted parent training program delivered by trained Navajo Family Advisors, focused on teaching parents/guardians evidence-based strategies to support their child's development and family well-being.
219659906|NCT07175753|OTHER|chiropractic applied clinical neuroscience care|Standard chiropractic care with physiotherapy and phototherapy over two sessions
219659907|NCT07174414|DRUG|Cilostazol 100 mg|Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.
219659908|NCT07174414|DRUG|Placebo|Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.
219659909|NCT07176780|DEVICE|Semiconductor embedded body sleeve|The active device contains semiconductors embedded into the body sleeve fabric
219659910|NCT07176780|DEVICE|Placebo Non-Compressive Body Sleeve|Identical body sleeve absent of semiconductors
219659911|NCT07175051|DRUG|Empagliflozin (oral)|10 mg
219659912|NCT07176936|DEVICE|Cymba Conchae stimulation|Electrical stimulation applied to the cymba conchae region of the outer ear
219659913|NCT07176936|DEVICE|Earlobe stimulation|Electrical stimulation applied to the earlobe region of the outer ear
218969166|NCT05310656|BEHAVIORAL|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
218969167|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
218969168|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
219659914|NCT07175103|BEHAVIORAL|Nurses' Stress Self-Care Educational Program (NSSCEP)|A control intervention consisting of four 1-hour sessions over one month, focusing on general technical skills relevant to pediatric oncology nursing (e.g., procedural updates, equipment use). The program does not include stress management content. Participants complete weekly checklists and pre- and post-intervention surveys to measure burnout and stress levels.
219659915|NCT07175103|OTHER|General Technical Skills Program|A control program with four 1-hour sessions over one month, focusing on technical skills (e.g., procedural updates, equipment use) without stress management content. Includes weekly checklists and pre/post surveys to measure burnout and stress.
219659916|NCT07171801|DEVICE|Three-Dimensional Endoscopic Visualization|Use of a stereoscopic 3D high-definition endoscopic system with dual optical channels, projecting to a stereoscopic monitor viewed with polarized glasses, to perform standardized spinal simulation tasks.
219659917|NCT07171801|DEVICE|Two-Dimensional Endoscopic Visualization|Use of the same high-definition endoscopic system with stereoscopic function deactivated, providing conventional monoscopic two-dimensional visualization, to perform standardized spinal simulation tasks.
219659918|NCT07174453|DRUG|Nivolumab|Immunotherapy
219659919|NCT07174453|DRUG|Pembrolizumab|Immunotherapy
219659920|NCT07176520|DEVICE|AI-assisted rehabilitation|Receives AI-assisted rehabilitation post-discharge at home in addition to usual care
218969169|NCT00760214|DRUG|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
218969170|NCT04134702|OTHER|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
218969171|NCT00493376|PROCEDURE|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
218969172|NCT00493376|PROCEDURE|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
218969173|NCT00493376|PROCEDURE|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
218969174|NCT00493376|PROCEDURE|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
219064232|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
219064233|NCT02391402|BEHAVIORAL|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
219064234|NCT02391402|BEHAVIORAL|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
219064235|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
219659921|NCT07176520|OTHER|usual care only|Verbal and written discharge summary, advice, and referral to outpatient physiotherapy (if applicable)
219659922|NCT07174804|OTHER|Yoga (IAYT) Intervention|Yoga practice for a period of three months
219659923|NCT07174544|BEHAVIORAL|Mobile Self-Management Program integrated with Positive Psychology and Behavioral Activation)|The mobile self-management program consisted of a 4-week guided intervention phase followed by a 4-week self-directed period to encourage continued use. The guided phase was organized around weekly objectives: (1) experiencing positive affect, (2) identifying personal strengths, (3) applying strengths in daily life, and (4) planning a positive future. Program activities included emotional check-ins, gratitude journaling, mindfulness practice, positive behavioral tasks, and goal setting. During the self-directed phase (Weeks 5-8), participants selected from 10 recommended activities tailored to their strengths, promoting sustained engagement and self-management. The program integrated Positive Psychology and Behavioral Activation strategies to reduce stress, enhance resilience, and foster positive behavioral change.
219659926|NCT07175038|DRUG|ROC-101|Oral, daily administered Rho kinase inhibitor
219659927|NCT07175766|DIETARY_SUPPLEMENT|Dachundou No Sugar Added Soymilk|Participants will consume two bottles of Dachundou No Sugar Added Soymilk daily (375 mL each; total 750 mL per day) for 8 consecutive weeks. The product is packaged in 375 mL cartons and made from non-GMO soybeans, containing approximately 4.2 g of soy protein per 100 mL. The soymilk is unsweetened and stored at 0-7°C.
219659928|NCT07176143|PROCEDURE|Delivering human bone marrow mesenchymal stem cells via the uterine artery|"Interventional Uterine Artery Infusion of Human Bone Marrow Mesenchymal Stem Cells (hBMSCs):~Subjects in the experimental group will undergo iodine allergy testing and groin area shaving/disinfection preoperatively. The procedure is performed on Day 10 of the endometrial proliferation phase.~Step-by-Step Procedure:~1. Positioning \& Anesthesia: (Patient placed in supine position; Local infiltration anesthesia administered)~2. Arterial Access: (Femoral artery punctured using Seldinger technique; Vascular sheath and catheter inserted)~3. Catheterization: (Catheter/microcatheter advanced into one uterine artery; Position confirmed by angiography)~4. Stem Cell Infusion: (Under fluoroscopic guidance, slowly inject 15mL solution containing 1×10⁶ cells/kg hBMSCs via microcatheter)~5. Postoperative Care: (Hospital observation for 48 hours)~6. Concurrent Treatment: (Hormone replacement therapy cycle maintained during the procedure month)~Treatment Frequency: Single intervention"
219659929|NCT07176052|PROCEDURE|cancer surgery|All surgery will be performed at Copenhagen University Hospital, Rigshospitalet, Denmark
219659930|NCT07176065|DRUG|Ropivacaine + saline solution|0.5% ropivacaine (19 mL) + 1 mL normal saline administered intraoperatively via periarticular injection.
219659931|NCT07176065|DRUG|Ropivacaine + Dexmedetomidine|0.5% ropivacaine (19 mL) + dexmedetomidine 100 µg in 1 mL administered intraoperatively via periarticular injection.
219659932|NCT07176156|OTHER|No intervention|Observational one-time questionnaire study without intervention
219659933|NCT07177118|DRUG|Ustekinumab|Ustekinumab group (induction phase with intravenous equivalent doses at weeks 0 and 8, maintenance phase with 90 mg subcutaneously every 8 weeks)
219659934|NCT07177118|DRUG|Risankizumab|Risankizumab group (induction phase with intravenous 600 mg at weeks 0, 4, and 8, maintenance phase with 360 mg subcutaneously every 8 weeks)
219659935|NCT07176832|DRUG|Stiripentol capsule (Diacomit®)|Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.
218969175|NCT03126370|DRUG|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
219659936|NCT07176832|DRUG|Stiripentol oral suspension (Diacomit®)|Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.
219659937|NCT07176871|PROCEDURE|Archwires|All patients were treated with 0.022-inch MBT brackets and sequential NiTi/HANT archwires. A 0.014 NiTi wire was placed initially, followed by monthly archwire changes if no deflection remained. Digital scans were taken from baseline (T0) to 6 months (T6) to measure alignment using Little's irregularity index. Pain was recorded at 24 hours, 3 days, and 1 week with a visual analog scale. CBCT scans before and after alignment assessed root length and alveolar bone changes, with standardized 3D superimpositions ensuring accurate comparisons.
219659938|NCT07175844|OTHER|Vocal exercises|"Participants performed six weekly sessions of 30 minutes, guided by videos focusing on diaphragmatic breathing and contemporary singing techniques. Initial exercises (weeks 1-2) included sustained s sounds, lip trills, humming, melodic vowel sequences, and Ja exercises. Weeks 3-6 included advanced solo exercises such as short and long S, humming variations, mum vocalizations, rhythmic patterns (cha-cha-cha), melodic sequences (Niemak 1-3), and counting exercises. Exercises were performed standing, preferably in front of a mirror."
219659939|NCT07175844|OTHER|Breathing exercises|"Participants in the breathing exercises group were given access to a 30-minute instructional video, in which a licensed physiotherapist demonstrated how to perform the exercises. Participants were instructed to complete the exercises twice per week at a time convenient for them. They could reflect on the exercises and submit questions to the physiotherapist within a closed social media group. Two weeks after the start of the intervention, participants were advised to increase the intensity of the exercises: lengthening inhalation, exhalation, and breath-holding during square breathing, and increasing the number of exhalations during Kapalabhati breathing from 20 to 60 per series, while respecting individual comfort and tolerance."
219659940|NCT07172074|DIAGNOSTIC_TEST|General Psych Trait Measure|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
219659941|NCT07172074|OTHER|Vaccine-Specific Psych Trait Measures|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
219659942|NCT07174557|OTHER|MoodTriggers Application|"The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the early warning system (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date."
219659943|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement creatine|Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
219659944|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement - placebo|Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
219659945|NCT07177183|OTHER|No intervention|Patients in Group 1 will serve as controls and will receive no intervention, only standard care.
219659946|NCT07176949|DRUG|0.01% atropine eye drops|Participants will use 0.01% atropine eyedrops nightly for myopia control.
219659947|NCT07176949|DRUG|0.05% atropine eye drops|Participants will use 0.05% atropine eyedrops nightly for myopia control.
218969176|NCT03126370|DRUG|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
218969177|NCT03126370|DRUG|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
218969178|NCT04157621|DEVICE|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
218969179|NCT04157621|DEVICE|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
218969180|NCT02854176|PROCEDURE|Somatosensory electrical stimulation|
218969181|NCT02854176|PROCEDURE|Control|
218969182|NCT03960554|DRUG|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
218969183|NCT03960554|OTHER|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
218969184|NCT04391413|DEVICE|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
218969185|NCT00430430|PROCEDURE|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
218969186|NCT00430430|PROCEDURE|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
218969187|NCT03865134|DIAGNOSTIC_TEST|Snellen Test|Visual acuity measurement
218969188|NCT03865134|DIAGNOSTIC_TEST|Autorefractometer|Refraction measurement
218969189|NCT03865134|DIAGNOSTIC_TEST|Titmus Stereo Fly Test|Stereopsis measurement
218969190|NCT03865134|DIAGNOSTIC_TEST|Optical Kohlerans Tomography|Retinal development measurement
219659948|NCT07176949|DEVICE|Spectacle lenses with highly aspherical lenslets|"These are a special type of eyeglass lenses designed primarily to slow down the progression of myopia (nearsightedness) in children. The center of the lens provides a clear correction for distance vision, just like regular glasses. The surrounding area contains hundreds of tiny, invisible, and highly aspherical (complex curved) microlenses. These microlenses create a special optical effect. While the child looks straight ahead clearly, peripheral light rays are focused in front of the retina. This is called myopic defocus. Research suggests that this myopic defocus signal helps to control the excessive elongation of the eyeball, which is the main cause of myopia getting worse."
219659949|NCT06410248|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219659950|NCT06410248|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219659951|NCT06410248|OTHER|Questionnaire Administration|Ancillary studies
219659952|NCT06410248|PROCEDURE|Resection|Undergo surgical resection
219659953|NCT06410248|DRUG|Temozolomide|Given PO
219659954|NCT06410248|DRUG|Triapine|Given PO
219659955|NCT07174609|DEVICE|Scrambler Therapy|"Adults with chronic pancreatitis and refractory abdominal pain will receive Scrambler Therapy, a non-invasive neuromodulation device. Electrodes are placed near the painful area to deliver non-pain signals aimed at reducing pain perception. Participants will complete 5-10 daily treatment sessions, each lasting 30-40 minutes, with pain ratings collected before and after sessions and follow-up assessments over 3 months."
219659956|NCT07177235|DRUG|Ketamine|Timing of ketamine initiation will differ between groups (early versus late ketamine)
219659957|NCT07177235|DRUG|Midazolam|Midazolam infusion will be initiated at the same time in both groups
219659958|NCT07175779|OTHER|Face-to-Face Preanesthesia Consultation|Participants receive a standard preoperative anesthesia consultation in person at the hospital
219659959|NCT07175779|OTHER|Telemedicine Preanestehsia Consultation|Participants receive a preoperative anesthesia consultation remotely via video conferencing using a secure telemedicine platform.
218969191|NCT03865134|BEHAVIORAL|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
218969192|NCT03865134|BEHAVIORAL|Peabody Developmental Motor Scales - II|Evaluation of motor development
218969193|NCT03865134|BEHAVIORAL|World Health Organization Quality of Life - BREF|Assesment of quality of life
218969194|NCT03865134|BEHAVIORAL|State - Trait Anxiety Inventory|Assesment of anxiety
219064236|NCT02328664|PROCEDURE|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
219064237|NCT04283929|OTHER|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
219064238|NCT04283929|OTHER|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
219064239|NCT04283929|OTHER|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
219064240|NCT05006625|OTHER|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
219064241|NCT00244608|DRUG|Budesonide/Formoterol Turbuhaler|
219659960|NCT07175818|PROCEDURE|Silk suture only|After third molar extraction, the surgical wound will be closed using silk sutures without plasma application.
219659961|NCT07175818|PROCEDURE|PTFE suture only|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
219659962|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric plasma before being used for wound closure.
219659963|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric Plasma|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
218969195|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
218969196|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
218969197|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
218969198|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
218969199|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
218969200|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
218969201|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
218969202|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
218969203|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
219659964|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric argon Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
219659965|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric argon Plasma|After third molar extraction, PTFE sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
219659966|NCT05414396|BEHAVIORAL|Behavioral Intervention|Attend EML program sessions
219659967|NCT05414396|OTHER|Questionnaire Administration|Ancillary studies
219659968|NCT02481180|DRUG|T0001|injection (SC) T0001 15mg weekly for 12 weeks
219659969|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg weekly for 12 weeks
219659970|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
219659971|NCT02481180|DRUG|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
219659972|NCT02481180|DRUG|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
218969204|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
218969205|NCT01454115|DRUG|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
218969206|NCT01454115|DRUG|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
218969207|NCT02922400|BEHAVIORAL|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
218969208|NCT02180269|DRUG|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
218969209|NCT02180269|DRUG|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
219659973|NCT05940129|BEHAVIORAL|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
219659974|NCT05284929|GENETIC|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
218969210|NCT02180269|DRUG|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
218969211|NCT02180269|DRUG|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
218969212|NCT00150540|DRUG|Lanthanum carbonate|
219659975|NCT00405743|DRUG|CP-4055|CP-4055 Continuous IV infusion
218969213|NCT03432312|DRUG|Nicotine lozenge|Nicotine mint lozenge, 4 mg
218969214|NCT03432312|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
218969215|NCT02097043|DRUG|DA-7218|
218969216|NCT02097043|DRUG|Placebo|
218969217|NCT01737450|DRUG|BKM120|
218969218|NCT01279031|DEVICE|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
218969219|NCT01279031|DEVICE|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
218969220|NCT02545075|DRUG|Ipilimumab|
218969221|NCT02545075|DRUG|Dacarbazine|
218969222|NCT05272462|DRUG|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
219064242|NCT00244608|DRUG|Budesonide Turbuhaler (Pulmicort)|
219064243|NCT00244608|DRUG|Terbutaline Turbuhaler|
219064244|NCT02580149|DRUG|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
218969223|NCT04538573|DEVICE|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
219064245|NCT02580149|DRUG|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
219064246|NCT01492881|DRUG|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
219064247|NCT01492881|DRUG|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
219659976|NCT00405743|DRUG|CP-4055|CP4055 2 and 4 hour IV infusion
219659977|NCT04739332|BEHAVIORAL|The Newborn behavioral observations system|The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
218969224|NCT04538573|DRUG|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
218969225|NCT00261300|DRUG|Pantoprazole|Long term Pantoprozole trial
218969226|NCT00530101|DRUG|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
218969227|NCT00533923|DRUG|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
219659978|NCT03298256|RADIATION|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
219659979|NCT00810017|DRUG|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
219659980|NCT00810017|DRUG|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
218969228|NCT00138177|DRUG|oxaliplatin|Given IV
218969229|NCT00138177|DRUG|leucovorin calcium|Given IV
218969230|NCT00138177|DRUG|vorinostat|Given orally
218969231|NCT00138177|DRUG|fluorouracil|Given IV
218969232|NCT00736879|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
218969233|NCT00736879|DRUG|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
218969234|NCT03090412|DRUG|HPPH|Given IV
218969235|NCT03090412|OTHER|Laboratory Biomarker Analysis|Correlative studies
218969236|NCT03090412|DRUG|Photodynamic Therapy|Undergo PDT
218969237|NCT03090412|OTHER|Quality-of-Life Assessment|Ancillary studies
218969238|NCT03090412|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
218969239|NCT01810432|DRUG|Evacetrapib|Administered orally
219208285|NCT06479174|BEHAVIORAL|CHAMPS-TR|Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
219659981|NCT03729414|PROCEDURE|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
219659982|NCT03729414|PROCEDURE|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
219659983|NCT00933582|DRUG|JNJ-39439335; Placebo; Naproxen|
219659984|NCT02397291|DRUG|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
219659985|NCT02397291|DRUG|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
219659986|NCT02397291|DRUG|Placebo|placebo
219659987|NCT04653623|PROCEDURE|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
219659988|NCT04653623|DRUG|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
219659989|NCT04236336|DEVICE|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
218969240|NCT01810432|OTHER|High-fat Meal|Administered orally, at breakfast.
218969241|NCT02360111|DRUG|Cyclophosphamide|
218969242|NCT04476550|DRUG|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
218969243|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
218969244|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
219659990|NCT00664794|PROCEDURE|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
219659991|NCT00664794|PROCEDURE|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
219659992|NCT00461110|DRUG|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
218969245|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
218969246|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
218969247|NCT03120442|DRUG|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
218969248|NCT03120442|DRUG|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
218969249|NCT03120442|DRUG|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
218969250|NCT05032248|DRUG|Tacrolimus ointment|oral gel
218969251|NCT00718302|DEVICE|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
218969252|NCT00718302|DEVICE|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
218969253|NCT00589901|DRUG|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
218969254|NCT00657449|DRUG|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
218969255|NCT00657449|DRUG|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
218969256|NCT04944095|OTHER|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
218969257|NCT04104334|DRUG|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
219659993|NCT04688398|DIETARY_SUPPLEMENT|Seal oil|Consumption of seal oil once per day (at breakfast)
219659994|NCT04688398|DIETARY_SUPPLEMENT|Control|Consumption of vegetable oil once per day (at breakfast)
219659995|NCT04023305|DRUG|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
219659996|NCT04647994|DIAGNOSTIC_TEST|SARS-CoV-2 serology|Serology test of SARS-CoV-2 for pregnant women
219659997|NCT00568568|DRUG|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
219659998|NCT06433817|RADIATION|Spectral computed tomography scan|Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
219659999|NCT06289998|DRUG|Tamibarotene|Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
219660000|NCT06289998|DRUG|Placebo|Subjects are administrated to placebo in daily for 52 weeks.
219660001|NCT02327013|DRUG|vortioxetine 10 mg tablet|Oral tablets, once daily
218969258|NCT04104334|DRUG|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
218969259|NCT01940562|DRUG|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
219660002|NCT02327013|DRUG|vortioxetine 20 mg tablet|Oral tablets, once daily
219660003|NCT02327013|OTHER|Placebo tablet|Oral tablets, once daily
219660004|NCT05913206|BEHAVIORAL|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
219660005|NCT05913206|BEHAVIORAL|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
219660006|NCT05913206|BEHAVIORAL|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
219660007|NCT05913206|BEHAVIORAL|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
219660008|NCT03593421|DRUG|synthetic PreImplantation Factor|peptide
219660009|NCT00034619|DRUG|ALIMTA|
219660010|NCT00034619|DRUG|Oxaliplatin|
219660011|NCT06292858|DRUG|IMB071703 injection|Intratumoral injection
219660012|NCT01984489|DRUG|Placebo|
219660013|NCT01984489|DRUG|SHR117887|
219660014|NCT06100692|DRUG|Vitamin D|the patients will receive a 30 pts a combination of oral vit D and zinc
218969260|NCT04757740|BIOLOGICAL|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
219064248|NCT01492881|DRUG|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
219064249|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
219064250|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
219064251|NCT01801059|OTHER|questionnaire administration|Ancillary studies
219064252|NCT06469320|OTHER|Online questionnaire|Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel
219660015|NCT01253668|DRUG|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
219660016|NCT01253668|GENETIC|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
219660017|NCT01253668|OTHER|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
219660018|NCT01253668|PROCEDURE|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
219660019|NCT01253668|GENETIC|Protein expression analysis|Correlative studies
219660020|NCT01253668|OTHER|Immunohistochemistry|correlative studies
219660021|NCT03041103|OTHER|Food Product 1|50 grams of fortified nutritious product from legumes
219660022|NCT03289325|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
219660023|NCT03289325|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation."
219660024|NCT02193139|DRUG|WL8713, 6 mg|
219660025|NCT02193139|DRUG|WL8713, 12 mg|
219660026|NCT02193139|DRUG|WL8713, 18 mg|
219660027|NCT02193139|DRUG|WL8713, 24 mg|
219660028|NCT02193139|DRUG|Placebo|
219660029|NCT06643767|DEVICE|Bexa and focus ultrasound|The Bexa exam uses pressure elastography to produce a map of the breast tissue's elasticity to identify any masses. Focused ultrasound is then used to further classify the mass into a BIRADS category.
219660030|NCT01397539|DRUG|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
219660031|NCT01397539|OTHER|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
219660032|NCT03160222|OTHER|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
218969261|NCT04757740|DRUG|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
218969262|NCT02706054|OTHER|saline|The patients received an IM injection of saline near the nerve root (periradicular)
218969263|NCT02706054|DRUG|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
218969264|NCT00876876|DRUG|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
218969265|NCT03923738|DRUG|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
218969266|NCT00620789|DRUG|Escitalopram + CBT-I|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase."
218969267|NCT00620789|BEHAVIORAL|CBT-I plus placebo antidepressant medication|"* CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months)."
218969268|NCT00620789|DRUG|Escitalopram|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase"
218969269|NCT01413412|PROCEDURE|Ventral hernia repair using full thickness skin graft|25 patients
218969270|NCT01413412|PROCEDURE|Ventral hernia repair using mesh|25 patients
218969271|NCT06087913|DRUG|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
218969272|NCT06087913|DRUG|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
218969273|NCT05369676|DRUG|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
218969274|NCT05369676|DRUG|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
218969275|NCT03320226|DIETARY_SUPPLEMENT|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
218969276|NCT04882046|OTHER|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
218969277|NCT04882046|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
218969278|NCT00735254|DEVICE|pulsed dye laser|patient will have scar treated with pulsed dye laser
219660033|NCT00616603|DRUG|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
218969279|NCT00735254|DEVICE|Affirm Laser|patient will have scar treated with Affirm laser
219660034|NCT00616603|DRUG|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
219660035|NCT00616603|DRUG|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
219660036|NCT00616603|DRUG|Normal Saline|2ml of normal saline given once intravenously.
219660037|NCT06648525|DRUG|Adebrelimab|Adebrelimab, IV
219660038|NCT06648525|DRUG|Irinotecan liposomes|Irinotecan liposomes, IV
219660039|NCT06648525|DRUG|Lenvatinib|Lenvatinib, po
219660040|NCT06648525|DRUG|5-Fluorouracil (5-FU)|5-Fluorouracil (5-FU), IV
219660041|NCT06648525|DRUG|Calcium Folinate|Calcium folinate, IV
219660042|NCT03147300|BEHAVIORAL|Current routine practice|Current routine practice for the primary care management of LBP
219660043|NCT03147300|BEHAVIORAL|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
219660044|NCT06623279|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
219660045|NCT04566133|DRUG|Trametinib|orally 2 mg once a day
219660046|NCT04566133|DRUG|Hydroxychloroquine|orally 600 mg twice a day-1,200 mg total dose
219660047|NCT04750733|OTHER|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
218969280|NCT00735254|DEVICE|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
218969281|NCT00735254|OTHER|Placebo|patient will receive no treatment
218969282|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
218969283|NCT04147572|DRUG|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
218969284|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
219660048|NCT04980651|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
219660049|NCT04980651|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
219660050|NCT05286359|DIAGNOSTIC_TEST|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
219660051|NCT05865275|DEVICE|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
219660052|NCT05865275|OTHER|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
219660053|NCT04960852|OTHER|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
219660054|NCT04428242|DEVICE|RHMS-RTM|Assessment of retinal thickness.
219660055|NCT04428242|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure.
218969285|NCT04147572|DEVICE|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
218969286|NCT04147572|DEVICE|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
218969287|NCT02835131|DRUG|Pasireotide|
218969288|NCT02976298|OTHER|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
218969289|NCT04176887|DRUG|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
218969290|NCT04176887|DRUG|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
218969291|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
218969292|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
218969293|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
218969294|NCT05053711|DEVICE|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219064253|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
219064254|NCT03145116|DEVICE|CT ASPHINA 509|Intraocular lens
219660056|NCT03738800|DRUG|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
218969295|NCT05053711|DEVICE|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
218969296|NCT05053711|DEVICE|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
219064255|NCT03399110|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
219064256|NCT03399110|DRUG|Capecitabine|Capecitabine 1000mg/m2
219660057|NCT03738800|DRUG|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
219660058|NCT03738800|DRUG|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
219660059|NCT04486170|OTHER|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
219660060|NCT03180515|DEVICE|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
219660061|NCT01642485|DRUG|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
219660062|NCT01642485|OTHER|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
219660063|NCT01642485|OTHER|Continental breakfast|High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
219660064|NCT01642485|DRUG|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
219660065|NCT01642485|PROCEDURE|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
218969297|NCT05053711|DEVICE|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
218969298|NCT05053711|DEVICE|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
219064257|NCT01477034|DIETARY_SUPPLEMENT|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
219064258|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
219064259|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
219064260|NCT06114823|PROCEDURE|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
219660066|NCT01642485|DRUG|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
219660067|NCT00148577|DEVICE|Transcutaneous Electrical Nerve Stimulation|
219660068|NCT05100953|BEHAVIORAL|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
219660069|NCT00901784|DRUG|Topiramate|25mg Tablets
219660070|NCT00766467|DRUG|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
219660071|NCT00766467|OTHER|Placebo|Placebo taken once a day in the morning
219660072|NCT02110940|OTHER|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
219660073|NCT02110940|OTHER|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
218969299|NCT05053711|DEVICE|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
219064261|NCT06114823|PROCEDURE|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
219208286|NCT06757062|DEVICE|Kinesiology Tape|The kinesiology tape (KT) is applied with the dorsal application for the treatment of carpal tunnel syndrome (CTS). This method is utilized and explained in Krause et al. (2020). This study will assess the efficacy of the application method as well as the varying effects of the color of the KT. Red KT will be compared to skin tone KT. The skin tone KT will be color-matched as closely as possible to each participant's skin tone to reduce the effect of the KT color. In this way, the study's second purpose is to understand the potential effect of color on psychological function and performance in the context of aggressive first-person shooter esports games.
219660074|NCT02893904|DEVICE|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
219660075|NCT02893904|DEVICE|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
219660076|NCT02718248|DEVICE|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
219660077|NCT02718248|BEHAVIORAL|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
219660078|NCT02863081|OTHER|Survey|Administered to healthcare providers
219660079|NCT02863081|OTHER|interview|Administered to patients and LAR (i.e., interviews)
219660080|NCT02307084|PROCEDURE|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
219660081|NCT00566956|PROCEDURE|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
219660082|NCT00800956|DRUG|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
218969300|NCT04034082|DEVICE|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
218969301|NCT04034082|OTHER|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
218969302|NCT05161195|DRUG|Ribociclib|Participants continue ribociclib as was administered in their parent study
218969303|NCT05161195|DRUG|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
218969304|NCT05161195|DRUG|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
218969305|NCT05161195|DRUG|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
218969306|NCT05161195|DRUG|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
218969307|NCT05161195|DRUG|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
218969308|NCT01404975|OTHER|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
218969309|NCT00132639|DRUG|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
218969310|NCT00132639|DRUG|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
218969311|NCT01251744|PROCEDURE|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
219208287|NCT06746168|PROCEDURE|Locoregional anesthesia|The FTB + iPACK group will receive 12 ml 0,5% ropivacaine for the FTB and 20 ml of ropivacaine 0.5% for the iPACK block under US guidance after spinal anesthesia
219208288|NCT06746168|PROCEDURE|Local Anesthetic Ropivacaine|The control group (LIA) will receive 120 ml 0.25% ropivacaine for surgical LIA placement.
219660083|NCT01284387|BIOLOGICAL|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
219660084|NCT05265156|OTHER|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
219660085|NCT02849067|OTHER|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
219660086|NCT02849067|OTHER|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
219660087|NCT03652948|BEHAVIORAL|Meru Health Ascend Program|Cognitive-behavioral skills, mindfulness
219660088|NCT01492725|DEVICE|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
219660089|NCT01492725|GENETIC|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
219660090|NCT03466125|PROCEDURE|Cardiac surgery|Retrospective cohort study
219660091|NCT01667939|BEHAVIORAL|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
219208289|NCT06918431|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
219660092|NCT00972634|OTHER|computer-assisted intervention|symptom assessment
219660093|NCT00972634|OTHER|questionnaire administration|Symptom assessment
219660094|NCT00972634|PROCEDURE|assessment of therapy complications|Symptom assessment
219660095|NCT00972634|PROCEDURE|quality-of-life assessment|Symptom assessment
219660096|NCT03435224|DEVICE|INVSENSOR00012|Noninvasive pulse oximeter sensor
219660097|NCT02523235|DRUG|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
219660098|NCT03678896|BEHAVIORAL|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
219660099|NCT03678896|BEHAVIORAL|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
219660100|NCT05259384|PROCEDURE|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
219660101|NCT05259384|PROCEDURE|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
219660102|NCT05259384|PROCEDURE|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
219660103|NCT05259384|PROCEDURE|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
219660104|NCT05400031|BIOLOGICAL|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
219660105|NCT05400031|BIOLOGICAL|Placebo|Placebo
219660106|NCT02604550|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
219660107|NCT02604550|DRUG|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
219208290|NCT06918431|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219660108|NCT02604550|DRUG|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
219660109|NCT02253550|DRUG|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
219660110|NCT02253550|DRUG|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
219660111|NCT02149316|PROCEDURE|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
219660112|NCT02149316|PROCEDURE|control|a deflated cuff placed on the right upper arm
219660113|NCT03014713|DRUG|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
219208291|NCT06918431|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsy
219208292|NCT06918431|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsy
219660114|NCT03014713|DRUG|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
219208293|NCT06918431|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219660115|NCT03014713|DRUG|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
219660116|NCT00801697|BIOLOGICAL|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
219660117|NCT00801697|BIOLOGICAL|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
219660118|NCT00801697|BIOLOGICAL|rAd35|VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL
219208294|NCT06918431|DRUG|Cyclophosphamide|Given IV
219208295|NCT06918431|DRUG|Cytarabine|Given IT
219208296|NCT06918431|DRUG|Cytarabine|Given IV or SC
219208297|NCT06918431|DRUG|Daunorubicin Hydrochloride|Given IV
219208298|NCT06918431|DRUG|Dexamethasone|Given PO
219208299|NCT06918431|PROCEDURE|Echocardiography|Undergo echocardiography
219660119|NCT00801697|BIOLOGICAL|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
219208300|NCT06918431|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219208301|NCT06918431|DRUG|Mercaptopurine|Given PO
219208302|NCT06918431|DRUG|Methotrexate|Given IT
219208303|NCT06918431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219208304|NCT06918431|BIOLOGICAL|Rituximab|Given IV
219208305|NCT06918431|DRUG|Vincristine Sulfate|Given IV
219208306|NCT03236428|DRUG|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
219208307|NCT06870058|DRUG|NH280105- SAD|Dose formulation: Capsule Route of administration: oral
219208308|NCT06870058|DRUG|NH280105- MAD|Dose formulation: Capsule Route of administration: oral
219208309|NCT06870058|DRUG|Placebo|Matching placebo comparator
219208310|NCT06874244|DRUG|Local Anesthesia (lidocaine hydrochloride)|Injection of lidocaine as local anesthesia
219660120|NCT00801697|BIOLOGICAL|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
219660121|NCT00801697|BIOLOGICAL|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
219660122|NCT01021488|DRUG|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
219660123|NCT01021488|DRUG|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
219660124|NCT01720329|DIETARY_SUPPLEMENT|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
219660125|NCT01720329|OTHER|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
219660126|NCT01273740|PROCEDURE|External support|Bypass surgery with externally supported graft
219660127|NCT01398189|DRUG|clozapine|C-11 clozapine
219660128|NCT03844594|DRUG|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
219660129|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
219660130|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
219660131|NCT00000865|DRUG|Abacavir sulfate|
219660132|NCT00000865|DRUG|Lamivudine|
218969312|NCT01251744|PROCEDURE|Cord blood sample|Cord blood sample taken at the time of delivery.
219660133|NCT00000865|DRUG|Stavudine|
219660134|NCT00000865|DRUG|Zidovudine|
218969313|NCT01251744|PROCEDURE|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
218969314|NCT01251744|PROCEDURE|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
218969315|NCT01251744|PROCEDURE|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
218969316|NCT01670604|DRUG|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
218969317|NCT01670604|DRUG|Tetraspan, B. Braun, Melsungen, Germany|
218969318|NCT01299701|DRUG|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
218969319|NCT00920101|DRUG|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
218969320|NCT00920101|BEHAVIORAL|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
218969321|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
218969322|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
218969323|NCT00751621|BIOLOGICAL|IgPro20|
218969324|NCT00953381|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
218969325|NCT00953381|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
218969326|NCT00953381|DRUG|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
218969327|NCT00953381|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
218969328|NCT04274387|BEHAVIORAL|Mindfulness-based Stress Reduction(MBSR)|A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
218969329|NCT04268589|OTHER|virtual reality game|routine
218969330|NCT04205994|DRUG|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
218969331|NCT04205994|OTHER|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
218969332|NCT01567735|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
218985427|NCT02676115|OTHER|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
219064262|NCT03425149|BIOLOGICAL|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
219064263|NCT03425149|BIOLOGICAL|Placebo|Phosphate buffered saline (PBS)
219660135|NCT00000865|DRUG|Didanosine|
219660136|NCT00079872|DRUG|Pemetrexed|
219660137|NCT01488669|PROCEDURE|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
219660138|NCT01488669|PROCEDURE|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
219064264|NCT00179088|BEHAVIORAL|Patient may be able to put weight on the operated leg|
218969333|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy)|"The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~For study GROUP 1:~Study drugs are:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 1 will receive one of the following for each treatment period: monotherapy with Indapamide, bitherapy with Indapamide plus Perindopril, or bitherapy with Perindopril plus Amlodipine."
218969334|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy)|"Study drugs:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 2 will receive one of the following monotherapies: Perindopril , Indapamide, or Amlodipine."
218969335|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment|"For study GROUP 3:~Subjects will be prescribed an individualized new antihypertensive treatment at their consultation with the Investigator at Visit 1."
218969336|NCT05314075|PROCEDURE|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
218969337|NCT05314075|PROCEDURE|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
218969338|NCT02978924|DEVICE|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
218969339|NCT05519241|DRUG|PLZ4-coated paclitaxel-loaded micelles (PPM)|PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
218969340|NCT06213545|DIAGNOSTIC_TEST|In-clinic interpretation|Reading patch test result at clinic
218969341|NCT06213545|DIAGNOSTIC_TEST|Photo interpretation|Reading patch test result by sending photo to clinic
218969342|NCT06273592|OTHER|Animal-based meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
218969343|NCT06273592|OTHER|Plant-based meat meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
218969344|NCT01764152|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
218969345|NCT05720702|DIETARY_SUPPLEMENT|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
218969346|NCT05669365|BEHAVIORAL|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
218969347|NCT05135403|DEVICE|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
218969348|NCT06562777|OTHER|Non-Interventional Study|Non-Interventional Study
219208311|NCT06874244|DRUG|Iontophoresis of Tetracaine and oxymetazoline|Injecting Tetracaine Hydrochloride 4% with 0.5% Oxymetazoline to the oral tissue using iontophoresis technique
218969349|NCT05781789|OTHER|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
218969350|NCT04723654|DEVICE|Wireless Wearable Vital Sign Monitor|Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours
218969351|NCT06223958|DRUG|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
218969352|NCT06223958|DRUG|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
218969353|NCT04189835|DIAGNOSTIC_TEST|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
218969354|NCT06494631|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
218969355|NCT04665180|DIAGNOSTIC_TEST|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
218969356|NCT02310321|DRUG|Gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
218969357|NCT02310321|DRUG|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
218969358|NCT02310321|DRUG|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
218969359|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
218969360|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
218969361|NCT02839278|BIOLOGICAL|Blood sample|
218969362|NCT06168058|DIAGNOSTIC_TEST|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
218969363|NCT06168058|PROCEDURE|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
218969364|NCT06584240|DRUG|Sequence 1|Single treatment, intramuscularly injected. The total injection 100-150U.
218969365|NCT06584240|DRUG|Sequence 2|Single treatment, intramuscularly injected. The total injection 200-250U.
218969366|NCT06584240|DRUG|Sequence 3|Single treatment, intramuscularly injected. The total injection 350-400U.
218969367|NCT06584240|DRUG|Sequence 4|Single treatment, intramuscularly injected. The total injection ≤400U.
218969368|NCT06584240|DRUG|Sequence 5|Single treatment, intramuscularly injected.
218969369|NCT03707431|BEHAVIORAL|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
219064265|NCT00746837|DRUG|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
219064266|NCT00746837|DRUG|AZD5672|50 mg od, 12 days
219660139|NCT00303212|OTHER|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
219660140|NCT04824755|PROCEDURE|Yune Zhao|Yune Zhao did congenital cataract surgeries
219660143|NCT02962323|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
219660144|NCT02962323|DRUG|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
219660145|NCT01404208|DRUG|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
219660146|NCT01404208|DRUG|Placebo|Sugar pill
219660147|NCT02570139|DEVICE|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
219660148|NCT02570139|DEVICE|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
219064267|NCT00746837|DRUG|AZD5672|150mg od, 12 days
219064268|NCT02614976|DEVICE|Padding|"Padding webrill (Covidian) TM 6"
219064269|NCT02653521|RADIATION|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
219064270|NCT00086346|DRUG|Sirolimus (Rapamune)|
219064271|NCT00086346|DRUG|Cyclosporine or Tacrolimus|
219208312|NCT06336681|DEVICE|PrO2Fit Device|The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
219660149|NCT02456038|DRUG|Asfotase Alfa (ALXN1215)|
219064272|NCT05544994|OTHER|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
219064273|NCT05544994|OTHER|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
219064274|NCT05197959|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
219660150|NCT01777295|BIOLOGICAL|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219660151|NCT01777295|BIOLOGICAL|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219660152|NCT01777295|BIOLOGICAL|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219660153|NCT00634595|DRUG|E10A|E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
219660154|NCT00634595|DRUG|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
219660155|NCT00634595|DRUG|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
219660156|NCT06478602|BIOLOGICAL|Fecal microbiota transplantation|Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
219660157|NCT06027502|BEHAVIORAL|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
219660158|NCT04122664|DEVICE|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
219660159|NCT04122664|DEVICE|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
219660160|NCT00339196|DRUG|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
219660161|NCT03684551|OTHER|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
219660162|NCT03684551|OTHER|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
219660163|NCT03684551|OTHER|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
219660164|NCT01685853|DRUG|Bisacodyl plus PEG-CS|"* the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
219660165|NCT01685853|DRUG|PEG 4 litres split|"* the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
219660166|NCT03499405|BEHAVIORAL|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
219660167|NCT05578105|OTHER|no intervention|No intervention, only observation
219660168|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
219660169|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Sucrosomial® B12
219660170|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|B-SUB® B12
219208313|NCT07031063|DRUG|DTG/3TC|Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group
219208314|NCT07031063|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
219208315|NCT07032285|DRUG|Cirtuvivint|Cirtuvivint (SM08502) will be administered orally at 80 mg/day, 5 days on/2 days off. Cirtuvivint is supplied as tablets containing 10 mg or 50 mg of the active pharmaceutical ingredient (API). Cirtuvivint is taken with water once a day (on dosing days) at the same time every day. Doses will be taken without food (foo restriciton 1 hour before treatment and 2 hours afterdosing). Doses delayed by 12 hours will be considered missed and should not be taken. If vomiting occurs,the dose must not be retaken. Cirtuvivint is dosed in 28-day continuous cycles (28 days of treatment will beconsidered as one cycle) Treatment will continue until disease progression, unacceptable toxicity or investigator/patient decision
219660171|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Mecogen SL® B12
219660172|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Evermin® B12
219660173|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Neuromax® B12
219660174|NCT00564044|PROCEDURE|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
219660175|NCT00908076|DRUG|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
219660176|NCT02382796|DRUG|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
219660177|NCT00782600|DRUG|suspension IR|50 mg IR suspension once daily for one day
219660178|NCT00782600|DRUG|CR 1|50 mg shorter release CR once daily for one day
219660179|NCT00782600|DRUG|CR 2|50 mg medium release CR once daily for one day
219660180|NCT00782600|DRUG|CR 3|longer release SR formulation once daily for one day
219660181|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
219660182|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
219660183|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
219660184|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
219660185|NCT04007107|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
219660186|NCT04007107|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
219660187|NCT06250907|PROCEDURE|The guidance of dynamic navigation|Osteotomy and implant placement with the guidance of dynamic navigation
219660188|NCT06250907|PROCEDURE|The guidance of static template|Osteotomy and implant placement with the guidance of static template
219660189|NCT03412188|DRUG|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
219660190|NCT03412188|DRUG|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
219660191|NCT05910060|DIAGNOSTIC_TEST|OTTAWA ANKLE RULES|count the ottawa score and do an x-ray if the score is greater than or equal to 1
219660192|NCT04448600|OTHER|MRI|"The patients included in the study will all have a cerebral MRI as part of the cholesteatoma follow-up or for the assessment of cerebral or inner ear pathology.~\- ENT evaluation"
219660193|NCT05729542|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
219660194|NCT05729542|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
219660195|NCT05648175|BEHAVIORAL|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
219660196|NCT05648175|BEHAVIORAL|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
219660197|NCT05648175|BEHAVIORAL|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
219660198|NCT05356975|BEHAVIORAL|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~1. One leg squat, side plank, and push up.~2. Deadlift, lumbar extension stretch, and row.~3. Glute bridge, crunches, and front raise."
219660199|NCT05356975|BEHAVIORAL|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
219660200|NCT06016985|DIETARY_SUPPLEMENT|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
219660201|NCT01678885|BEHAVIORAL|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
219660202|NCT01678885|OTHER|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
219660203|NCT01678885|DEVICE|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
218969370|NCT03707431|BEHAVIORAL|Pain Education|The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
219660204|NCT01678885|BEHAVIORAL|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
219660205|NCT01678885|DEVICE|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
219660206|NCT01678885|DEVICE|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
219660207|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
219660208|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
219660209|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
219660210|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
219660211|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
219660212|NCT06450639|DRUG|Satralizumab|Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
219660213|NCT06391593|DRUG|ALTO-203 25 μg|Active, ALTO-203 25 μg
219660214|NCT06391593|DRUG|ALTO-203 75 μg|Active, ALTO-203 75 μg
219660215|NCT06391593|DRUG|Placebo|Comparator, Placebo-to-match
219660216|NCT04068688|BEHAVIORAL|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
219660217|NCT04068688|BEHAVIORAL|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
219660218|NCT01901861|DRUG|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
219660219|NCT01901861|DRUG|Placebo|Placebo is given before meal ingestion
219660220|NCT03616561|DRUG|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
219660221|NCT05217511|BEHAVIORAL|Neuromuscular Electrical Stimulation|NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
219660222|NCT05225571|OTHER|no intervention|there is no any intervention in this study. it is an observational and cross-sectional study.
219660223|NCT05956353|BEHAVIORAL|Digital Storytelling Intervention|Culturally tailored narrative-based videos created by individuals to promote colorectal, breast and cervical cancer screening among eligible participants in a primary care practice.
219660224|NCT05123976|DRUG|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
219660225|NCT05123976|DRUG|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
219660226|NCT02618694|PROCEDURE|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
219660227|NCT02618694|PROCEDURE|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
219660228|NCT01286194|DRUG|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
219660229|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
219660230|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
219660231|NCT06622291|DRUG|Nitric Oxide|Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
219660232|NCT06622291|OTHER|Placebo|This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
219660233|NCT00156000|DEVICE|Fetal Fibronectin|fFN test done during pregnancy
219660234|NCT00156000|DEVICE|Salivary Estriol|Salivary Estriol done during pregnancy
219660235|NCT02554318|DRUG|Rifampicin|
219660236|NCT02554318|DRUG|Isoniazid|
219660237|NCT02554318|DRUG|Pyrazinamide|
219660238|NCT02554318|DRUG|Ethambutol|
219660239|NCT02554318|DIETARY_SUPPLEMENT|Fermented soybean|
219660240|NCT02248974|OTHER|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
219660241|NCT06126094|DIETARY_SUPPLEMENT|Myrkl|The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg
219660242|NCT06126094|DIETARY_SUPPLEMENT|dextrin|The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
219660243|NCT01122940|DRUG|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
219660244|NCT01122940|DRUG|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
219660245|NCT05189522|DEVICE|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
219660246|NCT05189522|OTHER|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
219660247|NCT02332239|BEHAVIORAL|iDOVE Intervention (ED+text)|"1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program"
219660248|NCT02332239|BEHAVIORAL|Control (EUC)|"1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program"
219660249|NCT00374218|DRUG|High Fructose Corn Syrup|
219660250|NCT00374218|DRUG|Sucromalt|
219660251|NCT02271724|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
219660252|NCT02271724|PROCEDURE|Blood sample|Blood sample
219660253|NCT05691764|DRUG|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
219660254|NCT05691764|PROCEDURE|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
219660255|NCT05691764|DRUG|Placebo|Intravenous placebo
219064275|NCT05197959|OTHER|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take \~ 30 minutes to complete.
219064276|NCT00035438|DRUG|St. John's Wort|
219064277|NCT06358482|BEHAVIORAL|oscillating toothbrush|oscillating toothbrush
219064278|NCT06358482|BEHAVIORAL|standard manual toothbrush|standard manual toothbrush
219064279|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
219064280|NCT04696068|OTHER|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
219064281|NCT01473654|BEHAVIORAL|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
219064282|NCT00022568|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|
219660256|NCT00504959|DRUG|ranibizumab|
219660257|NCT03212066|BEHAVIORAL|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
219660258|NCT01897610|DRUG|Immuncell-LC|intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
219660259|NCT05502991|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
219660260|NCT00115037|DRUG|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
219660261|NCT00115037|DRUG|placebo|placebo comparer for 16 weeks in phase 2.
219660262|NCT00115037|BEHAVIORAL|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
219660263|NCT00115037|BEHAVIORAL|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
219660264|NCT00115037|BEHAVIORAL|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
219660265|NCT03241537|RADIATION|Intensity modulated radiotherapy|
219660266|NCT00396877|DRUG|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
219660267|NCT00396877|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
219064283|NCT04180826|OTHER|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
219064284|NCT02416791|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
219064285|NCT02416791|DEVICE|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
219064286|NCT02416791|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
219064287|NCT02416791|OTHER|Physical Therapy|Physical therapy will be administered for 40 minutes.
219064288|NCT02416791|OTHER|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
219660268|NCT03168490|DIETARY_SUPPLEMENT|Gluten Friendly bread|parallel study
219660269|NCT00073502|DRUG|OSI-7904L|
219660270|NCT00334802|DRUG|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
219660271|NCT00334802|DRUG|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
219660272|NCT04289090|DRUG|Sevoflurane Inhalant Product|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
219660273|NCT04289090|DRUG|Propofol 10 MG/ML|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
219660274|NCT02274064|BEHAVIORAL|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
219660275|NCT00001300|DRUG|doxorubicin|
219660276|NCT00001300|DRUG|ifosfamide|
219660277|NCT00001300|DRUG|mesna|
219660278|NCT02009059|DEVICE|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
219660279|NCT03436199|DRUG|ADS-5102, 137 mg|Oral capsules
219660280|NCT03436199|DRUG|ADS-5102, 274 mg|Oral capsules
219660281|NCT03436199|OTHER|Placebo|Oral capsules
219660282|NCT00672399|DRUG|exenatide|Subcutaneously injected, 10 mcg, single doses
219660283|NCT00672399|DRUG|Moxifloxacin|oral, 400 mg tablet, single doses
218969371|NCT01698905|DRUG|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
218969372|NCT05731986|DIAGNOSTIC_TEST|Orthostatic challenge|"Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation."
218969373|NCT05731986|DEVICE|Biostim-5 transcutaneous spinal stimulation - Mapping|Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
218969374|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Optimal testing"|Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
218969375|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Sham testing"|Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
218969376|NCT02445443|DEVICE|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
219660284|NCT00672399|DRUG|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
219660285|NCT06731309|PROCEDURE|Punch Debridement|A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.
219660286|NCT06731309|PROCEDURE|Incision and Drainage|Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
219660287|NCT01792323|DRUG|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
219660288|NCT04559035|OTHER|Nasal lavage|Twice daily nasal lavage.
219660289|NCT02484638|DRUG|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
219660290|NCT02484638|DRUG|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
219660291|NCT02898558|BEHAVIORAL|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
219660292|NCT02898558|DEVICE|magnifying lenses|
219660293|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
219660294|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
219660295|NCT04189133|DRUG|Lutropin alfa|daily increasing dosages of lutropin alfa
219660296|NCT04189133|DRUG|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
219660297|NCT06125340|DRUG|Placebo|5 days of placebo to be given after 3-5 days of antibiotics
219660298|NCT06125340|DRUG|Amoxicillin|Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
219660299|NCT00085098|BIOLOGICAL|filgrastim|Given by infusion or injection
219660300|NCT00085098|DRUG|carboplatin|Given IV over 1 hour
219660301|NCT00085098|DRUG|cisplatin|Given IV over 6 hours
219660302|NCT00085098|DRUG|cyclophosphamide|Given IV over 1 hour
219660303|NCT00085098|DRUG|etoposide|Given IV over 2 hours
219660304|NCT00085098|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week
219660305|NCT04222140|COMBINATION_PRODUCT|ERIPTO Protocol|combination biologic treatment
219660306|NCT04222140|BIOLOGICAL|BMAC Only|BMAC treatment only
219660307|NCT04698421|BIOLOGICAL|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
219660308|NCT03515629|DRUG|REGN2810/ipi|REGN2810 plus ipilimumab
219660309|NCT03515629|DRUG|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
219660310|NCT03515629|DRUG|Pembrolizumab|Reference drug administered IV infusion
219660311|NCT04902729|DRUG|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
219660312|NCT04902729|DRUG|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
219660313|NCT03595865|DRUG|tafluprostin|Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
219064289|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
219660314|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
219660315|NCT00002048|DRUG|Zidovudine|
219660316|NCT00000448|DRUG|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
219660317|NCT00000448|DRUG|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
219660318|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
219660319|NCT06731595|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
219660320|NCT01886781|DRUG|Lactobacillus plantarum 299v|two capsules of 5 X 10 \^9 c.f.u each
219660321|NCT01886781|DRUG|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
219660322|NCT01886781|OTHER|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
219660323|NCT01886781|OTHER|Wash - out period|Wash - out period following treatment phase of eight weeks
219660324|NCT03493581|PROCEDURE|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
219660325|NCT03493581|DIAGNOSTIC_TEST|blood-sampled|"* after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~* after 6 weeks (V2),~* after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~* \- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~* after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~* after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
218969377|NCT04298723|DEVICE|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (Watchman or Watchman FLX) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
218969378|NCT03207555|DRUG|Ibrutinib|420 mg by mouth once daily.
218969379|NCT05900206|DRUG|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
218969380|NCT05900206|DRUG|Docetaxel|Active comparator. IV infusion.
218969381|NCT05900206|DRUG|Paclitaxel|Active comparator. IV infusion.
219660326|NCT03493581|OTHER|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
219660327|NCT03974841|PROCEDURE|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
218969382|NCT05900206|DRUG|Carboplatin|Active comparator. IV infusion.
218969383|NCT05900206|DRUG|Trastuzumab|Active comparator. IV infusion.
218969384|NCT05900206|DRUG|Pertuzumab|Active comparator. IV infusion.
218969385|NCT05900206|DRUG|Ribociclib|Experimental drug. Tablets.
218969386|NCT05900206|DRUG|Letrozole|Experimental drug. Tablets.
218969387|NCT05900206|DRUG|Epirubicin|Active comparator. IV infusion.
218969388|NCT05900206|DRUG|Cyclophosphamide|Active comparator. IV infusion.
219660328|NCT04570163|DEVICE|Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)|Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
219660329|NCT05725213|DRUG|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
219660330|NCT06730282|DRUG|Danggui Shaoyao San (DSS)|Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
219660331|NCT06730282|DRUG|Cuscuta Chinensis (Tu Si Zi)|Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
219660332|NCT06730282|DRUG|Combination Therapy (DSS + Tu Si Zi)|This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
219660333|NCT06730282|DRUG|Placebo|Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
219660334|NCT00123461|DRUG|Hectorol (doxercalciferol capsules), 0.5mcg|
219660335|NCT03442374|OTHER|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
219660336|NCT03769194|BIOLOGICAL|VLA15|a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
219660337|NCT03769194|BIOLOGICAL|Placebo|Placebo: PBS (Phosphate Buffered Saline)
219660338|NCT01944826|OTHER|Registry of patients with Tako-Tsubo cardiomyopathy|
219660339|NCT04262804|DRUG|Margetuximab|Margetuximab IV
218969389|NCT04107727|DRUG|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
218969390|NCT04107727|DRUG|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
218969391|NCT04107727|DRUG|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
218969392|NCT04107727|DRUG|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
218969393|NCT01106716|DRUG|Placebo|Placebo IV Infusion
218969394|NCT01106716|DRUG|KAI-1678|KAI-1678 IV Infusion
218969395|NCT01106716|DRUG|Lidocaine|Lidocaine
218969396|NCT05715333|BIOLOGICAL|CM326|CM326 Injection
218969397|NCT05715333|OTHER|Placebo|Subcutaneous injection
218969398|NCT02481453|DRUG|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
218969399|NCT02481453|DRUG|Placebo|Comparator: placebo
218969400|NCT04150406|DIETARY_SUPPLEMENT|Flexofytol|Curcuma extract
218969401|NCT04150406|OTHER|Placebo|placebo
218969402|NCT03784365|DRUG|One dose of Cefo-perazone Sulbactum|Antibiotic
218969403|NCT06327542|OTHER|Group Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
219660340|NCT04262804|DRUG|Trastuzumab|Trastuzumab IV
219660341|NCT04262804|DRUG|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
219660342|NCT04262804|DRUG|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
219660343|NCT04262804|DRUG|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
219660344|NCT06083701|DRUG|Linperlisib in combined with Chidamide|"* Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~* Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
219660345|NCT06655467|BEHAVIORAL|Routine Care|This study involves no change in clinical care and no study specific interventions for participants.
219660346|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
219660347|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System with In-office Follow-up|
219660348|NCT06247072|DEVICE|Tonometer|measures IOP
219660349|NCT01985958|DEVICE|Radiation therapy|
219660350|NCT05937607|BEHAVIORAL|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
219660351|NCT01672294|OTHER|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
219660352|NCT01672294|OTHER|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
219660353|NCT05370508|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
219660354|NCT06731543|OTHER|No interventions will be made|
219660355|NCT00203463|DRUG|topiramate|
219660356|NCT03887117|OTHER|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
219660357|NCT03887117|OTHER|IQOS without Exercise Training Program|Switch to IQOS use only, without participation in a training program
219660358|NCT03887117|OTHER|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
219660359|NCT03887117|OTHER|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
219660360|NCT04879836|DEVICE|Teething Gel|Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks
219660361|NCT04879836|DEVICE|Teething Ring|The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks
219660362|NCT05626218|OTHER|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
219660363|NCT01739764|DRUG|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
219660364|NCT06204120|DRUG|LPM3480392 Injection|PCA administration
219660365|NCT06204120|DRUG|Placebo|PCA administration
219660366|NCT06204120|DRUG|morphine hydrochloride injection|PCA administration
219660367|NCT05639504|DIAGNOSTIC_TEST|IMX-BVN-4 and IMX-SEV-4|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
219660368|NCT03717168|DRUG|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
219660369|NCT03717168|OTHER|Control|All patients will not receive growth hormone.
218969404|NCT06327542|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
218969405|NCT01180166|DRUG|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
218969406|NCT00282542|PROCEDURE|Hepatocyte Infusion|
219064290|NCT04040127|BIOLOGICAL|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
219660370|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
218969407|NCT01729247|DEVICE|NIOX MINO® Instrument (09-1100)|
219064291|NCT04040127|OTHER|Saline solution|saline solution used to rinse the canal.
219064292|NCT00311272|BIOLOGICAL|MelCancerVac|
219064293|NCT04192994|DRUG|Intravitreal Antibiotic Injection|Intravitreal Antibiotic Injection
219660371|NCT03544125|BIOLOGICAL|Durvalumab|Given IV
218969408|NCT00381953|DRUG|Peginterferon alfa-2a|
218969409|NCT00381953|DRUG|Interferon alfa-2a|
219064294|NCT04192994|PROCEDURE|Pars Plana Vitrectomy|Pars Plana Vitrectomy
219660372|NCT03544125|DRUG|Olaparib|Given PO
219660373|NCT06009289|BEHAVIORAL|Light therapy|One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
219660374|NCT01914965|DRUG|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
219660375|NCT01914965|DRUG|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
219660376|NCT01389258|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
219660377|NCT02772146|DEVICE|CLS UF|One single ultrafiltration session of 10 hours.
219064295|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
219064296|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
219064297|NCT02978144|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
219064298|NCT02978144|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
219064299|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
219064300|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
219064301|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
219660378|NCT01052623|DRUG|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
219660379|NCT01916421|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
219660380|NCT00926536|DEVICE|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
219660381|NCT00926536|DEVICE|DSA only|DSA imaging only
218969410|NCT00381953|DRUG|Ribavirin|
218969411|NCT04673981|DIAGNOSTIC_TEST|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
218969412|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with inner side of the graft|Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
218969413|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with outer side of the graft|The tunnel technique for root coverage with CTG with outer side of the graft
218969414|NCT02425527|BEHAVIORAL|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
218969415|NCT02425527|BEHAVIORAL|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
218969416|NCT01669707|DRUG|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
218969417|NCT01669707|DRUG|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
218969418|NCT01393015|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
219064302|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
219064303|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
219064304|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
219064305|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
219064306|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
219064307|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
219064308|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
219064309|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
219660382|NCT01385956|DRUG|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
219660383|NCT01385956|DRUG|Gemcitabine|Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
219660384|NCT05330585|DEVICE|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
219660385|NCT05330585|OTHER|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
219660386|NCT02612545|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
219660387|NCT02612545|DRUG|Mefloquine (MQ)|ACT partner drug
219660388|NCT05610579|OTHER|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.
219660389|NCT05610579|OTHER|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
219064310|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
219064311|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
218969419|NCT01393015|DEVICE|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
219064312|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
219064313|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
219064314|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
219064315|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
219064316|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
218969420|NCT00500305|PROCEDURE|Withhold standard INDO dose if BNP < 100 pg/ml|
218969421|NCT02594241|DRUG|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
218969422|NCT02594241|DRUG|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
218969423|NCT02325791|DRUG|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
218969424|NCT02325791|DRUG|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
218969425|NCT02325791|DRUG|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
218969426|NCT02325791|DRUG|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
218969427|NCT00877474|DRUG|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
218969428|NCT03895021|BEHAVIORAL|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\])."
219660390|NCT06618612|OTHER|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
219660391|NCT06618612|DEVICE|PuraPly AM|PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
219660392|NCT06618612|DEVICE|PuraPly XT|PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
219660393|NCT00449228|PROCEDURE|-preoperative education and total hip replacement|-preoperative education and total hip replacement
219660394|NCT00990665|DEVICE|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
218969429|NCT00752115|DRUG|sildenafil|50mg, day1,8 and 15 in each cycle
218969430|NCT00752115|DRUG|placebo|1 tab, day 1,8 and 15 in each cycle.
218969431|NCT00752115|DRUG|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
218969432|NCT00752115|DRUG|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
218969433|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
218969434|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
218969435|NCT03953183|OTHER|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
218969436|NCT03953183|OTHER|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
218969437|NCT00006324|DRUG|Ethinyl estradiol/levonorgestrel|
218969438|NCT00006324|DRUG|Medroxyprogesterone acetate|
218969439|NCT02658058|OTHER|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
219064317|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
219064318|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
219064319|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
219064320|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
219660395|NCT02460523|PROCEDURE|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
219660396|NCT02460523|PROCEDURE|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
219660397|NCT02656134|PROCEDURE|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
219660398|NCT02656134|GENETIC|Molecular analysis.|DNA analysis
219660399|NCT04568291|OTHER|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
219660400|NCT04568291|OTHER|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
219660401|NCT06648187|OTHER|Early motor-cognitive integrative training (e-MCIT)|Early motor-cognitive integrative training (e-MCIT) is an approach where motor and cognitive training are conducted simultaneously. The intervention consists of 30-minute sessions, conducted 4-5 times per week, until discharging from the hospital. Both motor and cognitive training have five stages each, and their progression is independent, meaning that during training, a participant might be in the fourth stage of motor training and the second stage of cognitive training. According to hospital's policy, occupational therapy and speech therapy will be provided in schedule if needed. Motor training is derived from a previous protocol of early mobilization intervention applied to a population with SAH, which based on the ICU Mobility Scale. The activities of cognitive training target areas such as attention, orientation, language ability, memory, calculation, judgment, working memory, executive function, and daily living functions.
219660402|NCT02660879|OTHER|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
219660403|NCT02660879|OTHER|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
219660404|NCT03838237|DIAGNOSTIC_TEST|Cardiological evaluation|"Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
219660405|NCT02143167|DRUG|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
219660406|NCT02143167|DRUG|Placebo|
218969440|NCT02658058|OTHER|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
219064321|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
219064322|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
219064323|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
219064324|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
219064325|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
219064326|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
219064327|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
219064328|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
219660407|NCT05541900|BEHAVIORAL|TEC-Sacredness|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a self-related word paired with a life-related stimulus, a sacredness of life-related stimulus paired with a pleasant stimulus, and a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
219660408|NCT05541900|BEHAVIORAL|TEC-Control|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
219660409|NCT01080391|DRUG|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
218969441|NCT02658058|OTHER|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
218969442|NCT01100736|DRUG|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
218969443|NCT01100736|DRUG|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
218969444|NCT01100736|DRUG|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
218969445|NCT01100736|BIOLOGICAL|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
218969446|NCT04568824|OTHER|GraphoLearn reading intervention|This is an Edtech reading intervention
218969447|NCT04568824|OTHER|Vektor math control intervention|This is an Edtech math/cognition intervention
218969448|NCT00880373|DRUG|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
218969449|NCT00880373|DRUG|Placebo|Matching placebo three times daily for 4 days
218969450|NCT00880373|DRUG|Diamorphine or Morphine|Diamorphine or Morphine by PCA
218969451|NCT01905410|DRUG|VVZ-149 Injection|VVZ-149 in water for injection
218969452|NCT01905410|DRUG|placebo|water for injection
218969453|NCT00068783|DRUG|imatinib mesylate|Given orally
218969454|NCT00068783|OTHER|laboratory biomarker analysis|Correlative studies
218969455|NCT06548165|DEVICE|Wearable|Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
218969456|NCT05345171|GENETIC|DTX301|non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
219064329|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
219064330|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
219064331|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
219064332|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
219064333|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
219064334|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
219064335|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
219064336|NCT04895241|DRUG|Litifilimab|Administered as specified in the treatment arm.
219660410|NCT01080391|DRUG|Lenalidomide|25 mg orally on days 1-21
219660411|NCT01080391|DRUG|Carfilzomib|20 mg/m², 27 mg/m² intravenously
219660412|NCT02877719|OTHER|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
219660413|NCT06505161|OTHER|Dry needling|It consists in application of dry needling on active and/or latent TPs in low back multifidus muscles
219660414|NCT06505161|OTHER|Percutaneous electrolysis|It consists in the application of intratissue percutaneous electrolysis with galvanic current as a cathodic flow electrode in the low back multifidus muscles. The intervention will be guided by ultrasound equipment medically certified.
219660415|NCT04204928|DRUG|pralsetinib (BLU-667)|Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
218969457|NCT05345171|OTHER|Placebo|normal saline infusion
218969458|NCT05345171|DRUG|Oral Corticosteroids|Participants who receive DTX301 solution will receive oral corticosteroids.
218969459|NCT05345171|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
218969460|NCT05345171|DRUG|Sodium Acetate|A tracer for the Ureagenesis Rate Test (URT)
218969461|NCT01913132|DEVICE|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
218969462|NCT05661357|DRUG|Disitamab Vedotin Combined With Fruquintinib|Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
218969463|NCT01763242|OTHER|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
218969464|NCT00000977|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
218969465|NCT02607839|BIOLOGICAL|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
219660416|NCT04501783|DRUG|Favipiravir|TL-FVP-t will be administered orally
219660417|NCT04501783|DRUG|Standard of care (SOC)|SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
219660418|NCT04501783|DRUG|standard concomitant therapy|Standard of care according to MoH of Russian Federation recomendation for COVID-19
219660419|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (330mg)|High dose capsules
219660420|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (165mg)|Low dose capsules
219660421|NCT03058367|DIETARY_SUPPLEMENT|Placebo|Placebo identical to verum capsules
219660422|NCT00672841|DRUG|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
218985428|NCT02676115|OTHER|Medipore Tape|"* One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
218985429|NCT01689168|BEHAVIORAL|Counseling|Tobacco cessation counseling
218985430|NCT01689168|PROCEDURE|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
219660423|NCT00672841|DRUG|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
219660424|NCT03578146|COMBINATION_PRODUCT|PRT064445/Rivaroxaban|
219064337|NCT04895241|DRUG|Placebo|Administered as specified in the treatment arm.
219064338|NCT02172209|DRUG|BI 10773|
219660425|NCT03578146|COMBINATION_PRODUCT|Placebo/Rivaroxaban|
219660426|NCT03578146|DRUG|Placebo|
219660427|NCT04164823|DEVICE|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
219660428|NCT04164823|DRUG|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
219660429|NCT03138200|BIOLOGICAL|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
219660430|NCT06143254|BEHAVIORAL|Infant sign training|Training session 1: Information is given about what infant signs are, how they originated, how speech and (gestural) language develop in young children with CP ± L, the possible advantages of using infant signs and tips for success. Twelve signs are chosen to start with: six narrative signs (mostly object concepts) and six steering signs (mostly non-object concepts). Training session 2: Experiences with using infant signs at home are shared, repetition of the 12 infant signs and tips for success are discussed. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Reading aloud while using infant signs is shown and practiced.
218969466|NCT03064581|BEHAVIORAL|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
218969467|NCT02925325|BEHAVIORAL|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
218969468|NCT02925325|OTHER|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
218969469|NCT03624296|DEVICE|MRI 7T|MRI 7T
218969470|NCT03624296|OTHER|TEST EDSS|EDSS - Expanded Disability Status Scale
218969471|NCT03624296|OTHER|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
218969472|NCT03987776|BEHAVIORAL|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
218969473|NCT03987776|BEHAVIORAL|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
218969474|NCT00249288|DRUG|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
218969475|NCT00249288|DRUG|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
218969476|NCT01558193|DIETARY_SUPPLEMENT|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
218969477|NCT01558193|DIETARY_SUPPLEMENT|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
218969478|NCT01558193|DIETARY_SUPPLEMENT|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
219064339|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
219064340|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
219064341|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
218969479|NCT01558193|DIETARY_SUPPLEMENT|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
218969480|NCT03059446|DRUG|Cenicriviroc|Cenicriviroc immediate release tablets
219360059|NCT02495922|DRUG|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
218969481|NCT01663168|DRUG|Rifabutin|
218969482|NCT02273739|DRUG|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
218969483|NCT04795622|DEVICE|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
218969484|NCT04795622|DEVICE|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
218969485|NCT02195284|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
218969486|NCT02195284|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
218969487|NCT02195284|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
218969488|NCT02195284|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
218969489|NCT03295526|PROCEDURE|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
218969490|NCT05779735|DIAGNOSTIC_TEST|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
218969491|NCT00996723|DRUG|vandetanib and dasatinib|Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
218969492|NCT00882492|BIOLOGICAL|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
218969493|NCT00882492|BIOLOGICAL|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
218969494|NCT01440790|DIETARY_SUPPLEMENT|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
218969495|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
218969496|NCT01440790|DIETARY_SUPPLEMENT|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
218969497|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
218969498|NCT02398409|BEHAVIORAL|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
218969499|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
218969500|NCT03799172|DRUG|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
218969501|NCT03799172|DRUG|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
218969502|NCT05808283|OTHER|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
218969503|NCT03309046|OTHER|REACH Individual Session|Individual telephone session with parent
218969504|NCT03309046|OTHER|Education Webinar|Videos with information on caregiving
218969505|NCT00401895|DEVICE|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
218969506|NCT01584570|DRUG|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
218969507|NCT04758845|DIETARY_SUPPLEMENT|Cocktail|Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.
218969508|NCT04758845|DIETARY_SUPPLEMENT|CGI314|Subjects will consume 1B CFU of CGI314 once daily for 45 days.
219660431|NCT06143254|BEHAVIORAL|Verbal training|Training session 1: Information is given about how speech and language develop in young children with CP ± L and how caregivers can support their child during this development Tips for success and suggestions on how to use these supportive verbal techniques at home are discussed. Training session 2: Experiences with using supportive verbal techniques at home are shared and supportive verbal techniques repeated. Information is provided about how children learn new words and tips for success are expanded. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Additionally, advances of reading aloud are discussed and reading aloud is practiced.
219660432|NCT04294251|DRUG|DWP450|Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
219660433|NCT04294251|DRUG|Placebo|Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
219660434|NCT01717391|DRUG|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
219660435|NCT01909726|OTHER|ScreenPlay|Interactive technology
219660436|NCT04251962|DRUG|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
219660437|NCT04251962|DRUG|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
219660438|NCT01731769|PROCEDURE|vacuum assisted closure in experimental arm|
219660439|NCT01731769|PROCEDURE|Axillary dissection|
219660440|NCT04172857|PROCEDURE|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch \& Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
219660441|NCT04338243|DRUG|Glumetinib|Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
219660442|NCT04192656|DEVICE|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
219660443|NCT04192656|DRUG|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
218969509|NCT04758845|DIETARY_SUPPLEMENT|CSI08|Subjects will consume 1B CFU of CSI08 once daily for 45 days.
218969510|NCT04758845|DIETARY_SUPPLEMENT|MIT411|Subjects will consume 1B CFU of MIT411 once daily for 45 days.
218969511|NCT00089674|DRUG|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
219660444|NCT04192656|DRUG|Ginaton|ginnaton is ginkgo biloba extract
219660445|NCT03677934|DRUG|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
219660446|NCT03677934|DRUG|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
219660447|NCT04201678|PROCEDURE|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
219660448|NCT04201678|PROCEDURE|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
219660449|NCT04201678|PROCEDURE|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
218969512|NCT00089674|DRUG|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
218969513|NCT00652639|DRUG|Clonazepam|Tablets, 1 mg, single-dose
219660450|NCT00003734|DRUG|flutamide|
219660451|NCT00003734|DRUG|triptorelin|
218969514|NCT00652639|DRUG|Klonopin|tablets, 1 mg, single-dose
218969515|NCT03279471|DRUG|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
218969516|NCT03279471|BEHAVIORAL|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
218969517|NCT03279471|DRUG|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
218969518|NCT03963401|DRUG|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
219660452|NCT00003734|RADIATION|radiation therapy|
219660453|NCT04604405|RADIATION|photobiomodulation|650nm low energy red light eye irradiation
219660454|NCT05509686|DEVICE|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
219660455|NCT05509686|DEVICE|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
219660456|NCT00519792|DRUG|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
219660457|NCT06516185|DEVICE|direct-printed aligner|Patients will be treated with direct-printed aligners until dental alignment is achieved.
219660458|NCT06516185|DEVICE|thermoformed aligner|Patients will be treated with thermoformed aligners until dental alignment is achieved.
219660459|NCT06228833|DEVICE|monopolar radiofrequency|Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
219660460|NCT06228833|OTHER|SkinCeuticals A.G.E and Skinceuticals CE FERULIC|Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC
219660461|NCT06228833|OTHER|Standard Cream|Control Side applies Standard Cream
219660462|NCT01260584|DRUG|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
219660463|NCT01260584|DRUG|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
219660464|NCT05489042|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
219660465|NCT05489042|DEVICE|sham rTMS|5 sessions of sham rTMS
219660466|NCT06977269|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency repetitive transcranial magnetic stimulation targeting the primary motor cortex (M1) of the limbs, delivered at a frequency above 5 Hz and an intensity of 90-100% of the resting motor threshold, across 10 sessions with up to 2400 stimuli per session, is a standard intervention used in various neurological disorders. However, its effects have not been studied in patients with spinal muscular atrophy (SMA).
219660467|NCT06977269|DIAGNOSTIC_TEST|lumbar puncture|Cerebrospinal fluid sampling to measure SMN protein and neurofilament concentrations before and after the TMS intervention.
219660468|NCT06601296|DRUG|IMSA101|"All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)"
219660469|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
219660470|NCT03295552|DRUG|Decitabine|decitabine 7mg/m2, d1-d5, q3w
219660471|NCT03295552|DRUG|Carboplatin|carboplatin AUC = 6, d6, q3w
219660472|NCT06648005|PROCEDURE|the spinal manipulative therapy combined brace|Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.
219660473|NCT06648005|OTHER|brace|Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
218969519|NCT03963401|OTHER|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
219660474|NCT00787098|OTHER|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
219660475|NCT02784522|DEVICE|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
219660476|NCT02784522|DEVICE|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
219660477|NCT06475885|OTHER|Infant Massage Program|The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
219660478|NCT02624388|DRUG|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
219660479|NCT02624388|DRUG|Placebo|Pill that contains no medicine
219660480|NCT04101032|BEHAVIORAL|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
219660481|NCT04977414|BEHAVIORAL|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
219660482|NCT04679636|BEHAVIORAL|heart rate variability biofeedback|receive biofeedback training for heart rate variability for eight weeks
219660483|NCT05753891|DEVICE|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
219660484|NCT05700812|PROCEDURE|Sound sparing levonorgestrel 52 mg IUD placement|"In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance."
219660485|NCT04316039|DRUG|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
219660486|NCT04316039|RADIATION|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
218969520|NCT03095768|OTHER|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
218969521|NCT05629000|PROCEDURE|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
218969522|NCT05629000|DIAGNOSTIC_TEST|MRI-PWI|Multi-modal MRI before and after surgery.
218969523|NCT05629000|DIAGNOSTIC_TEST|CTA|CTA before and after surgery.
219064342|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
219360060|NCT01960322|BEHAVIORAL|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
219360061|NCT00483886|DRUG|Prucalopride|2 mg o.d.
219064343|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
219064344|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
219064345|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
219064346|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
219064347|NCT05507411|RADIATION|Neoadjuvant Radiotherapy|41.4Gy/23F
219064348|NCT05507411|DRUG|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
219064349|NCT05507411|DRUG|Immunotherapy|Camrelizumab 200mg Q3W
219064350|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
218969524|NCT05629000|DIAGNOSTIC_TEST|PET/MRI|PET/MRI before surgery.
218969525|NCT05629000|DIAGNOSTIC_TEST|Ultrasound|Ultrasound before and after surgery.
218969526|NCT01834482|DIETARY_SUPPLEMENT|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
219064351|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
219360062|NCT00483886|OTHER|Placebo|Placebo o.d.
219360063|NCT00483886|DRUG|Prucalopride|4 mg o.d.
218969527|NCT01834482|DIETARY_SUPPLEMENT|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
219660487|NCT02387528|BEHAVIORAL|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
219660488|NCT02387528|BEHAVIORAL|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
219660489|NCT02387528|OTHER|3- Wait List Control Group|No intervention
219660490|NCT03058224|DRUG|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
219660491|NCT03058224|DRUG|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
219660492|NCT06252701|BEHAVIORAL|Reduction of Ultra-processed foods|Reduction of Ultra-processed foods for four weeks.
219660493|NCT02169206|RADIATION|Bilateral shoulder anteroposterior radiography|"1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction."
219660494|NCT00945204|OTHER|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
219660495|NCT04650906|BEHAVIORAL|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
219660496|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
218969528|NCT05025748|BEHAVIORAL|Behavioral Intervention|Complete questionnaires
219064352|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
219064353|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
219064354|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
219660497|NCT03434249|DIETARY_SUPPLEMENT|Bifidobacterium, BB-12® (Bifidolactis Infant)|
219660498|NCT03434249|DIETARY_SUPPLEMENT|Bifidolactis Infant Placebo|
219660499|NCT01044953|OTHER|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
219660500|NCT00561470|DRUG|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
219660501|NCT00561470|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
219660502|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
218969529|NCT02225392|PROCEDURE|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
218969530|NCT02225392|DEVICE|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
218969531|NCT02123628|DRUG|duration of the antibiotic therapy|
219660503|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
218969532|NCT06551103|BEHAVIORAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
218969533|NCT00273507|DRUG|Carboplatin and Paclitaxel|
218969534|NCT03973801|OTHER|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
218969535|NCT03488823|DIETARY_SUPPLEMENT|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
218969536|NCT03488823|DIETARY_SUPPLEMENT|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
219660504|NCT00426777|DRUG|risedronate|risedronate 35mg tablet, weekly for 12 months
219660505|NCT00426777|DRUG|risedronate|35mg weekly
219660506|NCT00426777|DRUG|Control|risedronate-matched placebo weekly
219660507|NCT06244498|DRUG|Tranexamic acid injection|Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
219660508|NCT03705000|DEVICE|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
219660509|NCT03705000|DEVICE|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
219660510|NCT03256292|DRUG|Testosterone replacement|Testosterone replacement therapy
219660511|NCT03256292|BEHAVIORAL|lifestyle|lifestyle intervention consisting of diet and increased physical activity
219660512|NCT02918552|DRUG|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
219660513|NCT02918552|DRUG|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
219660514|NCT00825526|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
219660515|NCT03652116|DRUG|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
219660516|NCT03652116|DRUG|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
219660517|NCT04003545|RADIATION|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
219660518|NCT04003545|OTHER|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
219660519|NCT06448858|DIAGNOSTIC_TEST|serum Mn, Se, iron, Cu & Zn levels|Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.
219660520|NCT05359770|DEVICE|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
219660521|NCT05359770|DEVICE|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
219660522|NCT03325894|DRUG|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
219660523|NCT02315872|DRUG|ACTH|ACTH injections twice weekly for 28 weeks.
218969537|NCT00225043|DRUG|Epinephrine/phenylephrine|
218969538|NCT02305043|OTHER|non-interventional|non-interventional
218969539|NCT05270421|DRUG|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
219660524|NCT02315872|DRUG|Placebo|Placebo injections twice weekly for 28 weeks.
219660525|NCT01920867|PROCEDURE|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
219660526|NCT01920867|PROCEDURE|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
219660527|NCT01920867|PROCEDURE|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
219660528|NCT01920867|PROCEDURE|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
219660529|NCT01920867|PROCEDURE|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
218969540|NCT05270421|OTHER|Conventional Treatment|Standard ESWL
219660530|NCT05961345|OTHER|late mobilization|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
218969541|NCT05075057|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
218969542|NCT03723200|OTHER|Fibrinogen and blood products|Fibrinogen and blood products
218969543|NCT04895800|DIETARY_SUPPLEMENT|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
218969544|NCT04895800|DIETARY_SUPPLEMENT|Placebo|Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)
218969545|NCT04895800|DIETARY_SUPPLEMENT|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
218969546|NCT01129570|DRUG|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
218969547|NCT00782327|DRUG|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
219064355|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
219064356|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
219064357|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
219660531|NCT02690519|DRUG|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
219660532|NCT02690519|DRUG|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
219660533|NCT00335959|DRUG|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
219660534|NCT00335959|DRUG|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
219660535|NCT00335959|PROCEDURE|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
219660536|NCT00335959|RADIATION|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
218969548|NCT00782327|DRUG|Placebo|Daily placebo capsule
218969549|NCT05982210|OTHER|Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol|The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
218969550|NCT03492411|OTHER|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
218969551|NCT00002898|BIOLOGICAL|dactinomycin|
218969552|NCT00002898|DRUG|carboplatin|
219064358|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
219064359|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
218969553|NCT00002898|DRUG|cyclophosphamide|
218969554|NCT00002898|DRUG|epirubicin hydrochloride|
218969555|NCT00002898|DRUG|etoposide|
218969556|NCT00002898|DRUG|ifosfamide|
218969557|NCT00002898|DRUG|vincristine sulfate|
218969558|NCT00002898|PROCEDURE|adjuvant therapy|
218969559|NCT00002898|PROCEDURE|conventional surgery|
218969560|NCT00002898|PROCEDURE|neoadjuvant therapy|
218969561|NCT00002898|RADIATION|brachytherapy|
219064360|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
219064361|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
219064362|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
219064363|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
219064364|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
219064365|NCT05515159|OTHER|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
219660537|NCT06413745|DRUG|SHR-A1811|SHR-A1811
218969562|NCT00002898|RADIATION|radiation therapy|
218969563|NCT03144024|DEVICE|band implantation|
218969564|NCT03144024|DEVICE|rigid ring implantation|
218969565|NCT04493879|OTHER|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
218969566|NCT02961218|DRUG|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
218969567|NCT02961218|DRUG|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
218969568|NCT01210573|DEVICE|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
218969569|NCT06135480|OTHER|subcision ,PRP or saline and microneedling|minimally invasive procedures
218969570|NCT02639156|DIETARY_SUPPLEMENT|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
218969571|NCT02793466|DRUG|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
218969572|NCT02800759|DIETARY_SUPPLEMENT|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
218969573|NCT02800759|DIETARY_SUPPLEMENT|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
219064366|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
219064367|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
219064368|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
219660538|NCT02450552|DRUG|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
219660539|NCT02450552|DRUG|Placebo|Matched placebo
219064369|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
219660540|NCT02722837|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
218969574|NCT02800759|DIETARY_SUPPLEMENT|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
218969575|NCT02800759|DIETARY_SUPPLEMENT|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
218969576|NCT02876744|OTHER|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
218969577|NCT05398926|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
218969578|NCT06550271|DRUG|Rapamycin|Rapamycin in 2 different dosage forms (compounded and generic)
219660541|NCT02903524|DRUG|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
219660542|NCT02903524|DRUG|pirarubicin and cyclophosphamide|
219660543|NCT03431662|PROCEDURE|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
218969579|NCT02606890|OTHER|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
219064370|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
219660544|NCT03431662|PROCEDURE|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
219660545|NCT06647680|DRUG|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
219660546|NCT02167815|DEVICE|Mepilex XT|Experimental arm
219660547|NCT02167815|OTHER|standard care|
219660548|NCT06183203|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
219660549|NCT06183203|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
219660550|NCT04321317|OTHER|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
219660551|NCT06696157|BEHAVIORAL|PRSS intervention for MOUD initiation|All participants of this expanded scope pilot study will be in a single-arm of an uncontrolled trial of PRSS intervention for MOUD initiation for a total of 8 weeks, starting in inpatient substance abuse treatment. This is distinguished from the R34 parent grant which targets MOUD retention and adherence rather than MOUD initiation.
219660552|NCT07027176|BEHAVIORAL|walking exercise|Divided into low-intensity and moderate-intensity exercise intervention groups, participants exercised either during the day or at night. The intervention lasted for 12 weeks.
219660553|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
219660554|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
219660555|NCT05156554|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
219660556|NCT05156554|DRUG|rhG-CSF|rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil\>0.5×10\^9 /L.
219660557|NCT01224652|DRUG|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
219660558|NCT01224652|DRUG|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
219660559|NCT03846115|BEHAVIORAL|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
219660560|NCT03846115|BEHAVIORAL|Control app|This app offers the Seeking Safety content but without the enhanced features
219660561|NCT04026334|DEVICE|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
219660562|NCT04149782|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219660565|NCT04132453|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
219660566|NCT04132453|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
219660567|NCT04132453|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
219660568|NCT00824382|DRUG|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
219660569|NCT00824382|DRUG|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
219660570|NCT00824382|DRUG|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
219660571|NCT00824382|DRUG|Placebo|2 puffs delivered by the RespimatÂ® inhaler
219660572|NCT01958216|OTHER|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
219660573|NCT06547424|DRUG|Chondroitin sulfate|Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
219660574|NCT05330702|DEVICE|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation|Fibro-gide is the VCMX
219660575|NCT05330702|PROCEDURE|Tuberosity Connective Tissue Graft (CTG)|CTG will be taken from the patient's own mouth
219660576|NCT05222022|DEVICE|Retitrack|Retitrack device measures and analyzes eye movement
219660577|NCT03471728|DRUG|linaclotide|Oral
219660578|NCT03535454|OTHER|working hours|weekly working hours
219660579|NCT02974920|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
219660580|NCT02974920|DRUG|Aspirin|Aspirin 100 mg once daily for 180 days
219660581|NCT05519137|DEVICE|Active lighting intervention|Lighting intervention designed to impact the circadian system
219660582|NCT05519137|DEVICE|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
219660583|NCT04491747|DIAGNOSTIC_TEST|functional capacity|Six minute walk test used assessment of functional capacity.
219660584|NCT00475345|BEHAVIORAL|Bedtime snacks|
219660585|NCT06128291|PROCEDURE|posterior colporrhaphy|posterior colporrhaphy for rectocele.
218969580|NCT05050552|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
218969581|NCT03488927|BEHAVIORAL|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
218969582|NCT01234207|DEVICE|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
218969583|NCT01234207|DEVICE|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
218969584|NCT00901927|DRUG|Bendamustine|Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
218969585|NCT00901927|DRUG|Mitoxantrone|10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
218969586|NCT00901927|DRUG|Rituximab|375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
218969587|NCT01889524|OTHER|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
218969588|NCT01889524|OTHER|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
218969589|NCT01889524|OTHER|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
218969590|NCT01135212|DRUG|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
218969591|NCT01135212|DRUG|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
218969592|NCT01135212|DRUG|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
218969593|NCT00062673|DRUG|Duloxetine|
219064371|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
219064372|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
219064373|NCT01431066|DEVICE|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
219064374|NCT01431066|DEVICE|ActiPatch PRFE Device|Actipatch PRFE device
219064375|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
219064376|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
218969594|NCT00062673|DRUG|Placebo|
218969595|NCT05237271|OTHER|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
219660586|NCT00718380|DRUG|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
219660587|NCT04514744|PROCEDURE|Knee bracing|Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
219660588|NCT04514744|OTHER|Unilateral Resistance Exercise Training|Participants will perform resistance training on 4 occasions throughout an 8 day time period.
219660589|NCT06451796|DEVICE|Obtinu|Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter
219660590|NCT04106050|DRUG|BIIB095|Administered as specified in the treatment arm.
219660591|NCT04106050|DRUG|BIIB074|Administered as specified in the treatment arm.
219660592|NCT04106050|DRUG|Placebo|Administered as specified in the treatment arm.
219660593|NCT04106050|DRUG|Lidocaine|Administered as specified in the treatment arm.
219660594|NCT00989456|BEHAVIORAL|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
219660595|NCT00989456|BEHAVIORAL|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
218969596|NCT05237271|OTHER|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
218969597|NCT02049320|DRUG|Remifentanil|
218969598|NCT02942420|DRUG|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
218969599|NCT05773703|DRUG|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
218969600|NCT05773703|DRUG|PTI-122|Cytoprotective agent
218969601|NCT00814151|OTHER|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
219660596|NCT06128785|DEVICE|Electroacupuncture group|Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal exhaust or until the fourth day.
219660597|NCT06128785|OTHER|Sham EA group|Sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output.
219660598|NCT01615211|DRUG|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
219660599|NCT01615211|DRUG|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
218969602|NCT05298306|DRUG|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A"
218969603|NCT05298306|DRUG|Placebo|Matching placebo'given as a single intravenous infusion at all dose levels
218969604|NCT03913403|PROCEDURE|ECHO|Echocardiogram at baseline and 24 hours later
218969605|NCT03913403|PROCEDURE|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
218969606|NCT02239627|DRUG|Epidural steroid|
218969607|NCT02239627|DRUG|Clonidine|
218969608|NCT04490239|DRUG|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
218969609|NCT03412071|DRUG|Oral Tinidazole|Please see description under arms
218969610|NCT03412071|DRUG|Topical metronidazole|Please see description under arms
218969611|NCT03412071|DRUG|Topical Clindamycin|Please see description under arms
218969612|NCT03412071|DRUG|Topical Hydrogen Peroxide|Please see description under arms
219660600|NCT01366859|DIETARY_SUPPLEMENT|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
219660601|NCT01366859|DIETARY_SUPPLEMENT|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
219660602|NCT02231593|OTHER|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
219660603|NCT04109937|RADIATION|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
219660604|NCT02407054|DRUG|LY3023414|Administered orally
219660605|NCT02407054|DRUG|Enzalutamide|Administered orally
219660606|NCT02407054|DRUG|Placebo|Administered orally
219660607|NCT03376347|DEVICE|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
219660608|NCT03195647|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
219660609|NCT04656197|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
219660610|NCT01091545|RADIATION|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
219660611|NCT05097547|BEHAVIORAL|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
218969613|NCT03625206|BEHAVIORAL|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
218969614|NCT03625206|BEHAVIORAL|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
218969615|NCT00410228|DRUG|AHT956|
218969616|NCT00979069|BEHAVIORAL|Aerobic group|12 weeks of aerobic exercise 3 times a week
218969617|NCT02981810|DEVICE|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
218969618|NCT02981810|PROCEDURE|tonsillectomy|
218969619|NCT06370273|DRUG|Rivaroxaban|10mg once daily via oral ingestion
218969620|NCT06370273|DRUG|Apixaban|2.5mg twice daily via oral ingestion
218969621|NCT06370273|DRUG|Enoxaparin Injectable Solution|40mg once daily via subcutaneous injection
219660612|NCT02039973|BEHAVIORAL|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
218969622|NCT06370273|DRUG|Tinzaparin Injectable Solution|4500 IU once daily via subcutaneous injection
218969623|NCT06370273|DRUG|Dalteparin Injectable Solution|5000 IU once daily via subcutaneous injection
218969624|NCT06370273|DRUG|Fondaparinux Injectable Product|2.5 mg once daily via subcutaneous injection
218969625|NCT01131767|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
219660613|NCT02039973|BEHAVIORAL|Enhanced standard of care|
219660614|NCT00131365|DEVICE|ExAblate 2000|
219660615|NCT04608344|DRUG|Atorvastatin|Administered as single dose tablet orally.
219660616|NCT04608344|DRUG|Pravastatin|Administered as single dose tablet orally.
218969626|NCT04407481|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
218969627|NCT04407481|DRUG|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
218969628|NCT04407481|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
218969629|NCT00006169|BEHAVIORAL|Behavioral Treatment|
218969630|NCT05266027|DRUG|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
218969631|NCT05266027|DRUG|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
218969632|NCT00397410|DEVICE|Hip protectors|
218969633|NCT00120354|PROCEDURE|Blood Testing|
218969634|NCT00120354|PROCEDURE|Percutaneous Liver Biopsy|
218969635|NCT00120354|PROCEDURE|Lamivudine Therapy|
218969636|NCT02676466|DIETARY_SUPPLEMENT|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
218969637|NCT02676466|DRUG|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
219064377|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
219660617|NCT04608344|DRUG|Rosuvastatin|Administered as single dose tablet orally.
219660618|NCT04608344|DRUG|Filgotinib|Administered as tablet orally once daily for 11 days.
219660619|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219660620|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase cognitive flexibility|Increase the intervention dose of cognitive flexibility in Mindfulness Intervention for Emotional Distress (MIED). For example, including more cognitive reappraisal practice, psychoeducational content and practice about regarding thoughts just as thoughts.
218969638|NCT02676466|OTHER|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
218969639|NCT02676466|OTHER|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
218969640|NCT01352468|OTHER|Multifaceted cognitive training|Four computerized training tasks
218969641|NCT01178073|DRUG|ambrisentan|ambrisentan (target dose: 10mg)
218969642|NCT01178073|DRUG|tadalafil|tadalafil (target dose: 40mg)
219064378|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
219064379|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
219660621|NCT02826265|DEVICE|multiple breath washout test (MBW)|
219660622|NCT02826265|DEVICE|impulse oscillometry (IOS)|
219660623|NCT02826265|DEVICE|body plethysmography (BP)|
219660624|NCT02826265|DEVICE|quantitative computed tomography (qCT)|ultra-low-dose qCT
218969643|NCT01936077|DRUG|Recombinant LH (Luveris)|150 IU recombinant LH daily.
218969644|NCT00589485|DEVICE|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
218969645|NCT00589485|DEVICE|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
218969646|NCT03927807|DRUG|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
218969647|NCT03496571|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
219064380|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
219064381|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
219064382|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
218969648|NCT03496571|OTHER|Placebo|Placebo
218969649|NCT00484718|DRUG|celecoxib|oral, 100 mg bid
218969650|NCT00484718|DRUG|Oxycodone|oral, 20 mg bid
218969651|NCT00484718|DRUG|placebo|oral bid
218969652|NCT02636374|BEHAVIORAL|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
218969653|NCT03192878|DRUG|Infliximab|infliximab biosimilar
218969654|NCT05876260|BEHAVIORAL|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
219064383|NCT05404529|DRUG|Tavapadon|Oral tablets
219064384|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
219064385|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
219064386|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
219064387|NCT04026100|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
219064388|NCT04975568|OTHER|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
219660625|NCT00645281|DRUG|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
219660626|NCT02781181|DEVICE|CAS with CPD|using a neuroprotection device
219660627|NCT02781181|OTHER|CAS without CPD|No Neuroprotection
219660628|NCT00846703|DRUG|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
219660629|NCT00846703|DRUG|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
219660630|NCT00058084|DRUG|ixabepilone|Given IV
219660631|NCT00058084|DRUG|mitoxantrone hydrochloride|Given IV
219660632|NCT00058084|DRUG|prednisone|Given orally
219660633|NCT04888403|DRUG|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
218969655|NCT05876260|BEHAVIORAL|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
218969656|NCT05876260|BEHAVIORAL|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
218969657|NCT02820714|DRUG|BLI801 Laxative|BLI801 Laxative
218969658|NCT04738409|OTHER|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
218969659|NCT04738409|OTHER|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
218969660|NCT06168227|DRUG|Disitamb Vedotin|RC48-ADC based therapy
219064389|NCT04975568|OTHER|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
219064390|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
219064391|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
219064392|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
219064393|NCT02348216|DRUG|Fludarabine|Administered according to package insert
219064394|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
219064395|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
219064396|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
219064397|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
219660634|NCT05545020|DRUG|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
218969661|NCT03901898|BEHAVIORAL|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
218969662|NCT03901898|BEHAVIORAL|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
218969663|NCT04990336|COMBINATION_PRODUCT|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
219064398|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
219064399|NCT02348216|DRUG|Bendamustine|Administered according to package insert
219064400|NCT02348216|DRUG|Rituximab|Administered according to package insert
219064401|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
219064402|NCT02348216|DRUG|Prednisone|Administered according to package insert
219064403|NCT02348216|DRUG|Vincristine|Administered according to package insert
219064404|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
219064405|NCT02348216|DRUG|Carboplatin|Administered according to package insert
219064406|NCT02348216|DRUG|Etoposide|Administered according to package insert
219064407|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
219064408|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
219064409|NCT02348216|DRUG|Cisplatin|Administered according to package insert
219064410|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
219660635|NCT04533191|PROCEDURE|LAL IOL lens|Standard of care Cataract surgery with IOL placement
219660636|NCT02549976|PROCEDURE|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
219660637|NCT02549976|PROCEDURE|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
219660638|NCT02549976|PROCEDURE|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
219660639|NCT02549976|PROCEDURE|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
219660640|NCT02044874|DRUG|APD356-lorcaserin hydrochloride|
219660641|NCT02044874|DRUG|Placebo|
219064411|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
219064412|NCT00519805|DRUG|dalteparin|
219064413|NCT00519805|PROCEDURE|quality-of-life assessment|
219064414|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
219064415|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
219064416|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
219064417|NCT00525317|DRUG|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
219064418|NCT00562159|DRUG|Placebo|Placebo sublingual tablet
219064419|NCT00562159|BIOLOGICAL|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
219064420|NCT00562159|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
219660642|NCT04506398|PROCEDURE|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
219660643|NCT04506398|DIAGNOSTIC_TEST|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
219660644|NCT04506398|DIAGNOSTIC_TEST|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
219660645|NCT00415597|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
219660646|NCT00389298|DRUG|VCH-759 (BCH-27759)|
219660647|NCT06512454|OTHER|No Intervention|This is a non-interventional study.
219660648|NCT05531305|DEVICE|Muscle ultrasound|Standardized ultrasonographic measurement of quadriceps muscle layer thickness.
219660649|NCT05531305|DEVICE|Indirect calorimetry|Non-invasive measurement of resting energy expenditure using the Q-NRG metabolic monitor with hood and canopy.
219660650|NCT05531305|DIAGNOSTIC_TEST|Hand dynamometry|Assessment of handgrip strength using hand dynamometry.
219064421|NCT00562159|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
219064422|NCT00562159|DRUG|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
219064423|NCT00562159|DRUG|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
219064424|NCT00562159|DRUG|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
219064425|NCT00562159|DRUG|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
219064426|NCT00562159|DRUG|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
219064427|NCT00610051|DRUG|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
219064428|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
219064429|NCT01391377|DRUG|Sugar pill|Placebo
219064430|NCT00918294|DEVICE|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
219064431|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
219064432|NCT01513850|DRUG|Hepabulin IV|I.V.
219064433|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
219660651|NCT05531305|DIAGNOSTIC_TEST|MRC Sum Score|Assessment of muscle function/limb strength using the Medical Research Council sum score (12-60 points).
219660652|NCT01447927|DRUG|metformin hydrochloride|Given PO QD and BID
219064434|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
219064435|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
219064436|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
219064437|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
219064438|NCT01620463|DRUG|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
219660653|NCT01447927|OTHER|placebo|Given PO QD and BID
219660654|NCT01043562|DIAGNOSTIC_TEST|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
219660655|NCT01043562|OTHER|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole \>4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a \>10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
219660656|NCT00222482|DRUG|Depakote ER|
219660657|NCT06730776|OTHER|Topical medication|It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
219660658|NCT06730776|OTHER|Transcutaneous electrical acupoint stimulation|This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
219660659|NCT04005144|DRUG|Binimetinib|Given PO
219660660|NCT04005144|DRUG|Brigatinib|Given PO
219064439|NCT01620463|DRUG|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
219064440|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
219660661|NCT04102865|DEVICE|Negative-Pressure Wound Therapy (NPWT)|Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
219064441|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
219660662|NCT06648291|DEVICE|QOCA EKG Device|The investigators scheduled telephone interviews every three days to encourage and monitor the development of good self-health care behaviors by: (1) asking about daily blood pressure, weight, and lower extremity edema; (2) providing medication counseling, as well as exercise and dietary hygiene recommendations; (3) offering wound care guidance; (4) advising on the proper use of wounds; (5) advising on avoiding cardiac risk factors such as smoking and secondhand smoke; and (6) following up on physical status at outpatient clinics and assisting with referrals to relevant clinics, such as nutrition or rehabilitation, based on the patient's condition. A QOCA portable electrocardiogram (ECG) measurement device will be provided for patients to use at home. In the event of abnormal physiological values, the investigator will contact the patient to assess his or her medical status and provide 24-hour online counseling.
218969664|NCT04990336|DRUG|Rhubarb single medicine|Rhubarb single medicine
218969665|NCT04990336|COMBINATION_PRODUCT|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
218969666|NCT01138839|DRUG|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
218969667|NCT01138839|DRUG|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
218969668|NCT02257853|OTHER|Stress reduction intervention|Gentle chair yoga and breath work
218969669|NCT06255210|DRUG|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
218969670|NCT02103218|BEHAVIORAL|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
218969671|NCT02103218|BEHAVIORAL|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
218969672|NCT00739596|DRUG|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
218969673|NCT00739596|DRUG|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
218969674|NCT00908011|DRUG|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
218969675|NCT00908011|DRUG|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
218969676|NCT05334511|OTHER|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
218969677|NCT00815724|BEHAVIORAL|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
218969678|NCT00817284|DRUG|bevacizumab and Irinotecan and radiotherapy|"* Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
219064442|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
219064443|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
218969679|NCT00817284|DRUG|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
218969680|NCT05904990|DEVICE|traditional exercise therapy only|50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises
219064444|NCT02010385|DRUG|Octreotide|
218969681|NCT05904990|DEVICE|HILT alongside traditional exercise therapy|YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2. It operates with short pulse durations between 120 and 150 μs, at low frequencies of 10 to 40 Hz, and has a duty cycle of about 0.1%.
218969682|NCT04620655|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
219064445|NCT02010385|DRUG|Saline|
219064446|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
219660663|NCT06648291|OTHER|Usual Care|Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
219660664|NCT05531448|OTHER|two way texting|"Automated 2WT-based adherence support messages combined with scheduled visit reminders focus on preventing visit default will be implemented. One-way blast motivational support messages will be sent to all new ART patients who opt-into 2WT. ART visit reminders 3- and 1- day before visits will ask clients to respond with 1=attend and 0=no, triggering 2wT responses to clients to reschedule visits, record transfers, etc. 2WT clerks proactively communicate with clients before a visit to prevent default or ascertain true outcomes for those who don't return. Those who miss visits receive additional 2wT reminders. On day 14 post visit, 2wT patients who missed visits, did not respond to text or did not have outcomes updated (transfer, stop, etc.), are identified by the 2WT system and referred to B2C for tracing, days or months earlier than routine B2C. The 2wT-generated tracing list is more timely and accurate, reducing workload and increasing B2C effectiveness"
219660665|NCT02063048|BEHAVIORAL|Text Message Based Weight Loss Support|
219660666|NCT03218319|BIOLOGICAL|Renin measurement|patients will have a blood sample for measuring renin activity
219660667|NCT00147784|DRUG|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
219660668|NCT00147784|DRUG|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
219660669|NCT00615979|DEVICE|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
218969683|NCT06131320|DIAGNOSTIC_TEST|PVSE Test|Completion of the PVSE test
218969684|NCT06131320|OTHER|Cerebral MRI|Cerebral MRI scan
218969685|NCT00089323|PROCEDURE|Bone Marrow Aspiration|
218969686|NCT06201195|PROCEDURE|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
218969687|NCT06201195|PROCEDURE|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
218969688|NCT06476964|PROCEDURE|skin biopsies|Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
218969689|NCT04572802|PROCEDURE|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
218969690|NCT05992480|BIOLOGICAL|rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)|It is an Ebola virus vaccine
218969691|NCT05597436|DRUG|Trehalose|Once weekly 0.75g/kg administration
218969692|NCT00644228|DRUG|Bortezomib|Given IV
218969693|NCT00644228|DRUG|Dexamethasone|Given PO
218969694|NCT00644228|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218969695|NCT00644228|DRUG|Lenalidomide|Given PO
218969696|NCT03475693|DRUG|Magnesium Oxide|400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
218969697|NCT03475693|DRUG|Acetaminophen|500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
218969698|NCT03475693|DRUG|Zofran ODT 4 MG Disintegrating Oral Tablet|Given once in the Emergency department
218969699|NCT00760084|DRUG|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
218969700|NCT04054570|OTHER|No intervention|No Intervention
219064447|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
219064448|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
219064449|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
219064450|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
218969701|NCT00491426|DRUG|Ampicillin|Drug prescribed per routine medical care.
219064451|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
219064452|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
219064453|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
219660670|NCT00223964|DRUG|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
218969702|NCT00491426|DRUG|Metronidazole|Drug prescribed per routine medical care.
218969703|NCT00491426|DRUG|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
218969704|NCT00491426|DRUG|Acyclovir|Drug prescribed per routine medical care.
218969705|NCT00491426|DRUG|Amphotericin B|Drug prescribed per routine medical care.
218969706|NCT00491426|DRUG|Ambisome|Drug prescribed per routine medical care.
218969707|NCT00491426|DRUG|Anidulafungin|Drug prescribed per routine medical care.
218969708|NCT00491426|DRUG|Caspofungin|Drug prescribed per routine medical care.
218969709|NCT06060821|OTHER|No intervention|No intervention
218969710|NCT02567552|DRUG|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
218969711|NCT02567552|DRUG|Intramuscular progesterone|intramuscular progesterone 50 mg/day
218969712|NCT00765024|DRUG|Ivermectin|single dose of 200 mcg/kg
218969713|NCT00765024|DRUG|ivermectin|two single dose of 200mcg/kg in 2 weeks
218969714|NCT00765024|DRUG|Albendazole|Albendazole 7 days
219660671|NCT02910570|DRUG|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
218969715|NCT03187756|DRUG|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
219064454|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
219660672|NCT02910570|DRUG|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
219660673|NCT05745207|DRUG|E2086|E2086 tablets.
219660674|NCT05745207|DRUG|Placebo|E2086 matched placebo tablets.
219660675|NCT00493233|DRUG|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
219660676|NCT00493233|DRUG|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
219660677|NCT03966937|OTHER|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
219660678|NCT03966937|OTHER|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
218969716|NCT01721707|DRUG|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
218969717|NCT01721707|DRUG|Latanoprost|1 drop in each eye, 1x/day, at 9PM
218969718|NCT04167371|BEHAVIORAL|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
219064455|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
219064456|NCT03286491|DIAGNOSTIC_TEST|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
219064457|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
219660679|NCT01764997|DRUG|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
219660680|NCT01764997|DRUG|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
219660681|NCT01764997|DRUG|Methotrexate|Dispensed according to local practice.
219660682|NCT01764997|DRUG|Placebo (for sarilumab)|
218969719|NCT04167371|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
218969720|NCT06965621|DRUG|18F-metaFluorobenzylguanidine|PET Radiopharmaceutical to assess myocardial sympathetic innervation
218969721|NCT06965621|DRUG|Rubidium-82|PET Radiopharmaceutical to assess myocardial perfusion
218969722|NCT03381573|DRUG|Roflumilast|Roflumilast
218969723|NCT06148389|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
218969724|NCT06148389|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
218969725|NCT05698810|OTHER|CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability|tests
219064458|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
219660683|NCT01764997|DRUG|Placebo (for etanercept)|
219660684|NCT01764997|DRUG|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
219660685|NCT02895646|OTHER|Collection of blood sample|
219660686|NCT06909292|DEVICE|Sacroiliac Joint transfixing and fusion system (Nevro1)|The Nevro1 is a titanium cage the is implanted in the sacroiliac join from a posterior direction, and then anchors are deployed that stabilize the joint. It has multiple openings to allow surgeons to fill them with autogenous bone graft to encourage bone bridging through the implant for SIJ fusion.
219660687|NCT00621465|BEHAVIORAL|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
219660688|NCT00621465|BEHAVIORAL|Usual care|Usual care will include the standard aftercare and community care services.
219660689|NCT04237129|DRUG|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
219660690|NCT02386930|BEHAVIORAL|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
219660691|NCT01893580|BEHAVIORAL|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
219660692|NCT01893580|BEHAVIORAL|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
219660693|NCT01893580|BEHAVIORAL|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
218969726|NCT05698810|OTHER|CE marked Medical Device Magnetic Resonance Imaging (MRI) usability|tests
218969727|NCT05698810|OTHER|CE marked Medical Device ElectroEncephaloGraphy (EEG) usability|tests
218969728|NCT05698810|OTHER|CE marked Medical Device ElectroCardioGraphy (ECG) usability|tests
218969729|NCT06403163|PROCEDURE|Transfusion|Transfusion of an hemostatic product
218969730|NCT05993767|DRUG|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
218969731|NCT05993767|DRUG|Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)|Single arm
218969732|NCT04799054|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT injection
218969733|NCT04799054|DRUG|Pembrolizumab|Pembrolizumab will be administered IV
218969734|NCT04295486|DRUG|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
218969735|NCT04025671|DEVICE|Nasal Spray Naloxone|Nasal spray naloxone device.
218969736|NCT04025671|DEVICE|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
218969737|NCT04025671|DEVICE|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
218969738|NCT03635788|DRUG|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
218969739|NCT03635788|DRUG|Oral RPV|RPV 25 mg tablets
218969740|NCT03635788|DRUG|Oral CAB|CAB 30 mg tablets
218969741|NCT03635788|DRUG|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
218969742|NCT03635788|DRUG|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
218969743|NCT03635788|DRUG|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
218969744|NCT03635788|DRUG|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
218985431|NCT05693883|OTHER|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
218985432|NCT00839852|DRUG|Cariprazine|Cariprazine was supplied in capsules.
219660694|NCT01893580|BEHAVIORAL|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
219660695|NCT03013296|OTHER|GIP-A|GIP-A
219660696|NCT03013296|OTHER|Placebo|Placebo
218969745|NCT06976450|OTHER|ChemoNurs Mobile Application Group|Participants in the mobile app group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. U
218969746|NCT06976450|DEVICE|Personal Smartphone|Used by participants to access and interact with the CHEMONURS mobile application during the study period.
218969747|NCT06805032|OTHER|Observation of EMG and AMG readings|Simultaneous readings from electromyograph and acceleromyograph
219660697|NCT03013296|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
219660698|NCT03013296|OTHER|GIP-A + Exendin[9-39]|GIP-A + Exendin\[9-39\]
219660699|NCT00979524|BEHAVIORAL|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
218969748|NCT01213784|OTHER|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
218969749|NCT02354157|OTHER|no intervention|no intervention
218969750|NCT04382755|DRUG|Zilucoplan®|14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
218969751|NCT04382755|DRUG|Placebo|standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
218969752|NCT03004144|OTHER|FLOAT|
218969753|NCT02624414|DEVICE|PillCam® COLON 2 Capsule Endoscopy|
218969754|NCT05114668|DRUG|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
218969755|NCT04777357|DRUG|Cariprazine|Oral Capsule
218969756|NCT04777357|DRUG|Placebo|Oral Capsule
218969757|NCT03107533|OTHER|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
218969758|NCT05000138|DIAGNOSTIC_TEST|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
218969759|NCT04548154|OTHER|Proximal Resistance Training|Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
218969760|NCT05674708|OTHER|Fat intake|Four different sources of dietary fat
219660700|NCT02921633|OTHER|Intervention letter|
219660701|NCT06908941|DIETARY_SUPPLEMENT|dark chocolate|Participants consumed 85% dark chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
218969761|NCT03811002|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
218969762|NCT03811002|DRUG|Atezolizumab|Given IV
218969763|NCT03811002|PROCEDURE|Biospecimen Collection|Correlative studies
218969764|NCT03811002|DRUG|Carboplatin|Given IV
218969765|NCT03811002|DRUG|Cisplatin|Given IV
218969766|NCT03811002|DRUG|Etoposide|Given IV
218969767|NCT03811002|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219064459|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
219064460|NCT05114681|OTHER|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
219064461|NCT03161834|OTHER|Observational|
219208316|NCT07039604|DEVICE|Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China|PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
219660702|NCT06908941|DIETARY_SUPPLEMENT|milk chocolate|Participants consumed milk chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
219660703|NCT06908941|BEHAVIORAL|high-intensity resistance exercise|Participants performed high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles.
219660704|NCT06182046|PROCEDURE|Complete decongestive treatment program|It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
219660705|NCT06182046|PROCEDURE|Balance exercises|These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
218969768|NCT03811002|OTHER|Quality-of-Life Assessment|Ancillary studies
218969769|NCT03811002|OTHER|Questionnaire Administration|Ancillary studies
218969770|NCT04701684|DEVICE|Direct to Angio Suite (DTAS) Philips' CBCT triage|Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
218969771|NCT04701684|PROCEDURE|Conventional CT/MR triage|First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
218969772|NCT06407427|DEVICE|App for in-bed conditioning exercises|Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients
218969773|NCT06407427|OTHER|Usual care|All participants will receive usual care in the post-operative setting.
218969774|NCT04191187|DRUG|Fludarabine|Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2
218969775|NCT04191187|DRUG|Melphalan|Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
218969776|NCT04191187|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
218969777|NCT06197685|BEHAVIORAL|The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
218969778|NCT06197685|BEHAVIORAL|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.
218969779|NCT06197685|BEHAVIORAL|Stretching and Toning (S/T)|The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
218969780|NCT01040078|BIOLOGICAL|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
218969781|NCT01040078|BIOLOGICAL|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
218969782|NCT01040078|BIOLOGICAL|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
219064462|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
219064463|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
219064464|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
219064465|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
219064466|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
219064467|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
219064468|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
219064469|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
219064470|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
219660706|NCT03383900|DEVICE|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
218969783|NCT00305825|BIOLOGICAL|bevacizumab|
218969784|NCT00305825|DRUG|letrozole|
218969785|NCT04893837|DEVICE|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
218969786|NCT06649721|DRUG|bedaquiline|400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)
218969787|NCT06649721|DRUG|delamanid|"* for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w"
218969788|NCT06649721|DRUG|linezolid|"* for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
218969789|NCT06649721|DRUG|Levofloxacin|"Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
218969790|NCT06649721|DRUG|Clofazimine|"Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
218969791|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
218969792|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
218969793|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
218969794|NCT06225596|DRUG|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
218969795|NCT06225596|DRUG|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
218969796|NCT06225596|DRUG|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
218969797|NCT04068584|OTHER|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
219660707|NCT01650545|DRUG|Liposomal aerosol cyclosporine|inhaled form of immune suppression
218969798|NCT05643560|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
218969799|NCT06587750|BEHAVIORAL|Cognitive Multisensory Rehabilitation|CMR targets somatosensory and multisensory and cognitive functions through sensory discrimination exercises.
218969800|NCT04582916|DRUG|11C-MCI|Injected IV followed by PET scanning
218969801|NCT04582916|DRUG|11CPS13|Injected IV followed by PET scanning
218969802|NCT05897398|OTHER|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
218969803|NCT05897398|OTHER|Blood sampling|Blood sampling for routine care (max 15mL)
218969804|NCT05897398|OTHER|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
218969805|NCT06817213|BEHAVIORAL|General education control|Participants will complete an online survey before reviewing education material for eosinophilic esophagitis, prior to patient's clinical physician's appointment (this appointment is a standard of care visit). Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
218969806|NCT06817213|BEHAVIORAL|Decision support tool|Participants will complete an online survey before reviewing tailored educational materials for eosinophilic esophagitis prior to patient's clinical physician's appointment (this appointment is a standard of care visit). The intervention is a tailored, electronic decision support intervention with a patient-facing decision aid (DA) with three components-EoE knowledge/education, values clarifications, and communication. Tailored feedback from the patient will be given to the patient's provider prior to the visit to facilitate shared decision-making in the visit. Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
218969807|NCT06068647|DIAGNOSTIC_TEST|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
218985433|NCT01518023|OTHER|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
219064471|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
219064472|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
219064473|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
219660708|NCT01650545|OTHER|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
219660709|NCT02505451|DRUG|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
219660710|NCT01264354|DRUG|Clevudine 30mg|Clevudine 30mg
219660711|NCT01264354|DRUG|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
219660712|NCT01264354|DRUG|Clevudine 20mg|Clevudine 20mg
219660713|NCT06649227|DRUG|CAR-T cell therapy|cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
219660714|NCT00001076|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
218969808|NCT02908893|BEHAVIORAL|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
218969809|NCT05407753|DIETARY_SUPPLEMENT|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
218969810|NCT05407753|DIETARY_SUPPLEMENT|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
218969811|NCT06981507|DEVICE|MARPE (Miniscrew-Assisted Rapid Palatal Expansion)|MARPE (Miniscrew-Assisted Rapid Palatal Expansion) is an orthodontic expansion technique that uses a palatal expander anchored with miniscrews inserted into the palatal bone. The device applies lateral force to widen the maxilla skeletally in patients with transverse maxillary deficiency. In this study, all participants will receive MARPE treatment as part of their orthodontic management, and its potential effects on speech will be evaluated over time.
218969812|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
218969813|NCT06991972|PROCEDURE|Needling + NBUVB|Participants in this arm will undergo needling using a sterile 30G (4mm) needle to manually puncture and implant melanocytes from perilesional pigmented skin into depigmented lesions. The procedure will be performed once every four weeks for a total of six sessions.
218969814|NCT06991972|PROCEDURE|Microneedling + NBUVB|Participants in this arm will undergo microneedling using a Dermapen device with 1.5 mm needles to create controlled micro-injuries in depigmented skin to enhance melanocyte migration and repigmentation. This procedure will be performed once every four weeks for six sessions.
218969815|NCT06615609|BEHAVIORAL|Smart family doctor|"Based on health managers, participants were additionally provided Smart family doctor, which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'."
219064474|NCT04450823|OTHER|no intervention|no intervention study, survey amongst health workers
219660715|NCT00001076|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219660716|NCT00001076|BIOLOGICAL|rgp120/HIV-1 SF-2|
219660717|NCT00834730|DRUG|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
219660718|NCT01463267|DEVICE|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
219660719|NCT01463267|BEHAVIORAL|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
219660720|NCT00737334|DEVICE|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
219660721|NCT05297084|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
219660722|NCT01013623|PROCEDURE|Surgery|surgical resection to remove all known disease
219660723|NCT01013623|PROCEDURE|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
219660724|NCT01013623|OTHER|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
219064475|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
219660725|NCT06618625|PROCEDURE|nasotracheal intubation|"For nasotracheal intubation, the nasal RAE tube will be inserted with it rotated by 90 degrees in counter-clockwise direction for patients in the 'Rotation' arm.~For nasotracheal intubation, the nasal RAE tube will be inserted without tube rotation for patients in the 'Neutral' arm."
219660726|NCT03211429|BEHAVIORAL|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
219660727|NCT03211429|OTHER|Tai chi|Tai Chi training in the Yang style of 24 movement
219660728|NCT03211429|OTHER|Postural control exercise|Individually adjusted progressive and specific postural control training,
219660729|NCT04659629|DRUG|NL-201|NL-201 is a de novo protein therapeutic.
219660730|NCT04659629|DRUG|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
219660731|NCT06909786|PROCEDURE|HPI guided hemodynamic management|"BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to the HPI (Edwards Lifesciences).~The treating anesthetist is trained to understand Acumen IQ parameters and the meaning of HPI, MAP, CI, SVI, SVR, SVV, Eadyn, dP/dtmax. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and how to treat hypotension. The hemodynamic management is performed according to the HPI guided algorithm."
219660732|NCT06909786|OTHER|standard arterial line|BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to TruWave DPT and run data via HemoSphere machine (Edwards Lifesciences). The target of intraoperative blood pressure was to maintain MAP \> 65mmHg. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
219660733|NCT06912139|DRUG|Nitroglycerin transdermal|Nitroglycerin cream is applied \~ 15 minutes before radial artery puncture for emergency or planned invasive cardiology procedure (example: coronary angiography), and radial artery spasm and diameter are determined by angiography, injecting contrast into the radial artery through the placed radial sheath.
218969816|NCT06615609|BEHAVIORAL|Health manager|Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
219660734|NCT06912139|OTHER|Placebo|Placebo cream with no active compounds is applied by the designated nurse to the radial puncture site, similar to NTG cream, with both patient and invasive cardiologist blinded wo which arm the patient is included in.
218969817|NCT06673212|OTHER|Control Wheat Bread|Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
218969818|NCT06673212|OTHER|Berneray Bere barley bread|Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
218969819|NCT06673212|OTHER|Black Barley bread|Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
218969820|NCT06666738|BEHAVIORAL|Structured antimicrobial review|The appropriateness of the documented indication, route of administration, expected duration and stop date of all antimicrobials will be reviewed within 48 hours of their prescription.
218969821|NCT06667622|DRUG|sodium glycididazole|Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
218969822|NCT07006324|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta. 3-4 home visits with appropriate interventions through a referral and support process.
218969823|NCT06114732|BEHAVIORAL|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
218969824|NCT06625801|DEVICE|IVUS|Intravascular Ultrasound
218969825|NCT06685172|OTHER|f-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
218969826|NCT06685172|OTHER|r-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
218969827|NCT06470711|OTHER|Non-Interventional Study|Non-interventional study
218969828|NCT05530850|BEHAVIORAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
218969829|NCT05530850|OTHER|Thoracic exercise program|Thoracic region focused exercise program
218969830|NCT06693960|DIETARY_SUPPLEMENT|Oregano|Oil of oregano administered as a softgel (180 mg).
219064476|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
219064477|NCT00053131|BIOLOGICAL|filgrastim|
219064478|NCT00053131|BIOLOGICAL|sargramostim|
219064479|NCT00053131|DRUG|cytarabine|
219064480|NCT00053131|DRUG|mitoxantrone hydrochloride|
219064481|NCT05745077|BEHAVIORAL|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
219064482|NCT05745077|BEHAVIORAL|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
219064483|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
219064484|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
219064485|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
219064486|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
219064487|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
219660735|NCT06911125|DEVICE|TENS|"TENS will be applied paravertebrally using four electrodes in the neck and back areas. Self-adhesive electrodes specific to each participant will be used for the application. TENS will run on symmetrical biphasic current at 100 Hz and 120 microseconds. The current intensity is determined by the level at which the person perceives the current. The participants are informed that they will get a current, which may induce a pins-and-needles sensation. It is essential for them to perceive the current distinctly; the intensity should be sufficient to be sensed without causing discomfort. The duration of the treatment is 20 minutes. Participants will receive exercises to strengthen the muscles around the neck.~All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks."
218969831|NCT06693960|DRUG|Drug cocktail|Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
218969832|NCT06630026|OTHER|The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.|• The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
218969833|NCT06698120|PROCEDURE|Awake prone positioning (APP)|"* APP are realized following the diagnosis of ACS~* Prone positioning or supine positioning are performed under supervision of a physician or a nurse~* Maximum session duration: 16 hours per day~* Sessions of prone positioning can be shortened, if necessary (30 minutes minimum), for better tolerance~* Tolerance of prone positioning is assessed by the physician in charge and sessions and may be stopped in case of poor tolerance"
218969834|NCT07025421|OTHER|Intervention Upright Bed positioning|Patient in receipt of the upright bed positioning will receive daily upright bed positioning time each day of mechanical ventilation following the time required by institutional protocol for ARDS - associated prone positioning
218969835|NCT06727773|DRUG|Memantine|memantine capsule
218969836|NCT06727773|DRUG|Placebo medication|placebo capsule
218969837|NCT06727773|OTHER|Exercise Intervention|Exercise Intervention participants will concurrently engage in remotely delivered Get Real \& Heel, 3d/week. Intensity for aerobic and strength-training components will progress as tolerated under the direction of a trained exercise physiologist.
218969838|NCT06727773|OTHER|Exercise Control|Exercise control will have access to a library of pre-recorded Get Real \& Heel sessions.
218969839|NCT06885697|DEVICE|mesothelin expression testing|Assay done at screening to determine mesothelin expression levels
218969840|NCT06885697|BIOLOGICAL|TNhYP217 CAR T Cells|Variable doses, administered intravenously on Day 0
218969841|NCT06885697|DRUG|fludarabine|30 mg/m\^2 IV infusion administered followed by cyclophosphamide on days both are given. Daily x 4 doses on Day -7, -6, -5 and -4
218969842|NCT06885697|DRUG|cyclophosphamide|600 mg/m\^2 IV infusion. Daily x 3 doses on Day -6, -5, -4
218969843|NCT06093360|PROCEDURE|flapless surgery|Implant-supported restorations were unscrewed and modified if necessary (biofilm control). All the restorations were relocated at the end of each intervention session. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement. Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was simultaneously performed to remove the granulation tissue. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Oral hygiene instructions were given. Systemic antibiotics, when prescribed, were metronidazole or azithromycin
218969844|NCT06731504|DRUG|Abatacept|Abatacept is a monoclonal antibody that suppresses T-cell activation through costimulatory blockade. In 2021, abatacept was FDA approved to prevent acute GVHD following allogeneic HCT.
218969845|NCT07053969|DEVICE|Enamel Matrix Derivative|EMD is an FDA approved medical device used in periodontal procedures since 1996. It has been shown to enhance soft and hard tissue healing, increased root coverage and aid in periodontal regeneration. It's use as an adjunct during implant uncovering may increase peri-implant mucosal thickness.
218985434|NCT04545554|DRUG|Romosozumab|Participants will receive multiple doses of romosozumab via a SC injection.
218985435|NCT04545554|DIETARY_SUPPLEMENT|Calcium|All participants will receive daily supplements of elemental calcium.
218985436|NCT04545554|DIETARY_SUPPLEMENT|Vitamin D|All participants will receive daily supplementation with vitamin D.
218985437|NCT04087304|BEHAVIORAL|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
218985438|NCT01863420|RADIATION|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
218985439|NCT05623839|DRUG|LY3305677|Administered SC
218985440|NCT05623839|DRUG|Placebo|Administered SC
218985441|NCT00494299|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
218985442|NCT00494299|DRUG|Placebo|Placebo: matching placebo
218985443|NCT04351854|OTHER|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
218985444|NCT03333304|DIAGNOSTIC_TEST|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
218985445|NCT05907590|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
219660736|NCT06911125|DEVICE|Diadinamic Current|Diadynamic current will be performed paravertebrally using two electrodes on the neck and back areas. Participant-specific self-adhesive electrodes will be utilized for the application. In diadynamic current, two distinct current modules, namely diphase-fixed (2 minutes) and short period (8 minutes), will be utilized. The cumulative duration of the treatment is 10 minutes. The program will provide the current intensity at the threshold perceived by the individual. The participants will be informed about the application as follows: 'You will receive a current; you may have a pins-and-needles sensation; it is crucial to perceive the current distinctly and thoroughly; the intensity should neither be insufficient to be felt nor excessive to cause discomfort.' Participants will receive exercises to strengthen the muscles around the neck.All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks.
219660739|NCT06911463|OTHER|suprainguinal fascia iliaca block group (SIFIB)|The anterior superior iliac spine is identified by a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) the inguinal ligament in the parasagittal plane, following appropriate disinfection and draping of the patient in the supine position. Then, the probe is moved medially, and the internal oblique muscle in the cranial direction, the sartorius muscle in the caudal direction, the bow-tie shape formed by these muscles, the underlying iliacus muscle, and the fascia iliaca surrounding it is visualized. (21) An 80-mm peripheral nerve block needle is inserted from the caudal side, and the iliac fascia is passed. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected.
219660740|NCT06911463|OTHER|iliohypogastric and ilioinguinal group (IL-IH)|Group II (I): iliohypogastric and ilioinguinal group (IL-IH) After preparation of the inguinal region sterile linear high frequency probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) is placed between the iliac crest and costal margin (more cephalad than the usual location for ilioinguinal block). In this location, the ilioinguinal and iliohypogastric nerves in between the transverses abdominus and internal oblique are well defined (22) After visualization, a 22G 1.5-inch needle is used in out of-plane approach to reach the nerves. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected (kayak sign).
219660741|NCT06911463|OTHER|Local infiltration|patients receive infiltration of 0.5% 10ml bupivacaine and 1% 10 ml lidocaine in the groin at the site of puncture.
219660742|NCT06911489|DIAGNOSTIC_TEST|68Ga-NRT6020 Injection|Participants will receive a single intravenous injection of 68Ga-NRT6020 Injection (3 mCi or 5 mCi) and PET/CT scans at multiple time points.
219660743|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 2)|It is planned to evaluate 4 dose levels of 177Lu-NRT6020 Injection: 50mCi, 100mCi, 150mCi and one/more adaptive dose groups (ranged from 150 to 250 mCi, the specific doses and/or doses with other frequencies within the range of 150\~250mCi, need to be determined after the completion of the dose-limiting toxicity (DLT) assessment for the previous three dose groups, in combination with the safety, pharmacokinetics and radiation dosimetry results of the participants, following confirmation by the SRC) which will be administered every 6 weeks (Q6W), and/or other dosing intervals determined by the SRC, for up to 6 cycles.
219660744|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 3)|Participants will receive intravenous injection of 177Lu-NRT6020 Injection, administered Q6W and/or other dosing intervals determined by the SRC, for up to 6 cycles.
219660745|NCT06910189|DEVICE|Fish Skin Graft (FSG)|FSG will be applied to the wound bed, followed by a wound VAC at the time of surgical debridement
219660746|NCT06910189|DEVICE|Wound Vacuum-Assisted Closure (VAC)|Participants will have a wound VAC applied to their wound bed at the time of surgical debridement.
219660747|NCT06909981|RADIATION|Low-Dose Computed Tomography Scan|Imaging of chest to screen for lung cancer.
219660748|NCT06911814|OTHER|kinesio taping|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
219660749|NCT06911814|OTHER|THE EXERCİSE|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
218969846|NCT07069374|BEHAVIORAL|Wellness, Intervention Strategies and HIV Care (WISH)|A structured behavioral group program consisting of five weekly sessions, each approximately 60-90 minutes in length. The intervention is designed for individuals living with HIV who use substances and focuses on: managing stress, addressing barriers to care, and enhancing engagement with HIV-related health services. Sessions are delivered in a small-group format and facilitated by trained staff using a manualized curriculum.
218969847|NCT07069374|BEHAVIORAL|Movie Night Club - Attention and Time Matched Control|Weekly 90-minute group sessions over 5 weeks in which participants watch non-therapeutic, neutral-content movies in a group setting. Sessions are facilitated to control for social interaction and time spent in a structured group environment but do not include any therapeutic content.
218969848|NCT07098130|OTHER|US-guided PNM 100 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 5 cycles of 5 seconds stimulation (100 Hz and 350 µs pulse width), followed by 55 seconds rest.
219064488|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
219064489|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
219660750|NCT06910995|BEHAVIORAL|AR location-based game|This study aims to utilize the AR location-based game Pikmin Bloom to gradually encourage middle-aged and older adults in the community to develop a habit of walking outdoors. A step goal will be set every two weeks to progressively increase daily walking activity. By integrating the AR game with a LINE chatbot for feedback and engagement, this approach aims to motivate older adults, enhance their willingness to go outside, and increase their daily step count.
219660751|NCT06911138|BEHAVIORAL|Behavorial|Behavioral intervention that focuses on improving syntactic knowledge.
219660752|NCT06912399|DEVICE|Transauricular Vagus Nerve Stimulation|Participants enrolled will have a commercial transcutaneous electrical nerve stimulation unit (tVNS501,RISHENA,Changzhou,China) attached to their left outer ear after VATS. The stimulation pulses will target at the cymba concha which is 100% dominated by the auricular branch of the vagus nerve. Stimulation pulses will be 25Hz in frequency according to current clinical research, 500µs in pulse width which has been suggested to be most biologically active, with its amplitude increasing to the maximum amount that the patients can tolerate without pain.
219660753|NCT06912399|DEVICE|Sham Transauricular Vagus Nerve stimulation|The only thing differs with the taVNS group is that the device will automatically shut down after running for 15 seconds.
219660754|NCT06911047|BEHAVIORAL|Education Intervention|Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components: 1. One multimedia e-learning lesson on promoting brain health and preventing dementia; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to dementia risk factors
219660755|NCT06911047|BEHAVIORAL|Education Control|Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components: 1. One multimedia e-learning lesson on mild cognitive impairment; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to mild cognitive impairment
219660756|NCT06911307|OTHER|standard care group|The standard care (SC) group will also include 80 participants. Wounds will be cleansed with sterile normal saline and managed using conventional wound care techniques. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
219660757|NCT06911307|OTHER|NPWT|The NPWT group will also include 80 participants. Wounds will be cleansed with sterile normal saline and coverd the SIMO NPWT dressing. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
219660758|NCT06911554|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
219660759|NCT06911554|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
219660760|NCT01715402|PROCEDURE|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
219660761|NCT02972333|DRUG|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
219660762|NCT02972333|RADIATION|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
219660763|NCT00094549|DRUG|olanzapine|
219660764|NCT00094549|DRUG|divalproex sodium|
219660765|NCT00094549|DRUG|placebo|
219660766|NCT02920814|OTHER|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
218969849|NCT07098130|OTHER|US-guided PNM 10 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 10 cycles of 10 seconds stimulation (10 Hz and 250 µs pulse width), followed by 10 seconds rest.
218969850|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
218969851|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
218969852|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
218969853|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
218985446|NCT05907590|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
218985447|NCT05907590|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
219660767|NCT06020209|DIAGNOSTIC_TEST|Cardiac Computed Tomography|A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.
219660768|NCT06020209|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
219660769|NCT06460337|OTHER|Modified Otago exercises|Participants will engage in modified Otago exercise sessions, either individually or in groups, for 45 minutes, thrice weekly over an 8-week period. The program entails moderate-intensity strengthening exercises targeting various muscle groups such as hip extensors, abductors, knee flexors and extensors, inner range quadriceps, ankle plantar flexors, and dorsiflexors, performed at 10 repetitions maximum (RM) with ankle cuff weights ranging from 0.5 to 1 kg. Additionally, balance exercises will be conducted, initially with support and gradually progressing to without support, including knee bends, backwards walking, sideways walking, tandem stance and walk, one leg stance, heel and toe walking, sit-to-stand, stair climbing, stepping over objects, and bending to pick up objects from the floor. Participants are also encouraged to walk outdoors at their usual pace for 30 minutes at least three times weekly.
219660770|NCT06460337|OTHER|Frenkel's exercises|Frenkel's exercise regimen comprises a series of movements performed in lying, sitting, stride standing, and standing positions aimed at improving coordination and motor control. In the lying position, exercises include alternating hip and knee flexion/extensions, hip abduction/adduction, pedaling the lower limbs, and simultaneous movements of hips and knees. These are executed slowly to enhance coordination. In sitting, exercises involve leg stretching, hip flexion with knees flexed or straightened, and transitions from sitting to standing and back. Stride standing exercises focus on weight transfer and sideways walking, while standing exercises encompass walking on marked paths, trunk rotations, 360-degree turns, smaller arcs of hip abduction/adduction and flexion/extension, straight-line walking, and directional changes to simulate real-life obstacles. 3 sets comprising 10 repetitions are performed for each exercise, aiming for motor skill improvement and balance enhancement
219660771|NCT02713854|PROCEDURE|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
219660772|NCT02539654|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
219660773|NCT02539654|PROCEDURE|Tympanostomy Tube Insertion|
219660774|NCT00715845|PROCEDURE|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
219660775|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
219660776|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
219660777|NCT04066777|PROCEDURE|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
218969854|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks~177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion. One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
218969855|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~Synonyms are:~177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE LUTATHERA, lutetium (177Lu) oxodotreotide 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
218969856|NCT06878664|DRUG|Amino acid solution|Renal protection starting 30 minutes before RLT and lasting 4 hours (iv) amino acid solution of 14.4-20 g of lysine and 14.9-20.7 g of arginine in 1 to 2 liters of solution)
219064490|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
219064491|NCT02911402|OTHER|sea sickness questionnaires|
219064492|NCT00723775|DRUG|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
219064493|NCT02973958|DRUG|Bupivacaine|See active comparator description
219660778|NCT06210373|DEVICE|Myrialen Gel|Myrialen Gel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment.
219660779|NCT06210373|DEVICE|Recugel|"Recugel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.~In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment."
219660780|NCT04247568|OTHER|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
219660781|NCT05331781|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
219660782|NCT05331781|DRUG|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
219660783|NCT01709773|PROCEDURE|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
219660784|NCT03318081|BEHAVIORAL|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
219660785|NCT04825496|GENETIC|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
219660786|NCT04825496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219660787|NCT04825496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219660788|NCT01892800|PROCEDURE|Lung resection|
219660789|NCT06910852|PROCEDURE|Vascular stapler|the utilization of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation for living donor liver transplantation
219660790|NCT05835427|OTHER|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
219660791|NCT05835427|OTHER|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
219660792|NCT04582565|COMBINATION_PRODUCT|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
219660793|NCT04582565|OTHER|Standard Care|
219660794|NCT04318171|DEVICE|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~* Plaque volume where detectable.~* Max area stenosis.~* Volumetric stenosis.~* Measured length.~* 3D GSM. The entire assessment should not take more than 45 minutes."
219660795|NCT00059878|BIOLOGICAL|recombinant interferon gamma|
219660796|NCT00059878|DRUG|voriconazole|
219660797|NCT03618563|OTHER|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
218969857|NCT06878664|DRUG|Lanreotide (Autogel formulation) or Octreotide LAR|Long-acting standard doses of SSA (Lanreotide autogel 120 mg subcutaneous (sc) or Octreotide LAR 30 mg im, starting 24h after RLT and every 4 weeks during RLT (q16w interval SSA administration should be adjusted to RLT administrations so that SSA is always given 24h after each RLT dose and at least 4 weeks prior to next RLT administration cycle) and q4w following last RLT administration until disease progression.
218969858|NCT07142603|OTHER|Metabolic response to protein source|Participants will be given a 350-400 kcal meal challenge containing 30% energy from animal protein. They will be given 10 minutes to consume the meal and meal response will be measured 240 minutes following the meal.
219064494|NCT02973958|DRUG|Sevoflurane|See active comparator description
219064495|NCT02973958|DRUG|Acetaminophen|See active comparator description
219064496|NCT02973958|DRUG|Ibuprofen|See active comparator description
219064497|NCT02973958|DRUG|Ketorolac|See experimental arm description
219660798|NCT00005941|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219660799|NCT00005941|DRUG|cyclosporine|
219660800|NCT00005941|DRUG|fludarabine phosphate|
219660801|NCT00005941|DRUG|mycophenolate mofetil|
219660802|NCT00005941|PROCEDURE|peripheral blood stem cell transplantation|
219064498|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
219064499|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
219064500|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
219660803|NCT00005941|RADIATION|radiation therapy|
219064501|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
219064502|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
219064503|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
219660804|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
219660805|NCT06910150|PROCEDURE|Non-invasive analgesic electrostimulation|Application of a single session of non-invasive analgesic electrostimulation to motor points of the vastus medialis and vastus lateralis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 200 μs, and an intensity adjusted to the patient's pain threshold for 30 minutes.
219660806|NCT06910150|PROCEDURE|Invasive analgesic electrostimulation|Application of a single session of invasive analgesic electrostimulation to a motor point of the vastus medialis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 250 μs, and an intensity defined as perceptible to the patient but never painful (200 μA above the detection threshold for each subject).
219660807|NCT06251024|BIOLOGICAL|RSV vaccine candidate|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219660808|NCT06251024|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219660809|NCT06912178|OTHER|Acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
219660810|NCT05125952|DEVICE|Viasys Avea Ventilator|Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.
219660811|NCT05125952|DEVICE|Philips Respironics NM3 device|Measuring static airway driving pressure during pressure support breath
219064504|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
219064505|NCT04587089|PROCEDURE|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
219064506|NCT04587089|PROCEDURE|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
219064507|NCT04587089|PROCEDURE|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula \& Ação (F\&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
219660812|NCT05125952|DEVICE|Servo U ventilator|Measuring static airway driving pressure and p0.1 during pressure support breath.
219660813|NCT05125952|DEVICE|Vyaire SmartCath adult nasogastric tube with Esophageal balloon|Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
219660814|NCT03632538|DIAGNOSTIC_TEST|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
219660815|NCT04683939|DRUG|BNT141|Intravenous (IV)
219660816|NCT04683939|DRUG|Nab-paclitaxel|IV
219660817|NCT04683939|DRUG|Gemcitabine|IV
219660818|NCT05875493|DRUG|JAB-21822|2 discrete single doses
219660819|NCT05875493|DRUG|JAB-21822|2 discrete single doses
219660820|NCT05179759|BEHAVIORAL|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
218969859|NCT07141836|PROCEDURE|Elastomeric chain|Elastic chain used to apply force that is capable of canine retraction. The chains were attached between canine bracket and molar band on the side that selected Randomly.
218969860|NCT07141836|PROCEDURE|Elastics|Elastics were used to bring a continuous force for maxillary canine retraction in orthodontic patients. Elastics were stretched between the canine bracket and the molar band to retract the canine distally
218969861|NCT07140796|BEHAVIORAL|Blood Flow Restriction Training|Participants perform squats with 15% of their body weight under blood flow restriction using a thigh cuff. Hip internal rotation is set at 15 degrees. The training is conducted twice a week for 4 weeks. Cuff pressure is estimated using a predictive formula based on thigh circumference and systolic blood pressure.
218969862|NCT07140796|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial extracorporeal shockwave therapy (rESWT) is applied to the gluteus medius region prior to each exercise session. The protocol includes 2000 pulses per session, applied twice per week for 4 weeks, using a radial shockwave device.
218969863|NCT04679844|DEVICE|MagnetOs Easypack Putty|MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.
219064508|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
219064509|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
219064510|NCT03361813|OTHER|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
219064511|NCT03361813|OTHER|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
219064512|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
219660821|NCT05179759|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
219660822|NCT02839382|OTHER|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
219660823|NCT02839382|OTHER|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
219660824|NCT02839382|OTHER|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
219660825|NCT01063894|OTHER|breakfast cereal|breakfast cereal and milk
219660826|NCT01063894|OTHER|water|water
219660827|NCT00946062|OTHER|orientation and mobility training|orientation and mobility training
219660828|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
219660829|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
219660830|NCT01733992|DRUG|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
219660831|NCT01733992|DRUG|Placebo|Placebo, single and multiple ascending dose
219660832|NCT03457844|DRUG|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219660833|NCT06468163|DEVICE|Drug infusion into joint through catheter.|With or without using catheter after DAIR operation for drug infusion.
218969864|NCT04679844|DEVICE|Demineralized Bone Matrix or Fibers mixed with local autograft bone|Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
218969865|NCT06933563|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
218969866|NCT06937944|BIOLOGICAL|Rcombinant botulinum toxin type A for injection（Eveotox)|Rcombinant botulinum toxin type A for injection（Eveotox)
218969867|NCT06937944|BIOLOGICAL|OnabotulinumtoxinA (Botox)|OnabotulinumtoxinA (Botox)
218969868|NCT06937944|BIOLOGICAL|Placebo|Placebo
218969869|NCT06941519|BEHAVIORAL|Telephonic Outreach|Higher Intensity (active telephonic outreach from a health navigator with follow-up contacts for up to 3 months)
218969870|NCT06941519|BEHAVIORAL|Virtual Outreach|Lower Intensity (outreach via text, email, and/or letter with materials that contain information about available local, state, and federal governmental benefits and services)
218969871|NCT06954623|RADIATION|Radiation Therapy|proton beam radiation
218969872|NCT07150754|DRUG|Heart failure pharmacological treatments|Identify a positive signal for fall with one or more of the recommended pharmacological treatments for heart failure
218969873|NCT07149545|DRUG|Arm A (Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after surgical site disinfection; during ablation, fentanyl 2 mL and midazolam 0.5 mg were administered intravenously. Additional fentanyl or midazolam was given if needed.
218969874|NCT07149545|DRUG|Arm B (Flurbiprofen axetil + Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; flurbiprofen axetil (100 mg) administered intravenously after transseptal puncture; fentanyl 2 mL and midazolam 0.5 mg administered during ablation. Additional fentanyl was given if needed.
218969875|NCT07149545|DRUG|Arm C (Fentanyl + Dexmedetomidine)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; dexmedetomidine continuous infusion (0.4 μg/kg/h) was administered throughout.
218969876|NCT07150364|OTHER|Square Stepping Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
218969877|NCT07150364|OTHER|Wobble Board Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
219660834|NCT00481013|DRUG|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
219660835|NCT00481013|DRUG|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
218969878|NCT07149441|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
218969879|NCT07149441|DRUG|infliximab|Intravenous infusion of infliximab once every 8 weeks.
218969880|NCT07149480|PROCEDURE|Underlay Tympanoplasty|Tympanoplasty performed using the underlay graft technique, where the graft is positioned beneath all three layers of the tympanic membrane remnant.
218969881|NCT07149480|PROCEDURE|Interlay Tympanoplasty|Tympanoplasty performed using the interlay graft technique, where the graft is positioned between the mucosal and fibrous layers of the tympanic membrane.
218969882|NCT07149701|DEVICE|Intervention|Treatment with intervention of catheter ablation or Implantable cardioverter defibrillator.
218985448|NCT05907590|OTHER|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
218985449|NCT05907590|OTHER|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
218985450|NCT04198597|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
218985451|NCT04198597|BEHAVIORAL|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
218985452|NCT00216710|BEHAVIORAL|Home Visiting|
218985453|NCT02409212|BEHAVIORAL|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
219660836|NCT00516490|DRUG|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
219660837|NCT00516490|DRUG|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
218985454|NCT02409212|BEHAVIORAL|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
218985455|NCT00801320|PROCEDURE|Tumor collection|Tumor collected at the time of planned surgery
218985456|NCT00120523|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
218985457|NCT00120523|DRUG|Topical corticosteroids|TCS
218985458|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (T4030)|Eye drop
218985459|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (Ganfort)|Eye drop
219660838|NCT03947775|DRUG|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
219660839|NCT06288542|OTHER|group d|this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
219660840|NCT06288542|OTHER|group R|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
219660841|NCT04624542|DEVICE|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
219660842|NCT00224406|DRUG|Repertaxin|An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
219660843|NCT00224406|OTHER|Placebo|An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
219660844|NCT00934232|DRUG|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
219660845|NCT04368832|OTHER|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
219660846|NCT05033483|DIETARY_SUPPLEMENT|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
219660847|NCT05033483|DIETARY_SUPPLEMENT|Placebo|Gelatin capsule containing microcrystalline cellulose
219660848|NCT01556997|DRUG|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
218969883|NCT07150468|OTHER|sampling blood|"Sampling~1. patient~   1. Peripheral blood samples in a volume of 25 cc will be collected before HCT and 2 weeks after HCT, and peripheral blood samples in a volume of 20 cc will be collected 4 weeks, 3 months, 6 months, and 12 months after HCT.~  2. If GVHD occurs, additional blood sample (20 cc) will be collected.~  3. In case of organ-specific GVHD including skin, gut, liver, muscle, etc., tissue samples from biopsy will be obtained for further analysis.~2. donor a. Peripheral blood samples in a volume of 20 cc will be collected before HCT"
218969884|NCT07150104|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
218969885|NCT07150104|DRUG|Nirogacestat|Nirogacestat will be administered.
218969886|NCT07150104|DRUG|Pomalidomide|Pomalidomide will be administered.
218969887|NCT07150104|DRUG|Dexamethasone|Dexamethasone will be administered.
218969888|NCT07149688|DEVICE|Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)|"Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)~Enhanced monitoring with 7-day ECG"
218969889|NCT07149467|DRUG|Ustekinumab (approximately 6 mg/kg)|"At Week 0:~≤55 kg: 260 mg administered by intravenous (IV) infusion.~\>55 kg and ≤85 kg: 390 mg administered by intravenous (IV) infusion.~\>85 kg: 520 mg administered by intravenous (IV) infusion.~From Week 8 onward (i.e., at Week 8 and then every 8 weeks up to Week 52 or the end of the follow-up period):~90 mg administered by subcutaneous (SC) injection."
218969890|NCT07149467|DRUG|Upadacitinib|"From Week 0 to Week 12: 45 mg once daily, administered orally.~From Week 13 through Week 52 or the end of the follow-up period: 30 mg once daily, administered orally."
218985460|NCT04299542|PROCEDURE|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
218985461|NCT04299542|PROCEDURE|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
218985462|NCT02890927|OTHER|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
218985463|NCT04151173|PROCEDURE|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
219660849|NCT01556997|DRUG|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
219660850|NCT01556997|DRUG|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
219660851|NCT02535377|OTHER|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
219660852|NCT03315598|PROCEDURE|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
219660853|NCT03529799|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
219660854|NCT00428012|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
219660855|NCT00428012|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
219660856|NCT03315962|BEHAVIORAL|SPIRIT Intervention|The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
219660857|NCT04063995|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
218969891|NCT07150819|BEHAVIORAL|Standard Nursing Care Protocol|The control group received standard perioperative nursing care in accordance with the Chinese Consensus and Clinical Guidelines for Enhanced Recovery After Surgery (2021 edition) and the Expert Consensus on Perioperative Nursing of Anorectal Diseases (2022 edition). Preoperative fasting included a 6-hour restriction on solid food and a 2-hour restriction on clear liquids. At 8:00 p.m. on the night before surgery, patients were instructed to orally ingest 500 mL of 10% glucose solution to supplement energy reserves. Fifteen minutes of structured health education was delivered preoperatively by the assigned nurse using 3D animations to explain the surgical process. Intraoperatively, an inflatable warming blanket was used to maintain the core temperature at 38°C, and all infusion fluids were pre-warmed to 37°C. For infection prophylaxis, 30 minutes before incision, patients received intravenous cefazolin (1 g for body mass index \[BMI\] \< 25 kg/m²; 2 g for BMI ≥ 25 kg/m²).
218969892|NCT07150819|BEHAVIORAL|MDC-based Pain Management|In accordance with the IASP Guidelines for Multidisciplinary Postoperative Pain Management (2023) and the Expert Consensus on Multidisciplinary Collaboration for Pain Management in China, a three-tier MDC framework was established;Surgeons were responsible for optimizing surgical procedures (e.g., using the tissue selecting technique for stapled hemorrhoidectomy) and administering a local injection of 5 mL 0.25% ropivacaine around the wound margin at the end of surgery. Anesthesiologists performed preoperative ASA physical status classification, monitored intraoperative vital signs, and configured postoperative patient-controlled analgesia (PCA) with sufentanil at 0.02 μg/kg/h.Compound Methylene Blue Nerve Block: A solution was prepared by mixing 2 mL of 1% methylene blue, 10 mL of 0.75% ropivacaine, and 8 mL of normal saline, yielding final concentrations of 0.02% methylene blue and 0.25% ropivacaine.
218969893|NCT07150871|OTHER|Patients diagnosed with syphilis|Collection of clinical data from patients aged ≥18 years with a microbiological and/or clinical diagnosis of syphilis, treated by the Infectious Diseases Department of the University Hospital of Alessandria from 2017 to 2025.
218969894|NCT05548738|DRUG|medthylprednisolone|a type of steroids injected in epidural space
218969895|NCT05548738|DRUG|prolotherapy|a type of hypertonic glucose
218969896|NCT02160782|DRUG|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
219064513|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
219660858|NCT00450853|DRUG|granisetron|Granisetron SC followed by granisetron IV
219660859|NCT00719394|DRUG|GSI 136|
219660860|NCT00719394|DRUG|placebo|
219660861|NCT01010009|DIETARY_SUPPLEMENT|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
219660862|NCT01010009|OTHER|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
219660863|NCT00401401|DRUG|zalutumumab|Eight weekly infusions
219660864|NCT00401401|DRUG|cisplatin|Infusions
219660865|NCT00401401|PROCEDURE|Radiotherapy|Daily in the treatment period
219660866|NCT05563935|DEVICE|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
219660867|NCT05459558|DRUG|Experimental Dentifrice 1|5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).
218969897|NCT02160782|DRUG|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
218969898|NCT00309738|DRUG|pitavastatin|
218969899|NCT00309738|DRUG|simvastatin|
218969900|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
219064514|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
219064515|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
219660868|NCT05459558|DRUG|Experimental Dentifrice 2|5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.
219660869|NCT05459558|DRUG|Reference Dentifrice|Regular Fluoride Dentifrice.
219660870|NCT05313802|DRUG|LY3502970|Administered orally.
219660871|NCT03758235|DRUG|IncobotulinumtoxinA 100 UNT Injection [Xeomin]|Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
219660872|NCT03758235|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
219660873|NCT00689624|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
219660874|NCT00689624|DRUG|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
219660875|NCT00689624|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
219660876|NCT00689624|DRUG|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
219660877|NCT00689624|DRUG|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
219660878|NCT00311103|PROCEDURE|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
219660879|NCT03321461|DRUG|TMTP1|Fluorescent sites will be removed
219660880|NCT03321461|DRUG|ICG|Fluorescent sites will be removed
219660881|NCT05264103|DEVICE|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
219660882|NCT05328388|DIETARY_SUPPLEMENT|Lycomato|Lycomato sof gels
218969901|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
218969902|NCT05979285|DEVICE|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
218969903|NCT01104701|DRUG|exenatide once weekly|subcutaneous injection, 2 mg, once a week
218969904|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
218969905|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
218969906|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
218969907|NCT04926623|DEVICE|FreeStyle Libre 24 weeks|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
218969908|NCT04926623|OTHER|SMBG (22 weeks) and blind CGM (2 weeks)|Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
218969909|NCT00437892|DRUG|atorvastatin|tablets, 40 mg day, 3 months
218969910|NCT00437892|DRUG|atorvastatin|tablets, 40 mg once daily
218969911|NCT00437892|BEHAVIORAL|diet|daily
218969912|NCT00437892|BEHAVIORAL|diet|daily diet
218969913|NCT04592107|DIAGNOSTIC_TEST|eGFR|estimated glomerular filtration rate
218969914|NCT03437512|DEVICE|Anodal tDCS|20 minutes of 2mA anodal stimulation.
218969915|NCT03437512|BEHAVIORAL|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
218969916|NCT03437512|DEVICE|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
218969917|NCT02583373|DRUG|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
218969918|NCT02583373|DRUG|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
218969919|NCT02583373|DRUG|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
218969920|NCT01413061|PROCEDURE|Subtalar Arthrodesis|
218969921|NCT06558539|DEVICE|Transcutaneous Tibial Nerve Stimulation(TTNS)|Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.
218969922|NCT06558539|COMBINATION_PRODUCT|Combination Therapy|Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device
218969923|NCT06558539|DRUG|Standard Medication Therapy|Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
218985464|NCT04151173|PROCEDURE|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
219660883|NCT02175381|DRUG|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
219660884|NCT02175381|DRUG|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
219660885|NCT03458923|DRUG|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
219660886|NCT03458923|DRUG|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
219660887|NCT02245113|OTHER|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
219660888|NCT03468452|OTHER|extubation|Time of extubation
219660889|NCT01361113|DRUG|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
219660890|NCT01765608|DRUG|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
219660891|NCT01765608|DRUG|Placebo|
219660892|NCT01765608|DEVICE|nCPAP|
219660893|NCT01631838|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
219660894|NCT01631838|DIETARY_SUPPLEMENT|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
219660895|NCT04395313|OTHER|no intervention carried out|no intervention was done
219660896|NCT01807728|OTHER|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
219660897|NCT01807728|OTHER|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
219660898|NCT02810015|DRUG|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
219660899|NCT03030274|DEVICE|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
219660900|NCT02513602|PROCEDURE|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
219660901|NCT00919542|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
219660902|NCT00919542|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
219660903|NCT01301885|PROCEDURE|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
219660904|NCT06355856|DRUG|DNN.22.17.036|Apply twice daily to the affected area and around it.
219660905|NCT06355856|DRUG|10573048700|Apply twice daily to the affected area and around it.
219660906|NCT05509764|DIAGNOSTIC_TEST|lung ultrasound score|determination of atelectasis by lung ultrasound score
219660907|NCT04167163|DRUG|Abaloparatide|18 month ABL treatment
219660908|NCT03292458|DRUG|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
219660909|NCT01378715|DRUG|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
219660910|NCT02461680|PROCEDURE|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
218969924|NCT02414672|BEHAVIORAL|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
219660911|NCT02461680|PROCEDURE|suture|
218969925|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
218969926|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
218969927|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
218969928|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
218969929|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
218969930|NCT00263276|DRUG|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
218969931|NCT00263276|DRUG|metformin|Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
218969932|NCT02919098|BEHAVIORAL|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
218969933|NCT02919098|BEHAVIORAL|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
218969934|NCT00674973|DRUG|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
218969935|NCT00674973|DRUG|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
218969936|NCT00763048|DRUG|Fluoride|Brush twice daily for 6 weeks
218969937|NCT00763048|DRUG|Fluoride, triclosan|Brush twice daily
218985465|NCT00907712|OTHER|cardiac echo examination|cardiac echo examination - before and after the surgery
218985466|NCT01880619|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
218985467|NCT01880619|DRUG|Solifenacin|Patients in the arm will receive Solifenacin
218985468|NCT01880619|DRUG|Control|Patients in this are will receive placebo
218985469|NCT01034189|DRUG|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
219660912|NCT06455397|BEHAVIORAL|The Building Emotional Awareness and Mental Health (BEAM) Program|"The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required."
219660913|NCT03564132|DRUG|Yigansan|Yigansan granules
219660914|NCT03564132|DRUG|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
219660915|NCT05030207|DIAGNOSTIC_TEST|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
218969938|NCT04824183|OTHER|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
218969939|NCT02136108|OTHER|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
218969940|NCT02136108|OTHER|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
218969941|NCT01002482|DEVICE|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
218969942|NCT01002482|DEVICE|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
218969943|NCT06337422|DRUG|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule
218969944|NCT05073640|DRUG|Oxopurin|Subjects will receive two capsules per day.
218969945|NCT04378946|BEHAVIORAL|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
218969946|NCT04378946|DEVICE|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
218969947|NCT04378946|DEVICE|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
218969948|NCT04378946|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
219064516|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
218969949|NCT04378946|DIAGNOSTIC_TEST|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
219660916|NCT05030207|DIAGNOSTIC_TEST|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
219660917|NCT05026580|BEHAVIORAL|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
219660918|NCT06404684|BEHAVIORAL|Cognitive behavioral therapy (CBT)|se above
219660919|NCT06285136|PROCEDURE|DEC3-VEN|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
219660920|NCT01326000|DRUG|FOLFIRI|standard iv chemotherapy
219660921|NCT01326000|DRUG|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
218969950|NCT00315159|PROCEDURE|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
218969951|NCT05272449|DEVICE|Sleep apnea diagnosis|Split-night
218969952|NCT03861611|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
218969953|NCT03861611|DRUG|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
218969954|NCT03861611|DRUG|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
218969955|NCT03861611|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
218969956|NCT02946320|DEVICE|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
219064517|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
219660922|NCT01326000|DRUG|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
219660923|NCT01197014|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan high dose
218969957|NCT02946320|DEVICE|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
218969958|NCT02946320|DEVICE|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
219660924|NCT01197014|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
219660925|NCT05850104|OTHER|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
219660926|NCT05850104|OTHER|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
219660927|NCT00593606|DRUG|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
219660928|NCT02897726|DRUG|NVP-1402|Oral
219660929|NCT02897726|DRUG|NVP-1402R|Oral
219660930|NCT01601457|DRUG|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
218969959|NCT00796185|DRUG|Paliperidone ER|
218969960|NCT00954304|DRUG|HM30181AK 1mg|HM30181AK 1mg tablet
218969961|NCT00954304|DRUG|HM30181AK 5mg|HM30181AK 5mg tablet
218969962|NCT00954304|DRUG|HM30181AK 15mg|HM30181AK 15mg tablet
218969963|NCT00954304|DRUG|HM30181AK 60mg|HM30181AK 60mg tablet
218969964|NCT00954304|DRUG|Loperamide 2mg|Loperamide 2mg capsule
218985470|NCT01034189|DRUG|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
218985471|NCT01034189|DRUG|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
218985472|NCT01034189|RADIATION|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
218985473|NCT02326662|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
218985474|NCT02549534|PROCEDURE|Axon Reflexes|"\*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
218985475|NCT02549534|PROCEDURE|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
219660931|NCT01601457|DRUG|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
219660932|NCT05948124|DRUG|L-carnitine|L-carnitine supplementation
219660933|NCT05948124|OTHER|isotonic saline|Intravenous 5 ml of isotonic saline
219660934|NCT06730503|DRUG|Immune checkpoint inhibitor|Observe a situation before and after immunotherapy
219660935|NCT06622525|DRUG|Sodium bicarbonate|This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
219660936|NCT06622525|OTHER|No intervention|The usual management for heat stroke will be given to this group
219660937|NCT01897662|DIETARY_SUPPLEMENT|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
219660938|NCT01897662|DIETARY_SUPPLEMENT|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
219660939|NCT01420562|PROCEDURE|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
219660940|NCT03145662|DEVICE|high pressure balloon|high pressure balloon will be used to treat stenosis
219660941|NCT03145662|DEVICE|cutting balloon|cutting balloon will be used to treat stenosis
219660942|NCT03416634|BEHAVIORAL|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
219660943|NCT03416634|BEHAVIORAL|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
219660944|NCT03416634|BEHAVIORAL|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
219660945|NCT03416634|BEHAVIORAL|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
219660946|NCT05523141|DRUG|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
219660947|NCT05523141|DRUG|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
219660948|NCT03035734|DRUG|BMS-986141 Form A Tablet|tablet
219660949|NCT03035734|DRUG|BMS-986141 Form B tablet (low dose)|tablet
219660950|NCT03035734|DRUG|BMS-986141 Form B tablet (high dose)|tablet
219064518|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
219064519|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
219064520|NCT04321460|DRUG|Placebo|Capsules containing placebo
219064521|NCT01886976|BIOLOGICAL|CART-138 cells|
219064522|NCT03788486|DEVICE|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
219660951|NCT04936698|DRUG|PTU 50 MG Oral Tablet|to treat if the patient has hyperthyroidism
219660952|NCT04936698|DRUG|Levothyroxin|to treat if the patient has hypothyroidism
219660953|NCT00018291|DRUG|Risperidone|
219660954|NCT00018291|DRUG|Gabapentin|
219660955|NCT03605940|COMBINATION_PRODUCT|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
219660956|NCT03605940|DRUG|Corticosteroids|2 mg/kg/day
219660957|NCT02839564|PROCEDURE|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
219660958|NCT02839564|PROCEDURE|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
219660959|NCT05792995|DRUG|Sindillimab|Any treatment regimen that includes immunotherapy.
219660960|NCT04977492|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
219660961|NCT04713436|DRUG|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
219660962|NCT04480567|DRUG|BMN 307|AAV Gene Therapy Infusion
219660963|NCT02278367|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
219660964|NCT02278367|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
219660965|NCT01022775|PROCEDURE|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
219660966|NCT01022775|PROCEDURE|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
219660967|NCT01493700|PROCEDURE|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
219660968|NCT01493700|PROCEDURE|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
219660969|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
219660970|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
219660971|NCT02340312|PROCEDURE|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
219064523|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
219064524|NCT05620758|OTHER|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
219064525|NCT05620758|OTHER|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
219064526|NCT05620758|OTHER|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
219064527|NCT05620758|OTHER|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
219064528|NCT05620758|OTHER|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
219064529|NCT04495712|DRUG|spironolactone|aldosterone blocker
219660972|NCT02340312|OTHER|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
219660973|NCT04643964|BEHAVIORAL|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
219660974|NCT04643964|BEHAVIORAL|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
219660975|NCT04643964|BEHAVIORAL|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
219660976|NCT04643964|BEHAVIORAL|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
218969965|NCT05536479|PROCEDURE|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
218969966|NCT05536479|PROCEDURE|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
218969967|NCT05036369|DEVICE|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
218969968|NCT05036369|DEVICE|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
218969969|NCT00604305|DEVICE|Acrysof|Monofocal IOL
218969970|NCT00604305|DEVICE|Acuity's AIOL|Accommodating IOL
218969971|NCT00051389|DRUG|Fosinopril|
219064530|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
219660977|NCT05932225|OTHER|Propylene glycol solution/drops|Commercially available eye drops
219660978|NCT02633566|DEVICE|Plantar orthoses|
218969972|NCT01039974|DRUG|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
219064531|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
219064532|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
218969973|NCT01039974|DRUG|Ketoconazole|400 mg
218969974|NCT04766710|OTHER|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
218969975|NCT04766710|OTHER|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
218969976|NCT03637023|BEHAVIORAL|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
219064533|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
219064534|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
219064535|NCT05906693|OTHER|Tremor amplitude|Electromyography
219064536|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
219660979|NCT02777281|BEHAVIORAL|Shoulder pain and SCI|Shoulder pain and SCI
219660980|NCT02777281|BEHAVIORAL|Shoulder pain and able bodies|
218969977|NCT03637023|BEHAVIORAL|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
218969978|NCT03084731|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
218969979|NCT00000842|DRUG|Nerve Growth Factor, Recombinant Human|
218969980|NCT02599896|BIOLOGICAL|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
218969981|NCT02599896|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
218969982|NCT03175757|DIETARY_SUPPLEMENT|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
218969983|NCT03175757|DIETARY_SUPPLEMENT|Placebo|Placebo
218969984|NCT00993902|PROCEDURE|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
218969985|NCT00993902|PROCEDURE|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
218969986|NCT02454725|BEHAVIORAL|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
218969987|NCT02454725|BEHAVIORAL|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
218969988|NCT01956435|DEVICE|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
218969989|NCT01483300|DRUG|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
218969990|NCT01483300|DRUG|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
218969991|NCT00401531|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
218969992|NCT00401531|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
218969993|NCT00287482|DRUG|Essiac|
218969994|NCT03502083|DRUG|GLP-1 (7-36)Amide|IV infusion
219064537|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
219064538|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
218969995|NCT00045968|DRUG|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
219660981|NCT00334191|DRUG|Sodium Bicarbonate|
219660982|NCT00334191|DRUG|Placebo|
219660983|NCT02638129|DRUG|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
219660984|NCT02638129|DRUG|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
219660985|NCT06201455|PROCEDURE|PEI+GT|After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
218969996|NCT06046885|DEVICE|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
218969997|NCT01801072|DRUG|Levetiracetam|Details covered in Arm Descriptions.
218969998|NCT01573351|DRUG|Asunaprevir|
218969999|NCT01573351|DRUG|Daclatasvir|
218970000|NCT01573351|DRUG|Peg-interferon Alfa-2a|
218970001|NCT01573351|DRUG|Ribavirin|
218970002|NCT05342610|OTHER|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
218970003|NCT06319638|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
219660986|NCT06201455|PROCEDURE|PEI+MED|Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
219660987|NCT02949908|DRUG|Rebif|Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
219660988|NCT01679912|OTHER|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
219660989|NCT03442166|RADIATION|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
219660990|NCT03442166|RADIATION|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
219660991|NCT00000774|BIOLOGICAL|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
219660992|NCT00000774|BIOLOGICAL|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
219660993|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
219660994|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
219660995|NCT01131039|DRUG|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression"
219660996|NCT01472939|DRUG|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
219660997|NCT01472939|DRUG|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
219660998|NCT01472939|DRUG|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
219660999|NCT01472939|DRUG|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
219661000|NCT00402610|DRUG|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
219661001|NCT01991899|BIOLOGICAL|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
219661002|NCT01991899|BIOLOGICAL|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
219661003|NCT06146699|DEVICE|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross-sectional view of the retina.
219661004|NCT06146699|DEVICE|Fundus fluorescein angiography (FFA)|Fundus fluorescein angiography (FFA) is an invasive diagnostic procedure. It helps to assess the anatomy, physiology, and pathology of retinal and choroidal circulation. It aids in the diagnosis of various ocular pathologies.
219661005|NCT00114738|DRUG|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
219208317|NCT07038577|OTHER|Fenugreek Seed Powder|Participants in the intervention group received 10 grams of ground Fenugreek seed powder, administered twice daily (before breakfast and dinner), for a total of 3 months. The Fenugreek powder was consumed mixed with water, in addition to the participants' regular antidiabetic medications and a standardized meal plan. The supplement was provided in a non-encapsulated, natural powdered form, and was not combined with any other herbal or pharmaceutical products.
219661006|NCT00114738|BIOLOGICAL|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
219661007|NCT00114738|DRUG|Bortezomib (B)|Bortezomib is given alone for one cycle.
219661008|NCT00114738|DRUG|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
219661009|NCT00114738|DRUG|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
219661010|NCT06212713|OTHER|Questionnaire administration|Questionnaire administration - version older adults and informal caregivers
219661011|NCT01137461|PROCEDURE|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
219661012|NCT02890849|OTHER|Liquid biopsy|
219661013|NCT04946552|DIAGNOSTIC_TEST|PET Scan|Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
219661014|NCT04946552|DIETARY_SUPPLEMENT|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
219661015|NCT04946552|DIAGNOSTIC_TEST|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
219661016|NCT04946552|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
218970004|NCT06319638|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218970005|NCT06319638|PROCEDURE|Placebo block|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
218970006|NCT06319638|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
218970007|NCT00632073|DRUG|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
218970008|NCT05760105|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
218970009|NCT02247531|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
218970010|NCT02247531|OTHER|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
218970011|NCT00053573|BIOLOGICAL|Myozyme|20 mg/kg to 40 mg/kg qow
218970012|NCT05931640|DEVICE|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
218970013|NCT05931640|DEVICE|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
218970014|NCT03920748|OTHER|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
219064539|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
219064540|NCT02349958|DEVICE|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
219064541|NCT02349958|DEVICE|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
219064542|NCT02349958|DEVICE|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
219064543|NCT02349958|DEVICE|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
219064544|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
219064545|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
219064546|NCT00706121|DRUG|Vitamin E|400 IU daily by mouth for 7 - 12 years
219064547|NCT00706121|DRUG|Selenium|200 mcg daily for 7 - 12 years
219064548|NCT00706121|DRUG|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
219064549|NCT00706121|DRUG|selenium placebo|1 pill by mouth daily for 7 - 12 years
219064550|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
219064551|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
219661017|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
219661018|NCT04946552|DIAGNOSTIC_TEST|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.
219661019|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
219661020|NCT03453112|DRUG|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
219661021|NCT03453112|DRUG|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA\_134a propellant
219661022|NCT06449508|DRUG|Probiotic Formula|drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
219661023|NCT00841308|OTHER|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
219661024|NCT04484155|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
219661025|NCT00092339|DRUG|MK0966, rofecoxib|
219661026|NCT00092339|DRUG|Comparator: valdecoxib, placebo|
219661027|NCT00337324|DEVICE|Frequency-modulated electromagnetic neural stimulation|
218970015|NCT03920748|OTHER|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
218970016|NCT05281016|BEHAVIORAL|Usual Care|"Participants will be offered standard care which consists of the following:~* Clinic consultation with physician and dietician,~* pamphlets on weight management principles."
218970017|NCT05281016|BEHAVIORAL|Online community LITE programme|"Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support."
218970018|NCT05374668|BEHAVIORAL|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
218970019|NCT03215979|PROCEDURE|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
218970020|NCT03215979|PROCEDURE|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
219064552|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
218970021|NCT02872168|OTHER|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
219661028|NCT02065063|DRUG|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
218970022|NCT06058559|DIETARY_SUPPLEMENT|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
218970023|NCT06058559|DIETARY_SUPPLEMENT|Olive oil|Extra virgin olive oil
219064553|NCT01308749|DRUG|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
219064554|NCT01308749|DRUG|Placebo|Placebo Nasal Spray
219064555|NCT05447546|DRUG|HT-6184|Oral capsule
219064556|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
219064557|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
219064558|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
219064559|NCT01116817|DRUG|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
219661029|NCT02065063|DRUG|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
219661030|NCT03528057|DEVICE|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
219661031|NCT03102697|DEVICE|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
219661032|NCT00729040|BEHAVIORAL|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
219661033|NCT04260386|OTHER|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
219661034|NCT00004892|DRUG|O6-benzylguanine|
219661035|NCT00004892|DRUG|polifeprosan 20 with carmustine implant|
219661036|NCT00004892|PROCEDURE|conventional surgery|
219661037|NCT04129840|OTHER|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
219661038|NCT04129840|OTHER|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
219661039|NCT04129840|OTHER|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
219661040|NCT02211092|BEHAVIORAL|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
219661041|NCT02211092|OTHER|Usual care|Access to usual community resources but no active lifestyle coaching.
219661042|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
219661043|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
219661044|NCT00763516|RADIATION|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
218970024|NCT04363177|BEHAVIORAL|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
218970025|NCT03906461|DEVICE|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
219661045|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
219661046|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
219661047|NCT00308750|DRUG|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
219661048|NCT00308750|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
219064560|NCT01116817|DRUG|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
219064561|NCT03793881|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
219064562|NCT03793881|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
219661049|NCT00308750|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
219661050|NCT00308750|DRUG|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
219661051|NCT03220568|OTHER|Fatty acids present in adipose tissue samples|
218970026|NCT05251311|BEHAVIORAL|Social Risk Screening Tool|"Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need."
218970027|NCT05251311|OTHER|Electronic Resource Map|All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
218970028|NCT05251311|BEHAVIORAL|Resource Menu|Participants randomized to this experimental arm will receive a social resource menu tool, which assess desire for social resources.
219661052|NCT02164032|DRUG|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
218970029|NCT05579691|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
218970030|NCT05579691|OTHER|Placebo|Placebo Comparator
219064563|NCT00674310|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
219661053|NCT02164032|DRUG|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
219661054|NCT02164032|OTHER|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
219661055|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|All drugs on awakening
219661056|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
219661057|NCT00741585|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
219661058|NCT02398513|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
219661059|NCT01358578|DRUG|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
219661060|NCT01358578|DRUG|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
219661061|NCT01358578|DRUG|etanercept|etanercept 50mg subcutaneous
219661062|NCT03535532|PROCEDURE|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
219661063|NCT03535532|DRUG|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
219661064|NCT06731829|DRUG|HRS-9231|HRS-9231
219661065|NCT06731829|DRUG|Gadobutrol|Gadobutrol
219661066|NCT00388297|DRUG|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
219661067|NCT00388297|DRUG|Placebo for Levothyroxine|
219661068|NCT02363985|DIETARY_SUPPLEMENT|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
219661069|NCT04959214|BEHAVIORAL|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
219661070|NCT05514743|PROCEDURE|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
219661071|NCT04087616|BEHAVIORAL|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
219661072|NCT04087616|BEHAVIORAL|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
219661073|NCT03623659|PROCEDURE|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
219661074|NCT06096298|OTHER|Vitamin B12 bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.
219661075|NCT06096298|OTHER|Control bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
219661076|NCT01185262|DRUG|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
219661077|NCT02607280|DRUG|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
218970031|NCT06064266|OTHER|plant-based mild ketogenic controlled diet|Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
218970032|NCT06064266|OTHER|high-fat shake|The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
218970033|NCT02560181|RADIATION|HDR brachytherapy|Whole gland salvage
218970034|NCT02886689|DRUG|TNF-alpha antagonist and other biotherapy|
219661078|NCT04480333|DRUG|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
219661079|NCT04480333|DRUG|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
219661080|NCT04480333|DRUG|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
219661081|NCT04480333|DRUG|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
219661082|NCT04480333|DRUG|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
219661083|NCT04480333|DRUG|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
219661084|NCT04480333|DRUG|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
219661085|NCT04480333|DRUG|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
219661086|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
219661087|NCT04480333|COMBINATION_PRODUCT|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
219661088|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
219661089|NCT04480333|COMBINATION_PRODUCT|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
219661090|NCT06401343|DRUG|Empagliflozin 10 MG|Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
219661091|NCT03745105|DRUG|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
219661092|NCT03745105|DRUG|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
219661093|NCT03745105|DRUG|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
219661094|NCT04148898|DRUG|Osimertinib|Treatment of LM With osimertinb
218970035|NCT06802172|BEHAVIORAL|Time-restricted eating|Participate in time-restricted eating plan
218970036|NCT06802172|OTHER|Questionnaire Administration|Complete questionnaire
218970037|NCT06802172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
218970038|NCT06802172|BEHAVIORAL|Health coaching|Receive nutrition counseling
218970039|NCT00660621|DRUG|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
218970040|NCT01050127|DRUG|ABT-436|See Arm Description for details.
219064564|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
219661095|NCT04148898|DRUG|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
218970041|NCT01050127|DRUG|Placebo|See Arm Description for details.
218970042|NCT00510874|BIOLOGICAL|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
218970043|NCT00510874|BIOLOGICAL|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
218970044|NCT06035055|DRUG|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
218970045|NCT03415100|BIOLOGICAL|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
218970046|NCT02772484|DEVICE|HS-1000|
218970047|NCT00941382|DRUG|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
218970048|NCT00941382|DRUG|Sibutramine|15 mg per day for 180 days
218970049|NCT00941382|DRUG|Metformin|Metformin 850 mg per day for 180 days
218970050|NCT00869843|PROCEDURE|RF Ablation|
218970051|NCT02525315|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
219661096|NCT00577005|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
219661097|NCT00577005|DRUG|Placebo|
219661098|NCT06428994|RADIATION|Radiotherapy|Post-operative radiotherapy for head and neck cancer
219661099|NCT02862132|DRUG|Vedolizumab|
219686386|NCT05782803|BEHAVIORAL|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
219661100|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
219661101|NCT01004432|DRUG|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
219661102|NCT01004432|DRUG|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
219661103|NCT01004432|DRUG|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
219661104|NCT01004432|DRUG|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
219661105|NCT01004432|DRUG|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
219661106|NCT01378832|PROCEDURE|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
219661107|NCT02022475|DRUG|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
218970052|NCT03447184|DRUG|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
219661108|NCT02022475|OTHER|placebo|2 placebo capsules will be applied as a single dose
219661109|NCT06731842|OTHER|18F-RO948|Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease
219661110|NCT00507065|DRUG|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
219661111|NCT00507065|DRUG|Placebo|
219661112|NCT05167331|DRUG|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
219661113|NCT05167331|DEVICE|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
219661114|NCT02667626|OTHER|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
219661115|NCT02667626|OTHER|Control|Web-based resource lists and text-based study adherence reminders
218970053|NCT06309537|DIAGNOSTIC_TEST|chemoreflex evaluation|the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
218970054|NCT02922933|DRUG|entinostat|HDAC (histone deacetylase inhibitor)
219661116|NCT00201812|DRUG|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
218970055|NCT02922933|DIETARY_SUPPLEMENT|Omeprazole|Proton pump inhibitor
218970056|NCT02922933|DIETARY_SUPPLEMENT|Famotidine|Histamine-2 blocker
218970057|NCT06418893|DRUG|Target control infusion propofol|target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
218970058|NCT06418893|DRUG|Inhalational isoflurane|Inhalational Isoflurane at concentration 1-2%
218970059|NCT00185991|DRUG|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
218970060|NCT03689673|OTHER|Data collection|
218970061|NCT03973073|COMBINATION_PRODUCT|CapulinTM|camouflage
218970062|NCT03973073|OTHER|topical applications and NB-UVB|combination therapy of vitiligo
219661117|NCT00201812|DRUG|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
219661118|NCT00201812|DRUG|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
219686387|NCT04685928|DIAGNOSTIC_TEST|MRI and MRI-guided prostate biopsy|Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.
219686388|NCT04685928|DIAGNOSTIC_TEST|TP-arm Systematic biopsy|Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
219686389|NCT05943470|DRUG|Icodextrin Peritoneal Dialysis Solution|alternative day use of icodextrin comparing with daily use of icodextrin
219686390|NCT04346160|DIAGNOSTIC_TEST|Schirmer Test I|Collection of tear fluid
219686391|NCT02012725|DRUG|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
219661119|NCT04909372|BEHAVIORAL|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
219661120|NCT06304922|BEHAVIORAL|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
219661121|NCT03933020|DEVICE|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
219661122|NCT03933020|BEHAVIORAL|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
219661123|NCT03933020|BEHAVIORAL|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
219661124|NCT02696434|DRUG|Naltrexone|daily dosing
219661125|NCT02696434|DRUG|Placebo|daily dosing
219661126|NCT02696434|DRUG|Buprenorphine|daily dosing
219661127|NCT02411318|BEHAVIORAL|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
218970063|NCT05290545|OTHER|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.
218970064|NCT05290545|OTHER|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
218970065|NCT05290545|OTHER|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
218970066|NCT03875118|BEHAVIORAL|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
218970067|NCT03875118|BEHAVIORAL|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
218970068|NCT05970718|DRUG|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
218970069|NCT05970718|DRUG|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
218970070|NCT00695578|DRUG|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
218970071|NCT00695578|DRUG|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
218970072|NCT04776031|DEVICE|R:GEN Laser System|Laser Treatment
218970073|NCT02778971|DRUG|[18F]Flutemetamol|amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
219661128|NCT02411318|DRUG|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
219661129|NCT02411318|OTHER|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
219661130|NCT02411318|DRUG|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
219661131|NCT02944435|DRUG|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
219661132|NCT02944435|DRUG|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
219661133|NCT03990779|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
219661134|NCT05480228|DRUG|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
219661135|NCT05480228|OTHER|Placebo|A matching placebo will be taken for up to 13 weeks.
219661136|NCT06127654|DEVICE|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
219661137|NCT06366620|BEHAVIORAL|FAST-B PEERS|FAST-B PEERS consists of trained Peer Support providing weekly check-in calls with families going through FAST-B behavioral parent training program. Peer Support are parents who have previously participated in a behavioral parent training program who have undergone 6-8 hours of additional dedicated training.
219686392|NCT00029393|PROCEDURE|Hematopoietic Stem Cell Transplantation|
219686393|NCT00029393|DRUG|Immunosuppression|
219686394|NCT01877161|DEVICE|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
219686395|NCT01877161|DEVICE|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
219686396|NCT01877161|DEVICE|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
219661138|NCT06366620|BEHAVIORAL|FAST-B (First Approach Skills Training - Behavior)|5-week parent behavioral management training program
219661139|NCT02539134|DRUG|TAK-935|TAK-935 oral solution
219661140|NCT02539134|DRUG|Placebo|TAK-935 placebo-matching oral solution
219661141|NCT01810705|DRUG|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
219661142|NCT01116713|DRUG|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
219661143|NCT01116713|DRUG|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
219661144|NCT03193749|DRUG|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
219661145|NCT03193749|DRUG|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
219661146|NCT02911259|DEVICE|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
219661147|NCT02911259|DEVICE|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
219661148|NCT02436902|PROCEDURE|TACE|TACE is performed one month after resection.
219661149|NCT02436902|DRUG|Sorafenib|Sorafenib is submitted one month after resection.
219661150|NCT02436902|DRUG|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
219661151|NCT02436902|OTHER|empty control|This group will not receive adjuvant therapy.
219661152|NCT02552498|PROCEDURE|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
219661153|NCT02971800|DRUG|sodium fluorescein injection 10%|
219661154|NCT04929860|BEHAVIORAL|social marketing campaign|social marketing campaign delivered over 4 weeks in 4 separate sessions
219661155|NCT02543320|OTHER|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
218970074|NCT06085794|PROCEDURE|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
218970075|NCT06085794|PROCEDURE|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
219661156|NCT02543320|OTHER|Questionnaire Administration|Ancillary studies
219661157|NCT06435351|PROCEDURE|Leukapheresis|"Removal of white blood cells (leukocytes) from the blood. The dendritic cells are harvested from the white blood cells that are collected and trained to recognize the specific abnormal proteins found in the tumor sample.~One needle is inserted in each arm. An apheresis machine removes blood from the vein in one arm, separates and retains the leukocytes from the blood, and then returns the rest of the blood to the other arm."
218970076|NCT00542568|BIOLOGICAL|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
218970077|NCT06515977|PROCEDURE|TXI (Group A)|Patients in Group A will undergo colonoscopy with TXI.
218970078|NCT06515977|PROCEDURE|TXI followed by WLI (Group B)|Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
218970079|NCT06515977|PROCEDURE|WLI (Group C)|Patients in Group C will undergo colonoscopy with WLI.
219661158|NCT06435351|BIOLOGICAL|Dendritic Cell (DC) Vaccine|"The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance using a dose of 40-50 million cells three times spaced 2 weeks apart for the initial priming sequence.~3 doses of the priming vaccines are given once every 2 weeks. 2 booster shots (if available) will be given 6 months and 12 months following completion of initial priming vaccines."
219661159|NCT02056106|DRUG|antidepressant therapy|
219661160|NCT01778738|PROCEDURE|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
219661161|NCT01778738|PROCEDURE|Sleeve gastrecomy|Vertical sleeve gastrectomy
219661162|NCT01778738|PROCEDURE|Bastric bypass|Gastric bypass surgery
219661163|NCT03613883|PROCEDURE|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
219661164|NCT04487483|BEHAVIORAL|Sleep App|A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
219661165|NCT06037525|DEVICE|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
219661166|NCT04443621|BEHAVIORAL|questionnaire|Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
219661167|NCT04443621|BEHAVIORAL|in-depth interview|Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
219661168|NCT03444051|PROCEDURE|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
219661169|NCT03444051|PROCEDURE|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
219686397|NCT01944748|BEHAVIORAL|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
219686398|NCT04423640|OTHER|Active COVID-19 disease|Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
218970080|NCT06515977|PROCEDURE|WLI followed by TXI (Group D)|Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
218970081|NCT04308603|DIAGNOSTIC_TEST|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
218970082|NCT00408538|DRUG|UC-781 microbicide gel (0.1% and 0.25%)|
219661170|NCT01811862|PROCEDURE|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
219661171|NCT01811862|PROCEDURE|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
218970083|NCT00408538|DRUG|placebo|
218970084|NCT04765215|BIOLOGICAL|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
218970085|NCT00214643|DRUG|Fosmidomycin|30 mg/kg
218970086|NCT00214643|DRUG|clindamycin|10 mg/kg
218970087|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
218970088|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
219661172|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
219661173|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219661174|NCT04355429|DRUG|captopril 25mg|Drug administration
219661175|NCT04336462|DEVICE|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
219661176|NCT04336462|DEVICE|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
219661177|NCT00002369|DRUG|Indinavir sulfate|
219661178|NCT00002369|DRUG|Lamivudine|
219661179|NCT00002369|DRUG|Stavudine|
219661180|NCT00002369|DRUG|Zidovudine|
219661181|NCT00067769|BEHAVIORAL|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
219661182|NCT00067769|BEHAVIORAL|treatment as usual|Routine clinical care.
219661183|NCT04701918|DRUG|Pembrolizumab|Intravenous injection through a vein (IV) every 3 weeks
219661184|NCT04701918|PROCEDURE|Cryoablation|Needle inserted through the skin and into the tumor using CT guidance
219661185|NCT04701918|DRUG|Avelumab|Intravenous injection through a vein (IV) every 2 weeks
219661186|NCT00034346|DRUG|ABX-EGF|
219661187|NCT00034346|DRUG|paclitaxel|
219661188|NCT00034346|DRUG|carboplatin|
219661189|NCT05190822|OTHER|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
219661190|NCT02454075|DRUG|YF476|Gastrin receptor antagonist
219661191|NCT00385775|DRUG|AEG35156|weekly IV solution infused over 2 hrs
219661192|NCT05520970|BIOLOGICAL|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
219661193|NCT03042871|DRUG|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
219661194|NCT00237471|DRUG|Insulin (tight blood glucose control)|
219661195|NCT02631278|DEVICE|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
219661196|NCT03194711|DEVICE|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
219661197|NCT00150397|DRUG|Tofimilast|
219661198|NCT03921970|OTHER|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
219661199|NCT02613429|BEHAVIORAL|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
219661200|NCT02613429|BEHAVIORAL|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
219661201|NCT00130429|DRUG|PYM50028|
219661202|NCT04395391|DIAGNOSTIC_TEST|SARS-CoV-2|Determine usability of study materials and kit
219661203|NCT04766255|PROCEDURE|Soft Tissue graft augmentation|"Donor site:~SCTG group: The SCTG will be harvested in the palat,In order to extract the same thickness in each grafts a double-bladed knife (separated by 1,5mm) will be used. The donor area will be sutured.~Recipient site:~SCTG group: the connective tissue graft will be trimmed to the correct dimensions (10mm height, 12mm length and 1,5mm thick) and placed and secured at the recipient site with a resorbable 5-0 suture CM group: The CM graft (Geistlich Fibro-gide) will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture PADM Group: the ADM (NovoMatrix, Biohorizons, Birmingham AL) graft will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture"
218970089|NCT01423019|OTHER|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
218970090|NCT00003742|DRUG|cisplatin|
218970091|NCT00003742|DRUG|irinotecan hydrochloride|
218970092|NCT00003742|DRUG|paclitaxel|
218970093|NCT02423109|DEVICE|fanfilcon A|contact lens
218970094|NCT02423109|DEVICE|enfilcon A|contact lens
218970095|NCT03956056|BIOLOGICAL|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
219208318|NCT07038187|BEHAVIORAL|Music Listening (Binaural Beats via Gnaural)|Modern 'relaxation' music regularly includes binaural beats. Binaural beats can be defined as a sensation produced by the arrival of sine tones of different frequencies in each ear. This sensation is created by the difference in frequency between the two tones reaching the ear. Music with binaural beats has been associated with reduced anxiety and increased relaxation by activating theta and delta wavelengths in the electroencephalography (EEG). The authors used Gnaural (GPL-2.0), a freely programmable sound generator, for the binaural beats. Two pieces of instrumental 7 Hz binaural beats were used, a piano and an instrumental. The music volume was between 50-60 decibels and was at a level where the participant could hear the healthcare professional performing the procedure.
218970096|NCT03956056|DRUG|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
218970097|NCT03956056|PROCEDURE|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
218970098|NCT01892215|PROCEDURE|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
218970099|NCT01892215|PROCEDURE|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
218970100|NCT06154538|DRUG|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
218970101|NCT06154538|DRUG|FOLFOX regimen|FOLFOX chemotherapy
218970102|NCT04375969|OTHER|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
219661204|NCT04766255|PROCEDURE|Implant Placement|A crestal incision will be made in the implant reception area, extending from the distal of the most mesial tooth to the mesial of the most distal tooth. A mucoperiosteal flap will be elevated in the most crestal part of the ridge. The receptor bed will be prepared following the established drilling protocol for the placement of a BioHorizons Tapered Pro Implant (Biohorizons, Birmingham AL). The diameter and length of the implant will be previously established during the implant study. Later a healing abutment will be placed.
219661205|NCT03754855|BEHAVIORAL|Questionnaire|Questionnaire
219661206|NCT03546010|BEHAVIORAL|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
219661207|NCT03546010|BEHAVIORAL|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
219661208|NCT02223819|DRUG|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
219661209|NCT01966419|DRUG|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
219661210|NCT01966419|DRUG|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
219661211|NCT06840080|OTHER|Placebo|Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules
219661212|NCT06840080|DIETARY_SUPPLEMENT|125mg OEA with LipiSperse|Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.
219661213|NCT06840080|DIETARY_SUPPLEMENT|250mg OEA with LipiSperse|Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.
219661214|NCT00259285|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
219661215|NCT00259285|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
219661216|NCT06618378|BEHAVIORAL|Biofeedback exercise combined with breathing exercise|Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.
219661217|NCT06618378|BEHAVIORAL|urotherapy educational group|"1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity."
219661218|NCT01484093|OTHER|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
219661219|NCT00266591|DRUG|topiramate|
219661220|NCT00985517|BIOLOGICAL|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
218970103|NCT04375969|OTHER|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
218970104|NCT04375969|OTHER|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
218970105|NCT04375969|OTHER|HIIT training group|This group will do the training program without cold exposure
218970106|NCT04138069|OTHER|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
218970107|NCT04138069|OTHER|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
218970108|NCT06403215|OTHER|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
218970109|NCT06403215|OTHER|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
219661221|NCT00985517|PROCEDURE|Sham Surgery|
219661222|NCT01152216|DRUG|Dimebon|20 mg orally three times daily
219661223|NCT02466217|OTHER|1: AID groups|Clinical and Biological investigations
219661224|NCT02466217|OTHER|2: Control groups|Clinical and Biological investigations
219661225|NCT04492917|OTHER|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
219661226|NCT04492917|OTHER|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
218970110|NCT06403215|OTHER|Chewing gum+Fennel tea group|Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
218970111|NCT06403215|OTHER|Control group|No intervention
218970112|NCT06255184|BEHAVIORAL|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
218970113|NCT00894023|DRUG|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
219208319|NCT07038525|OTHER|Suturing training|This intervention involves basic suturing skills training delivered either in-person or online. In the in-person group, participants receive live instruction and hands-on supervision. In the online group, participants watch a standardized video tutorial and receive remote feedback via Zoom. All participants use identical suturing kits and are evaluated using the same OSATS checklist by a blinded assessor. The content and learning objectives are standardized across both formats.
219661227|NCT04492917|OTHER|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
219661228|NCT04492917|OTHER|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
218970114|NCT00894023|DRUG|IV abciximab|IV abciximab + infusion
218970115|NCT06391346|DIAGNOSTIC_TEST|MSOT|Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
218970116|NCT01416844|BIOLOGICAL|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
218970117|NCT02919371|DRUG|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
218970118|NCT02919371|DRUG|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
219661229|NCT00104819|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219661230|NCT00104819|BIOLOGICAL|sargramostim|
218970119|NCT03403374|DRUG|evolocumab|Administered by SC injection via autoinjector (AI)/pen
219661231|NCT00002063|DRUG|Zidovudine|
219661232|NCT04984317|DRUG|onabotulinumtoxin A|One-time injection of 100U BOTOX
219661233|NCT05146063|DIAGNOSTIC_TEST|Take the patient's subcutaneous fat tissue to detect the expression of LNK|Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
218970120|NCT02563977|DEVICE|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
218970121|NCT01545258|OTHER|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
218970122|NCT00420667|DRUG|Enoxaparin|
218970123|NCT04875962|DRUG|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
218970124|NCT04875962|DRUG|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
218970125|NCT02310932|BEHAVIORAL|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
218970126|NCT03455127|OTHER|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
218970127|NCT05105230|DIAGNOSTIC_TEST|soluble programmed death 1biomarker|soluble programmed death 1biomarker
218970128|NCT00265551|DRUG|SCA-136 (200 mg)|
218970129|NCT00265551|DRUG|SCA-136 (400 mg)|
218970130|NCT00265551|DRUG|olanzapine (15 mg)|
218970131|NCT00265551|DRUG|placebo|
218970132|NCT03090841|BIOLOGICAL|Bio-specimen collected|
218970133|NCT06244017|DEVICE|EEG spectrogram|In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
218970134|NCT06244017|DEVICE|Bispectral index|In the control group, the general anesthesia is guided by using the bispectral index
218970135|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
218970136|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
218970137|NCT01298531|DRUG|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
218970138|NCT04343300|OTHER|Pilates|Intervention of12 weeks of Pilates
218970139|NCT04343300|OTHER|exercise without Pilates|exercise without Pilates
218970140|NCT05548309|DEVICE|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
218970141|NCT05548309|DEVICE|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
218970142|NCT00886184|PROCEDURE|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
219208320|NCT07038603|OTHER|BAPP-VR|A carefully considered adaptation of a BA protocol enhanced with the use of VR
219661234|NCT00367484|BIOLOGICAL|Rebif® (clone 484-39)|s.c. administered Rebif®
219661235|NCT01420679|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
219661236|NCT04605432|DRUG|PEG-FFI|"Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher."
219661237|NCT04605432|DRUG|PEG-nonFFI|"All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse."
219686399|NCT02975817|OTHER|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
219686400|NCT02975817|OTHER|Warm Air|Active, convective warming of patient using warm air blanket
219686401|NCT03334357|OTHER|PAR|
218970143|NCT00886184|PROCEDURE|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
219661238|NCT03757637|OTHER|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
219661239|NCT03757637|OTHER|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
219661240|NCT06718270|DRUG|CAR-T cells Infusion|chimeric antigen receptor T cells
219661241|NCT00943670|BIOLOGICAL|pertuzumab|Intravenous repeating dose
219661242|NCT00943670|BIOLOGICAL|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
219661243|NCT06519409|PROCEDURE|Open flap debridement and photodynamic therapy|
219661244|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
219661245|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
219661246|NCT03956615|OTHER|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
219661247|NCT05046431|DRUG|BAT2506|50mg/0.5mL
219661248|NCT05046431|DRUG|EU Simponi|50mg/0.5mL
219661249|NCT04472026|BEHAVIORAL|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
219661250|NCT03156907|DRUG|Buprenorphine|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
219661251|NCT00829088|DRUG|AZD2066|1 dose oral solution
219661252|NCT04374682|OTHER|exercises|stretching exercises - physiotherapy modalities - self care instructions
218970144|NCT02242188|DRUG|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
218970145|NCT02242188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (packed in identical sachets as active products)
218970146|NCT06269107|DRUG|IcoSema|IcoSema will be administered subcutaneously.
218970147|NCT06269107|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
218970148|NCT03205137|DRUG|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
218970149|NCT03205137|DRUG|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
218970150|NCT03205137|DRUG|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
219208321|NCT07039448|BEHAVIORAL|Acupressure|The acupressure intervention including the five acupoints. The acupressure will be performed once a day for 10 days in a group setting with same sex, supervised by a trained psychiatric nurse and preferably at least 2 hours after a meal.
219661253|NCT03713840|BEHAVIORAL|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
219661254|NCT03484221|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
219661255|NCT03484221|RADIATION|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.
218970151|NCT03205137|DRUG|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
218970152|NCT06175975|OTHER|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
218970153|NCT01589328|OTHER|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
218970154|NCT01683227|BEHAVIORAL|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
218970155|NCT01683227|BEHAVIORAL|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
219661256|NCT03484221|DRUG|XELOX|OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
219661257|NCT05483894|DRUG|Atorvastatin 10mg|Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
218970156|NCT01310881|DRUG|NSI-189 Phosphate|Once daily oral administration
219661258|NCT05483894|DRUG|Placebo|Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
219661259|NCT00073892|DRUG|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
219661260|NCT01038414|BEHAVIORAL|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
219661261|NCT05307796|BEHAVIORAL|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
219661262|NCT05260424|OTHER|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
219661263|NCT00624559|DRUG|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
219661264|NCT00624559|OTHER|Placebo|Placebo pill taken twice per day on each day of the diet
219661265|NCT04385875|BIOLOGICAL|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
219661266|NCT04385875|OTHER|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
219661267|NCT04526574|BIOLOGICAL|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
219661268|NCT04526574|OTHER|Saline|Normal saline for injection
219661269|NCT04526574|BIOLOGICAL|Influenza vaccine|Seasonal inactivated influenza vaccine (SIIV)
219661270|NCT05313282|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2\. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3\. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4\. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
219661271|NCT05313282|COMBINATION_PRODUCT|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
218970157|NCT04185870|DIAGNOSTIC_TEST|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
218970158|NCT04185870|DIAGNOSTIC_TEST|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
218970159|NCT03793218|DEVICE|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
218970160|NCT03793218|PROCEDURE|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
218970161|NCT04121988|DIAGNOSTIC_TEST|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging"
218970162|NCT03383471|BIOLOGICAL|Invossa K Inj.|Invossa K Inj.
218970163|NCT03383471|DRUG|Placebo|Placebo control
218970164|NCT03805607|DRUG|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
218970165|NCT03805607|DRUG|Placebos|Normal Saline
218970166|NCT02602899|PROCEDURE|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
219064565|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
218970167|NCT03300960|DRUG|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
218970168|NCT03300960|DRUG|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
218970169|NCT02380027|DEVICE|MRI|This will be a multi-parametric MRI of the prostate
218970170|NCT02380027|PROCEDURE|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
218970171|NCT02380027|PROCEDURE|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
219661272|NCT00970099|BEHAVIORAL|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
219661273|NCT00970099|BEHAVIORAL|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
219661274|NCT02340611|DRUG|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
219686402|NCT03334357|OTHER|HIIT|
219208322|NCT07039448|BEHAVIORAL|Sham Comparator|The sham group will be trained to perform acupressure in a similar way to the intervention group, except that they will use five sham acupoints. After completion of the project, patients in the sham group will receive the same interventions as the intervention group.
219208323|NCT07038291|OTHER|Not applicable- observational study|Observational study without intervention
219208324|NCT07039682|DEVICE|Digital HIV Education and Self-Screening (EKSTRIM Model)|Participants in this arm will receive access to the EKSTRIM platform, a web-based digital tool designed for adolescents. The platform includes interactive educational content on HIV prevention, a self-assessment screening tool to evaluate individual HIV risk, and online peer educator support. The intervention will be implemented over a 6-week period. Participants will be encouraged to use the platform independently, with monitoring of access logs and engagement levels.
219661275|NCT02340611|DRUG|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
218970172|NCT01288027|BIOLOGICAL|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
219661276|NCT05673161|OTHER|iron|iron treatment
219661277|NCT04717388|OTHER|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory"
219661278|NCT04717388|RADIATION|MRI|Anatomical and functional MRI at V2
219661279|NCT01916161|OTHER|Questionnaire|
219661280|NCT04076371|DRUG|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
219661281|NCT04076371|DRUG|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
219661282|NCT04076371|DRUG|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
219661283|NCT04076371|DRUG|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
219661284|NCT04076371|DRUG|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
219661285|NCT04076371|DRUG|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
219661286|NCT04076371|DRUG|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
219661287|NCT04076371|DRUG|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
219661288|NCT02889705|OTHER|Ultrasonographic examination|
219661289|NCT03603977|DRUG|Lpv/r+3TC|It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
219661290|NCT03859791|OTHER|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
219661291|NCT01099774|DRUG|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
219661292|NCT01099774|DRUG|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
219661293|NCT02939482|DRUG|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
219661294|NCT06649448|DRUG|Efbemalenograstim alfa Injection|This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
219661295|NCT06649448|DRUG|carboplatin/cisplatin-etoposide|one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
219661296|NCT06649448|DRUG|Carboplatin plus Paclitaxel|"For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W)."
219686403|NCT03334357|OTHER|WB-EMS|
219686404|NCT01664676|DRUG|Liraglutide|
219686405|NCT01664676|DRUG|Placebo-liraglutide|
219686406|NCT03995888|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
219686407|NCT04750057|DRUG|Anifrolumab|Multi-centre, open-label, early access program (EAP) designed to provide access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard therapy.
218970173|NCT06377306|BEHAVIORAL|Effect of training loads and sport performance level on health and sport performance|Effect of training loads and sport performance level on health and sport performance
218970174|NCT01240876|DRUG|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
218970175|NCT01240876|DRUG|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
218970176|NCT04367129|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram
218970177|NCT00455767|DRUG|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
218970178|NCT00455767|DRUG|Placebo|Placebo
218970179|NCT02225509|PROCEDURE|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
219686408|NCT01345656|DRUG|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
219661297|NCT06649448|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|"For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W)."
219661298|NCT06649448|DRUG|TP regimen|"The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W)."
219661299|NCT02167048|DRUG|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
219661300|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
219661301|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
219661302|NCT03025568|OTHER|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
219661303|NCT03025568|OTHER|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
219661304|NCT04734275|DRUG|AZD5718|Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
219661305|NCT00673426|BIOLOGICAL|Enoxaparin sodic|
219661306|NCT02879708|OTHER|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
219661307|NCT02879708|OTHER|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
219661308|NCT04507893|OTHER|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
219661309|NCT00424021|DRUG|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
219661310|NCT05123391|RADIATION|External beam image guided radiotherapy|Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
219686409|NCT01345656|DRUG|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
219686410|NCT01345656|DRUG|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
219686411|NCT01345656|DRUG|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
218970180|NCT05324618|DRUG|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
218970181|NCT05324618|DRUG|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
219064566|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
219064567|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
219686412|NCT01345656|DRUG|Placebo|Placebo tablets for duration of 4 weeks
218970182|NCT05855070|DRUG|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
218970183|NCT05855070|DRUG|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
218970184|NCT00994318|DRUG|FCM (Ferric carboxymaltose) high ferritin target|
218970185|NCT00994318|DRUG|FCM (Ferric carboxymaltose) low ferritin target|
218970186|NCT00994318|DRUG|Oral Iron (Ferrous sulphate)|
218970187|NCT01134315|DRUG|Paricalcitol|
218970188|NCT01134315|DRUG|Calcitriol|
218970189|NCT02896244|OTHER|no intervention|
219661311|NCT02219776|DRUG|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
219661312|NCT02219776|OTHER|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
219661313|NCT06725667|OTHER|Transversalis fascia plane block|Patients will receive transversalis fascia plane block after the induction of general anesthesia.
219661314|NCT06725667|OTHER|Caudal block|Patients will receive caudal block after the induction of general anesthesia.
219661315|NCT03138746|PROCEDURE|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
219661316|NCT03138746|PROCEDURE|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
219661317|NCT03597022|DRUG|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
219661318|NCT02716766|DRUG|Sorafenib|PO
219661319|NCT02716766|DRUG|Capecitabine|PO
219661320|NCT02716766|DRUG|Oxaliplatin|IV
219661321|NCT06255717|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219661322|NCT06255717|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
219661323|NCT05786638|DRUG|Allergen Immunotherapy Extract|Sublingual subcutaneous allergen immunotherapy
219661324|NCT02764203|OTHER|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
219661325|NCT02764203|DEVICE|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
219661326|NCT05462275|DEVICE|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
219661327|NCT00853879|DIETARY_SUPPLEMENT|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
219661328|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
219661329|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
219661330|NCT04126642|BEHAVIORAL|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
219661331|NCT04126642|BEHAVIORAL|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
219661332|NCT06240988|DEVICE|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy
219661333|NCT06240988|OTHER|Motor Imagery Technique|Motor Imagery Technique
219661334|NCT03881891|BEHAVIORAL|Follow-app intervention arm|The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
219661335|NCT01550107|DRUG|Allopurinol|300mg b.d for 24 weeks
219661336|NCT01550107|DRUG|Lactose tablets|matched placebo tablets b.d
219661337|NCT06368882|DRUG|Peg-Interferon α|Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
219686413|NCT01345656|DRUG|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
218970190|NCT03024814|DRUG|Acetaminophen|"The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
218970191|NCT03024814|DRUG|Dextrose 5|"The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
218970192|NCT02818231|OTHER|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
219661338|NCT02914431|DEVICE|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
219661339|NCT00511654|DRUG|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
219661340|NCT00511654|DRUG|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
219661341|NCT00511654|DRUG|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
219661342|NCT01304303|DRUG|SPARC1023 I|IV administration
219661343|NCT01304303|DRUG|SPARC1023 II|IV administration
219661344|NCT03457805|DEVICE|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
219661345|NCT00526565|BEHAVIORAL|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
219661346|NCT00526565|BEHAVIORAL|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
219661347|NCT01953835|DRUG|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
219661348|NCT01953835|DRUG|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
219661349|NCT01953835|DRUG|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
219661350|NCT01953835|DRUG|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
219661351|NCT02987569|BEHAVIORAL|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
219661352|NCT02987569|BEHAVIORAL|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
219661353|NCT00775554|OTHER|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
219661354|NCT00775554|OTHER|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
218970193|NCT05323110|DRUG|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
218970194|NCT05323110|DRUG|Placebo|CBS001 matched placebo
219064568|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
218970195|NCT04014309|OTHER|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
218970196|NCT04014309|OTHER|Usual care|Usual care
218985476|NCT02549534|PROCEDURE|Self-Reported Signs & Symptoms of CIPN|Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
219064569|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
218985477|NCT05424523|DRUG|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
218985478|NCT04685967|DEVICE|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
218985479|NCT04685967|DEVICE|Bulk-fill composite|SonicFill2, Orange, CA, USA
219064570|NCT02546544|DRUG|Linsitinib|
219064571|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
219064572|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
219064573|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
219661355|NCT05220566|BEHAVIORAL|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
219661356|NCT01361269|DRUG|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
219661357|NCT03806023|DEVICE|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
219661358|NCT05294159|OTHER|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
219661359|NCT05007574|DEVICE|Microphone MI-305|Remote data collection
219661360|NCT01323816|OTHER|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
218970197|NCT04575454|OTHER|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
219661361|NCT01479192|DRUG|Fenretinide|100mg (2cps/day) for 5 years
219661362|NCT01479192|OTHER|Placebo|2 cpr/day of matched placebo for 5 years
218970198|NCT01943773|PROCEDURE|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
219661363|NCT02027857|DEVICE|EIT monitoring|
219661364|NCT02027857|DEVICE|non-invasive ICP monitoring|
219661365|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
219661366|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
219661367|NCT04248504|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
219661368|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
219661369|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
219661370|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
219661371|NCT00971035|DRUG|placebo|Subcutaneous repeating dose
218970199|NCT01943773|PROCEDURE|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
218970200|NCT01722773|DEVICE|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
218970201|NCT00286507|PROCEDURE|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
219064574|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
219064575|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
219064576|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
219661372|NCT04191941|BIOLOGICAL|Novel CAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
219661373|NCT01534208|DRUG|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
219661375|NCT04377464|OTHER|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
219661376|NCT01904903|DRUG|Trastuzumab|HER2 therapy
219661377|NCT01904903|DRUG|Pertuzumab|HER2 therapy
219661378|NCT01904903|DRUG|Ado Trastuzumab Emtansine|HER2 therapy
219661379|NCT01616849|DRUG|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
219661380|NCT02453854|BEHAVIORAL|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
219661381|NCT04148859|PROCEDURE|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
219661382|NCT02561741|DRUG|COV155|COV155 tablets
219661383|NCT05559424|DIAGNOSTIC_TEST|OCT|OCT will be used to assess results after intervention
219661384|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
219661385|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
219661386|NCT00045734|DRUG|imatinib mesylate|Given orally
218970202|NCT01374711|DRUG|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
218970203|NCT01374711|DRUG|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
218970204|NCT01374711|OTHER|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
218970205|NCT04019431|DIETARY_SUPPLEMENT|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
218970206|NCT02694523|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
218970207|NCT02694523|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
219661387|NCT00045734|OTHER|laboratory biomarker analysis|Correlative studies
219661388|NCT00045734|OTHER|pharmacological study|Correlative studies
219661389|NCT02991417|BIOLOGICAL|CDVAX|
219661390|NCT00618241|DRUG|lamotrigine|100 mg
219661391|NCT00618241|DRUG|Raltegravir|400 mg BD
219661392|NCT00690300|DRUG|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
218970208|NCT02694523|DRUG|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
219661393|NCT00690300|DRUG|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
219661394|NCT04108221|PROCEDURE|laparoscopy or laparotomy withTransversusAbdominis Plane Block|"The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance."
219661395|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
219661396|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
219661397|NCT05490602|PROCEDURE|Running subcutaneous sutures technique|The Running subcutaneous sutures consist of running sutures in the profound and superficial dermis without knotting the thread (suture).
219661398|NCT05490602|PROCEDURE|Classical closures|Classical closures
219661399|NCT03482167|DRUG|Niagen®|250 mg capsules (4 capsules daily)
219661400|NCT03482167|OTHER|Placebo|placebo
219661401|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
219661402|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
219661403|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
219661404|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of placebo in each eye.
218970209|NCT02694523|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
218970210|NCT05289531|PROCEDURE|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
218970211|NCT04774120|DRUG|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
218970212|NCT01248481|DRUG|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
218970213|NCT00428129|DRUG|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
219064577|NCT02223390|BEHAVIORAL|Improving AIDS Care after Trauma (ImpACT)|
219661405|NCT00002615|DRUG|cisplatin|
219661406|NCT00002615|DRUG|epirubicin hydrochloride|
219661407|NCT00002615|DRUG|fluorouracil|
219661408|NCT00002615|PROCEDURE|conventional surgery|
219661409|NCT01319851|DRUG|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
219661410|NCT05958771|DRUG|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
219661411|NCT05958771|DRUG|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
219661412|NCT04836364|OTHER|No Intervention|There is no intervention; observation only.
219661413|NCT01001598|DRUG|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
219661414|NCT00737893|DRUG|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
219661415|NCT00737893|DRUG|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
219661416|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
219661417|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
219661418|NCT05640297|BEHAVIORAL|KMC with Massage therapy|investigator will provide tactile and kinesthetic massage
218970214|NCT03204461|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
218970215|NCT03204461|OTHER|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
218970216|NCT03736694|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
218970217|NCT03736694|BEHAVIORAL|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
218970218|NCT04453228|OTHER|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
218970219|NCT01417936|DRUG|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
218970220|NCT04102670|DEVICE|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
218970221|NCT04102670|DEVICE|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
218970222|NCT04102670|DEVICE|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
218970223|NCT04102670|DEVICE|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
219064578|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
219064579|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
219064580|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
219064581|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
219064582|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
219661419|NCT04746729|OTHER|No intervention|No intervention
219661420|NCT04568967|DIAGNOSTIC_TEST|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
219661421|NCT04568967|DIAGNOSTIC_TEST|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
219661422|NCT06350604|BEHAVIORAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
219661423|NCT04827537|DRUG|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
219661424|NCT04827537|DRUG|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
219661425|NCT04827537|DRUG|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
219661426|NCT04877535|DEVICE|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
219661427|NCT00005876|DRUG|rubitecan|
218970224|NCT04102670|OTHER|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
219064583|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
219661428|NCT00925652|DRUG|Bevacizumab|
219661429|NCT00925652|DRUG|Cyclophosphamide|
219661430|NCT00925652|DRUG|Methotrexate|
219661431|NCT00925652|BEHAVIORAL|Lifestyle: Diet|
219661432|NCT00925652|BEHAVIORAL|Lifestyle: Diet+Exercise|
219686414|NCT00870454|DRUG|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
219686415|NCT00870454|DRUG|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
219686416|NCT00870454|DRUG|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
219686417|NCT00870454|DRUG|Placebo|Placebo capsules twice daily
218970225|NCT05880654|PROCEDURE|Scaling & root planning|Non Surgical periodontal therapy
219661433|NCT05496283|OTHER|denture adhesive|After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
219686418|NCT00308789|PROCEDURE|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
219686419|NCT00308789|PROCEDURE|CPAP|Continuous positive airway pressure
219686420|NCT02223351|DRUG|ASP2151|
218970226|NCT00810524|DRUG|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
218970227|NCT00810524|DRUG|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
218970228|NCT00810524|DRUG|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
218970229|NCT00810524|DRUG|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
218970230|NCT00956956|DRUG|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
218970231|NCT00956956|DRUG|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
218970232|NCT05688007|DIAGNOSTIC_TEST|parathyroid hormone level|Serum level of parathyroid hormone
218970233|NCT05688007|DIAGNOSTIC_TEST|serum electrolytes|Serum levels of: magnesium, phosphorus, calcium, and albumin
218970234|NCT05952492|BEHAVIORAL|Stress Management Skills Training|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include stress management skills training and health education content.
218970235|NCT05295550|OTHER|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
218970236|NCT06158620|DRUG|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
219064584|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
219064585|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
219064586|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
219064587|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
219064588|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
219686421|NCT02223351|DRUG|ritonavir|
219686422|NCT05293782|OTHER|Kinesitaping|Kinesiotaping - muscle facilitation technique
219686423|NCT02590055|DRUG|gemcitabine/docetaxel combination|
219686424|NCT02459522|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
219686425|NCT02102048|DRUG|Atazanavir|
219686426|NCT00168571|BIOLOGICAL|Measles vaccine|
219686427|NCT05957185|DIETARY_SUPPLEMENT|OPTIZIOME® P³ HYDROLYZER® - WHEY|One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
219686428|NCT05957185|OTHER|Placebo|One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
219686429|NCT03049020|PROCEDURE|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
219686430|NCT04087837|DEVICE|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
219686431|NCT04087837|DEVICE|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
219686432|NCT00002424|DRUG|L-756423|
219686433|NCT00002424|DRUG|Indinavir sulfate|
219686434|NCT00002424|DRUG|Lamivudine|
219686435|NCT00002424|DRUG|Stavudine|
219686436|NCT00036283|DRUG|Celecoxib|
219686437|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
219686438|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
219686439|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
219686440|NCT05002504|DIAGNOSTIC_TEST|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
219686441|NCT05002504|DIAGNOSTIC_TEST|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
219208325|NCT07038512|DEVICE|Floora Pelvic Rehabilitation Vaginal Dilator|The Floora Pelvic Rehabilitation Vaginal Dilator, created by Hyivy Health Inc, is a multi-therapy hand held ergonomic intravaginal wand device that is designed to be used in the comfort of the user's home. The Floora has two main therapeutic functions, controllable dilation and thermal therapy. It is the first vaginal dilator that performs auto-dilation using one or two air chambers inflated from the device surface by an internal pump, eliminating the need for reinsertion. The device is equipped with biosensors that measure the pressure from the vaginal canal which allows this device to provide a gradual and gentle stretch to the pelvic floor muscles. The thermal therapy is achieved through an electrical circuit, changing the temperature of the device in small increments. Users are able to force-stop and change the temperature and dilation settings during a session.
219208326|NCT06702618|DRUG|TQB3616 capsule+Fulvestrant Injection|TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
219208327|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.)|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
219208328|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.) placebo|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
219661434|NCT05706038|DRUG|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
219661435|NCT03796338|DEVICE|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
219661436|NCT06084390|OTHER|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
219661437|NCT06084390|OTHER|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
219661438|NCT04797156|DRUG|High Dose Tranexamic acid|50mg/kg IV TXA
219661439|NCT04797156|DRUG|Low Dose Tranexamic acid|20mg/kg IV TXA
219661440|NCT04797156|DRUG|Tranexamic acid Topical|2g topical TXA
219208329|NCT07038395|DEVICE|workflow|Placement of the surgical device and its effect on workflow
219208330|NCT06882525|PROCEDURE|Lidocaine (drug)|Lidocain subcuteous infiltratyion will be done to rush area.
219208331|NCT03803787|DRUG|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
219661441|NCT04797156|DRUG|Normal saline|Normal saline poured on wound
219661442|NCT05519046|DEVICE|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
219661443|NCT05519046|DEVICE|CRT|Cardiac Resynchronization Therapy
218970237|NCT06158620|DRUG|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
218970238|NCT05539716|DEVICE|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
218970239|NCT05539716|BEHAVIORAL|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
218970240|NCT05449366|DRUG|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
219661444|NCT05069311|DRUG|Multimodal analgesia|"Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
219661445|NCT05069311|DRUG|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
219661446|NCT06649565|OTHER|no intervention|no intervention
219661447|NCT02519634|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
219661448|NCT02519634|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
219661449|NCT02852668|OTHER|Power Training|This experimental groups underwent an intervention period of power training
219661450|NCT02852668|OTHER|Strength Training|This experimental groups underwent an intervention period of strength training
218970241|NCT06631170|DRUG|Roflumilast Cream 0.15%|Roflumilast cream 0.15% is applied once daily for 4 weeks
218970242|NCT06631170|DRUG|Vehicle cream|Vehicle cream is applied once daily for 4 weeks
218970243|NCT02188225|PROCEDURE|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
218970244|NCT02188225|DRUG|fluoxetine|10 mg/ daily
218970245|NCT00085228|BIOLOGICAL|oblimersen sodium|
218970246|NCT00085228|DRUG|docetaxel|
218970247|NCT04095156|DIAGNOSTIC_TEST|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
218970248|NCT01867112|BEHAVIORAL|Physical Activity|Physical activity either by individualized program or general guidelines
218970249|NCT02091219|DRUG|Vitamin D|2400 IU/day by mouth for 16 weeks
218970250|NCT02091219|DRUG|25(OH)D3|20 micrograms/day by mouth for 16 weeks
218970251|NCT05789381|PROCEDURE|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
218970252|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
218970253|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
218970254|NCT03780777|BEHAVIORAL|Home Hazard Removal|Removal of home barriers or hazards
218970255|NCT06010251|OTHER|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
219064589|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
219064590|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
219064591|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
219064592|NCT01025713|DRUG|GS-9411|Inhaled GS-9411
219064593|NCT01025713|DRUG|Placebo|Inhaled Placebo
219064594|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
219064595|NCT01476046|DRUG|Placebo|Single intravenous dose
219064596|NCT00844623|GENETIC|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
219064597|NCT00600600|DRUG|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
219064598|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
219064599|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
219064600|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
219064601|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
219064602|NCT00001101|DRUG|ceftriaxone|
219064603|NCT00001101|DRUG|doxycycline|
219064604|NCT00930111|OTHER|2-week rotation|Attending physician is assigned to a 2-week rotation.
219661451|NCT05650346|OTHER|Deep Cervical Training|The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
219661452|NCT05650346|OTHER|Deep cervical training + Upper cervical mobilization group|"1. the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~2. The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk."
219661453|NCT05650346|OTHER|Deep cervical training + Upper thoracic mobilization group|"1. The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~2. The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2)."
219661454|NCT01046851|DRUG|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
219661455|NCT01046851|DRUG|Placebo|Placebo in a manner similar to the active comparator
219661456|NCT01343667|DEVICE|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
219661457|NCT01343667|DEVICE|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
219661458|NCT03720145|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
219661459|NCT01352247|PROCEDURE|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
219661460|NCT01352247|PROCEDURE|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
219661461|NCT04445844|BIOLOGICAL|Pelareorep|Given IV
219661462|NCT04445844|OTHER|Quality-of-Life Assessment|Ancillary studies
219661463|NCT04445844|OTHER|Questionnaire Administration|Ancillary studies
219661464|NCT04445844|BIOLOGICAL|Retifanlimab|Given IV
219661465|NCT04817566|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
219661466|NCT04817566|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
219661467|NCT04817566|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
219661468|NCT03899532|DEVICE|Remote Ischemic Conditioning|Standard manual blood pressure cuff
219661469|NCT03899532|OTHER|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
219661470|NCT05498792|DRUG|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
219661471|NCT05498792|DRUG|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
219661472|NCT05498792|DRUG|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
219661473|NCT04612777|BEHAVIORAL|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
218985480|NCT02640573|DRUG|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
219064605|NCT00930111|OTHER|4-week rotation|Attending physician is assigned to a 4-week rotation.
219661474|NCT04612777|BEHAVIORAL|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
219661475|NCT04612777|BEHAVIORAL|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
219661476|NCT01534780|PROCEDURE|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
219661477|NCT01534780|DEVICE|Protack|fixation of mesh with protack
219661478|NCT01534780|DEVICE|Securestrap|fixation of mesh with Securestrap
219661479|NCT01534780|DEVICE|Glubran|fixation of mesh with Glubran
219661480|NCT04492072|DRUG|Oxytocin|Intervention
219661481|NCT04492072|DRUG|Misoprostol|Control
219661482|NCT05621005|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
219661483|NCT00154050|DRUG|candesartan (drug) or quinapril (drug)|
219661484|NCT04407416|PROCEDURE|Breath sampling|The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
219661485|NCT02521558|BEHAVIORAL|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
219064606|NCT02251535|DEVICE|ATTUNE® Knee System|
219661486|NCT02521558|BEHAVIORAL|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
219064607|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
219661487|NCT00810446|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
219661488|NCT04546321|OTHER|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
219661489|NCT05433909|DIAGNOSTIC_TEST|Blood, fecal, vaginal and endometrial liquid samples|"During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling."
219661490|NCT02455609|PROCEDURE|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
219661491|NCT02455609|DRUG|Dexmedetomidine|
219661492|NCT02455609|DRUG|ketamine|
219661493|NCT02455609|DRUG|Bupivacaine|
219661494|NCT03978013|OTHER|Pomegranate juice|Pomegranate juice
219661495|NCT03978013|OTHER|Apple juice|Apple juice
219661496|NCT03451916|DRUG|PLX-PAD|PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
219661497|NCT03451916|DRUG|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
219661498|NCT03788980|PROCEDURE|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
219661499|NCT03788980|DIAGNOSTIC_TEST|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
219661500|NCT05079230|DRUG|Magrolimab|Administered intravenously (IV)
219661501|NCT05079230|DRUG|Venetoclax|Tablets administered orally
219661502|NCT05079230|DRUG|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
219661503|NCT05079230|DRUG|Placebo|Administered intravenously (IV)
219661504|NCT00169728|BIOLOGICAL|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
219661505|NCT00169728|BIOLOGICAL|heptavalent pneumococcal conjugate vaccine, Prevenar|
219661506|NCT01524783|DRUG|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
219661507|NCT01524783|DRUG|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
219661508|NCT01524783|OTHER|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
219661509|NCT01915654|PROCEDURE|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
219661510|NCT05564026|OTHER|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
219661511|NCT05564026|OTHER|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
219661512|NCT05564026|OTHER|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
219064608|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
219064609|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
219064610|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
219064611|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
219064612|NCT05164510|GENETIC|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
219064613|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
219661513|NCT05564026|PROCEDURE|Blood Sample Collection|Collection and storing of serum/plasma
219661514|NCT03817034|DRUG|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
219661515|NCT05420857|OTHER|Overground Visual Biofeeback|Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
219661516|NCT04181437|DRUG|NVP-1203-R1|1 tablet, Single oral dosing
219661517|NCT04181437|DRUG|NVP-1203-R2|1 tablet, Single oral dosing
219661518|NCT04181437|DRUG|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
219661519|NCT03482570|DEVICE|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
219661520|NCT06465134|OTHER|No intervention|There is no intervention
219661521|NCT00733083|DRUG|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
219661522|NCT00733083|DRUG|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
219661523|NCT00733083|DRUG|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
219661524|NCT00733083|DRUG|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
219661525|NCT00100841|BIOLOGICAL|cetuximab|Given IV
219661526|NCT00100841|BIOLOGICAL|bevacizumab|Given IV
219661527|NCT00100841|DRUG|oxaliplatin|Given IV
219661528|NCT00100841|DRUG|leucovorin calcium|Given IV
219661529|NCT00100841|DRUG|fluorouracil|Given IV
219064614|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
219661530|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
219661531|NCT05470816|DRUG|Placebo|Normal saline
219661532|NCT02920177|DRUG|platelet-rich plasma injection|platelet-rich plasma injection
219661533|NCT02920177|DRUG|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
219661534|NCT02054910|PROCEDURE|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
219661535|NCT02054910|PROCEDURE|Sham|Patients will not receive celiac plexus block during endoscopy.
219661536|NCT00936130|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
219661537|NCT00936130|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
219661538|NCT00936130|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
219661539|NCT00936130|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet Program
219661540|NCT06912542|OTHER|Whole flaxseed bread|French bread with the addition of 30g of whole flaxseed.
219661541|NCT06912542|OTHER|Ground flaxseed bread|French bread with the addition of 30g of ground flaxseed.
219661542|NCT06912542|OTHER|French bread|Plain French bread (control).
219661543|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
218985481|NCT01206166|DRUG|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
218985482|NCT00407329|PROCEDURE|transurethral resection of the prostate|resection of prostate
218985483|NCT03239600|DRUG|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
218985484|NCT03239600|DRUG|Placebo|Placebo solution will be administered by IV infusion.
218985485|NCT03239600|DRUG|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
219064615|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
219064616|NCT02548962|DRUG|Ibrutinib|
219064617|NCT02548962|DRUG|Pomalidomide|
219661544|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
219661545|NCT07024888|DRUG|SSS17|Single oral administration of SSS17
219661546|NCT01370824|PROCEDURE|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
219661547|NCT01370824|PROCEDURE|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
219661548|NCT01131065|DRUG|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
219661549|NCT04489875|BEHAVIORAL|Chewing Gum|The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
219661550|NCT03229629|BEHAVIORAL|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
219661551|NCT03229629|OTHER|Food Voucher (Monetary)|Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
219661552|NCT00181129|BEHAVIORAL|home based self paced walking program|
219661553|NCT01587417|DRUG|Placebo to BI 187004 CL|1 single dose per subject as oral solution
219661554|NCT01587417|DRUG|BI 187004 CL|1 single dose per subject as oral solution
219661555|NCT05237804|OTHER|Patient component|Video, booklet, website
219661556|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
219686442|NCT05002504|PROCEDURE|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
218970256|NCT04066959|BEHAVIORAL|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
218985486|NCT05392257|DRUG|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
219064618|NCT02548962|DRUG|Dexamethasone|
218985487|NCT00066365|BIOLOGICAL|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
219686443|NCT00050635|DRUG|Sandostatin LAR Depot|
219686444|NCT02085746|OTHER|Defining Sexual Activity Questionnaire|
219686445|NCT03285945|DRUG|PET3|Prednisolone 60 mg daily for 3 days
219686446|NCT03285945|DRUG|PET10|Prednisolone 60 mg daily for 10 days
219686447|NCT05404711|DEVICE|CGM|Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
219686448|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
219686449|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
219686450|NCT01779557|DRUG|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
219686451|NCT01779557|DRUG|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
219686452|NCT06611852|OTHER|Aerobic exercise|"Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue."
219686453|NCT06611852|OTHER|electronic cupping therapy in addition to aerobic exercise|Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).
219686454|NCT06611852|OTHER|interferential therapy in addition to aerobic exercise|interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy
219064619|NCT02548962|DRUG|Placebo|
219661557|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
219661558|NCT01902212|OTHER|Oral Nutritional Supplement|
219661559|NCT03679169|PROCEDURE|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
219064620|NCT00006172|DEVICE|Bright light box|60-min light therapy shortly after awakening
219661560|NCT06711146|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
219661561|NCT02143830|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
219661562|NCT02143830|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
218970257|NCT04066959|BEHAVIORAL|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
218970258|NCT04066959|BEHAVIORAL|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
218985488|NCT00066365|PROCEDURE|conventional surgery|thoracotomy
218985489|NCT02713373|BIOLOGICAL|Cetuximab|Given IV
218985490|NCT02713373|OTHER|Laboratory Biomarker Analysis|Correlative studies
218985491|NCT02713373|BIOLOGICAL|Pembrolizumab|Given IV
218985492|NCT03062007|DRUG|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
218985493|NCT03815474|DRUG|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
218985494|NCT04288752|DEVICE|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
218985495|NCT04288752|DEVICE|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
218985496|NCT01807039|PROCEDURE|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
218985497|NCT04200573|DRUG|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
218985498|NCT05264688|DIAGNOSTIC_TEST|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
218985499|NCT03939754|BEHAVIORAL|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
218985500|NCT04862377|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
218985501|NCT04862377|DRUG|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
218985502|NCT00005017|DRUG|Ritonavir|
218985503|NCT00005017|DRUG|Abacavir sulfate|
218985504|NCT00005017|DRUG|Amprenavir|
218985505|NCT00005017|DRUG|Efavirenz|
218985506|NCT00005017|DRUG|Lamivudine|
218985507|NCT00005017|DRUG|Stavudine|
218985508|NCT01934881|DEVICE|voltage adjustment only|Only voltage will be adjusted in all programming sections.
218985509|NCT01934881|DEVICE|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
218985510|NCT02635776|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
218985511|NCT02635776|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
218985512|NCT00092768|DRUG|MK0663, etoricoxib|
218985513|NCT00092768|DRUG|Comparator: celecoxib|
218985514|NCT01133041|OTHER|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
218985515|NCT01133041|OTHER|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
219661563|NCT02143830|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
219661564|NCT02143830|DRUG|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
219661565|NCT02143830|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
219661566|NCT02143830|BIOLOGICAL|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
219661567|NCT06886269|DRUG|14C-VX-993|Solution for Oral Administration.
219661568|NCT04963959|DEVICE|Peripheral blood mononuclear cell apheresis|mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
219661569|NCT02634372|BEHAVIORAL|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
219661570|NCT02634372|BEHAVIORAL|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
219661571|NCT00426140|DRUG|Patupilone|
219661572|NCT06888778|OTHER|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive brain stimulation technique that stimulates specific brain areas through repeated magnetic pulses to treat depression, anxiety and other mental illnesses, and to study brain function.
219661573|NCT06888778|OTHER|Non-stimulation|participants receive Non-stimulation:The side of the double cone coil is placed against the scalp, and the target of the coil is stimulated in the direction of air.
219661574|NCT05496608|PROCEDURE|L-PRF|a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
219661575|NCT05496608|PROCEDURE|OFD|Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
219661576|NCT05496608|PROCEDURE|CM|Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
219661577|NCT01428687|BEHAVIORAL|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
219661578|NCT01428687|BEHAVIORAL|No change in sleep|This group is taught to maintain their current sleep habits.
219661579|NCT00835627|DRUG|sertraline|flexible dose sertraline
219064621|NCT00006172|DEVICE|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
219064622|NCT00006172|DEVICE|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
219661580|NCT00835627|BEHAVIORAL|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
219661581|NCT00835627|OTHER|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
219661582|NCT00835627|OTHER|Standard Care|community care, treatment as usual: routine follow up with existing providers
219661583|NCT06448195|DRUG|Polyethylene Glycol Somatropin (rDNA origin) Injection|Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
219661584|NCT00671827|BEHAVIORAL|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
219686455|NCT06611852|OTHER|interferential therapy, electronic cupping therapy in addition to aerobic exercises|interferential therapy, electronic cupping therapy in addition to aerobic exercises
219686456|NCT06611709|DEVICE|sham taping (non-elastic medical cloth tape)|sham taping
219686457|NCT06611709|DEVICE|Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold|A standard 5-cm wide KinesioⓇ Tex Gold
219686458|NCT06611709|OTHER|exercises|home-based exercises
219686459|NCT06612983|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.
219686460|NCT06612983|OTHER|Walking Treatment|Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.
219686461|NCT06613152|DRUG|HS-IT201 Injection|Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
219686462|NCT06612619|BEHAVIORAL|Dyad instruction|Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
219686463|NCT06613113|DRUG|Fruquintinib|After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
219686464|NCT06612593|DRUG|Cilostazol|2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
219686465|NCT06612593|DRUG|Placebo|The patient will receive 2 tablets twice daily
219686466|NCT06612593|DRUG|Standard treatment|It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
219686467|NCT06611488|OTHER|No Intervention: Observational Cohort|No Intervention as the study is bservational Cohort
219064623|NCT01197950|DEVICE|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
219661585|NCT06738849|DEVICE|EkiYou V2|"Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment."
219661586|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
219661587|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
219661588|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
219661589|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
219661590|NCT01096589|DEVICE|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
219064624|NCT01197950|DEVICE|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
219064625|NCT06536114|OTHER|CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.
219064626|NCT06536114|OTHER|Standard of Care|The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
219064627|NCT05983601|DEVICE|Transcranial Direct Current Stimulation|The anode electrode will be placed at the midline of the Cz according to international 10-20 EEG system, and the cathode electrode will be placed at the midline of forehead. In this way, both hemisphere of motor cortex can be stimulated which is used as protocol in various balance studies (Siedel-Marzi and Ragert, 2020b; Saruco et al., 2017). Participants will continue their training with tDCS (2mA) for 20 minutes. This application will continue three times a week for four weeks. In the end of the study, participants will be asked to guess which group they were in (active or sham).
219064628|NCT04831736|DRUG|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
219661591|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
219661592|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
219661593|NCT06781827|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
219661594|NCT06781827|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
219661595|NCT04045899|DEVICE|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
219661596|NCT04045899|DEVICE|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
218970259|NCT04991103|DRUG|DaraVRD|"All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22)."
218970260|NCT03165292|RADIATION|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
219064629|NCT04831736|DRUG|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
219064630|NCT01745861|DIETARY_SUPPLEMENT|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
219064631|NCT01745861|DIETARY_SUPPLEMENT|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
219064632|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
219661597|NCT04045899|DEVICE|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
219661598|NCT04513444|OTHER|Relaxation with music listening and medical hypnosis during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~* Self-hypnosis during the 4th and 5th radiotherapy session,~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
219661599|NCT04513444|OTHER|Relaxation with music listening during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
219661600|NCT01294007|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
219064633|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
219064634|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
219661601|NCT01294007|PROCEDURE|Autograft bone|Iliac Crest and Local Autograft Bone
219661602|NCT04561102|DIAGNOSTIC_TEST|Diagnostic test for detection of SARS-CoV-2|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
219686468|NCT06613256|OTHER|Endothelial cell biopsy|Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
218970261|NCT03165292|DRUG|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
218970262|NCT03165292|DRUG|Thiotepa|Day 1-3 Thiotepa
218970263|NCT03165292|PROCEDURE|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
218970264|NCT05754996|DRUG|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
219661603|NCT02713438|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
219661604|NCT02713438|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
218970265|NCT05754996|DRUG|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
218970266|NCT05754996|DRUG|Rifaximin 550Mg Tab|Rifaximin 550 MG twice daily
218970267|NCT06511895|DRUG|AZD4205|AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
218970268|NCT02656407|DEVICE|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
218970269|NCT03275181|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
218970270|NCT03275181|DIAGNOSTIC_TEST|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
218970271|NCT03275181|DIAGNOSTIC_TEST|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
218970272|NCT04922723|DRUG|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
218970273|NCT05650242|DRUG|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
218970274|NCT05896748|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
218970275|NCT05896748|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
218970276|NCT03568890|DRUG|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
218970277|NCT03568890|DRUG|Clopidogrel -75 mg/day|Duration of treatment: 60 days
218970278|NCT03568890|DRUG|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
218970279|NCT03353389|OTHER|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
219064635|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
219064636|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
219064637|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
219064638|NCT00005633|BIOLOGICAL|OVA BiP peptide|
218970280|NCT03353389|OTHER|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
219064639|NCT00005633|BIOLOGICAL|gp209-2M antigen|
219064640|NCT00005633|BIOLOGICAL|recombinant 70-kD heat-shock protein|
219064641|NCT00005633|BIOLOGICAL|tyrosinase peptide|
219064642|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
219661605|NCT02713438|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
219661606|NCT02713438|BEHAVIORAL|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
219661607|NCT03326284|OTHER|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
219661608|NCT03326284|OTHER|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
219661609|NCT03326284|OTHER|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
218970281|NCT03353389|OTHER|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
218970282|NCT02779751|DRUG|Abemaciclib|Administered orally
219064643|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
219064644|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~\+~Continuing education activities: video classes and discussions of complex cases."
219064645|NCT03450031|OTHER|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
219208332|NCT06737744|OTHER|Active Games for Change (AG4C)|This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.
219661610|NCT03326284|OTHER|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
218970283|NCT02779751|DRUG|Pembrolizumab|Administered IV
218970284|NCT02779751|DRUG|Anastrozole|Administered orally
218970285|NCT00063375|BEHAVIORAL|Computer Based Cognitive Behavioral Therapy|
218970286|NCT05555758|DRUG|Adamgammadex Sodium|Aom0319 will be administered intravenously with water for injection.
219064646|NCT06534476|OTHER|Education|"Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room."
219064647|NCT00000218|DRUG|Carbamazepine|
219661611|NCT04245215|DRUG|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
219661612|NCT02252900|OTHER|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
219661613|NCT03439215|DRUG|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
219661614|NCT06815263|BEHAVIORAL|Listener Training|Partner participants are presented with individual audio phrases that make up passage reading speech stimuli and orthographic transcriptions of what the patient is saying. Partners are asked to listen carefully to the audio files and use the written subtitles to help them understand what is being said.
219661615|NCT06863636|DRUG|Celecoxib + Acetaminohen|One tablet of 200 mg / 200 mg a day
219661616|NCT06863636|DRUG|Celecoxi + Acetaminophen|One tablet of 200 mg / 500 mg a day
218970287|NCT05555758|DRUG|0.9% Sodium Chloride Injection|0.9% Sodium Chloride will be administered intravenously.
218970288|NCT05497700|DRUG|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
218970289|NCT05497700|DRUG|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
219064648|NCT00406575|DRUG|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
219064649|NCT00406575|DRUG|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
219661617|NCT06863636|DRUG|Celecoxib|One capsule of 200 mg a day
219661618|NCT01870804|DRUG|Rosuvastatin|
219661619|NCT01870804|DRUG|Atorvastatin|
219661620|NCT00992134|DRUG|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
219661621|NCT06745674|BEHAVIORAL|a mobile app-delivered Acceptance Commitment Therapy (ACT)|The study utilized a specially tailored internet-based self-help ACT program for cancer patients. It consisted of an introductory module and six core intervention modules: (1) Refusing Avoidance; (2) Accepting Distress; (3) Living in the Present Moment; (4) Observing Yourself Psychologically; (5) Exploring Meaningful Values; and (6) Committing to Action. Each module, designed to take 30-60 minutes, was delivered over a two-week period.
219661622|NCT02589327|OTHER|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
219661623|NCT06277869|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention Thermal Jacket as well as Kangaroo Mother Care.
218970290|NCT01755273|PROCEDURE|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
218970291|NCT06185127|DRUG|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
218970292|NCT06185127|DRUG|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
218970293|NCT06185127|DRUG|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
218970294|NCT06185127|DRUG|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
219064650|NCT03391648|OTHER|Observation|Observation only
219064651|NCT05575947|DEVICE|da Vinci Surgical System|da Vinci Surgical System
219064652|NCT05575947|PROCEDURE|laparoscopic bariatric surgery|laparoscopic bariatric surgery
219661624|NCT06277869|PROCEDURE|Kangaroo Mother Care|Skin-to-Skin care, provided by primary caregiver.
219661625|NCT03033316|DRUG|Dexamethasone|
219661626|NCT02202044|DEVICE|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
219661627|NCT03073694|DRUG|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
219661628|NCT03073694|DRUG|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
219661629|NCT06647706|DEVICE|Transthoracic echocardiography|MPNs patients who have echocardiographic probability of PH
219661630|NCT05718427|BEHAVIORAL|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
218970295|NCT00679744|DRUG|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
218970296|NCT05436223|DRUG|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
218970297|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
218970298|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
218970299|NCT05397132|GENETIC|Blood draw|Patients will provide a blood draw for research and repository
218970300|NCT03070366|DRUG|Chemotherapy|"* cisplatin~* 5FU~* carboplatin~* cetuximab"
218970301|NCT03070366|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy
218970302|NCT01465191|DRUG|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
218970303|NCT01298193|DRUG|Aprepitant|Efficacy phase (second cycle)
218970304|NCT03445182|PROCEDURE|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
219064653|NCT03398538|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
219064654|NCT03398538|OTHER|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
219661631|NCT02763982|OTHER|Physical evaluation|
219661632|NCT06648876|DRUG|YG1699|10mg qd for 8 days
219661633|NCT06648876|DRUG|Placebo|10mg qd for 8 days
219661634|NCT05918419|DRUG|Serplulimab|PD-1 antibody
219661635|NCT05179018|DIAGNOSTIC_TEST|Ribosomal p2 Autoantibodies as a Serum marker|Using serum marker
219661636|NCT04998721|BEHAVIORAL|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
219661637|NCT04998721|BEHAVIORAL|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
219661638|NCT05554913|DRUG|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
218970305|NCT03445182|DEVICE|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
218970306|NCT02815488|DRUG|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
218970307|NCT02815488|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
218970308|NCT02815488|DRUG|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
218970309|NCT02815488|DRUG|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
218970310|NCT02815488|DRUG|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
218970311|NCT02815488|DRUG|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
218970312|NCT02815488|DRUG|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
218970313|NCT02815488|DRUG|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
218970314|NCT04010539|DRUG|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
219661639|NCT05554913|DRUG|Placebo|Placebo comparator
219661640|NCT02838836|PROCEDURE|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
219661641|NCT02183259|DRUG|ESR 1150 CL, Capsule, oral|
219661642|NCT02183259|DRUG|ESR 1150 CL, solution, intravenous|
219661643|NCT02573831|DRUG|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
219661644|NCT02573831|DRUG|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
219661645|NCT05047731|DRUG|Antihypertensive medication|Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
219661646|NCT05836974|PROCEDURE|Ex-utero cord blood collection|SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
219661647|NCT05836974|PROCEDURE|In-utero cord blood collection|The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
219661648|NCT02535130|DEVICE|Positive expiratory pressure|
219661649|NCT02535130|DRUG|amikacine nebulization|
219661650|NCT05032274|OTHER|Home-based Exercise Program|The exercise program will include chink tuck and shoulder retraction exercises. The chin tuck exercise will be performed in standing position. The shoulder retraction exercise includes activation and strengthening components. The activation component will be performed in standing position and strengthening component will be performed in prone position.
219661651|NCT05296902|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
219661652|NCT03673345|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
219661653|NCT01483482|PROCEDURE|Conservative Treatment|Simple Sling
219661654|NCT01483482|PROCEDURE|Surgical treatment|Superior Locking plate
219661655|NCT00033176|DRUG|Alpha Lipoic Acid|
219661656|NCT01362244|DRUG|Mepolizumab|750 mg of mepolizumab by IV infusion
219661657|NCT01362244|DRUG|Placebo|Placebo by IV infusion
219661658|NCT01362244|DRUG|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
219661659|NCT04648527|PROCEDURE|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
219661660|NCT04455776|DRUG|Propofol|Sedation by propofol
219661661|NCT02000882|DRUG|BKM120|
219661662|NCT02000882|DRUG|capecitabine|
219661663|NCT02000882|DRUG|Trastuzumab|
219661664|NCT03964701|OTHER|no intervention|no interventional study
219661665|NCT00549601|DRUG|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
219661666|NCT00549601|DRUG|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
219661667|NCT00549601|DRUG|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
219661668|NCT03690362|DRUG|VNRX-5133 and VNRX-5022|intravenous infusion
219661669|NCT05816460|OTHER|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)
219661670|NCT05816460|OTHER|Sleep Hygiene Education (SHE)|Sleep Hygiene Education (SHE) will be provided electronically
219661671|NCT00004176|DRUG|amifostine trihydrate|
219661672|NCT00004176|DRUG|cisplatin|
219661673|NCT00004176|DRUG|etoposide|
219661674|NCT00004176|RADIATION|radiation therapy|
219661675|NCT02102594|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
219661676|NCT01145794|BEHAVIORAL|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
219661677|NCT04719429|DIETARY_SUPPLEMENT|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
219661678|NCT04719429|DIETARY_SUPPLEMENT|Beef-derived Protein|Beverage containing 25 g beef-derived protein
218970315|NCT04010539|DRUG|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
219661679|NCT03081091|DEVICE|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
219661680|NCT03081091|DEVICE|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
219661681|NCT02215746|DRUG|BI 44370 powder for oral solution|
218970316|NCT04010539|DRUG|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
218970317|NCT02089854|DRUG|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
218970318|NCT00398333|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
218970319|NCT03792243|PROCEDURE|Complication|Readmission, reoperation
218970320|NCT05570201|OTHER|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
218970321|NCT00548106|DIETARY_SUPPLEMENT|partially hydrolyzed whey|Total infant feeding by study formula.
218970322|NCT00548106|DIETARY_SUPPLEMENT|Nan HA|Total infant diet by study formula.
218970323|NCT04921215|BEHAVIORAL|Morning bright light|All participants will receive phase advancing morning bright light.
218970324|NCT04596553|DIETARY_SUPPLEMENT|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
218970325|NCT04596553|DIETARY_SUPPLEMENT|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
218970326|NCT04596553|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
218970327|NCT05716503|DEVICE|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
218970328|NCT05716503|OTHER|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
219064655|NCT03398538|OTHER|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
219064656|NCT03398538|OTHER|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
219064657|NCT03811067|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
219064658|NCT03811067|PROCEDURE|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
219064659|NCT05734846|DEVICE|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
219064660|NCT05734846|DEVICE|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
219064661|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
219064662|NCT03178357|OTHER|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
219064663|NCT03178357|OTHER|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
219064664|NCT03317704|BEHAVIORAL|Speed endurance training|Speed endurance training
219064665|NCT01666002|DEVICE|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
219661682|NCT02215746|DRUG|BI 44370 tablet|
219661683|NCT02215746|OTHER|high fat breakfast|
219661684|NCT00915265|OTHER|Multilobed catheter (group CPA)|\- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
219686469|NCT03971409|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
218970329|NCT04838197|OTHER|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
218970330|NCT01005043|RADIATION|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
219064666|NCT05883306|DRUG|[14C]LXI-15028|\[14C\]LXI-15028
219661685|NCT00915265|OTHER|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
219661686|NCT05063526|DEVICE|ultrasound|ultrasound on diaphragm
219661687|NCT02724566|DRUG|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
219661688|NCT02724566|DRUG|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
219661689|NCT04525326|DRUG|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
219661690|NCT04525326|DRUG|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
219661691|NCT04525326|DRUG|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
219661692|NCT02389374|DRUG|chloroquine|standard dose
219661693|NCT02389374|DRUG|Artemether-lumefantrine combination|standard dose
219661694|NCT02389374|DRUG|Primaquine|single dose
219661695|NCT02389374|DRUG|Primaquine|14 days
219661696|NCT00937092|DRUG|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
219661697|NCT00937092|DRUG|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
219661698|NCT04081857|DRUG|HGP1810|HGP1810: Vildagliptin/Metformin
219661699|NCT04081857|DRUG|HCP1704|HCP1704: Vildagliptin/Metformin
219661700|NCT04959292|DIAGNOSTIC_TEST|arthroscopy|arthroscopy
219661701|NCT06028386|DEVICE|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
219661702|NCT06028386|DEVICE|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
219661703|NCT00908596|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
218970331|NCT04561674|OTHER|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
218970332|NCT06346808|DRUG|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
218970333|NCT00003046|BIOLOGICAL|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
218970334|NCT05060887|BIOLOGICAL|OVX836-003|One single administration intramuscularly at Day 1.
218970335|NCT05060887|BIOLOGICAL|Saline solution|One single administration intramuscularly at Day 1.
218970336|NCT00002178|DRUG|Ritonavir|
218970337|NCT00002178|DRUG|Nelfinavir mesylate|
218970338|NCT00002178|DRUG|Saquinavir|
218970339|NCT00002178|DRUG|Delavirdine mesylate|
218970340|NCT04132245|BEHAVIORAL|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
218970341|NCT04132245|BEHAVIORAL|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
218970342|NCT04231318|DRUG|Cingal|Single intra-articular injection of Cingal into the knee.
218970343|NCT04231318|DRUG|Triamcinolone Hexacetonide (TH)|Single intra-articular injection of TH into the knee.
218970344|NCT04231318|DRUG|Placebo|Single intra-articular injection Placebo (0.9% Saline) into the knee.
218970345|NCT01036061|DRUG|GSK618334 Low Dose|GSK618334 low dose
218970346|NCT01036061|DRUG|GSK618334 PET subjects|PET subjects
218970347|NCT01036061|DRUG|GSK618334 Medium Dose|Medium Dose
218970348|NCT01036061|DRUG|GSK618334 High Dose|GSK618334 High Dose
218985516|NCT01085474|OTHER|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
218985517|NCT01085474|OTHER|2|The best intervention used in the pilot study will be chosen and included in the main study.
219661704|NCT00932386|DRUG|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
219661705|NCT00932386|DRUG|normal saline|0.9% normal saline infusing
219661706|NCT05365334|BEHAVIORAL|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
219661707|NCT05365334|BEHAVIORAL|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
219661708|NCT05365334|BEHAVIORAL|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
219661709|NCT03812263|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
219661710|NCT05919524|RADIATION|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~* mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~* Additional urethra and bladder trigone sparing constrains~* Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
219661711|NCT03010241|DRUG|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
219686470|NCT03971409|DRUG|Avelumab|Given IV
219686471|NCT03971409|DRUG|Binimetinib|Given PO
219686472|NCT03971409|BIOLOGICAL|Utomilumab|Given IV
219686473|NCT03971409|DRUG|Liposomal Doxorubicin|Given IV
219686474|NCT03971409|DRUG|Sacituzumab Govitecan|Given IV
219686475|NCT07000682|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
219661712|NCT03010241|DRUG|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
219661713|NCT02232555|DRUG|Duloxetine|
219661714|NCT02232555|DRUG|Placebo|
219661715|NCT02148016|PROCEDURE|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
219661716|NCT02148016|PROCEDURE|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
219661717|NCT02148016|PROCEDURE|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
219661718|NCT02148016|PROCEDURE|PRK only (Traditional Technique)|PRK alone will be performed.
219661719|NCT02148016|DRUG|Levofloxacin|
219661720|NCT02148016|DRUG|Betamethasone|
219661721|NCT02148016|DRUG|Limbal stem cells (LSCs)|
219661722|NCT05727150|PROCEDURE|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
218970349|NCT05240287|DIAGNOSTIC_TEST|Navicular Drop Test|The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
218970350|NCT05240287|DIAGNOSTIC_TEST|Foot Posture Index|The index consists of six items in which the foot is evaluated observationally. In the evaluation, the individual is asked to stand in a comfortable and relaxed position. The researcher observes the medial longitudinal arch structure, the structure of the talonavicular joint region, the degree of abduction/adduction in the forefoot relative to the hindfoot in the front part of the foot. In the back foot, inversion/eversion of the calcaneus, talus head position, and curvatures above and below the lateral malleolus are evaluated. The total score is reached by scoring each criterion between -2 and +2 values. 0; neutral position, (+) values; pronation (pes planus), (-) values indicate supination (pes cavus). Individuals with +6 to +12 points from this index will be included in our study.
218970351|NCT05240287|DIAGNOSTIC_TEST|Balance|Static and dynamic balance and stability limit values of individuals will be evaluated with the HUR Smart Balance (SME Inc, USA) balance measurement device. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals will be asked to place their feet on the marked places on the platform. The researchers will evaluate the balance in four different situations, 30 seconds each. In the first test, individuals keep the balance on firm ground with their eyes open. The second test performed on the firm ground with eyes closed, in the third test, on the soft ground with eyes open, and in the fourth test, on the soft ground with eyes closed. For dynamic balance, individuals will be asked to extend their body weight to the front, back, and sides with their feet in 4 different directions for 8 seconds.
218970352|NCT05240287|DIAGNOSTIC_TEST|Plantar Pressure Analysis|Plantar pressure analysis of individuals will be evaluated by measuring with the DIERS Pedoscan DICAM 3 v3.10.8 (2019) device. DIERS Pedoscan is a system integrated into the treadmill that measures the pressure distribution on the sole during stance. As a result of this evaluation, right-left and anterior-posterior weight transfer, left-right foot rotation, lateral mobility, the center of gravity movement, and swing area data will be recorded.
218970353|NCT05240287|DIAGNOSTIC_TEST|Gait Analysis|Gait analysis of individuals will be evaluated with the DIERS Leg Axis DICAM 3 v3.10.8 (2019) system. The system consists of a treadmill, computer, and cameras. Before the measurement, colored markers will be placed on the knee and ankle joints of the individual. For gait assessment, individuals will walk at their preferred comfortable walking speed. In the evaluation, joint angles, walking speed, step lengths are recorded. Evaluation time is approximately 5 minutes.
219661723|NCT01943955|BEHAVIORAL|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
219661724|NCT03747913|DIETARY_SUPPLEMENT|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
219661725|NCT03691506|OTHER|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
219661726|NCT03691506|OTHER|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
219661727|NCT05259618|OTHER|Tasso+ SST|alternative site blood sample collection.
219661728|NCT02219386|OTHER|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
219661729|NCT02219386|OTHER|group 2. Passive analitical stretch (performed in both groups)|
219661730|NCT05037890|DIETARY_SUPPLEMENT|Margarine|Intake of margarine
219661731|NCT01075464|DRUG|MEGF0444A|Intravenous escalating dose
219661732|NCT01075464|DRUG|bevacizumab|Intravenous repeating dose
219661733|NCT01075464|DRUG|paclitaxel|Intravenous repeating dose
219661734|NCT01281943|DRUG|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
219661735|NCT03793959|DIETARY_SUPPLEMENT|Synbiotic Supplement|
219661736|NCT03793959|DIETARY_SUPPLEMENT|Placebo|
219661737|NCT03259906|OTHER|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
219661738|NCT03259906|PROCEDURE|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
219661739|NCT03259906|PROCEDURE|posterior osteosynthesis|Osteosynthesis using a posterior plate
219661740|NCT03259906|PROCEDURE|Anterior osteosynthesis|Osteosynthesis using an anterior plate
218970354|NCT02622750|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
218970355|NCT02622750|PROCEDURE|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
218970356|NCT06822972|DRUG|Selinexor 40 mg|Patients will receive 40mg of oral SEL, weekly, beginning after they have completed step-up dosing and are 5 (± 2) days out from administration of the first full treatment dose of bispecific antibody therapy for 12 months or until disease progression.
218970357|NCT02852772|BEHAVIORAL|Cognitive function tests|
218970358|NCT03201627|DRUG|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
218970359|NCT01070043|DRUG|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
218970360|NCT01070043|DRUG|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
219661741|NCT03354052|DEVICE|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
219661742|NCT03354052|DEVICE|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
219661743|NCT04202536|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
218970361|NCT01194427|DRUG|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
218970362|NCT05160987|DRUG|Remimazolam|Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
218970363|NCT05160987|DRUG|Midazolam|Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
218970364|NCT01164540|DRUG|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
218970365|NCT01164540|DRUG|Placebo|Oral dose (od)
218970366|NCT05012436|DRUG|YHD1119 75mg|A single oral dose
218970367|NCT01323738|BEHAVIORAL|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
218970368|NCT04965558|OTHER|No intervention|No intervention
218970369|NCT03310827|BEHAVIORAL|Personalized Nutrition|Diet plan based on nutrition-related gene test results
218985518|NCT03608254|OTHER|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
219661744|NCT04202536|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
219661745|NCT01842906|DEVICE|Theravent|nasal EPAP device
219661746|NCT01842906|DEVICE|Control|Sham device without EPAP
219661747|NCT00095459|DRUG|Bevacizumab|
219661748|NCT00095459|DRUG|BAY 43-9006|
219661749|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
219208333|NCT06737744|BEHAVIORAL|Active Games for Change Group Working|The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.
219661750|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
219661751|NCT03695328|BEHAVIORAL|physical activity level|
219661752|NCT03695328|BEHAVIORAL|Dietary Intake|
219661753|NCT00638261|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
219661754|NCT00003328|DRUG|porfiromycin|
219661755|NCT00003328|RADIATION|radiation therapy|
219661756|NCT04852211|PROCEDURE|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~1. Laparoscopic group: LMH~2. Open group: OMH"
219661757|NCT00413309|PROCEDURE|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
219661758|NCT03290183|DEVICE|Confocal laser endomicroscopy|Real-time microscopic imaging technique
219661759|NCT06174545|DRUG|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
218985519|NCT03344133|BEHAVIORAL|Exercise|4-week moderate intensity exercise programme
218985520|NCT03141593|DRUG|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
218985521|NCT03141593|DRUG|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
218985522|NCT03141593|DRUG|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
218985523|NCT03141593|DRUG|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
218985524|NCT06557928|OTHER|measurement|Measurement of multiple physiological indicators and psychological status and multi-omics study
218985525|NCT05890950|DRUG|K-757 and K-833|Both administered orally
218985526|NCT05890950|DRUG|Matching placebo to K-757 and K-833|Both administered orally
218985527|NCT00376883|DRUG|pamidronate|
218985528|NCT03866954|COMBINATION_PRODUCT|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
218985529|NCT00640861|BIOLOGICAL|CpG oligodeoxynucleotide|
218985530|NCT00640861|BIOLOGICAL|HER-2/neu peptide vaccine|
218985531|NCT00640861|BIOLOGICAL|MUC-1 peptide vaccine|
218985532|NCT00640861|BIOLOGICAL|incomplete Freund's adjuvant|
218985533|NCT00640861|BIOLOGICAL|sargramostim|
218985534|NCT00640861|OTHER|immunoenzyme technique|
218985535|NCT00640861|OTHER|immunologic technique|
218985536|NCT03873025|COMBINATION_PRODUCT|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
218985537|NCT04838782|PROCEDURE|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
218985538|NCT05711394|DRUG|Atogepant|Oral Tablet
218985539|NCT05711394|DRUG|Placebo-Matching Atogepant|Oral Tablet
218985540|NCT00660673|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
218985541|NCT00660673|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
218985542|NCT00660673|DEVICE|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
218985543|NCT03884959|BIOLOGICAL|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
218985544|NCT01268020|DRUG|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
218985545|NCT05890339|PROCEDURE|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
218985546|NCT05890339|PROCEDURE|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
218985547|NCT03993470|BEHAVIORAL|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
218970370|NCT00473746|DRUG|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
218970371|NCT00473746|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
219208334|NCT05197400|DIAGNOSTIC_TEST|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
219661760|NCT02552953|DRUG|CYC065|
219661761|NCT00935454|PROCEDURE|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
219661762|NCT03331705|DEVICE|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
219661763|NCT03571776|PROCEDURE|Surgery|Laparoscopic ovarian cystectomy
219661764|NCT03571776|PROCEDURE|Sclerotherapy|US-aspiration and alcohol sclerosis
219661765|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
219661766|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
219661767|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
219661768|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
219661769|NCT02437188|BEHAVIORAL|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
219661770|NCT02517021|DRUG|Pro-netupitant/Palonosetron|
219661771|NCT02517021|DRUG|Netupitant/Palonosetron|
219661772|NCT02517021|DRUG|Dexamethasone|
219661773|NCT01172808|DRUG|Placebo|Placebo that represents comparator
219661774|NCT01172808|DRUG|tiotropium Respimat® low dose|IMP
219661775|NCT01172808|DRUG|Placebo|Placebo that represents comparator
219661776|NCT01172808|DRUG|Placebo|Placebo that represents comparator
219661777|NCT01172808|DRUG|tiotropium Respimat® high dose|IMP
219661778|NCT01172808|DRUG|50 mcg salmeterol HFA MDI|Active comparator
219661779|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
219661780|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
219661781|NCT00507858|DRUG|Pemetrexed|Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks
219661782|NCT00507858|DRUG|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
219661783|NCT05365919|OTHER|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
219661784|NCT00001646|DRUG|Voriconazole|
218970372|NCT00473746|DRUG|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
218970373|NCT04491253|BEHAVIORAL|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
218970374|NCT00832390|DRUG|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
219661785|NCT00001646|DRUG|Amphotericin B|
219661786|NCT01619098|OTHER|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
219661787|NCT01619098|OTHER|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
219661788|NCT02661061|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
219661789|NCT02661061|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
219661790|NCT02331784|BEHAVIORAL|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
219661791|NCT02331784|BEHAVIORAL|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
219686476|NCT06504485|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
219686477|NCT04817267|DEVICE|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
219686478|NCT06866275|DRUG|KZ101|For active treatment with KZ101, a loading dose of 454 mg/m2 (salt-free) will be followed by a treatment dose of 363 mg/m2 (salt-free).
219661792|NCT02993965|OTHER|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
219661793|NCT00183833|DRUG|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
219661794|NCT06291285|DRUG|Decitabine-THU|Orally administered immediate release tablets.
219661795|NCT06291285|DRUG|Decitabine-THU|Orally administered delayed release capsules.
219661796|NCT01013389|PROCEDURE|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
219661797|NCT01013389|PROCEDURE|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
219661798|NCT03917043|DRUG|APG-2449|Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
219661799|NCT02376205|DRUG|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
219661800|NCT02376205|DRUG|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
219661801|NCT06219018|DRUG|Medical grade honey formulation (MGH) (L-Mesitran®)|Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.
219661802|NCT03246061|DEVICE|Intracept System|BVN ablation using radiofrequency energy
219661803|NCT03246061|OTHER|Standard Care|Non-surgical standard care
219661804|NCT01937715|DRUG|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
219661805|NCT01937715|DRUG|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
218970375|NCT00667420|DRUG|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
218970376|NCT00312403|PROCEDURE|Blood Sample|A single venous blood sample will be taken (10 ml).
218970377|NCT03832244|DIAGNOSTIC_TEST|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
218970378|NCT02985203|DRUG|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
218970379|NCT01554969|DRUG|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
218970380|NCT00188708|PROCEDURE|hypoxia measurement|transrectal oxygen measurement
218970381|NCT03729973|DRUG|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
218970382|NCT03729973|DRUG|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
218970383|NCT03729973|DRUG|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
218970384|NCT03729973|DRUG|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
218970385|NCT01435317|DEVICE|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
218970386|NCT04405427|PROCEDURE|head acupoints acupuncture|The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
218970387|NCT04405427|PROCEDURE|body acupoints acupuncture|The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
218970388|NCT06666400|BEHAVIORAL|LHMoms Intervention|The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 12-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
218970389|NCT06666400|OTHER|No intervention|Standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
218970390|NCT04005989|BIOLOGICAL|Stromal Cells Injection|Adipose stromal cell
218970391|NCT03893331|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
218970392|NCT00983788|DRUG|Bezafibrate|3 x 200 mg/ day
218970393|NCT00983788|OTHER|Placebo|Placebo
219661806|NCT01937715|BIOLOGICAL|Bevacizumab|5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks
219661807|NCT01937715|DRUG|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
219661808|NCT01922856|BIOLOGICAL|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
219661809|NCT01922856|OTHER|No Intervention|Controls only receive challenge
218970394|NCT04732156|BIOLOGICAL|Blood sample|Measurement of PHI Index
218970395|NCT04732156|OTHER|Follow up questionnaire|3 years after inclusion
218970396|NCT04732156|DIAGNOSTIC_TEST|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
218970397|NCT02057627|BEHAVIORAL|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
219661810|NCT03331731|DRUG|pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
218970398|NCT02057627|BEHAVIORAL|Placebo Comparator|Standard care plus depression monitoring by phone
219661811|NCT05300659|OTHER|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
219661812|NCT03286660|DIAGNOSTIC_TEST|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise"
219661813|NCT01885663|PROCEDURE|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
219661814|NCT03341494|DRUG|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
219661815|NCT01760213|OTHER|CBT delivered via Internet|
219661816|NCT02020837|PROCEDURE|Lymphaticovenous Micro-Anastomosis|
219661817|NCT04421157|OTHER|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
219686479|NCT06866275|DRUG|Placebo|Dosing in the placebo group will consist of a volume of normal saline equivalent to that given during the active treatment period for each participant.
219686480|NCT05182411|OTHER|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
219686481|NCT00816777|PROCEDURE|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
219686482|NCT00816777|DRUG|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
218970399|NCT05671328|OTHER|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
218970400|NCT03967678|DIETARY_SUPPLEMENT|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
218970401|NCT05994560|OTHER|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
218970402|NCT01528215|DEVICE|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
218970403|NCT01528215|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
218970404|NCT01043510|DRUG|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
218970405|NCT01043510|DRUG|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
218970406|NCT05245253|RADIATION|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
218970407|NCT04793061|OTHER|blood sample collection|Blood is samples from peripheral vein during routine care
218970408|NCT00042367|DRUG|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
218970409|NCT00042367|DRUG|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
219686483|NCT04376515|BEHAVIORAL|HOPE intervention|Online peer support community of peers trained in behavior change science
219661818|NCT04421157|OTHER|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
219661819|NCT03986229|OTHER|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference."
219661820|NCT01822951|DRUG|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
219661821|NCT01822951|DRUG|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
219661822|NCT01048905|DRUG|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
219661823|NCT03790605|DRUG|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
219661824|NCT03790605|OTHER|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
219661825|NCT03790605|PROCEDURE|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
219661826|NCT00669851|DRUG|AI-700|
219661827|NCT06356818|OTHER|Conventional physiotherapy program|Physiotherapy and rehabilitation treatment program will be applied to the patients. In this program, a 30-40-minute exercise protocol covering proprioceptive, balance and strengthening exercises will be implemented. For a total of 12 sessions, 3 days a week, over a 4-week period
219661828|NCT06356818|OTHER|Virtual reality (VR)|virtual reality (VR) program will be applied using balance and strengthening games by Nintendo Wii Fit Plus; warm-up exercise (5 minutes), workout (20 minutes) and cool-down exercise (5 minutes) for a total of 30 minutes. For a total of 12 sessions, 3 days a week, over a 4-week period
219661829|NCT06356818|OTHER|Motor imagery (MI)|Patients will be introduced to explicit Motor imagery program which the content of the imagery program will last 20 minutes in total, with 5 minutes of relaxation and 15 minutes of imagery training. For a total of 12 sessions, 3 days a week, over a 4-week period.
218970410|NCT00042367|DRUG|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
218970411|NCT00042367|DRUG|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
219208335|NCT05197400|DIAGNOSTIC_TEST|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
219661830|NCT02106702|BEHAVIORAL|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
219661831|NCT02106702|BEHAVIORAL|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
219661832|NCT01492101|DRUG|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
219661833|NCT01492101|DRUG|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
219661834|NCT06386900|OTHER|Cyclist|Participating in the Grand Tour as cyclist
219661835|NCT05369689|OTHER|No interventions|As this is a prognosis evaluation study, there are no interventions.
219661836|NCT01055080|DIETARY_SUPPLEMENT|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
219064667|NCT04346758|PROCEDURE|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
219064668|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
219661837|NCT00770666|DRUG|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
219661838|NCT00770666|DRUG|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
219064669|NCT00001112|DRUG|Zidovudine|
219064670|NCT00001112|DRUG|Interferon gamma-1b|
219064671|NCT00925158|PROCEDURE|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
219064672|NCT02706158|DIETARY_SUPPLEMENT|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
219064673|NCT02706158|BEHAVIORAL|balanced diet|participants will get a balanced diet according to pregnancy stage
219661839|NCT01134289|PROCEDURE|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
219661840|NCT02114294|OTHER|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
219661841|NCT02114294|OTHER|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
219661842|NCT02114294|OTHER|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
219661843|NCT04219839|BEHAVIORAL|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
218970412|NCT00042367|DRUG|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
218970413|NCT00042367|DRUG|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1\."
218970414|NCT00042367|DRUG|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir."
218970415|NCT00042367|DRUG|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
218970416|NCT00042367|DRUG|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
219661844|NCT01652625|DRUG|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
219661845|NCT01652625|DRUG|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
219064674|NCT05219240|OTHER|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
219064675|NCT05224791|PROCEDURE|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
219064676|NCT05224791|PROCEDURE|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
219064677|NCT01233817|OTHER|Progressive strength training|the systematic increase in resistance weights
219064678|NCT02159482|DRUG|Interferon Alfa-2a|
219064679|NCT04121104|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
219064680|NCT04121104|OTHER|SCS is switched on|Spinal cord stimulator is on
218970417|NCT00042367|RADIATION|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
218970418|NCT03858231|DRUG|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
218970419|NCT03858231|DRUG|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
218970420|NCT03858231|DRUG|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
218970421|NCT01715714|DRUG|Statin Recapture Therapy|Given 12h and 2h before CABG
218970422|NCT01715714|DRUG|Placebo|Given 12h and 2h before CABG.
218970423|NCT01331941|DRUG|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
218970424|NCT01331941|DRUG|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
219064681|NCT05639738|OTHER|Clinical and instrumental measurements|"* Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations"
219064682|NCT00135954|DRUG|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
219064683|NCT04485962|BIOLOGICAL|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
219064684|NCT01513304|PROCEDURE|Manual therapy|
219064685|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
219064686|NCT03607448|DEVICE|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
219064687|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
219064688|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
218970425|NCT05553951|BEHAVIORAL|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
218970426|NCT05553951|BEHAVIORAL|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
219064689|NCT05053087|DRUG|Placebo|Saline filled catheter
219064690|NCT00235794|DRUG|temsirolimus|
219064691|NCT04388293|OTHER|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
219064692|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
219661846|NCT04501016|BEHAVIORAL|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
219661847|NCT04501016|DRUG|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
219661848|NCT04888858|DRUG|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
219661849|NCT00034918|DRUG|ZD6474|
219661850|NCT00235781|DRUG|Thymoglobulin|
219661851|NCT04895488|DRUG|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
219661852|NCT04895488|DRUG|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
219661853|NCT02435056|OTHER|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management"
219661854|NCT04657575|PROCEDURE|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
218970427|NCT00573365|DEVICE|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
219661855|NCT01200277|PROCEDURE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
219661856|NCT01200277|PROCEDURE|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
219661857|NCT00747253|DEVICE|AutoLITT system|laser treatment with the AutoLITT system
219661858|NCT06731751|OTHER|Management of spontaneous intracranial haemorrhage|Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
219661859|NCT05080361|DRUG|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
219661860|NCT04277767|DIAGNOSTIC_TEST|observational|No intervention
219661861|NCT02455973|BEHAVIORAL|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
219661862|NCT02455973|BEHAVIORAL|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
219661863|NCT00805519|DRUG|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
218970428|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
218970429|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
218970430|NCT01462227|DRUG|Naltrexone High Dose|Naltrexone 100mg for two administrations.
218970431|NCT01462227|DRUG|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
218970432|NCT01158703|DRUG|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
218970433|NCT01158703|DRUG|sugar pill|sugar pill by mouth daily for 12 months
218970434|NCT01158703|DRUG|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
218970435|NCT04165811|OTHER|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
218970436|NCT04165811|OTHER|Counselling|Only physical activity counseling will be given to the subjects in this group.
219661864|NCT00805519|DRUG|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
219661865|NCT00805519|DRUG|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
219661866|NCT00805519|DRUG|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
219661867|NCT04347655|PROCEDURE|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
218970437|NCT05045833|DRUG|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
219064693|NCT05870098|DIAGNOSTIC_TEST|All participants|"1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
219064694|NCT03356912|DRUG|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
219064695|NCT03356912|DRUG|Prednisone|Prednisone should be administred by oral route
219064696|NCT02127164|DEVICE|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
219064697|NCT04044677|DEVICE|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
219661868|NCT04655534|OTHER|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
219661869|NCT04655534|OTHER|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
219661870|NCT04655534|OTHER|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
219661871|NCT04103034|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
219661872|NCT04103034|DRUG|Desmopressin|Sterile solution for injection
218970438|NCT06065423|OTHER|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
218970439|NCT00606827|DRUG|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
219064698|NCT04044677|DEVICE|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
219064699|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
219064700|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
219064701|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
219064702|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
219064703|NCT00233935|OTHER|placebo|Given PO
219064704|NCT00233935|DRUG|defined green tea catechin extract|Given PO
219064705|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
219064706|NCT04000165|DRUG|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
219661873|NCT04103034|DRUG|Placebo|Sterile saline for injection
219661874|NCT05457114|DEVICE|Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)|PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
219661875|NCT05457114|DEVICE|FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)|Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
219661876|NCT00316914|DRUG|calcium gluconate|Given IV
219661877|NCT00316914|DRUG|magnesium sulfate|Given IV
219064707|NCT04071002|OTHER|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
219064708|NCT02024334|DRUG|Leflunomide|
219064709|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
219661878|NCT00316914|OTHER|placebo|Given IV
218970440|NCT00606827|DRUG|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
218970441|NCT03346044|DEVICE|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
218970442|NCT03346044|DEVICE|Medtronic Mosaic bioprostheses|
218970443|NCT03200665|DIAGNOSTIC_TEST|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
218970444|NCT00018070|PROCEDURE|Angiography|
218970445|NCT00018070|PROCEDURE|Laser Treatment|
219064710|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
219064711|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
219661879|NCT02687295|DIETARY_SUPPLEMENT|Thylakoids|
219661880|NCT02687295|OTHER|Control|
219661881|NCT01589679|OTHER|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
219661882|NCT01589679|DEVICE|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
219661883|NCT03038776|BIOLOGICAL|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
219661884|NCT04780633|BEHAVIORAL|Precede-Proceed based Training Program on Genital Hygiene Behaviors|A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.
219661885|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
219661886|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
219661887|NCT04035629|COMBINATION_PRODUCT|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
219661888|NCT04105010|DRUG|golidocitinib|golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions
219661889|NCT06944860|DEVICE|Conventional TBA|Conventional TBA fabricated with polymethylmethacrylate
219661890|NCT06944860|DEVICE|3D TBA|3D TBA made out of a 3D printing resin (Graphy TR07)
219661891|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
219661892|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
219661893|NCT04735471|GENETIC|ADI-001|Anti-CD20 CAR-T
219661894|NCT04735471|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
219661895|NCT04735471|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
219661896|NCT05279937|DRUG|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
218970446|NCT00440778|DRUG|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
219064712|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
219661897|NCT05279937|DRUG|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
218970447|NCT01500512|OTHER|Clinical Observation|Undergo observation
218970448|NCT03857906|DEVICE|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
218970449|NCT00291538|DRUG|bortezomib|
218970450|NCT03139695|DIAGNOSTIC_TEST|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
219064713|NCT01201525|PROCEDURE|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
219064714|NCT01201525|PROCEDURE|Control|Part 2 of the surgical scar will serve as a within patient control.
219064715|NCT03549689|DRUG|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
219064716|NCT03549689|DRUG|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
219064717|NCT00750789|DIETARY_SUPPLEMENT|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
219661898|NCT03701698|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.
219661899|NCT03701698|DRUG|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
219661900|NCT01675154|DRUG|SLx-4090 placebo|Given for 4 weeks
219661901|NCT01675154|DRUG|Orlistat Placebo|Given for 4 weeks
219661902|NCT01675154|DRUG|Orlistat|Given for 4 weeks
219661903|NCT01675154|DRUG|Slx-4090|Given for 4 weeks
219661904|NCT00541008|DRUG|sunitinib malate|
219661905|NCT06490172|DEVICE|Shock wave therapy|Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
219661906|NCT04202289|DEVICE|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
219661907|NCT04202289|DRUG|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
219064718|NCT00841867|PROCEDURE|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
219661908|NCT02210169|DRUG|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
219661909|NCT04268654|PROCEDURE|Preoperative Arterial Embolization|"PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized."
219661910|NCT00556738|PROCEDURE|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
219661911|NCT00556738|PROCEDURE|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
219661912|NCT00427999|DRUG|imatinib mesylate|
219661913|NCT00427999|DRUG|Treosulfane|
219661914|NCT00427999|DRUG|etoricoxib|
219661915|NCT00427999|DRUG|pioglitazone|
219661916|NCT00427999|DRUG|dexamethasone|
219661917|NCT03889938|DIAGNOSTIC_TEST|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
219661918|NCT02380859|BEHAVIORAL|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
219661919|NCT00098462|DRUG|gefitinib|
219064719|NCT04169841|DRUG|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
219661920|NCT00098462|DRUG|sirolimus|
219661921|NCT03767777|DEVICE|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
219661922|NCT06543719|OTHER|Simulated work in the heat|Participants perform a continuous heavy-intensity work bout (metabolic rate of \~260 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:1 work-rest allocation, starting with a 30 min rest break followed by a 30 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
219661923|NCT02284568|DRUG|Placebo|Placebo
219661924|NCT02284568|DRUG|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
219661925|NCT02284568|DRUG|Placebo|Placebo capsules
219661926|NCT05483101|OTHER|Alternative birth units|"Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room."
219661927|NCT02953587|PROCEDURE|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
219661928|NCT02953587|DRUG|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
219661929|NCT02953587|DRUG|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
219661930|NCT04738422|DRUG|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
219661931|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
219661932|NCT04643418|DRUG|MPB-1734|Administered once daily in a 21-day cycle
219661933|NCT02581228|DEVICE|ML-PrediCare|
219661934|NCT00641875|PROCEDURE|Nocturnal Hemodialysis|
219661935|NCT05167175|DRUG|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
219661936|NCT05167175|DRUG|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
219661937|NCT05167175|DRUG|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
219661938|NCT01685957|BEHAVIORAL|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
219661939|NCT01685957|BEHAVIORAL|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
219661940|NCT01685957|BEHAVIORAL|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
219661941|NCT02777944|BEHAVIORAL|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
219661942|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
219661943|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
219661944|NCT06016439|PROCEDURE|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
219661945|NCT06016439|DEVICE|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
219661946|NCT00697034|DRUG|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
219661947|NCT03905356|BEHAVIORAL|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
219661948|NCT03447652|OTHER|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
219661949|NCT03447652|OTHER|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
219661950|NCT03447652|OTHER|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
219661951|NCT06291740|DEVICE|continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
219661952|NCT06291740|DEVICE|Intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
219064720|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
219064721|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
219064722|NCT00383435|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
219064723|NCT00383435|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
219064724|NCT00383435|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
219064725|NCT01753193|BIOLOGICAL|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
219064726|NCT04792346|RADIATION|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
219064727|NCT05995912|DRUG|etoricoxib-tramadol|Oral administration (with or without food)
219064728|NCT05995912|DRUG|Naproxen|Oral administration (with or without food)
219064729|NCT05995912|DRUG|Tramadol|Oral administration (with or without food)
219661953|NCT01433744|PROCEDURE|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
219661954|NCT03129789|OTHER|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
219661955|NCT05808790|PROCEDURE|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
219661956|NCT05808790|RADIATION|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
219661957|NCT00849134|DRUG|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
219661958|NCT03853902|BEHAVIORAL|Mindfulness Program|Mindfulness Program
219661959|NCT01996657|DRUG|Warfarin|
219661960|NCT04240860|BIOLOGICAL|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
219661961|NCT04240860|PROCEDURE|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
219661962|NCT03000530|DRUG|SAGE-217|
219661963|NCT03000530|DRUG|Placebo|
219661964|NCT01018160|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
219661965|NCT04662294|BIOLOGICAL|CD70 CAR T-cells|Each subject receive CD70 CAR T-cells by intravenous infusion
219661966|NCT05414266|DRUG|Placebo|Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
219661967|NCT05414266|DRUG|SADBE 5%|SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
219064730|NCT06291272|DIETARY_SUPPLEMENT|Psyllium|15 g psyllium + 15 g inulin
219064731|NCT06291272|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose + 15 g inulin
219661968|NCT01281267|PROCEDURE|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
219661969|NCT05343104|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
219064732|NCT06291272|DIETARY_SUPPLEMENT|Inulin|15 inulin
219064733|NCT06291272|DIETARY_SUPPLEMENT|Maltodextrin|15 maltodextrin
219064734|NCT01131312|DEVICE|Thinprep|Pap test
219064735|NCT01131312|DEVICE|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
219064736|NCT01131312|PROCEDURE|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
219064737|NCT02682264|DRUG|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
219064738|NCT02934373|DEVICE|A New Sound Processor|
219064739|NCT01691300|OTHER|ACT PET/CT|Old tracer but new indication
219064740|NCT01601574|BEHAVIORAL|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
219661970|NCT00312572|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
219661971|NCT03195972|OTHER|Drug diary filling|patient will fill every day a drug diary
219064741|NCT01601574|OTHER|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
219661972|NCT02014922|DRUG|TheraTears® Lubricant Eye Drop|
219661973|NCT02014922|DRUG|TheraTears® preservative-free single-use containers|
219661974|NCT02014922|DIETARY_SUPPLEMENT|TheraTears® Nutrition|
219661975|NCT02014922|OTHER|TheraTears® TheraLid® Eyelid Cleanser|
219661976|NCT00601822|BEHAVIORAL|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
219661977|NCT00601822|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
219661978|NCT03012763|DRUG|Paracetamol|Oral administration of 250 mg paracetamol
219661979|NCT03012763|DRUG|Sulfasalazine|Oral administration of 50 mg sulfasalazine
219661980|NCT03012763|DRUG|Fexofenadine|Oral administration of 120 mg fexofenadine
219064742|NCT01155544|BEHAVIORAL|Behavioral Intervention|Preventing recurrence of substance use.
219064743|NCT00604981|BEHAVIORAL|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
219064744|NCT00604981|BEHAVIORAL|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
219064745|NCT00698568|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
219064746|NCT00698568|BIOLOGICAL|Placebo|Intramuscular injection, 3 doses
219064747|NCT05403541|DRUG|Batoclimab 680 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219064748|NCT05403541|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219064749|NCT05403541|DRUG|Matching Placebo SC|Placebo
219064750|NCT05403541|DRUG|Batoclimab 340 mg SC bi-weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219064751|NCT01278329|OTHER|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
219064752|NCT04939480|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenous solution
219064753|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
219064754|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
219064755|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
219064756|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
219064757|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
219661981|NCT03012763|DRUG|Valsartan|Oral administration of 40 mg valsartan
219064758|NCT04950699|GENETIC|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
219064759|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
219064760|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
219064761|NCT01985594|DRUG|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
219064762|NCT01985594|DRUG|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
219064763|NCT06636032|DRUG|AdMSC (CellReady®)|At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
219064764|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
219208336|NCT06863285|OTHER|Educational|"intervention included the usual counselling by pharmacist e.g. Patients Education regarding Medications~* Pharmacist counseling patients regarding their disease and severity~* Pharmacist counseling (5- to 10-minute sessions) on the proper and safe use of medication.~* Pharmacist counseling patients regarding the importance of their therapy (treatment), non-pharmacological treatment like diet and exercises.~pharmacist counselling regarding the preventive measures that prevent patient from triggers that can initiate asthmatic attacks."
219661982|NCT03012763|DEVICE|non-caloric water|Oral administration of 240 ml non-caloric water
219661983|NCT03012763|DEVICE|caloric drink|Oral administration of 240 ml caloric drink
219661984|NCT03012763|DEVICE|grapefruit juice|Oral administration of 240 ml grapefruit juice
219661985|NCT00997022|DRUG|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
219661986|NCT04825886|DEVICE|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
219661987|NCT02561663|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
219661988|NCT02561663|OTHER|Placebo|
219661989|NCT05476666|PROCEDURE|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
219661990|NCT03398863|PROCEDURE|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
219661991|NCT06206122|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219686484|NCT06624787|DEVICE|Rapid Diagnostic Test|The Liverpool School of Tropical Medicine (LSTM) in collaboration with Global Access Diagnostics (GADx) have achieved the development of the first RDT to detect CCHF viral antigens with a sensitivity and specificity that exceeds the minimum recommendation in the WHO target product profile (TPP)of \>80% and \>90% for sensitivity and specificity respectively for minimal performance in pre-clinical studies. The RDT is not only faster providing a test result within 20 minutes, but is also substantially cheaper than RT-PCR, and simpler to perform. A predicted price per test of around $5, whereas the current price of the RT-PCR test ranges from $1,000 to $1,200 for 96 reactions. The RDT does not require refrigeration or require specialist personnel to undertake, and the only additional apparatus needed is a stopwatch to monitor running time.
218970451|NCT05753631|PROCEDURE|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
218970452|NCT00413166|DRUG|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
218970453|NCT00413166|DRUG|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
219208337|NCT06734182|DRUG|Envafolimab injections+intravenous Disitamab Vedotin+carboplatin|Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
218970454|NCT00413166|DRUG|Idarubicin|"1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
218970455|NCT00413166|DRUG|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
218970456|NCT04490811|OTHER|no intervention. observational cohort study|blood sampling is part of care
218970457|NCT03469050|DRUG|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
218970458|NCT03469050|OTHER|Placebo|Placebo BID + Placebo BID
218970459|NCT05403333|DRUG|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
218970460|NCT01061983|DEVICE|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
218970461|NCT03965208|DRUG|Bivalirudin|titrated continuous infusion
218970462|NCT03965208|DRUG|Unfractionated heparin|titrated continuous infusion
218970463|NCT04702854|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
218970464|NCT00130676|DRUG|Mifepristone|daily for 7 days
218970465|NCT00130676|DRUG|matching placebo|daily for 7 days
218970466|NCT06102915|DRUG|Rocuronium Bromide 10 MG/ML|Comparative
218970467|NCT06102915|DRUG|Nimbex 10 MG in 5 ML Injection|Comparative
218970468|NCT02730338|BEHAVIORAL|High intensity aerobic and resistance training|
219208338|NCT06735365|OTHER|CRRT|Hemodiafiltration
219208339|NCT06747312|DRUG|Belimumab+SOC|10mg/kg once a month for 18 months
219661992|NCT06206122|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219661993|NCT06206122|BEHAVIORAL|Comprehensive rehabilitation training|"1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219661994|NCT00295516|PROCEDURE|Fetal Middle Cerebral Artery Doppler measurement|
219661995|NCT05200117|DEVICE|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
219661996|NCT05104424|DRUG|Insulin aspart|intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
219661997|NCT05140616|DRUG|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
219661998|NCT04916314|BEHAVIORAL|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
219661999|NCT03493022|OTHER|Test Granola|50.5 Test Granola
219662000|NCT03493022|OTHER|Control Granola|54.3 Control Granola
219662001|NCT06400407|DEVICE|Continuous Theta-burst Stimulation|Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.
219662002|NCT06400407|DEVICE|Sham stimulation|A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
219662003|NCT04753268|BEHAVIORAL|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
218970469|NCT02730338|BEHAVIORAL|Psychosocial support|
218970470|NCT06644118|BIOLOGICAL|OL-101 infusion|OL-101 infusion will be administered to patients via IV infusion at the assigned dose.
218970471|NCT00458068|DRUG|Oral administration of ferrous sulphate|
219662004|NCT01577719|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
219662005|NCT01577719|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
219662006|NCT02614131|DRUG|LY2599666|Administered SC
219662007|NCT02614131|DRUG|Solanezumab|Administered IV
219662008|NCT02614131|DRUG|Placebo SC|Administered SC
219662009|NCT02614131|DRUG|Placebo IV|Administered IV
219662010|NCT00655512|DRUG|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
219662011|NCT00655512|DRUG|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
219662012|NCT00655512|DRUG|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
219662013|NCT00655512|DRUG|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
219662014|NCT00655512|DRUG|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
219662015|NCT03080584|OTHER|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
219662016|NCT01562249|OTHER|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
219662017|NCT01562249|OTHER|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
219662018|NCT01562249|OTHER|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
219662019|NCT05901584|DRUG|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
219662020|NCT04240275|DEVICE|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
219662021|NCT05721638|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
219662022|NCT00354042|DRUG|GW597901X|
219208340|NCT06747312|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
219662023|NCT04665518|OTHER|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
219662024|NCT00798018|DRUG|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
219064765|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
219064766|NCT06636552|DRUG|Daratumumab (Subcutaneously)|"D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1"
219662025|NCT00798018|DRUG|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
219662026|NCT00798018|DRUG|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
219662027|NCT00798018|DRUG|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
219662028|NCT00840242|DRUG|Nicotine gum|8-12 pieces per day, maximum 24 daily
219662029|NCT00840242|DRUG|Placebo gum|8-12 pieces per day, maximum 24 daily
219662030|NCT00840242|DRUG|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
219662031|NCT00840242|DRUG|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
219662032|NCT04523870|DIETARY_SUPPLEMENT|Botanical extract|One capsule
219662033|NCT04523870|DIETARY_SUPPLEMENT|Main compound of the botanical extract|one capsule
219662034|NCT04523870|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, one capsule
219662035|NCT03888183|DRUG|salt solution without 0.15% HA|received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
219662036|NCT03888183|DRUG|preservative-free 0.15% HA|received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
219662037|NCT01285492|DRUG|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
219662038|NCT01285492|DRUG|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
219662039|NCT06112678|DRUG|CKD-348(6)|QD, PO
219662040|NCT06112678|DRUG|CKD-828, D097, D337|QD, PO
219662041|NCT03365453|OTHER|frailty evaluation|frailty and comorbidity scores
219662042|NCT01797094|BIOLOGICAL|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
219662043|NCT01797094|BIOLOGICAL|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
219662044|NCT03798392|DEVICE|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
219662045|NCT03798392|DEVICE|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
219662046|NCT00899613|OTHER|laboratory biomarker analysis|
219662047|NCT00899613|PROCEDURE|study of high risk factors|
219662048|NCT04373564|PROCEDURE|Motor Tests|To assess motor function annually
219662049|NCT04373564|PROCEDURE|Cognitive Tests|To assess cognitive function annually
219662050|NCT04373564|PROCEDURE|Unenhanced-MRI of the brain|The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
219662051|NCT04373564|PROCEDURE|Gadolinium Measurements|Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
219662052|NCT04373564|DRUG|Gadoxetate disodium|Administered as defined by the treating physician as part of routine clinical practice
219662053|NCT04373564|DRUG|Gadobenate dimeglumine|Administered as defined by the treating physician as part of routine clinical practice
219662054|NCT04373564|DRUG|Gadodiamide|Administered as defined by the treating physician as part of routine clinical practice
219662055|NCT04373564|DRUG|Gadoterate meglumine|Administered as defined by the treating physician as part of routine clinical practice
219662056|NCT04373564|DRUG|Gadobutrol|Administered as defined by the treating physician as part of routine clinical practice
219662057|NCT04373564|DRUG|Gadoteridol|Administered as defined by the treating physician as part of routine clinical practice
219662058|NCT05640388|OTHER|RV3278A - ET0943 cosmetic product|RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
219662059|NCT05640388|OTHER|RV4632A - RY1845 cosmetic product|RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
219662060|NCT00310076|DRUG|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
219662061|NCT00310076|PROCEDURE|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
219662062|NCT04591457|DRUG|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
219662063|NCT04591457|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
219662064|NCT03942926|DRUG|Sirolimus|Patients will receive sirolimus for 6 months.
219662065|NCT02203162|DEVICE|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
219662066|NCT05262166|DRUG|INTRATHECAL dexmedetomidine INJECTION|intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
219662067|NCT00630591|BEHAVIORAL|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
219662068|NCT00630591|BEHAVIORAL|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
219662069|NCT00630591|BEHAVIORAL|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
219662070|NCT05020704|DRUG|Empagliflozin 10 MG|SGLT2inhibitor
219662071|NCT05020704|DRUG|Placebo|Matched placebo
219662072|NCT03217968|DEVICE|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
219662073|NCT00625404|DRUG|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
219662074|NCT00625404|OTHER|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
219662075|NCT00886925|DRUG|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
219662076|NCT00886925|DRUG|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
219662077|NCT05590117|DRUG|Pentoxifylline|Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily
219662078|NCT05590117|DRUG|Placebo|placebo tablets
219662079|NCT05590117|DRUG|FOLFOX-6 regimen|12 cycles of FOLFOX-6 regimen
219662080|NCT01655134|OTHER|Blood simples|
219662081|NCT01655134|OTHER|Capillary punction|
219662082|NCT01655134|OTHER|Urine simples|
219662083|NCT06415396|OTHER|Complete Decongestive Therapy|conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.
219662084|NCT06415396|DEVICE|ESWT|ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .
219662085|NCT06415396|DEVICE|LLLT|In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
219662086|NCT06011096|OTHER|skin-to-skin contact and delayed cord clamping|Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
219662087|NCT06011096|OTHER|avoiding skin-to-skin contact and early cord clamping|After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
219662088|NCT03326752|DRUG|DV281|\- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
219662089|NCT03326752|DEVICE|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
219662090|NCT03326752|DRUG|DV281 (RP2D)|\- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
219662091|NCT03326752|DRUG|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
219662092|NCT02447575|OTHER|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
219662093|NCT04387799|DIAGNOSTIC_TEST|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
219662094|NCT05045404|DRUG|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
219662095|NCT05045404|BIOLOGICAL|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
219662096|NCT04622072|DRUG|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
219662097|NCT02407587|DEVICE|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
219662098|NCT00895570|DRUG|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
219662099|NCT00895570|DRUG|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
219662100|NCT00580749|PROCEDURE|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
219662101|NCT00580749|PROCEDURE|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
219662102|NCT00220948|PROCEDURE|CERSR Myoelectric monitoring during standardized tasks|
219662103|NCT04183569|OTHER|Sequencing RNA.|RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
219662104|NCT02488967|DRUG|Carboplatin|Given IV
218970472|NCT00972088|DEVICE|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
219662105|NCT02488967|DRUG|Cyclophosphamide|Given IV
219662106|NCT02488967|DRUG|Doxorubicin Hydrochloride|Given IV
219662107|NCT02488967|OTHER|Laboratory Biomarker Analysis|Correlative studies
219662108|NCT02488967|DRUG|Paclitaxel|Given IV
219662109|NCT01538394|DRUG|Varenicline|
219662110|NCT01538394|DRUG|Nicotine patches|
219662111|NCT01538394|DRUG|Placebo (nicotine patches)|
219662112|NCT04686812|BEHAVIORAL|Worksite health promotion program|Physical activity, nutrition, and stress management programs
218970473|NCT03925064|OTHER|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
219662113|NCT05664451|BEHAVIORAL|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
219662114|NCT05664451|OTHER|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
219662115|NCT02094950|PROCEDURE|Acupuncture|
219662116|NCT03489902|PROCEDURE|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
218970474|NCT02595996|DRUG|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
219662117|NCT03489902|PROCEDURE|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
219662118|NCT03486964|DRUG|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
219662119|NCT00191802|DRUG|teriparatide|
219662120|NCT02366403|BEHAVIORAL|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
219662121|NCT02366403|BEHAVIORAL|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
219662122|NCT02408952|BEHAVIORAL|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
219662123|NCT02408952|BEHAVIORAL|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
219064767|NCT06635278|BEHAVIORAL|Mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by a study researcher based on the Smith's (2005) protocol.~The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Meditation of the body (Body sense meditation)~* Meditation of the body (Rocking meditation)~* Meditation of the body (Breathing meditation)~* Meditation of mind (Mentra meditation)~* Meditation of mind (visual Image)~* Meditation of sense (External image)~* Meditation of the senses (A sound)~* Open monitoring (Mindfulness)"
219064768|NCT03343262|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
218970475|NCT01858584|DRUG|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
219064769|NCT03343262|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
219662124|NCT00520052|DRUG|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
219662125|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
219662126|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
219662127|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
219064770|NCT03539562|DRUG|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
219662128|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
219662129|NCT02830932|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
219064771|NCT02078323|DRUG|Linaclotide|
219064772|NCT02078323|DRUG|Placebo|
219064773|NCT01314651|BEHAVIORAL|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
219064774|NCT01314651|BEHAVIORAL|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
219064775|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
219064776|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
219064777|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
219064778|NCT06184698|DRUG|liposomal irinotecan|liposomal irinotecan 70 mg/m²
219064779|NCT06184698|DRUG|5-FU|5-FU 2400 mg/m²
219064780|NCT06184698|DRUG|LV|5-FU 2400 mg/m²
219064781|NCT06184698|DRUG|Bevacizumab|bevacizumab 5 mg/kg
219064782|NCT02610062|DRUG|AGS67E|Intravenous (IV) infusion
219064783|NCT05787418|DRUG|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
219064784|NCT05787418|DRUG|Placebo|Placebo 8 times per day for 7 consecutive days
219064785|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
219064786|NCT05659602|BIOLOGICAL|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
219064787|NCT05724186|DEVICE|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
219064788|NCT03447769|DRUG|Canakinumab|200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
219662130|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
219662131|NCT01438385|PROCEDURE|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
219662132|NCT01887678|DRUG|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
219662133|NCT01887678|DRUG|Placebo|Placebo is an injection of Saline
219662134|NCT02702232|OTHER|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
219662135|NCT03013985|DRUG|Glargine U300|Glargine U300 is a new generation long-acting insulin.
219662136|NCT03013985|DRUG|Glargine U100|Glargine U100 is a long-acting insulin.
219662137|NCT03013985|DRUG|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
219662138|NCT02456961|PROCEDURE|iontophoresis of riboflavin|
219662139|NCT02456961|PROCEDURE|epithelium-off|
219662140|NCT02456961|PROCEDURE|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
219662141|NCT02456961|DEVICE|galvanizator, Potok-1|Device for providing iontophoresis procedure
219662142|NCT02456961|DRUG|Dextralink|Riboflavin 0,1% + Dextran T-500
219662143|NCT02456961|DRUG|Riboflavin 0,1%|
219662144|NCT02456961|DEVICE|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
219662145|NCT00099177|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
219662146|NCT00099177|DRUG|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
219662147|NCT01714856|DRUG|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
219662148|NCT05288933|DEVICE|Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound|"Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects."
219662149|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|"* individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks"
219662150|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|\- placebo treatment: sham coil
219662151|NCT04509817|DEVICE|Acupuncture+Usual care|"Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise."
219662152|NCT04509817|BEHAVIORAL|Usual care|Usual care intervention The subjects will receive the health advice
219662153|NCT06526325|DEVICE|Enhanced golgi tendon organ stimulation|Enhanced Golgi Tendon Organ Stimulation is a method that can be used by physiotherapists and doctors. The Golgi tendon organ is the proprioceptors located in the tendon adjacent to the myotendinous junction. It is applied using two separate heads, the stimulator and the algometer. The sternocleidomastoideus, platysma, colli longus, capitis longus, scalene, rhomboid major and minor, levator scapulae and trapezius muscles and their tendons will be vibrated with a stimulator for 30 seconds, then 0.5 kilograms of pressure will be applied with an algometer from the origin to the insertion of the muscle in the region at 0.5 centimetre intervals at an angle of 90 degrees.
219662154|NCT01041677|DRUG|R256918|10 mg capsule twice daily
219662155|NCT01041677|DRUG|placebo|placebo capsule twice daily
219662156|NCT01041677|DRUG|R256918|15 mg capsule twice daily
219662157|NCT03556397|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
219662158|NCT03556397|PROCEDURE|Axillary dissection|Axillary dissection procedure will be performed in the patients
219662159|NCT01044589|DEVICE|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
219662160|NCT01044589|OTHER|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
219662161|NCT00791492|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
218970476|NCT01858584|DIETARY_SUPPLEMENT|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
218970477|NCT00895856|OTHER|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
218970478|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
219662162|NCT00927225|DRUG|ropivacaine 0.2%, 50 mL|
219662163|NCT00927225|DRUG|normal saline|
219662164|NCT05635500|PROCEDURE|Different Approach to endotracheal intubation.|Different insertion way.
219662165|NCT01465256|DRUG|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
219662166|NCT02322333|DRUG|MLD10|
219662167|NCT02322333|DRUG|Placebo|
219662168|NCT01017757|PROCEDURE|High-resolution CT scanning|High-resolution CT scanning
219662169|NCT06620419|DEVICE|Perineal-applied electrical stimulation|Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
219662170|NCT04844905|DRUG|Ivermectin|Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.
219662171|NCT04844905|DRUG|Placebo|Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
218970479|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
218970480|NCT00880165|DEVICE|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
218970481|NCT06252714|DEVICE|Defecation Posture Modification Device|Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
218970482|NCT03010761|DRUG|escitalopram|antidepressant use for the betel-quid abstinence
218970483|NCT03010761|DRUG|Moclobemide|antidepressant use for the betel-quid abstinence
218970484|NCT03010761|DRUG|Placebo - Cap|Placebo - Cap
218970485|NCT05250752|DRUG|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
218970486|NCT02459652|DRUG|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
218970487|NCT02459652|RADIATION|Radiation Therapy|Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
218970488|NCT05899010|DRUG|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
219064789|NCT03447769|DRUG|Placebo|Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
219064790|NCT05778305|DRUG|Dexmedetomidine|a central sympatholytic drug
219064791|NCT05778305|OTHER|normal saline|saline is given to control group
219208341|NCT05821283|PROCEDURE|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
218985548|NCT00506337|DRUG|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
218985549|NCT03867344|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
219064792|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
219064793|NCT04040985|PROCEDURE|Total Knee Arthroplasty using LEGION™ Total Knee System|Primary Total Knee Arthroscopy using LEGION™ Total Knee System
219064794|NCT03518177|OTHER|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
219662172|NCT04844905|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
219662173|NCT06618677|OTHER|LOW FODMAPs Diet|patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
219662174|NCT01115556|DRUG|Ranibizumab|2.0 mg
219662175|NCT01115556|DRUG|Ranibizumab|0.5 mg
219662176|NCT02648477|DRUG|Anastrozole|Given PO
219662177|NCT02648477|DRUG|Doxorubicin Hydrochloride|Given IV
219662178|NCT02648477|DRUG|Exemestane|Given PO
219662179|NCT02648477|OTHER|Laboratory Biomarker Analysis|Correlative studies
219662180|NCT02648477|DRUG|Letrozole|Given PO
219662181|NCT02648477|BIOLOGICAL|Pembrolizumab|Given IV
219662182|NCT02137109|DRUG|natalizumab|Administered as specified in the treatment arm.
219662183|NCT00713661|DRUG|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
219662184|NCT02119221|DRUG|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]
219662185|NCT00739505|BIOLOGICAL|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
219662186|NCT00739505|BIOLOGICAL|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
219662187|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
219662188|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
219662189|NCT06619431|DEVICE|Mobile Application|"Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies."
219662190|NCT02983435|OTHER|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
219662191|NCT02983435|OTHER|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
219662192|NCT04182568|DRUG|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
218970489|NCT05899010|DRUG|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
219662193|NCT04182568|DRUG|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
219662194|NCT03161626|DRUG|Coagadex|Plasma-driven blood coagulation factor X concentration
219662195|NCT02762552|DEVICE|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
219662196|NCT03799406|DRUG|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
219662197|NCT03799406|OTHER|Placebo|Placebo supplementation during acute episode of bronchiolitis
219662198|NCT03490396|DEVICE|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
219662199|NCT03490396|COMBINATION_PRODUCT|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
219662200|NCT06451328|DRUG|Lignosus rhinoceros TM02®|Lignosus rhinoceros TM02®
219662201|NCT06098417|DIAGNOSTIC_TEST|Plasma Test|IGF-2 (insulin-like growth factor 2)
219662202|NCT06098417|DIAGNOSTIC_TEST|Plasma test|SPARC (secreted protein acidic and rich in cysteine)
219662203|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EPICAN (heparan sulfate proteoglycan)
219662204|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EGFR (epidermal growth factor receptor)
219662205|NCT06098417|DIAGNOSTIC_TEST|Liver biopsy|Fibrosis and steatosis grade according to Brunt-Kleiner classification
219662206|NCT06098417|DIAGNOSTIC_TEST|Visceral adipose tissue biopsy|Presence of inflammation
219662207|NCT06098417|DIAGNOSTIC_TEST|Liver elastography|Grade of fibrosis according to Hamaguchi score
219662208|NCT06098417|DIAGNOSTIC_TEST|Blood test|Determination of surrogate based diagnostic tests/scores for liver fibrosis
219662209|NCT04986943|DEVICE|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
219662210|NCT02550704|PROCEDURE|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
219662211|NCT01097070|DRUG|Bevirimat|
219662212|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
219662213|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
219662214|NCT00719914|DRUG|normal saline|Intra-coronary injection, weight based, of normal saline.
219662215|NCT03533881|DIETARY_SUPPLEMENT|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
219662216|NCT03533881|BEHAVIORAL|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
219662217|NCT02046772|DRUG|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
219662218|NCT02046772|DRUG|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
219662219|NCT02046772|DRUG|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
219662220|NCT06045442|BEHAVIORAL|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
219662221|NCT06045442|BEHAVIORAL|Control|Usual care
219662222|NCT01367600|DRUG|SC Methylnaltrexone (MNTX)|
218970490|NCT01184131|OTHER|Mentor Training|Four 2 hour sessions of Mentor Training
219662223|NCT01162148|BEHAVIORAL|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
219662224|NCT01162148|DEVICE|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
219662225|NCT01162148|DEVICE|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
219662226|NCT01162148|DEVICE|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
219662227|NCT03333408|DRUG|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
219662228|NCT03600012|OTHER|Cycling Functional Electrical Stimulation|
219662229|NCT03600012|OTHER|Physiotherapy|
219662230|NCT01889121|BEHAVIORAL|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
219662231|NCT05656703|DEVICE|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
219662232|NCT05656703|OTHER|Standard of Care|Anesthesia is administered as usual
218970491|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
218970492|NCT00667602|BIOLOGICAL|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
219662233|NCT02018354|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
219662234|NCT02018354|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
218970493|NCT00667602|BIOLOGICAL|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
218970494|NCT00667602|BIOLOGICAL|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
218970495|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
218970496|NCT05961644|DRUG|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
219662235|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
219662236|NCT02150070|DRUG|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
219662237|NCT02150070|DRUG|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
219662238|NCT00004809|PROCEDURE|gene therapy|
219662239|NCT04962828|OTHER|Vocabulary based intervention- Non Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP
219662240|NCT04962828|OTHER|Vocabulary based intervention - Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
218970497|NCT05961644|DRUG|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
218970498|NCT05221827|DIAGNOSTIC_TEST|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
218970499|NCT01594385|BIOLOGICAL|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
218970500|NCT06484673|DRUG|Bosentan Dispersible Tablets|1 tablet of 32 mg Bosentan
218970501|NCT06484673|DRUG|Tracleer Tablet for Oral Suspension|1 tablet of 32 mg Bosentan
218970502|NCT00285467|DRUG|doxercalciferol|form of vitamin D that is already in active form.
218970503|NCT00285467|DRUG|Cholecalciferol|from of vitamin D that requires cells in the body to make active
219662241|NCT05032456|DEVICE|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
219662242|NCT06055998|DEVICE|MRI|MRI SPINE
219662243|NCT02733198|OTHER|Prognosis-guided therapy|
219662244|NCT01180556|DIETARY_SUPPLEMENT|Probiotics|Daily oral supplementation for four weeks
219662245|NCT01180556|DIETARY_SUPPLEMENT|Placebo|Placebo administration
219662246|NCT04477733|DRUG|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
219662247|NCT04477733|DRUG|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
219662248|NCT00206089|DRUG|EXANTA|
219662249|NCT01564641|DEVICE|iDuo G2|single comparator
219662250|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
218970504|NCT02698059|DEVICE|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
218970505|NCT06336759|DEVICE|Restylane Defyne|Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.
219662251|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
219662252|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
219662253|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
219662254|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
219662255|NCT00678470|DRUG|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
219662256|NCT00314132|BIOLOGICAL|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
218970506|NCT06336759|DEVICE|Restylane Lyft|Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.
219662257|NCT00314132|BIOLOGICAL|0.9% Saline|0.5 mL, Subcutaneous
219662258|NCT03383952|BIOLOGICAL|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
219662259|NCT03108937|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
219662260|NCT03108937|DRUG|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
219662261|NCT02461797|OTHER|healthy controls|biopsy of nasal mucosa for healthy controls
219662262|NCT02461797|OTHER|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
219662263|NCT02461797|OTHER|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
219662264|NCT03583905|DRUG|CKD-330|CKD-330 Tab.
219662265|NCT03583905|DRUG|Placebo of CKD-330|Placebo of CKD-330 Tab.
219662266|NCT03583905|DRUG|D086|D086 Tab.
219662267|NCT03583905|DRUG|Placebo of D086|Placebo of D086 Tab.
219662268|NCT03583905|DRUG|D723|D723 Tab.
219662269|NCT03583905|DRUG|Placebo of D723|Placebo of D723 Tab.
219662270|NCT00968097|DRUG|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
219662271|NCT00428922|DRUG|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
219662272|NCT00428922|DRUG|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
219662273|NCT00428922|DRUG|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
219662274|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
219662275|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
219662276|NCT03131934|PROCEDURE|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
219662277|NCT01380691|DRUG|LY2216684|Administered orally
219662278|NCT01380691|DRUG|Placebo-matching LY2216684|Administered orally
218970507|NCT00052780|DRUG|O6-benzylguanine|Given IV
218970508|NCT00052780|DRUG|temozolomide|Given PO
219662279|NCT01380691|DRUG|Placebo-matching alcoholic beverage|Administered orally
218970509|NCT00052780|BIOLOGICAL|filgrastim|Given SC or IV
219662280|NCT01380691|DRUG|Alcoholic beverage|Administered orally
219662281|NCT03996226|DRUG|E7386|E7386 oral tablets.
219662282|NCT05475626|PROCEDURE|Arthroereisis-|Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
219662283|NCT03930784|OTHER|Nil intervention|
219662284|NCT00815334|PROCEDURE|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
218970510|NCT00052780|OTHER|pharmacological study|Correlative studies
218970511|NCT00052780|OTHER|laboratory biomarker analysis|Correlative studies
218970512|NCT06229639|DEVICE|Passy Muir Valve|
218970513|NCT06229639|DEVICE|Tracheostomy Plug|
218970514|NCT03827837|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
219662285|NCT02247232|DRUG|Z-100|
219662286|NCT02247232|DRUG|Placebo|
219686485|NCT05223322|BEHAVIORAL|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
219686486|NCT06332612|DRUG|Metformin Hydrochloride|Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
219662287|NCT05360914|OTHER|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
219662288|NCT05360914|OTHER|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
219662289|NCT03151213|DRUG|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
219662290|NCT03151213|OTHER|Placebo|Placebo before RFA of liver cancer
219662291|NCT05269589|OTHER|Thermoneutral water|Participants will immerse their feet in a foot bath that contains thermoneutral water
219662292|NCT05269589|OTHER|Hot water|Participants will immerse their feet in a foot bath that contains hot water
219662293|NCT02811575|OTHER|Biopsy|Ileon and colon biopsy
219662294|NCT00571025|BEHAVIORAL|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
219662295|NCT05972941|BEHAVIORAL|Health communications|Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
219662296|NCT05636787|DRUG|Treosulfan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
219662297|NCT05636787|DRUG|Melphalan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
219662298|NCT01060605|DRUG|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
219662299|NCT01987232|DRUG|Carfilzomib|Administered by intravenous infusion.
219662300|NCT01987232|DRUG|Carboplatin|Administered by intravenous infusion.
219662301|NCT01987232|DRUG|Etoposide|Administered by intravenous infusion.
219662302|NCT06204406|OTHER|Observational|This is a prospective observational study with observation only and no intervention
218970515|NCT03827837|DRUG|Famitinib|a small-molecule multikinase inhibitor
218970516|NCT05578703|PROCEDURE|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
218970517|NCT05578703|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
218970518|NCT05578703|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
218970519|NCT00503295|BIOLOGICAL|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
219208342|NCT05821283|PROCEDURE|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
219662303|NCT00586508|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
219662304|NCT00586508|DRUG|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
218970520|NCT06561126|BEHAVIORAL|Participatory, Learning and Action Based Intervention|The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
219662305|NCT00586508|DRUG|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
219662306|NCT00586508|DRUG|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
219662307|NCT06465914|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
219662308|NCT06465914|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
219662309|NCT00051181|DRUG|Travoprost (0.004%)|
219662310|NCT00051181|DRUG|Latanoprost (0.005%)|
218970521|NCT05293964|DRUG|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
218970522|NCT05293964|DRUG|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
218970523|NCT05293964|DRUG|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
218970524|NCT05076071|GENETIC|NGS|Next Generation Sequencing
218970525|NCT06554821|DRUG|Rosuvastatin|Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
218970526|NCT06554821|DRUG|Ticagrelor|Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
218970527|NCT00973349|BIOLOGICAL|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
219662311|NCT04311281|BIOLOGICAL|[F-18]FDDNP-PET|\[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
219686487|NCT06332612|DRUG|betamethasone dipropionate|Group 1will recieve topical cream betamethasone thrice daily
219686488|NCT06332612|DRUG|Pentoxifylline|Group 1 will receive Pentoxifylline tablet 400 mg twice daily
219662312|NCT04904783|RADIATION|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
219662313|NCT02928146|PROCEDURE|Hernia Repair|
219662314|NCT00367419|DRUG|Erythromycin|
219662315|NCT00758147|DEVICE|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
219662316|NCT06731660|OTHER|Education with personalized performance feedback|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email
219662317|NCT06731660|DEVICE|Use of digital otoscope|Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
219662318|NCT00235066|DEVICE|PCI|PCI with Cypher Sirolimus-Eluting Stent
219662319|NCT06731361|COMBINATION_PRODUCT|Systematic multidisciplinary medication review + ACP (SMMR+)|"The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components:~1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy)~2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations.~Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned."
219662320|NCT05727306|OTHER|No intervention|Observational analysis of usual care only.
219662321|NCT06358729|BEHAVIORAL|Typical Nipple|Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
219662322|NCT06358729|BEHAVIORAL|Challenging Nipple|Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
219662323|NCT00885742|BIOLOGICAL|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023\_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
219662324|NCT02643797|BEHAVIORAL|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
219662325|NCT04430023|OTHER|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
219662326|NCT01067261|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
219662327|NCT01067261|OTHER|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
219662328|NCT06260046|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
219662329|NCT06260046|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
219662330|NCT02200237|BIOLOGICAL|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
219662331|NCT02200237|BIOLOGICAL|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
219662332|NCT02014220|OTHER|dietary treatment|
219662333|NCT01765244|DRUG|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
219662334|NCT01765244|OTHER|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
219662335|NCT05893004|DIAGNOSTIC_TEST|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
219662336|NCT01426464|DRUG|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
219662337|NCT04000698|DRUG|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
219662338|NCT05153148|DRUG|NDI-034858|NDI-034858 oral capsule
219662339|NCT05153148|OTHER|Placebo|NDI-034858-matching oral placebo capsule
219662340|NCT05137847|DRUG|Remitoro|Intravenous infusion.
219662341|NCT03357133|DRUG|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
219662342|NCT03357133|DRUG|Alteplase|Only alteplase intravenous thrombolysis
219662343|NCT01732471|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
219662344|NCT00232596|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
219662345|NCT00232596|DRUG|Placebo|Oral tablet.
219662346|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
219662347|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
219662348|NCT03668717|DEVICE|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
219662349|NCT01953432|DRUG|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
219662350|NCT01953432|DRUG|Placebo|Matched placebo daily dosing
219662351|NCT01253174|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
219662352|NCT01253174|DRUG|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
219662353|NCT01253174|DRUG|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
219662354|NCT06439589|DRUG|HRS2398|HRS2398: Tablets, 40mg/tablet, oral
219662355|NCT06439589|DRUG|Adebrelimab|Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion
219662356|NCT02244346|DRUG|Secotex®|
219662357|NCT02106663|PROCEDURE|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
219662358|NCT02106663|PROCEDURE|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
218970528|NCT02301988|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
218970529|NCT02301988|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
218970530|NCT02301988|DRUG|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
218970531|NCT00920205|DRUG|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
219662359|NCT04535050|DEVICE|Renal denervation|Renal Denervation: DENEX system
218970532|NCT04178473|PROCEDURE|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
218970533|NCT04178473|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
218970534|NCT06033716|OTHER|Measurement correlation variable|resilience and anxiety and depression
218985550|NCT03867344|OTHER|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
219662360|NCT04535050|PROCEDURE|Renal angiography|Renal angiography
219662361|NCT03426436|DIAGNOSTIC_TEST|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
219662362|NCT02123836|BIOLOGICAL|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
219686489|NCT06450457|DEVICE|Polar H10 heart rate monitor|Heart rate will be monitored using a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention.
219686490|NCT06450457|DEVICE|Therastride Treadmill System|Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.
219064795|NCT03518177|OTHER|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
219064796|NCT05462626|BEHAVIORAL|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
219064797|NCT04429490|OTHER|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
219662363|NCT02267135|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
219662364|NCT02267135|BIOLOGICAL|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
219662365|NCT02522013|DRUG|Aminophylline|
219662366|NCT02522013|DRUG|isotonic saline|
219662367|NCT02892513|DEVICE|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.
219662368|NCT02892513|DEVICE|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
219662369|NCT06486649|DIAGNOSTIC_TEST|Multimodal Large Language Model Diagnosis|Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.
219662370|NCT06486649|DIAGNOSTIC_TEST|Routine diagnostic and therapeutic procedure|Routine diagnostic and therapeutic procedure
219662371|NCT03273400|OTHER|Lumbar Mobilisations|Please see arm (intervention) description
219662372|NCT04367493|DIETARY_SUPPLEMENT|Chocolate|25 g of chocolate by day for 4 weeks
219662373|NCT06003907|OTHER|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
219662374|NCT06003907|OTHER|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
219662375|NCT06618209|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH
219662376|NCT06618209|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase
219662377|NCT06618209|DIAGNOSTIC_TEST|Oral Findings|DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion
219662378|NCT06618209|DIAGNOSTIC_TEST|Pediatric Oral Health Quality of Life|The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.
219662379|NCT06107907|DEVICE|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
219662380|NCT04398654|DEVICE|CardioMEMSTM HF sensor - pulmonary artery pressure measurement|CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
219662381|NCT03627377|BEHAVIORAL|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
219662382|NCT06624254|OTHER|lung mechanics, respiratory drive and effort|Patient lung mechanics and respiratory drive and effort will be measured
219662383|NCT00841347|BEHAVIORAL|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
219662384|NCT00841347|BEHAVIORAL|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
219662385|NCT04590677|OTHER|Samples required from group 1 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
219662386|NCT04590677|OTHER|Samples required from group 2 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs"
219662387|NCT05968027|OTHER|"Nouveal numeric application Onco'nect"|A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
219662388|NCT02631460|DRUG|S1 80-120 mg/d|d1, every 3 weeks
219662389|NCT02631460|DRUG|pemetrexed 500 mg/m2|d1, every 3 weeks
219662390|NCT02631460|DRUG|carboplatin AUC=5|d1, every 3 weeks
219662391|NCT05418894|DEVICE|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
219662392|NCT03129282|OTHER|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
219662393|NCT02261662|DRUG|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
219662394|NCT02261662|DRUG|Betamethasone|Topical Steroids alone will be used; Betamethasone
219662395|NCT04323267|DEVICE|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
219662396|NCT04323267|BEHAVIORAL|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
219662397|NCT03104426|DRUG|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
219662398|NCT00900731|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219662399|NCT00900731|DRUG|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
219662400|NCT00900731|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219662401|NCT00900731|DRUG|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
219662402|NCT03806231|DRUG|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
218970535|NCT04620707|DEVICE|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
219662403|NCT03806231|DRUG|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
219662404|NCT03379844|DEVICE|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
219662405|NCT02919267|DEVICE|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
219662406|NCT02919267|DEVICE|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
219662407|NCT04546516|DEVICE|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
219662408|NCT01759316|OTHER|heliox|heliox or oxygen is used in the two groups respectively
219662409|NCT05714046|BEHAVIORAL|Control|An informative presentation
219662410|NCT05714046|BEHAVIORAL|Yoga training|Yoga exercise training
219662411|NCT00256321|DRUG|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
219662412|NCT00256321|DRUG|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
219662413|NCT00256321|DRUG|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
219662414|NCT06157112|OTHER|Lifestyle behaviour (exposure in a observational study)|Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
219662415|NCT05546723|BIOLOGICAL|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
219662416|NCT05454046|OTHER|Food intake among women and men in fertility treatment|Filling in an FFQ
219662417|NCT00574210|DRUG|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
219662418|NCT00574210|DRUG|Placebo|Placebo Tablets administered twice per day
219662421|NCT00394433|DRUG|Bevacizumab|
219662422|NCT00394433|DRUG|Docetaxel|
218970536|NCT04620707|BEHAVIORAL|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
218970537|NCT05262959|DRUG|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
218970538|NCT05262959|PROCEDURE|TACE|TACE will be performed by the investigator based on the patient's tumor status.
218970539|NCT05368844|DEVICE|rTMS treatment using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of rTMS treatment
219662423|NCT00394433|DRUG|Cisplatin|
219662424|NCT00394433|DRUG|Irinotecan|
218970540|NCT05368844|DEVICE|sham TMS using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of sham iTBS treatment
218970541|NCT06458595|DRUG|KH658|KH658 Ophthalmic Injection
218970542|NCT03534518|OTHER|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
219662425|NCT01554176|DRUG|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
219662426|NCT01554176|DRUG|Placebo|Placebo, one tablet, orally, once daily at bedtime
219662427|NCT04954716|OTHER|Deep Neck Flexor Massage|Deep friction massage is a specific connective tissue massage that was given across the affected fibers.The therapist's fingers and patient's skin must move as one, otherwise moving subcutaneous fascia against muscle or ligament could lead to blister formation or subcutaneous bruising.The friction massage must have sufficient sweep and be deep enough.
219662428|NCT04954716|OTHER|Post-Isometric Relaxation Technique|The PIR technique is performed as follows.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted.A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction . The patient should inhale during this effort.After the isometric contraction the patient is asked to relax and exhale while doing so.Following this a gentle stretch is applied to take up the slack till the new barrier.Starting from this new barrier, the procedure is repeated two or three times.
219662429|NCT04777669|OTHER|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
219662430|NCT00503451|DRUG|LBH589|
219662431|NCT03328494|DRUG|BOS172722|Oral capsules
219662432|NCT03328494|DRUG|Paclitaxel|IV infusion
219662433|NCT06911411|OTHER|Prospective observational cohort study.|"No systematic approach exists for symptom assessment, management, and reporting in delivered basic palliative care within the Danish healthcare system, implying considerable variation in hospital-based palliative care. The PALMA study consists of two superior phases divided in a development and an implementation stage that anchors basic palliative assessment and management within existing geriatric workflows and cross-sectoral collaborative care.~The PALMA cohort will test the applicability of the EORTC-C15-PAL questionnaire along with measures of clinical frailty and sociodemographic risk factors.~The development phase will enable the development of a clinical algorithm for elderly patients' need for cross-sectoral palliation care planning."
219662434|NCT06911411|OTHER|A prospective observational cohort study|Observational design
219662435|NCT04470284|OTHER|Mobile Application|SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
219662436|NCT04470284|OTHER|Standard SMBP|Standard treatment (SMBP-alone)
219662437|NCT04104113|OTHER|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
219662438|NCT04104113|OTHER|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
219662439|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
219662440|NCT02696954|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
219662441|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
219662442|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
219662443|NCT02696954|DRUG|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
219662444|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
219662445|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
219662446|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
219662447|NCT00107354|BIOLOGICAL|aldesleukin|
219662448|NCT00107354|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219662449|NCT00107354|BIOLOGICAL|therapeutic autologous lymphocytes|
219662450|NCT00107354|DRUG|cytarabine|
219662451|NCT00107354|DRUG|etoposide|
218970543|NCT03534518|OTHER|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
219662452|NCT00107354|DRUG|mitoxantrone hydrochloride|
219662453|NCT00107354|PROCEDURE|allogeneic bone marrow transplantation|
219662454|NCT00107354|PROCEDURE|peripheral blood stem cell transplantation|
219662455|NCT02652598|DRUG|Tolcapone|
219662456|NCT05075044|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
218970544|NCT03911128|OTHER|Observational|Observational study - no intervention
219662457|NCT00465543|OTHER|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
219662458|NCT00465543|OTHER|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
219662459|NCT05286164|DRUG|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
219662460|NCT06911762|BEHAVIORAL|Exercise|Participants will receive a 6-week structured hand exercise program. Participants will attend a face-to-face exercise session to learn all hand exercises. The exercise program will include: (1) Finger flexor stretching, (2) Tendon gliding exercise and (3) Isometric finger flexor exercise. A weekly tele follow-up will be done to participants in the experimental group
219662461|NCT06911671|DEVICE|Virtual Reality Interface + Cerebellar iTBS (c-iTBS)|Subjects will sit in a chair with their forearm inserted in a splint attached to a force transducer. The subjects' view of their hand will be occluded by a mirror displaying the virtual scene. EMGs from arm and shoulder muscles will be recorded by surface EMG electrodes. Subjects will displace a virtual handle according to either the forces recorded by the force transducer or forces estimated from the recorded EMGs (EMG control).
219662462|NCT06911671|DEVICE|Vitual Reality + Sham Cerebellar iTBS (sham c-iTBS)|c-iTBS will be carried out using Magstim Rapid magnetic biphasic stimulator. Twenty 2-s trains of three-pulse bursts at 50 Hz repeated every 200 ms with an inter-train interval of 10 s, for a total of 190 s will be applied over the contralesional lateral cerebellum. The coil will be positioned tangentially to the scalp for real and 90° angled for sham c-iTBS.
219662463|NCT06911671|OTHER|Physical Therapy|Passive mobilization and motor recruitment of impaired upper limb will be performed with the support of a physical therapist specialized in neurological rehabilitation.
219662464|NCT05079776|OTHER|Physical length measurement|Physical length will be measured and images will be collected for AI to estimate the length
219662465|NCT01524068|DRUG|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
219662466|NCT01524068|DRUG|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
218970545|NCT06965946|PROCEDURE|Intermittent Hypoxia-Hyperoxia Therapy (IHHT)|Participants receive 4 cycles per session of 5 minutes of hypoxia (13-15% O₂) followed by 2 minutes of hyperoxia (40% O₂) using a hypoxia generator (Olive OLV 10H). Sessions are delivered before each conventional physical therapy session, 3 times per week for 4 weeks (total 12 sessions). Participants are monitored for heart rate, blood pressure, and oxygen saturation throughout the intervention.
218970546|NCT06965946|PROCEDURE|Conventional Physical Therapy|Participants receive individualized conventional physical therapy for knee osteoarthritis based on current clinical practices in tertiary hospitals of Peshawar. Therapy is delivered 3 times per week for 4 weeks (total 12 sessions) and includes strength training, mobility exercises, and patient education.
218970547|NCT06965946|PROCEDURE|Normoxic Air Placebo|Participants in the control group inhale normoxic air (19.8% O₂) using the same Olive OLV 10H hypoxia generator to maintain blinding. Each session consists of 4 cycles of 5 minutes of normoxia followed by 2 minutes of normoxia, simulating the timing of hypoxia-hyperoxia therapy. Sessions are administered prior to conventional physical therapy, 3 times per week for 4 weeks (total 12 sessions). Patients are monitored for vital signs throughout.
218970548|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
218970549|NCT05706779|DRUG|Encorafenib Oral Capsule + Cetuximab|Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
219662467|NCT06250634|DRUG|esomeprazole + amoxicillin|esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
219662468|NCT06250634|DRUG|esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent|20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
219662469|NCT06250634|DRUG|Vonoprazan + amoxicillin|20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
219662470|NCT06250634|DRUG|Vonoprazan + amoxicillin + clarithromycin|20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
219662471|NCT03510221|DIETARY_SUPPLEMENT|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
219662472|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
219662473|NCT06911606|DRUG|4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin|After 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin then MDT determines surgery or radical radiotherapy
219662474|NCT06912191|OTHER|Left cerebellar TMS stimulation combined with the RECT task|The first group will receive left cerebellar single-pulse TMS stimulation combined with the RECT task. RECT refers to rostral anterior cingulate cortexr (rACC)-engaging cognitive task. The theoretical basis of this task is that when subjects are in a state of focused attention, the power of theta neural oscillations in the midline of their frontal lobe will increase. By considering the features of post-stroke depression, this study combines the emotional recognition task with the RECT task. During each trial, individuals will view 4 faces consecutively, each displaying a different expression, and they will be required to memorize the sequence of expressions. Emoticons consist of joy, sorrow, and rage. After displaying four facial expressions, a brief text flowchart will appear. Participants need to check if the sequence reflected in the flowchart matches the order in which the four facial expressions appeared. If they match, click the left mouse button; if they do not match, click the
219662475|NCT06912191|OTHER|Right cerebellar TMS stimulation combined with the RECT task|Right cerebellar single-pulse TMS stimulation combined with the RECT task
219662476|NCT06912191|OTHER|Midline cerebellar TMS stimulation combined with the RECT task|Midline cerebellar single-pulse TMS stimulation combined with the RECT task
219662477|NCT06912191|OTHER|Sham cerebellar TMS stimulation combined with the RECT task|Sham cerebellar single-pulse TMS stimulation combined with the RECT task, The TMS coil was placed at the cerebellar site but tilted 90° to prevent effective magnetic field penetration.
219662478|NCT06912191|OTHER|The best stimulation protocol combined with left dorsolateral prefrontal cortex iTBS|The optimal stimulation protocol determined in Experiment 1 combined with stimulation of the left dorsolateral prefrontal cortex.
219662479|NCT06912191|OTHER|Left dorsolateral prefrontal cortex iTBS stimulation, as well as sham TMS stimulation and sham RECT task.|Subjects in the group underwent left dorsolateral prefrontal cortex iTBS stimulation, in addition to receiving sham TMS stimulation and participating in a sham RECT task. The sham RECT task involves having participants watch a continuous scroll of faces without needing to react.
218970550|NCT01055873|BIOLOGICAL|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
218970551|NCT02904447|OTHER|x-ray and pedobar foot pressure mapping|
218970552|NCT00177476|BEHAVIORAL|behavioral weight loss|
218970553|NCT00768937|DRUG|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
218970554|NCT00768937|PROCEDURE|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
218970555|NCT02750943|DRUG|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
218970556|NCT02750943|DRUG|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
218970557|NCT01012076|BEHAVIORAL|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
218970558|NCT00171054|DRUG|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
218970559|NCT00171054|DRUG|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
218970560|NCT00171054|DRUG|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
218970561|NCT03176875|OTHER|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
218970562|NCT03176875|OTHER|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
218970563|NCT06971263|BEHAVIORAL|Consultation on both nutrition, and palliative care|The intervention on the nutrition and palliative care components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian and one palliative care physician to discuss patient needs and required to improve their health consequences.
218970564|NCT06971263|BEHAVIORAL|Counselling on nutrition and healthy diet|The intervention on the nutrition and healthy diet components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian to discuss patient dietary needs for improving their health consequences.
218970565|NCT05548010|OTHER|No intervention as this is an observational study|No intervention
218970566|NCT06522997|DRUG|BAY3283142|Tablet, intake orally once daily
218970567|NCT06522997|DRUG|Placebo|Matching with BAY3283142
219662480|NCT06912191|OTHER|Sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.|The participants in this group received sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.
219662481|NCT06912412|OTHER|Community-based supervised remote cardiac rehabilitation|"Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training.~Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE)."
219662482|NCT06912412|OTHER|Home-based cardiac rehabilitation program|"Beyond the single supervised session, participants undertake four weekly home-based sessions.~* Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance.~* Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance.~* High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down)."
219662483|NCT06909812|DRUG|pirfenidone 8% gel|topic aplication
219662484|NCT06909812|DRUG|silicon gel|topic aplication
219662485|NCT06912516|PROCEDURE|Controlled desaturation|"A subject rests comfortably on a hospital bed, so that they do not have to move during the desaturation process.~The subject wears the altitude simulator head bivy and breathes freely without any oxygen regulation. During the measurement, the time in low O2 saturation plateaus is limited to ten minutes in each desaturation plateau.~They are monitored with ECG, clinical pulse oximeter, EtCO2 from non-invasive capnography with nasal cannulas and periodically non-invasive blood pressure. The monitoring is supervised by two medical doctors, present during the entire duration of the study."
219662486|NCT06910982|BEHAVIORAL|Sphinx Pose Yoga Therapy|A structured yoga-based intervention focusing on the Sphinx Pose, aimed at improving spinal flexibility and reducing pain. Participants will perform three sessions per week for 12 weeks.
219662487|NCT06910683|BEHAVIORAL|TREE-Connect|TREE-Connect is a mental health app that aims to increase engagement in rewarding activities
219662488|NCT06910683|BEHAVIORAL|Clinician-delivered psychotherapy|Clinician-delivered psychotherapy is delivered remotely and aimed to increase engagement in rewarding activities
219662489|NCT02622490|OTHER|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
219662490|NCT04284930|DRUG|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
219662491|NCT04284930|DRUG|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
219662492|NCT04284930|DRUG|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
218970568|NCT06297616|DRUG|LY3841136|Administered SC
218970569|NCT06297616|DRUG|LY3841136-Placebo|Administered SC
218970570|NCT06297616|DRUG|Tirzepatide|Administered SC
218970571|NCT06297616|DRUG|Tirzepatide-Placebo|Administered SC
218970572|NCT03763318|BIOLOGICAL|EQ001|Itolizumab \[Bmab 600\])
218970573|NCT03763318|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
218970574|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
219662493|NCT06910111|DEVICE|Polyglucosamine|The treatment will continue for 12 months administering a customized Polyglucosamine (formoline AtheroGuard) (twice/day) before the two main meals for a total of 4 tabs/day (each tab consists of 750 mg). Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
219662494|NCT06910111|DEVICE|Placebo|2x 2 Placebo tablets The treatment will continue for 12 months administering Placebo (twice/day) before the two main meals for a total of 4 tabs/day. Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
219662495|NCT05417308|DRUG|Minoxidil|Applied topically
219662496|NCT05417308|DRUG|Minoxidil|Given PO
219662497|NCT05417308|OTHER|Quality-of-Life Assessment|Ancillary studies
219662498|NCT05417308|OTHER|Questionnaire Administration|Ancillary studies
218970575|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
218970576|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
218970577|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
218970578|NCT02004574|DRUG|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
218970579|NCT01548586|DEVICE|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
218970580|NCT05450575|DRUG|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
218970581|NCT00056589|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
218970582|NCT04267757|PROCEDURE|rectovaginal fistula repair with Martius flap|rectovaginal fistula repair with Martius flap
218970583|NCT06378125|DRUG|controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
218970584|NCT06378125|DRUG|immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
219662499|NCT01879033|OTHER|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
218970585|NCT06378125|DRUG|Placebo controlled-ileal-release nicotinic acid (SAD/MAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
218970586|NCT06378125|DRUG|Placebo immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
218970587|NCT06016348|PROCEDURE|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
218970588|NCT01327911|BIOLOGICAL|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
218970589|NCT06417073|BEHAVIORAL|Face-To-Face Task-orianted Training|In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
218970590|NCT06417073|BEHAVIORAL|Tele-Rehabilitation Task-orianted Training|This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
219662500|NCT01879033|OTHER|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
219662501|NCT02093390|DRUG|TAK-385|TAK-385 tablets
219662502|NCT02093390|DRUG|Fluconazole|Fluconazole tablets
218970591|NCT06417073|BEHAVIORAL|Home-based Task-orianted Training|"Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention."
218970592|NCT01352351|BEHAVIORAL|Breastfeeding promotion intervention|"* Breastfeeding counseling during monthly microcredit meetings~* Weekly cell phone messages about breastfeeding"
218970593|NCT06488924|DRUG|JR-446|IV infusion
219662503|NCT02093390|DRUG|Atorvastatin|Atorvastatin tablets
219662504|NCT04381507|DEVICE|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
219662505|NCT06382441|BEHAVIORAL|tele-exercise|It is a prospective and pilot study of RCT. It will be a pilot to test acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
218970601|NCT04107259|DIAGNOSTIC_TEST|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
218970602|NCT01716325|OTHER|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
218970603|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
218970604|NCT05696860|DEVICE|Capnography Monitoring|Capnography monitoring
218970605|NCT02452697|BIOLOGICAL|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
218970606|NCT02452697|BIOLOGICAL|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
218970607|NCT02658097|DRUG|Pembrolizumab|200mg Pembrolizumab by IV infusion
218970608|NCT02658097|RADIATION|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
218970609|NCT06604624|DRUG|HD1916|HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
218970610|NCT06604624|DRUG|semaglutide|semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
218970611|NCT03552965|OTHER|Robust Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue
219662506|NCT04723953|DIAGNOSTIC_TEST|68Ga-FAPI PET/MRI|PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.
219662507|NCT05176548|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy|Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
219662508|NCT01408082|DRUG|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
219662509|NCT01408082|DRUG|Azasite|Azasite twice daily for 2 weeks
219662510|NCT01408082|DRUG|Dexamethasone|Dexamethasone twice daily for 2 weeks
218970612|NCT03552965|OTHER|Margin-Based Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
218970613|NCT06977152|DEVICE|Memory foam pillow|Patients in the memory foam pillow intervention group will have a memory foam pillow placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
219064798|NCT03913273|PROCEDURE|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
219064799|NCT03913273|PROCEDURE|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
219662511|NCT01408082|OTHER|Vehicle|Vehicle twice daily for 2 weeks
219662512|NCT01887288|DRUG|Capecitabine|650 mg/m\^2 PO b.i.d.
219662513|NCT01887288|DRUG|Digoxin|0.25 mg once daily
219662514|NCT01692002|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate capsule or tablet
218970614|NCT06977152|DEVICE|Fluidized Positioner|Patients in the fluidized positioner intervention group will have a fluidized positioner placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
219662515|NCT01692002|DIETARY_SUPPLEMENT|Sodium Chloride|Placebo capsule or tablet
219662516|NCT01692002|PROCEDURE|Oral glucose tolerance test|
219662517|NCT01692002|PROCEDURE|Intravenous glucose tolerance test.|
219662518|NCT04002778|DIAGNOSTIC_TEST|Fine needle aspiration|
219662519|NCT04002778|DIAGNOSTIC_TEST|Rapid on-site evaluation|
219662520|NCT00799799|BIOLOGICAL|NK cells|NK cells infusion after immunosuppressive chemotherapy
219662521|NCT00597064|DRUG|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
219662522|NCT02657824|OTHER|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
219662523|NCT03872141|DIAGNOSTIC_TEST|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
219662524|NCT00565227|DRUG|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
218970615|NCT06087640|BIOLOGICAL|aQIV or aTIV|Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
218970616|NCT06087640|BIOLOGICAL|QIV or TIV|Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
218970617|NCT06592378|DEVICE|Addinex|Medication dispensing system to control and monitor opioid use
218970618|NCT06592378|DEVICE|Standard Pill Bottle|Access and use of opioids in a standard pill bottle.
218970619|NCT06589154|DIAGNOSTIC_TEST|Multi-modal artificial intelligence model (BEAM)|Data from mpMRI and cfDNA analysis will be integrated and processed by deep learning. The model's output will be compared against the final pathological diagnosis from the prostate biopsy to evaluate its performance.
218970620|NCT02394002|DRUG|Propofol|
218970621|NCT05824364|OTHER|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
218970622|NCT05824364|OTHER|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
218970623|NCT06665932|PROCEDURE|Stereotactic radiotherapy|Stereotactic surgery is a minimally invasive form of surgical intervention that makes use of a three-dimensional coordinate system to locate small targets inside the body and to perform on them some action such as ablation, biopsy, lesion, injection, stimulation, implantation, radiosurgery, etc.
218970624|NCT06336928|OTHER|Non-Interventional Study|Non-interventional study
218970625|NCT06588049|DIETARY_SUPPLEMENT|Beet Root|Beet Root powder used as a mouth rinse in suspension with water
218970626|NCT06588049|OTHER|Water|Water used as a mouth rinse
218970627|NCT03316534|DRUG|Aspirin|Aspirin (100 mg once a day)
218970628|NCT04523779|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
219662525|NCT00565227|DRUG|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
219662526|NCT04616040|DRUG|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
218970629|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
218985551|NCT06284655|BEHAVIORAL|group-based combined with innovative technology education|The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.
218985552|NCT06284655|OTHER|Standard treatment|Treatment as usual.
219064800|NCT01343407|DRUG|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
219064801|NCT01343407|DRUG|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
219064802|NCT01343407|DRUG|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
219064803|NCT01343407|DRUG|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
219064804|NCT03950739|DRUG|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
219064805|NCT04639414|DRUG|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
219064806|NCT04639414|DRUG|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
219662527|NCT02272153|OTHER|Egg refined grain|
219662528|NCT02272153|OTHER|Egg Whole Grain|
219662529|NCT02272153|OTHER|Cereal Refined grain|
219662530|NCT00493987|DRUG|Testosterone Enanthate|testosterone ester
219662531|NCT00493987|DRUG|Dutasteride|5 alpha-reductase inhibitor
219662532|NCT02299505|DRUG|ceritinib|The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
219662533|NCT02503644|DRUG|IVA337|Capsules of 200mg IVA337
219662534|NCT02503644|DRUG|Placebo|Identical capsules without active substance
219662535|NCT05128045|BEHAVIORAL|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
218970630|NCT06994949|DEVICE|fCTOT cap|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the subarachnoid space (SAS), draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the neonatal intensive care unit (NICU) for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
218970631|NCT06994949|DEVICE|NIRF planar imaging|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
218970632|NCT06994949|DRUG|ICG|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
218970633|NCT06666582|DRUG|Paclitaxel and ramucirumab|Second-line treatment with paclitaxel/ramucirumab vs other regimens
218970634|NCT06514651|DRUG|MAQ-001|MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
218970635|NCT06514651|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
218985553|NCT04189575|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
218985554|NCT01216631|DRUG|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
218985555|NCT01216631|DRUG|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
219662536|NCT05601297|OTHER|questationair|acceptability of women to partner violance
219662537|NCT03706001|OTHER|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
219662538|NCT01906281|OTHER|Blood analyse, arthrocentesis, ultrasound examination|
219662539|NCT06537050|DRUG|JX2105|Oral capsule
219662540|NCT06537050|DRUG|Placebo|Oral capsule
218985556|NCT01216631|DRUG|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
218985557|NCT05433012|DEVICE|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
218985558|NCT02882412|OTHER|observational|
218985559|NCT05961579|DRUG|Barrier Renew|RoC Skincare (New York, New York, USA) has developed a gentle cleanser and moisturizer that are free of exfoliants, astringents, and other abrasive ingredients. The moisturizer contains emollients, humectants, and silicones to improve the functioning of the skin barrier while antioxidants protect against environmental damage and inflammation
218985560|NCT04652427|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
218985561|NCT04652427|DRUG|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
218985562|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|
218985563|NCT02197273|DRUG|Liposomal bupivacaine|
218985564|NCT02197273|DRUG|Standard of care analgesia|
218985565|NCT00499239|DRUG|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
218985566|NCT03412526|DRUG|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
218985567|NCT03412526|RADIATION|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
218985568|NCT03412526|BIOLOGICAL|TIL administration|TIL Administration
218985569|NCT03412526|DRUG|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
219064807|NCT04639414|DRUG|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
219662541|NCT01308632|DRUG|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
219064808|NCT02758431|DRUG|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
219064809|NCT02758431|DRUG|Placebo Gel|Placebo gel packet applied daily for 28 days.
219064810|NCT02758431|DRUG|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
219662542|NCT04656678|DEVICE|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
219064811|NCT02758431|DRUG|Testosterone Gel|Testosterone Gel applied daily for 28 days
219064812|NCT02758431|DRUG|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
218985570|NCT03451578|DEVICE|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
218985571|NCT00119431|DRUG|C1 inhibitor concentrate|
218985572|NCT02388919|DRUG|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
218985573|NCT02388919|DRUG|Placebo|Basic dosage, take once when limosis in the morning.
218985574|NCT04234074|DEVICE|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
218985575|NCT04049864|BIOLOGICAL|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
218985576|NCT04049864|BIOLOGICAL|Salmonella oral vaccine|suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
218985577|NCT04049864|DRUG|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
218985578|NCT02058693|DRUG|mixed salts amphetamine|adjunctive to ADT
218985579|NCT00722800|DRUG|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
218985580|NCT00722800|DRUG|Placebo|1 tablet daily for 24 weeks
218985581|NCT00316992|DRUG|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
218985582|NCT01810861|OTHER|There is no intervention in this study|This is a non-interventional study.
218985583|NCT04209517|OTHER|Filming|Behavioural markers selection from video-recordings of the interview
218985584|NCT00167648|DRUG|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
218985585|NCT00167648|DRUG|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
218985586|NCT01796483|DEVICE|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
219064813|NCT03526900|DRUG|Atezolizumab|"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
219064814|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
219064815|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
219064816|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
219662543|NCT05775861|DRUG|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
219686491|NCT06450457|DEVICE|VECTOR Bioness|Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.
219686492|NCT06450457|OTHER|Physical therapy|Physical therapy will be administered by a physical therapist and will include overground walking, treadmill walking, stairs, and resisted walking.
219064817|NCT06962774|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
219064818|NCT06961487|PROCEDURE|EndovascularThrombectomy|Endovascular thrombectomy is a minimally invasive procedure that uses catheters and devices to remove blood clots, restoring blood flow to the brain. The procedure involves inserting a catheter (a long, thin tube) into an artery, usually in the groin, and guiding it through the blood vessels to the site of the blocked artery/blood clot in the brain. After the catheter reaches the affected area, a specialized device is guided through the catheter to capture and remove the clot.
219064819|NCT06961487|DEVICE|Endovascular thrombectomy with any FDA-approved device|"The following FDA approved thrombectomy devices will be included:~Stryker Neurovascular Products:~* AXS Vecta 74 Aspiration System~* AXS Vecta Aspiration System (AXS Vecta 71 Aspiration Catheter and AXS Vecta 74 Aspiration Catheter)~* AXS Vecta Intermediate Catheters (AXS Vecta 71 Intermediate Catheter \& AXS Vecta 74 Intermediate Catheter)~* Trevo XP ProVue Retriever, 3x20 and 4x20~* Trevo XP ProVue Retriever, 4x30~* Trevo XP ProVue Retriever, 6x25~Medtronic Products:~Solitaire X Revascularization Devices:~* Solitaire X 4x20, 4x40, 6x40~* Solitaire X 3x20, 3x40~Aspiration catheters:~* React 68~* React 71~* REACT-71-115 \& REACT-71-125~MicroVention Inc. Products:~* SOFIA, Aspiration pump and tubing kit~  * SOFIA Plus Aspiration catheter~* BOBBY balloon guide catheter~* ERIC retrieval device"
219064820|NCT06962059|OTHER|Self-Administered Sample Collection|Participants will collect vaginal swabs and a stool sample.
219064821|NCT03264989|DRUG|crizanlizumab|Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
219686493|NCT04589884|OTHER|Hyperspectral Imaging|Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
219064822|NCT06357728|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
219686494|NCT06612931|PROCEDURE|Dual-lumen catheter-guided mini-forceps biopsy is performed first|In ERCP procedures, catheter-guided mini-forceps biopsy is performed before biliary brush cytology.
219686495|NCT06612931|PROCEDURE|Biliary brush cytology with vacuum aspiration is performed first|In ERCP procedures, biliary brush cytology with vacuum aspiration is performed before dilation catheter-guided mini-forceps biopsy.
219686496|NCT01683604|OTHER|Observational study|
219686497|NCT06875843|BEHAVIORAL|Contingent responses|The adult systematically responds to more complex child vocalizations with more complex responses. When the child first vocalizes, the adult imitates that vocalization. The child's response determines the next adult response. If the child produces a vocalization within 3 seconds, the adult imitates the child, provides a linguistic map (i.e., puts the apparent meaning into words), and complies nonverbally with the child's apparent intent (e.g., giving item or action). If the child does not produce another vocalization within 3 seconds, the adult remains quiet until the child vocalizes again.
218970636|NCT06208852|OTHER|Virtual Navigator Program|For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
218970637|NCT02160483|OTHER|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
218970638|NCT02943083|BEHAVIORAL|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
218970639|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
218970640|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
218970641|NCT02477696|DRUG|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
218970642|NCT02477696|DRUG|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
218970643|NCT07001930|DRUG|Epidiolex|Oral cannabidiol
218970644|NCT06679075|PROCEDURE|Full pulpotomy using propolis and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material
218970645|NCT06679075|PROCEDURE|Full pulpotomy using Propolis and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
218970646|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material
218985587|NCT01796483|DEVICE|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
219064823|NCT06634914|DIETARY_SUPPLEMENT|Moonbrew|A blend of adaptogens with Chamomile, Rose, and Magnesium in a powdered form, designed to be mixed in liquid and consumed 2-3 hours before bed.
219064824|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
219064825|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
219064826|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
219064827|NCT02192268|OTHER|PEP|
219064828|NCT02192268|OTHER|HFOO|
219064829|NCT02192268|OTHER|Assisted Coughing|
219064830|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
219686498|NCT06875843|BEHAVIORAL|Contingent responses plus vocal elicitation strategies|The adult follows the contingent responses condition protocol with the addition of using vocal toys (e.g., echo tubes, microphones that distort voices, and microphones that amplify voices) within exciting turn-taking activities/routines (e.g., blowing bubbles, balloons, and whoopee cushions). The vocal elicitation strategies emphasize the need to help children vocalize to initiate child-adult interactions. These strategies may be especially important for children who vocalize infrequently to benefit from other intervention aspects and enhance their spoken language skills. The vocal elicitation strategies are to be used when needed, rather than being obligatory for every adult-child interaction. If the child vocalizes without a vocal elicitation prompt, the adult still responds to the vocalization
219064831|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
219064832|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
219064833|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
219064834|NCT02083523|BEHAVIORAL|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
219662544|NCT05775861|DRUG|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
219662545|NCT06253000|PROCEDURE|Cryoablation|Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
219662546|NCT06253000|PROCEDURE|Radiofrequency ablation|"Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system."
219662547|NCT03420807|DEVICE|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
219662548|NCT05288296|DEVICE|dynamic taping|"1. The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~2. By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
219662549|NCT02090621|PROCEDURE|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
219662550|NCT05900089|DRUG|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
218970647|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
218970648|NCT06617832|DRUG|Active drug for acute migraine treatment|Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
218970649|NCT06617832|DRUG|Placebo Oral Tablet|Inactive placebo pill (100 mg) looking like the active drug
218970650|NCT03971266|OTHER|Activity Monitor|Wear a Fitbit
219064835|NCT02083523|BEHAVIORAL|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
219064836|NCT02270320|BEHAVIORAL|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
219064837|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
219662551|NCT00041665|DRUG|Recombinant Human Keratinocyte Growth Factor|
218970651|NCT03971266|OTHER|Media Intervention|Complete smartphone based PRO diary
218970652|NCT06679842|DIAGNOSTIC_TEST|ascitis paracentesis|ascitis paracentesis
218970653|NCT04658472|DRUG|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
218970654|NCT04658472|DRUG|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
219064838|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
219064839|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
219662552|NCT02060266|DRUG|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
219064840|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
219064841|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
219064842|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
219064843|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
219064844|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
219064845|NCT01776645|BEHAVIORAL|Compassion Cultivation Training Course|
219064846|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
219064847|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
219064848|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
218970655|NCT06120777|DEVICE|INVSENSOR00069|Noninvasive pulse oximeter
218970656|NCT06608212|DRUG|Finerenone (Kerendia, BAY948862)|Follow clinical practice/administration.
218970657|NCT06608212|DRUG|Others except finerenone|Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
218970658|NCT05419908|DRUG|Fezolinetant|Oral Capsule
218970659|NCT05419908|DRUG|Placebo|Oral Capsule
218970660|NCT06683664|OTHER|Integrated health service delivery for very young adolescents|The proposed HPV-PASSREV intervention will aim to increase adolescent-centered access to HPV vaccination and other very young adolescent health services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health facility and community levels.
218970661|NCT06680245|DRUG|Mitomycin c|Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
218970662|NCT04504812|DRUG|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
218970663|NCT04504812|COMBINATION_PRODUCT|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
218970664|NCT04504812|PROCEDURE|Nerve Procedure with long acting blocks|People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
218970665|NCT04504812|PROCEDURE|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
218970666|NCT04504812|BEHAVIORAL|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
218970667|NCT04504812|OTHER|Best Practices|Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
218970668|NCT07091539|OTHER|Fruit/vegetable vouchers|The intervention is $80 of fruit/vegetable vouchers (EatSF Veggies4Vouchers) per month x 6 months
218970669|NCT07125677|DEVICE|I-gel first|After general anesthesia, I-gel is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel plus is inserted, and the same procedure is repeated.
218970670|NCT07125677|DEVICE|I-gel plus first|After general anesthesia, I-gel plus is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel is inserted, and the same procedure is repeated.
219208343|NCT06797414|OTHER|Pilate Exercises|"PILATES EXERCISE METHODS:~1. The cranium, triceps, back, and shoulder blades against the mat, then breath while maintaining muscle contraction .~2. Arm circles (both directions) on the mat, then use strong ribcage breathing to connect into scapula.~3. Diamond press: lie prone on a mat, using the lower part of the trapezius and serratusanterior muscles to slide shoulder blades out and down. Move into slight back extension maintaining this position.~4. Diamond press: repeat above but add lateral arm movement to back extension .~5. Arm slides 90°: lies supine on mat with arms bent at 90° and thumbs on floor. Slide elbows on floor toward waistline while contracting serratus anterior muscle.Repeat on the floor with other fingers. Always maintain proper neck alignment .~6. Arm circles on a tiny barrel while lying on back with the head and neck supported by the barrel. Opened chest, then link the scapula to the barrel. Hold this position while performing arm circles."
219662553|NCT00460265|DRUG|ARM 2|Subjects will receive Cisplatin plus 5FU
219662554|NCT00460265|DRUG|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
219662555|NCT02289846|DRUG|IW-9179|
219662556|NCT02289846|DRUG|Matching Placebo|
219662557|NCT04692766|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
218985588|NCT02656914|DRUG|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
218985589|NCT02656914|DRUG|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
218985590|NCT00002688|DRUG|cyclosporine|
218985591|NCT00002688|DRUG|etoposide|
218985592|NCT00002688|DRUG|mitoxantrone hydrochloride|
218985593|NCT06005350|DIETARY_SUPPLEMENT|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
218985594|NCT06005350|OTHER|Placebo|Placebo Preperation
218985595|NCT03989895|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
218985596|NCT01449539|DRUG|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
218985597|NCT01269411|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
218985598|NCT01269411|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218985599|NCT01269411|OTHER|pharmacological study|Correlative studies
218985600|NCT01269411|OTHER|laboratory biomarker analysis|Correlative
219662558|NCT04692766|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
219662559|NCT05878821|DEVICE|Shockwave|Shockwave therapy session once a week for month 1000shock per session
219662560|NCT03616444|DRUG|Shenbai Granules|In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
219662561|NCT00880386|DRUG|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
219662562|NCT02416050|PROCEDURE|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
218970671|NCT02576431|DRUG|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
219662563|NCT02680613|BEHAVIORAL|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
218970672|NCT07150000|DIAGNOSTIC_TEST|Ex Vivo Assay|Ex vivo assay with patient's PBMCs. Cytokine quantification (e.g. TNFα, IL-1β). HCI with single-cell analysis (\>100 features/cell). Data preprocessing and normalization to transfer for machine learning.
218970673|NCT07150182|OTHER|The Integrated Shared Decision-making Program|The Integrated Shared Decision-making Program
218985601|NCT04793087|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
218985602|NCT02651818|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
218985603|NCT02259101|BEHAVIORAL|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
218985604|NCT02259101|BEHAVIORAL|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
218985605|NCT03506789|DRUG|Dexamethasone|Dexamethasone 24 mg
218985606|NCT03506789|DRUG|Placebos|Isotonic saline
218985607|NCT04821648|DRUG|RJV001|Subcutaneous injection in the abdomen
218985608|NCT04821648|DRUG|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
218985609|NCT00423904|BEHAVIORAL|Brief intervention|
218985610|NCT05409248|OTHER|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
218985611|NCT05409248|OTHER|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
218985612|NCT01972568|DRUG|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
218985613|NCT01972568|DRUG|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
218985614|NCT01972568|DRUG|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
218985615|NCT05182866|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
218985616|NCT00748735|PROCEDURE|Implantation of a cardiac resynchronization therapy device|
218985617|NCT00748735|PROCEDURE|Echocardiography (myocardial deformation imaging)|
219662564|NCT02680613|BEHAVIORAL|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
219662565|NCT01534364|OTHER|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
219662566|NCT05596500|DIETARY_SUPPLEMENT|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
219662567|NCT05596500|DIETARY_SUPPLEMENT|Blueberry gel|Sport gel with blueberry extract only.
219662568|NCT05596500|DIETARY_SUPPLEMENT|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
219662569|NCT03203759|OTHER|Home hospitalization|See above
219662570|NCT03203759|OTHER|Traditional inpatient hospitalization|See above
219662571|NCT04658706|OTHER|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
219662572|NCT04658706|OTHER|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
219662573|NCT02440542|OTHER|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
218970674|NCT07150624|DRUG|Experimental Group|Receiving 930mg of polyene phosphatidylcholine injection one day before the operation,twice a day. And 930mg of polyene phosphatidylcholine injection,twice a day, combined with 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
218970675|NCT07150624|DRUG|control group|Receiving 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
219662574|NCT01741506|DRUG|Dalteparin (Fragmin®)|
218970676|NCT07150169|DEVICE|Active TMS disruption|Active TMS disruption delivered to the personalized target
218970677|NCT07150169|DEVICE|Sham TMS disruption|Sham TMS disruption delivered to the personalized target
218970678|NCT07150091|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
218970679|NCT07150091|DRUG|Nirogacestat|Nirogacestat will be administered.
218970680|NCT07150091|DRUG|Lenalidomide|Lenalidomide will be administered.
218970681|NCT07150091|DRUG|Dexamethasone|Dexamethasone will be administered.
218970682|NCT07149909|OTHER|Other (Conventional Therapy)|Participants received standard therapy including culture-guided antibiotics, tracheal lavage, and aspiration. Sputum samples were collected from the lower trachea for culture and sensitivity testing to guide antibiotic selection.
218970683|NCT07149909|PROCEDURE|Fiberoptic Bronchoscopy|Participants underwent fiberoptic bronchoscopy through the endotracheal tube for secretion clearance, sample collection, and alveolar lavage once daily for one week. Sterile sodium chloride solution with ambroxol hydrochloride was instilled, and antibiotics were administered immediately after lavage. Samples were cultured to guide antibiotic therapy.
218970684|NCT07150208|DRUG|Bevacizumab (Bev)|Bevacizumab is a drug that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis, thereby inhibiting tumor growth and spread. In the treatment of breast cancer, Bevacizumab can be used in combination with chemotherapy to improve treatment outcomes and extend patients' progression-free survival and overall survival.
218970685|NCT07150208|DRUG|Trastuzumab Deruxtecan (T-DXd)|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients."
219208344|NCT06797414|OTHER|Whole-body vibration|Subjects were placed in a modified push-up position , put their hands in the middle of the platform, shoulder width apart, elbows slightly flexed, and their lower extremities were supported by kneeling on the floor . Vibration protocol included 5 sets of 60 s duration, at 5 mm amplitude and 30 Hz frequency, with a rest period of 60 s between sets . The subjects were reminded kneeling but upright and detached from the platform between sets.
219208345|NCT06797414|DEVICE|Hot Pack|for 10 to 15 minutes
219208346|NCT05759923|DRUG|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
219662575|NCT05939115|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
219662576|NCT06437275|OTHER|Questionnaire for the degree of knowledge and attitude|Questionnaire for the degree of knowledge and attitude of Egyptian physicians regarding emergency treatment of traumatic dental injuries.
219662577|NCT01992315|DEVICE|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
219662578|NCT03776071|DRUG|Enzastaurin Hydrochloride|mg
219662579|NCT03776071|OTHER|Placebo|mg
219662580|NCT03776071|DRUG|Temozolomide|mg/m\^2
219662581|NCT03776071|RADIATION|Radiotherapy|Gy
219662582|NCT06649071|OTHER|Naturalistic observation|Naturalistic observation
219662583|NCT04792671|BEHAVIORAL|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
219662584|NCT04792671|BEHAVIORAL|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
219064849|NCT04947111|DIAGNOSTIC_TEST|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
219064850|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
219064851|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
219064852|NCT03579745|PROCEDURE|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
219662585|NCT04792671|BEHAVIORAL|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
219662586|NCT04792671|BEHAVIORAL|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
219064853|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
219662587|NCT02719353|DEVICE|comfilcon A Extended Range test lens|contact lens
219662588|NCT02719353|DEVICE|comfilcon A control lens|contact lens
219662589|NCT05730153|BIOLOGICAL|advanced PRF|advanced PRF+ surgery
218970686|NCT07150637|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
218970687|NCT07150312|BEHAVIORAL|HIIT|"A 12-week home-based HIIT exercise plan (running). Duration: Each session consists of 10 x 1-minute high-intensity bouts interspersed with 10 x 1-minute recovery periods. Adding the 3-minute warmup and 3-minute cool-down, each session totals approximately 26 minutes. This protocol is followed for 12 weeks.~Intensity: High-intensity bouts are performed at 80-90% of HRmax (RPE 15-18). Recovery periods are at 40-50% of HRmax (RPE 11-13). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
218970688|NCT07150312|BEHAVIORAL|MICT|"A 12-week home-based MICT exercise plan (running). Duration: Each session consists of 20 minutes of continuous exercise. Including the 3-minute warm-up and 3-minute cool-down, each session totals 26 minutes. This protocol is followed for 12 weeks.~Intensity: Exercise is performed at 64-76% of HRmax (RPE 12-14). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
219064854|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
219064855|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
219064856|NCT00412087|DRUG|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
219064857|NCT00412087|DRUG|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
219064858|NCT00412087|DRUG|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
219662590|NCT02737228|DRUG|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
219662591|NCT02737228|DRUG|Gemcitabine|1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
219662592|NCT02737228|DRUG|Erlotinib|100 mg per oral daily per cycle (4 weeks)
219662593|NCT06025253|DEVICE|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
219662594|NCT06025253|DEVICE|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
219662595|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
218970689|NCT07150325|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
218970690|NCT07150325|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is commonly applied in Mirror therapy.
218970691|NCT07150325|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
218970692|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of dexamethasone and lidocaine 2%
218970693|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of alcohol 30%, dexamethasone and lidocaine 2%
218970694|NCT07149493|DEVICE|Placebo nanofiber floss|Identical floss without probiotic coating, used under the same conditions.
218970695|NCT07149493|DEVICE|Probiotic nanofiber floss|Nanofiber floss infused with Ligilactobacillus salivarius (strain BCRC 14759), used twice daily for 14 days.
219662596|NCT02651415|DRUG|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories."
219662597|NCT02651415|DRUG|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
219662598|NCT05620992|DEVICE|Echocardiography|Echocardiography 3 and 6 months post operative
219662599|NCT06355167|DIETARY_SUPPLEMENT|Bacopa monnieri|Daily oral intake of Bacopa monnieri during 6 weeks
219662600|NCT03284372|BEHAVIORAL|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
219662601|NCT03284372|BEHAVIORAL|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
219662602|NCT04258969|BEHAVIORAL|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
219662603|NCT04234269|OTHER|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
219662604|NCT00103922|DRUG|cilomilast|
219662605|NCT01917344|OTHER|MRI|
218970696|NCT07150052|OTHER|Artifical intelligence in whatsapp|AI-based tool Tia Bete, designed to assist patients with T1DM in carbohydrate counting and insulin dose adjustment. The tool provides real-time recommendations based on personalized insulin-to-carbohydrate ratios, insulin sensitivity factors, and individualized glycemic goals.
218970697|NCT07150481|DRUG|IV Lidocaine infusion|2 mg/kg/h (the total dose of lidocaine per hour will be calculated and add to normal saline 0.9% to total volume 50 ml and infused by a rate 50 ml/h till the end of the procedure
218970698|NCT07150481|DRUG|IV normal saline|IV normal saline 0.9% , rate 50 ml/h
218970699|NCT07150026|DRUG|Vorinostat (SAHA)|oral suspension
218970700|NCT07150026|DRUG|Placebo|placebo
218970701|NCT07150416|DRUG|Recombinant Human Ad-p53 Injection|A replication-deficient recombinant human type 5 adenovirus vector encoding the human wild-type p53 tumor suppressor gene. For this study, it will be administered via nebulized inhalation.
218970702|NCT07150065|DRUG|Levofloxacin|Oral 200 mg levofloxacin tablet
218970703|NCT07150065|DRUG|ciprofloxacin|Oral 900-1,000 mg ciprofloxacin tablet
218970704|NCT07150533|DIETARY_SUPPLEMENT|Placebo Arm|Participants receive a placebo consisting of maltodextrin in capsule form, matched in appearance and taste to the active supplements.
218970705|NCT07150533|DIETARY_SUPPLEMENT|Green Tea Extract|Participants receive 500 mg of standardized green tea extract in capsule form.
218970706|NCT07150533|DIETARY_SUPPLEMENT|Ginger|Participants receive 1 g of ginger supplement in capsule form.
218970707|NCT07150533|DIETARY_SUPPLEMENT|Combined Supplement (Green Tea + Ginger)|Participants receive a combination of 500 mg green tea extract and 1 g ginger, both administered in capsule form.
218970708|NCT07150988|DRUG|HSK44459 dose level 1|HSK44459 dose level 1 oral administration
218970709|NCT07150988|DRUG|HSK44459 dose level 2|HSK44459 dose level 2 orally administration
218970710|NCT07150988|DRUG|placebo|placebo oral adminisitration
218970711|NCT07150962|DRUG|HRS-9531 Tablet|HRS-9531 tablet.
219064859|NCT05916742|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions
219064860|NCT05916742|PROCEDURE|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
219662606|NCT06621667|OTHER|diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis|diaphragmatic myofascial release
219662607|NCT06621667|OTHER|traditional physical therapy exercises for hyperkyphosis|traditional physical therapy exercises for hyperkyphosis
219662608|NCT01497886|BEHAVIORAL|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
219662609|NCT01497886|BEHAVIORAL|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
219662610|NCT01626625|DRUG|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
219662611|NCT01626625|OTHER|autograft taken from iliac crest|patient will be transplanted with autograft
219662612|NCT03594019|PROCEDURE|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
219662613|NCT03594019|PROCEDURE|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
219662614|NCT03594019|PROCEDURE|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
219662615|NCT05388695|BIOLOGICAL|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
219662616|NCT06071182|DEVICE|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
218970712|NCT07150897|OTHER|exercise for lower abdominal muscle wall|the exercise session will start with light walking for 5 minutes followed by, posture correction exercises from crock lying, supine, and sitting and standing positions (each exercise will be maintained for 5 seconds and then the woman relaxed for 10 seconds and repeated each exercise 10 times) to overcome the effect of poor pregnancy posture. Then, participants will perform first step of prone plank exercises which is a stable prone plank with attention to maintain a neutral position in the hip joints, pelvis and lumbar spine. The feet will be placed to match the width of the hip and forearm and acted as support points. The elbows place under the glenohumeral joints, and the arms support the body vertically to the surface. Second step of prone plank exercises will involve performing the unilateral stable prone plank which is the same as the stable prone plank but with the dominant leg in a fully extended position. Third step includes, prone bridge on a Swiss Ball with a diameter of 65
218970713|NCT07151040|DRUG|TH9619|"Phase 1a - DOSE ESCALATION~Description:~Single arm dose escalation of TH9619 as monotherapy.~Phase 1b - DOSE EXPANSION~Description:~Single arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available."
218970714|NCT07149623|PROCEDURE|Experimental|sectioning and submitting fresh surgical specimens from the ileum mesentery
218970715|NCT07150715|DRUG|Actinium Ac 225 Vipivotide Tetraxetan|Given IV
218970716|NCT07150715|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218970717|NCT07150715|OTHER|Gallium Ga 68 Gozetotide|Given IV
218970718|NCT07150715|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
218970719|NCT07150715|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT scan
218970720|NCT07150715|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219064861|NCT05916742|DEVICE|VCMX|Porcine derived collagen matrix.
219662617|NCT06071182|OTHER|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
219662618|NCT00412217|DRUG|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
219662619|NCT00412217|DRUG|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
219662620|NCT00412217|OTHER|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
219662621|NCT04600063|PROCEDURE|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
219686499|NCT06875843|BEHAVIORAL|Non-contingent control|The adult provides non-contingent vocal responses based on audio recordings from prior contingent responses condition sessions transmitted via a wireless earpiece. Recordings from these yoked sessions control for number and type of adult vocalizations and minimize the degree of contingency between adult and child vocalizations in this condition.
219064862|NCT05916742|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
218970721|NCT07150013|DRUG|Vorinostat (SAHA)|oral suspension
218970722|NCT07150013|DRUG|Placebo|placebo
218970723|NCT07150676|OTHER|Long term follow-up|Long term follow-up as part of standard of care
219064863|NCT05916742|DRUG|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
219208347|NCT06745076|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218970724|NCT07150039|OTHER|Manual therapy intervention (Chaitow's myofascial diaphragm release)|Participants were given a myofascial release technique from a seated position, as described by Chaitow. With this technique, the athlete slightly bends his/her torso in order to relax the abdominal wall and breathes calmly and deeply (Figure 2). The therapist is behind the athlete holding his/her lower ribs, and during exhalation the therapist directs his hands caudally. This steady but gentle 'traction' is maintained throughout the breathing cycles for 4-5 minutes.
218970725|NCT07150039|OTHER|Sham Comparison|With this sham comparator technique, the therapist stood behind the athlete (who was sitting) touching the outside of the person's lower ribs without folding his or her fingers or applying any pressure. The athlete is verbally instructed, after fully exhaling the air in their lungs to take deep breaths opening his/her ribs as much as he/she can whistle the therapist's hands follow the movement (without applying any manual pressure or traction). The procedure here also lasted for 4-5 minutes
218970726|NCT07150832|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by individuals who are not mental health professionals. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy.
218970727|NCT07149363|DRUG|Durvalumab 50 MG/ML|Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).
218970728|NCT07150780|PROCEDURE|Pre-operative instructions to eat and drink at liberty|Subjects will be instructed to eat and drink at liberty prior to their schedule elective cardiac catheterization.
218970729|NCT07150858|OTHER|Erythropoietin and albumin PRF gel + implant placement|This group will be treated by transcrestal sinus lifting with erythropoietin and albumin PRF gel with simultaneous implant placement.
218970730|NCT07150858|OTHER|Albumin PRF gel +implant placement|This group (the Control group) will be treated with transcrestal sinus lifting using albumin PRF gel, with simultaneous implant placement.
218970731|NCT07150130|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
218970732|NCT07151001|DEVICE|No intervention|No intervention. Evaluate the automated DR screening software.
218970733|NCT07150286|DRUG|Levofloxacin-Based H. pylori Eradication Therapy|"This intervention consists of a 14-day levofloxacin-based triple therapy regimen for Helicobacter pylori eradication in ITP patients. The regimen follows current ACG guidelines and typically includes:~Levofloxacin - antibiotic targeting H. pylori~Amoxicillin - antibiotic used in combination for enhanced efficacy~Proton Pump Inhibitor (PPI) - to reduce stomach acid and improve antibiotic effectiveness~Patients will receive the full 14-day course, and platelet counts will be measured at baseline and four weeks post-therapy to assess hematological response. This intervention is unique to H. pylori-positive ITP patients in this study and is not administered to H. pylori-negative patients."
218970734|NCT07150650|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
218970735|NCT07149896|DEVICE|Collagen Scaffold (Colla-Plug)|The collagen cartilage scaffold(COLTRIX® CartiRegen) used in this study consist of an injection needle, a syringe, and a collagen gel prefilled in a syringe. The collagen gel contains phosphate buffer and type Ⅰ collagen which the telopeptides are removed.. After the product is implanted in the body, it forms a degradable three-dimensional scaffold to provide an environment for cells to adhere, proliferate, migrate, differentiate and secrete, thereby promoting cartilage repair. At present, it has been commercially applied to clinical repair of knee cartilage defect.
218970736|NCT07149896|PROCEDURE|microfracture|Microfracture to repair cartilage defect is a minimally invasive procedure that is usually done arthroscopically. The doctor first cleans the damaged cartilage area, and then uses a special microfracture cone to drill vertically in the subchondral bone plate, forming multiple tiny holes, allowing mesenchymal stem cells and growth factors in the bone marrow to overflow, forming a blood clot rich in repair components, and finally stimulating fibrocartilage regeneration to fill the defect area.
218970737|NCT05218239|BEHAVIORAL|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
218970738|NCT05218239|BEHAVIORAL|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
218970739|NCT04645888|PROCEDURE|Impacted tooth surgery|Surgical extraction of İmpacted tooth
218970740|NCT00482027|BIOLOGICAL|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
218970741|NCT02883192|DRUG|Ondansetron|Zofran 4 mg.
218970742|NCT02883192|DRUG|Placebo|Placebo
218970743|NCT05312073|OTHER|Biological samples|Blood samples Superficial skin Biopsy Collection of fallen squames Tapes - stripping
218970744|NCT05312073|OTHER|Skin biopsy|healthy skin from surgery interventions
218970745|NCT01329484|BEHAVIORAL|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
218970746|NCT01329484|BEHAVIORAL|Cognitive training|Cognitive training using a computerized system
218970747|NCT01329484|OTHER|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
219208348|NCT06745076|PROCEDURE|Computed Tomography|Undergo CT scan
219662622|NCT04600063|PROCEDURE|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
219662623|NCT06731114|PROCEDURE|Suboccipital muscle release|"Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total"
219662624|NCT06731114|PROCEDURE|Conventional physical therapy|TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks
219662625|NCT06731114|PROCEDURE|Sternocleidomastoid release|Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
219662626|NCT04453800|DRUG|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
219662627|NCT04453800|DRUG|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
219662628|NCT04453800|DRUG|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
219662629|NCT04453800|OTHER|placebo|Saline was administered intravenously
219662630|NCT04676685|DRUG|E2730|E2730 capsules.
219662631|NCT04676685|DRUG|E2730-matched placebo|E2730-matched placebo capsules.
219662632|NCT04072991|OTHER|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
219662633|NCT01007760|OTHER|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
219662634|NCT04958902|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
219662635|NCT01103947|DEVICE|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
219662636|NCT01103947|DEVICE|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
219662637|NCT01103947|DEVICE|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
219662638|NCT01103947|DEVICE|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
219662639|NCT00237250|DRUG|vildagliptin|
219662640|NCT00162175|DRUG|Muraglitazar|
219662641|NCT05873335|COMBINATION_PRODUCT|Mixtures of nitrogen, air, and carbon dioxide|Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
219662642|NCT00299559|DRUG|smart textiles containing menthol, camphor, cineol|application to skin
219662643|NCT04603794|DRUG|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
218970748|NCT04172896|PROCEDURE|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
219662644|NCT04603794|DRUG|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
219662645|NCT04603794|DRUG|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
219662646|NCT04603794|DRUG|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
219064864|NCT05916742|DRUG|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
219662647|NCT02615392|BEHAVIORAL|Park Prescription|Please refer to the information included in the arm description.
219662648|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
219662649|NCT00947024|DRUG|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
219662650|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
219662651|NCT04291495|DIAGNOSTIC_TEST|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
219662652|NCT03541109|DRUG|Polypill|fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
219208349|NCT06745076|DRUG|Dacarbazine|Given IV
219662653|NCT02783456|PROCEDURE|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
219662654|NCT02783456|PROCEDURE|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
219662655|NCT04505605|OTHER|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
219662656|NCT03526198|DEVICE|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
219064865|NCT04236557|BEHAVIORAL|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
219662657|NCT03011983|DEVICE|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
219662658|NCT03011983|DEVICE|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
219662659|NCT03011983|BEHAVIORAL|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
219662660|NCT03114657|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
219662661|NCT03114657|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
219662662|NCT06620250|COMBINATION_PRODUCT|Digital Prevention and control of myopia|The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
219662663|NCT01236950|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
219662664|NCT01236950|DRUG|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
219662665|NCT04840524|PROCEDURE|Laminate veneers preparation|facial laminate veneers teeth preparation
219662666|NCT03042416|DRUG|18F-DOPA|18F-DOPA intravenous injection single dose
219662667|NCT06304558|DEVICE|Non-Invasive Neuromodulation (NESA)|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
219662668|NCT03631719|BIOLOGICAL|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
219662669|NCT01075399|DRUG|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
219662670|NCT01135875|OTHER|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
219662671|NCT01135875|OTHER|Normal Controls|2 teaspoons of blood will be collected once.
219662672|NCT01179737|DRUG|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
219662673|NCT01179737|DRUG|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
219662674|NCT01326507|BIOLOGICAL|Dosage de l'h-FABP|Dosage de l'h-FABP
219662675|NCT00971061|DEVICE|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
219662676|NCT00971061|DEVICE|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
219662677|NCT03349905|PROCEDURE|fresh transfer|"Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved"
219662678|NCT03349905|PROCEDURE|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
219686500|NCT06465355|PROCEDURE|pharyngo-esophageal high-resolution manometry|The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
218970749|NCT04172896|PROCEDURE|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
218970750|NCT03436836|DRUG|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
219064866|NCT04236557|BEHAVIORAL|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
219064867|NCT02438449|PROCEDURE|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
218970751|NCT03436836|DRUG|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
218970752|NCT03436836|DRUG|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
218970753|NCT02413021|DRUG|Cytarabine|20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
218970754|NCT02413021|DRUG|Deferasirox|20 mg/kg ,oral, per day
218970755|NCT01722123|OTHER|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
218970756|NCT06331026|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
218970757|NCT06331026|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
218970758|NCT02602847|BIOLOGICAL|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
219064868|NCT06186648|DRUG|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
219064869|NCT06416215|OTHER|Psychological intervention based on WBT and cognitive restructuring|Participants will engage in 6 weekly group session of two hours. One part will be held by a trained dietician and will focus on nutritional education, particularly emphasizing the adoption of healthy and sustainable eating behaviors. The remaining part will be dedicated to a group psychological intervention inspired by the principles of Well-Being Therapy and will be held by a trained psychologist. During these sessions, participants will be introduced to the six dimensions of psychological well-being and will be gradually provided with cognitive-behavioral strategies to enhance psychological well-being and seek a balance between the presented dimensions. Participants will be given cognitive-behavioral tools to recognize justification cognitive mechanisms and replace them with more functional cognitions. These objectives will also be achieved through the use of a food diary to highlight emotions and thoughts experienced during food intake.
219662679|NCT04769505|BEHAVIORAL|digital mindfulness-based intervention (MBI)|The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.
219662680|NCT06507631|BEHAVIORAL|Blended care pirate group|During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
219662681|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
219662682|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
219662683|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
219662684|NCT01546038|DRUG|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
219662685|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
218970759|NCT04766827|DRUG|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
218970760|NCT02640040|DEVICE|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
218970761|NCT02640040|DEVICE|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
218970762|NCT02640040|PROCEDURE|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
218970763|NCT05318339|DRUG|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
219662686|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
218970764|NCT04105829|OTHER|Bond-a braid|Stainless steel lingual retainer application
218970765|NCT04105829|OTHER|EverStick-Ortho|Fiber reinforced lingual retainer
218970766|NCT04105829|OTHER|Ribbond|Fiber reinforced lingual retainer
219662687|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
219662688|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
218970767|NCT05522387|DRUG|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
218970768|NCT00664469|DRUG|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
218970769|NCT00664469|DRUG|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
219662689|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
218970770|NCT00664469|DRUG|Comparator: Atorvastatin|Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
218970771|NCT00664469|DRUG|Comparator: Rosuvastatin|Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
218970772|NCT06332248|DIETARY_SUPPLEMENT|Magnesium|The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
218970773|NCT06332248|DIETARY_SUPPLEMENT|Placebo|Placebo tablet, oral intake once a day for up to three months.
218970774|NCT01436916|DRUG|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
218970775|NCT01436916|DRUG|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
218970776|NCT00085124|BIOLOGICAL|oblimersen sodium|Given IV
219662690|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
218970777|NCT00085124|DRUG|cytarabine|Given IV
218970778|NCT00085124|DRUG|daunorubicin hydrochloride|Given IV
218970779|NCT00085124|OTHER|laboratory biomarker analysis|Correlative studies
218970780|NCT04925271|DEVICE|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
218970781|NCT04925271|DEVICE|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
218970782|NCT00426231|BEHAVIORAL|Navigation by a health worker|Help provided by health worker to navigate medication access programs
218970783|NCT00426231|BEHAVIORAL|Information control|Information about medication access programs provided to the participant and their healthcare provider
218970784|NCT04007211|DEVICE|ABT13107|Dose: 3mL, maximum 10mL
218970785|NCT04007211|DEVICE|Hyalobarrier|Dose: 10mL
218970786|NCT00000862|DRUG|Zidovudine|
218970787|NCT01795638|DRUG|Sodium chloride|
218970788|NCT01795638|DRUG|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
218970789|NCT01799031|OTHER|internet-based intervention|Receive access to the WISE web-based educational intervention
218970790|NCT01799031|PROCEDURE|management of therapy complications|Receive standard of care
218970791|NCT01799031|OTHER|educational intervention|Receive access to the WISE web-based educational intervention
218970792|NCT01799031|OTHER|questionnaire administration|Ancillary studies
218970793|NCT01799031|PROCEDURE|quality-of-life assessment|Ancillary studies
218970794|NCT01655680|DRUG|ABT-126|ABT-126 Middle Dose
218970795|NCT01655680|DRUG|ABT-126|ABT-126 Low Dose
218970796|NCT01655680|DRUG|ABT-126|ABT-126 High Dose
218970797|NCT01655680|DRUG|Placebo|Placebo
219064870|NCT06416215|OTHER|Basic Nutritional Intervention|Participants will receive treatment as usual (TAU) by participating in 6 weekly group sessions of two hours of a Basic Nutritional Intervention (BNI) held by a trained dietician. This course focuses on promoting healthier lifestyles through nutritional education, diet monitoring using a dedicated food diary, and recommendations for proper physical activity.
219064871|NCT01782989|DRUG|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
219662691|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
219662692|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
219662693|NCT03410810|DIAGNOSTIC_TEST|MRI|MRI analysis
219662694|NCT03410810|DIAGNOSTIC_TEST|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
219662695|NCT01980810|DRUG|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
218970798|NCT00697359|DEVICE|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
218970799|NCT03931824|OTHER|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
218970800|NCT03931824|OTHER|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
218970801|NCT02360995|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
218970802|NCT02360995|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
218970803|NCT02360995|DRUG|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
219662696|NCT01980810|DRUG|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
219662697|NCT04339010|OTHER|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
219662698|NCT04339010|OTHER|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
219662699|NCT02570334|OTHER|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
219686501|NCT06612190|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
219686502|NCT06612190|PROCEDURE|Control|The sham group will be given no real magnetic stimulation.
219686503|NCT06612671|PROCEDURE|tumor wide excision|patients received properative or post-operative radiotherapy
219686504|NCT06692296|BEHAVIORAL|Balance training over stabilometric platform|"The treatment using the stabilometric platform (a total of 20 sessions) generally includes an initial phase (approximately 5 minutes) of training and warm-up in monitor mode, during which the patient becomes familiar with the equipment. The patient then moves on to training library mode, which includes the following subcategories: (1) Stabilometric tracings in both static and dynamic phases (10 minutes); (2) Dexterity exercises in both static and dynamic phases (10 minutes); (3) Imbalance exercises in both static and dynamic phases (10 minutes).~The goal during this phase is to increase the patient's stability limits and provoke balance reactions through load shifts in all directions. The session concludes with 10 minutes of TecnoBody Exergames, which help to automate the functions learned within a more complex activity."
219686505|NCT06692296|BEHAVIORAL|Balance training by means of conventional rehabilitation|Conventional rehabilitation to improve balance includes an initial phase of tissue mobilization, particularly of the foot structures (approximately 5 minutes per foot), in order to prepare them for the subsequent activation phase. This is followed by a phase focused on activating the anti-gravity muscles and aligning the trunk within the chosen setting (10 minutes). The treatment continues with balance training, both static and dynamic, load transfers, and dual-task exercises using external references (15 minutes). The session concludes with functional exercises relevant to the patient's daily life context (10 minutes).
219686506|NCT02595385|DEVICE|Cell Salvage|Reinfusion of shed blood during the operation
219686507|NCT02595385|PROCEDURE|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
219686508|NCT06361706|BEHAVIORAL|VR-Enhanced Psychoeducational Program for Chronic Pain|Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
219686509|NCT05736328|PROCEDURE|Traction|Postoperative lower extremity traction
219686510|NCT04448275|OTHER|Neurodynamics Nerve flossing|"Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique"
219686511|NCT04448275|OTHER|conventional selected exercise program|Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
219686512|NCT05632263|DIAGNOSTIC_TEST|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
219686513|NCT06384742|BEHAVIORAL|Shift Worker Intervention for Sleep Health|SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across nine approximately weekly sessions that range in length from 15-60 minutes
219686514|NCT07023276|OTHER|Neuromuscular Training|Coaches implemented neuromuscular training at the start of all warm-ups for practices and games. The neuromuscular training program was developed by sports medicine professionals at the home institution and the National Basketball Association and incorporates established principles of motor learning and performance training and has an added emphasis of being basketball-specific.
219686515|NCT06692959|DRUG|PD-1 vaccine IMU-201 (PD1-Vaxx)|Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
219686516|NCT06713668|DEVICE|Backup Pacing Rate Change|Patients will have backup pacing programmed to A (75 bpm) and B (100 bpm), randomizing to sequence of exposure A-B or B-A
219686517|NCT06880653|BEHAVIORAL|DREAM Adaptive Intervention|6-month physical activity program (Dose Response of Exercise for Arthritis Management (DREAM)) which includes monthly phone coaching, Walk With Ease Guidebook, behavioral lessons, and a Fitbit. Participants may receive additional contact (email, text, or phone) if they struggle to meet activity goal.
219686518|NCT04921592|OTHER|upper extremity stimulation|transcutaneous stimulation of the upper extremities
219686519|NCT04369833|DEVICE|continuous glucose monitoring system|wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
219686520|NCT06888570|OTHER|To evaluate fat liver content in the cases/controls population.|The studied population includes participants aged 5-22 years old with/without T21 Down Syndrome.
219662700|NCT02235441|OTHER|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
219662701|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
219662702|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
219662703|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single sc injection
219662704|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
219662705|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
219662706|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single sc injection
219662707|NCT02818621|DRUG|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
219662708|NCT04245202|DEVICE|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
219662709|NCT04245202|OTHER|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
219662710|NCT02253121|DRUG|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
219662711|NCT02253121|DRUG|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
219662712|NCT04240964|OTHER||
219662713|NCT00696202|DRUG|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
219662714|NCT06013202|OTHER|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
219662715|NCT06013202|OTHER|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
219662716|NCT04295343|DIAGNOSTIC_TEST|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
219662717|NCT04295343|DIAGNOSTIC_TEST|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
219662718|NCT03146975|PROCEDURE|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
218970804|NCT02360995|DRUG|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
218970805|NCT02360995|DRUG|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
218970806|NCT06557109|OTHER|Popular Music|A funky D mix version of a popular Turkish song
218970807|NCT04764487|DEVICE|KidneyPRO|Web-application for symptoms assessment
218970808|NCT04764487|OTHER|standard follow-up|usual follow-up
218970809|NCT00887406|DRUG|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
218970810|NCT00887406|DRUG|GSK961081 3mcg SD|single dose delivered via nebulsier
218970811|NCT00887406|DRUG|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
218970812|NCT00887406|DRUG|Placebo SD|single dose via nebuliser
219662719|NCT01881087|DRUG|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
219662720|NCT00717275|DRUG|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
218970813|NCT00887406|DRUG|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
218970814|NCT00887406|DRUG|GSK961081 200mcg SD|single dose via nebuliser
218970815|NCT00887406|DRUG|GSK961081 300mcg SD|single dose via nebuliser
218970816|NCT00887406|DRUG|GSK961081 100mcg RD|repeat dose via nebuliser
218970817|NCT00887406|DRUG|GSK961081 300mcg RD|repeat dose vai nebuliser
218970818|NCT00887406|DRUG|Placebo RD|repeat dose via nebuliser
218970819|NCT02611960|BIOLOGICAL|Pembrolizumab|IV infusion
218970820|NCT02611960|DRUG|Capecitabine|oral tablet
218970821|NCT02611960|DRUG|Gemcitabine|IV infusion
218970822|NCT02611960|DRUG|Docetaxel|IV infusion
218985618|NCT02572401|BEHAVIORAL|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
219662721|NCT05570370|OTHER|This is an observational study|This is an observational study
219662722|NCT04205149|OTHER|ERAS post-operative pathway|ERAS Pathway
219662723|NCT01923337|DRUG|irinotecan hydrochloride|Given IV
219662724|NCT01923337|DRUG|alisertib|Given PO
219662725|NCT00711607|DRUG|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
219662726|NCT02193711|OTHER|Topical Arthritis Cream|
219662727|NCT04241393|DRUG|Tavapadon tablet|Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
219662728|NCT04241393|DRUG|Tavapadon [14C] suspension|Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
218970823|NCT01851460|DEVICE|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
219064872|NCT01782989|DRUG|Placebo|Placebo capsule daily for 24 months
219064873|NCT01175668|DRUG|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
219064874|NCT01175668|DRUG|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
218970824|NCT02395666|DRUG|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
219064875|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
219064876|NCT03832127|DRUG|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
219064877|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
219064878|NCT04790981|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
219064879|NCT04790981|OTHER|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
219064880|NCT03981458|DEVICE|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
218970825|NCT00805454|DRUG|OPC-34712|Single oral dose, 0.5 to 25 mg
218970826|NCT03570944|PROCEDURE|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
218970827|NCT05270122|DEVICE|Mechanical thrombectomy with ThrombX Retriever|Revascularization
218970828|NCT04123275|OTHER|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
219064881|NCT03981458|DEVICE|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
219064882|NCT01707602|BIOLOGICAL|INTANZA® 15|intradermal vaccination
219064883|NCT01707602|BIOLOGICAL|Vaxigrip®|Intramuscular vaccination
219064884|NCT01707602|BIOLOGICAL|INTANZA® 15 T|transcutaneous vaccination
219064885|NCT02328326|OTHER|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
219064886|NCT02328326|OTHER|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
218970829|NCT03470961|DRUG|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
219064887|NCT04223102|PROCEDURE|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
219208350|NCT06745076|DRUG|Doxorubicin|Given IV
218970830|NCT03470961|DRUG|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
218970831|NCT03269604|PROCEDURE|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
218970832|NCT03269604|PROCEDURE|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
218970833|NCT03269604|PROCEDURE|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
218970834|NCT00293215|DRUG|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
218970835|NCT00293215|DRUG|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
218970836|NCT01409434|DRUG|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
218970837|NCT01727401|DRUG|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
219662729|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
218970838|NCT05967000|OTHER|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching."
218970839|NCT05271461|RADIATION|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
218970840|NCT05271461|OTHER|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
218970841|NCT03189485|DRUG|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
218985619|NCT02572401|BEHAVIORAL|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
219064888|NCT05742373|OTHER|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
219064889|NCT05742373|OTHER|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
219064890|NCT01060865|DRUG|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
219064891|NCT02264795|DRUG|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
219064892|NCT02264795|DRUG|Placebo|0.9% Sodium Chloride Solution
219064893|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
219064894|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
219064895|NCT03452917|DRUG|Placebo|500 patients will 2 ml of normal saline
219064896|NCT03452917|DRUG|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
219064897|NCT03452917|DRUG|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
219064898|NCT01213758|OTHER|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
219064899|NCT06100497|DRUG|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
219064900|NCT06100497|DRUG|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
218985620|NCT01223131|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
219064901|NCT06100497|DRUG|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
219064902|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
219064903|NCT00093769|DRUG|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
219064904|NCT01914796|DRUG|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
219064905|NCT01914796|DRUG|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
219064906|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
219064907|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
219662730|NCT04146623|BIOLOGICAL|CodaVax-H1N1 influenza vaccine|CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).
219662731|NCT04146623|BIOLOGICAL|Normal Saline Placebo|Saline (0.9%) administered intranasally via sprayer
219662732|NCT00263055|DRUG|oxaliplatin|
219662733|NCT03794934|BEHAVIORAL|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
219662734|NCT03662113|DRUG|Domperidone|5ml Domperidone prior to VCE
219662735|NCT03662113|DIETARY_SUPPLEMENT|water|5ml water prior to VCE
219662736|NCT02564406|DEVICE|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
219662737|NCT02636556|RADIATION|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
219662738|NCT04742309|DRUG|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
219662739|NCT04742309|DRUG|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
218985621|NCT01223131|DRUG|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
218985622|NCT00306189|DRUG|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
218985623|NCT00306189|DRUG|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
218985624|NCT00306189|DRUG|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
219662740|NCT02634905|OTHER|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
219662741|NCT02634905|OTHER|Phone Call|
219662742|NCT05693545|DRUG|phenoxymethyl penicillin|Prophylaxis
219662743|NCT05693545|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
218985625|NCT00306189|DRUG|Placebo|Placebo SC every 6 months
218985626|NCT06502691|OTHER|Best Practice|Receive of standard care
218985627|NCT06502691|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
218985628|NCT06502691|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219662744|NCT06221098|PROCEDURE|bilateral medial rectus recession|release muuscle from its original insertion and backword inserted in sclera
219662745|NCT00047229|BIOLOGICAL|oblimersen sodium|
219662746|NCT00047229|DRUG|doxorubicin hydrochloride|
219662747|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219662748|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219662749|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
219662750|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
218970842|NCT06056557|DEVICE|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
219662751|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
219662752|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
219662753|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
218970843|NCT05777330|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
219662754|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219662755|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219662756|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219662757|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219662758|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
219662759|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219662760|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
219662761|NCT04812795|OTHER|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
219662762|NCT04812795|OTHER|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
219662763|NCT00421317|DRUG|Imatinib|800 mg/day until disease progression or toxicity
218985629|NCT06502691|OTHER|Electronic Health Record Review|Ancillary studies
218985630|NCT06502691|OTHER|Fludeoxyglucose F-18|Given FDG
218985631|NCT06502691|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
218985632|NCT06502691|DRUG|Immune Checkpoint Inhibitor|Receive ICI treatment
219662764|NCT01510535|DRUG|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
219662765|NCT01510535|DRUG|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
219662766|NCT01510535|DRUG|LBSA0103|at third week LBSA0103(60mg) once in experimental group
219662767|NCT01254721|DRUG|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
219662768|NCT01254721|DRUG|lithium|300mg tablet, oral
219662769|NCT02827643|DRUG|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
219662770|NCT02827643|OTHER|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
218985633|NCT06502691|DRUG|Poly (ADP-Ribose) Polymerase Inhibitor|Receive PARP inhibitor treatment
218985634|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET
218985635|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
218985636|NCT01088750|DRUG|cyclophosphamide|
218985637|NCT01088750|DRUG|prednisolone|
219662771|NCT04633902|DRUG|Olaparib|Olaparib 300 mg BID daily
219662772|NCT04633902|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
218970844|NCT05777330|DIAGNOSTIC_TEST|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
218970845|NCT05777330|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
218970846|NCT00841971|DRUG|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
218970847|NCT00841971|DRUG|Fluconazole|400 mg IV for 21 days
218970848|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
218970849|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
218970850|NCT03225742|DIAGNOSTIC_TEST|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
218970851|NCT06570395|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic)."
218970852|NCT02213042|DRUG|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
219662773|NCT03181243|PROCEDURE|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
219662774|NCT03181243|PROCEDURE|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
219662775|NCT00987402|OTHER|Plain soap and water (PSW)|Presence or absence of infection
219662776|NCT00987402|OTHER|Alcohol-based hand rub (ABHR)|Presence or absence of infection
219662777|NCT04685278|BIOLOGICAL|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
219662778|NCT05640661|DEVICE|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
218985638|NCT01088750|DRUG|vinblastine sulfate|
218985639|NCT01088750|OTHER|watchful waiting|
218985640|NCT01088750|PROCEDURE|therapeutic conventional surgery|
218985641|NCT00945893|BIOLOGICAL|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
218985642|NCT00945893|OTHER|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
218985643|NCT03766074|DIETARY_SUPPLEMENT|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
218985644|NCT03766074|DIETARY_SUPPLEMENT|Placebo|placebo
218985645|NCT02518256|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
218985646|NCT02447939|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
218985647|NCT02447939|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
218985648|NCT02866916|DRUG|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
218985649|NCT04442113|PROCEDURE|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
219064908|NCT01744236|DRUG|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
219064909|NCT01744236|DRUG|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
219662779|NCT05640661|DEVICE|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
218970853|NCT02213042|BIOLOGICAL|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
218970854|NCT02213042|DRUG|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
218970855|NCT05324137|DRUG|CM326|CM326 injection
218970856|NCT05324137|OTHER|Placebo|Placebo
218970857|NCT05630755|DRUG|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
218970858|NCT05630755|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
218970859|NCT05630755|DRUG|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
218970860|NCT05630755|DRUG|Placebo to DOR/ISL|0 mg oral tablets once daily
218970861|NCT05860933|DRUG|LY3537982|Administered orally.
218970862|NCT05860933|DRUG|Itraconazole|Administered orally.
218970863|NCT05860933|DRUG|Carbamazepine|Administered orally.
218970864|NCT04622735|COMBINATION_PRODUCT|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
218970865|NCT04622735|DRUG|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
219064910|NCT01744236|DRUG|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
219064911|NCT01744236|DRUG|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
219064912|NCT01744236|DRUG|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
219064913|NCT01744236|DRUG|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
219064914|NCT01744236|DRUG|L-NMMA|
218970866|NCT04622735|DRUG|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
218970867|NCT05314478|DEVICE|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored."
218970868|NCT06437353|DRUG|Paclitaxel|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
219064915|NCT00969033|DRUG|CS-1008|CS-1008
219064916|NCT00969033|DRUG|irinotecan|irinotecan
219208351|NCT06745076|PROCEDURE|Echocardiography Test|Undergo echocardiography
219208352|NCT06745076|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
218970869|NCT05775354|DIAGNOSTIC_TEST|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
218970870|NCT04763928|DRUG|Venetoclax+Decitabine|"Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes."
218970871|NCT05054036|DRUG|MoviPrep|Split-dose MoviPrep bowel preparation
218970872|NCT05054036|DRUG|Golytely|Split-dose GoLYTELY bowel preparation
219064917|NCT03689322|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
219662780|NCT00948415|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
219662781|NCT02538692|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
219662782|NCT02538692|DRUG|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
219662783|NCT02736591|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
219662784|NCT02736591|DRUG|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
219662785|NCT02736591|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
219662786|NCT02736591|DRUG|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
219662787|NCT00757029|GENETIC|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
219662788|NCT04621162|BEHAVIORAL|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
219662789|NCT04621162|BEHAVIORAL|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
218970873|NCT03241069|OTHER|Reference position|patient is put in a 30 degree supine position during 5 minutes
218970874|NCT03241069|OTHER|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
218970875|NCT03241069|OTHER|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
218970876|NCT03241069|OTHER|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
218970877|NCT04282798|OTHER|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
218970878|NCT04073368|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
218970879|NCT04073368|DIETARY_SUPPLEMENT|AXA1125|Amino acids, food study
219662790|NCT04621162|BEHAVIORAL|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
219662791|NCT04621162|BEHAVIORAL|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
219662792|NCT04621162|BEHAVIORAL|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
219662793|NCT04621162|BEHAVIORAL|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
218970880|NCT04073368|DIETARY_SUPPLEMENT|Placebo|Amino acids, food study
218970881|NCT02646254|OTHER|blood cardioplegia|
218970882|NCT02646254|OTHER|del nido cardioplegia|
218970883|NCT01229397|BIOLOGICAL|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
218970884|NCT01229397|BIOLOGICAL|Inflexal V|Inflexal V 0.5 mL administrated once only
218970885|NCT04541160|DIAGNOSTIC_TEST|CR|Lung imaging evaluation performed with CR
219064918|NCT03689322|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
219208353|NCT06745076|BIOLOGICAL|Nivolumab|Given IV
219208354|NCT06745076|PROCEDURE|Positron Emission Tomography|Undergo PET scan
218970886|NCT04541160|DIAGNOSTIC_TEST|ULDCT|Lung imaging evaluation performed with ULDCT
218970887|NCT04499976|DRUG|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
218970888|NCT04499976|DRUG|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
218970889|NCT04499976|DRUG|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
218970890|NCT02682407|BIOLOGICAL|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
218970891|NCT03880604|PROCEDURE|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
218970892|NCT03880604|DRUG|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
218970893|NCT03880604|OTHER|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
219064919|NCT03689322|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
219064920|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
219064921|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
219064922|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
219064923|NCT04740515|OTHER|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
219064924|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
219662794|NCT01772680|DIETARY_SUPPLEMENT|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
219064925|NCT02545907|DRUG|Thalidomide|50mg capsule.
219064926|NCT02545907|DRUG|Dexamethasone|2mg tablet.
219662795|NCT01805973|BEHAVIORAL|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
219662796|NCT00190372|BEHAVIORAL|Controlled diet|Controlled diet
219064927|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
219064928|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
219064929|NCT02444650|DEVICE|tonometer|
219064930|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
219662797|NCT00190372|BEHAVIORAL|Self-hypnotic relaxation|Self-hypnotic relaxation
219662798|NCT02647255|PROCEDURE|Plasma Exchange (PE)|PE treatment\>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
218970894|NCT00003548|DRUG|aminocamptothecin colloidal dispersion|
218970895|NCT02796742|OTHER|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
218970896|NCT03395925|DEVICE|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
218970897|NCT03012568|DEVICE|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
218970898|NCT02030054|DRUG|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
219064931|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
219064932|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
219208355|NCT06745076|DRUG|Vinblastine|Given IV
219208356|NCT06745076|OTHER|Questionnaire|Complete questionnaire
219208357|NCT05188664|DRUG|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
219208358|NCT05188664|DRUG|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
219208359|NCT06281054|PROCEDURE|Revascularization|Performing PCI or CABG
219208360|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
219208361|NCT01830595|DRUG|Recombinant Lactoferrin|
219662799|NCT02647255|DRUG|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
219662800|NCT02984514|RADIATION|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
219064933|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
219662801|NCT04012424|DRUG|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
218970899|NCT02030054|DRUG|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
218970900|NCT00708565|DRUG|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
218970901|NCT02476422|DRUG|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
218970902|NCT02476422|DRUG|Ibuprofen|Single dose of ibuprofen 400 mg tablet
218970903|NCT02476422|DRUG|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
218970904|NCT02476422|DRUG|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
218970905|NCT06345846|DEVICE|IFIOL|Implanted IFIOL
218970906|NCT06345846|DEVICE|SFIOL|Implanted SFIOL
218970907|NCT01236014|DRUG|Eltrombopag|Eltrombopag \& standard of care
218970908|NCT01236014|DRUG|Romiplostim|Romiplostim \& standard of care
218970909|NCT01236014|DRUG|Placebo|Placebo \& standard of care
218970910|NCT05276180|OTHER|Arm A) Multifactorial intervention strategy|"Implementation of the multifactorial intervention strategy will be supported by the following components:~1\) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3\) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4\) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection."
218970911|NCT05276180|OTHER|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
218970912|NCT06155643|DEVICE|Eko Sensora|The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
218970913|NCT03888924|DRUG|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
218970914|NCT03888924|DRUG|Placebo|isotonic solution of sodium chloride (2mL vials).
219064934|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
219064935|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
219662802|NCT04012424|DIETARY_SUPPLEMENT|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
218970915|NCT00546468|PROCEDURE|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
218970916|NCT00546468|PROCEDURE|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
218970917|NCT05920915|OTHER|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
218970918|NCT03599635|DRUG|liposomal bupivacaine|Experimental
218970919|NCT03599635|DRUG|Bupivacaine|Active Comparator
218970920|NCT03824171|DRUG|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
219208362|NCT01830595|DRUG|Placebo|
219662803|NCT03385616|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
219662804|NCT04929158|PROCEDURE|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
219662805|NCT01430624|BEHAVIORAL|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
219662806|NCT01430624|BEHAVIORAL|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
219662807|NCT05426824|DRUG|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
219662808|NCT05426824|DRUG|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
219662809|NCT03872258|BEHAVIORAL|Control|Counseling on physical activity
219662810|NCT03872258|BEHAVIORAL|Intervention group|Program of combined exercise and a Smartband for 6 months.
218970921|NCT03824171|DRUG|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
218970922|NCT00857415|DRUG|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
218970923|NCT02232334|OTHER|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
218970924|NCT01130103|DRUG|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
218970925|NCT01130103|BEHAVIORAL|Prolonged Exposure Therapy|Weekly for 10 weeks
218970926|NCT06019429|BEHAVIORAL|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 \& 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 \& 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
218970927|NCT06019429|BEHAVIORAL|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
218970928|NCT06019429|BEHAVIORAL|School as usual|Any amount of classes offered to promote social-emotional development
218970929|NCT04508140|PROCEDURE|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
218970930|NCT04508140|DRUG|BO-112 with pembrolizumab|BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
218970931|NCT03985384|DRUG|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
218970932|NCT03985384|DRUG|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
218970933|NCT01200862|DRUG|Investigational new drug company code: BGS649|
219662811|NCT05199896|BEHAVIORAL|Behavioral protocol|A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
219662812|NCT05199896|DEVICE|EEG protocol|"The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch.~Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products)."
218970934|NCT01200862|DRUG|Placebo|
218970935|NCT04150380|BIOLOGICAL|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
218970936|NCT04150380|OTHER|Placebo|See arm descriptions
218970937|NCT05146154|DRUG|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
218970938|NCT00985816|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
219662813|NCT05199896|DEVICE|fMRI protocol|"The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant.~During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position."
219662814|NCT00853515|OTHER|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
219662815|NCT01069315|PROCEDURE|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
219662816|NCT01069315|PROCEDURE|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
219662817|NCT01789671|BEHAVIORAL|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
219662818|NCT04578093|BEHAVIORAL|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
218970939|NCT00985816|DIETARY_SUPPLEMENT|Placebo|Placebo
218970940|NCT02992132|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
219662819|NCT05608278|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
219662820|NCT05608278|BEHAVIORAL|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
219662821|NCT03197194|DRUG|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
219662822|NCT03197194|DRUG|acetylsalicylic acid|one tablet of aspirin 300 mg
219662823|NCT03197194|DRUG|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
219662824|NCT03197194|DRUG|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
219662825|NCT02358772|OTHER|thrombolysis in a pre-hospital setting (STEMO concept)|
219662826|NCT02778386|DRUG|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
219662827|NCT02778386|OTHER|Placebo Capsule|Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
219662828|NCT06323317|BEHAVIORAL|Multi-component exercise programme|Each exercise session will start with a warm-up, followed by core exercise training and ending with a cool-down period. A series of flexibility training and stretching exercises will be performed during the warm-up and cool-down phases (10 minutes in total). The core exercise session will comprise aerobic (10 minutes), resistance (20 minutes), and balance (20 minutes) training, where resistance and balance exercises constitute the major components, as they are particularly effective in strengthening functional capacity, muscle strength, and balance function for mobility in frail patients.
218970941|NCT02992132|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
218970942|NCT02992132|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth
218970943|NCT05749211|DRUG|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
218970944|NCT01385007|BEHAVIORAL|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
218970945|NCT02914015|PROCEDURE|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
218970946|NCT02914015|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
219662829|NCT06323317|OTHER|Attention Placebo|The control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
219662830|NCT06323317|BEHAVIORAL|Structured preoperative education|The prehabilitation programme will begin with a 60-minute (group- or individual-based) structured education session at the centre. The content will cover frailty, its impacts on postoperative recovery, cardiovascular and overall health, and functional well-being. The importance of nutrition and exercise on their recovery potential and postoperative functional capacity will be elaborated. Their commitment to intervention engagement will be highlighted as the key to success. This session will also cover the principles of exercise, its progression, and exercise safety.
219662831|NCT06323317|BEHAVIORAL|Nutritional optimization|The Malnutrition Universal Screening Tool (MUST) will be used for a nutritional screening to determine the risk of malnutrition (low, medium, or high). The nurse will evaluate the dietary patterns of each participant, and provide tailored nutritional advice on daily protein intake according to a protein supplementation protocol. The participants and their caregivers will be provided with plenty of suggestions for high-quality protein foods according to patients' preferences. The nurse will follow-up with the participants to identify any barriers they encountered in real-world settings when they attend the exercise sessions. She will reinforce the advice and provide suggestions to overcome barriers according to the preference and lifestyle of the participants.
218970947|NCT02914015|DRUG|Ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
218970948|NCT02914015|DRUG|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
218970949|NCT04148833|DRUG|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
218970950|NCT04148833|DRUG|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
218970951|NCT01509508|DRUG|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
218970952|NCT01509508|OTHER|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
218970953|NCT05423054|OTHER|Abdominal massage|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
218970954|NCT05090462|DEVICE|PICO dressing|Negative Pressure Wound Therapy device
218970955|NCT04895540|DIAGNOSTIC_TEST|ECG|All study subjects will undergo ECG recording.
218970956|NCT04895540|DIAGNOSTIC_TEST|Echocardiography|All study subjects will undergo transthoracic echocardiography
218970957|NCT04895540|DIAGNOSTIC_TEST|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
218970958|NCT04895540|DIAGNOSTIC_TEST|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
218970959|NCT04895540|DIAGNOSTIC_TEST|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
218970960|NCT04895540|GENETIC|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
218970961|NCT02231047|DIETARY_SUPPLEMENT|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
219662832|NCT06323317|BEHAVIORAL|Stress management|Relaxation techniques to reduce tense arousal, including guide imagery and breathing techniques, will be taught. Guided imagery makes use of attention-focus to target mental arousal, whereas deep and diaphragmatic breathing is a fundamental relaxation method for various stress relieving techniques. Both techniques are designed to reduce sympathetic arousal, which is particularly beneficial to cardiac patients. Participants will be encouraged to self-practice on a daily basis, and a sound track will be provided to guide their practice.
219662833|NCT00201617|DEVICE|Bone-anchored hearing aid|
219662834|NCT01362517|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
219662835|NCT06084624|DRUG|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
219662836|NCT06084624|DRUG|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
219662837|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
218970962|NCT02231047|OTHER|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
218970963|NCT01289457|DRUG|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
218970964|NCT01289457|DRUG|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
218970965|NCT01289457|DRUG|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
218970966|NCT01289457|DRUG|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
218970967|NCT05961878|DIETARY_SUPPLEMENT|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
218985650|NCT04442113|PROCEDURE|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
218985651|NCT03799731|DRUG|GM102|GM102 7 mg/kg weekly
218985652|NCT03799731|DRUG|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
218985653|NCT03799731|DRUG|GM102 expansion|GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
218985654|NCT02647242|BEHAVIORAL|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
218985655|NCT05844410|DRUG|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
218985656|NCT04005911|DEVICE|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
218985657|NCT02074644|PROCEDURE|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
218985658|NCT02074644|PROCEDURE|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
218985659|NCT04034485|DRUG|lerodalcibep|PCSK9 inhibitor
218985660|NCT04034485|DRUG|evolocumab|PCSK9 inhibitor
218985661|NCT05144360|DRUG|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
219662838|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
219662839|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
219662840|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
219662841|NCT03878875|DIAGNOSTIC_TEST|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test (Around 35 minutes with breaks if required)~* Extended Frequency Audiometry (\~ 8 min), 0.25-16 kHz: Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~* DPOAE (\~ 5 min), 0.5-10 kHz: A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~* MEMR (\~ 8 min), 4 kHz: A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~* Speech-in-Noise Test (\~ 5 min): Participants asked to repeat back a list of words as best as they can.~* Tinnitus: Participants were also asked if they experience any tinnitus i.e. bilateral, lasting \> 5 minutes. This was reported as Y/N."
219662842|NCT03878875|DIAGNOSTIC_TEST|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital or sound level meter applications to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
218970968|NCT05789108|DIAGNOSTIC_TEST|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
219662843|NCT03878875|DIAGNOSTIC_TEST|Session Three Test Battery|1 week later (recovery): Repeat test battery.
219662844|NCT06083688|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
219662845|NCT06083688|DRUG|Chloroquine|Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.
219662846|NCT06083688|DRUG|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 2 (females less than 13 years old and all males).
219662847|NCT00296127|DRUG|Celecoxib|
219662848|NCT06400004|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
219662849|NCT06400004|DRUG|Lumason|Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
219662850|NCT04176081|DRUG|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
218985662|NCT05144360|DRUG|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
218985663|NCT00283400|DRUG|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
218985664|NCT04010149|DEVICE|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
218985665|NCT04010149|DEVICE|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
218985666|NCT01728064|DRUG|Placebo|Placebo capsules
218985667|NCT01728064|DRUG|EPI-743 400 mg|
218985668|NCT01728064|DRUG|EPI-743 200 mg|
218985669|NCT04171778|OTHER|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
218985670|NCT03920033|RADIATION|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
218985671|NCT05963659|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|nitrate-rich beetroot juice, \~750 mg NO3- /d
218985672|NCT05963659|DIETARY_SUPPLEMENT|nitrate-depleted beetroot juice|nitrate-depleted beetroot juice, \~1 mg NO3- /d
218985673|NCT03275454|DRUG|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
218985674|NCT03275454|DRUG|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
218985675|NCT05614505|DIETARY_SUPPLEMENT|Ready to use therapeutic foods|locally produced therapeutic foods
218985676|NCT00791570|BIOLOGICAL|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219662851|NCT04176081|DRUG|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
219662852|NCT04176081|RADIATION|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
219064936|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
219064937|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
219064938|NCT00000838|DRUG|Lamivudine|
219064939|NCT00000838|DRUG|Stavudine|
219662853|NCT06182618|OTHER|dietary, semaglutide or/and metformin|patients were prescribed dietary and pharmaceuticals for weight loss
219662854|NCT03209518|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
218970969|NCT03786614|OTHER|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
218970970|NCT03786614|OTHER|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
218970971|NCT03486431|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
218970972|NCT02909179|OTHER|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
219064940|NCT00000838|DRUG|Zidovudine|
219064941|NCT00000838|DRUG|Didanosine|
219064942|NCT04619641|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
219064943|NCT04619641|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
219064944|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
219064945|NCT00114686|DRUG|Quetiapine fumarate|
219064946|NCT00114686|DRUG|lithium|
219064947|NCT00114686|DRUG|divalproex|
219662855|NCT00718796|OTHER|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
219662856|NCT00718796|OTHER|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
219662857|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method A
219662858|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method B
219662859|NCT01507402|DRUG|Placebo|(inactive substance)
219662860|NCT05687838|OTHER|Music|Music medicine
219662861|NCT00236899|DRUG|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
219064948|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
219064949|NCT00724347|BEHAVIORAL|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
219662862|NCT00236899|DRUG|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
219662863|NCT00236899|DRUG|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
219662864|NCT00390624|DRUG|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
219662865|NCT00390624|DRUG|MANNITOL|
219662866|NCT00780624|DEVICE|NIPPV|Ventilator is Bird VIP.
219662867|NCT00780624|DEVICE|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
218970973|NCT03640767|BEHAVIORAL|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
218970974|NCT02240290|DRUG|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
218970975|NCT02240290|DRUG|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
218970976|NCT00557401|DRUG|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
218970977|NCT00557401|DRUG|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
218970978|NCT00557401|DRUG|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
218970979|NCT00557401|DRUG|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
219064950|NCT02332031|DRUG|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
219208363|NCT06754566|BEHAVIORAL|Caregiver-Assisted Rehabilitation with Strategy Training|CAR-ST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing daily activity limitations after stroke. The caregiver, as an active partner, not only supervises the participant but also co-participates in the practice. Caregivers are instructed on when and how to provide assistance during task practice, using physical, verbal, or visual guidance. As the participant's performance improves, the caregiver is empowered to motivate them to exert greater efforts, encouraging higher repetitions, longer durations of the same task, and an increased level of difficulty.
218970980|NCT00557401|DRUG|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
218970981|NCT05274139|DRUG|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
219208364|NCT06754566|BEHAVIORAL|Strategy Training|Compared to CAR-ST, ST is a home-based rehabilitation that guides stroke survivors only to implement strategy training for addressing daily activity limitations after stroke.
218970982|NCT05274139|DRUG|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
218970983|NCT01437878|DRUG|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
219662868|NCT00780624|DEVICE|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
218970984|NCT01437878|DRUG|Placebo|matching placebo
218970985|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
218970986|NCT04838392|DEVICE|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
218970987|NCT06264310|DRUG|Placebo|Matching placebo SC injection
218970988|NCT06264310|DRUG|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
218970989|NCT03722771|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
218970990|NCT03722771|OTHER|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
219064951|NCT02332031|DRUG|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
219064952|NCT04620473|DRUG|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
219064953|NCT04620473|DRUG|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
219064954|NCT01438541|DEVICE|Window|Dressing
219662869|NCT06018506|DRUG|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
219662870|NCT06301009|DIAGNOSTIC_TEST|AI-CAC score|Deep-learning based prediction of the coronary artery calcium score with a plain chest x-ray
219662871|NCT01469975|DRUG|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
219662872|NCT01469975|DRUG|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
219662873|NCT01469975|DRUG|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
219662874|NCT02388711|OTHER|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
219662875|NCT03009383|DEVICE|A bedside portable endoscopy|
219662876|NCT00416793|DRUG|bortezomib|Given IV
219662877|NCT00416793|DRUG|carboplatin|Given IV
219662878|NCT00416793|OTHER|laboratory biomarker analysis|Correlative studies
219662879|NCT06307509|OTHER|Diagnosis of sepsis|Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
219662880|NCT06504888|DRUG|Penicillin|Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
219662881|NCT00423397|BIOLOGICAL|PEG-interferon alfa-2a|
219662882|NCT00423397|DRUG|gefitinib|
219662883|NCT04413383|OTHER|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
219662884|NCT04413383|OTHER|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
219662885|NCT04413383|OTHER|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
219662886|NCT00237276|PROCEDURE|colonoscopy|
219662887|NCT03696485|BIOLOGICAL|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
219662888|NCT05619380|PROCEDURE|physiotherapy treatment|Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
219662889|NCT01429974|OTHER|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
219662890|NCT05977465|DRUG|Empagliflozin 25 MG|treatment
218970991|NCT03722771|OTHER|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
218970992|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
219662891|NCT03317457|BIOLOGICAL|Durvalumab and Tremelimumab|immun checkpoint inhibitor
219662892|NCT03317457|DRUG|Doxorubicin|Anthracycline
219662893|NCT02703818|DEVICE|Senza|Spinal Cord Stimulation
219662894|NCT05035849|DRUG|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
219662895|NCT00070213|DRUG|FOLFOX regimen|
218970993|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
218970994|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
218970995|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
219662896|NCT00070213|DRUG|capecitabine|
219662897|NCT00070213|DRUG|fluorouracil|
219662898|NCT00070213|DRUG|leucovorin calcium|
219662899|NCT00070213|DRUG|oxaliplatin|
219662900|NCT00070213|PROCEDURE|quality-of-life assessment|
219662901|NCT05674318|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
219662902|NCT01121536|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
219662903|NCT00387049|BEHAVIORAL|Anxiety Sensitivity Program for Smoking Cessation|
219662904|NCT06184906|DIETARY_SUPPLEMENT|Weaning by Mediterranean Diet|Introduce solid foods typical of the Mediterranean Diet at weaning of infants
219662905|NCT01487213|OTHER|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
219662906|NCT01589809|DRUG|nicotinamide|dose-escalation, 2-8 grams, oral
219662907|NCT05763056|PROCEDURE|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
219662908|NCT05763056|PROCEDURE|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
219662909|NCT05763056|DEVICE|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
219662910|NCT05805007|DRUG|ZVS203e|ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
219662911|NCT03896178|OTHER|None, observational study|None, observational study
219662912|NCT05580328|DRUG|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
219662913|NCT03146728|OTHER|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
219662914|NCT02696928|DRUG|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
219662915|NCT02696928|DRUG|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
219662916|NCT02696928|DRUG|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
219662917|NCT05135793|DRUG|Topoprazan|1 tablet contains 20 mg vonoprazan
219662918|NCT05135793|DRUG|Takecab|1 tablet contains 20 mg vonoprazan
219662919|NCT02860871|OTHER|infrared spectroscopy|
218970996|NCT02130726|PROCEDURE|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
218970997|NCT02130726|PROCEDURE|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
218970998|NCT02776371|DRUG|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
218970999|NCT02776371|DRUG|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
219208365|NCT06754566|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
219360259|NCT05120310|BEHAVIORAL|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
219662920|NCT00257205|DRUG|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
219662921|NCT00257205|DRUG|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
219662922|NCT00257205|DRUG|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
218971000|NCT04483167|DRUG|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
218971001|NCT06169631|DEVICE|Gen0b|The ultrasound will be administered to the brain region of interest.
218971002|NCT03538431|DRUG|Buspirone|Buspirone is an atypical anxiolytic medication.
219662923|NCT02977728|OTHER|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
219662924|NCT04436705|OTHER|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
219662925|NCT05197205|PROCEDURE|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
219662926|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
219064955|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
219662927|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
218971003|NCT01061632|PROCEDURE|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
218971004|NCT01061632|PROCEDURE|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
218971005|NCT05078502|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
218971006|NCT03210181|OTHER|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
218971007|NCT03210181|OTHER|Placebo|Patients will receive an equivalent volume of normal saline
218971008|NCT00620464|DRUG|Radiopaque Implanon|Radiopaque rod for 3 years
218971009|NCT00620464|DRUG|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
218971010|NCT03548233|BIOLOGICAL|bcg vaccine|live attenuated vaccine
218971011|NCT02271373|BEHAVIORAL|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
218971012|NCT00586066|DRUG|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
218971013|NCT00586066|DRUG|Placebo|Inactive comparator. Placebo-matching memantine tablet.
218971014|NCT01753804|OTHER|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
218971015|NCT03324672|PROCEDURE|TRIGGER|only TRIGGER point will be included for the manual therapy
218971016|NCT03324672|PROCEDURE|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
218971017|NCT01387373|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
218971018|NCT00227773|DRUG|octreotide acetate|
218971019|NCT00227773|DRUG|vatalanib|
218971020|NCT00227773|PROCEDURE|anti-cytokine therapy|
218971021|NCT00227773|PROCEDURE|antiangiogenesis therapy|
218971022|NCT00227773|PROCEDURE|biological therapy|
218971023|NCT00227773|PROCEDURE|endocrine therapy|
218971024|NCT00227773|PROCEDURE|enzyme inhibitor therapy|
218971025|NCT00227773|PROCEDURE|growth factor antagonist therapy|
218971026|NCT00227773|PROCEDURE|hormone therapy|
218971027|NCT00227773|PROCEDURE|protein tyrosine kinase inhibitor therapy|
218971028|NCT00227773|PROCEDURE|somatostatin analogue therapy|
218971029|NCT03359239|DRUG|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
219662928|NCT05022628|DRUG|Donafenib|"Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
219662929|NCT03345628|DRUG|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
219662930|NCT01290198|DRUG|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
219662931|NCT03205098|BIOLOGICAL|Blood analysis|Blood test of biological markers of mesenteric ischemia
219662932|NCT03924505|OTHER|Organize and Mobilize for Implementation Effectiveness|Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs
219662933|NCT03924505|OTHER|Dissemination|Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
219662934|NCT02854605|DRUG|GS-9674|Tablet administered orally once daily
219662935|NCT02854605|DRUG|Placebo to match GS-9674|Tablet(s) administered orally once daily
219662936|NCT05000853|DRUG|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
219662937|NCT02925377|BEHAVIORAL|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
219662938|NCT02925377|BEHAVIORAL|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
219662939|NCT00213577|DRUG|type A botulinum toxin|
219662940|NCT02644330|PROCEDURE|transthoracic device closure|minimally invasive transthoracic device closure
218971030|NCT03359239|BIOLOGICAL|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
218971031|NCT03359239|DRUG|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
218971032|NCT03359239|DRUG|Normal saline|0.19 mL
218971033|NCT01267656|DEVICE|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
218971034|NCT01267656|DEVICE|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
218971035|NCT03327454|BIOLOGICAL|Benepali|Administered as specified in the treatment arm.
218971036|NCT00642720|DRUG|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
219662941|NCT02644330|PROCEDURE|surgical repair|surgical repair with cardiopulmonary bypass
219662942|NCT03213925|RADIATION|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
219662943|NCT04191122|OTHER|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
219662944|NCT03014622|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
219662945|NCT03014622|BIOLOGICAL|Placebos|Intramuscular injection
219662946|NCT02560857|OTHER|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
219662947|NCT05869110|OTHER|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
219662948|NCT00153010|DRUG|NS 2330 (Tesofensine)|
219662949|NCT00568334|BIOLOGICAL|Varilrix (inactivated varicella vaccine)|subcutaneously injection
219662950|NCT06137534|OTHER|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
219662951|NCT05415241|DRUG|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
218971037|NCT02861989|OTHER|qualitative study|
218971038|NCT02320318|DRUG|Ibodutant 10 mg|Oral tablet, once daily.
218971039|NCT02320318|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
219064956|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
219662952|NCT05721690|DEVICE|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
219662953|NCT05721690|DEVICE|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
218971040|NCT03235843|DEVICE|AAIR pacing|Rate adaptive pacing using a MV sensor.
218971041|NCT03235843|DEVICE|DDI-pacing|Rate adaptive pacing OFF
218971042|NCT02173184|BIOLOGICAL|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
218971043|NCT02173184|BIOLOGICAL|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
218971044|NCT05659056|DRUG|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
218971045|NCT00287651|PROCEDURE|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
218971046|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
218971047|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
218971048|NCT05182099|DIAGNOSTIC_TEST|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
219064957|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
219064958|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
219064959|NCT03208972|DRUG|low dose hCG|
219064960|NCT03208972|DRUG|hp-FSH|
219064961|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
219064962|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
219064963|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
219662954|NCT00004770|DRUG|thioctic acid|
219662955|NCT01421745|OTHER|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
219662956|NCT01897571|DRUG|Tazemetostat|Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
219662957|NCT01897571|DRUG|Prednisolone|Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
219662958|NCT01897571|DRUG|Tazemetostat|Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
219064964|NCT02090907|DRUG|Levothyroxine|
219064965|NCT02090907|DRUG|Placebo|
219064966|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
219662959|NCT03777111|OTHER|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
219662960|NCT00939471|DEVICE|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
219662961|NCT00211315|DRUG|anecortave acetate|
219662962|NCT02357615|DRUG|nifedipine CR tablets (Xin Ran)|
219662963|NCT02357615|DRUG|Adalat|
219662964|NCT03299894|PROCEDURE|systematic calculation of qSOFA|calculation of qSOFA for each patient
219662965|NCT05172791|BEHAVIORAL|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
219662966|NCT00178269|DRUG|docetaxel|
219662967|NCT00178269|PROCEDURE|Radiation Therapy|
219662968|NCT01329666|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
219662969|NCT01329666|DIETARY_SUPPLEMENT|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
219064967|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
219064968|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
219064969|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
219064970|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
219064971|NCT02352038|DEVICE|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
219064972|NCT02352038|OTHER|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
219662970|NCT04720950|OTHER|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
219662971|NCT02168452|PROCEDURE|sentinel lymph node biopsy(SLNB)|"* incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~* double check after removal of the sentinel lymph node~* sending frozen biopsy"
219662972|NCT01600599|DRUG|Tranexamic Acid|intravenous 1g and topical 1g
219662973|NCT01600599|DRUG|saline|100mls of topical saline
219662974|NCT01528137|BIOLOGICAL|talactoferrin|Given PO
219662975|NCT01528137|OTHER|laboratory biomarker analysis|Correlative studies
219662976|NCT02089087|BIOLOGICAL|CFZ533|Single dose at varying dosage levels depending on treatment assignment
219662977|NCT02089087|DRUG|Placebo|
218971049|NCT02325661|OTHER|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
218971050|NCT03258138|BEHAVIORAL|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
218971051|NCT03258138|BEHAVIORAL|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
218971052|NCT03258138|BEHAVIORAL|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
218971053|NCT03258138|BEHAVIORAL|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
218971054|NCT03258138|BEHAVIORAL|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
218971055|NCT04398992|OTHER|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
218971056|NCT02968511|BIOLOGICAL|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
218971057|NCT03191240|DRUG|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
218971058|NCT03191240|DRUG|Normal saline|Placebo
218971059|NCT04644536|DEVICE|Bone graft substitute|Orthopaedic or Spine bony defects
218971060|NCT01982058|OTHER|communication intervention|
218971061|NCT01982058|OTHER|counseling intervention|
218971062|NCT01982058|OTHER|nutrition intervention|
218971063|NCT01982058|OTHER|questionnaire administration|
218971064|NCT00013234|PROCEDURE|Teledermatology|
219662978|NCT00306787|DRUG|Famciclovir|Famciclovir 500 mg tablet
219662979|NCT00306787|DRUG|Valacyclovir|Valacyclovir 500 mg capsule
219662980|NCT00306787|DRUG|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
219662981|NCT00306787|DRUG|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
219662982|NCT04422314|DIAGNOSTIC_TEST|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
219662983|NCT01126008|DRUG|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
219662984|NCT05922813|BIOLOGICAL|BMI2004|hyaluronidase, recombinant
218971065|NCT05794971|DRUG|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
219064973|NCT06348784|DIAGNOSTIC_TEST|Assesment of Different NEoplasias in the adenexa model|The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites
219064974|NCT06348784|DIAGNOSTIC_TEST|Risk of malignancy index|The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level
219064975|NCT06348784|DIAGNOSTIC_TEST|Histopathologic examination|Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy
219064976|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
219064977|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
219064978|NCT00390052|DRUG|triapine|Given IV and orally
219360260|NCT04093531|DRUG|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
219662985|NCT05922813|OTHER|0.9% NaCl|Normal Saline
219662986|NCT05106920|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
219662987|NCT04924023|BEHAVIORAL|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
219662988|NCT01436864|BIOLOGICAL|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
219662989|NCT01064635|DRUG|Letrozole|letrozole for 2-3 years after Tam
219662990|NCT01064635|DRUG|Letrozole|Letrozole for 5 years after Tam
219662991|NCT00469495|DRUG|Anti-helminthic|
219662992|NCT00469495|DRUG|meglumine antimony|
219662993|NCT02273908|OTHER|No intervention|The study is observational
218971066|NCT05794971|DRUG|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
218971067|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks from baseline
218971068|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
218971069|NCT04190173|DRUG|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
218971070|NCT04190173|DRUG|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
218971071|NCT01213550|DRUG|Chlorhexidine gluconate|
219064979|NCT00390052|OTHER|pharmacological study|correlative study
219064980|NCT00390052|PROCEDURE|laboratory biomarker analysis|Correlative study
219360261|NCT04911946|OTHER|Questionnaire|After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
219662994|NCT04352738|DIAGNOSTIC_TEST|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
219662995|NCT03472313|DRUG|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
219662996|NCT02106143|DEVICE|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
219662997|NCT01691703|DEVICE|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
219662998|NCT03371056|BIOLOGICAL|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
218971072|NCT01213550|DRUG|Placebo mouthrinse|
218971073|NCT00124488|DEVICE|Tomotherapy Treatment Planning|
218971074|NCT03219918|DEVICE|EndoRings II Distal Attachment|Colonoscopy cap
218971075|NCT00151853|DRUG|PPSB-SD|
218971076|NCT01498835|DRUG|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
219662999|NCT05917808|OTHER|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
219663000|NCT04908475|DRUG|Risankizumab|Subcutaneous injection
219663001|NCT04908475|DRUG|Apremilast|Oral Tablets
219663002|NCT02962206|DEVICE|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
219663003|NCT02962206|PROCEDURE|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
219064981|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
219663004|NCT03370458|DIETARY_SUPPLEMENT|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
219663005|NCT03370458|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
219663006|NCT05555602|DEVICE|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
219663007|NCT01980498|DRUG|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
219663008|NCT01980498|DRUG|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
219663009|NCT01644760|PROCEDURE|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
219663010|NCT05175820|OTHER|No intervention|Survey questions were sent through the mailing list of the Turkish Dental Association, where all dentists in Turkey are registered
219663011|NCT03303391|OTHER|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
219663012|NCT02103257|DRUG|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
219663013|NCT02103257|DRUG|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
219663014|NCT03913104|DRUG|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
219663015|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
219663016|NCT06215794|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
218971077|NCT06182280|BEHAVIORAL|PrEP4T|PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
218971078|NCT06182280|BEHAVIORAL|LS4TM|LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
218971079|NCT04082559|OTHER|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
218971080|NCT04082559|OTHER|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
219208366|NCT06847425|PROCEDURE|Sphenopalatine Ganglion Block trans oral approach saline injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of normal saline. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
219208367|NCT06847425|PROCEDURE|Sphenopalatine ganglion block trans oral approach bupivacaine injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of bupivacaine. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
219208368|NCT05510921|OTHER|Minimalist music group|Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.
219208369|NCT05510921|OTHER|Minimalist music + birdsongs group|Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
219208370|NCT06830941|DRUG|Iron isomaltoside|Intravenous infusion of 1000mg iron isomaltoside as a single dose for over 15min. Iron isomaltoside 1000mg was diluted in 100ml of 0.9% saline.
219208371|NCT06830941|DRUG|Ferrous succinate|Patients received ferrous succinate treatment orally given as 200mg twice a day for 8 weeks.
219208372|NCT06836037|DRUG|Efinopegdutide|Subcutaneous injection
219208373|NCT06836037|DRUG|Placebo|placebo matching efinopegdutide
219208374|NCT06786377|GENETIC|saliva sampling|saliva sampling
219208375|NCT01839747|PROCEDURE|PET-MRI|Imaging
219208376|NCT01839747|PROCEDURE|PET-CT|Imaging
219208377|NCT03487185|DEVICE|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
218971081|NCT04082559|OTHER|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
219663017|NCT06215794|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
218971082|NCT04082559|OTHER|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
218971083|NCT04082559|OTHER|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
218971084|NCT04082559|OTHER|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
218971085|NCT04082559|OTHER|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
218971086|NCT02207985|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
218971087|NCT01812590|BEHAVIORAL|Exercise|
218971088|NCT01743456|OTHER|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
218971089|NCT01216124|DRUG|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6"
218971090|NCT00467610|DRUG|Panhematin|
218971091|NCT02557659|DEVICE|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
219064982|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
219208378|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
219663018|NCT05338866|RADIATION|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
218971092|NCT01369615|DRUG|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
219064983|NCT01834417|DEVICE|TexiMat|
219064984|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
219064985|NCT02265042|DEVICE|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
219064986|NCT05427799|DIETARY_SUPPLEMENT|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
219064987|NCT05427799|DIETARY_SUPPLEMENT|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
219064988|NCT00244504|DRUG|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
219064989|NCT02669329|DEVICE|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
219360262|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
218971093|NCT03557554|OTHER|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
218971094|NCT03518931|DIAGNOSTIC_TEST|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
218971095|NCT04263454|DRUG|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
219064990|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
219360263|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
218971096|NCT04263454|PROCEDURE|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
218971097|NCT00417573|DRUG|IV Gamunex 10%|
218971098|NCT05093348|DEVICE|Click2Print artificial eye|Digitally designed and manufactured ocular prosthesis
218971099|NCT05093348|DEVICE|Hand-made artificial eye|Hand-made artificial eye
219663019|NCT05338866|DRUG|Chemotherapy|"For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
219360264|NCT02988765|PROCEDURE|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
219663020|NCT02734225|OTHER|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
219663021|NCT02734225|OTHER|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
219663022|NCT02734225|OTHER|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
219663023|NCT00089635|DRUG|Panitumumab|Administered by intravenous infusion
219663024|NCT01870167|DRUG|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
219663025|NCT01870167|DIETARY_SUPPLEMENT|Placebo|Placebo
219663026|NCT02254057|DRUG|BIBT 986 BS - single rising dose|
219663027|NCT02254057|DRUG|Placebo|
219663028|NCT00825981|OTHER|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
219663029|NCT02026869|DRUG|Metformin|Metformin is taken either orally or vaginally every 12 hours
219663030|NCT06000553|OTHER|blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.|If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
219663031|NCT05619770|DRUG|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
219663032|NCT01361867|DEVICE|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
219663033|NCT02550080|DRUG|Dapsone|For the HLA-B\*1301 positive subjects, dapsone will not be administrated.
219663034|NCT02550080|GENETIC|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
219663035|NCT06500650|BEHAVIORAL|Person-centred Occupational Therapy Intervention|Person-centred Occupational Therapy Intervention
219663036|NCT00939237|DRUG|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
219663037|NCT00939237|DRUG|Placebo|
219663038|NCT05656885|DEVICE|Lens A|Soft spherical hydrogel contact lens for 15 minutes
219663039|NCT05656885|DEVICE|Lens B|Soft spherical silicone hydrogel contact lens for 15 minutes
219663040|NCT01593254|DRUG|Imatinib|
219663041|NCT01593254|DRUG|Dasatinib|
219663042|NCT02242370|DRUG|Low dose of telmisartan|
219663043|NCT02242370|DRUG|High dose of telmisartan|
219663044|NCT01134861|DRUG|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
219663045|NCT01134861|DRUG|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
219663046|NCT01134861|DRUG|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
219663047|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
219663048|NCT01134861|DRUG|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
219663049|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
219663050|NCT01134861|RADIATION|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
219663051|NCT02748733|OTHER|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
219663052|NCT02748733|OTHER|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
219663053|NCT05345756|DEVICE|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
219663054|NCT05345756|DEVICE|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
219663055|NCT05501067|OTHER|tai chi exercise|specific tai chi exercise
219663056|NCT05501067|OTHER|no intervention|no intervention
219663057|NCT00076869|DRUG|MK0991, caspofungin acetate|
219663058|NCT00076869|DRUG|Comparator: amphotericin B|
219663059|NCT00076869|DRUG|Comparator: lipid formulation of amphotericin B and/or azole|
219663060|NCT04166058|DRUG|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
219663061|NCT04166058|DRUG|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
219663062|NCT00103298|DRUG|FOLFOX regimen|
219663063|NCT00103298|DRUG|fluorouracil|
219663064|NCT00103298|DRUG|isolated perfusion|
219663065|NCT00103298|DRUG|leucovorin calcium|
219663066|NCT00103298|DRUG|melphalan|
219663067|NCT00103298|DRUG|oxaliplatin|
219663068|NCT05559372|DIETARY_SUPPLEMENT|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
219663069|NCT04716036|OTHER|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
219663070|NCT04716036|OTHER|Placebo beverage|placebo beverage condition.
219663071|NCT05624736|DIAGNOSTIC_TEST|multi-parametric magnetic resonance imaging scan|Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
219663072|NCT05624736|DIAGNOSTIC_TEST|Pathology examination|The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
219663073|NCT03699813|OTHER|Comparison of two approaches to bleeding management|
219663074|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
219064991|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
219064992|NCT01318226|DRUG|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
219360265|NCT06584045|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
219663075|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
219663076|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
219663077|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
219663078|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
219663079|NCT06538285|DRUG|Ketamine|Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
219663080|NCT06538285|BEHAVIORAL|Psychotherapy|Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
219663081|NCT04296851|DRUG|Niclosamide|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
219663082|NCT04296851|DRUG|placebo|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
219663083|NCT05821296|DEVICE|Crystal Peel|3 applications performed by a dermatologist.
219663084|NCT03772977|BEHAVIORAL|Brain Health Champion|A health coach embedded within an existing clinical care team
219663085|NCT06079762|BEHAVIORAL|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
219663086|NCT04536961|DRUG|Reference Treatment- BMS-986165-01|Specified dose on specified days
219663087|NCT04536961|DRUG|Prototype BMS-986165|Specified dose on specified days
219663088|NCT04536961|DRUG|Famotidine|Specified dose on specified days
219663089|NCT04536961|OTHER|Alcohol|Specified quantity on specified days
219663090|NCT01939626|DEVICE|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
219663091|NCT01939626|DEVICE|Standard culture medium|This culture system needs media change on day 3 of culture.
219663092|NCT04291482|BEHAVIORAL|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
218971100|NCT05752981|DEVICE|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
218971101|NCT01785407|DIETARY_SUPPLEMENT|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
218971102|NCT03911154|DEVICE|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
218971103|NCT03911154|DEVICE|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
218971104|NCT03911154|DEVICE|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
218971105|NCT01600118|DEVICE|Extracorporeal shockwave therapy|1000 impulses
218971106|NCT01600118|DEVICE|No extracorporeal shockwave|0 impulses, acoustic effect
218971107|NCT05591846|BEHAVIORAL|Face-to-face training|Face-to-face training
218971108|NCT05591846|BEHAVIORAL|web-based training|web-based training
218971109|NCT05236153|DIAGNOSTIC_TEST|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
218971110|NCT03815617|DIETARY_SUPPLEMENT|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
218971111|NCT03815617|DIETARY_SUPPLEMENT|Placebo|Given as comparable packets. Same duration.
218971112|NCT00752037|DRUG|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
218971113|NCT03470571|DIAGNOSTIC_TEST|CMR|Outcome analysis of CMR features in suspected myocarditis patients
218971114|NCT03547986|DIAGNOSTIC_TEST|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
218971115|NCT03547986|DIAGNOSTIC_TEST|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
218971116|NCT04353414|PROCEDURE|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
218971117|NCT04353414|PROCEDURE|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
218971118|NCT04353414|DRUG|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
218971119|NCT03642743|OTHER|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
218971120|NCT01712646|DRUG|Intranasal Oxytocin|
218971121|NCT05560035|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
218971122|NCT05560035|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
219360266|NCT04102033|DRUG|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
219663093|NCT04291482|BEHAVIORAL|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
219663094|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
219663095|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
219663096|NCT06060106|PROCEDURE|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
219663097|NCT06060106|PROCEDURE|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
219663098|NCT01022164|PROCEDURE|fibrin glue|
219663099|NCT02603562|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
219663100|NCT02608255|OTHER|blood samples|
219663101|NCT04805359|BEHAVIORAL|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
219663102|NCT04805359|BEHAVIORAL|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
219663103|NCT06622096|DIAGNOSTIC_TEST|Evaluation of laboratory exams prescription|Evaluation of laboratory exams prescription
219663104|NCT04491305|PROCEDURE|Surgically treated women with endometriosis and confirmed diagnosis|Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
219663105|NCT05604872|PROCEDURE|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
219663106|NCT06290804|OTHER|education|Training program on Health Impacts of Sustainable Behaviors and Climate Change
218971123|NCT00023244|DRUG|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
218971124|NCT00023244|DRUG|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
218971125|NCT00023244|DRUG|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
219064993|NCT01318226|DRUG|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
219064994|NCT03704376|DRUG|30 ml of 0.2% ropivacaine|
219064995|NCT03704376|DRUG|15 ml of 0.2% ropivacaine|
219064996|NCT03704376|DRUG|100 mcg clonidine|
219663107|NCT04108663|BEHAVIORAL|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
219663108|NCT00438802|DRUG|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
219663109|NCT01724801|RADIATION|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
219663110|NCT01724801|DRUG|Icotinib|administered orally at a dose of 125 mg 3 times daily
219663111|NCT00497770|DRUG|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
219663112|NCT01481272|DRUG|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
219663113|NCT01481272|DRUG|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
219663114|NCT01481272|DRUG|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients \>/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
219663115|NCT01481272|DRUG|Mesna|300mg/m2 or 200mg/m2 (patients \>/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients \>/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
219663116|NCT01481272|DRUG|Cytarabine|2g/m2 or 0,5-1g/m2 (patients \>/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
219663117|NCT01481272|DRUG|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
219663118|NCT01481272|DRUG|Leukovorin|15mg, po 24 hours after methotrexate it
219064997|NCT03704376|DEVICE|High-frequency linear ultrasound transducer|
219064998|NCT04020991|DIAGNOSTIC_TEST|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
219064999|NCT02053948|PROCEDURE|Pursestring Wound Closure|
218971126|NCT00023244|DRUG|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
219065000|NCT02053948|PROCEDURE|Gunsight Skin Incision and Closure Technique|
219065001|NCT02201927|DEVICE|galvanic vestibular stimulation|
219663119|NCT01481272|DRUG|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC\>1.0x109/l
219663120|NCT02403349|DRUG|Fimasartan|
219663121|NCT02403349|DRUG|Valsartan|
219663122|NCT02403349|DRUG|Atenolol|
219663123|NCT00833118|PROCEDURE|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
219663124|NCT03750409|DEVICE|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
219663125|NCT06333405|DRUG|Fecal Microbiota Transplantation|"Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI"
219663126|NCT02472626|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
219663127|NCT02472626|DRUG|Cytarabine|Given IV
219663128|NCT02472626|DRUG|Daunorubicin Hydrochloride|Given IV
219663129|NCT04339309|PROCEDURE|Non-surgical periodontal treatment with interdental hygiene devices|
218971127|NCT00023244|DRUG|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
218971128|NCT00023244|DRUG|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
218971129|NCT00023244|DRUG|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
218971130|NCT02570841|DRUG|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
218971131|NCT02570841|DRUG|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
218971132|NCT00986479|DRUG|AZD6765|Single IV infusion of 150 mg AZD6765.
218971133|NCT00986479|DRUG|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
218971134|NCT02730520|OTHER|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
218971135|NCT04672330|DRUG|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
218971136|NCT02314390|BEHAVIORAL|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
218971137|NCT02314390|BEHAVIORAL|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
218971138|NCT03657862|DEVICE|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
218971139|NCT03657862|OTHER|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
218971140|NCT02534818|DRUG|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
219065002|NCT06269770|DRUG|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
219065003|NCT06269770|DRUG|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
219065004|NCT04712942|DRUG|Pevonedistat|Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
219065005|NCT04712942|DRUG|Azacitidine|azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
219663130|NCT04339309|PROCEDURE|Non-surgical periodontal treatment without interdental hygiene devices|
219663131|NCT06135025|OTHER|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
219663132|NCT05180370|OTHER|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
219663133|NCT00796744|DRUG|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
219663134|NCT03698968|DEVICE|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
219663135|NCT05299372|OTHER|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
219663136|NCT05721300|DRUG|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
219663137|NCT05721300|DRUG|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
219663138|NCT01782352|DRUG|Omega-3 fatty acids (fish oil)|
219663139|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3|
219663140|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
219663141|NCT01782352|DIETARY_SUPPLEMENT|Fish oil placebo|
219663142|NCT01589107|BEHAVIORAL|video decision aid|video decision aid
219663143|NCT04263636|PROCEDURE|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
219663144|NCT06901323|DRUG|L-carnitine|44 patients diagnosed as a case of phenylketonuria will receive l-carnitine at a dose of 100 mg/kg/day for 1 year and then blood sample will examined for level of brain-derived neurotrophic factor levels before and after therapy and another group composed of 44 patients diagnosed as a case of phenylketonuria will not receive l-carnitine and their blood sample will examined for level of brain-derived neurotrophic factor levels treated and untreated patients will compared with healthy children and infants has same age and sex .
219663145|NCT03968224|DRUG|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
219663146|NCT03968224|DRUG|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
219663147|NCT02086084|DEVICE|NIV|Standard care
218971141|NCT02534818|DRUG|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
218971142|NCT04332380|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
218971143|NCT01225107|DIETARY_SUPPLEMENT|Cranberry Extract|500mg TID
218971144|NCT01225107|DRUG|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
218971145|NCT02947412|OTHER|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
218971146|NCT02675712|OTHER|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
218971147|NCT02761434|OTHER|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
218971148|NCT02761434|OTHER|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
218971149|NCT00815243|PROCEDURE|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
219065006|NCT00074282|BIOLOGICAL|rituximab|
219065007|NCT00074282|DRUG|cyclophosphamide|
219065008|NCT00074282|DRUG|pentostatin|
219065009|NCT00074282|DRUG|Alemtuzumab|
219065010|NCT05973071|BEHAVIORAL|Tuune Supplemented Contraceptive Visit|Participants complete the Tuune contraceptive decision aid health questionnaire (Tuune for clinics) as part of their standard OBGYN clinic appointment.
219065011|NCT05973071|BEHAVIORAL|Traditional Contraceptive Visit|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire (Tuune for Clinics).
218971150|NCT00815243|PROCEDURE|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
219065012|NCT00464542|DRUG|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
219065013|NCT00740545|DRUG|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
219065014|NCT00740545|DRUG|placebo|Women inject ourselves every days with placebo
219065015|NCT00605241|DRUG|GSK598809|Drug
219065016|NCT00275093|DRUG|temsirolimus|Given IV
219065017|NCT00275093|OTHER|laboratory biomarker analysis|Correlative studies
219065018|NCT00275093|OTHER|pharmacological study|Correlative studies
219360267|NCT02798796|DEVICE|MRI|All patients will be submitted to MRI
219663148|NCT02086084|DEVICE|ECCO2R|Application of ECCO2R in addition to NIV
219663149|NCT05616117|OTHER|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
219663150|NCT05616117|OTHER|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
219663151|NCT01873300|PROCEDURE|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
219663152|NCT01228110|DRUG|Hydrocortison|
219663153|NCT01228110|DRUG|Saline Solution|
219663154|NCT02521532|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219663155|NCT02521532|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219663156|NCT00526903|BEHAVIORAL|Elimination Diet|Daily diet change for 8 days.
219663157|NCT04505384|PROCEDURE|left bundle branch pacing|left bundle branch pacing
219663158|NCT04505384|PROCEDURE|biventricular pacing|biventricular pacing
219663159|NCT04613193|OTHER|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
219663160|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
219663161|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
219663162|NCT05541978|OTHER|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
219663163|NCT06394856|PROCEDURE|Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques|rotator cuff tears with modified versus classic double row suture bridge
219663164|NCT02599597|BEHAVIORAL|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
219663165|NCT02599597|BEHAVIORAL|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
219663166|NCT00932698|DRUG|Ixazomib|Ixazomib capsules
218971151|NCT05588271|OTHER|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
218971152|NCT06644612|PROCEDURE|Light Weight Mesh|Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
218971153|NCT06644612|PROCEDURE|Heavy Weight Mesh|Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
218971154|NCT02035475|DEVICE|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
218971155|NCT02159612|OTHER|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
218971156|NCT00178750|DEVICE|18G Tuohy epidural needle|
218971157|NCT00178750|DEVICE|CompuFlo® computerized syringe pump|
218971158|NCT03828409|PROCEDURE|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
218971159|NCT03828409|PROCEDURE|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
219065019|NCT02861690|DRUG|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
219065020|NCT02861690|DRUG|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
219065021|NCT01773226|DEVICE|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
219065022|NCT01429259|DRUG|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
219360268|NCT00852293|OTHER|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
219360269|NCT05464784|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
219360270|NCT05464784|DRUG|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
219663167|NCT02829827|DRUG|Radiprodil|Radiprodil at individualized doses.
218971160|NCT05864170|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
219065023|NCT02699177|DEVICE|CBF measurements|CBF measurements
219065024|NCT04269772|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
219663168|NCT04299139|OTHER|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
218971161|NCT01776047|DRUG|Exforge®|
218971162|NCT01776047|DRUG|G-0081|
219065025|NCT04269772|OTHER|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
219065026|NCT01097135|DRUG|Duraprep Surgical Solution|
219065027|NCT06391112|OTHER|Painting Based Art intervention|Painting Based Art Effect of Intervention on Maternal Anxiety and Fetal Parameters
218971163|NCT01231347|DRUG|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
218971164|NCT01231347|DRUG|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
218971165|NCT01231347|DRUG|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
218971166|NCT01231347|DRUG|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
218971167|NCT01461278|DEVICE|iStent supra|Cataract surgery and implantation of one iStent supra
218971168|NCT01461278|PROCEDURE|Cataract surgery|Cataract surgery alone
218971169|NCT02085915|OTHER|strip Peri Screen|
218971170|NCT02322021|DRUG|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
219065028|NCT02081300|DRUG|Oral testosterone undecanoate, LPCN 1021|
219065029|NCT02081300|DRUG|Topical testosterone gel 1.62 %|
219065030|NCT02094703|DRUG|Levofloxacin|
219360271|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed under transabdominal ultrasound guidance|The placement of an ultrasound probe on the lower abdomen while a Pipelle® endometrial biopsy is obtained.
219663169|NCT00655681|DRUG|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
219663170|NCT00655681|OTHER|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
219663171|NCT00086112|DRUG|risperidone oral tablets|
219663172|NCT05822362|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
219663173|NCT05822362|OTHER|Placebo|Placebo arm.
219663174|NCT02594774|OTHER|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
219663175|NCT03493750|OTHER|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
219663176|NCT03604770|OTHER|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
219663177|NCT04805697|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
219663178|NCT04805697|DIETARY_SUPPLEMENT|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
219663179|NCT01519297|DRUG|Irbesartan|150mg orally for one dose
219663180|NCT03034473|OTHER|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\]."
219663181|NCT06619665|DRUG|MK-6552|MK-6552 gelatin coated capsules taken orally two times 8 hours apart
219663182|NCT06619665|DRUG|MK-6552 placebo|MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
219663183|NCT06619665|DRUG|Modafinil|Modafinil tablet taken once orally
219663184|NCT06619665|DRUG|Modafinil placebo|Modafinil placebo tablet taken once orally
219663185|NCT06648330|PROCEDURE|Paraaortic retroperitoneal lymph node dissection|The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
219663186|NCT00560586|DRUG|Budesonide|1 puff each nostril (32 micrograms) at bedtime
219663187|NCT00560586|DRUG|placebo|1 puff each nostril at bedtime
219663188|NCT06620874|BIOLOGICAL|STABHA Injection|Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval
219663189|NCT06620874|OTHER|High-Concentration Glucose Water Injection|Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval
219663190|NCT06620874|OTHER|Saline Injection|Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval
219663191|NCT03486002|DEVICE|Cleansweep|The Cleansweep closed suction system
219663192|NCT03486002|DEVICE|Halyard|Halyard Closed Suction System
219663193|NCT03240523|DRUG|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
219663194|NCT05561946|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
219663195|NCT02429310|DEVICE|Revitive IX|This is a neuromuscular electrical stimulation device
219663196|NCT02132975|DEVICE|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
219663197|NCT02132975|PROCEDURE|Biopsies using UroStation® (image fusion)|
219663198|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
219663199|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
219663200|NCT05992961|DIAGNOSTIC_TEST|Troponin I|"Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists."
219686521|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms
219065031|NCT02094703|DRUG|Solifenacin succinate|
219065032|NCT02094703|DRUG|Placebo (for Solifenacin succinate)|
219065033|NCT02055352|DRUG|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
219065034|NCT02055352|DRUG|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
219065035|NCT02055352|DRUG|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
219065036|NCT02055352|DRUG|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
219065037|NCT02180646|OTHER|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
219065038|NCT02180646|OTHER|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
219065039|NCT03809182|DRUG|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
219065040|NCT03809182|DRUG|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
219686522|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
218971171|NCT02322021|DRUG|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
218971172|NCT01702571|DRUG|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
218971173|NCT00326794|PROCEDURE|mobilisation (rehabilitation)|
218971174|NCT06333821|BIOLOGICAL|Nimotuzumab|Nimotuzumab 400mg
218971175|NCT06333821|DRUG|Cisplatin|Cisplatin 40mg/m\^2
218971176|NCT06333821|RADIATION|External Beam Radiotherapy (EBRT)|External Beam Radiotherapy (EBRT)
218971177|NCT06333821|RADIATION|Brachytherapy|Brachytherapy
218971178|NCT06333821|DRUG|placebo for Nimotuzumab|placebo for Nimotuzumab 400mg
218971179|NCT00232167|DRUG|Indiplon|
218971180|NCT00232167|DRUG|Sertraline|
218971181|NCT06327659|DEVICE|30 mL syringe manual thrombectomy catheter|30 mL syringe manual thrombectomy catheter
218971182|NCT06327659|DEVICE|50 mL syringe manual thrombectomy catheter|50 mL syringe manual thrombectomy catheter
218971183|NCT00135733|DRUG|Amevive (Alefacept)|
218971184|NCT00135733|DRUG|Placebo|
218971185|NCT03356054|COMBINATION_PRODUCT|R-DHAP|3 cycles q 3 weeks
218971186|NCT03356054|DRUG|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
218971187|NCT00406094|DRUG|montelukast|10mg
218971188|NCT00406094|DRUG|placebo|placebo
218971189|NCT05030246|DRUG|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
219360272|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed without ultrasound guidance|A Pipelle® endometrial biopsy is performed by using touch alone.
218971190|NCT00992329|DRUG|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
218971191|NCT05355610|DRUG|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
218971192|NCT05355610|DRUG|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
218971193|NCT02185846|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
218971194|NCT02185846|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
218971195|NCT01295229|PROCEDURE|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
218971196|NCT01295229|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
218971197|NCT04180774|BIOLOGICAL|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
218971198|NCT02269046|OTHER|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
218971199|NCT02269046|DRUG|Simvastatin|10mg/d,p.o,12 weeks.
218971200|NCT02269046|OTHER|Therapeutic Lifestyle Change|"* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity"
218971201|NCT00861536|DRUG|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
218971202|NCT00861536|DRUG|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
218971203|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
218971204|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
218971205|NCT04386031|DIAGNOSTIC_TEST|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
218971206|NCT02516254|DIETARY_SUPPLEMENT|fortified bread|50 g of fortified bread + placebo daily
218971207|NCT02516254|DIETARY_SUPPLEMENT|supplement|vitamin D supplement+ plain bread
218971208|NCT02516254|DIETARY_SUPPLEMENT|placebo|plain bread+placebo
218971209|NCT04160728|OTHER|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
218971210|NCT04160728|OTHER|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
218971211|NCT04160728|OTHER|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
219360273|NCT06213922|BEHAVIORAL|Food intake|Fast food
219360274|NCT00272987|DRUG|lapatinib|(GW572016) 1000 mg QD
219663201|NCT06620328|PROCEDURE|endoscopic ultrasonography-guided biliary drainage|"Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover"
219663202|NCT02707588|DRUG|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
219663203|NCT02707588|DRUG|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
219663204|NCT02707588|RADIATION|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
219663205|NCT02651805|DEVICE|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
219663206|NCT02651805|OTHER|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
219663207|NCT05640284|DIAGNOSTIC_TEST|Nuclear Factor-Kappa B Ligand (RANKL) analysis|samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
218971212|NCT04160728|OTHER|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
218971213|NCT04160728|OTHER|Business as usual scenario|No interference with the usual work day of the participants
218971214|NCT04160728|OTHER|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
218971215|NCT05665179|BEHAVIORAL|Removing Barriers to Recovery|Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
218971216|NCT02047227|DRUG|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
219065041|NCT03809182|DRUG|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
219065042|NCT03809182|DRUG|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
219065043|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~  * Type and duration of central venous catheter use~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
219065044|NCT04218929|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
219065045|NCT04218929|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
219065046|NCT03641482|DRUG|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
219360275|NCT00272987|DRUG|paclitaxel|80 mg/m2 IV weekly for three weeks
219360276|NCT00272987|DRUG|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
219663208|NCT05640284|DIAGNOSTIC_TEST|Osteoprotegerin (OPG) analysis|samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
219663209|NCT05640284|DIAGNOSTIC_TEST|Tumor Necrosis Factor Alpha (TNF-α) analysis|samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
219663210|NCT05640284|DIAGNOSTIC_TEST|MicroRNA-223 analysis|samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
219663211|NCT05640284|DIAGNOSTIC_TEST|Microrna-27a analysis|samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
219663212|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
219663213|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
219663214|NCT00411073|DRUG|Darapladib|
219663215|NCT06278727|DRUG|angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor|Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
219663216|NCT06278727|OTHER|The development of the prediction model|The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
219663217|NCT06903299|DRUG|Intra-articular Tranexamic acid application|Intra-articular Tranexamic acid application during THA and evaluation of postoperative blood losses, hemoglobin decline and associated blood transfusion, heterotopic ossification and other parameters.
219663218|NCT05330273|DRUG|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
219663219|NCT05330273|COMBINATION_PRODUCT|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
219663220|NCT05330273|DRUG|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
219663221|NCT06455124|RADIATION|Radiation|Shor-course radiotherapy: 25Gy/5Fx
219663222|NCT06455124|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
219663223|NCT06455124|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
219663224|NCT06455124|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219663225|NCT02103335|DRUG|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
219663226|NCT02103335|DRUG|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
218971217|NCT02047227|DRUG|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
218971218|NCT02047227|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
218971219|NCT02466373|DRUG|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
218971220|NCT01721473|OTHER|positron emission tomography scan|2-FA positron emission tomography scan
219663227|NCT02103335|DRUG|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
219663228|NCT05520021|DRUG|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
219663229|NCT05520021|DRUG|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
218971221|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
218971222|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
218971223|NCT01241773|DRUG|raltegravir|One 400 mg tablet twice daily for 7 days
218971224|NCT01241773|DRUG|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
218971225|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 7 days
218971226|NCT01241773|DRUG|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
218971227|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 14 days
218971228|NCT01241773|DRUG|efavirenz|One 600 mg tablet once daily for 14 days
218971229|NCT01977937|DRUG|Gabapentin 250mg/5mL NDC:59762-5025-01|
218971230|NCT01977937|DRUG|Simple Syrup|
219663230|NCT06906315|DRUG|Dexamethasone 4 mg|Participants in this group received a single 4 mg oral dose of dexamethasone 1 hour before undergoing endodontic treatment. No additional preoperative analgesics were administered. Standard endodontic procedures, including local anesthesia, were performed. Post-treatment, no routine analgesic medication was provided unless additional pain relief was required. Pain intensity was assessed at 4, 6, 8, 12, and 24 hours using the Visual Analog Scale (VAS) to evaluate the efficacy of preoperative dexamethasone in controlling postoperative pain and inflammation.
219663231|NCT06906315|DRUG|Ibuprofen group|Participants in this group received no preoperative medication but were prescribed 400 mg of ibuprofen every 4 hours postoperatively for pain management. The same standard endodontic procedures were performed. Pain levels were recorded at 4, 6, 8, 12, and 24 hours using the VAS scale to compare the effectiveness of postoperative ibuprofen with preoperative dexamethasone.
219663232|NCT01072513|OTHER|Semen analysis|Semen analysis before and after proton radiation therapy.
219663233|NCT03589118|OTHER|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
219663234|NCT01085136|DRUG|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
219663235|NCT01085136|DRUG|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
219663236|NCT06619470|OTHER|binaural beats|binaural beats
219663237|NCT05581433|OTHER|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
219663238|NCT05581433|OTHER|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
219065047|NCT03641482|DEVICE|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
219065048|NCT01309620|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
219065049|NCT01309620|DIETARY_SUPPLEMENT|Placebo|Placebo, Twice Daily
219663239|NCT06505551|BIOLOGICAL|SCG142|Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
219663240|NCT06505551|DRUG|Cyclophosphamide|for 3 consecutive days
219663241|NCT06505551|DRUG|Fludarabine|for 3 consecutive days
219663242|NCT01079754|DRUG|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
219663243|NCT01079754|DRUG|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
219663244|NCT01090154|DRUG|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
219663245|NCT03094676|OTHER|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
219663246|NCT03094676|OTHER|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
219663247|NCT05865847|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
219663248|NCT01725360|DRUG|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
219663249|NCT02178527|OTHER|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
219663250|NCT02178527|OTHER|Usual Care|Usual general podiatry care provded by UK National Health Service
219663251|NCT00004982|DRUG|Combination Iron Chelation Therapy|
219065050|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
219663252|NCT03903367|DRUG|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
219065051|NCT04712526|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
219065052|NCT00215852|DRUG|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
219065053|NCT06535412|DRUG|IMC-002 + SOC|intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
219065054|NCT06535412|DRUG|Placebo + SOC|intravenous injection of Placebo
219065055|NCT01636310|OTHER|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
219065056|NCT06386484|DEVICE|PolarCap System|The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
219065057|NCT04393545|DEVICE|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
219065058|NCT04393545|OTHER|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
219065059|NCT04393545|OTHER|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
219663253|NCT02978885|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
219663254|NCT02978885|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
219663255|NCT02978885|PROCEDURE|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
219663256|NCT02978885|PROCEDURE|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
219663257|NCT03121573|DRUG|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
219663258|NCT05807438|OTHER|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
219663259|NCT05807438|OTHER|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
219663260|NCT03286231|DIAGNOSTIC_TEST|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
219663261|NCT06474650|DRUG|LPM3770164 sustained release tablet|Single-dose of 30 mg of LPM3770164 sustained release tablet
219663262|NCT01764659|OTHER|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
219663263|NCT01210352|DRUG|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
219663264|NCT03279354|BEHAVIORAL|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
219663265|NCT03279354|BEHAVIORAL|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
219663266|NCT06906835|OTHER|RET-He-Guided Iron Supplementation|"Participants in this arm will receive intravenous (IV) iron therapy guided by reticulocyte hemoglobin equivalent (RET-He) levels.~Iron dosing will follow a protocol based on RET-He values:~* RET-He \< 26 pg: IV iron 100 mg weekly~* RET-He ≥ 26 pg and \< 30 pg: IV iron 100 mg every 2 weeks~* RET-He ≥ 30 pg and ≤ 36 pg: IV iron 100 mg every 4 weeks~* RET-He \> 36 pg or ferritin ≥ 800 ng/mL: Discontinue iron supplementation to prevent iron overload"
218971231|NCT00551044|DRUG|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
218971232|NCT01428362|DRUG|VI-1121|
218971233|NCT01428362|DRUG|Placebo|
218971234|NCT05032430|BEHAVIORAL|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
218971235|NCT05032430|BEHAVIORAL|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
218971236|NCT00225446|DEVICE|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
218971237|NCT01094756|DIETARY_SUPPLEMENT|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
218971238|NCT03144531|BEHAVIORAL|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
218971239|NCT05300633|BEHAVIORAL|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
218971240|NCT00915356|DRUG|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
218971241|NCT00915356|DRUG|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
218971242|NCT00390598|DRUG|PEG (solution given 4 L)|
218971243|NCT00390598|DRUG|senna glycoside 36 mg and PEG (solution given 2 L)|
218971244|NCT03031158|BEHAVIORAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
218971245|NCT03031158|BEHAVIORAL|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
218971246|NCT03267732|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
218971247|NCT00136331|BIOLOGICAL|Pandemic influenza vaccine|
218971248|NCT05276947|OTHER|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
218971249|NCT02073110|DEVICE|Percutaneous Optical Biopsy (OCT and DRS)|
218971250|NCT01782833|OTHER|This is Non-interventional study|
218971251|NCT01438073|DRUG|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
218971252|NCT01438073|DRUG|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
219663267|NCT06906835|OTHER|TSAT-Guided Iron Supplementation|"Participants in this arm will receive IV iron therapy guided by transferrin saturation (TSAT) and serum ferritin, as per the Thai Clinical Practice Guidelines for Anemia in CKD (2021).~Iron dosing will follow this TSAT-based protocol:~* TSAT \< 30% and ferritin \< 200 ng/mL: IV iron 100 mg weekly~* TSAT \< 30% and ferritin 200-500 ng/mL: IV iron 100 mg every 2 weeks~* TSAT \< 30% and ferritin 500-800 ng/mL or TSAT 30-40%: IV iron 100 mg every 4 weeks~* TSAT ≥ 40% or ferritin ≥ 800 ng/mL: Discontinue iron supplementation"
219663268|NCT06906835|OTHER|Common|"All participants will receive erythropoiesis-stimulating agents (ESAs) according to a standardized dose adjustment protocol based on hemoglobin levels.~Oral iron supplements will be discontinued."
219663269|NCT02187575|DRUG|UHAC 62 XX tablet|
219663270|NCT02187575|DRUG|UHAC 62 XX capsule|
219663271|NCT03795025|OTHER|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
219663272|NCT03795025|OTHER|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
219663273|NCT03795025|OTHER|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
219663274|NCT01298141|BIOLOGICAL|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
219663275|NCT03919591|OTHER|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
219663276|NCT03958942|OTHER|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
219663277|NCT03958942|OTHER|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
219663278|NCT06912334|DEVICE|tVNS|tVNS L is a battery-driven electrical stimulator connected to an ear electrode which is positioned over the skin of the cymba conchae. Thus, auricular vagal stimulation will be applied using the typical ear electrodes of the tVNS® L device. tVNS will be applied over the left branch for safety reasons. For sham auricular tVNS, the anodal electrode will be placed over the center of the left ear lobe. The cathode will be placed over the antitragus. This method and these stimulation parameters have been previously used for reliable blinding in other clinical studies. Series of electrical pulses with 250 μs pulse width, 25 Hz frequency, and 28 s inter-burst interval (32 sec on/28 sec off duty cycle) will be applied in each intervention session. Auricular tVNS will be applied at 1mA - 5mA intensity for 30 min per session (1 session per day, 7 consecutive days a week, 14 sessions in total)
219686523|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|"To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research."
219686524|NCT03862092|DIAGNOSTIC_TEST|Salivary VZV-DNA PCR|VZV-DNA PCR of saliva samples
218971253|NCT01699932|DRUG|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
218971254|NCT01370668|BEHAVIORAL|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
218971255|NCT01370668|BEHAVIORAL|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
218971256|NCT01370668|BEHAVIORAL|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
218971257|NCT02595359|DRUG|Moxifloxacin|Moxifloxacin intracameral
218971258|NCT00362037|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
219065060|NCT02553330|DRUG|Placebo Cream|
219065061|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
219065062|NCT03043183|PROCEDURE|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
218971259|NCT02715479|DRUG|Dolutegravir|Dolutegravir
218971260|NCT02715479|DRUG|BMS955176|BMS955176
218971261|NCT02101203|DRUG|Placebo|
218971262|NCT02101203|DRUG|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
218971263|NCT01209923|DEVICE|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
218971264|NCT03221907|DRUG|GLA5PR GLARS-NF1|Pregabalin tablet
219360277|NCT02574104|OTHER|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
219360278|NCT04575701|OTHER|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
219663279|NCT06911710|DRUG|CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）|"Phase I study: dose-escalation component.This part follows the 3+3 dose-escalation model, with 5 dose groups: 1×10\^6, 1.5×10\^6, 2×10\^6, 2.5×10\^6, 3×10\^6 CAR+ cells/kg (different target CAR-T can be adjusted by the investigator according to the dose used in the previous clinical trial). Each dose group enrolled 3\~6 patients with relapsed/refractory hematological diseases respectively, totaling 15\~30 subjects, in order to evaluate the safety of CAR-T cells for the treatment of relapsed/refractory malignant hematological neoplasms and to determine the MTD. Phase II study: dose-expansion portion. After the MTD was confirmed, in the dose-expansion portion of the study (Phase II), it was expected that 65\~60 subjects would receive the CAR-T cell injection infusion under RP2D to further evaluate the efficacy of CAR-T cell injection."
219663280|NCT03744845|OTHER|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
219663281|NCT01854879|DEVICE|Nucleus 6 sound processor|
218971265|NCT03221907|DRUG|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
218971266|NCT03221907|DRUG|Pregabalin|Pregabalin capsule
218971267|NCT03221907|DRUG|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
218971268|NCT05226273|OTHER|no intervention|no intervention
218971269|NCT04461288|BEHAVIORAL|Social media-based education, counseling, and support|This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
218971270|NCT04461288|OTHER|Nicotine replacement therapies (NRT)|"Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette."
218971271|NCT04461288|OTHER|Gamification|Gaming elements designed to encourage participation in the program and behavior change.
218971272|NCT00719095|DRUG|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
218971273|NCT00719095|BEHAVIORAL|Behavioral therapy|
218971274|NCT05716399|DEVICE|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
218971275|NCT05716399|DEVICE|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
219663282|NCT02301039|DRUG|Pembrolizumab|
219663283|NCT03811288|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
218971276|NCT05716399|DEVICE|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
218971277|NCT00046748|DRUG|Omalizumab|
218971278|NCT05255029|DEVICE|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
218971279|NCT05080907|OTHER|Observational|Subjects for observational study Various conditions \& healthy subjects
218971280|NCT00771316|DRUG|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
219663284|NCT01210677|DRUG|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
219663285|NCT02249689|OTHER|Definitive 65|
219663286|NCT02249689|OTHER|Definitive 74|
219663287|NCT02824562|BEHAVIORAL|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
219663288|NCT02824562|BEHAVIORAL|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
219663289|NCT04562857|BEHAVIORAL|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
219663290|NCT00161967|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
219663291|NCT02259686|DRUG|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
219663292|NCT02259686|DRUG|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
219663293|NCT02259686|DRUG|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
219663294|NCT02259686|DRUG|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
219663295|NCT02259686|DRUG|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
219663296|NCT03627650|PROCEDURE|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
218971281|NCT00771316|DRUG|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
218985677|NCT05004103|OTHER|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
219663297|NCT03627650|PROCEDURE|placebo injection|
219663298|NCT00678964|DRUG|Erlotinib|Erlotinib 150 mg, p.o., once daily
219663299|NCT00678964|DRUG|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
219663300|NCT03287011|OTHER|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
219663301|NCT03287011|OTHER|Colgate toothpaste|fluoridated
219663302|NCT03510078|DRUG|Insulin|Insulin for glycemic control according to the allocation
219663303|NCT05743647|DEVICE|Observation (OBS)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement."
219663304|NCT05743647|DEVICE|Observation and imagination (OBS-IM)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it."
219663305|NCT05743647|DEVICE|Observation and realization (OBS-REAL)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it"
219663306|NCT02084433|PROCEDURE|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
219663307|NCT02084433|PROCEDURE|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
219686525|NCT04748965|DIAGNOSTIC_TEST|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
219686526|NCT06544330|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
219686527|NCT06544330|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
219686528|NCT02338115|DRUG|Paclitaxel 80mg/m2 weekly x 12 weeks|
219686529|NCT01814215|BEHAVIORAL|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
219686530|NCT00004533|DRUG|Adeno-associated virus-CFTR vector|
219686531|NCT06236113|DRUG|Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution|administered at rate of 0.1 mg/kg/hr
219663308|NCT02121353|DRUG|Lucentis|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
219663309|NCT02121353|DRUG|PF582|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
219663310|NCT03545620|DEVICE|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
219663311|NCT00550576|DRUG|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
219663312|NCT01709864|DRUG|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
218971282|NCT05266716|BEHAVIORAL|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
218971283|NCT02526901|OTHER|No intervention|
218971284|NCT03163810|DEVICE|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
218971285|NCT03163810|DEVICE|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
218971286|NCT02055807|OTHER|PEEP and recruitment maneuvers|
218971287|NCT02055807|OTHER|ZEEP (no PEEP nor recruitment maneuver)|
218971288|NCT05511519|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
218971289|NCT05511519|DRUG|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
218971290|NCT02027376|DRUG|LDE225|
218971291|NCT02027376|DRUG|Docetaxel|
218971292|NCT05400915|DRUG|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
219360279|NCT01163786|DRUG|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
219663313|NCT01709864|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
219663314|NCT02510703|OTHER|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
219663315|NCT05668572|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
219663316|NCT05668572|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
219663317|NCT03436069|OTHER|Conventional treatment protocols of breast cancer|
218971293|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
219360280|NCT00634569|BIOLOGICAL|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
219360281|NCT02918019|DRUG|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
218971294|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
219360282|NCT02918019|DRUG|Placebo|Placebo matched with MSTT1041A.
219360283|NCT00311857|DRUG|Cetuximab|
219663318|NCT05942781|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
219663319|NCT05942781|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
219663320|NCT01265004|PROCEDURE|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
219663321|NCT01265004|PROCEDURE|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
219663322|NCT01265004|PROCEDURE|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
219663323|NCT01537991|RADIATION|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
219663324|NCT00533559|DRUG|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
219663325|NCT00533559|DRUG|Placebo|Placebo comparator
219663326|NCT01504191|BEHAVIORAL|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
219663327|NCT05639686|DRUG|Tranexamic acid injection|Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
219663328|NCT05639686|DRUG|Total Intravenous Anesthesia|Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
219663329|NCT05639686|DRUG|Inhalational isoflurane|Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
219663330|NCT06532058|DRUG|QHRD107 capsule，Venclexta and Azacitidine|QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
219663331|NCT05195099|OTHER|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
219663332|NCT02306421|PROCEDURE|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
218971295|NCT04069169|DRUG|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
219360284|NCT00311857|DRUG|Temozolomide|
219360285|NCT00311857|PROCEDURE|Radiation therapy|
219663333|NCT02306421|PROCEDURE|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
218971296|NCT04069169|DRUG|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
218971297|NCT01782911|DIETARY_SUPPLEMENT|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
218971298|NCT01782911|DIETARY_SUPPLEMENT|Placebo pills|The patients will take placebo for 40 days.
218971299|NCT01761864|BEHAVIORAL|academic detailing intervention|
218985678|NCT02443766|OTHER|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
218985679|NCT04753645|BEHAVIORAL|Handwashing stations at the public places and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
218985680|NCT04753645|BEHAVIORAL|No activities of the HBCC project and also no soap (Pure Control)|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
219663334|NCT02306421|PROCEDURE|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
219663335|NCT02306421|PROCEDURE|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
219663336|NCT02306421|PROCEDURE|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
219663337|NCT04843358|BEHAVIORAL|Emotional Disclosure|"The trial member will deliver instructions For the next three days, I want you to write about your experience with cancer. In your writing, I want you to really let go and explore your very deepest emotions and thoughts. It is critical that you delve deeply. Ideally, I would like you to write about those parts of the experience you found hard to share with others. Perhaps this will provide an opportunity to really examine those thoughts and emotions. You might tie your personal experiences to other parts of your life. How is it related to your family life, relationship with your spouse, your children, your sexuality, daily activities, hobbies, your past, your childhood, your work? These are just some examples."
219663338|NCT04843358|BEHAVIORAL|Non-Emotional Writing|"The trial member will deliver instructions were as follows. For the next three days, I want you to write about how you use your time. We are interested in everything you do during the course of a day. In your writing I want you to be completely objective. We are not interested in your emotions or opinions. Feel free to be as detailed as possible"
218971300|NCT03610451|BEHAVIORAL|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
218971301|NCT03610451|BEHAVIORAL|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
218971302|NCT00562250|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
218971303|NCT00562250|DRUG|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
218971304|NCT00562250|DRUG|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
218971305|NCT00723216|DRUG|enoxaparin|20 mg twice a day
219065063|NCT04729803|BEHAVIORAL|Experimental: Attention Guidance + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
218971306|NCT00723216|OTHER|Physical prophylaxis|
218971307|NCT05413031|DEVICE|relative motion splint|splint with ability to move the fingers
218971308|NCT05413031|DEVICE|static splint|splint with immobility of wrist, and fingers
218971309|NCT02095067|DEVICE|Video consultation|
218971310|NCT05475613|PROCEDURE|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
218971311|NCT05475613|PROCEDURE|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
218971312|NCT02526173|PROCEDURE|RALP using full nerve sparing technique|RALP using full nerve sparing technique
218971313|NCT02526173|OTHER|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
218971314|NCT05466448|DRUG|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
219065064|NCT04729803|BEHAVIORAL|Active Comparator: Exposure Alone|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
219663339|NCT03309345|OTHER|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
218971315|NCT05836090|BEHAVIORAL|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
219208379|NCT04338152|BEHAVIORAL|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
219663340|NCT01967979|DRUG|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
219663341|NCT01967979|DRUG|fluoxetine|Multiple doses
219663342|NCT01967979|DRUG|itraconazole|Multiple doses
219663343|NCT00632632|DRUG|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
219663344|NCT00632632|OTHER|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
219663345|NCT02864316|DRUG|Nivolumab|
218971316|NCT05836090|BEHAVIORAL|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
219663346|NCT05989971|OTHER|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
219065065|NCT04729803|BEHAVIORAL|Experimental: Attention Control + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
219663347|NCT00298363|DRUG|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
218971317|NCT00252629|OTHER|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
218971318|NCT02279238|PROCEDURE|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest \[Washout time\] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of \[HR, SPO2, PSG RPE scale, Distance walked, BP\] the participants are collected before, during and after the completion of each lap \[according to American Thoracic Society \[ATS\] protocol\]."
218971319|NCT03652376|DRUG|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
218971320|NCT01952782|DRUG|Kisspeptin 112-121|Subjects will receive up to 10 IV doses of kisspeptin 112-121
218971321|NCT01952782|DRUG|Naloxone|Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.
218971322|NCT01952782|DRUG|GnRH|Subjects will receive up to 10 doses of IV GnRH
218971323|NCT04112888|COMBINATION_PRODUCT|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
218971324|NCT04112888|PROCEDURE|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
218971325|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
218971326|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
218971327|NCT01278160|DRUG|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
218971328|NCT00575250|BEHAVIORAL|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
218971329|NCT00575250|BEHAVIORAL|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
218971330|NCT02966041|DRUG|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
218971331|NCT02966041|DRUG|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
218971332|NCT03171051|DEVICE|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
218971333|NCT03171051|DEVICE|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
218971334|NCT03164577|BEHAVIORAL|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
218971335|NCT03164577|OTHER|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
218971336|NCT00497276|PROCEDURE|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
219065066|NCT05879744|DRUG|CLN-978|CD19xCD3 T cell engager
219065067|NCT03551938|BEHAVIORAL|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
219663348|NCT00298363|DRUG|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
219663349|NCT00298363|DRUG|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
219663350|NCT00298363|DRUG|TDF placebo|Placebo to match TDF QD
219663351|NCT00298363|DRUG|FTC/TDF placebo|Placebo to match FTC/TDF QD
219663352|NCT00298363|DRUG|ETV placebo|Placebo to match ETV QD
218971337|NCT03882931|OTHER|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
218971338|NCT03882931|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
218971339|NCT03882931|OTHER|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
218971340|NCT02245178|PROCEDURE|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
218971341|NCT02245178|OTHER|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
218971342|NCT01483807|BEHAVIORAL|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
218971343|NCT01483807|BEHAVIORAL|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
218971344|NCT00806338|DRUG|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
219663353|NCT04793373|DEVICE|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
219663354|NCT04721366|OTHER|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
219663355|NCT03105856|BIOLOGICAL|CERVARIX|\- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
219663356|NCT03105856|BIOLOGICAL|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
219663357|NCT01793350|DRUG|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
219663358|NCT04710368|DRUG|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
218971345|NCT00806338|DRUG|Placebo|
218971346|NCT04866329|OTHER|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
219663359|NCT04393376|DIAGNOSTIC_TEST|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
219663360|NCT05885776|DRUG|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
218971347|NCT04866329|OTHER|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
218971348|NCT04866329|OTHER|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
218971349|NCT00745173|DRUG|Premarin|
218971350|NCT01502280|DRUG|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
219663361|NCT00914082|BEHAVIORAL|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
219663362|NCT00135356|DRUG|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
219663363|NCT00135356|DRUG|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor \[PI\] combination + 2 NRTIs
219663364|NCT00153816|DRUG|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
219663365|NCT00153816|DRUG|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
219663366|NCT00153816|DRUG|placebo|placebo; two tablets per day
219663367|NCT04638556|DIAGNOSTIC_TEST|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
219663368|NCT06180083|DRUG|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
218971351|NCT01502280|DRUG|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
218971352|NCT02872571|DRUG|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
218971353|NCT01900639|BEHAVIORAL|change time of intake of aspirin|
218971354|NCT06392802|DEVICE|Rehabilitation treatment using Muvity|The users have the support of the telerehabilitation system Muvity
218971355|NCT00201331|DRUG|leucovorin+5-FU|
218971356|NCT02819518|BIOLOGICAL|Pembrolizumab|IV infusion
218971357|NCT02819518|DRUG|Nab-paclitaxel|IV infusion
218971358|NCT02819518|DRUG|Paclitaxel|IV infusion
218971359|NCT02819518|DRUG|Gemcitabine|IV infusion
218971360|NCT02819518|DRUG|Carboplatin|IV infusion
218971361|NCT02819518|DRUG|Normale Saline Solution|IV infusion
218971362|NCT05833334|BEHAVIORAL|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
219663369|NCT06180083|DRUG|'DYMISTA' NASAL SPRAY|A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
219663370|NCT05327088|DRUG|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
219663371|NCT05327088|DRUG|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
219663372|NCT05274087|DRUG|Risankizumab|Subcutaneous autoinjector
219663373|NCT00846690|DRUG|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
219663374|NCT00846690|DRUG|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
219663375|NCT02883621|PROCEDURE|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
219663376|NCT02883621|PROCEDURE|standard upper endoscopy|standard examination without using a cap
219663377|NCT05481918|PROCEDURE|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
219663378|NCT05481918|PROCEDURE|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
219663379|NCT00253370|DRUG|BAY 43-9006|Given orally
219663380|NCT00253370|DRUG|docetaxel|Given IV
219663381|NCT00253370|DRUG|cisplatin|Given IV
219663382|NCT06187649|PROCEDURE|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
219663383|NCT06511271|OTHER|relaxation exercises|"The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation.~purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just consists of relaxation music"
219663384|NCT03576209|BEHAVIORAL|healthy lifestyle program|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
219663385|NCT03637309|BEHAVIORAL|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
219663386|NCT02847910|PROCEDURE|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
219663387|NCT02847910|PROCEDURE|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
219663388|NCT04343053|OTHER|SARS-Cov-2 infection|blood sample withdrawal
219663389|NCT03527862|OTHER|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
219663390|NCT05758272|BEHAVIORAL|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
218971363|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
218971364|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
218971365|NCT05833334|BEHAVIORAL|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
218971366|NCT06191835|BEHAVIORAL|myCare Start|The service consists of 2 times 10-minutes semi-structured pharmaceutical interventions between community pharmacist and patient, tailored to the patient's needs, positioned as partner, during the first 6 weeks after treatment initiation.
218971367|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
218971368|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
218971369|NCT01634763|DRUG|LDK378|
219663391|NCT05758272|BEHAVIORAL|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
219663392|NCT00941824|DRUG|mycophénolate acid|"* Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily"
219663393|NCT05921422|OTHER|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
219663394|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
219663395|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
219663396|NCT01955317|BEHAVIORAL|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
219663397|NCT01955317|BEHAVIORAL|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
219663398|NCT04111861|OTHER|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
219663399|NCT00935064|DRUG|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
219663400|NCT00935064|OTHER|Placebo|Placebo orally one tablet once a day for 6 weeks.
218971370|NCT06481631|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
218971371|NCT04989387|DRUG|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
218971372|NCT04989387|DRUG|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
218971373|NCT04989387|DRUG|INCB106385|INCB106385 will be administered orally once or twice a day.
218971374|NCT06352060|OTHER|No intervention or administration will be performed due to the observational nature of the study|Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
218971375|NCT00504036|DEVICE|inflatable intra-gastric balloon|inflatable intra-gastric balloon
218971376|NCT01138943|DRUG|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
219663401|NCT06201468|OTHER|Group A SCAPULAR MOBILIZATION|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."
219663402|NCT01723020|DRUG|AMG 232|Given an an oral tablet in escalating doses.
219663403|NCT01211483|DRUG|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
219663404|NCT01211483|DRUG|Erlotinib|Tablet 150 mg for oral administration
219663405|NCT01211483|DRUG|Placebo|Placebo liquid matching U3-1287 for IV infusion
219663406|NCT01700543|PROCEDURE|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
219663407|NCT05748158|BEHAVIORAL|Weight loss|"A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 35 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks."
219663408|NCT00805077|PROCEDURE|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
218971377|NCT01138943|DRUG|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
218971378|NCT06675812|OTHER|Information intervention|The participant will receive information on what treatment that is offered in their municipal, how the help-seeking process goes (where they can be anonymous etc), and tailored information regarding the barriers that the participant has stated preventing him or her for seeking help today.
218971379|NCT06871046|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over 7 days
218971380|NCT03306862|DIETARY_SUPPLEMENT|Whole yellow pea soup|Soup containing whole yellow peas
219663409|NCT00805077|OTHER|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
219663410|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
218971381|NCT03306862|DIETARY_SUPPLEMENT|Split yellow pea soup|Soup containing split yellow peas
218971382|NCT03306862|DIETARY_SUPPLEMENT|Potato soup|Soup containing potatoes
218971383|NCT06624449|BEHAVIORAL|Cold debriefing|Manipulation (experimental): The researcher assigned a cold debriefing (after one-day post-simulation) for undergraduate nursing students in the intervention group.
218971384|NCT06624449|BEHAVIORAL|Hot Debriefing|The control group received a hot debriefing (immediately after the simulation).
218971385|NCT06688851|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|A CBCT scan is performed before the surgical intervention.
219663411|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
219663412|NCT04351126|DRUG|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
219663413|NCT04351126|DRUG|Bromocriptine|2.5 mg prescribed Vaginally twice daily
219663414|NCT02332564|OTHER|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
219663415|NCT00365209|OTHER|laboratory biomarker analysis|Correlative studies
219663416|NCT00365209|OTHER|pharmacological study|Correlative studies
218971386|NCT06688851|PROCEDURE|Cystostomy|Under local anesthesia, a full-thickness flap is prepared and cystostomy is performed.
218971387|NCT06688851|DIAGNOSTIC_TEST|Histology to confirm the initial diagnosis|A sample of the cyst lining is sent for histologic diagnosis.
218971388|NCT06688851|DEVICE|Patient Specific Implant|The PSI is fixed on the surface of the bone using osteosynthesis screws.
218971389|NCT06688851|PROCEDURE|Cyst decompression|The PSI enables the discharge of the cystic liquid into the oral cavity. The resulting decrease in cystic pressure induces bone healing. Patients are recalled monthly for controls and panoramic X-rays are performed to monitor the decompression.
218971390|NCT06688851|DIAGNOSTIC_TEST|CBCT|Post-operative CBCT is performed six months after cystostomy to assess whether the cyst volume has been sufficiently reduced for enucleation, minimizing the risk of damage to anatomical landmarks.
218971391|NCT06688851|PROCEDURE|Enucleation|Under local anesthesia a full-thickness flap is raised and the PSI is removed by unscrewing the osteosynthesis screws. The wall of the cyst is completely enucleated and the flap is sutured.
218971392|NCT06688851|DIAGNOSTIC_TEST|Histology performed on the entire lining of the cyst|The residual cyst wall is sent for histopathologic examination.
218985681|NCT04753645|BEHAVIORAL|Soap distributed but no activities of the HBCC project|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
218985682|NCT04753645|BEHAVIORAL|HBCC project and Soap|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
219663417|NCT00365209|DRUG|curcumin|Given orally
219663418|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
219663419|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
219663420|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
218971393|NCT06934707|BEHAVIORAL|Three meals a day|This group will follow a dietary prescription consisting of three meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 30% for breakfast, 40% for lunch, and 30% for dinner, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 15-20% of the total carbohydrate intake, 7-10% of the total protein intake, and 10% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
218971394|NCT06934707|BEHAVIORAL|Six meals a day|This group will follow a dietary prescription consisting of six meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 20% for breakfast, 10% morning snack, 30% for lunch, 10% afternoon snack, 25% for dinner and 5% bedtime snack, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 5-10% of the total carbohydrate intake, 2-7% of the total protein intake, and 2-8% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
218971395|NCT04021563|DRUG|SR419|Ascending single and multiple doses of SR419 orally
218971396|NCT04021563|DRUG|Placebo|Ascending single and multiple doses of placebo orally
218971397|NCT06686238|DEVICE|MITOVIT® Hypoxic Training System|The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
218971398|NCT06686238|DEVICE|Sham MITOVIT® Hypoxic Training System|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
218971399|NCT06690814|OTHER|Ficus septica exudate (antiseptic plant exudates)|F. septica sap contains the antibacterial alkaloid ficuseptine which exhibits activivity agaisnt S. pyogenes and H. ducreyi, two pàthogens associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
219065068|NCT04050592|DRUG|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
219065069|NCT04050592|OTHER|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
219065070|NCT06534281|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
219065071|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
219065072|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
219208380|NCT04338152|BEHAVIORAL|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
219208381|NCT06747780|BEHAVIORAL|Text messaging|A digital booklet, text messages for two weeks, and two family-based activity boosters
219208382|NCT06747780|BEHAVIORAL|Control (Usual care)|Control only
219663421|NCT01618110|DEVICE|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
219663422|NCT01618110|OTHER|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
219663423|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
219663424|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
219663425|NCT02470403|DRUG|LIK066|LIK066 25 mg tablets
219663426|NCT02470403|DRUG|Placebo|Matching placebo tablets
219663427|NCT03628248|PROCEDURE|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
219663428|NCT03628248|PROCEDURE|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
219663429|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
218971400|NCT06690814|OTHER|Pterocarpus indicus exudate|P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
218971401|NCT06690814|OTHER|Curcuma longa aqueous extract|C. longa is a culinary herb that contains the antibatieral compound curcumin. Curcumin exhibits antibacterial activity agasint S. pyogenes and has profound effects on bacterial biofilms. This intervention uses a mulch of the rhizome that has been sqeeezed to produce a curcumin containing aqueous fluid.
218971402|NCT06690814|DRUG|Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)|Common over the counter antiseptic cream
218971403|NCT06686316|DEVICE|Device: Hypoxic Gas Mixture|The EG (Experimental Group) will undergo a 6-week intervention protocol of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
218971404|NCT06686316|OTHER|Sham Hypoxic-Hyperoxic exposure|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
218971405|NCT06698575|DRUG|ABI-1179|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
218971406|NCT06698575|DRUG|ABI-1179 Placebo|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
218971407|NCT03307057|BEHAVIORAL|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
218971408|NCT03307057|BEHAVIORAL|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
218971409|NCT03307057|BEHAVIORAL|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
218971410|NCT03307057|BEHAVIORAL|Usual Care|Care as recommended and provided by the child's pediatrician or other health care providers in the community.
218971411|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
218971412|NCT03727607|DRUG|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
218971413|NCT06682156|DRUG|Carfilzomib|carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。
218985683|NCT02509247|DEVICE|Telemonitoring|Wireless telemonitoring
218985684|NCT01225432|OTHER|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
218985685|NCT04445311|DRUG|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
219663430|NCT03724240|BIOLOGICAL|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
219663431|NCT03724240|BIOLOGICAL|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
219663432|NCT02176460|DRUG|Colchicine|0.5mg twice daily for 16 weeks
219663433|NCT02176460|DRUG|Placebo|1 tablet twice daily
218971414|NCT06698601|DIETARY_SUPPLEMENT|blueberry-rich diet|"The study participants follow a diet rich in blueberries for 12 weeks based on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will drink approximately 35g of a powder made from wild, freeze-dried blueberries containing 780mg of anthocyanines stirred in a glas of water every morning for a period of 12 weeks."
218971415|NCT06698601|OTHER|Control diet|"The study participants will focus on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will receive no additional blueberry treatment."
218971416|NCT06699888|OTHER|cervicothoracic manipulation group|"The participant lay prone with the head firmly into the head piece Palpation of the upper cervico-thoracic segment observed the side of the restriction.~The participants head was rotated to the contralateral side of the restriction. The practitioner's hand contacted the forehead and the other hand's thumb contacted the spinous process of the restricted side.~A low amplitude, high velocity thrust towards the axilla was applied, on the spinous process in PA direction.~Experimental group also received following exercises Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks"
218971417|NCT06699888|OTHER|forward head correction exercises traditional group|Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks.
218971418|NCT06878066|DRUG|thrombolysis therapy|All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.
218971419|NCT06708221|DEVICE|Real-Time Image Guided Radio Therapy (IGRT)|Real-time image guided radiation therapy (IGRT) methods image the cancerous tumour in real-time, enabling the treatment beam to focus its destructive energy on the patient's cancer, not their healthy tissue.
218971420|NCT06709274|DRUG|Osimertinib|80mg daily, for EGFR-positive patients
218971421|NCT06709274|DRUG|Alectinib|600mg BID, for ALK-rearranged patients
218971422|NCT06709274|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
218971423|NCT06707831|OTHER|Teleassessment|Children underwent assessments on two occasions: one in face-to-face within a clinical setting, and the other through teleassessment using video conferencing. This video conference session was recorded to be later reviewed and scored by two separate raters.
218971424|NCT06710639|BEHAVIORAL|Health Education Program|Instructions and recommendations will be provided in an informational leaflet to encourage an active and healthy lifestyle, promoting self-care and good health practices. This leaflet will include the new WHO guidelines recommending specific measures to reduce the risk of cognitive impairment.
218971425|NCT06710639|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study.
218971426|NCT06709924|OTHER|EXERCISE TRAINING WITHOUT MEDICATION|After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.
218971427|NCT06708767|DRUG|Contrast Media|IV contrast media administration
218971428|NCT06708767|DRUG|Placebo|Saline
218971429|NCT07131332|BEHAVIORAL|Mindful eating group|Behavioral group intervention involving 8, 2-hour long sessions
218971430|NCT06709352|OTHER|non|non
218971431|NCT06714396|DRUG|QRL-101|Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
218971432|NCT06714396|OTHER|Placebo|Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
218971433|NCT06702423|BEHAVIORAL|AI-based chatbot|A tailored Japanese HPV vaccination chatbot.
218971434|NCT06702423|BEHAVIORAL|Leaflet|A publicly accessible HPV vaccination leaflet prepared by the Ministry of Health, Labour, and Welfare.
219663434|NCT04587401|PROCEDURE|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
219663435|NCT04587401|PROCEDURE|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
218971435|NCT07039292|BEHAVIORAL|Harm Reduction (E-cigarette switching)|Participants will be assigned to receive an e-cigarette and try to switch completely from smoking to using the e-cigarette
218971436|NCT07039292|BEHAVIORAL|Standard of Care|Participants will be assigned to receive tobacco treatment referrals and the opportunity to re-enroll in the Tobacco Treatment Program
218971437|NCT07030543|BEHAVIORAL|Individualized Dietary Plan (IDP) for Type 2 Diabetes|This study evaluates the feasibility of an Individualized Dietary Plan (IDP), a structured, patient-tailored nutrition intervention designed to improve glycemic control and lipid profiles in adults with Type 2 Diabetes Mellitus (T2DM).
218971438|NCT07030543|BEHAVIORAL|Usual care|Standard dietary advice as per the current clinical practice.
218971439|NCT06709508|OTHER|Examination group|This study differs from other clinical studies because the participants of this study consisted of patients undergoing single-member implant-supported restoration treatment at the Department of Prosthodontics, Afyonkarahisar Health Sciences University.
218971440|NCT06708715|DEVICE|PEACE Patch|A topical patch that incorporates a sensory pattern of vibrotactile haptic technology.
218971441|NCT06708715|DEVICE|Topical Sham Patch|Sham Patch that does not include vibrotactile haptic technology
218971442|NCT07041853|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha|Root extract ashwagandha, KSM-66
219663436|NCT04587401|PROCEDURE|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
218971443|NCT07041853|DIETARY_SUPPLEMENT|Placebo|Organic chickpea flour
218971444|NCT06710743|OTHER|Glucose solution Day 1, Day 8, and Day 15|Glucodin powder diluted with water
218971445|NCT06710743|OTHER|Food (cereal). Ten different cereals served once each|Variety of cooked or flake cereal
218971446|NCT06708065|DEVICE|Armeo Power robot restores upper limb motor function.|"ArmeoPower is a robotic rehabilitation device developed by Hocoma, designed to assist patients with impaired upper limb motor functions following conditions such as stroke or neurological injuries. The device features an exoskeleton that supports and tracks movements of the arm and hand, utilizing motor-assisted motion based on the principle of adaptive support, which adjusts assistance levels according to the patient's capabilities. ArmeoPower integrates interactive exercises, often in the form of engaging games, to enhance patient motivation and maintain focus during therapy sessions. It also collects and tracks performance data, enabling clinicians to evaluate progress over time. This device is widely used in rehabilitation centers and hospitals to improve muscle control, strength, and range of motion in patients recovering from severe motor impairments."
218971447|NCT06708065|BEHAVIORAL|A Home Exercise Program|A Home Exercise Program (HEP) is a personalized set of exercises designed to support recovery and enhance functional abilities outside of clinical therapy sessions. For patients with hemiplegia due to cerebral infarction, the program typically includes range of motion (ROM) exercises to maintain joint flexibility and prevent stiffness, as well as strengthening exercises using resistance bands or light weights to improve muscle function. Balance and postural control exercises, such as weight shifting or standing on one leg, help enhance stability and reduce fall risks. Functional training focuses on practicing daily movements like reaching, grasping, or transferring between positions, while fine motor skill tasks aim to restore hand functionality. The program may also incorporate low-impact aerobic exercises, such as walking or seated cycling, to boost cardiovascular health, along with relaxation and breathing techniques to reduce stress and improve overall well-being. These exercises a
218971448|NCT06708065|BEHAVIORAL|Occupational therapy activities|Occupational therapy activities are designed to help individuals regain independence in daily life by addressing functional abilities, motor skills, and cognitive functions. For patients with hemiplegia due to cerebral infarction, these activities often include practicing Activities of Daily Living (ADLs) such as dressing, grooming, bathing, and feeding, as well as more complex tasks like cooking and managing finances. Fine motor skills development is emphasized through exercises involving tasks like buttoning, tying shoelaces, or handling small objects, sometimes using adaptive tools. Additionally, functional mobility training focuses on teaching safe movement strategies, such as transferring between surfaces or navigating stairs, and may include wheelchair mobility or energy conservation techniques. These activities are tailored to the patient's needs to enhance their ability to perform meaningful and necessary daily tasks independently.
218971449|NCT06708494|BEHAVIORAL|video decision aids|The video includes an introduction to geriatric frailty (3 minutes) and ACP (5 minutes). ACP includes three levels of medical care: life-prolonging care, limited care, and comfort care.
218971450|NCT03367013|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
218971451|NCT03367013|OTHER|No Bovine Lactoferrin added|Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
218971452|NCT06722183|DRUG|Futibatinib orally administered|Futibatinib will be administered 20mg orally, once daily, continously
218971453|NCT06722183|DRUG|Tislelizumab (i.v. 200mg)|Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle
218971454|NCT04721847|OTHER|Pain Neuroscience Education|In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
218971455|NCT04721847|OTHER|Conventional Physical therapy|Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
218971456|NCT06886256|DEVICE|Polar H10 Heart Rate Monitor|Wearable sensors to capture movement-based data during physical therapy session. The Polar H10 Heart Rate Monitor measures heart rate and will transfer the data to the mHealth app.
218971457|NCT06886256|DEVICE|Empatica EmbracePlus|Wearable sensors to capture movement-based data during physical therapy session. The Empatica EmbracePlus measures physiological parameters and will transfer the data to the mHealth app.
218971458|NCT06886256|DEVICE|Apple Watch Ultra 2|Wearable sensors to capture movement-based data during physical therapy session. The Apple Watch Ultra 2 measures heart rate, will transfer the data to the mHealth app, and will provide an alert when the heart rate is too high or too low.
219065073|NCT01718769|OTHER|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
219686532|NCT02185456|DRUG|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
219065074|NCT06270823|PROCEDURE|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
219686533|NCT02185456|DRUG|Standard of care|oral metronidazole 500 mg twice a day for 7 days
218971459|NCT07043088|PROCEDURE|Membrane sweeping|Serial membrane sweeping from gestational age 39+5-40+2 with 2-3 days interval and a maximum og three times.
218971460|NCT06707363|PROCEDURE|orthopedic surgery|Surgeries involving major interventions on the musculoskeletal system, such as joint replacement surgeries or fracture repairs.
218971461|NCT06709365|PROCEDURE|Tibiotalar calcaneal fusion by hindfoot|Hindfoot nail for ankle fusion
218971462|NCT06708975|OTHER|Insulin therapy phonophoresis|Insulin therapy phonophoresis is the use of ultrasound to deliver drugs through patients skin, Insulin therapy will be used to determine its effect on wound healing in patients with chronic diabetes mellites because in addition to its systemic impact, numerous reports suggest that applying insulin topically causes localized effects. Many trials and case reports have been released reporting positive effects of topical insulin for many diseases such as dermatological compromises, ophthalmological diseases and others
219208383|NCT06747988|DEVICE|Traction Device|After circumferential incision and trimming the submucosa at the incision's edge, dissection is initiated until approximately 20 to 30% of the anal side (for colonic lesions) or oral side (for gastric lesions) of lesion has been dissected leaving a flap of at least 1 cm in length. Once the mucosal flap is created the X-tack device is introduced through the endoscope channel. The first tack is placed on the opposite wall of the lesion, the 2nd and 3rd tack will then be placed next to each other on the mucosal flap portion of the lesion. The 4th tack does not have to be placed but can be used to generate further traction at any time. Clips can be placed along the suture and clipped to the wall at any point to change angulation of traction. The sutures can then be cut and released from the tissue
219663437|NCT03845101|BEHAVIORAL|CBT with virtual reality exposure therapy|The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.
219663438|NCT03845101|BEHAVIORAL|CBT in vivo|The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg \& Magee and Graske \& Barlow with worksheets from Arendt \& Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
219663439|NCT02258269|OTHER|SQ|
219663440|NCT02258269|OTHER|Control|
219663441|NCT00899704|GENETIC|microarray analysis|
219663442|NCT00899704|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
219663443|NCT00899704|OTHER|diagnostic laboratory biomarker analysis|
219663444|NCT05381922|OTHER|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
219663445|NCT00004866|DRUG|exatecan mesylate|
219663446|NCT03098017|OTHER|Short pasta (dry)|50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
219663447|NCT03098017|OTHER|Long pasta (dry)|50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
219663448|NCT03098017|OTHER|Couscous|50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water
219663449|NCT03098017|OTHER|Glucose|50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
219663450|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
219663451|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
218971463|NCT06708975|OTHER|Hyperpolarized light therapy and Standard wound cleaning and dressing.|Hyperpolarized light therapy safely accelerates wound healing by stimulating blood circulation, reducing inflammation and relieving muscle spasms.
218971464|NCT06707467|OTHER|occlusal splint|nineteen patients diagnosed with internal temporomandibular derangement will receive occlusal splint therapy, a treatment method with proven effectiveness.
218985686|NCT01034631|DRUG|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
218985687|NCT01034631|DRUG|BNC105P|BNC105P, up to 16 mg/m\^2
219208384|NCT02728336|PROCEDURE|Cardiac MRI|
219663452|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
219663453|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
219663454|NCT00265525|BEHAVIORAL|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
219663455|NCT02917824|DEVICE|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
219065075|NCT05881668|BIOLOGICAL|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
219065076|NCT00668460|DRUG|Lactic acid (Dermacid)|
219065077|NCT02167633|PROCEDURE|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
219065078|NCT02167633|RADIATION|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
219065079|NCT02167633|RADIATION|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
218971465|NCT06707467|OTHER|occlusal splints combined with rocabado exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with Rocabado exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether Rocabado exercises have a positive effect on the treatment process.
218971466|NCT06707467|OTHER|occlusal splint combined with posture exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with posture exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether posture exercises have a positive effect on the treatment process.
218971467|NCT06708923|PROCEDURE|Intervention Name: Acupuncture Therapy Before and After Embryo Transfer Description: The intervention involves acupuncture therapy performed at two key time points during the IVF cycle: 25 minutes be|"Acupuncture Therapy Before and After Embryo Transfer~This intervention consists of acupuncture sessions designed to support implantation and improve pregnancy outcomes during frozen embryo transfer (FET) cycles.~Procedure:~Acupuncture is performed using sterile, single-use needles by certified practitioners trained in reproductive health.~Sessions occur at two critical time points:~Before Embryo Transfer: A 25-minute session targeting acupoints such as Baihui (DU20), Guanyuan (CV4), and Sanyinjiao (SP6) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second 25-minute session targeting acupoints such as Zusanli (ST36) and Taichong (LR3) to promote implantation and relaxation.~Purpose:~Improve uterine blood flow and receptivity. Regulate hormonal balance to optimize the implantation environment. Reduce psychological stress associated with IVF procedures. This intervention is compared retrospectively to standard IVF protocols without acupuncture to asses"
218971468|NCT06707350|DEVICE|Remote ischemic preconditioning (RIPC)|8 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower limbs with a blood pressure cuff
219065080|NCT02167633|DRUG|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
219065081|NCT02167633|DRUG|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
219065082|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
219065083|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
219065084|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
219065085|NCT04517721|OTHER|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
219065086|NCT00957502|DEVICE|ENTact™ Septal Stapler|1 year aged septal staples
219065087|NCT00957502|DEVICE|ENTact™ Septal Stapler|18 Month Aged Staples
219208385|NCT05406349|BEHAVIORAL|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
219663456|NCT02917824|DEVICE|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
219663457|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
219663458|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
219663459|NCT00904839|DRUG|mFolfox|standard i.v chemotherapy
219663460|NCT00904839|DRUG|Bevacizumab|100 mg/Kg solution , IV infusion
219663461|NCT00904839|DRUG|mFolfox 6|IV standard chemotherapy
218971469|NCT06707350|DEVICE|sham condition (control group)|8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation.
218971470|NCT06707064|BEHAVIORAL|SFEE Diet Management Intervention|"A structured diet management program designed to improve glycemic control, dietary adherence, and maternal outcomes. It includes:~Self-empowerment: Goal-setting, dietary planning, and evaluation. Family empowerment: Emotional support and supervision. Environmental empowerment: Peer group interaction and education via WeChat groups and in-person meetings."
218971471|NCT06707064|BEHAVIORAL|Standard Dietary Advice|Routine nursing care, including dietary education, exercise planning, and self-monitoring for gestational diabetes management.
218971472|NCT05001542|OTHER|Educational moral injury video|Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
218971473|NCT06030622|DRUG|Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)|Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)
218971474|NCT06030622|DRUG|C3 (Metformin, Simvastatin, and Digoxin) only|C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
218971475|NCT06884410|DEVICE|MRI|Multiparametric renal MRI on 1.5T scanners
218971476|NCT04868045|DRUG|Thyrotropin Releasing Hormone (TRH)|TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
218971477|NCT04868045|DRUG|levothyroxine|"Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning."
218971478|NCT04868045|OTHER|Hypothyroidism QOL questionnaire|Administer standardized Hypothyroidism QOL questionnaire.
218971479|NCT05108636|OTHER|Therapeutic Touch|Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).
218971480|NCT05108636|OTHER|Music Rest|The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor \& Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
218971481|NCT04539899|OTHER|VR+|Use of a virtual reality helmet during IUD insertion
218971482|NCT06706921|DRUG|18F-Fluciclovine PET/CT Scan|In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
218971483|NCT06708871|PROCEDURE|Thermal ablation|Thermal ablation is a minimally invasive procedure used to treat primary hyperparathyroidism, a condition where one or more of the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). The treatment involves using heat to destroy the overactive parathyroid tissue. This can be done through various methods such as radiofrequency ablation (RFA) and microwave ablation(MWA).
218971484|NCT06708871|PROCEDURE|Parathyroidectomy|Parathyroidectomy is a surgical procedure to remove one or more of the parathyroid glands in cases of hyperparathyroidism.
218971485|NCT06709794|BEHAVIORAL|Informational flyer|In addition to a standard eligibility notice informing participants of their eligibility for marketplace coverage, they receive an informational flyer describing what Covered California is, the availability of financial assistance, and information on benefit design and private insurance terminology, such as deductibles and copays
218971486|NCT06709794|BEHAVIORAL|Modified eligibility notice with plan information|a modified eligibility notice that includes information on the pre-selected lowest-cost silver health insurance plan with a personalized quote for their net premium amount in addition to the informational flyer and instead of a standard eligibility notice
218985688|NCT01560403|DRUG|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
218985689|NCT05580393|DIAGNOSTIC_TEST|RFLP analysis of SSU rRNA|"1. Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~2. PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~3. The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
218985690|NCT03651544|BIOLOGICAL|GamFluVac|1 dose (0,5 ml)
218985691|NCT01890473|DRUG|Abatacept|
218985692|NCT03166735|DRUG|BI 1467335|once daily
218985693|NCT03166735|DRUG|Placebo|once daily
218985694|NCT04781023|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
218985695|NCT00049192|BIOLOGICAL|oblimersen sodium|Given IV
218985696|NCT00049192|DRUG|imatinib mesylate|Given PO
218985697|NCT00049192|OTHER|laboratory biomarker analysis|Correlative studies
218985698|NCT01099137|DRUG|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
218985699|NCT01099137|DRUG|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
218985700|NCT02513342|BIOLOGICAL|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
218985701|NCT02513342|DRUG|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
218985702|NCT02513342|DRUG|Cisplatin|d4，cisplatin，75（mg/m2），iv；
218971487|NCT06708013|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It\&#39;s primarily used to treat depression, especially in patients who haven\&#39;t responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
218971488|NCT06728891|OTHER|In addition to routine diagnosis and treatment, no additional intervention measures were taken.|This study does not impose any intervention on the patients
218971489|NCT04711187|DRUG|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
218971490|NCT04711187|OTHER|Placebo Comparator|Placebo Comparator
218971491|NCT04711187|DRUG|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
218971492|NCT06708273|OTHER|Constraint induced movement therapy|Constraint the sound side and encourage movement of the burned side
218971493|NCT06708273|OTHER|Positioning - stretching|Position hand in functional hand position - stretching against deformity position
218971494|NCT06708273|OTHER|constraint induced movement therapy|constraining sound hand to enforce patient to use affected burned dominant hand
218971495|NCT06733636|OTHER|Sudoku Puzzles|Sudoku puzzles of consistent and regular difficulty
218971496|NCT06733636|OTHER|ScentCare (Olfactory Training Device)|ScentCare is a smell training device with eight encapsulated scents housed in separate compartments and is contained using a charcoal filter, which will be dispersed in the base of our device to prevent smell contamination in the user's environment. The outer casing contains an opening that can be manually rotated to line up with the casing on each scent. This is facilitated by a rod in the center of the device, which serves as the axis of rotation. By pressing the capsule, the desired scent is released through a hole in the casing, similar to the mechanism of a pen. The user presses the compartment back downwards into the casing when done. The ScentCare mobile application offers clear instructions for at-home smell training and testing, with features like scent randomization to prevent users from getting accustomed to a specific order. It provides detailed guidance on device use and allows users to schedule sessions and receive daily reminders, ensuring a structured training regimen.
218971497|NCT03944746|OTHER|Education Curriculum|Different educational curriculums were applied to each cohort
218971498|NCT06633692|OTHER|Head down tilt (HDT)|In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
218971499|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback|Participants will receive accurate feedback about their sleep data.
218971500|NCT06602960|BEHAVIORAL|Inflated Sleep Data Feedback|Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).
218971501|NCT06602960|BEHAVIORAL|Deflated Sleep Data Feedback|Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).
218971502|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback + Sleep-related Educational Information|Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
218971503|NCT06878560|BIOLOGICAL|10 GE Xenokidney|Porcine-derived kidney containing intentional genomic alterations for xenotransplantation
218971504|NCT05889416|OTHER|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
218971505|NCT05889416|OTHER|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
218971506|NCT02981940|DRUG|Abemaciclib|Abemaciclib capsule
218971507|NCT02981940|PROCEDURE|Surgery|Surgery
218971508|NCT04938349|BEHAVIORAL|Dual task perturbation training|Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
219065088|NCT02206503|DRUG|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
219065089|NCT02206503|DRUG|Lenalidomide|
219065090|NCT02206503|DRUG|Dexamethasone|
219065091|NCT01733004|DRUG|MM-141|
218971509|NCT04967664|DRUG|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
218971510|NCT04967664|DRUG|capsaicin 0.04% topical system|Low-dose capsaicin control
219065092|NCT01741753|DRUG|BKM120|Orally, every morning
219065093|NCT01741753|DRUG|Abiraterone|Orally, 1000 mg, every morning
219065094|NCT01741753|DRUG|Prednisone|Orally, 5 mg, every morning
219663462|NCT00904839|DRUG|bevacizumab|100 mg/4 ml solution
219663463|NCT03398239|DEVICE|Noninvasive mechanical ventilation|
219663464|NCT04344535|BIOLOGICAL|Convalescent Plasma|450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally \> 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
218971511|NCT07057414|DRUG|GMDTC for injection|GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (e.g., The initial dose group: 2 g reconstituted in 500 mL, with each 1 g reconstituted in 250 mL, resulting in a 4 mg/mL concentration.). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
218971512|NCT07057414|OTHER|0.9% Sodium Chloride Injection(0.9% NaCl)|0.9% Sodium Chloride Injection with a specification of 250mL/bag, and administered by intravenous infusion. The infusion should be strictly adhering to the assigned dosage. All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
218971513|NCT06759701|DRUG|Tirzepatide|Participants will perform weekly self-injection of tirzepatide as standard of care, following manufacturer instructions
218971514|NCT06875960|DRUG|BMS-986165|Specified dose on specified days
218971515|NCT06883526|BIOLOGICAL|ZG005 for Injection|intravenous infusion
218971516|NCT06883526|DRUG|Gecacitinib Hydrochloride Tablets|Oral
218971517|NCT06749197|DEVICE|Rehacom|Home-based cognitive training program
218971518|NCT06897566|DIAGNOSTIC_TEST|Fasting lipid profile|Recruited patients will be requested to provide data from their most recent fasting lipid profile
218971519|NCT06776211|BEHAVIORAL|Virtual Reality Simulation|"Virtual reality simulation application:~The video content to be used in the virtual reality-based application was created by researchers from the Ministry of Health of the Republic of Turkey, General Directorate of Public Health, Neonatal Resuscitation Programme (NRP) Practitioner Certified Training Programme. The duration of the video was planned not to exceed 10 minutes in order not to reduce the interest and attention span."
218971520|NCT06776211|BEHAVIORAL|Low-Reality Simulation|Low reality simulation application: The low reality simulation application to be used will use a neonatal model as a teaching aid, with human anatomy and functional features designed to simulate neonatal resuscitation applications.
219065095|NCT06308939|DRUG|Eribulin|1.4mg/m\^2 day1、8，repeated every 3 week.
219065096|NCT06308939|DRUG|Sintilimab|500mg once every three weeks.
219065097|NCT01990235|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
219663465|NCT04344535|BIOLOGICAL|Standard Donor Plasma|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
219663466|NCT03598582|DRUG|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
219663467|NCT00553358|DRUG|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
219663468|NCT00553358|BIOLOGICAL|Trastuzumab|Therapeutic Monoclonal Antibody
219663469|NCT00553358|DRUG|Paclitaxel|antimicrotubule agent
219663470|NCT05292482|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
219663471|NCT05292482|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
218971521|NCT06776315|DEVICE|Resistive threshold inspiratory muscle training device|"In the other arm of the study, respiratory muscle training is performed in addition to the standard pulmonary rehabilitation program. Respiratory muscle strengthening training is performed with a resistive thereshold inspiratory muscle strengthening device. The exercise is performed at an intensity of 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The exercise is performed in 7 sets, with 2 minutes of work and 1 minute break for a total of 21 minutes."
218985703|NCT00347568|DEVICE|TX-plore|PI has terminated at institution and there is no one available to report.
218985704|NCT03989700|DRUG|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
218985705|NCT00667407|DRUG|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
219065098|NCT01865591|DEVICE|Ultrasound-based Renal Denervation|
219065099|NCT04749420|OTHER|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
219065100|NCT00695331|DRUG|Misoprostol|Titrated Misoprostol Solution
219065101|NCT00695331|DRUG|Oxytocin|Titrated Intravenous Oxytocin
219065102|NCT02187757|DIETARY_SUPPLEMENT|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
219065103|NCT02187757|DIETARY_SUPPLEMENT|Placebo|
219065104|NCT00003011|DRUG|marimastat|10 mg PO BID
219065105|NCT00003011|DRUG|Placebo|10 mg PO BID
219065106|NCT01098006|OTHER|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
219663472|NCT03887156|DIAGNOSTIC_TEST|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
219663473|NCT05840328|DRUG|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
219663474|NCT05840328|DRUG|Bupivacaine Injection|intervention drug will be administred epidurally
218971522|NCT06776315|PROCEDURE|Standard pulmonary rehabilitation programme|Patients are asked to perform thoracic, diaphragmatic breathing, and lower basal breathing exercises with 10 repetitions. Then, strengthening exercises are performed on the major muscle groups of the upper and lower extremities. In accordance with the resistance training program in the ATS/ERS guidelines for pulmonary rehabilitation, two to four sets of 6-12 repetitions are performed with intensities ranging from 50% to 85% of one maximum repetition, two to three times a week. During the exercises, the patient is questioned about their fatigue and dyspnea levels using the Borg scale, and breaks are given when necessary. The aerobic exercise program is performed as a 12-week, 3-day-a-week self-walking exercise. The walking program is performed in the form of walking on flat ground at 60% workload, based on the data obtained from the 6-minute walking test result (land-based walking).
218971523|NCT06776315|GENETIC|No intervention|Peripheral blood samples will be taken once from the participants in the control group and no other intervention will be performed.
218971524|NCT06775769|PROCEDURE|Sclerotherapy|Laparoscopic ethanol sclerotherapy of endometrioma
218971525|NCT06775769|PROCEDURE|Routine Care|Routine surgical management of endometrioma
218971526|NCT06765941|DEVICE|Probe-based near-infrared parathyroid autofluorescence detection system|The surgeon will use the PTeye as an intraoperative tool to identify whether a suspect tissue is parathyroid or not during the surgery. The surgeon will first take five baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent), to establish a reference point for subsequent measurements, using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements. The subsequent step involves touching the target tissue in the neck with the fiber optic probe, after which the PTeye will indicate to the surgeon whether the tissue is parathyroid or not. Parameters displayed on the PTeye console - Baseline values, Detection Intensity, Parathyroid Detection Ratio - will be recorded for each patient in the study arm. PTeye indicates that a tissue is parathyroid if the 'Parathyroid Detection Ratio' is greater than 1.2. The rest of the surgical procedure will follow the standard protocol.
218971527|NCT06765941|PROCEDURE|Surgeons naked eyes for parathyroid glands identification|The surgeons will not use the probe-based near-infrared parathyroid autofluorescence detection system and will proceed with the procedure as usual, relying on their surgical experience to identify parathyroid glands. At the end of the procedure, the thyroid specimen will be evaluated visually to search for inadvertently resected parathyroid glands. If this is the case, these parathyroid glands will be reimplanted in the sternocleidomastoid muscle, following standard protocol.
218971528|NCT06782139|DRUG|Enavogliflozin|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
218971529|NCT06782139|DRUG|Placebo|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
218971530|NCT07069660|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of solutions for each problem, implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
218971531|NCT07069660|BEHAVIORAL|Education Program|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
218971532|NCT07070427|OTHER|Exercise|Cognitive-based balance exercises.
218971533|NCT06900127|BEHAVIORAL|Safe Swaddling|newborns will be wrapped with the safe wrapping method.
218971534|NCT04268615|OTHER|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
218971535|NCT04268615|OTHER|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
218971536|NCT04268615|OTHER|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
219065107|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
219065108|NCT01876173|BEHAVIORAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
219663475|NCT03946228|BEHAVIORAL|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
219663476|NCT02929966|OTHER|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
218971537|NCT05069259|OTHER|Stool sample collection|collection for measuring calprotectin levels
218971538|NCT07068438|DEVICE|Pulse electric field ablation system|Bronchial rheoplasty (BR) is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
218971539|NCT07068438|DEVICE|Sham Procedure|Staged sham procedure: the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient).
218971540|NCT04876729|BEHAVIORAL|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
218971541|NCT07075185|DRUG|KLN-1010|Given at specified dose one time
218971542|NCT06927856|BEHAVIORAL|Test-to-PrEP|Participants, called Egos, will come once to the clinic throughout the duration of the study, for up to 1 hour. During the visit, participants will receive up to 4 Test-to-PrEP Packs, which include an HIV self-test kit and HIV prevention education materials and a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Test-to-PrEP Packs to Social Network Contacts (peers), called Alters.
218971543|NCT06927856|BEHAVIORAL|Access by Referral|Participants, called Egos, will receive up to 4 Access by Referral Cards once. Participants will receive a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Access by Referral Cards to Social Network Contacts (peers), also called Alters. The Referral Card can be used to order a Test-to-PrEP Pack, including the HIV self-test and HIV prevention education material, that will be mailed to an address of the Alter's choice.
218971544|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
218971545|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
218971546|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
219663477|NCT02929966|OTHER|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
219663478|NCT01325194|DRUG|liposomal cytarabine|50 mg intrathecally three times
219663479|NCT06308536|PROCEDURE|bone powder + collagen membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.
219663480|NCT06308536|PROCEDURE|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
218971547|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
218971548|NCT06665373|BEHAVIORAL|Modified Atkins Diet|The Atkins diet is a low-carb eating plan that focuses on balancing protein, fat, and carbohydrates.
218971549|NCT06665373|BEHAVIORAL|Fitness Program|12 weeks of two weekly supervised exercise sessions combined with an individualized home exercise program based on physical capabilities and available equipment.
218971550|NCT07076004|BEHAVIORAL|Medically Tailored Grocery Plus Nutrition Counseling Group|Weekly delivery of medically tailored groceries plus 8 remote nutritional counselling sessions.
218971551|NCT07076004|BEHAVIORAL|Experimental: Medically Tailored Grocery Group|Weekly delivery of medically tailored groceries.
218971552|NCT07076004|BEHAVIORAL|Standard of Care Group with Delayed Medically Tailored Grocery Delivery|Option to pick up fresh produce weekly from participating clinics. Medically tailored grocery delivery will be available for 6 months beginning at the end of the study.
218971553|NCT07078435|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
219065109|NCT04825457|PROCEDURE|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
218971554|NCT07078435|BIOLOGICAL|Blood test|Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
218971555|NCT07078435|BIOLOGICAL|Stool samples|Before the surgery, the patient will take a stool sample.
218971556|NCT07078435|BIOLOGICAL|Stool samples|After 1 year's follow-up, the patient will take a stool sample.
219065110|NCT02618473|OTHER|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
219065111|NCT04137380|DRUG|Mirikizumab - IV|Administered IV
219065112|NCT04137380|DRUG|Mirikizumab - SC|Administered SC
219663481|NCT06308536|PROCEDURE|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
219663482|NCT06308536|PROCEDURE|bone powder + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
219663483|NCT00495599|PROCEDURE|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
219663484|NCT01840137|OTHER|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
218971557|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
218971558|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
218971559|NCT06223750|OTHER|population-based screening for chronic kidney disease|Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
218971560|NCT06073132|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
218971561|NCT06073132|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
218971562|NCT02179658|DRUG|OPT-80|oral
218971563|NCT02179658|DRUG|vancomycin|oral
218971564|NCT07084129|OTHER|personalized dosing adjustment of vancomycin|A personalized vancomycin PK model that incorporates kidney injury biomarkers will be used for vancomycin dose adjustments to achieve goal AUC levels.
218971565|NCT05500248|BEHAVIORAL|Leave In Situ|"Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials."
218971566|NCT05500248|BEHAVIORAL|Standard|All identified polyps will be removed and sent to pathology.
218971567|NCT07132541|DRUG|Pancreatic parenchymal injection of N-butyl-2-cyanoacrylate(Histoacryl®)|"This procedure is integrated into the standard pancreaticoduodenectomy.~Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma circumferentially (3, 6, 9, and 12 o'clock positions) around the main pancreatic duct (MPD) orifice, extending 5-8 mm deep and 5-10 mm laterally from the future anastomotic line, avoiding the main pancreatic duct and vessels. Total volume injected typically ranges from 0.2 ml to 0.6 ml.~Follow with standard duct-to-mucosa pancreaticojejunostomy:~* Tying down the posterior duct-to-mucosa sutures.~* Placing and tying the anterior duct-to-mucosa sutures.~* Tying down the posterior outer layer sutures.~* Placing the anterior outer layer sutures. Meticulously avoid glue contact with sutures/mucosa~Reconstruction: Complete the hepaticojejunostomy and duodenojejunostomy (or gastrojejunostomy)."
218971568|NCT07089238|DIETARY_SUPPLEMENT|Citicoline|Oral
218971569|NCT07089238|DIETARY_SUPPLEMENT|Placebo|Oral
218971570|NCT07103993|OTHER|Low meal condition|Participants will consume a standardized meal (500 grams) with a low nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours
218971571|NCT07103993|OTHER|Moderate meal condition|Participants will consume a standardized meal (500 grams) with a moderate nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
218971572|NCT07103993|OTHER|High meal condition|Participants will consume a standardized meal (500 grams) with a high nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
218971573|NCT07103993|OTHER|Ad-libitum control condition|The ad-libitum meal consists of 600-700 g of a standardized control meal one time at all visits. Participants will attend one visit per week for 3 weeks. Each visit is separated by one week and each visit will take approximately 6 hours.
219663485|NCT01840137|OTHER|Exercise|Treadmill and muscle exercises.
218971574|NCT06437834|OTHER|Information Sheet|Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.
218971575|NCT06437834|OTHER|High-touch connect|Engagement with a patient navigator.
218971576|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
218971577|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
218971578|NCT05797246|DRUG|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
218971579|NCT07109726|DRUG|TER-2013|Oral Capsules
218971580|NCT07109726|DRUG|Fulvestrant injection|Fulvestrant 500 mg Intramuscular Injection
218985706|NCT00667407|DRUG|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
219663486|NCT02869841|DRUG|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
218985707|NCT01933061|DRUG|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
218985708|NCT01933061|DRUG|Abraxane|Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
218985709|NCT04669132|DRUG|Olanzapine|\- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
219663487|NCT02869841|DRUG|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
218971581|NCT07115966|BEHAVIORAL|Computerized decision support by best practice alert (BPA)|"The antimicrobial stewardship intervention encourages prescribers by a simple alert to follow guidelines for reviewing antimicrobial prescriptions after a set timeframe for potential de-escalation to targeted therapy or discontinuation of the antibiotics, as recommended by national and international guidelines.~An automated simple BPA will trigger after an antibiotic prescription with therapeutic indication (72 hours) or surgical prophylaxis (24 hours, reminding prescribers to reassess treatment for possible de-escalation, adaption to targeted therapy, or cessation.~If ignored, the prescription remains unchanged, but the alert will continue until addressed. Prescribers must select reasons for not changing the prescription, such as pending microbiology results. The control group corresponds to the inpatient wards not yet receiving the BPA, where antibiotics are managed according to standard-of-care."
218971582|NCT07118904|OTHER|Rapid weight loss through dehydration|Dehydration will be induced by exposing athletes to sauna heat with an average temperature of 70-80°C. The participants will undergo consecutive 15 minute sessions in sauna with 5 minute breaks until 3% weight loss is achieved. No liquids or food will be consumed between sessions.
218971583|NCT07116759|DEVICE|Real-time head stabilization with robotic platform|A robotic platform will use data from motion-detection cameras to position a person's head in real time. This procedure is non-invasive.
218971584|NCT07103772|DIETARY_SUPPLEMENT|Ananá|"The supplement consists of a box containing 14 sachets of the product for 14 days of treatment. Patients should preferably consume the supplement in the morning.~The Ananá's Nutraceutical Group will receive the real supplement for consumption over 14 days, while the Ananá's Placebo Group will receive a placebo supplement for comparison at the end of the trial."
218971585|NCT00182702|DRUG|ixabepilone|Given IV
218971586|NCT00182702|OTHER|laboratory biomarker analysis|Correlative studies
218971587|NCT06933771|OTHER|LAVENDER ESSENCE GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Afterwards, the researcher explained to the children in the intervention group and their parents how to apply the lavender essence and what kind of a plant lavender is, and showed the bottle of essential oil to be used during the procedure. A 5x5 cm sponge with 2 drops of almond oil that contains 1% lavender essence was located on the shoulder of the children to smell for 5 minutes.
218971588|NCT06933771|OTHER|CONTROL GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Routine nursıng care provıed.
218971589|NCT06934941|DRUG|NM-101|NM-101 IV versus placebo
218971590|NCT06934941|DRUG|Placebo|Placebo
218971591|NCT06933914|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d
219208386|NCT05406349|BEHAVIORAL|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
218971593|NCT06933654|PROCEDURE|IOL implantation surgery for aphkic eye|Aphakic eyes underwent secondary intraocular lens (IOL) implantation using one of two techniques. In Group A, an iris-claw IOL (Artisan aphakia IOL, Ophtec BV, The Netherlands) was implanted and fixated to the mid-peripheral iris via enclavation. In Group B, a posterior chamber foldable PMMA IOL was fixated to the iris using transscleral sutures passed through eyelets in the haptics. All procedures were performed under peribulbar anesthesia using standard aseptic technique, and postoperative management included topical antibiotics and corticosteroids.
218971594|NCT07143591|OTHER|Not found|No intervention
218971595|NCT06937892|BEHAVIORAL|Transdiagnostic metacognitive therapy|A single, generic treatment protocol focusing on metacognitions.
218971596|NCT06937892|BEHAVIORAL|Disorder-specific cognitive-behavioral therapy|Disorder-specific treatment protocols focusing on cognitions and/or behaviors.
218971597|NCT07140653|OTHER|Femto arcs|Femtosecond laser-assisted arcuate corneal relaxing incisions (AK) will be performed to correct astigmatism.
218971598|NCT07140653|DEVICE|Light Adjustable Lens (LAL)|The LAL is intended to replace the natural lens at time of lens removal.
218971599|NCT06946576|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure|FETO procedure involves insertion of a balloon into the fetal trachea under IV sedation with local anesthesia or combined spinal-epidural anesthesia. Balloon removal will take place up to 7 weeks after insertion.
219065113|NCT04137380|DRUG|Placebo - IV|Administered IV
219065114|NCT04137380|DRUG|Placebo - SC|Administered SC
219663488|NCT02869841|DRUG|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
219065115|NCT02995967|PROCEDURE|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
219065116|NCT02995967|DRUG|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
219065117|NCT02161744|BIOLOGICAL|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
219663489|NCT02869841|OTHER|Placebo|No rectus sheath analgesia
219663490|NCT05456854|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Administration of a hyperglycemic clamp
219663491|NCT05456854|DRUG|Kisspeptin-10|Administration of kisspeptin-10 \* 16 hr
219663492|NCT05456854|DRUG|Placebo|Administration of placebo \*16 hr
219663493|NCT01540084|DRUG|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
219663494|NCT05070143|BEHAVIORAL|RISE-UP Routine|The participants in this condition will be instructed to substitute their current sleep habits with the RISE-UP routine that has been developed by our team (Kaplan, Talavera, \& Harvey, 2018). This involves instructing participants to devise an individually tailored routine that will help them get up each morning (e.g., open blinds, make the bed, head for the shower).
219663495|NCT05070143|BEHAVIORAL|Awareness Training|The participants in this condition will be instructed in dismantling/disrupting the association between the cue and the habit via awareness training from habit reversal approaches (Azrin \& Nunn, 1973; Ladouceur, 1979). This condition involves instructing the participant to develop an awareness of their decisions to stay in bed and snooze.
219663496|NCT05070143|BEHAVIORAL|Vigilant Monitoring|"The participants in this condition will be instructed in vigilant monitoring which involves internal repetition of get up! and don't do it and watching carefully for slipups (Quinn, Pascoe, Wood, \& Neal, 2010)."
218971600|NCT06933758|DIAGNOSTIC_TEST|Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio|Demonstrate utility of LDCT in COPD characterization Determine exacerbation risk and symptom burden in this patient population Determine the severity of COPD identified through this process Describe phenotypic characteristics including imaging analysis of THCI population Determine the suitability and acceptance of patients to participate in COPD clinical trials Determine the incidence of comorbid lung (ILA, bronchiectasis, pulmonary artery enlargement) and non-lung problems (cardiac and aortic calcifications, osteopenia/osteoporosis and for gut abnormalities) identified by LDCT in a patient population at risk for lung cancer and/or COPD Determine the correlation between clinical measurements and imaging biomarkers
218971601|NCT07141849|BEHAVIORAL|Power Resistance Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
218971602|NCT07141849|BEHAVIORAL|Periodized Resistance Training|Participants will receive three weeks of hypertrophy training to increase muscle size followed by six weeks of strength training, and then three weeks of power training twice per week for a total of twenty-four 45-minutes in-person training sessions. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
218971603|NCT05578248|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
218971604|NCT05578248|PROCEDURE|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
218971605|NCT00414271|DRUG|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
218971606|NCT00414271|DRUG|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
218971607|NCT00518687|BIOLOGICAL|V710|0.5-mL single injection of V710 (60 µg)
218971608|NCT00518687|BIOLOGICAL|Placebo|0.5-mL single injection of matching placebo
218971609|NCT00881101|DRUG|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
218971610|NCT04027543|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
218971611|NCT04027543|PROCEDURE|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
218971612|NCT04027543|DRUG|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
218971613|NCT02223312|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
218971614|NCT04970784|OTHER|Activities of Daily Living (ADL) questionnaire (The Katz index )|"For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30."
219065118|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
219065119|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
219065120|NCT01173848|DRUG|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
219065121|NCT01173848|DRUG|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
219065122|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
219065123|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
219065124|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
219663497|NCT05070143|BEHAVIORAL|Implementation Intentions|"The participants in this condition will be instructed in counter habitual implementation intentions. This involves instructing the participant to engage in implementation intentions in which they imagine replacing snoozing with getting up out of bed (Adriaanse, Gollwitzer, De Ridder, De Wit, \& Kroese, 2011). The structure of this implementation intention is: If I wake up in the morning and I want a sleep-in then I will get up and start my day."
218971615|NCT04901546|OTHER|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
219663498|NCT05070143|BEHAVIORAL|Values-based Approach|The participants in this condition will be instructed in a values-based approach (Anshel, Brinthaupt, \& Kang, 2010; Anshel \& Kang, 2007). This involves asking the participants to reflect on how getting up consistently at the same time each day does or does not align with their values. They are asked to compare the costs and long-term consequences of continuing to engage in the unwanted habit and clearly articulating the disconnect between the habit and their values.
219663499|NCT05070143|BEHAVIORAL|Brief Education|"In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time.~First, education about the importance of regular wake times and sleep inertia that is a normal transitional stage between sleep and wake. The education will be delivered in this video format: https://www.youtube.com/watch?v=P6zcSFA7ymo. Second, after viewing the video, the key points will be summarized. Lastly, participants will be asked to summarize the four key takeaways for good sleep habits."
219663500|NCT05528484|PROCEDURE|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
219663501|NCT05528484|PROCEDURE|non eras nursing|Patients were under the routine management without eras protocol
219663502|NCT01287975|OTHER|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
219663503|NCT01287975|DEVICE|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
219663504|NCT01287975|DEVICE|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
219663505|NCT01612507|DRUG|600 mg Ceftaroline fosamil|1 h infusion
219663506|NCT01612507|DRUG|Placebo|1 h infusion
218971616|NCT05108922|DRUG|Donanemab|Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
218971617|NCT05108922|DRUG|Aducanumab|Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
218971618|NCT02876627|BEHAVIORAL|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
218971619|NCT00704912|DRUG|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
218971620|NCT00704912|DRUG|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
219208387|NCT06702657|DEVICE|balloon dilatation and/or stenting|balloon dilatation and/or stenting immediately after randomization
218971621|NCT00704912|DRUG|Combination of treatments|Medications will be administered as described for the other 2 arms.
219208388|NCT06702657|DRUG|medication|medication after randomisation, mechanical thrombectomy again if necessary, avoiding balloon dilatation and/or stenting.
219208389|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
218971622|NCT05765396|DEVICE|imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope|The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
218971623|NCT05265416|PROCEDURE|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
218971624|NCT05265416|OTHER|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.
218971625|NCT05265416|DEVICE|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
218971626|NCT02930330|BEHAVIORAL|INT|"* 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
218985710|NCT04669132|DRUG|Netupitant|\- Netupitanto 300 mg, once daily, on chemotherapy day;
219208390|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
219208391|NCT04809584|DRUG|F18-DCFPyL|Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
219208392|NCT04809584|DRUG|Gadolinium|Contrast agent
218985711|NCT04669132|DRUG|Palonesetron|\- Palonosetron 0.56 mg, once daily, on chemotherapy day;
218985712|NCT01519271|DRUG|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
218985713|NCT01519271|DRUG|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
219663507|NCT01612507|DRUG|600 mg Ceftaroline fosamil|2 h infusion
219663508|NCT01612507|DRUG|Placebo|2 h infusion
219663509|NCT05061485|OTHER|Sucrose|The participants consume A) water with 75 g sucrose
219663510|NCT05061485|OTHER|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
218971627|NCT02930330|BEHAVIORAL|CONT|"* 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
218971628|NCT00001624|DRUG|Insulin|
218971629|NCT05663567|BEHAVIORAL|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
218971630|NCT02260440|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
218971631|NCT02260440|DRUG|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
218971632|NCT01814384|DEVICE|prosthesis GMK ® without the ancillary MyKnee ® LBS|
218971633|NCT01814384|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
218971634|NCT06378931|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life.
218971635|NCT03484377|DEVICE|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
218971636|NCT03484377|DEVICE|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
218971637|NCT00115752|DRUG|Valdecoxib|
218971638|NCT00115752|DRUG|COX Inhibitor|
218971639|NCT00398411|DRUG|moxifloxacin|400 mg p.o. per day
218971640|NCT00398411|DRUG|placebo|one tablet per day p.o.
218971641|NCT05343442|PROCEDURE|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
218971642|NCT01937754|DIETARY_SUPPLEMENT|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
218971643|NCT01937754|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
219663511|NCT05061485|OTHER|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
219663512|NCT00208234|DRUG|Omalizumab|0.016 mg/kg IgE
218971644|NCT02095223|DEVICE|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
218971645|NCT02095223|BEHAVIORAL|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
218971646|NCT01397162|DRUG|Fluticasone propionate|Fluticasone propionate
218971647|NCT01397162|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
218971648|NCT01397162|DRUG|BI 54903|BI 54903
218971649|NCT02715180|RADIATION|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
218971650|NCT00931879|DRUG|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
218971651|NCT00931879|DRUG|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
218971652|NCT05561569|PROCEDURE|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
219208393|NCT04809584|PROCEDURE|Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan|Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)
219208394|NCT06812871|DRUG|furmonertinib|furmonertinib (160mg, once a day, continuous administration); bevacizumab (7.5 mg/kg body weight, once every 3 weeks); Pemetrexed (50 mg intrathecal injection chemotherapy, once every 3 weeks, up to 9 cycles).
219663513|NCT00208234|DRUG|Placebo for Omalizumab|Placebo
219663514|NCT00208234|DRUG|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
218971653|NCT01907997|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
218971654|NCT01907997|DRUG|normal saline infusion|In group C, the patients receive same volume of normal saline
218971655|NCT00282412|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
218971656|NCT00282412|DRUG|Fludarabine|inhibits DNA synthesis or repair
219663515|NCT01010399|DIETARY_SUPPLEMENT|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
219663516|NCT01010399|DRUG|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
219663517|NCT04129775|DRUG|OTO-413|Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
218971657|NCT00282412|DRUG|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
218971658|NCT00282412|DRUG|Campath 1H|humanized monoclonal antibody against CD52 antigen
218971659|NCT00282412|DRUG|GCSF|Hematopoietic growth factor
218971660|NCT00282412|DRUG|Cyclosporins|immune suppressive drug
218971661|NCT00282412|DRUG|Mycophenolate Mofetil|immune suppressive drug
218971662|NCT00750997|DRUG|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
219065125|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
219065126|NCT02265705|DRUG|Baricitinib|Administered orally
219065127|NCT02265705|DRUG|Placebo|Administered orally
219065128|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
219065129|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
218971663|NCT03095443|OTHER|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
218971664|NCT03095443|OTHER|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
218971665|NCT03095443|OTHER|Attention Control|Participant receives an audio-book.
218971666|NCT03211338|BIOLOGICAL|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
218971667|NCT03211338|BIOLOGICAL|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
218971668|NCT03211338|BIOLOGICAL|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
218971669|NCT01315912|DRUG|Letrozole|2.5 mg /day for 5 days
218971670|NCT00537238|DRUG|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
218971671|NCT00537238|DRUG|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
218971672|NCT03763864|OTHER|Skin Biopsy|Skin Biopsy
218971673|NCT01632046|DRUG|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
218971674|NCT00585390|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams"
218971675|NCT00585390|OTHER|Olive oil placebo|Olive oil capsules, 8 capsules per day
218971676|NCT00585390|DIETARY_SUPPLEMENT|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
218971677|NCT00585390|DRUG|Placebo|Olive oil capsule
218971678|NCT03454685|OTHER|without intervention type|Without intervention,this study is just an observational study.
218971679|NCT01501331|DEVICE|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
218971680|NCT03804008|DRUG|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
219065130|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
219065131|NCT05846009|DRUG|SAR442501|Subcutaneous injection
219065132|NCT05846009|DRUG|Placebo|Subcutaneous injection
219065133|NCT01060293|DRUG|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
219065134|NCT01060293|DRUG|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
219065135|NCT01060293|DRUG|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
219065136|NCT02853968|PROCEDURE|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
219663518|NCT04129775|DRUG|Placebo|Single intratympanic injection of placebo
219663519|NCT02900261|OTHER|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
219663520|NCT05538923|OTHER|No intervention was given to the patients|This study was an observational epidemiological study.
219663521|NCT01448603|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
219663522|NCT01448603|BIOLOGICAL|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
219663523|NCT00347321|PROCEDURE|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
219663524|NCT05268016|DRUG|ME3183|ME3183 capsule
219663525|NCT05268016|DRUG|Placebo|Placebo capsule
219663526|NCT02742714|DEVICE|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
219663527|NCT04122755|DRUG|ALA-1000|Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
219663528|NCT04122755|DRUG|buprenorphine sublingual film|ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
219663529|NCT01375634|DRUG|Midazolam|2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
219663530|NCT03727295|DRUG|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
218971681|NCT03804008|OTHER|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
219663531|NCT01733823|RADIATION|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
219663532|NCT03579823|DRUG|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
219663533|NCT03579823|DRUG|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
219663534|NCT03163459|DRUG|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
219663535|NCT03163459|DEVICE|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
219663536|NCT03900156|OTHER|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
218971682|NCT03804008|OTHER|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
218971683|NCT03438318|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
218985714|NCT01664546|PROCEDURE|Trophectoderm biopsy|
218985715|NCT01292746|DEVICE|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
218985716|NCT04713215|OTHER|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
218985717|NCT02348905|DRUG|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
218985718|NCT02348905|DRUG|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
218985719|NCT01489800|BEHAVIORAL|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
218985720|NCT06477081|PROCEDURE|FS-LASIK procedure|For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion o
218985721|NCT06477081|PROCEDURE|KLEx|For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complete
218985722|NCT03426813|OTHER|Historical control group for early mobilization|
218971684|NCT03438318|DRUG|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
218971685|NCT03438318|RADIATION|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
219663537|NCT06533267|PROCEDURE|Endoscopic nasopharyngectomy followed close follow-up|"Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years."
219663538|NCT06533267|RADIATION|Intensity-modulated Radiotherapy|"GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years."
219663539|NCT06135116|DIAGNOSTIC_TEST|Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA|"Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab."
219663540|NCT00000923|DRUG|Indinavir sulfate|
219663541|NCT00000923|DRUG|Lamivudine|
219663542|NCT00000923|DRUG|Stavudine|
219663543|NCT00000923|DRUG|Zidovudine|
219663544|NCT00000923|DRUG|Didanosine|
219663545|NCT00000923|DRUG|Aldesleukin|
219663546|NCT05127655|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
219663547|NCT04579614|BEHAVIORAL|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
219663548|NCT05482906|OTHER|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
219663549|NCT00394316|DRUG|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
219663550|NCT00404924|DRUG|ZD6474 (vandetanib)|once daily oral tablet
219663551|NCT00404924|OTHER|Best Supportive Care|standard of care
219663552|NCT02215785|OTHER|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
219663553|NCT03887429|DRUG|SXC-2023|SXC-2023 oral capsules
219663554|NCT03887429|DRUG|Placebos|Matching Placebo oral capsules
219663555|NCT00776620|DRUG|Glimepiride 1mg Tablets|
218971686|NCT00004347|BEHAVIORAL|diet|
218971687|NCT00526045|DRUG|AUY922 2 mg/m2|
218971688|NCT03538678|OTHER|Kwit smartphone app|Kwit smarphone app
218971689|NCT03791827|DRUG|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
218971690|NCT03791827|DRUG|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
218971691|NCT03791827|DRUG|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
218971692|NCT03791827|DRUG|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
218971693|NCT03791827|DRUG|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
218971694|NCT03791827|DRUG|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
218971695|NCT03791827|DRUG|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
218971696|NCT03791827|DRUG|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
218971697|NCT00446342|DRUG|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
218985723|NCT05089149|PROCEDURE|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
218985724|NCT05089149|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
218985725|NCT05089149|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
218985726|NCT05089149|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
218985727|NCT05089149|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
218985728|NCT00828932|DRUG|Lorcaserin|
218985729|NCT00194597|DRUG|Viagra (sildenafil citrate)|
218971698|NCT04012918|DRUG|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
219065137|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
219065138|NCT05465226|DRUG|Oliceridine|see arm description
219663556|NCT01197209|BIOLOGICAL|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
219663557|NCT03737266|PROCEDURE|Sonographically assisted breast surgery|Sonography
219663558|NCT03737266|PROCEDURE|Conventional breast surgery|Conventional
219663559|NCT01216046|DRUG|VX-809|capsule, taken once daily
219065139|NCT05465226|DRUG|Historical opioid use|Historical matched, control group in 2:1 ratio
218971699|NCT04012918|DRUG|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
218971700|NCT06008158|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI
218971701|NCT00006363|DRUG|cytarabine|Given IV
218971702|NCT00006363|DRUG|daunorubicin hydrochloride|Given IV
218971703|NCT00006363|DRUG|etoposide|Given IV
219663560|NCT01216046|DRUG|VX-770|tablet, taken once every 12 hours
218971704|NCT00006363|DRUG|valspodar|Given IV
218971705|NCT00006363|BIOLOGICAL|filgrastim|Given SC
218971706|NCT00006363|DRUG|busulfan|Given orally
218971707|NCT00006363|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
218971708|NCT00006363|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous PBSCT
218971709|NCT00006363|BIOLOGICAL|aldesleukin|Given SC
218971710|NCT00006363|OTHER|clinical observation|Undergo clinical observation
218971711|NCT00006363|OTHER|pharmacological study|Correlative studies
219663561|NCT01216046|DRUG|VX-809 placebo|capsule, taken once daily
219663562|NCT01216046|DRUG|VX-770 placebo|tablet, taken once every 12 hours
218971712|NCT02047149|DRUG|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
219663563|NCT05692804|DIAGNOSTIC_TEST|Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )|MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
218971713|NCT02047149|DRUG|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
218971714|NCT02047149|DRUG|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
218971715|NCT02047149|DRUG|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
218971716|NCT01297998|DRUG|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
218971717|NCT05454904|BEHAVIORAL|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) \<3 teaspoons/day of olive or Canola oil and \<3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
218971718|NCT05454904|BEHAVIORAL|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (\>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or \>3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) \>2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (\<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) \<1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and \<4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
218971719|NCT05454904|BEHAVIORAL|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
218971720|NCT03250429|PROCEDURE|Sinus surgery|Standard Clinical Sinus Surgery
218971721|NCT00032942|DRUG|Lofexidine|
218971722|NCT02831374|DRUG|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
218971723|NCT02831374|PROCEDURE|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
218971724|NCT02831374|BIOLOGICAL|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
218971725|NCT02831374|PROCEDURE|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
218971726|NCT02831374|PROCEDURE|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
218971727|NCT02831374|DRUG|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
218971728|NCT00610623|DRUG|azithromycin|300 mg/day, IV from day 1 to 20
218971729|NCT00610623|DRUG|placebo|once per day, IV from day 1 to 20
218971730|NCT06174064|DEVICE|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
219065140|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
219065141|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
219663564|NCT05956522|DRUG|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
219663565|NCT05956522|DRUG|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
219663566|NCT02084914|PROCEDURE|Endometrial scratching|Group A: pipelle Group B: sound
218971731|NCT06174064|DEVICE|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
219065142|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
219208395|NCT06716086|OTHER|shape memory alloy-based orthosis|The home program with the shape memory alloy-based orthosis contains warm-up part and correction part. The SMA-based orthosis is an improvement over traditional dynamic splint. This corrective device uses shape memory alloy as an elastic component specifically designed to address finger joint stiffness. It provides continuous force for stiff joint in order to address stiffness.
218971732|NCT00335920|DRUG|Dexamethasone-dihydrogenphosphate (4mg/ml)|
218971733|NCT03911713|DRUG|VX-561|VX-561 tablets for oral administration.
218971734|NCT03911713|DRUG|IVA|150-mg film-coated tablet for oral administration.
218971735|NCT03911713|DRUG|Placebo|Placebo matched to IVA.
218971736|NCT03911713|DRUG|Placebo|Placebos matched to VX-561.
218971737|NCT02436252|DRUG|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
218971738|NCT01690026|BEHAVIORAL|Motivation interviewing based brief intervention|
218971739|NCT01690026|BEHAVIORAL|Standard Intervention|
218971740|NCT02889692|DRUG|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
218971741|NCT02889692|DRUG|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
218971742|NCT02889692|DRUG|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
218971743|NCT02889692|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
219065143|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
219065144|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
219065145|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
219208396|NCT06716086|OTHER|conventional stretching program|The home program for the stretching group includes active joint range of motion exercises and passive stretching exercises. Participants will follow instructions to perform various joint movements, with a focus on their restricted fingers.
219208397|NCT06746389|DIETARY_SUPPLEMENT|3000 IU per Day Spray|Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
218971744|NCT02889692|DRUG|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
218971745|NCT02889692|DRUG|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
218971746|NCT02889692|DRUG|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
218971747|NCT00473473|DRUG|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
218971748|NCT00473473|DRUG|Placebo homeopathic remedy|identical to treatment without active component
218971749|NCT00729755|DIETARY_SUPPLEMENT|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
218971750|NCT00729755|DIETARY_SUPPLEMENT|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
218971751|NCT03054753|BEHAVIORAL|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
218971752|NCT04163497|DEVICE|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
218971753|NCT05432141|BIOLOGICAL|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
218971754|NCT05432141|BIOLOGICAL|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
218971755|NCT03956134|DRUG|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
218971756|NCT03956134|DRUG|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
218971757|NCT03956134|DRUG|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
219208398|NCT06747065|PROCEDURE|Radiotherapy|Radiotherapy post-mastectomy prepectoral implant-based breast reconstruction (IBBR)
219065146|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
219065147|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
219065148|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
219663567|NCT01074255|DRUG|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
219663568|NCT02797418|BEHAVIORAL|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
219663569|NCT03246919|DRUG|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
219663570|NCT03246919|DRUG|Placebo|Placebo will be administered after delivery of the placenta
219663571|NCT05239117|DEVICE|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
219663572|NCT03233789|BEHAVIORAL|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
219663573|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
219663574|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
219663575|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
218971758|NCT06496464|BEHAVIORAL|Intervention|"Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices."
218971759|NCT03802812|DEVICE|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
218971760|NCT01677546|DEVICE|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
218971761|NCT01677546|DEVICE|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
218971762|NCT00011973|DRUG|fenretinide|
219065149|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
219065150|NCT05042219|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
219663576|NCT00179894|BEHAVIORAL|Physician training|Physicians are trained in guidelines for medication management.
218971763|NCT03852004|OTHER|ostheopathy|standardized osteopathic treatment
218971764|NCT03852004|OTHER|simulated osteopathic treatment|standardized simulated osteopathic treatment
218971765|NCT00422097|DRUG|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
218971766|NCT00422097|DRUG|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
219065151|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
219065152|NCT04844281|DEVICE|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
219065153|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
219065154|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
218971767|NCT00422097|DRUG|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
218971768|NCT00422097|DRUG|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
218971769|NCT00422097|DRUG|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
218971770|NCT00422097|DRUG|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
218971771|NCT00422097|DRUG|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
218971772|NCT00422097|DRUG|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
218971773|NCT05504473|DEVICE|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
218971774|NCT00736957|DRUG|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
218971775|NCT00462540|DRUG|Formoterol Fumurate inhalation solution 20 mcg|
218971776|NCT00462540|DRUG|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
218971777|NCT02841189|DEVICE|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
218971778|NCT01368978|DEVICE|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
218971779|NCT03974360|DRUG|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
218971780|NCT02680509|PROCEDURE|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
218971781|NCT02970916|DRUG|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
218971782|NCT04171154|BEHAVIORAL|Expectation|writing task
218971783|NCT04171154|BEHAVIORAL|Acceptance|listening
219065155|NCT03988179|DIAGNOSTIC_TEST|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
218971784|NCT00484627|PROCEDURE|Use of creatine monohydrate (a dietary supplement)|
218971785|NCT00484627|BEHAVIORAL|Progressive resistance exercise training|
218971786|NCT00820352|DRUG|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
218971787|NCT00820352|DRUG|placebo|placebo twice a day for 12 weeks
218971788|NCT02536651|PROCEDURE|Ankle surgery|Plastic or orthopedic surgery of the ankle
218971789|NCT06199778|BEHAVIORAL|Rehabilitation therapy|"1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers."
218971790|NCT06199778|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
218971791|NCT06199778|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
218971792|NCT06199778|DRUG|Reserpine|Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
218971793|NCT06199778|DRUG|Levofloxacin|The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
218971794|NCT03728530|OTHER|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
218971795|NCT01554020|DIETARY_SUPPLEMENT|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
218971796|NCT01554020|DIETARY_SUPPLEMENT|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
218971797|NCT00994929|BIOLOGICAL|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
218971798|NCT04839146|BIOLOGICAL|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
218971799|NCT01238185|DRUG|acetylsalicylic acid|
219065156|NCT06031246|PROCEDURE|Selective Lymph Node Dissection|For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
219065157|NCT06580886|DEVICE|Ultrasound|All patients having ultrasound with Clarius L15/L20 and GE logic E9/E10 in same visit.
218971800|NCT01238185|GENETIC|gene expression analysis|
218971801|NCT01238185|GENETIC|protein expression analysis|
218971802|NCT01238185|OTHER|laboratory biomarker analysis|
218971803|NCT01238185|OTHER|questionnaire administration|
218971804|NCT01238185|PROCEDURE|biopsy|
218971805|NCT03468829|BIOLOGICAL|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
219065158|NCT05130112|DEVICE|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
219208399|NCT06741462|DEVICE|Digital health assistant ADELE A0004|The digital health assistant ADELE A0004 (ADELE for short) improves the daily lives of patients with care level and enables them to deal better and more independently with the everyday burdens resulting from the need for care. Participants in the intervention group were provided with ADELE to use during the study period for e.g., tracking of daily reminders, voice-based recording, interpretation and classification of their vital signs and body conditions.
218971806|NCT03468829|BIOLOGICAL|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
218971807|NCT03468829|BIOLOGICAL|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
218971808|NCT03798847|DEVICE|Journey II XR TKA|Journey II XR Total Knee System
218971809|NCT05136352|PROCEDURE|adductor canal block|loco-regional anesthesia using adductor canal block
218971810|NCT05136352|PROCEDURE|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
218971811|NCT03872323|PROCEDURE|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
218971812|NCT03872323|PROCEDURE|Open surgery|The arteries injuries are repaired by open surgical operation.
218971813|NCT02469740|DRUG|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
218971814|NCT02469740|DRUG|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
218971815|NCT05351502|DRUG|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
218971816|NCT05351502|DRUG|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
218971817|NCT05351502|DRUG|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
218971818|NCT05351502|DRUG|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
218971819|NCT06192784|PROCEDURE|DEB-TACE|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
218971820|NCT06192784|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
218971821|NCT01340547|DRUG|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
218971822|NCT01340547|DRUG|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
218971823|NCT05593133|OTHER|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
218971824|NCT05593133|OTHER|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
218971825|NCT03030807|DIAGNOSTIC_TEST|Right heart catheterization (in case of suspected PH)|
218971826|NCT00016159|BIOLOGICAL|filgrastim|
218971827|NCT00016159|BIOLOGICAL|lintuzumab|
218971828|NCT00016159|DRUG|arsenic trioxide|
218971829|NCT00016159|DRUG|idarubicin|
218971830|NCT00016159|DRUG|tretinoin|
218971831|NCT04429048|DEVICE|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
218971832|NCT04429048|DEVICE|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
218971833|NCT05267288|DRUG|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
218971834|NCT05264415|BEHAVIORAL|Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)|Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
218971835|NCT05264415|OTHER|Parenting Education Website|A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
218971836|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
218971837|NCT05672121|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
218971838|NCT00173888|DRUG|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
218971839|NCT00173888|DRUG|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
218971840|NCT00002895|DRUG|chemotherapy|
218971841|NCT05061966|BEHAVIORAL|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
218971842|NCT05061966|BEHAVIORAL|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
218971843|NCT01562158|PROCEDURE|standard therapy|Standard treatment of bleeding
218971844|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
218971845|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
218971846|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
218971847|NCT01562158|DRUG|placebo|Placebo
218971848|NCT02685514|DEVICE|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
218971849|NCT01554085|DRUG|ALS-002158|ALS-002158
218971850|NCT01554085|DRUG|Placebo|placebo
218971851|NCT01442454|OTHER|chronic pancreatitis|No intervention, subjects followed through surgery
218971852|NCT04402918|DIAGNOSTIC_TEST|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
218971853|NCT05718726|OTHER|Questionnaire, interview or observation study|Questionnaire administered by telephone
218971854|NCT04644003|DRUG|STP1|STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
218971855|NCT04644003|DRUG|Placebo|Placebo medication (capsule and tablet) identical in appearance to active medication
218971856|NCT01265251|DEVICE|Computerized neuropsychological test|Computerized neuropsychological test battery.
219065159|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
219065160|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
218971857|NCT01265251|OTHER|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
218971858|NCT04735536|DRUG|CT1812|Active Treatment- CT1812 at a dose of 300mg
219065161|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
219065162|NCT01610323|OTHER|Standard Care|
219065163|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
219065164|NCT06114797|OTHER|Chamomile|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
219065165|NCT06114797|OTHER|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
219065166|NCT03862404|DRUG|Bupivacaine-epinephrine|See previous description
219065167|NCT03862404|DRUG|Normal saline|See previous descreption
219208400|NCT06742749|PROCEDURE|Proximal level|For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected
219663577|NCT03953625|OTHER|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
218971859|NCT04735536|OTHER|Placebo|Placebo Comparator
219065168|NCT02079805|DRUG|Azilsartan|Azilsartan tablets
219065169|NCT02079805|DRUG|Telmisartan|Telmisartan tablets
219065170|NCT06148129|DIAGNOSTIC_TEST|Tissue Biopsy|The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
219208401|NCT06742749|PROCEDURE|Distal level|For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
219208402|NCT06742216|DRUG|Monosialoganglioside|Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
219663578|NCT00513266|BIOLOGICAL|bevacizumab|
219663579|NCT00513266|BIOLOGICAL|cetuximab|
219663580|NCT00513266|DRUG|fluorouracil|
219663581|NCT00513266|DRUG|irinotecan hydrochloride|
219663582|NCT00513266|DRUG|leucovorin calcium|
219663583|NCT00513266|DRUG|oxaliplatin|
219663584|NCT00513266|OTHER|laboratory biomarker analysis|
219663585|NCT00513266|PROCEDURE|adjuvant therapy|
218971860|NCT01910571|DRUG|P7435|
218971861|NCT01910571|OTHER|Placebo|
218971862|NCT02923427|DEVICE|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
218971863|NCT02923427|DEVICE|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
218971864|NCT01681797|DEVICE|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
219663586|NCT00513266|PROCEDURE|biopsy|
219663587|NCT00513266|PROCEDURE|conventional surgery|
219663588|NCT00513266|PROCEDURE|neoadjuvant therapy|
219065171|NCT06276855|OTHER|Sleep hygiene education|The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
219065172|NCT04631822|PROCEDURE|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
219663589|NCT02585687|DEVICE|liver Perfusion MRI|
219663590|NCT00166049|BEHAVIORAL|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
219663591|NCT00166049|BEHAVIORAL|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
219663592|NCT00166049|BEHAVIORAL|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
219663593|NCT01239524|PROCEDURE|denervation of thoracodorsal nerve or saving the nerve|
219663594|NCT00827658|PROCEDURE|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
219663595|NCT00827658|PROCEDURE|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
219663596|NCT02620358|OTHER|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
219208403|NCT06742216|DRUG|Placebo|Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
219208404|NCT06741254|OTHER|Stress Ball|During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST.
219663597|NCT02620358|OTHER|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
218971865|NCT01325623|DEVICE|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
219663598|NCT02477709|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
219663599|NCT02943785|DRUG|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
219663600|NCT02943785|DRUG|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
219663601|NCT01353573|RADIATION|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
218971866|NCT00728052|DRUG|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
219663602|NCT01353573|RADIATION|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
219663603|NCT05243667|OTHER|Wearable wrist Smart Device of Huami|"All enrolled patients underwent continuous monitoring by wearing huami blood oxygen testing equipment, and signed the informed consent for the clinical trial.Smart wrist wristbands will be issued, and patient information will be bound to the Migang Health platform, and clinical trial doctors will improve relevant personal information and clinical data.After binding to the APP Migu Health, you can start collecting and recording dynamic data such as peripheral blood oxygen saturation, heart rate, exercise steps, sleep data, etc., and upload the data once a day."
219663604|NCT02751164|OTHER|Day/time of admission to the critical care unit|
219663605|NCT00033306|DRUG|ixabepilone|
219663606|NCT00033306|DRUG|Fluoropyrimidine|
218971867|NCT00728052|DRUG|Placebo|Placebo capsules will be administered orally with water.
218971868|NCT00145600|DRUG|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
218971869|NCT00145600|DRUG|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
218971870|NCT00145600|DRUG|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
218971871|NCT00145600|DRUG|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
218971872|NCT01427322|DRUG|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
218971873|NCT01427322|RADIATION|Radiation therapy|Standard radiation therapy
218971874|NCT01420653|DRUG|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
218971875|NCT01420653|DRUG|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
218971876|NCT01420653|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
218971877|NCT01420653|DRUG|Placebo|placebo, three tablets four times a day, with food for 48 hours
218971878|NCT05377203|DRUG|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
218971879|NCT05377203|DRUG|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
218971880|NCT04465162|OTHER|Radiation Therapy|Undergo radiation therapy
218971881|NCT03098355|BIOLOGICAL|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
218971882|NCT03098355|DRUG|Interleukin-2|Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
218971883|NCT02518412|OTHER|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
218971884|NCT02518412|OTHER|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
218971885|NCT01969643|DRUG|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
219663607|NCT00033306|DRUG|Irinotecan|
219663608|NCT04103515|DEVICE|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
219663609|NCT04103515|DEVICE|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
219663610|NCT00821015|DEVICE|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
219663611|NCT01281956|DRUG|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
219663612|NCT01281956|DRUG|Placebo|Placebo
219663613|NCT03170609|BIOLOGICAL|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
218971886|NCT01969643|DRUG|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
218971887|NCT00426998|DRUG|Verteporfin|
218971888|NCT00426998|DRUG|Bevacizumab|
218971889|NCT03031535|DRUG|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
218971890|NCT03031535|DRUG|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
218971891|NCT03031535|DIAGNOSTIC_TEST|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
219663614|NCT03170609|BIOLOGICAL|Placebo|Saline Control
219663615|NCT02679456|DRUG|SCY-078|
219663616|NCT02679456|DRUG|Fluconazole|
218971892|NCT03031535|DIAGNOSTIC_TEST|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
218971893|NCT01384071|DEVICE|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
218971894|NCT01384071|DEVICE|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
218971895|NCT03644680|DIAGNOSTIC_TEST|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
218971896|NCT03644680|OTHER|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
218971897|NCT00167557|DRUG|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
219065173|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
219065174|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
219663617|NCT00359177|DRUG|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
218971898|NCT00167557|DRUG|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
218971899|NCT00167557|PROCEDURE|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
218971900|NCT05648760|BEHAVIORAL|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
219663618|NCT02929615|OTHER|Hematopoietic stem cell transplantation|
219663619|NCT01897792|DIETARY_SUPPLEMENT|Vitamin C|
219663620|NCT01897792|DIETARY_SUPPLEMENT|Vitamin E|
219663621|NCT01897792|DIETARY_SUPPLEMENT|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
219663622|NCT01897792|DRUG|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
219663623|NCT00265408|DRUG|aspirin|
219663624|NCT00265408|DRUG|warfarin|
218971901|NCT00635791|DRUG|Sorafenib|Given by mouth
218971902|NCT00635791|DRUG|Vorinostat|Given by mouth
218971903|NCT05622370|DRUG|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
218971904|NCT05622370|DRUG|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
219663625|NCT05698537|DIAGNOSTIC_TEST|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
219663626|NCT05698537|DIAGNOSTIC_TEST|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
219663627|NCT05698537|DIAGNOSTIC_TEST|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
219663628|NCT05698537|OTHER|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
219663629|NCT01033708|BEHAVIORAL|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
219663630|NCT02452255|DRUG|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
219663631|NCT02452255|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
219663632|NCT02452255|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
219663633|NCT06229899|DIAGNOSTIC_TEST|Serum follistatin levels|blood samples are taken
219663634|NCT02572856|DEVICE|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
219663635|NCT06165913|PROCEDURE|Early implant placement(type II)|in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed
219663636|NCT06165913|PROCEDURE|Early implant placement (type III)|in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
218971905|NCT05622370|DRUG|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
218971906|NCT01729260|DRUG|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
218971907|NCT02675101|OTHER|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
218971908|NCT02675101|OTHER|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
219663637|NCT04965428|BEHAVIORAL|Fear-focused Self-Compassion Therapy|The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
219663638|NCT06137911|DRUG|JYP0061|JYP0061 orally administered
219065175|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine"
219065176|NCT00513669|BIOLOGICAL|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
219065177|NCT00513669|BIOLOGICAL|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
219663639|NCT06137911|DRUG|placebo|Placebo orally administered
219663640|NCT05911672|DEVICE|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa\_token=tC5fSN8-k5EAAAAA:56\_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
219663641|NCT00072748|DRUG|EKB-569|
219663642|NCT01903759|OTHER|Blood samples|
219663643|NCT04283110|DRUG|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
219663644|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
219663645|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
218971909|NCT02675101|OTHER|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
218971910|NCT05152563|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
218971911|NCT05152563|OTHER|Placebo|Placebo
218971912|NCT02753218|DRUG|Midazolam|
218971913|NCT02753218|DRUG|LEO 32731|
218971914|NCT03183011|OTHER|MRI|Cardiac MRI
218971915|NCT00905216|DRUG|heparin sodium - Bergamo|5.000 UI/mL
218971916|NCT00905216|DRUG|heparin sodium - APP|5.000 USP
218971917|NCT03517124|OTHER|Ceramic tooth restoration|Dental restorations
218971918|NCT00111878|DRUG|MEDI-534|
218971919|NCT04870034|DRUG|Binimetinib|Given PO
218971920|NCT04870034|DRUG|Palbociclib|Given PO
218971921|NCT04870034|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
218971922|NCT00359918|DRUG|fibrinolysis|Primary PCI
218971923|NCT00359918|PROCEDURE|Primary PCI|Primary PCI
218971924|NCT05080127|COMBINATION_PRODUCT|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
218971925|NCT02474680|GENETIC|Pharmacogenetic testing|Psychotropic genotyping panel
218971926|NCT00950911|DRUG|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
218971927|NCT03570879|DEVICE|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
218971928|NCT03570879|PROCEDURE|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
218971929|NCT03136731|DIAGNOSTIC_TEST|Celiac disease antibody screening|Observational parameters
219360286|NCT02784938|BEHAVIORAL|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
219663646|NCT02463006|DRUG|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
219663647|NCT02463006|DRUG|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
219663648|NCT04482036|OTHER|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
218971930|NCT04416308|DIAGNOSTIC_TEST|NG test|rapid diagnosis Covid 19
218971931|NCT04416308|DIAGNOSTIC_TEST|Blood test|sample
218971932|NCT04416308|BEHAVIORAL|Self-questionnary|behavioral survey
219663649|NCT04482036|OTHER|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
219663650|NCT02410213|DRUG|Ferric Carboxymaltose (FCM)|
219663651|NCT00240656|DRUG|spironolactone captopril carvedilol|
219663652|NCT00149370|PROCEDURE|Breast reduction surgery|
218971933|NCT01742936|DEVICE|CoaguChek|Hand held coagulation monitor.
218971934|NCT01742936|OTHER|Hospital Laboratory|Coagulation testing done by hospital laboratory.
218971935|NCT02600351|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
218971936|NCT02600351|DRUG|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218971937|NCT03530566|OTHER|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
218971938|NCT03530566|OTHER|standard diet|standard low calorie diet for weight loss
218971939|NCT04087213|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
218971940|NCT00003678|DRUG|tamoxifen citrate|
218971941|NCT00003678|PROCEDURE|adjuvant therapy|
218971942|NCT01739114|PROCEDURE|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
218971943|NCT01739114|PROCEDURE|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
219663653|NCT05634642|DEVICE|Ultrasound|Using ultrasound to measure the diameter of distal radial artery
218971944|NCT01550471|DRUG|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
218971945|NCT01550471|DRUG|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
218971946|NCT01550471|DRUG|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
218971947|NCT01550471|DRUG|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
218971948|NCT01550471|DRUG|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
218971949|NCT01550471|DRUG|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
218971950|NCT00795925|DRUG|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
218971951|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
218971952|NCT02556203|DRUG|Acetylsalicylic Acid (ASA)|75-100mg OD
218971953|NCT02556203|DRUG|Clopidogrel|75mg OD
218971954|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
218971955|NCT02556203|DRUG|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
218971956|NCT05631665|OTHER|Survey results before and after laser treatment|Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
218971957|NCT00982124|DRUG|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
218971958|NCT01385631|DRUG|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
219065178|NCT01891123|DEVICE|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
219065179|NCT01891123|DRUG|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
219065180|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
219065181|NCT01970033|DRUG|Placebo|"* Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
218971959|NCT01385631|DRUG|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
218971960|NCT03875768|BEHAVIORAL|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
219663654|NCT00264030|DEVICE|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
218971961|NCT03895242|BEHAVIORAL|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
219065182|NCT01970033|DRUG|SP2086 50 mg b.i.d.|"* Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks"
219065183|NCT01970033|DRUG|SP2086 100 mg q.d.|"* Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks"
219663655|NCT00264030|OTHER|PTCA|PTCA
219663656|NCT01857102|DEVICE|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
219663657|NCT01857102|DEVICE|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
219065184|NCT01764984|DEVICE|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
219065185|NCT01300130|DIETARY_SUPPLEMENT|low docosahexaenoic acid formula|
219065186|NCT01300130|DIETARY_SUPPLEMENT|medium docosahexaenoic acid formula|
219065187|NCT01300130|DIETARY_SUPPLEMENT|high docosahexaenoic acid formula|
219663658|NCT03485937|BEHAVIORAL|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
219663659|NCT03485937|BEHAVIORAL|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
219663660|NCT03485937|BEHAVIORAL|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
218971962|NCT03895242|BEHAVIORAL|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
218971963|NCT02690883|DRUG|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
218971964|NCT02690883|DRUG|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
218971965|NCT01902238|PROCEDURE|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
218971966|NCT00436774|PROCEDURE|assessment of therapy complications|
218971967|NCT00436774|PROCEDURE|quality-of-life assessment|
218971968|NCT02737280|DEVICE|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
218971969|NCT02737280|DEVICE|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
218971970|NCT00145171|DRUG|apomorphine HCl injection|
218971971|NCT02907580|BEHAVIORAL|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
218971972|NCT02907580|BEHAVIORAL|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
218971973|NCT04537260|BEHAVIORAL|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
219065188|NCT01300130|DIETARY_SUPPLEMENT|breast milk|a non randomized group of breast milk fed infants was included
219065189|NCT04821596|OTHER|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
219065190|NCT00511576|DRUG|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
219065191|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
219663661|NCT01490697|DRUG|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
219663662|NCT01490697|DRUG|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
219663663|NCT01490697|DRUG|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
219663664|NCT01490697|DRUG|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
219663665|NCT06230029|OTHER|Music listening|Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.
218971974|NCT02138422|BIOLOGICAL|Xilonix|
218971975|NCT02138422|BIOLOGICAL|Placebo|
218971976|NCT03668769|OTHER|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
218971977|NCT03668769|OTHER|Interview|Ancillary studies
218971978|NCT03668769|OTHER|Questionnaire Administration|Ancillary studies
218971979|NCT03668769|BEHAVIORAL|Smoking Cessation Intervention|Participate in individual smoking cessation program
218971980|NCT04923815|DEVICE|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
219065192|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
219065193|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
219065194|NCT00583557|DRUG|belimumab|IV 10mg/kg Q28 days
219065195|NCT03273439|DEVICE|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
219065196|NCT03273439|DEVICE|Sham rTMS|Sham rTMS, without stimulation
219065197|NCT01040104|OTHER|Skin sample|Taken from regularly discarded tissue during routine operation
219065198|NCT01040104|OTHER|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
219065199|NCT01040104|OTHER|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
219065200|NCT01040104|OTHER|Blood taking|Blood taking on day 0
219065201|NCT01040104|OTHER|Blood taking|Blood taking on day 90
219065202|NCT02431039|DEVICE|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
219065203|NCT02431039|DEVICE|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
219065204|NCT05094323|DRUG|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
219065205|NCT05094323|DRUG|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
219065206|NCT05094323|DRUG|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
219065207|NCT02347761|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
219065208|NCT02347761|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
219065209|NCT02347761|DRUG|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
219065210|NCT02657278|PROCEDURE|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
219065211|NCT00059813|BIOLOGICAL|recombinant interferon alfa|Given SC
219065212|NCT00059813|BIOLOGICAL|oblimersen sodium|Given IV
219065213|NCT00059813|OTHER|pharmacological study|Correlative studies
219065214|NCT06162520|OTHER|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
219065215|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
219360287|NCT03222349|DRUG|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
218971981|NCT00580970|DRUG|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
219065216|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
219065217|NCT06582615|PROCEDURE|Biospecimen Collection|Undergo dried blood spot collection
219065218|NCT06582615|PROCEDURE|Cognitive Assessment|Ancillary studies
219065219|NCT06582615|OTHER|Dietary Intervention|Receive MIND counseling sessions
219360288|NCT02101970|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
219663666|NCT01585610|BEHAVIORAL|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (\< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
219065220|NCT06582615|OTHER|Dietary Intervention|Follow a personalized diet
219663667|NCT01585610|BEHAVIORAL|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (\< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
219663668|NCT04093791|BEHAVIORAL|"Collective Intervention G"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
219663669|NCT04093791|BEHAVIORAL|"Individual Intervention I"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
219065221|NCT06582615|OTHER|Dietary Intervention|Receive general health recommendations counseling sessions
219065222|NCT06582615|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
219065223|NCT06582615|OTHER|Questionnaire Administration|Ancillary studies
219065224|NCT03625570|BEHAVIORAL|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
219360289|NCT02101970|OTHER|Placebo Capsule|
219360290|NCT02101970|OTHER|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
219360291|NCT00065728|DRUG|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
219360292|NCT01744288|DRUG|Ticagrelor|Oral single loading dose 180ng
219663670|NCT04935008|DIAGNOSTIC_TEST|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
219663671|NCT00090584|DRUG|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
219663672|NCT00090584|BEHAVIORAL|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
218971982|NCT02018068|OTHER|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
218971983|NCT02018068|OTHER|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
218971984|NCT03342014|DEVICE|Ultrasound|3DPD and UAD acquisitions (10 min)
218971985|NCT03342014|BIOLOGICAL|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
218971986|NCT02672228|DEVICE|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
218971987|NCT04376892|OTHER|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
218971988|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
218971989|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
218971990|NCT05633225|OTHER|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
218971991|NCT01632137|DRUG|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
218971992|NCT01632137|DRUG|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
218971993|NCT03161821|OTHER|Observational|
218971994|NCT05473884|DEVICE|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
218971995|NCT05473884|DEVICE|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
218971996|NCT06150755|PROCEDURE|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
218971997|NCT06150755|PROCEDURE|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
218971998|NCT00557427|DRUG|hypericum|250mg tablets twice daily for 8 weeks
218971999|NCT00557427|DRUG|fluoxetine|20mg - 40mg daily for 8 weeks
218972000|NCT04647071|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
218972001|NCT04647071|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
218972002|NCT02155569|PROCEDURE|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
219360293|NCT01744288|DRUG|Clopidogrel|Oral single loading dose 600mg
219360294|NCT01744288|DRUG|ASA|81mg once daily from day -2 up to platelet transfusion
218972003|NCT02155569|PROCEDURE|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
218972004|NCT04648709|DIAGNOSTIC_TEST|ELISPOT|measure of immune response by ELISPOT
218972005|NCT04648709|DIAGNOSTIC_TEST|QUANTIFERON|measure of immune response by QUANTIFERON
218972006|NCT01086423|BIOLOGICAL|Infanrix-IPV/Hib™|Intramuscular, three doses
218972007|NCT01086423|BIOLOGICAL|Infanrix Hib™|Intramuscular, three doses
218972008|NCT01086423|BIOLOGICAL|Poliorix™|Intramuscular, three doses
218972009|NCT03075046|DEVICE|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
219663673|NCT01436331|OTHER|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
219686534|NCT02404129|OTHER|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
219065225|NCT03625570|BEHAVIORAL|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
219065226|NCT06962241|OTHER|Warming group|When the pregnant women in the experimental group were laid on the operating table, they were heated from the back with a heating pad. The heating pad remained on the pregnant woman's back throughout the cesarean section. The cesarean section took an average of 35 minutes from the first surgical incision to the completion of the incision after spinal/epidural anesthesia.
219065227|NCT06635798|BIOLOGICAL|GR2001|The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
219065228|NCT06635798|BIOLOGICAL|HTIG|The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
219065229|NCT04848025|DEVICE|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
219065230|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
219065231|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
219065232|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
219065233|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
219065234|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
219065235|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
219065236|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
219065237|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
219065238|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
219065239|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
219065240|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
219065241|NCT02923037|OTHER|ldex measurement of arms|
219065242|NCT02938416|DEVICE|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
219065243|NCT02938416|DEVICE|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
219065244|NCT02938416|BEHAVIORAL|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
219065245|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
219065246|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
219065247|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
219065248|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
219663674|NCT01436331|BEHAVIORAL|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
219663675|NCT05248724|COMBINATION_PRODUCT|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
219663676|NCT05248724|DRUG|placebo|50 ml of 0.9 saline
219663677|NCT01572311|BEHAVIORAL|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
219065249|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
219065250|NCT02785406|DRUG|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
219065251|NCT02785406|DRUG|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
219065252|NCT04579263|OTHER|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
219065253|NCT00991250|BIOLOGICAL|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
219065254|NCT00991250|DRUG|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
219065255|NCT02011880|DIETARY_SUPPLEMENT|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
219065256|NCT04096092|OTHER|No intervention|No intervention
219065257|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
219065258|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
219663678|NCT01572311|BEHAVIORAL|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
219663679|NCT02013661|PROCEDURE|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
219663680|NCT01461252|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
219663681|NCT01461252|PROCEDURE|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
218972010|NCT03075046|OTHER|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
218972011|NCT01225887|DRUG|Nintedanib|Given PO
218972012|NCT01017471|PROCEDURE|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
218972013|NCT03843112|DRUG|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
218972014|NCT03843112|DRUG|Placebo - Cap|Vaginal supplements
218972015|NCT02009007|DRUG|dopamine|continuous infusion during operation
218972016|NCT02009007|DRUG|phenylephrine|continuous infusion of phenylephrine during operation
218972017|NCT06637215|PROCEDURE|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
218972018|NCT06637215|PROCEDURE|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
218972019|NCT00925990|DRUG|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
219065259|NCT04001465|PROCEDURE|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
218972020|NCT00925990|DRUG|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
218972021|NCT00925990|DRUG|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
218972022|NCT00835159|DRUG|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
218972023|NCT00835159|OTHER|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
219065260|NCT04001465|PROCEDURE|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
219065261|NCT04160819|OTHER|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
218972024|NCT00749515|DRUG|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
218972025|NCT00749515|DRUG|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
218972026|NCT00749515|RADIATION|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
218972027|NCT05955053|OTHER|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
218972028|NCT01270542|DRUG|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
219065262|NCT05956431|DRUG|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
219360295|NCT00510809|DRUG|Policosanol|Policosanol 20 mg daily
218972029|NCT01270542|OTHER|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
218972030|NCT04058418|OTHER|Survey Administration|Completion of a short survey.
219663682|NCT04456166|DIETARY_SUPPLEMENT|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
219663683|NCT04937907|DRUG|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
219663684|NCT04937907|DRUG|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
219663685|NCT05614778|OTHER|Zoledronic Acid injection, 5mg/100mL|Zoledronic Acid injection, 5mg/100mL
218972031|NCT05266534|DRUG|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
218972032|NCT05266534|DRUG|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
219065263|NCT05956431|DRUG|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
219208405|NCT06748183|OTHER|Functional Power Training|Group A will participate in Functional Power Training (FPT) alongside routine physical therapy The exercise protocol aims to enhance strength, mobility, and endurance through resistance training across various functional activities. It includes exercises such as running, walking, chair pushing, stair climbing, propelling a stable scooter, and sideways walking, all performed at 50-70% of the participant's maximum speed. Resistance is added using methods like dragging a loaded box with a belt during running and walking, pushing a chair with a loaded box underneath, wearing a loaded vest while climbing stairs, and attaching a loaded box to a scooter for propulsion exercises. Each exercise involves 6 to 8 repetitions lasting 25 seconds, followed by 30 to 50 seconds of rest. This structured regimen focuses on controlled movement and endurance, providing a comprehensive approach to improving physical performance.
219663686|NCT03409120|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
219663687|NCT04442438|OTHER|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
218972033|NCT05266534|DRUG|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
218972034|NCT03432156|BIOLOGICAL|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
218972035|NCT02080858|DRUG|Ticagrelor + Apixaban + ASA|
218972036|NCT02080858|DRUG|Ticagrelor + Apixaban|
219065264|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
219065265|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
219208406|NCT06748183|OTHER|Routine physical therapy|Routine physical therapy for a child with Cerebral Palsy involves hot pack for muscle relaxation and isometric exercises to enhance motor skills, muscle strength, and coordination. Passive stretching will be given as a treatment plan. Therapists employ sit to stand exercise to improve gait, posture, and overall functional abilities. Regular progress evaluations are conducted to adjust interventions, ensuring ongoing improvements.
219360296|NCT00510809|OTHER|Placebo|Placebo daily
219663688|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
219065266|NCT00153049|DRUG|Telmisartan|
219065267|NCT00153049|DRUG|Hydrochlorothiazide|
219065268|NCT00153049|DRUG|Telmisartan + Hydrochlorothiazide|
219663689|NCT01147003|DRUG|Placebo|
219663690|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
219663691|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat drug screen|Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
219663692|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat laboratory analysis|Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
219663693|NCT01058902|DRUG|Aspirin 75 mg|Aspirin 75 mg
219663694|NCT01058902|OTHER|no aspirin|nothing
219663695|NCT04208321|OTHER|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
219663696|NCT04208321|DRUG|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
219065269|NCT03296995|DEVICE|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
219065270|NCT00319215|DRUG|Ramelteon 8 mg|
219663697|NCT03925584|OTHER|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
218972037|NCT05392517|OTHER|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
219663698|NCT00129181|DRUG|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
219663699|NCT00129181|DRUG|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
219663700|NCT00129181|PROCEDURE|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
219663701|NCT06645912|DIETARY_SUPPLEMENT|oral nutritional supplement|The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
219663702|NCT02117713|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
219663703|NCT01800019|DRUG|Nicotine Replacement Therapy (NRT)|
219663704|NCT01800019|DRUG|Varenicline|
219663705|NCT01800019|BEHAVIORAL|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
219663706|NCT03466749|DEVICE|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
219663707|NCT05284734|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
218972038|NCT05392517|OTHER|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
219065271|NCT00319215|DRUG|Zopiclone 7.5 mg|
219065272|NCT04183322|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
219065273|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
219065274|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
219065275|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
219208407|NCT06894147|PROCEDURE|Genicular nerve pulse radiofrequency|After performing a diagnostic block with 1 mL of 1% lidocaine on the superior medial, lateral, and inferior medial genicular nerve branches, patients who experience more than 50% benefit from the procedure will undergo pulsed radiofrequency aplication.
219208408|NCT06751459|DEVICE|MEMO Patch 2 - 14-day Monitoring|A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.
219065276|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
219065277|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
219663708|NCT04748172|BIOLOGICAL|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
219663709|NCT04748172|DIAGNOSTIC_TEST|AMH sampling|Blood sample for AMH on recruitment and after three months
219663710|NCT04748172|DIAGNOSTIC_TEST|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
219663711|NCT06671587|DRUG|iGlarLixi (insulin glargine/lixisenatide)|"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~\- iGlarLixi must not be mixed with other insulins nor diluted."
219663712|NCT06671587|DRUG|Gla-100 (insulin glargine)|Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
219663713|NCT02959515|PROCEDURE|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
219663714|NCT02959515|PROCEDURE|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
219065278|NCT03772080|OTHER|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
219065279|NCT05221164|DRUG|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
219065280|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
219065281|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
219065282|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
219663715|NCT06603220|DRUG|Oral EVO756|Oral EVO756, once daily
218972039|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
218972040|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
218972041|NCT05484908|OTHER|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
218972042|NCT05484908|OTHER|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
218972043|NCT05484908|OTHER|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
218972044|NCT00969904|DRUG|N-acetylcysteine|600 mg TID for 12 weeks
219663716|NCT06353646|BIOLOGICAL|XH001|XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)
219663717|NCT06353646|DRUG|Ipilimumab Injection|Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
219663718|NCT06353646|DRUG|Sintilimab injection|Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
219663719|NCT06353646|DRUG|Chemotherapy|gemcitabine + capecitabine
219663720|NCT05958069|DRUG|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
218972045|NCT00969904|DRUG|placebo|placebo tablet TID for 12 weeks
218972046|NCT02124486|PROCEDURE|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
218972047|NCT02124486|BEHAVIORAL|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
218972048|NCT02595138|DRUG|Zoledronic acid|
219065283|NCT03453606|OTHER|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
219065284|NCT03453606|OTHER|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
219065285|NCT02192437|OTHER|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
219065286|NCT01310036|DRUG|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
219065287|NCT00553267|DRUG|fixed dose combination of telmisartan+amlodipine|
219065288|NCT00553267|DRUG|amlodipine|
219065289|NCT04046874|DRUG|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
219663721|NCT06991686|DIAGNOSTIC_TEST|Blood samples|blood sample for CBC and procalcitonin
219663722|NCT06991686|DIAGNOSTIC_TEST|blood sample|blood sample for procalcitonin and CBC
219663723|NCT06011460|DRUG|Clozapine|"Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old."
219663724|NCT03599856|OTHER|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
219663725|NCT06173739|PROCEDURE|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
219663726|NCT04610502|BIOLOGICAL|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
219663727|NCT03259828|RADIATION|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
219663728|NCT02183805|DRUG|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
219663729|NCT03176667|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
219663730|NCT03176667|PROCEDURE|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
219663731|NCT05556850|BEHAVIORAL|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
219663732|NCT00083668|DRUG|Paliperidone ER|
219663733|NCT06600191|DEVICE|Capstan System transcatheter mitral valve replacement|This is a first human use trial exploring a novel transcatheter mitral valve replacement implant and electro-mechanical delivery system. The device offers a minimally invasive repair for patients who have at symptomatic regurgitation who are otherwise ineligable for surgical intervention, or who have no other prospects for treatment and in whom medical therapy has already been optimised.
219663734|NCT06624436|DRUG|Dexamethasone|Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
219663735|NCT06624436|DRUG|Tocilizumab|Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
219663736|NCT06624436|DRUG|Anakinra|Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
219663737|NCT06624436|DRUG|Placebo|Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
219663738|NCT06624436|BIOLOGICAL|LPS|This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.
219663739|NCT06625983|OTHER|CRC decision tool|CRC decision tool included in the primary care bundle questionnaire
219663740|NCT07014046|OTHER|Simple bed exercises|The participants will be asked to perform exercise by lying flat on bed in supine position with their eyes look towards to the ceiling of the ward and start focusing on deep breathing exercises with slow inhalations and exhalations. These exercises aim to achieve regular pattern of abdominal muscles and improve the coordination between breathing, abdominal muscle contractions and colonic propulsions. After one-minute deep-breathing exercises, intervention group participants will be asked to pull both knees towards chest in return and turning body from one side to another while lying on bed.
219663741|NCT07014631|DRUG|SSS17|The SSS17 treatment arm comprises three dose levels: the first two dose levels will have an 8-week treatment duration, while the third dose level will extend to 24 weeks. At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.
219663742|NCT07014631|DRUG|Placebo|At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.Placebo recipients will undergo weekly dosing identical to the active treatment group within their assigned dose cohort.
219686535|NCT03430856|DRUG|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
219686536|NCT03430856|DRUG|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
219686537|NCT00962078|OTHER|continuous endurance training|at 60 percent of peak Watt
219686538|NCT00962078|OTHER|interval training|at 100 percent of peak Watt
219663743|NCT05537610|BEHAVIORAL|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
219663744|NCT05537610|BEHAVIORAL|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
219065290|NCT04046874|OTHER|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
219065291|NCT00775749|DRUG|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
219065292|NCT00775749|DRUG|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
219065293|NCT03939468|DEVICE|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
219065294|NCT01562574|DRUG|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
219065295|NCT01562574|DRUG|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
219065296|NCT03332862|PROCEDURE|catheter ablation|catheter ablation for atrial fibrillation treatment
219065297|NCT04045392|BEHAVIORAL|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
219065298|NCT00346060|DEVICE|Retinal transplantation instrument|
219065299|NCT00346060|DEVICE|Fetal tissue.|
219065300|NCT03456908|COMBINATION_PRODUCT|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
219065301|NCT04464304|DEVICE|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
219065302|NCT04464304|DEVICE|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
219065303|NCT00153738|DRUG|phytosterol|
219065304|NCT01049425|DRUG|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
219065305|NCT01049425|DRUG|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
219065306|NCT01049425|DRUG|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
219065307|NCT01049425|DRUG|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
219663745|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
219663746|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
219065308|NCT01049425|DRUG|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
219065309|NCT06530017|DEVICE|Ingested, Space Occupying hydrogel capsules|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
219065310|NCT06530017|DEVICE|placebo|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
219065311|NCT05834504|OTHER|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
219065312|NCT00834457|DRUG|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
219065313|NCT00834457|DRUG|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
219065314|NCT01952535|DRUG|HMS5552|
219065315|NCT01952535|DRUG|Placebo|
219065316|NCT01269892|DIETARY_SUPPLEMENT|lactose-free milk|a milk without lactose
219065317|NCT01269892|DIETARY_SUPPLEMENT|conventional milk|a milk with lactose
219065318|NCT03867877|OTHER|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
219208409|NCT06751459|DEVICE|MEMO Patch 2 - 1-day Monitoring|A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.
219208410|NCT06751459|DEVICE|MEMO Link|A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
219208411|NCT06892301|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
219360297|NCT00510809|DRUG|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
219663747|NCT02909829|DEVICE|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
219663748|NCT02909829|DEVICE|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
219663749|NCT02909829|DEVICE|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
219663750|NCT06207240|DEVICE|NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve|Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
219663751|NCT06618521|DRUG|Anti-hypertensive drug (Methyldopa 250 mg)|Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.
219663752|NCT06618521|OTHER|Pilates exercise|Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.
219663753|NCT06618521|OTHER|Circuit exercise training|Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.
219663754|NCT05125913|DIAGNOSTIC_TEST|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
219663755|NCT05125913|DIAGNOSTIC_TEST|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
219663756|NCT05125913|DIAGNOSTIC_TEST|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
219663757|NCT05125913|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
219663758|NCT05125913|DIAGNOSTIC_TEST|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
219686539|NCT01949142|DRUG|OTO-201|Single, intratympanic injection
219686540|NCT01949142|DRUG|Sham|Simulated single, intratympanic injection
219686541|NCT02086955|BEHAVIORAL|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
219686542|NCT01900847|DRUG|Ketamine|0.3mg/kg ketamine
219686543|NCT01900847|DRUG|Morphine|Dosage of morphine determined by treating physician
218972049|NCT00737438|DRUG|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
219663759|NCT05125913|DIAGNOSTIC_TEST|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
219663760|NCT05125913|OTHER|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
219065319|NCT03867877|OTHER|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
219663761|NCT03564795|DEVICE|KeraStat Gel|Wound dressing for partial thickness burns
219663762|NCT03564795|DEVICE|Silver Sulfadiazine|Wound dressing for partial thickness burns
219663763|NCT02647489|BIOLOGICAL|PAMVAC|
219663764|NCT02647489|BIOLOGICAL|Alhydrogel|
219663765|NCT02647489|BIOLOGICAL|GLA-SE|
219663766|NCT02647489|BIOLOGICAL|GLA-LSQ|
219663767|NCT02647489|OTHER|Placebo|
219663768|NCT04877158|BEHAVIORAL|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
219663769|NCT04984759|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
219065320|NCT06371885|DEVICE|shock wave therapy|shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
219663770|NCT04984759|DRUG|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
219663771|NCT06875882|BEHAVIORAL|Occupational Stress in Surgeons and Musicians|Participants will complete 5 questionnaires about participants demographics, burnout rates, and anxiety levels after participants consent to this study. These questionnaires will be sent to participants via email and should take about 15-20 minutes to complete.
219663772|NCT07019857|DIAGNOSTIC_TEST|Blood sample collection at surgery time and 12 months later|"each participant undergoes a blood test 1) at surgery time and 2) 12 months after surgery. These 5mL samples include:~* Blood cell count~* TREC dosage~* Complete Lymphocytes immunophenotyping~* Immunoglobulin dosage"
219663773|NCT00770133|DRUG|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
219663774|NCT00770133|DRUG|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
219663775|NCT00770133|DRUG|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
219663776|NCT00770133|DRUG|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
219663777|NCT02580474|DRUG|Daclatasvir plus Asunaprevir|
219663778|NCT06113341|DRUG|IDegLira|Pre-filled pen injection.
219663779|NCT02906033|OTHER|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
219065321|NCT06371885|OTHER|traditional physical therapy|the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
219065322|NCT05732168|DIAGNOSTIC_TEST|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
219065323|NCT02443181|DEVICE|Activa PC+S|Implementation of closed loop DBS for essential tremor
219065324|NCT03236103|OTHER|Clinical Recommendations|"The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
219065325|NCT05209282|OTHER|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
219065326|NCT05209282|OTHER|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
219065327|NCT05209282|OTHER|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
219663780|NCT04650126|BIOLOGICAL|ATM001|monovalent anti-TNF-receptor 1 antibody format
219663781|NCT04650126|BIOLOGICAL|ATM001 Placebo|ATM001 Placebo
219663782|NCT00006341|OTHER|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
219663783|NCT06006273|DRUG|Eribulin|Given by vein (IV)
219663784|NCT06006273|DRUG|Irinotecan|Given by vein (IV)
219663785|NCT06006273|DRUG|Temozolomide|Given by PO
218972050|NCT01460316|BIOLOGICAL|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
218972051|NCT03767101|BEHAVIORAL|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
218972052|NCT04594148|BEHAVIORAL|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
218972053|NCT05391451|PROCEDURE|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
219065328|NCT05201157|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
219065329|NCT05201157|OTHER|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
219663786|NCT04402281|DIAGNOSTIC_TEST|suPAR algoritm|All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR \> 6 ng/mL) the Intervention will be carried out
219065330|NCT02078284|BIOLOGICAL|CPP|One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
219065331|NCT02078284|BIOLOGICAL|LSP|
219065332|NCT05409443|PROCEDURE|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"* Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~* The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
219065333|NCT05409443|PROCEDURE|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"* To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~* A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~* The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
219065334|NCT02565641|DRUG|Capecitabine|Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
219065335|NCT02565641|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
219065336|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
219065337|NCT01260246|DRUG|placebo|placebo match for 6 months
219065338|NCT00096135|BIOLOGICAL|filgrastim|given subcutaneously (SC)
219065339|NCT00096135|DRUG|cyclophosphamide|IV over 15-30 minutes
219065340|NCT00096135|DRUG|cytarabine|IV over 3 hours twice daily
219065341|NCT00096135|DRUG|daunorubicin hydrochloride|IV over 15 minutes
219065342|NCT00096135|DRUG|dexamethasone|oral twice daily
219065343|NCT00096135|DRUG|etoposide|IV over 1 hour
219663787|NCT07027189|DIAGNOSTIC_TEST|Artificial intelligence in diagnosis|AI-based diagnostic programs have proved to enhance diagnostic performance, however research on its effects on treatment decisions is scarce. In contrast to other studies focusing on AI's accuracy or the resulting increase in dentists' accuracy, this study aims to investigate the differences in dentists' treatment recommendations when supported by AI versus when they are not during caries detection.
219663788|NCT07027774|DRUG|Henagliflozin 5 mg Group|Henagliflozin 5 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
219663789|NCT07027774|DRUG|Henagliflozin 10 mg Group|Henagliflozin 10 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
219065344|NCT00096135|DRUG|leucovorin calcium|rescue IV over 24 hours
219065345|NCT00096135|DRUG|mercaptopurine|oral
219663790|NCT07027774|DRUG|Conventional therapy group|KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
219686544|NCT01900847|DRUG|placebo|saline of same volume as appropriate weight based dose of ketamine
219686545|NCT02002871|DEVICE|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
219663791|NCT07026851|BIOLOGICAL|Blood and bone marrow sampling|"This intervention involves the collection of peripheral blood before and 3 days after coronary artery bypass grafting (CABG), as well as a one-time collection of bone marrow sample during sternotomy.~Samples are analyzed using spectral flow cytometry to characterize the phenotype and maturation stages of circulating and medullary megakaryocytes using a panel of specific surface antibodies."
219663792|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
219663793|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
219663794|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
219663795|NCT05056792|OTHER|Isometric strength training for 8 week|Plyometric training for 8 week
219663796|NCT05056792|OTHER|Conventional training|Conventional training for 8 week
219663797|NCT04441476|OTHER|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~* The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~* At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
219663798|NCT04441476|OTHER|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
219663799|NCT01863498|OTHER|Epidural|Patients will have an epidural for pain control
219663800|NCT01863498|OTHER|PCA|Patients will have PCA for pain control
219663801|NCT03948035|DRUG|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
219663802|NCT03948035|DRUG|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
219663803|NCT03948035|DRUG|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
219663804|NCT03948035|DRUG|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
218972054|NCT05391451|PROCEDURE|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
218972055|NCT05914922|OTHER|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
218972056|NCT00734123|DRUG|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
218972057|NCT00734123|DRUG|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
218972058|NCT00734123|DRUG|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
218972059|NCT00734123|DRUG|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
218972060|NCT03751644|OTHER|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
218972061|NCT02027038|DEVICE|Pelvic belt application|
219065346|NCT00096135|DRUG|methotrexate|intramuscularly (IM)
219065347|NCT00096135|DRUG|pegaspargase|intramuscularly (IM)
219065348|NCT00096135|DRUG|therapeutic hydrocortisone|
219065349|NCT00096135|DRUG|vincristine sulfate|given IV
219065350|NCT00096135|RADIATION|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
219065351|NCT00107419|DRUG|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
219065352|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
219065353|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
219065354|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
219663805|NCT03948035|OTHER|autologous stem cell transplant|autologous stem cell transplant
219663806|NCT00643461|DEVICE|Adhesive A|Applied per manufacturer's instructions.
219663807|NCT00643461|DEVICE|Adhesive B|Applied per manufacturer's instructions.
219663808|NCT00643461|DEVICE|Adhesive C|Applied per manufacturer's instructions.
219686546|NCT04437836|DRUG|Evaluation of high dose rifampicin in children|Evaluation of severity of adverse event from grade 1 to 5
218972062|NCT06438939|OTHER|Biopsy for diagnostical purposes|Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
219663809|NCT05210153|DRUG|Sertraline|"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."
219663810|NCT05400395|DRUG|GNX80|GNX80 oral intake(BID) for 24 weeks
219663811|NCT05400395|DRUG|Placebo|Placebo oral intake(BID) for 24 weeks
219663812|NCT05964114|DRUG|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
219663813|NCT05493813|BEHAVIORAL|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
219663814|NCT05493813|BEHAVIORAL|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
219663815|NCT02494375|OTHER|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
219663816|NCT03646305|BEHAVIORAL|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
219663817|NCT06293105|OTHER|Qualitative interview, participant observation|Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
219663818|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
218972063|NCT00277446|DRUG|Soy isoflavones|
218972064|NCT01572259|DRUG|Growth Hormone|
218972065|NCT01572259|OTHER|interruption of the traitment with growth hormone|
218972066|NCT00661973|DRUG|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
219663819|NCT04624776|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
219065355|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
219663820|NCT04624776|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
218972067|NCT00917111|DRUG|Nasal CO2|Four times a day for 14 days
218972068|NCT00917111|DRUG|Inactive Placebo Gas|Placebo
218972069|NCT03861650|OTHER|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
218972070|NCT03861650|OTHER|Saline|Physiological saline is added in control group to act as placebo
218972071|NCT05668975|DEVICE|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
218972072|NCT04986644|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
219065356|NCT00004181|DRUG|busulfan|
219065357|NCT00004181|DRUG|cyclophosphamide|
219065358|NCT00004181|PROCEDURE|allogeneic bone marrow transplantation|
219065359|NCT00004181|RADIATION|radiation therapy|
219065360|NCT01829412|OTHER|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
218972073|NCT00431678|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
218972074|NCT00431678|DRUG|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
218972075|NCT05357638|BEHAVIORAL|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
218972076|NCT05357638|BEHAVIORAL|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
218972077|NCT05357638|BEHAVIORAL|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
218972078|NCT01982565|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
218972079|NCT01982565|OTHER|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
219065361|NCT04968938|DRUG|midomafetamine|80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
219065362|NCT04968938|BEHAVIORAL|Therapy|Manualized therapy
219663821|NCT02795520|DRUG|OTS167IV|
219663822|NCT03168919|RADIATION|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
219663823|NCT03168919|DRUG|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
219686547|NCT00565604|DEVICE|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
219663824|NCT03168919|DEVICE|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
219663825|NCT04605393|DRUG|Cannabidiol|CBD
219663826|NCT04605393|DRUG|Placebo|Placebo
219663827|NCT04605393|DRUG|Delta-9-THC|THC
219663828|NCT00083720|BIOLOGICAL|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
219663829|NCT00379431|DRUG|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
219663830|NCT03650725|OTHER|Mandatory Split bowel preparation|Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
219663831|NCT03330067|DEVICE|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
219663832|NCT03330067|DEVICE|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
219663833|NCT00386425|DRUG|Drotrecogin alfa (activated)|intravenous
219663834|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
219663835|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
219663836|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
219663837|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
219663838|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
219663839|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
219663840|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
218972080|NCT00011557|DEVICE|Assistance in Voiding|
218972081|NCT02791594|DRUG|Pembrolizumab|Patients were treated with pembrolizumab according to standard of care.
218972082|NCT04855864|OTHER|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
218972083|NCT04855864|OTHER|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
218972084|NCT04855864|OTHER|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
218972085|NCT03036605|DRUG|Bupivacaine|%0.5 bupivacaine
218972086|NCT03036605|DRUG|Dexamethasone|8 mg Dexamethasone
218972087|NCT01298973|DRUG|Viscoat|One group will receive Viscoat for incision closure
218972088|NCT01298973|DRUG|Saline|One group will receive Saline to irrigate the wound
218972089|NCT01327456|BEHAVIORAL|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
218972090|NCT00117195|DEVICE|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
218972091|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
218972092|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
218972093|NCT04926077|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
219663841|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
218972094|NCT05736783|OTHER|plyometric exercises|"1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
219663842|NCT06223321|DIAGNOSTIC_TEST|Computed Tomography in congenital heart diseases|"● CT examination will be done by~* 160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~* We used the following parameters during cardiac CT scanning:~  * Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~ * The radiation dose set to 80-100 kvp.~ * Tube current from 10 to 40 mA/kg.~ * The gantry rotation speed at 0.35-.4 sec.~ * ECG gated Retrospective With MA modulation.~ * Wide FOV.~* A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~* Scanning begins when contrast filled the LV by bolus tracking.~* All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
219663843|NCT00657306|DRUG|hydrocortisone|50 mg/6 h per day
219663844|NCT00657306|DRUG|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
219663845|NCT05497336|DRUG|IBI351|IBI351 is administered orally
219663846|NCT05497336|DRUG|Cetuximab|Cetuximab is administered intravenously
219663847|NCT03305900|OTHER|No Intervention|Cross-sectional study requiring a single serum sample
219663848|NCT03838406|GENETIC|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
219663849|NCT03838406|DRUG|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
218972095|NCT05736783|OTHER|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
218972096|NCT01038193|OTHER|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
219663850|NCT04412837|DRUG|Topical CBD Patch|35 mg CBD patch
219663851|NCT04412837|OTHER|Placebo Patch|Identical patch without active ingredient.
219663852|NCT02678000|DRUG|LHW090|LHW090 is orally administered
219663853|NCT02678000|DRUG|Placebo|Matching placebo of LHW090
219663854|NCT06245447|OTHER|Retrospective evaluation of specific brain MRI features|"* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
219663855|NCT01582659|OTHER|Telephone counseling|2 planned telephone counseling sessions are conducted.
219663856|NCT01582659|OTHER|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
219663857|NCT00441532|DRUG|Lidocaine|
219663858|NCT04220333|BEHAVIORAL|Mandalas of Emotions|Application of mandalas during 15 minutes
219663859|NCT04220333|BEHAVIORAL|Control|"Participants were requested to lie down, relax and pay attention to your breath."
219663860|NCT03897933|PROCEDURE|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219663861|NCT03897933|PROCEDURE|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219663862|NCT00857597|PROCEDURE|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
219663863|NCT00857597|DRUG|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
219663864|NCT01465633|DRUG|levothyroxine|
219663865|NCT01465633|DRUG|levothyroxine|
219663866|NCT02268747|DRUG|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction."
219663867|NCT02535351|DRUG|sunitinib or pazopanib|First-line treatment
219663868|NCT02535351|PROCEDURE|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
219663869|NCT01498705|OTHER|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
219663870|NCT06440733|OTHER|Multicomponent exercise program focused in elderly.|"Each of these sessions will be carried out taking into account the main physiotherapy objectives, such as gaining strength in both upper and lower limbs, as well as proprioception, balance, and promoting a pleasant and safe social environment where these older people feel valid.~All sessions will begin with a 5-minutes. It will begin with a general warm-up based on general joint mobility of the head and neck, shoulders, trunk, elbows, hands, wrists, hips, knees and ankles to begin to accustom the body to the physical work environment. And at the end of the sessions, a stretching program will be carried out, and it will end with a return to calm with a respiratory training program, in which you will be instructed to take in air through the nose and release it through the mouth, while the room is silent, and thus promote self-awareness."
219663871|NCT04447677|OTHER||
219663872|NCT04303754|OTHER|Diabetes-Specific Formula|Other: Diabetes Specific Formula
219663873|NCT04303754|OTHER|Bread with Spread|Other: White Bread with Spread
219663874|NCT04303754|OTHER|Rice Porridge|Other: Rice Porridge
219663875|NCT04038177|BEHAVIORAL|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
219663876|NCT04038177|BEHAVIORAL|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
219663877|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
219663878|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
219663879|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
219663880|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
219663881|NCT03984227|GENETIC|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
219663882|NCT03053427|DRUG|Placebo|Oral administration
219663883|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
219663884|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
219663885|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
219663886|NCT02334176|DRUG|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
219663887|NCT00407927|DRUG|Epinastine Nasal Spray|
219663888|NCT02604173|DRUG|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
219663889|NCT02604173|DRUG|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
219663890|NCT02604173|DRUG|Placebo|Placebo pill and sham inhaler
219663891|NCT01803776|BEHAVIORAL|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
219663892|NCT05530980|BEHAVIORAL|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
219663893|NCT00759057|DEVICE|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
218972097|NCT06146881|DRUG|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
218972098|NCT06146881|DRUG|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
218972099|NCT02234986|DRUG|ENMD-2076|250 mg oral dose, once daily (QD) for 28 day cycles
218972100|NCT04872218|DRUG|Abatacept|24 week treatment of IV abatacept following recommended dosages from the monograph
218972101|NCT04872218|DRUG|Placebo|24 week treatment of IV placebo following recommended dosages from the abatacept monograph
219065363|NCT04725721|BEHAVIORAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
219065364|NCT04725721|BEHAVIORAL|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
219663894|NCT04407429|DIAGNOSTIC_TEST|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
219663895|NCT02764567|OTHER|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
219663896|NCT04205344|DRUG|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
218972102|NCT04872218|OTHER|Peanut oral immunotherapy|Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
218972103|NCT04007198|DRUG|EQ001|Itolizumab \[Bmab 600\]
218972104|NCT04007198|DRUG|EQ001 Placebo|EQ001 Placebo
218972105|NCT05712369|OTHER|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
218972106|NCT04950166|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
218972107|NCT05745532|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
218972108|NCT06197347|BEHAVIORAL|Web-based nursing intervention : Ch@ngeons Ensemble|"The web-based nursing intervention, named Ch@ngeons Ensemble, was designed to increase physical activity and quality of life among older adults living with CHD. The intervention will be multicomponent, including educational content, videos, forums, goal planning, an electronic physical activity journal, and virtual written interactions with a nurse. An initial in-person meeting with the nurse will be provided to foster the older adult's commitment to the intervention and help build a relationship of trust. Throughout the intervention, the nurse will asynchronously provide counseling, feedback, and encouragement, and attempt to promote quality of life, knowledge, motivation, and self-efficacy among the older adults."
218972109|NCT04234386|RADIATION|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
219663897|NCT04205344|DRUG|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
219065365|NCT06059196|BEHAVIORAL|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
219065366|NCT06059196|BEHAVIORAL|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
219065367|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
219065368|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
219065369|NCT03473886|BEHAVIORAL|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
219065370|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
219663898|NCT06061172|OTHER|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
219663899|NCT00365001|DRUG|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
219663900|NCT00365001|DRUG|Methotrexate|10-25mg po/week
219663901|NCT00365001|DRUG|Simvastatin|40mg po on days 1, 15 and 43
219663902|NCT02172040|DRUG|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
219663903|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
219663904|NCT02172040|DRUG|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
219663905|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
219663906|NCT03112668|BEHAVIORAL|Cognitive Behavior Therapy|Undergo ACT
219663907|NCT03112668|OTHER|Quality-of-Life Assessment|Ancillary studies
218972110|NCT06414096|DRUG|Follicle Stimulating Hormone|Pulsatile FSH administration via a portable pump.
218972111|NCT02129829|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
218972112|NCT03660488|DRUG|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
218972113|NCT03660488|DRUG|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
218972114|NCT01580358|DRUG|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
218972115|NCT01580358|DRUG|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
218972116|NCT00187031|DRUG|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
218972117|NCT06202456|DRUG|Huazhi Rougan granule|Huazhi Rougan granule
219663908|NCT03112668|OTHER|Questionnaire Administration|Ancillary studies
219663909|NCT03112668|OTHER|Survey Administration|Ancillary studies
219663910|NCT03816644|OTHER|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
218972118|NCT05835531|DEVICE|Catheters comparation|Assessment of incidence of complications associated with midline catheters
218972119|NCT02998216|PROCEDURE|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
219663911|NCT03816644|OTHER|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
219663912|NCT04733716|PROCEDURE|Using Tourniquet|The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
219663913|NCT03903003|DEVICE|high flow nasal oxygen device (POİNT)|With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
219065371|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
219065372|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
219065373|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
219065374|NCT03524222|OTHER|Home Hospitalization|See above
219065375|NCT02124642|DIETARY_SUPPLEMENT|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
219065376|NCT02124642|DIETARY_SUPPLEMENT|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
219065377|NCT02961972|DIETARY_SUPPLEMENT|monohydrate and micronized creatine|oral supplementation with creatine
219065378|NCT02961972|OTHER|placebo|oral supplementation with maltodextrin (control group)
219065379|NCT01568047|DRUG|Placebo|once-daily
219663914|NCT03903003|DEVICE|Face mask|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
218972120|NCT05691907|DEVICE|THE therapy|"THE therapy consisting of:~* Heating Pad~* Interferential Therapy"
218972121|NCT05691907|PROCEDURE|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
218972122|NCT05691907|PROCEDURE|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
218972123|NCT05116007|DRUG|AK112|IV infusion
218972124|NCT05116007|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219065380|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
219065381|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
219065382|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
219065383|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
219065384|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
219065385|NCT00561223|DRUG|iloprost Inhalation|inhale 2.5 mg, repeat times one
219663915|NCT03248414|DIETARY_SUPPLEMENT|Lactobacillus sakei|1 pack contained 5 x 109 cfu
219663916|NCT05215379|DRUG|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
219663917|NCT05215379|OTHER|Control|neoadjuvant chemoradiation therapy
219663918|NCT01801241|DEVICE|Anatomic TSA using IRI Instrumentation|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
218972125|NCT05116007|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
218972126|NCT04149873|PROCEDURE|MIE|MIE
218972127|NCT04890431|DRUG|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
218972128|NCT04890431|DRUG|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
218972129|NCT03995836|DEVICE|CPAP|Decision of CPAP treatment is according to clinical guidelines
218972130|NCT03995836|PROCEDURE|Bariatric Surgery|All patients.
218972131|NCT02386969|DEVICE|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
218972132|NCT02386969|DEVICE|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
218972133|NCT00725504|DRUG|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
218972134|NCT06061731|DRUG|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
219065386|NCT00561223|DRUG|iloprost|inhaled 2.5 mg, repeat times one
219065387|NCT01663493|PROCEDURE|FNB|
219065388|NCT01384617|PROCEDURE|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
219065389|NCT01384617|PROCEDURE|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
219663919|NCT01801241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
219663920|NCT06287710|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output)."
219663921|NCT00001502|DRUG|RMP-7 and carboplatin|
219663922|NCT00756600|DRUG|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
219663923|NCT00756600|DRUG|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
218972135|NCT05685654|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
218972136|NCT06202690|PROCEDURE|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
218972137|NCT06202690|PROCEDURE|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
218972138|NCT02001181|DRUG|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
218972139|NCT02001181|DRUG|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
218972140|NCT01842815|DEVICE|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
218972141|NCT00292318|BEHAVIORAL|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
218972142|NCT00292318|BEHAVIORAL|control group|Medical counseling and ano-sphinctal exercises.
218972143|NCT04017247|DRUG|Oxytocin|Intermittent oxytocin Infusion
218972144|NCT04017247|DRUG|Oxytocin|Continous oxytocin Infusion for 16 hours
218972145|NCT04560790|DRUG|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
219065390|NCT03874676|OTHER|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
218972146|NCT00013468|PROCEDURE|Tinnitus|
218972147|NCT04148820|DRUG|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
218972148|NCT03442283|DIETARY_SUPPLEMENT|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
218972149|NCT04539145|DEVICE|Chocolate PTA Balloon|Chocolate PTA Balloon
218972150|NCT04539145|DEVICE|conventional balloon angioplasty|conventional bal-loon angioplasty
218972151|NCT03540043|DRUG|Administration of Placebo|Botanical Drug Phase 2 clinical study
218972152|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
218972153|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
218972154|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
218972155|NCT02815774|DRUG|SP2086|all subjects were given SP2086 50mg only one time.
218972156|NCT05449522|DIETARY_SUPPLEMENT|Vitamin D|High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
218972157|NCT05449522|DIETARY_SUPPLEMENT|Placebo|Medium-chain triglyceride (MCT)
218972158|NCT04169100|DRUG|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
218972159|NCT02186366|OTHER|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
218972160|NCT02186366|DRUG|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
218972161|NCT03606395|DRUG|NV-5138|single ascending dose
218972162|NCT03606395|DRUG|Placebos|Placebo liquid solution to mimic NV-5138
218972163|NCT03280095|DRUG|co-codamol 15mg/500mg capsule|
218972164|NCT03280095|DRUG|co-codamol 30mg/500mg tablet|
219065391|NCT03640910|DEVICE|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
219663924|NCT02607306|DRUG|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
219663925|NCT02607306|DRUG|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
219663926|NCT02607306|DRUG|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
219663927|NCT01324570|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
219065392|NCT03640910|DEVICE|Locator® (Zest)|Attachment systems to retain an implant overdenture
219663928|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
219663929|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
219663930|NCT02061449|DRUG|Romidepsin|
219065393|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
219663931|NCT02061449|DRUG|Poly ICLC|
219663932|NCT02061449|RADIATION|Focal lesional radiation|
219663933|NCT00792506|DRUG|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
219663934|NCT00142259|DEVICE|Deep brain stimulation of the internal globus pallidus|
219663935|NCT03026933|DRUG|KI1107 4 Capsules, QD|KI1107 4 Capsules
219663936|NCT03026933|DRUG|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
219663937|NCT06336278|DIAGNOSTIC_TEST|Pressure Algometer|Pressure algometer is used to detect pain pressure treshold.
219663938|NCT06622954|OTHER|Protein- and Calorie restriction|The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
219663939|NCT02811497|DRUG|Azacitidine|
219663940|NCT02811497|DRUG|Durvalumab|
219663941|NCT00756197|DEVICE|Cryo Spray Ablation Group 1|Cryo Spray Ablation
219663942|NCT00756197|DEVICE|Cryo Spray Ablation Group 2|cryo spray ablation
219663943|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
219663944|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
219663945|NCT03909854|PROCEDURE|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
219663946|NCT06088251|BEHAVIORAL|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
219663947|NCT06088251|BEHAVIORAL|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
218972165|NCT03979430|OTHER|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
219065394|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
219065395|NCT00874029|DEVICE|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
219065396|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
219065397|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
219065398|NCT04937374|OTHER|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
219065399|NCT04937374|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
219663948|NCT03407547|DIAGNOSTIC_TEST|Electroencephalography|EEG is a device to measure brain activity via surface electrodes
219663949|NCT02528890|OTHER|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
219663950|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219663951|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219663952|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219663953|NCT02360475|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
219663954|NCT01918150|DEVICE|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
219065400|NCT00856583|DRUG|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
219065401|NCT00856583|DRUG|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
219065402|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
219663955|NCT01918150|DEVICE|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
219663956|NCT03101722|DRUG|BTHE and Huperzine A|huperzine A intervention
219663957|NCT03101722|OTHER|BETH|basic treatment and health education
218972166|NCT05589272|OTHER|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
218972167|NCT05589272|OTHER|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
219065403|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
218972168|NCT04568993|PROCEDURE|Proximal phalangeal level|Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
218972169|NCT04568993|DRUG|Volar to the MCP-joint|Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
219065404|NCT06312839|OTHER|Collecting data from the medical record|"Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay"
219065405|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
219065406|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
219065407|NCT01084044|DRUG|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
219065408|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
219065409|NCT03020420|OTHER|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
219663958|NCT06035861|DRUG|XBD173|Participants will be treated with XBD173 90mg twice daily for 6 weeks
219663959|NCT03204487|DRUG|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
219663960|NCT00038623|DRUG|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
219663961|NCT00038623|DRUG|Rituximab|250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
219663962|NCT02484300|DIETARY_SUPPLEMENT|Melatonin|
219663963|NCT02484300|OTHER|Placebo|
219663964|NCT00316862|DRUG|cisplatin|Given IV
219663965|NCT00316862|DRUG|irinotecan hydrochloride|Given IV
219663966|NCT00316862|PROCEDURE|therapeutic conventional surgery|Undergo Surgery
219663967|NCT00316862|RADIATION|radiation therapy|Undergo radiation
219663968|NCT03017027|BEHAVIORAL|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
219663969|NCT03017027|BEHAVIORAL|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
219663970|NCT00207727|DRUG|CNTO 1275|
219663971|NCT00180427|DEVICE|ICD|
219663972|NCT03759366|DRUG|Eculizumab|Eculizumab will be administered by IV infusion.
219663973|NCT02381769|DIETARY_SUPPLEMENT|Soybean based lipid emulsion|
219663974|NCT00930631|DRUG|[3H] BMS747158|Single bolus intravenous injection of \[3H\] BMS747158
219663975|NCT00174226|DRUG|Atomoxetine|
219663976|NCT00174226|DRUG|Buspirone|
219663977|NCT04554992|BIOLOGICAL|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
219663978|NCT04268940|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time \[PT\], anti-Xa, activated clotting time\[ACT\], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
218972170|NCT01498328|DRUG|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
218972171|NCT01498328|DRUG|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
218972172|NCT01498328|DRUG|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
218972173|NCT01863238|OTHER|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
218972174|NCT01863238|DRUG|Ivacaftor Exposed|
219663979|NCT04279782|OTHER|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
219663980|NCT05616429|DIETARY_SUPPLEMENT|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
219663981|NCT05616429|DIETARY_SUPPLEMENT|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
218972175|NCT04595604|PROCEDURE|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
218972176|NCT04595604|PROCEDURE|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
218972177|NCT05603663|GENETIC|Informing study subjects about their high CVD polygenic risk score|During a visit, the family physician will announce the value of the subject's polygenic risk for CVD (either at the start or end of the trial, depending on the group) and discuss what it means, calculate the subject's overall risk for CVD using the Kardiokompass tool, advise the subject on weight loss and physical activity, and, if necessary, commence preventive treatment. Between visits, a mobile application will be utilized to collect data about the subjects' level of physical activity and body weight as well as to send reminders to the subjects every two weeks regarding exercise and healthy lifestyle choices.
219663982|NCT05616429|OTHER|usual care|usual care
218972178|NCT02134197|DRUG|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
218972179|NCT01880216|DRUG|Bemiparin sodium|subcutaneous application daily for 7±2 days
218972180|NCT01880216|DRUG|Enoxaparin sodium|subcutaneous for 7±2 days
219065410|NCT03958903|DEVICE|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
219065411|NCT03958903|BEHAVIORAL|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
219663983|NCT00622804|PROCEDURE|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
219663984|NCT00622804|PROCEDURE|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
219663985|NCT00622804|PROCEDURE|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
219663986|NCT04861116|BEHAVIORAL|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
218972181|NCT00406718|BEHAVIORAL|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
218972182|NCT00406718|BEHAVIORAL|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
218972183|NCT00406718|BEHAVIORAL|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
218972184|NCT06322979|PROCEDURE|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
218972185|NCT06322979|PROCEDURE|Premixed Bioceramic Putty|Apexification treatment was done with Premixed Bioceramic Putty (Well-Root™ PT)
218972186|NCT02765685|DEVICE|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
218972187|NCT02765685|OTHER|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
218972188|NCT05530031|PROCEDURE|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
218972189|NCT05965726|DRUG|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
219065412|NCT00283504|DRUG|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
219663987|NCT02983916|PROCEDURE|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
219663988|NCT00071968|DRUG|temsirolimus|
219663989|NCT00071968|PROCEDURE|conventional surgery|
219663990|NCT00071968|PROCEDURE|neoadjuvant therapy|
219663991|NCT04226495|DRUG|Sufentanil Infusion|Intra-operative sufentanil infusion
219663992|NCT04226495|DRUG|Sufentanil Bolus|Intra-operative sufentanil bolus
219663993|NCT05362695|DRUG|IW-3300|A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
219663994|NCT05362695|DRUG|Placebo|A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
219663995|NCT01466517|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
219663996|NCT01466517|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
219663997|NCT02596217|DRUG|ABBV-066|SC injection
219663998|NCT02596217|DRUG|ABBV-066|IV infusion
219663999|NCT02596217|DRUG|Placebo|SC injection (stage 1)
219664000|NCT02596217|DRUG|Placebo|IV infusion (stage 2)
218972190|NCT05965726|DRUG|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
219065413|NCT05222230|OTHER|FFP3 Mask|Participans will wear FFP3 respirators during the study.
219065414|NCT03520634|OTHER|PD-L1 PET imaging|PD-L1 PET imaging
219065415|NCT04357028|DRUG|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
219065416|NCT04357028|DRUG|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
219065417|NCT00133289|DEVICE|Pacemaker with Automatic Capture|
219664001|NCT06302088|OTHER|SAINTS program|A brief descriptive name used to refer to the intervention(s) studied in each arm of the clinical study. A non-proprietary name of the intervention must be used, if available. If a non-proprietary name is not available, a brief descriptive name or identifier must be used.
218972191|NCT05965726|DRUG|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
218972192|NCT05433584|DRUG|Tirzepatide|Administered SC
218972193|NCT05433584|DRUG|Antihyperglycemic medication|As prescribed
218972194|NCT04187677|PROCEDURE|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
218972195|NCT04187677|OTHER|classical hand therapy|classical hand therapy
218972196|NCT01389271|DRUG|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
218972197|NCT02176343|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
218972198|NCT03007901|BEHAVIORAL|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
218972199|NCT04061473|DRUG|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
218972200|NCT04061473|DRUG|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
218972201|NCT04061473|OTHER|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
219065418|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
219065419|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
219065420|NCT01944046|DRUG|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
219664002|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219664003|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219664004|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
219664005|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
219664006|NCT06910462|BEHAVIORAL|Integrated pest management (IPM) practices|Provide IPM resources to family child care home directors along with information about their exposure to pesticides and use of pesticides to lower their health risks.
219686548|NCT03904810|BEHAVIORAL|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); \[i.e., (maximal HR - resting HR) × intensity + resting HR\]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
218972202|NCT06134271|DRUG|Rezvilutamide|Rezvilutamide 240mg qd
218972203|NCT06134271|DRUG|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
218972204|NCT06134271|DRUG|Continue previous treatment|Continue using the previous treatment regimen for treatment.
218972205|NCT02898116|DRUG|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
218972206|NCT02898116|DRUG|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
218972207|NCT02780609|DRUG|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
218972208|NCT02780609|DRUG|Melphalan|Melphalan 100 mg/m\^2 IV over 30-45 minutes.
218972209|NCT02780609|DRUG|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
218972210|NCT02780609|PROCEDURE|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
218972211|NCT02780609|DRUG|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
218972212|NCT02312271|OTHER|enteral formula|standard tube feeding formulas
218972213|NCT03636737|OTHER|pathology associated|list of pathology associated to Pyoderma gangrenosum
218972214|NCT05120661|OTHER|food product|a food product containing 50 gram carbohydrates
218972215|NCT04179851|DIAGNOSTIC_TEST|Thermal imaging of neck veins|Thermal imaging of neck veins
218972216|NCT03381105|DIAGNOSTIC_TEST|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
218972217|NCT04755283|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
218972218|NCT04755283|DRUG|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
218972219|NCT04352231|DIETARY_SUPPLEMENT|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
218972220|NCT04352231|DIETARY_SUPPLEMENT|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
218972221|NCT04457219|DEVICE|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
218972222|NCT04457219|DEVICE|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
218972223|NCT04457219|DEVICE|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
218972224|NCT04457219|DEVICE|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
218972225|NCT02123043|BEHAVIORAL|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
218972226|NCT02123043|BEHAVIORAL|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
218972227|NCT01571297|DRUG|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
218972228|NCT01571297|DRUG|Placebo|Placebo given subcutaneously for 35 days
218972229|NCT02370446|OTHER|personalized medication log|
218972230|NCT02370446|OTHER|standard of care|
218972231|NCT02370446|BEHAVIORAL|questionnaires|
218972232|NCT02370446|BEHAVIORAL|Cognitive Interview|
218972233|NCT00415571|DRUG|Fispemifene (once daily for 8 weeks)|
218972234|NCT05629013|BEHAVIORAL|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
218972235|NCT04150029|DRUG|MBG453|Solution for intravenous infusion
218972236|NCT04150029|DRUG|Venetoclax|Tablet for oral administration
218972237|NCT04150029|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
218972238|NCT05353647|BIOLOGICAL|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
218972239|NCT06517784|OTHER|No treatment given|No treatment given
218972240|NCT03422601|DIAGNOSTIC_TEST|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
218972241|NCT04095195|RADIATION|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
218972242|NCT04095195|PROCEDURE|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
218972243|NCT03577613|PROCEDURE|Open radical hysterectomy|
219664007|NCT06911580|PROCEDURE|Graston Massage|The participant was positioned prone on the treatment table with the knee slightly flexed. A small amount of lubricating gel was applied to the entire gastrosoleus complex and the calcaneal tendon. For one minute, sweeping strokes were performed downwards on the gastrocnemius heads using the GT-5 tool. From the second to the fourth minute, the GT-5 was used in an upward direction to ensure that both the gastrocnemius and soleus were treated. Afterward, with the GT-2 tool, one minute of downward sweeping and one minute of upward sweeping were performed on the calcaneal tendon. Following the two minutes of sweeping, GT-3 was used to apply short, perpendicular strokes to the medial and lateral sides of the calcaneal tendon, with 30 seconds for each side. The total application lasted approximately 7 minutes (Palmer et al., 2017).
219664008|NCT06910891|DIAGNOSTIC_TEST|measurement of the peripheral perfusion index and marbling assessment|in addition to the classic hemodynamic parameters measured in all patients, a measurement of the peripheral perfusion index (from 1 sec to 10 sec) and marbling assessment (scale from 0 to 5) will be performed
218972244|NCT03577613|PROCEDURE|laparoscopic radical hysterectomy|
218972245|NCT03577613|PROCEDURE|Robotically assisted radical hysterectomy|
218972246|NCT05776316|BEHAVIORAL|Integrated Harm Reduction Intervention (IHRI)|8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.
218972247|NCT06211335|DRUG|Losartan|Given PO
218972248|NCT06211335|BIOLOGICAL|Pembrolizumab|Given IV
218972249|NCT06211335|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218972250|NCT01187680|DEVICE|Spraygel|
218972251|NCT01187680|DEVICE|Control|Good surgical technique, no adhesion barrier
218972252|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
218972253|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
218972254|NCT05169567|DRUG|Abemaciclib|Administered orally.
219664009|NCT06910501|OTHER|Traditional oral hygiene instruction|Individualized demonstration of proper toothbrushing techniques using a toothbrush and a dental model. Conducted by a trained dental professional.
219664010|NCT06910501|OTHER|Digital slide-based education|Educational session using a PowerPoint presentation on a tablet or projector. The session includes visual aids to explain proper brushing techniques, the importance of oral hygiene, and the effects of poor dental care.
218972255|NCT05169567|DRUG|Fulvestrant|Administered IM.
218972256|NCT05169567|DRUG|Placebo|Administered orally.
218972257|NCT01015131|RADIATION|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
218972258|NCT03980951|PROCEDURE|Dural Puncture Epidural Technique|three labor analgesia techniques
218972259|NCT03980951|PROCEDURE|Combined Spinal Epidural without intrathecal opioids|three labor analgesia techniques
218972260|NCT03980951|PROCEDURE|epidural|three labor analgesia techniques
218972261|NCT05411614|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip|Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation
218972262|NCT05411614|DEVICE|Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
218972263|NCT05495633|OTHER|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
218972264|NCT05495633|OTHER|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
218972265|NCT03671018|DRUG|Mosunetuzumab (IV)|Participants will receive intravenous (IV) mosunetuzumab.
218972266|NCT03671018|DRUG|Mosunetuzumab (SC)|Participants will receive subcutaneous (SC) mosunetuzumab.
218972267|NCT03671018|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin.
218972268|NCT03671018|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed.
218972269|NCT03671018|DRUG|Rituximab|Participants will receive IV rituximab.
219664011|NCT06910501|OTHER|Brush DJ mobile appliaction|Children use the Brush DJ app, which includes gamified elements such as music, timers, and oral hygiene tips to encourage proper brushing habits. The app provides reminders and engaging content to maintain motivation.
218972270|NCT05430022|BEHAVIORAL|Autism-adapted Group Cognitive Behavioral Therapy|The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
218972271|NCT04140097|OTHER|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
218972272|NCT05725668|BEHAVIORAL|dual-task tai ji quan|dual-task tai ji quan training
219065421|NCT01944046|DRUG|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
219065422|NCT01944046|DRUG|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
219065423|NCT00823082|DRUG|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
219664012|NCT06909929|DIETARY_SUPPLEMENT|Lipid IV 2 g|This group will get 2 g of lipid IV in the early 24 hours of life
218972273|NCT05725668|BEHAVIORAL|standard tai ji quan|standard tai ji quan training
218972274|NCT05725668|BEHAVIORAL|stretching|stretching exercise
218972275|NCT05532475|DIAGNOSTIC_TEST|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
218972276|NCT03029702|DRUG|Insulin|Insulin will be used for GDM treatment
218972277|NCT03029702|DRUG|Glyburide|Glyburide will be used for GDM treatment
218972278|NCT03029702|DRUG|Metformin|Metformin will be used for GDM treatment
218972279|NCT02741388|DRUG|selinexor|
219065424|NCT03023891|DRUG|Prednisone|Prednisone 60 mg tablet once
219065425|NCT00246636|DRUG|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
219065426|NCT00246636|DRUG|Antara (fenofibrate)|Antara (fenofibrate) + placebo
219664013|NCT06909929|DIETARY_SUPPLEMENT|lipid IV 1 gram|This group will get 1 g of lipid IV in the early 24 hours of life
219664014|NCT06909994|OTHER|individual assessments|Participants in the CP group underwent individual assessments using seven standardized instruments to evaluate sensory and motor function, as well as independence in daily activities. Data collection was conducted in person at the participating institutions by trained professionals following a structured protocol. All procedures were performed after verifying cognitive eligibility (score ≥ 19) and obtaining informed consent. The same protocol was applied across both centers to ensure consistency. The control group followed the same assessment process. Each evaluation session lasted approximately two hours per participant.
219664015|NCT00435019|DRUG|insulin detemir|s.c. injection, once or twice daily.
219664016|NCT00435019|DRUG|insulin NPH|s.c. injection, once or twice daily.
219664017|NCT00435019|DRUG|insulin aspart|s.c. injection, at main meals.
219664018|NCT05760742|DIETARY_SUPPLEMENT|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
219664019|NCT05760742|DIETARY_SUPPLEMENT|Placebo|2 months of supplementation with a placebo (Maltodextrin)
219664020|NCT05510219|DRUG|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
219065427|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
219664021|NCT00441818|DRUG|TNX-650|
219664022|NCT06912113|BEHAVIORAL|Motivational interviewing|What distinguishes this intervention from other clinical applications is that in this study, the clinical effectiveness of motivational interviewing was examined by using a smoking cessation intention scale before and after the intervention.
218972280|NCT02741388|DRUG|Rituximab|
218972281|NCT02741388|DRUG|Dexamethasone|
218972282|NCT02741388|DRUG|Oxaliplatin|
218972283|NCT02741388|DRUG|Cisplatin|
218972284|NCT02741388|DRUG|Cytarabine|
218972285|NCT02741388|DRUG|Gemcitabine|
219664023|NCT06911918|OTHER|time restricted eating with caloric restriction|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value and fasted from 18:00 to 8:00 daily (a 14-h fast) in the 12-weeks intervention
218972286|NCT00777218|DRUG|propranolol|standard pediatric doses, based on body weight
218972287|NCT00777218|DRUG|zonisamide|standard pediatric dosages, based on body weight
219664024|NCT06911918|OTHER|time restricted eating without caloric restriction|will be asked to maintain their normal diet to the acceptable normal distribution ranges and fast from 8:00 to 18:00. They do not need to restrict caloric intake during the feeding window
219664025|NCT06911918|OTHER|Caloric restriction without Time restricted eating|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value
219664026|NCT06911918|OTHER|No time restricted eating - Normal diet|will be asked to maintain their normal diet as the second intervention arm without time restricted eating throughout the trial
219664027|NCT06907056|DRUG|dual therapy|Intervention arm will be dual therapy oh DRV/C 800/150 mg + 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: DRV/c 800/150 mg + TDF/FTC 300/200 mg
219664028|NCT06907056|DRUG|Standard Medical Therapy|DRV/c+TDF/FTC
219664029|NCT03403946|DEVICE|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
219664030|NCT03403946|DEVICE|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
219664031|NCT03403946|DEVICE|Intubation|Intubation with C-MAC PM in combination with D-Blade
219664032|NCT06281626|OTHER|Data collection|Data collection
219664033|NCT06648694|PROCEDURE|Abdominoplasty surgery|Correlation between IAP and Diaphragmatic Mobility
219664034|NCT06648694|PROCEDURE|Abdominoplasty|For the practice of the surgical procedure, the region to be operated on was marked using a surgical marking pen (Textel®). With the patient in the orthostatic position, a median line was drawn from the xiphoid appendix to the pubic symphysis, reaching the anterior vulvar commissure. Then, with the patient in the dorsal position, a transverse line was drawn 6 cm above the vulvar commissure and elongated to the iliac spine on each side. From there, the lateral skin surplus was estimated by means of bidigital clamping. The excess tissue was marked in a triangular shape, with a slight arching up to the xiphoid appendix. To determine the horizontal skin surplus, marking was performed, similar to that performed in classic abdominoplasty described in the literature(AMORIM FILHO; AMORIM, 2012). In this study, an anchor incision was recommended for all volunteers. All patients underwent intravenous sedation followed by spinal anesthesia.
219664035|NCT05602129|DRUG|HSK36273|HSK36273
219664036|NCT05602129|DRUG|Heparin sodium|Heparin sodium
219664037|NCT06912425|BEHAVIORAL|Health prevention.|Unlike other projects, this study focuses on an underexplored area in exercise and kidney disease research. Typically, exercise recommendations are directed toward individuals undergoing hemodialysis or peritoneal dialysis. However, in the early stages of the disease, when the kidneys begin to show alterations, there is no established safe training protocol as a preventive measure. This clinical trial will fill that gap by providing references for an exercise program specifically designed for individuals in the early stages of kidney disease. The main objective will be to compare two different exercise strategies to determine potential benefits for renal health.
219664038|NCT03410901|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
219664039|NCT03410901|OTHER|Laboratory Biomarker Analysis|Correlative studies
219664040|NCT03410901|RADIATION|Radiation Therapy|Undergo radiation therapy
218972288|NCT00777218|DRUG|topiramate|standard pediatric dosages, based on body weight
218972289|NCT04208568|PROCEDURE|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
218972290|NCT02819661|DEVICE|SOMNOTOUCH RESP|Ventilatory effort recorder
218972291|NCT02819661|PROCEDURE|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
218972292|NCT02819661|DRUG|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
218972293|NCT06091787|DRUG|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
218972294|NCT06091787|OTHER|Standard Medical Treatment|Standard Medical Treatment
218972295|NCT00040261|DRUG|Memantine HCL|
218972296|NCT04081038|DIAGNOSTIC_TEST|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
219664041|NCT03410901|DRUG|TLR9 Agonist SD-101|Given intratumorally
219664042|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
219664043|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
219664044|NCT06912230|OTHER|Normoxia|Participants will undergo a 6-hour passive exposure to normoxia in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
219664045|NCT06912230|OTHER|Hypoxia (simulated altitude of 5000 meters above sea-level)|Participants will undergo a 6-hour passive exposure to a simulated altitude of 5000 meters above sea-level in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
219664046|NCT06910072|DRUG|paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab|paclitaxel polymeric micelles 300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.
219664047|NCT06910163|DIAGNOSTIC_TEST|Diagnostic standard of care|Participants will receive the diagnostic standard of care: standard laboratory workup, non-contrast brain CT, brain CTA, brain CTP, or brain MRI.
219664048|NCT06910163|DIAGNOSTIC_TEST|LVOne Test|Participants will receive the LVOne test, which will measure D-dimer and Glial Fibrillary Acidic Protein (GFAP) levels to diagnose acute stroke.
219664049|NCT06912022|DEVICE|FebriDx Device|Patients suspected of an acute respiratory infection were tested using the FebriDx POC assay.
218972297|NCT06404775|DRUG|mastalgia-oil, tamoxifen placebo|external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
218972298|NCT06404775|DRUG|mastalgia-oil placebo, tamoxifen|oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
218972299|NCT06666946|DEVICE|Electroacupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm), and SDZ-V EA apparatuses will be used. Participants in the EA group will receive acupuncture at bilateral ST36 and GB34. After sterilisation, sterile adhesive pads will be placed on bilateral ST36 and GB34, and acupuncture needles will be inserted through the adhesive pads approximately 20 to 30 mm into the skin. Following needle insertion, manual manipulation of needles will be performed on all needles to reach de qi (a composite of sensations including soreness, numbness, distention, heaviness, and other sensations). Then, paired electrodes from the EA apparatus will be attached transversely to the needle handles at bilateral ST36 and GB34. EA stimulation lasted for 30 minutes with a continuous wave of 10 Hz and a current intensity of 0.5 to 1 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 6 treatment sessions once daily for 6 consecutive days.
219065428|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
218972300|NCT06666946|DEVICE|Sham electroacupuncture|Non-insertive placebo needles (size 0.30 × 30 mm), and SDZ-V EA apparatuses will be used. Participants in the sham EA group will receive sham EA with a non-insertive placebo needle on sham acupoints. The sham ST36 point is located at 1 cun (≈20 mm) lateral to ST36, and the sham GB34 point is located at 1 cun (≈20mm) lateral to GB 34. Procedures, electrode placements, and other treatment settings will be the same as in the EA group but with no skin penetration, electricity output, or de qi.
218972301|NCT04468321|DEVICE|Apple Watch|Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
218972302|NCT04468321|DEVICE|Withings Move|Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
218972303|NCT02597153|DRUG|Mitoxantrone HCL Liposome Injection|
218972304|NCT04737135|OTHER|Non intervention|Patients without intervention
218972305|NCT06512545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)"
219065429|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
219065430|NCT05400096|OTHER|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
219065431|NCT04618354|OTHER|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
219065432|NCT03198000|DRUG|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
219065433|NCT03198000|DRUG|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
219065434|NCT03198000|DRUG|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
219065435|NCT04016597|DEVICE|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
219065436|NCT04016597|DEVICE|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
219065437|NCT03592212|DRUG|Salbutamol|Measurement of bronchodilator response (BDR)
219065438|NCT05309161|DIETARY_SUPPLEMENT|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
219664050|NCT03660150|OTHER|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
218972306|NCT06306144|BEHAVIORAL|Psychoeducation|Arm 1 : Psychoeducation aims to inform patients about post-stroke cognitive impairment, teach them coping strategies to compensate for these difficulties, provide information on symptom recognition and management, and offer emotional and psychological support to help them meet the challenges associated with these potential cognitive impairments.
218972307|NCT06306144|BEHAVIORAL|Computerised Cognitive Stimulation|Arm 2 :Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician
218972308|NCT06306144|BEHAVIORAL|Usual Care|Arm 3 : No specific care.
218972309|NCT04956250|OTHER|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
218972310|NCT04956250|OTHER|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
218972311|NCT00550251|DEVICE|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
218972312|NCT00550251|DEVICE|Placebo wristbands|Elasticated wrist bands without active bead.
218972313|NCT05644496|DRUG|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
218972314|NCT03237871|BEHAVIORAL|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
218972315|NCT05072886|DRUG|AT193|Topical applied to affected areas daily
218972316|NCT01334242|DRUG|Schedule A|Dosing 1 hour before breakfast
218972317|NCT01334242|DRUG|Schedule B|Dosing 0.5 hour before breakfast
218972318|NCT01334242|DRUG|Schedule C|Dosing immediately before breakfast
219065439|NCT05062928|OTHER|Virtual coach|This group will be trained and assessed by the virtual coach.
219664051|NCT03557684|DIETARY_SUPPLEMENT|leucine|amino acid leucine in powder
219664052|NCT03557684|OTHER|PO placebo|maltodextrin
219664053|NCT03557684|BIOLOGICAL|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
219664054|NCT03557684|OTHER|IV placebo|0.9% saline
219664055|NCT06911281|COMBINATION_PRODUCT|Mesenchymal Stem Cells；755nm picosecond laser treatment|Stem Cell Treatment Group 1 received intravenous infusion of MSCs followed by multi-point injection into the melasma area, combined with 755nm picosecond laser treatment. Stem Cell Treatment Group 2 received multi-point injection of MSCs into the melasma area, combined with 755nm picosecond laser treatment. The Control Group only received 755nm picosecond laser treatment.
219664056|NCT00089700|DRUG|TNX-355|
219664057|NCT04364464|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
219664058|NCT06018545|OTHER|Ground truthing|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration.
219664059|NCT06018545|OTHER|Reading|All 30 readers will review all 150 cases, in each of two study phases. The readers will provide their opinion on the presence or absence of some acute abnormalities, including intracranial haemorrhage, infarct, midline shift and fracture. They will provide a confidence in their diagnosis (10-point visual analogue scale), and a single click point to mark the location of each abnormality that they consider as being present. The time taken for each scan will be automatically recorded.
219664060|NCT03601273|PROCEDURE|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
219664061|NCT03257241|DRUG|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
218972319|NCT01334242|DRUG|Schedule D|Dosing immediately before lunch
218972320|NCT01334242|DRUG|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
218972321|NCT03959228|DRUG|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
218972322|NCT05595382|BEHAVIORAL|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
218972323|NCT05595382|BEHAVIORAL|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
218972324|NCT06656312|DEVICE|Use ASUS EndoAim as an assistant software to perform colonoscopy|Use ASUS EndoAim as an assistant software to perform colonoscopy
218972325|NCT00043121|DRUG|oxaliplatin|Given IV
218972326|NCT00043121|DRUG|leucovorin calcium|Given IV
219065440|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
219065441|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
219065442|NCT00827034|DRUG|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
219065443|NCT00827034|DRUG|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
218972327|NCT00043121|DRUG|fluorouracil|Given IV
218972328|NCT00043121|DRUG|capecitabine|Given orally
218972329|NCT00043121|OTHER|pharmacological study|Correlative studies
219664062|NCT03257241|DRUG|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
219664063|NCT03257241|DRUG|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
219664064|NCT03257241|DRUG|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
218972330|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
218972331|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
218972332|NCT06825494|DRUG|LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
218972333|NCT06825494|DRUG|Tislelizumab+Oxaliplatin+Capecitabine|"Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1).~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
218972334|NCT06825494|DRUG|LM-108 injection 10mg/kg +penpulimab|"LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
218972335|NCT06825494|DRUG|LM-108 injection 600mg + penpulimab|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
218972336|NCT02422940|DRUG|dalfampridine-ER 7.5 mg|
218972337|NCT02422940|DRUG|dalfampridine-ER 10 mg|
218972338|NCT06486558|DRUG|HU6 450 mg Tablet|new 450 mg tablet test formulation
218972339|NCT06486558|DRUG|HU6 150 mg Capsules x 3 (Total dose = 450 mg)|150 mg capsule reference formulation (3 x 150 mg).
218972340|NCT06145659|BEHAVIORAL|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
218972341|NCT06585982|DIETARY_SUPPLEMENT|Treatment|RILLUS is a synbiotic produced by Kalbe Farma
219065444|NCT00827034|DRUG|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
219065445|NCT03191084|DRUG|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
219664065|NCT02101749|BIOLOGICAL|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
219664066|NCT01074151|DRUG|duloxetine|any exposure to duloxetine that occurred during pregnancy
219664067|NCT01669785|DEVICE|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
218972342|NCT06585982|DIETARY_SUPPLEMENT|Control|Placebo produced by Kalbe Farma
218972343|NCT06591286|DEVICE|RT-CGM|This group of patients will wear RT-CGM for blood glucose monitoring for three months.
218972344|NCT06591286|DEVICE|SMBG|This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.
218972345|NCT02942329|DRUG|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
218972346|NCT02942329|DRUG|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
218972347|NCT02216825|DIETARY_SUPPLEMENT|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
218972348|NCT02216825|DIETARY_SUPPLEMENT|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
219065446|NCT03191084|DRUG|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
219065447|NCT03191084|DRUG|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
219664068|NCT01669785|DEVICE|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
219664069|NCT01669785|DEVICE|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
219664070|NCT03858283|BEHAVIORAL|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
219664071|NCT00372047|DEVICE|multiphoton laser imaging|
219664072|NCT01381991|DEVICE|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
219065448|NCT03668145|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
219065449|NCT01082666|DEVICE|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
219065450|NCT01082666|DEVICE|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
219065451|NCT00737841|DRUG|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
219065452|NCT00737841|DRUG|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
219664073|NCT05247021|PROCEDURE|erector spinae block for group E|. The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
219664074|NCT04239443|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
219664075|NCT04239443|DRUG|Apatinib|NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
218972349|NCT02445391|DRUG|Capecitabine|Given PO
218972350|NCT02445391|DRUG|Carboplatin|Given IV
218972351|NCT02445391|DRUG|Cisplatin|Given IV
218972352|NCT06608368|DRUG|Test Dentifrice (Sensodyne Repair and Protect Original Mint)|Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
218972353|NCT06608368|DRUG|Positive Control Dentifrice (Sensodyne Fresh Mint)|Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
218972354|NCT06608368|DRUG|Reference Dentifrice (Crest Cavity Protection Regular)|Dentifrice containing 1100 ppm fluoride as sodium fluoride.
218972355|NCT06587308|OTHER|Dorsal-Double-Layered 10% Circumferential Reduction (DD-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the DD-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
218972356|NCT06587308|OTHER|Single-Layered 10% Circumferential Reduction (S-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
219065453|NCT00633321|BIOLOGICAL|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
219065454|NCT00633321|BIOLOGICAL|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
219664076|NCT06169956|DRUG|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
219664077|NCT01635907|DRUG|Dovitinib|
219664078|NCT04886362|DRUG|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
219664079|NCT04886362|DRUG|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
219065455|NCT02429128|OTHER|14 weeks exercise training|
219065456|NCT02845908|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
219065457|NCT02845908|DRUG|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
219065458|NCT02845908|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
219686549|NCT04833062|DIAGNOSTIC_TEST|Ultrasound|In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
219065459|NCT03176680|PROCEDURE|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
219065460|NCT02280603|DRUG|DA-4001C|1ml by topical application twice a day
219065461|NCT02280603|DRUG|5% minoxidil|1ml by topical application twice a day
219065462|NCT03466580|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
219065463|NCT05255640|PROCEDURE|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
219664080|NCT05993091|OTHER|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
219664081|NCT05993091|OTHER|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
219664082|NCT05993091|OTHER|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
219664083|NCT03988673|OTHER|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
219664084|NCT03988673|OTHER|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
219664085|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
219664086|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
219664087|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
219664088|NCT00422292|BIOLOGICAL|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
219664089|NCT04616001|DRUG|IVIG|Patients will receive IVIG daily for four days.
219664090|NCT05105399|PROCEDURE|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
219664091|NCT05905133|DRUG|CBP-201|subcutaneous injection
219664092|NCT05517733|BIOLOGICAL|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
218972357|NCT06587308|OTHER|Single-Layered No Circumferential Reduction (S-0) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-0 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
218972358|NCT01176344|DRUG|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
218972359|NCT01176344|DRUG|Placebo|Inert placebo capsules once monthly for 2 years.
219664093|NCT05517733|DEVICE|Diode laser|"* A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~* The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
219664094|NCT00520754|DRUG|levocetirizine dihydrochloride|
219065464|NCT01412723|OTHER|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
219065465|NCT01412723|OTHER|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
219065466|NCT02096055|DRUG|Cladribine|Given IV
219065467|NCT02096055|DRUG|Guadecitabine|Given SC
219664095|NCT02440854|DRUG|afatinib|Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
219065468|NCT02096055|DRUG|Idarubicin|Given IV
219065469|NCT03719066|BIOLOGICAL|killed whole cell oral cholera vaccine|two week interval
219664096|NCT02174705|DRUG|Sucrose|Sucrose 24% orally prior to vaccine injections
219664097|NCT02174705|DRUG|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
219065470|NCT02080026|BIOLOGICAL|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
219065471|NCT02080026|BIOLOGICAL|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
219065472|NCT02080026|DRUG|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
219664098|NCT01758978|DRUG|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
219664099|NCT00699231|BIOLOGICAL|HBV-MPL vaccine 208129|IM injection
219664100|NCT00699231|BIOLOGICAL|Engerix™-B|IM injection
219664101|NCT03329105|OTHER|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
219664102|NCT03329105|OTHER|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
219664103|NCT03338569|DRUG|Vitamin C|Continuous infusion of vitamin C
219664104|NCT03338569|DRUG|Placebo|Placebo designed to mimic intervention
219664105|NCT02243046|DRUG|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
219664106|NCT02243046|DRUG|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
219664107|NCT02243046|DRUG|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
219664108|NCT02897180|BIOLOGICAL|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
219664109|NCT02897180|BIOLOGICAL|Placebo|Capsules containin Placebo
219664110|NCT04865991|PROCEDURE|TCI Propofol|Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
219664111|NCT04865991|PROCEDURE|Sevoflurane|subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
219664112|NCT05415371|BEHAVIORAL|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
218972360|NCT05928871|DRUG|Misoprostol 200mcg Tab|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
218972361|NCT05928871|DRUG|Misoprostol Pill|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
218972362|NCT03722173|DRUG|Itraconazole|Oral solution
218972363|NCT03722173|DRUG|BI 894416|Tablet
218972364|NCT00982696|BIOLOGICAL|Opioid Growth Factor|250ug per kilogram weekly IV infusions
218972365|NCT05024045|DRUG|LOXO-338|Oral
218972366|NCT05024045|DRUG|Pirtobrutinib|Oral
218972367|NCT06676709|BIOLOGICAL|IMMUNEPOTENT-CRP (I-CRP)|IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.
219664113|NCT05415371|OTHER|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
219664114|NCT02669082|DRUG|Ramelteon|Ramelteon tablets
219664115|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|dental implant will be inserted using blue sky plan computer software
218972368|NCT06676709|BIOLOGICAL|Placebo Comparator|The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
218972369|NCT06671002|DRUG|NSAID|"Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)"
218972370|NCT06671002|DRUG|Opioid|"Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses"
218972371|NCT06671002|DRUG|Acetaminophen|Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
218972372|NCT06671002|DRUG|Ibuprofen|Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
219664116|NCT06910007|PROCEDURE|dental implant|surgical guide will be fabricated using exoplan computer software
219664117|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|surgical guide will be fabricated using real guide computer software
219664118|NCT05883774|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
219664119|NCT05883774|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
219664120|NCT06209762|OTHER|Exercise|The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
219664121|NCT05682729|BEHAVIORAL|Book Reading Intervention|Children read books containing relevant stimuli.
219664122|NCT06376305|DEVICE|EndoBarrier|"During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires."
219664123|NCT06509347|OTHER|Preassure release|Preassure release in Flexor digitorum brevis trigger point muscle.
219664124|NCT06509347|OTHER|Non-emision laser|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
219664125|NCT02427243|DRUG|Crenezumab|
219664126|NCT02427243|DRUG|Crenezumab|
219664127|NCT02168777|DRUG|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
219664128|NCT02168777|DRUG|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
219664129|NCT05243563|DEVICE|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
219664130|NCT05243563|DRUG|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
219664131|NCT06728709|DIAGNOSTIC_TEST|ultrasound detection of any abnormal ultrasonographical findings.|"ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24.~posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter."
219664132|NCT02329782|BEHAVIORAL|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
219686550|NCT04833062|OTHER|Survey|"The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI."
219686551|NCT00834847|DRUG|pravastatin|40 mg tablet
219686552|NCT00834847|DRUG|Pravachol®|40 mg Tablet
218972373|NCT06678698|DEVICE|Panel Effective Photobiomodulation Therapy|"Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs"
218972374|NCT06678698|DEVICE|Sham Panel Photobiomodulation Therapy|Use of common red lamp to perform the sham photobiomodulation for the panel group
218972375|NCT06678698|DEVICE|Modified ILIB Sham Photobiomodulation Therapy|ILIB Therapy device turned off for the sham ILIB therapy
218972376|NCT06678698|DEVICE|Modified ILIB Photobiomodulation Therapy|Common laser used in ILIB mode for modified ILIB therapy
219065473|NCT02080026|DRUG|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
219065474|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
219065475|NCT05647447|DRUG|Osanetant|Osanetant 200 mg orally, twice per day
219065476|NCT02057055|OTHER|Soap 300000027003|
219065477|NCT02057055|OTHER|Soap 300000029240|
219065478|NCT01069783|DRUG|A3309|A3309 in two different dosage levels
219664133|NCT05240703|DEVICE|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
219664134|NCT03153345|DEVICE|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
219664135|NCT03153345|BEHAVIORAL|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
219664136|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
219664137|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
219664138|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
219664139|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
219664140|NCT06138717|OTHER|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
219664141|NCT00851188|BEHAVIORAL|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
218972377|NCT06677866|BEHAVIORAL|Cognitive behavioral therapy|"Cooperative Group Therapy (CGT) is a cognitive-behavioral group therapy based on the theoretical and practical principles of the Cooperative Parent-Mediated Therapy model \[Valeri et al., 2020\].~The goal of CGT is to promote the following core skills: Pragmatics, Executive Functions, and Cooperative Interactions. The CGT program consists of 15 sessions over a total duration of 6 months: 12 group therapy sessions with adolescents and 3 sessions with their parents. Each session focuses on a specific topic and lasts between 90 and 120 minutes.~The CGT therapist is a psychotherapist with a cognitive-behavioral orientation who utilizes evidence.-based strategies to enhance pragmatic, socio-conversational skills, cognitive flexibility, emotional regulation, and cooperative interactions. The CGT intervention is conducted by two cognitive-behavioral psychotherapists specialized respectively in the treatment of FXS and ASD."
218972378|NCT06677866|OTHER|Waiting List|The Waiting List (WL) is a control group in which participants who do not receive the experimental treatment are placed on a waiting list to receive the intervention after the active treatment group has completed it. In the case of the WL, the CGT intervention is carried out after at least 6 months to allow the patients in the first group to complete the treatment cycle. This approach enables a comparison between a group of treated patients and a group of patients who have not yet been treated, while still allowing the latter to access the treatment at a later stage.
218972379|NCT06900712|BEHAVIORAL|PATH-SS|"This single-session intervention includes the following components:~* Providing the PATH-SS rationale.~* A review of life events (PATH of life: negative and positive).~* A verbal narrative of the sexual assault (revisiting and processing as is done in imaginal exposure)~* Reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. In positive reminiscence, clients vividly remember the positive event providing details and focus on positive emotions. The therapist will encourage savoring of the experience and encourage facial expression of the positive emotions, so that clients do not dampen, avoid, or minimize the experience. This is particularly relevant with depression.~* Summary of content, integration and consolidation of learning, application of new learning and resilience in real life as next steps."
218972380|NCT03894137|DIETARY_SUPPLEMENT|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
218972381|NCT06886152|PROCEDURE|Transcutaneous Spinal Cord Stimulation|A portable transcutaneous spine stimulator (Digitimer ®, USA) will supply biphasic stimulation superficial to the thoracolumbar spine.
218972382|NCT06886152|OTHER|Sham|A portable transcutaneous spine stimulator (Digitimer ®, USA) will be applied superficially with no electrical current.
218972383|NCT07081815|DEVICE|JOCOAT(TM) APN-3003|10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery
218972384|NCT03148275|OTHER|Questionnaire Administration|Ancillary studies
219664142|NCT00851188|BEHAVIORAL|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
219664143|NCT00851188|OTHER|Waiting list|Waiting list
218972385|NCT03148275|DRUG|Trametinib|Given PO
218972386|NCT07087197|DRUG|SKB107 for injection|177Lu-DOTA-IBA is a Radionuclide conjugated drugs (RDC) targeting bone.
218972387|NCT06928766|DRUG|Eszopiclone 3 mg|Both eszopiclone and lemborexant taken together at bedtime for one night
218972388|NCT06928766|DRUG|Placebo|Placebo sugar pills that looks like the eszopiclone and lemborexant capsules taken at bedtime for one night.
218972389|NCT06928766|DRUG|Lemborexant 10mg|Both eszopiclone and lemborexant taken together at bedtime for one night
219664144|NCT00259428|DRUG|Dronedarone (SR33589)|oral administration
219664145|NCT00259428|DRUG|placebo|oral administration
219664146|NCT06033170|DEVICE|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
219664147|NCT02249507|OTHER|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
219065479|NCT01069783|DRUG|A3309|A3309 in two different dosage levels for the duration of the study
219065480|NCT01069783|DRUG|Placebo|Placebo comparator once daily for the duration of the trial
219065481|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
219065482|NCT05883852|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
219065483|NCT05883852|DRUG|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
219065484|NCT05883852|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
219065485|NCT05883852|DRUG|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
218972390|NCT06234930|DEVICE|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
218972391|NCT05176418|DRUG|low dose Nicotine|IV nicotine infused over different delivery rates
218972392|NCT05176418|DRUG|high dose Nicotine|IV Nicotine infused over different delivery rates
218972393|NCT06902805|DRUG|OnabotulinumtoxinA|intra-articular injection
218972394|NCT06902805|DRUG|Normal saline (placebo)|intra-articular injection
218972395|NCT07090395|DEVICE|EVO Sleep and Snore Device|ProSomnus EVO Sleep and Snore Device mandibular advancement device
218972396|NCT06903091|PROCEDURE|SMS|Usual follow-up
218972399|NCT06811493|PROCEDURE|bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients|using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process)
218972400|NCT07112521|DEVICE|active tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
218972401|NCT07112521|DEVICE|sham tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.
218972402|NCT06933680|PROCEDURE|Sphenopalatine Ganglion Block|"To perform an SPG block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of 0.5% bupivacaine is injected.~The procedure is performed on both sides"
219065486|NCT05883852|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
219065487|NCT05883852|DRUG|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
219065488|NCT03671603|DRUG|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
219065489|NCT05553691|DRUG|SPL026|Intravenous
219065490|NCT04191772|OTHER|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
219065491|NCT00921492|DEVICE|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
219065492|NCT00921492|OTHER|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
219065493|NCT05637021|OTHER|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
219065494|NCT00647712|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
219208412|NCT06894550|BEHAVIORAL|Participants will be escorted to high altitude and undergo a series of test|"Participants will be escorted to high altitude and undergo the following examination both at 540 and 3545m above sea level:~* 12-lead electrocardiogram~* Transthoracic echocardiography with measurement of left and right ventricular dimension and function, global longitudinal strain and transvalvular gradient~* Symptom-limited cardiopulmonary stress exercise test with a ramp protocol with a focused echocardiography for the assessment of cardiac output and transvalvular gradient and blood gas analysis~* 24 hours wearable rhythm monitoring~* Blood Work: cardiac biomarkers (Troponin T, CK, CK-MB, NT-pro-BNP), blood gas analysis, Hemoglobin, Hematocrit, Leucocytes, Thrombocytes, Creatinin, eGFR, Sodium, Potassium, ASAT, ALAT, Bilirubin)"
219664148|NCT05420493|BIOLOGICAL|CAR-T cells|Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219664149|NCT04247451|DIAGNOSTIC_TEST|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
219664150|NCT05290077|DIAGNOSTIC_TEST|NGAL|Serum NGAL in blood for early detection of CVR
219664151|NCT04535557|DRUG|Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
219664152|NCT03102671|OTHER|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
219664153|NCT03102671|OTHER|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
219664154|NCT02171832|DRUG|BI 1744 CL, low dose|
219664155|NCT02171832|DRUG|BI 1744 CL, high dose|
219664156|NCT01520519|DRUG|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
219664157|NCT01520519|DRUG|PCI-32765|420 mg (3 \* 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
219065495|NCT00647712|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fasting
219065496|NCT03146169|BEHAVIORAL|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
219065497|NCT04483869|OTHER|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
219065498|NCT01618838|RADIATION|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
219065499|NCT04575428|DRUG|Splanchnic nerve block|Percutaneous splanchnic nerve block
219208413|NCT05098847|DRUG|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
219664158|NCT06956625|OTHER|Topical cosmetic cleanser|After applying the model pollutant, the test area will be topically cleaned with the active cosmetic cleanser with Mitopure.
219664159|NCT06956625|OTHER|Topical tap water|After applying the model pollutant, the test area will be topically cleaned with tap water (control).
219664160|NCT05574829|DEVICE|Esophageal manometry and monitoring of electrical activity of the diaphragm|Esophageal manometry and monitoring of electrical activity of the diaphragm
219664161|NCT06327360|OTHER|Psychological questionnaires|The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
219664162|NCT00824707|DRUG|Entecavir|Entecavir 0.5mg per day
219664163|NCT00824707|DRUG|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
219664164|NCT04468815|DRUG|BMS-986278 Tablet|Specified dose on specified days
219664165|NCT04468815|DRUG|Esomeprazole|Specified dose on specified days
219664166|NCT04468815|DRUG|BMS-986278 suspension|Specified dose on specified days
219664167|NCT01958398|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback.
219664168|NCT01958398|BEHAVIORAL|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
219664169|NCT01698268|PROCEDURE|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
219664170|NCT01698268|PROCEDURE|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
219664171|NCT06323395|DRUG|Vizol S LIPID BALANCE eye drops|1 drop 4 times a day
219664172|NCT06323395|DRUG|ophthalmic saline eye drops|1 drop 4 times a day
219664173|NCT04024566|DEVICE|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
218972403|NCT06933680|PROCEDURE|Sham Block|"To perform a Sham block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of %0,9 NaCl is injected.~The procedure is performed on both sides."
219664174|NCT04112550|DRUG|Methadone Hydrochloride|FDA approved medication to treat pain
219664175|NCT04112550|DRUG|Oxycodone-Acetaminophen|FDA approved medication to treat pain
219664176|NCT01873157|DRUG|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
218972404|NCT06934460|DEVICE|Composite resin|Direct composite resin restoration after application of an adhesive system
218972405|NCT06934460|DEVICE|lithium disilicate endocrown|Lithium disilicate endocrown in conjunction with Immediate Dentin Sealing
218972406|NCT06934811|DRUG|Ciprofol|Continuous intravenous infusion (0.05-0.3 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
218972407|NCT06934811|DRUG|Midazolam|Continuous intravenous infusion (0.02-0.1 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
218972408|NCT06933407|DIAGNOSTIC_TEST|Strain Elastography|Strain elastography (SE) is a parametric imaging modality that assesses tissue deformation in response to externally applied pressure, providing qualitative and semi-quantitative information on tissue elasticity and mechanical properties. Unlike conventional 2D ultrasound, SE enables the objective evaluation of paraurethral tissue stiffness, which may play a role in the pathophysiology of stress urinary incontinence (SUI). SE will be performed on three predefined paraurethral regions to assess pelvic floor elasticity and biomechanical characteristics. A standardized protocol will be implemented to ensure high reproducibility, with controlled probe compression and precisely defined regions of interest. SE may improve the diagnostic accuracy and therapeutic decision-making for SUI by identifying differences in tissue compliance among affected women.
218972409|NCT06933615|OTHER|Training prepared with mobile application|The m-BAFY program will be loaded onto the mobile phones of patients in the mobile application group. Each patient will be informed on how to use the mobile program. In addition, a short training will be given on how to use the application. With this application, the symptoms and vital signs recorded by the patients will be monitored and individual feedback will be provided. Information on the management of the disease prepared in line with the guidelines is included.
218972410|NCT06934551|DEVICE|obturator|conventionally constructed and polished obturator
218972411|NCT06933966|OTHER|observation alone|Patient will not received post-operative chemotherapy. There will be only surveillance until progression.
218972412|NCT06933212|OTHER|Mediterranean Diet with Extra Virgin Olive Oil|participants in this group will follow a Mediterranean Diet enriched with extra virgin olive oil
219065500|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
219065501|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
219065502|NCT00288158|DRUG|Allopurinol|
218972413|NCT06933212|OTHER|Mediterranean Diet with Walnuts|participants in this group will follow a Mediterranean Diet enriched with walnuts
218972414|NCT06933212|OTHER|Low-Fat Control Diet|participants in this group will follow a low-fat control diet as a comparison to the Mediterranean Diet groups
219065503|NCT00288158|DRUG|Probenecid|
219065504|NCT00288158|DRUG|Placebo|
219208414|NCT05098847|DRUG|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219208415|NCT05098847|DRUG|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
219664177|NCT01873157|DRUG|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
219065505|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
219065506|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
219664178|NCT02102672|DRUG|Trimetazidine|
219664179|NCT04957199|OTHER||
219664180|NCT02812225|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
219664181|NCT01493115|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219664182|NCT01493115|DRUG|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219664183|NCT01533688|DRUG|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
219664184|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
219686553|NCT02523404|PROCEDURE|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
218972415|NCT06933264|DIETARY_SUPPLEMENT|Exclusion diet|Experimental Group: Patients will receive modifications to their pharmacological and will be assigned to an intervention consisting of an exclusion diet in conjunc-tion with supplemental enteral nutrition. This nutritional strategy will involve a progressive increase in the caloric intake derived from the diet, coupled with a corresponding reduction in supplemental enteral nutrition.
219065507|NCT05106231|BEHAVIORAL|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
219065508|NCT05106231|BEHAVIORAL|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
219065509|NCT00197977|BEHAVIORAL|Educational program to address patients' expectations|
219664185|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
219664186|NCT03126123|PROCEDURE|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
219664187|NCT03278847|DIETARY_SUPPLEMENT|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
218972416|NCT06934005|DEVICE|Baseplate type A|Type A: Acrylate tested for 35 days behind one ear
218972417|NCT06934005|DEVICE|Baseplate type C|Type C: Hydrocolloid tested for 35 days behind the other ear
218972418|NCT06933992|DEVICE|Chocolate PTA Balloon Catheter|The Chocolate PTA balloon catheter is a nitinol-constrained percutaneous transluminal angioplasty balloon designed to minimize vessel trauma during treatment of peripheral arterial lesions. The device is used according to its standard indications and instructions for use in patients with symptomatic peripheral artery disease.
218972419|NCT01828320|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
218972420|NCT01828320|BEHAVIORAL|Psychoeducation|
218972421|NCT03424473|DRUG|Tucatinib|
219664188|NCT03278847|DIETARY_SUPPLEMENT|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
219664189|NCT03278847|DIETARY_SUPPLEMENT|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
219664190|NCT03278847|DIETARY_SUPPLEMENT|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
218972422|NCT07149766|OTHER|Breast crawling|"The newborn will be placed on the mother's abdomen for no more than 60 minutes, during which breast crawling and suckling behaviors will be observed. Throughout this period, the researcher will maintain active communication with the mother, providing information on the importance of breastfeeding.~The mother will be gently guided to support the baby when necessary, without interfering with the baby's natural instincts. The newborn's heart rate, respiratory rate, and body temperature will be recorded at birth and at the 60th minute."
218972423|NCT07150975|DRUG|GZR18|Administered SC
218972424|NCT07150975|DRUG|Semaglutide(Wegovy® )|Administered SC
218972425|NCT04180085|DRUG|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
218972426|NCT07149987|PROCEDURE|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area. The implants used in this study were C-Tech® implants (C-Tech Implant, Italy) with the following dimensions: Diameter: 3.8 mm Length: 11 mm . Cone-Beam Computed Tomography (CBCT): To assess bone quality, quantity, and anatomical structures . Digital Intraoral Scans Heron Scanner (USA) to obtain detailed gingival contours, occlusion, and existing teeth. The scan data was exported as an STL file for digital planning. Easy Check Implant Stability Measuring System is used for implant stability measurement, the tapping rod was gently placed in slight contact with the healing abutment, avoiding any axial or lateral pressure, and aligned within 0°-30° relative to the abutment's occlusal surface. If the angle exceeded 30°, the device issued an alert and prevented measurement, ensuring consistent alignment
218972427|NCT07149818|DRUG|Parsaclisib|parsaclisib 40mg qd
219065510|NCT01253434|DRUG|E2022|E2022 Type A patch
219065511|NCT01253434|DRUG|E2022|E2022 Type B patch
219065512|NCT01253434|DRUG|E2022|E2022 Type C patch
219065513|NCT01253434|DRUG|E2022|E2022 Type D patch
219065514|NCT01253434|DRUG|E2022|E2022 Type E patch
219065515|NCT00690521|DRUG|Treatment of Furosemide + Hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
219065516|NCT00690521|DRUG|Treatment of Furosemide + Metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
219065517|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
219065518|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
219065519|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
219664191|NCT03748368|OTHER|Cataract presentation|Presentation about cataract surgery
219065520|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
219065521|NCT04711304|OTHER|Saline|Intraarticular injection
219065522|NCT05354700|DRUG|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
219065523|NCT05354700|DRUG|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
219065524|NCT05354700|DRUG|carboplatin and etoposide|chemotherapeutics
219065525|NCT03030300|DRUG|Novolin 30R;Pioglitazone;Metformin|"* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
219065526|NCT00210834|DRUG|epoetin alfa|
219065527|NCT01678326|PROCEDURE|EUS-Rendezvous or direct intervention|
219664192|NCT03748368|OTHER|Placebo presentation|Presentation about the history of the hospital
219664193|NCT02509078|DRUG|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
219664194|NCT03165084|BEHAVIORAL|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
219664195|NCT03165084|OTHER|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
219664196|NCT03165084|OTHER|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
219664197|NCT00452153|PROCEDURE|Characterization Legionnella|"* Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
219664198|NCT04844983|DRUG|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
219664199|NCT04844983|OTHER|Placebo Saline|Normal Saline
219664200|NCT02799888|DRUG|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
219664201|NCT02799888|DRUG|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
219664202|NCT02799888|DRUG|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
219664203|NCT02799888|DRUG|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
219664204|NCT01913522|PROCEDURE|Pulmonary Vein Isolation|
219664205|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
219664206|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
219664207|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
219664208|NCT06137066|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
219664209|NCT02253381|PROCEDURE|Right|Right lateral decubitus position during spinal anesthesia
219664210|NCT02253381|PROCEDURE|Left|Left lateral decubitus position during spinal anesthesia
219664211|NCT05212779|DIAGNOSTIC_TEST|Signatera testing|26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
219664212|NCT05212779|DIAGNOSTIC_TEST|Altera Testing|6ml blood and tissue sample.
219664213|NCT05089812|PROCEDURE|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
219664214|NCT00404716|DRUG|Cilostazol|
219664215|NCT02484768|DRUG|Iron isomaltoside 1000|Intravenous treatment
219664216|NCT02484768|DRUG|Sodium Chloride 0.9%|Intravenous treatment
219664217|NCT01327092|OTHER|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
219664218|NCT02527317|DRUG|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
219664219|NCT00000589|PROCEDURE|platelet transfusion|
219664220|NCT05870670|DRUG|NNC0519-0130|Administered subcutaneously.
219664221|NCT05870670|DRUG|Placebo|Administered subcutaneously.
219664222|NCT06557421|DRUG|Venetoclax|complete discontinuation of Venetoclax
218972428|NCT07149883|OTHER|Complete blood count|Complete blood count
218972429|NCT07149883|DEVICE|ECHO|device that used to evaluate the cardiac function
218972430|NCT07150546|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218972431|NCT07150546|DRUG|Lutetium Lu 177 Dotatate|Given IV
218972432|NCT07150546|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
218972433|NCT07150546|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218972434|NCT07150546|RADIATION|Gallium Ga 68-DOTATATE|Undergo gallium Ga 68-DOTATATE PET/CT
218972435|NCT07150546|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218972436|NCT07150546|OTHER|Questionnaire Administration|Ancillary studies
219208416|NCT06768060|BEHAVIORAL|Short mindfulness-based intervention|The intervention includes a short mindfulness-based intervention with a duration of 5 minutes. It involves a sitting mediation focused on breath adapted from the existing protocols of the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT). The intervention is audio-guided and will be delivered via headphones.
218972438|NCT07149805|PROCEDURE|open surgery or interventional treatment|open surgery or interventional treatment
218972439|NCT07150728|BEHAVIORAL|dignity therapy|"Dignity therapists use the Dignity Psychotherapy Question Protocol to guide patients through life's most important issues, providing them with the opportunity to participate in and discuss the things they would like their families to remember them for. During the process, dignity therapists use audio recording to fully record, transcribe, and edit the interview material, creating a valuable record that the patient wishes to preserve. The edited document is then returned to the patient, who then gives it to their family members."
218972440|NCT07150728|BEHAVIORAL|Hospice palliative care|Participants regularly receive hospice care
218972441|NCT07149454|DRUG|Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection|intramuscular injection
218972442|NCT07149454|DRUG|Human Tetanus Immunoglobulin|intramuscular injection
218972443|NCT07149454|DRUG|Placebo|intramuscular injection
218972444|NCT07150377|DRUG|First-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
218972445|NCT07150377|DRUG|Second-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
218972446|NCT07149740|DEVICE|OCT|A10900 is an optical coherence tomography device
218972447|NCT07150689|PROCEDURE|Rigid bronchoscopy|Participants will undergo rigid bronchoscopy under general anesthesia using an age-appropriate rigid bronchoscope. The airway will be systematically inspected. Any identified foreign body will be removed using appropriate retrieval devices (optical forceps, retrieval basket, suction). Post-removal, the airway will be re-examined to confirm clearance and detect trauma.
218972448|NCT07150689|PROCEDURE|Flexible scope|Participants will undergo flexible fiberoptic bronchoscopy under sedation or general anesthesia. The bronchoscope will be inserted transorally or transnasally. The airway will be inspected, and foreign body retrieval attempted using retrieval baskets, forceps, or cryoprobe
219208417|NCT06760897|DIETARY_SUPPLEMENT|Gastrogenic Microbiota|Take 1 sachet of gastric-origin probiotic powder (containing 5 x 1011 CFU per sachet) twice daily for 8 weeks.
219208418|NCT06760897|OTHER|Placebo|similar powder administered twice daily
219208419|NCT06754761|DRUG|[14C] AZD6738|radiolabeled AZD6738 / ceralasertib
219208420|NCT06754761|DRUG|AZD6738 / ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR
219208421|NCT04198194|DIAGNOSTIC_TEST|Predictors of events|Apple Heart \& Movement Study in Apple Research app
219208422|NCT04908514|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
219208423|NCT05977023|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
219208424|NCT05977023|DRUG|Placebo Cap|Use of placebo as a comparator.
219664223|NCT06557421|DRUG|Azacitidine|complete discontinuation of Azacitidine
219664224|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
219664225|NCT04349046|DEVICE|Total hip arthoplasty (THA)|Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relieve pain and debilitating symptoms. THA was traditionally performed on patients over 60 years old, but now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications of THA include osteoarthritis, rheumatoid arthritis, avascular necrosis and hip fractures. The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.
218972449|NCT07150689|PROCEDURE|Combined Flexible-Rigid Bronchoscopy|Initial flexible bronchoscopy will be performed to locate the foreign body and inspect distal airways, followed by rigid bronchoscopy for definitive removal.
218972450|NCT07150689|PROCEDURE|Imaging-Guided Bronchoscopy|Participants will undergo pre-procedure high-resolution CT or virtual bronchoscopy. Based on imaging, either rigid or flexible bronchoscopy will be performed, targeting the suspected location to reduce procedure time.
218972451|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
218972452|NCT06275620|BIOLOGICAL|AGTC-501 (low dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
218972453|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and modified corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
218972454|NCT02286557|DRUG|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
218972455|NCT02286557|DRUG|Placebo|
218972456|NCT05165225|DRUG|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
218972457|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
218972458|NCT00492050|DRUG|Bortezomib|1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
218972459|NCT00492050|DRUG|Rituximab|375 mg/m\^2 IV on Day 8 and 22.
218972460|NCT00492050|DRUG|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
218972461|NCT05766501|DRUG|DOR/ISL|FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
218972462|NCT00239902|DRUG|FTY720|
218972463|NCT02037958|DEVICE|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
218972464|NCT02037958|DEVICE|Endotracheal Tube|Patients who receive endotracheal intubation
218972465|NCT04954287|BIOLOGICAL|CVXGA1 low dose|see arm/group description
218972466|NCT04954287|BIOLOGICAL|CVXGA1 high dose|see arm/group description
218972467|NCT02947555|OTHER|Non interventional|
218972468|NCT05693116|PROCEDURE|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
218972469|NCT05594654|OTHER|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
218972470|NCT02207023|BEHAVIORAL|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
218972471|NCT02932215|DRUG|lorcaserin|Open label
218972472|NCT02932215|OTHER|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
218972473|NCT05289427|PROCEDURE|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
218972474|NCT05289427|PROCEDURE|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
218972475|NCT04625816|DEVICE|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
218972476|NCT04046198|OTHER|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
218972477|NCT04231890|OTHER|IPI monitoring|Patients in this arm will have IPI monitoring
218972478|NCT04567823|DIETARY_SUPPLEMENT|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
218972479|NCT02828969|OTHER|Phone call or physical consultation|
218972480|NCT02400177|BEHAVIORAL|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
218972481|NCT05191563|DRUG|HCP1904-1|Take it once per period.
218972482|NCT05191563|DRUG|RLD2006|Take it once per period.
218972483|NCT05191563|DRUG|RLD2001-2|Take it once per period.
219065528|NCT01678326|PROCEDURE|Advanced ERCP Biliary Access Techniques|
219065529|NCT03779386|OTHER|music|music during labor and delivery
219065530|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
219065531|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
219065532|NCT01286259|DRUG|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
219065533|NCT06262035|OTHER|Periodontitis and Peri-implantitis|Defined periodontitis at ≤ 2 non-adjacent teeth AND Defined peri-implantitis at ≤ 1 implant, in function of at least 1 year.
219065534|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
219065535|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
219065536|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
219065537|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
219065538|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
219065539|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
219065540|NCT03607305|PROCEDURE|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
219065541|NCT03607305|PROCEDURE|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
219065542|NCT03348254|DRUG|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
219664226|NCT05567406|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
219664227|NCT05064553|DEVICE|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
218972484|NCT05830773|OTHER|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
218972485|NCT03400995|DRUG|AK0529|A solution containing 300 mg radiolabelled AK0529.
218972486|NCT01297556|BEHAVIORAL|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
218972487|NCT04359667|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
218972488|NCT01817244|OTHER|care management|6-month care management
218972489|NCT02652832|DEVICE|non invasive brain stimulation|non invasive brain stimulation
218972490|NCT01897714|DRUG|Melflufen|
218972491|NCT01897714|DRUG|Dexamethasone|
218972492|NCT03905408|DRUG|50 mL of 50% Glucose|1st dose
218972493|NCT03905408|DRUG|100 mL of 50% Glucose|2nd dose
218972494|NCT03905408|DRUG|150 mL of 50% Glucose|3rd dose
218972495|NCT03905408|DRUG|200 mL of 50% Glucose|4th dose
218972496|NCT06129162|DEVICE|Conventional Syringe|Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
218972497|NCT06129162|DEVICE|STA Single Tooth Anesthesia® System.|Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
218972498|NCT06129162|DEVICE|Star Pen anesthesia device.|Dental local anesthesia injection is given by Star Pen anesthesia device by two injection methods inferior alveolar nerve block and buccal infiltration.
218972499|NCT06556836|DEVICE|Doppler color and M-Mode ultrasound|A diagnostic test intervention using color Doppler and M-Mode ultrasound will be conducted to localize the catheter within the epidural space and compared with epidurography.
218972500|NCT06556836|DEVICE|Epidurography|An epidurography is an imaging procedure used to visualize the epidural space of the spine. The process involves inserting an epidural catheter, through which a contrast dye is injected. Fluoroscopy or X-rays are then used to capture real-time images of the contrast flow, helping to ensure the catheter's correct placement and to detect any localization anomalies. In this study, the epidurography will be performed in the radiology department by a radiologist and a pain management interventionist.
218972501|NCT05938842|BEHAVIORAL|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
219664228|NCT05064553|DEVICE|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
219065543|NCT03348254|DRUG|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
219664229|NCT05064553|DIAGNOSTIC_TEST|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
219664230|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
219664231|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
219664232|NCT05783466|OTHER|Low-fat dairy products|3-month intervention
219664233|NCT05783466|OTHER|Whole-fat dairy products|3-month intervention
219664234|NCT05783466|OTHER|Milk polar lipid enriched whole-fat dairy products|3-month intervention
219065544|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
219065545|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
219065546|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
219065547|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
219664235|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
218972502|NCT05938842|BEHAVIORAL|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz \& Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz \& Oz, 2020; Dowd et al., 2015).
218972503|NCT03102333|DEVICE|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
218972504|NCT03102333|DEVICE|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
218972505|NCT00423722|DRUG|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
218972506|NCT00423722|DRUG|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
219065548|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
219065549|NCT01334697|DRUG|recombinant human cardiotrophin-1|Single dose intravenous administration
219065550|NCT01334697|OTHER|Placebo|Single dose intravenous administration
219065551|NCT02416323|OTHER|AIM HI Training|
219065552|NCT00325299|DRUG|Magnesium|
219065553|NCT06446804|OTHER|None, pure observationnal study|Pure observatonnal study
219065554|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
219065555|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
219664236|NCT01166854|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
219664237|NCT06517797|DRUG|S1B-509 low dose|S1B-509 has multiple neurotransmitter activities
218972507|NCT05922111|DEVICE|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
218972508|NCT05922111|DEVICE|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
218972509|NCT06354062|BEHAVIORAL|Talent management intervention program|Talent management intervention program
219664238|NCT06517797|DRUG|Placebo|matched pills to S1B-509
219664239|NCT06517797|DRUG|S1B-509 High Dose|S1B-509 has multiple neurotransmitter activities
218972510|NCT00293527|DRUG|Interferon Alpha-2b|
219065556|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
219686554|NCT00523055|DRUG|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
219686555|NCT00003522|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219686556|NCT00540670|DRUG|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
218972511|NCT04205708|DIAGNOSTIC_TEST|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
218972512|NCT04205708|DIAGNOSTIC_TEST|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
218972513|NCT04205708|DIAGNOSTIC_TEST|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
218972514|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
218972515|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
218972516|NCT06204978|OTHER|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
218972517|NCT05578079|OTHER|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
218972518|NCT05578079|OTHER|Music|Intervention-2 group will listen to lullaby.
218972519|NCT02604056|BEHAVIORAL|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
218972520|NCT02604056|BEHAVIORAL|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
218972521|NCT03507231|BEHAVIORAL|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
218972522|NCT03507231|BEHAVIORAL|Incentive for Vaccination|$5 gift card offered for vaccination
218972523|NCT03507231|BEHAVIORAL|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
218972524|NCT02746172|DEVICE|Cochlear implant with in-situ audiometry|
218972525|NCT05509270|BEHAVIORAL|Letter|Mailed letter about flu vaccination
218972526|NCT05509270|BEHAVIORAL|Patient portal|Patient portal message about flu vaccination
218972527|NCT05509270|BEHAVIORAL|SMS|SMS about flu vaccination
218972528|NCT00683085|BIOLOGICAL|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
218972529|NCT01842022|DIETARY_SUPPLEMENT|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
218972530|NCT01842022|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
218972531|NCT01842022|DIETARY_SUPPLEMENT|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
218972532|NCT01846104|BIOLOGICAL|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
218972533|NCT03094403|DRUG|Azelaic Acid 15% topical gel|Gel
218972534|NCT03094403|DRUG|Finacea® (azelaic acid) Gel, 15%|Gel
218972535|NCT03094403|DRUG|Placebo|Gel
218972536|NCT01262131|DEVICE|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
218972537|NCT01262131|DEVICE|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
218972538|NCT01262131|DEVICE|placebo therapy|Application of inactive magnetic fields using the Resonator device
218972539|NCT02983565|DEVICE|Intelligent oxygen therapy system (iO2Ts)|
218972540|NCT05210673|OTHER|ERAS|Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
218972541|NCT05210673|OTHER|Non ERAS pathway|standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
219065557|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
219065558|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
219065559|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
219065560|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
219065561|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
219065562|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
218972542|NCT00851630|DRUG|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
219664240|NCT05485233|DEVICE|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
219664241|NCT06279494|DRUG|Sirolimus|Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT
219664242|NCT06279494|DRUG|Abatacept|5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT
219664243|NCT06279494|DRUG|MMF|0.5g bid orally, from -3d to +60d post haplo-HSCT
219664244|NCT06279494|DRUG|ATG|2.5 mg/kg, from -5d to -2d
219664245|NCT03832673|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
218972543|NCT03940287|OTHER|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
218972544|NCT03940287|OTHER|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
218972545|NCT03940287|OTHER|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
218972546|NCT03464578|PROCEDURE|Therapy of proximal humeral fractures (irrespective conservative or operative)|
218972547|NCT02349061|DRUG|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
218972548|NCT02349061|DRUG|Placebo Infusion|Placebo intravenously at Week 0.
218972549|NCT02349061|DRUG|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
218972550|NCT02349061|DRUG|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
218972551|NCT02349061|OTHER|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
218972552|NCT05500157|PROCEDURE|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
218972553|NCT02772107|DRUG|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
219664246|NCT03832673|DRUG|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
219664247|NCT05916131|BEHAVIORAL|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
219664248|NCT05916131|BEHAVIORAL|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
219664249|NCT05916131|BEHAVIORAL|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
219664250|NCT06271486|DRUG|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
219664251|NCT06271486|BIOLOGICAL|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
219664252|NCT06271486|COMBINATION_PRODUCT|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
219065563|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
219065564|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
219664253|NCT04404829|OTHER|Manual Therapy|"The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM."
219664254|NCT02289105|BEHAVIORAL|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
218972554|NCT02772107|DRUG|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
218972555|NCT02772107|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
218972556|NCT02772107|RADIATION|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
218972557|NCT03691155|OTHER|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
218972558|NCT02883959|OTHER|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
218972559|NCT03854201|BEHAVIORAL|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
218972560|NCT05138211|DEVICE|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. \- Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. \- Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. \- Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
218972561|NCT05565131|DEVICE|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
218972562|NCT02339285|DEVICE|tACS (alpha)|
218972563|NCT02339285|DEVICE|tACS (gamma)|
219065565|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
219065566|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
219065567|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
219065568|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
219065569|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
219664255|NCT03943823|DRUG|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
219664256|NCT03943823|DRUG|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
219065570|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
219065571|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
219065572|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
219065573|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
219065574|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
219065575|NCT05509972|DEVICE|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
219065576|NCT02578524|OTHER|Survey|
219065577|NCT04202159|DRUG|Perampanel|Perampanel tablets.
219065578|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
219065579|NCT00111943|DRUG|1% tenofovir gel|
219065580|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
219065581|NCT00142909|DRUG|Placebo|Lofexidine Placebo
219664257|NCT02590874|DRUG|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
219664258|NCT02590874|DRUG|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
219664259|NCT03453281|DRUG|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
219664260|NCT05861102|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
219664261|NCT05861102|DRUG|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
219664262|NCT01010958|DRUG|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
219664263|NCT01306435|OTHER|Laser|3-week treatment with three Laser sessions per week
219664264|NCT01306435|OTHER|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
218972564|NCT05457426|PROCEDURE|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
218972565|NCT06556498|PROCEDURE|Proflor group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Proflor mesh.
218972566|NCT06556498|PROCEDURE|Progrip group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Progrip mesh.
218972567|NCT00342940|BIOLOGICAL|influenza surface antigen inactivated vaccine|
218972568|NCT03714971|BEHAVIORAL|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
218972569|NCT03024619|OTHER|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
218972570|NCT03228264|DEVICE|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
219065582|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
219065583|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
219065584|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
219065585|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
219065586|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
219065587|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
219065588|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
219664265|NCT06254235|DRUG|The test octreotide microsphere|A single intramuscular dose of the test octreotide microsphere 30mg,
219664266|NCT06254235|DRUG|The reference octreotide microsphere|A single intramuscular dose of the reference octreotide microsphere 30mg
219664267|NCT06330220|DRUG|Aflibercept Injection [Eylea]|intravitreal injection
219664268|NCT01688141|OTHER|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
219664269|NCT02129634|DEVICE|CB-PTA|
219664270|NCT02129634|DEVICE|DEB-PTA|
219664271|NCT04110717|DEVICE|Vestal Device|Vestibular nerve stimulator
219664272|NCT04110717|DEVICE|Control Device|Control Device
219664273|NCT04110717|BEHAVIORAL|Hypocaloric Diet|Hypocaloric diet
219686557|NCT00540670|DRUG|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
219686558|NCT00540670|DRUG|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
219686559|NCT00540670|DRUG|Placebo|Placebo (tablet) taken orally, once a day.
219664274|NCT01167634|BEHAVIORAL|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
219664275|NCT01167634|BEHAVIORAL|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
219664276|NCT01167634|BEHAVIORAL|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
219664277|NCT00822224|DRUG|MEOPA|inhalation of MEOPA during the painful care
219664278|NCT01768221|BEHAVIORAL|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
219664279|NCT01179789|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
219664280|NCT01179789|DIETARY_SUPPLEMENT|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
219664281|NCT01179789|DIETARY_SUPPLEMENT|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
219664282|NCT01179789|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
219664283|NCT03462992|DIAGNOSTIC_TEST|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
219664284|NCT00346567|DRUG|Zidovudine and Lamivudine (Combivir)|
219664285|NCT00346567|DRUG|Emtricitabine and Tenofovir (Truvada)|
219664286|NCT05476640|GENETIC|NGS|In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
219664287|NCT06014125|OTHER|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
219664288|NCT02603107|DRUG|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
218972571|NCT03228264|DEVICE|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
218972572|NCT05993039|DRUG|Isoflurane Inhalant Product|1.5-2%
218972573|NCT05993039|DRUG|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
219664289|NCT02603107|DRUG|ATV|300 mg capsule administered orally once daily with food
218972574|NCT05993039|DRUG|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
218972575|NCT05993039|DRUG|Remifentanil Injection|0.05-2ug/kg/min adults and children
218972576|NCT06077448|DEVICE|MRI|imaging modality
219065589|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
218972577|NCT02469207|OTHER|Removal of tissue post-mortem|
218972578|NCT03061097|BIOLOGICAL|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
219065590|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
219065591|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
219065592|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
219065593|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
219065594|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
219664290|NCT02603107|DRUG|DRV|800 mg tablet administered orally once daily with food
219664291|NCT02603107|DRUG|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
219664292|NCT02603107|DRUG|ATV/co|300/150 mg FDC tablet administered orally once daily with food
219664293|NCT02603107|DRUG|DRV/co|800/150 mg FDC tablet administered orally once daily with food
219664294|NCT02603107|DRUG|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
219664295|NCT02603107|DRUG|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
219664296|NCT02603107|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
219664297|NCT02001272|DRUG|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
219664298|NCT02001272|DRUG|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
219664299|NCT02001272|DRUG|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
219664300|NCT04170101|PROCEDURE|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
218972579|NCT03061097|OTHER|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
218972580|NCT05410015|OTHER|Normal clinical treatment without intervention|Normal clinical treatment without intervention
219065595|NCT01089140|DRUG|Saline solution|Saline placebo
219065596|NCT02221115|DEVICE|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
218972581|NCT05803629|DIAGNOSTIC_TEST|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
218972582|NCT05803629|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
218972583|NCT05712876|DRUG|CK-0045|Interleukin-22 agonist
218972584|NCT05712876|DRUG|Placebo|Matching placebo
218972585|NCT00004920|DRUG|cisplatin|
218972586|NCT00004920|DRUG|raltitrexed|
218972587|NCT04877743|OTHER|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
218972588|NCT02616419|DEVICE|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
218972589|NCT02616419|DRUG|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
219065597|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
219664301|NCT04170101|PROCEDURE|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
219664302|NCT00812500|OTHER|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
219664303|NCT00812500|OTHER|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
219664304|NCT00812500|OTHER|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
219664305|NCT05180981|DEVICE|Transcutaneous vagal nerve stimulation|Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
219664306|NCT05180981|BEHAVIORAL|Breathing task|Participants will be asked to breathe in specific patterns.
219664307|NCT01000181|OTHER|PET-CT with CuATSM|PET-CT with CuATSM
219664308|NCT00013923|DRUG|Nutritional Supplement|
219686560|NCT04536675|DRUG|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
219686561|NCT04536675|DRUG|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
219686562|NCT03442231|DEVICE|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
219686563|NCT01570842|OTHER|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
219686564|NCT01570842|PROCEDURE|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
219686565|NCT03831919|DEVICE|SYNC III|Hoya SYNC III design spectacle lenses
219686566|NCT03831919|DEVICE|single vision lenses|single vision spectacle lenses with no addition
219686567|NCT04961697|BEHAVIORAL|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
219686568|NCT05027815|BIOLOGICAL|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
219664309|NCT01956864|DRUG|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
219664310|NCT00951106|DRUG|Pyrimethamine/sulfdoxine (Fansidar)|
219065598|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
219664311|NCT02565199|DEVICE|rTMS over Premotor Cortex (Contralateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
219664312|NCT02565199|DEVICE|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
219664313|NCT02565199|DEVICE|rTMS (Control 1)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
219664314|NCT02565199|DEVICE|rTMS (Control 2)|"* Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
219664315|NCT02565199|DEVICE|rTMS (Control 3)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
219664316|NCT02565199|OTHER|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
219664317|NCT02826252|DRUG|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
219664318|NCT02826252|DEVICE|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
219664319|NCT02503371|OTHER|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
219664320|NCT01325571|DRUG|Tacrolimus capsule|oral
218972590|NCT03180697|DIAGNOSTIC_TEST|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
218972591|NCT02746068|DRUG|AXS-02|
218972592|NCT02746068|DRUG|Placebo|
219065599|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
219065600|NCT02855905|OTHER|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
219664321|NCT01325571|DRUG|Placebo|oral
219664322|NCT05606770|BEHAVIORAL|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
219664323|NCT05606770|BEHAVIORAL|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
219664324|NCT03681041|OTHER|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
219664325|NCT02227719|DEVICE|CTI|CTI is the titanium mesh
218972593|NCT02580903|RADIATION|Radiology|Only a small subsample will require CT and right heart catherisation
218972594|NCT00612183|DRUG|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
218972595|NCT03498066|DRUG|Beta-blockers withdrawal|withdrawal of all type of betablockers
219065601|NCT03500874|DRUG|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
219065602|NCT03500874|DRUG|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
218972596|NCT03498066|DRUG|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
219065603|NCT03500874|DRUG|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
219065604|NCT03500874|DRUG|5FU|5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
219065605|NCT03500874|DRUG|Irinotecan|Irinotecan 180mg/m2
219664326|NCT02227719|DEVICE|Collagen membrane|
219664327|NCT05332717|DIETARY_SUPPLEMENT|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
219664328|NCT05332717|DIETARY_SUPPLEMENT|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
218972597|NCT02479269|OTHER|Aerobic exercise|Aerobic exercise for 8 weeks
218972598|NCT06170892|OTHER|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
218972599|NCT03996759|DIAGNOSTIC_TEST|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
218972600|NCT00137631|BEHAVIORAL|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
218972601|NCT04202471|DEVICE|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
218972602|NCT02601599|BEHAVIORAL|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
218972603|NCT05149599|DRUG|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
218972604|NCT06558084|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor in first and second lines
218972605|NCT03179527|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
218972606|NCT03179527|DRUG|Lipid Regulating Drugs|Mainly including statins
218972607|NCT03179527|DRUG|Coronary Vasodilator|Mainly including nitrates
218972608|NCT03179527|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
218972609|NCT06569251|DRUG|Dexamethasone 12 mg QD|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
218972610|NCT06569251|DRUG|Dexamethasone 6 mg BID|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
218972611|NCT04920981|OTHER|atezolizumab|observational
218972612|NCT00560469|OTHER|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
219065606|NCT02985658|DRUG|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
219065607|NCT02985658|DRUG|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
219065608|NCT02985658|DRUG|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
219065609|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
219664329|NCT04862832|OTHER|Music intervention|"The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions."
219664330|NCT01841801|DEVICE|Thermal Adhesive Patch|
219664331|NCT01841801|DEVICE|Marketed Thermal Adhesive Patch|
219664332|NCT01841801|DEVICE|Placebo Patch|
219664333|NCT03668522|OTHER|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
219664334|NCT03191123|PROCEDURE|hepatic resection|The aim of this intervention is to reach curative resection.
219664335|NCT03191123|PROCEDURE|TACE|The aim of this intervention is one of the palliative treatment.
218972613|NCT04860427|DEVICE|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
218972614|NCT04860427|DEVICE|two miniplates|two miniplates open reduction and fixation
218972615|NCT00761579|DRUG|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
218972616|NCT03253458|DEVICE|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
218972617|NCT01749774|BEHAVIORAL|Physical activity counseling|
218972618|NCT00598702|DRUG|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
218972619|NCT04920422|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
219065610|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
219664336|NCT00714155|OTHER|Questionnaires, Physical Examination|Questionnaires, Physical Examination
219664337|NCT00814541|DRUG|Bortezomib|
219664338|NCT00814541|DRUG|Doxorubicin|
219664339|NCT00814541|DRUG|Dexamethasone|
219664340|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
219664341|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
219664342|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
219664343|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
218972620|NCT01556737|DIETARY_SUPPLEMENT|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
218972621|NCT01556737|DIETARY_SUPPLEMENT|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
218972622|NCT03287583|BEHAVIORAL|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
218972623|NCT03287583|OTHER|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
218972624|NCT01387399|PROCEDURE|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
218972625|NCT05385185|DRUG|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
218972626|NCT05123911|OTHER|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
218972627|NCT05123911|OTHER|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
218972628|NCT05123911|OTHER|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
218972629|NCT02607007|OTHER|2% M.F. Milk|
218972630|NCT02607007|OTHER|White Bread|
218972631|NCT02607007|OTHER|Strawberry Jam|
218972632|NCT02607007|OTHER|31% M.F. Cheddar Cheese|
218972633|NCT02607007|OTHER|2% M.F. Plain Greek yogurt|
218972634|NCT02607007|OTHER|Soy Beverage|
218972635|NCT02607007|OTHER|Water|
218972636|NCT01813110|DRUG|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
218972637|NCT01813110|DRUG|Placebo|olive oil
218972638|NCT01621503|DEVICE|NT-530P|intraocular pressure and central corneal thickness measurement
218972639|NCT00289484|DRUG|Omega-3 Polyunsaturated Fatty Acids|
218972640|NCT04708600|BEHAVIORAL|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
218972641|NCT04708600|BEHAVIORAL|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise"
218972642|NCT04708600|BEHAVIORAL|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns"
218972643|NCT01859143|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
218972644|NCT01859143|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
218972645|NCT02712255|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
219065611|NCT01910519|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
219065612|NCT01910519|BIOLOGICAL|H5N1 vaccine without adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
219065613|NCT04266028|BIOLOGICAL|DM-101|DM-101 administered by subcutaneous (SC) injection
219664344|NCT03439410|OTHER|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
219664345|NCT04933864|DRUG|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed."
219664346|NCT00460356|OTHER|Laboratory Biomarker Analysis|Correlative studies
219664347|NCT00460356|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
219664348|NCT00869583|BEHAVIORAL|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
219664349|NCT01621828|OTHER|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
218972646|NCT02712255|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
218972647|NCT02712255|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
218972648|NCT02712255|BEHAVIORAL|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
218972649|NCT02126358|DRUG|Gemigliptin and/or Rosuvastatin|
218972650|NCT00438451|DRUG|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
218972651|NCT00438451|DRUG|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
218972652|NCT00438451|DRUG|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
218972653|NCT00540319|BEHAVIORAL|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
218972654|NCT05702866|DIAGNOSTIC_TEST|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
218972655|NCT04672720|DRUG|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
218972656|NCT04433533|DRUG|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
218972657|NCT04433533|DRUG|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
218972658|NCT00689598|DRUG|Spironolactone|25 mg po qd 25 mg po bid
218972659|NCT00689598|DRUG|Placebo|Spironolactone 25 mg po qd
218972660|NCT06038981|DRUG|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
218972661|NCT02413372|DRUG|BMS-986036|
218972662|NCT02413372|DRUG|BMS-986036|
218972663|NCT02413372|DRUG|Placebo|
218972664|NCT02404467|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
219065614|NCT04266028|BIOLOGICAL|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
219065615|NCT01563861|GENETIC|RNA analysis|
219065616|NCT01563861|GENETIC|gene expression analysis|
219065617|NCT01563861|OTHER|immunohistochemistry staining method|
219065618|NCT01563861|OTHER|laboratory biomarker analysis|
219664350|NCT01621828|OTHER|leaflet|a written leaflet, about the operating room experience and environment.
219664351|NCT05196477|DRUG|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
219664352|NCT05196477|DRUG|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
219664353|NCT04819477|BEHAVIORAL|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
219664354|NCT04819477|BEHAVIORAL|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
219664355|NCT03411902|DRUG|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
219664356|NCT03411902|OTHER|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
219664357|NCT00839787|DRUG|Morphine Sulfate|Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
219664358|NCT01322698|BIOLOGICAL|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
219664359|NCT05777083|DIAGNOSTIC_TEST|KardiaMobile 6L|Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).
218972665|NCT05092854|OTHER|PR Lotion - AMP Human Performance|"Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03"
218972666|NCT05092854|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
218972667|NCT05092854|OTHER|AminoVital - Rapid Recovery|AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
218972668|NCT05092854|OTHER|Placebo Supplement|Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
218972669|NCT00452855|PROCEDURE|Sevoflurane-remifentanil anaesthesia|
218972670|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
218972671|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
219360298|NCT06541873|OTHER|Clinical and gait evaluation|The dual-task conditions to be assessed during gait performance will include: counting backwards by 3 (executive simple task); counting backwards by 7 (executive complex task); mnemonic recall of the Rey's Auditory Verbal Learning Test (RAVLT). Performance scores will be correlated with cognitive status and clinical features. Data will be collected at the baseline (i.e., only) visit within the enrollment timeframe of 3 years from study initiation.
219664360|NCT00456261|DRUG|Pemetrexed|pemetrexed 500 mg/m2
219664361|NCT00456261|DRUG|Gemcitabine|gemcitabine 1500 mg/m2
219664362|NCT00456261|DRUG|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
219664363|NCT00456261|DRUG|Carboplatin|carboplatin AUC=5
219664364|NCT02156063|DRUG|NT100|
219664365|NCT02156063|DRUG|Placebo|
218972672|NCT04587271|DIETARY_SUPPLEMENT|Placebo|Mothers and children will receive porridge with placebo.
219664366|NCT00624039|OTHER|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
219664367|NCT00190658|DRUG|Somatropin (rDNA origin) for injection|
219664368|NCT04217824|PROCEDURE|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
219664369|NCT02917655|BEHAVIORAL|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
219664370|NCT02917655|BEHAVIORAL|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
219664371|NCT02917655|BEHAVIORAL|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
219664372|NCT02917655|BEHAVIORAL|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
219664373|NCT02917655|BEHAVIORAL|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
219664374|NCT02917655|BEHAVIORAL|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
219664375|NCT02917655|BEHAVIORAL|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
219664376|NCT02917655|BEHAVIORAL|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
219664377|NCT02917655|BEHAVIORAL|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
219664378|NCT02917655|BEHAVIORAL|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
219664379|NCT02917655|BEHAVIORAL|Sessions with the physical educators team|Participate in a extra session group with the physical educators
219664380|NCT02917655|BEHAVIORAL|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
219664381|NCT02917655|BEHAVIORAL|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
219664382|NCT03485703|DRUG|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
219664383|NCT03485703|DRUG|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
219664384|NCT06070675|DEVICE|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
219664385|NCT06070675|OTHER|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
219664386|NCT03147807|DEVICE|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
219664387|NCT03613688|DIETARY_SUPPLEMENT|Deepure|Pu'erh Tea extract
218972673|NCT06407271|DEVICE|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
218972674|NCT06407271|DEVICE|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
218972675|NCT05906979|OTHER|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
218972676|NCT05906979|OTHER|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
219664388|NCT05008471|DIETARY_SUPPLEMENT|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
219664389|NCT02945111|BEHAVIORAL|Real-time view|
219664390|NCT02945111|BEHAVIORAL|No visual support|
219664391|NCT05891106|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
219664392|NCT01981070|BEHAVIORAL|Mindfulness Intervention for Parents|See Study Arms
218972677|NCT00739999|DRUG|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
218972678|NCT00739999|DRUG|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
219360299|NCT02021409|DRUG|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
219360300|NCT02021409|BIOLOGICAL|Darbepoetin alfa|
219664393|NCT01981070|BEHAVIORAL|Support and Information for Parents|See Study Arms
219664394|NCT02206737|DEVICE|No nicotine e-cigarette|
219664395|NCT02206737|DEVICE|Low dose nicotine e-cigarette|
219664396|NCT02206737|DEVICE|High dose nicotine e-cigarette|
219664397|NCT05872659|OTHER|normal saline|iv at D0, D30, D60
219664398|NCT05872659|BIOLOGICAL|Mesenchymal stem cells|iv at D0, D30, D60
219664399|NCT00419159|DRUG|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
219664400|NCT04859309|BEHAVIORAL|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
219664401|NCT04859309|PROCEDURE|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
219664402|NCT00187278|DEVICE|Biventricular Pacing|Biventricular Pacemaker implant
219664403|NCT00187278|DEVICE|RV Pacing|Standard Pacemaker implant
219664404|NCT04949204|PROCEDURE|Wearable sensor detection|Empatica E4 wearable wrist sensor
219664405|NCT06320158|OTHER|clinical evaluation of sarcopenic obesity|completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
219664406|NCT00803205|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
219664407|NCT00803205|DRUG|Placebo|Placebo matching to ataluren will be provided.
219664408|NCT02126124|DEVICE|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
219065619|NCT04450589|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
219065620|NCT04450589|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219065621|NCT04450589|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219664409|NCT02126124|DEVICE|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
219664410|NCT00146900|PROCEDURE|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
219664411|NCT00146900|PROCEDURE|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
219664412|NCT00146900|DRUG|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
219664413|NCT00146900|OTHER|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
218972679|NCT01310504|PROCEDURE|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
218972680|NCT01310504|PROCEDURE|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
218972681|NCT02586051|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
218972682|NCT02586051|DRUG|Intravenous Immunoglobulin|High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
218972683|NCT05546918|OTHER|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups"
218972684|NCT02563990|PROCEDURE|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
218972685|NCT02563990|PROCEDURE|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
218972686|NCT00093782|DRUG|temsirolimus|Given IV
219065622|NCT04450589|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
219360301|NCT02303717|DEVICE|Percutaneous coronary intervention|Percutaneous coronary stent implantation
219664414|NCT06730620|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
219664415|NCT06730620|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）|Cholinergic agonists
219664416|NCT04885894|DRUG|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
219664417|NCT03276468|DRUG|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
219664418|NCT03276468|DRUG|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
218972687|NCT00093782|OTHER|laboratory biomarker analysis|Correlative studies
218972688|NCT02010827|BIOLOGICAL|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
218972689|NCT02010827|BIOLOGICAL|Oral glucose tolerance test, day A|
218972690|NCT02010827|BIOLOGICAL|intravenous iv glucose infusion, day B|
218972691|NCT01490554|PROCEDURE|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
218972692|NCT01995630|DEVICE|AMO Tecnis ZA9003|
218972693|NCT01995630|DEVICE|AMO Sensar AR40e|
218972694|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
218972695|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
218972696|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
218972697|NCT00395772|DRUG|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
218972698|NCT02180165|DRUG|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
218972699|NCT02180165|DRUG|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
218972700|NCT00826761|DIETARY_SUPPLEMENT|probiotic|One capsule per meal test (high dose or low dose)
219664419|NCT03276468|DRUG|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
219664420|NCT05604794|COMBINATION_PRODUCT|Ketamine-Assisted Psychotherapy (KAP)|KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
219664421|NCT04116723|DEVICE|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
219664422|NCT00270231|DRUG|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
219664423|NCT00270231|DRUG|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
219664424|NCT03099772|BEHAVIORAL|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
219664425|NCT02735096|DEVICE|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
219664426|NCT00379808|DRUG|montelukast|10 mg tablet (masked by capsule) daily for 1 month
219664427|NCT00379808|DRUG|Placebo|1 lactose-containing capsule daily for 1 month
219664428|NCT04097197|BEHAVIORAL|Brief educational intervention|same as before
219664429|NCT01432561|DRUG|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
219664430|NCT03689101|PROCEDURE|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
219664431|NCT01388504|DRUG|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
219664432|NCT01388504|OTHER|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
219664433|NCT02930746|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
218972701|NCT00826761|DIETARY_SUPPLEMENT|placebo|1 capsuel every morning
218972702|NCT06392607|DEVICE|Euclid orthokeratology (standard coating)|Lens with the current coating
218972703|NCT06392607|DEVICE|Euclid orthokeratology (enhanced coating)|Lens with the enhanced coating
218972704|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
219664434|NCT00540904|DRUG|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
219664435|NCT00540904|DRUG|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
219664436|NCT02638376|RADIATION|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
219664437|NCT02638376|PROCEDURE|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
219664438|NCT01904318|DRUG|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
219664439|NCT01904318|DRUG|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
219664440|NCT01904318|DRUG|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
219664441|NCT01904318|DRUG|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
219664442|NCT01904318|DRUG|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
219664443|NCT01904318|DRUG|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
219664444|NCT01904318|DRUG|Placebo|Placebo single dose administration
219664445|NCT05521841|PROCEDURE|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
219686569|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
219065623|NCT04450589|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
219065624|NCT04450589|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219065625|NCT04450589|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219065626|NCT04450589|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
219065627|NCT03846700|DEVICE|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
219065628|NCT03846700|DEVICE|holep|holmium laser enucleation of prostate
219065629|NCT03846700|DEVICE|pvp|photoselectivevaporization of prostate
219065630|NCT06558318|OTHER|Assessment of temporomandibular dysfunction|TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
219065631|NCT01694537|DRUG|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
219065632|NCT01694537|DRUG|placebo|Placebo is made with same size and shape with study drug.
219065633|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
219360302|NCT02303717|DRUG|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
219664446|NCT05521841|PROCEDURE|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
219664447|NCT05999838|DIAGNOSTIC_TEST|HRCT chest visual scoring|"CT-based semi-quantitative scoring will be calculated according to number of lung segments affected on both sides.~The finding on each segment will be given a score from 1 to 4 as follows:~1. for ground glass opacities.~2. for reticulations and fibrotic changes.~3. for bronchiectatic changes.~4. for honeycombing and sub-pleural cysts."
219664448|NCT01451138|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
219664449|NCT01707251|DRUG|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
219664450|NCT01707251|DRUG|Saline|Placebo control
219664451|NCT03901053|DEVICE|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
219664452|NCT03901053|DEVICE|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
219664453|NCT04787328|DRUG|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
219664454|NCT03310892|BEHAVIORAL|Generic message|Generic message
219664455|NCT03310892|BEHAVIORAL|Tailored message|Tailored message
219664456|NCT00703287|OTHER|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
219664457|NCT00703287|OTHER|Physiotherapy|Generic physiotherapy
219664458|NCT04789928|DRUG|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
219664459|NCT01917604|PROCEDURE|open exposure|the open surgical methods of exposing the canine is compared with control
219664460|NCT01917604|PROCEDURE|closed exposure|closed exposure is compared with control
219664461|NCT01186380|DEVICE|PET-512MC|Transesophageal Transducer
219664462|NCT00966901|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
219664463|NCT00966901|DRUG|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
219664464|NCT00966901|DRUG|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
219664465|NCT00966901|RADIATION|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
219664466|NCT00629876|DRUG|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
219664467|NCT04493151|DRUG|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
219664468|NCT02166749|PROCEDURE|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
219664469|NCT03661216|DIETARY_SUPPLEMENT|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
219664470|NCT03661216|OTHER|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
218972705|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
218972706|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
218972707|NCT01884623|DRUG|Cetuximab|
218972708|NCT01884623|DRUG|Methotrexate|
218972709|NCT01008397|DRUG|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
218972710|NCT03036306|DRUG|SCX-001|Nefopam cream formulation
218972711|NCT03036306|OTHER|Placebo|Cream formulation without Nefopam
218972712|NCT01146275|RADIATION|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
219664471|NCT00781170|PROCEDURE|allogeneic hematopoietic SCT|
219664472|NCT04063605|OTHER|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
218972713|NCT03677908|OTHER|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
218972714|NCT05780697|PROCEDURE|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
218972715|NCT02775604|BEHAVIORAL|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
218972716|NCT02775604|BEHAVIORAL|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
218972717|NCT01303354|PROCEDURE|Lumbar Transforaminal Epidural Steroid Injection|
218972718|NCT00051454|BIOLOGICAL|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
218972719|NCT05790083|OTHER|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
218972720|NCT03222011|PROCEDURE|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
219065634|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
219664473|NCT04063605|OTHER|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
219664474|NCT02268370|DRUG|Dasatinib|
219664475|NCT02934087|PROCEDURE|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
219065635|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
219664476|NCT05290480|OTHER|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
219664477|NCT05290480|DEVICE|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
219664478|NCT00207792|DRUG|filgrastim|
218972721|NCT03222011|PROCEDURE|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
218972722|NCT02943460|DRUG|Cilofexor|Tablet(s) administered orally once daily with food
218972723|NCT02943460|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
218972724|NCT05631600|BIOLOGICAL|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
218972725|NCT01176331|PROCEDURE|20 and 23 gauge pars plana vitrectomy|
218972726|NCT02161029|DEVICE|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
218972727|NCT02161029|DEVICE|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
218972728|NCT05400863|BEHAVIORAL|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
218972729|NCT05400863|BEHAVIORAL|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
218972730|NCT03057509|DRUG|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
218972731|NCT03057509|DEVICE|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
218972732|NCT03057509|OTHER|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
219664479|NCT02568618|GENETIC|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
218972733|NCT03057509|DRUG|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
219664480|NCT00162994|PROCEDURE|adenoidectomy and tymapanostomy|
219664481|NCT05648240|OTHER|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
218972734|NCT01925274|DRUG|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
218972735|NCT01925274|DRUG|irinotecan|90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
218972736|NCT01925274|DRUG|Cetuximab|120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
218972737|NCT01925274|DRUG|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
218972738|NCT03761667|OTHER|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
218972739|NCT01967433|DRUG|Diphenhydramine|
218972740|NCT01967433|DRUG|Placebo|
218972741|NCT01031381|DRUG|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
219664482|NCT04779606|DRUG|Ocular gel|3 drops instilled in the right eye
219664483|NCT01561599|DRUG|BB3|Daily intravenous administration of 2mg/kg for 4 days
219664484|NCT01561599|DRUG|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
219664485|NCT02569086|OTHER|Blood draw|
219664486|NCT03914027|BEHAVIORAL|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
219664487|NCT04299048|DRUG|PF-06946860|subcutaneous injection
219664488|NCT00231439|DRUG|IvIg|
219065636|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
219065637|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
219664489|NCT00001047|DRUG|Ethambutol hydrochloride|
219664490|NCT00001047|DRUG|Clarithromycin|
219664491|NCT00001047|DRUG|Clofazimine|
219664492|NCT00001047|DRUG|Rifabutin|
219664493|NCT03784859|DEVICE|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
219664494|NCT06499012|DIETARY_SUPPLEMENT|All-plant Protein Booster Product Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
219664495|NCT06499012|DIETARY_SUPPLEMENT|Placebo Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
219664496|NCT04220086|PROCEDURE|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
219664497|NCT04220086|PROCEDURE|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
219664498|NCT04220086|OTHER|No intervention|No intervention for healthy controls
218972742|NCT01031381|DRUG|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
218972743|NCT05555771|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
218972744|NCT05555771|BEHAVIORAL|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
219664499|NCT05716217|OTHER|Arm training|Daily arm training program
219664500|NCT05576441|PROCEDURE|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
219664501|NCT05576441|PROCEDURE|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
219664502|NCT06446349|OTHER|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
219664503|NCT02140983|DRUG|Liraglutide|90 days of liraglutide up to 1.8mg/day.
219664504|NCT02140983|DRUG|Placebo|Placebo medication
219664505|NCT02262156|OTHER|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
219664506|NCT02262156|DRUG|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
219664507|NCT03559803|DRUG|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
219664508|NCT02710344|BEHAVIORAL|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
219664509|NCT05489419|BEHAVIORAL|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
219664510|NCT06509672|OTHER|Combined Plyometric and Endurance Training|this include Combined Plyometric and Endurance Training for 12 weeks
218972745|NCT00537992|PROCEDURE|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
219664511|NCT06509672|OTHER|Plyometric Training|this include Plyometric Training for 12 weeks
219664512|NCT06509672|OTHER|Endurance training|this include Endurance Training for 12 weeks
219664513|NCT04609241|DRUG|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
219686570|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
219065638|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
219065639|NCT02291627|DEVICE|MAC|direct laryngoscopy
219065640|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
219664514|NCT04229199|BEHAVIORAL|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
219664515|NCT03973333|DRUG|IMC-C103C|Weekly IV infusions
219664516|NCT03973333|DRUG|Atezolizumab|IV infusions every 3 weeks
219664517|NCT03973333|DRUG|IMC-C103C|Weekly subcutaneous Injection
219664518|NCT02722161|DRUG|[14C]BI 1482694|
219664519|NCT02622087|BEHAVIORAL|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
219664520|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
219664521|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
219664522|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
219664523|NCT06731517|PROCEDURE|intubation|Double-Lumen Tube Intubation
218972746|NCT00723398|DIETARY_SUPPLEMENT|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
218972747|NCT00723398|DRUG|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
218972748|NCT00723398|DRUG|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
218972749|NCT00723398|DRUG|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
218972750|NCT05482542|OTHER|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
218972751|NCT05482542|DRUG|Cyclophosphamide/ATG|Cyclophosphamide/ATG
219065641|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
219065642|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
219664524|NCT03066583|BIOLOGICAL|trephination with placebo|trephination under US guidance and placebo injection
219664525|NCT03066583|BIOLOGICAL|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
219664526|NCT04172428|DIAGNOSTIC_TEST|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
219664527|NCT03926468|DIAGNOSTIC_TEST|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
219664528|NCT05830669|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
218972752|NCT05482542|DRUG|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
218972753|NCT06301217|OTHER|There is no intervention|There is no intervention
219664529|NCT05830669|PROCEDURE|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
219686571|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
219065643|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
219208425|NCT06757673|DEVICE|Robot-Assisted Therapy using Kebbi Air|Participants in this group will engage with the Kebbi Air smart robot, which is programmed with interactive scripts designed to enhance social-emotional regulation skills. The intervention includes weekly 30-minute sessions over a 12-week period, where the robot simulates real-life social scenarios and provides verbal and visual responses to guide participants in developing emotional and social skills. Occupational therapists will supervise these sessions to ensure the appropriateness of interactions and provide additional support as needed.
218972754|NCT05927701|OTHER|Group comparaison|Questionnaires
218972755|NCT05044091|DRUG|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
218972756|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
218972757|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
219664530|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
219664531|NCT04875689|OTHER|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations"
219664532|NCT04875689|DIAGNOSTIC_TEST|Group B (Control)|"1\. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
219664533|NCT00221039|DRUG|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
219664534|NCT02801526|DRUG|CKD-330 16/5mg - A|
219664535|NCT02801526|DRUG|Candesartan 16mg and Amlodipine 5mg|
219664536|NCT05412966|DEVICE|PEAR-002B|PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
219664537|NCT05412966|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
219664538|NCT03942003|PROCEDURE|rhomboid blocks|Rhomboid nerve block was performed
219664539|NCT03942003|PROCEDURE|PEC blocks|PEC I-II blocks was performed
219664540|NCT03942003|PROCEDURE|Control groups|Infiltration analgesia was performed
219664541|NCT02942043|DRUG|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
219664542|NCT04292639|DEVICE|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
219664543|NCT04736732|OTHER|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
219664544|NCT05892549|DEVICE|COVOICE application use - initial|Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
219664545|NCT05892549|DEVICE|COVOICE application use - follow-up|Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
218972758|NCT03533101|DRUG|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
218972759|NCT03283111|BIOLOGICAL|autologous stem cell transplantation|autologous stem cell transplantation
218972760|NCT06556784|BEHAVIORAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
218972761|NCT02224092|DIETARY_SUPPLEMENT|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
218972762|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the power arm will be used for canine retraction.
218972763|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the canine bracket will be used for canine retraction.
218972764|NCT00002665|DRUG|asparaginase|10,000 units/d IV or IM 15 - 24
218972765|NCT00002665|DRUG|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
218972766|NCT00002665|DRUG|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
218972767|NCT00002665|DRUG|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
218972768|NCT00002665|DRUG|dexamethasone|main: 10 mg/m2/day PO 1 - 28
218972769|NCT00002665|DRUG|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
218972770|NCT00002665|DRUG|etoposide|60 mg/kg based on ideal body weight day -3
218972771|NCT00002665|DRUG|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
219664546|NCT06366698|DRUG|Venofer 200 MG Per 10 ML Injection|200 mg IV every 2 days until the targeted dose
219664547|NCT06366698|DRUG|Ferrous sulfate|Take 1 tablet every other day with lemon/orange juice
219664548|NCT03423147|DRUG|2% chlorhexidine gluconate cloth|applied to their abdomen
219664549|NCT03423147|DRUG|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
219664550|NCT05508945|DEVICE|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
219664551|NCT05508945|DEVICE|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
219664552|NCT05508945|DEVICE|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
219664553|NCT05913596|DRUG|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
219664554|NCT00508157|DRUG|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
219664555|NCT00508157|DRUG|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
219664556|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
219664557|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
219664558|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219664559|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219664560|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
219664561|NCT02069093|DRUG|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
219664562|NCT02069093|DRUG|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
219664563|NCT02069093|DRUG|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
219664564|NCT06266520|PROCEDURE|MNK therapy to release the superficial fascia|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
219664565|NCT06266520|PROCEDURE|acupuncture|Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
219664566|NCT06811389|BEHAVIORAL|Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP)|"The RISE-HP intervention consists of three components: peer support (peer coach), cognitive restructuring, and patient education. It consists of 10 weekly one-on-one meetings with a peer coach (a person with lived experience with HP who has been trained to deliver the content of the RISE-HP intervention to another person with HP).~The RISE-HP intervention delivered by peer coaches using the principles of cognitive behavioral therapy combined with theory driven patient education targets the health-related quality of life of patients living with hypersensitivity pneumonitis."
219664567|NCT06811389|BEHAVIORAL|Staying Well|The Staying Well intervention consists of 12 weeks of educational sessions. The participants can choose the 10 education sessions out of the 12 they want to cover with the research assistant. Participants will meet weekly with the research coordinator for an estimated 30-45 minutes per session.
219664568|NCT06977230|PROCEDURE|Remote Ischemic Preconditioning|Remote ischemic preconditioning (RIPC) will be performed after anesthesia induction and before surgical incision. A standard blood pressure cuff will be placed on the upper limb (without arterial cannulation), inflated to 200 mmHg for 5 minutes, and then deflated for 5 minutes. This cycle will be repeated five times prior to sternotomy. The procedure will be carried out under general anesthesia, ensuring patient blinding. No pharmacological agents are involved in this intervention
218972772|NCT00002665|DRUG|mercaptopurine|con: 60 mg/m2 PO 1 - 28
218972773|NCT00002665|DRUG|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
218972774|NCT00002665|DRUG|prednisone|"ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
218972775|NCT00002665|DRUG|thioguanine|main: 60 mg/m2/day PO 1 - 14
218972776|NCT00002665|DRUG|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
219664569|NCT03905746|OTHER|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
219664570|NCT03905746|OTHER|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
219664571|NCT03905746|OTHER|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
219664572|NCT05345444|DEVICE|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
218972777|NCT00002665|PROCEDURE|allogeneic bone marrow transplantation|day 0
218972778|NCT00002665|RADIATION|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
218972779|NCT05532787|OTHER|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
219065644|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
219065645|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
219065646|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
219065647|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
219065648|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
219065649|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
219065650|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
219065651|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
219065652|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
219065653|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
219065654|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
219065655|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
219065656|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
219664573|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
219664574|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
219664575|NCT03123029|DRUG|Venetoclax|Venetoclax will be administered orally.
218972780|NCT04396665|BEHAVIORAL|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
218972781|NCT00121264|DRUG|sorafenib tosylate|Given orally
218972782|NCT00121264|DRUG|tanespimycin|Given IV
218972783|NCT00121264|OTHER|laboratory biomarker analysis|Correlative studies
219664576|NCT05981755|OTHER|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
218972784|NCT00121264|OTHER|pharmacological study|Correlative studies
218972785|NCT00121264|PROCEDURE|magnetic resonance imaging|Correlative studies
218972786|NCT01395862|DRUG|Salmeterol and Fluticasone|
218972787|NCT03714802|PROCEDURE|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
218972788|NCT03714802|PROCEDURE|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
218972789|NCT02126371|DRUG|LEO32731|
219664577|NCT05981755|DEVICE|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
218972790|NCT02015585|PROCEDURE|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
218972791|NCT02015585|PROCEDURE|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
218972792|NCT02015585|PROCEDURE|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
218972793|NCT01543971|DRUG|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
218972794|NCT01543971|DRUG|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
218972795|NCT03918889|DRUG|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
218972796|NCT03918889|DRUG|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
218972797|NCT00777205|BEHAVIORAL|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
218972798|NCT00777205|BEHAVIORAL|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
218972799|NCT04298372|DRUG|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
219065657|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
219065658|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
219208426|NCT06757673|BEHAVIORAL|Sensory Integration Therapy|Participants in this group will receive traditional sensory integration therapy guided by occupational therapists. The therapy focuses on improving sensory processing and emotional regulation through structured activities targeting visual, auditory, and tactile stimuli. Each session is conducted weekly, lasting 30 minutes, for a total of 12 weeks. The therapy aims to help children adapt to sensory inputs and enhance their ability to engage in social interactions and manage emotions effectively.
219208427|NCT06757452|DIETARY_SUPPLEMENT|Supplement with curcuminoids|Cal LX is a food-grade dietary supplement based on turmeric, it has been designed to improve physical resistance during exercise, accelerate post-exercise recovery, and reduce the feeling of muscle soreness. Cal LX was determined as not cytotoxic or genotoxic. The supplement or placebo dosage was one (1) 250 mg capsule 45 minutes before exercising.
219208428|NCT06757452|OTHER|Physical excercise|Participants performed 45 minutes of physical activity twice a week. The intervention program included a five-minute warm-up, composed of two series of joint mobility and three series of eight seconds of lower limbs stretching. Then, a routine of intermittent training composed of four six-minute rounds was directed. Each routine included running for 10 seconds and a pause between them. The first round had a 20 s pause, the second round 15 s, and the third and fourth rounds 10 s. Between the rounds was a two-minute passive pause. Finally, three series of twenty seconds of elongation of the lower extremities were required as colling down.
219208429|NCT06757907|DRUG|Acyclovir 400 MG|Acyclovir is used to treat infections caused by certain types of viruses.
219664578|NCT01982838|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
219664579|NCT01982838|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
219664580|NCT01884012|PROCEDURE|long term oxygen therapy|
219208430|NCT06757907|DRUG|Ganciclovir (GCV)|Ganciclovir is an anti-viral drug
219065659|NCT01503905|DRUG|Docetaxel|75mg/m2, iv injection, day1, every 21 days
219065660|NCT01503905|DRUG|epirubicin|80mg/ m2, iv injection, day1, every 21 days
219065661|NCT01503905|DRUG|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
219065662|NCT01503905|PROCEDURE|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
219664581|NCT04306250|PROCEDURE|Apical prolapse fixation - anterior access|The surgery is done in anterior access
219664582|NCT04306250|PROCEDURE|Apical prolapse fixation - posterior access|The surgery is done in posterior access
219065663|NCT01503905|DRUG|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
219065664|NCT01503905|DRUG|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
219664583|NCT00638209|DRUG|Human insulin|
219664584|NCT00638209|DRUG|Saline|
219065665|NCT01503905|DRUG|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
219664585|NCT03274362|BEHAVIORAL|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
219664586|NCT02409381|DRUG|Motore|250 mg
219664587|NCT02409381|DRUG|Alivium|600 mg
219664588|NCT04764786|OTHER|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
219664589|NCT04764786|OTHER|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
219664590|NCT02739308|OTHER|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
219664591|NCT02739308|OTHER|Control Group|The control group will not make the intervention and will continue with usual training fencing.
219664592|NCT02567864|OTHER|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
219664593|NCT02567864|OTHER|control|participants maintain their daily activities.
219664594|NCT06731790|OTHER|Blood sampling for inflammatory phenotype analysis|Blood sampling for basal and post-stimulation inflammatory phenotype analysis
219664595|NCT06731790|GENETIC|Blood sampling for genetic analysis|Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.
218972800|NCT04835519|BIOLOGICAL|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
219664596|NCT03148717|DRUG|Misoprostol|Cytotec
218972801|NCT04674579|DEVICE|MRI|magnetic resonance imaging
218972802|NCT00630474|DRUG|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
218972803|NCT04240470|PROCEDURE|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
218972804|NCT02116218|PROCEDURE|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
218972805|NCT02116218|PROCEDURE|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
218972806|NCT01031602|BEHAVIORAL|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
218972807|NCT03388515|BIOLOGICAL|SSS11|IV infusion for 60 min.
219664597|NCT03148717|OTHER|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
218972808|NCT03388515|OTHER|placebo|IV infusion for 60 min.
218972809|NCT02080910|BEHAVIORAL|Psychoeducation|
218972810|NCT01287078|DRUG|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
218972811|NCT02626767|OTHER|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
218972812|NCT01354067|BEHAVIORAL|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
219664598|NCT05167279|BIOLOGICAL|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
219664599|NCT05167279|BIOLOGICAL|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
219065666|NCT01503905|RADIATION|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
219065667|NCT01503905|DRUG|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
219065668|NCT01503905|DRUG|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
219065669|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
219065670|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
219065671|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
219065672|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
219065673|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
219065674|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
219065675|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
219065676|NCT02720484|DRUG|Nivolumab|Given IV
219664600|NCT04045080|DEVICE|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
219664601|NCT04045080|OTHER|Training|training
219664602|NCT04045080|OTHER|OT Training|training
219664603|NCT01889355|DEVICE|AgaMatrix Blood Glucose Monitor|
219664604|NCT05324280|PROCEDURE|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
219664605|NCT00004358|DRUG|calcitonin|
219664606|NCT04819412|BIOLOGICAL|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
219664607|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
219664608|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F2|ROTAVAC 5C formulation BBIL-R2014-2
219664609|NCT03232164|DRUG|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
218972813|NCT01354067|BEHAVIORAL|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
218972814|NCT05734300|PROCEDURE|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
218972815|NCT05734300|PROCEDURE|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
219065677|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
219065678|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
219065679|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
219065680|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
219065681|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
219065682|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
219065683|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
218972816|NCT01578330|DRUG|Fingolimod|Fingolimod 0.5mg orally once a day without food.
218972817|NCT01676727|DEVICE|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
219065684|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
219065685|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
219065686|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
219065687|NCT03325413|DEVICE|Temperature management|Perioperative warming
219065688|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
219065689|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
219065690|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
219664610|NCT03130283|OTHER|Home Hospitalization|Visit every 24 hours
219664611|NCT03130283|OTHER|Conventional Hospitalization|No intervention
219664612|NCT03854604|OTHER|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
219664613|NCT01222377|PROCEDURE|endoscopic surgery|Undergo endoscopic breast surgery
219664614|NCT01222377|PROCEDURE|quality-of-life assessment|Ancillary studies
219664615|NCT06648720|DRUG|DAPT de-escalation|Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
218972818|NCT04088643|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
218972819|NCT04088643|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
218972820|NCT05464550|BEHAVIORAL|Eye tracker|Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
218972821|NCT00000631|BIOLOGICAL|HIVAC-1e|
218972822|NCT00000631|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
218972823|NCT06210464|OTHER||Trial have no Intervention measures.
218972824|NCT06202417|DRUG|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
218972825|NCT02297243|DEVICE|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
218972826|NCT00544999|DRUG|cytarabine|
218972827|NCT00544999|DRUG|daunorubicin hydrochloride|
218972828|NCT00544999|DRUG|everolimus|
218972829|NCT00544999|OTHER|laboratory biomarker analysis|
218972830|NCT00544999|OTHER|pharmacological study|
219065691|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
219065692|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
219065693|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
219065694|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
219065695|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
219664616|NCT05051800|BEHAVIORAL|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
218972831|NCT03248843|DRUG|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
218972832|NCT03707054|DIAGNOSTIC_TEST|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
218972833|NCT04865640|DIAGNOSTIC_TEST|Noninterventional and noninvasive|The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
218972834|NCT03053271|DRUG|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
218972835|NCT03053271|DRUG|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
218972836|NCT03781544|DRUG|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
218972837|NCT03781544|DRUG|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
218972838|NCT03781544|DRUG|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
219664617|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
219664618|NCT02258334|BIOLOGICAL|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
219664619|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
219664620|NCT02258334|BIOLOGICAL|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
219664621|NCT03532815|BEHAVIORAL|Lifestyle Modification|
219664622|NCT02352987|DRUG|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
219664623|NCT02352987|DRUG|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
219664624|NCT05307185|DIETARY_SUPPLEMENT|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
219664625|NCT00473785|BEHAVIORAL|Group-based motivational interviewing|
219664626|NCT00473785|BEHAVIORAL|Individual CVD-risk factor feedback|
218972839|NCT03105804|OTHER|FT21039|An electronic cigarette
218972840|NCT03105804|OTHER|FT21041|An electronic cigarette
218972841|NCT03105804|OTHER|FT21044|An electronic cigarette
218972842|NCT03105804|OTHER|FT21042|An electronic cigarette
218972843|NCT01292785|DRUG|Hormones|"FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
218972844|NCT03712631|PROCEDURE|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
219664627|NCT00473785|BEHAVIORAL|Education for protective health behavior change|
219664628|NCT01688778|BEHAVIORAL|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
219664629|NCT06020339|OTHER|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
219664630|NCT06613698|DRUG|GSK4532990|GSK4532990 will be administered
219664631|NCT06613698|DRUG|Placebo|Placebo will be administered
219664632|NCT01037036|DRUG|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
218972845|NCT04064385|DEVICE|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
218972846|NCT03830385|DRUG|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
218972847|NCT00600444|PROCEDURE|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
218972848|NCT00600444|PROCEDURE|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
219065696|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
219664633|NCT01037036|DRUG|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
218972849|NCT06058403|DIETARY_SUPPLEMENT|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
218972850|NCT06058403|DIETARY_SUPPLEMENT|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
218972851|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
218972852|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
218972853|NCT02045173|OTHER|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
218972854|NCT02045173|DEVICE|Polysomnography/polygraphy|1 night polysomnography/polygraphy
219664634|NCT07004881|PROCEDURE|Group A (Active Comparator) Mulligan's Mobilization With Movement (MWM)|"This group will receive two techniques of mulligan i.e. Medial Patellar Glide relative to femoral trochlea and other is tibial internal rotation relative to femoral condyles.In Medial Patellar Glide; patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes the posterior aspect of tibia and fibula and with mobilizing hand, the therapist gently glides the patella medially. With that, the patient is asked to actively flex and then extend the knee.~In the tibial internal rotation technique; similarly the patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes t~After mobilization; following exercises are to be performed all in 3 sets of 7 repetitions:~1. Side-lying hip abduction~2. Clamshell exercises~3. Quadriceps setting exercise~4. Vastus Medialis Oblique strengthening~5. Mini squats~6. Hamstring stretch~7. Iliotibial band stretch"
219664635|NCT07004881|PROCEDURE|Group B(Experimental) Maitland's Patellar Mobilizations|"For all the mobilizations the patient is positioned either in supine or sitting with 30-0 degree knee flexion or full knee extension. The therapist holds patella between his/her thumb and index finger and glides it cranially (Superior Patellar glide), caudally (Inferior Patellar Glide) and medially (Medial Patellar Glide). The fourth one i.e. Patellofemoral Distraction is given by grasping the patella between two fingers and lifting it above/away from underlying femoral trochlea. All 4 of these techniques are repeated 10 times with total 3 sets. 3 sessions are performed in a week on alternate days. Total duration of interventions is 2 weeks.~Both groups receive similar exercises therapy following mobilizations."
219664636|NCT04874532|OTHER|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
219664637|NCT04874532|OTHER|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
219664638|NCT06869551|DRUG|Deucravacitinib|Specified dose on specified days
219664639|NCT06869551|OTHER|Placebo|Specified dose on specified days
219664640|NCT06681896|OTHER|MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice|"MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3."
219664641|NCT07015866|OTHER|Guided therapy group|Participants will engage in guided group discussions over five sessions. Each session will include a guided discussion focusing on self-care topics such as sleep hygiene, dental hygiene, nutrition, and personal interests and hobbies. The first individual session, 'Sleep hygiene, will be used to educate the participants of the importance of sleep and strategies to improve sleep quality. The four other sessions will be group-based (with four participants per group), focusing on dental hygiene, nutrition, personal interests and hobbies and general well-being and reflection. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre.
219664642|NCT07015866|OTHER|Creative arts therapy|"The intervention will be offered throughout five sessions. Session themes are as follows: 'bridge drawing', 'analogue drawing', 'life-sized body outline', a 'free session' to allow patients to express their feelings, and a final review with the art therapist in which all sessions will be brought to a conclusion.~The first individual session, 'bridge drawing', will be used to introduce the creative arts therapy approach and to elaborate on this project. The four other sessions will be group-based (with four participants per group), providing a supportive and communal environment where participants can engage in creative expression alongside others who may have had similar experiences or challenges. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre that has been equipped and prepared for the intervention."
219664643|NCT06618326|DEVICE|Acupuncture|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received acupuncture regardless of the number of acupuncture points, frequency, and courses of treatment in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g
219664644|NCT06618326|DEVICE|biofeedback|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary
219664645|NCT04777448|PROCEDURE|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
218972855|NCT04585373|OTHER|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
219664646|NCT03139864|PROCEDURE|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
219664647|NCT00862459|DRUG|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
218972856|NCT04585373|OTHER|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
218972857|NCT04585373|OTHER|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
218972858|NCT03114488|DEVICE|tDCS|Transcranial electrical stimulator
218972859|NCT00559936|DRUG|Topical Avastin 1%|Avastin (bevacizumab) 1%
218972860|NCT02331875|DRUG|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
218972861|NCT02331875|PROCEDURE|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
218972862|NCT02331875|RADIATION|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
218972863|NCT02276404|BEHAVIORAL|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
218972864|NCT02276404|OTHER|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
218972865|NCT00414921|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
218972866|NCT00414921|DRUG|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
218972867|NCT00414921|OTHER|placebo|inactive substance
218972868|NCT01669928|DRUG|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
218972869|NCT06136247|DIAGNOSTIC_TEST|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
218972870|NCT06136247|DIAGNOSTIC_TEST|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
218972871|NCT01682668|PROCEDURE|Bilateral subthalamic stimulation|
218972872|NCT04856202|BEHAVIORAL|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
218972873|NCT03509610|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
218972874|NCT04429243|DEVICE|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
218972875|NCT05113095|BIOLOGICAL|Darvadstrocel|Darvadstrocel injection
218972876|NCT04045301|BIOLOGICAL|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
219664648|NCT00862459|DRUG|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
219664649|NCT00862459|DRUG|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
219664650|NCT00862459|DRUG|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
219664651|NCT05188404|BEHAVIORAL|Choice of cannabis product|Participants choose and purchase their own cannabis product
219664652|NCT06624865|OTHER|Blood and stool sampling|Blood and stool sampling
219664653|NCT07012408|OTHER|Return to play program with progressive design|This design has more open objectives than the regressive design. In the progressive design, the duration of the return-to-play program is not determined by a future date, but rather by the player's daily progress. This design is less commonly used for scheduling tasks and planning work. It is intended to be compared with the regressive design to determine which is more appropriate.
219664654|NCT07012408|OTHER|Return to play program with regressive design|Control Group: Subjects with muscle injuries assigned to this group will follow a Return to Play program with a regressive design. This design has fixed times and objectives from the beginning of the program to predict the athlete's exact discharge time. This design is commonly used for scheduling tasks and planning work. It is intended to evaluate the benefits and drawbacks of the design and compare them with those of the progressive design to determine which is more appropriate.
219664655|NCT07015723|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
219664656|NCT04296786|DRUG|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
219664657|NCT04296786|DRUG|Chidamide|20mg po per week continuously
219664658|NCT04246502|DRUG|Capecitabine and Pyrotinib|Pyrotinib 400mg orally daily until progressive disease
219664659|NCT04246502|DRUG|Capecitabine,Trastuzumab, and Pertuzumab|as instruction
218972877|NCT04045301|BIOLOGICAL|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
218972878|NCT04045301|BIOLOGICAL|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
218972879|NCT04045301|OTHER|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
218972880|NCT00815269|DRUG|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
219664660|NCT01921738|DRUG|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
219664661|NCT01921738|DRUG|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
219664662|NCT01921738|DRUG|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
219664663|NCT01921738|DRUG|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
218972881|NCT00815269|DRUG|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
219664664|NCT00546741|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
219664665|NCT00546741|DRUG|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
219664666|NCT00546741|DRUG|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
219664667|NCT07026474|OTHER|radiotherapy|single doses of 1.8Gy up to a total dose of 55.8Gy to 63.0Gy
218972882|NCT00815269|DRUG|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
218972883|NCT00815269|DRUG|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
218972884|NCT00815269|DRUG|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
218972885|NCT04640181|DRUG|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
218972886|NCT04640181|DRUG|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
218972887|NCT04165642|OTHER|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
218972888|NCT05693844|BIOLOGICAL|Pan-T booster co-expressing MSLN CAR T cell|Starting Dose: 1×10\^6 cells/kg
218972889|NCT05693844|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
218972890|NCT05693844|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
218972891|NCT05693844|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
219664668|NCT07026474|DRUG|Cisplatin|40mg/m² BSA weekly concomitant to re-irradiation
219664669|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w
219664670|NCT07026474|DRUG|cisplatin + 5-fluorouracil (5FU)|Cisplatin: 100mg/m² BSA d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
219664671|NCT07026474|DRUG|Alternative medications: carboplatin + 5-fluorouracil (5FU)|Carboplatin: AUC5 d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
219664672|NCT07026474|DRUG|Alternative medications: carboplatin|AUC2 weekly
219664673|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 8-14 days after completion of RCT
219664674|NCT07026604|DRUG|Daratumumab|Participants receive intravenous daratumumab (16 mg/kg weekly for 8 weeks), diluted in 1000 mL (first dose) or 500 mL (subsequent doses) of saline, with infusion rates escalated stepwise from 50 to 200 mL/h under vital sign monitoring. Premedication (antihistamines/analgesics) is administered 30 minutes prior to each infusion to mitigate reactions.
219664675|NCT07026955|OTHER|colorectal cancer in patients over 50 years of age|description
219664676|NCT07027514|DRUG|tolododekin alfa|Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks (Q3W).
219664677|NCT07027514|DRUG|Cetrelimab|Participants will receive cetrelimab Q3W.
219664678|NCT07026110|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
219664679|NCT07026110|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
218972892|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
218972893|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
218972894|NCT03785288|RADIATION|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
218972895|NCT04766073|PROCEDURE|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
218972896|NCT00554112|BEHAVIORAL|Exercise|Exercise
218972897|NCT00570414|DEVICE|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
218972898|NCT00570414|DEVICE|Endotracheal tube|Airway management by the use of endotracheal tube
218972899|NCT00289367|DRUG|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
218972900|NCT00289367|DRUG|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
219664680|NCT07026110|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
219664681|NCT07026110|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
219664682|NCT07026110|DRUG|[18F]F-RESCA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-EPCD6 injection.
218972901|NCT01199731|DRUG|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
218972902|NCT01199731|DRUG|GSK2248761 200 mg once daily|2 100mg capsules OAD
218972903|NCT01199731|DRUG|Etravirine|2 100mg tablets twice daily
218972904|NCT01284530|DRUG|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
218972905|NCT01727908|OTHER|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
219664683|NCT07026110|DRUG|[68Ga]Ga-NOTA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-EPCD6 injection.
219664684|NCT07027033|OTHER|acid-rich sunflower oil oleic acid|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid
219664685|NCT07027033|OTHER|conventional sunflower oil|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil
219664686|NCT07027709|DEVICE|BeautiBond Xtreme pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with BeautiBond Xtreme, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were also treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following a standardized clinical protocol.
219664687|NCT07027709|PROCEDURE|HC Primer pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with HC Primer, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following the same clinical protocol used in the experimental grou
218972906|NCT04466176|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
218972907|NCT04466176|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
218972908|NCT04648254|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
218972909|NCT03024697|PROCEDURE|Pectoral Plane Block|
218972910|NCT03024697|PROCEDURE|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
219664688|NCT07027397|OTHER|Exercise|All participants will conduct a 2-day-a-week resistance training (RT) routine using the velocity-based method in the leg press exercise for one year. A tailored and constant intensity will be performed at 60% of the theoretical maximal isometric strength (F0) during the training intervention. Participants will conduct 3-4 sets, individualizing the repetitions numbers until they reach a velocity loss of 10-20%. A rest of 2 minutes was imposed between sets. A standardized warm-up will preced all RT session as follows: 4 minutes walking at usual gait speed and 6 minutes performing dynamic balance exercises.
219664689|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR and SMV|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV
219664690|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
219664691|NCT07027124|DRUG|Darolutamide|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg for 16 weeks prior to RP.
219664692|NCT07027124|DRUG|Pembrolizumab|Administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 5 cycles prior to RP (Neoadjuvant phase, study weeks 1, 4, 7, 10, 13 \& 16), and every 3 weeks, for a total of 12 cycles post-RP (Adjuvant phase, study weeks, 19, 22, 25, 28, 31, 34, 37, 40 43, 46, 49, \& 52). Total Pembrolizumab cycles=17
219664693|NCT07027124|DRUG|Lupron|Androgen deprivation, GnRH agonist Leuprolide will be administered at a dose of 22.5 mg SQ (Eligard)/IM Lupron every 12 weeks prior to RP (Study weeks, 1 and 13).
219664694|NCT07027618|BEHAVIORAL|AI-based Software for Personalized End-of-Life Care|This intervention involves the use of an AI-powered software system designed to personalize end-of-life care for elderly patients. The software continuously monitors vital signs and behavior through wearable sensors, sends smart medication reminders, issues preventive alerts to care providers, delivers customized care plans, and provides psychological and social support through communication features.
219664695|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space isolated corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
219664696|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
219664697|NCT06493656|DRUG|1mL of Triamcinolone (40mg/1mL) Injectable Solution|1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
218972911|NCT03964766|DEVICE|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
218972912|NCT03964766|DEVICE|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
218972913|NCT04623307|DIAGNOSTIC_TEST|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
218972914|NCT03839082|OTHER|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
218972915|NCT03839082|OTHER|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
218972916|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
218972917|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
218972918|NCT01822678|DRUG|Placebo|Placebo
218972919|NCT05542186|PROCEDURE|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
218972920|NCT03480867|DRUG|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
218972921|NCT03480867|RADIATION|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
218972922|NCT05438641|DRUG|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
219664698|NCT06493656|DRUG|4mL of Lidocaine 1% Solution Injectable Solution|4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
219664699|NCT06493656|DRUG|15mL of Normal Saline|15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
219686572|NCT01213446|BIOLOGICAL|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
218972923|NCT05438641|DRUG|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
218972924|NCT00005928|DRUG|Ramipril|
218972925|NCT00233428|PROCEDURE|Blood Draw|
218972926|NCT00943124|DRUG|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
218972927|NCT00943124|DRUG|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
218972928|NCT00943124|DRUG|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
218972929|NCT02034071|DRUG|DCCR|
218972930|NCT02034071|DRUG|Placebo|
218972931|NCT03332550|PROCEDURE|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
218972932|NCT03332550|PROCEDURE|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
218972933|NCT02687373|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
218972934|NCT02687373|OTHER|Normal Saline|0.9% Sodium chloride
218972935|NCT05486741|OTHER|Optical cehernce tomography|OCT macula and disc
219664700|NCT03438734|DEVICE|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
219664701|NCT03438734|DEVICE|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
219664702|NCT01236326|PROCEDURE|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
219664703|NCT01236326|PROCEDURE|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
219664704|NCT00416689|PROCEDURE|assessment of therapy complications|
219664705|NCT00416689|PROCEDURE|quality-of-life assessment|
219664706|NCT05998317|DRUG|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
219664707|NCT05998317|DRUG|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
219664708|NCT03626324|DEVICE|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
219664709|NCT02127736|DRUG|Amitriptyline|
219664710|NCT02127736|DRUG|Placebo|
218972936|NCT02255578|DEVICE|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
218972937|NCT02255578|DRUG|clomiphene citrate treatment|
219664711|NCT00889187|RADIATION|Neoadjuvant Short-Course Photon Radiation|
219664712|NCT00889187|DRUG|Capecitabine|
219664713|NCT03092934|DRUG|LY3295668|Oral capsules
219664714|NCT06877572|BEHAVIORAL|Weight loss with pharmacotherapy|Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.
219664715|NCT06877572|BEHAVIORAL|Weight loss without pharmacotherapy|Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits
219664716|NCT06717412|DRUG|Conbercept|Administered as an intravitreal injection
219664717|NCT01468753|PROCEDURE|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
219664718|NCT02535169|BEHAVIORAL|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
219664719|NCT02535169|BEHAVIORAL|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
218972938|NCT03773445|DIAGNOSTIC_TEST|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
218972939|NCT03773445|DIAGNOSTIC_TEST|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
218972940|NCT03773445|DIAGNOSTIC_TEST|Histology|Histology of colonic biopsies using the Geboes Index
218972941|NCT03773445|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
218972942|NCT01726660|DEVICE|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
218972943|NCT05205967|OTHER|MCED|Multi-cancer early detection (MCED) test
218972944|NCT05205967|OTHER|SOC|Standard of care cancer screening
218972945|NCT06084598|DRUG|BMS-986446|Specified dose on specified days
218972946|NCT06084598|OTHER|Placebo|Specified dose on specified days
219664720|NCT06724666|BEHAVIORAL|Transdiagnostic Internet-delivered intervention|The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
219664721|NCT02237924|DRUG|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
219664722|NCT02237924|DRUG|DDP|DDP:100mg/m2 for 2-3 cycles
218972947|NCT00595777|BEHAVIORAL|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
219664723|NCT02237924|RADIATION|IMRT|IMRT:70-74Gy for 2-3 cycles
219664724|NCT03693469|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219664725|NCT03449992|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
219664726|NCT03449992|DIETARY_SUPPLEMENT|Placebo|Placebo drink
219664727|NCT00065767|DRUG|Raloxifene|
219664728|NCT07027202|PROCEDURE|Early Left Ventricle unloading|"An Intraortic balloon pump will be systematically inserted as soon as possible, within 12 hours post-randomization.~* A pulmonary artery catheter (PAC) will enable hemodynamic monitoring of cardiac filling pressures, cardiac output and pulmonary artery pressures.~* Doppler Echocardiography will be performed at least daily to monitor LV ejection, LV dimension, appearance of LV blood stagnation, aortic time-velocity integral (VTI) and aortic valve opening.~* Escalation to a microaxial LV venting pump, central ECMO or atrial septostomy will be possible and discussed by the Shock team (as suggested by international recommendations) in case of~* Overt cardiogenic pulmonary edema requiring invasive mechanical ventilation~* Persisting more than 6 hours despite IABP support and optimization of patient's management (titration of ECMO blood flow, inotropes, non-invasive mechanical ventilation with PEEP, diuretics or hemofiltration)."
219664729|NCT03916731|DEVICE|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
219664730|NCT03916731|DEVICE|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
219664731|NCT01333956|DRUG|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
219664732|NCT01333956|DRUG|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
219664733|NCT01333956|DRUG|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
219664734|NCT01333956|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
219664735|NCT02240069|BEHAVIORAL|Education (Tx1)|Education on best burn practices
219664736|NCT02240069|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
219664737|NCT02240069|DEVICE|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
219664738|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
219664739|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
219664740|NCT04907227|BIOLOGICAL|Pembrolizumab|IV infusion
219664741|NCT04907227|DRUG|Docetaxel|IV infusion
219664742|NCT04907227|DRUG|Prednisone|Oral tablets
219664743|NCT04907227|DRUG|Placebo|IV infusion
219664744|NCT04907227|DRUG|Dexamethasone|Oral tablets
219664745|NCT00576810|DRUG|sodium picosulphate|
218972948|NCT02267642|BIOLOGICAL|AbGn-168H|monoclonal antibody
219664746|NCT00410462|DRUG|brostallicin|
219664747|NCT00410462|DRUG|doxorubicin hydrochloride|
218972949|NCT00596180|DRUG|HBOT|total body exposure to greater than atmospheric pressure oxygen
218972950|NCT00005851|DRUG|fludarabine phosphate|Given IV
218972951|NCT00005851|RADIATION|total-body irradiation|Undergo TBI
219664748|NCT06740019|DRUG|JMKX000197|for pleural perfusion
219664749|NCT06740019|PROCEDURE|Tube thoracostomy drainage|Tube thoracostomy drainage
219664750|NCT06655701|DIAGNOSTIC_TEST|No intervention|No intervention
219065697|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
219065698|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
218972952|NCT00005851|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
218972953|NCT00005851|DRUG|cyclosporine|Given PO or IV
218972954|NCT00005851|DRUG|mycophenolate mofetil|Given PO or IV
218972955|NCT00005851|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
218972956|NCT00005851|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
218972957|NCT00005851|OTHER|laboratory biomarker analysis|Correlative studies
218972958|NCT03783247|PROCEDURE|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
218972959|NCT03783247|PROCEDURE|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
219664751|NCT05073354|DEVICE|Full SWOT Model|Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
219664752|NCT02773745|BEHAVIORAL|Aquatic Prehab|Pool therapy
219664753|NCT04527211|DRUG|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
219664754|NCT00236275|DRUG|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
219664755|NCT02679833|DIETARY_SUPPLEMENT|Placebo|Toothpaste not containing the vitamin.
218972960|NCT04172662|BEHAVIORAL|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
218972961|NCT02686281|DRUG|GMC-252-L-Lysine|
219065699|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
219664756|NCT02679833|DIETARY_SUPPLEMENT|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
219664757|NCT03723070|DEVICE|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
219664758|NCT02208050|DRUG|Fampridine|
218972962|NCT02686281|OTHER|Placebo|
218972963|NCT05715801|PROCEDURE|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
218972964|NCT05715801|PROCEDURE|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
219065700|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
219065701|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
219065702|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
219664759|NCT02208050|DRUG|Placebo|
219664760|NCT00824434|DEVICE|PROMUS Element™|Drug eluting coronary stent system
219664761|NCT00474786|DRUG|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
218972965|NCT02592811|PROCEDURE|ERCP|Common bile duct cannulation with a cannulation catheter
218972966|NCT02592811|PROCEDURE|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
218972967|NCT02592811|DEVICE|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
218972968|NCT02592811|PROCEDURE|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
218972969|NCT03150667|DRUG|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
218972970|NCT03150667|DRUG|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
218972971|NCT03206255|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
218972972|NCT03206255|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
218972973|NCT03568084|OTHER|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
218972974|NCT03568084|OTHER|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
218972975|NCT06387160|DRUG|as per institutional protocol|This is an observational study. Treatment will be given to the patients as per institutional protocol
218972976|NCT01627171|DRUG|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
218972977|NCT01627171|DRUG|Polyethelene Glycol|280g reconstituted in 4 liters of water
218972978|NCT01627171|DRUG|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
218972979|NCT00179127|DRUG|glargine|0.3u/kg of glargine, subcutaneously, once
218972980|NCT00179127|DRUG|saline|0.3u/kg of saline, subcutaneously, once
218972981|NCT00129818|DRUG|Famciclovir|
218972982|NCT03194503|DEVICE|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
218972983|NCT03497793|OTHER|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
218972984|NCT04707352|DRUG|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
218972985|NCT03961074|OTHER|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
218972986|NCT01180530|DEVICE|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
218972987|NCT03491943|PROCEDURE|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
218972988|NCT03491943|PROCEDURE|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
218972989|NCT03216031|BEHAVIORAL|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
218972990|NCT04957355|DEVICE|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
218972991|NCT00462371|DEVICE|Insulin pump (CSII)|
218972992|NCT04692740|DRUG|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
219664762|NCT00474786|DRUG|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
219664763|NCT04496505|DEVICE|Device|is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
219664764|NCT04496505|DEVICE|Sham Device|The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
219664765|NCT00432276|DRUG|Alogliptin|Alogliptin tablets.
219664766|NCT00432276|DRUG|Pioglitazone|Pioglitazone tablets.
219664767|NCT00432276|DRUG|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
219664768|NCT00432276|DRUG|Placebo|Matching placebo tablets.
219664769|NCT02985073|DEVICE|Veritas®|Biologic mesh
219664770|NCT02985073|DEVICE|TIGR®|Non biologic mesh
219664771|NCT02330757|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
219664772|NCT02330757|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
219664773|NCT05135884|BEHAVIORAL|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
219664774|NCT06618443|OTHER|Scapular mobilization with movement|The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
219664775|NCT01454843|PROCEDURE|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
219664776|NCT01454843|PROCEDURE|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
219664777|NCT01101659|DRUG|JNJ-40411813|500 mg as 20 mL of oral suspension
219065703|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
219065704|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
219065705|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
219065706|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
219664778|NCT01101659|DRUG|normal saline|single dose
219664779|NCT01101659|DRUG|ketamine|20 mL of oral suspension
219664780|NCT01101659|DRUG|Placebo|single dose
219664781|NCT00467961|COMBINATION_PRODUCT|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
219664782|NCT02250261|BEHAVIORAL|KÄPY|
219664783|NCT05249127|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
219664784|NCT01619020|DIETARY_SUPPLEMENT|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
219664785|NCT02720900|DIETARY_SUPPLEMENT|B-GOS|1.8 g/day for 6 weeks
219664786|NCT02720900|DIETARY_SUPPLEMENT|Maltodextrin|1.8 g/day for 6 weeks
219664787|NCT00326170|DRUG|5-Azacytidine (5-aza)|Start at 75 mg/m\^2 subcutaneously daily for 7 days.
219664788|NCT00326170|DRUG|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
219664789|NCT00326170|DRUG|All-Trans Retinoic Acid (ATRA)|45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
219664790|NCT01528943|DRUG|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
219664791|NCT01528943|DRUG|Isotonic saline|same volume as the group that are allocated to prostacycline
219664792|NCT03359798|BEHAVIORAL|Narcotic counseling script|Script regarding post-cesarean section narcotic use
219664793|NCT03359798|BEHAVIORAL|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
219664794|NCT00322127|DRUG|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
219664795|NCT02250066|OTHER|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
219664796|NCT02073565|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
219664797|NCT02073565|DEVICE|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
219664798|NCT00698074|DEVICE|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
219664799|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
219664800|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
219664801|NCT00898599|DIETARY_SUPPLEMENT|Prebiotic|Inulin type fructooligosaccharides
219664802|NCT00898599|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
219664803|NCT05455359|DRUG|Prucalopride|Prucalopride 0.04 mg/kg/day
219664804|NCT05455359|DRUG|Famotidine|Famotidine 0.4 mg/kg/day
219664805|NCT06617988|OTHER|Not applicable- observational study|Not applicable- observational study
219664806|NCT04397471|PROCEDURE|Bone Marrow Harvest|Healthy volunteer bone marrow harvest
219664807|NCT05766345|BIOLOGICAL|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
219664808|NCT05766345|BIOLOGICAL|Placebo|Nothing to add
219664809|NCT02436031|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
219664810|NCT02436031|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
219664811|NCT02971540|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
219664812|NCT02971540|DRUG|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
219664813|NCT02971540|DRUG|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
219664814|NCT02971540|DRUG|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
219664815|NCT02971540|OTHER|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
219664816|NCT01382316|BEHAVIORAL|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
219664817|NCT01382316|BEHAVIORAL|Usual care|Group format, six weekly education sessions about alcohol and drugs
219664818|NCT03417024|DEVICE|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
219664819|NCT03417024|DEVICE|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
218972993|NCT02003339|OTHER|Additional RMIs|
219664820|NCT06009016|DIAGNOSTIC_TEST|Inflammatory factors and coagulation factors level in cerebrospinal fluid after subarachnoid hemorrhage|Inflammatory factors and coagulation factors level in cerebrospinal fluid will be tested by ELISA kits.
218972994|NCT02841527|PROCEDURE|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
219664821|NCT03641534|PROCEDURE|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
219664822|NCT03641534|PROCEDURE|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
219664823|NCT03641534|PROCEDURE|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
219664824|NCT03641534|PROCEDURE|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
219664825|NCT03641534|PROCEDURE|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
219664826|NCT03641534|PROCEDURE|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
219664827|NCT03641534|PROCEDURE|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
219664828|NCT03641534|PROCEDURE|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
219664829|NCT03641534|PROCEDURE|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
219664830|NCT03641534|PROCEDURE|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
219664831|NCT06090617|PROCEDURE|Skin Biopsy|Skin biopsies were obtained in all recruited patients.
219664832|NCT06090617|PROCEDURE|Video-laparoscopic adrenalectomy|Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
219664833|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
219664834|NCT04015518|DRUG|Placebo|Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
219664835|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
219664836|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
219664837|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
219664838|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
218972995|NCT02841527|PROCEDURE|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
219065707|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
219664839|NCT05278338|DRUG|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
219664840|NCT05278338|DRUG|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
219664841|NCT05278338|DRUG|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
219664842|NCT01851187|BEHAVIORAL|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
219664843|NCT01851187|BEHAVIORAL|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
219664844|NCT03525028|DRUG|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
219664845|NCT03525028|DRUG|Placebo|The investigators use placebo in the control group.
219664846|NCT02742454|PROCEDURE|Standard 30-60 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, the cord is clamped at 30 seconds. If the baby is breathing well, the cord is clamped at 60 seconds. Ventilatory assistance is given after cord clamping.
219664847|NCT02742454|PROCEDURE|VentFirst 120 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, PPV by face mask is given starting at 30 seconds. If the baby is breathing well, CPAP is given starting at 30 seconds. The cord is clamped at 120 seconds.
218972996|NCT02841527|PROCEDURE|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
218972997|NCT03522753|DEVICE|Metal skin staples|Routine closure methods/material for surgical wounds
219065708|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
219065709|NCT06057246|OTHER|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
219664848|NCT04469673|BIOLOGICAL|Biological：JS002|Administered by subcutaneous injection
218972998|NCT03522753|DEVICE|Nylon sutures|Routine closure methods/material for surgical wounds
219664849|NCT04469673|BIOLOGICAL|Placebo|Administered by subcutaneous injection
219664850|NCT02195427|DEVICE|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
219664851|NCT02195427|DEVICE|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
219664852|NCT04969380|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219664853|NCT05432050|DEVICE|Bispectral index and Patient state index monitoring|The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
219664854|NCT02655419|DRUG|ATM-AVI|"Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
219664855|NCT02655419|DRUG|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
219664856|NCT00431873|DRUG|MGCD0103|MGCD0103 Administered orally three times per week.
219664857|NCT06617351|DIETARY_SUPPLEMENT|Melatonin|Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.
219664858|NCT06617351|DIETARY_SUPPLEMENT|Placebo|Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
219664859|NCT02195726|PROCEDURE|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
219664860|NCT02195726|PROCEDURE|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
219664861|NCT05995249|DRUG|TAK-279|TAK-279 capsules
219664862|NCT05995249|DRUG|Erythromycin|Erythromycin tablets
219664863|NCT05995249|DRUG|Phenytoin|Phenytoin capsules
219664864|NCT05995249|DRUG|Efavirenz|Efavirenz tablets
219664865|NCT03499275|DEVICE|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
219664866|NCT03499275|DEVICE|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
219664867|NCT03499275|OTHER|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
219664868|NCT03499275|OTHER|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
219664869|NCT06912035|DRUG|Diacerein 50 mg Capsule|The patients received diacerein capsules
218972999|NCT04255797|BEHAVIORAL|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
218973000|NCT03364907|OTHER|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
218973001|NCT03364907|OTHER|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
219065710|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
219065711|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
219065712|NCT03832946|DRUG|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
218973002|NCT00381381|DRUG|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
219065713|NCT03832946|DRUG|Placebo|Placebo is administered as inhalation once a day
219065714|NCT05341089|DRUG|LY3502970|Administered orally.
219065715|NCT02228213|BIOLOGICAL|MIS416|Intravenous administration weekly for 52 weeks
219065716|NCT02228213|DRUG|Saline|Intravenous administration weekly for 52 weeks
219664870|NCT06912035|DRUG|Placebo|Patients received placebo capsules
219664871|NCT06911021|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|A single-dose intravenous injection of the radiotracer 68Ga-FAPI-46 will be administered to participants. Approximately 60 minutes after injection, a whole-body PET/CT scan will be performed. The scan is designed to detect areas of high fibroblast activation protein (FAP) expression in and around pancreatic tumors, providing high-resolution images of tumor margins and potential spread. The goal is to evaluate whether this imaging method offers more accurate and useful information than standard imaging (MRI and CT) for preoperative staging and surgical planning.
219664872|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
219664873|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
219664874|NCT06533852|DRUG|Fecal Microbiome Transplantation (FMT)|"Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months."
219664875|NCT06533852|OTHER|FMT Placebo|"Two doses:~First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months."
219664876|NCT00505661|DRUG|Letrozole|2.5 mg PO Once Daily
219664877|NCT06911333|DRUG|AD1208|Up to 6 of cohorts will be applied sequentially in phase Ia part.
219664878|NCT02795845|DIETARY_SUPPLEMENT|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
219664879|NCT02795845|OTHER|Placebo|capsule without active ingredient
219065717|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
219664880|NCT03630913|PROCEDURE|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
218973003|NCT00711074|DRUG|AZD5672|single dose 200mg aqueous solution
218973004|NCT02997267|PROCEDURE|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
219065718|NCT06535815|OTHER|Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
219664881|NCT05391919|OTHER|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
219664882|NCT05391919|OTHER|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
219664883|NCT05627752|DRUG|Enzalutamide 40 MG|Adding Enzalutamide to Docetaxel chemotherapy
219664884|NCT05627752|DRUG|Docetaxel injection|Docetaxel chemotherapy
219664885|NCT01861873|OTHER|measuring liver function by 18-FDGal PET/CT|
219664886|NCT00463840|DRUG|Oxaliplatin|
219664887|NCT00463840|DRUG|5FU|
219664888|NCT00463840|RADIATION|Radiation|
219664889|NCT00463840|PROCEDURE|Surgery|
219664890|NCT00463840|DRUG|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
219664891|NCT04812405|DIAGNOSTIC_TEST|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
219664892|NCT01653327|DRUG|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
219664893|NCT01653327|DRUG|Placebo|
219664894|NCT00002131|DRUG|Vesnarinone|
219664895|NCT05735912|PROCEDURE|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
219664896|NCT05735912|PROCEDURE|Surgery|Surgical resection of pancreatic insulinoma
219664897|NCT05015543|OTHER|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
219664898|NCT04291742|DIAGNOSTIC_TEST|cognitive vs software|cognitive vs software
219664899|NCT06442449|BIOLOGICAL|sIPV|vaccination with sIPV
219664900|NCT06442449|BIOLOGICAL|MMR|vaccination with MMR
218973005|NCT02746003|OTHER|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
218973006|NCT01916967|DRUG|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
218973007|NCT01916967|DRUG|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
218973008|NCT05062278|DRUG|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
218973009|NCT05062278|DRUG|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
218973010|NCT04516044|BEHAVIORAL|Video games|See arm description
218973011|NCT04256889|DEVICE|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
218973012|NCT00160966|DRUG|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
219065719|NCT00333593|DEVICE|Large pore dialyser|
219065720|NCT00333593|DEVICE|Standard dialyser|
219065721|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
219065722|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
219664901|NCT06442449|BIOLOGICAL|HepA-I|vaccination with HepA-I
219664902|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
219664903|NCT03129711|OTHER|glazed Celtra Duo|zirconia reinforced lithium silicate
219664904|NCT03129711|OTHER|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
219664905|NCT01689233|DRUG|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
219664906|NCT01689233|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
219664907|NCT03856333|OTHER|Assigned Interventions|exercises, physical agents
219664908|NCT05935033|DRUG|Emraclidine|Tablet
219664909|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
219664910|NCT01738191|DRUG|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
218973013|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
218973014|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
218973015|NCT00337350|DRUG|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
218973016|NCT00337350|DRUG|placebo|matched placebo for rosiglitazone 4mg/day
218973017|NCT00846287|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
218973018|NCT00846287|DRUG|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
218973019|NCT00846287|DRUG|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
219664911|NCT01738191|DRUG|Placebo|
219664912|NCT04562220|OTHER|Routine conventional physical therapy plus Vibration session|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
219664913|NCT04562220|OTHER|Routine conventional physical therapy|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
219664914|NCT05343091|DEVICE|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
219664915|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
219664916|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
219664917|NCT05628298|DEVICE|Soovu Pain Relief System|The Soovu Pain Relief system uses pulses of heat to block the TRPV-1 calcium channel on peripheral pain nerves. The study will determine if the FDA cleared device significantly reduces the subject's pregnancy related pain.
219664918|NCT00560911|BEHAVIORAL|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
219664919|NCT00560911|BEHAVIORAL|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
218973020|NCT02273518|DRUG|Asasantin ER, new formulation I|
218973021|NCT02273518|DRUG|Asasantin ER, new formulation II|
219664920|NCT06910475|OTHER|Resistance training|"The training program will follow a periodized approach, starting with a low total volume (loads x sets x repetitions), ensuring gradual adaptation, patient safety, and performance progression. Strength training will begin 48 hours after muscle strength tests.Sessions will occur 2 to 4 times per week on non-consecutive days. Each session will include 6-12 exercises, with 1-3 seconds for concentric and eccentric actions, 6-20 repetitions, 1-6 sets, and 1-3 minutes of rest. Intensity will be gauged by perceived exertion, ranging from easy to hard, with load adjustments every 2 months based on progress.Patients undergoing hemodialysis may perform the sessions during or between treatments. Portable equipment like free weights, ankle weights, and resistance bands will be used."
219686573|NCT04602156|PROCEDURE|Trocar percutaneous cholecystostomy|Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
218973022|NCT02273518|DRUG|Asasantin ER, present commercial formulation|
218973023|NCT05569811|DRUG|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
218973024|NCT05569811|DRUG|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
218973025|NCT05569811|DRUG|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
218973026|NCT01967758|BIOLOGICAL|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
218973027|NCT01967758|BIOLOGICAL|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
218973028|NCT01967758|BIOLOGICAL|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
218973029|NCT01967758|DRUG|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
218973030|NCT00014404|DRUG|celecoxib|
218973031|NCT02135939|BEHAVIORAL|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
218973032|NCT01912963|DRUG|Pertuzumab|
218973033|NCT01912963|DRUG|Trastuzumab|
218973034|NCT01912963|DRUG|eribulin|
218973035|NCT00817583|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
218973036|NCT00817583|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
218973037|NCT04167722|PROCEDURE|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
218973038|NCT03005171|DRUG|Bupivacaine|Thoracic epidural bupivacaine infusion
218973039|NCT03005171|DRUG|Lidocaine|Intravenous lidocaine infusion
219065723|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
219065724|NCT06112236|OTHER|no intervention|no intervention
219065725|NCT04511689|DEVICE|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
218973040|NCT03616171|BEHAVIORAL|SLEEP-Extend intervention|"1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
219065726|NCT04045457|PROCEDURE|dry needling|insertion of needle into active myofascial trigger point
218973041|NCT03616171|OTHER|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
218973042|NCT01384279|DRUG|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
218973043|NCT01181648|BEHAVIORAL|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
219065727|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
219065728|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
219065729|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
219065730|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
219065731|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
219065732|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
219065733|NCT05430529|BEHAVIORAL|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
219065734|NCT05430529|BEHAVIORAL|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
219065735|NCT05430529|BEHAVIORAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
219065736|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
219664921|NCT06910475|OTHER|Endurance training|Training sessions will be conducted 2 to 4 times per week on non-consecutive days. Patients will perform aerobic training on different ergometers, namely: bicycle, treadmill, and stair climber. The choice will depend on the patient's needs/abilities and/or equipment availability. The load will be adjusted between 50% and 100% of the ventilatory threshold, according to the patient's cardiorespiratory capacity. The duration of the training will vary between 10 and 60 minutes, always starting with low load and volume, with gradual progression to ensure patient comfort and safety.
219664922|NCT06910475|OTHER|Concurrent training|Training sessions will be conducted 2 to 6 times per week, alternating between strength training one day and aerobic training the next, as described above. As patients improve their physical fitness, strength and aerobic training may be performed on the same day.
219065737|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
218973044|NCT02406950|DRUG|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
218973045|NCT05462470|PROCEDURE|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
218973046|NCT05462470|PROCEDURE|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
219664923|NCT06910904|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT)|CIMT is a intensive training sessions of 6 hours/day for 5 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016). Most commonly, the protocol continues to be 2 weeks in duration but the intensity is adjusted such that the restraint is worn for approximately 6 h per day and therapy is administered for 2 to 3 h per day (MacKenzie \& Viana, 2024). But this study implementing a 2 hour CIMT protocol with 6h restrain for 8 weeks in sub-acute stroke rehabilitation balances therapeutic intensity with practical considerations, potentially enhancing patient engagement and rehabilitation outcomes within clinical settings (Chen et al., 2014; Udoeyop, 2017).
219664924|NCT06910904|COMBINATION_PRODUCT|Mirror Therapy (MT)|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. In mirror therapy, the patient is asked to move the unaffected limb while watching the moving limb being reflected in the mirror. The congruent visual feedback through the mirror affects brain lesions and motor-related areas on the affected side, facilitating motor recovery. Patients with chronic stroke who can benefit from visual feedback to enhance motor recovery (Gandhi et al., 2020; Rothgangel \& Braun, 2013). Mirror therapy sessions should last at least 10 minutes daily, with the option to increase up to 30 minutes for optimal benefits. Practice mirror therapy exercises at least once a day. Perform gentle movements with the intact limb while observing its reflection in the mirror(Crosby et al., 2016).
219664925|NCT01318746|PROCEDURE|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
219664926|NCT01051440|DRUG|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
218973047|NCT02554188|BIOLOGICAL|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
219664927|NCT01051440|DRUG|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
219664928|NCT05093985|OTHER|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
219664929|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
219664930|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
219664931|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
219664932|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
218973048|NCT02554188|OTHER|Diet|A 5-day low calorie fasting-mimicking diet
218973049|NCT05587218|BEHAVIORAL|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
218973050|NCT01638819|BIOLOGICAL|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
218973051|NCT01638819|BIOLOGICAL|Placebo|Saline
218973052|NCT06025851|DRUG|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
219664933|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
219664934|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
219664935|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
219664936|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
219664937|NCT04291456|DRUG|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
219664938|NCT06911086|DEVICE|3D printed models|A three-dimensional digital model is constructed based on the patient's preoperative CT/MRI images, and a personalized physical model is created using 3D printing. This model has the ability to self-heal after being cut. Surgeons can perform multiple simulated surgeries on the model to plan the optimal surgical path before the authetic surgery
219664939|NCT06911086|OTHER|CT or MRI image|Obtain the patient's CT/MRI images and determine the definitive surgical path based on the two-dimensional images.
219664940|NCT05380986|DRUG|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
219664941|NCT01636648|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
218973053|NCT06025851|DRUG|Placebo|Placebo Comparator
218973054|NCT00590798|BEHAVIORAL|Walking|Patient will walk within 30 minutes of vascular closure system procedure
218973055|NCT00813033|OTHER|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
218973056|NCT03111966|OTHER|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
219664942|NCT06912282|DEVICE|deep brain stimulation|bilateral single-electrode VO combined with STN target implantation
219664943|NCT00727090|DRUG|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
219664944|NCT04651946|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
219664945|NCT06911697|DIAGNOSTIC_TEST|18F-TSPF PET/CT|Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.
218973057|NCT02526836|PROCEDURE|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
218973058|NCT02526836|PROCEDURE|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
218973059|NCT02795793|DRUG|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
218973060|NCT02795793|PROCEDURE|Appendectomy group (Operative management, OM)|
218973061|NCT01008631|DRUG|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
218973062|NCT00537784|BIOLOGICAL|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
218973063|NCT00537784|BIOLOGICAL|no injection|
218973064|NCT00074438|DRUG|methotrexate|Oral or parenteral repeating dose
218973065|NCT00074438|DRUG|rituximab|Intravenous repeating dose
218973066|NCT00074438|DRUG|corticosteroids|Intravenous repeating dose
218973067|NCT00074438|DRUG|placebo|Intravenous repeating dose
218973068|NCT01942473|DEVICE|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
218973069|NCT06023524|DEVICE|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
218973070|NCT06023524|DEVICE|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
218973071|NCT03625934|BIOLOGICAL|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
218973072|NCT03625934|BIOLOGICAL|Placebo|5 s.c. injections of matching Placebo four weeks apart
219664946|NCT05052606|OTHER|No intervention|This study is an observational study without treatment intervention.
219664947|NCT04747990|PROCEDURE|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
218973073|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% gel pump|
218973074|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% tube|
218973075|NCT06518902|DRUG|mesenchymal stem cells (umbilical cord) injection|Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
218973076|NCT00135070|DRUG|Detemir|
218973077|NCT04025281|OTHER|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
218973078|NCT04025281|OTHER|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
218973079|NCT05708027|PROCEDURE|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
218973080|NCT05895864|DRUG|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
218973081|NCT03857035|OTHER|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
218973082|NCT00402272|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
218973083|NCT00070655|DRUG|SR34006 (idraparinux sodium) Injection|
218973084|NCT00070655|DRUG|vitamin K antagonist (warfarin or acenocoumarol) tablets|
218973085|NCT04406610|BIOLOGICAL|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
218973086|NCT04542044|OTHER|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
218973087|NCT00237185|DRUG|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
218973088|NCT04920682|DRUG|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
218973089|NCT04920682|DRUG|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
218973090|NCT04920682|DRUG|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
218973091|NCT04920682|DRUG|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
218973092|NCT00959712|BEHAVIORAL|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
218973093|NCT03368703|DEVICE|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
218973094|NCT03368703|DEVICE|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
218973095|NCT01302379|DRUG|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
218973096|NCT01302379|DRUG|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
219664948|NCT05988905|OTHER|robot assited gati training|SUBAR® (CRETEM, Korea) is a exoskeletal-robot with a footplate that assists gait movements. The patient's thigh length and lower leg length were measured before training, so that the SUBAR® can be adjusted to patient's size to ensure accurate training. During training, the therapist facilitated the treatment and stood by the patients' side to adjust the direction and speed. RAGT is programmed automatically, and it can be performed regularly over a long period. The patients received 30 min of robot-assisted training using SUBAR® once a day for 5 days a week for 8 weeks. Each training session lasted up to 40 min.
219664949|NCT05988905|OTHER|conventional traiing|Patients also received conventional exercise rehabilitation with the same duration and frequency. Conventional rehabilitation therapy, which consisted of active assistive knee exercises, knee stretching, patellar mobilization exercises, and quadriceps setting exercises, was performed every day throughout the rehabilitation period.
219664950|NCT01833936|DEVICE|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
219664951|NCT01833936|DEVICE|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
219664952|NCT02163616|DRUG|Misoprostol|800 mcg of sublingual misoprostol
219664953|NCT04742660|DRUG|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
219664954|NCT04861194|RADIATION|Neurovascular-sparing|Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT
219664955|NCT03728361|BIOLOGICAL|Nivolumab|Given IV
218973097|NCT01302379|BEHAVIORAL|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
218973098|NCT01302379|BEHAVIORAL|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
218973099|NCT03875820|DRUG|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
219065738|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
219065739|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
219065740|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
219065741|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
219664956|NCT03728361|DRUG|Temozolomide|Given PO
219664957|NCT04579445|OTHER|Education on tailored Quality Improvement measures|Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
219664958|NCT05721677|DEVICE|2-octyl cyanoacrylate based topical skin adhesive|Tissue adhesive on CVL exit-site
219664959|NCT05229627|DRUG|MPH|the drug would be prescribed to patients without any contraindication
219664960|NCT05229627|DRUG|ATX|the drug would be prescribed to patients without any contraindication
219664961|NCT03115593|PROCEDURE|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
219664962|NCT03115593|PROCEDURE|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
219664963|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
219664964|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
219664965|NCT00963846|DRUG|placebo|matching pill placebo
219664966|NCT00963846|DRUG|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
219664967|NCT00963846|DRUG|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
219664968|NCT00963846|DRUG|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
219664969|NCT06515964|OTHER|observational study|observational study, no intervention
219664970|NCT03260114|OTHER|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
219664971|NCT01238341|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
219664972|NCT04047823|DEVICE|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
219664973|NCT00546312|DEVICE|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
219664974|NCT02117219|BIOLOGICAL|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
219664975|NCT02117219|DRUG|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
219664976|NCT02117219|BIOLOGICAL|tremelimumab|tremelimumab will be administered by IV infusion
219664977|NCT02889614|OTHER|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
219664978|NCT03300414|OTHER|One time blood draw|Same as part 1
219664979|NCT04826835|BEHAVIORAL|Prehabilitation intervention|"Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care."
219664980|NCT04826835|BEHAVIORAL|Health education control|"Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care."
219664981|NCT00499343|DRUG|Etoposide|150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.
219664982|NCT00499343|DRUG|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
218973100|NCT03875820|DRUG|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
219065742|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
219065743|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
219065744|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
219664983|NCT00499343|DRUG|GM-CSF|250 mcg/m\^2 injection given every evening till the completion of apheresis.
219664984|NCT00499343|DRUG|Isophosphamide|10 g/m\^2 given intravenously continuous infusion over 72 hours.
219664985|NCT00499343|DRUG|Rituximab|Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.
219664986|NCT00499343|PROCEDURE|Apheresis|Peripheral blood stem cell collection.
219664987|NCT05992259|DEVICE|TENS|TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
219664988|NCT02153125|DRUG|Eplerenone|
219664989|NCT03584230|BEHAVIORAL|Assigned to positive group|See arm description
219664990|NCT03584230|BEHAVIORAL|Assigned to negative group|See arm description
219664991|NCT04542876|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
219664992|NCT03870750|OTHER|Supportive Palliative Care|focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
219664993|NCT03870750|OTHER|Clinical Management|physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
219664994|NCT03870750|OTHER|Best Practice|Given standard of care
219664995|NCT03870750|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
218973101|NCT00756015|OTHER|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
218973102|NCT00756015|OTHER|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
218973103|NCT06359431|DEVICE|Novel Smart Speculum|"The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
218973104|NCT06359431|DEVICE|Standard speculum|"he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
218973105|NCT05616715|DEVICE|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
218973106|NCT05616715|OTHER|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
218973107|NCT03084510|DEVICE|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
218973108|NCT00603421|OTHER|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
218973109|NCT00603421|OTHER|treatment as usual|Treatment as usual
218973110|NCT00540098|DRUG|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
218973111|NCT00540098|DRUG|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
218973112|NCT00540098|DRUG|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
218973113|NCT00540098|DRUG|Placebo + relaxation|placebo pill once daily + regular relaxation training
219065745|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
218973114|NCT03504670|PROCEDURE|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
218973115|NCT03504670|PROCEDURE|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
218973116|NCT03112590|BIOLOGICAL|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
218973117|NCT03112590|DRUG|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
218973118|NCT03112590|DRUG|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
219065746|NCT04442555|DIETARY_SUPPLEMENT|HVMN Ketone Ester|Commercially available ketone supplement
219065747|NCT04442555|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
219065748|NCT02445820|DRUG|HES|2500 mL of balanced HES 130/0.4
219065749|NCT02445820|DRUG|Crystalloid|2500 mL of balanced crystalloid.
219664996|NCT03870750|OTHER|Questionnaire Administration|Ancillary studies
219664997|NCT03870750|OTHER|Quality-of-Life Assessment|Ancillary studies
219664998|NCT03870750|OTHER|Survey Administration|Complete surveys
219664999|NCT05572892|OTHER|FAC scale|"Measurement of walking dependency according to the FAC scale :~* in the first week after stroke (in neurology by physiotherapists),~* then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
219665000|NCT00020202|DRUG|FR901228|
219665001|NCT00000613|BEHAVIORAL|dietary supplements|
219665002|NCT00000613|DRUG|genistein|
219665003|NCT00000613|BEHAVIORAL|diet, soy proteins|
219665004|NCT01482299|DRUG|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
219665005|NCT05492747|OTHER|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
219665006|NCT03872817|OTHER|Intervention ProLiSMentAl|"Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available."
219665007|NCT04557436|DRUG|PBLTT52CAR19|gene therapy
219665008|NCT02626650|OTHER|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
219665009|NCT06443515|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score
219665010|NCT04524767|BEHAVIORAL|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
219665011|NCT04524767|BEHAVIORAL|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
219665012|NCT04024878|DRUG|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
218973119|NCT03112590|OTHER|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
218973120|NCT03112590|PROCEDURE|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
218973121|NCT00843726|RADIATION|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
218973122|NCT00843726|RADIATION|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
218973123|NCT03161132|DRUG|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
218973124|NCT03161132|DRUG|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
218973125|NCT01444131|DRUG|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
219665013|NCT04024878|BIOLOGICAL|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
219665014|NCT04024878|PROCEDURE|Core Needle Biopsy|Surgical procedure
219665015|NCT02474355|PROCEDURE|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
219665016|NCT02474355|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
219665017|NCT02474355|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
219665018|NCT02474355|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
219665019|NCT02474355|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
219665020|NCT05753540|OTHER|Laser therapy|Multiwave locked system laser therapy
219665021|NCT05753540|OTHER|Sham laser therapy|Sham laser therapy
219665022|NCT05545085|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
218973126|NCT01444131|DRUG|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
218973127|NCT01837732|OTHER|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
218973128|NCT01837732|OTHER|Relational:|Relational: 10 mn verbal patient's centered exchanges
218973129|NCT03167905|DEVICE|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
218973130|NCT03167905|DRUG|Entonox|Entonox will be given upon request in non-epidural group.
218973131|NCT03167905|DRUG|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
219665023|NCT01082796|DRUG|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
219665024|NCT03484624|DEVICE|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
219665025|NCT03298308|DEVICE|Cranial Electric Stimulation|Micro amperage TCDS
219665026|NCT04747665|OTHER|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
219665027|NCT04653155|BEHAVIORAL|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
219665028|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
219665029|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
219665030|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
219665031|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
219665032|NCT04605926|BIOLOGICAL|EQ001|itolizumab \[Bmab600\]
218973132|NCT03167905|DRUG|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
218973133|NCT03167905|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
218973134|NCT03167905|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
218973135|NCT00625066|OTHER|biologic sample preservation procedure|
219665033|NCT04605926|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
219665034|NCT04209907|OTHER|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
218973136|NCT00625066|OTHER|cytology specimen collection procedure|
218973137|NCT00625066|OTHER|medical chart review|
218973138|NCT00625066|OTHER|questionnaire administration|
218973139|NCT00625066|OTHER|survey administration|
218973140|NCT00625066|PROCEDURE|biopsy|
218973141|NCT00625066|PROCEDURE|evaluation of cancer risk factors|
218973142|NCT00625066|PROCEDURE|screening colonoscopy|
218973143|NCT06296212|DRUG|TAD® 600 mg/4 mL powder and solvent for solution for injection|TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
218973144|NCT06296212|DRUG|Saline solution 0.9% of sodium chloride|Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
219065750|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
219665035|NCT04688606|DIAGNOSTIC_TEST|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
219665036|NCT01859871|BEHAVIORAL|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
219665037|NCT00004464|DRUG|cyclophosphamide|
219665038|NCT00004464|DRUG|filgrastim|
219665039|NCT01066793|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
219665040|NCT01066793|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
218973145|NCT05035511|DEVICE|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
218973146|NCT05569473|PROCEDURE|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
218973147|NCT05156073|OTHER|Educational Materials|"1. Patient care partner cohort:~   a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~2. Primary care physician cohort:~   1. education on deprescribing through a 15-45-minute presentation~  2. one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations."
218973148|NCT03602820|BIOLOGICAL|AAV2-hRPE65v2|
218973149|NCT02745210|DIAGNOSTIC_TEST|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
218973150|NCT02891161|DRUG|durvalumab|1500 mg Q4 weekly
218973151|NCT02891161|RADIATION|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
218973152|NCT06557187|RADIATION|ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
218973153|NCT03309150|DRUG|Berzosertib|Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.
218973154|NCT05446181|BEHAVIORAL|Perioperative delirium|Perioperative delirium
218973155|NCT05446181|PROCEDURE|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
218973156|NCT05281211|DIETARY_SUPPLEMENT|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
218973157|NCT05281211|BEHAVIORAL|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
219665041|NCT05118048|DIAGNOSTIC_TEST|Lactate, Hemoglobin, Hematocrit|Compare diagnostic tests to reference methods
219665042|NCT05033977|OTHER|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
219665043|NCT05033977|OTHER|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
219665044|NCT02844036|PROCEDURE|Percutaneous angioplasty|
219665045|NCT02844036|PROCEDURE|Balloon angioplasty|
218973158|NCT04401605|OTHER|Fermented Food-supplemented Diet|Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
218973159|NCT04401605|OTHER|Regular Diet|No change in diet.
218973160|NCT05916560|DRUG|LY3437943|Administered SC.
218973161|NCT05266898|BIOLOGICAL|Human papillomavirus 9-valent vaccine, recombinant|Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
218973162|NCT05266898|BIOLOGICAL|human papillomavirus vaccine, recombinant|Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus. Administered as part of participant's clinical care prior to study enrollment (intervention not delivered as part of study design).
218973163|NCT06785428|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d.
218973164|NCT01512290|OTHER|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
218973165|NCT02734433|DRUG|Pexidartinib|
218973166|NCT00883584|DRUG|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
218973167|NCT00883584|DRUG|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
218973168|NCT00990938|DRUG|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
218973169|NCT00990938|DRUG|Saline|Subcutaneous injection once per week for four weeks
218973170|NCT05726734|DRUG|Vonoprazan|potassium-competitive acid blocker
218973171|NCT05726734|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
218973172|NCT05726734|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
218973173|NCT05726734|DRUG|Esomeprazole|Proton pump inhibitor
218973174|NCT05568407|DRUG|Avelumab|As used in real world practice
218973175|NCT04407611|BEHAVIORAL|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
218973176|NCT04407611|BEHAVIORAL|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
218973177|NCT06575309|BIOLOGICAL|Blood test|The procedures added as part of this research are 6 blood samples, the volumes of which do not exceed the volume authorized in the order of February 17, 2021, i.e. 27mL.
218973178|NCT05588778|BEHAVIORAL|BAILAMOS™ @home/en casa|The BAILAMOS™ dance program and dance manual. BAILAMOS™ originally encompassed four dance styles: Merengue, Cha Cha Cha, Bachata, and Salsa. These four styles of Latin dance are generally considered the most popular in terms of recognition and preference. We have added two styles to appeal to the largely Mexican-origin Latinos in Chicago (i.e., Cumbia and Samba). The dances were jointly choreographed by the PI and Mr. Mendez, a professional dance instructor and owner of The Dance Academy of Salsa and http://www.salsachicago.com/. The PI and dance instructor co-developed the extensive manual is used by program instructors and includes background information on the authors, an introduction describing the goals of the program, and descriptions of the various styles of dance. The manual also has photos and descriptions of each dance broken down into its component parts.
219665046|NCT02844036|PROCEDURE|Right heart catheterization|
219665047|NCT02844036|PROCEDURE|Echocardiography|
219665048|NCT02844036|OTHER|A six-minute walking test|
219665049|NCT02844036|PROCEDURE|Functional respiratory investigations|
218973179|NCT05588778|BEHAVIORAL|¡En Forma y Fuerte! @home/en casa|The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
218973180|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
218973181|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
219065751|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
219065752|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
219065753|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
219065754|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
219065755|NCT01853150|DEVICE|rTMS Motor cortex|
219065756|NCT01853150|DEVICE|rTMS Supplementary motor area|
219065757|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
219065758|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
219065759|NCT05294757|OTHER|Physical exercise|1\. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
219065760|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
219065761|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
219065762|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
219065763|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
219065764|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
219065765|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
218973182|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
219065766|NCT01651429|BEHAVIORAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
219065767|NCT02693873|BEHAVIORAL|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
219065768|NCT02663817|DEVICE|CT Scan|
219065769|NCT01471002|DEVICE|Galil Medical patented 17G Cryoablation Needles|
219065770|NCT00147186|DEVICE|Hylan G-F 20|
219065771|NCT00901290|DRUG|monophasic oral contraceptive|mg, oral dose
219065772|NCT00901290|DRUG|AZD7325|mg, oral dose
219065773|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
219665050|NCT02844036|PROCEDURE|Pulmonary tomography or pulmonary angiography|
219665051|NCT02844036|OTHER|Biological parameters|
218973183|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.
218973184|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
219665052|NCT00315484|DRUG|Epoetin alfa and Darbepoetin alfa|
218973185|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
218973186|NCT05521906|BEHAVIORAL|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
218973187|NCT06656208|OTHER|Pubic symphysis manipulation|Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.
218973188|NCT06656208|OTHER|Traditional sacroiliac treatment|Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
218973189|NCT01993784|DRUG|nimotuzumab|
218973190|NCT00560885|DEVICE|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
218973191|NCT06680115|DRUG|Sintilimab|Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
218973192|NCT06682169|DRUG|Rovadicitinib|Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
218973193|NCT06682169|DRUG|Imatinib|Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.
218973194|NCT06682169|DRUG|Methotrexate|Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
218973195|NCT06682169|DRUG|Mycophenolate mofetil|Metoprolol ester is an organic compound mainly used as an immunosuppressant
218973196|NCT06682169|DRUG|Rituximab|Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
219065774|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
218973197|NCT06682065|OTHER|Telemedicine for contraceptive counseling (TECC)|WhatsApp algorithmic chatbot that screens preferences and medical eligibility to recommend two methods, informs about all methods, allows choice out of all methods, produce summary to substitute for clinical record
218973198|NCT06682065|OTHER|Standard Care|In-personcontraceptive counseling with a nurese according to clinical standard of care
218973199|NCT06334276|OTHER|Drowning|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
218973200|NCT06696586|DRUG|Fentanyl infusion|will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.
218973201|NCT06696586|DRUG|Fentanyl Injection|will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
218973202|NCT06620042|DRUG|Ketamine|Open-label Ketamine
218973203|NCT06620042|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) of the brain
218973204|NCT06709560|OTHER|Moderate Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer at moderate intensity (50% HRR)
219065775|NCT00003801|PROCEDURE|management of therapy complications|
219065776|NCT00003801|PROCEDURE|quality-of-life assessment|
219665053|NCT05992688|OTHER|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
218973205|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer, at a vigorous intensity (80% HRR).
218973206|NCT06709560|OTHER|Moderate Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at moderate intensity (50% HRR).
219065777|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
219065778|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
219065779|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
219065780|NCT01924325|DRUG|placebo|
218973207|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a different cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at vigorous intensity (80% HRR).
218973208|NCT06710431|DRUG|AFA-281|AFA-281
219065781|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
219065782|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
219065783|NCT01629329|DRUG|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
219065784|NCT01629329|DRUG|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
219665054|NCT05992688|OTHER|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
219065785|NCT04829838|DRUG|intravenous levetireacetam|phenytoin is considered as control drug in the study
219665055|NCT05992688|OTHER|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
219665056|NCT01090297|DEVICE|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
219665057|NCT01090297|DEVICE|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
219665058|NCT01090297|DEVICE|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
219665059|NCT01911793|DEVICE|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
219665060|NCT03774394|DRUG|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
219665061|NCT03774394|DRUG|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
219665062|NCT03334422|DRUG|Baricitinib|Administered orally
219665063|NCT03334422|DRUG|Placebo|Administered orally
219665064|NCT02697916|DRUG|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
219665065|NCT00293800|DRUG|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219665066|NCT00293800|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
219665067|NCT00293800|DRUG|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
219665068|NCT00293800|OTHER|Timolol Vehicle|Placebo
219665069|NCT05880667|RADIATION|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
219665070|NCT00525876|DRUG|Cyclophosphamide|"Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
219665071|NCT00525876|DRUG|Fludarabine|"30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
218973209|NCT06706765|BEHAVIORAL|Behavioral Treatment|Behavioral cough suppression therapy delivered in a group setting via telehealth.
218973210|NCT06709326|DIAGNOSTIC_TEST|Apheresis|Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.
218973211|NCT06709326|OTHER|Androgen deprivation therapy|Apheresis will be performed before initiation of systemic therapy (androgen deprivation therapy) and 4 weeks after. Androgen deprivation therapy is treatment as per clinical routine and not part of the protocol.
218973212|NCT06709326|DIAGNOSTIC_TEST|Anti androgen therapy|Apheresis will be performed before initiation of systemic therapy (anti androgen therapy). Anti androgen therapy is treatment as per clinical routine and not part of the protocol.
219665072|NCT00525876|DRUG|Rituximab|"Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
219665073|NCT00525876|DRUG|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
219665074|NCT00525876|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells.
219665075|NCT01313221|BIOLOGICAL|etanercept|Administered by subcutaneous injection
219665076|NCT01313221|DRUG|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%"
219665077|NCT01516294|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
219665078|NCT06337747|DEVICE|Traditional technique|Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.
219665079|NCT06337747|DEVICE|Experimental technique|Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
219665080|NCT00003781|DRUG|docetaxel|
219665081|NCT00003781|PROCEDURE|pain therapy|
219665082|NCT00003781|PROCEDURE|quality-of-life assessment|
219665083|NCT00333632|DRUG|Dexmedetomidine|
219665084|NCT00333632|DRUG|Propofol|
218973213|NCT06709313|DRUG|Chromium|Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
218973214|NCT06707285|DEVICE|MRI|1.5T siemens
218973215|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg
218973216|NCT06710600|RADIATION|UVA and UVB radiation|The skin of the inner arm will be exposed to five fixed incremental doses of UVA and UVB. Each dose will be applied to a circular area on the inner forearm of 1 cm diameter for both UVA and UVB.
218973217|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|"acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg"
218973218|NCT06708585|OTHER|progressive relaxation exercises and training|Considering the high incidence of cesarean section and the prevalence of anxiety and fear as psychological symptoms, providing comfort and pain support to women is of great importance. Therefore, the effect of progressive relaxation exercise and education before cesarean section surgery on care outcomes will be determined.
218973219|NCT06709638|OTHER|Placebo Comparator|Placebo Comparator
218973220|NCT06709638|DRUG|Zhilong Huoxue Tongyu capsule|Zhilong Huoxue Tongyu capsule
218973221|NCT06706947|PROCEDURE|Lymphaticovenous Anastomosis|"Lymphaticovenous Anastomosis (LVA) is an emerging super-microsurgical procedure pioneered by Professor Xie Qingping and his team, a group of Chinese microsurgery experts. This technique has been published in the official journal of the American Society of Plastic Surgeons (ASPS), confirming its effectiveness in improving the drainage function of the brain and reducing lymphatic pressure in deep brain tissues. By establishing an anastomosis between lymphatic vessels and veins in the neck, the surgery enhances the drainage of cerebrospinal fluid, alleviating the accumulation of toxins and waste within the brain, thereby easing the symptoms of Alzheimer's disease. Due to its significant contribution to the field of microsurgery, this innovative surgery has been selected as one of the Top Seven Advances in Microsurgery for 2022."
218973222|NCT06708858|DRUG|Surufatinib|200mg，qd，po
218973223|NCT06708858|DRUG|Gemcitabine|1000mg/ m2, IV，d1，8，q3w
218973224|NCT06708858|DRUG|Cisplatin|25mg/m2，IV，d1，8，q3w
219065786|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
219065787|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
219065788|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
219065789|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
219065790|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
219065791|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
219065792|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
219065793|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
219065794|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
219665085|NCT00333632|DRUG|Midazolam|
219665086|NCT00333632|DRUG|Fentanyl|
218973225|NCT06708858|DRUG|Durvalumab|1500mg，IV，d1，q3w
218973226|NCT06708858|DRUG|Pembrolizumab|200mg，IV，d1，q3w
219065795|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
219065796|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219065797|NCT03096782|DRUG|Busulfan|Given IV
219065798|NCT03096782|DRUG|Clofarabine|Given IV
219065799|NCT03096782|DRUG|Cyclophosphamide|Given IV
219065800|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
219065801|NCT03096782|DRUG|Fludarabine|Given IV
219065802|NCT03096782|DRUG|Melphalan|Given IV
219065803|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
219065804|NCT03096782|BIOLOGICAL|Rituximab|Given IV
219665087|NCT00333632|DRUG|Isoflurane|
219665088|NCT05947435|DRUG|Tranexamic acid|Tranexamic acid was administered in intravenous or locally within irrigation fluid
219665089|NCT01716611|DRUG|Tolvaptan|15 - 60 mg/day for 28 days
219665090|NCT01716611|DRUG|placebo|
219065805|NCT03096782|DRUG|Tacrolimus|Given IV
219665091|NCT02708030|OTHER|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
219665092|NCT02708030|OTHER|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
218973227|NCT06708650|RADIATION|Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF|Patients received intravenous PD-1 inhibitor 200mg(Camrelizumab, Tislelizumab, or Sintilimab) plus oral Apatinib 250 mg or Lenvatinib 12mg (for bodyweight ≥60 kg) or 8 mg/kg (for bodyweight \<60 kg) daily, and additional SFRT for primary liver tumor. PD-1 inhibitor is administered for 2 years or until disease progression or intolerance. Anti-VEGFR is continued until disease progression or intolerance. SFRT implementation plan is as follows: The GTV consists of 2-5 sub-target volumes, which are cylindrical shapes with a diameter of 1.6cm, a height of 2cm, and an interval of 3-5cm. The total volume of the GTV is about 8-20cc, and the distance between the GTV and the OARs is greater than 2cm. The prescribed dosage for each course of radiotherapy is 24 Gy in 3 daily fractions (8Gy x 3F), with a 3-week interval between courses (Q3W). The total courses of radiotherapy shall not be less than 2 (depending on the efficacy and cumulative dose of OARs).
219665093|NCT02708030|OTHER|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
219665094|NCT00994214|DRUG|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
219665095|NCT03917979|BEHAVIORAL|Individual GIM|Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
219665096|NCT03917979|BEHAVIORAL|Waitlist Control|Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
219665097|NCT02217800|DRUG|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
219665098|NCT02217800|DRUG|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
218973228|NCT06705062|DRUG|reduced-dose PTCy|Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.
218973229|NCT06705062|DRUG|Standard dose PTCY|Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
219065806|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
219065807|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
219065808|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
219065809|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
219065810|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
219665099|NCT02217800|DRUG|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
218973230|NCT06707779|OTHER|PNF with electrical stimulation|"Group A receive PNF including combination of isotonic and rhythmic stabilization on trunk with electrical stimulation Participants perform three sets10 repetitions at maximal resistance The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes. 'BURST' TENS (acupuncture-like TENS), characterized by discontinuous stimulation at low frequencies (1-4 Hz), with wave durations of 100-400 ms and high intensities, inducing weak muscle twitches for 10 minutes."
218973231|NCT06707779|OTHER|PNF without electrical stimulation|"Group B receive PNF including combination of isotonic and rhythmic stabilization on trunk without electrical stimulation. Participants perform three sets of 10 repetitions at maximal resistance will be provided by the same physiotherapist.~The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes."
218973232|NCT06709729|DEVICE|Insulin pump with closed-loop system|Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS
218973233|NCT04275635|DEVICE|Orthokeratology lenses|Orthokeratology lenses
218973234|NCT06879249|DEVICE|critical ultrasonography|In the CUGP group, attending physicians utilized a designed fluid management strategy guided by ultrasonographic evaluation of the inner diameter of IVC, ejection fraction (EF) value and passive leg raising-induced changes in VTI (ΔVTI). This ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. Additionally, patients did not preclude the concurrent use of conventional hemodynamic monitoring methods. At each of these time points, attending physicians would make comprehensive decisions on fluid management based on the results of ultrasonographic evaluation, along with other monitoring methods. The researcher recorded the basis of decisions, disposal strategy and outcomes.
218973235|NCT06877923|DIETARY_SUPPLEMENT|Elemental 028 Extra|Elemental 028 Extra formulations. Both powder and liquid versions will be used
218973236|NCT06906120|BEHAVIORAL|Virtual Reality-Based Operating Room Education|"For the Intervention Group:~Written informed consent will be obtained one day before surgery when patients visit the anesthesia clinic.~Subsequently, the Patient Introduction Form, State-Trait Anxiety Inventory (STAI-I, STAI-II), and Surgical Fear Scale will be completed, and electrodermal activity data and physiological parameters will be recorded for 5 minutes.~Participants will watch a 3D training video created by the researcher using Meta Quest 3 virtual reality headsets. This video will provide an introduction to the operating room environment and related procedures.~After the video, physiological parameters will be recorded again, and STAI-I and the Surgical Fear Scale will be completed.~On the day of the surgery, after the patients are admitted and necessary preparations are made, STAI-I and the Surgical Fear Scale will be completed again, and physiological parameters will be recorded.~Electrodermal activity data will be recorded 15-20 minutes before anesthesia is administ"
218973237|NCT06923345|COMBINATION_PRODUCT|Reduced CTV|"Long-course radiotherapy with selective CTV reduction (lower to S2/S3 level) + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
219065811|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
219065812|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
219665100|NCT03488602|BEHAVIORAL|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
219665101|NCT03488602|BEHAVIORAL|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
219665102|NCT04441749|DEVICE|Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)|Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
219665103|NCT02981732|OTHER|Liuwei Dihuang Pill|
219665104|NCT01599481|BEHAVIORAL|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
219065813|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
219065814|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
219065815|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
219065816|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
219065817|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
219665105|NCT01599481|BEHAVIORAL|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
219665106|NCT04802083|BIOLOGICAL|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
219665107|NCT02982148|DEVICE|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
218973238|NCT06923345|COMBINATION_PRODUCT|Conventional CTV|"Long-course radiotherapy with conventional CTV irradiation + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
218973239|NCT06933394|DRUG|Arsenic trioxide|Patients will receive 9 cycles of chemotherapy. ATO dosing: Arsenic trioxide（ATO） is administered 0.18mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10.
218973240|NCT06933394|DRUG|MAPK inhibitors|"The dosage of MAPK inhibitors is adjusted based on the specific drug. For example, Trametinib is used as follows: Trametinib will be administered daily from Cycle 5 until the end of induction chemotherapy. Patients start at Dose Level I; if no hematologic toxicity or severe drug-related complications occur after 1 cycle, the dose is escalated to the next level, otherwise, it is maintained. Dose Level I: 0.016 mg/kg/day (\<6 years) or 0.012 mg/kg/day (\>6 years), po. qd. Dose Level II: 0.024 mg/kg/day (\<6 years) or 0.018 mg/kg/day (\>6 years), po. qd. Dose Level III: 0.032 mg/kg/day (\<6 years) or 0.025 mg/kg/day (\>6 years), po. qd.~The dosages of other MAPK inhibitors should be modified according to their respective recommended therapeutic guidelines."
218973241|NCT06933394|DRUG|Chemotherapy|"The conventional chemotherapy regimens are as follows:~Cycles 1, 2, 4, and 6 follow the CAV regimen (cyclophosphamide(1.2g/m2.d, d3-d4), pirarubicin(25mg/m2.d,d3-d5), vincristine(0.022mg/kg.d or 0.67mg/m2.d，d3-d5)).~Cycles 3, 5, and 7 follow the PVP regimen (cisplatin(50mg/m2.d, d3-d6), etoposide(200mg/ m2.d, d3-d5)).~Cycles 8 and 9 follow the CT regimen (cyclophosphamide(1.2g/m2.d, d3-d4), topotecan(2mg/m2.d, d3-d5))."
218973242|NCT06934304|OTHER|new preoperative handout|A new preoperative handout for robotic sacrocolpopexy was designed at a lower reading level and providing more perioperative details
218973243|NCT06934304|OTHER|old preoperative handout|The old or standard preoperative handout for robotic sacrocolpopexy
218973244|NCT06934824|PROCEDURE|Sixty patients with early gastric cancer in stage T1bN0-1M0 were divided into Group A-N0 and Group B-N + according to the presence or absence of lymph node metastasis. When the enrolled patients und|"Patients in group A-No lymph node metastasis, who underwent simple Double-Endoscopic Combined with local full-thickness resection.~Patients in group B-imaging examination showed lymph node metastasis. patients were randomly divided into Group N + a and Group N + b.~Group N + a: Local full-thickness gastric wall and lymph nodes dissection on D1 or D1 + were performed with Double-Endoscopic Group N + b: Traditional standard surgical gastrectomy and D1 or D1 + lymph nodes dissection was performed ."
218973245|NCT06934486|DEVICE|TissuePatch Sealant Film|Sealant film
218973246|NCT06933849|BEHAVIORAL|Structured case management|When a Bluestone Accountable Care Organization registers in an emergency department, a Bluestone chronic care manager contacts emergency department clinicians by phone and fax to provide up-to-date clinical and discharge support information.
218973247|NCT06933836|DEVICE|DSLT enables newly diagnosed patients to remain well controlled and off medications|DSLT enables newly diagnosed patients to remain well controlled and off medications
218973248|NCT06933303|DEVICE|Distraction with kaleidoscope|During the intervention measurement, the pediatric patient will be distracted by the use of a kaleidoscope during the procedure. Distraction by use of the kaleidoscope will be initiated at the start of the procedure (dressing change) and the kaleidoscope will be offered until at least a minute after the procedure is completed. Removal of the dressing will be started when the child seems distracted as indicated by response with a smile or laughter, or a verbal response
219065818|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
219065819|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
219065820|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
219665108|NCT02982148|DEVICE|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
219665109|NCT04321941|DIAGNOSTIC_TEST|Lumentin|Contrast agent used in combination with CTE
219065821|NCT02760238|OTHER|Observational|
219665110|NCT04321941|DIAGNOSTIC_TEST|Movprep|Contrast agent used in combination with MRE
219665111|NCT05891717|OTHER|Resistance training|Twice per week for 8 weeks. Total 16 sessions will given.
219665112|NCT05891717|OTHER|Flexibility training|Twice per week for 8 weeks. Total 16 sessions will given.
218973249|NCT06933147|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|This intervention involved constraining the unaffected upper limb for 6 hours per day and performing 3-hour intermittent daily sessions of functional task practice with the affected limb for 12 weeks, 5 days per week. Exercises included stretching, grasping, dexterity tasks, and functional activities like self-feeding and button pressing. The program used shaping techniques to increase task difficulty and improve motor recovery. A home exercise program was also prescribed for daily practice.
218973250|NCT06933147|BEHAVIORAL|Resistance Training (RT)|This intervention consisted of structured progressive resistance exercises targeting the affected upper limb muscles (shoulder, elbow, wrist) using weight cuffs (½-1 kg). Sessions were 60 minutes/day, 5 days/week, for 12 weeks. Intensity progressed from 50% to 70% of 1-repetition maximum (1RM) based on individual capacity. Exercises were performed in 3 sets of 8 repetitions for each muscle group, with 2-minute rest intervals. A home program included additional wrist and hand strengthening tasks.
218973251|NCT06934096|DEVICE|Ultrasound Pulsed Doppler Imaging System|Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.
218973252|NCT03803683|DEVICE|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
218973253|NCT03803683|BEHAVIORAL|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
219665113|NCT01575002|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
219665114|NCT06397209|OTHER|Propioceptive Neuromascular facilitation|Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks
219665115|NCT06397209|OTHER|Neural Flossing|Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
219665116|NCT06199544|DRUG|Metformin|Comparing the effect of drugs on symptoms of PCOS
219665117|NCT00394394|DRUG|Amiloride 2,5/d or Enalapril/d 10 mg|
219665118|NCT05693025|BEHAVIORAL|Group Exercise|The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
219665119|NCT05693025|BEHAVIORAL|Behavioral Training|The study evaluates two different approaches for promoting behavior change. Participants in the Standard Training (ST) model follow the standardized Walk with Ease training to support behavior change. Participants are provided with goal setting tools and an online tracker to monitor their progress. Weekly video-based lessons, resource links and eBook content support behavior change. Primary BCTs include Goal Setting (BCT #1.1) and self-monitoring (BCT#2.3). Participants in the Enhanced Training (ET) model access the same basic content as the ST model, but the weekly education-based videos are replaced with lessons focus on habit-formation training. Student coaches are also assigned to individual participants to support behavior change efforts using motivational interviewing strategies. Thus, participants in the ET model also receive two additional theory- and evidence-based BCTs: (1) habit formation training (BCT#1.2, #1.4, #8.3) and (2 health coaching (BCT# 3.3).
219665120|NCT03531476|BEHAVIORAL|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
219665121|NCT01375452|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
219665122|NCT00851864|DRUG|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
219665123|NCT02436499|DRUG|Botulinum Toxin-A|
218973254|NCT03803683|DEVICE|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
218973255|NCT04125277|OTHER|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
218973256|NCT00775216|BEHAVIORAL|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
218973257|NCT00195572|DRUG|Isovorin|
218973258|NCT00195572|DRUG|TS-1|
218973259|NCT00960739|DRUG|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
219665124|NCT02614404|DRUG|Imatinib combination therapy|Imatinib plus dihydroartemisinin plus piperaquine
219665125|NCT02614404|DRUG|Dihydroartemisinin-piperaquine|Standard of care
219665126|NCT05205629|DRUG|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
219665127|NCT04591015|BEHAVIORAL|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
218973260|NCT00960739|PROCEDURE|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
218973261|NCT00960739|RADIATION|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
218973262|NCT00960739|RADIATION|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
218973263|NCT00413400|DRUG|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
218973264|NCT00413400|DRUG|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
218973265|NCT02505178|OTHER|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
218973266|NCT02387177|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
218973267|NCT02387177|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
218973268|NCT02504996|DRUG|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
218973269|NCT02504996|DRUG|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
218973270|NCT02504996|DRUG|Placebo|Intravenous 100 ml normal saline
218973271|NCT01149837|DEVICE|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
218973272|NCT04710134|BIOLOGICAL|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
218973273|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
218973274|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
218973275|NCT00891462|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
218973276|NCT00970073|BIOLOGICAL|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
218973277|NCT00970073|BIOLOGICAL|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
218973278|NCT00970073|DRUG|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
218973279|NCT00970073|DRUG|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
218973280|NCT00970073|DRUG|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
218973281|NCT01786655|DRUG|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
218973282|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
218973283|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
218973284|NCT01786655|OTHER|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
218973285|NCT01757262|DRUG|90 mg Ticagrelor|Morning and Evening dose for 5 days
218973286|NCT01757262|DRUG|75mg Clopidogrel|Morning dose for 5 days
218973287|NCT03063242|DRUG|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
218973288|NCT03063242|BIOLOGICAL|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
218973289|NCT05948787|BEHAVIORAL|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
218973290|NCT04864301|PROCEDURE|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
218973291|NCT03431766|DEVICE|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
219665128|NCT04591015|BEHAVIORAL|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
219665129|NCT02686814|DEVICE|17mm MDT-2215 aortic valve bioprosthesis|
219665130|NCT04051814|OTHER|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
219665131|NCT02401698|OTHER|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
219665132|NCT05124483|BIOLOGICAL|AKS-452X|subcutaneous injection of 90 µg AKS-452X
219665133|NCT02110628|PROCEDURE|Roux-en-Y anastomosis|Roux-en-Y anastomosis
219665134|NCT02110628|PROCEDURE|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
219665135|NCT02097771|DEVICE|LMA SupremeTM|
219665136|NCT02097771|DEVICE|AuraOnceTM|
219665137|NCT01609088|DIETARY_SUPPLEMENT|Erythritol-containing beverage|Orange flavored beverage containing erythritol
218973292|NCT03431766|DEVICE|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
218973293|NCT05040048|OTHER|Clinical, biological and imaging assessment|
218973294|NCT04672395|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
218973295|NCT04672395|BIOLOGICAL|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
218973296|NCT04672395|BIOLOGICAL|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
218973297|NCT04672395|BIOLOGICAL|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
218973298|NCT00121381|DRUG|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
218973299|NCT00121381|DRUG|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
218973300|NCT03545100|OTHER|motor control therapy|scapular muscle progressive resistive exercise(PRE)
218973301|NCT03545100|OTHER|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
218973302|NCT02474381|BIOLOGICAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
218973303|NCT02474381|DEVICE|Single PTA|Angioplasty of arteries below tibial plateau level only
218973304|NCT03029442|DRUG|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
219665138|NCT04665973|BEHAVIORAL|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
219665139|NCT04665973|BEHAVIORAL|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
219665140|NCT00290693|DRUG|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
219665141|NCT00290693|DRUG|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
218973305|NCT03029442|OTHER|Placebo (normal saline)|Identical Denosumab volume of normal saline
218973306|NCT01595672|DEVICE|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
218973307|NCT01595672|OTHER|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
219665142|NCT03797131|OTHER|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
219665143|NCT02907619|BIOLOGICAL|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
219665144|NCT01908582|DRUG|Evacetrapib|Administered orally
219665145|NCT01908582|DRUG|Rifampin|Administered orally
219665146|NCT00163033|DRUG|estetrol|
219665147|NCT05831306|OTHER|Diet A|Modified Diet A
219665148|NCT05831306|OTHER|Diet B|Modified Diet B
219665149|NCT00431899|BEHAVIORAL|fish oil supplementation|
219665150|NCT05440721|DEVICE|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
219665151|NCT05440721|DEVICE|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
219665152|NCT00004197|BIOLOGICAL|keyhole limpet hemocyanin|
219665153|NCT00004197|BIOLOGICAL|sargramostim|
219065822|NCT04823598|PROCEDURE|Coached pushing and Finnish manual perineal protection|"Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin."
219665154|NCT00004197|BIOLOGICAL|tumor cell-based vaccine therapy|
219665155|NCT00004197|DRUG|cyclophosphamide|
219665156|NCT00004197|DRUG|doxorubicin hydrochloride|
219665157|NCT00004197|DRUG|mitoxantrone hydrochloride|
219665158|NCT00004197|DRUG|prednisone|
219665159|NCT00004197|DRUG|vincristine sulfate|
219665160|NCT05254470|DEVICE|Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
219665161|NCT00888290|DRUG|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
219665162|NCT00888290|DRUG|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
218973308|NCT04382391|DEVICE|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
218973309|NCT04382391|OTHER|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
218973310|NCT03124446|BEHAVIORAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
218973311|NCT03124446|BEHAVIORAL|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
218973312|NCT04601402|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
218973313|NCT04601402|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
218973314|NCT03531125|PROCEDURE|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
219208431|NCT06760195|PROCEDURE|Intra-arterial hypothermic magnesium sulfate infusion|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
218973315|NCT03531125|PROCEDURE|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
218973316|NCT00257608|DRUG|bevacizumab|Intravenous repeating dose
219665163|NCT00073645|BEHAVIORAL|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
219665164|NCT00073645|BEHAVIORAL|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
219665165|NCT04886752|DIETARY_SUPPLEMENT|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
219665166|NCT04886752|DIETARY_SUPPLEMENT|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
219665167|NCT04886752|DIETARY_SUPPLEMENT|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
219665168|NCT05509101|OTHER|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
218973317|NCT00257608|DRUG|placebo|Oral repeating dose
218973318|NCT00257608|DRUG|erlotinib HCl|Oral repeating dose
218973319|NCT05207254|DIAGNOSTIC_TEST|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
218973320|NCT05390931|BEHAVIORAL|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
218973321|NCT05390931|OTHER|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
218973322|NCT05390931|OTHER|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
218973323|NCT05390931|OTHER|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
218973324|NCT01197664|DRUG|paricalcitol|Given PO
218973325|NCT01197664|RADIATION|radiation therapy|Undergo radiotherapy
218973326|NCT01197664|OTHER|laboratory biomarker analysis|Correlative studies
218973327|NCT01197664|DRUG|fluorouracil|Given PO
218973328|NCT00000337|DRUG|Selegiline|
218973329|NCT02171065|DEVICE|sham|
218973330|NCT02171065|DEVICE|ABSORB BVS|
218973331|NCT05015439|DRUG|Cannabidiol|The study intervention will be supplied as a softgel capsule containing cannabidiol.
218973332|NCT05015439|DRUG|Placebo|The study intervention will be supplied as a softgel capsule containing inert filler.
218973333|NCT00562029|PROCEDURE|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
218973334|NCT05414877|DRUG|Ephedrine|vasopressor
218973335|NCT05414877|DRUG|Phenylephrine|vasopressor
218973336|NCT05414877|DRUG|Norepinephrine|vasopressor
218973337|NCT06558513|DRUG|XNW5004 tablets|XNW5004 an EZH2 inhibitor, BID, administered in continuous
218973338|NCT03245684|DIAGNOSTIC_TEST|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
218973339|NCT03134404|OTHER|No Intervention|No Intervention is required for this study
218973340|NCT06169046|DRUG|Clenbuterol|tablets
218973341|NCT06169046|DRUG|Placebo|tablets
218973342|NCT01435278|DEVICE|Glucosanol|2 tablets taken 3 times a day.
218973343|NCT00066638|DRUG|Romidepsin|Given IV
218973344|NCT00066638|OTHER|Laboratory Biomarker Analysis|Correlative studies
218973345|NCT04672343|OTHER|Data collection|from D0 to hospital discharge
218973346|NCT04672343|OTHER|Querying the INSEE database|Vital status at 3 months and 12 months
218973347|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
218973348|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
218973349|NCT01705990|BIOLOGICAL|Ad35-GRIN (0.5mL)|(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
218973350|NCT05557435|OTHER|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
218973351|NCT05557435|OTHER|Placebo|Placebo
218973352|NCT02007993|OTHER|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
218973353|NCT02007993|OTHER|Tongue Scraper|The pacient will scrap the tongue 10 times.
218973354|NCT03816488|DRUG|Metformin|Metformin (usual dose) administered 2 h before surgery
218973355|NCT03816488|DRUG|Salsalate|Salsalate 1.5 g administered 2 h before surgery
219208432|NCT06760195|PROCEDURE|Endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
219665169|NCT05509101|OTHER|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
218973356|NCT04394611|OTHER|Obstetric ultrasound- doppler examination|Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
218973357|NCT02874157|BIOLOGICAL|blood draw|
218973358|NCT05282329|DEVICE|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
218973359|NCT05282329|DEVICE|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
218973360|NCT02793921|BEHAVIORAL|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
218973361|NCT04423783|BEHAVIORAL|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
219208433|NCT06760195|DRUG|Intravenous thrombolysis|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
219208434|NCT06759246|PROCEDURE|implant placement|Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.
219665170|NCT02008032|DEVICE|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
219665171|NCT05573438|OTHER|Group fructose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
218973362|NCT04423783|BEHAVIORAL|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
218973363|NCT06706856|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.
218973364|NCT06706856|DIAGNOSTIC_TEST|US exam|Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.
218973365|NCT06706856|OTHER|Blood draw|Participants will undergo a blood draw of approximately 25 mL volume.
218973366|NCT06706856|OTHER|Physical measurements|Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.
218973367|NCT06706856|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).
218973368|NCT03621774|BEHAVIORAL|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
218973369|NCT03621774|BEHAVIORAL|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
218973370|NCT00694915|BIOLOGICAL|Mycobacterium w|Immunomodulator
218973371|NCT00694915|BIOLOGICAL|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
218973372|NCT03851471|DRUG|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
218973373|NCT01334892|DRUG|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
218973374|NCT01614600|DEVICE|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
218973375|NCT01030068|BEHAVIORAL|Yoga|Yoga twice weekly
218973376|NCT01030068|BEHAVIORAL|Wellness|Health and wellness classes twice weekly
218973377|NCT01030068|OTHER|Smoking cessation therapy|Smoking cessation therapy
218973378|NCT03484637|OTHER|Lifestyle-medicine intervention|
219665172|NCT05573438|OTHER|Group Sucrose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
219665173|NCT05573438|OTHER|Group Glucose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
219665174|NCT05161572|DRUG|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
218973379|NCT03855956|OTHER|KB174|KB174 is a novel mixture of oligosaccharides.
218973380|NCT03855956|OTHER|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
218973381|NCT03926871|OTHER|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
218973382|NCT04687384|PROCEDURE|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
218973383|NCT04687384|PROCEDURE|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
218973384|NCT05472324|DRUG|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
218973385|NCT05472324|DRUG|Placebo|The drug is a placebo Comparator.
218973386|NCT02437513|DEVICE|NewBreez|Intralaryngeal prosthesis to protect the airways
218973387|NCT01230723|DEVICE|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
218973388|NCT01230723|DEVICE|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
219065823|NCT04823598|PROCEDURE|Uncoached pushing and Hands-poised perineal protection|Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
218973389|NCT01896336|DRUG|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
218973390|NCT01391754|BEHAVIORAL|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
219065824|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
219065825|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
219065826|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
219665175|NCT05161572|DRUG|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
219665176|NCT05161572|DRUG|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
219665177|NCT05161572|RADIATION|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
219665178|NCT05161572|PROCEDURE|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
219665179|NCT05087446|BEHAVIORAL|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
218973391|NCT01391754|OTHER|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
218973392|NCT01391754|BEHAVIORAL|Services As Usual|Home based services not using the SafeCare model
218973393|NCT01391754|OTHER|Uncoached|No in vivo coached quality control or fidelity monitoring
219065827|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
219065828|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
219065829|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
219065830|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
219065831|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
219065832|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
219065833|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
219065834|NCT01385345|DRUG|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
219065835|NCT04202380|DRUG|Azithromycin|Patients will receive Azithromycin orally 1000 mg
219065836|NCT04202380|DRUG|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
219065837|NCT04202380|DRUG|Azithromycin|Azithromycin 500 mg orally once
218973394|NCT00141388|DRUG|Pregabalin|
218973395|NCT02457481|DEVICE|Embryo Culture medium|Two step sequential embryo culture medium system
218973396|NCT04269590|BEHAVIORAL|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
218973397|NCT04269590|BEHAVIORAL|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
218973398|NCT05320185|DEVICE|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
219665180|NCT05087446|BEHAVIORAL|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
219665181|NCT03196375|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
219665182|NCT03196375|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
219665183|NCT03267602|DEVICE|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI\> 15 and present obvious symptoms or~2. less than 18 years, AHI still\> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
218973399|NCT02708901|DIETARY_SUPPLEMENT|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
218973400|NCT02708901|DIETARY_SUPPLEMENT|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
218973401|NCT03836703|DRUG|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
218973402|NCT03836703|DRUG|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
218973403|NCT01874743|DRUG|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
218973404|NCT00110903|DRUG|Etanercept Liquid|
218973405|NCT03347188|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
218973406|NCT03347188|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
218973407|NCT04156477|DIETARY_SUPPLEMENT|Ketone ester|Intake of weight adjusted drink of a ketone ester
218973408|NCT04156477|DIETARY_SUPPLEMENT|Glucose|Isocaloric and - volumetric taste adjusted drink
218973409|NCT04156477|DIETARY_SUPPLEMENT|Tap water|Isovolumetric taste adjusted tap water (placebo)
218973410|NCT03368612|OTHER|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
218973411|NCT03368612|OTHER|Electronic evaluation system|AirGo recording
218973412|NCT04937855|OTHER|no intervention|no intervention
218973413|NCT03998878|BEHAVIORAL|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
218973414|NCT03998878|BEHAVIORAL|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
219665184|NCT05230199|BEHAVIORAL|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
219665185|NCT05230199|BEHAVIORAL|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
219665186|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
218973415|NCT03998878|BEHAVIORAL|Hunger Training|Participants will be instructed to follow Hunger Training.
218973416|NCT06115785|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
219065838|NCT04202380|DRUG|Azithromycin|Azithromycin 250 mg orally daily for 4 days
218973417|NCT02537782|DEVICE|Cardiac resynchronisation therapy|
218973418|NCT02537782|OTHER|Echocardiography|
218973419|NCT02537782|OTHER|Magnetic Resonance Imaging|
218973420|NCT02537782|OTHER|Positron Emission Tomography|
218973421|NCT06393543|OTHER|No intervention, only registration|No intervention, only registration
218973422|NCT02954627|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
218973423|NCT05413070|BEHAVIORAL|Multimodal approach to QI for Low-Value Care|Up to 4 brief educational components in existing quality meetings Informational email/newsletter Individualized performance feedback reports Educational resources for patients
218973424|NCT02219347|DRUG|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
218973425|NCT01593189|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
218973426|NCT00195273|DRUG|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
218973427|NCT00195273|DRUG|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
218973428|NCT00195273|DRUG|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
218973429|NCT00195273|DRUG|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
218973430|NCT00195273|DRUG|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
218973431|NCT02186873|DRUG|Placebo|Participants will receive matching placebo.
218973432|NCT02186873|DRUG|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
218973433|NCT01680965|DRUG|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
218973434|NCT01681017|BEHAVIORAL|HBB/ENC Training and Equipment|See the detailed description section
218973435|NCT01681017|OTHER|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
218973436|NCT05883423|OTHER|FPCMP-Old Age|"1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
218973437|NCT00595465|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
218973438|NCT00004868|DRUG|semaxanib|
218973439|NCT03878238|DIETARY_SUPPLEMENT|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
218973440|NCT03878238|OTHER|Placebo|Placebo with maltodextrin base.
218973441|NCT01519232|RADIATION|Liver Irradiation|Patients already scheduled to undergo radiation treatment
218973442|NCT05285800|DRUG|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
218973443|NCT02343107|BEHAVIORAL|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
218973444|NCT00244062|BEHAVIORAL|counseling|
218973445|NCT06435728|DIAGNOSTIC_TEST|AccuIMR and AccuFFR|AccuFFR and AccuIMR were obtained by reviewing coronary angiography at the time of primary PCI
219065839|NCT04437251|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
219065840|NCT01016665|DRUG|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
219665187|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
219665188|NCT06118450|OTHER|Non-intervention|non-intervention
219665189|NCT05090306|DIAGNOSTIC_TEST|Routine ultrasound examination|ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
219665190|NCT02119806|DRUG|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
219665191|NCT02119806|DRUG|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
219665192|NCT02119806|DRUG|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
219665193|NCT03484403|OTHER|Lumbar back brace|A brace that supports the lumbar region of the spine.
219665194|NCT03484403|BEHAVIORAL|Back school|Back school consists of patient education physical therapy exercise instruction.
219665195|NCT02060864|DIETARY_SUPPLEMENT|AN-PEP|Two pills are consumed in the morning with a breakfast
219065841|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
219665196|NCT02060864|DIETARY_SUPPLEMENT|Placebo|
219065842|NCT03380442|DRUG|Psilocybin|Psilocybin ingested orally
219065843|NCT03380442|DRUG|Ketamine (Ketalar)|Ketamine administered intranasally
219665197|NCT04187716|DRUG|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
219665198|NCT01114295|DEVICE|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
219665199|NCT01114295|RADIATION|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
219665200|NCT03699371|PROCEDURE|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
219665201|NCT02263014|BEHAVIORAL|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
219665202|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
219065844|NCT05476224|BIOLOGICAL|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
219065845|NCT02136173|DEVICE|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
219665203|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
219665204|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
219665205|NCT05993234|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
219665206|NCT05960357|OTHER|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
219665207|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous injection
219665208|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous injection
219665209|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
219665210|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
219065846|NCT04824313|DIAGNOSTIC_TEST|Chest CT|Chest CT without intravenous contrast material
219665211|NCT06251518|BEHAVIORAL|vimida|Participants will receive access to the digital health intervention vimida in addition to TAU.
219665212|NCT05118724|DRUG|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
219665213|NCT05118724|DRUG|IMM-101|Suspension of Heat-Killed Whole Cell Mycobacterium obuense (NCTC 13365) in Borate Buffered Saline for Intradermal Injection
219665214|NCT04767529|DRUG|Efruxifermin|subcutaneous injection
219065847|NCT04824313|DIAGNOSTIC_TEST|Chest CTA|Chest CT with intravenous contrast material
219065848|NCT04006977|DIETARY_SUPPLEMENT|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
219065849|NCT04006977|DIETARY_SUPPLEMENT|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
219065850|NCT06535594|OTHER|Laser acupuncture|Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
219665215|NCT04767529|DRUG|Placebo|subcutaneous injection
219665216|NCT03674437|BEHAVIORAL|Traditional Neurocognitive Assessments|Traditional Neurocognitive Assessments given with pen and paper
219665217|NCT03674437|BEHAVIORAL|Online Cognitive Battery (Cogsuite)|Cognition (Cogsuite) for a battery that consists of seven measurements.
219665218|NCT06464302|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
219065851|NCT06535594|OTHER|Physical therapy|Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
219065852|NCT03082963|DEVICE|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
219065853|NCT00142974|DRUG|Tegaserod|
219665219|NCT06464302|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
218973446|NCT04996381|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
218973447|NCT04750603|DRUG|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
218973448|NCT04750603|DRUG|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
218973449|NCT02595970|DRUG|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
218973450|NCT06130917|OTHER|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
218973451|NCT06130917|OTHER|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
218973452|NCT00241085|DRUG|valsartan|
218973453|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
218973454|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
218973455|NCT02537028|DRUG|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
218973456|NCT01613365|DRUG|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
218973457|NCT01613365|DRUG|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
218973458|NCT00107783|DRUG|Nitisinone (NTBC)|Treatment
218973459|NCT00315536|DRUG|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
218973460|NCT02910362|DEVICE|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
218973461|NCT02910362|DEVICE|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
218973462|NCT05663229|DEVICE|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
218973463|NCT05129670|DEVICE|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
218973464|NCT05129670|DEVICE|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
218973465|NCT02187705|DRUG|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
218973466|NCT02547948|BIOLOGICAL|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
218973467|NCT03820180|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
219065854|NCT03551015|OTHER|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
219065855|NCT00547391|PROCEDURE|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
219065856|NCT00547391|OTHER|no intervention|No intervention (controls). Follow up started from the day of randomization.
219065857|NCT04401579|OTHER|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
218973468|NCT03820180|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
218973469|NCT05877768|DIAGNOSTIC_TEST|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
218973470|NCT01051466|DRUG|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
218973471|NCT05626582|PROCEDURE|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
218973472|NCT05626582|PROCEDURE|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
218973473|NCT02231918|DRUG|MIRAPEX® - low|
218973474|NCT02231918|DRUG|MIRAPEX® - medium|
219208435|NCT06759883|COMBINATION_PRODUCT|local dishes using the my plate concept|The intervention in this study consists of replacing the ready-to-use therapeutic foods prescribed in phase 2 of the management of acute severe malnutrition with balanced local dishes.
219665220|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
219665221|NCT01450072|DEVICE|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
219665222|NCT01450072|OTHER|Control arm|Venography and sham angioplasty
219665223|NCT04060771|DRUG|Palonosetron|prophylaxis of postoperative nausea and vomiting
219665224|NCT04060771|DRUG|Dexamethasone|prophylaxis of postoperative nausea and vomiting
219665225|NCT04500678|DRUG|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
219665226|NCT06640946|DRUG|Topical lidocaine|Topical lidocaine cream prior to laser follicle ablation
219665227|NCT06640946|DRUG|Sham cream|Placebo cream without lidocaine will be placed and removed before laser.
219665228|NCT03128034|DRUG|Cyclosporine|Given PO or IV
219665229|NCT03128034|DRUG|Fludarabine Phosphate|Given IV
218973475|NCT02231918|DRUG|MIRAPEX® - high|
218973476|NCT06270329|OTHER|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
218973477|NCT06270329|OTHER|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
218973478|NCT00794781|DRUG|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
218973479|NCT04355507|DIAGNOSTIC_TEST|Chest computed tomography (CT)|Chest computed tomography (CT) examination
218973480|NCT04355507|DIAGNOSTIC_TEST|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
218973481|NCT04045548|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
218973482|NCT04045548|DRUG|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
218973483|NCT01568515|PROCEDURE|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
218973484|NCT00234273|PROCEDURE|Rehabilitation programme in Adapted Physical Activity (APA)|
218973485|NCT00234273|BEHAVIORAL|Therapeutic education primarily focused on dietary|
218973486|NCT00579592|DRUG|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
218973487|NCT05143450|OTHER|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
218973488|NCT05391529|BEHAVIORAL|Interview|Semi structured patient interview via telephone
218973489|NCT00772473|OTHER|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
218973490|NCT00072657|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
218973491|NCT00072657|BEHAVIORAL|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
218973492|NCT00072657|BEHAVIORAL|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
219665230|NCT03128034|DRUG|Mycophenolate Mofetil|Given PO or IV
219665231|NCT03128034|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
219665232|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 211\^At-BC8-B10 IV
219665233|NCT03128034|RADIATION|Total-Body Irradiation|Undergo TBI
219665234|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 131\^I-BC8-B10 IV
219665235|NCT03128034|PROCEDURE|Biospecimen Collection|Undergo blood and bone marrow aspirate sample collection
219665236|NCT03128034|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
219208436|NCT06760065|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.
219665237|NCT04542434|DRUG|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
219665238|NCT04542434|DRUG|Placebo|Matching placebo tablets 3 times daily for 14 days
219665239|NCT00021645|DRUG|Vitamin E|
219665240|NCT02711943|DRUG|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
219665241|NCT03749499|OTHER|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
218973493|NCT03562910|OTHER|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
218973494|NCT03419520|BEHAVIORAL|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
218973495|NCT05014217|BEHAVIORAL|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
218973496|NCT05014217|BEHAVIORAL|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
218973497|NCT00547196|BIOLOGICAL|filgrastim|
218973498|NCT00547196|DRUG|Busulfan|
218973499|NCT00547196|DRUG|Cyclophosphamide|
218973500|NCT00547196|DRUG|Cyclosporine|
218973501|NCT00547196|DRUG|Fludarabine phosphate|
218973502|NCT00547196|DRUG|Melphalan|
218973503|NCT00547196|DRUG|Mycophenolate Mofetil|
218973504|NCT00547196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218973505|NCT00547196|PROCEDURE|umbilical cord blood transplantation|
218973506|NCT00547196|RADIATION|total-body irradiation|
218973507|NCT00547196|RADIATION|Fractionated total body irradiation|
218973508|NCT01381484|DRUG|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
218973509|NCT04140838|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
218973510|NCT04140838|BEHAVIORAL|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
218973511|NCT04140838|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
218973512|NCT02020187|OTHER|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
218973513|NCT04425356|BEHAVIORAL|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
218973514|NCT06203379|OTHER|Neuromuscular Exercise Training|Neuromuscular Exercise Training
218973515|NCT06203379|OTHER|control exercise|Exercise Training
218973516|NCT00331864|DRUG|Ranibizumab|
218973517|NCT03234673|DRUG|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
218973518|NCT03234673|DRUG|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
219208437|NCT06760065|DRUG|Susceptibility-Guided Quadruple Therapy|Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
219208438|NCT06760091|OTHER|baseline data collection and follow-up|At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
219208439|NCT06759779|DEVICE|inspiratory muscle training|Inspiratory muscle training will be performed
219208440|NCT06759779|DEVICE|expiratory muscle training|Expiratory muscle training will be performed
219208441|NCT06759051|DEVICE|tDCS|The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.
219665242|NCT03749499|OTHER|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
219665243|NCT03749499|OTHER|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
219665244|NCT03749499|OTHER|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
219665245|NCT03208413|DRUG|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
219665246|NCT05199935|BEHAVIORAL|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
219665247|NCT05199935|OTHER|Control|Control video on healthy pregnancy
219665248|NCT02958410|BIOLOGICAL|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
218973519|NCT03234673|DRUG|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
218973520|NCT06556693|DEVICE|Dual Channel Stimulation|implant of dual channel stimulation device
218973521|NCT03898843|OTHER|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
218973522|NCT03898843|BIOLOGICAL|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
218973523|NCT03898843|BEHAVIORAL|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
218973524|NCT03898843|PROCEDURE|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
218973525|NCT03898843|OTHER|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
218973526|NCT03898843|BEHAVIORAL|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
218973527|NCT03898843|BEHAVIORAL|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
218973528|NCT03898843|BIOLOGICAL|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
218973529|NCT00555685|DRUG|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
218973530|NCT00555685|DRUG|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
218973531|NCT01092507|BIOLOGICAL|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
218973532|NCT01092507|BIOLOGICAL|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
218973533|NCT00351000|DRUG|Ziprasidone|
218973534|NCT03813667|BEHAVIORAL|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
218973535|NCT02829255|OTHER|altitude exposure|altitude exposure
218973536|NCT00100061|DRUG|Cranberry juice|liquid juice taken daily
218973537|NCT00100061|DIETARY_SUPPLEMENT|Cranberry Juice|Taken orally
219208442|NCT06759051|DEVICE|Sham (No Treatment)|In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.
219208443|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic based dosage change|This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B
219208444|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic dosing|Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint
219208445|NCT06794593|DRUG|Camostat Mesylate|Oral Camostat Mesylate 200 mg x 3 daily for 4 days.
219208446|NCT06797154|BEHAVIORAL|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
219208447|NCT06797154|OTHER|Usual Care + Sham|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
219665249|NCT03701685|PROCEDURE|nerve flap|sensory reconstruction via a nerve graft included in the flap
219208448|NCT01871766|DRUG|Vincristine|"Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants."
219208449|NCT01871766|DRUG|Dactinomycin|"Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
219208450|NCT01871766|DRUG|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)"
219208451|NCT01871766|PROCEDURE|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
219208452|NCT01871766|PROCEDURE|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
219208453|NCT01871766|DRUG|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
219208454|NCT01871766|DRUG|Sorafenib|Dosage and route of administration: 90 mg/m\^2/dose twice daily.
219665250|NCT04250428|BEHAVIORAL|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
219665251|NCT04250428|BEHAVIORAL|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
219665252|NCT05119686|DRUG|AR882 Dose 1|Solid Oral Capsule
219665253|NCT05119686|DRUG|AR882 Dose 2|Solid Oral Capsule
219665254|NCT05119686|DRUG|Placebo|Matching Solid Oral Capsule Placebo
219665255|NCT03495115|DEVICE|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
218973538|NCT00100061|DIETARY_SUPPLEMENT|Placebo cranberry juice|Placebo comparitor
218973539|NCT01228864|PROCEDURE|quality of life|survey
218973540|NCT01228864|PROCEDURE|Quality of life|
218973541|NCT01565720|DRUG|Isavuconazole|oral
218973542|NCT01565720|DRUG|Placebo|oral
218973543|NCT01565720|DRUG|Moxifloxacin|oral
218973544|NCT01542333|GENETIC|gene expression analysis|
218973545|NCT01542333|GENETIC|proteomic profiling|
218973546|NCT01542333|GENETIC|reverse transcriptase-polymerase chain reaction|
218973547|NCT01542333|GENETIC|western blotting|
218973548|NCT01542333|OTHER|immunohistochemistry staining method|
218973549|NCT01542333|OTHER|laboratory biomarker analysis|
218973550|NCT01542333|PROCEDURE|spectroscopy|
218973551|NCT01871142|DRUG|Placebo|100 mL
218973552|NCT01871142|DRUG|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
218973553|NCT01871142|DRUG|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
218973554|NCT06402630|DRUG|STS01|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
218973555|NCT06402630|DRUG|Placebo|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
218973556|NCT04799327|DRUG|SHR20004|SHR20004：low dose
218973557|NCT04799327|DRUG|SHR20004|SHR20004: medium dose
218973558|NCT04799327|DRUG|SHR20004|SHR20004: high dose
218973559|NCT04799327|DRUG|placebo|Placebo
218973560|NCT01815983|OTHER|Videolaryngoscopy review.|Review of video recordings.
218973561|NCT05500599|DRUG|Fentanyl Citrate|Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
218973562|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
218973563|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
219665256|NCT03495115|DEVICE|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
219665257|NCT05626075|DIAGNOSTIC_TEST|Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.|Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
219665258|NCT04480996|DRUG|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
219665259|NCT05647720|PROCEDURE|Distalization combined with upper third molars extraction|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
218973564|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
218973565|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
218973566|NCT05015530|DEVICE|Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract|Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
218973567|NCT03257176|BEHAVIORAL|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
218973568|NCT06025643|OTHER|TENS - Cervical stimulation group|TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.
218973569|NCT06025643|OTHER|TENS - Plus cervical stimulation group|TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.
218973570|NCT06025643|OTHER|TENS - Renal stimulation group|TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
218973571|NCT01539642|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
218973572|NCT01539642|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
218973573|NCT00898378|GENETIC|gene expression analysis|gene expression analysis
218973574|NCT00898378|GENETIC|polymerase chain reaction|polymerase chain reaction
218973575|NCT00898378|GENETIC|polymorphism analysis|polymorphism analysis
218973576|NCT00898378|GENETIC|protein expression analysis|protein expression analysis
218973577|NCT00898378|GENETIC|proteomic profiling|proteomic profiling
218973578|NCT00898378|OTHER|gas chromatography|gas chromatography
218973579|NCT00898378|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
218973580|NCT00898378|OTHER|liquid chromatography|liquid chromatography
218973581|NCT00898378|OTHER|mass spectrometry|mass spectrometry
218973582|NCT00898378|OTHER|questionnaire administration|questionnaire administration
218973583|NCT04758078|OTHER|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
218973584|NCT04758078|OTHER|Placebo|Nebulized 0.9% saline will be given four times per day
218973585|NCT00877110|DRUG|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
218973586|NCT05551208|DRUG|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
218973587|NCT00001966|DRUG|Mind-body therapy|
218973588|NCT06029738|BEHAVIORAL|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
218973589|NCT02364921|DEVICE|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
219065858|NCT04401579|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
219065859|NCT04401579|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
219208455|NCT01871766|DRUG|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
219665260|NCT05647720|PROCEDURE|Distalization without upper third molars extraction|The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
219665261|NCT05745753|OTHER|sample blood|At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
219665262|NCT00998205|DRUG|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
219665263|NCT00998205|DRUG|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
219665264|NCT02026596|PROCEDURE|Magnetic resonance imaging|
219665265|NCT02026596|PROCEDURE|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
219665266|NCT04063722|PROCEDURE|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
219665267|NCT03099226|DRUG|Placebo|Placebo blue hard gelatine capsules
219665268|NCT03099226|DRUG|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
218973590|NCT02364921|DEVICE|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
218973591|NCT06228274|DEVICE|ARTHRUM 2.5%|ARTHRUM 2.5%
218973592|NCT03731845|GENETIC|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
218973593|NCT03731845|BIOLOGICAL|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
218973594|NCT03731845|OTHER|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
218973595|NCT01933958|DRUG|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
218973596|NCT04102943|DRUG|tacrolimus tablet|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
218973597|NCT04102943|DRUG|tacrolimus capsules|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
218973598|NCT00011661|BEHAVIORAL|Education on behaviors to reduce lead exposure|
218973599|NCT05117333|OTHER|Reminder (information letter)|Reminders
218973600|NCT05769309|PROCEDURE|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
218973601|NCT05769309|DRUG|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
218973602|NCT03584100|DEVICE|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
218973603|NCT00122109|BEHAVIORAL|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
218973604|NCT02655978|OTHER|Magnetic Resonance Imaging|
218973605|NCT03153956|DEVICE|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
218973606|NCT03153956|DEVICE|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
218973607|NCT00480285|PROCEDURE|Laparoscopic Nissen Fundoplication|
218973608|NCT00480285|PROCEDURE|Laparoscopic anterior partial fundoplication|
218973609|NCT02540226|DRUG|Intravenous tranexamic acid|
218973610|NCT02540226|DRUG|Topical tranexamic acid|
218973611|NCT02540226|DRUG|Intravenous saline|
219665269|NCT06307171|DIAGNOSTIC_TEST|In-house Western blot, specific for Leishmania|"Sample will be collected at the collaborating centres and at the DITM, if not already stored at -80°C. The samples will be delivered to the DITM. For the CONTROL groups, two serological tests for Leishmaniasis, based on different antigenic fraction, will be performed on serum samples.~Different strains of Leishmania infantum and Leishmania donovani will be cultivated axenically at the DITM.~Whole soluble fraction of promastigote (WSF), the whole membrane protein fraction (WMF) and the whole soluble fraction secreted by promastigotes (WSFe) of Leishmania spp. will be obtained and the ARPs from WSF, WMF and WSFe, of each Leishmania will be checked trough Western-blot analysis testing at a final dilution of 1/100 each serum sample. The predominant bands detected by Western-blot analysis will be identified by SDS-PAGE separation. Selected bands, corresponding to the immunogenic bands, will be excised, digested and identified with Mass Spectrometry analysis."
218973612|NCT02540226|DRUG|Topical saline|
218973613|NCT00809354|DRUG|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
218973614|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
218973615|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
218973616|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
219665270|NCT04889170|OTHER|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
219665271|NCT02722746|DRUG|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
219665272|NCT02722746|DRUG|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
219665273|NCT04402450|PROCEDURE|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
219665274|NCT04402450|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
219665275|NCT04617964|OTHER|Ultrasound|Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
219665276|NCT01615159|BEHAVIORAL|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
219665277|NCT00682994|BEHAVIORAL|Interview|Interview lasting about 5-10 minutes.
219665278|NCT00682994|BEHAVIORAL|Questionnaire|Questionnaires taking 20-30 minutes to complete.
219665279|NCT02806830|DRUG|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
219665280|NCT00072488|PROCEDURE|computed tomography|
219665281|NCT00072488|PROCEDURE|magnetic resonance imaging|
219665282|NCT00072488|PROCEDURE|positron emission tomography|
218973617|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
218973618|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
218973619|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
218973620|NCT00267189|DRUG|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
218973621|NCT00267189|DRUG|Calcineurin inhibitors (CNI)|
219665283|NCT03807622|DEVICE|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
219665284|NCT05979207|DRUG|MMV367|Single dose
219665285|NCT05979207|OTHER|P. falciparum IBSM infection|Induced Blood Stage Malaria
218973622|NCT00267189|DRUG|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
218973623|NCT00267189|DRUG|Steroids|
219065860|NCT00618514|DEVICE|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
219065861|NCT00618514|DEVICE|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
219065862|NCT03418454|DIAGNOSTIC_TEST|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
219065863|NCT03521635|DRUG|Pramipexole SR|Tablets
219065864|NCT03521635|DRUG|Pramipexole IR|Tablets
219208456|NCT01871766|PROCEDURE|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
219665286|NCT05812430|DRUG|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
219686574|NCT04602156|PROCEDURE|Seldinger percutaneous cholecystostomy|Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
218973624|NCT05559398|DRUG|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
218973625|NCT05559398|DRUG|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
218973626|NCT03970642|OTHER|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
218973627|NCT01489397|DEVICE|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
218973628|NCT05978778|DEVICE|wii sports game|wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
218973629|NCT05978778|OTHER|pre-hand writing skills|pre-hand writing skills
218973630|NCT01556880|BEHAVIORAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
218973631|NCT00100178|DRUG|Mycophenolate mofeteil (MMF)|
218973632|NCT00100178|DRUG|Daclizumab (DZB)|
218973633|NCT00100178|DRUG|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
218973634|NCT00100178|DRUG|Placebo control for Daclizumab (DZB)|saline intravenous infusions
218973635|NCT05712434|OTHER|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
218973636|NCT05712434|OTHER|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
218973637|NCT05712434|OTHER|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
218973638|NCT03458962|GENETIC|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
218973639|NCT00783965|DRUG|tazarotene|Applied to the skin
218973640|NCT00783965|OTHER|placebo|Applied to the skin
218973641|NCT03427112|DEVICE|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
218973642|NCT02781779|DEVICE|Silverlon®|Silverlon wound dressings
219208457|NCT01871766|DRUG|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
219686575|NCT02252107|DRUG|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
219686576|NCT02521597|DEVICE|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
219686577|NCT02521597|DEVICE|Traditional otoscope|Use of a regular otoscope
219686578|NCT01307878|DRUG|chemotherapy ± targeted therapy|Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
219686579|NCT04784507|PROCEDURE|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
219208458|NCT01871766|DRUG|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
218973643|NCT02781779|DEVICE|AQUACEL® AG|AQUACEL® AG wound dressings
218973644|NCT04137029|DRUG|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
218973645|NCT04137029|DRUG|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
218973646|NCT04137029|DIAGNOSTIC_TEST|metacholine test|The participants will receive inhalation of metacholine once
218973647|NCT00745940|BEHAVIORAL|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
218973648|NCT03617354|PROCEDURE|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
218973649|NCT03610282|DRUG|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
218973650|NCT03610282|DRUG|Propofol|Subjects will received propofol for up to 100 minutes.
218973651|NCT06025305|DIAGNOSTIC_TEST|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
218973652|NCT01439568|DRUG|LY2510924|Administered subcutaneous injection
218973653|NCT01439568|DRUG|Carboplatin|Administered intravenously
218973654|NCT01439568|DRUG|Etoposide|Administered intravenously
218973655|NCT03459261|DIAGNOSTIC_TEST|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
218973656|NCT04749875|OTHER|blood sample|sampling of blood for research during routine care
218973657|NCT02414451|DRUG|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
219665287|NCT05437016|BEHAVIORAL|HUBER exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.
219665288|NCT05437016|BEHAVIORAL|Standard exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
219208459|NCT01871766|DRUG|Etoposide|"Dosage and Route of Administration:~Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis"
219665289|NCT03706469|DRUG|TAK-831 T2|TAK-831 T2 Tablets.
219665290|NCT03706469|DRUG|TAK-831 T3|TAK-831 T3 Tablets.
218973658|NCT02414451|DRUG|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
218973659|NCT02002390|DRUG|Fingolimod|A sphingosine-1-phosphate receptor regulator
218973660|NCT04137224|BIOLOGICAL|IgPro20|Human normal immunoglobulin for subcutaneous administration
218973661|NCT04137224|BIOLOGICAL|IgPro10|Human normal immunoglobulin for intravenous administration
218973662|NCT02892032|BEHAVIORAL|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
218973663|NCT02892032|BEHAVIORAL|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
219208460|NCT01871766|DRUG|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
219208461|NCT01871766|DRUG|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
219208462|NCT01871766|DRUG|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
219208463|NCT01871766|DRUG|^1^1C-methionine|Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
219665291|NCT04242485|OTHER|Osteopathic manipulative treatment|Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques
219665292|NCT04242485|OTHER|Sham treatment|"The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure"
219665293|NCT00564291|OTHER|Examination with an OCT device|
218973664|NCT02423837|DRUG|Rituximab, bendamustine|
218973665|NCT01826721|OTHER|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
218973666|NCT02439879|DRUG|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
218973667|NCT05342402|OTHER|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
218973668|NCT05342402|OTHER|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
218973669|NCT00004637|DRUG|Vitamin E|
218973670|NCT04693455|DRUG|ZD03|ZD03 capsule
218973671|NCT04693455|OTHER|Placebo|placebo capsule
218973672|NCT02098824|DRUG|Galantamine|Single administration of capsule containing 16 mg of Galantamine
218973673|NCT02098824|DRUG|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
218973674|NCT02098824|DRUG|Placebo|Single administration of capsule containing placebo
218973675|NCT04965051|DRUG|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
218973676|NCT04965051|DRUG|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
218973677|NCT03425513|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
218973678|NCT03425513|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
218973679|NCT00566501|DRUG|Donepezil|Donepezil SR 23 mg once daily orally.
218973680|NCT04558281|DRUG|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
218973681|NCT04558281|DRUG|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
218973682|NCT03583723|RADIATION|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
218973683|NCT05111808|DEVICE|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
219665294|NCT00675337|PROCEDURE|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
218973684|NCT00679055|DRUG|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
218973685|NCT00679055|DRUG|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
218973686|NCT03711201|BEHAVIORAL|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
218973687|NCT04418284|OTHER|survey|online survey
218973688|NCT03580148|DRUG|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
219665295|NCT00675337|PROCEDURE|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
218973689|NCT03580148|BIOLOGICAL|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
218973690|NCT01368432|DRUG|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
218973691|NCT01368432|DRUG|Placebo|Sugar pill placebo
218973692|NCT00744276|DRUG|danazol|danazol applied topically once per day for 4 treatment cycles
218973693|NCT00744276|DRUG|Placebo|placebo topically applied once daily for 4 treatment cycles
218973694|NCT04348110|DIETARY_SUPPLEMENT|Placebo tablets|consume 2 tablets per day for 8 weeks
218973695|NCT04348110|DIETARY_SUPPLEMENT|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
218973696|NCT00535366|DRUG|Tiotropium|Oral inhalation by HandiHaler® device
218973697|NCT00535366|DRUG|Salmeterol|Oral inhalation from Diskus®
218973698|NCT00535366|DRUG|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
218973699|NCT00535366|DRUG|Ciclesonide low|Oral inhalation from MDI
218973700|NCT00535366|DRUG|Ciclesonide high|Oral inhalation from MDI
218973701|NCT00535366|DRUG|Placebo|Oral inhalation from MDI
218973702|NCT00935051|OTHER|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
219065865|NCT00272168|BEHAVIORAL|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
219665296|NCT01249586|OTHER|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
219665297|NCT02635009|RADIATION|Three-Dimensional Conformal Radiation Therapy|daily fractions
218973703|NCT02409810|DRUG|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
218973704|NCT04462510|PROCEDURE|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
218973705|NCT01008150|DRUG|Paclitaxel|
218973706|NCT01008150|DRUG|Trastuzumab|
218973707|NCT01008150|DRUG|Neratinib|
218973708|NCT01008150|DRUG|Doxorubicin|
218973709|NCT01008150|DRUG|Cyclophosphamide|
218973710|NCT00251355|DRUG|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
218973711|NCT00251355|DRUG|5-Fluorouracil|5-FU via continuous IV infusion.
218973712|NCT00251355|PROCEDURE|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
218973713|NCT04633356|DEVICE|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
218973714|NCT00003307|DRUG|amifostine trihydrate|
218973715|NCT00003307|RADIATION|radiation therapy|
218973716|NCT03564028|OTHER|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
218973717|NCT03564028|OTHER|control session|Patients will realize one session of stair climbing at their own pace
218973718|NCT00480883|DRUG|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
218973719|NCT00480883|DRUG|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
218973720|NCT00480883|DRUG|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
218973721|NCT02016430|BEHAVIORAL|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
218973722|NCT02016430|BEHAVIORAL|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling.
218973723|NCT02016430|BEHAVIORAL|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
218973724|NCT04798456|BEHAVIORAL|Coma scales|CRS-R and GOSE
218973725|NCT04798456|DIAGNOSTIC_TEST|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
218973726|NCT04798456|BEHAVIORAL|Questionnaires|several questionnaires and an interview with the caregiver
219065866|NCT00272168|OTHER|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
219208464|NCT06515223|DEVICE|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training
218973727|NCT00437320|DRUG|Metvix Cream 160 mg/g|Participants were treated with topical administration of Metvix cream.
218973728|NCT00437320|DRUG|Metvix Vehicle Group|Participants were treated with topical administration of Metvix Vehicle cream.
218973729|NCT01741090|BIOLOGICAL|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
218973730|NCT01995643|DIETARY_SUPPLEMENT|Active Capsule|GSE Capsule
218973731|NCT01995643|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo Capsule
218973732|NCT01938573|DRUG|Cisplatin|Given IV
218973733|NCT01938573|DRUG|Gemcitabine Hydrochloride|Given IV
218973734|NCT01938573|DRUG|Sirolimus|Given PO
218973735|NCT01938573|PROCEDURE|Cystectomy|Undergo cystectomy when appropriate
218973736|NCT05705414|DRUG|Valine|A medical food intended for use under medical supervision
218973737|NCT05705414|DRUG|EEA|A medical food intended for use under medical supervision
218973738|NCT01649609|DRUG|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
218973739|NCT01649609|DRUG|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
218973740|NCT01649609|DRUG|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
219065867|NCT01214772|DRUG|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
219208465|NCT03944941|DRUG|Avelumab|Given IV
219208466|NCT03944941|DRUG|Cetuximab|Given IV
219665298|NCT02635009|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
218973741|NCT06218212|DIETARY_SUPPLEMENT|Renastart formula|"* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium."
218973742|NCT06218212|DRUG|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
218973743|NCT00139061|DRUG|Torcetrapib/Atorvastatin|
218973744|NCT00139061|DRUG|Fenofibrate|
218973745|NCT02617888|RADIATION|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
218973746|NCT02148107|DRUG|BI 691751|BI 691751 Dose 1
218973747|NCT02148107|DRUG|BI 691751|BI 691751 Dose 2
218973748|NCT02148107|DRUG|BI 691751|BI 691751 Dose 3
218973749|NCT02148107|DRUG|BI 691751|BI 691751 Dose 4
218973750|NCT02148107|DRUG|BI 691751|BI 691751 Dose 5
218973751|NCT02148107|DRUG|BI 691751|BI 691751 Dose 6
218973752|NCT02148107|DRUG|Placebo|Placebo
218973753|NCT01225796|DRUG|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
218973754|NCT04814862|BEHAVIORAL|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
218973755|NCT00762216|DEVICE|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
218973756|NCT00484809|DRUG|Enbrel (Etanercept)|
218973757|NCT01408797|PROCEDURE|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
218973758|NCT01408797|DRUG|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
218973759|NCT01408797|PROCEDURE|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
218973760|NCT02302534|DEVICE|MRI|MRI
218973761|NCT03845543|DEVICE|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
218973762|NCT01799577|PROCEDURE|Laparoscopic surgery|Two methods will be compare
218973763|NCT00398827|DRUG|Dexmedetomidine|
218973764|NCT00398827|DRUG|Placebo|
218973765|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
218973766|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
218973767|NCT05816031|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
218973768|NCT03686514|BIOLOGICAL|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
218973769|NCT01400815|DRUG|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
218973770|NCT01400815|DRUG|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
218973771|NCT05550844|RADIATION|Chest HRCT|A chest HRCT to identify emphysema
218973772|NCT05550844|GENETIC|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
218973773|NCT05550844|OTHER|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
218973774|NCT05010408|OTHER|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
219208467|NCT06349707|OTHER|other: Observational|For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)
218973775|NCT01192373|OTHER|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
219208468|NCT06830135|DEVICE|Continues glucose monitoring with remote glucose monitoring for 90 days|CGM + RPM
219208469|NCT06837714|OTHER|PİLATES GROUP|A total of 16 sessions were applied for 8 weeks, 2 sessions per week.
219665299|NCT02838472|DRUG|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
219665300|NCT02636699|BIOLOGICAL|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
219665301|NCT02636699|BIOLOGICAL|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
219665302|NCT06378866|DRUG|Abiraterone|Given abiraterone
219665303|NCT06378866|DRUG|Apalutamide|Given apalutamide
219665304|NCT06378866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219665305|NCT06378866|PROCEDURE|Bone Scan|Undergo bone scan
219665306|NCT06378866|PROCEDURE|Computed Tomography|Undergo CT
219665307|NCT06378866|DRUG|Darolutamide|Given darolutamide
218973776|NCT01192373|OTHER|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
218973777|NCT00037960|PROCEDURE|Constrained Induced Therapy|
219665308|NCT06378866|DRUG|Degarelix|Given degarelix
219665309|NCT06378866|DRUG|Enzalutamide|Given enzalutamide
219665310|NCT06378866|DRUG|Goserelin|Given goserelin
219665311|NCT06378866|DRUG|Histrelin|Given histrelin
219665312|NCT06378866|DRUG|Leuprolide|Given leuprolide
219665313|NCT06378866|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219665314|NCT06378866|OTHER|Patient Observation|Undergo watchful waiting
218973778|NCT04247776|COMBINATION_PRODUCT|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
218973779|NCT04247776|OTHER|ERAS|Enhanced Recovery After Surgery guidelines are applied.
218973780|NCT04247776|BEHAVIORAL|Fitbit|Fitbit is worn to monitor step counts.
218973781|NCT05012657|DEVICE|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
218973782|NCT04242173|DRUG|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
218973783|NCT03420859|DIAGNOSTIC_TEST|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
219065868|NCT04011553|OTHER|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
219065869|NCT00071669|PROCEDURE|Acupuncture|
219665315|NCT06378866|PROCEDURE|Positron Emission Tomography|Undergo PET
219665316|NCT06378866|DRUG|Prednisone|Given prednisone
219665317|NCT06378866|OTHER|Questionnaire Administration|Ancillary studies
219665318|NCT06378866|DRUG|Relugolix|Given relugolix
219065870|NCT02744534|DRUG|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
219208470|NCT06837714|OTHER|Behavioral: lifestyle changes|presentation including lifestyle changes was prepared and training was provided.
219208471|NCT05684705|DRUG|BV100|Intravenous infusion
219665319|NCT06378866|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
218973784|NCT02193581|DEVICE|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
219665320|NCT06378866|DRUG|Triptorelin|Given triptorelin
219665321|NCT05578131|PROCEDURE|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was \> 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
219665322|NCT05578131|PROCEDURE|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
219686580|NCT04784507|PROCEDURE|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
219686581|NCT00523692|DRUG|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
219686582|NCT00523692|DRUG|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
219686583|NCT05758818|DRUG|Placebo|Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
219686584|NCT05758818|DRUG|Moxifloxacin (positive control)|Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
218973785|NCT03805906|PROCEDURE|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
218973786|NCT00805948|DEVICE|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
218973787|NCT01123850|DEVICE|Copios|Bone Void Filler
218973788|NCT05135247|OTHER|Exercise|3 different types of training or control
218973789|NCT04627662|BEHAVIORAL|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
219665323|NCT05869864|BEHAVIORAL|Schools Championing Safe South Africa|The intervention consists of 2 parts - a poster campaign with social norms messages on violence and HIV risk, and 2 lessons in life orientation (a health curriculum delivered during school).
219665324|NCT03477513|RADIATION|Radation Therapy|Personalized Radiation Therapy
219665325|NCT06189794|OTHER|Rosa damascena oil|Essential oils will used by inhalation
218973790|NCT03739671|DIETARY_SUPPLEMENT|Vitamin D|Group will receive 5000 units of vitamin D daily
218973791|NCT03739671|DIETARY_SUPPLEMENT|No Vitamin D|No vitamin D supplementation
218973792|NCT00482261|DRUG|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
218973793|NCT00482261|DRUG|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
218973794|NCT00482261|DRUG|aspirin|100mg/day
218973795|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
218973796|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
219065871|NCT02744534|PROCEDURE|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
219208472|NCT02606526|BIOLOGICAL|BCG at birth|See previous description
219208473|NCT02606526|BIOLOGICAL|Control arm: Delayed BCG|See previous description
219665326|NCT06386185|DIAGNOSTIC_TEST|Electrocardiogram|Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart
219665327|NCT06386185|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound
219665328|NCT06386185|DIAGNOSTIC_TEST|Right heart catheter|Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
219665329|NCT05841524|DIAGNOSTIC_TEST|Vector flow imaging measurement|Ultrasound measurement, using high framerate measurement techniques.
218973797|NCT06514976|DRUG|Cytoflavin|Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
218973798|NCT00775476|DRUG|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
218973799|NCT00775476|DRUG|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
218973800|NCT02883647|DRUG|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
218973801|NCT04783597|DIAGNOSTIC_TEST|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
218973802|NCT04255927|DRUG|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
219665330|NCT05952817|DEVICE|virtual reality|Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
219665331|NCT04687644|BEHAVIORAL|Online education|Education group
219665332|NCT05880342|DRUG|Reboxetine Pill|8 mg
219665333|NCT05880342|DRUG|Methylphenidate Oral Product|20 mg
219665334|NCT00851019|BEHAVIORAL|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
219665335|NCT00851019|BEHAVIORAL|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
219665336|NCT04032951|OTHER|Fine Needle Tissue Acquisition|diagnostic
219665337|NCT00047736|DRUG|Tarceva (erlotinib HCl)|
219665338|NCT04856631|DRUG|Toripalimab Injection|240mg once per 3 weeks
219665339|NCT04856631|DRUG|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
219686585|NCT05758818|DRUG|Milademetan|"Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2"
219686586|NCT03470454|DRUG|Linagliptin Oral Tablet|Linagliptin for blood glucose control
219686587|NCT03770026|DRUG|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
218973803|NCT04255927|DRUG|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
218973804|NCT05783986|OTHER|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
218973805|NCT02649114|BEHAVIORAL|Cognitive-Behavioural Therapy|
218973806|NCT02649114|BEHAVIORAL|Compassion-Focused Therapy|
218973807|NCT04805944|DRUG|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
218973808|NCT04805944|DRUG|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
219665340|NCT01973335|DRUG|Combination therapy with acetazolamide and low-dose loop diuretics|"* Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
219665341|NCT01973335|DRUG|High-dose loop diuretics|"* Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
219665342|NCT01973335|DRUG|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
219665343|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
219665344|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
219665345|NCT04698174|PROCEDURE|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
219665346|NCT00506714|DEVICE|single point cane|Adjustable single point cane with SureGrip handle
219665347|NCT06365450|OTHER|Educational Intervention|Participants will receive hybrid educational intervention on breast and cervical cancer
219665348|NCT05884294|DEVICE|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
219665349|NCT00290381|PROCEDURE|Oxagen OC000459|
219665350|NCT04607681|BEHAVIORAL|EDUCATION|WEB BASED EDUCATION
219665351|NCT01084395|BEHAVIORAL|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
218973809|NCT04805944|DRUG|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
218973810|NCT04805944|DRUG|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
218973811|NCT04805944|DRUG|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
218973812|NCT03467607|PROCEDURE|tidal volume ventilation|low tidal volume ventilation
218973813|NCT04708119|PROCEDURE|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
218973814|NCT03578757|BEHAVIORAL|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
219208474|NCT03612258|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
219208475|NCT05699226|DEVICE|Soterix Medical Incorporated 4x1 adapter|Device permits individualized amplitudes
219065872|NCT02744534|PROCEDURE|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
219208476|NCT05699226|DEVICE|Traditional ECT device|FDA approved ECT device with fixed amplitude.
219665352|NCT01084395|BEHAVIORAL|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
219665353|NCT01084395|OTHER|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
219665354|NCT01084395|OTHER|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
219665355|NCT01164917|DRUG|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
219665356|NCT01164917|DRUG|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
219665357|NCT02305446|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
218973815|NCT06523283|OTHER|Natural Landscape Pictures Accompanied by Music|after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
218973816|NCT00662688|DRUG|daltéparine|
219208477|NCT06793072|DIAGNOSTIC_TEST|Leptin concentration in blood serum|Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms
219208478|NCT06793072|DIAGNOSTIC_TEST|Resistin concentration in blood serum|Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms
219208479|NCT06793072|DIAGNOSTIC_TEST|Omentin-1 concentration in blood serum|Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
219686588|NCT03770026|DRUG|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
219208480|NCT06772012|OTHER|Low-Level Laser Therapy (LLLT)|"* Frequency: LLLT was administered 3 times per week.~* Duration: Each session lasted approximately 15-20 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.(50)"
219686589|NCT03770026|BIOLOGICAL|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
219686590|NCT02905045|DRUG|Ketoprofen|
219686591|NCT02905045|DRUG|placebo|
218973817|NCT00662688|DRUG|Chemotherapy at the investigator's discretion|
219686592|NCT04019145|DRUG|EverX Posterior|fiber reinforced bulk fill resin composite
219686593|NCT04019145|DRUG|Resins, Composite|incremental packing of Nanohybrid Resin composite
219686594|NCT04655326|BIOLOGICAL|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
219686595|NCT03677869|DEVICE|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
219686596|NCT06765954|DRUG|N-803 (IL-15 Superagonist)|Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
219686597|NCT06765954|DRUG|ETBX-071 (PSA-based Oncolytic Virus)|Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
219686598|NCT06765954|DRUG|M-CENK (Activated NK Cells)|Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
219686599|NCT06765954|RADIATION|External Beam Radiation Therapy (EBRT)|This is a standard treatment administered to all participants. The specific dose and schedule (40 Gy in 5 fractions over 2 weeks or up to 9 weeks) are determined by the investigator based on clinical judgment.
219686600|NCT06765954|RADIATION|Androgen Deprivation Therapy (ADT)|May be used in conjunction with the other therapies. The specific type and duration of ADT are at the investigator's discretion, and it may be initiated up to 6 months after the completion of radiotherapy. This treatment is not part of the experimental treatment regimen.
219686601|NCT06765954|RADIATION|Post-radiation immunotherapy|The post-radiation immunotherapy phase in the ResQ110B-PROS study involves the continued administration of N-803, ETBX-071, and M-CENK, but with a specific schedule and after the completion of radiation therapy.
219686602|NCT07072546|PROCEDURE|free gingival graft + gelatin sponge|Free gingival graft surgery and application of gelatin sponge to the palatal wound
219665358|NCT06158009|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219665359|NCT06158009|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
219665360|NCT03919344|OTHER|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
219665361|NCT03919344|OTHER|Acoustic pharyngometry|Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
219665362|NCT03919344|OTHER|High density surface electroencephalogram neural mapping|Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
219665363|NCT01636947|DRUG|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
219665364|NCT01636947|DRUG|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
219665365|NCT01636947|DRUG|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
219665366|NCT01636947|DRUG|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
219665367|NCT01636947|DRUG|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
219665368|NCT01636947|DRUG|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
218973824|NCT05693766|DRUG|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
218973825|NCT05693766|OTHER|Endocrine-therapy|Endocrine therapy administered
219665369|NCT02696447|BIOLOGICAL|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
219665370|NCT00957424|BEHAVIORAL|telephone-based intervention|10-15 minute web-based survey on a computer
219665371|NCT00957424|DRUG|nicotine replacement therapy|One week supply
219665372|NCT00957424|OTHER|informational intervention|
219665373|NCT00957424|OTHER|internet-based intervention|
219665374|NCT00957424|OTHER|questionnaire administration|Given out week 2, 3 and 4.
218973826|NCT05693766|OTHER|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
218973827|NCT04072562|DRUG|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
218973828|NCT04374071|DRUG|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
218973829|NCT03750370|DEVICE|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity \[PSV\] and end diastolic velocity \[EDV\]) and the resistance indices against this flow (resistive index \[RI\] and pulsatility index \[PI\]) in the testis can be measured with this technique.
218973830|NCT03295461|PROCEDURE|SRP+ 10% Emblica officinalis irrigation|
218973831|NCT03295461|PROCEDURE|SRP + 0.2% Chlorhexidine irrigation)|
218973832|NCT03295461|PROCEDURE|SRP + 0.9% Saline irrigation|
218973833|NCT03295461|PROCEDURE|SRP +10% E. officinalis gel application.|
218973834|NCT03295461|PROCEDURE|SRP+ placebo gel application.|
218973835|NCT00558779|PROCEDURE|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
219665375|NCT00146913|DRUG|Imatinib mesylate 600mg/day|
219665376|NCT00146913|DRUG|Peg-Interféron at 90 microg/week|
219665377|NCT01840800|DRUG|Ropivacaine|
219665378|NCT01840800|DRUG|placebo|
219665379|NCT02097459|DRUG|Anastrozole|
219665380|NCT02097459|DRUG|Tamoxifen|
219665381|NCT02097459|DRUG|Toremifene|
219665382|NCT02332161|OTHER|surveys, evaluative tests for leg function|See outcome measures
219665383|NCT06192498|OTHER|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
219665384|NCT06192498|OTHER|Kaleidoscope|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
219665385|NCT06192498|OTHER|Distraction Cards|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
218973836|NCT00558779|PROCEDURE|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
218973837|NCT03843827|DEVICE|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
218973838|NCT03843827|DEVICE|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
218973839|NCT03292211|BEHAVIORAL|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
218973840|NCT03292211|BEHAVIORAL|early standard intervention|Conventional early in-bed activities within three days after stroke
218973841|NCT01456390|DEVICE|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
218973842|NCT06123663|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
218973843|NCT06123663|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
218973844|NCT02923258|DRUG|Docetaxel|20mg/m2/w
218973845|NCT02923258|DRUG|Cisplatin|100mg/m2/q3w
218973846|NCT02923258|RADIATION|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
218973847|NCT03649867|OTHER|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
218973848|NCT03242538|BEHAVIORAL|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
218973849|NCT03706131|OTHER|cervical mobilisation|manual therapy
218973850|NCT02724150|DRUG|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
218973851|NCT02724150|DRUG|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
218973852|NCT02640469|OTHER|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
218973853|NCT02640469|OTHER|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
218973854|NCT02640469|OTHER|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
219665386|NCT01713894|OTHER|Decision Aid|
219665387|NCT01713894|OTHER|Standard|
218973855|NCT03071159|DEVICE|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
218973856|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
218973857|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
218973858|NCT02448810|BIOLOGICAL|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
218973859|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
218973860|NCT02448810|BIOLOGICAL|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
218973861|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
218973862|NCT02448810|DRUG|Standard of Care|"* Investigator's choice~* Dose according to drug label"
218973863|NCT02448810|BIOLOGICAL|Standard of Care|"* Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only"
218973864|NCT02185755|OTHER|Internet-Based Glucose Monitoring System|
218973865|NCT02185755|DRUG|Normal Medication Positive Control|
218973866|NCT06045104|DIETARY_SUPPLEMENT|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
218973867|NCT06045104|DIETARY_SUPPLEMENT|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
219665388|NCT05542394|DIETARY_SUPPLEMENT|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
219665389|NCT02370069|BIOLOGICAL|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
219665390|NCT06731465|DEVICE|Clear aligner therapy|Participants in this group will receive clear aligners (EON Aligner, Minneapolis), designed and customized based on a digital model of each patient's dental structure. Aligners will be worn for at least 22 hours daily, and patients will change to a new aligner depending on treatment progress.
219686603|NCT07072546|PROCEDURE|free gingival graft + chitosan|free gingival graft surgery and application of chitosan to the palatal wound
219686604|NCT07072546|PROCEDURE|free gingival graft + chitosan and i-PRF|free gingival graft surgery and application of chitosan and i-PRF to the palatal wound
219686605|NCT00674206|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
219065873|NCT03321331|COMBINATION_PRODUCT|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
219065874|NCT03321331|COMBINATION_PRODUCT|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
219065875|NCT01153633|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
219665391|NCT06731465|DEVICE|Fixed pre-adjusted edgewise orthodontic appliance|Participants in this group will be treated with pre-adjusted fixed orthodontic appliances (Master Series®, American Orthodontics™, WI, USA). This system includes fixed brackets bonded on the labial surface of teeth and a sequence of progressively larger arch wires aimed at achieving alignment over time.
219065876|NCT01153633|DEVICE|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
219065877|NCT03365765|DRUG|Apatinib|Apatinib tablet
219065878|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
219065879|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
219065880|NCT00071487|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
219065881|NCT00071487|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
219065882|NCT00071487|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
219665392|NCT04856397|DRUG|Intravitreal Implant in Applicator|Dexamethasone intravitreal implant
219665393|NCT04856397|DRUG|Eylea|anti-VEGF medication
219665394|NCT04485494|DIAGNOSTIC_TEST|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
219665395|NCT02041052|PROCEDURE|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
219665396|NCT02041052|PROCEDURE|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
219665397|NCT01851980|OTHER|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
219665398|NCT01851980|DRUG|Furosemide|40 mg and 120 mg
219665399|NCT01851980|DRUG|Placebo|0.9% saline
219665400|NCT00192348|BIOLOGICAL|CAIV-T|
219665401|NCT03582319|OTHER|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
219665402|NCT03582319|OTHER|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
218973868|NCT00730197|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
218973869|NCT00730197|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
218973870|NCT05708586|BEHAVIORAL|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
218973871|NCT05708586|DEVICE|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
218973872|NCT00470847|DRUG|Lapatinib|Orally twice daily
218973873|NCT00470847|PROCEDURE|Whole Brain Radiation|15 treatments over a period of 3 weeks
218973874|NCT00470847|DRUG|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
218973875|NCT05504395|DRUG|CSTI-500|Single 10 mg capsule
218973876|NCT05584332|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
218973877|NCT05584332|BIOLOGICAL|Placebo|0.5 ml injection in 3 dosing regimen
219065883|NCT00071487|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
219065884|NCT03725982|DEVICE|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
219065885|NCT03725982|DEVICE|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
219065886|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
219065887|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
219665403|NCT00318175|DRUG|Bosentan (Tracleer)|
219665404|NCT02401061|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
218973878|NCT03071146|DEVICE|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
218973879|NCT00125684|DRUG|morphine|
218973880|NCT01355029|BEHAVIORAL|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
218973881|NCT04304157|DRUG|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
218973882|NCT01719978|DRUG|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
218973883|NCT01719978|PROCEDURE|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
218973884|NCT01719978|DRUG|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
218973885|NCT01719978|DRUG|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
218973886|NCT03258177|OTHER|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
219065888|NCT03790176|DRUG|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
219065889|NCT06633263|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
219665405|NCT02508415|OTHER|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
219665406|NCT03899207|OTHER|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
219665407|NCT03899207|OTHER|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
218973887|NCT05653726|OTHER|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
219665408|NCT00445744|DRUG|cyclophosphamide|Given IV
219665409|NCT00445744|DRUG|busulfan|Given IV
219665410|NCT00445744|DRUG|tacrolimus|Given IV or PO
219665411|NCT00445744|DRUG|methotrexate|Given IV
218973888|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
218973889|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
218973890|NCT06198764|DRUG|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
218973891|NCT06198764|DRUG|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
218973892|NCT06198764|DRUG|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
218973893|NCT01082731|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
218973894|NCT01082731|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
218973895|NCT02905656|BEHAVIORAL|Brief Advice|Psychoeducation
219065890|NCT06633263|BEHAVIORAL|Behavioral Activation Treatment for Depression|Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
219665412|NCT00445744|GENETIC|cytogenetic analysis|Correlative studies
219665413|NCT00445744|OTHER|flow cytometry|Correlative studies
218973896|NCT02905656|BEHAVIORAL|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
219065891|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
219065892|NCT02239887|DEVICE|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
219665414|NCT00445744|OTHER|pharmacological study|Correlative studies
219665415|NCT00445744|OTHER|pharmacogenomic studies|Correlative studies
219665416|NCT00445744|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBPC transplantation
219665417|NCT00445744|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
219665418|NCT01004718|RADIATION|Fludeoxyglucose F18|Undergo FDG PET/CT scans
219665419|NCT01004718|PROCEDURE|Computed Tomography|Undergo FDG PET/CT scans
219665420|NCT01004718|PROCEDURE|Positron emission tomography|Undergo FDG PET/CT scans
219665421|NCT02245919|OTHER|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
219665422|NCT02343380|OTHER|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
219665423|NCT03394417|DEVICE|StrataXRT|randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
219665424|NCT05964010|BEHAVIORAL|Standard Screening|All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report \> 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
219665425|NCT05964010|BEHAVIORAL|Standard Psychoeducation|In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
219686606|NCT00674206|DRUG|Oxaliplatin|Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
219686607|NCT03054285|DRUG|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
219686608|NCT01719159|DRUG|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
219065893|NCT05192525|DEVICE|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
219065894|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
219065895|NCT06297538|DEVICE|gamma transcranial alternating current stimulation (tACS)|Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
219065896|NCT06297538|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
219065897|NCT01836692|RADIATION|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
219065898|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
219065899|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
219065900|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
219686609|NCT04265261|DRUG|Placebo|Participants will receive oral placebo matched to RG7774
219686610|NCT04265261|DRUG|RG7774|Participants will receive oral RG7774
219686611|NCT02930681|DIETARY_SUPPLEMENT|Glucosanol 500mg|
219686612|NCT02930681|DIETARY_SUPPLEMENT|Placebo|
219686613|NCT00330044|DRUG|Premetrexed (Alimta)|
219686614|NCT00330044|DRUG|Carboplatin|
219065901|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
219686615|NCT03877224|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
219686616|NCT03877224|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
219686617|NCT05837546|OTHER|Animal-assisted intervention|presence of a dog, contact between dog and participant
219686618|NCT05837546|OTHER|Factice dog intervention|presence of a factice dog, contact between factice dog and participant
219686619|NCT05837546|OTHER|Plant intervention|presence of a plant, contact between plant and participant
219686620|NCT05438966|OTHER|No intervention|No intervention
219686621|NCT02814617|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
219686622|NCT02814617|DIETARY_SUPPLEMENT|Placebo|
219686623|NCT05483465|DRUG|Nicotinamide riboside|Oral NR, 1g/day per os for 8 weeks
219686624|NCT05483465|DRUG|Placebo|Visually identical pill to NR, daily per os for 8 weeks
219686625|NCT00348465|PROCEDURE|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
219686626|NCT03152266|OTHER|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
219065902|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
219665426|NCT05964010|BEHAVIORAL|Standard Brief Negotiated Interview (BNI)|In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
219665427|NCT05964010|BEHAVIORAL|Standard Referral to Treatment (RT)|In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes \& Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
219665428|NCT05964010|BEHAVIORAL|Family Screening|Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach \& Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
219665429|NCT05964010|BEHAVIORAL|Family Psychoeducation|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche \& Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
219665430|NCT05964010|BEHAVIORAL|Family Brief Negotiated Interview (BNI)|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
219665431|NCT05964010|BEHAVIORAL|Family Facilitated Conversation (FC) & Referral to Treatment (RT)|In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
219665432|NCT01303614|DRUG|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
219665433|NCT01303614|DRUG|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
219665434|NCT00396916|DEVICE|PET/CT imaging|
219665435|NCT01544764|OTHER|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
219665436|NCT02882464|DEVICE|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
218973897|NCT02905656|BEHAVIORAL|Rate Reduction|Reducing the number of cigarettes consumed.
218973898|NCT02905656|DRUG|Pharmacological|Nicotine Replacement Therapy in the form of gum.
218973899|NCT02905656|BEHAVIORAL|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
218973900|NCT00066144|DRUG|Cimicifuga racemosa|
218973901|NCT00066144|DRUG|Trifolium pratense|
218973902|NCT00066144|DRUG|Black cohosh|
218973903|NCT00066144|DRUG|Red clover|
218973904|NCT00844818|BEHAVIORAL|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
218973905|NCT00116662|DRUG|Resiquimod|
218973906|NCT06143774|DRUG|TRX-920 Oral Gel (10 mg and 30 mg)|"TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified."
218973907|NCT00823342|DRUG|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
218973908|NCT00823342|DRUG|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
218973909|NCT00823342|DRUG|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
218973910|NCT02119091|DRUG|Moxifloxacin|
218973911|NCT03456440|DIAGNOSTIC_TEST|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
218973912|NCT05323578|OTHER|Survey|Prevalence of safe caffeine consumption among anesthetists
219665437|NCT02882464|DEVICE|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
219665438|NCT02882464|PROCEDURE|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
219665439|NCT03905538|DRUG|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
219665440|NCT01189708|DEVICE|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
219665441|NCT01189708|OTHER|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
219665442|NCT02483325|DRUG|Allogeneic transplant conditioning|Allogeneic transplant
219665443|NCT00830635|OTHER|educational intervention|
219665444|NCT00830635|OTHER|informational intervention|
219665445|NCT00830635|OTHER|internet-based intervention|
219665446|NCT00830635|OTHER|questionnaire administration|
219665447|NCT00830635|OTHER|study of socioeconomic and demographic variables|
218973913|NCT00397566|DRUG|HIV Integrase Inhibitor (BMS-707035)|
219665448|NCT00830635|OTHER|survey administration|
219665449|NCT00830635|PROCEDURE|psychosocial assessment and care|
219665450|NCT00830635|PROCEDURE|quality-of-life assessment|
219665451|NCT02143934|DRUG|Primaquine|
219665452|NCT02143934|DRUG|Placebo|Sugar pills, appearance identical to Primaquine tablets
218973914|NCT03439943|DRUG|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
218973915|NCT03439943|DRUG|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
218973916|NCT04654884|OTHER|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
218973917|NCT02759354|OTHER|Blood Sample|Blood sample at approx. 4 years of age
219665453|NCT02143934|DRUG|Chloroquine|
219665454|NCT02143934|DRUG|Artemether Lumefantrine|
219665455|NCT05047614|DEVICE|including sham|Repositiong feedback training and biofeedback pressure training unit
219665456|NCT04422964|DEVICE|3D Obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
219665457|NCT02741466|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
219665458|NCT05899712|OTHER|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
219665459|NCT05203965|DRUG|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
219665460|NCT05203965|DRUG|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
219665461|NCT06057831|RADIATION|Total Neo-adjuvant Therapy|"* TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
219665462|NCT06057831|OTHER|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
219665463|NCT04422730|BEHAVIORAL|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
218973918|NCT00678340|DEVICE|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
218973919|NCT00678340|DEVICE|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
218973920|NCT01590992|BEHAVIORAL|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
218973921|NCT01590992|BEHAVIORAL|Relaxation therapy|Progressive muscle relaxation (Jacobson)
218973922|NCT04805827|DRUG|Gabapentin|1 tablet contains 600 mg Gabapentin
218973923|NCT04805827|DRUG|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
218973924|NCT03701737|OTHER|questionnaires|"* VAS on the feeling of hunger~* Evaluation of food wanting by the Finlayson test~* PREFQUEST Questionnaire~* 24-hour food recall~* Stunkard Questionnaire~* Measurement of daytime sleepiness by Epworth score"
218973925|NCT03701737|DEVICE|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
218973926|NCT03701737|BIOLOGICAL|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
218973927|NCT02198872|OTHER|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
218973928|NCT02198872|OTHER|Land Group|Patients of this group perform physical training on bicycle.
218973929|NCT04234139|PROCEDURE|liver transplant|solid organ transplant
218973930|NCT00284622|PROCEDURE|Arthroscopy|HTO with pre-scope
218973931|NCT02313324|DEVICE|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
218973932|NCT02313324|DEVICE|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
218973933|NCT03458663|DEVICE|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
218973934|NCT01551537|OTHER|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
218973935|NCT01551537|OTHER|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
218973936|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
218973937|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
218973938|NCT02462174|DRUG|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
218973939|NCT02462174|DRUG|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
218973940|NCT00976170|DRUG|GC33(RO5137382)|IV administration at 6 escalating dose levels.
218973941|NCT00976170|DRUG|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
218973942|NCT04243785|DRUG|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
218973943|NCT04243785|DRUG|Azacitidine|Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
218973944|NCT05348135|OTHER|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
218973945|NCT05348135|OTHER|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
218973946|NCT05348135|OTHER|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
218973947|NCT03462069|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
218973948|NCT03462069|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219665464|NCT04033211|DEVICE|Novosyn® CHD for fascia and skin closure|Experimental
219665465|NCT04033211|DEVICE|Novosyn® for fascia and skin closure|Comparator
219665466|NCT02736695|DRUG|F-18 AV 1451|Tau binding agent
219665467|NCT06029374|PROCEDURE|Functional Treatment|Patients receiving buddy taping for fingers IV and V and an elastic bandage in terms of a functional treatment. Duration of bandage treatment is determined with 4 weeks.
219665468|NCT06029374|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
219665469|NCT05723913|DIETARY_SUPPLEMENT|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
219665470|NCT05048589|DRUG|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
218973949|NCT03462069|DRUG|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
218973950|NCT03462069|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
218973951|NCT00478374|DRUG|Sorafenib|Sorafenib 400mg bid
218973952|NCT00478374|PROCEDURE|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
218973953|NCT04856891|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
218973954|NCT04856891|OTHER|Placebo|Placebo
218973955|NCT05144204|BEHAVIORAL|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
218973956|NCT00568685|DRUG|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
218973957|NCT00568685|DRUG|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
219665471|NCT05048589|DRUG|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
219665472|NCT02773277|OTHER|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
219665473|NCT04799106|BEHAVIORAL|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
219665474|NCT03319810|BIOLOGICAL|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
219665475|NCT03395847|BIOLOGICAL|Pembrolizumab|Given IV
219665476|NCT05182606|BEHAVIORAL|Pilot study of algorithms implementation package|The algorithm implementation package includes a link to the algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions.
219665477|NCT05988333|OTHER|Psychoeducational Family Intervention|Supportive intervention administered to families with a member affected by MDD
219665478|NCT05988333|OTHER|Informative intervention|Informative intervention administered to families with a member affected by MDD
219665479|NCT03473613|DRUG|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
219665480|NCT03473613|DRUG|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
219665481|NCT06976138|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|This program will focus on changing the participant's sleep patterns, activities, and habits.
219665482|NCT06976138|DEVICE|Bright Light therapy via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer® The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
219665483|NCT06976138|DEVICE|Negative Ion exposure via IonMi Device|This procedure involves wearing a light weight negative ionizer (IonMi Device) around neck for one hour in the morning. An ionizer gives off special negatively charged ions into the air. The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
219665484|NCT06976138|BEHAVIORAL|Sleep / Knee Osteoarthritis Education|This program will focus on increasing The participant's knowledge about sleep, sleep disorders and knee osteoarthritis.
219665485|NCT00191659|DRUG|Atomoxetine Hydrochloride|
219665486|NCT03839875|DRUG|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
218973958|NCT00568685|DRUG|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
218973959|NCT00390234|DRUG|ziv-aflibercept|Given IV
219065903|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
219665487|NCT06406634|DRUG|Cadonilimab|Injectable solution
219665488|NCT06406634|DRUG|Lenvatinib|capsule
219665489|NCT01425567|DRUG|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
219665490|NCT05405894|DRUG|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
219665491|NCT01087840|DRUG|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
218973960|NCT00792831|DRUG|ITF2357|Histone-Deacetylase Inhibitor
218973961|NCT05697744|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
218973962|NCT00845780|DRUG|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
218973963|NCT01147172|DEVICE|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
218973964|NCT02171572|DRUG|Dabigatran etexilate low|
219665492|NCT04935840|DIETARY_SUPPLEMENT|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
219665493|NCT04935840|OTHER|Control|400 mcg of folic acid
219665494|NCT01464801|DIETARY_SUPPLEMENT|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
219665495|NCT01464801|DIETARY_SUPPLEMENT|Placebo|Tablet Placebo 3 times daily for 6 months
219665496|NCT05760222|OTHER|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
219665497|NCT05753059|DRUG|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
218973965|NCT02171572|DRUG|Dabigatran etexilate high|
218973966|NCT05025254|OTHER|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
218973967|NCT02787551|DRUG|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973968|NCT02787551|DRUG|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973969|NCT02787551|DRUG|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973970|NCT02787551|DRUG|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973971|NCT02787551|DRUG|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973972|NCT02787551|DRUG|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
218973973|NCT02787551|DRUG|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
218973974|NCT00753779|DRUG|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
218973975|NCT00753779|DRUG|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
218973976|NCT04810663|RADIATION|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
218973977|NCT02957565|BEHAVIORAL|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
218973978|NCT02957565|OTHER|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
218973979|NCT02957565|BEHAVIORAL|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
218973980|NCT05530785|COMBINATION_PRODUCT|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
218973981|NCT00229151|BEHAVIORAL|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
218973982|NCT00229151|OTHER|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
218973983|NCT02715973|DIETARY_SUPPLEMENT|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
219665498|NCT05753059|DRUG|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
219665499|NCT05753059|DRUG|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
218973984|NCT02715973|DIETARY_SUPPLEMENT|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
219665500|NCT05990959|OTHER|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
219665501|NCT06622863|BEHAVIORAL|Standard oral hygiene instructions will be given verbally by the periodontics resident|Standard oral hygiene instructions will be given verbally by the periodontics resident
219665502|NCT06622863|BEHAVIORAL|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
219665503|NCT03981965|OTHER|Physical activity|Physical activity as described previously.
219665504|NCT06138002|DEVICE|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
219665505|NCT06138002|PROCEDURE|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
219665506|NCT02174575|DRUG|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
219665507|NCT02174575|DRUG|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
219665508|NCT06270017|DRUG|Chemotherapy drug|rsponse evaluation in zebrafish embryo model
219665509|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
218973985|NCT05663268|BIOLOGICAL|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
218973986|NCT00069433|PROCEDURE|Social skills and symptom management training|
219665510|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
219665511|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
219665512|NCT04140240|BEHAVIORAL|intervention group|Parallel Assignment a experimental design with pre test and post test
219665513|NCT00002266|DRUG|AS-101|
219665514|NCT05587426|DIETARY_SUPPLEMENT|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
219665515|NCT05587426|DIETARY_SUPPLEMENT|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
219665516|NCT05587426|DIETARY_SUPPLEMENT|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
219665517|NCT05587426|DIETARY_SUPPLEMENT|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
219665518|NCT01294748|DEVICE|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
219665519|NCT01294748|DEVICE|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
219665520|NCT03212391|BEHAVIORAL|Diet|52 weeks of Diet supervised by a dietician
219665521|NCT03212391|BEHAVIORAL|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
219665522|NCT03212391|BEHAVIORAL|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
219665523|NCT02954822|DRUG|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
219665524|NCT02954822|DRUG|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
218973987|NCT00441454|DEVICE|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
218973988|NCT00441454|DEVICE|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
219665525|NCT04520334|OTHER|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
218973989|NCT02210468|DEVICE|APIC-CF, 4 cc|
218973990|NCT02210468|DEVICE|APIC-CF, 2 cc|
218973991|NCT02210468|OTHER|Placebo Comparator: Saline|Placebo Comparator: Saline
218973992|NCT05693727|DIAGNOSTIC_TEST|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
218973993|NCT02038452|DRUG|Depo-Medrone|Steroid Injection
218973994|NCT02038452|DEVICE|Wrist Splint|Simple wrist splint
218973995|NCT02617784|DRUG|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
218973996|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
219665526|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
219665527|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
219665528|NCT01262924|BIOLOGICAL|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
219665529|NCT04813913|DRUG|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
219665530|NCT01955109|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
219665531|NCT04820231|OTHER|intra-articular PRP injection|
219665532|NCT02600767|DRUG|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
219665533|NCT01323504|OTHER|Music|Patient are listen music during their local care
219665534|NCT01323504|OTHER|no music|There are no music during the local care
219665535|NCT06044272|OTHER|Factors associated|Factors associated with the type of resistance by microorganisms.
218973997|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
218973998|NCT00859183|DRUG|Placebo|Placebo oral
218973999|NCT04084327|OTHER|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
218974000|NCT06090591|OTHER|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
218974001|NCT02366858|PROCEDURE|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
218974002|NCT02366858|PROCEDURE|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
219065904|NCT03517774|DEVICE|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
219065905|NCT02286544|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
219665536|NCT05957224|OTHER|Shake 1 then Shake 2|Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
219665537|NCT05957224|OTHER|Shake 2 then Shake 1|Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
219665538|NCT03174678|DRUG|Dexmedetomidine|1µg/kg dexmedetomidine oral
219665539|NCT03174678|OTHER|apple juice|apple juice
219665540|NCT03896672|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
218974003|NCT05689944|BEHAVIORAL|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
219065906|NCT02286544|DRUG|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
219065907|NCT02286544|DRUG|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
219208481|NCT06772012|OTHER|Orofacial Physical Therapy|"* Frequency: Orofacial physical therapy sessions were conducted 3 times per week.~* Duration: Each session lasted around 30-40 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.~* Components:~  * Manual Therapy: Included techniques such as joint mobilization, soft tissue manipulation, and muscle stretching.~ * Therapeutic Exercises: Focused on strengthening, coordination, and improving mobility of the masticatory muscles.~ * Postural Training: Addressed poor posture and cervical muscle spasm.(50)"
219665541|NCT05040334|DRUG|Group 1: Antibiotic receiving group|Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
219665542|NCT03486119|OTHER|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
219665543|NCT02631902|BEHAVIORAL|Exercise|Community-based exercise program with 3 weekly exercise sessions
219665544|NCT02631902|BEHAVIORAL|Dietary intervention|Community-based dietary intervention program
219665545|NCT05961475|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snacks with original level of sugar
219665546|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
219665547|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 3|Fruit snacks with reduced level of sugar
219665548|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 4|Fruit snacks with zero added sugar
219665549|NCT05961475|DIETARY_SUPPLEMENT|White Bread|White bread with matched carbohydrate as control
219665550|NCT04548388|OTHER|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
219665551|NCT00458575|DRUG|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
219665552|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation A (light)|Omega-3 monoglyceride based serum and cream of lighter formulation
219065908|NCT05741736|BEHAVIORAL|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
219065909|NCT04471818|DRUG|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
219065910|NCT04471818|OTHER|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
219065911|NCT01504594|PROCEDURE|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
219065912|NCT00974168|RADIATION|Cumulative BED ≤ 100|Radiation
219065913|NCT00974168|RADIATION|Cumulative BED ≤ 130 Gy2|Radiation
219065914|NCT00382057|DRUG|Testosterone|
219065915|NCT00382057|DRUG|Anastrozole|
219665553|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation B (rich)|Omega-3 monoglyceride based serum and cream with a richer formulation
219665554|NCT03292471|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
219665555|NCT03324828|DRUG|Hydroxyzine|Hydroxyzine solution
219665556|NCT03324828|OTHER|Clowns intervention|Clowns intervention
219665557|NCT00911586|DRUG|Testosterone undecanoate|
219065916|NCT00382057|DRUG|Goserelin|
219065917|NCT01227889|DRUG|GSK2118436|150 mg twice daily
219065918|NCT01227889|DRUG|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
219065919|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
219208482|NCT06800482|BEHAVIORAL|online outpatient follow-up|The investigators use Huayitong APP for the post-operating follow-up of participants with papillary thyroid cancer
219665558|NCT00676416|DRUG|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
219065920|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
219065921|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
219065922|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
219065923|NCT01421875|GENETIC|DNA methylation analysis|
219065924|NCT01421875|GENETIC|RNA analysis|
219065925|NCT01421875|GENETIC|gene expression analysis|
219065926|NCT01421875|GENETIC|microarray analysis|
219065927|NCT01421875|GENETIC|nucleic acid sequencing|
219065928|NCT01421875|OTHER|laboratory biomarker analysis|
219065929|NCT05481762|DEVICE|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
219065930|NCT00364481|DRUG|omeprazole|
219065931|NCT00364481|BEHAVIORAL|Tongue exercises|
219665559|NCT02397824|OTHER|Salivary and blood samples|
219665560|NCT00279006|PROCEDURE|Percutaneous coronary intervention|
219665561|NCT04346771|BEHAVIORAL|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
218974004|NCT05689944|BEHAVIORAL|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
218974005|NCT05689944|BEHAVIORAL|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
219065932|NCT02340039|DIETARY_SUPPLEMENT|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
219065933|NCT02824913|DRUG|P-321 Ophthalmic Solution|
219665562|NCT04346771|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
219665563|NCT03271671|OTHER|NAVA during Non invasive ventilation|NIV during respiratory failure
219665564|NCT03271671|OTHER|PSV during Non invasive ventilation|PSV during respiratory failure
219665565|NCT03423966|DEVICE|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
219665566|NCT02555930|OTHER|No Intervention|No intervention - observational only
219665567|NCT04625933|OTHER|No intervention|No intervention
219665568|NCT01555918|DRUG|Isavuconazole|oral
219665569|NCT01555918|DRUG|Isavuconazole (IV)|intravenous (IV)
219665570|NCT00369161|DRUG|Everolimus (RAD001)|
219665571|NCT00369161|DRUG|Tacrolimus|
219665572|NCT00369161|DRUG|Basiliximab|
219665573|NCT00369161|DRUG|Corticosteroids|
219665574|NCT04402359|DRUG|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
218974006|NCT05063890|PROCEDURE|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
219065934|NCT02824913|DRUG|P-321 Ophthalmic Solution placebo|
219065935|NCT00220194|DRUG|leuprolide acetate|
219065936|NCT02090738|DRUG|Acetazolamide group|
219065937|NCT02090738|DRUG|Standard regimen group|
219208483|NCT06752135|PROCEDURE|cervical biopsies/conization,|Diagnostic laparoscopy was used in selected cases to evaluate potential peritoneal spread.
219665575|NCT04402359|DRUG|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
219665576|NCT04402359|DEVICE|ventilator|all patients selected to be ventilated for 14 days
219665577|NCT04766099|OTHER|Childbirth Educational Video|Educational video describing techniques for pushing
219665578|NCT01250353|PROCEDURE|pterygium surgery|pterygium was removed surgically
219665579|NCT04606667|OTHER|Exercise Program|Exercise program
219665580|NCT04110496|DRUG|RTX-134|RTX-134 is a cellular therapy containing AvPAL
219665581|NCT04727255|BEHAVIORAL|Engaged and Resilient intervention|"Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology."
219665582|NCT04725123|DIAGNOSTIC_TEST|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
219665583|NCT05958108|BEHAVIORAL|SinergiAPS intervention|Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
219665584|NCT03039608|DRUG|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
219665585|NCT03039608|DRUG|oral steroid administration（prednisone）|oral steroid
219665586|NCT00750919|DRUG|esmirtazapine|
219665587|NCT06174818|PROCEDURE|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
219665588|NCT05507502|BIOLOGICAL|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
219665589|NCT05249621|DRUG|MZE001|Small molecule inhibitor of muscle glycogen synthase
219665590|NCT05249621|DRUG|Placebo|Product containing excipients with no active ingredients
219665591|NCT02290379|DRUG|TNX-201 35 mg|Drug: TNX-201 35 mg
219665592|NCT02290379|DRUG|TNX-201 70 mg|Drug: TNX-201 70 mg
219665593|NCT02290379|DRUG|TNX-201 140 mg|Drug: TNX-201 140 mg
219665594|NCT02290379|DRUG|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
218974007|NCT05063890|PROCEDURE|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
219665595|NCT02290379|DRUG|Placebo|Drug: Placebo
219665596|NCT04848259|DRUG|Normal saline|Saline will be applied after surgery
219665597|NCT04848259|DRUG|Dexamethasone|Dexamethason will be given IV before surgery
219665598|NCT04848259|DRUG|Honey|Honey will be applied locally after surgery
219665599|NCT04848259|DRUG|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
219665600|NCT02612688|BEHAVIORAL|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
219665601|NCT06038006|DIAGNOSTIC_TEST|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
219665602|NCT00506207|DRUG|S-1, Irinotecan, Oxaliplatin|
219665603|NCT03538067|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
219665604|NCT01273662|DRUG|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
219665605|NCT01232374|DRUG|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
219665606|NCT01232374|DRUG|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
219665607|NCT01232374|DRUG|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
219665608|NCT01232374|RADIATION|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
219665609|NCT03793374|OTHER|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
219665610|NCT00255320|DRUG|VIP|
219665611|NCT00256620|PROCEDURE|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
219665612|NCT03737630|DEVICE|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
219665613|NCT02147067|DRUG|Ranolazine|Ranolazine 1,000 mg twice daily
219665614|NCT02147067|DRUG|Placebo|Placebo
219665615|NCT01869569|DRUG|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
219665616|NCT01869569|DRUG|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
219665617|NCT00146666|DEVICE|Intermittent compression|
219665618|NCT05484596|PROCEDURE|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
219665619|NCT05397340|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
219665620|NCT06171568|OTHER|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~* Modified Rankin Scale;~* Instrumental Activities of Daily Living (IADL) questionnaire;~* Montreal Cognitive Assessment (MoCA);~* Frontal assessment battery (BREF);~* Rivermead questionnaire;~* Short Form (36) Health Survey (SF-36)~* Community Integration Questionnaire - Revised (CIQ-R)~* Posttraumatic stress disorder CheckList (PCL-5)"
218974008|NCT05063890|PROCEDURE|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
218974009|NCT05063890|PROCEDURE|Heating and TENS|Heating and TENS for 10 minutes
218974010|NCT04307914|RADIATION|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
218974011|NCT04307914|PROCEDURE|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
219665621|NCT02150681|BEHAVIORAL|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
219665622|NCT00537355|BIOLOGICAL|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
219665623|NCT00537355|DRUG|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
219665624|NCT01129271|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
219665625|NCT01129271|DRUG|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
218974012|NCT06356090|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE)|SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
218974013|NCT04964843|DRUG|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
218974014|NCT04964843|DRUG|Placebo|Placebo
218974015|NCT02637336|DEVICE|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
219065938|NCT04965844|DEVICE|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
219065939|NCT04965844|DEVICE|No intervention|Manual FiO2 adjustment according to SpO2 values
219065940|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
219065941|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
219065942|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
219065943|NCT00731315|OTHER|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
219065944|NCT00731315|OTHER|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
219065945|NCT00559559|DEVICE|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
219065946|NCT00559559|PROCEDURE|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
219208484|NCT06752135|DIAGNOSTIC_TEST|imaging tests (TCTB, TC-PET, MRI)|The staging procedures included imaging such as chest CT, abdomino-pelvic MRI, and PET-CT to assess tumor spread and lymph node involvement.
219665626|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for two weeks|nutritional intervention received two weeks before surgical intervention
219665627|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for one week|nutritional intervention received one weeks before surgical intervention
219665628|NCT01404949|DRUG|Tretinoin and Arsenic Trioxide|See Detailed Description
219665629|NCT00032630|PROCEDURE|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
219665630|NCT00032630|PROCEDURE|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
219665631|NCT01180023|PROCEDURE|Sweeping|Sweeping of membranes during digital exam
219686627|NCT00673374|DEVICE|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
218974016|NCT02637336|DEVICE|Aerobic exercise|aerobic exercise of moderate intensity
218974017|NCT02637336|DEVICE|Aromatherapy|inhalation of eucalyptus essential oil
218974018|NCT04940208|OTHER|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
218974019|NCT04940208|DIAGNOSTIC_TEST|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
218974020|NCT02864719|OTHER|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
218974021|NCT02290327|DRUG|Pantoprazole|Proton pump inhibitor
218974022|NCT02290327|DRUG|Placebo|50 ml of 0.9% normal saline
218974023|NCT05268107|DRUG|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
218974024|NCT05199493|DRUG|Angiotensin II|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
219208485|NCT06752135|DRUG|neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel)|Patients received three cycles of platinum-based neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), followed by imaging to assess treatment response.
219665632|NCT05718141|OTHER|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~* Cognitive Restructuring (labelled Flexible Thinking)~* Behavioural Activation (labelled Positive Activities)~* Gratitude~* Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
219665633|NCT05614583|DEVICE|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
219665634|NCT05614583|OTHER|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
218974025|NCT05199493|DRUG|Control|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
218974026|NCT01841177|DRUG|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
218974027|NCT00017017|DRUG|paclitaxel poliglumex|
218974028|NCT04206007|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
218974029|NCT00614328|DRUG|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
218974030|NCT06008028|DRUG|BR1015|One tablet administered alone
218974031|NCT06008028|DRUG|BR1015-1|One tablet administered alone
218974032|NCT06008028|DRUG|BR1015-2|One tablet administered alone
218974033|NCT03405610|BEHAVIORAL|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
218974034|NCT01962831|DRUG|Dinoprostone|
219065947|NCT02312739|PROCEDURE|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
219065948|NCT02312739|DRUG|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
219065949|NCT02312739|DRUG|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
218974035|NCT01962831|DEVICE|Single balloon foley catheter|
218974036|NCT02499978|DRUG|Darunavir/Cobicistat|Fixed dose combination medication
218974037|NCT02499978|DRUG|Dolutegravir|single tablet medication
218974038|NCT05635071|DRUG|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
218974039|NCT05635071|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
218974040|NCT02069132|DRUG|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
218974041|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
218974042|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
218974043|NCT01464944|DRUG|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
218974044|NCT01464944|DRUG|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
218974045|NCT01464944|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
218974046|NCT02091973|DRUG|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
218974047|NCT02091973|DRUG|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
218974048|NCT01090973|DRUG|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
218974049|NCT03648827|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
218974050|NCT05239260|DIAGNOSTIC_TEST|CMR|CMR
218974051|NCT03401736|DEVICE|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
218974052|NCT03401736|DRUG|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
218974053|NCT03401736|DRUG|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
219065950|NCT02312739|DRUG|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
219065951|NCT02312739|OTHER|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
219065952|NCT02312739|OTHER|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
219665635|NCT03057067|PROCEDURE|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
219665636|NCT06041906|PROCEDURE|Shunt Closure|Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
219665637|NCT00004794|DRUG|cidofovir|
219665638|NCT04677452|BIOLOGICAL|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
219665639|NCT02195596|OTHER|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
219665640|NCT02195596|OTHER|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~\--------------------------------------------------------------------------------"
219665641|NCT02205294|OTHER|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
219665642|NCT00618852|DRUG|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
218974054|NCT02054377|OTHER|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
219065953|NCT05675345|DEVICE|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
219065954|NCT05675345|DEVICE|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
219065955|NCT05675345|DEVICE|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
219065956|NCT05675345|DEVICE|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
219665643|NCT00618852|DRUG|Saline|1 mg/kg by intravenous bolus injection
219665644|NCT01422707|DRUG|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
219065957|NCT00444548|DRUG|[S,S]-Reboxetine|
219065958|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
219665645|NCT06139705|OTHER|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
219665646|NCT06139705|OTHER|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
219665647|NCT05326256|OTHER|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
219665648|NCT05326256|OTHER|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
219665649|NCT00003703|DRUG|SarCNU|
219665650|NCT01634568|DRUG|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
219665651|NCT00093977|DRUG|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
219665652|NCT01017601|BIOLOGICAL|Seneca Valley virus-001|Given IV
219665653|NCT01017601|OTHER|placebo|Given IV
219665654|NCT05005767|PROCEDURE|scaling and root planing|will receive scaling and root planing only
219665655|NCT05005767|PROCEDURE|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
219665656|NCT05919355|OTHER|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
219665657|NCT02051335|DRUG|Roflumilast|Roflumilast tablets
219665658|NCT02051335|DRUG|Roflumilast placebo|Roflumilast placebo-matching tablets
219665659|NCT02051335|DRUG|Donepezil|Donepezil overencapsulated tablets
219665660|NCT02051335|DRUG|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
219665661|NCT02051335|DRUG|Scopolamine|Scopolamine subcutaneous injection
219665662|NCT00274378|DEVICE|ALLOMATRIX injectable putty in distal radius fractures|
219665663|NCT06081491|DIAGNOSTIC_TEST|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
219665664|NCT03362801|DIAGNOSTIC_TEST|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
219665665|NCT01292343|OTHER|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
219665666|NCT01292343|OTHER|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
219665667|NCT04612972|BIOLOGICAL|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
219665668|NCT05571176|DRUG|S-ketamine|S-ketamine infusion 0.29 mg/kg/h for 4 hours
219665669|NCT02503072|BEHAVIORAL|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
219665670|NCT02503072|BEHAVIORAL|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
219665671|NCT03174691|DIAGNOSTIC_TEST|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
219665672|NCT01587625|DRUG|Oxytocin|
219665673|NCT01240395|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
219686628|NCT03285165|DRUG|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
219686629|NCT03285165|DRUG|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
219686630|NCT00816322|DIETARY_SUPPLEMENT|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
219686631|NCT00816322|DIETARY_SUPPLEMENT|Placebo|high oleic oil
219686632|NCT01494701|DRUG|nusinersen|Administered by intrathecal (IT) injection
219686633|NCT05167916|PROCEDURE|Outpatient check cytoscopy|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
219686634|NCT05167916|DIAGNOSTIC_TEST|Urine cytology|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
219686635|NCT04059341|DEVICE|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
219686636|NCT00120341|DEVICE|Anodyne Therapy System|
219686637|NCT02940236|OTHER|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
219686638|NCT02788318|OTHER|Brain samples|Collected in patients died
218974055|NCT00706810|DRUG|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
218974056|NCT00706810|DRUG|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
218974057|NCT02292342|DIETARY_SUPPLEMENT|Water|Control
218974058|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
218974059|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.5 mg/kg|EC 0.5
219686639|NCT02788318|OTHER|Skin samples|Collected in patients died
219686640|NCT00933114|PROCEDURE|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
219686641|NCT02360787|BEHAVIORAL|Energy restriction|
219686642|NCT02360787|BEHAVIORAL|Almonds (15% kcal/day)|
219686643|NCT03951545|PROCEDURE|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
218974060|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 1.0 mg/kg|EC 1.0
218974061|NCT05879835|DEVICE|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
218974062|NCT05879835|DEVICE|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
218974063|NCT05860803|DEVICE|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
219065959|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
219065960|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
219065961|NCT06526572|DIAGNOSTIC_TEST|Brain wave analysis using electroencephalography (EEG).|Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
219065962|NCT06526572|DIAGNOSTIC_TEST|Numerical rate Scale (NRS)|Asessment of pain with the subjective numercal rate scale method (NRS
219065963|NCT03750487|BEHAVIORAL|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
219065964|NCT03750487|BEHAVIORAL|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
219665674|NCT03827551|BEHAVIORAL|Delivery of oral hygiene advices|Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
219665675|NCT00944307|DRUG|raltegravir|raltegravir 400mg orally once
219665676|NCT00944307|DRUG|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
219665677|NCT06250179|PROCEDURE|free gingiva graft surgery|For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.
219665678|NCT06621199|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 24 mg/m\^2 on day 1, every 4 weeks
219665679|NCT06621199|DRUG|Cytarabine|Cytarabine 100 mg/m\^2 on day 1-5, every 4 weeks
219665680|NCT06621199|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
219665681|NCT04336813|OTHER|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
219665682|NCT00926640|DRUG|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
219665683|NCT00926640|DRUG|Cisplatin|6 cycles at 60mg/m2 IV on day 2
219665684|NCT00926640|DRUG|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
219665685|NCT05391945|DIAGNOSTIC_TEST|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
219665686|NCT05749068|DEVICE|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
219665687|NCT00032721|PROCEDURE|Reiki; Subtle energy therapy|
219665688|NCT00574795|BIOLOGICAL|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
219665689|NCT02656563|RADIATION|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
219665690|NCT06230666|RADIATION|SBRT|Stereotactic Body Radiation Therapy
219665691|NCT02870842|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
219665692|NCT02870842|OTHER|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
218974064|NCT05860803|BEHAVIORAL|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
218974065|NCT03861702|DRUG|FOLFOX regimen|FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)
218974066|NCT03861702|DRUG|Liposomal Irinotecan|Liposomal Irinotecan
219665693|NCT02638259|DRUG|GP2015|Enbrel comparator
219665694|NCT03910530|DRUG|Retifanlimab|Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
219665695|NCT03910530|DRUG|INCB001158|Part 1: INCB001158 75 or 100 mg twice daily administered orally.
219665696|NCT03910530|DRUG|Retifanlimab + INCB001158|Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
219665697|NCT01593280|DEVICE|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
219665698|NCT01593280|DRUG|intrathecal morphine|0.3 mg
219665699|NCT03118791|DIETARY_SUPPLEMENT|anthocyanins|Acute intake of capsules
219665700|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
219665701|NCT01925157|BIOLOGICAL|LY3090106 - SQ|Administered SQ.
219665702|NCT01925157|BIOLOGICAL|LY3090106 - IV|Administered IV.
219665703|NCT01925157|BIOLOGICAL|Placebo - SQ|Administered SQ.
219665704|NCT06653101|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
219665705|NCT06653101|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
219665706|NCT05347134|DRUG|SKB264|"SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
219665707|NCT01706575|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
219665708|NCT01706575|DRUG|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
219665709|NCT05260775|OTHER|Evaluation test: cataract surgery steps|The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
219665710|NCT01550016|OTHER|Observation|Clinical follow-up and laboratory investigations.
219665711|NCT06176313|OTHER|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~* Two days before the intervention day, students will be contacted and invited to participate in the study.~* Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~* After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
218974067|NCT00267618|BEHAVIORAL|FHP Pain|Evidence-based psychological and behavioural Intervention
218974068|NCT05897099|BEHAVIORAL|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
218974069|NCT05897099|BEHAVIORAL|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
218974070|NCT04911257|DEVICE|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
218974071|NCT03805646|OTHER|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
218974072|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
219665712|NCT06176313|OTHER|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~* One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
218974073|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
218974074|NCT06236243|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
219065965|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
219065966|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
219065967|NCT03197792|OTHER|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
219065968|NCT01205685|DRUG|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day"
219065969|NCT01205685|DRUG|Erlotinib|"During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d"
219065970|NCT01205685|DRUG|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
219065971|NCT01205685|DRUG|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
219065972|NCT02599168|DRUG|Propofol|
219208486|NCT06752135|PROCEDURE|hysterectomy, salpingo-oophorectomy, and lymphadenectomy|Eligible patients underwent radical surgery, including hysterectomy, salpingo-oophorectomy, and lymphadenectomy, with adjuvant therapy administered as needed based on surgical findings. Follow-up included regular clinical exams, imaging, and tests to monitor for recurrence.
219208487|NCT06752135|RADIATION|brachytherapy|alternative to cCRT-B.
219208488|NCT06751745|BEHAVIORAL|Online Emotional Intelligence Training|The intervention is a 4-week online Emotional Intelligence (EI) training program for Bangladeshi youth. It includes weekly one-hour sessions focusing on self-awareness, self-regulation, social awareness, and relationship management. Led by experts, the program uses interactive activities and practical exercises to enhance emotional skills. Pre- and post-training assessments with the Bengali Emotional Intelligence Scale measure outcomes.
218974075|NCT05473897|DEVICE|Catalyst Cryohelmet|The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
218974076|NCT06184867|BEHAVIORAL|Relational Agent (RA)|Consists of a clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among cancer survivors.
218974077|NCT06184867|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of a clinical letter and recommendation for genetic testing for hereditary cancer risk among cancer survivors.
218974078|NCT03806491|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
218974079|NCT03806491|BEHAVIORAL|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
218974080|NCT03806491|BEHAVIORAL|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
218974081|NCT03193190|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
218974082|NCT03193190|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
219065973|NCT02599168|DRUG|Dexmedetomidine|
219065974|NCT02599168|DRUG|Placebo (normal saline)|
219065975|NCT00354523|DRUG|Capecitabine (Xeloda)|Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
219065976|NCT00354523|DRUG|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
219065977|NCT00354523|DRUG|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
219065978|NCT01193803|PROCEDURE|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
219065979|NCT05734508|BIOLOGICAL|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
219065980|NCT05321524|DRUG|OCA 0.1mg|Tablets administered orally once daily.
219065981|NCT05321524|DRUG|OCA 1.5mg|Tablets administered orally once daily.
219065982|NCT05321524|DRUG|OCA 5mg|Tablets administered orally once daily.
219665713|NCT06176313|OTHER|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~* At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~* Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~* On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
219665714|NCT01094782|OTHER|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
219665715|NCT01094782|OTHER|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
219665716|NCT01968902|BIOLOGICAL|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
219665717|NCT01968902|BIOLOGICAL|Placebo|Saline injection on the day of injection visit
219665718|NCT03180424|DRUG|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
219665719|NCT03180424|BEHAVIORAL|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
219665720|NCT03180424|DRUG|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
219665721|NCT03180424|BEHAVIORAL|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
218974083|NCT03193190|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
218974084|NCT03193190|DRUG|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
219665722|NCT03738449|DRUG|CKD-387|Test drug
219665723|NCT03738449|DRUG|D484|reference drug
219665724|NCT06390761|PROCEDURE|Acupuncture|All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.
218974085|NCT03193190|DRUG|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
218974086|NCT03193190|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
218974087|NCT03193190|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
218974088|NCT03193190|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
218974089|NCT03193190|DRUG|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
218974090|NCT03193190|DRUG|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
218974091|NCT03193190|DRUG|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
218974092|NCT03193190|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
218974093|NCT03193190|DRUG|AB928|AB928 will be administered as per the schedule specified in the respective arm.
218974094|NCT03193190|DRUG|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
218974095|NCT03193190|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
218974096|NCT03493516|DIAGNOSTIC_TEST|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195
218974097|NCT05979727|DRUG|RE02|Low, medium or high dose of RE02
218974098|NCT05979727|DRUG|Manitol|Placebo Comparator
218974099|NCT04552925|OTHER|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
218974100|NCT02458456|OTHER|Isometric resistance training|Isometric exercise using a hand dynamometer.
218974101|NCT06857006|PROCEDURE|brain metastases radiosurgery|Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
218974102|NCT03955380|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
218974103|NCT06207604|PROCEDURE|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
218974104|NCT06207604|PROCEDURE|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
218974105|NCT04272853|OTHER|Interview|Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
219208489|NCT06841523|DEVICE|Intelligent Pressure and Temperature-Controlled Ureteroscope System|RIRS procedure for upper ureteral or renal stone lithotripsy with Intelligent Pressure and Temperature-Controlled Ureteroscope System
219665725|NCT06619028|DEVICE|Weighted vest|During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
219665726|NCT01190111|BIOLOGICAL|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
219665727|NCT04237558|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
219665728|NCT04237558|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
219665729|NCT02918643|OTHER|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
219665730|NCT05854043|OTHER|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)\>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
219665731|NCT05854043|OTHER|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
219665732|NCT06059157|DEVICE|Advanced MRI|resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
219665733|NCT05932849|DRUG|Benralizumab|Patients were initiated on benralizumab as part of routine clinical practice
219665734|NCT03558841|OTHER|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
219665735|NCT03558841|OTHER|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
219665736|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
219665737|NCT06230952|OTHER|BASDAI and BASFI reliability|The study will be carried out on volunteer patients who are diagnosed with axial spondyloarthritis and are followed up in the outpatient clinic of Dokuz Eylül University, Department of Internal Medicine, Rheumatology and Immunology Department, and who meet the inclusion criteria. Patients who volunteer to participate in the study will be contacted by phone and BASDAI and BASFI questionaires will be administered.
219665738|NCT03871959|DRUG|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
219665739|NCT03871959|DRUG|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
219665740|NCT02952872|BEHAVIORAL|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
219665741|NCT04047849|DRUG|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
219665742|NCT03218228|PROCEDURE|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
219665743|NCT00082459|BIOLOGICAL|autologous human tumor-derived HSPPC-96|
219665744|NCT03834714|DEVICE|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
219665745|NCT03834714|OTHER|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
218974106|NCT01542671|BEHAVIORAL|Intervention|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals"
218974107|NCT01542671|BEHAVIORAL|Control|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period"
219208490|NCT06841523|DEVICE|Conventional Ureteroscope|RIRS procedure for upper ureteral or renal stone lithotripsy with conventional ureteroscope
219208491|NCT06862453|OTHER|Normal Saline (Placebo)|The blinded control group (n = 6) of the main cohort will receive normal saline as placebo, also by DVI.
219665746|NCT03834714|DEVICE|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
219665747|NCT02536781|DRUG|Anthocyanin|Anti-inflammation gel
219665748|NCT02536781|DRUG|Placebo|Blank gel
219665749|NCT03406624|PROCEDURE|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
219665750|NCT01048099|PROCEDURE|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
219665751|NCT01048099|DRUG|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
219208492|NCT06862453|BIOLOGICAL|PfSPZ-LARC2 Vaccine|Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).
219208493|NCT06862453|BIOLOGICAL|PfSPZ Challenge (NF54)|Main cohort participants will undergo homologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (NF54), which are infectious cryopreserved Pf sporozoites.
219208494|NCT06617780|RADIATION|X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction|One addition x-ray and on addition CT scan of the wrist
219665752|NCT01048099|DRUG|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
219665753|NCT04606875|DIAGNOSTIC_TEST|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
219665754|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
219665755|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
218974108|NCT06863571|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
218974109|NCT02887859|BIOLOGICAL|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
218974110|NCT06623721|DEVICE|Movement-evoked transcutaneous auricular Vagus nerve stimulation|"Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur."
218974111|NCT00814788|DRUG|Bicalutamide|50 mg oral tablet daily
218974112|NCT00814788|DRUG|Everolimus|10 mg oral capsule daily
218974113|NCT06518642|DEVICE|Sooma tDCS portable device - active stimulation|Treatment followed common tDCS protocol upon considering safety and tolerability, comprising five consecutive sessions in five days of 30-minute 2 mA tDCS. We utilized the Soterix Medical tDCS device (Soterix Medical, New York, NY, USA, Model 1x1 tDCS-CT) in the research lab and the Sooma Oy device (Sooma Depression Therapy Comfort, Helsinki, Finland) for patient self-administration.Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device.Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or. Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or the Soterix device based on availability during their initial session. A current of 2 mA was applied with the anode positioned left DLPFC, corresponding to area F3 in the international 10-20 system. The cathode (reference electrode) was applied at the right dPLFC, F4.
218974114|NCT06518642|DEVICE|Sooma tDCS portable device - sham stimulation|Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device for effective blinding, distinguishable only by serial number and managed by an external data manager following the randomization sequence.To ensure blinding to the participant and their caregiver, at the beginning of the stimulation sessions, participants receiving both the active and sham stimulation would experience a ramp-up in current from 0 to 2 mA, and then the current would ramp down to 0 mA for participants receiving sham stimulation. Participants were told that they may experience sensations such as tingling, headache, or mild burning during the first 30-60 seconds of the stimulation session but that they may subside afterwards as they got used to it. In other words, participants would not be able to tell if diminishing of side effects were due to habituation (active tDCS) or ramping down of current (sham tDCS).
218974115|NCT06933576|DEVICE|DSOC EyeMAX 11Fr|digital single-operator cholangioscopy using the new EyeMAX™ 11Fr (Micro-Tech Endoscopy, Nanjing, China)
218974116|NCT06930898|BEHAVIORAL|Gamified Mammoverse Platform|A gamified, metaverse-based platform delivering breast health education through story-based tasks, interactive challenges, points, rewards, badges, and virtual incentives.
218974117|NCT06930898|BEHAVIORAL|Standard Mammoverse Platform|A non-gamified version of the Mammoverse platform that provides the same breast health educational content.
218974118|NCT04099407|DRUG|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
218974119|NCT04099407|OTHER|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
218974120|NCT00252395|DEVICE|PDA-based Electronic Prescribing Software|
218974121|NCT00250055|PROCEDURE|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
218974122|NCT03832777|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
218974123|NCT00282074|PROCEDURE|laparoscopic bilateral hernia repair|
218974124|NCT05005910|DRUG|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
218974125|NCT05005910|DRUG|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
218974126|NCT03531983|PROCEDURE|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
218974127|NCT01628705|OTHER|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
218974128|NCT01628705|DIETARY_SUPPLEMENT|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
218974129|NCT02538328|DEVICE|Harmonic scapel|different surgical devices used in the obesity surgery
218974130|NCT02538328|DEVICE|Ligasure|Bipolar vessel sealing system used in obesity surgery
219065983|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
219065984|NCT00530361|DRUG|Nesiritide|
219065985|NCT01053026|DRUG|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
219065986|NCT02345057|DRUG|CS-3150|
219065987|NCT02345057|DRUG|placebo|
219065988|NCT02855099|OTHER|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
219065989|NCT04863066|BIOLOGICAL|CAR-T cells|The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
219065990|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
219065991|NCT06033261|BIOLOGICAL|mRNA-1608|Sterile liquid for injection
219065992|NCT06033261|BIOLOGICAL|BEXSERO|A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.
219208495|NCT06870500|DRUG|Methotrexate|"1. Assess the response of psoriasis and psoriatic arthritis to Methotrexate.~2. Assess the relation between Card14 gene(rs 34367357 ) Polymorphism in psoriatic and psoriatic arthritis patients and their clinical response to methotrexate"
219208496|NCT06870500|DRUG|Placebo|Placebo
219208497|NCT06744556|DRUG|daunorubicin|Used in combination with cytarabine and venetoclax for induction therapy in DAV.
218974131|NCT02084212|OTHER|Microperimetry|
218974132|NCT02572362|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
218974133|NCT03734575|DEVICE|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
218974134|NCT06291974|DIAGNOSTIC_TEST|electromyography|"Surface Electromyography (SEMG) is a measurement of the electrical activity in muscles as a byproduct of contraction.~It is the summation of action potentials from the muscle fibers under the electrodes placed on the skin"
218974135|NCT03376100|PROCEDURE|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
218974136|NCT03376100|PROCEDURE|Hematoma Block|Conventional local anesthetic method using hematoma block
218974137|NCT04858256|DRUG|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
218974138|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
218974139|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
218974140|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
219208498|NCT06744556|DRUG|Venetoclax|Used in combination with cytarabine and daunorubicin for induction therapy in DAV.
219208499|NCT06744556|DRUG|cytarabine|Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.
219665756|NCT03452241|OTHER|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
219665757|NCT03452241|OTHER|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
219665758|NCT02295761|BEHAVIORAL|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
219665759|NCT02295761|BEHAVIORAL|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
219665760|NCT05191368|OTHER|No intervention|No intervention
218974141|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
218974142|NCT01920555|DRUG|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
218974143|NCT00697073|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
218974144|NCT05997771|OTHER|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
218974145|NCT04437849|DEVICE|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
218974146|NCT06708052|BEHAVIORAL|voodoo flossing|"The voodoo flossing intervention used the standard voodoo flossing, wrapping a voodoo flossing (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
218974147|NCT06708052|BEHAVIORAL|Control group|The control group did not use voodoo flossing.
218974148|NCT06434818|COMBINATION_PRODUCT|EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)|EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.
218974149|NCT06434818|COMBINATION_PRODUCT|CBOT with olfactory stimulants & OFC tasks|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
218974150|NCT06434818|COMBINATION_PRODUCT|CBOT Sham|CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
219065993|NCT05562440|OTHER|Focus Group Discussion|Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
219065994|NCT03190382|OTHER|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
219208500|NCT06744556|DRUG|azacitidine|Used in combination with venetoclax for maintenance therapy.
219208501|NCT06744556|DRUG|Homoharringtonine|Used in combination with cytarabine and venetoclax for induction therapy in HAV.
219208502|NCT06744556|DRUG|Idarubicin|Used in combination with cytarabine and venetoclax for induction therapy in IAV.
219665761|NCT05423366|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
219665762|NCT00553293|DRUG|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
219665763|NCT00553293|DRUG|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
219665764|NCT01368887|DRUG|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
219665765|NCT01368887|OTHER|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
219665766|NCT01368887|DRUG|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
219065995|NCT05150730|OTHER|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
219065996|NCT04320069|DEVICE|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
219065997|NCT06042348|DIAGNOSTIC_TEST|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
219065998|NCT01844323|OTHER|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
219065999|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
219066000|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
219066001|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
219066002|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
219665767|NCT01368887|DRUG|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
218974151|NCT03068598|DEVICE|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
218974152|NCT05250089|OTHER|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
219066003|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
219066004|NCT01169467|DRUG|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
219066005|NCT01169467|OTHER|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
219066006|NCT00329277|PROCEDURE|perimetry|
219066007|NCT04827212|BEHAVIORAL|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
219066008|NCT01008033|DRUG|IDP-108|Topical application once a day for 48 weeks
219066009|NCT01008033|DRUG|Vehicle|Topical application once a day for 48 weeks
219066010|NCT04250272|PROCEDURE|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
219066011|NCT03058679|OTHER|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
219066012|NCT04898608|OTHER|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
219066013|NCT04691765|DRUG|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
219665768|NCT01969084|DRUG|Linagliptin|
219066014|NCT01796574|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
219066015|NCT02264067|DRUG|Talsaclidine|
219066016|NCT02264067|DRUG|Placebo|
219066017|NCT03108924|DRUG|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
219066018|NCT05997043|DRUG|oral anti-Parkinson drugs and injection of botulinum toxin|The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
219066019|NCT05997043|DRUG|oral anti-Parkinson's drugs|The control group only took oral anti-Parkinson's drugs.
219066020|NCT03302962|BEHAVIORAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
219665769|NCT01969084|DRUG|Placebo|
219665770|NCT01969084|OTHER|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
219208503|NCT06745115|DIAGNOSTIC_TEST|Blood fluorescence metabolite analyzer|This study does not involve Intervention. The fluorescence intensity quantified by the blood fluorescence metabolite analyzer does not affect or interfere with clinical diagnosis and treatment. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient's blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 10 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results.
219665771|NCT01969084|OTHER|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
219665772|NCT01969084|OTHER|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
219665773|NCT05822648|BEHAVIORAL|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
218974153|NCT05305339|OTHER|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
218974154|NCT03238742|DRUG|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
218974155|NCT03238742|DRUG|normal saline|200ml normal saline every 12 hours for 5 days
218974156|NCT05788900|BIOLOGICAL|Heparin|intravenous Heparin
218974157|NCT04625790|DEVICE|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
218974158|NCT04625790|OTHER|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
218974159|NCT00145704|DRUG|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
218974160|NCT00145704|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
218974161|NCT00145704|DIETARY_SUPPLEMENT|Calcium|calcium supplement given to patients with growth hormone deficiency
218974162|NCT01088737|DRUG|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
218974163|NCT04738851|OTHER|Therapy Mirror task|"The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
219066021|NCT06086730|DEVICE|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.
219066022|NCT06086730|DEVICE|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes"
219208504|NCT06763380|DIAGNOSTIC_TEST|Ultrasound|Detection of uterine abnormalities in patients who are infertile buy using Ultrasound
219066023|NCT03517644|OTHER|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
219066024|NCT03517644|OTHER|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
219066025|NCT03517644|OTHER|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
219066026|NCT03517644|OTHER|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
219066027|NCT03517644|OTHER|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
219066028|NCT03939286|OTHER|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
219066029|NCT03939286|DIAGNOSTIC_TEST|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
219066030|NCT03939286|OTHER|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
219066031|NCT03939286|OTHER|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
219066032|NCT06486259|OTHER|Controlled mechanical ventilation|Patients were ventilated under similar tidal volume, respiratory rate, and plateau pressure. PEEP was the adjustment variable to reach a similar plateau pressure
219066033|NCT02544243|DRUG|Vinorelbine|
219208505|NCT06763380|DIAGNOSTIC_TEST|ultrasound then hysterosalpingography|If uterine abnormality could not diagnosed with ultrasound then hysterosalpingography would be performed
219208506|NCT06742632|BEHAVIORAL|Symptoms checklist-90|The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.
219208507|NCT06735196|DEVICE|sampling capsule endoscopy|Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.
219208508|NCT06740682|BEHAVIORAL|Podcast olumlu doğum hikayeler|"ositive birth stories were listened to by women who gave birth in the hospital included in the study and created with their permission. The podcast recording was done in a single session. These positive birth stories were expertly reviewed by 3 obstetricians and 3 academics. Each podcast content is 10 to 20 minutes (Cai et al., 2023). A WhatsApp reminder msg will be sent so that the stories are not forgotten.~In addition, the pregnant woman will be contacted by phone and trained to listen (Cai et al., 2023).~Participants will be allowed to listen to the podcasts as much as they want (Cai et al., 2023). After listening to each story, their feedback will be received and the participants' doubts will be clarified. (Cai et al., 2023; Çankaya and Şimşek, 2021; Mousavi et al., 2022).~Based on multimedia principles, podcast positive birth experiences will be prepared (Clark and Mayer, 2023). Week 24, Week 30-32, Week 36-38 First story"
219208509|NCT06764628|DRUG|SHR-4375|SHR-4375 injection
219665774|NCT05822648|OTHER|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
219665775|NCT01288092|DRUG|BEZ235|
219208510|NCT06763393|RADIATION|Ultrasound|To determine the correlation between adnexal masses and endometrial thickness measured with ultrasound in adults women.
219665776|NCT00106834|DRUG|Infliximab|
219665777|NCT00157716|DRUG|(MC-1) Pyridoxal-5'-phosphate|
219066034|NCT02544243|DRUG|Gemcitabine|
219066035|NCT02544243|DRUG|Cisplatin|
219066036|NCT00599326|DRUG|Deferasirox|250 mg of deferasirox once daily for 6 months
219066037|NCT06143618|BEHAVIORAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
219665778|NCT04077710|RADIATION|Radioactive Iodine-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing template includes information on the path of the implantation needle, characteristics of the surface of the therapy area of the patient, and positioning and orientation effects which can make the operation more accurate.
219665779|NCT04760106|DIAGNOSTIC_TEST|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
219665780|NCT03519100|OTHER|quality of life evaluation|quality of life evaluation post surgery
219665781|NCT01506687|BEHAVIORAL|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
219665782|NCT01506687|BEHAVIORAL|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
219665783|NCT04304261|DRUG|Canagliflozin|12 weeks of Canagliflozin(100mg/day) treatment
219665784|NCT04304261|DRUG|Sitagliptin|12 weeks of Sitagliptin (100mg/day) treatment
219665785|NCT02192853|DRUG|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
219665786|NCT02192853|DRUG|Placebo|Day 4: placebo tablet
219665787|NCT03089853|DEVICE|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
219665788|NCT04857853|OTHER|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
219665789|NCT04857853|OTHER|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
218974164|NCT03265665|BEHAVIORAL|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
218974165|NCT03265665|OTHER|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
218974166|NCT02525276|BEHAVIORAL|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
219066038|NCT06143618|BEHAVIORAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
219066039|NCT04302857|OTHER|routine MRI|MRI with routine DTI sequence
219066040|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
219066041|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
219066042|NCT00120172|DRUG|oxaliplatin, capecitabine, bevacizumab|
219066043|NCT01257295|DIETARY_SUPPLEMENT|control: no fiber addition|liquid breakfast without addition of fiber
219665790|NCT04857853|OTHER|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
219665791|NCT01742754|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
219665792|NCT00025753|DRUG|rosiglitazone (Avandia)|
219665793|NCT00025753|BEHAVIORAL|Aerobic and weight lifting exercise training|
219665794|NCT05436353|OTHER|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
219665795|NCT02419651|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
219665796|NCT02419651|DRUG|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
219208511|NCT06835764|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) twice per week over the course of 4 hospice telehealth visits (one episode per visit). All four visits will use telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
219208512|NCT06765083|DIAGNOSTIC_TEST|POCUS of the hip|POCUS of the hip (proximal femur) by the (resident) emergency physician, prior to radiograph imaging.
218974167|NCT02525276|DRUG|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
218974168|NCT06374771|DRUG|Melatonin 10 MG|10 mg of Melatonin will be given orally pre and post-operative
218974169|NCT06374771|DRUG|Vitamin C|1 gm of Vitamin C will be given orally pre and post-operative
218974170|NCT00199069|DRUG|Asparaginase|
218974171|NCT00199069|DRUG|Vincristine|
218974172|NCT00199069|DRUG|Daunorubicin, Adriamycin|
218974173|NCT00199069|DRUG|Cyclophosphamide|
219066044|NCT01257295|DIETARY_SUPPLEMENT|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
219066045|NCT01257295|DIETARY_SUPPLEMENT|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
218974174|NCT00199069|DRUG|Ifosfamide|
218974175|NCT00199069|DRUG|Cytarabine|
218974176|NCT00199069|DRUG|Mitoxantrone|
219066046|NCT01257295|DIETARY_SUPPLEMENT|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
219066047|NCT01257295|DIETARY_SUPPLEMENT|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
219066048|NCT01257295|DIETARY_SUPPLEMENT|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
219066049|NCT00784810|DRUG|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
218974177|NCT00199069|DRUG|Methotrexate|
218974178|NCT00199069|DRUG|6-Mercaptopurine|
218974179|NCT00199069|DRUG|6-Thioguanine|
218974180|NCT00199069|DRUG|VM26|
218974181|NCT00199069|DRUG|Dexamethasone / Prednisolone|
218974182|NCT00199069|PROCEDURE|CNS Irradiation|
218974183|NCT00199069|PROCEDURE|Mediastinal Irradiation|
219066050|NCT00784810|DRUG|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
219066051|NCT02630667|OTHER|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
219066052|NCT02630667|OTHER|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
219066053|NCT02630667|OTHER|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
219208513|NCT06765915|DRUG|Avapritinib|After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.
219208514|NCT06766084|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques
219665797|NCT02419651|DRUG|Placebo|Women will receive a placebo 1 hour before the procedure
219665798|NCT02142205|BIOLOGICAL|BG00002|IV Infusion
219665799|NCT01957839|DRUG|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
218974184|NCT00199069|PROCEDURE|Stem Cell Transplantation|
219665800|NCT03446118|DIAGNOSTIC_TEST|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
219665801|NCT03257761|BIOLOGICAL|Durvalumab|Given IV
219665802|NCT03257761|DRUG|Guadecitabine|Given SC
219665803|NCT01307384|DEVICE|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
219665804|NCT00441363|DRUG|Bromocriptine Mesylate|0.8 mg tablet
219665805|NCT01043094|DRUG|Pitavastatin 4mg|Pitavastatin 4mg single dose
219665806|NCT00006087|PROCEDURE|annual screening|
219665807|NCT00006087|PROCEDURE|bronchoscopic and lung imaging studies|
219665808|NCT00006087|PROCEDURE|comparison of screening methods|
219665809|NCT00006087|PROCEDURE|computed tomography|
219665810|NCT00006087|PROCEDURE|radiography|
219665811|NCT00006087|PROCEDURE|study of high risk factors|
219665812|NCT05513755|PROCEDURE|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
219665813|NCT00031772|PROCEDURE|psychosocial assessment and care|Questionnaire and telephone intervention
219665814|NCT04974606|DIETARY_SUPPLEMENT|Cherry-flavored still beverage|10 oz bottle
218974185|NCT06516484|DRUG|Romiplostim|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
218974186|NCT03150160|DRUG|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
218974187|NCT03150160|DRUG|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
218974188|NCT03150160|DRUG|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
218974189|NCT00729599|DRUG|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
218974190|NCT02562833|DEVICE|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
218974191|NCT02562833|DEVICE|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
219066054|NCT00208793|DIETARY_SUPPLEMENT|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
219066055|NCT00208793|DRUG|Placebo|Placebo
219066056|NCT00208793|DIETARY_SUPPLEMENT|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
219066057|NCT00208793|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
219066058|NCT01101737|OTHER|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
219066059|NCT02862106|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
219066060|NCT02806180|PROCEDURE|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
219066061|NCT02806180|PROCEDURE|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
219066062|NCT01088451|DRUG|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
218974192|NCT01303328|DRUG|C1|Local application of the experimental gel or placebo gel.
218974193|NCT01475409|BIOLOGICAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
219066063|NCT04981665|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
219066064|NCT04981665|DRUG|TACE|TACE will be performed after curative resection (4±1w)
219066065|NCT02508480|BEHAVIORAL|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
219665815|NCT04974606|OTHER|Placebo cherry-flavored still beverage|10 oz bottle
219665816|NCT04818723|DRUG|Montelukast|We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
219665817|NCT00153725|DRUG|Aspirin and Pantoloc|
219665818|NCT04114656|DRUG|Placebo|Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).
219665819|NCT04114656|DRUG|GSK3858279|GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
219665820|NCT02849210|BIOLOGICAL|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
219665821|NCT02061644|OTHER|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
219665822|NCT04755738|COMBINATION_PRODUCT|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
219665823|NCT02542137|RADIATION|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
219665824|NCT02542137|DRUG|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
219665825|NCT01473017|BEHAVIORAL|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
219665826|NCT05964920|DRUG|Saline|Two placebo injections one at baseline and one week 3.
219665827|NCT05964920|DRUG|Testosterone Undecanoate|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
219665828|NCT05964920|DRUG|Saline + Resistance exercise training|Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
219665829|NCT05964920|DRUG|Testosterone Undecanoate + Resistance exercise training|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
219665830|NCT01304290|OTHER|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
219665831|NCT05772507|DEVICE|URGO AWC_008 dressing or URGO AWC_022 dressing|local management of acute or chronic wounds
219665832|NCT05731752|DRUG|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
218974194|NCT04507100|BEHAVIORAL|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
218974195|NCT05231044|DRUG|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
218974196|NCT05231044|DRUG|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
218974197|NCT06076954|BEHAVIORAL|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
218974198|NCT04036734|DIAGNOSTIC_TEST|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
218974199|NCT04036734|DIAGNOSTIC_TEST|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
218974200|NCT04754243|DRUG|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
218974201|NCT04754243|DRUG|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
219066066|NCT02508480|BEHAVIORAL|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
219066067|NCT00077025|DRUG|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
219066068|NCT00077025|DRUG|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
219066069|NCT04017026|DEVICE|Implantation|Implantation of 6 mm short implants
219665833|NCT01156883|DRUG|asparaginase|
219665834|NCT01156883|DRUG|cyclophosphamide|
219665835|NCT01156883|DRUG|cytarabine|
219665836|NCT01156883|DRUG|daunorubicin hydrochloride|
218974202|NCT01193660|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
219066070|NCT01840423|DRUG|ODM-104|ODM-104
219066071|NCT01840423|DRUG|Placebo|Placebo
219066072|NCT01840423|DRUG|Entacapone|entacapone + levodopa/carbidopa
219665837|NCT01156883|DRUG|dexamethasone|
219665838|NCT01156883|DRUG|doxorubicin hydrochloride|
219665839|NCT01156883|DRUG|ifosfamide|
219665840|NCT01156883|DRUG|mercaptopurine|
219665841|NCT01156883|DRUG|methotrexate|
219665842|NCT01156883|DRUG|methylprednisolone|
219665843|NCT01156883|DRUG|prednisone|
219665844|NCT01156883|DRUG|thioguanine|
219665845|NCT01156883|DRUG|vincristine sulfate|
218974203|NCT01193660|DRUG|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
218974204|NCT01193660|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
219665846|NCT01156883|DRUG|vindesine|
219665847|NCT06094543|BEHAVIORAL|Patient Engagement Tool|8 week daily patient education and engagement tool
219665848|NCT03236129|PROCEDURE|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
219665849|NCT03236129|PROCEDURE|Standard DLI|The patients in this arm benefit of a standard DLI.
219665850|NCT00102154|DRUG|MK0928, gaboxadol / Duration of Treatment: 10 months|
219665851|NCT04730752|DIAGNOSTIC_TEST|Appendicitis Inflammatory Response|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
219665852|NCT04730752|DIAGNOSTIC_TEST|Adult Appendicitis Score|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
219665853|NCT02578940|DRUG|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
219665854|NCT05373030|BIOLOGICAL|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
218974205|NCT01193660|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
218974206|NCT01193660|OTHER|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
218974207|NCT01886716|BEHAVIORAL|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
218974208|NCT01886716|BEHAVIORAL|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
218974209|NCT01886716|BEHAVIORAL|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
218974210|NCT05059171|DEVICE|OneSahpe single file|The rotary motion of OneShape single file
218974211|NCT05059171|DEVICE|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
218974212|NCT02116231|DRUG|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
218974213|NCT02116231|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
218974214|NCT03388385|DRUG|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
219665855|NCT04586465|DRUG|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
219665856|NCT02915822|PROCEDURE|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
218974215|NCT03388385|DRUG|Ferinject|Ferric carboxymaltose will be infused in day 2.
218974216|NCT04879225|BEHAVIORAL|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
218974217|NCT04879225|BEHAVIORAL|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
218974218|NCT04879225|BEHAVIORAL|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
218974219|NCT04879225|BEHAVIORAL|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
218974220|NCT01854203|DRUG|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
218974221|NCT01854203|DRUG|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
218974222|NCT04200560|OTHER|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
218974223|NCT04200560|OTHER|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
219665857|NCT02915822|PROCEDURE|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
219665858|NCT05118217|OTHER|This is a non-interventional study|This is a non-interventional study
219665859|NCT05682274|PROCEDURE|Partial restoration approach combined with CAF+CTG|The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
219665860|NCT03447106|PROCEDURE|laparotomy|This is a kind of traditional surgical method.
218974224|NCT00806975|DEVICE|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
219665861|NCT03447106|PROCEDURE|Laparoscopic|laparoscopic surgery
219665862|NCT03447106|PROCEDURE|Robotic|the Da Vinci robot assisted gastric resection
219665863|NCT03127761|OTHER|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
219665864|NCT02301845|DRUG|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
219665865|NCT03175315|BEHAVIORAL|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
219665866|NCT04303234|OTHER|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
219665867|NCT04303234|OTHER|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
219665868|NCT03664921|DRUG|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
219665869|NCT03664921|DRUG|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
219665870|NCT06069895|DRUG|NNC0113-6856|NNC0113-6856 will be administered as oral tablets.
219665871|NCT06069895|DRUG|Placebo|NNC0113-6856 matching placebo will be administered as oral tablets.
219665872|NCT03304275|BEHAVIORAL|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
219665873|NCT04104997|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
218974225|NCT03257696|DIAGNOSTIC_TEST|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
219066073|NCT01840423|DRUG|levodopa/carbidopa|entacapone + levodopa/carbidopa
219066074|NCT05250596|DRUG|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
219066075|NCT05250596|DRUG|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
219665874|NCT04104997|DRUG|Placebos|Placebo as eye drops
219665875|NCT04513899|BEHAVIORAL|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
219665876|NCT04513899|BEHAVIORAL|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
219665877|NCT02720159|DEVICE|Percutaneous Osseintegrated Prosthesis|
219665878|NCT03370185|DRUG|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
219665879|NCT03282591|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
218974226|NCT04953429|BEHAVIORAL|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
219066076|NCT05061264|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
219066077|NCT00563784|DRUG|Erlotinib|150 mg by mouth daily for 7 Weeks
219066078|NCT00563784|DRUG|Carboplatin|2 AUC by vein weekly for 7 Weeks
219066079|NCT00563784|DRUG|Paclitaxel|45 mg/m\^2 by vein weekly for 7 Weeks
219066080|NCT00563784|RADIATION|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
219066081|NCT00281541|DRUG|YM155|
219066082|NCT04499794|DRUG|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
219066083|NCT03966976|DEVICE|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
219665880|NCT03282591|DRUG|Matching Placebo Tablets|Placebo Tablets
219665881|NCT03627715|DRUG|Propagermanium|Immediate release capsule
219665882|NCT03627715|DRUG|Placebo|Placebo capsule
219665883|NCT03955588|DIAGNOSTIC_TEST|aCGH|
218974227|NCT01114152|DRUG|AZD9742|IV Formulation
218974228|NCT01114152|DRUG|Placebo|IV Formulation
219066084|NCT03966976|OTHER|Conventional follow-up|Conventional follow-up
219665884|NCT01254084|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
219665885|NCT01254084|DIETARY_SUPPLEMENT|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
219665886|NCT00086398|BEHAVIORAL|Behavior Therapy|
219665887|NCT01198535|BIOLOGICAL|Cetuximab|Given IV
219665888|NCT01198535|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219665889|NCT01198535|OTHER|Laboratory Biomarker Analysis|Correlative studies
219665890|NCT01198535|OTHER|Pharmacological Study|Correlative studies
219665891|NCT00442819|PROCEDURE|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
219665892|NCT03937674|BEHAVIORAL|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
219665893|NCT04425811|OTHER|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
219665894|NCT00312767|DRUG|Fabrazyme (agalsidase beta)|
219665895|NCT00214656|DRUG|Recombinant Activated Factor VII|
219665896|NCT01241331|DRUG|BLI1100|BLI110 topical cream
219665897|NCT01241331|DRUG|Vehicle cream|Vehicle topical cream
219665898|NCT03110081|PROCEDURE|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
219665899|NCT03110081|PROCEDURE|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
219665900|NCT00633490|DRUG|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
219665901|NCT05162430|DRUG|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
219665902|NCT03941028|DEVICE|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
219665903|NCT02674126|BEHAVIORAL|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
219665904|NCT02674126|BEHAVIORAL|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
219665905|NCT00940576|DIETARY_SUPPLEMENT|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
218974229|NCT02367131|DRUG|JARDIANCE®|JARDIANCE®
218974230|NCT00290277|BIOLOGICAL|HPV-16/18 L1/AS04|
218974231|NCT06357312|DEVICE|hip trochanteric nail|hip trochanteric nail with and without distal interlocking screw
218974232|NCT02725034|DEVICE|Standard endoscopy|
218974233|NCT02725034|DEVICE|High definition endoscopy with Optic Enhancement|
218974234|NCT05596942|DIETARY_SUPPLEMENT|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
219665906|NCT00940576|OTHER|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
219665907|NCT04987931|DRUG|Talazoparib|This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
219665908|NCT02824211|DEVICE|Right Dose System|Automated titration of oxygen system during exertion
219665909|NCT02435563|DRUG|ticagrelor 180 mg administrated alone|
218974235|NCT00418639|DRUG|Nitazoxanide|
219665910|NCT02435563|DRUG|Ticagrelor adjusted dose + ritonavir 100mg|
219665911|NCT02624154|PROCEDURE|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
219665912|NCT03090503|DRUG|Aripiprazole|Initial dose: 10 mg.
218974236|NCT05688449|DRUG|Bupivacaine-fentanyl|A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
218974237|NCT05688449|DRUG|Saline|A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
218974238|NCT02138773|DRUG|Tamsulosin formulation-A|oral
218974239|NCT02138773|DRUG|Tamsulosin formulation-B|oral
218974240|NCT02572388|BIOLOGICAL|R21|
218974241|NCT02572388|BIOLOGICAL|Matrix-M1|
218974242|NCT00161473|DRUG|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
218974243|NCT00161473|DRUG|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
218974244|NCT01973569|DRUG|denosumab|denosumab administered subcutaneously
218974245|NCT01973569|DRUG|placebo|placebo administered subcutaneously to match denosumab
218974246|NCT05816720|DRUG|Lutetium-177 DOTATATE|Intravenous administration
219665913|NCT03090503|DRUG|Risperidone|Initial dose: 2 mg.
219665914|NCT03038711|DRUG|BMS-986166|Specified dose on specified days
219665915|NCT03038711|OTHER|Placebo matching BMS-986166|Specified dose on specified days
219665916|NCT06397053|PROCEDURE|robotic surgery|robotic surgery
219665917|NCT05382429|PROCEDURE|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
219665918|NCT05382429|PROCEDURE|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
219665919|NCT01130324|DRUG|VIBATIV|Observational
219066085|NCT03652311|DEVICE|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
219066086|NCT04461977|OTHER|True acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
219066087|NCT04461977|OTHER|Sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
219066088|NCT01479920|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
219665920|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (active)|The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
219665921|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (Sham)|"The tDCS Acti- Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest."
219665922|NCT04512352|OTHER|Online curriculum|"The psychologist and our advisory team had successfully developed a total of 100 hours of parenting curriculum.~The adopted curriculum had focused on using play to facilitate parents in promoting their children's development in cognitive, motor, emotional and social aspects. Play-based activities are instrumental in improving children's development. Given that parents in poverty had difficulties spending time and money travelling back-and-forth to the training site and their homes, the research team decided to use e-learning as the medium of learning for our parenting programme. Web-based learning has the advantage of cutting time and travelling costs, which are luxuries to many parents in poverty."
219665923|NCT03928275|BIOLOGICAL|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
219665924|NCT03928275|BIOLOGICAL|Combination therapy Interleukin-2 and Bacillus Calmette Guerin|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
219665925|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
219665926|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
218974247|NCT03559673|DRUG|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
218974248|NCT00810108|DRUG|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
218974249|NCT01291953|PROCEDURE|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
218974250|NCT01291953|PROCEDURE|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
218974251|NCT01232231|DRUG|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
218974252|NCT01232231|BEHAVIORAL|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
218974253|NCT01446107|OTHER|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
218974254|NCT01446107|OTHER|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
218974255|NCT01446107|OTHER|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
218974256|NCT01446107|OTHER|placebo control|application of water onto tooth surface every year
218974257|NCT04045275|BEHAVIORAL|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
218974258|NCT03326726|DRUG|2% CHG|Chlorhexidine Gluconate
219665927|NCT02290119|DEVICE|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
219665928|NCT02290119|PROCEDURE|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
219665929|NCT03670511|OTHER|sit-to-stand test|to sit and stand from a chair
219665930|NCT03670511|OTHER|six minute walking test|to walk for six minutes
219665931|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
219665932|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
219665933|NCT03309228|OTHER|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
219665934|NCT05445388|DEVICE|Aurisvue|OCT imaging of the middle ear
219665935|NCT01717157|DRUG|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
219665936|NCT01717157|DRUG|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
219665937|NCT01717157|DRUG|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
219665938|NCT01717157|DRUG|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
219665939|NCT01717157|DRUG|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
219665940|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
219665941|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
219665942|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
219665943|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
219665944|NCT01722032|OTHER|Childhood Obesity|
219665945|NCT03326518|DIAGNOSTIC_TEST|Lumentin® 44|Contrast agent
219665946|NCT03326518|DIAGNOSTIC_TEST|Diluted Omnipaque®|Contrast agent
219665947|NCT03326518|DIAGNOSTIC_TEST|Movprep®|Contrast agent
219665948|NCT02400892|OTHER|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
218974259|NCT05089162|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
218974260|NCT05089162|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
218974261|NCT05089162|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
218974262|NCT05089162|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
218974263|NCT05089162|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
218974264|NCT01286727|DRUG|BB3|intravenous drug
219665949|NCT06124651|PROCEDURE|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
219665950|NCT06124651|PROCEDURE|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
218974265|NCT06432231|OTHER|Low glycemic index diet treatment|This study was a non-randomized, single centre, pre/post-intervention study. A low glycemic index diet was prescribed by a dietician for 3 months. LGID treatment consisted of 10% (40-60 g) low glycaemic index (glycaemic index \<50) carbohydrate, 20-30% protein and 60-70% lipid
218974266|NCT01526772|PROCEDURE|Endoscopy|Transoral endoscopy versus transoral endoscopy
218974267|NCT00632840|DRUG|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
218974268|NCT00949273|PROCEDURE|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
218974269|NCT03714620|DRUG|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
218974270|NCT00508222|DRUG|Kaletra Tablets|Kaletra 800/200 OD
218974271|NCT06119035|OTHER|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
218974272|NCT04781504|BEHAVIORAL|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
218974273|NCT05038670|DEVICE|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
218974274|NCT03115047|DRUG|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
218974275|NCT03115047|DRUG|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
218974276|NCT02431338|PROCEDURE|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
218974277|NCT02484183|DEVICE|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
218974278|NCT05341687|OTHER|No applicable|No applicable
219665951|NCT06252467|DEVICE|Photobiomodulation Therapy|"Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
219066089|NCT01479920|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
219665952|NCT06252467|DEVICE|Placebo Photobiomodulation|The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
219665953|NCT02653898|DRUG|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
218974279|NCT05686954|OTHER|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
219665954|NCT02653898|DRUG|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
219665955|NCT02653898|DRUG|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
219665956|NCT02653898|DRUG|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
219665957|NCT02030886|DEVICE|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
218974280|NCT05686954|OTHER|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
218974281|NCT05686954|OTHER|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
218974282|NCT05686954|OTHER|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
218974283|NCT02284542|PROCEDURE|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
219066090|NCT01479920|PROCEDURE|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
219066091|NCT04634604|DRUG|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
219066092|NCT04634604|PROCEDURE|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
219066093|NCT03874364|DEVICE|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
219066094|NCT03874364|OTHER|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
219066095|NCT03874364|OTHER|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
219066096|NCT03874364|DEVICE|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
219066097|NCT03874364|OTHER|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
219066098|NCT03874364|OTHER|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
219066099|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
219066100|NCT03507166|DRUG|RC48-ADC|2 mg/kg IV every 2 weeks
219066101|NCT03434119|DRUG|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
219066102|NCT03434119|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
219066103|NCT03434119|DRUG|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
219066104|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2\) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
219066105|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
219066106|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
219066107|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
219066108|NCT02700282|BEHAVIORAL|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
219066109|NCT00304070|DRUG|Cisplatin|Given IV
219066110|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
219066111|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
219066112|NCT00304070|DRUG|Etoposide|Given IV
219066113|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
219066114|NCT00304070|DRUG|Mitotane|Given orally
219665958|NCT04786366|OTHER|The study does not have an intervention, but observe the AF incidence of the UK disease-free population|The study does not have an intervention, but observe the AF incidence of the UK disease-free population.
219665959|NCT02303834|DEVICE|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
219665960|NCT01375374|DRUG|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
219665961|NCT01375374|DRUG|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
219066115|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
219665962|NCT05948332|BEHAVIORAL|Delphi Rounds to generate consensus opinions among Experts|The Investigators (Steering Committee) will select the experts from across the globe based on pre-specified qualification criteria and will conduct iterative Delphi rounds to generate consensus on the definition and management of acute RVI in patients with receiving V-V ECMO, among the Experts. The selection criteria will be self-assessed through a survey among the potential Experts.
219066116|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
219066117|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
219066118|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
219066119|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
219066120|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
219066121|NCT06430567|DEVICE|Blood flow restriction (50% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 1) BFR Group with 50% AOP compression~Group 1 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 30-15-15-15 at 40% 1RM (repetition maximum)~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
219665963|NCT02550925|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
219665964|NCT02550925|BEHAVIORAL|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
219665965|NCT01734083|DEVICE|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
219665966|NCT01734083|BEHAVIORAL|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
218974284|NCT02284542|PROCEDURE|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
218974285|NCT05511194|OTHER|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
218974286|NCT05511194|OTHER|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
218974287|NCT02486302|DRUG|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
218974288|NCT02299882|DRUG|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
218974289|NCT02754557|OTHER|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
218974290|NCT02754557|DEVICE|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
218974291|NCT00997061|DRUG|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
218974292|NCT04487522|PROCEDURE|Open retromuscular ventral hernia repair|With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
218974293|NCT04487522|PROCEDURE|Laparoscopic retromuscular ventral hernia repair|With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
218974294|NCT04487522|DEVICE|Robotic-assisted retromuscular ventral hernia repair|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
218974295|NCT04384783|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
219360303|NCT04389177|DRUG|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
218974296|NCT04148690|OTHER|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
218974297|NCT04148690|OTHER|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
218974298|NCT01237821|DRUG|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
218974299|NCT01237821|DRUG|Effaclar|Topical, Bid, 12 weeks
218974300|NCT00975520|OTHER|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
218974301|NCT00975520|RADIATION|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
218974302|NCT00261079|DRUG|Fexofenadine|
218974303|NCT03699683|OTHER|Combined aerobic and resistance training program|
219665967|NCT06075043|DRUG|AND017|Oral administration of AND017 capsules three times per week
219665968|NCT00621998|DRUG|risperidone|0.5-6 mg/day
219665969|NCT00621998|DRUG|olanzapine|2.5-20 mg/day
219665970|NCT04019262|RADIATION|Radiation Therapy|Radiation
219665971|NCT04019262|DRUG|Temozolomide Oral Product|Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)
219665972|NCT03135574|DIAGNOSTIC_TEST|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
219665973|NCT00039481|BIOLOGICAL|oblimersen sodium|Given IV
219665974|NCT00039481|DRUG|dexrazoxane hydrochloride|Given IV
219665975|NCT00039481|DRUG|doxorubicin hydrochloride|Given IV
218974304|NCT03424668|BEHAVIORAL|diet|lifestyle factors
218974305|NCT05644769|OTHER|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
218974306|NCT05644769|DRUG|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
218974307|NCT05962749|OTHER|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
219066122|NCT06430567|DEVICE|Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
219066123|NCT03421197|DRUG|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
219066124|NCT03421197|DRUG|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
219066125|NCT03421197|DRUG|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
219066126|NCT03421197|DRUG|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
219665976|NCT00039481|DRUG|cyclophosphamide|Given IV
219665977|NCT00039481|BIOLOGICAL|filgrastim|Given SC
219665978|NCT00039481|OTHER|laboratory biomarker analysis|Correlative studies
219665979|NCT00039481|OTHER|pharmacological study|Correlative studies
219665980|NCT00003902|DRUG|capecitabine|
219665981|NCT00003902|DRUG|vinorelbine tartrate|
218974308|NCT03534934|DIAGNOSTIC_TEST|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
219665982|NCT06040671|OTHER|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
219665983|NCT00109941|BIOLOGICAL|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
219665984|NCT00109941|BIOLOGICAL|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
219665985|NCT02776540|DRUG|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
219665986|NCT02776540|DRUG|Aspirin|there's another group will receive 400 mg Aspirin
219665987|NCT02065518|DEVICE|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
219665988|NCT02065518|BEHAVIORAL|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
219665989|NCT02065518|BEHAVIORAL|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
219665990|NCT05621707|DRUG|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
219665991|NCT04095299|RADIATION|50.4 Gy to the tumor and elective volume|Standard radiotherapy
219665992|NCT04095299|RADIATION|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
219665993|NCT04095299|DRUG|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
219665994|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219665995|NCT05642572|DRUG|Capmatinib|Given PO
219665996|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
219665997|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219665998|NCT05642572|DRUG|Osimertinib|Given PO
219665999|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
219666000|NCT04055649|DRUG|Akt/ERK Inhibitor ONC201|Given orally (PO)
219666001|NCT04055649|DRUG|Paclitaxel|Given IV
219666002|NCT04055649|OTHER|Questionnaire Administration|Ancillary studies
219066127|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
219066128|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
219066129|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
219666003|NCT05429619|OTHER|PeerOnCall|A mobile health peer-to-peer support platform that consists of two inter-connected apps: PeerOnCall and PeerOnCall Support. The apps were co-designed by and for the public safety community in Canada, with customized content for correctional workers, emergency communicators, firefighters, paramedics and police.
219666004|NCT04849416|DRUG|LOXO-305|Administered orally.
219666005|NCT05666479|DEVICE|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
219666006|NCT03798327|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
218974309|NCT03534934|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
218974310|NCT03534934|OTHER|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
218974311|NCT03534934|DIAGNOSTIC_TEST|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
218974312|NCT03534934|DIAGNOSTIC_TEST|Duel-energy X-ray absorptiometry scan|Bone density measurement
218974313|NCT03534934|DIAGNOSTIC_TEST|Multi-detector computed tomography|Hip and ankle CT scan
218974314|NCT03534934|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
218974315|NCT06187662|BEHAVIORAL|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
218974316|NCT06187662|BEHAVIORAL|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
218974317|NCT06529965|BEHAVIORAL|covivio|Participants will receive access to the digital health intervention covivio in addition to TAU.
218974318|NCT03304821|DRUG|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
218974319|NCT03304821|DRUG|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
218974320|NCT05436275|BIOLOGICAL|CM310|300 mg every two weeks
218974321|NCT05436275|BIOLOGICAL|Placebo|once every two weeks
219666007|NCT06038149|DIAGNOSTIC_TEST|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
219666008|NCT05467813|OTHER|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
219666009|NCT05467813|OTHER|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
219666010|NCT05467813|OTHER|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
219666011|NCT03894475|DEVICE|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
219666012|NCT03894475|DEVICE|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
219666013|NCT04886388|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
219666014|NCT04886388|OTHER|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
219666015|NCT02598778|DRUG|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
219666016|NCT02598778|DRUG|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
219666017|NCT02598778|OTHER|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
218974322|NCT04910256|DRUG|Huatuo Zaizao Pills|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
218974323|NCT04910256|OTHER|Basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
218974324|NCT04968847|DEVICE|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
218974325|NCT02722486|DEVICE|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
218974326|NCT02722486|OTHER|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
218974327|NCT05804474|OTHER|Observational study|Observational study
218974328|NCT04840173|BEHAVIORAL|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
218974329|NCT03611010|DRUG|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
218974330|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
218974331|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
218974332|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
219666018|NCT02598778|OTHER|Deionized water|30 second oral rinse of 10mL of solution
219666019|NCT02128334|DRUG|Eligard 45 mg Exposure|Subcutaneous injections
218974333|NCT01444352|BIOLOGICAL|Placebo|0.5 mL, Intramuscular
218974334|NCT05919004|DIAGNOSTIC_TEST|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
219066130|NCT05319691|BEHAVIORAL|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
218974335|NCT00354471|PROCEDURE|Uterine Artery Embolization|
218974336|NCT02063880|OTHER|Urgent ART|Children will be started on HAART \<48 hours after enrollment.
218974337|NCT02063880|OTHER|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
218974338|NCT00567593|DRUG|Rosiglitazone|8mg tablet once a day for 14 days
218974339|NCT02521766|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
219066131|NCT03579459|BIOLOGICAL|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
219066132|NCT03579459|BIOLOGICAL|placebo|Normal saline solution
219066133|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
219066134|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
219066135|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
219066136|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
219066137|NCT04153409|DRUG|Placebo|Two capsules of placebo
219066138|NCT02446808|DEVICE|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
219066139|NCT02866890|DEVICE|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
219066140|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
219066141|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
219066142|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
219066143|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
219666020|NCT00463034|GENETIC|microarray analysis|
219666021|NCT00463034|GENETIC|polymerase chain reaction|
219666022|NCT00463034|GENETIC|polymorphism analysis|
219666023|NCT00463034|OTHER|high performance liquid chromatography|
219666024|NCT00463034|OTHER|immunohistochemistry staining method|
219666025|NCT00463034|OTHER|laboratory biomarker analysis|
219666026|NCT00463034|OTHER|questionnaire administration|
218974340|NCT02521766|DEVICE|Commercially Available Intraocular Lens|IOL per investigator's standard of care
218974341|NCT02521766|PROCEDURE|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
219066144|NCT02317458|BIOLOGICAL|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
219666027|NCT01014481|DRUG|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
219666028|NCT05885061|DEVICE|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
219666029|NCT05885061|DEVICE|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
219666030|NCT05885061|DEVICE|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
219666031|NCT04350879|OTHER|Data record|Data record
219666032|NCT00146549|DRUG|Trastuzumab|
219666033|NCT00146549|DRUG|Vinorelbine|
219666034|NCT00146549|DRUG|Paclitaxel|
219666035|NCT00146549|DRUG|Docetaxel|
219666036|NCT01716520|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
219066145|NCT02317458|BIOLOGICAL|Sham comparator|One arm with standard of care undergoing a sham procedure
219066146|NCT04442217|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
219066147|NCT01090804|DEVICE|BreatheMAX breathing device|secretion clearance, breathing exercise
219066148|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
219066149|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
219066150|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
219066151|NCT02528214|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
219066152|NCT02528214|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
219066153|NCT02528214|DRUG|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
219066154|NCT02528214|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
219666037|NCT01716520|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
219666038|NCT01716520|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
219666039|NCT02370056|DIAGNOSTIC_TEST|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
219666040|NCT02370056|DIAGNOSTIC_TEST|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
219666041|NCT04186897|PROCEDURE|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
219666042|NCT04186897|PROCEDURE|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
219666043|NCT04875572|DEVICE|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
218974342|NCT06412575|PROCEDURE|JNT Guided OGT-overlap Oesophagojejunostomy|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
219666044|NCT02072070|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
219666045|NCT02072070|DRUG|Placebo|Placebo control(Normal Saline)
219666046|NCT06006637|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
219666047|NCT00791037|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
219666048|NCT00791037|PROCEDURE|leukapheresis|Undergo leukapheresis
218974343|NCT06412575|PROCEDURE|TNT Guided OGT-overlap Oesophagojejunostomy|In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
218974344|NCT02106910|DEVICE|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
218974345|NCT00696683|OTHER|None, this is an observational study|
218974346|NCT01675427|OTHER|Interleukin 28B testing|Blood sampling for ILB28 genotyping
218974347|NCT05997758|OTHER|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
218974348|NCT05997758|BEHAVIORAL|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
218974349|NCT04343729|DRUG|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
218974350|NCT04343729|DRUG|Placebo solution|injectable saline solution
218974351|NCT01291654|DRUG|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
218974352|NCT01291654|DRUG|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
219066155|NCT02528214|DRUG|Albuterol/Salbutamol|Oral inhalation as needed.
219666049|NCT00791037|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
219666050|NCT00791037|DRUG|cyclophosphamide|Given IV
219066156|NCT02528214|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
219066157|NCT03660683|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
219066158|NCT03660683|DRUG|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
219066159|NCT03660683|DRUG|Placebo Oral Tablet|Matching Placebo Tablets
219066160|NCT00941603|DRUG|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
219666051|NCT00791037|BIOLOGICAL|sargramostim|Given ID
219066161|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
219066162|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
219066163|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
219066164|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
219066165|NCT00941603|DRUG|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
219666052|NCT00791037|OTHER|laboratory biomarker analysis|Correlative study
219666053|NCT06543420|PROCEDURE|lateral reconstruction|In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
219666054|NCT06543420|PROCEDURE|posterior reconstruction|In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
219666055|NCT06228495|BEHAVIORAL|Daily Intervention for Active Recovery|"Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy."
219666056|NCT02553798|DRUG|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
218974353|NCT01291654|DRUG|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
218974354|NCT05068024|DRUG|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
218974355|NCT00002121|DRUG|Diethylhomospermine|
218974356|NCT01524757|DRUG|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
218974357|NCT04322981|BEHAVIORAL|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
218974358|NCT04322981|BEHAVIORAL|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
218974359|NCT00700570|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
219066166|NCT02513654|DRUG|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
219066167|NCT04272281|PROCEDURE|medical shared decision|The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
219066168|NCT04272281|PROCEDURE|Standard medical care|control group will act as usual in their practice.
219066169|NCT05818735|OTHER|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
219066170|NCT05818735|OTHER|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
219066171|NCT05818735|DRUG|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
219066172|NCT05818735|DRUG|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
219066173|NCT02014116|DRUG|LY3009120 capsule|Administered orally.
219360304|NCT05211557|BIOLOGICAL|fhB7H3.CAR-Ts|"Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan"
219360305|NCT05120739|DRUG|2% CHX cloths|skin preparation in 2% CHX cloths
219666057|NCT05906654|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
219666058|NCT05411601|OTHER|Methodology of attachment of external foot prothesis|establishing the methodology of specific measurements of attachment of external foot prothesis
219666059|NCT00983541|DRUG|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
218974360|NCT00700570|DRUG|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
218974361|NCT00700570|DRUG|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
218974362|NCT04379544|OTHER|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
218974363|NCT05895071|DRUG|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
218974364|NCT05895071|DRUG|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
218974365|NCT04040270|BEHAVIORAL|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
219666060|NCT00983541|RADIATION|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
219666061|NCT00983541|DRUG|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
219666062|NCT01937884|DRUG|Parenteral Nutrition|
219666063|NCT00401492|DRUG|gemcitabine prolonged continuous infusion|
219666064|NCT00401492|DRUG|cisplatin|
219666065|NCT00401492|DRUG|vinorelbine|
218974366|NCT04040270|BEHAVIORAL|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
218974367|NCT01796756|OTHER|Handover program|
218974368|NCT05734573|BEHAVIORAL|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
218974369|NCT01316471|BEHAVIORAL|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
218974370|NCT01316471|OTHER|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
218974371|NCT04708379|BEHAVIORAL|Lifestyle intervention|Nutrition and physical activity education.
218974372|NCT00611533|DRUG|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
218974373|NCT00611533|DRUG|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
218974374|NCT02727413|PROCEDURE|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
218974375|NCT02727413|OTHER|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
218974376|NCT01431131|PROCEDURE|Intrasocket graft|Intrasocket mineralized cancellous allograft
218974377|NCT01431131|PROCEDURE|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
218974378|NCT00968318|PROCEDURE|Excision of strip of deep fascia|operative technique to excise deep fascia.
218974379|NCT05246397|DRUG|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
219066174|NCT04866264|DEVICE|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH \[56\] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
219066175|NCT04099069|PROCEDURE|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
219066176|NCT04546087|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
219066177|NCT02522533|OTHER|Physical Therapy|6 weeks of an exercise program.
219066178|NCT01230476|DRUG|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
219666066|NCT02211664|DEVICE|Passeo-18 balloon|
219666067|NCT02211664|DEVICE|Passeo-18 Lux drug releasing balloon|
219666068|NCT02211664|DEVICE|Pulsar-18 stent|
219666069|NCT04740996|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
219666070|NCT00004088|BIOLOGICAL|filgrastim|
218974380|NCT04899427|DRUG|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
218974381|NCT04899427|DRUG|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
218974382|NCT04899427|DRUG|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
218974383|NCT01924988|DEVICE|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
218974384|NCT04666675|DRUG|Upadacitinib|Oral; Tablet
218974385|NCT04666675|DRUG|Placebo for Upadacitinib|Oral; Tablet
218974386|NCT01297075|BEHAVIORAL|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
218974387|NCT01787422|OTHER|Traditional versus Telemedicine office visit|
218974388|NCT00921128|DRUG|Muscimol|
218974389|NCT00152360|DRUG|Orlistat|See Detailed Description.
218974390|NCT01978418|DRUG|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
218974391|NCT01978418|DRUG|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
218974392|NCT01006460|DRUG|Rhodiola rosea, L|3 Capsules twice a day
218974393|NCT01006460|DRUG|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
218974394|NCT01006460|DRUG|Panax ginseng|3 capsules twice a day
218974395|NCT01006460|DRUG|Placebo - dark brown sugar|3 capsules twice a day
218974396|NCT00400738|DRUG|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
218974397|NCT01359007|DRUG|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
218974398|NCT02860377|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
218974399|NCT02860377|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
219066179|NCT06152536|OTHER|Vegetarian Meal|"meal with vegetarian protein and meal with animal protein"
219066180|NCT05225818|BEHAVIORAL|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
219066181|NCT00428454|DEVICE|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
219360306|NCT05600595|PROCEDURE|Operation for snoring in children|Tonsillectomy and/or adenoidectomy
219666071|NCT00004088|BIOLOGICAL|recombinant interferon alfa|
219666072|NCT00004088|DRUG|busulfan|
219666073|NCT00004088|DRUG|cyclophosphamide|
219666074|NCT00004088|DRUG|melphalan|
219666075|NCT00004088|DRUG|pamidronate disodium|
219666076|NCT00004088|DRUG|thalidomide|
219666077|NCT00004088|PROCEDURE|peripheral blood stem cell transplantation|
218974400|NCT01892267|DEVICE|PEG-J placement|PEG-J placement
218974401|NCT06534749|DEVICE|ultrasound|Ultrasound screening: by (SonoScape A6, Yizhe Building, Yuquan, Road Shenzhen, 518051, China). General-purpose diagnostic abdominal ultrasound equipment was used, with a 7.5-MHz linear-type probe. Screenings will be performed by radiologist with appropriate practice. The ultrasound examination will take 10 min for each patient. The recordings will consist of two bilateral renal images will be obtained and one transverse and longitudinal images. The urinary bladder will be observed with the patient in a supine position, and images will be recorded when abnormalities will be identified. The following will be investigated by ultrasound: number, size (including differences between sides), and location of the kidneys; pelvic dilatation; echogenicity, and other findings indicating cysts or tumours. Shape and wall thickening of the urinary bladder, as well as ureter dilatation, will be also examined
219666078|NCT05804253|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
219666079|NCT02445742|DRUG|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
219666080|NCT05952791|OTHER|Surgery|Laparoscopic transabdominal preperitoneal (TAPP) groin hernia repair
219666081|NCT02838875|PROCEDURE|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
219666082|NCT04325867|OTHER|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
219666083|NCT00000290|DRUG|Cocaine|
219666084|NCT01543737|DEVICE|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
218974402|NCT03702517|DEVICE|lateral stair walking exercise|15 minutes of lateral stair walking exercise
218974403|NCT03702517|DEVICE|traditional physiotherapy|strengthening exercise, balance training and gait training
218974404|NCT05296733|DRUG|BI 456906|BI 456906
218974405|NCT06173934|DRUG|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
218974406|NCT06173934|DRUG|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
218974407|NCT04138004|DRUG|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
218974408|NCT04138004|DRUG|polyethylene glycol alone|4-litre polyethylene glycol split-dose
218974409|NCT00190970|DRUG|Ruboxistaurin|
218974410|NCT03563287|DRUG|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
218974411|NCT00135564|BIOLOGICAL|MenC-TT|
218974412|NCT00135564|BIOLOGICAL|Hib-MenC-TT|
218974413|NCT01825525|DEVICE|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
218974414|NCT00922233|DRUG|levonorgestrel|oral contraceptive pills
219066182|NCT03111927|OTHER|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
219666085|NCT01543737|DEVICE|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
219666086|NCT03728621|BEHAVIORAL|Normocaloric and balanced diet, physical activity|Promotion of normocaloric \& balanced diet and physical activity
219666087|NCT05164198|BIOLOGICAL|Adalimumab and its biosimilars|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
218974415|NCT02540616|DEVICE|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
218974416|NCT04256226|PROCEDURE|Tumor excision|Excision of GIST
218974417|NCT00630643|BIOLOGICAL|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
218974418|NCT00630643|DRUG|Placebo|Placebo
218974419|NCT01461980|BIOLOGICAL|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
218974420|NCT01461980|BIOLOGICAL|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
218974421|NCT01461980|BIOLOGICAL|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
219066183|NCT03111927|OTHER|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
219666088|NCT05164198|BIOLOGICAL|Biological: Etanercept and its biosimilars|"1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection"
219666089|NCT05164198|BIOLOGICAL|Golimumab|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
219666090|NCT05164198|BIOLOGICAL|Infliximab biosimilar|"1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection"
219666091|NCT05301582|DIAGNOSTIC_TEST|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
219666092|NCT04754087|DEVICE|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
218974422|NCT00179543|BEHAVIORAL|Relaxation response|
218974423|NCT02785315|BEHAVIORAL|rehabilitation & remediation approach|The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
218974424|NCT02785315|BEHAVIORAL|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
218974425|NCT00808678|DRUG|ABT-143|once, see arm description for more information
218974426|NCT00808678|DRUG|ABT-335|once, see arm description for more information
218974427|NCT00808678|DRUG|rosuvastatin|once, see arm description for more detail
218974428|NCT06556524|BEHAVIORAL|observation|Behavioral observation and trauma measurement in live mannequin application
219666093|NCT00981058|BIOLOGICAL|Necitumumab|"Administered intravenously.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
219666094|NCT00981058|DRUG|Gemcitabine|"Administered intravenously.~Continues for a maximum of six cycles."
219666095|NCT00981058|DRUG|Cisplatin|"Administered intravenously.~Continues for a maximum of six cycles."
218974429|NCT00111982|BIOLOGICAL|Liatermin|Liatermin
218974430|NCT05958732|OTHER|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
218974431|NCT05958732|OTHER|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
218974432|NCT04903665|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
218974433|NCT03491306|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
218974434|NCT03491306|OTHER|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
218974435|NCT01341197|OTHER|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
218974436|NCT00109200|DRUG|Xolair (omalizumab)|
218974437|NCT03416907|BEHAVIORAL|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
218974438|NCT03416907|BEHAVIORAL|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
218974439|NCT03416907|BEHAVIORAL|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
218974440|NCT03416907|BEHAVIORAL|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
218974441|NCT03416907|BEHAVIORAL|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
219066184|NCT04082065|OTHER|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
219066185|NCT04082065|OTHER|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
219666096|NCT03846557|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
219666097|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
219666098|NCT06560008|DIETARY_SUPPLEMENT|Caffeine (200 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
218974442|NCT03177057|BEHAVIORAL|Compliance Monitoring|Record behavior
218974443|NCT03177057|OTHER|Health Telemonitoring|Receive health monitoring text messages
219666099|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Caffeine (200 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
219666100|NCT06560008|DIETARY_SUPPLEMENT|Placebo (MCC 300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
218974444|NCT03177057|OTHER|Questionnaire Administration|Ancillary studies
219666101|NCT02667587|DRUG|Nivolumab|
219666102|NCT02667587|DRUG|Temozolomide|
219666103|NCT02667587|RADIATION|Radiotherapy|
219666104|NCT02667587|OTHER|Nivolumab Placebo|
218974445|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
218974446|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
218974447|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
218974448|NCT02736994|DRUG|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
218974449|NCT02736994|DRUG|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
218974450|NCT02736994|OTHER|Water|Water
218974451|NCT02544178|RADIATION|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
218974452|NCT03458975|RADIATION|MRI|Magnetic Resonance Imaging
218974453|NCT03458975|RADIATION|Perfusion CT scan|Perfusion Computerized tomography scan
218974454|NCT03458975|OTHER|Contrast enhanced ultrasound|Contrast enhanced ultrasound
218974455|NCT03458975|DRUG|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
218974456|NCT02477839|DRUG|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
219066186|NCT00769366|BEHAVIORAL|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
219066187|NCT00769366|DRUG|Medical therapy|Optimal medical therapy after Acute myocardial infarction
219666105|NCT05294302|BEHAVIORAL|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
219666106|NCT05294302|BEHAVIORAL|Coping Space|Coping Space is a psychosocial informational website for PCCC.
219666107|NCT03919435|DRUG|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
219666108|NCT04708275|PROCEDURE|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
219666109|NCT01541761|BEHAVIORAL|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
219666110|NCT04451525|DEVICE|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
219666111|NCT05739617|OTHER|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
219666112|NCT05739617|OTHER|Sleep hygiene education|Sleep hygiene education
219666113|NCT05155449|DIETARY_SUPPLEMENT|Probiotics|Capsule
219666114|NCT05155449|DIETARY_SUPPLEMENT|Placebo|Capsule
219666115|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
219666116|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
219666117|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
219666118|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
219666119|NCT01134263|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 ml, SC
219666120|NCT03418194|PROCEDURE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
218974457|NCT02477839|OTHER|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
218974458|NCT06317376|OTHER|MICT with Aerobic exercise on treadmill|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
218974459|NCT06317376|OTHER|standard hospital protocol|standard hospital protocol
218974460|NCT04743076|PROCEDURE|Endovascular treatment|Endovascular treatment
218974461|NCT04743076|OTHER|Standard medical treatment|Standard medical treatment
218974462|NCT02268955|DRUG|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
218974463|NCT02268955|DRUG|Saline|Saline will be administered to the placebo group
218974464|NCT00365144|BIOLOGICAL|bevacizumab|
218974465|NCT00365144|DRUG|erlotinib hydrochloride|
218974466|NCT00365144|OTHER|laboratory biomarker analysis|
218974467|NCT05720260|DRUG|Goserelin|Hormone therapy
218974468|NCT05720260|DRUG|Fulvestrant|Hormone therapy
218974469|NCT05720260|DRUG|Capivasertib|AKT inhibitor
218974470|NCT05720260|DRUG|Durvalumab|immunotherapy
218974471|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS at sham point
219666121|NCT03418194|PROCEDURE|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
219666122|NCT04108780|DEVICE|T-tube|T shaped tube used as stent after CBD exploration
219666123|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
219666124|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
219666125|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
219666126|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
219666127|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
219666128|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
219666129|NCT00409032|DRUG|Strontium malonate|
219666130|NCT02562092|BEHAVIORAL|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
219666131|NCT02562092|BEHAVIORAL|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
219666132|NCT06654297|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
219666133|NCT06654297|DRUG|Palbociclib(100mg)|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
219666134|NCT06654297|DRUG|Palbociclib(125mg)|Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
219666135|NCT04785040|OTHER|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
219666136|NCT03945994|OTHER|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
219666137|NCT04790097|RADIATION|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
219666138|NCT00061750|DRUG|ICL670|
219666139|NCT00061750|DRUG|deferoxamine|
219666140|NCT04034316|OTHER|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
219666141|NCT03503734|BEHAVIORAL|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
219666142|NCT01022216|DEVICE|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
219666143|NCT01022216|DEVICE|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
219666144|NCT04165135|DRUG|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
218974472|NCT01492569|OTHER|questionnaire administration|Ancillary studies
218974473|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS
219666145|NCT04549623|DEVICE|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
219666146|NCT04549623|DEVICE|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
219666147|NCT00404833|DRUG|prednisolone and mycophenolate mofetil|
219666148|NCT00404833|DRUG|prednisolone and chlorambucil|
219666149|NCT04624178|DRUG|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
219666150|NCT04624178|DRUG|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
218974474|NCT05107427|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
219066188|NCT03879798|DRUG|DS-3201b|100 mg daily
219066189|NCT03879798|DRUG|irinotecan|Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
219666151|NCT05890274|OTHER|AF and EKG Interpretation Project ECHO|The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q\&A. Supplementary materials are made available to all participants.
219666152|NCT03724084|DRUG|Cytarabine|Given IV
219666153|NCT03724084|DRUG|Daunorubicin|Given IV
219666154|NCT03724084|DRUG|Daunorubicin Hydrochloride|Given IV
219666155|NCT03724084|DRUG|Pinometostat|Given IV
219666156|NCT02537652|OTHER|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
219666157|NCT05688254|BEHAVIORAL|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
219066190|NCT04723875|DRUG|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
219066191|NCT05681559|BEHAVIORAL|Medi for All|Please see description of Medi for All arm
219066192|NCT05681559|DIETARY_SUPPLEMENT|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
219066193|NCT05748405|DRUG|Placebo|Matching Tablets
219066194|NCT05748405|DRUG|AEF0217|Tablets of 100 mcg AEF0217
219066195|NCT03750318|DEVICE|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
219066196|NCT06962657|DIETARY_SUPPLEMENT|Ubiquinone 100 mg Oral Soft Gel|Active comparator arm receives three ubiquinone 100mg soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
219066197|NCT06962657|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm receives three placebo soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
219066198|NCT06961474|PROCEDURE|Endoscopic treatment|The endoscopic treatment methods for patients with esophageal variceal rupture bleeding usually include variceal ligation and injection of tissue adhesive.
219066199|NCT06962540|DEVICE|Hearing aid with settings customized to match their individual listening strategy|Behind-the-ear hearing aids that have been programmed based on the participant's individual listening strategy and hearing loss.
219066200|NCT06962540|DEVICE|Hearing Aid with settings based on audiogram alone|Behind-the-ear hearing aids that have been programmed based on their hearing loss and typical clinical settings.
219066201|NCT06963255|PROCEDURE|arterial revascularization|arterial revascularization
219666158|NCT04856059|DIAGNOSTIC_TEST|Cardiac MRI, ECG/Holter and Blood Biomarkers|Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
219666159|NCT06286475|DRUG|VRG50635|Specified dose on specified days
219666160|NCT06286475|DRUG|Placebo|Specified dose on specified days
219666161|NCT05935995|OTHER|microscopy confocal (Histolog Scanner)|"Surgical margins of tumor samples will be examined by conventional histopathology (H\&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase."
218974475|NCT05107427|BIOLOGICAL|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
218974476|NCT05401968|BEHAVIORAL|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
218974477|NCT04937361|OTHER|rectal swab|collection of rectal swabs
218974478|NCT00275964|DRUG|TMN-1|
218974479|NCT02678273|OTHER|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
218974480|NCT00691067|DRUG|mifepristone|200 mg po per day x 6 weeks
218974481|NCT00691067|DRUG|Placebos|placebo
218974482|NCT04373174|DEVICE|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
219066202|NCT05678348|DRUG|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
219066203|NCT03370887|DRUG|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
219066204|NCT03370887|DRUG|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
219066205|NCT02807597|DRUG|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
219066206|NCT02807597|DEVICE|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
219066207|NCT02807597|PROCEDURE|Surgery|-Standard of care
219066208|NCT05084196|DRUG|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
218974483|NCT04373174|PROCEDURE|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
218974484|NCT06134908|BEHAVIORAL|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
219066209|NCT05084196|OTHER|Placebo Capsule|Placebo capsule by mouth at bedtime
219066210|NCT06635746|DRUG|Vinpocetine|Increasing doses of vinpocetine to assess tolerability.
219066211|NCT01136837|OTHER|primary pcı|
219066212|NCT04034433|PROCEDURE|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
219066213|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
219066214|NCT04145752|PROCEDURE|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
219360307|NCT02976870|RADIATION|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
219666162|NCT03884816|OTHER|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
219066215|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
219208515|NCT06766188|OTHER|Online Video training for Teachers based on Reading for all|"Reading intervention over a year for students with intellectual disabilities who use AAC. This study included teachers from 14 different schools and 8 municipalities and their students. It is two arms in the intervention, with approximately 7 schools and their teachers in video training for teachers and in person mentoring for teachers. The schools are randomized into these two groups, but in both groups, they will carry out the same intervention.~The students in both groups will work explicitly and systematically with the reading material Reading for all, which is based on the research of, among others, Janice Light and David McNaughton, and their reading program Accessible Literacy Learning (ALL)."
219666163|NCT03729323|BEHAVIORAL|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
218974485|NCT04726670|OTHER|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
218974486|NCT01784848|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
219066216|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
219066217|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
218974487|NCT01784848|OTHER|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
218974488|NCT02607930|DRUG|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
218974489|NCT02607930|DRUG|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
218974490|NCT02607930|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
218974491|NCT02607930|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
218974492|NCT03198078|DRUG|Brexpiprazole (OPC-34712)|Once-daily, tablets
219066218|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
219066219|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
219066220|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
219066221|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
219066222|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
219066223|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
219066224|NCT00216151|DRUG|Zoledronic Acid|Zoledronic Acid 4mg, every three months
218974493|NCT03198078|DRUG|Aripiprazole|Once-daily, tablets
218974494|NCT03198078|DRUG|Placebo|Once-daily, tablets
218974495|NCT01400165|DRUG|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
218974496|NCT01400165|DRUG|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
218974497|NCT01400165|DRUG|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
219066225|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
219066226|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
219066227|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
219066228|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
219066229|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
219066230|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
219066231|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
219066232|NCT01595919|OTHER|Nutritional Intervention|Ad libitum amounts of beverage at a meal
219066233|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
219066234|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
219066235|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
219066236|NCT02669823|OTHER|None, treatment as actual best practice|
219066237|NCT05383248|BEHAVIORAL|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
218974498|NCT01400165|PROCEDURE|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
218974499|NCT06428682|DRUG|Tranexamic acid|Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
218974500|NCT06428682|DRUG|Placebo|Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
218974501|NCT00630370|DRUG|Placebo|2 Placebo tablets, TID, orally, 58 days
218974502|NCT00630370|DRUG|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
218974503|NCT00630370|DRUG|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
218974504|NCT00630370|DRUG|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
218974505|NCT06421116|PROCEDURE|Synovial ultrasound-guided biopsy Intestinal biopsy|Patients will undergo biopsies if needed for standard-of-care follow-up and after clinical indication.
218974506|NCT02777619|DRUG|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
218974507|NCT02777619|DRUG|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
218974508|NCT02777619|DRUG|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
218974509|NCT02777619|DRUG|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
219066238|NCT05383248|BEHAVIORAL|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
219666164|NCT03729323|BEHAVIORAL|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
218974510|NCT02777619|DRUG|Propofol|
219066239|NCT03124641|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
219066240|NCT03124641|PROCEDURE|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
219066241|NCT03194802|BEHAVIORAL|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
219066242|NCT03194802|BEHAVIORAL|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
219066243|NCT02775526|PROCEDURE|TOT|70 patients
219066244|NCT02775526|PROCEDURE|TVT|70 patients
218974511|NCT01924507|DEVICE|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
218974512|NCT00111488|DEVICE|Flex 4 and Generator|
218974513|NCT00860444|BEHAVIORAL|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
219066245|NCT02775526|PROCEDURE|Burch Colposuspension|70 patients
219066246|NCT04733560|PROCEDURE|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
219066247|NCT04733560|PROCEDURE|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
219066248|NCT04733560|DRUG|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
219066249|NCT01176253|PROCEDURE|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
219066250|NCT00177229|BEHAVIORAL|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
219066251|NCT01485510|BEHAVIORAL|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
218974514|NCT00860444|BEHAVIORAL|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
218974515|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
218974516|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
218974517|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
219066252|NCT01485510|BEHAVIORAL|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
219066253|NCT01761747|DRUG|ponatinib|
219066254|NCT02937545|OTHER|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
219066255|NCT02937545|OTHER|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
219066256|NCT02095262|OTHER|reactive auditory training|
219066257|NCT02095262|OTHER|Interactive auditory training|
219066258|NCT00273117|PROCEDURE|transnasal gastroscopy|
219066259|NCT01228162|PROCEDURE|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
219066260|NCT02635477|BEHAVIORAL|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
219208516|NCT06792682|BIOLOGICAL|Dose escalation|"Three dose groups are preset. The doses are 2.0×10\^6/kg/time, 3.5×10\^6/kg/time and 5.0×10\^6/kg/ time respectively, in accordance with the 3+3 dose escalation principle, and proceed in turn.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
219666165|NCT05157698|DRUG|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
219666166|NCT05157698|BEHAVIORAL|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
219066261|NCT02635477|BEHAVIORAL|Control|Behavioral: actigraphy device, step count measurement only
219066262|NCT02007577|DRUG|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
219066263|NCT02007577|DRUG|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
219066264|NCT02605980|BEHAVIORAL|Sedentary time|
219066265|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
219066266|NCT03437499|PROCEDURE|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
219066267|NCT03437499|PROCEDURE|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
219066268|NCT04595708|BEHAVIORAL|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
219066269|NCT02504294|BIOLOGICAL|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
219066270|NCT02504294|OTHER|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
219066271|NCT02504294|DRUG|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
219066272|NCT02504632|OTHER|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
219066273|NCT02504632|OTHER|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
219066274|NCT05255016|COMBINATION_PRODUCT|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
218974518|NCT06198283|OTHER|Low Level LASER Therapy with Pressure Garment|This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
218974519|NCT06198283|OTHER|Low Level LASER Therapy without Pressure Garment|This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
218974520|NCT00476359|DRUG|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
218974521|NCT05486754|BEHAVIORAL|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
218974522|NCT05486754|BEHAVIORAL|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
218974523|NCT04130984|DEVICE|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
218974524|NCT05661123|OTHER|Complete decongestive therapy|"1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
219208517|NCT06792682|BIOLOGICAL|Dose extension|"According to the safety data of dose escalation stage, one dose group is selected for extension.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
219208518|NCT04095572|DRUG|intravesical instillation with HA-CS|intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
219666167|NCT05157698|OTHER|Placebo|Participants in this intervention will take inactive (placebo) pills.
219666168|NCT01618916|DRUG|LY3015014|Administered SC
219666169|NCT01618916|OTHER|Placebo|Administered SC
219666170|NCT04521114|DRUG|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
219666171|NCT04521114|DRUG|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
219666172|NCT04521114|DRUG|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
219066275|NCT05255016|OTHER|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
219208519|NCT04095572|DRUG|intravesical instillation of sterile purified water|intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
219208520|NCT05784883|DIAGNOSTIC_TEST|Echocardiography|A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
219208521|NCT06418061|DRUG|IBI3005|Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
219208522|NCT06794294|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 1x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
219208523|NCT06761378|PROCEDURE|Renal stent|Renal stent before flexible uretroscopy
219666173|NCT03774134|PROCEDURE|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
218974525|NCT06364475|BEHAVIORAL|16:8 Time-Restricted Intermittent Fasting Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.
218974526|NCT06364475|BEHAVIORAL|Energy-Restricted Six-Meal Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
218974527|NCT04056351|DIAGNOSTIC_TEST|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
218974528|NCT04056351|OTHER|Questionnaires on patient activity and comorbidities|"* Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score"
218974529|NCT04056351|OTHER|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
218974530|NCT04056351|OTHER|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
218974531|NCT01782547|BEHAVIORAL|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
218974532|NCT01782547|OTHER|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
219066276|NCT04614389|OTHER|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
219208524|NCT06761378|DEVICE|Flexible uretroscopy|Renal stent for 2 weeks prior flexible uretroscopy
218974533|NCT00366977|BEHAVIORAL|Multi-session telephone counseling|
218974534|NCT00366977|DRUG|NRT patches|
218974535|NCT03272516|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
218974536|NCT03272516|OTHER|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
219666174|NCT03774134|PROCEDURE|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
219666175|NCT04674735|DRUG|APSLXR|Oral coated tablets once a day for 60 days.
218974537|NCT04234607|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219666176|NCT00394134|BEHAVIORAL|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
219666177|NCT04369235|DEVICE|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
219666178|NCT04369235|DEVICE|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
218974538|NCT04234607|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219666179|NCT00865241|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
219666180|NCT00865241|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
219666181|NCT03684421|DIAGNOSTIC_TEST|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
218974539|NCT04234607|DRUG|Etoposide|Etoposide is a cell cycle-specific antitumor drug
218974540|NCT04234607|DRUG|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
218974541|NCT04234607|DRUG|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
218974542|NCT04234607|DRUG|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
218974543|NCT04784039|DIAGNOSTIC_TEST|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
219066277|NCT04614389|OTHER|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
218974544|NCT04784039|DIAGNOSTIC_TEST|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
219666182|NCT02867202|DEVICE|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
219666183|NCT02867202|DEVICE|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
219666184|NCT04847102|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine|"The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000)."
219666185|NCT04847102|BIOLOGICAL|Placebo|0.9% sodium chloride solution, 0.5 mL/vial
219666186|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
219666187|NCT06260475|PROCEDURE|Aortobifemoral bypass|Open surgery with aortic and iliac reconstruction
218974545|NCT01298310|DRUG|Xylocaine|1 mg/mL solution for injection
218974546|NCT01298310|DRUG|Xylocaine|10 mg/mL solution for injection
218974547|NCT01298310|DRUG|Placebo|solution for injection
218974548|NCT03935412|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
218974549|NCT06638268|PROCEDURE|Acute TAVI|TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
218974550|NCT06638268|OTHER|Stabilization and subacute TAVI|Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
219066278|NCT04614389|DEVICE|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
219066279|NCT00003289|DRUG|7-hydroxystaurosporine|
219066280|NCT01985126|DRUG|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
219066281|NCT01985126|DRUG|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
218974551|NCT02977130|BEHAVIORAL|Map group|diabetes shared care plus conversation map intervention
218974552|NCT02977130|BEHAVIORAL|Control group|diabetes shared care
218974553|NCT00057876|DRUG|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
218974554|NCT00057876|RADIATION|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
218974555|NCT04721951|PROCEDURE|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
219666188|NCT06260475|PROCEDURE|aortoiliac stenting|"Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand"
219666189|NCT01133288|DEVICE|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (\~30 minutes per day) over a 3 month period.
218974556|NCT03036904|DRUG|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
218974557|NCT03036904|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
218974558|NCT03036904|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218974559|NCT03036904|DRUG|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218974560|NCT03036904|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218974561|NCT03036904|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
218974562|NCT03036904|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
218974563|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
218974564|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
218974565|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
218974566|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
219666190|NCT02735707|DRUG|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
219666191|NCT02735707|DRUG|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
219666192|NCT02735707|DRUG|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
219666193|NCT02735707|DRUG|Ceftaroline|"The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Note: this intervention is now closed."
219666194|NCT02735707|DRUG|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
219666195|NCT02735707|DRUG|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
219666196|NCT02735707|DRUG|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
219666197|NCT02735707|OTHER|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
219666198|NCT02735707|DRUG|Fixed-duration Hydrocortisone|"50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed."
219666199|NCT02735707|DRUG|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
219666200|NCT02735707|DRUG|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
219666201|NCT02735707|OTHER|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
219666202|NCT02735707|DRUG|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
218974567|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
218974568|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
218974569|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
218974570|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
218974571|NCT01028885|PROCEDURE|radiation therapy treatment planning/simulation|
218974572|NCT01028885|PROCEDURE|intensity-modulated radiation therapy|
219666203|NCT02735707|DRUG|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
219666204|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
218974573|NCT01028885|PROCEDURE|image-guided radiation therapy|
218974574|NCT01028885|PROCEDURE|magnetic resonance imaging|
219066282|NCT01985126|DRUG|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
219066283|NCT01985126|DRUG|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
219066284|NCT01985126|DRUG|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
219066285|NCT01985126|DRUG|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
219066286|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
219066287|NCT00366626|DRUG|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
219066288|NCT00366626|DRUG|Placebo|Placebo for 7 days matched to Naltrexone
219066289|NCT04423068|BEHAVIORAL|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
219066290|NCT04423068|DRUG|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
219066291|NCT02255175|DRUG|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
219066292|NCT02255175|DRUG|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
219066293|NCT01953926|DRUG|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
219066294|NCT01953926|DRUG|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
219066295|NCT01953926|DRUG|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
219066296|NCT01953926|DRUG|Paclitaxel|80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
219666205|NCT02735707|DRUG|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
219666206|NCT02735707|DRUG|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
219066297|NCT01276587|DRUG|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
219066298|NCT01602848|OTHER|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
219066299|NCT00941187|OTHER|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
219066300|NCT04302792|BEHAVIORAL|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
219066301|NCT04302792|BEHAVIORAL|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
219066302|NCT01153646|GENETIC|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
219066303|NCT01142557|DRUG|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
219208525|NCT04939272|DRUG|Copanlisib Hydrochloride|"Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level."
218974575|NCT01028885|PROCEDURE|computed tomography|
218974576|NCT01649804|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
218974577|NCT06495866|RADIATION|ultrasound|Ultrasound finding of entheseal sites of upper \& lower limbs of all groups and scoring according to enthesitis scoring system
218974578|NCT04228393|DRUG|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
218974579|NCT04228393|PROCEDURE|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
218974580|NCT04228393|PROCEDURE|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
218974581|NCT02801305|DRUG|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
218974582|NCT02801305|DRUG|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
218974583|NCT02801305|DRUG|Vaseline|This is used as the topical placebo agent.
218974584|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
218974585|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in PA, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
218974586|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
218974587|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
218974588|NCT00920634|DRUG|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
218974589|NCT02907268|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
218974590|NCT02907268|DRUG|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
219066304|NCT04686448|DRUG|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
219066305|NCT04686448|DRUG|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
219066306|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
219066307|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
219066308|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
219066309|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
219066310|NCT00358046|DRUG|ILY101|
219066311|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
219208526|NCT04939272|DRUG|Venetoclax|Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
218974591|NCT01687036|DEVICE|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
218974592|NCT00457366|DRUG|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
218974593|NCT00457366|DRUG|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
218974594|NCT00457366|DRUG|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
218974595|NCT00457366|DRUG|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
218974596|NCT00892658|DRUG|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
218974597|NCT03130491|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
218974598|NCT03130491|DEVICE|EMBLOK filter|Embolic Filter Protection System During TAVR
218974599|NCT04326959|BIOLOGICAL|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
218974600|NCT04326959|BIOLOGICAL|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
218974601|NCT04326959|BIOLOGICAL|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
218974602|NCT04515927|DRUG|JS002|Biological: JS002 Administered by subcutaneous injection
218974603|NCT03589781|DIETARY_SUPPLEMENT|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
218974604|NCT03589781|DIETARY_SUPPLEMENT|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
218974605|NCT05689697|DIETARY_SUPPLEMENT|PanTrek|administration of exogenouse keton body
218974606|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
218974607|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
218974608|NCT04336410|DRUG|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
218974609|NCT04336410|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
218974610|NCT02434367|BEHAVIORAL|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
218974611|NCT06298890|DEVICE|Artificial tears (sodium hyaluronate 0.2%)|Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
218974612|NCT01369160|BEHAVIORAL|Quality of Life measures|measuring QOL with different therapies
218974613|NCT03986151|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
218974614|NCT05215990|DRUG|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
219208527|NCT06825585|DEVICE|Orthokeratology with 5.0mm back optical zone diameter|The orthokeratology lenses used in this study were Double Reservoir Lenses (DRL) manufactured by Precilens (Creteil, France). The lenses feature a dual reverse-curve design with a back optic zone diameter (BOZD) of 5.0 mm.
218974615|NCT05215990|DRUG|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
218974616|NCT03325088|PROCEDURE|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
218974617|NCT03325088|PROCEDURE|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
218974618|NCT03325088|PROCEDURE|Bronchial alveolar enema|For participants who had signed ancillary research consent
218974619|NCT01739673|OTHER|Ultraviolet-A and riboflavin|
218974620|NCT01798680|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
219666207|NCT02735707|DRUG|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
219666208|NCT02735707|DRUG|Ivermectin|"Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.~Note: this intervention is now closed."
219666209|NCT02735707|OTHER|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
219666210|NCT02735707|DRUG|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
219666211|NCT02735707|DRUG|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
218974621|NCT01798680|OTHER|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
218974622|NCT00126607|BIOLOGICAL|trastuzumab|Given IV
218974623|NCT00126607|OTHER|laboratory biomarker analysis|Correlative studies
218974624|NCT05043558|DRUG|beprostaglandin sodium|beprostaglandin sodium
218974625|NCT00957112|PROCEDURE|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
218974626|NCT00957112|PROCEDURE|standard follow-up care|Patients receive standard care
218974627|NCT00703196|DIETARY_SUPPLEMENT|folic acid|Given orally once daily
218974628|NCT00703196|OTHER|placebo|Given orally once daily
218974629|NCT06207838|DEVICE|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
218974630|NCT06147453|DEVICE|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
219066312|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
219666212|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.~Note: this intervention is now closed."
219666213|NCT02735707|DRUG|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
219666214|NCT02735707|DRUG|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
218974631|NCT00160173|DRUG|Estrogel|
218974632|NCT00160173|OTHER|Placebo|
218974633|NCT04595240|DIAGNOSTIC_TEST|semen analysis|semen analysis
219066313|NCT02124967|OTHER|Exercise|A one hour exercise class including both aerobic activity and resistance training
219066314|NCT01012882|BIOLOGICAL|sublingual immunotherapy with allergen extract|sublingual application
219066315|NCT01012882|BIOLOGICAL|sublingual immunotherapy with placebo|sublingual application
219066316|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
219066317|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
218974634|NCT02969551|DEVICE|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
218974635|NCT02080637|DRUG|Ambrisentan|Once daily oral dosing
218974636|NCT02080637|OTHER|Placebo|
218974637|NCT04252365|DRUG|Sintilimab|Given i.v.
218974638|NCT04252365|DRUG|Pembrolizumab|Given i.v.
218974639|NCT02854150|GENETIC|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
218974640|NCT03132012|BEHAVIORAL|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
218974641|NCT03132012|BEHAVIORAL|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
218974642|NCT04317976|OTHER|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
218974643|NCT04317976|OTHER|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
218974644|NCT03835910|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
219066318|NCT00784043|DEVICE|Cochlear Implant|Bilateral Implantation in children
219066319|NCT00375089|OTHER|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
219066320|NCT00375089|OTHER|Group 2|Individuals with Early-onset Morbid Obesity.
219066321|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
219066322|NCT02541253|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
219066323|NCT02541253|BIOLOGICAL|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
219666215|NCT02735707|DRUG|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
219666216|NCT02735707|DRUG|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
218974645|NCT03835910|PROCEDURE|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
218974646|NCT03835910|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
218974647|NCT03835910|PROCEDURE|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
218974648|NCT03109054|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
218974649|NCT03848104|OTHER|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
218974650|NCT01626495|BIOLOGICAL|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
218974651|NCT01149811|DRUG|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
218974652|NCT01149811|DRUG|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
218974653|NCT04324931|OTHER|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
218974654|NCT04324931|OTHER|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
218974655|NCT03949985|OTHER|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
218974656|NCT01451580|DRUG|Lipo-Dox|
218974657|NCT04290312|OTHER|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
218974658|NCT03298373|DRUG|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
218974659|NCT03298373|DRUG|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
218974660|NCT02808377|OTHER|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
218974661|NCT04171284|DRUG|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
218974662|NCT04171284|DRUG|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
218974663|NCT04171284|DRUG|Placebo|200 mg, Q3W, maximum treatment up to six cycles
218974664|NCT02368704|OTHER|No intervention|
218974665|NCT00650234|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
218974666|NCT00650234|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
218974667|NCT05625893|RADIATION|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
218974668|NCT02193477|DEVICE|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
218974669|NCT02193477|DEVICE|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
219066324|NCT06042647|DRUG|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
219066325|NCT06042647|DRUG|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
219066326|NCT06042647|DRUG|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
219066327|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
219066328|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
219066329|NCT05162820|DIETARY_SUPPLEMENT|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
219666217|NCT02735707|DRUG|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
218974670|NCT02196207|DRUG|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
219666218|NCT02735707|DRUG|Continuation of therapeutic dose anticoagulation|"Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
218974671|NCT02196207|DRUG|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
218974672|NCT02196207|DRUG|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
218974673|NCT02196207|DRUG|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
218974674|NCT06286358|DIAGNOSTIC_TEST|Kinocardiography|Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
218974675|NCT01934972|OTHER|CR + DCS (D-cycloserine)|CR + DCS
218974676|NCT01934972|OTHER|CR + placebo|CR + placebo
218974677|NCT03131453|DRUG|CNP520 50mg|50 mg capsule
218974678|NCT03131453|DRUG|CNP520 15mg|15 mg capsule
218974679|NCT03131453|OTHER|Matching placebo|Matching placebo for 15 and 50 mg capsules
218974680|NCT03864770|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
218974681|NCT03864770|PROCEDURE|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
218974682|NCT00950495|DEVICE|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
218974683|NCT00950495|DEVICE|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
218974684|NCT00950495|DEVICE|placebo|as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
219666219|NCT02735707|OTHER|No immunoglobulin|No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
219666220|NCT02735707|BIOLOGICAL|Convalescent plasma|Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
219666221|NCT02735707|BIOLOGICAL|Delayed administration of convalescent plasma|Note: this intervention is now closed.
219666222|NCT02735707|OTHER|No vitamin C|"No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed."
218974685|NCT03975062|DRUG|dabigatran etexilate|150 mg twice daily (BID)
218974686|NCT00006223|BIOLOGICAL|recombinant flt3 ligand|
218974687|NCT01945112|DEVICE|Paper Tape|Applied to blister prone areas of the foot
218974688|NCT02770170|DRUG|BI 655064 dose 1|
218974689|NCT02770170|DRUG|BI 655064 dose 2|
218974690|NCT02770170|DRUG|BI 655064 dose 3|
218974691|NCT02770170|DRUG|Placebo|
218974692|NCT04205253|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
218974693|NCT04840732|BEHAVIORAL|VR training program|Use VR software to make a training education program.
218974694|NCT04840732|BEHAVIORAL|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
218974695|NCT04768725|BEHAVIORAL|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
218974696|NCT04768725|BEHAVIORAL|Dietary intervention|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
218974697|NCT04768725|BEHAVIORAL|Physical-cognitive intervention|Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
218974698|NCT04020328|DRUG|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
218974699|NCT02988154|OTHER|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
219666223|NCT02735707|DRUG|Vitamin C|"Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed."
219666224|NCT02735707|OTHER|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
219666225|NCT02735707|DRUG|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
219666226|NCT02735707|DRUG|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
218974700|NCT02988154|OTHER|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
218974701|NCT00445978|DRUG|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
218974702|NCT01483768|PROCEDURE|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
218974703|NCT02378623|DRUG|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
218974704|NCT02378623|DRUG|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
218974705|NCT02497300|DRUG|Spironolactone|
218974706|NCT02497300|DRUG|Amiloride|
218974707|NCT00087165|BIOLOGICAL|GTI-2040|
218974708|NCT00087165|DRUG|docetaxel|
218974709|NCT00087165|DRUG|prednisone|
218974710|NCT05913648|OTHER|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
218974711|NCT02670434|DRUG|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
218974712|NCT02670434|DRUG|Placebo|Placebo daily for 12 weeks
218974713|NCT02670434|DRUG|Livalo|Livalo® IR daily from week 12 to week 52
218974714|NCT05306431|DRUG|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
218974715|NCT05306431|DRUG|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
218974716|NCT05078242|DEVICE|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
218974717|NCT01822496|RADIATION|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
218974718|NCT01822496|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
219666227|NCT02735707|OTHER|No simvastatin|"No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed."
218974719|NCT01822496|DRUG|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
218974720|NCT01822496|DRUG|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
218974721|NCT01822496|DRUG|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
218974722|NCT01822496|DRUG|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
218974723|NCT01822496|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
218974724|NCT05843955|OTHER|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
219666228|NCT02735707|DRUG|Simvastatin|"Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed."
219666229|NCT02735707|DRUG|Eritoran|"Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed."
219666230|NCT02735707|DRUG|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
219666231|NCT02735707|PROCEDURE|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
219666232|NCT02735707|PROCEDURE|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
219666233|NCT02735707|OTHER|No renin-angiotensin system inhibitor|"No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed."
219666234|NCT02735707|DRUG|Angiotensin converting enzyme inhibitor|"Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
219666235|NCT02735707|DRUG|Angiotensin Receptor Blockers|"Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
218974725|NCT03946488|DEVICE|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
218974726|NCT03267251|OTHER|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
218974727|NCT03267251|OTHER|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
218974728|NCT00304239|COMBINATION_PRODUCT|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
218974729|NCT00304239|COMBINATION_PRODUCT|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
218974730|NCT02902068|DEVICE|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
218974731|NCT06047925|PROCEDURE|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
218974732|NCT06047925|PROCEDURE|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
218974733|NCT05227378|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
218974734|NCT00244517|DRUG|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
218974735|NCT00244517|DRUG|Sevoflurane, Isoflurane, Desflurane|1 MAC
218974736|NCT04867057|DRUG|Trichomylin for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
218974737|NCT04867057|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
219666236|NCT02735707|DRUG|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed."
219666237|NCT02735707|OTHER|No cysteamine|"No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed."
219666238|NCT02735707|DRUG|Cysteamine|"Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
219666239|NCT02735707|DRUG|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
219666240|NCT02735707|DRUG|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
219666241|NCT02735707|DRUG|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
219066330|NCT05162820|DIETARY_SUPPLEMENT|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
219066331|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
219066332|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
219066333|NCT05071001|PROCEDURE|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes."
219066334|NCT04279808|PROCEDURE|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
219066335|NCT05216172|DRUG|AZD1656|active drug
219066336|NCT05216172|DRUG|Placebo|placebo
219066337|NCT03564912|DRUG|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
219066338|NCT00906672|DEVICE|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
219066339|NCT00906672|PROCEDURE|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
219066340|NCT00167544|DRUG|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
219666242|NCT02735707|DRUG|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
219666243|NCT02735707|OTHER|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
219666244|NCT02735707|DRUG|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
219666245|NCT02735707|OTHER|No Immune Modulator for Influenza|No immune modulating agent intended to be active against influenza is to be administered.
219666246|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
218974738|NCT04867057|DRUG|Trichomylin for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
218974739|NCT04867057|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
218974740|NCT04956926|DRUG|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
219666247|NCT02735707|DRUG|Baricitinib|Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
218974741|NCT01960673|DEVICE|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
218974742|NCT01960673|DEVICE|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
219066341|NCT00167544|DRUG|Placebo|Saline
219066342|NCT04318340|OTHER|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
219066343|NCT04318340|OTHER|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
219666248|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
219666249|NCT02735707|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
219666250|NCT02735707|DRUG|Remdesivir|Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
219666251|NCT02735707|DRUG|Nirmatrelvir/ritonavir + remdesivir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
219666252|NCT00968188|BEHAVIORAL|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
219666253|NCT00968188|BEHAVIORAL|Information only|Medically fact based HIV information delivered online.
219066344|NCT00680316|DRUG|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
219066345|NCT00680316|DRUG|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
219666254|NCT02466607|DEVICE|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
219666255|NCT02466607|DEVICE|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
218974743|NCT01960673|DEVICE|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
218974744|NCT01960673|DEVICE|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
218974745|NCT05280210|OTHER|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
218974746|NCT02979197|DRUG|OE 10 mg amlodipine besylate tablet|
218974747|NCT02979197|DRUG|OE 200 mg celecoxib capsule|
218974748|NCT02979197|DRUG|Matched placebo for OE amlodipine besylate tablet|
218974749|NCT02979197|DRUG|Matched placebo for OE celecoxib capsule|
218974750|NCT00384254|BEHAVIORAL|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
218974751|NCT00384254|BEHAVIORAL|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
218974752|NCT05969431|DIAGNOSTIC_TEST|measurement of cortisol level|We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.
218974753|NCT02660931|OTHER|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
218974754|NCT03572751|DIAGNOSTIC_TEST|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
218974755|NCT04876144|DEVICE|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
219066346|NCT04396951|DEVICE|Active external overheating with heating plate, Aragonia ® MTC 400|It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
219066347|NCT04396951|DEVICE|Active external overheating with air blanket, Equator Level 1® de Smiths Medical|Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
219066348|NCT06465849|PROCEDURE|Dentin Etching time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
219066349|NCT06465849|DEVICE|Scotchbond Universal Plus; 3M|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
219066350|NCT06465849|DEVICE|Gluma Universal Bond; Kulzer|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
219666256|NCT02466607|OTHER|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
219666257|NCT00438256|PROCEDURE|Proton Beam Radiation|Given over different schedules and duration
219666258|NCT00438256|DRUG|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
219666259|NCT06417866|OTHER|informed consent|standard verbal and written informed consent
218974756|NCT03126903|DEVICE|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
218974757|NCT01056731|DRUG|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
219066351|NCT06465849|PROCEDURE|Dentin Etching time for 15 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
219066352|NCT04069975|OTHER|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
219666260|NCT06417866|OTHER|spine model|standard verbal and written informed consent + visual spine model
219666261|NCT00167401|DRUG|docetaxel|
219666262|NCT00167401|DRUG|cisplatin|
219666263|NCT00167401|PROCEDURE|radiation treatment|
219666264|NCT01918072|OTHER|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
219666265|NCT04151238|BEHAVIORAL|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
219666266|NCT02893423|DRUG|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
219666267|NCT01861418|OTHER|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
219666268|NCT01861418|OTHER|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
219066353|NCT03305679|PROCEDURE|Direct provisional technique|The method of implantation will be accomplished directly.
219066354|NCT03305679|PROCEDURE|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
219066355|NCT03408912|DIAGNOSTIC_TEST|FFR|FFR from CMR compared to invasive FFR
219066356|NCT03585244|OTHER|weekly weight|weekly weight data collection for six months
219066357|NCT01904812|OTHER|Questionnaire about quality of life and satisfaction|
219066358|NCT01138332|GENETIC|western blotting|
219066359|NCT01138332|OTHER|laboratory biomarker analysis|
219066360|NCT02388633|PROCEDURE|Plasmapharesis|Clinically-indicated LDL apheresis
219066361|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
219066362|NCT05847777|RADIATION|CBCT|cone beam computer tomography
219066363|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
219066364|NCT04827004|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219066365|NCT06281548|BEHAVIORAL|RESTART|Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
219066366|NCT02461121|GENETIC|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
219066367|NCT02461121|GENETIC|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
219066368|NCT02461121|DRUG|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
219666269|NCT03555942|DRUG|Follicular phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
219666270|NCT03555942|DRUG|Luteal phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
219066369|NCT02461121|DRUG|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
219066370|NCT02461121|DRUG|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
219066371|NCT02461121|DRUG|fludarabine|30 mg/m2/d for 5days
219066372|NCT02461121|DRUG|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
219066373|NCT02461121|DRUG|cyclophosphamide|40 mg/kg/d for 2 days
219066374|NCT04300738|DEVICE|CCS wit CT Scann measurement|Measurement with 2 devices
219666271|NCT03602794|PROCEDURE|PECs Block|Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
219066375|NCT05493553|DIETARY_SUPPLEMENT|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
219066376|NCT05493553|OTHER|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
219066377|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients on Hydroxyurea
219066378|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients on Hydroxyurea
219066379|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients not on Hydroxyurea
219066380|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients not on Hydroxyurea
219066381|NCT01958151|OTHER|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
219066382|NCT00733265|DRUG|AZD6140|single oral dose
219066383|NCT01476215|DRUG|Paracetamol fast dissolution suspension|
219066384|NCT01476215|DRUG|Paracetamol medium dissolution suspension|
219066385|NCT01476215|DRUG|Paracetamol slow dissolution suspension|
219666272|NCT03602794|PROCEDURE|Local infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
219666273|NCT00232466|PROCEDURE|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
219666274|NCT03092336|OTHER|Electrical Stimulation|electrical stimulation training
219666275|NCT03092336|OTHER|Strength training|strength training group
219666276|NCT02865811|DRUG|Pembrolizumab|"Please see Arms for description."
219666277|NCT02865811|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
219666278|NCT02771925|DRUG|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
219666279|NCT02771925|DRUG|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
219666280|NCT02412254|OTHER|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
219666281|NCT02412254|OTHER|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
219666282|NCT01051258|DEVICE|AeriSeal System|AeriSeal System for Lung Volume Reduction
219666283|NCT02415062|DRUG|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
219666284|NCT04065581|DRUG|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
219666285|NCT04065581|DRUG|Glucobay|Single dose: 50 mg tablet, oral
219066386|NCT01476215|DRUG|Paracetamol|
219666286|NCT04065581|DRUG|Glucophage|Single dose: 500 mg tablet, oral
219666287|NCT02454634|DRUG|IDH1 peptide vaccine|
219666288|NCT04104087|PROCEDURE|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
219666289|NCT05537285|DEVICE|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
219066387|NCT02167828|BEHAVIORAL|Social Support|
219066388|NCT05408494|BEHAVIORAL|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
219666290|NCT05537285|DEVICE|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
219666291|NCT05537285|DEVICE|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
219666292|NCT00576004|PROCEDURE|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
219666293|NCT06730724|OTHER|No intervention|No intervention
219666294|NCT03994406|DRUG|CLM2 topical gel|Active topical gel for forehead dermal application
219666295|NCT03994406|DRUG|Placebo topical gel|Placebo topical gel for forehead dermal application
219666296|NCT02794506|DRUG|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
218974758|NCT03643159|COMBINATION_PRODUCT|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
218974759|NCT03643159|DRUG|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
218974760|NCT01828879|DRUG|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
218974761|NCT00177996|DRUG|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
218974762|NCT01819376|OTHER|Facebook Status Update|
218974763|NCT05060484|BIOLOGICAL|SCT1000|HPV vaccine
218974764|NCT05060484|BIOLOGICAL|Gardasil®9|HPV vaccine
218974765|NCT05060484|BIOLOGICAL|Gardasil®|HPV vaccine
218974766|NCT05060484|OTHER|placebo|adjuvent
218974767|NCT01407744|OTHER|laboratory biomarker analysis|Correlative studies
218974768|NCT04086875|BEHAVIORAL|Focus Group|Participate in focus group
218974769|NCT04086875|OTHER|Text Message|Receive text messages
218974770|NCT04086875|OTHER|Best Practice|Receive usual care
218974771|NCT04086875|OTHER|Questionnaire Administration|Ancillary studies
218974772|NCT03438383|DEVICE|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
219666297|NCT02794506|DRUG|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
218974773|NCT03438383|DEVICE|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
218974774|NCT06557174|DRUG|IMC-002|intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
218974775|NCT06557174|DRUG|mycophenolate mofetil， MMF|daily oral 0.2g
218974776|NCT04627025|DRUG|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
218974777|NCT02766465|DRUG|Busulfan|"A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics."
219666298|NCT04234594|DRUG|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
219666299|NCT04234594|DRUG|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
219666300|NCT03478189|PROCEDURE|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
219666301|NCT06730789|DEVICE|Epicondylitis bandage|A conservative treatment method of lateral epicondylitis.
219666302|NCT06730789|DEVICE|Wrist dorsiflexion splint|A conservative treatment method of lateral epicondylitis.
219666303|NCT06730789|DEVICE|Kinesio tape|A conservative treatment method of lateral epicondylitis
219666304|NCT04731077|DEVICE|Avenir Complete Femoral Stem|All enrolled subjects will receive the Avenir Complete Femoral Stem
219666305|NCT03394625|PROCEDURE|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
219666306|NCT03394625|PROCEDURE|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
219666307|NCT01487239|DRUG|[14C]-GDC-0980|100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
219066389|NCT05408494|BEHAVIORAL|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
219066390|NCT03538626|BIOLOGICAL|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
219666308|NCT06239805|DEVICE|QMR|"A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off."
219666309|NCT03922282|PROCEDURE|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
219666310|NCT03922282|PROCEDURE|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
219666311|NCT06525974|DRUG|Febuxostat|40mg of Febuxostat once daily
219666312|NCT06525974|DRUG|Mesalamine|1 g mesalamine three times daily for 3 months.
219666313|NCT03763058|OTHER|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
219666314|NCT00005821|DRUG|patent blue V dye|
219666315|NCT00005821|PROCEDURE|conventional surgery|
219666316|NCT00005821|PROCEDURE|lymphangiography|
219666317|NCT00005821|PROCEDURE|radionuclide imaging|
219666318|NCT00005821|PROCEDURE|sentinel lymph node biopsy|
218974778|NCT02766465|DRUG|Fludarabine|"A:~Fludarabine dose will be 35 mg/m\^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m\^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4"
218974779|NCT02766465|DRUG|r-ATG|"A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg)."
218974780|NCT02766465|PROCEDURE|Hematopoietic Cell Transplant|"A,B,C:~Day 0 is the day of transplantation."
218974781|NCT02766465|DRUG|Tacrolimus|"A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines"
218974782|NCT02766465|DRUG|Methotrexate|"A:~Methotrexate will be administered intravenously on day+1 at 15mg/m\^2, day+3 at 10mg/m\^2, day+6 at 10mg/m\^2, and day+11 at 10mg/m\^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant"
218974783|NCT02766465|PROCEDURE|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
218974784|NCT02766465|DRUG|Alemtuzumab|"B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days."
218974785|NCT02766465|DRUG|Total Body Irradiation (TBI)|Total Body Irradiation 300 cGY on Day -2
218974786|NCT02766465|DRUG|Sirolimus|Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ \>50%
218974787|NCT02766465|DRUG|Melphalan|"C:~Melphalan 140 mg/m2 IV dose will be given on Day -3"
218974788|NCT02766465|DRUG|G-CSF|G-CSF 5 μg/kg/day continue until neutrophil engraftment.
218974789|NCT00914680|PROCEDURE|magnetic seizure therapy|antidepressant treatment with MST
218974790|NCT03516825|OTHER|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
219666319|NCT00005821|RADIATION|Technetium Tc 99m human serum albumin colloid|
218974791|NCT04143893|DEVICE|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
219066391|NCT03538626|BIOLOGICAL|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
219066392|NCT00652665|DRUG|Leflunomide|Tablets, 20mg, single-dose
219066393|NCT00652665|DRUG|ARAVA|Tablets, 20mg,single-dose
219066394|NCT00288587|DRUG|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
219066395|NCT00288587|DEVICE|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
219066396|NCT01156701|DRUG|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
219066397|NCT01156701|OTHER|No prophylaxis with Relenza|No prophylaxis with Relenza
219666320|NCT06730659|BIOLOGICAL|CHT101|CHT101: CD 70 UCAR T
219666321|NCT05816759|DRUG|CKD-383|QD, PO
219666322|NCT05816759|DRUG|CKD-501, D744, D150|QD, PO
218974792|NCT04143893|DRUG|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
218974793|NCT01528033|DEVICE|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
218974794|NCT01528033|OTHER|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
218974795|NCT00808561|OTHER|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
218974796|NCT00808561|OTHER|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
218974797|NCT05350306|DEVICE|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
218974798|NCT05350306|OTHER|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
218974799|NCT01936727|PROCEDURE|cataract surgery|
218974800|NCT03813823|BEHAVIORAL|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
218974801|NCT05517993|DRUG|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
218974802|NCT02520661|BEHAVIORAL|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
219066398|NCT01434602|DRUG|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
219066399|NCT01434602|DRUG|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
219066400|NCT05960500|PROCEDURE|implant|All on six versus parallel implant distribution
219066401|NCT00778466|DRUG|metformin hydrochloride 1000 mg tablets|
219066402|NCT00022464|DRUG|temsirolimus|
219066403|NCT01835626|DRUG|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
219066404|NCT01835626|RADIATION|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
219066405|NCT05035719|DEVICE|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
219066406|NCT05413876|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
219066407|NCT05413876|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
219066408|NCT05472428|COMBINATION_PRODUCT|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
219066409|NCT01108081|BEHAVIORAL|Physical activity|Moderate-intensity physical activity
219066410|NCT01108081|BEHAVIORAL|Diet|Dietary weight loss
219066411|NCT01108081|BEHAVIORAL|Health education|Attention control intervention
219066412|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
219066413|NCT00648908|DRUG|Fampridine-SR|Tablets, 10 mg, BID
219208528|NCT06825585|DEVICE|Orthokeratology with a 6.2 mm back optical zone diameter|The orthokeratology lenses used were Euclid lenses manufactured by Euclid Systems (Herndon, VA, USA). These lenses feature a four-zone, five-curve design with a back optic zone diameter (BOZD) of 6.2 mm.
219066414|NCT04545268|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
219066415|NCT04545268|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
219066416|NCT03449602|DEVICE|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
219066417|NCT03449602|DEVICE|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
219066418|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
219066419|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
219066420|NCT00586105|DRUG|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
219066421|NCT01733654|BIOLOGICAL|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
219066422|NCT02679690|BEHAVIORAL|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
219066423|NCT02679690|BEHAVIORAL|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
219666323|NCT05456633|DEVICE|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
219666324|NCT05456633|OTHER|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
219666325|NCT05456633|DEVICE|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
219666326|NCT01455285|DEVICE|transcutaneous electrical nerve stimulation|
219066424|NCT00389558|PROCEDURE|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
219066425|NCT00389558|PROCEDURE|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
219066426|NCT03819660|DRUG|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
219066427|NCT05218967|OTHER|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
219666327|NCT01827709|OTHER|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
219666328|NCT01827709|OTHER|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
219666329|NCT01827709|OTHER|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
219666330|NCT01827709|OTHER|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
219666331|NCT01827709|OTHER|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
219066428|NCT05203419|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
219066429|NCT05203419|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
219066430|NCT01507168|DRUG|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
219066431|NCT01507168|DRUG|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
219066432|NCT03835533|DRUG|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
219066433|NCT03835533|DRUG|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
219666332|NCT02637388|DIETARY_SUPPLEMENT|Oatwell28 Oatwell Original Powder|
219666333|NCT02637388|DIETARY_SUPPLEMENT|Control Breakfast|Isocaloric breakfast without added beta-glucans
219066434|NCT03835533|RADIATION|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
219666334|NCT03279601|DRUG|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
219666335|NCT03279601|DRUG|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
218974803|NCT02165371|BEHAVIORAL|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
218974804|NCT05420792|BEHAVIORAL|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
218974805|NCT00384527|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
219666336|NCT00397592|DRUG|Growth Hormone|
219666337|NCT00004901|DRUG|ethynyluracil|
219666338|NCT00004901|DRUG|fluorouracil|
219666339|NCT00004901|DRUG|hydroxyurea|
218974806|NCT00384527|DRUG|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
218974807|NCT06072248|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
218974808|NCT06072248|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
218974809|NCT06072248|DEVICE|ventilator|ventilator
218974810|NCT03170856|OTHER|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
218974811|NCT00163111|DRUG|VFENDÂ® I.V., Oral|
218974812|NCT00163111|DRUG|Conventional amphotericin B|
218974813|NCT00163111|DRUG|Diflucan IV, oral|
218974814|NCT03788629|OTHER|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
218974815|NCT03788629|OTHER|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
218974816|NCT04660253|BEHAVIORAL|LTP Plus Dads|
218974817|NCT00302198|BEHAVIORAL|ALS Registry|
218974818|NCT02856698|DRUG|Midazolam|Dose use according to the product technical sheet
218974819|NCT02856698|DRUG|Morphine|Dose use according to the product technical sheet
218974820|NCT03318900|BIOLOGICAL|Aldesleukin|Given IV
218974821|NCT03318900|DRUG|CD8-Positive T-Lymphocyte|Given IV
218974822|NCT03318900|DRUG|Cyclophosphamide|Given IV
218974823|NCT03318900|PROCEDURE|Leukapheresis|Undergo leukapheresis
218974824|NCT03318900|BIOLOGICAL|Utomilumab|Given IV
218974825|NCT02443519|BEHAVIORAL|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
218974826|NCT04155489|PROCEDURE|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
219666340|NCT00004901|RADIATION|radiation therapy|
219666341|NCT03129295|DRUG|MPC-SHRC|Oral tablet four times a day for 3 days
219666342|NCT03129295|DRUG|Placebo Oral Tablet|Oral tablet four times a day for 3 days
219666343|NCT03756818|DRUG|Mivavotinib|Given PO
219666344|NCT03756818|DRUG|Paclitaxel|Given IV
219666345|NCT03756818|OTHER|Pharmacokinetic Study|Correlative studies
219666346|NCT01170819|DEVICE|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
219666347|NCT01170819|DRUG|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
219666348|NCT05410704|OTHER|exercises|Pelvic floor muscle exercises and diaphragmatic breathing exercise
219666349|NCT02540967|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
219666350|NCT02634944|DIAGNOSTIC_TEST|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
219666351|NCT03738761|DRUG|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
219666352|NCT03738761|DRUG|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
219666353|NCT03173261|DIAGNOSTIC_TEST|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
219666354|NCT05041660|OTHER|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
219666355|NCT05041660|OTHER|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
219666356|NCT05041660|OTHER|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
219666357|NCT05041660|OTHER|Computerized training|Uses a relatively simplistic computerized training.
219666358|NCT03904316|BIOLOGICAL|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
219666359|NCT03904316|OTHER|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
219666360|NCT01872650|DEVICE|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
219666361|NCT02256306|OTHER|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
219666362|NCT03048071|OTHER|Data collection within medical files|Data collection within medical files
219666363|NCT02104167|DEVICE|ROIC interbody cage with VerteBRIDGE plating|
219666364|NCT01464853|OTHER|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
219666365|NCT01464853|OTHER|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
219666366|NCT00426972|DRUG|estradiol (Zesteem)|
219666367|NCT00004896|DRUG|busulfan|
219666368|NCT00004896|DRUG|cyclophosphamide|
219666369|NCT00004896|PROCEDURE|allogeneic bone marrow transplantation|
218974827|NCT04022434|DIETARY_SUPPLEMENT|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
218974828|NCT04022434|DIETARY_SUPPLEMENT|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
218974829|NCT00932737|DRUG|Placebo|1-5 tablets per episode
218974830|NCT00932737|DRUG|HBB 20 mg|Active drug, one to five tablets per episode
218974831|NCT01812772|DEVICE|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
218974832|NCT01812772|DEVICE|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
218974833|NCT06450158|DEVICE|Robot (Amadeo)-assisted Training|"Amadeo® is an FDA Class I Exempt hand/finger robot that has the capacity to precisely measure hand/finger functions.~To use Amadeo, a participant will be seated in a chair. The height of the robot arm support will be adjusted to achieve a comfortable position for the participant. One of the participant's arms will be will be placed on the robot arm support. Magnetic finger tips will then be attached to fingers and thumb. After this, fingers and thumb will be connected to the robot finger sliders. To use Amadeo, the movement range and maximal force of each finger will be configured according to the finger's capability. The following four types of function assessments will be performed with Amadeo: Force, range of motion, tone, and spasticity. Each session will last approximately one hour."
218974834|NCT04126551|OTHER|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
218974835|NCT01042574|DRUG|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
218974836|NCT01689636|DRUG|Tc 99m EC20|
219666370|NCT00004896|PROCEDURE|bone marrow ablation with stem cell support|
219666371|NCT00004896|RADIATION|radiation therapy|
219666372|NCT01687855|DEVICE|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
219666373|NCT01699308|DRUG|Genotropin|
219666374|NCT02599337|DRUG|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
219666375|NCT02599337|DRUG|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
219666376|NCT02548715|DRUG|Levothyroxine|
219666377|NCT02548715|DRUG|Placebo|
219666378|NCT03103685|DRUG|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
219666379|NCT06265571|OTHER|perineural injection|perineural injection of local anesthestetic for postoperative pain management
219666380|NCT02774187|DRUG|Sorafenib|administration of Sorafenib
219666381|NCT02774187|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219666382|NCT02774187|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
219666383|NCT01773356|DIETARY_SUPPLEMENT|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
219666384|NCT05981014|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
219666385|NCT05981014|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219666386|NCT05981014|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219666387|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219666388|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
218974837|NCT05325060|DEVICE|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
218974838|NCT05325060|DEVICE|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
218974839|NCT04831606|PROCEDURE|debridement|Cleaning of the wound area
218974840|NCT04831606|DEVICE|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
218974841|NCT04831606|DEVICE|Advanced dressing|Protect the wound with Advanced dressing
218974842|NCT04831606|DEVICE|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
218974843|NCT04985370|OTHER|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
218974844|NCT04985370|OTHER|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
218974845|NCT03451942|DRUG|FLOT regimen chemotherapy|FLOT regimen chemotherapy
218974846|NCT03451942|PROCEDURE|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
218974847|NCT06281288|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive behavioral therapy
218974848|NCT06281288|OTHER|Exercise Training|Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
218974849|NCT04399837|DRUG|Spesolimab|Solution for injection
218974850|NCT04399837|DRUG|Placebo|Solution for injection
218974851|NCT04879277|BIOLOGICAL|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
218974852|NCT05361785|BIOLOGICAL|FMT|FMT from healthy donor or placebo
218974853|NCT03239158|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
218974854|NCT03239158|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
218974855|NCT01638364|DRUG|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
219666389|NCT05981014|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
219666390|NCT05981014|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
219666391|NCT05981014|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
219666392|NCT05981014|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
219666393|NCT03949738|DIAGNOSTIC_TEST|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
219666394|NCT00164164|DRUG|HalfLytely|
219666395|NCT00164164|DRUG|NuLytely|
219666396|NCT05298436|OTHER|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
219666397|NCT05749406|OTHER|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
219666398|NCT05749406|OTHER|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
219666399|NCT02393326|PROCEDURE|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
219066435|NCT03835533|DRUG|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
219666400|NCT02393326|PROCEDURE|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
219666401|NCT06718673|OTHER|virtual delivery room visit|The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)
219666402|NCT06718673|OTHER|standart of care|Pregnant women in the control group did not receive any intervention other than routine care and counselling.
219066436|NCT03835533|DRUG|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
219066437|NCT03835533|DRUG|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
219666403|NCT01520194|OTHER|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
219666404|NCT01520194|OTHER|medical records|medical chart review of patients assisted January 2009 to December 2010
219066438|NCT03835533|DEVICE|Cellectra 2000|Electroporation device
219666405|NCT05160194|BEHAVIORAL|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
219666406|NCT02860117|DEVICE|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
219666407|NCT02860117|DRUG|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
218974856|NCT01638364|DRUG|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
218974857|NCT01122433|DEVICE|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
219666408|NCT01813513|DRUG|IDX719|50 mg tablet for oral administration
219666409|NCT01813513|DRUG|Simeprevir|150 mg capsule for oral administration
219666410|NCT01902875|DRUG|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
219666411|NCT01902875|BIOLOGICAL|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
219666412|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
218974858|NCT01532973|DRUG|Elbasvir|Elbasvir was administered orally by tablet(s)
218974859|NCT01532973|DRUG|Placebo|Dose-matched placebo tablets were administered orally.
219066439|NCT05213845|PROCEDURE|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
219666413|NCT02912455|DRUG|canagliflozin|encapsulated (gelatin capsule).
219666414|NCT02912455|DRUG|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
219666415|NCT04454710|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
219066440|NCT02556021|DRUG|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
219066441|NCT02556021|DRUG|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
219066442|NCT02556021|DRUG|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
219066443|NCT03137147|BEHAVIORAL|Intervention for Sleep and Pain in Youth|See arm description.
219066444|NCT02824276|DRUG|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
219066445|NCT02824276|DRUG|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
219066446|NCT04622358|DRUG|AD-214-02|1 tablet administered before the breakfast during 7 days
219066447|NCT04622358|DRUG|Rabeprazole|1 tablet administered before the breakfast during 7 days
219666416|NCT05040100|OTHER|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
219666417|NCT05281900|DIAGNOSTIC_TEST|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
219666418|NCT05281900|OTHER|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
219666419|NCT05281900|OTHER|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank"
219666420|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
219666421|NCT02668159|DIETARY_SUPPLEMENT|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
219666422|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
219666423|NCT02668159|DIETARY_SUPPLEMENT|Placebo|7 tablets of placebos administered prior to one the OGTT
219666424|NCT00797407|DIETARY_SUPPLEMENT|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
219666425|NCT02272933|DEVICE|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
219666426|NCT02272933|DEVICE|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
218974860|NCT06441955|DRUG|Ritonavir-Boosted Nirmatrelvir (Paxlovid)|"Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment."
218974861|NCT06441955|DIAGNOSTIC_TEST|Physiological Evaluation|Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.
218974862|NCT06441955|BIOLOGICAL|Moderna COVID-19 Vaccine|Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
218974863|NCT06441955|BEHAVIORAL|Biopsychological|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
218974864|NCT06441955|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
219066448|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
219066449|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
219066450|NCT03989817|DRUG|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
219066451|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
219666427|NCT00957905|DRUG|Alvocidib Hydrochloride|Given IV
219666428|NCT00957905|DRUG|Fluorouracil|Given IV
219666429|NCT00957905|DRUG|Leucovorin Calcium|Given IV
219666430|NCT00957905|DRUG|Oxaliplatin|Given IV
219666431|NCT05469022|DRUG|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
219666432|NCT00667797|DRUG|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
219666433|NCT00667797|DRUG|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
219666434|NCT02073656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219666435|NCT02073656|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219666436|NCT00755885|DRUG|abiraterone acetate|
219666437|NCT00755885|OTHER|laboratory biomarker analysis|
219666438|NCT00755885|OTHER|pharmacogenomic studies|
218974865|NCT06441955|GENETIC|Genetic (including gene transfer, stem cell and recombinant DNA)|Full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time to address the intersection of genomics and health disparities, recognizing that genetic variations can contribute to health disparities in several ways. Understanding these genetic contributions to health disparities is crucial for developing targeted interventions and personalized healthcare strategies that can help address these disparities. genetics, epidemiology, public health, and social sciences, the study aims to shed light on the complex interplay between genomics and health equity. To evaluate cellular errors and the effects of myocardial DNA, you may need to consider tests such as DNA sequence.
218974866|NCT06441955|COMBINATION_PRODUCT|Multidisciplinary approach|The aim of utilizes psychology-applied science and science in nursing frameworks to address health disparities and promote health and wellness across the health span to improve patient population outcomes, evaluate cost-effectiveness, and patient health literacy competencies. The experimental framework of a compilation of the bio-psychosocial model, Eric Erickson developmental stages, AI/AML, and cognitive learning theories address system decision making factors, for sound decision making and behavioral change cognitive behavioral therapies protocol segmentation demographic and urban areas affected by social-economic access to healthcare and related ethical stance of United States healthcare policy developmental outlines. Biology plays a role in the content of development stages, and the great debate of nurture vs. nature sets the foundation for addressing the psychosocial approach to healthcare integration as an applied science model for strengthening primary services and improving
218974867|NCT06223737|DIAGNOSTIC_TEST|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
218974868|NCT06223737|DIAGNOSTIC_TEST|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
218974869|NCT04266769|DEVICE|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
218974870|NCT02628769|DRUG|Solithromycin|
218974871|NCT02628769|DRUG|Placebo|
218974872|NCT02374086|BEHAVIORAL|Exercise training|
219666439|NCT03059251|BIOLOGICAL|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
219666440|NCT05245045|PROCEDURE|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
219666441|NCT05245045|PROCEDURE|Red light|Red light
219666442|NCT02638051|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
219666443|NCT02638051|DIETARY_SUPPLEMENT|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
219666444|NCT02638051|DRUG|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
219666445|NCT06444828|PROCEDURE|Non-operative|Non-operative treatment versus operative treatment (surgery)
219666446|NCT01835028|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
219666447|NCT01835028|OTHER|Computed tomography|Observational Study using Imaging and Biomarkers
219666448|NCT01835028|OTHER|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
219666449|NCT01835028|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
219666450|NCT01835028|OTHER|Stress echocardiography|Observational Study using Imaging and Biomarkers
218974873|NCT04417543|DRUG|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
218974874|NCT04417543|DRUG|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
218974875|NCT02906371|DRUG|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
218974876|NCT02906371|DRUG|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
218974877|NCT02906371|BIOLOGICAL|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
218974878|NCT00990873|GENETIC|gene expression analysis|
218974879|NCT00990873|GENETIC|microarray analysis|
218974880|NCT00990873|GENETIC|reverse transcriptase-polymerase chain reaction|
218974881|NCT00990873|OTHER|laboratory biomarker analysis|
218974882|NCT02024555|DRUG|Levofloxacin|
218974883|NCT02024555|DRUG|Ethambutol|
218974884|NCT02024555|DRUG|Azithromycin|
218974885|NCT02024555|DRUG|Rifampin|
218974886|NCT02024555|DRUG|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
219066452|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
219066453|NCT05531396|OTHER|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
219066454|NCT05531396|OTHER|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
219066455|NCT03421691|DEVICE|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
219066456|NCT00084058|DRUG|Lopinavir/ritonavir|
219066457|NCT00084058|DRUG|Saquinavir|
218974887|NCT06087458|BIOLOGICAL|VOY-101|VOY-101
218974888|NCT01397669|PROCEDURE|Colon biopsy, lymph node biopsy, lumbar puncture, Leukapheresis, Brain MRI/MRS/DTI|"Eligible subjects will undergo a flexible sigmoidoscopy/biopsy and Brain MRI/MRS/DTI at Chulalongkorn University Hospital.~Lumbar puncture, lymph node biopsy, and leukapheresis will be done at TRCARC or IHRI."
218974889|NCT03950791|BEHAVIORAL|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
218974890|NCT03950791|BEHAVIORAL|Health Education|Education about improving lifestyle factors to improve participants' overall health.
218974891|NCT06458855|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
218974892|NCT05076565|DEVICE|Airbag Belt Fall Protection System|Both versions of Airbags features different number of IMU sensors. Participant's will be randomly assigned one of the two versions. The algorithms developed in this project will help the researcher to identify the optimal performance (sensitivity and specificity values for detecting falls). Based on this information the research team will be able to choose a version for home/community deployment portion of the study. Based on the performance of the airbags in detecting true positives (falls) and true negatives (non-falls) accurately one of the airbags will be used in community deployment phase of the study.
218974893|NCT02719327|DRUG|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
219066458|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
219666451|NCT03592498|DRUG|Sulfadiazine, Silver|Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
218974894|NCT02719327|OTHER|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
218974895|NCT03350620|DRUG|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
218974896|NCT03350620|DRUG|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
218974897|NCT03350620|DRUG|Placebo|Vehicle (placebo) will be administered, once daily (QD)
218974898|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
218974899|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
218974900|NCT06509334|DRUG|Omalizumab|Participants will receive Omalizumab every 4 weeks for 12 weeks
219666452|NCT03592498|DEVICE|Skin of Nile tilapia|Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
219666453|NCT03216655|OTHER|phone call|Investigators give a regular follow-up to participants: phone call monthly
219666454|NCT03216655|OTHER|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
219666455|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
219666456|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
219666457|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
218974901|NCT01645722|PROCEDURE|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
218974902|NCT03733340|DRUG|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
218974903|NCT00586131|DRUG|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
218974904|NCT00586131|DRUG|Sodium citrate/citratic acid|dictated by pH
218974905|NCT04012125|DEVICE|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
219066459|NCT02015897|PROCEDURE|Physical TherapyA|"Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity"
219066460|NCT02015897|PROCEDURE|Physical TherapyB|"Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity"
219066461|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
219066462|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
219066463|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
219066464|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
219066465|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
219066466|NCT02796339|DIETARY_SUPPLEMENT|Mastiha|
219066467|NCT02796339|DIETARY_SUPPLEMENT|Placebo|
219066468|NCT00125489|DRUG|chloroquine sulfate|
219066469|NCT00125489|DRUG|sulfadoxine/pyrimethamine|
219066470|NCT00735046|BEHAVIORAL|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
219066471|NCT00735046|OTHER|Control|Patients and proxies who are assigned to treatment as usual
219066472|NCT00884585|DRUG|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
219066473|NCT00884585|DRUG|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
219066474|NCT05626829|DRUG|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
219066475|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
219066476|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
219066477|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
219666458|NCT05226234|DEVICE|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
219666459|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
219066478|NCT02308033|DRUG|Metronidazole|
219066479|NCT02308033|DRUG|Gel vehicle|
219066480|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
219066481|NCT04280198|BEHAVIORAL|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
219666460|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
219666461|NCT01207115|DRUG|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
219666462|NCT01207115|DRUG|Placebo|Placebo capsules - twice daily for 8 weeks
219666463|NCT01207115|DRUG|Naproxen|Naproxen capsules - twice daily for 8 weeks
218974906|NCT04000230|BEHAVIORAL|TCIT|"TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
218974907|NCT04000230|BEHAVIORAL|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
218974908|NCT01470859|DRUG|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
218974909|NCT01470859|DRUG|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
218974910|NCT05816096|COMBINATION_PRODUCT|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
218974911|NCT05816096|COMBINATION_PRODUCT|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
218974912|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
218974913|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
218974914|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
218974915|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
218974916|NCT03051854|BEHAVIORAL|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
218974917|NCT01066000|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
218974918|NCT02706678|DRUG|Tacrolimus sustained-release capsule|Oral
218974919|NCT06019507|BIOLOGICAL|TCD601|Investigational Product
218974920|NCT06019507|BIOLOGICAL|Cyclophosphamide|Conditioning Regimen
218974921|NCT06019507|DRUG|TAC|Immunosuppression Therapy
218974922|NCT06019507|DRUG|MMF|Immunosuppression Therapy
218974923|NCT06019507|DRUG|Corticosteroids|Immunosuppression Therapy
219666464|NCT01786538|DRUG|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
218974924|NCT04926376|DEVICE|Eye90 Microspheres|Y90 glass microspheres
218974925|NCT03979131|COMBINATION_PRODUCT|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
218974926|NCT02812407|DEVICE|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm"
218974927|NCT06654791|DRUG|[14C] SIM0270 Oral Preparation|Use according to the prescribed protocol
218974928|NCT06016907|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
218974929|NCT06016907|BEHAVIORAL|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
218974930|NCT04981067|OTHER|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
218974931|NCT04981067|OTHER|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
218974932|NCT04981067|OTHER|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
218974933|NCT06708247|PROCEDURE|Standard Peri-implant Reconstructive Surgery|This intervention involves standard peri-implant reconstructive surgery without the additional step of electrolytic cleaning. The procedure includes mechanical debridement of the implant surface to remove biofilm, followed by bone grafting using autogenous bone harvested from the tuberosity and coverage with a resorbable collagen membrane for bone regeneration and stabilization of the implant.
218974934|NCT06708247|PROCEDURE|Electrolytic Cleaning with Peri-implant Reconstructive Surgery|This intervention involves peri-implant reconstructive surgery with an added step of electrolytic cleaning for enhanced implant surface decontamination. The procedure starts with mechanical debridement of the implant surface, followed by the use of an electrolytic cleaning device to remove biofilm and contaminants without damaging the implant surface. This is then followed by bone grafting using autogenous tuberosity bone and coverage with a resorbable collagen membrane to promote bone regeneration and implant stability.
219666465|NCT01786538|DRUG|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
219666466|NCT03704116|BEHAVIORAL|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
219666467|NCT04554758|PROCEDURE|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
219666468|NCT04554758|PROCEDURE|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
219666469|NCT06730035|OTHER|Blood analysis|This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
219666470|NCT04719195|OTHER|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
219666471|NCT04656366|DIAGNOSTIC_TEST|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
218974935|NCT02948283|OTHER|Laboratory Biomarker Analysis|Correlative studies
218974936|NCT02948283|DRUG|Metformin Hydrochloride|Given PO
218974937|NCT02948283|OTHER|Pharmacological Study|Correlative studies
219066482|NCT04280198|BEHAVIORAL|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
219066483|NCT05561959|OTHER|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
219066484|NCT05561959|OTHER|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
218974938|NCT02948283|DRUG|Ritonavir|Given PO
218974939|NCT02948283|OTHER|Quality-of-Life|Ancillary studies
218974940|NCT02948283|OTHER|Questionnaire|Ancillary studies
218974941|NCT00757107|DEVICE|Taperloc Microplasty|primary total hip arthroplasty
218974942|NCT00757107|DEVICE|Taperloc standard|primary total hip arthroplasty
219066485|NCT04056806|DRUG|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
219066486|NCT03339986|BEHAVIORAL|Reduction or Replacement|
218974943|NCT05268055|OTHER|"Sign Here training intervention"|Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.
218974944|NCT05268055|OTHER|Intervention as usual|"Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
218974945|NCT06842004|OTHER|Participatory action|The reality of audiovisual fiction in Spain and professionals' perceptions of how motherhood is portrayed will be explored. Through participatory action, participants will share their experiences and knowledge to identify areas for improvement in the representation of reproductive processes. The result will be a manual of good practices for fiction production, aimed at promoting more inclusive, realistic and stereotype-free representations, in order to improve both public perception and professional training in the audiovisual field.
218974946|NCT02208700|OTHER|Oxepa|Therapeutic nutrition with EPA, GLA\< and antioxidants
218974947|NCT02208700|OTHER|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
219066487|NCT04895267|DEVICE|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
219066488|NCT01823744|DIETARY_SUPPLEMENT|micronutrient supplementation|
219666472|NCT05073861|BEHAVIORAL|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
218974948|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
218974949|NCT04949685|PROCEDURE|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
218974950|NCT04266249|DRUG|Docetaxel|Given IV
218974951|NCT04266249|PROCEDURE|Lumpectomy|Undergo lumpectomy
218974952|NCT04266249|PROCEDURE|Mastectomy|Undergo mastectomy
218974953|NCT04266249|DRUG|Nab-paclitaxel|Given IV
218974954|NCT04266249|DRUG|Paclitaxel|Given IV
218974955|NCT04266249|BIOLOGICAL|Pertuzumab|Given IV
218974956|NCT04266249|RADIATION|Radiation Therapy|Undergo radiation therapy
218974957|NCT04266249|BIOLOGICAL|Trastuzumab|Given IV
218974958|NCT04266249|BIOLOGICAL|Trastuzumab Emtansine|Given IV
218974959|NCT05469685|DRUG|Vonoprazan|Potassium-competitive acid blocker
218974960|NCT05469685|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
218974961|NCT05209178|DIAGNOSTIC_TEST|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
218974962|NCT06434298|BEHAVIORAL|Choose to Move|As described under study arm description
218974963|NCT03262402|PROCEDURE|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
218974964|NCT06665802|BEHAVIORAL|Questionnaire|Questionnaire completion
218974965|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
218974966|NCT02367989|DIETARY_SUPPLEMENT|2g barley β-glucan|Food containing low amounts of barley β-glucan
218974967|NCT02367989|DIETARY_SUPPLEMENT|4g barley β-glucan|Food containing medium amounts of barley β-glucan
219066489|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
219066490|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
219066491|NCT02088996|DEVICE|longwave diathermy on low power|
219066492|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
219066493|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
219666473|NCT04175431|PROCEDURE|Positron Emission Tomography|Undergo fluciclovine PET/CT
219666474|NCT04175431|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
219666475|NCT04175431|RADIATION|Radiation Therapy|Undergo radiation therapy
218974968|NCT02367989|DIETARY_SUPPLEMENT|6g barley β-glucan|Food containing high amounts of barley β-glucan
218974969|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
218974970|NCT06679933|OTHER|Hand grip strength measurament|That intervention includes making the patient sit down and rest for 5 minutes on a comfortable chair. Then make them handle a hand dynamometer with their dominant hand and ask them to squeeze it with all of their effort. Repeat that squeeze three times with 2-minute intervals. The highest number recorded on the dynamometer is the hand grip strength of the patient.
218974971|NCT06681415|DRUG|Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution|"Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion."
218974972|NCT06934031|OTHER|translation software|ChatGPT, Google Translate, and UD talk
218974973|NCT06934525|BEHAVIORAL|Team-delivered, exposure-based CBT|Patient sees licensed provider 1x/month and non-licensed provider 3x/month for exposure-based cognitive behavioral therapy
218974974|NCT06933290|OTHER|Beverage|15 milliliter aliquot interspersed with tastants with a 3 minute break between tastants
218974975|NCT06934733|OTHER|Oral cryotherapy|Patients randomly assigned to the experimental group underwent TROP2-ADC treatment. They continuously held ice cubes and ice water from 15 minutes before the infusion, throughout the infusion process, and for 15 minutes after the infusion. Ice cubes were promptly replaced with fresh ones as they melted. Patients were instructed not to consume any food or liquids orally for 1 hour following the completion of the ice therapy.
219066494|NCT02449538|DRUG|everolimus|everolimus 10 mg qd daily one cycle is 28days.
219066495|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
218974976|NCT06934733|OTHER|Routine oral care|Patients in the control group did not receive oral cryotherapy during the TROP2-ADC infusion but only received routine oral care.
218974977|NCT06934902|BEHAVIORAL|"Old vs new objects encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks.~The following week, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase."
218974978|NCT06934902|BEHAVIORAL|" incongruent vs. congruent contexts  encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. This time, the objects will be chosen according to the participant's location.~The following week, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent/incongruent contexts."
218974979|NCT06933953|OTHER|Questionnaires|"Patients will complete various questionnaires at J0: FHSQ-Fr, EQ-5D-5L, Foot Function Index, Visual analog pain scale, SF-12.~Patients who needs to come back for a visit at Day 7 (+ 3 days) will complete the FHSQ-Fr questionnaire for a second time"
219666476|NCT04175431|DRUG|Abiraterone Acetate|Given PO
219666477|NCT04175431|DRUG|Prednisone|Given PO
218974980|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session, once daily for five consecutive days, with EEG monitoring conducted before and after electrical stimulation.
218974981|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
218974982|NCT03968770|DIETARY_SUPPLEMENT|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
218974983|NCT03968770|DIETARY_SUPPLEMENT|Control group|Placebo of Probiotic once daily taken by 6 weeks.
218974984|NCT03968770|OTHER|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
218974985|NCT01121653|DRUG|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
219066496|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
219066497|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
219066498|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
219066499|NCT01870843|DRUG|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
219666478|NCT04175431|PROCEDURE|Computed Tomography|Undergo fluciclovine PET/CT
219666479|NCT04175431|DRUG|Abiraterone|Given PO
219666480|NCT04175431|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
218974986|NCT05863338|BEHAVIORAL|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
218974987|NCT04512417|DRUG|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
218974988|NCT04512417|DRUG|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
219066500|NCT03710434|DRUG|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
219066501|NCT03710434|DRUG|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
219066502|NCT03710434|DRUG|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
219666481|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
219666482|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
219666483|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
219666484|NCT03871725|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
219666485|NCT04164004|OTHER|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
219666486|NCT03053648|OTHER|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
219666487|NCT03053648|OTHER|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
219666488|NCT02974205|PROCEDURE|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
218974989|NCT03137342|BEHAVIORAL|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
218974990|NCT04680091|DRUG|Pyrotinib Maleate|single oral dose, 400 mg, fed.
218974991|NCT04680091|DRUG|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
218974992|NCT03616275|OTHER|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
218974993|NCT00004075|DRUG|tanespimycin|
218974994|NCT02829632|BEHAVIORAL|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
218974995|NCT02829632|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
218974996|NCT02829632|BEHAVIORAL|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
218974997|NCT05900271|DEVICE|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
218974998|NCT05900271|DEVICE|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
218974999|NCT04571814|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
218975000|NCT01634009|DIETARY_SUPPLEMENT|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
218975001|NCT04281303|PROCEDURE|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
218975002|NCT00378339|DEVICE|gold berlocks|
218975003|NCT00292214|DRUG|Paracetamol (acetaminophen)|
218975004|NCT05928260|DEVICE|Medtronic Guardian Connect Sensor 3|This is a real-time CGMS which transmits all the blood glucose readings into the application downloaded in a device continuously and also gives alarms and alerts to the person.
218975005|NCT05928260|DEVICE|Abott Freestyle Libre Sensor|This system is an is-CGMS in which the participant gets his blood glucose only when the device is scanned.
218975006|NCT05928260|OTHER|Self blood Glucose monitoring by a glucometer|In this all patients will check their blood glucose using a needle prick and glucometer at pre-specified intervals.
219666489|NCT02974205|DEVICE|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
219666490|NCT02974205|DEVICE|össur brace|Rehabilitation after acute isolated PCL rupture
219666491|NCT00380666|PROCEDURE|PET/CT scan|
219666492|NCT01878734|DIETARY_SUPPLEMENT|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
219666493|NCT01990872|DIETARY_SUPPLEMENT|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
219666494|NCT01990872|DIETARY_SUPPLEMENT|Placebo|Placebo (0 micrograms vitamin D3/day)
218975007|NCT06250777|DRUG|Trastuzumab deruxtecan|"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~\- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"
218975008|NCT06130527|PROCEDURE|Nicardipine|Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.
218975009|NCT06130527|PROCEDURE|Remifentanil|Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
218975010|NCT03725215|BEHAVIORAL|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
218975011|NCT05700318|DEVICE|neurostimulator|The ShiraTronics Migraine Therapy System
219666495|NCT03851978|BEHAVIORAL|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
219666496|NCT06995690|DRUG|Ketamine|Patients receive crystalloid preloading of 15ml/kg (Ringer's lactate) +the sub-anesthetic dose of ketamine of 0.5 mg/kg IV added to the first bottle of ringer for blinding over 20 min before the spinal injection.
218975012|NCT03025841|DRUG|Ceftaroline|
218975013|NCT05412875|OTHER|Best Practice|Given usual care
218975014|NCT05412875|DRUG|Nicotine Replacement|Given JUUL
218975015|NCT05412875|OTHER|Quality-of-Life Assessment|Ancillary studies
218975016|NCT05412875|OTHER|Questionnaire Administration|Ancillary studies
218975017|NCT03383458|BIOLOGICAL|Nivolumab|Specified dose on specified days
218975018|NCT03383458|OTHER|Placebo|specified dose on specified days
218975019|NCT01411618|OTHER|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
218975020|NCT04041297|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
218975021|NCT03140228|DEVICE|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
218975022|NCT03140228|DEVICE|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
218975023|NCT03071471|DEVICE|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~* Only two screws are used~* Incision size is much smaller~* Simpler operation with shorter operative time~* Less complication thanks to the three points above.~* Minimal spinal mobility loss"
218975024|NCT03798197|DRUG|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
218975025|NCT04234802|OTHER|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
218975026|NCT04537455|DIAGNOSTIC_TEST|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
218975027|NCT05770869|DEVICE|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
218975028|NCT05420675|OTHER|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
219066503|NCT03710434|DRUG|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
219066504|NCT03710434|DRUG|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
218975029|NCT03657446|DRUG|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
218975030|NCT03657446|DRUG|Placebo|Matching placebo infusion
218975031|NCT03657446|DRUG|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
219066505|NCT03710434|DRUG|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
219066506|NCT03710434|DRUG|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
219666497|NCT06995690|DRUG|Normal Saline|Patients receive a crystalloid preloading of 15 ml/kg (Ringer's lactate)+ 0.5 mg/kg IV of Normal Saline added to the first bottle of ringer for blinding, over 20 min before the spinal injection.
219666498|NCT06995053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219666499|NCT06995053|PROCEDURE|Computed Tomography|Undergo CT
219666500|NCT06995053|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT with intrafraction motion monitoring
219666501|NCT06995053|OTHER|Intrafraction Motion Monitoring|Undergo CT-guided SBRT with intrafraction motion monitoring
219666502|NCT06995053|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218975032|NCT00251212|BEHAVIORAL|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
218975033|NCT05449769|BEHAVIORAL|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
218975034|NCT00302185|PROCEDURE|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
218975035|NCT00302185|BEHAVIORAL|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
218975036|NCT02515643|OTHER|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method"
218975037|NCT03793556|DEVICE|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
218975038|NCT03793556|DRUG|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
218975039|NCT04828239|DEVICE|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
218975040|NCT04828239|OTHER|acupuncture|Needle type: C\&G, gauge and size: 0.25x40mm
218975041|NCT04828239|DEVICE|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
218975042|NCT00398788|DRUG|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
218975043|NCT01805804|DRUG|placebo/valsartan|
218975044|NCT06111521|DRUG|LY3537982|Administered orally
218975045|NCT06111521|DRUG|Digoxin|Administered orally
218975046|NCT06111521|DRUG|Rosuvastatin|Administered orally
218975047|NCT06111521|DRUG|Midazolam|Administered orally
218975048|NCT06111521|DRUG|Midazolam|Administered IV
218975049|NCT05727462|OTHER|Manual Therapy with TECAR|"The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference."
218975050|NCT05727462|OTHER|Manual Therapy without TECAR|Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
218975051|NCT05509751|BEHAVIORAL|GAM, exercise, health education|geriatric assessment, exercise and health education
218975052|NCT05509751|BEHAVIORAL|online chair-based exercise combined with health education|online chair-based exercise and health education for 12 weeks
218975053|NCT04416633|DRUG|Durvalumab|500-mg/120-mg IV
218975054|NCT06288009|PROCEDURE|Running locking suture|In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
219666503|NCT06995053|OTHER|Questionnaire Administration|Ancillary studies
219666504|NCT05724485|DRUG|Branched-chain Amino Acid|12.45 grams of BCAA orally per day before bedtime
219666505|NCT05724485|DRUG|Placebo|12.45 grams of Maltodextrin orally per day before bedtime
219666506|NCT00486707|BEHAVIORAL|Questionnaire|A questionnaire will be completed.
219666507|NCT02905643|OTHER|Study subjects|This study does not include an intervention it is only observational.
219666508|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus Anodic transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Anodal tDCS over DLPFC (20 min) daily for 1 month
219666509|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus sham transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Sham tDCS over DLPFC (20 min) daily for 1 month
219666510|NCT05573529|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
219666511|NCT05573529|DEVICE|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
219666512|NCT01565798|OTHER|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
218975055|NCT06288009|PROCEDURE|Standard running suture|In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
218975056|NCT04612790|BIOLOGICAL|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
218975057|NCT04612790|BIOLOGICAL|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
218975058|NCT03881410|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
218975059|NCT05554588|PROCEDURE|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
218975060|NCT05554588|PROCEDURE|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
218975061|NCT03764007|DRUG|18F-Fluorocholine|Given intravenously
218975062|NCT03764007|PROCEDURE|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
218975063|NCT04255030|BEHAVIORAL|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
218975064|NCT04255030|BEHAVIORAL|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
218975065|NCT04255030|BEHAVIORAL|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
218975066|NCT03460938|PROCEDURE|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
218975067|NCT05233293|PROCEDURE|Spyglass + RFA|SpyGlass direct Vision guided RFA
218975068|NCT05233293|PROCEDURE|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
218975069|NCT02671409|OTHER|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
218975070|NCT05221307|OTHER|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
218975071|NCT02405754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
218975072|NCT00098098|BIOLOGICAL|rBV A/B|
219666513|NCT05158686|DEVICE|Paclitaxel-coated Balloon dilation angioplasty|Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
219666514|NCT05158686|DEVICE|Non-coated Balloon dilation angioplasty|Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
219666515|NCT04744259|BEHAVIORAL|Behavioural Activation|A psychological intervention which aims to increase activity and reduce depressive symptoms.
219666516|NCT05519072|DRUG|Nitrofurantoin|For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
219666517|NCT07019350|OTHER|Upfront DCB-based hybrid strategy|In upfront DCB-based hybrid strategy group, stepwise provisional strategy with side branch DCB angioplasty will be performed according to the follow standardized procedural steps. In this group, provisional stenting strategy will be performed in accordance with the European Bifurcation Club (EBC) consensus. Bail-out stenting will be performed using operator's preferred technique (e.g. T, TAP, culotte) when there will be one of the following after hybrid strategy: \<TIMI 3 flow in the side branch, severe (\>90%) ostial pinching, or flow-limiting dissection.
218975073|NCT01914731|DRUG|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
218975074|NCT02938039|DEVICE|Ambu LMA|Ambu Laryngeal Mask Airways
218975075|NCT02938039|DEVICE|I-Gel LMA|I-Gel Laryngeal Mask Airways
218975076|NCT00807131|BEHAVIORAL|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
219066507|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
219066508|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
219066509|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
219066510|NCT03920917|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
219066511|NCT03920917|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
219066512|NCT06316362|DRUG|SMOF lipid 20%|SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
219066513|NCT06316362|OTHER|Standard treatment for carbamazepine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
219066514|NCT00005981|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
219066515|NCT00005981|DRUG|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
219066516|NCT00841581|DRUG|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
219066517|NCT04936412|DEVICE|Rehabilitation brace|Rehabilitation brace
219066518|NCT03960190|DEVICE|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
219066519|NCT04243876|DIAGNOSTIC_TEST|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
219666518|NCT07019350|OTHER|Upfront 2-stenting strategy|In upfront 2-stenting strategy group, systematic planned 2-stenting will be performed according to EBC recommendations. The stent technique will be at the discretion of the operator but could be one of culotte, DK-culotte, mini-crush, DK-crush, T or TAP.
218975077|NCT00807131|BEHAVIORAL|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
218975078|NCT00807131|BEHAVIORAL|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
219066520|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
218975079|NCT00807131|BEHAVIORAL|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
218975080|NCT00251173|BEHAVIORAL|Strengths Based Case Management (SBCM)|
219066521|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
219066522|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
218975081|NCT00251173|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
218975082|NCT00251173|BEHAVIORAL|Brief Informational Feedback (BIF) session|
218975083|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~\- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
218975084|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
219666519|NCT07026006|OTHER|Active Release Technique|Patients will receive Active Release Technique (ART) protocol will be applied to 4 muscles Including; trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles (for 15 minutes)
219666520|NCT07026006|OTHER|Strain-counterstrain|Patients will receive Strain-counterstrain (SCS) protocol will be applied to 4 muscles Including the trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles for 15 minutes.
218975085|NCT03412708|OTHER|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
218975086|NCT02402101|DEVICE|Procedure: active tDCS|Intensity 2 mA during 20 minutes
218975087|NCT02402101|DEVICE|Procedure: sham tDCS|sham condition as delivered by the stimulator
218975088|NCT01649050|DRUG|BGG492|
218975089|NCT01649050|DRUG|Placebo|
218975090|NCT00320931|DEVICE|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
218975091|NCT03572244|DEVICE|Laser-Lok|A microgrooved abutment will be placed
218975092|NCT03572244|DEVICE|Machined|A machined transmucosal healing abutment will be placed
218975093|NCT00252824|DRUG|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
219066523|NCT03355079|DRUG|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
219066524|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
219066525|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
219066526|NCT02279641|DRUG|RDEA3170 10 mg|
219066527|NCT02279641|DRUG|allopurinol 300 mg|
219066528|NCT02396641|OTHER|Best Supportive Care Checklist|
219066529|NCT00648479|DEVICE|The Guiding Star|
219666521|NCT07025941|OTHER|Standard Critical Care Nursing Protocol|"The Standard Critical Care Nursing Protocol encompasses evidence-based, routine nursing practices for critically ill patients in the intensive care unit (ICU). This protocol serves as the control intervention in comparative studies evaluating novel nursing strategies.~Key Components:~Basic Physiological Monitoring:~Continuous assessment of vital signs (heart rate, blood pressure, respiratory rate, SpO₂).~Strict intake/output monitoring and electrolyte balance management.~Airway Management:~Standard oxygen therapy (nasal cannula, face mask) or mechanical ventilation as prescribed.~Scheduled suctioning, positional changes, and oral care (every 4-6 hours).~Infection Prevention:~Aseptic techniques for invasive procedures (e.g., central line care, urinary catheter management).~Ventilator-associated pneumonia (VAP) bundle compliance (e.g., head-of-bed elevation, sedation vacations).~Mobility \& Skin Integrity:~Passive range-of-motion exercises for immobilized patients (2×/day).~Pr"
219686644|NCT01065298|BIOLOGICAL|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of \>40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
218975094|NCT00235469|DRUG|SPM 927|
218975095|NCT03349931|DIAGNOSTIC_TEST|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
218975096|NCT00408629|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
218975097|NCT00408629|BIOLOGICAL|placebo|Matching Placebo for prefilled syringe, 40 mg,
218975098|NCT06441669|DRUG|Letermovir|Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
219066530|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
219066531|NCT00920192|DRUG|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
219066532|NCT01556113|OTHER|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
219066533|NCT03021187|DRUG|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
219066534|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
219066535|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
219066536|NCT03021187|DRUG|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
219066537|NCT06352853|OTHER|Skin incision in Cesarean Section by Diathermy|Skin incision by diathermy
219066538|NCT06352853|OTHER|Skin incision in Cesarean Section by Scalpel|Skin incision by scalpel
219066539|NCT01664078|DEVICE|Endovascular AAA repair with InCraft®|
219066540|NCT01631032|DRUG|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
219066541|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
219066542|NCT06563089|OTHER|blood sampling|Albumin level in blood
219686645|NCT03836534|BEHAVIORAL|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
218975099|NCT01660204|OTHER|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
218975100|NCT01315964|DIETARY_SUPPLEMENT|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
218975101|NCT06169293|BEHAVIORAL|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
218975102|NCT00191906|DRUG|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
218975103|NCT00191906|DRUG|placebo|Placebo, every day (QD), by mouth (PO)
218975104|NCT06533917|DEVICE|Main Group|Thoracolumbar spine AP, Thoracolumbar spine LAT
218975105|NCT01800396|DIETARY_SUPPLEMENT|Milk protein|
218975106|NCT01800396|DIETARY_SUPPLEMENT|Milk protein rich in phospholipids|
218975107|NCT05247593|DRUG|Dayingpian|The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
218975108|NCT05247593|DRUG|conventional mood stabilizers|Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
218975109|NCT06167564|DIAGNOSTIC_TEST|Routine allergy tests|Prick test, specific IgE detection
218975110|NCT06167564|DIAGNOSTIC_TEST|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
218975111|NCT04948515|DIAGNOSTIC_TEST|laboratory test|genotyping of IL 17 and IL23
218975112|NCT04948515|DIAGNOSTIC_TEST|laboratory test|estimation of serum level of IL 17
218975113|NCT00573937|DRUG|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
219066543|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
219066544|NCT06308159|DRUG|Vebeglogene autotemcel|Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
219066545|NCT05093452|BEHAVIORAL|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
218975114|NCT00573937|DRUG|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
218975115|NCT06333301|OTHER|Surveys|Group will complete several surveys
218975116|NCT00333801|BEHAVIORAL|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
218975117|NCT00333801|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
219066546|NCT05093452|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
218975118|NCT00689780|DRUG|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
219066547|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
219066548|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
219686646|NCT06481943|DEVICE|Sponsor MCG device (CardiAQ)|Unshielded magnetocardiography device for measuring cardiac magnetic fields
219686647|NCT03099603|DRUG|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
218975119|NCT00689780|DRUG|Midazolam|Oral solution given orally once daily on day -1 and day 14
218975120|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
218975121|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
218975122|NCT05642078|BIOLOGICAL|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
218975123|NCT00037622|DRUG|ACH-126, 443 (beta-L-Fd4C)|
219686648|NCT03202446|DRUG|1% Glycated Chitosan|
219686649|NCT03202446|DEVICE|Photothermal Laser|
219686650|NCT03202446|DRUG|Placebo|
219666522|NCT07025941|BEHAVIORAL|ICU-PRO Nursing Protocol (Integrated Critical Care Protocol for Rehabilitation Outcomes)|"The intervention group received a standardized 14-day nursing protocol combining three evidence-based components:~Comprehensive Rehabilitation Nursing:~Early mobilization protocol with passive/active exercises (3-4 sessions/day)~Respiratory training using incentive spirometry (Triflo II® devices)~Swallowing rehabilitation with VitalStim® electrical stimulation~Refined Airway Management:~Humidification via Fisher \& Paykel® MR850 systems (33-44 mg/L)~Closed suction systems (Ballard® Trach Care) with strict aseptic technique~Oral care with 0.12% chlorhexidine solution (Peridex®) 4×/day~Nutritional Support:~Enteral feeding using Abbott Nutrition® formulas~Parenteral nutrition via Baxter®/Fresenius Kabi® solutions~Gastric residual monitoring with Kangaroo™ feeding pumps~Key Features:~Implemented by specialized ICU nurses, respiratory therapists, and dietitians~Daily monitoring using Philips® IntelliVue patient monitors~Protocol adjustments based on weekly APACHE II scoring"
219666523|NCT07025928|BEHAVIORAL|Decreased Salt High Potassium Tool (DSHP Tool)|Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
219666524|NCT07026019|OTHER|Bruegger's relief exercise|Participant will be in a high sitting position. An elastic resistance band will be wrapped on each hand of the participant leaving the palm open and will be told to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant will be instructed to perform scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension and chin tuck. The treatment protocol will be for 4 weeks, having 3 sessions in a week and 4 sets of 12 repetitions in each session. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds.
219666525|NCT07026019|OTHER|Multimodal exercise program|Multimodal exercise program including chin tucks, bilateral pectoral stretching, scapular region strengthening exercises and Wand exercises. The training program applied 3 times a week, 50 minutes each time, for 4 weeks
219686651|NCT03202446|DRUG|Cyclophosphamide|
218975124|NCT04171765|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
218975125|NCT04171765|DRUG|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
218975126|NCT03633617|DRUG|Dupilumab|Solution for injection administered subcutaneously
218975127|NCT03633617|DRUG|Placebo|Matching placebo
218975128|NCT03028103|DRUG|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
218975129|NCT03028103|DRUG|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
218975130|NCT03028103|DRUG|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
219066549|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
219066550|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
219066551|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
219066552|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
219066553|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
219686652|NCT03202446|DRUG|Standard of Care|
218975131|NCT03028103|DRUG|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
218975132|NCT04558580|DRUG|Rufinamide|Rufinamide
218975133|NCT04612582|DRUG|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
218975134|NCT04612582|DRUG|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
218975135|NCT01701921|DRUG|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
218975136|NCT01701921|DRUG|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
219666526|NCT07026877|DEVICE|Fenestrated TREO Stent Graft System|"The Fenestrated TREO Stent-Graft System is a modular, endoluminal, over-the-wire system intended for the endovascular treatment of juxtarenal and pararenal to paravisceral aneurysms requiring a fenestrated stent-graft and having suitable morphology. The system is composed of the following components:~Fenestrated TREO Bifurcate Stent-Graft - The main body fenestrated bifurcate provides the following; proximal seal, fenestrations and gates for connection to the leg extensions.~Bridging Stents - The bridging stent connects the main body bifurcated device to the target visceral artery allowing the target anatomy to maintain perfusion while keeping the pathology sealed~TREO Leg and Straight Extension Stent-Grafts: The Leg Extension and Straight Extension stent-grafts are used to complete coverage of the pathology from the main body bifurcated device to the distal landing zones (usually the common iliac artery just proximal to the iliac bifurcation)."
219666527|NCT07025876|BIOLOGICAL|low dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (low-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~* 3 serotypes (3, 6B, 12F): 4.0 μg per vial each~* 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
219666528|NCT07025876|BIOLOGICAL|high dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 serotypes (3, 6B, 12F): 8.0 μg per vial each 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
219666529|NCT07025876|BIOLOGICAL|PPV23|"The 23-valent pneumococcal polysaccharide vaccine (PPV23) produced by Chengdu Institute of Biological Products is available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration. It contains the following pneumococcal polysaccharides for each serotype:~Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F: 25 μg per vial for each serotype.~Additionally, it contains sodium chloride and water for injection."
219666530|NCT07025876|BIOLOGICAL|Placebo|"In addition to the antigen components, the 24-valent pneumococcal polysaccharide conjugate vaccine developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. contains the following excipients:~Aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose) Sodium chloride Succinic acid Polysorbate 80 Water for injection It is a liquid formulation, available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration."
219686653|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
219686654|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
218975137|NCT01701921|DRUG|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
218975138|NCT01385761|DEVICE|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
218975139|NCT01385761|DEVICE|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
218975140|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
218975141|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
218975142|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
218975143|NCT04275570|BEHAVIORAL|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
218975144|NCT00002451|DRUG|Indinavir sulfate|
218975145|NCT00002451|DRUG|Ritonavir|
218975146|NCT00002451|DRUG|Lamivudine|
218975147|NCT00002451|DRUG|Stavudine|
218975148|NCT00448838|BIOLOGICAL|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
218975149|NCT00448838|DRUG|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
218975150|NCT00448838|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
218975151|NCT00436241|DRUG|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
218975152|NCT00436241|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
218975153|NCT02904889|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
218975154|NCT02904889|OTHER|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
218975155|NCT02787382|DEVICE|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
219066554|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
219066555|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
219066556|NCT00054899|BIOLOGICAL|EP2101|
219666531|NCT07026188|OTHER|Ultrasound with SMI|The use of ultrasound allows observation of new bone formation in the distraction gap, also visualize the formation of blood vessels in the distraction gap with SMI, including the velocity and resistance of blood vessels, and can also indicate the environment of new bone formation. All US examination were performed by one US doctor.
218975156|NCT04894695|DIAGNOSTIC_TEST|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
218975157|NCT01480089|DRUG|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
218975158|NCT01480089|DRUG|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
218975159|NCT03434574|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
219066557|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
219066558|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
219066559|NCT00005787|BIOLOGICAL|epoetin alfa|
219066560|NCT00005787|BIOLOGICAL|filgrastim|
219066561|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
219066562|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
219666532|NCT01625689|BIOLOGICAL|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
218975160|NCT03434574|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
218975161|NCT04589455|DIETARY_SUPPLEMENT|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
218975162|NCT05801133|DRUG|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
218975163|NCT01622803|PROCEDURE|parallel stent|bilateral parallel stent insertion (right and left side)
218975164|NCT01622803|DEVICE|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
218975165|NCT04256096|DEVICE|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
219066563|NCT00005787|BIOLOGICAL|sargramostim|
219066564|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219066565|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
219066566|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
219066567|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
219066568|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
219066569|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
219066570|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
219066571|NCT06575218|DEVICE|Virtual reality training|Virtual reality training
219066572|NCT06575218|OTHER|Conventional exercise and cognitive exercise|Conventional exercise and cognitive exercise
219066573|NCT06575218|OTHER|control|no intervention
219066574|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
219666533|NCT01625689|BIOLOGICAL|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
219666534|NCT02927496|DRUG|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)"
219666535|NCT02927496|DRUG|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
219666536|NCT01162720|PROCEDURE|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
219666537|NCT01162720|PROCEDURE|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
219066575|NCT04712318|PROCEDURE|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
219666538|NCT03218267|OTHER|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
219666539|NCT03218267|OTHER|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
219666540|NCT01807416|PROCEDURE|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
219666541|NCT03657940|BEHAVIORAL|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
219666542|NCT06728657|RADIATION|HFRT targeted to the primary lesion and positive lymph nodes|Hypofractionated radiotherapy (HFRT) targeted to the primary lesion and positive lymph nodes (4Gy × 6 fractions)
219666543|NCT06728657|RADIATION|PULSAR targeted to the primary lesion and positive lymph nodes|Irradiation targeted to the primary lesion and positive lymph nodes (6 Gy/1 fraction)
218975166|NCT04452032|PROCEDURE|Dental avulsion|Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.
218975167|NCT04452032|RADIATION|Radiotherapy|"Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT)."
218975168|NCT01050543|DRUG|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
218975169|NCT01050543|DRUG|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
218975170|NCT05432375|DRUG|Tinostamustine|infusion given over 60 minutes
218975171|NCT04091009|DRUG|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
218975172|NCT04091009|DRUG|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
218975173|NCT03710005|PROCEDURE|Ascent|Dehydrated Cell and Protein Concentrate injection
219066576|NCT04712318|PROCEDURE|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
218975174|NCT03710005|PROCEDURE|Standard|Standard corticosteroid injection
218975175|NCT04004546|BEHAVIORAL|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
218975176|NCT03913546|PROCEDURE|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
218975177|NCT03913546|OTHER|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
219666544|NCT06728657|DRUG|Anti-PD-1 monoclonal antibody|The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status. The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once daily, Q3W.
218975178|NCT01504568|OTHER|Treatment|Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
218975179|NCT00003254|DRUG|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
218975180|NCT00003254|DRUG|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
218975181|NCT01595711|DEVICE|Pain Monitor|Measurement of cutaneous conductance
218975182|NCT01146990|DRUG|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
218975183|NCT03525093|BEHAVIORAL|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
218975184|NCT03525093|BEHAVIORAL|Health education|Participants receive a health education booklet on improving coping with stress.
218975185|NCT02325986|DRUG|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
218975186|NCT02325986|DRUG|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
218975187|NCT02325986|RADIATION|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
218975188|NCT04478981|OTHER|No intervention|This concerns a natural history study; no interventions will be used
218975189|NCT05129423|DRUG|MTPS9579A|MTPS9579A will be administered.
218975190|NCT05129423|DRUG|Placebo|Placebo matched with MTPS9579A will be administered.
218975191|NCT00643773|DIETARY_SUPPLEMENT|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
218975192|NCT00643773|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour
218975193|NCT00570765|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
219066577|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
219066578|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
219066579|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
219666545|NCT06728657|DRUG|Chemotherapy|CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks
219666546|NCT06728657|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For resectable participants, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion.
218975194|NCT00570765|DRUG|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
218975195|NCT03463174|PROCEDURE|Mandibular overdenture|Placement of an implant in the mandibular midline.
218975196|NCT03463174|OTHER|Mandibular complete denture|No intervention.
218975197|NCT00215748|DRUG|Dexamethasone|
218975198|NCT04329442|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
218975199|NCT01129674|DRUG|LY2140023|Administered orally, twice daily for 104 weeks
218975200|NCT01129674|DRUG|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
218975201|NCT01129674|DRUG|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
218975202|NCT01129674|DRUG|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
218975203|NCT01129674|DRUG|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
218975204|NCT03180593|DRUG|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
218975205|NCT04238416|DRUG|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
218975206|NCT04238416|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
218975207|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
218975208|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
219066580|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
219066581|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
219066582|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
219066583|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
219666547|NCT03816852|BIOLOGICAL|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
219666548|NCT00691639|OTHER|Blood Collection Only|Blood Collection Only
218975209|NCT05883683|OTHER|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
218975210|NCT05870293|BEHAVIORAL|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
218975211|NCT00234234|DRUG|Adalimumab|
218975212|NCT05371678|OTHER|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
218975213|NCT05371678|OTHER|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
218975214|NCT03711266|BEHAVIORAL|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
218975215|NCT03366779|DEVICE|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
218975216|NCT01646073|BIOLOGICAL|Adalimumab|adalimumab eow
218975217|NCT01646073|BIOLOGICAL|placebo|placebo
218975218|NCT00259454|BEHAVIORAL|In-home intervention|occupational therapy techniques to reduce caregiver stress
218975219|NCT05841836|DEVICE|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
218975220|NCT05841836|DEVICE|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
218975221|NCT04040244|OTHER|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
218975222|NCT04040244|OTHER|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
218975223|NCT04210583|DEVICE|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
219066584|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
219666549|NCT02990351|PROCEDURE|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
219666550|NCT05545345|PROCEDURE|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
219666551|NCT05545345|PROCEDURE|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
219666552|NCT03647605|BEHAVIORAL|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
218975224|NCT02103712|OTHER|Qualitative|
218975225|NCT00079768|DRUG|Alemtuzumab (Campath)|
218975226|NCT01747226|OTHER|Fluoride rinse|rinse with 15 ml for 1 minute
218975227|NCT01747226|OTHER|Halita|rinsing with 15 ml for 1 minute
218975228|NCT01747226|OTHER|Meridol Halitosis|rinsing with 15 ml for 1 minute
218975229|NCT01747226|OTHER|Water|rinsing with 15ml for 1 minute
218975230|NCT04470271|OTHER|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
218975231|NCT02697487|OTHER|No treatment|This is an observational study with no intervention.
218975232|NCT03500575|DEVICE|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
219666553|NCT06614842|BEHAVIORAL|Common Factors Group Psychotherapy|This intervention will not contain active ingredients from established specific forms of psychotherapy (e.g., cognitive-behavioral therapy, dialectical behavioral therapy)
219666554|NCT03035006|DRUG|Lipotecan|Lipotecan based concurrent chemoradiotherapy
219666555|NCT06767423|BEHAVIORAL|Text Message + Automated Caller (Intervention)|Standard text message appointment reminders to English and Spanish-speaking patients. Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment. If patient has not confirmed their appointment after the 3-week and 3-day reminders they will receive an automated caller.
219666556|NCT06890650|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
219666557|NCT06890650|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
219666558|NCT06890650|OTHER|Crohns disease exclusion diet|The modified diet plan will be given to each study participant
219666559|NCT06890650|OTHER|Sham diet|Dietary counselling alone
219666560|NCT02149095|DRUG|TransCon PEG treprostinil|
219666561|NCT00970424|DRUG|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
218975233|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
218975234|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
218975235|NCT00875979|DRUG|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
218975236|NCT00366132|DEVICE|Extracorporeal Shockwaves|
218975237|NCT05720208|DEVICE|SCiP|Noninvasive Spinal Cord Neuromodulator
218975238|NCT04926142|DEVICE|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
218975239|NCT04926142|PROCEDURE|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
218975240|NCT06319131|PROCEDURE|TIPS|Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
218975241|NCT06319131|DRUG|Nadroparin|Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
218975242|NCT03938467|DRUG|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
218975243|NCT04214873|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
218975244|NCT00739050|DRUG|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
219066585|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
219066586|NCT05599594|OTHER|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
219666562|NCT00970424|DRUG|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
219666563|NCT04457934|DRUG|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
218975245|NCT00739050|DRUG|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
219066587|NCT02500225|DRUG|Etomidate|0.2 mg/kg etomidate
219066588|NCT02500225|DRUG|Sevoflurane|8% Sevoflurane
219066589|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
218975246|NCT02605785|DRUG|F-18 AV 1451|Tau PET scan
218975247|NCT05780931|BEHAVIORAL|Study-specific rehabilitation (SSR) procedures|Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
218975248|NCT05704010|DEVICE|Video capsule endoscopy|Video capsule endoscopy every 2 years
218975249|NCT05120609|DEVICE|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
219666564|NCT01649310|OTHER|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
219666565|NCT04925284|DRUG|XB002|IV administration of XB002
219666566|NCT04925284|DRUG|Nivolumab|IV administration of Nivolumab
219666567|NCT04925284|DRUG|Bevacizumab|IV administration of bevacizumab
219666568|NCT06850857|OTHER|IMPACT-G Module|Administration of the general IMPACT survey module.
219666569|NCT06850857|OTHER|IMPACT-N Module|Administration of the IMPACT-N survey module.
219666570|NCT06850857|OTHER|IMPACT-O Module|Administration of the IMPACT-O survey module.
219666571|NCT06850857|OTHER|IMPACT-J Module|Administration of the IMPACT-J survey module.
218975250|NCT05120609|DEVICE|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
218975251|NCT04753307|DIAGNOSTIC_TEST|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
218975252|NCT06254378|PROCEDURE|Sinus lifting with allograft|Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
218975253|NCT06254378|OTHER|Sinus lifting without graft|Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
218975254|NCT03378375|OTHER|nutritional assessement|
218975255|NCT00619138|BEHAVIORAL|individual cognitive-behavioural therapy|1 session per week for 12 weeks
218975256|NCT00619138|BEHAVIORAL|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
218975257|NCT02841436|DEVICE|Irreversible Electroporation (IRE) System|
218975258|NCT03275792|DRUG|D5-0.9%NS|Admission for intravascular volume expansion
218975259|NCT03275792|DRUG|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
218975260|NCT02943031|OTHER|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
218975261|NCT01461083|DRUG|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
218975262|NCT02456103|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
218975263|NCT02083081|BEHAVIORAL|Community level intervention|Community intervention plus individual counseling
218975264|NCT01975961|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
218975265|NCT03495037|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
218975266|NCT03495037|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
218975267|NCT03003611|PROCEDURE|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
218975268|NCT03003611|PROCEDURE|general anesthesia|Patient will be anesthetized with a classical general anesthesia
218975269|NCT03149510|BEHAVIORAL|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
218975270|NCT01336296|DRUG|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
218975271|NCT02209831|DEVICE|BIBR 796 BS|single dose
218975272|NCT02209831|DRUG|Pantoprazole|5 days
218975273|NCT02575131|OTHER|whole wheat bread yeast basis|
218975274|NCT02575131|OTHER|Oatmeal|
218975275|NCT02575131|OTHER|Cheerios|
218975276|NCT02575131|OTHER|whole wheat sourdough bread|
218975277|NCT02575131|OTHER|standard breakfast|
218975278|NCT01066403|DRUG|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
218975279|NCT04108676|DRUG|Fluzoparib|PARP inhibitor
218975280|NCT04108676|DRUG|Omeprazole|proton pump inhibitor
218975281|NCT03775031|DEVICE|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
218975282|NCT04504773|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
218975283|NCT04462185|DIAGNOSTIC_TEST|A genomic and transcriptomic landscape analysis|A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
218975284|NCT00602173|DRUG|Cilostazol|
218975285|NCT04493580|BEHAVIORAL|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
218975286|NCT04493580|BEHAVIORAL|In-Person DBT|In-person DBT
218975287|NCT02028871|DRUG|Intranasal Insulin|
218975288|NCT02028871|DRUG|Placebo|
218975289|NCT05140850|BIOLOGICAL|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
219666572|NCT06850857|OTHER|15D Control Survey|Administration of the 15D QOL control survey.
219666573|NCT05029609|DRUG|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
219666574|NCT05029609|DRUG|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
218975290|NCT00520832|DEVICE|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
219666575|NCT06006143|DRUG|Varenicline|All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
219666576|NCT02770768|DRUG|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
219666577|NCT02770768|DRUG|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
219666578|NCT01810783|DRUG|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
219666579|NCT06749392|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
218975291|NCT00520832|DEVICE|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
218975292|NCT00496223|DRUG|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
219666580|NCT03283059|DRUG|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
219666581|NCT03283059|DRUG|Aricept|Aricept 5mg/day, P.O.
219666582|NCT03283059|DRUG|Placebos|Placebo Tablet: P.O. tid
218975293|NCT00496223|DRUG|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
218975294|NCT01360281|OTHER|Neuromuscular Electrical Stimulation|
218975295|NCT01360281|OTHER|ECR|Resisted exercises
218975296|NCT03661710|OTHER|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
218975297|NCT01691898|DRUG|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
218975298|NCT01691898|DRUG|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
218975299|NCT01691898|DRUG|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
218975300|NCT01691898|DRUG|Rituximab|RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
218975301|NCT04911413|DRUG|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
218975302|NCT05005078|DRUG|WST-057|WST-057 topical solution
218975303|NCT05005078|DRUG|Placebo|WST-057 Matching placebo
218975304|NCT04190667|DIAGNOSTIC_TEST|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
218975305|NCT01913223|DEVICE|Nestis® jet injector system with a bi-functional catheter|
218975306|NCT06418750|OTHER|dermo-cosmetic product|For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
218975307|NCT05353309|PROCEDURE|Standard Angioplasty|Angioplasty Iliac done following standard practice
218975308|NCT05353309|PROCEDURE|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
219066590|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
219666583|NCT02134353|DRUG|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
219666584|NCT02134353|DRUG|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
219666585|NCT06905210|DRUG|Placebo of the experimental drug|Subjects randomized to this group will receive one (01) placebo of the experimental drug everyday for 28 weeks.
219666586|NCT06905210|DRUG|Experimental drug|Subjects randomized to this group will receive one (01) experimental drug everyday for 28 weeks.
219666587|NCT06831916|DIETARY_SUPPLEMENT|Active Cannabinoid Product|Participants will be administered a product with minor cannabinoids and terpenes.
219666588|NCT06831916|OTHER|Placebo|Participants will be administered a placebo.
219666589|NCT04735770|PROCEDURE|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
219666590|NCT00477607|DRUG|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
219666591|NCT00477607|BEHAVIORAL|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
219666592|NCT00477607|BIOLOGICAL|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
219666593|NCT00477607|DRUG|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
219666594|NCT03542331|DRUG|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
219666595|NCT03542331|DEVICE|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
219666596|NCT03784794|DIAGNOSTIC_TEST|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
219666597|NCT03784794|DIAGNOSTIC_TEST|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
219666598|NCT03784794|DRUG|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 \< 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
219666599|NCT03784794|DRUG|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT \> 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
219666600|NCT03784794|OTHER|Platelets|PLATELETS EXTEM A5 \< 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 \< 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 \< 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT \< 100/µL PLT \< 100/µL → 1 PLATELET POOL OR APHERESIS; PLT \> 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT \> 100/µL
219666601|NCT03784794|OTHER|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels \< 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb \> 7.5 G/DL"
219666602|NCT03784794|OTHER|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR \< 2.0
219666603|NCT03784794|OTHER|cryoprecipitates|FIBRINOGEN (CLAUSS) \< 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB \< 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB \> 250 MG/DL
219666604|NCT03164655|DRUG|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
219666605|NCT00358956|DRUG|ZD6474 (vandetanib)|100 mg once daily oral tablet
218975309|NCT02938845|BEHAVIORAL|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
218975310|NCT02938845|PROCEDURE|total laparoscopic hysterectomy(TLH)|
218975311|NCT02938845|PROCEDURE|total abdominal hysterectomy(TAH)|
218975312|NCT06352983|PROCEDURE|Fixed dental prosthesis|Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
218975313|NCT02291536|DRUG|tetrahydrocannabinol|
218975314|NCT02291536|DRUG|cannabidiol|
219066591|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
219666606|NCT05387681|DRUG|Envafolimab|short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
219666607|NCT06266156|BEHAVIORAL|Score of anxiety questionnaire|All participants were answered the dental anxiety questionnaire.
219666608|NCT06266156|DIAGNOSTIC_TEST|Heart rate|All participants heart rate were measured with finger type pulse oxymeter.
219666609|NCT06266156|DIAGNOSTIC_TEST|Oxygen saturation|All participants oxygen saturation were measured with finger type pulse oxymeter.
219666610|NCT05432947|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
218975315|NCT02291536|OTHER|placebo|
218975316|NCT02276326|DIETARY_SUPPLEMENT|VSL#3 sachets|4 sachets a day for 4 months
218975317|NCT03459482|OTHER|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
218975318|NCT02225769|OTHER|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
218975319|NCT02225769|OTHER|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
219666611|NCT05432947|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
218975320|NCT00590460|BIOLOGICAL|CAMPATH-1H|Given intravenous on days -8, -7, and -6
218975321|NCT00590460|BIOLOGICAL|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
218975322|NCT00590460|DRUG|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
218975323|NCT00590460|PROCEDURE|Stem cell infusion|Stem cells are infused on day 0
218975324|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
218975325|NCT01070862|DRUG|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
219066592|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
219066593|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
219066594|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
219066595|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
219066596|NCT04315311|DRUG|CREON|Capsule: Oral
219066597|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
219066598|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
219066599|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
219066600|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
219066601|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
219066602|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
219666612|NCT03852927|PROCEDURE|Computer guided contouring|Using virtual planing and rapid prototyping a surgical guide will be fabricated, and will be used for bone contouring of the bone lesion.
219666613|NCT00437827|OTHER|Star*D algorithm|Standard of care based upon the therapies selected in the Star\*D study.
219666614|NCT00437827|OTHER|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
218975326|NCT01070862|DRUG|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
218975327|NCT01070862|DRUG|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
219066603|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
219066604|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
218975328|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
218975329|NCT00001443|DRUG|indinavir (MK-0639)|
219066605|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
219066606|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.
219066607|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.
219666615|NCT00284427|DRUG|vitamin C|IV Vitamin C given 2-3 times a week
219666616|NCT04761081|BEHAVIORAL|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
218975330|NCT04856475|DRUG|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
219066608|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.
219666617|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
219066609|NCT02762526|PROCEDURE|Lipoabdominoplasty|
219066610|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
219066611|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
219066612|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
219066613|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
219066614|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
219066615|NCT01704092|DRUG|Dexmedetomidine|
219066616|NCT03130582|DRUG|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
219066617|NCT05108337|PROCEDURE|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
219066618|NCT05108337|OTHER|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
219066619|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
219066620|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
219066621|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
219066622|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
219066623|NCT01274546|DEVICE|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
219066624|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
219549999|NCT02976064|BEHAVIORAL|Rehabilitation in chronic stable patients in primary care|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease."
219666618|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
219666619|NCT05654428|OTHER|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
218975331|NCT05533476|BEHAVIORAL|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
218975332|NCT05533476|BEHAVIORAL|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
218975333|NCT05664607|OTHER|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
218975334|NCT00000328|DRUG|Opioid-Related Disorders|
218975335|NCT06420128|OTHER|Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
218975336|NCT02378675|OTHER|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
218975337|NCT04375618|DRUG|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
218975338|NCT04375618|DRUG|Plain Collagen|A collagen membrane without FGF-2 will be used.
218975339|NCT04723901|BIOLOGICAL|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
218975340|NCT05560204|DEVICE|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
218975341|NCT00331253|PROCEDURE|Indocyanine Green-Mediated Photothrombosis|
218975342|NCT03775291|DIAGNOSTIC_TEST|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
219066625|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
219066626|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
219066627|NCT02276300|DRUG|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
219066628|NCT02276300|DRUG|Sargramostim|Sargramostim is part of Her2 vaccination
219066629|NCT02276300|DRUG|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
219066630|NCT02276300|DRUG|Imiquimod|Imiquimod is part of Her2 vaccination
219666620|NCT05654428|OTHER|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
219066631|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
219666621|NCT05716854|DRUG|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
219666622|NCT05716854|DRUG|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
219066632|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
219666623|NCT05716854|DRUG|Placebo (Part 1)|Subjects receive matching placebo for treatments.
219666624|NCT05716854|DRUG|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
219666625|NCT05716854|DRUG|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
219666626|NCT05716854|DRUG|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
219666627|NCT05716854|DRUG|Placebo (Part 2)|Subjects receive matching placebo for treatments.
219666628|NCT06225154|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
219666629|NCT04776018|DRUG|TAK-981|TAK-981 IV infusion.
219666630|NCT04776018|DRUG|Mezagitamab|Mezagitamab SC injection.
219666631|NCT04776018|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
219666632|NCT03005431|BEHAVIORAL|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
219666633|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement
219666634|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement
218975343|NCT01104155|DRUG|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
218975344|NCT01104155|DRUG|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
218975345|NCT00975637|DRUG|70 mg SC|70 mg SC
218975346|NCT00975637|DRUG|210 mg SC|210 mg SC
218975347|NCT00975637|DRUG|140 mg SC|140 mg SC
218975348|NCT00975637|DRUG|280 mg SC|280 mg SC
219066633|NCT00098124|DRUG|milnacipran hydrochloride|
219066634|NCT06099171|DRUG|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
219666635|NCT05583643|OTHER|Scaling and debridement only|Scaling and debridement only
219666636|NCT02344797|PROCEDURE|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures \>185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
219666637|NCT02978391|DEVICE|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
218975349|NCT00975637|DRUG|Placebo|Placebo SC
218975350|NCT01484132|PROCEDURE|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
218975351|NCT03176758|DRUG|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
218975352|NCT03176758|DRUG|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
219666638|NCT02978391|DRUG|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
219666639|NCT03870776|DRUG|MAP4343|Daily oral administration of MAP4343
218975353|NCT03176758|DEVICE|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
219666640|NCT03870776|DRUG|Placebo|Daily oral administration of Placebo
219666641|NCT02908074|DRUG|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
219666642|NCT06612463|DIETARY_SUPPLEMENT|Caffeine 6mg/kg|In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day
219666643|NCT06612463|DIETARY_SUPPLEMENT|Placebo|In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
219666644|NCT02602613|DEVICE|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
219666645|NCT01827215|BEHAVIORAL|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
219666646|NCT00093847|DRUG|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
219666647|NCT00093847|DRUG|Placebo|Placebo to be taken daily for 6 weeks
219666648|NCT06618846|PROCEDURE|laparoscopic sleeve gastric bypass|This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
219666649|NCT05236972|DRUG|Sintilimab|Sintilimab 200mg iv drip Q3W
219666650|NCT05236972|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
219666651|NCT05236972|DRUG|capecitabine|1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
219666652|NCT01658592|OTHER|Deep brain stimulation|Stimulator setting is ON
219666653|NCT01658592|OTHER|Placebo|Stimulator setting is OFF
219666654|NCT01189734|PROCEDURE|laparoscopic common bile duct exploration|
218975354|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
218975355|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
218975356|NCT00000671|DRUG|Zidovudine|
218975357|NCT00000671|DRUG|Didanosine|
218975358|NCT03139318|RADIATION|GRID radiotherapy|Patients will be treated with GRID radiotherapy
218975359|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
218975360|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
218975361|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
218975362|NCT01199900|DRUG|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
218975363|NCT01199900|DRUG|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
218975364|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
218975365|NCT01199900|DRUG|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
218975366|NCT03850665|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
219066635|NCT06099171|DEVICE|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
218975367|NCT03850665|PROCEDURE|Anterolateral approach|Anterolateral approach surgery to replace the hip.
218975368|NCT05319769|PROCEDURE|Atrial fibrillation ablation|Pulmonary vein isolation
218975369|NCT02374515|DEVICE|EndoCuff-assisted colonoscopy|Adenoma detection rate
218975370|NCT02374515|DEVICE|Standard Colonoscopy|
218975371|NCT02276365|DRUG|BI 10773|
218975372|NCT02276365|DRUG|Pioglitazone|
218975373|NCT04807140|DRUG|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
218975374|NCT04807140|DRUG|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
219666655|NCT01189734|PROCEDURE|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
219666656|NCT01458717|DRUG|Neoadjuvant chemoradiation|"* Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
218975375|NCT04807140|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
218975376|NCT03799211|BEHAVIORAL|Motivational Interviewing|Phone call using motivational interviewing technique
218975377|NCT03799211|BEHAVIORAL|Treatment as Usual|will receive a regular study phone call after three months
218975378|NCT03182062|PROCEDURE|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
218975379|NCT03182062|PROCEDURE|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
218975380|NCT03182062|PROCEDURE|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
218975381|NCT05432362|OTHER|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
218975382|NCT05432362|OTHER|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
218975383|NCT04743349|PROCEDURE|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
218975384|NCT03509831|DRUG|INT-2150|"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
218975385|NCT03509831|DRUG|Irsogladine maleate 2 mg+Nizatidine 150 mg|"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"
218975386|NCT02826135|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
218975387|NCT00041821|PROCEDURE|Nasal irritation thresholds and irritant provocation|
218975388|NCT04265469|OTHER|Diabetic foot education|Give Diabetic foot education via mobile phone
218975389|NCT00764491|DEVICE|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
218975390|NCT00764491|DEVICE|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
218975391|NCT01922674|PROCEDURE|Standard open tension-free inguinal hernia repair with mesh|
218975392|NCT04777838|DRUG|Citalopram 10 MG|10 mg of citalopram every day
218975393|NCT04777838|DRUG|Amitriptyline|25mg of Amitriptyline every
218975394|NCT04777838|DEVICE|Bite Splint|Night use of occlusal splint
218975395|NCT00002664|BIOLOGICAL|edrecolomab|
218975396|NCT00002664|BIOLOGICAL|sargramostim|
218975397|NCT02693392|DRUG|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents"
218975398|NCT02693392|DIETARY_SUPPLEMENT|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
218975399|NCT00424801|DRUG|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
218975400|NCT00424801|DRUG|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
218975401|NCT00424801|DRUG|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
218975402|NCT00424801|DRUG|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
218975403|NCT00424801|DRUG|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
218975404|NCT00424801|DRUG|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
218975405|NCT00424801|DRUG|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
218975406|NCT06621316|DRUG|HRS-7535 Tablet|at multiple dose levels
218975407|NCT06621316|DRUG|Placebo|at multiple dose levels (matching active arm HRS-7535 Tablet)
218975408|NCT00542971|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily (days 1-3)
218975409|NCT00542971|DRUG|Sorafenib|Starting dose 400 mg by mouth for 7 days
218975410|NCT00542971|DRUG|Ara-C|1.5 g/m\^2 IV over 24 hours daily (days 1-4)
218975411|NCT06216834|OTHER|No intervention|No intervention
218975412|NCT05561374|DRUG|Low-dose OKN-007, BID|Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
218975413|NCT05561374|DRUG|Low-dose OKN-007, TID|Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
219066636|NCT02730819|DRUG|Illuminate Cream|Topical compound applied daily
219066637|NCT02446561|DRUG|MRXXX|
219066638|NCT02446561|DRUG|MR1XXX|
219066639|NCT02446561|DRUG|MR2XXX|
219066640|NCT02446561|DRUG|MR3XXX|
219066641|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
219666657|NCT01458717|PROCEDURE|Upfront surgery|"* Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
219666658|NCT05296200|DEVICE|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
219666659|NCT03572361|BIOLOGICAL|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
219666660|NCT03403621|DRUG|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
219666661|NCT03403621|DRUG|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
219666662|NCT00583102|DRUG|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
219666663|NCT00583102|DRUG|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
219666664|NCT06910332|OTHER|Joint mobilization|Participants receive passive shoulder joint mobilization on the dominant-side glenohumeral joint. The mobilization includes inferior, anterior, and posterior glide techniques, each performed for 1 minute at a frequency of 0.5 Hz, with a 30-second rest between each mobilization. The participant is positioned comfortably to support the joint's range of motion.
218975414|NCT05561374|DRUG|Mid-dose OKN-007, TID|Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
218975415|NCT05561374|DRUG|High-dose OKN-007, TID|Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
218975416|NCT00447317|BEHAVIORAL|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
218975417|NCT00447317|BEHAVIORAL|Attention control|Standard peritoneal dialysis dietary education
218975418|NCT02484287|DEVICE|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
218975419|NCT02484287|DEVICE|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
218975420|NCT02484287|DEVICE|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
218975421|NCT02979717|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|
218975422|NCT02979717|OTHER|Low protein, low fiber comparator|
218975423|NCT01248845|OTHER|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
218975424|NCT03654443|DIAGNOSTIC_TEST|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
218975425|NCT04524169|DRUG|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
218975426|NCT02355496|OTHER|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
218975427|NCT05869565|DRUG|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
218975428|NCT02344615|PROCEDURE|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
218975429|NCT02344615|PROCEDURE|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
218975430|NCT00896636|PROCEDURE|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
219666665|NCT06910332|OTHER|Sham|In the sham intervention, the practitioner mimics the technique of shoulder mobilization but does not apply any actual movement or glide effect on the joint. The procedure is designed to closely resemble the real intervention in terms of duration, rhythm, and the practitioner's handling of the participant's shoulder. The practitioner will use superficial touch on the glenohumeral joint without applying any of the mobilizing forces necessary to move the joint.
219666666|NCT01093651|DRUG|Sitagliptin|100 mg sitagliptin daily for 4-6 months
219666667|NCT01093651|DRUG|Placebo|Daily placebo for 4-6 months
219686655|NCT03182790|BEHAVIORAL|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
218975431|NCT00896636|OTHER|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
218975432|NCT02066220|RADIATION|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
218975433|NCT02066220|DRUG|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
218975434|NCT02066220|RADIATION|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
218975435|NCT02066220|DRUG|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
218975436|NCT02066220|RADIATION|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
218975437|NCT02066220|RADIATION|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
218975438|NCT02066220|DRUG|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
218975439|NCT02066220|RADIATION|SHH-TP53 M0|"* with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
218975440|NCT02066220|RADIATION|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
218975441|NCT02066220|RADIATION|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
218975442|NCT02066220|DRUG|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
218975443|NCT02121990|DRUG|Paclitaxel,|
218975444|NCT02121990|DRUG|Bevacizumab|
218975445|NCT02121990|DRUG|Cisplatin|
218975446|NCT02121990|DRUG|Olaparib|
218975447|NCT00837928|DRUG|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
219666668|NCT06909903|PROCEDURE|Autogenous drainage of sputum caused by hypertonic saline in adolescents with cystic fibrosis.|"The procedure will be performed at the same session as follows :~* 30 minutes of autogenous drainage, followed by collection of secretions.~* 10 minutes of HSS followed by 30 minutes of autogenous drainage before secretions are collected.~The intervention first step involves verifying patient tolerance to Hypertonic saline solution nebulization (Auscultation, peak flow, saturtion levels), followed by the inhalation of 2 puffs of Ventolin® to prevent bronchospasm. Ten minutes later, the patient undergoes a 10-minute nebulization of 4 mL SSH 6% carried out according to the HAS recommendations.~The patient tolerance to SSH is reassessed. If there are no adverse reactions, the patient continues the protocol. If issues like wheezing, a ≥5% drop in SpO2, or a ≥20% drop in Peak Flow occur, 4 more puffs of Ventolin® are given, and the patient is reassessed.If still intolerant, the patient exits the study.~The session ends with physiotherapy (autogenous drainage) to aid mucus clearance."
218975448|NCT00837928|OTHER|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
219066642|NCT03372226|BEHAVIORAL|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
218975449|NCT00837928|PROCEDURE|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
219066643|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
219066644|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
219066645|NCT01660906|DRUG|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
219066646|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
219066647|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
219066648|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
219208529|NCT06893913|BEHAVIORAL|pyramidal training plus intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days.~also this group will receive a pyramidal training nearly 60 minutes (nearly two rounds of 21 minutes of running on treadmill will be separated with 10 min of rest between the two rounds. Also, warming (4 min before start of pyrimidal trianing) and cooling (4 minu after pyramidal training) will be done through gentle stretching. the exercise will be applied 3 times weekly for 12 weeks"
219208530|NCT06893913|BEHAVIORAL|intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days."
219666669|NCT06912503|DEVICE|Device to deliver trial restoration matrix|"Auto-polymerization bisacrylic material (Luxatemp Star, DMG) was used to perform the trial restoration for condensation silicone matrix, addition PVS-silicone matrix with external resin-based shell and CAD/CAM combination matrix. Light-cured flowable composite-resin (Filtek Flow, 3M Dental Products) was used to perform the trial restoration for transparent addition PVS-silicone matrix. The rationale behind using different material stands on the material selection usually chosen by clinicians for each matrix.~In the same appointment 4 trial restorations were performed to each patient using the four different matrixes."
219686656|NCT03182790|BEHAVIORAL|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
218975450|NCT00837928|RADIATION|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
218975451|NCT00208299|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
218975452|NCT00208299|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
218975453|NCT03139279|DRUG|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
218975454|NCT03139279|OTHER|Saline placebo|Intravenous saline/placebo
219686657|NCT03182790|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
219686658|NCT03182790|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
219066649|NCT03478891|BIOLOGICAL|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
219066650|NCT05794867|DIAGNOSTIC_TEST|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
219066651|NCT04979819|OTHER|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
219066652|NCT03385876|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
219666670|NCT06911853|OTHER|Virtual Reality Videos|Based on the Phase of Engagement Framework, two online orthopaedic modules focusing on interprofessional and intercultural educations on low back pain (LBP) and adolescent idiopathic scoliosis (AIS) were developed. The students (n=104) were randomized into two groups. In the first module, the Virtual Reality Group as the intervention group received a virtual reality (VR)-enhanced LBP education, while the Case-based Learning Group as the control group engaged with a case study on LBP. After a 3-week washout period, the groups crossed over: the the Virtual Reality Group as the intervention group received the VR-enhanced education on AIS, and the Case-based Learning Group as the control group focused on an AIS case study.
219666671|NCT06912347|OTHER|Intervention Group|Starting 24 hours before pre-treatment, you will receive herbal fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 5 minutes. Additionally, starting 30 minutes after each meal, acupoint application will be performed on five acupoints: Shenque (CV8), Tianshu (ST25), and bilateral Zusanli (ST36). The application will last 4 hours per day.
219666672|NCT06912347|OTHER|control group|Starting 24 hours before pre-treatment, you will receive povidone-iodine warm water fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 15 minutes.
219666673|NCT06910098|DRUG|Rosuvastatin|a dose of 5mg were given and were compared for the cpk, ast and ldl levels
219666674|NCT06910098|DRUG|Rosuvastatin|a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
219666675|NCT06910098|DRUG|Rosuvastatin|a dose of 20 mg were given and were compared for the cpk, ast and ldl levels
218975455|NCT03139279|DRUG|Propofol|Propofol titrated intravenous boluses
218975456|NCT00486174|DRUG|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
218975457|NCT01223638|OTHER|Audiometry|Audiometry
218975458|NCT00402142|BIOLOGICAL|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
218975459|NCT00402142|BIOLOGICAL|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
219666676|NCT06911528|PROCEDURE|EndoScell Scaner (ES) novel intraoperative cellular probing technology|In this project, we utilize the miniature wide-angle focusing microscope for intraoperative cell-level observation and detection, a technology in which our hospital has conducted extensive research and accumulated rich experience.
219666677|NCT06109376|PROCEDURE|hypothermia|In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
219666678|NCT06109376|PROCEDURE|thrombectomy|Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
219666679|NCT03376191|DRUG|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
218975460|NCT00402142|BIOLOGICAL|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
218975461|NCT00402142|BIOLOGICAL|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
218975462|NCT00402142|BIOLOGICAL|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
218975463|NCT02354183|BEHAVIORAL|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
218975464|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
218975465|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
218975466|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
219666680|NCT03611582|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
219666681|NCT03611582|DRUG|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
219666682|NCT03127813|OTHER|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
218975467|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
218975468|NCT03866187|BIOLOGICAL|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
219208531|NCT06744049|DEVICE|Transfer Direct System (TDS)|Class IIA medical device (according to rule 5 of Annex VIII of Regulation (EU) 2017/745 for medical devices). A semi-automated medical equipment designed to inject an embryo into the maternal uterine endometrium through the lumen of the female reproductive system.
219666683|NCT00000298|DRUG|Buprenorphine/naloxone|
219666684|NCT05995405|DRUG|GTX-104|Nimodipine IV infusion
219666685|NCT05995405|DRUG|Nimotop 30 MG Oral Capsule|Oral nimodipine capsules
219666686|NCT04459598|DRUG|Efavirenz|Single oral dose, 600-mg tablet
219666687|NCT04459598|DRUG|Quizartinib|Single oral dose, 60 mg (2 x 30 mg) tablets
219666688|NCT05658952|OTHER|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
219666689|NCT05658952|OTHER|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
218975469|NCT03866187|BIOLOGICAL|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
218975470|NCT03866187|DRUG|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
218975471|NCT03182803|BIOLOGICAL|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
218975472|NCT02890667|OTHER|Incident cancer|The number of incident cancer cases
218975473|NCT01460368|DRUG|LY2409021|Administered orally
218975474|NCT01460368|DRUG|Placebo|Administered orally
218975475|NCT01460368|DRUG|Moxifloxacin|Administered orally
218975476|NCT02866994|BEHAVIORAL|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
218975477|NCT02866994|BEHAVIORAL|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
218975478|NCT00629174|BEHAVIORAL|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
218975479|NCT00629174|BEHAVIORAL|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
218975480|NCT04529915|DIAGNOSTIC_TEST|Exosome sampling|"* Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis"
218975481|NCT01516229|DRUG|somatropin|Prescription of somatropin at the discretion of the physician
218975482|NCT05235139|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
218975483|NCT05235139|DEVICE|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
218975484|NCT00147758|DRUG|Colesevelam hydrochloride|
218975485|NCT05019794|DRUG|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
218975486|NCT05126498|OTHER|no intervention|no intervention was applied
218975487|NCT00273910|DRUG|gp100:209-217 (210M)|
218975488|NCT00273910|DRUG|Montanide ISA-51|
218975489|NCT00273910|DRUG|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
218975490|NCT05177133|DRUG|Capecitabine|PO Capecitabine
218975491|NCT05177133|DRUG|Oxaliplatin|IV Oxaliplatin
218975492|NCT05177133|DRUG|Retifanlimab|IV retifanlimab
219066653|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
219066654|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
219208532|NCT06759298|DRUG|methylphenidate|patient group will recieve methylphenidate
219666690|NCT05658952|OTHER|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
219666691|NCT05768009|PROCEDURE|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
218975493|NCT03300323|DIAGNOSTIC_TEST|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
218975494|NCT04753476|BIOLOGICAL|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
218975495|NCT04753476|DRUG|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
218975496|NCT05579925|BIOLOGICAL|CM310|CM310 600 mg + 300 mg, subcutaneous injection
218975497|NCT05058352|DRUG|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
218975498|NCT04025983|DIETARY_SUPPLEMENT|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
218975499|NCT04025983|OTHER|Placebo|The placebo contains neither IgY nor L. johnsonii.
218975500|NCT04559360|DEVICE|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
219666692|NCT01078298|DRUG|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
219666693|NCT01078298|DRUG|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
219666694|NCT04908202|DRUG|Deucravacitinib|Specified dose on specified days
218975501|NCT06207968|DEVICE|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
219066655|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
219066656|NCT00060450|DRUG|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
219666695|NCT04908202|OTHER|Placebo|Specified dose on specified days
219666696|NCT00866333|DRUG|Entinostat|Entinostat tablets
219066657|NCT00060450|DRUG|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
219066658|NCT06052501|PROCEDURE|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
219066659|NCT00845572|BEHAVIORAL|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
219066660|NCT05457946|BIOLOGICAL|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
219066661|NCT05457946|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
219666697|NCT03252197|DEVICE|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
219666698|NCT03252197|DEVICE|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
219666699|NCT02095405|DRUG|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
219666700|NCT02095405|OTHER|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
218975502|NCT02620007|DRUG|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
218975503|NCT02620007|DRUG|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
218975504|NCT02620007|DRUG|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
218975505|NCT02620007|DRUG|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
218975506|NCT05075382|PROCEDURE|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
218975507|NCT01244945|DIETARY_SUPPLEMENT|L. reuteri DSM 17938|L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
219066662|NCT04617028|DRUG|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
219066663|NCT04617028|DRUG|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
219066664|NCT04617028|DRUG|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
219066665|NCT04617028|DRUG|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
219066666|NCT00119509|PROCEDURE|HPV DNA testing|
219066667|NCT00119509|PROCEDURE|Conventional management (repeat Pap smear at 6 months)|
219066668|NCT00119509|PROCEDURE|Decision aid with choice of management|
219066669|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
219066670|NCT05709743|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
219066671|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
219066672|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
219066673|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
219066674|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
218975508|NCT01244945|OTHER|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
219666701|NCT01108237|OTHER|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
219666702|NCT01108237|DEVICE|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
219666703|NCT02851316|OTHER|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
219666704|NCT01829997|DEVICE|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
219686659|NCT03182790|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
218975509|NCT04733144|DRUG|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
218975510|NCT04733144|DRUG|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
218975511|NCT05055453|DEVICE|MyPhonak Junior App|The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
218975512|NCT05055453|DEVICE|Phonak Sky hearing aid|A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
218975513|NCT03796832|DEVICE|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
218975514|NCT03796832|DEVICE|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
218975515|NCT03796832|OTHER|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
218975516|NCT04669327|OTHER|gait analysis|Vicon nexus with MTI force plate form
218975517|NCT05276154|OTHER|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
218975518|NCT03169309|DEVICE|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
218975519|NCT01224665|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
218975520|NCT01224665|PROCEDURE|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
218975521|NCT01224665|PROCEDURE|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
218975522|NCT05389046|DRUG|Escitalopram|Escitalopram
218975523|NCT05389046|DRUG|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
218975524|NCT05389046|DRUG|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
218975525|NCT05389046|DRUG|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
218975526|NCT05726916|DRUG|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
218975527|NCT05726916|DRUG|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
218975528|NCT06170203|OTHER|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
218975529|NCT02427828|DEVICE|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
218975530|NCT00810381|DRUG|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
218975531|NCT00810381|DRUG|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
218975532|NCT00810381|DRUG|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
218975533|NCT00810381|DRUG|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
219066675|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
219686660|NCT03182790|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
219686661|NCT03182790|BEHAVIORAL|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
219686662|NCT03182790|BEHAVIORAL|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
219666705|NCT05003830|DEVICE|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
219666706|NCT05029245|BIOLOGICAL|Comirnaty®|intradermal injection or intramuscular injection
219666707|NCT00370435|DRUG|GW274150|
219666708|NCT02446535|OTHER|achievement of the DW by means of the BIA DW (RE.S.T.)|
218975534|NCT04185376|OTHER|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
218975535|NCT04398316|DRUG|Lidocaine Iv|2 mg/kg over 5 minutes
218975536|NCT04398316|DRUG|HYDROmorphone Injection|1 mg over 5 minutes
218975537|NCT02463968|PROCEDURE|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
219066676|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
219066677|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
219066678|NCT00346008|GENETIC|mutation analysis|
219066679|NCT00346008|OTHER|high performance liquid chromatography|
219066680|NCT00346008|OTHER|laboratory biomarker analysis|
219066681|NCT00346008|OTHER|questionnaire administration|
219066682|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
219066683|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
218975538|NCT02463968|PROCEDURE|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
218975539|NCT00154492|DRUG|activated recombinant human factor VII|
218975540|NCT05210231|OTHER|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
218975541|NCT03624231|DRUG|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
218975542|NCT03624231|DRUG|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
219066684|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
219066685|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
219066686|NCT03763422|DRUG|Temozolomide|Oral Administration of Temozolomide
219066687|NCT03763422|RADIATION|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
219066688|NCT03763422|PROCEDURE|Surgery|Surgery
219066689|NCT03813446|DEVICE|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
219066690|NCT02945384|BEHAVIORAL|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
219066691|NCT03579329|PROCEDURE|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
219066692|NCT02803775|DEVICE|CRT Algorithm|Programming based on Electrogram measurement
219066693|NCT06454032|BEHAVIORAL|Fitness walking|Fitness walking for 12 weeks.
219208533|NCT06759298|DRUG|matched placebo tablet|placebo gtoup will recieve matched placebo tablet
219208534|NCT06751108|DRUG|Corticosteroids (CS)|Concomitant use of immune checkpoint inhibitors and corticosteroids
219666709|NCT05223803|RADIATION|Prostate radiation (XRT)|Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.
219666710|NCT05223803|DRUG|Systemic Therapy|All systemic therapy is provided as best prescribed for patient per their medical oncologist.
219666711|NCT05223803|RADIATION|Stereotactic ablative radiation therapy (SABR)|SABR is delivered to those randomized to Arm 2.
219666712|NCT01100190|DEVICE|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
219666713|NCT06321497|DEVICE|Extracorporeal carbon dioxide removal|Low flow extracorporeal carbon dioxide removal with PrismaLung+
219666714|NCT05712837|DRUG|25% TRICHLOROACETIC ACID|Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
219666715|NCT05712837|DRUG|30% salicylic acid|Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
219666716|NCT04185584|OTHER|Not Applicable (Observational Study)|Not Applicable (Observational Study)
219666717|NCT01071434|PROCEDURE|MR Imaging|
219666718|NCT05742074|OTHER|Faecal microbiota transplantation|25-30 capsules of faecal material
219666719|NCT05742074|OTHER|Placebo|25-30 placebo capsules
218975543|NCT03624231|RADIATION|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
218975544|NCT00857428|DRUG|oxymorphone|Tablets
218975545|NCT00857428|DRUG|Oxymorphone|40 mg tablets
218975546|NCT01565642|BEHAVIORAL|Goals of care decision support|Decision aid and care plan meeting
218975547|NCT02608203|DRUG|[68Ga]-DOTANOC PET/CT|
218975548|NCT03784417|DEVICE|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
218975549|NCT00156702|BEHAVIORAL|Feedback and Motivational Interviewing|
218975550|NCT00156702|BEHAVIORAL|Smoking Prevention Video|
218975551|NCT01580514|DRUG|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
218975552|NCT01580514|DRUG|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
218975553|NCT01488500|OTHER|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
218975554|NCT00213408|PROCEDURE|Radiofrequency catheter ablation of typical atrial flutter|
218975555|NCT05678582|DIAGNOSTIC_TEST|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
218975556|NCT01898208|DEVICE|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
218975557|NCT01898208|BEHAVIORAL|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
218975558|NCT01898208|OTHER|Bacterial culture|This test identifies the pathogen responsible for an infection.
218975559|NCT01898208|OTHER|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
218975560|NCT05986760|BEHAVIORAL|SPARK|Functional Motor training
219208535|NCT06751108|DRUG|Immune Checkpoint Inhibitors|Non-concomitant use of corticosteroids
219208536|NCT06746493|OTHER|Rehabilitation|People after a stroke participated in a standard rehabilitation process carried out at the neurological rehabilitation department.
218975561|NCT01631812|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
218975562|NCT03469388|DIAGNOSTIC_TEST|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
218975563|NCT02496065|DRUG|BLZ-100|
218975564|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TEA LIQUID PACKETS|JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
219666720|NCT00930527|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|4g per day for 3 weeks
219666721|NCT05273905|DIAGNOSTIC_TEST|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
219666722|NCT00564278|DRUG|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
219666723|NCT00564278|BEHAVIORAL|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
219666724|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Rind|watermelon rind
219666725|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Flesh|watermelon flesh
219666726|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Seeds|watermelon seeds
219666727|NCT03365960|DIETARY_SUPPLEMENT|Placebo|Control Comparator
219666728|NCT02333500|OTHER|olfactory workshop|olfactory workshop
219666729|NCT02333500|OTHER|other workshop|other workshop: discussion group, dance and body Expression
219666730|NCT02333500|OTHER|No intervention|control group
219666731|NCT05962788|DRUG|voclosporin|Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
218975565|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TANG HENG POWDER DRINK|JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
219066694|NCT06454032|BEHAVIORAL|Maintained lifestyle|Maintained their normal lifestyle, without exercise intervention.
219066695|NCT01314040|OTHER|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
219066696|NCT01314040|OTHER|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
219066697|NCT01314040|OTHER|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
219066698|NCT01314040|OTHER|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
219066699|NCT01903538|DEVICE|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
219066700|NCT01903538|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
219066701|NCT00203359|DRUG|etanercept given by perispinal administration|
219066702|NCT02301702|BIOLOGICAL|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
218975566|NCT05890742|DRUG|Sintilimab|In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
218975567|NCT05890742|DRUG|IBI310&Sintilimab|In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
218975568|NCT05890742|PROCEDURE|Radical surgery|In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
218975569|NCT05781373|PROCEDURE|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
218975570|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
218975571|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
218975572|NCT00715455|DRUG|Unfractionated Heparin|Heparin will be administered per standard of care at sites
218975573|NCT03513523|DIETARY_SUPPLEMENT|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
218975574|NCT03513523|DIETARY_SUPPLEMENT|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
219066703|NCT02301702|BIOLOGICAL|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
219066704|NCT01881139|BEHAVIORAL|exercise training|
219066705|NCT00136955|DRUG|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
219066706|NCT06223412|BEHAVIORAL|video-based climate change program|The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.
219066707|NCT06094088|BEHAVIORAL|Heated Yoga|Heated yoga described in arm/group description
219066708|NCT06094088|BEHAVIORAL|Non-Heated Yoga|Non-heated yoga described in arm/group description
218975575|NCT03513523|OTHER|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
218975576|NCT02435069|DRUG|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
219066709|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
218975577|NCT02435069|DRUG|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
218975578|NCT02682771|DEVICE|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
218975579|NCT02682771|DEVICE|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
218975580|NCT02682771|PROCEDURE|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
218975581|NCT01242683|BEHAVIORAL|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
218975582|NCT02800902|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
218975583|NCT02800902|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
218975584|NCT02800902|DRUG|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
218975585|NCT04407052|DRUG|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
218975586|NCT04407052|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
218975587|NCT03588871|OTHER|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
218975588|NCT03588871|OTHER|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
218975589|NCT03588871|OTHER|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
218975590|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
218975591|NCT03588871|OTHER|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
218975592|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
218975593|NCT02994134|BEHAVIORAL|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
218975594|NCT02994134|BEHAVIORAL|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
218975595|NCT06151431|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
219066710|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
219066711|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
218975596|NCT06151431|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
218975597|NCT06520670|DIAGNOSTIC_TEST|Urinary galectin-3 binding protein|Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
218975598|NCT05303077|DIETARY_SUPPLEMENT|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
218975599|NCT05303077|DIETARY_SUPPLEMENT|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
218975600|NCT05303077|DIETARY_SUPPLEMENT|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
218975601|NCT01854996|DRUG|PF-05089771|450mg
218975602|NCT01854996|DRUG|PF-05089771|450mg
218975603|NCT01854996|DRUG|PF-05089771|450mg
218975604|NCT04021420|DEVICE|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
219066712|NCT05678634|BEHAVIORAL|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
219066713|NCT05678634|BEHAVIORAL|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
219066714|NCT05678634|BEHAVIORAL|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
219066715|NCT05678634|BEHAVIORAL|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
219066716|NCT05678634|BEHAVIORAL|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
219066717|NCT05678634|BEHAVIORAL|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
219066718|NCT00811148|PROCEDURE|Tissue Bank|Collection of clinical data and tumor tissue.
219066719|NCT01724138|DRUG|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
219066720|NCT02374827|PROCEDURE|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
219066721|NCT02374827|PROCEDURE|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
219066722|NCT05462366|OTHER|Sample collection|Collect breast-milk and feces from mother-infant-pairs.
219066723|NCT02194049|DRUG|BKM120|Given PO
219066724|NCT02194049|DRUG|cisplatin|Given IV
219066725|NCT02194049|DRUG|etoposide|Given IV
219066726|NCT04425083|OTHER|no intervention|no intervention
219066727|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
219066728|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
219066729|NCT05349617|BIOLOGICAL|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
219066730|NCT05349617|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
219066731|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
219066732|NCT05032703|DEVICE|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
219208537|NCT06745245|DIETARY_SUPPLEMENT|Nutritional counseling and supplementation with a gelatin with prebiotic fiber and probiotic microorganisms|One serving (15 g) of symbiotic gelatin
218975605|NCT04021420|DRUG|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
218975606|NCT02643173|OTHER|Volatile anesthetics|
218975607|NCT02643173|OTHER|Intravenous anesthetics|
218975608|NCT02436681|DEVICE|MIROMESH|
218975609|NCT01498601|OTHER|Enhanced oral care protocol|"* Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care"
218975610|NCT02030938|DEVICE|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
218975611|NCT01879514|DRUG|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
218975612|NCT01879514|DRUG|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
219208538|NCT06739720|DRUG|LingZhi capsule|Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
218975613|NCT00819299|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
218975614|NCT00752544|DRUG|TMC435350|
218975615|NCT00805701|DRUG|avodart|0.5 avodart once daily for 13 weeks
218975616|NCT00805701|DRUG|Placebo|placebo
218975617|NCT01599832|DRUG|pazopanib hydrochloride|Given PO
218975618|NCT01599832|OTHER|laboratory biomarker analysis|Correlative studies
218975619|NCT01599832|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
218975620|NCT01599832|OTHER|pharmacogenomic studies|Correlative studies
218975621|NCT02571036|DRUG|DCC-2618|50 mg formulated tablets
218975622|NCT02571036|DRUG|DCC-2618|10 mg and 50 mg formulated tablets
218975623|NCT05293015|OTHER|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
218975624|NCT00046514|DRUG|ABI-007|
219066733|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
219066734|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
219066735|NCT02370212|DIETARY_SUPPLEMENT|Creatine|
219066736|NCT02370212|DIETARY_SUPPLEMENT|Placebo|
219066737|NCT02370212|OTHER|High intensity interval training|
218975625|NCT00000663|DRUG|CD4-IgG|
218975626|NCT05882188|PROCEDURE|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
218975627|NCT05882188|PROCEDURE|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
218975628|NCT00000432|BEHAVIORAL|Education about disease prevention|
218975629|NCT03169686|BEHAVIORAL|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
218975630|NCT00399620|PROCEDURE|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
218975631|NCT05186285|DRUG|CM338|CM338 : a humanized monoclonal antibody.
218975632|NCT05186285|DRUG|Placebo|Placebo.
218975633|NCT05770583|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
218975634|NCT05770583|PROCEDURE|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
218975635|NCT00334607|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
218975636|NCT04017000|DIAGNOSTIC_TEST|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
218975637|NCT04017000|OTHER|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
218975638|NCT01480648|DRUG|BI 144807 Placebo|Placebo that represents BI drug
218975639|NCT01480648|DRUG|BI 144807|single dose (low to high dose)
218975640|NCT00121095|DRUG|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
218975641|NCT02359344|DRUG|CNV1014802|
218975642|NCT02359344|DRUG|Placebo|
218975643|NCT03954132|DRUG|Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
218975644|NCT03954132|DRUG|Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
218975645|NCT05508997|DEVICE|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
218975646|NCT00005673|DRUG|Capravirine|
218975647|NCT05250128|PROCEDURE|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
218975648|NCT05933824|DRUG|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
218975649|NCT00302263|DRUG|Metobes-compound|
218975650|NCT03676335|DRUG|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
218975651|NCT03676335|DRUG|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
218975652|NCT03676335|DRUG|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
218975653|NCT05354154|PROCEDURE|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
218975654|NCT02035501|DRUG|L-Tyrosine|
218975655|NCT02035501|DRUG|Placebo|
218975656|NCT06560619|BEHAVIORAL|MENTOR|Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
218975657|NCT00662220|DRUG|ribavirin|25-29 mg/kg/day
218975658|NCT00662220|DRUG|ribavirin|12-15 mg/kg/day
218975659|NCT03107663|DRUG|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
218975660|NCT03512899|PROCEDURE|Right internal jugular access.|Implantation using percutaneous puncture.
218975661|NCT03512899|PROCEDURE|Left internal jugular access.|Implantation using percutaneous puncture.
218975662|NCT03512899|PROCEDURE|Right axillary vein access.|Implantation using percutaneous puncture.
218975663|NCT03512899|PROCEDURE|Left axillary vein access.|Implantation using percutaneous puncture.
218975664|NCT02869997|DEVICE|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
218975665|NCT05097612|DEVICE|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
218975666|NCT05097612|DEVICE|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
219066738|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
219066739|NCT04381026|DIETARY_SUPPLEMENT|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
218975667|NCT05097612|DEVICE|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
218975668|NCT05097612|DEVICE|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
218975669|NCT05500547|OTHER|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
218975670|NCT02812173|DEVICE|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
219066740|NCT04381026|DIETARY_SUPPLEMENT|Placebo|Filler agent
219066741|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
219066742|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
219066743|NCT00536133|DRUG|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
219066744|NCT00536133|OTHER|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
219066745|NCT01759589|DRUG|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
219066746|NCT01759589|DRUG|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
219066747|NCT01759589|DRUG|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
219066748|NCT05869305|DIETARY_SUPPLEMENT|whey protein isolate|Take 1 sachet/day for 12 weeks.
219666732|NCT06439095|GENETIC|Salivary Collection|Expression levels of IL-2, IL-5 and IL-17 in the saliva of individuals aged 3-9 years who underwent stainless steel crown will be recorded before and after the procedure. Before the saliva sample collection procedure, the patient will be asked to rinse their mouth with sterile water and then spit into sterile plastic cups. After collecting approximately 3 ml of saliva, the saliva will be transferred to appropriate eppendorfs and stored at -40 degrees Celsius. For the second post-procedure, the same algorithms will be applied for saliva collection seven days after the crown procedure.
219666733|NCT06439095|DIAGNOSTIC_TEST|Ph and ion level measurement of saliva|Salivary concentration of nickel, chrome ions will be measured using an atomic absorption spectrophotometer.
219666734|NCT06445647|OTHER|core Stability exercise|core stability exercise training
219666735|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
219666736|NCT04544189|DRUG|Alpelisib|300mg (oral) once daily, in a 28-day cycle
218975671|NCT02812173|DEVICE|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
218975672|NCT02812173|DEVICE|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
219666737|NCT04544189|DRUG|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
219666738|NCT04544189|DRUG|Placebo|300 mg by mouth once daily, in a 28-day cycle
219666739|NCT03789591|DRUG|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg\*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
219666740|NCT05564689|PROCEDURE|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
219666741|NCT05978232|BEHAVIORAL|NAVAH|Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
219666742|NCT06216093|BIOLOGICAL|EuRSV|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
219666743|NCT06216093|OTHER|Placebo Comparator|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
218975673|NCT02883166|DRUG|abiraterone|integested with a continental breakfast
218975674|NCT03838146|BEHAVIORAL|Types of Exercise|moderate intensity exercise
219066749|NCT05869305|DIETARY_SUPPLEMENT|isolated soy protein|Take 1 sachet/day for 12 weeks.
219066750|NCT05869305|DIETARY_SUPPLEMENT|placebo|Take 1 sachet/day for 12 weeks.
219066751|NCT00993447|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
219066752|NCT00993447|BIOLOGICAL|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
219066753|NCT01820728|DRUG|DA-3801 Injection|
219066754|NCT01820728|DRUG|Gonal-F®|
219066755|NCT05409014|OTHER|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
219666744|NCT03341936|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
219666745|NCT03341936|DRUG|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
218975675|NCT00834678|DRUG|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
218975676|NCT00834678|DRUG|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
218975677|NCT00834678|DRUG|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
218975678|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
218975679|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
218975680|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
218975681|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
218975682|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
218975683|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
219666746|NCT02368886|DRUG|Clobetasol Propionate|Given topically
219666747|NCT02368886|OTHER|Pharmacological Study|Correlative studies
219666748|NCT02368886|OTHER|Quality-of-Life Assessment|Ancillary studies
219666749|NCT02368886|DRUG|Regorafenib|Given PO
219666750|NCT05680337|DEVICE|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
219666751|NCT06564428|GENETIC|Suspective gene mutations and family history|To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
219666752|NCT01744171|BIOLOGICAL|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
219666753|NCT01744171|OTHER|Laboratory Biomarker Analysis|Correlative studies
219666754|NCT04460534|DIAGNOSTIC_TEST|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
219666755|NCT02485418|DRUG|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
218975684|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
218975685|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
218975686|NCT04107779|OTHER|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
218975687|NCT04107779|OTHER|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
219208539|NCT06748794|DIAGNOSTIC_TEST|group 1|A comparative analysis was conducted to assess sensory and motor block characteristics, postoperative analgesia duration, maternal hemodynamic stability, and neonatal outcomes. Results demonstrated that intrathecal midazolam significantly prolonged postoperative analgesia and reduced analgesic requirements while maintaining hemodynamic stability and maternal-neonatal safety. This combination provides a potential enhancement to spinal anesthesia techniques, improving maternal comfort and overall perioperative outcomes in obstetric patients.
219666756|NCT05056571|BEHAVIORAL|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
219666757|NCT02960477|OTHER|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
219666758|NCT02960477|OTHER|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
219666759|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
219666760|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
219666761|NCT03944993|DEVICE|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
219666762|NCT05461365|DRUG|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
218975688|NCT04107779|OTHER|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
218975689|NCT01739361|DRUG|Acetaminophen|
218975690|NCT01739361|DRUG|placebo|
218975691|NCT02370277|OTHER|Cytology Specimen Collection Procedure|Undergo collection of stool samples
218975692|NCT02370277|OTHER|Laboratory Biomarker Analysis|Correlative studies
218975693|NCT02370277|OTHER|Questionnaire Administration|Ancillary studies
219666763|NCT00111306|DRUG|epratuzumab|
219666764|NCT01824121|BIOLOGICAL|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
219666765|NCT00235248|DRUG|Warfarin|Warfarin
219666766|NCT00235248|DRUG|Clopidogrel-aspirin|Clopidogrel-aspirin
219666767|NCT02173379|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
219666768|NCT02173379|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
219666769|NCT04414163|DRUG|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
219666770|NCT05989386|PROCEDURE|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
218975694|NCT00067574|BEHAVIORAL|Structured treatment interruption|
219666771|NCT05989386|PROCEDURE|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
218975695|NCT01904565|RADIATION|Hyperthermia and Proton Beam|"1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
219066756|NCT05131295|DRUG|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
219066757|NCT05131295|DRUG|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
219066758|NCT00000831|DRUG|Lamivudine|
219066759|NCT00000831|DRUG|Stavudine|
219066760|NCT00000831|DRUG|Zidovudine|
218975696|NCT05738629|DRUG|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
218975697|NCT02422173|DEVICE|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
219066761|NCT00000831|DRUG|Didanosine|
219066762|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
219066763|NCT00655187|OTHER|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
219666772|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
219666773|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
219666774|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
219666775|NCT04997265|OTHER|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
219686663|NCT06936319|BEHAVIORAL|Best clinical practice plus CPM-biofeedback training|The CPM-biofeedback training consists of a baseline 2-minutes active standing and the following four different physical maneuver: leg crossing and muscle tensing, heel raises (10 tiptoeing per minute), squatting, unilateral handgrip (20 times per minute). All exercises will be performed under continuous heart rate and blood pressure monitoring to enable the study participants to gain feedbacks on the effect of the maneuvers on their own biosignals.
219686664|NCT06936319|OTHER|Best clinical practice|Recommendations about life-style and behavioural measures to mitigate POTS symptoms in daily life.
219666776|NCT04997265|OTHER|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
219666777|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
219666778|NCT04354649|DRUG|Hydroxychloroquine|Hydroxychloroquine 5mg/kg PO daily
219666779|NCT04354649|OTHER|Placebo|Hydroxychloroquine-matching placebo
219666780|NCT05682352|DRUG|LEO 158968|IV infusion or SC injection
219666781|NCT05682352|DRUG|Placebo|IV infusion or SC injection
219666782|NCT05682352|DRUG|LEO 158968|SC injection
218975698|NCT02422173|DEVICE|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
218975699|NCT02422173|DEVICE|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
218975700|NCT02422173|DEVICE|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
218975701|NCT06309186|OTHER|Evaluation of midwifes' burnout|Burnout evaluated by questionnaires
219666783|NCT05682352|DRUG|Placebo|SC injection
219666784|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
219666785|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
219666786|NCT04716153|OTHER|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
218975702|NCT04864418|DRUG|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
218975703|NCT00775073|DRUG|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
218975704|NCT02216760|DEVICE|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
219066764|NCT00655187|PROCEDURE|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
218975705|NCT02216760|DEVICE|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
218975706|NCT04736342|OTHER|PALI questionaire|Survey comprised of a series of multiple choice questions
219208540|NCT06754254|DIAGNOSTIC_TEST|blood biomarkers from the internal jugular vein|blood biomarkers (Aβ42/40, p-tau217, p-tau181, NFL, GFAP, etc.) from the internal jugular vein
219208541|NCT06755151|DRUG|Fenofibrate|Fenofibrate 200mg
219208542|NCT06757153|DRUG|NRG-103|NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
219208543|NCT06754384|BIOLOGICAL|Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)|Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）
219208544|NCT06754384|BIOLOGICAL|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
219208545|NCT06754384|BIOLOGICAL|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
219666787|NCT04716153|OTHER|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
218975707|NCT02681601|DIETARY_SUPPLEMENT|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
218975708|NCT02681601|OTHER|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
218975709|NCT02681601|DIETARY_SUPPLEMENT|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
218975710|NCT01398553|DEVICE|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
218975711|NCT01398553|OTHER|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
218975712|NCT01881373|OTHER|CHL program|Multiple component environmentally focused program designed with community engagement.
219666788|NCT04716153|OTHER|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
219666789|NCT01690195|DRUG|ABT-126|See arm description
219666790|NCT05560698|OTHER|Motivation-enhancing intervention|The web app is designed as an efficient and easy-to-use app configurable to personal preferences. Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. The questionnaire addresses the same questions as the questionnaire in the standard intervention, but the format is different, and some shortcuts makes it easier to answer. When the questionnaire is answered, the web app gives access to different features. The following features distinct the motivation-enhancing intervention from the standard intervention (1) only complete the entire questionnaire on days with symptoms, (2) integration of grass pollen counts and forecasts, (3) showing personal response rate, (4) access to own data via a graph, (5) advice against grass pollen allergy, (6) status of the study, (7) individually choosing the time of response, (8) option to download an icon for the home screen and (9) contact information. The development is an ongoing iterative process
219666791|NCT05560698|OTHER|Standard intervention|Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. When the questionnaire is answered, the tab needs to be closed.
219666792|NCT04196335|DEVICE|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
219666793|NCT02145143|DRUG|Vemurafenib|
219666794|NCT02145143|DEVICE|serial 124I PET/CT|
219666795|NCT02145143|DRUG|thyrotropin alpha|
219666796|NCT04404985|PROCEDURE|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
219666797|NCT04404985|PROCEDURE|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
219666798|NCT06538636|OTHER|PCP-Facing Tools|PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
219666799|NCT06538636|OTHER|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
219666800|NCT02250950|BEHAVIORAL|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
219666801|NCT02250950|BEHAVIORAL|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
219666802|NCT01056913|DEVICE|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
219666803|NCT01056913|OTHER|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
218975713|NCT01881373|OTHER|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
218975714|NCT05888454|OTHER|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
218975715|NCT05888454|OTHER|Conventional treatment for T2DM|Conventional medical treatment for T2DM
218975716|NCT00772304|DRUG|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
218975717|NCT01628172|DEVICE|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
218975718|NCT04110587|BIOLOGICAL|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
218975719|NCT04110587|PROCEDURE|Temporomandibular Joint Arthroscopy|Lysis and Lavage
218975720|NCT04110587|DRUG|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
218975721|NCT04110587|DRUG|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
218975722|NCT04110587|DRUG|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
218975723|NCT04110587|DRUG|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
218975724|NCT04110587|OTHER|Exercise program|Home exercise program
218975725|NCT04112459|OTHER|prolonged mechanical ventilation|No intervention will be applied in this study
218975726|NCT02906332|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
218975727|NCT02906332|DRUG|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
218975728|NCT02906332|DRUG|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
218975729|NCT02384161|OTHER|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
218975730|NCT02949700|DRUG|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
218975731|NCT06273631|OTHER|diverse carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 45\~50% of carbohydrate supply sources are refined grains, 45\~50% of carbohydrate supply sources are whole grains or beans.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
219066765|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
219066766|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
219066767|NCT00870805|PROCEDURE|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
219066768|NCT00870805|PROCEDURE|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
219066769|NCT00870805|PROCEDURE|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
219066770|NCT00870805|PROCEDURE|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
218975732|NCT06273631|OTHER|middle carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 90\~95% of carbohydrate supply sources are refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
218975733|NCT01403311|DRUG|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
218975734|NCT01793831|PROCEDURE|FMT|Standard FMT
218975735|NCT06612853|OTHER|Sleep Quality Scale (SQS)|"For the pilot testing, each patient will complete the pre-final version of the SQS.~The patients involved in the field study will have to fill in the SQS twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale."
218975736|NCT06612853|OTHER|Pittsburgh Sleep Quality Index (PSQI)|The patients involved in the field test will have to fill in the PSQI twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.
218975737|NCT04330183|DRUG|Ketamine|0.3mg/kg of ketamine
218975738|NCT04330183|DRUG|Normal Saline|3cc of normal saline
219066771|NCT06104215|BIOLOGICAL|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
219066772|NCT05234892|DEVICE|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
219666804|NCT06172790|OTHER|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
219666805|NCT02374437|DRUG|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
219666806|NCT02374437|DRUG|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
219666807|NCT02530697|DRUG|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
219666808|NCT02530697|DRUG|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
219666809|NCT02530697|DRUG|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
219666810|NCT00487097|DIETARY_SUPPLEMENT|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
219666811|NCT02290145|DRUG|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
219666812|NCT02290145|PROCEDURE|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
219666813|NCT02290145|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
218975739|NCT05184478|DRUG|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached."
218975740|NCT05184478|DRUG|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
219666814|NCT00119483|DRUG|Nebido (Testosterone Undecanoate)|
219666815|NCT03700918|DEVICE|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
219666816|NCT04040647|BEHAVIORAL|mobilization and ambulation|6-min walk test (6-MWT)
219666817|NCT05048615|DRUG|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
219666818|NCT05048615|DRUG|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
219666819|NCT05048615|DRUG|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
219666820|NCT00170352|PROCEDURE|Hyperbaric Oxygen Treatment (HBOT)|
218975741|NCT06482307|DIAGNOSTIC_TEST|[18F]-olaparib PET scan|The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
218975742|NCT06709937|OTHER|Prospective multicenter registry of patients with cutaneous metastases from breast carcinoma treated with electrochemotherapy.|electrochemotherapy.
218975743|NCT06545825|OTHER|Standard enteral nutrition|Enteral nutrition will be given with standard isocaloric mixtures. Mixture volume calculation will be performed after indirect calorimetry, adjusted for daily nitrogen loss.
218975744|NCT06681675|PROCEDURE|The group that applied the Intrapartum Care Model|"In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied."
218975745|NCT05249790|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
218975746|NCT05249790|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
218975747|NCT01298635|PROCEDURE|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
218975748|NCT01298635|PROCEDURE|trabeculectomy|
219066773|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
219066774|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
219666821|NCT00170352|PROCEDURE|Enhanced Oxygen Treatment (Enhanced FiO2)|
219666822|NCT00702026|DIETARY_SUPPLEMENT|multispecies probiotic (Ecologic 801)|once daily, 5 gram \[10e9 cfu/gram\]
218975749|NCT06614829|DEVICE|Stratafix Suture|Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
218975750|NCT06614829|DEVICE|DERMABOND PRINEO|"DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure."
218975751|NCT06703242|OTHER|Health promotion for mothers of children with ADHD in the ultra-orthodox community|The intervention will consist of 3 modules with six sessions. Mothers will gain knowledge in topics related to understanding the ADHD health condition and its biological origins, optimal and recommended treatment options, school management techniques, and the importance of taking care of their own health.
218975752|NCT06712446|BEHAVIORAL|EFT|Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.
218975753|NCT06712446|DEVICE|high frequency rTMS|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling . For dlPFC, we will measure position F3. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. Intermittent theta burst stimulation (iTBS) (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the resting motor threshold (RMT) and will last \~3 minutes. Participants will receive 2 sessions of iTBS to the dlPFC brain region with a 15-20-minute interval between sessions
218975754|NCT06712446|DEVICE|sham frequency rTMS|Participants will receive sham TMS to the dlPFC. They may feel the TMS from the A/P coil electrodes, but there will not be any real stimulation of the brain.
218975755|NCT06709768|BEHAVIORAL|Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)|This is a pilot test of the MAPSS-MS intervention in a virtual delivery format.
218975756|NCT06706726|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy during the management of breast cancer
218975757|NCT06706726|PROCEDURE|Single-port robotic-assisted axillary lymph node dissection|Single-port robotic-assisted（Endoscopic Instrument Control System SP1000) axillary lymph node dissection during the management of breast cancer
218975758|NCT06710652|DEVICE|rTMS|Stimulation coil Cool-B65 A CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
218975759|NCT06710652|DEVICE|Sham Comparator|Stimulation coil Cool-B65 P CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
218975760|NCT06706895|DRUG|Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules|"Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles. If the patient has AE of grade 3 or above, the dose of fruquintinib capsules is reduced to 3 mg / day(dose discontinuation to dose reduction).~Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle. Do not need special infusion device.~Paclitaxel Polymeric Micelles for Injection and Fruquintinib Capsules are used for 6 cycles. Subsequently, dual-drug or single-drug maintenance therapy was selected according to the tolerance of the patients. Subsequently, Paclitaxel Polymeric Micelles for Injection ( 120mg / m2, if the patient is intolerable, the dose can be reduced to 100mg / m2 ), until occur the disease progress, the intolerant toxicity or the patient withdrawal."
218975761|NCT06709027|DEVICE|Intervention Group (Mobile Health Management Intervention)|Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring,et al， with the aim of improving the mental health status of elderly patients with depression.
218975762|NCT06709092|DRUG|lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)|For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
219666823|NCT00702026|DIETARY_SUPPLEMENT|Placebo|once daily, 5 gram \[10e9 cfu/gram\]
219666824|NCT02342145|DRUG|Basiliximab,|Basiliximab was used on 0d (after transplantation) and +4d (10mg for weight under 35kg, 20mg for over 35kg) .
219666825|NCT02342145|DRUG|Tacrolimus|Specifically Tacrolimus was used by intravenous drip infusion on 0.03mg/kg dosage from -1d and change to 0.1mg/kg oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 5-10 ng/ml.
219666826|NCT02342145|DRUG|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3d,+6d,+11d by intravenous for prevention of graft-versus-host-disease.
219666827|NCT02342145|DRUG|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g per day from -1d to 90d for prevention of graft-versus-host-disease.
218975763|NCT06774196|BEHAVIORAL|Behavioral Therapy Group|Includes Cognitive Behavioral Therapy (CBT), relaxation techniques, and biofeedback.
218975764|NCT06774196|PROCEDURE|Standard Care Group|Includes pharmacological treatment (e.g., NSAIDs, muscle relaxants) and physical therapy interventions
219666828|NCT04942210|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
219666829|NCT04942210|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
219666830|NCT04218617|DEVICE|Diagnostic MRI|Diagnostic MRI
219666831|NCT04218617|DEVICE|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
219666832|NCT04218617|OTHER|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
219666833|NCT04218617|OTHER|QOL assessment|QOL assessment
218975765|NCT04538053|DRUG|Oral cefalexin only|High-dose oral cefalexin
218975766|NCT04538053|DRUG|IV cefazolin or IV flucloxacillin followed by oral cefalexin|Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
219666834|NCT04218617|OTHER|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
219666835|NCT04218617|RADIATION|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
219666836|NCT04218617|RADIATION|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
219666837|NCT01874418|OTHER|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
219666838|NCT03421275|DRUG|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
219666839|NCT03421275|DRUG|Fentanyl Citrate|intravenous fentanyl given intranasally
219666840|NCT03421275|DRUG|Saline Nasal|intravenous saline given intranasally as placebo
219666841|NCT02570750|BEHAVIORAL|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
219666842|NCT02373007|PROCEDURE|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
219666843|NCT04122625|DRUG|Debio 1143|Administered as capsules.
219666844|NCT04122625|DRUG|Nivolumab|Administered as IV infusion.
219666845|NCT05176925|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
219666846|NCT05176925|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
219666847|NCT00369772|DRUG|darbepoetin alfa|
219666848|NCT00002478|DRUG|etoposide|
219666849|NCT02776670|OTHER|Propylene glycol, 0.6% eye drops|
219666850|NCT02776670|OTHER|Lubricant eye drops|
219666851|NCT00323076|DRUG|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
218975767|NCT02875132|DRUG|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
218975768|NCT06460922|PROCEDURE|Radial osteotomy|3D printing models and personalized guides in surgical planning in distal radius osteotomies for Kienböck´s disease. Osteosynthesis with a plate in distal radius.
218975769|NCT06929442|BEHAVIORAL|Resilience Training (RT)|RT is a 4-week program of weekly 90-minute sessions in which participants are taught the following skills: mindfulness, self-compassion and mentalization.
218975770|NCT06929442|BEHAVIORAL|Life Skills Training (LST)|LST is a 4-week program of weekly 90-minute sessions, in which participants are provided information about helpful life skills, including financial literacy, health, physical and internet safety.
219666852|NCT03402425|DIAGNOSTIC_TEST|18F-FET PET|Patient are investigated with an 18F-FET PET
219666853|NCT06012526|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is done for patients to find any sleep disordered breathing
219666854|NCT01902511|DRUG|G-CSF+Erythropoetin|
219666855|NCT01902511|DRUG|G-CSF|
219666856|NCT01489852|DRUG|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
219666857|NCT03610321|DRUG|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
219666858|NCT03610321|DRUG|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
219666859|NCT02743065|DEVICE|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
219666860|NCT01917695|DRUG|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
219666861|NCT01917695|RADIATION|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
219666862|NCT01917695|RADIATION|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
219066775|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
218975771|NCT06929390|PROCEDURE|BTVA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the BTVA group will undergo BTVA treatment.
218975772|NCT06929390|PROCEDURE|MWA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the MWA group will undergo MWA treatment.
218975773|NCT06905132|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
218975774|NCT05283382|DRUG|Cannabidiol Oral Product|Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
218975775|NCT05283382|OTHER|Placebo|Participants will receive a one-time dose of placebo capsules in the form of six capsules.
218975776|NCT06240741|DRUG|[68Ga]Ga-DOTA-TATE|Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
218975777|NCT06240741|DRUG|68Ge/68Ga Generator|Radionuclide generator
218975778|NCT06933420|DEVICE|Cern Device|The Cern Device is an Intravaginal device utilizing low level microbicidal visible light at a 450nm low level microbicidal light, in visible spectrum for treatment of vaginitis, including both bacterial vaginosis and fungal vaginitis.
218975779|NCT06935071|OTHER|Data Collection and Analysis|Patient data will be analyzed to ensure that all data fields are available and that suitable sample size is available to answer the research objectives. The rate of ambulation at discharge, ambulation at 3 month follow up (if available), time to death, and pain score between the historic cohort with a current cohort of patients will be compared.
218975780|NCT06935045|DRUG|Placebo Beverage|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow placebo beverage consumption (180 minutes total).
218975781|NCT06935045|DRUG|Alcohol (Ethanol)|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow alcoholic beverage consumption (180 minutes total).
218975782|NCT06934330|BEHAVIORAL|Mindfulness practice with Tao Art (Calligraphy and Song Greatest Love)|During mindfulness practice with Tao Art (Calligraphy and Song Greatest Love), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for six weeks.
218975783|NCT06934330|OTHER|Drinking Energized water|Participants will drink energized water from a bottle that received subtle energy transmission. They will replenish water daily and activate the transmission in the bottle to energize the water. Participants will drink about 1 litre of energized water a day for six weeks.
218975784|NCT06934746|OTHER|DSM-5 criteria.|The DSM-5 defines three levels of ADHD severity based on symptom count and frequency: 1. Mild ADHD • Symptom Count: Just meets the diagnostic criteria (6 symptoms in children for either inattention or hyperactivity/impulsivity). • Frequency: Symptoms occur but are not excessively frequent. 2. Moderate ADHD • Symptom Count: More than the minimum required for diagnosis. • Frequency: Symptoms occur frequently (e.g., several times a week). 3. Severe ADHD • Symptom Count: Many symptoms well beyond the diagnostic threshold. • Frequency: Symptoms occur daily or multiple times per day.(National Center for Biotechnology Information, n.d.)
218975785|NCT06933641|PROCEDURE|Regional Analgesia|20 cc of local anesthetic solution, comprising 10 cc of 0.5% bupivacaine and 10 cc of 0.9% NaCl bilaterally, was injected into each side once
218975786|NCT06935032|DEVICE|Twin block appliance|An appliance that facilitates forward positioning of the mandible and soft tissues
218975787|NCT06935032|OTHER|Fixed orthodontic treatment|Patients undergoing orthodontic treatment with fixed appliances
218975788|NCT06934850|OTHER|Hand grip strength|Collection Tools a) Hand Grip Force Measurement: Hand grip strength will be measured using a digital dynamometer. The measurement will be performed three times in the dominant and nondominant hand of the participant and the average value will be taken (1). b) Trunk Control Assessment: Trunk control will be assessed with the McGill core endurance test. This scale is a valid and reliable tool to objectively measure trunk stability and dynamic control levels (2). c) Motor skill assessment: Timed Up and Go Test: The Timed Up and Go Test was used to assess functional mobility and dynamic balance (3). The patient was told to get up from the chair, walk 3 meters, return and sit back in the chair. The time was recorded. Timed Stair Climbing Test: It consists of the individual climbing the stairs and returning to the starting point. The elapsed time was recorded
218975789|NCT06934655|DRUG|Semaglutide 2.4 mg|The dosing regimen will follow standard titration protocols, starting with a dose of 0.25 mg weekly for the first month, with gradual increases in dosage each month to a target dose of 2.4 mg weekly by the fifth month. To minimize the potential for side effects impacting daily activities, youth in the semaglutide group will be instructed to administer the medication weekly on Fridays.
218975790|NCT01254097|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule, 2 capsules twice daily
218975791|NCT02515448|DRUG|gentamicin|
218975792|NCT03332290|BEHAVIORAL|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
218975793|NCT04663373|OTHER|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
218975794|NCT02598960|DRUG|BMS-986156|
219208546|NCT06754384|BIOLOGICAL|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
218975795|NCT02598960|DRUG|Nivolumab|
218975796|NCT04258514|PROCEDURE|Virtual Reality during vasectomy|Virtual Reality
218975797|NCT04258514|PROCEDURE|Standard Vasectomy|No Virtual Reality
219066776|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
219066777|NCT06478927|DRUG|Palbociclib capsules|Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
219066778|NCT00002334|DRUG|Saquinavir|
219066779|NCT00002334|DRUG|Zidovudine|
219066780|NCT00002334|DRUG|Zalcitabine|
219066781|NCT04993924|DRUG|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
219066782|NCT04390438|PROCEDURE|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
219066783|NCT04390438|PROCEDURE|Dry needling|Needle emplacement without electrical current nor substance
218975798|NCT06311825|OTHER|Horticultural Therapy|"One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up."
218975799|NCT05608759|BEHAVIORAL|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
218975800|NCT03555032|DRUG|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
218975801|NCT00232973|DRUG|ICXP007|
218975802|NCT03449875|DEVICE|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
218975803|NCT04796545|DEVICE|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
218975804|NCT02053051|DEVICE|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
218975805|NCT02053051|DEVICE|Standard bolus calculator|
218975806|NCT02467400|DRUG|Atenolol|beta blocker
219066784|NCT01349634|OTHER|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
219066785|NCT04337099|DRUG|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
219066786|NCT00967850|DRUG|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
219066787|NCT00967850|DRUG|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
219066788|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
219066789|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
219066790|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
219066791|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
219066792|NCT01863680|DRUG|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
219066793|NCT01863680|DRUG|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
219208547|NCT06754384|BIOLOGICAL|placebo (for ages 6-12 years)|placebo (for ages 6-12 years)
219666863|NCT01917695|PROCEDURE|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
219666864|NCT00968357|DRUG|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
219666865|NCT00460863|PROCEDURE|using cool versus warm dialysate during hemodialysis|
219666866|NCT02032771|DEVICE|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
219666867|NCT05478551|DRUG|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
219666868|NCT05478551|DRUG|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
219666869|NCT03877588|DIETARY_SUPPLEMENT|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
219666870|NCT04848246|DRUG|Bupropion|This group received Bupropion 150 mg twice daily for 10 weeks
219666871|NCT04848246|BEHAVIORAL|Behavioural Change Communication|This group will receive Behavioural Change Communication
219666872|NCT03998371|DIAGNOSTIC_TEST|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
219666873|NCT03630029|DRUG|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
219066794|NCT01863680|DRUG|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
219066795|NCT01863680|DRUG|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
219066796|NCT06536127|DIAGNOSTIC_TEST|Blood samples|Nk cells and ImmunoScore
218975807|NCT02467400|DRUG|Nebivolol|beta blocker
219066797|NCT06322472|OTHER|The Turkish Early Language Development Test (TEDIL)|The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
219066798|NCT06322472|OTHER|The Family Literacy Scale|The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.
219066799|NCT06322472|OTHER|The Early Childhood Phonological Sensitivity Scale (PASECP)|The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).
219666874|NCT03923452|BEHAVIORAL|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
219666875|NCT05689008|BIOLOGICAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
219666876|NCT06080425|BEHAVIORAL|Medical Nutrition Therapy|Counselling
219666877|NCT05387512|DRUG|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
219066800|NCT06322472|OTHER|The Early Literacy Home Environment Scale (ELHES)|The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)
219066801|NCT06322472|OTHER|Demographic Questionaries|The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
219066802|NCT05294068|OTHER|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
219066803|NCT05294068|OTHER|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
219666878|NCT00495859|DIETARY_SUPPLEMENT|Immunonutrition|food for special medical purpose (FSMP)
219666879|NCT00495859|DIETARY_SUPPLEMENT|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
219666880|NCT00005796|PROCEDURE|filgrastim|GCSF is given after chemo administration
219666881|NCT00005796|BIOLOGICAL|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
219666882|NCT00005796|DRUG|lomustine|chemotherapy is administered every 21 days
219666883|NCT00005796|DRUG|procarbazine hydrochloride|chemotherapy is administered every 21 days.
219666884|NCT00005796|DRUG|vincristine sulfate|chemotherapy is administered every 21 days
219666885|NCT00005796|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
219666886|NCT04177966|BEHAVIORAL|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
219666887|NCT04177966|BEHAVIORAL|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
219066804|NCT05294068|OTHER|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
219666888|NCT00596063|BIOLOGICAL|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
219666889|NCT00596063|BIOLOGICAL|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
219666890|NCT03642444|DEVICE|Cane|Assistive walking device
219666891|NCT03642444|DEVICE|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
219666892|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
219666893|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
219666894|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
219666895|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
218975808|NCT02467400|DRUG|Propranolol|beta blocker
218975809|NCT02467400|DRUG|placebo|placebo
218975810|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
218975811|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
218975812|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
219066805|NCT00566228|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
219066806|NCT00566228|PROCEDURE|leukapheresis|Stem cells collected
219066807|NCT00694317|DRUG|Zaleplon|Short term treatment of insomnia
219066808|NCT00956865|OTHER|Voucher|Vouchers given to reimburse transportation
219066809|NCT00956865|OTHER|Telephone Call|Telephone reminder calls
219066810|NCT00956865|OTHER|Contact|Contact at senior center to encourage follow up
219066811|NCT03806153|OTHER|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
219066812|NCT05518955|BEHAVIORAL|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
219066813|NCT02267395|OTHER|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
219066814|NCT02267395|OTHER|(2) scapular dyskinesis test|Test to determine scapular control
219066815|NCT02267395|OTHER|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
219066816|NCT02053350|DRUG|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
219066817|NCT00672048|OTHER|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
219066818|NCT00672048|OTHER|Continuing Education Course|Annual standard continuing education
219066819|NCT00672048|OTHER|Continuing education|Annual standard continuing education materials
219066820|NCT06241404|PROCEDURE|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
219066821|NCT06241404|PROCEDURE|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
219066822|NCT02244944|DRUG|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
219066823|NCT05938634|BEHAVIORAL|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
219666896|NCT01366794|OTHER|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
219666897|NCT00894244|DEVICE|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
219666898|NCT05290428|DIAGNOSTIC_TEST|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
219666899|NCT04764383|DRUG|L-Histidine|1000 mg capsules taken by mouth (PO) twice daily (BID).
219666900|NCT04764383|DRUG|Placebo|Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
219666901|NCT04764383|DRUG|Lodosyn|50 mg capsules taken PO BID.
219666902|NCT04953286|OTHER|Measure of visual acuity|ETDRS and Parinaud scale
219666903|NCT04953286|OTHER|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
219666904|NCT04953286|OTHER|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
219066824|NCT00492349|DRUG|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
219066825|NCT00492349|DRUG|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
219066826|NCT04764058|DRUG|Tienam 500|Imipenem and cilastatin sodium
219066827|NCT04764058|DEVICE|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
219066828|NCT00414700|DRUG|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
219066829|NCT00414700|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
219066830|NCT02367911|DRUG|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
219066831|NCT02367911|DRUG|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
219066832|NCT00373776|DRUG|miltefosine 2.5 mg/kg/day for 28 days|
219066833|NCT04584112|DRUG|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
219066834|NCT04584112|DRUG|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
219066835|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
219066836|NCT04584112|DRUG|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
219066837|NCT04584112|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
219066838|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
219666905|NCT04953286|OTHER|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
219666906|NCT04953286|OTHER|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
219666907|NCT04953286|OTHER|Conjunctival impression|Conjunctival impression with anesthetic instillation
219666908|NCT04953286|OTHER|Evaluation of the corneal innervation|Contact corneal confocal microscopy
219666909|NCT05765448|OTHER|Soy control|Soy isolate control meal
219666910|NCT05765448|OTHER|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
219066839|NCT04584112|DRUG|Carboplatin|Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
219066840|NCT04584112|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
219666911|NCT05765448|OTHER|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
219666912|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
219666913|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
219066841|NCT04584112|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
219066842|NCT04584112|DRUG|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
219066843|NCT04584112|DRUG|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
219066844|NCT04797338|DRUG|Synarel, 0.2 Mg/Inh Nasal Spray|Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
219066845|NCT04797338|DRUG|Estrofem|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
219066846|NCT04797338|DRUG|Utrogestan|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
219066847|NCT04797338|DRUG|Hydroxyprogesterone Caproate|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
219066848|NCT01852539|DRUG|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
219066849|NCT01852539|DRUG|propofol|Propofol 2.0 mg/kg was administrated
219208548|NCT06761846|BIOLOGICAL|Sintilimab plus Chemotherapy|chemotherapy includes SOX and XELOX
219360308|NCT02800655|DEVICE|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
219666914|NCT01038752|DRUG|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
219666915|NCT01038752|DRUG|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
219666916|NCT02109406|DRUG|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
219666917|NCT02109406|DRUG|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
219666918|NCT02109406|DRUG|Placebo MDI|Placebo MDI administered as two inhalations BID
219666919|NCT04780243|OTHER|counseling|Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
219666920|NCT06281158|DRUG|[14C]-DNL343|Single dose
219666921|NCT00530790|DRUG|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
219666922|NCT04735159|DEVICE|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
219666923|NCT02623608|OTHER|Reference breakfast|A high fat, high calorie breakfast
219666924|NCT02623608|OTHER|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
219666925|NCT02623608|OTHER|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
219666926|NCT02623608|OTHER|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
219666927|NCT02623608|OTHER|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
219666928|NCT06613542|DIETARY_SUPPLEMENT|4g of taurine daily|Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
219666929|NCT06613542|DIETARY_SUPPLEMENT|Placebo|Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
219666930|NCT03318679|OTHER|No intervention is planned.|None is planned
218975813|NCT04847856|BEHAVIORAL|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
218975814|NCT04929574|DIAGNOSTIC_TEST|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
218975815|NCT00646919|PROCEDURE|Nose swab|
218975816|NCT02609009|OTHER|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
218975817|NCT02609009|OTHER|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
218975818|NCT01570556|OTHER|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
218975819|NCT00685542|DRUG|diacerein|Diacerein 50mg bid
218975820|NCT00685542|DRUG|placebo|placebo
218975821|NCT05776368|OTHER|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
218975822|NCT05776368|OTHER|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
218975823|NCT05776368|OTHER|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~* Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~* Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~* Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~* Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
218975824|NCT05776368|OTHER|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
218975825|NCT05776368|OTHER|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
218975826|NCT05776368|OTHER|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
218975827|NCT05776368|OTHER|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
218975828|NCT05776368|OTHER|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
218975829|NCT01854658|DRUG|GFF MDI (PT003)|GFF MDI administered as two puffs BID
218975830|NCT01854658|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
219360309|NCT02061852|DEVICE|Simeox|
219360310|NCT02061852|PROCEDURE|Physiotherapy|
219360311|NCT03317769|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
218975831|NCT01854658|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
218975832|NCT01854658|DRUG|Placebo|
218975833|NCT06323187|DIAGNOSTIC_TEST|Cervical Sampling|Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
219066850|NCT01852539|DEVICE|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
219360312|NCT03317769|OTHER|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
219666931|NCT04697212|BEHAVIORAL|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
219666932|NCT04697212|BEHAVIORAL|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
219066851|NCT04966468|DEVICE|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
219066852|NCT04966468|OTHER|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
219066853|NCT00342316|PROCEDURE|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"
219066854|NCT03412669|OTHER|Supporting Addiction Affected Families Effectively|Counselling
219066855|NCT03412669|OTHER|Enhanced Usual Care|Information sheet
219066856|NCT06530940|DIAGNOSTIC_TEST|Buccal Schirmer Test|"For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) ."
219066857|NCT01114568|DRUG|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
219066858|NCT01114568|DRUG|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
219066859|NCT01114568|DRUG|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
219066860|NCT05544799|OTHER|No intervention|No intervension
219066861|NCT03119454|DRUG|Diprospan|Intramuscular
219066862|NCT04502329|OTHER|Diet|Energy Restriction Intermittent Fasting Diet
219066863|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via prepared syringe
219666933|NCT06355843|DRUG|68Ga-PSMA|"PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved."
219666934|NCT00300443|DRUG|bimatoprost|
219666935|NCT02214862|DRUG|[F18]-FDDNP|radiopharmaceutical tracer
219666936|NCT03007134|OTHER|Retrospective Chart Review|No intervention.
219666937|NCT05857670|BEHAVIORAL|Genetic predisposition to breast cancer|Guilt feelings about procreating
219666938|NCT00315042|DRUG|Telithromycin (HMR3647)|
219666939|NCT00315042|DRUG|Penicillin|
219066864|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via syringe pump
219066865|NCT02763527|BEHAVIORAL|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
219066866|NCT02763527|BEHAVIORAL|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
219066867|NCT02460718|BEHAVIORAL|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
219066868|NCT00629187|DRUG|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
219066869|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
219066870|NCT00902304|DRUG|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
218975834|NCT01858376|DIETARY_SUPPLEMENT|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
218975835|NCT04484948|OTHER|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
218975836|NCT02834728|BEHAVIORAL|telephone interview|
218975837|NCT01593410|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
218975838|NCT01593410|DRUG|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
218975839|NCT00940030|OTHER|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
219666940|NCT04000360|OTHER|High-Intensity Aerobic Exercise (AE)|The home-based exercise group will have a Peloton indoor cycle, heart rate monitor strap, and Garmin activity monitor to track daily activity levels delivered to the home. Participants will be asked to cycle 3x/week for 12 months on this bike with heart rate monitor at aerobic intensity 60-80% of heart rate reserve and target cadence 80-90 revolutions per minute. Study team members will telephone all participants biweekly for similar contact times between treatment groups. During these calls, a study team member reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times on the Garmin Connect website (https://connect.garmin.com). For those in the AE group, exercise recommendations, e.g., increase duration, cadence or heart rate, are given based on review of exercise session data on the Peloton portal (onepeloton.com). Compliance barriers or technical challenges with the activity monitor or exercise cycle are addressed.
219666941|NCT04000360|OTHER|Usual and Customary Care (UCC)|Participants in this group will continue to receive their usual care. They will also receive activity monitors to monitor their daily activity levels, and telephone monitoring throughout the study. Study team members telephone all participants every 2 weeks for similar amounts of contact time between treatment groups. During the calls, a study team member of the reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times via the Garmin Connect website (https://connect.garmin.com).
219666942|NCT06241066|OTHER|no-Intervention|no-Intervention
219666943|NCT00744406|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
219666944|NCT00744406|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
219666945|NCT00744406|DRUG|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
219666946|NCT05525780|DRUG|GB-5001|Depending on the cohort, volume will be varied to administer.
218975840|NCT00940030|OTHER|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
218975841|NCT04048187|DEVICE|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
218975842|NCT00014118|DRUG|carboplatin|
218975843|NCT00014118|DRUG|paclitaxel|
218975844|NCT00014118|PROCEDURE|conventional surgery|
218975845|NCT00014118|RADIATION|radiation therapy|
219066871|NCT00902304|DRUG|Usual care|As directed by investigator
219066872|NCT00902304|DRUG|Valsartan|Valsartan 160mg per day to 320mg per day orally
219066873|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
219066874|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
219066875|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
219066876|NCT03466333|DRUG|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
219666947|NCT05525780|DRUG|Placebo|A matched volume of placebo product will be administered to each subject in each cohort.
219666948|NCT05525780|DRUG|Oral cohort|Single dose of Aricept tablet
219666949|NCT00006220|DRUG|arsenic trioxide|
219666950|NCT00006220|DRUG|tretinoin|
219666951|NCT01249326|OTHER|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
219666952|NCT03245190|DRUG|Chiauranib|50mg, orally once daily
219666953|NCT04650334|BEHAVIORAL|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
218975846|NCT06340061|OTHER|Observational study|The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
218975847|NCT01413477|DRUG|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
218975848|NCT06009029|RADIATION|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
218975849|NCT06009029|DRUG|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
218975850|NCT03894046|DRUG|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
218975851|NCT03894046|DRUG|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
218975852|NCT03894046|DRUG|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
218975853|NCT03894046|DRUG|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
218975854|NCT03587948|DIAGNOSTIC_TEST|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
218975855|NCT03654859|OTHER|cardiopulmonary resuscitation|no pre-specified
218975856|NCT05657925|DRUG|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
218975857|NCT05657925|DRUG|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
218975858|NCT03835871|DRUG|Placebo|Intervention: Drug: placebo
218975859|NCT03835871|DRUG|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
218975860|NCT03835871|DRUG|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
218975861|NCT03835871|DRUG|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
218975862|NCT00486473|DRUG|Multihance|0.5 Molar at a single dose injection
218975863|NCT00486473|DRUG|Magnevist|0.5M at a single dose injection
218975864|NCT06306053|COMBINATION_PRODUCT|tDCS+EuleriaLab|Home based: Non invasive Neuromodulation treatment + Motor Training
218975865|NCT06306053|DEVICE|tDCS|Non invasive brain stimulation
218975866|NCT06306053|OTHER|EuleriaLab|Home Motor Training
218975867|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
218975868|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
218975869|NCT01823354|OTHER|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
218975870|NCT01823354|OTHER|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
219666954|NCT02074319|DRUG|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
219666955|NCT05266924|DRUG|Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen|fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
219666956|NCT00001037|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219666957|NCT01583205|BEHAVIORAL|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
219666958|NCT03246191|OTHER|blood sample collection|blood sample collection
219666959|NCT03316066|PROCEDURE|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
219666960|NCT03316066|PROCEDURE|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
219066877|NCT03466333|DRUG|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
219066878|NCT05976282|OTHER|Fecal Immunochemical Test|The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.
219066879|NCT05976282|OTHER|Septin9 Test|Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
219066880|NCT05706506|DRUG|Tirzepatide|Administered SC
219066881|NCT03278015|DRUG|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
219066882|NCT03278015|DRUG|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
219066883|NCT03278015|DRUG|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
219066884|NCT06961825|DIETARY_SUPPLEMENT|Dietary Supplement|complete, semi-elemental formula for tube feeding and orla intake based on peptides, in powder form, low in fat (32% of energy), high in MCTs (\>90% of total fat) free of fiber and gluten
219066885|NCT06962618|BEHAVIORAL|Music Motion Group|"Participants will engage in personalized, home-based motor training programs tailored to their individual goals. Each will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, which transmits movement data via Bluetooth to a tablet app. The training emphasizes task specificity and intensity, with five virtual check-ins to review progress and adjust training parameters.~The intervention studied is extrinsic feedback; the app analyzes movement data and provides feedback through music. Before each training session, the app guides participants to set personalized intensity thresholds based on current capacity. When participants meet the intensity threshold, musical elements (e.g., drumbeats, vocals) play. If they fall short, elements drop out, providing knowledge of erroneous performance."
219066886|NCT06962618|BEHAVIORAL|Control|Participants will follow personalized, home-based motor training programs designed like the Music motion group. They will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, transmitting movement data via Bluetooth to a tablet app. However, unlike the Music Motion Feedback group, participants in the Control group will not receive any extrinsic feedback during their training.
219066887|NCT04293146|PROCEDURE|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
219066888|NCT04293146|PROCEDURE|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
219666961|NCT04374292|BEHAVIORAL|Family intervention|"Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
219066889|NCT03932643|DRUG|ONC-201|"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
219066890|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
219066891|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
219066892|NCT03108534|DRUG|Placebo|Rescue treatment
219066893|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
219066894|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
219066895|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
219066896|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
219360313|NCT03317769|OTHER|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
218975871|NCT01823354|OTHER|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
218975872|NCT01823354|OTHER|Medical consultation|open questions
218975873|NCT01768052|DEVICE|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
218975874|NCT02545257|OTHER|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
218975875|NCT02796703|DIETARY_SUPPLEMENT|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
218975876|NCT02796703|DIETARY_SUPPLEMENT|Placebo|2 cc of milk will be given to control group
218975877|NCT01006369|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
218975878|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|
218975879|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|
218975880|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|
218975881|NCT02439294|DEVICE|CPAP|
218975882|NCT05843760|OTHER|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
218975883|NCT05843760|OTHER|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
219360314|NCT03317769|OTHER|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
218975884|NCT05843760|OTHER|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
218975885|NCT06467942|DRUG|Chinese medicine and Lactobacillus|combined drug group
218975886|NCT06467942|DRUG|Chinese medicine|Single Chinese medicine group
218975887|NCT06467942|DRUG|Lactobacillus|Single Lactobacillus group
218975888|NCT03461263|OTHER|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
219360315|NCT01808612|DRUG|Fluoxetine|
219208549|NCT06762301|BEHAVIORAL|sexual education and counseling|After the initial evaluation, pregnant women who will be included in the study group will be given an appointment for 1 week later, they will be asked to come with their partners and couples will be given sexual education and counseling in line with the PLISSIT model. After the initial evaluation, couples will be interviewed in the 1st, 2nd and 3rd trimesters, their sexuality since the previous evaluation according to the PLISSIT model, their problems, if any, will be discussed and short counseling will be given if necessary. In the first 4 weeks after delivery, couples in the study group will receive sexual education and counseling for the postpartum period in line with the PLISSIT model. They will be interviewed at the 3rd and 6th month after delivery and their postpartum sexuality and problems, if any, will be discussed and the sexual functions of the couples for the last 4 weeks will be evaluated.
219208550|NCT06762301|OTHER|Routine clinical care|Control Group
219208551|NCT06760767|BEHAVIORAL|sexual therapy|In sexual therapy sessions, sexual education, cognitive restructuring, body awareness exercises, systematic desensitization, relaxation training, individual and partner home exercise training and dilator treatment were applied with the supervision of a physiotherapist. All techniques and stages were not applied in the same session and were used with a certain progression
219208552|NCT06760767|BEHAVIORAL|Pelvic floor physiotherapy combined with sexual therapy|Pelvic floor physiotherapy combined with sexual therapy was applied in the experimental group. Sexual therapy techniques were added appropriately before, during and after the pelvic floor physiotherapy session. In the pelvic floor physiotherapy sessions, pelvic floor muscle training, biofeedback, electrotherapy, manual therapy applications, breathing exercises, stretching and relaxation exercises were applied with the physiotherapist. Pelvic floor physiotherapy techniques and stages were applied in the same session and followed a certain progression.
219208553|NCT06764732|BIOLOGICAL|bioactive glass|supplied as resorbable form, (400-800um) particle siz
219208554|NCT06764732|RADIATION|bioactive glass graft and PBM irradiation|The used laser parameters were set as: wavelength, 980 nm; power, 0.55 W; energy, 36 J; power density, 0.76 W cm2
219360316|NCT01808612|DRUG|Placebo|
219360317|NCT04823949|DEVICE|Home blood pressure monitoring|See arm description
219666962|NCT04374292|OTHER|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
219666963|NCT01243294|DEVICE|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
219666964|NCT01243294|DEVICE|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
219666965|NCT06033677|PROCEDURE|Distal radial artery cannulation|Interventional application for invasive blood pressure monitoring
219666966|NCT06033677|PROCEDURE|Forearm radial artery cannulation|Interventional application for invasive blood pressure monitoring
219666967|NCT05072587|BEHAVIORAL|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
219666968|NCT05072587|BEHAVIORAL|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
219666969|NCT00925197|OTHER|INR self-testing program|
218975889|NCT02821637|OTHER|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
218975890|NCT02821637|BEHAVIORAL|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
218975891|NCT02821637|OTHER|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
219666970|NCT02445859|DRUG|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
219666971|NCT04967859|DRUG|0.1% gentamicin|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
218975892|NCT03475680|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
218975893|NCT03475680|DRUG|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
218975894|NCT03475680|DRUG|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
218975895|NCT03475680|DRUG|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
218975896|NCT03475680|DRUG|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
219666972|NCT04967859|DRUG|Placebo|Patients using placebo ointment at the exit site of the hemodialysis catheter
218975897|NCT03830242|DIAGNOSTIC_TEST|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
218975898|NCT03830242|DIAGNOSTIC_TEST|B-ultrasonography|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
218975899|NCT06181578|PROCEDURE|ganglionated plexus ablation|This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
218975900|NCT05169996|OTHER|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
218975901|NCT05169996|OTHER|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
218975902|NCT05169996|OTHER|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
218975903|NCT05169996|OTHER|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
218975904|NCT05169996|OTHER|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
218975905|NCT02219438|DRUG|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
218975906|NCT02219438|DRUG|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
218975907|NCT04673968|OTHER|prehabilitation|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
218975908|NCT03378661|DRUG|Benznidazole|Benznidazole tablet
218975909|NCT03378661|DRUG|E1224|E1224 capsules
218975910|NCT03378661|DRUG|E1224 Placebo|E1224 matched placebo capsules
218975911|NCT03378661|DRUG|Benznidazole Placebo|Benznidazole matched placebo tablets
218975912|NCT06558058|DRUG|Rivaroxaban 10 mg film-coated tablet|One tablet of the test drug was given orally after an overnight fast.
218975913|NCT06558058|DRUG|Xarelto 10 mg film-coated tablet|One tablet of the reference drug was given orally after an overnight fast.
218975914|NCT00326066|DEVICE|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
218975915|NCT00326066|PROCEDURE|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
218975916|NCT01722396|DIETARY_SUPPLEMENT|Vitamin D|
219066897|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
219666973|NCT05067894|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
219666974|NCT05067894|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
219666975|NCT00575510|BEHAVIORAL|Intervention|Multiple component intervention based in the unified theory of behavior
219666976|NCT00575510|BEHAVIORAL|Active control|Partial intervention (full intervention minus cultural-specific component)
219666977|NCT00999700|DRUG|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
219666978|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
219666979|NCT00999700|DRUG|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
219666980|NCT00999700|DRUG|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
219666981|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
219666982|NCT03489200|OTHER|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
219666983|NCT03489200|OTHER|Placebo|No intervention- placebo
219666984|NCT01267422|DRUG|rAAV2-ND4|injection
219666985|NCT04046822|DRUG|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
218975917|NCT05143385|OTHER|Virtual reality|"* Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
218975918|NCT03089320|BEHAVIORAL|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
218975919|NCT03089320|BEHAVIORAL|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
218975920|NCT03089320|BEHAVIORAL|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
218975921|NCT02875912|BEHAVIORAL|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
218975922|NCT05115669|DEVICE|Wortie freeze plus|treatment of common and plantar warts
218975923|NCT02570074|DRUG|Fosfomycin|Broad spectrum antibiotic
218975924|NCT02129114|DEVICE|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
218975925|NCT02129114|DEVICE|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
218975926|NCT00192361|BIOLOGICAL|CAIV-T|
218975927|NCT03302195|DRUG|Heparin|Based on patient body weight (UI/kg)
218975928|NCT03302195|PROCEDURE|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
219666986|NCT04046822|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
219666987|NCT04118777|DRUG|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
219666988|NCT04043208|BEHAVIORAL|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
219666989|NCT04043208|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
219666990|NCT01084538|DRUG|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
219666991|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
219666992|NCT02279745|DRUG|Ralinepag|Active
219666993|NCT05982808|PROCEDURE|CLIF correction|CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach
219666994|NCT05982808|PROCEDURE|conventional correction strategy|conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
219666995|NCT04893356|GENETIC|O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients|"Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent."
218975929|NCT05007093|DRUG|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
218975930|NCT02436304|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
218975931|NCT02436304|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
218975932|NCT02818361|DRUG|Topical tripterygium gel|
218975933|NCT02818361|DRUG|Placebo gel|
218975934|NCT06061354|DRUG|Teriparatide|mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
218975935|NCT06061354|PROCEDURE|Maxillary Sinus Augmentation|Local anesthesia will be performed, mucoperiosteal flap will be raised to access the anterior wall of the maxillary sinus. Access to the maxillary sinus will be done through osteotomy, using a piezosurgery under irrigation with saline solution. Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material (Bio-Oss® mixed with saline solution or Bio-Oss® mixed with Forteo®) will be delivered for placement on the sinus floor maxilla below Schneider's membrane.Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed.
218975936|NCT06061354|PROCEDURE|Dental Implant Installation|Local anesthesia will be performed a mucoperiosteal flap will be raised in the area for implant placement and a bone core 10 mm high and 2 mm in diameter will be removed with a 2 mm trephine bur. The bone biopsied through this nucleus is part of the region where the implant will be installed, and the height of the sample depends on the surgical planning carried out previously (3-month radiographic control). The sequence of drills to place the implant will continue, installation of the implant itself and, finally, verification of the insertion torque and measurement of the resonance frequency in the already installed implant. The mucoperiosteal flap must be repositioned and sutured.
218975937|NCT06061354|COMBINATION_PRODUCT|Bone graft|One arm:mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® In other arm: 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
218975938|NCT00920933|BIOLOGICAL|AIN457|
218975939|NCT00920933|OTHER|Placebo|
218975940|NCT00920933|DRUG|prednisolone|
219066898|NCT02626559|DRUG|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
219066899|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
219066900|NCT06092996|OTHER|Time of Sling Use|Standard sling worn for only three days post operatively
219066901|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
219066902|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
219066903|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
218975941|NCT00185562|DRUG|Adalimumab|
218975942|NCT04295551|DRUG|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
218975943|NCT04295551|DRUG|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
218975944|NCT00785928|BIOLOGICAL|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
218975945|NCT00785928|DRUG|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
218975946|NCT02373722|PROCEDURE|Mohs Surgery|Undergo Mohs surgery
218975947|NCT02373722|OTHER|Internet-Based Intervention|Watch website application based educational video
218975948|NCT02373722|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
218975949|NCT02373722|OTHER|Educational Intervention|Watch website application based educational video
218975950|NCT02373722|BEHAVIORAL|Exercise Intervention|Use Fitbit
218975951|NCT02373722|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
218975952|NCT02373722|OTHER|Questionnaire Administration|Ancillary studies
219066904|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
219066905|NCT06057389|DIETARY_SUPPLEMENT|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
219666996|NCT06314451|OTHER|Cognitive Interview|"The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles."
219066906|NCT02673658|BEHAVIORAL|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
219066907|NCT02673658|BEHAVIORAL|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
219066908|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
219066909|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
219066910|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
219666997|NCT00380718|DRUG|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting)."
219666998|NCT06436391|OTHER|Kinesio taping|Kinesio taping will be applied to the lateral part of the baby's heel to increase blood flow. Blood collection will always be performed by the same nurse
219666999|NCT06436391|OTHER|ShotBlocker|Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal pressure.
219667000|NCT01108419|OTHER|Fermented dairy product|
219667001|NCT01108419|OTHER|milk-based non-fermented dairy product|
219667002|NCT06075550|OTHER|single cone technique using TotalFill BC Sealer|Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
219667003|NCT06075550|OTHER|warm vertical compaction technique using TotalFill BC Sealer HiFlow|TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
219667004|NCT03387501|DRUG|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
219667005|NCT04764084|DRUG|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
219667006|NCT04764084|DRUG|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
219667007|NCT01993641|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
219667008|NCT01993641|DRUG|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
219667009|NCT01993641|DRUG|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
219667010|NCT00272870|DRUG|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
219667011|NCT00272870|GENETIC|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
219667012|NCT00272870|DEVICE|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
219667013|NCT00087425|BIOLOGICAL|rituximab|
219667014|NCT00087425|DRUG|bryostatin 1|
219667015|NCT04169438|OTHER|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
218975953|NCT02373722|OTHER|Survey Administration|Ancillary studies
219667016|NCT04169438|OTHER|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
219667017|NCT06289686|PROCEDURE|Rotator cuff repairs with BioEnthesis augmentation|Rotator cuff repair using BioEnthesis allograft patch
219667018|NCT06289686|PROCEDURE|Rotator cuff repairs without BioEnthesis augmentation|Rotator cuff repair using standard of care sutures and anchors
219667019|NCT04322786|DRUG|ACE inhibitor|Any prescription of ACE inhibitor
218975954|NCT05804097|DRUG|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
218975955|NCT05441761|DRUG|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
218975956|NCT01252381|OTHER|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
218975957|NCT06101550|PROCEDURE|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
218975958|NCT06101550|PROCEDURE|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
218975959|NCT04603612|PROCEDURE|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
218975960|NCT04872153|BEHAVIORAL|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
218975961|NCT00093548|BIOLOGICAL|alpha fetoprotein adenoviral vector vaccine|
218975962|NCT00093548|BIOLOGICAL|alpha fetoprotein plasmid DNA vaccine|
218975963|NCT00093548|BIOLOGICAL|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
218975964|NCT00760500|OTHER|Nasopharyngeal Swab|Nasopharyngeal Swab
218975965|NCT03731039|OTHER|Observational study|Pain assessment, Anxiety assessment, Depression assessment
218975966|NCT01669499|DRUG|Dexamethasone acetate|
219667020|NCT01712308|BIOLOGICAL|Sotatercept|Given SC
219667021|NCT01712308|DRUG|Ruxolitinib|
218975967|NCT01669499|DRUG|Placebo|
218975968|NCT05021081|DEVICE|TRP-200|JJVC Investigational Contact Lens
218975969|NCT05021081|DEVICE|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
218975970|NCT03055182|OTHER|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
219066911|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
218975971|NCT04935281|OTHER|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
218975972|NCT04935281|OTHER|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
218975973|NCT05438784|PROCEDURE|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
219066912|NCT01359553|OTHER|Quantitative MRI imaging of knee|
219066913|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
219667022|NCT03070041|OTHER|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
219667023|NCT03725033|DRUG|Subetta|Oral administration.
219667024|NCT03725033|DRUG|Placebo|Oral administration.
219667025|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
219667026|NCT05270915|BEHAVIORAL|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
219667027|NCT03534115|DIETARY_SUPPLEMENT|NAC|solution containing NAC
219667028|NCT03534115|DIETARY_SUPPLEMENT|Placebo|Placebo
219667029|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice with 12% ethanol|
218975974|NCT05438784|PROCEDURE|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
219667030|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice|
219667031|NCT06979089|BEHAVIORAL|Doing What Matters in Times of Stress|"DWM is the illustrated guide of the original stress management intervention - Self-Help Plus and can be offered online through a web-based application.~DWM is a low-intensity and transdiagnostic intervention that has been designed to be widely applicable to a variety of mental health problems (depression, anxiety and PTSD). DWM is based on acceptance and commitment therapy (ACT), a modern form (third wave) of cognitive-behavioural therapy with a strong focus on mindfulness practices and identification of values, with exercises which aim to reduce distress and build social support, adaptive coping and resilience.~DWM includes five modules, each of which focuses on a specific skill. The online version of DWM has been designed to release a module every week, so the program is finalized in 5 weeks. In this trial, participants will receive the guided version of DWM: participants will have a short (15 minutes) weekly support call with a helper (6 calls in total)."
219667032|NCT01499641|DRUG|Methylprednisolone|Epidural methylprednisolone 40 mg or none
219667033|NCT04505449|DIAGNOSTIC_TEST|Left heart catheterization|Patients who underwent left heart catheterization
219667034|NCT00004036|BIOLOGICAL|sargramostim|
219667035|NCT00004036|DRUG|amifostine trihydrate|
219667036|NCT00004036|DRUG|carboplatin|
219667037|NCT00004036|DRUG|cyclophosphamide|
219667038|NCT05920668|DRUG|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
219667039|NCT05353634|DIAGNOSTIC_TEST|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
219667040|NCT01743118|DRUG|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
218975975|NCT04137432|DRUG|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
218975976|NCT04137432|DRUG|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
218975977|NCT00369122|BIOLOGICAL|Bevacizumab|Given IV
218975978|NCT00369122|DRUG|Cisplatin|Given IV
218975979|NCT00369122|RADIATION|External Beam Radiation Therapy|Undergo EBRT
218975980|NCT00369122|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
218975981|NCT00334685|DRUG|[S,S]-Reboxetine + Pregabalin|\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
218975982|NCT00334685|DRUG|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
218975983|NCT06557486|BEHAVIORAL|Mindfulness-Based Stress reduction|Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
218975984|NCT02112344|RADIATION|IMRT|
218975985|NCT04051281|BEHAVIORAL|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
218975986|NCT03683160|OTHER|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
218975987|NCT03761693|OTHER|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast."
218975988|NCT03676998|DEVICE|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
218975989|NCT02059902|DRUG|Lidocaine|Lidocaine infusion runs for a total of 24 hours
218975990|NCT02059902|OTHER|Placebo|Normal saline runs for a total of 24 hours
218975991|NCT04537039|DIAGNOSTIC_TEST|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
218975992|NCT04348643|BIOLOGICAL|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
219667041|NCT01743118|DRUG|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
219667042|NCT01743118|DRUG|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
219667043|NCT02710916|DEVICE|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
218975993|NCT00232089|DRUG|Tegaserod|
219667044|NCT01007292|DRUG|YM155|intravenous infusion
219667045|NCT01007292|BIOLOGICAL|Rituximab|intravenous infusion
218975994|NCT00693849|DRUG|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
218975995|NCT00693849|DRUG|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
218975996|NCT00693849|DRUG|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
218975997|NCT04543825|DEVICE|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
218975998|NCT05543889|OTHER|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
218975999|NCT00978978|DRUG|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
218976000|NCT00951548|DIETARY_SUPPLEMENT|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
218976001|NCT00951548|DIETARY_SUPPLEMENT|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
219667046|NCT00898326|OTHER|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
219667047|NCT05935423|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell transplantation|50 million UC MSC will be transplanted 10-15 days after primary PCI
219667048|NCT02673242|DEVICE|Threshold IMT Philips Respironics|Inspiratory muscle training
219667049|NCT01848509|DEVICE|With teletransmission|Teletransmission of alerts
219667050|NCT01299415|DRUG|Vadimezan™|
219667051|NCT03278405|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
219667052|NCT01938989|DEVICE|Clear clip-on glasses|Clip-on glasses with no light filtering properties
219667053|NCT01938989|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
219667054|NCT03409445|OTHER|no intervention|no intervention (observational study)
218976002|NCT00631696|DRUG|Pregabalin|pregabalin 600 mg given twice a day
218976003|NCT00631696|DRUG|Placebo|Placebo
218976004|NCT03532061|BEHAVIORAL|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
218976005|NCT03532061|OTHER|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
219066914|NCT04450615|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
219066915|NCT01703455|DRUG|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
219066916|NCT03904472|BEHAVIORAL|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
219066917|NCT03432624|DIAGNOSTIC_TEST|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
219667055|NCT02260349|DRUG|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
219667056|NCT01057797|BEHAVIORAL|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
219667057|NCT01057797|BEHAVIORAL|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
218976006|NCT05273333|DEVICE|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
218976007|NCT03041857|RADIATION|Observational use of fluoroscopy|
218976008|NCT02169973|DRUG|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
219066918|NCT00000457|DRUG|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
219667058|NCT01057797|BEHAVIORAL|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
219667059|NCT03634683|BIOLOGICAL|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
218976009|NCT02169973|DRUG|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
218976010|NCT06114160|OTHER|Data collection|Data collection
218976011|NCT05773443|DEVICE|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
218976012|NCT03985111|DEVICE|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
219066919|NCT00000457|DRUG|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
219066920|NCT05483348|PROCEDURE|Endometrial Ablation|Thermal endometrial ablation
219066921|NCT05483348|PROCEDURE|Repeated gynecological procedure|subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
219066922|NCT05240105|OTHER|no intervention, purely observational|There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
219066923|NCT00991926|DRUG|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
219066924|NCT00991926|OTHER|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
219066925|NCT06175819|OTHER|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
219066926|NCT01742767|DRUG|Cisplatinum|
219066927|NCT01742767|DRUG|Pemetrexed|
219066928|NCT04897958|DRUG|Degarelix|Degarelix dispensing claim is used as the reference group.
218976013|NCT00149734|DRUG|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
218976014|NCT00149734|DRUG|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
218976015|NCT03810339|DRUG|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
218976016|NCT00154622|BEHAVIORAL|work hardening program|
218976017|NCT00412542|DRUG|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
218976018|NCT00412542|DRUG|CPT-11|125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
219066929|NCT04897958|DRUG|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
219066930|NCT06532175|DEVICE|Su-Jok|Su-jok seed therapy
219066931|NCT00352365|DRUG|lenalidomide|Given orally
219066932|NCT00170118|BEHAVIORAL|motivational interviewing|
219066933|NCT03132454|DRUG|Decitabine|Given IV
219066934|NCT03132454|DRUG|Dexamethasone|Given IV or PO
218976019|NCT00412542|PROCEDURE|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
218976020|NCT00412542|PROCEDURE|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
218976021|NCT02654314|DRUG|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
218976022|NCT02654314|OTHER|Placebo|Blue capsule matching the melatonin arm
218976023|NCT02670720|DRUG|avoralstat|
218976024|NCT01976195|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
218976025|NCT01976195|DRUG|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
218976026|NCT01200849|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
218976027|NCT00709657|DRUG|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
218976028|NCT04477889|OTHER|Treatment for COVID-19|Patients treated for COVID-19
219066935|NCT03132454|DRUG|Palbociclib|Given PO
219066936|NCT03132454|DRUG|Sorafenib|Given PO
219066937|NCT04743908|OTHER|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
219066938|NCT04837482|DRUG|AGN-190584|Topical eyedrop
219066939|NCT04837482|DRUG|Vehicle|Topical eyedrop
219066940|NCT01088932|DRUG|SRX246|capsules
219066941|NCT04941755|DRUG|BMS-986256|Specified dose on specified days
219066942|NCT04941755|DRUG|Famotidine|Specified dose on specified days
219208555|NCT06764732|BIOLOGICAL|Platelet rich fibrin|10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained
218976029|NCT02986971|DEVICE|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
218976030|NCT04894448|BIOLOGICAL|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
218976031|NCT01690637|DRUG|Oseltamivir phosphate suspension|
218976032|NCT01690637|DRUG|Placebo|
218976033|NCT00804622|DRUG|telbivudine|daily oral administration,600mg,over 12 weeks
218976034|NCT00804622|DRUG|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
218976035|NCT00804622|DRUG|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
218976036|NCT01199328|DRUG|Aspirin|81mg Tablet oral, once daily
218976037|NCT01199328|DRUG|Esomeprazole|20 mg Tablet oral, once daily
218976038|NCT05818098|DEVICE|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
218976039|NCT00351988|BEHAVIORAL|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
218976040|NCT00351988|BEHAVIORAL|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
218976041|NCT06643026|OTHER|Food preference|Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
218976042|NCT05735353|BEHAVIORAL|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
218976043|NCT05735353|BEHAVIORAL|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
218976044|NCT03076619|OTHER|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
218976045|NCT00690222|PROCEDURE|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
218976046|NCT06556290|OTHER|Gluten free and casein free diet|Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
218976047|NCT01473043|DRUG|Axitinib|5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
219066943|NCT02507895|DEVICE|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
219066944|NCT04097132|DEVICE|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
219066945|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
219066946|NCT02537912|DIETARY_SUPPLEMENT|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
219066947|NCT02537912|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
219066948|NCT03227770|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
219208556|NCT06764550|OTHER|This is an observational study, participants are not assigned an intervention as part of the study.|This is an observational study, participants are not assigned an intervention as part of the study.
219208557|NCT06762210|OTHER|AI Molar Mind|a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
218976048|NCT02140112|BIOLOGICAL|Trichuris suis ova|
218976049|NCT02140112|OTHER|Placebo|
218976050|NCT04547790|DIETARY_SUPPLEMENT|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
218976051|NCT04547790|DIETARY_SUPPLEMENT|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
218976052|NCT05034718|OTHER|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
218976053|NCT05034718|OTHER|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
218976054|NCT02836275|OTHER|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
218976055|NCT03387683|DRUG|dapagliflozin|dapagliflozin 10mg
218976056|NCT03387683|DRUG|placebo|placebo to match dapagliflozin
219066949|NCT03227770|DEVICE|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
219066950|NCT05489926|DRUG|Pamiparib|Pamiparib, 60mg PO BID
219066951|NCT03335553|DRUG|BMS-986235|Specified dose on specified days
219066952|NCT03335553|OTHER|Placebo|Specified dose on specified days
219667060|NCT07026630|DEVICE|Cooking In the Kitchen|"The virtual reality (VR) training tool simulates cooking, an activity of daily living (ADL). The layout of VR environments intentionally place ingredients, tools, and the recipe book far away from the user to require gross upper-limb physical movements. Successful step completion requires reaching to obtain ingredients or turn book pages, grabbing to hold or release objects, and chopping, scooping, stirring, and pouring motions to prepare food items. The VR tool includes three versions of varying graphical complexity: Simple, Standard, and Complex.~Complexity is controlled by stimuli count and detail level. For example, Simple features an empty room with monotone colors, basic shapes, and no extra features. In contrast, Complex resembles a fully-fledged kitchen with color patterns, textures, background details, and sounds."
219667061|NCT07026214|BEHAVIORAL|Vitalis Cancer|Participants receive five free health coaching sessions with a trained student health coach, access to three health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
219667062|NCT07027215|COMBINATION_PRODUCT|Gradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique|PNF technique
219667063|NCT07027215|COMBINATION_PRODUCT|selected physical therapy program as arm excercises|selected physical therapy program only. The program consisted of (core exercises, AROM exercises, and stretching exercises for LL for 18 sessions every other day, over 6 weeks
219667064|NCT07026799|OTHER|Exercise|Orthopedic consultation and home-based, individualized, structured resistance training during induction therapy.
218976057|NCT06557694|OTHER|Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
218976058|NCT02869503|OTHER|Data collection|
219066953|NCT01230593|DRUG|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
219066954|NCT01230593|DRUG|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
219066955|NCT01230593|OTHER|Hot Compresses|Hot compresses 3x/day to eyelids
219066956|NCT05905952|DIAGNOSTIC_TEST|balance and ROM assessment|assessment of postural stability and ankle range of motion
219066957|NCT06241326|OTHER|Immunotherapy-based Combination Therapies|immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
219066958|NCT03510572|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
218976059|NCT05191654|DIAGNOSTIC_TEST|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
218976060|NCT06302478|BEHAVIORAL|5E program|"Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission"
218976061|NCT05782712|BIOLOGICAL|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
218976062|NCT00794703|DRUG|micafungin (Mycamine)|Intravenous
218976063|NCT00794703|DRUG|itraconazole|oral
219066959|NCT06070714|DEVICE|Holmium laser with pulse modulation|The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.
219066960|NCT06070714|DEVICE|Thulium fiber laser|The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
219066961|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
219066962|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
219066963|NCT02061384|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
219066964|NCT02061384|DRUG|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
219066965|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
219208558|NCT06763614|BEHAVIORAL|Dog assisted therapy - animal interventions|Animal Assisted Therapy is when animals are used in goal directed treatment sessions. These goals are working emotionalaspects pf childres and adolescents with SAF
218976064|NCT00643396|RADIATION|thoracic radiotherapy|
219360318|NCT01308411|OTHER|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
219667065|NCT07026799|OTHER|Control group|Orthopedic consultation and stretching exercises/walking. No resistance training.
219667066|NCT01507532|OTHER|pharmacokinetic monitoring|pharmacokinetic monitoring
219667067|NCT04554342|OTHER|V01 candy|candy with sweetener (Isomalt) and apple flavour
219667068|NCT04554342|OTHER|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
219667069|NCT04554342|OTHER|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
219667070|NCT04554342|OTHER|V04 candy|candy with sweetener (Isomalt) (control group 1)
219667071|NCT04554342|OTHER|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
219667072|NCT07025889|DRUG|IBI343|"Subjects in the phase 1b stage will receive IBI343 3/4.5/6mg/kg intravenous infusion (IV) D1 Q3W in 3-week cycles.~Subjects in the phase 2 stage will receive IBI343 RP2D intravenous IV D1 Q3W in 3-week cycles."
219667073|NCT07025889|DRUG|Sintilimab|Subjects will receive sintilimab 200mg IV D1 Q3W in 3-week cycles.
218976065|NCT00722423|BEHAVIORAL|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
218976066|NCT00722423|BEHAVIORAL|Usual Care Model|
218976067|NCT01804023|OTHER|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
218976068|NCT01497275|DRUG|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
218976069|NCT06426719|PROCEDURE|Alveolar ridge wideninig via applying osseodensification protocol using densah burs|alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion
218976070|NCT06426719|PROCEDURE|Alveolar ridge widening via hand osteotomes|Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
218976071|NCT04400942|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
219066966|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
219066967|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
219066968|NCT00987467|DRUG|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
219667074|NCT07025889|DRUG|Oxaliplatin|Subjects will receive oxaliplatin 130mg/m2 IV D1 Q3W in 3-week cycles.
219667075|NCT07025889|DRUG|S-1|Subjects will receive S-1 40-60mg BID PO D1-14 Q3W in 3-week cycles.
219667076|NCT07027384|DEVICE|Web-Based Apps PRIMA|Apps PRIMA (posyandu monitoring tools) is delivered using a web-based app accessible through web browsers with basic core functionalities
219667077|NCT07027384|DEVICE|Apps PRIMA Mobile|Enhancement of Apps PRIMA delivered using a standalone mobile app. Enhanced core functionalities include the looping system of children measurements, automatic charts, and GEDSI-sensitive features
219667078|NCT07027384|BEHAVIORAL|Advance GEDSI Training|Additional training to address vulnerabilities in communities and empathetic service from CHWs to caregivers. The training is a follow-up training from a basic GEDSI materials already delivered to CHWs
219667079|NCT06884397|PROCEDURE|Abdominal aortic endoprosthesis|An endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta.
218976072|NCT04400942|BEHAVIORAL|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
219066969|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
219667080|NCT00106639|DRUG|CP-690,550|15 mg twice daily
219667081|NCT00106639|DRUG|CP-690,550|30 mg twice daily
219667082|NCT00106639|DRUG|tacrolimus|dose adjusted according to level
219667083|NCT02105389|BEHAVIORAL|Individualized Yoga Intervention|
219667084|NCT06750445|DRUG|Fluoxetine|Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
219667085|NCT06750445|DRUG|Polyethylene Glycol 400 0.4%|The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
219667086|NCT06759415|OTHER|Exercise|Exercise therapy was applied to individuals in both groups.
218976073|NCT04400942|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
218976074|NCT01950169|DRUG|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
218976075|NCT01950169|OTHER|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
218976076|NCT01950169|DIETARY_SUPPLEMENT|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
218976077|NCT00503529|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
218976078|NCT03948607|OTHER|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
218976079|NCT03292575|DRUG|Anticoagulants|
218976080|NCT04531839|BEHAVIORAL|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
218976081|NCT02899845|OTHER|postural task|
218976082|NCT02899845|OTHER|walk task|
218976083|NCT06206642|DIAGNOSTIC_TEST|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
218976084|NCT01424709|DRUG|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
218976085|NCT01424709|DRUG|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
218976086|NCT01954160|DEVICE|Symplicity Renal Denervation|Renal denervation
218976087|NCT05627297|OTHER|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
218976088|NCT05447897|OTHER|Qualitative Group Interviews|One time interview, 60-90 minutes
218976089|NCT05447897|OTHER|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
218976090|NCT03849248|OTHER|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
218976091|NCT04010032|DEVICE|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
218976092|NCT04010032|DEVICE|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
218976093|NCT05469581|OTHER|A set of preventive interventions to improve adherence in vulnerable elderly people|"* reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
218976094|NCT01680887|DRUG|Varenicline|
218976095|NCT01680887|DRUG|Placebo|
218976096|NCT05578911|OTHER|"medical students group"|medical student in general practice or in specialty medicine
218976097|NCT03920787|DIETARY_SUPPLEMENT|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
218976098|NCT03920787|OTHER|Placebo|2 capsules every day for 1 month
218976099|NCT02309593|DEVICE|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
219066970|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
219667087|NCT06770933|DRUG|VX-01|There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
219667088|NCT06770933|DRUG|Placebo|Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
218976100|NCT04915898|OTHER|Oral Hygiene - teeth brushing|Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
219066971|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
219066972|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
219667089|NCT04636671|DRUG|Methylprednisolone|Per-protocol methylprednisolone administration and tapering (see arm description)
219667090|NCT04636671|DRUG|Dexamethasone|Per-protocol dexamethasone administration (see arm description)
219066973|NCT06635031|PROCEDURE|Oral surgery|The patients were undergone routine oral surgeries. Surgical procedures included an incision on the oral mucosa and full-thickness flap reflection, and the primary wound closure was achieved by polyglactin absorbable sutures.
219667091|NCT06899451|OTHER|systematic desensitization and balance|"1. Systematic desensitization: 2 techniques~   1. Jacobson's technique (progressive muscle relaxation):~  2. Guided imagery training is a relaxation technique~2. Goal-directed paradigm (selected program)"
219667092|NCT04958291|DRUG|CC-99677|CC-99677
219667093|NCT04958291|OTHER|Placebo|Placebo
219667094|NCT02360202|PROCEDURE|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
219667095|NCT02360202|DRUG|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
219667096|NCT04328415|RADIATION|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
218976101|NCT05842733|DRUG|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
218976102|NCT05842733|DRUG|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
218976103|NCT05842733|DRUG|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
218976104|NCT01717911|DRUG|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
218976105|NCT01717911|DRUG|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
218976106|NCT01717911|DRUG|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
218976107|NCT03239184|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
219667097|NCT06762457|DRUG|MT-501|MT-501 Tablets
219667098|NCT03193034|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
219667099|NCT01490606|OTHER|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
219667100|NCT01490606|OTHER|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
219667101|NCT06906107|PROCEDURE|Cervical Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine facet joints
219667102|NCT06906107|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic, and scapular musculature
218976108|NCT03239184|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
218976109|NCT00702104|OTHER|survey administration|
218976110|NCT05189080|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
219066974|NCT05190081|OTHER|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
219667103|NCT06906107|PROCEDURE|Mobilization|Low velocity, low amplitude movements applied to the cervical spine facet joints (Grade I or II)
219667104|NCT00005817|DRUG|becatecarin|Given IV
218976111|NCT05189080|OTHER|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
219667105|NCT00005817|OTHER|laboratory biomarker analysis|Correlative studies
219667106|NCT05011890|DEVICE|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
219667107|NCT06649279|DEVICE|Oxygen reserve index|Measuring oxygen reserve index during preoxygenation and under general anesthesia
219667108|NCT04791605|OTHER|Gait analysis|Kinematic and kinetic analysis
219667109|NCT00771329|DRUG|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
219667110|NCT00771329|OTHER|Placebo (sterile normal saline)|Single IV dose of Placebo
219667111|NCT01210144|DRUG|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
219667112|NCT01210144|DRUG|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
219667113|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
219667114|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
219667115|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
219667116|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
219667117|NCT02664922|DRUG|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
219667118|NCT02664922|DRUG|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
218976112|NCT05189080|OTHER|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
218976113|NCT03673579|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
218976114|NCT03841812|DRUG|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
218976115|NCT03841812|DRUG|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
218976116|NCT03841812|DRUG|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
218976117|NCT03106350|OTHER|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
218976118|NCT01606644|PROCEDURE|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
218976119|NCT02055417|BEHAVIORAL|Personal Approaches to Treatment Choices for HIV|
218976120|NCT02055417|BEHAVIORAL|Stress Reduction Skills Program|
218976121|NCT01770496|BEHAVIORAL|Childhood vaccination reminder / recall notification|
218976122|NCT02518204|OTHER|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
218976123|NCT02518204|OTHER|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV"
218976124|NCT01340612|DEVICE|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
218976125|NCT01340612|DEVICE|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
218976126|NCT01554436|BEHAVIORAL|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
218976127|NCT03130608|OTHER|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
219667119|NCT02664922|DRUG|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
219667120|NCT02664922|DRUG|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
218976128|NCT01248208|BIOLOGICAL|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
219066975|NCT03999606|BEHAVIORAL|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
219066976|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
219360319|NCT06548659|BEHAVIORAL|screen-based simulation|Randomization took place among 198 people. The intervention group was given training on pediatric medication administration through screen-based simulation.
219667121|NCT02035774|PROCEDURE|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
219667122|NCT02865603|BEHAVIORAL|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
219667123|NCT05883059|DEVICE|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
219667124|NCT05883059|OTHER|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
219667125|NCT02913027|OTHER|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
219667126|NCT02913027|OTHER|Bimanual Exam|
219667127|NCT02913027|OTHER|Speculum Exam|
219667128|NCT04898972|BEHAVIORAL|Mindfulness-based stress reduction intervention|The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months. Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week. For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice. During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants. This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel. The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
219667129|NCT04898972|BEHAVIORAL|Information on stress reduction|"COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet Coping with your chronic disease, targeting COPD patients, to teach them how to manage stress. This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress."
219667130|NCT05542667|COMBINATION_PRODUCT|Giomer varnish|* After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
219667131|NCT05542667|COMBINATION_PRODUCT|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
219667132|NCT02660606|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
219667133|NCT04840459|BIOLOGICAL|BAMLANIVIMAB|n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
219667134|NCT04840459|BIOLOGICAL|CASIRIVIMAB|CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
218976129|NCT01248208|BIOLOGICAL|"Intramuscular influenza injection (flu shot)"|"Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
218976130|NCT01922557|DEVICE|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
219066977|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
219066978|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
219066979|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
219066980|NCT00512135|DRUG|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
219066981|NCT00761501|DRUG|PN400|Oral
219066982|NCT00761501|DRUG|Naproxen (Proxen S)|Oral
219066983|NCT00761501|DRUG|Naproxen (Naprosyn E)|Oral
219066984|NCT02646423|BEHAVIORAL|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
219066985|NCT01853449|DRUG|Fentanyl Citrate|
219667135|NCT04840459|BIOLOGICAL|IMDEVIMAB|IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
219667136|NCT06215300|GENETIC|coronary artery bypass grafting|coronary artery bypass grafting
219667137|NCT00494221|DRUG|AZD2171|oral tablet
219667138|NCT00494221|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
219667139|NCT00494221|DRUG|Placebo Cediranib|oral tablet
219667140|NCT00874562|DRUG|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
219667141|NCT00874562|DRUG|Rapamycin|Taken orally mixed with water or orange juice
219066986|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
219066987|NCT01853449|DRUG|Placebo|0.9% saline
219667142|NCT05922527|PROCEDURE|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
219667143|NCT05922527|PROCEDURE|Open flap debridement|Open flap debridement
219667144|NCT06729931|DIAGNOSTIC_TEST|Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement|The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
219667145|NCT04477694|PROCEDURE|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
219667146|NCT00732680|DRUG|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
219667147|NCT01900431|DRUG|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
219667148|NCT01900431|DRUG|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
219667149|NCT01900431|DRUG|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
219667150|NCT01900431|DRUG|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
219667151|NCT01900431|OTHER|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
219667152|NCT03526926|DRUG|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
219667153|NCT03040427|DRUG|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
219667154|NCT05655468|DRUG|Dronedarone|oral administration fed conditions
219667155|NCT05655468|DRUG|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
219667156|NCT02452840|OTHER|No Intervention|No Intervention
219667157|NCT03765424|DIAGNOSTIC_TEST|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
219667158|NCT00475514|DRUG|Frovatriptan 2.5mg QD|
219667159|NCT00475514|DRUG|Frovatriptan 2.5 mg BID|
219667160|NCT00475514|DRUG|placebo|
219066988|NCT00898716|DRUG|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
219066989|NCT02807948|DEVICE|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
219066990|NCT02138591|PROCEDURE|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
219066991|NCT02138591|PROCEDURE|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
219066992|NCT02138591|PROCEDURE|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
219066993|NCT04507191|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
219066994|NCT02937246|DEVICE|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
219066995|NCT02937246|DEVICE|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
219360320|NCT01420146|DRUG|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
219360321|NCT01846286|BEHAVIORAL|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
219667161|NCT04527913|BEHAVIORAL|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
219667162|NCT04527913|PROCEDURE|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
219667163|NCT04527913|PROCEDURE|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
219667164|NCT03755518|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
219667165|NCT03005613|PROCEDURE|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
219667166|NCT03005613|PROCEDURE|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
219667167|NCT03172364|OTHER|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
219667168|NCT03172364|OTHER|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
219667169|NCT01902355|PROCEDURE|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
218976131|NCT05962437|DEVICE|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
218976132|NCT05962437|DEVICE|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
218976133|NCT05962437|BEHAVIORAL|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
218976134|NCT04391491|DIAGNOSTIC_TEST|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
218976135|NCT00004198|BIOLOGICAL|keyhole limpet hemocyanin|
218976136|NCT00004198|BIOLOGICAL|sargramostim|
218976137|NCT00004198|BIOLOGICAL|tumor cell-based vaccine therapy|
218976138|NCT04554173|PROCEDURE|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
218976139|NCT01076231|RADIATION|proton beam radiation therapy|
218976140|NCT01076231|DRUG|cisplatin|Given IV
218976141|NCT01076231|DRUG|etoposide|Given IV
218976142|NCT01076231|PROCEDURE|therapeutic conventional surgery|
218976143|NCT01948037|OTHER|hydrotherapy|30-minutes/per day,for 4weeks
218976144|NCT01948037|OTHER|hydrotherapy|30-minutes/per day;4weeks
218976145|NCT02910869|GENETIC|Pathway Genomics FIT test|
218976146|NCT00142610|DIETARY_SUPPLEMENT|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
218976147|NCT03577873|OTHER|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
218976148|NCT03577873|PROCEDURE|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
218976149|NCT04956952|DEVICE|EECP|1 hour of treatment with EECP
218976150|NCT04810481|DEVICE|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
218976151|NCT04683562|OTHER|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
218976152|NCT04683562|OTHER|at delivery|women delivered at term
218976153|NCT02664610|BEHAVIORAL|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
218976154|NCT06448078|DEVICE|External chest wall fixator|External chest wall fixator is applied in the form of external bonding to the rib fracture area
219066996|NCT03830034|DRUG|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
219360322|NCT01846286|OTHER|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
219360323|NCT05483530|BIOLOGICAL|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
219667170|NCT01902355|PROCEDURE|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
219667171|NCT01348113|OTHER|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
219667172|NCT04936659|OTHER|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
218976155|NCT02585583|RADIATION|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
218976156|NCT03606629|DEVICE|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
219667173|NCT04463732|OTHER|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
219667174|NCT01714609|DRUG|Placebo|Placebo Comparator: Placebo
218976157|NCT01474369|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
218976158|NCT01474369|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
218976159|NCT01474369|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
218976160|NCT03369470|BEHAVIORAL|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
218976161|NCT03369470|BEHAVIORAL|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
219667175|NCT01714609|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
219066997|NCT03830034|DRUG|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
219066998|NCT04810598|DRUG|Venetoclax|Oral Tablet
219066999|NCT04962464|DIETARY_SUPPLEMENT|Peak Human Labs calorie mimetic supplement|Supplement
219067000|NCT04962464|BEHAVIORAL|Fasting Mimicking Diet|Diet
219067001|NCT04242927|DRUG|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
219067002|NCT04242927|DRUG|Routine care|Routinely apply urea ointment and provide best supportive care.
219067003|NCT06167668|OTHER|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
219067004|NCT06167668|OTHER|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
219067005|NCT03845608|COMBINATION_PRODUCT|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
219067006|NCT05880992|BEHAVIORAL|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
219067007|NCT05880992|DIETARY_SUPPLEMENT|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
219067008|NCT05880992|BEHAVIORAL|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
219067009|NCT02982252|BEHAVIORAL|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
219067010|NCT02624804|BIOLOGICAL|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
219067011|NCT02359526|DRUG|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
219067012|NCT01206738|BEHAVIORAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
219067013|NCT01206738|BEHAVIORAL|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
219067014|NCT01206738|BEHAVIORAL|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
219067015|NCT01331473|PROCEDURE|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
219667176|NCT04722952|DRUG|Visilizumab|Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) \> 5X109／L or white blood cell（WBC）\> 20X109／L.
219067016|NCT01331473|PROCEDURE|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
219067017|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
219067018|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
219667177|NCT06510387|DEVICE|Ultrasound using suprasternal method|"The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan."
219667178|NCT06510387|DEVICE|Ultrasound using subxiphoid method|Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.
219667179|NCT05449938|PROCEDURE|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
219667180|NCT00630747|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
219067019|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
219067020|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
219067021|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
219067022|NCT00317239|DRUG|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
219208559|NCT06763237|DEVICE|abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS)|"The TEAS intervention is delivered using an electroacupuncture device (SDZ-V, Hwato, Soochow Medical Instruments Co., Ltd., China). Self-adhesive electrodes are placed at acupoints Zhongwan (RN12), bilateral Tianshu (ST25), Qihai (RN6), and Guanyuan (RN4). Stimulation is applied using dense-sparse wave alternating frequencies (3 Hz for 2 s cycles) at an intensity of 3-10 mA, adjusted to the participant's tolerance. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions.~The ABA therapy focuses on enhancing skills in areas such as social interaction, communication, academics, motor function, and self-care. ABA is delivered in a variety of settings, including school, home, clinic, and other community settings. The goal of treatment is to help children function as independently and successfully as possible. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions."
218976162|NCT00061347|PROCEDURE|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
218976163|NCT01986946|OTHER|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
219067023|NCT00317239|DRUG|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
219067024|NCT00815841|DRUG|METHYLPHENIDATE|15-20mg during one of the two sessions
218976164|NCT01986946|DRUG|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
218976165|NCT01232595|DRUG|LFF571|
219067025|NCT02358577|DEVICE|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
219067026|NCT02358577|OTHER|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
218976166|NCT01232595|DRUG|Vancomycin (POC)|
218976167|NCT02263131|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
218976168|NCT02263131|BIOLOGICAL|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
218976169|NCT01230710|DRUG|Erlotinib|Erlotinib was supplied as tablets.
218976170|NCT00750386|DRUG|Paclitaxel|175 mg/m2, I.V, every 2 weeks
218976171|NCT00750386|DRUG|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
218976172|NCT03645590|BEHAVIORAL|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
218976173|NCT05843162|DRUG|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
219067027|NCT00798798|DEVICE|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
219208560|NCT06323837|DRUG|Mirtazapine|This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.
218976174|NCT05843162|DRUG|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
218976175|NCT00096083|DRUG|isolated perfusion|
218976176|NCT00096083|DRUG|melphalan|
218976177|NCT05982548|OTHER|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
218976178|NCT05982548|OTHER|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
218976179|NCT01570296|DRUG|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
219067028|NCT04157244|BEHAVIORAL|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
219067029|NCT01301963|DRUG|plerixafor|Given SC
219067030|NCT01301963|BIOLOGICAL|filgrastim|Given SC
219067031|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
219067032|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
219067033|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
219208561|NCT06323837|DRUG|Placebo|Placebo to match.
219208562|NCT06773403|DRUG|Upadacitinib|All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
218976180|NCT05601037|PROCEDURE|Axilla dissection + Lymphovenous anastomosis|surgical bypass between lymphatic vessel and vein
218976181|NCT00967629|DRUG|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
218976182|NCT00967629|DRUG|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
218976183|NCT03400566|BEHAVIORAL|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
218976184|NCT03400566|BEHAVIORAL|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
218976185|NCT04537429|DRUG|Eptinezumab|up to four iv infusions of eptinezumab
218976186|NCT04429360|PROCEDURE|pelvic reconstructive surgery|Pelvic reconstructive surgery
218976187|NCT04377243|BIOLOGICAL|V8|one pill per day either V8 or placebo
218976188|NCT01866722|BEHAVIORAL|Usual care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
218976189|NCT01866722|BEHAVIORAL|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
218976190|NCT01866722|BEHAVIORAL|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
218976191|NCT06203574|RADIATION|[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4|The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
218976192|NCT02490410|DIETARY_SUPPLEMENT|protein supplement|
218976193|NCT00452478|DRUG|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
218976194|NCT05581875|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
218976195|NCT05581875|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
218976196|NCT05581875|DRUG|Pomalidomide|Pomalidomide will be administered per os.
219667181|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
219667182|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
219667183|NCT03858894|DRUG|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
218976197|NCT05581875|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
218976198|NCT02808650|OTHER|Laboratory Biomarker Analysis|Correlative studies
219067034|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
219067035|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
219067036|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
219067037|NCT06531720|OTHER|control group|no medication has been prescribed
219067038|NCT04933682|DRUG|ALXN2050|Oral tablet.
219667184|NCT03858894|DRUG|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
219667185|NCT02732327|DRUG|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
219667186|NCT02732327|DRUG|Vancomycin|15 mg/kg
219667187|NCT02732327|DRUG|Linezolid|600 mg
219067039|NCT04933682|DRUG|Fluconazole|Oral tablet.
219667188|NCT02732327|DRUG|Cefepime|2 g
219667189|NCT02732327|DRUG|Meropenem|1 g
219667190|NCT02732327|DRUG|Piperacillin/tazobactam|4.5 g
219667191|NCT04592627|OTHER|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
219067040|NCT04933682|DRUG|Rifampin|Oral capsule.
219067041|NCT02600130|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
219067042|NCT02600130|BIOLOGICAL|Placebo|via peripheral intravenous infusion
219067043|NCT03900260|DEVICE|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
219067044|NCT03430154|OTHER|No treatment given|No treatment given
219067045|NCT00941239|DRUG|metformin ER|850mg daily for 30 days
219067046|NCT00941239|DRUG|metformin|850 mg daily for 30 days
219067047|NCT04511715|DRUG|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
219067048|NCT04511715|OTHER|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
219208563|NCT06781138|DEVICE|Conventional stabilization splint|conventional versus 3D designed and printed stabilization splints
219667192|NCT04803591|DRUG|Tranexamic Acid|Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
219667193|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
219667194|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
219667195|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
219667196|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
219667197|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
219667198|NCT02306694|DRUG|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
219667199|NCT04775576|OTHER|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
218976199|NCT02808650|OTHER|Pharmacokinetic (PK) study|Correlative studies
218976200|NCT02808650|DRUG|Prexasertib|Given IV
218976201|NCT03630367|DRUG|Dexamethasone|Intramuscular injection 8 mg
218976202|NCT03630367|DRUG|L-Carnitine 1G/5mL Injection|slow intravenous injection
218976203|NCT02350673|DRUG|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
218976204|NCT02350673|DRUG|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
218976205|NCT02939079|DRUG|Fingolimod|Produced by Osveh ® Pharm Company in Iran
218976206|NCT02939079|DIETARY_SUPPLEMENT|Fish Oil|produced by Zahravi ® Pharm Company in Iran
218976207|NCT02939079|DRUG|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
218976208|NCT00537875|DIETARY_SUPPLEMENT|Ginger|Capsule, 1000 mg, BID, 3 days
218976209|NCT00537875|DIETARY_SUPPLEMENT|Placebo|Capsule, 1000 mg, BID, 3 days
218976210|NCT04093414|DEVICE|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
218976211|NCT02666716|DRUG|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
218976212|NCT04209348|BEHAVIORAL|Physical Activity Intervention|Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
219667200|NCT04775576|OTHER|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
219667201|NCT04775576|OTHER|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
219667202|NCT00034944|DRUG|MK0869, aprepitant|
219667203|NCT00034944|DRUG|Comparator: placebo|
219667204|NCT03788668|PROCEDURE|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
219667205|NCT00902980|OTHER|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
219667206|NCT00603382|DRUG|GW685698X|GW685698X
219667207|NCT00603382|DRUG|Placebo|placebo comparator
219667208|NCT02237560|BEHAVIORAL|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
219667209|NCT02237560|BEHAVIORAL|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
219667210|NCT02237560|BEHAVIORAL|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
219667211|NCT03782974|DIETARY_SUPPLEMENT|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
219667212|NCT04437472|OTHER|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
219667213|NCT04728373|PROCEDURE|surgery|the need for surgery after aircraft accidents
219667214|NCT01500967|OTHER|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
219667215|NCT01500967|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
219667216|NCT03802435|PROCEDURE|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
219667217|NCT03802435|PROCEDURE|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
219667218|NCT03802435|PROCEDURE|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
219667219|NCT05869279|BIOLOGICAL|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
219667220|NCT04504149|BEHAVIORAL|Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD|A primary care-based shared decision making intervention
219667221|NCT00395642|DEVICE|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
219667222|NCT02119975|BEHAVIORAL|Working memory training|
219667223|NCT02119975|BEHAVIORAL|Placebo training|
219667224|NCT05273775|DRUG|HRS5091 Tablets|HRS5091 Tablets once daily
218976213|NCT04209348|OTHER|Wellness Education|The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
219067049|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
219067050|NCT02179112|PROCEDURE|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
219067051|NCT03360461|DRUG|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
219067052|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
219067053|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
219667225|NCT05273775|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
219667226|NCT05273775|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
219667227|NCT05273775|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
218976214|NCT05185323|OTHER|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
218976215|NCT05185323|OTHER|Breastfeeding usual known aids|Breastfeeding usual known aids
219067054|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
219667228|NCT05273775|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
219667229|NCT05273775|DRUG|Digoxin Tablets|Digoxin Tablets single dose
219667230|NCT05273775|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin Calcium Tablets single dose
219667231|NCT05202275|DRUG|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
219667232|NCT01569256|DRUG|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
219667233|NCT04684875|DEVICE|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
219667234|NCT01366300|DRUG|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
219667235|NCT01366300|OTHER|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
219667236|NCT01366300|DRUG|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
219667237|NCT01366300|PROCEDURE|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
218976216|NCT03236831|OTHER|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)"
218976217|NCT02396251|DEVICE|HA experimental|
218976218|NCT02396251|DEVICE|HA comparator|
218976219|NCT04868058|DRUG|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
218976220|NCT03539354|DEVICE|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
219067055|NCT03883672|BEHAVIORAL|Personality and transactional factors|"1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
219067056|NCT01659021|DRUG|Idelalisib|150 mg tablets administered orally twice daily
219067057|NCT01659021|DRUG|Ofatumumab|Administered intravenously
219067058|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
219208564|NCT06781138|DEVICE|3D designed and printed stabilization splints|Conventional versus 3D designed and printed stabilization splints
219667238|NCT05539261|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
219667239|NCT05539261|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
218976221|NCT03539354|PROCEDURE|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
218976222|NCT03539354|DRUG|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
218976223|NCT01367431|DIETARY_SUPPLEMENT|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
218976224|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
218976225|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
218976226|NCT01598168|DRUG|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
218976227|NCT02927262|DRUG|Gilteritinib|Oral tablet
218976228|NCT02927262|DRUG|Placebo|Oral tablet
218976229|NCT06344182|OTHER|Step Up and Down Test|Step Up and Down Test In the StUD test, the patient completes maximum number of step-up-down repetitions in 15 seconds. Starting from a standing position, the participant took a full step up, leading with the test leg, then the non-testing leg, until both knees were fully extended and both hips were at least in neutral extension. In order to stress the testing limb concentrically and eccentrically, the participant stepped off the step first with the non-testing limb, then the testing limb. The patient was asked to repeat for 15 seconds as quickly as possible. The physical therapist stood to the side of the step for safety and so that he/she could observe the technique and ensure that the participant came to a full step up and down during the test.
218976230|NCT00923936|DRUG|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
218976231|NCT00923936|DRUG|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
218976232|NCT01697358|DEVICE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
218976233|NCT01697358|DRUG|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
218976234|NCT00240227|DRUG|Prazosin|FDA approved medication for hypertension
218976235|NCT00240227|DRUG|placebo|
218976236|NCT02874287|DRUG|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
218976237|NCT02874287|DRUG|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
218976238|NCT01225627|OTHER|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
218976239|NCT01225627|OTHER|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
218976240|NCT00831350|DRUG|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
218976241|NCT05440188|DIAGNOSTIC_TEST|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
218976242|NCT06215612|OTHER|Blood draw, MRI|Blood draw, MRI
218976243|NCT04996641|PROCEDURE|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
218976244|NCT04485910|OTHER|Single step media|Usage of single step media in embryo culture
218976245|NCT04485910|OTHER|Sequential media|Usage of sequential media in embryo culture
218976246|NCT01237964|DRUG|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
218976247|NCT03694912|PROCEDURE|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
219067059|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
219067060|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
219067061|NCT04727866|DEVICE|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
218976248|NCT05394350|DRUG|MK-1088|Oral Tablet
219667240|NCT06911879|OTHER|Ketogenic diet with caloric restriction|Participants in this group will follow a ketogenic diet with caloric restriction (-550 kcal/day), consisting of approximately 5-10% carbohydrates, 15-25% protein, 70-80% fat. The daily carbohydrate intake will be limited to less than 50g per day. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
218976249|NCT05394350|BIOLOGICAL|Pembrolizumab|IV Infusion
218976250|NCT01336569|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
218976251|NCT03530800|DRUG|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
219067062|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
219067063|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
219067064|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
219067065|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
219667241|NCT06911879|OTHER|Normal diet with caloric restriction|Participants in this group will follow a normal diet with caloric restriction (-550 kcal/day), consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
219667242|NCT06911879|OTHER|Normal diet without caloric restriction|Participants in this group will follow a normal diet without caloric restriction, consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
219667243|NCT02993354|DEVICE|The EUM300 (electrical uterine myography)|This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
219667244|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
219667245|NCT00714753|RADIATION|brachytherapy|
219667246|NCT00714753|RADIATION|hypofractionated radiation therapy|
219667247|NCT00714753|RADIATION|image-guided radiation therapy|
218976252|NCT03530800|DRUG|Placebo|Placebo for 10 weeks
218976253|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
218976254|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
218976255|NCT02963935|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
218976256|NCT02963935|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
218976257|NCT02963935|BEHAVIORAL|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
218976258|NCT02993718|DRUG|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
218976259|NCT02993718|DRUG|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
218976260|NCT01296438|DRUG|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
218976261|NCT01296438|DRUG|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
218976262|NCT02192073|PROCEDURE|Suprapectoral Biceps tenodesis|
218976263|NCT02192073|PROCEDURE|Subpectoral biceps tenodesis|
218976264|NCT03929627|OTHER|Cortisol awakening response|Cortisol awakening response
218976265|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
218976266|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
218976267|NCT01924624|DRUG|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
218976268|NCT05661214|OTHER|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
218976269|NCT02273531|DRUG|Asasantin ER, new formulation|
219067066|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
219067067|NCT02620553|DRUG|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
219067068|NCT02620553|OTHER|Oral Placebo|Oral Placebo is given orally daily
219067069|NCT05605119|DRUG|AUR105|Once daily
219067070|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
219067071|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
219067072|NCT01842139|BIOLOGICAL|basiliximab|Given IV
219067073|NCT01842139|BIOLOGICAL|WT1 126-134 peptide vaccine|Given SC
219067074|NCT01842139|DRUG|Montanide ISA 51 VG|Given SC
219067075|NCT01842139|DRUG|poly ICLC|Given SC
219067076|NCT01842139|OTHER|laboratory biomarker analysis|Correlative studies
219067077|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
219667248|NCT00714753|RADIATION|intensity-modulated radiation therapy|
219667249|NCT02930161|DRUG|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
219067078|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
219067079|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
219067080|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
219067081|NCT00407537|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
219067082|NCT03787394|OTHER|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
219067083|NCT03094689|OTHER|Cold water immersion|
219067084|NCT03094689|OTHER|Water immersion|
219667250|NCT02930161|OTHER|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
219667251|NCT01578954|DRUG|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
219667252|NCT04747951|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
218976270|NCT02273531|DRUG|Asasantin ER, present commercial formulation|
218976271|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
218976272|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
218976273|NCT04037046|BEHAVIORAL|Screening HCV at primary care center|DBS for HCV screening at primary care center
218976274|NCT04348461|DRUG|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
218976275|NCT05806723|DRUG|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
218976276|NCT02337738|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
218976277|NCT02337738|DRUG|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
218976278|NCT02337738|DRUG|Placebo|Placebo Tablets
218976279|NCT04945031|OTHER|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
218976280|NCT00253760|DRUG|dietary amino acids; cysteine and methionine|
219667253|NCT04747951|PROCEDURE|TME|Total mesorectal excision
219667254|NCT04747951|DRUG|consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
219667255|NCT04747951|DRUG|adjuvant chemotherapy|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
219667256|NCT00409851|DRUG|valsartan+amlodipine|
219667257|NCT06618053|OTHER|cost-effectiveness and audiometry outcomes|Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
219667258|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
219667259|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
219667260|NCT05947227|OTHER|Buteyko breathing technique|Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise
219667261|NCT05947227|OTHER|Diaphragmatic breathing technique.|Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
219667262|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
218976281|NCT05612698|BEHAVIORAL|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
218976282|NCT05612698|BEHAVIORAL|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
218976283|NCT05612698|BEHAVIORAL|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
218976284|NCT00406354|DRUG|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
218976285|NCT00406354|DRUG|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
218976286|NCT00186329|DRUG|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
219667263|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
219667264|NCT04312282|DRUG|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
218976287|NCT01641510|DRUG|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
219667265|NCT04312282|DRUG|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
219667266|NCT03296020|OTHER|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
219667267|NCT04747873|BEHAVIORAL|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
219667268|NCT04747873|BEHAVIORAL|Stepped Care|Stepped care procedure (see arm/group descriptions).
219667269|NCT04724031|DRUG|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
219667270|NCT05690165|BEHAVIORAL|Walking Exercise|Heart rate controlled walking exercise
219667271|NCT04236167|DEVICE|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
219667272|NCT02804867|PROCEDURE|Online questionnaire and self-administered blood spot|
219667273|NCT04666844|OTHER|no intervention|Observational Study
218976288|NCT01641510|DRUG|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
219667274|NCT02951572|DEVICE|NIV|
219667275|NCT04910672|OTHER|Control Group|"Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression."
219667276|NCT04910672|OTHER|Experimental Group|"Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion."
219667277|NCT05233384|BIOLOGICAL|Blood test|"For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation)."
219667278|NCT02418741|OTHER|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
219667279|NCT06731439|OTHER|Starting feeds within 6 hours of life|Starting feeds within 6 hours of life
219667280|NCT06731439|OTHER|Standard feeding protocol|Starting feeds based on standard protocol as per primary team
218976289|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
218976290|NCT05427591|PROCEDURE|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
218976291|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
218976292|NCT05427591|PROCEDURE|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
218976293|NCT01304160|RADIATION|stereotactic body radiotherapy|30Gray in 5 fractions
218976294|NCT02207673|PROCEDURE|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
218976295|NCT03392077|PROCEDURE|Caesarean section|Caesarean section will be done to deliver the baby
218976296|NCT03392077|OTHER|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
218976297|NCT03392077|OTHER|No cervical dilatation|after delivery of the baby cervix will be remain closed
218976298|NCT02720237|BEHAVIORAL|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
218976299|NCT02720237|BEHAVIORAL|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
218976300|NCT02720237|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
218976301|NCT04595344|OTHER|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
218976302|NCT04595344|OTHER|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
219067085|NCT06486740|DEVICE|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
218976303|NCT04595344|OTHER|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
218976304|NCT05777343|OTHER|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
218976305|NCT05777343|OTHER|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
218976306|NCT05777343|OTHER|Cognitive training|Online sessions of cognitive training.
218976307|NCT01517685|DIETARY_SUPPLEMENT|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
218976308|NCT01517685|DIETARY_SUPPLEMENT|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
218976309|NCT00747461|DEVICE|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
218976310|NCT04870281|DEVICE|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
218976311|NCT01212107|DRUG|FGF Receptor|LY2874455 administered orally.
218976312|NCT01212107|DRUG|Phosphate Binders|
218976313|NCT00973271|DRUG|290 mg DCCR|290 mg diazoxide choline
219667281|NCT01676818|DRUG|eribulin mesylate|Given IV
219667282|NCT06460610|OTHER|Blow Bottle technique|Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing
219667283|NCT06460610|OTHER|Acapella along with Diaphragmatic Breathing|Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
219667284|NCT06730581|DRUG|Utidelone Capsule 60mg/m2/d|60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
219667285|NCT06730581|DRUG|Utidelone capsule 75mg/m2|75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
219667286|NCT06730581|DRUG|Utidelone Capsule|Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
219667287|NCT01174810|DRUG|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
219667288|NCT03349281|DRUG|Pevonedistat|Administered each cycle on days 1, 3 and 5.
219667289|NCT03349281|DRUG|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
219667290|NCT03349281|DRUG|Dexamethasone|Taken orally each cycle on days 2 through 15.
219667291|NCT03349281|DRUG|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
219667292|NCT03349281|DRUG|Doxorubicin|Administered via IV each cycle on day 2.
219667293|NCT03349281|DRUG|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
219667294|NCT03349281|DRUG|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
219667295|NCT03349281|DRUG|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
218976314|NCT00973271|DRUG|435 mg DCCR|435 mg diazoxide choline
218976315|NCT00973271|DRUG|135 mg fenofibric acid|135 mg fenofibric acid
218976316|NCT00973271|DRUG|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
218976317|NCT00973271|DRUG|atorvastatin|20 mg atorvastatin
218976318|NCT00753428|OTHER|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
218976319|NCT03276988|DRUG|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
218976320|NCT03276988|DRUG|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
219667296|NCT01507714|PROCEDURE|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
219667297|NCT01523210|OTHER|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
219667298|NCT06075810|DRUG|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
219667299|NCT05598710|PROCEDURE|Pigtail Insertion|Pigtail is inserted for any reason of ureteral obstruction except for malignant
219667300|NCT06446336|OTHER|HASS Score|Creation of a pre-operative score
219667301|NCT01432964|PROCEDURE|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
218976321|NCT02031211|DRUG|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
218976322|NCT02031211|DRUG|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
218976323|NCT05428098|OTHER|education|Oral and written education according to the life model
218976324|NCT05884710|OTHER|Foot core exercises|2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
218976325|NCT05884710|OTHER|Conventional Physiotherapy|Electrotherapeutic modalities and range of motion exercises
219667302|NCT01783821|DRUG|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
219667303|NCT01783821|DRUG|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
219667304|NCT01783821|DRUG|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
218976326|NCT02296944|OTHER|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
218976327|NCT00218127|DRUG|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
218976328|NCT00218127|DRUG|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
218976329|NCT00218127|DRUG|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
218976330|NCT00740077|OTHER|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
218976331|NCT06021665|OTHER|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
219667305|NCT03669484|DRUG|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
219667306|NCT03669484|DRUG|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
219667307|NCT03669484|DRUG|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
219667308|NCT03669484|DRUG|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
219667309|NCT02510313|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
219667310|NCT03723421|OTHER|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
219667311|NCT03723421|OTHER|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
219667312|NCT01029613|DRUG|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
218976332|NCT06021665|OTHER|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
218976333|NCT00299182|DRUG|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
218976334|NCT00299182|DRUG|Rituximab|375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
218976335|NCT00299182|DRUG|Cyclophosphamide|300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
218976336|NCT00299182|DRUG|Vincristine|1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
218976337|NCT00299182|DRUG|Doxorubicin|50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
218976338|NCT00299182|DRUG|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
218976339|NCT00299182|DRUG|Methotrexate|200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
219667313|NCT05306236|OTHER|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
218976340|NCT00299182|DRUG|Cytarabine|3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
218976341|NCT00299182|DRUG|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
218976342|NCT03325049|BEHAVIORAL|The health-promoting conversations|The health-promoting conversations
218976343|NCT03325049|OTHER|Usual Care|Usual Care
218976344|NCT04102956|DRUG|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
219667314|NCT02769936|DRUG|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
219667315|NCT02769936|OTHER|Placebo|Placebo administered orally as encapsulated pill
219667316|NCT02101333|DRUG|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
219667317|NCT05633277|PROCEDURE|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
219667318|NCT01665677|DRUG|Atorvastatin calcium|40 mg PO daily
219667319|NCT02333383|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
219667320|NCT02425033|PROCEDURE|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
219667321|NCT04294797|DIAGNOSTIC_TEST|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
219667322|NCT04270227|OTHER|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
219667323|NCT04956627|DRUG|BMS-986166|Specified dose on specified days
219667324|NCT04956627|DRUG|Itraconazole|Specified dose on specified days
219667325|NCT04956627|DRUG|Extended Phenytoin Sodium|Specified dose on specified days
219667326|NCT04956627|DRUG|Gemfibrozil|Specified dose on specified days
219667327|NCT01907217|DEVICE|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
219667328|NCT01907217|DRUG|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
218976345|NCT04609969|DIAGNOSTIC_TEST|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
218976346|NCT04609969|DIAGNOSTIC_TEST|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
219067086|NCT05369650|DRUG|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
219208565|NCT06779045|DRUG|AK-1286|Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
219208566|NCT04529616|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
219208567|NCT06752434|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
219667329|NCT01907217|DRUG|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
219667330|NCT00001863|DRUG|Leflunomide|
219667331|NCT00722163|OTHER|Cognitive Behavioural Therapy|
219667332|NCT00722163|OTHER|befriending|
219667333|NCT03409939|DIETARY_SUPPLEMENT|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
219667334|NCT03337035|DRUG|intranasal oxytocin|4-24 IU per day, dosage gradually increases
219667335|NCT03337035|DIETARY_SUPPLEMENT|oral probiotics|200 million cfu per day
219667336|NCT03337035|DIETARY_SUPPLEMENT|oral placebo|2 pills per day
219067087|NCT05841784|BEHAVIORAL|MBCT-T|MBCT-T is an 8-week group-based program that combines training in mindfulness and cognitive-behavioral therapy to reduce psychological distress and negative emotions. Each weekly 1-hour session will consist of a check-in, discussion, teaching, mindfulness or cognitive behavioral practice or exercise, inquiry by the facilitator, and summary of the at-home practice.
219067088|NCT05841784|BEHAVIORAL|Booster Mindfulness Sessions|Following the standard 8-week MBCT-T program, participants in certain arms will receive monthly MBCT-T booster sessions for 4 months of follow up. Each booster session will be 1 hour long. The sessions will include a concise review and summary of the main MBCT-T sessions.
219067089|NCT05841784|BEHAVIORAL|Website Support|Participants in certain arms will receive continuous intervention support via the use of an online study website. The website will provide quick access to intervention materials and support to encourage participants to complete the at-home practice and apply the content of the MBCT-T program to real life situations.
219067090|NCT06962501|DIETARY_SUPPLEMENT|Oral ketone monoester (KME)|The oral ketone monoester supplement should increase the global CBF and improve resting-state connectivity in the DMN in adults with SCD or MCI. The participants will take one dose of the supplement followed by measurement, to figure out if there are any noticeable changes.
219067091|NCT06636409|OTHER|Collection of medical data|A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
219067092|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
219067093|NCT05395494|DRUG|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
219067094|NCT05395494|DRUG|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
219067095|NCT05395494|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
219067096|NCT06635733|BEHAVIORAL|Rhapsode Capable™ Platform (Intervention Group)|Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
219067097|NCT06635733|BEHAVIORAL|Paper-based ISP (Control Group)|Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
219067098|NCT01316133|DRUG|tacrolimus|oral
219067099|NCT02842398|BEHAVIORAL|Balance Master|
219067100|NCT02842398|BEHAVIORAL|Customary Care|
219067101|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
219208568|NCT06752967|OTHER|High protein liquid test meal|High protein liquid test meal consisting of whey protein, water and sugar-free coadial mix for flavour.
219667337|NCT00001043|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219067102|NCT02736539|DRUG|Placebo|Placebo treatment
219067103|NCT05348681|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
219067104|NCT05348681|DRUG|Placebo|Matching placebo
219067105|NCT00782340|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219067106|NCT00782340|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219067107|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
219067108|NCT06059703|PROCEDURE|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
219067109|NCT06059703|PROCEDURE|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
219667338|NCT06318819|DEVICE|Dental Floss Holders|Dental Floss Holders for flossing purposes
219067110|NCT06059703|PROCEDURE|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
219067111|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
219067112|NCT05808725|DRUG|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
219667339|NCT03027323|DEVICE|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
219667340|NCT03652584|OTHER|High Protein Diet|
219667341|NCT03652584|OTHER|Control Diet|
219667342|NCT06514456|OTHER|no intervention|no intervention
219667343|NCT04580537|DRUG|Enstilar|Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
219667344|NCT04580537|DEVICE|Ablative fractional laser|Pre-treatment of affected fingers (nail plates, nail folds)
219667345|NCT00618709|DRUG|ATX-101|ATX-101 single dose
219667346|NCT00774007|DRUG|mesalazine|
219667347|NCT00774007|DRUG|placebo|
219667348|NCT03402347|RADIATION|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
219667349|NCT00986947|DRUG|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
219667350|NCT04038554|DIAGNOSTIC_TEST|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
219667351|NCT05106751|DEVICE|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
219667352|NCT02342977|DRUG|Placebo|Patients will randomly receive placebo
219667353|NCT02342977|DRUG|Lacosamide|Patients will randomly receive lacosamide
219667354|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Boost motivation and self-efficacy|"In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!."
219667355|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Future-selves and implementation intentions|"In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker."
219667356|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Identity-related positive self-talk|"In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud.."
218976347|NCT02413177|BEHAVIORAL|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
218976348|NCT02413177|BEHAVIORAL|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
218976349|NCT04685031|DRUG|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
218976350|NCT04685031|DRUG|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
218976351|NCT05956873|DEVICE|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
218976352|NCT01604187|DRUG|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
218976353|NCT01604187|DRUG|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
218976354|NCT03885440|OTHER|Age|Age\<40 years old is chosen as the cutoff value.
218976355|NCT03885440|OTHER|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
218976356|NCT06534034|PROCEDURE|Dental implant placement|Dental implant placement on edentulous jaw.
218976357|NCT00449410|DRUG|Atorvastatin|
218976358|NCT00449410|DRUG|ezetimibe|
219067113|NCT05808725|DRUG|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
219067114|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
219067115|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
219067116|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
219208569|NCT06752967|OTHER|High carbohydrate liquid test meal|High carbohydrate liquid test meal consisting of sucrose, water and sugar-free coadial mix for flavour.
219067117|NCT00595244|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
219067118|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
219208570|NCT06750848|DRUG|Chidamide，Fulvestrant，angiogenesis inhibitors|chidamide，30mg，po. biw fulvestrant ，500mg， im., d1(c1d15), q4w angiogenesis inhibitors , according to the doctor's advice
219208571|NCT06752616|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
219208572|NCT06752616|DRUG|Buccal midazolam|Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs
219667357|NCT05654545|BEHAVIORAL|Attention control dialog: neutral topic|"The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!)."
219667358|NCT03667027|DEVICE|Respiratory support|Mechanical ventilation or extracorporeal life support
219067119|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
219067120|NCT05970393|PROCEDURE|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
219067121|NCT01283269|BEHAVIORAL|Memory Support System|Training in use of a memory notebook system
219067122|NCT01283269|BEHAVIORAL|Computer Training|Computer brain fitness training
219067123|NCT00518947|DRUG|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
219067124|NCT00518947|DRUG|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
219067125|NCT00518947|DRUG|verapamil plus lithium|
219067126|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
219067127|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
219067128|NCT02107521|OTHER|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
219067129|NCT02107521|OTHER|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
219067130|NCT04276545|DRUG|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
219067131|NCT04276545|DRUG|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
219067132|NCT02958436|DRUG|REGN3500|
219067133|NCT02958436|DRUG|Placebo|
219067134|NCT02976766|DRUG|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
219067135|NCT02976766|DRUG|Placebo|Participants will receive placebo three times a day for 10 days.
219067136|NCT01788683|PROCEDURE|Regenexx SD|stem cell treatment
219208573|NCT06752616|DRUG|Oral lorazepam|Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
219208574|NCT06761911|DRUG|Brentuximab Vedotin (Bv)|1.2mg/kg/2w or 1.8mg/kg/3w
219667359|NCT00701480|OTHER|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
219667360|NCT00701480|OTHER|marketed skin cleanser|face washing 2-3 times/day
219667361|NCT03362580|DEVICE|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
219067137|NCT01788683|OTHER|Exercise Therapy|exercise therapy control
219667362|NCT03362580|DEVICE|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
219667363|NCT03362580|DEVICE|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
219667364|NCT03362580|DEVICE|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
219667365|NCT00030680|RADIATION|radiation therapy|
219667366|NCT06925854|DRUG|AZD4144|Oral tablet of AZD4144 will be administered.
219667367|NCT06925854|DRUG|Rosuvastatin|Oral tablet of rosuvastatin will be administered.
219667368|NCT01580176|DEVICE|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
219667369|NCT05083676|BEHAVIORAL|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
219667370|NCT06147960|DIAGNOSTIC_TEST|Immunohistochemistry|Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.
219667371|NCT01226680|DRUG|Tasocitinib|0.005% QD for 12 weeks
219667372|NCT01226680|DRUG|Tasocitinib|0.003% QD for 12 weeks
219667373|NCT01226680|DRUG|vehicle for Tasocitinib|vehicle QD for 12 weeks
219667374|NCT06531629|PROCEDURE|Surgery, radiation therapy and chemotherapy|Surgery, radiation therapy and chemotherapy
219667375|NCT03704948|BEHAVIORAL|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
219667376|NCT03704948|BEHAVIORAL|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
219667377|NCT03704948|BEHAVIORAL|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
219667378|NCT06379568|OTHER|No intervention|No intervention
219667379|NCT03832504|OTHER|No intervention|The participant will rest in a seated position.
219667380|NCT03832504|OTHER|Fan|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
219067138|NCT05212974|OTHER|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
219067139|NCT06528119|OTHER|COVID 19 pandemic|Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).
219067140|NCT03631979|OTHER|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
219067141|NCT04644328|BEHAVIORAL|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
219208575|NCT06761911|DRUG|Sintilimab|200mg/3w
219667381|NCT03832504|OTHER|Skin Wetting|Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
219067142|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
219067143|NCT02081651|DIETARY_SUPPLEMENT|Parmigiano Reggiano cheese|
219208576|NCT06761911|DRUG|Tislelizumab|200mg/3w
219208577|NCT06761911|DRUG|Bendamustine|90mg/m2/3w
219667382|NCT03832504|OTHER|Fan + Skin wetting|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
219667383|NCT03489941|DRUG|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
219067144|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
219067145|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
219067146|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
219067147|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
219067148|NCT06015776|OTHER|Gender|Differences between men and women will be observed
219067149|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
219067150|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
219067151|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
219067152|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
219067153|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
219067154|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
219067155|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
219067156|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
219067157|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067158|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067159|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067160|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067161|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067162|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
219067163|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
219067164|NCT06403592|OTHER|optic nerve sheath diamater|Measurement of optic nerve sheath diameter
219067165|NCT02596724|OTHER|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
219067166|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
219067167|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
219067168|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
219067169|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
219067170|NCT01455441|OTHER|Training and liraglutide|
219067171|NCT01455441|OTHER|Training and placebo|
219067172|NCT04757012|DEVICE|calinange|calinange
219067173|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
219067174|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
219067175|NCT00097812|DRUG|zoledronic acid|
219067176|NCT01693432|DRUG|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
219067177|NCT03144557|OTHER|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
219067178|NCT06532955|DEVICE|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|"The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure."
219667384|NCT03489941|DRUG|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
219667385|NCT03489941|DRUG|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
219667386|NCT01726621|DEVICE|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
219667387|NCT04361214|DRUG|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
219667388|NCT00198913|BEHAVIORAL|lower fat food supplied and education|
219667389|NCT00198913|BEHAVIORAL|gift cards for grocery foods and written education|
218976359|NCT03847870|DIAGNOSTIC_TEST|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
218976360|NCT01703273|BEHAVIORAL|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
218976361|NCT01703273|BEHAVIORAL|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
218976362|NCT03467048|DEVICE|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
218976363|NCT03467048|DEVICE|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
219067179|NCT06532955|PROCEDURE|Lymphaticovenous anastomosis (manual)|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
219067180|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
219067181|NCT05907369|OTHER|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
219067182|NCT05907369|OTHER|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
219067183|NCT05907369|OTHER|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
219067184|NCT05907369|OTHER|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
219667390|NCT04621838|OTHER|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
218976364|NCT03658057|DRUG|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
218976365|NCT04266223|DEVICE|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
219667391|NCT03001479|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
219667392|NCT03715387|DRUG|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
219667393|NCT03715387|DRUG|Polysporin Ointment|Polysporin ointment
219667394|NCT03718754|DEVICE|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
219667395|NCT03718754|DEVICE|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
219667396|NCT02314754|DRUG|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
219667397|NCT03632577|DEVICE|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
219667398|NCT03632577|DEVICE|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
218976366|NCT02284360|DRUG|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
218976367|NCT02281565|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
218976368|NCT05910814|BEHAVIORAL|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
218976369|NCT05910814|BEHAVIORAL|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
218976370|NCT05910814|BEHAVIORAL|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
218976371|NCT05910814|BEHAVIORAL|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
218976372|NCT05910814|BEHAVIORAL|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
219067185|NCT00810134|PROCEDURE|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
219067186|NCT00810134|PROCEDURE|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
219067187|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
219067188|NCT01736813|DRUG|Maraviroc|Twelve patients with 300 mg/bid
219067189|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
219067190|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
219067191|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
219067192|NCT00320658|BIOLOGICAL|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
219208578|NCT04789044|DRUG|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
219208579|NCT06752629|DRUG|Bupivacaine and Dexmedetomidine|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Dexmedetomidine 1mic/kg in the bilateral T5\&6 preoperatively
219067193|NCT00320658|BIOLOGICAL|CPG 7909|Adjuvant
219067194|NCT04153266|OTHER|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
219067195|NCT02580097|OTHER|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
219067196|NCT04144673|OTHER|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
219067197|NCT04144673|OTHER|Placebo|Placebo water with no active ingredients
219067198|NCT01704339|DRUG|QUTENZA|Single treatment with topical capsaicin 8%
219067199|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
219067200|NCT04993326|BEHAVIORAL|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
219667399|NCT05329727|DRUG|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
219667400|NCT05329727|DRUG|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
218976373|NCT05910814|BEHAVIORAL|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
218976374|NCT00224848|BEHAVIORAL|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
218976375|NCT02297048|DIETARY_SUPPLEMENT|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
218976376|NCT04170842|OTHER|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
218976377|NCT04143087|DRUG|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
218976378|NCT04459624|PROCEDURE|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
218976379|NCT04459624|PROCEDURE|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
218976380|NCT00590889|DEVICE|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
218976381|NCT00194909|DRUG|sildenafil (Viagra)|
218976382|NCT02561624|BEHAVIORAL|Behaviour change communication via text message|
218976383|NCT02402829|PROCEDURE|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
218976384|NCT00560768|DEVICE|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
218976385|NCT04612439|DEVICE|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
218976386|NCT04612439|DEVICE|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
218976387|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
218976388|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
218976389|NCT03344354|DEVICE|Biogel|Sterile surgical gloves used during surgical procedures.
218976390|NCT03344354|DEVICE|Ansell|Sterile surgical gloves used during surgical procedures.
218976391|NCT03344354|DEVICE|Cardinal|Sterile surgical gloves used during surgical procedures.
218976392|NCT03344354|DEVICE|Medline|Sterile surgical gloves used during surgical procedures.
218976393|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
218976394|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
218976395|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
219067201|NCT00259051|DRUG|Omeprazole|
218976396|NCT00072176|DRUG|temsirolimus|Given IV
218976397|NCT00072176|OTHER|laboratory biomarker analysis|Correlative studies
218976398|NCT03521219|DRUG|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
219067202|NCT02369029|DRUG|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
219208580|NCT06752629|DRUG|Bupivacaine and Fentanyl|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Fentanyl 20 microgram with the bilateral T5\&6 preoperatively
218976399|NCT04863235|BEHAVIORAL|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
218976400|NCT04863235|BEHAVIORAL|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
218976401|NCT06119724|PROCEDURE|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
218976402|NCT06119724|PROCEDURE|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
219067203|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)"
219208581|NCT06768125|RADIATION|Hypofractionated Radiation Therapy|95% PGTVp: 33 Gy in 3.3 Gy per session for 10 sessions, and 95% PTV1: 25 Gy in 1.5 Gy per session for 10 sessions, with an interval of 1-2 weeks, for a total of 2 cycles.
219067204|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
219067205|NCT03140436|DRUG|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
219067206|NCT03140436|DRUG|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
218976403|NCT00200096|PROCEDURE|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
218976404|NCT00200096|PROCEDURE|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
218976405|NCT03374631|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
218976406|NCT03374631|DEVICE|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
218976407|NCT00514566|DEVICE|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
218976408|NCT03980431|DIAGNOSTIC_TEST|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
218976409|NCT01902433|PROCEDURE|Astym|
218976410|NCT00065208|BEHAVIORAL|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
218976411|NCT00065208|BEHAVIORAL|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
218976412|NCT00065208|BEHAVIORAL|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
218976413|NCT04489459|DRUG|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
218976414|NCT04489459|DRUG|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
218976415|NCT04489459|DRUG|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
218976416|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
219067207|NCT05655793|DIAGNOSTIC_TEST|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
219067208|NCT05655793|DIAGNOSTIC_TEST|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
219067209|NCT02830594|RADIATION|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
219067210|NCT02830594|OTHER|Laboratory Biomarker Analysis|Correlative studies
219067211|NCT02830594|BIOLOGICAL|Pembrolizumab|Given IV
219067212|NCT05839769|DIAGNOSTIC_TEST|Evaluation of median nerve with ultrasound|ultrasound examination wrist
219067213|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
219067214|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
219067215|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
219067216|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
219067217|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
219067218|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
219067219|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
219067220|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
219667401|NCT00659776|DRUG|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
218976417|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
218976418|NCT02876094|DRUG|celecoxib|dose-response
219667402|NCT03972020|BEHAVIORAL|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
219667403|NCT03972020|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
219667404|NCT04332731|DEVICE|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
219667405|NCT04332731|DIAGNOSTIC_TEST|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
219667406|NCT02055274|DRUG|LY03003|
218976419|NCT03237078|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
218976420|NCT05396807|DEVICE|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
218976421|NCT05660681|DRUG|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
218976422|NCT05660681|DRUG|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
218976423|NCT04128774|DRUG|Dexamethasone|The case group receives dexamethasone based on the clinical indication.
218976424|NCT04502979|BEHAVIORAL|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
218976425|NCT02815410|DRUG|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
218976426|NCT04794088|DRUG|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
218976427|NCT04794088|DRUG|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
218976428|NCT00002078|DRUG|Interferon alfa-n3|
218976429|NCT03158987|OTHER|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
219067221|NCT05188846|OTHER|SDF|"1\. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
219667407|NCT02055274|DRUG|Neupro|
219667408|NCT01196663|DEVICE|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
219667409|NCT01196663|DEVICE|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
219667410|NCT00005624|DRUG|CI-994|CI-994 as outlined in treatment arm.
219667411|NCT01180049|DRUG|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
219667412|NCT01180049|DRUG|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
219667413|NCT03050112|OTHER|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
219667414|NCT00659542|PROCEDURE|cyanoacrylate glue|1 ml glue
218976430|NCT03049527|BEHAVIORAL|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
218976431|NCT01658852|DRUG|metronidazole|
218976432|NCT01658852|DRUG|Placebo|
218976433|NCT04399226|DRUG|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
219067222|NCT05188846|OTHER|SDF + ART (SMART technique )|2\. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
219067223|NCT05465889|DRUG|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
219067224|NCT05465889|DRUG|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
219067225|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
219067226|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
219067227|NCT02911948|DRUG|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
219067228|NCT02911948|DRUG|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
219067229|NCT03887468|DEVICE|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
219067230|NCT03887468|DEVICE|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
219067231|NCT05268146|BEHAVIORAL|Lifestyles|Co-creation process and participatory research; lifestyles
219067232|NCT00124527|DRUG|Irofulven + capecitabine|
219067233|NCT02866253|DRUG|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
219067234|NCT01204151|BEHAVIORAL|discrete-trial training|
219067235|NCT04340206|BEHAVIORAL|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
219067236|NCT04340206|BEHAVIORAL|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
219067237|NCT04340206|BEHAVIORAL|Control group, no intervention|Behavioral: No intervention
219067238|NCT05967520|DRUG|JMKX000189|JMKX000189 will be administered orally once a day
219067239|NCT05967520|DRUG|Placebo|Placebo will be administered orally once a day
219067240|NCT02040480|DRUG|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
219667415|NCT04504175|DRUG|Ketamine|ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
219067241|NCT02040480|DRUG|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
219067242|NCT03498248|DRUG|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
219067243|NCT05913622|DEVICE|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
219067244|NCT00291785|DRUG|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 \& 29 of each 42-day cycle
219067245|NCT00291785|DRUG|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
219067246|NCT00291785|DRUG|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
219067247|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
218976434|NCT03629210|DRUG|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
218976435|NCT03629210|BIOLOGICAL|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
218976436|NCT02929914|PROCEDURE|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
218976437|NCT02929914|PROCEDURE|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
218976438|NCT02929914|PROCEDURE|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
218976439|NCT02929914|PROCEDURE|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
218976440|NCT02929914|PROCEDURE|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
218976441|NCT01522508|PROCEDURE|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
218976442|NCT02966769|OTHER|Overall survival|Compare overall survival between both groups.
218976443|NCT04637113|OTHER|This is a non-interventional study|This is a non-interventional study.
218976444|NCT03191279|PROCEDURE|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
218976445|NCT04934475|DRUG|Isatuximab|Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
218976446|NCT04934475|PROCEDURE|ASCT|ASCT for ams B, C and D during consolidation
218976447|NCT01915966|DIETARY_SUPPLEMENT|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
218976448|NCT01915966|DIETARY_SUPPLEMENT|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
218976449|NCT04331236|BEHAVIORAL|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
218976450|NCT04331236|OTHER|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
218976451|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
219067248|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
219067249|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
219067250|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
218976452|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
218976453|NCT01751893|DRUG|Henna|natural henna in the form of paste
218976454|NCT01751893|DRUG|Placebo|placebo
218976455|NCT05269732|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
218976456|NCT03708848|DRUG|Esomeprazole|Proton pump inhibitor
218976457|NCT03708848|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
218976458|NCT03708848|DRUG|Clarithromycin|antibiotic for H. pylori eradication
218976459|NCT03708848|DRUG|Metronidazole|antibiotic for H. pylori eradication
218976460|NCT03708848|DRUG|Levofloxacin|antibiotic for H. pylori eradication
218976461|NCT03708848|DRUG|Tetracycline|antibiotic for H. pylori eradication
219067251|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
219067252|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
219067253|NCT05641493|COMBINATION_PRODUCT|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
219667416|NCT05920785|DIAGNOSTIC_TEST|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~* general blood test, general urine test,~* biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~* hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~* glycated hemoglobin,~* \- glucose tolerance test,~* ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~* blood pressure monitoring.~Special laboratory methods:~* Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~* analysis of feces for microbiota by MALDI-TOF mass spectrometry,~* bioimpedance measurement."
219667417|NCT00182000|DRUG|seromycin|100mg tablet administered 1 hour prior to each therapy session
218976462|NCT05769998|BEHAVIORAL|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
219667418|NCT00182000|BEHAVIORAL|Behavior Therapy|10 weekly hour-long behavior therapy sessions
219667419|NCT00750256|DRUG|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
218976463|NCT05769998|OTHER|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
218976464|NCT01237938|BEHAVIORAL|Low Glycemic Diet|Changing to low glycemic diet
218976465|NCT05772208|DRUG|Camrelizumab|camrelizumab 200mg q3w
218976466|NCT05772208|DRUG|Nimotuzumab|nimotuzumab 200mg qw
218976467|NCT05772208|DRUG|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
218976468|NCT01161784|DIETARY_SUPPLEMENT|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
219067254|NCT02096653|PROCEDURE|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
219067255|NCT02096653|PROCEDURE|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
219067256|NCT04488536|DIAGNOSTIC_TEST|Clinical Frailty Scale|Frailty assessment
219067257|NCT00518024|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
219067258|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
219067259|NCT03052179|DIETARY_SUPPLEMENT|Poly-biotic|Before-after treatment
219067260|NCT03756181|BEHAVIORAL|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
219067261|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
219067262|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
218976469|NCT01161784|DIETARY_SUPPLEMENT|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
219067263|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
219067264|NCT00424437|DRUG|Inhaled human insulin|
219067265|NCT03034148|DIAGNOSTIC_TEST|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
219667420|NCT01559688|BEHAVIORAL|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
219667421|NCT01559688|BEHAVIORAL|Waitlist|Fitness assessment or career counseling
219667422|NCT02585388|DRUG|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
219667423|NCT02585388|DRUG|Letrozole|Lestrozole at 2,5 mg every day , per oral
219667424|NCT02585388|DRUG|Anastrozole|Anastrozole at 1 mg every day, per oral
219667425|NCT00696228|DIETARY_SUPPLEMENT|Placebo|Placebo
219667426|NCT00696228|DIETARY_SUPPLEMENT|MUFA|MUFA
219667427|NCT00696228|DIETARY_SUPPLEMENT|PUFA|PUFA
219667428|NCT00696228|DIETARY_SUPPLEMENT|SFA|SFA
219067266|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
219067267|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
219067268|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
219067269|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
219067270|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
219067271|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
219667429|NCT04409015|DEVICE|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
219067272|NCT02261116|DRUG|Telmisartan|
219067273|NCT02261116|DRUG|Candesartan|
219067274|NCT02261116|DRUG|Placebo|
219667430|NCT04177888|DEVICE|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
219667431|NCT06731231|DRUG|SGLT2 inhibitor|Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
218976470|NCT04676698|BEHAVIORAL|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
218976471|NCT04676698|BEHAVIORAL|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
218976472|NCT01892865|OTHER|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
218976473|NCT01892865|OTHER|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
218976474|NCT04967378|BEHAVIORAL|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
218976475|NCT05345873|BIOLOGICAL|SCTV01E|one dose of SCTV01E on D0, intramuscular
218976476|NCT05345873|BIOLOGICAL|mRNA-1273|one dose of mRNA-1273 on D0, intramuscular
218976477|NCT05212519|OTHER||For observational research
218976478|NCT03645564|OTHER|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
218976479|NCT00646789|DRUG|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
218976480|NCT06966583|DIETARY_SUPPLEMENT|NAD supplement|NAD supplement NMN：NMN12000 GeneHarbor
219067275|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
219067276|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
219067277|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
219067278|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
219067279|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
219067280|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
219067281|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
219067282|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
219667432|NCT02004327|DRUG|DW1029M300mg|DW1029M300mg PO Once
219067283|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
219067284|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
219067285|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
219067286|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
219067287|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
219067288|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
219667433|NCT02004327|DRUG|DW1029M600mg|DW1029M300mg 2 tablets Once
219667434|NCT02004327|DRUG|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
219667435|NCT03875976|PROCEDURE|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
219667436|NCT03875976|PROCEDURE|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
218976481|NCT06966583|RADIATION|Radiotherapy|Low Dose Radiotherapy or Stereotactic Ablative Radiotherapy or Conventional Radiotherapy
218976482|NCT06966583|DRUG|Immunotherapy|PD-1 inhibitor
218976483|NCT01823978|BIOLOGICAL|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
218976484|NCT05951257|BEHAVIORAL|Personalized multimodal intervention involving hypnosis and/or music|"The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself."
219667437|NCT05731167|BEHAVIORAL|Multidomain frailty prevention method|We use the nutrition, physical training, medication consultation, cognition training to prevent the occurrence of frailty or other adverse outcome.
219667438|NCT05731167|OTHER|Regular follow up|Subjects will receive regular follow up and suggestion in outpatient department.
218976485|NCT06543043|DRUG|Phenytoin|Administered orally.
218976486|NCT06543043|DRUG|Itraconazole|Administered orally.
218976487|NCT06543043|DRUG|sonrotoclax|Administered orally.
218976488|NCT01558739|DRUG|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
218976489|NCT05201924|BEHAVIORAL|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
218976490|NCT05201924|BEHAVIORAL|Control|a healthy control checklist
218976491|NCT06424834|DRUG|Amlodipine|Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
219067289|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
219067290|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
219067291|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
219067292|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
219067293|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
219667439|NCT04792372|PROCEDURE|Initial periodontal treatment|Conventional periodontal treatment (scaling and root debridement) will be conducted
219667440|NCT04691167|DEVICE|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
219667441|NCT04008264|DRUG|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
219667442|NCT01036633|DEVICE|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
219667443|NCT00300833|DRUG|Tirofiban|pci
219667444|NCT03986554|PROCEDURE|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
218976492|NCT06424834|DRUG|Nebivolol|Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
218976493|NCT06424834|DRUG|Placebo|Placebo taken once orally daily.
218976494|NCT05652283|DRUG|Pamiparib|Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
218976495|NCT05652283|DRUG|Surufatinib|Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
219667445|NCT03986554|PROCEDURE|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (\< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
219667446|NCT06184139|DRUG|Misoprostol|Oral misoprostol for induction of labor in late term pregnancies
219667447|NCT00760812|BEHAVIORAL|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
218976496|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
218976497|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
219067294|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
219067295|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
218976498|NCT01049399|DRUG|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
218976499|NCT01049399|DRUG|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
218976500|NCT01049399|DRUG|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
218976501|NCT05606718|DRUG|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
218976502|NCT05606718|OTHER|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
218976503|NCT04048200|DRUG|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
218976504|NCT04048200|DRUG|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
218976505|NCT04938479|BIOLOGICAL|blood sample|D-dimer measurement in blood sample
218976506|NCT00894127|DEVICE|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
218976507|NCT02386306|DRUG|GC021109|
218976508|NCT02386306|OTHER|Placebo|
218976509|NCT06402643|PROCEDURE|Pterygium Excision|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
219667448|NCT00760812|BEHAVIORAL|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
219667449|NCT00350779|DRUG|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
219667450|NCT00350779|DRUG|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
219667451|NCT00350779|DRUG|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
219667452|NCT00350779|DRUG|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
219667453|NCT00350779|DRUG|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
219667454|NCT00005762|DRUG|Indinavir sulfate|
219667455|NCT00005762|DRUG|Ritonavir|
219667456|NCT00005762|DRUG|Amprenavir|
219667457|NCT00005762|DRUG|Nelfinavir mesylate|
219667458|NCT00005762|DRUG|Efavirenz|
219667459|NCT00005762|DRUG|Saquinavir|
219667460|NCT00427427|DRUG|Trastuzumab|
219667461|NCT02968680|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
219667462|NCT02968680|DEVICE|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
219667463|NCT02968680|DRUG|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
219667464|NCT03482895|BIOLOGICAL|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
218976510|NCT01945827|DEVICE|DeltaMaxx Microcoil System|
218976511|NCT03036319|DEVICE|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
219667465|NCT03482895|BIOLOGICAL|Feces sampling|Intestinal absorption assessment
219667466|NCT01053338|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
219667467|NCT03337906|OTHER|Observation|
218976512|NCT03036319|DEVICE|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
218976513|NCT03036319|BEHAVIORAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
218976514|NCT03036319|DEVICE|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
219667468|NCT04318262|BIOLOGICAL|Determination of the clinical and biological characteristics|"* clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
219667469|NCT04318262|BIOLOGICAL|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
219667470|NCT04318262|BIOLOGICAL|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
219667471|NCT03464474|DEVICE|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
219667472|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
219667473|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
219667474|NCT02972450|DRUG|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
219667475|NCT02972450|OTHER|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
219667476|NCT05206786|OTHER|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
219667477|NCT05206786|OTHER|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~1. Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~2. Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~3. Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~4. Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
219667478|NCT00588939|DEVICE|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
219667479|NCT02094248|DRUG|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
219667480|NCT02094248|DRUG|control|Normal saline，1ml/day, s.c injection
219667481|NCT05059925|OTHER|Structured gym activities|"Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
219667482|NCT05059925|OTHER|Traditional aerobic activities|"Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
219667483|NCT03571022|BEHAVIORAL|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
219667484|NCT06040216|OTHER|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
219667485|NCT01864252|OTHER|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
219667486|NCT01864252|DRUG|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
219667487|NCT01864252|DRUG|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
219667488|NCT01995864|BEHAVIORAL|CTI-TS|"The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
219667489|NCT00989859|DEVICE|Plethysmographic monitoring|Plethysmographic monitoring
219667490|NCT00482599|DRUG|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
218976515|NCT03036319|DEVICE|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
218976516|NCT03036319|DEVICE|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
218976517|NCT03036319|DEVICE|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
218976518|NCT03561753|DRUG|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
218976519|NCT03561753|DRUG|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
218976520|NCT05633693|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
219667491|NCT06101537|DEVICE|Brain temperature-pressure monitoring|An intracranial pressure monitoring device that continuously records brain temperature-pressure data was used during treatment.
219667492|NCT02087137|BEHAVIORAL|Memory and Aging Program|
219667493|NCT01979237|PROCEDURE|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
219667494|NCT02012959|DRUG|Tolvaptan|
219667495|NCT06052644|OTHER|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
219667496|NCT01865604|DEVICE|Anodal tDCS|
219667497|NCT01865604|DEVICE|Cathodal tDCS|
219667498|NCT01865604|DEVICE|sham tDCS|
219667499|NCT00726258|DRUG|ketamine|ketamine with various concentrations
219667500|NCT00726258|DRUG|placebo|physiological serum
219667501|NCT01687283|DRUG|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
219667502|NCT01687283|DRUG|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
218976521|NCT05633693|BEHAVIORAL|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
218976522|NCT05630092|DIAGNOSTIC_TEST|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
218976523|NCT05630092|DIAGNOSTIC_TEST|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
218976524|NCT06101563|PROCEDURE|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
218976525|NCT06101563|PROCEDURE|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
218976526|NCT06648798|DEVICE|Limber Limb|Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
218976527|NCT06386146|DRUG|JAB-30355|Oral administration
218976528|NCT06386146|DRUG|JAB-30355|Oral administration
218976529|NCT05868044|DEVICE|PRIMUS|PRIMUS system
218976530|NCT03408314|OTHER|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
219667503|NCT03351153|RADIATION|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
219667504|NCT03351153|RADIATION|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
219667505|NCT03351153|OTHER|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
219667506|NCT00642954|DRUG|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
219667507|NCT00642954|DRUG|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
218976531|NCT03408314|OTHER|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
219067296|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
219067297|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
219067298|NCT00893659|DIETARY_SUPPLEMENT|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
219667508|NCT00642954|DRUG|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
219667509|NCT02863653|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
219667510|NCT04361097|BIOLOGICAL|Faecal microbiota transplant|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
219667511|NCT04361097|BIOLOGICAL|Placebo|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
219667512|NCT06262022|OTHER|cold therapy|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
219667513|NCT01663857|DRUG|LY2228820|Administered Orally
219667514|NCT01663857|DRUG|Carboplatin|Administered IV
219067299|NCT00893659|DIETARY_SUPPLEMENT|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
219067300|NCT02200822|DRUG|beta blockers|
219667515|NCT01663857|DRUG|Placebo|Administered Orally
219667516|NCT01663857|DRUG|Gemcitabine|Administered IV
219667517|NCT01399398|PROCEDURE|Brain Scan-PET|
219667518|NCT01399398|PROCEDURE|Brain Scan-MRI|
219667519|NCT01399398|PROCEDURE|Arterial Line|
219667520|NCT01399398|PROCEDURE|Venous Line|
219667521|NCT01399398|PROCEDURE|Blood Sampling|
219667522|NCT06067581|BIOLOGICAL|SENL103|Patients will be treated with BCMA CAR-T cells
219667523|NCT00761371|DRUG|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
219667524|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
219667525|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
219667526|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
219667527|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
218976532|NCT04294277|DRUG|Pemigatinib|At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
218976533|NCT00430651|DRUG|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
218976534|NCT00430651|DRUG|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
218976535|NCT01067976|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
218976536|NCT00566111|DRUG|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
218976537|NCT00566111|DRUG|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
218976538|NCT03397173|DRUG|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
218976539|NCT03397173|DRUG|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
218976540|NCT05891561|DRUG|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
218976541|NCT06685250|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
218976542|NCT06683235|DIETARY_SUPPLEMENT|flaxseed|Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.
218976543|NCT06683222|DIAGNOSTIC_TEST|Blood sample|36 ml of blood in 3 x 7 ml dry tubes, 1 x 5 ml EDTA tube, 1 x 5 ml heparinized tube, 1 x 5 ml anti-protease tube)
218976544|NCT06683222|DIAGNOSTIC_TEST|Saliva sample|5 ml of saliva will be taken.
219067301|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
219667528|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
218976545|NCT06683222|DIAGNOSTIC_TEST|Grip test|The grip strength of the dominant arm will be measured with the participant in a standing position, with the arm close to the body and the elbow at 90◦ flexion, while the non-dominant arm will be positioned alongside the body. Three measurements will be taken for the dominant hand, and the mean value will be calculated and used for analysis. One minute is allowed between each repetition, to avoid muscle fatigue. Dynamometer quality control is ensured by regularly checking known resistance values.
218976546|NCT06683222|OTHER|MicroFET2® maximum isometric force test|The microFET2 device is used to test isometric force. The microFET2 dynamometer is battery-powered and ergonomically designed to fit in the palm of the hand. The system is microprocessor-controlled to provide accurate, repeatable muscle force readings. The microFET Clinical software automatically performs calculations and validity tests, and allows graphs to be generated from the data, enabling reports of different patient tests to be compared
218976547|NCT06683222|OTHER|Maximum isometric knee extension bench test.|The maximal isometric knee extension strength test on a specially-adapted strength bench consists in performing 3 maximal contractions with 1 minute's rest between each test.
218976548|NCT06683222|OTHER|The SPPB (Short Physical Performance Battery)|Battery of tests comprising a balance test, a walking speed test and a chair-lift test
219067302|NCT02276482|DRUG|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
219067303|NCT02276482|DRUG|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
219067304|NCT02276482|DRUG|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
219667529|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
219667530|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
219667531|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
219667532|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
219667533|NCT04521842|PROCEDURE|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
219667534|NCT03548350|BEHAVIORAL|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
219667535|NCT00806858|DEVICE|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
219667536|NCT00797940|DRUG|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
219667537|NCT03041467|DEVICE|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
219667538|NCT03041467|DEVICE|Standard Balloon Angioplasty|Standard PTA Balloon
219667539|NCT05777564|OTHER|High intensity exercise|High intensity exercise on a indoor aerobic exercise device.
219667540|NCT04505254|DRUG|Acalabrutinib|Given PO
219667541|NCT04505254|BIOLOGICAL|Obinutuzumab|Given IV
219667542|NCT00274547|DRUG|Tiotropium|
219667543|NCT05319262|RADIATION|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
219667544|NCT05319262|RADIATION|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
219667545|NCT01569698|PROCEDURE|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
219667546|NCT05599386|DIAGNOSTIC_TEST|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
219667547|NCT02528617|DRUG|Velaglucerase alfa|Enzyme replacement therapy
218976549|NCT06683222|OTHER|The 6-minute walking test.|Muscular function will be determined by the 6-minute walk test to assess aerobic endurance. Participants will be asked to walk for 6 min as fast as possible on a shuttle track. The distance (m) covered in 6 min will be measured. Walking speed (m/s) will be calculated as the distance (m) covered in 6 min. A walking speed \<0.8 m/s has been defined as a low value.
218976550|NCT06683222|OTHER|Segmental impedancemetry examination.|Segmental impedancemetry involves measuring body composition using the body's resistance to the passage of a low-intensity electric current. This test is harmless to the body.
219067305|NCT02276482|DRUG|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
219067306|NCT00172510|PROCEDURE|blood drawing|
219067307|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
219067308|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
219067309|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
219067310|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
219667548|NCT05614401|OTHER|functional and medical information|1\) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
219667549|NCT05968430|DRUG|lorundrostat|Tablet, administered orally
219667550|NCT05968430|DRUG|Placebo|Tablet, administered orally
219667551|NCT06549881|PROCEDURE|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
219067311|NCT02267382|DRUG|VT-1161|
219067312|NCT02267382|DRUG|Placebo|
219067313|NCT05046457|DIETARY_SUPPLEMENT|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
219067314|NCT01165281|DRUG|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
219067315|NCT01165281|DRUG|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
219067316|NCT00058266|DIETARY_SUPPLEMENT|genistein|Given orally
219067317|NCT00058266|PROCEDURE|conventional surgery|Patients undergo surgery
219067318|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
219667552|NCT02732015|DRUG|Dexamethasone|Given IV
218976551|NCT06683222|OTHER|Indirect calorimetry test.|An Indirect calorimetry is the standard method for measuring energy expenditure at rest. It is based on the principle that the human body burns nutrients using O2 and producing CO2.
218976552|NCT06683222|OTHER|Fardellone's questionnaire|Completion of a questionnaires on calcium intake (Fardellone)
218976553|NCT06683222|OTHER|ONAPS questionnaire|The ONAPS questionnaire contains questions on physical activity and sedentariness
218976554|NCT06683222|OTHER|Dietary intake.questionnaire|The dietary intake questionnaire contains questions regarding the person's eating habits - how many meals a day, where they eat, whether they eat alone, what foods they eat/drink and whether they are following a particular diet and, if so, the reasons why.
219667553|NCT02732015|DRUG|Doxorubicin|Given IV
219667554|NCT02732015|DRUG|Fosaprepitant Dimeglumine|Given IV
219667555|NCT02732015|DRUG|Ifosfamide|Given IV
219667556|NCT02732015|OTHER|Laboratory Biomarker Analysis|Correlative studies
219667557|NCT02732015|DRUG|Mesna|Given IV
219667558|NCT02732015|DRUG|Ondansetron|Given IV
219667559|NCT02732015|OTHER|Questionnaire Administration|Ancillary studies
219667560|NCT02732015|DRUG|Rolapitant Hydrochloride|Given PO
219667561|NCT02732015|DRUG|Vincristine Sulfate|Given IV
219667562|NCT03052920|DEVICE|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
219667563|NCT00488137|DRUG|Prucalopride|2 mg o.d.
219667564|NCT00488137|OTHER|Placebo|o.d.
219667565|NCT00488137|DRUG|Prucalopride|4 mg o.d.
219667566|NCT01980628|DRUG|ibrutinib|
219667567|NCT04465656|DIAGNOSTIC_TEST|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)"
219667568|NCT03550547|OTHER|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
219667569|NCT03550547|OTHER|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
219667570|NCT06955689|OTHER|Non invasive focal vibration with heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 120 Hz for 10 minutes while pedaling at 90-100 rpm
219667571|NCT06955689|OTHER|Non invasive focal vibration without heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 0 Hz for 10 minutes while pedaling at 90-100 rpm
219667572|NCT03015194|DEVICE|Edwards SAPIEN 3 transcatheter heart valve|"Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position."
219667573|NCT03015194|DEVICE|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
219667574|NCT02707172|BEHAVIORAL|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
219667575|NCT02707172|BEHAVIORAL|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
218976555|NCT01554397|RADIATION|PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing
218976556|NCT01554397|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
219067319|NCT00113438|DRUG|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
218976557|NCT01554397|RADIATION|IMRT|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
219067320|NCT01700608|DRUG|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
219067321|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
219067322|NCT00005853|BIOLOGICAL|etanercept|
219067323|NCT00006060|DRUG|standard gadolinium contrast|
219067324|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
219067325|NCT03591744|DRUG|Bortezomib|Given SC
219067326|NCT03591744|BIOLOGICAL|Daratumumab|Given IV
219067327|NCT03591744|DRUG|Dexamethasone|Given IV and PO
219667576|NCT02844894|DRUG|Dexmedetomidine|
219667577|NCT02844894|DRUG|Esmolol|
219667578|NCT02844894|DRUG|Placebo|normal saline
219667579|NCT03866629|DRUG|Lifitegrast|Lifitegrast ophthalmic solution 5%
219667580|NCT05633589|BIOLOGICAL|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
219667581|NCT04611282|PROCEDURE|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
219667582|NCT05989919|OTHER|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
219667583|NCT06304402|DEVICE|The Percussive Massage Treatment|In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.
219667584|NCT06304402|BEHAVIORAL|The Proprioceptive Neuromuscular Facilitation Stretching|Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
219667585|NCT04757805|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
219667586|NCT02469168|DEVICE|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
219067328|NCT03591744|DRUG|Lenalidomide|Given PO
219067329|NCT03591744|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219067330|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
219067331|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
219067332|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
219067333|NCT01154634|DRUG|Placebo|Capsule, oral
219067334|NCT02069600|DEVICE|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
219067335|NCT01510847|DRUG|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
219067336|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
219067337|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
219067338|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
219067339|NCT00326378|DRUG|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
219067340|NCT00326378|DRUG|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
219667587|NCT02469168|PROCEDURE|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
219667588|NCT04191343|DRUG|Toripalimab injection combined with GEMOX|Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
218976558|NCT06708533|BEHAVIORAL|Physical Activity|"This intervention involves a structured 12-week walking program designed to increase routine physical activity among participants diagnosed with IBS. The intervention focuses on moderate-intensity walking, performed regularly, in line with World Health Organisation (WHO) guidelines with the aim of relieving IBS symptoms.~Key elements include:~Participants will be guided to adhere to an individualised walking protocol, ensuring consistency in activity levels.~Physical activity levels will be monitored using self-reported diaries and wearable activity trackers to ensure compliance.~Participants will also attend three scheduled visits to the university (baseline, week 6, and week 12) for biological sample collection, sub-maximal fitness assessments, and the completion of validated questionnaires on IBS symptoms, quality of life (QoL), anxiety, and depression."
218976559|NCT06707129|OTHER|life-style|The patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.
219067341|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
219067342|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
219067343|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
218976560|NCT06707948|PROCEDURE|Arthroscopic meniscus surgery|Comparison of the incidence of osteoarthritis with conservative treatment as well as arthroscopic partial resection as well as arthroscopic repair surgery for a condition known as posterior meniscus root injury.
218976561|NCT06710236|DEVICE|Hearing instrument|Conventional, daily wear hearing instruments will be used in this study.
219067344|NCT00171977|DRUG|Imatinib Mesylate|
219067345|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
219067346|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
219067347|NCT02005471|DRUG|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
219667589|NCT03323970|OTHER|semi-structured interviews|individual semi-structured interviews
219667590|NCT03955900|OTHER|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
219667591|NCT05498064|DRUG|Ensartinib|Ensartinib 225 mg administered once daily orally
219667592|NCT04823806|DIETARY_SUPPLEMENT|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
219667593|NCT01872806|RADIATION|a dialing smartphone will be placed on the chest and the ear|
219667594|NCT04563637|DIAGNOSTIC_TEST|Computer based vision application by video|patients will be tested by computer based analysis of a video as well as by dexa scan.
219667595|NCT04563637|RADIATION|whole body dual energy x-ray absorptiometry scan|subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
219667596|NCT04193553|DRUG|Lenvatinib|"Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met."
219667597|NCT04193553|DRUG|Placebo|"Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm."
219667598|NCT04193553|OTHER|Best supportive care|At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
219667599|NCT00562731|DRUG|ARD-0403|Daily transdermal ARD-0403
219667600|NCT01741350|BEHAVIORAL|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
219067348|NCT02005471|DRUG|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
219067349|NCT02005471|DRUG|Rituximab|"Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
219067350|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
219550000|NCT02976064|BEHAVIORAL|Rehabilitation in mild chronic patients and citizens at risk|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
218976562|NCT06710808|OTHER|Virtual walking and transcranial direct current stimulation|"Participants will receive VW-therapy combined with tDCS. The intervention is adapted from Soler et al. 2010 and consists of 10 sessions over 2 weeks, each session lasting around 20 minutes.~For the virtual walking the participant sits on a modified wheelchair, which is positioned at a distance of two meters from the screen. The setting provides an illusion of a third person perspective and the participant can see himself/herself walk through a forest ambience.~The tDCS session is according the same protocol from Soler et al., 2010. Hereby, the device from Starstim, Neuroelectrics will be used, which is equipped with a neoprene cap containing electrodes. The anodes will be placed over C3 or C4 (EEG 10/20 system) to target the motor cortex (M1) contralateral to the painful side and the cathodes will be placed over the contralateral supraorbital area. Symmetric pain participants receive stimulation on the dominant hemisphere. The tDCS applies a constant current of 2 mA over 20 minutes."
218976563|NCT06706843|BEHAVIORAL|Transtheoretical Model Based Motivational Interviewing|Transtheoretical Model Based Motivational Interviewing was applied to haemodialysis patients in 6 sessions.
218976564|NCT06706843|OTHER|routine clinical care|routine clinical care
218976565|NCT02137421|DIETARY_SUPPLEMENT|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
219067351|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
219667601|NCT01741350|BEHAVIORAL|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
219067352|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
219067353|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
219067354|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
219067355|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
219667602|NCT03952026|PROCEDURE|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
219667603|NCT02686788|DRUG|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
219667604|NCT06458777|DIAGNOSTIC_TEST|poligraphy|OSA diagnosis
219667605|NCT00335010|DRUG|Nitroglycerin|
219667606|NCT00495690|DRUG|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
219667607|NCT04990765|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
219667608|NCT04990765|BEHAVIORAL|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
219667609|NCT02644447|BIOLOGICAL|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
219667610|NCT02644447|BIOLOGICAL|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
219667611|NCT04457401|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
218976566|NCT06908382|DRUG|Iparomlimab and Tuvonralimab Injection|QL1706 (5 mg/kg, q3w) +Paclitaxel for injection (albumin bound) (260mg/m2 D1, q3w)+cisplatin (75mg/m2 D1, q3w)/carboplatin (AUC 5 D1) ， 3 cycles
218976567|NCT06913569|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
218976568|NCT06913569|PROCEDURE|EBUS-TTFB|Participants with lymphadenopathy would receive EBUS-TTFB attempts to conduct diagnoses.
218976569|NCT06921655|PROCEDURE|Variation of Pressure Support Levels|Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).
218976570|NCT06924073|OTHER|ATP-Youth Enhanced Strategy (ATP-YES)|ATP-YES is a multi-component youth led implementation strategy that incorporates data audits and feedback, cyclical small tests of change and learning collaboratives
218976571|NCT06934629|DEVICE|TECAR therapy|TECAR application will be 20 mins per session (10 mins capacitive and 10 mins resistive) during ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
218976572|NCT06934629|OTHER|therapeutic exercises|the conventional therapy which is ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
218976573|NCT06933823|BEHAVIORAL|Dietary modification intervention involving family support|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The participants will be asked to invite one of their family members to attend the sessions together. Family members will be engaged in discussions to help enhance the participant's adherence to the recommended diet regimen. The aims of the sessions are to raise awareness among participants and their families about sarcopenia obesity and the recommended dietary modifications, emphasizing the critical role of family in supporting adherence to these changes. It also focuses on boosting participants' motivation, reducing barriers to dietary adjustments, and enhancing family-driven social support to help sustain long-term adherence to the prescribed regimen.
219067356|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
219550001|NCT00842816|DRUG|ST101|10 mg; administered once/day
219550002|NCT00842816|DRUG|ST101|60 mg; administered once/day
219550003|NCT00842816|DRUG|ST101|120 mg; administered once/day
219550004|NCT00842816|DRUG|Placebo|placebo tablets to match ST101 tablets
219550005|NCT03968016|DEVICE|SYSMEX HLSCL|Diagnostic device
219550006|NCT02223169|DIETARY_SUPPLEMENT|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
219550007|NCT01390948|DRUG|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
219208582|NCT06769893|DIAGNOSTIC_TEST|68Ga-NOTA-RCCB6 PET/CT Scan|"The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations.~Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL."
219667612|NCT04457401|DIETARY_SUPPLEMENT|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
219667613|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
219667614|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
219667615|NCT00255840|DRUG|Efavirenz|600 mg tablet taken orally daily
218976574|NCT06933823|BEHAVIORAL|Dietary modification intervention|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The sessions will only focus on educating the participants on following the dietary regimen and addressing the barriers they may encounter during dietary modification without family involving in the intervention.
218976575|NCT06934317|DIAGNOSTIC_TEST|measurement of maximum bite force using bite fork|using bite fork the bite force will be recorded for all teeth preoperative and post operative
218976576|NCT06934317|PROCEDURE|conventional root canal treatment|General principles of conventional endodontic treatment will be applied in all cases, such as the administration of an appropriate local anaesthetic and rubber dam isolation. access and cleaning and shaping using rotary files and obturation. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
218976577|NCT06934317|PROCEDURE|pulp revascularization by induced bleeding|Regeneration procedures will be conducted in two appointments, adhering to the 'Clinical Considerations for a Regenerative Procedure' proposed by the American Association of Endodontists (AAE) in 2021. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
218976578|NCT06934317|PROCEDURE|MTA apexification|MTA apical plug will be randomly applied to teeth with open apex
219667616|NCT00255840|DRUG|Lamivudine|150 mg tablet taken orally daily
219667617|NCT00255840|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
218976579|NCT06934967|DRUG|LNP023|Cohort 1-administered orally a dosing scheme of 200 mg twice-daily (two 100 mg capsules). Cohort 2- administered orally a dosing scheme based on weight at the Day 1, Week 12, 26 and 38.
219667618|NCT00255840|DRUG|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
219667619|NCT00255840|DRUG|Stavudine|Tablet taken orally daily. Dosage depends on weight.
218976580|NCT06934759|OTHER|No Intervention: Observational Cohort|There is no intervention
218976581|NCT06934928|DEVICE|GentleMax Pro (with skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration.~The laser system includes a dynamic cryogen spray cooling device (DCD) for epidermal protection. A spurt of cryogen cools the epidermis just before arrival of the treatment laser pulse."
218976582|NCT06934928|DEVICE|GentleMax Pro (without skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration."
218976583|NCT06933186|BEHAVIORAL|Neuropsychological rehabilitation|Neuropsychological rehabilitation includes an integrated approach, consisting of three components: cognitive training; psychoeducation; and social skills/emotional management training. Cognitive training uses a combination of different tasks (always covering attention, memory and executive functions exercises), with a 30-minute session on the online cognitive training platform and 1 hour of pencil and paper exercises in a group, in a total of 36 sessions . Psychoeducation addresses specific topics related to Alcohol Use Disorder and its cognitive impact. Social skills/emotional management training includes problem-solving exercises, assertiveness training, emotion identification and management, among others. These sessions will be held once a week, for a total of 12 sessions.
218976584|NCT06933186|BEHAVIORAL|Weekly therapeutic groups|The control group will attend weekly therapeutic groups, which consist of open groups, aimed to promote abstinence and relapse prevention, supporting the management of difficulties in the person's daily life related to consumption, promoting psychoeducation about the disease and coping strategies to deal with craving
218976585|NCT06933719|OTHER|Study on existing health data|Study on existing health data
218976586|NCT06933667|BEHAVIORAL|Physical Activity|Participants can chose (with input from a kinesiologist as required) from courses of varying intensity in our gym, warm water pool, or classrooms.
218976587|NCT06933667|BEHAVIORAL|Brain-healthy Eating|Participants take five foundational courses: Brain-healthy eating, Healthy protein choices, Colour your diet: Maximize the benefits of fruits and vegetables; Interpreting nutrition facts labels; and Salt and sugar: How much is too much? They are also encouraged to take additional nutrition programs.
218976588|NCT06933667|BEHAVIORAL|Cognitive Engagement|Participants can sign up for any lecture, discussion group, book club, creative arts program, etc. linked to the Cognitive Engagement risk factor.
219067357|NCT05016492|DEVICE|Visual-perceptual interactive game system|Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.
219067358|NCT05016492|BEHAVIORAL|standard rehabilitation|Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
219067359|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
219067360|NCT04295226|OTHER|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
219067361|NCT04708873|OTHER|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
219067362|NCT04708873|OTHER|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
219067363|NCT03538535|BEHAVIORAL|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
219067364|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
219067365|NCT03066531|BEHAVIORAL|ACT-based intervention|
219067366|NCT03066531|BEHAVIORAL|CBT-based intervention|
219667620|NCT06473766|DIAGNOSTIC_TEST|RF data extraction|"To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural."
219067367|NCT03248284|PROCEDURE|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
219667621|NCT05810896|OTHER|AF at Home|The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q\&A. Supplementary educations materials will be made available to participants.
219667622|NCT03714711|PROCEDURE|total hip arthroplasty|Total hip replacement
219667623|NCT03714711|PROCEDURE|total knee arthroplasty|Total knee replacement
218976589|NCT06933667|BEHAVIORAL|Social Connections|Social Connections are baked into all other programming. Our instructors are trained in how to foster connections among participants, through peer coaching, ice-breakers, etc., and are asked to leave some time at the beginning and end of programs for participants to chat. We also hold special social events such as game nights.
218976590|NCT06933667|BEHAVIORAL|Mental Wellbeing|Participants are encouraged to enroll in one a week of relevant programming (e.g., meditation, relaxation).
218976591|NCT06934083|BEHAVIORAL|E-health education briefs|Participants will be asked to complete self-administered questionnaire regarding the six healthy lifestyles delivered via text message to their cell phone. Then, during the six-month intervention, participants will receive text messages at intervals set by their preference but at least 2 times per week to ensure adequate space for education delivery and assessment through Likert scale text message surveys relating to Lifestyle Health Education topics including Nutrition, Physical Activity, Tobacco Avoidance, Sleep, Stress Management, and Social Connection. As to the clinical outcomes, self-reported blood pressure, blood glucose, total cholesterol, waist circumference, and body mass index (BMI) will be collected from the participants at enrollment and at the live or virtual community celebration at the close of the study.
218976592|NCT06933446|OTHER|Myofascial Release|A myofascial release protocol, applied to the thigh muscles in post-effort recovery in water polo athletes.
218976593|NCT06933446|OTHER|Classic Massage|Massagem clássica, com pressão superficial, utilizada para atingir apenas tecidos subcutâneos, sem que haja ação sobre músculos e fáscias
218976594|NCT06350474|OTHER|Discontinuation of dornase alfa (Dnase)|Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
218976595|NCT06350474|OTHER|Continuation of dornase alfa (Dnase)|Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
218976596|NCT00219167|DRUG|aliskiren|
218976597|NCT06401707|DRUG|Perampanel|Perampanel is a non-competitive AMPA glutamate receptor antagonist.
218976598|NCT06401707|DRUG|Placebo|Placebo
218976599|NCT00427271|DRUG|aspirin|
218976600|NCT01080742|DRUG|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
218976601|NCT06489925|DRUG|Cerebrolysin|The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
218976602|NCT03748693|PROCEDURE|Hysterectomy|Surgery performed on women with a variety of gynecological indications
218976603|NCT03748693|PROCEDURE|Colporrhaphy|Surgery performed on women with POP
218976604|NCT06063278|BEHAVIORAL|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
218976605|NCT01139931|GENETIC|DNA methylation analysis|
218976606|NCT01139931|GENETIC|gene expression analysis|
218976607|NCT01139931|GENETIC|microarray analysis|
219667624|NCT05245422|OTHER|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
219667625|NCT05245422|OTHER|Infant Formula - Intact protein|Intact cow's milk protein
219667626|NCT05603923|BEHAVIORAL|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
218976608|NCT01139931|GENETIC|polymorphism analysis|
218976609|NCT01139931|OTHER|laboratory biomarker analysis|
218976610|NCT04716088|DIAGNOSTIC_TEST|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
218976611|NCT00000519|BEHAVIORAL|diet, reducing|
218976612|NCT00000519|BEHAVIORAL|exercise|
218976613|NCT00000519|BEHAVIORAL|diet, fat-restricted|
218976614|NCT05444621|RADIATION|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
218976615|NCT05932966|DEVICE|Insulin closed-loop delivery system|Insulin closed-loop delivery system
218976616|NCT00090168|DRUG|MK0653A , ezetimibe (+) simvastatin|
218976617|NCT00090168|DRUG|Comparator: atorvastatin|
218976618|NCT00090168|DRUG|Duration of Treatment: 6 weeks|
218976619|NCT04813640|DEVICE|Spectacles|Novel spectacles for myopia control
218976620|NCT06285708|BEHAVIORAL|Prolonged exposure|PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
219667627|NCT05603923|BEHAVIORAL|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
219667628|NCT05603923|BEHAVIORAL|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
218976621|NCT03220984|BIOLOGICAL|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
218976622|NCT02597868|DRUG|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
218976623|NCT02597868|PROCEDURE|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
218976624|NCT02641132|DRUG|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
218976625|NCT02641132|PROCEDURE|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
218976626|NCT04449887|DRUG|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
218976627|NCT01317381|PROCEDURE|Observational|Blood draw
218976628|NCT01012167|DRUG|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
218976629|NCT01012167|DRUG|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
218976630|NCT01012167|OTHER|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
218976631|NCT01012167|OTHER|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
218976632|NCT00641303|PROCEDURE|acupuncture therapy|Given weekly for 8 sessions
218976633|NCT00641303|PROCEDURE|sham intervention|Given weekly for 8 sessions
218976634|NCT04260711|DRUG|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
218976635|NCT03350165|DRUG|K-877|0.2mg tablet
218976636|NCT03350165|DRUG|Placebo|K-877 matching placebo tablet
218976637|NCT03364569|PROCEDURE|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
218976638|NCT03186495|DRUG|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
218976639|NCT03192956|OTHER|No active intervention|No active intervention is performed
218976640|NCT00026962|PROCEDURE|measuring estradiol and progesterone levels in saliva|
218976641|NCT01966601|DRUG|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
218976642|NCT01966601|DRUG|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
219067368|NCT03068403|PROCEDURE|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
218976643|NCT01966601|DRUG|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
218976644|NCT01966601|DRUG|Placebo|Placebo continuous intravenous infusion
218976645|NCT06556641|DRUG|GZR33 Injection|Administered as once daily subcutaneous dose
218976646|NCT06556641|DRUG|GZR101 Injection|Administered as once daily subcutaneous dose
218976647|NCT06556641|DRUG|Placebo|Administered as once daily subcutaneous dose
218976648|NCT06556641|DRUG|Insulin Degludec|Administered as once daily subcutaneous dose
218976649|NCT05405933|DIAGNOSTIC_TEST|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
218976650|NCT05405933|DIAGNOSTIC_TEST|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
219067369|NCT00627705|DRUG|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
218976651|NCT04242550|BEHAVIORAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
218976652|NCT04242550|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
218976653|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
218976654|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
218976655|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
218976656|NCT00809848|DRUG|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
218976657|NCT00809848|DRUG|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
218976658|NCT03633136|BEHAVIORAL|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
218976659|NCT03039452|BEHAVIORAL|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
218976660|NCT05314738|COMBINATION_PRODUCT|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
218976661|NCT05314738|COMBINATION_PRODUCT|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
218976662|NCT05314738|COMBINATION_PRODUCT|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
219067370|NCT00627705|OTHER|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
219067371|NCT03151434|DRUG|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
219667629|NCT04680832|DIAGNOSTIC_TEST|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
218976663|NCT05314738|COMBINATION_PRODUCT|Sham Treatment|Sham Drops and No exposure to NXL system
218976664|NCT00935948|DRUG|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
218976665|NCT00935948|DRUG|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
218976666|NCT03047876|PROCEDURE|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
218976667|NCT01664065|DRUG|200 mg Ceftaroline fosamil|1 h infusion
218976668|NCT01664065|DRUG|600 mg Ceftaroline fosamil|1 h infusion
219067372|NCT03151434|DRUG|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
219067373|NCT03151434|DRUG|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
219067374|NCT00838344|OTHER|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
219067375|NCT04398524|DRUG|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
219067376|NCT00768274|DRUG|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
219067377|NCT00768274|DRUG|Placebo|Placebo twice daily (b.i.d.) for 28 days
219067378|NCT01674036|DRUG|Genz-682452|Capsules for oral administration.
219067379|NCT01674036|DRUG|Placebo|Placebo to Genz-682452
218976669|NCT02160990|DRUG|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
218976670|NCT02160990|DRUG|Placebo|placebo subcutaneously twice daily for 30 days
218976671|NCT00734474|DRUG|LY2189265|
218976672|NCT00734474|DRUG|Sitagliptin|
218976673|NCT00734474|DRUG|Placebo solution|
218976674|NCT00734474|DRUG|Placebo tablet|
218976675|NCT00734474|DRUG|Metformin|
218976676|NCT01137396|DRUG|Modafinil|Modafinil 400mg PO QDaily following up-titration for \~8weeks
218976677|NCT01137396|BEHAVIORAL|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
219208583|NCT06776861|DRUG|PD-1 / PD-L1 monoclonal antibody|Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
219550008|NCT01390948|RADIATION|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
218976678|NCT01601860|OTHER|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);"
218976679|NCT01601860|OTHER|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
218976680|NCT04497935|DRUG|PLENVU|Bowel preparation for a colonoscopy
218976681|NCT04497935|DRUG|MoviPrep|Bowel preparation for a colonoscopy
218976682|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
218976683|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
218976684|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
218976685|NCT00942448|OTHER|Placebo s.c.|1 single injection at day of dental surgical extraction
218976686|NCT06389500|DRUG|Adebrelimab|Adebrelimab, IV
218976687|NCT06389500|DRUG|Lenvatinib|Lenvatinib, PO
218976688|NCT06389500|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|GC regimen±5-FU
218976689|NCT05194865|DEVICE|cardiac MRI|assessment of the viability using CMR
218976690|NCT05194865|PROCEDURE|Percutaneous coronary intervention|direct revascularization using PCI
218976691|NCT04960631|DIAGNOSTIC_TEST|Double site CT guided needle biopsy|Double site CT guided needle biopsy
218976692|NCT02021578|BEHAVIORAL|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
218976693|NCT02021578|BEHAVIORAL|Written information|Reading materials about depression
218976694|NCT03061383|OTHER|8% Arginine based toothpaste|toothpaste
218976695|NCT03061383|OTHER|8% strontium acetate based toothpaste|toothpaste
219208584|NCT06767657|PROCEDURE|CEA (carotid endarterectomy)|Intervention (CEA) is associated to both arms (group A and B)
219208585|NCT06761300|OTHER|Psychological assessment|Psychological assessment evaluation at different time points and its correlation with pain outcomes and satisfaction with the SCS intervention.
219208586|NCT06826417|DRUG|Xanax|double-blind randomized controlled clinical trial: in a double-blind manner, to receive Xanax
219550009|NCT01390948|DRUG|Temozolomide (TMZ)|75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
219550010|NCT02979041|BEHAVIORAL|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
219550011|NCT02979041|OTHER|Standard Care|physiotherapy and medical care as provided currently
219550012|NCT03935737|DIAGNOSTIC_TEST|Full Dose Chest X-Ray|Full dose X ray at Day 1
219550013|NCT03935737|DIAGNOSTIC_TEST|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
219550014|NCT02117505|DRUG|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
219550015|NCT02117505|DRUG|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
219550016|NCT01487629|DRUG|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
219550017|NCT01487629|DRUG|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
219550018|NCT03694236|DRUG|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
219550019|NCT01602328|BIOLOGICAL|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
219550020|NCT01602328|BIOLOGICAL|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
219550021|NCT05016986|OTHER|Standard clinical management|outcomes in GSW cardiac injuries
219550022|NCT00983996|DRUG|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
219550023|NCT00983996|DRUG|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
219550024|NCT05779358|OTHER|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
219550025|NCT05315713|DRUG|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
219550026|NCT05315713|DRUG|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
218976696|NCT03061383|OTHER|placebo|toothpaste
218976697|NCT06276231|DRUG|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
218976698|NCT06276231|OTHER|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
218976699|NCT06276231|DRUG|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
218976700|NCT01585870|DRUG|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
218976701|NCT01585870|DRUG|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
218976702|NCT04539873|DRUG|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
218976703|NCT04539873|COMBINATION_PRODUCT|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
218976704|NCT02497612|DRUG|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
218976705|NCT02497612|DRUG|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
218976706|NCT02497612|OTHER|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
218976707|NCT06306989|DRUG|Letermovir|Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
218976708|NCT04533633|PROCEDURE|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
218976709|NCT02231697|OTHER|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
218976710|NCT05677022|OTHER|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
218976711|NCT00001438|DRUG|all-trans-retinoic acid with IFN-alpha2a|
218976712|NCT02286583|DEVICE|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
218976713|NCT03378765|BEHAVIORAL|Diet and physical activity monitoring|Lifestyle monitoring
218976714|NCT01781533|PROCEDURE|algorithm|
218976715|NCT04734951|OTHER|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
218976716|NCT04734951|DIETARY_SUPPLEMENT|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
218976717|NCT05731323|DRUG|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
219067380|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
219067381|NCT04019847|DEVICE|STAK Tool|Medical stretching device
219067382|NCT04019847|OTHER|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
219067383|NCT01649284|DRUG|afatinib|40, 30, and 20 mg film-coated tablets
219067384|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
219067385|NCT05997004|DRUG|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
219067386|NCT05997004|DRUG|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
219067387|NCT01028573|DRUG|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
219067388|NCT01028573|DRUG|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
219067389|NCT01028573|DRUG|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
219067390|NCT01028573|DRUG|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
219067391|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
219067392|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
219067393|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
219067394|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
219067395|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
219067396|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
219067397|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
219067398|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
219067399|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
219067400|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
219067401|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
219067402|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
219067403|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
219067404|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
219067405|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
219067406|NCT03447418|PROCEDURE|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
219067407|NCT02727101|DRUG|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
219067408|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
219067409|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
219208587|NCT06826417|OTHER|placebo tablets|double-blind randomized controlled clinical trial: in a double-blind manner, to receive a placebo (identical in appearance to Xanax but without any active effects)
219208588|NCT03732703|DRUG|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
219667630|NCT06125535|DIAGNOSTIC_TEST|Sub-phenotyping by biomarkers concentration|Plasma will be collected at ICU admission (i.e., \< 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: Interleukin-1β, Interleukin-2, Interleukin-6, Interferon-γ, Tumor Necrosis Factor-alpha (TNF-α), chemokine (C-C motif) ligand-2 (CCL-2), Interleukin-15 (IL-15), Ferritin, and D-dimer, by a point-of-care biochip-array device (RANDOX, Multistat)
219667631|NCT02339974|DEVICE|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
219067410|NCT03431168|DRUG|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
219208589|NCT03732703|DRUG|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
219208590|NCT03732703|DRUG|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
219208591|NCT03732703|DRUG|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
219208592|NCT03732703|DRUG|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
219067411|NCT03431168|DRUG|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
219067412|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
219067413|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
219067414|NCT04982042|OTHER|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
219067415|NCT03955653|PROCEDURE|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
219667632|NCT04415021|OTHER|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
219667633|NCT04415021|OTHER|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
218976718|NCT05731323|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
219067416|NCT02967302|DRUG|Morphine Sulfate|active intervention
219667634|NCT04555499|OTHER|Standardized neurological examination|
219667635|NCT06046209|DEVICE|Control Lens|Daily disposable contact lens for 90 minutes
219667636|NCT06046209|DEVICE|Test Lens|Monthly replacement contact lens for 90 minutes
219667637|NCT04525131|DRUG|CPX-POM|CPX-POM
219667638|NCT02131636|DRUG|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
218976719|NCT03502096|BEHAVIORAL|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
218976720|NCT03502096|OTHER|Control|Subjects were not provided a to-go container with the meal
219067417|NCT02967302|DRUG|Triamcinolone|active control
219067418|NCT02967302|DRUG|placebo|placebo control
219067419|NCT05178628|DRUG|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
219067420|NCT05178628|DRUG|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
219067421|NCT04697758|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
219067422|NCT04697758|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
219667639|NCT02131636|DRUG|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
219667640|NCT03887624|DRUG|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
219067423|NCT04697758|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
219067424|NCT00506961|DRUG|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
219067425|NCT00506961|DRUG|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
219067426|NCT01410448|DRUG|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
219067427|NCT01410448|DRUG|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
219067428|NCT01410448|DRUG|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
219067429|NCT01410448|DRUG|Steroids|Steroids were administered according to local clinical practice.
218976721|NCT02167425|OTHER|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
218976722|NCT05828134|OTHER|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
218976723|NCT02651467|OTHER|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
218976724|NCT02651467|OTHER|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
218976725|NCT02651467|OTHER|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
218976726|NCT00176787|DRUG|Capecitabine|
218976727|NCT00176787|PROCEDURE|Radiation|
218976728|NCT00176787|PROCEDURE|Surgery|
218976729|NCT01157923|DEVICE|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
218976730|NCT00004635|DRUG|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
218976731|NCT00004635|DRUG|leuprolide acetate|Injections of leuprolide once a month for six months.
218976732|NCT00004635|DRUG|goserelin|Injections of Goserelin once a month for six months.
218976733|NCT00004635|OTHER|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
218976734|NCT05514418|PROCEDURE|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
218976735|NCT05938530|DEVICE|Sirolimus drug-coated balloon|The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.
219067430|NCT01640691|BIOLOGICAL|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
219067431|NCT06486753|PROCEDURE|Chevron osteotomy bunion surgery with lateral soft tissue release|Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
219067432|NCT01060215|PROCEDURE|Normal saline|20 cc normal saline injection into the knee joint
219067433|NCT04985591|PROCEDURE|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
219067434|NCT04985591|PROCEDURE|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
219067435|NCT03362255|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
219067436|NCT02759900|DEVICE|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
219067437|NCT02759900|DEVICE|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
218976736|NCT05938530|DEVICE|Stent graft|Stent graft has been shown to be superior than plain balloon angioplasty in the treatment of AVG dysfunction.
218976737|NCT02301130|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
218976738|NCT02301130|BIOLOGICAL|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
218976739|NCT02301130|BIOLOGICAL|tremelimumab|Tremelimumab will be administered intravenously (IV).
218976740|NCT02387138|DRUG|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
218976741|NCT02387138|DRUG|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
218976742|NCT02387138|DRUG|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
218976743|NCT02387138|OTHER|G-csf|G-csf : d8 to d13 systematically
218976744|NCT00082589|DRUG|Eplerenone|
218976745|NCT06556550|RADIATION|stereotactic ablative radiation therapy|stereotactic ablative radiation therapy in effective doses to each metastatic site
218976746|NCT06556550|RADIATION|palliative radiation therapy|palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
218976747|NCT06556550|DRUG|Chemotherapy|prescribed drug line
218976748|NCT01890746|DRUG|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
218976749|NCT01890746|DRUG|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
218976750|NCT01890746|DRUG|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
219067438|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
219067439|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
218976751|NCT01890746|DRUG|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
218976752|NCT02642029|DEVICE|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
218976753|NCT02642029|DEVICE|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
218976754|NCT02642029|DEVICE|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
219067440|NCT00360529|DRUG|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
219067441|NCT04695327|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
219067442|NCT00505739|DRUG|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
219067443|NCT05044572|OTHER|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
219067444|NCT05044572|OTHER|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
219067445|NCT05155436|DRUG|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
219550027|NCT05315713|DRUG|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
219550028|NCT05315713|OTHER|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
219550029|NCT01261767|DRUG|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
219550030|NCT01261767|DRUG|placebo|Placebo for subcutaneous (under the skin) injection
219550031|NCT02795572|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000 IU oral once daily
219550032|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 100 mg oral once daily
219550033|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 100 mcg oral once daily
219550034|NCT02795572|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
219550035|NCT04548258|DEVICE|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
219550036|NCT04548258|DEVICE|casting|casting metal framework
219550037|NCT04206267|DEVICE|Acceledent|Device for accelerating tooth movement
219550038|NCT05203146|DEVICE|PIMPmyHospital (mobile health tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
219550039|NCT05203146|OTHER|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
219550040|NCT05940233|DRUG|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
219550041|NCT03385863|DRUG|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
219550042|NCT03385863|OTHER|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
219550043|NCT02721563|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
219550044|NCT02721563|DRUG|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
219550045|NCT06319482|DEVICE|Proactive CPAP Therapy|CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
219667641|NCT03887624|DRUG|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
219667642|NCT03887624|DRUG|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
219667643|NCT02493530|DRUG|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
219667644|NCT02493530|DRUG|ruxolitinib|
219667645|NCT00674479|DRUG|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
219667646|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
219667647|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
219667648|NCT05280197|DRUG|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
219667649|NCT05280197|DRUG|normal saline|TAP block using normal saline
219667650|NCT06347575|DEVICE|Implantation of the caverStim device|Implantation of caverStim in SCI patients.
219667651|NCT04220190|BIOLOGICAL|RAPA-501 Autologous T stem cells|Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
219667652|NCT06226649|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
219667653|NCT05208905|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
219667654|NCT02632448|DRUG|LY2880070|Capsules
219667655|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
219667656|NCT06319222|OTHER|DALC Digital Clinic|Providers randomized to the intervention arm will be able to refer their patients with ALD, to the DALC in addition to standard of care. Patients with providers randomized to the intervention arm will be consented by the study team. After appropriate consent, the referred patients will be instructed by our study team to download the RTP application in their smart devices (smartphones or tablets).
219667657|NCT04847232|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
219667658|NCT04847232|DRUG|SZC Placebo|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
219667659|NCT05429008|DRUG|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
219667660|NCT06101095|DRUG|Dupilumab|Subcutaneous injection (SC) as per protocol
219667661|NCT06101095|DRUG|Placebo|SC injection as per protocol
219667662|NCT06444139|DIETARY_SUPPLEMENT|Probiotics|Probiotics
219067446|NCT02588391|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
219067447|NCT02588391|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
219667663|NCT06444139|DIETARY_SUPPLEMENT|Placebo|Placebo
219667664|NCT06114056|BIOLOGICAL|JWK007 Single intravenous infusion administration|"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."
219667665|NCT01560715|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
219667666|NCT01300156|DRUG|Oxaliplatin-based chemotherapy (ESHAOx)|"* Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1"
219667667|NCT03307187|BEHAVIORAL|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
219667668|NCT02500771|BEHAVIORAL|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
219667669|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
219667670|NCT00715520|DRUG|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
219667671|NCT00715520|DRUG|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
219667672|NCT00715520|DRUG|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
219667673|NCT00715520|DRUG|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
219667674|NCT00715520|OTHER|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
218976755|NCT05493332|PROCEDURE|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
218976756|NCT05493332|DRUG|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
219067448|NCT02588391|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
219067449|NCT01601587|OTHER|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
219067450|NCT03103555|DRUG|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
219067451|NCT03103555|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
219067452|NCT03712917|PROCEDURE|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
219067453|NCT03712917|DRUG|Topiramate|An antiepileptic agent used for migraine prophylaxis.
219067454|NCT03712917|DRUG|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
219067455|NCT02045758|DEVICE|Fingerstick|
219067456|NCT02045758|DEVICE|TAP20-C|
219067457|NCT03297840|BEHAVIORAL|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
219067458|NCT02098200|DEVICE|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
219067459|NCT04937569|DRUG|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
219067460|NCT04160780|PROCEDURE|L-PRF|sinus augmentation using L-PRf as sole graft material
219067461|NCT04160780|PROCEDURE|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
219067462|NCT04160780|PROCEDURE|xenograft|sinus augmentation using xenograft as sole graft material
219067463|NCT01218438|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
218976757|NCT05493332|DRUG|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
218976758|NCT05493332|DRUG|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
218976759|NCT05493332|DRUG|Toripalimab|240mg IVdrip，D3, Q3W
218976760|NCT05493332|DRUG|Donafenib|0.1g. P.O, BID, continuously
219667675|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
218976761|NCT04046055|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
218976762|NCT04046055|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
218976763|NCT04046055|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
218976764|NCT05704231|BEHAVIORAL|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
218976765|NCT01173757|DRUG|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
218976766|NCT05476406|OTHER|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
218976767|NCT05476406|OTHER|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
218976768|NCT01588639|DRUG|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
218976769|NCT01588639|DRUG|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
218976770|NCT01588639|DRUG|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
218976771|NCT06343233|OTHER|usual care|The aim is to set up a collection of clinical and instrumental data of usual care from patients hospitalized for acute heart failure aged ≥ 65; at the time of admission and after 6-12 and 18 months from the event (admission).
218976772|NCT01971242|DRUG|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
218976773|NCT01971242|OTHER|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
218976774|NCT01984788|DRUG|BCX4161|
218976775|NCT01984788|DRUG|Placebo|
219067464|NCT01218438|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
218976776|NCT02422472|DEVICE|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
218976777|NCT03200184|DRUG|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
218976778|NCT05761041|DRUG|Sodium Fluoride Varnish (5%)|Applied at baseline
218976779|NCT05761041|BEHAVIORAL|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
218976780|NCT05761041|DRUG|SDF|Applied bianually
218976781|NCT04076878|DEVICE|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
218976782|NCT00676338|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
218976783|NCT00676338|DRUG|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
218976784|NCT00676338|DRUG|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
218976785|NCT00676338|DRUG|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
218976786|NCT02703233|DRUG|Nitrous Oxide|
218976787|NCT02703233|OTHER|Oxygen|
218976788|NCT01100346|DRUG|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
218976789|NCT01278836|PROCEDURE|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
218976790|NCT00017199|DRUG|bortezomib|
218976791|NCT01497717|DRUG|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
219067465|NCT02084966|PROCEDURE|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
219667676|NCT04912414|BEHAVIORAL|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
219667677|NCT02139774|BEHAVIORAL|Walk with Ease|A six week walking program by the Arthritis Foundation
219667678|NCT03761004|DRUG|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
219667679|NCT05352880|DIAGNOSTIC_TEST|serum magnesium level, FEMg|"Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination."
219667680|NCT03900572|BIOLOGICAL|HPV Vaccine|Intramuscular injection, 3 doses
219667681|NCT03900572|DRUG|Placebo|Intramuscular injection, 3 doses
219667682|NCT02290925|DRUG|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
219667683|NCT02290925|DIETARY_SUPPLEMENT|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
219667684|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation A
219667685|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation B
219667686|NCT06631430|DRUG|Placebo|Placebo
219667687|NCT05296447|OTHER|No Intervention|All subjects that previously received RGX-314 in a parent study
219667688|NCT03547232|DRUG|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
219667689|NCT03547232|DRUG|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
219667690|NCT06434727|OTHER|observational study|Observational Study
218976792|NCT02411760|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
218976793|NCT01549470|BIOLOGICAL|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
218976794|NCT01549470|BIOLOGICAL|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
218976795|NCT02122458|DEVICE|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
218976796|NCT04055961|DEVICE|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
218976797|NCT00394823|BEHAVIORAL|Set of supportive tools/measures vs. standard care|
218976798|NCT03161093|DRUG|Fasinumab|Solution for injection in pre-filled syringe
218976799|NCT03161093|DRUG|Naproxen|Pharmaceutical form: Capsule
218976800|NCT03161093|DRUG|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
218976801|NCT03161093|DRUG|Naproxen-matching placebo|Capsule
219067466|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
219067467|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
219067468|NCT00690703|DEVICE|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
219067469|NCT01932164|PROCEDURE|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
219067470|NCT01932164|PROCEDURE|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
219067471|NCT02591654|DRUG|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
219667691|NCT03688802|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
219667692|NCT03688802|DRUG|Placebo (vehicle control) nasal spray|Placebo
219667693|NCT05697627|DEVICE|Computerized cognitive training (CCT) using EndeavorRx|"The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks"
219667694|NCT02283320|DRUG|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
219667695|NCT02066077|DRUG|Etomidate|
218976802|NCT04532502|DRUG|Anesthetics, Inhalation|Work environmental exposure
219667696|NCT02066077|DRUG|Propofol|
219667697|NCT02066077|DEVICE|Bilateral temporal MECT|
219667698|NCT02066077|DEVICE|The right temporal MECT|
219667699|NCT02066077|DEVICE|Bilateral frontal MECT|
219667700|NCT03549065|DEVICE|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
219067472|NCT02591654|DRUG|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
218976803|NCT03565978|DEVICE|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
218976804|NCT05499715|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
218976805|NCT03949530|DRUG|IDL-2965 Oral Capsule|Investigational drug
218976806|NCT03949530|DRUG|Placebos|Placebo
218976807|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
219067473|NCT00052468|DRUG|TCG|
218976808|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
218976809|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
219067474|NCT00052468|DRUG|TC|
219067475|NCT05149274|DRUG|DWP14012 Tablet A|DWP14012 10mg
218976810|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
218976811|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
218976812|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
218976813|NCT04014946|DEVICE|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
218976814|NCT03173027|DRUG|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
218976815|NCT06534684|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
218976816|NCT04226560|DEVICE|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
218976817|NCT04226560|DEVICE|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
218976818|NCT04226560|OTHER|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
219067476|NCT05149274|DRUG|DWP14012 Tablet B|DWP14012 40mg
219067477|NCT02409173|DEVICE|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
219067478|NCT02409173|PROCEDURE|Bariatric Surgery|Standard Roux-en-Y gastric bypass
219067479|NCT06412276|BEHAVIORAL|Control|Food menu will be provided as is typical for the out of home outlet
219067480|NCT06412276|BEHAVIORAL|Product price promotions removed|Food menus with no price reductions to products
218976819|NCT04226560|OTHER|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
218976820|NCT02517866|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
218976821|NCT00778544|DRUG|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
218976822|NCT01903174|DEVICE|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
218976823|NCT01907581|OTHER|Quality of life questionnaires|
218976824|NCT01957774|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
218976825|NCT01957774|DRUG|Placebo|
219067481|NCT06412276|BEHAVIORAL|Bulk buy reductions removed|Food menus with bundles provided but not at reduced prices
219067482|NCT06412276|BEHAVIORAL|Volume value pricing removed|Food menus with proportionate pricing for multi-size products
219067483|NCT06412276|BEHAVIORAL|No price-based incentives|Food menus with no price-based incentives offered
219067484|NCT04679129|DRUG|ASC42|Oral tablets
219067485|NCT04679129|DRUG|Placebo|Oral tablets
219208593|NCT03732703|DRUG|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
219550046|NCT06319482|DEVICE|Conventional APAP Therapy|CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
219550047|NCT05336097|OTHER|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
219550048|NCT05050851|DIETARY_SUPPLEMENT|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
219550049|NCT03581630|DRUG|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
219550050|NCT03581630|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
219550051|NCT02271035|DRUG|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
219550052|NCT02271035|DRUG|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
219550053|NCT03694535|DRUG|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
219550054|NCT06322251|BEHAVIORAL|Use of instrument to identify exposure to violence in close relationships|Use of instrument to identify exposure to violence in close relationships
219550055|NCT01687335|OTHER|answering questionnare in differents time of the treatment|
219550056|NCT04007835|DRUG|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
219550057|NCT03142620|DRUG|Esomeprazole|40mg twice daily
219067486|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
219067487|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
219067488|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
219067489|NCT02555046|PROCEDURE|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
219067490|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
219067491|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
218976826|NCT00569465|DRUG|Arginine|1200 mg, once a day
218976827|NCT00569465|DRUG|Acetylcysteine|600 mg twice a day
218976828|NCT00569465|DRUG|Placebo|3 vials a day
218976829|NCT01826773|DRUG|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
218976830|NCT05993819|OTHER|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
218976831|NCT05993819|OTHER|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
218976832|NCT01797731|DEVICE|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
218976833|NCT01797731|DEVICE|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
218976834|NCT03231657|DIAGNOSTIC_TEST|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
218976835|NCT03878953|DRUG|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
218976836|NCT03711318|DRUG|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
218976837|NCT04803539|DRUG|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
218976838|NCT04803539|DRUG|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
218976839|NCT00091442|DRUG|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
218976840|NCT00091442|DRUG|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
218976841|NCT02163980|DRUG|Caudal ropivacaine + normal saline|
218976842|NCT02163980|DRUG|Caudal ropivacaine + dexmedetomidine|
218976843|NCT00002240|DRUG|Atazanavir|
218976844|NCT00002240|DRUG|Nelfinavir mesylate|
218976845|NCT00002240|DRUG|Stavudine|
218976846|NCT00002240|DRUG|Didanosine|
219667701|NCT04998383|DEVICE|HVNI|High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
218976847|NCT01631110|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
218976848|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
218976849|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
218976850|NCT02175628|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
218976851|NCT03263585|DEVICE|Spinal orthosis Spinomed|
218976852|NCT03263585|OTHER|Equipment training|
218976853|NCT06465095|GENETIC|Baseline|Measurements and sampling
218976854|NCT04840069|DRUG|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV\_5400. The GTV\_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV\_5400 will include the GTV\_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV\_5400 must also include the entirety of the GTV\_6000. There is no CTV\_6000. PTV\_5400 is the CTV\_5400 plus a geometric 3 mm expansion in all dimensions; PTV\_6000 is GTV\_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV\_5400 must contain the PTV\_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV\_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV\_6000. PTV\_6000 will be defined as GTV\_6000 plus a geometric 3 mm expansion in all dimensions.
218976855|NCT03722069|OTHER|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
218976856|NCT03722069|OTHER|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
218976857|NCT01387620|DRUG|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
218976858|NCT05111704|OTHER|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
219067492|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
219067493|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
219067494|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
219067495|NCT03975283|DRUG|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
219067496|NCT03975283|DRUG|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
219067497|NCT01746342|DEVICE|Effective continuous positive airway pressure (CPAP)|
219667702|NCT01256580|DRUG|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
218976859|NCT03634644|DRUG|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
218976860|NCT03634644|DRUG|Placebo oral capsule|mainly composed of corn oil
218976861|NCT05406141|DIETARY_SUPPLEMENT|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
219067498|NCT01746342|DEVICE|Sham continuous positive airway pressure (CPAP)|
219067499|NCT01704313|PROCEDURE|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
219067500|NCT01704313|PROCEDURE|Continuous|Continuous suturing technique used for the anastomosis
219067501|NCT06787040|OTHER|Resource-Stratified Protocol|The interventions are a set of protocols that accounts for varying levels of resources available at any given time for patients with severe traumatic brain injury across prehospital, ED, neurosurgery, and ICU. Protocols are available in the NIH-PMC website at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7055642/
219550058|NCT03142620|DRUG|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
219550059|NCT03142620|DRUG|Clarithromycin|500mg twice daily
219550060|NCT03142620|DRUG|Vitamin D3|5000IU
219550061|NCT04106063|OTHER|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
219550062|NCT02553863|PROCEDURE|Acupuncture|Acupuncture for 30min \[twice weekly for 8 weeks\]
219550063|NCT02553863|PROCEDURE|Standard care|Standard care
219550064|NCT01202435|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
219550065|NCT01202435|DRUG|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
219667703|NCT01256580|DRUG|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
219067502|NCT01343550|OTHER|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
219667704|NCT02390713|DEVICE|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
219667705|NCT01962246|DRUG|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
219667706|NCT01962246|OTHER|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
219667707|NCT05394454|PROCEDURE|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
219667708|NCT04348500|DRUG|Clazakizumab|IV Infusion
219667709|NCT01410240|PROCEDURE|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
219667710|NCT01410240|DRUG|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~\+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
219667711|NCT05251636|RADIATION|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
219667712|NCT05251636|DRUG|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
218976862|NCT03464877|OTHER|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
218976863|NCT00425347|DRUG|HuLuc63|Not applicable for HuLuc63.
218976864|NCT02470416|DEVICE|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
218976865|NCT02566447|DEVICE|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
218976866|NCT05175027|DRUG|hypochlorous acid|Randomize
218976867|NCT01365247|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
218976868|NCT01365247|BEHAVIORAL|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
219067503|NCT00712023|DEVICE|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
219067504|NCT05903144|OTHER|manual therapy|manual diaphragmatic release technique combined with breathing exercise
219067505|NCT05903144|OTHER|breathing exercise and prone position alone|deep breathing exercise and prone position
219667713|NCT03425994|DRUG|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
219667714|NCT02542592|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
218976869|NCT01365247|BEHAVIORAL|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
219667715|NCT02542592|DRUG|Isotonic Sodium Chloride|Placebo
219667716|NCT02061423|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
219067506|NCT01629004|OTHER|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
219067507|NCT01629004|OTHER|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
219208594|NCT03732703|DRUG|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
219667717|NCT03699540|DRUG|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
219667718|NCT03699540|DRUG|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
219667719|NCT03699540|DRUG|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
219667720|NCT03699540|DRUG|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
219667721|NCT01309750|RADIATION|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
219667722|NCT02066727|DRUG|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
218976870|NCT02407418|OTHER|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
218976871|NCT02407418|OTHER|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
218976872|NCT00629772|DRUG|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
218976873|NCT00629772|DRUG|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
218976874|NCT02548416|PROCEDURE|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
218976875|NCT02548416|PROCEDURE|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
218976876|NCT03218709|COMBINATION_PRODUCT|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
218976877|NCT03218709|COMBINATION_PRODUCT|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
218976878|NCT03218709|COMBINATION_PRODUCT|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
218976879|NCT03218709|COMBINATION_PRODUCT|Placebo|The placebo tablets contained maltodextrin and tartrazine.
218976880|NCT01393301|BEHAVIORAL|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
218976881|NCT01393301|BEHAVIORAL|Control|Enhanced standard smoking cessation treatment and NRT.
218976882|NCT02215031|DRUG|BI 44370|
218976883|NCT02215031|DRUG|Placebo|
218976884|NCT03221699|OTHER|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
218976885|NCT03221699|OTHER|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
218976886|NCT00833820|PROCEDURE|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
219067508|NCT04075500|DEVICE|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
219067509|NCT01682460|DRUG|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
219067510|NCT05924152|DRUG|Adagrasib|Adagrasib
219067511|NCT05924152|DRUG|Eltrombopag + adagrasib|Eltrombopag + adagrasib
219067512|NCT00639717|PROCEDURE|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
219667723|NCT02066727|DRUG|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
219667724|NCT00910546|DEVICE|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
219667725|NCT05460078|BEHAVIORAL|Virtual Psychiatric Transition of Care Program|"Behavioral Health facility or units that have discharged patients meeting inclusion criteria will be randomly assigned as either an intervention or standard care site. Intervention sites will be those using the VPTC program. This evaluation design will integrate into current workflows for the measurement of outcomes. Prior to discharge, patients may be referred to the VPTC program if they report residency or shelter in North Carolina, are 18 years of age or older on the day of discharge and can access virtual care (phone/video).~The VPTC program is defined by:~* Psychiatric consultation~* Medication management services with pharmacological consultation~* following of Health Coaching participation and provide treatment recommendations~* Tracking of behavioral health symptoms and provide treatment recommendations~* Health coaching; Psychoeducational support~* Treatment and safety planning~* Assistance connecting with an outpatient care provider"
219667726|NCT04617483|BIOLOGICAL|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
219667727|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
218976887|NCT00833820|PROCEDURE|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
218976888|NCT03207204|PROCEDURE|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
218976889|NCT03207204|PROCEDURE|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
218976890|NCT03207204|PROCEDURE|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
218976891|NCT03207204|PROCEDURE|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
218976892|NCT03207204|PROCEDURE|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
218976893|NCT03207204|PROCEDURE|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
218976894|NCT03207204|PROCEDURE|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
218976895|NCT03207204|PROCEDURE|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
218976896|NCT05330572|OTHER|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
218976897|NCT02758171|DRUG|Empagliflozin|
218976898|NCT02758171|DRUG|Linagliptin|
218976899|NCT00853073|DRUG|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
218976900|NCT00853073|OTHER|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
218976901|NCT01999114|DRUG|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
218976902|NCT01999114|DRUG|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
218976903|NCT01999114|DRUG|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
218976904|NCT01999114|DRUG|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
218976905|NCT02047383|OTHER|Respiratory infection|An assessment of the patients included in the study will be conducted
218976906|NCT06341101|DRUG|Perindopril|In case of side effects Perindopril will be replaced by Valsartan
219667728|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
219667729|NCT02697591|DRUG|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
219667730|NCT05732077|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
219667731|NCT05732077|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
219667732|NCT05732077|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
219667733|NCT05061381|BEHAVIORAL|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
218976907|NCT04659720|DEVICE|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
218976908|NCT04659720|BEHAVIORAL|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
218976909|NCT05052658|PROCEDURE|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
218976910|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
219667734|NCT05180890|DRUG|Danavorexton|Danavorexton intravenous infusion.
219667735|NCT05180890|DRUG|Placebo|Placebo intravenous infusion.
219667736|NCT00895934|DRUG|vorinostat|Given orally
218976911|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
219067513|NCT00639717|DRUG|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
219067514|NCT00639717|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
219067515|NCT00639717|DRUG|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
219067516|NCT00639717|DRUG|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
219067517|NCT05190393|PROCEDURE|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
219067518|NCT05190393|PROCEDURE|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
219067519|NCT01756092|PROCEDURE|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
219067520|NCT00724282|DRUG|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
219067521|NCT00724282|DRUG|Placebo|Placebo by mouth daily at bedtime for 9 days
219067522|NCT01495429|PROCEDURE|Central venous catheter|Placement of a peripherally inserted central venous catheter
219067523|NCT01495429|PROCEDURE|Central venous catheter|Placement of a centrally inserted central venous catheter
219067524|NCT06223620|OTHER|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
219067525|NCT01941862|BEHAVIORAL|Psychoeducation and Cognitive Bias Modification|
219067526|NCT01694303|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
219067527|NCT02043496|BEHAVIORAL|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
219067528|NCT02043496|BEHAVIORAL|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
219067529|NCT01837381|PROCEDURE|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
219067530|NCT04933955|PROCEDURE|vital pulp therapy|pulpotomy
219667737|NCT00895934|DRUG|gemtuzumab ozogamicin|Given intravenously (IV)
219667738|NCT00895934|DRUG|azacitidine|Given IV or subcutaneously (SC)
219667739|NCT00560898|DRUG|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
219667740|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
219667741|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
219667742|NCT00560898|DRUG|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
219667743|NCT01331135|DRUG|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
219667744|NCT05447026|DEVICE|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
218976912|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
218976913|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
218976914|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
218976915|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
218976916|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
218976917|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
219067531|NCT00070473|DRUG|pemetrexed disodium|
219067532|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
219067533|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
219067534|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
219067535|NCT02701218|PROCEDURE|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
219667745|NCT05447026|DEVICE|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
218976918|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
218976919|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
218976920|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
219067536|NCT01739829|DEVICE|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
219067537|NCT01739829|DEVICE|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
219550066|NCT03324139|DRUG|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
219667746|NCT05447026|DEVICE|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
219067538|NCT06134544|DIETARY_SUPPLEMENT|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
219067539|NCT01785329|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
219067540|NCT01956526|DEVICE|CORolla™ TAA device|
219067541|NCT00057096|PROCEDURE|On-site vs. referral methods of care|
219067542|NCT03640351|DRUG|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
219208595|NCT03732703|DRUG|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
219667747|NCT05447026|DEVICE|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
219667748|NCT00624832|DRUG|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
219667749|NCT00624832|DRUG|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
219667750|NCT05356650|OTHER|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
219208596|NCT06774079|DRUG|Tirzepatide|Patients in this arm will receive tirzepatide starting at 2.5 mg subcutaneous (SC) weekly for 4 weeks, then increase to 5 mg SC weekly for 4 weeks and then 7.5 mg SC weekly for the last 4 weeks of the intervention period. Place of injection includes abdomen, thigh, or upper arm.
219550067|NCT03324139|DRUG|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
219550068|NCT03748381|PROCEDURE|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
218976921|NCT05235477|PROCEDURE|Tube technique|"An excavator (smaller than the width of the defect; evaluated pre-surgically on a study model) is used to carefully reflect the papilla away from the alveolar bone and root surfaces on the buccal aspect to access the interproximal region to prepare the bed for the graft. The excavator is used to do the same on the palatal aspect. The amount of reflection should yield a very relaxed papilla flap that permits placement of the papilla at the new coronal position without tension. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect."
219667751|NCT05356650|OTHER|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
219667752|NCT00299403|PROCEDURE|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
219667753|NCT00299403|PROCEDURE|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
219667754|NCT04379700|PROCEDURE|Transcatheter arterial embolization|Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.
219667755|NCT04379700|DEVICE|Embozene™ Microspheres|Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
219667756|NCT05439057|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
219550069|NCT05451264|DIAGNOSTIC_TEST|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
219667757|NCT05439057|DRUG|Control|Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
219667758|NCT04920097|OTHER|In-person training for seed placement and APA|In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
219667759|NCT04920097|OTHER|Virtual training for seed placement and APA|Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
219667760|NCT04920097|OTHER|Usual Care|Participants will continue with usual care from oncologist.
219667761|NCT04920097|OTHER|Post-training zoom session for seed placement and APA coaching|Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
218976922|NCT02437383|DRUG|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
218976923|NCT02437383|DRUG|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
218976924|NCT02351375|OTHER|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
218976925|NCT02351375|DEVICE|IntelliCap® system|
218976926|NCT02722369|DRUG|Gemcitabine|Chemotherapy
218976927|NCT02722369|DRUG|Carboplatin|Chemotherapy
218976928|NCT02722369|DRUG|Etoposide|Chemotherapy
218976929|NCT02722369|DRUG|Hydroxychloroquine|Maintenance Agent
218976930|NCT04108702|DEVICE|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
218976931|NCT04108702|DEVICE|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
218976932|NCT04108702|OTHER|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
218976933|NCT00053937|DRUG|pirfenidone|
218976934|NCT01388595|DRUG|FLUTICASONE PROPRIONATE|1\. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
218976935|NCT01388595|DRUG|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
219067543|NCT03640351|DRUG|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
219067544|NCT03640351|DRUG|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
219067545|NCT05732454|DRUG|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
219667762|NCT06012253|OTHER|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
219067546|NCT05732454|DRUG|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
219067547|NCT06128616|DEVICE|ESWT|Extracorporeal Shock Wave Therapy
219067548|NCT06128616|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
219667763|NCT05108987|BEHAVIORAL|Morning Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
219667764|NCT05108987|BEHAVIORAL|Afternoon Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
219667765|NCT00991094|OTHER|Quality-of-Life Assessment|Complete questionnaires
219667766|NCT00991094|OTHER|Questionnaire Administration|Complete questionnaires
219667767|NCT06205134|DRUG|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
219667768|NCT06205134|DRUG|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
219667769|NCT06205134|DRUG|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
219667770|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
219667771|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
219067549|NCT06128616|OTHER|Serial Casting|Serial Casting
219208597|NCT06774079|BEHAVIORAL|Mediterranean diet|The diet is comprised of a content of 25-30 grams of fiber per day (from fruits, vegetables, whole grains) that is low in animal protein and minimally processing of foods The diet arm will receive dietary guidance from our dietician on weekly 30-minute guided sessions. Participants will be encouraged to adhere to the diet for up to three meals per day for the duration of the study.
219208598|NCT06772610|DRUG|Ensartinib group|Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
219208599|NCT06774443|OTHER|Neuropsychological assessment|Neuropsychological assessment consisting of tests measuring social cognition and memory
219667772|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
219667773|NCT00592592|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
219667774|NCT01028495|DRUG|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
219067550|NCT06128616|BEHAVIORAL|Physical Therapy|Physical Therapy
219208600|NCT06772389|OTHER|Peer Tutoring|"Peer tutoring is defined as individuals who are in a similar social group and are not professional teachers helping each other to learn and teach. For peer tutoring, the subject of EFM was grouped under 6 headings. The students in the Peer tutoring group were divided into groups of 6. The researcher explained a heading of the EFM subject to each of these 6 groups. Then, new groups were formed by taking one student from each group. In these new groups, each student explained his/her own subject to his/her peers."
219208601|NCT06770244|BEHAVIORAL|positive psychology-based intervention package|The postpartum depression intervention program will be developed in accordance with the principles of positive psychology, incorporating online psychological interventions as the primary mode of delivery. Specifically, psychological courses and training based on positive psychology will be conducted in addition to the usual community-based primary health care. Interventions use formats that include online videos and supplemental materials. The aim of the intervention is to help pregnant and postpartum women understand mental health, enhance positive emotions, improve negative emotions, maintain interpersonal relationships, and explore life meaning. Additionally, one-on-one online consultations based on positive psychology will be offered to high-risk women.
219067551|NCT06128616|BEHAVIORAL|Occupational Therapy|Occupational Therapy
219067552|NCT01281358|OTHER|HOP-ON|A programme of activities which promote motor development
219067553|NCT01281358|OTHER|SMILES|Details are provided on ways for parents to interact with their premature infants
219067554|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
219067555|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
219067556|NCT02875587|DRUG|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
219067557|NCT02875587|DRUG|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
219067558|NCT01427244|DRUG|trastuzumab|monoclonal antibody
219067559|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
219067560|NCT00686400|OTHER|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
219208602|NCT06773429|DRUG|E2 Valerate|To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
219208603|NCT06773429|DRUG|Placebo|Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
219208604|NCT06749080|BEHAVIORAL|Assist Reablement (including education and mentoring)|Reablement on-line education will be standard and mandatory for both intervention groups. Mentoring will be formed according to the pre-requisites at the site.
219208605|NCT06760910|PROCEDURE|tDCS Stimulation|Anode tDCS or sham stimulation for amblyopia of Adolescents
219067561|NCT03021382|OTHER|data collection, non-intervention|
219067562|NCT02995603|DEVICE|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
219067563|NCT02808962|PROCEDURE|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
219067564|NCT04035941|BEHAVIORAL|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~1. Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~2. Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~3. Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~4. Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
219208606|NCT06760910|DEVICE|Anodal tDCS|Anodal tDCS
219208607|NCT06760910|DEVICE|Sham tDCS|Sham tDCS
219208608|NCT06776107|OTHER|Risk factor present|Demographic, and severity.
219208609|NCT06776432|DRUG|Sivopixant|Administered as specified in the treatment arm
219208610|NCT06776432|DRUG|Placebo|Administered as specified in the treatment arm.
219208611|NCT06776432|DRUG|Acetazolamide|Administered as specified in the treatment arm
219208612|NCT06776432|DRUG|SASS-001|Administered as specified in the treatment arm
219208613|NCT06776185|PROCEDURE|Liver Surgery|Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
219667775|NCT01030471|BEHAVIORAL|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
219667776|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan|Porridge rich in arabinoxylan
219667777|NCT01583270|DIETARY_SUPPLEMENT|Rye kernel|Porridge made of rye kernels
219667778|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
219667779|NCT01583270|DIETARY_SUPPLEMENT|Semolina|Semoline porridge. control meal.
219667780|NCT00285792|BEHAVIORAL|Physical Activity|
219067565|NCT03755505|DIAGNOSTIC_TEST|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
219067566|NCT03319277|OTHER|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
219067567|NCT03319277|OTHER|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
219067568|NCT05826392|OTHER|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
219067569|NCT03089086|BIOLOGICAL|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
218976936|NCT01388595|DRUG|PLACEBO|4\. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
219667786|NCT06959381|OTHER|Fascial release with instrument assisted soft tissue mobilization|The fascial release group will be treated with the Graston device to the superficial and deep fascia of the hamstrings and the gastro-soleus muscle complex in both extremities for a total of 16 minutes.
219667787|NCT06959381|OTHER|Fascial release with foam roller|Fascial release with a foam roller will be applied to the fascia of the hamstring and gastro-soleus muscle complex with a self-foam roller for a total of 16 minutes.
219667788|NCT03836456|BEHAVIORAL|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
218976937|NCT04336358|OTHER|Telemedicine|Telemedicine consultation online
218976938|NCT04297059|OTHER|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
218976939|NCT04882384|PROCEDURE|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
218976940|NCT01501370|DRUG|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
218976941|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
218976942|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
219067570|NCT04649398|DRUG|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
219067571|NCT05388253|BEHAVIORAL|Static Stretching|Using Static Stretching exercises
219067572|NCT05388253|BEHAVIORAL|Deep Kneading Massage|Using Deep Kneading Massage technique
219067573|NCT04806880|DEVICE|Web-application|support for olfactory coaching consisting of the inhalation of fragrant essential oils.
219067574|NCT03876080|OTHER|Dry needling|The use of a solid filiform needle to treat trigger points
219067575|NCT03876080|OTHER|Sham needling|Simulated needling
219067576|NCT04840550|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
219067577|NCT04840550|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
218976943|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
218976944|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
218976945|NCT03135626|DRUG|Biodentine|
219067578|NCT06177964|DRUG|Lerapolturev|"Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor."
219067579|NCT06177964|DRUG|Lomustine Pill|Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
219067580|NCT04332705|DIAGNOSTIC_TEST|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
219067581|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
219067582|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
219067583|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
219667789|NCT03836456|BEHAVIORAL|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
218976946|NCT03135626|DRUG|ProRoot (Aggregate)|
218976947|NCT03135626|DRUG|MTA Plus|
218976948|NCT03135626|DRUG|Ferric Sulfate 20 % Dental Gel|
218976949|NCT01309165|BEHAVIORAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
218976950|NCT01309165|BEHAVIORAL|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
218976951|NCT04558944|DEVICE|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
218976952|NCT06378580|DRUG|Surufatinib combine immune checkpoint inhibitor|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"
218976953|NCT06378580|DRUG|AG/FOLFIRINOX|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."
218976954|NCT02103907|OTHER|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
218976955|NCT01108120|DRUG|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
218976956|NCT01108120|DRUG|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
218976957|NCT01000402|DRUG|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
218976958|NCT04069962|BEHAVIORAL|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
218976959|NCT03594526|BEHAVIORAL|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
218976960|NCT03594526|BEHAVIORAL|Control Group: usual care|"This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding."
218976961|NCT02508857|DRUG|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
218976962|NCT02508857|DRUG|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
218976963|NCT02508857|DRUG|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
219067584|NCT01093729|DRUG|HM11260C|HM11260C 0.5mcg/kg or Placebo
219067585|NCT01093729|DRUG|HM11260C|HM11260C 2mcg/kg or Placebo
219067586|NCT01093729|DRUG|HM11260C|HM11260C 4mcg/kg or Placebo
219067587|NCT01093729|DRUG|HM11260C|HM11260C 8mcg/kg or Placebo
219067588|NCT01093729|DRUG|HM11260C|HM11260C 14mcg/kg or Placebo
219067589|NCT05997238|DRUG|without triamcinolone|The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
219067590|NCT05997238|DRUG|20mg triamcinolone|20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
219067591|NCT05997238|DRUG|40mg triamcinolone|40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
218976964|NCT04423510|PROCEDURE|Crystallized phenol treatment|
218976965|NCT05143541|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
218976966|NCT03420625|DEVICE|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
218976967|NCT03420625|DEVICE|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
218976968|NCT03420625|DEVICE|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
219067592|NCT05997238|DRUG|80mg triamcinolone|80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
219067593|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
219667790|NCT02325245|DRUG|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
219667791|NCT02325245|DRUG|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
219667792|NCT00429845|BEHAVIORAL|Nutritional|
219667793|NCT02287259|DRUG|olanzapine|
219667794|NCT02287259|DRUG|lithium|
218976969|NCT03420625|DEVICE|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
218976970|NCT03671980|OTHER|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
218976971|NCT05133232|DEVICE|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
218976972|NCT00736814|DRUG|carboplatin|Given intravenously
218976973|NCT00736814|DRUG|docetaxel|Given intravenously
218976974|NCT00736814|DRUG|gemcitabine hydrochloride|Given intravenously
218976975|NCT00736814|DRUG|vinorelbine tartrate|Given intravenously
218976976|NCT04962048|DEVICE|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
218976977|NCT04962048|OTHER|Control - no intervention|The other leg serves as non-treated control
218976978|NCT02315989|RADIATION|proton therapy|proton therapy
218976979|NCT02410551|DRUG|Pacritinib|200 mg by mouth twice a day for 60 days.
218976980|NCT02410551|DRUG|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
218976981|NCT02410551|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
218976982|NCT02410551|BEHAVIORAL|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
218976983|NCT02410551|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
218976984|NCT02410551|DRUG|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
218976985|NCT01274650|PROCEDURE|Indirect Calorimetry|Indirect Calorimetry
219067594|NCT00838110|DRUG|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
219067595|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
219067596|NCT00838110|DRUG|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
218976986|NCT00854542|BEHAVIORAL|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
219067597|NCT06097949|DEVICE|AcuPebble SA100|This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.
219067598|NCT04636255|PROCEDURE|Physical Characteristics|Body Weight, Height
219067599|NCT04636255|DIAGNOSTIC_TEST|Assessment of Heart rate variability|Holter 24h
219067600|NCT04636255|DIAGNOSTIC_TEST|Blood Pressure and Cardiac Autonomic Control|Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
219067601|NCT04636255|DIAGNOSTIC_TEST|Evaluation of Baroreflex Control|The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
219067602|NCT04636255|DIAGNOSTIC_TEST|Cardiac Function and Structure|Echocardiogram
219667795|NCT03159845|DRUG|Zinc Sulfate Oral Product|
219667796|NCT03159845|DRUG|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
219667797|NCT03159845|DRUG|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
219667798|NCT03159845|DRUG|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
219667799|NCT01935245|DEVICE|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
219667800|NCT01935245|DEVICE|Conventional extracorporeal circulation|
219667801|NCT02981563|OTHER|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
219667802|NCT00407407|DRUG|ABI-007|80mg/m\^2 to 150mg/m\^2 IV every 3 weeks
219667803|NCT00407407|DRUG|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
219667804|NCT03013790|DRUG|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
219667805|NCT02499510|DEVICE|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
219667806|NCT05491395|RADIATION|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
219067603|NCT04636255|DIAGNOSTIC_TEST|Assessment of Coronary Anatomy and Calcium Score|Angiotomography
219067604|NCT04636255|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
219067605|NCT04636255|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary Exercise Test.
219067606|NCT04636255|PROCEDURE|Physical Training|Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
219067607|NCT05926401|OTHER|ECG monitoring prior and after cardioversion|Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
219067608|NCT02057822|PROCEDURE|Cytokins assay in tears|
219067609|NCT01262651|DRUG|Nabiximols|
219067610|NCT01262651|DRUG|Placebo (GA-0034)|
219067611|NCT06333483|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
219067612|NCT04050189|BIOLOGICAL|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
219067613|NCT04050189|OTHER|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
219067614|NCT06481501|BEHAVIORAL|ONE Mindfulness-Oriented Recovery Enhancement|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
219067615|NCT04969783|OTHER|Ventilated Cigarette Filter|Ventilated Cigarette Filter
219067616|NCT04969783|OTHER|Unventilated Cigarette Filter|Unventilated Cigarette Filter
219067617|NCT00328510|DEVICE|GTC frame|
219067618|NCT00328510|DEVICE|Thermoplastic facemask|
219667807|NCT04801043|DRUG|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
219667808|NCT04801043|DRUG|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
219667809|NCT04801043|DRUG|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
219067619|NCT00328510|RADIATION|Stereotactic radiation therapy|
219067620|NCT06006520|OTHER|control|No exercises will be given.
219067621|NCT06006520|OTHER|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
219067622|NCT06006520|OTHER|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
219067623|NCT01248832|BEHAVIORAL|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
219067624|NCT01248832|BEHAVIORAL|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
219067625|NCT06499870|PROCEDURE|Biopsy|Undergo biopsy
219667810|NCT06356324|OTHER|Music Intervention|Participants assigned to 20 minutes of music listening
219067626|NCT06499870|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219067627|NCT06499870|PROCEDURE|Computed Tomography|Undergo CT
219067628|NCT06499870|DRUG|Enzalutamide|Given PO
219067629|NCT06499870|OTHER|Fluorine F 18 Piflufolastat|Undergo fluorine F 18 piflufolastat PET/MRI
219067630|NCT06499870|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
219067631|NCT06499870|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219667811|NCT06356324|OTHER|Television Intervention|Participants assigned to 20 minutes of television viewing
219667812|NCT00456781|DEVICE|Augmentation|Rotator Cuff Repair plus Graft Jacket
219067632|NCT06499870|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219667813|NCT00456781|PROCEDURE|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
219667814|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
219667815|NCT06965504|DEVICE|Impella 5.5 SmartAssist|The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).
219667816|NCT05258318|PROCEDURE|DK crush|Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
219667817|NCT05258318|PROCEDURE|DR crush|Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
219067633|NCT06499870|OTHER|Questionnaire Administration|Ancillary studies
219067634|NCT06499870|DRUG|Relugolix|Given PO
219667818|NCT06966765|PROCEDURE|Continuous Veno-Venous Hemodiafiltration|CVVHDF will be delivered following hemoperfusion with a dialysate-to-replacement fluid ratio maintained at 1:1, a blood flow rate of 150-200 mL/min, and a target dialysis dose of 30 mL/kg/h (excluding additional fluid removal). Regional anticoagulation (e.g., heparin or other agent per device requirements) will be used to prevent clotting within the circuit. Once CVVHDF is initiated in either arm, it will not be discontinued until one of the following encountered: (i) death; or (ii) a change in goals of care with withdrawal of life-sustaining interventions; or (3) recovery of kidney function, as determined by treating clinician(s), such that CVVHDF will be no longer required. However, CVVHDF will be reinitiated at the discretion of treating clinician(s), if kidney function comes suboptimal after a period of discontinuation.
219667819|NCT00901979|DRUG|LCQ908A|
218976987|NCT01792271|OTHER|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
218976988|NCT01739309|DRUG|Abemaciclib|Administered orally
218976989|NCT01724879|DRUG|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
218976990|NCT02337270|BIOLOGICAL|Ad5Ag85A|Aerosol administration of Ad5Ag85A
218976991|NCT04112420|DIAGNOSTIC_TEST|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
218976992|NCT05426772|OTHER|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
218976993|NCT06362070|DEVICE|DaVinci® Surgical System|Assisted-robotic radical Gastrectomy
218976994|NCT06362070|DEVICE|Hugo™ RAS System|Assisted-robotic radical Gastrectomy
218976995|NCT06362070|DEVICE|Versius® Robotic Surgery System|Assisted-robotic radical Gastrectomy
218976996|NCT00881673|DRUG|AL38583 Ophthalmic Solution|Topical ophthalmic
218976997|NCT00881673|DRUG|Maxidex|Topical ophthalmic
218976998|NCT00881673|DRUG|Vehicle|AL38583 Vehicle
218976999|NCT00929123|PROCEDURE|neural mobilization|manual therapy technique known to directly stress the median nerve
218977000|NCT00929123|PROCEDURE|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
218977001|NCT00929123|OTHER|healthy controls|People without carpal tunnel syndrome for comparison
218977002|NCT00239304|DRUG|Gefitinib|
218977003|NCT00239304|DRUG|Cisplatin|
218977004|NCT00239304|PROCEDURE|Radiotherapy|
218977005|NCT01495975|OTHER|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
218977006|NCT03326739|PROCEDURE|Arterial Line Placement|arterial line placement
218977007|NCT03949842|DRUG|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
218977008|NCT03949842|DRUG|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
218977009|NCT01512212|PROCEDURE|biopsy|fnab
219067635|NCT02488486|DEVICE|Automated postoperative sedation|
219067636|NCT02488486|DRUG|propofol|
219067637|NCT02488486|DRUG|remifentanil|
219067638|NCT02298218|DRUG|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
219067639|NCT05941650|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
219067640|NCT05941650|OTHER|Corn Starch|This group will receive 12 g of corn starch as a control group.
219067641|NCT04015648|BIOLOGICAL|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
219067642|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
219667820|NCT00901979|DRUG|LCQ908A|
219667821|NCT00901979|DRUG|LCQ908A|
219667822|NCT00901979|DRUG|LCQ908A|
219667823|NCT00901979|DRUG|LCQ908A|
219667824|NCT00901979|DRUG|Placebo|
219667825|NCT00901979|DRUG|Sitagliptin|
219667826|NCT00901979|DRUG|metformin|
219667827|NCT02779660|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
218977010|NCT03617510|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
218977011|NCT03617510|DRUG|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
218977012|NCT02501226|OTHER|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
218977013|NCT02501226|BEHAVIORAL|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
218977014|NCT03064230|OTHER|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
218977015|NCT02903641|BEHAVIORAL|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
218977016|NCT02903641|BEHAVIORAL|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
218977017|NCT04525352|BIOLOGICAL|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
218977018|NCT05191342|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
219067643|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
219067644|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
219067645|NCT03240588|DEVICE|Neurostimulation System|Spinal cord stimulation
219067646|NCT06516588|DEVICE|Transcranial Dirrect Current Stimulation|tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
219067647|NCT03199365|BEHAVIORAL|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
219067648|NCT03199365|BEHAVIORAL|Behavioral Intervention|Undergo TSSC intervention sessions
219067649|NCT06634992|OTHER|Oral immunotherapy|Clinical Follow up
219067650|NCT05853848|BEHAVIORAL|Postcard|Postcard with phone number to call for help scheduling a mammogram.
219667828|NCT02779660|PROCEDURE|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
219667829|NCT03813134|PROCEDURE|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
219667830|NCT03813134|OTHER|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure \>75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
219067651|NCT05853848|BEHAVIORAL|Letter|Letter with phone number to call for help scheduling a mammogram.
219067652|NCT05853848|BEHAVIORAL|Auto-dialer|Auto-dialer with option to press button for help scheduling a mammogram.
219067653|NCT05853848|BEHAVIORAL|Live call|Live call offering help scheduling a mammogram.
219208614|NCT06775288|OTHER|Hypoglycemia prevention and awareness program (HypoPAP)|Online hypoglycemia prevention and awareness training Supporting the prevention of hypoglycemia with the use of evidence-based diabetes-friendly plates Encouraging physical activity and supporting glycemic control with a pedometer Filling in a weekly problem-solving notebook Conducting weekly online problem-solving meetings Online counseling service when needed
219208615|NCT06775561|GENETIC|PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.|Samples are collected by UO1/UO2/UO3. DNA/RNA samples are sent to UO3 for genome and transcriptome sequencing. In vitro systems or patient-derived cell models are used for in vitro experimental validation (UO2) or development of therapeutical approaches (UO2/UO4). Samples of cases still undiagnosed after the combined sequencing and validation approaches undergo long-read sequencing by an outsourcing facility. Sequencing data are transferred to UO1 for bioinformatic analysis and may be deposited into RDconnect for still inconclusive cases. Variants of interest from bioinformatic analyses and in vitro validations are collectively discussed by UO1/UO2/UO3 to evaluate their clinico-molecular significance and to be selected for testing therapeutic approaches by UO2/UO4. Blue arrows and shapes denote samples and personal data, while green data that make no identifiable person.
219208616|NCT06777407|BEHAVIORAL|Brief Mindfulness-Based Intervention to Reduce Psychological Distress|The brief mindfulness-based intervention is an eight-week training program designed for groups of 15 to 20 participants. The weekly sessions will last 90 minutes for the first session and 60 minutes for the following seven sessions. The program will be led by a certified mindfulness trainer, who is not part of the research team and will be solely responsible for training-related activities.
219208617|NCT06777407|OTHER|Psychoeducational brochure|Information on self-care and managing psychological distress will be provided. Once the study is completed and the data has been collected, participants in the control group will receive the intervention.
219067654|NCT06635473|BEHAVIORAL|Information support|The experimental group was given intervention measures. According to the general data survey, discharge readiness and self-efficacy assessment, parents were divided into low, middle and high discharge readiness groups and low, middle and high self-efficacy groups, respectively, using WeChat mini programs to push different content.
219067655|NCT06635473|BEHAVIORAL|Stress and coping|According to the results of self-efficacy and anxiety assessment, different interventions were based on different scores. Give encouragement and affirmation to parents with low anxiety and high self-efficacy. Parents with high anxiety and low self-efficacy should push stress relief methods such as mindfulness relaxation therapy in time. And through the wechat mini program to provide parents to respond to the pressure of the problem, the medical staff to give timely feedback.
219067656|NCT06635473|BEHAVIORAL|Specialist guidance|Carry out offline science popularization education and specialized training, and highly qualified specialist doctors and nurses will train parents, and parents will be assessed after training, and personalized guidance will be given according to the weak points of each parent\&#39;s assessment.
219667831|NCT03813134|DEVICE|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
219667832|NCT06020196|PROCEDURE|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
219208618|NCT06775522|DRUG|YHP2205|Test drug: YHP2205 Comparator: YHR2401
218977019|NCT05600660|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
219067657|NCT06635473|OTHER|Social support and interaction|Support and encouragement for parents continue from admission to discharge, so that parents feel that even after discharge, there are people to accompany and support them.
219067658|NCT06635473|BEHAVIORAL|Parentage development|Since parents and children are separated during the hospitalization of preterm infants, we will create an environment where parents still play the role of parents, and stimulate parental competence through kangaroo care, parental touch, and breastfeeding.
219208619|NCT06775522|DRUG|YHR2401|Test drug: YHP2205 Comparator: YHR2401
219208620|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
219208621|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
219667833|NCT06020196|PROCEDURE|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
219667834|NCT04851418|DEVICE|Possible NSTE-ACS|As mentioned in the group description
218977020|NCT05600660|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
218977021|NCT05600660|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
218977022|NCT06144892|DEVICE|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
218977023|NCT01685892|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
218977024|NCT01685892|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
218977025|NCT04164355|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
218977026|NCT03266523|OTHER|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
218977027|NCT02208531|BEHAVIORAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
218977028|NCT05941559|OTHER|EMDR|Eye Movement Desensitization and Reprocessing
219667835|NCT00528632|OTHER|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
218977029|NCT05739630|DRUG|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
219067659|NCT06634758|BEHAVIORAL|Nursing interventions based on the Watson Human Caring Model|In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
219067660|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
219067661|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
219067662|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
219067663|NCT06532266|DEVICE|TechTrade Ready Heat Half Body Temperature Management Blankets|"The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn."
219067664|NCT06532266|OTHER|Control|3 layers of 100% cotton woven blankets
219067665|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
219067666|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
219667836|NCT01656187|DRUG|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
219067667|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
219667837|NCT01656187|DRUG|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
219667838|NCT02005627|DRUG|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
218977030|NCT05739630|DRUG|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
218977031|NCT04319731|BIOLOGICAL|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
219067668|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
219067669|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
219067670|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
219067671|NCT00004010|BIOLOGICAL|bleomycin sulfate|
219067672|NCT00004010|BIOLOGICAL|filgrastim|
219067673|NCT00004010|DRUG|ABVD regimen|
219067674|NCT00004010|DRUG|cyclophosphamide|
219067675|NCT00004010|DRUG|dacarbazine|
219067676|NCT00004010|DRUG|doxorubicin hydrochloride|
219067677|NCT00004010|DRUG|etoposide|
219067678|NCT00004010|DRUG|prednisone|
219067679|NCT00004010|DRUG|procarbazine hydrochloride|
219067680|NCT00004010|DRUG|vinblastine sulfate|
219067681|NCT00004010|DRUG|vincristine sulfate|
219067682|NCT00004010|RADIATION|radiation therapy|
219067683|NCT05063344|DEVICE|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
219067684|NCT03666039|BEHAVIORAL|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
219067685|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
219067686|NCT02703883|DEVICE|BWST|BWST (six weeks, 3 times/week)
219067687|NCT03812146|BEHAVIORAL|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
219067688|NCT03812146|BEHAVIORAL|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
219067689|NCT05130658|DEVICE|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
219067690|NCT05130658|OTHER|Treadmill Training|Conventional gait and balance training using treadmill.
219067691|NCT00377819|DRUG|alendronate|70 mg oral QW
219067692|NCT00377819|DRUG|Denosumab (AMG 162)|60 mg SC q 6 mos
219067693|NCT05133557|OTHER|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
219067694|NCT02091726|PROCEDURE|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
219067695|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
219067696|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
219067697|NCT04295733|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
219067698|NCT01278277|DIETARY_SUPPLEMENT|Saffron supplementation|Saffron supplementation 20 mg
219067699|NCT01278277|OTHER|placebo|placebo supplementation
219667839|NCT02005627|DRUG|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
219667840|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
218977032|NCT03825523|OTHER|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
218977033|NCT03825523|OTHER|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
218977034|NCT02044835|DRUG|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
218977035|NCT00351546|DRUG|Vildagliptin|
218977036|NCT00135044|PROCEDURE|intravenous taurine in nutritional supplement|
218977037|NCT04426708|DRUG|HMS5552|single dose of HMS5552 25mg
218977038|NCT00411437|DRUG|Tolterodine ER|
218977039|NCT00411437|DRUG|Oxybutynin ER|
218977040|NCT05812274|OTHER|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
219067700|NCT03727750|DRUG|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
219067701|NCT00093301|DRUG|Levosimendan|
219067702|NCT00093301|DRUG|Dobutamine|
219067703|NCT06496932|OTHER|Listen to music|Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
219067704|NCT03523533|PROCEDURE|Angiocatheter|Placement of angiocatheter in internal jugular vein
219067705|NCT06471465|DRUG|Bevacizumab|Drug: bevacizumab IV
219067706|NCT06471465|DRUG|Placebo|Drug: placebo IV
219667841|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
219667842|NCT03525782|BIOLOGICAL|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
218977041|NCT04771884|DRUG|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
218977042|NCT01069627|DRUG|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
218977043|NCT01069627|DRUG|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
218977044|NCT02863276|PROCEDURE|Intensified insulin therapy|
218977045|NCT02061618|BEHAVIORAL|Bollywood Dance Exercise|
218977046|NCT00412568|PROCEDURE|Photorefractive Keratectomy (PRK)|vision correction with PRK
218977047|NCT00464269|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
218977048|NCT00464269|DRUG|Brivaracetam 2.5 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
218977049|NCT00464269|DRUG|Brivaracetam 10 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
218977050|NCT00464269|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
218977051|NCT05213000|BEHAVIORAL|Exercise|90 minute exercise session
218977052|NCT04894292|OTHER|Non intervention|During the study there is no extra intervention planned for the participants.
218977053|NCT04441671|DRUG|Disodium Pyrophosphate|Absorption trial
218977054|NCT04196751|OTHER|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
218977055|NCT05792787|DIAGNOSTIC_TEST|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
218977056|NCT01333579|OTHER|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
218977057|NCT05055128|DRUG|X842|Patients will receive X842 tablets.
218977058|NCT05055128|DRUG|X842 Dummy|Patients will receive matching placebo tablets for X842.
218977059|NCT05055128|DRUG|Lansoprazole|Patients will receive Lansoprazole capsule.
218977060|NCT05055128|DRUG|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
219067707|NCT06471465|DRUG|Prednisolone|Drug: corticosteroids IV
219667843|NCT03525782|COMBINATION_PRODUCT|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
219667844|NCT03525782|BIOLOGICAL|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
219667845|NCT03525782|DRUG|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
218977061|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day screener|See descriptions
218977062|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day information sheet|See descriptions
219067708|NCT03421054|DIETARY_SUPPLEMENT|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
219667846|NCT03525782|OTHER|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
219667847|NCT04846816|COMBINATION_PRODUCT|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
219667848|NCT01291134|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
219667849|NCT04757324|OTHER|breastfeeding education|
219667850|NCT00507832|DRUG|Pimecrolimus|twice daily topical
219667851|NCT00507832|DRUG|Hydrocortisone|twice daily topical
219667852|NCT00507832|DRUG|Pimecrolimus|topical application as a cream twice daily
219667853|NCT00938587|DRUG|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
219667854|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
218977063|NCT00005602|DRUG|carboplatin|
218977064|NCT00005602|DRUG|cereport|
218977065|NCT00005602|RADIATION|radiation therapy|
218977066|NCT04161027|DRUG|Pregabalin 75mg|Pregabalin 75 mg capsule
218977067|NCT04161027|DRUG|Placebos|Placebo capsule
219667855|NCT00938587|DRUG|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
219667856|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
219667857|NCT00938587|DRUG|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
219667858|NCT00938587|OTHER|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
219667859|NCT00938587|OTHER|Placebo|Placebo tablet every day for 14 days
219667860|NCT00938587|OTHER|Placebo for PF-04171327|Placebo tablet every day for 14 days
219667861|NCT03464942|RADIATION|SABR|Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
219667862|NCT03464942|DRUG|Atezolizumab|All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
219667863|NCT03998137|DEVICE|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
219667864|NCT03998137|PROCEDURE|Standard of Care|Autologous Bone Graft
219667865|NCT03085771|DRUG|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
219667866|NCT03085771|DRUG|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
219667867|NCT03437161|RADIATION|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
219667868|NCT03743402|BEHAVIORAL|Pain self-management training|"This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider."
219667869|NCT03743402|BEHAVIORAL|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
219067709|NCT05222191|DRUG|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
219667870|NCT03743402|BEHAVIORAL|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
219667871|NCT03743402|BEHAVIORAL|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
219667872|NCT03743402|OTHER|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
219667873|NCT02065414|OTHER|Listerine Advance Gum Defense|
219667874|NCT02065414|OTHER|Mouth rinse containing Chlorhexidine|
219667875|NCT02065414|OTHER|Mouth rinse containing 5% Hydroalcohol|
219667876|NCT04712513|DIAGNOSTIC_TEST|Dynamic cardiac CT perfusion imaging|Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
219667877|NCT01179438|DRUG|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
219067710|NCT05222191|DRUG|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
219067711|NCT05222191|DRUG|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
219667878|NCT01403506|DRUG|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
219667879|NCT01025375|DIETARY_SUPPLEMENT|inulin|10gram/day inulin for 13-day treatment
219667880|NCT01025375|DIETARY_SUPPLEMENT|inulin|16gram/day inulin for 13-day treatment
219667881|NCT01025375|DIETARY_SUPPLEMENT|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
219667882|NCT03104218|OTHER|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
218977068|NCT02942875|OTHER|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
219067712|NCT00407992|DEVICE|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
218977069|NCT02942875|OTHER|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
218977070|NCT04579029|PROCEDURE|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
219067713|NCT00407992|DEVICE|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
219067714|NCT00311077|DRUG|Insulin Glulisine|
219067715|NCT04412395|DIETARY_SUPPLEMENT|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
219067716|NCT04412395|DRUG|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
219067717|NCT01298791|BEHAVIORAL|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
219067718|NCT01298791|BEHAVIORAL|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
219067719|NCT00000974|DRUG|Pentamidine isethionate|
218977071|NCT03521427|OTHER|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
218977072|NCT03521427|OTHER|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
219067720|NCT03339050|BEHAVIORAL|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
219067721|NCT03546244|BEHAVIORAL|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
219067722|NCT03546244|BEHAVIORAL|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
219667883|NCT03104218|OTHER|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
219067723|NCT03388619|RADIATION|Prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
219067724|NCT03388619|RADIATION|Prostate bed irradiation only|Radiation will be delivered to the prostate bed only.
219067725|NCT03388619|DIAGNOSTIC_TEST|Whole Body Bone Scan|At screening, if required by clinician.
219067726|NCT03388619|DIAGNOSTIC_TEST|18F-NaF PET Imaging|At screening, if required by clinician.
219067727|NCT03388619|DIAGNOSTIC_TEST|CT|Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
219067728|NCT03388619|DIAGNOSTIC_TEST|mpMRI|mpMRI of the prostate bed at screening and 6 month follow up.
219667884|NCT02781376|OTHER|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
219067729|NCT03388619|DRUG|ADT|After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
219067730|NCT01483001|DRUG|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
219067731|NCT01914926|DRUG|Metoprolol|
219067732|NCT01914926|DRUG|Diltiazem|
219067733|NCT03877523|DIETARY_SUPPLEMENT|Cocarnit|a metabolic complex
219067734|NCT05461872|OTHER|No intervention|No intervention
219667885|NCT02781376|OTHER|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
219667886|NCT02648464|DRUG|Hydroxychloroquine|
219667887|NCT02648464|DRUG|Placebo|
218977073|NCT04650776|OTHER|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
218977074|NCT00085904|DRUG|SB-485232|
218977075|NCT06345131|OTHER|Non invasive blood pressure monitoring|Non invasive blood pressure monitoring
218977076|NCT05073978|OTHER|No intervention|This is an observational study without any intervention
218977077|NCT05027672|DRUG|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
218977078|NCT02356315|OTHER|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
218977079|NCT01385371|BIOLOGICAL|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
218977080|NCT01385371|BIOLOGICAL|Placebo for SCH 697243|One dissolving tablet sublingually once daily
218977081|NCT02478372|DRUG|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
218977082|NCT02478372|DRUG|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
218977083|NCT04968795|OTHER|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
218977084|NCT04627337|DRUG|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
218977085|NCT04627337|BEHAVIORAL|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
218977086|NCT00546650|DRUG|Sumatriptan succinate|NP101 iontophoretic transdermal system
218977087|NCT00546650|DRUG|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
218977088|NCT04181320|DEVICE|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
218977089|NCT01469624|DRUG|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
218977090|NCT02164773|DRUG|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
218977091|NCT02164773|DRUG|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
218977092|NCT03029273|DRUG|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
218977093|NCT03029273|BIOLOGICAL|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
218977094|NCT02315573|PROCEDURE|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
218977095|NCT05840718|DRUG|Thiamin|Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
218977096|NCT00732797|BEHAVIORAL|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
218977097|NCT00732797|BEHAVIORAL|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
218977098|NCT04737928|DRUG|Latanoprost|latanoprost 0.05%(one drop, once daily)
218977099|NCT04737928|DRUG|tafluprost|tafluprost 0.015% (one drop, once daily)
218977100|NCT04515446|DIAGNOSTIC_TEST|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
218977101|NCT04515446|DIAGNOSTIC_TEST|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
219667888|NCT05247346|DEVICE|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
219667889|NCT00048997|RADIATION|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
219667890|NCT00048997|OTHER|Observation|
219667891|NCT02819440|DRUG|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
219667892|NCT02819440|DRUG|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
218977102|NCT00239395|DRUG|Meloxicam ampoule|
219067735|NCT03816904|OTHER|Blood samples|Blood samples before the introduction of chemotherapy
219067736|NCT02721238|BIOLOGICAL|20% Albumin|
219067737|NCT02721238|OTHER|Plasmalyte|
219067738|NCT04672304|OTHER|Al-Husban University Naser|filling a questionnaire
219067739|NCT00252642|DRUG|Peginterferon Alpha-2a|
219067740|NCT05099848|DRUG|Camrelizumab|"Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
219067741|NCT06429020|BIOLOGICAL|the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.|record the condition of vaccination
219067742|NCT05234827|OTHER|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
219067743|NCT05234827|OTHER|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
219067744|NCT00855517|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
219067745|NCT00108225|OTHER|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
219067746|NCT00108225|OTHER|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
219067747|NCT00618475|BEHAVIORAL|Cognitive behavioral therapy|"10 sessions~1 hour per week"
219667893|NCT02252926|DRUG|Bupivacaine|25 mg bupivacaine lozenge
218977103|NCT00239395|DRUG|Meloxicam tablet|
218977104|NCT00449527|DRUG|Budesonide/formoterol pMDI|
218977105|NCT00449527|DRUG|Budesonide HFA pMDI|
218977106|NCT00619593|OTHER|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"* Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication"
219067748|NCT00467870|DRUG|Testosterone Undecanoate 750 mg|
219067749|NCT00467870|DRUG|Testosterone Undecanoate 1000 mg|
219067750|NCT02630264|DRUG|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
219667894|NCT02252926|DRUG|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
219667895|NCT04644159|OTHER|Human biological samples|Blood , saliva, nasopharyngeal mucosa
219667896|NCT02007278|DRUG|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
219667897|NCT02007278|DRUG|glimepiride|
219667898|NCT02007278|DRUG|Metformin|
218977107|NCT00619593|OTHER|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
218977108|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
218977109|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
218977110|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219667899|NCT01063231|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
219667900|NCT02886884|DRUG|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
219667901|NCT02886884|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
219667902|NCT02372435|PROCEDURE|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
219667903|NCT05279118|DIETARY_SUPPLEMENT|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
219667904|NCT05279118|DRUG|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
219667905|NCT02865200|OTHER|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
218977111|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
218977112|NCT02577562|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
218977113|NCT02730689|DRUG|DP-R207|
218977114|NCT02730689|DRUG|Rosuvastatin|
218977115|NCT02730689|DRUG|Ezetimibe|
218977116|NCT01825070|DIETARY_SUPPLEMENT|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
218977117|NCT05665023|DRUG|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
218977118|NCT00412997|DRUG|LBH589|
218977119|NCT01443273|OTHER|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
218977120|NCT00622973|OTHER|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
218977121|NCT00622973|OTHER|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
218977122|NCT00003976|DRUG|indisulam|
218977123|NCT04245072|PROCEDURE|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
218977124|NCT04245072|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
218977125|NCT04245072|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
219067751|NCT02630264|DRUG|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
219067752|NCT02630264|DRUG|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
219067753|NCT01466998|OTHER|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
219067754|NCT01466998|OTHER|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
218977126|NCT04245072|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
218977127|NCT04245072|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
218977128|NCT04245072|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
218977129|NCT04245072|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
218977130|NCT00003927|BIOLOGICAL|filgrastim|
218977131|NCT00003927|DRUG|amifostine trihydrate|
218977132|NCT00003927|DRUG|cyclophosphamide|
218977133|NCT00003927|DRUG|doxorubicin hydrochloride|
218977134|NCT00003927|DRUG|paclitaxel|
218977135|NCT00003927|PROCEDURE|peripheral blood stem cell transplantation|
218977136|NCT01033461|DIETARY_SUPPLEMENT|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
218977137|NCT01033461|DIETARY_SUPPLEMENT|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
218977138|NCT01033461|OTHER|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
218977139|NCT02482207|DRUG|Rosuvastatin|
218977140|NCT02482207|BEHAVIORAL|Life style modification|
218977141|NCT00237887|DRUG|adalimumab|
219067755|NCT05080569|DRUG|Progesterone Vaginal Product|3dd200mg
219067756|NCT05080569|DRUG|Placebo|3dd1 vaginal capsule
219667906|NCT02865200|OTHER|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
219667907|NCT00033878|DRUG|Noni Extract|
219667908|NCT00435188|BEHAVIORAL|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
219667909|NCT01040715|BIOLOGICAL|TNFa Kinoid|TNFa kinoid
219667910|NCT01040715|BIOLOGICAL|TNF kinoid|IM administration 2 or 3 injections within 28 days
219667911|NCT00478907|DRUG|KETAMINE, PROPOFOL, THIOPENTAL|
219667912|NCT03497767|DRUG|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
219667913|NCT03497767|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
219667914|NCT00497055|DRUG|Aripiprazole|
219667915|NCT00497055|DRUG|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
219667916|NCT01745107|RADIATION|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
219667917|NCT06414876|BEHAVIORAL|Hospital dog|The hospital dog always has a well educated dog instructor beside.
219667918|NCT01608191|BEHAVIORAL|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
219667919|NCT00459368|BEHAVIORAL|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
219667920|NCT00459368|BEHAVIORAL|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
218977142|NCT04834232|DEVICE|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
218977143|NCT04834232|PROCEDURE|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
218977144|NCT02213354|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
218977145|NCT02213354|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
218977146|NCT04248803|OTHER|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
218977147|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
218977148|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
218977149|NCT01498978|BIOLOGICAL|ipilimumab|Given IV
218977150|NCT01498978|OTHER|laboratory biomarker analysis|Correlative studies
218977151|NCT00561769|DRUG|Norditropin pen|12 IU per day
218977152|NCT02952729|DRUG|XMT-1522|one intravenous dose administered in-clinic every 21 days
218977153|NCT03577288|BEHAVIORAL|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
219667921|NCT03002532|RADIATION|whole brain radiotherapy|
219667922|NCT05127928|DIETARY_SUPPLEMENT|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
219667923|NCT05127928|DIETARY_SUPPLEMENT|Placebo|Placebo administration
219667924|NCT00055497|BIOLOGICAL|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
219667925|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
219667926|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
218977154|NCT03577288|BEHAVIORAL|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
218977155|NCT03577288|BEHAVIORAL|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
218977156|NCT03577288|BEHAVIORAL|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
218977157|NCT05361421|DRUG|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
219667927|NCT00055497|BIOLOGICAL|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
219667928|NCT00441987|DRUG|GSI-953|
219667929|NCT03584425|DIAGNOSTIC_TEST|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
219667930|NCT03584425|DIAGNOSTIC_TEST|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
219667931|NCT03584425|DIAGNOSTIC_TEST|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
219667932|NCT01812616|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
219667933|NCT01812616|DRUG|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
219667934|NCT00731731|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
219667935|NCT00731731|PROCEDURE|Cognitive Assessment|Ancillary studies
219667936|NCT00731731|OTHER|Laboratory Biomarker Analysis|Correlative studies
218977158|NCT05361421|DRUG|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
218977159|NCT05002283|OTHER|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
218977160|NCT04834674|COMBINATION_PRODUCT|DEB-TACE combined with apatinib and PD-1 antibody|combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
218977161|NCT01716390|DIETARY_SUPPLEMENT|Drink that contains plant stanols|
219067757|NCT04824404|BEHAVIORAL|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
219067758|NCT02475096|BEHAVIORAL|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
219067759|NCT02813850|DEVICE|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
219208622|NCT06777212|BEHAVIORAL|Mindfulness Training Program|The Mindfulness Training Program is a 30-day behavioral intervention designed to help children with body-focused repetitive behaviors (BFRBs) such as nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program includes daily audio-guided exercises focused on mindfulness techniques such as deep breathing, body scans, and emotional awareness. Children will be encouraged to practice mindfulness for 10-15 minutes each day, with the goal of improving emotional regulation, reducing impulsive behavior, and enhancing self-awareness. Family support is involved, with parents helping children track their progress and offering reinforcement.
219208623|NCT06777212|BEHAVIORAL|Psychosocial Education Program|The Psychosocial Education Program is a 30-day behavioral intervention designed for children with body-focused repetitive behaviors (BFRBs), including nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program provides daily educational content in the form of articles and coping strategies. The intervention focuses on improving emotional regulation, promoting family support, and developing positive behavioral strategies. Parents play an active role by reviewing the content with their children and helping them apply the strategies in daily life. Behavioral and psychological assessments are conducted at baseline, one month, and three months to evaluate the program's impact.
219667937|NCT00731731|DRUG|Temozolomide|Given PO
219667938|NCT00731731|DRUG|Vorinostat|Given PO
219667939|NCT05790642|DEVICE|Pulse wave measurement and analysis|Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.
219667940|NCT05232799|OTHER|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
219667941|NCT03471806|BEHAVIORAL|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
219667942|NCT03471806|BEHAVIORAL|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
218977162|NCT01716390|DIETARY_SUPPLEMENT|Placebo drink|
219667943|NCT03970200|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
219667944|NCT03970200|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
218977163|NCT03230253|BEHAVIORAL|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
218977164|NCT03230253|BEHAVIORAL|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
218977165|NCT03230253|BEHAVIORAL|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
218977166|NCT05912660|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
218977167|NCT01165580|DRUG|valganciclovir [Valcyte]|oral dose, Days 1 and 2
219667945|NCT03970200|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
219667946|NCT03970200|DRUG|Antibiotics|Standard of care antibiotics
218977168|NCT06558175|RADIATION|stereotactic body radiation therapy (SBRT)|Patients will be assigned to treatment doses using the TITE-CRM model.
218977169|NCT02711345|DRUG|LTT462|ERK Inhibitor
218977170|NCT00961649|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
218977171|NCT00961649|DRUG|Brinzolamide ophthalmic suspension, 1%|
218977172|NCT00961649|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
218977173|NCT00961649|OTHER|Vehicle|Inactive ingredients used as placebo
218977174|NCT01315184|BEHAVIORAL|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
218977175|NCT04043728|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
218977176|NCT05923528|DEVICE|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
218977177|NCT05923528|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
218977178|NCT05923528|DEVICE|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
218977179|NCT05923528|DEVICE|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
218977180|NCT05160090|DRUG|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
218977181|NCT01033851|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course
218977182|NCT01033851|BEHAVIORAL|Stress Management Education|8 week course
218977183|NCT02349542|DRUG|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
218977184|NCT01570166|PROCEDURE|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
218977185|NCT01570166|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
219208624|NCT05130983|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219667947|NCT03521752|OTHER|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
219667948|NCT04102332|DEVICE|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
219667949|NCT01211132|DEVICE|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
219667950|NCT01211132|DEVICE|Standard|Without attaching a transparent cap to the tip of colonoscope.
219667951|NCT01139671|DRUG|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
219667952|NCT02112877|DEVICE|Veniti Vici™ Venous Stent System|
219667953|NCT02587754|DEVICE|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
219667954|NCT04006678|PROCEDURE|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
219667955|NCT06485011|PROCEDURE|Paltysma suturing|platysma muscle was sutured in this group with vicryl
219667956|NCT06485011|PROCEDURE|Without Platysma suturing|platysma muscle was not sutured in this group
219667957|NCT04213833|DRUG|Propofol Injection [Diprivan]|patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
218977186|NCT01093638|BIOLOGICAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
218977187|NCT01093638|BIOLOGICAL|Placebo|Oral formulation of placebo fed concomitantly with infant formula
219667958|NCT04213833|DRUG|Dexmedetomidine [Precedex]|patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
219667959|NCT04213833|DRUG|Palatable Lidocaine Topical Gel|15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
219667960|NCT00151164|PROCEDURE|donor bone marrow cell injection into thymus gland|
219667961|NCT03183479|DRUG|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
219667962|NCT03183479|DRUG|Normal saline|100mL normal saline will be administered to patients in control group as placebo
219667963|NCT01693185|DRUG|Remifentanil|continuous infusion 0.4 mcg/kg/min
218977188|NCT04197752|OTHER|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
218977189|NCT04979520|DRUG|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
218977190|NCT00114387|DRUG|DL-alpha-tocopherol|
218977191|NCT06340516|DIAGNOSTIC_TEST|Plasma NT-proBNP|Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
218977192|NCT00800748|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
218977193|NCT00800748|DRUG|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
218977194|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
218977195|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
218977196|NCT04080960|BEHAVIORAL|Lifestyle modification education|Lifestyle modification education and goal setting
218977197|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
218977198|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
218977199|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
218977200|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
218977201|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
218977202|NCT01303783|DRUG|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
218977203|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
218977204|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
218977205|NCT04708106|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
218977206|NCT04708106|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
218977207|NCT04708106|OTHER|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
219067760|NCT04522401|DIAGNOSTIC_TEST|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
219067761|NCT06203509|BEHAVIORAL|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
219067762|NCT05006781|DRUG|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
219667964|NCT01693185|DRUG|Midazolam|bolus injection
219667965|NCT01693185|DRUG|Meperidine|bolus injection for 30 sec 1.0 mg/kg
219667966|NCT01693185|DRUG|placebo (for remifentanil)|normal saline mimic diluted remifentanil
219667967|NCT01693185|DRUG|placebo (for midazolam)|normal saline mimic to midazolam injection
219667968|NCT01693185|DRUG|placebo (for meperidine)|normal saline mimic meperidine injection
219667969|NCT04375098|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
219667970|NCT05061901|DRUG|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
219667971|NCT05061901|DRUG|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
219667972|NCT03876496|DEVICE|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
219667973|NCT04331093|DRUG|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
219667974|NCT03817099|OTHER|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
219667975|NCT03817099|OTHER|Usual Care|Subjects in the group continue with the usual care
219667976|NCT05848596|OTHER|hand hygiene theoretical training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,"
218977208|NCT01502007|OTHER|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
218977209|NCT01502007|OTHER|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
218977210|NCT04298515|DIAGNOSTIC_TEST|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
219067763|NCT05517317|COMBINATION_PRODUCT|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
219067764|NCT03796624|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
219067765|NCT03796624|DEVICE|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
219067766|NCT01754662|DIETARY_SUPPLEMENT|Soy protein|2 bars daily for 8 weeks.
219667977|NCT05848596|OTHER|hand hygiene theoretical + simulation training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,~Hand hygiene simulation training will be carried out by the researcher in an environment with a sink.~* Simulation-based training on standard patients,~* Hand hygiene application and important points to be considered during the application will be emphasized."
219667978|NCT00003045|DEVICE|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
219667979|NCT00003045|RADIATION|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
219667980|NCT00987597|BEHAVIORAL|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
219667981|NCT00987597|BEHAVIORAL|conventional follow-up|nicotinic substitutes
219067767|NCT01754662|DIETARY_SUPPLEMENT|Isoflavones|2 bars daily for 8 weeks.
219067768|NCT01754662|DIETARY_SUPPLEMENT|Cocoa|2 bars daily for 8 weeks.
219067769|NCT01754662|DIETARY_SUPPLEMENT|Placebo|
219667982|NCT01300208|DRUG|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
219667983|NCT01300208|OTHER|Placebo|
219667984|NCT00595101|DRUG|PF-03187207|
219667985|NCT00595101|DRUG|Latanoprost 0.005%|
219667986|NCT00595101|DRUG|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
219667987|NCT00595101|DRUG|Latanoprost Vehicle|
219667988|NCT00890240|DRUG|JNJ-31001074|
218977211|NCT04383158|OTHER|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
218977212|NCT00600535|DRUG|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
218977213|NCT00600535|DRUG|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
218977214|NCT00600535|DRUG|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
218977215|NCT00600535|DRUG|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
218977216|NCT00600535|DRUG|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
218977217|NCT00600535|DRUG|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
218977218|NCT00600535|DRUG|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
218977219|NCT04135742|DEVICE|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
218977220|NCT04135742|BEHAVIORAL|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
218977221|NCT01617525|OTHER|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
218977222|NCT06556355|OTHER|neoadjuvant chemoradiation and McKeown esophagectomy|"Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen)."
218977223|NCT01163266|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
218977224|NCT01163266|DRUG|Placebo|Vortioxetine placebo-matching capsules
218977225|NCT03686761|PROCEDURE|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
218977226|NCT01046162|DRUG|Alprazolam|Single tablet
218977227|NCT01046162|DRUG|Alprazolam|Single tablet
218977228|NCT02919696|DRUG|Abemaciclib|Administered orally
219067770|NCT03455426|DRUG|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
219067771|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
218977229|NCT03882190|DRUG|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
219067772|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
219667989|NCT01549262|DEVICE|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
218977230|NCT04308304|DRUG|MK-1942|MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
218977231|NCT04308304|DRUG|Donepezil|Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
218977232|NCT04308304|DRUG|Placebo|Placebo capsule matched to MK-1942 taken BID by mouth.
218977233|NCT01588249|DIETARY_SUPPLEMENT|Pasteurized maple syrup|
218977234|NCT01588249|DIETARY_SUPPLEMENT|Placebo|
218977235|NCT01270061|BEHAVIORAL|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
218977236|NCT01270061|BEHAVIORAL|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
218977237|NCT00945555|DRUG|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
218977238|NCT01033188|PROCEDURE|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
219067773|NCT04475913|OTHER|DIG Axial|patients received 4 axial implants and digital impression
219067774|NCT04475913|OTHER|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
219067775|NCT04475913|OTHER|CIG Axial|patients received 4 axial implants and conventional impression
219067776|NCT04475913|OTHER|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
219067777|NCT05355974|DRUG|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
219067778|NCT05355974|DRUG|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
219067779|NCT05355974|DRUG|normal saline|500mL infusion run at 999mL/hr
219067780|NCT05355974|DRUG|Plasma-lyte|500mL infusion run at 999mL/hr
219667990|NCT01549262|DEVICE|Observe embryo development|Observe embryo development in the traditional manner
219667991|NCT01242501|BEHAVIORAL|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
218977239|NCT01033188|PROCEDURE|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
219067781|NCT04372771|OTHER|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
219067782|NCT04372771|OTHER|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
219067783|NCT03877042|DEVICE|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
219067784|NCT03877042|DEVICE|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
218977240|NCT01527175|OTHER|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
218977241|NCT03877549|DRUG|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
218977242|NCT01706822|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
218977243|NCT04276337|DIAGNOSTIC_TEST|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
218977244|NCT04113720|DRUG|Levobupivacaine hydrochloride|levobupivacaine 0.25%
219067785|NCT03735329|DEVICE|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
219067786|NCT06352710|OTHER|OP-Tracker App|"There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery."
219067787|NCT03139487|DRUG|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
218977245|NCT04113720|DRUG|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
218977246|NCT02024438|DRUG|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
218977247|NCT02024438|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
218977248|NCT03297814|BIOLOGICAL|Platelet lysate|Intramuscular injection of platelet lysate
218977249|NCT03297814|BIOLOGICAL|Placebo|intramuscular injection of normal saline
218977250|NCT03664180|DRUG|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
218977251|NCT03664180|DRUG|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
218977252|NCT03664180|DRUG|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
218977253|NCT03664180|DRUG|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
219067788|NCT03139487|DRUG|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
218977254|NCT03664180|DRUG|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
218977255|NCT03664180|DRUG|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
219067789|NCT03139487|DRUG|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
219067790|NCT02771951|BEHAVIORAL|"Lights of Change"|
219067791|NCT02771951|BEHAVIORAL|Usual Care|
219067792|NCT02261363|OTHER|Ecig group 1|E-cigarettes were 3% nicotine and of tobacco or menthol flavor, depending on participants' usual flavor preference.
219067793|NCT01517802|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
219667992|NCT01242501|BEHAVIORAL|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
219667993|NCT05207722|BIOLOGICAL|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
219667994|NCT05207722|DRUG|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
219667995|NCT05207722|DRUG|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
219667996|NCT05207722|DRUG|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
219667997|NCT05207722|DRUG|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
219667998|NCT05207722|DRUG|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
219208625|NCT06775171|BEHAVIORAL|video training group|"Creation of the Education Booklet While creating the education booklet that includes the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support, it will be created by the researcher by scanning the current literature and taking the opinions of the Faculty Members from the Nursing Fundamentals field in terms of scope, comprehensibility and scientific content.~Creation of Videos The videos will be prepared in five separate videos that will include the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support in line with the education booklet. QR codes of the prepared videos will be created. Each video will be planned to be 5-10 minutes. The videos will be checked by the Advisor Faculty Member and corrections will be made in line with his/her suggestions."
219208626|NCT06771804|DIETARY_SUPPLEMENT|Cricket Protein|Participants are provided with muffins containing either whey or cricket protein.
219208627|NCT06774651|PROCEDURE|Procedure: Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure using FEMTO LDV Z8 laser system for correction of Myopia.
219208628|NCT06774651|PROCEDURE|Procedure: Small Incision Lenticule Extraction (SMILE)|Routinely conducted procedure using VisuMax laser system for correction of Myopia.
219667999|NCT05207722|DRUG|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
219668000|NCT04447495|DIAGNOSTIC_TEST|iAMP test|The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
218977256|NCT05013034|DRUG|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
218977257|NCT05013034|DRUG|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
218977258|NCT02831140|BEHAVIORAL|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
218977259|NCT02831140|BEHAVIORAL|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
218977260|NCT02831140|BEHAVIORAL|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
218977261|NCT02831140|BEHAVIORAL|commun interventions|"* In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
218977262|NCT04820517|OTHER|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management"
218977263|NCT06441448|BEHAVIORAL|case focus groups|The study is in a monocentric, exploratory, participatory study conceptualization phase. Within the study, a mixed-methods assessment involves various interview and group exercise formats among scientists, medical personnel, affected individuals, and their caregivers to develop components for a future psychotherapeutic program for ALS patients and their caregivers. Therapists provide an overview of therapy forms by presenting components based on format, content, and applied techniques. Case studies and focus groups are used for practical experience for the participants. Participants qualitatively assess the significance of therapeutic approaches and make a quantitative prioritization to establish a ranking of therapy components.
218977264|NCT01686828|DRUG|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
218977265|NCT01686828|DRUG|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
218977266|NCT01686828|DRUG|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
218977267|NCT01686828|DRUG|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
218977268|NCT01686828|DRUG|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
218977269|NCT00305214|PROCEDURE|T Wave Alternans Test|
218977270|NCT01635335|BEHAVIORAL|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
218977271|NCT00393354|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
218977272|NCT00393354|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
219668001|NCT00842400|DRUG|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~* metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~* sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~* VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~* 2 g (four 500 mg) probenecid tablets on Day 29."
219668002|NCT05724459|OTHER|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
219668003|NCT03285659|OTHER|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
218977273|NCT06272201|DEVICE|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
219668004|NCT01606748|BIOLOGICAL|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
219668005|NCT01606748|DRUG|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
218977274|NCT01062204|DEVICE|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
218977275|NCT01062204|DEVICE|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
218977276|NCT01791010|OTHER|Inspiratory muscle training|
218977277|NCT01791010|OTHER|Training sham|Conducting fake training with the aim of blind the control group
218977278|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
218977279|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
218977280|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
218977281|NCT05086952|DRUG|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
218977282|NCT01642654|OTHER|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
218977283|NCT01642654|OTHER|Educational lectures|Educational lectures
218977284|NCT04746716|OTHER|Phone call|Phone call to the patient to complete quality of life scales
218977285|NCT04680156|DRUG|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
219067794|NCT01517802|DRUG|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
219067795|NCT04195464|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
219208629|NCT06772454|DRUG|Antitumor therapy|"All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles"
219668006|NCT01606748|DRUG|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
218977286|NCT00359697|DRUG|Hypertonic Saline, Mannitol|
218977287|NCT02908243|OTHER|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
218977288|NCT00136071|DEVICE|Transobturator tape-ARIS|
218977289|NCT00136071|DEVICE|TVT-O|
218977290|NCT04264689|PROCEDURE|serratus anterior block|ultrasound guided block
218977291|NCT04264689|PROCEDURE|thoracic epidural|thoracic epidural
218977292|NCT04264689|PROCEDURE|erector spinae block|ultrasound guided block
219067796|NCT04195464|OTHER|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
219067797|NCT06219759|OTHER|Observational study|Observational study.
219067798|NCT00885404|DRUG|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
219067799|NCT02590354|OTHER|ART interruption|
219067800|NCT06496529|BEHAVIORAL|DoF intervention|Training of specific uniarticular and single plane movement of the upper limb through an exoskeleton and videogames that will be supervised by a physiotherapist.
219668007|NCT06648954|DEVICE|multisite HD-tDCS|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
218977293|NCT05885854|DRUG|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
218977294|NCT04117139|DIAGNOSTIC_TEST|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
218977295|NCT03848338|PROCEDURE|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
218977296|NCT01467583|DRUG|Fondaparinux|2.5 mg every 48 hours
218977297|NCT02717273|DRUG|standard|peri-operative antibiotic regimen only
218977298|NCT02717273|DRUG|extended|extended three-day course of antibiotics
218977299|NCT02717273|OTHER|liver transplant|orthotopic liver transplantation
219067801|NCT06496529|BEHAVIORAL|Task intervention|Training of multiarticular upper limb movements (vertical, horizontal and diagonal) through videogames and also training of functional task (raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass). This activities will be supervised by a physiotherapist.
219067802|NCT00760929|DRUG|Placebo|iv 9mg/kg weekly
219067803|NCT00760929|DRUG|Placebo|iv 16mg/kg every 3 weeks
219067804|NCT00760929|DRUG|RG1507|iv 9mg/kg weekly
219067805|NCT00760929|DRUG|RG1507|iv 16mg/kg every 3 weeks
219067806|NCT00760929|DRUG|erlotinib [Tarceva]|150mg oral daily
219067807|NCT04609254|DRUG|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
219067808|NCT04609254|DRUG|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
219067809|NCT04609254|DRUG|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
219067810|NCT02099838|DRUG|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
219067811|NCT02099838|DRUG|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
218977300|NCT06260098|BEHAVIORAL|Yoga with High Breath work & meditation; Low movement/postures|Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
218977301|NCT06260098|BEHAVIORAL|Yoga with Low Breath work & meditation; High movement/postures|Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
218977302|NCT05274165|DEVICE|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
219067812|NCT04957966|BEHAVIORAL|self-selected relaxing music|20 minutes music listening
219067813|NCT02301143|DRUG|nab-Paclitaxel|
218977303|NCT05274165|DEVICE|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
218977304|NCT04637490|DEVICE|patellar component|patellar resurfacing
218977305|NCT02827916|DEVICE|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
218977306|NCT02827916|DEVICE|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
218977307|NCT02827916|DEVICE|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
218977308|NCT01690429|DEVICE|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
219067814|NCT02301143|DRUG|Gemcitabine|
219067815|NCT02301143|DRUG|Chemoradiation|
219067816|NCT02301143|DRUG|Capecitabine|
219067817|NCT02301143|PROCEDURE|Surgery|Surgical intervention
219668008|NCT06648954|DEVICE|Conventional tDCS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
219668009|NCT06648954|DEVICE|Sham stimulation|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
219067818|NCT04064034|OTHER|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
219067819|NCT06580626|PROCEDURE|decompression technique|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
219067820|NCT06580626|PROCEDURE|guided bone regenaration using Ethoss|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.
219067821|NCT06580626|PROCEDURE|ridge splitting technqiue|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
218977309|NCT03360747|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
218977310|NCT02484690|DRUG|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
218977311|NCT02484690|DRUG|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
218977312|NCT02484690|DRUG|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
218977313|NCT02643030|BEHAVIORAL|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
218977314|NCT02643030|BEHAVIORAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
218977315|NCT04432272|BIOLOGICAL|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
218977316|NCT02127723|DEVICE|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
218977317|NCT01860781|DRUG|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
219067822|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
219067823|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
219067824|NCT03740490|COMBINATION_PRODUCT|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
219067825|NCT03740490|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
219067831|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
219067832|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
219067833|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
219067834|NCT00242034|PROCEDURE|CT and MRI with contrast|
219067835|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
219067836|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
219067837|NCT02536508|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
219067838|NCT02536508|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
219067839|NCT02536508|DRUG|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
219668010|NCT00389051|DRUG|bendamustine hydrochloride|1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)
218977318|NCT04603716|OTHER|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
218977319|NCT04603716|OTHER|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
218977320|NCT02389985|DRUG|CRLX101|
218977321|NCT02389985|DRUG|Paclitaxel|
219668011|NCT03150394|DIETARY_SUPPLEMENT|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
219668012|NCT03150394|OTHER|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
218977322|NCT00343590|DEVICE|Whole Body Vibration machine|
219668013|NCT02590757|DEVICE|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
219668014|NCT02590757|DEVICE|N-CPAP|Nasal-continuous positive airway pressure
219668015|NCT02603926|DRUG|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
219668016|NCT03066219|DRUG|BRM421|A topical solution of BRIM421 ophthalmic drops
219668017|NCT03066219|DRUG|Placebo|vehicle ophthalmic drops
219668018|NCT06368323|BEHAVIORAL|Choir singing|The 12-week intervention will consist of 12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master in addition to home training (3 x 30-minutes-sessions/week, total 18h). In total, participants will undergo the intervention for 3 hours/week for 12 weeks (i.e., 36 hours).
218977323|NCT05750160|OTHER|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
218977324|NCT00802087|DRUG|hydrocodone|Extended Release tablet
218977325|NCT00802087|DRUG|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
218977326|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with applesauce
218977327|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with yogurt
218977328|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of intact bosutinib capsules
218977329|NCT03772678|DRUG|LSALT peptide|novel 16 amino acid peptide
218977330|NCT03772678|OTHER|0.9% Saline|saline
218977331|NCT05483270|BIOLOGICAL|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
218977332|NCT05417217|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
218977333|NCT05417217|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
218977334|NCT04093349|GENETIC|SPK-3006|adeno-associated viral (AAV) vector
219668019|NCT06368323|OTHER|Usual care|Rehabilitation services received by patients and social activities will be monitored and documented.
219668020|NCT04505202|DRUG|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
218977335|NCT03783091|DRUG|Hydroxocobalamin|Single IV administration of Vitamin B12
218977336|NCT03783091|DRUG|Placebo|Single IV administration of saline
218977337|NCT05636826|DRUG|atherolive-drug|The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
218977338|NCT05636826|DRUG|Placebo Atherolive|The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
218977339|NCT06008613|DEVICE|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
218977340|NCT06572241|DRUG|Intrathecal morphine|morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
218977341|NCT06572241|OTHER|Saline solution (placebo)|normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).
218977342|NCT05029700|OTHER|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
218977343|NCT05029700|OTHER|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
218977344|NCT00818675|DRUG|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
219208630|NCT06772454|DRUG|Inhaled preparation for COPD|"60 patients were randomly assigned to the following two groups in a 1:1 ratio, with about 30 patients in each group.~Group A: Receiving a long-acting beta-2 agonist (LABA) + a long-acting anticholinergic (LAMA) combination: Glonium bromide formoterol inhalation aerosol (7.2ug/5ug, trade name: Biwapin, Astrazeneca), 2 inhalations twice a day.~Group B: Received inhaled glucocorticoid (ICS) +LABA+LAMA as a three-drug combination: budesonide/glononium bromide/formoterol :160ug/7.2ug/4.8ug, Astrazeneca), 2 inhalations twice daily."
219668021|NCT04505202|DRUG|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
219668022|NCT00004759|DRUG|methylprednisolone|
219668023|NCT00004759|DRUG|tirilazad|
218977345|NCT00818675|DRUG|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
218977346|NCT00818675|DRUG|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
218977347|NCT04428437|DRUG|Lenvatinib|Prescribed by physician.
218977348|NCT01515007|DRUG|Ciprofloxacin dispersion for inhalation|
218977349|NCT01515007|DRUG|Placebo|
218977350|NCT04282278|DRUG|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
218977351|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
218977352|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
218977353|NCT03753269|DRUG|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
218977354|NCT03753269|DRUG|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
218977355|NCT02788760|DEVICE|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
218977356|NCT03659955|OTHER|Autologous blood applied to dry eye|See previous description for the study arm.
218977357|NCT03200158|OTHER|Endoscopy biopsy and blood|Medical operation
218977358|NCT01814618|DRUG|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
218977359|NCT04747639|OTHER|500 ml glucose-depleted apple juice|
218977360|NCT04747639|OTHER|500 ml conventional apple juice|
218977361|NCT04747639|OTHER|250 ml glucose-depleted apple juice|
218977362|NCT04747639|OTHER|250 ml conventional apple juice|
218977363|NCT01982578|DIETARY_SUPPLEMENT|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
218977364|NCT01982578|OTHER|Placebo|360 days of double blind treatment of placebo.
218977365|NCT06019585|DEVICE|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
218977366|NCT06019585|DEVICE|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
218977367|NCT02562768|DRUG|LY3154207|Administered orally
218977368|NCT02562768|DRUG|Placebo|Administered orally
218977369|NCT01386008|DEVICE|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
218977370|NCT01386008|DEVICE|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
218977371|NCT03001882|BIOLOGICAL|Nivolumab|Specified dose on specified days
218977372|NCT03001882|BIOLOGICAL|Ipilimumab|Specified dose on specified days
218977373|NCT04676854|DEVICE|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
218977374|NCT06345092|DRUG|Vitamin C|addition of vitamin C to IPRF
219208631|NCT06779721|OTHER|Sestrin-2|Sestrin-2 levels were studied in three different groups
219668024|NCT04936113|BIOLOGICAL|FB-401|Topical
219668025|NCT02557373|DIETARY_SUPPLEMENT|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
219668026|NCT02557373|DIETARY_SUPPLEMENT|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
219668027|NCT04092829|PROCEDURE|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
219668028|NCT02230540|DEVICE|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
219668029|NCT02230540|DEVICE|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
219668030|NCT02230540|DEVICE|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
218977375|NCT06345092|OTHER|Injectable platelet rich fibrin|injection of IPRF alone
218977376|NCT06225037|DEVICE|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
218977377|NCT06225037|DEVICE|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
218977378|NCT05907122|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
218977379|NCT05907122|DRUG|FDA-licensed Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
219668031|NCT05896800|OTHER|Inhaled nitric oxide (NO)|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
219668032|NCT05896800|OTHER|air|use air（21%O2）as the placebo of inhaled treatment
218977380|NCT05907122|DRUG|EU-authorized Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
218977381|NCT00589290|DRUG|Belinostat (PDX101)|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
218977382|NCT01555983|DRUG|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
218977383|NCT02755298|DRUG|Acetazolamide|
218977384|NCT02755298|DRUG|Placebo|
218977385|NCT02475031|DEVICE|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
218977386|NCT02475031|DRUG|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
218977387|NCT06593106|PROCEDURE|Cryosurgery|Undergo cryodevitalization
219208632|NCT06778733|DRUG|Clomiphane citrate|Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))
218977388|NCT06593106|PROCEDURE|Robotic Bronchoscopy|Undergo standard of care robotic bronchoscopy with biopsy
218977389|NCT06593106|PROCEDURE|Bronchoscopy with Biopsy|Undergo standard of care robotic bronchoscopy with biopsy
218977390|NCT06593106|PROCEDURE|Resection|Undergo standard of care surgical resection
218977391|NCT06593106|PROCEDURE|Chest Radiography|Undergo chest x-ray
218977392|NCT06593106|PROCEDURE|Computed Tomography|Undergo Computed Tomography
218977393|NCT06593106|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
218977394|NCT06593106|OTHER|Electronic Health Record Review|Ancillary studies
218977395|NCT04128579|DRUG|Itolizumab [Bmab 600]|EQ001
218977396|NCT06602102|DEVICE|Mixed reality Glasses|Mixed reality glasses are devices that combine elements of augmented reality and virtual reality. They allow users to overlay digital images onto the real world, enabling interaction with virtual objects in a physical environment. These glasses typically use sensors, cameras, and tracking technology to map the surroundings and provide an immersive experience. They are used in various applications, such as gaming, education, design, and professional training.
219208633|NCT06778733|DRUG|recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)|"All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)"
219668033|NCT00095589|GENETIC|loss of heterozygosity analysis|
218977397|NCT06680154|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current was delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) were used throughout the stimulation. Before placing the electrodes on the head, the subject's hair was moved to the side
219668034|NCT00095589|GENETIC|microarray analysis|
219668035|NCT00095589|GENETIC|microsatellite instability analysis|
219668036|NCT00095589|OTHER|cytology specimen collection procedure|
219668037|NCT00095589|OTHER|laboratory biomarker analysis|
219668038|NCT00095589|PROCEDURE|computed tomography|
219668039|NCT00095589|PROCEDURE|cystoscopy|
219668040|NCT05800496|DIETARY_SUPPLEMENT|SesZen-Bio™|mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
219668041|NCT05800496|OTHER|Placebo|Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
219668042|NCT05299619|DEVICE|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
218977398|NCT06680154|DEVICE|Theta burst stimulation|the intermittent theta burst stimulation (iTBS) which is regarded as safe for high-frequency neuromodulation. Compared to classical rTMS, where pulses are applied repeatedly at a fixed frequency, iTBS consists of bursts of pulse triplets. In the classical protocol, the bursts are applied for two seconds in 5Hz intervals followed by an eight-second break, before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol.
219067840|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
219067841|NCT05245058|DRUG|SPH5030 tablets|SPH5030 tablets orally once or twice daily.
219067842|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
219668043|NCT02671019|BEHAVIORAL|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
219668044|NCT03742258|DRUG|Cyclophosphamide|Given IV
219668045|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
219668046|NCT03742258|DRUG|Prednisone|Given PO
219668047|NCT03742258|BIOLOGICAL|Rituximab|Given IV
218977399|NCT06680154|DEVICE|Sham (No Treatment)|In the case of sham TMS, two different sham coils (double 70mm pCool-SHAM coil, Mag\&More GmbH, Munich, Germany) will produce audible clicks at the decibel intensity corresponding to an active coil without the induction of an electromagnetic pulse. Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
218977400|NCT06686264|OTHER|core stability group A|Abdominal hollowing in supine (10 reps \& 2 sets) Single leg bridge (10 reps \& 2 sets), 3 session per week for 6 weeks Prone Single leg raise(10 reps \& 2 sets) Double leg bridge (10 reps \& 2 sets) Abdominal hallowing in 4 point kneeling(10 reps \& 2 sets), Complete Back stretch Pelvic rotations Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
218977401|NCT06686264|OTHER|traditional exercises group B|Complete Back stretch Pelvic rotations, 3 sessions per week for 6 week Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
219067843|NCT04483479|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
219067844|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
219067845|NCT05969353|OTHER|accupunture|BFA
219067846|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
219067847|NCT04768010|DRUG|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
219067848|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
219067849|NCT05266690|DIETARY_SUPPLEMENT|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
219067850|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
219668048|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
219668049|NCT03742258|DRUG|Vincristine Sulfate|Given IV
219668050|NCT06602167|COMBINATION_PRODUCT|True electroacupuncture + True self-administered acupressure|"True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes."
219668051|NCT06602167|DRUG|Doctor-prescribed treatment|Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
219668052|NCT06602167|COMBINATION_PRODUCT|Sham electroacupuncture + Sham self-administered acupressure|"Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
219668053|NCT01511003|DRUG|Tacrolimus|oral
219668054|NCT05980143|OTHER|Metacognitive Therapy|The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
219668055|NCT04760379|OTHER|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
219668056|NCT04760379|OTHER|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
219668057|NCT04310475|OTHER|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
219668058|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
219668059|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve injection.|"While in prone position, lumbar facet joints are identified by fluoroscopy. An anteroposterior image of the lumbar vertebrae is obtained. Then, the fluoroscope is tilted between 10 to 20 degrees to the side to inject. 22 gauge needles are then advanced aiming to the medial branch of lumbar facet joints.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous medial branch nerve injection."
218977402|NCT05807763|PROCEDURE|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
218977403|NCT06695312|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise
218977404|NCT06695312|DEVICE|High Tone Power Therapy|High Tone Power Therapy delivered in cervical region 3 times per week for four weeks
218977405|NCT06706479|DEVICE|high-definition transcranial direct current stimulation|High-definition transcranial direct current stimulation is a novel non-invasive brain stimulation technique based on the principle that when weak intensity electric currents are targeted on specific areas of the scalp, they cause underlying cortical stimulation. The anode increases cortical excitability, while cathode decreases cortical excitability.
219067851|NCT05266690|DIETARY_SUPPLEMENT|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
219067852|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
219067853|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
219067854|NCT05975190|OTHER|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R\&R training provided on an MP3-player for daily practice
219067855|NCT05233826|BIOLOGICAL|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
219067856|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
219067857|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
218977406|NCT06709742|OTHER|Gross Motor Function Measure-88 Based Therapy|Children will be assessed initially by using GMFM-88 and selecting specific items for individuals according to his/her needs with the help of experts and family. At least 3 items will be selected for each subject in which they score less such that 0, 1 or 2. Training based on those specific items will be given to the children. This is goal-oriented training in which, according to the needs of children training will be provided.
218977407|NCT06707597|OTHER|Patient Interaction Group|No interventions or procedures will be applied to the patients. To evaluate whether the pain, anxiety, and comfort of patients undergoing the same surgical procedure are influenced by each other, the average scale scores of patients in double and single rooms will be compared.
218977408|NCT06709105|OTHER|Kinesiotape|The application was performed using 5 cm x 5 m kinesio tape material. After preparing the standing patient in terms of clothing and skin readiness, the patient was asked to lean forward. To adhere the tape to the right paravertebral region, the lower end of the tape was first adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. Then, while the patient was leaning forward, a slight rotation to the left was requested, and in this position, the tape was adhered upwards along the paravertebral muscles without any tension. When applying the tape to the left paravertebral region, the same procedure was mirrored as on the right, with the tape again applied without any tension. The third tape was applied while the patient was standing upright and leaning slightly forward, placed over the sacroiliac joints and parallel to the floor, stretching the tape by 25%.
219668060|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
219668061|NCT04451252|PROCEDURE|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
219668062|NCT04451252|PROCEDURE|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
219668063|NCT04451252|PROCEDURE|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
219668064|NCT04761159|DRUG|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
219668065|NCT02503254|OTHER|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
219668066|NCT02503254|OTHER|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
219668067|NCT00196430|DEVICE|silver-contained textiles|
219668068|NCT00196430|DRUG|corticosteroid|
219668069|NCT00964015|DRUG|6% Hydroxyethyl Starch 130/0.4|
219668070|NCT00964015|DRUG|0.9% Normal Saline|
219668071|NCT02083653|DRUG|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
219668072|NCT02083653|DRUG|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
219668073|NCT02083653|OTHER|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
219668074|NCT02083653|DRUG|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
219668075|NCT02083653|DRUG|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
219668076|NCT06536322|OTHER|OHS-interRAI|An oral health screening tool is being tested. Former name was the optimized oral health-related section of the interRAI (ohr-interRAI). This was further optimized into the OHS-interRAI. The OHS-interRAI comprises of 3 oral health-related items that are assessed through questioning the resident, and 6 items that require visual inspection of the mouth.
219668077|NCT03327961|DEVICE|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
219668078|NCT05846217|DEVICE|Multiwave Locked System|Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
218977409|NCT06709105|OTHER|Sham (no implant)|Sham Kinesio taping was applied to the patients in the control group. In this sham protocol, Kinesio bands were attached between the 12th rib on both sides and the corresponding sacroiliac joint, passing over the paravertebral muscles without employing any specific banding technique. The third tape was adhered between both sacroiliac joints, also without any adhesive technique. Patients were inquired about any discomfort and informed that the tapes would remain in place until the second session.
218977410|NCT03524352|OTHER|fecal microbiota|fecal microbiota in suspension
218977411|NCT03524352|OTHER|Placebo|sterile saline
218977412|NCT05540782|BEHAVIORAL|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
218977413|NCT06934408|DRUG|HRS-5817 Injection|HRS-5817 injection administered subcutaneously (SC).
219067858|NCT00244738|DIETARY_SUPPLEMENT|Castor oil|Patients who received castor oil for labor induction
219067859|NCT00244738|DIETARY_SUPPLEMENT|Sunflower oil|Patients who received sunflower oil as a placebo
219668079|NCT03742856|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
219668080|NCT04558489|BEHAVIORAL|IPR + GMI|The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
219668081|NCT00623051|PROCEDURE|Male Circumcision|
219668082|NCT03906851|BEHAVIORAL|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
219668083|NCT03142373|OTHER|CV4 technique|
219668084|NCT03142373|OTHER|RR technique|
218977414|NCT06934408|DRUG|HRS-5817 Injection Placebo|HRS-5817 injection placebo administered subcutaneously (SC).
218977415|NCT03246984|DEVICE|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
218977416|NCT04387721|OTHER|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
218977417|NCT00385762|DRUG|paroxetine|paroxetine 10-40mg daily x 5 weeks
218977418|NCT01251939|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
218977419|NCT02531204|DRUG|ASP1585|oral
218977420|NCT04676178|DRUG|PRA023|PRA023
218977421|NCT04676178|OTHER|Placebo|Placebo
218977422|NCT04424810|OTHER|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
218977423|NCT04424810|OTHER|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
218977424|NCT02021032|DEVICE|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
218977425|NCT05259514|DEVICE|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
218977426|NCT04068935|PROCEDURE|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
218977427|NCT05027464|BEHAVIORAL|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
218977428|NCT05361161|DRUG|Transarterial Chemoembolization|Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
218977429|NCT00244283|DRUG|Sevoflurane|
218977430|NCT00244283|PROCEDURE|High thoracic epidural analgesia|
218977431|NCT06406790|DEVICE|CraniSeal|CraniSeal is a PEG Dural Sealant
218977432|NCT06406790|DEVICE|DuraSeal|DuraSeal is a PEG Dural Sealant
218977433|NCT05901311|DRUG|LY3537982|Administered orally.
218977434|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered orally.
218977435|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered IV.
218977436|NCT05476536|BEHAVIORAL|self-management skills and healthy technology APP|self-management skills and healthy technology APP
218977437|NCT01953861|DRUG|EC905|Oral
218977438|NCT00168701|DRUG|BG00012|
218977439|NCT04749667|OTHER|MSCs|Autologous bone-marrow derived mesenchymal stem cells
218977440|NCT04749667|DRUG|Saline|Isotonic saline
218977441|NCT01275456|PROCEDURE|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
218977442|NCT00268866|BEHAVIORAL|Education|
218977443|NCT04512170|DRUG|HEC585|single or Mulltiple doses up to 10 days
218977444|NCT04512170|DRUG|placebo|single or Mulltiple doses up to 10 days
218977445|NCT05746962|DEVICE|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
218977446|NCT05746962|DEVICE|Navigation screen|ScopeGuide's 3D visualisation screen
218977447|NCT03299270|OTHER|Questionnaires|Quality of Life and Functional recovery questionnaires
219668085|NCT03142373|OTHER|Placebo treatment|
219668086|NCT05322356|OTHER|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
219668087|NCT02671656|DEVICE|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
219668088|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
219668089|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
219668090|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
219668091|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
219668092|NCT05350345|OTHER|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
219668093|NCT01980745|DRUG|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
219668094|NCT01980745|DRUG|Placebo|
219668095|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
219668096|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
219668097|NCT04517045|DRUG|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
219668098|NCT04517045|DRUG|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
219668099|NCT04517045|OTHER|Conventional treatment|Conventional treatment
219668100|NCT01272375|DRUG|Treatment A|PF-04764793 250/50 using inhaler A
219668101|NCT01272375|DRUG|Treatment B|PF-04764793 250/50 using inhaler A
219668102|NCT01272375|DRUG|Treatment C|PF-04764793 250/50 using inhaler A
218977448|NCT03824418|PROCEDURE|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
218977449|NCT04446572|BIOLOGICAL|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
218977450|NCT05254223|OTHER|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
219208634|NCT04468178|DEVICE|Total joint arthroplasty of the glenohumeral joint|The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
219668103|NCT01272375|DRUG|Treatment D|PF-04764793 250/50 using inhaler A
219668104|NCT01272375|DRUG|Treatment E|PF-04764793 250/50 using inhaler B
219208635|NCT06762678|DIAGNOSTIC_TEST|RNA sequencing and whole genome sequencing in a trio way|Patient is not required to be blinded
219208636|NCT06769971|DRUG|Ivonescimab|20mg/kg，IV infusion，Day1，Q3W
219208637|NCT06769971|DRUG|Cadonilimab|10mg/kg，IV infusion，Day8，Q6W
219208638|NCT06769971|DRUG|Etoposide|100mg/kg，IV infusion，Day1-3，Q3W
219208639|NCT06769971|DRUG|Carboplatin|AUC 5，IV infusion，Day1，Q3W
219668105|NCT01272375|DRUG|Treatment F|PF-04764793 250/50 using inhaler B
219668106|NCT01272375|DRUG|Treatment G|PF-04764793 250/50 using inhaler B
218977451|NCT05254223|OTHER|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
218977452|NCT05594810|BEHAVIORAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
219208640|NCT06769152|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219208641|NCT06769152|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219668107|NCT04371211|BEHAVIORAL|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
219668108|NCT05437237|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
219668109|NCT05631782|DRUG|Shenkang decoction|Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
219668110|NCT00858715|DRUG|aspirin|100 mg aspirin
219668111|NCT00858715|DRUG|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
218977453|NCT05594810|BEHAVIORAL|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
218977454|NCT01331733|DRUG|hMG-HP|
218977455|NCT01331733|DRUG|hMG + GnRH antagonist|
219067860|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
219067861|NCT06300021|DIETARY_SUPPLEMENT|TPG capsule|A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
219067862|NCT06300021|DIETARY_SUPPLEMENT|TPG ready to drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
219067863|NCT06300021|DIETARY_SUPPLEMENT|TPG dairy analog|Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
218977456|NCT00882466|DRUG|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
218977457|NCT00269594|DRUG|Lamictal (lamotrigine)|
218977458|NCT04553354|PROCEDURE|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
218977459|NCT02288598|DEVICE|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
218977460|NCT02288598|BEHAVIORAL|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
218977461|NCT00608972|DRUG|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
218977462|NCT00608972|DRUG|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
218977463|NCT00608972|DRUG|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
218977464|NCT04812730|OTHER|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
218977465|NCT04812730|OTHER|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
218977466|NCT04812730|OTHER|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
218977467|NCT04812730|OTHER|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
218977468|NCT00336154|DRUG|tetracyclin|
218977469|NCT03048474|DRUG|nivolumab and ipilimumab|
218977470|NCT00221260|PROCEDURE|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
218977471|NCT00063323|DRUG|Bupropion|
218977472|NCT01455831|DRUG|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
218977473|NCT01455831|DRUG|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
218977474|NCT02817074|BEHAVIORAL|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
219668112|NCT06264037|OTHER|semi structured interview|semistructured interview on patient\&#39;s experience of hospitalization.
219668113|NCT03796715|DIAGNOSTIC_TEST|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
219668114|NCT03796715|DIAGNOSTIC_TEST|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
219668115|NCT01663194|PROCEDURE|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
219668116|NCT03988972|DEVICE|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
219668117|NCT03988972|DEVICE|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
219668118|NCT04365049|RADIATION|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
219668119|NCT04365049|DRUG|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
219668120|NCT04365049|DRUG|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
219668121|NCT04365049|DRUG|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
219668122|NCT00940641|DRUG|AZD7325|IV Dose
219668123|NCT00940641|DRUG|AZD7325|oral dose
218977475|NCT02817074|BEHAVIORAL|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
218977476|NCT05203289|DRUG|BI 695501 - higher concentration|BI 695501 - higher concentration
218977477|NCT05203289|DRUG|BI 695501 - lower concentration|BI 695501 - lower concentration
218977478|NCT03270644|DRUG|Lasmiditan|Administered orally
218977479|NCT03270644|DRUG|Propranolol|Administered orally
218977480|NCT04464057|DIETARY_SUPPLEMENT|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
219067864|NCT06300021|DIETARY_SUPPLEMENT|TPG probiotic drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
219067865|NCT06300021|DIETARY_SUPPLEMENT|TPG gummies|Pectin gummies containing 300 mg Turmipure Gold®
219067866|NCT06300021|DIETARY_SUPPLEMENT|TPG sport bar|Sport nutrition bar containing 300 mg Turmipure Gold®
219668124|NCT03230136|OTHER|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
219067867|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
219067868|NCT03088384|DRUG|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
219208642|NCT06769152|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219668125|NCT03230136|OTHER|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
219668126|NCT03289299|DRUG|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
219668127|NCT03289299|DRUG|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
219668128|NCT03289299|DRUG|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
219668129|NCT03289299|DRUG|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
219067869|NCT00803647|BIOLOGICAL|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
219668130|NCT02468713|DRUG|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
219668131|NCT02468713|DRUG|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
219067870|NCT00803647|DRUG|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
219067871|NCT00803647|DRUG|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
218977481|NCT01999153|DRUG|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
218977482|NCT01999153|DRUG|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
218977483|NCT01072669|DRUG|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
218977484|NCT02024529|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
218977485|NCT02024529|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
219067872|NCT00803647|DRUG|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
219067873|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
219067874|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
219067875|NCT03064425|BIOLOGICAL|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
219067876|NCT04920760|DIETARY_SUPPLEMENT|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children \> 1 or for infants of \< 1 year of age, respectively).
219067877|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
219067878|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
219067879|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
219668132|NCT03084315|DEVICE|E-Cig Zero Nicotine|E-Cig Zero Nicotine
219668133|NCT03084315|DEVICE|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
219668134|NCT02536274|DEVICE|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
219668135|NCT02536274|DEVICE|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
218977486|NCT00354614|DEVICE|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
218977487|NCT02624960|DEVICE|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
218977488|NCT00376064|DRUG|Octreotide acetate and cabergoline/Octrotide and Somavert|
219067880|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
219668136|NCT00110799|DRUG|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
219668137|NCT00110799|OTHER|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
219668138|NCT04286334|DEVICE|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
219668139|NCT04787614|OTHER|No intervention|No intervention
219668140|NCT03963180|OTHER|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
219668141|NCT01952080|DRUG|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
219668142|NCT06614933|DEVICE|Biphasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.
218977489|NCT01426438|DRUG|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
218977490|NCT01426438|DRUG|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
218977491|NCT01426438|DRUG|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
218977492|NCT01134731|DRUG|paliperidone|1-5 mg daily (QD)
218977493|NCT01134731|DRUG|lithium|300-1500mg QD
218977494|NCT01134731|DRUG|Placebo|1-5 placebo capsules
218977495|NCT04521816|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
219067881|NCT00863850|DRUG|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
219208643|NCT06771531|DEVICE|transcranial direct current stimulation|tDCS can safely and selectively modulate cortical excitability (specifically neuronal firing likelihood) by transferring weak electrical currents between scalp electrodes. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA in this study.
219668143|NCT06614933|DEVICE|Monophasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
219668144|NCT05669469|PROCEDURE|Bariatric surgery|1\) gastric pouch creation, 2) creation of biliopancreatic limb, 3) jejunojejunostomy creation, and 4) creation of gastrojejunostomy.
219668145|NCT00564395|DRUG|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
218977496|NCT00469378|DRUG|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
218977497|NCT05975879|DIETARY_SUPPLEMENT|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
218977498|NCT05975879|DIETARY_SUPPLEMENT|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
218977499|NCT00165659|DRUG|DONEPEZIL HYDROCHLORIDE|
219067882|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
219067883|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
219067884|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
219208644|NCT06771531|DEVICE|active sham stimulation|sham stimulation will implement the same protocol of the tDCS intervention; however, only very low-level currents (no more than 0.5 mA) are transferred between the same electrodes used for the tDCS throughout the 20-minute session. This strategy effectively mimics the cutaneous sensations and skin redness induced by creating only micro cortical electric fields.
219668146|NCT00564395|DRUG|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
219668147|NCT07026357|DEVICE|3D-planimetric measurement|Esophageal stenosis is evaluated by 3D-planimetric measurement
219668148|NCT07026357|RADIATION|Fluoroscopic control|Fluoroscopic control of dilatation therapy
219668149|NCT07026357|DIAGNOSTIC_TEST|Endoscopic control|Macroscopic endoscopic control of dilatation therapy
219067885|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
219067886|NCT04174092|OTHER|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
219067887|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
219668150|NCT07026565|BEHAVIORAL|Psychotherapy group for parents|The psychotherapy group will consist of 10 virtual sessions, each lasting 1 hour and 15 minutes. Each session will begin with a mindfulness exercise to bring the participants into the present moment, followed by a pre-determined topic for discussion. At the end of each session, there will be a closing segment to summarize the reflections and teachings of the day, and a homework assignment will be provided. The topics covered will be: Opening, Psychoeducation, Diagnosis Report, Acceptance, Psychological Flexibility, Cognitive Defusion, Self as Context, Values, Committed Action, and Closure.
219668151|NCT07026565|BEHAVIORAL|Control Group|For the parents who will participate in the control group, the steps undertaken will include the administration of the Self-Reporting Questionnaire, Parental Stress Scale, Acceptance and Action Questionnaire, Cognitive Fusion Questionnaire, and Freiburg Mindfulness Inventory, before the intervention, after the intervention, and after 3 months.
219668152|NCT07027579|OTHER|Nutrineal|"The Education for Thyroid Patients' Nutrition power point presentation prepared by the researcher will also be done using a computer."
218977500|NCT02322346|OTHER|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
218977501|NCT02322346|DRUG|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
219067888|NCT00010517|PROCEDURE|Acupuncture|
219067889|NCT01540123|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
219067890|NCT01540123|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
219067891|NCT02649686|DRUG|Durvalumab|
219067892|NCT02649686|DRUG|Trastuzumab|
219067893|NCT02575092|DRUG|Enalapril Maleate Tablets(as the program-based antihypertension)|
219067894|NCT02575092|DRUG|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
219067895|NCT02575092|DRUG|Placebo|
219067896|NCT05305144|PROCEDURE|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam"
219067897|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
219668153|NCT07026721|PROCEDURE|Retrograde intrarenal surgery (RIRS)|"The intervention involves Retrograde Intrarenal Surgery (RIRS) performed using a flexible ureteroscope to access the renal collecting system via a retrograde (urethra → bladder → ureter → kidney) approach. Stones are fragmented using a holmium:YAG laser, with or without the use of a ureteral access sheath, depending on the case.~What distinguishes this intervention from others is the integration of preoperative scoring systems-specifically the RIRS Scoring System and the Resorlu Unsal Stone Score (RUSS)-to predict stone-free outcomes and guide case selection and surgical planning. Additionally, all procedures are performed by experienced endourologists following a standardized protocol, including consistent patient positioning, anesthesia, access technique, and post-operative imaging at defined intervals to assess outcomes."
219067898|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
219067899|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
219067900|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
219067901|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
219067902|NCT05878639|DRUG|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
219067903|NCT05878639|DRUG|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
219067904|NCT02308436|DEVICE|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries \& acidic challenges
219067905|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
219067906|NCT00823719|DRUG|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle."
219208645|NCT04924491|BIOLOGICAL|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
219668154|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668155|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668156|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668157|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% + 10 Hz)|High frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
219067907|NCT00823719|DRUG|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle."
219067908|NCT00025350|DRUG|gefitinib|
219067909|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
219668158|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 10 Hz)|High frequency stimulation (10 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
218977502|NCT02322346|DRUG|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
218977503|NCT05550285|DEVICE|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
218977504|NCT01147640|DRUG|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
218977505|NCT01147640|DRUG|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
219067910|NCT00861939|DRUG|Bupropion HCI 300 mg Extended-Release Tablets EON|
219067911|NCT00861939|DRUG|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
219067912|NCT05056103|DEVICE|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
219067913|NCT05512494|BIOLOGICAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
218977506|NCT01364077|DRUG|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
218977507|NCT01364077|DRUG|Placebo|Matched placebo
218977508|NCT00844584|PROCEDURE|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
218977509|NCT02650635|DRUG|Cyclophosphamide|Given IV
219067914|NCT04923386|OTHER|None (not interventional)|This is not an intervention
219067915|NCT05302466|DEVICE|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
219668159|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 10 Hz)|High frequency stimulation (10 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668160|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 25 Hz)|High frequency stimulation (25 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668161|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 25 Hz)|High frequency stimulation (25 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
218977510|NCT02650635|OTHER|Laboratory Biomarker Analysis|Correlative studies
218977511|NCT02650635|BIOLOGICAL|Pegfilgrastim|Given SC
218977512|NCT02650635|OTHER|Pharmacological Study|Correlative studies
218977513|NCT02650635|DRUG|TLR8 Agonist VTX-2337|Given SC
218977514|NCT04489797|DRUG|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
218977515|NCT04489797|DRUG|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
219668162|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 25 Hz)|High frequency stimulation (25 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
219668163|NCT07026643|DEVICE|active aVNT vs. Sham|Patients in both groups will receive daily stimulation with the Parasym device, temporarily connected to the tragus of the right ear (Fig 2).54 The stimulation parameters will be frequency of 20 Hz, pulse width of 200 µs, and the stimulation amplitude will be titrated to 1 mA below the discomfort threshold, consistent with parameters used in published clinical studies.54-56 With this stimulation at just below the discomfort threshold, people will often feel the stimulation for less than 60 seconds before they lose awareness of the ongoing stimulation. The stimulation will continue for 1 hour daily for 3 months, and we will track its use with a patient diary. Participants can continue their regular activities while wearing the aVNT device, as long as it is not soaked in water. Parasym will obtain Health Canada approval for use of their device in the study.
219668164|NCT07025980|DIETARY_SUPPLEMENT|The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS|The test product is a ready-to-use preparation PROBalansHepatocare, manufactured by PharmaS d.o.o., which contains 8 strains of live cultures of microorganisms (Bifidobacteriumbreve BBR8, Bifidobacteriuminfantis SP37, Bifidobacteriumlongum SP54, Lactobacillus acidophilus LA1, Lactobacillus bulgaricus LB2, Lactobacillus paracasei IMC502®, Lactobacillus plantarum BG 112, Streptococcusthermophilus SP4) with about 100 billion bacteria (50x109 CFU/capsule) in two capsules per day. In addition, the test product contains 100 mg of fructooligosaccharides, 210 mg of Ca-butyrate, and 10 ug (400 IU) of vitamin D in each capsule.
219668165|NCT07025980|DIETARY_SUPPLEMENT|Placebo Drug|Contains only excipients (cellulose; hydroxypropyl-methyl cellulose) and 10 ug (400 IU) of vitamin D. They do not contain dyes, flavors or preservatives, and contain traces of soy and milk, the levels of which do not affect people who are lactose intolerant.
219668166|NCT07027410|DEVICE|Intermittent normobaric hypoxia|Participants in the experimental group undergo a single session of intermittent normobaric hypoxia simulated by the iAltitude device. The session consists of breathing air with 12% oxygen concentration (equivalent to 4400 meters altitude) for a specified duration. Cognitive tests are administered before and after the hypoxia exposure to assess executive functions.
219668167|NCT07027410|OTHER|Normoxia|Participants undergo the same cognitive tests without exposure to hypoxia, serving as the control condition.
219668168|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Escalation)
219668169|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Escalation)
219668170|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Expansion)
219668171|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Expansion)
219668172|NCT07026045|OTHER|Post isometric relaxation (Lewit,s)|Post-isometric relaxation technique for the erector spinae, Iliopsoas, Quadratus Lumborum
219668173|NCT07026045|OTHER|Post-Facilitation Stretch Technique (Janda's technique)|Post-Facilitation Stretch Technique for the erector spinae, Iliopsoas, Quadratus Lumborum
219668174|NCT07025798|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, Specification: 2g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
219668175|NCT07026396|OTHER|Creative drama group|In the intervention phase of the study, creative drama training was given to adolescents one day a week for 4 weeks. Before the training, permission was obtained from the families of the individuals, and only voluntary adolescents were allowed to participate. The empty classroom in the school was made suitable for creative drama activities. Adolescents gathered in the empty classroom one day a week, and the models and activity materials prepared by the researcher were taken to the classroom during the implementation week.
219668176|NCT07025863|BEHAVIORAL|Alarm Fatigue Intervention Program|Train nurses in terms of alarm fatigue stressors, coping resources, and cognition. The training content for stress management includes forming a multidisciplinary team, selecting appropriate equipment, replacing accessories and dressings in a timely manner, and comforting the children promptly. The training content for dealing with resources includes standardizing alarm response procedures, increasing manpower allocation, enhancing knowledge, skills, and psychological adjustment, etc. The training content of cognition includes fostering a positive attitude and strengthening responsibility, etc.
218977516|NCT00581243|DRUG|SLV-313 SR|sustained relase tablets taken once daily for 14 days
218977517|NCT02008175|RADIATION|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
218977518|NCT00903318|BEHAVIORAL|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
218977519|NCT05288478|COMBINATION_PRODUCT|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
218977520|NCT06556303|OTHER|Acupressure|Acupressure
218977521|NCT02148159|DEVICE|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
218977522|NCT02148159|DEVICE|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
218977523|NCT00394160|DRUG|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
218977524|NCT00000471|BEHAVIORAL|diet, vegetarianism|
218977525|NCT00000471|BEHAVIORAL|diet, fat-restricted|
218977526|NCT00000471|BEHAVIORAL|exercise|
218977527|NCT00000471|BEHAVIORAL|smoking cessation|
218977528|NCT00227929|PROCEDURE|Care Management|
218977529|NCT05920694|DEVICE|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
218977530|NCT05920694|OTHER|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
218977531|NCT00236444|DRUG|risperidone|
218977532|NCT03785938|DIETARY_SUPPLEMENT|Probiotic|Liquid probiotic supplied by the company Symprove
218977533|NCT03785938|OTHER|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
219668177|NCT07026175|OTHER|Diet-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing restricted energy intake on the control trial.
219668178|NCT07026175|OTHER|Exercise-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing increased exercise energy expenditure on the control trial.
219668179|NCT07027241|BEHAVIORAL|Exercise Intervention|"This arm will include and exercise and nutritional intervention in addition to usual postoperative hip fracture care.~The exercise program will be delivered 3-5 times per week, each session lasting between 20-30 minutes depending on patient tolerance. The program will be progressed gradually between sessions and be guided by patient tolerance. The program will involve bed/ chair-based aerobic and resistance training (using an arm crank ergometer, resistance bands and ankle weights). The program will be delivered over the entire length of a patient's hospital stay up to a duration of 6 weeks for prolonged stays.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain."
219668180|NCT07027241|OTHER|Usual Care|"This arm will assess all aspects of usual postoperative hip fracture care which will include multidisciplinary team assessment which include physiotherapists, occupational therapists, dieticians as well as specialist nurses and doctors working as part of the orthogeriatric team (falls and bone health assessment). They will receive daily physiotherapy training starting on the first postoperative day which will include mobility, balance, strength and gait training. This group will also receive additional protein supplementation in the form of a nutritional supplement twice daily as part of usual postoperative hip fracture care.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain.~All patients will be asked to maintain a three-day food diary to monitor their protein intake."
219668181|NCT07027241|DIETARY_SUPPLEMENT|Nutritional Intervention|The nutritional intervention will take the form of a protein fortified evening snack administered by nursing staff (additional 20g of protein).
218977534|NCT01781364|BEHAVIORAL|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
218977535|NCT05095454|DEVICE|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
218977536|NCT05095454|DEVICE|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
218977537|NCT05840640|DRUG|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
218977538|NCT05840640|DRUG|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
218977539|NCT05840640|DRUG|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
218977540|NCT04943718|BIOLOGICAL|personalized vaccine|Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
218977541|NCT04974983|OTHER|Observation of neurological deficits|Observation of neurological deficits
218977542|NCT03227185|DEVICE|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
218977543|NCT03227185|DEVICE|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
218977544|NCT02153333|PROCEDURE|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
218977545|NCT03254290|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
218977546|NCT03254290|BIOLOGICAL|Formocresol|Control group
218977547|NCT03857399|DRUG|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
218977548|NCT03624985|DRUG|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
219668182|NCT07026058|OTHER|Sound Wave Treatment|"Sound wave treatment with 6 sessions initially, 3 times a week, followed by the next 6 sessions with a frequency of 2 times a week. Patient's position was analysed through digital X-ray of cervical spine, 80 pulses are typically administered in a session. These pulses are applied generally, targeting the 1st cervical vertebra of the spine. This method aims to achieve spinal alignment through the vibrations generated by the treatment. Before and after the treatment, a patient assessment is conducted to observe visible improvements. A mixed waveform of 8Hz-202 Hz resonated throughout the spine, with intensities ranging from 0.3 to 1. In order to affect the lumbar region, where they are also applied, sound waves are employed to activate C1.~After First 3 sessions vibrations on pain focal points also given to the patient the 40 pulses are typically administrated at pain point."
219668183|NCT07026058|OTHER|Standard physiotherapy|Flexibility Training: Stretching exercises are crucial to improve the flexibility of the spine and surrounding muscles. This includes stretches for the hamstrings, hip flexors, and lower back Strengthening Exercises: Focus on strengthening the core muscles, including the abdominal and back muscles. Common exercises include pelvic tilts, bridging, and lumbar stabilization exercises Postural Training: Education and exercises to correct posture are vital. Proper posture reduces strain on the spine and helps prevent further injury.(31). Techniques such as ergonomic adjustments at work and home, along with exercises like seated squats and calf stretches Manual Therapy: Techniques such as myofascial release (32) and spinal mobilization. Spinal mobilization as one of the most preferable approaches for the management of LBP
219668184|NCT07027566|DRUG|Potassium nitrate and sodium fluoride|Gel with 5% potassium nitrate and 2% sodium fluoride gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
219668185|NCT07027566|DRUG|Cannabidiol (CBD) Gel|Cannabidiol gel for teeth ( 2% cannabidiol oil) before bleaching with hydrogen peroxide
219668186|NCT07027566|DRUG|Natrosol 4% Gel|placebo gel (natrosol-based gel 4%) for topical application to teeth before bleaching with hydrogen peroxide.
219668187|NCT07026578|PROCEDURE|Blood draw for the laboratory assessment|This is an observational study . The procedures will be carried out in according to clinical practice
219668188|NCT07027085|DEVICE|virtual reality|The intervention group will be applied 14 sessions of virtual reality application, each session lasting 30 minutes and 2 sessions per week. The sessions will be held in a room allocated for this study in the community mental health center. The device on which the application will be made was determined as Meta Quest 3. The contents to be used in the device were determined to be in line with the areas to be examined.
219668189|NCT07027371|BEHAVIORAL|Health education|Health education was given in the form of a printed colored brochure designed in easy-to-understand Arabic language. Participants were encouraged to read the brochure thoroughly and as many times as needed and to ask questions to the researchers if they had any.
219668190|NCT07021352|PROCEDURE|Ear acupuncture|Ear Acupuncture: Participants will receive bilateral NADA ear acupuncture protocol treatment for a one-time insertion in addition to the weekly mindfulness therapy received by participants. The NADA consists of 5 ear acupuncture points inserted bilaterally: shen men, sympathetic, kidney, liver, and lung. Sterile, semi-permanent acupuncture needles (2mm) will be inserted into the participant's ear and left in place until they naturally fall out, typically within 3-7 days.
218977549|NCT03624985|DRUG|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
218977550|NCT02917850|PROCEDURE|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
218977551|NCT02917850|PROCEDURE|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
218977552|NCT03032133|PROCEDURE|Regional pain control|Regional pain catheter
218977553|NCT03032133|PROCEDURE|Local pain control|Local intraarticular pain catheter
218977554|NCT01842100|DRUG|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
218977555|NCT01842100|OTHER|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
218977556|NCT01553383|DEVICE|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
218977557|NCT03342963|DRUG|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
218977558|NCT03342963|DRUG|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
218977559|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
218977560|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
218977561|NCT00879099|DRUG|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
218977562|NCT00879099|DRUG|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
218977563|NCT00879099|DRUG|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
218977564|NCT00879099|DRUG|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
218977565|NCT01667484|DRUG|Adderall XR 5mg|
218977566|NCT01667484|DRUG|Adderall XR 10 mg|
218977567|NCT01667484|DRUG|Placebo|
218977568|NCT02284269|DRUG|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
219668191|NCT07021352|BEHAVIORAL|Mindfulness therapy|Mindfulness: Participants will receive virtual mindfulness therapy weekly for 30 minutes each session via the MS Teams platform.
219668192|NCT07027254|DIAGNOSTIC_TEST|68Ga-pentixafor PET/CT|Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).
219668193|NCT07026838|BEHAVIORAL|The Light Building Emotional Awareness and Mental Health (BEAM) Program|"The LightBEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving parental mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy.~Program delivery will be facilitated through a mobile application. The LightBEAM program consists of four different components; weekly parenting and mental health videos, weekly progress tracking, a group forum, and exercises designed to reinforce skills learned through the video content."
219668194|NCT07025902|DIAGNOSTIC_TEST|Standardized Psychological Screening Using EPDS and HAM-D|Participants will undergo a standardized psychological screening protocol for postpartum depression within 72 hours after delivery. The protocol includes: (1) completion of the Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-administered questionnaire assessing depressive symptoms; and (2) administration of the Hamilton Depression Rating Scale (HAM-D), a 17-item clinician-administered tool for evaluating the severity of depressive symptoms. The combined use of these tools allows early detection and stratification of postpartum depressive symptoms in a clinical population.
219668195|NCT07026123|DRUG|Nal-IRI (Onivyde®)-based treatment|Nal-IRI (Onivyde®) combined with 5-FU/LV is used for metastatic pancreatic ductal adenocarcinoma patients who have progressed after treatment with gemcitabine. The recommended dose of Nal-IRI (Onivyde®) is 70 mg/m\^2, administered intravenously for 90 minutes, once every 2 weeks. In patients known to be homozygous for the UGT1A1 \* 28 allele, the recommended starting dose of Nal-IRI (Onivyde®) is 50 mg/m\^2, administered intravenously within 90 minutes. Based on tolerance, increase the dose of Nal-IRI (Onivyde®) to 70 mg/m\^2 in subsequent cycles.
219668196|NCT07026123|DRUG|Other second-line treatment|Other second-line treatment
219668197|NCT07027150|DEVICE|Chest Worn Pulse Oximeter|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including photoplethysmography (PPG), oxygen saturation (SpO₂), electrocardiography (ECG), and other health metrics. In this study, the device will be evaluated for its ability to accurately measure SpO₂ during controlled hypoxemia in healthy adult volunteers. The SpO₂ values recorded by the Perin Health Patch will be compared against arterial oxygen saturation values (SaO₂) obtained via co-oximetry, following the UCSF Hypoxia Lab protocol aligned with ISO 80601-2-61 standards.~This device integrates PPG and ECG sensors into a single chest-applied unit, distinguishing it from conventional finger or earlobe pulse oximeters. The intervention in this study is limited to the application and use of the device for data collection under clinically controlled oxygen saturation conditions."
218977569|NCT03643575|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
218977570|NCT03643575|DRUG|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
218977571|NCT03643575|DRUG|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
218977572|NCT04709471|DRUG|Nicotine|Participants will reduce their nicotine intake
218977573|NCT04709471|DEVICE|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
218977574|NCT04709471|BEHAVIORAL|Reduction|Participants will reduce the number of Juul pods that they use
218977575|NCT03380715|DEVICE|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
218977576|NCT03380715|DEVICE|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
219067916|NCT05302466|OTHER|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
219067917|NCT02357836|DRUG|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
219668198|NCT07027592|OTHER|Survey Study|The injury risk in veteran football players will be assessed based on FIFA 11+.
219668199|NCT07026149|DRUG|Apatinib+Camrelizumab+SOX|Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w
219668200|NCT07026149|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.
218977577|NCT01189604|DRUG|Placebo|Infusion of placebo, same infusion rates as for arm 2
218977578|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
218977579|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
219668201|NCT07025837|DEVICE|iRESTORE Illumina LED Face Mask and Neck & Chest Mask|A pair of light-emitting diode (LED) therapy devices designed for at-home use. The facial and neck/chest masks deliver low-level red light therapy through embedded LEDs to improve visible signs of skin aging.
219668202|NCT07026097|OTHER|Pilates Exercise - Online|Will receive Pilates exercise protocol online under supervision as patient will instructed to join online meeting and do their exercise 02 times a week along with standard physical therapy protocol for 4 weeks. The Pilates exercise protocol will be of 30 minutes. Repetitions: Exercises started with 6 to 10 reps. and hold time for 30 sec for each exercise. Rest period of 2 mins will be given
219668203|NCT07026097|OTHER|Pilates Exercise - Supervised|Will receive Pilates exercise protocol clinically supervised as patient will instructed to do their exercise 0 times a week along with standard physical therapy protocol for 4 weeks. The Pilates and common standard physical therapy protocol will be the same which is mention in detail in group A description
219668204|NCT07026461|DEVICE|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that uses pulsed magnetic fields to activate or suppress specific brain regions. It is used to treat various conditions, including major depressive disorder, by inducing small electrical currents that stimulate nerve cells.
219668205|NCT07026461|DEVICE|intermittent theta burst stimulation|Intermittent theta-burst stimulation (iTBS) is a form of transcranial magnetic stimulation (TMS) used to modulate brain activity. It involves delivering brief bursts of magnetic pulses to specific brain regions, typically the left dorsolateral prefrontal cortex (DLPFC)
219668206|NCT07027761|BEHAVIORAL|Online self-help|Online Self-Help refers to a 24/7 accessible, internet-based platform that offers digital modules grounded in evidence-based approaches, including infant mental health, cognitive-behavioral therapy (CBT), and psychodynamic interventions, aimed at addressing perinatal depression (https://perinatalehulp.be/). Upon logging in, participants receive an overview of the available modules and can select from three distinct treatment trajectories, ideally to be completed over the course of 10 weeks: (a) a self-directed option allowing free choice among all modules; (b) a structured CBT trajectory incorporating both second-wave and third-wave cognitive-behavioral strategies; or (c) a psychodynamic trajectory primarily focused on relational and attachment-related factors contributing to the onset and maintenance of perinatal depression.
219668207|NCT07027761|BEHAVIORAL|Maternal Mental Health Intervention (MaMHI)|A brief, eight-session face-to-face intervention designed for (expectant) mothers and their infants across the perinatal period, consisting of four prenatal sessions (during the second and third trimesters of pregnancy) and four postnatal sessions conducted within the first three months postpartum. The intervention is grounded in psychodynamic principles and informed by mentalization-based approaches
219668208|NCT07027761|OTHER|Usual Care|Prenatal care is provided through follow-up by a general practitioner and a gynecologist and/or a midwife, while postnatal follow-up is conducted by Child and Family Care Services.
218977580|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
218977581|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
218977582|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
218977583|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
218977584|NCT04336540|OTHER|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
218977585|NCT04336540|OTHER|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
218977586|NCT03081468|DEVICE|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
218977587|NCT03081468|DEVICE|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
218977588|NCT04099095|BEHAVIORAL|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
219067918|NCT00752375|DRUG|Trimethoprim Sulfamethoxazole|"* Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
218977589|NCT04099095|BEHAVIORAL|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
218977590|NCT02758314|OTHER|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
218977591|NCT04555343|DRUG|Tranexamic acid|1gm instilled instravesically
218977592|NCT01056029|DRUG|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
219668209|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (active)|"This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function."
219668210|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
219668211|NCT07027540|DRUG|Bupivacaine 0.25% 20ml|Adult patients will take a total 20 ml of Bupivacaine 0.25%
219668212|NCT07027540|DRUG|2mg of dexamethasone|2mg of dexamethasone in the right T7
219668213|NCT07027540|DRUG|35 ml of Bupivacaine 0.25%|Adult patients will take a total 35 ml of Bupivacaine 0.25%
219668214|NCT07026292|PROCEDURE|Immediate Distal Lymphaticovenous Anastomosis (ID-LVA)|ID-LVA (Immediate Distal Lymphaticovenous Anastomosis) is an supermicrosurgical technique performed during axillary lymph node dissection (ALND) to prevent breast cancer-related lymphedema, offering the dual advantages of immediate intervention and radiation-field avoidance. Compared to LYMPHA (Lymphatic Microsurgical Preventive Healing Approach), which utilizes proximal axillary anastomoses within the radiation field with larger vessels and higher venous pressure, ID-LVA creates precise anastomoses between 0.3-0.8mm distal superficial lymphatic vessels and low-pressure venules in the upper arm. In contrast to DD-LVA (Delayed Distal Lymphaticovenous Anastomosis) performed postoperatively (typically 4-12 weeks after ALND) for subclinical lymphedema, ID-LVA provides earlier prevention by utilizing undamaged lymphatics and avoids the need for a second procedure.
219668215|NCT07026240|DIAGNOSTIC_TEST|DNA test|a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood
219668216|NCT07026201|OTHER|colectomy with primary anastomosis|left hemicolectomy or sigmoidectomy, formal resection was carried out following conventional steps of radical resection.with primary anastomosis
219668217|NCT07027267|DEVICE|Implantation of Spirair device into the middle turbinates|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.
219668218|NCT07027267|DEVICE|TurbAlign|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery
219668219|NCT07027501|OTHER|The video based education group|The parents in the intervention group were provided with a video-based educational material on febrile seizures, which they accessed via a QR code.
219668220|NCT07026227|DRUG|Xuebijing Injection|Xuebijing injection (Tianjin Hongri Pharmaceutical Co., Ltd., National Drug Standard Z20040033).
219668221|NCT07026227|PROCEDURE|Conventional Treatment for High-Voltage Electrical Burns and AKI|Standard multidisciplinary care including general burn assessment, wound management (cleaning, debridement, dressings), fluid resuscitation as per burn protocols, management of electrolyte imbalances
219668222|NCT07027137|DRUG|SRP+ANB+SURG|SRP (scaling and root planing) with ANB (local antibiotic application- 10%doxycycline) and SURG (regeneration procedure according to MIST/M-MIST)
219668223|NCT07027137|PROCEDURE|SRP+SURG|SRP (scaling and root planing) and SURG (regeneration procedure according to MIST/M-MIST)
219668224|NCT07027436|DRUG|Chemotherapy/Radiation|Combination of radiation and chemotherapy
219668225|NCT07027020|DRUG|Oxybutynin Hydrochloride|Pharmaceutical form: solution. Route of administration: Intravesical. Medicinal product unique ID: PRD8074745. EU active substance code: SUB03581MIG.
219668226|NCT07027020|DRUG|Placebo|Pharmaceutical form: solution. Route of administration: Intravesical.
219668227|NCT07026422|COMBINATION_PRODUCT|Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy|"1. Radiotherapy:~   Radiotherapy location: primary site and the corresponding draining lymph node. Radiotherapy techniques: IMRT/VMRT.~   Radiotherapy dose and fractionation pattern: conventional external irradiation, 50Gy/25 fx/5 weeks or 25Gy/5fx/1 week.~2. Chemotherapy:~Long-course radiotherapy concurrent with chemotherapy: capecitabine 825mg/m2, bid, d1-5/week.~Short-course radiotherapy without concurrent chemotherapy. Consolidation chemotherapy and immunotherapy: QL1706 (iparomlimab and tuvonralimab 5mg/kg, d1) and CAPOX (Oxaliplatin 130mg/m2, d1 + capecitabine 1000mg/m2, bid, d1-14), repeated on a 21-day cycle, for 6 cycles. 3. Surgery or watch-and-wait Total mesorectal excision (TME), or watch-and-wait (for patients with clinical complete response)."
219668228|NCT07026747|BEHAVIORAL|Standard Hand Rehabilitation Only|Standard Hand Rehabilitation Program will be delivered over a total duration of six weeks. During the first three weeks, the program will be administered five days per week, and during the following three weeks, it will be performed three days per week. The rehabilitation program will include scar tissue massage, passive and active range of motion exercises for the fingers and wrist, sensory re-education, and edema control using retrograde massage and Coban wrapping. Joint mobilization techniques will be applied to the finger and wrist joints, along with tendon gliding and tendon blocking exercises. Strengthening and stretching exercises targeting the hand and wrist muscles will be progressively introduced throughout the program. Functional training and moderate-level activities will be included as tolerated, particularly in the later stages of the program. The intervention will be structured to gradually increase in intensity and complexity across three phases, each lasting two weeks.
218977593|NCT05877573|DRUG|Toripalimab|Toripalimab 240mg,d1,q3w
218977594|NCT05877573|RADIATION|short-term radiotherapy|25Gy/5Fx
218977595|NCT05877573|DRUG|Oxaliplatin|135mg/m2 d1 q3w
218977596|NCT05877573|DRUG|Capecitabine|1200mg/m2 d1-14 q3w
218977597|NCT00497315|DRUG|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
218977598|NCT00497315|RADIATION|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
218977599|NCT03505554|DRUG|Lorlatinib|100 mg QD
218977600|NCT03216642|DIAGNOSTIC_TEST|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
219668229|NCT07026747|BEHAVIORAL|Supervised Core Stabilization + Standard Hand Rehabilitation|"The second group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days per week for the first 3 weeks, and 3 days per week for the last 3 weeks). In addition, participants will perform a Supervised Core Stabilization Exercise Program three times per week for six weeks under a physiotherapist's supervision.The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability.Each session will include a warm-up, main core exercises, and a cool-down.In weeks 0-2, the program will include diaphragmatic breathing, transversus abdominis activation, curl-ups, and bridging. In weeks 2-4, it will progress to cross arm-leg extensions, side planks, the hundred exercise, and single-leg bridging. In weeks 4-6, Swiss ball exercises will be introduced, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm.The program will advance in intensity across three phases."
219668230|NCT07026747|BEHAVIORAL|Unsupervised Core Stabilization + Standard Hand Rehabilitation|"he third group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days/week for 3 weeks, then 3 days/week for 3 weeks). They will also do an Unsupervised Core Stabilization Exercise Program three times a week for six weeks in the same clinic. Exercises will be the same as the supervised group but done alone using videos without a physiotherapist. The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability. Each session includes warm-up, main exercises, and cool-down. In weeks 0-2, exercises include diaphragmatic breathing, transversus activation, curl-ups, and bridging. Weeks 2-4 add cross arm-leg extensions, side planks, the hundred, and single-leg bridging.Weeks 4-6 introduce Swiss ball exercises, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm lifts. The program will advance in intensity across three phases."
219668231|NCT07027683|DIAGNOSTIC_TEST|Cardiac MRI|Post-MI cardiac MRI
219668232|NCT02901301|DRUG|Pembrolizumab|200mg, IV, q3weeks, Day 1
219668233|NCT02901301|DRUG|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
219668234|NCT02901301|DRUG|Capecitabine|1000mg/m2, PO, BID, Day 1-14
219668235|NCT02901301|DRUG|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
219668236|NCT06885580|BEHAVIORAL|Education|Students will be provided with digital privacy literacy training designed using the puzzle method, which will consist of 8 sessions over a 12-week period.
219668237|NCT06728722|DIAGNOSTIC_TEST|ultrasound detection of body composition|"Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length."
219668238|NCT03904368|PROCEDURE|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
219668239|NCT03904368|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
219668240|NCT03904368|DRUG|Human chorionic gonadotropin|HCG triggering of ovulation
219668241|NCT03904368|PROCEDURE|Ovum pick up|34 to 36 hours after HCG triggering
219668242|NCT03904368|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
219668243|NCT06417307|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
219668244|NCT06417307|BEHAVIORAL|Control group|Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
219668245|NCT06879145|DRUG|SHR-A2102；Adebrelimab|Treatment with SHR-A2102 in combination with fixed dose Adebrelimab
219668246|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
219668247|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
219668248|NCT06369519|PROCEDURE|Surgery treatment or local tumor destruction.|Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
219668249|NCT02973334|OTHER|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
219668250|NCT02973334|OTHER|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
219668251|NCT02973334|OTHER|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
219668252|NCT00594386|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
218977601|NCT06058026|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
218977602|NCT05553314|DRUG|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
218977603|NCT05553314|DRUG|Placebo|patients randomized to placebo group will receive placebo.
218977604|NCT04610385|PROCEDURE|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
218977605|NCT04137627|DRUG|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
218977606|NCT04137627|DRUG|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
218977607|NCT04786392|DIETARY_SUPPLEMENT|Lutein supplement|5 mg lutein supplement.
219668253|NCT04192058|DEVICE|Sham transcranial direct current stimulation (tDCS)|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
218977608|NCT04786392|OTHER|Food, blended|5 mg lutein from baby spinach, blended.
218977609|NCT04786392|OTHER|Food, unprocessed|5 mg lutein from baby spinach, in whole food form.
218977610|NCT03248336|PROCEDURE|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
218977611|NCT04945512|PROCEDURE|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
218977612|NCT03436004|DEVICE|Colonoscopy|Patients undergoing screening colonoscopy
218977613|NCT03436004|DEVICE|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
218977614|NCT05489757|DEVICE|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
218977615|NCT00986830|DEVICE|FinESS Sinus Treatment|
218977616|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
218977617|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
218977618|NCT01457820|DRUG|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
218977619|NCT02702804|OTHER|High Intensity Interval Training|High Intensity Interval Training
218977620|NCT04354142|DEVICE|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
219067919|NCT00752375|DRUG|placebo|"* Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
219067920|NCT06349161|PROCEDURE|One-trocar-assisted pyeloplasty|Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
219067921|NCT04757649|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
219067922|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
219067923|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
219067924|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
219067925|NCT06114420|PROCEDURE|salvage surgery|Some patients who cannot undergo surgery
219668254|NCT04192058|DEVICE|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
219668255|NCT03679286|DEVICE|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
218977621|NCT01784757|DRUG|ODM-201 Tablet A|Tablet A formulation of ODM-201
218977622|NCT01784757|DRUG|ODM-201 Tablet B|Tablet B formulation of ODM-201
218977623|NCT01784757|DRUG|ODM-201 capsule formulation|Capsule formulation of ODM-201
218977624|NCT04317404|DRUG|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
218977625|NCT01592682|BEHAVIORAL|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
218977626|NCT00332878|BEHAVIORAL|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
218977627|NCT00332878|BEHAVIORAL|stepping Stones short|3 hour intervention on HIV and safer sex
219668256|NCT04040634|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
219668257|NCT04040634|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
219668258|NCT02098616|DRUG|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
218977628|NCT01923831|DRUG|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
218977629|NCT01923831|DRUG|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
218977630|NCT04746196|OTHER|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
218977631|NCT00946361|OTHER|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
218977632|NCT06506682|BEHAVIORAL|Constraint Induced Movement Therapy|CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
219067926|NCT01286779|BIOLOGICAL|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
219067927|NCT05498259|DRUG|Orelabrutinib|Orelabrutinib 150mg qd PO
219067928|NCT05498259|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
219067929|NCT05498259|DRUG|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
219067930|NCT00344682|DRUG|memantine|memantine 5mg - 20mg PO daily
219067931|NCT00344682|DRUG|Placebo|5mg - 20mg PO daily over 8 weeks
219067932|NCT02896855|DRUG|Docetaxel|Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
219668259|NCT02098616|DRUG|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
219668260|NCT05068492|DIAGNOSTIC_TEST|CT|enhanced CT with standard procedure
219668261|NCT05068492|DIAGNOSTIC_TEST|MRI|enhanced MRI with standard procedure
219668262|NCT05068492|DIAGNOSTIC_TEST|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
219668263|NCT05068492|DIAGNOSTIC_TEST|Ultrasound|Digestive ultrasound with standard procedure
219668264|NCT00924391|DIETARY_SUPPLEMENT|phytosterol enhanced soy based beverage|
219668265|NCT00924391|DIETARY_SUPPLEMENT|1% milk|
219668266|NCT04747444|OTHER|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
219668267|NCT03260426|DIETARY_SUPPLEMENT|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
219668268|NCT03260426|DIETARY_SUPPLEMENT|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
219668269|NCT03260426|DEVICE|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
218977633|NCT06506682|BEHAVIORAL|CIMT + VR|Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
218977634|NCT03584061|PROCEDURE|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
219067933|NCT02896855|DRUG|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
219067934|NCT02896855|DRUG|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
219067935|NCT02896855|DRUG|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
219067936|NCT02332070|PROCEDURE|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
219067937|NCT02508311|DRUG|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
219067938|NCT02508311|DRUG|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
219067939|NCT04106999|DRUG|Dexmedetomidine|Drug infusion will be delivered intra-operatively
219067940|NCT04106999|DRUG|Placebos|Normal Saline will be infused as a control drug
219067941|NCT03601832|PROCEDURE|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
219668270|NCT03736330|BIOLOGICAL|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck \& Co., Inc.） and were transferred to participants via intravenous infusion .
219668271|NCT04687748|DEVICE|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
219668272|NCT04687748|OTHER|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
219668273|NCT06454422|OTHER|wu qinxi|"Wuqinxi, also known as the Hundred-step Sweating Exercise, is one of the most emblematic Health qigong exercises. Huatuo, guided by the principle, formulated the 'Wuqinxi':  Running water is never stale and a door-hinge is never gets worm-eaten, and sums up the experiences of the fitness activities of Huatuo's predecessors that imitate the movements of tigers, deer, bears, apes, birds, and other animals, and are associated with human organs, meridians, and 'qi'"
219668274|NCT05159102|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
219668275|NCT05159102|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
219668276|NCT00094536|DEVICE|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
219668277|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
219668278|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
219668279|NCT00684632|DRUG|Placebo|Placebo
219668280|NCT00684632|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
219668281|NCT05501327|DRUG|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
219668282|NCT01855282|BEHAVIORAL|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
219668283|NCT06205173|OTHER|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
219668284|NCT06205173|OTHER|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
219668285|NCT03969264|OTHER|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
219668286|NCT04585620|DRUG|Onabotulinum Toxin A|Series of subcutaneous injections
219668287|NCT04585620|DRUG|Normal saline|Series of subcutaneous injections
219668288|NCT06910722|PROCEDURE|Liver transplant|follow-up of liver transplant patients after selective internal radiotherapy (SIRT) with Yttrium-90 and chemotherapy
219668289|NCT06233877|DRUG|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
219668290|NCT06002776|OTHER|a retrospective study|a retrospective study
219668291|NCT03943927|OTHER|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
219668292|NCT04064580|OTHER|diagnostic test|performing a capnography examination
219067942|NCT00646802|DRUG|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
219067943|NCT00646802|DRUG|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
219067944|NCT01792089|OTHER|fat+protein meal|cream+ whey protein
219067945|NCT01792089|OTHER|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
219067946|NCT01792089|OTHER|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
219067947|NCT01792089|OTHER|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
219067948|NCT01792089|OTHER|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
219067949|NCT02169674|BIOLOGICAL|EngerixB, GlaxoSmithKline Vaccines|
219067950|NCT03769623|DEVICE|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
219067951|NCT03769623|DEVICE|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
219668293|NCT06517173|DRUG|Y-3 for injection|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
219668294|NCT06517173|DRUG|Placebo control group|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
219668295|NCT04849533|DRUG|Belatacept|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
219668296|NCT04849533|DRUG|Everolimus|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
219668297|NCT04849533|DRUG|mycophenolate mofetil|belatacept with mycophenolate is approved regimen for prevention of rejection
219668298|NCT04849533|DRUG|corticosteroids|belatacept with chronic steroids is approved regimen for prevention of rejection
219668299|NCT04849533|DRUG|rabbit antithymocyte globulin|rabbit antithymocyte globulin induction for prevention of rejection
219668300|NCT05342428|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
219668301|NCT03213197|OTHER|CPR video|Patient watches a short CPR video
219668302|NCT04159324|OTHER|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
219668303|NCT01832909|OTHER|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
219668304|NCT01832909|OTHER|Control Diet|Controlled diet without walnuts.
219668305|NCT06910280|PROCEDURE|conservative surgery for breast cancer with local anesthesia|conservative surgery for breast cancer with local anesthesia
219668306|NCT06910280|PROCEDURE|conservative surgery for breast cancer with general anesthesia|conservative surgery for breast cancer with general anesthesia
219668307|NCT01905592|DRUG|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
218977635|NCT02053870|OTHER|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
218977636|NCT02053870|DRUG|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
218977637|NCT02760797|DRUG|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
218977638|NCT02760797|DRUG|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
218977639|NCT05085730|DEVICE|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
218977640|NCT03585842|OTHER|No intervention|No intervention
218977641|NCT04712383|COMBINATION_PRODUCT|Fitbit Care intervention arm|Entire suite of Fitbit Care.
218977642|NCT05487352|OTHER|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
218977643|NCT00963222|DRUG|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
218977644|NCT00963222|DRUG|placebo|1 cap placebo/day for 3 month
218977645|NCT06248060|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
218977646|NCT06248060|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
218977647|NCT02583282|OTHER|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
218977648|NCT02583282|OTHER|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
219668308|NCT01905592|DRUG|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
219668309|NCT02946489|DRUG|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
219668310|NCT01356329|DRUG|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
219668311|NCT02360748|DIETARY_SUPPLEMENT|Plant based high protein food items|Patients will add high protein plant based food items to their diet
219668312|NCT01358240|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
219668313|NCT01358240|DRUG|Vehicle Foam|Vehicle Foam applied once a day for 4 week
219668314|NCT01358240|DRUG|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
219668315|NCT01358240|OTHER|Placebo Cream|Placebo cream applied once a day for 4 weeks
219668316|NCT04137341|DRUG|GLPG1972 - A|Film-coated tablet, formulation A
219668317|NCT04137341|DRUG|GLPG1972 - B|Film-coated tablet, formulation B
219668318|NCT04137341|DRUG|GLPG1972 - C|Film-coated tablet, formulation C
219668319|NCT03996564|DEVICE|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
219668320|NCT03996564|DRUG|Acetaminophen|Acetaminophen 500mg-1000mg,
219668321|NCT03996564|DRUG|Diclofenac|Diclofenac 50mg-75 mg orally
219668322|NCT03996564|DRUG|Diazepam|Diazepam 5mg-10 mg intravenous or oral
219668323|NCT03996564|DRUG|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
219668324|NCT03996564|DRUG|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
219668325|NCT05050500|DRUG|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
219668326|NCT05050500|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
219668327|NCT00105287|DRUG|OraVescent fentanyl (OVF)|
219668328|NCT02919007|DEVICE|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
219668329|NCT01158014|PROCEDURE|Fibrin Glue, Quixil|quixil 0.1 ml
218977649|NCT01549600|DIETARY_SUPPLEMENT|psyllium|1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
218977650|NCT01549600|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
218977651|NCT01039870|PROCEDURE|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
218977652|NCT01039870|PROCEDURE|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
218977653|NCT01976676|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate|
218977654|NCT01976676|DIETARY_SUPPLEMENT|folic Acid|
218977655|NCT03507803|OTHER|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
218977656|NCT06557096|DRUG|Osimertinib 80 MG|Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.
218977657|NCT06557096|DRUG|Bevacizumab|Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
218977658|NCT01419522|OTHER|Gait Training Method|Treadmill training at constant velocity
218977659|NCT02038881|BIOLOGICAL|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
219668330|NCT01158014|PROCEDURE|Suture|vicryl 10/0
219668331|NCT00724802|DIETARY_SUPPLEMENT|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
219668332|NCT00724802|DRUG|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
219668333|NCT00884845|DRUG|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
219668334|NCT00884845|DRUG|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
218977660|NCT00699764|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
218977661|NCT00699764|BIOLOGICAL|Placebo injection|Intramuscular injection, 3 doses
218977662|NCT04664192|OTHER|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
219668335|NCT04622761|DRUG|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)"
219668336|NCT04564105|BEHAVIORAL|simulation education|Intubation protocol will be trained by simulation exercise.
219668337|NCT00028522|DRUG|R(+)XK469|Given IV
219668338|NCT06938477|OTHER|THERA-TRAINER BASED EXERCISES|The interventions will carried out two days a week and 40 minutes for eight weeks
219668339|NCT06938477|OTHER|FUNCTIONAL STROKE TRAİNİNG|he interventions will carried out two days a week and 40 minutes for eight weeks
219668340|NCT02135705|DRUG|Lomitapide|As prescribed by Physician.
219668341|NCT06954246|DRUG|MHB088C for Injection|2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle
219668342|NCT06954246|DRUG|Topotecan|1.25 mg/m\^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle
219668343|NCT06954246|DRUG|Irinotecan|65 mg/m\^2 intravenous dose on Day 1 and Day 8 of each 21-day cycle
219668344|NCT06954246|DRUG|Paclitaxel|135 mg/m\^2 intravenous dose on Day 1 of each 21-day cycle
219668345|NCT03850691|DRUG|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
219668346|NCT03850691|DRUG|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
219668347|NCT03850691|DRUG|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
218977663|NCT04928443|OTHER|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
218977664|NCT04928443|OTHER|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
218977665|NCT00333840|DRUG|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
218977666|NCT00333840|DRUG|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
218977667|NCT00333840|DRUG|cytarabine (ARA-C)|cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
218977668|NCT03969732|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
218977669|NCT03870100|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
218977670|NCT03870100|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
218977671|NCT05604677|PROCEDURE|Breast Surgery|Breast-conserving Surgery or modified radical mastectomy
218977672|NCT02211625|DRUG|Open-label TRV734 125 mg|125 mg
218977673|NCT02211625|DRUG|TRV734 blinded|blinded, multiple ascending dose
218977674|NCT02211625|DRUG|Oxycodone IR 10 mg|
218977675|NCT02211625|DRUG|Placebo|TRV734-matched and oxycodone placebo
218977676|NCT01975714|DRUG|Preservative-free latanoprost|
218977677|NCT01975714|DRUG|Preservative-free bimatoprost|
218977678|NCT00014482|PROCEDURE|pain therapy|
218977679|NCT00014482|PROCEDURE|psychosocial assessment and care|
218977680|NCT01453725|BIOLOGICAL|Golimumab|Golimumab 50 mg SC injection every 4 weeks
219067952|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
219067953|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
219067954|NCT03135951|DRUG|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
219067955|NCT00955084|DRUG|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
219668348|NCT03850691|DRUG|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
218977681|NCT01453725|BIOLOGICAL|Placebo|Placebo SC injection every 4 weeks
219067956|NCT02585895|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once every 2 weeks
219668349|NCT04121767|DRUG|Edoxaban|oral edoxaban 60mg once daily for 3 months
218977682|NCT05979506|PROCEDURE|Cutaneous wraps|"The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel"
218977683|NCT05332730|DRUG|BAT2506 injection|50 mg, subcutaneous administration
218977684|NCT05332730|DRUG|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
218977685|NCT05332730|DRUG|Simponi® (US commercially available product)|50 mg, subcutaneous administration
218977686|NCT05285072|RADIATION|PET-CT scan|PET-CT scan using 68Ga-DFO
218977687|NCT01955564|DRUG|NW-3509a|single dose
218977688|NCT00763711|DEVICE|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
218977689|NCT05914012|OTHER|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
218977690|NCT06277557|OTHER|Virtual Reality|Virtual reality learning platform as intervention in this study
218977691|NCT02736760|DRUG|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
219668350|NCT04121767|DRUG|Warfarin|oral warfarin once daily for 3 months according to prothrombin time
219668351|NCT00038805|DRUG|Mylotarg|
219668352|NCT00347230|DEVICE|Intacs intracorneal ring insertion for the treatment of keratoconus|
219668353|NCT05331105|DRUG|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
219668354|NCT05488951|OTHER|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
219668355|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
219668356|NCT05400486|OTHER|Therapeutic exercise|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
218977692|NCT02736760|PROCEDURE|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
218977693|NCT03719586|DRUG|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
218977694|NCT03719586|DRUG|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
219067957|NCT02585895|PROCEDURE|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
219668357|NCT05400486|OTHER|Therapeutic exercise group + high frequency TENS|TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce the impedance at the interface electrode skin. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, and a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012).
219668358|NCT05400486|OTHER|Therapeutic exercise group + Interferential|In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
219668359|NCT04136262|DRUG|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
219668360|NCT04136262|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
219668361|NCT04136262|OTHER|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
219668362|NCT04122209|OTHER|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
219668363|NCT04122209|OTHER|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
219668364|NCT00088309|PROCEDURE|Eye exam|
219668365|NCT00088309|PROCEDURE|Oral exam|
219668366|NCT00088309|PROCEDURE|CT scan|
219668367|NCT00088309|PROCEDURE|Neuropsychological testing|
219668368|NCT00088309|PROCEDURE|Electrocardiogram|
218977695|NCT03719586|DRUG|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
218977696|NCT03719586|DRUG|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
218977697|NCT03656770|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
218977698|NCT06246175|DRUG|HRS9531|Receive a single dose of HRS9531 injection
218977699|NCT00303901|PROCEDURE|cryosurgery|
219668369|NCT00088309|PROCEDURE|Echocardiogram|
219668370|NCT05363956|DRUG|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
219668371|NCT05363956|DRUG|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
219668372|NCT04494425|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
219668373|NCT04494425|DRUG|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
219668374|NCT04494425|DRUG|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
219668375|NCT04494425|DRUG|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
219668376|NCT00034047|PROCEDURE|Acupuncture|
219668377|NCT00034047|DRUG|Chinese Products|
219668378|NCT00034047|DRUG|Nafarelin|
219668379|NCT02822833|PROCEDURE|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
219668380|NCT01342783|GENETIC|DNA analysis|
219668381|NCT01342783|GENETIC|RNA analysis|
219668382|NCT01342783|GENETIC|mutation analysis|
219668383|NCT01342783|GENETIC|nucleic acid sequencing|
219668384|NCT01342783|OTHER|laboratory biomarker analysis|
219668385|NCT03840408|OTHER|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
219668386|NCT03840408|PROCEDURE|Surgery|Patients will be treated with surgery
218977700|NCT00303901|PROCEDURE|positron emission tomography|
218977701|NCT00189995|DRUG|clozapine|
219668387|NCT02209818|RADIATION|Laser Irradiation One dose|
218977702|NCT00189995|DRUG|haloperidol|
218977703|NCT05194657|DEVICE|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
218977704|NCT05194657|DEVICE|monofocal IOL|Acrysof IQ, monofocal IOL
219668388|NCT02209818|RADIATION|Laser Irradiation Two doses|
219668389|NCT03454386|BEHAVIORAL|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
219668390|NCT03454386|BEHAVIORAL|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
219668391|NCT03151083|BEHAVIORAL|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
219668392|NCT02116725|OTHER|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
219668393|NCT02116725|OTHER|Plain shower gel|Standard shower gel (Sanex).
219668394|NCT02116725|OTHER|Distilled water|Sterile distilled Water.
219668395|NCT05176613|DEVICE|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
218977705|NCT02298608|DEVICE|Nano Knife|Percutaneous, CT guided, ablation of renal mass
218977706|NCT01332331|DRUG|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
218977707|NCT01332331|DRUG|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
218977708|NCT06192277|OTHER|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
218977709|NCT06192277|DRUG|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
218977710|NCT06192277|DRUG|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
218977711|NCT06192277|OTHER|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
219668396|NCT05176613|BEHAVIORAL|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
219668397|NCT05176613|DEVICE|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
219668398|NCT04854941|OTHER|Probiotics|Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
219668399|NCT00063297|DRUG|R209130|
219668400|NCT04100655|DRUG|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
219668401|NCT04100655|DRUG|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
219668402|NCT04473534|BEHAVIORAL|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
219668403|NCT02330224|OTHER|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses"
218977712|NCT00178633|PROCEDURE|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
218977713|NCT01457469|OTHER|questionnaire administration|Ancillary studies
218977714|NCT01457469|PROCEDURE|quality-of-life assessment|Ancillary studies
218977715|NCT01457469|OTHER|counseling intervention|Undergo counseling session
218977716|NCT01457469|OTHER|internet-based intervention|Receive enhanced quitline intervention
218977717|NCT01457469|BEHAVIORAL|telephone-based intervention|Receive enhanced quitline intervention
218977718|NCT01457469|OTHER|educational intervention|Receive usual care plus
218977719|NCT01457469|DRUG|nicotine replacement therapy|Receive nicotine replacement patches
218977720|NCT01457469|OTHER|educational intervention|Receive enhanced quitline intervention
218977721|NCT00257374|DRUG|Gatorade, Pedialyte and New Solution|
219668404|NCT01190189|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
219668405|NCT00708474|DEVICE|OsseoFit™ Porous Tissue Matrix™|Bone void filler
219668406|NCT03166839|OTHER|Experiencing PPH|No intervention given
218977722|NCT00144196|DRUG|tiotropium (Spiriva)|
218977723|NCT04680130|DRUG|C-11 PiB|Completing PET scan looking for amyloid protein
218977724|NCT04680130|DRUG|AV1451 Tau|Completing PET scan looking for tau protein
218977725|NCT04680130|DRUG|C-11 ER176|Completing PET scan looking for neuroinflammation
218977726|NCT04299074|OTHER|addiction|questionnaire
218977727|NCT04482881|DRUG|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
218977728|NCT04482881|DRUG|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
218977729|NCT04482881|DRUG|Misoprostol|Giving women misoprostol
218977730|NCT05929053|OTHER|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
218977731|NCT00924079|DRUG|nalbuphine|oral dosage form, 66 mg, single dose
218977732|NCT02575742|DEVICE|3D-Transit system|
218977733|NCT01934244|DEVICE|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
218977734|NCT05962671|DRUG|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
219668407|NCT04064515|DIAGNOSTIC_TEST|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
219668408|NCT04626700|DEVICE|iNAP|iNAP for the treatment of OSA
219668409|NCT04626700|DEVICE|CPAP|CPAP for the treatment of OSA
219668410|NCT00433017|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
219668411|NCT00433017|DRUG|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
219668412|NCT00433017|DRUG|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
219668413|NCT02222116|DEVICE|MGuard Prime|
219668414|NCT02222116|DEVICE|Control BMS DES|
219668415|NCT03180931|DEVICE|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
218977735|NCT05962671|DRUG|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
218977736|NCT00857883|DRUG|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
218977737|NCT00369707|DRUG|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
218977738|NCT00369707|DRUG|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
218977739|NCT04719637|DEVICE|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
218977740|NCT06247423|DEVICE|Active group 10kHz|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group."
219067958|NCT01692704|DRUG|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
219067959|NCT02738177|DRUG|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
219067960|NCT02738177|DRUG|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
219668416|NCT01277432|OTHER|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)"
219668417|NCT01277432|OTHER|Depression screening - control|"All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life"
219668418|NCT04379765|BEHAVIORAL|Exercise and physical therapy|Decompression operation
219668419|NCT01383252|PROCEDURE|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
219668420|NCT01383252|PROCEDURE|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
219668421|NCT03815435|PROCEDURE|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field.
219668422|NCT04163926|PROCEDURE|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
219668423|NCT04163926|PROCEDURE|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
219668424|NCT01888653|BEHAVIORAL|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
219668425|NCT01888653|BEHAVIORAL|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
219668426|NCT00002255|DRUG|Filgrastim|
219668427|NCT00002255|DRUG|Epoetin alfa|
219067961|NCT02738177|DRUG|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
219067962|NCT01373086|DRUG|LFF269|
219668428|NCT00002255|DRUG|Zidovudine|
219668429|NCT05000736|DRUG|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
219668430|NCT05000736|DRUG|fulvestrant|fulvestrant monotherapy
219668431|NCT06435078|DEVICE|mPETS(modified-PETS system)|The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
219668432|NCT02874716|OTHER|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
219668433|NCT05869396|DIAGNOSTIC_TEST|echocardiography|Bedside echocardiography
219668434|NCT04056312|BEHAVIORAL|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
219668435|NCT04056312|BEHAVIORAL|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
219668436|NCT00084877|DRUG|triapine|Given IV
219668437|NCT00084877|DRUG|irinotecan hydrochloride|Given IV
219668438|NCT00084877|OTHER|laboratory biomarker analysis|Correlative studies
219668439|NCT00084877|OTHER|pharmacological study|Correlative studies
219668440|NCT06543082|DRUG|Colchicine 0.6 mg|Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
219668441|NCT03959488|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
219668442|NCT03959488|DRUG|Palivizumab|Approved anti-RSV monoclonal antibody
219668443|NCT01026818|DRUG|Tadalafil|Administered by mouth for 9 months
219668444|NCT01026818|DRUG|Placebo|Administered by mouth, daily or on demand for 9 months
219668445|NCT02502695|OTHER|VATS-associated best practices|
219668446|NCT05695118|DIAGNOSTIC_TEST|Non-contrast low-dose abdomen CT|target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
219067963|NCT01373086|DRUG|Eplerenone|
219067964|NCT01373086|DRUG|Placebo|
219067965|NCT01281930|PROCEDURE|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
219067966|NCT01281930|PROCEDURE|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
219067967|NCT00142480|DRUG|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
219067968|NCT00142480|DRUG|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
219067969|NCT00142480|DRUG|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
219668447|NCT05695118|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
219668448|NCT05695118|DIAGNOSTIC_TEST|bioelectrical impedance analysis (BIA)|BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
219668449|NCT02975531|OTHER|Simulator's construction|Model to build the mold for the simulator
219668450|NCT02975531|OTHER|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
219668451|NCT02975531|OTHER|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
219668452|NCT02975531|OTHER|Simulator training|Training of pompage technique using the simulator.
219668453|NCT02975531|OTHER|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
219668454|NCT02963129|DRUG|Mupirocin|Mupirocin ointment in the nose for 5 days
219668455|NCT02963129|OTHER|Placebo|Placebo ointment in the nose for 5 days
219668456|NCT01760447|DRUG|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
219668457|NCT01760447|DRUG|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
219668458|NCT01760447|DRUG|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
219668459|NCT01760447|DRUG|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
219668460|NCT01760447|DRUG|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
218977741|NCT06247423|DEVICE|Sham intervention|"Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
218977742|NCT04335838|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
218977743|NCT06161610|DEVICE|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
218977744|NCT06161610|OTHER|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
218977745|NCT03594435|DRUG|Ibudilast|targets neurotrophin signaling and neuroimmune function
218977746|NCT03594435|DRUG|Placebo oral capsule|matched to active drug, ibudilast
218977747|NCT05659992|DRUG|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
218977748|NCT06051214|BIOLOGICAL|thrombogram|blood sampling every month for 12 months
218977749|NCT03436654|DRUG|Apalutamide|240mg daily orally
218977750|NCT03436654|DRUG|Abiraterone Acetate|1000mg daily orally
218977751|NCT03436654|DRUG|Prednisone|5mg BID orally
218977752|NCT03436654|PROCEDURE|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
218977753|NCT03436654|PROCEDURE|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
218977754|NCT03436654|DRUG|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
218977755|NCT03436654|RADIATION|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
218977756|NCT00597974|PROCEDURE|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
218977757|NCT00597974|DEVICE|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
218977758|NCT00597974|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
218977759|NCT00597974|PROCEDURE|Angiography|(non-experimental) Coronary angiography
218977760|NCT01563744|PROCEDURE|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
218977761|NCT01563744|PROCEDURE|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
218977762|NCT00002311|DRUG|Wobenzym|
218977763|NCT03361254|BIOLOGICAL|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
219067970|NCT00142480|PROCEDURE|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
218977764|NCT03605212|DRUG|Febuxostat|Intervention is orally administered to patients in this arm.
218977765|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
218977766|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
219668461|NCT01760447|DRUG|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
219668462|NCT01760447|DRUG|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
219668463|NCT01760447|DRUG|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
219668464|NCT01760447|DRUG|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
219668465|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts supplemented with L. Rhamnosus GG|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
219668466|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
219668467|NCT02875873|DRUG|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
219668468|NCT02875873|DRUG|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
219668469|NCT02875873|OTHER|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
219668470|NCT02875873|OTHER|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
219668471|NCT00311870|DRUG|nisoldipine|
219668472|NCT00311870|DRUG|lisinopril|
219668473|NCT00176514|DRUG|Administration of the antineoplastic|
219668474|NCT05393687|OTHER|Eccentric exercise|progressive eccentric exercise with elastic band
219668475|NCT00571116|DRUG|Disulfiram|Given PO
219668476|NCT00571116|DRUG|Arsenic trioxide|Given IV
219668477|NCT00441038|BEHAVIORAL|The Back Guide|Education on postural hygiene and handout of The Back Guide
219668478|NCT00441038|BEHAVIORAL|The Back Book|Education on active management and Handout of The Back Book
219668479|NCT00441038|BEHAVIORAL|Cardiovascular and general health|Education on cardiovascular and general health
219668480|NCT03996122|OTHER|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
219668481|NCT00068029|DRUG|Pegvisomant/ Sandostatin LAR|
219668482|NCT00068029|DRUG|Sandostatin LAR|
219668483|NCT00068029|DRUG|Pegvisomant|
219668484|NCT02004314|DRUG|Chloroquine|
219668485|NCT05768997|DRUG|Ferric Derisomaltose Injection|Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
219668486|NCT05768997|DRUG|Darbepoetin Alfa Injection|Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
219668487|NCT03488563|BIOLOGICAL|B244|B244 Suspension
219668488|NCT03488563|BIOLOGICAL|Vehicle|Vehicle Suspension
219668489|NCT02462109|DRUG|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.
218977767|NCT03971123|DRUG|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
219668490|NCT02588729|OTHER|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
219067971|NCT05343702|DRUG|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
219067972|NCT05014594|DRUG|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
219067973|NCT05014594|DRUG|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
219668491|NCT04108741|DEVICE|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
219668492|NCT06329986|DEVICE|TAMER Lens Spectacle|Regular daily wear of TAMER lens spectacle
219668493|NCT06329986|DEVICE|SV lenses|SV lenses
219668494|NCT02815267|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
219668495|NCT02815267|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
219668496|NCT04330222|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
219668497|NCT04330222|OTHER|Brief Memory and Executive Test|Cognitive Assessment
219668498|NCT03221179|BIOLOGICAL|RO7049665|A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.
219668499|NCT03221179|BIOLOGICAL|Placebo|Matching placebo will be administered SC once.
218977768|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
218977769|NCT06449898|OTHER|hemodialysis group|Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.
219668500|NCT06025201|BEHAVIORAL|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
219668501|NCT06025201|BEHAVIORAL|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
219668502|NCT06025201|BEHAVIORAL|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
219668503|NCT01955577|DRUG|Placebo orally everyday|
219668504|NCT01955577|DRUG|Vitamin D3 cholecalciferol|
219067974|NCT05170373|PROCEDURE|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
219668505|NCT01681095|DRUG|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
219067975|NCT02509533|DEVICE|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
219067976|NCT02509533|DEVICE|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
219067977|NCT01930773|DEVICE|Genotyping|Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
219067978|NCT01930773|DEVICE|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
219067979|NCT00574080|DRUG|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
219668506|NCT01681095|DRUG|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
219668507|NCT03594955|DRUG|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
219668508|NCT04925778|DRUG|monomethyl fumarate|Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,
219668509|NCT00000888|DRUG|Ritonavir|
219668510|NCT00000888|DRUG|Lamivudine|
219668511|NCT00000888|DRUG|Zidovudine|
219668512|NCT03152487|OTHER|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
219668513|NCT03152487|OTHER|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
219668514|NCT01602679|DRUG|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
219668515|NCT01602679|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
219668516|NCT03271099|OTHER|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
219067980|NCT00574080|DRUG|Induction/Consolidation Dexamethasone|40 mg Days 1-4
219067981|NCT00574080|DRUG|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
219067982|NCT00574080|DRUG|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
219067983|NCT00574080|DRUG|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
219067984|NCT00574080|DRUG|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
219067985|NCT00574080|DRUG|Induction Pegfilgrastim|6 mg Days 6 and 13
219668517|NCT00504543|DRUG|AEB071|oral, twice daily
219668518|NCT00504543|DRUG|Certican|twice daily
219668519|NCT00504543|DRUG|Neoral|twice daily
219668520|NCT00270621|BEHAVIORAL|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
218977770|NCT01756053|DRUG|ABT-089|Selective neuronal nicotinic receptor agonist.
218977771|NCT01756053|DRUG|Placebo|Matched placebo capsules supplied by study drug supplier.
218977772|NCT04888078|PROCEDURE|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
218977773|NCT00900107|PROCEDURE|Exercise|
218977774|NCT03997604|DEVICE|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
218977775|NCT01254292|DRUG|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
219668521|NCT01010802|DRUG|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
219668522|NCT06844617|DEVICE|BathMat|Repositioning patients using the BathMat
219668523|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
219668524|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
219668525|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
219668526|NCT05786547|DRUG|Varenicline|Per package dosing, tablet taken orally
219668527|NCT05786547|BEHAVIORAL|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
219668528|NCT05786547|BEHAVIORAL|Standard Care|Brief cessation advice plus referral to local tobacco quitline
219668529|NCT00766623|DIETARY_SUPPLEMENT|high fat meal|milkshake containing 95g fat
219668530|NCT00766623|DIETARY_SUPPLEMENT|control meal|milkshake comparable with a normal breakfast
219668531|NCT06235606|DRUG|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
219668532|NCT06235606|DRUG|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
219668533|NCT06147752|BEHAVIORAL|"mobile internet healthcare and co-management of three disciplines"|"co-management of three disciplines:~Endocrinologist:~Assess disease status and rule out secondary obesity; Identify the causes of overweight/obesity and the status and extent of associated diseases; receive patients for return visits. Timely reply to patients' questions on the mobile medical platform, and timely adjust medication plans according to changes in patients' conditions.~Dietitians:~Conduct diet assessment, develop personalized medicine nutrition treatment plan and provide daily real-time guidance and follow up patients' daily diet outside the hospital.~Weight managers:~Establish weight loss record for patients, guide the installation and use of mobile medical Application , including weight monitoring, real-time uploading of daily diet and online interactive consultation; Follow up patients' weight changes; Assist patients in making appointments for follow-up visits."
219668534|NCT04278924|DRUG|Placebo|TAK-079 placebo-matching SC injection.
219668535|NCT04278924|DRUG|TAK-079|TAK-079 SC injection.
219668536|NCT06463301|OTHER|Treadmill Training In CP child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy."
219067986|NCT00574080|DRUG|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
219067987|NCT00574080|DRUG|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
219067988|NCT00574080|DRUG|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
219067989|NCT00574080|DRUG|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
219067990|NCT00574080|DRUG|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
219067991|NCT00574080|DRUG|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
219067992|NCT00574080|DRUG|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
219067993|NCT00574080|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
219067994|NCT00574080|DRUG|Transplant 2 Carmustine|300 mg/m2 Day -5
219668537|NCT06463301|OTHER|Conventional Physical Therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
219668538|NCT06056635|DEVICE|Karl Storz Curved Scope|The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
219668539|NCT06056635|DEVICE|Karl Storz Straight Scope|The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
219668540|NCT05600036|DRUG|ESK-001|Oral tablet
219668541|NCT05600036|DRUG|Placebo|Oral tablet
219668542|NCT04003272|DEVICE|Comprehensive Reverse Versa-Dial Titanium Glenosphere|Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
219067995|NCT00574080|DRUG|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
219067996|NCT00574080|DRUG|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
219067997|NCT00574080|DRUG|Transplant 2 Melphalan|140 mg/m2 Day -1
219067998|NCT00574080|DRUG|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
219067999|NCT00574080|DRUG|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
219068000|NCT00574080|DRUG|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
219068001|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
219068002|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
219068003|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
219068004|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
219068005|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
219068006|NCT06183801|DIETARY_SUPPLEMENT|Placebo 1|Subjects take capsule three times a day before meal.
219068007|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
219668543|NCT06377332|DIAGNOSTIC_TEST|High density electroencephalogram (HdEEG)|High-density electroencephalography (HdEEG) will be utilised in the investigation of sleep-mediated neuronal functions in controls, OSA, COPD and overlap syndrome and the association with accelerated brain ageing and cognitive impairment.
219068008|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
219068009|NCT06183801|DIETARY_SUPPLEMENT|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
219068010|NCT04071938|OTHER|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
219068011|NCT04071938|OTHER|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
219068012|NCT02529774|DRUG|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
219068013|NCT02529774|DRUG|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
219068014|NCT04258020|DEVICE|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
219068015|NCT04258020|DEVICE|HFNC|Heated High Flow Nasal Cannula oxygen administration
219068016|NCT01141192|DIETARY_SUPPLEMENT|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
219208646|NCT06891989|OTHER|Mindfulness meditation (MM) Intervention|"Participants will be asked to download the Mindfulness Coach app that provides simple instructions and brief meditation exercises.This is a a gradual training program of 14 levels which will be completed in the first 2-3 weeks. Each level provides short readings about mindfulness and one or two guided meditations (a silent seated practice for increasing lengths of time plus typically an additional 8-13-minute meditation). As participants progress through the levels, they earn badges displayed in the app, and an image of a tree on the home screen grows as each successive level is completed.For the remaining weeks of the intervention, participants will select at least one (and ideally two) guided meditation per day from the complete list of available meditations.Participants will track their progress through weekly logs."
219668544|NCT06377332|DIAGNOSTIC_TEST|Functional near infrared spectroscopy (fNIRS)|Functional near infrared spectroscopy (fNIRS) is one of the most advanced techniques in measuring brain oxygen content and hemodynamic activity. This information indirectly displays neuronal activity and provides a novel opportunity understand brain oxygenation, neurodegenerative diseases, and cognitive function.
219668545|NCT06377332|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be utilised to assess potential structural neuronal changes associated with neurodegenerative disease in those with COPD, OSA and overlap syndrome. MRI has the capacity to provide vital information regarding neuroimaging standards in cerebral vascular damage such as white matter hyperintensities (WMH), lacunes, cerebral microbleeds, brain atrophy and subcortical infarct. Through the utility of MRI sequences such as T1 and T2 weighted imaging, diffusion weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) and resting-state fMRI (rs-fMRI), the investigators will assess neurodegenerative-related structural brain changes in individuals with COPD, OSA and overlap syndrome and examine the differences between these target groups.
219068017|NCT01141192|DIETARY_SUPPLEMENT|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
219068018|NCT01846338|DIETARY_SUPPLEMENT|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
219068019|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 60 mg dextrose
219068020|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 80 mg dextrose
219068021|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 100 mg dextrose
219068022|NCT05921877|DIAGNOSTIC_TEST|venous sampling|venous sampling
219068023|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
219068024|NCT00745017|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
219668546|NCT06377332|BIOLOGICAL|Blood collection|"A fasting 50mL blood sample will be collected at the experimental visit in the morning following the overnight sleep study. Blood samples will be processed after collection and stored at -80 degrees for future batch analyses. Analyses will include markers for inflammation and dementia including but not limited to ptau217 and beta amyloid. Routine blood analyses will be conducted on 17.5mL of the sample collected for baseline measures. Routine blood analyses includes lipid profile, glucose studies, insulin, high-sensitivity C-reactive protein (hs-CRP), iron studies, thyroid function, b12/folate, homocysteine, prolactin, calcium, full blood count and biochemistry panel for the OSA, COPD and overlap syndrome groups.~Routine blood analyses for controls include glucose studies, lipid profile, hs-CRP and biochemistry panel."
219668547|NCT06377332|DIAGNOSTIC_TEST|Neuropsychological battery|"A. Montreal Cognitive Assessment (MoCA):~B. Test of Premorbid Functioning (TOPF):~C. Rey Auditory Verbal Learning Test (RAVLT):~D. D-KEFS Colour Word Interference Test (D-CWIT):~E. Trail Making Test (TMT):~F. Symbol Digit Modalities Test (SDMT) - Oral Version:~G. RAVLT 20-minute recall~H. Controlled Oral Word Association Test (COWAT):"
219668548|NCT06377332|OTHER|Questionnaires|"1. Epworth Sleepiness Scale (ESS)~2. PROMIS sleep questionnaire 8a,~3. PROMIS sleep questionnaire 8b~4. EQ-5D-5L~5. Insomnia Severity Index (ISI)~6. Pittsburgh Sleep Quality Index (PSQ-I)~7. St George's Respiratory Questionnaire (SGRQ)~8. COPD Assessment Test (CAT)"
219068025|NCT00745017|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
219668549|NCT06377332|DIAGNOSTIC_TEST|Pulmonary Function Test (PFT)|Full pulmonary function testing will be conducted in control, COPD, OSA and overlap syndrome groups. Full lung function testing will include spirometry with pre and post bronchodilator, oscillometry, lung diffusion testing (DLCO) and lung volumes.
219668550|NCT06377332|OTHER|Cognitive Assessment|"The following cognitive assessments will be administered using a digital format on CANTAB:~1. Motor Screening Task (MOT) Used to assess sensorimotor function and comprehension and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease. This task acts as a practice trial for the subsequent tasks.~2. Reaction Time (RTI) Used to assess processing and psychomotor speed and is applicable in the assessment of general cognitive function and Alzheimer's disease.~3. Paired Associate Learning (PAL) Used to assess visual episodic memory and is applicable in the assessment of general cognitive function, Alzheimer's disease, Parkinson's disease and cerebrovascular disease.~4. Spatial Working Memory (SWM) Used to assess working memory and strategy and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease."
219668551|NCT06377332|DIAGNOSTIC_TEST|Polysomnogram (PSG)|During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.
219668552|NCT00671047|OTHER|non-interventional|SLE nature history observational
219668553|NCT04640155|BEHAVIORAL|Low FODMAP Diet|Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
219668554|NCT04640155|BEHAVIORAL|Regular Diet|Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
219668555|NCT05068011|DEVICE|Spinal Cord Stimulation|differential target multiplexed stimulation
219668556|NCT03534999|DEVICE|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
219068026|NCT00745017|DRUG|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
219068027|NCT05745857|DRUG|Avastin|Orally administered
219068028|NCT05745857|DRUG|Erbitux|Orally administered
219068029|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
219068030|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
219068031|NCT05135910|DRUG|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
219068032|NCT01387568|DRUG|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
219068033|NCT01387568|DRUG|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
219068034|NCT04833023|DRUG|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
219668557|NCT03534999|OTHER|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
219668558|NCT00498810|PROCEDURE|complete repair|
219668559|NCT00498810|PROCEDURE|partial repair of the abdominal wall|
219668560|NCT01006590|DRUG|Saxagliptin|5 mg, oral tablet, once daily
219668561|NCT01006590|DRUG|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
219668562|NCT03332095|DRUG|Doravirine (DOR)|100 mg of DOR administered orally
219668563|NCT03332095|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
219668564|NCT03332095|DRUG|Antiretroviral (ARV) medications|Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
219068035|NCT04833023|DRUG|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
219068036|NCT00919282|DRUG|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
219068037|NCT06529588|RADIATION|Radiation|HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
219068038|NCT04399629|BEHAVIORAL|PCIT-ED|12 sessions of PCIT-ED therapy
219068039|NCT04399629|BEHAVIORAL|Parenting Wisely|Teaches parents how to set more effective limits
219068040|NCT04272450|DIAGNOSTIC_TEST|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
219068041|NCT01299493|OTHER|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
219068042|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
219068043|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
219068044|NCT01134029|BEHAVIORAL|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
219068045|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
219068046|NCT06380231|OTHER|kangaroo mother care (KMC)|"Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index."
219068047|NCT03579979|DRUG|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
219068048|NCT03579979|DRUG|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
219068049|NCT01519206|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
219068050|NCT00102895|DRUG|CP-724,714|
219068051|NCT02009176|PROCEDURE|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
219068052|NCT02009176|PROCEDURE|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
219068053|NCT02356380|OTHER|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
219068054|NCT03892772|DRUG|SAS0421a|treatment will be given for 3 days
219068055|NCT03892772|DRUG|SAS0421b|treatment will be given for 3 days
219068056|NCT03892772|DRUG|SAS0421c|treatment will be given for 3 days
219668565|NCT02957487|DEVICE|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
219668566|NCT05627947|DRUG|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
219668567|NCT06276023|BEHAVIORAL|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
219668568|NCT06276023|BEHAVIORAL|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
219668569|NCT06035211|OTHER|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
219668570|NCT03970226|DRUG|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."
219668571|NCT02742675|DRUG|Bicalutamide|Given orally
219668572|NCT02742675|DRUG|goserelin acetate|Given subcutaneously or as an injection
219668573|NCT02742675|DRUG|flutamide|Given orally
219668574|NCT02742675|DRUG|leuprolide acetate|Given subcutaneously or as an injection
218977776|NCT01254292|DRUG|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
218977777|NCT01951222|DRUG|V0162|
218977778|NCT01951222|OTHER|Placebo|
218977779|NCT06334458|DIAGNOSTIC_TEST|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
218977780|NCT00285818|DRUG|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
218977781|NCT00285818|DRUG|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
218977782|NCT02344862|DRUG|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
219068057|NCT03892772|DRUG|placebo|placebo will be given for 3 days
219068058|NCT05152693|OTHER|Low variety|Meal components are mixed together on the plate
219068059|NCT05152693|OTHER|High Variety|Meal components are served separately on the plate
219668575|NCT02742675|DRUG|triptorelin|Given subcutaneously or as an injection
219668576|NCT02742675|PROCEDURE|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
219668577|NCT04169997|DRUG|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
219668578|NCT04169997|DRUG|Placebos|Placebos tablet.The starting dose from 100mg QD
219668579|NCT03848624|DEVICE|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
219668580|NCT01124799|DRUG|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
219668581|NCT01124799|DRUG|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
219668582|NCT01124799|DRUG|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
219668583|NCT05988671|DRUG|normal Saline|Intraperitoneal route
219668584|NCT05988671|DRUG|Dexamethasone|Intraperitoneal route
219668585|NCT05988671|DRUG|Dexmedetomidine|Intraperitoneal route
219668586|NCT05988671|DRUG|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
218977783|NCT02344862|DRUG|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
218977784|NCT02344862|DRUG|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
218977785|NCT02344862|DRUG|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
218977786|NCT03868761|BEHAVIORAL|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
218977787|NCT03823508|DEVICE|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
218977788|NCT03823508|DEVICE|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
218977789|NCT00007683|DRUG|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
219068060|NCT05152693|OTHER|Small Portion Size|Small meal portion size
219068061|NCT05152693|OTHER|Large Portion Size|Large meal portion size
219068062|NCT05152693|OTHER|With Beverage|Meal served with water
219068063|NCT05152693|OTHER|Without Beverage|Meal served without water
219068064|NCT00712842|OTHER|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
219208647|NCT06891989|OTHER|Health Education Active Control Intervention|Participants will be asked to download and use the free TED Talk app, which will have 50 TED talk videos related to health that range from 3-20 minutes. Participants will be asked to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week and complete weekly logs of the TED Talk app use.
219668587|NCT05859061|DEVICE|cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe|Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
219668588|NCT04634032|GENETIC|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
219668589|NCT04634032|DIAGNOSTIC_TEST|Blood sampling|Peripheral blood sampling for SNP analysis
219668590|NCT06283680|PROCEDURE|Lung transplantation|Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.
219668591|NCT03901508|DEVICE|TDCS|20 minutes, 2 electrodes (C3/FP2)
218977790|NCT00007683|DRUG|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
218977791|NCT00007683|DRUG|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
218977792|NCT04090073|PROCEDURE|Electroacupuncture|As above
218977793|NCT04090073|OTHER|Fast-track Perioperative program|As above
218977794|NCT05118243|OTHER|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
218977795|NCT05118243|OTHER|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
218977796|NCT01986140|DEVICE|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
218977797|NCT01986140|OTHER|Control No treatment|No treatment to prevent hair loss
218977798|NCT04802070|DRUG|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
218977799|NCT04573998|PROCEDURE|LSG|bariatric surgery
218977800|NCT04447378|DRUG|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
218977801|NCT02378727|DEVICE|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
219068065|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
219068066|NCT01380327|OTHER|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.
219068067|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
218977802|NCT02378727|DEVICE|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
219208648|NCT06762327|DRUG|Ensartinib|ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
219208649|NCT06761703|DEVICE|TAP® Micro Select Device (Touch Activated Phlebotomy)|The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.
219208650|NCT06875232|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
219208651|NCT06640543|OTHER|Kinesiotape|Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
219208652|NCT06640543|OTHER|Myofascial release|Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
219668592|NCT03728998|OTHER|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~* 1\. Starting in semi-succumbed position (45 degree head-up)~* 2\. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
218977803|NCT03453411|OTHER|Non interventional study|Non interventional study
218977804|NCT04981392|BEHAVIORAL|Primary care text message outreach to unvaccinated patients and resources to support PCPs|"Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase)."
218977805|NCT05899088|OTHER|Mindful Movement|Mindful Movement Program with Researcher Follow-up
218977806|NCT03219541|BEHAVIORAL|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
219668593|NCT03728998|OTHER|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
219668594|NCT04104594|DIAGNOSTIC_TEST|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
219668595|NCT04104594|OTHER|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
219668596|NCT04104594|OTHER|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
219208653|NCT04233853|BEHAVIORAL|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
219208654|NCT04233853|OTHER|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
219668597|NCT04104594|OTHER|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
219668598|NCT04104594|BIOLOGICAL|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
219668599|NCT04701489|DEVICE|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
219668600|NCT04153968|DIETARY_SUPPLEMENT|β-cryptoxanthin|"Phase 1:~2.0mg of \[13C14\]β-cryptoxanthin, 1.0mg of \[13C10\]β-carotene and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of \[13C14\]β-cryptoxanthin, 0.75mg of \[13C10\]β-carotene, 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of \[13C14\]β-cryptoxanthin, 1.5mg of \[13C10\]β-carotene, and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
219668601|NCT03280316|PROCEDURE|surgery|patients with SVMs receive surgery
218977807|NCT03219541|BEHAVIORAL|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
218977808|NCT03819673|BEHAVIORAL|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
218977809|NCT03853343|DIETARY_SUPPLEMENT|Seaweed extract|1 capsule 3 times per day
218977810|NCT03853343|DIETARY_SUPPLEMENT|Placebo|1 capsule 3 times per day
218977811|NCT04288271|BEHAVIORAL|Adherence Intervention|"Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
218977812|NCT04288271|OTHER|Healthy living education intervention|"Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
218977813|NCT01527318|DRUG|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
218977814|NCT01600807|DRUG|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
218977815|NCT01600807|DRUG|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
218977816|NCT03576222|DEVICE|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
218977817|NCT03576222|DEVICE|MEPORE dressing|MEPORE dressing
218977818|NCT01624337|DRUG|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
219668602|NCT03280316|PROCEDURE|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
219668603|NCT03280316|PROCEDURE|botulinum toxin A injection|BOTOX
218977819|NCT01624337|DRUG|placebo|
218977820|NCT05420727|DRUG|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
218977821|NCT05420727|DRUG|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
218977822|NCT01833546|DRUG|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
219068068|NCT01223313|DEVICE|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
219668604|NCT03280316|DRUG|M receptor antagonist|Tolterodine
219668605|NCT05409508|OTHER|mindfulness meditation care|mindfulness meditation care
219668606|NCT05409508|OTHER|no mindfulness meditation care|no mindfulness meditation care
218977823|NCT01833546|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
219068069|NCT00781300|DRUG|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
219068070|NCT00781300|DRUG|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
219668607|NCT05741814|DRUG|Propofol|Gynecologist guided individualised propofol only sedation
219668608|NCT00366652|DRUG|desvenlafaxine SR|
219668609|NCT00366652|DRUG|desipramine|
219668610|NCT00366652|DRUG|duloxetine|
219668611|NCT00653978|PROCEDURE|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
219668612|NCT00653978|PROCEDURE|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
219668613|NCT00819949|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
219668614|NCT01118572|DRUG|YM177|oral
219668615|NCT01118572|DRUG|etodolac|oral
219668616|NCT01118572|DRUG|Placebo|oral
219668617|NCT01081405|OTHER|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
219668618|NCT03470623|DEVICE|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
219668619|NCT03470623|DEVICE|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
219668620|NCT03867968|BEHAVIORAL|TIPS Intervention|Web-based training for family member.
219668621|NCT03867968|BEHAVIORAL|Control|Traumatic Brain Injury website for family members.
219668622|NCT05553535|DIAGNOSTIC_TEST|MRI|retrospective review of shoulder MRI
219668623|NCT04505306|PROCEDURE|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
219668624|NCT02994641|PROCEDURE|COMA Score Assessment|
219668625|NCT01343966|DRUG|MABT5102A|Repeating subcutaneous injection
219668626|NCT01343966|DRUG|MABT5102A|Repeating intravenous infusion
219668627|NCT01343966|DRUG|placebo|Repeating subcutaneous injection
219668628|NCT01343966|DRUG|placebo|Repeating intravenous infusion
219668629|NCT00703118|DRUG|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
219668630|NCT00703118|DRUG|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
219668631|NCT00703118|DRUG|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
219668632|NCT00703118|DRUG|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
219668633|NCT04290325|DRUG|HMPL-453|HMPL-453 tablet
219668634|NCT02593955|BEHAVIORAL|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
219668635|NCT02593955|BEHAVIORAL|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
219668636|NCT06142734|PROCEDURE|pyeloplasty|"* For laparoscopic pyeloplasty:~* Anaesthesia: general~* Position: a 45-degree lateral decubitus position with the concerned side up. Patient is secured to the operating table. Pneumoperitoneum is adopted through a camera port lateral to the umbilicus~* extra operating ports are created at subcostal and at spinoumbilial line.~* the UPJ is transperitoneally accessed by incising the white line of Toldt and the ipsilateral colon is reflected and the proximal ureter and the pelvis are identified an mobilized~* then Anderson- Hynes pyeloplasty is carried out with insertion of nephroureterostomy or pyeloureterostomy tube."
219068071|NCT03861598|DRUG|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
219668637|NCT01054313|DRUG|Docetaxel (Taxotere)|Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
219668638|NCT01054313|DRUG|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
219668639|NCT01054313|DRUG|Prednisone|5 mg by mouth twice a day with prostate cancer.
219668640|NCT03922841|OTHER|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
219668641|NCT02703896|DRUG|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
219668642|NCT02703896|PROCEDURE|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
219668643|NCT02963519|DEVICE|VistaCare®|
219668644|NCT02963519|DEVICE|Dressings|
218977824|NCT06228885|BEHAVIORAL|handwriting experiment and motor ability test|Participants will be instructed to participate in a handwriting experiment, which involves utilizing a Force Acquisition Pen (FAP) system and Near Infrared Spectroscopy (NIRS) to collect force data and cortical activation, respectively, during handwriting tasks. Children will be tasked with completing various assignments, such as tracing lines, writing numbers, and characters, among others. Additionally, assessments of motor ability and handwriting proficiency will be conducted using the Movement Assessment Battery for Children (MABC) and the Chinese Handwriting Evaluation Form (CHEF). The Pinch Holding Up Activity (PHUA) Test will also be administered to assess their sensorimotor ability.
218977825|NCT03903601|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
218977826|NCT03903601|DIAGNOSTIC_TEST|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
218977827|NCT03903601|DIAGNOSTIC_TEST|Neuropsychological tests|Cognitive functions assessment
218977828|NCT04048122|BEHAVIORAL|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
218977829|NCT04048122|BEHAVIORAL|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
218977830|NCT05577871|DRUG|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
218977831|NCT05577871|DRUG|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
219208655|NCT06848452|OTHER|no-intervention|no-intervention
219208656|NCT05849727|DRUG|TQH3821 tablets 200 mg|TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
219668645|NCT04448639|DIAGNOSTIC_TEST|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
219668646|NCT04448639|DIAGNOSTIC_TEST|Bloodtest|cardiac biomarkers
219668647|NCT02419794|PROCEDURE|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
219668648|NCT04595084|BEHAVIORAL|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
218977832|NCT00471146|DRUG|AG-013736|oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
218977833|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
218977834|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
218977835|NCT00471146|DRUG|placebo|placebo
218977836|NCT05657431|OTHER|essential oils (Ylang ylang oil)|inhaler aromatherapy
218977837|NCT05657431|OTHER|placebo (saline solutions)|placebo saline solutions
219068072|NCT03899883|DRUG|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
219068073|NCT03295188|DIETARY_SUPPLEMENT|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
218977838|NCT05657431|OTHER|essential oils (lemon oil)|inhaler aromatherapy
219068074|NCT03295188|DIETARY_SUPPLEMENT|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
219068075|NCT05230238|DEVICE|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
219068076|NCT05288543|DRUG|IPG7236- Single ascending dose|Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
219068077|NCT05288543|DRUG|IPG7236- Multiple ascending dose|Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
219068078|NCT05288543|OTHER|Placebo (Part A)|Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
219068079|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
219068080|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
219068081|NCT05308836|COMBINATION_PRODUCT|adipose-derived messenchymal stem cell|Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates
219208657|NCT05849727|DRUG|TQH3821 tablets matching placebo|TQH3821 tablets matching placebo without active substance.
219208658|NCT06765447|PROCEDURE|hemostasis with 3% NaOCl in direct pulp capping|after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.
218977839|NCT02149875|DRUG|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
218977840|NCT02149875|DRUG|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
218977841|NCT02149875|DRUG|Placebo|100 ml saline intravenous infusion once daily for 10 days.
218977842|NCT03503136|DRUG|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
218977843|NCT03503136|DRUG|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
218977844|NCT03503136|DRUG|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
218977845|NCT03503136|DRUG|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
219668649|NCT04595084|BEHAVIORAL|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
219668650|NCT04595084|BEHAVIORAL|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
218977846|NCT03503136|DRUG|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
218977847|NCT03503136|DRUG|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
218977848|NCT02643290|DEVICE|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
219668651|NCT04728984|DRUG|Nalfurafine Hydrochloride|"Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days"
219668652|NCT04728984|DRUG|Nalfurafine Hydrochloride+Placebo|Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
219668653|NCT04728984|DRUG|Placebo|two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
219668654|NCT04691687|DRUG|Furosemide|IV loop diuretic therapy
219668655|NCT04691687|DRUG|IV Solution|IV Placebo comparator
219668656|NCT00670657|DRUG|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
219668657|NCT01522131|PROCEDURE|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
219668658|NCT04423562|OTHER|No intervention|No intervention
219668659|NCT03693001|DEVICE|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
219668660|NCT01905774|DRUG|Deferasirox|
219668661|NCT04265300|DIETARY_SUPPLEMENT|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
219668662|NCT03280706|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 50g in water 500ml
219668663|NCT03280706|DIETARY_SUPPLEMENT|Orange Juice|Orange juice 480ml + 20ml of water
219668664|NCT03280706|DIETARY_SUPPLEMENT|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
219668665|NCT03339557|DEVICE|NexGen|Comparing two conventional designs and one novel design
219668666|NCT03339557|DEVICE|Persona|Comparing two conventional designs and one novel design
219668667|NCT03339557|DEVICE|PFC|Comparing two conventional designs and one novel design
219668668|NCT05357885|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
219668669|NCT03714776|DRUG|Placebo|Placebo matching solution administered as SC injection.
219668670|NCT03714776|DRUG|ISIS 757456|Administered as SC injection.
219550070|NCT03012451|BEHAVIORAL|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
219550071|NCT06331572|DIAGNOSTIC_TEST|17-HAMD|Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
219550072|NCT03401281|OTHER|Coconut oil|50g extra virgin coconut oil daily for four weeks
219668671|NCT01269099|DRUG|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
219668672|NCT01269099|DRUG|Control|control group (No-PCA group)
219550073|NCT03401281|OTHER|Butter|50g butter daily for four weeks
219550074|NCT03401281|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
219550075|NCT00556673|DRUG|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
219550076|NCT00556673|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
219550077|NCT00556673|DRUG|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
219550078|NCT05402046|OTHER|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
219550079|NCT04401137|DRUG|Topiramate|Topiramate
219550080|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
219550081|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
219550082|NCT03860441|OTHER|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
219550083|NCT02228486|DEVICE|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
219550084|NCT02228486|BEHAVIORAL|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
219668673|NCT01122069|OTHER|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
219550085|NCT00755235|OTHER|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
219550086|NCT01401062|DRUG|Fresolimumab|
219550087|NCT01401062|RADIATION|Radiation Therapy|
219550088|NCT00869193|DIETARY_SUPPLEMENT|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
219550089|NCT00869193|DIETARY_SUPPLEMENT|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
219550090|NCT01131260|DEVICE|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
219550091|NCT05659316|OTHER|MRI imaging|Knee MRI imaging
219550092|NCT00757172|BIOLOGICAL|panitumumab|
219550093|NCT00757172|DRUG|cisplatin|
219550094|NCT00757172|DRUG|docetaxel|
219550095|NCT00757172|PROCEDURE|neoadjuvant therapy|
219550096|NCT00757172|PROCEDURE|therapeutic conventional surgery|
219550097|NCT00757172|RADIATION|radiation therapy|
219550098|NCT03555695|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
219550099|NCT03555695|BEHAVIORAL|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
219550100|NCT03555695|BEHAVIORAL|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
219550101|NCT01574027|DRUG|Vitamin D3 (cholecalciferol)|One capsule per day for six months
219550102|NCT01574027|DRUG|Placebo|One capsule per day for six months
219550103|NCT03409315|PROCEDURE|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
219550104|NCT00792753|DEVICE|Medtronic Endeavor Coronary Stent System|coronary stent implantation
219550105|NCT00792753|DEVICE|DESyne BD Novolimus Stent System|coronary stent implantation
219550106|NCT00792753|DEVICE|DESyne Novolimus Stent System|coronary stent implantation
219550107|NCT06238388|DRUG|HSK21542 Injection|A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
219550108|NCT06627257|DRUG|LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
219550109|NCT06627257|DRUG|LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
219550110|NCT06627257|OTHER|Placebo Comparator: Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
219550111|NCT05226702|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
219550112|NCT05226702|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
219550113|NCT04889014|GENETIC|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
219550114|NCT04889014|GENETIC|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
219550115|NCT06106490|OTHER|the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients|"Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds."
219550116|NCT04538677|DEVICE|Video consultation|A two-way audio and visual connection between patients and surgeons
219550117|NCT02975856|DIETARY_SUPPLEMENT|Table Red Wine|
219550118|NCT02975856|DIETARY_SUPPLEMENT|Young Port Red Wine|
219550119|NCT00099151|BEHAVIORAL|Caloric Restriction (CR)|
219550120|NCT00099151|BEHAVIORAL|Exercise|
219550121|NCT06108557|DIAGNOSTIC_TEST|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
219208659|NCT06765447|PROCEDURE|hemostasis with diode laser in direct pulp capping|Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
219668674|NCT00423358|DIETARY_SUPPLEMENT|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
218977849|NCT04281641|DIAGNOSTIC_TEST|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
219668675|NCT00423358|DIETARY_SUPPLEMENT|placebo|matching placebo
219668676|NCT04279990|OTHER|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
219668677|NCT06195176|OTHER|Shoulder exercises|"Operational Definition:~* Lift the shoulders as high as possible toward the ears.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
219668678|NCT06195176|OTHER|Hand exercises|"Operational Definition:~* Open and close the hands, making a fist and applying force.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
218977850|NCT04352946|DRUG|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
218977851|NCT04352946|DRUG|Placebo oral tablet|Placebo tablets 400mg daily
218977852|NCT06076707|DRUG|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
218977853|NCT01529684|DRUG|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
218977854|NCT01529684|DRUG|OSI-906|Part B: oral tablets OSI-906
218977855|NCT04234451|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
218977856|NCT04234451|PROCEDURE|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
218977857|NCT05399303|PROCEDURE|obturation|obturation using different types of sealers
218977858|NCT00698984|DIETARY_SUPPLEMENT|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
218977859|NCT00698984|DIETARY_SUPPLEMENT|Placebo|2 capsules per day over a period of 6 months
218977860|NCT01262573|PROCEDURE|Closure of vaginal cuff|Closure of the vaginal cuff
218977861|NCT04483973|DRUG|Ebselen|Glutathione peroxidase mimetic
218977862|NCT04483973|DRUG|Placebo|Matching placebo containing excipients
218977863|NCT02810977|DEVICE|Ultrasound|Ultrasound assessment of gastric content and volume
218977864|NCT06476327|BEHAVIORAL|experimental 1 group|"A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
219068082|NCT04695171|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
219068083|NCT04695171|PROCEDURE|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
219068084|NCT02964936|DRUG|roxadustat|Oral administration
219068085|NCT05026736|OTHER|Quality-of-Life Assessment|Ancillary studies
219208660|NCT06876025|OTHER|questionnaires|Application of the questionnaires Measure of Participation and Environment - Children and Youth, (PEM-CY), or Measure of Participation and the environment - young children (YC-PEM), and the Pediatric Disability Assessment Inventory (PEDI).
218977865|NCT06476327|BEHAVIORAL|experimental 2 group|"Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
219668679|NCT03636048|DRUG|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
219668680|NCT03636048|DRUG|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
219668681|NCT05053035|DRUG|AL001|Administered via intravenous (IV) infusion
219668682|NCT05053035|DRUG|Placebo|Administered via intravenous (IV) infusion
219668683|NCT05835063|BEHAVIORAL|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
219668684|NCT05835063|BEHAVIORAL|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
219668685|NCT06361498|DEVICE|Ultrasound Imaging|Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
219668686|NCT01245816|DRUG|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
219668687|NCT01245816|DRUG|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
219668688|NCT01245816|DRUG|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
219668689|NCT05008445|BIOLOGICAL|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
219668690|NCT05008445|COMBINATION_PRODUCT|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
219668691|NCT05804227|DRUG|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
219668692|NCT05503875|BIOLOGICAL|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
219668693|NCT00913224|DRUG|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
219668694|NCT00913224|DRUG|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
219668695|NCT02671734|BEHAVIORAL|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
219668696|NCT00864136|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
218977866|NCT04970641|BEHAVIORAL|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
219668697|NCT00864136|DRUG|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
219668698|NCT00864136|DRUG|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
219668699|NCT05587413|PROCEDURE|periodontal care|periodontal treatment
219668700|NCT04965103|PROCEDURE|SCR|Superior Capsule reconstruction
219668701|NCT04965103|PROCEDURE|Bridging|Tendon repair with graft interposition
219668702|NCT01069770|DRUG|Sunitinib|50mg daily(4 weeks on \& 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
219068086|NCT05026736|BIOLOGICAL|Sintilimab|Given IV
219068087|NCT05794191|BIOLOGICAL|Vaccine Administration|PCV13 administration
219068088|NCT04081259|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
219068089|NCT04139317|DRUG|Capmatinib|INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
219068090|NCT04139317|BIOLOGICAL|Pembrolizumab|Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
219068091|NCT05857163|DRUG|Rifasutenizol capsules|400 mg, BID, taken orally within half an hour after breakfast and dinner.
219668703|NCT00772187|DRUG|morphine|Single dose: 0.1-0.5 mg
219668704|NCT00772187|DRUG|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
219668705|NCT00772187|DRUG|general anesthesia (fentanyl)|general anesthesia alone
219668706|NCT03811054|DRUG|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
219668707|NCT00543920|DRUG|MK0777|
219668708|NCT05277350|DRUG|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
219668709|NCT05277350|DRUG|Placebo|Matching placebo
219668710|NCT05328284|DEVICE|PASCAL leaflet repair system|transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
219668711|NCT05952713|DRUG|Antidepressant|Treatment with an antidepressant according to Danish register data.
219668712|NCT04412642|DRUG|Methoxyflurane, MEOF|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
219668713|NCT05590533|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
219668714|NCT03580499|DIETARY_SUPPLEMENT|Vitamin B6|Given PO
219668715|NCT03580499|OTHER|Questionnaire Administration|Ancillary studies
219668716|NCT04224220|OTHER|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
219668717|NCT04224220|OTHER|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
219668718|NCT03865394|BIOLOGICAL|Application of allogeneic ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
219668719|NCT03865394|PROCEDURE|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
219668720|NCT01054391|DEVICE|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
219668721|NCT00946894|PROCEDURE|Total thyroidectomy|Total thyroidectomy
219668722|NCT00946894|PROCEDURE|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
219668723|NCT00946894|PROCEDURE|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
219668724|NCT05672589|DIAGNOSTIC_TEST|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
219668725|NCT05672589|DIAGNOSTIC_TEST|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
219668726|NCT05948839|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
219668727|NCT05948839|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219668728|NCT01192724|DRUG|Cilostazol|100 mg BID, for 3 months
219668729|NCT01192724|DRUG|Aspirin|Aspirin 100 mg QD, for 1 year
219668730|NCT01192724|DRUG|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
219668731|NCT03438058|OTHER|Graft survival and/or Rejection appearance|
219668732|NCT03274752|DRUG|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
219668733|NCT03274752|DRUG|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
219668734|NCT00548249|DEVICE|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
219668735|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
219668736|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
219668737|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
219668738|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
219668739|NCT02958332|OTHER|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
219668740|NCT03003000|DRUG|ibuprofen|
219668741|NCT03003000|DRUG|caffeine|
219668742|NCT03003000|DRUG|placebo|
219668743|NCT01678599|DRUG|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
219668744|NCT02527915|OTHER|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
219668745|NCT02527915|OTHER|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
219668746|NCT01715142|DRUG|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
219668747|NCT01715142|DRUG|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
219668748|NCT01178814|DRUG|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
219668749|NCT00490672|BEHAVIORAL|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
219668750|NCT00490672|BEHAVIORAL|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
219668751|NCT04933617|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 intravenous (IV) per protocol on Day 1 of each cycle up to 6 cycles
219668752|NCT04933617|DRUG|Etoposide|Etoposide 50 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
219668753|NCT04933617|BIOLOGICAL|Copanlisib|Copanlisib intravenous (IV) is administered at a fixed dose (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle for up to 6 cycles
219668754|NCT04933617|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
219668755|NCT04933617|DRUG|Doxorubicin|Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
219668756|NCT04933617|DRUG|Vincristine|Vincristine 0.4 mg/m\^2/day (no cap) continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
219668757|NCT04933617|DRUG|Prednisone|Prednisone 60 mg/m\^2 by mouth (PO) twice a day (BID) Days 1-5 (total 120mg/m\^2/day)
219668758|NCT04933617|DIAGNOSTIC_TEST|ECHO|At screening.
219668759|NCT04933617|DIAGNOSTIC_TEST|EKG|At screening.
219068092|NCT05857163|DRUG|Rabeprazole sodium enteric-coated tablets|20 mg, BID, taken orally within half an hour before breakfast and dinner.
219068093|NCT05857163|DRUG|Amoxicillin Capsules|1 g, BID, taken orally within half an hour after breakfast and dinner.
219068094|NCT05857163|DRUG|Clarithromycin placebo tablets|BID, taken orally within half an hour after breakfast and dinner.
219668760|NCT04933617|DIAGNOSTIC_TEST|MRI Brain|At screening.
219668761|NCT04933617|DIAGNOSTIC_TEST|18F-FDG - PET|At screening, baseline, after cycle 1, 3, and 6, and end of treatment.
219668762|NCT04933617|DIAGNOSTIC_TEST|CT Scan|At screening, baseline, after cycle 1, 3, and 6, end of treatment and follow-up.
219668763|NCT04933617|PROCEDURE|Bone Marrow Aspiration|At screening and end of treatment.
219668764|NCT04933617|PROCEDURE|Bone Marrow Biopsy|At screening and end of treatment.
219668765|NCT04933617|DIAGNOSTIC_TEST|Lumbar Puncture (LP)|Baseline and end of treatment.
219668766|NCT04344522|PROCEDURE|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
219668767|NCT04344522|PROCEDURE|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
219668768|NCT04344522|PROCEDURE|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
219668769|NCT04344522|PROCEDURE|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
219668770|NCT00466206|DEVICE|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
219668771|NCT00466206|DEVICE|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
219668772|NCT00466206|PROCEDURE|3MP (Magnetic Mini-Mover Procedure)|"* Subject has EKG performed to measure baseline cardiac activity.~* Magnimplant is implanted.~* After one week, Magnatract is fitted.~* Chest x-ray and 2nd EKG performed 30 days post-implantation.~* Patient and parents complete QoL questionnaire 30d post-implantation.~* Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~* At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~* At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~* Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~* CT scan and third EKG performed after explanation.~* Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
219668773|NCT02658708|OTHER|Bright blue-green light using light visor cap|
219668774|NCT02658708|OTHER|Dim red light using light visor cap|
219668775|NCT02658708|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
219668776|NCT02658708|OTHER|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
219668777|NCT02658708|OTHER|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
219668778|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
219668779|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
219668780|NCT02658708|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
219668781|NCT02658708|DIAGNOSTIC_TEST|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
219668782|NCT02658708|OTHER|Horne-Ostberg Morningness-Eveningness Questionnaire|
219668783|NCT02658708|OTHER|Daily Fatigue and Sleep Log|"* Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~* Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
219668784|NCT03726736|DRUG|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
219668785|NCT03726736|DRUG|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
219668786|NCT02616718|RADIATION|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
219668787|NCT00974038|BEHAVIORAL|psychotherapy|1\) cognitive-behavioral therapy or 2) supportive psychotherapy
219668788|NCT03603288|DRUG|idebenone 150 mg film-coated tablets|900 mg idebenone/day
219668789|NCT02191046|DEVICE|squeezable bottle|nasal irrigation twice daily for 2 weeks period
219668790|NCT02191046|DEVICE|syringe 20 ml|nasal irrigation twice daily for 2 weeks
219668791|NCT02286375|BEHAVIORAL|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
219668792|NCT01592604|DEVICE|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
219668793|NCT01592604|DEVICE|Below knee walking cast|Below knee walking cast for 4 weeks
219668794|NCT03061799|DIETARY_SUPPLEMENT|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
219068095|NCT05857163|DRUG|Bismuth potassium citrate placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
219668795|NCT03061799|DIETARY_SUPPLEMENT|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
219668796|NCT05480553|DRUG|NPC-06|"1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
219668797|NCT05480553|DRUG|Placebo|"1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
219668798|NCT02451397|OTHER||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
219668799|NCT04049305|DEVICE|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
219668800|NCT04049305|PROCEDURE|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
219668801|NCT04049305|PROCEDURE|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
219668802|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
219668803|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
219668804|NCT02515084|DEVICE|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
219668805|NCT02515084|DEVICE|MRI imaging|
219668806|NCT05432219|PROCEDURE|endoscopic surgery|endoscopic resection of recurrent nasopharyngeal carcinoma via the transoral retropterygoid nasopharyngectomy approach
219668807|NCT06405659|OTHER|correction for pedicle fixation|The patient was diagnosed with idiopathic scoliosis and underwent a posterior idiopathic scoliosis procedure and correction for pedicle fixation.
219668808|NCT03921359|BEHAVIORAL|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
218977867|NCT03339687|BEHAVIORAL|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
219068096|NCT05857163|DRUG|Clarithromycin tablets|500 mg, BID, taken orally within half an hour after breakfast and dinner.
219068097|NCT05857163|DRUG|Bismuth potassium citrate capsules|240 mg, BID, taken orally within half an hour before breakfast and dinner.
219068098|NCT05857163|DRUG|Rifasutenizol placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
219668809|NCT03921359|BEHAVIORAL|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
219668810|NCT05571215|DEVICE|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
219668811|NCT05571215|BEHAVIORAL|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
219668812|NCT04006509|BEHAVIORAL|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
219668813|NCT04373850|BEHAVIORAL|Home Visit|Physical exam, medication dose titration
219668814|NCT04707560|PROCEDURE|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
219668815|NCT04497974|OTHER|Dietary intervention|Varying the exposure to sweetness via diet manipulation.
219668816|NCT04282720|DEVICE|SurgiMend Mesh|Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
219668817|NCT01660802|DRUG|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
219668818|NCT01660802|OTHER|Sham|Sham administered in the study eye on Day 1.
218977868|NCT04644991|OTHER|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
218977869|NCT04644991|OTHER|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
218977870|NCT04644991|OTHER|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
218977871|NCT06243484|DIETARY_SUPPLEMENT|TOTUM-070|12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
218977872|NCT06243484|DIETARY_SUPPLEMENT|PLACEBO|8 capsules per day to consume orally in two intakes
218977873|NCT00005878|DRUG|celecoxib|
218977874|NCT02002273|PROCEDURE|Switching level of suction|
218977875|NCT05192473|DEVICE|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
218977876|NCT05421871|BEHAVIORAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
219668819|NCT06333782|DEVICE|Experimental- Genefill Contour®|Genefill Contour® Hyaluronic Acid Injection
219668820|NCT06333782|DEVICE|Marketed comparator - Desirial®Plus|DESIRIAL®PLUS Hyaluronic Acid Injection
219668821|NCT04384198|PROCEDURE|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
219668822|NCT05981404|DIETARY_SUPPLEMENT|β-glucan|Consuming 3g β-glucan with each meal.
219668823|NCT05981404|DIETARY_SUPPLEMENT|Placebo|Consuming 3g Cellulose with each meal.
219668824|NCT02295267|OTHER|walnut allergy provocation|double blind placebo controlled food challenge
219668825|NCT00316329|DRUG|Artesunate + Amodiaquine|
219668826|NCT05250986|DEVICE|GoCheck Kids (iOS)|"Visual Acuity method is used to measure of the sharpness or clearness of vision.~Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors."
219668827|NCT05250986|DEVICE|GoCheck Kids (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
219668828|NCT05250986|DEVICE|GoCheck at Home (iOS)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
219668829|NCT05250986|DEVICE|GoCheck at Home (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
218977877|NCT05421871|BEHAVIORAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
218977878|NCT03821207|BEHAVIORAL|The exercise group|The students will make exercise during the first three days of the menstrual period
218977879|NCT03821207|BEHAVIORAL|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
218977880|NCT03821207|BEHAVIORAL|Control Group|The students will nor massage or exercise
218977881|NCT00166465|DRUG|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
218977882|NCT04836312|BEHAVIORAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
218977883|NCT00004364|DRUG|desmopressin|
218977884|NCT05634915|DRUG|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
218977885|NCT05634915|DRUG|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
219668830|NCT05943431|DEVICE|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
218977886|NCT00812851|DRUG|Dronabinol|
218977887|NCT02819869|DRUG|Statin and Metformin use|
218977888|NCT03860597|DRUG|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
218977889|NCT03860597|DRUG|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
218977890|NCT01768767|DRUG|Placebo|
218977891|NCT01768767|DRUG|Ketamine|
218977892|NCT01768767|DRUG|Ketamine/Lithium|
218977893|NCT02940080|OTHER|Dietary|
219068099|NCT05865106|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
219668831|NCT05943431|DEVICE|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
219668832|NCT05943431|DEVICE|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
219668833|NCT04309487|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
219668834|NCT02281240|DRUG|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
219668835|NCT04089878|PROCEDURE|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
219668836|NCT04089878|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
219668837|NCT00374257|PROCEDURE|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
219668838|NCT04187274|DEVICE|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
218977894|NCT01931332|PROCEDURE|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
219668839|NCT05659303|PROCEDURE|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
218977895|NCT01931332|PROCEDURE|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
218977896|NCT04686604|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
218977897|NCT03800173|DRUG|galidesivir|galidesivir IV infusion
218977898|NCT03800173|DRUG|placebo|placebo IV infusion
218977899|NCT05537896|DRUG|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"
219668840|NCT04876313|DRUG|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8
219668841|NCT04876313|DRUG|Nivolumab|360 mg IV Q3W x 13 cycles
219668842|NCT01490307|BEHAVIORAL|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
219668843|NCT03585946|DRUG|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
219668844|NCT03758105|OTHER|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
219668845|NCT03758105|OTHER|Usual care|Medication and psychotherapy as prescribed in usual care
219668846|NCT01701505|DRUG|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
219668847|NCT01701505|DRUG|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
219668848|NCT01701505|DRUG|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
219668849|NCT06524167|RADIATION|adjuvant radiotherapy|The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose.
218977900|NCT05862597|DIAGNOSTIC_TEST|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
218977901|NCT00936611|DRUG|LBH589|
218977902|NCT02507973|OTHER|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
219068100|NCT05865106|OTHER|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
219668850|NCT05086666|DRUG|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
219668851|NCT00960167|RADIATION|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
219668852|NCT02443272|PROCEDURE|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
219668853|NCT02443272|PROCEDURE|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
219668854|NCT01924104|DRUG|Low molecular weight heparin|2500 mIU/day, subcutaneously
219668855|NCT01924104|DRUG|Low dose aspirin|75 mg/day, orally
219208661|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan (Probiotic Supplement)|This intervention involves daily supplementation of Lactogemikan from Pescado Company, which contains Lactobacillus plantarum, a well-known probiotic strain. The probiotic is intended to improve gut microbiota balance, which may lead to improved nutritional status and health outcomes in hemodialysis patients. The dosage is one tablet daily for a duration of six months.
219668856|NCT01924104|DRUG|Heparin & aspirin|Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)
219668857|NCT01924104|OTHER|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
219668858|NCT06553079|OTHER|Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy|"The intervention in this study involves the administration of the Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy, a newly developed tool designed to measure various aspects of surgeon satisfaction related to shoulder arthroscopy procedures."
219668859|NCT03012295|OTHER||
219668860|NCT00072059|BIOLOGICAL|methoxy polyethylene glycol epoetin beta|
218977903|NCT02507973|OTHER|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
218977904|NCT00376376|DRUG|levofloxacin at 250, 500, 750, and 1000 mg doses|
218977905|NCT00140946|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
218977906|NCT00140946|DRUG|Comparator: placebo / Duration of Treatment: 16 weeks|
218977907|NCT04120948|DEVICE|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
218977908|NCT04120948|DEVICE|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
218977909|NCT02519465|OTHER|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min
218977910|NCT02519465|OTHER|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
218977911|NCT02519465|OTHER|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
218977912|NCT01074372|DRUG|REGN727|4 cohorts (dose 1, 2, 3, 4)
218977913|NCT01074372|DRUG|Placebo|4 cohorts (dose 1, 2, 3, 4)
219068101|NCT06963268|PROCEDURE|Sentinel Node Technique|A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.
219068102|NCT06962982|BEHAVIORAL|Therapeutic Exercises|Therapeutic exercises including stretching and active exercises for neck and shoulder.
219068103|NCT06962982|BEHAVIORAL|Ergonomic Training|Recommendations for adjustments to the chair, desk, and equipment to optimize comfort and efficiency and reduce unnecessary stress and loading on neck muscles.
219668861|NCT04996836|BIOLOGICAL|Next Generation Sequencing and Network Analysis|Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
219668862|NCT01584700|PROCEDURE|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
219668863|NCT05411380|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
219668864|NCT05411380|DRUG|Capecitabine|500mg orally three times a day (continuously)
219668865|NCT05411380|DRUG|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
219668866|NCT02759835|DRUG|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
219668867|NCT02759835|OTHER|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
219668868|NCT00198432|DRUG|Paclitaxel, vinorelbine, cisplatin|
219668869|NCT02080338|DEVICE|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
218977914|NCT05820061|DIAGNOSTIC_TEST|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
218977915|NCT02372240|DRUG|VLX1570 and dexamethasone|
218977916|NCT00036296|DRUG|talampanel|75mg per day divided into 3 doses for 22 days
218977917|NCT03773380|COMBINATION_PRODUCT|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
218977918|NCT01783054|PROCEDURE|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
218977919|NCT01783054|GENETIC|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
218977920|NCT01783054|DRUG|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
219668870|NCT05999656|BIOLOGICAL|human cord blood-derived mononuclear cells (HCB-MNCs)|All patients received cell therapy for the first time. HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet, with an interval of about a centimeter between every two points and an injection volume of 0.2ml at each puncture point. The total injection volume required by the patients was the injection needles multiply 0.2ml (about 2ml of suspended cell in total). The remaining suspension was injected on both sides of the center of the main ischemic site. All patients received three injections of umbilical cord blood mononuclear cells at a week interval, with the latter two injections located around the site of the first injection. The adjuvant therapy remained unchanged within two weeks after cell injection. The follow-up period is 12 weeks after treatment to observe safety and efficacy. If the patient does not recover after 12 weeks, the follow-up period can be extended to 24 weeks.
219668871|NCT01530711|DRUG|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
219668872|NCT00371709|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
219668873|NCT00371709|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
219668874|NCT04539756|BEHAVIORAL|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
219668875|NCT04539756|BEHAVIORAL|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
218977921|NCT00002746|BIOLOGICAL|aldesleukin|
218977922|NCT06134960|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
218977923|NCT06279520|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
218977924|NCT06279520|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
219668876|NCT01593449|BEHAVIORAL|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
219668877|NCT05951920|PROCEDURE|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
219668878|NCT03366961|PROCEDURE|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
219668879|NCT00038311|DRUG|PN-152,243)/PN-196,444|
219668880|NCT06199271|DRUG|Adebrelimab and dalpiciclib|Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
219668881|NCT02028962|BEHAVIORAL|Lifestyle counseling|
219668882|NCT00677573|DRUG|Fostimon|450 IU for 4 days then adjusted
219668883|NCT04687566|DRUG|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
219668884|NCT04687566|DRUG|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
218977925|NCT06279520|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
218977926|NCT06279520|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
218977927|NCT05660226|OTHER|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
218977928|NCT05660226|OTHER|Standard care|Standard outpatient blood pressure management
218977929|NCT04064177|DEVICE|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
218977930|NCT01674283|DRUG|Glucagon|
218977931|NCT01674283|DRUG|placebo|
218977932|NCT02228434|BEHAVIORAL|Monitoring and Tailored prescription|
218977933|NCT02228434|BEHAVIORAL|Happy 10 program|
218977934|NCT02228434|BEHAVIORAL|Specified nutrition education|
218977935|NCT02228434|BEHAVIORAL|General Health Education|
218977936|NCT03012724|DEVICE|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
218977937|NCT03012724|DEVICE|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
218977938|NCT02263209|DEVICE|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
218977939|NCT02263209|DEVICE|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
218977940|NCT02759874|DEVICE|specialized breathalyzer w face recognition technology|
218977941|NCT05189379|OTHER|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
219668885|NCT04687566|DRUG|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
219668886|NCT04687566|DRUG|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
219668887|NCT03647072|DRUG|CHOP|CHOP only
219668888|NCT03647072|DRUG|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
219668889|NCT03647072|DRUG|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
218977942|NCT05189379|OTHER|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
218977943|NCT05189379|OTHER|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
218977944|NCT05189379|OTHER|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
218977945|NCT04160962|PROCEDURE|lappg|Laparoscopic gastrectomy for pylorus preservation
218977946|NCT01090284|DEVICE|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
218977947|NCT00754988|DRUG|Metformin|As prescribed
218977948|NCT00754988|DRUG|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
218977949|NCT00754988|DRUG|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
218977950|NCT00754988|DRUG|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
218977951|NCT00754988|DRUG|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
218977952|NCT01596387|DRUG|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
218977953|NCT01858571|DRUG|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
218977954|NCT01923987|RADIATION|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
219668890|NCT01111422|DRUG|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
219668891|NCT02745483|DEVICE|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
219668892|NCT00002525|DRUG|fluorouracil|"Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5"
219668893|NCT00002525|DRUG|leucovorin calcium|given after surgery at dose of 20mg/m\^2 IV push on days 1-5
219668894|NCT04221022|OTHER|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
219668895|NCT04221022|OTHER|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
219668896|NCT04221022|OTHER|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
219668897|NCT00768339|DRUG|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
219668898|NCT00002379|DRUG|Indinavir sulfate|
219668899|NCT00002379|DRUG|Levocarnitine|
219668900|NCT00002379|DRUG|Adefovir dipivoxil|
218977955|NCT01923987|DRUG|Chemotherapy|"* Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
218977956|NCT01923987|PROCEDURE|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
218977957|NCT03989765|OTHER|Programme to reduce involuntary treatment episodes|See description of trial arms
218977958|NCT00195546|DRUG|DVS-233|
218977959|NCT00785018|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
218977960|NCT00785018|DRUG|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
219668901|NCT00002379|DRUG|Lamivudine|
219668902|NCT00002379|DRUG|Stavudine|
219668903|NCT00002379|DRUG|Zidovudine|
219668904|NCT01315288|OTHER|One of 6 video presentation by one of 4 presenters|
219668905|NCT04622202|DRUG|Pregabalin 150mg|oral capsule pregabalin 150 mg.
219668906|NCT04622202|DRUG|multivitamin|oral placebo in the form of oral multivitamin capsule.
219668907|NCT04475718|BEHAVIORAL|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
219668908|NCT03230838|DRUG|Ceftolozane/Tazobactam|12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
218977961|NCT05148065|DEVICE|BIS|Bispectral index monitoring
218977962|NCT05148065|DEVICE|PSi|Patient state index monitoring
218977963|NCT00543543|BIOLOGICAL|Comparator: GARDASIL|GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
218977964|NCT00543543|BIOLOGICAL|Experimental: V503|V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
218977965|NCT00865670|DRUG|Azithromycin Monohydrate 600 mg Tablets|
218977966|NCT00865670|DRUG|Zithromax (azithromycin dihydrate) 600 mg Tablets|
218977967|NCT05024604|DRUG|Progesterone Only Product in Oral Dose Form|mini pills as a contraceptive method
218977968|NCT05024604|OTHER|office hysterscopy|office hysteroscoy
218977969|NCT02586064|BEHAVIORAL|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
218977970|NCT02586064|BEHAVIORAL|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
218977971|NCT05540444|DEVICE|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
218977972|NCT05600738|DEVICE|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
218977973|NCT00943696|DIETARY_SUPPLEMENT|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
219668909|NCT03230838|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
219668910|NCT02636803|DRUG|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
219668911|NCT02636803|DRUG|albendazole|group receives one 400 mg dose of albendazole
219668912|NCT05409755|OTHER|Vivacy|Vivacy and minoxidil
219668913|NCT03604575|DRUG|Insulin Lispro|
219668914|NCT03604575|DRUG|Humalog®|
219668915|NCT01505179|DRUG|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
218977974|NCT04293731|DIETARY_SUPPLEMENT|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
218977975|NCT04293731|DIETARY_SUPPLEMENT|Placebo|Placebo
218977976|NCT06573931|OTHER|Lumbar Erector Spinae Plane Block|Patients will receive lumbar erector spinae plane block at the end of surgery.
218977977|NCT06573931|OTHER|Fascia Iliaca Block|Patients will receive fascia iliaca block at the end of surgery.
219668916|NCT01505179|DRUG|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
219668917|NCT05262790|OTHER|This is not an intervention study|
218977978|NCT06573931|OTHER|Lumbar Plexus Block|Patients will receive lumbar plexus block at the end of surgery.
218977979|NCT03312998|RADIATION|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
218977980|NCT02958501|DRUG|Colecalciferol|Drug
218977981|NCT01044251|DRUG|Frovatriptan|2.5 mg po bid for 10 days
218977982|NCT01044251|DRUG|Placebo|1 tab po bid for 10 days
219668918|NCT05262790|OTHER|This is not an intervention study|
219668919|NCT05262790|OTHER|This is not an intervention study|
219668920|NCT04045990|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
219668921|NCT05610475|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
219668922|NCT00886964|BIOLOGICAL|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
219668923|NCT00886964|BIOLOGICAL|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
219668924|NCT00675870|DRUG|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
219668925|NCT00521885|DRUG|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
219668926|NCT00521885|DRUG|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
219668927|NCT02236078|DRUG|High dose isoniazid|See arm description
219668928|NCT04106271|OTHER|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
219668929|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
219668930|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
219668931|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
219668932|NCT00978393|DRUG|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
219668933|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
219668934|NCT00978393|DRUG|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
219668935|NCT01915771|DRUG|lomitapide|20 mg dose
219668936|NCT01683877|PROCEDURE|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
218977983|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
219668937|NCT01683877|PROCEDURE|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
219668938|NCT05869877|DEVICE|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
219668939|NCT02700880|DEVICE|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
219668940|NCT00335855|DEVICE|Auto-injector for IM/SC vaccine administration|
219668941|NCT03582514|RADIATION|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
218977984|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
218977985|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
218977986|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
218977987|NCT00734370|BEHAVIORAL|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention"
218977988|NCT00734370|BEHAVIORAL|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)"
218977989|NCT01516073|DRUG|Fluticasone Propionate|FP BID for 12 weeks
219068104|NCT06962982|DEVICE|Human XR device - Oculus Quest 3|Meta Quest 3 is a standalone virtual reality headset by Meta Platforms featuring a slimmer design, higher-resolution dual LCD displays, improved performance with the Snapdragon XR2 Gen 2 chip, and advanced mixed reality capabilities through color passthrough cameras and a depth sensor.
219068105|NCT06961539|OTHER|The group with virtual visits|"On the first day after open-heart surgery in the intensive care unit, in addition to face-to-face visits, video calls were made through the researcher's phone in the morning and evening."
219668942|NCT01210014|DRUG|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
219668943|NCT01210014|DRUG|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
219668944|NCT00001119|BIOLOGICAL|Tetanus Toxoid Vaccine|
219668945|NCT00001119|DRUG|Indinavir sulfate|
218977990|NCT06393036|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
218977991|NCT03883399|OTHER|Survey|Survey among colorectal surgeons
218977992|NCT03715101|DRUG|Rosuvastatin|Open-label, one-sequence, multiple administration
218977993|NCT05667194|DRUG|KH617|KH617 is s freeze-dried powder injection
218977994|NCT00424450|PROCEDURE|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
218977995|NCT00424450|PROCEDURE|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
218977996|NCT05758571|DRUG|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
218977997|NCT02738034|OTHER|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
218977998|NCT00004397|DRUG|heme arginate|
218977999|NCT00004397|DRUG|tin mesoporphyrin|
218978000|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 1|The product under investigation is a unique probiotic.
218978001|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 2|The product under investigation is a unique probiotic.
218978002|NCT03482765|OTHER|Placebo|Microcrystalline Cellulose
218978003|NCT00484094|DRUG|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
218978004|NCT04118504|DEVICE|Mobile application|Lifestyle intervention on through mobile application
219668946|NCT00001119|DRUG|Lamivudine/Zidovudine|
219668947|NCT00001119|DRUG|Ritonavir|
219668948|NCT00001119|DRUG|Abacavir sulfate|
219668949|NCT00001119|DRUG|Amprenavir|
219668950|NCT00001119|DRUG|Efavirenz|
219668951|NCT00001119|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
219668952|NCT00001119|DRUG|Lamivudine|
218978005|NCT01658631|DEVICE|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
218978006|NCT00586625|DRUG|Bepreve|One drop, both eyes, twice a day
219668953|NCT00001119|DRUG|Zidovudine|
219668954|NCT02907775|DEVICE|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
219668955|NCT02907775|DEVICE|Electrodes|electrodes placed over the radial nerve in radial grove
218978007|NCT00586625|DRUG|Placebo|One drop, both eyes, twice a day
218978008|NCT05991167|DEVICE|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
218978009|NCT03991858|OTHER|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
218978010|NCT03991858|OTHER|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
218978011|NCT02752204|DRUG|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
218978012|NCT02752204|DRUG|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
219668956|NCT06721637|COMBINATION_PRODUCT|Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.|Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds
219208662|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan + Prebiotic Fiber (Synbiotic Supplement)|This intervention involves daily supplementation of Lactogemikan (containing Lactobacillus plantarum) combined with prebiotic fibers from oat (3g per day). The synbiotic is designed to provide the benefits of both probiotics (to balance gut microbiota) and prebiotics (to support the growth of beneficial bacteria). This intervention is intended to improve the nutritional status of hemodialysis patients over a 6-month period. The dosage is one tablet daily, combined with 3g of oat fiber.
219668957|NCT06721637|DEVICE|Group B (n = 20): received whole body vibration trained three times a week for 8 weeks|The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
219668958|NCT02756598|DRUG|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
219668959|NCT02756598|DRUG|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
219668960|NCT02756598|DRUG|Propofol I|Continued dose of propofol 0.03 mg/kg/min
219668961|NCT02756598|DRUG|Propofol II|Continued dose of propofol 0.06 mg/kg/min
219668962|NCT02362152|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
219668963|NCT02362152|DRUG|5-fluorouracil|Topical field treatment as prescribed by dermatologist
219668964|NCT02362152|DRUG|Imiquimod|Topical field treatment as prescribed by dermatologist
219668965|NCT02362152|DRUG|Diclofenac|Topical field treatment as prescribed by dermatologist
219668966|NCT00657995|DEVICE|Artificial Pancreas (STG-22)|safe tool
219668967|NCT02226848|DRUG|Erythropoeitin|
219668968|NCT03420222|DRUG|AVP-786|oral capsules
219668969|NCT03420222|DRUG|Placebo|oral capsules
219668970|NCT04081116|OTHER|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
219668971|NCT04081116|OTHER|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
219668972|NCT04081116|OTHER|Preinclusion settings|Settings in use at start of study
219668973|NCT04066322|PROCEDURE|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
219668974|NCT04066322|OTHER|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
219668975|NCT02697734|DRUG|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
219668976|NCT02697734|DRUG|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
219208663|NCT06891248|PROCEDURE|Osteopathic Manipulative Treatment|See treatment arm
219208664|NCT06762158|RADIATION|Neoadjuvant Chemoradiotherapy|"Neoadjuvant chemoradiotherapy:~1. Radiation dose: 1.8Gy/Fx, DT41.4Gy/23Fx.~2. Concurrent chemotherapy: Albumin-bound paclitaxel 60mg/m² + Cisplatin 25mg/m² on D1, D8, D15, D22, D29."
219668977|NCT00001341|DRUG|ZD1694 (TOMUDEX)|
219668978|NCT01500655|PROCEDURE|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
219668979|NCT01500655|PROCEDURE|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
219668980|NCT03704506|DRUG|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
219668981|NCT03704506|DRUG|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
219668982|NCT03704506|DRUG|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
219668983|NCT03704506|DRUG|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
219668984|NCT04785560|DEVICE|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
219668985|NCT02483494|OTHER|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
219668986|NCT05808816|DRUG|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
219668987|NCT02334384|BIOLOGICAL|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
219668988|NCT01077102|OTHER|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
219668989|NCT02651688|DRUG|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
219668990|NCT02651688|DRUG|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
219668991|NCT01194193|DRUG|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
219668992|NCT03174288|OTHER|Exercise|24 weeks of exercise treatment
219668993|NCT03174288|DRUG|Spironolactone|24 weeks of spironolactone
218978013|NCT04941963|DIAGNOSTIC_TEST|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
219668994|NCT00006378|DRUG|carboplatin|
219668995|NCT00006378|DRUG|paclitaxel|
219668996|NCT00006378|RADIATION|radiation therapy|
218978014|NCT02140242|DRUG|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
218978015|NCT02140242|PROCEDURE|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
219068106|NCT06961448|DEVICE|Hyaluronate Gel for Injection|Apply a maximum of 1.5 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
219068107|NCT06961448|DEVICE|Polycaprolactone microsphere filler|Apply a maximum of 1.0 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
219068108|NCT06962150|PROCEDURE|Surgeon-placed transversus abdominis plane block|Participants will receive a transversus abdominis plane (TAP) block intraoperatively, administered by the operating plastic surgeon. The drug components of the TAP block are 20 ml liposomal bupivacaine (Exparel) mixed with 20 ml 0.5% bupivacaine.
219668997|NCT04971083|BEHAVIORAL|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
219668998|NCT05576428|BEHAVIORAL|Diet and exercise|diet and exercise in patients of NAFLD
219668999|NCT05576428|DRUG|NAC with diet and exercise|NAC with diet and exercise in patients of NAFLD
219669000|NCT01648192|DRUG|Losmapimod for single dose|Film coated white tablet
219669001|NCT01648192|DRUG|Losmapimod for repeat dose|Film coated white tablet
219669002|NCT04477967|OTHER|No intervention|There are no interventions because it is a protocol study
219669003|NCT05383833|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
219208665|NCT06762158|DRUG|neoadjuvant immunotherapy|Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
219208666|NCT06762158|PROCEDURE|Surgery|Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.
219208667|NCT06762158|DRUG|adjuvant immunotherapy|Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
219208668|NCT07039188|DEVICE|Use device in home environment|Patients will use the device in their home environment for four weeks.
219208669|NCT06777823|BEHAVIORAL|Social Rejection Task|All participants will receive this
219208670|NCT04150965|DRUG|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
219208671|NCT04150965|DRUG|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
219208672|NCT04150965|DRUG|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
218978016|NCT05352100|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
218978017|NCT06535425|OTHER|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
218978018|NCT06535425|OTHER|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
219208673|NCT04150965|DRUG|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
219208674|NCT04150965|DRUG|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
219208675|NCT06832566|DRUG|Fludrocortisone 0.1 Milligrams (mg)|Treatment of hypotension with fludrocortisone 0.05mg/day in patients with secondary adrenal insufficiency before Ramadan fasting. Outcomes (number of fasted days and complications during fasting) will be compared between Ramadan fasting 2025 (with fludrocortisone) and Ramadan 2023 (without fludrocortisone).
219208676|NCT06825598|BEHAVIORAL|Constraint-induced movement therapy|Constraint-induced movement therapy is a therapy for post-stroke patients to improve their motor functions
219208677|NCT06825598|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging is performed to monitor the changes in the brain of post-stroke patients along the course of intervention
219208678|NCT05501548|DRUG|Olaparib|Olaparib 300mg by mouth twice daily
218978019|NCT06535425|OTHER|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
218978020|NCT06535425|OTHER|Control|Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
219208679|NCT05501548|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
219208680|NCT06843278|OTHER|maternal breast milk|Very preterm infants receiving maternal breast milk
219208681|NCT06843278|OTHER|Donor breast milk|Very preterm infants receiving donor breast milk
219208682|NCT06844344|DIAGNOSTIC_TEST|forceps biopsies|5 forceps biopsies
219208683|NCT06844344|DIAGNOSTIC_TEST|Cryo biosies|5 cryo biopsies
219208684|NCT06855459|DEVICE|Biophoton Generators|Users will be receiving biophotons emitted from the 4 devices during sleep and other time.
219208685|NCT06745726|DRUG|Zestril|N/A, this is an observational study.
219208686|NCT06881836|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
219669004|NCT03910140|PROCEDURE|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
219669005|NCT00048165|DRUG|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
219669006|NCT00048165|DRUG|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
219669007|NCT00048165|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
219669008|NCT00048165|DRUG|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
219669009|NCT00048165|DRUG|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
219669010|NCT06352125|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
219669011|NCT06352125|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
219669012|NCT00279604|BEHAVIORAL|'Problem Profile Intervention' vs. WHO-Brief Intervention|
219669013|NCT03899012|PROCEDURE|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
219669014|NCT04303468|DIETARY_SUPPLEMENT|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
219669015|NCT04303468|OTHER|Placebo|Gelatin capsule containing powdered cellulose
219669016|NCT02387424|BEHAVIORAL|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
218978021|NCT03945266|BEHAVIORAL|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
218978022|NCT03945266|BEHAVIORAL|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
218978023|NCT03483025|OTHER|Skin Testing of Hair cleansing products|6 different commercially available shampoos
219068109|NCT06962150|PROCEDURE|Ultrasound-guided quadratus lumborum block|Participants will receive a quadratus lumborum (QL) block preoperatively, administered by the anesthesiologist under ultrasound guidance. The drug components of the QL block are 10 mg dexamethasone, 80 mg methylprednisolone acetate, plus either 0.25% or 0.5% bupivacaine at the dose of 0.25 mg/kg bupivacaine.
219669017|NCT02387424|BEHAVIORAL|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
219669018|NCT05715424|OTHER|Six interventions for children and adolescents|"* Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action."
219669019|NCT05216640|DEVICE|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
219669020|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
219669021|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
219068110|NCT02175433|DRUG|AGS67E|intravenous (IV) infusion
219068111|NCT03348670|DRUG|Abiraterone - Usual|"* Oral~* Abiraterone Combined Chemotherapy"
219068112|NCT03348670|DRUG|Abiraterone - Study|"* Oral~* Abiraterone Combined Chemotherapy"
219208687|NCT06881836|DRUG|Placebo|Placebo group: Two ONO-2020 placebo tablets will be orally administered once daily.
219208688|NCT06884813|DRUG|Conventional nanohybrid multishade composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with conventional multi shade nanohybrid Resin Based Composite (RBC) Filtek Z350Xt (3M ESPE, San Paul, MN, USA) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
219669022|NCT01575730|DRUG|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
219669023|NCT00018421|PROCEDURE|Treadmill Exercise|
219669024|NCT03344146|BEHAVIORAL|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
219669025|NCT03344146|BEHAVIORAL|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
219669026|NCT00600158|DRUG|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
219669027|NCT00600158|DRUG|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients \> 70 kg)
219669028|NCT01429441|DRUG|Ocriplasmin|0.125 mg single intravitreal injection
219669029|NCT01429441|OTHER|Sham injection|Sham injection
219669030|NCT00715871|DRUG|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
219669031|NCT00715871|DEVICE|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
219669032|NCT00042653|DRUG|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
219669033|NCT00042653|DRUG|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
219669034|NCT06055621|DRUG|Dasatinib|Daily orally administration of DASATINIB
218978024|NCT03206437|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
218978025|NCT03206437|BEHAVIORAL|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
218978026|NCT05171543|PROCEDURE|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
218978027|NCT04346082|BEHAVIORAL|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
218978028|NCT05886504|OTHER|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
218978029|NCT05984472|PROCEDURE|Edelweiss prefabricated veneers|Individual Randomized Clinical Trial
218978030|NCT05984472|PROCEDURE|Ceram-X Duo SphereTec with U-Veneer|Ceram-X Duo SphereTec with U-Veneer
218978031|NCT06966570|OTHER|Study Product A: Mixed-macronutrient beverage|Participants will consume a beverage that contains mixed macronutrients.
218978032|NCT06966570|OTHER|Study Product B: Single-macronutrient beverage|Participants will consume a beverage that contains a single macronutrient.
219669035|NCT03780972|DRUG|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
219669036|NCT03780972|PROCEDURE|Intravitreal Injection|Injection of study drug into the eye
219669037|NCT03780972|PROCEDURE|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
218978033|NCT04560543|PROCEDURE|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
218978034|NCT04560543|PROCEDURE|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
218978035|NCT04570267|BIOLOGICAL|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
218978036|NCT04570267|DRUG|Placebo|Sterile solution of CSL324 formulation buffer for injection
218978037|NCT04041739|DIAGNOSTIC_TEST|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
219068113|NCT05935540|OTHER|ACP-Family|"It consists of two sessions (45-60 mins) to be delivered within one month in a face-to-face format as long as the patient is still in the hospital. The treatment will be continued in the patient's home if he/she is discharged before the two sessions are completed.~The treatment will cover five elements in ACP, namely (1) patients' understanding of their illness, (2) patients' values and beliefs underpinning care preferences, (3) possible health conditions in the future, (4) introducing the idea of AD and its arrangement, and (5) construction of the role of substituted decision maker. A 3-min video on end-of-life treatment options will be shown to help patients and family members to clearly understand the related topic. However, there will be no restriction on the order of the five topics to be discussed during the intervention."
218978038|NCT03242824|DRUG|Fluorine F 18 Fluorodopa|Contrast used in PET
218978039|NCT03242824|RADIATION|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
218978040|NCT03242824|PROCEDURE|Positron Emission Tomography|imaging test
218978041|NCT03342521|DIAGNOSTIC_TEST|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
218978042|NCT04562493|PROCEDURE|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
219669038|NCT04159168|BEHAVIORAL|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
219669039|NCT04159168|BEHAVIORAL|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
218978043|NCT02972853|BEHAVIORAL|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
218978044|NCT02149615|OTHER|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
219669040|NCT00655603|OTHER|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
218978045|NCT03698331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
218978046|NCT03698331|DRUG|Placebo oral capsule|non-active dosage form
218978047|NCT03779958|OTHER|Mobile App|a mobile app that demonstrates hand therapy exercises
218978048|NCT03830112|BEHAVIORAL|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
218978049|NCT03830112|BEHAVIORAL|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
218978050|NCT02362178|PROCEDURE|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
218978051|NCT02362178|PROCEDURE|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
218978052|NCT00185770|BEHAVIORAL|Reducing television and other screen time (SMART curriculum)|
218978053|NCT02130024|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
218978054|NCT02130024|DRUG|Aflibercept 2.0 mg|Administered as an intravitreal injection
218978055|NCT03423134|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive
218978056|NCT03764085|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
218978057|NCT03764085|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
218978058|NCT02517216|OTHER|parabolic flight|
218978059|NCT02517216|DEVICE|MRI|
218978060|NCT05927584|PROCEDURE|Transanal local excision|Transanal full thickness local excision
218978061|NCT02933112|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
218978062|NCT01887223|PROCEDURE|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
218978063|NCT01887223|DRUG|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
218978064|NCT00398294|DRUG|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
218978065|NCT03878342|RADIATION|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
218978066|NCT03878342|OTHER|No Radiotherapy|No Irradiation- Active surveillance
218978067|NCT06312722|DEVICE|Optilume® BPH Catheter System|The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
218978068|NCT04183062|DRUG|Chemotherapy (gemcitabine & docetaxel) plus BIO-11006|"BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8."
218978069|NCT05732623|BEHAVIORAL|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions"
219669041|NCT01708720|DRUG|IPV|
219669042|NCT01708720|DRUG|Sabin-IPV|
219669043|NCT01708720|DRUG|Adjuvanted Sabin-IPV|
219669044|NCT05827588|DEVICE|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
219669045|NCT01349933|DRUG|Akt inhibitor MK2206|Given PO
219669046|NCT03142256|BEHAVIORAL|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
219669047|NCT03142256|DRUG|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
218978070|NCT05736198|DRUG|Dexmedetomidine|dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
218978071|NCT04490161|OTHER|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
219669048|NCT02957604|DRUG|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
218978072|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
218978073|NCT02799485|OTHER|Pharmacological Study|Correlative studies
218978074|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
218978075|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
218978076|NCT05942261|OTHER|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
218978077|NCT05635851|DRUG|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
218978078|NCT05635851|OTHER|Placebo sublingual spray|A placebo sublingual spray will be administered.
218978079|NCT04829448|DIETARY_SUPPLEMENT|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
218978080|NCT03755388|DEVICE|Episealer|Placing Episealer device
218978081|NCT06388382|OTHER|Alert tone demonstration|Patients are demonstrated the alert tone of their ICD
218978082|NCT06051591|BEHAVIORAL|Food FARMacia Program|Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.
218978083|NCT06051591|BEHAVIORAL|Self-directed meal preparation support|Nutrition education and anticipatory guidance to support healthy meal preparation
218978084|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, partial LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.
218978085|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
218978086|NCT06405139|DRUG|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
218978087|NCT06578559|DRUG|Cetuximab|500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
218978088|NCT06578559|DRUG|Encorafenib|300 mg once daily (four 75 mg oral capsules).
218978089|NCT04481113|DRUG|Abemaciclib|Given PO
218978090|NCT04481113|DRUG|Niraparib Tosylate Monohydrate|Given PO
218978091|NCT04526509|DRUG|GSK3901961|GSK3901961 as an IV infusion.
219068114|NCT06636604|OTHER|DSA(Decision Support Algorithm)|Intramuscular injection will be given to 30 volunteer patients using the decision support algorithm.
219068115|NCT06635772|DRUG|HS-10390|HS-10390 will be administered daily
219068116|NCT06635772|DRUG|Irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
219068117|NCT06634966|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
219068118|NCT06635096|DEVICE|Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)|These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
219068119|NCT06634446|DEVICE|a mobile application for cognitive training|"Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.~HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.~Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.~User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians."
219068120|NCT06634446|DEVICE|video games|Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement
219669049|NCT05971472|PROCEDURE|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior Root tears
219669050|NCT05971472|PROCEDURE|High tibial osteotomy|Open Wedge High tibial osteotomy for medial meniscus posterior Root tears
219669051|NCT00286065|DRUG|AeroLEF|
219669052|NCT01624402|BEHAVIORAL|Education on Stroke and Depression (ESD)|"* Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
219669053|NCT01624402|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|"1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
219669054|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
219669055|NCT00621517|DRUG|Bupropion|Partipants will receive 150 mg bupropion per night
219669056|NCT00621517|DRUG|Placebo|1 capsule nightly for six weeks
219669057|NCT05376020|DEVICE|Densah Burs|Densah Burs will be used in the intervention group
219669058|NCT05376020|DEVICE|Conventional Burs|Conventional Burs will be used in the control group
219669059|NCT01758159|DIETARY_SUPPLEMENT|Iron supplementation|
219669060|NCT01758159|OTHER|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
219669061|NCT04466605|OTHER|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
218978092|NCT04526509|DRUG|GSK3845097|GSK3845097 as an IV infusion.
218978093|NCT04526509|DRUG|GSK4427296|GSK4427296 as an IV infusion.
218978094|NCT04526509|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
219068121|NCT06635330|BIOLOGICAL|anti-CD19 CAR T cell therapy|Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
218978095|NCT04526509|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
218978096|NCT05491538|BEHAVIORAL|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
218978097|NCT05935514|BEHAVIORAL|WW Intervention|The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.
218978098|NCT05935514|BEHAVIORAL|Usual Care|The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
218978099|NCT04309812|DEVICE|transcranial direct current stimulation (tDCS)|Electrical stimulation of scalp over a seizure focus
219068122|NCT05059678|OTHER|Best Practice|Receive standard of care
219669062|NCT04466605|OTHER|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
219669063|NCT02949141|DEVICE|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
219669064|NCT02949141|DEVICE|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
219669065|NCT02949141|DEVICE|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
219669066|NCT03213418|BEHAVIORAL|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
219669067|NCT02779270|DRUG|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
219669068|NCT02779270|DRUG|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
219669069|NCT02249013|PROCEDURE|Cytoreductive Surgery (CRS)|CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
219669070|NCT02249013|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
219669071|NCT02249013|DRUG|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
219669072|NCT02249013|DRUG|Adjuvant Chemotherapy|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
219669073|NCT02249013|PROCEDURE|Fast-track recovery strategy|A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
219669074|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
219669075|NCT03429283|OTHER|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
218978100|NCT05925075|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
218978101|NCT03143322|RADIATION|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
218978102|NCT06235983|DRUG|LY3537982|Administered orally.
218978103|NCT05885542|DRUG|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
218978104|NCT05885542|DRUG|Placebo|Double-blind placebo oral solution administered once
218978105|NCT06277037|OTHER|Non-interventional|This is a rollover study
218978106|NCT03448653|OTHER|Colonoscopy with NBI|Colonoscopy with NBI
218978107|NCT02385214|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
218978108|NCT02385214|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
218978109|NCT05309590|DRUG|Dose|The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
219669076|NCT03063099|OTHER|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
219669077|NCT01425606|OTHER|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
219669078|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
219669079|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
219669080|NCT04498039|DEVICE|Portable Neuromodulation Stimulator|Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
219669081|NCT04475770|OTHER|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
219669082|NCT04475770|OTHER|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
218978110|NCT06501690|BEHAVIORAL|Late bedtime|Participants will go to bed 1 hour later than their habitual bedtime
218978111|NCT06501690|BEHAVIORAL|Variable bedtime|Participants will go to bed at a prescribed time that varies each day within +/-1 hour of habitual bedtime
218978112|NCT04340193|DRUG|nivolumab|Specified dose on specified days
218978113|NCT04340193|DRUG|ipilimumab|Specified dose on specified days
218978114|NCT04340193|PROCEDURE|TACE|TACE (Trans-arterial ChemoEmbolization)
218978115|NCT05274659|DRUG|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
218978116|NCT05274659|DRUG|Placebo|Placebo
218978117|NCT02912988|DRUG|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
218978118|NCT05455385|OTHER|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
218978119|NCT05455385|OTHER|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
218978120|NCT05455385|OTHER|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
218978121|NCT01999101|DRUG|Px-104|28 days treatment
218978122|NCT06529042|OTHER|Non-Interventional|Non-Interventional
218978123|NCT04449861|DRUG|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
218978124|NCT06541314|DRUG|Fluzoparib|Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.
218978125|NCT05084651|DRUG|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
218978126|NCT05084651|COMBINATION_PRODUCT|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
218978127|NCT05084651|DRUG|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
218978128|NCT05303272|DRUG|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
218978129|NCT05303272|DRUG|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
218978130|NCT00976677|DRUG|erlotinib hydrochloride|Given PO
218978131|NCT00976677|DRUG|paclitaxel|Given IV
218978132|NCT00976677|DRUG|carboplatin|Given IV
218978133|NCT00976677|BIOLOGICAL|bevacizumab|Given IV
218978134|NCT01689961|BEHAVIORAL|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
218978135|NCT06588218|OTHER|Watermelon|2.5 cups of whole fresh watermelon (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks
218978136|NCT06588218|OTHER|Belvita Breakfast Sandwich + 12 oz Water|Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
218978137|NCT04175054|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
218978138|NCT03507400|BEHAVIORAL|Introvision: mental and emotional self-regulation|Participants learn Introvision
218978139|NCT06589661|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
219669083|NCT02800395|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
219669084|NCT03353181|DEVICE|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
219669085|NCT03353181|DEVICE|Biliary stent|Standard placement of biliary stent
218978140|NCT05881460|DEVICE|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
218978141|NCT05881460|DEVICE|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
218978142|NCT01336192|DRUG|Gemcitabine|Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
218978143|NCT01336192|DRUG|Best supportive care|Best supportive care
218978144|NCT03260920|DRUG|Syntocinon|Intranasal Oxytocin
218978145|NCT00485433|DRUG|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
218978146|NCT00485433|DRUG|SKY0402|SKY0402 given during hernia repair
218978147|NCT03239964|DRUG|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
218978148|NCT03239964|OTHER|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
218978149|NCT06660550|PROCEDURE|laparoscopic inguinal hernia repair|traditional laparoscopic repair
218978150|NCT06660550|PROCEDURE|Needlescopic inguinal hernia repair|Needlescopic inguinal hernia repair
218978151|NCT04834752|OTHER|No intervention (Retrospective Cohort Observational)|History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
219068123|NCT05059678|OTHER|Educational Intervention|Receive educational materials and attend videoconference sessions
219068124|NCT05059678|OTHER|Questionnaire Administration|Ancillary studies
219068125|NCT06634628|RADIATION|Radioligand [11C]CHDI-00491009|Intravenous injection of radioligand in the arm with PET imaging of the brain.
219669086|NCT00073008|DRUG|GW572016 (lapatinib)|tyrosine kinase inhibitor
219669087|NCT06364202|DIETARY_SUPPLEMENT|Peanut Butter|2 tablespoons of peanut butter
219669088|NCT02130700|DRUG|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
219669089|NCT02130700|DRUG|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
219669090|NCT05194852|PROCEDURE|ultrasound-guided posterior hydrodilatation|Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
219669091|NCT05194852|DRUG|corticosteroid, saline, and local anesthetic|corticosteroid, saline, and local anesthetic
218978152|NCT06598033|DRUG|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
218978153|NCT06597760|DRUG|Enlicitide|Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
219068126|NCT06027216|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
219068127|NCT05997693|DRUG|Ticagrelor 90 MG|Ticagrelor 90 mg twice daily taken orally for one month
219068128|NCT05997693|DRUG|Low-dose aspirin|75-150 mg once daily taken orally
219068129|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
219068130|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
219068131|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
219669092|NCT05194852|OTHER|guided stretching and strengthening exercise program|guided stretching and strengthening exercise program
219669093|NCT00623857|DIETARY_SUPPLEMENT|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
219669094|NCT00623857|DIETARY_SUPPLEMENT|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
219669095|NCT00623857|DIETARY_SUPPLEMENT|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
219669096|NCT00623857|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
219669097|NCT04491526|DRUG|TAMSULOSIN Mepha Ret Depocaps 0.4 mg|"0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)"
219669098|NCT04491526|DRUG|Control Intervention|One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
218978154|NCT06597760|DRUG|Digoxin|Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
218978155|NCT02353754|DRUG|Intrathecal morphine injection|0.2 mg
218978156|NCT02353754|DRUG|EXPAREL|266 mg
218978157|NCT06002490|DRUG|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
218978158|NCT06002490|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
218978159|NCT06002490|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
218978160|NCT05961059|BIOLOGICAL|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
218978161|NCT05961059|BIOLOGICAL|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
218978162|NCT05961059|BIOLOGICAL|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
218978163|NCT05961059|BIOLOGICAL|Placebo|Placebo vaccination with commercially available saline solution.
218978164|NCT01672762|DRUG|ipragliflozin|oral
218978165|NCT06597916|BIOLOGICAL|Arexvy powder and suspension for injection|Arexvy powder and suspension for injection (RSV vaccine)
218978166|NCT06592300|DRUG|Tenofovir Alafenamide Film coated Tablet|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
218978167|NCT06592300|DRUG|Vemlidy® film-coated tablets|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
218978168|NCT06668155|PROCEDURE|Autograft Group|If assigned the autograft group, the surgeon will choose either bone patella tendon bone (BPTB) or all soft tissue quadriceps tendon for the graft. The graft choice will be based upon surgeon preference.
219068132|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
219068133|NCT00003878|PROCEDURE|conventional surgery|
219669099|NCT04842552|DRUG|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
219669100|NCT04842552|DRUG|Placebo|Placebo
219669101|NCT04540731|OTHER|This is an observational study without intervention|This is an observational study without intervention
219669102|NCT02392702|DRUG|C-10355|
219669103|NCT02392702|DRUG|C-10358|
219669104|NCT02392702|DRUG|Kalydeco|
219669105|NCT05569993|DRUG|Glutamine|.3 mg/kg of glutamine
219669106|NCT05569993|OTHER|Placcebo|Patients will recieve placcebo
219669107|NCT02676635|BEHAVIORAL|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
219669108|NCT03846128|BIOLOGICAL|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
218978169|NCT06668155|PROCEDURE|Allograft with LET Group|The allograft used will be a non-irradiated quadriceps tendon with bone plug allograft with a donor age less than 45 years.
218978170|NCT06468215|DRUG|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.|Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
218978171|NCT00630695|DRUG|Lanreotide LP 90|Lanreotide LP 90
218978172|NCT00630695|DRUG|Placebo lanreotide|Placebo
218978173|NCT03335111|OTHER|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
218978174|NCT03335111|PROCEDURE|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
218978175|NCT00289718|BIOLOGICAL|Twinrix™ adult|Intramuscular administration
219669109|NCT02862925|PROCEDURE|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
219669110|NCT00649233|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
219669111|NCT00649233|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
219669112|NCT02669667|DRUG|MEDI9314|single dose of MEDI9314
219669113|NCT02669667|DRUG|placebo|single dose of placebo
219669114|NCT00811993|DRUG|RG1507|Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
219669115|NCT00811993|DRUG|RO1507|27mg/kg iv, monotherapy
219669116|NCT00811993|DRUG|bevacizumab [Avastin]|as prescribed
219669117|NCT00811993|DRUG|capecitabine [Xeloda]|as prescribed
219669118|NCT00811993|DRUG|carboplatin|as prescribed
218978176|NCT05184075|PROCEDURE|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
219068134|NCT03850392|DEVICE|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
219669119|NCT00811993|DRUG|cetuximab|as prescribed
219669120|NCT00811993|DRUG|docetaxel|as prescribed
219669121|NCT00811993|DRUG|erlotinib [Tarceva]|as prescribed
219669122|NCT00811993|DRUG|etoposide|as prescribed
219669123|NCT00811993|DRUG|gemcitabine|as prescribed
219669124|NCT00811993|DRUG|irinotecan|as prescribed
219669125|NCT00811993|DRUG|mFOLFOX6|as prescribed
219669126|NCT00811993|DRUG|paclitaxel|as prescribed
219669127|NCT00811993|DRUG|pemetrexel|as prescribed
219669128|NCT00811993|DRUG|sorafenib|as prescribed
219669129|NCT00811993|DRUG|temozolomide|as prescribed
219669130|NCT00811993|DRUG|trastuzumab [Herceptin]|as prescribed
219669131|NCT02839876|DRUG|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
219669132|NCT02839876|DRUG|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
219669133|NCT00000997|DRUG|Zalcitabine|
219669134|NCT03985488|RADIATION|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
219669135|NCT04261010|PROCEDURE|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
219669136|NCT05513768|DIAGNOSTIC_TEST|level of myosin binding protein c in serum|Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
219669137|NCT05739656|PROCEDURE|CATARACT SURGERY|Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.
219669138|NCT01841034|DRUG|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
219669139|NCT04973241|RADIATION|OPG & CBCT|panoramic images , cone beam computed tomography
219669140|NCT00610233|PROCEDURE|deep brain stimulation ON|deep brain stimulation in the ON state
219669141|NCT00610233|PROCEDURE|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
218978177|NCT05184075|PROCEDURE|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
218978178|NCT02577497|DRUG|beclomethasone|
218978179|NCT02577497|DRUG|fluticasone|
218978180|NCT06517823|DRUG|Etoricoxib + Cyanocobalamin fixed dose|One tablet of 90 mg / 0.50 mg a day
218978181|NCT06517823|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
218978182|NCT03553771|DEVICE|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
218978183|NCT06557031|DIAGNOSTIC_TEST|ABTest Card®REF and ABTest Card®NEW|Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device).
218978184|NCT04029506|OTHER||this is an obsevational study which needs no interventions
218978185|NCT03252860|OTHER|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
218978186|NCT03866031|OTHER|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
218978187|NCT02165709|PROCEDURE|Salpingectomy|
218978188|NCT02165709|PROCEDURE|Traditional sterilization|
218978189|NCT05617443|DEVICE|stackable guide|different types of stackable guide
218978190|NCT00108433|DRUG|Cefazolin IV|
218978191|NCT00108433|DRUG|Linezolid IV|
218978192|NCT00108433|DRUG|Vancomycin (IV)|
218978193|NCT03243942|DRUG|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
218978194|NCT05409495|PROCEDURE|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
219068135|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
219068136|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
219068137|NCT01470027|DRUG|Placebo|effervescent tablets
219068138|NCT04704336|BEHAVIORAL|Task-shifting strategy for HTN control (TASSH) protocol|The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
219669142|NCT02721303|DIETARY_SUPPLEMENT|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
219669143|NCT02721303|PROCEDURE|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
219669144|NCT02721303|PROCEDURE|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
219669145|NCT06505278|DRUG|Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
219669146|NCT01218971|DRUG|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
219669147|NCT01218971|DRUG|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
219669148|NCT03406000|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
219669149|NCT03581617|DIAGNOSTIC_TEST|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~\- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
219669150|NCT03581617|DIAGNOSTIC_TEST|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
219669151|NCT03581617|DIAGNOSTIC_TEST|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
218978195|NCT05409495|PROCEDURE|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
219669152|NCT03581617|DIAGNOSTIC_TEST|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
219669153|NCT03581617|DIAGNOSTIC_TEST|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
218978198|NCT05544812|DRUG|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
218978199|NCT02319512|OTHER|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
218978200|NCT02319512|OTHER|Glucose|12ml glucose solution (13,6g) per day
218978201|NCT03473951|DIAGNOSTIC_TEST|Hyperuricemia|Hyperuricemia vs. normouricemia
218978202|NCT00978770|DRUG|systemic chemotherapy|
218978203|NCT00978770|PROCEDURE|diffusion-weighted magnetic resonance imaging|
218978204|NCT00978770|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
218978205|NCT00978770|PROCEDURE|magnetic resonance spectroscopic imaging|
218978206|NCT00978770|PROCEDURE|neoadjuvant therapy|
219669154|NCT06670833|OTHER|Lung ultrasound|Portable lung ultrasound
219669155|NCT06670833|OTHER|Standard of Care (SOC)|SOC antibiotic treatment
219669156|NCT04660773|DEVICE|NB UVB phototherapy|ultraviolet phototherapy sessions
219669157|NCT04660773|DRUG|Pregabalin|oral medication
219669158|NCT00347594|DEVICE|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
218978207|NCT05399654|DRUG|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
218978208|NCT01854242|OTHER|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
218978209|NCT02322073|PROCEDURE|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
218978210|NCT03002363|BEHAVIORAL|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
218978211|NCT03002363|BEHAVIORAL|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
218978212|NCT05890144|OTHER|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
219669159|NCT00347594|DEVICE|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
219669160|NCT04320953|DEVICE|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
219669161|NCT07005518|OTHER|No Intervention: Observational Cohort|This is a non-interventional observational study. It will simply look at the data and compare them between the monitors provided.
219669162|NCT06183125|BEHAVIORAL|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
219669163|NCT07019831|PROCEDURE|Body positioning|Each subject will breathe in both the supine and prone positions, randomly applied for 15 minutes each. The procedure will be performed twice: once for the assessment of respiratory physiology, and once for computed tomography acquisition.
219669164|NCT03443258|OTHER|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
219669165|NCT07022821|DRUG|Dexmedetomidine|"Dexmedetomidine infusion at one of the following doses:~Group A: 0.2 µg/kg/hr Group B: 0.3 µg/kg/hr Group C: 0.4 µg/kg/hr Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
219669166|NCT07022821|DRUG|ketamine|"Ketamine infusion at a fixed dose of 0.25 mg/kg/hr administered in all three groups.~Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
219669167|NCT07022951|OTHER|Preoperative fasting|This cohort study assesses the duration of preoperative fasting and its clinical effects
219669168|NCT00687882|OTHER|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
219669169|NCT00687882|OTHER|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
219669170|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
219669171|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
219669172|NCT07025967|BEHAVIORAL|Mölkky|The Mölkky group participants receive two-hour weekly or bi-weekly Mölkky training sessions at their elderly community centers. In the sessions, participants are divided into two teams, taking turns throwing a wooden pin called the Mölkky to hit 12 smaller skittles. The fallen skittles are placed upright where they landed after each turn. The first team that reaches exactly 50 points wins.
219669173|NCT07025967|BEHAVIORAL|Home activity|The participants in the home program receive weekly visits by social workers, physiotherapists, or occupational therapists at their homes for an activity regime including closed-skilled exercises and cognitive training. The closed-skilled exercises included stretching, elastic band exercises and functional exercises like tandem standing and bridging. Cognitive training included reality orientation, memory exercises, calculation, and mind-body exercises like Baduanjin.
218978213|NCT05890144|OTHER|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
218978214|NCT05890144|OTHER|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
218978215|NCT02372370|PROCEDURE|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
218978216|NCT02372370|PROCEDURE|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
218978217|NCT02372370|PROCEDURE|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
218978218|NCT02372370|PROCEDURE|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
219068139|NCT03646513|DEVICE|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
219068140|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
219068141|NCT01993524|OTHER|placebo|antibiotic plus placebo
219208689|NCT06884813|DRUG|Single shade nanohybrid composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
219208690|NCT06842160|DEVICE|intervention group|A smart electrocardiogram watch based on the PPG algorithm for monitoring atrial fibrillation load after catheter ablation.
219669174|NCT00653302|DRUG|Lantus (insulin glargine) + Glucophage (Metformin)|
219669175|NCT05447676|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
219208691|NCT06818513|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
219669176|NCT05447676|OTHER|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
219669177|NCT05447676|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
219669178|NCT05447676|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
219669179|NCT02071082|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
219669180|NCT04620954|DRUG|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
219669181|NCT04620954|DRUG|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
219669182|NCT04620954|DRUG|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
219669183|NCT00624650|DRUG|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
219669184|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP\<8 or measured PaOP \<12mmHg in addition to concurrent urine output of \<0.5 ml/kg/hr
219669185|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases \> 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map \< 60 or who are on vasopressors that also have a measured GEDI less than goal"
219669186|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
219669187|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60"
218978219|NCT02372370|PROCEDURE|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
218978220|NCT02372370|DRUG|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
218978221|NCT02372370|OTHER|Untreated Control|Untreated control. No interventions.
218978222|NCT03487523|BEHAVIORAL|Text Message|As already stated
218978223|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
218978224|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
218978225|NCT04948788|DRUG|Gemcitabine-Oxaliplatin|Gemcitabine-Oxaliplatin
218978226|NCT06556628|DEVICE|Increased Body Temperatures|Collecting data on patients whose body temperatures increase due to fighting an illness.
218978227|NCT00068328|PROCEDURE|psychosocial assessment and care|
218978228|NCT00068328|PROCEDURE|quality-of-life assessment|
218978229|NCT00971880|OTHER|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
218978230|NCT02753933|OTHER|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
218978231|NCT02753933|OTHER|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
218978232|NCT01081288|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
218978233|NCT02266498|DRUG|BIBB 515 BS|
218978234|NCT02266498|OTHER|Standard breakfast (40 g fat)|
219208692|NCT06818513|DIETARY_SUPPLEMENT|Gastrostomy|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
219669188|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5"
219669189|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
219669190|NCT00624650|OTHER|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP \> 60 and off vasopressors for \>12 hours, as well as patients with a measured cardiac index \>2.5 that also have a measured GEDI \> goal."
219669191|NCT00624650|DRUG|Diuresis (furosemide) part II|"Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period"
219669192|NCT00624650|PROCEDURE|Dialysis|"1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
219669193|NCT02320227|DEVICE|Miami w/o frag Personal lubricant|
219669194|NCT00038870|BIOLOGICAL|Dendritic Cell Activated Lymphocyte|
218978235|NCT00082342|DEVICE|Phoressor II (IOMED)|sham stimulation
218978236|NCT00082342|DEVICE|Phoressor II (IOMED)|real tDCS stimulation
218978237|NCT03302650|DRUG|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
218978238|NCT03302650|DRUG|Normal saline|Patients will receive normal saline.
219208693|NCT06818513|DIETARY_SUPPLEMENT|Oral tube feeding|During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219669195|NCT06648889|DRUG|Isatuximab|Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
219669196|NCT06648889|DRUG|Isatuximab|Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
219669197|NCT00840697|BEHAVIORAL|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
219669198|NCT00840697|BEHAVIORAL|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
219669199|NCT00840697|BEHAVIORAL|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
219669200|NCT04561297|DIAGNOSTIC_TEST|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
219669201|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
219669202|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
219669203|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
219669204|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
219669205|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
219669206|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
219669207|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
219669208|NCT06915883|DEVICE|Relaxation virtual reality (VR)|A newly developed self-guided app BreezeTrerraVR that helps patients practice relaxation breathing in an immersive virtual environment, using voice prompts, visual cues, and respiratory biofeedback for guidance. The app was developed in the VR center at the National Institute of Mental Health, Czech Republic (supported by THE JOHANNES AMOS COMENIUS PROGRAMME (OP JAC) EXCELLENCE IN RESEARCH, Title: Research of Excellence on Digital Technologies and Wellbeing, Project Registration Number: CZ. 02.01.01/00/22\_008/0004583).
219669209|NCT06915883|DEVICE|Experiential virtual reality (VR)|"The experiential VR intervention will use the VR program Ocean Rift (an experience of the underwater world and its animals). It is a calm experiential and distraction game program that does not require much mobility and interaction and is therefore suitable for pediatric patients and hospital environments. This VR application is also used in available published research."
219669210|NCT00958412|DRUG|Proellex®|one (1) 25 mg capsule daily
219669211|NCT06066723|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
219669212|NCT05037084|OTHER|no intervention|no intervention
219669213|NCT05940025|DEVICE|MORT-LBP|The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
219669214|NCT05940025|OTHER|treatment as usual (TAU)|In the control group, education and physiotherapy is delivered and self-exercise is recommended.
219669215|NCT06326411|DRUG|NST-628|NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
219208694|NCT06810869|DRUG|human induced pluripotent stem cell derived exosomes （GD-iExo-003）|human induced pluripotent stem cell derived exosomes （GD-iExo-003）
219208695|NCT06810869|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|a placebo of exosomes derived from human induced pluripotent stem cell for injection
219208696|NCT06820151|OTHER|Sample collection|Sample collection: EVT sponges, tissue brushings and pinch biopsies
219669216|NCT03862872|DIETARY_SUPPLEMENT|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
219669217|NCT03862872|DIETARY_SUPPLEMENT|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
219669218|NCT03862872|OTHER|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
219669219|NCT02227368|DRUG|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
219669220|NCT02227368|DRUG|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
219669221|NCT02411344|DRUG|Pertuzumab|"* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
218978239|NCT03302650|DRUG|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
218978240|NCT04806503|DRUG|UNR844|Ophthalmic solution for topical ocular administration
218978241|NCT04806503|DRUG|Placebo|Placebo
218978242|NCT03589469|DRUG|Loncastuximab tesirine|intravenous infusion
218978243|NCT01182610|DRUG|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
218978244|NCT01182610|DRUG|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
219360324|NCT05381246|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
219669222|NCT04337476|DEVICE|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
219669223|NCT06045494|DIETARY_SUPPLEMENT|Meiji Yogurt Group|Participants in this arm need to eat assigned product for 12 weeks, one bottle each day.
219669224|NCT00495989|PROCEDURE|saliva sampling + dental calculus collection|
219669225|NCT02175329|DEVICE|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
219669226|NCT02175329|DEVICE|Manually layered veneering|
218978245|NCT01182610|DRUG|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
218978246|NCT01182610|DRUG|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
218978247|NCT01694264|DRUG|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
218978248|NCT01694264|DRUG|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
218978249|NCT03267836|DRUG|Avelumab|-10mg/kg IV
218978250|NCT03267836|RADIATION|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
219669227|NCT03765229|DRUG|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
219669228|NCT03765229|DRUG|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
219669229|NCT01160380|DRUG|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
219669230|NCT01160380|DRUG|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
219669231|NCT02851212|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
219669232|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219669233|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219669234|NCT02851212|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219669235|NCT04798326|DRUG|MW032|Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
219669236|NCT04798326|DRUG|Xgeva®|Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
218978251|NCT03267836|PROCEDURE|Surgery|-Standard of care
218978252|NCT04650022|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
218978253|NCT02031796|OTHER|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
218978254|NCT04195906|DRUG|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
218978255|NCT04195906|DRUG|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
219068142|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
219068143|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
218978256|NCT04195906|DRUG|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
219669237|NCT02524626|PROCEDURE|Sham stimulation|Sham stimulation
218978257|NCT05377879|DEVICE|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
218978258|NCT03950479|DIAGNOSTIC_TEST|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
218978259|NCT04418674|DRUG|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
218978260|NCT04418674|DRUG|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
219068144|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
219068145|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
219068146|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
219669238|NCT02524626|PROCEDURE|Vagus stimulation|Vagus stimulation
219669239|NCT02510820|DEVICE|comfilcon A|soft contact lens
219669240|NCT02510820|DEVICE|Synergi|Multipurpose solution
219669241|NCT02510820|DEVICE|Biotrue|Multipurpose solution
219669242|NCT02510820|OTHER|stenfilcon A|daily disposable contact lenses for washout period
219669243|NCT00479830|BEHAVIORAL|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
219669244|NCT00479830|BEHAVIORAL|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
219669245|NCT00479830|BEHAVIORAL|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
219669246|NCT05050422|DIAGNOSTIC_TEST|Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)|control/study group
218978261|NCT03746171|DIAGNOSTIC_TEST|Colonic polyp characterization by BLI|"All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
218978262|NCT03127046|DRUG|Aceclofenac|Oral single dose administration of aceclofenac 200mg
218978263|NCT03127046|DRUG|Esomeprazole|Oral single dose administration of aceclofenac 200mg
218978264|NCT03127046|DRUG|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
218978265|NCT00546104|DRUG|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
218978266|NCT04725422|DRUG|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978267|NCT04725422|DRUG|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978268|NCT04725422|DRUG|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978269|NCT04725422|DRUG|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978270|NCT04725422|DRUG|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978271|NCT04725422|DRUG|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978272|NCT04725422|DRUG|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978273|NCT04725422|DRUG|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978274|NCT04725422|DRUG|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978275|NCT04725422|DRUG|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
218978276|NCT04725422|DRUG|NSAID|first-line treatment
218978277|NCT02006888|DRUG|IBI-10090|
218978278|NCT02006888|DRUG|Placebo|Placebo
218978279|NCT02554695|DRUG|placebo|subcutaneous saline injection
218978280|NCT02554695|DRUG|denosumab|single subcutaneous injection of denosumab 60 mg
218978281|NCT05204251|BEHAVIORAL|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
218978282|NCT03485391|BEHAVIORAL|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
218978283|NCT00371826|DRUG|Everolimus (RAD001)|
219068147|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
219360325|NCT05381246|OTHER|Reiki|In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
219360326|NCT02900703|BIOLOGICAL|stool samples|
219360327|NCT00598299|PROCEDURE|venous puncture|venous puncture
218978284|NCT00371826|DRUG|Cyclosporine (Calcineurin Inhibitor (CNI))|
218978285|NCT00371826|DRUG|Methylprednisone/prednisone|
219068148|NCT03116139|DIAGNOSTIC_TEST|V/Q imaging|Standard of care
218978286|NCT00371826|DRUG|Mycophenolate sodium (MPA)|
218978287|NCT02649270|BIOLOGICAL|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
219068149|NCT03116139|DIAGNOSTIC_TEST|Computed tomography scan|Standard of care
219068150|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
219360328|NCT00598299|OTHER|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
219360329|NCT01765894|OTHER|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
219669247|NCT00719940|BEHAVIORAL|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
219669248|NCT00719940|OTHER|Waiting group|No intervention
219669249|NCT06122467|OTHER|EQ Exfoliating Cleanser|Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
219669250|NCT06122467|OTHER|EQ Gel|Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
218978288|NCT05682365|BEHAVIORAL|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
218978289|NCT02488161|OTHER|No intervention|
218978290|NCT05652881|PROCEDURE|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
218978291|NCT02050243|DRUG|5ALA|20mg/kg of oral suspension of 5ALA
219669251|NCT06122467|OTHER|EQ Moisturizer|Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
218978292|NCT04775069|BIOLOGICAL|BNT162b2|Intramuscular injection
218978293|NCT04775069|BIOLOGICAL|CoronaVac|Intramuscular injection
218978294|NCT04775069|BIOLOGICAL|AZD1222|Intramuscular injection
218978295|NCT03100097|DEVICE|Aspen Horizon 627 LSO|
219068151|NCT03869229|BIOLOGICAL|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
219068152|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
219068153|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
219068154|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
219068155|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
219068156|NCT05770544|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80 m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
219068157|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
219068158|NCT00001059|DRUG|Doxorubicin hydrochloride (liposomal)|
219068159|NCT00001059|DRUG|Filgrastim|
219068160|NCT00001059|DRUG|Bleomycin sulfate|
219068161|NCT00001059|DRUG|Vincristine sulfate|
219068162|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
219068163|NCT02219932|DRUG|fampridine|
219068164|NCT02219932|DRUG|Placebo|Matched placebo
219669252|NCT01512433|PROCEDURE|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
219068165|NCT01866410|DRUG|Cabozantinib S-malate|Given PO
219068166|NCT01866410|DRUG|Erlotinib Hydrochloride|Given PO
219669253|NCT01512433|PROCEDURE|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
219669254|NCT03046056|DRUG|Filgotinib|Tablet(s) administered orally once daily
218978296|NCT06222190|RADIATION|online-adaptive radiotherapy|A conebeam CT is taken to determine the current tumour extent and the deformations occurring in comparison to the dose distribution to be applied. Normal tissues heart, lung and tracheal tree are automatically contoured by the Ethos therapy system in that cone-beam CT. A specialist physician and a physicist are present during this process. These organ contours are used to determine the extent of the current target volume and the adaptive radiotherapy plan is adjusted to the new target volume. If the current tumour extent is not sufficiently covered by the initial radiotherapy plan planned for the series with its planned tolerances, or if the surrounding normal tissue is exposed to too much radiation, then the online adaptive radiotherapy plan for the current treatment is selected by the specialist. Otherwise, the initial radiotherapy plan is used for IGRT.
218978297|NCT05218135|OTHER|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
218978298|NCT04047329|OTHER|general anesthesia or neuraxial anesthesia|
218978299|NCT06463834|DRUG|Sintilimab|"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"
219068167|NCT01866410|OTHER|Laboratory Biomarker Analysis|Correlative studies
219068168|NCT02742727|BIOLOGICAL|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
219068169|NCT06529653|PROCEDURE|autogenous bone wedge|autogenous bone block harvested from chin and adjusted to be wedged intercortical in split ridge
219068170|NCT00489450|DRUG|SK3530|
219068171|NCT01490346|DRUG|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
219068172|NCT03497923|DRUG|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
219068173|NCT01989650|OTHER|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
219068174|NCT01989650|OTHER|No break|No break will be provided
219068175|NCT00112073|DRUG|bapineuzumab|IV, Q13w
219068176|NCT00112073|OTHER|placebo|IV Q13w
219068177|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
219068178|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
219068179|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
219068180|NCT00003269|BIOLOGICAL|sargramostim|
219068181|NCT00003269|DRUG|amifostine trihydrate|
219068182|NCT00003269|DRUG|cisplatin|
219068183|NCT00003269|DRUG|cyclophosphamide|
219068184|NCT00003269|DRUG|etoposide|
219669255|NCT03046056|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
219669256|NCT03001245|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
219669257|NCT03001245|BEHAVIORAL|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
219669258|NCT01282333|DRUG|gemcitabine hydrochloride|Given IV
219669259|NCT01282333|DRUG|veliparib|Given orally
219669260|NCT01282333|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219669261|NCT01282333|OTHER|pharmacological study|Correlative studies
219669262|NCT01282333|DRUG|cisplatin|Given IV
219669263|NCT05683951|DRUG|DWKH|Administration of DWKH three times daily
219669264|NCT05683951|DRUG|DWKH-R|Administration of DWKH-R three times daily
219669265|NCT05683951|DRUG|Placebo|Administration of Placebo three times daily
219669266|NCT02874833|OTHER|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
219669267|NCT00500253|DEVICE|exhaled nitric oxide measurement|exhaled nitric oxide measurement
219669268|NCT00500253|PROCEDURE|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
219669269|NCT00500253|PROCEDURE|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
219669270|NCT06320353|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
219669271|NCT06320353|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
219669272|NCT03492905|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
219669273|NCT02913105|DRUG|LMB763|Hard Gelatin Capsules
218978300|NCT05508711|DEVICE|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
218978301|NCT03402646|BEHAVIORAL|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
218978302|NCT03402646|BEHAVIORAL|Photovoice|Same as described under arm/group descriptions
218978303|NCT00573183|BEHAVIORAL|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
218978304|NCT00573183|BEHAVIORAL|Treatment as Usual|
218978305|NCT01164800|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
218978306|NCT01164800|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
218978307|NCT01126801|DRUG|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
219068185|NCT03330665|BEHAVIORAL|Meditation|Meditate 3 times a week using headspace app
219068186|NCT00216684|DRUG|fentanyl|
219068187|NCT04389840|DRUG|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
219068188|NCT04389840|DRUG|Placebo|0.9% Normal Saline
219068189|NCT03057548|PROCEDURE|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
219068190|NCT03057548|PROCEDURE|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
219068191|NCT03577002|OTHER|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
219068192|NCT04279249|OTHER|HEPA Air Filtration|2 HEPA air filters placed in home (one in bedroom, one in living room) for 30 days
219669274|NCT02913105|DRUG|Placebo|Hard Gelatin Capsule
219669275|NCT00543998|DEVICE|Optical Measurement transillumination|Optical Measurement of sinus
219669276|NCT02924805|OTHER|Telemedical care|Telemedically guided care based on a standard operating procedure
219669277|NCT00202891|DRUG|sisomicin|
218978308|NCT01126801|OTHER|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
218978309|NCT00004488|DRUG|alendronate sodium|
218978310|NCT00004488|DRUG|calcium carbonate|
218978311|NCT00004488|DRUG|cholecalciferol|
218978312|NCT03994107|DRUG|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
218978313|NCT03994107|DRUG|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
218978314|NCT03994107|DRUG|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
219669278|NCT01317004|DRUG|Fingolimod|0.5 mg/day oral capsule
219669279|NCT01317004|DRUG|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
219669280|NCT03370692|OTHER|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
219669281|NCT00818740|DRUG|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
219669282|NCT04118179|OTHER|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
219669283|NCT02727309|DRUG|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
219669284|NCT00768573|DRUG|sildenafil|Oral suspension of sildenafil.
219669285|NCT04645329|DEVICE|shoulder immovilization sling|immobilization of the arm after surgery
219669286|NCT02379455|OTHER|Comprehensive drug review|1\) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
219669287|NCT04409977|DIAGNOSTIC_TEST|MRI examination|Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
219669288|NCT02092649|DIETARY_SUPPLEMENT|Omega-3 Complete|
219669289|NCT02092649|DIETARY_SUPPLEMENT|Placebo Pill|
219669290|NCT01526278|DRUG|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
219669291|NCT00300846|DRUG|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
219669292|NCT00300846|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
219669293|NCT04067596|PROCEDURE|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
219669294|NCT04835883|BIOLOGICAL|CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)|Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
219669295|NCT02642783|BEHAVIORAL|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
219669296|NCT02642783|BEHAVIORAL|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
219669297|NCT04664907|OTHER|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
219669298|NCT03092947|OTHER|No intervention|
218978315|NCT01805375|DRUG|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
218978316|NCT04467606|BEHAVIORAL|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
218978317|NCT00428792|DRUG|Methylphenidate 20 mg long-acting capsules|
218978318|NCT04816266|DEVICE|Iol master|Iol master measures the distance between anterior pole of the cornea and the anterior surface of the lens to calculate the anterior chamber depth
218978319|NCT04816266|DEVICE|Pentacam|The Pentacam HR calculates Anterior chamber depth from the corneal endothelial layer along a line from the apex of the cornea to the anterior surface of the lens
218978320|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
218978321|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
219669299|NCT00264251|BEHAVIORAL|Weight loss through diet and exercise|
219669300|NCT00264251|DRUG|Rosiglitazone insulin sensitizing agent|
219669301|NCT00640731|DEVICE|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
219669302|NCT01533948|DRUG|axitinib|Given PO
219669303|NCT01533948|OTHER|laboratory biomarker analysis|Correlative studies
219669304|NCT01156909|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
219669305|NCT06478082|DEVICE|Home-based virtual reality training|8-week training with an advised frequency of 30 minutes per day, for 5 days per week.
219669306|NCT03726801|OTHER|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
219669307|NCT01221558|DIETARY_SUPPLEMENT|lycopene|
219669308|NCT01212146|DIETARY_SUPPLEMENT|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.
219669309|NCT01212146|DIETARY_SUPPLEMENT|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
219669310|NCT01344759|DRUG|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
219669311|NCT01344759|DRUG|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
219669312|NCT02664064|BEHAVIORAL|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
219669313|NCT01153009|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
219669314|NCT01153009|DRUG|Duloxetine|Overencapsulated duloxetine delayed-release capsules
219669315|NCT01153009|DRUG|Placebo|Placebo-matching capsules
219669316|NCT01856998|DRUG|Propofol|
219669317|NCT01856998|DRUG|Diprivan|
219669318|NCT05788484|DRUG|CDX-585|CDX-585 is administered by infusion every 2 weeks
219669319|NCT00399711|DRUG|repaglinide and metformin combination tablet|
219669320|NCT00399711|DRUG|rosiglitazone and metformin combination tablet|
219669321|NCT04723589|BIOLOGICAL|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
219669322|NCT04444336|BEHAVIORAL|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
219669323|NCT00910117|DRUG|nimotuzumab|nimotuzumab 400 mg d1
219669324|NCT00910117|DRUG|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
219669325|NCT04003623|DRUG|Pemigatinib|Pemigatinib administered orally once daily.
219669326|NCT01469598|DRUG|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
219669327|NCT00623298|BEHAVIORAL|Narrative Exposure Therapy|
219669328|NCT00623298|BEHAVIORAL|group IPT|
219669329|NCT00623298|OTHER|6 months-baseline|
219669330|NCT02918097|DRUG|Lithium Carbonate|
219669331|NCT02918097|DRUG|Sertraline|
219669332|NCT02918097|DRUG|Nortriptyline|
219669333|NCT02918097|DRUG|Risperidone|
219669334|NCT00703326|BIOLOGICAL|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
219669335|NCT00703326|DRUG|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
219669336|NCT00703326|OTHER|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
219669337|NCT00892814|RADIATION|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
219669338|NCT00892814|RADIATION|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
219669339|NCT00063336|BEHAVIORAL|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
219669340|NCT00063336|BEHAVIORAL|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
219669341|NCT02076347|BEHAVIORAL|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
219669342|NCT02076347|BEHAVIORAL|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
219669343|NCT02961387|DEVICE|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
219669344|NCT02961387|DEVICE|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
219669345|NCT05964439|DEVICE|HoloUS app for ultrasound visualization|Study participants will wear HoloLens see-through glasses and use the HoloUS app for ultrasound visualization in the conduct of a vascular access procedure in a phantom.
219669346|NCT01673087|DRUG|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
219669347|NCT01673087|DRUG|Dexamethasone|"Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
219669348|NCT01673087|DRUG|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
219669349|NCT01673087|DRUG|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
219669350|NCT02242019|DEVICE|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
219669351|NCT02425462|DRUG|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
219669352|NCT04316260|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
219669353|NCT04316260|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
219669354|NCT06427629|DEVICE|Imaging of conjunctival goblet cell|After instillation of moxifloxacin and illuminating with a 405nm light source using confocal fluorescence microscopy, conjunctival goblet cell imaging will be performed in patients with ocular surface disease and patients scheduled for ocular surgery without ocular surface disease
219669355|NCT01744483|DEVICE|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
219669356|NCT01744483|DEVICE|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
219669357|NCT01744483|DEVICE|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
218978322|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
219669358|NCT05727748|OTHER|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
219669359|NCT05727748|OTHER|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
219669360|NCT05727748|OTHER|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
219669361|NCT02942121|OTHER|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
219669362|NCT02375425|OTHER|no intervention|no intervention-specimen collection study only
219669363|NCT01589588|DEVICE|Open Hudson Mask|Mask type 1 oxygen
219669364|NCT01589588|DEVICE|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
218978323|NCT01926015|BIOLOGICAL|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
218978324|NCT01926015|BIOLOGICAL|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
218978325|NCT00639678|DRUG|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
218978326|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
218978327|NCT00639678|DRUG|placebo|40 mg/kg placebo, single dose (day 0), Group 4
218978328|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
219669365|NCT01589588|DEVICE|Mask 3|Mask type 3 oxygen
219669366|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 oxygen
219669367|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 placebo
219669368|NCT04690335|BIOLOGICAL|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
219669369|NCT04690335|OTHER|Placebo|Saline solution
219669370|NCT05201443|DEVICE|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
219669371|NCT05201443|DEVICE|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
219669372|NCT02287688|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
219068193|NCT04279249|OTHER|Sham HEPA Air Filtration|2 HEPA air filter devices with filter removed placed in home (one in bedroom, one in living room) for 30 days
218978329|NCT00897208|OTHER|high performance liquid chromatography|
218978330|NCT00897208|OTHER|laboratory biomarker analysis|
218978331|NCT00897208|OTHER|mass spectrometry|
218978332|NCT00897208|OTHER|medical chart review|
219068194|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
219068195|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
219068196|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
218978333|NCT00897208|PROCEDURE|evaluation of cancer risk factors|
218978334|NCT05938517|DRUG|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
218978335|NCT05938517|DRUG|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
219068197|NCT03776981|OTHER|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
219068198|NCT03776981|OTHER|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
219068199|NCT05898867|OTHER|Saline|Open label intra-articular injection of isotonic saline.
219068200|NCT01659723|DRUG|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
219068201|NCT03806985|DRUG|Placebo oral capsule|microcrystalline cellulose capsule
219068202|NCT03806985|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
219068203|NCT03806985|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
219068204|NCT02252211|DRUG|DS-8895a 1 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
219669373|NCT02888561|DRUG|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
219669374|NCT02888561|DRUG|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
219669375|NCT04895852|DEVICE|TEAS|The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
219669376|NCT04895852|DEVICE|Sham TEAS|The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
219669377|NCT01115387|OTHER|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
219669378|NCT01115387|OTHER|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
219669379|NCT00161668|DRUG|Mylotarg|
219669380|NCT02603510|DRUG|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
219669381|NCT02603510|DRUG|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
219669382|NCT05372185|BEHAVIORAL|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
219669383|NCT05372185|BEHAVIORAL|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
219669384|NCT02827175|OTHER|blood sample|
219669385|NCT03214679|OTHER|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
219669386|NCT03214679|OTHER|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
219669387|NCT03992677|OTHER|No intervention|No intervention
219669388|NCT01227525|DEVICE|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
219669389|NCT05212584|BIOLOGICAL|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219669390|NCT02889146|OTHER|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
219669391|NCT02889146|OTHER|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
219068205|NCT02252211|DRUG|DS-8895a 3 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
219068206|NCT02252211|DRUG|DS-8895a 10 mg/kg|Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
219068207|NCT05499429|DEVICE|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
219068208|NCT03116594|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
219068209|NCT03116594|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
219068210|NCT03727191|OTHER|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
219068211|NCT03727191|OTHER|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
219669392|NCT02889146|OTHER|Respiratory therapy|Respiratory therapy according to the service routine.
219669393|NCT03147976|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
219669394|NCT00645372|DRUG|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
219068212|NCT02540200|DEVICE|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
219669395|NCT00645372|DRUG|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
219068213|NCT02540200|PROCEDURE|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
219669396|NCT05155956|OTHER|transcranial Doppler ultrasonography (TCD)|"Transcranial Doppler (TCD) is a non-invasive ultrasound-based technique that facilitates insonation of the cerebral arteries. TCD probe design enables continuous monitoring of cerebral blood flow velocity (CBFv). TCD has a variety of clinical applications, including intraoperative monitoring for detection of microemboli. The TCD probe can be comfortably secured to the patient's head by a headframe in order to maintain continuous vessel insonation. Microembolic signals (MES) can be reliably detected based on standard criteria:~1. Brief in duration (\<300msec)~2. High intensity (amplitude \>3 dB above background)~3. Unidirectional~4. Audible chirp or snap~Further, CBFv monitoring during may inform flow perturbations that occur during cardiac or vascular manipulations."
219669397|NCT04013685|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
219669398|NCT01601067|BEHAVIORAL|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
219669399|NCT01601067|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
219669400|NCT03231137|COMBINATION_PRODUCT|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
219669401|NCT03231137|DRUG|ATV gel|Atorvastatin gel
219669402|NCT03231137|BIOLOGICAL|PRF|Platelet rich fibrin
219669403|NCT03231137|BIOLOGICAL|PRGF|plasma rich in growth factor
219669404|NCT04722536|PROCEDURE|Cervico-isthmic cerclage|There is no intervention in this study. It's an observational retrospective study, before/after.
219669405|NCT05922137|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
219669406|NCT05922137|BEHAVIORAL|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
219068214|NCT04481048|DRUG|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
219068215|NCT04481048|OTHER|Placebo|Eight (8) weeks of treatment with placebo.
219068216|NCT03569280|COMBINATION_PRODUCT|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
219068217|NCT05467644|PROCEDURE|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
219669407|NCT00693485|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
219669408|NCT00693485|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
219669409|NCT00693485|DRUG|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
219068218|NCT00968669|BIOLOGICAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
219669410|NCT01142492|DRUG|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
219669411|NCT05612269|DIAGNOSTIC_TEST|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
219669412|NCT03156569|DIAGNOSTIC_TEST|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
219068219|NCT00968669|BIOLOGICAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
219068220|NCT00968669|BIOLOGICAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
219068221|NCT00968669|OTHER|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
219068222|NCT01560520|BEHAVIORAL|Physical activity|Observation only
219360330|NCT03078465|DRUG|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
219360331|NCT03078465|DRUG|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
219360332|NCT04480177|DEVICE|foot insole|the subject was instructed to wear foot insole for 8 hours.
219669413|NCT01712048|PROCEDURE|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
219669414|NCT01712048|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
219669415|NCT04901234|RADIATION|Standard radiotherapy +/- chemotherapy|No radiotherapy adaptation unless major dosimetric deviation
219669416|NCT04901234|RADIATION|Experimental radiotherapy +/- chemotherapy|Systemic MRI-based radiotherapy adaptation mid-treatment
219669417|NCT00313287|DRUG|clevudine|
219669418|NCT06380933|OTHER|experimental group|first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
219669419|NCT03923049|DIAGNOSTIC_TEST|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
219669420|NCT03083353|DRUG|Isradipine|Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
219068223|NCT04669704|OTHER|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
219360333|NCT04480177|OTHER|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
219669421|NCT03083353|BEHAVIORAL|Cue Exposure|Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
219669422|NCT05251064|DEVICE|Suture|Standard suture wound closure device.
219669423|NCT05251064|DEVICE|Clozex|Interlaced adhesive wound closure device.
219669424|NCT05251064|DEVICE|Zipline|Adhesive wound closure device using zip-tie like strips.
219669425|NCT02771860|DRUG|denosumab|60mg sc
219669426|NCT02771860|DRUG|Placebo|identical syringe
219669427|NCT02771860|DIETARY_SUPPLEMENT|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
219669428|NCT01754766|DRUG|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
219669429|NCT01754766|OTHER|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
219669430|NCT05671159|OTHER|Blood sample|A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
218978336|NCT04883229|DEVICE|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
218978337|NCT00536679|DRUG|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
218978338|NCT00536679|DRUG|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
218978339|NCT00536679|DRUG|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
218978340|NCT06398236|DIETARY_SUPPLEMENT|SE5-OH tablets|SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
218978341|NCT01364649|DRUG|Vortioxetine|Vortioxetine tablets
218978342|NCT01364649|DRUG|Escitalopram|Escitalopram tablets
218978343|NCT01364649|DRUG|Placebo|Vortioxetine Placebo-matching capsules
218978344|NCT04863040|BEHAVIORAL|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
218978345|NCT01566734|OTHER|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
218978346|NCT01566734|OTHER|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
218978347|NCT00257465|BIOLOGICAL|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
218978348|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
218978349|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|2.5 million cells
218978350|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0.5 million cells
218978351|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0 cells
218978352|NCT04166500|PROCEDURE|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
218978353|NCT02538081|DRUG|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
218978354|NCT02538081|DRUG|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
218978355|NCT03760055|DEVICE|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
218978356|NCT04715425|PROCEDURE|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
218978357|NCT04715425|PROCEDURE|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
218978358|NCT05225649|BEHAVIORAL|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
218978359|NCT00972582|DIETARY_SUPPLEMENT|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
218978360|NCT04443699|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
218978361|NCT05591807|OTHER|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
218978362|NCT03299465|BEHAVIORAL|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
219669431|NCT03435159|DIAGNOSTIC_TEST|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
219669432|NCT03435159|PROCEDURE|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
219669433|NCT03435159|DEVICE|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
218978363|NCT02938429|OTHER|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
218978364|NCT00545766|DRUG|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
218978365|NCT02114801|DEVICE|manual brushing|Tooth brushing
218978366|NCT02114801|DEVICE|electric toothbrush linked|Tooth brushing
218978367|NCT02114801|DEVICE|off electric toothbrush|Tooth brushing
218978368|NCT03116360|DIAGNOSTIC_TEST|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
218978369|NCT03423641|DRUG|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
218978370|NCT00804284|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
218978371|NCT00804284|BIOLOGICAL|Other DTap Vaccines|0.5 mL, Intramuscular
218978372|NCT02710396|DRUG|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
219068224|NCT04669704|OTHER|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
218978373|NCT02710396|DRUG|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
218978374|NCT02710396|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
218978375|NCT02710396|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
218978376|NCT05170464|BEHAVIORAL|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
218978377|NCT05170464|DRUG|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
218978378|NCT04732143|OTHER|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
219669434|NCT06174194|DIETARY_SUPPLEMENT|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
219669435|NCT06020248|OTHER|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
219669436|NCT00559169|DRUG|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
219669437|NCT02163317|RADIATION|stereotactic radiosurgery|Undergo MRI-guided focal SRS
219669438|NCT02163317|DEVICE|magnetic resonance imaging|Undergo staging MRI with contrast
219669439|NCT02163317|OTHER|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
219669440|NCT02163317|PROCEDURE|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
219669441|NCT02163317|PROCEDURE|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
219669442|NCT02163317|BEHAVIORAL|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
219669443|NCT05926466|DRUG|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
218978379|NCT02010710|DEVICE|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
218978380|NCT06516822|PROCEDURE|CPVI-MLA|The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.
218978381|NCT06516822|PROCEDURE|CPVI only|After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
218978382|NCT00889408|BIOLOGICAL|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
218978383|NCT01115361|BEHAVIORAL|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
218978384|NCT03154593|OTHER|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
218978385|NCT03652883|OTHER|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
218978386|NCT03652883|OTHER|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
218978387|NCT02298985|DRUG|Curcumin|3 g/day (3 capsules/day) for 6 months
218978388|NCT02298985|DRUG|placebo|3 g/day (3 capsules/day) for 6 months
218978389|NCT01459237|DRUG|Acthrel|Ovine Corticorelin
218978390|NCT04066647|DRUG|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
218978391|NCT00902668|DRUG|lovastatin|
218978392|NCT00902668|OTHER|questionnaire administration|
218978393|NCT00902668|PROCEDURE|adjuvant therapy|
218978394|NCT00902668|RADIATION|accelerated partial breast irradiation|
218978395|NCT00902668|RADIATION|external beam radiation therapy|
218978396|NCT01209507|OTHER|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
218978397|NCT01914757|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
218978398|NCT01914757|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
218978399|NCT04224038|OTHER|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
218978400|NCT02973490|DEVICE|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
218978401|NCT05130918|DEVICE|Phenolmicin P3 and Bosexil suppository|The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
218978402|NCT05139082|DRUG|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
218978403|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
218978404|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
218978405|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
219669444|NCT05926466|DRUG|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
219669445|NCT05926466|DRUG|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
218978406|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
218978407|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
218978408|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
218978409|NCT03509883|DRUG|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
218978410|NCT03509883|DRUG|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
218978411|NCT01499758|DRUG|Atorvastatin|80 Mg tablets
219669446|NCT05926466|DRUG|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
218978412|NCT00333177|BEHAVIORAL|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
218978413|NCT00333177|BEHAVIORAL|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
218978414|NCT00333177|DRUG|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
218978415|NCT00333177|DRUG|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
218978416|NCT03564431|DEVICE|Magnetic resonance|magnetic resonance spectrum of brain
218978417|NCT03959631|BEHAVIORAL|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
219669447|NCT02309450|DRUG|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
219669448|NCT00855699|DRUG|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
219669449|NCT05742113|DEVICE|Masimo Radical-7|perfusion index measuring device
219669450|NCT02752711|PROCEDURE|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
219669451|NCT02006433|DEVICE|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
219669452|NCT03972501|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
219669453|NCT03972501|DRUG|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
219669454|NCT01709409|DRUG|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
219669455|NCT01709409|DRUG|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
218978418|NCT04799574|OTHER|music therapy activities|"Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities."
218978419|NCT02884882|OTHER|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
218978420|NCT03278756|BEHAVIORAL|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
218978421|NCT03278756|BEHAVIORAL|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
219068225|NCT03675386|OTHER|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
219068226|NCT03675386|OTHER|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
219068227|NCT05282381|BEHAVIORAL|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
219068228|NCT03818139|OTHER|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
219068229|NCT05542368|DIAGNOSTIC_TEST|Thyroid tests|Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
219669456|NCT02412878|DRUG|Carfilzomib|Carfilzomib was administered as an IV infusion
219669457|NCT02412878|DRUG|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
219669458|NCT02190721|DRUG|tbo-filgrastim|5 μg/kg
219669459|NCT04482738|OTHER|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
219669460|NCT03703674|DRUG|GCSF|Granulocyte-colony stimulating factors (G-CSF)
219669461|NCT02377128|PROCEDURE|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
219669462|NCT02377128|PROCEDURE|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
219669463|NCT04571385|DRUG|AP30663|Administer by intravenous infusion.
219669464|NCT04571385|DRUG|Placebo|Placebo matched to AP30663.
219669465|NCT04831996|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
219669466|NCT04046263|DRUG|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
219068230|NCT05487508|DRUG|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
219068231|NCT05487508|DRUG|Normal saline|Placebo (NaCl 0.9%)
219068232|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219068233|NCT03926507|OTHER|Fluciclovine F18|Given IV
219068234|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219068235|NCT00061295|PROCEDURE|Body weight support treadmill training|
219068236|NCT00144339|DRUG|tiotropium|
219068237|NCT00144339|DRUG|placebo|
219068238|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
219068239|NCT02268838|DRUG|E6007|
219068240|NCT02268838|DRUG|E6007 matching placebo|
219068241|NCT02529319|PROCEDURE|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
219068242|NCT02529319|PROCEDURE|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
219068243|NCT01273727|DRUG|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
219068244|NCT01273727|DRUG|dexamethasone|intravitreal implant 0.7 mg duration 6 months
219068245|NCT01109992|DRUG|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
219068246|NCT01109992|DRUG|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
219068247|NCT00232804|DEVICE|Bx Cypher stent|
219068248|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
219068249|NCT06270901|OTHER|High Protein Planetary Health Diet|Planetary Health Diet Meal with 62 g of protein primarily from plant origin
219068250|NCT06270901|OTHER|Low Protein Planetary Health Diet|Planetary Health Diet Meal with 36 g of protein primarily from plant origin
219068251|NCT06270901|OTHER|High Protein Western Diet|Western Diet Meal with 62 g of protein primarily from animal origin
219068252|NCT06270901|OTHER|Low Protein Western Diet|Western Diet Meal with 36 g of protein primarily from animal origin
219068253|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
219068254|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
219068255|NCT00013312|PROCEDURE|Determine colonic tone|
219068256|NCT05059691|OTHER|Electronic Health Record Review|Review of medical records
219669467|NCT01142505|DRUG|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
219669468|NCT01142505|DRUG|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
219669469|NCT02263729|DRUG|Losartan|Cozaar
219669470|NCT02263729|DRUG|Placebo|
219669471|NCT02562599|DRUG|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
219669472|NCT02562599|RADIATION|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
219068257|NCT05059691|PROCEDURE|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
219068258|NCT02564575|BIOLOGICAL|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
219068259|NCT05794464|PROCEDURE|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
219068260|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
219068261|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
219068262|NCT01752192|DEVICE|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
218978422|NCT00004195|DRUG|eniluracil|Will be given to either subject pre-operative and metastatic disease
218978423|NCT00004195|PROCEDURE|conventional colon surgery|Only if the subject is amenable to surgical resections
218978424|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|UNSUP will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
219068263|NCT04626791|DRUG|Acalabrutinib|Given PO
219669473|NCT01212159|DEVICE|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
219669474|NCT05025332|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
219669475|NCT02301819|DEVICE|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
219669476|NCT02301819|OTHER|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
219669477|NCT05475834|DRUG|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
219669478|NCT06133959|BEHAVIORAL|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
219669479|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
219669480|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
219669481|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
219068264|NCT04626791|DRUG|Bortezomib|Given SC
219669482|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
219669483|NCT01306214|DRUG|BI 10773|BI 10773 low dose once daily
219669484|NCT01306214|DRUG|BI 10773|BI 10773 high dose once daily
219669485|NCT04663854|DRUG|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
218978425|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|UNSUP+ will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
218978426|NCT05619250|BEHAVIORAL|Supervised center-based exercise group without motivational intervention (SUP)|SUP will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
219068265|NCT04626791|DRUG|Cyclophosphamide|Given IV
219068266|NCT04626791|DRUG|Cytarabine|Given IV
219068267|NCT04626791|DRUG|Doxorubicin Hydrochloride|Given IV
219068268|NCT04626791|DRUG|Prednisone|Given PO
219068269|NCT04626791|BIOLOGICAL|Rituximab|Given IV
219068270|NCT04626791|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV
219068271|NCT02532660|DRUG|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
219068272|NCT02532660|DRUG|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
219068273|NCT02532660|DRUG|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
219068274|NCT02532660|DRUG|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
219208697|NCT06773832|DIAGNOSTIC_TEST|Real-time Artificial Intelligence Model for Diagnosing Colorectal Polyp Pathology and Endoscopic Classification|"During the AI model development phase, the aim is to include as many samples as possible. Given the focus on the diagnostic accuracy of serrated lesions, we retrospectively collected approximately 400 cases serrated lesions with pathological diagnosis by the department of pathology at Peking Union Medical College Hospital to date. Additionally, we matched with 400 cases each of hyperplastic polyps, conventional adenomas, and early-stage colorectal cancer, totaling approximately 1600 cases.~The model employs mainstream AI classification algorithms to construct the model and compare the predictive performance of different models. Utilizing the dataset established in the first phase, which contains static images of polyp lesions along with their corresponding pathological diagnosis and endoscopic classifications, we developed and optimized the AI model. Then the model will be be compared with endoscopists in a prospective cohort to investigate the efficacy."
219208698|NCT06872983|PROCEDURE|cyanoacrylate tissue adhesive beside sutures|"A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication.~In this study group, the implant is secured to the vaginal wall with cyanoacrylate tissue adhesive. Fixation of the implant to the cervix and promontory will be identical to the control group."
219208699|NCT06872983|PROCEDURE|Suture|A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication. In this control group, the mesh will be fixed to the cervix with four non-absorbable sutures. In addition, the implant will be fixed to the anterior vaginal wall with four absorbable sutures and to the posterior vaginal wall with four absorbable sutures. The implant will be secured to the promontory with one non-absorbable suture.
219068275|NCT05727605|BEHAVIORAL|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
219068276|NCT05727605|DIAGNOSTIC_TEST|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
219068277|NCT05727605|BEHAVIORAL|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
219208700|NCT06851494|DEVICE|PMMA|Safety and efficacy evaluation of PMMA LinneaSafe 30% use for gluteal augmentation. Linnea Safe is a water-based gel containing Polymethylmethacrylate (PMMA) in concentrations of 2%, 10% or 30%. LInnea Safe is indicated for facial and body volumetric correction in cases of lipodystrophy due to the use of antiretrovirals in HIV-positive patients. It is also indicated for facial volumetric correction, and can be used in nasolabial folds, glabellar lines, corners of the mouth, upper lip lines, chin lines/chin lines, in the malar region, in acne scars, on the nose, to increase lips and facial contour.
219208701|NCT06841874|DRUG|Taletrectinib|Oral capsule
219208702|NCT06865430|DRUG|Tamsulosin Hydrochloride|Alpha blockers will be started and symptoms will be questioned.
219208703|NCT06865430|OTHER|Sham|Patients who were not started on alpha blockers will constitute this group.
219669486|NCT00779753|DIETARY_SUPPLEMENT|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
219669487|NCT04116775|BIOLOGICAL|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
219669488|NCT04116775|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
219669489|NCT04116775|DRUG|Enzalutamide|Daily oral dose.
219669490|NCT02956707|OTHER|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
219208704|NCT04446442|DEVICE|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
219208705|NCT06873542|DRUG|DC05F01|DC05F01 capsule
219208706|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
219669491|NCT01928199|DRUG|Sitagliptin|
219669492|NCT01928199|DRUG|Placebo|
219669493|NCT06311071|DIAGNOSTIC_TEST|calcium score|Calcium score of coronaries obtained fro coronary CT angiography
219669494|NCT06311071|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography from radial artery with contrast injection
219669495|NCT00046540|DRUG|Liposome-encapsulated SN38|
219068278|NCT05727605|OTHER|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
219068279|NCT05847218|DRUG|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
219068280|NCT05847218|DRUG|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
219068281|NCT03131076|DIAGNOSTIC_TEST|IPMN follow up|Follow up with MRI and laboratory blood tests
219669496|NCT02799121|DEVICE|ReGenerCell™ Autologous Cell Harvesting Device|
219669497|NCT06186596|DEVICE|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
219669498|NCT03405571|OTHER|No intervention|No intervention
219669499|NCT02748759|DEVICE|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
219068282|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
219068283|NCT01990469|DRUG|Gemigliptin|DPP-4 inhibitor
219068284|NCT01990469|DRUG|Gemigliptin placebo|Placebo of Gemigliptin
219068285|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
219068286|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
219068287|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
219068288|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
219068289|NCT03578900|DRUG|Xeros|
219068290|NCT03578900|DRUG|Citric Acid based Mouthwash|
219068291|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
219068292|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
219068293|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
219208707|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
219208708|NCT04794114|DEVICE|experimental ankle foot orthosis|On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
219068294|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
219068295|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
219068296|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
219068297|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
219669500|NCT02748759|OTHER|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
219669501|NCT03574688|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
219669502|NCT04099537|BEHAVIORAL|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
219068298|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
219068299|NCT01903447|DRUG|SSRI|
219068300|NCT01903447|BEHAVIORAL|CBT|
219068301|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
219068302|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
219068303|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
219068304|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
219068305|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
219068306|NCT00221793|PROCEDURE|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
219068307|NCT03149783|DRUG|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
219068308|NCT03149783|DRUG|sodium chloride|Placebo
219068309|NCT02897804|BEHAVIORAL|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
219068310|NCT02897804|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068311|NCT02897804|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219068312|NCT02897804|BEHAVIORAL|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068313|NCT02897804|BEHAVIORAL|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219068314|NCT02897804|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219669503|NCT02926261|OTHER|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
219669504|NCT00003190|DRUG|cytarabine|Given IV
219669505|NCT00003190|DRUG|daunorubicin hydrochloride|Given IV
219669506|NCT00003190|DRUG|etoposide|Given IV
219669507|NCT00003190|DRUG|valspodar|Given IV
219669508|NCT03479138|DIAGNOSTIC_TEST|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
219669509|NCT05274529|BEHAVIORAL|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
218978427|NCT05619250|BEHAVIORAL|Supervised center-based exercise group with motivational intervention (SUP+)|SUP+ will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
218978428|NCT04613050|OTHER|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
218978429|NCT04613050|OTHER|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
218978430|NCT00386386|OTHER|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
218978431|NCT02833350|DRUG|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
218978432|NCT02833350|DRUG|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
218978433|NCT02833350|DRUG|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
218978434|NCT02833350|DRUG|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
218978435|NCT02833350|DRUG|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
218978436|NCT06166485|OTHER|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
218978437|NCT03343379|OTHER|Core stability tests|A test battery comprised of field tests to evaluate core stability
219068315|NCT02897804|BEHAVIORAL|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219208709|NCT04794114|DEVICE|traditional ankle foot orthosis|The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
219208710|NCT06752122|DRUG|Placebo (in SAD)|Inhalation once daily in the SAD part
219208711|NCT06752122|DRUG|RCS-21 (in SAD)|Inhalation once daily in the SAD part
219669510|NCT05274529|BEHAVIORAL|Work ability|A remote coaching programme concentrating on work ability
219669511|NCT05274529|BEHAVIORAL|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
219669512|NCT05274529|BEHAVIORAL|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
219669513|NCT05274529|OTHER|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
219669514|NCT04150536|DRUG|Lidocaine topical system 1.8%|
219669515|NCT05208268|DRUG|Pariet|Pariet Tablets.
219669516|NCT00823485|PROCEDURE|fibrinolysis in situ|intraventricular injection of actilyse
219669517|NCT00823485|PROCEDURE|drainage|drainage
218978438|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
218978439|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
218978440|NCT02915796|BIOLOGICAL|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
219669518|NCT04295369|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
218978441|NCT02915796|BIOLOGICAL|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
218978442|NCT02915796|PROCEDURE|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
219068316|NCT02897804|BEHAVIORAL|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219669519|NCT03027245|DRUG|Eribulin|
219669520|NCT06699381|DEVICE|use of spinal mouse|Spinal Mouse (SM) is an external non-invasive measurement device that evaluates the spinal angle and shape in the frontal and sagittal planes
219669521|NCT06699381|DIAGNOSTIC_TEST|Brunnstrom's Hemiplegia Recovery Staging|According to Brunnstrom's stages of recovery, the individual will be identified at which stage
218978443|NCT02915796|BIOLOGICAL|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
218978444|NCT00567307|DRUG|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
218978445|NCT00567307|OTHER|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
218978446|NCT05155150|BEHAVIORAL|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
218978447|NCT03922997|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
218978448|NCT03879395|PROCEDURE|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
218978449|NCT05138107|OTHER|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
218978450|NCT05138107|OTHER|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
218978451|NCT01500031|DEVICE|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
218978452|NCT05560776|PROCEDURE|Endobronchial ultrasound|Two or three passes per lymph node
218978453|NCT02210546|OTHER|Magnetic Resonance Imaging (MRI)|
218978454|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|
218978455|NCT03809676|OTHER|periodontal examination|clinical measurements were recorded
219068317|NCT02897804|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
219068318|NCT02897804|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219208712|NCT06752122|DRUG|Placebo (MAD)|Inhalation once daily for seven days in the MAD part
219208713|NCT06752122|DRUG|RCS-21 (in MAD)|Inhalation once daily for seven days in the MAD part
219669522|NCT06699381|DIAGNOSTIC_TEST|The six minute walking test (6MWT)|It evaluates the functional capacity of the individual and it provides valuable information regarding all the systems during physical activity, including pulmonary and cardiovascular systems, blood circulation, neuromuscular units, body metabolism, and peripheral circulation
218978456|NCT04940767|DRUG|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
218978457|NCT04940767|DRUG|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
218978458|NCT02420522|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
218978459|NCT02420522|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
218978460|NCT01414660|PROCEDURE|transplantation|transplantation of islet, kidney or liver
218978461|NCT05280171|OTHER|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
218978462|NCT05280171|OTHER|Standard of care|Standard of care
218978463|NCT04284852|DRUG|Niraparib|PARP inhibitor
218978464|NCT02657538|OTHER|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
218978465|NCT02657538|OTHER|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
218978466|NCT02657538|DEVICE|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
219208714|NCT06751966|COMBINATION_PRODUCT|Combination Product: Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
219669523|NCT06699381|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|"Functional Reach Test (FRT) is a clinical outcome measure and assessment tool for ascertaining dynamic balance in in simple task.~In standing, measures the distance between the length of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support.~This information is correlated with risk of falling A number of factors exert a major influence on this evaluation: Research revealed that movement strategy and reduced spinal flexibility both affect reach distance."
219669524|NCT06699381|DIAGNOSTIC_TEST|Mini Balance Evaluation Systems Test (Mini-BESTest)|"This test measures dynamic balance, functional mobility, and gait. It is commonly used in populations who have or have had multiple sclerosis (MS), Parkinson disease (PD), strokes, spinal cord injury (SCI), or cancer.~The Mini-BESTest was developed in 2010 from the Balance Evaluation Systems Test (BESTest), then revised in 2013 to clarify inconsistencies in scoring. The scoring instructions were different in the published and online versions. The revision clarified that the Mini-BESTest should be scored out of 28 points. Explanations for how to score items 3, 6, and 14 were also given.~The Mini-BESTest consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest."
219669525|NCT06699381|DIAGNOSTIC_TEST|The five Times Sit to Stand Test (5x Sit-To-Stand Test)|It's used to asses functional lower limbs strength, transitional movements, balance, and fall risk in older adults.
219669526|NCT06699381|DIAGNOSTIC_TEST|The Postural Assessment Scale for Stroke (PASS)|The Postural Assessment Scale for Stroke (PASS) is an outcome measure specifically designed to assess and monitor postural control after stroke. It was developed in 1999 as an adaptation of the Fugl-Meyer Assessment balance subscale\[1\]. It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting or standing posture
219669527|NCT06699381|DIAGNOSTIC_TEST|Postural Symmetry Index and Weight Transfer Symmetry|It is a form of measurement in which two scales are used to calculate the weight transferred to the intact and stroke limb. The values obtained as a result of the test are calculated with formulas.
219669528|NCT06699381|DIAGNOSTIC_TEST|Measurement of the craniovertebral angle|Measurement of the craniovertebral angle; the patient is asked to find the most natural position by flexion and extension of the head in the standing position and a photograph is taken with a digital camera from a distance of 1.5 m to the shoulder level of the patient and this process is repeated 3 times. The images obtained are then digitally calculated with the help of an appropriate program.
219669529|NCT00285376|DRUG|vilazodone|titration to 40mg tablets qd for 8 weeks
219669530|NCT06490250|OTHER|Inspiratory Muscle Training|The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day
219669531|NCT06490250|OTHER|Baduanjin Exercise|The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
219669532|NCT03451955|OTHER|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
219669533|NCT02625246|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
219669534|NCT03993977|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
219669535|NCT03993977|OTHER|Conventional treatment|Clinical judgement and conventional coagulation tests
219669536|NCT01889732|DEVICE|ROTEM|
218978467|NCT02657538|OTHER|Visual examination and bitewing (BW) radiography|established diagnostic methods
218978468|NCT02802943|BIOLOGICAL|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
218978469|NCT02802943|DRUG|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
218978470|NCT03356756|DIAGNOSTIC_TEST|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
218978471|NCT03764696|DEVICE|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
218978472|NCT03169543|BEHAVIORAL|Sleep deprivation|36-hours total sleep deprivation
218978473|NCT02100800|OTHER|MR and CT measurements of emphysema quantification|
218978474|NCT04337268|DRUG|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
218978475|NCT04337268|DRUG|saline 0.9%|Intravenous infusion for 60 min.
219669537|NCT03921632|BEHAVIORAL|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
219669538|NCT04575584|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
219669539|NCT04575584|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
219669540|NCT03541447|DRUG|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
219669541|NCT03541447|DRUG|Octreotide LAR|A single dose of two 20 mg i.m. injections.
219669542|NCT03541447|OTHER|Placebo|A single dose of two 20 mg i.m. injections.
219669543|NCT06148155|RADIATION|[68Ga]Ga-NOTA-RG2 PET Imaging|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
219669544|NCT05481827|GENETIC|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
219669545|NCT00528918|DRUG|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
219669546|NCT03243123|DEVICE|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
218978476|NCT02927327|DEVICE|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
218978477|NCT02927327|DEVICE|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
218978478|NCT01814631|OTHER|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
219068319|NCT02897804|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219669547|NCT05080738|OTHER|Upper Extremity Home Exercises|"The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders."
219669548|NCT03033160|DRUG|Estradiol Ring|
219669549|NCT03739801|DRUG|Liposomal Irinotecan|Given IV
219669550|NCT03739801|OTHER|Quality-of-Life Assessment|Ancillary studies
218978479|NCT01814631|OTHER|image quality and resolution|image quality and resolution will be viewed on the EU-me2
218978480|NCT00815607|DRUG|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
218978481|NCT00815607|BIOLOGICAL|INXN-3001|Intratumoral injection
218978482|NCT01856907|DRUG|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
219669551|NCT03739801|OTHER|Questionnaire Administration|Ancillary studies
219669552|NCT03739801|BIOLOGICAL|Ramucirumab|Given IV
219669553|NCT02788188|BIOLOGICAL|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
219669554|NCT02788188|OTHER|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
219068320|NCT02897804|BEHAVIORAL|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219208715|NCT06751966|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219208716|NCT06766643|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;
218978483|NCT01856907|DRUG|Metformin|Biguanide- insulin sensitizer
218978484|NCT01856907|DRUG|Placebo pill|Will evaluate effect of lifestyle and diet only
218978485|NCT01604408|BIOLOGICAL|LY2495655|Administered SC
218978486|NCT01604408|DRUG|Placebo|Administered SC
218978487|NCT03660345|PROCEDURE|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
218978488|NCT03660345|DRUG|Intravitreal injection|Intravitreal ziv-Aflibercept
218978489|NCT00917501|DRUG|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
218978490|NCT00917501|DRUG|Placebo|Placebo given twice a day which will be compared to Omega 3
218978491|NCT05668884|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
218978492|NCT01691131|OTHER|Exercise training|Comparison of high intensity exercise training on land versus water.
218978493|NCT04553679|BEHAVIORAL|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
218978494|NCT02759484|BEHAVIORAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
218978495|NCT02759484|BEHAVIORAL|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
218978496|NCT00722332|BIOLOGICAL|HepaGam B|Hepatitis B Immunoglobulin
218978497|NCT04435587|DRUG|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
218978498|NCT04435587|DRUG|Combined ART/hydroxychloroquine|"1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
218978499|NCT00111501|BEHAVIORAL|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
219068321|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219068322|NCT02897804|BEHAVIORAL|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219208717|NCT06766643|PROCEDURE|Radiofrequency ablation therapy|Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions
219208718|NCT06771609|DRUG|Adebry single antibody + VEX metronomic chemotherapy + radiotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
218978500|NCT00111501|BEHAVIORAL|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
218978501|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
218978502|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
218978503|NCT00871325|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
218978504|NCT01232777|DRUG|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
218978505|NCT03151343|DRUG|Empagliflozin|Empagliflozin tablet
218978506|NCT03151343|DRUG|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
218978507|NCT03945214|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
218978508|NCT03945214|BEHAVIORAL|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
218978509|NCT03945214|BEHAVIORAL|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
218978510|NCT00392860|DEVICE|Natural-Fit|Ergonomic handrim for wheelchairs
218978511|NCT00392860|DEVICE|PalmRim|Ergonomic handrim for wheelchair
218978512|NCT00392860|DEVICE|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
218978513|NCT02573168|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
218978514|NCT02573168|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
218978515|NCT02573168|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
218978516|NCT02847975|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium nitrate will be ingested orally
218978517|NCT00388830|PROCEDURE|Ultrasound|
218978518|NCT06365112|PROCEDURE|Endoscopy assisted|Endoscopy
218978519|NCT03109730|DRUG|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
218978520|NCT03109730|DRUG|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
218978521|NCT03109730|DRUG|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
218978522|NCT03109730|DRUG|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
218978523|NCT03109730|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
218978524|NCT02418429|OTHER|waxy maize starch|pancake test meal with waxy maize starch only
218978525|NCT02418429|OTHER|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
219068323|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219208719|NCT06771609|DRUG|debry single antibody + VEX metronomic chemotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
218978526|NCT02418429|OTHER|Resistant Starch|pancake test meal with resistant starch only
218978527|NCT02418429|OTHER|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
218978528|NCT01733784|OTHER|Induced central apneas|
218978529|NCT02328183|DRUG|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
218978530|NCT05820945|OTHER|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
218978531|NCT03566784|PROCEDURE|Inguinal hernia repair|Standard procedure for inguinal hernia repair
218978532|NCT03441269|DRUG|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
218978533|NCT03359772|OTHER|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
218978534|NCT03855969|PROCEDURE|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
218978535|NCT02940535|DRUG|Diphereline (Triptorelin embonate)|
218978536|NCT02940535|DRUG|Decapeptyl (Triptorelin)|
218978537|NCT02940535|DRUG|human menopausal gonadotropin|
218978538|NCT02940535|DRUG|human chorionic gonadotropin|
218978539|NCT00538291|BIOLOGICAL|cetuximab|
218978540|NCT00538291|DRUG|capecitabine|
218978541|NCT00538291|GENETIC|gene expression analysis|
218978542|NCT00538291|GENETIC|microarray analysis|
218978543|NCT00538291|GENETIC|polymorphism analysis|
218978544|NCT00538291|GENETIC|reverse transcriptase-polymerase chain reaction|
219669555|NCT05979896|DRUG|Standard age based SPAQ administration for SMC|"Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine."
219068324|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068325|NCT02897804|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
219068326|NCT02897804|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068327|NCT02897804|BEHAVIORAL|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219669556|NCT00758329|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
219669557|NCT02860962|DRUG|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
219669558|NCT05844085|OTHER|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
219669559|NCT05844085|OTHER|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
219669560|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
219669561|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
219669562|NCT03738163|DEVICE|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
218978545|NCT00538291|OTHER|immunohistochemistry staining method|
218978546|NCT00591344|BEHAVIORAL|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
219068328|NCT02897804|BEHAVIORAL|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068329|NCT02897804|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219068330|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
218978547|NCT00591344|BEHAVIORAL|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
218978548|NCT02464371|OTHER|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
219068331|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219208720|NCT06762990|RADIATION|Plain radiographs|Plain radiographs, including the lumbar spine, pelvis, and the upper half of both femora, will be obtained using the lowest radiation dose possible. The radiographs will be obtained in five positions representing the Muslim Prayers positions, namely 1-standing, 2-Sitting in 90 degrees (both 1 and 2 are the standard positions obtained in all previous studies), 3-bowing (Ruku), 4-prostration (sujud), and 5-sitting with knees bent (Tashahud).
219669563|NCT03671512|DEVICE|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
219669564|NCT03671512|DEVICE|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
219669565|NCT05768529|DRUG|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
219669566|NCT01515566|DRUG|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
219669567|NCT01515566|OTHER|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
219669568|NCT01515566|OTHER|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
219669569|NCT01515566|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
218978549|NCT01342276|BEHAVIORAL|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
218978550|NCT02460107|BIOLOGICAL|Botulinum toxin type A|
218978551|NCT02460107|OTHER|Normal saline|Placebo
218978552|NCT03308032|BEHAVIORAL|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
218978553|NCT03308032|BEHAVIORAL|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
218978554|NCT02640716|BEHAVIORAL|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
218978555|NCT02640716|BEHAVIORAL|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
218978556|NCT03420417|DEVICE|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
218978557|NCT03181815|DRUG|Cladribine|5mg/㎡ d1-5
218978558|NCT03181815|DRUG|G-CSF|300ug d0-9
218978559|NCT03181815|DRUG|Aclarubicin|10mg d3-6
218978560|NCT03181815|DRUG|Cytarabine|10mg/㎡ q12h SC d3-9
218978561|NCT01641874|PROCEDURE|Exercise|Directional specific exercise
218978562|NCT01641874|PROCEDURE|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
218978563|NCT01464996|PROCEDURE|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
218978564|NCT01464996|PROCEDURE|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
218978565|NCT01904058|DRUG|LUM001|
218978566|NCT01904058|DRUG|Placebo|
218978567|NCT01904058|DRUG|Ursodeoxycholic Acid|
218978568|NCT03959072|DEVICE|Robotic CTO PCI|Randomized to robotic CTO PCI.
219669570|NCT02085070|DRUG|MK-3475|IV MK-3475
219669571|NCT04584840|PROCEDURE|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
219669572|NCT06135571|PROCEDURE|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
219669573|NCT00985933|DRUG|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
219669574|NCT00985933|DRUG|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
219669575|NCT02104882|RADIATION|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
218978569|NCT03959072|PROCEDURE|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
218978570|NCT04436211|PROCEDURE|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
219068332|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068333|NCT02897804|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
219068334|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068335|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219068336|NCT02897804|BEHAVIORAL|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068337|NCT02897804|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219068338|NCT02897804|BEHAVIORAL|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068339|NCT02897804|BEHAVIORAL|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219208721|NCT06891157|DRUG|Chidamide plus R-CHOP|Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)
219669576|NCT00469248|DEVICE|Intra-aortic balloon pump counterpulsation|
219669577|NCT04808258|DEVICE|C3+ Holter Monitor|Long-Term ECG monitoring (up to 7 days)
219669578|NCT00812175|DRUG|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
219669579|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
219669580|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
219669581|NCT02769312|DEVICE|Theta burst stimulation|Theta burst transcranial magnetic stimulation
219669582|NCT02769312|DEVICE|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
219669583|NCT01810744|OTHER|capillaroscopy|
219669584|NCT01810744|OTHER|blood pressure measurement|
218978571|NCT05485454|DEVICE|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
218978572|NCT05485454|DEVICE|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
218978573|NCT05038046|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
218978574|NCT01118871|DRUG|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
218978575|NCT01118871|DRUG|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
218978576|NCT03096483|DEVICE|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
218978577|NCT00097318|DRUG|Interferon beta-1a|
219669585|NCT01680952|DRUG|A) TEST|"1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
219669586|NCT01680952|DRUG|B) CONTROL|"1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
219669587|NCT01584505|DRUG|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
219669588|NCT01584505|DRUG|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
219669589|NCT01584505|DRUG|CHF1535 daily dose|CHF1535 daily dose for 14 days
219669590|NCT06548633|OTHER|Lumbar Vertebral Mobilisation|The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
219669591|NCT02634619|PROCEDURE|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
218978578|NCT01435070|PROCEDURE|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
218978579|NCT01435070|PROCEDURE|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
218978580|NCT00751218|DRUG|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
218978581|NCT00751218|DRUG|placebo|placebo, once daily for 28 days
218978582|NCT00751218|DRUG|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
218978583|NCT03428607|DRUG|AZD6738|AZD6738 160mg QD
218978584|NCT03428607|DRUG|Olaparib|Olaparib 300mg BID
218978585|NCT03678883|DRUG|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
218978586|NCT03678883|DRUG|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
218978587|NCT03678883|DRUG|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
218978588|NCT03678883|DRUG|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
218978589|NCT03678883|DRUG|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
218978590|NCT03678883|DRUG|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
218978591|NCT03678883|DRUG|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
218978592|NCT03678883|DRUG|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
218978593|NCT03678883|DRUG|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
218978594|NCT04805177|PROCEDURE|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
218978595|NCT01318642|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
218978596|NCT01318642|DRUG|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
218978597|NCT01318642|DRUG|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
218978598|NCT06059573|PROCEDURE|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
218978599|NCT06059573|PROCEDURE|Freehand surgery|Implant will be placed under freehand surgery.
219068340|NCT02897804|BEHAVIORAL|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219068341|NCT02331992|BEHAVIORAL|Adherence program|Participants will receive supportive messages while enrolled in the program.
219068342|NCT00809757|DRUG|Levalbuterol|90 ug Levalbuterol (2 actuations)
219068343|NCT00809757|DRUG|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
219068344|NCT00809757|DRUG|Placebo|Placebo (2 actuations)
219068345|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
219669592|NCT02634619|PROCEDURE|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
218978600|NCT05007210|OTHER|Prenatal massage therapy|Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
218978601|NCT03749473|BEHAVIORAL|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
218978602|NCT03749473|BEHAVIORAL|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
218978603|NCT03749473|BEHAVIORAL|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
218978604|NCT03749473|BEHAVIORAL|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
218978605|NCT03749473|BEHAVIORAL|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
218978606|NCT03749473|BEHAVIORAL|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
218978607|NCT05887414|OTHER|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
219669593|NCT05369390|DRUG|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
218978608|NCT05887414|OTHER|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
219669594|NCT05369390|DRUG|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
219669595|NCT05369390|OTHER|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
219669596|NCT05369390|OTHER|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
219669597|NCT04159441|OTHER|None intervetion|None intervetion
219669598|NCT03984955|DEVICE|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
219669599|NCT03984955|DEVICE|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
219669600|NCT03984955|OTHER|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
219669601|NCT04146857|OTHER|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
219669602|NCT04146857|OTHER|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
219669603|NCT04146857|OTHER|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
219068346|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
219068347|NCT04121728|DRUG|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
219669604|NCT05613179|PROCEDURE|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
219068348|NCT04121728|DRUG|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
219068349|NCT01538017|DRUG|Xiapex|Collagenase Clostridium Histolyticum
219068350|NCT01538017|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
219068351|NCT01185574|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
219669605|NCT05613179|PROCEDURE|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
219669606|NCT05908487|BEHAVIORAL|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
218978609|NCT02320617|PROCEDURE|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
218978610|NCT05000697|DRUG|Oxaliplatin|Patients will receive 5FU + Oxaliplatin during the consolidation chemotherapy after long course chemoradiation
218978611|NCT05000697|DRUG|5FU|Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
218978612|NCT05735197|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
218978613|NCT05735197|DRUG|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
218978614|NCT06525597|BIOLOGICAL|Stapokibart Injection|IL-4Rα monoclonal antibody
218978615|NCT06525597|DRUG|Placebo|Placebo
218978616|NCT06416033|PROCEDURE|Serum Irisin|Measurement of plasma irisin level in leprosy patients.
219068352|NCT05262153|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
219068353|NCT02367261|DEVICE|SPI implant|SPI implant - the original spiral implant
219068354|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
219068355|NCT00102791|DRUG|ICA-17043|
219068356|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
219068357|NCT06296719|OTHER|Chit-Chat|Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
218978617|NCT02556736|DRUG|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
218978618|NCT04434066|PROCEDURE|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
218978619|NCT05421923|DRUG|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
218978620|NCT05421923|OTHER|Placebo|Ascending single and multiple doses of Placebo orally
218978621|NCT02798146|OTHER|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
218978622|NCT05836181|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
218978623|NCT01971840|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
219068358|NCT04897893|OTHER|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
219068359|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
219068360|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
219068361|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
219068362|NCT02575599|BEHAVIORAL|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
219669607|NCT03602196|OTHER|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
218978624|NCT04041375|BEHAVIORAL|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
218978625|NCT04041375|OTHER|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
218978626|NCT00515177|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
218978627|NCT00515177|DRUG|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
218978628|NCT01967342|BEHAVIORAL|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
218978629|NCT01967342|BEHAVIORAL|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
218978630|NCT01967342|OTHER|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
218978631|NCT04225962|OTHER|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
218978632|NCT04674644|BEHAVIORAL|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
218978633|NCT02178085|OTHER|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
218978634|NCT03789214|DRUG|Placebo oral capsule|Placebo Sleep Medication
218978635|NCT03789214|DRUG|Low Dose Suvorexant|Low Dose Suvorexant
218978636|NCT03789214|DRUG|High Dose Suvorexant|High Dose Suvorexant
218978637|NCT00107393|BIOLOGICAL|trastuzumab|
218978638|NCT00107393|DRUG|capecitabine|
218978639|NCT05962931|BIOLOGICAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
218978640|NCT05962931|PROCEDURE|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
219068363|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
219068364|NCT00198640|PROCEDURE|Antibiotic use|
219068365|NCT01489579|BEHAVIORAL|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
218978641|NCT04229784|PROCEDURE|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
218978642|NCT04200859|OTHER|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
218978643|NCT05435209|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
219068366|NCT01489579|BEHAVIORAL|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
219669608|NCT03602196|OTHER|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
219669609|NCT03602196|OTHER|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
219669610|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
218978644|NCT02884531|OTHER|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
218978645|NCT02884531|BEHAVIORAL|Patient Education|Patient education (1/2 day)
218978646|NCT06010706|OTHER|Supervised physical therapy manual exercise program.|"1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
218978647|NCT06010706|OTHER|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
218978648|NCT00627549|PROCEDURE|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
218978649|NCT00627549|PROCEDURE|Conventional surgery (anterior repair)|Anterior repair surgery
218978650|NCT03277690|DRUG|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
218978651|NCT03277690|DRUG|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
218978652|NCT04562467|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
218978653|NCT03815539|DEVICE|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
218978654|NCT00747812|DEVICE|Precision|Implantable Neurostimulator
218978655|NCT04852497|PROCEDURE|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
219068367|NCT05031702|DIETARY_SUPPLEMENT|Camellia Sinensis leaf extract|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
219068368|NCT05031702|COMBINATION_PRODUCT|Placebo|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
218978656|NCT03812120|PROCEDURE|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
218978657|NCT03812120|PROCEDURE|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
218978658|NCT03540212|DRUG|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
218978659|NCT05168449|OTHER|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
218978660|NCT04932759|BEHAVIORAL|music listening|music listening during dental treatment
219068369|NCT00808379|DRUG|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
219669611|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
218978661|NCT00416546|DRUG|AEB071|
218978662|NCT02831452|OTHER|pelvic floor muscle strength evaluation|
218978663|NCT01708161|DRUG|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
218978664|NCT01708161|DRUG|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
218978665|NCT03599388|BEHAVIORAL|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
218978666|NCT02019277|DRUG|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
218978667|NCT02019277|DRUG|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
218978668|NCT02019277|DRUG|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
218978669|NCT02019277|DRUG|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
218978670|NCT02019277|DRUG|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
218978671|NCT01780571|PROCEDURE|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
218978672|NCT05077527|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
219068370|NCT00808379|RADIATION|Additional Radiation boost to the primary tumor volume|15-20Gy
219068371|NCT03369548|OTHER|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
219068372|NCT03369548|OTHER|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
218978673|NCT05077527|DRUG|Cyclophosphamide|Given IV
218978674|NCT05077527|DRUG|Fludarabine|Given IV
218978675|NCT02869607|OTHER|Data collection|
218978676|NCT01349231|DRUG|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
218978677|NCT04213482|RADIATION|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
218978678|NCT01988220|OTHER|sensory retraining|
218978679|NCT01988220|OTHER|repeated sensory input|sensory stimulation without attentive learning focus
218978680|NCT01944033|DRUG|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
218978681|NCT01944033|DRUG|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
218978682|NCT04951804|PROCEDURE|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
218978683|NCT04951804|PROCEDURE|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
218978684|NCT03472651|DRUG|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
218978685|NCT03472651|DRUG|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
218978686|NCT06041490|DRUG|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
218978687|NCT00341055|DRUG|Epoetin alfa|
219068373|NCT03369548|DIETARY_SUPPLEMENT|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
219068374|NCT03369548|OTHER|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
219068375|NCT01534598|DRUG|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
219068376|NCT00175604|DRUG|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
219669612|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
219669613|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
219669614|NCT00162084|DRUG|apadenoson|
218978688|NCT04110678|DRUG|NeuroEPO|NeuroEPO \[CIMAB S.A, Havana, Cuba\]
218978689|NCT02633501|DRUG|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
218978690|NCT02633501|DRUG|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
218978691|NCT02633501|DEVICE|MRI|
218978692|NCT00140933|DRUG|MK0966; rofecoxib|
218978693|NCT00140933|DRUG|Comparator: diclofenac, placebo|
219068377|NCT04218461|DIAGNOSTIC_TEST|PRE-DELIRIC model|To predict delirium according to risk factors in the PRE-DELIRIC model
219068378|NCT04295564|OTHER|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
219068379|NCT00605436|BEHAVIORAL|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
219068380|NCT03228511|DEVICE|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
219068381|NCT03575923|BEHAVIORAL|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
219068382|NCT06180564|OTHER|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
219068383|NCT05363033|DEVICE|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
219550122|NCT06108557|DIAGNOSTIC_TEST|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
219669615|NCT03957590|DRUG|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
219669616|NCT03957590|DRUG|Placebo|Placebo to match tislelizumab
218978694|NCT02326675|OTHER|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
218978695|NCT02326675|OTHER|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
218978696|NCT00156520|DRUG|aprotonin; epsilon aminocaproic acid|
218978697|NCT01931930|DIETARY_SUPPLEMENT|Perilla extract|
218978698|NCT01931930|DIETARY_SUPPLEMENT|Maltodextrin|
218978699|NCT04677790|BEHAVIORAL|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
218978700|NCT00352443|DRUG|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
219669617|NCT03957590|DRUG|Paclitaxel|Administered as 135 mg/m² IV injection
219669618|NCT03957590|DRUG|Cisplatin|Administered as 25 mg/m² IV injection
219669619|NCT03957590|RADIATION|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
219669620|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
218978701|NCT00352443|DRUG|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
219669621|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
219669622|NCT06476431|OTHER|dual task|The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.
218978702|NCT06143800|BEHAVIORAL|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
218978703|NCT06143800|BEHAVIORAL|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
218978704|NCT02544646|OTHER|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
218978705|NCT03352479|OTHER|Opioid Return|Calculate the percentage of prescribed to returned opioids
218978706|NCT05371730|DRUG|NCR300|Intravenous infusion of NK cells（NCR300）
218978707|NCT05854199|BEHAVIORAL|Telehealth solution|Telehealth nutrition education platform
218978708|NCT04059198|DRUG|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
218978709|NCT04059198|DRUG|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
218978710|NCT04728867|OTHER|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
218978711|NCT06463574|OTHER|self-adhesive resin restoration|Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
218978712|NCT00137683|BEHAVIORAL|one-on-one education, group education, small media|
218978713|NCT04676217|PROCEDURE|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
218978714|NCT02702063|OTHER|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
218978715|NCT02702063|PROCEDURE|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
218978716|NCT02702063|OTHER|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
218978717|NCT06210581|OTHER|Supervised Exercise Program Group|The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
218978718|NCT06210581|OTHER|Internet Based Exercise Program Group|"Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system."
219068384|NCT06780995|OTHER|Power Exercise for Stroke Recovery (POWER)|"POWER incorporates 3 progressive phases: Phase 1 Familiarization (Week 1) as a low-intensity version of the training program to acclimate participants to the movements (body weight resisted or light weights, RPE 2-3 Fairly light to Moderate). Phase 2 Strength (Weeks 2-5) progresses loads to achieve volitional fatigue within 6-8 repetitions (RPE 7-9 Very hard to Very very hard). Phase 3 Power (Weeks 6-10) will use intensities RPE 4-6 (Somewhat hard to Very hard), and exercises will be executed at the highest possible velocity to focus on muscle power. The Power phase is intentionally designed with exercises to emphasize functional movements such as fast sit to stands, lunging and calf raises."
219550123|NCT04976179|DRUG|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
219550124|NCT04976179|DRUG|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
219550125|NCT01177657|PROCEDURE|Stool sampling|Stool samples collected and checked for the presence of rotavirus
219550126|NCT00120783|DRUG|Indinavir|
219550127|NCT00120783|DRUG|Lamivudine|
219550128|NCT00120783|DRUG|Ritonavir|
219550129|NCT03929016|DRUG|DNDI-0690|capsules of 10, 100 and 200 mg
219550130|NCT03929016|DRUG|Placebo of DNDI-0690|capsules of matching placebo
218978719|NCT02422316|OTHER|Non-contrast Cardiac CT scan|
218978720|NCT02072239|DEVICE|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
218978721|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
218978722|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
218978723|NCT00517803|DIETARY_SUPPLEMENT|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
218978724|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
218978725|NCT05607771|DEVICE|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
218978726|NCT05607771|DEVICE|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
218978727|NCT00242073|PROCEDURE|MRI Prostate|
219550131|NCT03544216|DEVICE|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
219550132|NCT03544216|DEVICE|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
219550133|NCT03050424|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
218978728|NCT05082831|BIOLOGICAL|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
218978729|NCT04497207|OTHER|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
218978730|NCT04886739|DRUG|CGB-400|Topical gel
218978731|NCT04886739|DRUG|Vehicle Gel|Topical gel
219068385|NCT06780995|OTHER|Strength Training Engaging Guidelines to Enhance Total Health (STRENGTH)|"STRENGTH is based on current clinical practice guidelines for RET after stroke. It will include the same Familiarization week as the POWER program (Week 1), followed by progressive conventional RET involving 3 sets of 10-15 repetitions at moderate to high intensities (RPE 4-5 Somewhat hard to Hard) (Weeks 2-10). The external resistance will be progressed to maintain this target RPE range. STRENGTH is matched with POWER in length (60-minute sessions over 10 weeks), frequency (3x/week) and format (in-person supervision)."
219068386|NCT04246034|PROCEDURE|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
219068387|NCT03726905|OTHER|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
219068388|NCT03726905|OTHER|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
219068389|NCT03726905|OTHER|aerobic training|12 weeks treadmill walking
219550134|NCT03050424|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9%
219550135|NCT04699396|PROCEDURE|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
219550136|NCT04699396|PROCEDURE|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
219550137|NCT04699396|OTHER|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
219550138|NCT01076491|DRUG|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
219550139|NCT02955628|DRUG|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
219550140|NCT02665962|OTHER|Perioperative Caloric Restriction Program|
219550141|NCT04671147|PROCEDURE|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
219550142|NCT03152162|DEVICE|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
219550143|NCT05502055|OTHER|Individual interviews|One on One interviews by Zoom video conferencing, \< 2 hours in duration
219550144|NCT05502055|OTHER|Focus Groups|Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
219550145|NCT05502055|OTHER|National Survey|Survey conducted online and distributed nationally
219550146|NCT05055713|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
219550147|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219550148|NCT05055713|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
219550149|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219550150|NCT05055713|PROCEDURE|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
219550151|NCT05055713|PROCEDURE|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219550152|NCT02621190|DRUG|cabazitaxel|25mg/m2 q3w
219550153|NCT02763696|OTHER|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
219550154|NCT00453258|OTHER|Eye Examination|Subjects receiving eye examination
219550155|NCT04194151|DRUG|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
219550156|NCT00538863|DRUG|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
218978732|NCT03225274|OTHER|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
218978733|NCT06402084|DIAGNOSTIC_TEST|abdominal ultrasound|abdominal ultrasound and lipid profile will be done
218978734|NCT05252065|OTHER|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
218978735|NCT01419639|DRUG|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
218978736|NCT03714308|DRUG|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
218978737|NCT05567315|DRUG|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
218978738|NCT05567315|DEVICE|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
218978739|NCT01162928|DRUG|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
218978740|NCT01162928|DRUG|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
219068390|NCT03400540|DIAGNOSTIC_TEST|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
219068391|NCT04207099|DEVICE|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
219068392|NCT04952324|OTHER|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
219068393|NCT02114593|BEHAVIORAL|Parent support program|Parent support program
219550157|NCT01499043|DRUG|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
219550158|NCT05832424|BEHAVIORAL|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
219550159|NCT04203823|DEVICE|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
219550160|NCT02609191|DEVICE|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
219550161|NCT02609191|DEVICE|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
219550162|NCT02609191|DEVICE|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
219550163|NCT05724394|OTHER|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
219550164|NCT04917393|DEVICE|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
219550165|NCT04917393|OTHER|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
219669623|NCT06476431|OTHER|non dual task|No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
219669624|NCT04721353|DRUG|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
219669625|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
219669626|NCT06087185|BEHAVIORAL|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
219669627|NCT06087185|BEHAVIORAL|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
219669628|NCT06343714|DRUG|FB1003|Subcutaneous (SC) injection
219669629|NCT06343714|DRUG|Placebo|Subcutaneous (SC) injection
219669630|NCT00201318|DRUG|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
219669631|NCT05355311|DRUG|L-carnitine|L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
219669632|NCT05386576|DRUG|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
218978741|NCT03102112|OTHER|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
218978742|NCT04597164|OTHER|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
218978743|NCT04357340|OTHER|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
218978744|NCT05285657|DIAGNOSTIC_TEST|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~* PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~* PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~* PfHRP2(-)/pLDH(-): negative results~* PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~* If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~* If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
218978745|NCT05040399|OTHER|Locking Compression Plates|Plates and screws for sternal fixation
218978746|NCT05040399|OTHER|Sternal Wires|sternal wires used for fixation of sternum
218978747|NCT03090438|PROCEDURE|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
219068394|NCT01787617|BEHAVIORAL|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
219068395|NCT01787617|BEHAVIORAL|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
219068396|NCT00211679|DRUG|Botulinum Toxin Type A|
219068397|NCT01505296|DRUG|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
219068398|NCT01505296|PROCEDURE|Catheter ablation|Complete PVI
219068399|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
219669633|NCT04752306|OTHER|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
219068400|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
219068401|NCT03582176|DRUG|Lactose Placebo|One capsule by mouth twice per day
219068402|NCT03582176|DRUG|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
219068403|NCT03582176|DRUG|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
219068404|NCT02100176|OTHER|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
219068405|NCT02100176|DRUG|Rotigotine|Rotigotine 2-8 mg/24 h
219068406|NCT01928719|DRUG|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
219068407|NCT01928719|DRUG|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
219068408|NCT04118153|DRUG|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
219068409|NCT03775239|BEHAVIORAL|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
219068410|NCT03775239|BEHAVIORAL|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
219068411|NCT00260468|OTHER|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
219068412|NCT04440553|BEHAVIORAL|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
219068413|NCT04440553|BEHAVIORAL|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
219068414|NCT02151279|OTHER|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
219068415|NCT02151279|OTHER|Control|
219068416|NCT02372201|OTHER|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
219068417|NCT02250612|DRUG|1 drop of 0.375% SYL040012 (bamosiran)|
219068418|NCT02250612|DRUG|1 drop of 0.750% SYL040012 (bamosiran)|
219068419|NCT02250612|DRUG|1 drop of 1.125% SYL040012 (bamosiran)|
219068420|NCT02250612|DRUG|1 drop of 1.5% SYL040012 (bamosiran)|
219068421|NCT02250612|DRUG|1 drop of 0.5 % timolol maleate|
219669634|NCT05160298|DRUG|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
219669635|NCT05160298|OTHER|Control group|Sham block
219669636|NCT00561535|DIETARY_SUPPLEMENT|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
219669637|NCT00561535|DIETARY_SUPPLEMENT|placebo (starch)|Once daily
219669638|NCT06187233|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
219669639|NCT05187091|RADIATION|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
219669640|NCT00631163|DRUG|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
219669641|NCT02750696|DRUG|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
219669642|NCT02750696|DRUG|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
219669643|NCT06636812|DRUG|Losartan potassium|Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
219669644|NCT06636812|OTHER|Placebo|Single tablet encapsulated identically to placebo
218978748|NCT04997278|DEVICE|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006)."
219068422|NCT02105116|DRUG|fludarabine phosphate|Given IV
219068423|NCT02105116|DRUG|cytarabine|Given IV
219068424|NCT02105116|BIOLOGICAL|donor lymphocytes|Undergo infusion of donor lymphocytes
219068425|NCT02105116|OTHER|laboratory biomarker analysis|Correlative studies
219068426|NCT02105116|DRUG|G-CSF|Given IV
219068427|NCT06133400|OTHER|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
218978749|NCT02081183|DRUG|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
219550166|NCT06435793|PROCEDURE|MEP measurement - Surface EMG - IOPI|"Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument."
219550167|NCT02070783|DRUG|ARA290|
218978750|NCT02081183|DRUG|Cyclophosphamide, Maintenance Phase|0.5-1 g/m\^2 IV pulse once every 3 months
218978751|NCT02081183|DRUG|Cyclophosphamide, Induction Phase|0.5 - 1 g/m\^2 IV pulse once per month
219068428|NCT06133400|OTHER|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
219068429|NCT06133400|OTHER|Biological samples|Collect venous blood, saliva and stool samples
219550168|NCT02070783|DRUG|Placebo|
219550169|NCT04071613|DRUG|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
219550170|NCT04071613|DRUG|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
219550171|NCT01316536|OTHER|provide headphones with music playing|Participants will be provided with music through headphones
219550172|NCT01316536|OTHER|Sounds|recorded ICU sounds will be provided to participants through headphones
219550173|NCT06065839|OTHER|non-nutritive sucking 5 minutes|Give pacifier non-nutritive sucking for 5 minutes before feeding
219550174|NCT06065839|OTHER|non-nutritive sucking 15 minutes|Give pacifier non-nutritive sucking for 15 minutes before feeding
219550175|NCT02456285|PROCEDURE|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
219550176|NCT02456285|PROCEDURE|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
219550177|NCT02456285|PROCEDURE|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
219550178|NCT02456285|PROCEDURE|No surgery|Patients who have no surgery.
219550179|NCT01897207|BIOLOGICAL|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
219550180|NCT06559293|DIAGNOSTIC_TEST|laryngeal ultrasound|laryngeal ultrasound with linear probe will be positioned on the patient's neck. A list of anatomical sites to be visualised will be determined beforehand. Once all the pre-determined structures have been visualised, in an axial and sagittal plane, we will note the position of the ultrasound probe and its orientation. This will enable us to determine the ideal position of the ultrasound probe for obtaining all the elements of interest on a section that will be called the reference section.
219550181|NCT03129841|BEHAVIORAL|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
219550182|NCT03129841|BEHAVIORAL|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
219550183|NCT02901028|OTHER|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
219550184|NCT02901028|OTHER|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
219550185|NCT00898664|GENETIC|cytogenetic analysis|
219550186|NCT00898664|GENETIC|gene expression analysis|
219550187|NCT00898664|GENETIC|mutation analysis|
219550188|NCT00898664|GENETIC|polymerase chain reaction|
219550189|NCT00898664|OTHER|immunohistochemistry staining method|
219550190|NCT00898664|OTHER|laboratory biomarker analysis|
219550191|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI.
219550192|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep Iearning.
219068430|NCT04469179|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
219068431|NCT04469179|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
219068432|NCT03667950|PROCEDURE|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
219068433|NCT00272857|GENETIC|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
219068434|NCT03577600|PROCEDURE|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
219068435|NCT00773968|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
219068436|NCT02263651|PROCEDURE|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
219068437|NCT02263651|PROCEDURE|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
219068438|NCT06956287|DEVICE|LensHooke CA0|The intervention involves the use of the LensHooke CA0 sperm-wash device, which incorporates filtration and swim-up techniques to isolate motile and morphologically normal sperm with intact DNA integrity. It is used for sperm preparation in intrauterine insemination (IUI) cycles. The device is designed to reduce oxidative stress and facilitate physiological sperm selection, providing a potential improvement over conventional density gradient centrifugation (DGC).
219068439|NCT06956287|PROCEDURE|Density Gradient Centrifugation (DGC)|The control procedure involves the standard density gradient centrifugation (DGC) method, a widely accepted technique for sperm preparation in IUI. Semen samples are processed using commercially available gradient media to isolate progressively motile sperm. This method serves as the comparator to assess the clinical performance of the LensHooke CA0 device.
219550193|NCT01604239|DRUG|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
219550194|NCT04345133|DEVICE|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
219550195|NCT06623227|DIETARY_SUPPLEMENT|Placebo|Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
219550196|NCT06623227|DIETARY_SUPPLEMENT|Vitamin E and C|Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
219550197|NCT06623162|DRUG|gemcitabine + cisplatine|4 cycles
219550198|NCT06098313|DRUG|Cyclophosphamide|-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
219550199|NCT01791686|DRUG|CDX-1135|
219550200|NCT05011695|OTHER|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
219550201|NCT01881165|DRUG|Cranberry|
219550202|NCT01881165|DRUG|Placebo|
219550203|NCT03299829|DRUG|Trientine|Trientine is a chelating agent for removing the copper from the body
219550204|NCT02517554|BEHAVIORAL|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
219550205|NCT02517554|BEHAVIORAL|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
219550206|NCT02517554|BEHAVIORAL|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
219550207|NCT01152645|DRUG|ARQ 197|Orally twice daily administration of ARQ 197
219550208|NCT00000159|DRUG|Sorbinil|
219550209|NCT02191059|DRUG|Icotinib|
219550210|NCT02191059|DRUG|Docetaxel|
219550211|NCT05748561|DRUG|Recombinant human erythropoietin 4,000 UI and 2,000 UI|Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)
219550212|NCT05748561|DRUG|Methylprednisolone succinate 500 mg|Intravenous Methylprednisolone succinate (1 g daily for 5 days)
219550213|NCT06502301|OTHER|Cross-sectional study|This is not intervention study.
219550214|NCT01243983|DRUG|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
219550215|NCT02716311|DRUG|Afatinib|
219550216|NCT02716311|DRUG|Cetuximab|
219669645|NCT05362370|DEVICE|Stryker's PEEK Customized Implant|The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
219669646|NCT02714036|DRUG|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
218978752|NCT02081183|DRUG|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
219068440|NCT05922358|COMBINATION_PRODUCT|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours."
219068441|NCT02100982|OTHER|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
219068442|NCT02100982|OTHER|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
219068443|NCT03562000|DEVICE|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
219068444|NCT03562000|PROCEDURE|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
219068445|NCT00263666|BIOLOGICAL|Rotarix|Oral vaccination
219068446|NCT00263666|BIOLOGICAL|Placebo|Oral administration
219068447|NCT00263666|BIOLOGICAL|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
219068448|NCT00263666|BIOLOGICAL|Polio Sabin|Oral administration, concomitant routine vaccination
219068449|NCT06104410|RADIATION|Standard fractioned dose|Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
219068450|NCT06104410|RADIATION|Experimental single dose|Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
219068451|NCT01427868|DRUG|LB80380 maleate salt|183 mg (150 mg as a free base)
219068452|NCT01427868|DRUG|LB80380 free base|150 mg
219550217|NCT03815903|DRUG|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
219550218|NCT03815903|COMBINATION_PRODUCT|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
219669647|NCT02714036|DRUG|Ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
219669648|NCT06551298|OTHER|Menggongzi Tibetan Tea Special Drink|Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
219669649|NCT06551298|DRUG|Atorvastatin Calcium 20Mg Tab|Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
219669650|NCT06551298|OTHER|Low fat diet|Low fat diet
219669651|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
219669652|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
219669653|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
219669654|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
219669655|NCT05353660|OTHER|No intervention|No intervention
219669656|NCT01080859|DEVICE|OCT|Optical coherence tomography
219669657|NCT01080859|DEVICE|OCT|Optical coherence tomography
219669658|NCT00408187|DRUG|voclosporin|voclosporin 0.4 mg/kg po BID
219669659|NCT00408187|DRUG|Ciclosporin|ciclosporin 1.5 mg/kg po BID
219669660|NCT00408187|DRUG|Placebo|Placebo
219669661|NCT03141034|DRUG|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
218978753|NCT01021306|DEVICE|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
218978754|NCT01021306|DEVICE|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
218978755|NCT01021306|OTHER|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
219669662|NCT03141034|DRUG|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
219669663|NCT03141034|GENETIC|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
219669664|NCT03141034|GENETIC|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
219669665|NCT03590223|PROCEDURE|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
219669666|NCT02146820|DEVICE|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
219669667|NCT00329745|BIOLOGICAL|Rotarix™|Oral administration, 2 doses
218978756|NCT01021306|OTHER|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
218978757|NCT03203070|DRUG|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
218978758|NCT03203070|PROCEDURE|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
219669668|NCT00329745|BIOLOGICAL|Placebo|Oral administration, 2 doses
219669669|NCT02649517|PROCEDURE|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
219669670|NCT02486172|BEHAVIORAL|Peer support program|Peer support program as an additional service to the routine clinical service
219669671|NCT01597492|BIOLOGICAL|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
219669672|NCT01597492|BIOLOGICAL|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
219669673|NCT03961516|DEVICE|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
219669674|NCT03961516|RADIATION|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
219669675|NCT04269720|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
219669676|NCT05443503|OTHER|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
219669677|NCT03675893|DRUG|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
219669678|NCT03675893|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
219669679|NCT03675893|DRUG|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
219669680|NCT03675893|DRUG|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
219669681|NCT03675893|DRUG|Zotatifin|Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.
219669682|NCT03675893|DRUG|Gedatolisib|Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.
219669683|NCT01660347|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
219669684|NCT01660347|BIOLOGICAL|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
219669685|NCT01660347|PROCEDURE|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
218978759|NCT00913575|OTHER|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
219669686|NCT01633970|DRUG|5-FU|Participants will receive 5-FU 400 mg/m\^2 IV q2w.
219669687|NCT01633970|DRUG|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
219669688|NCT01633970|DRUG|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
219669689|NCT01633970|DRUG|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
219669690|NCT01633970|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV q2w.
219669691|NCT01633970|DRUG|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.
219669692|NCT01633970|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.
219669693|NCT01633970|DRUG|Paclitaxel|Participants will receive paclitaxel 200 mg/m\^2 IV q3w.
219669694|NCT01633970|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
219669695|NCT05987059|BEHAVIORAL|SBIRT Intervention|"Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies."
219669696|NCT03561545|OTHER|weightlessness (parabolic flight)|weightlessness (parabolic flight)
219669697|NCT06187272|BEHAVIORAL|Listening to music|Students listened to background music during a practical examination of 60 bpm.
219669698|NCT04733222|OTHER|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
219669699|NCT04733222|OTHER|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
218978760|NCT00913575|BEHAVIORAL|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
218978761|NCT04993560|BIOLOGICAL|BBIBP-CorV|Inactivated virus COVID-19 vaccine
218978762|NCT04993560|BIOLOGICAL|BNT162b2|mRNA-based COVID-19 vaccine
218978763|NCT05248620|DRUG|Amoxicillin Clavulanic 500/125mg or placebo|Prophylactic antibiotic treatment
218978764|NCT04958668|OTHER|Post-operative intensive care using volatile sedation|Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
219068453|NCT01380340|OTHER|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
219669700|NCT03850405|DIETARY_SUPPLEMENT|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
219669701|NCT04438798|OTHER|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
219669702|NCT04438798|OTHER|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
219669703|NCT06498726|DEVICE|transcranial doppler|Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
219669704|NCT01016574|DEVICE|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
218978765|NCT00910273|DRUG|etanercept|etanercept 50 mg/week
218978766|NCT01882348|BEHAVIORAL|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
219068454|NCT05495854|DIAGNOSTIC_TEST|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
219068455|NCT03553589|OTHER|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
219068456|NCT04014608|OTHER|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
219068457|NCT03906227|DEVICE|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
219068458|NCT03165526|DEVICE|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
219068459|NCT06266767|DRUG|Levobupivacaine and Fentanyl|Programmed Intermittent Epidural Bolus
219669705|NCT03299725|DRUG|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
219669706|NCT02400203|OTHER|Control|
219669707|NCT02400203|OTHER|Hemp foods|
219669708|NCT00441948|DEVICE|Peterio|
218978767|NCT04473846|DRUG|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
219068460|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
219669709|NCT06201208|BEHAVIORAL|The ST-Facilitation Psychoeducation Program|"One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse."
219068461|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
219068462|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
219068463|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
219068464|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
219068465|NCT00492999|DRUG|dexamethasone|Given by hepatic arterial infusion
219669710|NCT01454219|OTHER|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
219669711|NCT03301935|PROCEDURE|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
219669712|NCT03102008|BEHAVIORAL|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
219068466|NCT00492999|DRUG|floxuridine|Given by hepatic arterial infusion
219068467|NCT00492999|DRUG|fluorouracil|Given IV
219068468|NCT00492999|DRUG|irinotecan hydrochloride|Given IV
219068469|NCT00492999|DRUG|leucovorin calcium|Given IV
219068470|NCT00492999|DRUG|oxaliplatin|Given IV
219068471|NCT03884751|BIOLOGICAL|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
219068472|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
219068473|NCT05356221|DEVICE|Ponto Sound processor|Bone Anchored Hearing solution fitted to compensate for the subjects hearing loss
219068474|NCT06958094|OTHER|Gamified mobile health applications|"* Voice Volume Catcher: A game where players control a character's movement by modulating their voice volume. Louder or softer sounds move a basket to collect different types of fruits, encouraging continuous vocal engagement and fine control of breath intensity.~* Scream Go Hero: A voice-controlled platform game where players produce short or long vocalizations to make the hero character jump or move across obstacles. The game demands breath control and supports prolonged exhalations for larger jumps with an open glottis, which is beneficial for airway clearance.~* Chicken Scream: A voice-activated game where players guide a chicken character by varying their vocal intensity to make it walk, jump, and avoid enemies. Participants must dynamically adjust their breath pressure and vocal intensity while maintaining open-glottis breathing, promoting agility in respiratory control."
219068475|NCT06958094|OTHER|Conventional Airway Clearance Therapy|"* Autogenic Drainage: A technique where participants perform a series of controlled breathing cycles-deep inhalations followed by forceful exhalations-to mobilize mucus from the lower airways to the upper airways. The technique encourages breath control and helps clear secretions without the need for coughing, promoting efficient airway clearance.~* Active Cycle of Breathing Techniques (ACBT): In this technique, participants alternate between relaxed breathing, deep breaths, and huffing to mobilize and expel mucus from the lungs. It focuses on breathing control to loosen and expel secretions effectively while maintaining a steady airflow throughout the process.~* Positive Expiratory Pressure (PEP) Therapy: This technique involves exhaling against a resistance through a device, which helps to open the airways and prevent their collapse. The resistance promotes prolonged exhalations, facilitating the movement of mucus from the small airways to the larger airways for easier clearance."
219068476|NCT06958094|OTHER|Combination Treatment|"\- Gamified mHealth Apps (10 minutes):~Voice Volume Catcher~Scream Go Hero~Chicken Scream~\- Conventional Airway Clearance Techniques (10 minutes):~Autogenic Drainage~Active Cycle of Breathing Techniques (ACBT)~Positive Expiratory Pressure (PEP) Therapy"
219068477|NCT03363373|BIOLOGICAL|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
219068478|NCT05027477|DEVICE|Radical Prostatectomy|If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
219669713|NCT04708496|DRUG|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
219669714|NCT00005896|DRUG|filgrastim|
219669715|NCT00005896|GENETIC|Autologous stem cells transduced with FACC retroviral vector|
219669716|NCT00005896|PROCEDURE|Autologous Stem Cell Transplantation|
218978768|NCT04473846|DRUG|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
218978769|NCT05965778|DEVICE|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
218978770|NCT05965778|DEVICE|Vismed® Multi|Hyaluronic acid
218978771|NCT06098274|BEHAVIORAL|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
218978772|NCT05592951|DIETARY_SUPPLEMENT|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
218978773|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
218978774|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
219669717|NCT05975918|BEHAVIORAL|Motivational İnterview|Participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.
219669718|NCT05975918|OTHER|Psychoeducation|2 hours of training on coping with stress and problem solving skills will be provided.
219068479|NCT05027477|DEVICE|TULSA Procedure|If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in a MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.
219669719|NCT05881122|BEHAVIORAL|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
219669720|NCT06257160|PROCEDURE|Surgical infiltration|"During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles."
219669721|NCT06257160|PROCEDURE|PENG Block ultrasound-guided|"We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases."
219669722|NCT03132974|DRUG|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
219669723|NCT03132974|OTHER|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
219669724|NCT03132974|OTHER|Placebo with manipulation procedure|Placebo granule with manipulation procedure
219669725|NCT01259674|DEVICE|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
219669726|NCT01259674|OTHER|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
219669727|NCT03409484|OTHER|Concord Grape Juice|Concord Grape Juice
219669728|NCT03409484|OTHER|Low flavoniod low essence beverage|Low flavoniod low essence beverage
218978775|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
218978776|NCT04953351|PROCEDURE|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
218978777|NCT04953351|PROCEDURE|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
218978778|NCT03784703|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
218978779|NCT03784703|DRUG|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
218978780|NCT02440971|DEVICE|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
218978781|NCT01747148|DRUG|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
218978782|NCT04488939|DEVICE|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
218978783|NCT05405413|OTHER|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
218978784|NCT00968864|DEVICE|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
218978785|NCT03904732|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
219669729|NCT03409484|OTHER|Low flavonoid beverage|Low flavonoid beverage
218978786|NCT01346969|DRUG|EXC 001|Single-dose administered by injection four different times
218978787|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
219068480|NCT06042517|DEVICE|Ultrasound|The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.
219669730|NCT04350931|BIOLOGICAL|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
219669731|NCT04350931|OTHER|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
219669732|NCT00528073|DRUG|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
219068481|NCT06042517|DIAGNOSTIC_TEST|OGTT with unlabeled glucose and liver NMR|Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.
219669733|NCT01111682|DRUG|Mannitol|0.9% normal saline infusion and boluses of mannitol
219669734|NCT01111682|DRUG|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
219669735|NCT01404897|OTHER|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
219669736|NCT01404897|OTHER|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
219669737|NCT01404897|OTHER|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
219669738|NCT00650728|PROCEDURE|placing gastric tube|
219669739|NCT00497341|DRUG|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
219669740|NCT00497341|DRUG|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
219669741|NCT03514056|DIAGNOSTIC_TEST|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
219669742|NCT03514056|DIAGNOSTIC_TEST|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
219669743|NCT01204918|DRUG|Riluzole|Riluzole 100mg PO
219669744|NCT01204918|DRUG|placebo|placebo
219669745|NCT04140084|DEVICE|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
218978788|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
218978789|NCT01346969|DRUG|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
218978790|NCT00115648|DRUG|Nevirapine|Oral NVP daily dosage
218978791|NCT00115648|DRUG|AZT|Oral AZT daily
218978792|NCT00115648|DRUG|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
218978793|NCT00115648|DRUG|NVP|Oral NVP daily to age 14 weeks
218978794|NCT00115648|DRUG|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
218978795|NCT05535231|DIETARY_SUPPLEMENT|Turmeric test product|2 capsules of 490 mg Turmeric are taken with water once
218978796|NCT05535231|DIETARY_SUPPLEMENT|Turmeric comparator|2 capsules of 200 mg Turmeric are taken with water once
219669746|NCT00004500|DRUG|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
218978797|NCT02407795|RADIATION|conventional radiotherapy|1x8Gy
218978798|NCT02407795|RADIATION|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
219068482|NCT06042517|DIAGNOSTIC_TEST|OGTT with carbon-13 labeled glucose and liver NMR|Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.
218978799|NCT00563420|PROCEDURE|Bronchoscopy|
218978800|NCT00118690|DRUG|Fluticasone propionate/salmeterol|
218978801|NCT00211484|DRUG|Anecortave Acetate|
218978802|NCT04925726|OTHER|Land based exercise|The patients who had land based exercise
218978803|NCT04925726|OTHER|Water based exercise|The patients who had water based exercise
218978804|NCT05426798|DRUG|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
218978805|NCT00479323|BIOLOGICAL|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
218978806|NCT02308189|BEHAVIORAL|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
219068483|NCT06042517|DIAGNOSTIC_TEST|CGM glucose reading|A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
219068484|NCT06042517|DIAGNOSTIC_TEST|HEC - Hyperinsulinemic-Euglycemic-Clamp|A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
219068485|NCT00290940|DRUG|CS-917|
219669747|NCT00004500|OTHER|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
219669748|NCT03517449|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
219669749|NCT03517449|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
219669750|NCT03517449|DRUG|Paclitaxel|80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
219669751|NCT03517449|DRUG|Doxorubicin|60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
219669752|NCT04384757|PROCEDURE|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
219669753|NCT01859962|DRUG|PPI-668|
219669754|NCT01859962|DRUG|BI 207127 Dose 1|
219669755|NCT01859962|DRUG|BI 207127 Dose 2|
219669756|NCT01859962|DRUG|Faldaprevir|
219669757|NCT01859962|DRUG|Ribavirin|
219669758|NCT01859962|DRUG|BI 207127 Placebo|
219669759|NCT02109016|DRUG|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
219669760|NCT04645134|BEHAVIORAL|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
219669761|NCT05442541|BEHAVIORAL|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
219669762|NCT01238094|DRUG|Simvastatin|simvastatin 40 mg qd daily until disease progression
219669763|NCT02798120|DRUG|SB204 4%|Open label, topical SB204 4%
219669764|NCT01981148|DEVICE|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
219669765|NCT00431067|DRUG|BIBW 2992|
219669766|NCT03062995|OTHER|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
219669767|NCT03062995|OTHER|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
219669768|NCT00849290|BIOLOGICAL|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
219669769|NCT01912352|DRUG|Methylphenidate|
219669770|NCT01687387|DRUG|IPH2102 at 0.1 mg/kg|every 3 months
219669771|NCT01687387|DRUG|IPH2102 at 1 mg/kg|every 4 weeks
219669772|NCT01687387|DRUG|Placebo (normal saline solution)|every 4 weeks
219669773|NCT00001031|BIOLOGICAL|rgp120/HIV-1MN|
219669774|NCT00001031|BIOLOGICAL|rgp120/HIV-1 SF-2|
218978807|NCT02308189|BEHAVIORAL|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
218978808|NCT00291889|BIOLOGICAL|Mtb72F/AS02.|
219669775|NCT01557192|DEVICE|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
219669776|NCT03450616|DEVICE|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
219669777|NCT03450616|PROCEDURE|Compression Dressing|Standard of Care Compression Dressing
218978809|NCT05077878|BIOLOGICAL|DSPP level in GCF|quantification of DSPP
218978810|NCT02549729|BEHAVIORAL|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
219669778|NCT05145608|DRUG|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
219669779|NCT05987943|PROCEDURE|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
219669780|NCT03947502|BEHAVIORAL|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
219669781|NCT05529732|OTHER|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
218978811|NCT05610514|OTHER|E-Cigarette|Altering the availability of e-cigarettes
218978812|NCT05610514|BEHAVIORAL|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
218978813|NCT02728622|DRUG|Tamoxifen|endocrine treatment
218978814|NCT02728622|DRUG|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
219669782|NCT01096680|DRUG|SPD489 20 mg|Single oral dose of 20 mg
219669783|NCT01096680|DRUG|SPD489 50 mg|Single oral dose of 50 mg
219669784|NCT01096680|DRUG|SPD489 70 mg|Single oral dose of 70 mg
219669785|NCT01096680|DRUG|Armodafinil|Single oral dose of 250 mg
219068486|NCT00290940|DRUG|metformin hydrochloride|
219068487|NCT00290940|DRUG|pioglitazone|
219068488|NCT06275646|OTHER|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
219068489|NCT06275646|OTHER|dartos flap|dartos flap alone was used
219068490|NCT03001648|PROCEDURE|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
219068491|NCT01477827|OTHER|None - observational study|
219068492|NCT03943732|DIAGNOSTIC_TEST|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
219068493|NCT03422250|DEVICE|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks.
219068494|NCT02068573|DEVICE|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
219068495|NCT02068573|DEVICE|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
219068496|NCT00440050|DRUG|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
219669786|NCT01096680|DRUG|Placebo|Single oral dose
219669787|NCT05087121|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
219669788|NCT05087121|DEVICE|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
219669789|NCT00284154|DRUG|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
219669790|NCT04389307|OTHER|Electrical stimulation (IVES)|IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
219068497|NCT00440050|DRUG|Placebo|2 placebo capsules twice a day for 18 months
219068498|NCT00579917|BEHAVIORAL|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
219068499|NCT00579917|BEHAVIORAL|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
219068500|NCT04233268|DIAGNOSTIC_TEST|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
219068501|NCT01780922|OTHER|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
219068502|NCT01780922|OTHER|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
219068503|NCT01780922|OTHER|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
219068504|NCT03179228|DEVICE|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
219068505|NCT06346288|PROCEDURE|Breast Milk Sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)
219068506|NCT06346288|DRUG|Risankizumab|Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
219068507|NCT06089161|OTHER|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
219068508|NCT06089161|BEHAVIORAL|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
219669791|NCT04389307|OTHER|Bladder Training|Bladder Training
219669792|NCT02693899|OTHER|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
219669793|NCT06222814|PROCEDURE|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
219068509|NCT03929146|DRUG|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
219068510|NCT03929146|PROCEDURE|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
219068511|NCT00328419|DEVICE|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
219068512|NCT00328419|DEVICE|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
219068513|NCT05069350|DRUG|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
219068514|NCT02059694|DRUG|Hyaluronidase|
219068515|NCT02059694|OTHER|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
219068516|NCT01826591|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
219068517|NCT01826591|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
219068518|NCT01826591|BEHAVIORAL|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
219669794|NCT06222814|PROCEDURE|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
219669795|NCT05614635|DEVICE|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
219669796|NCT03237052|OTHER|model|a model that has been established in advance.
219669797|NCT03237052|OTHER|non-model|real-world psychiatrist decision
219669798|NCT03418142|BEHAVIORAL|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
218978815|NCT02662634|BIOLOGICAL|AGS-003-LNG|autologous dendritic cell immunotherapy
218978816|NCT02662634|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
218978817|NCT02662634|DRUG|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
218978818|NCT02662634|DRUG|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
218978819|NCT02662634|DRUG|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
218978820|NCT02662634|DRUG|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
218978821|NCT02662634|RADIATION|Radiation Therapy|Causes DNA strand breaks.
218978822|NCT04498312|OTHER|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
218978823|NCT01736462|DRUG|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
218978824|NCT02328417|OTHER|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
218978825|NCT05995119|DRUG|Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)|The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
218978826|NCT01020149|OTHER|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
218978827|NCT04040946|DIAGNOSTIC_TEST|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
218978828|NCT04040946|DIAGNOSTIC_TEST|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
218978829|NCT04098848|OTHER|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
218978830|NCT02605070|DRUG|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
218978831|NCT01172236|DRUG|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
218978832|NCT01172236|DRUG|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
218978833|NCT03565601|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
218978834|NCT02967432|DRUG|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
218978835|NCT02967432|DRUG|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
218978836|NCT05570383|DRUG|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
219068519|NCT00938873|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
219068520|NCT00692172|DRUG|Alefacept|intramuscular injection (IM)
219068521|NCT05676684|DRUG|Dapagliflozin|A: Dapagliflozin 10 mg once daily
219068522|NCT05676684|DRUG|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)
219068523|NCT02766543|DEVICE|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
219068524|NCT05051566|DRUG|LY3502970|Administered orally.
219068525|NCT05051566|DRUG|Esomeprazole|Administered orally.
219068526|NCT04443738|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for recieved treatment will be conducted over the phone for patients.
219068527|NCT02057146|PROCEDURE|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
219068528|NCT01917526|DEVICE|oxygen mask|
219068529|NCT01917526|DEVICE|oxygen cannula|
219068530|NCT05633784|OTHER|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
219669799|NCT03418142|OTHER|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
219669800|NCT06146634|BEHAVIORAL|Hazard Perception Training|The hazard perception training is comprised of three modules. Each module is comprised of four scenarios. Each hazard perception scenario has two activities. The entire training is expected to take approximately an hour to complete.
219068531|NCT05633784|OTHER|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
219068532|NCT05633784|OTHER|Telerehabilitation|Support from a physiotherapist (if needed)
219068533|NCT05633784|OTHER|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
219068534|NCT05633784|OTHER|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
219068535|NCT05633784|OTHER|telepsycology|Psychological support (if necessary)
219068536|NCT05633784|OTHER|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
219068537|NCT05633784|OTHER|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
219068538|NCT05633784|OTHER|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
219669801|NCT06146634|BEHAVIORAL|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using a series of short videos. These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Altogether the videos will last approximately 1 hour.
219669802|NCT06146634|BEHAVIORAL|Attention Maintenance Training|The attention maintenance training is comprised of three modules. Each module is comprised of four scenarios, with each scenario corresponding to one activity. The entire training is expected to take approximately an hour to complete.
219669803|NCT02039323|DRUG|Tenofovir|
219669804|NCT02039323|DRUG|Maraviroc|
219669805|NCT00639392|DRUG|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
219669806|NCT00639392|DRUG|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
219669807|NCT00550264|OTHER|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
219669808|NCT02033200|DRUG|Stendra 200 mg|
218978837|NCT05244304|DRUG|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
218978838|NCT05244304|DRUG|Placebo|Not active drug
218978839|NCT03745807|BIOLOGICAL|NKTR-214|Specified dose on specified days
218978840|NCT03745807|BIOLOGICAL|Nivolumab|Specified dose on specified days
218978841|NCT01047670|DRUG|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
219669809|NCT02033200|DRUG|Placebo|
219669810|NCT05267223|OTHER|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
219669811|NCT04288817|BIOLOGICAL|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
219669812|NCT03362138|DEVICE|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
218978842|NCT04128085|DRUG|TQB3804|A kind of tyrosine kinase inhibitor.
218978843|NCT05444101|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
218978844|NCT05444101|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
218978845|NCT05444101|BEHAVIORAL|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
219068539|NCT05633784|OTHER|State of health of the patient|Severity Index and Comordbidity index
219068540|NCT04717596|OTHER|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
219068541|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
219068542|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
219068543|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
219068544|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
219068545|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
218978846|NCT01414608|RADIATION|Brachytherapy|Undergo brachytherapy
218978847|NCT01414608|DRUG|Carboplatin|Given IV
218978848|NCT01414608|DRUG|Cisplatin|Given IV
218978849|NCT01414608|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
218978850|NCT01414608|DRUG|Paclitaxel|Given IV
219068546|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
219669813|NCT00830518|DRUG|Alisertib|Alisertib capsules
219669814|NCT04080089|COMBINATION_PRODUCT|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
219669815|NCT03439462|DRUG|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
219669816|NCT03920423|PROCEDURE|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
219669817|NCT00523809|DRUG|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
219669818|NCT00523809|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
219669819|NCT00523809|DRUG|Fludarabine|25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days
219669820|NCT00523809|DRUG|Melphalan|70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days
219669821|NCT00523809|DRUG|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
219669822|NCT00808470|DRUG|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
219669823|NCT00808470|OTHER|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
219669824|NCT04091815|OTHER|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
219669825|NCT00913770|BEHAVIORAL|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
219669826|NCT00913770|DRUG|Buprenorphine Initiation|
219669827|NCT00555776|DRUG|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
219669828|NCT00555776|DRUG|placebo|placebo is given with the same definition as Gabapentin
219669829|NCT03337048|DEVICE|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
219669830|NCT00320697|DRUG|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
219669831|NCT00320697|DRUG|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
219669832|NCT03260790|BIOLOGICAL|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
218978851|NCT01414608|OTHER|Quality-of-Life Assessment|Ancillary studies
218978852|NCT02635763|PROCEDURE|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
218978853|NCT02635763|PROCEDURE|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
218978854|NCT05051995|DRUG|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
218978855|NCT05051995|OTHER|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
218978856|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
219068547|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
219669833|NCT03260790|BIOLOGICAL|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
219669834|NCT06854809|BEHAVIORAL|Cognitive functional therapy|"The intervention consists of a Cognitive-Functional Therapy (CFT) program for individuals with shoulder pain, conducted by trained physiotherapists (106 hours of training) under the supervision of an expert with over 8 years of experience. CFT adopts a biopsychosocial approach and is structured into three main components:~Making Sense of Pain - A cognitive component aimed at reinterpreting dysfunctional beliefs about pain through a reflective process based on the patient's life history, promoting understanding and self-efficacy.~Graded Exposure with Control - Gradual exposure to functional activities, aiming to modify maladaptive associations between movement and pain, fostering the development of movement confidence.~Lifestyle Change - Discussion and implementation of strategies to promote a healthy lifestyle, including physical activity, sleep habits, and stress management.~All three components are integrated from the first session, with initial focus on building the therapeutic all."
219669835|NCT06854809|OTHER|Therapeutic exercise|Participants in the Therapeutic Exercises Group will engage in individualized exercises targeting the scapulothoracic musculature and rotator cuff. The exercises, performed bilaterally, include lateral arm rotation, T, W, wall hand slide, and diagonal arm movement upwards. Each participant will be guided by one of two physiotherapists, randomly assigned. The exercises will follow a protocol consisting of 3 sets of 12 repetitions, with 1-minute rest between sets, using progressively resistant Thera-Bands®. Resistance will increase when pain is ≤2 on the Numerical Rating Scale and perceived exertion is \<3 on the Borg Scale. The protocol was designed based on scientific literature and shoulder pain treatment guidelines to address muscle activation deficits and rotator cuff and scapulothoracic imbalances.
219669836|NCT03286933|BEHAVIORAL|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
219669837|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
218978857|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
219669838|NCT05278494|DRUG|Placebo|PO
219669839|NCT05687682|BIOLOGICAL|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
219669840|NCT03955809|DRUG|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
219669841|NCT03955809|DRUG|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
219669842|NCT03955809|DRUG|% 0.9 NaCl|Intraarticular %0.9 NaCl
219669843|NCT01531595|DRUG|Bevacizumab plus alternating XELOX/XELIRI|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
219669844|NCT02838589|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
219669845|NCT02838589|DRUG|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
219669846|NCT02507024|OTHER|Online questionnaire|
219669847|NCT02791438|DRUG|Azilsartan|Azilsartan granules and tablets
219669848|NCT02791438|DRUG|Placebo|Placebo-matching azilsartan granules and tablets
218978858|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
218978859|NCT00876525|DEVICE|Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis|The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.
218978860|NCT02465645|DRUG|Carvedilol|
218978861|NCT02465645|DRUG|Carvedilol + Simvastatin|
219068548|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
219068549|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
219068550|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
219068551|NCT05802459|OTHER|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
219669849|NCT02298413|DEVICE|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
219669850|NCT04938414|DIAGNOSTIC_TEST|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
219669851|NCT02910726|PROCEDURE|Sentinel Lymph Node Biopsy|
219669852|NCT02910726|DRUG|indocyanine green (ICG)|
219669853|NCT05310526|OTHER|Training Group|Training for prescribing the Brazilian cardioprotective diet
219669854|NCT04892992|BEHAVIORAL|DFG|
218978862|NCT02008578|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
218978863|NCT02008578|BIOLOGICAL|Placebo|
218978864|NCT04337385|BEHAVIORAL|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
219068552|NCT05802459|OTHER|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
219669855|NCT03713996|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
219669856|NCT03713996|OTHER|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
219669857|NCT00600405|DRUG|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
219669858|NCT00600405|DRUG|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
219669859|NCT00003028|DRUG|sabarubicin|
219669860|NCT01916902|DRUG|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
219669861|NCT01916902|DRUG|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
219669862|NCT01916902|PROCEDURE|Optical Coherence Tomography|
219669863|NCT02093403|DRUG|decitabine|Given IV
219669864|NCT02093403|DRUG|selinexor|Given PO
219669865|NCT02093403|OTHER|pharmacological study|Correlative studies
219669866|NCT02093403|OTHER|laboratory biomarker analysis|Correlative studies
219669867|NCT00055679|DRUG|cyclophosphamide|
219669868|NCT00055679|DRUG|epirubicin hydrochloride|
219669869|NCT00055679|DRUG|fluorouracil|
219068553|NCT05802459|OTHER|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
219068554|NCT05802459|OTHER|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
219068555|NCT05802459|PROCEDURE|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
219068556|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
219068557|NCT02460991|DEVICE|DEB-TACE|
219068558|NCT02460991|DRUG|Sorafenib|
219068559|NCT02360709|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
219068560|NCT04781972|DRUG|Methylphenidate|single dose of 10 mg or 15 mg
219669870|NCT01239836|BEHAVIORAL|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
219068561|NCT04781972|DRUG|Placebo|Matching placebo
219068562|NCT03537924|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219068563|NCT03537924|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219068564|NCT01891825|PROCEDURE|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
219068565|NCT01891825|PROCEDURE|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
219068566|NCT01318889|DRUG|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
219068567|NCT00434057|DEVICE|MelaFind(R)|Biopsy ratio comparison
219068568|NCT05970029|BEHAVIORAL|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
219068569|NCT00396604|DRUG|indacaterol maleate|
219068570|NCT00044382|DRUG|CC-5013|
219068571|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
219068572|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
219068573|NCT01391104|DRUG|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
219068574|NCT01391104|DRUG|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
219068575|NCT02003001|DRUG|Botulinum Toxin|
219068576|NCT06535984|OTHER|White Noise|White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.
219068577|NCT06535984|OTHER|Swaddling|Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.
219068578|NCT06535984|OTHER|White Noise+Swaddling|White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
219068579|NCT01525290|DRUG|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
219068580|NCT01525290|DRUG|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
219068581|NCT03058770|OTHER|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
219068582|NCT03058770|OTHER|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
219068583|NCT04122417|OTHER|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
219068584|NCT02473952|DRUG|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
219068585|NCT02473952|DRUG|Placebo|
219068586|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
219068587|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
219669871|NCT01239836|BEHAVIORAL|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
219669872|NCT01239836|BEHAVIORAL|General health lecture|Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
219669873|NCT05244434|OTHER|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
219669874|NCT05244434|PROCEDURE|Biopsy|Undergo biopsy of tumor tissue
219669875|NCT05244434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218978865|NCT04337385|BEHAVIORAL|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
218978866|NCT00000574|DRUG|ibuprofen|
218978867|NCT06365541|DRUG|Dapagliflozin|oral Dapagliflozin tablets 10mg/day for 6 months
218978868|NCT03750461|DEVICE|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
218978869|NCT02202525|DRUG|Micardis®|
218978870|NCT02202525|DRUG|Other hypertensives|
218978871|NCT03553927|DIETARY_SUPPLEMENT|Low Energy Diet|Caloric restriction to achieve weight loss
218978872|NCT03553927|OTHER|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
218978873|NCT00531401|DRUG|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
218978874|NCT04902131|DRUG|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
218978875|NCT04902131|DRUG|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
218978876|NCT01688518|DRUG|Heated Lidocaine/Tetracaine Patch|
218978877|NCT01688518|DRUG|5% Lidocaine Patch|
218978878|NCT05083468|DRUG|SR750 tablet|The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
219068588|NCT00455195|BIOLOGICAL|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
218978879|NCT05083468|DRUG|matching placebo|The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
218978880|NCT00659750|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
219669876|NCT05244434|OTHER|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
218978881|NCT00659750|DRUG|Placebo|placebo
218978882|NCT06242600|DEVICE|Drainage of the bladder by indwelling Foley catheter|Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
218978883|NCT03098459|OTHER|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
218978884|NCT04176705|DRUG|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
218978885|NCT04176705|DRUG|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
218978886|NCT04176705|DEVICE|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
218978887|NCT02423772|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
219669877|NCT03385369|DRUG|MEDI0382|Single dose of MEDI0382
219669878|NCT03385369|DRUG|Placebo|Single dose of placebo
219669879|NCT05392088|OTHER|DATA EXTRACTION|"For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status."
219068589|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
219068590|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
219068591|NCT01753024|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
219068592|NCT04846504|BEHAVIORAL|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
219068593|NCT04846504|BEHAVIORAL|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
219068594|NCT04846504|BEHAVIORAL|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
219669880|NCT05392088|OTHER|FOLLOW-UP|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
219669881|NCT02414802|DEVICE|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
219669882|NCT02414802|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
218978891|NCT01350518|DIETARY_SUPPLEMENT|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
219669883|NCT02414802|DRUG|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
219669884|NCT02414802|DRUG|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
218978892|NCT01350518|DIETARY_SUPPLEMENT|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
219068595|NCT04846504|BEHAVIORAL|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
219068596|NCT06245785|PROCEDURE|transarterial chemoembolisation|Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
219068597|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
219068598|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
219068599|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
219068600|NCT03669029|DRUG|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
219068601|NCT03669029|DRUG|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
219068602|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
219068603|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
219068604|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
219068605|NCT05540236|OTHER|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
219068606|NCT05540236|OTHER|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
219068607|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
219669885|NCT05735678|DEVICE|Single-Use Duodenoscopes|Single-Use Duodenoscopes
219669886|NCT06730178|BEHAVIORAL|relaxation training|The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
219669887|NCT02455713|DEVICE|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
219669888|NCT03406988|PROCEDURE|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
219669889|NCT03406988|PROCEDURE|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
218978893|NCT02887573|DRUG|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
218978894|NCT02887573|DRUG|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
218978895|NCT02887573|PROCEDURE|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
218978896|NCT02887573|DRUG|2L PEG|2L PEG are laxatives for experiment group.
218978897|NCT02887573|DRUG|4L PEG|4L PEG are laxatives in the control group.
218978898|NCT02887573|DRUG|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
218978899|NCT02887573|DRUG|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
219068608|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
218978900|NCT01607671|DRUG|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
219669890|NCT02721017|DEVICE|Cryoanalgesia|
219669891|NCT02721017|DRUG|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
219669892|NCT00571753|DRUG|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
219669893|NCT00571753|DRUG|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
219669894|NCT00413933|PROCEDURE|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
219669895|NCT00430456|PROCEDURE|Exercise|Treadmill Training
219669896|NCT03872765|DEVICE|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
219669897|NCT01156051|DRUG|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
219669898|NCT01156051|DRUG|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
219669899|NCT01313351|DEVICE|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
219669900|NCT01892878|PROCEDURE|VerteLoc|Single Arm
219669901|NCT05574907|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
219669902|NCT00041041|DRUG|imatinib mesylate|Given PO
219669903|NCT00041041|OTHER|laboratory biomarker analysis|Correlative studies
218978901|NCT01806727|BEHAVIORAL|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
219669904|NCT03963778|BEHAVIORAL|Improving nutritional care|The interventions will be co-designed with the action research team
219669905|NCT00478088|DEVICE|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
219669906|NCT00478088|DEVICE|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
219669907|NCT06863298|OTHER|Podcast|A podcast is content that can be listened to on any digital audio listening device, including a computer, that supports audio file playback.
219669908|NCT01846806|OTHER|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
219669909|NCT03813641|DRUG|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
219669910|NCT03813641|DRUG|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
219669911|NCT03979183|BEHAVIORAL|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
219669912|NCT05006846|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
218978902|NCT01806727|BEHAVIORAL|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
218978903|NCT02138435|OTHER|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
218978904|NCT02138435|OTHER|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
218978905|NCT03882788|DRUG|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
218978906|NCT03882788|DRUG|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
218978907|NCT03882788|DRUG|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
218978908|NCT01193842|DRUG|Cyclophosphamide|Given IV
218978909|NCT01193842|DRUG|Doxorubicin Hydrochloride|Given IV
218978910|NCT01193842|DRUG|Etoposide|Given IV
218978911|NCT01193842|OTHER|Laboratory Biomarker Analysis|Correlative studies
219068609|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
219068610|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
219068611|NCT02563912|OTHER|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
219669913|NCT02570035|DRUG|Mirabegron|oral
218978912|NCT01193842|OTHER|Pharmacological Study|Correlative studies
218978913|NCT01193842|DRUG|Prednisone|Given PO
218978914|NCT01193842|BIOLOGICAL|Rituximab|Given IV
218978915|NCT01193842|DRUG|Vincristine Sulfate|Given IV
218978916|NCT01193842|DRUG|Vorinostat|Given PO
218978917|NCT04460456|DRUG|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
219669914|NCT07010952|DIAGNOSTIC_TEST|AI-based image analysis|AI-based imaging analysis
219669915|NCT07010952|OTHER|AI-based imaging analysis|AI-based imaging analysis
219669916|NCT02393430|DRUG|Rebamipide|Rebamipide is a
219669917|NCT02393430|BEHAVIORAL|optimization of life style|
219669918|NCT06731400|DIETARY_SUPPLEMENT|EPA supplementation|Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
219669919|NCT07018232|BEHAVIORAL|Unplanned healthcare encounter|Patient needing to connect with healthcare to fill a medication gap
219669920|NCT07015996|BIOLOGICAL|Tezepelumab|"Monotherapy Period: Participants randomized to tezepelumab will receive two subcutaneous (SQ) injections of tezepelumab 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to Tezepelumab will continue to receive Tezepelumab 210 mg every 4 weeks.~Withdrawal Period: Participants will stop receiving Tezepelumab injections."
219669921|NCT07015996|DRUG|Peanut Oral Immunotherapy (OIT)|"Monotherapy Period: Not Applicable. Combination Therapy Period: During combination therapy period, each participant will start peanut OIT. Participants will start on a minimum of 0.1 mg peanut OIT, with starting dose depending on last tolerated dose from screening double-blind placebo-controlled food challenge (DBPCFC) and build to a maximum of 6 mg peanut OIT on the initial dose escalation (IDE) day. Participants will return every 2 weeks for dose escalation to a goal maintenance dose of 2000 mg peanut protein.~Withdrawal Period: Participants will stop peanut OIT."
219669922|NCT07015996|BIOLOGICAL|Placebo for Tezepelumab|"Monotherapy Period: Participants randomized to placebo for tezepelumab will receive two subcutaneous (SQ) injections of placebo 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to placebo will continue to receive placebo for Tezepelumab every 4 weeks.~Withdrawal Period: Participants will stop receiving placebo injections."
219669923|NCT07023198|OTHER|Clinical breast examination and Navigation|trained nurses on clinical breast examination and navigation will provide screening for all eligible women and they will follow those women who will have suspicious breast lesions until they have completed their final diagnosis of breast cancer and initiation of breast cancer treatment
218978918|NCT04460456|DRUG|pembrolizumab|400 mg IV
218978919|NCT04460456|DRUG|Cemiplimab|350 mg IV
218978920|NCT04621565|DRUG|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
218978921|NCT04621565|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
218978922|NCT03903653|DRUG|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
218978923|NCT03903653|DEVICE|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
218978924|NCT03862859|DRUG|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
218978925|NCT01468103|PROCEDURE|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
218978926|NCT01468103|PROCEDURE|Laser Iridotomy|alternative choice to surgical iridectomy
218978927|NCT04966052|OTHER|No intervention|No intervention
218978928|NCT06033521|DRUG|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
218978929|NCT02715401|DRUG|HCP1303|
218978930|NCT02715401|DRUG|HGP1201|
218978931|NCT02715401|DRUG|HIP1402|
218978932|NCT02788929|DEVICE|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
219068612|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
218978933|NCT03727425|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
218978934|NCT01759511|DRUG|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
218978935|NCT03377114|PROCEDURE|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
218978936|NCT03377114|PROCEDURE|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
219068613|NCT05734482|BIOLOGICAL|Secukinumab|for subcutaneous injection only
219068614|NCT01019330|OTHER|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
219068615|NCT01019330|OTHER|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
219669924|NCT07027358|DEVICE|NETSmart software|Use of NETSmart software by healthcare professionals
219669925|NCT07026487|OTHER|Music intervention|This group will receive music therapy while performing Needle EMG
219669926|NCT07026500|BIOLOGICAL|EV71 Vaccine|EV71 vaccine of commercial production batch
219669927|NCT07026682|DRUG|Low Osmolar ORS|"Composition: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl- 65 mmol/L, citrate 10 mmol/L, glucose 75 mmol/L; osmolarity 245 mmol/L.~Administered orally in rehydration regimen over 24 hours."
219669928|NCT07026682|DRUG|ReSoMal|"Composition: Na⁺ 45 mmol/L, K⁺ 40 mmol/L, Cl- 76 mmol/L, citrate 7 mmol/L, glucose 125 mmol/L, Mg 6 mmol/L, Zn 300 µmol/L, Cu 45 µmol/L; osmolarity 300 mmol/L.~Administered orally over 24 hours according to rehydration protocol."
219669929|NCT07026136|OTHER|Hybrid Digital Learning with AI Chatbot for Geriatric Communication|A web-based, self-directed learning program integrated with a conversational AI chatbot. The chatbot reinforces learning and allows for flexible post-training practice.
219669930|NCT07026136|OTHER|Traditional Learning: Printed Educational Materials|Traditional teaching materials, printed document including structured readings on aging knowledge, empathy, communication barriers, and case-based communication strategies with older adults.
219669931|NCT07026916|DRUG|GFH375|GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity.
219669932|NCT02855177|DRUG|Placebo|Placebo as suspension administered every 8 hours, with food
219669933|NCT02855177|DRUG|PF-06427878|500 mg suspension administered every 8 hours, with food
219669934|NCT06757634|DRUG|Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant|"Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off~Other Names:~• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks~Other Names:~• Faslodex"
219669935|NCT06757634|DRUG|Arm B: Palbociclib or Ribociclib + Fulvestrant|"Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI®~Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4~Other Names:~• Faslodex"
219669936|NCT00366119|DRUG|Ramipril|
219669937|NCT02620384|DRUG|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
219669938|NCT02620384|DRUG|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
219669939|NCT00259974|DRUG|Rituximab|Rituximab
219068616|NCT03701555|OTHER|PvP001 placebo|placebo
219068617|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
219068618|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
219068619|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
219669940|NCT02870127|OTHER|blood sample|
219669941|NCT06150768|DEVICE|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
219669942|NCT06150768|DEVICE|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
219669943|NCT06150768|DEVICE|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
219669944|NCT06061211|OTHER|TREADMILL(SIDEA-Germany treadmill ) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
219669945|NCT02727426|OTHER|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
219669946|NCT02727426|OTHER|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
219669947|NCT05247892|PROCEDURE|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
219669948|NCT05247892|PROCEDURE|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
219669949|NCT04148963|DRUG|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
219669950|NCT04148963|DRUG|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
219669951|NCT00785902|DEVICE|AtriCure Bipolar System|
219669952|NCT04181268|DEVICE|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
219669953|NCT01704001|DRUG|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
219068620|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
219068621|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
219068622|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
219068623|NCT03701555|OTHER|PvP002 placebo|Placebo
219068624|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
219068625|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
219068626|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
219068627|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
219669954|NCT03387345|OTHER|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
219068628|NCT01186523|OTHER|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
219068629|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
219068630|NCT00546728|DRUG|Exenatide|exenatide 10 mcg twice daily
219068631|NCT00546728|DRUG|Metformin|metformin 500 twice daily
219068632|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
219068633|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
219068634|NCT04842357|OTHER|standardised video concerning clinical skill|watching a video concerning clinical skills.
219068635|NCT02637297|PROCEDURE|Hypnotherapy|Undergo hypnotherapy
219068636|NCT02637297|OTHER|Questionnaire Administration|Ancillary studies
219208722|NCT06885684|BEHAVIORAL|Cognitive Control Training + Metacognition Coaching|Computer training is delivered in person by a coach. Training consists of four games; each requires multiple aspects of cognitive control. Training levels progress in difficulty by increasing the number of items or simultaneous dimensions, decreasing the available response time, requiring greater accuracy, or adjusting the proportion of distractors or their complexity. Parameters that influence the difficulty of each level and passing criteria are fixed, but children progress from level to level at their own pace. Training is accompanied by manualized metacognition coaching to provide strategies to meaningfully engage with the tasks, simplify the tasks, support sustained effort, emphasize key cognitive control skills needed, provide coping strategies to reduce frustration associated with challenging aspects of the games, and use guided conversations to highlight metacognition.
219208723|NCT06794762|OTHER|Conventional exercises|"Aerobic exercise and stretching exercises will be applied in the conventional exercise program.~A 20-30 minute walking will be done as aerobic exercise. Stretching exercises will be done for major muscle groups in 3 sets and 10 repetitions."
219208724|NCT06794762|OTHER|Core stabilization exercises in addition to conventional exercises|In addition to the conventional exercise program, core stabilization exercises will be applied. During the exercises, participants will be trained on neutralizing the spine and working the transverse abdominis and multifidus muscles, correct postural control, and performing the exercises with diaphragmatic breathing.
219208725|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
219208726|NCT06881940|OTHER|Rehabilitation Program|"Three of the five weekly sessions will take place at the gym in the Functional Unit of Breast Tumors at INCAN, under the supervision of Physical and Sports Medicine specialists and three physical therapists. These sessions allow for personalized feedback, enabling participants to confidently perform prescribed aerobic exercises at home on the remaining two days.~Each session starts with a 10- to 15-minute warm-up focused on joint mobility. Aerobic training is conducted at moderate intensity (40-59% VO2max or heart rate reserve), monitored with a Polar® FT1 device. Intensity is periodically adjusted based on the Borg Rating of Perceived Exertion and the talk test. Over 4-6 weeks, session duration will gradually increase to 90 minutes per week, remaining consistent thereafter.~Following aerobic training, resistance exercises targeting major muscle groups are performed using gym machines and dumbbells. The program includes seven exercises, progressively increasing load over 3-4 weeks."
219669955|NCT03387345|OTHER|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
219669956|NCT03387345|OTHER|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
219669957|NCT03387345|OTHER|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
219669958|NCT03387345|OTHER|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
219669959|NCT03387345|OTHER|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
219669960|NCT01968512|DEVICE|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
219669961|NCT01968512|DEVICE|Sham|Same character of Transcranial Direct Current Stimulation but without current
219669962|NCT02086409|DIETARY_SUPPLEMENT|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
219669963|NCT02086409|DIETARY_SUPPLEMENT|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
219669964|NCT02628509|DEVICE|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
219068637|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
219068638|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
219068639|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
219068640|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
219669965|NCT00369148|DRUG|nateglinide(drug) mitiglinide(drug)|
218978937|NCT04976062|DIAGNOSTIC_TEST|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
218978938|NCT02772055|OTHER|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
218978939|NCT02772055|OTHER|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
218978940|NCT01161108|DRUG|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
218978941|NCT01161108|DRUG|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
218978942|NCT01161108|DRUG|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
218978943|NCT01161108|DRUG|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
218978944|NCT03318666|BEHAVIORAL|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
218978945|NCT03318666|OTHER|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
218978946|NCT03306927|DIETARY_SUPPLEMENT|Whole yellow pea chili|Chili containing whole yellow peas
218978947|NCT03306927|DIETARY_SUPPLEMENT|Split yellow pea chili|Chili containing split yellow peas
218978948|NCT03306927|DIETARY_SUPPLEMENT|Rice chili|Chili containing long grain white rice
219068641|NCT05164822|OTHER|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
219068642|NCT02370602|DRUG|TAK-063|TAK-063 tablets
219068643|NCT02370602|DRUG|[^11C]T-773|\[\^11C\]T-773 IV solution
219068644|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
219068645|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
219068646|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
219068647|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
219068648|NCT04336215|OTHER|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
219068649|NCT03269474|PROCEDURE|Experimental Group|Subjects with EB diagnosis
219669966|NCT02518841|DEVICE|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
219669967|NCT02518841|OTHER|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
219669968|NCT00723463|PROCEDURE|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
219669969|NCT02836951|OTHER|Withdrawal of blood|Withdrawal of blood
219669970|NCT05096598|DRUG|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
219669971|NCT05096598|DRUG|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
219669972|NCT03267459|DEVICE|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
219669973|NCT01484860|DRUG|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
218978949|NCT06122116|OTHER|Physical Therapy|The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
218978950|NCT06122116|BIOLOGICAL|Platelet-Rich Plasma Injection|PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
218978951|NCT06122116|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm\^2 and applied in a circular pattern to the knee area.
218978952|NCT02197793|BEHAVIORAL|Community Mobilization Program|
218978953|NCT01818661|DRUG|AV-1451|This is used to assess Tau burden in the brain.
218978954|NCT03672643|DRUG|Crizotinib|receive crizotinib orally
218978955|NCT04430192|DRUG|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
218978956|NCT06554730|OTHER|Belzutifan|There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.
218978957|NCT05736224|DRUG|Sunscreen|The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
218978958|NCT05736224|OTHER|UV Light|UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
218978959|NCT06934369|OTHER|Strategies to improve HIV care engagement|Based on the barriers to HIV care experienced by the pre-intervention cohort, we will design a system intervention to be implemented at the Radiotherapy Centre at Parirenyatwa Hospital. This intervention will include 2-3 components, each intended to improve engagement in HIV care or address specific barriers to HIV care. It may include strategies like improving documentation of HIV-related information in oncology patient records, improving processes for referrals and access to HIV-related prescriptions, and supporting better communication between oncology and HIV clinical care teams.
218978960|NCT00094029|DRUG|Sutent|Sutent, 25, 37.5, or 50 mg daily
218978961|NCT04593849|OTHER|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
218978962|NCT06654258|BEHAVIORAL|Spiritual Self-Care Smartphone App|"Participants will be asked to engage with a commercially available spiritual self-care smartphone app on a daily basis for 6 weeks. The content spans several domains, including meditation, prayer, affirmations, movement (i.e., stretching and yoga), and music. The user experience is highly personalized, allowing the user to select content that matches their current: mood or needs (e.g., anxiety, loneliness, stress, self-esteem, and sleep), time of day (e.g., recommendations for morning and evening practices), and/or availability (e.g., very brief micro-interventions lasting no more than 90 seconds or longer activities up to 30 minutes in duration). The content is delivered via a combination of audio and visual modalities on a personal smartphone that can be toggled on and off to adjust to surroundings."
218978963|NCT00914173|DEVICE|Scanlaf Circulator and water bath|Cold Pressor Test
219669974|NCT01500044|PROCEDURE|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
219669975|NCT01500044|PROCEDURE|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
219669976|NCT03070405|DRUG|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
219669977|NCT03070405|DRUG|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
218978964|NCT00914173|DEVICE|Medoc TSA 2000|Thermal stimuli pain
218978965|NCT04060849|DRUG|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
218978966|NCT04060849|OTHER|Best Practice|Receive standard of care
219068650|NCT00001601|PROCEDURE|Electrocardiogram|
219068651|NCT00001601|PROCEDURE|Biopsies|
219669978|NCT05368909|DIETARY_SUPPLEMENT|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
219669979|NCT05368909|DIETARY_SUPPLEMENT|Placebo|Placebo product
219669980|NCT02824588|BEHAVIORAL|Working Memory Training|Training mental flexibility
219669981|NCT02824588|BEHAVIORAL|Internet use|Used as control for time spent on computer
219669982|NCT06216405|PROCEDURE|Colonoscopy|Colonoscopy
219669983|NCT01630356|BEHAVIORAL|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
219068652|NCT00001601|PROCEDURE|Diagnostic imaging|
219669984|NCT01630356|DEVICE|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
219068653|NCT04141306|OTHER|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
219068654|NCT04141306|OTHER|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
219068655|NCT04141306|OTHER|Histological data|Evaluation of Pathology report of thyroid surgery
219068656|NCT04141306|OTHER|Imaging data|Evaluation of scintigraphy, MRI, scan
219068657|NCT04141306|OTHER|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
219068658|NCT04141306|OTHER|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
219068659|NCT03223363|DIAGNOSTIC_TEST|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
219068660|NCT01906294|DRUG|antidiabetic treatment (ATC A10B)|
219068661|NCT01015742|DRUG|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
219068662|NCT01326364|PROCEDURE|Stereotactic body radiotherapy|Standard of Care
219068663|NCT01326364|DRUG|Iodixanol|IV, calculated per patient
219068664|NCT01326364|DRUG|Iohexol|IV, Calculated per patient
219068665|NCT01981135|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219068666|NCT01981135|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219068667|NCT00607451|DRUG|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
219068668|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
219068669|NCT06035133|DRUG|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
219068670|NCT06035133|DRUG|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
219669985|NCT01630356|BEHAVIORAL|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
219669986|NCT01630356|BEHAVIORAL|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
219669987|NCT06916312|BEHAVIORAL|High ventilation breathwork|Single guided conscious connected breathing session.
219068671|NCT06035133|RADIATION|radiotherapy|radiotherapy
219068672|NCT05156138|OTHER|no interventions as it is a case control observational study|no interventions as it is a case control observational study
219068673|NCT05624242|PROCEDURE|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
219068674|NCT00542802|DRUG|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
219068675|NCT00542802|DRUG|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
219068676|NCT02362490|DRUG|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
219068677|NCT01127178|DRUG|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
219068678|NCT05410977|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
219068679|NCT05410977|OTHER|Electronic Health Record Review|Medical records reviewed
219208727|NCT06881940|OTHER|No Rehabilitation Program|The control group will continue standard oncological treatment in addition to general recommendations regarding diet and physical activity, but without a structured exercise protocol.
219208728|NCT01513122|DRUG|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
219208729|NCT01513122|DRUG|2-3N(t)RTI|
219208730|NCT01513122|DRUG|raltegravir|raltegravir 400mg 1 tablet twice daily.
219669988|NCT06916312|BEHAVIORAL|Meditation|Single guided body scan meditation session.
218978967|NCT05633797|DEVICE|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
218978968|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
218978969|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
218978970|NCT05348473|DEVICE|Alpha type|Tips of the seton will be tied as alpha-shaped.
218978971|NCT05348473|DEVICE|Beta type|Tips of the seton in this group will be overlapped and tied
218978972|NCT05348473|DEVICE|Comfort type|Knotless seton will be applied
218978973|NCT04375228|DRUG|Rituximab|375mg/m\^2 IV weekly for 4 doses
218978974|NCT04375228|DRUG|Tocilizumab|4mg/kg IV once a month for up to 2 doses
218978975|NCT06709118|DEVICE|fiberoptic|Tracheal intubation was performed with different outer diameters of fiberoptic.
218978976|NCT06707454|DEVICE|Digital Electroencephalography (DEEG)|The enrolled patients will undergo Digital Electroencephalography (DEEG) monitoring for at least two hours. A senior epileptologist will make a DEEG interpretation to detect DEEG abnormality. DEEG patterns will be categorized according to the American Clinical Neurophysiology Society's standardized critical care DEEG terminology(normal, slowing and asymmetry, sharp and wave, periodic discharges, ictal patterns burst suppression, and electrocerebral silence)
218978977|NCT06710691|OTHER|Physical activity intervention using traditional strength training protocols|Strength training participants performed the 6 reps of the first exercise at the prescribed RPE and then rested for 1 minute. Participants then completed another set of their first exercise with the required rest until the prescribed sets were completed. Participants performed the second and third exercises in the same fashion. Once the first block was completed, participants rested 5 min, then completed the second block. Six exercises were completed.
218978978|NCT06710691|OTHER|Physical activity intervention using high-resistance circuit training.|An adapted version of Alcaraz's high-resistance circuit training (HRC) was utilized in the intervention. Exercises and intensities used by strength training was the same for HRC except HRC participants performed the first three exercises as a circuit with 35 seconds rest between exercises, then completed the second block of exercises in the same fashion.
218978979|NCT06710912|BEHAVIORAL|Group acceptance and commitment therapy (ACT)|The ACT intervention module utilized in this study was adapted from Hayes foundational work on ACT and Harris. A summary of the general contents and exercises in each week was in accordance with the 6 core processes of Acceptance and Commitment Therapy based on Hayes. It was conducted in the Malay language. The same workbook with guided exercise and homework were used by all the therapists to assure standardization of the intervention to ensure that each group received similar contents in each session.
218978980|NCT06710912|OTHER|Treatment as usual|Standard care and follow-up for major depressive disorder
218978981|NCT06707857|OTHER|tendon neuroplastic training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
218978982|NCT06707857|OTHER|conventional training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
218978983|NCT06708741|DRUG|Vitamin D|High dose oral vitamin D supplementation (50,000 IU/once per month)
218978984|NCT06708624|DRUG|FYB201 0.5 mg (0.05 mL of 10 mg/mL)|IVT administration of FYB201 in a PFS
218978985|NCT06710470|DRUG|Deucravacitinib|As per product label
218978986|NCT06710470|DRUG|Systemic psoriasis medications|As per product label
218978987|NCT06710470|OTHER|No systemic medications|Participants not exposed to any systemic medications
218978988|NCT00427947|DRUG|ropivacaine/placebo|Continuous sciatic nerve bloc
218978989|NCT04147533|DRUG|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
218978990|NCT04147533|DRUG|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
218978991|NCT04147533|DRUG|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
219669989|NCT05347290|DEVICE|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
219669990|NCT05347290|DEVICE|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
219669991|NCT05347290|DEVICE|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
219669992|NCT02494401|OTHER|Internet-based self-management program|
218978992|NCT06933238|DRUG|Fuzheng Tongfu Jiedu prescription (FZTFJD)|"Fuzheng Tongfu Jiedu prescription (FZTFJD), a kind of Traditional Chinese medicine (TCM).Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
218978993|NCT06933238|DRUG|Placebo|"Fuzheng Tongfu Jiedu prescription plaebo. Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
218978994|NCT03319173|BEHAVIORAL|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
218978995|NCT05928793|BEHAVIORAL|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
218978996|NCT03673046|DEVICE|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
218978997|NCT03817879|PROCEDURE|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
218978998|NCT03817879|PROCEDURE|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
218978999|NCT00522015|DRUG|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
218979000|NCT05900609|DIETARY_SUPPLEMENT|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (\~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes + 2 snacks per day. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
218979001|NCT05900609|DIETARY_SUPPLEMENT|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
218979002|NCT05900609|DIETARY_SUPPLEMENT|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
219068680|NCT06250751|BEHAVIORAL|Behavioral Exercise Training (BET) intervention|Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
219068681|NCT06513429|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells by intravenous infusion.
219068682|NCT03541096|BEHAVIORAL|Winter Swimming|Supervised Winter Swimming in Copenhagen
219068683|NCT03541096|BEHAVIORAL|Control group|No winter swimming activities.
219068684|NCT03315000|DRUG|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
219068685|NCT03315000|DRUG|Fluticasone Furoate|Same as fluticasone arm description
219068686|NCT03315000|DRUG|Placebos|Same as placebo arm description
219068687|NCT05831358|OTHER|Multiple Myeloma M-Protein Analysis|Participants will be screened with a blood test for monoclonal protein analysis
219068688|NCT05831358|OTHER|Multiple Myeloma Knowledge Questionnaires|Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
219068689|NCT06295120|DRUG|Phenoxymethylpenicillin 1.2 MIE 4 times daily|The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
219208731|NCT05604963|PROCEDURE|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
219208732|NCT05604963|PROCEDURE|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
219208733|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
219208734|NCT03133988|BIOLOGICAL|Margetuximab|anti-HER2 monoclonal antibody
219669993|NCT02494401|OTHER|Scleroderma book|
219669994|NCT00003215|BIOLOGICAL|filgrastim|
219669995|NCT00003215|DRUG|CHOP regimen|
219669996|NCT00003215|DRUG|cyclophosphamide|
219068690|NCT04158375|BEHAVIORAL|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
219068691|NCT06510075|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
219068692|NCT06510075|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
219068693|NCT06510075|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
219068694|NCT06001775|BEHAVIORAL|Patient Priorities Care|According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
219068695|NCT02365467|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|
219068696|NCT03948724|BEHAVIORAL|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
219068697|NCT03948724|BEHAVIORAL|Usual Information|Patient receive usual informations
219068698|NCT02277782|DRUG|Hydromorphone|
219068699|NCT02277782|DRUG|Hyperbaric bupivacaine|
219068700|NCT02277782|DRUG|Fentanyl|
219068701|NCT02043782|DEVICE|Coloplast Test|Newly developed 1-piece convex ostomy product
219068702|NCT02043782|DEVICE|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
219068703|NCT02043782|DEVICE|Competitor soft convex|A commercially available soft convex product
219068704|NCT04571346|PROCEDURE|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
219068705|NCT06534151|DEVICE|CRT implantation|A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
219068706|NCT05157191|OTHER|Observational|Observational
219669997|NCT00003215|DRUG|cytarabine|
219068707|NCT05136573|BEHAVIORAL|Combined Exercises|Combined Exercises
219068708|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
219068709|NCT01306162|DRUG|Dabigatran etexilate|150 mg as single dose
219208735|NCT06680297|DIETARY_SUPPLEMENT|Carbohydrates loading|Patient who is randomised in the intervention group will receive Nestle drink 2hours before the operation and a night before operation. They will receive 10mls/kg a night before operation and 5mls/kg 2 hour before operation of the carbohydrate drink.
219669998|NCT00003215|DRUG|doxorubicin hydrochloride|
219669999|NCT00003215|DRUG|etoposide|
219670000|NCT00003215|DRUG|leucovorin calcium|
219670001|NCT00003215|DRUG|melphalan|
219670002|NCT00003215|DRUG|methotrexate|
219670003|NCT00003215|DRUG|methylprednisolone|
219670004|NCT00003215|DRUG|mitoxantrone hydrochloride|
219670005|NCT00003215|DRUG|prednisone|
219670006|NCT00003215|DRUG|therapeutic hydrocortisone|
219670007|NCT00003215|DRUG|vincristine sulfate|
219670008|NCT00003215|PROCEDURE|bone marrow ablation with stem cell support|
219670009|NCT00003215|PROCEDURE|peripheral blood stem cell transplantation|
219670010|NCT00003215|RADIATION|radiation therapy|
219670011|NCT00966355|DRUG|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
219670012|NCT00966355|DRUG|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
219670013|NCT00966355|DRUG|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
219670014|NCT05288855|DRUG|Voclosporin|calcineurin inhibitor
219670015|NCT05288855|DRUG|Placebo Oral Capsule|matching placebo capsule
219670016|NCT03934359|DRUG|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
219670017|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219670018|NCT05077813|COMBINATION_PRODUCT|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219670019|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219670020|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219068710|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
218979003|NCT00825578|DEVICE|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
218979004|NCT05449119|BIOLOGICAL|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
218979005|NCT05449119|OTHER|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
218979006|NCT05449119|OTHER|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
218979007|NCT05449119|OTHER|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
218979008|NCT05449119|OTHER|Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)|at T0, T3 months, T6 months, T9 months and T12 months
218979009|NCT05449119|OTHER|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
218979010|NCT05449119|OTHER|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
219068711|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
219068712|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
219670021|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219670022|NCT05077813|OTHER|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
219670023|NCT03646487|DIETARY_SUPPLEMENT|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
219670024|NCT03646487|OTHER|Placebo in capsule form|Daily placebo in capsule form
219670025|NCT03339336|DRUG|BIIB074|Administered as specified in the treatment arm.
219670026|NCT03339336|DRUG|Placebo|Administered as specified in the treatment arm.
219670027|NCT00777192|BEHAVIORAL|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
219670028|NCT06286020|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
219670029|NCT06286020|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
219670030|NCT06950762|PROCEDURE|Giomer based injectable composite|Giomers utilize surface pre-reacted glass (SPRG) technology, which involves an acid-base reaction between fluorine-containing glass particles and polymer-containing acid when exposed to water. This reaction results in the formation of a glass ionomer phase, which is then dispersed throughout the resin. Furthermore, the S-PRG fillers present in giomer materials enable the continuous release and replenishment of fluoride, offering long-lasting protection against the recurrence of caries
219670031|NCT06950762|PROCEDURE|Universal injectable resin composite|Conventional injectable resin composite
219670032|NCT04413942|BIOLOGICAL|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
219670033|NCT04413942|OTHER|Placebo|Formulation buffer
218979011|NCT01896050|DRUG|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
218979012|NCT01896050|DRUG|Tamoxifen|Patients were treated with tamoxifen for up to one year
218979013|NCT00392015|BIOLOGICAL|NMRC-M3V-Ad-PfCA|Malaria Vaccine
218979014|NCT00392015|BIOLOGICAL|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
218979015|NCT06956781|BEHAVIORAL|Emotion Regulation|Participants learn to reduce acute subjective distress, stabilize negative mood, promote positive mood, and alter physiological responses to trauma
218979016|NCT06956781|BEHAVIORAL|Exposure|Participants engage in written exercises to reduce avoidance of trauma reminders and reinforce approach behaviors consistent with personal goals
218979017|NCT06956781|BEHAVIORAL|Cognitive Processing|Participants learn ways to identify, challenge, and overcome the influence of cognitive distortions resulting from trauma exposure
218979018|NCT06956781|BEHAVIORAL|Bi-lateral Stimulation|Participants engage in horizontal eye movements while recalling a traumatic memory and describing their affective and physiological state
218979019|NCT06956781|BEHAVIORAL|Psychological Placebo|Participants receive non-directive support therapy, where they will guide the treatment session but not be required to discuss prior trauma exposure
218979020|NCT03693300|DRUG|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
218979021|NCT01891110|PROCEDURE|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
218979022|NCT01891110|PROCEDURE|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
218979023|NCT01891110|PROCEDURE|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
218979024|NCT02582502|OTHER|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
218979025|NCT02206048|DRUG|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
218979026|NCT02206048|PROCEDURE|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
219208736|NCT06680297|DIETARY_SUPPLEMENT|Control group|Patient assigned to this group will receive standard surgical fasting treatment which include 6hrs of fasting and 2 hrs of clear fluid prior operation
218979027|NCT02598804|OTHER|5 educational workshop|
218979028|NCT02598804|OTHER|written information booklet|
218979029|NCT01685866|DEVICE|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
218979030|NCT04325646|OTHER|Human Biological samples|Blood samples for serological tests
218979031|NCT04325646|OTHER|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
219208737|NCT05418101|DRUG|VIS171|Participants will receive VIS171 via SC route of administration.
219208738|NCT05418101|DRUG|Placebo|Participants will receive Placebo via SC route of administration
219670034|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
219670035|NCT06042244|OTHER|Multimodal Exercise Group|Listed in arm/ group descriptions
219670036|NCT06042244|OTHER|Waitlist|listed in arm/group description
219670037|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
219670038|NCT05124132|BEHAVIORAL|Exercise|Exercise
219670039|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
219670040|NCT05124132|BEHAVIORAL|Health Education|Health Education
219670041|NCT05651828|DRUG|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
219670042|NCT00743847|DRUG|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
219670043|NCT00743847|DRUG|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
219670044|NCT00743847|DRUG|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
218979032|NCT02925923|DRUG|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
219670045|NCT00532727|DRUG|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
219670046|NCT00532727|DRUG|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
219670047|NCT02132728|OTHER|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
219670048|NCT02927678|OTHER|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
219670049|NCT02182986|PROCEDURE|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
219670050|NCT02182986|DRUG|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
219670051|NCT01380652|PROCEDURE|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
219670052|NCT03218371|PROCEDURE|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
219670053|NCT01270321|DRUG|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
219670054|NCT01270321|DRUG|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
218979033|NCT02925923|DRUG|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
218979034|NCT02925923|DRUG|Clopidogrel|
218979035|NCT02692222|OTHER|Calculation of PPV and CO with two methods|
218979036|NCT01970657|BIOLOGICAL|No treatment specified|No intervention
218979037|NCT01970657|BIOLOGICAL|No treatment|None specified
218979038|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
218979039|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
218979040|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
218979041|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
218979042|NCT03643354|DIAGNOSTIC_TEST|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
218979043|NCT05367427|DIETARY_SUPPLEMENT|Heat treated postbiotic Bifidobacterium Longum consumption|Regular consumption in breakfast of heat treated postbiotic B. longum
218979044|NCT05367427|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
218979045|NCT01577368|DRUG|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
218979046|NCT01577368|DRUG|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
219670055|NCT01270321|DRUG|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
219670056|NCT01875263|DRUG|Cloxacilin|2g/4 hours i.v., 5 days
219068713|NCT02626715|DRUG|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
219068714|NCT02626715|DRUG|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
219068715|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
219068716|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
219068717|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
219068718|NCT02959437|DRUG|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
219208739|NCT04591080|DEVICE|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
219208740|NCT04591080|DEVICE|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
219670057|NCT01875263|DRUG|Cloxacillin|2g/4h 14 days Standard therapy
219670058|NCT01875263|DRUG|Levofloxacin|500 mg v.o./24h, 9 days
218979047|NCT00866788|DRUG|omalizumab|Administered by subcutaneous injection
218979048|NCT00866788|DRUG|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
218979049|NCT00866788|DRUG|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
218979050|NCT00866788|DRUG|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
218979051|NCT05662007|OTHER||no intervention
218979052|NCT01509092|PROCEDURE|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
219068719|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
218979053|NCT06556316|BEHAVIORAL|Cognitive Intervention with the Categorization Program|Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
218979054|NCT06556316|BEHAVIORAL|Social Cognitive Communication Program|An 11 week group intervention targeting social and cognitive-communication abilities
218979055|NCT06556316|DEVICE|Non-Invasive Brain Stimulation with tDCS|20 minute tDCS intervention as a non-invasive neuromodulation treatment
219068720|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily.
219068721|NCT02959437|DRUG|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
219068722|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
219068723|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
219068724|NCT02959437|DRUG|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
219068725|NCT03877718|DRUG|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
219068726|NCT03877718|DRUG|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
219068727|NCT03877718|DRUG|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
219068728|NCT03877718|DRUG|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
219068729|NCT03877718|DRUG|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
219068730|NCT03877718|OTHER|Placebo|One capsule of placebo
219068731|NCT00659633|DRUG|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
219208741|NCT06696092|DEVICE|Hemostatic Agent|WoundClot Surgical may be used in a single target bleeding site of each subject.
219208742|NCT06697678|OTHER|No Intervention: Observational Cohort|No intervention
219670059|NCT02751619|DRUG|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
219670060|NCT02751619|DRUG|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
219670061|NCT01613079|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
219670062|NCT01613079|DRUG|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
219670063|NCT04565483|DRUG|Benralizumab Prefilled Syringe|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
219670064|NCT05624216|DEVICE|BTL-084|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
219670065|NCT03518398|DEVICE|Intense Pulsed Light|E\> Eye (E-SWIN, Paris, France) IPL machine
219670066|NCT03518398|COMBINATION_PRODUCT|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
219670067|NCT04927923|OTHER|hope-focused motivational interview|The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
219670068|NCT03364036|DRUG|Mavenclad®|Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
219670069|NCT04198142|BEHAVIORAL|Imagery Rehearsal Therapy|"The Imagery Rehearsal Therapy (IRT) intervention used in this study is a short version of the treatment, consisting of 1-2 sessions.~The protocol starts with a very brief explanation of the treatment. Then the patient will be guided through an imagery exercise. The next step is to choose a nightmare. This nightmare is then rescripted to a new narrative, which is in no way distressing to the patient anymore. Subsequently, the therapist will guide the patient through an imagery exercise with the new narrative. The new narrative is then either written down or recorded. Lastly, the therapist will explain to the patient, that he or she should rehearse the new narrative daily with imagery exercises."
219670070|NCT04198142|BEHAVIORAL|Treatment as Usual with dream diaries|Treatment as Usual means that patients in this arm will receive usual inpatient care. Additionally, they will keep a dream diary. It has been shown in previous studies that keeping a dream diary has a positive effect on nightmares.
219670071|NCT03172377|OTHER|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
219670072|NCT01865656|OTHER|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
219670073|NCT01865656|OTHER|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
219670074|NCT01865656|OTHER|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
219670075|NCT01865656|OTHER|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
219670076|NCT01865656|OTHER|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
219670077|NCT01905332|OTHER|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
219670078|NCT01905332|OTHER|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
219670079|NCT04554381|BIOLOGICAL|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
219670080|NCT02394119|DRUG|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
219670081|NCT02394119|DRUG|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
219670082|NCT01393106|DRUG|Idelalisib|Idelalisib tablets administered orally
219670083|NCT02157571|DRUG|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
219670084|NCT02157571|DRUG|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
219670085|NCT02157571|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
219670086|NCT02157571|DRUG|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
219670087|NCT04569929|OTHER|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
219670088|NCT05805111|DEVICE|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
219670089|NCT02951793|OTHER|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.
219670090|NCT02951793|OTHER|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
219670091|NCT02951793|OTHER|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
219670092|NCT02666820|PROCEDURE|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
219670093|NCT02666820|PROCEDURE|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
219670094|NCT01084148|DRUG|V0034CR01B|
219670095|NCT01084148|DRUG|V0034CR01B vehicle|
219670096|NCT03971916|DRUG|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
219670097|NCT03971916|DRUG|Placebo|Subcutaneous injection; Single dose on Day 1
219670098|NCT00334165|PROCEDURE|Auricular acupuncture (procedure)|
219670099|NCT04310293|OTHER|Femara,Grotwth hormone,HMG|NOVEL THERAPY
219670100|NCT02032615|DIETARY_SUPPLEMENT|Education plus Gudness Nutritional Bar|
219670101|NCT02032615|OTHER|Education|
219670102|NCT04177992|OTHER|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
219670103|NCT01550523|DRUG|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
219670104|NCT01550523|DEVICE|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
219670105|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 LipoMicel® soft gels|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
219670106|NCT05394701|DIETARY_SUPPLEMENT|RxOmega-3 soft gels (Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
219670107|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 Complete soft gels (Non-Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
219670108|NCT03074604|PROCEDURE|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
219670109|NCT03074604|PROCEDURE|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
219670110|NCT03074604|PROCEDURE|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
219068732|NCT00986999|DRUG|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
219670111|NCT05437640|BEHAVIORAL|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
219068733|NCT03335358|BEHAVIORAL|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
219068734|NCT00833989|DRUG|GSK249320|I.V. infusion
219068735|NCT00833989|DRUG|PLACEBO|Placebo
218979056|NCT01403181|DRUG|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
218979057|NCT01805440|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
219068736|NCT02370654|BEHAVIORAL|Tai chi|
219068737|NCT02370654|BEHAVIORAL|Conventional exercise|
219670112|NCT05437640|BEHAVIORAL|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
219068738|NCT05293080|OTHER|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
219068739|NCT05293080|OTHER|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
219068740|NCT02199262|OTHER|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
219068741|NCT02199262|OTHER|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
219068742|NCT02199262|OTHER|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
219068743|NCT04094454|DEVICE|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
219068744|NCT04094454|DEVICE|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
219068745|NCT03663751|DRUG|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
219068746|NCT01949480|PROCEDURE|Thoracotomy|
219068747|NCT01949480|PROCEDURE|Video-Assisted Thoracoscopic Surgery (VATS)|
219068748|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
219068749|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
219068750|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
219068751|NCT02149589|PROCEDURE|Mechanical ventilation|
219068752|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
219068753|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
219670113|NCT00904917|BEHAVIORAL|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
219670114|NCT00904917|BEHAVIORAL|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
219670115|NCT05206734|OTHER|No specific intervention|Observational analysis of usual care only.
219670116|NCT04250415|PROCEDURE|Surgery|
219670117|NCT04228965|DRUG|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
219670118|NCT04228965|BEHAVIORAL|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
219068754|NCT05805397|BEHAVIORAL|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
219068755|NCT05805397|BEHAVIORAL|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
219068756|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
219068757|NCT01661660|OTHER|observationnal|Observation during a physical exercise
219670119|NCT04228965|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
219670120|NCT02330172|OTHER|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
219670121|NCT00329589|DRUG|Velcade (bortezomib)|
219670122|NCT04544163|DRUG|Magnesium sulfate- Fentanyl|drug administration before intubation
219670123|NCT04544163|DRUG|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
218979058|NCT01805440|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
218979059|NCT04450446|DRUG|Low molecular weight heparin|Anticoagulation therapy
218979060|NCT04244682|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
218979061|NCT04307303|DEVICE|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
218979062|NCT03022136|OTHER|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
218979063|NCT02742441|DRUG|122-0551 Foam|Topical Foam containing active drug
218979064|NCT02742441|DRUG|Vehicle Foam|Topical Foam containing no active drug
218979065|NCT05993377|OTHER|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
218979066|NCT06556446|DRUG|Tenecteplase and Alteplase|The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
218979067|NCT01564914|DRUG|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
218979068|NCT01564914|DRUG|Bevacizumab|IV
218979069|NCT03616626|RADIATION|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
218979070|NCT03616626|RADIATION|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
218979071|NCT03616626|RADIATION|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
218979072|NCT00252915|BIOLOGICAL|GM-CSF (verum)|sagramostim
219068758|NCT04996784|OTHER|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
219068759|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
219068760|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
219068761|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
219068762|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
219068763|NCT03007927|DRUG|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
219068764|NCT03007927|DRUG|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
219068765|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
219068766|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
219068767|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
218979073|NCT03052491|DIETARY_SUPPLEMENT|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
218979074|NCT06324812|DRUG|Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)|subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
218979075|NCT06271213|OTHER|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
219068768|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
219068769|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
219068770|NCT01272934|DRUG|Diclofenac Sodium|Topical gel 1%-4 times daily
219068771|NCT01272934|OTHER|Placebo|Topical gel-4 times daily
219670124|NCT04544163|DRUG|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
219670125|NCT04544163|DRUG|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
219670126|NCT00734656|DRUG|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
219670127|NCT00734656|DRUG|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
219670128|NCT00734656|DRUG|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
219670129|NCT00734656|DRUG|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
219670130|NCT04647513|DEVICE|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
219670131|NCT04469634|DIAGNOSTIC_TEST|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
219670132|NCT01127594|DRUG|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
219670133|NCT04298879|DRUG|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
219670134|NCT02100735|OTHER|Sedation protocol|Nursing driven sedation protocol
219670135|NCT03915626|DRUG|Rivastigmine (RLD) transdermal patch|brand name patch
219670136|NCT03915626|DRUG|Rivastigmine (generic) transdermal patch|generic patch
219670137|NCT03628833|DEVICE|Incontinence Management System|Incontinence detection device
219670138|NCT06954805|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B cell lysis. 375 mg/m2 Rituximab will be administered to participants by IV.
219670139|NCT06954805|DRUG|Etoposide|Etoposide is a topoisomerase II inhibitor and appears to cause DNA strand breaks. It has been shown to delay transit of cells through S phase and arrest cells in late S or early G2 phase. 50 mg/m2 Etoposide will be administered to participants by IV.
219670140|NCT06954805|DRUG|Prednisone|Prednisone can prevent or suppress inflammation and immune responses. Prednisone's action may include the inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, and suppression of humoral immune responses. 60 mg/m2 Prednisone will be administered to participants by PO.
218979076|NCT04793217|BEHAVIORAL|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
218979077|NCT04793217|BEHAVIORAL|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
218979078|NCT03268837|DEVICE|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
218979079|NCT03268837|DEVICE|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
218979080|NCT01645137|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
218979081|NCT01645137|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
218979082|NCT04222231|OTHER|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
219068772|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
219670141|NCT06954805|DRUG|Vincristine|Vincristine is a vinca alkaloid. The mechanism of action of vincristine is thought to be due to inhibition of microtubule formation in the mitotic spindle. This leads to arrest of dividing cells during the metaphase stage. 0.4 mg/m2 Vincristine will be administered to participants by IV.
219068773|NCT04331600|DRUG|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
219068774|NCT04331600|OTHER|Telemedicine|Telemedical supervision for 42 days
219670142|NCT06954805|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA. Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites which are thought to cross-link to tumor cell DNA. These metabolites interfere with the growth of rapidly proliferating susceptible malignant cells. 375 mg/m2 Cyclophosphamide will be administered to participants by IV.
219068775|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
219670143|NCT06954805|DRUG|Doxorubicin|Doxorubicin is an anthracycline, topoisomerase II inhibitor. It is isolated from cultures of Streptomyces peucetius var. caesius. The cytotoxic effect of doxorubicin is related to nucleotide base intercalation and cell membrane lipid binding activities. It blocks nucleotide replication and the action of DNA and RNA polymerases. The interaction between doxorubicin and topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of its cytocidal activity. 10 mg/m2 Doxorubicin will be administered to participants by IV.
219670144|NCT06954805|DEVICE|CAPP-seq|Next generation sequencing (NGS) tool used to detect tiny amounts of cancer DNA in the blood, allowing for early diagnosis and monitoring of cancer in a non-invasive way.
219670145|NCT03166488|DEVICE|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
219670146|NCT05933694|OTHER|Artificial Intelligence-powered Spirometry Interpretation Report|A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
219670147|NCT02603965|RADIATION|Copper Cu 64 TP3805|Given IV
218979083|NCT04222231|OTHER|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
218979084|NCT01999751|DEVICE|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
218979085|NCT03848442|OTHER|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
218979086|NCT04877483|PROCEDURE|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
218979087|NCT04877483|DIAGNOSTIC_TEST|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
218979088|NCT04877483|DIAGNOSTIC_TEST|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
218979089|NCT04877483|DIAGNOSTIC_TEST|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
218979090|NCT04877483|DIAGNOSTIC_TEST|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
218979091|NCT04877483|DIAGNOSTIC_TEST|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
218979092|NCT04877483|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
218979093|NCT04877483|DIAGNOSTIC_TEST|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
218979094|NCT04877483|DIAGNOSTIC_TEST|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
218979095|NCT04877483|DIAGNOSTIC_TEST|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
218979096|NCT04877483|DIAGNOSTIC_TEST|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
218979097|NCT04877483|DIAGNOSTIC_TEST|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
218979098|NCT04877483|DIAGNOSTIC_TEST|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
218979099|NCT04877483|DIAGNOSTIC_TEST|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
218979100|NCT04877483|DIAGNOSTIC_TEST|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
219068776|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
219670148|NCT02603965|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
219670149|NCT02603965|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
219670150|NCT02603965|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219670151|NCT02603965|OTHER|Laboratory Biomarker Analysis|Correlative studies
219670152|NCT01051726|OTHER|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
218979101|NCT03386318|DRUG|Oxycodone|Serum concentration per hour from 1 to 5 h
218979102|NCT01629992|OTHER|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
218979103|NCT02585154|PROCEDURE|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
219068777|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
219670153|NCT01051726|OTHER|None essential oil|Baby oil
219670154|NCT06321341|DRUG|Vespireit|Buspirone
219670155|NCT06321341|DRUG|Arlevert|Dimenhydrinate + Cinnarizine
218979104|NCT02585154|PROCEDURE|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
218979105|NCT02585154|PROCEDURE|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
218979106|NCT02585154|DEVICE|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
218979107|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
218979108|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
218979109|NCT00619736|DRUG|NSA-789|
218979110|NCT00619736|OTHER|Placebo|
218979111|NCT01404273|BEHAVIORAL|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
218979112|NCT04479930|OTHER|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
218979113|NCT02008318|DRUG|Galunisertib|Administered orally
218979114|NCT02008318|DRUG|Placebo|Administered orally
218979115|NCT00992290|BIOLOGICAL|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
218979116|NCT00992290|BIOLOGICAL|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
218979117|NCT06110078|DRUG|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
218979118|NCT00481143|DRUG|ICL670/Deferasirox|
218979119|NCT06157359|PROCEDURE|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
218979120|NCT00231842|DRUG|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
218979121|NCT00231842|DEVICE|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
218979122|NCT00231842|DRUG|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
218979123|NCT02422303|DRUG|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
218979124|NCT00541684|DRUG|MK0954, /Duration of Treatment : 16 Weeks|
218979125|NCT00541684|DRUG|Comparator : atenolol /Duration of Treatment : 16 Weeks|
218979126|NCT04958135|DRUG|Acoramidis|Film-coated immediate release oral tablet.
218979127|NCT05692128|OTHER|Hematological and chemistry tests|Laboratory tests
218979128|NCT00228683|PROCEDURE|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
218979129|NCT02114671|DRUG|Faldaprevir high dose|capsules, oral
218979130|NCT02114671|DRUG|Placebo|capsule, oral
219670156|NCT03585517|DRUG|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
219670157|NCT03102749|OTHER|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
219670158|NCT03039465|DEVICE|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
218979131|NCT02114671|DRUG|Ciprofloxacin|tablets, oral
218979132|NCT02114671|DRUG|Faldaprevir low dose|capsules, oral
218979133|NCT00008203|BIOLOGICAL|aldesleukin|
218979134|NCT00008203|BIOLOGICAL|recombinant interferon gamma|
218979135|NCT00008203|DRUG|carboplatin|
218979136|NCT00008203|DRUG|cyclophosphamide|
218979137|NCT00008203|DRUG|cyclosporine|
218979138|NCT00008203|DRUG|thiotepa|
218979139|NCT00008203|PROCEDURE|autologous bone marrow transplantation|
218979140|NCT00008203|PROCEDURE|peripheral blood stem cell transplantation|
218979141|NCT00976040|OTHER|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
218979142|NCT02296281|DRUG|Pirfenidone|
218979143|NCT02254941|DRUG|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
218979144|NCT02254941|BIOLOGICAL|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
219670159|NCT01881698|OTHER|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
219670160|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
219670161|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
218979145|NCT03836599|DRUG|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
218979146|NCT03836599|DRUG|Allopurinol|Participants will receive allopurinol 300 mg once daily.
218979147|NCT03836599|DRUG|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
218979148|NCT05915078|COMBINATION_PRODUCT|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
218979149|NCT00818597|DEVICE|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
218979150|NCT06159790|DRUG|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
218979151|NCT06159790|DRUG|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
218979152|NCT02646514|DEVICE|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
218979153|NCT02646514|DEVICE|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
218979156|NCT05177705|BEHAVIORAL|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
218979157|NCT00812669|BIOLOGICAL|pegfilgrastim|
218979158|NCT00812669|BIOLOGICAL|rituximab|
218979159|NCT00812669|DRUG|cyclophosphamide|
218979160|NCT00812669|DRUG|fludarabine phosphate|
218979161|NCT00812669|GENETIC|cytogenetic analysis|
218979162|NCT00812669|GENETIC|fluorescence in situ hybridization|
219670162|NCT02829502|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
218979163|NCT00812669|GENETIC|gene expression analysis|
218979164|NCT00812669|GENETIC|mutation analysis|
218979165|NCT00812669|GENETIC|protein expression analysis|
218979166|NCT00812669|OTHER|flow cytometry|
218979167|NCT00812669|OTHER|laboratory biomarker analysis|
218979168|NCT02672280|DEVICE|Medical Collagen Membrane with MSC|
218979169|NCT02672280|DEVICE|Medical Collagen Membrane|
218979170|NCT01348607|DRUG|methylphenidate hydrochloride|Given orally
218979171|NCT01348607|DRUG|modafinil|Given orally
218979172|NCT01348607|DRUG|placebo|Given orally
218979173|NCT00493623|DRUG|Placebo|Placebo i.v. single dose
218979174|NCT00493623|DRUG|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
218979175|NCT02081131|PROCEDURE|Open surgery|pancreatic head resection by open method
218979176|NCT02081131|PROCEDURE|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
218979177|NCT06181591|DRUG|Mirabegron 50 MG|Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
218979178|NCT06181591|DRUG|Oxybutynin Chloride 5 MG|Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
218979179|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
218979180|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
219670163|NCT02829502|DRUG|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
219670164|NCT05366296|BIOLOGICAL|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide), DSPC \[1,2- distearoyl-sn-glycero-3-phosphocholine\], Cholesterol, Trometamol and Sucrose
219670165|NCT05366296|BIOLOGICAL|Placebo|Normal saline (0.9% sodium chloride solution
219670166|NCT04938596|COMBINATION_PRODUCT|Respiratory bundle|"* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~* Promotion of strategies to improve house ventilation during 2 weeks~* Provision of a TB leaflet and nurse education about TB transmission."
219670167|NCT01797588|PROCEDURE|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
219670168|NCT01797588|PROCEDURE|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
219670169|NCT04010084|RADIATION|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
219670170|NCT04010084|PROCEDURE|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
219670171|NCT00001070|DRUG|Oral Vitamin C|
219670172|NCT02965508|OTHER|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
219670173|NCT02965508|OTHER|Usual Care|Office based care
219670174|NCT00692497|BEHAVIORAL|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
219670175|NCT01830907|DIETARY_SUPPLEMENT|carbohydrates|
219670176|NCT01830907|DIETARY_SUPPLEMENT|vitamins|
219670177|NCT04676152|DEVICE|Masimo Noninvasive Blood Pressure Device|Non-invasive blood pressure device
219670178|NCT00370422|DRUG|Triamcinolone, Bevacizumab|
219670179|NCT01532258|BEHAVIORAL|Go! Foods for You without Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
218979181|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
218979182|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
218979183|NCT00529984|BIOLOGICAL|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
218979184|NCT06198127|OTHER|combination of core stability exercises and kinesio-taping|the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
218979185|NCT06198127|OTHER|Core stability exercises|After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
219068778|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
219670180|NCT01532258|BEHAVIORAL|Go! Foods for You with Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
219068779|NCT01318187|DRUG|paracetamol|1 gr
219068780|NCT01318187|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
219068781|NCT01318187|DRUG|Paracetamol|1 gr intravenous
219068782|NCT01318187|DRUG|Paracetamol|intravenous 1 gr
219068783|NCT01318187|DRUG|Morphine|0.1 mg/kg intravenous
219068784|NCT02427529|DRUG|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
219670181|NCT00662987|DRUG|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
219670182|NCT00662987|DRUG|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
219670183|NCT01319487|DRUG|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
219670184|NCT01319487|DRUG|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
219670185|NCT01319487|DRUG|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
218979186|NCT01877018|BEHAVIORAL|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
218979187|NCT05707936|DRUG|Normal Saline Flush 20 ml|Normal Saline Flush 20 ml
218979188|NCT05707936|DRUG|Normal Saline Flush 10 ml|Normal Saline Flush 10 ml
219068785|NCT02427529|DRUG|Placebo|
219068786|NCT02427529|OTHER|Low calorie diet|
219068787|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
219068788|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
219068789|NCT00357305|DRUG|vorinostat|Given orally
219670186|NCT03894761|OTHER|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
219670187|NCT00675077|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
219670188|NCT01713296|DRUG|Pazopanib|
219670189|NCT00624364|DRUG|biphasic insulin aspart|
219670190|NCT00624364|DRUG|metformin|
219670191|NCT02954588|DIETARY_SUPPLEMENT|Pyridoxamine|
218979189|NCT05707936|DRUG|Heparin Flush (1000 USP, 10ml)|Heparin Flush (1000 USP, 10ml)
218979190|NCT03334110|PROCEDURE|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
219670192|NCT02954588|DIETARY_SUPPLEMENT|Placebo|
219670193|NCT00315718|DRUG|Extract from Hintonia latiflora bark|
219670194|NCT00755261|DRUG|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
219670195|NCT00755261|DRUG|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
219670196|NCT03879551|DEVICE|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
219068790|NCT00357305|DRUG|cytarabine|Given IV
219068791|NCT00357305|DRUG|etoposide|Given IV
219068792|NCT00357305|OTHER|pharmacological study|Correlative studies
219068793|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
219068794|NCT04313634|DRUG|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
219068795|NCT04313634|DRUG|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
219068796|NCT04313634|DRUG|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
219068797|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
219068798|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
219068799|NCT04254900|OTHER|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
219068800|NCT00002934|PROCEDURE|long-term screening|
219670197|NCT03321409|DIAGNOSTIC_TEST|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
219670198|NCT03321409|DIAGNOSTIC_TEST|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
218979191|NCT03334110|PROCEDURE|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
218979192|NCT01039844|DRUG|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
219670199|NCT03671785|DRUG|PRIM-DJ2727|Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
219670200|NCT03671785|DRUG|Placebo oral capsule|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
218979193|NCT04027829|DRUG|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
218979194|NCT05133908|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
218979195|NCT05133908|BEHAVIORAL|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
218979196|NCT02248831|DEVICE|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
218979197|NCT02556658|DEVICE|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
218979198|NCT02556658|DEVICE|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
218979199|NCT00444652|DRUG|Enoxaparin|injection of enoxaparin a few time
218979200|NCT05879601|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
218979201|NCT05879601|OTHER|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
218979202|NCT03395665|OTHER|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
218979203|NCT03395665|OTHER|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
218979204|NCT03395665|OTHER|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
218979205|NCT02056639|DEVICE|Bioteque cup pessary|
218979206|NCT02239354|COMBINATION_PRODUCT|VC-01™ Combination Product|Biologic and Device
218979207|NCT03285672|DRUG|FP-101|Dose 1
218979208|NCT03285672|DRUG|Placebo Comparator|Dose 1
218979209|NCT02664259|PROCEDURE|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
218979210|NCT02664259|PROCEDURE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
218979211|NCT02664259|PROCEDURE|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
218979212|NCT03965767|DRUG|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
218979213|NCT01482273|PROCEDURE|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
218979214|NCT01482273|PROCEDURE|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
218979215|NCT00224705|DEVICE|Molecular Adsorbent Recirculating System (MARS®)|
218979216|NCT02280070|OTHER|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
218979217|NCT02280070|OTHER|Medical history and physical examination|medical history and physical examination
218979218|NCT02280070|OTHER|BW and height|Body weight (kg) and height (cm)
218979219|NCT02280070|OTHER|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
218979220|NCT02280070|OTHER|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
218979221|NCT02280070|OTHER|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
218979222|NCT02280070|RADIATION|Contrasting CT|Computed tomography
219068801|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
219068802|NCT06442371|OTHER|High Intensity interval training + Quranic Listening|In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
219068803|NCT06442371|OTHER|High intensity interval training|In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
219670201|NCT01089452|DRUG|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
218979223|NCT02280070|OTHER|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
219068804|NCT05801224|DEVICE|Nitric Oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
219068805|NCT02952924|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
219670202|NCT01089452|DRUG|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
219670203|NCT01089452|DRUG|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
218979224|NCT02280070|OTHER|HBs antigen and HCV antibody|check for exclusion criteria
218979225|NCT02280070|OTHER|Endoscopy|Endoscopy for lower digestive tract
218979226|NCT02280070|OTHER|HBs antibody and HBc antibody|Check according to hepatitis B guideline
218979227|NCT02280070|DRUG|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
218979228|NCT02280070|DRUG|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
218979229|NCT02280070|DRUG|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
218979230|NCT02280070|DRUG|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
218979231|NCT02280070|DRUG|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
218979232|NCT02285647|DRUG|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
218979233|NCT02285647|DRUG|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
218979234|NCT04768075|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
218979235|NCT04768075|DRUG|Placebo|IV infusion Simulator of Camrelizumab
218979236|NCT04768075|DRUG|Cisplatin|IV infusion
218979237|NCT04768075|DRUG|Carboplatin|IV infusion
218979238|NCT04768075|DRUG|Pemetrexed|IV infusion
218979239|NCT04768075|DRUG|Paclitaxel|IV infusion
218979240|NCT04768075|DRUG|Albumin paclitaxel|IV infusion
218979241|NCT02875054|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
218979242|NCT02875054|BEHAVIORAL|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
218979243|NCT04172623|BEHAVIORAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
218979244|NCT04172623|BEHAVIORAL|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
218979245|NCT05737849|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
218979246|NCT03368534|DEVICE|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
218979247|NCT01250431|BEHAVIORAL|EFT (Emotional Freedom Techniques)|10 EFT sessions
218979248|NCT01136031|DRUG|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week"
219670204|NCT03963921|DRUG|HepaStem|Heterologous human adult liver-derived progenitor cells
219670205|NCT05126173|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
218979249|NCT04962620|DRUG|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
218979250|NCT00050271|DRUG|Acetyl-L-carnitine|
218979251|NCT03328767|BEHAVIORAL|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
219670206|NCT05242536|OTHER|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
219670207|NCT02081014|DRUG|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
219670208|NCT06196697|BIOLOGICAL|Cadonilimab|Subjects will receive AK104 by intravenous administration
218979252|NCT01069016|PROCEDURE|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
218979253|NCT01069016|PROCEDURE|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
218979254|NCT04709107|OTHER|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
218979255|NCT04709107|OTHER|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
218979256|NCT03614364|DRUG|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
218979257|NCT03614364|DRUG|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
218979258|NCT05116215|DRUG|Hydrogen|Hydrogen supplement
218979259|NCT05862831|BIOLOGICAL|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
218979260|NCT00384657|DRUG|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
218979261|NCT01788046|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
219068806|NCT02952924|OTHER|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
219068807|NCT02952924|DRUG|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
219068808|NCT03085563|DRUG|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
219068809|NCT03085563|DRUG|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
219068810|NCT03825380|DRUG|Bimatoprost|Eyedrops
219068811|NCT03825380|DRUG|Lumigan®|Eyedrops
219068812|NCT03738540|BEHAVIORAL|TALK study group|Telephone Delivered Intervention
219068813|NCT03738540|BEHAVIORAL|TALK control group|Telephone Delivered Intervention
219068814|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
219068815|NCT01063257|DRUG|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
219068816|NCT00832923|BEHAVIORAL|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
219068817|NCT05973526|PROCEDURE|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
219068818|NCT05973526|PROCEDURE|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
219068819|NCT02352311|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
219068820|NCT02352311|DRUG|AVODART|Dutasteride 0.5 mg
219068821|NCT02352311|DRUG|CIALIS|Tadalafil 5 mg
219068822|NCT02158299|DRUG|Avitene|
219068823|NCT02158299|DRUG|Sapylin|
219068824|NCT02158299|BEHAVIORAL|axillary drainage|
219068825|NCT02158299|OTHER|reexamine|
219068826|NCT00329069|DRUG|atorvastatin (drug)|
219670209|NCT06196697|BIOLOGICAL|Ivonescimab|Subjects will receive AK112 by intravenous administration
219670210|NCT06196697|DRUG|XELOX|Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
218979262|NCT01788046|DRUG|Placebo|Administered intravenously (IV) three times per week.
219068827|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
219068828|NCT05469321|OTHER|None, pure observationnal study|None, pure observational study following the usual management of the patients
219068829|NCT04509947|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
219068830|NCT04509947|BIOLOGICAL|Placebo|Placebo will be administered as IM injection.
219068831|NCT05591352|DIETARY_SUPPLEMENT|Chenopodium formosanum extracts sachet|consume 1 sachet per day
219068832|NCT05591352|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
219068833|NCT01757964|BIOLOGICAL|Bacteriotherapy|
219068834|NCT00126516|DRUG|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
219068835|NCT00126516|DRUG|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
218979263|NCT00751166|DRUG|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
218979264|NCT00751166|DRUG|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
218979265|NCT00751166|DRUG|placebo|placebo once daily for 28 days
218979266|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, single, 1 day
218979267|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, twice a day, 14 days
218979268|NCT01691274|DRUG|PF-04895162|Tablets, to be decided, twice a day, 14 days
218979269|NCT01691274|DRUG|Placebo|Tablets, twice a day, 14 days
218979270|NCT06468852|PROCEDURE|Goal-Directed Fluid Therapy|Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
219068836|NCT05930327|OTHER|Unconditional Cash Transfer (High-Value)|Monthly, Unconditional Cash Transfer ($325) for 4-months
219068837|NCT05930327|OTHER|Unconditional Cash Transfer (Low-Value)|Monthly, Unconditional Cash Transfer ($25) for 4-months
219068838|NCT05680103|RADIATION|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
219068839|NCT02393079|DEVICE|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
219068840|NCT02393079|DEVICE|Sham|A SHAM identical helmet will be used in the control group.
219068841|NCT02105948|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
219068842|NCT02105948|DRUG|Placebo|Sterile 0.9% sodium chloride solution
218979271|NCT00133029|DRUG|Timing of prophylactic antibiotic administration|
219068843|NCT01600157|PROCEDURE|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
219068844|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
219068845|NCT04169139|DEVICE|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
219068846|NCT05284968|DRUG|Cell injection|All subjects will be treated with cell injection
219670211|NCT06196697|DRUG|SOX|Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
219670212|NCT04162405|BEHAVIORAL|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
218979272|NCT01031706|DRUG|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
218979273|NCT01031706|DRUG|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
219670213|NCT02878096|DRUG|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
219068847|NCT04698980|DIAGNOSTIC_TEST|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
218979274|NCT04396340|BIOLOGICAL|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
218979275|NCT00303173|BEHAVIORAL|Guided Imagery|
218979276|NCT00225069|PROCEDURE|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
218979277|NCT01529242|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
218979278|NCT01529242|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
218979279|NCT00850070|DRUG|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
218979280|NCT00850070|DRUG|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
218979281|NCT06051370|PROCEDURE|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
218979282|NCT06051370|PROCEDURE|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
218979283|NCT04382300|DRUG|pyrotinib combined with thalidomide|Single Group Assignment
218979284|NCT03307642|OTHER|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
218979285|NCT03845777|DIAGNOSTIC_TEST|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
218979286|NCT04871971|DIETARY_SUPPLEMENT|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
218979287|NCT04871971|DIETARY_SUPPLEMENT|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
218979288|NCT04871971|DIETARY_SUPPLEMENT|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
219068848|NCT01873365|OTHER|Data collection|Case report forms (CRFs), logbooks and booklets.
219068849|NCT04051372|DIAGNOSTIC_TEST|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS"
218979289|NCT04871971|DIETARY_SUPPLEMENT|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
218979290|NCT04871971|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
218979291|NCT04769661|DIAGNOSTIC_TEST|Cytokines|Doing cord blood cytokines level in preterm infants
218979292|NCT02835742|DRUG|Sargramostim|
218979293|NCT02835742|DRUG|Placebo|
218979294|NCT01181908|DRUG|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
218979295|NCT04002739|DIAGNOSTIC_TEST|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
218979296|NCT02470832|DRUG|RG1662|
218979297|NCT02470832|DRUG|itraconazole|
218979298|NCT00074984|BIOLOGICAL|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
218979299|NCT00074984|BIOLOGICAL|Placebo|1 mg/kg placebo intravenously every 2 weeks
218979300|NCT02023593|DRUG|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
218979301|NCT01148888|DRUG|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
218979302|NCT00994071|DRUG|Temozolomide|
218979303|NCT00994071|DRUG|ABT-888|
218979304|NCT02960152|OTHER|diagnostic|full-mouth periodontal examination
218979305|NCT02700113|OTHER|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
218979306|NCT05384964|OTHER|Questionnaire|Questionnaire completed by ICU nurses
218979307|NCT01170143|DRUG|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
218979308|NCT01956383|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
218979309|NCT01720056|DRUG|Verapamil|
218979310|NCT01720056|DRUG|Kenalog 10|
219068850|NCT03447782|DRUG|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
219068851|NCT06324435|DRUG|Apremilast|60mg/day
219068852|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068853|NCT04213196|DRUG|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219208743|NCT06828510|DEVICE|With device|"Medical Device Installation Visit (V2, Day 0 + 21 ± 10 days): This visit, lasting approximately 1.5 hours, takes place in a consultation room at the center. A representative from ORTHOPUS adapts and installs the Partner on the patient's wheelchair, and an initial training session on the use of the medical device is provided.~Use of the Medical Device in Ecological Conditions (between V2 and V3): Between Day 21 and Day 42, the patient is invited to use the MD without restrictions in real-life conditions.~Final Evaluation Visit (V3, three weeks after V2, up to four weeks if necessary): The assessment session for the primary outcome-functional goal achievement using the GAS method-is conducted following the SCED (Single-Case Experimental Design) procedure, with multiple introduction-withdrawal phases and randomized phase sequencing and repeated measures :"
219208744|NCT07034053|DRUG|Clofarabine|Patients receive i.v. clofarabine in a dose-escalation regimen
219208745|NCT06713720|DEVICE|Remote Ischemic Conditioning Device|Participants in this group will use a remote ischemic conditioning device that applies five cycles of 5-minute inflation at 200 mmHg followed by 5-minute deflation on both arms, twice daily, for at least five days per week over one year. The device is designed to enhance retinal oxygenation and reduce hypoxia-related damage.
219208746|NCT06713720|DEVICE|Sham Remote Ischemic Conditioning Device|Participants in this group will use the same remote ischemic conditioning device set to an inflation pressure of 60 mmHg to simulate the treatment. This placebo intervention follows the same timing and cycle frequency as the active intervention group.
219670214|NCT01502956|DEVICE|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
219670215|NCT01502956|DRUG|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
219670216|NCT06257953|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
219670217|NCT00639106|PROCEDURE|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
219670218|NCT00639106|PROCEDURE|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
219670219|NCT03909698|OTHER|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
218979311|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
218979312|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
218979313|NCT05806086|OTHER|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
218979314|NCT03437096|OTHER|venipuncture pain|postoperative sleeve gastrectomy patients pain
218979315|NCT02031068|BEHAVIORAL|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation."
219208747|NCT06880757|OTHER|Radionuclide treatment with Lu-177 FAPI|Systemic radionuclide treatment with Lu-177 FAPI
219670220|NCT01317498|OTHER|Standard Care|CD4, liver function and CBC every 6 months
219670221|NCT01317498|OTHER|Virological Monitoring|Viral Load test every 6 months
218979316|NCT02031068|BEHAVIORAL|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
218979317|NCT03459170|BIOLOGICAL|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
218979318|NCT03459170|DRUG|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
218979319|NCT02283619|OTHER|None - no intervention, observational study|No intervention, observational study
218979320|NCT06311786|DRUG|[14C]-BIIB091|Administered as specified in the treatment arm.
218979321|NCT00143182|DRUG|Asenapine|Asenapine , 9 weeks
218979322|NCT00143182|DRUG|Olanzapine|Olanzapine, 9 weeks
218979323|NCT02182102|DRUG|BIBF 1120|
218979324|NCT02182102|DRUG|Pemetrexed|
218979325|NCT05815641|DIETARY_SUPPLEMENT|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
218979326|NCT05681663|OTHER|Electroshock Wave therapy|Randomized- Controlled trial
218979327|NCT03562533|DRUG|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
218979328|NCT03562533|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
218979329|NCT00965809|DRUG|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
218979330|NCT00965809|OTHER|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
218979331|NCT03004742|DIETARY_SUPPLEMENT|Flavonoid|Flavonoid rich supplement
219068854|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068855|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
219068856|NCT04213196|DRUG|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068857|NCT04213196|DRUG|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068858|NCT04213196|DRUG|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068859|NCT04213196|DRUG|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
219068860|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
219068861|NCT01658787|DEVICE|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
219068862|NCT05062252|DEVICE|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
219068863|NCT05062252|DEVICE|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
219068864|NCT03705091|DIAGNOSTIC_TEST|Magnetic resonance imaging|ASL and DWI MRI
219068865|NCT01892748|DRUG|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
219068866|NCT01892748|DRUG|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
219068867|NCT04493398|PROCEDURE|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
219068868|NCT04493398|PROCEDURE|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
219068869|NCT04493398|PROCEDURE|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
219670222|NCT02501941|DRUG|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
219670223|NCT06218342|DRUG|Henagliflozin|Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
219670224|NCT06218342|OTHER|Background medication|Participants will only receive lifestyle intervention and background medication.
218979332|NCT03004742|DIETARY_SUPPLEMENT|Placebo|Placebo
219670225|NCT02190123|DRUG|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
219670226|NCT00104377|BIOLOGICAL|Grass MATA MPL|
218979333|NCT06034847|DEVICE|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
218979334|NCT06034847|DEVICE|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
218979335|NCT02272426|BEHAVIORAL|CARET|Combined Aerobic and Resistance Exercise Training
218979336|NCT02272426|BEHAVIORAL|CTI|Cognitive Training Intervention
218979337|NCT02272426|BEHAVIORAL|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
218979338|NCT02272426|BEHAVIORAL|Sham CTI|Sham Cognitive Training Intervention
218979339|NCT04312750|DRUG|Lidocaine topical system 1.8%|
218979340|NCT03713892|DRUG|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
218979341|NCT03713892|DRUG|Placebo|orally administered
219208748|NCT06880822|BEHAVIORAL|Closed-Loop and Neuroplasticity-Based Mindfulness Program|The intervention includes three weekly 90-minute face-to-face mindfulness training sessions and daily guided self-practice using a closed-loop, neuroplasticity-based mobile app over 8 weeks. Training integrates mindfulness practices (e.g., mindful eating, body scanning) to help caregivers apply mindfulness in daily life. During self-practice, participants listen to a lesson, monitor distractions, and refocus on their breathing. Initial trials start at 20 seconds, adjusting by 10% if focused or decreasing by 20% if distracted, helping participants regulate attention. Progress is stored to continue in later sessions, with instant feedback during trials and delayed feedback on overall progress. Facilitators provide weekly follow-ups via the app to monitor caregivers' progress.
219208749|NCT06880822|BEHAVIORAL|Traditional Mindfulness Program (Without the Closed-Loop Approach)|Family caregivers in the traditional mindfulness group will participate in general mindfulness practices (e.g., mindful eating, body scanning, and mindful walking) without the closed-loop approach. These practices aim to help caregivers learn mindfulness skills and integrate them into their everyday life. Sessions will be delivered through a mobile approach with the same group size, duration, and frequency as the intervention groups.
219670227|NCT05190965|DEVICE|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
219670228|NCT03453957|OTHER|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
219068870|NCT00550225|DRUG|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
219670229|NCT01420341|DRUG|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
219670230|NCT01420341|DRUG|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
219670231|NCT03999528|DIAGNOSTIC_TEST|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
219670232|NCT00190398|DEVICE|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
219670233|NCT02365038|OTHER|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
219670234|NCT02365038|OTHER|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
219670235|NCT00280696|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use"
219670236|NCT00280696|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use"
219068871|NCT00550225|DRUG|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
219068872|NCT01934218|DEVICE|Gel-One|
219068873|NCT01934218|DEVICE|PBS|
219068874|NCT03910153|DIETARY_SUPPLEMENT|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
219068875|NCT03910153|OTHER|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
219068876|NCT04763850|OTHER|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
219208750|NCT06880822|BEHAVIORAL|Psychoeducation|Family caregivers in the control group will receive self-directed e-learning on dementia care with support from a registered nurse experienced in dementia care or elderly care. This group will serve as a control for socialization and interaction aspects with peers and the interventionist (nurse). The self-directed learning will be delivered through a mobile approach, maintaining the same group size, duration, and frequency as the intervention groups. Educational content will include brief sessions on dementia care, caregiving skills, and group sharing of caregiving tasks.
219670237|NCT00280696|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use"
219670238|NCT01166711|DEVICE|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
219068877|NCT02930239|OTHER|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
219068878|NCT02930239|OTHER|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
219670239|NCT01166711|DEVICE|Coroflex Please (DES)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type"
219670240|NCT02830074|BEHAVIORAL|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
219670241|NCT02830074|BEHAVIORAL|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
219670242|NCT02834832|DEVICE|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
219670243|NCT01059019|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
219670244|NCT02393131|RADIATION|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
218979342|NCT01360593|DRUG|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
218979343|NCT01360593|DRUG|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
218979344|NCT01360593|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
218979345|NCT05395689|BIOLOGICAL|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
218979346|NCT05395689|BIOLOGICAL|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
218979347|NCT04471142|DEVICE|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
218979348|NCT03159117|DRUG|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
218979349|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
218979350|NCT00571610|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
218979351|NCT04671524|OTHER|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
218979352|NCT05119673|OTHER|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
218979353|NCT04568889|BEHAVIORAL|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
218979354|NCT04568889|BEHAVIORAL|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
218979355|NCT04568889|BEHAVIORAL|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
218979356|NCT04568889|BEHAVIORAL|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
218979357|NCT04568889|BEHAVIORAL|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
218979358|NCT04568889|BEHAVIORAL|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
218979359|NCT04568889|BEHAVIORAL|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
218979360|NCT04568889|BEHAVIORAL|No Messaging|Individuals will see no messaging in the baseline survey.
218979361|NCT00514423|OTHER|Psychoeducation by professonals|
219068879|NCT04239313|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
219670245|NCT02393131|RADIATION|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
219670246|NCT01439490|OTHER|FES-PET|Patients undergo FES-PET prior to obtaining histology
219670247|NCT00547417|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
219670248|NCT03157596|OTHER|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
219670249|NCT01031004|DEVICE|narafilcon B|contact lens
219670250|NCT01031004|DEVICE|etafilcon A|contact lens
219670251|NCT04794673|OTHER|brain damage|Have or not have the brain damage and the location of the damage
219670252|NCT02740790|BIOLOGICAL|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
219670253|NCT02740790|BIOLOGICAL|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
219670254|NCT01641471|DEVICE|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
218979362|NCT00514423|OTHER|Psychoeducation by peer-moderators|
218979363|NCT00514423|OTHER|Video-education|
218979364|NCT00514423|OTHER|Noneducational video group (control group)|
218979365|NCT04081324|DRUG|Lasmiditan|Administered orally
218979366|NCT04081324|DRUG|Placebo|Administered orally
218979367|NCT02046733|DRUG|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
218979368|NCT02046733|DRUG|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
218979369|NCT06469515|OTHER|Elective or urgent cardiac surgery|This is a longitudinal observational study to explore postoperative cognitive recovery among older persons (aged 65 or older) undergoing elective or urgent cardiac surgery via sternotomy.
218979370|NCT06533735|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
218979371|NCT01296360|BIOLOGICAL|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
218979372|NCT01296360|BIOLOGICAL|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
218979373|NCT02835560|DRUG|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
219670255|NCT01641471|DEVICE|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
219670256|NCT02135016|DRUG|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
219670257|NCT02135016|DRUG|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
219670258|NCT02135016|DRUG|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
219670259|NCT01982799|DRUG|Oral placebo|placebo
219670260|NCT01982799|DRUG|Oral ibuprofen|Ibuprofen
219670261|NCT01982799|DRUG|oral naproxen|naproxen
219670262|NCT01982799|DRUG|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
219670263|NCT00575471|DRUG|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
219670264|NCT00575471|DRUG|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
219670265|NCT00575471|DRUG|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
219670266|NCT00575471|DRUG|Placebo|Matching placebo tablets once daily for 12 weeks
219670267|NCT02932605|DRUG|Placebo|Placebo
218979374|NCT02835560|DRUG|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
219670268|NCT02932605|DRUG|Cannabidiol|Cannabidiol
219670269|NCT00211432|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
219670270|NCT02295332|DRUG|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
219670271|NCT02295332|DRUG|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
219670272|NCT01653340|DEVICE|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
219670273|NCT00077155|DRUG|cilengitide|
219670274|NCT03782129|BIOLOGICAL|blood samples|Blood samples drawn during hospitalisations when needed
219670275|NCT03782129|OTHER|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
219670276|NCT02865629|DRUG|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
219670277|NCT02634801|DRUG|Fumaric Acid Esters|Administered orally
219670278|NCT02634801|DRUG|Methotrexate|Administered orally
219670279|NCT02634801|DRUG|Ixekizumab|Administered SC
219670280|NCT00280514|DRUG|cefpirome and moxifloxacin administration|
218979375|NCT02394548|RADIATION|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
218979376|NCT01354327|DIETARY_SUPPLEMENT|Limicol|3 tablets / day during 4 months
218979377|NCT01354327|DIETARY_SUPPLEMENT|Placebo|3 tablets / day during 4 months
219068880|NCT04239313|BIOLOGICAL|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
218979378|NCT05122871|OTHER|Scape Room|Practical training through scape-room with simulator
218979379|NCT05122871|OTHER|Simulation|Practical training through simulator
219068881|NCT04239313|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
218979380|NCT02857985|DEVICE|3D RA|3D RA is realised just after angioplasty.
218979381|NCT02857985|DEVICE|MRI|MRI is realised between 24h and 96h post angioplasty.
218979382|NCT04562792|DRUG|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
219068882|NCT05496582|DIAGNOSTIC_TEST|No intervention|No intervention
219068883|NCT02804854|DRUG|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
219068884|NCT02232893|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
219068885|NCT02232893|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
219208751|NCT07039487|OTHER|Blood sampling collection|"CBC performed on the background of an EDTA tube, collected routinely allowing neutrophil fluorescence measurements.~This tube will then be passed over on the automaton for a CBC measurement with leukocyte differentiation."
219068886|NCT03369600|DEVICE|Supersonic Imagine Aixplorer SWE Ultrasound Imaging|Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
219068887|NCT06495736|DIAGNOSTIC_TEST|Experimental: ROSE technique stain|The ROSE technical group uses Diff-Quick stain for diagnosis
219068888|NCT04928950|DRUG|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
219068889|NCT04747977|DRUG|OTX-DED|0.2mg dexamethasone ophthalmic insert
219068890|NCT04747977|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
219068891|NCT04747977|DRUG|OTX-DED|Hydrogel vehicle ophthalmic insert
219068892|NCT03634774|OTHER|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
219208752|NCT07038096|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219208753|NCT07038096|DRUG|ZG005|ZG005 will be administered as an intravenous (IV) infusion.
219208754|NCT07038434|DIAGNOSTIC_TEST|Multimodal AI-Based Pain Assessment|A non-invasive, multimodal diagnostic procedure combining self-reported pain scales (NRS, DN-4, BPI), wearable biosignal acquisition (EDA, EMG, HRV, EEG), facial thermography (HIRA system), video-based facial expression analysis, linguistic interview, and the Stroop Test. Data are used to train and validate machine learning models for automatic pain assessment in chronic pain patients.
219208755|NCT07038226|BIOLOGICAL|Placebo|a visually identical capsule containing skim milk powder
219208756|NCT07038226|BIOLOGICAL|Oral capsule-delivered FMT|Oral capsules of lysophilized fecal microbiota
219670281|NCT01366183|PROCEDURE|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
219670282|NCT01366183|DRUG|Carboplatin|Undergo chemotherapy
219670283|NCT01366183|BIOLOGICAL|Filgrastim|Undergo chemotherapy
219670284|NCT01366183|DRUG|Paclitaxel|Undergo chemotherapy
219670285|NCT01366183|OTHER|Pharmacological Study|Correlative studies
219670286|NCT01366183|OTHER|Quality-of-Life Assessment|Ancillary studies
219670287|NCT01366183|OTHER|Questionnaire Administration|Ancillary studies
219670288|NCT00106158|BIOLOGICAL|protein vaccination|
219670289|NCT01711008|DIETARY_SUPPLEMENT|Cereal|
218979383|NCT03616132|DEVICE|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
218979384|NCT03849807|OTHER|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
218979385|NCT03849807|OTHER|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
218979386|NCT00886912|OTHER|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
218979387|NCT00886912|OTHER|normoxia|training under normoxic conditions
218979388|NCT00570167|PROCEDURE|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
219670290|NCT01711008|DIETARY_SUPPLEMENT|No breakfast|
219670291|NCT01756339|DRUG|Solithromycin|
219670292|NCT01756339|DRUG|Moxifloxacin|
219670293|NCT01756339|OTHER|Placebo to match solithromycin|
219670294|NCT06472687|OTHER|FIFA 11+ warm-up exercise training|FIFA 11+ warm-up training program was applied to the experimentel group. control group (CG) did their usual warm-up program.
219670295|NCT06472687|OTHER|warm-up exercise training|exercise training
219670296|NCT00292916|BEHAVIORAL|whole body vibration|
219670297|NCT00292916|BEHAVIORAL|resistance exercise|
219670298|NCT00292916|BEHAVIORAL|"wellness"|
219670299|NCT03020277|OTHER|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
219670300|NCT02482545|DIETARY_SUPPLEMENT|Meal replacement|
219670301|NCT04394156|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
219670302|NCT04356599|OTHER|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
219670303|NCT06237608|BEHAVIORAL|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
219670304|NCT03195322|PROCEDURE|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
219670305|NCT00198523|DRUG|Prednisolone and Tobramycin|
219670306|NCT00198523|DRUG|Prednisolone|
218979389|NCT00570167|PROCEDURE|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
218979390|NCT05416151|OTHER|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
218979391|NCT05416151|OTHER|Maltodextrin|2 sticks of 3g consumed daily for 28 days
218979392|NCT03499548|OTHER|INSPiRe Programme|Intensive CBT for suicide
218979393|NCT02848170|DRUG|CS-3150|CS-3150 2.5mg, oral
218979394|NCT02848170|DRUG|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
218979395|NCT02329821|OTHER|hartmann solution|hartmann solution infusion in patients for hepatic resection
218979396|NCT02787265|DEVICE|spinal cord stimulation|
218979397|NCT05099081|PROCEDURE|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
218979398|NCT05099081|PROCEDURE|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
218979399|NCT03334591|DRUG|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
218979400|NCT04687995|PROCEDURE|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
218979401|NCT02651831|OTHER|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
219208757|NCT07037836|DRUG|Inhaled Treprostinil (Tyvaso Nebulizer)|Participants will receive inhaled Treprostinil (Tyvaso nebulizer), 6 µg per breath, administered four times daily for 4 weeks. The starting dose will be 3 breaths per session. The dose will increase by 1 breath per session each week, as tolerated, to a target of 6 breaths per session by week 4. If adverse effects occur, participants will remain at the highest tolerated dose. The drug will be administered using the Tyvaso inhalation system provided by United Therapeutics. No changes to baseline COPD maintenance medications are allowed during the treatment period. Participants will be monitored for safety throughout the study.
219208758|NCT07037849|DEVICE|Robot-assisted overground gait training|Post-stroke patients were required to complete a session of robot-assisted training, which involved nine repetitions of 5-meter overground walking (three trials for each of the three controllers).
219670307|NCT02025933|OTHER|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
219670308|NCT02025933|OTHER|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
219670309|NCT02025933|OTHER|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
219670310|NCT00501709|DRUG|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
219670311|NCT03300362|DRUG|Seasonal influenza vaccine|Seasonal influenza vaccine
219670312|NCT03300362|DRUG|MVA-NP+M1|Trial vaccine
219670313|NCT03300362|DRUG|Sodium chloride|Saline placebo
219670314|NCT03543176|OTHER|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
219670315|NCT03543176|OTHER|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
219670316|NCT03543176|OTHER|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
219670317|NCT03543176|OTHER|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
219670318|NCT03543176|DEVICE|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
219670319|NCT03543176|DEVICE|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
219670320|NCT00284011|DIETARY_SUPPLEMENT|SAMe|800 mg dose daily for 4 weeks.
219670321|NCT00284011|OTHER|Placebo|2 placebo pills daily for 4 weeks.
219670322|NCT04241822|BEHAVIORAL|Vestibular exercises combined with body awareness exercises and cognitive therapy|The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
219670323|NCT04241822|BEHAVIORAL|Exergaming|The intervention consists of different balance exercises using non-immersive virtual reality
218979402|NCT02651831|OTHER|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
218979403|NCT04728022|BEHAVIORAL|Education program|Mentored high school summer research program
218979404|NCT05898685|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
218979405|NCT05898685|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
218979406|NCT00199875|DRUG|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
218979407|NCT06535165|DIETARY_SUPPLEMENT|Red Beetroot Juice|200ml/d for 14 days
218979408|NCT06535165|OTHER|Placebo|200ml/d for 14 days
218979409|NCT03506932|DIETARY_SUPPLEMENT|Untreated|Bread made with 20% yellow pea flour that was untreated.
218979410|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
218979411|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
218979412|NCT03506932|DIETARY_SUPPLEMENT|Wheat|Bread made with 100% wheat
218979413|NCT01024231|DRUG|BMS-936558 (MDX1106-04)|
218979414|NCT01024231|DRUG|Ipilimumab|
218979415|NCT02514603|DRUG|Prexasertib|Administered IV
218979416|NCT05088720|DRUG|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
218979417|NCT05088720|DRUG|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
219208759|NCT07039370|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses.~This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry."
219208760|NCT06716957|OTHER|Schroth exercise|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
218979418|NCT00169754|OTHER|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
218979419|NCT04666480|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
218979420|NCT02883842|BEHAVIORAL|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
218979421|NCT02703831|PROCEDURE|Dual attending|Two attending spine surgeons perform surgery
218979422|NCT02703831|PROCEDURE|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
218979423|NCT01488305|DIETARY_SUPPLEMENT|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
218979424|NCT01488305|OTHER|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
218979425|NCT00887874|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
218979426|NCT00395733|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
218979427|NCT00395733|DRUG|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
218979428|NCT00585962|RADIATION|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
218979429|NCT03295500|RADIATION|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
218979430|NCT05835323|DEVICE|Robotic-assisted mini-PCNL|Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
218979431|NCT06417125|DRUG|Dexmedetomidine Hydrochloride|Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.
218979432|NCT06417125|DRUG|Midazolam|Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
219670324|NCT02626000|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
219670325|NCT02626000|BIOLOGICAL|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
219670326|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
219670327|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
219670328|NCT05745233|DRUG|Nivolumab|Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
219670329|NCT05745233|DRUG|Pembrolizumab|Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
219670330|NCT06239025|OTHER|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
219670331|NCT04392219|DRUG|EIDD-2801|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
219670332|NCT04392219|DRUG|Placebo|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
219670333|NCT06054763|COMBINATION_PRODUCT|Buyang Huanwu Decoction|Buyang Huanwu Decoction is a common prescription for treating stroke. The possible mechanism is to replenish qi, activate blood circulation, and remove blood stasis.
219670334|NCT06054763|OTHER|Placebo|90% starch and 10% Buyang Huanwu Decoction
219068893|NCT01587651|DRUG|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
219670335|NCT02335346|DRUG|Duloxetine|Administered orally
219670336|NCT04034511|OTHER|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
219670337|NCT00195195|DRUG|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
219670338|NCT03300050|BIOLOGICAL|cH8/1N1 LAIV|"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."
219670339|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
219670340|NCT03300050|BIOLOGICAL|cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
219670341|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH8/1N1 IIV|"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
219670342|NCT03300050|BIOLOGICAL|Normal saline|Administered intranasally as 0.25 mL nasal drops per nostril
219670343|NCT03300050|BIOLOGICAL|Phosphate buffered saline (PBS)|Administered intramuscularly as 0.5 mL injection
219068894|NCT01587651|DRUG|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
219068895|NCT01587651|DRUG|Ticagrelor Maintenance Dose|one 90mg film coated tablet
219068896|NCT03277222|BIOLOGICAL|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
219068897|NCT03277222|BIOLOGICAL|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
219208761|NCT06716957|OTHER|Dynamic Stabilization exercises|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 12 weeks
219068898|NCT04838743|DRUG|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
219068899|NCT01696422|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
219068900|NCT01696422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
219068901|NCT01696422|OTHER|Placebo|Route:subcutaneous
219670344|NCT03287648|DIAGNOSTIC_TEST|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
219670345|NCT00791427|DRUG|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
219670346|NCT01898052|DRUG|single anaesthetic drug|inject periarticular tissue of the knee after implantation
219670347|NCT01898052|DRUG|multimodal drug injection|inject periarticular tissue of the knee
219208762|NCT06708455|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
219208763|NCT06708455|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Carboplatin + Paclitaxel Regimen (CP Regimen)
219670348|NCT03580395|DRUG|Apatinib|500mg, day1-21,neoadjuvant therapy
219670349|NCT03580395|DRUG|paclitaxel|paclitaxel 165mg/m2 day 1
219670350|NCT03580395|DRUG|cisplatin|cisplatin 40mg, day 1-3
219670351|NCT04652518|DRUG|LYT-100|oral administration
219670352|NCT04652518|OTHER|Placebo|oral administration
218979433|NCT06417125|DRUG|normal Saline|Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
218979434|NCT06417125|DRUG|Glucose solution|Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
219670353|NCT04767971|DEVICE|Standard Colonoscopy|Colonoscopy with a standard colonoscope
219670354|NCT04767971|DEVICE|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
219670355|NCT02178358|DRUG|LY2157299|Administered orally
219670356|NCT02178358|DRUG|Sorafenib|Administered orally
219670357|NCT02178358|DRUG|Placebo|Administered orally
219670358|NCT02018770|RADIATION|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
219670359|NCT02018770|RADIATION|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
219670360|NCT00621725|DRUG|AZD2171|Oral dose
219670361|NCT01066663|DRUG|pyrimethamine|Taken orally once a day
219670362|NCT01090050|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
218979435|NCT02826278|OTHER|External genitalia measurements in female newborns|
218979436|NCT04633577|DRUG|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
218979437|NCT04633577|DRUG|0.9% normal saline|0.9% normal saline
218979438|NCT04135365|BEHAVIORAL|neurocognitive assessment|Observational study therefore there are no interventions
218979439|NCT04135365|BEHAVIORAL|neuroimaging assessment|Observational study therefore there are no interventions
218979440|NCT02894632|DEVICE|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
219068902|NCT01657422|BEHAVIORAL|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
219068903|NCT03069222|OTHER|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
219068904|NCT03786679|DEVICE|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
219068905|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
219068906|NCT02152267|DEVICE|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
219068907|NCT03934502|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
219068908|NCT05680168|DEVICE|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
219068909|NCT05680168|BEHAVIORAL|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
218979441|NCT05337293|BEHAVIORAL|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
218979442|NCT05337293|OTHER|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
218979443|NCT03637179|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
218979444|NCT03637179|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
218979445|NCT01672736|DRUG|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
218979446|NCT06551636|OTHER|respiratory physiotherapy (AAD)|The AAD technique involves placing the physiotherapist's hands on the chest where the secretions are identified and applying pressure to the chest. The maneuver will last according to the patient's tolerance, in an average of approximately 10 min.
218979447|NCT01024218|DEVICE|NovoFine® needle 8 mm|
218979448|NCT01024218|DEVICE|autocover needle|
218979449|NCT02634281|DRUG|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
218979450|NCT02634281|DRUG|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
218979451|NCT01773772|DRUG|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
218979452|NCT01773772|DRUG|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
218979453|NCT01736020|DRUG|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
218979454|NCT01736020|DRUG|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
218979455|NCT01736020|DRUG|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
218979456|NCT01736020|DRUG|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
218979457|NCT01736020|DRUG|Placebo|Placebo
218979458|NCT05785351|PROCEDURE|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
218979459|NCT04211168|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
218979460|NCT02366988|DEVICE|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
218979461|NCT02366988|PROCEDURE|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
218979462|NCT00521612|DRUG|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
218979463|NCT00521612|DRUG|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
218979464|NCT02542982|DEVICE|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
218979465|NCT00493532|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
218979466|NCT03384888|DEVICE|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
218979467|NCT03384888|DEVICE|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
218979468|NCT00767949|BIOLOGICAL|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
219068910|NCT06114446|OTHER|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
219670363|NCT01090050|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
219670364|NCT03539484|DRUG|RO7172508|RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
219670365|NCT03539484|DRUG|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
219670366|NCT03539484|DRUG|Tocilizumab|Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
218979469|NCT06341764|DRUG|Durvalumab 1120 mg|Durvalumab 1120 mg day 1 i.v
218979470|NCT06341764|DRUG|Durvalumab 1500 mg|Durvalumab i.v. at 1500 mg once every 4 weeks
218979471|NCT06341764|DRUG|Tremelimumab i.v. at 300 mg|Single dose
218979472|NCT06341764|COMBINATION_PRODUCT|Cisplatin (CDDP) 25 mg/mq i.v|Four cycles
218979473|NCT06341764|COMBINATION_PRODUCT|Gemcitabine (GEM) 1000 mg/mq i.v.|Days 1 and 8 every 21 days
218979474|NCT02495012|DRUG|placebo|Freeze-dried powder without snake venom will be dissovled in saline
218979475|NCT02495012|DRUG|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
218979476|NCT04112524|DEVICE|App|"* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
218979477|NCT00660751|DRUG|Duloxetine|SNRIs
218979478|NCT02590926|PROCEDURE|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
218979479|NCT04977921|OTHER|lab session|assign students to clinical modules for study the clinical lab scope of practice
218979480|NCT01035580|DRUG|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
218979481|NCT01035580|DRUG|curcumin|all patients received the drug
218979482|NCT05554575|BIOLOGICAL|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
218979483|NCT04510376|DEVICE|Test Article|Omeza Collagen Matrix
218979484|NCT04510376|OTHER|Positive Control|1.0 mg/mL Histamine Base
218979485|NCT04510376|OTHER|Negative Control|Aqueous Negative Control
218979486|NCT06203236|DRUG|Furosemide 20 MG|"1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
218979487|NCT06203236|OTHER|diuretic therapy|diuretic therapy
218979488|NCT05290207|DIAGNOSTIC_TEST|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
218979489|NCT00361582|DRUG|CG5503 IR; tapentadol|
218979490|NCT04124653|DRUG|PF-06842874|Single dose administration of PF-06842874
218979491|NCT04124653|DRUG|Placebo|Single dose administration of placebo
218979492|NCT04124653|DRUG|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
218979493|NCT02612038|DEVICE|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
218979494|NCT02612038|DEVICE|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
218979495|NCT04757246|OTHER|MouthLab Device|Use of MouthLab system
218979496|NCT02450188|DRUG|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
218979497|NCT02450188|BEHAVIORAL|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
218979498|NCT06330454|DEVICE|I-ONE|Pulsed Electromagnetic fields joint therapy
218979499|NCT05820373|BEHAVIORAL|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
218979500|NCT05820373|BEHAVIORAL|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
219670367|NCT06955455|DRUG|Triamcinolone and Bupivacaine Injection|A single injection consisting of 1 cc of 0.25% bupivacaine mixed with 2 cc (20 mg) of triamcinolone (40 mg/mL) is administered under ultrasound guidance. The injection targets the extratemporal portion of the facial nerve approximately 1.5-2 cm distal to the stylomastoid foramen in an inferior and anterior direction. The intervention is designed to reduce inflammation and pain, potentially accelerating facial nerve recovery in acute Bell's palsy.
219670368|NCT05597449|BEHAVIORAL|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
219670369|NCT06336811|DEVICE|passive virtual reality distraction|watching the application by wearing virtual glasses to the child during the phlebotomy
219068911|NCT06114446|OTHER|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
219068912|NCT06114446|OTHER|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
219068913|NCT00922493|OTHER|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
219068914|NCT04323436|DRUG|Spartalizumab|Concentrate for solution for infusion
219068915|NCT04323436|DRUG|Capmatinib|Film-coated tablet
219068916|NCT04323436|DRUG|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
219068917|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
219670370|NCT06336811|DEVICE|active virtual reality distraction|The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.
219670371|NCT02232061|DRUG|Fingolimod|Fingolimod 0.5 mg tablet
218979501|NCT05820373|BEHAVIORAL|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
218979502|NCT05088395|OTHER|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
218979503|NCT05088395|OTHER|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
218979504|NCT01044706|DRUG|Bicalutamide|50 mg Oral Tablet
218979505|NCT02767505|OTHER|gastric bypass|Type of surgery: gastric bypass
218979506|NCT02767505|OTHER|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
218979507|NCT01485393|DRUG|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
218979508|NCT01485393|DRUG|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
218979509|NCT02853344|BIOLOGICAL|Pembrolizumab|IV infusion
218979510|NCT00799110|DRUG|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
218979511|NCT00799110|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
218979512|NCT00799110|DRUG|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
218979513|NCT03868306|OTHER|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
218979514|NCT02913612|DRUG|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
218979515|NCT02913612|DRUG|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
218979516|NCT00140478|DRUG|Mifepristone|200mg orally once daily
218979517|NCT03134833|BEHAVIORAL|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
219068918|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
219068919|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
219670372|NCT02256735|DRUG|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
219670373|NCT02256735|DRUG|Treatment B|
219670374|NCT02256735|DRUG|Treatment C|
219670375|NCT02256735|DRUG|Treatment D|
219670376|NCT02256735|DRUG|Placebo|
219670377|NCT02256735|DRUG|Moxifloxacin|
219670378|NCT04378595|OTHER|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
219670379|NCT04378595|OTHER|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
219670380|NCT02878200|BIOLOGICAL|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
219670381|NCT04605718|DRUG|RO7223280|For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
219670382|NCT03108066|DRUG|MK-3795|800 mg twice daily (four 200 mg oral tablets twice daily)
219670383|NCT00144950|DRUG|insertion of a chest drain with urokinase instillation|
219670384|NCT00144950|PROCEDURE|primary video-assisted thorascopic surgery|
219670385|NCT04726111|OTHER|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
219068920|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
219068921|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
219068922|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
219068923|NCT05038644|DRUG|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
219068924|NCT05038644|DRUG|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
219670386|NCT04161521|PROCEDURE|Novel Technique of Placenta Accreta in Menoufia University Hospital|"* Classical CS to decrease haemorrhage from placental bed.~* Delievery of the fetus.~* At the delivery 10 UI of oxytocin IV will be injected.~* The placenta is not attempted to be delievered.~* Opening of the broad ligament via round ligament division and ligation.~* Gentle dissection of the urinary bladder from lateral to medial.~* Bilateral uterine artery clamping at low level below the placental bed .~* Gentle attempt to deliver The placenta.~* If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~* If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~* Intraperitoneal drain insertion."
219670387|NCT00931112|OTHER|individualized exercise training|Lower extremities resistance exercise and bicycle training
219670388|NCT00560703|DRUG|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
219670389|NCT00560703|DRUG|placebo|sugar capsule
219670390|NCT05723952|OTHER|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
219670391|NCT05723952|OTHER|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
219670392|NCT03244267|BEHAVIORAL|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
219670393|NCT03244267|BEHAVIORAL|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
219670394|NCT02693717|OTHER|Laboratory Biomarker Analysis|Correlative studies
219670395|NCT02693717|DRUG|Pemetrexed Disodium|Given IV
219068925|NCT05038644|DRUG|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
219068926|NCT05038644|DRUG|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
219068927|NCT05038644|DRUG|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
219068928|NCT01745263|DRUG|Vitamin D3|2000 IU/d
219068929|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
219068930|NCT01745263|PROCEDURE|Strength Home Exercise|
219068931|NCT01745263|PROCEDURE|Flexibility Home Exercise|
219068932|NCT01383538|DRUG|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
219670396|NCT00156091|DRUG|Olanzapine|5- 20 mg QD
219068933|NCT05860322|DIETARY_SUPPLEMENT|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
219670397|NCT00156091|DRUG|Asenapine|5 or 10 mg BID
219670398|NCT00156091|OTHER|Placebo|
219670399|NCT05912075|DRUG|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
219670400|NCT05912075|RADIATION|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
219670401|NCT05912075|DRUG|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
219670402|NCT05912075|DRUG|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
219670403|NCT05912075|RADIATION|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
219670404|NCT05912075|DRUG|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
219670405|NCT05912075|DRUG|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
219068934|NCT05860322|OTHER|Placebo|Placebo control
219670406|NCT01315522|DEVICE|ComVi stent|Endoscopic insertion of ComVi stent
219670407|NCT01315522|DEVICE|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
219670408|NCT03675529|BEHAVIORAL|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
219068935|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
219068936|NCT01324492|DRUG|RAD001|
219068937|NCT01660763|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
219068938|NCT01660763|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
219068939|NCT02282501|OTHER|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
219068940|NCT06189040|DRUG|BNT162b2 30µg|intramuscular administration of 30µg
219208764|NCT06874829|OTHER|Electrical Muscle Stimulation|EMS will be applied bilaterally to the wrist flexor and elbow extensor muscles using a portable EMS stimulator (Compex Rehab 400, Medicompex SA, Ecublens, Switzerland). Four 2 mm thick, self-adhesive electrodes (5x5 cm) will be placed on the superficial aspect of each muscle group. The athletes will simultaneously receive EMS intervention with a pulse frequency of 75 Hz and a duration of 400 μs (19 seconds rest between pulses) during bench press and triceps pushdown exercises. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
219670409|NCT00383370|DRUG|VEGF Trap|VEGF Trap formulation 1, ITV-1
219670410|NCT00383370|BIOLOGICAL|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
219670411|NCT04410471|DIAGNOSTIC_TEST|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
219670412|NCT04678609|OTHER|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
219670413|NCT02943187|BEHAVIORAL|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
219068941|NCT06189040|DRUG|BNT162b2 20µg|intramuscular administration of 20µg
219068942|NCT06189040|DRUG|BNT162b2 6µg|intradermal administration of 6µg
219068943|NCT06189040|DRUG|mRNA-1273 100µg|intramuscular administration of 100µg
219068944|NCT06189040|DRUG|mRNA-1273 50µg|intramuscular administration of 50µg
219068945|NCT06189040|DRUG|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10\^8 infectious units
219068946|NCT03325712|DRUG|BI 705564|Film-coated tablet
219068947|NCT03325712|DRUG|Placebo|Film-coated tablet
219068948|NCT03325712|DRUG|Midazolam|Solution for injection
219068949|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
219068950|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
219670414|NCT02943187|DIETARY_SUPPLEMENT|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
219670415|NCT04923880|OTHER|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
219670416|NCT02186899|OTHER|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
219670417|NCT02186899|OTHER|General Anesthesia femoral bolus|
219670418|NCT02186899|OTHER|General anesthesia femoral continuous|
219670419|NCT00914498|DRUG|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
219670420|NCT00339833|DRUG|Salsalate|The intervention was salsalate (3g/day) for 7 days.
219670421|NCT00339833|DRUG|Placebo|Identical placebo for 7 days.
218979518|NCT03134833|BEHAVIORAL|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
219068951|NCT02692300|PROCEDURE|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
219068952|NCT02848417|DRUG|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
219068953|NCT02848417|DRUG|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
218979519|NCT03134833|BEHAVIORAL|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
218979520|NCT04300439|DEVICE|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
218979521|NCT05742958|DRUG|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
218979522|NCT05742958|DRUG|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
218979523|NCT04215250|OTHER|andropulous method|Counts the CVC depth using specific equation
219068954|NCT02848417|OTHER|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
219068955|NCT00202163|DRUG|DHEA|
219068956|NCT00202163|DRUG|Testosterone|
219068957|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
219670422|NCT05761119|OTHER|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
219670423|NCT03891355|DRUG|Carfilzomib|Carfilzomib
219068958|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
219068959|NCT05088213|PROCEDURE|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
219068960|NCT05088213|PROCEDURE|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
219068961|NCT04463641|DEVICE|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
219068962|NCT00017381|BIOLOGICAL|rituximab|Given IV
219068963|NCT00017381|DRUG|cyclophosphamide|Given IV
219068964|NCT00017381|BIOLOGICAL|filgrastim|Given SC
219068965|NCT00017381|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219068966|NCT00017381|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
219068967|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
219670424|NCT03891355|DRUG|Lenalidomide|Lenalidomide
219670425|NCT03891355|DRUG|Dexamethasone|Dexamethasone
219670426|NCT06101888|DEVICE|TaurusTrio™ Heart Valve System|The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
219670427|NCT01745614|DRUG|Nimesulide 100 mg tablets|Reference product
218979524|NCT04215250|DEVICE|ECG|Using ECG to monitor the insertion of the CVC
218979525|NCT00487682|DRUG|ASP2151|oral
218979526|NCT00487682|DRUG|Valacyclovir hydrochloride|oral
218979527|NCT04549246|RADIATION|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
218979528|NCT00004756|PROCEDURE|Tailored educational program|
219068968|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
219670428|NCT01745614|DRUG|Nimesulide 100 mg tablets|Test product
219670429|NCT03306095|OTHER|Early refeeding group|Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
218979529|NCT00004756|PROCEDURE|Educational materials|
218979530|NCT03352310|BIOLOGICAL|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
218979531|NCT03352310|PROCEDURE|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
219670430|NCT03306095|OTHER|Delayed refeeding group|Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure
219670431|NCT03621436|DEVICE|TRVD Therapy|A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
218979532|NCT05031273|BEHAVIORAL|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
218979533|NCT05400824|DIAGNOSTIC_TEST|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
218979534|NCT01372228|BIOLOGICAL|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
218979535|NCT04605042|PROCEDURE|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
218979536|NCT04605042|PROCEDURE|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
218979537|NCT02891109|BIOLOGICAL|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
218979538|NCT01710046|DRUG|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
218979539|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
219670432|NCT00925808|BEHAVIORAL|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
219670433|NCT03001908|OTHER|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
219670434|NCT03001908|OTHER|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
219670435|NCT03634943|OTHER|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
219670436|NCT06239350|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
219670437|NCT06239350|BEHAVIORAL|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
218979540|NCT01710046|DRUG|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
218979541|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
218979542|NCT00001122|DRUG|Nelfinavir mesylate|
218979543|NCT00001122|DRUG|Efavirenz|
218979544|NCT00001122|DRUG|Stavudine|
218979545|NCT00001122|DRUG|Didanosine|
218979546|NCT05888077|OTHER|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
219068969|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
219068970|NCT00760864|DRUG|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
219068971|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
219670438|NCT06239350|BEHAVIORAL|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
219670439|NCT05936853|OTHER|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
219670440|NCT05936853|OTHER|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
219670441|NCT03591224|OTHER|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
219670442|NCT03591224|OTHER|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
219670443|NCT02723994|DRUG|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
219670444|NCT02723994|DRUG|Asparaginase Erwinia Chrysanthemi|
218979547|NCT00851344|DRUG|GSK835726 (10mg)|GSK835726 (10mg) tablet
218979548|NCT00851344|DRUG|GSK835726 (50mg)|GSK835726 (50mg) tablet
218979549|NCT00851344|DRUG|GSK835726 (100mg)|GSK835726 (100mg) tablet
218979550|NCT00851344|DRUG|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
218979551|NCT00851344|OTHER|Placebo|Placebo to match active
218979552|NCT03091933|BIOLOGICAL|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
218979553|NCT06157255|DRUG|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
218979554|NCT06157255|DRUG|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
218979555|NCT06157255|DRUG|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
218979556|NCT01987635|DEVICE|MEMO 3D ring|The experimental MEMO 3D ring is placed.
218979557|NCT01987635|DEVICE|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
218979558|NCT01987635|PROCEDURE|3D Echocardiography|
218979559|NCT05824988|OTHER|Drug exposure|Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
218979560|NCT01435902|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
219208765|NCT06874829|OTHER|Blood Flow Restriction|The arterial occlusion pressures (AOP) of the athletes randomized to the experimental group will be obtained automatically with the digital LED display CAC device BFR Unit (Fit Cuffs BFR Unit, Denmark). The AOP pressure device BFR Unit (Fit Cuffs BFR Unit, Denmark) will be used to apply 50% occlusion pressure during exercise. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
218979561|NCT01435902|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
218979562|NCT04325178|OTHER|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
218979563|NCT02406183|RADIATION|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
219670445|NCT02723994|DRUG|Cyclophosphamide|
219670446|NCT02723994|DRUG|Cytarabine|
219670447|NCT02723994|DRUG|Dexamethasone|
219670448|NCT02723994|DRUG|Doxorubicin|
219670449|NCT02723994|DRUG|Leucovorin Calcium|
219670450|NCT02723994|DRUG|Mercaptopurine|
219670451|NCT02723994|DRUG|Methotrexate|
219670452|NCT02723994|DRUG|Pegaspargase|
219670453|NCT02723994|DRUG|Prednisone|
219670454|NCT02723994|DRUG|Thioguanine|
219670455|NCT02723994|DRUG|Vincristine Sulfate|
219670456|NCT06536296|OTHER|Music|Arm 1: Music only
219670457|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
219670458|NCT06536296|OTHER|Standard Care|Standard Care
219670459|NCT04008797|DRUG|E7386|E7386 dosing.
219670460|NCT04008797|DRUG|Lenvatinib|Lenvatinib, capsules, orally.
219670461|NCT04008797|DRUG|Doxorubicin|Doxorubicin dosing.
219670462|NCT04008797|DRUG|Paclitaxel|Paclitaxel dosing.
219670463|NCT02476916|DRUG|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
219670464|NCT05090384|DRUG|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
219068972|NCT02265237|DRUG|ombitasvir/paritaprevir/ritonavir|tablets
219068973|NCT02265237|DRUG|ribavirin|tablets
219068974|NCT04781764|PROCEDURE|surgery|surgery
219068975|NCT04607967|DEVICE|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
218979564|NCT02406183|DRUG|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
218979565|NCT00498524|DEVICE|ICD|Received an ICD
218979566|NCT00498524|DEVICE|ICD|Have not received an ICD
219068976|NCT01898338|DRUG|Fosfomycin 2gr/6h iv|
218979567|NCT06285331|DEVICE|Automatic Bed|The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
218979568|NCT06285331|DEVICE|Manual|The clinicians will perform passive leg raising on patients by touching their legs physically.
218979569|NCT00992277|PROCEDURE|Ablation and skin resurfacing|
218979570|NCT01776411|DRUG|forodesine hydrochloride|
218979571|NCT03841448|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
218979572|NCT03841448|DRUG|Cemdisiran|Cemdisiran was administered by SC injection.
218979573|NCT03896165|OTHER|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
218979574|NCT02152800|DRUG|valacyclovir hydrocholoride|
218979575|NCT01904227|BEHAVIORAL|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
218979576|NCT01904227|BEHAVIORAL|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
218979577|NCT00645723|DRUG|Colistin|intravenous colistin and nebulized colistin
219068977|NCT01898338|DRUG|Daptomycin 10mg/kg/24h iv|
219068978|NCT03593668|DRUG|Metformin|"2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
218979578|NCT00645723|DRUG|Colistin and saline solution|intravenous colistin and nebulized saline solution
218979579|NCT00199485|DRUG|Angelica Sinensis|Angelica Sinensis / placebo
218979580|NCT05405465|DRUG|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
218979581|NCT03078400|DRUG|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
218979582|NCT03844932|DRUG|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
218979583|NCT00002008|DRUG|Sargramostim|
218979584|NCT01193270|DRUG|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
219068979|NCT03593668|DRUG|Benaglutide|"2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
219068980|NCT00650546|DRUG|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
219068981|NCT02495753|PROCEDURE|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
218979585|NCT01193270|DRUG|Placebo|Sterile water in volume equal to that of the comparator drug
219068982|NCT02495753|PROCEDURE|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
219068983|NCT01178853|DRUG|Warfarin|Warfarin 5 mg once daily
219068984|NCT01178853|DRUG|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
219670465|NCT05351749|BEHAVIORAL|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
219670466|NCT05351749|BEHAVIORAL|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
219670467|NCT05351749|BEHAVIORAL|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
219670468|NCT05351749|BEHAVIORAL|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
219670469|NCT06961643|DRUG|HRS-7535 Tables|Oral HRS-7535 tables.
219670470|NCT05923359|OTHER|Apple Watch|Apple Watch
219670471|NCT05542277|DEVICE|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
219670472|NCT06010732|DRUG|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
219670473|NCT06010732|DRUG|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
218979586|NCT05936268|DRUG|Genakumab for injection|150 mg/1ml/bottle
218979587|NCT05936268|DRUG|Colchicine|0.5mg/table
218979588|NCT03181893|DRUG|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
218979589|NCT03181893|DRUG|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
218979590|NCT03181893|DRUG|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
218979591|NCT02532530|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
219068985|NCT01178853|DRUG|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
218979592|NCT04924205|DEVICE|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
218979593|NCT00309478|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
218979594|NCT00309478|DRUG|Methotrexate|Methotrexate 40mg/m2
218979595|NCT00309478|DRUG|Fluorouracil implant|Fluorouracil 600mg/m2
218979596|NCT00309478|DRUG|Goserelin|Zoladex 3.6mg/28 days for 3 years
218979597|NCT00309478|DRUG|Tamoxifen|Nolvadex 20mg/day for 5 years
219068986|NCT01412008|DRUG|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
219068987|NCT03550313|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
219068988|NCT03550313|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
219068989|NCT02870790|DRUG|TDF/FTC|one pill daily
219068990|NCT05330962|OTHER|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
219068991|NCT00839072|DRUG|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
219068992|NCT00839072|DRUG|Trazodone HCl|300 mg extended-release caplet, single dose
219068993|NCT04894604|DEVICE|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
219670474|NCT06010732|DRUG|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
219670475|NCT05367024|OTHER|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
219670476|NCT05367024|OTHER|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
219670477|NCT06556069|OTHER|Peer-Support Enhanced Agitation Code Team (PACT)|"PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress."
219068994|NCT00139750|DRUG|CP-526,555 (varenicline)|
219208766|NCT06874829|OTHER|Low-Load Resistance Exercise|Bench press and triceps pushdown exercises will be performed with 30% 1RM, 30-15-15-15 repetitions and 30 seconds rest between sets.
219208767|NCT05023382|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
219068995|NCT06197893|PROCEDURE|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
219068996|NCT06197893|PROCEDURE|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
219670478|NCT04401202|DIETARY_SUPPLEMENT|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
219670479|NCT03491397|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
219670480|NCT02233621|OTHER|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with \[18F\]FES before coelioscopy
219670481|NCT05223166|DRUG|Pitolisant|Wakix tablet
219670482|NCT05223166|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
219670483|NCT04124328|PROCEDURE|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
219670484|NCT04124328|PROCEDURE|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
219670485|NCT02088398|DRUG|ACY-1215|
219670486|NCT01482234|BEHAVIORAL|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
219670487|NCT05396859|DRUG|Decitabine and Cedazuridine|Given PO
219670488|NCT05396859|DRUG|Entrectinib|Given PO
219670489|NCT05396859|OTHER|Laboratory Biomarker Analysis|Correlative studies
219670490|NCT06564649|DIAGNOSTIC_TEST|CXCL10 Monitoring at clinical frequency|The intervention is the implementation of real-time, serial urinary CXCL10 monitoring, with protocolized further clinical responses in the setting of elevated urinary CXCL10 levels.
219670491|NCT03696199|DRUG|Long-Acting Local Anesthesia|"The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
219670492|NCT03696199|DRUG|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
219670493|NCT02650700|RADIATION|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
219670494|NCT00913302|BEHAVIORAL|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
219670495|NCT06300411|DRUG|SRG-514|SRG-514 monotherapy
219670496|NCT01387945|BEHAVIORAL|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
219670497|NCT02710552|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
219670498|NCT02710552|DRUG|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
219670499|NCT02546596|DEVICE|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
219670500|NCT01979601|DRUG|LGT209|150 mg lyophilized powder in glass vial
219670501|NCT01979601|DRUG|Placebo|Placebo comparator
219670502|NCT00057005|DRUG|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
219670503|NCT00057005|DRUG|Anti-CD45|Day-5 400 μg/kg
219670504|NCT00057005|DRUG|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
219670505|NCT00057005|DRUG|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
219670506|NCT00057005|DRUG|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
219670507|NCT00057005|RADIATION|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
219670508|NCT03518502|PROCEDURE|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
219670509|NCT03518502|DRUG|Sorafenib|Standard therapy for advanced HCC
219670510|NCT00647595|BEHAVIORAL|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
219670511|NCT00178646|DRUG|Botox|Botox 75-150 units, single treatment only
219670512|NCT03564093|DRUG|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
219670513|NCT03564093|DRUG|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
219670514|NCT02148315|BEHAVIORAL|garden|
219208768|NCT06719791|DRUG|Sirolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².
219208769|NCT07038707|OTHER|Extract the serum and feces of the patients for standard screening of early biomarkers|In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified
219670515|NCT04897035|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
219670516|NCT03232268|BIOLOGICAL|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
219670517|NCT01729858|DEVICE|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
219670518|NCT01729858|DEVICE|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
218979598|NCT05666622|OTHER|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
219208770|NCT07038707|OTHER|Meningeal lymphatic vessel imaging|The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging
219360334|NCT04536883|PROCEDURE|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
218979599|NCT04128371|BIOLOGICAL|mepolizumab|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
218979600|NCT02121782|BIOLOGICAL|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
218979601|NCT02121782|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
218979602|NCT03250871|OTHER|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
218979603|NCT03250871|OTHER|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
218979604|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
218979605|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
219208771|NCT07040007|BEHAVIORAL|Strengthening Exercises|"In the strengthening exercises, the amount of weight was determined based on 40 to 60 percent of the one-repetition maximum. Each exercise was performed in two sets of six to eight repetitions. The exercise sessions lasted approximately 40 minutes and included a 10-minute warm-up, 20 minutes of strengthening exercises, and a 10-minute cool-down period. To perform the strengthening exercises, resistance bands (Theraband), dumbbells, weighted balls, sandbags, and a resistance bicycle were used. The exercises were performed for both the upper and lower extremities.~For the upper extremities, shoulder abduction, elbow extension, and shoulder extension exercises were performed using a theraband; elbow flexion, shoulder flexion, and elbow extension exercises were performed using dumbbells; and shoulder abduction exercises were performed using a weighted ball. For the lower extremities, knee extension, hip extension, and hip abduction exercises were performed using a resistance bicycle."
219670519|NCT06349811|DRUG|BL-M05D1|Administration by intravenous infusion for a cycle of 3 weeks.
219670520|NCT05977881|OTHER|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
219670521|NCT06634108|DRUG|Genistein|The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
218979606|NCT02297191|PROCEDURE|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
218979607|NCT02297191|DRUG|Ropivicaine|
218979608|NCT06149026|OTHER|Physical and nutritional therapy|The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
218979609|NCT02353520|OTHER|motricity index strength assessment|
218979610|NCT04815031|BIOLOGICAL|BNT162b2|Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.
218979611|NCT00232648|DRUG|Pulmicort (budesonide) Respules|
218979612|NCT05995808|PROCEDURE|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
218979613|NCT05995808|DIAGNOSTIC_TEST|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
218979614|NCT04004962|DEVICE|Infrared spectroscopy|Infrared spectroscopy
218979615|NCT02718066|DRUG|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
218979616|NCT03022435|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
218979617|NCT03022435|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
218979618|NCT03022435|BIOLOGICAL|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
218979619|NCT06452589|DEVICE|FieldForce Ablation System|The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
218979620|NCT00524381|DRUG|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
218979621|NCT00524381|DRUG|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
218979622|NCT00644189|DRUG|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
218979623|NCT01805128|OTHER|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
219068997|NCT06197893|PROCEDURE|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
219208772|NCT07040007|BEHAVIORAL|Balance Exercises|"Each session was carried out over approximately 40 minutes, consisting of a 10-minute warm-up, 20 minutes of balance exercises, and a 10-minute cool-down period. The exercises were individually planned based on the participant's performance. To perform the balance exercises, supportive equipment such as balance discs and Pilates balls, as well as environments such as soft surfaces and stairs, were used.~The balance exercises applied during the intervention included standing on a balance disc with weight shifting, walking on a soft surface, tandem walking, walking while stepping over obstacles, and cross-step walking. Additionally, seated balance activities, standing trunk rotations using a Pilates ball, sit-to-stand exercises from a chair, and stair climbing exercises were also performed as part of the program."
219208773|NCT07038824|DRUG|ENTR-601-45|intravenous infusion
219208774|NCT07038824|DRUG|ENTR-601-45 - matching placebo|intravenous infusion
219208775|NCT07039318|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells
219208776|NCT07039318|DRUG|Normal Saline (Placebo)|Normal Saline (Placebo)
219068998|NCT06197893|PROCEDURE|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
219208777|NCT06754020|DEVICE|Heart Rate Variability,HRV - ANSWatch|Please have the participant lie down and rest for 10 minutes, and remove any metallic items from their body. Next, put on the wrist-worn monitor, and avoid moving during the monitoring process. The device will emit a sound when the monitoring session is complete.
219208778|NCT06754020|DEVICE|Traditional Chinese Medicine Tongue Imaging|Use a camera to capture images of the tongue, and then have a Traditional Chinese Medicine (TCM) practitioner perform the diagnosis based on these images.
219208779|NCT06884800|PROCEDURE|Laparoscopic toupet fundoplication|Patients will undergo laparoscopic toupet fundoplication.
219208780|NCT07039643|OTHER|Pilates exercise|This study investigates a novel Pilates-based rehabilitation program for Achilles tendinopathy (AT). While eccentric loading is the standard treatment, many patients experience persistent symptoms or poor adherence. Pilates emphasizes core stability, neuromuscular control, and functional movement, offering a holistic approach that addresses kinetic chain dysfunction and movement impairments often overlooked in standard protocols. This trial will assess the feasibility and effectiveness of Pilates in improving pain, function, and movement quality in adults with AT. To our knowledge, this is the first clinical trial to evaluate Pilates as a targeted intervention for AT.
219068999|NCT04950101|OTHER|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
219069000|NCT04050293|DRUG|SPN-538|Patients will receive SPN-538
219069001|NCT04050293|DRUG|Placebo|Patients will receive Placebo
219069002|NCT00380068|DRUG|Ambrisentan|Oral tablets taken once daily.
219069003|NCT05234164|DEVICE|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
219069004|NCT05234164|DEVICE|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
219069005|NCT04207190|DRUG|Gemtuzumab Ozogamicin|Given IV
219069006|NCT04207190|OTHER|Quality-of-Life Assessment|Ancillary studies
219069007|NCT04207190|OTHER|Questionnaire Administration|Ancillary studies
219069008|NCT04207190|DRUG|Talazoparib|Given PO
219069009|NCT04207190|DRUG|Talazoparib Tosylate|Given PO
219069010|NCT02936557|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)"
219069011|NCT01297062|DRUG|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
219069012|NCT01297062|DRUG|Moxifloxacin|Oral Moxifloxacin (400 mg)
219069013|NCT01297062|DRUG|Placebo comparator|IV Placebo (matching volume of placebo)
219208781|NCT07039643|OTHER|Alfredson protocol|At our knowledge this is the first study that will compare the most popular protocol in Achilles Tendinopathy to an alternative exercise method
219069014|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 14
219069015|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 23
219069016|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 8
219069017|NCT04783753|DRUG|Itraconazole|Subjects will receive itraconazole QD for 14 days
219208782|NCT07039968|RADIATION|Spine Stereotactic Radiosurgery (SSRS)|A non-invasive procedure that uses highly focused, high-energy radiation beams to precisely target metastatic tumors in the spine. The procedure is delivered using advanced techniques like Intensity Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT/RapidArc), which allow the radiation dose to conform tightly to the shape of the tumor. This approach maximizes the dose to the cancer while carefully sparing surrounding healthy tissues, especially the critical spinal cord. The entire course of treatment is delivered in a single session, guided by on-board imaging to ensure sub-millimeter accuracy.
219208783|NCT07032532|DRUG|Golidocitinib|Golidocitinib 150mg orally once daily in a 21-day cycle
219208784|NCT07032532|DRUG|Golidocitinib plus CHOP|Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.
219360335|NCT00356642|DRUG|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
219670522|NCT04577859|DEVICE|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
219069018|NCT04783753|DRUG|Carbamazepin|Subjects will receive carbamazepine BID for 23 days
219670523|NCT04577859|DEVICE|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
219670524|NCT03911947|DEVICE|Vibrolung|Device for vibroacoustic respiratory therapy
219670525|NCT02247297|PROCEDURE|Blood collection|Diagnostic blood collection
219069019|NCT04783753|DRUG|Quinidine|Subjects will receive quinidine BID for 8 days
218979624|NCT01805128|OTHER|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
219670526|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
219670527|NCT05286060|DRUG|GX-188E, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
219670528|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
219670529|NCT05286060|DRUG|GX-188E, GX-I7|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
219670530|NCT02826577|DRUG|Pregnenolone 175mg|Single Dose 175mg
218979625|NCT01805128|OTHER|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
218979626|NCT03355781|DEVICE|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
218979627|NCT03355781|PROCEDURE|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
218979628|NCT03355781|OTHER|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
218979629|NCT02291354|DRUG|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
218979630|NCT02291354|OTHER|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
218979631|NCT02291354|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
218979632|NCT00397215|BIOLOGICAL|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
218979633|NCT00397215|BIOLOGICAL|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
218979634|NCT02128932|DRUG|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
218979635|NCT02128932|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
218979636|NCT01872221|PROCEDURE|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
219069020|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
219069021|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
219069022|NCT01416792|PROCEDURE|Centrifugation|
219069023|NCT01416792|PROCEDURE|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
219069024|NCT02635841|DRUG|Deferiprone|Ferriprox (deferiprone) 100 mg/mL oral solution
219069025|NCT01458574|DRUG|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
219670531|NCT02826577|DRUG|Pregnenolone 400mg|Single Dose 400mg
219670532|NCT02826577|DRUG|Placebo|Single Dose
219670533|NCT04081831|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
219670534|NCT02053259|BEHAVIORAL|Adaptive Goals|
219670535|NCT02053259|BEHAVIORAL|Reinforcement|
219670536|NCT02053259|BEHAVIORAL|Static Goals|
219670537|NCT00591019|DRUG|Modafinil|200 mg/day, morning dose
219670538|NCT00591019|OTHER|Placebo|Sugar pill once per day in the morning.
218979637|NCT02122432|OTHER|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
218979638|NCT01836965|BEHAVIORAL|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
218979639|NCT05188196|PROCEDURE|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
218979640|NCT02824237|DEVICE|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
218979641|NCT06117358|OTHER||Descriptive cross section study
218979642|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
218979643|NCT01361568|DRUG|Placebo|Single i.v. dose administered preoperatively
218979644|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
218979645|NCT01361568|DRUG|Placebo|Single i.v. dose administered postoperatively for pain
218979646|NCT01433731|DRUG|placebo for SHAPE (SHP-141)|topical gelled solution
218979647|NCT01433731|DRUG|SHAPE (SHP-141) 0.1% BID|topical gelled solution
218979648|NCT01433731|DRUG|SHAPE (SHP-141) 0.5% BID|topical gelled solution
218979649|NCT01433731|DRUG|SHAPE (SHP-141) 1.0% BID|topical gelled solution
218979650|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
218979651|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
218979652|NCT01206075|DRUG|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
218979653|NCT03515252|BIOLOGICAL|Immune Killer Cells (IKC)|
218979654|NCT02225197|RADIATION|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
218979655|NCT06151132|PROCEDURE|Direct current cardioversion|Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
218979656|NCT00885287|DRUG|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
218979657|NCT01846390|DRUG|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
218979658|NCT01846390|DRUG|Dexamethasone|40 mg D1 - D4
218979659|NCT01846390|DRUG|Cisplatin|75 mg/m2 D1
218979660|NCT01846390|DRUG|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
218979661|NCT04905888|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
219069026|NCT01458574|DRUG|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
219069027|NCT01458574|DRUG|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
218979662|NCT00044720|DRUG|Rapamune|
218979663|NCT04668573|OTHER|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
219208785|NCT07039994|OTHER|Standard intervention|"Routine intervention in the service:~* Good control: In-person visit every 4 weeks.~* Poor control: Nurse calls at 1 week to assess and decide on treatment changes, visits, or referral. In-person visit by need or after 1 month."
219670539|NCT04671355|DRUG|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
219670540|NCT04671355|DRUG|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
219670541|NCT05388084|BEHAVIORAL|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
219670542|NCT05388084|BEHAVIORAL|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
219670543|NCT00489294|DRUG|Syntropin|
219670544|NCT04885790|OTHER|"Respiratory assessment using Spiropalm 6MWT portable spirometry"|"Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry."
219670545|NCT04885790|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity of patients will be evaluated using six-minute walk test.
219670546|NCT04885790|OTHER|Evaluation of peripheral muscle strength|Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.
219670547|NCT04885790|OTHER|Evaluation of chronic cough|The Leicester Cough Questionnaire will be used for evaluating cough.
219670548|NCT04365673|OTHER|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
219670549|NCT01684124|OTHER|conservative O2 therapy|target lower O2 saturation
219670550|NCT01684124|OTHER|standard care|
219670551|NCT05057858|DRUG|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
219670552|NCT01096498|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
219670553|NCT01096498|DRUG|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
219670554|NCT06217445|DEVICE|high intensity focused ultrasound|High-intensity focused ultrasound (HIFU) therapy is becoming more familiar in medical field because it is non-invasive technique with fewer side effects and provides promising therapeutic results. Several HIFU therapy applications have approved by many approval authorities of deferent countries since last decade
219670555|NCT06217445|OTHER|Doubled chin exercises|1\. Straight jaw jut. 2-ball exercise. 3-Pucker up 4. Tongue stretch 5. Neck stretch 6-bottom jaw jut.
219670556|NCT02683408|OTHER|placebo|inactive placebo
219069028|NCT04110808|DRUG|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
219069029|NCT02125786|RADIATION|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
219670557|NCT02683408|DIETARY_SUPPLEMENT|diosmiplex|diosmiplex is an FDA regulated medical food product
219670558|NCT02976402|RADIATION|SBRT|"Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
219670559|NCT05463939|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
219670560|NCT06822075|BEHAVIORAL|SANTE program|"The intervention will consist of distinct period. Fisrt, 3 complete assessment periods will be realized : pre-intervention (week 1-2) ; mid-intervention (week 8-9) ; post-intervention (week 15 - 16) for evaluate the evolution of the health-related behavior, mental and physical health. Second, the SANTE program intervention will be implemented. Intervention 1 (week 3 and 7) for INT-1 group receive the SANTE program and INT-2 group do noting ; Intervention 2 (week 10-14) for INT-2 group receive the SANTE program and INT-1 do noting.~The SANTE intervention will consist of (at a minimum):~* 1 to 2 group physical activity sessions per week~* 1 outdoor outing (full-day or half-day) per month~* 1 individual meeting with a physical activity and sports expert"
219670561|NCT05903313|DRUG|Chang Gung ECG Abnormality Detection Software|This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
219670562|NCT01230216|DRUG|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
219670563|NCT01230216|DRUG|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
219670564|NCT05742191|OTHER|Daylight Savings time transitions|Daylight Savings time transitions.
218979664|NCT02674776|DRUG|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
218979665|NCT02674776|DRUG|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
218979666|NCT04759144|DEVICE|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
219670565|NCT06972875|DRUG|Fezolinetant|Participants will receive fezolinetant for 28 days at FDA approved dosing and schedule of 45 mg po (per os/by mouth) once daily for treatment of hot flashes in menopausal women.
219670566|NCT06416969|DRUG|Somatostatin|Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
219670567|NCT06416969|DRUG|Epinephrine|Intravenous infusion
219670568|NCT01532206|OTHER|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
219670569|NCT05013281|PROCEDURE|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
219670570|NCT01420042|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
219670571|NCT01420042|DRUG|Placebo|Lemon flavoured cordial and Water for Injection
219670572|NCT01853696|DRUG|loteprednol etabonate|
219670573|NCT01853696|DRUG|prednisolone acetate 1%|
219069030|NCT02125786|PROCEDURE|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
219069031|NCT02125786|DRUG|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
219069032|NCT02125786|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
219670574|NCT01173419|DEVICE|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
219069033|NCT02125786|DEVICE|Photon therapy|Participants will receive one or both: Photon or proton therapy.
219069034|NCT02125786|DEVICE|Proton therapy|Participants will receive one or both: Photon or proton therapy.
219069035|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
219069036|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
219069037|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
219069038|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
219670575|NCT01173419|DEVICE|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
219670576|NCT00309790|DRUG|sildenafil|
219069039|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
219069040|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
219069041|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
219069042|NCT04964089|DRUG|KSI-301|Intravitreal Injection
219069043|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
219069044|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
219069045|NCT01042457|DRUG|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
219069046|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
219069047|NCT06444282|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
219069048|NCT03969238|BEHAVIORAL|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
219069049|NCT04867564|DIAGNOSTIC_TEST|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
219360336|NCT00356642|DRUG|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
219670577|NCT03570008|BEHAVIORAL|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
219069050|NCT05846724|DRUG|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
219360337|NCT02346188|DIETARY_SUPPLEMENT|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
219670578|NCT03570008|BEHAVIORAL|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
218979667|NCT04759144|DEVICE|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
218979668|NCT04079010|PROCEDURE|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
218979669|NCT04079010|DIETARY_SUPPLEMENT|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
218979670|NCT04079010|DIETARY_SUPPLEMENT|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
218979671|NCT00318058|BIOLOGICAL|influenza vaccine Fluarix, Adjuvanted Fluarix|
218979672|NCT00657358|DRUG|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
218979673|NCT04304274|PROCEDURE|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
218979674|NCT04304274|PROCEDURE|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
218979675|NCT04304274|DRUG|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
218979676|NCT04932460|PROCEDURE|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
218979677|NCT04932460|PROCEDURE|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
218979678|NCT06180746|BEHAVIORAL|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
218979679|NCT02959983|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
218979680|NCT02959983|DRUG|Placebo|Placebo matching eluxadoline oral tablets BID with food.
218979681|NCT05328674|PROCEDURE|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
218979682|NCT05328674|PROCEDURE|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
218979683|NCT05791175|DEVICE|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
218979684|NCT03951714|BEHAVIORAL|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
219360338|NCT02346188|DIETARY_SUPPLEMENT|Zinc oxide|Tablet formulated from 30 mg zinc oxide
219360339|NCT02346188|DIETARY_SUPPLEMENT|Placebo|
219670579|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
219670580|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
219670581|NCT06426160|DRUG|Tocilizumab 20 MG/ML [Actemra]|Tocilizumab 8 mg/kg every four weeks for 24 weeks.
219670582|NCT06426160|DRUG|Sodium Chloride 0.9% Inj|Placebo (Sodium chloride) every four weeks for 24 weeks.
219670583|NCT03152994|OTHER|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
219670584|NCT04365075|DEVICE|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
219670585|NCT04365075|DEVICE|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
219670586|NCT04519762|DRUG|Glycophos (Sodium Glycerophosphate)|Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
219670587|NCT04519762|DRUG|Antibiotics|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
219670588|NCT04519762|DRUG|Inotropes|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
218979685|NCT06112548|PROCEDURE|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
218979686|NCT06112548|DRUG|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
218979687|NCT06112548|DRUG|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
218979688|NCT06112548|DRUG|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
218979689|NCT06112548|DRUG|Paracetamol|IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
218979690|NCT06112548|DRUG|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
218979691|NCT06112548|DRUG|Tramadol|IV Tramadol \[Ultram\] introduced when needed after surgery
218979692|NCT05072782|DRUG|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
218979693|NCT05072782|DRUG|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
218979694|NCT03860610|DIAGNOSTIC_TEST|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
218979695|NCT03860610|DIAGNOSTIC_TEST|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
218979696|NCT03860610|DIAGNOSTIC_TEST|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
218979697|NCT03860610|DIAGNOSTIC_TEST|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
218979698|NCT03860610|DIAGNOSTIC_TEST|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
218979699|NCT03860610|DIAGNOSTIC_TEST|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
218979700|NCT03860610|DIAGNOSTIC_TEST|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
219360340|NCT00063401|BIOLOGICAL|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
219670589|NCT05041777|DEVICE|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
218979701|NCT00912860|DRUG|Interferon beta-1a|serum free Avonex given IM once a week
218979702|NCT04432025|PROCEDURE|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
218979703|NCT04432025|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
218979704|NCT01225692|BEHAVIORAL|Head Injury Guideline|
218979705|NCT00002449|DRUG|Aldesleukin|
218979706|NCT03314142|OTHER|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219360341|NCT00063401|DRUG|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
219360342|NCT00063401|DRUG|Carboplatin|AUC = 6 Day1, six 21-day cycles
218979707|NCT03314142|OTHER|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219069051|NCT03445468|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
219069052|NCT03445468|BIOLOGICAL|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
219069053|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
219670590|NCT03300713|OTHER|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
219670591|NCT03300713|OTHER|usual follow-up|usual follow-up
219670592|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
219670593|NCT01025648|DRUG|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
219670594|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
219670595|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
219670596|NCT01025648|DRUG|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
218979708|NCT03314142|OTHER|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218979709|NCT03314142|OTHER|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218979710|NCT03314142|OTHER|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
218979711|NCT06436261|PROCEDURE|Hybrid Fractional Laser|A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
218979712|NCT06436261|OTHER|Facial Cleanser|Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
218979713|NCT06436261|OTHER|Facial Moisturizer|"Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon)."
218979714|NCT06436261|OTHER|Sunscreen|During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
218979715|NCT04444388|DIETARY_SUPPLEMENT|cocoa|Sachets of 5 grams of cocoa daily supplementation
218979716|NCT04444388|DIETARY_SUPPLEMENT|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
218979717|NCT01052571|PROCEDURE|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
218979718|NCT01020383|DRUG|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
218979719|NCT01020383|DRUG|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
218979720|NCT02728596|OTHER|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
218979721|NCT02728596|OTHER|Quality-of-Life Assessment|Ancillary studies
218979722|NCT02728596|OTHER|Questionnaire Administration|Ancillary studies
218979723|NCT03892070|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
218979724|NCT03892070|DIETARY_SUPPLEMENT|Mannitol|1.5 g twice daily for 12 weeks
218979725|NCT04232774|DEVICE|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
219069054|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
219069055|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
219069056|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
219670597|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
218979726|NCT03221270|DEVICE|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
219069057|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
219069058|NCT06057350|PROCEDURE|Tumor removal|Removal of incompletely removed early-stage colon cancer
219670598|NCT03761225|DRUG|Masitinib|
219670599|NCT03761225|DRUG|Docetaxel|
219670600|NCT03761225|DRUG|Prednisone|
219670601|NCT03761225|DRUG|Placebo|
219670602|NCT05843032|DIAGNOSTIC_TEST|3D ultrasound, MRI, resected specimen examination by surgeon|3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
219670603|NCT03992898|OTHER|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
218979727|NCT03221270|DEVICE|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
218979728|NCT03221270|DEVICE|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
218979729|NCT03221270|DEVICE|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
219069059|NCT05548595|DIETARY_SUPPLEMENT|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
218979730|NCT01578421|DEVICE|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
218979731|NCT03114774|DEVICE|The bispectral index (BIS) monitoring|
219069060|NCT05548595|OTHER|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
219670604|NCT06145113|DEVICE|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
219670605|NCT02782754|DRUG|Carboplatin|
219670606|NCT02782754|DRUG|Etoposide|
218979732|NCT03114774|BEHAVIORAL|Ramsay Sedation Scale (RSS) Score monitoring|
218979733|NCT01408264|DEVICE|Conventional 0.035 guidewire|0.035 guidewire
218979734|NCT01408264|DEVICE|Olympus Visiglide 0.025 guidewire|0.025 guidewire
218979735|NCT00955318|DRUG|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
218979736|NCT05788653|PROCEDURE|Thiele Massage|Transvaginal Massage
219670607|NCT02782754|DRUG|Cyclophosphamide|
219670608|NCT02782754|DRUG|Bleomycin|
218979737|NCT05788653|PROCEDURE|Transverse Friction Massage|Transvaginal Massage
218979738|NCT06184386|OTHER|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
218979739|NCT06184386|BEHAVIORAL|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
218979740|NCT04286399|DRUG|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
218979741|NCT04286399|DRUG|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
219069061|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
219670609|NCT02782754|RADIATION|Reduced dose of radiotherapy|
219670610|NCT02468999|DRUG|human insulin|
219069062|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
219069063|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
219069064|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
219069065|NCT03691805|DEVICE|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
219069066|NCT03691805|DEVICE|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
219069067|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
219069068|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
219069069|NCT01813240|DRUG|Minocycline|
219069070|NCT01813240|DRUG|placebo|
219208786|NCT07039994|OTHER|E-health intervention|"Combined system using ICT and in-person care. It includes spontaneous use (symptom tracking, messages, reminders via app) and scheduled use:~* Good symptom control: Basic Telematic Evaluation (BTE) at 1 month. If stable, videoconference at 2 months, BTE at 3 months, and in-person visit at 4 months.~* Poor symptom control: BTE at 1 week. If warning signs appear, a nurse evaluates by phone and may adjust treatment, schedule a visit (in-person or video), or refer to emergency care. In-person visit by need or after 1 month."
219670611|NCT05266859|OTHER|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
219208787|NCT06729190|DEVICE|biofeedback|biofeedback therapy and FES at anti spastic muscles(shoulders flexors, elbow and wrist extensors) while doing specific exercises (including basic reaching, grasping, carrying, release
219670612|NCT05266859|OTHER|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
219670613|NCT05266859|OTHER|PRF|PRF will be placed directly over the exposed pulp
219670614|NCT02124070|DRUG|rh Growth Hormone|
219670615|NCT05788107|DRUG|HLX51|anti-OX40 tetravalent agonistic humanized monoclonal antibody
219670616|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
219670617|NCT02131116|BEHAVIORAL|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
219670618|NCT02131116|BEHAVIORAL|Treatment as Usual|Treatment as Usual
219670619|NCT02608814|PROCEDURE|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
219670620|NCT02608814|OTHER|Ultrasound|
218979742|NCT04286399|DRUG|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
218979743|NCT03985306|PROCEDURE|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
218979744|NCT04306029|OTHER|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
218979745|NCT00365222|DRUG|Temozolomide|temozolomide 75 mg/m2 /d
218979746|NCT03353246|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
218979747|NCT03101787|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes."
218979748|NCT03646825|DIETARY_SUPPLEMENT|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
218979749|NCT03147677|DRUG|Alfacalcidol|
218979750|NCT03147677|DRUG|Irbesartan|
218979751|NCT00880984|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
218979752|NCT02655133|DRUG|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
219069071|NCT05528120|DRUG|VC004 Capsules|Oral administration after fasting/high-fat meal
219069072|NCT05528120|DRUG|VC004 Capsules|Oral administration after high-fat/fasting meal
218979753|NCT02655133|DRUG|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
218979754|NCT00993681|BIOLOGICAL|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
218979755|NCT00993681|BIOLOGICAL|TD Vaccine System|placebo
218979756|NCT03316365|OTHER|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
218979757|NCT00907868|RADIATION|partial breast irradiation|Patients undergo radiation tumor bed boost
218979758|NCT00907868|RADIATION|whole breast irradiation|Patients undergo whole breast irradiation
218979759|NCT01375426|DRUG|Oral amoxicillin|
218979760|NCT00603785|DRUG|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
218979761|NCT00603785|DRUG|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
218979762|NCT05991349|DRUG|IBI129|Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
218979763|NCT01736124|OTHER|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
218979764|NCT01736124|OTHER|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
218979765|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
218979766|NCT02634749|OTHER|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
218979767|NCT02634749|OTHER|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
218979768|NCT02634749|OTHER|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
218979769|NCT02760576|DRUG|BAY 987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
218979770|NCT03025009|DRUG|LY3192767|Administered SC.
218979771|NCT03025009|DRUG|Basal Insulin Peglispro|Administered SC.
218979772|NCT03025009|DRUG|Insulin Glargine|Administered SC.
218979773|NCT03025009|DRUG|Placebo|Administered SC.
218979774|NCT05338359|BIOLOGICAL|Blood sample|Blood sample of 34 mL
218979775|NCT05338359|OTHER|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
218979776|NCT02325648|DRUG|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
218979777|NCT05985343|DRUG|Neostigmine / Glycopyrrolate|Patients will receive standard of care for reversal of neuromuscular blockade
218979778|NCT05985343|DRUG|Sugammadex|Patients will receive sugammadex for reversal of neuromuscular blockade
218979779|NCT06966531|PROCEDURE|Coronary angiography|distinguish between true MI with significant lesion and MINOCA with insignificant lesions (less than 50%)
218979780|NCT04426812|OTHER|No intervention; just data collection|No intervention; just data collection
218979781|NCT06271538|COMBINATION_PRODUCT|Skal Pro|One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
218979782|NCT06271538|OTHER|Placebo|One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
218979783|NCT03472872|DRUG|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
218979784|NCT03472872|DRUG|Acetaminophen|1,000mg acetaminophen IVPB
218979785|NCT04932512|DRUG|ION224|ION224 will be administered by SC injection.
218979786|NCT04932512|OTHER|Placebo|ION224-matching placebo solution will be administered by SC injection.
218979787|NCT06091579|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
218979788|NCT06091579|DRUG|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
218979789|NCT05137990|BEHAVIORAL|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
219670621|NCT03633916|BEHAVIORAL|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
219670622|NCT03633916|BEHAVIORAL|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
219670623|NCT01119846|DRUG|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
219670624|NCT01119846|DRUG|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
219670625|NCT01119846|DRUG|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
219670626|NCT05940766|OTHER|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
219670627|NCT04592679|DEVICE|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
219670628|NCT04592679|OTHER|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
219670629|NCT03646071|DRUG|RX108|RX108
219670630|NCT02651649|DEVICE|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
219670631|NCT01557868|DEVICE|hylan G-F 20|Three 2 cc injections at weekly intervals
219670632|NCT01557868|DEVICE|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
218979790|NCT05137990|BEHAVIORAL|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
218979791|NCT04195282|OTHER|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
218979792|NCT04195282|OTHER|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
218979793|NCT04622462|PROCEDURE|Standard of Care Histopathology|Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
218979794|NCT04622462|PROCEDURE|STRATICYTE Assessment|Assessment for risk of progression to oral cancer
218979795|NCT06679998|DRUG|Single dose, AAPB by injection, intravenous drip.|Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
218979796|NCT06679998|OTHER|Single dose, placebo, intravenous drip.|Subjects received a single intravenous infusion of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time.
219069073|NCT01638923|DRUG|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
219069074|NCT01638923|DRUG|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
219069075|NCT05872633|BEHAVIORAL|Online self-management intervention|
219069076|NCT05872633|OTHER|Care-as-usual|
219069077|NCT04336202|RADIATION|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
219670633|NCT03739580|DEVICE|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
219670634|NCT03739580|DEVICE|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
219670635|NCT00795769|DRUG|ondansetron|Given IV
219670636|NCT00795769|OTHER|survey administration|Correlative studies
219670637|NCT00795769|PROCEDURE|management of therapy complications|Ondansetron IV
219670638|NCT00602446|DRUG|deferasirox|20 mg/kg once daily orally for 6 months
219670639|NCT05309239|OTHER|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
219670640|NCT03304184|DEVICE|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
219670641|NCT03304184|DEVICE|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
219670642|NCT00893906|BIOLOGICAL|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
219670643|NCT00893906|BIOLOGICAL|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
219670644|NCT02062775|PROCEDURE|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
219670645|NCT02062775|PROCEDURE|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
218979797|NCT06679998|DRUG|Multiple dosing, AAPB for injection, intravenous drip|Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
218979798|NCT06679998|OTHER|Multiple dosing, placebo, IV drip|Subjects received multiple intravenous doses of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time for 7 consecutive days.
218979799|NCT03615573|OTHER|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
218979800|NCT06680895|OTHER|FeNO Observation|FeNO was observed and measured among patients with advanced respiratory support
218979801|NCT06681532|PROCEDURE|Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars|The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.
218979802|NCT06681532|PROCEDURE|Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars|the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
218979803|NCT05574998|DRUG|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
218979804|NCT06707168|DIAGNOSTIC_TEST|Digital palpation|Digital palpation for IOP measurement
218979805|NCT06707168|DIAGNOSTIC_TEST|Cotton-tipped applicator (CTA)|Cotton-tipped applicator (CTA) for IOP measurement
218979806|NCT06710769|PROCEDURE|Ovarian tissue removal will be performed laparoscopically|under general anesthesia concomitantly with another scheduled procedure if possible. Following removal, ovarian tissue will be shipped to University of Pittsburg Medical Center, Magee-Womens Research Institute for processing. Freezing and storing techniques will be in accordance with FDA regulations for reproductive tissues, guidelines of the American Association of Tissues Banks and any other applicable federal, state and local regulations. The tissue will be carefully separated dividing the cortex from the medulla. The cortex will then be cryopreserved for long term storage. The medulla will be shipped overnight back to the PCH Department of Pathology for histological evaluation. If pathology finds evidence of cancer in the ovarian tissue provided, they may request that all of the patient's tissue be returned to pathology for a more detailed examination, which may eliminate the tissue available for the patient's future use.
218979807|NCT06708845|BIOLOGICAL|zamtocabtagene autoleucel|chimeric antigen receptor T-cell (CAR-T) therapy
218979808|NCT06708845|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
218979809|NCT06708845|DRUG|Fludarabine|Lymphodepleting chemotherapy
218979810|NCT06708546|DIETARY_SUPPLEMENT|Dielac Grow Plus|"Dialac Grow Plus is an Oral Nutritional Supplementation made by Vietnam Dairy Products Joint Stock Company - Vinamilk.~Condition: Liquid~Color: White~Date of use: 8 months from the manufactured date.~Preserve: Store in a clean, dry place, and avoid direct sunlight."
218979811|NCT06709586|PROCEDURE|Thermal ablation|Thermal ablation is a treatment for secondary hyperparathyroidism. There are radiofrequency ablation (RFA) and microwave ablation (MWA). For RFA, an electrode needle is inserted into the parathyroid under imaging guidance. High - frequency current heats the tissue to cause necrosis. MWA uses electromagnetic waves to generate heat by friction. Before ablation, imaging and lab tests are done for evaluation. During the process, precise positioning and real - time monitoring are key. After that, patients are observed for bleeding, swelling and other symptoms, and tests are repeated to assess the effect.
218979812|NCT06709586|PROCEDURE|parathyroidectomy|Parathyroidectomy for secondary hyperparathyroidism is a common approach. The surgeon first makes an incision in the neck area under general or local anesthesia. Then, the enlarged parathyroid glands are carefully identified and dissected. Precise surgical skills are required to avoid damaging nearby structures such as the recurrent laryngeal nerve and blood vessels. After the removal of the abnormal parathyroid tissue, the wound is closed.
218979813|NCT06707311|OTHER|patients received calcium hydroxide with glass ionomer restorative material|patients received calcium hydroxide with glass ionomer restorative material
218979814|NCT06707311|OTHER|patients received TheraCal LC with glass ionomer restorative material|patients received TheraCal LC with glass ionomer restorative material
218979815|NCT06707311|OTHER|patients received bioactive bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
218979816|NCT06707311|OTHER|patients received universal bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
218979817|NCT03366012|DEVICE|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
219670646|NCT02062775|PROCEDURE|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures \>2cm
219670647|NCT03236571|DEVICE|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
219670648|NCT03202732|OTHER|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
219670649|NCT02547701|DRUG|P-3058|
219670650|NCT01608516|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
219670651|NCT05854849|DRUG|Camrelizumab|200mg, D1, Q3W, iv drip.
219670652|NCT05854849|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
219670653|NCT05854849|DRUG|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
219670654|NCT05854849|DRUG|Apatinib|250mg, PO, QD
219670655|NCT04527978|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
218979818|NCT06710821|DRUG|Liposomal irinotecan in combination with vincristine and temozolomide|Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1. Q3W, 4 cycles expected until disease progression or intolerable toxicity occurs
218979819|NCT06708884|OTHER|Exercise|exercise programme will be implemented via telerehabilitation
218979820|NCT06708884|OTHER|Exercise|exercise programme will be implemented via face-to-face
218979821|NCT06709703|PROCEDURE|Kinematic aligned total knee replacement|Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
218979822|NCT06710301|OTHER|Preliminary assessment|Evaluation of the cognitive level through the Raven test and of spatial navigation skills through the Corsi test and the maze sub-test of the WISC-III.
218979823|NCT06710301|OTHER|Navigation task with EEG recording|Administration of the navigation task in an immersive virtual reality environment and EEG signal recording. The participant will wear virtual reality viewers and EEG cap. The task consists in moving and orienting themselves inside a five-way maze in order to reach a treasure. The participant will be asked to carry out 30 trials lasting a maximum of 120s each.
218979824|NCT06707181|DRUG|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
218979825|NCT06710496|OTHER|analysis of medical records|analysis of medical records of the patients
218979826|NCT06921915|OTHER|eLearning|Participants in the intervention arms view a website developed by urinary bladder experts that presents information about how to prevent inconvenient urinary urges.
218979827|NCT06924840|OTHER|Utixira Lotion tablet as regimen|"Mode of Usage: To be applied over the affected areas twice a day as a thin film and rubbed in gently and completely. Take 1 capsule twice a day for better results.~Marketed By: SAVA Healthcare Ltd Frequency: Twice a Day"
218979828|NCT06933082|BEHAVIORAL|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers t|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers to implementing the occupational health and safety program despite the existence of this program in the company.this intervention program based on health belief model in improventing workers' adherence related to occupatioan hazards prevention by wearing PPE. Validity and pre-test are applied prior to the implementation of the intervention program. The program is comprised of five main lecture each lecture is designed and scheduled for at least (45) minutes which deals with changing of workers' health beliefs about occupatioan hazards prevention.All lectures are presented at conference hall in the company.The implementation of health intervention program is initiated during the period of June 20th, 2024 to June 25th, 2024. Each lecture is designed and scheduled for approximately (45)
218979829|NCT06935006|PROCEDURE|Sonographic guided Erector spinae plane block|Ultrasound guided plane block using 20 ml of 0.25% bupivacaine at the level of transverse process of T8
218979830|NCT06935006|DRUG|Intravenous opioid|0.1 mg/kg morphine intravenous pre operative
218979831|NCT04033510|OTHER|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
218979832|NCT06702878|COMBINATION_PRODUCT|nasal antimicrobial photodisinfection therapy|Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
218979833|NCT00292396|DRUG|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
219670656|NCT04527978|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
219670657|NCT01370616|DRUG|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
219670658|NCT01370616|DRUG|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
219670659|NCT01370616|DRUG|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
219670660|NCT01370616|DRUG|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
219670661|NCT00031044|DRUG|Enfuvirtide|
219670662|NCT00031044|DRUG|Amdoxovir|
218979834|NCT00292396|DRUG|placebo|12 doses
218979835|NCT01748266|OTHER|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
218979836|NCT02848404|DEVICE|Categorical Language Fluency Smartphone Application|4 weeks' training
218979837|NCT04652440|DRUG|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
218979838|NCT04652440|PROCEDURE|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
218979839|NCT02555774|BEHAVIORAL|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
218979840|NCT02555774|BEHAVIORAL|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
218979841|NCT00227838|BEHAVIORAL|Behavior Therapy|
218979842|NCT02681783|DRUG|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
218979843|NCT04360941|DRUG|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
218979844|NCT04360941|DRUG|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
218979845|NCT06129565|DEVICE|Q-collar|Q-collar is placed for all patients that are admitted with low-pressure hydrocephalus
218979846|NCT05037292|OTHER|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
218979847|NCT05117515|DEVICE|Vascular reconstruction|Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
218979848|NCT06215807|PROCEDURE|Femtosecond laser arcuate keratotomy|The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
218979849|NCT06215807|PROCEDURE|Toric intraocular lens implantation|The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
218979850|NCT03428932|DEVICE|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
218979851|NCT03428932|OTHER|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
218979852|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to 24 months post index surgery
218979853|NCT06257628|DEVICE|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
218979854|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
218979855|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
218979856|NCT05159388|DRUG|PRS-344/S095012|PRS-344/S095012 Monotherapy
218979857|NCT03591835|OTHER|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
218979858|NCT03591835|OTHER|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
218979859|NCT01628315|DEVICE|MRI|Annual MRIs as part of participation in the ASA study.
218979860|NCT03940040|OTHER|Usual care|Usual Care
218979861|NCT03940040|OTHER|High flow nasal oxygen|High flow nasal oxygen
218979862|NCT06233981|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
218979863|NCT06233981|DRUG|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
218979864|NCT01057095|GENETIC|RNA analysis|
218979865|NCT01057095|GENETIC|gene expression analysis|
218979866|NCT01057095|GENETIC|reverse transcriptase-polymerase chain reaction|
218979867|NCT01057095|OTHER|laboratory biomarker analysis|
218979868|NCT03652168|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
219208788|NCT06729190|PROCEDURE|Physical therapy program|Flexibility exercises for shorted muscles and spastic muscles, Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles, Postural control exercise in different positions and different surfaces, General endurance training, Exercises to facilitate hand function, Exercises included, grasping a cube, transferring cube, removing and placing pegs, releasing cube and placing cubes. Strengthening exercises of the intrinsic muscles of the hand
219670663|NCT00386230|DRUG|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
219670664|NCT00386230|DRUG|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
219069078|NCT03331120|DEVICE|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
219069079|NCT01494051|BEHAVIORAL|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
219069080|NCT01388387|OTHER|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
219069081|NCT02422277|DEVICE|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
219069082|NCT02422277|DRUG|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
219069083|NCT01736826|BIOLOGICAL|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
219069084|NCT01736826|BIOLOGICAL|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 \& 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
219069085|NCT01736826|BIOLOGICAL|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
219069086|NCT05706805|DEVICE|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
219069087|NCT02959073|OTHER|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
219069088|NCT03388580|PROCEDURE|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
219069089|NCT04728243|OTHER|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
219208789|NCT06728462|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
219670665|NCT00386230|DRUG|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
219670666|NCT00386230|DRUG|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
219670667|NCT02940873|BEHAVIORAL|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
219670668|NCT02940873|BEHAVIORAL|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
219670669|NCT02888275|DRUG|Dexmedetomidine|
219670670|NCT02888275|DRUG|normal saline|
219670671|NCT02324699|DRUG|Prednisone|
218979869|NCT00686283|BEHAVIORAL|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
218979870|NCT00089414|DRUG|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
218979871|NCT00089414|DRUG|Placebo|
218979872|NCT00089414|DRUG|CDB 2914|
218979873|NCT01754870|DRUG|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
218979874|NCT02221830|DRUG|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
218979875|NCT02221830|DRUG|Placebo|This intervention utilizes a Placebo Camparator
218979876|NCT03848429|PROCEDURE|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
218979877|NCT02883686|BEHAVIORAL|Alma|Alma peer-mentoring
218979878|NCT04853550|DEVICE|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
218979879|NCT05464693|DIAGNOSTIC_TEST|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~1. Its macroscopic appearance will be analyzed: yellow, black, or purulent.~2. Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
218979880|NCT06275347|OTHER|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
218979881|NCT06275347|OTHER|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
218979882|NCT02837289|OTHER|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
218979883|NCT02837289|OTHER|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
219670672|NCT02324699|DRUG|Placebo|
219670673|NCT02324699|DRUG|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
219670674|NCT01614106|BEHAVIORAL|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
219670675|NCT03782532|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219670676|NCT03782532|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219670677|NCT03782532|DRUG|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
219670678|NCT03782532|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
219670679|NCT02651493|DEVICE|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
219670680|NCT05436171|OTHER|No intervention|No intervention
219670681|NCT04538287|DEVICE|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
219670682|NCT04553003|DRUG|Glucocorticoids+hepatoprotectant|Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
219670683|NCT04553003|DRUG|hepatoprotectant|Participants received hepatoprotectants (i.v.gtt.) for 7 days.
219670684|NCT06074627|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
219670685|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
219670686|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
219670687|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
219670688|NCT03292614|DIAGNOSTIC_TEST|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
219670689|NCT00212264|BEHAVIORAL|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
218979884|NCT03252119|DEVICE|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
218979885|NCT03424200|BEHAVIORAL|Routine care|Participants will receive routine care
218979886|NCT03424200|OTHER|Coaching plus routine care|Participants will receive coaching plus routine care
218979887|NCT02495831|DRUG|Diclofenac sodium|Diclofenac sodium 50 mg single dose
218979888|NCT02495831|DRUG|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
218979889|NCT00112008|DRUG|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
218979890|NCT06012474|OTHER|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
218979891|NCT06012474|OTHER|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
219670690|NCT00212264|DEVICE|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
219670691|NCT00212264|BEHAVIORAL|Biofeedback|Pelvic Floor Muscle training via biofeedback
219670692|NCT00212264|OTHER|No Treatment|No treatment
219670693|NCT06488872|PROCEDURE|comparison of CT scan with routinely assessed methods of muscle mass and strength|comparison of CT scan with routinely assessed methods of muscle mass and strength
219670694|NCT04779710|OTHER|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
219670695|NCT01605825|DRUG|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
219670696|NCT01605825|DRUG|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
219670697|NCT03476902|BEHAVIORAL|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
219670698|NCT04723407|OTHER|questionnaires|Questionnaire completion
219670699|NCT05152199|PROCEDURE|Cystoscopy - with use of obturator sheath|The intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
219670700|NCT05152199|PROCEDURE|Cystoscopy - without use of obturator sheath|The intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
219670701|NCT00691561|BEHAVIORAL|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
219069090|NCT04728243|OTHER|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
219069091|NCT05427786|DRUG|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
219069092|NCT06265116|OTHER|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
219069093|NCT04572256|DRUG|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
219069094|NCT04572256|DRUG|Placebo|An oral placebo will be taken daily for 6 months post surgery.
219069095|NCT06667180|DEVICE|Low-intensity TMS|Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 mT and frequency of 50 Hz in theta bursts.
219069096|NCT06667180|DEVICE|Transcranial Magnetic Stimulation Sham|The control group will receive the simulation of low-intensity TMS without magnetic field induction.
219069097|NCT05699759|DRUG|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
219670702|NCT02740335|DRUG|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
219670703|NCT02740335|DRUG|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
219670704|NCT02415231|BEHAVIORAL|humor|
218979892|NCT06012474|OTHER|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~* Loosen any tight clothing, especially around neck.~* Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~* The patient will be instructed to exhale letting all the breath out.~* patient will asked to close the lips around the mouthpiece of the spirometer.~* patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~* patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~* Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~* Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
218979893|NCT05780190|DEVICE|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
218979894|NCT03320317|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
218979895|NCT03320317|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
218979896|NCT03320317|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
218979897|NCT03320317|OTHER|Learning session 4|Feedback report, Best practice symposium
218979898|NCT03789396|OTHER|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
219069098|NCT06053489|OTHER|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
219069099|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
219670705|NCT03973697|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
219670706|NCT03973697|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
219670707|NCT03973697|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
219670708|NCT05687409|DRUG|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
219670709|NCT05687409|DRUG|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
219670710|NCT05687409|DIETARY_SUPPLEMENT|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
219670711|NCT00464295|DRUG|Capecitabine in HCC|
219069100|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
219069101|NCT05774808|PROCEDURE|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
219670712|NCT03474146|OTHER|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
219670713|NCT03474146|OTHER|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
218979899|NCT03789396|OTHER|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
218979900|NCT00928395|DEVICE|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
218979901|NCT04540276|DRUG|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
218979902|NCT06166589|DRUG|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
218979903|NCT06166589|DRUG|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
218979904|NCT06166589|DRUG|S-1|S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
218979905|NCT06166589|DRUG|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
218979906|NCT03460275|DRUG|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
218979907|NCT02095418|DRUG|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
218979908|NCT02095418|DRUG|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
218979909|NCT03768232|OTHER|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
218979910|NCT04750512|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
218979911|NCT04750512|PROCEDURE|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
218979912|NCT02281773|DRUG|BI 409306 100 mg QD|
218979913|NCT02281773|DRUG|BI 498306 50 mg QD|
218979914|NCT02281773|DRUG|Placebo|
218979915|NCT02281773|DRUG|BI 498306 25 mg QD|
218979916|NCT02281773|DRUG|BI 409306 10 mg QD|
218979917|NCT01551901|DEVICE|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
218979918|NCT02778087|BEHAVIORAL|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
218979919|NCT02778087|BEHAVIORAL|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
218979920|NCT04576325|DRUG|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
218979921|NCT04576325|DRUG|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
218979922|NCT01041326|RADIATION|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
219069102|NCT05774808|PROCEDURE|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
219069103|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
219069104|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
219069105|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~\- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
218979923|NCT01041326|PROCEDURE|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
218979924|NCT01130675|OTHER|caffeinated coffee|8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
218979925|NCT05944211|DRUG|Hetrombopag Olamine|"The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator."
218979926|NCT04549857|BEHAVIORAL|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment."
218979927|NCT01259765|DRUG|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
218979928|NCT01259765|DRUG|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
218979929|NCT03056404|OTHER|additional blood sample|
218979930|NCT03056404|OTHER|respiratory functional exploration|
218979931|NCT02104752|DRUG|Curcumin|360 mg/day (divided into twice daily oral doses)
218979932|NCT02104752|DRUG|Placebo|"Inactive, matched placebo (Sugar Pill)"
218979933|NCT05439941|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
218979934|NCT05981339|OTHER|breathing exercises|For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
218979935|NCT05981339|OTHER|osteopathic manual therapy techniques|"* Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006)."
218979936|NCT03538548|BEHAVIORAL|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
218979937|NCT03069443|OTHER|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
219069106|NCT02450994|DRUG|Dexamethasone|
219069107|NCT02450994|DRUG|Placebo|
219069108|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
219069109|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
219069110|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
219069111|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
219670714|NCT03474146|OTHER|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
219670715|NCT00813436|DRUG|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
219670716|NCT00813436|DRUG|Placebo|saline liquid, intranasally administered
219670717|NCT01578499|DRUG|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
218979938|NCT02899299|BIOLOGICAL|Nivolumab|
218979939|NCT02899299|BIOLOGICAL|Ipilimumab|
219670718|NCT01578499|DRUG|Methotrexate|Methotrexate tablets.
219670719|NCT01578499|DRUG|Bexarotene|Bexarotene tablets.
219670720|NCT01756248|DRUG|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
219670721|NCT01622725|PROCEDURE|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
219670722|NCT01622725|PROCEDURE|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
219670723|NCT05454254|OTHER|Individualised muscle strengthening exercise training protocol.|Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
219670724|NCT05403528|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
219670725|NCT05403528|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
219670726|NCT05403528|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
219670727|NCT02670382|DIETARY_SUPPLEMENT|EPA|10 week supplementation
219670728|NCT02670382|DIETARY_SUPPLEMENT|DHA|10 week supplementation
218979940|NCT02899299|DRUG|Pemetrexed|
219069112|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
219069113|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
219069114|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
218979941|NCT02899299|DRUG|Cisplatin|
218979942|NCT02899299|DRUG|Carboplatin|
218979943|NCT03481907|DEVICE|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
218979944|NCT01577420|OTHER|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
218979945|NCT01577420|OTHER|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
218979946|NCT03534414|DIETARY_SUPPLEMENT|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)"
218979947|NCT03534414|DIETARY_SUPPLEMENT|NCEP Based Diet|A low saturated fat, low cholesterol diet.
218979948|NCT01931592|DRUG|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
219069115|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
219069116|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
219069117|NCT05843968|DRUG|Rituximab|"2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
219670729|NCT02670382|DIETARY_SUPPLEMENT|sunflower oil|4-week lead-in
219670730|NCT00214734|DRUG|rAHF-PFM|
219670731|NCT03244618|DEVICE|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
219670732|NCT03244618|DEVICE|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
219670733|NCT02771600|DEVICE|Buzzy|See arm description
219670734|NCT02771600|DRUG|Topical anaesthetic cream|See arm description
219670735|NCT02003456|DRUG|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
219670736|NCT01354548|DEVICE|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
219670737|NCT02209025|DIETARY_SUPPLEMENT|Theobromine|Theobromine a compound for cocoa
219670738|NCT02209025|DIETARY_SUPPLEMENT|Placebo drink|
219670739|NCT02200991|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
219670740|NCT02200991|DRUG|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
219670741|NCT02200991|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
218979949|NCT01931592|DRUG|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
218979950|NCT00761904|BEHAVIORAL|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
218979951|NCT00055250|DRUG|Gemcitabine|
218979952|NCT00055250|DRUG|LY293111|
218979953|NCT00055250|DRUG|placebo|
218979954|NCT03470870|OTHER|Comparative analysis of the characteristics|"* Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program"
218979955|NCT02433561|PROCEDURE|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
218979956|NCT02433561|PROCEDURE|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
219069118|NCT05843968|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
219069119|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
219670742|NCT02397434|RADIATION|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
218979957|NCT02966431|BEHAVIORAL|Counseling|
218979958|NCT02966431|BEHAVIORAL|No Counseling|
218979959|NCT00440583|DRUG|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
218979960|NCT02321410|OTHER|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
219069120|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
219670743|NCT01611428|DRUG|Ipragliflozin|Oral and Intravenous (i.v.)
219670744|NCT03086109|OTHER|Risk factors|Risk factors associated bone degenerative diseases
219670745|NCT05268354|OTHER|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
219670746|NCT02574416|OTHER|There is no intervention|The study is observational and there is no intervention
219670747|NCT00513890|DEVICE|Infantflow [EME, Brighton, England]|
219670748|NCT04350814|BEHAVIORAL|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
219670749|NCT04350814|BEHAVIORAL|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
219670750|NCT00006110|BIOLOGICAL|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
219670751|NCT00006110|DRUG|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
219670752|NCT00006110|DRUG|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
219670753|NCT00006110|DRUG|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
219670754|NCT00006110|PROCEDURE|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
219670755|NCT01122017|PROCEDURE|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
219670756|NCT01826045|DRUG|Poly-gamma Glutamic Acid|
219670757|NCT01826045|DRUG|Placebo|
219670758|NCT03469999|DRUG|Dysport Injectable Product|Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
218979961|NCT02321410|OTHER|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
218979962|NCT02327065|DEVICE|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
218979963|NCT02327065|DEVICE|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
219069121|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
219069122|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
219670759|NCT02998359|DEVICE|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
219670760|NCT02998359|DEVICE|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
219670761|NCT05699785|OTHER|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
219670762|NCT05699785|OTHER|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
219670763|NCT06345014|DRUG|OM-89 [Uro-Vaxom® Capsule]|Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
219670764|NCT06345014|DRUG|OM-89 Placebo [Uro-Vaxom® Capsule Placebo]|Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
218979964|NCT00313300|DRUG|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
218979965|NCT00313300|DRUG|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
218979966|NCT00313300|DRUG|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
218979967|NCT00313300|DRUG|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
218979968|NCT01334346|OTHER|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
218979969|NCT01334346|OTHER|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
218979970|NCT01334346|OTHER|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
219069123|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
219069124|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
219069125|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
219069126|NCT06206005|OTHER|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
218979971|NCT03145233|OTHER|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
218979972|NCT03145233|OTHER|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
219670765|NCT02336009|DEVICE|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
219670766|NCT03828682|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet \[Envarsus\]
219670767|NCT03828682|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
219670768|NCT03828682|DRUG|Mycophenolic Acid Oral Product|mycophenolic acid tablets
219670769|NCT03828682|DRUG|Tacrolimus|Twice daily tacrolimus
219670770|NCT03828682|DRUG|Methylprednisolone|Methylprednisolone taper
219670771|NCT03828682|DRUG|Prednisone|Prednisone taper
219670772|NCT03828682|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
219670773|NCT03080480|DRUG|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
218979973|NCT03954197|OTHER|No hormone|No hormonal injection before oocytes retrieval
218979974|NCT03954197|OTHER|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
218979975|NCT03954197|OTHER|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
218979976|NCT02336373|DRUG|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
219069127|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
219069128|NCT03032692|OTHER|Exercise with biofeedback|
219670774|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
219069129|NCT03032692|OTHER|exercise without biofeedback|
219670775|NCT00553852|DRUG|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
219670776|NCT06263517|DRUG|Clodronate|For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
219670777|NCT06263517|DRUG|Clodronate|For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
219670778|NCT06263517|DRUG|Clodronate|For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
219670779|NCT06263517|DRUG|Placebo|For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
219670780|NCT00394771|DRUG|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
219069130|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
219069131|NCT02520934|DRUG|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
219670781|NCT00394771|DRUG|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
219670782|NCT00394771|DRUG|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
219670783|NCT01195181|DRUG|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
219670784|NCT04586335|DRUG|CYH33|Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
219670785|NCT01945294|DRUG|Boceprevir|800 mg three times daily orally
219670786|NCT01945294|BIOLOGICAL|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
219670787|NCT01945294|DRUG|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
219670788|NCT04832750|DEVICE|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
219670789|NCT04765670|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
219670790|NCT04765670|OTHER|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
219670791|NCT03201393|DRUG|Low-dose naltrexone and acetaminophen combination|Twice a day
218979977|NCT02543710|PROCEDURE|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
219069132|NCT02520934|DRUG|ERT|enzyme replacement therapy
219069133|NCT00147966|DRUG|rituximab|treatment with rituximab
219069134|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
219069135|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
219069136|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
219670792|NCT03201393|DRUG|Placebo|Twice a day
219670793|NCT00384371|DRUG|Botulinum Toxin A|Botulinum Toxin A
219670794|NCT00384371|DRUG|Placebo|Placebo
219670795|NCT04938713|DRUG|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
219670796|NCT04938713|DRUG|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
219670797|NCT00586898|DRUG|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
219069137|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
219069138|NCT04859166|PROCEDURE|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
219069139|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
219069140|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
219069141|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
219069142|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
219069143|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
219069144|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
219069145|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
219069146|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
219670798|NCT00586898|DRUG|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
219670799|NCT00586898|DRUG|Bicalutamide|A pure nonsteroidal antiandrogen
219670800|NCT00586898|DRUG|Testosterone transdermal gel|an androgenic anabolic steroid
219670801|NCT00586898|DRUG|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
219670802|NCT06396013|DRUG|Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
219670803|NCT06396013|DRUG|placebo|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
219670804|NCT00379171|BEHAVIORAL|Cow's milk with fish oil|
219670805|NCT00379171|BEHAVIORAL|Cow's milk without fish oil|
219670806|NCT00379171|BEHAVIORAL|Formula with fish oil|
219670807|NCT00379171|BEHAVIORAL|Formula without fish oil|
219670808|NCT03983785|OTHER|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
219670809|NCT03983785|OTHER|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
219670810|NCT04641533|PROCEDURE|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
219670811|NCT04641533|PROCEDURE|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
219670812|NCT01700738|PROCEDURE|gastric ring surgery|
219670813|NCT01700738|OTHER|nutritional help|
219670814|NCT05386732|DEVICE|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
219670815|NCT00133653|BEHAVIORAL|Observational|
219670816|NCT03530319|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
219670817|NCT03530319|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
219670818|NCT00540488|OTHER|Adult enteral formula|
219670819|NCT03816007|BEHAVIORAL|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
219670820|NCT03816007|BEHAVIORAL|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
219670821|NCT06614673|OTHER|text in non-narrative form|Participants will be asked to read a text and complete questionnaires
219670822|NCT06614673|OTHER|text in narrative form|Participants will be asked to read a text and complete questionnaires
219670823|NCT06614673|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and complete questionnaires
219670824|NCT06614673|OTHER|animated video in narrative form|Participants will be asked to watch a video and complete questionnaires
219069147|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
219069148|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
219670825|NCT06993740|DRUG|NaCl 0,9%|NaCl 0.9% continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively.
219670826|NCT06993740|DRUG|Dexmedetomidine|Dexmedetomidine continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively, titrated to maintain target sedation and hemodynamic stability.
219670827|NCT06613035|DRUG|Selinexor|Selinexor: 60 mg/day from days -9 to -5.
219670828|NCT06613035|DRUG|Melphalan|Selinexor: 60 mg/day from days -9 to -5.
219670829|NCT06613035|DRUG|Intravenous Busulfan|3.2 mg/kg on days
219670830|NCT06613035|DRUG|Fludarabine|30 mg/m² on days
219670831|NCT00268684|DRUG|Erlotinib, Temozolomide|
219670832|NCT00572975|OTHER|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
219670833|NCT06616246|BEHAVIORAL|HealthyLifetime|HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
219670834|NCT03289806|PROCEDURE|Samples of fibroblasts from Tenon's capsule|
219670835|NCT01926197|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
219670836|NCT01926197|DRUG|Irinotecan|Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.
219670837|NCT01926197|DRUG|Leucovorin|Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
219670838|NCT01926197|DRUG|5FU|5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
219670839|NCT01926197|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.
219670840|NCT07007598|DEVICE|Hemostatic clip|The hemostatic clip is endoscopically applied after a colorectal polypectomy to close the mucosal defect.
219069149|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
219069150|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
219670841|NCT07006558|DIETARY_SUPPLEMENT|Diamino Oxidase|The investigational product is a dehydrated power of DAO enzyme from green pea (Pisum sativum L.) sprouts (adiDAO®Veg, DR Healthcare, S.L.U., Barcelona, Spain), with an enzymatic activity \> 298 mU/g (\> 14,500 kHDU/g).
219670842|NCT05776914|BIOLOGICAL|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
219670843|NCT05776914|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
219670844|NCT07009184|DRUG|[111In]In-DOTA-TCO-trastuzumab|\[111In\]In-DOTA-TCO-trastuzumab is a chemically cleavable \[111In\]In-labeled trastuzumab conjugate that is administered first to the patient, it accumulates in HER2-positive tumors and internalizes in HER2-expressing tumor cells.
219670845|NCT07009184|DRUG|Small molecule tetrazine trigger component|TRG001 is a small molecule tetrazine trigger that reacts with \[111In\]In-TGW211-DC in blood and extracellular space thus releasing a fast clearing \[111In\]In-DOTA containing fragment which is rapidly eliminated via the kidney. Because of its non-cell permeable nature, TRG001 does not reach \[111In\]In-TGW211-DC inside tumor cells and therefore the radioactivity inside tumor cells is retained by the tumor.
219670846|NCT07007104|BEHAVIORAL|Mindful Eating Intervention|The mindful eating intervention consisted of six structured group sessions delivered over a six-week period, each lasting approximately 60-90 minutes. The sessions were led by a registered dietitian certified in both Mindful Eating (The Center of Mindful Eating, EatRight Certified, 2023) and Mindfulness-Based Eating Awareness Training (MB-EAT, 2019). The curriculum was designed to improve participants' awareness of hunger and satiety cues, reduce emotional eating, enhance eating satisfaction, and foster non-judgmental eating practices. Each session incorporated guided mindfulness practices, cognitive-behavioral techniques, and experiential activities such as sensory-focused eating. The intervention was provided in addition to standard post-treatment care, which included nutritional counseling by an oncology dietitian.
219670847|NCT07007104|BEHAVIORAL|Oncology Nutrition Counseling|Participants in this group received individualized nutrition counseling and education from a registered oncology dietitian as part of standard post-treatment care for breast cancer survivors. The counseling focused on balanced eating, long-term weight management, and general lifestyle guidance based on survivorship needs. No additional behavioral or mindful eating interventions were delivered.
219670848|NCT03884985|OTHER|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
219670849|NCT01781052|DRUG|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
219670850|NCT05960149|DRUG|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
219670851|NCT05960149|PROCEDURE|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
219670852|NCT03609957|OTHER|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
219670853|NCT03609957|OTHER|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
219670854|NCT07023146|DEVICE|Moderate to high intensity (PTMH; 65-80% of 1-repetition maximum [1RM]) )|Power training performed at maximum velocity in the concentric phase with moderate to high intensity
219670855|NCT07023146|DEVICE|low to moderate intensity (PTLM; 40-60% of 1-repetition maximum [1RM])|Power training performed at maximum velocity in the concentric phase with lower to moderate intensity
219069151|NCT02578394|DRUG|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
219069152|NCT02578394|DRUG|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
219069153|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
219670856|NCT07021937|DRUG|Semaglutide 1.7mg subcutaneous|Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
219670857|NCT07021937|DRUG|Placebo|Placebo saline solution subcutaneous
219670858|NCT06088368|PROCEDURE|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
219670859|NCT06088368|PROCEDURE|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
219069154|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
219069155|NCT03086447|DEVICE|Investigational Contact Lens|Senofilcon C Toric
219069156|NCT03086447|DEVICE|Marketed Contact Lens|Air Optix for Astigmatism
219069157|NCT00217698|DRUG|cisplatin|
219069158|NCT00217698|DRUG|gefitinib|
219670860|NCT00815477|BEHAVIORAL|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
219670861|NCT00815477|BEHAVIORAL|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
219670862|NCT05674877|DRUG|Opioid-based group (OB) (placebo/saline)|Patients in the opioid-based group will receive placebo boluses and infusions of saline.
219670863|NCT05674877|DRUG|"Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)"|"Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine."
219670864|NCT00524004|BIOLOGICAL|Anti-CsbD Bovine IgG|Three times a day for seven days
219670865|NCT00524004|OTHER|Placebo|Three times a day for seven days
219670866|NCT00524004|BIOLOGICAL|Anti-CS17 Bovin IgG|Three times a day for seven days
219670867|NCT00777322|PROCEDURE|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
219670868|NCT00691873|DRUG|Placebo|placebo
219670869|NCT00691873|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
219670870|NCT02101359|DRUG|T2380|200 microlitres of T2380 will be administrated intracamerally
219670871|NCT02101359|DRUG|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
219670872|NCT02101359|DRUG|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
219670873|NCT03093051|DEVICE|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
219069159|NCT00217698|DRUG|gemcitabine hydrochloride|
219069160|NCT02804607|OTHER|questionnaire|
218979978|NCT02543710|DRUG|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
219069161|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
219069162|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
219069163|NCT02006030|DRUG|ADI-PEG 20|
219069164|NCT02006030|DRUG|Transarterial chemoembolization|
219069165|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
219670874|NCT04094831|OTHER|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
219069166|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
219069167|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
219670875|NCT05612802|DIAGNOSTIC_TEST|IGF-1|We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
219670876|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
219670877|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
219670878|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
219670879|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
219670880|NCT04268628|OTHER|Serum and plasma samples analysis|This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
219670881|NCT01240928|DRUG|MSK-2206|Level 1: MK-2206 135mg weekly
219360343|NCT05866198|DIAGNOSTIC_TEST|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
219670882|NCT01240928|DRUG|Exemestane|Level 1: Exemestane - 25mg daily
219670883|NCT01240928|DRUG|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
219670884|NCT02003261|BEHAVIORAL|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
218979979|NCT05344911|DRUG|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
218979980|NCT05344911|DRUG|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
218979981|NCT04840004|DRUG|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
218979982|NCT04803461|DIAGNOSTIC_TEST|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
219670885|NCT02003261|OTHER|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
219670886|NCT00931827|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
219670887|NCT00931827|DRUG|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
219670888|NCT06131216|DRUG|SHR-2022 Injection|SHR-2022 Injection is administered by intravenous (IV) infusion
218979983|NCT00726375|DRUG|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
218979984|NCT04716465|OTHER|Dysautonomia|Indicators of dysautonomia
218979985|NCT03703115|BEHAVIORAL|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
218979986|NCT00850343|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
218979987|NCT00745329|OTHER|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
218979988|NCT03552731|BEHAVIORAL|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
219069168|NCT00318006|PROCEDURE|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
219069169|NCT00318006|PROCEDURE|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
219069170|NCT06534788|OTHER|Reciprocal Inhibition MET|Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.
219069171|NCT06534788|OTHER|Post-facilitation MET|Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.
219069172|NCT06534788|OTHER|Conventional physical therapy|"TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
219360344|NCT04146142|PROCEDURE|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
219670889|NCT03077386|BEHAVIORAL|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
219670890|NCT00416429|BIOLOGICAL|aldesleukin|
219670891|NCT00416429|BIOLOGICAL|recombinant interferon alpha-2a|
219670892|NCT00416429|DRUG|medroxyprogesterone|
218979989|NCT04923438|OTHER|Telerehabilitation|The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
218979990|NCT04923438|OTHER|Control|The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.
218979991|NCT00699569|DIETARY_SUPPLEMENT|hyperimmune colostrum|hyperimmune colostrum
218979992|NCT00699569|DIETARY_SUPPLEMENT|Placebo|
218979993|NCT03120000|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
219670893|NCT02811380|DEVICE|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
219670894|NCT02811380|DEVICE|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
219670895|NCT01483599|DRUG|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
219670896|NCT01483599|DRUG|CNTO 1959 (15 mg)|SC injections
219670897|NCT01483599|DRUG|CNTO 1959 (50 mg)|SC injections
219670898|NCT01483599|DRUG|CNTO 1959 (100 mg)|SC injections
219670899|NCT01483599|DRUG|CNTO 1959 (200 mg)|SC injections
219670900|NCT01483599|DRUG|Adalimumab|SC injections
219670901|NCT01483599|DRUG|Placebo|SC injections
219670902|NCT02041780|PROCEDURE|Shearwave electrography|
219670903|NCT02995629|PROCEDURE|laser indirect ophthalmoscopy pan retinal photocoagulation|"* Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
219670904|NCT02482753|DRUG|Chidamide|30 mg, administered orally twice per week (BIW)
219670905|NCT02482753|DRUG|exemestane|25 mg, PO daily
219670906|NCT02482753|DRUG|placebo|Administered orally twice per week (BIW)
219670907|NCT04542278|DRUG|Prednisone|used to reduce inflammation
219670908|NCT03816618|DRUG|Medihoney Gel in A Tube|TREATMENT1
219670909|NCT03816618|DRUG|Hydrogel|PURLOIN GEL
219670910|NCT03816618|DRUG|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
219670911|NCT03438942|DIETARY_SUPPLEMENT|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
219670912|NCT03438942|DIETARY_SUPPLEMENT|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
219670913|NCT04322084|OTHER|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
219670914|NCT01859949|DRUG|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
219670915|NCT01890759|BIOLOGICAL|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
219069173|NCT05904847|BEHAVIORAL|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
219069174|NCT01250860|OTHER|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
219069175|NCT01250860|BEHAVIORAL|Sham therapy|
219069176|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
219069177|NCT01538745|DRUG|Ketamine|0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.
219069178|NCT01538745|DRUG|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
219069179|NCT06040489|DRUG|Miltefosine 50mg|Oral Miltefosine 50mg bid
219069180|NCT06040489|DRUG|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
219069181|NCT06040489|DRUG|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
219069182|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
219069183|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
219069184|NCT02389543|DRUG|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
219069185|NCT02389543|DRUG|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
219360345|NCT03861637|OTHER|ESA for correction of PTA to 12-13g/dl|To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
219670916|NCT04037800|PROCEDURE|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
219069186|NCT02389543|DRUG|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
219069187|NCT05651477|DEVICE|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
219069188|NCT05651477|DEVICE|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
219069189|NCT02252055|BIOLOGICAL|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
219069190|NCT00290823|DRUG|Albendazole|400 mg tablet taken orally twice daily
219069191|NCT00290823|DRUG|Dexamethasone|6mg or 8mg taken daily
219069192|NCT00290823|DRUG|Omeprazole|20 mg tablet taken orally daily
219069193|NCT00659334|DRUG|Ferumoxtran-10 (Combidex)|2.6 mg/kg
219670917|NCT04037800|PROCEDURE|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
219670918|NCT01015105|OTHER|observation|observation
219670919|NCT05309694|COMBINATION_PRODUCT|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
219670920|NCT00385827|DRUG|Mitoxantrone|Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
219670921|NCT00385827|DRUG|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
219670922|NCT00385827|DRUG|Prednisone|Prednisone 5 mg orally twice daily
219069194|NCT00659334|PROCEDURE|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
219069195|NCT01053858|PROCEDURE|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
219069196|NCT03448146|DRUG|Para-Toluenesulfonamide|
219670923|NCT01909960|OTHER|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
219069197|NCT00875680|DEVICE|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
219069198|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
219670924|NCT01273909|PROCEDURE|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
219670925|NCT01273909|PROCEDURE|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
219069199|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
219069200|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
219069201|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
219069202|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
219069203|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
219670926|NCT02527174|DRUG|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
219670927|NCT02527174|DRUG|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
219670928|NCT02527174|DRUG|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
219670929|NCT05525000|DEVICE|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
219670930|NCT00008125|BIOLOGICAL|filgrastim|
219670931|NCT00008125|DRUG|carboplatin|
219670932|NCT00008125|DRUG|docetaxel|
219670933|NCT00008125|DRUG|gemcitabine hydrochloride|
219670934|NCT01857180|OTHER|Curriculum|
219670935|NCT06476405|OTHER|Study Product A: Ploom® Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
219670936|NCT06476405|OTHER|Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
219670937|NCT06476405|OTHER|Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
219670938|NCT06476405|OTHER|Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
219670939|NCT02374424|DRUG|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
219670940|NCT00410072|DRUG|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
218979994|NCT04023435|OTHER|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
219069204|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
219069205|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
219069206|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
219069207|NCT04198662|DEVICE|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
219670941|NCT00410072|DRUG|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
219670942|NCT03692637|BIOLOGICAL|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
219670943|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
219670944|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219670945|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
219670946|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
219670947|NCT03523312|RADIATION|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
219069208|NCT04198662|DRUG|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
219069209|NCT04198662|DEVICE|Sham cryoneurolysis with a Painblocker|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
219069210|NCT04198662|DRUG|Placebo intercostal nerve block with normal saline|3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
219069211|NCT04458350|BEHAVIORAL|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
219069212|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
219069213|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
219670948|NCT03523312|DRUG|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
219670949|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
219670950|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
219670951|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
219670952|NCT02106598|DRUG|fluorescent cRGDY-PEG-Cy5.5-C dots|
219670953|NCT05123482|DRUG|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
219670954|NCT05123482|DRUG|AZD8205 and AZD2936 (Rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
219670955|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
219670956|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
219670957|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
219670958|NCT05295459|DRUG|Sham procedure control|Sham procedure control
219670959|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
219670960|NCT00116636|DRUG|Kaletra|
219670961|NCT05636137|OTHER|Survey application|Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
219670962|NCT04156451|PROCEDURE|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
219069214|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
219069215|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
219069216|NCT00189631|PROCEDURE|UFT/LV|
219670963|NCT04156451|PROCEDURE|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
219670964|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
219670965|NCT03900247|DEVICE|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
219670966|NCT03276845|DIAGNOSTIC_TEST|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
219670967|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
219069217|NCT00189631|PROCEDURE|Observation|
219069218|NCT00931073|DRUG|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
219670968|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
219670969|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
219670970|NCT03767426|BEHAVIORAL|Sleep Deprivation|Subjects are sleep deprived for an entire night
219670971|NCT03767426|BEHAVIORAL|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
219069219|NCT00931073|DRUG|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
219069220|NCT00931073|DRUG|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
219069221|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
219069222|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
219069223|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
219069224|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
219069225|NCT05437510|BIOLOGICAL|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
219069226|NCT02265562|DRUG|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
219069227|NCT02265562|DRUG|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
219069228|NCT00001768|DRUG|Intravenous immunoglobulin|
219069229|NCT03261518|PROCEDURE|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
219069230|NCT01453816|PROCEDURE|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
219069231|NCT00896168|DRUG|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
219069232|NCT00896168|DRUG|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
219069233|NCT02492100|BEHAVIORAL|Multi-modality sexual dysfunction intervention|
219069234|NCT00563108|DRUG|Basiliximab|
219069235|NCT00563108|DRUG|Placebo|
219670972|NCT01362023|BEHAVIORAL|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home"
219670973|NCT06034132|OTHER|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
219670974|NCT06034132|OTHER|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
219670975|NCT00810498|DEVICE|Trilogy|Exposure for one hour on the Trilogy ventilator
219670976|NCT00810498|DEVICE|Standard of Care|Exposure to participants current ventilator
219670977|NCT05708352|BEHAVIORAL|Keto Diet|The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.
219670978|NCT05708352|BEHAVIORAL|Standard Anti-Cancer Diet|Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.
219670979|NCT06495801|BEHAVIORAL|Frendie PRO mobile application|Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
219670980|NCT02548884|PROCEDURE|Biliary cannulation|
219670981|NCT03185494|BIOLOGICAL|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
219670982|NCT02557685|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
219670983|NCT03234920|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
219670984|NCT03234920|OTHER|Placebo|The placebo will be 200 ml of fruit juice given twice daily
219670985|NCT06079632|BEHAVIORAL|parent coaching via telehealth|Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.
219670986|NCT06079632|BEHAVIORAL|weekly self-learning materials and group discussion session|Participants receive 1-hour self-learning materials, including parent-child interaction and sensory processing strategies, and 1-hour remote group discussion session weekly.
219670987|NCT01832883|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
219670988|NCT01962623|OTHER|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
219670989|NCT04930705|DEVICE|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
219670990|NCT01421147|DRUG|LY2963016|Administered subcutaneously
219670991|NCT01421147|DRUG|Lantus|Administered subcutaneously
219670992|NCT01421147|DRUG|Insulin Lispro|Administered subcutaneously
219670993|NCT02660684|DRUG|Prograf|Injection or oral
219670994|NCT02660684|DRUG|Methotrexate|Injection
219670995|NCT02660684|DRUG|Cyclosporine|Injection or oral
219069236|NCT04654780|BEHAVIORAL|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
219670996|NCT03581955|OTHER|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
219670997|NCT03581955|OTHER|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
219670998|NCT03581955|OTHER|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
219670999|NCT06402877|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219671000|NCT04640038|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
219671001|NCT03887208|PROCEDURE|Laser therapy|non-ablative fractional laser therapy of skin
219671002|NCT03887208|BIOLOGICAL|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
219671003|NCT03887208|PROCEDURE|Normal saline injection|Subcutaneous Normal saline injection
219671004|NCT02802696|DRUG|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
219671005|NCT02802696|DRUG|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
219069237|NCT04654780|BEHAVIORAL|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
219069238|NCT04654780|BEHAVIORAL|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
219069239|NCT05973110|BEHAVIORAL|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
219671006|NCT03802734|DEVICE|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
219671007|NCT03307837|DRUG|CA-008|Local administration during surgery
219671008|NCT03307837|DRUG|Placebo|Local administration during surgery
219671009|NCT03510975|DRUG|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
219671010|NCT03510975|BEHAVIORAL|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
219671011|NCT03510975|BEHAVIORAL|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
219671012|NCT01904747|DRUG|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
218979995|NCT04245852|OTHER|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
218979996|NCT04245852|OTHER|standard PT care|standard PT care
218979997|NCT03380403|RADIATION|PDT|clinical treatment of infected diabetic foot
218979998|NCT03380403|OTHER|Ciprofloxacin|antibiotics and or surgical debridment
218979999|NCT03243604|DRUG|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
218980000|NCT00760123|OTHER|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
218980001|NCT05325788|OTHER|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
219671013|NCT01904747|DRUG|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
219671014|NCT01904747|DRUG|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
219671015|NCT01904747|DRUG|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
219671016|NCT03714477|PROCEDURE|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
218980002|NCT05325788|OTHER|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
218980003|NCT03824288|DIAGNOSTIC_TEST|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
218980004|NCT03824288|PROCEDURE|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
218980005|NCT03894332|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT\_0) and the last (SBT\_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB\_0) and 30 minutes after extubation (SB\_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
218980006|NCT00273832|PROCEDURE|coronary artery computed tomography angiogram|
219671017|NCT01268189|DEVICE|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
219671018|NCT01268189|DEVICE|Standard of care dressing|Xeroform control dressing applied to control wound
218980007|NCT00273832|PROCEDURE|single photon emission computed tomography|
219069240|NCT05973110|BEHAVIORAL|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
219671019|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
219671020|NCT01141166|BEHAVIORAL|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
219671021|NCT03525808|DEVICE|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
219671022|NCT06406166|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
219671023|NCT06406166|OTHER|Conventional treatment with Western medicine|Conventional treatment with Western medicine
219671024|NCT03308929|DEVICE|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
219671025|NCT02449421|BEHAVIORAL|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
218980008|NCT03692468|BEHAVIORAL|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
218980009|NCT00550524|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
219069241|NCT01560390|DRUG|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
219671026|NCT02449421|BEHAVIORAL|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
219671027|NCT06405802|OTHER|Tele-evaluation|Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
219671028|NCT03373747|DIAGNOSTIC_TEST|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
219671029|NCT03373747|DIAGNOSTIC_TEST|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
219671030|NCT02155309|DRUG|Scopolamine|
219671031|NCT02155309|DRUG|Placebo|
219671032|NCT00833014|DEVICE|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
219671033|NCT00618124|DRUG|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
219671034|NCT05337995|OTHER|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
219671035|NCT05600153|PROCEDURE|implant exchange operation|To perform implant exchange via axillary incision.
219671036|NCT04474977|OTHER|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
219671037|NCT04592796|DEVICE|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
219671038|NCT04592796|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
219671039|NCT04592796|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
219671040|NCT04592796|OTHER|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
219671041|NCT04592796|OTHER|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
219671042|NCT04592796|OTHER|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
219671043|NCT04592796|OTHER|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
219671044|NCT05861895|DRUG|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
218980010|NCT04198298|DRUG|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
218980011|NCT04198298|DRUG|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
219069242|NCT01560390|DRUG|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
219671045|NCT05861895|DRUG|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
219671046|NCT05861895|DRUG|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
219069243|NCT03377491|DEVICE|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
219069244|NCT03377491|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
219671047|NCT05861895|DRUG|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
219671048|NCT05861895|DRUG|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
219671049|NCT05861895|DRUG|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
219671050|NCT06127758|OTHER|virtual reality glasses application|The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.
219671051|NCT06127758|OTHER|classical training|Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
219671052|NCT02799914|DEVICE|Sinus-Venous stent (Optimed GmbH)|Stent implantation
219671053|NCT00568893|DRUG|drotrecogin alfa (activated)|
219671054|NCT04705532|DEVICE|tDCS|Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
219671055|NCT04705532|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
219671056|NCT04705532|OTHER|Music|Subjects will listen to their preferred music for 20 minutes
219671057|NCT04705532|OTHER|White noise|Subjects will listen to a white noise for 20 minutes
219671058|NCT05403840|PROCEDURE|Mitral valve surgery|Surgical mitral valve repair or replacement
219671059|NCT05403840|PROCEDURE|Transcatheter mitral valve intervention|Transcatheter mitral valve repair or replacement
219671060|NCT04158505|OTHER|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
219671061|NCT02662335|OTHER|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
219671062|NCT02662335|OTHER|Questionnaire Administration|Ancillary studies
219671063|NCT02662335|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
219671064|NCT03678675|DRUG|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
219671065|NCT00003974|BIOLOGICAL|lung tumor associated antigen|
219671066|NCT00003974|DRUG|DetoxPC|
219671067|NCT00003974|DRUG|chemotherapy|
219671068|NCT00003974|DRUG|cyclophosphamide|
219671069|NCT04129112|DRUG|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
219671070|NCT01141920|BEHAVIORAL|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
219671071|NCT01141920|BEHAVIORAL|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
218980012|NCT04198298|DRUG|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
218980013|NCT05476198|PROCEDURE|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
218980014|NCT05476198|PROCEDURE|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
218980015|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
218980016|NCT01935791|DRUG|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
218980017|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
218980018|NCT01935791|DRUG|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
218980019|NCT01935791|DRUG|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
219069245|NCT03377491|DRUG|nab paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
219069246|NCT05200195|PROCEDURE|Liver transplantation|Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
219671072|NCT04762563|OTHER|IASTM application|IASTM application .
219671073|NCT04762563|OTHER|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
219671074|NCT06229041|DRUG|Camrelizumab ＋Immunotherapy|Camrelizumab was used in preoperative treatment.
219671075|NCT00143169|DRUG|Parecoxib and placebo|
219671076|NCT03961750|OTHER|OTAGO|12 Week exercise class programme
219671077|NCT05009134|BIOLOGICAL|There is no intervention in this study.|There is no intervention in this study.
219671078|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support \& cognitive distortions, social skills \& peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
219671079|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support \& cognitive distortions, social skills \& peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
219671080|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
219671081|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support \& cognitive distortions, social skills \& peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
219671082|NCT03097926|PROCEDURE|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
219069247|NCT01021969|OTHER|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
219069248|NCT05561738|DIETARY_SUPPLEMENT|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
219671083|NCT05110365|OTHER|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
219671084|NCT01442649|DRUG|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
219671085|NCT01442649|DRUG|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
218980020|NCT01935791|DRUG|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
219069249|NCT05561738|DIETARY_SUPPLEMENT|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
219069250|NCT05561738|OTHER|Standard of Care|Standard of Care
219069251|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
219069252|NCT03170960|DRUG|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
219069253|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
219069254|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
219671086|NCT01442649|DRUG|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
219671087|NCT01442649|DRUG|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
219671088|NCT01442649|DRUG|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
219671089|NCT01442649|DRUG|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
219671090|NCT00662311|DRUG|vorinostat|Given PO
219069255|NCT05872347|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
219069256|NCT06027515|BEHAVIORAL|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
219069257|NCT00660842|PROCEDURE|carboplatin|AUC 6 IV day 1 every 21 days
218980021|NCT01935791|DRUG|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
218980022|NCT01935791|DRUG|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
218980023|NCT01935791|DRUG|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
218980024|NCT02341365|OTHER|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
218980025|NCT03018769|DRUG|Chinese Herb|
218980026|NCT01626456|DRUG|ALKS 9072, Low|IM injection, given monthly
218980027|NCT01626456|DRUG|ALKS 9072, High|IM injection, given monthly
219069258|NCT00660842|DRUG|paclitaxel|175 mg/m2 IV day 1 every 21 days
219069259|NCT00660842|DRUG|carboplatin|AUC 2 IV every week
219671091|NCT00662311|DRUG|paclitaxel|Given IV
219671092|NCT00662311|RADIATION|radiation therapy|Undergo radiation therapy
219671093|NCT06503289|DEVICE|Cytosorb therapy|Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
219671094|NCT03699072|DEVICE|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
219671095|NCT03615820|DRUG|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
219671096|NCT03615820|DRUG|Oromucoadhesive film|Oromucoadhesive film without PPE control testing which represents Placebo group
219671097|NCT00617747|DRUG|Zolmitriptan|5mg Nasal Spray
219671098|NCT00617747|DRUG|Placebo|
219671099|NCT04391777|OTHER|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
219671100|NCT04391777|OTHER|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
219671101|NCT01176123|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
219671102|NCT03528382|BEHAVIORAL|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
219671103|NCT00603603|OTHER|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
219069260|NCT00660842|DRUG|paclitaxel|60mg/m2 IV every week
219069261|NCT02552524|DEVICE|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
219069262|NCT02552524|DEVICE|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
219671104|NCT00603603|OTHER|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
219671105|NCT04948827|DRUG|SBP-9330|SBP-9330 oral capsules
219671106|NCT04948827|DRUG|Placebo|Placebo oral capsules
219671107|NCT01024361|DEVICE|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
219671108|NCT04377971|BEHAVIORAL|SOC education|Standard participant education from researcher
219671109|NCT04377971|BEHAVIORAL|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
219671110|NCT04377971|OTHER|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
219671111|NCT04377971|OTHER|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
219671112|NCT00548483|DRUG|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
219069263|NCT00933569|DRUG|LACTIC ACID(ND)|treatment period: 21 consecutive days
219069264|NCT02880800|DRUG|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
219069265|NCT02880800|DRUG|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
219069266|NCT02880800|DRUG|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
219069267|NCT02880800|DRUG|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
219069268|NCT02635633|DEVICE|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
219671113|NCT00615147|PROCEDURE|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
219671114|NCT00429975|DRUG|levofloxacin|
219671115|NCT00429975|DRUG|ceftriaxone|
219671116|NCT05060107|BIOLOGICAL|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
219671117|NCT04184011|DEVICE|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
219671118|NCT02871284|BEHAVIORAL|Exercise|
219671119|NCT03795285|DIAGNOSTIC_TEST|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
219671120|NCT01185002|OTHER|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
219671121|NCT01185002|OTHER|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
219671122|NCT01185002|OTHER|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
219671123|NCT05446051|DEVICE|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
219671124|NCT05446051|DEVICE|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
219671125|NCT03247322|OTHER|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
218980028|NCT05756491|OTHER|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
218980029|NCT05756491|OTHER|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
218980030|NCT05756491|OTHER|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
218980031|NCT05756491|OTHER|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
218980032|NCT05384574|DIETARY_SUPPLEMENT|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
219671126|NCT03730376|OTHER|Cost Information|participants will be given information on the personal and societal costs
219671127|NCT00806208|DRUG|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
219671128|NCT00806208|DRUG|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
218980033|NCT02468232|DRUG|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
218980034|NCT02468232|DRUG|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
218980035|NCT02468232|DRUG|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
218980036|NCT02468232|DRUG|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
218980037|NCT00497718|PROCEDURE|Chiropractic Manipulation|
218980038|NCT00506662|DRUG|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
218980039|NCT00506662|DRUG|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
218980040|NCT00002914|DRUG|piritrexim|
218980041|NCT02677532|DRUG|Paracetamol|1 g every 8 hours
218980042|NCT02677532|DRUG|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
218980043|NCT02677532|DRUG|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
219671129|NCT00806208|DRUG|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
218980044|NCT02677532|DRUG|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
219671130|NCT00806208|DRUG|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
219671131|NCT00806208|OTHER|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
219671132|NCT05718440|OTHER|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
219671133|NCT04035525|DIETARY_SUPPLEMENT|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
219671134|NCT04035525|DIETARY_SUPPLEMENT|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
219069269|NCT05684328|PROCEDURE|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
219671135|NCT04035525|DIETARY_SUPPLEMENT|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
219671136|NCT01873118|OTHER|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
219671137|NCT01873118|OTHER|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
219671138|NCT01873118|OTHER|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
219671139|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
219671140|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
219671141|NCT05548361|COMBINATION_PRODUCT|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
219671142|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
218980045|NCT02677532|DRUG|Morphine|Intravenous slow bolus of 10 mg morphine
218980046|NCT02677532|DEVICE|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
219069270|NCT05684328|PROCEDURE|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
218980047|NCT02677532|DEVICE|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
218980048|NCT02677532|DRUG|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
218980049|NCT02677532|DRUG|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
218980050|NCT02080234|DRUG|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
218980051|NCT02080234|RADIATION|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
218980052|NCT03499704|DRUG|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
218980053|NCT03499704|DRUG|Alogliptin|Alogliptin tablets.
218980054|NCT03499704|DRUG|Metformin|Metformin tablets.
218980055|NCT03499704|DRUG|Dapagliflozin|Dapagliflozin tablets.
218980056|NCT01924000|DRUG|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
218980057|NCT01924000|DRUG|Placebo|
218980058|NCT05723302|DIAGNOSTIC_TEST|MIP/MEP|MIP/MEP
218980059|NCT00246753|DRUG|lapatinib ditosylate|1500 mg, daily until disease progression
218980060|NCT04654676|DRUG|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
218980061|NCT01994447|OTHER|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
218980062|NCT06266572|BEHAVIORAL|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
218980063|NCT06391840|OTHER|Airway ultrasound|Pre-operative airway ultrasound
218980064|NCT05968456|OTHER|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
218980065|NCT06103539|DEVICE|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
219069271|NCT03902704|DEVICE|Cleverscope|the device is used in patients without difficult airways predictors
218980066|NCT03643796|DRUG|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
218980067|NCT03643796|DRUG|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
218980068|NCT03643796|DRUG|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
218980069|NCT01529047|BEHAVIORAL|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
218980070|NCT00270790|DRUG|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
218980071|NCT00270790|DRUG|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
218980072|NCT00270790|DRUG|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
218980073|NCT00270790|DEVICE|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
218980074|NCT01919593|DRUG|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
218980075|NCT01919593|DRUG|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
218980076|NCT01986283|DRUG|Capsule|Taken once
218980077|NCT01986283|DRUG|PF-00345439|40 mg capsule swallowed whole, taken once
218980078|NCT01986283|DRUG|PF-00345439|40 mg capsule chewed, taken once
218980079|NCT01986283|DRUG|oxycodone|40 mg solution, taken once
218980080|NCT03460860|DIETARY_SUPPLEMENT|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
218980081|NCT03460860|DIETARY_SUPPLEMENT|Placebo|The intervention is to be taken once daily, for 12 weeks.
218980082|NCT05969808|OTHER|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
218980083|NCT05969808|OTHER|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
218980084|NCT02764333|BIOLOGICAL|TPIV200|
218980085|NCT02764333|BIOLOGICAL|Durvalumab|
219671143|NCT05876429|OTHER|New Standardized Accept Note|A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.
219671144|NCT05876429|OTHER|Existing Transfer Patient Admission Process|Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
219069272|NCT03902704|DEVICE|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
219069273|NCT05134012|DRUG|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
219069274|NCT04253522|BEHAVIORAL|Cognitive training|Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
219069275|NCT06182254|BEHAVIORAL|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
219069276|NCT06182254|OTHER|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
219069277|NCT02274714|OTHER|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
219671145|NCT04264897|DRUG|Metformin|"Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks."
219671146|NCT04264897|DRUG|Placebo oral tablet|Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
219069278|NCT00787657|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
219069279|NCT02332720|DRUG|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
219069280|NCT02332720|DRUG|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
219069281|NCT02332720|DRUG|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
219069282|NCT02332720|DRUG|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
219069283|NCT02332720|DRUG|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
219069284|NCT02332720|DRUG|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
219069285|NCT05566041|DRUG|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
219069286|NCT05566041|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
219671147|NCT05288946|OTHER|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
219671148|NCT05288946|OTHER|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
219671149|NCT05288946|OTHER|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
219671150|NCT02671617|OTHER|High intensity interval training (HIIT)|Preoperative HIIT protocol.
219671151|NCT03369626|BEHAVIORAL|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
219671152|NCT01263717|DRUG|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
219069287|NCT05736341|DRUG|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
219069288|NCT05736341|DRUG|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
219069289|NCT05154864|PROCEDURE|SBUF-SMUF|Intra-operative continuous ultrafiltration
219671153|NCT01263717|DRUG|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
219671154|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
219671155|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
219671156|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
219671157|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
218980086|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
218980087|NCT06285773|DRUG|RIFPB block|For RIFPB, a local anesthetic will be injected into the plane between the costal cartilage and the rectus abdominis muscle at the 6th-7th costal cartilage under US guidance. The in-plane technique will be used. After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).
218980088|NCT06285773|OTHER|Postoperative analgesia management|"Patients will be administered 10mg/kg paracetamol in the postoperative period every eight hours.~If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administered as a rescue analgesic."
218980089|NCT06285773|DRUG|PIFPB block|For PIFPB; the ultrasound probe for PIFB is placed 2-3 cm lateral to the upper third of the sternum, parallel to the sternum. A local anesthetic of 15 ml of 0.25% concentration of marcaine (bupivacaine) will be used between the pectoralis major and external intercostal muscles (bilateral).
218980090|NCT06832059|OTHER|The precise diet intervention|The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l
218980091|NCT00175695|DRUG|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
218980092|NCT02685046|DRUG|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
218980093|NCT05058716|DIAGNOSTIC_TEST|blood sample|weekly blood sample - coenzym q10 levels
218980094|NCT05722093|DRUG|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
218980095|NCT03274232|DEVICE|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
218980096|NCT04568421|DRUG|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
218980097|NCT04292769|DRUG|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
218980098|NCT04292769|BIOLOGICAL|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
218980099|NCT00812747|OTHER|observation|
218980100|NCT05698056|OTHER|No intervention.|No intervention.
218980101|NCT05813145|DRUG|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
218980102|NCT05813145|DRUG|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
218980103|NCT00560274|DRUG|Pegasys|As prescribed
218980104|NCT00560274|DRUG|Ribavirin|As prescribed
218980105|NCT00560274|DRUG|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
218980106|NCT00617851|BIOLOGICAL|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
219671158|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
219671159|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
219671160|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
219671161|NCT06022419|PROCEDURE|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
219671162|NCT06022419|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
219671163|NCT01234701|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
219671164|NCT01234701|PROCEDURE|Liver resection|Hepatectomy with an intention to cure
219671165|NCT01234701|OTHER|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
219671166|NCT05637190|OTHER|Expressive Arts Therapy group intervention|Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
219671167|NCT03294200|DEVICE|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
219671168|NCT06046131|OTHER|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
219671169|NCT02582697|DRUG|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
219671170|NCT02582697|DRUG|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
219671171|NCT02582697|DRUG|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
219671172|NCT02582697|DRUG|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
219671173|NCT02582697|DRUG|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles."
219069290|NCT05428566|DIETARY_SUPPLEMENT|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
219069291|NCT05428566|DIETARY_SUPPLEMENT|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
219069292|NCT03832010|DRUG|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
219069293|NCT03832010|DRUG|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
219069294|NCT03832010|DRUG|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
219069295|NCT03832010|DRUG|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
219069296|NCT06258967|DRUG|ciprofol|Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
219069297|NCT06258967|DRUG|propofol|Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
219069298|NCT00858065|BEHAVIORAL|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
219069299|NCT00858065|BEHAVIORAL|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
219069300|NCT02597400|DRUG|Metformin|"* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
219069301|NCT02597400|DRUG|HMS5552|"* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
219069302|NCT02323971|DRUG|Ticagrelor|
219671174|NCT02288481|DRUG|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
219671175|NCT02288481|OTHER|Placebo|Placebo Suspension
219671176|NCT03404934|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
219671177|NCT00332774|DRUG|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
219671178|NCT00332774|DRUG|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
219671179|NCT00332774|OTHER|Nepafenac ophthalmic suspension vehicle|
219671180|NCT01939223|DRUG|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
219069303|NCT00710047|DRUG|ZD4054|one single 10mg dose
219671181|NCT01939223|DRUG|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
219069304|NCT01037920|BEHAVIORAL|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
219069305|NCT01037920|BEHAVIORAL|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
219069306|NCT05244473|DRUG|brentuximab vedotin|Given into the vein (IV; intravenously)
219069307|NCT05244473|DRUG|Placebo|Given by IV
219671182|NCT05041075|DEVICE|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
219671183|NCT04786678|DEVICE|Cell phone notification|Habitual bed and wake times will be detected using a wearable for 4 weeks. Using habitual wake time, a minimum bedtime to achieve adequate sleep will be calculated (8 hours). If phone usage is detected after this minimum bedtime, participants will receive a notification informing them they are awake past their minimum bedtime and recommend they go to bed to obtain adequate sleep.
219671184|NCT05732402|DRUG|Povetacicept|Administered by subcutaneous injection every 4 weeks
219671185|NCT06484699|PROCEDURE|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
219671186|NCT06484699|PROCEDURE|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
219671187|NCT06206954|BEHAVIORAL|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
219671188|NCT06206954|BEHAVIORAL|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
219671189|NCT03624569|OTHER|Bagel|A bagel will be consumed daily for 2 weeks.
219671190|NCT03624569|OTHER|Potato|A potato will be consumed daily for 2 weeks.
218980107|NCT00617851|BIOLOGICAL|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
218980108|NCT00617851|BIOLOGICAL|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
218980109|NCT00617851|BIOLOGICAL|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
218980110|NCT00617851|BIOLOGICAL|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
218980111|NCT01175460|DRUG|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
218980112|NCT00528827|DRUG|Cardene® I.V.|"* 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V."
218980113|NCT05718804|OTHER|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
218980114|NCT01557049|OTHER|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
218980115|NCT01557049|OTHER|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
218980116|NCT01572350|OTHER|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
218980117|NCT01572350|DRUG|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
218980118|NCT01572350|DRUG|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
218980119|NCT01200524|DRUG|AZD2423|20 mg tablet
218980120|NCT01200524|DRUG|AZD2423|50 mg tablet
218980121|NCT01200524|DRUG|Placebo|Placebo
218980122|NCT00752102|DRUG|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
218980123|NCT00752102|DRUG|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
218980124|NCT01303861|DRUG|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
218980125|NCT01303861|DRUG|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
218980126|NCT01303861|DRUG|Nicotine patches|"Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week"
218980127|NCT01303861|DRUG|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
218980128|NCT02234570|DRUG|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
218980129|NCT02234570|OTHER|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
218980130|NCT02520830|DIETARY_SUPPLEMENT|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
218980131|NCT02520830|DIETARY_SUPPLEMENT|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
218980132|NCT05064319|DRUG|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
219671191|NCT04838457|BEHAVIORAL|Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
219671192|NCT03965429|OTHER|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
219671193|NCT03965429|OTHER|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
219671194|NCT01557517|DRUG|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
219671195|NCT01557517|DRUG|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
219671196|NCT04072731|OTHER|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
219671197|NCT03729622|OTHER|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
219671198|NCT04273867|OTHER|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
219671199|NCT04358211|BIOLOGICAL|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
219671200|NCT06145529|OTHER|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
219671201|NCT01785758|DRUG|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
219671202|NCT06482619|DIETARY_SUPPLEMENT|Creatine supplementation|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained creatine monohidrate (Creapure, Crown Sport Nutrition, Arnedo, Spain)
218980133|NCT05064319|DRUG|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
218980134|NCT00659360|DRUG|saracatinib|Given orally
218980135|NCT01061216|DEVICE|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
219671203|NCT06482619|DIETARY_SUPPLEMENT|Placebo|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained placebo (i.e., sucrose)
218980136|NCT01061216|DEVICE|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
219069308|NCT05244473|DRUG|ART|Daily use of a combination of HIV medicines
219069309|NCT01003899|DRUG|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
219069310|NCT02805569|DEVICE|articulating stylet|patient who intubated with articulating stylet
219069311|NCT02805569|DEVICE|conventional stylet|patient who intubated with conventional stylet
219069312|NCT04389762|DIETARY_SUPPLEMENT|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
219069313|NCT01045629|OTHER|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
219069314|NCT03822533|OTHER|Physiotherapist as primary assessor|Physiotherapist diagnose and treat the patient.
219069315|NCT03822533|OTHER|Physician as primary assessor|Physician diagnose and treat the patient.
219671204|NCT02349282|DIETARY_SUPPLEMENT|Calcifediol 10ug/day|
219671205|NCT02349282|DIETARY_SUPPLEMENT|Vitamin D3 20ug/day|
219671206|NCT02349282|DIETARY_SUPPLEMENT|Placebo|
219671207|NCT04627558|OTHER|stroke patients, balance assessment|validity relability dubousset functional test
219671208|NCT04170036|DIETARY_SUPPLEMENT|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
219671209|NCT04078724|DIETARY_SUPPLEMENT|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
219671210|NCT04078724|OTHER|Without 5-HTP|Subject will not take 5-HTP
219671211|NCT00814593|BIOLOGICAL|lymphokine-activated killer cells|Instilled into the tumor bed cavity
219671212|NCT00814593|DRUG|polifeprosan 20 with carmustine implant|Intracranial placement
219671213|NCT01453790|BEHAVIORAL|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
219671214|NCT01453790|BEHAVIORAL|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
219069316|NCT02291887|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab
219671215|NCT03181685|DRUG|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
219671216|NCT03181685|DRUG|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
219671217|NCT03181685|DRUG|recombinant FSH|Controlled ovarian stimulation (COS)
219671218|NCT03181685|DRUG|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
219671219|NCT03176641|OTHER|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
219671220|NCT03176641|OTHER|control|Meniscus repair surgery only
219671221|NCT01963091|DRUG|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
219671222|NCT01963091|DRUG|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
219671223|NCT00915603|DRUG|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
219671224|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
219671225|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
219671226|NCT00915603|DRUG|Placebo|Placebo PO daily continuously for all 28 days of a cycle
219671227|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
219671228|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
219671229|NCT03585712|DRUG|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
219069317|NCT02291887|DRUG|Aflibercept|Intravitreal injection of Aflibercept
219069318|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
219069319|NCT01512225|DRUG|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
219069320|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
219069321|NCT02489500|DRUG|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
219069322|NCT02489500|DRUG|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
219069323|NCT02489500|DRUG|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
219671230|NCT02746094|DEVICE|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
219671231|NCT03360214|DRUG|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
219671232|NCT03360214|OTHER|Placebo Drug|For sham drug, 0.9% saline, will be used.
219671233|NCT03360214|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
219671234|NCT03360214|OTHER|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
219671235|NCT03360214|DRUG|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
219671236|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Pomegranate extract|Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period
219671237|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Microcrystalline cellulose|Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period
219671238|NCT06192888|DRUG|Glofitamab|IV Glofitamab
219671239|NCT06192888|DRUG|Obinutuzumab|IV Obinutuzumab
218980137|NCT04761510|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
218980138|NCT04157543|OTHER|electroacupuncture|acupuncture with electricity
218980139|NCT03352973|OTHER|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
218980140|NCT03352973|OTHER|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
218980141|NCT04753528|DEVICE|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
218980142|NCT04753528|DEVICE|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
218980143|NCT04753528|DEVICE|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
218980144|NCT01238354|BEHAVIORAL|With friend|
218980145|NCT01238354|BEHAVIORAL|Without friend|
218980146|NCT03959254|PROCEDURE|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
218980147|NCT02758132|BIOLOGICAL|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
218980148|NCT02758132|DRUG|Enzalutamide|160 mg enzalutamide by mouth daily
218980149|NCT02758132|DRUG|Abiraterone|1000 mg abiraterone by mouth daily
218980150|NCT02758132|DRUG|Prednisone|5 mg prednisone by mouth twice daily
218980151|NCT04970355|BIOLOGICAL|Erenumab|Pre-filled syringe; s.c. injection
218980152|NCT04970355|DRUG|Placebo|Pre-filled syring; s.c. injection
219069324|NCT02489500|PROCEDURE|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
219069325|NCT02489500|PROCEDURE|Stem cell infusion|infusion of previously collected autologous stem cells
219671240|NCT06192888|DRUG|Lenalidomide|Oral Lenalidomide
219671241|NCT06973330|DRUG|SOX regimen combined with Sintilimab and Apatinib|Patients who met the inclusion criteria were treated with SOX regimen combined with Sintilimab plus Apatinib every 3 weeks(4 cycles) followed by sintilimab+apatinib until disease progression or intolerable adverse reactions or death(up to 24 months).
219671242|NCT05169788|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
219671243|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-1Gy|1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
219671244|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-2-3Gy|ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
219069326|NCT05861934|BEHAVIORAL|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
219671245|NCT06076135|DRUG|PD-1/PD-L1 Inhibitors|The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
219069327|NCT00963365|DRUG|AZD6765|Single oral dose and single IV infusion of AZD6765
219671246|NCT05223829|DRUG|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
219671247|NCT04421014|DIETARY_SUPPLEMENT|Ketone Ester drink|The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
219671248|NCT04421014|DIETARY_SUPPLEMENT|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
219671249|NCT06383091|BEHAVIORAL|Anterior Neck Manual Therapy|Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
219671250|NCT06383091|BEHAVIORAL|Pain Neuroscience Education|Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
219671251|NCT06383091|BEHAVIORAL|Neck Stretches|Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
219671252|NCT06383091|BEHAVIORAL|Scar massage|Digital manipulation of the scar itself in circles.
219671253|NCT06383091|BEHAVIORAL|Voice Exercises|Stemple Voice Exercises
219671254|NCT06383091|BEHAVIORAL|Placebo Anterior Neck Manual Therapy|Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
219671255|NCT06383091|BEHAVIORAL|Placebo Pain Neuroscience Education|Will discuss how pain will as a result of the surgical intervention.
219671256|NCT06383091|BEHAVIORAL|Placebo Neck Stretches|Will ask patient to look down as a neck stretch held for 20 seconds x3.
219671257|NCT06671366|DEVICE|external and internal shoulder rotation using a Cybex dynamometer|"Measurement of the reproducibility, in this precise evaluation position, of the results obtained between the different tests carried out 30 minutes apart, and thus the reliability of each measurement in this test.~measures :~* Concentric internal rotation 60degrees/sec~* Concentric external rotation 60 degrees/sec~* Concentric internal rotation 180 degrees/sec~* Concentric external rotation 180 degrees/sec~* Eccentric internal rotation 60degrees/sec~* Eccentric external rotation 60degrees/sec"
219671258|NCT04296669|DEVICE|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
219671259|NCT00594074|OTHER|white wine|3.25 ounces of white wine twice a day with lunch and dinner
219069328|NCT00963365|DRUG|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
219069329|NCT00780208|DRUG|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
219069330|NCT04266782|OTHER|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
219069331|NCT04266782|OTHER|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
219069332|NCT04166994|BEHAVIORAL|Exercise and diet|IMPACT Intervention
219069333|NCT04166994|OTHER|No Intervention: Usual Care|No exercise or diet specialization.
219671260|NCT01954199|PROCEDURE|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
219671261|NCT00212316|DRUG|sodium phenylbutyrate|
219671262|NCT03004924|DRUG|SHP640|Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
219671263|NCT03004924|DRUG|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
219671264|NCT03004924|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
219671265|NCT01280682|DRUG|rituximab|anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
219671266|NCT02816541|OTHER|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
219671267|NCT02816541|OTHER|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
219671268|NCT02816541|OTHER|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
219671269|NCT03103217|BEHAVIORAL|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
219671270|NCT04677387|BEHAVIORAL|Nalox-comm Training Module|The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
219671271|NCT04677387|BEHAVIORAL|Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists|A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
219671272|NCT02057432|DEVICE|intra-operative MRI|Patients will undergo an MRI during surgery.
219671273|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219671274|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219671275|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219671276|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219671277|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
219671278|NCT04598308|DIAGNOSTIC_TEST|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
219671279|NCT04350164|DRUG|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
219671280|NCT01879202|DRUG|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
219671281|NCT01879202|DRUG|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
219671282|NCT04281628|DRUG|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
219671283|NCT04281628|DRUG|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
219671284|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
219671285|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
219671286|NCT05327751|DRUG|Celecoxib 200mg|200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.
219671287|NCT05327751|DRUG|Capecitabine-based chemotherapy|Capecitabine-based chemotherapy
219671288|NCT05677958|DIETARY_SUPPLEMENT|125 mL Fortimel/Nutridrink Compact Protein|125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
219671289|NCT03386188|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
219671290|NCT03386188|DEVICE|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
219671291|NCT02535754|BEHAVIORAL|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
219671292|NCT02535754|BEHAVIORAL|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
219671293|NCT02535754|BEHAVIORAL|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
218980153|NCT02476201|DEVICE|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
218980154|NCT04206059|RADIATION|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
218980155|NCT04206059|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
218980156|NCT04206059|DIAGNOSTIC_TEST|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
218980157|NCT04206059|OTHER|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
218980158|NCT04206059|OTHER|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
218980159|NCT04206059|OTHER|0 db with QST|sham stimulation (0 dB volume)
218980160|NCT04206059|DRUG|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
218980161|NCT04206059|OTHER|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
218980162|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
218980163|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
218980164|NCT04212871|OTHER|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
218980165|NCT04212871|OTHER|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
218980166|NCT04212871|OTHER|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
219671294|NCT05527899|DRUG|Zinc gluconate|30 and 60 mg/d of zinc gluconate
218980167|NCT02585843|DRUG|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
218980168|NCT02585843|DRUG|Spironolactone 25mg|25mg/day of spironolactone
219671295|NCT03717649|DEVICE|Conventional 2-stage venous cannula|venous cannula
219671296|NCT03717649|DEVICE|Conventional 3-stage venous cannula|venous cannula
219671297|NCT03717649|DEVICE|Fenestrated 3-stage venous cannula|venous cannula
219671298|NCT04235842|OTHER|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
219671299|NCT04235842|OTHER|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
219671300|NCT05541913|OTHER|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
219671301|NCT01234064|DEVICE|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
219671302|NCT01234064|DEVICE|No Graduated Compression Stockings|No stockings will be applied.
219671303|NCT01464619|OTHER|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
218980169|NCT04524806|OTHER|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
219671304|NCT01464619|OTHER|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
219671305|NCT00102856|DRUG|Pramipexole|
219671306|NCT00102856|DRUG|Rivastigmine|
219671307|NCT02540161|DRUG|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
219671308|NCT02540161|DRUG|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
219671309|NCT02263378|DRUG|ellagic acid + annona muricata|pills
219671310|NCT00629538|PROCEDURE|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
219671311|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
219671312|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
219671313|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
219671314|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
219671315|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
219671316|NCT04396522|DEVICE|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
218980170|NCT00628485|DEVICE|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
218980171|NCT00628485|DEVICE|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
218980172|NCT00628485|DEVICE|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
218980173|NCT06276673|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
218980174|NCT00398918|DRUG|zonisamide|zonisamide (100 mg)one time
218980175|NCT00398918|DRUG|Placebo|Placebo Comparator
218980176|NCT00371072|PROCEDURE|trabeculectomy with mitomycin-C|
219671317|NCT01008813|BIOLOGICAL|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A
219671318|NCT01008813|BIOLOGICAL|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
219671319|NCT00921713|OTHER|Oncology Nurse Care Management|
219671320|NCT00921713|OTHER|Patient-centered materials|
219208790|NCT06656975|BEHAVIORAL|Brief Cognitive Therapy|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
219208791|NCT06656975|BEHAVIORAL|Social Prescribing|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
219208792|NCT06656975|OTHER|Enhanced Usual Care|Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
219208793|NCT06722547|OTHER|Standard PR|PLB, ACBT, Aerobic exercise, Education
219208794|NCT06722547|OTHER|Standard PR plus Respiratory Muscle Stretching|Standard PR plus Respiratory Muscle Stretching (RMS)
219208795|NCT06724692|OTHER|Ultra-processed breakfast|With this intervention, participants will consume ultra-processed foods
219208796|NCT06724692|OTHER|Low-processed breakfast|With this intervention, participants will consume low-processed foods
219069334|NCT06788496|BEHAVIORAL|Art-based Beauty Appreciation Intervention Program (Learning to See Beauty)|The goals of the intervention program are to help individuals develop an aesthetic mindset, practice observation and appreciation skills, learn how to apply these skills to their day-to-day lives, practice emotion regulation with beauty, and incorporate more beauty into their lives. The program is designed to create a slow skill transfer from appreciation in art contexts to natural beauty and to everyday life. In the 14-day program, participants visit an art museum with guided audio, watch instructional videos about observing and appreciating beauty, and complete daily written or photo beauty journals that document the beauty they see. In addition, participants will watch video art showing how to find beauty in mundane objects, practice this in a beauty walk, and complete a planning session to include more beauty in their lives.
219069335|NCT06788496|BEHAVIORAL|Observation Program (Learning to Observe Life)|The active, matched control group will focus on developing pragmatic observation skills. Participants will be instructed to pay attention to and identify objects and elements in their surroundings without emphasizing their aesthetic value. For example, they should pay attention and count objects of the same colour they encounter, social behaviour, the people they pass on the street, or the types of buildings. The 14-day program includes a tourist trip with guided audio instruction, watching instructional videos about increasing observation skills and completing daily written or photo journals to document their observations. Further, participants will take an observation walk and plan to include more observation in their lives.
219069336|NCT06014996|DEVICE|Pulsed Field Ablation (PFA) Therapy|In the test group, subjects will undertake PVI using the PFA system including a nanosecond-scale pulsed field generator (InRythm, Insight Lifetech, Shenzhen, China), a lotos catheter that is expandable over the wire (LotosPFA, Insight Lifetech), and a customized 12-French steerable sheath (InBridge, Insight Lifetech).
219069337|NCT06014996|DEVICE|Radiofrequency Ablation（RAF）Therapy|In the control group, subjects will undergo PVI using an RFA system including CARTO VISITAG Module and the THERMOCOOL SMARTTOUCH Catheter (Biosense Webster Inc., Diamond Bar, CA, USA). PVI was performed with AI values of 400-450 in the anterior, 300-350 at the posterior wall of the LA.
219069338|NCT06429748|DEVICE|rTMS|repetitive Transcranial Magnetic Stimultion
219069339|NCT06151353|DIAGNOSTIC_TEST|REMS|Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation
219069340|NCT02475408|DEVICE|Amplatzer vascular plug|
219069341|NCT04586101|DEVICE|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
219069342|NCT02349295|DRUG|Placebo|Administered SC
219069343|NCT02349295|DRUG|Ixekizumab 80 mg Q4W|Administered SC
219069344|NCT02349295|DRUG|Ixekizumab 80 mg Q2W|Administered SC
219069345|NCT04273230|OTHER|Microalbuminuria detection|Detection of microalbumin in urine
219069346|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
219069347|NCT06957938|DRUG|Neoadjuvant Chemotherapy (NACT)|Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin
219069348|NCT06957938|DRUG|Neoadjuvant and maintenance Tislelizumab|Neoadjuvant and maintenance Tislelizumab
219069349|NCT06957938|RADIATION|Concurrent chemo-radiotherapy (CCRT)|Concurrent chemo-radiotherapy (CCRT), with cisplatin-based chemotherapy
219069350|NCT06957938|PROCEDURE|Surgery and adjuvant (chemo-)radiotherapy|Definitive surgery, with adjuvant (chemo-)radiotherapy, depending on pathologic findings.
219069351|NCT01259713|DRUG|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
219069352|NCT01259713|DRUG|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
219069353|NCT06111742|DEVICE|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
219069354|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
219671321|NCT03130270|DRUG|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
219671322|NCT03992833|OTHER|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume \> 300 mm3 (positive)."
219671323|NCT05401461|OTHER|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
219671324|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
219671325|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
219671326|NCT03001466|DRUG|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
219671327|NCT03001466|DRUG|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
219069355|NCT06361147|OTHER|Psychoeducational program for ASD|6 psychoeducation trainings for Autism Spectrum Disorder
219069356|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
219069357|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
219069358|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
219069359|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
219069360|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
219069361|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
219069362|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
219069363|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
219069364|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
219069365|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
219069366|NCT06390098|DRUG|ASN51|Oral
219069367|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
219208797|NCT06723145|DRUG|Aspirin|perioperative aspirin continuation
219069368|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
219069369|NCT05915728|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
219069370|NCT05915728|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219069371|NCT05915728|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219069372|NCT05915728|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219069373|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
219069374|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
219208798|NCT06723145|DRUG|Aspirin interruption|Aspirin interruption 5-7 days before surgery
219671328|NCT05808270|BEHAVIORAL|Nutrition care process|"According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities."
219671329|NCT05459194|DEVICE|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
219671330|NCT04100590|DRUG|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
219671331|NCT05186259|DIAGNOSTIC_TEST|Self-reported signs of central sensitization|Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
219671332|NCT05186259|DIAGNOSTIC_TEST|Objective signs of central sensitization|Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
219671333|NCT05186259|DIAGNOSTIC_TEST|Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain|"* Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~* Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~* Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. ."
219671334|NCT05186259|DIAGNOSTIC_TEST|Cognitive functioning|"Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task"
219069375|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
219069376|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
219069377|NCT02073513|DEVICE|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
219069378|NCT02073513|DEVICE|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
219069379|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
219069380|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
219069381|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
219069382|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
219069383|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
219069384|NCT02194426|DRUG|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
219069385|NCT00085410|DRUG|bortezomib|Given IV
219069386|NCT04255160|DRUG|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
219208799|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
219208800|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
219671335|NCT05186259|DIAGNOSTIC_TEST|Listening effort|Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .
219671336|NCT05186259|DIAGNOSTIC_TEST|Self-reported psychological factors|"Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale"
219671337|NCT05186259|DIAGNOSTIC_TEST|Self-reported lifestyle factors|"Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21"
219069387|NCT04255160|OTHER|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
219069388|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
219208801|NCT05856266|PROCEDURE|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
219208802|NCT05856266|OTHER|Haemophilia Joint Health Score (HJHS)|Functional joint examination
219671338|NCT05186259|DIAGNOSTIC_TEST|Self-reported measure of pain processing|Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
219671339|NCT05186259|DIAGNOSTIC_TEST|Self-reported quality of life|Self-reported quality of life by means of the SF-36 questionnaire
219671340|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus severity and impact on daily life|Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
219671341|NCT05186259|DIAGNOSTIC_TEST|Self-reported hyperacusis|Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
219671342|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus characteristics|Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
219671343|NCT05186259|DIAGNOSTIC_TEST|Self reported neck pain related disability|Evaluation of self-reported neck pain related disability using the Neck Disability Index
218980177|NCT04123652|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
218980178|NCT02552784|BEHAVIORAL|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
218980179|NCT00723580|DRUG|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
218980180|NCT03429660|OTHER|Medical information|"The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)"
218980181|NCT02037022|BEHAVIORAL|Pivotal Response Treatment Package (PRT-P)|
218980182|NCT02364492|DRUG|MAG-TN3 + AS15|
218980183|NCT03781843|DRUG|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
218980184|NCT03781843|DRUG|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
218980185|NCT03781843|DRUG|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
218980186|NCT05629078|DEVICE|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
218980187|NCT01852305|OTHER|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
218980188|NCT01852305|DEVICE|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
218980189|NCT03745131|OTHER|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
218980190|NCT02505295|DIETARY_SUPPLEMENT|Selenium|4 vials selenase stat and 2 vials daily for 5 days
218980191|NCT02505295|DRUG|normal saline|Normal saline infusion like intervention group
218980192|NCT03414281|PROCEDURE|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
219069389|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
219671344|NCT04707365|BIOLOGICAL|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
219671345|NCT04876976|DRUG|Cyanoacrylate, Isobutyl|using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
219671346|NCT04876976|PROCEDURE|Classic surgical repair|classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
219671347|NCT00346736|PROCEDURE|Acupuncture (Procedure)|
219671348|NCT04926506|DRUG|Xiyanping injection|Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
219671349|NCT05912985|OTHER|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
219671350|NCT04212832|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
219671351|NCT04212832|OTHER|Standard pain|Standard pain follow up and monitorization
219671352|NCT05292612|BEHAVIORAL|iCBT(C&W) for SAD|iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
219671353|NCT01724684|OTHER|Telehealth program|
219671354|NCT01724684|OTHER|Usual care|
219671355|NCT01863732|BIOLOGICAL|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
219671356|NCT01863732|OTHER|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
219671357|NCT02342600|DRUG|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
219671358|NCT02342600|DRUG|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
218980193|NCT03414281|PROCEDURE|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
219671359|NCT04102683|BEHAVIORAL|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
219671360|NCT03567161|PROCEDURE|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
219671361|NCT02795936|PROCEDURE|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
219671362|NCT05921240|OTHER|observational study, no intervention|no intervention
218980194|NCT03414281|PROCEDURE|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
218980195|NCT02916589|DIETARY_SUPPLEMENT|Diet|
218980196|NCT01848496|PROCEDURE|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
218980197|NCT04061265|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
218980198|NCT04061265|DRUG|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
218980199|NCT03094429|DRUG|NaBen®|2000 mg/day or 1000 mg/day, twice daily
218980200|NCT03094429|OTHER|Placebo|0 mg total, twice daily
218980201|NCT02125968|OTHER|interactive video game|short- and medium-term therapeutic effects
218980202|NCT02125968|OTHER|therapeutic exercise|short- and medium-term therapeutic effects
218980203|NCT02505763|PROCEDURE|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
218980204|NCT00821106|PROCEDURE|Right radial|diagnostic or interventional procedures performed through right transradial approach
218980205|NCT00821106|PROCEDURE|left radial|diagnostic or interventional procedures performed through left transradial approach
218980206|NCT03144921|BEHAVIORAL|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
219069390|NCT01889537|BEHAVIORAL|Virtual Reality|The patient will receive virtual reality during a burn care procedure
219671363|NCT03972241|DEVICE|foot insole|arch support and toe extension
219671364|NCT01456364|DRUG|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
219671365|NCT01456364|DRUG|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
219069391|NCT02414893|PROCEDURE|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
219069392|NCT02148250|DRUG|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
219069393|NCT02148250|DRUG|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
219671366|NCT02820181|DEVICE|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
219671367|NCT02820181|DEVICE|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
219069394|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
219069395|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
219069396|NCT01529957|DRUG|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
219069397|NCT00591292|DRUG|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
219671368|NCT02350088|DRUG|probiotics|probiotics
219671369|NCT02350088|DRUG|placebo|placebo
219671370|NCT05911698|DEVICE|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
219069398|NCT00695903|DRUG|daptomycin|daptomycin 10 mg/kg IV every 24 hours
219069399|NCT00695903|DRUG|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
219069400|NCT00648076|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
219069401|NCT00648076|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fed
219069402|NCT01296568|DRUG|LY2603618|Administered intravenously
219069403|NCT01296568|DRUG|Pemetrexed|Administered intravenously
219069404|NCT01296568|DRUG|Gemcitabine|Administered intravenously
219208803|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
219069405|NCT02545673|BEHAVIORAL|Enhanced linkage to care|
219069406|NCT02545673|BEHAVIORAL|Standard-of-care plus|
219069407|NCT00237744|DEVICE|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
219069408|NCT00237744|DEVICE|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
219069409|NCT00237744|OTHER|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
219069410|NCT01863277|DRUG|Melatonin|
219069411|NCT01863277|DRUG|placebo|
219069412|NCT01100164|DRUG|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
219069413|NCT01100164|DRUG|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
219069414|NCT02877290|DEVICE|non-invasive ventilation (NIV)|
219069415|NCT03821311|RADIATION|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
219069416|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
219069417|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
219671371|NCT06330571|DEVICE|Molar distalization by aligners with attachment|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months."
219671372|NCT05237739|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.
219671373|NCT05237739|PROCEDURE|Open Flap Debridement (OFD)|Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
219671374|NCT00460746|DRUG|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
219671375|NCT05450406|OTHER|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
219671376|NCT03078309|DRUG|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
219671377|NCT01836185|DRUG|Evacetrapib|
219671378|NCT01068587|DRUG|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
219671379|NCT01068587|DRUG|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
219671380|NCT01068587|OTHER|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
219671381|NCT03994237|OTHER|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
219671382|NCT02811653|DEVICE|Brain MRI|
219671383|NCT02811653|OTHER|neuropsychological evaluation|
219671384|NCT02811653|BIOLOGICAL|Blood|
219671385|NCT01473225|OTHER|Calorie information|Nutrition label featuring calorie information will be provided.
219671386|NCT01473225|OTHER|No calorie information|No nutrition label will be provided in this condition.
219671387|NCT01209247|OTHER|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
219671388|NCT00822328|DIETARY_SUPPLEMENT|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
219671389|NCT00822328|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
218980207|NCT05532917|OTHER|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
219671390|NCT02982044|OTHER|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
219671391|NCT02982044|OTHER|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
219671392|NCT02982044|OTHER|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
219671393|NCT01603394|DRUG|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
219671394|NCT04168840|DIAGNOSTIC_TEST|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
219069418|NCT06019468|OTHER|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
219671395|NCT01819844|DEVICE|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose \> 2 u/kg).
219671396|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
219671397|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
219671398|NCT05704179|OTHER|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
219671399|NCT00840034|DRUG|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
219671400|NCT00840034|DRUG|Placebo|3 tablets PO QD for up to 12 weeks
219671401|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
219671402|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
219671403|NCT02870205|DRUG|GSP 301 NS|2 spray in each nostril twice daily for 14 days
219671404|NCT02870205|DRUG|GOM-NS|2 spray in each nostril twice daily for 14 days
219671405|NCT02870205|DRUG|GMM-2 NS|2 spray in each nostril twice daily for 14 days
219671406|NCT02870205|DRUG|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
219671407|NCT05866549|OTHER|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
219671408|NCT00325624|DEVICE|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
219671409|NCT03557476|DIETARY_SUPPLEMENT|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
219671410|NCT03557476|DIETARY_SUPPLEMENT|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
219671411|NCT05572372|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
219671412|NCT02423668|PROCEDURE|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
219671413|NCT02423668|PROCEDURE|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
219671414|NCT02423668|PROCEDURE|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
219671415|NCT03071510|DEVICE|Atlas Genetics io® system|Specimen Collection
219671416|NCT03602833|DRUG|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
219671417|NCT05621967|BEHAVIORAL|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
219671418|NCT05621967|BEHAVIORAL|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
219671419|NCT05621967|BEHAVIORAL|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
219671420|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
219069419|NCT04196400|DRUG|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
219069420|NCT02129738|DEVICE|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
219671421|NCT06338215|BEHAVIORAL|Moderate Alcohol Drinking Pattern|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake."
219671422|NCT06338215|BEHAVIORAL|Abstention|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol."
219671423|NCT05799404|DIAGNOSTIC_TEST|ultra-high resolution CT|stapes footplate thickness measurement
219671424|NCT07010380|DEVICE|PTFinder Dual-Channel NIR Autofluorescence Imaging System|Ex vivo, non-contact imaging of resected thyroid/parathyroid specimens; captures near-infrared autofluorescence and overlays it on white-light video to highlight parathyroid glands (2-5 min per specimen).
219671425|NCT07010380|OTHER|Offline Machine-Learning Algorithm (PTFinder-AI Beta)|training/validation on de-identified NIR/RGB frames.
219671426|NCT07011641|BEHAVIORAL|Structured Online CBT Program|The interventions consisted of eight weekly group sessions (1.5-2 hours each), with each session addressing a specific theme identified through literature as closely related to parental burnout. The sequential themes were the social pressure on parenting, the dynamic balance of parental stressors and resources, parental perfectionism, personal emotional competencies, parent-child relationship quality, co-parenting quality, help seeking, with a last session focused on relapse prevention.
219671427|NCT04006522|DRUG|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
219671428|NCT04006522|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
219671429|NCT07012577|OTHER|GPT-4 Assessment|Diagnostic/Prognostic evaluation of any single case provided by AI (GPT-4). GPT-4 provides diagnosis/treatment recommendations via standardized prompts
219671430|NCT07012577|OTHER|Arthroplasty Fellow Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
219671431|NCT07012577|OTHER|Specializing Resident (4th year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
219069421|NCT03305016|DRUG|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
219069422|NCT02999776|DEVICE|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
219069423|NCT02999776|DRUG|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
219069424|NCT02999776|DRUG|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
219208804|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
219208805|NCT06733220|PROCEDURE|Surgery for strabismus|Patients will undergo surgery to correct strabismus, congenital or acquired
219671432|NCT07012577|OTHER|Junior Resident (3rd year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
219671433|NCT07016594|BEHAVIORAL|Aerobic exercise|Aerobic exercise was done with and without neuromuscular electrical stimulation
219671434|NCT07015268|DRUG|KLH-2109|"\- KLH-2109 tablet: Oral administration~\- Leuprorelin acetate placebo: Subcutaneous administration"
219671435|NCT07015268|DRUG|Leuprorelin acetate|"\- KLH-2109 placebo tablet: Oral administration~\- Leuprorelin acetate: Subcutaneous administration"
219671436|NCT02425202|DRUG|Ketamine|Post-operative continuous infusion until 0600 the next day
219671437|NCT02425202|OTHER|Saline infusion|Post-operative continuous infusion until 0600 the next day
219671438|NCT02470663|DIETARY_SUPPLEMENT|DENSITYTM caplets (marketed as Amorphical)|supplementation
219671439|NCT02470663|DIETARY_SUPPLEMENT|Calcium carbonate 600 mg once daily|supplementation
219671440|NCT07020637|DEVICE|Cheetah NICOM|Bioreactance-based noninvasive cardiac output monitoring device used to measure stroke volume before and after passive leg raising. Used solely for observational measurement. No therapeutic intervention is performed.
219671441|NCT02929134|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
219671442|NCT02929134|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
219671443|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
219671444|NCT07022171|DEVICE|transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving transcutaneous auricular vagus nerve stimulation for a period of six weeks. Transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes, depending on patient tolerance.
219069425|NCT04134442|DRUG|Bupivacaine Liposome Injection|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
219671445|NCT07022171|DEVICE|sham transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving sham transcutaneous auricular vagus nerve stimulation for a period of six weeks. Sham transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes. The procedures for sham tVNS will be identical to tVNS, with the only exception that the sham tVNS will be performed with no current output
219671446|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
219671447|NCT02314312|DRUG|Everolimus + low dose cyclosporin A + prednisolone|
219671448|NCT02314312|DRUG|Standard immunosupressive regimen|
219069426|NCT04134442|OTHER|Standard Therapy|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
219069427|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
218980208|NCT03265301|PROCEDURE|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
218980209|NCT03265301|PROCEDURE|Office hysteroscopy|will be done in out patient clinic without anesthesia
218980210|NCT03265301|PROCEDURE|Conventional hysteroscopy|will be done in operative room under general anesthesia
218980211|NCT02550262|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
219069428|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
219069429|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
219069430|NCT00436059|DRUG|bortezomib|
219069431|NCT02293629|DRUG|BMS-986147|
219069432|NCT02293629|DRUG|Placebo matching BMS-986147|
219069433|NCT01415791|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
219069434|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
219069435|NCT06580678|DRUG|KH001|topical application of KH001
219069436|NCT06580678|DRUG|Placebo|topical application of Water for Injection
219069437|NCT06579547|RADIATION|Low Dose Computer Tomography|Participants will undergo MRI scans of their skeletal system, followed by the Intervention of a Low Dose CT scan of the same body region for comparison purposes.
219069438|NCT00496041|PROCEDURE|Registry|A Registry will be used.
218980212|NCT02550262|DRUG|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
219069439|NCT05046795|DRUG|Revefenacin 175 mcg in 3 ML Inhalation Solution|Revefenacin
219069440|NCT05046795|DRUG|Placebo inhalation solution QD|Placebo
219069441|NCT06635044|OTHER|intradialytic exercise|HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
218980213|NCT02550262|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
218980214|NCT05981430|BIOLOGICAL|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
219069442|NCT04678648|DRUG|RSC-1255 Dose Escalation|Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
219069443|NCT04678648|DRUG|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
219069444|NCT06543979|DRUG|lubiprostone , single arm|laxative
219069445|NCT06543979|PROCEDURE|biofeed back sessions|Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
219069446|NCT06543979|PROCEDURE|botox injection|Botulinum toxin injection for participants suffering from elevated anal canal pressure
219208806|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo"
219671449|NCT07021560|DEVICE|ZEISS MyoCare spectacle lenses|Spectacle lenses with conventional power profile including myopia control design.
218980215|NCT05981430|BIOLOGICAL|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
218980216|NCT01806558|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
218980217|NCT00890266|PROCEDURE|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
218980218|NCT00443495|DRUG|Chitin microparticles by nasal route|
218980219|NCT03202888|BEHAVIORAL|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
219069447|NCT06961981|BEHAVIORAL|Vinyasa Yoga|Each yoga session will begin with 2 minutes of integration poses (Child's Pose, Downward Facing Dog, Ragdoll, and Mountain Pose), followed by \~20 minutes of Sun Salutations A and B (up to 5 of each). The Standing Series, lasting \~25 minutes, will include various standing and balancing poses from the Journey into Power sequence. Seated and supine stretches (including seated stretches, a yoga inversion, a reclined twist) will last \~8 minutes, and the session will conclude with 5 minutes of Savasana for final relaxation.
219069448|NCT05526001|BIOLOGICAL|ELIXCYTE|ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.
219069449|NCT05526001|DRUG|Saline|Placebo control used in the study.
219069450|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
219069451|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
218980220|NCT02438020|DRUG|Metformin|One tablet of 500 mg will be ingested before the main meal
218980221|NCT02438020|OTHER|Placebo|A placebo tablet will be ingested daily before main meal.
219069452|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
219069453|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
219069454|NCT03011684|DRUG|Tamoxifen|Given orally
219069455|NCT03011684|DRUG|Letrozole|Given orally
219069456|NCT06005818|DRUG|Pembrolizumab injection|PD-1 antibody
219208807|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)"
219208808|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)"
219671450|NCT07021560|DEVICE|ZEISS SV RX SPH 1.5|Commercially available single vision
219671451|NCT07021560|DEVICE|ZEISS Clearview|Commercially available single vision
219671452|NCT07027098|PROCEDURE|Perflurocarbon liquid|Used to facilitate surgery of retinal detachment to stabilise macular during surgery.
218980222|NCT01963273|PROCEDURE|Video Assisted Ablation of Pilonidal Sinus|
218980223|NCT00839722|PROCEDURE|embolization|fertility after embolization
218980224|NCT01374828|DRUG|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
218980225|NCT04517500|BEHAVIORAL|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
218980226|NCT04517500|BEHAVIORAL|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
218980227|NCT04517500|BEHAVIORAL|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
218980228|NCT04747080|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
218980229|NCT04747080|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
219208809|NCT06732245|DRUG|NA-931|"NA-931, an oral, daily~• A quadruple receptor agonist"
219671453|NCT07027098|PROCEDURE|Without Perflurocarbon liquid|Standard retinal detachment surgery (vitrectomy) without the use of Perflurocarbon liquid (PFCL).
219671454|NCT07027332|DIAGNOSTIC_TEST|FibroScan® (Echosens, Paris, France)|A non-invasive liver elastography device used for clinical assessment. Liver steatosis and stiffness are measured in participants using the FibroScan device.
219671455|NCT07027449|BEHAVIORAL|Screening and Referral Workflow|The Screening and Referral Workflow intervention will include screening eligible patients for employment-related needs and referring those who require support to community-based employment resources.
219671456|NCT07027111|DRUG|NVG-2089|Study drug
219671457|NCT05443750|BEHAVIORAL|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
219671458|NCT05443750|BEHAVIORAL|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
219671459|NCT05703464|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
219671460|NCT02253576|OTHER|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
219671461|NCT02253576|OTHER|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
219671462|NCT06703034|OTHER|Biological Sampling|"The procedures specifically carried out for the study during a single visit are as follows:~* 1 nasopharyngeal swab for the baseline measurement of the nasal IFN-I score and to check for the presence of infection~* Blood sample collection in:~o1 yellow tube (5mL) for anti-interferon antibody measurement o1 PAXgene tube (2.5mL) for the baseline IFN score without stimulation o3 green heparin tubes (12mL) for performing immune-functional tests o2 large purple tubes (20mL) for biological collection (if the patient provides specific consent) oA total of 39.5mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota."
219671463|NCT03358680|DEVICE|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
219671464|NCT00581425|BIOLOGICAL|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
219671465|NCT06731881|DEVICE|Nasal PDT|Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.
219671466|NCT06731881|COMBINATION_PRODUCT|Photosensitizer formulation only|Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).
219671467|NCT06731881|OTHER|Standard follow-up|All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.
219671468|NCT06731881|DIAGNOSTIC_TEST|Nasal culture|Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).
219671469|NCT06731881|DIAGNOSTIC_TEST|Flexible nasendoscopy|Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).
219671470|NCT06731881|OTHER|In-person review|On Week 2 (±7 days), the participant will undergo an in-person review conducted in the ENT Outpatient department, 2nd floor Southwark wing, Guy's Hospital by the CI, PI or Co-investigator. During this appointment, concomitant medications and use of post-operative antibiotics will be reviewed.
219671471|NCT06731881|OTHER|Telephone Follow-up|"On day 30, the research nurse will telephone participants from the ENT research office.~* Review of adverse events/adverse device effects~* Review of concomitant medications~* Signs and symptoms post-surgery~* Nasal washout~* Record any use of post-operative antibiotics, both local and systemic"
218980230|NCT06050005|DIAGNOSTIC_TEST|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
219069457|NCT04940325|DRUG|DS-1062a|First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
219069458|NCT05008354|DRUG|Pyridoxine|Pyridoxine tablet 40mg once daily
219069459|NCT05008354|DRUG|Placebo|Placebo tablet once daily
219069460|NCT02904304|DRUG|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
219671472|NCT05663944|DRUG|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
219671473|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
218980231|NCT05276518|PROCEDURE|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
218980232|NCT04242329|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
218980233|NCT04242329|DRUG|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
218980234|NCT02973061|OTHER|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
218980235|NCT03009500|DRUG|Bupivacaine|
219069461|NCT02904304|DRUG|Placebo|01 tablet, orally, every 12 hours.
219069462|NCT02938000|DEVICE|Theraband with exercise video|Theraband exercise band for resistance training
219208810|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
219069463|NCT02938000|OTHER|usual care with advice to exercise|advice to exercise
219069464|NCT01242475|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
219208811|NCT06732245|DRUG|NA-931|"NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
219208812|NCT06732245|DRUG|NA-931 150 mg + no Tirzepatide|NA-931 150 mg + no Tirzepatide
219208813|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
218980236|NCT03009500|DRUG|Depo-Medrol Injectable Product|
218980237|NCT03009500|OTHER|Saline (Sodium Chloride) solution|
218980238|NCT03009500|DRUG|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
218980239|NCT06464796|OTHER|Motor Imagery Techniques|"* Play a video of person doing a toe-raise exercise where carrying a big barbell on his shoulders.~* The individual in the video proceeded from a neutral upright position to a tiptoe standing while loud a heavy barbell; the plantar-flexors are used in this workout.~* The members were said to imagine engaging their ankle flexor muscles in an effort to generate ankle flexion. Both limbs were used during the 10-second imaginary contraction, which was tailed by a 10-second rest. Subsequently five repetitions of the contraction, there was a 30 second pause. Two-minutes of rest were interspersed between five-sets of five-contractions. Fifty imaginary contractions in total."
219069465|NCT01242475|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
219208814|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
219208815|NCT03213457|DRUG|Estradiol/Norethindrone Acetate|Tablets
219208816|NCT03213457|DRUG|Placebo for Elagolix|Tablet
219069466|NCT02810054|PROCEDURE|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
219069467|NCT02810054|PROCEDURE|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
219208817|NCT03213457|DRUG|Elagolix|Tablet
219208818|NCT03213457|DRUG|Placebo for E2/NETA|Tablets
219069468|NCT04559789|BEHAVIORAL|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
219069469|NCT04559789|OTHER|Health Education|Health education materials delivered electronically
219208819|NCT06740539|PROCEDURE|Catheter ablation of atrial fibrillation|Catheter ablation of atrial fibrillation
219208820|NCT06573385|OTHER|Questionnaire|Questionnaire application
219208821|NCT06069570|BIOLOGICAL|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
219208822|NCT06843057|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique that involves applying a special elastic tape to the skin to support and stabilize muscles and joints without restricting their range of motion.
219671474|NCT05663944|PROCEDURE|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
218980240|NCT06464796|OTHER|Conventional Exercise Therapy|"1. ROM drills for pronation, flexion and extension.~2. Ankle strengthening trainings include stand-up on tiptoe, walking on toe-tip, hopping on single foot, and resistance exercise with a latex elastic band.~3. Proprioceptive exercise include the following exercises: (a) sit on a proprioception board and move the injured limb in a round motion; (b) stand-up with both legs on the board while performing both eyes open and closed; (c) standing with single leg on the board while performing both eyes open; and (d) exercises on a mini-tramp (stand-up on double legs, single leg stances, hops on both left and right legs and on single leg).~4. Strengthening of the muscles of ankle completed with flexible bands at moderate Intensities.~5. Training on a stationary bicycle.~6. lunges forward into a wall.~7. Steps up and down on the transverse or sagittal plane."
218980241|NCT00816296|OTHER|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
218980242|NCT00816296|OTHER|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
218980243|NCT00816296|OTHER|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
218980244|NCT00816296|OTHER|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
219069470|NCT04445805|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
219069471|NCT04445805|BEHAVIORAL|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
219069472|NCT04445805|BEHAVIORAL|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
219069473|NCT03101735|DRUG|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
219069474|NCT06580574|DRUG|PD1/PDL1 antibody monotherapy, up to 24 weeks|non-specific, according to Drug Instructions
219069475|NCT06580574|COMBINATION_PRODUCT|Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd
219069476|NCT06580574|PROCEDURE|Radical surgery|Radical surgery will be recommended per local treatment standards.
219069477|NCT00872144|DRUG|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
219208823|NCT06843057|OTHER|Mulligan's mobilization with movement techniques|Mulligan's mobilization with movement (MWM) techniques involve the application of a sustained manual force or glide to a joint while the patient actively performs a movement that is typically painful or restricted.
219208824|NCT06843057|OTHER|Conventional physiotherapy|Mulligan Mobilization with Movement, Ultrasound Therapy, Active assisted ROM exercises for shoulder, Capsular Stretching exercises
219208825|NCT06841926|DRUG|ZX-7101A dry suspension|Test formulation (T) : ZX-7101A dry suspension Specification: 10 mg/ bag Dosage：40 mg (4 bags)、 once
218980245|NCT03270371|DEVICE|Medium cut off dialysis|Hemodialysis
219671475|NCT05663944|DRUG|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
219671476|NCT05663944|DIAGNOSTIC_TEST|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
219208826|NCT06841926|OTHER|ZX-7101A tablet|Reference formulation (R): ZX-7101A tablet Specification: 40 mg/ tablet Dosage：40 mg (1 tablet)、 once
219671477|NCT05663944|DIAGNOSTIC_TEST|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
219671478|NCT05663944|DIAGNOSTIC_TEST|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
219671479|NCT05663944|OTHER|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
219671480|NCT05663944|DIAGNOSTIC_TEST|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
219671481|NCT05663944|OTHER|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
218980246|NCT03270371|DEVICE|Standard High Flux Dialyzer|Hemodialysis
218980247|NCT03138304|BEHAVIORAL|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
218980248|NCT03138304|BEHAVIORAL|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
218980249|NCT05622695|DEVICE|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
218980250|NCT02183896|BIOLOGICAL|Platelet-rich plasma (PRP)|
218980251|NCT02183896|DRUG|Saline|
218980252|NCT06255964|DRUG|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
218980253|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
219069478|NCT05228574|DIETARY_SUPPLEMENT|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
219069479|NCT05228574|DIETARY_SUPPLEMENT|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
219069480|NCT05228574|DRUG|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
219069481|NCT05856656|BEHAVIORAL|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
219069482|NCT04242355|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
219069483|NCT06319443|DIETARY_SUPPLEMENT|Liquid vinegar|3.5 g acetic acid
219069484|NCT06319443|DIETARY_SUPPLEMENT|vinegar pill|0.022 g acetic acid
219069485|NCT06287359|OTHER|individual interviews|Qualitative research with individual interviews
219069486|NCT05177770|DRUG|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
219069487|NCT05177770|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
219069488|NCT05177770|DRUG|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
219671482|NCT05663944|DIAGNOSTIC_TEST|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
219671483|NCT05663944|OTHER|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
219671484|NCT05663944|DIAGNOSTIC_TEST|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
219671485|NCT05663944|PROCEDURE|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
219671486|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
219671487|NCT02336347|DRUG|AVP-786|
219671488|NCT02336347|DRUG|AVP-923|
219671489|NCT05612464|OTHER|No intervention|No intervention
219671490|NCT02467894|OTHER|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
219671491|NCT04672876|DRUG|Telotristat Ethyl Oral Tablet|XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
219671492|NCT00652717|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
219671493|NCT00652717|DRUG|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
219671494|NCT02380963|DIETARY_SUPPLEMENT|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
219671495|NCT02380963|BEHAVIORAL|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
219671496|NCT00752869|DRUG|dutasteride|0.5mg by mouth one time per day for 1 year
219671497|NCT00752869|DRUG|placebo|one tablet per day for 1 year
219671498|NCT03795662|OTHER|No intervention|Obervational
219671499|NCT05546320|DRUG|Aspirin 100mg|Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
219671500|NCT05546320|DRUG|Metoprolol 25 Mg Oral Tablet|Metoprolol 25mg will be provided for the participants twice a day.
219671501|NCT05546320|DRUG|Clopidogrel 75mg|Clopidogrel 75mg will be provided for the participant once a day.
219069489|NCT05259436|BEHAVIORAL|Caregiver-child Intervention|"Intervention Groups:~1. Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~2. ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~   and,~3. Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
219671502|NCT05546320|DRUG|Rivaroxaban 20mg|Rivaroxaban 20mg will be provided for the participant once a day.
219069490|NCT05259436|BEHAVIORAL|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
219671503|NCT00994799|DRUG|ranibizumab|10mg/ml intravitreal injection
219671504|NCT00994799|RADIATION|macular grid-pattern laser|macular grid-pattern laser therapy
219671505|NCT00573586|DEVICE|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
219671506|NCT02179749|DRUG|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
219671507|NCT02179749|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
219671508|NCT02179749|DRUG|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
219671509|NCT01897766|DRUG|Somatropin|0.23 mg to 0.48 mg/kg/week
219671510|NCT03588013|OTHER|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
219671511|NCT03588013|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food|If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
219671512|NCT03588013|PROCEDURE|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
219671513|NCT06811298|OTHER|Breast massage|The breast massage group will receive a 15-minute breast massage administered by the researchers at postoperative Day 0, Hour 3, and Hour 24. The aim of this intervention is to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
219671514|NCT06811298|OTHER|Virtual Reality|Postpartum women who undergo virtual reality headset application will watch a 15-minute river and forest video using the headset on postoperative day 0, hour 3, and hour 24. This intervention aims to help them feel in a relaxing and soothing environment and to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
219671515|NCT02780960|DEVICE|HPV self-testing|Patients will perform HPV testing themselves at home.
219671516|NCT04131491|PROCEDURE|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
219671517|NCT05175950|BIOLOGICAL|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
219671518|NCT05175950|OTHER|Normal saline|Normal saline
219671519|NCT05887024|DEVICE|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
219671520|NCT05887024|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
219671521|NCT05887024|PROCEDURE|McKenzie Back exercises|Graduated Progressive back exercise program.
219671522|NCT05887024|DEVICE|electric heating pads|electrical conducting heat pack.
219671523|NCT02756364|DRUG|Fulvestrant|Fulvestrant IM injection.
219671524|NCT02756364|DRUG|Sapanisertib|Sapanisertib capsule.
218980254|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
218980255|NCT03626168|DIETARY_SUPPLEMENT|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
219069491|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
219069492|NCT06083207|DRUG|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
219671527|NCT05451953|PROCEDURE|Apneic Oxygenation|Nasal cannula at a rate of 6L/min with 100% FiO2 during laryngoscopy and intubation attempt(s)
219671528|NCT05451953|PROCEDURE|Standard of Care|No respiratory support during laryngoscopy and intubation attempt(s) (current standard of care)
219671529|NCT02223364|DRUG|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
219671530|NCT02223364|DRUG|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
218980256|NCT03626168|OTHER|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
218980257|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
218980258|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
218980259|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
218980260|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
219671531|NCT02223364|DRUG|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
219671532|NCT06026839|OTHER|Conventional nursing|Conventional nursing
219671533|NCT06618573|DRUG|Isoniazid/Pyridoxine|Treatment group received isoniazid 300mg and pyridoxine 10mg/day
219671534|NCT06618573|DRUG|Saccharum Lactis|Control group received placebo
219671535|NCT00793546|DRUG|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
219671536|NCT00793546|DRUG|exemestane|25 mg tablet once daily
218980261|NCT01620554|DRUG|Placebo|1 capsule per week during 2 weeks
218980262|NCT00878670|DRUG|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
218980263|NCT02248701|DRUG|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
219671537|NCT00793546|DRUG|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
219671538|NCT01334580|BEHAVIORAL|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
219671539|NCT01334580|BEHAVIORAL|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
219671540|NCT00113191|DRUG|Veronate|
219671541|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
218980264|NCT02248701|DRUG|Finasteride|Subjects receive finasteride (5 mg/day) orally
218980265|NCT02248701|DRUG|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
218980266|NCT02248701|DRUG|Placebo pill|Subjects receive placebo pill (daily) orally
218980267|NCT04304742|PROCEDURE|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
218980268|NCT02025166|DRUG|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
218980269|NCT02025166|DRUG|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
218980270|NCT00185835|DRUG|ZD-1839|
218980271|NCT00185835|DRUG|Cisplatin|
219069493|NCT03015792|DRUG|Dexamethasone|Given PO
219069494|NCT03015792|DRUG|Ibrutinib|Given PO
219069495|NCT03015792|OTHER|Laboratory Biomarker Analysis|Correlative studies
219069496|NCT03015792|DRUG|Lenalidomide|Given PO
219069497|NCT03015792|OTHER|Pharmacological Study|Correlative studies
219069498|NCT03015792|OTHER|Quality-of-Life Assessment|Ancillary studies
219069499|NCT05093075|OTHER|Therapeutic Plasma Exchange|TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
219069500|NCT06300814|OTHER|Progressive relaxation exercise group|A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).
219069501|NCT06300814|OTHER|Music recital group|The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
219208827|NCT06820580|OTHER|Salutogenic Approach Based Interview|Salutogenic Approach Based Interviewing Program consists of 8 sessions. The interview will be conducted for four weeks and on two specific days of the week. Interviews will be conducted in groups of 6-8 people. The interview will last 30-40 minutes on average.
219671542|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
219671543|NCT04312594|DRUG|Placebo|Patients were administered Placebo taken orally as tablets twice daily
219671544|NCT01841567|DEVICE|Mepilex border post. op|
219671545|NCT01841567|DEVICE|Mepilex border post op|
219671546|NCT01416155|DRUG|natalizumab|
219671547|NCT05400889|DRUG|tofacitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
219671548|NCT00065195|PROCEDURE|Moving touch therapy|
219671549|NCT00065195|PROCEDURE|Nonmoving touch therapy|
219671550|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
218980272|NCT05303363|DEVICE|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
218980273|NCT05515315|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
219671551|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
219671552|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
219671553|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
219671554|NCT04068740|PROCEDURE|Surgical treatment of valvular heart disease|Valve replacement or repair
219671555|NCT04068740|DIAGNOSTIC_TEST|Virtual treatment|Virtual valve replacement or repair surgery
219671556|NCT02984267|DEVICE|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
219671557|NCT02984267|OTHER|Palpation|Using palpation only to evaluate the spine prior to epidural placement
219671558|NCT00650416|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
219671559|NCT00650416|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
218980274|NCT05515315|DRUG|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
218980275|NCT05515315|DRUG|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
218980276|NCT05515315|RADIATION|radiotherapy|50-60Gy/25-30f
218980277|NCT02074930|DEVICE|Microporation by P.L.E.A.S.E. Professional / Prick needle|
218980278|NCT05291325|DRUG|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
218980279|NCT05291325|DRUG|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
218980280|NCT05291325|DRUG|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
218980281|NCT00003568|BIOLOGICAL|aldesleukin|
218980282|NCT00003568|BIOLOGICAL|gp100 antigen|
218980283|NCT00003568|BIOLOGICAL|incomplete Freund's adjuvant|
218980284|NCT00808483|OTHER|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
218980285|NCT05211362|BIOLOGICAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
218980286|NCT05211362|BIOLOGICAL|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
218980287|NCT01941693|BEHAVIORAL|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
219069502|NCT04043689|DEVICE|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
219069503|NCT01022814|DEVICE|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
219671560|NCT03376217|OTHER|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
219671561|NCT00230919|BEHAVIORAL|Diet counseling|
219671562|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
219671563|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
219671564|NCT03631654|DRUG|Placebos|Placebo
219671565|NCT00701844|BEHAVIORAL|Writing A (Experimental informative writing)|Experimental informative writing
219671566|NCT00701844|BEHAVIORAL|Writing B (Experimental noninformative writing)|Experimental noninformative writing
219671567|NCT00701844|BEHAVIORAL|Writing C (Control informative writing)|Control informative writing
219671568|NCT00701844|BEHAVIORAL|Writing D (Control noninformative writing)|Control noninformative writing
219671569|NCT00742027|DRUG|Panobinostat|Panobinostat hard gelatin capsules.
219671570|NCT02927002|DEVICE|Noninvasive brain stimulation|
219671571|NCT00002575|PROCEDURE|conventional surgery|
219671572|NCT00002575|PROCEDURE|laparoscopic surgery|
219671573|NCT06271759|OTHER|Fragrance inhalation|Inhalation of fragranced essential oils
219671574|NCT06339359|OTHER|Exmainations including clinical measurement, kinetic and kinematic measurmetns. Behavioral assessments|Collection of clinical data including K-Bayley Scales of Infant and Toddler Development Third Edition (K-BSID-Ⅲ), , Beery-Buktenica Visual-Motor Integration, Sixth Edition (VMI-6) and clinical measurement. motor analysis and eye tracking
219671575|NCT04627961|DRUG|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
219671576|NCT01442727|DRUG|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
219671577|NCT01442727|DRUG|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
219671578|NCT05998460|BEHAVIORAL|Glucose-Guided Eating with CGM|The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
219671579|NCT05998460|OTHER|CGM only|Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
219671580|NCT05616091|DEVICE|painful stimulation by using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In each of the two sessions, 80 experimental painful stimuli of different intensities (2.5 J, 3 J, 3.5 J, 4 J) will be applied using the laser device listed above.
219671581|NCT03863691|DRUG|Amisulpride 300 MG|A single dose of 300 mg amisulpride that looks identical to placebo control capsules.
219671582|NCT03863691|DRUG|Placebo oral capsule|A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
219671583|NCT03597139|DRUG|Voclosporin Ophthalmic Solution|Investigational Drug
219671584|NCT03597139|DRUG|Restasis®|Comparator
219671585|NCT01342172|DRUG|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
219671586|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management|The children will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.
219671587|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management + short peptide ONS|"During the study period, an additional 3 months of short peptide ONS enteral nutrition intervention is expected to be performed in children enrolled from Dec 1, 2024 to Feb 28, 2025 to explore the improvement of the nutritional status of the children. Short peptide type ONS 30ml/(kg.d) will be taken orally for children under 3 years old, and 20ml/(kg.d) for children over 3 years old. Due to conditional restrictions, standardized nutritional management + short peptide ONS intervention is only carried out in this subgroup.~Inclusion criteria for short peptide ONS enteral nutrition intervention:~1. Male and female, age 1-10 years old~2. Pathological diagnosis is malignant solid tumor with untreated initial onset~3. It is expected to receive enteral nutrition intervention for 3 months~4. Clear consciousness, willing to cooperate, no serious dysfunction of major organ functions"
219671588|NCT00520767|DRUG|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
219671589|NCT00520767|DRUG|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
219671590|NCT00520767|DRUG|melphalan|Melphalan 9 mg/m2/day days 1-4
219671591|NCT00520767|GENETIC|microarray analysis|≤28 days prior to enrollment
219671592|NCT00520767|OTHER|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
219069504|NCT03073889|PROCEDURE|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
219069505|NCT03073889|PROCEDURE|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
219069506|NCT03073889|DRUG|Ropivacaine|
219069507|NCT06108622|DIAGNOSTIC_TEST|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
219671593|NCT00520767|OTHER|laboratory biomarker analysis|≤28 days prior to enrollment
219671594|NCT00520767|PROCEDURE|quality-of-life assessment|Start of each cycle
219671595|NCT00312104|DRUG|insulin detemir|
219671596|NCT00312104|DRUG|insulin glargine|
219671597|NCT00312104|DRUG|insulin aspart|
219671598|NCT03307122|OTHER|Routine Infant Formula 1|Routine infant formula with probiotic
219671599|NCT03307122|OTHER|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
219671600|NCT02464644|OTHER|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
219671601|NCT01310244|DRUG|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
219671602|NCT00477204|DRUG|Simvastatin|simvastatin 20 mg daily
219671603|NCT00477204|DRUG|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
219671604|NCT01770067|DRUG|CITA-RNPT|
219671605|NCT01770067|PROCEDURE|Extraction of infected CIED|
219671606|NCT04902079|DEVICE|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
219671607|NCT01120132|DRUG|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
219671608|NCT01120132|DRUG|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
218980288|NCT01941693|BEHAVIORAL|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
218980289|NCT01171040|OTHER|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
218980290|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
219671609|NCT01120132|DRUG|PA|Suspension of Prednisolone Acetate administered during 28 days
218980291|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
218980292|NCT02357979|DEVICE|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
218980293|NCT02357979|OTHER|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
219671610|NCT01120132|DRUG|Placebo|Placebo solution administered during 28 days
218980294|NCT05403788|DEVICE|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
219671611|NCT04441385|DRUG|Maraviroc 300 mg|Patients will receive maraviroc 300 mg twice daily for 14 days
219671612|NCT04441385|OTHER|Standard care therapy|Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
219671613|NCT03131700|BIOLOGICAL|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
219671614|NCT03131700|BIOLOGICAL|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
219671615|NCT05054699|DEVICE|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
219671616|NCT05054699|DEVICE|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
219671617|NCT00382109|DRUG|thiotepa|Given IV
219671618|NCT00382109|DRUG|cyclophosphamide|Given IV
219671619|NCT00382109|DRUG|tacrolimus|Given IV or orally
219671620|NCT00382109|DRUG|methotrexate|Given IV
219671621|NCT00382109|DRUG|sirolimus|Given orally
219671622|NCT00382109|RADIATION|total body irradiation|Part of the transplant preparatory regimen
219671623|NCT00001237|DRUG|granulocyte-macrophage colony stimulating factor (GM-CSF)|
219671624|NCT03412006|DRUG|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
219671625|NCT03412006|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
219671626|NCT06143787|DRUG|Tranexamic acid|7 days Oral rinsing following tooth extraction
219671627|NCT02941354|DRUG|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
219671628|NCT01249833|DRUG|Oseltamivir|Oseltamivir 75mg BID for 5 days
219671629|NCT04061733|DEVICE|Hydrogel injection|Hydrogel injection
219671630|NCT00700154|PROCEDURE|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
219671631|NCT01039805|DRUG|GSK962040 (50 mg)|Cohort 1 = 50 mg
219671632|NCT01039805|DRUG|Placebo|matching placebo
219671633|NCT01039805|DRUG|GSK962040 (75 mg)|Cohort 2 = 75 mg
219671634|NCT05068479|DEVICE|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
218980295|NCT04746222|BIOLOGICAL|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
219671635|NCT01900860|DIETARY_SUPPLEMENT|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
218980296|NCT04746222|OTHER|Placebo|Single dose of 30 oral placebo capsules
218980297|NCT02277730|DEVICE|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
218980298|NCT02277730|DRUG|phenylephrine|
219069508|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
219069509|NCT04667117|BIOLOGICAL|Quadrivalent influenza vaccine|2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
219069510|NCT04667117|DRUG|Ofatumumab|"Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab."
219069511|NCT04667117|DRUG|iDMT|Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
219069512|NCT05531539|DEVICE|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
219671636|NCT06725680|OTHER|Retrolaminar block|Patients will receive retrolaminar block after the induction of general anesthesia.
219671637|NCT06725680|OTHER|Erector spinae plane block|Patients will receive erector spinae plane block after the induction of general anesthesia.
219671638|NCT03796676|DRUG|Placebo|Placebo
219671639|NCT03796676|DRUG|PF-04965842|100 mg QD
218980299|NCT02277730|DRUG|ephedrine|
218980300|NCT02277730|DEVICE|manual vasopressor delivery|
218980301|NCT03108274|DRUG|Danicopan|Oral tablet.
218980302|NCT03108274|DRUG|Midazolam|Oral syrup.
218980303|NCT03108274|DRUG|Fexofenadine|Oral tablet.
219671640|NCT03796676|DRUG|PF04965842|200 mg QD
219671641|NCT00535392|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
219671642|NCT00766844|DEVICE|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
219671643|NCT03130140|PROCEDURE|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
219671644|NCT03130140|OTHER|Control|Conventional EUS-FNA
219671645|NCT05155930|BEHAVIORAL|Internal Family Systems (IFS)|Weekly individual psychotherapy
219671646|NCT04588844|DRUG|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
219671647|NCT04629872|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
218980304|NCT03108274|DRUG|Mycophenolate Mofetil|Oral tablet.
218980305|NCT02435446|DEVICE|Cone-beam computed tomography|Cone-beam computed tomography
218980306|NCT03300284|BEHAVIORAL|Questionnaires|Quality of Life Questionnaires
218980307|NCT03474861|BIOLOGICAL|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
218980308|NCT06442280|DRUG|Dapagliflozin tablet|Dapagliflozin 10 mg 1 tablet once daily
218980309|NCT06442280|DRUG|Hypertonic Saline Solution, 1 Ml|Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
219671648|NCT02724410|DRUG|home intravenous ertapenem|see arm description
219671649|NCT02724410|DRUG|home oral amoxicillin-clavulanate|see arm description
219671650|NCT02724410|DEVICE|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
219671651|NCT06147323|OTHER|Normal Healthy Diet|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
219671652|NCT06147323|DIETARY_SUPPLEMENT|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
219671653|NCT06147323|OTHER|Placebo Diet Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
219671654|NCT03284112|BEHAVIORAL|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
219671655|NCT03284112|BEHAVIORAL|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
219671656|NCT04256213|DRUG|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
219671657|NCT01163006|OTHER|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
218980310|NCT06442280|DRUG|Furosemide Injection|Furosemide 20 mg
218980311|NCT02391701|BEHAVIORAL|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
218980312|NCT00589992|DRUG|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
218980313|NCT05490303|OTHER|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
218980314|NCT06189690|DEVICE|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
218980315|NCT03566862|DIAGNOSTIC_TEST|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
218980316|NCT04289623|BEHAVIORAL|Email|Email
218980317|NCT04289623|BEHAVIORAL|Loss frame|Email
218980318|NCT04289623|BEHAVIORAL|Testimonial (medical expert)|Email
218980319|NCT04289623|BEHAVIORAL|Testimonial (rank-and-file)|Email
218980320|NCT04289623|BEHAVIORAL|Social norms (percentage)|Email
218980321|NCT04289623|BEHAVIORAL|Social norms (number)|Email
219671658|NCT00248833|BIOLOGICAL|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
219671659|NCT00248833|BIOLOGICAL|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
219671660|NCT01329432|PROCEDURE|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
219671661|NCT01329432|PROCEDURE|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
219671662|NCT01900899|PROCEDURE|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
219671663|NCT02006056|DRUG|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
219671664|NCT03414905|DEVICE|Aspira Catheter|"* 15.5Fr catheter~* Standard of care"
219671665|NCT03414905|PROCEDURE|Ultrasound|Standard of care
219671666|NCT00723697|DRUG|buprenorphine|0.4, 2, or 8 mg sublingual tablets
219671667|NCT05292976|OTHER|Methacholine Chloride|Serial Methacholine dilutions
219671668|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
219671669|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
219671670|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
219671671|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
219671672|NCT05292976|DRUG|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
219671673|NCT05058092|DEVICE|Immediate Remedee Solution|"* D0 to M3: Remedee Solution + medical care~* M3 to M6: Remedee Solution without personalized support + medical care~* M6 to M9: medical care only"
219671674|NCT05058092|DEVICE|Delayed Remedee Solution|"* D0 to M3: medical care only~* M3 to M6: Remedee Solution + medical care~* M6 to M9: Remedee Solution without personalized support + medical care"
219671675|NCT02546076|DEVICE|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
219671676|NCT02546076|DEVICE|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
219671677|NCT05049473|DRUG|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
219671678|NCT05049473|DRUG|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
219671679|NCT05049473|DRUG|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.
219671680|NCT05049473|DRUG|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*."
219671681|NCT05049473|DRUG|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*
219671682|NCT05049473|DRUG|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.
219671683|NCT05049473|DRUG|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*
219671684|NCT05049473|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
219671685|NCT05049473|DRUG|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
219671686|NCT05049473|DRUG|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
219671687|NCT05049473|DRUG|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
219671688|NCT05049473|DRUG|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
219671689|NCT05049473|DRUG|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
218980322|NCT04185948|BEHAVIORAL|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
218980323|NCT04185948|BEHAVIORAL|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
218980324|NCT02646657|DRUG|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
218980325|NCT05614232|RADIATION|Chest X-ray|Chest radiographs
219671690|NCT05049473|DRUG|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
219671691|NCT06371066|OTHER|experimental group|the experimental group was educated by video
219671692|NCT06371066|OTHER|Control group|the control group was educated by traditional formal training
219671693|NCT02770846|PROCEDURE|Immediate loading|
219671694|NCT02770846|PROCEDURE|Delayed loading|
219671695|NCT06731725|DEVICE|DayDrop®|The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
219671696|NCT04291365|DIAGNOSTIC_TEST|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
219671697|NCT00069563|BEHAVIORAL|Reaching Educators, Children, and Parents (RECAP)|
219671698|NCT05337384|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
219671699|NCT02068859|DRUG|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
219671700|NCT02068859|DRUG|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
219671701|NCT00607542|DRUG|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
219671702|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
219671703|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
219671704|NCT03374163|DRUG|intralipid 20%|milky soulation for energey supplement.
219671705|NCT03077100|OTHER|Laboratory identification of positive cultures|Laboratory identification of positive cultures
219671706|NCT04436653|DEVICE|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
219671707|NCT06178562|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219671708|NCT06178562|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219671709|NCT06178562|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219671710|NCT00072904|DRUG|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
219671711|NCT00072904|DRUG|Repaglinide|0.5mg tab with meals tid
219671712|NCT01741155|DRUG|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
218980326|NCT01484223|BEHAVIORAL|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
218980327|NCT05541042|OTHER|Observational only|This is an observational study
219069513|NCT05593835|DEVICE|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
219671713|NCT01741155|DRUG|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
219671714|NCT03576352|OTHER|a rapid sequence tracheostomy (RST) on rabbit cadaver|"The Rapid Sequence Tracheostomy (RST) consists of the following steps:~1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated."
219671715|NCT01072747|BIOLOGICAL|bovine heparin|5.000UI/mL bottle with 5mL
219671716|NCT01072747|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
219671717|NCT00003178|BIOLOGICAL|filgrastim|
219671718|NCT00003178|DRUG|cladribine|
219671719|NCT00003178|DRUG|idarubicin|
218980328|NCT05021263|DRUG|IV Medications|IV magnesium sulfate, used to replete magnesium stores
218980329|NCT05021263|OTHER|placebo|placebo
218980330|NCT00827528|PROCEDURE|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
218980331|NCT00827528|PROCEDURE|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
218980332|NCT03133130|DRUG|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
218980333|NCT03133130|DRUG|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
218980334|NCT00013962|DRUG|Vitamin D|
218980335|NCT00843531|DRUG|RAD001|5 mg/day PO (oral)
218980336|NCT00843531|DRUG|erlotinib|100 mg/day (oral)
219671720|NCT06730841|DEVICE|Dose-Optimized and Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
219671721|NCT06730841|DEVICE|Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
219671722|NCT06730841|DEVICE|Sham Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
218980337|NCT01845142|DRUG|single administration of 100.000 I.U. vitamin D|
219671723|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
219671724|NCT03975725|DEVICE|the use of the WitCard|electrocardiogram (ECG)
219069514|NCT05593835|OTHER|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
218980338|NCT01845142|DRUG|Placebo|
218980339|NCT01633073|DEVICE|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
219069515|NCT05036616|DEVICE|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
219069516|NCT02418325|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
219671725|NCT03975725|OTHER|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
219671726|NCT02254798|OTHER|no intervention|this is a non interventional study
219069517|NCT02418325|OTHER|Liberation therapy|
219069518|NCT01634698|DIETARY_SUPPLEMENT|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
219069519|NCT01195012|BEHAVIORAL|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
218980340|NCT01633073|DEVICE|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
218980341|NCT02632331|DRUG|ASP8825|Oral
218980342|NCT02182739|DRUG|Meloxicam|tablets or injectable solution
218980343|NCT01772160|OTHER|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
219069520|NCT00644722|DEVICE|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
219069521|NCT00644722|DEVICE|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
219069522|NCT05373394|OTHER|Test battery|motor and neuropsychological test battery
219069523|NCT02883725|OTHER|data collection|
219069524|NCT03646786|DEVICE|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
219208828|NCT06817473|BEHAVIORAL|CAST|CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated AS, particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention. CAST contains video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In this study, participants complete CAST as a group alongside other participants.
219671727|NCT05275634|OTHER|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
219671728|NCT05275634|DEVICE|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
219671729|NCT05275634|DEVICE|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
219671730|NCT05275634|DEVICE|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
219671731|NCT05275634|DEVICE|placebo interferential current|Interferential current intensity will not be raised.
218980344|NCT02016001|OTHER|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
218980345|NCT02016001|OTHER|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
218980346|NCT03855865|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
218980347|NCT03855865|DRUG|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
218980348|NCT03855865|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
218980349|NCT03722823|DRUG|Tucatinib|300mg oral single dose
218980350|NCT00901407|DRUG|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
218980351|NCT00901407|DRUG|placebo|placebo: 1-2 tablets bid; 10 weeks
218980352|NCT00901407|DRUG|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
219671732|NCT06544746|RADIATION|Periapical radiographs|oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
219671733|NCT02872233|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219671734|NCT02872233|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
219671735|NCT00002479|DRUG|tretinoin|
218980353|NCT06227260|OTHER|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
218980354|NCT01813188|PROCEDURE|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
218980355|NCT01813188|PROCEDURE|autologous bone graft|autologous bone graft
218980356|NCT04306848|DEVICE|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
218980357|NCT01865097|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
218980358|NCT01865097|BEHAVIORAL|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
218980359|NCT02488850|PROCEDURE|Surgery|
218980360|NCT02488850|RADIATION|SABR|
218980361|NCT00667160|DRUG|tacrolimus ointment|topical
218980362|NCT00667160|DRUG|pimecrolimus cream|topical
218980363|NCT00576784|DRUG|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
218980364|NCT01522248|BIOLOGICAL|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
218980365|NCT03391089|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
218980366|NCT00694707|DRUG|Placebo|Placebo was supplied in capsules.
218980367|NCT00694707|DRUG|Cariprazine|Cariprazine was supplied in capsules
218980368|NCT00694707|DRUG|Risperidone|Risperidone was supplied in capsules
218980369|NCT05908110|BEHAVIORAL|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
219208829|NCT06817473|BEHAVIORAL|HET|The HET protocol covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, stress management as well as other healthy lifestyle tips. HET was administered in a group format for this study.
219671736|NCT05339919|DIAGNOSTIC_TEST|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
219671737|NCT00800111|PROCEDURE|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
219671738|NCT06695910|DIETARY_SUPPLEMENT|Monoglyceride Eicosapentaenoic acid (omega-3)|515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days (or 112 days in phase 2) followed by a wash-out period of 28 days.
219671739|NCT06695910|OTHER|Sunflower Oil|698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 112 days followed by a wash-out period of 28 days.
219671740|NCT01501032|DEVICE|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
219671741|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
219671742|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
219671743|NCT01504139|DRUG|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
219671744|NCT01504139|DRUG|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
219671745|NCT01971515|DRUG|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
219671746|NCT01971515|DRUG|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
218980370|NCT05739565|BEHAVIORAL|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
218980371|NCT06310915|DRUG|Navelbine oral,Pembrolizumab|Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks
218980372|NCT00731016|DRUG|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
218980373|NCT03172819|BIOLOGICAL|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
218980374|NCT03172819|DRUG|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
219671747|NCT01971515|DRUG|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
219671748|NCT05163730|DEVICE|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
219671749|NCT02584374|OTHER|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
219671750|NCT05627648|DRUG|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
219671751|NCT05627648|DRUG|Placebo|Intracordal injection, once per week, 3 weeks
219671752|NCT03250338|DRUG|Crenolanib|Crenolanib will be administered orally
219671753|NCT03250338|DRUG|Cytarabine|"HAM regimen~FLAG-Ida"
219069525|NCT01947946|BIOLOGICAL|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
219069526|NCT01947946|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
219069527|NCT05013333|DEVICE|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
219069528|NCT02539264|OTHER|Smoking|Influence of smoking on parameters derived from overnight PSG
219069529|NCT02539264|OTHER|Obesity|Influence of obesity on parameters derived from overnight PSG
219069530|NCT02539264|OTHER|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
219671754|NCT03250338|DRUG|Mitoxantrone|HAM regimen
219671755|NCT03250338|DRUG|Placebo Oral Tablet|Placebo will be administered orally
219671756|NCT03250338|DRUG|Fludarabine|FLAG-Ida regimen
219671757|NCT03250338|DRUG|Idarubicin|FLAG-Ida regimen
219069531|NCT00864032|DRUG|Sorafenib|400mg twice daily
219069532|NCT03446443|DRUG|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
219069533|NCT03446443|DRUG|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
219069534|NCT01059760|BEHAVIORAL|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
219069535|NCT01059760|BEHAVIORAL|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
219069536|NCT02176135|DRUG|Auranofin|3 mg tablets
219069537|NCT04717011|DIAGNOSTIC_TEST|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
219069538|NCT00421252|DRUG|clopidogrel 600 mg|Clopidogrel load \> 2hrs pre-angiography
219069539|NCT00421252|DEVICE|arterial access sheath|randomize to 5Fr vs 6Fr
219069540|NCT00385931|DRUG|Valsartan and simvastatin|
219069541|NCT03358667|PROCEDURE|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
219069542|NCT03836287|DRUG|Sofpironium Bromide Gel, 15%|Active
219069543|NCT03836287|DRUG|Vehicle|Vehicle gel
219069544|NCT06163755|DRUG|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
219069545|NCT02000245|BEHAVIORAL|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
219069546|NCT02000245|BEHAVIORAL|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
219069547|NCT00563199|BEHAVIORAL|nurse-delivered stage-matched smoking cessation counseling|
219671758|NCT03250338|DRUG|G-CSF|FLAG-Ida regimen
219671759|NCT01559610|OTHER|Intervention Group|The patients were instructed by a nurse
219671760|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
219671761|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
219671762|NCT02721914|PROCEDURE|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
219671763|NCT05418959|DIAGNOSTIC_TEST|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
219671764|NCT00458861|BIOLOGICAL|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
219671765|NCT00458861|OTHER|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
219671766|NCT00171158|DRUG|imatinib mesylate|
219671767|NCT01305772|DRUG|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.
219671768|NCT01305772|PROCEDURE|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
219671769|NCT01305772|PROCEDURE|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
219671770|NCT06019026|DEVICE|Tri-Lock|Implant Stem
219671771|NCT06019026|DEVICE|Summit|Implant Stem
218980375|NCT02956070|DRUG|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
219069548|NCT02494791|BEHAVIORAL|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
219069549|NCT00433069|DRUG|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
219069550|NCT00433069|DRUG|Interferon Alfa-2a|Standard of care for chronic hepatitis C
219069551|NCT00433069|DRUG|Ribavirin|Standard of care for chronic hepatitis C
219069552|NCT04159688|DRUG|Alcohol|Alcohol Challenge
219069553|NCT04287374|BEHAVIORAL|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
219069554|NCT04287374|BEHAVIORAL|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
219069555|NCT00854451|DRUG|omeprazole plus amoxicillin|
219069556|NCT00854451|DRUG|omeprazole plus amoxicillin|
219069557|NCT00854451|DRUG|omeprazole plus amoxicillin|
219069558|NCT00854451|DRUG|omeprazole plus amoxicillin|
219069559|NCT03661853|BEHAVIORAL|Control|60 minute psycho-education on alcohol and drugs.
219069560|NCT03661853|BEHAVIORAL|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
219069561|NCT03661853|BEHAVIORAL|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
219671772|NCT03075332|OTHER|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
219671773|NCT02844270|DEVICE|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
219671774|NCT00823602|DRUG|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
219671775|NCT00823602|DRUG|suprefact|GnRH agonist, standard protocol
219671776|NCT04710680|OTHER|no intervention|no intervention
219671777|NCT04230343|BEHAVIORAL|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
219671778|NCT04230343|BEHAVIORAL|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
219671779|NCT03536663|DEVICE|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
219671780|NCT01542086|PROCEDURE|Myocardial SPECT|
219671781|NCT01542086|PROCEDURE|64-channel coronary CT angiography (CCTA)|
219671782|NCT03312465|DEVICE|AS Domelock System|Hemi or Total Shoulder Arthroplasty
219671783|NCT04945174|BEHAVIORAL|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
219671784|NCT03361735|DRUG|Leuprolide Acetate|Intramuscular or subcutaneous injection
218980376|NCT02956070|DRUG|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
218980377|NCT05797259|DRUG|Danosumab|60 mg subcutaneous Danosumab
218980378|NCT05797259|OTHER|Normal Saline|Placebo comparator arm
219069562|NCT03661853|BEHAVIORAL|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
219671785|NCT03361735|DRUG|Goserelin Acetate|Subcutaneous injection
219671786|NCT03361735|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219671787|NCT03361735|RADIATION|Radium Ra 223 Dichloride|Given IV
219671788|NCT03361735|OTHER|Laboratory Biomarker Analysis|Correlative studies
219671789|NCT03361735|DRUG|Degarelix|Subcutaneous injection
219671790|NCT06955247|OTHER|sensory motor integration|Study group (1) sensory motor integration for 45 minutes/time ,3 days per week for 3 months Treatment program included two parts; tactile sensation and proprioception stimulation programs. Each of them accounted half of the session and in terms of the type of activity it was divided into three categories: active, passive
219671791|NCT06955247|OTHER|bobath technique|"\*study group ( 2) bobath techniquefor 45 minutes/time 3 days per week for 3 months in the form of:~1. Preparation phase~2. Intervention program (Movement facilitation \&Functional training)"
219671792|NCT06956105|DEVICE|Modius Calm|The Modius Calm device is a transdermal neurostimulation product. It consists of a battery-powered headset designed to deliver low-level energy in the form of a neurostimulation waveform that modulates the activity of the vestibular cranial nerve. The active Modius Calm device utilizes a technology called electrical vestibular nerve stimulation (VeNS). In the envisaged configuration the device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current (a maximum of 1.5mA) to the skin behind the ears over the mastoid processes.
218980379|NCT05337696|PROCEDURE|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
219671793|NCT06956105|DEVICE|Sham device|The sham device is identical in appearance. The Modius Calm sham device follows this pattern by applying some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device.
219671794|NCT04433923|DEVICE|Phototherapy with aluminum foil|
219671795|NCT04433923|DEVICE|Phototherapy without aluminum foil|
219671796|NCT00762034|DRUG|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
219671797|NCT00762034|DRUG|Pemetrexed|Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
219671798|NCT00762034|DRUG|Paclitaxel|Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
219671799|NCT00762034|DRUG|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
219671800|NCT00762034|BIOLOGICAL|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
219671801|NCT00762034|BIOLOGICAL|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
219671802|NCT02671552|DRUG|Perflutren Protein-Type A Microspheres|Given IV
219671803|NCT02671552|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
219671804|NCT03685500|DRUG|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
219671805|NCT03685500|DRUG|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
219671806|NCT02442206|DRUG|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
219671807|NCT02442206|DRUG|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
219671808|NCT01883739|OTHER|Parental Presence at Handover Rounds|
219671809|NCT00497146|DRUG|paricalcitol|2 µg capsule
219671810|NCT00497146|DRUG|placebo|placebo capsule
219671811|NCT03016468|DRUG|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
219671812|NCT03016468|DRUG|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
219671813|NCT01471444|DRUG|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
219671814|NCT01471444|DRUG|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
218980380|NCT05337696|DEVICE|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
218980381|NCT01191411|OTHER|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
218980382|NCT01191411|OTHER|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
218980383|NCT01191411|OTHER|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
219671815|NCT01471444|DRUG|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
219671816|NCT01471444|DRUG|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
219671817|NCT01471444|PROCEDURE|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
219671818|NCT01471444|DRUG|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
219671819|NCT01471444|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
219671820|NCT01225926|DEVICE|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
219671821|NCT01225926|DEVICE|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
219671822|NCT06485570|OTHER|creative drama training|"The trainings prepared by the researcher in line with the literature information on Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with creative drama teaching method to the experimental group. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
219671823|NCT06485570|OTHER|control|control group
219671824|NCT06154720|DRUG|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
219671825|NCT01956188|DIETARY_SUPPLEMENT|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
219671826|NCT01956188|DIETARY_SUPPLEMENT|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
219671827|NCT02594059|OTHER|endothelial function|measure of reactive hyperemia-peripheral artery tone index
219671828|NCT03351634|DEVICE|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
219671829|NCT06062095|PROCEDURE|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
219671830|NCT06480019|BEHAVIORAL|Interpersonal psychotherapy|Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
219671831|NCT04140812|DIAGNOSTIC_TEST|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
219671832|NCT01619072|OTHER|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
219671833|NCT01619072|OTHER|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
219671834|NCT04198909|DIAGNOSTIC_TEST|Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways|Electrocochleography is a technique that analyses the functionality of inner ear.
219671835|NCT05977855|OTHER|BPSDiary|The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
219671836|NCT06291129|PROCEDURE|Periodontal therapy|Supragingival scaling sessions were performed with ultrasonic scalers (Dabi Atlante, Rio de Janeiro, RJ, Brazil) to remove all calculus and biofilms, in addition to oral hygiene guidelines, including brushing technique and interdental cleaning with dental floss.
219671837|NCT05851638|DEVICE|Lung Oxygen measurement with GASMAS system|A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.
219671838|NCT04712409|PROCEDURE|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
219671839|NCT04712409|PROCEDURE|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
219671840|NCT04712409|PROCEDURE|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
219671841|NCT04712409|PROCEDURE|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
219671842|NCT05992402|BEHAVIORAL|ReBOOT program|This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
218980384|NCT05864755|DRUG|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
218980385|NCT03569033|DRUG|Gefapixant|Gefapixant 45 mg will be administered orally.
218980386|NCT03569033|DRUG|Placebo|Placebo tablet matching gefapixant will be administered orally.
219671843|NCT06956053|DIAGNOSTIC_TEST|Rapid ID/AST method|"1. BioFire® Film Array® Blood Culture Identification 2 BCID2 panel, bioMérieux/BioFire Diagnostics, CE marked (FDA cleared)~2. BioFire® FilmArray® Pneumonia Panels, CE marked (FDA cleared)~3. SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility test (AST) System, bioMérieux/Specific Diagnostics, CE-IVD and -IVDR marked"
219671844|NCT06956053|DIAGNOSTIC_TEST|Conventional biological methods|Usual care
218980387|NCT03561363|BEHAVIORAL|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
218980388|NCT05582031|COMBINATION_PRODUCT|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
219671845|NCT06955637|DEVICE|dental movement|Possibility to reduce the protrusion of upper incisors
219671846|NCT00437476|DRUG|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
218980389|NCT01268150|DRUG|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
218980390|NCT00553943|DRUG|Rituximab|375 mg/m2 D1
218980391|NCT00553943|DRUG|Cytarabine|50 mg D3
218980392|NCT03725852|DRUG|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
219671847|NCT00437476|DRUG|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
219671848|NCT00437476|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
219671849|NCT00437476|DRUG|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
219671850|NCT02306369|BEHAVIORAL|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
219671851|NCT02083796|PROCEDURE|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
219671852|NCT02083796|PROCEDURE|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
219671853|NCT02083796|PROCEDURE|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
219671854|NCT02083796|PROCEDURE|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
219671855|NCT02217111|BEHAVIORAL|Adventures in Voice: Pediatric Voice Therapy|
219671856|NCT05496465|DRUG|ARS-1|A single treatment of ARS-1.
219671857|NCT05496465|DRUG|Placebo|A single treatment of placebo nasal spray
219671858|NCT01031017|DRUG|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
219671859|NCT01031017|DRUG|placebo|placebo
219671860|NCT06323343|OTHER|Video Intervention|Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.
219671861|NCT06323343|OTHER|Webpage links|Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
219671862|NCT04578509|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
218980393|NCT03725852|DRUG|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
218980394|NCT01790880|BEHAVIORAL|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
219671863|NCT04578509|DIAGNOSTIC_TEST|Saliva sample|Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
219671864|NCT04578509|DIAGNOSTIC_TEST|axillary sweat sample|Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
219671865|NCT04578509|OTHER|Data collection|Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
219671866|NCT02652559|DEVICE|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
219671867|NCT02652559|DEVICE|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
218980395|NCT01790880|BEHAVIORAL|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
219208830|NCT06820073|BEHAVIORAL|Global Postural Reeducation (RPG) using the K-Stretch hammock|The intervention involves Global Postural Reeducation (RPG) using the K-Stretch hammock. This therapeutic approach focuses on sustained stretching of muscle chains to improve posture, reduce cervical and lumbar musculoskeletal discomfort, and enhance flexibility. Participants complete 12 sessions over six weeks, with two 30-minute sessions per week. Each session includes guided exercises that target muscle imbalances, improve alignment, and alleviate tension caused by prolonged sedentary behavior. The K-Stretch hammock provides support for optimized stretching and alignment during the exercises.
219671868|NCT02652559|DEVICE|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
219671869|NCT02652559|OTHER|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
219671870|NCT02652559|OTHER|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
219671871|NCT00152243|DRUG|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
219671872|NCT00152243|PROCEDURE|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
219208831|NCT06752083|DIETARY_SUPPLEMENT|AHCC® (Active Hexose Correlated Compound)|3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
219671873|NCT03747718|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
219671874|NCT03747718|OTHER|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
219671875|NCT04255758|OTHER|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
219671876|NCT03769701|PROCEDURE|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
219671877|NCT01299896|OTHER|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
219671878|NCT01299896|OTHER|Usual Care|Standard therapy to help participants with smoking cessation.
219671879|NCT04652947|DIAGNOSTIC_TEST|MRI diagnostic|no intervention, patient only have MRI
219671880|NCT04663932|PROCEDURE|immediate stenting group(one-step strategy)|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
219671881|NCT04663932|PROCEDURE|deferred stenting group (two-step strategy)|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
219671882|NCT01269619|DEVICE|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
219671883|NCT01269619|DEVICE|Static back support|A standard wrap-around sacro lumbar support
219671884|NCT03139409|PROCEDURE|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
219671885|NCT03139409|OTHER|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
218980396|NCT01191918|DRUG|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
219208832|NCT06752083|BIOLOGICAL|Gardasil 9®|Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
219671886|NCT03181945|OTHER|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
219671887|NCT03181945|OTHER|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
219671888|NCT05911789|RADIATION|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
219671889|NCT01359020|DRUG|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
218980397|NCT01191918|DRUG|Placebo plus Lithium|
219208833|NCT06671600|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic manipulative treatment(OMT) protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMT procedures performed on the treatment group will consist of~1. suboccipital decompression/release~2. base spread~3. occipitoatlantal (OA) decompression~4. venous sinus drainage~5. compression of the fourth ventricle~6. cervical myofascial (unilateral perpendicular stretch)~7. thoracic inlet release (direct or indirect)~8. Bilateral rib raising~9. thoracoabdominal diaphragm doming (direct technique)~10. pedal pump (Dalrymple lymphatic pump)"
219671890|NCT03817905|OTHER|Patient navigator|Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
218980398|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of uphill exercise|40 minutes of uphill exercise
218980399|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
218980400|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of uphill exercise|40 minutes of uphill exercise
218980401|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
218980402|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of downhill exercise|40 minutes of downhill exercise
218980403|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
219671891|NCT01586702|BEHAVIORAL|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~* Measurement of risk factors~* Assessment of medication intake~* Monitoring of antithrombotic therapy~* Joint agreement of an individual target plan~Target values for risk factors:~* Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile~* HbA1c \<7.5%~* Nicotine abstinence~* LDL \< 100mg/dl (\< 70mg/dl in high risk patients)~* Physical activity ≥ 30min \>2 x / week~Targets for pharmaceutical treatment:~* Platelet inhibitors for strokes / TIA of arterial etiology~* Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~* Cumarins (INR 2-3) or new oral anticoagulants in AF patients~* Statin treatment in patients with LDL \>100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
219671892|NCT03848897|OTHER|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
219671893|NCT03058718|OTHER|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
219671894|NCT03058718|OTHER|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
219671895|NCT02688803|DRUG|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
219671896|NCT02688803|DRUG|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
219671897|NCT02688803|DRUG|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
219671898|NCT05161026|OTHER|Bone osteodensitometry|Evaluation of bone osteodensitometry
219671899|NCT04769492|OTHER|#ChopViolence/#ChopHIV|Tailored, community-based violence prevention intervention
219671900|NCT06364436|BEHAVIORAL|Reiki energy therapy|In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
219671901|NCT02107313|DRUG|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
219671902|NCT02107313|DRUG|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
219671903|NCT00864305|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
219671904|NCT00864305|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
219671905|NCT00864305|DRUG|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
219671906|NCT04515277|DIETARY_SUPPLEMENT|40 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
219671907|NCT04515277|DIETARY_SUPPLEMENT|20 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
219671908|NCT04515277|DIETARY_SUPPLEMENT|0 g Gum acacia (FibregumTM)|300 mL of orange juice with breakfast (single use at visit)
219671909|NCT05253144|RADIATION|Radiotherapy|Radiotherapy
219208834|NCT06671600|PROCEDURE|Sham (No Treatment)|The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch.
219671910|NCT05253144|PROCEDURE|Surgery|Surgery
219671911|NCT02875717|DRUG|Acetylsalicylic acid|
219671912|NCT02875717|DRUG|low molecular weight heparin|
218980404|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
218980405|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
218980406|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
218980407|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
218980408|NCT03210623|DEVICE|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
218980409|NCT03210623|DEVICE|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
219671913|NCT00170391|BEHAVIORAL|Quarter of an Hour rule|
219671914|NCT01913574|DEVICE|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
218980410|NCT01931618|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
219671915|NCT01913574|PROCEDURE|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
219671916|NCT04123249|DRUG|Propofol|Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation
219671917|NCT04123249|DRUG|Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation；
219671918|NCT02357745|PROCEDURE|Non surgical periodontal therapy|scaling and root planing
219671919|NCT04027179|DRUG|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
219671920|NCT04027179|PROCEDURE|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
219671921|NCT04027179|DRUG|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
219671922|NCT00263419|BEHAVIORAL|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
219671923|NCT03625700|DRUG|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
219671924|NCT03513471|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
219671925|NCT03513471|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
219671926|NCT03513471|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
219671927|NCT06322277|OTHER|Analysis of biological sample|Confermation of type of infection with RT-PCR.
219671928|NCT02796521|OTHER|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
219671929|NCT02796521|OTHER|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
219671930|NCT04098796|DRUG|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
219671931|NCT04098796|DRUG|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
219671932|NCT02712918|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
219671933|NCT02712918|OTHER|Standard Care|Treatment as usual at the ward
219671934|NCT04357938|DEVICE|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
219671935|NCT04886297|DRUG|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
219671936|NCT04886297|DRUG|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
219671937|NCT00420953|DRUG|Cordarone|
219671938|NCT00888498|OTHER|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
219671939|NCT00888498|OTHER|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
219671940|NCT00888498|OTHER|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
219671941|NCT02228018|DEVICE|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
219671942|NCT01088711|DRUG|Omarigliptin|Once-weekly 50 mg capsule
219671943|NCT01088711|DRUG|Placebo|Once-weekly placebo capsule
219671944|NCT04406116|DEVICE|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
219671945|NCT05050305|DRUG|Marizomib|Intravenous Infusion
219671946|NCT05050305|DRUG|Pomalidomide|Taken orally
219671947|NCT05050305|DRUG|Dexamethasone|Taken orally
219671948|NCT01240902|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
219671949|NCT01240902|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
219671950|NCT04078854|BEHAVIORAL|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
219671951|NCT00027287|DRUG|Vitamin E|
219671952|NCT02085928|OTHER|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"* The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
219671953|NCT05524727|OTHER|Concept-guided, personalized, motor-cognitive training by means of an exergame|12 weeks, two times per week for 30-40min
219208835|NCT06739551|DRUG|Methotrexate (drug)|oral methotrexate 10 mg per week for 12 weeks
219208836|NCT06739551|DRUG|Acitretin|oral acitretin 50 mg once daily for 12 weeks
219671954|NCT05686460|BEHAVIORAL|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
219671955|NCT05686460|BEHAVIORAL|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
219671956|NCT01441245|DRUG|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
219671957|NCT00582426|DRUG|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
219671958|NCT00582426|OTHER|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
219671959|NCT00373126|DRUG|transdermal nicotine patch|
219671960|NCT06786832|BEHAVIORAL|Cognitive behavioral therapy for persistent fatigue|"The treatment is based on a treatment manual that has previously been evaluated in several randomized controlled trials for persistently fatigued patients with various types of chronic somatic disorders (primarily in specialized healthcare settings).~In this trial we have translated the treatment manual to Swedish and adopted it for implementation in a Swedish primary care setting. The treatment format is blended, meaning that the treatment is administered both via an online platform (where the participant can communicate with the therapist through asynchronous text-messages) and via face-to-face therapy sessions with the therapist."
219671961|NCT06786832|OTHER|Care as usual|Since there are no standardized, structured care programs and guidelines for the patient group, CAU may include a broad variety of psychosocial support, psychological treatment, physiotherapy, occupational therapy, pharmacological treatment, follow-up within specialist healthcare, and/or follow-up by general practitioners. An important aim of the project is to carefully map the content and scope of the care offered to patients in the study within the framework of CAU.
219671962|NCT06451666|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
219671963|NCT06451666|DRUG|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
219671964|NCT05588934|DIETARY_SUPPLEMENT|Caffeine Gum|Commercially available caffeinated gum that contains 100mg of caffeine per piece of gum.
218980411|NCT01931618|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
218980412|NCT01931618|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
218980413|NCT03557853|DRUG|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
218980414|NCT03738033|OTHER|educational platform|The platform would be opened before they entered the study.
218980415|NCT02700022|DRUG|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
218980416|NCT04738734|DEVICE|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
218980417|NCT04738734|DEVICE|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
218980418|NCT01827956|OTHER|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
218980419|NCT03072732|DEVICE|u-Cor System|Monitoring System
218980420|NCT03072732|DEVICE|ZOE Fluid Status Monitor|Monitoring System
219208837|NCT06862700|OTHER|Vasopressor Exposure Levels|This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.
219671965|NCT05588934|OTHER|Placebo Gum|Commercially available non-caffeinated gum.
219671966|NCT00872612|PROCEDURE|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
219671967|NCT00872612|PROCEDURE|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
219671968|NCT04877899|DEVICE|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
219671969|NCT02164318|OTHER|Handgrip training|
219671970|NCT02164318|DRUG|Nitroglycerin ointment|
219671971|NCT01285778|DRUG|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
219671972|NCT01649362|OTHER|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
219671973|NCT02508103|DRUG|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
219671974|NCT02508103|DRUG|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
219671975|NCT04321083|DIAGNOSTIC_TEST|INVOS|INVOS monitoring brain o2 saturation
218980421|NCT06391385|PROCEDURE|protective ileostomy|Preparation of the bowel was performed before surgery with the administration of intravenous perioperative antibiotic prophylaxis. The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn.
218980422|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
218980423|NCT05751642|BIOLOGICAL|Placebo|Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
218980424|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by SC infusion.
218980425|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
218980426|NCT03048461|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
218980427|NCT03048461|DRUG|Placebo|intradermal injections to an area of alopecia
218980428|NCT01724411|OTHER|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
218980429|NCT03361267|DIAGNOSTIC_TEST|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
219208838|NCT06596356|DRUG|[14C] TS-172|Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
219671976|NCT05233215|BEHAVIORAL|GROW (Glioma Specialists Reaching Out With Support) Support Program|Follow-up survivorship care plan for patients and caregivers
219671977|NCT01548768|DRUG|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
219671978|NCT01548768|DRUG|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
219671979|NCT02806271|BEHAVIORAL|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
218980430|NCT03361267|DIAGNOSTIC_TEST|CLO test|CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
218980431|NCT05358015|PROCEDURE|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
219208839|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
218980432|NCT02435147|DRUG|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
218980433|NCT05115578|DRUG|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
219208840|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
219208841|NCT04751331|BIOLOGICAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
219671980|NCT02806271|BEHAVIORAL|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
219671981|NCT05865158|OTHER|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
219671982|NCT01207011|DRUG|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
219671983|NCT01207011|DRUG|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
219671984|NCT04051697|BEHAVIORAL|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
219671985|NCT04156386|DIETARY_SUPPLEMENT|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
219671986|NCT04156386|DIETARY_SUPPLEMENT|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
219671987|NCT04156386|DIETARY_SUPPLEMENT|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
219671988|NCT00572871|OTHER|plyometric exercise|single bout of plyometric exercise
219671989|NCT00572871|OTHER|resistance exercise|single bout of resistance exercise
219671990|NCT00572871|OTHER|No exercise|Will not do any exercise
219671991|NCT06540560|BEHAVIORAL|My Pelvic Plan website|"Following the baseline interview, participants will receive a link to a web-based self-guided program and have access for two weeks My Pelvic Plan that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Subsequent to this, participants will then complete another brief questionnaire after a two-week interval. This questionnaire will focus on willingness to consider specific treatment modalities, credibility/expectancy for specific treatment modalities, and a brief measure assessing self-efficacy for managing symptoms."
219671992|NCT05798143|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
219671993|NCT02532062|DIETARY_SUPPLEMENT|Cholecalciferol|4,000 IU, oral, once a day for one year
219671994|NCT02532062|DIETARY_SUPPLEMENT|multivitamin|oral, once a day for one year
219671995|NCT02532062|DIETARY_SUPPLEMENT|Placebo|oral, once a day for one year
219671996|NCT03837457|DRUG|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
219671997|NCT02953483|OTHER|Red blood cells|Packed red blood cells to final hematocrit of 14%
219671998|NCT04069728|OTHER|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
219671999|NCT04069728|OTHER|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
219208842|NCT04751331|BIOLOGICAL|Saline|0.9% saline administered as an intravenous bolus
219672000|NCT04468893|BEHAVIORAL|Online Intervention Mental Health COVID-19|The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
219672001|NCT00929994|BEHAVIORAL|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
219672002|NCT01675674|OTHER|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
218980434|NCT05115578|DRUG|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
218980435|NCT05115578|DRUG|Saline solution|Group III Control
218980436|NCT05115578|DEVICE|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
218980437|NCT01753102|DRUG|Estradiol|one tablet will be inserted daily for 14 days
218980438|NCT00891007|BIOLOGICAL|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
218980439|NCT00891007|BIOLOGICAL|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
218980440|NCT00891007|BIOLOGICAL|Rouvax|Standard measles vaccine, approved in South Africa
218980441|NCT05192733|OTHER|Survey|This is a cross-sectional practice survey. There is no intervention.
218980442|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
218980443|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
218980444|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
219672003|NCT02446548|DRUG|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
219672004|NCT02446548|DRUG|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
219672005|NCT02446548|OTHER|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
219672006|NCT01214668|DRUG|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
219672007|NCT01214668|DRUG|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
219672008|NCT04624048|DIAGNOSTIC_TEST|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
219069563|NCT04529213|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
219069564|NCT00935025|DRUG|AZD1305|single and multiple oral doses, extended-release capsule
219069565|NCT00935025|DRUG|Placebo|single and multiple oral doses, capsule
219069566|NCT03264872|BEHAVIORAL|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
219069567|NCT03264872|OTHER|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
219069568|NCT04974216|DRUG|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
219069569|NCT04974216|DRUG|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
219069570|NCT04974216|DRUG|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
219069571|NCT02428868|DRUG|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
219069572|NCT02428868|DRUG|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
219069573|NCT02428868|OTHER|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
219069574|NCT04635722|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
219069575|NCT02978274|DRUG|MMF|MMF withdrawal by engraftment post haplo-SCT
219069576|NCT02978274|DRUG|MMF|MMF withdrawal by 2 month post haplo-SCT
219069577|NCT06336096|DRUG|Suzetrigine|Tablet(s) for oral administration.
219069578|NCT06336096|DRUG|Suzetrigine|Tablet(s) and Suspension for oral administration.
219069579|NCT05234138|OTHER|Blood Sample|Blood Sample
219069580|NCT02401191|DRUG|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
219550219|NCT02286466|BEHAVIORAL|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
219069581|NCT02320604|DRUG|Administration of study drug|i.v. administration of Ambisome in two different dossages
219069582|NCT02324933|DRUG|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
219069583|NCT01265069|DRUG|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
219672009|NCT01964989|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
219672010|NCT01964989|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
219672011|NCT06259149|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
219672012|NCT04145206|BEHAVIORAL|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
219672013|NCT04868578|DIETARY_SUPPLEMENT|study treatment PPI|patient take PPI every day during 12 months
219672014|NCT04868578|DIETARY_SUPPLEMENT|Placebo comparator|patient take PPI placebo every day during 12 months
219672015|NCT03014141|OTHER|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
219672016|NCT03014141|OTHER|Maltodextrin|11 g of Maltodextrin
219672017|NCT03176121|DRUG|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
219672018|NCT00005872|DRUG|rubitecan|
219672019|NCT04039425|PROCEDURE|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
219672020|NCT00556257|DRUG|Cyclosporine|Standard of care
219672021|NCT00556257|DRUG|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
219672022|NCT01344473|DEVICE|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
219672023|NCT01280071|DRUG|aminophylline|
218980445|NCT01164683|BEHAVIORAL|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
219672024|NCT01308034|DRUG|sunitinib|"All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
219672025|NCT00874913|DEVICE|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
219672026|NCT05640063|OTHER|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
219672027|NCT03441685|BEHAVIORAL|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
219672028|NCT06679855|DRUG|Milrinone infusion|An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
219672029|NCT06679855|DRUG|Placebo infusion|An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
219672030|NCT04126317|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
219672031|NCT04126317|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
219672032|NCT00104806|DIETARY_SUPPLEMENT|cholecalciferol|100 milligrams orally once a day for 28 days
219672033|NCT00104806|DRUG|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
219069584|NCT01265069|DRUG|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
219069585|NCT00250887|DRUG|Gefitnib|
219672034|NCT04829630|BIOLOGICAL|rabies vaccine|"* day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~* day 7 : questionnaire and blood sampling"
219069586|NCT00137033|DRUG|Celecoxib|
219069587|NCT00137033|DRUG|Naproxen|
219069588|NCT00137033|DRUG|ASA|
219672035|NCT00424593|DRUG|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
219672036|NCT00424593|DRUG|Placebo|every day (QD), by mouth (PO), 13 weeks
219672037|NCT01796301|DRUG|Romozosumab|Administered by subcutaneous injection once a month.
219672038|NCT01796301|DRUG|Teriparatide|Administered by subcutaneous injection once a day.
219672039|NCT00667563|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
219672040|NCT00667563|GENETIC|DNA analysis|Weeks 0, 2, 10, 26, and 52.
219672041|NCT00667563|GENETIC|polymerase chain reaction|Screening, week 36, and week 52.
219672042|NCT00667563|OTHER|cytology specimen collection procedure|Screening, week 36, and week 52.
219672043|NCT00667563|PROCEDURE|colposcopic biopsy|Screening, week 36, and week 52.
219672044|NCT00029783|PROCEDURE|Distant Healing|
219672045|NCT03701152|DEVICE|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
219672046|NCT02696174|OTHER|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
219672047|NCT03302507|PROCEDURE|BESS|Biportal endoscopic surgery
219672048|NCT03302507|PROCEDURE|ULBD|Unilateral laminotomy bilateral decompression
219672049|NCT05172401|DEVICE|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
219672050|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
219672051|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
219672052|NCT02855710|OTHER|Rhythm workers training Perceptive timing|Perceptive timing training
219672053|NCT02855710|OTHER|Rhythm workers training sensorimotor timing|Sensorimotor timing training
219672054|NCT02855710|OTHER|No Rhythm workers training|No training
219672055|NCT03229850|DRUG|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
219672056|NCT04293172|DRUG|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
219672057|NCT04293172|DRUG|Placebo|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
219672058|NCT01155349|BEHAVIORAL|InSight|A cognitive intervention designed to enhance speed of visual processing.
219672059|NCT01155349|OTHER|No contact-control group|No contact-control group.
219672060|NCT03568383|DRUG|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
219672061|NCT03568383|DRUG|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
219672062|NCT03568383|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
219672063|NCT04150653|DEVICE|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
219672064|NCT02164071|OTHER|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
218980446|NCT01164683|OTHER|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
219672065|NCT02293239|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
219672066|NCT00151086|DRUG|Estramustine|
219672067|NCT00151086|DRUG|Vinorelbine|
219672068|NCT02985021|DRUG|Carboplatin|Chemotherapy
219672069|NCT02985021|DRUG|Docetaxel|Chemotherapy
219672070|NCT02756819|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
218980447|NCT02787460|BEHAVIORAL|Behavioral Text Messages|
218980448|NCT00001095|DRUG|Indinavir sulfate|
218980449|NCT00001095|DRUG|Amprenavir|
218980450|NCT00001095|DRUG|Nevirapine|
219069589|NCT05208073|BEHAVIORAL|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
219069590|NCT04230473|BIOLOGICAL|single dose of CNCT19|"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
219069591|NCT01265329|OTHER|Negative selection|Sperm selection to continue the treatment with healthy sperm
219069592|NCT05110859|OTHER|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
219672071|NCT01138527|OTHER|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
219672072|NCT05799898|OTHER|No intervention for research purposes only|No intervention for research purposes only
219672073|NCT00985660|DRUG|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
219672074|NCT00985660|DRUG|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
219672075|NCT02204436|OTHER|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
219672076|NCT01689753|DEVICE|TEGO connector®|
219672077|NCT01689753|DRUG|Trisodium citrate|
219672078|NCT06060340|DRUG|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
219672079|NCT00264290|DRUG|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
219672080|NCT00264290|DRUG|Placebo|Placebo designed to resemble Valganciclovir
219672081|NCT04325165|DEVICE|DBS Implantation|Bilateral implantation of PPN DBS electrodes
219672082|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
219069593|NCT04699838|DRUG|Cisplatin|Cisplatin
219069594|NCT04699838|DRUG|Carboplatin|Carboplatin
219672083|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
219672084|NCT02044653|DRUG|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
219672085|NCT02044653|DRUG|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
219672086|NCT02044653|DRUG|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
219672087|NCT03405168|DRUG|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
219672088|NCT03939650|DEVICE|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
219672089|NCT02777424|DRUG|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
219672090|NCT02777424|BIOLOGICAL|Fresh Frozen Plasma|Pooled collection of plasma from donors
219672091|NCT00951158|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
219672092|NCT00951158|DRUG|Conjugated Linoleic Acid|Phase I Dose Escalation Study
219672093|NCT00475293|DRUG|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
219069595|NCT04699838|DRUG|Etoposide|Etoposide
219069596|NCT04699838|DRUG|Durvalumab|Durvalumab
219069597|NCT04699838|DRUG|Ceralasertib|Ceralasertib
219069598|NCT05124457|DRUG|Insulin Detemir|Patients are to receive insulin detemir
219672094|NCT05693753|DEVICE|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
219672095|NCT05693753|PROCEDURE|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
219672096|NCT04853966|BEHAVIORAL|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
219672097|NCT06052995|DRUG|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
219672098|NCT00230724|BEHAVIORAL|Exercise Counseling|
219672099|NCT04386161|OTHER|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
219672100|NCT06274242|DIETARY_SUPPLEMENT|Haruna|Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
219672101|NCT06274242|DIETARY_SUPPLEMENT|Placebo Powder|Isolate Soy Protein and Isomalt
219672102|NCT00000548|PROCEDURE|mechanical ventilation|
219672103|NCT04171193|DRUG|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
219672104|NCT04171193|DRUG|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
219672105|NCT00790556|DRUG|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
219672106|NCT00790556|DRUG|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
219672107|NCT00270504|DEVICE|Memokath stenting|Urethral Stenting
219672108|NCT02149563|DEVICE|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
219672109|NCT01679028|DRUG|T89 Group A|150mg single dose on day 1
219672110|NCT01679028|DRUG|Placebo Group A|150mg single dose
219672111|NCT01679028|DRUG|Placebo Group B|300mg single dose
219672112|NCT01679028|DRUG|T89 Group B|300mg single dose
219672113|NCT01679028|DRUG|Placebo Group C|225mg bid
219672114|NCT01679028|DRUG|T89 Group C|225mg bid
219672115|NCT03140098|DEVICE|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
219672116|NCT06501599|DIAGNOSTIC_TEST|Medical software (AI-based system)|Retrospective analysis of chest CT images with medical software (AI-based system)
219672117|NCT02333994|DEVICE|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
218980451|NCT00001095|DRUG|Lamivudine|
218980452|NCT00001095|DRUG|Stavudine|
218980453|NCT00001095|DRUG|Zidovudine|
218980454|NCT02589379|PROCEDURE|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
218980455|NCT06410404|PROCEDURE|transversus thoracis plane block|with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
218980456|NCT06410404|DRUG|Dexmedetomidine|the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
218980457|NCT06410404|DRUG|Levobupivacaine|A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
218980458|NCT00885053|DIETARY_SUPPLEMENT|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
218980459|NCT00885053|DIETARY_SUPPLEMENT|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
218980460|NCT01434407|OTHER|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
218980461|NCT05074043|COMBINATION_PRODUCT|antiviral, surgical|surgical debridment
218980462|NCT02120612|OTHER|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
218980463|NCT00389727|DRUG|Radiotherapy|Radiotherapy
218980464|NCT02471976|OTHER|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
218980465|NCT01561378|DRUG|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
219672118|NCT02333994|OTHER|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
219672119|NCT00177866|DRUG|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
219672120|NCT00177866|DRUG|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
219069599|NCT05124457|DRUG|Insulin NPH|Patients are to receive insulin NPH
219069600|NCT05819333|OTHER|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
219672121|NCT01692522|PROCEDURE|Intubation|visualized blind intubation
219672122|NCT01023425|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
219672123|NCT05765071|BIOLOGICAL|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
219672124|NCT05765071|BIOLOGICAL|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
219672125|NCT04017871|OTHER|MRI|MRI at baseline and J90
219672126|NCT04017871|OTHER|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
219672127|NCT04017871|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
219672128|NCT04017871|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
219672129|NCT04017871|DEVICE|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
219672130|NCT04412798|OTHER|orange juice concentrate|250mL of 100% orange juice made from concentrate
219672131|NCT04412798|OTHER|Sugar-sweetened orange-flavoured beverage|Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
219672132|NCT04412798|OTHER|Whole orange juice with skin removed|Whole orange pieces with skin removed, energy-matched to the orange juice condition
219672133|NCT00771940|DRUG|Ghrelin|Solvent, cont. infusion
219672134|NCT04399889|BIOLOGICAL|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
219672135|NCT04399889|OTHER|Placebo|Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
219069601|NCT05819333|OTHER|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
219069602|NCT04833647|DIAGNOSTIC_TEST|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
219069603|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
219672136|NCT00217581|BIOLOGICAL|Bevacizumab|Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
219672137|NCT00217581|DRUG|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
219672138|NCT00217581|DRUG|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
219672139|NCT00911417|DEVICE|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
219672140|NCT06373055|OTHER|neoadjuvant chemotherapy followed by radical cystectomy|combination of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or combination of gemcitabine and cisplatin (GC) followed by radical cystectomy
219672141|NCT01357395|DRUG|Amuvatinib|Amuvatinib 300 mg PO TID
219672142|NCT01537835|OTHER|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
219672143|NCT05055154|DEVICE|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
219069604|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
219069605|NCT02542748|DRUG|Norepinephrine|norepinephrine injection
219069606|NCT02542748|DRUG|Ephedrine|Ephedrine injection
219069607|NCT05207059|BEHAVIORAL|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
219069608|NCT06400186|BEHAVIORAL|High intensity gait training in varying external environments|Participants will engage in two 45-minutes treadmill-based gait training sessions. These training sessions will occur on separate days. One session will be performed in a natural unmodified environment. One session will be performed in a movement amplification environment. The goal of each session will be to achieve 40-minutes of walking within a target heart rate range of 70-85% of estimated heart rate max. Each session will begin and end with a 2.5 minute warm-up and cool down respectively. Participants will be given rest breaks as needed.
219069609|NCT06400186|BEHAVIORAL|Treadmill walking in varying external environments|Participants will perform a series of treadmill walking trials. Each trial will consist of 400 total steps. The first 100 steps will be performed in a natural unmodified environment. The next 200 steps will be performed in 1 of 3 external environments (natural unmodified, movement amplification, or unpredictable lateral perturbations). The final 100 steps will be performed in a natural unmodified environment. Participants will be given rest breaks between trials.
219069610|NCT03391479|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
219069611|NCT03391479|OTHER|Best Supportive Care|As required.
219069612|NCT04065438|DEVICE|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
219069613|NCT01673139|BEHAVIORAL|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
219069614|NCT01673139|BEHAVIORAL|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
219069615|NCT01673139|BEHAVIORAL|Control|Given information on recommendations for physical activity.
219069616|NCT06530823|DRUG|Pemigatinib and Durvalumab|Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
219069617|NCT04396613|PROCEDURE|Closure technique|Randomized assignment to one of three known, effective closure techniques
219069618|NCT04152733|DEVICE|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
219069619|NCT03297268|OTHER|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
219672144|NCT01345214|DRUG|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
219069620|NCT04637204|DRUG|Cabozantinib|oral therapy
219069621|NCT04637204|DRUG|Axitinib|oral therapy
219069622|NCT01262066|BEHAVIORAL|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
219069623|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
219069624|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
219069625|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
219069626|NCT06372093|DEVICE|Picterus Jaundice Pro|Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
219069627|NCT00443248|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
219069628|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
219069629|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
219069630|NCT01881308|DRUG|TNF inhibitors|
219069631|NCT01881308|DRUG|Synthetic DMARD(s)|
219069632|NCT01881308|DRUG|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
219069633|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
219069634|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
219069635|NCT03186846|DEVICE|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
219069636|NCT03186846|DEVICE|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
219069637|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
219069638|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
219069639|NCT05501093|OTHER|sample collection|Blood, plaque, and other oral samples
219672145|NCT05457179|BEHAVIORAL|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
219672146|NCT05457179|BEHAVIORAL|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
219672147|NCT02865694|OTHER|Cascade|
219672148|NCT04441632|BEHAVIORAL|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
219672149|NCT05161845|BIOLOGICAL|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
219672150|NCT06185439|BEHAVIORAL|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
219672151|NCT02020135|DRUG|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
219069640|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
219069641|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
219069642|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
219069643|NCT02372396|BEHAVIORAL|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
219672152|NCT04504578|PROCEDURE|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
219672153|NCT03513666|COMBINATION_PRODUCT|Drug intervention|anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
219672154|NCT02680171|BEHAVIORAL|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
219672155|NCT02680171|OTHER|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
219672156|NCT04192890|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
219672157|NCT01963507|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
219672158|NCT03777280|DEVICE|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
219672159|NCT03777280|DEVICE|cobalt chromium framework RPD|standard framework device
219672160|NCT01042821|PROCEDURE|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
219672161|NCT01042821|PROCEDURE|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
219672162|NCT00836446|OTHER|physical activity|physical activity routines 5 times a weeks for 12 weeks.
219672163|NCT04919603|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
219069644|NCT02372396|BEHAVIORAL|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
219672164|NCT04919603|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
219672165|NCT03077607|DRUG|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
219672166|NCT03077607|DRUG|Itraconazole|100 mg oral dose
219672167|NCT03077607|DRUG|Rifampin|600 mg oral dose
219672168|NCT06014164|DIAGNOSTIC_TEST|Interview|An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
219672169|NCT03169907|RADIATION|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
219672170|NCT00576862|DRUG|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
219672171|NCT04452552|OTHER|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
219672172|NCT00412126|DRUG|Insulin|
219672173|NCT00411723|DRUG|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
219672174|NCT00411723|DRUG|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
219672175|NCT00301457|DRUG|Anastrozole|1 mg once daily oral dose
219672176|NCT04169737|DRUG|Acalabrutinib|Given PO
219672177|NCT04169737|BIOLOGICAL|Obinutuzumab|Given IV
219069645|NCT00417001|PROCEDURE|Aroma therapy|
219672178|NCT04169737|DRUG|Venetoclax|Given PO
219672179|NCT02875795|PROCEDURE|automatic speech processing tool|
219672180|NCT05018676|DRUG|ARX788|1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
219672181|NCT01005901|DRUG|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
219672182|NCT01005901|DRUG|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
219672183|NCT00760487|DEVICE|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
219672184|NCT06229223|BEHAVIORAL|PALOMA|Partnering with Parents of Adolescent Latinos on Mental Health Assistance
219672185|NCT05535387|BEHAVIORAL|FamilyNet smart speaker/mobile application|In a 4-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
219672186|NCT05471960|OTHER|Natural progression over time|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
219672187|NCT05520866|BEHAVIORAL|PrehabPal|Web based application
219672188|NCT05789069|DRUG|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
219360346|NCT04733690|DIETARY_SUPPLEMENT|Common bean product|"Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected"
219672189|NCT05789069|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
219672190|NCT04099342|DEVICE|FEAST|FEAST with standard electrode configuration and current flow
219672191|NCT04099342|DEVICE|FEAST RP|FEAST with standard electrode configuration and reversed current flow
219672192|NCT06360588|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219672193|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219672194|NCT06360588|DRUG|Copanlisib|Given IV
219672195|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219672196|NCT01067898|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
219672197|NCT01067898|OTHER|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
219672198|NCT01067898|DIETARY_SUPPLEMENT|calcium carbonate|1000 mg calcium per os every day for one year
219672199|NCT05013242|DRUG|Zoladex|evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
219672200|NCT05013242|DRUG|Visanne|valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
219672201|NCT04430088|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
219672202|NCT04430088|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
219672203|NCT05012774|BEHAVIORAL|Speech Recognition Training|Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
219672204|NCT04465526|DIAGNOSTIC_TEST|computed tomography perfusion imaging|The new-generation dual-source computed tomography scanner Somatom® Force will be used for all CTP studies. Myocardial perfusion will be evaluated in a stress dynamic CT protocol. The scan range will be determined based on a low-dose non-contrast scan. Subsequently, regadenoson will be administered intravenously at a single dose of 0.4 mg, and followed after 50 seconds delay by 35 mL of the iodinated contrast agent (iohexol, concentration 350 mg I/mL) injected at the flow rate of 5 mL/s. Finally, low-dose non-contrast dual-energy CT scan will be performed 5-6 min after the dynamic scan to assess late enhancement of the myocardium.
219672205|NCT00338221|DRUG|alanyl-glutamine|
219672206|NCT00338221|DRUG|glycine|
219672207|NCT02785562|OTHER|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
219672208|NCT06087497|OTHER|Early mobilization|Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
219672209|NCT05811884|DEVICE|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
219672210|NCT05108584|PROCEDURE|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
219672211|NCT05108584|PROCEDURE|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
219672212|NCT05108584|PROCEDURE|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
219672213|NCT03887377|DRUG|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
219672214|NCT03887377|OTHER|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
219672215|NCT05430659|OTHER|observational study|Retrospective observational study
219672216|NCT05885646|DRUG|Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
219672217|NCT05617963|DRUG|Durvalumab|Patients showing a disease control (defined as stable disease \[SD\], partial response \[PR\], or complete response \[CR\] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
219672218|NCT06384053|COMBINATION_PRODUCT|Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined|The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
219672219|NCT06384053|RADIATION|Radiotherapy (RT)|Radiotherapy is applied.
219672220|NCT06439524|DRUG|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate|if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
219672221|NCT03079973|DRUG|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
219672222|NCT03079973|DRUG|Vehicle of P-3073|Once daily for 24 weeks.
219672223|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
219672224|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
219672225|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
219672226|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
219069646|NCT05629351|OTHER|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
219069647|NCT06958081|DEVICE|Active transcranial direct current stimulation (tDCS)|2.0 mA anodal stimulation applied over FCz with cathode over Fp2 for 30 minutes using a transcranial direct current stimulation device.
219069648|NCT06958081|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham stimulation mimicking the sensations of tDCS; the current will be turned off after 30 seconds while maintaining electrode placement over FCz and Fp2.
219069649|NCT03955393|OTHER|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
219672227|NCT02716506|PROCEDURE|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
219672228|NCT01308996|DEVICE|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
219672229|NCT01308996|PROCEDURE|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
219672230|NCT04838847|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection
219672231|NCT04648852|OTHER|Heart failure risk estimation|Evaluation by heart failure risk score
219672232|NCT05750173|OTHER|Streamlining of the pre-procedural patient pathway|"Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety."
219672233|NCT03894033|DEVICE|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
219672234|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
219672235|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
219672236|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
219672237|NCT05526248|DRUG|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
219672238|NCT05526248|DRUG|Enzalutamide|tablet, oral
219672239|NCT04885231|BEHAVIORAL|Perioperative Pain Management Education and Counseling|All patients will receive both verbal postoperative pain management education and counseling as well as a written handout. Multi-modality non-opioid methods of pain control will be thoroughly discussed.
219672240|NCT04977830|DEVICE|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
219672241|NCT02387229|DRUG|Rivaroxaban|15 mg
219672242|NCT02387229|OTHER|standard of care|
219672243|NCT06391229|BEHAVIORAL|Project Support|"Caregivers will receive up to four, 60- to 90-minute sessions focused on teaching two parenting skills - attentive listening and comforting. Attentive listening involves providing accurate and timely responses to show interest and keep the child engaged until they are ready to end the conversation. Comforting involves using the same attentive listening skills when the child is upset or distressed. Effective mastery of the listening and comforting skills also requires caregivers to withhold any non-listening or non-comforting responses (e.g., interruptions, criticisms).~The program is individually tailored such that caregivers with stronger skills could complete the program in less time (i.e., fewer sessions). Service providers educate caregivers about the skills, then engage in an iterative process of modeling the skills, engaging the caregivers in behavioral practice, and providing tailored, supportive feedback to help caregivers gain mastery."
219672244|NCT04442061|DEVICE|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
219069650|NCT05061121|OTHER|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
219360347|NCT06409676|PROCEDURE|ERAS protocols|Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
219360348|NCT03592160|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
219672245|NCT04442061|DEVICE|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
219672246|NCT04442061|DEVICE|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
219672247|NCT04442061|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
219672248|NCT04442061|GENETIC|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
219672249|NCT04442061|OTHER|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
219208843|NCT06862232|PROCEDURE|"Modified Winograd Bird Flap Technique"|"In the first group (n=36), the modified Winograd Bird Flap technique will be performed for medially ingrown toenails. Local anesthesia with 1% lidocaine will be administered at the base of the first toe, and a temporary tourniquet will be applied using a sterile glove to minimize bleeding.~This technique modifies the Winograd method, optimizing functional and cosmetic outcomes while reducing recurrence rates. A sparrow-shaped incision will be made, encompassing the lateral nail bed, proximal germinal matrix, and underlying bone tissue, improving surgical access while preserving the healthy nail structure.~Granulated and infected tissue will be excised completely down to the periosteum to prevent recurrence. The wound will be sutured using 3/0 prolene sutures, ensuring optimal healing and minimal scarring. This method aims to reduce pain, shorten recovery time, and improve patient satisfaction compared to traditional approaches."
219672250|NCT03836209|DRUG|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
219672251|NCT03836209|DRUG|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
219672252|NCT03836209|DRUG|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
219672253|NCT03836209|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
219672254|NCT05350813|PROCEDURE|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
219672255|NCT05350813|PROCEDURE|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
218980466|NCT01561378|DRUG|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
219672256|NCT05679349|OTHER|Survey Administration|Complete survey
219672257|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
219672258|NCT05679349|OTHER|Survey Administration|Complete survey
219069651|NCT04297540|DEVICE|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
219672259|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
219672260|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
219672261|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
219672262|NCT05679349|OTHER|Survey Administration|Complete survey
218980467|NCT01561378|DEVICE|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
218980468|NCT06174259|OTHER|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
218980469|NCT02385370|DRUG|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
219672263|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
219672264|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
219672265|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
219672266|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
219672267|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
218980470|NCT02385370|DRUG|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
218980471|NCT04756869|OTHER|COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology|Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
218980472|NCT01050491|DRUG|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
218980473|NCT01050491|DRUG|placebo|placebo, one per day, during one year. Bronchial fibroscopy
219672268|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
219672269|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
219672270|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
219672271|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
219672272|NCT04146558|DRUG|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
218980474|NCT06333093|PROCEDURE|Cold snare|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
218980475|NCT02645721|BEHAVIORAL|Extended self-help program with guidance|See arm description for Experimental
218980476|NCT02645721|BEHAVIORAL|Briefer Self-help program, no guidance|See arm description for Active Comparator
218980477|NCT02645721|BEHAVIORAL|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
219672273|NCT04146558|OTHER|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
219672274|NCT02913781|PROCEDURE|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
218980478|NCT00973674|DRUG|Premarin IV|One time dose of Premarin IV
218980479|NCT00973674|DRUG|Placebo|One time dose of Placebo
218980480|NCT02666885|RADIATION|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
218980481|NCT03274271|BEHAVIORAL|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
219672275|NCT02913781|PROCEDURE|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
219672276|NCT03927326|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
219672277|NCT06364176|DRUG|Losartan|Treatment with losartan through week 12
219672278|NCT06364176|DRUG|Placebo|Treatment with placebo through week 12
219672279|NCT05800210|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
219672280|NCT00604747|OTHER|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
219672281|NCT01381380|PROCEDURE|Manual therapy|Manual therapy, once a week for 8 weeks
219672282|NCT01233752|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
219672283|NCT01424241|DRUG|Sandostatin LAR|Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
219672284|NCT00005049|DRUG|carboplatin|
219672285|NCT00005049|DRUG|cisplatin|
219672286|NCT00005049|DRUG|floxuridine|
219672287|NCT05644288|OTHER|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
219672288|NCT05259917|DRUG|Placebo|Placebo to KVD900 Tablet
219672289|NCT05259917|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
219672290|NCT05259917|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
219672291|NCT05133336|DRUG|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
218980482|NCT03274271|BEHAVIORAL|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
218980483|NCT03274271|BEHAVIORAL|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
218980484|NCT03274271|BEHAVIORAL|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
219672292|NCT05133336|DRUG|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
219672293|NCT05133336|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
218980485|NCT00014261|BIOLOGICAL|PEG-interferon alfa-2b|
218980486|NCT00014261|DRUG|temozolomide|
218980487|NCT04087174|DRUG|Capivasertib|Patients will receive multiple oral dose of capivasertib.
218980488|NCT04087174|DRUG|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
219672294|NCT06277739|PROCEDURE|Spinal Manipulative Therapy|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment. If a cavitation (ie, an audible pop) occurred, the treatment was considered complete. If no cavitation was produced, the participant was repositioned and the manipulation was attempted again. A maximum of 2 attempts per side was permitted. If no cavitation was produced after the 4 attempts (ie, 2 per side), the treatment was considered complete.
219672295|NCT06277739|OTHER|Sham Laser Treatment|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
219672296|NCT02656511|DRUG|Dolutegravir|Dolutegravir 50 mg PO daily
219672297|NCT02656511|DRUG|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
219672298|NCT05548972|DEVICE|G7 Dual Mobility with Vivacit-E bearing|hip arthroplasty with G7 Dual Mobility Vivacit-E bearing
219672299|NCT05548972|DEVICE|G7 Dual Mobility Longevity bearing|hip arthroplasty with G7 Dual Mobility Longevity bearing
218980489|NCT04087174|DRUG|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
218980490|NCT02447562|DEVICE|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
218980491|NCT02447562|OTHER|Phone-based care group|
218980492|NCT02447562|OTHER|Usual care group|
218980493|NCT00549380|DEVICE|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
218980494|NCT02838446|PROCEDURE|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
219672300|NCT06305559|DRUG|obicetrapib 10 mg + ezetimibe 10 mg FDC daily|Active treatment
219672301|NCT06305559|OTHER|Placebo|Baseline lipid modifying therapy
219672302|NCT05180565|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
219672303|NCT02831946|DEVICE|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
219672304|NCT02831946|DEVICE|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
219672305|NCT00482170|DEVICE|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
219672306|NCT00482170|DEVICE|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
219672307|NCT02025270|BIOLOGICAL|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
219672308|NCT06149403|GENETIC|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
219672309|NCT06149403|GENETIC|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
219672310|NCT05090267|DIETARY_SUPPLEMENT|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
219672311|NCT05090267|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
219672312|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Photon Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
219672313|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Proton Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).
219672314|NCT06392295|DRUG|Androgen Deprivation Therapy|Androgen deprivation therapy will be administered as per standard of care.
219672315|NCT06392295|DRUG|Androgen Receptor Signaling Inhibitor|Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
218980495|NCT05352373|DIETARY_SUPPLEMENT|calcium|calcium carbonate
218980496|NCT05352373|DIETARY_SUPPLEMENT|placebo|sodium bicarbonate
218980497|NCT00978471|DRUG|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
218980498|NCT00116428|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
219069652|NCT04297540|DEVICE|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
219069653|NCT05761431|DRUG|SYHX2008 injection|Subcutaneous administration on Day 1.
219069654|NCT05761431|DRUG|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
219069655|NCT05761431|DRUG|Sandostatin ® injection|Subcutaneous administration on Day 1.
219069656|NCT05761431|DRUG|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
219069657|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
219069658|NCT00762125|BEHAVIORAL|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
219069659|NCT00762125|BEHAVIORAL|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
219069660|NCT00762125|BEHAVIORAL|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
219672316|NCT06318156|DIAGNOSTIC_TEST|Infrared thermal imaging|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
219672317|NCT06625463|BEHAVIORAL|Home based cardiac rehabilitation|12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
219672318|NCT03489629|DRUG|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
219672319|NCT03489629|DRUG|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
219672320|NCT03489629|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
219672321|NCT03489629|DRUG|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
219672322|NCT03489629|BEHAVIORAL|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
219672323|NCT04185272|BIOLOGICAL|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
219672324|NCT03808103|BIOLOGICAL|Placebo|Orally, twice a day, for a period of fifteen days
219672325|NCT03808103|BIOLOGICAL|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
219672326|NCT06104631|OTHER|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
219672327|NCT06104631|OTHER|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
219672328|NCT05339165|BEHAVIORAL|Psychotherapy|
219069661|NCT04349787|OTHER|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
219672329|NCT00442481|DRUG|Escitalopram|
219672330|NCT00442481|PROCEDURE|A baseline overnight polysomnography (oPSG)|
219672331|NCT04698083|DIAGNOSTIC_TEST|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
219672332|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
219672333|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
219672334|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
219672335|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
219672336|NCT05516771|DEVICE|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
219672337|NCT06055803|BEHAVIORAL|Intake Session|Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.
219672338|NCT06055803|BEHAVIORAL|Individual Sessions|Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.
219672339|NCT06055803|BEHAVIORAL|Group Sessions|Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.
219672340|NCT06055803|BEHAVIORAL|Graduation|At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention
219672341|NCT06055803|BEHAVIORAL|Exercise|Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
219672342|NCT06666335|DRUG|Anakinra|Subcutaneous injections once daily for 6 months
219672343|NCT06949592|DIETARY_SUPPLEMENT|Placebo|Intake of 400 mg placebo (maltodextrin; encapsulated) in the morning (09:00)
219672344|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the morning (09:00)
219672345|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the evening (19:00)
219672346|NCT04006262|DRUG|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~\- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
219672347|NCT04006262|DRUG|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
219672348|NCT06402357|DEVICE|Focal One high intensity focused ultrasound device|Participants will be treated with one session of high intensity focused ultrasound using the Focal One device.
219672349|NCT04427488|OTHER|Morning Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
219672350|NCT04427488|OTHER|Evening Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
219672351|NCT02627482|DEVICE|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
219672352|NCT04050085|BIOLOGICAL|Nivolumab|Given IV
219672353|NCT04050085|RADIATION|Radiation Therapy|Undergo radiation therapy
219672354|NCT04050085|DRUG|TLR9 Agonist SD-101|Given intratumorally
219672355|NCT03611101|COMBINATION_PRODUCT|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
219672356|NCT03611101|DRUG|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
219069662|NCT04349787|OTHER|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
219069663|NCT01018901|OTHER|Survey Administration|Patients complete survey
219069664|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
219069665|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
219069666|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
219208844|NCT06862232|PROCEDURE|Classic Winograd Technique|"The classic Winograd technique, a widely used traditional surgical approach, will be performed. Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A linear incision will be made to separate the nail bed from the soft tissue, followed by the excision of the lateral nail bed and germinal matrix in a linear fashion to ensure complete removal of the affected nail portion. The wound will then be sutured using 3/0 prolene sutures.~This method is a standard approach for ingrown toenail surgery, offering high recurrence prevention rates but carrying a risk of cosmetic and structural nail alterations."
219672357|NCT03611101|DEVICE|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
219672358|NCT00983138|DRUG|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
219069667|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
219069668|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
219069669|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
219069670|NCT03298126|PROCEDURE|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
219069671|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
219069672|NCT01435577|DRUG|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
219069673|NCT01435577|DRUG|Matching Placebo|Maximum 12 administrations over 48 hours
219069674|NCT04523545|DEVICE|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
219069675|NCT05797285|DEVICE|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
219069676|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
219069677|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
219069678|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
219069679|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
219069680|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
219208845|NCT06862232|PROCEDURE|Modified Noel Technique|"Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A 4-6 mm semi-elliptical incision will be made adjacent to the lateral borders of the nail bed to access the granulated tissue.~Unlike the Bird Flap technique, this method preserves both the nail bed and proximal germinal matrix, ensuring that only the inflamed soft tissue and granulated tissue are excised. The remaining tissue will be sutured subungually using 3/0 prolene sutures, promoting proper healing and maintaining the nail's structural integrity. This technique is designed to be less invasive while effectively treating infected and inflamed tissue."
219208846|NCT06778889|BEHAVIORAL|Undergraduate Medical Students|This is an observational study without any intervention. Data will be collected using standardized questionnaires to assess physical activity, mental health, and stress levels in the participants.
219672359|NCT03838510|BEHAVIORAL|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
219672360|NCT04686825|DRUG|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
219672361|NCT04686825|DRUG|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
219672362|NCT04686825|DRUG|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
219672363|NCT04686825|DRUG|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
219069681|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
219069682|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
219069683|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
219069684|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
219069685|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
219069686|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
219069687|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
219069688|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
219208847|NCT06858033|DEVICE|Clear aligner|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
219672364|NCT02629042|PROCEDURE|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
219672365|NCT02629042|DRUG|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
219672366|NCT04260568|OTHER|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
219672367|NCT00251498|DRUG|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
219672368|NCT04075136|DRUG|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
219672369|NCT04075136|DEVICE|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
219672370|NCT04075136|DRUG|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
219672371|NCT04075136|DRUG|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
219672372|NCT02394184|PROCEDURE|transcatheter aortic valve replacement|
219672373|NCT02344771|PROCEDURE|Elective colon cancer surgery|
219672374|NCT02853071|DRUG|Estramustine|
219672375|NCT02853071|DRUG|standard practice|standard practice
218980499|NCT00116428|DRUG|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
218980500|NCT02321631|DIETARY_SUPPLEMENT|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
218980501|NCT02321631|DIETARY_SUPPLEMENT|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
218980502|NCT00365651|PROCEDURE|Youth Soccer|
218980503|NCT04504279|BIOLOGICAL|FB-401|Topical application
218980504|NCT04504279|BIOLOGICAL|Placebo|Vehicle
219208848|NCT06858033|DEVICE|Labiolingual spring hawley|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
219208849|NCT06879860|PROCEDURE|3D Mesh Single-Suture Fixation|3D mesh fixation in 1 points
219672376|NCT01474161|DRUG|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
219672377|NCT01474161|DRUG|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
219672378|NCT01474161|DRUG|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
219672379|NCT01474161|DRUG|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
219672380|NCT01474161|DRUG|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
219672381|NCT01474161|DRUG|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
219672382|NCT02202889|BEHAVIORAL|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
219672383|NCT00121290|DRUG|SJG-136|Given IV
219672384|NCT00121290|OTHER|laboratory biomarker analysis|Correlative studies
219672385|NCT00121290|OTHER|pharmacological study|Correlative studies
219672386|NCT05061602|DIAGNOSTIC_TEST|Evaluation of biomechanics and viscoelastic properties of plantar fascia|The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
219672387|NCT05735275|DRUG|SHR-A2102|All participants receive SHR-A2102 alone.
219672388|NCT04085159|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
219672389|NCT02504047|PROCEDURE|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
219672390|NCT05772611|BIOLOGICAL|Genetic and immunology tests|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes."
219672391|NCT01539928|OTHER|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
219672392|NCT05497817|BEHAVIORAL|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
219672393|NCT05497817|BEHAVIORAL|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
219672394|NCT01459835|BEHAVIORAL|media diet|advice and tips and tools for healthy non violent TV viewing
219672395|NCT01459835|BEHAVIORAL|nutritional intervention|advice on healthy eating
219672396|NCT01658904|DRUG|Carfilzomib|
219672397|NCT01658904|DRUG|Melphalan|
219672398|NCT01658904|DRUG|Filgrastim|
219672399|NCT04544839|DEVICE|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
219672400|NCT00080483|DRUG|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
219672401|NCT00080483|DRUG|testosterone|AndroGel transdermally 5 g a day for two years
219672402|NCT00161694|DIETARY_SUPPLEMENT|sucrose solution|
219672403|NCT05062720|RADIATION|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
219672404|NCT03801577|DIETARY_SUPPLEMENT|Hepaxa|High concentrate EPA and DHA
219208850|NCT06879860|PROCEDURE|3D mesh Non-FIxation|3D mesh fixation with non-flxation
219069689|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
219069690|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
219069691|NCT01196975|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
219069692|NCT01196975|BIOLOGICAL|FluLavalTM-VB|Single intramuscular dose
219069693|NCT01196975|BIOLOGICAL|FluLavalTM-YB|Single intramuscular dose
219069694|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
219069695|NCT00554866|OTHER|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
219069696|NCT01365494|BIOLOGICAL|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
219069697|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
219069698|NCT03183427|DIAGNOSTIC_TEST|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
219069699|NCT01024322|DRUG|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
219069700|NCT01024322|DRUG|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
219069701|NCT01024322|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
219069702|NCT03399695|PROCEDURE|preoxygenation|spontaneous breathing
219069703|NCT00411567|DRUG|inhaled corticosteroid therapy|
219069704|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
219672405|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
219069705|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
219069706|NCT06235216|DRUG|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
219069707|NCT03516318|BEHAVIORAL|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
219069708|NCT06961435|BIOLOGICAL|Vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
219069709|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
219069710|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
219672406|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
219672407|NCT05415514|OTHER|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
219672408|NCT02469012|DRUG|Combination #1|Sofosbuvir + Ribavirin
219672409|NCT02469012|DRUG|Combination #2|Sofosbuvir + Daclatasvir
219672410|NCT02469012|DRUG|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
219672411|NCT02469012|DRUG|Combination #4|Sofosbuvir + Ledipasvir
219672412|NCT02469012|DRUG|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
219672413|NCT01476397|OTHER|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
219672414|NCT01476397|OTHER|Test infant formula|partially hydrolyzed whey formula with probiotic
219672415|NCT05840549|PROCEDURE|TURP|TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
219672416|NCT05840549|PROCEDURE|UroLift|UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
219672417|NCT04161105|PROCEDURE|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
219672418|NCT00386074|DRUG|NaFeEDTA, Electrolytic Iron|
219672419|NCT01251159|GENETIC|mutation analysis|
219672420|NCT01251159|GENETIC|polymerase chain reaction|
219672421|NCT01251159|OTHER|immunologic technique|
219672422|NCT01251159|OTHER|laboratory biomarker analysis|
219672423|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 \& W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
219672424|NCT03474094|COMBINATION_PRODUCT|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 \& W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
219672425|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 \& W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
219069711|NCT00781625|DIETARY_SUPPLEMENT|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
219069712|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069713|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069714|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069715|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069716|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069717|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219672426|NCT05441891|OTHER|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH \& Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
219208851|NCT06876376|PROCEDURE|intraoperative ultrasound for the assessment of bowel deep infiltrating endometriosis|Women with posterior compartment deep infiltrating endometriosis with or without bowel involvement scheduled for surgical treatment at the Department of Obstetrics, Gynecology, and Reproductive Medicine of Dexeus University Hospital.
219208852|NCT06882161|BIOLOGICAL|Acetal resin|Effect of acetal resin versus Polyether ether ketone (PEEK) partial dentures on abutment teeth supporting structures in Kennedy class I mandibular partial denture cases
218980505|NCT00743899|PROCEDURE|The aggressive group|Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.
218980506|NCT00743899|PROCEDURE|The conservative group|Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
218980507|NCT02563951|DRUG|GNS Spray 0.5mg|
218980508|NCT02563951|DRUG|GNS Spray 1.0mg|
218980509|NCT02563951|DRUG|GNS Spray 2.0mg|
218980510|NCT02563951|DRUG|Kytril 1mg (IV injection)|
218980511|NCT02563951|DRUG|Kytril 1mg (Tablet)|
218980512|NCT02387931|DIETARY_SUPPLEMENT|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
218980513|NCT02387931|DIETARY_SUPPLEMENT|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
218980514|NCT02387931|OTHER|Placebo|Placebo capsule, 2 taken daily
218980515|NCT00020774|DRUG|gemcitabine hydrochloride|
218980516|NCT00020774|DRUG|lonafarnib|
218980517|NCT00020774|PROCEDURE|conventional surgery|
218980518|NCT06191523|OTHER|Control Group|The control group will receive standard therapy and placebo.
218980519|NCT06191523|DRUG|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
218980520|NCT03452228|DRUG|evinacumab|Administered by Intravenous (IV)
218980521|NCT03452228|DRUG|Placebo|Administered by Intravenous (IV)
218980522|NCT02699359|DEVICE|HS-1000 recording|
218980523|NCT05377008|BEHAVIORAL|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
218980524|NCT01725607|DRUG|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
218980525|NCT01725607|PROCEDURE|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
218980526|NCT02713204|DRUG|REGN910-3|
218980527|NCT02713204|DRUG|Intravitreal Aflibercept Injection (IAI)|
218980528|NCT00669396|DRUG|Copper T380 IUD|Copper T380 IUD
218980529|NCT00669396|DRUG|levonorgestrel|1.5 mg
218980530|NCT01222624|DRUG|PankoMab-GEX™|
218980531|NCT02395783|DRUG|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
219672427|NCT05418660|DRUG|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
219672428|NCT04184596|OTHER|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
219672429|NCT01050335|BEHAVIORAL|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
219672430|NCT05158842|DEVICE|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
219672431|NCT02134392|BIOLOGICAL|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
219672432|NCT03264534|PROCEDURE|limbal relaxing incisions|Manually performed surgical procedure
219672433|NCT03264534|PROCEDURE|astigmatic keratotomy|femtosecond laser guided surgical procedure
219672434|NCT00462449|DEVICE|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
219672435|NCT05537649|DIETARY_SUPPLEMENT|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
219672436|NCT01941836|DRUG|ETC-1002|Patients receive ETC-1002
219672437|NCT01941836|DRUG|Ezetimibe|Patients receive ezetimibe
219672438|NCT02972749|BEHAVIORAL|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
219672439|NCT03112733|DIAGNOSTIC_TEST|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
219672440|NCT06528509|BEHAVIORAL|AI-Generated Informative Videos|"Participants in the experimental arm will receive an AI-generated video designed to provide comprehensive information about cataract surgery. The video will cover key aspects of the procedure, including the nature of the surgery, potential risks, benefits, and postoperative care. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.~The video will be delivered to participants via a secure link sent to their mobile devices or email. Patients can watch the video at their convenience, and they are encouraged to view it as many times as necessary to fully understand the information provided. The video link will be provided once after the initial clinic appointment, but patients can access and watch the video multiple times.~The videos will be created using the Synthesia platform, which uses artificial intelligence to generate realistic, photo-realistic digital avatars that deliver the information in a personalized and engaging manner."
219672441|NCT06528509|BEHAVIORAL|Standard Written Information Brochures|Participants in the control arm will receive traditional written information brochures about cataract surgery. These brochures are designed to deliver detailed and essential information in a clear and understandable format. The brochures will be handed to participants during their face-to-face clinic appointment. Patients can read the material at their convenience and keep it for future reference. These brochures follow standardized guidelines and recommendations to ensure that all relevant information is included and presented in an accessible manner. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
219672442|NCT01762449|OTHER|Followup survey|
219672443|NCT01160094|DRUG|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
219672444|NCT00970515|PROCEDURE|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
219672445|NCT00970515|PROCEDURE|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
219672446|NCT02563691|RADIATION|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
219672447|NCT06730165|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation of the vagus nerve through the tragus and concha in the ear
219672448|NCT06730165|DEVICE|Transcutaneous Auricular Trigeminal Nerve Stimulation|Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
219672449|NCT04667533|DRUG|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg"
219672450|NCT02444039|DEVICE|SL-D301|Slit Lamp
219672451|NCT02444039|DEVICE|DC-4|Digital Camera Attachment
219672452|NCT02444039|DEVICE|SL-3G|Slit Lamp
219672453|NCT04333225|DRUG|Hydroxychloroquine|Weekly treatment in individuals at high risk
219672454|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
219672455|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
219672456|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
219672457|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
219672458|NCT01703559|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
219672459|NCT02356107|DRUG|5-hydroxytryptophan and Creatine monohydrate|
219672460|NCT06188845|OTHER|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
219672461|NCT01140828|DRUG|Rabeprazole|Rabeprazole 20mg once daily
219672462|NCT01140828|DRUG|Rabeprazole Placebo|one tab once daily
219672463|NCT03518411|OTHER|Cognitive Behavioral Therapy|One-Session Unified Protocol
219672464|NCT00789685|DRUG|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
219672465|NCT03031041|PROCEDURE|Ultrasound-guided short-axis hydrodissection with 5cc normal saline|Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
219672466|NCT03031041|PROCEDURE|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
219672467|NCT00085813|DRUG|Ispinesib|
219672468|NCT01296594|OTHER|Usual Care|Usual Care
219672469|NCT01296594|BEHAVIORAL|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
219672470|NCT03079076|DRUG|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
219672471|NCT03079076|DRUG|Saline|2 ml saline subcutaneously bilaterally
219672472|NCT05908747|DRUG|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
219672473|NCT03293446|DIAGNOSTIC_TEST|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
219672474|NCT06217744|BEHAVIORAL|Automated Intervention|Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.
219672475|NCT06217744|BEHAVIORAL|Blended Intervention|Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
219208853|NCT06877442|DIAGNOSTIC_TEST|serum level of neurofilament light chain|labarotory investigation to evaluate serum level of neurofilament light chain
219672476|NCT04399538|DRUG|PF-06865571|Tablet
219672477|NCT04399538|DRUG|PF-05221304|Tablet
219672478|NCT04399538|DRUG|Placebo|Tablet
219672479|NCT06366438|BEHAVIORAL|ABC-teen|See above
219672480|NCT06366438|BEHAVIORAL|ParentWeb|See above
219672481|NCT03420287|COMBINATION_PRODUCT|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
219672482|NCT03420287|OTHER|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
219672483|NCT01420016|OTHER|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR \>= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
219672484|NCT01438372|DRUG|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
219672485|NCT01438372|DRUG|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
219672486|NCT04026711|DRUG|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
219672487|NCT04026711|DRUG|Placebo oral tablet|Placebo daily for 12 weeks
219069718|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069719|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219069720|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
219069721|NCT02302079|DRUG|ASP8232|oral capsule
219672488|NCT05112159|DRUG|IPG1094|The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.
219672489|NCT05112159|DRUG|placebo|Matching placebo tablets to IPG1094 50mg and 100mg
219069722|NCT02302079|DRUG|ranibizumab|intravitreal (IVT) injection
219069723|NCT02302079|DRUG|Placebo|oral capsule
219069724|NCT02302079|OTHER|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
219069725|NCT04709536|DRUG|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
219208854|NCT06885554|DEVICE|SANA|SANA is an audio-visual stimulation device found to reduce symptoms commonly found in AjDs. SANA is an eye mask that delivers coordinated pulses of light and sound that facilitate relaxation in the wearer. The device's mechanism of action is neuromodulation through audiovisual stimulation (AVS). When the brain receives a stimulus through the eyes or ears, it emits a responsive electrical charge, called a Cortical Evoked Response (CER). The brain responds by synchronizing to it, a process known as Frequency Following Response (FFR). FFR can be used to trigger each electrical pattern to facilitate a state of relaxation. The Sana device utilizes AVS to induce FFR.
219672490|NCT03447964|OTHER|dosing of sphingolipids|\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
219672491|NCT00636961|DRUG|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
219672492|NCT00636961|DRUG|Placebo|Matching placebo devices and hard gelatin capsules
219672493|NCT05358977|BIOLOGICAL|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of \< 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
219069726|NCT04709536|DRUG|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
219069727|NCT05511987|DEVICE|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
219069728|NCT05511987|DEVICE|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
219069729|NCT03320447|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
219069730|NCT03320447|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
219208855|NCT06746467|DEVICE|pentacam|evaluate corneal changes by pentacam
219208856|NCT06732167|PROCEDURE|GBR Lyoplant|GBR surgical procedure with simultaneous implant placement including membrane placement
219208857|NCT06732167|PROCEDURE|GBR Bio-Gide|GBR surgical procedure with simultaneous implant placement including membrane placement
219208858|NCT06739837|DIAGNOSTIC_TEST|traditional physiotherapy|Participants in this arm will undergo traditional physiotherapy exercises for managing tennis elbow.
219672494|NCT02181218|DRUG|Romidepsin|
219672495|NCT02181218|DRUG|Gemcitabine|
219672496|NCT02181218|DRUG|Oxaliplatin|
219672497|NCT02181218|DRUG|Dexamethasone|
219672498|NCT02181218|DRUG|Pegfilgrastim|
219672499|NCT01904630|GENETIC|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
219672500|NCT06618547|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
219672501|NCT02572960|DRUG|Valsartan|2 weeks of Valsartan 80 mg per day
219672502|NCT02572960|DRUG|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
219672503|NCT02572960|DIETARY_SUPPLEMENT|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
219672504|NCT02572960|DIETARY_SUPPLEMENT|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
219672505|NCT07016516|DRUG|PRT-064040 nasal spray|A single dose of PRT-064040 nasal spray at one of six dose levels
219672506|NCT07016516|DRUG|Placebo|A single dose of Placebo at one of six dose levels
219672507|NCT07016516|DRUG|PRT-064040 nasal spray|Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
219672508|NCT07016516|DRUG|Placebo|Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
219672509|NCT01530724|OTHER|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
219672510|NCT01530724|OTHER|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
219672511|NCT00410059|DRUG|Erlotinib|150 mg by mouth daily x 28 days
219672512|NCT07016932|BEHAVIORAL|Education with mobile application|"The I Can Do It Independently mobile application developed by the researchers includes two training videos on hand hygiene and menstruation management. Adolescents will be asked to play the games related to the training after watching the training videos. Thus, it is aimed for the participant to reinforce the training. The mobile application was developed by a multidisciplinary team of special education, nurse, midwife and software engineering academicians specifically for female adolescents with mild intellectual disabilities. Adolescents in the intervention group will be asked to use the mobile application for approximately 30 minutes every day. (https://play.google.com/store/apps/details?id=com.hookey.bagimsizyapabilirim\&pcampaignid=web\_share)"
219672513|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
219672514|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
219672515|NCT05749497|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
219672516|NCT07022561|BEHAVIORAL|Social Prescribing|A social prescribing intervention is a non-clinical approach to improving health and wellbeing by connecting individuals to community-based services and activities that address social, emotional, and practical needs. These may include arts programs, physical activity, peer support, volunteering, or nature-based activities. Facilitated by a link worker or navigator, social prescribing is tailored to the individual and aims to enhance mental health, reduce isolation, and support overall wellness beyond traditional medical care.
218980532|NCT02395783|DRUG|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
219672517|NCT07021651|PROCEDURE|Erector Spinae Plane (ESP) block admistring|In the ESPB group, the probe was placed longitudinally at the level of the T5 transverse process, 2-3 cm lateral from the midline. The muscles were visualized superior to the transverse process ; then, the needle was inserted in the craniocaudal direction using the in-plane technique. A dose of 2 mL normal saline were injected into the two layers of the interfacial area under the erector spinae muscle, and the proper injection site was confirmed. After visualizing the linear spread of saline in the fascial plane, 20 mL of 0.25% bupivacaine was injected there for the block.
219672518|NCT07021651|PROCEDURE|Thoracic Paravertebral Block administring|In the TPVB group, the probe was placed 2-3 cm laterally and vertically of the T5 spinous process. Once the transverse process, corresponding paravertebral space, internal intercostal membrane, and pleura was identified , the needle was inserted in the lateromedial direction using the in-plane technique. After confirmation of pleural displacement with 2 mL saline, 20 mL of 0.25% bupivacaine was administered for the block.
219672519|NCT00194194|BEHAVIORAL|moderate|moderate behavioral management with RD
219672520|NCT00194194|DEVICE|Resting Metablic Rate measurements|intensive behavior management
219672521|NCT07026032|OTHER|Biofeedback tool|Biofeedback tool (tongueometer) will be used for experimental group, where as for control group the intervention used in traditional exercises.
219672522|NCT07026032|OTHER|traditional exercises|traditional exercises were used for the control group
219672523|NCT07025993|OTHER|Muscle Energy Technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch.
219069731|NCT03320447|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
219672524|NCT07025993|OTHER|Eccentric muscle energy technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. Three to five repetitions will performed.
219672525|NCT03373357|OTHER|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~* Cardiovascular events arisen during the duration of the study~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
219672526|NCT03373357|OTHER|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~* Questionnaire of evaluation of the global quality of life of the SAHOS~* Appearance of new cardiovascular risk factors~* Cardiovascular events arisen during the duration of the study~* Modification of the current treatments~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
219672527|NCT06820723|DRUG|CYB003|synthetic, deuterated isotopomer of psilocin
219672528|NCT06820723|DRUG|Placebo|Placebo orange drink solution
219672529|NCT05573178|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
219672530|NCT03745248|BEHAVIORAL|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
219672531|NCT03745248|BEHAVIORAL|Balance Training|Standard of care
219672532|NCT00762190|DRUG|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
219672533|NCT00762190|DRUG|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
219672534|NCT03724019|DRUG|Ketamine|Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
219672535|NCT00616876|DRUG|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
219672536|NCT00616876|DIETARY_SUPPLEMENT|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
219672537|NCT00811980|DRUG|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
219672538|NCT04849663|BIOLOGICAL|free fat graft|fat harvested from patient will be used to cover exposed root
219672539|NCT04849663|BIOLOGICAL|subepithelial graft|subepitheial graft harvested from palate
218980533|NCT02395783|OTHER|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
218980534|NCT00358423|DRUG|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
218980535|NCT00358423|DRUG|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
218980536|NCT04248751|DEVICE|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
218980537|NCT04248751|PROCEDURE|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
219069732|NCT03320447|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
219069733|NCT06305351|DRUG|K-757 and K-833 QD|Both administered orally once daily
219069734|NCT06305351|DRUG|K-757 and K-833 BID|Both administered orally twice daily
219672540|NCT02483988|DEVICE|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
219672541|NCT03017391|DRUG|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
219672542|NCT03017391|DRUG|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
219672543|NCT03017391|DRUG|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
219672544|NCT03017391|DRUG|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
219672545|NCT05400044|PROCEDURE|Three dimensional maxillary bone augmentation|mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
219672546|NCT03620526|DRUG|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
219672547|NCT03620526|DRUG|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
219672548|NCT00620646|DRUG|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
219672549|NCT00620646|DRUG|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
219672550|NCT03096561|DIAGNOSTIC_TEST|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
219672551|NCT04245917|OTHER|Non-interventional|Non-interventional natural history study
219672552|NCT01292707|BEHAVIORAL|Control|Standard national training
219069735|NCT06305351|DRUG|Matching placebo to K-757 and K-833 QD|Both administered orally once daily
219069736|NCT06305351|DRUG|Matching placebo to K-757 and K-833 BID|Both administered orally twice daily
219069737|NCT06098521|BEHAVIORAL|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
219069738|NCT05564663|BEHAVIORAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
219069739|NCT05564663|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
219672553|NCT01292707|BEHAVIORAL|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
219069740|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
219069741|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
219069742|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
219069743|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
219069744|NCT03449303|OTHER|EOI|Topically-applied oil
219069745|NCT03449303|OTHER|Placebo|Topically-applied oil
219069746|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
219069747|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
219069748|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
219069749|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
219208859|NCT06739837|COMBINATION_PRODUCT|Non-immersive VR therapy|Participants undergo a VR-based rehabilitation program targeting tennis elbow symptoms. Sessions last 30 minutes, conducted 3 times per week for 6 weeks. Exercises focus on improving grip strength, wrist flexibility, and functional movement through interactive VR environments that visually engage the affected arm, promoting adherence and motivation without full immersion. The VR setup includes headsets or screens that enable visual interaction, enhancing the rehabilitation experience. The goal is to alleviate pain, increase range of motion, and restore muscle strength.
219208860|NCT06886308|DEVICE|Repetitive trans-spinal magnetic stimulation|For repetitive trans-spinal magnetic stimulation - rTsMS (high-frequency or sham), volunteers will be positioned comfortably in a lateral decubitus position. High-frequency rTsMS will be applied with an eight-shaped coil over the tenth thoracic vertebra (10 Hz; 100 pulses per train, 20-second interval between trains; 100% resting motor threshold). For sham rTsMS, two coils will be used: (i) a coil connected to the stimulator will be placed behind the patient (away from the spine) to generate the characteristic sound, and (ii) another coil, disconnected from the stimulator, will be placed on the tenth thoracic vertebra. Both real and sham stimulation will last 20 minutes. Gait training with body weight support will be performed on a Biodex Rehabilitation treadmill for 20 minutes. Researchers will assist the patient in foot placement, knee extension, and pelvis/trunk alignment. Body weight support and treadmill speed will be adjusted based on the patient's performance.
219360349|NCT05771727|OTHER|survey|The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).
219672554|NCT01292707|BEHAVIORAL|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
219672555|NCT05639218|DRUG|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
219672556|NCT03908554|OTHER|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
219672557|NCT02711020|BEHAVIORAL|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
219672558|NCT02711020|BEHAVIORAL|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
219672559|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
219672560|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
219672561|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
219672562|NCT05784701|DRUG|Placebo|Placebo
219672563|NCT01994707|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
219069750|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
219069751|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
219069752|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
219069753|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
219069754|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
219672564|NCT01994707|PROCEDURE|Placebo|Deflated cuff on arm for 30 minutes.
219672565|NCT04687540|DRUG|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
219672566|NCT04687540|DRUG|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
219672567|NCT02437643|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
219672568|NCT02437643|DIETARY_SUPPLEMENT|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
219672569|NCT02437643|BEHAVIORAL|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
219069755|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
219069756|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
219069757|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
219069758|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
219069759|NCT02516059|DEVICE|epidural catheter|
219069760|NCT05317468|OTHER|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
219672570|NCT00402623|DIETARY_SUPPLEMENT|quercetin|1000 mg quercetin within 24 hours
219672571|NCT00402623|OTHER|placebo|
219672572|NCT03545633|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
219672573|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
219672574|NCT02187029|OTHER|Placebo|Daily dosing (tablet) for 14 days
219069761|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
219069762|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
219069763|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
219069764|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
219069765|NCT01713803|DRUG|Buprenorphine and naloxone|
219069766|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
219069767|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
219069768|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
219069769|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
219069770|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
219069771|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
219208861|NCT06885814|DRUG|Adebrelimab: 20mg/kg day1, Q3W, 3 times|Concurrent Chemoradiotherapy combined with Immunotherapy，including： Radiotherapy: intensity modulated radiotherapy, PGTV 50-50.4Gy/25-28F, 1.8-2Gy/F, 5 times a week; Chemotherapy: paclitaxel 50mg/ m2 + cisplatin 25mg/ m2, intravenous infusion of day1, once a week, a total of 5 times; Adebrelimab: 20mg/kg day1, Q3W, 3 times.
219672575|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
219069772|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
219069773|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
219069774|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
219069775|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
219069776|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
219069777|NCT01803997|BEHAVIORAL|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
219208862|NCT06886022|PROCEDURE|Colorectal cancer procedures|Procedures
219208863|NCT06749730|DRUG|Adebrelimab|adepelizumab ,1200mg, q3w
219208864|NCT06749730|DRUG|Apatinib|apatinib，250mg，QD
219672576|NCT02187029|OTHER|Placebo|Daily dosing (tablets) for 14 days
219672577|NCT01983163|OTHER|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
219672578|NCT01983163|OTHER|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
219672579|NCT01449864|RADIATION|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
219672580|NCT00815503|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
219069778|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
219208865|NCT06749730|DRUG|gemcitabine and cisplatin|cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
219208866|NCT06742229|DEVICE|Research Ultrasound scan|Both the study groups will be asked to undergo a research scan performed by an FDA approved ultrasound device
219208867|NCT06742567|DRUG|Apixaban 2.5 MG PO BID|Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.
219672581|NCT00815503|DRUG|Placebo|Saline
219672582|NCT00012389|DRUG|irinotecan hydrochloride|
219672583|NCT00012389|DRUG|oxaliplatin|
219672584|NCT03349489|OTHER|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
219672585|NCT03349489|OTHER|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
219672586|NCT03349489|DEVICE|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
219208868|NCT06742567|DRUG|Control (Standard treatment)|DAPT plus guideline directed medical therapy
219672587|NCT03349489|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used.
219672588|NCT03349489|DEVICE|Insulin pump|Participant's insulin pump will be used to infuse insulin.
219672589|NCT03042910|DRUG|Talazoparib|Talazoparib 1 mg orally once daily.
219672590|NCT04810910|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
219672591|NCT04810910|OTHER|GM-CSF|GM-CSF: 40 mcg
219672592|NCT00639925|BIOLOGICAL|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
219672593|NCT05635877|DRUG|Esmolol|The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
218980538|NCT04701788|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
219069779|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
219069780|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
219069781|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
219069782|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
219069783|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
219672594|NCT05635877|DRUG|Placebo Comparator: Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
219672595|NCT04272047|OTHER|Knee Control+ program|15-20 minute training program to be performed at all team training sessions during the season.
219672596|NCT04272047|OTHER|Adductor strengthening program|Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
219672597|NCT04272047|OTHER|Knee Control program|15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
219672598|NCT02082769|DRUG|Febuxostat|
219672599|NCT02082769|DRUG|Allopurinol|
219672600|NCT05307003|DRUG|Trazodone|Medication used to treat ICU delirium
219672601|NCT05307003|DRUG|Quetiapine|Medication used to treat ICU delirium
219672602|NCT00405340|DRUG|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
219672603|NCT01496417|DRUG|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
219672604|NCT00493506|DRUG|ProAlgaZyme|
219672605|NCT06283433|DIAGNOSTIC_TEST|Finger Prick|Blood sample obtained via drop of capillary blood by finger prick onto filter paper
219672606|NCT06283433|DIAGNOSTIC_TEST|Venipuncture|Blood sample obtained trough venipuncture
219672607|NCT00124085|BEHAVIORAL|Disease Management|
219672608|NCT00124085|BEHAVIORAL|Disease Management + Educational Home Visits|
219672609|NCT05811559|OTHER|No intervention|No intervention
219672610|NCT03083808|DRUG|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~\+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8"
219672611|NCT06400485|DRUG|AMT-676|Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
219672612|NCT02944474|DRUG|Lucerastat|Capsule for oral administration containing lucerastat
219672613|NCT02944474|DRUG|Placebo|Placebo capsules matching lucerastat capsules
219069784|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
219672614|NCT02889770|OTHER|PEEP titration|Exposure to different PEEP levels
219672615|NCT01491841|DRUG|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
219672616|NCT01491841|DRUG|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
219069785|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
219069786|NCT02917109|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
219069787|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
219069788|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
219672617|NCT05327595|DRUG|LY3549492|Administered orally.
219672618|NCT05327595|DRUG|Placebo|Administered orally.
219672619|NCT05327595|DRUG|Atorvastatin|Administered orally.
219672620|NCT05327595|DRUG|Midazolam|Administered orally.
219672621|NCT05556941|BEHAVIORAL|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
219672622|NCT05556941|BEHAVIORAL|Occupational therapy standard care|Occupational therapy standard care
219672623|NCT03711136|PROCEDURE|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
219672624|NCT04276077|OTHER|High-frequency electrical muscle stimulation training|High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks
219672625|NCT04276077|OTHER|Low-frequency electrical muscle stimulation training|Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
219672626|NCT02933528|DRUG|DSXS Topical product|once daily for 28 days
219069789|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
219672627|NCT04699370|OTHER|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
219672628|NCT04699370|BEHAVIORAL|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
219672629|NCT04699370|OTHER|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
219672630|NCT00845936|DRUG|Metformin|Metformin 850 mg bid
219672631|NCT00396474|OTHER|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
219672632|NCT01301079|DRUG|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
219672633|NCT01301079|DRUG|Saline|Patients in group N (placebo) was administrated saline during surgery.
219672634|NCT05621850|OTHER|Blood sample|Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
219672635|NCT03453814|OTHER|Music Therapy|Subjects will receive one hour of music twice a day for three days.
219672636|NCT02477371|PROCEDURE|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values \> 0,8 are deferred.
219672637|NCT02477371|PROCEDURE|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
219672638|NCT04059939|OTHER|Reading|Small group reading instruction
219672639|NCT04059939|BEHAVIORAL|Anxiety Management|small group anxiety management skills instruction
219672640|NCT04059939|OTHER|Classroom Business as Usual|Classroom Business as Usual
219672641|NCT04059939|OTHER|Attention Control (math practice)|Attention Control (math practice)
219672642|NCT00002261|BIOLOGICAL|Smallpox Vaccine|
219672643|NCT00002261|BIOLOGICAL|HIVAC-1e|
219672644|NCT00002261|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219672645|NCT03377062|DIAGNOSTIC_TEST|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
219672646|NCT02842008|BEHAVIORAL|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
219069790|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
219208869|NCT06821711|OTHER|Intensive LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin + PCSK9i; for LDL-C level ≥ 3.0 mmol/L, statin + ezetimibe + PCSK9i"
219069791|NCT03457259|DEVICE|Midline|Pt. will receive midline
219672647|NCT02155088|DRUG|BYL719|Dose escalation beginning at 250 mg/day
219672648|NCT02155088|DRUG|Gemcitabine|Dose escalation beginning at 800 mg/m\^2
219672649|NCT02155088|DRUG|(nab)-paclitaxel|125 mg/m\^2 dose
219672650|NCT02857036|OTHER|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
219672651|NCT02857036|BEHAVIORAL|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
219672652|NCT05761457|OTHER|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
219069792|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
219069793|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
219069794|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
219672653|NCT04369963|PROCEDURE|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
219672654|NCT00479115|DRUG|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
219672655|NCT00479115|DEVICE|AmCell CliniMACs|CD34+ cell selection from peripheral collection
219672656|NCT02496039|DRUG|NUEDEXTA®|NUEDEXTA® only
219672657|NCT02968459|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
219672658|NCT02968459|OTHER|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
219672659|NCT05121805|PROCEDURE|Snare tip soft coagulation|Thermal ablation of the entire resection margin
219208870|NCT06821711|OTHER|Conventional LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin alone or statin + ezetimibe; for LDL-C level ≥ 3.0 mmol/L, statin + PCSK9i"
219208871|NCT06746077|OTHER|No intervention|No intervention
219672660|NCT04472494|BIOLOGICAL|Abatacept|Specified dose on specified days
219672661|NCT04472494|OTHER|Placebo|Specified dose on specified days
219672662|NCT00571103|DRUG|acamprosate|Two 333mg tablets taken three times daily.
219672663|NCT01915901|DRUG|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
219672664|NCT01915901|DRUG|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
219672665|NCT01915901|DRUG|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
219672666|NCT06462170|DIETARY_SUPPLEMENT|Boost Original meal replacement shake|One bottle of Boost Original meal replacement shake.
219672667|NCT02029482|DRUG|ACT-128800|
219672668|NCT02029482|DRUG|Placebo|
219672669|NCT02699827|DRUG|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
219672670|NCT02699827|DRUG|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
219672671|NCT02699827|DRUG|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
219672672|NCT05294965|DRUG|Fenoterol|Intravenous infusion
219672673|NCT05294965|OTHER|Mild cold exposure|Body surface cooling
219672674|NCT04626258|DRUG|Fluconazole|Fluconazol once a month 150 mg capsule
219672675|NCT04626258|OTHER|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
219672676|NCT01728441|DEVICE|Paclitaxel Eluting Stent|
219672677|NCT01728441|DEVICE|Paclitaxel Eluting Balloon|
219672678|NCT05345678|DRUG|Durvalumab|Dose: 1500mg Route: IV
219672679|NCT05345678|DRUG|Tremelimumab|Dose: 300mg Route: IV
219672680|NCT05588752|OTHER|TAP block|TAP block under ultrasound
219672681|NCT03954002|DIAGNOSTIC_TEST|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
219672682|NCT04786236|DEVICE|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
219672683|NCT04186624|DRUG|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
219069795|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
219069796|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
219208872|NCT06753656|PROCEDURE|Open Surgery|Open surgery technique: A longitudinal incision is made over the lateral malleolus, followed by sharp dissection down to the bone. The fracture is reduced under direct visualization and fixed with a plate and screws.
219672684|NCT02547909|PROCEDURE|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
219672685|NCT02547909|DEVICE|Cellvizio|
219672686|NCT02547909|DRUG|fluorescein 10%|
219672687|NCT02103699|DRUG|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
219672688|NCT02641275|OTHER|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
219672689|NCT01308463|DEVICE|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
219672690|NCT02624635|OTHER|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
218980539|NCT02785484|OTHER|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
219069797|NCT03022357|RADIATION|DATScan|In small subgroup
219069798|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
219069799|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
219069800|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
219069801|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
219069802|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
219069803|NCT02584049|OTHER|Osteopathy|3 sessions of osteopathy during 60 minutes each
219069804|NCT02584049|OTHER|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
219069805|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
219069806|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
219069807|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
219069808|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
219208873|NCT06753656|PROCEDURE|Minimally Invasive Surgery|Closed surgery technique: A 2-3 cm longitudinal incision is made distal to the lateral malleolus to allow for plate placement. A periosteal elevator is used to create a pathway for the plate. The fracture is reduced in a closed manner using reduction clamps, and the plate position is confirmed fluoroscopically. A second longitudinal incision is made proximal to the fracture, and the plate is temporarily fixed with Kirschner wires. The plate is then used as an external guide, with screws placed through mini-incisions. The fracture is fixed with the plate-screw system in a minimally invasive manner.
219208874|NCT06769620|DRUG|ORT247|ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
219208875|NCT06769620|DRUG|Placebo|Placebo consists of normal saline
219069809|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
219069810|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
219069811|NCT01859455|DRUG|Placebo|Placebo comparator
219208876|NCT06768931|OTHER|Biolosion (oral probiotic compound preparation)|Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.
219672691|NCT02624635|OTHER|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
219672692|NCT05035875|DEVICE|ultrasonography|ultrasound assessment of diaphragm function
219672693|NCT04648657|DEVICE|Lung Ultrasound|Echography of Lungs based on artifacts study
219672694|NCT04648657|DEVICE|Electric impedance tomography|Low alternating electrical currents (usually \<5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
219069812|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
218980540|NCT02785484|OTHER|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
219672695|NCT01514877|DRUG|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
219672696|NCT01238419|DEVICE|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
219672697|NCT01238419|DEVICE|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
219672698|NCT03297021|DRUG|Ondansetron 4 MG|dose as per arm selection
219672699|NCT03297021|DRUG|Ondansetron 8mg|dose as per arm selection
219672700|NCT01191099|DEVICE|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
219672701|NCT02477436|DRUG|Avanafil|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks."
219672702|NCT02477436|DRUG|Placebo|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks."
219672703|NCT03401632|OTHER|Enteral nutrition|Enteral nutrition support
219672704|NCT03731208|DEVICE|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~* a tablet with a keyboard and a fingerprint sensor~* two wearable sensors~* a wireless modem~* measuring tape"
218980541|NCT05202028|OTHER|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
218980542|NCT05202028|OTHER|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
218980543|NCT05202028|OTHER|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
219672705|NCT01912053|RADIATION|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
219672706|NCT03635008|DEVICE|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
219672707|NCT02112019|PROCEDURE|Sialoendoscopy|
219672708|NCT02112019|DRUG|saline|
219672709|NCT02112019|DRUG|hydrocortisone|
219672710|NCT06832202|DRUG|HLX22|HLX22 15mg/kg Q3W
219672711|NCT06832202|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan 5.4mg/kg Q3W
219672712|NCT00898755|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219672713|NCT00898755|OTHER|Laboratory Biomarker Analysis|Correlative studies
219672714|NCT02640898|RADIATION|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
219672715|NCT02640898|RADIATION|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
219208877|NCT06758726|DRUG|Mitoxantrone Hydrochloride Liposome combined with BU/Cy|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
219208878|NCT06764173|OTHER|Oat drink|6 dl of oat drink daily
219672716|NCT03776526|BEHAVIORAL|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
219672717|NCT04414423|PROCEDURE|bone marrow concentrate alveolar cleft grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
219672718|NCT04414423|PROCEDURE|Autogenous alveolar grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft
219672719|NCT03577379|OTHER|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
219672720|NCT03597321|BIOLOGICAL|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
219672721|NCT04096001|DEVICE|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
219672722|NCT05535426|DEVICE|Tetranite Implant Stabilization Material|Dental adhesive for increased implant stabilization
219672723|NCT03594799|OTHER|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
219672724|NCT03594799|DIETARY_SUPPLEMENT|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
219672725|NCT04717089|OTHER|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A\&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
219672726|NCT03105557|DEVICE|Urinary collecting device|Urinary collecting device
219672727|NCT04319653|DEVICE|Dynamic pelvic MRI with intravaginal probe with pressure sensor|Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel
219672728|NCT00948922|DRUG|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
218980544|NCT00300105|DRUG|Tesaglitazar|
218980545|NCT05263596|DIAGNOSTIC_TEST|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA"
218980546|NCT00276146|DRUG|oral dipyridamole, oral magnesium, or a combination of both|
219208879|NCT06764173|OTHER|Cow's milk|6 dl of cow's milk daily
219672729|NCT00948922|DRUG|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes.
219672730|NCT00948922|PROCEDURE|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
219672731|NCT00948922|DRUG|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
219672732|NCT00948922|PROCEDURE|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
219672733|NCT03336931|DIAGNOSTIC_TEST|Molecular profiling and drug testing|"1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy"
219672734|NCT02784288|PROCEDURE|Neck Dissection|All patients will undergo neck dissection of the cervical lymph nodes
218980547|NCT04587544|BEHAVIORAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
218980548|NCT05271071|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
218980549|NCT03397615|BEHAVIORAL|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
218980550|NCT02714907|DEVICE|Cortrium C3 device|Data is read from Cortrium C3 monitor
218980551|NCT02714907|DEVICE|Holter device|Date is read from Holter device
218980552|NCT04402060|DRUG|APL-9|Complement (C3) Inhibitor
218980553|NCT04402060|OTHER|Vehicle Control|Normal saline of equal volume to active arm
218980554|NCT05382533|DIETARY_SUPPLEMENT|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
218980555|NCT03145363|BEHAVIORAL|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
218980556|NCT03145363|BEHAVIORAL|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
218980557|NCT02350569|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
218980558|NCT00263731|OTHER|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
218980559|NCT03998566|DEVICE|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
218980560|NCT02754154|DRUG|Warfarin|
218980561|NCT02754154|DRUG|Apixaban|
219208880|NCT06764251|DRUG|Tislelizumab + SOX|tislelizumab combined with SOX
218980562|NCT02754154|DRUG|Dabigatran|
218980563|NCT02754154|DRUG|Rivaroxaban|
218980564|NCT05406648|OTHER|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
218980565|NCT02572609|DRUG|Ambroxol hydrochloride soft pastille|
218980566|NCT02572609|DRUG|Mucosolvan ® adult syrup|
218980567|NCT04920344|PROCEDURE|Transoral Surgery|Patients will undergo transoral surgery
218980568|NCT04920344|RADIATION|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
218980569|NCT04920344|DRUG|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
218980570|NCT04920344|PROCEDURE|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
219360350|NCT03369964|DRUG|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
218980571|NCT04920344|OTHER|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
218980572|NCT04920344|OTHER|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
218980573|NCT04920344|OTHER|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
219069813|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
219069814|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
219069815|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
219069816|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
219069817|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
219069818|NCT02067403|OTHER|Pressure-support Eadi optimization|
219672735|NCT02784288|PROCEDURE|Standard-of-Care (SOC) Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
219672736|NCT02784288|RADIATION|SOC Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
219672737|NCT02784288|DRUG|SOC Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
219672738|NCT02784288|DRUG|SOC Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
219672739|NCT02784288|PROCEDURE|Videofluoroscopy|All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
219672740|NCT02734862|DRUG|CD101|Intravenous antifungal therapy
219672741|NCT02734862|DRUG|Caspofungin|Intravenous antifungal therapy
219672742|NCT02734862|DRUG|Fluconazole|oral antifungal therapy
219672743|NCT02734862|DRUG|intravenous placebo|normal saline
219672744|NCT02734862|DRUG|oral placebo|microcrystalline cellulose
219672745|NCT02757625|DRUG|Dexmedetomidine hydrochloride|"* 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
219672746|NCT03943797|BIOLOGICAL|Cultivated oral mucosal epithelial cell transplantation|Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
219672747|NCT06043492|OTHER|High Intensity Interval Training|10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
219672748|NCT06043492|OTHER|Coninuous Running|40 min continuous running at lactate threshold
219672749|NCT06043492|OTHER|Control Trial|The participants will perform only the baseline and post acute-training evaluations, without performing exercise
219672750|NCT04305860|DIETARY_SUPPLEMENT|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
219672751|NCT04305860|DIETARY_SUPPLEMENT|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
219672752|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
219672753|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
219672754|NCT04838431|OTHER|Blood sample and ultrasound at first trimester|The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants
219672755|NCT04421352|DRUG|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
219069819|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
219069820|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
219069821|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
219069822|NCT02826226|DEVICE|multiple-breath-washout test|
219069823|NCT02826226|DRUG|Bronchodilator Agents|
219672756|NCT00888797|DRUG|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
219672757|NCT05969587|COMBINATION_PRODUCT|5% cysteamine cream|5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
219672758|NCT05969587|COMBINATION_PRODUCT|hydroquinone cream group|4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
219672759|NCT04854057|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
219672760|NCT04854057|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
219672761|NCT04854057|DEVICE|TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice|Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
219672762|NCT03917277|DEVICE|Musculoskeletal ultrasound|"Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal"
219672763|NCT04755894|DRUG|HDDO-1756|single dose
219672764|NCT04755894|DRUG|HDDO-17561/HDDO-17562|single dose
219672765|NCT05750459|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
219672766|NCT02131233|DRUG|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
219672767|NCT02131233|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily
219672768|NCT02131233|DRUG|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
219672769|NCT02131233|DRUG|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
219672770|NCT02131233|DRUG|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
219672771|NCT00824629|PROCEDURE|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
219672772|NCT00824629|PROCEDURE|Direct embryo transfer procedure|Direct embryo transfer procedure
219672773|NCT02298036|BEHAVIORAL|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
219672774|NCT05823103|DIAGNOSTIC_TEST|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
218980574|NCT04920344|OTHER|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
218980575|NCT04920344|DIAGNOSTIC_TEST|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
218980576|NCT02942927|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
218980577|NCT02145585|DEVICE|Test of pharmacologic anesthesia robot (labVIEW® software)|
218980578|NCT00331422|DRUG|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
219672775|NCT05823103|DIAGNOSTIC_TEST|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
219672776|NCT03519919|DEVICE|somofilcon A multifocal lens|contact lens
219672777|NCT04893187|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
219672778|NCT04893187|DRUG|Placebo|Matched placebo.
219672779|NCT03183843|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
219672780|NCT03183843|DRUG|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
219672781|NCT02095197|DRUG|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
219672782|NCT02567097|BEHAVIORAL|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
219672783|NCT03475758|DRUG|Goserelin|adding goserelin with chemotherapy
219672784|NCT06175039|OTHER|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
219672785|NCT06175039|OTHER|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
219672786|NCT06144541|OTHER|Survey administration for Fitzpatrick skin type|Survey administration for Fitzpatrick skin type
219672787|NCT06144541|DEVICE|Measurement of ITA based on SkinColorCatch instrument|Measurement of ITA based on SkinColorCatch instrument
219672788|NCT00507520|PROCEDURE|Full dose almonds|
219672789|NCT00507520|PROCEDURE|Half dose almonds+half dose muffin|
219672790|NCT00507520|PROCEDURE|Full dose whole wheat muffin|
219672791|NCT05114564|DEVICE|Lens A (comfilcon A lens)|1 month
219672792|NCT05114564|DEVICE|Lens B (lehfilcon A lens)|1 month
219672793|NCT00463008|DRUG|methotrexate|
219672794|NCT00463008|OTHER|pharmacological study|
219672795|NCT00493311|DRUG|IV Placebo|IV Placebo
219672796|NCT00493311|DRUG|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
219672797|NCT00493311|BIOLOGICAL|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
219672798|NCT05667818|DRUG|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
219672799|NCT05667818|DRUG|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
219672800|NCT04299867|PROCEDURE|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
219672801|NCT04714190|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
219672802|NCT04714190|DRUG|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
219672803|NCT04714190|DRUG|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
219672804|NCT04714190|DRUG|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
219672805|NCT05437614|PROCEDURE|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
219672806|NCT05437614|PROCEDURE|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
218980579|NCT00331422|DRUG|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
218980580|NCT00331422|PROCEDURE|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
218980581|NCT04515173|DIAGNOSTIC_TEST|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
218980582|NCT02345226|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
218980583|NCT02345226|DRUG|EFV/FTC/TDF Placebo|Tablets administered orally once daily
218980584|NCT02345226|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
218980585|NCT02345226|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
218980586|NCT05321108|OTHER|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
218980587|NCT05321108|OTHER|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
219672807|NCT04241016|PROCEDURE|Endoscopic sinus surgery (ESS)|Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
219672808|NCT00860080|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
219672809|NCT00860080|DRUG|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
219672810|NCT02347735|OTHER|No interventions, only data collection|Only data is collected from the subjects in both groups.
219672811|NCT03639129|DEVICE|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
219672812|NCT03639129|PROCEDURE|Biopsy|Standard of care
219069824|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
219069825|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
219069826|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
219069827|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
219069828|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
219069829|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
219069830|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219069831|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
219069832|NCT04461522|PROCEDURE|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
219069833|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
219069834|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
219069835|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
219069836|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
219069837|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
219672813|NCT03061487|PROCEDURE|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
219672814|NCT06163027|DEVICE|Shotblocker|Shotblocher will be administered during spinal needle injection
219672815|NCT06163027|OTHER|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
219672816|NCT05951361|DEVICE|980nm Diode Laser|300 mW, 4 J/cm2, 2mm non-contact mode up to 10 sessions
219672817|NCT05951361|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|three times daily for 4 weeks
219672818|NCT04416646|DRUG|Cabozantinib|The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.
219672819|NCT01765816|BEHAVIORAL|high intensity interval training|
219672820|NCT01765816|BEHAVIORAL|moderate intensity training|
219672821|NCT02628158|PROCEDURE|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
219672822|NCT01825746|OTHER|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
219672823|NCT05781022|PROCEDURE|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
219672824|NCT00257738|BIOLOGICAL|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
219672825|NCT00257738|BIOLOGICAL|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
219208881|NCT06772883|BEHAVIORAL|sexual education and counseling|The women included in the Working Group were contacted by phone and invited to the hospital. Sexual education and counseling were provided in accordance with the PLISSIT model. A total of 5 interviews were conducted with the women, the first face-to-face interview and the subsequent ones by telephone. FSFI assessments in the study FSFI assessments were performed 5 times (initial, 1st, 3rd, 6th months and 1 year later). According to the PLISSIT model, their sexuality and any problems since the previous assessment were discussed and a short counseling was given if necessary.
219208882|NCT06772883|OTHER|control group|routine clinical care
219208883|NCT06773728|DEVICE|Record occlusal contacts|Register using a digital device (t-scan) the occlusal contacts
219672826|NCT02460432|DEVICE|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
219672827|NCT02460432|DEVICE|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
219672828|NCT03416478|DIAGNOSTIC_TEST|ctDNA test|ctDNA test to find some possible mutation.
219672829|NCT02359279|DEVICE|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
219672830|NCT01488747|DIETARY_SUPPLEMENT|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
219672831|NCT01488747|DIETARY_SUPPLEMENT|Coromega Nectar|660 mg EPA, 436 mg DHA
219672832|NCT01488747|DIETARY_SUPPLEMENT|Barleans Swirl|660 mg EPA, 660 mg DHA
219672833|NCT01488747|DIETARY_SUPPLEMENT|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
219069838|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
219069839|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
219069840|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
219672834|NCT03000322|DEVICE|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
219672835|NCT03456687|DRUG|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
219672836|NCT04153955|BEHAVIORAL|Mobilization|Any movement out of bed
219069841|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
219069842|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
219672837|NCT03051438|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
219672838|NCT03051438|PROCEDURE|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
219672839|NCT05867680|BEHAVIORAL|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
219672840|NCT05890014|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
219672841|NCT01343537|OTHER|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
219672842|NCT02829047|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
219672843|NCT00428428|DRUG|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
219672844|NCT04724603|OTHER|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
219672845|NCT02247882|OTHER|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
219069843|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
219672846|NCT02247882|OTHER|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
219672847|NCT05916807|OTHER|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
219672848|NCT05916807|OTHER|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
219672849|NCT03055910|DIAGNOSTIC_TEST|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
219672850|NCT03668665|DRUG|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
219672851|NCT03668665|DEVICE|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
219672852|NCT02225808|BEHAVIORAL|CBT for anxiety in autism|
219672853|NCT02455453|DRUG|18F-FFNP|
219672854|NCT02455453|DEVICE|CTI/Siemens Biograph 40 PET/CT Scanner|"* Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans"
219672855|NCT02455453|DRUG|Estradiol|
219672856|NCT02455453|DRUG|18F-FDG|
219672857|NCT01084902|DRUG|Latanoprost|once daily
219672858|NCT01084902|DRUG|Brinzolamide|Two times daily
219672859|NCT00866957|PROCEDURE|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
219672860|NCT01996150|DRUG|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
219672861|NCT04339205|OTHER|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
219672862|NCT00368459|DRUG|raloxifene|Raloxifene is a selective estrogen receptor modulator
219672863|NCT00368459|DRUG|Placebo|Identical appearing placebo
219672864|NCT03989596|RADIATION|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
219672865|NCT03989596|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
219672866|NCT01373034|DIETARY_SUPPLEMENT|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
219672867|NCT01373034|DIETARY_SUPPLEMENT|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
219672868|NCT00094679|DEVICE|Eye patch|adhesive patch to cover the sound eye
219672869|NCT00248157|DRUG|Octreotide acetate in microspheres|
219672870|NCT00934245|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
219069844|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
219069845|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
219069846|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
219069847|NCT02568787|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
219069848|NCT02568787|DIETARY_SUPPLEMENT|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
219069849|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
219208884|NCT06773728|DEVICE|Tracking of jaw movement|An optical jaw tracking system (Modjaw, Modjaw) is going to be implemented
219208885|NCT06773728|DEVICE|Tracking of jaw movement|Jaw tracking will be performed using an optical jaw tracking system (Zebris, Zebris medical)
219672871|NCT00934245|BIOLOGICAL|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
219672872|NCT05386290|DRUG|Infliximab|A TNFα inhibitor in UC and CD treatment
219672873|NCT05386290|DRUG|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
219672874|NCT05386290|DRUG|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
219672875|NCT05386290|DRUG|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
219672876|NCT03689153|DRUG|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
219672877|NCT03689153|DRUG|Placebo|Participants will receive matching placebo intravenously.
219672878|NCT03157076|DEVICE|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
219672879|NCT01073826|BEHAVIORAL|Sport|
219672880|NCT01073826|DRUG|Tocilizumab|
219672881|NCT01073826|DRUG|Sitagliptin|
219672882|NCT06845215|PROCEDURE|Transversus abdominis plane (TAP) block|Ultrasound-guided TAP block
219672883|NCT06845215|PROCEDURE|Erector spina plane block (ESP)|Ultrasound-guided ESP block
219672884|NCT00563914|DRUG|ferroquine (SSR97193)|associated with artesunate
219672885|NCT00563914|DRUG|amodiaquine|associated with artesunate
219672886|NCT06844045|BEHAVIORAL|Gonorrhea/chlamydia Point-of-Care Testing|Point-of-care testing for sexually transmitted infections.
219672887|NCT04425681|DRUG|Osimertinib|Treatment of LM With osimertinb
219672888|NCT04425681|DRUG|Bevacizumab|Treatment of LM With Bevacizumab
219672889|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
219672890|NCT01438242|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
218980588|NCT05613881|OTHER|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
219672891|NCT01349088|DRUG|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
219672892|NCT01349088|DRUG|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
219672893|NCT01349088|DRUG|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
219672894|NCT06438419|OTHER|Electrophysiological recordings|"Electrophysiological recordings will be made during a motor task in four different conditions:~1. without pharmacological treatment and without stimulation (Off condition),~2. without pharmacological treatment and during stimulation (DBS condition),~3. during pharmacological treatment and without stimulation (DOPA condition),~4. during pharmacological treatment and stimulation (DOPA+DBS condition)."
219672895|NCT04953715|OTHER|collection of body microbiome|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
218980589|NCT02623920|DRUG|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
218980590|NCT02623920|DRUG|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
218980591|NCT02623920|DRUG|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
219672896|NCT06363292|DRUG|PRO-231|Moxifloxacin 0.5% Ophthalmic solution.
219672897|NCT06363292|DRUG|VIGAMOXI®|Moxifloxacin 0.5% Ophthalmic solution.
218980592|NCT04651985|OTHER|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
219672898|NCT04217317|DRUG|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
219672899|NCT04217317|DRUG|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
218980593|NCT04473092|DEVICE|TMVR|Patients who undergo TMVR for MR at the PI´s site
218980594|NCT06544122|DEVICE|Transcranial direct current stimulation|Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
218980595|NCT02282358|DRUG|Mocetinostat|
218980596|NCT02477969|DRUG|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
218980597|NCT02477969|DRUG|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
218980598|NCT02477969|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
218980599|NCT02477969|DRUG|Metformin|0.5mg,oral,tid.
218980600|NCT03814473|OTHER|Diet|"Participants provided with a brochure providing a thorough description of the diet, \~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
218980601|NCT03780543|DRUG|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
218980602|NCT04131725|DEVICE|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
218980603|NCT03144973|DIAGNOSTIC_TEST|periosafe|mouth rinsing quick-test
219069850|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
219069851|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
219069852|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
219069853|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
219069854|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
219069855|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
219069856|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
219069857|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
219208886|NCT06775145|DEVICE|HD-R_cDC+cTBS & sham-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
219672900|NCT05515991|OTHER|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
219672901|NCT05515991|OTHER|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
219672902|NCT05499663|BEHAVIORAL|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
219672903|NCT03836105|DRUG|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
219672904|NCT05197946|DIAGNOSTIC_TEST|MRI|Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
219672905|NCT05346484|BIOLOGICAL|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
219672906|NCT05346484|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
219672907|NCT05346484|DRUG|Modified FOLFOX|"28 day cycle of:~* Leucovorin calcium/folinic acid~* Fluorouracil~* oxaliplatin"
218980604|NCT04548037|OTHER|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
218980605|NCT05123196|DRUG|MT-8554|Oral Capsule
218980606|NCT05123196|DRUG|Placebo|Oral Capsule
218980607|NCT02526446|BEHAVIORAL|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
218980608|NCT02526446|OTHER|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
218980609|NCT01180101|BEHAVIORAL|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
218980610|NCT01180101|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery
218980611|NCT05379777|DRUG|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
218980612|NCT00446420|DRUG|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
218980613|NCT03012009|DEVICE|full ablative CO2 laser|ablation to the level of de dermal papilla
218980614|NCT03012009|DEVICE|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
218980615|NCT03012009|DRUG|MAL|
218980616|NCT03012009|DEVICE|LED lamp|peak wavelength 630 nm, 37J/cm2
218980617|NCT03012009|DRUG|lidocaine hydrochloride 2% with epinephrine|
219672908|NCT06098235|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
219672909|NCT06098235|BEHAVIORAL|ORIENT diet intervention|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
219672910|NCT03606083|DEVICE|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
219672911|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
219672912|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
219672913|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
219672914|NCT02279290|BEHAVIORAL|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
219672915|NCT02279290|BEHAVIORAL|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
219672916|NCT05255445|BIOLOGICAL|Red Blood Cell (RBC) Transfusion|Simple RBC transfusion or partial manual exchange
219672917|NCT01461473|DEVICE|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
218980618|NCT02401022|DRUG|AZD8529|comparison of different dosages of drug
218980619|NCT04032652|PROCEDURE|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
218980620|NCT04032652|DRUG|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
218980621|NCT04250922|DRUG|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
218980622|NCT04250922|DRUG|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
218980623|NCT04250922|RADIATION|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
218980624|NCT01152983|DEVICE|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
218980625|NCT01864941|PROCEDURE|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
218980626|NCT01864941|DEVICE|Catheter venography with balloon venoplasty and balloon|
218980627|NCT05164250|DRUG|REGN5458|
218980628|NCT04686214|PROCEDURE|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
218980629|NCT06652529|DRUG|AROG4-01|AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
218980630|NCT06652529|DRUG|AROG4-01|"AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2)."
219672918|NCT01461473|DEVICE|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
219672919|NCT01397149|DRUG|Placebo|Dosage form, frequency and duration exactly as experimental arm.
219672920|NCT01397149|DRUG|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to \> 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
219672921|NCT00936676|DRUG|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
219672922|NCT06203782|PROCEDURE|endoscopic stricturoplasty|Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
219672923|NCT06203782|PROCEDURE|endoscopic balloon dilation|Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
219672924|NCT01784926|PROCEDURE|Intraocular lens repositioning by scleral suturing|
219672925|NCT01784926|PROCEDURE|Intraocular lens exchange with retropupillary iris-claw lens|
219672926|NCT01179932|OTHER|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
219672927|NCT04582201|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
219672928|NCT04292067|BIOLOGICAL|Faecal sampling|Faecal sampling at baseline
219672929|NCT04292067|BIOLOGICAL|Blood sampling|Blood sampling at baseline
219672930|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
219672931|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
219672932|NCT02265939|DRUG|NPO-13|
219672933|NCT03570203|DIAGNOSTIC_TEST|Serum Sodium|Measurement of serum sodium.
219672934|NCT01724944|PROCEDURE|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
219672935|NCT05302947|DRUG|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
219672936|NCT05302947|DRUG|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
219672937|NCT05302947|DRUG|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
219672938|NCT05302947|OTHER|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
219672939|NCT02298088|DRUG|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
219672940|NCT02298088|DRUG|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg."
219672941|NCT02258906|DRUG|ulinastatin|
219672942|NCT02258906|DRUG|normal saline|
219672943|NCT04954417|DIAGNOSTIC_TEST|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
219672944|NCT04954417|OTHER|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
219672945|NCT04954417|PROCEDURE|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
219672946|NCT00202943|PROCEDURE|TCRFVR and LAUP|
218980631|NCT06517836|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
218980632|NCT06710678|BEHAVIORAL|Physical Activity Study Break|A 10-minute walking/upper extremity light movement indoor break from study session
218980633|NCT06710678|BEHAVIORAL|Social Media Study Break|Participants will engage in social media use/engagement during a 10-minute study session break
218980634|NCT06058078|DRUG|RY_SW01 cell injection|Injected RY\_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
218980635|NCT06058078|DRUG|Basic treatment|Drugs for LN treatment
218980636|NCT03227328|DRUG|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
218980637|NCT03227328|DRUG|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
218980638|NCT05426096|OTHER|Best Practice Advisory|The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
218980639|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
218980640|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
218980641|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 3|One dose of Reinovax PCV24 formulation 1（0.5mL）
218980642|NCT06678620|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
218980643|NCT06680726|OTHER|Matching with RWD|A set of clinical and genetic data are matched to generate a RWD cohort for comparison.
218980644|NCT06680726|OTHER|Imaging Mass Cytometry|Protein expression patterns in tumor tissue and tumor microenvironment are analyzed by Imaging Mass Cytometry.
218980645|NCT06710171|BEHAVIORAL|Counseling|"The intervention consists of using a theory-informed approach to user-centered brief counselling about PrEP uptake, designed specifically to help busy front-line providers in public health, sexual health and primary care settings advance clients along the PrEP cascade (specifically, supporting clients who meet evidence-based criteria for PrEP in accepting provider recommendations to use it) and provide linkage to care for related conditions.~The intervention will be delivered to GBM through participating healthcare providers who would have completed an online training designed by the research team."
218980646|NCT06710171|OTHER|List of resources|This list includes webpages which contain generic information about GBMs sexual health, PrEP, mental health, information about province-wide info lines for the general public about sexual health and/or educational resources for providers.
218980647|NCT06708143|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
218980648|NCT06709950|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
218980649|NCT06709950|BEHAVIORAL|Regular therapy|Standard treatment
218980650|NCT06707246|DRUG|Secukinumab 300 MG; Tofacitinib 11mg|Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
218980651|NCT06710704|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous PRF at the affected elbow.
218980652|NCT06710704|DRUG|Methylprednisolone and mepacaine|Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
218980653|NCT01484041|DRUG|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
218980654|NCT01484041|DRUG|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
218980655|NCT01059084|DRUG|Valacyclovir|1000 mg tid
219672947|NCT04680247|PROCEDURE|VA-LCP|Surgery using the VA-LCP implant
219672948|NCT04680247|PROCEDURE|NCB-PT|Surgery using the NCB-PT implant
219672949|NCT04324528|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
219672950|NCT04324528|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
219672951|NCT06645769|DRUG|Sodium Phenylbutyrate|will be compared to placebo
219672952|NCT06645769|OTHER|Placebo|will be compared to NaPB
219672953|NCT00916981|PROCEDURE|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
219672954|NCT06514911|PROCEDURE|primary closure following Laparoscopic cholodochotomy in management of CBD stones|primary closure of cholodochotomy incision in laparoscopic CBD exploration avoiding T-tube insertion
219672955|NCT06514911|PROCEDURE|T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones|drainage of bile by T-tube insertion in laparpscopic CBD exploration
219672956|NCT03571178|OTHER|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
219672957|NCT06367738|DRUG|Psilocybin|Psilocybin 1-30 mg
219672958|NCT05537428|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
219672959|NCT06315296|BEHAVIORAL|Behavioral Dietary Intervention|Follow a time-restricted diet
219672960|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive interactive positive reinforcement messages
219672961|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
219672962|NCT06315296|BEHAVIORAL|Dietary Counseling and Surveillance|Receive counseling calls
219672963|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219672964|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219672965|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
219672966|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
219672967|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
219672968|NCT06315296|OTHER|Interview|Ancillary studies
219672969|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
219672970|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219672971|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive text messages about healthy eating habits and food suggestions
219672972|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218980656|NCT00382304|DRUG|tolevamer potassium-sodium (GT267-004)|
218980657|NCT04751565|OTHER|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
218980658|NCT00082979|GENETIC|cytogenetic analysis|
218980659|NCT00082979|GENETIC|proteomic profiling|
219672973|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
219672974|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
218980660|NCT00082979|OTHER|cytology specimen collection procedure|
218980661|NCT00082979|OTHER|immunohistochemistry staining method|
218980662|NCT00082979|OTHER|laboratory biomarker analysis|
218980663|NCT00082979|PROCEDURE|breast duct lavage|
218980664|NCT03642119|DEVICE|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
218980665|NCT01517074|DRUG|Sirolimus|Subconjunctival injection
218980666|NCT04279405|DRUG|YY-20394|YY-20394 80mg tablet administered orally once daily
218980667|NCT06101758|DIAGNOSTIC_TEST|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
218980668|NCT06101758|DIAGNOSTIC_TEST|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
218980669|NCT06101758|DIAGNOSTIC_TEST|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
218980670|NCT00690105|DRUG|tacrolimus 0.1%|ointment
218980671|NCT00690105|DRUG|fluticasone 0.005 %|ointment
218980672|NCT00795496|PROCEDURE|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
218980673|NCT00795496|PROCEDURE|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
218980674|NCT00795496|PROCEDURE|Serum IgE blood testing|One blood test to measure total serum IgE
219672975|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
219672976|NCT06315296|OTHER|Interview|Ancillary studies
219672977|NCT06220487|DRUG|Prednisone, Olverembatinib, Blinatumomab, Chidamide|"Phase One. Induction Consolidation, for 1 year. 1.1 Pretreatment ×1 cycle. Prednisone，1mg/kg/d, from day 1 to 14;~1.2 Induction Therapy × 1 cycle. A: OlverembAtinib (at a dose of 40 mg Qod), from day 8 to 42. B: Blinatumomab (at a dose of 28 μg per day), from day 15 to 28. C: Chidamide (at a dose of 10 mg Qod), from day 9 to 41.~1.3 Consolidation Block × 5 cycles. A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42. B: Blinatumomab (at a dose of 28 μg perday) was administered from day 1 to 14. C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Two. Maintenance Therapy, for 3 years. 2.1 A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42.~C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Three. Follow-up, for 5 years."
219672978|NCT02108899|BEHAVIORAL|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
219672979|NCT00892515|BEHAVIORAL|exercise intervention|
219672980|NCT00892515|OTHER|counseling intervention|
219672981|NCT00892515|OTHER|gas chromatography|
219672982|NCT00892515|OTHER|immunoenzyme technique|
219672983|NCT00892515|OTHER|immunologic technique|
219672984|NCT00892515|OTHER|laboratory biomarker analysis|
219672985|NCT00892515|OTHER|mass spectrometry|
219672986|NCT00892515|OTHER|physiologic testing|
219672987|NCT00892515|OTHER|questionnaire administration|
219672988|NCT00892515|OTHER|survey administration|
219672989|NCT00892515|PROCEDURE|dual x-ray absorptometry|
219672990|NCT00892515|PROCEDURE|magnetic resonance imaging|
219672991|NCT00892515|PROCEDURE|study of high risk factors|
219672992|NCT02334098|DIETARY_SUPPLEMENT|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
219208887|NCT06775145|DEVICE|sham-R_cDC+cTBS & HD-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
219672993|NCT02334098|DIETARY_SUPPLEMENT|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
219672994|NCT00694720|DRUG|AVE0657|capsules once a day at bedtime
219672995|NCT00694720|DRUG|placebo|capsules once a day at bedtime
219672996|NCT01808222|DRUG|FACBC|Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
219672997|NCT02254356|DEVICE|Zilver Flex Bare Metal Stent|
219672998|NCT02641405|DEVICE|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
219672999|NCT02641405|DEVICE|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
219673000|NCT00177645|PROCEDURE|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
219673001|NCT00599742|BEHAVIORAL|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
219673002|NCT00599742|BEHAVIORAL|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
219673003|NCT00002773|BIOLOGICAL|allogeneic tumor cell vaccine|
219673004|NCT00002773|BIOLOGICAL|recombinant interferon alfa|
218980675|NCT00795496|PROCEDURE|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
218980676|NCT03777774|PROCEDURE|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
218980677|NCT03777774|PROCEDURE|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
218980678|NCT03777774|PROCEDURE|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
218980679|NCT06120270|DEVICE|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
218980680|NCT05480930|OTHER|paper-based clinical decision support (dCDS) tool|The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
218980681|NCT05480930|OTHER|digital clinical decision support (dCDS) tool|The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
218980682|NCT01863953|DRUG|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
218980683|NCT01863953|DRUG|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
218980684|NCT01863953|DRUG|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
218980685|NCT01863953|DRUG|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
218980686|NCT03716193|OTHER|Oxygen|Patients will be given oxygen via a facemask during the measurement session
218980687|NCT00509041|DRUG|dasatinib|50 mg PO bid
218980688|NCT02221024|PROCEDURE|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
218980689|NCT02221024|DRUG|Normal saline|
218980690|NCT02221024|DEVICE|MicroClave ICU Medica|
218980691|NCT00814866|DRUG|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
219673005|NCT00002773|BIOLOGICAL|sargramostim|
219673006|NCT00002773|DRUG|cyclophosphamide|
219673007|NCT02652702|PROCEDURE|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
219673008|NCT02652702|PROCEDURE|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
219673009|NCT02383355|DRUG|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
219673010|NCT02383355|DRUG|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
219673011|NCT01183416|DRUG|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
219673012|NCT02799277|DRUG|Testosterone|Effect of testosterone on moral decision making
219673013|NCT02799277|DRUG|Placebo|Effect of testosterone on moral decision making
219673014|NCT04624607|DEVICE|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219673015|NCT04624607|DEVICE|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219673016|NCT01026337|GENETIC|mutation analysis|Correlative study
219673017|NCT01026337|OTHER|pharmacological study|Correlative study
219673018|NCT01026337|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219673019|NCT01026337|DRUG|sunitinib malate|Given orally
219673020|NCT01026337|OTHER|immunohistochemistry staining method|Correlative study
219673021|NCT01026337|OTHER|laboratory biomarker analysis|Correlative study
218980692|NCT06039488|BEHAVIORAL|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
218980693|NCT02098252|PROCEDURE|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
218980694|NCT02098252|RADIATION|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
218980695|NCT02098252|PROCEDURE|Embolization|Curative embolization, when the lesion is considered curable by embolization.
218980696|NCT04771312|BEHAVIORAL|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
218980697|NCT04771312|BEHAVIORAL|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
218980698|NCT02486666|DRUG|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
218980699|NCT05920278|DEVICE|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
218980700|NCT04406974|PROCEDURE|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
219069858|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
219069859|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
219069860|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
219069861|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
219069862|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
219069863|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
219069864|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
219069865|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
219069866|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
219069867|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
219069868|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
219069869|NCT02266628|BIOLOGICAL|Saline Placebo|
219673022|NCT01146561|BIOLOGICAL|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
219673023|NCT01146561|OTHER|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
219673024|NCT04231968|DRUG|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
219673025|NCT04231968|DRUG|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
219673026|NCT03510429|DIETARY_SUPPLEMENT|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
219673027|NCT03510429|OTHER|Routine post-op care|Routine post-operative care
219673028|NCT03123003|DEVICE|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
219673029|NCT03123003|DEVICE|Wrist X-ray|Bone age assessment by Wrist X-ray
219673030|NCT03326232|DEVICE|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
219673031|NCT04745507|OTHER|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
218980701|NCT04406974|PROCEDURE|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
218980702|NCT06384898|OTHER|Remote Tai Chi|Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
219673032|NCT04978805|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
219673033|NCT01915524|BIOLOGICAL|CV9202|Intradermal injection of CV9202
219673034|NCT01915524|RADIATION|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
219673035|NCT02295787|DRUG|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
219673036|NCT02295787|DRUG|Placebo|
218980703|NCT03031132|BEHAVIORAL|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
218980704|NCT03031132|BEHAVIORAL|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
218980705|NCT03031132|BEHAVIORAL|Breakfast Skipping|Participants will skip breakfast each morning.
218980706|NCT00384410|DRUG|Nabilone|
218980707|NCT02806531|BIOLOGICAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
218980708|NCT03240354|DEVICE|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
218980709|NCT03240354|DEVICE|Control|Cuff of endotracheal tube inflated with air
218980710|NCT06209931|PROCEDURE|RIRS|RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
218980711|NCT02105883|OTHER|Use of identification badge during scenarios|
218980712|NCT01824342|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
218980713|NCT05823532|DRUG|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
218980714|NCT05823532|DRUG|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
218980715|NCT03862560|OTHER|Strength training program|Strength training program in female soccer players
218980716|NCT02661685|BIOLOGICAL|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
219673037|NCT01516645|DRUG|KHK2898|injection
218980717|NCT01313858|DRUG|Simponi®|
218980718|NCT01313858|DRUG|Methotrexate|Given concomitantly with Simponi®
218980719|NCT04992598|OTHER|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
218980720|NCT04992598|PROCEDURE|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
219673038|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
219673039|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
219673040|NCT02036541|DEVICE|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
219673041|NCT01778751|BEHAVIORAL|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
219673042|NCT05626257|OTHER|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
219673043|NCT00410618|PROCEDURE|cognitive assessment|
219673044|NCT00410618|PROCEDURE|magnetic resonance imaging|
219673045|NCT00410618|PROCEDURE|management of therapy complications|
219673046|NCT03960424|OTHER|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
219673047|NCT03960424|BEHAVIORAL|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
219673048|NCT03850990|BEHAVIORAL|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
219673049|NCT04671056|DRUG|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
219673050|NCT04671056|DRUG|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
219673051|NCT04659902|DIETARY_SUPPLEMENT|Protein form|Protein form and absence or presence of calcium manipulated
219673052|NCT01454414|OTHER|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
219673053|NCT04517578|OTHER|Survey|Participants will be asked to fill in an online survey that will be anonimized.
219673054|NCT03609190|DRUG|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
219673055|NCT03609190|DRUG|Placebo|i.v. infusion of NaCl over 40 min
219673056|NCT05681637|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
219673057|NCT06612502|BEHAVIORAL|Static stretching|The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. The subjects were instructed to perform the following sequence of stretches: forward lunge, supine knee flexion, lateral quadriceps stretch, sitting toe touch, semi-straddle, straddle, butterfly stretch, and a straight knee ankle extensor wall stretch. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
219673058|NCT06612502|DEVICE|Fascia gun ( Short-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The short time PMT was applied for 2.5 minutes per muscle site for a total of 25 minutes.
219673059|NCT06612502|DEVICE|Fascia gun ( Long-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The long time PMT was applied for 4 minutes per muscle site for a total of 40 minutes.
219673060|NCT06612372|BEHAVIORAL|60-day-6° head-down bed rest|Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
219673061|NCT05018988|DIETARY_SUPPLEMENT|Oral vitamin D spray|1 spray (10µg) /day for 12 weeks
219673062|NCT05018988|DIETARY_SUPPLEMENT|Placebo|1 spray / day for 12 weeks
219673063|NCT06601738|OTHER|Isomeric Hand Grip Exercises|Patients will be instructed to squeeze and sustain the dynamometer for 2 min at 30% M.V.C. The dynamometer pointer which read the scale provided visual feedback to the subjects for the maintenance of the 30% M.V.C. This procedure will be repeated twice for each training session with a 5-minute rest in between.
219673064|NCT06601738|OTHER|Dynamic Hand Grip Exercises|Dynamic handgrip exercise was performed with both-sided, metronome-guided rhythmic hand contractions for 2min. The handgrip ring, closest to 20% of MVC, was chosen for DHE which was performed at a frequency of 30/min, acoustically indicated by a metronome beat.
218980721|NCT03033485|RADIATION|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
218980722|NCT04253223|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
218980723|NCT04731181|BEHAVIORAL|mobile application (little lovely dentist).|mobile application
218980724|NCT00845104|DRUG|fludarabine phosphate|Given IV
218980725|NCT00845104|BIOLOGICAL|rituximab|Given IV
218980726|NCT00845104|BIOLOGICAL|bevacizumab|Given IV
218980727|NCT00845104|OTHER|laboratory biomarker analysis|Correlative studies
218980728|NCT00845104|OTHER|flow cytometry|Correlative studies
218980729|NCT00845104|GENETIC|polymerase chain reaction|Correlative studies
218980730|NCT00845104|GENETIC|fluorescence in situ hybridization|Correlative studies
218980731|NCT06037070|BIOLOGICAL|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
218980732|NCT03673449|DEVICE|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
218980733|NCT01011777|DRUG|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
218980734|NCT03041077|DIETARY_SUPPLEMENT|Instaflex Advanced|Joint function
219673065|NCT03628716|BIOLOGICAL|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
219673066|NCT03628716|BIOLOGICAL|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
219673067|NCT07006623|BEHAVIORAL|CoMBI-SMI|CoMBI-SMI (Cognitive Model for Behavioral Interventions - Severe Mental Illness) is a structured, team-based behavioral intervention for individuals with severe mental illness. It consists of four steps: (1) analyzing misunderstood behavior and identifying unmet core needs, (2) selecting the most relevant core need, (3) choosing appropriate nursing interventions, and (4) developing a CoMBI care plan. The model is based on cognitive-behavioral principles and personality-based formulations grounded in the DSM. It describes self-image, perception of others, triggers, and problematic behaviors. CoMBI-SMI is implemented by the entire team in a cyclical process, with periodic evaluation and a focus on consistent, team-aligned strategies.
219673068|NCT04735796|DRUG|Drug：LM-102|Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
219673069|NCT04869111|BEHAVIORAL|Brain Health Training|"1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index"
219673070|NCT04039321|DRUG|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
219673071|NCT04039321|DRUG|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
219673072|NCT00003418|DRUG|exemestane|
219673073|NCT00003418|DRUG|tamoxifen citrate|
219673074|NCT05954936|OTHER|Risk factor|No therapeutic or diagnostic intervention will be provided; it is an observational study.
219673075|NCT04691206|OTHER|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
219673076|NCT05297929|DRUG|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
219673077|NCT02061683|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
219673078|NCT01573754|DRUG|Hydroxychloroquine|100 mg by mouth twice weekly
219673079|NCT01573754|PROCEDURE|Phlebotomy|450 mL every 2 weeks
219673080|NCT00908427|PROCEDURE|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
218980735|NCT03041077|DIETARY_SUPPLEMENT|Placebo|Placebo
218980736|NCT01134276|PROCEDURE|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
218980737|NCT01191333|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
218980738|NCT01191333|DEVICE|Sham Device|Placebo Device that simulates active rTMS treatment
218980739|NCT00036829|PROCEDURE|pain therapy|
218980740|NCT00071474|PROCEDURE|shamanic healing|
218980741|NCT04015336|BIOLOGICAL|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
218980742|NCT06793540|BEHAVIORAL|SELF POSTUROTHERAPIE|a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.
218980743|NCT03792191|RADIATION|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
218980744|NCT03792191|RADIATION|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
218980745|NCT03792191|PROCEDURE|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
218980746|NCT03792191|PROCEDURE|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
218980747|NCT03792191|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
218980748|NCT03792191|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
218980749|NCT00277836|DRUG|MST-997|
219673081|NCT00908427|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
219673082|NCT03376373|BEHAVIORAL|neurofeedback|real-time feedback on accuracy of emotion recognition
219673083|NCT00829829|OTHER|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
219673084|NCT00829829|DRUG|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
219673085|NCT00829829|DRUG|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
219673086|NCT02583867|BEHAVIORAL|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
219673087|NCT02685072|DRUG|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
219673088|NCT02685072|DRUG|Placebo|TNP + Placebo
219673089|NCT05543031|OTHER|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
219673090|NCT05543031|DIAGNOSTIC_TEST|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
219673091|NCT05543031|DIAGNOSTIC_TEST|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
219673092|NCT05543031|DIAGNOSTIC_TEST|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
219673093|NCT05543031|DIAGNOSTIC_TEST|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
219673094|NCT00190112|PROCEDURE|ventral cardiac denervation|
219673095|NCT03563664|PROCEDURE|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
219673096|NCT03563664|DRUG|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
219673097|NCT03563664|PROCEDURE|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
219673098|NCT04934982|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
219673099|NCT04934982|OTHER|Total Abdominal Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
218980750|NCT03423082|DRUG|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
218980751|NCT03423082|DEVICE|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
218980752|NCT05340023|BIOLOGICAL|blood sample|to realize proteomic analysis.
218980753|NCT06549790|DRUG|NMS-03597812|Route of Administration: Oral
218980754|NCT04149626|DRUG|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
218980755|NCT04149626|DRUG|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
218980756|NCT04149626|DRUG|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
219069870|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
219069871|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
218980757|NCT01965821|DEVICE|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
218980758|NCT01965821|DEVICE|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
219069872|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
219208888|NCT06775145|DEVICE|HD-R_cDC+cTBS & HD-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
219208889|NCT06775145|DEVICE|sham-R_cDC+cTBS & sham-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
219208890|NCT06772545|PROCEDURE|Epidural Analgesia|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.
219208891|NCT06772545|DEVICE|Paravertebral Block|Using an in-plane technique, the puncture needle was advanced from lateral to medial under real-time ultrasound guidance to the target paravertebral space, passing through the intercostal fascia, avoiding the parietal pleura, and positioning the needle tip superior to the costotransverse ligament. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block.
219208892|NCT06772545|DEVICE|Transversus Abdominis Plane Block|The plane of blockade and whether to perform a single or double injection technique were determined based on the incision location. Under real-time ultrasound guidance, the puncture needle was advanced to the target transversus abdominis plane. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was injected slowly in a fractionated manner while observing the local anesthetic spread to ensure effective blockade.
219208893|NCT06772545|DEVICE|patient-controlled intravenous analgesia (PCA)|The patient-controlled analgesia (PCA) device was programmed to deliver bolus doses of 15 μg fentanyl, with a 10-minute lockout period and no background infusion. The PCA solution consisted of 1 mg fentanyl and 8 mg of tropisetron mixed in 100 mL of normal saline.
219208894|NCT06771518|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy using 4D technique by irradiating the initial sites of disease (primary tumor and involved hilo-mediastinal lymph nodes). The treatments must be provided with the modulated intensity technique (IMRT or VMAT), treatments with conformal technique (3DCRT) are not permitted, where necessary, the Simultaneous Integrated Boost (SIB) technique can be used.
219208895|NCT06771518|DRUG|Atezolizumab 1200 mg e.v. q21|Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice
219208896|NCT06771362|PROCEDURE|ART with Bulk-Fill composite|Restoration using Bulk-fill flowable self-cured composite
219208897|NCT06771362|PROCEDURE|ART with Glass Ionomer|Restoration Using High-Viscosity Glass Ionomer Cement
219208898|NCT06831331|OTHER|REK-diet|Personalized diet- the participants will get individual advice how to adapt their habitual diet to the Nordic Nutrition Recommendations 2023
219208899|NCT06831331|OTHER|RICH-diet|Diet rich in nutrients and with high quality protein
219208900|NCT05346718|OTHER|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
219208901|NCT06056141|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
219208902|NCT06056141|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
219208903|NCT06822166|DRUG|rifampicin|rifampicin capsule，600 mg
219208904|NCT06822166|DRUG|Fluconazole|Fluconazole capsules: 400 mg for the first dose and 200 mg for the remaining doses
219208905|NCT06822166|DRUG|Omeprazole|Omeprazole enteric-coated capsules: 20 mg
219208906|NCT06822166|DRUG|midazolam|midazolam injection 0.05 mg/kg was administered intravenously
219208907|NCT06822166|DRUG|ET-26|the dose is 0.8 mg/kg, single dose, Infusion time was 60seconds ± 5seconds
219208908|NCT06734936|OTHER|Playing videos with sgg|Playing videos with sgg
219208909|NCT06746532|BIOLOGICAL|Intranasal breast milk|"Own-mother's fresh breast milk (within 4 hours of having been expressed), is administered intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days.~Dose: 2 times daily, 0.4 ml in each nostril."
219208910|NCT06746103|PROCEDURE|Surgery|Surgery may be instrumented stabilization surgery alone, instrumented stabilization and decompression, or decompression surgery alone.
218980759|NCT05626426|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
218980760|NCT05265039|BEHAVIORAL|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
218980761|NCT05265039|BEHAVIORAL|Relaxation Training|Guided relaxation
218980762|NCT05955261|DRUG|Venetoclax|Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
218980763|NCT05955261|DRUG|Azacitidine|Given IV over 30 minutes on days 1-5
218980764|NCT05955261|DRUG|Cytarabine|Given IV over 30 minutes q12 hours on days 1-8 (16 doses)
218980765|NCT05955261|DRUG|Gemtuzumab Ozogamicin|Given IV
218980766|NCT05955261|DRUG|Daunorubicin Hydrochloride|IV over 1 hour on days 1, 3, and 5
218980767|NCT05955261|DRUG|Fludarabine Phosphate|Given IV over 30 minutes on days 1-5
218980768|NCT05955261|DRUG|Idarubicin Hydrochloride|Given IV over 15 minutes on days 3-5
218980769|NCT05955261|DRUG|Mitoxantrone Hydrochloride|IV over 1 hour on days 2-4
218980770|NCT05955261|DRUG|Etoposide|Given IV over 1 hour on days 1-5
218980771|NCT05955261|DRUG|Gilteritinib|PO on days 8-28 (21 doses)
219673100|NCT04547231|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|"1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
219673101|NCT01994902|DEVICE|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
219673102|NCT01994902|DEVICE|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
219673103|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
219673104|NCT05509010|PROCEDURE|CTCA|CTCA is performed as part of routine care procedure.
219673105|NCT05242133|DRUG|Pegylated interferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
219673106|NCT05242133|DRUG|Interferon Beta-1A Prefilled Syringe|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
219673107|NCT00681265|DRUG|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
219673108|NCT00681265|DRUG|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
219673109|NCT04209439|DRUG|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
219673110|NCT04209439|DRUG|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
219673111|NCT04786665|OTHER|Strawberry|Freeze dried strawberry powder
219673112|NCT04786665|OTHER|Placebo group|Comparative placebo powder
218980772|NCT03921073|DRUG|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
218980773|NCT01884532|DEVICE|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
218980774|NCT01816074|DRUG|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
218980775|NCT01816074|BEHAVIORAL|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
218980776|NCT02993393|OTHER|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
218980777|NCT02993393|OTHER|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
219069873|NCT01527201|PROCEDURE|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
219069874|NCT01517698|DRUG|Placebo|placebo to RO4917523 orally once a day for 12 weeks
219069875|NCT01517698|DRUG|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
219069876|NCT01517698|DRUG|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
219069877|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
219673113|NCT02895139|DEVICE|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
218980778|NCT02737696|BEHAVIORAL|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
218980779|NCT02737696|BEHAVIORAL|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
218980780|NCT03826589|DRUG|Avelumab|an anti-programmed cell death ligand 1
218980781|NCT03826589|DRUG|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
218980782|NCT02563015|DIETARY_SUPPLEMENT|cholecalciferol|liquid drops
218980783|NCT02563015|DIETARY_SUPPLEMENT|Reference 400|liquid drops
218980784|NCT05812755|DRUG|Vericiguat|Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
219069878|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
219069879|NCT02790385|OTHER|Standard Gauze Treatment|
219069880|NCT02752620|OTHER|Osteopathic Manipulative Treatment|
219069881|NCT02752620|OTHER|Exercise Therapy|
219673114|NCT02895139|DEVICE|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
219673115|NCT02895139|DEVICE|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
219673116|NCT01491269|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
219673117|NCT01994473|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
219673118|NCT01994473|DRUG|Placebo|single oral dose placebo
219673119|NCT01994473|DRUG|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
218980785|NCT05812755|DRUG|Placebo|Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
219673120|NCT06729944|DIAGNOSTIC_TEST|NGS|Tissue samples will be processed and analysed at the U.O. of Pathological Anatomy
219673121|NCT04484844|DRUG|TOKUYAMA SHIELD FORCE PLUS|Self-reinforcing (SR) monomer technology
219673122|NCT04484844|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
219673123|NCT04026932|OTHER|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
219673124|NCT04026932|OTHER|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
219673125|NCT02620085|PROCEDURE|blood sampling|blood sampling
219673126|NCT02717442|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
219673127|NCT02717442|DRUG|Placebo|Single intratympanic injection of placebo
219673128|NCT06137209|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
219673129|NCT06137209|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
219673130|NCT06718387|OTHER|PsychoEducation Program|6 sessions of PsychoEducational Program
219673131|NCT02798354|BEHAVIORAL|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
219673132|NCT03721211|DRUG|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
219673133|NCT03721211|DEVICE|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
219673134|NCT05219097|DIAGNOSTIC_TEST|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
219673135|NCT00538954|DRUG|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
219673136|NCT00538954|DIETARY_SUPPLEMENT|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
219673137|NCT00538954|OTHER|Standard ERAS group|
218980786|NCT00628056|DRUG|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
218980787|NCT04756843|DEVICE|Quad-helix|Fixed orthodontic appliance
218980788|NCT00645385|OTHER|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
218980789|NCT05388929|DRUG|Methocarbamol|Methocarbamol after surgery
219069882|NCT04211103|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
219208911|NCT05453851|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
219208912|NCT05453851|OTHER|Quality-of-Life Assessment|Ancillary studies
219208913|NCT05453851|OTHER|Treatment Planning|Undergo IV autologous islet cell transplant
219673138|NCT05872880|PROCEDURE|Modified radical surgery|The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.
219673139|NCT05872880|PROCEDURE|Radical surgery|Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
219673140|NCT04401280|DRUG|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
219673141|NCT04401280|DRUG|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
219673142|NCT04401280|DRUG|CPP-ACP|applied in accordance with the manufacturer's specifications
218980790|NCT05388929|DRUG|Standard Opioid|Standard opioid after surgery or at discharge
218980791|NCT05388929|DRUG|Standard opioid plus methocarbamol|Standard opioid plus methocarbamol after surgery or at discharge
219069883|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
219069884|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
219069885|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
219069886|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
219069887|NCT04533841|DRUG|Placebo|placebo
219069888|NCT04533841|DRUG|Propranolol|Propranolol
219208914|NCT06757465|OTHER|Counseling education based on Watson's Theory of Human Caring|In this study, a total of 75 interviews were conducted with 25 participants in the intervention group in three sessions. During the interviews, counseling training based on Watson IBK developed by the researchers was applied. Each session lasted between 30-45 minutes per participant. The first session was conducted face-to-face, and the second and third sessions were conducted using online platforms (Zoom, Microsoft Teams, WhatsApp video call) within the scope of telehealth applications. Sessions were structured according to the individual needs of the participants and the durations were arranged flexibly when necessary. Telehealth applications provided easy access to the participants during the counseling process and supported the continuity of individual counseling services.
219208915|NCT06757998|PROCEDURE|Mesh|Compare between On-lay versus pre-peritoneal hernioplasty in incisional lumbar herni
219673143|NCT05032729|OTHER|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
219673144|NCT05032729|OTHER|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
219673145|NCT00528372|DRUG|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
219673146|NCT00528372|DRUG|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
219673147|NCT00528372|DRUG|Metformin|
219673148|NCT03718169|BEHAVIORAL|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
219673149|NCT02238938|PROCEDURE|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
218980792|NCT06562725|OTHER|specific ventilator settings|The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
218980793|NCT06507358|BEHAVIORAL|Parent-Child Interaction group|The intervention for the Parent-Child Interaction group consists of a 6-week program involving weekly 40-minute sessions of therapeutic horticulture in a group setting, with 4-6 participants per group. The sessions focus on sensory-motor activities aimed at helping children engage in daily tasks and activities. Various sensory stimuli are provided through different materials used in gardening activities, including visual, auditory, gustatory, tactile, and olfactory stimuli. The program encourages mutual support and sharing among group members, showcases different outcomes, and emphasizes a sense of responsibility for home care. With a family-centered approach, parental involvement serves as a mediator to promote children's overall development and abilities. Participants are required to complete homework assignments and maintain activity records, including documentation of the 6 sessions through photos and written records.
218980794|NCT05194566|DEVICE|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
219069889|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
219673150|NCT02238938|PROCEDURE|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
219673151|NCT04467710|PROCEDURE|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
219673152|NCT06393010|BEHAVIORAL|online rehabilitation program|Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
219673153|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
219673154|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
219673155|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
219673156|NCT03965455|DEVICE|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
219069890|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
219069891|NCT02359721|DRUG|tablet clarithromycin 500 mg (Clarino-500) orally|orally
219069892|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
219673157|NCT03965455|PROCEDURE|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
219069893|NCT01194141|BEHAVIORAL|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
219069894|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
219069895|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
219673158|NCT00006355|DRUG|pyrazoloacridine|
219673159|NCT00006355|PROCEDURE|adjuvant therapy|
219673160|NCT00006355|RADIATION|radiation therapy|
219673161|NCT04782414|PROCEDURE|Hot AXIOS® prosthesis|endoscopic trans digestive drainage using of the Hot AXIOS prosthesis in the treatment of pancreatic collections (incompletely fluid or necrotic)
219673162|NCT00973895|BIOLOGICAL|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
219673163|NCT05271123|DIAGNOSTIC_TEST|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
219673164|NCT06303414|PROCEDURE|Carotid Endarterectomy (CEA)|Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
219673165|NCT06303414|PROCEDURE|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.
219673166|NCT06303414|PROCEDURE|Hybrid Surgery|Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
219673167|NCT03818555|OTHER|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
219673168|NCT02350699|DEVICE|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
219673169|NCT05210270|RADIATION|Hypofractionation|"Phase 1 (Dose Escalation Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with nSIB 45 Gy (first dose level) and 48 Gy (second dose level); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)~Phase 2 (Efficacy Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with (or without) nSIB 45-48 Gy (depending on phase 1 results); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)"
219673170|NCT03461302|DRUG|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
219673171|NCT03461302|DRUG|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
219069896|NCT02467777|DEVICE|Bair Hugger|
219069897|NCT02467777|DEVICE|VitaHeat|
219069898|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
219069899|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
219360351|NCT03369964|DRUG|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
219673172|NCT05822206|BEHAVIORAL|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
219673173|NCT05822206|BEHAVIORAL|Life Steps and Sexual Decision-Making|
219673174|NCT00671099|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
219673175|NCT00671099|DIETARY_SUPPLEMENT|Placebo|Placebo
219673176|NCT04267159|OTHER|Acute cardioversion|Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
219673177|NCT04267159|OTHER|Delayed cardioversion|Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
219673178|NCT04282837|DIAGNOSTIC_TEST|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
219360352|NCT03369964|DRUG|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
219360353|NCT03754309|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
219673179|NCT05131932|PROCEDURE|Endoscopic ablation of inlet patch|Endoscopic ablation of inlet patch using argon plasma coagulation (APC)
219673180|NCT00003037|DRUG|cisplatin|
219673181|NCT00003037|DRUG|docetaxel|
219673182|NCT00003037|DRUG|gemcitabine hydrochloride|
219069900|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
219673183|NCT05460637|BEHAVIORAL|No BS just Fitness|The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
219069901|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
219069902|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
219069903|NCT03900936|DIAGNOSTIC_TEST|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
219069904|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
219069905|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
219069906|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
219069907|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
219069908|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
219069909|NCT01474135|DRUG|0.004% Travoprost|
219069910|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
219069911|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
219069912|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
219673184|NCT02169388|DRUG|Probiotic|Microbial composition using probiotic
219673185|NCT02169388|DRUG|placebo（for probiotic）|microbiota modulation using placebo
219673186|NCT03090451|BEHAVIORAL|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
219673187|NCT02860507|DRUG|sugammadex|
219673188|NCT02860507|DRUG|Neostigmine|
219673189|NCT02860507|DRUG|Glycopyrrolate|
219673190|NCT06220409|OTHER|Dance classes|A 12-week dance class training program two times a week for 3 months
219069913|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
219069914|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
219069915|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
219069916|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
219069917|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
219069918|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
219069919|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
219069920|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
219069921|NCT01303289|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
219069922|NCT01303289|DIETARY_SUPPLEMENT|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
219069923|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
219360354|NCT03754309|DRUG|Placebo|Matched placebo
219069924|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
219673191|NCT02772809|DEVICE|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
219673192|NCT00534105|OTHER|Total Cholesterol|
219673193|NCT00534105|OTHER|Triglyceride|
219069925|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
219069926|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
219673194|NCT00534105|OTHER|HDL|
219673195|NCT00534105|OTHER|LDL|
219673196|NCT00479297|DRUG|SAM-531|
219673197|NCT02774005|DRUG|Idebenone|
219673198|NCT04978077|OTHER|Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)|After a night fast participants will drink the test meal
219673199|NCT04262960|DEVICE|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
219673200|NCT04262960|DEVICE|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
219673201|NCT02156973|OTHER|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
219069927|NCT02386566|DRUG|natalizumab|As described in the treatment arm
219069928|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
219673202|NCT02577627|DEVICE|PrediCare|
219673203|NCT05547776|BEHAVIORAL|Mindfulness app|The mindfulness app contains 6 modules with a variety of features to help caregivers reduce their stress.
219673204|NCT04858360|DRUG|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
219673205|NCT04858360|DRUG|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
219069929|NCT00201383|DRUG|cisplatin|
219069930|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
219069931|NCT05253898|PROCEDURE|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
219673206|NCT04858360|OTHER|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
219673207|NCT04858360|OTHER|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
219069932|NCT05253898|PROCEDURE|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
219069933|NCT03387852|DRUG|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
219069934|NCT03387852|DRUG|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
219069935|NCT03387852|DRUG|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
219069936|NCT03387852|DRUG|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
219069937|NCT03387852|DRUG|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
219069938|NCT05430412|DEVICE|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
219673208|NCT04858360|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
219673209|NCT06731257|OTHER|virtual ward early discharge|Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
219673210|NCT02259829|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
219673211|NCT02259829|DRUG|Telmisartan|
219673212|NCT02259829|DRUG|Amlodipine|
219673213|NCT03419130|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
219673214|NCT03419130|OTHER|Laboratory Biomarker Analysis|Correlative studies
219673215|NCT03419130|BIOLOGICAL|Pembrolizumab|Given IV
219673216|NCT03419130|RADIATION|Radiation Therapy|Undergo conventionally fractionated RT
219673217|NCT04151966|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
219673218|NCT00332631|DRUG|N-acetylcysteine|
219069939|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
219069940|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
219069941|NCT02596451|DRUG|Voltaren® Gel|
219069942|NCT02596451|DRUG|Placebo|
219673219|NCT00332631|DRUG|Placebo|
219673220|NCT03402230|DRUG|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
219673221|NCT03402230|OTHER|Laboratory Biomarker Analysis|Correlative studies
219673222|NCT03402230|OTHER|Questionnaire Administration|Ancillary studies
219673223|NCT05636982|OTHER|Telecare-based intervention program|A 3-month telecare-based intervention program
219673224|NCT02379273|DEVICE|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
219069943|NCT03590301|BEHAVIORAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
219069944|NCT03590301|BEHAVIORAL|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
219069945|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
219069946|NCT05812261|OTHER|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
219673225|NCT01443325|DRUG|lidocaine patch|1 patch for 12 hours within each 24 hours period
219069947|NCT00004093|DRUG|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
219069948|NCT00004093|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
219069949|NCT00004093|DRUG|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
219069950|NCT00004093|DRUG|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
219069951|NCT00004093|RADIATION|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
219673226|NCT06730048|OTHER|Experimental Group|An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
219673227|NCT06730048|OTHER|Control group (placebo)|After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
219673228|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
219673229|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
219673230|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
219673231|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
219673232|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
219673233|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
219673234|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
219673235|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
219208916|NCT06757127|OTHER|ERAS Protocol Adaptation for Emergency Laparotomy|The intervention incorporated a comprehensive quality improvement approach, including a presentation, live demonstrations, and an instructional video to support the implementation of ERAS protocols. These methods emphasized the key components outlined by the ERAS ® Society guidelines for emergency laparotomy, ensuring that participants understood the importance of each protocol step and its application in clinical practice. As part of the quality improvement initiative, efforts were made to engage key stakeholders, including local governance and healthcare authorities, to align the intervention with policy frameworks. Training materials, including videos and manuals, were reviewed by a consultant surgeon to ensure accuracy and relevance. Additionally, a consultant surgeon conducted individual demonstrations in the operating room and ward, supplemented by weekly morning meetings with nurses, anesthesiologists, residents, and doctors for one month.
219673236|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
219673237|NCT03275389|BIOLOGICAL|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
219673238|NCT03275389|BIOLOGICAL|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
219673239|NCT05144048|OTHER|Inpatient setting|These women stay at the maternity unit
219673240|NCT05144048|OTHER|Outpatient setting|These women leave the maternity unit
219673241|NCT00214292|PROCEDURE|fluorescence spectroscopy and diffuse spectroscopy|
219673242|NCT02432144|DRUG|UX003|solution for intravenous (IV) infusion
219673243|NCT04559425|DRUG|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
219673244|NCT04559425|OTHER|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
219673245|NCT05765825|DRUG|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
219673246|NCT05765825|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
219069952|NCT00004093|DRUG|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
219069953|NCT00004093|DRUG|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
219069954|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
219069955|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
219673247|NCT05765825|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
219673248|NCT05765825|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219673249|NCT05765825|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
219673250|NCT01222663|DEVICE|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
219673251|NCT01222663|DEVICE|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
219673252|NCT04861441|DEVICE|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
219673253|NCT04861441|DEVICE|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
219673254|NCT00978341|DRUG|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
219673255|NCT00978341|DRUG|Placebo for pregabalin|Placebo capsules BID for 7.5 days
219069956|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
219069957|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
219069958|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
219069959|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
219673256|NCT05879224|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total)(Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
219069960|NCT04695834|PROCEDURE|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
218980795|NCT05826561|OTHER|Childhood Asthma Passive Digital Marker|"A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care."
218980796|NCT04638296|OTHER|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
218980797|NCT05561205|DEVICE|rTMS|repetitive transcranial magnetic stimulation
219069961|NCT04695834|OTHER|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
219069962|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
219069963|NCT04108312|DIAGNOSTIC_TEST|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
218980798|NCT05561205|DRUG|methylphenidate|methylphenidate
218980799|NCT00817544|DRUG|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
218980800|NCT06113016|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218980801|NCT06113016|OTHER|Educational Intervention|Receive handout on physical activity
218980802|NCT06113016|OTHER|Exercise Intervention|Receive individually tailored exercise intervention
218980803|NCT06113016|DRUG|Fisetin|Given PO
219069964|NCT00265057|DRUG|ADH -1 (Exherin™)|
218980804|NCT06113016|OTHER|Physical Performance Testing|Ancillary studies
218980805|NCT06113016|DRUG|Placebo Administration|Given PO
219069965|NCT00438386|DRUG|Aripiprazole|
219069966|NCT02269293|DRUG|Paclitaxel|
219069967|NCT02269293|DRUG|Carboplatin|
219673257|NCT04788186|DRUG|De-prescribe beta blocker therapy|"Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue"
219673258|NCT05859763|DRUG|99mTc-HFAPI|Each patient receive a intravenous injection of 99mTc-HFAPI, and undergo SPECT/CT scan within specified time.
219673259|NCT04284163|BEHAVIORAL|Gamification|Teaching through gamification
219673260|NCT04284163|BEHAVIORAL|Traditional teaching|Teaching through master lesson methodology
219673261|NCT00752141|DRUG|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
218980806|NCT06113016|OTHER|Quality-of-Life Assessment|Ancillary studies
218980807|NCT06113016|OTHER|Questionnaire Administration|Ancillary studies
218980808|NCT04319991|DIETARY_SUPPLEMENT|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
218980809|NCT00258284|DRUG|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
218980810|NCT00258284|DRUG|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
219069968|NCT02269293|DRUG|Selinexor|
219673262|NCT00752141|DRUG|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
219673263|NCT00752141|OTHER|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
219673264|NCT00564317|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
219673265|NCT00564317|BEHAVIORAL|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
219673266|NCT06141421|PROCEDURE|procedure|procedure
219673267|NCT06314412|OTHER|Stoller's Afferent Nerve Stimulation (SANS)|15 sessions of SANS (5 sessions/week for 3 weeks)
219673268|NCT03891823|DEVICE|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
219673269|NCT03891823|DRUG|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
219673270|NCT05983510|PROCEDURE|Aortic endarteriectomy|Thoraco-phreno-lumbotomy with thoracic aortic cross clamping Longitudinal aortotomy Endarteriectomy of the aorta Direct closure more or less bypass to the visceral arteries and downstream aorta reconstruction.
219673271|NCT03035916|OTHER|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
219673272|NCT03035916|OTHER|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
219673273|NCT03035916|OTHER|control|The Control group receives standard IV-inhaled general anesthesia.
219673274|NCT00448812|DEVICE|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
219673275|NCT06521112|DRUG|Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.|Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
219673276|NCT02479464|GENETIC|Genotyping results|Genotyping results provided in Phase II
219673277|NCT02194764|DRUG|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
219673278|NCT02194764|DRUG|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
219673279|NCT01135836|PROCEDURE|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
219673280|NCT01135836|PROCEDURE|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
219673281|NCT01135836|PROCEDURE|Control group|CO2 was removed by passive exsufflation through the port site.
219673282|NCT03885999|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
219673283|NCT02105649|OTHER|Strengthening exercise + Electrical stimulation of calf muscle|
219673284|NCT02105649|OTHER|selected physical therapy program|
219673285|NCT02304354|DRUG|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
219673286|NCT01630954|PROCEDURE|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
219673287|NCT01630954|PROCEDURE|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
219673288|NCT02452554|OTHER|Laboratory Biomarker Analysis|Correlative studies
218980811|NCT03225729|DEVICE|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
218980812|NCT03225729|DEVICE|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
218980813|NCT03183531|DIAGNOSTIC_TEST|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
218980814|NCT00261118|DRUG|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
218980815|NCT02616848|DRUG|Everolimus|
218980816|NCT02616848|DRUG|Eribulin|
218980817|NCT04785248|PROCEDURE|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
218980818|NCT00095992|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
218980819|NCT05049681|DRUG|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
218980820|NCT05049681|DRUG|Apatinib|Apatinib 250mg, q.d.po
219673289|NCT02452554|BIOLOGICAL|Lorvotuzumab Mertansine|Given IV
219069969|NCT04695223|DRUG|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
219069970|NCT04590703|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
218980821|NCT04835480|DRUG|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
218980822|NCT04835480|DRUG|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
218980823|NCT03375008|DIAGNOSTIC_TEST|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
218980824|NCT01865188|DRUG|LCZ696|Experimental monotherapy doses
218980825|NCT01865188|DRUG|Amlodipine|Active comparator monotherapy doses
218980826|NCT01865188|DRUG|LCZ696 and amlodipine combination|Experimental combination doses
218980827|NCT01865188|DRUG|Placebo|Placebo comparator dose
218980828|NCT02777710|DRUG|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
218980829|NCT02777710|DRUG|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
218980830|NCT01582568|DRUG|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
218980831|NCT01422460|BIOLOGICAL|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
218980832|NCT01801826|DEVICE|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
218980833|NCT03285854|DIAGNOSTIC_TEST|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
219069971|NCT04590703|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
219069972|NCT04105023|DIETARY_SUPPLEMENT|genistein|Administered orally once every 12 hours
219069973|NCT04105023|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
219069974|NCT02142049|DRUG|Ibrutinib|Ibrutinib
219069975|NCT02142049|DRUG|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
218980834|NCT02007616|OTHER|Non-action video game training|Based on cognitive training Lumosity
218980835|NCT01636531|DRUG|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
218980836|NCT01636531|DRUG|gantenerumab|Lyophilized formulation (LyoF), single dose sc
218980837|NCT05515471|DRUG|SHR8058 eye drops|SHR8058 eye drops
218980838|NCT05515471|DRUG|saline eye drops.|saline eye drops.
218980839|NCT03286738|DRUG|FOLFIRI, target agent|"* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
218980840|NCT01228643|BIOLOGICAL|Pancreatic enzimes|\- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
218980841|NCT01228643|DEVICE|Creon ®|\- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
218980842|NCT02359422|BEHAVIORAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
218980843|NCT02995031|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
218980844|NCT02995031|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
218980845|NCT02371304|RADIATION|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
218980846|NCT02371304|PROCEDURE|Additional TME surgery|
218980847|NCT02371304|DRUG|capecitabine|
218980848|NCT03650556|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
218980849|NCT00691301|DRUG|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
219069976|NCT02142049|DRUG|Lenalidomide|Lenalidomide
219069977|NCT05374980|DIETARY_SUPPLEMENT|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
219069978|NCT05374980|DIETARY_SUPPLEMENT|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
219069979|NCT02997566|OTHER|Autonomic evaluation|
219069980|NCT02501460|OTHER|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
219673290|NCT02452554|OTHER|Pharmacological Study|Correlative studies
219673291|NCT06313554|DRUG|Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin|"The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
219673292|NCT06274151|DRUG|Naproxen 500 Mg|Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
219673293|NCT06274151|PROCEDURE|Rehabilitation|Rehabilitation after muscle strain injury
219673294|NCT06274151|DRUG|Placebo|Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
219673295|NCT02313805|OTHER|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
219673296|NCT01658397|BEHAVIORAL|Fasting|Ten day fast
219673297|NCT05740345|DRUG|Metformin|Metformin
219673298|NCT02533297|OTHER|Providing clinical skills conditions|
219673299|NCT04792047|DIAGNOSTIC_TEST|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
219673300|NCT06234527|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
219673301|NCT04891627|DIAGNOSTIC_TEST|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
219673302|NCT05964127|DEVICE|Air flow device|An air/powder device for surface decontamination
218980850|NCT00691301|DRUG|pemetrexed disodium|
218980851|NCT02698878|DIETARY_SUPPLEMENT|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
218980852|NCT02698878|OTHER|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
218980853|NCT02698878|DEVICE|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
218980854|NCT02213640|DEVICE|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
218980855|NCT02213640|DEVICE|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
218980856|NCT05729230|BEHAVIORAL|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
218980857|NCT00463580|DRUG|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
218980858|NCT00463580|DRUG|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
218980859|NCT06068023|DRUG|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
218980860|NCT06068023|DRUG|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
218980861|NCT05875571|DRUG|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
218980862|NCT05875571|DRUG|Placebo|Patients will get IV placebo during IUD placement under sedation
218980863|NCT06043882|PROCEDURE|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
218980864|NCT04216966|DEVICE|Control group|No intervention was given
218980865|NCT04216966|DEVICE|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
218980866|NCT04216966|DEVICE|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
218980867|NCT04216966|DEVICE|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
218980868|NCT03431870|OTHER|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
218980869|NCT03917459|DRUG|LCZ696|sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
218980870|NCT03917459|DRUG|Enalapril matching placebo|Placebo to Enalapril 10 mg film-coated tablets
218980871|NCT03917459|DRUG|Enalapril|Enalapril 10 mg film-coated tablets
218980872|NCT03917459|DRUG|LCZ696 matching placebo|Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
218980873|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
218980874|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
218980875|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
218980876|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
218980877|NCT00491764|DRUG|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
218980878|NCT00491764|DRUG|Placebo|Placebo for 24 weeks.
219673303|NCT05964127|OTHER|Hand instruments|Periodontal hand instruments
219673304|NCT05964127|PROCEDURE|Access flap surgery|To improve the surgical access for implant decontamination
218980879|NCT05455268|OTHER|eHOPE|"e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations."
218980880|NCT05455268|OTHER|Usual care|Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
218980881|NCT01253473|DRUG|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
218980882|NCT01253473|DRUG|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
218980883|NCT01253473|DRUG|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
218980884|NCT03888586|DEVICE|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
218980885|NCT03888586|OTHER|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
218980886|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
218980887|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
218980888|NCT01282632|DRUG|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
219069981|NCT02501460|OTHER|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
219069982|NCT02501460|DIETARY_SUPPLEMENT|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
219673305|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
219673306|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
219673307|NCT01349127|DIETARY_SUPPLEMENT|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
219673308|NCT05535322|DRUG|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
219673309|NCT05535322|DRUG|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
219673310|NCT05535322|DRUG|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
219673311|NCT05535322|DRUG|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
219673312|NCT01665482|OTHER|A 2000 kcal test meal|
219673313|NCT01665482|OTHER|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
219673314|NCT03402672|OTHER|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
219673315|NCT01560572|DRUG|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
219673316|NCT01065363|BEHAVIORAL|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
219673317|NCT03712267|BEHAVIORAL|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
219673318|NCT03712267|BEHAVIORAL|Treatment as Usual|Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
219673319|NCT01317524|DIETARY_SUPPLEMENT|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
219673320|NCT01317524|DIETARY_SUPPLEMENT|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
219673321|NCT01317524|DIETARY_SUPPLEMENT|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
219673322|NCT05491863|OTHER|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
218980889|NCT01282632|DRUG|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
218980890|NCT04824950|OTHER|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
218980891|NCT04333550|DRUG|Deferoxamine|Intravenous infusion of Deferoxamine
218980892|NCT03720353|DRUG|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
218980893|NCT03720353|DRUG|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
218980894|NCT03720353|DRUG|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
218980895|NCT00001963|PROCEDURE|hemoglobin-transported nitric oxide|
218980896|NCT05687175|OTHER|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
218980897|NCT02704260|GENETIC|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
218980898|NCT05276037|OTHER|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
218980899|NCT02451111|DRUG|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
218980900|NCT02451111|DRUG|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
218980901|NCT04312581|DEVICE|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
218980902|NCT04312581|OTHER|Conventional rehabilitation|physical \& occupational therapy
218980903|NCT01142271|PROCEDURE|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
218980904|NCT01142271|PROCEDURE|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
218980905|NCT05347277|DIAGNOSTIC_TEST|Kappa Free Light Chain (K-FLC)|A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
219673323|NCT05491863|OTHER|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
219673324|NCT01422746|DRUG|Metformin|500-1000 mg PO BID (X12 weeks)
219673325|NCT03295175|DIAGNOSTIC_TEST|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
219673326|NCT03552042|BEHAVIORAL|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
218980906|NCT01479478|DRUG|Placebo|One placebo capsule daily.
218980907|NCT01479478|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
218980908|NCT00419276|PROCEDURE|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
218980909|NCT00435864|PROCEDURE|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
218980910|NCT06295302|DRUG|HWH486|HWH486 capsule was administrated orally
218980911|NCT06295302|DRUG|Placebo|Matching placebo was administrated orally
218980912|NCT03473535|COMBINATION_PRODUCT|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
218980913|NCT03473535|BEHAVIORAL|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
218980914|NCT00697788|DRUG|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
218980915|NCT02432742|DEVICE|Restylane Perlane|Intradermal injection
218980916|NCT02432742|DEVICE|Restylane|Intradermal injection
218980917|NCT05374733|DIAGNOSTIC_TEST|Coronary Physiology assessment|"1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
218980918|NCT05521620|BEHAVIORAL|The father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
218980919|NCT06277596|OTHER|Exercise|Clinical Pilates exercises (basic and advanced stabilization exercises)
218980920|NCT04496700|PROCEDURE|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
218980921|NCT00594048|DEVICE|Resperate|Use of the device 15 minutes a day for 9 weeks
218980922|NCT00594048|DEVICE|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
218980923|NCT05527197|DEVICE|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
218980924|NCT06557382|BEHAVIORAL|Cognitive tests and reading-related evaluations|Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
218980925|NCT05295056|DEVICE|AFGen1 Device Wear Test|Participant wears the device for 7 days
218980926|NCT05295056|DEVICE|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
218980927|NCT06315348|PROCEDURE|flapless alveolar decortication with augmentation|piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
219069983|NCT02501460|OTHER|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
219069984|NCT00427050|DRUG|PEP005|
219069985|NCT05268666|DRUG|JBI-802|LSD1/HDAC6 inhibitor
219069986|NCT04719793|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
219069987|NCT04658251|GENETIC|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
219069988|NCT04805125|BIOLOGICAL|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
219208917|NCT06757829|BEHAVIORAL|inspiratory muscle training and acupucnture like transcutanoeus electrical nerve stimulation|sickle cell disease patients whose number will be 20 patients will be trained with IMT (threshold inspiratory muscle training) and treated with AC-tens. The number of sessions per week will be three sessions for IMT or AC-tens for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles. Also the session of AC-tens will be 45 minute on bilateral Ex-B1 acupoint. the parameters of AC-tens will be four hertz and 200 microsecond pulse duration.
219208918|NCT06757829|BEHAVIORAL|inspiratory muscle training|sickle cell disease patients whose number will be 20 patients who will trained with IMT (threshold inspiratory muscle training). The number of sessions per week will be three sessions for IMT for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles.
219208919|NCT06757816|PROCEDURE|accessory rod and iliac fixation for distal augmentation for S1 fixation.|patients who were admitted to the spine unit and needed extension of fixation for L5 S1 fusion due to failed previous surgery, instability, or degenerative changes ,infection, tumors and pseudoarthrosis.
219673327|NCT03552042|BEHAVIORAL|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
219673328|NCT00596999|PROCEDURE|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
219673329|NCT06255600|OTHER|High Definition-transcranial Direct Current Stimulation|High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
219673330|NCT06255600|DIETARY_SUPPLEMENT|Chlorella Pyrenoidosa|functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
219673331|NCT00239499|DRUG|Tiotropium|
219673332|NCT00239499|DRUG|Salmeterol plus Fluticasone|
219069989|NCT04805125|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
219069990|NCT02535065|DEVICE|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
219069991|NCT00748046|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
219069992|NCT04763122|OTHER|not applicable as it is a retrospective study|It is a retrospective study
219069993|NCT05450432|DRUG|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
219069994|NCT05450432|DRUG|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
219069995|NCT01592643|DEVICE|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
219069996|NCT02662842|DEVICE|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
219069997|NCT02662842|DEVICE|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
219673333|NCT02247271|BEHAVIORAL|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
219673334|NCT02346994|DIETARY_SUPPLEMENT|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
219673335|NCT02346994|DIETARY_SUPPLEMENT|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
219673336|NCT04516863|DIAGNOSTIC_TEST|German Autobiographical Memory Interview short-form|Diagnostic Test
219673337|NCT03634813|DEVICE|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
219673338|NCT03634813|PROCEDURE|Usual Care|Usual Care
219673339|NCT02197442|DRUG|Valsartan|
219673340|NCT03890978|OTHER|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
219673341|NCT00467402|DRUG|agomelatine|
219673342|NCT00467402|DRUG|placebo|
219673343|NCT06168747|OTHER|Passive Joint Mobilization|Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
219673344|NCT00047788|DRUG|ZD6474|
219673345|NCT00047788|DRUG|VEGF-receptor tyrosine kinase (KDR)|
219673346|NCT01343992|BEHAVIORAL|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
219673347|NCT01343992|BEHAVIORAL|No bedrest|Patients will not rest in bed after the embryo transfer.
219673348|NCT05427747|DRUG|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
219673349|NCT02529098|OTHER|fMRI|functional magnetic resonance imaging
219673350|NCT00005711|BEHAVIORAL|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
219673351|NCT00467558|DRUG|Naltrexone|daily
219673352|NCT00467558|DRUG|Sugar pill|daily
219673353|NCT00650286|DRUG|Modafinil Tablets 200 mg|200mg, single dose fed
219673354|NCT00650286|DRUG|Provigil® Tablets 200 mg|200mg, single dose fed
218980928|NCT03005145|OTHER|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
218980929|NCT03005145|OTHER|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
218980930|NCT00689078|DRUG|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
218980931|NCT00689078|DRUG|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
218980932|NCT00689078|DRUG|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
218980933|NCT00689078|DRUG|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
218980934|NCT00385710|DRUG|valproic acid|Depakine
218980935|NCT00385710|DRUG|Placebo|Placebo
218980936|NCT03515083|DEVICE|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
218980937|NCT00989105|OTHER|immunohistochemistry staining method|
218980938|NCT00989105|OTHER|laboratory biomarker analysis|
218980939|NCT00989105|OTHER|pharmacological study|
218980940|NCT00989105|PROCEDURE|computed tomography|
218980941|NCT00989105|PROCEDURE|magnetic resonance imaging|
218980942|NCT00989105|PROCEDURE|single photon emission computed tomography|
218980943|NCT00989105|RADIATION|technetium Tc 99m demobesin-4|
218980944|NCT01188421|DRUG|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
218980945|NCT01188421|DRUG|Clonidine|up to 0.8 mg per day (oral)
218980946|NCT01188421|DRUG|Tramadol ER|up to 600 mg per day
218980947|NCT01506258|PROCEDURE|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
218980948|NCT01506258|PROCEDURE|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
218980949|NCT05536583|PROCEDURE|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
218980950|NCT00075218|DRUG|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
218980951|NCT00075218|DRUG|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
218980952|NCT03534362|DEVICE|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
218980953|NCT03534362|DEVICE|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
219673355|NCT02636439|BEHAVIORAL|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
219673356|NCT02636439|BEHAVIORAL|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
219673357|NCT04679948|DRUG|Percoffedrinol®|Tablet
218980954|NCT03401593|DRUG|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
218980955|NCT01870050|DRUG|Dapsone gel - verum|
218980956|NCT01919671|DRUG|Tongxinluo capsule|for 90 days
218980957|NCT01919671|DRUG|placebo capsule|for 90 days
218980958|NCT06292234|DEVICE|PSI|Fabrication of PSI implants using virtual surgical planning
218980959|NCT06292234|DEVICE|Conventional miniplates|Ready made miniplates
218980960|NCT03840174|BIOLOGICAL|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
218980961|NCT03840174|OTHER|Placebo|Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
219069998|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
219069999|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
219070000|NCT06371794|PROCEDURE|skin punch biopsy|skin punch biopsy (around 4 mm2) from each studied subject.
219070001|NCT05892354|DIETARY_SUPPLEMENT|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
219070002|NCT05892354|DIETARY_SUPPLEMENT|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
219673358|NCT04679948|DRUG|Coumadin®|Tablet
219673359|NCT04679948|DRUG|Antra MUPS®|Gastro-resistant tablet
219673360|NCT04679948|DRUG|Midazolam-ratiopharm®|Oral solution
219673361|NCT04679948|DRUG|BI 730357|Film-coated tablet
219673362|NCT05761704|DRUG|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
219673363|NCT05761704|DRUG|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
219673364|NCT00002267|DRUG|Rifabutin|
219673365|NCT06920797|DIAGNOSTIC_TEST|Reproductive tract microbiome analysis|Assessment of the endometrial and vaginal microbiome in three different samples: endometrial biopsy (EB), endometrial fluid (EF) and vaginal swab (VS).
219673366|NCT05188729|DRUG|Part 1: VP-315 3 Day Dosing/Week|2-8 mg of VP-315 administered via intratumor injection into a single target lesion on W1D1. Each 500-μL dose will be divided into 2 injections given at least 15 minutes and no more than 30 minutes apart, with 30% (150 μL) administered in the first injection and the remaining 70% (350 μL) with the second injection. In all parts of the study, the targeted total volume of delivery is 500 μL daily.
219070003|NCT00974857|DEVICE|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
219070004|NCT00974857|OTHER|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
219070005|NCT00110617|DRUG|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
219673367|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Loading Dose|4mg (halt the target dose) loading dose on W1D1 administered via intratumor injection into a single target lesion, followed by total daily doses at the full target dose of 8 mg on the remaining days of treatment.
219673368|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - No Loading Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
219673369|NCT05188729|DRUG|Part 2: VP-315 2 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 2 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
219673370|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
219673371|NCT01699724|DRUG|JZoloft|50 mg tablet on Day 1 of each period
219673372|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
219673373|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
219673374|NCT00528359|DRUG|quetiapine or olanzapine or risperidone or aripiprazole|
219673375|NCT04227405|BEHAVIORAL|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
219070006|NCT00110617|DRUG|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
219070007|NCT00755482|DRUG|Aquamin F|
219070008|NCT00755482|DRUG|Placebo (maltodextran)|
219070009|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
219070010|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
219070011|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
219673376|NCT04227405|BEHAVIORAL|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
219673377|NCT04227405|BEHAVIORAL|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
219070012|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
219070013|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
219070014|NCT01781572|DRUG|LEE011|LEE011 will be administered orally once daily
219070015|NCT01781572|DRUG|MEK162|MEK162 will be administered orally twice daily
219070016|NCT00454558|DRUG|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
219070017|NCT01438866|OTHER|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
219673378|NCT00869908|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219070018|NCT01438866|OTHER|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
219070019|NCT00240318|DRUG|Rosuvastatin calcium|
219070020|NCT00778674|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
219070021|NCT00093054|DRUG|Cranberry juice|TID dosage for UTI treatment
219208920|NCT06749613|DIETARY_SUPPLEMENT|digestive enzymes|A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.
219673379|NCT00869908|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219673380|NCT00869908|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219070022|NCT00093054|DIETARY_SUPPLEMENT|Placebo cranberry juice|TID placebo dosage to match active comparator
219070023|NCT01697293|DRUG|Cyclophosphamide|Given IV
219070024|NCT01697293|DRUG|Doxorubicin Hydrochloride|Given IV
219070025|NCT01697293|OTHER|Laboratory Biomarker Analysis|Correlative studies
219070026|NCT01697293|DRUG|Paclitaxel|Given IV
219070027|NCT01697293|PROCEDURE|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
219673381|NCT06462742|PROCEDURE|Microwave ablation (MWA) versus Liver Resection (LR)|"Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors."
219673382|NCT05828316|BEHAVIORAL|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
219673383|NCT04594655|PROCEDURE|surgery|colectomy
219673384|NCT03367975|OTHER|near infrared spectroscopy|
219673385|NCT03372382|DRUG|Ibuprofen|NSAID
219673386|NCT03372382|DRUG|Acetaminophen|analgesic
219070028|NCT01697293|DRUG|Triciribine Phosphate|Given IV
219673387|NCT03372382|DRUG|Norco|acetaminophen plus opioid
219070029|NCT05802238|DRUG|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
219070030|NCT05802238|OTHER|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
219070031|NCT00045110|DRUG|erlotinib hydrochloride|given orally
219070032|NCT00045110|OTHER|laboratory biomarker analysis|correlative studies
219070033|NCT00045110|OTHER|pharmacological study|correlative studies
219070034|NCT03118960|DEVICE|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
219070035|NCT03118960|DEVICE|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
219070036|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
219070037|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
219070038|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
219070039|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
219673388|NCT00643981|BIOLOGICAL|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
219673389|NCT00920504|BEHAVIORAL|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
219673390|NCT00920504|OTHER|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
219070040|NCT03567538|PROCEDURE|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
219070041|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
219070042|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
219070043|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
219070044|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
219070045|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
219673391|NCT01393418|OTHER|Cardiac Surgery|
219673392|NCT06552403|DIETARY_SUPPLEMENT|A modified 5:2 intermittent fasting diet|The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
219070046|NCT05700799|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
219673393|NCT02757352|DRUG|Ixekizumab|Administered SC
219673394|NCT02757352|DRUG|Placebo|Administered SC
219673395|NCT02112409|PROCEDURE|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
219673396|NCT02112409|PROCEDURE|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
219070047|NCT03680755|BEHAVIORAL|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
219070048|NCT05692388|OTHER|Patient and Community Stakeholder Interviews|Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
219208921|NCT06749535|RADIATION|group 1|The aim of my study, we should diagnose diabetes on time. If diabetes mellitus untreated or uncontrolled for a long they directly affect all over the body, mostly they caused chronic disease due to hyperglycemia that damages the blood vessels. Rapture or damages the blood vessels of the lung causes COPD.
219673397|NCT05581524|DEVICE|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
219673398|NCT03565003|DRUG|JAB-3068|25 mg,100 mg
219673399|NCT06956079|PROCEDURE|EIP-first|EIP is applied for 20 minutes immediately after the initiation of one-lung ventilation, followed by conventional mechanical ventilation.
219673400|NCT06956079|PROCEDURE|EIP-later|Conventional mechanical ventilation is applied for 20 minutes after the initiation of one-lung ventilation, followed by EIP application.
219673401|NCT06169163|OTHER|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
219673402|NCT06955208|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Participants will undergo preoperative 3D MRE to quantify tumor stiffness and generate adhesion maps. MRE is performed as an adjunct to standard brain MRI, using 60 Hz vibration frequency and specialized elastogram processing software. The resulting stiffness and adhesion data are made available to the neurosurgical team for surgical planning.
219070049|NCT05692388|OTHER|Cross-sectional Study Participants|Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.
219070050|NCT05692388|OTHER|Focus Groups and Intervention Mapping|A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
219673403|NCT06955208|PROCEDURE|Intraoperative Assessment and Recording|During surgical resection, the neurosurgical team will systematically assess and record tumor stiffness, adhesion to surrounding structures, vascularity, resection time, and technical difficulty using a standardized intraoperative scale. These intraoperative findings will be compared to preoperative MRE parameters to evaluate the diagnostic and predictive value of MRE.
219673404|NCT02830399|DEVICE|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
219673405|NCT02830399|DEVICE|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
219673406|NCT02804048|OTHER|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
219673407|NCT02804048|OTHER|superficial heat low back|Superficial heat application in the low back
219208922|NCT06748105|DRUG|Dapagliflozin (DAPA)|"Participants will receive 10mg/day of dapagliflozin orally. The administration will occur within a synchronous range, meaning that the time difference between dapagliflozin administration and glucocorticoid administration should not exceed 12 hours."
219673408|NCT02804048|OTHER|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
219673409|NCT02804048|OTHER|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
219673410|NCT02804048|OTHER|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
219673411|NCT02804048|OTHER|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
219673412|NCT05705921|RADIATION|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
219673413|NCT05705921|RADIATION|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
219673414|NCT06515626|BIOLOGICAL|CAR-T cell reinfusion|Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
219673415|NCT06349239|OTHER|No intervention|Follow-up of disease
219673416|NCT04117542|OTHER|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
219673417|NCT01329770|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
219673418|NCT01329770|DIETARY_SUPPLEMENT|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
219673419|NCT01456546|DRUG|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
219673420|NCT01456546|DRUG|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
219070051|NCT05764850|GENETIC|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
219208923|NCT06750471|BIOLOGICAL|Dupilumab|Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
219673421|NCT05693324|BEHAVIORAL|Minority stress|Intervention based on Cognitive Behavioural and Compassion Focused Treatments
219673422|NCT00802672|DRUG|Ciclopirox Olamine Cream|topical cream
219673423|NCT00802672|DRUG|Loprox Cream 0.77%|topical cream
219673424|NCT00802672|DRUG|Placebo|topical cream
219673425|NCT04077749|BIOLOGICAL|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
219673426|NCT04077749|OTHER|Normal Saline|50 mL normal saline at room temperature
219673427|NCT05903755|DEVICE|speed dependent treadmill training on moderate speed|Experimental group will receive 14 session of speed dependent treadmill training on moderate speed (3 to 6) for 25 minutes along with strengthening, stretching and range of motion exercises.
219673428|NCT05903755|DEVICE|speed dependent treadmill training on slow speed|Control group will receive 14 session of speed dependent treadmill training on slow speed (1 to 2) for 25 min along with physiotherapy.
219673429|NCT01437371|DRUG|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
219673430|NCT05773339|OTHER|AIMS65 score|"The AIMS65 score consists of five factors:~(i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years)."
219673431|NCT03116295|DRUG|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
219673432|NCT03067922|OTHER|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
219673433|NCT05325372|PROCEDURE|axillary block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
219673434|NCT05325372|PROCEDURE|infraclavicular block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
219673435|NCT01044368|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
219673436|NCT02904395|OTHER|observational (no intervention)|
219673437|NCT00087464|DRUG|Emtricitabine|
219673438|NCT00087464|DRUG|Nevirapine|
219673439|NCT00087464|DRUG|Tenofovir disoproxil fumarate|
219673440|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
219673441|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
219070052|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
219070053|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
219070054|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
219070055|NCT05195996|DRUG|Saline|intravenous saline for placebo
219070056|NCT05321498|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
219070057|NCT05321498|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
219070058|NCT04392505|DRUG|Durvalumab Injection|Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
219070059|NCT02026089|BIOLOGICAL|Varicella vaccine|Varivax 0.5ml subcutaneous injection
219673442|NCT03222453|BIOLOGICAL|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
219070060|NCT06509906|DRUG|M9466|M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
219673443|NCT05165719|DIAGNOSTIC_TEST|Corona-T-test|Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
219673444|NCT03295032|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
219673445|NCT00950729|PROCEDURE|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
219673446|NCT00950729|PROCEDURE|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
219673447|NCT00950729|PROCEDURE|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
219070061|NCT06509906|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
219070062|NCT06509906|DRUG|Folinic acid|Folinic acid will be administered intravenously q2w as per standard of care.
219070063|NCT06509906|DRUG|Fluorouracil (5-FU)|Fluorouracil will be administered intravenously as per standard of care.
219070064|NCT06509906|DRUG|Bevacizumab|Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
219208924|NCT06749561|DIAGNOSTIC_TEST|Group 1|To Compare the safety and effectiveness of boyh types
219673448|NCT00240968|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
219673449|NCT04297696|OTHER|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
219673450|NCT02561546|DRUG|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
219673451|NCT02561546|DRUG|Trans-catheter embolization|Trans-catheter embolization alone
219673452|NCT06788275|BEHAVIORAL|Aerobic exercise (MIT)|Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
219673453|NCT06788275|BEHAVIORAL|Aerobic exercise (Short HIIT)|Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
219673454|NCT06788275|BEHAVIORAL|Aerobic exercise (Long HIIT)|Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
219673455|NCT06103071|PROCEDURE|Sweeping of membranes|After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
219673456|NCT05122780|PROCEDURE|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
219673457|NCT05122780|DIAGNOSTIC_TEST|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
219673458|NCT05122780|PROCEDURE|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
219673459|NCT05122780|DIAGNOSTIC_TEST|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
219673460|NCT05122780|DIAGNOSTIC_TEST|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
219673461|NCT05122780|DIAGNOSTIC_TEST|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
219673462|NCT05122780|DIAGNOSTIC_TEST|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
219673463|NCT05122780|DIAGNOSTIC_TEST|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
219673464|NCT05122780|DRUG|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
219673465|NCT05122780|DRUG|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
219673466|NCT05122780|DRUG|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
219673467|NCT05122780|DRUG|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
219673468|NCT05122780|DRUG|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
219673469|NCT05122780|DRUG|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
219070065|NCT06509906|DRUG|Granulocyte colony stimulating factor (G-CSF)|G-CSF will be administered subcutaneously at every cycle of study intervention as per standard of care.
219070066|NCT05422417|DEVICE|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
219070067|NCT05422417|DEVICE|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
219673470|NCT05122780|DRUG|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
219673471|NCT02696486|BEHAVIORAL|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
219070068|NCT05422417|DEVICE|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
219070069|NCT03570684|DEVICE|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
219070070|NCT04184193|OTHER|Pulmonary Rehabilitation|Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
219070071|NCT00022412|DIETARY_SUPPLEMENT|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
219673472|NCT04656301|DRUG|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
219673473|NCT05165641|PROCEDURE|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
219673474|NCT05621395|OTHER|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
219673475|NCT05621395|OTHER|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
219673476|NCT03370965|DIAGNOSTIC_TEST|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
219673477|NCT01528280|BIOLOGICAL|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
219673478|NCT01528280|OTHER|No Intervention|No Intervention
219673479|NCT00469716|DRUG|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
219673480|NCT05472571|OTHER|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
218980962|NCT05043909|BEHAVIORAL|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
218980963|NCT04312204|DRUG|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
219070072|NCT00022412|PROCEDURE|conventional surgery|Procedure: Prostatectomy for prostate cancer
219673481|NCT01575418|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
219673482|NCT01575418|DRUG|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
219673483|NCT01575418|DRUG|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
219673484|NCT01575418|RADIATION|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
219673485|NCT02801461|DEVICE|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
219673486|NCT06408337|PROCEDURE|implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).|cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
219673487|NCT03646747|DIAGNOSTIC_TEST|MRI scan|Additional imaging using MRI scan
219673488|NCT03063619|DRUG|Afimoxifene|Applied topically
219673489|NCT03063619|OTHER|Laboratory Biomarker Analysis|Correlative studies
219673490|NCT03063619|OTHER|Placebo|Applied topically
219673491|NCT03063619|OTHER|Questionnaire Administration|Ancillary studies
219673492|NCT01360788|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
219673493|NCT04156243|BIOLOGICAL|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219673494|NCT00731796|DEVICE|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
219673495|NCT02052297|OTHER|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
219673496|NCT06001853|DRUG|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
219673497|NCT06001853|DRUG|DSMO Injection|After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
219673498|NCT04331834|DRUG|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
219673499|NCT04331834|DRUG|Placebos|"Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
219673500|NCT05468983|PROCEDURE|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
219673501|NCT00002917|DRUG|paclitaxel|
219673502|NCT02360423|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
219673503|NCT02360423|DEVICE|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
219673504|NCT02090283|DRUG|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
219673505|NCT02033707|DRUG|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
219673506|NCT03508349|DIAGNOSTIC_TEST|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
219070073|NCT05829655|DRUG|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
219673507|NCT00288418|DEVICE|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
219673508|NCT01516489|BEHAVIORAL|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
219673509|NCT01516489|BEHAVIORAL|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
219673510|NCT00092976|DRUG|ReFacto|
219673511|NCT05269368|PROCEDURE|Wicking|Absorbable or non-absorbable wicking
219673512|NCT05269368|PROCEDURE|No wicking|No wicking after surgery
219673513|NCT06005753|PROCEDURE|Ostheosynthesis of acetabular fractures|The using of plate for fixation of acetabular fractures in surgical treatment
219673514|NCT03283046|DRUG|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
219673515|NCT03283046|DRUG|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
219673516|NCT03283046|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
219673517|NCT03283046|DRUG|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
219673518|NCT01263067|BEHAVIORAL|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
219673519|NCT01263067|BEHAVIORAL|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
219673520|NCT04026750|DRUG|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
219673521|NCT03654703|DRUG|Cyclophosphamide|cyclophophamide
219673522|NCT02421302|DIETARY_SUPPLEMENT|RUTF|This is ready-to-use-therapeutic-food
219673523|NCT02050139|DIETARY_SUPPLEMENT|L-cysteine|
219673524|NCT02050139|OTHER|Placebo|
219673525|NCT05054205|BEHAVIORAL|Motivational İnterviewing|"The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy."
219673526|NCT04498702|DRUG|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
219673527|NCT01867515|OTHER|Acoustic distortion of speech|
219673528|NCT01653457|DRUG|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily"
219673529|NCT01653457|DRUG|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
219673530|NCT03363308|BEHAVIORAL|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
219673531|NCT00019461|DRUG|carboxyamidotriazole|
219673532|NCT00019461|DRUG|chemotherapy|
219673533|NCT01411319|RADIATION|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
219673534|NCT01411319|RADIATION|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
219673535|NCT01737411|DRUG|solifenacin|
219673536|NCT01737411|PROCEDURE|cesa/vasa|surgical repair of USL
219673537|NCT00926757|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
219070074|NCT05829655|DRUG|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
219070075|NCT05829655|DRUG|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
219673538|NCT00926757|DRUG|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
219673539|NCT03609814|DRUG|Clofarabine|Given IV
219673540|NCT03609814|DRUG|Fludarabine Injection|Given IV
219673541|NCT01637714|DRUG|Multi-strain probiotics|"* B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
219673542|NCT01637714|DRUG|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
219673543|NCT00160121|DRUG|Lanthanum carbonate|
219673544|NCT01008774|DEVICE|Paxman Cooling Machine|Scalp cooling procedures
219673545|NCT01008774|DEVICE|Cold Caps|Scalp cooling procedures
219673546|NCT03800680|BEHAVIORAL|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed."
219673547|NCT03800680|BEHAVIORAL|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
219673548|NCT00484926|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
219673549|NCT00484926|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
219673550|NCT01005784|DRUG|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
219673551|NCT01005784|DRUG|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
219673552|NCT01579669|BEHAVIORAL|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
219673553|NCT02515903|PROCEDURE|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
219673554|NCT02515903|PROCEDURE|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
219673555|NCT04999943|BIOLOGICAL|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
219673556|NCT04959799|DRUG|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
219673557|NCT01512589|RADIATION|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
219673558|NCT01512589|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
219673559|NCT01512589|BEHAVIORAL|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
219673560|NCT01455584|DRUG|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
219673561|NCT05105672|DRUG|Sintilimab|IV infusion
219673562|NCT05105672|DRUG|Cisplatin|IV infusion
219673563|NCT05105672|RADIATION|External Beam Radiotherapy (EBRT)|Undergo pelvic EBRT
219673564|NCT05105672|RADIATION|brachytherapy|brachytherapy
219673565|NCT05366114|OTHER|No intervention, additional video data collection only|No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time
219673566|NCT03519126|OTHER|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
219673567|NCT05392595|OTHER|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
219070076|NCT05829655|DRUG|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
219070077|NCT05829655|DRUG|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
219070078|NCT05829655|DRUG|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
219070079|NCT06487455|DRUG|SPH7485|SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
219070080|NCT04827576|DRUG|Magrolimab|Administered intravenously
219070081|NCT04827576|DRUG|Docetaxel|Administered intravenously
219070082|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
219673568|NCT05392595|OTHER|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
219673569|NCT01624480|DRUG|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
219673570|NCT00527124|DRUG|cediranib maleate|Given orally
219673571|NCT00527124|DRUG|docetaxel|Given IV
219673572|NCT00527124|DRUG|prednisone|Given orally
219673573|NCT00527124|OTHER|laboratory biomarker analysis|Correlative studies
219673574|NCT05488769|DEVICE|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
219673575|NCT03540069|BEHAVIORAL|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
219673576|NCT00214214|DRUG|Campath 1H® (Alemtuzumab)|
219673577|NCT02239445|DRUG|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
219673578|NCT02239445|DRUG|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
219673579|NCT02239445|DRUG|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
219673580|NCT06107855|OTHER|Leg Press Resistance Training Machine|Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
219673581|NCT00679848|DEVICE|RS2 (RESTORe Suturing System)|Suturing in stomach
219673582|NCT05964153|DIAGNOSTIC_TEST|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
219673583|NCT02210325|DRUG|solithromycin|
219673584|NCT02210325|DRUG|ceftriaxone|
219673585|NCT02210325|DRUG|azithromycin|
219673586|NCT01742416|PROCEDURE|Ultrasound|Arterial cannulation facilitated by ultrasound.
219673587|NCT01742416|PROCEDURE|Palpation Method|Arterial cannulation by palpation method.
219673588|NCT05737901|OTHER|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
219070083|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
219070084|NCT06479447|OTHER|PORTAL-PTSD|Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
219070085|NCT06495853|PROCEDURE|Continuous Circumferential Reinforcement of the Anastomotic|The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
219673589|NCT05737901|OTHER|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
219673590|NCT00828269|PROCEDURE|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
219673591|NCT05044247|PROCEDURE|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
219673592|NCT03498729|OTHER|Peripheral Blood Sample|30mL peripheral whole blood sample
219673593|NCT01218815|PROCEDURE|IRA stenting in culprit lesion only|stenting
219673594|NCT01218815|PROCEDURE|IRA stenting|Complete IRA revascularization
219673595|NCT01915550|DRUG|Metformin|
219673596|NCT01915550|DRUG|Humulin Insulin Mixtard|
219673597|NCT03365518|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
219673598|NCT03365518|BEHAVIORAL|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
219673599|NCT02915250|DRUG|BioChaperone® Combo|Injection of BioChaperone® Combo
219673600|NCT02915250|DRUG|Humalog® Mix25|Injection of Humalog® Mix25
219673601|NCT02915250|DRUG|Humalog®|Injection of Humalog®
219673602|NCT02915250|DRUG|Lantus®|Injection of Lantus®
219673603|NCT02915250|DRUG|Placebo|Injection of 0.9% NaCl
219673604|NCT03382405|BIOLOGICAL|mRNA-1647|Escalating dose levels
219673605|NCT03382405|BIOLOGICAL|mRNA-1443|Escalating dose levels
219070086|NCT03069482|DEVICE|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
219673606|NCT03382405|OTHER|Placebo|Saline
219673607|NCT01556230|PROCEDURE|Surgical intervention for CNFA|(non-experimental) standard procedure
218980964|NCT03656107|BEHAVIORAL|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
219070087|NCT03069482|DRUG|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
219673608|NCT01556230|RADIATION|Radiotherapy for CNFA|(non-experimental) standard procedure
219673609|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
219673610|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
218980965|NCT05203640|BEHAVIORAL|High repetition (HI)|Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum
219070088|NCT03069482|DRUG|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
219673611|NCT05118763|DRUG|INNA-051|Liquid for intranasal administration
219673612|NCT05118763|OTHER|Placebo|Liquid for intranasal administration
219673613|NCT00632645|DRUG|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
219673614|NCT00632645|DRUG|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
219673615|NCT00632645|DRUG|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
219673616|NCT05682599|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
219673617|NCT05682599|DRUG|Placebo|Placebo
219673618|NCT01041274|DRUG|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
219673619|NCT01041274|DRUG|Placebo|Placebo by mouth daily for 12 months.
219673620|NCT01041274|BEHAVIORAL|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
219673621|NCT01041274|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
219673622|NCT01041274|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
219673623|NCT02075008|DRUG|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
219673624|NCT05438758|BEHAVIORAL|Almond Therapy|Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
219673625|NCT05438758|DRUG|Intranasal ketamine (Esketamine)|Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
219673626|NCT05438758|BEHAVIORAL|Treatment as Usual|Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
219673627|NCT04097769|DRUG|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
219673628|NCT00660595|DRUG|Quetiapine|Oral administration
219070089|NCT03069482|BEHAVIORAL|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
219070090|NCT03069482|DEVICE|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
219070091|NCT04425564|DRUG|metronomic XELOX|
219070092|NCT04425564|DRUG|Classic XELOX|
219673629|NCT00660595|DRUG|Risperidone|Oral administration
219673630|NCT02801799|DRUG|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
219673631|NCT05846568|BIOLOGICAL|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
219673632|NCT05846568|BIOLOGICAL|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
219070093|NCT04425564|OTHER|Blood samples for pharmacological studies|
219070094|NCT05711654|BEHAVIORAL|Health coaching|Coaching interview will be held with patients at regular intervals.
219070095|NCT00490191|DRUG|Somatropin|
219070096|NCT01570101|DEVICE|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
219070097|NCT01445938|DRUG|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
219070098|NCT01445938|DRUG|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
219070099|NCT04537923|DRUG|Tirzepatide|Administered SC
219070100|NCT04537923|DRUG|Insulin Lispro (U100)|Administered SC
219070101|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
219070102|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
219673633|NCT05846568|BIOLOGICAL|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
219673634|NCT02028780|DRUG|Placebo to dose|placebo
219673635|NCT02028780|DRUG|Idarucizumab|short infusion
219673636|NCT02028780|DRUG|Placebo to Idarucizumab|Placebo to Idarucizumab
219673637|NCT02028780|DRUG|dabigatran|2 capsules dabigatran
219673638|NCT02028780|DRUG|Idarucizumab|short infusion
219673639|NCT00777335|DRUG|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
219673640|NCT00777335|DRUG|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
219673641|NCT00898872|OTHER|cryopreservation|
219673642|NCT04656184|DRUG|ANAKINRA|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
219070103|NCT01261611|DRUG|Placebo|I.M. injection on day 1 of treatment cycle 1.
219070104|NCT03495050|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
219673643|NCT04656184|DRUG|Intravenous immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
219070105|NCT02527798|DRUG|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
219070106|NCT02527798|DRUG|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
219070107|NCT02527798|DRUG|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
219070108|NCT02527798|OTHER|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
219070109|NCT02498483|DRUG|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
219673644|NCT01302210|DRUG|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
219673645|NCT01945476|DRUG|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
219673646|NCT01113307|BIOLOGICAL|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
219673647|NCT03637790|DRUG|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
219673648|NCT03637790|OTHER|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
219673649|NCT05205005|DRUG|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
219673650|NCT05205005|DRUG|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
219673651|NCT06031675|OTHER|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
219673652|NCT00323843|DRUG|Isoproterenol|
219673653|NCT00909220|BEHAVIORAL|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis \& Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
218980966|NCT05203640|BEHAVIORAL|Moderate repetition (MOD)|Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
219208925|NCT06755515|DRUG|Rulonilimab|"Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
219673654|NCT03675971|DRUG|Cannabinol|Postoperative pain treatment
219673655|NCT03675971|DRUG|Placebo oral capsule|Placebo comparator
219673656|NCT01148459|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
219673657|NCT01148459|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
219673658|NCT01148459|BIOLOGICAL|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
219673659|NCT04565405|OTHER|Detergent|The tracheostomy inner cannulas will be washed with detergent.
219673660|NCT04565405|OTHER|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
219673661|NCT04866082|OTHER|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
219673662|NCT05868278|OTHER|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
219673663|NCT00694356|BIOLOGICAL|Dalotuzumab|IV infusion
219673664|NCT06171516|BEHAVIORAL|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
219673665|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
219673666|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
219673667|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
219673668|NCT01247675|DRUG|Omnitrope|s.c., daily injection
219673669|NCT00954200|DRUG|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
219673670|NCT00954200|DRUG|ibuprofen|10mg/kg syrup - single dose
219673671|NCT04075669|DIAGNOSTIC_TEST|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
219673672|NCT05886907|DEVICE|Lehfilcon A multifocal toric contact lenses|Investigational silicone hydrogel contact lenses
219673673|NCT05886907|DEVICE|Samfilcon A multifocal toric contact lenses|Commercially available silicone hydrogel contact lenses
219673674|NCT05886907|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
218980967|NCT01757327|DRUG|Erismodegib|
219673675|NCT02634632|BEHAVIORAL|Choosing to write advance directives|
219673676|NCT04769102|DEVICE|seat cushions|flat versus contoured customized seat cushions
219673677|NCT05582759|BEHAVIORAL|teleCBT-I + SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
219673678|NCT05582759|BEHAVIORAL|SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics and education on sleep hygiene
218980968|NCT01757327|DRUG|Placebo|
218980969|NCT02201849|DRUG|Study Drug|
218980970|NCT02201849|DRUG|Active Control|
218980971|NCT02201849|DRUG|Placebo|
218980972|NCT00171483|DRUG|Tegaserod|
218980973|NCT00131508|DRUG|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
218980974|NCT00131508|DRUG|Placebo|Placebo
218980975|NCT04948528|OTHER|Active Comparator: Surgery Pathology or Cystoscopy|Case group will be followed up with surgery pathology or cystoscopy.
218980976|NCT04948528|OTHER|Active Comparator: Clinical Diagnosis|Control group will be diagnosed in clinical.
218980977|NCT05994365|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
218980978|NCT04269707|DRUG|Ferric carboxymaltose|IV iron
218980979|NCT02824575|DRUG|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218980980|NCT02824575|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218980981|NCT02824575|DRUG|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
218980982|NCT02987842|DEVICE|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
218980983|NCT03922126|OTHER|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
218980984|NCT03922126|DIAGNOSTIC_TEST|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
218980985|NCT05393011|DRUG|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
218980986|NCT00250120|DRUG|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
219673679|NCT04084587|DEVICE|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
219673680|NCT02700425|DEVICE|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
218980987|NCT01880281|OTHER|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
218980988|NCT03555734|OTHER|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
218980989|NCT04391361|DRUG|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
218980990|NCT04391361|DRUG|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
218980991|NCT03477123|DEVICE|Walking therapy with Exo-H2 exoskeleton|
218980992|NCT03954691|OTHER|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
218980993|NCT00002133|DRUG|Itraconazole|
218980994|NCT06383065|OTHER|IMT Group|Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
218980995|NCT00845858|DRUG|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
218980996|NCT00845858|DRUG|Placebo|30 minutes before meals and at bedtime
218980997|NCT04383483|OTHER|COVICU|COVICU
218980998|NCT01402765|DEVICE|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
218980999|NCT01402765|DEVICE|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
218981000|NCT01077570|DRUG|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
218981001|NCT00880542|DRUG|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
218981002|NCT00880542|DRUG|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
218981003|NCT05047770|BIOLOGICAL|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
218981004|NCT05047770|COMBINATION_PRODUCT|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
218981005|NCT05047770|BIOLOGICAL|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
219070110|NCT03297788|RADIATION|SRS|"For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
218981006|NCT01878279|OTHER|Underlying medical illness|
218981007|NCT02371148|DRUG|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
218981008|NCT01724931|DRUG|LD-aminopterin|
219070111|NCT03297788|RADIATION|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
218981009|NCT01724931|DRUG|placebo|
218981010|NCT03214315|PROCEDURE|Visceral adipose tissue specimen|specimen
218981011|NCT03719820|DRUG|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
218981012|NCT03047655|BEHAVIORAL|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
218981013|NCT03047655|DIETARY_SUPPLEMENT|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
218981014|NCT01830231|DRUG|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
219673681|NCT03735407|DEVICE|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
219673682|NCT02290847|BEHAVIORAL|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
219673683|NCT05326438|BEHAVIORAL|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
219673684|NCT01994421|OTHER|Kinesiotape|
219673685|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
219673686|NCT02399969|OTHER|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
219673687|NCT05030571|DEVICE|DPMAS|DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
219673688|NCT05030571|OTHER|standard treatment|standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
219673689|NCT00645671|DRUG|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
219673690|NCT00645671|DRUG|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
219673691|NCT03278236|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
219673692|NCT03999359|OTHER|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
219673693|NCT02779075|DRUG|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
219673694|NCT02779075|DRUG|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
219673695|NCT05743777|DRUG|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
218981015|NCT01830231|DRUG|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
218981016|NCT05819281|DIETARY_SUPPLEMENT|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
218981017|NCT05819281|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin
218981018|NCT03468803|DIAGNOSTIC_TEST|Beta D Glucan test|Measurement of BDG before, during and after surgery
219673696|NCT05743777|DRUG|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
219673697|NCT05743777|DRUG|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
219673698|NCT01462656|DRUG|Non-EZG containing AED polytherapy|AED polytherapy without EZG
218981019|NCT02322476|OTHER|No intervention will be performed|No intervention will be performed
218981020|NCT03758443|DRUG|TD-1473 Dose A|See Arm description
218981021|NCT03758443|DRUG|TD-1473 Dose B|See Arm description
218981022|NCT03758443|DRUG|TD-1473 Dose C|See Arm description
218981023|NCT03758443|DRUG|Placebo|See Arm description
218981024|NCT05234996|DEVICE|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
218981025|NCT00899769|GENETIC|protein expression analysis|
218981026|NCT00899769|GENETIC|proteomic profiling|
218981027|NCT00899769|OTHER|immunoenzyme technique|
218981028|NCT00899769|OTHER|laboratory biomarker analysis|
218981029|NCT00899769|OTHER|liquid chromatography|
218981030|NCT00899769|OTHER|mass spectrometry|
218981031|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
218981032|NCT01436396|BIOLOGICAL|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
219673699|NCT01462656|DRUG|EZG containing AED polytherapy|AED polytherapy including EZG
219673700|NCT01462656|DRUG|Non-EZG AED monotherapy|AED monotherapy without EZG
219673701|NCT01462656|DRUG|EZG AED monotherapy|Any off-label use of EZG as monotherapy
219673702|NCT04824742|PROCEDURE|Neoadjuvant PDT + radical surgery|Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
218981033|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
218981034|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
218981035|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
219070112|NCT05490615|BEHAVIORAL|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
219673703|NCT04824742|PROCEDURE|Radical surgery|Patients with cholangiocarcinoma will only receive radical surgery
218981036|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
218981037|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
218981038|NCT01436396|BIOLOGICAL|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
218981039|NCT01436396|BIOLOGICAL|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
218981040|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
219673704|NCT05333796|BEHAVIORAL|gait with leg length discrepancy|After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.
218981041|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
218981042|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
219673705|NCT04728698|DRUG|COVI-MSC|1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
219673706|NCT04728698|DRUG|Placebo|Equivalent volume of placebo will be administered
219673707|NCT05905081|OTHER|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
219673708|NCT01104987|DRUG|alendronate|One tablet of alendronate à 70 mg once a week during two years.
219673709|NCT03435627|DRUG|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
219673710|NCT03578445|DEVICE|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
219673711|NCT03578445|DIAGNOSTIC_TEST|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
219673712|NCT05646732|DEVICE|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
219673713|NCT00699023|DRUG|ezetimibe tablets|ezetimibe tablets 10 mg/die
219673714|NCT00699023|DRUG|simvastatin tablets|simvastatin tablets 20 mg/die
219673715|NCT00699023|DRUG|placebo|placebo
219673716|NCT02117609|DIETARY_SUPPLEMENT|New DELICAL formula|3 months with the option of continuing until 6 months.
219673717|NCT02117609|DIETARY_SUPPLEMENT|Standard DELICAL formula|3 months with the option of continuing until 6 months.
219673718|NCT01460602|DRUG|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
219673719|NCT01057290|GENETIC|gene expression analysis|
219673720|NCT01057290|GENETIC|protein expression analysis|
219673721|NCT01057290|OTHER|fluorescence activated cell sorting|
219673722|NCT01057290|OTHER|immunologic technique|
219673723|NCT01057290|OTHER|laboratory biomarker analysis|
219673724|NCT03440138|PROCEDURE|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
219673725|NCT05795972|DIETARY_SUPPLEMENT|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
219673726|NCT05795972|OTHER|standard therapy|control group (patients treated also with standard therapy)
219673727|NCT03785314|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different posture
219673728|NCT04324762|BEHAVIORAL|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
219673729|NCT00970671|OTHER|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
219673730|NCT00970671|OTHER|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
219673731|NCT00970671|OTHER|No treatment|No laser treatment
218981043|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
218981044|NCT01064596|OTHER|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
218981045|NCT01102270|DRUG|Eszopiclone|3mg tablet once prior to sleep
218981046|NCT01102270|DRUG|Placebo|1 placebo capsule prior to sleep
218981047|NCT01363674|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
218981048|NCT00618683|PROCEDURE|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
218981049|NCT00250302|PROCEDURE|autologous mesenchymal stem cells implantation|
218981050|NCT00812682|DRUG|Symbicort|
218981051|NCT00004006|BIOLOGICAL|filgrastim|
218981052|NCT00004006|DRUG|carboplatin|
218981053|NCT00004006|DRUG|cyclophosphamide|
219673732|NCT01951573|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
219673733|NCT01951573|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
219673734|NCT02296762|DRUG|Sirolimus|Sirolimus tablets 2 mg
219673738|NCT00258193|DRUG|MD-1100 Acetate|
219673739|NCT05644678|DEVICE|Fixed appliances|Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
219673740|NCT05644678|PROCEDURE|Corticotomy|Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
219673741|NCT04200183|BEHAVIORAL|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
219673742|NCT04200183|BEHAVIORAL|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
219673743|NCT04407143|DIAGNOSTIC_TEST|IgG test|IgG+ blood test by ELISA method.
219673744|NCT04116008|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
219673745|NCT00707980|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
219673746|NCT03545932|OTHER|exercise program hydrogymnastics|4 months of practice hydrogymnastics
219673747|NCT04404348|BEHAVIORAL|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
219673748|NCT04404348|BEHAVIORAL|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
219673749|NCT00734461|DRUG|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
219673750|NCT00190164|PROCEDURE|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
219673751|NCT00190164|PROCEDURE|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
219673752|NCT04061278|DRUG|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
219673753|NCT04061278|DRUG|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
219673754|NCT00680615|BEHAVIORAL|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
219673755|NCT00680615|BEHAVIORAL|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
219673756|NCT02479113|PROCEDURE|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
219673757|NCT01909973|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
219673758|NCT05849363|PROCEDURE|Posterior fossa decompression|Posterior fossa decompression：Posterior arch of atlas removal, decompression of cerebellum, detection of foramen magnum.
219673759|NCT05849363|PROCEDURE|Posterior Compression-Distraction-Reduction-Fixation|"Posterior Compression-Distraction-Reduction-Fixation：After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
218981054|NCT00004006|DRUG|doxorubicin hydrochloride|
218981055|NCT00004006|DRUG|etoposide|
218981056|NCT00004006|DRUG|topotecan hydrochloride|
218981057|NCT00004006|PROCEDURE|autologous bone marrow transplantation|
219070113|NCT05589051|DIETARY_SUPPLEMENT|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
219070114|NCT03215446|DRUG|maintenance of anaesthesia with propofol|
219673760|NCT00242515|PROCEDURE|CD8+ T-cell depleted donor lymphocyte infusion|
218981058|NCT00004006|RADIATION|radiation therapy|
218981059|NCT05239975|BIOLOGICAL|SCTV01C|intramuscular injection
218981060|NCT05239975|BIOLOGICAL|Comirnaty|intramuscular injection
218981061|NCT02707107|DRUG|Intravenous infusions of WCK 5222|
218981062|NCT02707107|DRUG|Placebo|
218981063|NCT02005731|DEVICE|Low intensity linear focused shockwave device ('Renova')|
219070115|NCT03215446|DRUG|maintenance of anaesthesia with sevoflurane|
219070116|NCT04112004|OTHER|Collecting sodium reports and outcome measures|
219070117|NCT04538729|BEHAVIORAL|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
219070118|NCT06086327|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
219673761|NCT00624689|DIETARY_SUPPLEMENT|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
219673762|NCT00297661|DEVICE|Sirolimus-eluting stent|
219673763|NCT00297661|DEVICE|Paclitaxel-eluting stent|
219673764|NCT02695862|DRUG|Terlipressin|
219673765|NCT01226017|OTHER|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
219673766|NCT05276583|BEHAVIORAL|Motivated Learning Task|"The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure)."
219673767|NCT01505231|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.
219673768|NCT01505231|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
219673769|NCT00460239|DRUG|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
219673770|NCT00460239|DRUG|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
219673771|NCT00460239|DRUG|Placebo|Intramuscular; double blind; once per week
219673772|NCT03387969|PROCEDURE|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
219673773|NCT06525051|DRUG|Tiotropium|Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.
219673774|NCT01462305|DEVICE|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
218981064|NCT02191137|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
219070119|NCT03577717|OTHER|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
219070120|NCT03577717|OTHER|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
219070121|NCT00291148|DRUG|paroxetine|
219070122|NCT00291148|DRUG|pregabalin|
218981065|NCT05101785|DRUG|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
218981066|NCT05101785|DRUG|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
219070123|NCT04690855|DRUG|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
219070124|NCT04690855|DRUG|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
219070125|NCT04690855|RADIATION|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
219070126|NCT03031652|DEVICE|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
219070127|NCT00527566|BIOLOGICAL|Mepolizumab|IV mepolizumab, 750 mg
219673775|NCT01462305|DEVICE|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
219673776|NCT00348335|DRUG|Cyclosporine 0.05%|
219673777|NCT00348335|DRUG|Ocular lubricant|
219673778|NCT00165217|DRUG|Capecitabine|
219673779|NCT00165217|DRUG|Thalidomide|
219673780|NCT04141397|GENETIC|Initiation of POG-related WGTA|POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
219673781|NCT04141397|GENETIC|Usual care|Usual care, not involving the initiation of POG-related WGTA
218981067|NCT06051422|DEVICE|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
218981068|NCT01479127|DRUG|ABT-SLV187|
218981069|NCT01479127|DRUG|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
218981070|NCT01479127|DEVICE|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
218981071|NCT01479127|DEVICE|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
218981072|NCT01479127|DEVICE|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
218981073|NCT04079946|PROCEDURE|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
218981074|NCT04079946|PROCEDURE|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
218981075|NCT01224964|DRUG|Montelukast|Montelukast, 10 mg
218981076|NCT01224964|DRUG|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
218981077|NCT01460017|PROCEDURE|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
218981078|NCT01460017|PROCEDURE|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
218981079|NCT00531973|DRUG|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
218981080|NCT00531973|DRUG|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
218981081|NCT00769210|DRUG|Simvastatin|Simvastatin 40 mg tablet
218981082|NCT02527993|DRUG|Glucobay (acarbose)|Se arm description
218981083|NCT02527993|DRUG|Januvia (sitagliptin)|Se arm description
218981084|NCT02527993|DRUG|Verapamil HEXAL (verapamil)|Se arm description
218981085|NCT02527993|DRUG|Victoza (liraglutide)|Se arm description
219070128|NCT02248870|DRUG|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
219070129|NCT02248870|DRUG|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
219208926|NCT06755515|DRUG|Placebo|"Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
218981086|NCT02527993|DRUG|Signifor (pasireotide)|Se arm description
218981087|NCT02527993|DEVICE|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
218981088|NCT02527993|DIETARY_SUPPLEMENT|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
218981089|NCT00242437|DEVICE|Hemostatic matrix|
218981090|NCT00242437|DEVICE|bovine thrombin|
218981091|NCT05274737|DEVICE|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
218981092|NCT05274737|DEVICE|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
218981093|NCT05340075|PROCEDURE|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
218981094|NCT01205204|DRUG|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
218981095|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
218981096|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
219070130|NCT03911492|PROCEDURE|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
219208927|NCT06755515|DRUG|cisplatin/carboplatin + paclitaxel ± bevacizumab|cisplatin/carboplatin + paclitaxel ± bevacizumab
219208928|NCT06751524|DRUG|Botensilimab|Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
219208929|NCT06751524|DRUG|Balstililmab|Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).
219673782|NCT06222970|PROCEDURE|Bone lid repositioning in course of sinus lift|"A full-thickness flap was elevated to access the lateral maxillary bone wall. Subsequently, a lateral access window was prepared using a piezoelectric device with specific bone tips, delimitating a trapezoidal bone lid.~Once the antrostomy was completed, the bone lid was gently removed with a Lucas surgical curette and anatomical tweezers, with great care to avoid damages to the Schneiderian membrane. The Schneiderian membrane was detached from the bone layer using specific sinus curettes. In case of sinus membrane perforation, the membrane was raised in all directions. All clinical cases received a cortical bone lamina to avoid graft particles displacement in the maxillary sinus. The elevated space was filled with chips of cortico-spongious bone. The antrostomy was then covered with the bone lid (osteotomy window), previously removed and preserved in physiological solution and fixed in the original anatomical position with a surgical glue. The flap was then repositioned and sutured."
219673783|NCT03526991|DEVICE|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
219673784|NCT00649792|DRUG|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
219673785|NCT00032500|DRUG|Echinacea|
219673786|NCT05569369|PROCEDURE|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
219673787|NCT02627456|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
219673788|NCT02627456|BIOLOGICAL|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
219673789|NCT02627456|DRUG|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
219070131|NCT04745169|BEHAVIORAL|8 week home-based exercise program|Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
218981097|NCT01205204|DRUG|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
218981098|NCT03389620|DRUG|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
218981099|NCT00967603|DRUG|sunitinib|oral sunitinib 37.5 mg daily
218981100|NCT05231681|DIETARY_SUPPLEMENT|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
218981101|NCT05288413|DEVICE|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
218981102|NCT06316115|OTHER|In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement|Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
218981103|NCT00835822|DRUG|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
218981104|NCT00835822|DRUG|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
218981105|NCT05985005|OTHER|online simulation of high alert medication safety training|online simulation of high alert medication safety training
219070132|NCT04296565|BEHAVIORAL|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
219208930|NCT05178472|OTHER|Immunotherapy|Receive SOC immunotherapy
219208931|NCT05178472|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219208932|NCT05178472|PROCEDURE|Vertebroplasty|Undergo vertebroplasty
218981106|NCT03810391|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
218981107|NCT03810391|OTHER|physiological saline|intravenous infusion of the same volume of physiological saline
218981108|NCT02715245|PROCEDURE|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
218981109|NCT02387710|DRUG|Tiagabine|GABA reuptake inhibitor
218981110|NCT02387710|DRUG|Placebo|Placebo comparator
218981111|NCT01539798|OTHER|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
218981112|NCT01539798|OTHER|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
218981113|NCT00071396|DRUG|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
218981114|NCT00071396|DRUG|Rituximab|375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
218981115|NCT06022601|DEVICE|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
218981116|NCT01021579|DRUG|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
218981117|NCT01021579|DRUG|Metfomin plus Simvastatin|
218981118|NCT04642612|DEVICE|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block"
218981119|NCT02256072|OTHER|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
218981120|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
218981121|NCT04139473|PROCEDURE|Hepaticojejunostomy / Duct-to-duct anastomosis|
218981122|NCT00539669|DRUG|Docetaxel|
218981123|NCT02648269|DRUG|SEL-110|
218981124|NCT02648269|BIOLOGICAL|SEL-212|
218981125|NCT02648269|BIOLOGICAL|SEL-037|
218981126|NCT01297920|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
218981127|NCT01297920|DRUG|Brinzolamide ophthalmic suspension, 1%|
218981128|NCT01297920|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
218981129|NCT00132210|DRUG|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
218981130|NCT05548673|BEHAVIORAL|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
218981131|NCT02534220|DEVICE|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
218981132|NCT02534220|DEVICE|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
218981133|NCT05685836|DRUG|Bevacizumab Zirconium Zr-89|See Arm description.
218981134|NCT00474760|DRUG|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
218981135|NCT02976792|PROCEDURE|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
218981136|NCT03211871|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
218981137|NCT03211871|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
218981138|NCT03376269|BIOLOGICAL|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
218981139|NCT03376269|BEHAVIORAL|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
218981140|NCT05824091|DRUG|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
218981141|NCT05824091|OTHER|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
218981142|NCT01571310|OTHER|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
218981143|NCT01571310|OTHER|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
218981144|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
218981145|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
218981146|NCT04141046|DEVICE|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
218981147|NCT03757338|DRUG|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
219673790|NCT02627456|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
219673791|NCT02627456|DRUG|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
219673792|NCT02627456|DRUG|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
219673793|NCT03610334|DRUG|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
219673794|NCT03610334|DRUG|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
219673795|NCT03610334|DRUG|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
219673796|NCT03610334|DRUG|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
219070133|NCT04296565|BEHAVIORAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
219070134|NCT01704417|DRUG|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
219070135|NCT01704417|DRUG|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
219070136|NCT05450848|DEVICE|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
219070137|NCT05450848|OTHER|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
219070138|NCT03312556|DEVICE|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
219070139|NCT03312556|DRUG|Placebo|Placebo pill or patch. Single dose
219673797|NCT00412789|DRUG|Patupilone|
219673798|NCT02855801|OTHER|constant exercise|
219673799|NCT02855801|OTHER|cryotherapy|
219070140|NCT02891187|BEHAVIORAL|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
219070141|NCT02891187|BEHAVIORAL|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
219070142|NCT02820779|DEVICE|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
219070143|NCT02420002|DRUG|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
219208933|NCT06757257|DRUG|fostamatinib|oral administration
219673800|NCT02855801|OTHER|intermittent exercise|
219673801|NCT03653312|DEVICE|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
219673802|NCT01017081|OTHER|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
219673803|NCT01017081|OTHER|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
219673804|NCT04621032|DIAGNOSTIC_TEST|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
219673805|NCT04621032|DIAGNOSTIC_TEST|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
219673806|NCT04252885|DRUG|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
219673807|NCT04252885|DRUG|Arbidol|As indicated in arm/group descriptions
219673808|NCT02363712|DEVICE|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
219673809|NCT02363712|DEVICE|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
219673810|NCT05300334|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase deficiency test
219673811|NCT06845865|DIETARY_SUPPLEMENT|enteric dyed solution|Oral administration of 0.5 mg/kg of body weight of food coloring dye
219673812|NCT02813473|RADIATION|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
219673813|NCT02813473|RADIATION|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
219673814|NCT06583798|PROCEDURE|Resurgery In Silicone Oil Filled Eyes|"* Alcon Luxor Biomicroscope with Non-contact BIOM (binocular indirect ophthalmomicroscope) viewing system was used.~* 2 ports were made in Pars plana.~* Top up of Silicone oil was done whenever needed.~* Membrane peeling with relaxing retinectomy / drainage retinotomy, haemostasis and endolaser were done under Silicone oil as required.~* After the re surgery, the patients were advised to maintain prone position."
219673815|NCT03560063|PROCEDURE|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
219673816|NCT03560063|PROCEDURE|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
219673817|NCT06070493|OTHER|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
219673818|NCT06070493|OTHER|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
219673819|NCT05892211|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
219070144|NCT02420002|OTHER|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
219070145|NCT02420002|PROCEDURE|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
219070146|NCT02615223|PROCEDURE|cryoablation|Cryoablation therapy
219070147|NCT02615223|DRUG|Bicalutamide|bicalutamide
219070148|NCT02615223|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
219070149|NCT03278665|DRUG|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
219673820|NCT05892211|DIAGNOSTIC_TEST|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
219673821|NCT05892211|GENETIC|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
219673822|NCT05892211|DIAGNOSTIC_TEST|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
219673823|NCT05892211|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
219673824|NCT05347966|OTHER|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
219673825|NCT02145910|DRUG|Vemurafenib|Given PO
219673826|NCT02145910|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
219673827|NCT02145910|RADIATION|Radiosurgery (SRS)|Undergo SRS
219673828|NCT00000200|DRUG|Methadone|normal maintenance dose
219673829|NCT06331975|DIAGNOSTIC_TEST|Radiomic signature|Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
219673830|NCT04375904|RADIATION|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
219673831|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
219673832|NCT01690299|DRUG|Apremilast|Apremilast 30 mg tablet orally BID
219673833|NCT01690299|DRUG|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
219673834|NCT01690299|DRUG|Placebo tablet|Placebo tablets BID
219673835|NCT01690299|DRUG|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
219673836|NCT02608242|DRUG|YH22189|
219673837|NCT02608242|DRUG|Twynsta 80/10mg|
219673838|NCT02608242|DRUG|Crestor 20mg|
219673839|NCT04199923|BEHAVIORAL|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
219673840|NCT06500026|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219673841|NCT06500026|DRUG|Topotecan|Administration by intravenous infusion for a cycle of 3 weeks.
219673842|NCT06514573|DIETARY_SUPPLEMENT|Sodium Butyrate|Daily supplementation with 1 sachet per day for 16 weeks
219673843|NCT06514573|DIETARY_SUPPLEMENT|Placebo (cornstarch)|Daily supplementation with 1 sachet per day for 16 weeks
219673844|NCT05080218|DRUG|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
219673845|NCT05080218|DRUG|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
219673846|NCT05080218|DRUG|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
219673847|NCT05080218|DRUG|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
219673848|NCT05080218|DRUG|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
219673849|NCT05080218|DRUG|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
219673850|NCT05080218|DRUG|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
219673851|NCT05080218|DRUG|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
219673852|NCT01753115|BIOLOGICAL|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
219673853|NCT01753115|DRUG|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
219673854|NCT03642067|DRUG|Nivolumab|Nivolumab was administered IV on day 1 of each 28 day cycle.
219673855|NCT03642067|DRUG|Relatlimab|Relatlimab was administered IV on day 1 of each 28 day cycle.
219673856|NCT03726307|BIOLOGICAL|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
219673857|NCT03726307|BIOLOGICAL|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
219673858|NCT03726307|BIOLOGICAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
219673859|NCT03326115|BEHAVIORAL|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
219673860|NCT02839031|BEHAVIORAL|"CBT (Cognitive-Behavioral Therapy)"|
219673861|NCT02839031|BEHAVIORAL|Control (telephonic support without CBT content)|
219673862|NCT00949871|OTHER|communication analysis|
219673863|NCT00949871|OTHER|questionnaire administration|
219673864|NCT00949871|PROCEDURE|psychosocial assessment and care|
219673865|NCT00949871|PROCEDURE|support group therapy|
219673866|NCT02748291|OTHER|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
219070150|NCT05804773|DIAGNOSTIC_TEST|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
219070151|NCT04852081|DRUG|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
219070152|NCT04852081|DRUG|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
219673867|NCT02748291|OTHER|Department of Health Physical Activity Guidelines|"1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.~4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
219673868|NCT06635850|DRUG|Mosliciguat|Dose level 1, 2, or 3 for inhalation
219673869|NCT06635850|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat or placebo delivery
219673870|NCT06635850|DRUG|Placebo|Matching placebo for inhalation
219673871|NCT01637883|DRUG|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
219673872|NCT04438616|PROCEDURE|dome magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia~* A crestal incision is made using No. 15 c blade .~* Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure"
219673873|NCT04438616|PROCEDURE|flat magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia.~* A crestal incision is made using No. 15 c blade~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
219673874|NCT00003032|BIOLOGICAL|filgrastim|
219673875|NCT00003032|DRUG|cisplatin|
219673876|NCT00003032|DRUG|cyclophosphamide|
219673877|NCT00003032|DRUG|mitoxantrone hydrochloride|
219673878|NCT00003032|DRUG|tamoxifen citrate|
219673879|NCT01014078|DRUG|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
219673880|NCT01014078|DRUG|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
218981148|NCT03757338|DRUG|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
219673884|NCT03678194|DEVICE|Smartphone Support System|6 weeks smartphone application with daily evaluations
218981149|NCT01848704|BEHAVIORAL|interpretation of the abstract|
218981150|NCT03405896|OTHER|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
218981151|NCT02229331|OTHER|Gait analysis|
218981152|NCT03086278|DRUG|AST-008|AST-008 is a toll-like receptor 9 agonist.
219208934|NCT06758284|OTHER|Laughter Yoga|The first component of the intervention is laughter therapy, which is a combination of warm-up exercises, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy via WhatsApp video call. Laughter yoga will be a single session and will last approximately 30 minutes.
219208935|NCT06756698|OTHER|conventional treatment plus music intervention|Each music therapy session will include 5 stages. In stage 1, an emotional assessment is conducted to observe the patient's current emotional experience and feelings (provide a VAD score), which lasts about 1 minute. In stage 2, relaxation exercises (breathing relaxation, progressive muscle relaxation, and imaginary relaxation) are conducted under the guidance of the therapist to the music corresponding to the relaxation target VAD, which lasts about 8 minutes. In stage 3, the patient independently selects the music and discusses it with the therapist, which lasts about 10 minutes. In stage 4, the patient listens to resource and positive-oriented music and discusses specific topics with the therapist, which lasts about 10 minutes. Finally, in stage 5, the therapist again conducts an emotional assessment of the patient and observes the patient's current emotional experience and feelings, which lasts about 1 minute.
219208936|NCT06756698|OTHER|conventional treatment|The conventional treatment group received DBT group therapy 5 times a week, each session lasting 1 hour, and also received individual personalized therapy twice a week.
219208937|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, standard limb lengths of 75cms BP limb and 125cms Alimentary limb were measured and performed, irrespective of the total bowel length
219208938|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, limb lengths are tailored according to the total small bowel length, 1/3rd of the total bowel length is measured and in that 3/8th and 5/8th were kept as BP limb and alimentary limb respectively.
219208939|NCT06756633|OTHER|Respiratory Function Test|A spirometer (microQuark, COSMED) will be used to assess respiratory functions. During a forced expiratory maneuver after a deep, full inspiration, airway and lung volumes are measured. During the measurement, a deep inspiration followed by a strong, fast, and continuous expiration until unable to exhale anymore should be performed. The expiration time should be at least 6 seconds, and if necessary, extended up to 15 seconds. More than eight repetitions at one time are not recommended.
219673885|NCT05578677|OTHER|Biopsy technique|"* Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively."
219673886|NCT04624802|BEHAVIORAL|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
219673887|NCT05186051|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
219673888|NCT03363893|DRUG|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
219673889|NCT03363893|DRUG|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
219673890|NCT00496587|DRUG|Capecitabine|800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
219673891|NCT00496587|DRUG|Gemcitabine|900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
219673892|NCT00496587|DRUG|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
218981153|NCT05840731|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
218981154|NCT05840731|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
218981155|NCT04924959|OTHER|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
218981156|NCT04206800|DIAGNOSTIC_TEST|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
218981157|NCT02503410|BEHAVIORAL|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
218981158|NCT02503410|BEHAVIORAL|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
218981159|NCT06556472|DRUG|Terlipressin|1\. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
219070153|NCT04852081|DRUG|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
219070154|NCT04852081|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
219070155|NCT04852081|DRUG|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
219070156|NCT04852081|DRUG|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
219070157|NCT04852081|DRUG|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
219070158|NCT04852081|DRUG|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
219070159|NCT04852081|DRUG|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
219070160|NCT00489606|DRUG|SK3530|
219070161|NCT02644460|DRUG|Abemaciclib|
219070162|NCT05155826|DEVICE|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
219070163|NCT01615731|DRUG|Mifepristone|200mg Mifepristone orally
219070164|NCT01615731|OTHER|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
219070165|NCT01615731|DRUG|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
219070166|NCT01615731|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op
219070167|NCT06204731|OTHER|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
219070168|NCT05921968|DRUG|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
219070169|NCT05921968|DRUG|Lactoferrin|100 mg twice daily orally before breakfast and dinner
219070170|NCT06085170|DIAGNOSTIC_TEST|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
219070171|NCT04480112|BEHAVIORAL|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
219070172|NCT04480112|OTHER|No research related technology based social interactions|No technology based social interactions with the research team.
219070173|NCT02041195|DRUG|Setmelanotide|
219070174|NCT02041195|DRUG|Placebo|
219673893|NCT02728817|PROCEDURE|End-cephalic vein to side-radial artery fistula creation|"* Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
219673894|NCT02728817|PROCEDURE|RADAR fistula creation|"* Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
219673895|NCT04041492|DIETARY_SUPPLEMENT|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
219070175|NCT04250649|PROCEDURE|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
219070176|NCT00908479|BEHAVIORAL|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
219070177|NCT00908479|BEHAVIORAL|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
219070178|NCT02395120|BEHAVIORAL|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
219673896|NCT04442152|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
219673897|NCT02099383|OTHER|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
219673898|NCT04235322|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
219673899|NCT04235322|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
219673900|NCT00519584|DRUG|Ropivacaine|30 ml 0.5%
219673901|NCT00519584|DRUG|dex|8 mg (2 ml)
219673902|NCT00519584|DRUG|Bupivacaine|30 ml 0.5%
219673903|NCT00519584|DRUG|Saline|0.9% saline; systemic and local
219673904|NCT01648920|DEVICE|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
219673905|NCT02047994|DRUG|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days"
219673906|NCT03376126|OTHER|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
219673907|NCT03519685|BEHAVIORAL|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
219673908|NCT03519685|BEHAVIORAL|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
219673909|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
219673910|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
219673911|NCT04819841|GENETIC|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
219673912|NCT04595279|BEHAVIORAL|Smoking sessions|Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
219673913|NCT06126796|DIAGNOSTIC_TEST|CxBladder Monitor|CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.
219673914|NCT06126796|DIAGNOSTIC_TEST|Cystoscopy|Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
219673915|NCT04008485|DEVICE|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
219673916|NCT00956488|BEHAVIORAL|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
218981160|NCT06556472|DRUG|Norephrine|1\. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
218981161|NCT02773290|BIOLOGICAL|Romiplostim|Weekly SC administration
218981162|NCT03386474|DRUG|Brolucizumab 6 mg|Administered as opthalmic solution for an intravitreal injection to the study eye
218981163|NCT03386474|DRUG|Aflibercept 2 mg|Administered as an opthalmic solution for intravitreal injection to the study eye
219673917|NCT02891486|PROCEDURE|Spinal surgery|Elective spinal surgery performed
219673918|NCT05208580|BEHAVIORAL|Virtual education|Participants undergo virtual education activities on an on-line platform 10-14 days before the surgery
219673919|NCT05208580|BEHAVIORAL|Contact education|Participants attend live educational classes 10-14 days before the surgery
219673920|NCT04617405|OTHER|No interventions|No interventions
218981164|NCT06127615|DEVICE|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
218981165|NCT05458934|OTHER|No intervention|no intervention
218981166|NCT00599950|DRUG|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
218981167|NCT05369767|DRUG|SAD, SHR-2004|Ascending dose
219208940|NCT06756633|OTHER|Structured light plethysmography|Participants' thoracoabdominal movements will be assessed using the PneumoCare device that measures with the SLP technique. The evaluation begins with positioning participants wearing a white tank top, t-shirt, or with a bare chest. In our study, measurements will be taken with participants seated, supported by their backs, and their chest area exposed. The participant's age, height, and weight information are entered into the system. After the participant is positioned, the lights of the SLP measuring device are set up 90-100 cm away to encompass the chest area. The light field, which is in a checkerboard pattern, rectangular or square, should align its upper edge with the participant's clavicles and its lower edge with the anterior-superior iliac spine. During this measurement, the participant is asked to look straight ahead and breathe normally for five minutes. At the end of the measurement, the three-dimensional movements of the chest and respiratory parameters are recorded.
219208941|NCT06756633|OTHER|6 Minute Walking Test|"For Ambulatory Participants:~Exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). The test will be performed according to ATS/ERS guidelines . The test involves walking for six minutes at a submaximal level in a 20-meter corridor. Blood pressure, heart rate, respiratory rate, oxygen saturation, and dyspnea, general fatigue, and leg fatigue according to the Modified BORG Scale (MBS) will be assessed before and after the test. Participants can stop and rest during the test. In such cases, the test duration is paused, and the rest time is recorded, then the test resumes from where it was left off. The distance walked in meters at the end of the test is recorded."
219208942|NCT06756633|OTHER|6-Minute Peg Board Ring Test|"For Non-Ambulatory Participants:~The 6-Minute Pegboard Ring Test will be used to assess upper extremity exercise capacity . Pre- and post-test evaluations of heart rate, blood pressure, respiratory rate, and MBS for dyspnea and fatigue will be made. The board used for the test has a total of 6 holes spaced 10 cm apart horizontally and another set of 6 holes 20 cm below aligned with the top row. There are four 20 cm long iron rods suitable for the holes. A total of 20 rings suitable for the iron rods will be used. The iron rods will be placed in the designated holes according to the patients' shoulder width. An adjustable chair will be used to suit the patients' heights, and the distance between the chair and the board will be adjusted according to arm length. Patients will be asked to place the rings from top to bottom and bottom to top with both hands simultaneously. The total number of rings placed in six minutes will be recorded in units."
219208943|NCT06756633|OTHER|Hand Grip Strength|Hand grip strength will be measured using a digital hand dynamometer (CAMRY Digital Hand Dynamometer) . The device handle will be adjusted according to the participants' hand size. The test is conducted while seated, with the dominant upper extremity in 90 degrees of elbow flexion. Participants are asked to squeeze the dynamometer as strongly as possible. The value displayed on the dynamometer is recorded. The measurement is repeated three times, and the average of the three measurements is taken to determine the participant's hand grip strength. The measurement takes five minutes and does not need to be repeated.
219208944|NCT06759545|OTHER|Dietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) with addition of three tablespoon (42 ml) EVOOEH (up to 0.8% free acidity) per day at each morning for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
219208945|NCT06759545|OTHER|Dietary MOH recommendations|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
219208946|NCT06759272|GENETIC|CYP2C19 genotype-guided antiplatelet therapy|A panel of genes including CYP2C19\*2 (rs4244285) and CYP2C19\*3 (rs4986893) will be genotyped using the real-time PCR and the expected turnover time will be 48 hours. Patients who are identified to have reduced function CYP2C19 allele will receive 90 mg ticagrelor and patients with wild-type CYP2C19 allele will receive clopidogrel 75 mg in the next scheduled dose. The switching done from clopidogrel to ticagrelor is supported by Antiplatelet Therapy Switching Clinician Guideline, whereby in the maintenance or low risk phase, there is generally no need to administer a loading dose of ticagrelor; one can switch directly to ticagrelor maintenance dose 24 hours after the last dose of clopidogrel
219673921|NCT04979416|BEHAVIORAL|Video messages|video messages aimed at increasing vaccination
218981168|NCT05369767|DRUG|SAD, SHR-2004 placebo|Ascending dose
218981169|NCT00052273|DRUG|capecitabine|
218981170|NCT00052273|DRUG|enzastaurin hydrochloride|
218981171|NCT05576675|DRUG|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
218981172|NCT05576675|DRUG|Sufentanil|sufentanil 200 μ g
218981173|NCT05576675|DRUG|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
218981174|NCT05283278|DRUG|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
218981175|NCT05283278|COMBINATION_PRODUCT|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
218981176|NCT05283278|OTHER|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
218981177|NCT02051231|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
218981178|NCT04238585|BEHAVIORAL|Mobile messaging|Mobile health messages
218981179|NCT03281707|PROCEDURE|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
218981180|NCT03281707|OTHER|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
218981181|NCT03687112|OTHER|non ontervention / observational study|non intervention
218981182|NCT04442139|OTHER|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
218981183|NCT00202059|DRUG|Zoledronic acid|
218981184|NCT00202059|BEHAVIORAL|Physical activity intervention|
218981185|NCT02096237|DEVICE|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
219673922|NCT06055153|DRUG|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If \> 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
219673923|NCT04668443|OTHER|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
219673924|NCT00098540|DRUG|sorafenib tosylate|Given orally
219673925|NCT00098540|OTHER|laboratory biomarker analysis|Correlative studies
219673926|NCT01831271|OTHER|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
219673927|NCT01831271|OTHER|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
219673928|NCT02334826|PROCEDURE|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
219673929|NCT02334826|PROCEDURE|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
218981186|NCT02954250|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
218981187|NCT06382831|DRUG|Dexmedetomidine|Opioid free anesthesia
218981188|NCT06382831|DRUG|Fentanyl|Control given Opioid balanced anesthesia
218981189|NCT02004600|PROCEDURE|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
218981190|NCT03980977|OTHER|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
218981191|NCT03980977|OTHER|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
218981192|NCT03980977|OTHER|blood sample|blood sample will be taken for biological collection
218981193|NCT02155881|DRUG|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
218981194|NCT02155881|DRUG|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
218981195|NCT04901676|DRUG|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
218981196|NCT04901676|DRUG|Placebo|Placebo
218981197|NCT05322733|DRUG|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
218981198|NCT05322733|DRUG|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
219070179|NCT02395120|BEHAVIORAL|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
219070180|NCT02395120|BEHAVIORAL|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
218981199|NCT05322733|DRUG|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
218981200|NCT05322733|DRUG|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
218981201|NCT04357782|DRUG|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
218981202|NCT01771042|OTHER|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
218981203|NCT02188771|DEVICE|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
218981204|NCT01786148|BEHAVIORAL|mobile phone application|
218981205|NCT03388931|RADIATION|Radiation Therapy|Increased radiation therapy dose
218981206|NCT03388931|COMBINATION_PRODUCT|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
218981207|NCT01356927|DRUG|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
218981208|NCT01356927|DRUG|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
218981209|NCT00675259|DRUG|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
219070181|NCT02395120|BEHAVIORAL|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
219070182|NCT02395120|BEHAVIORAL|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
219070183|NCT01748929|DRUG|Albendazole|
219070184|NCT01748929|DRUG|Placebo|
219070185|NCT02658643|PROCEDURE|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
219070186|NCT02658643|PROCEDURE|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
219070187|NCT00674986|DEVICE|Accu-Chek 360° View Blood Glucose Analysis Tool|
219070188|NCT00674986|DEVICE|Accu-Chek Aviva Glucose Meter|
219070189|NCT03477448|DRUG|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
218981210|NCT00675259|DRUG|carboplatin|AUC 2 IV on days 1, 8, and 15
218981211|NCT00675259|DRUG|nab-paclitaxel|100 mg/M2 IV
218981212|NCT00675259|PROCEDURE|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
218981213|NCT00675259|DRUG|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
218981214|NCT04849923|OTHER|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
218981215|NCT03845751|DRUG|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
218981216|NCT01384942|BEHAVIORAL|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
218981217|NCT01384942|BEHAVIORAL|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
218981218|NCT00443105|DRUG|Tacrolimus 0.03% ointment (Protopic)|
219070190|NCT03477448|DRUG|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
219070191|NCT01461668|DRUG|Retapamulin|Two times a day for 5 days
219070192|NCT01461668|DRUG|Placebo|Two times a day for 5 days
219070193|NCT01251003|BIOLOGICAL|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
219070194|NCT00931372|DRUG|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
219070195|NCT00931372|DRUG|Placebo|Subcutaneous injection
219070196|NCT02816580|OTHER|Blood collection|
219070197|NCT01611701|PROCEDURE|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
218981219|NCT05043675|DRUG|[18F]APN-1607|Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
218981220|NCT02028312|DRUG|Loteprednol etabonate|
218981221|NCT02028312|DRUG|Artificial Tears|
218981222|NCT02028312|DRUG|Restasis|
218981223|NCT00468468|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
218981224|NCT01089673|OTHER|data collection|retrospective data collection
218981225|NCT02935231|DRUG|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
218981226|NCT02935231|BEHAVIORAL|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
218981227|NCT02935231|OTHER|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
218981228|NCT01874600|DEVICE|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
218981229|NCT05586646|DIETARY_SUPPLEMENT|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
218981230|NCT05916820|OTHER|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
218981231|NCT05916820|OTHER|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
218981232|NCT02969330|DEVICE|Stimulator|
218981233|NCT02969330|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose
218981234|NCT05342792|DRUG|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
218981235|NCT05342792|DRUG|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
218981236|NCT06557824|OTHER|speleotherapeutic intervention|In the study, medical records of 415 Czech children diagnosed with bronchial asthma who took part in speleotherapeutic intervention between January 2022 and October 2023 were analysed.
218981237|NCT03505190|DRUG|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
218981238|NCT03505190|DRUG|Placebo|Matching placebo will be administered subcutaneously (SC).
218981239|NCT02001103|DRUG|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
218981240|NCT02001103|DRUG|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
218981241|NCT03488355|OTHER|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
218981242|NCT00066729|BIOLOGICAL|NY-ESO-1 peptide vaccine|NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
218981243|NCT00000209|DRUG|Buprenorphine|
218981244|NCT04361825|DRUG|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
218981245|NCT06512597|BEHAVIORAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
218981246|NCT06512597|BEHAVIORAL|Time and Attention Control - IBD Support Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
218981247|NCT03189420|PROCEDURE|Tumor resection|The tumors will be resected in routine therapeutic surgeries
218981248|NCT02298231|OTHER|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
218981249|NCT02298231|OTHER|Mystic Isle Balance Intervention|Balance therapy using virtual reality
218981250|NCT02298231|OTHER|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
218981251|NCT00704678|DRUG|SBR759|1g tid
218981252|NCT00704678|DRUG|Sevelamer HCl|1.6 g tid
218981253|NCT00704678|DRUG|Sevelamer HCl|1.5 g tid
218981254|NCT00704678|DRUG|Sevelamer HCl|0.8 g tid
218981255|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 500mg tablet, orally once on Day 1
218981256|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 750mg tablet, orally once on Day 1
218981257|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
218981258|NCT06473948|DRUG|Placebo|Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
218981259|NCT06557252|BEHAVIORAL|PDCA training|Improve diagnostic rate
218981260|NCT00276497|DRUG|Pioglitazone|
218981261|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
218981262|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
218981263|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
218981264|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
219070198|NCT01611701|PROCEDURE|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
219070199|NCT06117982|DRUG|Neupogen|Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
219070200|NCT00379613|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
219070201|NCT00379613|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
219673930|NCT01043484|DRUG|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
219673931|NCT01043484|DRUG|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
219673932|NCT04958161|OTHER|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
219673933|NCT02193555|DEVICE|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
219673934|NCT00957489|OTHER|Dynamax appliance|
219673935|NCT00957489|OTHER|Twin-block appliance|
219673936|NCT00524680|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
219673937|NCT00549471|OTHER|physiotherapy|CG children will undergo a program of intensive physiotherapy
219673938|NCT00549471|OTHER|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
219673939|NCT02079298|DRUG|Treatment with fluconazole.|
219673940|NCT02079298|DRUG|2. Treatment with both fluconazole and Ibuprofen.|
219673941|NCT02079298|DRUG|3. Treatment with ibuprofen.|
219673942|NCT02079298|OTHER|4. No treatment with either fluconazole nor ibuprofen.|
219673943|NCT00123656|DRUG|esomeprazole|esomeprazole dosed qam for 8 weeks
219673944|NCT00123656|DRUG|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
219673945|NCT03124537|BEHAVIORAL|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
219673946|NCT03124537|BEHAVIORAL|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
219673947|NCT00960973|DRUG|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
219673948|NCT00960973|DRUG|Placebo|Placebo
219673949|NCT04221568|DRUG|Bupivacaine-fentanyl|local anathetic\&analgesic drugs
218981265|NCT01811225|DRUG|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
218981266|NCT01811225|DRUG|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
218981267|NCT02789631|OTHER|assessment|
218981268|NCT04344548|BIOLOGICAL|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
218981269|NCT04216121|RADIATION|Local ablative therapy|Stereotactic body radiotherapy
218981270|NCT04216121|PROCEDURE|Local ablative therapy|Surgery
218981271|NCT00137215|DEVICE|Silverlon|dressing for donor site mamagement
218981272|NCT03883360|DRUG|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
218981273|NCT03883360|DRUG|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
218981274|NCT02397031|BEHAVIORAL|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
218981275|NCT02397031|BEHAVIORAL|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
218981276|NCT03813043|DRUG|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
218981277|NCT04955132|BEHAVIORAL|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
219673950|NCT04221568|DRUG|levobupivacaine-fentanyl|local anathetic\&analgesic drugs
219673951|NCT00312117|DRUG|Sodium bicarbonate|
219673952|NCT01627795|DRUG|Oshadi D and Oshadi R|anti cancer agents
219673953|NCT03338244|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
219673954|NCT03338244|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
219673955|NCT01607346|DRUG|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
219673956|NCT04920890|DEVICE|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
219673957|NCT06345391|OTHER|Co-creation|Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.
219070202|NCT03321916|DEVICE|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
219070203|NCT05166408|PROCEDURE|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
219070204|NCT05166408|PROCEDURE|Bardach two flap palatoplasty|Bardach two flap palatoplasty
219070205|NCT05365087|PROCEDURE|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
219070206|NCT05365087|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
219070207|NCT01847703|PROCEDURE|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
219070208|NCT01847703|PROCEDURE|Abdominal surgery|Current gold standard
219070209|NCT00157807|PROCEDURE|bipolar radiofrequency ablation of persistent and permanent AF|
219070210|NCT04429516|DRUG|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
219070211|NCT04429516|DRUG|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
219070212|NCT02732418|DRUG|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
219070213|NCT02732418|DRUG|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
219070214|NCT04897074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
219070215|NCT03789266|PROCEDURE|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
219070216|NCT00256581|PROCEDURE|Additional rest and stress image sets on new camera|
219070217|NCT03801239|DIAGNOSTIC_TEST|Urodynamic Study|during visit Week 0 patients had urodynamic study
219070218|NCT03801239|DIAGNOSTIC_TEST|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
219070219|NCT03801239|DIAGNOSTIC_TEST|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
219673958|NCT06345391|OTHER|Concept Mapping|Concept mapping to create a pain science education intervention for children living beyond cancer.
219673959|NCT06977581|DRUG|PF-07275315|subcutaneous injection
219673960|NCT06977581|OTHER|Placebo|subcutaneous injection
219070220|NCT03801239|DIAGNOSTIC_TEST|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
219070221|NCT03328754|DEVICE|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
219070222|NCT03328754|DEVICE|Group 2 Forsus|Forsus placed bilaterally for class II correction
219673961|NCT01558713|DRUG|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
219673962|NCT01558713|DRUG|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
219673963|NCT01558713|DRUG|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
219673964|NCT01558713|DRUG|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
219673965|NCT01558713|DRUG|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
219673966|NCT01558713|DRUG|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
219070223|NCT06369259|DRUG|Defactinib|Given by PO
219070224|NCT06369259|DRUG|Cetuximab|Given by IV
219673967|NCT04049006|OTHER|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
219070225|NCT06369259|DRUG|Avutometinib|Given by PO
219070226|NCT05109299|OTHER|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
219070227|NCT05109299|OTHER|Fluoride toothpaste|1450 ppm fluoride toothpaste
219070228|NCT04396834|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
219070229|NCT04396834|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
219070230|NCT03839251|DRUG|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
219070231|NCT03861013|BEHAVIORAL|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
219070232|NCT01024569|BEHAVIORAL|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
219070233|NCT02210364|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
219208947|NCT06748625|BEHAVIORAL|Luci Coach-Assisted Intervention|The Luci intervention is a personalized behaviour change program delivered via an interactive web platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement. Participants will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining SMART goals to progressively adopt and maintain a healthier lifestyle. Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
218981278|NCT05581966|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
218981279|NCT02554942|DRUG|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
218981280|NCT04992910|DEVICE|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
218981281|NCT04992910|OTHER|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
219070234|NCT02210364|DRUG|capecitabine|capecitabine 150 mg tablets
219070235|NCT00302796|DRUG|Bioclavid|500 + 125 mg times 3 or 6
218981282|NCT01816529|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
218981283|NCT01816529|DRUG|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
218981284|NCT01816529|DRUG|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
218981285|NCT01816529|DRUG|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
218981286|NCT02158975|DRUG|MLN9708|
218981287|NCT03000569|DRUG|SAGE-217|
218981288|NCT03000569|DRUG|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
219070236|NCT00302796|DRUG|Placebo|
219070237|NCT01659931|DRUG|Montelukast|10 mg Tablet
219070238|NCT01659931|DRUG|Singulair|10 mg Tablet
218981289|NCT03000569|DRUG|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
218981290|NCT02524405|OTHER|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
218981291|NCT00265629|DEVICE|RF catheter ablation|RF ablation using mesh device
218981292|NCT02550041|OTHER|T specific response for diagnostic of aspergillus bronchitis|
218981293|NCT06119399|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
218981294|NCT06119399|OTHER|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
219070239|NCT02676167|BEHAVIORAL|PrEP Intervention|
219070240|NCT05028218|DRUG|TQB3824 tablets|TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
218981295|NCT06119399|OTHER|Doming of the diaphragm|"* The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
219070241|NCT00450762|DRUG|gemcitabine|
219070242|NCT00450762|DRUG|carboplatin|
219070243|NCT04137042|DRUG|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
219070244|NCT04137042|DRUG|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
219070245|NCT05184725|DEVICE|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
219070246|NCT02527668|DIETARY_SUPPLEMENT|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
219070247|NCT02527668|DIETARY_SUPPLEMENT|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
219070248|NCT02527668|OTHER|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
219070249|NCT05463328|PROCEDURE|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
219673968|NCT02024737|OTHER|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
219673969|NCT05138328|DEVICE|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
219673970|NCT06730191|PROCEDURE|soft tissue graft covering immediate dental implant|soft tissue graft covering immediate dental implant
219673971|NCT05390385|DIETARY_SUPPLEMENT|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
219673972|NCT05390385|DIETARY_SUPPLEMENT|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
219673973|NCT05390385|DIETARY_SUPPLEMENT|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
219673974|NCT05390385|DIETARY_SUPPLEMENT|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
219673975|NCT05390385|OTHER|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
219673976|NCT04037852|DEVICE|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
219673977|NCT04037852|PROCEDURE|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
218981296|NCT06119399|OTHER|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
219070250|NCT05463328|PROCEDURE|Open pancreaticduodenctomy|Open pancreaticduodenctomy
219070251|NCT05777642|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
219070252|NCT05777642|DIETARY_SUPPLEMENT|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
219070253|NCT01219348|BIOLOGICAL|IDO peptide vaccination|Vaccination every second week
219070254|NCT02274779|DRUG|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
219070255|NCT03754296|DEVICE|CATCHVIEW|Revascularization device
219070256|NCT03894865|OTHER|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
219070257|NCT03894865|OTHER|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
219070258|NCT02141126|OTHER|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
219070259|NCT02141126|OTHER|Usual care|Standard inpatient 'usual care' physiotherapy
219070260|NCT04593446|DRUG|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
219070261|NCT04593446|DRUG|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
219673978|NCT04037852|PROCEDURE|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
219208948|NCT06761092|DRUG|Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children|"Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room"
219673979|NCT01553435|DRUG|Dextromethorphan|The study medicines shall be administered via tube.
219208949|NCT06761092|PROCEDURE|Nebulized 0.9% Normal Saline|Nebulization with normal saline 0.9% 3 ml, administered before the induction of anesthesia in the reception area. After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
219673980|NCT01553435|DRUG|Placebo|The study medicines shall be administered via tube.
219673981|NCT00019656|DRUG|perifosine|
218981297|NCT05968131|OTHER|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
218981298|NCT05968131|OTHER|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
218981299|NCT03468101|OTHER|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
218981300|NCT00507091|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
219070262|NCT01464203|OTHER|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
219070263|NCT01464203|OTHER|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
219070264|NCT01691066|BEHAVIORAL|Infant Toddler Years PRT|
219070265|NCT05629052|PROCEDURE|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
219070266|NCT05629052|PROCEDURE|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
219673982|NCT02159885|OTHER|Telemonitoring|
219673983|NCT01459393|DRUG|5-ALA Photodynamic Therapy|
219673984|NCT01459393|DRUG|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
219673985|NCT00868751|BIOLOGICAL|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
219673986|NCT06673160|BEHAVIORAL|Pumping every 2 hours|The intervention will be pumping every 2 hours.
219673987|NCT06673160|BEHAVIORAL|breast pumping every 3 hours|The intervention will be pumping every 3 hours
219673988|NCT01956760|OTHER|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
219208950|NCT02382003|BEHAVIORAL|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
219673989|NCT01415375|BEHAVIORAL|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
219673990|NCT01415375|BEHAVIORAL|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
219070267|NCT05629052|DRUG|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
219070268|NCT04546581|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
219070269|NCT04546581|OTHER|Placebo|Participants will receive a single infusion of the placebo (saline).
219070270|NCT04546581|DRUG|Remdesivir|Remdesivir will be given to participants in both groups as standard of care (SOC).
219070271|NCT04756765|DRUG|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
219070272|NCT05123274|BEHAVIORAL|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
219070273|NCT05123274|BEHAVIORAL|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
219208951|NCT02382003|BEHAVIORAL|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
218981301|NCT00507091|DRUG|Irinotecan|intravenous infusion
218981302|NCT00507091|DRUG|5-Fluorouracil|intravenous infusion
218981303|NCT00507091|DRUG|Leucovorin|intravenous infusion
218981304|NCT00507091|DRUG|ZD6474 (vandetanib) 300mg|once daily oral tablet
218981305|NCT04122534|BEHAVIORAL|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
218981306|NCT06057077|DRUG|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
218981307|NCT00579878|DRUG|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
219070274|NCT05933031|DRUG|Tegoprazan 50 mg Triple Therapy|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
219673991|NCT04581018|OTHER|Health supplements|28 days of health supplements (synbiotic), 4g daily
219673992|NCT00405782|BEHAVIORAL|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
219070275|NCT05933031|DRUG|Tegoprazan 100 mg Triple Therapy|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
219070276|NCT05933031|DRUG|Lansoprazole Triple Therapy|Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
219070277|NCT01187758|BEHAVIORAL|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
219070278|NCT02526693|DIAGNOSTIC_TEST|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
219070279|NCT01983293|DEVICE|QLV based implant strategy|
219070280|NCT01983293|DEVICE|Standard of care implant strategy|
219070281|NCT01275625|DRUG|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
219070282|NCT03716713|DEVICE|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
219070283|NCT03009045|DRUG|Tedizolid|200mg oral tedizolid one pill per day
219070284|NCT01585103|DEVICE|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
219208952|NCT02382003|BEHAVIORAL|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
219673993|NCT06866717|OTHER|Hybrid prehabilitation|"Hybrid prehabilitation group (15 sessions in total over 3 weeks): participants will complete 3 center-based sessions and 12 home-based sessions over three weeks. The home-based sessions will mirror those in the center-based group (initiation, training session, final session).~For the home-based component, participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application for guidance throughout the program, remote monitoring and communication (TELEREHAPP). Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* Physical activity coaching with daily step count objective;~* Regular remote monitoring and support via the tablet application, with weekly check-ins from healthcare professionals."
219673994|NCT06866717|OTHER|Center-based prehabilitation|"Center-based prehabilitation group (15 sessions in total over 3 weeks): participants will attend 15 sessions in the center, over three weeks, comprising:~* 1 initiation session (approximately 3 hours) including preoperative patient education, instructions on the use of inspiratory muscle training device, endurance training on a cycle ergometer, strength training, and balance exercises.~* 13 endurance training sessions (1.5 to 2 hours each) focusing on endurance training (15 to 45 minutes), strength training (30 minutes), and inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* 1 final session (2 to 2.5 hours) with a review of the program and educational reinforcement."
219673995|NCT03938688|PROCEDURE|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
219673996|NCT07016308|DRUG|Sevoflurane|Sevoflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 2-3% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group S (Sevoflurane Low-Flow Anesthesia Arm).
219673997|NCT07016308|DRUG|Desflurane|Desflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 4-6% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group D (Desflurane Low-Flow Anesthesia Arm).
219673998|NCT07015944|OTHER|Non-specialist delivered Low intensity guided self-help (Khushi and Khatoon)|This is a manualised intervention comprising of 8 chapters. This is being further co-adapted to contexualise this for breast cancer survivours. The original manual is focused on stories of two breast cancer survivors , Mrs Khushi, means happiness) and Khatoon, means woman in Urdu, with depression and anxiety, describing how they help themselves using CBT strategies.
219673999|NCT07015944|OTHER|Moving on After Breast Cancer (ABC) plus|This is a high intensity manualised intervention consisting of 12 sessions (60-90 minutes). This manual offers practical support and advice on life after breast cancer, managing difficulties, mindfulness, addressing fatigue, understanding the participant's model of illness, improving personal effectiveness and social relationships. The sessions also include therapist delivered psychoeducation using a CBT model of case formulation and goal setting: identification and formulation of predisposing, precipitating, perpetuating and protective factors of depression and/or anxiety, helping participants to identify core beliefs, where necessary, using downward arrow technique, identifying, and challenging unhealthy thinking patterns at the level of core beliefs using cognitive restructuring, and problem-solving techniques
219674000|NCT07015944|DRUG|Standardised pharmacological treatment (antidepressants)|Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks. After that, flexible titation of sertraline will be permitted, by 50mg increment every 1 to 2 weeks, as clinically indicated and tolerated to a maximum daily dose of 200 mg
219674001|NCT07015944|OTHER|Enhanced Treatment As Usual (E-TAU)|Participants in this arm will continue to follow their routine visits to healthcare facilities. They will be regularly monitored by trained research team and will be assessed at weeks 6,18,30, and 48. In addition to psychological assessment at each follow-up, this will include information leaflets based on a brief psychoeducational module to educate participants and families about the risks, symptoms, management, and referral support information for anxiety and depression
218981308|NCT00579878|DRUG|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
219070285|NCT02434692|DEVICE|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
219070286|NCT06535451|OTHER|Screening|Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
219070287|NCT01183663|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
219070288|NCT01183663|DRUG|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
219070289|NCT01183663|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
219070290|NCT01183663|DRUG|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
219070291|NCT01183663|DRUG|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
219070292|NCT01183663|DRUG|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
219070293|NCT01183663|DRUG|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
219070294|NCT01183663|DRUG|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
219070295|NCT05275894|BEHAVIORAL|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
219674002|NCT07015606|OTHER|Sciatic nerve mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
219674003|NCT07015606|OTHER|Femoral neural mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
219674004|NCT07017660|OTHER|virtual reality glasses|Patients will be asked to wear virtual reality glasses starting three minutes before the procedure and until it is completed. With the virtual reality glasses, the patient will be shown a video of nature scenes and made to listen to the sounds of water and birds. Routine institutional procedures will be applied during the cystoscopy procedure.
219674005|NCT07017660|OTHER|No intervention|Routine institution procedures will be applied during the cystoscopy procedure.
219674006|NCT06618729|OTHER|Pea protein|Ingestion of a meal containing 40 g of protein from pea protein extrudate
219674007|NCT06618729|OTHER|Wheat protein|Ingestion of a meal containing 40 g of protein from wheat protein extrudate
219674008|NCT06618729|OTHER|Soy protein|Ingestion of a meal containing 40 g of protein from soy protein extrudate
219674009|NCT06618729|OTHER|Chicken|Ingestion of a meal containing 40 g of protein from chicken
219674010|NCT03748121|BEHAVIORAL|Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)|The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
219674011|NCT03748121|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
219674012|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"Phase 1 (Neoadjuvant Chemotherapy):~Patients will receive 2 units of Impact oral supplement and 1 sachet of protein module daily, for 7 days prior to each chemotherapy cycle.~During the interval between the end of one cycle and 7 days before the next, 2 sachets of protein module per day will be maintained.~Phase 2 (Surgery):~2 units of Impact once daily, for 7 days prior to surgery.~Phase 3 (Radiotherapy):~2 units of Impact and 1 sachet of protein module daily, for 7 days prior to starting radiotherapy (RT), followed by 1 unit of Impact once daily throughout the course of RT.~Protein module: 13 g/day until the end of treatment."
219674013|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"2 units of Impact oral supplement and 1 sachet of protein module once daily, starting 1 week before the initiation of radiotherapy (RT).~During RT: 1 unit of Impact and 1 sachet of protein module daily, until 1 week before the end of RT.~2 units of Impact and 1 sachet of protein module daily until the end of treatment, starting from 1 week before the end of RT.~Protein module: 13 g/day throughout the entire treatment period."
219674014|NCT07021378|OTHER|Control Cohort A|Control cohort A: According to the institutional routine nutritional orientation
219674015|NCT07021378|OTHER|Control cohort B|Control cohort B: According to the institutional routine nutritional orientation
219674016|NCT07021469|OTHER|Sound origins|"Parents:~1. Playlists created by parents with lived experience for parents to use as ideas for music they could use for themselves or with baby on the unit.~2. Parent Journal: This journal provides a guide for using music and self-reflection. It also has the link for the playlists.~3. 'Musical gifts' created with the support of a music therapist from external family/ friends to the baby on the unit.~Nursing staff caring for families participating in the study:~1. Nurses shared playlist. Suggested creation of 3 playlists for nursing staff to create their own shared playlist using their music.~2. 'Ask me' badges. These badges are optional for nurses to wear during their shifts but will act as a symbol to parents that their nurse is available to speak to about music."
219070296|NCT05275894|PROCEDURE|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
219070297|NCT05275894|PROCEDURE|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
219070298|NCT05275894|PROCEDURE|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
219070299|NCT05275894|PROCEDURE|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
219070300|NCT05275894|DRUG|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
219674017|NCT07026617|OTHER|Rocabado's approach in addition to LLLT|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to low power gallium aluminum arsenide (GaAlAs).
219674018|NCT07026617|OTHER|control group|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to lplacebo ow power gallium aluminum arsenide (GaAlAs).
219674019|NCT07026786|BEHAVIORAL|Mindfulness Intervention|Those in the Mindfulness Intervention group will have a 30-minute Zoom session before surgery to learn simple mindfulness exercises like deep breathing, using senses, and staying focused on the present. After surgery, these participants will receive a refresher on the mindfulness curriculum.
219674020|NCT07022158|OTHER|The patients participating in the study were between 6 and 16 weeks of pregnancy. Height, body weight, and waist circumference were measured at the first antenatal visit at 2 weeks.|170 patients at 6-16th weeks of gestation were prospectively analyzed. Body mass index (BMI) and ABSI were calculated. Patients were analyzed according to the presence of GDM, GHT and preeclampsia at follow-up.
219674021|NCT07021404|OTHER|Semi-structured interview (Guideline for Suicide care and Evaluation =LOES)|"A semi-structured interview is utilized in general hospitals and other healthcare institutions by clinicians and nurses as part of the psychosocial assessment, with the aim of collecting standardized data on episodes of self-harm and individuals experiencing suicidal ideation.~The interview consists of two parts:~Part 1 is administered shortly after admission to the healthcare facility due to an episode of self-harm or reported suicidal thoughts. It is conducted by a trained nurse or psychologist. This section collects demographic information, characteristics of the self-harm episode, history of self-harm behavior, perceived social support, level of hopelessness, and current suicidal ideation.~Part 2 focuses on a more in-depth exploration of the individual's psychological state. It assesses underlying motives for the self-harm or suicidal thoughts, perceived personal and interpersonal problems, and current and current thoughts of self-harm."
219674022|NCT00247988|DRUG|Weekly Taxotere with weekly carboplatin|
219674023|NCT05690763|OTHER|XP-endo Finisher to use irrigation activation|XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.
219674024|NCT05690763|OTHER|EndoActivator to use irrigation activation|The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
219674025|NCT00043563|BEHAVIORAL|Cognitive-Behavior Therapy|
219674026|NCT05700331|PROCEDURE|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
219674027|NCT05700331|PROCEDURE|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
219070301|NCT05275894|PROCEDURE|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
219070302|NCT00249236|DRUG|Risperidone, oral tablets|
219070303|NCT01349569|DRUG|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
219070304|NCT01349569|BIOLOGICAL|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
219208953|NCT02382003|BEHAVIORAL|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
219674028|NCT00856843|DRUG|BLI800|Solution for oral administration prior to colonoscopy
219674029|NCT00856843|DRUG|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
219674030|NCT02841956|OTHER|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
219674031|NCT02841956|OTHER|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis \& building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms \& changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy \& treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
219674032|NCT02841956|OTHER|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
219674033|NCT02841956|OTHER|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
219070305|NCT01349569|BIOLOGICAL|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
219070306|NCT04798976|DRUG|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
219070307|NCT05564234|PROCEDURE|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
219070308|NCT05564234|PROCEDURE|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
219070309|NCT02883114|DRUG|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
219070310|NCT02883114|DRUG|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
219070311|NCT00716872|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
219070312|NCT00716872|BEHAVIORAL|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
219070313|NCT04247620|BEHAVIORAL|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
219070314|NCT04247620|BEHAVIORAL|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
219070315|NCT04898101|DRUG|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
219070316|NCT04898101|DRUG|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
219070317|NCT00594269|DRUG|Risperidone|Discontinuation
219070318|NCT00594269|DRUG|Escitalopram|Discontinuation
219674034|NCT03825068|PROCEDURE|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
219674035|NCT03825068|DRUG|general anesthetic|patient receive general anaesthetic only
219674036|NCT05112094|DEVICE|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
219674037|NCT05112094|OTHER|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
219674038|NCT03078127|OTHER|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
219674039|NCT03078127|DEVICE|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
219674040|NCT03078127|DEVICE|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
219674041|NCT03078127|DEVICE|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
219674042|NCT05622227|DIAGNOSTIC_TEST|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
219674043|NCT03216603|BEHAVIORAL|Health literacy intervention group|In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
219674044|NCT03268018|DEVICE|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
219674045|NCT06909591|OTHER|Self-assessment questionnaire|150 patients aged of 65 or older will pass the Lubben Social Network Scale questionnaire. The Duke Health Profile questionnaire will be also passed by the subject, for the convergent validity.
219674046|NCT03514979|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
219674047|NCT00842777|BEHAVIORAL|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
219674048|NCT00842777|BEHAVIORAL|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
219674049|NCT03229967|DIAGNOSTIC_TEST|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
219674050|NCT01187264|DRUG|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
219674051|NCT01687842|OTHER|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
219674052|NCT03118479|DRUG|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
219070319|NCT00594269|DRUG|Citalopram|Discontinuation
219674053|NCT03118479|DRUG|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
219674054|NCT03118479|DRUG|Placebo Oral Tablet|One tablet to be taken daily for 3 months
219674055|NCT04939454|PROCEDURE|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
219070320|NCT00594269|DRUG|Sertraline|Discontinuation
219070321|NCT00594269|DRUG|Paroxetine|Discontinuation
219070322|NCT01741623|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
219070323|NCT01741623|DRUG|Bisoprolol|10 mg tablet once a day
219070324|NCT00958269|DRUG|dutogliptin|100 mg QD
219070325|NCT00958269|DRUG|dutogliptin|200 mg QD
219070326|NCT00958269|DRUG|placebo|
219070327|NCT00958269|DRUG|sitagliptin|25 mg QD
219070328|NCT00958269|DRUG|sitagliptin|50 mg QD
219070329|NCT03581305|DRUG|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
219070330|NCT03581305|DRUG|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
219674056|NCT01612078|DRUG|Droxidopa|200mg/tab 2tablets, po, three times a week
219674057|NCT01612078|DRUG|Placebo|200mg/tab, po, three times a week.
219070331|NCT00829257|DRUG|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
219070332|NCT00829257|DRUG|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
219070333|NCT00829257|DRUG|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
219070334|NCT00778648|DIETARY_SUPPLEMENT|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
219070335|NCT00778648|DIETARY_SUPPLEMENT|Placebo|Four capsules of placebo daily.
219070336|NCT02201069|BEHAVIORAL|health coaching|
219070337|NCT01747772|DEVICE|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
219070338|NCT01798927|DEVICE|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
219070339|NCT03701568|DRUG|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
219070340|NCT01201590|DIETARY_SUPPLEMENT|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
219070341|NCT01201590|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
219208954|NCT06754293|BEHAVIORAL|rehabilitation exercise|"The intervention group will participate in a home-based exercise program alongside standard rehabilitation guidance. Patients will receive exercise materials developed by the intervention team, along with a detailed explanation of the program, including its components, specific exercises, and expected benefits.~The exercise program focuses on aerobic warm-ups and functional training, targeting key areas such as the hands, arms, shoulders, hips, legs, and back. It is designed to meet the rehabilitation needs of breast cancer patients undergoing endocrine therapy after surgery, addressing their unique challenges and enhancing recovery.~The intervention team, composed of specialists in breast cancer treatment, rehabilitation therapists, nursing experts, and methodologists, has created a professional exercise guidance manual. This manual provides detailed descriptions of exercise types, specific methods, and safety precautions. To ensure effective implementation, instructional videos have"
219208955|NCT06737770|PROCEDURE|osseointegrated surgery for transfemoral amputation|osseointegrated surgery for transfemoral amputation
219070342|NCT03302338|DRUG|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
219070343|NCT03302338|DRUG|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
219674058|NCT03277716|PROCEDURE|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
219674059|NCT03277716|PROCEDURE|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
219070344|NCT05920551|OTHER|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
219070345|NCT05920551|OTHER|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
219674060|NCT03277716|DEVICE|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
219070346|NCT05415813|OTHER|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
219070347|NCT05415813|OTHER|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
219070348|NCT02172508|DRUG|Tiotropium Inhalation Capsule|
219070349|NCT02172508|DRUG|Placebo Lactose Capsule|
219070350|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
219070351|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
219070352|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
219070353|NCT01064037|DRUG|Placebo|Infusion during 48h
219070354|NCT03750552|DRUG|ampreloxetine|Oral tablet, QD
219070355|NCT03750552|DRUG|Placebo|Oral tablet, QD
219070356|NCT00656591|DRUG|Methotrexate|Methotrexate
219070357|NCT06252129|OTHER|Subjects undergoing a lung specimen lymph node dissection|"A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging."
219070358|NCT06252129|OTHER|Control group|Control group
219070359|NCT02776358|OTHER|High Fidelity Simulation|"A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
219070360|NCT02776358|OTHER|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
219070361|NCT05674422|DRUG|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
219070362|NCT01421563|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
219070363|NCT03853629|OTHER|None. Not applicable|None. Not applicable
219070364|NCT02212028|DRUG|prasugrel|the effects of whole tablets versus crushed tablets will be compared
219070365|NCT02062632|DRUG|Doxepin Hydrochloride|Given orally
219070366|NCT02062632|OTHER|Placebo|Given orally
219070367|NCT02062632|OTHER|Quality-of-Life Assessment|Ancillary studies
219070368|NCT02062632|OTHER|Questionnaire Administration|Ancillary studies
219070369|NCT01495065|DRUG|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
219070370|NCT01495065|DRUG|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
219070371|NCT01495065|DRUG|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
219070372|NCT01495065|DRUG|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
219070373|NCT01495065|DRUG|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
219070374|NCT01495065|DRUG|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
219070375|NCT01702337|OTHER|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
219070376|NCT05833750|OTHER|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
219070377|NCT00978601|PROCEDURE|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
219070378|NCT01049113|DRUG|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
219070379|NCT01043666|DRUG|YM178|oral
219070380|NCT01043666|DRUG|Placebo|oral
219070381|NCT01043666|DRUG|tolterodine ER|oral
219674061|NCT03277716|DRUG|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
219674062|NCT01451554|BEHAVIORAL|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
219674063|NCT01451554|BEHAVIORAL|Usual Care|self-help booklets
219674064|NCT02348554|BEHAVIORAL|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
219674065|NCT02348554|BEHAVIORAL|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
219674066|NCT03024827|DRUG|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
219674067|NCT00942539|DRUG|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
219674068|NCT00852280|DEVICE|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
219674069|NCT00671125|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
219674070|NCT00671125|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
219674071|NCT00671125|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
219674072|NCT01402986|OTHER|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
219674073|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
219674074|NCT01402986|OTHER|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
219070382|NCT00626522|DRUG|Aclidinium bromide and formoterol|once daily
219070383|NCT00626522|DRUG|Aclidinium bromide and formoterol placebo|once daily
219070384|NCT02449200|OTHER|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
219070385|NCT02280044|BIOLOGICAL|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
219070386|NCT02280044|BIOLOGICAL|Placebo intervention|Placebo administered then Challenge with C jejuni
219070387|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
219070388|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
219070389|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
219070390|NCT05119920|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
219070391|NCT04499092|OTHER|Personalized Neuropsychological treatment (CORE-ABI)|Personalized neuropsychological treatment. In the CORE-ABI intervention, the stimulation of cognitive functions will be provided based on a weekly evaluation of child's cognitive profile by a qualified neuropsychologist. Each session will have a duration of 45 min. While the first 30 minutes will be devoted to the stimulation of the most impaired cognitive function(s), the remaining 15 minutes will ensure the stimulation of the other cognitive subdomains. Domains addressed by the intervention will be the following: selective attention, sustained and divided attention, inhibition and shifting, visual-perceptual abilities, visual-spatial abilities, visual-constructional abilities, short-term memory, long-term memory, working-memory, categorization/reasoning/abstraction, problem-solving/planning and socio-emotional skills.
219070392|NCT04499092|OTHER|Sequential Neuropsychological treatment (SET-ABI)|"Sequential Neuropsychological Treatment. In the SET-ABI intervention, the stimulation of cognitive functions will be provided following a sequential order, identical for each child and for each session in each setting (neuropsychological treatment, speech therapy treatment and psychoeducational treatment). Each session will have a duration of 45 min.~Specifically, the first three weeks (weeks 1-3) of treatment will target attention; in weeks 4-6, the domain of visual-spatial and visual-constructional abilities will be addressed; in weeks 7-9, memory will be the target domain; in weeks 10-12, executive functions and socio-emotional skills will be addressed."
219070393|NCT03955601|DRUG|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
219674075|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
219674076|NCT00280813|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|
219674077|NCT02427802|DRUG|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
219674078|NCT02427802|OTHER|Placebo|Matching collagen sponge
219674079|NCT01997970|BEHAVIORAL|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
219674080|NCT01997970|BEHAVIORAL|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
219674081|NCT01085084|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
219674082|NCT01085084|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
219674083|NCT02749799|DRUG|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
219674084|NCT00783328|DRUG|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
219070394|NCT04857268|DEVICE|wearable continuous ECG monitoring patch, ATP-C120|"ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside."
219070395|NCT03618238|DRUG|Anlotinib|12 mg daily for continus 14 days every 21 days
219070396|NCT01766557|OTHER|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
219070397|NCT01766557|OTHER|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
219070398|NCT06831071|DRUG|Pimonidazole|Drug: Pimonidazole Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
219070399|NCT01085851|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
219070400|NCT01085851|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
219070401|NCT02730494|DEVICE|Lcr Regenerans® vaginal capsules|
219070402|NCT02730494|DEVICE|Lcr Regenerans® vaginal tablet|
219070403|NCT02156674|DRUG|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
219070404|NCT04232423|DRUG|Olanzapine 10 Mg ORAL TABLET|"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
219070405|NCT04232423|DRUG|Olanzapine 5 Mg ORAL TABLET|"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
219070406|NCT04232423|DRUG|Placebo ORAL TABLET|"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
219070407|NCT04483050|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
219070408|NCT00581230|DEVICE|Laryngoscopy with RAMP|inflatable positioning ramp
219070409|NCT00581230|DEVICE|Laryngoscopy without RAMP|Laryngoscopy without RAMP
219070410|NCT00001533|DRUG|cyclosporine|
219070411|NCT02598492|OTHER|arterial blood gas|Just record clinical lab data
219070412|NCT01192906|DRUG|Placebo|Oral doses, once a day for 52 weeks
219070413|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
219070414|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
219674085|NCT02634983|DRUG|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
219674086|NCT02634983|DRUG|Placebo|Matching placebo
219070415|NCT05164159|DRUG|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
219070416|NCT05164159|DRUG|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
219070417|NCT03112382|DRUG|zinc supplement plus vitamin A and E|
219070418|NCT03112382|DRUG|vitamin A and E|
219070419|NCT04274608|DRUG|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
219070420|NCT04274608|BEHAVIORAL|Weight Management Program|12 week weight management program
219070421|NCT01562756|OTHER|HVLA-SM|High velocity, low amplitude spinal manipulation
219070422|NCT01490632|DRUG|Placebo|Administered orally
219070423|NCT01490632|DRUG|Baricitinib|Administered orally
219674087|NCT00701571|PROCEDURE|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
219674088|NCT02070978|DRUG|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
219674089|NCT02070978|DRUG|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
219674090|NCT02070978|DRUG|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
219674091|NCT03749109|DRUG|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
219070424|NCT02241967|DEVICE|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
219070425|NCT02241967|DEVICE|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
219674092|NCT03749109|DRUG|Placebo|Matching placebo
219674093|NCT00269828|DRUG|paclitaxel|
219674094|NCT00269828|DRUG|paclitaxel poliglumex|
219674095|NCT01804153|DRUG|Adipose-derived expanded stem cells|Intralesional application ASC
219070426|NCT02241967|DEVICE|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
219070427|NCT02241967|DEVICE|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
219070428|NCT05211765|DIAGNOSTIC_TEST|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
219070429|NCT05253625|OTHER|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
219070430|NCT04326543|DIAGNOSTIC_TEST|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"* Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
219070431|NCT05556863|DRUG|ELA026|Single dose of ELA026
219070432|NCT05556863|DRUG|ELA026|Multiple doses of ELA026
219070433|NCT05232045|DRUG|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
219070434|NCT05362864|PROCEDURE|Fracture fixation via Intramedullary Nailing|Fixation of trochanteric, sub-trochanteric, and shaft fractures and osteotomies.
219070435|NCT01801020|OTHER|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
219070436|NCT01801020|OTHER|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
219070437|NCT00575575|BEHAVIORAL|cognitive behavior therapy|cognitive behavior therapy once a week
219674096|NCT05585554|RADIATION|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
219674097|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
219674098|NCT03178851|DRUG|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
219674099|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
219674100|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
219674101|NCT03951753|DRUG|Tirzepatide|Administered SC
219070438|NCT03008148|RADIATION|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
219070439|NCT03008148|DRUG|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
219070440|NCT03008148|DRUG|Siroquine|"1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
219070441|NCT00381966|DEVICE|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
219070442|NCT02031887|DIETARY_SUPPLEMENT|formula with synbiotics|
219070443|NCT02031887|DIETARY_SUPPLEMENT|formula without synbiotics|
219070444|NCT04035967|OTHER|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
219070445|NCT04988854|BEHAVIORAL|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
219070446|NCT04517396|OTHER|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
219070447|NCT04517396|OTHER|Placebo|The control intervention will be a placebo, for 10 days.
219070448|NCT04517396|OTHER|Usual care|All participants will otherwise receive usual medical care
219070449|NCT03724643|OTHER|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
219070450|NCT03093831|DRUG|Ibrutinib|560mg administered orally once daily.
219070451|NCT02002403|DRUG|Danazol|
219070452|NCT03283540|PROCEDURE|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
219208956|NCT06807333|BEHAVIORAL|Pharmacist led Education|Pharmacist-led education for diabetic patients focuses on enhancing their understanding of the disease, improving self-management skills, and promoting better health outcomes. The education covers key aspects of diabetes, such as the importance of blood sugar control, the role of diet and exercise, and how to monitor blood glucose levels. Patients are also taught effective self-management strategies, including how to make healthy food choices, incorporate physical activity into daily routines, and manage potential complications. By providing tailored education, pharmacists aim to empower patients to take an active role in their care, which can lead to improved disease management, better glycemic control, and reduced risk of complications.
219070453|NCT03283540|PROCEDURE|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
219070454|NCT06962176|PROCEDURE|Anterior Mitral Line Ablation|First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.
219070455|NCT06962176|PROCEDURE|Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion|Pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.
219208957|NCT06813547|BEHAVIORAL|emotional freedom techniques|emotional freedom techniques
219208958|NCT06813547|BEHAVIORAL|emotional freedom techniques and virtual reality|emotional freedom techniques and virtual reality
219208959|NCT06813547|BEHAVIORAL|control group/ none intervention|None intervention
219208962|NCT06841666|DRUG|Atomoxetine|Atomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.
219208963|NCT06841666|DRUG|Placebo|Placebo identical in form and dosing schedule for six months.
219674102|NCT03951753|DRUG|Semaglutide|Administered SC
219674103|NCT03951753|DRUG|Placebo|Administered SC
219674104|NCT00509353|DRUG|irinotecan hydrochloride|
219674105|NCT00509353|DRUG|vincristine sulfate|
219674106|NCT00509353|RADIATION|iobenguane I 131|
219674107|NCT04633291|DEVICE|Novel swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
219674108|NCT04633291|DEVICE|Comparator swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
219070456|NCT06963164|OTHER|Helping Hand - Joint Protection Program|"Joint protection refers to a set of techniques and strategies that help reduce stress on the joints, manage pain, and prevent further joint damage. These techniques are particularly important for people with hand arthritis, as the small joints in the hands are often affected, leading to pain, stiffness, and difficulty performing daily tasks. Key principles of joint protection include:~1. Using larger, stronger joints whenever possible (e.g., using the forearm instead of the fingers to push open a door).~2. Reducing strain by spreading the load across multiple joints (e.g., carrying items with two hands instead of one).~3. Avoid tight gripping or pinching motions that can overstrain the joints.~4. Incorporating assistive devices to reduce effort during tasks (e.g., jar openers or ergonomic tools).~5. Pacing and prioritizing activities to avoid overuse of the joints and allow for adequate rest"
219070457|NCT01217710|BEHAVIORAL|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
219070458|NCT04088552|OTHER|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
218981309|NCT00579878|DRUG|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
218981310|NCT01254630|BIOLOGICAL|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
218981311|NCT01254630|BIOLOGICAL|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
219208964|NCT06842758|OTHER|Rehabilitation Treatment|Group A patients came to our department to perform rehabilitation treatment. They underwent rehabilitation treatment for a total of 20 rehabilitation sessions, performed on a daily basis lasting 60 minutes, on a 1:1 basis with a physical therapist, . They performed postural re-education and posterior kinetic chain strengthening exercises.
219208965|NCT06842758|OTHER|None Treatment|Group B patients did not undergo rehabilitation treatment. They underwent subcutaneous Teriparatide drug treatment on a daily basis for the treatment of osteoporosis
219674109|NCT00456820|DRUG|Wellbutrin XL|
219674110|NCT02273765|DRUG|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
218981312|NCT02020577|DRUG|Cetuximab( erbitux®)|once per week
218981313|NCT02020577|DRUG|Afatinib|once per day
218981314|NCT01910961|PROCEDURE|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
218981315|NCT02239588|OTHER|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
218981316|NCT02735408|OTHER|Kinesiotape (KT)|
218981317|NCT04539353|OTHER|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
218981318|NCT04539353|OTHER|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
219208966|NCT06861777|OTHER|Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy|"Neoadjuvant treatment:~adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 followed by chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), surgical resection 4-8 weeks later neoadjuvant treatment."
219208967|NCT06861777|OTHER|chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), followed by adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 surgical resection 4-8 weeks later neoadjuvant treatment."
219208968|NCT06861777|OTHER|TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]|"Neoadjuvant treatment:~TNT treatment \[TNT group one (phase 2) or TNT group two (phase 2)\] followed by surgical resection 4-8 weeks later adjuvant treatment: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year"
219208969|NCT06861777|OTHER|Chemoradiotherapy|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel 50 mg/m2/nab-paclitaxel 60 mg/m2 d1, 8, 15, 22,29 + cisplatin 25 mg/m2 d1, 8, 15, 22,29 + 41.4Gy/23f), followed by surgical resection 4-8 weeks later. adjuvant treatment: non-pCR: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year pCR: observation"
219208970|NCT06860451|DEVICE|TMS|The single-pulse TMS
219208971|NCT06763809|DIETARY_SUPPLEMENT|PMS Capsule|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
219070459|NCT04088552|BEHAVIORAL|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
219070460|NCT03042065|DEVICE|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
219070461|NCT03042065|DEVICE|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
219208972|NCT06763809|DIETARY_SUPPLEMENT|Capsule Placebo|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
218981319|NCT03113916|BEHAVIORAL|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
218981320|NCT00183989|DRUG|Fludarabine, Mitoxantrone and Rituximab|
218981321|NCT00241358|DRUG|AMD3100|
218981322|NCT00241358|PROCEDURE|Stem Cell Transplant|
218981323|NCT04036019|BIOLOGICAL|CD20-directed CAR-T cells with CliniMACS Prodigy® system|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
218981324|NCT00154557|BEHAVIORAL|elite judo athletes program|
218981325|NCT02398396|BIOLOGICAL|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
218981326|NCT02486523|BEHAVIORAL|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
218981327|NCT02486523|DEVICE|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
218981328|NCT02486523|BEHAVIORAL|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
218981329|NCT02486523|BEHAVIORAL|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
218981330|NCT02486523|PROCEDURE|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
218981331|NCT01363648|DRUG|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
218981332|NCT01363648|DRUG|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
219674111|NCT02273765|DRUG|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
219674112|NCT04012346|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
219674113|NCT04418089|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
219674114|NCT04418089|DRUG|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
219208973|NCT06763809|DIETARY_SUPPLEMENT|PMS Gummy|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
219208974|NCT06763809|DIETARY_SUPPLEMENT|Gummy Placebo|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
219208975|NCT06767007|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will begin SBRT treatment within 2 weeks after the first round of chemotherapy. Intensity-modulated radiation therapy (IMRT) technology will be used, with a target gross tumor volume (GTV) of 5-8Gy/5 sessions, a total dose of 25-40Gy equivalent to a biological effective dose (BED) of 37.5-72Gy, administered from Monday to Friday. For patients who have previously received pelvic radiotherapy, the re-irradiation dose will be 3-5Gy/5 sessions, a total dose of 15-25Gy equivalent to a BED of 19.5-37.5Gy, administered from Monday to Friday.
219208976|NCT06767007|DRUG|PD1|The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
219208977|NCT06767007|DRUG|Chemotherapy|First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
219208978|NCT06764056|DRUG|semaglutide|Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.
219208979|NCT06764056|OTHER|Diet|Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.
219208980|NCT06763302|DRUG|Blinatumomab|The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
218981333|NCT00041288|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218981334|NCT00041288|DRUG|cyclophosphamide|
218981335|NCT00041288|DRUG|cyclosporine|
218981336|NCT00041288|DRUG|fludarabine phosphate|
218981337|NCT00041288|DRUG|methotrexate|
218981338|NCT00041288|DRUG|mycophenolate mofetil|
218981339|NCT00041288|DRUG|tacrolimus|
218981340|NCT00041288|PROCEDURE|peripheral blood stem cell transplantation|
218981341|NCT00041288|RADIATION|radiation therapy|
218981342|NCT06045780|OTHER|nothing|disease
218981343|NCT03477136|DIAGNOSTIC_TEST|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
218981344|NCT00061477|DRUG|Pemetrexed|
218981345|NCT00061477|DRUG|Gemcitabine|
218981346|NCT04214171|DIAGNOSTIC_TEST|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
218981347|NCT03417323|OTHER|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
218981348|NCT03805425|RADIATION|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
218981349|NCT02885207|BIOLOGICAL|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
218981350|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
218981351|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
219208981|NCT06892132|OTHER|Supervised feeding intervention|Participants will be fed a peanut product during a supervised feeding visit and observed for an allergic reaction.
219208982|NCT06892132|OTHER|Handout|Participants will receive a handout on how to introduce peanut products.
219674115|NCT05313646|BIOLOGICAL|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
219674116|NCT05313646|BIOLOGICAL|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
219674117|NCT05313646|BIOLOGICAL|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
218981352|NCT04330053|OTHER|Experimental|"* Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
219208983|NCT06891807|DEVICE|Robotics Assisted TKA|Skywalker Robotics Assisted TKA using Evolution Medial Pivot Knee
219208984|NCT06891807|DEVICE|Augmented Reality assisted TKA|Pixee Knee+ assisted TKA using Evolution Medial Pivot Knee
219208985|NCT06763029|DRUG|Irinotecan liposomes combined with cetuximab + vermofenib|Vermofenil 960mg orally twice daily; Irinotecan liposomes, 70mg/m2, d1, 90 min intravenously, Q2W; Cetuximab 500mg/m2, d1, Q2W;
219208986|NCT06763692|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
219208987|NCT06764147|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
219208988|NCT06764394|OTHER|Exercise|home based exercise 5 days/week
218981353|NCT04330053|OTHER|Control|"* Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
218981354|NCT00646074|BEHAVIORAL|Self-Care Talk|6 conversational sessions
218981355|NCT00749060|OTHER|conventional treatment|with our without brace
218981356|NCT00749060|PROCEDURE|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
218981357|NCT00749060|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
218981358|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
218981359|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
218981360|NCT02663908|DRUG|Degarelix|
218981361|NCT02663908|DRUG|Leuprolide|
219070462|NCT06518421|BEHAVIORAL|Neuropsychological assessments|"* Pain questionnaires such as Numerical Pain Rating Scale is one of the most widely used multidimensional pain scales to assesses a person's pain based on the words they use to describe their pain.~* Battery of Cognitive questionnaires = The cognitive test battery was designed to assess key cognitive abilities including attention, concentration, verbal learning and memory, verbal fluency, working memory and executive function as well as global cognitive functioning and fear and anxiety~* Mnemonic Simulation Test and Rey Auditory Verbal Learning Test are the neuropsychological assessments designed to evaluate recognition and verbal memory, respectively. Both tasks have been shown to be very sensitive to hippocampal engagement and damage.~* Memory-recall interview is an interview for the interviewees to recall the event from different perspectives, such as from the preadmission date, 2-week post- and 6-month post-surgical date. This supports the memory retrieval process."
219208989|NCT06764394|OTHER|Exercise|home based exercise plus myofacial release exercise Myofascial release exercises will continue for 6 weeks, 2 sessions per week and each session will continue for 30 minutes.All evaluations will be performed at the beginning of radiotherapy treatment and at the end of the 6th week.
219208990|NCT04261790|DRUG|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
218981362|NCT00963131|DRUG|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
219070463|NCT06518421|DIAGNOSTIC_TEST|MR Imaging|Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels. MRI scanners create images of the body using a large magnet and radio waves.
219208991|NCT06263166|BEHAVIORAL|Stress ball intervention|Women should squeeze and loosen the stress ball given to them during the vaginal examination and continue this process until the examination is completed.
219674118|NCT00076258|BEHAVIORAL|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
219208992|NCT04366310|DEVICE|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
219208993|NCT04366310|PROCEDURE|rewarming|warming fingertip skin temperature using an instant hot pack
219208994|NCT06762756|BEHAVIORAL|Messages on tobacco packaging labels|The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.
219208995|NCT06811740|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
219208996|NCT06811740|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
219208997|NCT02586974|DEVICE|Humigard|warmed and humidified CO2 insufflation
219674119|NCT00076258|BEHAVIORAL|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
219674120|NCT01897519|DRUG|Placebo|Placebo infusion
219674121|NCT01897519|DRUG|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
219674122|NCT00427219|DRUG|Ozarelix|Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
219674123|NCT00427219|DRUG|Placebo|Placebo will be administered IM on Day 0 and Day 14.
219674124|NCT00200941|DRUG|Topiramate|
219674125|NCT02669043|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
219674126|NCT03757403|DRUG|RDD1609|RDD1609 to be applied on the perianal area BID
219674127|NCT03757403|DRUG|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
219674128|NCT00373802|DRUG|Phenylephrine|
219674129|NCT04217642|PROCEDURE|Osteosynthesis|The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
219674130|NCT03884270|BEHAVIORAL|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
219674131|NCT00391742|BEHAVIORAL|Brief intervention|
219674132|NCT05837793|BEHAVIORAL|Modified frailty index|The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
219674133|NCT03947593|OTHER|No Intervention|No intervention is being administered.
219674134|NCT06197477|DEVICE|OurAir SQ 1750 - Mobile Air Purification System for indoor|Filtration device will be placed in classrooms. Computational Fluid Dynamics simulations will be used to find optimal position and operation mode for air purification systems in classrooms.
219674135|NCT06197477|DEVICE|Sham intervention|Filtration will be turned off in the control part of the study and then will be turned on during the intervention.
219674136|NCT00661453|DRUG|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
218981363|NCT03308786|DRUG|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
218981364|NCT01630057|DRUG|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
218981365|NCT01630057|DRUG|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
218981366|NCT02987556|DEVICE|Continuous Glucose Monitoring|Collection of glucose data
218981367|NCT02987556|DEVICE|External Insulin Pump|insulin delivery
218981368|NCT02987556|OTHER|telemdecine|Remote follow up by care health providers team
218981369|NCT02987556|DEVICE|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
218981370|NCT03374969|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
219674137|NCT01880905|PROCEDURE|Measure of uteroovarian ligament length during gynecological surgery|
219674138|NCT01158105|DRUG|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
219674139|NCT05047484|DRUG|ALXN2050|Powder-in-capsule (PIC).
219674140|NCT05047484|DRUG|Placebo|PIC.
219674141|NCT04991038|DEVICE|DAISe Device|Thrombectomy using the DAISE device
219674142|NCT04991038|DEVICE|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
219674143|NCT06463379|DRUG|Solumedrol|2 days pulse steroid injection 125 mg methylrednisolone
219674144|NCT01309984|DRUG|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
219674145|NCT01309984|DRUG|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
219674146|NCT01638403|DRUG|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
219674147|NCT01638403|DRUG|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
218981371|NCT03374969|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
218981372|NCT02056977|OTHER|Titration|Individualized PEEP according to PEEP titration monitored by EIT
219674148|NCT01638403|DRUG|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
219674149|NCT02803359|PROCEDURE|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
218981373|NCT02056977|OTHER|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
218981374|NCT01932359|OTHER|rapidly absorbable suture (Vicryl Rapide)|
218981375|NCT01932359|OTHER|non-absorbable suture (Ethilon)|
218981376|NCT06097169|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
218981377|NCT06097169|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
218981378|NCT06419738|BEHAVIORAL|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
219070464|NCT04196179|DRUG|ANG3070|ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
219070465|NCT04196179|DRUG|Placebo oral capsule|ANG-3070 placebo capsules visually match the drug product.
219070466|NCT06233513|BEHAVIORAL|Exp 3 Speaking Task|Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
219070467|NCT05356052|COMBINATION_PRODUCT|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
219674150|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
219674151|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
219674152|NCT05683925|DEVICE|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
219674153|NCT05583786|DIAGNOSTIC_TEST|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
219674154|NCT06111001|OTHER|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
219674155|NCT06111001|OTHER|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
219674156|NCT06111001|OTHER|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
219674157|NCT04202315|OTHER|Virtual Reality|Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
219674158|NCT05293873|BIOLOGICAL|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
219674159|NCT05293873|OTHER|Rehabilitation therapy|Rehabilitation therapy
219674160|NCT01438931|DRUG|DA-9501|Dexmedetomidine hydrochloride variable dose
219674161|NCT01438931|DRUG|placebo|
219674162|NCT04544943|DRUG|BioLexa- Cohort 1|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
219674163|NCT04544943|DRUG|BioLexa- Cohort 2|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
218981379|NCT06419738|RADIATION|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
219674164|NCT04544943|DRUG|Placebo|Twice daily (BID) application of placebo for 14 days
219674165|NCT04544943|DRUG|Gentamicin|Twice daily (BID) application of Gentamicin for 14 days
219674166|NCT02552888|DRUG|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
219674167|NCT02552888|DIETARY_SUPPLEMENT|Isoquercetin|Isoquercetin 225 mg by mouth once per day
219674168|NCT02552888|OTHER|placebos|placebos
219674169|NCT06931431|BEHAVIORAL|Transition of Care Model (TCM)|Key components of the TCM include discharge assessment, care planning, provider communication with outpatient follow-up teams, and community-based follow-up
219674170|NCT05273489|PROCEDURE|Hepatectomy|Neoadjuvant treatment
219674171|NCT02014051|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
219674172|NCT01116076|BEHAVIORAL|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
219674173|NCT00248976|BEHAVIORAL|Net-present value of individual health behaviors in years|
219674174|NCT01732445|DRUG|ruxolitinib phosphate|Given PO
218981380|NCT06419738|DEVICE|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
218981381|NCT00846235|OTHER|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
218981382|NCT01131611|BEHAVIORAL|CBPT|Cognitive-Behavioral Based Physical Therapy
218981383|NCT01131611|OTHER|Control-Attention|Standard of Care + weekly phone calls
218981384|NCT06318234|DIAGNOSTIC_TEST|18F-FAPI，18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
218981385|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
218981386|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
219674175|NCT01732445|DRUG|danazol|Given PO
219674176|NCT01732445|OTHER|quality-of-life assessment|Ancillary studies
219674177|NCT01732445|OTHER|questionnaire administration|Ancillary studies
219674178|NCT03345888|OTHER|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
219674179|NCT02371668|BIOLOGICAL|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
219208998|NCT05841420|DRUG|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
219674180|NCT02371668|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
219674181|NCT03340298|DIETARY_SUPPLEMENT|fiber|the intervention of different sources of dietary fibers
219686665|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + copaiba softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• dōTERRA Copaiba Essential Oil (CEO) softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~CEO is a softgel containing Copaifera (copaiba) essential oil and extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
219686666|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + placebo softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• Olive oil placebo softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~The placebo is a softgel containing extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
219686667|NCT02166359|DRUG|Extraneal (Icodextrin)|
219070468|NCT05917405|DRUG|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
219070469|NCT05917405|DRUG|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
219070470|NCT05917405|DRUG|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
219070471|NCT05917405|DRUG|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
219070472|NCT01351285|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
219070473|NCT02346383|DEVICE|preset program|Change to different present program using epidural and peripheral lead to cover pain
219070474|NCT03833999|DRUG|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
219070475|NCT03833999|DIAGNOSTIC_TEST|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
219070476|NCT03833999|DRUG|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
219208999|NCT05841420|DRUG|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
219209000|NCT06786728|DRUG|frusemide|in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group
219686668|NCT02166359|DRUG|Glucose solution|
219686669|NCT06948019|BIOLOGICAL|BFB-101 (AAV9-CBh-AP4B1)|The AAV9-CBh-AP4B1 biological drug product is an aqueous suspension of a gene transfer vector intended for CSF injection. It consists of replication deficient adeno-associated virus (AAV) vector with the AAV serotype 9 capsid enclosing a single stranded DNA with an expression cassette of AP4B1 driven by CBh promoter.
219686670|NCT02798107|DRUG|idarucizumab|drug
219070477|NCT03833999|DRUG|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
219070478|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
219070479|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
219070480|NCT05662033|DRUG|AZD6793|AZD6793 will be administered orally
219070481|NCT05662033|DRUG|Placebo|Placebo will be administered orally
219070482|NCT04337710|PROCEDURE|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
219070483|NCT04337710|PROCEDURE|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
219070484|NCT03406247|DRUG|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~\- nivolumab 240 mg every 2 weeks during 6 months"
219070485|NCT03406247|DRUG|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~\- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
219070486|NCT01944631|DEVICE|Placebo|Nasal spray saline
219209001|NCT06769308|DEVICE|Sedation titration according to qEEG|Sedation will be titrated according to the EEG derived indexes (qCON/qNOX)
219209002|NCT06769308|PROCEDURE|Sedation titration according to standard of care|Sedation will be provided according to the standard of care of the unit (clinical scales)
219674182|NCT00401193|DRUG|Tranexamic acid tablets|3900 mg/Day
219674183|NCT00401193|DRUG|Tranexamic acid tablets|1950 mg/Day
219674184|NCT00401193|DRUG|Placebo tablets|
219674185|NCT04130074|DEVICE|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
219674186|NCT00398216|DRUG|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
219674187|NCT02820519|DRUG|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
219674188|NCT04959409|DRUG|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
219674189|NCT00289588|DRUG|Mupirocin (drug)|
219674190|NCT02267070|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
219674191|NCT02267070|BEHAVIORAL|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
219674192|NCT02267070|BEHAVIORAL|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
219674193|NCT02267070|BEHAVIORAL|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
218981387|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
218981388|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
218981389|NCT03960814|DRUG|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
218981390|NCT02067130|PROCEDURE|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
219070487|NCT01944631|DEVICE|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
219070488|NCT02330835|BEHAVIORAL|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
219070489|NCT02330835|BEHAVIORAL|School bus driver training videos|Basic bus driving safety videos
219070490|NCT05803226|BEHAVIORAL|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
219070491|NCT05831332|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
219070492|NCT05048147|BEHAVIORAL|Community Mobilization|The Community Mobilization (CM) strategy will include: (1) Community advisory board \[comprising local community-based organizations, government officials, and residents\], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
219070493|NCT06525194|BEHAVIORAL|Education|"An Interprofessional Education Program Based on the ARCS-V Motivation Model on the Theme of Chronic Disease Management and Patient Safety"
219070494|NCT00668122|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
219070495|NCT00668122|DRUG|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
219070496|NCT01621698|PROCEDURE|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
219070497|NCT01621698|PROCEDURE|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
219070498|NCT06237205|DRUG|Niraparib|a highly selective PARP1 and PARP2 inhibitor
219070499|NCT05154682|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
219070500|NCT05154682|DRUG|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
219070501|NCT05154682|DRUG|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
219070502|NCT06491147|OTHER|Emergency front of neck access|"The algorithm in the DAS manual will be explained. Following this, the researcher will demonstrate the scalpel spark plug technique with a 4-step approach that is frequently used in skill teaching.~In step 1 of this approach, the technique will be demonstrated without any verbal explanation.~In the 2nd step, the technique will be demonstrated with verbal expression. In the 3rd step, the participant will be asked to have the trainer do it. In the 4th and last step, the participant will apply eFONA from start to finish."
219070503|NCT03326687|BEHAVIORAL|Treatment ABAB|Participants will perform the phases in the ABAB order.
219674194|NCT03169478|PROCEDURE|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
219674195|NCT06288243|DIAGNOSTIC_TEST|Clinician-observed assessment tests|Turkish Modified Mann Swallowing Ability Test, which evaluates swallowing skills Standardized Mini-Mental Test assessing Cognitive Status Modified Rankin Scale to evaluate functionality
219674196|NCT00415896|DEVICE|positive pressure ventilation|
219674197|NCT01048944|DRUG|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
219674198|NCT01048944|DRUG|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
219674199|NCT01048944|DRUG|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
218981391|NCT01372592|PROCEDURE|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
219674200|NCT00615810|DRUG|Atripla|Open label once daily for oral administration to be taken on an empty stomach
219674201|NCT00615810|DRUG|Kivexa plus Sustiva|Open label once daily for oral administration
219674202|NCT01844817|DRUG|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
218981392|NCT04016064|PROCEDURE|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives."
218981393|NCT02272075|DEVICE|Mobile OCT M3 scope|
218981394|NCT02864602|DRUG|IV dexamethasone|An infusion of IV dexamethasone
218981395|NCT00062946|DRUG|(18F)fallypride|
218981396|NCT03919331|DIAGNOSTIC_TEST|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
218981397|NCT04308096|DRUG|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
218981398|NCT03348137|OTHER|Questionnaire Administration|Ancillary studies
218981399|NCT02351999|DEVICE|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
218981400|NCT02701023|DRUG|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
218981401|NCT00354822|DRUG|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts\>150x10\^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10\^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
219674203|NCT01844817|DRUG|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
219070504|NCT03326687|BEHAVIORAL|Treatment BABA|Participants will perform the phases in the BABA order.
219070505|NCT05582876|RADIATION|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
219070506|NCT04074785|DRUG|Abemaciclib|Abemaciclib 150 mg po bid
219070507|NCT04074785|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
219070508|NCT05197192|DRUG|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
219209003|NCT06785571|DRUG|Nalbuphine hydrochloride injection|a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
219209004|NCT06785571|DRUG|Hydromorphone hydrochloride injection|A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
219209005|NCT06792071|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|The intervention is a psychological treatment using Radically Open Dialectical Behavior Therapy (RO-DBT), consisting of individual therapy and skills training in group for approximately 22 weeks. Additionally, a parent group consisting of four sessions will be included as an adaptation to the adolescent group.
219209006|NCT06786078|DEVICE|Lily Device|Participants will wear the Lily Device at each chemotherapy session for the prescribed duration, where the device must be used during infusion and for at least two (2) hours and up to four (4) hours post infusion.
219674204|NCT00352625|DRUG|Ketoprofen Topical Patch 20%|
219674205|NCT03679143|DRUG|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
219674206|NCT03679143|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
219674207|NCT03679143|DRUG|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
219674208|NCT03679143|DRUG|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
219674209|NCT03679143|DRUG|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
219070509|NCT05197192|DRUG|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
219070510|NCT05197192|DRUG|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
219070511|NCT02207010|BIOLOGICAL|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
219070512|NCT00656838|BEHAVIORAL|Patients receives letter, phone call, office visit, educational materials|Behavioral
219070513|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
219070514|NCT01412944|DRUG|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
219070515|NCT01412944|DRUG|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
219070516|NCT01332877|BEHAVIORAL|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
219070517|NCT01332877|BEHAVIORAL|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
219070518|NCT01280487|DRUG|ZSTK474|Daily oral dosing for 21 days each cycle
219209007|NCT06768047|OTHER|Microporous tape|Microporous tape is a dressing tape that was discovered to have scar modulating effects. It is made up of a conformable, inextensible, nonwoven fabric manufactured from 100% viscose and coated with a layer of acrylic adhesive. It is cheap, cost-effective, readily available, and relatively affordable for post surgical patients.
219674210|NCT03679143|DRUG|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
219674211|NCT03679143|DRUG|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
219674212|NCT03679143|DRUG|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
219674213|NCT03679143|DRUG|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
219674214|NCT03679143|DRUG|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
219674215|NCT03679143|DRUG|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
219674216|NCT03679143|DRUG|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
219674217|NCT03679143|DRUG|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
219674218|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
219674219|NCT03679143|DRUG|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
219674220|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
218981402|NCT02317588|DIETARY_SUPPLEMENT|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
218981403|NCT02317588|DIETARY_SUPPLEMENT|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
218981404|NCT02399553|OTHER|Soccer boot intervention|
218981405|NCT00761631|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
218981406|NCT00239109|DRUG|Ziprasidone|
218981407|NCT00239109|DRUG|Olanzapine|
218981408|NCT00239109|PROCEDURE|Scales|
218981409|NCT00239109|PROCEDURE|measures of the body (Weight...)|
218981410|NCT00239109|PROCEDURE|Serum analysis|
218981411|NCT03999177|BEHAVIORAL|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
218981412|NCT00417118|DRUG|Saredutant|oral administration (capsules)
218981413|NCT00417118|DRUG|Escitalopram|oral administration (capsules)
218981414|NCT00417118|DRUG|Placebo|oral administration (capsules)
218981415|NCT01590459|DRUG|VX-509|50 mg oral tablet
218981416|NCT01590459|DRUG|VX-509 matching placebo|0 mg oral tablet
218981417|NCT01242462|PROCEDURE|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
218981418|NCT01242462|OTHER|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
218981419|NCT03820271|OTHER|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
218981420|NCT00507923|DEVICE|Actigraph|Wear actigraph
218981421|NCT00507923|OTHER|Best Practice|Receive usual care
218981422|NCT00507923|OTHER|Quality-of-Life Assessment|Ancillary studies
218981423|NCT00507923|OTHER|Questionnaire Administration|Ancillary studies
218981424|NCT00507923|OTHER|Sleep Diary|Complete sleep diary
218981425|NCT00507923|OTHER|Stretching|Participate in stretching sessions
218981426|NCT00507923|PROCEDURE|Yoga|Participate in Tibetan yoga
218981427|NCT01610661|OTHER|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
218981428|NCT01402011|PROCEDURE|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
218981429|NCT01402011|PROCEDURE|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
218981430|NCT01402011|PROCEDURE|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
218981431|NCT02789995|PROCEDURE|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
218981432|NCT05514483|DRUG|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
219674221|NCT03679143|DRUG|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
219674222|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
219674223|NCT03679143|DRUG|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
219674224|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
219070519|NCT01990950|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
219070520|NCT04227015|DRUG|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
219070521|NCT05225493|BEHAVIORAL|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
219070522|NCT05225493|DIAGNOSTIC_TEST|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
219674225|NCT04845880|DIAGNOSTIC_TEST|Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2|Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
218981433|NCT05514483|DRUG|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
219674226|NCT02207400|DRUG|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
219674227|NCT02207400|DRUG|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
219674228|NCT03396822|DRUG|Gadoteridol|gadolinium MRI contrast
219674229|NCT02574663|DRUG|TGR-1202|TGR-1202 oral daily dose
219674230|NCT02574663|DRUG|nab-paclitaxel + gemcitabine|IV infusion
219674231|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
219674232|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
219674233|NCT02834078|DIETARY_SUPPLEMENT|BGG|
218981434|NCT02748473|OTHER|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
218981435|NCT02748473|OTHER|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
218981436|NCT02748473|OTHER|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
218981437|NCT06680856|COMBINATION_PRODUCT|PRP+HA|treatment of diabetic foot ulcers with allogeneic PRP+HA
218981438|NCT06680856|COMBINATION_PRODUCT|HA|treatment of diabetic foot ulcers with HA
218981439|NCT06681688|DRUG|Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}|Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
218981440|NCT06681688|DRUG|Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}|"On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)"
218981441|NCT06680388|DRUG|Drug：CD19 CAR-T|A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
218981442|NCT06680999|OTHER|Data collection|Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
218981443|NCT02637622|OTHER|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
218981444|NCT02637622|OTHER|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
218981445|NCT04638400|DRUG|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
218981446|NCT04638400|DRUG|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
219070523|NCT05965011|OTHER|Exercise training|The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
219674234|NCT02834078|OTHER|Placebo|
219674235|NCT05305456|DRUG|Tanreqing capsule|3 capsules per time, 3 times a day
219674236|NCT05305456|DRUG|Tanreqing capsule simulator|3 capsules per time, 3 times a day
219070524|NCT05884697|OTHER|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
219070525|NCT05884697|OTHER|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
219070526|NCT05884697|OTHER|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
219070527|NCT05884697|OTHER|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
219070528|NCT04938245|DEVICE|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
219070529|NCT01672775|DRUG|AGS-16C3F|intravenous (IV) infusion
219070530|NCT01640522|OTHER|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
219070531|NCT01640522|OTHER|Enhanced usual Care|
219070532|NCT05155865|DEVICE|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
219070533|NCT05155865|DEVICE|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
219070534|NCT05779995|DRUG|XW001|Inhalation solution
219070535|NCT05779995|DRUG|Placebo|Inhalation solution with matched volume
219070536|NCT05840198|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
219070537|NCT05840198|OTHER|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
219070538|NCT06282341|OTHER|Race: Simulated marathon|Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
219070539|NCT06282341|OTHER|Race: Simulated trail|Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
219674237|NCT05119036|RADIATION|44 doses of radiation|Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
219674238|NCT05119036|RADIATION|54 doses of radiation|Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
219674239|NCT06581250|BEHAVIORAL|Reminder Messages|Dental clinic staff will use scripts to contact patients 24 and 48 hours before appointments. These scripts will guide staff in confirming the patient will appear for their appointment.
219674240|NCT06581250|BEHAVIORAL|Walk-in Visits|When contacting patients to schedule an appointment (by phone, email, text, or other methods), dental clinic staff will notify patients of times during which patients can walk-in for a dental visit, if convenient for them; otherwise, a regular appointment will be arranged. Scheduled appointments will continue to be available in addition to the walk-in hours.
219674241|NCT06581250|BEHAVIORAL|Motivation-enhanced Communication|Participating clinic site staff will be trained in motivation-enhanced communication techniques using the guide for dental clinic sites and coaching. Topics to be included in the motivation-enhanced communication training are a) to determine what patients hope to gain from their dental care, steps needed to succeed, how the agency and client will work together to attain the goals, and b) to identify patient barriers to attending their visit (e.g., transportation, payment, do not understand need for visit, etc.), and what the agency and patient will do to overcome those barriers. Staff will be instructed to use these techniques with patients at every contact about an upcoming appointment.
219674242|NCT06954779|DRUG|Colgate Cavity Protection|1000ppm fluoride
219674243|NCT06954779|DRUG|TOM's Superior Sensitivity Relief Toothpaste|fluoride free
219674244|NCT03638466|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
219674245|NCT03638466|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
219674246|NCT03638466|BEHAVIORAL|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
219674247|NCT03638466|DRUG|SPN-810|Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score
219070540|NCT06282341|OTHER|Race: Trail in nature|Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
219070541|NCT06636630|PROCEDURE|Quadruple scleral flap|Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
219070542|NCT06636630|PROCEDURE|Double scleral flap|The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
219070543|NCT05531994|DRUG|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
219070544|NCT05531994|DRUG|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
219070545|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
219070546|NCT06030726|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
219070547|NCT02811237|OTHER|HESTIA|"Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
219070548|NCT02811237|OTHER|sPESI|"Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
219674248|NCT03638466|DRUG|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
219674249|NCT06955780|OTHER|Emotional Freedom Techniques|Emotional Freedom Techniques
219674250|NCT03251482|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
219070549|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
219070550|NCT00958919|DRUG|normal saline|25 ml
219070551|NCT03722160|DEVICE|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
219674251|NCT03251482|DRUG|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
219674252|NCT03251482|DRUG|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
219674253|NCT03251482|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
219674254|NCT03251482|DRUG|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
219674255|NCT03251482|DRUG|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
219674256|NCT03251482|DRUG|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
219674257|NCT03251482|DRUG|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
219674258|NCT03251482|DRUG|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
219674259|NCT03251482|DRUG|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
219674260|NCT03251482|DRUG|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
219070552|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
219070553|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
219674261|NCT04242979|BEHAVIORAL|Questionnaire about albumin use in liver cirrhosis|"1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~3. A pilot study will be 10% done to test the clarity and feasibility of developed tool.~4. Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
219070554|NCT01552213|OTHER|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
219070555|NCT01552213|OTHER|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
219070556|NCT00026533|DRUG|thalidomide|
219070557|NCT05877001|DRUG|Tislelizumab|200mg, IV, Q3W
219070558|NCT05877001|DRUG|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
219070559|NCT05877001|OTHER|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
219070560|NCT04723576|BEHAVIORAL|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
219070561|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
219070562|NCT01757769|DRUG|Silodosin|8 mg daily for 24 weeks
219070563|NCT03682094|DRUG|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
219070564|NCT00244075|DIETARY_SUPPLEMENT|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
219070565|NCT00244075|DRUG|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
219070566|NCT00244075|BEHAVIORAL|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
219070567|NCT02978027|BEHAVIORAL|Brief Advice|
219070568|NCT02978027|BEHAVIORAL|NIAAA Clinician's Guide|
219070569|NCT02978027|BEHAVIORAL|Motivational Interviewing (MI)|
219070570|NCT03822299|DIETARY_SUPPLEMENT|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
219070571|NCT02811562|DEVICE|manikin|
219070572|NCT02811562|DEVICE|fiberoptic bronchoscope|
219070573|NCT02811562|DEVICE|pentax-airwayscope|
219070574|NCT01311492|BEHAVIORAL|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
219674262|NCT02204644|DRUG|Flumatinib 600mg qd|
219674263|NCT02204644|DRUG|Imatinib 400mg qd|
219674264|NCT01614444|OTHER|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
219674265|NCT01614444|OTHER|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
219674266|NCT00387972|DRUG|denagliptin (GW823093)|
219674267|NCT05418907|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
219674268|NCT02362425|DRUG|N-acetylcysteine|
219674269|NCT02362425|DRUG|Placebo|
219674270|NCT00596453|DRUG|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
219070575|NCT01311492|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
219070576|NCT00372463|BEHAVIORAL|6-week Online Diabetes Self-Management Educational Program|
219070577|NCT02097472|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
219070578|NCT02097472|BIOLOGICAL|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
219070579|NCT02097472|BIOLOGICAL|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
219070580|NCT02097472|OTHER|Saline|0.9% Sodium Chloride Injection, USP
219209008|NCT06768047|OTHER|Tradition physical therapy|"Tradition physical therapy as stretching exercises and deep friction massage, Stretching is a form of physical exercise in which a specific muscle or tendon (or muscle group) is deliberately expanded and flexed in order to improve the muscle's felt elasticity and achieve comfortable muscle tone. The result is a feeling of increased muscle control, flexibility, and range of motion.~Deep friction massage also known as cross friction massage, is a specific connective tissue massage which maintain the mobility within the soft tissue structures of ligament, tendon, and muscle, and prevent adherent scars from forming."
219674271|NCT00596453|DRUG|Placebo|Placebo twice a day for 14 days
219674272|NCT00140036|PROCEDURE|Blood draw|
219674273|NCT06300879|PROCEDURE|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique|"Surgical Operation:~1. Gastric Resection Range:Proximal gastrectomy, preserving 2/3 of the distal stomach.~2. Lymph Node Dissection Range:D1+ to D2 lymph node dissection.~3. Anastomosis Method: esophagogastrostomy by fissure technique.~4. Anastomosis Risk Management Plan:For a rupture with a maximum diameter less than or equal to 5mm, repair with 4-0/3-0 absorbable sutures and proceed with the anastomosis.For a rupture with a maximum diameter greater than 5mm or failed anastomosis, resect that part of the remaining stomach, change to proximal gastrectomy, and perform double-channel anastomosis.~5. Surgical Approach:Totally laparoscopic proximal gastrectomy."
219674274|NCT05880095|OTHER|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
219674275|NCT05880095|OTHER|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
219674276|NCT05880095|OTHER|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
219674277|NCT03417752|OTHER|Exposure to firearm safety PSA|Exposed to firearm safety PSA
219674278|NCT03417752|OTHER|Exposure to health promotion PSA|Exposed to general health promotion PSA
219070581|NCT03966157|DEVICE|Nasal Bridle|Feeding tube secured with nasal bridle
219070582|NCT05464459|PROCEDURE|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
219209009|NCT06788626|DRUG|Semaglutide 0.5 mg|0.5mg semaglutide injection before and 1 week after endovascular treatment.
219209010|NCT06788626|OTHER|Standard medical treatment|Standard medical management
219209011|NCT06794918|DIAGNOSTIC_TEST|progressive relaxation exercise|Researchers will teach individuals pge exercises to help them relax
219209012|NCT05714059|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
219674279|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
219674280|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
219674281|NCT03208894|DRUG|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
219209013|NCT06840054|DRUG|Sodium Pentaborate Pentahydrate|will receive 1000 mg of sodium pentaborate pentahydrate daily along with donepezil.
219209014|NCT06840054|DRUG|Placebo|will receive a placebo along with donepezil
219674282|NCT00409279|BEHAVIORAL|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
219674283|NCT00813878|GENETIC|protein analysis|protein analysis
219674284|NCT00813878|GENETIC|protein expression analysis|protein expression analysis
219674285|NCT00813878|GENETIC|proteomic profiling|proteomic profiling
219674286|NCT00813878|OTHER|diagnostic laboratory biomarker analysis|Performed one time on study
219674287|NCT00813878|OTHER|immunohistochemistry staining method|Performed one time on study
219674288|NCT00813878|OTHER|liquid chromatography|Performed on samples collected one time on study
219674289|NCT00813878|OTHER|mass spectrometry|Performed on samples collected one time on study
219674290|NCT00813878|PROCEDURE|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
219674291|NCT00813878|PROCEDURE|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
219070583|NCT00345904|BIOLOGICAL|Fluarix|
219070584|NCT03392311|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
219070585|NCT03392311|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
219070586|NCT02119416|DRUG|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
219209015|NCT06838559|DRUG|Short-Duration Oral Prednisolone with Extended Tapering|In treatment arm A, oral prednisolone will be administered in tablet form (5 mg strength) as follows: an initial phase of 10 mg four times daily (total 40 mg/day) for 7 days, followed by a 15-day tapering phase-10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. After tapering, a prolonged low-dose maintenance phase will be implemented, where 10 mg is given once daily twice a week for an additional 10 weeks. This regimen is designed to test whether a shorter high-dose course, combined with extended low-dose maintenance, can provide equivalent control of infantile epileptic spasms syndrome while reducing the adverse effects associated with longer high-dose therapy, compared to the standard 14-day high-dose regimen (treatment arm B).
219209016|NCT06838559|DRUG|Standard Oral Prednisolone Regimen with Tapering|Prednisone oral tablets, 10 mg, administered four times daily (40 mg/day) for 14 days, followed by a tapering phase over 15 days: 10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. No further tapering will be implemented after the initial 14-day treatment period. This regimen represents the standard therapy for Infantile Spasms in Sri Lanka.
219674292|NCT00813878|PROCEDURE|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
219674293|NCT00874159|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
219674294|NCT05676788|DEVICE|Hyperspectral Imaging|Identification of the intersegmental plane
219674295|NCT06344689|OTHER|Surgical treatment|Patients underwent surgical treatment of ectropion were included in this study.
219674296|NCT04972422|DRUG|ZN-c3|ZN-c3 is a study drug
219674297|NCT02624882|PROCEDURE|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
219674298|NCT02624882|PROCEDURE|Negative rapid GAS test|Usual care
219674299|NCT03190785|OTHER|Benzoic acid washout and exposure|see above
219070587|NCT02119416|DRUG|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
219674300|NCT05491681|BIOLOGICAL|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
219674301|NCT04966650|BEHAVIORAL|5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)|The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
219674302|NCT04973709|DIAGNOSTIC_TEST|Confussion assessment method (CAM)|Participants enrolled in the Delirium group according to the CAM.
219070588|NCT02119416|DRUG|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
219070589|NCT03953092|DRUG|YG1699|YG1699 at Multiple Doses
219070590|NCT03953092|DRUG|Placebos|Placebos
219070591|NCT02205710|OTHER|Computerized cognitive training|
219674303|NCT04973709|DIAGNOSTIC_TEST|Dementia diagnosis|Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria
219674304|NCT02688764|DRUG|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
219070592|NCT02205710|OTHER|Computerized games|
219070593|NCT04540536|OTHER|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
219070594|NCT04540536|OTHER|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
219070595|NCT04323852|DRUG|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
219674305|NCT02688764|DRUG|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
219674306|NCT04733625|DRUG|Cholecalciferol|single injection of Vitamin D (200000 I.U
219674307|NCT04733625|DRUG|Placebo|placebo medication
219674308|NCT04660786|DRUG|triamcinolone acetonide|local immunosuprresent
219674309|NCT04660786|DRUG|vitamin D|local immunomodulator
219674310|NCT06087315|OTHER|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
219070596|NCT04323852|DRUG|Placebo|Placebo
219070597|NCT03131388|DIAGNOSTIC_TEST|Access AMH Assay|
219070598|NCT04589923|DEVICE|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
219070599|NCT04589923|DEVICE|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
219070600|NCT02345148|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
219070601|NCT05496881|OTHER|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
219209017|NCT06837818|DRUG|Dexmedetomidine|The first patient was started on dexmedetomidine Cp 0.4 ng/ml, 2 minutes before the procedure, and the up and down method was used, with the Cp of dexmedetomidine adjusted to 0.05 ng/ml each time. The analgesia nociception index (ANI) during skull pin fixation is lower than (\<) 30 and the heart rate (HR) and arterial blood pressure (ABP) exceed (\>) 20% of the baseline (or the HR is \>100 bpm and the ABP is \>180/100 mmHg), indicating insufficient analgesia or hemodynamics (failure). If the patient is failure for the procedure, increase the Cp by 0.05 ng/ml for the next patient; the ANI is higher than or equal to (≥30) and the HR and ABP do not exceed 20% of the baseline or the HR is ≤100 bpm and the ABP is ≤180 /100 mmHg) indicates that the analgesia and hemodynamic stability are acceptable (success), and the next patient will be adjusted downward by 0.05 ng/ml.
219070602|NCT05496881|OTHER|Exercise Group 2|Prescribed exercises will focus on physical fitness.
219070603|NCT05496881|OTHER|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
219674311|NCT00060372|DRUG|ipilimumab|Given IV
219070604|NCT04163705|DIAGNOSTIC_TEST|blood sample collection|Routine Laboratory Analysis
219070605|NCT04461002|OTHER|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
219070606|NCT05387005|DIAGNOSTIC_TEST|UBT|H. pylori diagnostic test: C13 urea breath test
219070607|NCT05387005|DIAGNOSTIC_TEST|HPSA|H. pylori diagnostic test: H. pylori stool antigen test
219070608|NCT05387005|DIAGNOSTIC_TEST|UBT and HPSA|H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test
219070609|NCT05387005|DIAGNOSTIC_TEST|Serology (two stage)|H. pylori diagnostic test: If H. pylori serology is positive, confirmation UBT will be done.
219070610|NCT00463710|DRUG|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
219070611|NCT04193800|OTHER|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
219070612|NCT04199949|BEHAVIORAL|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
219070613|NCT05443035|PROCEDURE|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula \& Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
219070614|NCT05443035|PROCEDURE|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
219209018|NCT01202708|DEVICE|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
219674312|NCT00060372|DRUG|therapeutic allogeneic lymphocytes|Given IV
219674313|NCT00717795|BEHAVIORAL|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
219674314|NCT00717795|BEHAVIORAL|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
219209019|NCT01202708|DEVICE|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
219209020|NCT06483789|DRUG|HB-1|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
219070615|NCT05443035|PROCEDURE|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
219070616|NCT02464735|DEVICE|Polysomnography|
219070617|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
219070618|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
219070619|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
219070620|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
219674315|NCT01658254|OTHER|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
219674316|NCT00006244|DRUG|melphalan|Given IV
219674317|NCT00006244|BIOLOGICAL|recombinant interferon alfa|Given SC
219674318|NCT00006244|BIOLOGICAL|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
219070621|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
218981447|NCT06681792|BEHAVIORAL|Climate Change Workshops Based on Protection Motivation Theory|"The experimental group will take part in seven weekly workshops. One workshop will last 40 minutes.The workshop to be applied to the experimental group will take place every week and will last 40 minutes. The workshops, which are based on the Protection Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring environmentally friendly behaviour, recycling and the Green School Programme for sustainable environmental education.~The workshops include interactive applications such as students expressing their thoughts on the weekly themes, games, brainstorming, word cloud, planting trees, painting cloth bags, watching videos, making presentations on the themes. Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring enviro"
219070622|NCT05360875|PROCEDURE|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
218981448|NCT06680843|PROCEDURE|Whole blood collection|30 mL at Day 0 with optional visits for up to 2 additional whole blood collections at least 30 days apart
218981449|NCT06702007|BEHAVIORAL|eHaRT-A|Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
218981450|NCT04508335|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
218981451|NCT06703697|OTHER|eDrugSafe|The eDrugSafe mobile web platform enables management of medication history and provides electronic access to medicinal product information (ePI). QR codes are separately provided for prescription records to facilitate direct access to ePI.
219070623|NCT05476146|PROCEDURE|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
219070624|NCT04528511|DEVICE|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
219070625|NCT02120508|DEVICE|rTMS|To test the efficacy of this specific setting.
219070626|NCT04082949|BIOLOGICAL|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
219070627|NCT04082949|OTHER|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
219070628|NCT02010840|BEHAVIORAL|Psychoeducation program|
219070629|NCT03593655|DEVICE|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
219674319|NCT00006244|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
219674320|NCT03216369|OTHER|MRI|MRI perfusion imaging
219674321|NCT03011437|OTHER|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
219674322|NCT00463489|BEHAVIORAL|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
219674323|NCT00463489|BEHAVIORAL|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
219674324|NCT01220726|DRUG|Botox|Botox injection
219674325|NCT01220726|DRUG|Placebo|Placebo injection
219674326|NCT02579382|DRUG|TDF|300 mg tablets administered orally once daily
219674327|NCT02579382|DRUG|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
219674328|NCT02579382|DRUG|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
219674329|NCT03818009|OTHER|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
219674330|NCT04474054|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
219674331|NCT04825925|DEVICE|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
219674332|NCT06454643|DRUG|Flucloxacillin and gentamicin|This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
219674333|NCT06454643|DRUG|Flucloxacillin and ceftriaxone|Control group
219674334|NCT01834664|BIOLOGICAL|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
219674335|NCT03026283|DEVICE|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
219674336|NCT02328482|DRUG|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
219209021|NCT06483789|DRUG|Telmisartan Only Product in Oral Dose Form|Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
219674337|NCT03403452|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
219674338|NCT03782571|DEVICE|etafilcon a Test 1|1-DAY ACUVUE® MOIST
219674339|NCT03782571|DEVICE|etafilcon A Test 2|1-DAY ACUVUE® MOIST for ASTIGMATISM
219674340|NCT03782571|DEVICE|etafilcon A Test 3|1-DAY ACUVUE® MOIST MULTIFOCAL
219674341|NCT03782571|OTHER|Control|Bare Eye
219674342|NCT03565705|PROCEDURE|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
219674343|NCT02456025|DRUG|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
219674344|NCT02187237|DEVICE|YOLO TOUCH Low Level Laser|
219674345|NCT04618991|OTHER|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
219674346|NCT03743727|DRUG|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
219674347|NCT04418050|PROCEDURE|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
218981452|NCT06703385|OTHER|Instrument Assisted soft tissue mobilization|The blade is a surgical instrument for soft tissue mobilization, made of 100% surgical stainless steel with 8 treatment planes and 2 treatment edges. It is used to locate muscle limitations and apply gentle strokes along the affected muscle, detecting changes in soft tissue consistency. The procedure is repeated three times a week for four weeks.
219070630|NCT03593655|DRUG|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
219070631|NCT04678466|BIOLOGICAL|flotetuzumab|CD123 x CD3 bispecific DART® antibody
219070632|NCT03961620|DEVICE|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
219070633|NCT05219149|BEHAVIORAL|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
219070634|NCT03732209|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
219209022|NCT06483789|DRUG|Verapamil Only Product in Oral Dose Form|Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
219209023|NCT06483789|DRUG|Placebo|Matched Placebo will be supplied as a tablet.
219209024|NCT06637774|DEVICE|Aspirometer|a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively
219674348|NCT02511132|BIOLOGICAL|Vigil|Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
219674349|NCT02511132|DRUG|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
219674350|NCT02511132|DRUG|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
219070635|NCT03732209|BEHAVIORAL|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
219209025|NCT06637774|DEVICE|Videofluoroscopic X-ray|MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
219674351|NCT02511132|DRUG|Gemcitabine|675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
219674352|NCT02511132|DRUG|Docetaxel|75 mg/m2 IV administered on Day 8 and every 21 days
219674353|NCT03845621|DEVICE|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
219674354|NCT03845621|DEVICE|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
219674355|NCT05313399|DEVICE|Palatal Crib|An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
219674356|NCT05313399|DEVICE|bonded spur|Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
219674357|NCT03077425|BEHAVIORAL|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
219674358|NCT03077425|BEHAVIORAL|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
219674359|NCT05467852|DRUG|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
219674360|NCT04230772|PROCEDURE|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
219674361|NCT04230772|PROCEDURE|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
219674362|NCT03188523|DRUG|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
219674363|NCT06365190|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
218981453|NCT06703385|OTHER|Suboccipital release|The patient will lie in a relaxed supine position, with a therapist sitting on a chair. The therapist will apply pressure to the C2 area, holding it until a melting sensation is felt. The intervention time is 4 minutes. The patient will close both eyes during the Suboccipital release procedure to prevent eye movements affecting muscle tone. Interventions will be three times a week for four weeks.
218981454|NCT06703385|OTHER|conventional physical therapy program|The patient is placed in a sitting position and a hot pack is applied to the back of the neck for 15 minutes. The therapist then performs active range of motion exercises for neck flexion, extension, rotation, and lateral flexion without resistance. They also perform stretching exercises for upper Trapezius muscle and suboccipital muscle. Strengthening exercises for neck muscles are performed through isometric exercises, such as side pending to right, side pending to left, extension, and flexion. The interventions are conducted three times, peer-wise, for four weeks. The treatment aims to improve neck flexibility and overall well-being.
219070636|NCT06634745|PROCEDURE|Standard Needle Irrigation (SNI)|"Standard Needle Irrigation (SNI):~Utilizes standard needle irrigation techniques for activating the antimicrobial solution within the root canal."
219070637|NCT06634745|PROCEDURE|Passive Ultrasonic Irrigation (PUI|"Passive Ultrasonic Irrigation (PUI):~Employs ultrasonic energy to enhance the activation and effectiveness of the antimicrobial solution in the root canal."
219070638|NCT06634745|PROCEDURE|EndoActivator (EA)|"EndoActivator (EA):~Uses a sonic activation device to facilitate the distribution and activation of the antimicrobial solution in the root canal."
219070639|NCT06634745|PROCEDURE|EDDY|"EDDY:~Involves the use of a sonic activation device that operates at high frequency to activate the antimicrobial solution within the root canal.~These descriptions focus on the general method and purpose of each intervention without delving into the specific procedural details already covered in the arm/group descriptions."
219209026|NCT06746870|DRUG|IMM2510|"Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion"
219209027|NCT06746870|DRUG|Chemotherapy (pemetrexed + cisplatin/carboplatin)|Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed
219209028|NCT06746870|DRUG|Chemotherapy (paclitaxel + cisplatin/carboplatin)|Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.
219209029|NCT06746870|DRUG|Chemotherapy(Nab-paclitaxel)|Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
219674364|NCT06365190|DRUG|Pharmacotherapy（antiparkinsonian drugs）|Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
219674365|NCT00664365|DRUG|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
219674366|NCT00664365|DRUG|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
219674367|NCT01341899|PROCEDURE|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
219674368|NCT01983826|DIETARY_SUPPLEMENT|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
219674369|NCT01983826|OTHER|Placebo|Microcrystalline cellulose (daily) for 8 weeks
219674370|NCT06548503|DIETARY_SUPPLEMENT|Si.Pi.Mi product|Assumption of the product as detailed in the protocol
219674371|NCT06548503|OTHER|Placebo|Assumption of placebo
219674372|NCT02442648|DRUG|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
219674373|NCT02442648|DRUG|Rituximab|Rituximab will be administered for desensitization per study protocol.
219674374|NCT05645302|DRUG|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
219674375|NCT03989336|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
219674376|NCT03989336|DRUG|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
219674377|NCT03989336|DRUG|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
219674378|NCT03989336|DRUG|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
219674379|NCT00576524|DEVICE|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
219674380|NCT00576524|DEVICE|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
219674381|NCT03140540|OTHER|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.
219674382|NCT03140540|OTHER|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV \>10, 200 ml of colloid bolus to be given
219674383|NCT05576961|DRUG|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
219674384|NCT05576961|DRUG|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
219674385|NCT05576961|DRUG|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
219674386|NCT04153474|PROCEDURE|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
219674387|NCT04153474|PROCEDURE|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
219209030|NCT06747676|DEVICE|Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.
219674388|NCT01696656|DRUG|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
219674389|NCT04382716|OTHER|No intervention|No intervention; observation only
219674390|NCT02213380|PROCEDURE|method of anesthesia|"General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
219674391|NCT00730574|DIETARY_SUPPLEMENT|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
219674392|NCT01314027|DRUG|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
219674393|NCT01314027|DRUG|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
219674394|NCT02198508|DRUG|DFX(Deferasirox)|
219674395|NCT02198508|DRUG|DFP(Deferiprone)|
219674396|NCT00540839|DRUG|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
219674397|NCT00540839|DRUG|Placebo to montelukast|Placebo OG or CT
219674398|NCT00540839|DRUG|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
219674399|NCT00540839|DRUG|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
219674400|NCT02366299|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
219674401|NCT02366299|DRUG|Propofol|Treatment of delirium by Propofol i.v. infusion
219674402|NCT05130996|DEVICE|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
219674403|NCT02537600|DRUG|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
219674404|NCT05703334|OTHER|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
219674405|NCT00033319|DIETARY_SUPPLEMENT|folic acid|
219674406|NCT00033319|DRUG|acetylsalicylic acid|
219674407|NCT02073526|DRUG|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
219674408|NCT02517736|DRUG|Sorafenib at a dose of 800 mg / day|
219674409|NCT00184002|DRUG|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
219674410|NCT02380937|PROCEDURE|ablation for typical atrial flutter|ablation for typical atrial flutter
218981455|NCT06706804|BEHAVIORAL|Wipe Bathing|In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate times, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, women will be provided to perform the procedure on the model appropriate to the gender of their babies for genital area cleaning based on the gender of newborns. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
218981456|NCT06710327|DRUG|Tranexamic Acid (IV)|The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.
218981457|NCT06710327|DRUG|Placebo|Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
218981458|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail A|Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.
218981459|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail B|Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.
219070640|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
219070641|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
219070642|NCT02864082|DRUG|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
219070643|NCT02864082|DRUG|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
219674411|NCT02380937|DEVICE|Vision Ablation Catheter|
219674412|NCT04628000|OTHER|Vitamin D|Clinical Correlation
219674413|NCT03573570|OTHER|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
219674414|NCT01763203|BEHAVIORAL|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
219674415|NCT01763203|BEHAVIORAL|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
219674416|NCT02187861|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
219674417|NCT02187861|DRUG|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
219674418|NCT02187861|DRUG|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
219674419|NCT06463197|BEHAVIORAL|Self-Administered Acupressure Group|Subjects will attend two weekly 120-minute of self-administered acupressure training according to the group allocation in a classroom at the School Nursing, the Hong Kong Polytechnic University. The subjects will be trained to perform self-administered acupressure by an acupuncturist. To enhance interaction and ensure the quality of teaching, each class will be conducted in a small group of 5 to 7 subjects. Participants in this group will learn the self-acupressure technique and passed fidelity check. The treatment protocol included 6 acupoints, namely, Baihui (GV20) and bilateral Fenchi (GB20), Neiguan (PC6), Shenmen (HT7), Shenxu (BL23) and Yongquan (KI1) (Table 1). Subjects were given an acupressure log to record their practice at home, and they were phoned twice a week to remind their practice during the 4-week treatment period.
219674420|NCT06463197|BEHAVIORAL|Sleep Hygiene Education group|The participants in this group will receive education on sleep hygiene. The treatment duration, frequency, and telephone follow-up schedule for the SHE group will be the same as the self-administered acupressure group (2 sessions, 2 hours each). Sleep hygiene education is often used as a comparison group in randomized controlled trials of self-help and psychological interventions for insomnia. The SHE group will provide subjects with the same amount of contact hours with the healthcare professional (instructor) in order to control the non-specific effects of practitioner-patient interaction in the self-administered acupressure group.
218981460|NCT06710392|DIETARY_SUPPLEMENT|Placebo A|Placebo A matching investigational product A given 3 times a day for 4 weeks.
218981461|NCT06710392|DIETARY_SUPPLEMENT|Placebo B|Placebo B matching investigational product B given 3 times a day for 4 weeks.
218981462|NCT06708481|DRUG|P11-4, a self-assembling peptide|rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
219070644|NCT02864082|DRUG|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
219070645|NCT02864082|DRUG|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
218981463|NCT06708481|DRUG|P11-4, a self-assembling peptide with flouride|self assembling peptide with 500 ppm sodium fluoride
218981464|NCT06708481|DRUG|resin infilteration|Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion
218981465|NCT06709066|DRUG|mivacurium chloride|mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
218981466|NCT06709066|DRUG|succinylcholine|succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
218981467|NCT06709157|DIAGNOSTIC_TEST|P24 antigens and antibody|estimation of antigens and antibodies to diagnose HIV
218981468|NCT06709157|DIAGNOSTIC_TEST|zeihl - Nelsen stain|staining sputum from patients with HIV to detect tubercle bacilli
218981469|NCT06709157|DIAGNOSTIC_TEST|culture on Lowenstein jensen media|spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies
218981470|NCT06709157|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|to see the pattern of antibiotic resistance of tubercle bacilli
218981471|NCT06709625|PROCEDURE|Transversus thoracis plane block|Transversus thoracis plane block will be applied to provide postoperative analgesia.
218981472|NCT06709625|PROCEDURE|Erector spina plane block (ESP)|Erector spina plane block will be applied to provide postoperative analgesia.
218981473|NCT06933121|DEVICE|Digital twin for personalized recommendations|"The intervention is the developed eHealth solution, i.e. the healthy lifestyle recommender system. It is based on a previously developed meal recommender system, but will be much extended, resulting in a multilevel portfolio intervention regarding:~1. Suggesting personalized meal recommendations,~2. Proposing physical activities tailored to the individuals' capabilities and preferences,~3. Measuring and considering emotional and psychological parameters,~4. Proposing additional healthy life-style patterns regarding e.g. sleeping patterns, alcohol and tobacco consumption, engaging in social activities etc.~The detailed nature of the interventions will first be developed during co-creation and then targeted to the participating individual. Moreover, particular attention will be given, since this needs to be a eHealth solution easy to be used by children. The intervention will include collecting urine and saliva samples, as well as measuring anthropometrics and collecting data (persona"
218981474|NCT06934954|BEHAVIORAL|EASE|This is the first time EASE is being used in New York to support youth community mental health.
219070646|NCT02271126|DEVICE|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
219070647|NCT02271126|DEVICE|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
219070648|NCT02271126|DRUG|Heparin|Anticoagulation provided to patients in ECMO
219674421|NCT02923401|OTHER|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
218981475|NCT06933316|OTHER|the intervention group|the intervention group received additional FIC-based care, including individualized health plans, education, daily care guidance, dietary recommendations, micronutrient supplementation, early intervention, growth monitoring, and vaccination support.
218981476|NCT06933316|OTHER|the control group|Infants receive routine healthcare guidance provided by pediatric healthcare professionals. This includes regular check-ups scheduled via phone appointments, general health consultations, vaccinations according to regulations, and tailored feeding and parenting guidance based on examination results.
218981477|NCT06933862|DIETARY_SUPPLEMENT|Striatin|striation or placebo given for 90 days assigned to striatin
218981478|NCT06933862|DIETARY_SUPPLEMENT|Placebo|placebo
218981479|NCT06934135|DEVICE|Bilateral Near-Infrared Transcranial Light Therapy (NIR-TLT)|"The NIR-TLT system consists of a laser console coupled via fiber optics to a custom-designed helmet. The console generates 810 nm near-infrared light, formatted by the helmet into a uniform 12 cm² square beam centered over EEG sites F3 and F4, targeting the dorsolateral prefrontal cortex.~The console supports blinded randomization to one of four groups: three active NIR-TLT doses or sham. Active groups receive group-dependent irradiances for \~7 minutes (429 seconds). The sham is indistinguishable from active treatment, with identical helmet placement, session duration, sounds, and visual cues but no therapeutic NIR light.~Participants receive two or three sessions per week for six weeks, followed by a two-week observation period. The intervention evaluates NIR-TLT's impact on depressive symptoms and explores changes in brain metabolism and neural activity."
218981480|NCT06934109|OTHER|Narrative Exposure Therapy (NET)|NET is a psychological talking therapy that has been designed for people who have experienced multiple and prolonged traumatic experiences. It is typically 12-sessions, involving first a psychoeducation session, then laying a lifeline where stones are lain to represent traumatic events, and flowers positive life events. The following sessions the person is asked to talk through their life, going into detail on the traumatic memories that they have experienced.
218981481|NCT06934434|OTHER|FMF Study Group|In the study group consisting of children with FMF, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
218981482|NCT06934434|OTHER|control group|In the control group consisting of healthy children, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
218981483|NCT02675114|PROCEDURE|SAVR|SAVR with a commercially available bioprosthetic valve.
219674422|NCT02923401|BEHAVIORAL|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
219674423|NCT02923401|BEHAVIORAL|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
219674424|NCT02923401|BEHAVIORAL|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
219674425|NCT02923401|OTHER|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
219674426|NCT02858271|DRUG|AKB-9778 subcutaneous injection|
219674427|NCT05421780|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
219674428|NCT05421780|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
219674429|NCT05421780|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits as breakfast.
219070649|NCT03505632|DEVICE|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
219070650|NCT03505632|DEVICE|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
219070651|NCT05848141|BEHAVIORAL|Exercise training|This is a single site center-based supervised exercise intervention.
219070652|NCT05542355|DRUG|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
218981484|NCT02675114|DEVICE|SAPIEN 3 THV|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
219674430|NCT04716621|OTHER|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
219674431|NCT04716621|OTHER|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
218981485|NCT00645112|DRUG|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
218981486|NCT00645112|DRUG|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
218981487|NCT06558305|OTHER|blood sample|Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
218981488|NCT04058873|DRUG|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
219674432|NCT05587894|DRUG|Paxlovid 5 days|"Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19."
219674433|NCT05587894|DRUG|Paxlovid 10 days|Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
219674434|NCT05587894|DRUG|Veklury|"Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound."
218981489|NCT06570707|OTHER|Brighter Bites|Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
218981490|NCT02418598|GENETIC|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
218981491|NCT02418598|GENETIC|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
218981492|NCT02082275|OTHER|OB Nest|"* Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires."
219674435|NCT04168255|PROCEDURE|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
219674436|NCT01152996|DRUG|Vortioxetine|Vortioxetine tablets
219674437|NCT02072941|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
219674438|NCT05982197|DRUG|Curcumin Gel|Curcuma longa oral gel for prevention radiation induced oral mucositis
219674439|NCT05982197|DRUG|Standard Preparation|Standard preparation for prevention radiation induced oral mucositis
219674440|NCT02020889|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
219674441|NCT02020889|DRUG|Placebo|Placebo will be available as 0.9% sodium chloride
219674442|NCT00401128|DRUG|gemcitabine hydrochloride|
219674443|NCT00401128|DRUG|irinotecan hydrochloride|
219674444|NCT00893074|DRUG|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
219674445|NCT00893074|DRUG|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
218981493|NCT01306396|BEHAVIORAL|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
219674446|NCT00893074|DRUG|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
219674447|NCT00893074|DRUG|Placebo|placebo dronabinol administered 3x/day for 5 days
218981494|NCT06792721|GENETIC|Mutation Burden cfMB analysis|Blood samples will be collected (one time only)
218981495|NCT03695744|DRUG|Daratumumab|Daratumumab
218981496|NCT03695744|DRUG|Bortezomib|Bortezomib
218981497|NCT03695744|DRUG|Dexamethasone|Dexamethasone
218981498|NCT01868503|DRUG|lapatinib ditosylate|Given PO
218981499|NCT01868503|RADIATION|radiation therapy|Undergo radiation therapy
218981500|NCT01868503|OTHER|laboratory biomarker analysis|Correlative studies
218981501|NCT00547573|DRUG|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
218981502|NCT00547573|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
218981503|NCT00547573|DRUG|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
218981504|NCT01127035|BIOLOGICAL|sublingual immunotherapy|
218981505|NCT01127035|BIOLOGICAL|placebo|
218981506|NCT03898258|OTHER|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
218981507|NCT03898258|OTHER|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
218981508|NCT00446615|BEHAVIORAL|computer decision support tool|
219070653|NCT05542355|DRUG|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
218981509|NCT00446615|BEHAVIORAL|audit and feedback|
219070654|NCT05542355|OTHER|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
219070655|NCT05542355|OTHER|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
219674448|NCT00744718|DRUG|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
219674449|NCT00744718|DRUG|Carboplatin|Carboplatin AUC 5 every 5 weeks
219674450|NCT02048124|DEVICE|25g standard needle|
219674451|NCT02048124|DEVICE|25d ProCor needle|
218981510|NCT00446615|BEHAVIORAL|group learning session|
218981511|NCT00325702|BEHAVIORAL|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
218981512|NCT04042181|DIETARY_SUPPLEMENT|Placebo|standard food grade excipients
218981513|NCT04042181|DIETARY_SUPPLEMENT|Bifidobacterium longum|Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
219070656|NCT06401148|BEHAVIORAL|Cardiac rehab intervention group|Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
219674452|NCT01351454|BEHAVIORAL|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
219674453|NCT01351454|BEHAVIORAL|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
219674454|NCT06101355|OTHER|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
219674455|NCT06101355|OTHER|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
219674456|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
219674457|NCT05419713|OTHER|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
219674458|NCT03131726|DRUG|Simvastatin 40mg|see arm description
219674459|NCT04719598|BEHAVIORAL|congnitive behavioural therapy|CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
219674460|NCT03124160|DRUG|Mona Lisa® NT Cu380 Mini|copper intrauterine device
219674461|NCT03124160|DRUG|ParaGard® TCu380A|copper intrauterine device
219674462|NCT05459337|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
219674463|NCT04512950|DRUG|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
219674464|NCT04512950|DRUG|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
219674465|NCT06644079|DRUG|Tranexamic acid|Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
218981514|NCT03253575|DIAGNOSTIC_TEST|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
218981515|NCT05140785|DIAGNOSTIC_TEST|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
218981516|NCT00275457|DRUG|pramipexole|
218981517|NCT03369093|DRUG|Amoxicillin|Twice daily doses of injectable amoxicillin
219070657|NCT06961890|BEHAVIORAL|Principals of cognitive behavioral therapy on guided changing hygiene and sugar comsuption habits|The twin pairs will also receive guidance on healthy sugar consumption and oral hygiene habits, as the first intervention among the dental interventions received. For the baseline assessment, each participant answered a questionnaire about their diet the day before and about oral hygiene, in addition to demonstrating how they perform it. Thus, the cognitive behavioral theory was applied, so that the participant can record the goals achieved weekly and monthly.
219070658|NCT05327803|DRUG|Epetraborole|500 mg taken orally QD
219070659|NCT05327803|DRUG|Placebo|Placebo taken orally QD
219674466|NCT03884309|OTHER|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
219674467|NCT00608218|DRUG|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
218981518|NCT01049568|BEHAVIORAL|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
218981519|NCT03236025|COMBINATION_PRODUCT|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
218981520|NCT03236025|COMBINATION_PRODUCT|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
218981521|NCT03236025|OTHER|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
218981522|NCT04488796|BEHAVIORAL|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
219070660|NCT04481919|DRUG|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
219070661|NCT01919008|DRUG|FK949E|Oral
219070662|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
219070663|NCT03621696|DRUG|Cisplatin|-100 mg/m\^2 intravenous push bolus (IVPB)
219070664|NCT03621696|RADIATION|Intensity modulated radiation therapy|-IMRT or IMPT can be used
219070665|NCT03621696|RADIATION|Intensity modulated proton therapy|-IMRT or IMPT can be used
219070666|NCT03621696|PROCEDURE|Surgery|-Standard of care
219070667|NCT03621696|OTHER|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
219070668|NCT03621696|OTHER|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
219070669|NCT03621696|OTHER|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
219070670|NCT03621696|OTHER|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
219070671|NCT03621696|OTHER|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
219070672|NCT04349553|BIOLOGICAL|ZH9PA and ZH9|150mL vaccine for oral administration
219070673|NCT04349553|BIOLOGICAL|Placebo|150mL vaccine for oral administration
219070674|NCT04349553|BIOLOGICAL|ZH9PA|150mL vaccine for oral administration
219070675|NCT06326606|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
219674468|NCT03522818|BEHAVIORAL|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
219674469|NCT03522818|BEHAVIORAL|Normal|Will use the alarm as provided by the manufacture.
219674470|NCT01471275|DRUG|Metformin|250 mg or 500mg three times a day
219674471|NCT01471275|DRUG|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
219674472|NCT00667303|OTHER|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
219674473|NCT00667303|OTHER|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
219674474|NCT00667303|OTHER|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
219070676|NCT06326606|DRUG|Placebo|Capsule with no active ingredients
219070677|NCT04459650|PROCEDURE|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
219070678|NCT05360615|DRUG|Empagliflozin 10 MG|SGLT2 inhibitors
219070679|NCT05360615|DRUG|Placebo|Placebo
219070680|NCT06525181|OTHER|Generative Artificial Intelligence|Gen AI assisted symptom intake summarization
219070681|NCT06525181|OTHER|Standard weekly symptom intake|Standard weekly symptom intake performed by a physician
219070682|NCT02063724|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
219070683|NCT01574300|OTHER|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
219674475|NCT04095325|DEVICE|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
219070684|NCT03582124|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo imaging
219674476|NCT06439472|OTHER|Suboccipital Inhibition Technique|"The researcher will place their palms under the patient's head and use their fingers to contact the occipital condyles. Next, the researcher will place the 3rd and 4th fingers of each hand in the space between the occiput and the spinous process of C2. The metacarpophalangeal joints are at 90º flexion, with the base of the skull resting on their hands while they apply constant, non-painful pressure in a postero-anterior direction, keeping the 2nd, 3rd and 4th fingers together in extension. Afterwards, the researcher applies a light and gentle traction in a cephalad direction in order to relieve the suboccipital area. Once the suboccipital muscles have relaxed, the researcher gently removes the contact, leaving the participant's head resting on the table.~This technique is performed for 4 minutes."
219674477|NCT06439472|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 4 minutes.
219674478|NCT05660668|OTHER|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
219674479|NCT05660668|OTHER|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
219674480|NCT03825081|DRUG|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
219674481|NCT03783286|DRUG|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
218981523|NCT04488796|BEHAVIORAL|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
219674482|NCT02096562|OTHER|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
219674483|NCT02096562|OTHER|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
219674484|NCT03683563|OTHER|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
219674485|NCT03683563|OTHER|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
218981524|NCT04488796|BEHAVIORAL|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
218981525|NCT04488796|BEHAVIORAL|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
218981526|NCT04488796|BEHAVIORAL|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
218981527|NCT04488796|BEHAVIORAL|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
218981528|NCT03531697|DRUG|Generic Loteprednol Etabonate|Drug
218981529|NCT03531697|DRUG|Reference Listed Drug (RLD)|Drug
218981530|NCT05747287|DEVICE|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
218981531|NCT05382663|DEVICE|Alio Device|Non-invasive device worn over vasculature.
218981532|NCT00875264|DRUG|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
218981533|NCT04544423|OTHER|Block group|Patients received lumbar erector spinae plane Block before operation
218981534|NCT03605407|OTHER|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
219070685|NCT03582124|DRUG|Panitumumab-IRDye800|Given IV
219674486|NCT03224624|OTHER|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
218981535|NCT02293057|BEHAVIORAL|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
218981536|NCT02293057|BEHAVIORAL|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
218981537|NCT05636644|DRUG|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
219070686|NCT03582124|OTHER|Pharmacokinetic Study|Correlative studies
219070687|NCT03582124|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219070688|NCT05087628|BIOLOGICAL|PRV-3279|Bi-specific antibody-based molecule
219070689|NCT05087628|OTHER|Placebo|Placebo
219070690|NCT04740294|DRUG|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
219070691|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
219070692|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
219070693|NCT01715805|DRUG|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
219070694|NCT01715805|DRUG|Placebo|Dose-matched placebo capsule once per day
219209031|NCT06747676|DEVICE|Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.
219209032|NCT05116774|DRUG|Eculizumab|Administered by intravenous infusion per current dose regimen
219209033|NCT05116774|DRUG|Ravulizumab|Administered by intravenous infusion per current dose regimen
219674487|NCT04837287|OTHER|Static Stretching Exercise for 10 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
219674488|NCT04837287|OTHER|Static Stretching Exercise for 30 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
219674489|NCT00440635|DRUG|Bortezomib, tradename Velcade|
219674490|NCT01884545|BEHAVIORAL|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
219674491|NCT01884545|GENETIC|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
219674492|NCT01884545|BEHAVIORAL|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
218981538|NCT06270771|DEVICE|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
219209034|NCT05116774|DRUG|BCX9930|Administered orally twice daily
219209035|NCT06756828|DRUG|Melatonin|3months melatonin
219209036|NCT06756828|BEHAVIORAL|Cognitive behavioral therapy group for insomnia|15minutes of sleep hygiene education on the first day of visiting the hospital
219209037|NCT06756815|OTHER|Cross bracing and conservative treatment|Week Exercise Training Frequency (sets x reps) Week 1-2 1. Cross Bracing (Isometric Holds) 2. Quad Sets 3. Straight Leg Raise 4. Ankle Pumps 5. Heel and Toe Raises 6. Glute Bridge 2 sets x 10 reps Week 3-4 1. Cross Bracing (Isometric Holds) 2. Hamstring Curls 3. Step-ups 4. Mini Squats (with support) 5. Leg Press 6. Lateral Leg Raises 3 sets x 12 reps Week 5-6 1. Cross Bracing (Isometric Holds) 2. Single-leg Balance (with support) 3. Lunges (with proper technique) 4. Squats (bodyweight) 5. Box Jumps 6. Lateral Step-ups 3 sets x 15 reps
219209038|NCT06756815|OTHER|Cross bracing and DNS with conservative treatment|"Week Exercise Training Frequency (sets x reps) Week 1-2~1. Cross Bracing (Isometric Holds)~2. DNS Core Activation (supine, prone positions)~3. Quad Sets~4. Straight Leg Raise~5. Ankle Pumps~6. Heel and Toe Raises~7. Glute Bridge 2 sets x 10 reps Week 3-4~1\. Cross Bracing (Isometric Holds) 2. DNS Core Stabilization (advanced activation) 3. Hamstring Curls 4. Step-ups 5. Mini Squats 6. Leg Press 7. Lateral Leg Raises 8. Pelvic Tilts 3 sets x 12 reps Week 5-6~1. Cross Bracing (Isometric Holds)~2. DNS Dynamic Stabilization (with resistance)~3. Single-leg Balance (with and without support)~4. Lunges (with added resistance)~5. Squats (bodyweight or weighted)~6. Box Jumps~7. Lateral Step-ups~8. Running Drills (if tolerated) 3 sets x 15 reps"
218981539|NCT03080454|DEVICE|sham Doublestim|PathMaker MyoRegulator device
218981540|NCT03080454|DEVICE|anodal Doublestim|PathMaker MyoRegulator device
218981541|NCT01195246|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injection on Day1
218981542|NCT01195246|BIOLOGICAL|Engerix-B|Intramuscular (IM) injection on Day 1
218981543|NCT01195246|BIOLOGICAL|Fendrix|Intramuscular (IM) injection on Day 1
218981544|NCT05708274|DRUG|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
218981545|NCT05708274|DRUG|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
218981546|NCT05708274|DRUG|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
219209039|NCT03392467|BIOLOGICAL|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
219209040|NCT03392467|OTHER|Placebo|normal saline
219209041|NCT06757244|DRUG|Dostarlimab|Intra-venous (i.v) dostarlimab: day1 - d21: 500mg IV q3Weeks (cycle 1 to cycle 4) then 1000 mg IV q6Weeks (from cycle 5 onwards)
219209042|NCT06757244|DRUG|Vitamin D3 (Cholecalciferol)|Oral vitamin D3 8000 IU/d for 14 days, then 4000IU/d
219209043|NCT06757244|DRUG|mFOLFIRINOX Treatment Regimen|mFOLFIRINOX d1, d15, d29 cycle 1 to cycle 4 is administered as follow: oxaliplatin 85 mg/m2 on day1, IV infusion over 2 h, immediately followed by folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion, with the addition of irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion through a Y-connector immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion.
219209044|NCT06757244|DRUG|LV5FU2|folinic acid 400 mg/m2 Or calcium levofolinate 200 mg/m2 2-h IV infusion 5- fluoro-uracil 2400 mg/m2 Over 46 h continuous infusion. From cycle 5 onwards, D1=D43
219209045|NCT03150862|DRUG|Pamiparib|Administered as specified in the treatment arm
219209046|NCT03150862|DRUG|TMZ|Administered as specified in the treatment arm
219674493|NCT03816111|BEHAVIORAL|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
219674494|NCT03816111|BEHAVIORAL|Current standard PD training|Current PD training materials and plan
219674495|NCT01411514|DRUG|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
219674496|NCT01411514|DRUG|Placebo|Placebo tablets. They will be administered during 25 days
219674497|NCT00877539|DRUG|PF-03526299|Inhaled, two doses 4 hours apart
218981547|NCT05708274|DRUG|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
218981548|NCT03086993|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
218981549|NCT03086993|DRUG|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
218981550|NCT00053443|DEVICE|Medication Reminder System/Adherence Tracker|
218981551|NCT00216476|DRUG|Aripiprazole|10-30 mg oral once daily for 104 weeks
218981552|NCT00216476|DRUG|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
218981553|NCT00216476|DRUG|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
218981554|NCT03385200|DRUG|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
218981555|NCT00705926|DRUG|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
218981556|NCT00705926|OTHER|No treatment|Participants in this group will not receive treatment at this stage of their infection.
218981557|NCT04850820|DIETARY_SUPPLEMENT|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
218981558|NCT04850820|DIETARY_SUPPLEMENT|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
218981559|NCT04850820|DIETARY_SUPPLEMENT|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
218981560|NCT05771012|DRUG|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
218981561|NCT05771012|DEVICE|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
218981562|NCT06437496|DRUG|68Ga-AAZTA-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
218981563|NCT06437496|DRUG|68Ga-PSMA-11//68Ga-PSMA-617|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
218981564|NCT04508348|OTHER|Human Milk|Exclusive Human Milk diet
218981565|NCT04508348|OTHER|Standard of Care|This diet will include mother's milk and/or formula
218981566|NCT01437969|GENETIC|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
218981567|NCT00696800|DRUG|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
219209047|NCT03150862|RADIATION|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
219209048|NCT06758908|DEVICE|Antibiotic|SALI
219209049|NCT06759948|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg."
219674498|NCT00877539|DRUG|Placebo|Inhaled, two doses 4 hours apart
219674499|NCT00877539|DRUG|Fluticasone propionate|Inhaled
219674500|NCT04037293|DIAGNOSTIC_TEST|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
219674501|NCT02521792|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
218981568|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
218981569|NCT00696800|DRUG|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
218981570|NCT00696800|DRUG|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
218981571|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
218981572|NCT00696800|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
218981573|NCT00696800|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
218981574|NCT00696800|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
218981575|NCT02672800|BEHAVIORAL|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
218981576|NCT00298584|PROCEDURE|Percutaneous Suprapubic Aspiration|
218981577|NCT00298584|PROCEDURE|Urethral Catheterization|
218981578|NCT02981264|DRUG|Transcricoid Injection|
218981579|NCT02981264|DRUG|Spray as you go|
218981580|NCT06632002|OTHER|DSF1|220 mL
218981581|NCT06632002|OTHER|DSF2|220 mL
218981582|NCT06632002|OTHER|Standard of Care (SOC)|Standard of care
218981583|NCT04796571|BEHAVIORAL|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
218981584|NCT04378127|OTHER|Educational program|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
218981585|NCT02034032|PROCEDURE|Regenexx SD|stem cell treatment
218981586|NCT02034032|BEHAVIORAL|Exercise Therapy|exercise therapy control
218981587|NCT00058487|DRUG|epirubicin hydrochloride|
218981588|NCT00058487|DRUG|thalidomide|
218981589|NCT03445520|BEHAVIORAL|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
218981590|NCT05806983|OTHER|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
218981591|NCT02151695|PROCEDURE|panretinal photocoagulation|
218981592|NCT02151695|DRUG|Aflibercept intravitreal injections|
218981593|NCT00629720|DRUG|alfuzosin (SL770499)|
218981594|NCT01511965|OTHER|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
218981595|NCT06557317|BEHAVIORAL|Black Girls for Wellness In-Person|Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
218981596|NCT04228874|DEVICE|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as \> 70 % luminar diameter stenos. The following data was obtained:~* Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~* Length, diameter and number of stents.~* TIMI flow after stent deployment."
219070695|NCT01715805|DRUG|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
219674502|NCT03687866|GENETIC|non invasive prenatal testing|
219674503|NCT00685867|OTHER|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
219674504|NCT00685867|BEHAVIORAL|Hand hygiene promotion|"* Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)"
219674505|NCT04506931|OTHER|SMS Survey|Participants will receive a SMS survey
219674506|NCT04506931|OTHER|IVR Survey|Participants will receive an IVR survey
219070696|NCT04936230|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219070697|NCT04936230|PROCEDURE|Bone Scan|Undergo bone scan
219070698|NCT04936230|PROCEDURE|Computed Tomography|Undergo CT scan
219070699|NCT04936230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219674507|NCT04506931|OTHER|CATI Survey|Participants will receive a CATI survey
219674508|NCT03454477|PROCEDURE|conventional open surgery|conventional open surgery
219674509|NCT03454477|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy
219070700|NCT04936230|BIOLOGICAL|Pembrolizumab|Given IV
219070701|NCT04936230|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219070702|NCT04936230|OTHER|Questionnaire Administration|Ancillary studies
219070703|NCT04936230|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219070704|NCT06258213|DRUG|ABP-745|0.5, 5 or 25 mg tablet
219070705|NCT06258213|DRUG|Placebo|Placebo tablet
219070706|NCT04479813|DRUG|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
219070707|NCT04479813|OTHER|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
219070708|NCT01821664|DEVICE|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
219070709|NCT03457532|DRUG|Gumarontinib Tablets|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
219674510|NCT03454477|DEVICE|robotic thyroidectomy|robotic thyroidectomy
219674511|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
219674512|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
219674513|NCT02424994|OTHER|No intervention|
219674514|NCT01530802|PROCEDURE|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
219674515|NCT00303472|DRUG|Romiplostim|
219674516|NCT06226337|OTHER|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
219674517|NCT00638092|DRUG|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
219674518|NCT00638092|DRUG|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
218981597|NCT04046484|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
218981598|NCT04046484|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
218981599|NCT00392080|DRUG|CJ-023,423|75 mg BID
218981600|NCT00392080|DRUG|placebo|placebo
218981601|NCT00392080|DRUG|naproxen|naproxen
219070710|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
219070711|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
219209050|NCT06755580|PROCEDURE|spinopelvic fixation|open and minimally invasive spinopelvic fixation for unstable or dislocated high-energy sacral fractures
218981602|NCT00000702|DRUG|Zidovudine|
218981603|NCT04686695|DEVICE|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
218981604|NCT03499925|BEHAVIORAL|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
218981605|NCT03499925|BEHAVIORAL|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
218981606|NCT04674202|OTHER|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
218981607|NCT05038943|DEVICE|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
218981608|NCT00287365|DRUG|ozone|2 hour exposure to 0.4 ppm ozone
218981609|NCT06177522|DRUG|Adebrelimab|1200mg，i.v. , q3w
218981610|NCT06177522|DRUG|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
219070712|NCT06536881|BEHAVIORAL|Fasting|The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
219070713|NCT05217732|DRUG|ZX-7101A|tablet
219070714|NCT05217732|DRUG|Placebo|Tablet
218981611|NCT06177522|DRUG|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
218981612|NCT02000180|BEHAVIORAL|Progressive Group|
218981613|NCT02298023|BIOLOGICAL|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
218981614|NCT02298023|BIOLOGICAL|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
218981615|NCT02298023|BIOLOGICAL|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
218981616|NCT01139489|OTHER|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
218981617|NCT05069610|BIOLOGICAL|AD17002|A recombinant protein
218981618|NCT05069610|BIOLOGICAL|Placebo (Formulation buffer)|Formulation buffer
218981619|NCT03047707|DIAGNOSTIC_TEST|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
218981620|NCT04597229|DIETARY_SUPPLEMENT|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
218981621|NCT01728350|BEHAVIORAL|HOPE - Helping Others through Purpose and Engagement|
219209051|NCT06760247|PROCEDURE|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|endotracheal intubation by using direct laryngoscopy
219209052|NCT06769659|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment
219209053|NCT06769659|OTHER|Placebo|Placebo Comparator
219209054|NCT06768619|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
219209055|NCT06768619|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
219209056|NCT06768749|OTHER|Melatonin lotion|3 g lotion applied one hour before bedtime
219674519|NCT04878939|OTHER|Power chain used for anterior segment retraction|Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
219674520|NCT04878939|OTHER|T-loop fabricated to perform anterior segment retraction|In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
219674521|NCT00351936|DRUG|Aripiprazole|
219674522|NCT00351936|DRUG|placebo|
219674523|NCT04504747|OTHER|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
219674524|NCT04850495|DRUG|Cyclophosphamide|Given IV
219674525|NCT04850495|DRUG|Doxorubicin Hydrochloride|Given IV
219674526|NCT04850495|DRUG|Prednisone|Given PO
219674527|NCT04850495|BIOLOGICAL|Rituximab|Given IV
219674528|NCT04850495|DRUG|Vincristine Sulfate|Given IV
219674529|NCT04850495|DRUG|Zanubrutinib|Given PO
218981622|NCT04118842|DRUG|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
218981623|NCT04118842|DRUG|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
218981624|NCT03948243|DIETARY_SUPPLEMENT|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
218981625|NCT03948243|DRUG|Alprazolam 2 MG|probe substrate
218981626|NCT03948243|DRUG|Caffeine 100 MG|probe substrate
218981627|NCT03948243|DRUG|Tolbutamide 250 mg|probe substrate
218981628|NCT03948243|DRUG|Dextromethorphan 30mg|probe substrate
218981629|NCT02552992|BEHAVIORAL|Yoga|
218981630|NCT02552992|BEHAVIORAL|Self-Directed Mind-Body Program|
218981631|NCT04406220|OTHER|Small clog size|Participants will be randomized to run in small clogs
218981632|NCT04406220|OTHER|Large clog size|Participants will be randomized to run in large clogs
218981633|NCT02642302|BEHAVIORAL|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
218981634|NCT02642302|BEHAVIORAL|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
218981635|NCT02642302|BEHAVIORAL|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
218981636|NCT00472719|BIOLOGICAL|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
218981637|NCT00472719|BIOLOGICAL|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
218981638|NCT00472719|BIOLOGICAL|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
218981639|NCT01928173|BEHAVIORAL|Abbreviated cognitive behavioral therapy|see arm description
218981640|NCT01928173|BEHAVIORAL|Sleep education/sleep hygiene|see arm description
218981641|NCT01997853|DRUG|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
218981642|NCT01997853|DRUG|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
218981643|NCT03005418|BIOLOGICAL|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
218981644|NCT00325273|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
218981645|NCT02840721|DRUG|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
219070715|NCT04956393|BEHAVIORAL|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
219070716|NCT04956393|BEHAVIORAL|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
219070717|NCT06193421|DRUG|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
219070718|NCT00958035|DRUG|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
219070719|NCT00958035|DRUG|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
219070720|NCT00413504|DRUG|Fondaparinux|
219070721|NCT05860465|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
219070722|NCT05860465|DRUG|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
219674530|NCT05399316|DIETARY_SUPPLEMENT|Inulin|Natural fiber supplement extracted from chicory
219674531|NCT05399316|DIETARY_SUPPLEMENT|Maltodextrin|Natural non-fermentable sugar
219674532|NCT02937636|OTHER|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
219674533|NCT02937636|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
218981646|NCT04280835|BEHAVIORAL|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
219674534|NCT00770913|DRUG|E3810|20 mg taken orally, once a day for 8 weeks.
219674535|NCT00770913|DRUG|E3810|10 mg, taken orally, twice a day for 8 weeks.
219674536|NCT00770913|DRUG|E3810|20 mg taken orally, twice a day for 8 weeks.
219674537|NCT00596102|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
219674538|NCT03919656|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
219674539|NCT03919656|DRUG|Placebo Oral Tablet|Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
219674540|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
219674541|NCT06726122|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
219674542|NCT00359294|DRUG|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
219674543|NCT00583011|DRUG|Local Anesthesia|Local anesthesia: 2 cc of 1% Lidocaine
219674544|NCT00583011|DRUG|Placebo Group|Placebo Group: 2cc Normal Saline
219674545|NCT06621823|PROCEDURE|image-guided surgery technique|The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
219674546|NCT01985061|DRUG|BX2|
219674547|NCT01985061|DRUG|BX3|
219674548|NCT01985061|DRUG|BX4-Suspended|Suspended
219674549|NCT06968650|BEHAVIORAL|Digital and Coordinated Maternial Care|The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.
219674550|NCT05177549|OTHER|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
218981647|NCT04354103|DRUG|Atomoxetine|Atomoxetine
218981648|NCT05244993|DRUG|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
218981649|NCT05244993|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
218981650|NCT05244993|DRUG|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
218981651|NCT03636165|DRUG|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
218981652|NCT03636165|DRUG|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
218981653|NCT05342935|DEVICE|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
219209057|NCT06768749|OTHER|Placebo lotion|3 g of placebo lotion (scent-matched control) applied one hour before bedtime
218981654|NCT06306820|OTHER|Fixed PEEP|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
219674551|NCT03860766|OTHER|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
219674552|NCT00305422|DRUG|Quetiapine fumarate|
219674553|NCT00305422|DRUG|Risperidone|
219674554|NCT03706716|OTHER|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
219674555|NCT01125085|RADIATION|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"* Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks"
219674556|NCT02347072|DRUG|GFF MDI (PT003)|
219674557|NCT02347072|DRUG|Placebo MDI|
219674558|NCT02347072|DRUG|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
219674559|NCT06442202|DIETARY_SUPPLEMENT|Balanced Nutritional Diet|"Food was provided during the intervention period 3 (three) times each day, i.e. breakfast, lunch and dinner. The food menu used a 30-day menu cycle. The characteristics of the Balanced Nutrition Diet that have been provided based on the distribution of the composition of the macronutrients that will be intervened in are as follows: 45-55% carbohydrates, 15-20% protein, and 20-25% fat (Ministry of Health 2014). The type of diet and portions that were given were the same for each menu unless there were certain food restrictions or allergies, and then the type of food was adjusted specifically to that individual. The calories that will be given range from 300-400 Cal for breakfast, 400-500 Cal for lunch, and 300-500 Cal for dinner.~The choice of carbohydrates should be varied and prioritise complex carbohydrates such as whole grains. The choice of protein type is prioritised from low-fat protein sources and half of it is vegetable protein."
219070723|NCT02116634|BIOLOGICAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
219209058|NCT06758921|DEVICE|Oscar Peripheral Multifunctional Catheter|"Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon.~Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU)."
219674560|NCT06442202|BEHAVIORAL|Nutritional Education|Nutritional education is provided via online Zoom meetings with the help of educational media in the form of PowerPoint presentations/videos before entering the intervention period. The educational material that will be provided is regarding Guidelines for Balanced Nutrition, Food Safety, and Healthy Lifestyles (stress management and sleep time). The subject's understanding of the material provided was evaluated using an online quiz platform.
219674561|NCT05206396|DIAGNOSTIC_TEST|TIL assessment in pre-existing histopathological specimens|TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
219674562|NCT01961167|DEVICE|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
219674563|NCT00964405|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist
219674564|NCT00964405|DRUG|Placebo|Matching placebo
219674565|NCT00722683|PROCEDURE|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
219674566|NCT01396551|DEVICE|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
218981655|NCT06306820|OTHER|Ultrasound-guided lung recruitment|Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
218981656|NCT06306820|OTHER|Individualized PEEP|Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
218981657|NCT01967173|DRUG|Flovent Diskus® 100 mcg|Flovent is an ICS
218981658|NCT01967173|DRUG|Flovent Diskus® 250 mcg|Flovent is an ICS
218981659|NCT01967173|DRUG|Flovent Diskus® 500 mcg|Flovent is an ICS
219674567|NCT02591030|DRUG|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
218981660|NCT01967173|DRUG|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
218981661|NCT01967173|DRUG|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
218981662|NCT02096679|DRUG|AZD9291|Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
218981663|NCT04015492|BIOLOGICAL|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
219674568|NCT02591030|DRUG|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
219674569|NCT04805164|PROCEDURE|Corticotomy and use of the bone substitute : Cerament-G device.|Corticotomy and Cerament-G device
218981664|NCT04015492|BIOLOGICAL|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
218981665|NCT02502175|DRUG|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
219209059|NCT06041256|COMBINATION_PRODUCT|AURN001|Corneal Endothelial Cells and Y27632
219209060|NCT06750224|OTHER|Alexander technique|24 sessions for 8 weeks, per week 3 sessions will be given
219674570|NCT04805164|PROCEDURE|Corticotomy|Corticotomy
218981666|NCT02502175|DRUG|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
218981667|NCT04057508|OTHER|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
218981668|NCT02002832|DRUG|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
218981669|NCT02002832|DRUG|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
219070724|NCT05568992|DEVICE|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
219070725|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
219070726|NCT02310750|DRUG|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
219209061|NCT06750224|OTHER|Feldenkrais method|The method is divided into eight lessons according to 'Awareness Through Movement'. Each lesson will be given three times for one week.
219674571|NCT03056014|DRUG|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
219674572|NCT03056014|DIETARY_SUPPLEMENT|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
219674573|NCT03056014|DIETARY_SUPPLEMENT|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
219070727|NCT02310750|OTHER|Placebo|Matching placebo given during the single ascending and multiple dose periods
219070728|NCT02310750|DRUG|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
219674574|NCT00802321|DRUG|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
219674575|NCT00275015|BIOLOGICAL|filgrastim|
219209062|NCT06398860|PROCEDURE|SIOHPS|The intervention is comprised of several core components such as targeted education, daily team reflections and support for systematic management. First, a two hour education will be conducted for management, HCW involved in patient safety work, safety representatives and intervention facilitators. The second core component is a short daily team reflection conducted by HCW at the unit in connection to the end of work shifts. These are standardized to support identification of situations at work related to both Safety I and II perspective for both occupational health and patient safety as well as learning. The third component includes risk assessment, planning and implementation of appropriate measures, follow up and evaluation, based in information identified in the second component. The steps in this component targets the management and should be conducted in close collaboration with HCW involved in patient safety work and the safety representatives.
219209063|NCT06398860|PROCEDURE|Wait-list|No intervention
218981670|NCT03307785|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
218981671|NCT03307785|DRUG|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
218981672|NCT03307785|DRUG|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
218981673|NCT03307785|DRUG|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
218981674|NCT03307785|DRUG|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
218981675|NCT03307785|DRUG|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
218981676|NCT03307785|DRUG|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
218981677|NCT03623555|BEHAVIORAL|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
218981678|NCT03623555|BIOLOGICAL|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
218981679|NCT01330784|DRUG|hMG-HP|
218981680|NCT03021304|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
218981681|NCT03166059|DEVICE|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
218981682|NCT05767125|DEVICE|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
218981683|NCT05767125|DEVICE|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
219674576|NCT00275015|DRUG|carmustine|
219674577|NCT00275015|DRUG|cyclophosphamide|
219674578|NCT00275015|DRUG|cytarabine|
219674579|NCT00275015|DRUG|dexamethasone|
219674580|NCT00275015|DRUG|etoposide|
219674581|NCT00275015|DRUG|fludarabine phosphate|
219674582|NCT00275015|DRUG|melphalan|
219674583|NCT00275015|PROCEDURE|bone marrow ablation with stem cell support|
219674584|NCT00275015|PROCEDURE|peripheral blood stem cell transplantation|
219674585|NCT00275015|RADIATION|radiation therapy|
219674586|NCT00351559|DEVICE|AlloMap molecular expression testing|
219674587|NCT00351559|PROCEDURE|Right ventricular endomyocardial biopsy|
219674588|NCT04843540|DRUG|CTP-543|Rifampin as oral capsule
218981684|NCT01868464|BIOLOGICAL|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
219674589|NCT02446847|DRUG|3BNC117|3BNC117 infusions
219674590|NCT02446847|OTHER|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
219674591|NCT01883661|BIOLOGICAL|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
219674592|NCT04210739|DRUG|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
219674593|NCT05406271|DIAGNOSTIC_TEST|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
219674594|NCT01478607|DRUG|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
219674595|NCT06041282|PROCEDURE|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
219674596|NCT06041282|PROCEDURE|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
219674597|NCT00779987|DRUG|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
219674598|NCT00779987|DRUG|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
219674599|NCT02383303|BEHAVIORAL|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
219674600|NCT05844072|PROCEDURE|Mobilization with movement|All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
219674601|NCT05143606|OTHER|3D-printed airway simulator|Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
219674602|NCT05143606|OTHER|virtual reality software, AirwayEx|Two self-directed training on AirwayEx. With additional training as necessary.
219674603|NCT01472978|DRUG|metronidazole|Metronidazole, 500 mg three times a for 10 days
219070729|NCT00395876|DRUG|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
219070730|NCT00395876|DRUG|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
219070731|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
219070732|NCT00628771|BEHAVIORAL|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
219070733|NCT00628771|BEHAVIORAL|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
219209064|NCT06762353|PROCEDURE|3-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 3-month frequency after surgical treatment of peri-implantitis.
219674604|NCT02714556|OTHER|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
219674605|NCT01047111|PROCEDURE|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
219674606|NCT04280614|BEHAVIORAL|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
219674607|NCT04878302|BEHAVIORAL|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
219674608|NCT01758042|PROCEDURE|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
219674609|NCT01066702|BIOLOGICAL|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
219674610|NCT01066702|PROCEDURE|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
219674611|NCT03577132|DRUG|Neoadjuvant atezolizumab|"Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy"
219674612|NCT02094313|DRUG|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
219674613|NCT03062397|DRUG|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
219674614|NCT03062397|DRUG|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
219674615|NCT03062397|DRUG|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
219674616|NCT03171740|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
219674617|NCT03171740|DRUG|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
218981685|NCT00669656|DRUG|Prostate Health Cocktail|3 capsules daily PO up 12 months
219674618|NCT03171740|DRUG|Oral saline|Oral saline, 0.25ml/kg
219674619|NCT03171740|DRUG|Nasal saline|Nasal saline 0.01ml/kg
219674620|NCT02699476|BEHAVIORAL|Psycho-Social Therapy|
218981686|NCT06161272|DRUG|Fluzoparib|single
218981687|NCT06161272|DRUG|Fluzoparib+Apatinib|combination
218981688|NCT04108871|PROCEDURE|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
218981689|NCT01811680|DEVICE|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
218981690|NCT03918161|DEVICE|MRE exam|Magnetic Resonance Elastography
218981691|NCT05744284|DEVICE|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
218981692|NCT04127942|PROCEDURE|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
218981693|NCT03524742|OTHER|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
218981694|NCT03524742|OTHER|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
218981695|NCT00492531|DRUG|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
218981696|NCT00492531|DRUG|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
218981697|NCT00001067|DRUG|Lamivudine|
218981698|NCT00001067|DRUG|Stavudine|
218981699|NCT00001067|DRUG|Zidovudine|
218981700|NCT02037360|BEHAVIORAL|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
219674621|NCT02699476|DEVICE|Cognitive Behavioral Computer Training|
219674622|NCT02699476|BEHAVIORAL|Interactive Trainer-Subject Sessions|
219674623|NCT02699476|DEVICE|Active Control Games|
219674624|NCT06207760|DRUG|Minocycline|Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
219674625|NCT03120494|DRUG|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
218981701|NCT02037360|BEHAVIORAL|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
218981702|NCT00860288|DRUG|Vildagliptin|
218981703|NCT00860288|DRUG|Metformin|
218981704|NCT00860288|DRUG|Placebo|
219674626|NCT02352376|OTHER|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
219674627|NCT02352376|OTHER|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
219674628|NCT03706976|DEVICE|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
219674629|NCT02328794|BEHAVIORAL|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
219674630|NCT02328794|BEHAVIORAL|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
219674631|NCT02328794|BEHAVIORAL|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
219674632|NCT02328794|BEHAVIORAL|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
219674633|NCT02328794|BEHAVIORAL|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
219674634|NCT02801370|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
219674635|NCT02801370|DRUG|Sham Control|Simulated, single adminstration
219674636|NCT00307853|DRUG|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
219674637|NCT00307853|OTHER|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
219674638|NCT00307853|OTHER|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
219674639|NCT06369610|DRUG|Abiraterone Acetate|Given abiraterone acetate
219674640|NCT06369610|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219674641|NCT06369610|PROCEDURE|Computed Tomography|Undergo CT
219674642|NCT06369610|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC or IM
219674643|NCT06369610|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218981705|NCT00860288|DRUG|Sitagliptin|
218981706|NCT05363410|DIETARY_SUPPLEMENT|MagnéVie B6®|micronutrient supplement
218981707|NCT05363410|OTHER|Placebo|placebo supplement
218981708|NCT00842582|DRUG|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
218981709|NCT00842582|DRUG|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
218981710|NCT00842582|DRUG|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
218981711|NCT02857582|BIOLOGICAL|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
218981712|NCT02857582|DRUG|Vancomycin|Active comparator to treatment with ACHIM
218981713|NCT02857582|DRUG|Metronidazole|Primary treatment for C diff in all treatment arms
218981714|NCT02772887|DIETARY_SUPPLEMENT|L-Citrulline|amino acid supplement
218981715|NCT02772887|OTHER|Placebo|placebo
218981716|NCT05531331|BEHAVIORAL|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
218981717|NCT00423514|BIOLOGICAL|filgrastim|
218981718|NCT00423514|DRUG|clofarabine|
218981719|NCT00423514|DRUG|melphalan|
218981720|NCT00423514|DRUG|mycophenolate mofetil|
218981721|NCT00423514|DRUG|tacrolimus|
218981722|NCT00423514|DRUG|thiotepa|
218981723|NCT00423514|PROCEDURE|allogeneic bone marrow transplantation|
218981724|NCT00423514|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
218981725|NCT00423514|PROCEDURE|peripheral blood stem cell transplantation|
218981726|NCT04111575|BEHAVIORAL|Music Therapy|Music Therapy
218981727|NCT00003591|DRUG|paclitaxel|
218981728|NCT00003591|RADIATION|radiation therapy|
218981729|NCT02623140|DEVICE|Biofreedom|PCI with Biofreedom stent
218981730|NCT02623140|DEVICE|Orsiro|PCI with Orsiro stent
218981731|NCT00310648|BIOLOGICAL|Influenza vaccine|
218981732|NCT06201663|DRUG|Romiplostim|Weekly subcutaneous injections
218981733|NCT04786938|DRUG|Saccharomyces Boulardii-Containing Product in Oral Dose Form|S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
218981734|NCT02418078|PROCEDURE|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
218981735|NCT01462643|DRUG|LAS41004|once daily, topical ointment, 100 microgram per day
218981736|NCT03569085|DRUG|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
219674644|NCT06369610|PROCEDURE|Positron Emission Tomography|Undergo PET
219674645|NCT06369610|OTHER|Questionnaire Administration|Ancillary studies
219674646|NCT06369610|RADIATION|Radiation Therapy|Undergo radiation therapy
218981737|NCT03569085|DRUG|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
219070734|NCT00891566|PROCEDURE|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
219070735|NCT00982462|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
219070736|NCT00982462|DIETARY_SUPPLEMENT|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
219070737|NCT04021953|BEHAVIORAL|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
219070738|NCT04021953|BEHAVIORAL|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
219070739|NCT02792075|OTHER|5-year Follow-up|
219070740|NCT04838574|OTHER|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
219070741|NCT01573845|BEHAVIORAL|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
219070742|NCT01573845|BEHAVIORAL|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
219070743|NCT03955432|DEVICE|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
219674647|NCT03681184|DRUG|Placebo|Placebo by SC injection
219674648|NCT03681184|DRUG|Lumasiran|Lumasiran by SC injection
219674649|NCT02509793|DRUG|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
219674650|NCT05318833|DRUG|HRS7415|Drug: HRS7415
219674651|NCT00226525|PROCEDURE|skin sensitivity test|
219674652|NCT04968522|DRUG|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
218981738|NCT00607984|DRUG|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
218981739|NCT04330274|OTHER|Bipedal with open eyes|Standing bipedal with open eyes on force platform
218981740|NCT04330274|OTHER|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
218981741|NCT04330274|OTHER|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
218981742|NCT04330274|OTHER|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
219674653|NCT04968522|DRUG|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
219674654|NCT04968522|DRUG|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
219674655|NCT04968522|DRUG|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
219674656|NCT04968522|DRUG|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
219674657|NCT04598295|DRUG|DS-01|synbiotic
219674658|NCT02725437|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection
219674659|NCT02725437|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
219674660|NCT01447641|OTHER|Polysomnography|Overnight physiological recording of sleep
219674661|NCT01447641|OTHER|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
219674662|NCT00343655|DRUG|Atorvastatin|
219674663|NCT00159952|PROCEDURE|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
219674664|NCT00625183|DIETARY_SUPPLEMENT|selenomethionine|
219674665|NCT00625183|DRUG|capecitabine|
219674666|NCT00625183|DRUG|oxaliplatin|
219674667|NCT00625183|OTHER|laboratory biomarker analysis|
219674668|NCT00625183|OTHER|pharmacological study|
219674669|NCT00625183|PROCEDURE|adjuvant therapy|
218981743|NCT04433663|OTHER|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
219674670|NCT00625183|PROCEDURE|neoadjuvant therapy|
219674671|NCT00625183|PROCEDURE|therapeutic conventional surgery|
219674672|NCT00625183|RADIATION|radiation therapy|
219674673|NCT03634527|BEHAVIORAL|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
219674674|NCT03634527|BEHAVIORAL|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
219674675|NCT05506514|OTHER|Water immersion|Comparison of 3 different water temperatures
219674676|NCT06653439|PROCEDURE|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block|Bilateral ultrasound-guided subcostal quadratus lumborum block (20 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
219674677|NCT06653439|PROCEDURE|Control|Patients in this group will not undergo plane blocks. IV morphine PCA multimodal analgesia will be provided: all patients will receive a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated for all patients using a PCA device, programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). Upon arrival in PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW), administered slowly in 50-100 mg doses (max 400 mg/day). All patients will receive IV dexamethasone (8 mg) before induction and IV ondansetron (0.15 mg/kg IBW) near surgery end.
219674678|NCT06653439|DRUG|IV morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). No basal infusion will be used.
219674679|NCT04302480|OTHER|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
219674680|NCT04302480|OTHER|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
219674681|NCT04302480|OTHER|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
219674682|NCT04302480|OTHER|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
218981744|NCT05727436|DIETARY_SUPPLEMENT|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
218981745|NCT05727436|DIETARY_SUPPLEMENT|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
218981746|NCT02437812|DRUG|Metformin|Metformin with standard chemotherapy
218981747|NCT02437812|DRUG|Paclitaxel|Standard chemotherapy
218981748|NCT02437812|DRUG|Carboplatin|Standard chemotherapy
218981749|NCT01132365|DEVICE|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
218981750|NCT04872400|DRUG|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
218981751|NCT04872400|DRUG|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
219070744|NCT01220557|BEHAVIORAL|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
219674683|NCT01990716|OTHER|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
219674684|NCT02704559|DRUG|DWC20155|
219674685|NCT02704559|DRUG|DWC20156|
219674686|NCT03731026|COMBINATION_PRODUCT|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
219674687|NCT03731026|DRUG|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
219674688|NCT00897975|DIETARY_SUPPLEMENT|red yeast rice|600 mg 3 capsules bid
219674689|NCT00897975|DRUG|phytosterol|phytosterol 450 mg 2 tabs bid with food
218981752|NCT01823302|DIETARY_SUPPLEMENT|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
218981753|NCT01823302|OTHER|nutritional counseling|nutritional counseling
218981754|NCT03596008|DIETARY_SUPPLEMENT|Active drink|The freeze-dried strawberry powder (25 g) in active drink
218981755|NCT03596008|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink
218981756|NCT03685123|BEHAVIORAL|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
218981757|NCT03685123|BEHAVIORAL|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
218981758|NCT03685123|BEHAVIORAL|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
218981759|NCT02416219|PROCEDURE|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
218981760|NCT02416219|DEVICE|Ultrasound|
218981761|NCT03555760|BEHAVIORAL|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
218981762|NCT00400764|DRUG|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
218981763|NCT00400764|DRUG|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
218981764|NCT05351021|DRUG|Metformin|cidophage 850 gm twice daily
218981765|NCT05351021|DRUG|Placebo|placebo twice daily for treatment period
218981766|NCT03439917|DIETARY_SUPPLEMENT|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
218981767|NCT03439917|DIETARY_SUPPLEMENT|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
218981768|NCT03439917|DIETARY_SUPPLEMENT|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
218981769|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
218981770|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
218981771|NCT04042896|BEHAVIORAL|exergame|Exergame is 'exercise + game'.
218981772|NCT04042896|BEHAVIORAL|treadmill exercise|traditional aerobic exercise
218981773|NCT02195336|DEVICE|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
218981774|NCT02195336|DRUG|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
218981775|NCT02195336|DRUG|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
218981776|NCT05095038|DIETARY_SUPPLEMENT|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
218981777|NCT05095038|DIETARY_SUPPLEMENT|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
218981778|NCT03308955|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
218981779|NCT03308955|PROCEDURE|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
219674690|NCT00897975|BEHAVIORAL|therapeutic lifestyle program|TLC - 12 weeks
219674691|NCT00897975|DRUG|placebo|placebo
219674692|NCT04318132|DEVICE|Nidek Mirante|The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
218981780|NCT03308955|PROCEDURE|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
218981781|NCT00270335|DRUG|Propofol|
219070745|NCT01220557|BEHAVIORAL|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
219070746|NCT05609578|DRUG|Adagrasib oral dose of 400 mg twice daily tablets|oral dose of 400 mg twice daily tablets
219070747|NCT05609578|COMBINATION_PRODUCT|Pembrolizumab|IV infusion once every 3 weeks
219070748|NCT05609578|COMBINATION_PRODUCT|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
219070749|NCT05609578|COMBINATION_PRODUCT|Cisplatin/Carboplatin|IV infusion once every 3 weeks
219070750|NCT04636190|DEVICE|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
219070751|NCT04849884|DEVICE|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
219070752|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
219070753|NCT02522715|DRUG|Cabazitaxel|Given IV
219070754|NCT02522715|DRUG|Enzalutamide|Given PO
218981782|NCT02628938|OTHER|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
218981783|NCT02628938|OTHER|Miswak stick|Miswak stick twice a day for 7 days
218981784|NCT02628938|OTHER|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
218981785|NCT00529334|RADIATION|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
219070755|NCT02522715|OTHER|Laboratory Biomarker Analysis|Correlative studies
219070756|NCT02522715|OTHER|Pharmacological Study|Correlative studies
219070757|NCT02522715|DRUG|Prednisone|Given PO
219070758|NCT04388982|BIOLOGICAL|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
219070759|NCT04388982|BIOLOGICAL|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
219070760|NCT04388982|BIOLOGICAL|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
219070761|NCT04724317|PROCEDURE|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
219070762|NCT04724317|PROCEDURE|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
219070763|NCT04724317|PROCEDURE|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
219070764|NCT03609827|DRUG|Melphalan|
219070765|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
219070766|NCT03360253|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
219070767|NCT03360253|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
219070768|NCT04537195|BEHAVIORAL|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
219674693|NCT04318132|DEVICE|Optovue RTVue XR Avanti|The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
219674694|NCT04318132|DEVICE|Optos P200DTx|The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
218981786|NCT04234360|DRUG|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
218981787|NCT04234360|DRUG|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
218981788|NCT03064750|BEHAVIORAL|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
218981789|NCT03064750|OTHER|Waiting list|patients wait as usual until surgery without special treatment.
218981790|NCT03585062|DRUG|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
219674695|NCT04638803|DRUG|PRX-P4-003, (-)-FCF|sequential study
218981791|NCT03585062|DRUG|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
218981792|NCT03015857|DRUG|phenylephrine|\- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
218981793|NCT03015857|DRUG|Norepinephrine|\- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
218981794|NCT03015857|DRUG|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
218981795|NCT03015857|DRUG|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
218981796|NCT03015857|DRUG|Placebo (normal saline)|
218981797|NCT02932202|OTHER|Longitudinal Nutritional Counseling|
218981798|NCT02932202|OTHER|Standard Care|
218981799|NCT04584970|DEVICE|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
218981800|NCT04584970|DEVICE|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
218981801|NCT01790854|DRUG|Prasugrel dose 5 mg/day|
218981802|NCT01790854|DRUG|Prasugrel dose 10 mg/day|
219674696|NCT03662815|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
219674697|NCT03662815|OTHER|GM-CSF|immune adjuvant
218981803|NCT02029170|PROCEDURE|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
218981804|NCT02029170|PROCEDURE|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
218981805|NCT06260215|OTHER|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
218981806|NCT05252455|BEHAVIORAL|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
218981807|NCT00246623|DRUG|Exubera (inhaled insulin)|
218981808|NCT00246623|PROCEDURE|8-point glucose diary (to assess pre- and post prandial glucoses)|
218981809|NCT00246623|PROCEDURE|Meal Tolerance Test|
218981810|NCT00246623|PROCEDURE|24-hour continuous glucose monitoring (at select sites)|
218981811|NCT00246623|PROCEDURE|Pulmonary Function Testing|
218981812|NCT00246623|PROCEDURE|Hypoglycemic Event Monitoring|
218981813|NCT00246623|PROCEDURE|Laboratory Assessments|
219674698|NCT00617513|DRUG|Prucalopride|0.5 mg once daily
219674699|NCT00617513|OTHER|Placebo|o.d.
219674700|NCT00617513|DRUG|Prucalopride|1 mg o.d.
219674701|NCT00617513|DRUG|Prucalopride|2 mg o.d.
219674702|NCT02046278|DEVICE|LifeSeal™ Kit|
219674703|NCT04424914|DIAGNOSTIC_TEST|Scintigraphy|scintigraphy
219674704|NCT04485637|OTHER|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
219674705|NCT04485637|OTHER|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
219674706|NCT04485637|OTHER|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
219674707|NCT03173495|DIETARY_SUPPLEMENT|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
219674708|NCT03173495|DIETARY_SUPPLEMENT|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
219674709|NCT03173495|DIETARY_SUPPLEMENT|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
219674710|NCT00674895|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
219674711|NCT01047124|OTHER|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
219674712|NCT02787681|DEVICE|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
219674713|NCT05413473|DEVICE|MR guided radiotherapy|MR guided radiotherapy using the Alberta linac-MR P3 system
219674714|NCT06812832|DRUG|Simethicone 80 MG|Patients will receive simethicone 80mg four times per day for 2 weeks post-operatively.
219674715|NCT06812832|DRUG|Placebo|Patients in the control group will receive a placebo pill four times per day for 2 weeks
219674716|NCT03383692|DRUG|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
219674717|NCT03383692|DRUG|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
219674718|NCT03383692|DRUG|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
219674719|NCT01446250|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
219674720|NCT01446250|DRUG|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
219674721|NCT01446250|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
219674722|NCT01446250|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
219674723|NCT05216458|BEHAVIORAL|Emails and letter intervention|Emails and letters for households assigned to the treatment group
218981814|NCT00246623|BEHAVIORAL|Nutritional Counseling and Diabetes Education|
218981815|NCT04575623|DIAGNOSTIC_TEST|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function."
218981816|NCT04575623|DEVICE|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240."
218981817|NCT00843856|DRUG|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
218981818|NCT00843856|DRUG|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
218981819|NCT06021288|OTHER|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
218981820|NCT04296110|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
218981821|NCT04296110|OTHER|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
218981822|NCT00635375|DEVICE|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
218981823|NCT00635375|DEVICE|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
218981824|NCT00635375|DEVICE|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
218981825|NCT00635375|DEVICE|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
218981826|NCT02866708|DEVICE|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
219070769|NCT03188939|PROCEDURE|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
219070770|NCT03188939|PROCEDURE|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
219070771|NCT03188939|PROCEDURE|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
219070772|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
219070773|NCT00747799|DRUG|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
219070774|NCT03563495|OTHER|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
219070775|NCT03563495|PROCEDURE|autogenous bone graft group|
219070776|NCT03815851|DEVICE|prophylactic drainage|place prophylactic drainage after surgery
219070777|NCT03815851|DEVICE|no prophylactic drainage|Not place prophylactic drainage after surgery
219209065|NCT06762353|PROCEDURE|6-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 6-month frequency after surgical treatment of peri-implantitis.
219209066|NCT06761209|OTHER|blood sampling|For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
219209067|NCT06762106|RADIATION|shockwave therapy|solid unite made with metal frame and case
219209068|NCT06762106|RADIATION|hot back|thermal hot back
219209069|NCT06826261|DEVICE|transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, a frequency of 40 Hz (gamma frequency) is used to enhance oscillatory activity related to cognitive functions often impaired in Alzheimer's disease (AD). The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the one-hour tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
219550220|NCT02286466|BEHAVIORAL|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
219674724|NCT05216458|BEHAVIORAL|Control group|No outreach during the intervention period.
219674725|NCT03600246|DEVICE|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
219674726|NCT02325921|DEVICE|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
219674727|NCT01555710|DRUG|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
219674728|NCT01555710|DRUG|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
219674729|NCT01555710|DRUG|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
219674730|NCT01555710|DRUG|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
219674731|NCT05559944|BEHAVIORAL|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.
219674732|NCT05559944|BEHAVIORAL|Self-Affirmation|Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
219674733|NCT05559944|BEHAVIORAL|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
219674734|NCT06450093|OTHER|Preformed stainless steel crown.|A well-fitted preformed stainless-steel crown will be chosen by measuring the mesiodistal dimension of the tooth or its contralateral counterpart, using a graduated periodontal probe for guidance. (6) Tooth preparation will be carried out with #835 diamond fissure bur to reduce occlusal surface up to 1 to 1.5 mm. The interproximal reduction will be made mesially and distally using #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. The selected crown size will be checked, and a trial fit will be done before cementation. The crown will be cemented using self-cured RMGI luting cement. The excess will be removed, and proper occlusion will be checked.
219674735|NCT06450093|OTHER|Preformed zirconia crown|The material for crown restoration for this group is the preformed zirconia crown. Tooth preparation will be started by occlusal reduction (1 to 1.5 mm) using #835 diamond fissure bur. The interproximal reduction will be done mesially and distally with #169 L tapered diamond bur in such a way that a straight probe passes freely through the contact area. Rounding of line angles will be done and a knife-edge finish margin of the proximal surface will be obtained avoiding any ledge formation. The selected crown will be placed and checked for a passive fit. Consistent firm finger pressure will be applied during cementation with self-cured RMGI luting cement. Finally, crown placement will be checked.
219674736|NCT06450093|OTHER|Preformed BioFlx crown|The prefabricated BioFlx crown will be used in this group. A similar-sized preformed crown will be selected. Tooth preparation will be carried out similarly to traditional SSCs with #835 diamond fissure bur for occlusal reduction by 1-1.5 mm including the central groove. The proximal preparation will be done mesially and distally with #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. Placement of the crown will be achieved by a snug fit. Crown cementation will be carried out using self-cured RMGI luting cement and the excess cement will be removed using a floss or an explorer. (13) Finally, crown placement will be checked
219674737|NCT04184778|DEVICE|Smaller tube size|Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
219674738|NCT02182154|DRUG|BIBF 1120 ES|
219674739|NCT00405847|DRUG|Dexmedetomidine|
219674740|NCT00893971|DRUG|PT001|Inhaled PT001, single dose
219674741|NCT00893971|DRUG|PT005|Inhaled PT005, single dose
219674742|NCT00893971|DRUG|PT003|Inhaled PT003, single dose
219674743|NCT00893971|DRUG|PT001 + PT005|Inhaled PT001 + PT005, single dose
219674744|NCT03116009|DRUG|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
219674745|NCT04910243|OTHER|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
219674746|NCT04183166|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
219674747|NCT02707900|DRUG|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
219674748|NCT02707900|BIOLOGICAL|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
219674749|NCT06434688|OTHER|Mental Fatigue:|The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.
219674750|NCT06434688|OTHER|Body Awareness:|"Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~\- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~\- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception."
219674751|NCT06434688|OTHER|Neck Disability Level|Neck disability index will be used to assess this parameter.
218981827|NCT05807230|BEHAVIORAL|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
218981828|NCT04597775|DRUG|hydroxychloroquine|hydroxychloroquine
218981829|NCT03042325|DRUG|Alogliptin|Alogliptin tablets
218981830|NCT02318537|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
218981831|NCT02318537|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol.
218981832|NCT02000934|DRUG|TAK-659|TAK-659 tablet
218981833|NCT05592262|DRUG|SHR2554|On an empty stomach - after meals
218981834|NCT05592262|DRUG|SHR2554|After meals - on an empty stomach
219070778|NCT04360148|DIETARY_SUPPLEMENT|very-low-calorie-ketogenic-diet|VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
219070779|NCT04360148|OTHER|hypocaloric-balanced-diet|HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
219070780|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
219070781|NCT06118814|OTHER|Body Awareness Therapy Exercise|Body awareness therapy exercises were applied to the subjects in this group.
219070782|NCT06118814|OTHER|Virtual Reality Exercise|Virtual reality exercises were applied to the subjects in this group.
219070783|NCT06118814|OTHER|Core Stability Exercise|Core stabilization exercises were applied to the subjects in this group.
219070784|NCT06118814|OTHER|Home Exercise|Subjects in this group implemented a home exercise program.
219070785|NCT03772990|DRUG|Calcium Chloride|Calcium Chloride
219070786|NCT03772990|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride
219070787|NCT04508322|DEVICE|HGA|Headgear Activator
219070788|NCT04508322|DEVICE|FA|Fixed Orthodontic Appliance
219070789|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
219070790|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
219070791|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
219070792|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
219070793|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
219070794|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
219070795|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
219070796|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
219070797|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
219070798|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
219070799|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
219070800|NCT03266250|PROCEDURE|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
219070801|NCT05503108|OTHER|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
219070802|NCT00063947|DRUG|erlotinib hydrochloride|Given orally
219070803|NCT00063947|DRUG|gemcitabine hydrochloride|Given IV
219070804|NCT00063947|RADIATION|radiation therapy|Undergo radiotherapy
219550221|NCT01276496|DRUG|Cilengitide|Given IV
219550222|NCT01276496|OTHER|Laboratory Biomarker Analysis|Correlative studies
219070805|NCT00063947|OTHER|laboratory biomarker analysis|Correlative studies
219070806|NCT02311179|DEVICE|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
219070807|NCT02311179|DEVICE|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
219070808|NCT04177758|DRUG|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
219070809|NCT04177758|DRUG|Control|Patients randomized to the control will receive a placebo
219070810|NCT05788549|BEHAVIORAL|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
219550223|NCT01276496|DRUG|Paclitaxel|Given IV
219550224|NCT01276496|OTHER|Pharmacological Study|Correlative studies
219674752|NCT06434688|OTHER|Quality Of Life|SF-12 will be used to assess quality of life.
219070811|NCT05788549|BEHAVIORAL|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
219070812|NCT00010491|PROCEDURE|Acupuncture|
219674753|NCT06434688|OTHER|Pain Assessment:|Pain intensity will be assessed by Visual Analog Scale (VAS). In addition, pain duration and pain frequency will be questioned. The Pain Self-Efficacy Questionnaire will be used to assess the confidence of people with chronic pain to perform certain tasks and behaviors despite their pain.
219070813|NCT00010491|PROCEDURE|Moxibustion|
219070814|NCT02574546|PROCEDURE|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
219070815|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
219070816|NCT03441425|OTHER|Unexpected death|
219070817|NCT03119857|DRUG|Antiandrogen|
219070818|NCT03119857|DRUG|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
219070819|NCT04383912|DRUG|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
219070820|NCT04383912|OTHER|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
219070821|NCT05715580|OTHER|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
219070822|NCT05715580|OTHER|Usual clinical practice|Nursing information following the usual clinical practice
219070823|NCT04465006|OTHER|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
219070824|NCT04465006|OTHER|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
219070825|NCT02571569|DRUG|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
219674754|NCT06434688|OTHER|Physical Condition:|"Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated."
219674755|NCT06434688|OTHER|Anxiety and Depression:|Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.
219674756|NCT00004832|DRUG|3,4-diaminopyridine|
219674757|NCT02328573|BEHAVIORAL|Communal singing|
219674758|NCT06263426|OTHER|HIV D+/R+|Receipt of kidney transplant from a deceased donor with HIV.
219674759|NCT06263426|OTHER|HIV D-/R+|Receipt of kidney transplant from a deceased donor without HIV.
219674760|NCT00170014|DEVICE|Magnetocardiograph|
219674761|NCT00623389|DEVICE|IST (Implanted Stimulator-Telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode and IST- implanted pulse generator insertion, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
219674762|NCT04285216|OTHER|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
219674763|NCT04285216|OTHER|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
219674764|NCT02945696|PROCEDURE|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
219674765|NCT02945696|DRUG|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
219209070|NCT06826261|DEVICE|sham transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, the stimulation will be delivered in 'sham' mode which is characterized by 30 seconds of tACS stimulation at the beginning and end of the protocol to help with blinding. During the rest of the stimulation period (1h) no stimulation will be delivered. The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the sham tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
219209071|NCT06816056|OTHER|Manual Therapy|The patients included in the experimental group will receive a 50-minute physiotherapy intervention involving global passive mobilisation, calcaneocuboid mobilisation, talus-navicular mobilisation, talar manipulation, tibial displacement manipulation, tibiotarsal decompression, plantar fascia induction, tibiotarsal unwinding and triceps surae induction techniques
219209072|NCT06816056|OTHER|Placebo|The patients included in the control group will receive a 50-minute physiotherapy intervention in which the physiotherapist's hands and the times per technique will be the same as in the experimental group, but without applying any sliding, mobilisation or manipulation
219674766|NCT06668103|DRUG|ABSK043 in combination with Firmonertinib|"Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
219209073|NCT06855940|OTHER|Bleaching Agents|whitening agent containing fluoride and 40% hydrogen peroxide
219209074|NCT06855940|OTHER|Bleaching Agents|whitening agent containing calcium and 35% hydrogen peroxide
219209075|NCT06855940|OTHER|Bleaching Agents|whitening agent containing hydroxyapatite and 18% hydrogen peroxide
219674767|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
219674768|NCT05512741|OTHER|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
219674769|NCT06080165|DRUG|Sirolimus|Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
219674770|NCT06080165|DRUG|Placebo|matching placebo
219674771|NCT07013617|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Each participant will receive 20 minutes of TENS, Electrodes will be positioned around the patella with a 5 - 7 cm distance in between, The TENS settings include a continuous asymmetric biphasic square-pulse wave, a pulse width of 120 microseconds, and a pulse rate of 180 Hz.
219674772|NCT07013617|OTHER|Strength exercises for lower limb|Each participant will receive progressive strengthening program targeting the hip and knee, begin with 3 sets of 10 repetitions and progress to 3 sets of 20 repetitions.
218981835|NCT01893203|DRUG|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
218981836|NCT01893203|DRUG|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
219070826|NCT02571569|DRUG|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
219070827|NCT01815177|DEVICE|Arthroscopic transosseous fixation|
219070828|NCT01815177|DEVICE|Suture anchors|
219070829|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
219070830|NCT02157038|DEVICE|Pedometer|
219070831|NCT02157038|DEVICE|MRI|
219070832|NCT04208022|OTHER|Respiratory evaluation|Hypermobility and Respiratory evaluation
219070833|NCT01986257|BEHAVIORAL|Emotion Regulation Group Therapy (ERGT).|
219070834|NCT03557437|DRUG|Esomeprazole|Proton pump inhibitor
219070835|NCT03557437|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
219070836|NCT03557437|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219209076|NCT06588231|BEHAVIORAL|Individual rehabilitation exercise training|Under the guidance of a specialist, medium-and high-intensity interval training was conducted for 16 weeks, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period, during which the exercise included 4 intervals, with the 85-95% pre intensity of HR reserve for 15-18 minutes, and then with the 50-70% pre intensity of HR reserve for 12-14 minutes, exercise for 3 minutes, and so on for 4 times. Warm-up and cooling-off periods can be done through stretching exercises, flexibility exercises (that is, neck, shoulders, upper back, buttocks and ankles) and low and medium intensity (50-70% heart rate reserve)
219209077|NCT06588231|DRUG|optimal medical therapy ：aspirin, clopidogrel, statins.|those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
219209078|NCT06755957|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise and postural correction exercise will be applied.
219209079|NCT06755957|OTHER|CONTROL|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise will be applied.
219209080|NCT06511843|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
219674773|NCT07013617|OTHER|Hamstring Stretch Muscle Energy Technique(MET) (General )|The participant will be supine and the leg will be taken into hip flexion until a tightness is felt then patient will be asked to push down with his lower leg and hold the contraction for 10 seconds then relax for 2 to 3 seconds then the therapist will take the patient's leg into further flexion for 30 seconds this will be repeated for 3 times each session .
219674774|NCT07013617|OTHER|Medial Hamstring Muscle energy technique(MET) stretch|The Participant will be supine' then the therapist will take his leg in flexion, abduction and external rotation at the same time until he feels tightness then he will ask the patient to push his leg down and in or toward him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more abduction 'external rotation and flexion for 30 seconds, this will be repeated for 3 times each session
219070837|NCT06257069|DEVICE|Tremor Retrainer Smartphone Application|The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
219070838|NCT06161987|BEHAVIORAL|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
219070839|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
219070840|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
219070841|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
219070842|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
219070843|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
219070844|NCT01290367|PROCEDURE|Single injection of saline solution|Intradiscal control injection with saline solution
219070845|NCT01290367|PROCEDURE|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
219070846|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
219209081|NCT06511843|BEHAVIORAL|Lyrical Music|"A 4-minute audio recording of Leonard Cohen's song Hallelujah sung by Rufus Wainwright with choral accompaniment."
219209082|NCT06511843|BEHAVIORAL|Instrumental Music|A 4-minute audio recording of instrumental, theta wave music.
219209083|NCT06769958|BEHAVIORAL|Reflexology|Reflexology application
219209084|NCT06883604|RADIATION|Proton therapy.|Pencil beam scanning proton therapy to a dose of 20 or 29.75 Gy (RBE) after standard chemotherapy (2-4 ABVD).
219209085|NCT06734559|DIAGNOSTIC_TEST|Patients who have not antibiotic treatment for acute apical periodontitis in the last month and have not taken any anti-inflammatory medication in the past 24 hours.|Patients with acute apical periodontitis will first have masseter muscle measurements in the relevant area and then the decayed tooth will be treated with calcium hydroxide for 14 days. Then the dressing will be applied with calcium hydroxide again. At the end of 28 days, the patient will be measured again by ultrasonography and the initial and final data will be compared.
219674775|NCT07013617|OTHER|Lateral hamstring Muscle Energy Technique(MET)Stretch|The Participant will be supine' then the therapist will take his leg in flexion, adduction and internal rotation at the same time until he feels a tightness then he will ask the patient to push his leg down and out or away from him him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more adduction 'internal rotation and flexion for 30 seconds, this will be repeated for 3 times each session
219674776|NCT02380118|DRUG|Olanzapine|Intramuscular injection
219674777|NCT02380118|DRUG|Haloperidol|Intramuscular injection
219674778|NCT02380118|DRUG|Midazolam|Intramuscular injection
218981837|NCT05522452|OTHER|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
219209086|NCT06734559|OTHER|patients who have not acute apical periodontitis|Masseter measurements will be made from day 1 to day 28 in healthy subjects without acute apical periodontitis.
218981838|NCT05522452|OTHER|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
218981839|NCT00621959|DRUG|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
218981840|NCT00621959|DRUG|placebo|0mg (matching oral tablet)for 14 days
218981841|NCT03465358|OTHER|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
218981842|NCT01758523|DRUG|Dutasteride|
218981843|NCT01758523|DRUG|sugar pill|
218981844|NCT02985437|DRUG|Surfactants|
218981845|NCT02985437|DRUG|Saline Solution|
218981846|NCT05101642|PROCEDURE|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
218981847|NCT01847742|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|
218981848|NCT00590135|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
218981849|NCT06263556|BEHAVIORAL|Pelvic floor exercises|"Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day"
218981850|NCT06263556|DEVICE|Transcutaneous posterior tibial nerve stimulation|Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
218981851|NCT06263556|DEVICE|Sham stimulation|Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
218981852|NCT05100901|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
218981853|NCT02652065|OTHER|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
218981854|NCT02652065|OTHER|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
218981855|NCT02652065|OTHER|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
218981856|NCT02652065|OTHER|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
218981857|NCT04729621|COMBINATION_PRODUCT|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
218981858|NCT04729621|COMBINATION_PRODUCT|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
218981859|NCT03439657|BIOLOGICAL|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
218981860|NCT03439657|BIOLOGICAL|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
218981861|NCT02592525|BEHAVIORAL|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
218981862|NCT02245984|OTHER|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
218981863|NCT02245984|OTHER|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
218981864|NCT02489760|BIOLOGICAL|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
219674779|NCT07019441|OTHER|Daily-Activity-Focused, Strategy-Based Educational Program|The proposed Educational Program will have one face-to-face education session and three follow-up telephone support sessions. Strategies to assist the people with dementia with daily activities, developed from our prior work, have been compiled into a Strategies Package. Healthcare professionals will deliver the program and work collaboratively with the carers to identify issues that arise during caregiving and problem-solve using the strategies included in the package. Carers are provided with support and are encouraged to locate an appropriate strategy using the Strategies Package to help them assist in a daily task in which they want their care recipient to engage.
219674780|NCT07019441|OTHER|Usual Carer support|This group will receive emotional support from trainers on the caring issues raised. It will include the same number of sessions as in the experimental group.
219674781|NCT05432895|DEVICE|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
219674782|NCT07021625|DEVICE|Kunbot|A chatbot designed based on cognitive behavioral therapy for insomnia
219674783|NCT07021625|OTHER|Treatment as usual|Treatment as usual
218981865|NCT02489760|BIOLOGICAL|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
218981866|NCT03526575|DRUG|Zolpidem|
218981867|NCT00065988|DEVICE|Dispersed phase amalgam restoration /composite restoration|
218981868|NCT05221710|BEHAVIORAL|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
218981869|NCT04980781|BEHAVIORAL|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
218981870|NCT04980781|PROCEDURE|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
218981871|NCT01910948|DRUG|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
218981872|NCT00000546|BEHAVIORAL|meditation|
218981873|NCT05827731|BEHAVIORAL|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
218981874|NCT01354587|DRUG|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
218981875|NCT00193258|DRUG|Bevacizumab|10mg/kg IV infusion every 2 weeks
218981876|NCT00193258|DRUG|Erlotinib|150 mg po daily
218981877|NCT00193258|DRUG|Imatinib|400-600mg daily
218981878|NCT04094129|DIETARY_SUPPLEMENT|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
218981879|NCT04094129|DIETARY_SUPPLEMENT|Placebo|placebo
218981880|NCT02394483|DRUG|F901318 safety|Safety assessments
218981881|NCT02394483|DRUG|F901318 tolerability|Tolerability assessments
218981882|NCT02394483|DRUG|F901318 pharmacokinetics|Pharmacokinetic assessments
218981883|NCT02394483|OTHER|Placebo safety|Safety assessments
218981884|NCT02394483|OTHER|Placebo tolerability|Placebo tolerability
218981885|NCT02394483|OTHER|Placebo pharmacokinetics|Plaacebo pharmacokinetics
218981886|NCT05353179|DRUG|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
218981887|NCT05353179|DRUG|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
218981888|NCT04273373|BIOLOGICAL|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
218981889|NCT04273373|BIOLOGICAL|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
218981890|NCT03698409|DRUG|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
218981891|NCT00219973|DRUG|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
218981892|NCT05460260|DEVICE|Cascade CGM|21-days of CGM wear
218981893|NCT01393223|DRUG|LP-08 80mg|Intravesical instillation of 80mg LP08
218981894|NCT01393223|DRUG|Normal saline|Intravesical instillation of normal saline
218981895|NCT01393223|DRUG|LP-08 20mg|Intravesical instillation of 20mg LP08
218981896|NCT00370071|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
218981897|NCT02741856|DRUG|Carboplatin|For more information please see the arm descriptions section.
218981898|NCT02741856|DRUG|Paclitaxel|For more information please see the arm descriptions section.
218981899|NCT02741856|DRUG|Cisplatin|For more information please see the arm descriptions section.
218981900|NCT02741856|DRUG|Capecitabine|For more information please see the arm descriptions section.
218981901|NCT02741856|RADIATION|Radiotherapy|For more information please see the arm descriptions section.
218981902|NCT04053231|OTHER|liver resection|all type of liver surgical procedures
218981903|NCT01196507|DRUG|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
218981904|NCT01196507|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
219070847|NCT03013010|DRUG|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
219070848|NCT03013010|RADIATION|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
219070849|NCT03013010|PROCEDURE|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
219070850|NCT03013010|DRUG|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
218981905|NCT00229073|DRUG|dapoxetine|
218981906|NCT00194883|DRUG|Recombinant Human Growth Hormone|
218981907|NCT06556901|OTHER|retrospective study about reasons for consultations|retrospective study about reasons for consultations
218981908|NCT03175978|DRUG|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
218981909|NCT06142708|DRUG|Dual trigger (human chorionic gonadotropin plus GnRH-agonist)|Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
218981910|NCT06142708|DRUG|GnRH-agonist only trigger|GnRH-agonist only will be used for final maturation
218981911|NCT01999868|BIOLOGICAL|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab."
218981912|NCT01999868|BIOLOGICAL|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
218981913|NCT01999868|DRUG|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
218981914|NCT01999868|DRUG|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
218981915|NCT00391729|DRUG|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
218981916|NCT00391729|DRUG|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
218981917|NCT03831789|DEVICE|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
218981918|NCT05239442|OTHER|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
218981919|NCT05239442|OTHER|Evaluation of the taste commissions|"At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
218981920|NCT05239442|OTHER|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
218981921|NCT02956031|OTHER|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
218981922|NCT02956031|OTHER|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
218981923|NCT02956031|PROCEDURE|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
218981924|NCT00502944|BEHAVIORAL|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
218981925|NCT00502944|BEHAVIORAL|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
218981926|NCT04734938|DIETARY_SUPPLEMENT|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
218981927|NCT02921542|DEVICE|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
218981928|NCT00310401|DRUG|Albuterol|5 mg nebulized q4h
219070851|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
219070852|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
219070853|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
218981929|NCT00310401|DRUG|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
219070854|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
219070855|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
219674784|NCT07021833|DEVICE|Cryosa Procedure|The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).
219674785|NCT07022197|DRUG|BAFF-R CART|"Biological: BAFF-R CART cells Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture BAFF-R CART cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with BAFF-R CART cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CART cells/kg will be infused on day 0.~Drug: Cyclophosphamide and fludarabine Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to BAFF-R CART cells infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 250 mg/m2/day on day -5, -4 and -3, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
219674786|NCT07021755|OTHER|midazolam|
219674787|NCT07022990|OTHER|Educational brochure for deprescribing|"Study participant will be provided information (i.e., educational brochure) about one of the five medication classes participants may be taking that are known to have potential side effects for older adults: proton pump inhibitors (PPIs), benzodiazepine (BZs) and non-benzodiazepine sedative hypnotics (Z-drugs), first-generation antihistamines (FGA), and skeletal muscle relaxants (SMR) to determine their necessity."
219674788|NCT07022288|OTHER|LA ROCHE-POSAY CICAPLAST BALM, Standard cream|"After enrollment, the investigator will generate random serial numbers for grouping through simple randomization.~LA ROCHE-POSAY CICAPLAST BALM：8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period.~Standard cream:8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period."
219674789|NCT07021391|BEHAVIORAL|Primary care healthy food prescription plus incentive|Primary care healthy food prescription with $40 monthly incentive for four months to purchase 2 and 3 starred (via Guiding Stars) groceries at the supermarket
219674790|NCT07021508|DEVICE|Temporal Interference Stimulation|A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
219674791|NCT07021508|DEVICE|Sham Temporal Interference Stimulation|The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.
219674792|NCT07027462|DIETARY_SUPPLEMENT|Mushroom blend|A mushroom blend that is targeted to improve gastrointestinal symptoms.
219674793|NCT07027462|OTHER|Placebo|Placebo product.
219674794|NCT07026903|BEHAVIORAL|resistance exercise and calorie restrictive diet|experimental group will be randomized to isCGM during the lifestyle intervention trial while control group will participate in the same lifestyle intervention but will not use isCGM
218981930|NCT05073601|DIAGNOSTIC_TEST|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (\> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
218981931|NCT00760422|DEVICE|NIR|Thermometer
218981932|NCT00037804|DRUG|Irinotecan|
218981933|NCT03925857|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
218981934|NCT03585231|BEHAVIORAL|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
218981935|NCT03585231|BEHAVIORAL|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
218981936|NCT03585231|BEHAVIORAL|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
218981937|NCT01203631|DRUG|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
218981938|NCT01203631|DRUG|Placebo|A single dose administered subcutaneously (s.c., under the skin)
218981939|NCT00289016|DRUG|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
218981940|NCT00319501|DRUG|Placebo|Intramuscular autoinjector; administered at onset of an episode
218981941|NCT00319501|DRUG|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
218981942|NCT00561457|DEVICE|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
218981943|NCT03360604|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
218981944|NCT03360604|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
218981945|NCT05462483|OTHER|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
218981946|NCT01951937|DIETARY_SUPPLEMENT|Fish Meals|Meals containing salmon
218981947|NCT01951937|DIETARY_SUPPLEMENT|Placebo|No fish meals
218981948|NCT06068608|DRUG|TNM005|single,intramuscular injection
218981949|NCT06068608|DRUG|Placebo|single,intramuscular injection
218981950|NCT06068608|DRUG|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
219070856|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
219070857|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
218981951|NCT04412434|DIAGNOSTIC_TEST|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
218981952|NCT04209192|DRUG|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
219070858|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
219070859|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
219070860|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
219070861|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
219070862|NCT02009475|OTHER|Interval exercise training|
219070863|NCT02009475|OTHER|Continues aerobic training|
219070864|NCT00034034|PROCEDURE|Acupuncture|
219070865|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
219070866|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
219070867|NCT05911854|DEVICE|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
219070868|NCT05911854|DEVICE|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
219070869|NCT05911854|OTHER|complete decongestive therapy|"Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
219070870|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
219070871|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
219070872|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
219070873|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
219070874|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
219209087|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Active comparator|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10
219209088|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Experimental product|Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10
218981953|NCT04209192|DRUG|Amikacin|Is the prophylactic drug which will be used in the control group.
218981954|NCT02298530|OTHER|Combination of caffeine and theanine|Beverage containing caffeine and theanine
218981955|NCT02298530|OTHER|Caffeine|Beverage containing caffeine
218981956|NCT05393674|DRUG|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
218981957|NCT05393674|DRUG|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
218981958|NCT03097913|DEVICE|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
218981959|NCT01214343|DRUG|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
218981960|NCT01214343|DRUG|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
218981961|NCT01264783|DRUG|RNS60|RNS60 for intravenous administration
219209089|NCT06891690|OTHER|tDSC stimulation|tDCA stimulation not exceeding 2 mA
219209090|NCT06892717|OTHER||
219209091|NCT06749015|OTHER|Non interventional study|Non interventional study
219674795|NCT02453256|DRUG|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
219674796|NCT02453256|DRUG|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
219674797|NCT07022366|DRUG|Pimavanserin 10mg|Single dose of pimavanserin (10mg)
219674798|NCT07022366|DRUG|Placebo|Sucrose tablet
218981962|NCT01264783|DRUG|Placebo|0.9% normal saline for injection
218981963|NCT05491720|DRUG|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
219070875|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
219070876|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
219070877|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
218981964|NCT05491720|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
218981965|NCT05491720|DRUG|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
218981966|NCT05491720|DEVICE|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
218981967|NCT00555451|DRUG|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
218981968|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
218981969|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
218981970|NCT03549169|BEHAVIORAL|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
218981971|NCT03549169|BEHAVIORAL|Regular attention|Regular attention focused on education for therapeutic adherence
218981972|NCT06254651|OTHER|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
218981973|NCT06254651|OTHER|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
218981974|NCT00003433|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
218981975|NCT02242266|DRUG|Tiotropium low dose|inhalation powder, hard PE capsule
218981976|NCT02242266|DRUG|Tiotropium medium dose|inhalation powder, hard PE capsule
218981977|NCT02242266|DRUG|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
218981978|NCT02242266|DRUG|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
218981979|NCT02242266|DRUG|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
218981980|NCT00499499|DRUG|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
218981981|NCT03854188|PROCEDURE|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
218981982|NCT01209728|OTHER|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
218981983|NCT05805930|DRUG|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
218981984|NCT05805930|DRUG|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
218981985|NCT02764697|DRUG|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
219070878|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
219070879|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
219070880|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
219070881|NCT03891810|BEHAVIORAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
219070882|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
219070883|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
219070884|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
219070885|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
219070886|NCT01920295|DEVICE|Cryoballoon ablation|
219070887|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
219070888|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
219070889|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
219070890|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
219070891|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
219070892|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
219070893|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
219070894|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
219070895|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
219070896|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
219070897|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
219070898|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
219070899|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
219674799|NCT07023185|DEVICE|Cold and Compression|External mechanical compression therapy (e.g., compression stockings) has been shown to reduce swelling and risk of deep vein thrombosis in the lower limbs following TKA.12,13 Combining advanced cryotherapy (continuous circulating cold flow) and dynamic compression may offer added benefits than either traditional cryotherapy (e.g., cold packs) or compression (e.g., stockings) alone.
219674800|NCT07023185|OTHER|SOC (Standard of care)|Patients enrolled in this arm will be discharged with 28 hydrocodone/APAP 7.5 mg pills taken every 6 hours as needed (or its MME equivalent), 1 identical refill if patient calls, and cold therapy (bag of ice or gel pack)
219674801|NCT07022301|DRUG|sintilimab combined with anlotinib|Patients who met the inclusion criteria were treated with Sintilimab plus anlotinib every 3 weeks until disease progression or intolerable adverse reactions or death(up to 24 months).
219674802|NCT07021612|DEVICE|JenaValve|JenaValve is a newly developed advanced TAVI system developed by Jenavalve Technology Inc.
219674803|NCT07021612|DEVICE|J-Valve|J-Valve is a newly developed advanced TAVI system developed by Genesis Medtech.
219674804|NCT02034760|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
219070900|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
219070901|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
219070902|NCT00726752|DRUG|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
219070903|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
219070904|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
219070905|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
219070906|NCT02590718|PROCEDURE|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
219070907|NCT01665235|DRUG|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
219070908|NCT01665235|DRUG|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
219070909|NCT01665235|DRUG|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
219674805|NCT02034760|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
219070910|NCT01665235|DRUG|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
219070911|NCT03570398|OTHER|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
219070912|NCT03570398|OTHER|abdominal ultrasound|abdominal ultrasound
219070913|NCT01472198|DRUG|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
219070914|NCT01472198|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
219070915|NCT01472198|DRUG|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
219070916|NCT05596305|BEHAVIORAL|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
219070917|NCT03344679|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
219070918|NCT03344679|DRUG|Adenosine 12mg|Adenosine 12 mg for PECS block
219674806|NCT02034760|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
219674807|NCT02034760|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
219674808|NCT02034760|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
219674809|NCT01239082|PROCEDURE|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
219674810|NCT01239082|PROCEDURE|FIT|Annual FIT testing
219674811|NCT06887413|PROCEDURE|THROMBOASPIRATION WITH INDIGO SYSTEM|Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.
219674812|NCT06771102|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
219674813|NCT06771102|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
219674814|NCT00049075|DRUG|fludarabine phosphate|
219674815|NCT01540136|DRUG|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
219674816|NCT01540136|DRUG|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
219674817|NCT04338191|DRUG|mFOLFOXIRI adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
218981986|NCT02511990|BIOLOGICAL|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
218981987|NCT02511990|BIOLOGICAL|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
218981988|NCT02511990|BIOLOGICAL|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
218981989|NCT04410029|OTHER|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
218981990|NCT04410029|OTHER|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
218981991|NCT03901885|OTHER|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
218981992|NCT03866460|DIAGNOSTIC_TEST|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
218981993|NCT03550664|DEVICE|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
218981994|NCT00302107|DRUG|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
218981995|NCT00302107|DRUG|Placebo|Look-a-like placebo tablets under double-blind conditions
218981996|NCT00400283|DRUG|NNC 55-0414|
218981997|NCT03206411|DIAGNOSTIC_TEST|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
218981998|NCT04112407|DEVICE|Blue Light Phototherapy|Phototherapy in the blue light spectrum
218981999|NCT04112407|DRUG|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
218982000|NCT04112407|OTHER|Control|Standard surgical site preparation with no P. acnes pretreatment
218982001|NCT01595633|DRUG|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
218982002|NCT00431288|BEHAVIORAL|diet high in fruits, vegetables, and dairy|
218982003|NCT00431288|OTHER|Routine nutrition care|
218982004|NCT01790932|DRUG|BKM120|
218982005|NCT04185064|DEVICE|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
218982006|NCT04185064|OTHER|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
218982007|NCT06404671|PROCEDURE|Delayed interval cytoreductive surgery (DICS)|"patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
218982008|NCT06404671|PROCEDURE|Early interval cytoreductive surgery (EICS)|"patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
218982009|NCT04665856|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
218982010|NCT04665856|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
218982011|NCT04665856|DRUG|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
218982012|NCT04665856|DRUG|Etoposide|Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
219070919|NCT03344679|DRUG|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
219070920|NCT04473885|OTHER|Perturbation-based balance training|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
219070921|NCT04811430|DEVICE|Randomized Traditional|Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients
219070922|NCT04811430|DEVICE|Cue(TM) Needle Tracking Technology|Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
219070923|NCT02676102|BEHAVIORAL|Control Group|Generic Video about organ donation
219070924|NCT02676102|BEHAVIORAL|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
219070925|NCT02676102|BEHAVIORAL|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
219070926|NCT00976599|DRUG|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
219070927|NCT00976599|DRUG|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
219070928|NCT00791765|BIOLOGICAL|Etanercept|Etanercept for subcutaneous injection.
219070929|NCT00791765|BIOLOGICAL|Placebo|Placebo for subcutaneous injection.
219070930|NCT03037710|DEVICE|HealthPatch|A multi-sensor device to collect continuous vital signs
219674818|NCT04338191|DRUG|mFOLFOX6 adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
219674819|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
219674820|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
219674821|NCT06258187|DEVICE|Pedi-Cap|The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
219070931|NCT05309304|DRUG|Cefazolin|Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
219070932|NCT01877408|PROCEDURE|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
219070933|NCT01877408|DEVICE|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
219070934|NCT06832007|DEVICE|AYO light glasses (experimental)|OUD patients are asked to wear AYO light therapy glasses (wavelength 470nm ± 2nm, irradiance 250 μW/cm2 or approx.1500 m-EDI) daily for 30 min after habitual wake-up times for two weeks.
219070935|NCT06832007|DEVICE|AYO light glasses (comparator)|The comparison group will wear the same AYO glasses but with lower intensity (1% light intensity) compared to the experimental group. This group will also self-administer 30 min of light from commercially available light glasses each morning for two weeks
219070936|NCT00156065|DRUG|Haloperidol|2-8 mg BID
219070937|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
219070938|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
219674822|NCT05304494|OTHER|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
219674823|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
219070939|NCT02675361|BEHAVIORAL|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
219070940|NCT04341701|PROCEDURE|MRI|The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
219070941|NCT04225208|DRUG|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
219070942|NCT04473131|OTHER|No intervention|Only blood samples will be taken from participants for this study
219070943|NCT04757623|PROCEDURE|Purse string closure of Ileostomy|conventional proceedure
219070944|NCT05695365|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
219674824|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
219674825|NCT01934127|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
219674826|NCT02787733|DIETARY_SUPPLEMENT|Citrus flavonoid|Daily dose of 500mg divided over two capsules
219674827|NCT02787733|DIETARY_SUPPLEMENT|Placebo|Daily dose of 500mg divided over two capsules
219674828|NCT00429611|PROCEDURE|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
219674829|NCT03203174|DEVICE|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
219674830|NCT03203174|DEVICE|Sham Microneedle|Flat roller with no needles on the roller
219674831|NCT03203174|DRUG|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
219674832|NCT03203174|OTHER|Saline|Saline applied to the palm
219674833|NCT05903040|DRUG|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
219674834|NCT05729581|BEHAVIORAL|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
219674835|NCT05933564|OTHER|No intervention (cross-sectional study)|This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
219674836|NCT01366638|DRUG|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
219674837|NCT01366638|DRUG|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
219674838|NCT01366638|DRUG|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
219674839|NCT06406413|DIAGNOSTIC_TEST|micro-movement; electroencephalogram; MRI|micro-movement; electroencephalogram; MRI
218982013|NCT04665856|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
219070945|NCT04942171|PROCEDURE|Atrial fibrillation catheter ablation group|"1. Pulmonary vein isolation~2. Additional treatment for lesions caused by non-pulmonary veins~3. Esophageal temperature monitoring to prevent damage to the esophagus~4. Evaluation of procedure time and radiofrequency ablation time~5. Evaluation of complications after the procedure~6. Rhythm follow-up after the procedure is conducted in accordance with the above study design.~7. Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
219070946|NCT04942171|DRUG|Medical therapy group|"1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
219070947|NCT02417038|DEVICE|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
219674840|NCT04074382|OTHER|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
219674841|NCT04074382|OTHER|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
219674842|NCT01237327|DRUG|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
218982014|NCT04223973|DEVICE|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM (Continuous Glucose Measurement)
219070948|NCT00920426|DRUG|GSK1265744 30mg|GSK1265744 30 mg
219070949|NCT00920426|DRUG|Placebo|Placebo to match GSK1265744
219070950|NCT00920426|DRUG|GSK1265744 5mg|GSK1265744 5mg
219070951|NCT01292603|DRUG|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
218982015|NCT04223973|BIOLOGICAL|Lab A1C|Measure of Lab A1C at baseline and end of study
219674843|NCT01237327|DRUG|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
219674844|NCT04772521|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
219674845|NCT04772521|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
219674846|NCT04772521|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
219674847|NCT04772521|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
219674848|NCT04772521|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
219674849|NCT04233671|BEHAVIORAL|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
219674850|NCT04517773|OTHER|writting test|Patients will be invitated to fill a questionary about self-autonomy
219674851|NCT02483572|BEHAVIORAL|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
219674852|NCT03350204|PROCEDURE|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
219674853|NCT03350204|OTHER|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
219674854|NCT05837702|PROCEDURE|ESPB|Erector spinae plane block
219674855|NCT05837702|PROCEDURE|PVB|Paravertebral Block
219674856|NCT05837702|PROCEDURE|CONTROL|No block has been done
219674857|NCT01065064|PROCEDURE|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
219674858|NCT06719232|DEVICE|Catheter-Free Intravesical Instillation with a special syringe adapter|The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
218982016|NCT06966544|OTHER|Conventional Physiotherapy|"All subjects to be included in our study were evaluated before and after treatment by a physiotherapist acting as a blinded evaluator. In the treatment, conventional physiotherapy approaches are applied twice a week for 8 weeks by the physiotherapist conducting the thesis study. In parallel with the initial evaluation, an individualized conventional physiotherapy program is created according to the functional status of the children and the severity and type of the affected area.~The main topics of this program consist of the following: Normal range of motion exercises for shoulder, elbow, wrist and fingers, strengthening exercises for scapulothoracic, shoulder, elbow, hand-wrist joints in all directions, stretching exercises for shoulder, elbow, wrist, fingers (to be selected depending on the patient's involvement), scapulothoracic mobilization, glenohumeral mobilization and elbow according to possible limitations, hand-wrist joint mobilization techniques (myofascial release, gliding"
219070952|NCT01292603|DRUG|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
219070953|NCT01292603|DRUG|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
219070954|NCT01292603|DRUG|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
219070955|NCT01292603|DRUG|rituximab [MabThera]|6 cycles of intravenous MabThera
219674859|NCT02163642|DEVICE|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
219674860|NCT05052697|BIOLOGICAL|mIRV|Intramuscular injection
219674861|NCT05052697|BIOLOGICAL|bIRV AB|Intramuscular injection
219674862|NCT05052697|BIOLOGICAL|qIRV|Intramuscular injection
219674863|NCT05052697|BIOLOGICAL|QIV|Intramuscular injection
219070956|NCT03282981|DRUG|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
219070957|NCT03282981|DRUG|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
219070958|NCT00463190|DRUG|Biothree|
219674864|NCT05052697|BIOLOGICAL|bIRV AA|Intramuscular injection
219674865|NCT05052697|BIOLOGICAL|bIRV BB|Intramuscular injection
219674866|NCT01929954|BIOLOGICAL|Gintuit|One time placement of Gintuit over socket graft.
219674867|NCT01929954|DEVICE|Bio-Gide|One time placement of Bio-Gide over socket graft.
219674868|NCT04351477|DEVICE|Massage chair|Mechanical massage chair
219674869|NCT00211627|DEVICE|KEEPASLEEP enhanced breathing device|
219070959|NCT03664713|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
219209092|NCT06748742|DRUG|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by using the fluorescence imaging equipment that comes with the device. Guided by real-time fluorescence imaging, the urethra is precisely dissected and severed in front of the bladder neck. Through this improved operation, the bladder neck is protected, the neck injury that is common in conventional surgical operations is reduced, and the reconstructive surgical operations necessary after loss are reduced, and the surgical efficiency is improved. By protecting the bladder neck, the sphincter is better preserved, postoperative urinary incontinence is reduced, and the surgical outcome is improved.
219209093|NCT06750549|DEVICE|ENGAGE-HF Mobile Application|"The mobile app aids ambulatory heart failure monitoring and patient engagement through several features:~Physiologic Monitoring: Daily tracking of blood pressure, weight, and heart rate using Bluetooth devices. Data is shown in graphical and tabular formats.~Health Status Assessment: Biweekly KCCQ-12 surveys and dizziness questions provide scores (0-100), helping visualize therapy benefits and medication adherence, and reducing clinician inertia.~Medication Checklist: Lists current medications and target doses for common heart failure therapies, encouraging adherence and optimization, with alerts for potential improvements.~Education: Animated videos from heart failure experts and societies explain medications, monitoring rationale, app features, and interpretation of data.~The app enhances heart failure management via consistent monitoring, assessment, medication adherence, and educational content."
219209094|NCT06738823|PROCEDURE|INTERVENTION GROUP : TRAINING WITH WIIFIT|RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
219070960|NCT05651581|OTHER|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
219070961|NCT03434925|GENETIC|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
219070962|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
219070963|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
219070964|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
219070965|NCT05239234|OTHER|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
219209095|NCT06738823|PROCEDURE|VESTIBULAR REHABILITATION TRAINING|WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
219209096|NCT06739980|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
219209097|NCT06757569|DEVICE|PET|Feasibility assessment of using the Radialis PET Imager for the detection of amyloid plaque burden using PET amyloid tracer.
219209098|NCT06891183|RADIATION|Percutaneous thermal ablation of lung tumors|Percutaneous radiofrequency ablation
219674870|NCT05885633|PROCEDURE|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
219674871|NCT03459859|DRUG|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
219674872|NCT03459859|DRUG|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
219674873|NCT06133478|DRUG|NUV001 active cohort 1|6 participants will be assigned to receive active treatment
219674874|NCT06133478|DRUG|NUV001 active cohort 2|6 participants will be assigned to receive active treatment
219209099|NCT06757374|DIAGNOSTIC_TEST|Resistin|Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity
219674875|NCT06133478|DRUG|NUV001 active cohort 3|6 participants will be assigned to receive active treatment
219674876|NCT06133478|DRUG|NUV001 active cohort 4|6 participants will be assigned to receive active treatment
219674877|NCT06133478|DRUG|NUV001 placebo cohort 1|2 participants will be assigned to receive placebo
219674878|NCT06133478|DRUG|NUV001 placebo cohort 2|2 participants will be assigned to receive placebo
219674879|NCT06133478|DRUG|NUV001 placebo cohort 3|2 participants will be assigned to receive placebo
219674880|NCT06133478|DRUG|NUV001 placebo cohort 4|2 participants will be assigned to receive placebo
219674881|NCT01657656|DIETARY_SUPPLEMENT|Vitamin D|
219674882|NCT01289574|DRUG|ASC-J9|Cream for twice daily topical application to the face
219674883|NCT03710369|DRUG|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
219674884|NCT03710369|DRUG|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
219674885|NCT00262002|BIOLOGICAL|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
218982017|NCT06966544|OTHER|Graded Motor Imagery|"All approaches applied to the conventional physiotherapy group are applied to this group in the same manner and duration (8 weeks-twice a week). However, in addition to conventional physiotherapy, progressive motor imagery (AMI) training program is being applied twice a week for 8 weeks.~In the GMI program, in addition to this program, components of GMI training will be applied to sequentially activate cortical motor networks and improve cortical organization. These are;~* Laterality training with the help of visuals selected in the first stage (0-2 weeks)~* In the second stage, motor imagery activities designed in the form of scenarios to be developed specifically for motor activity deficiencies seen in OBPY (2-5 weeks)~* In the third stage, a mirror therapy program will be prepared (5-8 weeks)."
219070966|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
219070967|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
219070968|NCT04432597|BIOLOGICAL|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
219070969|NCT04432597|DIAGNOSTIC_TEST|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
219070970|NCT04432597|DIAGNOSTIC_TEST|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
219070971|NCT04432597|DIAGNOSTIC_TEST|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
219070972|NCT04432597|DIAGNOSTIC_TEST|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
219070973|NCT04432597|DIAGNOSTIC_TEST|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
219070974|NCT04432597|PROCEDURE|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
219070975|NCT04432597|PROCEDURE|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
219209100|NCT06751381|DEVICE|IVIM Imaging MRF Imaging|"IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of nasopharyngeal carcinoma patients undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage.~MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI."
219674886|NCT00262002|BIOLOGICAL|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
218982018|NCT05456009|OTHER|No intervention|No intervention
218982019|NCT04908709|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
218982020|NCT04908709|DEVICE|Proton Therapy|Target volume treatment
218982021|NCT02573688|BEHAVIORAL|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
218982022|NCT05867303|DRUG|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
218982023|NCT06045884|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
218982024|NCT06045884|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
219674887|NCT00262002|BIOLOGICAL|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
218982025|NCT06045884|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
218982026|NCT03572972|DRUG|Apixaban|Treatment for NVAF patients
218982027|NCT03572972|DRUG|Dabigatran|Treatment for NVAF patients
218982028|NCT03572972|DRUG|Rivaroxaban|Treatment for NVAF patients
218982029|NCT03572972|DRUG|warfarin|Treatment for NVAF patients
218982030|NCT03572972|DRUG|Antiplatelets|Treatment for NVAF patients
218982031|NCT06409923|DEVICE|Stimulation of mandibular growth.|orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
219070976|NCT06034860|DRUG|MT-8421|Experimental treatment with MT-8421
219070977|NCT06034860|DRUG|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
219070978|NCT01545011|OTHER|Inspiratory muscle training|Inspiratory muscle training
219070979|NCT05615792|OTHER|No intervention|No intervention
219070980|NCT02345031|DRUG|AUT00063|600 mg, orally, once a day, for 4 weeks
219674888|NCT00262002|BIOLOGICAL|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
219674889|NCT00262002|BIOLOGICAL|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
219674890|NCT00262002|BIOLOGICAL|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
219674891|NCT00262002|BIOLOGICAL|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
218982032|NCT05768919|DRUG|Treatment Period 1|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
218982033|NCT05768919|DRUG|Treatment Period 2|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
218982034|NCT05768919|DRUG|Treatment Period 3|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
218982035|NCT05768919|DRUG|Treatment Period 4a|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
218982036|NCT04899102|BEHAVIORAL|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
218982037|NCT04376463|DIETARY_SUPPLEMENT|Branched Chain Aminoacid|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
218982038|NCT01441180|DRUG|GS7977|drug intervention
218982039|NCT01441180|DRUG|RBV|drug intervention
218982040|NCT01267045|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
219070981|NCT02345031|DRUG|Placebo|orally, once a day, for 4 weeks
219070982|NCT02247427|DEVICE|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
219070983|NCT05247996|PROCEDURE|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
219674892|NCT00262002|BIOLOGICAL|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
219070984|NCT05247996|DRUG|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
219070985|NCT05247996|DRUG|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
219070986|NCT05247996|PROCEDURE|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
219070987|NCT04156607|OTHER|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
219070988|NCT04156607|OTHER|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
219070989|NCT02188433|BEHAVIORAL|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
219070990|NCT02970500|DRUG|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
219070991|NCT02970500|DRUG|Placebo Group|Placebo
219070992|NCT05616533|OTHER|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
219070993|NCT01900990|DEVICE|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
219070994|NCT03586648|DEVICE|senofilcon A Multifocal|TEST Lens
219209101|NCT06748638|DRUG|Lactulose|At 20:00 the night before the examination, pour 2 boxes of lactilose into a cup, add 1000ml of water and drink it; 4 to 6 hours before the examination, dissolve the third box of lactulose into 1000ml water, and drink it; Until pale yellow or clear dung water is drawn.
219674893|NCT01590849|DRUG|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
219674894|NCT01230099|BEHAVIORAL|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
219674895|NCT03501654|DEVICE|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
219674896|NCT03623633|DRUG|denosumab|denosumab 60 milligrams subcutaneously every 6 months
219674897|NCT03623633|DRUG|alendronate|alendronate 70 milligrams weekly
219674898|NCT03623633|DRUG|raloxifene|raloxifene 60 milligrams daily
219674899|NCT01620333|DRUG|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
218982041|NCT05984095|OTHER|Telerehabilitation|The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
218982042|NCT00078793|DRUG|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
218982043|NCT02702219|BEHAVIORAL|Mobility of the hamstrings muscles|
218982044|NCT03942666|DRUG|Treatment A|tablet of CHF 6532
218982045|NCT03942666|DRUG|Treatment B|tablet of CHF 6532
218982046|NCT03942666|DRUG|Treatment C|tablet of CHF 6532
218982047|NCT03942666|DRUG|Treatment D|tablet of CHF 6532
218982048|NCT03942666|DRUG|Treatment E|Placebo tablet of CHF 6532
218982049|NCT03942666|DRUG|Treatment F|tablet of CHF 6532
218982050|NCT01771952|DEVICE|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
218982051|NCT01771952|OTHER|Sham Treatment|A single needle stick without arthrocentesis or injection.
218982052|NCT05678569|DIAGNOSTIC_TEST|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
218982053|NCT03204019|DRUG|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
218982054|NCT03204019|DRUG|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
218982055|NCT01801878|BIOLOGICAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
218982056|NCT01801878|BIOLOGICAL|Normal saline|Normal saline inject to the half of irradiated breast
218982057|NCT00797771|DEVICE|"Adi Insulin pump"|insulin delivery will be defined by the physician
219070995|NCT03586648|DEVICE|senofilcon A Sphere|TEST Lens Sphere
219070996|NCT03586648|DEVICE|etafilcon A Multifocal|CONTROL Lens
219070997|NCT03586648|DEVICE|etafilcon A Sphere|CONTROL Lens Sphere
219674900|NCT01620333|DRUG|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
219674901|NCT06124105|DIAGNOSTIC_TEST|arterial blood gases|measurement of partial oxygen pressure in urine by arterial blood gas device
219674902|NCT05583045|OTHER|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
219674903|NCT05583045|BEHAVIORAL|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
219209102|NCT06748638|DRUG|Lactulose+ linaclotide|1 capsule of linalotide (290ug) taken orally half an hour before meal at 12:00 noon on the previous day， and two doses were taken after 20:00 according to the above Lactulose-taking method.
219674904|NCT05583045|OTHER|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
219674905|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
219674906|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
219674907|NCT02445131|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
219674908|NCT02445131|DRUG|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
219674909|NCT02445131|DRUG|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
219674910|NCT04774276|OTHER|cardiac rehabilitation protocol without occupational therapist|cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
219674911|NCT04774276|OTHER|cardiac rehabilitation protocol with occupational therapist|"This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month."
219674912|NCT05699876|DRUG|Melatonin 6 MG|melatonin will be administered orally preoperatively as premedication
219674913|NCT05699876|DRUG|Gabapentin|melatonin will be administered orally preoperatively as premedication
219070998|NCT01719952|DRUG|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
219070999|NCT01719952|DRUG|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
219071000|NCT04543123|DEVICE|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
219071001|NCT04543123|DRUG|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
219674914|NCT01891682|OTHER|Observational|Observational, Translational non-treatment study
219071002|NCT00282620|DRUG|Magnesium L-lactate|
219071003|NCT01821469|BEHAVIORAL|psychoeducation|Bipolar disorders are educated to learn about their pathology
219071004|NCT00377234|DRUG|Risedronate|35mg po weekly for 12 weeks
219071005|NCT00377234|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
219071006|NCT06402734|BEHAVIORAL|Adherence to Gluten Free Diet|Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
219071007|NCT03747926|DRUG|BI 705564|single-rising oral dose
219071008|NCT03747926|DRUG|Placebo|single-rising oral dose
219209103|NCT06748638|DRUG|polyethylene glycol (PEG)|a bag of PEG was dissolved into 1L at 20:00 1d before the examination, and was drunk at a constant rate within 2h; 4 to 6 hours before the inspection, dissolve the second bag of PEG into 2L water and drink it.
219674915|NCT02179476|DEVICE|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
219674916|NCT01519973|RADIATION|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
219674917|NCT02278965|DRUG|Metformin|Metformin 850mg, oral, twice a day for 12 months
219674918|NCT02278965|DRUG|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
219674919|NCT02570230|OTHER|NSS|NSS infusion
219674920|NCT02570230|DRUG|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
219674921|NCT02283580|OTHER|Single limb|"Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
219674922|NCT02283580|OTHER|Two limb|"Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
219674923|NCT04699825|OTHER|Cardiovascular and immunological changes|performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
219674924|NCT03494244|PROCEDURE|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
219674925|NCT03494244|DEVICE|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
219674926|NCT04460963|OTHER|Adrenomedullin|Adrenomedullin sample evaluation
219071009|NCT05308251|PROCEDURE|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
219674927|NCT01048086|DRUG|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.
219674928|NCT01048086|DRUG|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
219674929|NCT04091204|DRUG|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
219674930|NCT01790516|DRUG|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
219674931|NCT01790516|DRUG|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
219674932|NCT01790516|RADIATION|Radiation|daily radiation for 7 weeks
219674933|NCT01108692|OTHER|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
219674934|NCT01554163|DRUG|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
219071010|NCT04534595|OTHER|COVID-19|To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
219071011|NCT02242474|DRUG|Anti-TNF suspended perioperatively|
219071012|NCT02242474|DRUG|Anti-TNFα continued perioperatively|
219071013|NCT00479245|OTHER|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
219071014|NCT01987648|PROCEDURE|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
219071015|NCT05697848|OTHER|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
219071016|NCT05697848|OTHER|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
219071017|NCT00675740|DRUG|rosiglitazone|tablets 4 mg daily
219071018|NCT00675740|BEHAVIORAL|physical exercise|stationary bike 5-6 times a week
219071019|NCT00675740|OTHER|control|control without intervention
219071020|NCT00000648|DRUG|Penicillin G potassium|
219674935|NCT01554163|DRUG|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
219674936|NCT04239196|DRUG|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
219674937|NCT04239196|OTHER|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
219674938|NCT02922075|BIOLOGICAL|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
219071021|NCT00000648|DRUG|Ceftriaxone sodium|
219071022|NCT02612948|DRUG|Quetiapine|escalating dose to prevent delerium.
219071023|NCT03621605|BIOLOGICAL|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
219071024|NCT03621605|DRUG|Placebos|Placebo administered by slow IV infusion or SC injection.
219071025|NCT00907153|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
219071026|NCT00907153|DRUG|Placebo|Placebo by mouth once daily for 12 weeks
219071027|NCT05800132|DEVICE|MammoScreen|Diagnostic reading aid for breast cancer screening
219071028|NCT02212756|DRUG|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
219071029|NCT02212756|DRUG|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
219071030|NCT01921569|BEHAVIORAL|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
219071031|NCT01921569|OTHER|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
219071032|NCT01921569|OTHER|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
219071033|NCT05558033|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
219674939|NCT02922075|BIOLOGICAL|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
219674940|NCT02922075|DEVICE|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque \> 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
219674941|NCT02922075|PROCEDURE|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
219674942|NCT02922075|DEVICE|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
219071034|NCT05558033|OTHER|Football Training|Routine football trainings
219071035|NCT01478867|OTHER|Detection of gluten in feces|Detection of Gluten in Feces
219071036|NCT05079620|DRUG|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
219071037|NCT05079620|DRUG|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
219071038|NCT05079620|DRUG|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
219071039|NCT05079620|DRUG|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
219071040|NCT05079620|DRUG|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
219071041|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
219071042|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (90 mg) by single SC injection every other week
219071043|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week
219071044|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
219071045|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
219071046|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
219071047|NCT02111590|DRUG|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
219071048|NCT03768479|DEVICE|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
219071049|NCT05148377|DRUG|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
219071050|NCT05148377|DRUG|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
219071051|NCT04431596|DEVICE|Forearm cooling|forearm immersion will be performed for active cooling assessment.
219071052|NCT04431596|OTHER|Mist-fan cooling|A mist-fan will be placed in front of the participant for active cooling.
219071053|NCT05168241|OTHER|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
219071054|NCT05168241|OTHER|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
219071055|NCT03929029|DRUG|Nivolumab (480 mg infusion)|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
219674943|NCT02922075|BIOLOGICAL|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
219674944|NCT02922075|DRUG|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
219071056|NCT03929029|BIOLOGICAL|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
219674945|NCT02922075|DEVICE|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
219674946|NCT02922075|OTHER|No soft tissue graft|No soft tissue graft was used
219674947|NCT04833400|DEVICE|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
219071057|NCT03929029|DRUG|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
219071058|NCT03771976|PROCEDURE|Cesarean section|Risk of cesarean section between the cohorts
219071059|NCT03771976|PROCEDURE|No cesarean section|Vaginal birth rate between the cohorts
219071060|NCT04907708|DRUG|Metformin|Euglycemic agent
219071061|NCT04907708|DRUG|Insulin|Hypoglycemic agent
219071062|NCT05446987|OTHER|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
219071063|NCT05446987|OTHER|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
219071064|NCT01804920|DIETARY_SUPPLEMENT|D-serine|
219071065|NCT01804920|DIETARY_SUPPLEMENT|Placebo|
219071066|NCT02672631|OTHER|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
219674948|NCT04833400|DEVICE|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
219674949|NCT02215499|DRUG|Placebo|
219674950|NCT02215499|DRUG|Sodium Oxybate|
219674951|NCT02215499|DRUG|JZP-386|
219674952|NCT01132300|DEVICE|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
219674953|NCT03111615|DRUG|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
219674954|NCT00037037|BIOLOGICAL|MAGE-10.A2|
219674955|NCT00037037|BIOLOGICAL|MART-1 antigen|
219674956|NCT00037037|BIOLOGICAL|NY-ESO-1 peptide vaccine|
219674957|NCT00037037|BIOLOGICAL|sargramostim|
219674958|NCT00037037|BIOLOGICAL|tyrosinase peptide|
219674959|NCT01777737|DRUG|Cotrimoxazole|24 weeks of treatment
219674960|NCT01777737|DRUG|Placebo|Identical capsules to cotrimoxazole
219674961|NCT01950156|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
219071067|NCT02672631|OTHER|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
219071068|NCT02672631|OTHER|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
219071069|NCT06489743|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
219071070|NCT00628732|DRUG|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
219071071|NCT05646875|OTHER|hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
219674962|NCT04273932|DRUG|Lithium|Lithium aspartate of lithium carbonate will be administered by mouth.
219674963|NCT00784056|DRUG|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH\_DETINLYN Tangerine Mix)
219674964|NCT01894971|DEVICE|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
219674965|NCT04884971|DRUG|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
219071072|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
219071073|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
219674966|NCT02739451|PROCEDURE|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]"
219674967|NCT02739451|PROCEDURE|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
219674968|NCT01146028|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
219071074|NCT00006123|BIOLOGICAL|trastuzumab|
219071075|NCT00006123|DRUG|carboplatin|
219071076|NCT00006123|DRUG|carmustine|
219674969|NCT06188676|DRUG|Cyclophosphamide|Ciclofosfamida
219674970|NCT06188676|DRUG|Doxorubicin Hydrochloride|Adriamycin
219674971|NCT06188676|DRUG|Etoposide Phosphate|Etopophos
219674972|NCT06188676|DRUG|Prednisolone|Prednisolonum
219674973|NCT06188676|DRUG|Rituximab|Chimeric Anti-CD20 Antibody
219674974|NCT06188676|DRUG|Vincristine Sulfate|Oncovin
219071077|NCT00006123|DRUG|cisplatin|
219071078|NCT00006123|DRUG|cyclophosphamide|
219071079|NCT00006123|DRUG|thiotepa|
219071080|NCT00006123|PROCEDURE|peripheral blood stem cell transplantation|
219071081|NCT00090389|PROCEDURE|Chinese Acupuncture|
219071082|NCT01298960|DRUG|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
219071083|NCT00791024|DRUG|CRC-Pharma 001|50 mg
219674975|NCT06188676|DRUG|Filgrastim|G-CSF
219674976|NCT06188676|DRUG|Pegfilgrastim|PEG-filgrastim
219674977|NCT06188676|DRUG|Nivolumab 40 mg in 4 ml Injection|Opdivo
219674978|NCT00946127|PROCEDURE|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
219674979|NCT00946127|PROCEDURE|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
219674980|NCT02226120|DRUG|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
219674981|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
219674982|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
219674983|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
218982058|NCT03110094|OTHER|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
218982059|NCT03110094|OTHER|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
218982060|NCT03630042|DRUG|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
218982061|NCT03630042|DRUG|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
218982062|NCT05598385|PROCEDURE|Open cannulation|A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
218982063|NCT05598385|PROCEDURE|Percutaneous cannulation|Cannulation is performed through a suture-mediated closure system.
218982064|NCT01918384|DRUG|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
218982065|NCT01918384|DRUG|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
218982066|NCT05026008|DRUG|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
218982067|NCT05026008|DRUG|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
218982068|NCT04210323|DEVICE|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
218982069|NCT04210323|DEVICE|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
218982070|NCT01135290|DRUG|Aquaphor|
218982071|NCT01135290|DRUG|HP828-101|
218982072|NCT01491971|DRUG|Degarelix|
218982073|NCT03277157|DIETARY_SUPPLEMENT|B. lactis B94|A probiotic dose of 15 billion per capsule.
218982074|NCT03277157|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
218982075|NCT04549961|OTHER|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
218982076|NCT05220917|DRUG|SGLT2 inhibitor|Any SGLT2i dispensing claim
218982077|NCT05220917|DRUG|DPP-4 inhibitor|Any DPP-4 inhibitor claim
218982078|NCT05220917|DRUG|GLP-1RA|Any SGLT2i dispensing claim
218982079|NCT05220917|DRUG|2nd generation SU|Any 2nd generation SU claim
219071084|NCT00791024|DRUG|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
219071085|NCT02388724|DRUG|Vonoprazan|Vonoprazan tablets
219071086|NCT02388724|DRUG|Lansoprazole|Lansoprazole capsules
219071087|NCT02388724|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
219071088|NCT02388724|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
219071089|NCT05917327|DEVICE|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
219674984|NCT01351948|BIOLOGICAL|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
219674985|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
219071090|NCT02232113|DRUG|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
219071091|NCT02268201|DRUG|Advagraf|oral
219071092|NCT02268201|DRUG|Prograf|oral
219071093|NCT02716974|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
219071094|NCT02716974|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
219071095|NCT02716974|DRUG|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
219071096|NCT02716974|PROCEDURE|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
219071097|NCT02716974|RADIATION|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
219071098|NCT02425839|DEVICE|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
219071099|NCT02425839|DEVICE|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
219071100|NCT02724553|DEVICE|Acrylic lens implantation|
219071101|NCT03603665|BIOLOGICAL|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
219071102|NCT03603665|OTHER|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
219071103|NCT03181880|DRUG|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
219071104|NCT03181880|DRUG|Standard of Care|Brochodilators
219071105|NCT04068337|PROCEDURE|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
219071106|NCT01717118|BIOLOGICAL|Bivalent Vaccines|
219071107|NCT01717118|BIOLOGICAL|Tetravalent Vaccine|
219071108|NCT05403580|DRUG|Olanzapine|Given PO
219071109|NCT05403580|DRUG|Placebo Administration|Given PO
219071110|NCT05403580|OTHER|Questionnaire Administration|Ancillary studies
219071111|NCT02605954|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
219071112|NCT02605954|DRUG|ABC/3TC|600/300 mg tablets administered orally once daily
219674986|NCT02910934|OTHER|Actellic CS|Indoor residual spray with Actellic CS
219674987|NCT03034135|DRUG|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
219674988|NCT03034135|DRUG|Temozolomide (TMZ)|TMZ is given per standard of care
219674989|NCT04931719|COMBINATION_PRODUCT|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
219071113|NCT02605954|DRUG|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
219071114|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
219071115|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
219674990|NCT04931719|COMBINATION_PRODUCT|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
219674991|NCT05277064|OTHER|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
219674992|NCT02324621|DRUG|Oral ONC201|Given PO
219674993|NCT02324621|OTHER|pharmacological study|Correlative studies
219674994|NCT02324621|OTHER|laboratory biomarker analysis|Correlative studies
219209104|NCT06897410|OTHER|Interdisciplinary Program for Post-Hospitalization / Hospital at home Management and Long-Term Outcomes in Older Adults with Chronic Cardiorespiratory Condition|"Intervention Phase 1: Feasibility Assessment Duration: January 7, 2025 - January 11, 2025 Participants: 10-15 patients~Description:~All involved services will be available to address and resolve potential issues.~The objective is to assess the feasibility of the program, ensuring that the intervention can be implemented as planned and identifying any practical or logistical challenges.~Phases 2 \& 3: Comprehensive Intervention Duration: January 12, 2025 - June 30, 2025 Participants: 200 patients~Description:~Full-scale implementation of the intervention. Includes interdisciplinary care, home follow-ups, therapeutic optimization, functional rehabilitation, health education, and psychosocial support.~Phase 4: Long-Term Follow-Up Duration: April 7, 2025 - June 30, 2026 Participants: 200 patients~Description:~Follow-up assessments at 3, 6, 9, and 12 months post-intervention. Evaluates hospital readmissi"
219674995|NCT06070753|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
219071116|NCT02734342|OTHER|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
219071117|NCT04063189|DRUG|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
219071118|NCT02561858|OTHER|acid load test|
219071119|NCT04217863|BEHAVIORAL|GDP|Guided Disclosure Protocol
219071120|NCT03398005|DRUG|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
219071121|NCT03398005|DRUG|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
219071122|NCT05969093|DIAGNOSTIC_TEST|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
219071123|NCT01043770|BEHAVIORAL|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
219071124|NCT02216175|OTHER|SLIT to cow's milk|Sublingual immunotherapy
219071125|NCT02216175|OTHER|Low dose OIT|Oral Immunotherapy (low dose)
219071126|NCT02216175|OTHER|Conventional OIT to cow's milk|Oral Immunotherapy
219071127|NCT06386107|BIOLOGICAL|Thrombin Generation Assay (TGA)|Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
219071128|NCT03084055|BEHAVIORAL|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
219071129|NCT01206530|DRUG|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
219071130|NCT01206530|DRUG|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
219071131|NCT01206530|DRUG|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
219071132|NCT01206530|DRUG|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
219071133|NCT01206530|DRUG|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
219071134|NCT01206530|DRUG|Bevacizumab|
219209105|NCT06742424|DRUG|PD-L1 antibody|1200mg intravenously every 3 weeks
219209106|NCT06742424|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
219209107|NCT06742424|PROCEDURE|HAIC-FOLFOX|Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles
219209108|NCT06739759|DRUG|Antagonist protocol for IVF|antagonist protocol with triggering by Decapeptyl
219209109|NCT06739759|DRUG|Modified Agonist protocol for IVF with additive treatments as HCQ|giving additive drugs to agonist protocolas HCQ
219674996|NCT02157597|OTHER|NIRS based management|"1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
219674997|NCT02157597|OTHER|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
219674998|NCT02758197|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
219071135|NCT03429413|BEHAVIORAL|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
219071136|NCT03429413|BEHAVIORAL|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
219071137|NCT05250180|OTHER|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
219071138|NCT05250180|OTHER|Control|treatment as usual as dictated by their treatment team
219071139|NCT03212469|DRUG|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
219071140|NCT03212469|DRUG|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
219071141|NCT03212469|RADIATION|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
219071142|NCT00501384|DRUG|satavaptan (SR121463B)|
219071143|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
219071144|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
219071145|NCT06571656|OTHER|FID123359 test formulation|Investigational product
219071146|NCT06571656|OTHER|FID123360 test formulation|Investigational product
219071147|NCT06571656|OTHER|FID123361 test formulation|Investigational product
219071148|NCT06571656|OTHER|FID121843 ocular lubricant|Commercially available, preservative-free eye drops
219071149|NCT01761435|BIOLOGICAL|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
219071150|NCT05653505|OTHER|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
219071151|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
219209110|NCT06745609|OTHER|Prehabilitation|"Pre-KiT prehabilitation consists of~1. A geriatric guided assessment with relevant interventions. The assessment will include cognitive evaluation, screening for depression, functional assessment, as well as evaluation of nutritional risk, assessment of past and current diseases, and a thorough review of the patient's medication list focusing on drug interactions. It will also include social history and standard laboratory results,~2. Physical activity. A four week home exercise program, adjusted to the participants physical abilities.~3. Assisted smoking cessation"
219209111|NCT06753474|BIOLOGICAL|Influenza Virus influenza A H3N2 strain|"Live Influenza Virus RG-A/Texas/71/2017 (H3N2). It is a cell-grown, reverse genetics-derived influenza A virus manufactured to conduct clinical trials that involve controlled human infection with influenza A virus. This influenza human challenge virus was produced for the National Institute of Allergy and Infectious Diseases (NIAID).~The final Drug Product Live Influenza Virus RG-A/Texas/71/2017 (H3N2) (Lot #1507-232149) vial contains 1.86 X 106 median tissue culture infectious doses (TCID50)/mL formulated in 1X sucrose-phosphate-glutamate (SPG; 7.4% sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 5.4 mM L-glutamic acid) in Ex-Cellä 293 serum-free medium (Sigma-Aldrich). It is susceptible to the FDA-approved neuraminidase (NA) inhibitors (NAI) oseltamivir phosphate, zanamivir, and peramivir, and the polymerase acidic (PA) inhibitor (PAI) baloxavir marboxil.x"
219209112|NCT06769516|DEVICE|Auricular Vagus Nerve Stimulation (aVNS)|"This intervention involves transcutaneous auricular vagus nerve stimulation (taVNS) using the VagusStim device. The device consists of earphones tailored to fit the individual's ear size (S, M, L) and is connected to a TENS unit. The stimulation is applied to the tragus and concha of the ear for 30 minutes, three times a week, over a 4-week period. The device operates with a pulse duration of less than 500 microseconds, a frequency of 10 Hz, and in a modulated TENS mode. The current intensity is individually adjusted to the participant's sensory threshold. This method targets the vagus nerve to potentially regulate autonomic activity and improve symptoms of Irritable Bowel Syndrome (IBS).~The study combines this intervention with a low FODMAP diet for all participants, distinguishing it from studies focused solely on vagus nerve stimulation or dietary changes."
219209113|NCT06769516|BEHAVIORAL|Aerobic Exercise Therapy|"This intervention involves a structured aerobic exercise program designed to improve physical activity levels and modulate symptoms of Irritable Bowel Syndrome (IBS). Participants engage in walking exercises at a moderate intensity, maintaining 50-70% of their maximum heart rate, ensuring the ability to converse comfortably during the activity. The exercise sessions last for at least 30 minutes, three days a week, on alternate days, over a 4-week period.~Participants are individually trained and monitored to ensure proper technique and adherence to the exercise protocol. The intervention is combined with a low FODMAP diet, providing a multimodal approach to IBS symptom management. This distinguishes it from other interventions by emphasizing physical activity's role in enhancing gastrointestinal and overall health."
219209114|NCT06769516|BEHAVIORAL|Low FODMAP Diet Intervention|"This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications."
219209115|NCT06756945|DRUG|aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
219209116|NCT06756945|DRUG|aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
218982080|NCT02210650|PROCEDURE|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
218982081|NCT02210650|PROCEDURE|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
219071152|NCT03706599|BEHAVIORAL|Therapeutic education on fever|Session for therapeutique education on fever
219071153|NCT03706599|BEHAVIORAL|Therapeutic education on household accidents|Session for therapeutic education on household accidents
219071154|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
219071155|NCT03599063|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
219071156|NCT03599063|OTHER|Placebo|Placebo, administered subcutaneously
219071157|NCT05550246|DRUG|Atomoxetine|Treatment given for 3 nights
219071158|NCT05550246|DRUG|Oxybutynin|Treatment given for 3 nights
218982082|NCT01580085|OTHER|polysomnography|full night supervised laboratory polysomnography
218982083|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
218982084|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
219071159|NCT05944419|DEVICE|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
219071160|NCT04829344|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
219071161|NCT04829344|DRUG|Placebo|Placebo Topical Ophthalmic Solution
219071162|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
219071163|NCT03814889|DEVICE|Vibration pattern|Vibration patterns applied to the affected limb based on pilot study results.
219071164|NCT03814889|DEVICE|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
219071165|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
219071166|NCT05935501|DEVICE|Formaderm Young|Dermal filler injection to facial areas.
219071167|NCT05935501|DEVICE|Restylane|Dermal filler injection to facial areas.
219071168|NCT04992715|DIAGNOSTIC_TEST|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
219071169|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
219071170|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
219674999|NCT05302024|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
219675000|NCT02205697|BEHAVIORAL|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
219071171|NCT04154124|DIAGNOSTIC_TEST|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
219071172|NCT06060691|DRUG|Kaempferol|Kaempferol
219071173|NCT01847846|DEVICE|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
219675001|NCT00565097|DRUG|Placebo|
218982085|NCT04849754|DIAGNOSTIC_TEST|bone scintigraphy|Bone scintigraphy
218982086|NCT02890095|PROCEDURE|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~* 1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* 1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
219071174|NCT05127343|PROCEDURE|Sealing deep pits and fissures|Application of the pit and fissure sealant
219071175|NCT06503276|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm
219071176|NCT06503276|RADIATION|Ultra-low dose radiotherapy|2 Gy radiotherapy will be administerd twice in the first cycle
219071177|NCT00448539|DRUG|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
219071178|NCT03589456|OTHER|No intervention|There are no interventions associated with this registry as it is purely observational.
219675002|NCT00565097|DRUG|Lanreotide|
219675003|NCT05584085|BEHAVIORAL|ACT-DE|Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
219675004|NCT05388422|DEVICE|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
219675005|NCT04166292|DEVICE|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
219675006|NCT02938234|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
219675007|NCT01037816|DRUG|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
219675008|NCT01037816|OTHER|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
219675009|NCT06731062|DEVICE|EF192A|EF192A will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. EF192A will be reapplied to the participants' back in a naive area and removed after 48 hours.
219675010|NCT06731062|DEVICE|Saline solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back in a naive area and removed after 48 hours.
219675011|NCT06918808|BIOLOGICAL|DB-3Q|DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.
219675012|NCT06918808|BIOLOGICAL|Placebo|0.9% NaCl
219675013|NCT06920459|DEVICE|Alliance™ Glenoid|Total Shoulder Arthroplasty using the Alliance™ Glenoid implant
219675014|NCT04736641|OTHER|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
219675015|NCT06006598|DRUG|BI 1584862|BI 1584862
219675016|NCT06006598|DRUG|Placebo matching BI 1584862|Placebo matching BI 1584862
219675017|NCT06006598|DRUG|midazolam|midazolam
219675018|NCT06931691|DRUG|LNP023|Capsules for oral administration
219675019|NCT03973255|BEHAVIORAL|Rehabilitation|Posturography, Whole body vibration
219675020|NCT06367777|DEVICE|cervical a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
219675021|NCT06367777|DEVICE|thoracic a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
219675022|NCT06367777|DEVICE|sham tsDCS|Sham transcutaneous spinal direct current stimulation (s-tsDCS)
219675023|NCT03215407|DRUG|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
219675024|NCT03215407|DRUG|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
219675025|NCT01529411|DRUG|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).
219675026|NCT01529411|OTHER|Undefined (standard care)|All the current interventions used by each institution for the study disease.
219675027|NCT03341117|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
219675028|NCT03341117|DRUG|Calcined magnesia|Calcined magnesia 300 mg per capsule
219675029|NCT00817505|DRUG|AZD1656|Single dose oral tablet
219675030|NCT00817505|DRUG|AZD1656|Single dose oral suspension
219675031|NCT02013102|DRUG|Decitabine Injection|Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
219675032|NCT06756776|DEVICE|Hot pack|The Hot Pack is a therapeutic intervention device designed to deliver localized heat to targeted areas of the body for a duration of 15 minutes. It provides deep, soothing heat that helps to relax muscles, increase blood circulation, and reduce pain and stiffness. The device is typically used to treat conditions such as muscle tension, joint pain, and chronic discomfort. By applying consistent heat, the Hot Pack promotes improved tissue flexibility and alleviates muscle spasms. It is user-friendly, ensuring safe and effective use when applied to affected areas, with adjustable heat settings to accommodate individual needs.
219675033|NCT06756776|OTHER|Sustained Natural Apophyseal Glides (SNAG)|The Mulligan Sustained Natural Apophyseal Glides (SNAG) technique for the lumbar spine will be applied to participants in both groups. Participants will assume a stride standing position. The therapist will stand behind the participant as described by Mulligan, supporting the patient during the application of the technique and ensuring the required movement can be performed easily. The therapist will apply the mobilizing force parallel to the facet joint plane (in the cephalic direction) over the spinous processes of the respective symptomatic spinal levels in a sustained manner while the patient performs trunk flexion. The flexion position will be maintained for a few seconds, after which the participant will return to the starting position, with the therapist continuing to maintain the mobilizing force. Three sets of six repetitions will be performed on each symptomatic lumbar spinal level.
219675034|NCT06756776|OTHER|Passive Hamstring (HM) stretching|Passive Hamstring (HM) stretching will be performed by a physical therapist experienced in the treatment of chronic low back pain (CLBP) and trained in the study protocol. The procedure will follow manual therapy stretching standards \[22\]. First, the physical therapist will explain the procedure to the participant and reassure them that the stretching can be stopped if it becomes too difficult to tolerate. With the participant lying supine, the stretched limb will be placed in maximal, pain-free hip flexion with the knee flexed. The physical therapist will then slowly and gradually extend the knee to the maximal pain-free position. In this position, participants should feel an intense stretching sensation in the back of the thigh. If this position causes pain in the lower back, the hip flexion will be reduced to the maximal, pain-free range of motion (ROM). A stopwatch will be used to ensure that the final position is held for 1 minute for each limb.
219209117|NCT06755463|OTHER|Self-acupressure education|Participants will undergo acupressure therapy for 8 weeks, with twice-weekly sessions between 8:00 AM and 10:00 AM. A certified practitioner will train participants on target points, pressure techniques, frequency, and duration. Practical demonstrations will ensure correct application. Groups of up to 10 participants will be trained in a comfortable setting and practice techniques under supervision until proficient. The treatment protocol, based on literature, focuses on beta-endorphin and hypocretin levels, cognition, and patient-reported outcomes (pain, fatigue, depression, and quality of life). Participants will apply 3-5 kg pressure for 2 minutes per point at 12 symmetrical points (LI4, SP6, GV20, HT7, EX-HN3, LV3) using rhythmic movements, totaling 24 minutes. They will receive a diary to track home practices and a visual guide explaining each point's location and steps for application.
218982087|NCT02890095|PROCEDURE|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~* measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
218982088|NCT04589325|DRUG|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
218982089|NCT04589325|DRUG|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
218982090|NCT02291874|DRUG|Ipragliflozin|oral
218982091|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by three human doctors|This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.
218982092|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982093|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982094|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982095|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
219071179|NCT02606838|DEVICE|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
219071180|NCT02103439|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
219675035|NCT06756776|OTHER|Dry needling|"Subjects will be positioned prone on a treatment table with their feet over the edge of the table. Dry needling (DN) will be applied to the hamstring muscles at three locations, each for 1 minute, using a fast in-out, cone-shaped technique.~Subjects will receive DN three times a week. To standardize the approach and optimize the application of DN, the points will be located approximately close to the motor points of the hamstring muscles.~Two of the locations are in the long and short heads of the biceps femoris, at points located at 30% and 60% of a straight line from the ischial tuberosity to the fibular head. For the semitendinosus and semitendinosus muscles, the DN location will be selected at 60% of a straight line from the ischial tuberosity to the medial femoral epicondyle.~Disposable sterilized stainless steel needles (0.3×60 mm; DongBang AcuPrime Ltd, Korea) will be used."
219675036|NCT06756776|DEVICE|Transcutaneous Electrical Nerve Stimulation|The TENS (Transcutaneous Electrical Nerve Stimulation) unit is a therapeutic device designed to alleviate pain through the use of electrical impulses. It works by delivering low-voltage electrical currents via electrodes placed on the skin, targeting the affected area. These electrical pulses help to block pain signals sent to the brain and stimulate the production of endorphins, the body's natural pain relievers. The TENS unit is commonly used for managing both acute and chronic pain conditions, including muscle pain, joint pain, and nerve-related discomfort. The device is adjustable, allowing users to customize the intensity, duration, and frequency of the electrical stimulation to meet their individual needs. It is non-invasive, easy to use, and can be applied at home or in clinical settings for effective pain management.
219675037|NCT06946992|OTHER|video supported cooperative learning|Video supported cooperative learning will be used in the experimental group. The process will be student-centered. Students will support each other's learning. While practicing on the models in the form of cooperative learning, they will reinforce their practices by watching videos prepared for each psychomotor skill learning.
219675038|NCT04084899|DEVICE|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
219675039|NCT06955624|GENETIC|RNA and/or DNA methylation and/or protein analysis|RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells
219675040|NCT06954974|DEVICE|CPAP device|CPAP device
219675041|NCT06954974|DEVICE|CPAP device and exercise|CPAP device
219675042|NCT06954974|OTHER|Exercise|"1. Retropalatal level: Phase I: • Open your mouth • Pronounce A for 5 seconds • Stop. Close your mouth. Procedure: 2 sets of 10 repetitions.~2. Retroglossal level: Phase I: • Push the tongue against the front of the palate • Move it back to perform a click sound, Phase II: • Move the tongue from right to left and from up to down The sequence of movement directions can be randomized to increase the challenge for repetitions., Phase III: • In this exercise, the tongue of the patient will scroll • Circle with the tongue on the inside of the lips • Draw 10 circles per set.~   Phase IV: • pressing the back of the tongue firmly on the oral cavity's floor for 8 seconds. Phase V: • Step 1, bite the tongue depressor. • Step 2, push the tongue against the tongue depressor and hold for 8 seconds. Procedure: 2 sets of 10 repetitions.~3. Deglutition level: Phase I: • Gently hold the tongue between the front teeth • Maintain this position Then, close your mouth and swallow. Phase II: • This vers"
219675043|NCT01313013|BEHAVIORAL|question prompt sheet|
219675044|NCT01972464|DRUG|Progesterone|oral micronized progesterone
219675045|NCT01972464|DRUG|Placebo|
219675046|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
219675047|NCT02845531|DRUG|Optimal Medical Therapy|
219071181|NCT02103439|DRUG|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
219071182|NCT06370767|BEHAVIORAL|Bike-Share Travel Training|Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.
219071183|NCT06370767|BEHAVIORAL|Public Transportation Travel Training|Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
219071184|NCT00426504|PROCEDURE|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
219071185|NCT02696317|DEVICE|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
219071186|NCT02696317|DEVICE|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
219071187|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
219675048|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
219071188|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
219071189|NCT01343368|DRUG|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
219675049|NCT01251497|BEHAVIORAL|diabetes self-management education|
219675050|NCT04394936|DRUG|Guselkumab|100 mg guselkumab administered subcutaneously
219675051|NCT04394936|DRUG|Placebos|Sodiumchloride 0,9% solution for injection
219675052|NCT06438666|DEVICE|Anodic Transcranial Direct Current Stimulation|This study will apply the anodic transcranial direct current stimulation over 20 children between 14-18 years old. The protocol that it will follow is the next one: 3 days to value the outcome measures, 4 days (1 sessions per day of 17 minutes and 30 seconds) to apply the protocol of anodic transcranial direct current stimulation (0,6 mA of intensity). It will use the EPTE V07 Bipolar System by IONCLINICS ®; 3 days to value the outcome measures studying the effects produced at the affected upper limb. Another evaluation will be realized 3 weeks after the last sessions of anodic transcranial direct current stimulation to know if the effects obtained last at medium-long term.
219675053|NCT05131022|DRUG|NX-5948|Oral NX-5948
219675054|NCT04418362|OTHER|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
219675055|NCT01133704|BIOLOGICAL|sipuleucel-T|
219675056|NCT01133704|BIOLOGICAL|APC-Placebo|
219675057|NCT00320268|DRUG|Quetiapine fumarate|
219675058|NCT03271632|BIOLOGICAL|CAR T cells|Infusion of multi-CAR T cells
219071190|NCT01343368|BIOLOGICAL|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
219071191|NCT01343368|BIOLOGICAL|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
219209118|NCT06752863|DRUG|Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions|The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries
219675059|NCT00565201|DRUG|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
219675060|NCT00565201|DRUG|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
219675061|NCT02232477|DRUG|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
219675062|NCT05447455|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
219675063|NCT05447455|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
219675064|NCT02512172|DRUG|Oral CC-486|
219675065|NCT02512172|DRUG|Romidepsin|
219675066|NCT02512172|DRUG|MK-3475|
219675067|NCT02149407|DRUG|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
219675068|NCT02149407|PROCEDURE|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
219675069|NCT02149407|OTHER|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
219675070|NCT00481364|DRUG|atorvastatin|atorvastatin 40 mg/day
219675071|NCT00481364|DRUG|placebo|1 tb/day
219675072|NCT05714826|OTHER|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
219675073|NCT05714826|OTHER|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
219675074|NCT05182749|BIOLOGICAL|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
219675075|NCT05182749|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
219675076|NCT02447328|DRUG|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
219675077|NCT00546169|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
219675078|NCT01156493|OTHER|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
219675079|NCT01863719|DRUG|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
219675080|NCT01863719|DRUG|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
219675081|NCT06490081|DRUG|Trilaciclib|During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
219675082|NCT00431327|BEHAVIORAL|Peer coach phone call|
219071192|NCT06133894|BEHAVIORAL|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
219071193|NCT01925079|BEHAVIORAL|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
219675083|NCT04808414|DRUG|QPX9003 for IV Infusion|antibiotic
219675084|NCT04808414|DRUG|Placebo for IV infusion|Placebo comparator
219675085|NCT03630133|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
219675086|NCT01759719|DEVICE|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
219675087|NCT03942367|DEVICE|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
219675088|NCT03942367|DEVICE|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
219675089|NCT00314808|DRUG|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
219675090|NCT00964379|PROCEDURE|intraperitoneal or extraperitoneal colostomy|creation of colostomy
219675091|NCT04435899|OTHER|Physical exercise|Multi-modal exercise protocol
219675092|NCT04304508|DRUG|BAY2433334|Tablet, taken orally once a day.
219675093|NCT04304508|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
219675094|NCT05273229|OTHER|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
219675095|NCT05273229|OTHER|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~* Coordination exercises: normal and lateral parallel walking and walking with obstacles.~* Functional exercises such as climbing stairs, etc.~* Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
219675096|NCT05273229|OTHER|Sham Virtual Gait|only the placebo virtual gait.
218982096|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (with search capabilities)|This intervention involves answering patient inquiries by Claude instant with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982097|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (without search capabilities)|This intervention involves answering patient inquiries by Claude instant without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982098|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (with search capabilities)|This intervention involves answering patient inquiries by Claude 2 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982099|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (without search capabilities)|This intervention involves answering patient inquiries by Claude 2 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
219675097|NCT02113007|DRUG|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
219675098|NCT01331707|DEVICE|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
219675099|NCT01331707|DEVICE|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
219675100|NCT00885378|DRUG|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
219675101|NCT00885378|DRUG|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
219675102|NCT01759394|DRUG|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
219675103|NCT04750278|DRUG|FP-025 100 mg|FP-025 100 mg BID
219675104|NCT04750278|DRUG|FP-025 300 mg|FP-025 300 mg BID
219675105|NCT04750278|DRUG|Placebo|Placebo BID
219675106|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
219675107|NCT02349139|DRUG|ASN001: Escalating dose Part A|Androgen inhibitor
219675108|NCT03883776|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
219675109|NCT03883776|DEVICE|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
219675110|NCT03883776|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
219675111|NCT01730716|DEVICE|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
219675112|NCT03987113|OTHER|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
219675113|NCT04703010|DEVICE|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
219675114|NCT04703010|DEVICE|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
219675115|NCT04703010|BEHAVIORAL|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
218982100|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (with search capabilities)|This intervention involves answering patient inquiries by Gemini Pro with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
218982101|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (without search capabilities)|This intervention involves answering patient inquiries by Gemini Pro without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
219071194|NCT01925079|OTHER|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
219071195|NCT02535208|OTHER|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
219675116|NCT01775787|DRUG|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
219675117|NCT00482482|BEHAVIORAL|psychoeducation|on weekly basis for 8 weeks
219675118|NCT00482482|BEHAVIORAL|Yoga|on weekly basis for 8 weeks
219675119|NCT02706145|OTHER|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
219675120|NCT04424472|DIAGNOSTIC_TEST|Ultrasonography|Abdominal Ultrasonography
219675121|NCT06414772|OTHER|Use of MARTI application in addition with a classical consultation/support|Participants will use MARTI in order to establish the medical history during their waiting time.
219675122|NCT00208260|DRUG|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
219071196|NCT02535208|OTHER|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
219071197|NCT02794402|DRUG|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
219071198|NCT02794402|BEHAVIORAL|Placebo|Placebo once weekly injections sc
219071199|NCT00484705|PROCEDURE|Electroacupuncture|
219071200|NCT00484705|PROCEDURE|Physical exercise|
219071201|NCT00484705|PROCEDURE|Untreated control|
219071202|NCT01178151|DRUG|Everolimus|10mg daily orally
219675123|NCT00208260|DRUG|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
219675124|NCT00208260|DRUG|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
219675125|NCT00208260|DRUG|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
219675126|NCT00208260|DRUG|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
219071203|NCT02105506|DRUG|Tachosil patch|
219071204|NCT04116931|DRUG|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
219071205|NCT02186119|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
219071206|NCT02186119|DRUG|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
219071207|NCT02186119|OTHER|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
219071208|NCT02485470|OTHER|MPACT|Maintaining Physical Activity during Cancer Treatment
219071209|NCT04955639|OTHER|Control|Standard of Care - Control Smoking Cessation Program
219675127|NCT01523834|DRUG|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
219675128|NCT04879706|OTHER|None planned|No intervention planned
219675129|NCT04981197|BEHAVIORAL|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
219071210|NCT04955639|OTHER|Pivot|Pivot Program Smoking Cessation Program
219071211|NCT04447404|DRUG|DUR-928|IV infusion
219071212|NCT04447404|DRUG|Placebo|IV infusion
219071213|NCT00321854|DRUG|pramipexole|
219071214|NCT05509829|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
219071215|NCT02501343|DRUG|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
219071216|NCT02501343|DRUG|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
219071217|NCT05003531|DRUG|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
219675130|NCT05725824|DEVICE|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
219675131|NCT03207490|DEVICE|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
219675132|NCT04131582|COMBINATION_PRODUCT|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
219675133|NCT04131582|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
219675134|NCT00667914|PROCEDURE|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
219071218|NCT05003531|DRUG|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
219209119|NCT06753877|BEHAVIORAL|holistic rehabilitation|Holistic rehabilitation service All participants in the study were cared for in the inpatient unit. The same physician and nurses followed the participants for 1 month. The participants were regularly taking their medication and had no co-morbidities. All participants stayed in double rooms and all stayed with their caregivers. The assessments were carried out within the first 3 days of admission to the inpatient unit. The second assessments were repeated by the same professional. Rehabilitation interventions were provided by different therapists. Participants were given standard physiotherapy services (electrotherapy, exercise, gait training, hydrotherapy, respiratory therapy) and standard occupational therapy services. Occupational therapy interventions were provided by the researchers. Physiotherapy services were provided by physiotherapists working full-time in the hospital. Physiotherapy was provided 5 days a week and occupational therapy was provided 3 days a week.
219209120|NCT03849131|BIOLOGICAL|Biological collection|"Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.~It will include:~* DNA samples collection~* RNA samples collection~* Blood sample collection"
219209121|NCT06749678|BEHAVIORAL|Prehabilitation|In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period. It includes the following strategies: (1) Exercise: Exercise should be carried out when the patient's condition allows, and the exercise programme should be dynamically adjusted according to the patient's tolerance, and it is advisable to maintain the Borg score between 11\~13 points (i.e., subjectively feel relaxed or a little strained). (2) Nutritional support: ensure that the patient's daily energy intake is 20\~25kcal/kg (the target energy reaches 30\~35kcal/kg), and the protein intake is 1.2\~1.5g/(kg·d). (3) Psychological intervention: for patients with mild to moderate anxiety or depression, health education, music therapy and other psychological interventions are carried out. For patients with severe anxiety or depression, psychologists will conduct psychological consultation for patients and provide professional psychological therapy.
219675135|NCT00667914|PROCEDURE|Orthopedic care as usual|treatment in ordinary orthopedic unit
219675136|NCT01616758|DRUG|GTx-024 9mg|
219675137|NCT03107559|DIAGNOSTIC_TEST|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
219675138|NCT06323213|DRUG|610|610 subcutaneously injection.
219071219|NCT05003531|DRUG|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
218982102|NCT05847283|PROCEDURE|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
219071220|NCT05003531|DRUG|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
219071221|NCT05003531|DRUG|placebo|Participants will receive placebo SC
219071222|NCT02123693|OTHER|Osteopathic manipulative treatment|
219071223|NCT02123693|OTHER|Sham Therapy|
219071224|NCT02123693|OTHER|No Intervention|
219071225|NCT00396903|DEVICE|catheter|
219071226|NCT01850680|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
219071227|NCT01850680|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
219071228|NCT01850680|DRUG|methotrexate|Pharmaceutical form:capsule Route of administration: oral
219071229|NCT01850680|DRUG|folic acid|Pharmaceutical form:tablet Route of administration: oral
219071230|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071231|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071232|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219675139|NCT06323213|DRUG|Placebo|Placebo subcutaneously injection.
219071233|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071234|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071235|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219675140|NCT04736719|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure group
219675141|NCT04736719|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
219675142|NCT03934918|OTHER|Treatment|Patients for IOL are sent home after placement of intracervical balloon
219675143|NCT01909843|BIOLOGICAL|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
218982103|NCT05847283|PROCEDURE|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
219071236|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071237|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
219071238|NCT00175682|DRUG|Prazosin HCL|See Detailed Description
219675144|NCT03004768|DRUG|BMS-986165|Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
219675145|NCT03059537|DRUG|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
219209122|NCT06749678|BEHAVIORAL|Routine nursing measures|Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
219209123|NCT06760975|OTHER|Vestibular Habituation Exercises|The vestibular habituation exercise group follows a structured progression over six weeks. in week 1 participants perform large amplitude, rapid cervical rotations seated, completing 3 sets of five cycles each. By week 2, the exercises increase in complexity , incorporates standing pivots or seated trunk flexion extension. in week 3 the cervical rotations are continued with seated or standing posture. week 4 introduces a busy visual background during the exercise to challenge visual-vestibular integration. In week 5 the exercises are performed standing with the addition complex visual target against a busy background. finally week 6 includes most advance movement including standing pivots 180 degrees and brand-daroff exercises with further visual challenges of near and far targets in busy background. Each exercise session last for 2 minutes and is aimed at progressively enhancing vestibular processing and adaptability.
219209124|NCT06760975|OTHER|Ocular Reflex Excercises|The Ocular reflex exercises focuses on enhancing visual tracking and reflexes through targeted viewing exercises. In week 1, participants perform horizontal and vertical X1 viewing exercises with a near target, holding each position for 1 minute while seated. In week 2 the duration of the X1 exercises is extended to 2 minutes with the near target still in seated position. Week 3 shift to a far target for the X1 exercises and the participants performs them while standing increasing the challenge. By week 4 the exercise incorporate both near and far target in front of a busy background. extending the duration to 2 minutes while standing. In week 5 horizontal and vertical X2 viewing exercises are added with a plain background, while still using near and far targets in front of a busy background . finally week 6 continues the X1 and X2 exercises with near and far targets in a busy background, performed for 2 minutes while standing. This aims to improve visual tracking.
219209125|NCT06828003|BEHAVIORAL|Resistance Training|The resistance training intervention will consist of two remotely-delivered exercise sessions per week for eight weeks (16 sessions total). One session will be a live, remotely delivered 1:1 class led by a qualified exercise professional (\~one hour). The second session will be unsupervised, completed by watching a pre-recorded workout video that will vary bi-weekly to elicit progressive overload. Pre-recorded workout videos will be emailed and feature the qualified exercise professional who will provide instruction to mimic live sessions. Both sessions will involve a dynamic warm-up (\~10 minutes), 8 resistance-band exercises (\~30-45 minutes), followed by a cool-down (\~10 minutes).
219675146|NCT05613959|DEVICE|Veress +|The Veress+ safety mechanism was used
219675147|NCT05613959|DEVICE|Conventional Veress|The Conventional Veress Needle was used
219675148|NCT03323697|OTHER|SZ-05|2.5g a day (3 capsules twice a day)
219675149|NCT03323697|DRUG|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
219675150|NCT00829699|PROCEDURE|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
219675151|NCT00829699|PROCEDURE|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
219675152|NCT00829699|PROCEDURE|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
219675153|NCT00829699|PROCEDURE|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
218982104|NCT06562803|DEVICE|double plasma cytokine adsorption system with sequential low-dose plasma exchange|"Both groups received comprehensive medical treatment, including antiviral therapy for hepatitis B, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. Artificial liver therapy was initiated for both groups on the day of enrollment, with treatments administered every other day for a total of two sessions.~The experimental group underwent treatment with the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused."
218982105|NCT06562803|OTHER|plasma exchange|Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.
218982106|NCT04910945|DEVICE|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
218982107|NCT06974097|OTHER|blood sampling|blood sampling
218982108|NCT05048459|OTHER|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
218982109|NCT05048459|OTHER|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
219209126|NCT06762652|OTHER|Wash-in period|The goal of the wash-in period between the control and intervention period is to intensively educate and train physicians to use the algorithm as intended during daily postoperative care. The coordinating investigator along with the local principal investigator will be responsible for this training. Training will be performed in a standardized approach in order to guarantee uniformity across centres.
219209127|NCT06762652|DIAGNOSTIC_TEST|Algorithm-based care|During the intervention period, (participating) patients will receive algorithm-based care. The RESCUE algorithm is a consensus-based clinical care algorithm developed to standardize postoperative care. The algorithm includes the same modalities as applied in usual care, and does not include novel/experimental modalities, but rather offers a novel, standardized approach to guide the use of common modalities during postoperative care. The daily objective evaluation of patients' condition, vital signs and biochemical parameters is thought to aid early diagnosis of complications after esophagectomy which enables treatment before systemic symptoms become apparent and prevent development of sepsis. Physicians are always allowed to deviate from the RESCUE, but reasons for deviating will be recorded.
219209128|NCT06759077|DRUG|Dapagliflozin (DAPA)|adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
219209129|NCT06761183|GENETIC|intracerebral stereotactic injection of NXL-001|intracerebral stereotactic injection of NXL-001: with 3 subjects in each group to receive a single stereo-tactically intracerebral injection of NXL-001 at escalating doses.
219209130|NCT06515275|OTHER|Education via video (QR code links)|Video education on self-administered medications for women undergoing IVF treatment
218982110|NCT05048459|OTHER|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
218982111|NCT05627765|BEHAVIORAL|Standard treatment (ST) arm|"participants who are ready to quit smoking: a brief smoking cessation intervention based on the 5A models and STAR method as quitting skills.~participants who are not yet ready to quit smoking: a brief smoking cessation intervention based on the 5R models."
218982112|NCT05627765|BEHAVIORAL|Integrated Intervention (II) arm|"brief advice on alcohol use based on the FRAMES model and the brief smoking cessation intervention based on the 5A and 5R models."
218982113|NCT03739502|DRUG|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
218982114|NCT06271733|DEVICE|TMS|2 sessions of iTBS per day for 5 days
218982115|NCT06271733|DEVICE|Sham|2 sessions per day for 5 days of sham condition
218982116|NCT05727904|BIOLOGICAL|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
218982117|NCT05727904|BIOLOGICAL|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
218982118|NCT04028778|DRUG|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
218982119|NCT04028778|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
218982120|NCT04028778|OTHER|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
218982121|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
218982122|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
218982123|NCT06385522|BIOLOGICAL|BITR2101|TNFR2 monoclonal antibody
218982124|NCT04885192|OTHER|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
218982125|NCT02612129|DRUG|arimoclomol|
218982126|NCT02612129|DRUG|Placebo|
218982127|NCT06388291|DEVICE|Deep Brain Stimulation|ON/OFF stimulation vs OFF/ON stimulation
218982128|NCT02504684|DEVICE|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
219675154|NCT02417558|BEHAVIORAL|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
219675155|NCT02417558|BEHAVIORAL|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
219675156|NCT01247389|PROCEDURE|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
219675157|NCT03282422|DEVICE|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
218982129|NCT02504684|DEVICE|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
218982130|NCT04225507|BEHAVIORAL|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
218982131|NCT04225507|OTHER|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
218982132|NCT06277219|DRUG|LAT010|LAT010 monotherapy
218982133|NCT06277219|DRUG|LAT010 + ICI|LAT010 combination with PD-1 inhibitor
218982134|NCT02649088|DEVICE|Microscan|It allows to look at sublingual microcirculation
218982135|NCT02649088|DEVICE|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
218982136|NCT01422252|DEVICE|Vigi'Fall®|Precocious fall detection device
218982137|NCT04122690|BEHAVIORAL|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
218982138|NCT04122690|BEHAVIORAL|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
218982139|NCT04893226|BEHAVIORAL|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
218982140|NCT06215131|BEHAVIORAL|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
218982141|NCT06215131|BEHAVIORAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
218982142|NCT04574323|RADIATION|Curative radiotherapy|Standard curative radiotherapy
218982143|NCT04574323|OTHER|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
218982144|NCT05911321|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
218982145|NCT05911321|DRUG|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
218982146|NCT05911321|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
218982147|NCT06601751|OTHER|Neurobic Exercise Program|6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.
218982148|NCT06601751|OTHER|Traditional Brain Exercise|activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
218982149|NCT04332133|PROCEDURE|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
218982150|NCT02923596|PROCEDURE|History of prior Surgery|History of prior Surgery will be reviewed
218982151|NCT02923596|RADIATION|History of Radiation Therapy|History of prior radiation therapy will be reviewed
219209131|NCT06753799|BEHAVIORAL|The intervention group received training based on Social Cognitive Learning Theory.|One of the theories that provides a conceptual framework for the learning and behavior change process is Social Cognitive Learning Theory. Verbal information is commonly provided in the education of individuals with diabetic foot ulcers. The difference of this study from other studies is that an educational booklet, an educational video and a demonstration method with a diabetic foot model are used during the education within the scope of theory-based education.
219209132|NCT06753058|DIETARY_SUPPLEMENT|25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.|Although 45 g of different carbohydrate solutions either Gatorade 54 g carbohydrate or clear apple juice 56 g carbohydrate in non-diabetic women have been recommended by SOAP, we preferred 25 g of carbohydrate, fantomalt, nutricia, diluted in the 330 mL in both diabetic and non-diabetic pregnant women.
219071239|NCT01920230|BEHAVIORAL|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
219071240|NCT01920230|BEHAVIORAL|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
219209133|NCT06753058|BEHAVIORAL|Mother baby bonding|In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
219209134|NCT06752681|DRUG|DAY301|DAY301 will be administered as IV infusion
219209135|NCT06765005|DRUG|MG-K10|Subcutaneous injection, once every 4 weeks
219209136|NCT06766461|DRUG|Double dosing of beta-lactam antibiotic|This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
219209137|NCT06763068|OTHER|Skeletal muscle mass and frailty|Measurement correlation variable
219675158|NCT03282422|DEVICE|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
219675159|NCT05917483|DIAGNOSTIC_TEST|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
219675160|NCT04437797|PROCEDURE|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
219675161|NCT04437797|PROCEDURE|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
219071241|NCT01138904|DRUG|irinotecan, oxaliplatin|"OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
219071242|NCT01138904|DRUG|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
219071243|NCT00000893|DRUG|Nelfinavir mesylate|
219209138|NCT06762236|OTHER|Pillatate Training|.The session will repeated three times per week for 6 weeks with 40-minute sessions In Pilates we include 5 Pilate exercise, The Hundred (Rhythmic Breathing), Single Leg Stretch (Rhythmic Breathing), side kick, Toe Taps (Set Breathing Pattern) ,leg pull front for 6 weeks.
219209139|NCT06774300|BEHAVIORAL|BASICS|The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.
219071244|NCT00000893|DRUG|Efavirenz|
219209140|NCT06774300|BEHAVIORAL|Online alcohol programming|This is a control intervention that is used as the first-line sanction for students at the two universities. It is an online program, informed by BASICS content, but contains no facilitator and is self-directed.
219209141|NCT06775184|DEVICE|a native video image system|The visualization of the glottic structures through the SaCoVLM™ imaging system is graded as follows: Grade1: Visibility of the lateral portion of the right epiglottic fold and part of the laryngeal inlet. Grade 2: Visibility of both epiglottic folds and part of the laryngeal inlet. Grade 3: Visibility of the laryngeal inlet and part of the vocal cords. Grade 4: Visibility of the entire vocal cords.
219209142|NCT06775184|DEVICE|Fiberoptic bronchoscope|The position of the i-Gel is checked using a fiberoptic endoscope
219209143|NCT06776809|OTHER|Music listening|Selection of Sufi music will be played to the patients during the course of the operation.
219071245|NCT02190331|OTHER|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
219071246|NCT02190331|OTHER|Control Group physical education classes|Only performed the physical education classes
219071247|NCT01603576|DEVICE|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
219071248|NCT01923727|BIOLOGICAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
219071249|NCT03155607|BEHAVIORAL|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
219071250|NCT06055296|OTHER|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
219071251|NCT04158531|DEVICE|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
219071252|NCT06426537|DRUG|Colchicine 0.5 MG Oral Tablet|Oral administration of Colchicine in STEMI patients
219071253|NCT03455972|BIOLOGICAL|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
219071254|NCT03455972|DRUG|Immunomodulatory drugs|Maintenance therapy
219071255|NCT06385158|DRUG|GS1-144 tablet|GS1-144 tablet is an NK3R antagonist.
219675162|NCT00222014|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
219675163|NCT00222014|PROCEDURE|Paracenthese|Paracenthese
219071256|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
219071257|NCT04829370|OTHER|PLT|The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled will be applied 2 mL PLT solution on the right face. Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
219071258|NCT04829370|OTHER|Saline|"The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled left face be applied 2 mL normal saline.~Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed."
219071259|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
219071260|NCT01617421|BEHAVIORAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
219209144|NCT06777472|OTHER|lung-benefiting moxibustion|A kind of external treatment，the treatment theory is to treat winter diseases in summer.
219209145|NCT06777472|DRUG|"The specific drug comes from GINA (2024)"|"Refer to GINA (2024)."
219675164|NCT01137656|DRUG|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
219675165|NCT06236854|OTHER|Delirium assessment (observational, not interventional)|As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
219675166|NCT06407492|OTHER|Leech|The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.
219675167|NCT06407492|OTHER|Conventional Physiotherapy|Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
219675168|NCT06407492|OTHER|Kinesiotape|"In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%."
219675169|NCT05514613|OTHER|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
219675170|NCT00461929|PROCEDURE|bone marrow aspiration|
219675171|NCT00306410|DRUG|colecalciferol|
219675172|NCT02773420|PROCEDURE|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
219071261|NCT06265103|OTHER|Clinical care and quality improvement|All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
219071262|NCT02384759|DRUG|aflibercept|
219071263|NCT02384759|DRUG|LV5FU2|
219071264|NCT02368353|OTHER|Cognitive behavioral therapy|
219071265|NCT02368353|OTHER|Supportive therapy|
219071266|NCT00235976|DRUG|Gantacurium Chloride for Injection (AV430A)|
219071267|NCT01595295|OTHER|non interventional|
219071268|NCT06293729|DRUG|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
219071269|NCT03043664|DRUG|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
219071270|NCT03043664|DRUG|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
219071271|NCT01440153|OTHER|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
219071272|NCT01440153|OTHER|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
219071273|NCT04699266|DEVICE|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
219071274|NCT00000985|DRUG|Vidarabine|
219071275|NCT00000985|DRUG|Acyclovir|
219071276|NCT00000985|DRUG|Foscarnet sodium|
219071277|NCT04745182|BEHAVIORAL|MASTERY|A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
219071278|NCT01063400|OTHER|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
219071279|NCT01886898|OTHER|Infant formula|infant formula
219071280|NCT01886898|OTHER|Breastfeeding|
219071281|NCT03798860|DIAGNOSTIC_TEST|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
219209146|NCT06775509|DEVICE|Ortho-K|Utilization of Ortho-K Contact Lenses for The Treatment of Myopia
219209147|NCT05504278|DRUG|IBI351|recommended dose, po
219675173|NCT03534739|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
219675174|NCT03534739|OTHER|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
219209148|NCT05504278|DRUG|Cetuximab|500mg/m\^2, Q2W, day1, i.v.
219209149|NCT05504278|DRUG|pemetrexed|500mg/m\^2, Q3W, day1, i.v.
219209150|NCT05504278|DRUG|Carboplatin|AUC=5, Q3W, day1, i.v.
219209151|NCT05504278|DRUG|Sintilimab|200mg, Q3W, day1, i.v.
219209152|NCT05504278|DRUG|cis-platinum|75mg/m\^2, Q3W, day1, i.v.
219675175|NCT03534739|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
219675176|NCT03231397|DRUG|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
219675177|NCT03231397|DRUG|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
219675178|NCT03231397|DIAGNOSTIC_TEST|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
219675179|NCT06224218|PROCEDURE|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
219675180|NCT06224218|PROCEDURE|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
219071282|NCT03902587|DEVICE|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
219071283|NCT01426165|DRUG|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
219071284|NCT06580665|PROCEDURE|Cryoablation|Patients undergo cryoablation.
219209153|NCT06776081|OTHER|Weight loss without pharmacotherapy|Adults with obesity participating in the 12-week hypocaloric diet-induced weight loss intervention will be individually counseled by the Clinical and Translational Research Center (CTRC) bionutritionist to consume a hypocaloric diet consistent with current dietary recommendations for weight loss until a 6-10% weight loss is achieved.
219209154|NCT06768242|RADIATION|Cone beam CT|Each patient will undergo three cone beam CTs per session, and a total of three sessions.
219209155|NCT06771427|OTHER|acupuncture GB20 or GB20 plus BL2|acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.
219209156|NCT06771427|DRUG|Chinese herbal tea TBDESJS|Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
219209157|NCT06777719|DRUG|Eight Treg|"The experimental drug Eight Treg is given to patients with a peripheral IV infusion the day before the graft (cf section 5.1.5. Infusion of the experimental drug of this protocol) in addition to the maintenance protocol combining corticosteroids, tacrolimus and MPA which are classically pre-scribed in kidney graft patients from a living donor at the Nantes CHU."
219209158|NCT06777602|DRUG|[14C] MK-5475|\[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.
219209159|NCT06778304|DRUG|Gonal F|The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
219209160|NCT06778304|DRUG|jzb30|The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
219209161|NCT06777940|OTHER|Kegel exercises|It consists of 25 patients who will receive Kegel exercises with Myokinetic active release of trigger points in quadratus lumborum, rectus abdominis and gluteus medius. Patient will be in lying position with empty bladder. Ask patient to tight pelvic floor muscle group and hold tight from 3-5 seconds Then relax muscle group from 3-5 seconds with Myokinetic therapy targeted at releasing muscle of quadratus lumborum, rectus abdominis and gluteus medius release was applied passively by sustained pressure for 8-10 seconds. This protocol consisted of three sets with 2 minutes of rest..Participants will be asked to perform exercise 30 times each session following hold and relax of muscle group for 3-5 seconds
219209162|NCT06777810|OTHER|The infected wound of the patient's foot ulcer was collected|The infected wound of the patient's foot ulcer was collected
219209163|NCT06779110|PROCEDURE|Percutaneous Coronary Intervention|Using OCT to guide PCI in ISR
219209164|NCT06778044|OTHER|ReDirection 1.0|A free, anonymous, online, self-guided cognitive behavioral therapy (CBT) intervention. Consists of 6 modules.
219209165|NCT06778044|OTHER|ReDirection 2.0|A free, anonymous, online, self-guided, cognitive behavioural therapy (CBT) intervention. Consists of 5 modules and the option for asynchronous messaging with a ReDirection specialist.
219209166|NCT06778044|OTHER|Waitlist|Participants in the waitlist control will wait six weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing sexual urges and behaviour.
219675181|NCT03184779|OTHER|Ski and Snowboard Safety Video|The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
219675182|NCT04076319|BEHAVIORAL|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
219071285|NCT06580665|DRUG|Serplulimab|Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
219071286|NCT01631630|DRUG|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
219071287|NCT01631630|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
219071288|NCT01981564|BEHAVIORAL|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
219071289|NCT01981564|BEHAVIORAL|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
219071290|NCT04182620|DEVICE|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
219071291|NCT04182620|DEVICE|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
219071292|NCT05080790|DRUG|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
219071293|NCT04777019|OTHER|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
219071294|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
219071295|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
219071296|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol + geranylgeraniol|Combination of ubiquinol and geranylgeraniol
219071297|NCT06640465|DIETARY_SUPPLEMENT|Geranylgeraniol|Geranylgeraniol alone
219071298|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol alone
219071299|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinone|Ubiquinone alone
219071300|NCT06640465|OTHER|Placebo|Placebo capsule
219071301|NCT06595888|RADIATION|Computed Tomography|X-ray by Computed Tomography
219071302|NCT06497491|BIOLOGICAL|GNR-086|GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
219071303|NCT06497491|BIOLOGICAL|Ilaris®|Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
219071304|NCT05577026|BEHAVIORAL|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
219071305|NCT05577026|BEHAVIORAL|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
219071306|NCT06034990|OTHER|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
219071307|NCT04738643|OTHER|Tobacco Use Treatment Service and Varenicline Management|The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
219071308|NCT05584215|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
219071309|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
219071310|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
219071311|NCT05222802|DRUG|ERAS-801|Administered orally
219071312|NCT03759873|BEHAVIORAL|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
219071313|NCT03759873|BEHAVIORAL|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
219209167|NCT06779279|DEVICE|Water flosser and super flosser|Participant will use in one area superfloss and the other area waterfloss
219071314|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
219071315|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
219071316|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
219071317|NCT04732403|OTHER|Patient Position|The patient will be placed in an angle on the surgical table during cystoscopy.
219071318|NCT06086223|PROCEDURE|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
219071319|NCT06086223|PROCEDURE|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
219071320|NCT04986553|DEVICE|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
219071321|NCT04336254|BIOLOGICAL|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
219071322|NCT04336254|OTHER|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
219071323|NCT02676479|DEVICE|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
219071324|NCT06195917|DEVICE|Robotic-assisted Interventional Percutaneous transhepatic puncture|Robotic-assisted Interventional Percutaneous transhepatic puncture
219071325|NCT05362903|OTHER|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
219071326|NCT03579563|OTHER|AUD fitting|Prescription hearing aids will be fitted by audiologists using established procedures.
219071327|NCT03579563|OTHER|OTC+ fitting|Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
219071328|NCT03579563|OTHER|OTC fitting|In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
219071329|NCT03579563|DEVICE|High-end HA|High-end hearing aids will be used.
219071330|NCT03579563|DEVICE|Low-end HA|Low-end hearing aids will be used.
219071331|NCT06402331|DRUG|FPI-2265|"Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac.~Other Names:~225Ac-PSMA-I\&T"
219071332|NCT05605964|DRUG|Relugolix|Relugolix tablet
219071333|NCT05605964|DRUG|Leuprolide Acetate|Leuprolide acetate injection
219071334|NCT04635605|DRUG|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
219675183|NCT05348954|OTHER|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
219071335|NCT04635605|DRUG|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
219209168|NCT06779279|DEVICE|Orthodontic brush|Participant will use orthodontic brush to brush in the upper/lower quadrant
219209169|NCT06779084|OTHER|contemporary fasting principle|(clear fluids for up to 2 hours before anesthesia)
219675184|NCT02840773|OTHER|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
219675185|NCT02840773|OTHER|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
219675186|NCT02840773|OTHER|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
219675187|NCT02840773|OTHER|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
219675188|NCT02840773|OTHER|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
218982152|NCT05514340|DRUG|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
218982153|NCT05514340|DRUG|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
218982154|NCT00169793|OTHER|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
218982155|NCT00169793|OTHER|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
219209170|NCT06779084|OTHER|conventional fasting time|(≥ 8 hours)
219071336|NCT06962683|OTHER|Blood-Flow-Restriction Training|For the pBFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Intervention-Group performed the training at 80% of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
219071337|NCT06962683|OTHER|Sham-BFR|For the sham-BFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Control-Group was trained with a fixed pressure of 20 mmHg, independent of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
219071338|NCT06956495|DRUG|Tasipimidine|Tasipimidine solution
219071339|NCT06956495|DRUG|Tasipimidine placebo|Tasipimidine placebo solution
219675189|NCT04686708|OTHER|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
219071340|NCT06961682|DIETARY_SUPPLEMENT|MD|Red meats and sweets minimal consumption once or twice per month Eggs, cheese, poultry and yoghurt weekly consumption Fish and seafood two to three times per week Olive oil varing amount daily Vegetables and fruits daily consumption Legumes and whole grains (bread, pasta, rice and nuts )daily consumption Measure the effect of Mediterranean diet on patient with MetS to control hypertension, diabetes, obesity and dyslipidemia by measuring blood pressure mmHg regularly, Hba1c before, lipid profile LDL, HDL, TG weight (kg) and height (m) to calculate BMI wt kg/ht\^2 m and waist hip ratio by measuring waist and hip circumference before and after the MD
219071341|NCT06962046|PROCEDURE|Virtual Reality|"* VR~* Spinal anaesthesia~* Limited propofol aiming for OAA/S of 4-5 (light sedation)"
219071342|NCT06962644|OTHER|Preeclampsia developed|Preecalmpsia will be defined as per study protocol
219071343|NCT06961799|DIAGNOSTIC_TEST|Multifactorial algorithm to predict fall risk|"In this new multifactorial algorithm we will add baseline data (personal characteristics, medical history, and physical and psychological measurements) to predict an older adults risk on falls. The accuracy of this new model will be tested with a 1-year follow up on falls.~The new algorithm is inspired by the study of Lusardi et al. (2017): Lusardi MM, Fritz S, Middleton A, Allison L, Wingood M, Phillips E, Criss M, Verma S, Osborne J, Chui KK. Determining Risk of Falls in Community Dwelling Older Adults: A Systematic Review and Meta-analysis Using Posttest Probability. J Geriatr Phys Ther. 2017 Jan/Mar;40(1):1-36. doi: 10.1519/JPT.0000000000000099. PMID: 27537070; PMCID: PMC5158094."
219071344|NCT06093113|BEHAVIORAL|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
219071345|NCT06093113|BEHAVIORAL|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
219071346|NCT03199729|OTHER|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
219071347|NCT03199729|OTHER|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
219071348|NCT03199729|OTHER|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
219071349|NCT05445804|DRUG|300 mg Cannabidiol|300 mg CBD in Medium Chain Triglyceride oil b.i.d.
219071350|NCT05445804|DRUG|600 mg Cannabidiol|600 mg CBD in Medium Chain Triglyceride oil b.i.d.
219071351|NCT05445804|DRUG|Placebo|Medium Chain Triglyceride oil
219071352|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
219071353|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
219071354|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
219071355|NCT06575140|DEVICE|Associative Peripheral Stimulation (APS) 1.0|Associative peripheral stimulation paired with rehabilitative exercises.
219209171|NCT06760689|DEVICE|virtual reality glasses|One of the videos chosen by the patient will be opened in the virtual reality glasses and will be played for 20 minutes.
219209172|NCT06760689|OTHER|scale|The patient received standard nursing care. Scales were filled in after the course.
219209173|NCT02158507|DRUG|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
219209174|NCT06775743|DRUG|ORIENT-31 regimen|Sintilimab plus bevacizumab plus platinum-doublet chemotherapy
219675190|NCT05194241|BEHAVIORAL|One MORE|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
219675191|NCT00005822|DRUG|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
219675192|NCT00005822|DRUG|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
219071356|NCT06575140|DEVICE|Peripheral Neuromuscular Stimulation|Random peripheral stimulation paired with rehabilitative exercises.
219071357|NCT06054724|OTHER|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
219071358|NCT06054724|OTHER|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
219071359|NCT06076642|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
219071360|NCT06076642|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
219071361|NCT06634472|OTHER|AI|AI-enabled skin perforator segmentation tool
219071362|NCT03526250|OTHER|Laboratory Biomarker Analysis|Correlative studies
219071363|NCT03526250|DRUG|Palbociclib|Given PO
219071364|NCT03526250|OTHER|Pharmacological Study|Correlative studies
219071365|NCT06008717|DEVICE|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
219071366|NCT06008717|DEVICE|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
219071367|NCT05653921|OTHER|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
219071368|NCT04458051|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
219071369|NCT04458051|DRUG|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
219071370|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
219071371|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
219071372|NCT06167681|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
219071373|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
219675193|NCT00005822|PROCEDURE|conventional surgery|Patients undergo a modified radical mastectomy.
219675194|NCT00005822|RADIATION|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
219675195|NCT00005822|DRUG|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
219071374|NCT01903473|DRUG|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
219675196|NCT01962194|DEVICE|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
219675197|NCT04211558|DRUG|Ozanimod|Ozanimod
219071375|NCT01903473|OTHER|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
219071376|NCT05646953|OTHER|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
219071377|NCT03217045|OTHER|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
219071378|NCT02773615|PROCEDURE|Cardiac computed tomography|Non-invasive CT scan of the heart
219071379|NCT02868359|OTHER|No Intervention|The study is observational.
219071380|NCT04126226|OTHER|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
219071381|NCT04126226|OTHER|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
219071382|NCT04126226|OTHER|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
219071383|NCT04653103|PROCEDURE|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
219071384|NCT02742844|BIOLOGICAL|APZ2 application|Application of IMP on patients wound.
219071385|NCT01618864|DEVICE|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
219071386|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
219071387|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
219071388|NCT05976074|DEVICE|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
219071389|NCT05976074|OTHER|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
219071390|NCT04224389|PROCEDURE|transoral resection|The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
219071391|NCT04224389|RADIATION|IMRT|Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
219071392|NCT06646666|DRUG|All-trans retinoic acid|10mg，tid，po (After apheresis and continued until post-infusion)
219675198|NCT02374619|DIETARY_SUPPLEMENT|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]
219675199|NCT02374619|DIETARY_SUPPLEMENT|Placebo|
219675200|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
219675201|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
219675202|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
219675203|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
219675204|NCT06307405|DIAGNOSTIC_TEST|next generation sequencing|All the enrolled patients had undergone fiberbronchoscopy and sputum had been retained. The collected alveolar lavage fluid and sputum were examined for mNGS and routine etiology, respectively
219071393|NCT06646666|DRUG|zanubrutinib|160mg，bid，po (prior to apheresis and continued until post-infusion)
219071394|NCT06646666|RADIATION|radiotherapy|If the patient's specific lesions are suitable for radiotherapy
219071395|NCT06646666|DRUG|CAR-T|CAR-T cell therapy
219071396|NCT06646666|DRUG|PD-1 inhibitor|IV 200 mg on D1, Q3W
219071397|NCT02513563|DRUG|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219071398|NCT02513563|DRUG|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219071399|NCT02513563|DRUG|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219071400|NCT06056180|OTHER|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
219071401|NCT06056180|OTHER|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
219071402|NCT06056180|OTHER|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
219071403|NCT03125720|OTHER|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
219071404|NCT06121661|DEVICE|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
219071405|NCT02214134|GENETIC|Tumour markers testing|
219071406|NCT01391962|DRUG|Cediranib|Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
219071407|NCT01391962|DRUG|Sunitinib|Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
219071408|NCT01391962|OTHER|Prochlorperazine|10mg every 6 hours orally as needed for nausea,
219071409|NCT01391962|OTHER|Promethazine|12.5-25mg intravenous every 6 hours as needed for nausea.
219071410|NCT01391962|OTHER|Benzodiazepine|If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.
219071411|NCT01391962|OTHER|Filgrastim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
219675205|NCT05391880|DRUG|BEBT-503 20mg|BEBT-503 capsule
219675206|NCT05391880|DRUG|BEBT-503 40mg|BEBT-503 capsule
219071412|NCT01391962|OTHER|Sargramostim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
219071413|NCT01391962|OTHER|Lomotil|2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.
219071414|NCT01391962|OTHER|Loperamide|4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.
219071415|NCT01391962|OTHER|Vitamin B6|50-150mg orally each day for hand-foot syndrome.
219071416|NCT01391962|OTHER|Aquaphor|Topical emollient for hand-foot syndrome.
219071417|NCT01391962|DRUG|Acetaminophen|Analgesic for hand foot syndrome as needed.
219071418|NCT01391962|DRUG|Levothyroxine|Replacement therapy for participants with increases in thyroid-stimulating hormone.
219071419|NCT01391962|DRUG|Warfarin|2mg daily for prophylaxis of thrombosis.
219071420|NCT05761223|DRUG|Phase Ia dose-escalation part of FB849 Monotherapy|At a given level dose once daily
219675207|NCT05391880|DRUG|BEBT-503 80mg|BEBT-503 capsule
219675208|NCT05391880|DRUG|BEBT-503 120mg|BEBT-503 capsule
219675209|NCT05391880|DRUG|BEBT-503 180mg|BEBT-503 capsule
219675210|NCT05391880|DRUG|placebo 20mg|placebo capsule
219675211|NCT05391880|DRUG|placebo 40mg|placebo capsule
219071421|NCT05761223|DRUG|Phase Ib dose-expansion of FB849 monotherapy|At recommended dose for expansion cohort once daily
219071422|NCT05761223|DRUG|Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab|At recommended dose for expansion cohort once daily in combination with pembrolizumab
219071423|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
219071424|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
219071425|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
219675212|NCT05391880|DRUG|placebo 80mg|placebo capsule
219675213|NCT05391880|DRUG|placebo 120mg|placebo capsule
219675214|NCT05391880|DRUG|placebo 180mg|placebo capsule
219675215|NCT04711343|DRUG|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
219675216|NCT04711343|DRUG|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
219675217|NCT04711343|DRUG|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
219675218|NCT04094116|PROCEDURE|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
219675219|NCT06477380|BEHAVIORAL|ACCEPT intervention|"* Training package (1 day)~* A toolkit/manual for clinicians to guide them through the disclosure process~* Trauma-informed changes to the physical environment~* Monthly trauma-focussed reflective group for care co-ordinators"
219209175|NCT06775743|RADIATION|SBRT|"Based on the results of the response evaluation, personalized SBRT will be arranged after cycle 4:~A. Complete response, CR: continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression, intolerable toxic side effects, or up to two years.~B. Stable disease, SD/partial response, PR: if the residual lesions do not exceed three organs and five lesions, and if the investigator deems SBRT feasible, curative-dose stereotactic radiotherapy covering all residual lesions will be administered, with dosing based on the NRG-BR001 study.~C. If the residual lesions exceed three organs or five lesions, SBRT (24 Gy/3 Fx) targeting 1-3 selected tumor lesions will be performed, and then continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression.~D. Progressive disease, PD: subsequent treatment is conducted according to the standard guidelines."
219071426|NCT03428711|DRUG|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
219071427|NCT03428711|DRUG|Placebo Oral Tablet|Indistinguible placebo tablet
219209176|NCT06776302|DIAGNOSTIC_TEST|Raise of blood flow through the brain|At each patient two test are preformed. The first test is based on increasing blood flow through the brain through a controlled gradual infusion of norepinephrine (noradrenalin). The patient will receive such an infusion immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission. The second test is based on passive elevation of the lower extremities. The second test will also be performed on the patient immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission.
219209177|NCT06777264|BIOLOGICAL|Biological: single dose of Inaticabtagene autoleucel|Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
219209178|NCT06765525|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
219209179|NCT06765525|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system.
219209180|NCT06765525|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
219675220|NCT06178042|COMBINATION_PRODUCT|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
219675221|NCT06178042|COMBINATION_PRODUCT|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
219071428|NCT04111549|OTHER|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
219071429|NCT04111549|OTHER|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
219209181|NCT06765525|OTHER|AI-assisted junior sonographer meaturement of DDH|Participants will receive visual cues from the DeepDDH system.
219209182|NCT06767501|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
219209183|NCT06767501|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
219209184|NCT06843460|BIOLOGICAL|Sotatercept|Single subcutaneous injection
219209185|NCT06843460|OTHER|Placebo|Single subcutaneous injection
219675222|NCT06178042|COMBINATION_PRODUCT|Control|Patients instructed to follow a routine home care.
219675223|NCT01183507|BEHAVIORAL|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
219071430|NCT05671848|OTHER|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
219071431|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
219071432|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
219209186|NCT06750627|PROCEDURE|Continuous Erector Spinae Plane Block|Catheter are placed between the erector spinae muscle and the transversus processus with ultrasound guidance, blocking the dorsal and ventral ramus from the thorax and abdominal spinal nerves, at the level of T5. Local anesthesia is injected. Drugs used are Bupivacaine 0.25% with volume of 25 ml.
219209187|NCT06750627|DRUG|Multimodal Intravenous Analgesia|"Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)"
219209188|NCT06767046|DRUG|KRAS-specific Autologous TCR-T cell injection|Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
219209189|NCT06763783|DRUG|Shingrix|all participants vaccinates with two doses of Shingrix vaccine
219675224|NCT01183507|BEHAVIORAL|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
219071433|NCT06033235|DIAGNOSTIC_TEST|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
219071434|NCT05539989|BIOLOGICAL|VPM1002 Vaccine|0.1 mL (2-8x10\^5 CFU)
219071435|NCT05539989|BIOLOGICAL|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
219071436|NCT05539989|DRUG|Placebo|0.1 mL (sodium chloride for injection 0.9%)
219071437|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
219209190|NCT06763783|DRUG|vaccination with 2 doses of Shingrix vaccine|all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
219209191|NCT06768801|BEHAVIORAL|WPAPP-Latina|The WPAPP Latina intervention provides 1) educational information via modules and online resources and 2) coaching via an online forum with a chat function. The educational modules include 11 modules on physical activity promotion and 7 modules on depressive symptoms. The women are also invited to share their experiences with culturally matched interventionists (e.g., Spanish speaking graduate research assistant with expertise in depressive symptoms and physical activity) and with peer participants using a de-identified name in the online chat forum. Participants will be directed to information about physical activity with age-appropriate guidelines from the Centers for Disease Control and Prevention.
219209192|NCT06768359|PROCEDURE|Manual acupuncture and standard therapy|"Manual acupuncture is acupuncture needle insertion was done perpendicularly to the acupuncture points GV20, EXHN3, HT7, and PC6 using Huanqiu needle measuring 0.25 x 25mm with mild stimulation rotation technique at a speed of 60x/minute and needle retention for 30 minutes. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
219209193|NCT06768359|PROCEDURE|Sham acupuncture and standard therapy|"Sham acupuncture is when acupuncture needles are inserted into acupuncture points, but do not actually penetrate the skin, only attached to the plaster. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
219675225|NCT05345366|OTHER|non-applicable|non-applicable
219675226|NCT00193739|DRUG|NACT|3 cycles of neoadjuvant chemotherapy
219675227|NCT00193739|PROCEDURE|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
219675228|NCT00193739|DRUG|Inj.Cisplatin|Concurrent chemo radiotherapy
219071438|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
219071439|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
219071440|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
219071441|NCT06010589|DRUG|DWJ1558|DWJ1558
219071442|NCT06010589|DRUG|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
219071443|NCT05800392|DRUG|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
219071444|NCT05800392|DRUG|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
219071445|NCT05019339|BEHAVIORAL|Healthy HomeStyles|Comparison of 2 educational interventions
219071446|NCT05019339|BEHAVIORAL|Eat Healthy Be Active|Comparison of 2 educational interventions
219071447|NCT01546194|OTHER|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
219071448|NCT05034705|DEVICE|Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
219071449|NCT05034705|DEVICE|Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
219071450|NCT02032472|OTHER|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
219071451|NCT01201629|DEVICE|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
219209194|NCT06780722|OTHER|blood sampling|"* The first sample is taken at the start of the therapeutic stop.~* The second sample is taken when the mean arterial pressure drops to 45mmHg.~* The third sample is taken when circulatory arrest occurs.~* The fourth sample is taken at the start of extracorporeal circulation. These four samples will be destroyed at the end of the study."
219209195|NCT06774911|OTHER|YUIT|Product with protein source from pea and rice.
219209196|NCT06774911|OTHER|P_PS|Product with protein source from soy protein.
219209197|NCT06781684|PROCEDURE|ulna shaft fracture fixation in children by intramedullary k wire|"* In the 1st group The Antegrade intramedullary k wire with appropriate diameter according to the child ulna diameter is introduced from the olecranon of the fractured ulna,cross the fracture site after good reduction under C arm in the anterioposterior and lateral views and the wire continues until reaching before the distal ulna .~* In the 2nd group The Retrograde intramedullary k wire with appropriate diameter is introduced from the diatal end of the ulna and cross the fracture site after good reduction under C arm and continues until reaching before the olecranon."
219675229|NCT00193739|RADIATION|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
219071452|NCT01201629|DEVICE|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
219071453|NCT00164437|BEHAVIORAL|educational CD-ROM|
219071454|NCT04214132|OTHER|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
219071455|NCT01275573|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
219071456|NCT04226924|DRUG|Trehalose|90 mg/ml trehalose solution for IV infusion
219209198|NCT06781021|PROCEDURE|Tourniquet|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
219675230|NCT02797145|DRUG|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
219675231|NCT02797145|DRUG|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
219675232|NCT05937516|DEVICE|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
219071457|NCT04333667|BEHAVIORAL|Intervention group|The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
219071458|NCT01140191|DRUG|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
219071459|NCT03649828|DIETARY_SUPPLEMENT|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
219071460|NCT03649828|DIETARY_SUPPLEMENT|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
219071461|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
219071462|NCT02001727|OTHER|Questionaire|
219071463|NCT00144703|DRUG|Sirolimus|
219071464|NCT00144703|DRUG|Tacrolimus|
219209199|NCT06781021|PROCEDURE|TXA|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
219209200|NCT06781125|DRUG|JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion|"JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions."
219209201|NCT06780540|OTHER|Operation Alert: Support prgram|"Substudy 1:~Testing of a newly developed psycho-education tool will occur across four partner hospitals and participating nonprofit organizations (NGOs). Victims of violence seeking care at these sites will receive immediate support, with the pilot study integrated into standard care practices. The psycho-education toolkit enhances the foundational care already provided. The tool supports healthcare providers in offering psycho-education about e.g. violence and (the effects) of trauma, ...~Substudy 2:~This pilot study evaluates the Operation Alert guidelines within the geriatrics departments of four hospitals. A geriatric assessment is standard care during admission to these departments. The pilot will be embedded into this existing practice to ensure alignment with routine care. Additional questions will be embedded in a geriatric assessment/intake focusing on older adults' well-being, relationships and social network, and potential life events (e.g. experiences of violence)."
219071465|NCT06705855|DEVICE|NIRS sensor placement|After written informed consent, the patient will be brought to the operating room. Skin tone will be assessed using the Monk scale. Prior to induction of general anesthesia, the right kidney will be located by surface ultrasound, the distance between the renal capsule and the skin will be measured, and a NIRS sensor will be placed on the skin overlaying the kidney. If the patient has had a right nephrectomy, the left kidney will be used. Additional NIRS sensors will then be placed over the patient's ipsilateral biceps and vastus lateralis muscles. The distance from the skin to the muscle tissue will be measured and recorded using ultrasound. NIRS sensors will also be placed on the patient's forehead to measure cerebral oximetry as is current practice at our institution for all cardiac surgeries requiring cardiopulmonary bypass.
219071466|NCT01913067|DRUG|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
219071467|NCT01913067|PROCEDURE|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
219071468|NCT04561479|OTHER|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
219071469|NCT04561479|OTHER|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
219071470|NCT05246423|DIAGNOSTIC_TEST|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
219071471|NCT01650259|DRUG|OAD|OAD except Trazenta tablets
219071472|NCT01650259|DRUG|Trazenta|Linagliptin
219071473|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
219071474|NCT00355082|DRUG|lamotrigine, 300 mg/day|300 mg/day
219071475|NCT00355082|DRUG|lamotrigine, 250 mg/day|250 mg/day
219071476|NCT04139395|DRUG|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
219071477|NCT04139395|DRUG|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
219071478|NCT04139395|DEVICE|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
219071479|NCT04139395|DEVICE|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
219071480|NCT04139395|DEVICE|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
219071481|NCT02998567|DRUG|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
219071482|NCT02998567|DRUG|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
219071483|NCT02998567|DRUG|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
219071484|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
219071485|NCT04020913|DRUG|Somatropin injection|"Boys with short stature will be studied for measures of:~1. skeletal muscle strength, power, and endurance~2. muscle agility~3. lean body mass accrual~4. bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
219071486|NCT06410066|OTHER|no intervention|
219071487|NCT03467659|OTHER|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
219071488|NCT03467659|OTHER|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
219071489|NCT03467659|OTHER|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
219071490|NCT03467659|OTHER|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
219071491|NCT03467659|OTHER|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
219071492|NCT03467659|OTHER|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
219675233|NCT05937516|DEVICE|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
219071493|NCT00323102|DRUG|Multihance|
219071494|NCT00444782|BIOLOGICAL|GV1001|
219675234|NCT04558671|OTHER|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
219071495|NCT06971497|DEVICE|ActivBraid™Collagen Co-Braid suture (Zimmer Biomet)|ActivBraid™ is a suture made from approximately half ultra-high molecular weight polyethylene and and half collagen derived from cow skin. Collagen is the most abundant protein in our bodies and serves as the building block for tendons and bones. The collagen in ActivBraid™ is intended to enhance cell attachment and tissue integration which may improve the healing of a rotator cuff repair. ActivBraid™ suture has been shown to have equivalent strength as other high strength sutures used in orthopaedic procedures and has been approved by the Food and Drug Administration (FDA) for repairing tendons. ActivBraid™ is a commercially available product that has been and is used in humans. This is the first post-market clinical study with ActivBraid™.
219071496|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
219071497|NCT00497653|DRUG|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
219071498|NCT00497653|DRUG|Placebo|Placebo, twice daily for 6 weeks
219071499|NCT05226208|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
219071500|NCT05226208|DIAGNOSTIC_TEST|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
219071501|NCT02960529|PROCEDURE|extra-peritoneal high ligation of hernia|
219071502|NCT02960529|PROCEDURE|intraabdominal high ligation of hernia|
219071503|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
219071504|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
219071505|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
219071506|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
219071507|NCT02676869|DRUG|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
219071508|NCT02676869|DRUG|Pembrolizumab|Administered according to the approved label.
219071509|NCT05514431|PROCEDURE|Epidural|Traditional epidural catheter placement
219071510|NCT05514431|PROCEDURE|Dural Puncture Epidural (DPE) technique|Epidural catheters placed via DPE technique
219071511|NCT05514431|PROCEDURE|Combined Spinal-Epidural (CSE) technique|Epidural catheters placed via CSE technique
219071512|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
219071513|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
219071514|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
219675235|NCT03252145|DEVICE|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
219675236|NCT03252145|OTHER|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
219675237|NCT01533961|DRUG|SCYX-7158|
219675238|NCT01533961|DRUG|Placebo|
219675239|NCT04168320|RADIATION|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
219675240|NCT03504189|DEVICE|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
219675241|NCT03504189|DEVICE|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
219675242|NCT04307524|PROCEDURE|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
219675243|NCT04307524|DRUG|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
219675244|NCT03286621|OTHER|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
219675245|NCT04595929|PROCEDURE|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
219675246|NCT04595929|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
219675247|NCT04595929|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
219675248|NCT04595929|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
219675249|NCT04595929|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
219675250|NCT04595929|PROCEDURE|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
219675251|NCT04595929|PROCEDURE|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
219675252|NCT04595929|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
219675253|NCT01398657|DRUG|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
219675254|NCT03091738|DRUG|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
219071515|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
219071516|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
219675255|NCT01147562|PROCEDURE|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
219675256|NCT04336475|OTHER|orofacial exercise program|combined stretching\&strengthening exercise regimen
218982156|NCT06857383|OTHER|Fremantle Headache Awareness Questionnaire|"It is a simple Likert-type questionnaire that evaluates individual-specific altered perception (0 = Never/Never feel like this, 1 = Rarely feel like this, 2 = Sometimes or sometimes feel like this, 3 = Often feel like this, 4 = Always or most of the time feel like this). The questionnaire asks individuals 9 questions about how they perceive their heads and headaches in relation to their bodies. The questionnaire was developed by Wand et al. in its first version as The Fremantle Back Awareness Questionnaire. With permission from the author, the questionnaire was created by adapting the questions of the Fremantle Back Awareness Questionnaire to headache."
218982157|NCT06664606|BEHAVIORAL|Pain Neuroscience Education Program (PNE)|The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
218982158|NCT00987545|DRUG|QAX576|QAX576 injection
218982159|NCT00987545|DRUG|QAX576 placebo|Placebo to QAX576 injection
218982160|NCT01984983|BIOLOGICAL|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
218982161|NCT01984983|OTHER|0.9% saline placebo|
218982162|NCT06608472|DRUG|N0877|1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®
218982163|NCT06608472|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
218982164|NCT00892242|DRUG|Zoledronic acid|
218982165|NCT00904397|DRUG|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
219071517|NCT03858803|BEHAVIORAL|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
219071518|NCT03858803|BEHAVIORAL|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
219071519|NCT05353790|OTHER|Meals + snacks: control|8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
218982166|NCT00904397|DRUG|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
219209202|NCT06770010|BEHAVIORAL|Cogmed+|"Cogmed is a home-based, digital working memory training program compatible with tablet devices. The program, designed for children ages 7 and older, consists of engaging cognitive exercises that target skills involving visuospatial and verbal working memory. An essential component of Cogmed training involves assignment of an intervention coach who has access to detailed data on the user's training data. Families will have videoconference meetings once per week with an intervention coach to review progress, provide feedback and answer any questions that arise during treatment. In addition, participants' coaching calls will be supplemented with direct instruction on the use of memory strategies. Social support interventions will also be provided involving three primary approaches: (1) multi-family Cogmed Kickoff social events; (2) social incentives; and (3) peer navigator support."
219675257|NCT01258478|OTHER|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
219675258|NCT01258478|OTHER|Usual care|Usual care
218982167|NCT06162429|PROCEDURE|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
218982168|NCT06162429|PROCEDURE|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
218982169|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
218982170|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
219675259|NCT03335683|DRUG|Lenidase|drug per os twice day for 7 days, or for 10 days
218982171|NCT03049722|DEVICE|Pacemaker|
218982172|NCT03105583|DRUG|Medication use during pregnancy|
218982173|NCT03105583|DIETARY_SUPPLEMENT|Supplement use during pregnancy|
219071520|NCT05353790|OTHER|Meals + snacks: Avocado mango|8 weeks meal plans provide1 avocado + 1 cup of mango per day
219071521|NCT05893992|DEVICE|Hearing aids with noise management features for listening in noise|Device for hearing loss compensation with digital noise management features
219071522|NCT05893992|DEVICE|Hearing aid for listening in quiet environments|Device for hearing loss compensation for listening in quiet environments
219071523|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
219675260|NCT03592849|PROCEDURE|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
219675261|NCT04762394|BEHAVIORAL|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
219675262|NCT01863342|PROCEDURE|CSI score < 40|
219675263|NCT01863342|PROCEDURE|CSI score ≥ 40|
219675264|NCT04240951|OTHER|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
219675265|NCT05660252|OTHER|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
219675266|NCT02164643|DRUG|Flutemetamol (18F)|
219675267|NCT02164643|DRUG|Florbetapir (18F)|
219675268|NCT03629808|PROCEDURE|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
219675269|NCT03629808|PROCEDURE|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
219675270|NCT03304106|DEVICE|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
219675271|NCT04238338|OTHER|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
218982174|NCT03105583|OTHER|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
218982175|NCT05670847|DRUG|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
218982176|NCT06617026|DRUG|Sucralfate|a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
218982177|NCT06617026|DRUG|Azadirachtin|a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
218982178|NCT06617026|PROCEDURE|fissurectomy and lateral sphincterectomy|fissurectomy and lateral sphincterectomy
218982179|NCT06680505|DRUG|YZJ-1139 10mg|YZJ-1139 10mg tablets
218982180|NCT06680505|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets
218982181|NCT06680505|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets
218982182|NCT06680505|DRUG|YZJ-1139 60mg|YZJ-1139 60mg tablets
218982183|NCT06680505|DRUG|Placebo|Match placebo tablets
218982184|NCT06680336|DIAGNOSTIC_TEST|Mulit-componant neuropsychological assessment|Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.
218982185|NCT06680336|DIAGNOSTIC_TEST|Multimodal MRI|Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
218982186|NCT06681597|DIETARY_SUPPLEMENT|Raspberry ketone|Human consumed 500mg of raspberry ketone
218982187|NCT06680466|DRUG|YZJ-4729|Dose Group 1
218982188|NCT06680466|DRUG|morphine|morphine,
218982189|NCT06680466|DRUG|placebo|placebo
218982190|NCT06680466|DRUG|YZJ-4729|Dose Group 2
218982191|NCT06680466|DRUG|YZJ-4729|Dose Group 3
218982192|NCT06680466|DRUG|YZJ-4729|Dose Group 4
218982193|NCT06680557|BEHAVIORAL|Aerobic and resistance exercises|"* Aerobic exercise session: A 30-minutes of brisk walking exercise on an indoor track without speed walking or running .~* Resistant exercise session: A 30-minutes of resistance exercise using rubber bands including warm-up and cool-down periods. Rubber band exercises are composed of seven exercises: squat, leg extension, pull apart, seated row, standing biceps curl, overhead press and lateral raise. Each exercise consists of three sets of 10 repetitions with 1 minute rest between each exercise set."
218982194|NCT06681844|OTHER|Tooth Shape assessed using an intraoral scanner one after avulsion|"* Tooth Shape assessed using an intraoral scanner one after avulsion and stored as StereoLithography (STL) file~* Age, gender, reason of avulsion, type of tooth taken from the database and stored in a google sheet"
218982195|NCT06680167|DRUG|Spinal anesthesia (heavy bupivacaine 0.5%)|12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
218982196|NCT06680167|DRUG|spinal anesthesia (hyperbaric Prilocaine 2%)|60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
218982197|NCT06681636|BIOLOGICAL|Human papillomavirus 9-valent vaccine, Recombinant|HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
218982198|NCT06681519|PROCEDURE|Experimental Group 1 - Acupoint Pressure Experimental Group 2 - Pressure Ball Control Group - Conventional Treatment|"Interventions Group 1 - Acupoint Pressure Group 2 - Hand-Held Pressure Ball Control Group 3 - Conventional Treatment Other Names: Stress ball holding, acupoint pressure, conventional treatment~Description: Before the intervention, subjects completed a pre-test. Afterward, they assumed a relaxed, comfortable lying position. The examiner applied acupoint pressure at four specific points: Hegu (LI4), Shenmen (HT7), Neiguan (PC6), and Zhongchong (PC9).~The technique involves using the thumb pad to apply circular and vertical pressure on each acupoint, with the other four fingers stabilizing against the skin to ensure even pressure. The pressure is gradually increased from light to moderate until the patient experiences sensations of soreness, numbness, or swelling, commonly described as deqi (Ye Meiling et al., 2020).~Each acupoint is pressed vertically for 3 seconds, then rotated clockwise at a rate of 2-3 rotations per second for another 3 second"
219071524|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
219675272|NCT00510055|PROCEDURE|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
218982199|NCT06238362|OTHER|TPAP|Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP
218982200|NCT06238362|DEVICE|CPAP|Gold standard for treating sleep apnea.
218982201|NCT05136690|DRUG|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
218982202|NCT05136690|DRUG|MK-4334|MK-4334 250 mg capsule taken by mouth.
218982203|NCT05136690|DRUG|Placebo patch|Placebo patch.
218982204|NCT05136690|DRUG|Placebo capsule|Placebo capsule taken by mouth.
218982205|NCT03419611|BEHAVIORAL|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
218982206|NCT03419611|OTHER|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
219071525|NCT06850558|PROCEDURE|Four parallel implants were installed in the interforaminal region|All participants administrated prophylactic antibiotics one day before implant placement and continued 7 days after surgery. Participants were asked to rinse their mouth with chlorhexidine mouthwash just before surgery and 7 days after surgery. Under local anesthesia, four implants were placed bilaterally in the interforaminal region. Four parallel implants (TioLogic, Dentaurum) were inserted in the inter-foraminal area using the submerged surgical approach and delayed loading protocol. By using the stereolithographic surgical guide the Implants were installed by the same surgeon with a minimum torque of 35 Ncm to give high initial stability. Relief was done in the mandibular denture over the implants and tissue conditioner (Visco-gel; DENTSPLY, Weybridge, UK) was used as a relining material. osseointegration was allowed to occur for a period of 3-6 months prior to final restoration.
219071526|NCT06560918|DEVICE|hearing aids|OTC devices for a week
219071527|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
219071528|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
219071529|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
219675273|NCT00510055|PROCEDURE|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
219675274|NCT04649879|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
219675275|NCT04649879|OTHER|Standard of care|Standard of care as determined by hospital practices for COVID-19 patients.
219675276|NCT00030485|DRUG|erlotinib hydrochloride|
219675277|NCT06121531|DEVICE|Soft Contact Lens|Vision Correction
218982207|NCT03419611|BEHAVIORAL|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
218982208|NCT06595121|DRUG|budesonide|Budesonide 1 mg/2mL nebuliser suspension
218982209|NCT06595121|DRUG|budesonide|Pulmicort(r) 1 mg/2mL nebuliser suspension
218982210|NCT06595121|OTHER|Activated Charcoal|suspension of 10g activated charcoal slurried in 70mL of water
218982211|NCT06680973|OTHER|Hospital-Based Resistance Training|"Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks."
219209203|NCT06782412|DIAGNOSTIC_TEST|[18F]AlF-FAPI-74 PET/CT|A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.
219209204|NCT06780072|OTHER|Activation Massage therapy|"Massage Sessions~Activation (Sports) massage The activation (sports) type of massage will be used as one of the massage interventions. This technique will be performed on a full body with more attention given to specific leg muscle groups such as the feet, the gastrocnemius, the femoral biceps and quadriceps and in upper body muscle groups such as the triceps, the rhomboid, the deltoid, the trapezius and head areas. Briefly, this type of massage involves a wide range of techniques that include effleurage, palmar sliding, pounding and hacking. The total duration of the activation message will be 30 minutes."
219209205|NCT06780072|OTHER|Relaxation Massage Therapy|Relaxation massage The Relaxation type of massage will be used as the second type of intervention in this study. This technique is designed to promote deep relaxation, reduce stress and enhance overall well-being. It is characterized by the use of four primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage
219209206|NCT06780982|BEHAVIORAL|Balloon-Blowing exercise program|"he program begins with a one-on-one session on the first day of the research project and continues with home-based care through the LINE application on a smartphone for 5 weeks. The program consists of four steps:~1. Decision-Making in Self-Care~2. Setting Goals and Planning Self-Care~3. Self-Care Implementation: practicing the balloon-blowing exercise daily for 3 sets of 3 balloons per set (a total of 9 balloons/day), with a 1-minute rest between sets, over a period of 5 weeks.~4. Maintaining Self-Care Behaviors"
219675278|NCT06274619|BIOLOGICAL|RSV A Memphis 37|RSV A Memphis 37 challenge agent
219675279|NCT02888990|DRUG|Dasatinib|
218982212|NCT06680973|OTHER|Home-Based Resistance Training|"Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded."
218982213|NCT06681038|DRUG|Standard Medical Therapy|"Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses."
218982214|NCT06681038|PROCEDURE|PIPAC|"In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks."
218982215|NCT06681506|DEVICE|Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.|Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)
218982216|NCT06681506|DEVICE|bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation|Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)
218982217|NCT06680947|DRUG|610|Subcutaneously injection.
218982218|NCT06680947|DRUG|610|Subcutaneously injection.
218982219|NCT06680947|DRUG|Placebo|Subcutaneously injection.
218982220|NCT06086353|DRUG|Tafamidis|Patients on tafamidis will be observed
218982221|NCT07016802|DRUG|GenSci134|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
218982222|NCT07016802|DRUG|GenSci134 Placebo|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
218982223|NCT07016802|DRUG|Recombinant Human Growth Hormone Injection (Norditropin®)|A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.
219675280|NCT02665741|DEVICE|Olympus transparent cap|distal colonoscope attachment
219675281|NCT02665741|DEVICE|Medivators Endocuff|distal colonoscope attachment
219675282|NCT02665741|DEVICE|Control|No distal colonoscope attachments
219675283|NCT06474572|DEVICE|Direct laryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
219675284|NCT06474572|DEVICE|Videolaryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
219675285|NCT06474572|DEVICE|Direct laryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
219675286|NCT06474572|DEVICE|Videolaryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
219675287|NCT05883163|DEVICE|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
219675288|NCT01267929|PROCEDURE|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
219675289|NCT01267929|PROCEDURE|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
219675290|NCT05996822|DRUG|ACF injection|AcF injection 1 month after a DXM injection
219675291|NCT01351207|OTHER|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
219675292|NCT03094793|OTHER|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
219675293|NCT03597191|OTHER|Exercises|Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
218982224|NCT06251544|GENETIC|HTR2 T Cells|"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"
218982225|NCT06251544|GENETIC|HTR2 T Cells|"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"
218982226|NCT06681025|DIAGNOSTIC_TEST|NeuMoDx EBV Quant 2.0 Assay|The NeuMoDx™ EBV Quant Assay 2.0 is an automated in vitro nucleic acid amplification test for the quantification of Epstein-Barr virus (EBV) DNA in EDTA plasma from immunocompromised transplant patients. Transplant patients are screened for EBV viral load as part of their standard of care. The remaining samples from these in vitro diagnostic nucleic acid amplification tests (NAAT) will be analyzed using the NeuMoDx EBV Quant Assay 2.0 to quantify EBV DNA in EDTA plasma. That result will be compared to a comparator in vitro diagnostic assay to evaluate the performance of the NeuMoDx EBV Quant 2.0 assay.
218982227|NCT06681337|BIOLOGICAL|BCMA CART + CD19 CART|BCMA CART + CD19 CART
218982228|NCT06710587|BEHAVIORAL|Voy Program|Voy Program - coaching and access to the Voy app to support behavioural changes
218982229|NCT06708676|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
218982230|NCT06710782|DRUG|Hyaluronic acid|Patients underwent intra-articular hyaluronic acid injection.
218982231|NCT06710782|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
218982232|NCT06708442|BEHAVIORAL|School-based CBT intervention|School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.
219675294|NCT04605653|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
219675295|NCT04260997|DIETARY_SUPPLEMENT|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
219675296|NCT04260997|OTHER|Placebo capsule|Once per day (QD), 12 weeks
218982233|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) Writing|Guided Narrative Technique (GNT) Writing : GNT writing is an intervention through writing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Writing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
219675297|NCT03803163|DRUG|TransCon Treprostinil|
219675298|NCT06548854|DRUG|STC314 Injection/STC314 Injection Placebo|All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
219675299|NCT00071838|DRUG|Daclizumab|
219675300|NCT02352961|OTHER|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
219209207|NCT06780982|BEHAVIORAL|Standard nursing care|The actions of nurses towards school-age children with obstructive sleep apnea at the hospital involve screening patient records and distributing educational materials in the form of brochures to individual pediatric patients and their parents. The knowledge provided in the brochures includes instructions on how to administer inhaled medication, avoiding allergens, performing facial and neck muscle exercises, and attending follow-up appointments as scheduled.
219675301|NCT05118997|DEVICE|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
219675302|NCT05118997|DEVICE|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
219675303|NCT01355562|DRUG|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
219675304|NCT00514982|DRUG|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
219675305|NCT00514982|DRUG|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
218982234|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) drawing|Guided Narrative Technique (GNT) Drawing: GNT drawing is an intervention through drawing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Drawing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
218982235|NCT06710041|DEVICE|Kinesiotape|Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression
218982236|NCT06710041|OTHER|Exercise|Tendon and nerve gliding exercise
218982237|NCT06710041|DEVICE|sham taping|In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
218982238|NCT06707649|OTHER|Self Management Education|Patients in this group will receive self-management education during the 3 days when they are in the hospital. On the first day of the training, COPD disease, causes of the disease, symptoms, reasons for alleviating complaints, practical information for living comfortably with COPD will be given. On the second day, emergency situations in COPD, what is an exacerbation and prevention suggestions and diaphragmatic breathing-cough exercises will be taught. On the last day, training will be given on pursed lip breathing, medication use, oxygen and nebulizer treatments. The education will be accompanied by a educational booklet prepared by researchers and expert opinion.
218982239|NCT06707649|OTHER|Telephone Follow-up|Patients will receive their first call one week after discharge. The calls will be scheduled weekly during the first month, biweekly in the second month, and monthly starting from the third month. During the calls, it is planned to repeat the educational content and answer the patient's questions.
218982240|NCT06709417|DRUG|Sintilimab|Sintilimab 200mg iv Q3W
218982241|NCT06709417|DRUG|Chemotherapy|Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
218982242|NCT06709417|RADIATION|radiotherapy|The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).
218982243|NCT06708637|DRUG|FYB203 2 mg (0.05 mL of 40 mg/mL)|IVT administration of FYB203 in a PFS
218982244|NCT06707428|OTHER|compression stockings|compression stockings used during cesarean section
218982245|NCT06708078|OTHER|Follow-up according to the Canhope allied health support program|"The Canhope allied health support program consists in:~* providing information tailored to patients' needs, with a dedicated time for patients to ask questions, obtain answers tailored to their needs, and be aware of the resources available to them;~* organizing peer-patient focus groups.~And aims at:~* reducing anxiety and improving patients' quality of life;~* better taking into account the impact of the announcement of intracranial Aneurysm, and to provide them with specific support.~* managing the emotional consequences of the announcement and the uncertainty of living with an intracranial Aneurysm."
218982246|NCT06709885|DRUG|Chidamide + Tislelizumab + chemotherapy (CapeOX )|Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox
218982247|NCT06709885|DRUG|CapeOX|4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
218982248|NCT06708728|OTHER|blood samples|blood samples for CBC parameters , peripheral blood smear, bilirubin levels and kidney function tests
219209208|NCT02355639|DRUG|Clobetasol propionate 0.05 % ointment|
219209209|NCT02355639|DRUG|Betamethasone dipropionate 0.064 % ointment|
219209210|NCT02355639|DRUG|Petrolatum ointment|
219675306|NCT00514982|DRUG|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
219675307|NCT00514982|DRUG|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
219675308|NCT00514982|DRUG|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
219675309|NCT00514982|DRUG|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
219675310|NCT05051891|DRUG|Orelabrutinib and R-CHOP|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
219675311|NCT05051891|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
219675312|NCT01944644|DEVICE|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
219675313|NCT01944644|DEVICE|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
219675314|NCT00193583|DRUG|Topotecan|
219675315|NCT00193583|DRUG|Carboplatin|
219675316|NCT00122525|PROCEDURE|Male Circumcision|
219675317|NCT03660891|DIAGNOSTIC_TEST|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
219675318|NCT03132415|BEHAVIORAL|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
219675319|NCT03132415|BEHAVIORAL|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
218982249|NCT06709755|BEHAVIORAL|Supporting Teen Problem Solving|STePS is a group-based, teen-focused intervention aimed at reducing diabetes-specific emotional distress and building diabetes resilience. STePS is grounded in both cognitive-behavioral and social problem-solving theories, which recognize the interrelationships among difficult situations, beliefs related to the cause and consequences of those situations, and the emotional and behavioral consequences of those beliefs, and which addresses problem solving strategies that influences ones' adaptive functioning in real-life social settings, distinguishing between problem solving and solution implementation. STePS reduces distress by teaching: 1) emotion regulation, helping teens learn to link beliefs, emotions, and behaviors; to challenge negative thinking by evaluating the accuracy of one's beliefs; and learning new coping skills.2) perspective taking, helping teens learn to identify their own thinking style.
218982250|NCT06709755|BEHAVIORAL|Diabetes Education|Arm Description: The Participants will receive diabetes education directed toward adolescents matching time, group experience and homework assignments, delivered virtually
218982251|NCT06708195|DEVICE|Group experimental|Type: Inactive TENS (placebo) Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glan
218982252|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia after us-assisted technique
218982253|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia using the surface landmark-guided
218982254|NCT07041268|BIOLOGICAL|rituximab|"Rituximab will be administered intravenously in three courses. The 1st course (loading dose) will include six rituximab infusions on days 1, 3, 5, 8, 14, and 21 of the study. On days 1, 3, and 5 rituximab will be infused at doses of 50, 125, and 200 mg per m2 of the participant's body surface area, respectively. On days 8, 14, and 21 rituximab will be infused at doses of 375 mg/m2, but not more than 500 mg total dose.~The 2nd course (maintenance therapy) will include four rituximab infusions on days 63, 70, 77, and 85 at doses of 375 mg/m2, but not more than 500 mg total dose.~The 3rd course (maintenance therapy) will include four rituximab infusions on days 119, 126, 134, and 140 at doses of 375 mg/m2, but not more than 500 mg total dose"
218982255|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with hypertension|Colorectal cancer patients with hypertension
218982256|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with diabetes|Colorectal cancer patients with diabetes
219675320|NCT01676103|DIETARY_SUPPLEMENT|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
219675321|NCT01676103|OTHER|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
219675322|NCT03498313|DRUG|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
219675323|NCT03498313|DRUG|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
219675324|NCT03498313|DRUG|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
219675325|NCT01439243|DRUG|Donepezil|10 mg Tablet
218982257|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with fatty liver|Colorectal cancer patients with fatty liver
218982258|NCT06709664|BEHAVIORAL|Questionnaire|Questionnaire study
219675326|NCT01439243|DRUG|Aricept®|10 mg Tablet
219675327|NCT02171429|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
219675328|NCT02171429|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
219675329|NCT02171429|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
219675330|NCT02171429|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
219675331|NCT00003007|BIOLOGICAL|recombinant interferon alfa|
219675332|NCT00003007|BIOLOGICAL|sargramostim|
219675333|NCT00003007|DRUG|cyclophosphamide|
219675334|NCT00003007|DRUG|dexamethasone|
219675335|NCT00003007|DRUG|melphalan|
219675336|NCT00003007|PROCEDURE|peripheral blood stem cell transplantation|
219675337|NCT00640406|DEVICE|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
219071530|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
219071531|NCT02693444|DRUG|Lidocaine|
219071532|NCT02693444|DRUG|Saline|
219071533|NCT02779257|DRUG|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
219071534|NCT02779257|DRUG|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
219071535|NCT02663128|DRUG|Lanabecestat|Administered orally
219071536|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
219071537|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
219071538|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
219071539|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
219675338|NCT00640406|DRUG|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
219675339|NCT00392756|DRUG|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
219675340|NCT05825963|DIETARY_SUPPLEMENT|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
219071540|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
219071541|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
219071542|NCT01903655|OTHER|telomere length|
219071543|NCT02313012|DRUG|CC-90003|CC-90003 PO once daily
219071544|NCT06645119|DIETARY_SUPPLEMENT|Whey Protein Supplement|Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
219675341|NCT04654715|PROCEDURE|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
219675342|NCT00980733|DIETARY_SUPPLEMENT|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
219675343|NCT00980733|DIETARY_SUPPLEMENT|Yoghurt|Plain yoghurt same as in intervention group without fortification
219675344|NCT00588705|BEHAVIORAL|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
219675345|NCT05223790|DEVICE|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
219675346|NCT02406963|OTHER|Digital Photograph|A digital photograph sent by the family of the surgical site
219675347|NCT02406963|OTHER|Telephone Call|Standard telephone call with the nurse practitioner
219675348|NCT04332003|DEVICE|Remote Ischemic Conditioning (RIC) Treatment|RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
219675349|NCT01481402|DRUG|Liothyronine|Liothyronine 40 microgram per day
219675350|NCT01481402|DRUG|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
219675351|NCT02163681|DRUG|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
219675352|NCT04164797|DRUG|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
219675353|NCT04164797|OTHER|chemoradiotherapy|chemoradiotherapy
219675354|NCT01067417|DRUG|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
219675355|NCT01067417|DRUG|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
219675356|NCT04400149|DIAGNOSTIC_TEST|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
219675357|NCT04957212|DRUG|Trastuzumab|An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
219675358|NCT04957212|DRUG|Pertuzumab|An initial dose of 840 mg, followed by 420 mg every 3-weeks
218982259|NCT06708403|OTHER|Judo-Specific Injury Prevention Exercise Program|The intervention includes a structured program designed specifically for judo athletes to prevent injuries and enhance performance. The program consists of warm-up exercises, strength and conditioning drills, balance improvement exercises, agility training, and sport-specific movements. It is delivered over six weeks, with participants completing three sessions per week. Each session is progressively tailored to improve overall motor skills, prevent overuse injuries, and enhance judo-specific abilities.
218982260|NCT06708806|PROCEDURE|cataract surgery|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (XY1) vs. an toric IOL (XY1A)
218982261|NCT06709170|DEVICE|Novel asymmetrical linear stapler|Novel asymmetrical linear stapler
218982262|NCT06709170|DEVICE|Signia™|Signia™
218982263|NCT06707532|DRUG|Propofol|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~\- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v."
219071545|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
219071546|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
219071547|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
219071548|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
219071549|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells
219071550|NCT05544968|DRUG|GM-CSF|Hematopoietic agent that helps form white blood cells.
219071551|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
219071552|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
219071553|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
219071554|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
219071555|NCT04695301|OTHER|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
219071556|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
219071557|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
219071558|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
219071559|NCT04173533|DRUG|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
219071560|NCT04173533|DRUG|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
219071561|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
219071562|NCT03822923|OTHER|Control group|Conventional treatment
219675359|NCT04957212|DRUG|Carboplatin|A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
219675360|NCT04957212|DRUG|Docetaxel|75 mg/m2 every 3-weeks
219675361|NCT04816760|BIOLOGICAL|Peripheral blood samples|Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
219675362|NCT02768792|DRUG|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
219071563|NCT05043649|DRUG|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
219071564|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
219071565|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
219071566|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
219071567|NCT03351023|OTHER|no intervention-this was an observational study|
219071568|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
219071569|NCT01748916|OTHER|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
219071570|NCT01748916|OTHER|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
219071571|NCT01748916|OTHER|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
219071572|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
219675363|NCT01438112|BIOLOGICAL|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
219675364|NCT01438112|OTHER|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
218982264|NCT06707532|DRUG|Rocuronium|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~\- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v."
218982265|NCT06707415|DIAGNOSTIC_TEST|Auditory evoked potentials|Auditory evoked potentials in parallel systems
218982266|NCT06707480|DRUG|Taurolidine and Heparin|Catheter Lock Solution
218982267|NCT06710665|DRUG|Chemotherapy|Chemotherapy
218982268|NCT06707714|DIAGNOSTIC_TEST|hypertension|Gastric cancer patients with hypertension
218982269|NCT06707714|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
218982270|NCT06707714|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver
218982271|NCT07045233|DEVICE|Sentinel® Cerebral Protection System|Deploy a Sentinel cerebral protection device during TAVR for patient with aortic stenosis.
218982272|NCT07045233|DIAGNOSTIC_TEST|MRI|Patients receive head MRI before and after the surgery in order to determine the stroke incidence.
218982273|NCT06733038|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at first infusion) day 1
218982274|NCT06733038|DRUG|Bevacizumab|5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
218982275|NCT06733038|DRUG|Irinotecan (CPT-11)|165 mg/sqm iv over 60 minutes day 1
218982276|NCT06733038|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
218982277|NCT06733038|DRUG|Leucovorin|200 mg/sqm iv over 2 hours day 1
218982278|NCT06733038|DRUG|Fluorouracil (5-FU)|3200 mg/sqm 48 h-continuous infusion, starting on day 1
218982279|NCT07041294|DEVICE|7 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (7 vs. 5 mm)
218982280|NCT07041294|DEVICE|5 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (5 vs. 7 mm)
218982281|NCT06709144|PROCEDURE|SMA lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
218982282|NCT06709144|PROCEDURE|SMV lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
218982283|NCT07049978|OTHER|Observational follow-up of standard Dupilumab treatment|Patients undergoing Dupilumab treatment for N-ERD will be observed after three to four years of treatment to assess long term changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
218982284|NCT06285461|BEHAVIORAL|Non-palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.
218982285|NCT06285461|BEHAVIORAL|Palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
218982286|NCT07054073|OTHER|None - observational study|None - observational study
218982287|NCT07054814|DEVICE|samsung gear VR google|"do some of games based VR exercise Headmaster 3.0 Dream Match Tennis Beat Saber (PSVR) Knockout League Hoops Richie's Plank Experience Pong It VR Egg Time VR Sparc VR plus accelerated functional rehab protocol~General Principles:~Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
218982288|NCT07054814|OTHER|Traditional theraapy|"General Principles: accelerated functional rehab protocol Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
218982289|NCT07053124|OTHER|Hand-drawn navigation|Hand-drawn navigation employed for diagnosing patients with PPN in Hand-drawn group.
218982290|NCT07053124|OTHER|Virtual bronchoscopy navigation|Virtual bronchoscopy navigation employed for diagnosing patients with PPN in VBN group.
218982291|NCT07054112|OTHER|Mindfulness-Based Stress Reduction (MBSR) meditation program|"The sessions of the meditation program (Mindfulness on Stress Reduction) will be delivered online, outside of the dialysis sessions. They will receive standard care during their hemodialysis sessions.~The program is composed of 8 sessions of 2h30 + 1 day of mindfulness, during 2 months."
218982292|NCT07054112|OTHER|Control group|Patients in the control group will be in a wait list group. They will receive standard care during their hemodialysis sessions. they will receive the MBSR meditation program between M8 and M10.
218982293|NCT07055243|DRUG|Mitapivat|Mitapivat will be given to adult patients with erythrocyte membranopathies
218982294|NCT07054203|DEVICE|Water Flosser|Participants in this Arm used a powered oral irrigator delivering a pulsed water stream at 50-90 psi. The intervention consisted of once-daily full-mouth irrigation, added to routine tooth brushing, for a duration of six months.
218982295|NCT07054203|DEVICE|Interdental Brush|Participants in this Arm used cylindrical, color-coded interdental brushes matched to individual embrasure sizes. The intervention involved once-daily cleaning of all interproximal spaces for six months, in addition to routine twice-daily tooth brushing.
218982296|NCT07053072|DRUG|Low Dose PD-1 mRNA LNP Vaccine|Patients will receive PD-1 mRNA LNP vaccine at 50 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
218982297|NCT07053072|DRUG|Medium dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 75 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
218982298|NCT07053072|DRUG|High dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 100 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
218982299|NCT07053501|DEVICE|Urinary Catheter Carrying Bag Use|A wearable catheter carrying bag was provided to participants. It was designed to conceal the urine bag and increase comfort, privacy, and psychosocial well-being. Participants received training on its use and wore it during all daily activities for 21 days.
219209211|NCT06777134|OTHER|Assessment of pelvic floor dysfunction|Pelvic floor dysfunctions in patients with multiple sclerosis will be assessed using the Pelvic Floor Distress Inventory-20 (PFDI-20). The scale is designed to assess all symptoms related to pelvic floor disorders and the severity of the distress they cause. The PFDI-20 consists of 3 subscales and 20 items, with each item rated on a scale from 0 (none) to 4 (quite a bit). To determine the scale scores, the average of the responses for each item in the subscales is multiplied by 25, resulting in a subscale score ranging from 0 to 100, and a total score ranging from 0 to 300. The Turkish validity and reliability of the scale were conducted by Çelenay et al.
219209212|NCT06777134|OTHER|The Quality of Life Assessment|The quality of life of the patients will be assessed using the Multiple Sclerosis International Quality of Life Questionnaire. The questionnaire consists of 31 questions and 9 subscales. The lowest score that can be obtained from the scale is 0, the highest score is 124, and a high score indicates a low quality of life. The subscales of the questionnaire include daily living activities, psychological well-being, relationships with friends, symptoms, relationships with family, relationships with the healthcare system, emotional and sexual life, coping, and rejection. The Turkish validation of the questionnaire has been conducted.
219209213|NCT06777134|OTHER|Core endurance assessment|"Core endurance in patients will be assessed using McGill's core endurance tests Trunk Flexor Test: Patients sit at a 60° trunk angle with knees bent, arms crossed, and feet stabilized. Time holding the position is recorded.~Trunk Extensor Test: Patients lie prone with the pelvis stabilized, lift the upper body above table level, and hold. Time is recorded until the body drops.~Lateral Trunk Test: In a modified side plank (knees bent, elbow support), patients lift hips off the mat. Time is recorded until hips lower or extra support is needed."
219209214|NCT06777134|OTHER|Hip strength assessment|The assessment of hip strength will specifically focus on the hip adductor and hip external rotator muscle strength. Both muscle groups are considered to be associated with the pelvic floor. Among the hip external rotators, the piriformis muscle functions as an internal stabilizer for the hip joint, while the obturator internus muscle shares fascial connections with the pelvic floor, playing a significant role in pelvic floor function. MR and EMG studies have demonstrated that the levator ani and gluteus maximus muscles are morphologically and functionally connected, and that the contraction of hip adductor and gluteal muscles facilitates the synergistic contraction of pelvic floor muscles. Based on this information, a handheld dynamometer will be used to measure the strength of the two muscle groups planned for evaluation. Measurements will be performed three times, and the average value will be recorded.
219209215|NCT06777134|OTHER|Tibialis posterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the posterior tibialis muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned at the exact midpoint between the tibial tuberosity and the medial malleolus (32,33); the passive electrode will be placed 4 cm distal; and the reference electrode will be placed on the lateral malleolus.~The patient will be asked to perform isometric plantar flexion + inversion movement of the ankle against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
219209216|NCT06777134|OTHER|Tibialis anterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the tibialis anterior muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned on the muscle body of the tibialis anterior, the passive electrode will be placed 4 cm distal, and the reference electrode will be placed on the lateral malleolus (34,35).~The patient will be asked to perform isometric ankle dorsiflexion against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
219209217|NCT06769932|DIAGNOSTIC_TEST|preoperative computed tomography|subject's muscle mass from preoperative computed tomography (CT) images.
219209218|NCT06774976|OTHER|8-week Evidence-Based Neck Resistance Training Program|See arm/group description.
218982300|NCT07053267|DIETARY_SUPPLEMENT|Funrional Ice Cream|Single 100 g serving of ice cream enriched with 10 g of Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
218982301|NCT07053267|DIETARY_SUPPLEMENT|Placebo Ice Cream|Single 100 g serving of placebo ice cream identical in flavor, texture, and appearance, but without Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
218982302|NCT07055100|DIAGNOSTIC_TEST|Needle stick injuries|A descriptive cross-sectional study design will be employed, and data will be collected from all staff working in the trauma center through census sampling. A structured questionnaire will capture demographic data, occupational risk factors, and KAP regarding bloodborne pathogens. Blood samples will be collected to screen for HBV, HCV, and HIV infections.
218982303|NCT07055074|DIAGNOSTIC_TEST|Low Pressure Pneumoperitoneum|Low Pressure Pneumoperitoneum (8-10 mmHg) Details: CO₂ insufflation to 8-10 mmHg IAP, continuous monitoring, measurement at baseline, insufflation, and desufflation.
219071573|NCT06650527|BEHAVIORAL|Cognitive Empathy Training|Participants will engage in a mentalization activity by captioning photos of their care recipients, reflecting on what the care recipient might be thinking or feeling. Over 10 days, caregivers will take 3-5 daily pictures of their care recipient and caption each with descriptive text representing the recipient's inner voice. This task encourages caregivers to consider the care recipient's perspective and motivations behind their behavior or emotional experiences. Photos will be shared securely via encrypted email. Utilizing accessible smartphone technology, the study allows caregivers to capture and reflect on meaningful moments with their care recipients
219071574|NCT06650527|BEHAVIORAL|Control Condition|In the control condition, participants will be asked to take 3-5 daily photographs of nature over 10 days. They will be asked to caption each photo with a description of what they see. This exercise will involve many of the same activities as the cognitive empathy training, except that participants will not be mentalizing or taking the the perspective of their PLWD or anyone else.
219071575|NCT06650527|PROCEDURE|Pre and post intervention blood spot collection|At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.
219071576|NCT06650527|PROCEDURE|Pre and post intervention MRI session|In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.
219071577|NCT00000216|DRUG|Buprenorphine|
219071578|NCT00850616|BIOLOGICAL|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
219071579|NCT00850616|BIOLOGICAL|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
219071580|NCT00274534|DRUG|Tiotropium|
219071581|NCT00274534|DRUG|Salmeterol|
219071582|NCT01311102|DRUG|Lidocaine|1.33 cc 2% liquid lidocaine
219209219|NCT06861387|DEVICE|Cryotherapy|AtriCure's cryoICE cryoSPHERE probe will be inserted through one of the incisions used for VATS/RATS. Cryo-analgesia will be performed unilaterally on the intercostal nerve at the level Th3-Th7. Thus, cryo-analgesia will be applied on 5 intercostal levels. The probe will be placed at the inferior aspect of the ribs, posterior to the mid-axillary line, directly on the neurovascular bundle. One freezing cycle takes approximately 2 minutes and a temperature of between minus 50 and 70 degrees Celsius will be applied.
219209220|NCT06861387|DRUG|PAiN - multimodal analgesia|Our standard postoperative pain management plan consists of intercostal nerve block, patient controlled analgesia and acetaminophen
219209221|NCT06860893|DRUG|Spinal Anesthesia with Bupivacaine|After obtaining return of cerebrospinal fluid, hyperbaric bupivacaine 5 mg/mL 1,5 mL (7,5 mg) and morphine 200 µg/mL, 0.5 mL (100 µg) was injected intrathecally.
219209222|NCT06860893|DRUG|Placebo|Local skin infiltration with lidocaine
219209223|NCT06884098|DRUG|AD-228B|AD-228B, 1Tab., Per Oral
218982304|NCT07055074|DIAGNOSTIC_TEST|Medium Pressure Pneumoperitoneum|Medium Pressure Pneumoperitoneum (12-14 mmHg) Details: CO₂ insufflation to 12-14 mmHg IAP, parameters measured at key intervals, standard general anesthesia used. High Pressure Pneumoperitoneum (15-20 mmHg) Details: Standard high-pressure technique, monitoring of hemodynamic and respiratory parameters.
219209224|NCT06884098|DRUG|AD-2284|AD-2284, 1Tab., Per Oral
219209225|NCT06886763|OTHER|Liver innervation markers|Liver innervation markers will be quantified immediately after resection by transparisation technique.
218982305|NCT07053514|BEHAVIORAL|SD-ART|SD-ART protocol for PWH with both patients and their HIV clinicians
218982306|NCT05870189|BEHAVIORAL|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
218982307|NCT05870189|BEHAVIORAL|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
218982308|NCT06403228|OTHER|Mindfulness Based Structured Nursing Interventions|In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
218982309|NCT06454435|DRUG|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
218982310|NCT06454435|DRUG|Sintilimab + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
218982311|NCT01869881|DRUG|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
218982312|NCT01869881|DRUG|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
218982313|NCT03009409|DRUG|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
218982314|NCT03009409|OTHER|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
218982315|NCT03989414|DRUG|CC-92480|Specified dose on specified days
218982316|NCT03989414|DRUG|Bortezomib|Specified dose on specified days
218982317|NCT03989414|DRUG|Dexamethasone|Specified dose on specified days
218982318|NCT03989414|DRUG|Daratumumab|Specified dose on specified days
218982319|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
218982320|NCT03989414|DRUG|Elotuzumab|Specified dose on specified days
218982321|NCT03989414|DRUG|Isatuximab|Specified dose on specified days
218982322|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
218982323|NCT06000111|BEHAVIORAL|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
218982324|NCT06000111|BEHAVIORAL|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
218982325|NCT02280538|DEVICE|Intra-Articular Hyaluronic Acid|
218982326|NCT02280538|DEVICE|Placebo|
218982327|NCT06495021|PROCEDURE|Lymphatic Pump Osteopathic Manipulative Therapy|OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
218982328|NCT06933589|OTHER|Test meal with plant protein|The plant protein blend is made up of 5 protein ingredients for which the food grade is guaranteed: a rice protein isolate, a potato protein isolate, a lupin protein isolate, a corn protein isolate.
218982329|NCT06933589|OTHER|Test meal with milk protein|The milk protein product is a food-grade protein isolate.
218982330|NCT06071845|DEVICE|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
218982331|NCT06071845|DIAGNOSTIC_TEST|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
218982332|NCT06090331|DIAGNOSTIC_TEST|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
218982333|NCT00531934|DRUG|Doxycline|100mg po daily
218982334|NCT00531934|DRUG|erlotinib [Tarceva]|150mg po daily
218982335|NCT00721500|DEVICE|etafilcon A|contact lens
218982336|NCT00721500|DEVICE|narafilcon A|contact lens
218982337|NCT01543698|DRUG|LGX818|
218982338|NCT01543698|DRUG|MEK162|
219071583|NCT01311102|DRUG|Normal Saline|1.33cc normal saline
219209226|NCT06887166|PROCEDURE|Platelet Rich Plasma|injection of PRP IN PERIANAL WOUNDS AFTER FISTULOTOMY OPERATIONS
218982339|NCT01543698|DRUG|LEE011|
218982340|NCT01429415|DRUG|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
218982341|NCT01429415|DRUG|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
218982342|NCT00150709|DRUG|Levetiracetam|"* Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use"
218982343|NCT02809404|DRUG|Everolimus|
218982344|NCT02975336|DRUG|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
218982345|NCT02975336|DRUG|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
218982346|NCT02975336|DRUG|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
218982347|NCT02975336|DRUG|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
219071584|NCT03277313|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
219071585|NCT05273710|OTHER|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
219071586|NCT05273710|OTHER|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
219675365|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
219675366|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
219675367|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
219675368|NCT06099041|DEVICE|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
219675369|NCT05522946|OTHER|Gameplay between parent and child or adolescent with or without a disability|Parent and child or adolescent will play the game using the provided sensors for 10-15 minutes total. Depending on the cognitive and/or physical ability of the child or adolescent, the two may take turns wearing the sensors or if the child or adolescent does not have the physical or cognitive ability to deliberately touch the sensor, then the child or adolescent will wear the sensors and the parent will touch the sensors in order to move the game forward.
219675370|NCT06304480|DIETARY_SUPPLEMENT|100g fermented Tofu|"* Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.~* Participants will consume the first Study Product on the day of their Visit 3 (Day 0) and will consume their last Study Product the day prior to Visit 5 (Day 56).~* Participants will be instructed to return any unused Study Product at Visit 5 (Day 56)."
219675371|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.05%|
219675372|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.10%|
219675373|NCT00893139|DRUG|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
219675374|NCT01838772|DRUG|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
219675375|NCT00533221|DRUG|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
219675376|NCT00533221|DRUG|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
219675377|NCT06071546|DEVICE|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
219675378|NCT02003755|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
219675379|NCT04283435|DRUG|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
219675380|NCT04283435|OTHER|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
219675381|NCT04283435|DRUG|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
219675382|NCT02472158|DEVICE|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
219675383|NCT02472158|DEVICE|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
219675384|NCT03288545|DRUG|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
219675385|NCT03288545|DRUG|pembrolizumab|IV infusion on day 1 every 21 days
218982348|NCT02975336|DRUG|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
218982349|NCT00808860|DIETARY_SUPPLEMENT|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
218982350|NCT00808860|DIETARY_SUPPLEMENT|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
218982351|NCT06540729|DRUG|Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer|Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
218982352|NCT05517551|PROCEDURE|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
218982353|NCT03659539|DRUG|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
219675386|NCT03288545|DRUG|cisplatin|IV infusion on day 1 every 21 days
219675387|NCT03288545|DRUG|carboplatin|IV infusion on day 1 every 21 days
219675388|NCT03288545|DRUG|gemcitabine|IV infusion on days 1 and 8 every 21 days
219675389|NCT05514457|BEHAVIORAL|visual stimulation with I pad|"At the beginning of the study, for baseline condition, children will do 4 tests (visuo-spatial perception test, visual attention span, visual research, phonology tests).~In the first group of the study, the children will do visual research exercises on I pad 10 minutes per day during one month = remediation. They will also do 4 reading aloud tests, once a month, for 3 months. The remediation exercises will be realized during the first, second or third month."
219675390|NCT05514457|BEHAVIORAL|visual stimulation with lamp|"At the beginning of the study, for baseline condition, children will do the 4 tests like group 1.~In the second group of the study, the children will do reading aloud tests, with lamp adjusted with different parameters = remediation (passive visual stimulation of a specific frequency believed to promote visual processing of written symbols)."
219675391|NCT05753735|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
219675392|NCT05753735|DRUG|Amoxicillin/ Clavulanic acid|Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
219675393|NCT05964907|DEVICE|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
218982354|NCT03659539|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
218982355|NCT01612104|BEHAVIORAL|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
219675394|NCT05964907|DEVICE|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
219675395|NCT00770471|DRUG|temozolomide|
219675396|NCT00770471|DRUG|veliparib|
219675397|NCT00770471|GENETIC|DNA methylation analysis|
219675398|NCT00770471|GENETIC|gene expression analysis|
219675399|NCT00770471|GENETIC|mutation analysis|
219675400|NCT00770471|GENETIC|proteomic profiling|
219675401|NCT00770471|OTHER|high performance liquid chromatography|
218982356|NCT03824184|PROCEDURE|manipulation of endometrium|Manipulation of endometrium with saline
218982357|NCT00418249|DRUG|AS101|
218982358|NCT04120441|BEHAVIORAL|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
218982359|NCT06261918|PROCEDURE|Influence of metabolic syndrome on the achievement of pathological complete response|The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
218982360|NCT02519218|DEVICE|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
218982361|NCT02528604|PROCEDURE|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
218982362|NCT02528604|PROCEDURE|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
218982363|NCT02528604|PROCEDURE|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
218982364|NCT02528604|DEVICE|Implantable loop recorder|
218982365|NCT04668807|DEVICE|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
218982366|NCT04668807|DEVICE|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
218982367|NCT04001933|OTHER|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
218982368|NCT04500730|DRUG|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
218982369|NCT00357357|DRUG|HF0220|comparison of different dosages of drug
218982370|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
218982371|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
218982372|NCT01001013|DRUG|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
218982373|NCT00489060|PROCEDURE|Cryoablation and External Beam Radiation|
218982374|NCT01457222|BEHAVIORAL|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
218982375|NCT01457222|BEHAVIORAL|Music relaxation|Music relaxation 10 minutes daily
218982376|NCT00810914|DRUG|bupivicaine epidural|bupivicaine continuous epidural infusion
218982377|NCT00810914|DRUG|bupivicaine epidural infusion patient epidural|bupivicaine
218982378|NCT00810914|DRUG|bupivicaine|patient controlled anesthesia only
218982379|NCT02836392|BEHAVIORAL|Questionnaire|
218982380|NCT01890941|DRUG|KCT-0809 ophthalmic solution|
219209227|NCT06737497|PROCEDURE|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia
218982381|NCT01890941|DRUG|Placebo|
218982382|NCT01823146|DRUG|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
219675402|NCT00770471|OTHER|immunoenzyme technique|
219675403|NCT00770471|OTHER|laboratory biomarker analysis|
219675404|NCT00770471|OTHER|mass spectrometry|
219675405|NCT00770471|OTHER|pharmacogenomic studies|
219675406|NCT00770471|OTHER|pharmacological study|
219675407|NCT00770471|PROCEDURE|adjuvant therapy|
219675408|NCT00770471|RADIATION|radiation therapy|
219675409|NCT00102115|DRUG|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
219675410|NCT03026829|DEVICE|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
219675411|NCT02388087|DEVICE|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
219675412|NCT02388087|PROCEDURE|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
219675413|NCT05266482|OTHER|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
219675414|NCT00078845|DRUG|Amifostine|500 mg three times a week.
219675415|NCT01534416|DRUG|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
219675416|NCT01534416|DRUG|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
219675417|NCT04462822|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
219675418|NCT04462822|DRUG|ADVAIR DISKUS® 250/50|2 inhalations of Test and Reference product in each study period
219675419|NCT01768559|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
219675420|NCT01768559|DRUG|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
219675421|NCT01768559|DRUG|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
219675422|NCT01768559|DRUG|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
219675423|NCT01768559|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
219675424|NCT03486405|OTHER|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
218982383|NCT01823146|DRUG|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
218982384|NCT03490708|DRUG|Tranilast|Subjects will be treated with tranilast
218982385|NCT02624674|DEVICE|Multi-spectral Imaging Device (MSID)|
218982386|NCT02675985|OTHER|Physical Therapy|Early Intensive Physical therapy in the ICU
218982387|NCT06314308|BEHAVIORAL|CATCHES|At the baseline visit (T0), informed consent will be obtained, and baseline questionnaires and measurements completed. A physical activity monitor will be provided. After discharge, Task Specific Training guided by Cognitive Behavioral Therapy with Exposure delivered over 7 one-hour sessions including two intake sessions by specialists and five follow up sessions delivered by CHWs individually at home over 3 months. After the final session at 12 weeks (about 3 months), participants will complete a study end visit (T1) which will include follow up questionnaires and measurements.
219071587|NCT05273710|OTHER|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
219071588|NCT00335660|DRUG|AV608|
219071589|NCT00507793|DRUG|Sirolimus|
219071590|NCT00507793|DRUG|Cyclosporine|
219071591|NCT03269812|PROCEDURE|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
218982388|NCT02110238|DEVICE|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
218982389|NCT02110238|DEVICE|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
218982390|NCT03532958|DRUG|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
218982391|NCT03532958|DRUG|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
218982392|NCT00826046|DRUG|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
218982393|NCT05817318|DEVICE|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
218982394|NCT01024335|DRUG|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
219071592|NCT02353793|DEVICE|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
219071593|NCT02353793|DEVICE|Cotton wool blanket|Using cotton wool blanket for patient warming
219071594|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
219071595|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
219071596|NCT02324491|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
219071597|NCT02324491|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
219209228|NCT06744530|PROCEDURE|stereotactic radiotherapy ablation|Single dose of 25 Gy up to 32.5 Gy on the myocardium in patients with therapy-refractory ventricular tachycardia
219209229|NCT06744608|OTHER|Structured Myofascial Release|haftada 2 seans 8 hafta boyunca toplam 16 seans uygulama yapıldı
219071598|NCT02132611|DEVICE|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
219071599|NCT00581529|RADIATION|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
219071600|NCT03136614|DEVICE|Arteriograph|
219071601|NCT06261151|OTHER|Clinical data collection|Clinical data of elderly patients with gastric cancer who underwent open gastrectomy were collected and analyzed.
219071602|NCT04377646|DRUG|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
219071603|NCT04377646|DRUG|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
219071604|NCT04377646|DRUG|Zinc|15 mg per day up to 2 months
219071605|NCT04377646|DRUG|Zinc (Placebo)|1 pill per day up to 2 months
219071606|NCT05818449|OTHER|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee"
219071607|NCT02182193|DRUG|BIBF 1120 capsules charge 1|
219071608|NCT02182193|DRUG|BIBF 1120 capsules charge 2|
219071609|NCT02182193|DRUG|BIBF 1120 drinking solution|
219071610|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
219071611|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
219071612|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
219071613|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
219209230|NCT06744608|DEVICE|tens (transcutaneous electrical nerve stimulation)|A total of 16 sessions of application were applied to the groups, 2 sessions per week for 8 weeks.
219209231|NCT06744608|BEHAVIORAL|lifestyle changes|A presentation including lifestyle changes was prepared and training was provided.
219209232|NCT06740552|DRUG|Evolocumab|Evolocumab 140mg every two weeks
219209233|NCT06740552|DRUG|Lipid Lowering Medication|Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
219675425|NCT03486405|OTHER|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
219071614|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
219071615|NCT05437627|DIAGNOSTIC_TEST|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
219071616|NCT02763384|DRUG|BL-8040|
219071617|NCT02763384|DRUG|Nelarabine|
219071618|NCT02594891|DEVICE|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
219071619|NCT02594891|DEVICE|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
219071620|NCT04952545|DRUG|ALXN2050|Oral tablet.
219071621|NCT04952545|DRUG|Placebo|Oral tablet.
219071622|NCT02493127|OTHER|Standard PCS|Subject completes the standard version of the PCS Questionnaire
219071623|NCT02493127|OTHER|Grip Strength|Research Assistant takes Grip Strength Measurements
219071624|NCT02493127|OTHER|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
219071625|NCT06299397|BEHAVIORAL|breastfeeding - humor training|Breastfeeding and humor-based practice will continue for 35-45 minutes, once a week for 2 weeks.
219071626|NCT06299397|OTHER|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
219071627|NCT04915963|DIETARY_SUPPLEMENT|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
219071628|NCT00959023|OTHER|laboratory biomarker analysis|
219071629|NCT00959023|OTHER|medical chart review|
219071630|NCT00959023|OTHER|questionnaire administration|
219071631|NCT02978365|OTHER|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
219209234|NCT06746220|OTHER|Microbiota sample|Microbiota sample: one sample at inclusion and one sample at the end of the study
219209235|NCT06746220|OTHER|Salivary sample|Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.
219675426|NCT04769674|OTHER|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
219675427|NCT04995263|BEHAVIORAL|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
219675428|NCT04995263|BEHAVIORAL|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
219675429|NCT04995263|BEHAVIORAL|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
219675430|NCT04995263|BEHAVIORAL|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
219675431|NCT04995263|OTHER|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
219675432|NCT04995263|DEVICE|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
219675433|NCT05654064|DRUG|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
219675434|NCT05654064|DRUG|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
219675435|NCT04031326|BEHAVIORAL|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
219675436|NCT03146741|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
219675437|NCT01889368|DIETARY_SUPPLEMENT|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
219675438|NCT01889368|DIETARY_SUPPLEMENT|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
219675439|NCT04814589|DRUG|ezetimibe tablets|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
219675440|NCT04814589|DRUG|ezetimibe tablets(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
219675441|NCT01149031|DEVICE|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
219675442|NCT02589847|BIOLOGICAL|RBX2660|suspension of intestinal microbes
219675443|NCT02589847|DRUG|Standard of Care Antibiotics|Standard of Care Antibiotics
219675444|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
219675445|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
218982395|NCT01024335|DRUG|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
218982396|NCT00002561|BIOLOGICAL|bleomycin sulfate|10 units/m2
219675446|NCT05649696|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
219675447|NCT05649696|DRUG|Normal Saline|Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
219675448|NCT04759911|OTHER|Quality-of-Life Assessment|Ancillary studies
219675449|NCT04759911|OTHER|Questionnaire Administration|Ancillary studies
218982397|NCT00002561|DRUG|dacarbazine|375mg/m2
218982398|NCT00002561|DRUG|doxorubicin hydrochloride|25mg/m2
218982399|NCT00002561|DRUG|vinblastine|6mg/m2
218982400|NCT00002561|RADIATION|radiation therapy|35Gy in 20 fractions (daily)
218982401|NCT03273543|DEVICE|Restylane® Defyne|hyaluronic acid filler injection
218982402|NCT06088108|DEVICE|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
218982403|NCT02761070|DRUG|Temozolomide|
218982404|NCT02761070|DRUG|Bevacizumab|
218982405|NCT00673504|DRUG|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
218982406|NCT00673504|DRUG|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
219675450|NCT04759911|DRUG|Selpercatinib|Given PO
219675451|NCT04759911|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219675452|NCT05345847|OTHER|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
219675453|NCT05345847|OTHER|Early initiation|Immediate start of high-dose steroids
219675454|NCT05621837|OTHER|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
219675455|NCT04499196|DRUG|GlucoCorticoid|Administering glucocorticoid
219209236|NCT06746220|OTHER|Quality of life questionnaires|Quality of life questionnaires: 5 auto-questionnaires to be filled at inclusion and at the end of the study
219209237|NCT06746220|OTHER|Nutritional evaluation|Nutritional evaluation: food diary completed by participants for 3 consecutive days at inclusion and at the end of the study
219209238|NCT06746220|OTHER|Assessment of physical health|Assessment of physical health : 3 tests to assess strength and endurance. These tests will be performed at inclusion and at the end of the study.
219071632|NCT02978365|DEVICE|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
219675456|NCT05437445|DIAGNOSTIC_TEST|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
219071633|NCT00003135|DRUG|fluorouracil|
219071634|NCT00003135|DRUG|pegylated liposomal doxorubicin hydrochloride|
219071635|NCT00003135|PROCEDURE|hyperthermia treatment|
219071636|NCT05794854|OTHER|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
219071637|NCT05794854|OTHER|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
219071638|NCT02169908|DEVICE|Thermotest|
219071639|NCT02169908|DEVICE|von Frey hairs|
219071640|NCT00168025|DRUG|Immunoglobulins Intravenous (Human)|
219209239|NCT06746220|OTHER|Physical activity|Physical activity: 2 sessions per week for 6 weeks. For each session, 45 minutes of physical activity consisting of muscle strengthening and endurance exercises.
219675457|NCT06399016|DEVICE|augmented reality book|The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.
219675458|NCT06399016|DEVICE|book|This group will be asked to just read the book without turning on the augmented reality feature of the book.
219071641|NCT00325793|DRUG|Nicardipine|
219209240|NCT06746220|OTHER|Treatment with placebo or probiotic|Treatment with placebo or probiotic: 1 capsule per day during 42 consecutive days. In the morning, on an empty stomach with a large glass of water 20 minutes before the meal
219209241|NCT06892054|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|A minimum of 6 and a maximum of 15 patients will be enrolled to receive first-line chemotherapy (gem/nab-P or mFOLFIRINOX) in combination with sotorasib 960 mg daily (QD). The treatment with gem/nab-P and mFOLFIRINOX should be managed as per clinical practice.
219071642|NCT01640756|DEVICE|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
219675459|NCT05362149|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
219675460|NCT05362149|DRUG|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
219071643|NCT05918094|DRUG|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
219071644|NCT05918094|DRUG|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
219071645|NCT02037347|DRUG|Palifermin|
219071646|NCT01870271|BEHAVIORAL|Developmentally adapted cognitive processing therapy|
219071647|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
219071648|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
219071649|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
219071650|NCT00006325|DRUG|Peginterferon alfa-2b|
219071651|NCT03787940|DRUG|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
219071652|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
219071653|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
219071654|NCT01118208|OTHER|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
219209242|NCT06747429|OTHER|High fat diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).
219209243|NCT06747429|OTHER|Standard diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.
219209244|NCT06888141|BEHAVIORAL|Virtual Sequential Emotional Processing Task|A 20-minute interactive session delivered 3 times over a one week period.
219675461|NCT05362149|DRUG|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
219071655|NCT01118208|OTHER|Dispense as usual|Dispensing prescription medications in standard pill bottles.
219675462|NCT05088681|OTHER|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
219675463|NCT05977101|BIOLOGICAL|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
219675464|NCT05977101|OTHER|Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
219675465|NCT04763616|DRUG|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
219675466|NCT04763616|DRUG|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
219675467|NCT00565890|DRUG|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
219675468|NCT00547924|BEHAVIORAL|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
219675469|NCT01679444|PROCEDURE|Magnetic Resonance Spectroscopy|
219675470|NCT05103306|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
219675471|NCT05103306|DRUG|INS|Basal insulin add on the background OADs
219675472|NCT00361803|DRUG|topotecan|topotecan
219675473|NCT03305692|DIAGNOSTIC_TEST|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
219675474|NCT00002071|DRUG|Epoetin alfa|
219675475|NCT04319926|DRUG|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
219675476|NCT04319926|DRUG|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
219675477|NCT01515696|DRUG|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
219675478|NCT01515696|DRUG|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
219675479|NCT02903810|BIOLOGICAL|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
219209245|NCT06888141|BEHAVIORAL|Virtual Control Task|A time-matched (ie., 20 minute) interactive session delivered 3 times over a one week period.
218982407|NCT05058235|OTHER|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
218982408|NCT05058235|OTHER|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
218982409|NCT00115635|DRUG|docetaxel|
218982410|NCT00115635|DRUG|gemcitabine|
218982411|NCT06125561|OTHER|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
218982412|NCT03421535|PROCEDURE|Sleeper Stretch|Internal Range of motion of dominant shoulder
218982413|NCT03421535|PROCEDURE|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
218982414|NCT00515489|DRUG|Risperidone|as prescribed
218982415|NCT05195190|OTHER|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
218982416|NCT06558097|DRUG|XXB750|Single SC dose of XXB750 (administered by single or multiple injections)
218982417|NCT06558097|OTHER|Placebo|Single SC dose of matching placebo (administered by single or multiple injections)
218982418|NCT03913988|BEHAVIORAL|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
218982419|NCT03913988|BEHAVIORAL|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
218982420|NCT03913988|BEHAVIORAL|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
218982421|NCT03985254|OTHER|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
218982422|NCT03985254|OTHER|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
218982423|NCT04261036|DRUG|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
218982424|NCT04261036|OTHER|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
218982425|NCT05081765|DRUG|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
219071656|NCT00634608|OTHER|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
219071657|NCT03034577|DRUG|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
219071658|NCT03034577|DRUG|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
219071659|NCT03919422|PROCEDURE|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
219675480|NCT01761929|RADIATION|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
219675481|NCT03461783|DEVICE|Zorflex Activated Carbon Dressing|Antimicrobial dressing
219675482|NCT03461783|DEVICE|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
219675483|NCT05157555|OTHER|Data collection|Description: quality of life assessment
219675484|NCT04396379|DEVICE|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
219675485|NCT03489980|OTHER|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
218982426|NCT05081765|DEVICE|Lynparza|correlation between C through and taken drug
218982427|NCT01033760|DRUG|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
218982428|NCT01033760|DRUG|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
219675486|NCT05102435|OTHER|Tool Translation & Validation study|In this English version of POMA scale will be translated into Urdu.
219675487|NCT05205980|BEHAVIORAL|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
219675488|NCT01541072|DRUG|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
219675489|NCT01541072|DRUG|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
219675490|NCT03839329|BEHAVIORAL|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
219675491|NCT00441519|DRUG|aspirin|
219675492|NCT00441519|DRUG|omeprazole|
219675493|NCT06248684|OTHER|standardized prevention and therapy measures|Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
219675494|NCT00398047|DRUG|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
218982429|NCT05100459|DIETARY_SUPPLEMENT|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
218982430|NCT05100459|DIETARY_SUPPLEMENT|Conventional whey protein|25 grams of protein delivered 3 times daily
218982431|NCT05100459|DIETARY_SUPPLEMENT|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
218982432|NCT02662829|BEHAVIORAL|Community-based intervention|
218982433|NCT02662829|OTHER|Standard of care|
219209246|NCT06732531|DRUG|BH011|BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
219209247|NCT04121676|DRUG|AGEN2373|An Anti-CD137 Monoclonal Antibody
219675495|NCT05887960|OTHER|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
219675496|NCT00114829|PROCEDURE|MR colonography with dynamic contrast uptake|
219675497|NCT02411734|BEHAVIORAL|Rehabilitation|Rehabilitation after hospitalization
219675498|NCT00192777|DRUG|Xeloda|
219675499|NCT00192777|PROCEDURE|External Beam Radiotherapy|
219675500|NCT00538226|DEVICE|External Electric Muscle Stimulation|
219675501|NCT00455676|PROCEDURE|Chevron osteotomy versus Scarf osteotomy|
219675502|NCT02571062|DRUG|Fexinidazole|
219675503|NCT05195216|BEHAVIORAL|Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form|Online questionnaires were administered to individuals.
219675504|NCT01188668|DRUG|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
219675505|NCT01188668|DRUG|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
219675506|NCT04017117|PROCEDURE|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
219675507|NCT05538936|OTHER|Baby SPA|"Salus Per Aquam, Sanitas Per Aquam, Salut Per Aqua or Solus Per Aqua (SPA) means health that comes with water. Baby SPA is a physiotherapy method that stimulates the baby's motor movements through water (hydrotherapy) and performs it in an integrated way to balance the body, mind, and emotions. Baby SPA is applied in specially designed bathtubs. The size of the tub is designed in such a way that children can move their hands and feet freely and not be narrow. A neck ring/ring is used to keep the baby on the water surface during SPA treatment."
219675508|NCT05538936|OTHER|Massage|"The best way to communicate with a baby is to touch it. When babies are born, unlike their other senses, the most developed one is the sense of touch. Because this process begins while in the womb. The baby communicates by touch and begins to recognize his environment. The sense of touch is a priority for the development of all senses. They need to perceive their environment, especially in newborns and infancy periods. Touching the body in a systematic way for a therapeutic purpose is called Massage. Massage is soft touches to body tissues to relax muscles, accelerate circulation, reduce infantile colic symptoms and pain, regulate sleep, and increase its duration. Baby massage has many benefits such as reducing colic symptoms, increasing weight gain, providing motor development and coordination, strengthening the parent and baby bond, supporting growth and development, and reducing stress."
218982434|NCT02121431|BEHAVIORAL|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
218982435|NCT05792501|DEVICE|Mechanical ventilation|type of therapy that helps you breathe or breathes for you when you can't breathe on your own
218982436|NCT00324909|DRUG|Hyperbaric Oxygen Therapy|
218982437|NCT03242889|DRUG|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
218982438|NCT04767620|DRUG|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
218982439|NCT02509481|DRUG|Ivermectin|
218982440|NCT02509481|DRUG|Albendazole|
218982441|NCT03226860|DEVICE|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
218982442|NCT03226860|OTHER|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
218982443|NCT01549678|OTHER|Total contact insole|EVA insole shaped on patient´s foot.
218982444|NCT01549678|OTHER|placebo insole|EVA insole flat
218982445|NCT01760720|BEHAVIORAL|MMT CARE|
218982446|NCT05587803|DEVICE|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
218982447|NCT03617497|DIAGNOSTIC_TEST|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
218982448|NCT03617497|DIAGNOSTIC_TEST|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
218982449|NCT03918473|OTHER|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
218982450|NCT03918473|OTHER|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
218982451|NCT05397964|DEVICE|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
218982452|NCT03433157|DEVICE|Hall technique|Metal Stainless stain crown placed with Hall technique
218982453|NCT03433157|DEVICE|Traditional technique|Metal Stainless stain crown placed with Traditional technique
218982454|NCT04007926|BEHAVIORAL|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
219675509|NCT05292014|DEVICE|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
219675510|NCT03121794|PROCEDURE|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
219209248|NCT04121676|DRUG|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
219209249|NCT06751199|DRUG|human umbilical cord mesenchymal stem cells|Portal vein infusion human umbilical cord mesenchymal stem cells
219675511|NCT03121794|DEVICE|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
219675512|NCT04726774|BEHAVIORAL|Hypnosis|"Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion."
219675513|NCT04726774|BEHAVIORAL|Rehabilitation program|Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
219675514|NCT00902746|DRUG|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
219675515|NCT01385540|BEHAVIORAL|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
218982455|NCT04007926|BEHAVIORAL|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
218982456|NCT04820166|OTHER|monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly
218982457|NCT04116788|DEVICE|Artefact IRM assessment|IRM
218982458|NCT02354495|DIETARY_SUPPLEMENT|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
218982459|NCT05896397|PROCEDURE|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
218982460|NCT04742959|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
218982461|NCT04742959|COMBINATION_PRODUCT|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
218982462|NCT01419626|DEVICE|Interdental cleaning device with water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
218982463|NCT01419626|DEVICE|Interdental cleaning device with essential-oil mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
218982464|NCT04153942|BEHAVIORAL|Mobilization|Any movement out of bed
219071660|NCT03919422|PROCEDURE|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
219071661|NCT05610553|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
219071662|NCT05610553|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
219071663|NCT01892072|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
219071664|NCT01408160|DRUG|Cytarabine|Given IV
219071665|NCT01408160|BIOLOGICAL|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
219071666|NCT01408160|OTHER|Laboratory Biomarker Analysis|Correlative studies
219675516|NCT05601180|OTHER|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
219675517|NCT05601180|OTHER|Standard of care|standard treatment is prescribed by the treating physician.
219675518|NCT00939588|DRUG|Aliskiren/ Valsartan|
219675519|NCT00939588|DRUG|Telmisartan/ Ramipril|
219675520|NCT03964259|DRUG|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
219675521|NCT05622643|OTHER|MRI|Comparison between groups
219675522|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
219675523|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
219675524|NCT02302040|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
219675525|NCT02302040|BEHAVIORAL|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
219675526|NCT00000332|DRUG|Nimodipine|
219675527|NCT04575532|DEVICE|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
219675528|NCT00084227|DRUG|Azithromycin/Chloroquine|
219675529|NCT00084227|DRUG|Atovaquone/Proguanil|
219675530|NCT00478075|DRUG|bortezomib|
219675531|NCT00478075|OTHER|immunologic technique|
219675532|NCT00478075|RADIATION|samarium Sm 153 lexidronam pentasodium|
219675533|NCT02334345|DRUG|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
219675534|NCT02334345|DRUG|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
219675535|NCT02739659|DEVICE|carbon-ion radiotherapy|
219675536|NCT02191345|BEHAVIORAL|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
219675537|NCT00956332|BIOLOGICAL|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
219675538|NCT00956332|BIOLOGICAL|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
219675539|NCT00004067|BIOLOGICAL|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
219675540|NCT00004067|DRUG|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
219675541|NCT00004067|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
218982465|NCT03703622|BEHAVIORAL|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
218982466|NCT00180544|DEVICE|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
218982467|NCT04020380|DRUG|Azithromycin 250Mg Capsule|250 mg OD
218982468|NCT04609761|DRUG|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
218982469|NCT00562835|DRUG|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
219071667|NCT01408160|OTHER|Pharmacological Study|Correlative studies
219071668|NCT04482751|DRUG|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
219071669|NCT02534857|PROCEDURE|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
219071670|NCT02931734|DRUG|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
219071671|NCT02931734|DRUG|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
219071672|NCT02931734|PROCEDURE|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
219675542|NCT00004067|DRUG|taxol|175 mg/m2 IV every 21 days for 4 cycles
219675543|NCT00279383|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
219675544|NCT02081001|DRUG|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
219675545|NCT02081001|DRUG|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
219675546|NCT03295136|BEHAVIORAL|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
219675547|NCT06800339|DRUG|Nivolumab|This will be administered intravenously once every 3 weeks for up to 3 cycles (i.e. 9 weeks of total systemic therapy)
219675548|NCT06800339|DRUG|Chemotherapy|Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine
219675549|NCT06800339|RADIATION|SBRT|Three fractions of radiation delivered every other day, for three total days. The final dose of radiation will happen within 7 days of starting chemoimmunotherapy
219675550|NCT06800339|PROCEDURE|Surgical Resection|Post treatment patient will be evaluated for surgical resection
219675551|NCT04541212|DIAGNOSTIC_TEST|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
219675552|NCT04541212|OTHER|Data Collection|Collection of retrospective data
219675553|NCT05934266|DEVICE|Use of n-hexyl cyanoacrylate for mesh fixation|Mesh fixation with tissue adhesive (n-hexyl cyanoacrylate) in open hernia repair
219675554|NCT04685096|OTHER|Test product creme|twice daily application of creme containing 2% NMN
219675555|NCT04685096|OTHER|Reference creme|twice daily application of reference creme
218982470|NCT00562835|OTHER|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
218982471|NCT03123367|DEVICE|Group 1: Nella VuSleeve|Sleeve
218982472|NCT03123367|DEVICE|Group 2: Nella NuSpec|Speculum
218982473|NCT03123367|DEVICE|Group 3: NellaSpec|Speculum
218982474|NCT03123367|DEVICE|Group 4: Nella Insert|Sleeve
218982475|NCT01365052|DRUG|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
218982476|NCT01365052|DRUG|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
218982477|NCT01146912|OTHER|Text Message|Text message vaccine reminders
218982478|NCT01146912|OTHER|automated call|Automated call
218982479|NCT03342677|DIAGNOSTIC_TEST|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
218982480|NCT02462252|DRUG|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
218982481|NCT02462252|DRUG|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
218982482|NCT02462252|DRUG|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
218982483|NCT02462252|DRUG|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
218982484|NCT01935297|BEHAVIORAL|Exercise|endurance and resistance exercise 3x/week for 8 weeks
218982485|NCT03393130|DIAGNOSTIC_TEST|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
218982486|NCT01524731|DRUG|Saline|Normal Saline
218982487|NCT01524731|DRUG|Dexamethasone|4 mg
218982488|NCT01524731|DRUG|Dexamethasone|8 mg
218982489|NCT01145625|DRUG|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
218982490|NCT01145625|DRUG|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
218982491|NCT02680535|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
218982492|NCT02518074|OTHER|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
218982493|NCT05648578|OTHER|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
218982494|NCT03979612|GENETIC|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
218982495|NCT04184544|OTHER|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
218982496|NCT05405868|DRUG|Nicotinomide|Nicotinamide tablets (750mg)
218982497|NCT05405868|DRUG|Matching placebo|Matching placebo
218982498|NCT02017418|DIETARY_SUPPLEMENT|zeaxanthin|softgel
218982499|NCT02017418|DIETARY_SUPPLEMENT|combinatory supplement|softgel
218982500|NCT01068834|GENETIC|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
219209250|NCT06751199|DRUG|allogeneic islet|Portal vein infusion of allogeneic islet
218982501|NCT03663946|OTHER|Non-Interventional|Non-Interventional
218982502|NCT02479607|DEVICE|Smartphone or tablet|
218982503|NCT01907243|PROCEDURE|spreader flap|producing of upper lateral cartilage flap as a spreader flap
218982504|NCT00547235|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218982505|NCT00547235|PROCEDURE|allogeneic bone marrow transplantation|
218982506|NCT00547235|RADIATION|total-body irradiation|
218982507|NCT02241252|DEVICE|iPhone ECG|Please see detailed description for additional information.
218982508|NCT01573260|OTHER|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
218982509|NCT01573260|OTHER|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
218982510|NCT02202980|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219209251|NCT06750406|OTHER|mind body exercises|intervention might consist of a structured program of mind-body exercises designed specifically for pregnant women. This could involve a combination of yoga sessions, mindfulness meditation practices, deep breathing exercises, and progressive muscle relaxation techniques. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
219675556|NCT03557814|DEVICE|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
219675557|NCT03557814|DEVICE|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
219675558|NCT03557814|DEVICE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
219675559|NCT01826097|DEVICE|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
219675560|NCT01648998|DRUG|Fludrocortisone|single dose 500 mg, capsule
219675561|NCT01648998|DRUG|Placebo|
219675562|NCT02609373|BEHAVIORAL|Sleep intervention|"Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring."
219675563|NCT00328445|BEHAVIORAL|Positive Action|See publications
219675564|NCT05447910|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219071673|NCT02266069|OTHER|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
219071674|NCT01995123|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
219071675|NCT01995123|BEHAVIORAL|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
219071676|NCT01995123|BEHAVIORAL|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
219209252|NCT06750406|OTHER|relaxation exercises|It involves relaxation exercises including deep breathing, relaxing postures etc. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
219209253|NCT06749470|DRUG|Jieyu Chufan Capsules|4 capsules, tid; 8 weeks
219209254|NCT06749470|DRUG|Jieyu Chufan Capsules simulant|4 capsules, tid; 8 weeks
219675565|NCT00889915|DRUG|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
219209255|NCT06755502|COMBINATION_PRODUCT|Garlic oil|garlic oil mixed with zinc oxid powder, as root canal filling material
219209256|NCT06755502|DRUG|Calcium Hydroxide, Iodoform, paste|Metapex as root canal filling materials
219675566|NCT00889915|DRUG|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
219675567|NCT00889915|DRUG|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
219675568|NCT00889915|DRUG|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
219675569|NCT03596515|OTHER|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
219675570|NCT01786031|OTHER|metastasis biopsy|
219675571|NCT04813107|DRUG|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
219675572|NCT04813107|DRUG|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
219675573|NCT04233242|OTHER|Clinical management informed by HIV-1 genotypic resistance testing|"The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support."
219675574|NCT06249607|OTHER|storytelling|Storytelling android program: Subjects in group A or the storytelling group will be given headphones to listen to stories for 30 min (i.e., between 9 and 10 pm). While the subject listens to the story, a relative will present in a corner of the room to record when they fell asleep, the relative will present again in the room to record the time of falling asleep. The intervention will be done 7 nights a week for a period of 6 weeks.
219675575|NCT06249607|OTHER|Mindfulness breathing|"android program: Individuals in group B are instructed to sit upright in a comfortable position with eyes closed, focus on diaphragm movements while breathing in a slow, deep, relaxed manner, and to nonjudgmentally acknowledge and accept unwanted thoughts, ideas or images and return attention to the diaphragmatic breathing. In this exercise, individuals are instructed to notice the physical sensations of breathing, both inhalations and exhalations, with a focus on the natural rate of respiration as opposed to forcibly controlling the breath. Duration: 5 minutes in duration per session, before sleep for 7 days a week for a total duration of 6 weeks"
219675576|NCT06249607|OTHER|Sleep hygiene|"Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom."
219675577|NCT06508060|DEVICE|Neosensory Wristband|"The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location."
219675578|NCT06508060|OTHER|Tones only|Tones will be played through an app
219675579|NCT00090870|BIOLOGICAL|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
219675580|NCT00090870|BIOLOGICAL|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
219675581|NCT00090870|DRUG|thalidomide|200mg daily by mouth
219675582|NCT01205880|DRUG|Calcitriol ointment|twice daily
219675583|NCT01205880|DRUG|Clobetasol spray|twice daily
219675584|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
219675585|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
218982511|NCT02202980|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218982512|NCT02202980|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
218982513|NCT02202980|DRUG|VOX|100 mg tablet administered orally once daily with food
218982514|NCT05200832|OTHER|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
218982515|NCT05200832|OTHER|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
218982516|NCT02328300|DRUG|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
218982517|NCT01418170|OTHER|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
218982518|NCT04715633|DRUG|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
218982519|NCT05224986|BEHAVIORAL|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
218982520|NCT05839600|DRUG|BI 1821736|Solution for infusion
218982521|NCT06221462|DRUG|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
218982522|NCT06221462|DRUG|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
218982523|NCT05788120|OTHER|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
218982524|NCT00766025|DRUG|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
218982525|NCT00562471|OTHER|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
218982526|NCT00562471|OTHER|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
218982527|NCT00822042|OTHER|Samples and procedures|"* Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits"
218982528|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
219675586|NCT05889572|DRUG|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
219675587|NCT01523327|OTHER|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
219675588|NCT00344838|DEVICE|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
219675589|NCT00079885|DRUG|tigecycline|
219675590|NCT01227239|DRUG|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
219675591|NCT01227239|DRUG|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
219675592|NCT01227239|RADIATION|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
219675593|NCT00873067|PROCEDURE|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
219675594|NCT00873067|PROCEDURE|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
219675595|NCT03522207|DIAGNOSTIC_TEST|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
219675596|NCT03522207|DRUG|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
219675597|NCT03522207|DRUG|Placebos|placebo per os 30 minutes prior to 2nd PSG
219675598|NCT03522207|DIAGNOSTIC_TEST|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
219675599|NCT03522207|DRUG|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
219675600|NCT03522207|DRUG|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
219675601|NCT03522207|DIAGNOSTIC_TEST|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
218982529|NCT05294640|DRUG|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
218982530|NCT05294640|DRUG|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
218982531|NCT05294640|PROCEDURE|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
218982532|NCT03779711|BIOLOGICAL|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
218982533|NCT03779711|PROCEDURE|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
218982534|NCT04711252|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
218982535|NCT04711252|DRUG|Anastrozole|Dosage formulation: Anastrozole tablets will be administered orally.
218982536|NCT04711252|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
218982537|NCT04711252|DRUG|AZD9833 placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
218982538|NCT04711252|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
218982539|NCT04711252|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
218982540|NCT03153280|DRUG|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
218982541|NCT03153280|DRUG|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
218982542|NCT03153280|DRUG|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
218982543|NCT05625594|PROCEDURE|Aspiration|Undergo CSF aspiration
218982544|NCT05625594|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219071677|NCT05967572|OTHER|Research processes;|"1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values."
219675602|NCT06252155|OTHER|Music|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
219675603|NCT04306393|DRUG|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively."
219675604|NCT05816070|DRUG|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
219675605|NCT05816070|DRUG|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
219675606|NCT05620914|DRUG|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
219675607|NCT00505063|BIOLOGICAL|Immunization Schedule patients <7 years.|"* Time 0 months: Prevnar 13 #1, Hib #1~* Time 1 months: Pediarix #1~* Time 2 months: Prevnar 13 #2, Hib #2~* Time 3-4 months: Pediarix #2~* Time 4-6 months: Draw post vaccine titers~* Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
219675608|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 7 years and <11 years of age|"* Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~* Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~* Time 2-3 months: Prevnar 13 #2, Hib #2~* Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
219675609|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 11 years of age|"* Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~* Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~* Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~* Time 3-6 months: IPV, Draw post vaccine titers~* Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
219675610|NCT03666741|DEVICE|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
219675611|NCT03370406|DRUG|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
219675612|NCT03370406|DRUG|Calcipotriene|Topical application of .005% cream two (2) times daily for four (4) days one (1) day after each of three (3) 5FU injections..
219675613|NCT03473795|BEHAVIORAL|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
219675614|NCT03473795|OTHER|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
218982545|NCT05625594|PROCEDURE|Catheterization|Undergo catheterization
218982546|NCT05625594|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes|Given ICV
218982547|NCT05625594|PROCEDURE|Computed Tomography|Undergo CT
218982548|NCT05625594|DRUG|Cyclophosphamide|Given IV
218982549|NCT05625594|DRUG|Fludarabine|Given IV
218982550|NCT05625594|PROCEDURE|Leukapheresis|Undergo leukapheresis
218982551|NCT05625594|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
218982552|NCT05625594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218982553|NCT05625594|PROCEDURE|Positron Emission Tomography|Undergo PET
218982554|NCT06297902|RADIATION|Dose painting|Dose painting
218982555|NCT04596514|PROCEDURE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
218982556|NCT04596514|PROCEDURE|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
218982557|NCT03983824|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218982558|NCT03983824|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218982559|NCT03983824|DRUG|Cytarabine|Given IV
218982560|NCT03983824|PROCEDURE|Echocardiogram Recording|Undergo ECHO
218982561|NCT03983824|DRUG|Etoposide Phosphate|Given IV
218982562|NCT03983824|DRUG|Mitoxantrone Hydrochloride|Given IV
218982563|NCT03983824|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218982564|NCT03983824|DRUG|Peposertib|Given PO
218982565|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
219675615|NCT05893888|DRUG|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
219675616|NCT05893888|DRUG|PRV111 (Cisplatin Transmucosal System)|PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
219675617|NCT06570694|BEHAVIORAL|OverThinking|OverThinking is a mobile application ecological momentary intervention for iOS and Android, which has been designed for the reduction of experiential avoidance in rumination. The application primarily consists of psychoeducation content and related exercises intended to be delivered over a four-week period. In order to examine the effectiveness of the application during the course of the intervention and to examine user-experiences of using the application for the purpose of rumination intervention, a number of self-report tools are embedded.
219071678|NCT03925376|PROCEDURE|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
219675618|NCT06298383|DRUG|Trypsin, Bromelain and Rutoside|Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
219675619|NCT06298383|DRUG|Diclofenac Potassium|Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
219675620|NCT06298383|DRUG|Prednisolone Oral Tablet|Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
219675621|NCT06298383|OTHER|Placebo|A tablet of Compacted powdered milk
219675622|NCT05053100|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219675623|NCT05053100|OTHER|Electronic Health Record Review|Undergo electronic health record review
219675624|NCT04006405|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
219675625|NCT06526676|DEVICE|Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft|Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches
219675626|NCT06278922|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.
219675627|NCT06278922|BEHAVIORAL|Treatment as usual|NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
219675628|NCT06969274|PROCEDURE|Ultrasound guided sacral erector spinae plane block (SESPB)|Patients will receive an Ultrasound guided sacral erector spinae plane block (SESPB)
219675629|NCT06969274|PROCEDURE|Saddle block.|Patients will receive a Saddle block.
219675630|NCT04109456|DRUG|IN10018|100 mg or 50mg, orally once daily continuously;
219675631|NCT04109456|DRUG|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
219675632|NCT04109456|BIOLOGICAL|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
219675633|NCT05820672|OTHER|No intervention|No intervention
219675634|NCT06852365|DIETARY_SUPPLEMENT|wheat dextrin|participants will take 15 grams per day for 12 weeks
219675635|NCT06852365|DRUG|Oral Contraceptives, Low-Dose|20 micrograms ethinyl estradiol and desogestrel 0.15mg
219675636|NCT06852365|DIETARY_SUPPLEMENT|Maltodextrin|participants will take 15 grams per day for 12 weeks
219071679|NCT03708198|DRUG|Liposomal Bupivacaine|intercostal block
219071680|NCT03362554|BEHAVIORAL|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
219071681|NCT01554072|OTHER|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
219071682|NCT00157326|DRUG|tadalafil|
219071683|NCT00818948|DRUG|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
219209257|NCT06756087|RADIATION|Radiofrequency Ablation (RFA)/Vertebroplasty+Stereotactic Radiotherapy|"All patients received OsteoCool™ radiofrequency ablation + vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital.~Standard Control Group: Patients received SBRT (Stereotactic Body Radiation Therapy) from the Department of Radiation Oncology 2-3 weeks post-surgery. This included pre-radiation positioning, mold preparation, and radiation therapy. After radiation therapy, patients rested for 2 weeks before resuming their original anti-tumor treatment and starting follow-up.SBRT therapy was administered according to the recommendations, using one of the following dose and fractionation schemes: 4 sessions of 24 Gy, 5 sessions of 30 Gy, 6 sessions of 36 Gy, or 7 sessions of 42 Gy."
219209258|NCT06756087|PROCEDURE|Experimental|patients received OsteoCool™ radiofrequency ablation+vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital. patients continued their original anti-tumor treatment within 1-2 weeks based on their recovery. No further local intervention was performed at the surgical site, and normal follow-up was started.
219209259|NCT06760676|RADIATION|Pulsed low dose rate radiotherapy (PLDR)|Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.
219209260|NCT06760676|DRUG|Alpaloritovorelli antibodies|PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
219209261|NCT06761443|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
219209262|NCT06761443|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
219209263|NCT06784050|PROCEDURE|Bilateral Balanced Occlusion|Dentures designed under this scheme feature a fully bilateral balanced articulation, ensuring bilateral, simultaneous contact of the anterior and posterior denture teeth in both centric and eccentric positions. This occlusal scheme is aimed at promoting stability and functionality of the dentures during various mandibular movements.
219209264|NCT06784050|PROCEDURE|Monoplane Occlusion|This scheme utilizes zero-degree teeth to create a flat occlusal plane, which is designed to simplify the occlusal contacts and minimize the transmission of lateral forces during mastication. The aim is to improve masticatory efficiency by reducing the complexity of tooth contact
219209265|NCT05147636|PROCEDURE|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
219209266|NCT05147636|PROCEDURE|Endotracheal Aspiration|Aspiration during cuff deflation
219209267|NCT04056910|DRUG|ivosidenib and nivolumab|Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events. Nivolumab will be administered at 480 mg IV every 28 days.
219209268|NCT06755073|RADIATION|Pulmonary artery Doppler ultrasound|Doppler ultrasound of fetal pulmonary artery
219209269|NCT06784128|OTHER|Therapeutic Exercise Program|All patients were administered a therapeutic exercise program that included passive, active-assisted, and active range of motion exercises, stretching, strengthening, and mobilization exercises based on their level of movement restriction and pain intensity for 5 sessions per week for 2 weeks under the supervision of an experienced physiotherapist.
219675637|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
219675638|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
219675639|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
219071684|NCT01093352|PROCEDURE|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
219071685|NCT06113250|DEVICE|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
219209270|NCT06784128|OTHER|Hot Pack|As part of the treatment protocol, a hot pack was applied to the affected shoulder area for 30 minutes prior to any other therapeutic interventions. This initial application of heat was intended to promote muscle relaxation, increase local blood circulation, and reduce joint stiffness, effectively preparing the shoulder for the subsequent treatments, including therapeutic exercise, TENS and TECAR therapy. The hot pack was maintained at a temperature between 40-45°C, which is considered optimal for achieving therapeutic heat without causing discomfort or skin irritation.
219209271|NCT06784128|DEVICE|TECAR Therapy|TECAR therapy was administered using the BTL-6000 TR-Therapy PRO device which emitted energy at a frequency of approximately 500 kHz and used three types of electrodes: active, neutral, and static application electrodes. Each patient was seated in a comfortable position with the affected shoulder exposed, ensuring adequate support and stability throughout the treatment session. The affected shoulder was prepared with a conductive gel to enhance energy transfer. During the session, the capacitive electrode was initially applied, targeting the superficial muscles and tendons around the shoulder joint using circular or linear movements for 5 min. Following this, the resistive electrode was employed to target deeper structures, focusing on the joint capsule and rotator cuff muscles for 10 min. The output power was adjusted based on the patient's tolerance, ensuring a comfortable warm sensation without causing discomfort or burning feeling or pain.
219209272|NCT06784128|DEVICE|TENS|TENS was employed as a non-invasive pain management technique in this study, utilizing the Intellect Advanced device manufactured by Chattanooga Group. Electrodes were strategically placed over the affected shoulder, ensuring coverage of the most painful areas as well as relevant nerve pathways to maximize the analgesic effect. A symmetric biphasic waveform was selected, with a frequency of 100 Hz and a pulse duration of 100 microseconds. The intensity of the stimulation was adjusted according to the patient's tolerance, typically aiming for a strong, yet comfortable tingling sensation.
219209273|NCT05029414|PROCEDURE|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
219209274|NCT06840249|PROCEDURE|surgery|surgery by graft or repair or thrombectomy and completion angiography
219209275|NCT05407038|OTHER|Exercise Counseling|Receive call from health coach
219209276|NCT05407038|OTHER|Exercise Intervention|Undergo routine exercise
219209277|NCT05407038|OTHER|Internet-Based Intervention|Receive Android tablet
219675640|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
219675641|NCT06097871|DIETARY_SUPPLEMENT|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
219675642|NCT06097871|OTHER|Placebo pill|A placebo pill containing non-active ingredients
219675643|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
219675644|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
219675645|NCT05319561|OTHER|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
219675646|NCT02372942|DRUG|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
219675647|NCT02372942|DRUG|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
219209278|NCT05407038|OTHER|Interview|Complete a qualitative interview
219071686|NCT06113250|DEVICE|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
219071687|NCT06113250|OTHER|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
219071688|NCT06196268|OTHER|core strengthening exercise|CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge
219071689|NCT06196268|OTHER|Pilates exercise|Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
219071690|NCT05710601|PROCEDURE|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
219071691|NCT02587351|DRUG|Metoprolol succinate|Extended release Metoprolol succinate
219071692|NCT02587351|OTHER|Placebo|Matching placebo
219071693|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
219071694|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
219071695|NCT06670547|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Endoscopic retrograde cholangiopancreatography (ERCP)
219071696|NCT06994195|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219071697|NCT06994195|DRUG|Liposomal doxorubicin, Paclitaxel or Topotecan|Administration by intravenous infusion for a cycle of 4 weeks.
219071698|NCT07127562|BEHAVIORAL|Mindfulness intervention|"Intermittent period: from the first day to at least the 21st day, and up to the 28th day, continuous implementation~Content of intervention (daily completion):~1. Mindfulness breathing exercise (10 minutes) Content: Close your eyes to perceive the breath coming in and out, pay attention to the present moment, without judgment; Tools: Chinese voice-guided audio (nurses check room or patients scan code to play); Time: to be completed between 9am and 10am;~2. Body Scan Exercise (15 minutes) Content: gradually perceive the tension, pain or relaxation of each part of the body from head to toe; Tools: Chinese audio guidance, which can be played during the infusion or before going to bed; Time: between 7-8pm;"
219071699|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale peppermint oil
219071700|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale lavender oil
219071701|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale ginger oil
219071702|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale placebo jojoba oil
219071703|NCT07126301|OTHER|Questionnaire Administration|Ancillary studies
219071704|NCT00404157|DRUG|Rituximab|
219071705|NCT03399422|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
219071706|NCT03399422|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
219071707|NCT07032493|OTHER|Humidity-Ramp Protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which rectal temperature inflect is subsequently determined.
219071708|NCT07032493|OTHER|Above-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' rectal esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
219071709|NCT07032493|OTHER|Below-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
219071710|NCT07032493|OTHER|Below-inflection fixed-condition exposure (10%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~10% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
219071711|NCT07032493|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
219675648|NCT05233579|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
219675649|NCT06245798|PROCEDURE|transarterial chemoembolisation|During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
219675650|NCT05710510|BEHAVIORAL|Local Care + Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity."
219675651|NCT05710510|BEHAVIORAL|Team Care Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience."
218982566|NCT05224141|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
218982567|NCT05224141|DRUG|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
218982568|NCT05224141|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
218982569|NCT05224141|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
218982570|NCT05224141|BIOLOGICAL|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
218982571|NCT05224141|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
218982572|NCT05139004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
218982573|NCT05139004|BIOLOGICAL|Basiliximab|Given IV
218982574|NCT05139004|DRUG|Fludarabine Phosphate|Given IV
218982575|NCT05139004|DRUG|Indium In 111-DOTA-Basiliximab|Given IV
218982576|NCT05139004|DRUG|Melphalan|Given IV
218982577|NCT05139004|BIOLOGICAL|Palifermin|Given IV
218982578|NCT05139004|RADIATION|Total Lymphoid Irradiation|Undergo TMLI
218982579|NCT05139004|RADIATION|Total Marrow Irradiation|Undergo TMLI
218982580|NCT05139004|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
218982581|NCT05744232|BEHAVIORAL|Low calorie total diet replacement|"Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase"
218982582|NCT05744232|OTHER|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
218982583|NCT03901547|BEHAVIORAL|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
218982584|NCT03901547|BEHAVIORAL|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
218982585|NCT03901547|OTHER|Maslach burnout inventory|Maslach burnout inventory
218982586|NCT03901547|OTHER|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
218982587|NCT03901547|OTHER|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
218982588|NCT03901547|BEHAVIORAL|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
219209279|NCT05407038|OTHER|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
219209280|NCT05407038|OTHER|Questionnaire Administration|Ancillary studies
219209281|NCT02923011|DEVICE|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
219209282|NCT02923011|DEVICE|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
219071712|NCT06708182|BEHAVIORAL|SAGE LEAF Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
219071713|NCT07039929|DRUG|INCB000631|Oral; Tablet
219071714|NCT07039929|DRUG|Placebo|Oral; Tablet
219209283|NCT06877455|PROCEDURE|Fractional CO2 laser assisted PDT|"One side of the body will receive fractional CO2 laser combined with methotrexate 1% gel , while the other side will receive topical methotrexate alone (or vice versa, randomized to avoid bias) for 3 months.~Laser therapy will be performed as 4 sessions of 3 weeks interval using fractional ablative CO2 10,600 nm laser device (Daeshin Enterprise Co., Ltd. Model: Multixel, Seoul, Korea). A single pass will be performed at the following parameters: pulse energy 42-45 mJ, density of 100 spots/cm2 depth level of 1-2 covering an area of 1 cm2 MTX gel will be prepared in the Department of Pharmaceutics at Assiut University Patients will be followed up for total 6 months (e.g., baseline, weeks 3, 6,9,12,15 and post-treatment at months 4 and 6)."
219675652|NCT06585085|BEHAVIORAL|In person PA sessions|Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.
219209284|NCT06891716|OTHER|[18F]ACI-19626|\[18F\]ACI-19626 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of TDP-43 deposits.
219675653|NCT06585085|BEHAVIORAL|Interactive videoconference PA sessions|Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.
219675654|NCT06585085|BEHAVIORAL|In person and by videoconference (mixed format) PA sessions.|Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
219675655|NCT02153151|OTHER|Cytology specimen|Correlative studies
219675656|NCT02153151|OTHER|Laboratory biomarker analysis|Correlative studies
219675657|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
219675658|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
219675659|NCT03079414|PROCEDURE|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
219675660|NCT04156906|BIOLOGICAL|D+ RH genotype matched red cell units for transfusion|Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
219675661|NCT05940961|DRUG|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
219675662|NCT05633810|DRUG|Aspirin|40 mg non-enteric-coated tablet taken twice daily.
219675663|NCT05633810|DRUG|Aspirin Placebo|non-enteric-coated tablet taken twice daily.
219675664|NCT05633810|DRUG|Colchicine|0.5 mg tablet taken once daily
219675665|NCT05633810|DRUG|Colchicine Placebo|tablet taken once daily.
219675666|NCT02946021|DEVICE|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
219675667|NCT02946021|DRUG|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
219675668|NCT02588092|DRUG|ADCT-301|Intravenous infusion
219675669|NCT06194058|OTHER|rapid sequence anesthetic induction|Rapid sequence induction and intubation (or crash induction) is a process for inducing general anesthesia when the patient is at a high risk of pulmonary aspiration. It aims at minimizing the time between giving the induction drugs and securing the tube, during which period the patient's airway is essentially unprotected.
219071715|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
219071716|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
219071717|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
219071718|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
219071719|NCT04579367|DRUG|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
219071720|NCT07098091|DRUG|YD0293|YD0293 tablet for oral administration
219071721|NCT07098091|DRUG|YD0293 placebo|YD0293 placebo tablet for oral administration
219071722|NCT07127822|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and tuvonralimab for experimental arm
219071723|NCT07127822|DRUG|First line chemotherapy plus PD-1/PD-L1 antibody|standard first-line chemotherapy（FOLFOX/XELOX/SOX）combined with PD-1/PD-L1 antibody for control arm
219071724|NCT07128186|OTHER|follow-up observation|In this study, no additional interventions were administered to any enrolled participants; only 3-5 years of follow-up observation were conducted, with cognitive status data collected at both baseline and endpoint.
219071725|NCT07127289|BIOLOGICAL|Autologous hematopoietic stem cell infusion|Autologous hematopoietic stem cell infusion (0.5-3.0×10\^6/kg)
219071726|NCT07127224|DIAGNOSTIC_TEST|Olfactory stimulation|"Olfactory stimulation (sniff test) combined with auditory and somatosensory stimulations during bedside neurophysiological assessments to evaluate neurological prognosis in ICU patients."
219071727|NCT07126821|OTHER|No Interventions|No Interventions
219071728|NCT07126054|BEHAVIORAL|bibliotherapy|Bibliotherapy is a therapeutic approach that uses carefully prepared reading materials (My Surgery Story) to support individuals' understanding, coping, and anxiety, facilitated through guided reading and discussion.
219071729|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Carfentanil|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Carfentanil and will last for 51 minutes in a resting state. The dose will be 250 MBq/kg +-10 %.
219071730|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Yohimbine|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Yohimbine and will last for 70 minutes in a resting state. The dose will be 370 MBq/kg +- 10 %.
219071731|NCT07127354|DRUG|Continue GLP/GIP|Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
219071732|NCT05229068|BIOLOGICAL|RSV MAT|Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
219071733|NCT05308732|DRUG|Copaiba|A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
219071734|NCT03327766|DIAGNOSTIC_TEST|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
219071735|NCT05105594|OTHER|survey application|Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
219071736|NCT00652158|DRUG|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
219675670|NCT04536272|DRUG|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
219675671|NCT04536272|DRUG|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
219675672|NCT01090141|DRUG|Micafungin|100 mg IV infusion over 1 hour
218982589|NCT04448938|OTHER|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
219071737|NCT00002507|DRUG|mitomycin C|
219675673|NCT01090141|DRUG|Micafungin|300 mg IV infusion over 1 hour
219675674|NCT01030718|DRUG|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
219071738|NCT00002507|DRUG|porfiromycin|
219071739|NCT00002507|RADIATION|brachytherapy|
219071740|NCT00002507|RADIATION|radiation therapy|
219071741|NCT05125770|BIOLOGICAL|New crown vaccine|New Coronavirus vaccine
219071742|NCT04575896|DRUG|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
219071743|NCT04942106|OTHER|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
219360355|NCT04127448|OTHER|Exergaming Training Group|"Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down."
219675675|NCT04564924|RADIATION|DXA|Bone mineral density was examined in all cases and controls
219675676|NCT03240185|BEHAVIORAL|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
219675677|NCT01294059|DRUG|Milnacipran|50 mg BID Oral x 6 Weeks
219675678|NCT05435781|DRUG|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
219675679|NCT05435781|DRUG|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
219675680|NCT03236116|OTHER|Almonds|Participants will consume almonds everyday for 6 months.
219675681|NCT03236116|OTHER|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
219675682|NCT00423813|DRUG|placebo|Oral Solution
219675683|NCT00423813|DRUG|Xyrem®|two doses
219675684|NCT01638195|DEVICE|Focused Ultrasound|Focused Ultrasound
219675685|NCT00349635|DRUG|Metformin and Metformin + Fenofibrate|
219675686|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
218982590|NCT04448938|OTHER|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
218982591|NCT04432259|DRUG|Dexamethasone|4 mg bid for 4 days
218982592|NCT04432259|DRUG|Placebo|oral placebo
218982593|NCT05335629|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
218982594|NCT00443092|OTHER|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
218982595|NCT00443092|OTHER|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
218982596|NCT00004431|DRUG|L-baclofen|
218982597|NCT02707939|OTHER|Observation|Patients will be observed before and after they receive anesthesia
218982598|NCT05176743|BEHAVIORAL|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
218982599|NCT06429111|PROCEDURE|Epidural analgesia|Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
218982600|NCT06429111|PROCEDURE|Immersion water|Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
218982601|NCT05454280|PROCEDURE|Intensified post-discharge surveillance|"* TCC Nurse Televisit at post-discharge day 1 and 7~* Televisit with APP/Resident/Fellow between post-discharge day 3-5~* Referral for home health nursing evaluation upon discharge"
218982602|NCT05454280|PROCEDURE|Standard post-discharge surveillance|Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.
218982603|NCT02272660|DRUG|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
218982604|NCT02272660|DRUG|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
218982605|NCT06544889|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
219071744|NCT04942106|OTHER|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
219071745|NCT02754648|PROCEDURE|laparoscopic ovarian endometriotic cyst|
219071746|NCT02276846|DEVICE|Paclitaxel-Eluting Balloon|
219675687|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
219675688|NCT02610530|OTHER|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
219675689|NCT00607659|OTHER|No intervention, only observational|No intervention, only observational
219675690|NCT04881279|OTHER|Event|Ransomware attack
219675691|NCT00290654|DRUG|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
219071747|NCT00215267|DRUG|praziquantel|
219675692|NCT00290654|PROCEDURE|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
219675693|NCT00290654|RADIATION|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
219675694|NCT02343432|DRUG|Triamcinolone|Triamcinolone
219675695|NCT02343432|DRUG|Epidural Volume|Epidural Volume
219675696|NCT02343432|DRUG|Bupivacaine|Bupivacaine
219675697|NCT05435560|DRUG|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
219675698|NCT05435560|DRUG|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
219675699|NCT02074332|BEHAVIORAL|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement
219675700|NCT02074332|BEHAVIORAL|Health education|Knowledge of obesity prevention and control
219675701|NCT05334459|RADIATION|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~  o ER / PR /Her2 /Ki67 study)~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice."
219675702|NCT04160637|DIAGNOSTIC_TEST|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
219675703|NCT02840227|PROCEDURE|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
219675704|NCT02840227|PROCEDURE|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
219675705|NCT01173900|BIOLOGICAL|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
219675706|NCT03385551|DRUG|Estradiol|Estradiol or Promestriene depending on the arm
219071748|NCT02711774|DEVICE|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
219071749|NCT00103246|DRUG|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
219071750|NCT00222534|DRUG|Acetazolamide|
219071751|NCT00222534|DRUG|Placebo|
219675707|NCT00135590|DIETARY_SUPPLEMENT|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
219675708|NCT00135590|DIETARY_SUPPLEMENT|Spread diet|Dietary protein was spread over the four meals.
219675709|NCT04883684|OTHER|Personal health wallet service for Chronic Patients in Emergency Department|Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
219675710|NCT04242407|DRUG|DMTS|DMTS applied before surgery and worn for 96 hours
219675711|NCT04242407|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 96 hours
219675712|NCT00134758|DRUG|Ursodeoxycholic acid|"During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day"
219675713|NCT00134758|DRUG|Placebo|"During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day"
219675714|NCT02792335|DRUG|apixaban|
219675715|NCT02792335|DRUG|dabigatran|
219675716|NCT02792335|DRUG|rivaroxaban|
219071752|NCT04704375|DEVICE|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
219071753|NCT04704375|PROCEDURE|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
219071754|NCT04704375|PROCEDURE|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
219071755|NCT01114854|DRUG|Topiramate IR|
219071756|NCT01114854|DRUG|Topiramate ER|
219071757|NCT02247609|GENETIC|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
219071758|NCT01429532|PROCEDURE|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
219071759|NCT06156930|OTHER|Intervention group lavender oil|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
219071760|NCT06156930|OTHER|Placebo group sesame oil|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
219071761|NCT06534632|OTHER|Mother's colostrum|Oropharyngeal administration of mother's colostrum
219071762|NCT06534632|OTHER|Placebo|Oropharyngeal administration of sterile water
219071763|NCT05613660|DIETARY_SUPPLEMENT|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
219071764|NCT05613660|DIETARY_SUPPLEMENT|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
219071765|NCT05613660|DIETARY_SUPPLEMENT|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
219071766|NCT05613660|DIETARY_SUPPLEMENT|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
219071767|NCT00783744|DRUG|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
219071768|NCT00783744|DRUG|Glimepiride|Glimepiride 3 or 4 mg
219071769|NCT00783744|DRUG|Metformin|At least 850 mg od
219071770|NCT00783744|DRUG|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
219071771|NCT01432366|OTHER|SC anti-TNF|Subcutaneous (SC) anti-TNF
219071772|NCT04222348|DRUG|Metformin|850-2550 mg every 24h.
219071773|NCT04222348|DRUG|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
219071774|NCT04525404|DIAGNOSTIC_TEST|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
219071775|NCT04525404|DIAGNOSTIC_TEST|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
219071776|NCT04525404|OTHER|Cognitive testing|NIH toolbox Cognitive Measures
219071777|NCT04525404|OTHER|Olfaction testing|Brief Smell Identification Test (BSIT)
219071778|NCT04525404|DIAGNOSTIC_TEST|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
219071779|NCT04525404|OTHER|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
219071780|NCT01808690|DRUG|Metformin|
219071781|NCT01808690|DRUG|Placebo|
219071782|NCT05750290|DRUG|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
219071783|NCT03576547|DRUG|Dexamethasone|Given PO or IV
219071784|NCT03576547|DRUG|Ponatinib Hydrochloride|Given PO
219071785|NCT03576547|BIOLOGICAL|Rituximab|Given IV
219071786|NCT03576547|DRUG|Venetoclax|Given PO
219071787|NCT01880424|DRUG|Placebo|matching Placebo Capsules, Oral, once daily
219071788|NCT01880424|DRUG|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
219071789|NCT03190473|DEVICE|DES|PCI with implantation of a DES
219071790|NCT03248102|DIAGNOSTIC_TEST|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
219071791|NCT04958018|DIETARY_SUPPLEMENT|Almonds|almond (Prunus dulcis) consumption
219071792|NCT04958018|DIETARY_SUPPLEMENT|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
219071793|NCT01402453|BEHAVIORAL|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
219360356|NCT04127448|OTHER|Aerobic Exercise Group|Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
219360357|NCT03669783|DRUG|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
219675717|NCT02792335|DRUG|warfarin|
219071794|NCT01402453|BEHAVIORAL|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
219675718|NCT00565175|DRUG|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
219071795|NCT01089426|DRUG|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
219071796|NCT01089426|OTHER|Historical Controls|Standard of Care
219071797|NCT00609687|PROCEDURE|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
219071798|NCT00506259|DRUG|dTR Melatonin (NIH CC PDS)|
219071799|NCT00506259|DEVICE|Phototherapy (Bright Light)|
219071800|NCT00506259|DRUG|Melatonin CR|
219071801|NCT05311592|BEHAVIORAL|HERO Dads Program|The HERO Dads Program is a 4-week series of workshops for non-custodial fathers that focuses on improving parenting, offering job support, and financial counseling.
219071802|NCT04578990|OTHER|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
219071803|NCT04578990|OTHER|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
219360358|NCT03669783|DRUG|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
219360359|NCT03669783|DRUG|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
219360360|NCT03669783|DRUG|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
219675719|NCT00565175|DRUG|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
219675720|NCT04891926|DIAGNOSTIC_TEST|ICIQ FLUTS Questionaires|Questionnaire observing the impact on voiding disfunctions
219675721|NCT04891926|DIAGNOSTIC_TEST|Frequency Volume Chart|Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency
219675722|NCT04891926|DIAGNOSTIC_TEST|Renal Function Profile|The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.
219675723|NCT04891926|DIAGNOSTIC_TEST|Blood Analysis|Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
219675724|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract|2 capsules, one dose
219675725|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract with mustard seed powder|2 capsules, one dose
219360361|NCT03669783|DRUG|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
219360362|NCT00788346|BEHAVIORAL|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
219360363|NCT00788346|BEHAVIORAL|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
219071804|NCT04578990|OTHER|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
219071805|NCT00957866|DRUG|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
219071806|NCT05156658|DRUG|Etonogestrel (ENG) Subdermal Implants|Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
219071807|NCT03491644|DRUG|Titrated Oxygen|Restrictive treatment with oxygen.
219071808|NCT03491644|DRUG|Liberal Oxygen|Liberal treatment with oxygen.
219071809|NCT02565290|DIETARY_SUPPLEMENT|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
219360364|NCT01076257|BEHAVIORAL|Modified Constraint-induced Movement Therapy|"Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)"
219675726|NCT03494049|PROCEDURE|Veil sparring HoLEP|"Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
219675727|NCT03494049|PROCEDURE|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
219675728|NCT04125940|DIETARY_SUPPLEMENT|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
219675729|NCT04125940|DIETARY_SUPPLEMENT|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
219675730|NCT04125940|OTHER|Placebo|12oz water + food coloring
219675731|NCT04040465|DRUG|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
219675732|NCT00154843|DRUG|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
219071810|NCT02565290|DIETARY_SUPPLEMENT|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
219071811|NCT03326375|RADIATION|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
219675733|NCT02496741|DRUG|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
219675734|NCT03848793|DRUG|HS-20004|treatment
219675735|NCT04054674|PROCEDURE|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
219675736|NCT00651144|DRUG|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
219675737|NCT00651144|DRUG|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
219675738|NCT00651144|DRUG|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
219071812|NCT01436058|BIOLOGICAL|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
219071813|NCT04386681|BEHAVIORAL|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
219071814|NCT04806828|OTHER|Preoperative classification|Score of inguinal hernia
219071815|NCT04788667|OTHER|A health education programme using a telerehabilitation platform|All patients enrolled in the study will receive information through the tele rehabilitation platform, although the experimental group will have specific training/education whereas the control group will only receive some general recommendations as control/sham
219071816|NCT01271322|RADIATION|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
219071817|NCT04666129|DRUG|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
219071818|NCT04666129|DRUG|Abiraterone|Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
219071819|NCT04666129|DRUG|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
219071820|NCT04666129|DRUG|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
219071821|NCT04666129|DRUG|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
219071822|NCT04666129|DRUG|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
219071823|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
219071824|NCT04321837|DRUG|Ibandronate|Bisphosphonate
219071825|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
219071826|NCT02419157|DRUG|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
219071827|NCT02419157|DRUG|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
219071828|NCT02419157|DEVICE|Clearfil SE Bond|
219675739|NCT00651144|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
219675740|NCT00683306|DRUG|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
219071829|NCT02419157|DEVICE|Xeno V|
219071830|NCT03930472|BEHAVIORAL|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
219071831|NCT05160051|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
219675741|NCT04150120|DEVICE|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
219675742|NCT01682018|DEVICE|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
219675743|NCT03883477|DEVICE|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
219675744|NCT03883477|PROCEDURE|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
219071832|NCT00384553|DRUG|Rituximab|
219071833|NCT00384553|DRUG|DHAP|
219071834|NCT00384553|DRUG|TEC|
219675745|NCT05007171|DEVICE|Very low calorie diet|During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
219675746|NCT03853291|BEHAVIORAL|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
219675747|NCT03853291|BEHAVIORAL|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
219675748|NCT03610880|DRUG|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
219675749|NCT03610880|DRUG|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
219675750|NCT00777062|DRUG|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
219675751|NCT00777062|DRUG|Placebo|Placebo injection at the start of weeks 2 and 6.
219675752|NCT02069106|DIETARY_SUPPLEMENT|Pro-Omega LDL|
219675753|NCT02069106|OTHER|Placebo|
219675754|NCT02073539|DEVICE|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
219675755|NCT02073539|DEVICE|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
219675756|NCT03732222|PROCEDURE|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
219071835|NCT00384553|DRUG|autologous stem cell transplantation|
219675757|NCT03732222|PROCEDURE|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
219675758|NCT03732222|PROCEDURE|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
219675759|NCT00635986|DRUG|Fentanyl|100 mcg Fentanyl intravenous or epidural route
219675760|NCT02650492|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
219675761|NCT00230984|BEHAVIORAL|education|
219675762|NCT00230984|DRUG|Oral dietary supplements (563 kcal/d), RESPIFOR|
219675763|NCT00230984|BEHAVIORAL|exercises on an ergometric bicycle 3 to 5 times a week|
219675764|NCT00230984|DRUG|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
219675765|NCT03148067|PROCEDURE|Intramedullary nailing for fracture fixation|
219071836|NCT04647851|OTHER|Remote exercise intervention Down syndrome|See arm description
219071837|NCT02102308|OTHER|Exercise|Multicomponent exercise
219071838|NCT02102308|OTHER|Education classes|
219071839|NCT00231634|DRUG|topiramate|
219071840|NCT05804877|BEHAVIORAL|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
219071841|NCT05804877|OTHER|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
219071842|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
219360365|NCT01004302|PROCEDURE|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
219675766|NCT03752060|BEHAVIORAL|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
219071843|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
219675767|NCT03752060|BEHAVIORAL|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
219675768|NCT02934555|DRUG|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
219675769|NCT02934555|DIETARY_SUPPLEMENT|Ensure|50 mL Ensure
219675770|NCT02583412|BIOLOGICAL|Bexsero®|Multicomponent meningococcal B vaccine
219675771|NCT02583412|BIOLOGICAL|Havrix®|Hepatitis A vaccine
219675772|NCT05202535|OTHER|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
219675773|NCT05202535|OTHER|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
219675774|NCT06384235|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
219675775|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
219675776|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
219071844|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
219071845|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
219071846|NCT04117087|DRUG|KRAS peptide vaccine|"1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
219071847|NCT04117087|DRUG|Nivolumab|"1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV"
219071848|NCT04117087|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV"
219071849|NCT04758312|BEHAVIORAL|MY-Skills Mobile|Yoga and Self-Management Education
219071850|NCT03620344|OTHER|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
219071851|NCT03620344|OTHER|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
219071852|NCT03222518|DRUG|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
219071853|NCT03222518|DRUG|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
219209285|NCT06893003|OTHER|Baby Bridge|The Baby Bridge program is an evidence-based implementation strategy aimed at enhancing early and continuous therapy services following NICU discharge for infants with alterations in neurodevelopment. The Baby Bridge program utilizes an occupational or physical therapist to see the infant and family in the NICU prior to discharge, complete a comprehensive neurodevelopmental and feeding assessment to inform targeted interventions, and provide early therapy services in the home environment within one week of discharge and weekly thereafter, until other community-based services commence. While most of the program occurs after NICU discharge, a hallmark of the Baby Bridge program is that families establish rapport with the therapist while the infant is still in the NICU. The therapist also educates the family on ways to support their infant's development between sessions and offers support and assistance during the transition from hospital to home.
219209286|NCT06762496|OTHER|Healthcare professionals|healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews
219209287|NCT06762496|OTHER|Patients PDA group|Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires
219675777|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
219675778|NCT00003513|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219675779|NCT06007937|DRUG|Lorlatinib|Lorlatinib 100 mg orally daily
219675780|NCT06007937|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.
219675781|NCT05880173|DIAGNOSTIC_TEST|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
219071854|NCT03222518|DRUG|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
219071855|NCT06019312|DIETARY_SUPPLEMENT|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
219071856|NCT03769142|PROCEDURE|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
219071857|NCT05974527|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
219209288|NCT06762496|OTHER|Patients control group|Participants will receive only the online link with the battery of questionnaires
219209289|NCT06756009|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
219675782|NCT05584878|OTHER|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
219071858|NCT02742948|DRUG|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
219071859|NCT05373251|DIAGNOSTIC_TEST|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
219071860|NCT04969250|BIOLOGICAL|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
219675783|NCT05584878|OTHER|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
219675784|NCT05584878|OTHER|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
219675785|NCT04746365|DRUG|ivermectin|ivermectin is anthelmintic
219071861|NCT04969250|BIOLOGICAL|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
219071862|NCT06264050|DIAGNOSTIC_TEST|evalutaion scales|four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
219071863|NCT00142493|DRUG|Propofol|1.2ug/ml
219071864|NCT00142493|DRUG|Thiopental Sodium|2.0ug/ml
219071865|NCT00142493|DRUG|Dexmedetomidine Hydrochloride|0.5ng/ml
219071866|NCT00142493|DRUG|Midazolam Hydrochloride|60ng/ml
219071867|NCT00142493|DRUG|placebo|intralipid, saline, saline with multi-Vit solution
219071868|NCT00251953|DRUG|Tesaglitazar|
219071869|NCT00251953|DRUG|Metformin|
219071870|NCT03299608|DIAGNOSTIC_TEST|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
219071871|NCT03919383|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
219071872|NCT03919383|DRUG|Toripalimab|240mg intravenously every 3 weeks
219071873|NCT02211716|DEVICE|BeGraft Peripheral Stent Graft System|
219071874|NCT02854774|BEHAVIORAL|Muscle activation exercises|Activation of either muscles activating the knee or hip.
219071875|NCT01347333|RADIATION|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
219071876|NCT01347333|RADIATION|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
219071877|NCT04817553|OTHER|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
219071878|NCT02500992|PROCEDURE|Transrectal sigmoidectomy|
219071879|NCT04501315|DIAGNOSTIC_TEST|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
219675786|NCT04746365|DRUG|hydroxychloroquine|hydroxychloroquine is antimalarial.
219071880|NCT00847262|DRUG|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
219071881|NCT00847262|DRUG|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
219071882|NCT00925613|DEVICE|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
219071883|NCT00925613|DEVICE|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
219071884|NCT02779153|DRUG|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
219071885|NCT02779153|DRUG|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
219071886|NCT00130533|DRUG|Capecitabine|
219675787|NCT04746365|DRUG|Placebo|Standard treatments
219675788|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
219675789|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
219675790|NCT02897063|DRUG|Placebo|sugar pill
219675791|NCT02261103|DRUG|Pramipexole ER tablets|
219675792|NCT02261103|DRUG|Pramipexole IR tablets|
219071887|NCT02952352|BEHAVIORAL|Diabetes Prevention Program|Culturally adapted diabetes prevention program
219071888|NCT01059565|DRUG|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
219071889|NCT01059565|DRUG|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
219071890|NCT06336668|DIETARY_SUPPLEMENT|Human milk-based HMF|The study subject will be fed human milk fortified with a human-milk-based HMF.
219071891|NCT00574587|DRUG|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
219071892|NCT00574587|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
219675793|NCT02261103|DRUG|Placebo matching Pramipexole ER tablets|
219675794|NCT02261103|DRUG|Placebo matching Pramipexole IR tablets|
219675795|NCT02261103|OTHER|Standard high-fat breakfast|
219675796|NCT01685385|OTHER|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
219675797|NCT06513975|DEVICE|CART BP|A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
219675798|NCT06513975|DEVICE|sphygmomanometer|Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
219675799|NCT06613178|DRUG|acetaminophen|Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
219675800|NCT05150782|DIETARY_SUPPLEMENT|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
219675801|NCT00492232|DRUG|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
219675802|NCT00492232|DRUG|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
219675803|NCT07015307|BEHAVIORAL|Sustainable Diet Program|Intervention based on the Mediterranean sustainable diet. It emphasizes the consumption of fish, fruits, and vegetables, while reducing the intake of meat and meat-derived products. The diet is tailored to the participants' health status, activity level, and nutritional requirements, following the recommendations of the Spanish Society of Cardiology and Endocrinology. Macronutrient and micronutrient goals follow national guidelines and are tracked using specialized dietary software.
219675804|NCT07015307|BEHAVIORAL|Supervised Physical Exercise Program|A 12-week supervised physical exercise program led by certified professionals in Sport Sciences. Exercise prescriptions are tailored individually based on baseline assessments and international guidelines from fields such as cardiology and metabolism. The sessions may include strength, endurance, or combined training. In the supervised period, the instructor guides the sessions, while during the unsupervised period, exercises are followed via an online platform that provides detailed explanations and graphics.
219675805|NCT07015307|BEHAVIORAL|Combined Sustainable Diet and Exercise Program|This experimental arm combines the dietary intervention based on the sustainable Mediterranean diet with the structured physical exercise program. Both components are personalized and adhere to national and international health and nutrition recommendations. The program includes a 12-week supervised phase and an unsupervised online phase, aiming to maximize improvements in metabolic, physical, and psychosocial health in older women with metabolic alterations.
219686671|NCT06948864|DRUG|Ferric Carboxymaltose (FCM)|Patients in the intervention group underwent surgery from 2020 to end-2022 and were managed according to the surgery prehabilitation protocol. Once the surgeon has included the patient on the SWL, they were evaluated and followed up by the prehabilitation nurse (no more than 72 hours in the case of cancer patients) together with the study internist. The protocol at this preoperative stage consists of a comprehensive biopsychosocial assessment and an analysis of lab and nutritional parameters, which are optimized using targeted treatment. One of the lab parameters analyzed was Hb. Study patients with Hb \< 13 g/dL received 500 mg, 1000 mg, 1500 mg or 2000 mg FCM, depending on their levels of Hb, ferritin, transferrin saturation index, and weight. The lab test was repeated immediately before surgery or 30 days after administration of FCM in order to determine whether Hb levels had improved with FCM therapy
219071893|NCT00574587|DRUG|Trastuzumab|Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
218982606|NCT05595941|OTHER|tele-yoga|"Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant."
218982607|NCT06445881|DRUG|Modified Si Jun Zi Tang|Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
218982608|NCT03050099|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
219071894|NCT00574587|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
218982609|NCT02967731|DRUG|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
219071895|NCT00574587|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
219071896|NCT00574587|PROCEDURE|Surgery|Surgical excision of tumor from breast
219071897|NCT03973619|PROCEDURE|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
219071898|NCT03973619|PROCEDURE|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
219071899|NCT00722891|DEVICE|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
219071900|NCT00722891|DEVICE|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
219071901|NCT03952832|DRUG|Leflunomide|Given PO
219071902|NCT03952832|OTHER|Quality-of-Life Assessment|Ancillary studies
219071903|NCT03952832|OTHER|Questionnaire Administration|Ancillary studies
219071904|NCT02139033|DRUG|Retaine™|
219071905|NCT02941302|PROCEDURE|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
219071906|NCT02105363|OTHER|measure of skin movement on surface of the back|
219071907|NCT02105363|OTHER|Measurement of skin movement on surface of back|
219675806|NCT07017556|BEHAVIORAL|Views on Information Resources for Kidney Transplantation Patients|"A pilot study to improve kidney transplant patient education. The study explores whether videos help patients to better understand and remember important information regarding the benefits and risks of receiving a kidney transplant.~Currently, patients receive transplant information through written materials, and clinician discussions. However, not everyone has the same level of language literacy and medical understanding, which can lead to critical knowledge gaps, misunderstandings, and misinterpretations.~Patients may also not know about lifelong medication needs, and complications which may follow transplantation, such as diabetes, making patient education and understanding essential.~This study explores whether video materials helps patients feel more informed and satisfied with the clinical information they receive, and whether they can better retain this information. The investigators aim to support more informed patients, making transplant education clearer, and accessible."
219071908|NCT03263429|DRUG|Glutaminase Inhibitor CB-839|Given by mouth
219071909|NCT03263429|BIOLOGICAL|Panitumumab|Given by vein
219071910|NCT03263429|DRUG|Irinotecan Hydrochloride (phase I only)|Given by vein
219071911|NCT03263429|OTHER|Laboratory Biomarker Analysis|Correlative studies
219675807|NCT06613321|DIAGNOSTIC_TEST|Respiratory function tests before introduction of vasodilator therapy|Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
219675808|NCT06613321|DIAGNOSTIC_TEST|3 month follow up evaluation of response to treatment.|Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
219071912|NCT03263429|OTHER|Pharmacological Study|Correlative studies
219675809|NCT07022470|RADIATION|3-Fraction HDR Brachytherapy|8 Gy per fraction for 3 fractions (total 24 Gy) for patients with locally advanced cervical cancer, based on individualized planning.
219675810|NCT07022470|RADIATION|4-Fraction HDR Brachytherapy|7 Gy per fraction for 4 fractions (total 28 Gy) as the standard-of-care brachytherapy regimen.
219675811|NCT07022626|PROCEDURE|CTCA|Computed Tomography Coronary Angiography (CTCA) performed prior to invasive coronary angiography (ICA)
219686672|NCT06950229|DRUG|Povidone-Iodine|Hundred (100) ml of 5% povidone iodine was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of 5% povidone iodine and was allowed to be well soaked with 5% povidone iodine and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500mg of metronidazole was given prior to the procedure.
219071913|NCT03263429|DEVICE|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
219071914|NCT00698490|BIOLOGICAL|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
219071915|NCT00698490|BIOLOGICAL|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
219071916|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
219071917|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
219071918|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
219071919|NCT00443976|DRUG|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
219071920|NCT06111716|OTHER|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
219071921|NCT06111716|OTHER|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
219071922|NCT06270966|DEVICE|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
219071923|NCT00820833|OTHER|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
219071924|NCT00820833|OTHER|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
219071925|NCT06429176|DRUG|SPL84|SPL84 solution for nebulization
219071926|NCT06429176|OTHER|Placebo|Placebo solution for nebulization
219675812|NCT07022613|OTHER|Mindfulness-Based Stress Reduction Program|"The Mindfulness-Based Stress Reduction (MBSR) program is considered to offer healthcare professionals working under high levels of stress the opportunity to develop knowledge and skills in consciously recognizing their emotions, compassionately accepting painful feelings without suppression, and transforming negative thoughts and emotions into more constructive ones.~In the first and last sessions, the Perceived Stress Scale (PSS), the Mindful Attention Awareness Scale (MAAS), the Self-Compassion Scale (SCS), and the Visual Analog Scale (VAS) will be administered, and saliva samples will be collected.~In the remaining sessions, only the VAS-one of the stress measurement parameters-will be verbally administered. In this way, participants will be informed weekly about the progression of their stress levels.~The program to be implemented in the study will consist of weekly sessions held over eight weeks. Each session will be conducted for groups of 10 participants, three consecutive days"
219675813|NCT07021417|BEHAVIORAL|Workshop|includes a single 4-hour session
219675814|NCT07021417|BEHAVIORAL|Course|Includes four weekly sessions totaling 8 hours (2 hours each)
219675815|NCT07022574|BEHAVIORAL|Low inflammation diet intervention|Autoimmune Protocol Diet intervention
219675816|NCT07022665|PROCEDURE|Appendicectomy|Appendicectomy for appendicitis
219675817|NCT07022665|PROCEDURE|Cholecystectomy|Cholecystectomy for cholecystolithiasis and/or cholecystitis
219675818|NCT07022665|PROCEDURE|Umbilical hernia repair|Any kind of umbilical hernia repair
219675819|NCT07022665|PROCEDURE|Inguinal and/or femoral hernia repair|Any kind of inguinal and/or femoral hernia repair
219675820|NCT04673435|DEVICE|PermeaDerm for temporary coverage|See above
219675821|NCT04673435|DEVICE|FHCA for temporary coverage|See above
219675822|NCT04673435|DEVICE|PermeaDerm over autograft|See above
219675823|NCT04673435|DEVICE|FHCA over autograft|see above
219675824|NCT03737565|DEVICE|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
219675825|NCT06703216|DRUG|Anakinra (Kineret®)|Pre-emptive Anakinra at the initial onset of CRS.
219675826|NCT06225791|BEHAVIORAL|MMS (90x2) + BCC or expanded BCC|Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
219675827|NCT06225791|BEHAVIORAL|MMS (180x1) + BCC or expanded BCC|Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
219675828|NCT06715852|BEHAVIORAL|PHYSBI: a 12-week physical exercise program|An individualized 12-week training program including 3 occasions/week of moderate-high intensity.
219675829|NCT06715852|BEHAVIORAL|Modified eHealth Lift: a digital, evidence based lifestyle-intervention for health promotion.|Through questionnaires, the patients answers questions regarding lifestyle habits and the results are converted into a health profile. A care manager will together with the patient decide appropriate health promoting activities to engage in.
219675830|NCT03590990|DIAGNOSTIC_TEST|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
219675831|NCT00312052|DRUG|E5555|50 mg or 100 mg E5555 tablets
218982610|NCT04887844|DRUG|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
218982611|NCT04887844|DRUG|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
218982612|NCT04887844|OTHER|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
218982613|NCT05331651|DRUG|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
218982614|NCT05331651|DRUG|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
218982615|NCT03434197|DRUG|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
218982616|NCT03434197|DRUG|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
218982617|NCT04707508|DRUG|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
218982618|NCT04707508|DRUG|Metformin|Metformin monotherapy
218982619|NCT01259596|BEHAVIORAL|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
218982620|NCT01259596|BEHAVIORAL|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
218982621|NCT06201520|PROCEDURE|manual acupuncture|manual acupuncture
219675832|NCT00312052|DRUG|Placebo|50 mg and/or 100 mg placebo tablets
219071927|NCT02371954|BEHAVIORAL|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
219071928|NCT02371954|OTHER|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
219071929|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
219071930|NCT05898217|OTHER|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
219071931|NCT05898217|OTHER|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
219675833|NCT01216332|DRUG|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
219675834|NCT01216332|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
218982622|NCT06201520|DEVICE|laser acupuncture|laser acupuncture therapy
218982623|NCT06201520|DEVICE|sham laser acupuncture|sham laser acupuncture
218982624|NCT06201520|DEVICE|wrist splint|wear wrist splint at night
218982625|NCT03469934|BIOLOGICAL|Etokimab|Administered on Day 1 over 1 hour by IV infusion
218982626|NCT03469934|DRUG|Placebo|Administered on Day 1 over 1 hour by IV infusion
218982627|NCT04405583|DEVICE|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
218982628|NCT00876746|PROCEDURE|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
218982629|NCT00183820|DRUG|paclitaxel, gemcitabine, and oxaliplatin|"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"
218982630|NCT00765557|DRUG|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
218982631|NCT00765557|DRUG|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
218982632|NCT05945628|BEHAVIORAL|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
218982633|NCT05945628|OTHER|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
218982634|NCT01949831|OTHER|Assessment of functional ability in combination with follow-up at home|
218982635|NCT01630642|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
218982636|NCT03062982|DRUG|Fluzoparib|2 doses separated by 7 days.
218982637|NCT03881670|DEVICE|Lotrafilcon B|commercially available contact lens
218982638|NCT03881670|DEVICE|lotrafilcon B with Hydraluxe|commercially available contact lens
218982639|NCT05085574|DRUG|Famotidine|80 mg tablet, QID for 14 days
218982640|NCT05085574|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
218982641|NCT05085574|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
218982642|NCT03092271|BEHAVIORAL|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
218982643|NCT03092271|BEHAVIORAL|Zero Suicide Quality Improvement|ZSQI
218982644|NCT04305418|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
219675835|NCT06359197|DRUG|Caffeine Pill|Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
219071932|NCT05898217|OTHER|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
219071933|NCT05898217|OTHER|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
219071934|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
219071935|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
219071936|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
219071937|NCT05444504|DEVICE|Cup|an insertable vaginal cup ('cup')
219071938|NCT05444504|DEVICE|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
218982645|NCT00335413|DRUG|Spironolactone|
218982646|NCT04342377|DIAGNOSTIC_TEST|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
218982647|NCT04342377|DIAGNOSTIC_TEST|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
218982648|NCT04326075|DEVICE|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
218982649|NCT02314234|DRUG|sugammadex (Bridion)|single dose of sugammadex at skin incision
218982650|NCT03590873|DRUG|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
218982651|NCT04576624|BEHAVIORAL|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
218982652|NCT04576624|BEHAVIORAL|social activity|24 social gathering events
218982653|NCT00914485|BEHAVIORAL|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
218982654|NCT03364790|PROCEDURE|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
218982655|NCT03364790|PROCEDURE|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
218982656|NCT00174811|DRUG|telithromycin (HMR3647)|
218982657|NCT04814732|DRUG|Surufatinib|HMP-012
218982658|NCT04889222|DEVICE|INVSENSOR00050|Noninvasive pulse oximeter sensor
218982659|NCT04889222|DEVICE|RD SET SpO2|Noninvasive pulse oximeter sensor
219071939|NCT03638141|DRUG|Durvalumab|Durvalumab 1500mg IV every 4 weeks for up to a maximum of 13 cycles (about 12 months) or until confirmed disease progression.
219071940|NCT03638141|DRUG|Tremelimumab|Tremelimumab 300 mg IV in combination with Durvalumab 1500mg about 2 weeks after their first DEB-TACE.
219071941|NCT06317051|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin will be administered as a comparator to the placebo to assess its effects on weight reduction
219071942|NCT06317051|DRUG|Pitavastatin 4 Mg Oral Tablet|Pitavastatin tablets will be administered as a comparator to Rosuvastatin/Ezetimibe 10mg/10mg tablets to assess and compare their effects on LDL concentrations
219209290|NCT06756009|DIAGNOSTIC_TEST|General Condition Examination|Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
219675836|NCT06359197|DRUG|Placebo|Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
219675837|NCT06359197|DEVICE|TASSO+ Device|TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
219675838|NCT06359197|DEVICE|Finger prick and collection on Whatman Protein 903 Saver Cards|The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
219675839|NCT06359197|DEVICE|Intravenous Sampling|Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
219675840|NCT05521152|DRUG|Norepinephrine Bitartrate|"anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision."
219675841|NCT05521152|DRUG|Placebo|Placebo
219675842|NCT00636636|DRUG|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
219675843|NCT00636636|DRUG|Placebo|Once daily; 300 mg and 600 mg tablets
219675844|NCT04777656|DIETARY_SUPPLEMENT|Phase1 : CDED/Modulen™IBD® + Maintenance therapy|from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
219675845|NCT04777656|DIETARY_SUPPLEMENT|Phase2 and 3 :|from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
219675846|NCT03348098|DRUG|Apatinib|500 mg, po, qd. 12weeks
219675847|NCT03348098|DRUG|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
219675848|NCT04151745|PROCEDURE|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
219675849|NCT00189527|PROCEDURE|respiratory settings|
219071943|NCT06317051|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin/Ezetimibe 10mg/10mg tablets will be administered as a comparator to pitavastatin to assess and compare their effects on LDL concentrations
219071944|NCT06317051|DRUG|Placebo|The placebo tablets are visually identical to the active drug tablets and will be administered as a comparator to Dapagliflozin.
219071945|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219071946|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
219209291|NCT06847568|DRUG|Adrenaline|Intracoronary 10 mcg adrenaline will be given via the guiding catheter in study group after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and/or passage of a deflated balloon and/or PTCA with a small balloon, and/or use of thrombus aspiration and before stenting.
219209292|NCT06752369|BEHAVIORAL|T1D-specific depression SSI|The T1D-specific depression SSI will include 1) psychoeducation about depression, including how behavior shapes feelings and thoughts, 2) a values assessment, where youth will identify key areas (i.e., family relationships, friendships, school, or hobbies) from which they draw (or once drew) enjoyment and meaning, and 3) the creation of an activity action plan, wherein youth identify (from pre-generated lists) and personalize (in guided exercises) three activities to target for change.
219071947|NCT03733262|OTHER|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
219071948|NCT05680129|DRUG|Ecnoglutide high dosage|Administered subcutaneously
219071949|NCT05680129|DRUG|Ecnoglutide low dosage|Administered subcutaneously
219071950|NCT05680129|DRUG|Dulaglutide|Administered subcutaneously
219675850|NCT01537276|PROCEDURE|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
219071951|NCT05680129|DRUG|Metformin|Administered orally
219071952|NCT06038123|DEVICE|China market released 3.0T Magnetic resonance (MR) conditional CIED systems|To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)
219071953|NCT06088771|BIOLOGICAL|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
219071954|NCT06088771|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
219071955|NCT06230757|DRUG|Psilocybin 25mg|25mg psilocybin capsule
219071956|NCT06230757|DRUG|Placebo (active placebo)|1mg psilocybin capsule
219071957|NCT06962189|DRUG|chemoimmunothrapy|Patients will receive 3-4 cycles of induction therapy with Sintilimab combined with platinum-based doublet chemotherapy, followed by multidisciplinary team (MDT) evaluation. For patients deemed eligible for radical lung primary lesion resection, surgery should be performed within 4-6 weeks after completing the final cycle of chemoimmunotherapy. The timing of radiotherapy for metastatic lymph nodes will be determined by MDT discussion. If deemed inoperable after induction therapy by MDT, definitive radiotherapy will be administered subsequently. All patients, in the absence of contraindications, will receive PD-1 inhibitor maintenance therapy for 1 year following local treatment.
219071958|NCT04597190|DRUG|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
219071959|NCT04597190|DRUG|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
219071960|NCT04597190|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
219071961|NCT05826379|BEHAVIORAL|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
219071962|NCT05826379|BEHAVIORAL|Interim Goal Prompt|Short-term step goals
219071963|NCT06375265|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Preoperative hybrid intervention (in-person or via phone/video) over 4 weeks, and at 2 weeks, and 1 month after surgery using content from the CBT-I Coach app from Veteran Affairs.
219071964|NCT06375265|BEHAVIORAL|Sleep Health Education|Sleep Health Education materials provided
219071965|NCT06002165|BEHAVIORAL|Usual Care|"All clinics in North Carolina Perinatal Region IV have access to Severe HTN Bundle resources on the AIM website (https://saferbirth.org/psbs/severe-hypertension-in-pregnancy) and the locally adapted Outpatient HTN Bundle resources on the North Carolina Perinatal Region IV Provider Support Network website (https://www.mombaby.org/outpatient-bundle-for-severe-hypertension/). At baseline, the clinical leadership of all enrolled sites will receive direct communication via email that describes and provides links to the available resources. This will constitute usual care."
219209293|NCT06752369|BEHAVIORAL|T1D Educational|T1D Educational Material
219209294|NCT06869343|OTHER|Physical Therapy|Subjects will begin physical therapy at either 2 or 6 weeks s/p a rTSA.
219209295|NCT06878768|DEVICE|Additional free breathing MR acquisitions|
219209296|NCT06883929|DEVICE|virtual reality glasses|"Animation video application with virtual glasses by the researcher himself was applied. The application was performed in a quiet environment in the patient's room, in a sitting area where the child was comfortable.~position and wearing virtual goggles over his eyes."
219209297|NCT06883929|DEVICE|virtual reality goggles|vr 360 degree screen viewing
219360366|NCT06344845|DIAGNOSTIC_TEST|18F-PBB3 PET/CT scan|Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
219360367|NCT03029975|BEHAVIORAL|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
219675851|NCT00524173|DRUG|Tenofovir & Emtricitabine|
219675852|NCT00524173|DRUG|Tenofovir|
219675853|NCT05475457|BEHAVIORAL|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
219675854|NCT02464865|DRUG|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
219675855|NCT02464865|OTHER|Non-thiamine|no symptoms and signs of thiamine deficiency
219675856|NCT02464865|DRUG|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
219675857|NCT04583358|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
219675858|NCT04583358|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
219675859|NCT05638516|BEHAVIORAL|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
219675860|NCT05638516|BEHAVIORAL|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
219071966|NCT06002165|BEHAVIORAL|ACHIEVE Multi-component Implementation Strategy|The intervention is comprised of four implementation strategies: facilitation/coaching, training, simulation, and delivering educational materials. The ACHIEVE study team, primarily the Nurse Coordinator, will engage teams within each clinic to participate in quality improvement activities utilizing these four strategies. The Nurse Coordinator will train the providers/staff on the O-HTN bundle components, facilitate corresponding office systems and workflow changes, and conduct simulations of patients with severe hypertension so care teams can practice the steps involved in recognizing and responding to episodes of severe hypertension in a timely manner.
219071967|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
219675861|NCT04633603|DEVICE|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
219675862|NCT06907355|DRUG|Codeine|Codeine 10mg/5ml + Pseudoephedrine 7.5mg/5ml + Chlorphenamine 0.5mg/5ml: 10ml three times per day during 4 days
219675863|NCT06907355|DRUG|Levodropropizine|Levodropropizine 30mg/5ml: 10ml three times per day during 4 days
219675864|NCT06907355|DRUG|Ivy Leaves Cough Liquid|Ivy Leaf (Hedera Helix Extract) 35 mg/5ml: 10ml three times per day during 4 days
219675865|NCT06907355|DRUG|Placebo|Vitamins: 10ml three times per day during 4 days
219675866|NCT01399476|PROCEDURE|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
219675867|NCT01399476|PROCEDURE|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
219675868|NCT03488069|OTHER|Survey|Submission of survey answers
219675869|NCT05433272|BIOLOGICAL|Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain|The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
219675870|NCT05433272|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
219071968|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
219071969|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
219675871|NCT03704012|BEHAVIORAL|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
219675872|NCT03466879|DEVICE|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
218982660|NCT06275568|BEHAVIORAL|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
218982661|NCT06275568|BEHAVIORAL|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
218982662|NCT01609231|DRUG|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
218982663|NCT01609231|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
218982664|NCT01609231|DRUG|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
218982665|NCT01180647|DRUG|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
218982666|NCT01180647|BEHAVIORAL|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
218982667|NCT05352178|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
219071970|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
219071971|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
219071972|NCT00460889|PROCEDURE|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
219675873|NCT04811664|BIOLOGICAL|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
219675874|NCT00591929|OTHER|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
219675875|NCT02526160|BIOLOGICAL|burosumab|solution for SC injection
219675876|NCT02526160|OTHER|Placebo|saline solution for SC injection
219675877|NCT04351451|PROCEDURE|thyroidectomy|total thyroidectomy
219675878|NCT04396132|DIAGNOSTIC_TEST|Subjective Visual Vertical with Virtual SVV instrument|The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
219675879|NCT00570960|DRUG|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
219675880|NCT00570960|BIOLOGICAL|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
219675881|NCT02506699|OTHER|analgesic effect of rTMS|
219675882|NCT04579003|OTHER|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
219675883|NCT04579003|OTHER|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
219675884|NCT04501484|PROCEDURE|Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy|Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
219675885|NCT00536770|DRUG|placebo + gemcitabine + erlotinib|
219675886|NCT00536770|DRUG|Placebo + gemcitabine|
219675887|NCT00536770|DRUG|calcitriol + gemcitabine|
219675888|NCT00536770|DRUG|calcitriol + gemcitabine + erlotinib|
219675889|NCT00720070|PROCEDURE|positron emission tomography/computed tomography|Patients undergo PET/CT scan
219675890|NCT00720070|PROCEDURE|therapeutic conventional surgery|Patients undergo neck dissection
219675891|NCT04237545|DEVICE|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
219675892|NCT04237545|DEVICE|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
219675893|NCT02099253|DRUG|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
219675894|NCT02099253|DRUG|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
219675895|NCT00329693|DRUG|Norprolac|Placebo
219675896|NCT00329693|DRUG|Norprolac|Quinagolide
219675897|NCT00329693|DRUG|Norprolac|Quinagolide
219675898|NCT00329693|DRUG|Norprolac|Quinagolide
219675899|NCT00650819|DRUG|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
219675900|NCT00650819|DRUG|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
218982668|NCT05352178|DRUG|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
218982669|NCT05352178|DRUG|Androgen receptor targeted therapy|Enzalutamide
218982670|NCT04763785|DEVICE|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
218982671|NCT04763785|DEVICE|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
219071973|NCT03775850|BIOLOGICAL|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
219071974|NCT03775850|BIOLOGICAL|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
219071975|NCT02125526|DEVICE|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
218982672|NCT04763785|DEVICE|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
219071976|NCT05809037|DEVICE|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
219071977|NCT05809037|DEVICE|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
219071978|NCT01715987|DRUG|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
219071979|NCT01715987|DRUG|Entecavir|0.5mg oral daily for two years.
219071980|NCT01792063|DRUG|Sevoflurane|
219071981|NCT01792063|DRUG|Sevoflurane|
219071982|NCT01921673|DRUG|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
219071983|NCT03353935|OTHER|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
219071984|NCT01722968|DRUG|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
219071985|NCT01722968|DRUG|Paclitaxel|80mg/m2 iv weekly
219071986|NCT03345238|PROCEDURE|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
219071987|NCT05022030|DRUG|mCapOX plus cetuximab|capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
219071988|NCT05022030|DRUG|mFOLFOX6 plus cetuximab|oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
219071989|NCT05604430|DEVICE|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
219071990|NCT06089083|OTHER|Physical function assessment|Physical assessments of frailty will be conducted in person.
219071991|NCT06089083|OTHER|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
219071992|NCT06089083|PROCEDURE|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
219071993|NCT03695497|PROCEDURE|Direct anterior approach|total hip arthroplasty with DAA
219071994|NCT03695497|PROCEDURE|Direct Lateral Approach|total hip arthroplasty with DLA
219071995|NCT05900882|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
219071996|NCT05900882|DRUG|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
219071997|NCT05900882|DRUG|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
219071998|NCT05900882|DRUG|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
219071999|NCT06096597|DRUG|Clarix Flo|100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
219072000|NCT06096597|DRUG|Placebo|10 mL of 0.9% preservative-free sodium chloride
219072001|NCT06082167|DRUG|Zanzalintinib|Specified doses on specified days
219675901|NCT00650819|DRUG|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
219675902|NCT04282629|DRUG|Milrinone Injection|administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14
219675903|NCT04282629|OTHER|Placebo|administration of placebo (intravenous glucose 5%) from Day 4 to Day 14
219675904|NCT03727399|OTHER|blood withdrawal|Blood withdrawal
219675905|NCT05194683|BEHAVIORAL|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
219675906|NCT06410417|BEHAVIORAL|Shorten abstinence time|In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
219675907|NCT01997801|DRUG|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
219675908|NCT01997801|DRUG|NS infusion|Normal saline will be infused intraoperatively.
219675909|NCT03944278|DEVICE|Thulium Laser|Thulium laser for skin resurfacing procedures
219675910|NCT00634296|OTHER|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
219675911|NCT03963219|DEVICE|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
219675912|NCT03963219|DEVICE|Standard Bolus Calculator|Standard bolus calculator
219675913|NCT00001296|DRUG|melphalan|
219675914|NCT00001296|DRUG|tumor necrosis factor|
219675915|NCT00001296|DRUG|interferon-gamma|
219072002|NCT06082167|DRUG|Zanzalintinib-matched Placebo|Specified doses on specified days
218982673|NCT04763785|OTHER|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
219072003|NCT06082167|BIOLOGICAL|Pembrolizumab|Specified doses on specified days
219072004|NCT04267705|OTHER|Control|This group will receive a cup of rice 7 days/week over a 12-week period
219072005|NCT04267705|OTHER|Black bean|This group will receive a cup of black bean7 days/week over a 12-week period
219072006|NCT04267705|OTHER|Chickpea|This group will receive a cup of chick pea 7 days/week over a 12-week period
219675916|NCT00001296|PROCEDURE|hyperthermic isolated limb perfusion|
219675917|NCT00073762|DRUG|DVS-233 SR|
219675918|NCT00136214|DIAGNOSTIC_TEST|MR brain and neuropsychiatric tests|
219675919|NCT02841475|OTHER|Charlson comorbidity index|Charlson comorbidity index
218982674|NCT02243969|DIETARY_SUPPLEMENT|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
218982675|NCT02243969|DIETARY_SUPPLEMENT|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
218982676|NCT04288180|OTHER|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
218982677|NCT06421207|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
218982678|NCT06293131|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
218982679|NCT03530527|PROCEDURE|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
218982680|NCT03530527|PROCEDURE|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
218982681|NCT00912678|DRUG|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
218982682|NCT00912678|DRUG|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
218982683|NCT02740439|OTHER|Avocado|The intervention meals will contain 1 large avocado.
218982684|NCT02740439|OTHER|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
218982685|NCT02100579|DRUG|Bupivacaine|10 ml of 0.25% bupivacaine
218982686|NCT02100579|DRUG|Preservative free normal saline|10 ml of preservative free normal saline
218982687|NCT06282393|DEVICE|FibriCheck recordings|PPG and single-lead ECG measurements
218982688|NCT00439023|PROCEDURE|dialysis with glucose in dialysis water|
218982689|NCT00040339|PROCEDURE|hypothermia (body temperature lowered to 33°C or 91.4°F)|
218982690|NCT00815399|DRUG|Pioglitazone|15-45 mg/die
218982691|NCT00815399|DRUG|Metformin|500-2000 mg/die
218982692|NCT00152529|BEHAVIORAL|Screening (Behavior)|
218982693|NCT01067066|DRUG|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
218982694|NCT01067066|DRUG|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
219675920|NCT02407847|OTHER|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
219675921|NCT05420142|DIETARY_SUPPLEMENT|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
219675922|NCT04985942|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
219675923|NCT04985942|DRUG|Placebo|Matching capsules administered orally, once daily.
219675924|NCT06517095|PROCEDURE|improved capsular polishing|In the polished group,utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. This process also allows for simultaneous polishing of a portion of the posterior capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.
219675925|NCT06517095|PROCEDURE|the conventional I/A polishing|the conventional I/A polishing the capsule
219675926|NCT03630705|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
219675927|NCT03630705|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
219675928|NCT03630705|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
218982695|NCT02639546|DRUG|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
218982696|NCT00524654|PROCEDURE|HVLA chiropractic manipulation|
218982697|NCT03783975|GENETIC|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
218982698|NCT00933829|PROCEDURE|Absorbable Suture Arm|use of irradiated polyglactin 910
219072007|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
219072008|NCT04278768|DRUG|Venetoclax|"Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
219675929|NCT03630705|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219675930|NCT03630705|BIOLOGICAL|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
219675931|NCT03630705|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
218982699|NCT00933829|DEVICE|Non-absorbable suture (Prolene)|suture
218982700|NCT00933829|PROCEDURE|suture|non-absorable sutures and absorable sutures
218982701|NCT03143543|DRUG|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
218982702|NCT03143543|DRUG|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
219072009|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
219675932|NCT03630705|BIOLOGICAL|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
219072010|NCT05023252|OTHER|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
219675933|NCT03630705|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
218982703|NCT03143543|OTHER|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
219675934|NCT03612479|BEHAVIORAL|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
218982704|NCT03143543|OTHER|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
218982705|NCT01147588|DRUG|lansoprazole|60 mg (2x30-mg capsule), once daily
218982706|NCT01147588|DRUG|omeprazole|80 mg (2x40-mg capsule), once daily
218982707|NCT01147588|DRUG|esomeprazole|40 mg (1x40-mg capsule), once daily
218982708|NCT01147588|DRUG|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
219675935|NCT03612479|BEHAVIORAL|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
219675936|NCT06503068|OTHER|Questionnaire|A questionnaire in both digital and written forms in both Arabic and English versions.
219675937|NCT02849704|DRUG|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
219675938|NCT02731274|OTHER|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
219675939|NCT00559663|DIETARY_SUPPLEMENT|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
219675940|NCT00559663|DIETARY_SUPPLEMENT|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
219675941|NCT01290952|PROCEDURE|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
219675942|NCT01290952|PROCEDURE|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
219675943|NCT03603197|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
219675944|NCT03603197|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
219675945|NCT04482907|DIETARY_SUPPLEMENT|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
219675946|NCT06080672|OTHER|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
219675947|NCT04833426|DRUG|Testosterone gel|Topical gel containing testosterone
219675948|NCT04833426|DRUG|Placebo|Topical gel without active substance
219675949|NCT05312138|DEVICE|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
219675950|NCT05312138|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
219675951|NCT00574691|DEVICE|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
218982709|NCT04670055|DRUG|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
218982710|NCT06324331|PROCEDURE|Decidual sparing|Endometrial free uterine closure technique
218982711|NCT06324331|PROCEDURE|Non decidual sparing|Routine uterine closure technique including endometrium
218982712|NCT03508375|BIOLOGICAL|blood samples|blood samples
218982713|NCT00113087|DRUG|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
218982714|NCT00113087|DRUG|Placebo|Participants will receive placebo
218982715|NCT03316339|DRUG|Dexmedetomidine|Opioid-free anesthesia
218982716|NCT03316339|DRUG|Remifentanil|Opioid anesthesia
219675952|NCT05897372|DRUG|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
219675953|NCT06954753|PROCEDURE|Pancreatic surgery|Pancreatic resective surgery performed for pancreatic cystic lesions with high risk of malignant degeneration based on clinical, biochemical, and/or radiological features following current guidelines on pancreatic cystic lesions management.
219675954|NCT02261831|OTHER|obese patients|collection of blood sampling and biopsies
219675955|NCT02261831|OTHER|diabetic patients|collection of blood sampling and biopsies
218982717|NCT04997915|OTHER|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
218982718|NCT00386607|DRUG|Aliskiren|Aliskiren 300 mg
218982719|NCT00386607|DRUG|Valsartan|Valsartan 320 mg
218982720|NCT00386607|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
218982721|NCT00341445|BEHAVIORAL|Effect of Cockroach Allergen|
218982722|NCT00904319|OTHER|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
218982723|NCT04251273|OTHER|This is Quitting|Text message-based intervention for quit vaping support.
218982724|NCT04251273|OTHER|Assessment only Control|Assessment only
218982725|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
218982726|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
218982727|NCT00810693|DRUG|Placebo|Matching Placebo tid orally for 12 weeks
218982728|NCT03212690|DRUG|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
218982729|NCT03212690|PROCEDURE|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
218982730|NCT03282370|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
218982731|NCT03282370|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
219675956|NCT02261831|OTHER|patients free of obesity and diabetes|collection of blood sampling and biopsies
219675957|NCT02261831|OTHER|patients free type 2 diabetes|collection of blood sampling and biopsies
219675958|NCT00328458|DRUG|EPO906 (epothilone B)|
218982732|NCT05476458|RADIATION|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
218982733|NCT05476458|RADIATION|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
218982734|NCT00312182|DRUG|Nelfinavir|
218982735|NCT03675620|DEVICE|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
218982736|NCT03675620|OTHER|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
218982737|NCT00003821|DRUG|aminopterin|
218982738|NCT03008226|DEVICE|Implementation of 9 mm intrabronchial valves|
218982739|NCT03146377|DRUG|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
218982740|NCT03146377|DRUG|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
219675959|NCT02576977|BIOLOGICAL|Pembrolizumab|pembrolizumab 200 mg IV infusion
219675960|NCT02576977|DRUG|Pomalidomide|pomalidomide 4 mg capsules
219675961|NCT02576977|DRUG|Dexamethasone|dexamethasone 40 mg tablets
219675962|NCT04428528|DEVICE|Photoacoustics Imaging System|Characterizing breast masses for photoacoustic markers measurements
219675963|NCT03102957|OTHER|functional MRI|
218982741|NCT03146377|DRUG|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
218982742|NCT03724786|DIAGNOSTIC_TEST|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
218982743|NCT01514331|OTHER|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
218982744|NCT01514331|OTHER|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
219072011|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
219675964|NCT00359320|PROCEDURE|pancreaticojejunostomy|
219675965|NCT04481594|DRUG|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
219675966|NCT04481594|DRUG|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
219072012|NCT05980442|DEVICE|Navigated total knee arthroplasty|Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
219072013|NCT05980442|DEVICE|Robot assisted total knee arthroplasty|Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
219072014|NCT04876248|BIOLOGICAL|Belantamab Mafodotin|Given IV
219072015|NCT04876248|DRUG|Lenalidomide|Given PO
219072016|NCT05815108|OTHER|NO INTERVENTION|NO INTERVENTION
219072017|NCT04618718|DEVICE|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
219072018|NCT05505747|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
219072019|NCT05505747|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
219072020|NCT00933231|DRUG|tacrolimus|Standard dose, Oral
219209298|NCT06885736|BEHAVIORAL|Resistance exercise|Participants assigned to the resistance exercise group will be asked to perform exercises 3 times a week for the intervention period. The first 3 sessions of the exercise will be performed under the supervision of a qualified exercise specialist to ensure that the participants are happy with the exercises and are performing them appropriately. These will also be group sessions to encourage participants to build social connections to support them during the intervention. A similar group social session will take place at week 4 and then every 4 weeks of the study to overcome any issues with the exercises and to ensure progression to an appropriate intensity.
219675967|NCT02016911|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
219675968|NCT04508647|DRUG|Ublituximab|"Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes."
219675969|NCT04508647|DRUG|Umbralisib|Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
219675970|NCT01013831|DRUG|Erlotinib Hydrochloride|Given PO
219675971|NCT01013831|OTHER|Laboratory Biomarker Analysis|Correlative studies
219675972|NCT01013831|OTHER|Pharmacological Study|Correlative studies
219675973|NCT04481763|DRUG|Camrelizumab|Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
219675974|NCT04481763|RADIATION|radiotherapy|radiotherapy
219675975|NCT02425735|BIOLOGICAL|DC-CIK cells|DC-CIK cells will be used against tumor cells.
219675976|NCT02425735|BIOLOGICAL|γδ T cells|γδ T cells will be used against breast tumor.
219675977|NCT02425735|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
219675978|NCT02413671|DIETARY_SUPPLEMENT|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
219675979|NCT02413671|DIETARY_SUPPLEMENT|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
219675980|NCT02413671|OTHER|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
219675981|NCT06955351|OTHER|Survey by Questionnaire|The questionnaire is designed to collect the following information: demographic data (including gender, age, education level, marital status, place of residence, and whether the respondent is a healthcare provider), the respondent's status of basic life support (BLS) training, attitudes and willingness to use an automated external defibrillator (AED), and their knowledge of emergency medical service regulations.
218982745|NCT03796533|DRUG|Posaconazole|"* PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
218982746|NCT05887232|PROCEDURE|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
218982747|NCT05887232|PROCEDURE|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
218982748|NCT02927782|PROCEDURE|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
219072021|NCT00933231|DRUG|tacrolimus|Low dose, Oral
219072022|NCT00933231|BIOLOGICAL|Simulect|IV
219072023|NCT00933231|DRUG|Cellcept|Oral
219072024|NCT00933231|DRUG|Corticosteroids|IV and Oral
219072025|NCT00933231|DRUG|Ramipril|Oral
219072026|NCT00933231|DRUG|Irbesartan|Oral
219072027|NCT05565716|OTHER|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
219360368|NCT03029975|BEHAVIORAL|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
219675982|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
219675983|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
219675984|NCT00523770|PROCEDURE|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
219675985|NCT00787163|PROCEDURE|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
219675986|NCT00035269|DRUG|Antibiotic|
219675987|NCT01856738|DRUG|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
219072028|NCT05565716|OTHER|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
218982749|NCT02927782|PROCEDURE|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
218982750|NCT02846324|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
218982751|NCT02846324|DRUG|Placebo|Placebo capsules
218982752|NCT05593471|OTHER|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
218982753|NCT05593471|OTHER|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
218982754|NCT01365065|DRUG|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
218982755|NCT00193531|DRUG|Paclitaxel|
218982756|NCT00193531|DRUG|Carboplatin|
218982757|NCT00193531|DRUG|Etoposide|
218982758|NCT00469651|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
218982759|NCT00469651|BIOLOGICAL|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
219072029|NCT05813912|DRUG|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
219675988|NCT01856738|DRUG|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
219675989|NCT04639557|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
218982760|NCT00469651|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
218982761|NCT00469651|BIOLOGICAL|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
218982762|NCT00469651|BIOLOGICAL|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
218982763|NCT00263770|DEVICE|soft palate implant|
218982764|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
218982765|NCT05218720|DIAGNOSTIC_TEST|EuroSCORE II|"* Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk \<1, low risk 1-2.99, moderate risk 3-4.99, high risk \>5.~* CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
218982766|NCT05690646|DRUG|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
219072030|NCT05813912|DRUG|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
219072031|NCT04380636|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
218982767|NCT05690646|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
218982768|NCT00147212|DRUG|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
218982769|NCT02976922|DIETARY_SUPPLEMENT|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
218982770|NCT04264338|DIAGNOSTIC_TEST|Thyromental height test|Assessment of difficult airway
218982771|NCT02851940|PROCEDURE|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
218982772|NCT02851940|PROCEDURE|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
218982773|NCT03358797|BEHAVIORAL|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
218982774|NCT03358797|BEHAVIORAL|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
219072032|NCT04380636|DRUG|Olaparib|oral tablets
219072033|NCT04380636|DRUG|Placebo for olaparib|oral tablets
219675990|NCT03111277|DEVICE|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
219675991|NCT00869310|DRUG|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
218982775|NCT03358797|BEHAVIORAL|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
218982776|NCT03358797|BEHAVIORAL|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
219360369|NCT02815839|DRUG|SHR4640|
219675992|NCT00869310|DRUG|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
218982777|NCT04569253|DEVICE|TempSure|Non-invasive radiofrequency treatments
218982778|NCT01844557|OTHER|Swallowing Exercises|Participants perform 3 swallowing exercises.
218982779|NCT01844557|BEHAVIORAL|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
218982780|NCT01844557|BEHAVIORAL|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
218982781|NCT05602350|BEHAVIORAL|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
218982782|NCT05602350|BEHAVIORAL|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
218982783|NCT00394446|DRUG|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
218982784|NCT02059252|DEVICE|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
218982785|NCT00833716|DRUG|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
218982786|NCT02173938|OTHER|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
218982787|NCT01927627|DRUG|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
218982788|NCT02212470|DEVICE|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
218982789|NCT02212470|DEVICE|Nitinol stenting|Nitinol stent deployment
218982790|NCT04032548|DRUG|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
218982791|NCT04032548|DRUG|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
218982792|NCT04032548|DRUG|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
218982793|NCT02127710|DRUG|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
218982794|NCT02744703|DRUG|total-etch adhesive|comparator use of total-etch adhesive
218982795|NCT02744703|DRUG|CAPE-T|experimental group
218982796|NCT02744703|DRUG|self-etch adhesive|comparator use of total-etch adhesive
219072034|NCT04380636|DRUG|Etoposide|IV infusion
219072035|NCT04380636|DRUG|Carboplatin|IV infusion
218982797|NCT02744703|DRUG|CAPE-S|experimental group
219072036|NCT04380636|DRUG|Cisplatin|IV infusion
219072037|NCT04380636|DRUG|Paclitaxel|IV infusion
219072038|NCT04380636|DRUG|Pemetrexed|IV infusion
219072039|NCT04380636|RADIATION|Thoracic Radiotherapy|external beam radiation
219072040|NCT04380636|DRUG|Durvalumab|IV infusion
219072041|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
219072042|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
219072043|NCT02388386|DEVICE|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
219360370|NCT02815839|DRUG|Placebo|
219360371|NCT02609360|OTHER|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
219360372|NCT02609360|OTHER|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
219360373|NCT02609360|OTHER|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
219360374|NCT00401271|DRUG|OPC-67683|
219360375|NCT00401271|DRUG|Rifafour e-275|
219675993|NCT02118350|BEHAVIORAL|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
219675994|NCT00349193|DRUG|laquinimod 0.3|laquinimod 0.3mg
219675995|NCT00349193|DRUG|laquinimod 0.6|laquinimod 0.6mg
219675996|NCT00349193|OTHER|Placebo|Blinded Placebo
219675997|NCT00219219|DRUG|Zoledronic acid|
219072044|NCT01360359|OTHER|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
219072045|NCT01360359|OTHER|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
219072046|NCT02127801|DRUG|REGN1908-1909|
219675998|NCT03911076|BIOLOGICAL|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
219675999|NCT03911076|OTHER|Placebo|PBS and PGC
219676000|NCT03970759|DRUG|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
219676001|NCT03970759|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
219676002|NCT03970759|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
219676003|NCT06454123|DEVICE|OTX-401|Evidence-based treatments for obesity and binge eating
219072047|NCT02127801|DRUG|placebo|
219072048|NCT05894343|GENETIC|AAV-GAD|Bilateral infusion of AAV-GAD
219072049|NCT04818346|DRUG|INCB054707|INCB054707 will be administered once daily
219072050|NCT04818346|DRUG|Placebo|Placebo or INCB054707 will be administered once daily
219072051|NCT04112147|DRUG|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
219072052|NCT04112147|DRUG|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
219072053|NCT04112147|DRUG|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
219072054|NCT05695183|DEVICE|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
219072055|NCT01672801|DRUG|Placebo|oral administration
219072056|NCT01672801|DRUG|Nimodipine|oral administration
219072057|NCT06111950|OTHER|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
219676004|NCT03925337|DEVICE|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
219676005|NCT02710487|BEHAVIORAL|REMSA|Awakening from REM sleep during the last hour of the sleep period
219676006|NCT02710487|BEHAVIORAL|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
219676007|NCT00134966|DRUG|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
219676008|NCT04445090|DRUG|BI 1569912|BI 1569912
219676009|NCT04445090|DRUG|Placebo|Placebo
219676010|NCT03835507|DRUG|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
219676011|NCT01466075|DEVICE|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
218982798|NCT01975051|DRUG|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
218982799|NCT00467857|PROCEDURE|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
218982800|NCT00467857|OTHER|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
218982801|NCT02701699|BIOLOGICAL|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
218982802|NCT04069078|DRUG|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
218982803|NCT04069078|OTHER|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
218982804|NCT04203810|DEVICE|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
218982805|NCT04203810|DEVICE|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
218982806|NCT00989157|DRUG|Duloxetine|Single dose of 60 mg of duloxetine
218982807|NCT04416659|DEVICE|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
218982808|NCT05137704|OTHER|No intervention|This is a non-interventional study.
218982809|NCT00586651|DRUG|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
218982810|NCT02605304|DRUG|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
218982811|NCT02605304|DRUG|Ribavirin|"Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
218982812|NCT02058472|DRUG|G3041|
219072058|NCT06111950|OTHER|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
219072059|NCT06111950|OTHER|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
219072060|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
219072061|NCT00481429|DRUG|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
219072062|NCT06481917|OTHER|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
219072063|NCT06481917|OTHER|Ergonomic analysis|Ergonomic analysis throughout the intervention
219072064|NCT06481917|OTHER|Evaluation of intervention acceptability|Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
219072065|NCT00222339|BEHAVIORAL|task-specific training|
219072066|NCT02765529|PROCEDURE|Blood sampling|
219072067|NCT00837863|DRUG|Somatropin|ALTU-238 0.3 mg/kg daily
219072068|NCT00837863|DRUG|Somatropin|ALTU-238 0.6 mg/kg daily
219072069|NCT00837863|DRUG|Somatropin|ALTU-238 0.9 mg/kg daily
219072070|NCT00837863|DRUG|Somatropin|Nutropin AQ 0.043 mg/kg daily
219072071|NCT06529952|PROCEDURE|hysteroscopic surgery by resection and endocoagulation|resection of lower edge, resection of upper edge and endocoagulation
219072072|NCT06529952|PROCEDURE|hysteroscopic surgery by endocoagulation only|hysteroscopic endocoagulation to the base of the niche by roller ball
219072073|NCT06529952|DRUG|hormonal treatment|using 3rd generation contraceptive pills
219676012|NCT00199849|BIOLOGICAL|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
219676013|NCT06171529|DEVICE|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
219676014|NCT06171529|OTHER|Placebo|placebo/Saline control injection
219676015|NCT01116622|DRUG|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
219676016|NCT01116622|DRUG|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
219676017|NCT05236855|DIAGNOSTIC_TEST|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
219676018|NCT04727528|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
219676019|NCT04727528|DRUG|Placebo|Plabeco comparator
219676020|NCT02711566|DEVICE|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
219676021|NCT02711566|DEVICE|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
219676022|NCT00022750|BEHAVIORAL|Nurse Case Manager and Community Health Worker Team|
219676023|NCT01662856|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
218982813|NCT02058472|DRUG|SEVIKAR®|
218982814|NCT00003023|BIOLOGICAL|BCG vaccine|
218982815|NCT00003023|BIOLOGICAL|monoclonal antibody A1G4 anti-idiotype vaccine|
218982816|NCT02547675|DRUG|Rociletinib|Rociletinib will be administered to patients orally
218982817|NCT03576495|OTHER|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
218982818|NCT03576495|OTHER|Standard Residency Curriculum|The standard residency curriculum consists of previously scheduled resident didactic sessions at all academic medical centers that may or may not include topics on cultural competency or cross-cultural care.
218982819|NCT03120559|DEVICE|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
218982820|NCT03120559|DEVICE|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
218982821|NCT02162316|DRUG|Motilitone®|
218982822|NCT02162316|DRUG|A-Cilin®, Clari® and Pantoline®|
218982823|NCT03781427|DEVICE|Cardiac resynchronization therapy|Left ventricular pacing
218982824|NCT06449417|BEHAVIORAL|Experimental Aurora Training|Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
218982825|NCT00000304|DRUG|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
218982826|NCT00000304|DRUG|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
218982827|NCT00000304|DRUG|Placebo|Placebo
219072074|NCT02494284|DRUG|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
219072075|NCT02494284|DRUG|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
219072076|NCT06100926|DEVICE|software|virtual reality scene
219072077|NCT00504270|DRUG|Placebo|po daily
219072078|NCT00504270|DRUG|RG3421 120mg|120mg po daily
219072079|NCT00504270|DRUG|RG3421 20mg|20mg po daily
219072080|NCT04329624|DRUG|Levosimendan|Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
219072081|NCT04329624|DRUG|Placebo|"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."
219676024|NCT01662856|PROCEDURE|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
219676025|NCT01763827|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219676026|NCT01763827|DRUG|Ezetimibe|Administered orally once a day
219676027|NCT01763827|BIOLOGICAL|Placebo to Evolocumab|Administered by subcutaneous injection
219676028|NCT01763827|OTHER|Placebo to Ezetimibe|Administered orally once daily
219676029|NCT01127048|DRUG|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
219676030|NCT01127048|DRUG|Placebo|Suppositories containing no Ivy leaves dry extract
219676031|NCT05006274|DEVICE|Persona Trabecular Metal Tibia|Total knee arthroplasty
219676032|NCT05006274|DEVICE|Verasense technology|Instrumented tibial trial component
219676033|NCT05006274|DEVICE|MUVR|Knee motion and gait sensing wearable device
219072082|NCT00207272|BEHAVIORAL|1170-1870 kcal/day liquid diet|
219676034|NCT03343366|DRUG|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
219676035|NCT03343366|PROCEDURE|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
219676036|NCT03343366|BEHAVIORAL|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
219676037|NCT05381454|DRUG|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
219676038|NCT00168428|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
219676039|NCT00168428|OTHER|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
219676040|NCT01826981|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
219072083|NCT00207272|PROCEDURE|Gastric bypass surgery|
219072084|NCT00207272|PROCEDURE|Biopsy.visceral adipose tissue|
219072085|NCT00207272|PROCEDURE|Biopsy.omental adipose tissue|
219072086|NCT00207272|PROCEDURE|Biopsy. subcutaneous abdominal adipose tissue|
219072087|NCT00207272|PROCEDURE|Blood sample|
219072088|NCT00687037|DRUG|Cetylpyridinium chloride|
219072089|NCT01362140|DRUG|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
219072090|NCT01362140|DRUG|Placebo|Administered by subcutaneous injection every 3 weeks
219072091|NCT02090101|DRUG|ANAKINRA|
219072092|NCT05369585|DIETARY_SUPPLEMENT|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
219072093|NCT01673802|DRUG|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
219072094|NCT00492284|DRUG|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
219676041|NCT01826981|DRUG|SOF|SOF 400 mg tablet administered orally once daily
219676042|NCT01826981|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219676043|NCT01826981|DRUG|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
219676044|NCT01826981|DRUG|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
219676045|NCT01826981|DRUG|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
219072095|NCT00492284|DRUG|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
219072096|NCT00492284|DRUG|ranibizumab|0.5 mg intravitreal injection
219072097|NCT00492284|DRUG|dexamethasone|0.5 mg intravitreal injection
219072098|NCT05281380|DIETARY_SUPPLEMENT|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
219072099|NCT01964573|DRUG|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
219072100|NCT01964573|OTHER|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
219676046|NCT02906579|DRUG|Matching Placebo|
219676047|NCT02906579|DRUG|IW-1973|
219676048|NCT01481883|DRUG|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
219676049|NCT01481883|DRUG|Placebo|1 capsule daily for 12 week trial
219676050|NCT03681899|OTHER|Questionnaires|"* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
219676051|NCT03230435|OTHER|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
219676052|NCT03701438|BIOLOGICAL|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
219676053|NCT02030119|BEHAVIORAL|Financial Incentives|
219676054|NCT02030119|BEHAVIORAL|Daily feedback|
219676055|NCT06267820|DRUG|Bupivacain|analgesia
219676056|NCT06267820|DRUG|Ketorolac|analgesia
219676057|NCT02330185|DEVICE|ultrasonography|spinal anesthesia guided with ultrasonography
219676058|NCT00759655|BIOLOGICAL|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
219676059|NCT05736692|BEHAVIORAL|Brief Sleep Intervention|A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
219676060|NCT00447551|DRUG|Poly-L-Lactic Acid|Deep dermal injection
219676061|NCT03559751|OTHER|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
219676062|NCT03559751|OTHER|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
219676063|NCT03559751|DRUG|Nicotine gum (C)|4 mg nicotine gum
219676064|NCT04301739|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
219676065|NCT04301739|DRUG|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
219676066|NCT04301739|DRUG|Placebo|Placebo
219676067|NCT01352273|DRUG|MEK162 + RAF265|
219676068|NCT01259934|DRUG|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
219676069|NCT01259934|DRUG|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
219676070|NCT00593424|OTHER|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
219676071|NCT00593424|OTHER|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
219676072|NCT04974229|OTHER|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
219676073|NCT06079749|PROCEDURE|Simultaneous BTKA|Simultaneous BTKA
219676074|NCT06079749|PROCEDURE|Staged BTKA|Staged BTKA
219676075|NCT00187785|BEHAVIORAL|Spanish speaker level|
219676076|NCT01347593|DRUG|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
219676077|NCT03321201|PROCEDURE|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
219676078|NCT03321201|PROCEDURE|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
219676079|NCT02793947|DRUG|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
219072101|NCT06042829|DEVICE|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
219072102|NCT06042829|DEVICE|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
219072103|NCT06476366|DRUG|Azathioprine|azathioprine will be started at 0.3mg/kg orally daily. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking TPMT levels)
219072104|NCT06476366|DRUG|Methotrexate|Methotrexate will be started at 5mg/week and dose escalated by 2.5mg weekly to ultimately 10mg/week. Tablet Folic acid 0.5mg will be given orally daily, skipping the day of methotrexate
219072105|NCT03179839|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
219072106|NCT03179839|BEHAVIORAL|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
219072107|NCT03179839|DRUG|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
219072108|NCT02951104|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM) system|
219072109|NCT03861962|OTHER|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
219072110|NCT02256462|DRUG|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
219072111|NCT04153370|DEVICE|Airtraq|airtraq video laryngoscope was used for intubation of the infant
219072112|NCT04153370|DEVICE|glidescope|glidescope video laryngoscope was used for intubation of the infant
219072113|NCT04153370|DEVICE|c-mac|c-mac video laryngoscope was used for intubation of the infant
219072114|NCT04172792|DIETARY_SUPPLEMENT|high-caloric fatty diet|see arm/group description
219072115|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric fatty diet|see arm/group description
219360376|NCT01700192|BIOLOGICAL|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
219360377|NCT01700192|BIOLOGICAL|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
219676080|NCT02793947|DRUG|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
219360378|NCT01700192|DRUG|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
219676081|NCT02793947|DRUG|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
219676082|NCT02793947|DRUG|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
219676083|NCT04983290|DIETARY_SUPPLEMENT|weancare-domus|Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
219676084|NCT06331832|BIOLOGICAL|IGM2323|Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε.
219676085|NCT00004763|DRUG|leuprolide|
219676086|NCT00004763|DRUG|Ethinyl estradiol/norethindrone|
219676087|NCT01727856|DEVICE|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
219676088|NCT02179047|PROCEDURE|coronary angiography|percutaneous coronary intervention. coronary angiography.
219676089|NCT00151437|DRUG|Pegvisomant treatment|
219360379|NCT01700192|DRUG|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
219072116|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric carbohydrate-rich diet|see arm/group description
219072117|NCT06340269|DEVICE|MEX-CD1 Dialysis|"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."
219072118|NCT04445818|BEHAVIORAL|More appreciation|
219072119|NCT04445818|BEHAVIORAL|Less criticism|
219676090|NCT00151437|PROCEDURE|Medical History, demographics|
219676091|NCT00151437|PROCEDURE|Sign and symptoms: questionnaire|
219072120|NCT04445818|BEHAVIORAL|More Fruit and Vegetable|
219072121|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
219676092|NCT00151437|PROCEDURE|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
219676093|NCT00151437|PROCEDURE|MRI|
219072122|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
219072123|NCT03934385|BEHAVIORAL|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
219072124|NCT03934385|BEHAVIORAL|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
219360380|NCT01700192|DRUG|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
219360381|NCT01700192|DRUG|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
219360382|NCT05697510|DRUG|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
219676094|NCT02868021|DEVICE|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
219676095|NCT02868021|BEHAVIORAL|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
219676096|NCT02868021|BEHAVIORAL|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
219676097|NCT02868021|BEHAVIORAL|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
219676098|NCT02868021|BEHAVIORAL|Self-assessed function|Using the Late Life Function and Disability Instrument.
219676099|NCT02868021|PROCEDURE|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
219676100|NCT02868021|DEVICE|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
219676101|NCT02868021|DEVICE|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
219676102|NCT02868021|BEHAVIORAL|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
219676103|NCT03457818|DRUG|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
219072125|NCT06957795|OTHER|Intensive Pelvic Floor Exercise Program|Intensive pelvic floor exercise program targeting the fast (tap) and slow twitch fibers (elevator) of the pelvic floor. The tap exercise will be performed by instructing the patient to quickly contract and release the pelvic floor muscles. For the elevator exercise, the patient will be asked to contract the pelvic floor muscles for 5 seconds and hold them for 5 seconds and then slowly relax them within 5 seconds. Patients will do the exercises as a home program. The exercise program will last for 6 weeks. One set of exercise will be counted as 10 taps and 10 elevator. In the first week, patients will be asked to do 5 sets of exercises per day and the number of sets will be increased by five for 6 weeks.
219072126|NCT03150056|DRUG|GSK525762|GSK525762 will be administered.
219072127|NCT03150056|DRUG|Abiraterone|Abiraterone will be administered.
219072128|NCT03150056|DRUG|Enzalutamide|Enzalutamide will be administered.
219072129|NCT03150056|DRUG|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
219072130|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
219676104|NCT03457818|OTHER|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
219676105|NCT04658433|DIETARY_SUPPLEMENT|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
219676106|NCT05074524|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
219676107|NCT05074524|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
219209299|NCT06885736|DIETARY_SUPPLEMENT|Protein Intake|The aim of this arm of the intervention is to ensure a protein intake of 1.6g/kg/day, as this was the intake level identified as the level after which no further effect was found on muscle mass in the meta-regression from (Morton et al., 2018). For the initial 2 weeks of the study, we will ask participants to consume 2 protein drinks, containing 25g protein (3g leucine), per day - one in the morning and one in the evening. At this stage, we won't know the magnitude of reduction of protein intake following initiation of semaglutide/tirzepatide treatment. After 2 weeks, when the first assessment of dietary intake after beginning semaglutide/tirzepatide treatment occurs, the additional protein will be based on the amount required to ensure 1.6g/kg/day with an aim to spread protein evenly across the day and aim for at least 25g protein (3g leucine) per meal or snack.
219209300|NCT06885736|COMBINATION_PRODUCT|Resistance exercise + protein intake|Participants in this arm will follow the above resistance exercise and protein intake interventions
219209301|NCT06736301|DEVICE|a fully covered stent|a double pig-tail stent for cross fixation of a fully covered stent
219676108|NCT01393522|DRUG|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
219676109|NCT01393522|DRUG|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
219676110|NCT00941200|BIOLOGICAL|Blood collection|
219676111|NCT03212014|OTHER|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
219676112|NCT03212014|OTHER|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
219676113|NCT03212014|OTHER|Traditional rehabilitation|traditional exercise models in currently clinical use
219676114|NCT05927168|DEVICE|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
219676115|NCT04911595|DIAGNOSTIC_TEST|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km\*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
219072131|NCT01108653|OTHER|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
219072132|NCT01108653|OTHER|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
219072133|NCT00091312|DRUG|FOLFIRI regimen|
219072134|NCT00091312|DRUG|fluorouracil|
219676116|NCT04911595|DIAGNOSTIC_TEST|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km\*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
219676117|NCT02936089|OTHER|Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)|"For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT."
219676118|NCT02936089|OTHER|Consolidation with auto-HSCT or HLA-matched HSCT|"For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients."
219676119|NCT02936089|OTHER|allogeneic HSCT|For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
219072135|NCT00091312|DRUG|irinotecan hydrochloride|
219072136|NCT00091312|DRUG|leucovorin calcium|
219072137|NCT00091312|PROCEDURE|adjuvant therapy|
219072138|NCT01581281|DRUG|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
219072139|NCT01581281|DRUG|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
219072140|NCT01581281|DRUG|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
219072141|NCT04223180|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
219072142|NCT01558622|DRUG|dexketoprofen trometamol|50mg intravenous infusion
219072143|NCT01558622|DRUG|tramadol hydrochloride|100mg intravenous infusion
219072144|NCT01558622|DRUG|pethidine hydrochloride|50mg intravenous infusion
219072145|NCT01558622|DRUG|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
219676120|NCT02080208|DEVICE|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
219676121|NCT00642005|PROCEDURE|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
219676122|NCT00642005|PROCEDURE|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
219072146|NCT01558622|DRUG|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
219072147|NCT01558622|DRUG|vitamin c|500mg intravenous infusion
219072148|NCT03066336|DEVICE|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
219072149|NCT00388414|DRUG|duloxetine|30-60mg of duloxetine daily
219072150|NCT00388414|DRUG|Placebo|Placebo pill once daily
219072151|NCT05892679|OTHER|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
219072152|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
219072153|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
219072154|NCT00241254|DRUG|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
219072155|NCT00241254|DRUG|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
219072156|NCT05520580|PROCEDURE|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
219072157|NCT04104867|DRUG|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
219072158|NCT04104867|DRUG|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
219072159|NCT04104867|OTHER|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
219072160|NCT00059800|RADIATION|boron neutron capture therapy|
219209302|NCT06796842|OTHER|Ballistic Exercises|Ballistic training program was set for 6 weeks. Each week consisting of 5 exercises with sets of 3 and repetitions of 10,15 and 20 times, recovery time and training intensity differed each week.
219209303|NCT06796842|OTHER|Plyometric exercises|Plyometric training program was set for 6 weeks. With four exercises in 1st week. Five in 2nd and 3rd weeks, six exercises in 4th and seven exercises in last two weeks. Each exercise consisted of 3 sets with 10, 15 and 20 repetitions in each. Recovery time and training intensity differed each week.
219072161|NCT01939028|PROCEDURE|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
219209304|NCT06799988|BEHAVIORAL|Digitally Delivered Lifestyle Performance Medicine intervention|Participating is realized by downloading the application to their phone with the privacy statement for participation in the study must be read and accepted before use can begin. Application can be removed at any stage. Intervention protocol and implementation responsibility is in the University of Helsinki and digital coaching tools is provided by the Metabite Ltd. Digital tool in the intervention is Metabite (https://www.metabite.com/) with specified version designed with the Finnish Defense Force. All content within the application is based on scientific evidence and has been reviewed for relevance and applicability to the Finnish context by local healthcare professionals
219676123|NCT01912794|OTHER|Sensory Intervention|"1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs."
219676124|NCT04136483|BEHAVIORAL|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
219072162|NCT01939028|PROCEDURE|sentinel lymph node biopsy|Undergo SLN biopsy
219209305|NCT06816394|DRUG|Tarlatamab|All subjects will receive a step dose (1 mg tarlatamab) on cycle 1 day 1 administered as a 60-minute intravenous (IV) infusion then 10 mg tarlatamab IV administered on cycle 1 day 8, cycle 1 day 15, and every 2 weeks (Q2W) thereafter.
219676125|NCT00313833|DRUG|Buprenorphine transdermal delivery system|
219209306|NCT06830967|OTHER|Prehabilitation|Prehabilitation will consist of exercise therapy, smoking cessation, nutritional counselling, psychological intervention and patient education.
219072163|NCT01939028|DRUG|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
219072164|NCT01939028|DRUG|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
219072165|NCT01939028|PROCEDURE|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
219360383|NCT05699720|DRUG|Nebulized Magnesium Sulphate|Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
219360384|NCT01727895|DIETARY_SUPPLEMENT|Beta-glucan (Glucan #300®)|
219676126|NCT02816320|OTHER|Hospitalization|Patients who were hospitalized in acute care
219072166|NCT01939028|PROCEDURE|lymphadenectomy|Undergo para-aortic lymphadenectomy
219072167|NCT00875836|DRUG|Buspirone|Flexible dose, up to 60 mg daily
219072168|NCT00875836|DRUG|Placebo|Flexible dose, up to 60 mg daily
219072169|NCT01319448|DRUG|Proguanil|Proguanil tablets, 1.5mg/kg/day
219072170|NCT01319448|DRUG|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
219072171|NCT01319448|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
219072172|NCT06119633|PROCEDURE|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
219072173|NCT02242747|DRUG|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
219209307|NCT06830967|BEHAVIORAL|Exercise therapy|Exercise therapy will consist of tailored 6-week prescribed exercise program consisting of 150-minutes of moderate-vigorous exercise weekly based on patient-to-patient resource availability (eg. neighborhood walk, body-weight exercises). It will target moderate intensity (11-13 on the Borg Rating of perceived exertion scale) and will be adjusted throughout the program as required. It will target aerobic, strength and inspiratory muscle training (IMT). Participants will receive a logbook where the exercise specialist will prescribe the intensity, type, time, and frequency of aerobic, strength and IMT exercises. Each time the participant performs the prescribed home-based exercises they will register their activity in the logbook provided. Exercise specialist will review the logbook every week and will adjust the home-based exercise plan accordingly to ensure both safety and exercise progression.
219676127|NCT02096276|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires.
219676128|NCT01955239|RADIATION|Intensity-modulated Radiotherapy|
219676129|NCT05991960|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
219676130|NCT01923324|BEHAVIORAL|Physician telephone consultation|Pain physician support for family physician treating patient
219676131|NCT01923324|BEHAVIORAL|Usual family physician care|Usual family physician care without telephone consultation with pain physician
219676132|NCT00551395|PROCEDURE|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
219072174|NCT02242747|DRUG|5% 5-FU|two applications a day for four weeks in a pre-determined area
219072175|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
219072176|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
219072177|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
219072178|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
219072179|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
219072180|NCT02082054|DRUG|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
219072181|NCT02082054|DRUG|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
219072182|NCT05974969|DRUG|BCD-264|a single intravenous infusion of BCD-264
219072183|NCT05974969|DRUG|Darzalex|a single intravenous infusion of Darzalex
219072184|NCT00342862|DRUG|Amevive exposure|Observational
219072185|NCT00198562|DRUG|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
219209308|NCT06830967|BEHAVIORAL|Smoking cessation counselling|Smoking cessation will be provided through motivational interviewing with a counselor who will assess participant's smoking status, willingness and readiness to quit and provide prescriptions for nicotine replacement therapy in combination with non-nicotinic pharmacotherapy (Varenicline, Buprorprion) as appropriate
219676133|NCT00551395|PROCEDURE|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
219676134|NCT02090777|BEHAVIORAL|Health Coach|
219676135|NCT05205499|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
219676136|NCT03746405|DEVICE|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
219676137|NCT03746405|DEVICE|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
219072186|NCT06490484|DRUG|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
219072187|NCT06490484|DRUG|Pregabalin 150mg BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
219072188|NCT04519918|BEHAVIORAL|AOA|AOA represents an invasive non-physiological technique.
219072189|NCT00549926|DRUG|Fluvastatin|
219072190|NCT00549926|DRUG|Pravastatin|
219072191|NCT00549926|DRUG|Pitavastatin|
219072192|NCT00549926|DRUG|Atorvastatin|
219072193|NCT05057533|OTHER|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~1. Related to defecation (may be increased or unchanged by defecation)~2. Associated with a change in stool frequency~3. Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. \[2\] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
219676138|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
219676139|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
219676140|NCT04719845|PROCEDURE|Endoscopic laser resection|Laser resection
219676141|NCT04719845|PROCEDURE|Dilatation|Dilatation
219676142|NCT05516238|OTHER|Case management|Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
219676143|NCT03832829|DEVICE|Indirect composite restoration|Restoration of tooth with extensive substance loss
219676144|NCT04484194|BEHAVIORAL|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
219676145|NCT03558685|BEHAVIORAL|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
219676146|NCT00116714|DRUG|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
219676147|NCT06118463|DIAGNOSTIC_TEST|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
219676148|NCT01085708|DRUG|rabeprazole|10 mg normal tablet
219676149|NCT01085708|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
219676150|NCT01085708|DRUG|rabeprazole|Type 2 granules containing rabeprazole 10 mg
219072194|NCT00981591|DRUG|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
219072195|NCT00981591|DRUG|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
219072196|NCT01404572|DRUG|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
219072197|NCT01404572|DRUG|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
219072198|NCT01404572|DRUG|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
219072199|NCT06512662|PROCEDURE|Consultations with paramedics|"Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status)."
219072200|NCT05989503|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titration at the discretion of the treating physician
219072201|NCT05989503|DRUG|SGLT2 inhibitor|Either empagliflozin or dapagliflozin 10 mg/day
219072202|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
219072203|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
219072204|NCT03282890|OTHER|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
219676151|NCT01085708|DRUG|rabeprazole|Type 3 granules containing rabeprazole 10 mg
219676152|NCT04275453|DRUG|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
219676153|NCT04275453|DIETARY_SUPPLEMENT|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
219676154|NCT04275453|OTHER|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
219072205|NCT01870141|BEHAVIORAL|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources"
219072206|NCT02955511|DEVICE|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
219072207|NCT02955511|DEVICE|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
219072208|NCT02955511|DEVICE|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
219072209|NCT04179487|DIAGNOSTIC_TEST|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
219072210|NCT04273945|DRUG|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
219072211|NCT04273945|DRUG|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
219072212|NCT04273945|DRUG|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
219072213|NCT04273945|DRUG|Placebo|Participants will receive matching placebo film-coated tablets orally.
219072214|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
219072215|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
219072216|NCT03913741|DRUG|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
219676155|NCT03479008|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
219676156|NCT00677313|DRUG|metreleptin|metreleptin injection
219676157|NCT06202014|RADIATION|concurrent radiotherapy with envafolimab and capecitabine|Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
219676158|NCT03534167|BEHAVIORAL|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
219676159|NCT00005959|BIOLOGICAL|filgrastim|
219676160|NCT00005959|BIOLOGICAL|rituximab|
219676161|NCT00005959|DRUG|cyclophosphamide|
219676162|NCT00005959|DRUG|doxorubicin hydrochloride|
219676163|NCT00005959|DRUG|prednisone|
219676164|NCT00005959|DRUG|vincristine sulfate|
219676165|NCT00412932|DRUG|Olmesartan medoxomil|Tablets
219676166|NCT00412932|DRUG|Olmesartan medoxomil/hydrochlorothiazide|Tablets
219676167|NCT01945047|DRUG|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
219676168|NCT01945047|DRUG|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
219676169|NCT01490840|OTHER|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
219676170|NCT01581515|DEVICE|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
219676171|NCT01581515|DEVICE|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
219676172|NCT00362947|DRUG|LMWH parnaparin subcutaneously|
219676173|NCT00818155|DRUG|desvenlafaxine succinate SR|desvenlafaxine succinate SR
219676174|NCT00818155|OTHER|Placebo|
219676175|NCT00594893|PROCEDURE|Mini Incision Approach|Mini Incision Approach
219676176|NCT00594893|PROCEDURE|2 Incision Approach|2 Incision Approach
219072217|NCT06529107|BEHAVIORAL|intermittent catheterization protocol based on the best evidence|A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
219676177|NCT00823030|PROCEDURE|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
219676178|NCT00823030|DRUG|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
219676179|NCT00823030|OTHER|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
219676180|NCT04089501|DIAGNOSTIC_TEST|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
219676181|NCT04089501|DIAGNOSTIC_TEST|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
219676182|NCT05772117|BEHAVIORAL|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
219676183|NCT05772117|BEHAVIORAL|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
219676184|NCT02805296|OTHER|Light irradiance|Comparison of double vs. single phototherapy
219676185|NCT05755646|OTHER|Ice Plant Intensive Cream plus Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome. The nursing consultation on the standard treatment includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
219676186|NCT05755646|OTHER|Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome. The nursing consultation includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
219072218|NCT00700401|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
219072219|NCT00700401|DRUG|ribavirin [Copegus]|800mg po daily for 24 weeks
219360385|NCT01157039|DIETARY_SUPPLEMENT|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
219676187|NCT01673581|OTHER|Survey|
219676188|NCT03245320|DEVICE|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
219676189|NCT05619315|OTHER|Charcoal -based whitening toothpaste|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
219676190|NCT05619315|OTHER|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
219676191|NCT04887350|BEHAVIORAL|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
219676192|NCT04887350|BEHAVIORAL|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
219676193|NCT02364297|DEVICE|Early TIPS|TIPS (first 5 days)
219676194|NCT01703169|DRUG|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
219676195|NCT02381613|OTHER|Baked beef|A meal based on baked beef
219072220|NCT05338788|OTHER|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
219072221|NCT03273946|DRUG|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
219072222|NCT03910257|BEHAVIORAL|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
219072223|NCT02999165|OTHER|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
219072224|NCT02999165|OTHER|Nasogastric feeding|The control intervention is feeding via nasogastric tube
219072225|NCT02541929|DIETARY_SUPPLEMENT|Docosahexaenoic acid|
219072226|NCT06435234|BEHAVIORAL|risky sexual behavior intervention|Intervening in risky sexual behaviors among college students
219072227|NCT04789057|DRUG|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
219072228|NCT04789057|DRUG|Placebo|p.o., once daily
219072229|NCT03969069|DEVICE|MAPLe|Additional assessment with MAPLe
219072230|NCT04721054|DRUG|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
219676196|NCT02381613|OTHER|Baked herring|A meal based on baked herring
219072231|NCT04721054|DRUG|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
219072232|NCT05715294|OTHER|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
219072233|NCT04075123|OTHER|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
219072234|NCT04984148|DIAGNOSTIC_TEST|CT|Contrast-enhanced thoracic computed tomography
219676197|NCT02381613|OTHER|Pickled herring|A meal based on pickled herring
219676198|NCT02753816|DRUG|Tranexamic Acid|
219676199|NCT02753816|DRUG|Placebo Comparator|
219676200|NCT05482503|DEVICE|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
219676201|NCT01465230|DRUG|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
219676202|NCT04028323|DRUG|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
219360386|NCT03884582|DEVICE|Cova Monitoring System 3|Healthy Volunteers
219676203|NCT04028323|DRUG|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
219676204|NCT02014519|PROCEDURE|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
219676205|NCT02014519|OTHER|Data collection|Active questioning
219676206|NCT04241510|DEVICE|Kinesio Taping|Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
219676207|NCT03875469|DEVICE|Centargo injector (BPI 1000045)|Contrast-enhanced computer tomography conducted with Centargo injector
219676208|NCT03875469|DEVICE|Stellant MP injector|Contrast-enhanced computer tomography conducted with Stellant MP injector
219676209|NCT02362191|DEVICE|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
219676210|NCT02208076|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
219676211|NCT02767778|DEVICE|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
219676212|NCT02767778|DEVICE|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
219676213|NCT02320708|DRUG|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
219676214|NCT02320708|DRUG|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
219676215|NCT02320708|DRUG|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
219676216|NCT02320708|DRUG|Placebo|2 placebo caplets for acetaminophen taken orally one time
219676217|NCT02320708|DRUG|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
219676218|NCT02320708|DRUG|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
219676219|NCT01738919|PROCEDURE|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
219676220|NCT01738919|PROCEDURE|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
219676221|NCT00947310|DEVICE|Standard ICD programming|Standard ICD programming
219676222|NCT00947310|DEVICE|High rate cutoff|Programming of a high rate cutoff
218982828|NCT02867150|DEVICE|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
218982829|NCT01154829|DRUG|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
218982830|NCT01154829|DRUG|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
218982831|NCT05235087|DEVICE|Bovine atelocollagen intradermal injection|Intradermal skin test injection
218982832|NCT06557018|DRUG|liposomal bupivacaine|liposomal bupivacaine group
218982833|NCT06557018|DRUG|traditional peri-articular injection|traditional peri-articular injection group
218982834|NCT04977674|DRUG|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
218982835|NCT04977674|DRUG|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
218982836|NCT04977674|DRUG|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
218982837|NCT02633813|DRUG|Naftifine hydrochloride 2%|Topical application for two weeks
218982838|NCT02633813|DRUG|Placebo|Topical application for two weeks
218982839|NCT02633813|DRUG|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
218982840|NCT02108782|DRUG|dovitinib lactate|Given PO
218982841|NCT02108782|OTHER|pharmacological study|Correlative studies
218982842|NCT02108782|OTHER|laboratory biomarker analysis|Correlative studies
218982843|NCT06556459|PROCEDURE|Bariatric Surgery|"The patient performs:~* psychological clinical interview~* psychodiagnostic examination~* internal medical examination~* blood tests~* electrocardiogram~* bariatric surgery~* surgical visit"
218982844|NCT01561729|DEVICE|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
219676223|NCT00947310|DEVICE|Long delay|Programming of a prolonged delay
219676224|NCT04566718|DRUG|Metformin|metformin cessation
219072235|NCT06180824|DRUG|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
219072236|NCT00092131|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
219072237|NCT00092131|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
219072238|NCT04494152|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
219072239|NCT06073574|DIAGNOSTIC_TEST|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
219072240|NCT02814318|BIOLOGICAL|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
219072241|NCT02576067|DRUG|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
219072242|NCT02576067|DRUG|Placebo|
219676225|NCT03200561|DRUG|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
219072243|NCT06537453|OTHER|Virtual Care|Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
219072244|NCT05808309|OTHER|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
219676226|NCT03200561|BIOLOGICAL|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
219676227|NCT03793647|DEVICE|Electrical muscle devise|evaluate two types of EMS stimulation of legs
219676228|NCT02716792|DRUG|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
219676229|NCT01473940|BIOLOGICAL|ipilimumab|Given IV
219676230|NCT01473940|DRUG|gemcitabine hydrochloride|Given IV
219676231|NCT01473940|OTHER|laboratory biomarker analysis|Correlative studies
219676232|NCT00024440|BIOLOGICAL|filgrastim|
219072245|NCT02372409|DEVICE|MRI-guided laser ablation|
219676233|NCT00024440|BIOLOGICAL|oblimersen sodium|
219676234|NCT00024440|DRUG|cyclophosphamide|
219676235|NCT00024440|DRUG|fludarabine phosphate|
219072246|NCT02372409|DRUG|Doxorubicin|
219072247|NCT02372409|DRUG|Etoposide|
219072248|NCT02372409|DEVICE|Dynamic contrast-enhanced (DCE) MRI|
219676236|NCT06488898|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|"Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention."
219676237|NCT06358118|DRUG|Buyuan Zhixiao Formula|Buyuan Zhixiao Formula
219676238|NCT06358118|DRUG|Placebo|The placebo contains 10% of the active ingredients of the Chinese medicine group
219072249|NCT02372409|DEVICE|Dynamic susceptibility contrast (DSC) MRI|
219072250|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
219072251|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
219676239|NCT06080542|PROCEDURE|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
219676240|NCT06080542|PROCEDURE|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
219676241|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 60L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
219676242|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 40L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
219676243|NCT01754324|DRUG|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
219072252|NCT04989790|OTHER|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
219072253|NCT05977140|DRUG|CDI-988|SARS-CoV-2 3CL protease inhibitor
219072254|NCT05977140|DRUG|Placebo|matching placebo
219072255|NCT00054535|BIOLOGICAL|aldesleukin|
219072256|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
219072257|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
219072258|NCT01437592|DRUG|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
219072259|NCT00477191|DRUG|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
219072260|NCT01211626|DRUG|ANA773|ANA773 Tosylate Capsule
219072261|NCT01211626|DRUG|Placebo|Matching Placebo Capsule
219072262|NCT01116570|OTHER|Physical training|Physical training during 24 weeks
219072263|NCT01116570|OTHER|Control|No intervention
219072264|NCT05814523|DRUG|Ganaxolone|Ganaxolone will be administered as IV solution.
219072265|NCT05814523|DRUG|Placebo|Placebo will be administered as IV solution.
219072266|NCT05814523|DRUG|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
219072267|NCT05229692|DEVICE|NEUBIE|"Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques"
219072268|NCT04977882|PROCEDURE|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
219072269|NCT04977882|DRUG|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
219072270|NCT04977882|PROCEDURE|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
219072271|NCT04977882|PROCEDURE|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
219072272|NCT03722134|PROCEDURE|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
219209309|NCT06830967|BEHAVIORAL|Nutritional counselling|Nutritional counseling will be provided through consultation with a registered dietician. Participants will be educated on correct portion sizes, building a balanced plate, learning sources and importance of protein, importance of timing and spacing of meals, along with practicing mindful eating. Promotion and encouragement of dietary changes to ensure balanced intake with adequate protein, weight management, and the regulation of blood glucose will be discussed. Possible barriers to attain the proposed dietary changes and ways to overcome them will also be discussed along with the importance of perioperative nutrition. Based on estimated habitual protein intake, participants will receive a tailored dietary advice aiming a total protein intake of 1,2-1,5g /kg daily, unless contraindicated. Also, participants will be recommended to evenly 'spread' their protein intake over 3 meals with a minimum of 25-30 gram of protein/ meal.
219072273|NCT03722134|PROCEDURE|EVLA|Great saphenous vein occlusion with a thermal laser chateter
219209310|NCT06830967|BEHAVIORAL|Psychological intervention|"Participants will receive one hourly session of psychological intervention called surgical stress tolerance training with a trained counselor. In this session the psychosocial specialist will address the patient's anxieties, coping strategies, and post-operative expectations, with the goal of optimizing psychological well-being and ways of coping with surgery. The importance of the patient's active participation in the preparation for surgery and healing process will also be discussed. All participants will be given instructions on relaxation and deep breathing techniques."
219360387|NCT04479800|DRUG|ASTX660|Form: capsule; Route of administration: oral
219360388|NCT01290965|DRUG|Placebo|Oral tablet given once or three times daily for 15 consecutive days
219072274|NCT03722134|PROCEDURE|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
219072275|NCT01930110|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
219072276|NCT01930110|OTHER|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
219072277|NCT01990196|DRUG|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
219072278|NCT01990196|DRUG|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
219072279|NCT01990196|DRUG|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
219676244|NCT05936021|PROCEDURE|Algorithm model-based Aranesp doses|Patients will receive doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been. The model-based dosing will be more flexible than the protocol-based dosing. Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels. The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.
219676245|NCT05936021|PROCEDURE|Standard of care|Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
219676246|NCT01147718|BIOLOGICAL|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
219676247|NCT00547248|BIOLOGICAL|Synflorix|Intramuscular injection, 1 dose
219676248|NCT00547248|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 1 dose
219676249|NCT00547248|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix-Hep B before injection
219676250|NCT00547248|BIOLOGICAL|Polio Sabin|Oral, 1 dose
219676251|NCT00547248|BIOLOGICAL|Poliorix|Intramuscular injection, 1 dose
219676252|NCT00547248|BIOLOGICAL|Prevenar (Wyeth)|Intramuscular injection, 1 dose
219676253|NCT03744403|DRUG|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
219676254|NCT06161714|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
219676255|NCT06161714|DRUG|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
219676256|NCT00534248|BIOLOGICAL|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
219676257|NCT00534248|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
219676258|NCT00197431|DRUG|S-1|
219676259|NCT04221269|BEHAVIORAL|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
219676260|NCT04221269|BEHAVIORAL|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
218982845|NCT01561729|RADIATION|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
218982846|NCT04203797|DRUG|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
218982847|NCT04203797|DRUG|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
218982848|NCT02637154|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing method
218982849|NCT02637154|BEHAVIORAL|Standard Education|Standard Education material will be used
218982850|NCT01454960|BEHAVIORAL|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
218982851|NCT01454960|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
218982852|NCT01454960|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
218982853|NCT00456157|DRUG|Intra-articular Injection of OP-1 to affected knee|
218982854|NCT05868759|RADIATION|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
218982855|NCT05868759|DEVICE|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
218982856|NCT05868759|DIAGNOSTIC_TEST|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
218982857|NCT05868759|DEVICE|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
218982858|NCT05868759|OTHER|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
219072280|NCT01990196|DRUG|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
219072281|NCT05318976|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
219072282|NCT05318976|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
219072283|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
219072284|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
219072285|NCT02221206|DEVICE|Mini-Screw implant|Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
219072286|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
219072287|NCT03216837|DEVICE|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
219360389|NCT01290965|DRUG|SCY-635|oral capsule
219360390|NCT04717674|DRUG|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|\[18F\]FPIA radiotracer administration
219676261|NCT02020369|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
219676262|NCT03319316|DRUG|Durvalumab|Combination of durvalumab + tremelimumab treatment
219676263|NCT03319316|DRUG|Tremelimumab|Combination of durvalumab + tremelimumab treatment
219676264|NCT02849171|DEVICE|PET scan|
219676265|NCT02849171|RADIATION|C-Choline|
219676266|NCT01534117|BIOLOGICAL|Platelets|1 unit of platelets
219676267|NCT01534117|DRUG|DDAVP|Desmopressin 0.3mcg/kg IV x 1
219072288|NCT03216837|DEVICE|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
219360391|NCT04717674|PROCEDURE|PET/CT|PET/CT scan
219360392|NCT02793232|DRUG|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
219676268|NCT05833919|DRUG|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
219676269|NCT05833919|DRUG|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
219676270|NCT02532257|DRUG|Ibrutinib|Given PO
219676271|NCT02532257|OTHER|Laboratory Biomarker Analysis|Correlative studies
219676272|NCT02532257|DRUG|Lenalidomide|Given PO
219676273|NCT02532257|BIOLOGICAL|Rituximab|Given IV
219676274|NCT00988104|BEHAVIORAL|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
219072289|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
219072290|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
219072291|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
219072292|NCT02021279|PROCEDURE|native tissue repair|
219072293|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
219072294|NCT00337766|DRUG|Desmopressin (DDAVP)|
219072295|NCT00337766|DRUG|Placebo|
219072296|NCT00423124|GENETIC|HSV-TK|Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
219072297|NCT03633383|DEVICE|Transcatheter aortic valve|Self-expandable aortic valve prothesis
219072298|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
219072299|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
219072300|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
219209311|NCT06830967|BEHAVIORAL|Patient Education|Patient education will be provided through virtual consultations with a vascular surgery nurse practitioner. These consultations will describe to the patient their journey pre and post-operatively, what to expect and what they are likely to experience, both physically and emotionally. These consultations will also ensure participants have a support person at home available for supervision during prehabilitation and available during their recovery. Additionally, they will ensure that their home is organized for their discharge from hospital and if required, an occupational therapy home consultation may be organized.
219209312|NCT06118034|DRUG|Colchicine 0.5 MG|Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
219209313|NCT06118034|DRUG|Placebo|Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
219676275|NCT00988104|BEHAVIORAL|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
219072301|NCT03674177|DRUG|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
219072302|NCT04321720|OTHER|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
219072303|NCT04321720|OTHER|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
219209314|NCT06888700|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with substance use disorder (SUD), specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
219072304|NCT04321720|OTHER|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
219072305|NCT04321720|OTHER|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
219072306|NCT00451854|PROCEDURE|Random, no advanced notice drug and alcohol testing|
219072307|NCT04025073|OTHER|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
219072308|NCT04025073|OTHER|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
219072309|NCT01436994|PROCEDURE|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
219676276|NCT05695963|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
219676277|NCT05695963|BEHAVIORAL|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
219676278|NCT05695963|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
219072310|NCT01436994|PROCEDURE|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
219072311|NCT01436994|DRUG|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
219072312|NCT01436994|DRUG|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
219072313|NCT01436994|DRUG|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
219072314|NCT02096900|DRUG|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
218982859|NCT05868759|OTHER|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
219209315|NCT06844565|PROCEDURE|Immunohistochemistry procedure|"Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4).~All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline.~If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA)."
219676279|NCT05695963|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
219676280|NCT04727736|DRUG|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
219676281|NCT03204617|BIOLOGICAL|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
219676282|NCT03204617|BIOLOGICAL|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
219676283|NCT03204617|DRUG|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
219676284|NCT00459810|DRUG|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
219676285|NCT00459810|DRUG|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
219676286|NCT02259400|DEVICE|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.
219676287|NCT02259400|DEVICE|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
219676288|NCT00315614|BIOLOGICAL|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
219676289|NCT03905837|DRUG|Lidocaine|Intravenous or paravertebral lidocaine
218982860|NCT05868759|OTHER|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
218982861|NCT04648228|BEHAVIORAL|ACT+MBRP|Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
218982862|NCT04648228|BEHAVIORAL|Education control|Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
218982863|NCT04842734|OTHER|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
218982864|NCT04842734|OTHER|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
219072315|NCT02096900|DRUG|Midazolam|
219676290|NCT03905837|DRUG|Remifentanil|intravenous remifentanil
219676291|NCT00697593|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
219686673|NCT06950229|DRUG|Normal Saline|Hundred (100) ml of Normal saline was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of Normal Saline and was allowed to be well soaked with Normal saline and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500 mg of metronidazole was given prior to the procedure.
219072316|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
219072317|NCT01579708|BEHAVIORAL|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
219676292|NCT01618786|OTHER|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
219676293|NCT01618786|OTHER|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
219072318|NCT05084872|DRUG|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
219676294|NCT06008210|BEHAVIORAL|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
219676295|NCT06008210|BEHAVIORAL|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
219676296|NCT00249418|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
219676297|NCT03420430|BIOLOGICAL|GL-ONC1|
219676298|NCT04529239|DEVICE|Abbott Freestyle Libre Pro|Continuous glucose monitoring device to analyze diabetes biomarkers.
219676299|NCT02964338|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
219676300|NCT02964338|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
219676301|NCT00005033|BIOLOGICAL|trastuzumab|
218982865|NCT04896879|BEHAVIORAL|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
218982866|NCT04599829|DEVICE|AnkleSTRONG100/500/900|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
218982867|NCT03610360|DRUG|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
218982868|NCT05366517|DEVICE|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
218982869|NCT04999488|DRUG|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
219072319|NCT01817049|BEHAVIORAL|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
219072320|NCT01817049|BEHAVIORAL|placebo attention control|
219072321|NCT01561248|DRUG|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
218982870|NCT04999488|OTHER|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
218982871|NCT02296073|DRUG|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
218982872|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
218982873|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
219676302|NCT00005033|PROCEDURE|conventional surgery|
219676303|NCT00112918|BIOLOGICAL|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
219676304|NCT00112918|DRUG|Capecitabine|Film-coated tablets
219676305|NCT00112918|DRUG|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
219676306|NCT00112918|DRUG|Leucovorin calcium|Administered as a 200 mg/m\^2 infusion over 2 hours.
219676307|NCT00112918|DRUG|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
219686674|NCT06954935|OTHER|periorbital massage|An electronic eye massager (irest manufacturing company, China) will be applied. The massager has a vibration function and massages with a warm air bag.
219686675|NCT06956066|BIOLOGICAL|shotblocker|SHOTBLOCKER Shotblocker is a drug-free and non-invasive plastic device for all age groups that is placed during injection to press against the site of administration. It has standardized dimensions and is designed in a small, flat, horseshoe (U) shape with several blunt points on one surface in direct contact with the skin.
219072322|NCT03580265|DEVICE|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
219209316|NCT06777173|DRUG|Peg interferon alfa-2b|NA combined with Peg interferon alfa-2b
219209317|NCT06760442|PROCEDURE|Subcrestal implant placement|Delayed implant placement 2 mm subcrestally in missing mandibular posterior site.
219676308|NCT04875910|OTHER|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
219676309|NCT04761757|OTHER|Booklet of Scripts of Doctors|"The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context."
219676310|NCT04761757|OTHER|Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)|"The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context."
219676311|NCT02372383|DRUG|Ethambutol|Anti-mycobacterial oral drug
219676312|NCT02372383|DRUG|Rifampin|Anti-mycobacterial oral drug
219676313|NCT02372383|DRUG|Azithromycin|Anti-mycobacterial oral drug
219676314|NCT02372383|DRUG|Pancrelipase|Pancreatic enzyme replacement therapy
219676315|NCT01216878|DRUG|losartan potassium|100 mg tablet
219676316|NCT00631982|PROCEDURE|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
219676317|NCT01442012|OTHER|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
219676318|NCT05076604|DRUG|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
218982874|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
218982875|NCT02296073|DRUG|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
218982876|NCT02296073|OTHER|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
218982877|NCT04977557|DIETARY_SUPPLEMENT|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
218982878|NCT00092807|DRUG|MK0653, ezetimibe|
218982879|NCT00092807|DRUG|Comparator: placebo|
218982880|NCT03208127|DRUG|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
219072323|NCT03436394|DRUG|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
219072324|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
219072325|NCT05934734|OTHER|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
219072326|NCT00374842|BIOLOGICAL|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
219072327|NCT00374842|BIOLOGICAL|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
219072328|NCT00863096|BIOLOGICAL|Gardasil|HPV vaccine
219072329|NCT03371420|DRUG|PU-AD|
219072330|NCT03371420|DEVICE|PET Scan|
219209318|NCT06760442|PROCEDURE|Crestal implant placement|Delayed implant placement equicrestally in missing mandibular posterior site.
218982881|NCT00776282|DRUG|loratadine 10 mg orally disintegrating|
219072331|NCT03371420|OTHER|Blood Draws|
219209319|NCT06858670|PROCEDURE|Auxiliary Segmental Lingual Appliances|This intervention involves the use of auxiliary segmental lingual appliances specifically designed to level the Curve of Wilson at the second molars in patients undergoing labial fixed orthodontic treatment. The primary goal is to adjust the lingual inclination of the mandibular second molar, thereby achieving a more balanced and functional occlusal plane.
219360393|NCT02793232|DRUG|Placebo single dose|Matched Placebo suspension administered as single dose
219360394|NCT02793232|DRUG|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
219676319|NCT05076604|DRUG|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
219676320|NCT03258645|DRUG|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
219676321|NCT04033978|BEHAVIORAL|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
219676322|NCT04033978|BEHAVIORAL|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
219676323|NCT05850702|DRUG|Lidocaine|inhale 5ml of 2% lidocaine by nebulization
219676324|NCT05850702|DRUG|Saline|inhale 5ml of saline by nebulization
219676325|NCT05328453|DIAGNOSTIC_TEST|Fetal prenatal ultrasonographic evaluation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
219676326|NCT01676051|OTHER|Skin culture|Culture swab used to culture skin adjacent to incision
219676327|NCT03013712|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
219676328|NCT01947101|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
219676329|NCT00882271|OTHER|Acupuncture|Ten Acupuncture treatments within six weeks
219676330|NCT01898169|OTHER|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
219676331|NCT01704755|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
219676332|NCT01704755|DRUG|Ribavirin (RBV)|Capsule
219676333|NCT03293745|BEHAVIORAL|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
219676334|NCT03293745|BEHAVIORAL|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
219676335|NCT03529708|RADIATION|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
219676336|NCT02974348|DRUG|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
219676337|NCT02974348|DRUG|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
219676338|NCT02974348|DRUG|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
219676339|NCT02974348|DRUG|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
219676340|NCT02974348|DRUG|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
219676341|NCT02974348|DRUG|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
219676342|NCT04105842|DEVICE|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
219676343|NCT02742025|OTHER|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
219676344|NCT02742025|OTHER|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
218982882|NCT05913258|DEVICE|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
219072332|NCT01094080|OTHER|standard infant formula|infants are fed a commercial formula
219072333|NCT01094080|OTHER|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
219072334|NCT01094080|OTHER|breast milk|infants are breast fed
219072335|NCT00793468|DRUG|GSK598809|GSK598809 once daily for 12 weeks
219072336|NCT00793468|DRUG|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
219072337|NCT00793468|DRUG|Placebo|Placebo once daily for 12 weeks
219072338|NCT04899518|DRUG|ALY688 Ophthalmic Solution|Ophthalmic Solution
219072339|NCT00848679|DRUG|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
219072340|NCT00848679|DRUG|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
219072341|NCT00821418|DEVICE|PulseHaler treatment|treatment is for two weeks, 3 times per day
218982883|NCT05913258|DEVICE|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
219676345|NCT02742025|OTHER|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
219676346|NCT02742025|PROCEDURE|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
219676347|NCT02425423|DIETARY_SUPPLEMENT|New thickened formula|
219676348|NCT03566381|DEVICE|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
219676349|NCT05667168|PROCEDURE|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
219676350|NCT02087670|OTHER|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
218982884|NCT00579098|DRUG|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
218982885|NCT00579098|DRUG|Placebo|Placebo tablet taken by mouth once daily for 90 days
218982886|NCT01713608|DRUG|OZ439|OZ439 x mg once daily for 3 days with milk
218982887|NCT02273232|OTHER|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
218982888|NCT02273232|OTHER|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
218982889|NCT02273232|OTHER|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
218982890|NCT03349697|DIETARY_SUPPLEMENT|Phyllantus amarus|
218982891|NCT03349697|OTHER|Placebo|
219072342|NCT00821418|DEVICE|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
219072343|NCT02647398|BEHAVIORAL|Vigorous aerobic training|Supervised vigorous aerobic training
219072344|NCT03460223|BIOLOGICAL|MSC|conventional plus MSC or placebo treatment
219072345|NCT02007850|DRUG|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
219072346|NCT05008679|DRUG|Oseltamivir|at a dose of 75 mg twice daily
219072347|NCT06038565|DEVICE|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
218982892|NCT02121522|DRUG|BI 144807|twice daily
218982893|NCT03081975|DEVICE|HD white light or NBI|Use of NBI or HD white light
218982894|NCT06232694|DRUG|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
218982895|NCT06232694|DRUG|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
218982896|NCT06232694|OTHER|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
218982897|NCT00098956|DRUG|topotecan hydrochloride|Given IV
218982898|NCT00098956|DRUG|7-hydroxystaurosporine|Given IV
219072348|NCT06038565|DEVICE|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
219072349|NCT01128413|DEVICE|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
219360395|NCT02793232|DRUG|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
219360396|NCT02793232|DRUG|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
219072350|NCT01128413|DEVICE|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
219676351|NCT02087670|OTHER|exercise protocol no supervised|Exercise program at the community
219676352|NCT01639703|DRUG|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
219676353|NCT05091996|PROCEDURE|Post-isometric muscle relaxation technique|"1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier."
219676354|NCT05091996|PROCEDURE|Myofascial release technique|The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
219676355|NCT00030628|RADIATION|radiation therapy|
219676356|NCT00030628|PROCEDURE|surgery|
219676357|NCT00030628|RADIATION|WBRT|
219676358|NCT01272505|PROCEDURE|converntional SILC|
219676359|NCT01272505|PROCEDURE|Harmonic scalpel Single incision laparoscopic cholecystectomy|
219676360|NCT00387283|DRUG|AVI-4020 Injection|
219676361|NCT03747783|PROCEDURE|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
219676362|NCT01597297|DRUG|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
219676363|NCT01597297|OTHER|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
219676364|NCT03974529|BEHAVIORAL|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
219676365|NCT03974529|BEHAVIORAL|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
219676366|NCT05100303|DRUG|Mitoxantrone Hydrochloride liposome injection|Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
219676367|NCT05100303|DRUG|Cytarabine (LoDAC)|Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
219676368|NCT05972642|DEVICE|HIFU-treatment|The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
219360397|NCT02793232|DRUG|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
219360398|NCT02507362|RADIATION|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
219360399|NCT02507362|RADIATION|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
219676369|NCT06056453|BEHAVIORAL|Interpersonal Psychotherapy|IPT group-virtual
219676370|NCT03711305|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
219676371|NCT03711305|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
219676372|NCT03711305|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
219072351|NCT01128413|DEVICE|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
219072352|NCT01128413|BEHAVIORAL|CURVES Questionnaire|The CURVES (CardiovascUlar Response \& Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
219072353|NCT01128413|BIOLOGICAL|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, \& 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
219072354|NCT01128413|BIOLOGICAL|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
219676373|NCT03711305|DRUG|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
219676374|NCT04264754|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
219676375|NCT02869477|OTHER|Data collection|
219676376|NCT01042392|DRUG|Aliskiren|150 mg Aliskiren as film-coated tablet
219676377|NCT01042392|DRUG|Ramipril|Ramipril 5 mg was given in capsule form.
219676378|NCT01042392|DRUG|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
219676379|NCT01042392|DRUG|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
219676380|NCT05802303|DRUG|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
219676381|NCT05802303|DRUG|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
219676382|NCT03318367|OTHER|Educational Intervention|Complete virtual reality education module
219676383|NCT00612651|DRUG|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
219676384|NCT04455217|OTHER|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
219676385|NCT06212284|DRUG|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
219072355|NCT01128413|BIOLOGICAL|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
219072356|NCT03204097|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
219072357|NCT03204097|DRUG|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
219072358|NCT03204097|DRUG|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
219072359|NCT02570490|DRUG|sodium fusidate|
219072360|NCT02570490|DRUG|linezolid|
219072361|NCT04622579|DRUG|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
219676386|NCT06212284|DRUG|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
219676387|NCT06350201|BEHAVIORAL|cognitive behavior therapy|Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
219360400|NCT02507362|DRUG|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
219360401|NCT02507362|PROCEDURE|epithelial debridement|corneal epithelium will be removed by a cottons swab
219676388|NCT06350201|OTHER|control group|Routine psychological care and guidance on mood management
219676389|NCT00587795|DEVICE|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
219676390|NCT00587795|OTHER|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
219676391|NCT02146209|DRUG|Metronidazole benzoate|Single oral dose of 400 mg
219676392|NCT02146209|DRUG|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
219676393|NCT02146209|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
219072362|NCT06273644|OTHER|Carbohydrates|Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
219072363|NCT03766022|DEVICE|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
219072364|NCT04873375|DRUG|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
219072365|NCT00722761|DRUG|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
219072366|NCT00722761|DRUG|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
219072367|NCT02407509|DRUG|VS-6766|
219072368|NCT02407509|DRUG|Everolimus|
219072369|NCT06505200|OTHER|No intervention|No intervention
219072370|NCT05054816|DEVICE|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
219072371|NCT05054816|DEVICE|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
219072372|NCT05054816|DEVICE|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
219072373|NCT01973881|PROCEDURE|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
219072374|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
219072375|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
219072376|NCT04915261|BEHAVIORAL|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
219072377|NCT04915261|BEHAVIORAL|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
219072378|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
219209320|NCT06894316|DEVICE|Inspiratory muscle warm-up training|The Powerbreathe brand device was used to perform inspiratory muscle pre-activation. Two sets of 30 breaths were carried out at 40% of each participant's maximal inspiratory mouth pressure (MIP), with a one-minute rest in between. MIP was measured once at the first session, and that value determined 40% and 5% for IMpa and IMPpa, respectively, in later visits. Participants were seated, wearing a nose clip, instructed to exhale forcefully, then inhale forcefully against a closed airway for one to three seconds. Measurements were repeated until values within 5 cmH₂O of each other were obtained, recording the best result in cmH₂O.
219209321|NCT06894316|OTHER|General Warm-up Protocol|The participants engaged in a 10-minute jogging activity, which was followed by a 10-minute stretching exercise. Subsequently, the general warm-up protocol was completed with shooting drills tailored to the specific requirements of basketball, without inducing fatigue.
219209322|NCT06894316|DEVICE|Placebo inspiratory muscle warm-up training|The Powerbreathe brand inspiratory muscle warm-up device was employed to facilitate an exercise regimen comprising two sets of 30 breaths, performed at an intensity of 5% of the participants' maximal inspiratory mouth pressure (MIP), with a one-minute interval between sets. This minimal load was intended as a placebo-like condition for inspiratory muscle usage.
219209323|NCT06779019|DIAGNOSTIC_TEST|LSCI|LSCI evaluates at 2 timings:immediately after the mastectomy (prior to immediate reconstruction) and again following reconstruction (after the skin was sutured). The perfusion score was calculated by normalizing these values against the perfusion value of a control.
219676394|NCT03928379|DRUG|LY3305677|Administered SC
219676395|NCT03928379|DRUG|Placebo|Administered SC
219209324|NCT06779019|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Performed immediately after the mastectomy (prior to immediate reconstruction) .Perfusion scores were determined by comparing the fluorescence intensity of the target area to that of the non-surgical region on the contralateral chest wall.
219209325|NCT06852196|PROCEDURE|orthognathic surgery ,lefort 1,bsso ,DO|Le Fort I osteotomy is often used in the correction of dental occlusion and maxillary hypoplasia in cleft patients. In addition, the osteotomy may also improve patients' facial appearance and self-esteem
219676396|NCT00700024|DRUG|Testim|50 mg/dose7day
219676397|NCT00700024|BEHAVIORAL|Strength training|three times a week
219676398|NCT00700024|DRUG|placebo|placebo
219676399|NCT00079053|DRUG|erlotinib hydrochloride|
219676400|NCT00079053|PROCEDURE|adjuvant therapy|
219676401|NCT04360473|OTHER|General anesthesia|Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
219676402|NCT04360473|DRUG|Ketamine plus general anesthesia|ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
219072379|NCT05672628|DEVICE|Oculus VR|During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
219072380|NCT03595345|PROCEDURE|Liver transplantation|Liver transplantation
219072381|NCT06532708|OTHER|5x Oxycodone Oral Tablets|Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
219072382|NCT06532708|OTHER|16x Oxycodone Oral Tablets|Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
219676403|NCT04360473|DRUG|Magnesium sulfate plus general anesthesia|Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
219676404|NCT04360473|DRUG|ketamine plus magnesium sulfate plus general anesthesia|Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
219072383|NCT07119853|OTHER|Microteaching|"Students in the experimental group watched the Advanced Life Support Team Dynamics Video. The video was uploaded to the university's education management system, and a student monitoring report was generated, ensuring that all students could watch it."
219072384|NCT07126652|DRUG|MF-59|MF-59 influenza vaccination
219072385|NCT07126652|DRUG|cell-based|cell-based influenza vaccination
219676405|NCT03059732|OTHER|Treatment|Observe the treatments of gastric cancer in each group
219072386|NCT07126652|DRUG|egg-based|egg-based influenza vaccination
219072387|NCT07127770|DRUG|PF-07104091|Cyclin-dependent kinase-2 inhibitor
219676406|NCT03476642|DRUG|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
219676407|NCT03476642|DRUG|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
219676408|NCT02826161|DRUG|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
219676409|NCT02826161|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
219676410|NCT05515237|BEHAVIORAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
219676411|NCT03786900|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727|
219676412|NCT05641935|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
219676413|NCT05641935|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219676414|NCT05641935|PROCEDURE|Computed Tomography|Undergo CT
219676415|NCT05641935|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219072388|NCT07127341|DEVICE|Patient with removable functional appliance|Survey (quiz) for patient who had malocclusion and/or a dysfunction treated removable functional appliance about the treatment, before, during and after treatment
219072389|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
219072390|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
219072391|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
219072392|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
219072393|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
219209326|NCT06852196|PROCEDURE|distraction osteogenesis|Distraction osteogenesis is a surgical technique that uses body's own repairing mechanisms for optimal reconstruction of the tissues.
219209327|NCT06842849|OTHER|Exercise program|Multimodal and multicompetent exercise program 2 days a week for 60 minutes and 1 day of walking exercise for 60 minutes.
219676416|NCT05641935|OTHER|Electronic Health Record Review|Review electronic medical record
219209328|NCT06601257|DRUG|Vancomycin (IV)|Vancomycin weight-based or kidney function-based dosing
219676417|NCT05607316|DRUG|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study."
219676418|NCT06404749|DIETARY_SUPPLEMENT|fungal fiber|fungal fiber from mycelium
219676419|NCT06404749|DIETARY_SUPPLEMENT|inulin|long chain, degree of polymerization DP\>23
219676420|NCT05258682|DRUG|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
219676421|NCT05258682|DRUG|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
219676422|NCT05100381|OTHER|dry needling|The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
218982899|NCT03867279|OTHER|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
218982900|NCT03867279|OTHER|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
218982901|NCT00516074|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
218982902|NCT00516074|DRUG|placebo|subcutaneous injection, volume equivalent to active, twice a day
218982903|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
218982904|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
218982905|NCT05254808|DRUG|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
218982906|NCT05254808|DRUG|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
218982907|NCT05089955|BEHAVIORAL|Ambient Experience|MRI examination with Ambient Experience
218982908|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
218982909|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
218982910|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
218982911|NCT03476278|OTHER|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
218982912|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
219209329|NCT06175936|OTHER|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
219209330|NCT06891365|DRUG|NNC0581-0001|NNC0581-0001 will be administered subcutaneously.
219209331|NCT06891365|DRUG|Placebo (NNC0581-0001)|Placebo matched to NNC0581-0001 will be administered subcutaneously.
219209332|NCT06762886|DEVICE|Cycle ergometer|The case was lying back in a comfortable position on the stationary bike ergometer when the exercise test was conducted. The exercise test began with a 3-minute warm-up session of unloaded cycling on a cycle ergometer, and then progressed at a rate of 10 W per minute up to the subject's threshold. After cycling for 30 W to warm up, the intensity was raised by 15 W every 60 seconds until fatigue, after which the individuals cycled for 30 W to cool down. This treatment protocol was administered to each patient 3 times/week for a total of 15 minutes of treatment, broken into intervals of two to three minutes each.
219209333|NCT06762886|DEVICE|Low-level laser therapy|The laser probe was administered using the contact approach on the dorsal midline, in the depression below the spinous process of C7 at Governor Vessel, with the patient seated in a chair with back support (GV - 14 Dazhui). The primary power switch was activated. The following settings were used for applying laser puncture: 5 mW, the maximum average power. Type of laser: gallium arsenide (Ga-As), 904 nm wavelength, 5 kHz maximum repetition rate - Program: Maintaining programs for people who had their neck lymph nodes removed and have a low leukocyte count, up to 30 J/cm2 of energy, a 2 J/cm2 energy density, and protective glasses were required to prevent irreversible eye injury from either direct or indirect laser exposure. The treatment took place for 15 minutes.
219209334|NCT06764563|BEHAVIORAL|Mediterranean Medical Nutrition Therapy (counselling)|The participants in the intervention group will receive dietary guidance on the Mediterranean diet during 9 sessions over six months. The sessions which will be held in groups of ten individuals. In-person group sessions will be held three times: at the first meeting, after three months, and after six months. During the remaining six sessions, 6 online video sessions (by the institutional telemedicine program) will be delivered and include 60 minutes of nutritional educational sessions with a registered dietitian once a month
219209335|NCT06781112|DRUG|albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).|"Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined."
219209336|NCT06796192|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.
219209337|NCT06796192|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219209338|NCT06790407|DIETARY_SUPPLEMENT|Mimio Study Product|Active ingredients in the Mimio study product include Nicotinamide 250mg, Ultra-Micronized Palmitoylethanolamide 600mg, Oleoylethanolamide 400mg, Spermidine 8mg; Other Ingredients: Hydroxypropyl-Methylcellulose (capsule), Silicon Dioxide, Magnesium Stearate.
219209339|NCT06790407|DIETARY_SUPPLEMENT|Placebo|Non-active study ingredients in the placebo include Micro Crystalline Cellulose 250mg, Hypromellose, Titanium Dioxide.
219209340|NCT06795932|DEVICE|Tendon Vibration|"Vibration can create kinesthetic illusions when applied at some modalities. The vibration will be put at 80 Hz and 1 mm of amplitude for 10 seconds to create 1 illusion/minute, during 20 minutes.~Two interventions per week, for three weeks. Total : 6 interventions"
219676423|NCT05100381|OTHER|sham (placebo) dry needling|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
219676424|NCT05010317|BEHAVIORAL|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
219676425|NCT05010317|BEHAVIORAL|Standard of care|Usual clinic based counselling offered as routine care to adolescents
219676426|NCT00565552|DRUG|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
219209341|NCT06795932|OTHER|Exercices|Standardized exercise protocol, performed daily for 3 weeks, with a diary.
219209342|NCT06795932|DEVICE|Tendon vibration|"Tendon vibration will not induce kinesthetic illusions, since it will be applied 40 Hz and 1 mm of amplitude for 10 seconds.~Two interventions per week, for three weeks. Total : 6 interventions"
219209343|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
219676427|NCT04084002|OTHER|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
218982913|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
218982914|NCT01141452|DRUG|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
218982915|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
218982916|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
218982917|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
219676428|NCT00003115|DRUG|hydromorphone hydrochloride|
219676429|NCT06643585|DRUG|Trastuzumab-Deruxtecan|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
219676430|NCT06643585|OTHER|Physicians Choice (PhC).|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
219676431|NCT00421109|DRUG|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
219676432|NCT00421109|DRUG|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
219676433|NCT00421109|DRUG|Placebo|Encapsulated tablet. Once daily for 28 days
219676434|NCT03372642|DEVICE|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
218982918|NCT01141452|DRUG|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
218982919|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
218982920|NCT06426433|OTHER|Proprioceptive Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
218982921|NCT06426433|OTHER|Upper Extremity Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
218982922|NCT01331122|DRUG|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
218982923|NCT04610970|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
218982924|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
218982925|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
218982926|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
218982927|NCT05108714|PROCEDURE|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
218982928|NCT00152620|DRUG|Dexamethasone|
218982929|NCT00152620|DRUG|Methylprednisolone|
218982930|NCT00633750|DRUG|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
218982931|NCT00633750|GENETIC|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
218982932|NCT00633750|GENETIC|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
218982933|NCT00633750|OTHER|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
218982934|NCT00633750|OTHER|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
218982935|NCT00633750|OTHER|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
218982936|NCT00633750|OTHER|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
218982937|NCT00633750|OTHER|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
218982938|NCT00633750|PROCEDURE|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
218982939|NCT05997550|OTHER|Pursed Lip Breathing Exercise|Pursed Lip Breathing Exercise for The COPD
218982940|NCT05997550|OTHER|Laughter Therapy|Laughter Therapy for the COPD
218982941|NCT05997550|OTHER|the control group.|Attention-match training is given to the patients in the control group.
219676435|NCT04990271|DRUG|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0\~5 months
219676436|NCT04053244|BEHAVIORAL|internet-based cognitive behavioural therapy|Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
219676437|NCT01981811|DRUG|Aripiprazole|
219676438|NCT01981811|DEVICE|Ingestible Event Marker (IEM)|
219676439|NCT02869893|DRUG|Secretin|
219676440|NCT03182881|OTHER|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
219676441|NCT03182881|OTHER|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
219676442|NCT00289224|BIOLOGICAL|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
219676443|NCT00289224|BIOLOGICAL|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
219676444|NCT01734057|DRUG|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)
219676445|NCT01734057|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
219676446|NCT03163316|OTHER|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
219676447|NCT04273997|DRUG|Metronidazole 10% ointment|Metronidazole 10% ointment
219676448|NCT04273997|DRUG|Placebo ointment|Placebo ointment
219676449|NCT00837967|DRUG|Symbicort Turbuhaler|160/4.5μg for 3 days
219676450|NCT00837967|DRUG|Terbutaline Turbuhaler|0.4 mg for 3 days
219676451|NCT05098366|DRUG|Furosemide|0.1mg/kg (max 5mg) of IV furosemide
219676452|NCT05098366|DRUG|Normal saline|20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
219676453|NCT05364086|PROCEDURE|Biospecimen Collection|Undergo collection of tumor, blood, saliva and stool samples
219676454|NCT05364086|OTHER|Electronic Health Record Review|Review of medical records
219676455|NCT05364086|OTHER|Interview|Complete an interview
219676456|NCT05364086|OTHER|Quality-of-Life Assessment|Ancillary studies
219676457|NCT05364086|OTHER|Questionnaire Administration|Complete questionnaires
219676458|NCT02074800|DRUG|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
219676459|NCT02074800|DRUG|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
219676460|NCT02074800|DRUG|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
219676461|NCT03593330|OTHER|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
219676462|NCT03376113|BEHAVIORAL|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
219676463|NCT05735639|DRUG|Dalteparin Sodium|Low molecular weight heparin
219676464|NCT05735639|DRUG|Tinzaparin Sodium|Low molecular weight heparin
219676465|NCT05735639|DRUG|Enoxaparin Sodium|Low molecular weight heparin
219676466|NCT05735639|DRUG|Rivaroxaban|Direct oral anticoagulant
219676467|NCT05735639|DRUG|Apixaban|Direct oral anticoagulant
218982942|NCT02810522|DEVICE|OneTouch Select® Plus Glucose Test Strips|
219676468|NCT05735639|DRUG|Dabigatran Etexilate|Direct oral anticoagulant
219676469|NCT06355726|BIOLOGICAL|Plasma Exchange|Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure
219676470|NCT06355726|OTHER|Standard Medical Treatment|Standard Medical Treatment
219676471|NCT04003376|DEVICE|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
219676472|NCT04003376|DRUG|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
219676473|NCT04003376|BIOLOGICAL|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
219676474|NCT04003376|DRUG|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
219676475|NCT00551525|RADIATION|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
219676476|NCT00551525|DRUG|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
219676477|NCT00442234|DRUG|Monteplase|
219676478|NCT03072823|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
219676479|NCT03072823|DIETARY_SUPPLEMENT|placebo|olive oil ethyl esters
219676480|NCT04676724|DRUG|GSK3228836|Participants will be administered GSK3228836.
219676481|NCT04676724|DRUG|PegIFN|Participants will be administered PegIFN.
219676482|NCT04676724|DRUG|NA therapy|Participants will continue to receive their NA therapy for the duration of the study.
219676483|NCT00287729|DRUG|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
219676484|NCT00287729|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
219072394|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
219072395|NCT05044663|OTHER|No intervention|This is an observational study
219072396|NCT02010060|BEHAVIORAL|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
219072397|NCT02010060|BEHAVIORAL|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
219072398|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
219072399|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
219072400|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
219072401|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
219072402|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
219072403|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
219072404|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
219072405|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
219072406|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
219072407|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
219072408|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
219072409|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
219072410|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
219072411|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
219209344|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
219360402|NCT06449768|BEHAVIORAL|Diabetic Macular Edema|observing the eye behavior in Diabetic Macular Edema
219360403|NCT04248738|BEHAVIORAL|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
219676485|NCT03190980|OTHER|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
219676486|NCT03190980|OTHER|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
219676487|NCT03190980|OTHER|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
219676488|NCT05979480|DIAGNOSTIC_TEST|Dual energy X-ray absorptiometry (DXA)|DXA scan to assess bone mineral density, fat mass and muscle mass.
219676489|NCT04321486|OTHER|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
219072412|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
219360404|NCT03254966|DRUG|SHR0302|Oral tablets
219360405|NCT03254966|DRUG|Placebo|Oral tablets
219360406|NCT01219231|BEHAVIORAL|Exercise|6 months of aerobic exercise
219676490|NCT03990311|OTHER|Sodium Restricted Meals|2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
218982943|NCT01667692|DRUG|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
218982944|NCT01667692|DRUG|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
218982945|NCT05317624|COMBINATION_PRODUCT|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
218982946|NCT05317624|COMBINATION_PRODUCT|Methylprednisolone|1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
218982947|NCT00591994|DRUG|piribedil|50 mg once a day, after lunch 3 month therapy
218982948|NCT02272478|DRUG|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
218982949|NCT02272478|DRUG|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
218982950|NCT02272478|DRUG|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
218982951|NCT02272478|DRUG|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
218982952|NCT02272478|DRUG|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
218982953|NCT02272478|DRUG|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
218982954|NCT00968890|BIOLOGICAL|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
218982955|NCT00968890|BIOLOGICAL|Fluarix™|Intramuscular injection, 1 dose
218982956|NCT00968890|BIOLOGICAL|Placebo|Intramuscular injection, 1 dose
218982957|NCT04348279|DEVICE|propylene mesh|propylene mesh as a palatal stent for palatal wound
218982958|NCT02925832|PROCEDURE|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
218982959|NCT02925832|DRUG|Ropivacaine|0.75% ropivacaine soaked sponges
218982960|NCT02925832|DRUG|Bupivacaine|0.5% bupivacaine soaked sponges
218982961|NCT02925832|DRUG|Proparacaine|For anaesthetising conjunctiva
218982962|NCT02215096|DRUG|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
218982963|NCT02215096|DRUG|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
218982964|NCT05668429|DRUG|Ibrexafungerp|carbon-14 (\[14\^C\])-Ibrexafungerp
218982965|NCT04313842|DEVICE|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
218982966|NCT03204201|DRUG|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
218982967|NCT03088371|DRUG|Bupivacaine 0.25%|For psoas sciatic block.
218982968|NCT03088371|OTHER|Pajunk Needle|For local anaesthesia application in psoas sciatic block
218982969|NCT03088371|OTHER|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
218982970|NCT03088371|DRUG|Lidocaine 1%|For psoas sciatic block.
218982971|NCT03088371|DRUG|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
218982972|NCT03088371|DRUG|Lidocaine 2 %|For psoas sciatic block in the post-operative period
218982973|NCT03088371|DRUG|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
218982974|NCT01126970|DRUG|Velneperit 400 mg|Velneperit 400 mg q.d.
218982975|NCT01126970|DRUG|Orlistat 120 mg|Orlistat 120 mg t.i.d
218982976|NCT01126970|DRUG|Orlistat Placebo|Orlistat Placebo t.i.d.
218982977|NCT01126970|DRUG|Velneperit Placebo|Velneperit Placebo q.d
218982978|NCT01126970|OTHER|Reduced Calorie Diet|Reduced calorie diet
218982979|NCT04401826|PROCEDURE|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
218982980|NCT04401826|PROCEDURE|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
218982981|NCT04544085|BEHAVIORAL|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
218982982|NCT00934479|DRUG|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
219360407|NCT04792710|DRUG|Metronidazole|Metronidazole 500 mg intravenous stat dose prior to skin incision
219209345|NCT06846814|DIAGNOSTIC_TEST|CEM protocol|"The intervention consists of Second-Look Ultrasound (SLUS) performed following Contrast-Enhanced Mammography (CEM) to further evaluate additional lesions detected during routine breast imaging.~When CEM identifies additional or suspicious lesions not clearly characterized by mammography alone, targeted ultrasound is conducted to assess lesion morphology, vascularity, and acoustic characteristics. Radiologists with expertise in both CEM and ultrasound interpretation will perform SLUS to determine whether the lesions require biopsy, short-term follow-up, or no further action. Findings will be correlated with histopathological results (if biopsy is performed) or follow-up imaging to assess diagnostic accuracy."
219209346|NCT03971669|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
219676491|NCT03990311|OTHER|Control|Usual Care
219072413|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
219072414|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
219072415|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
219072416|NCT06668493|DRUG|Nadofaragene Firadenovec|Repeat dose trial to investigate the safety and efficacy of nadofaragene firadenovec instilled into the renal pelvis
219072417|NCT04232254|BEHAVIORAL|Animal-based Protein Foods|Participants will consume animal-based protein foods.
219072418|NCT04232254|BEHAVIORAL|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
219072419|NCT04232254|BEHAVIORAL|Plant-based Protein Foods|Participants will consume plant-based protein foods.
219072420|NCT04232254|BEHAVIORAL|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
219072421|NCT05819749|BEHAVIORAL|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
219072422|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
219072423|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
219072424|NCT03574571|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
219072425|NCT03574571|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
219072426|NCT03574571|DRUG|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
219072427|NCT06617455|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219072428|NCT06617455|DRUG|Fezolinetant|Given PO
219209347|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
219209348|NCT04603898|DIETARY_SUPPLEMENT|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
219209349|NCT04603898|DIETARY_SUPPLEMENT|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
219209350|NCT04219709|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
219209351|NCT04219709|OTHER|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
219360408|NCT00496314|DEVICE|e2TM Cervical Cell Collector|
219676492|NCT03845244|DEVICE|Flow reduction first|-10L/min q 1hr
219072429|NCT06617455|DRUG|Placebo Administration|Given PO
219072430|NCT06617455|OTHER|Quality-of-Life Assessment|Ancillary studies
219072431|NCT06617455|OTHER|Questionnaire Administration|Ancillary studies
219072432|NCT07127991|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation (NMES)|"The medium-frequency NMES protocol, as reported in previous studies, consists of a carrier frequency of 2,500 Hz, a treatment frequency of 100 Hz, an ON time of 5 seconds (1 second ramp-up, 3 seconds contraction, and 1 second ramp-down), and an OFF time of 10 seconds. This stimulation protocol will be applied for 20 minutes per session (40 minutes of NMES per treatment day).~Two electrodes will be placed on each thigh, located at the motor point of the quadriceps muscle. Electrode positions will be marked with a semi-permanent marker to ensure consistent placement across sessions."
219072433|NCT07127991|PROCEDURE|Standard physical therapy|Participants of the fourth age (≥80 years old) will receive the standard physical therapy routinely provided during their hospitalization. This intervention involves passive mobilization of the lower limbs, specifically within the ranges of hip flexion, knee flexion and extension, and ankle flexion and extension. One set of 10 bilateral repetitions will be performed while the patient is under sedation in the ICU. Once the patient is awake, the mobilization protocol routinely used in the same unit will be followed.
219072434|NCT07020312|OTHER|Visualization training with neurofeedback|This technology uses electroencephalography (EEG) to measure brain activity through passive sensors placed on a cap aligned with the motor and frontal cortices. These sensors detect changes in electrical signals when patients imagine performing rehabilitation movements. The EEG data is sent to a computer, where iBrainTech™ software translates it into a virtual avatar that mimics the imagined actions. This real-time feedback-called neurofeedback-helps patients see how well they are engaging their brain during visualization. By turning the process into a video game controlled by brain signals, the platform motivates patients to focus deeply on visualizing the exercises. Repeated activation of these brain regions may help rebuild neuromuscular pathways, improve muscle control, and reduce the effects of Arthrogenic Muscle Inhibition (AMI), a common issue after orthopedic surgery.
219072435|NCT07020312|OTHER|Standard post-surgical rehabilitation therapy|Patients will follow a standard physical therapy protocol. The protocol will be assigned by their respective surgeon who conducted the procedure and will be specific to the procedure that the patient underwent.
219072436|NCT02863562|OTHER|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
219209352|NCT03891758|BIOLOGICAL|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
219676493|NCT03845244|DEVICE|FiO2 reduction first|\- 0.1 q 1hr
219676494|NCT03845244|DEVICE|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
219676495|NCT04455737|OTHER|injection of indigo carmine|Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
219676496|NCT02890563|DEVICE|Class II Compression Stockings|
219676497|NCT01150903|OTHER|no intervention|non-interventional study
219072437|NCT02863562|OTHER|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
219072438|NCT02863562|OTHER|Placebo Kinesio taping|
219072439|NCT06698666|DRUG|Rosuvastatin 10 mg tablet.|"The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12.~At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count."
219072440|NCT06698666|DRUG|Sertraline Pill|Both control and intervention group will receive the sertraline as a standard therapy
219072441|NCT03277235|BEHAVIORAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
219072442|NCT03277235|BEHAVIORAL|Standard Care (in control arm)|standard care
219072443|NCT06712251|DEVICE|Velocity pAVF System|The Velocity Percutaneous Arterio-Venous Fistula System consists of a percutaneous method designed to create an arteriovenous fistula for hemodialysis vascular access.
219072444|NCT06720467|BIOLOGICAL|Intralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)|Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.). The same injection was repeated every 2 weeks until complete clearance for a maximum of six treatment sessions.
219072445|NCT07076134|OTHER|FCHVs and FLHWs in a community managing HTN using primary care based approach and mobile health technology|Our intervention utilizes FCHVs as a bridge between the community and health facilities to improve HTN care. FCHVs and FLHWs will receive 2 days of training to use an Android app. The app provides prompts for BP measurement and educational content on healthy lifestyles. For 3 months, FCHVs will conduct bimonthly meetings, measure BP, height, and weight, provide awareness and enter sociodemographic details of participants into the app. Participants with BP ≥130/85 mmHg (unmedicated) or ≥120/80 mmHg (on medication) will be referred to a nearby health facility by FCHVs. The data entered by FCHVs will be linked to FLHWs' terminals. FLHWs will enter required information about medication use, referrals, and follow-ups into the app and take necessary actions for the treatment of referred patients. The intervention includes 795 participants from 10 clusters with BP ≥130/85 mmHg. Data on BP, medication adherence, quality of life, and physical activity will be collected at baseline and endline.
219209353|NCT03891758|BIOLOGICAL|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
219209354|NCT03891758|BIOLOGICAL|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
219209355|NCT01643954|PROCEDURE|robotic radical prostatectomy|robotic assisted surgery
219209356|NCT06776653|OTHER|Tovertafel Pixie|The Tovertafel Pixie® projector has a distracting effect, which can help divert the patient's attention while waiting for or undergoing treatment.
219209357|NCT05725876|DRUG|Ustekinumab|Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
219676498|NCT01150903|OTHER|no intervention|non-interventional study
219676499|NCT02078596|DRUG|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
219209358|NCT06780787|BIOLOGICAL|Balstilimab|Given IV
219676500|NCT03864523|DRUG|Pioglitazone|
219676501|NCT01537380|DRUG|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
219676502|NCT00657657|BIOLOGICAL|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
219676503|NCT00457288|DRUG|TF 002|
219676504|NCT05413226|DIETARY_SUPPLEMENT|Celastrol|Four increasing doses of Celastrol to each of five men.
219676505|NCT05073445|BEHAVIORAL|SDNN measurement|SDNN measurement during pediatric simulation
219676506|NCT04204304|DRUG|Isotretinoin|ISO
219676507|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
219676508|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
219676509|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
219676510|NCT05311020|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
219676511|NCT05311020|DIETARY_SUPPLEMENT|Pitaya Ovule Extract Drink|consume 1 bottle per day
219676512|NCT01986738|RADIATION|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
219676513|NCT01986738|DEVICE|Active Breathing Control Device (ABC)|
219676514|NCT01986738|DEVICE|Computed Tomography Scan (CT)|
219072446|NCT05116163|BEHAVIORAL|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
219072447|NCT05116163|OTHER|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
219072448|NCT07099339|BEHAVIORAL|Behavioral Therapy|Behavioral Therapy in form of: Learning and advices, Dietary modifications, Toilet pattern modification, Motivational rewarding system, and Diary documentation.
219072449|NCT07099339|OTHER|Kegel Exercise|Kegel Exercise done by contracting and relaxing pelvic floor muscles for seconds with hold and repetitions.
219072450|NCT07099339|DEVICE|Pudendal Nerve Electrical Stimulation|Pudendal Nerve Electrical Stimulation applied bilateral to the right and left pudendal by inserting rectal stimulator electrode anally with the other surface electrode at sacral region.
219072451|NCT07099339|DIAGNOSTIC_TEST|Anal Sphincter Muscle Activity Peak|Anal Sphincter Muscle Activity Peak was evaluated using anal pressure sensor (in mmHg) = anal squeeze pressure during maximum voluntary contraction - resting anal pressure at rest or resting tone as baseline activity
219072452|NCT07099339|DIAGNOSTIC_TEST|Bowel Diary Documentation|"Defecation Frequency and Fecal Leakage Episodes collected from the Bowel Diary that documenting bowel events daily through a period of time a week."
219072453|NCT07097558|OTHER|Mandala coloring group|The mandala painting intervention will be administered twice a week for 8 weeks for the mandala coloring group.
219072454|NCT07097558|OTHER|Music listening group|The music listening group will listen to classical music twice a week for 8 weeks for 30 minutes, twice a day.
219072455|NCT07097558|OTHER|control group|The control group will not receive any intervention.
219072456|NCT06496867|PROCEDURE|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
219209359|NCT06780787|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219209360|NCT06780787|BIOLOGICAL|Botensilimab|Given IV
219209361|NCT06780787|DRUG|Capecitabine|Given PO
219676515|NCT03060057|DEVICE|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
219676516|NCT01386931|PROCEDURE|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
219676517|NCT01386931|PROCEDURE|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
219676518|NCT01151969|BEHAVIORAL|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
219676519|NCT04408651|BEHAVIORAL|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
219676520|NCT04408651|BEHAVIORAL|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
219676521|NCT06304974|DRUG|BL-B01D1|Administration by intravenous infusion
219676522|NCT06304974|DRUG|Irinotecan|Administration by intravenous infusion
219676523|NCT06304974|DRUG|paclitaxel|Administration by intravenous infusion
219676524|NCT06304974|DRUG|docetaxel|Administration by intravenous infusion
219676525|NCT00665483|OTHER|Skin Prick Test|Skin Prick Test
219676526|NCT01341288|DEVICE|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
219676527|NCT05531318|OTHER|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
219676528|NCT02548468|DRUG|Fludarabine|Given IV
219676529|NCT02548468|RADIATION|Total-Body Irradiation|Undergo TBI
219676530|NCT02548468|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
219676531|NCT02548468|DRUG|Cyclophosphamide|Given IV
219676532|NCT02548468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
219676533|NCT02548468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219676534|NCT02548468|DRUG|Mycophenolate mofetil|Given IV
219676535|NCT02548468|DRUG|Tacrolimus|Given IV
219072457|NCT06496867|OTHER|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
219072458|NCT07100405|DRUG|PD-1 inhibitor|An approved agent (e.g., Pembrolizumab, Nivolumab, Sintilimab, Tislelizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.
219072459|NCT07100405|PROCEDURE|TACE|TACE is performed by using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
219072460|NCT04980482|DRUG|AB-729|subcutaneous injection
219072461|NCT04980482|DRUG|Peg-IFNα-2a|subcutaneous injection
219072462|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
219072463|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
219072464|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
219072465|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
219072466|NCT06573983|OTHER|Strengthening (Physical Therapy, Gerofit)|Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).
219072467|NCT06573983|OTHER|Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)|Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.
219072468|NCT06573983|OTHER|Medication Reconciliation (Clinical Pharmacology)|Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.
219072469|NCT06573983|OTHER|Home Safety Modification (Occupational Therapy)|Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.
219072470|NCT07107217|DRUG|Camrelizumab|200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 10 times
219072471|NCT07107217|DRUG|Doxorubicin +cyclophosphamide+ filgrastimum|Doxorubicin 60mg/m² + cyclophosphamide 600 mg/m² on Day 1 of Cycles 1-4 (Q2W) of the first neoadjuvant phase of the study, IV infusion. filgrastim (G-CSF) subcutaneously on days 2-6 of Cycles 1-4
219072472|NCT07107217|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 2 and paclitacel 80 mg/m² will be given on day 1 every 12 weeks of the second neoadjuvant phase of the study, IV infusion.
219209362|NCT06780787|PROCEDURE|Computed Tomography|Undergo CT
219209363|NCT06780787|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
219209364|NCT06780787|PROCEDURE|Endoscopic Biopsy|Undergo biopsy with endoscopic exam
219209365|NCT06780787|DRUG|Fluorouracil|Given IV
219209366|NCT06780787|DRUG|Leucovorin Calcium|Given IV
219209367|NCT06780787|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219676536|NCT05593770|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
219676537|NCT05593770|DRUG|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
219676538|NCT02237040|PROCEDURE|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
219676539|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
219676540|NCT01309451|DRUG|Bevacizumab|intravitreal, 1.25mg., monthly
219676541|NCT01309451|DRUG|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
219676542|NCT04274075|DRUG|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
219676543|NCT04274075|DRUG|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
219676544|NCT04274075|DRUG|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
219676545|NCT02768922|OTHER|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
219676546|NCT02768922|OTHER|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
219676547|NCT05040919|OTHER|collection of medical and socio-demographic data|collection of medical and socio-demographic data
219676548|NCT04465084|OTHER|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
219676549|NCT04465084|OTHER|Withness|Experimental language tasks MRI
219676550|NCT02731547|BEHAVIORAL|Education Against Tobacco School-Based Intervention|
219676551|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
219676552|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
219676553|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
219676554|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
219676555|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
219676556|NCT06226519|DIAGNOSTIC_TEST|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
219209368|NCT06780787|DRUG|Oxaliplatin|Given IV
219209369|NCT06780787|RADIATION|Radiation Therapy|Undergo radiation therapy
219209370|NCT06780787|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219209371|NCT06774885|DRUG|Folic Acid 1 Mg Oral Tablet|1 mg oral folic acid tablet
219209372|NCT06774885|DRUG|Folic Acid 5 Mg Oral Tablet|5 mg oral folic acid tablet
219209373|NCT06863376|DRUG|Carbocysteine 375 MG|Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders
219209374|NCT06863376|OTHER|Physical activity, walking, and calorie restriction|• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients
219209375|NCT01225081|DRUG|ipragliflozin|oral
219676557|NCT04133597|DEVICE|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
219676558|NCT02091401|DEVICE|Springfusor infusion pump|
219676559|NCT02091401|OTHER|IV administration|
219676560|NCT02091401|DRUG|Magnesium Sulfate|
219676561|NCT02217852|DRUG|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
219676562|NCT02217852|DRUG|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
219209376|NCT01225081|DRUG|Placebo|oral
219209377|NCT01225081|DRUG|Pioglitazone|oral
219209378|NCT04990479|BIOLOGICAL|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
219209379|NCT04990479|BIOLOGICAL|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
219209380|NCT06888947|PROCEDURE|use immediate implant in socket with collagen cone|use immediate implant in socket with collagen cone
219209381|NCT06749704|DIETARY_SUPPLEMENT|High protein diet|High protein diet
219209382|NCT06749704|DIETARY_SUPPLEMENT|Normal Protein diet|Normal protein diet
219360409|NCT01306227|DRUG|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
219676563|NCT02217852|DRUG|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
219676564|NCT02217852|DRUG|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
219676565|NCT00099632|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
219676566|NCT00099632|DRUG|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
219676567|NCT00099632|DRUG|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
219676568|NCT00099632|DRUG|single dose Nevirapine|one 200 mg tablet taken orally
219676569|NCT01256099|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
219676570|NCT01256099|BEHAVIORAL|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
219676571|NCT01256099|BEHAVIORAL|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
219676572|NCT04966819|OTHER|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
219676573|NCT03658642|BEHAVIORAL|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
219676574|NCT01397240|DRUG|Albis Tab|2 Tab, twice a day, 12 weeks
219676575|NCT01397240|DRUG|Placebo|2 Tab, twice a day, 12 weeks
219676576|NCT06224686|OTHER|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
219072473|NCT07105215|DRUG|RC278|Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.
219072474|NCT07105748|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
219072475|NCT07105748|DRUG|Rivoceranib (Apatinib)|Rivoceranib will be administered by oral 250 mg once daily.
219072476|NCT07105748|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 4 weeks for up to 6 cycles. Camrelizumab plus rivoceranib will be administered 1-3 days after HAIC.
219072477|NCT07113249|OTHER|Foam Rolling (FR)|For the FR, participants were asked to place the roller behind their leg. Three sets, each lasting 60 seconds, with a 30-second break between sets, were performed, for a total of 90 rolls per set.
219072478|NCT07114003|BEHAVIORAL|virtual reality application|The Oculus Meta Quest Pro is a virtual reality headset with 256 GB of storage. Its LCD screen offers a resolution of 1800 x 1920 pixels per eye and supports refresh rates from 90 Hz to 120 Hz. It is powered by a Qualcomm Snapdragon XR2+ processor. It features eye tracking and facial tracking, controllers with TruTouch haptics and precision tracking, and built-in 3D spatial audio support. The program, which will be played through the VR headset, is designed to use licensed programs featuring nature scenes (forest, sea, beach, etc.) and relaxing music for 20-30 minutes. The program content will be created by selecting nature sounds and music known to be effective in reducing stress and anxiety. To ensure the program's internal validity, the opinions of healthcare professionals with clinical experience will be obtained to assess whether the program achieves the intended relaxing effect.
219072479|NCT07109427|OTHER|Annual PSA Health Maintenance Reminder|The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.
219072480|NCT07116083|DIAGNOSTIC_TEST|µQFR|Patients with bifurcation lesions undergoing single-stent intervention are recruited. Wire-based FFR and intravascular imaging is performed, according to current guidelines, to guide PCI strategy. Angiography will be saved anonymously and sent to an independent core lab for µQFR calculation. Operaters are blinded to µQFR results.
219072481|NCT07114016|DRUG|Glucosamine Hydrochloride|GlcN.H is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan known for its immunoregulatory capacity and anti-inflammatory effects.
219072482|NCT07114016|DRUG|Triamcinolone Acetonide|Topical corticosteroid (triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, anti-allergic, and immunosuppressive properties which is used commonly in topical formulations)
219072483|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
219072484|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
219072485|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
219072486|NCT07118748|OTHER|Share making decision tool|the experimental group will apply the delegation protocol, but if the protocol recommends antibiotic therapy, the researchers will propose a shared decision using a specific tool to determine with the patient whether to deliver the antibiotic
219072487|NCT07118748|OTHER|Delegation protocol|the control group will apply the delegation protocol alone
219072488|NCT07117942|DRUG|Fermented Deglycyrrhizinated Licorice (FDGL)|Fermented Deglycyrrhizinated Licorice (FDGL) in oral powder capsules; prepared through three consecutive steps: fermentation of licorice roots, removal of glycyrrhizinic acid content (deglycyrrhizination), and lyophilization according to EUROPEAN PATENT SPECIFICATION Ep 1 925 312 B
219072489|NCT07118111|PROCEDURE|Resin infiltration|Application of a low-viscosity resin infiltrant to the anterior teeth affected by enamel defects. This procedure aims to reduce dental hypersensitivity and improve esthetic appearance.
219072490|NCT07121556|DEVICE|MFAT + HA left knee - MFAT + placebo right knee|The left knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The right knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
219072491|NCT07121556|BIOLOGICAL|MFAT + HA right knee - MFAT + placebo left knee|The right knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The left knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
219072492|NCT07118189|DEVICE|N95 masks and indoor air cleaner|Participants who are randomized into the intervention will receive N95 masks to be worn outdoors and an indoor air cleaner in the room that the participant spends the most time in their home. Both intervention and control arms will receive education.
219072493|NCT05568459|OTHER|Non-Interventional|No study treatment will be administered in this study.
219072494|NCT07121868|DRUG|Test Product (Vocarzine)|hard capsule formulation
219072495|NCT07121868|DRUG|Reference (R) Reagila ®|hard capsule formulation
219072496|NCT07122817|OTHER|Assessment|The group to be evaluated is comprised of individuals over 65 years of age, who can independently carry out their daily living activities, and whose cognitive level is sufficient to understand and answer the surveys and tests in the study.
219072497|NCT07125495|OTHER|Suction tootbrush and distiled water|All tooth surfaces, oral mucosa, and the tongue and surrounding area were cleaned every 8 hours (3x1) with distilled water and a suction toothbrush. The aspiration feature of the suction toothbrush enabled oral care and simultaneous aspiration of oropharyngeal secretions.
219072498|NCT07125495|OTHER|suction tootbrush and .12% chlorhexidine gluconate|Every 8 hours (3x1) 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) will be used with a suction toothbrush to clean all tooth surfaces, the oral mucosa, and the tongue. The aspiration feature of the suction toothbrush allows for the aspiration of oropharyngeal secretions during oral care.
219072499|NCT07125495|OTHER|Oral care sponge and with 15 ml of 0.12% chlorhexidine gluconate oral solution|All tooth surfaces, oral mucosa, and the tongue and surrounding tongue were cleaned with 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) every 8 hours (3x1) and an oral care sponge used in oral care in the intensive care unit. After oral care, oropharyngeal secretions were aspirated.
219072500|NCT07126925|BEHAVIORAL|Personalized Fall Prevention Program|An intervention package featuring a comprehensive, multidimensional risk assessment using an improved form and a dynamic functional test (Obstacle Physical Activity Ability Test). The assessment guided the development of a personalized prevention plan, including targeted exercises, environmental adjustments, and enhanced patient/family education.
219072501|NCT07126925|BEHAVIORAL|Standard Fall Prevention Care|Standard hospital care for fall prevention, including universal precautions (e.g., clutter-free environment, non-slip footwear) and risk assessment using a standard hospital checklist.
219072502|NCT07126639|DRUG|bedaquiline|Administer 400 mg orally once daily for the first two weeks, followed by 200 mg orally three times a week for the subsequent 22 weeks.
219072503|NCT07126639|DRUG|Pretomanid (Pa)|Administer 200 mg orally once daily for six months.
219072504|NCT07126639|DRUG|linezolid|Administer 600 mg orally once daily for six months.
219072505|NCT07126639|DRUG|Moxifloxacin (M)|Administer 400 mg orally once daily for six months.
219072506|NCT07126639|DRUG|Delamanid (D)|Administer 100 mg orally twice daily for six months.
219072507|NCT07126639|DRUG|Levofloxacin|Administer 800 mg orally once daily for six months.
219072508|NCT07126639|DRUG|clofazimine|Administer 100 mg orally once daily for six months.
219072509|NCT07126184|DIAGNOSTIC_TEST|Extended Cardiac Monitoring|This observational study involved the use of standard cardiac monitoring methods to detect atrial fibrillation in patients initially diagnosed with cryptogenic ischemic stroke. Monitoring techniques included 12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders (ILRs). No experimental interventions were assigned; patients received routine clinical care.
219072510|NCT07127003|PROCEDURE|Immediate Lymphatic Reconstruction|Preserved lymphatic channels are connected to nearby veins to prevent lymphedema during the axillary lymph node dissection.
219072511|NCT07128173|OTHER|Incubator Cover Group|"Incubator Cover Group: Neonatal information form was filled and consent was obtained.~Actigraphy and 24-hour sleep duration were recorded before incubator cover application.The incubators were covered with incubator covers for 24 hours.24-hour sleep durations were recorded again by actigraphy."
219072512|NCT07128173|OTHER|Control Group|Control Group:Neonatal information form was filled and consent was obtained. Actigraphy and 24-hour sleep duration were recorded. No practice other than routine medical treatment follow-up and nursing care was performed.24-hour sleep durations were recorded again by actigraphy.
219072513|NCT07126119|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125mg/m\^2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
219072514|NCT07126119|DRUG|Tislelizumab|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
219072515|NCT07126119|PROCEDURE|Radical nephroureterectomy (RNU)|Radical nephroureterectomy (RNU) will conducted after the completion of neoadjuvant therapy.
219072516|NCT07126587|BEHAVIORAL|Nutrition Education and Food Delivery|Healthy frozen meals, produce boxes, and nutrition counseling
219072517|NCT07126587|BEHAVIORAL|Physical Activity Comparator|Physical activity counseling, mHealth text messaging
219072518|NCT07127133|DEVICE|Insole and ankle device|Device that is worn as a shoe insole and around the ankle which will measure gait parameters to detect cognitive decline
219072519|NCT07128212|DRUG|Atorvastatin 10 mg daily|Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.
219072520|NCT07128212|DRUG|Placebo matching atorvastatin|Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.
219072521|NCT07127315|DRUG|Gonadotropin-releasing hormone agonist|Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.
219072522|NCT07127315|DRUG|Chemotherapy|Patients received chemotherapy alone.
219072523|NCT07126171|DRUG|Reduning injection|reduning Injection, intravenous drip, 20 ml per time, once a day;
219072524|NCT07126171|DRUG|The simulant of Reduning Injection|The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day
219072525|NCT07127588|OTHER|Simulation based clinical ultrasound education|At the two hands-on teaching seminars, GPs in the intervention arm will receive training in five different clinical ultrasound examinations using an ultrasound phantom and an ultrasound simulator (Simbionix U/S Mentor). At the start of the first course day (8 hours), three basic modules will be conducted on the simulator, aimed at training hand-eye coordination and developing fundamental skills in probe movement, enhancing three-dimensional perception, and learning to use the various settings on the ultrasound simulator to achieve optimal imaging. At the first course day, the five clinical ultrasound examinations will be trained through a total of 13 simulation cases. On the second course day (4 hours), the participants will repeat the 13 simulation cases.
219072526|NCT07127588|OTHER|Traditional ultrasound education|At the two hands-on teaching seminars, GPs in the control arm will receive training in five different clinical ultrasound examinations as according to an established and validated training program. At the start of the first course day (8 hours), the five clinical ultrasound examinations will be trained using healthy volunteers and still pictures for visualizing pathology. On the second course day (4 hours), the participants will train by repeating the five clinical ultrasound examinations on healthy volunteers.
219072527|NCT07127705|DIETARY_SUPPLEMENT|Placebo|2 capsules
219072528|NCT07127705|DIETARY_SUPPLEMENT|Chaga Mushroom|2 capsules
219072529|NCT07127705|DIETARY_SUPPLEMENT|Ginseng extract|2 capsules
219072530|NCT07127705|DIETARY_SUPPLEMENT|Olive extract|2 capsules
219072531|NCT07127705|DIETARY_SUPPLEMENT|Potassium Hydrogen Glucarate|2 capsules
219072532|NCT07127393|OTHER|Food|Meal with seaweed
219072533|NCT07126405|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
219072534|NCT07127107|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|"For mild and moderate migraines e.g Ibuprofen and aspirin.~* Aspirin: Peroral (PO) tablet with standard dosages of 325 mg, 500 mg, and 400 mg effervescent; treatment dosage of up to 1000 mg~* Ibuprofen: PO tablet with standard dosages of 200 mg, 400 mg, 600 mg, and 800 mg; treatment dosage of 200 to 800 mg"
219072535|NCT07127107|OTHER|Manual therapy techniques|"Cranial manipulative osteopathy: Tension release of cranial sutures is applied while the patient in supine lying position, a pressure of 200g to3kg is applied with both thumbs for 30-40 sec or till release occurs. it includes:~1. Coronal suture The head is directed to one side and the pressure is applied with both thumbs directed parallel to each otheralong the coronal suture.~2. Sagital suture distraction The head is in the central position and the pressure is applied with both thumbs directed parallel to each other along the sagittal suture.~3. Squamous suture distraction The head is directed to one side and the pressure is applied with both thumbs parallel along the squamous suture.~4. Lamboidal suture distraction:~   The head is directed to one side and the thumbs directed parallel to each other along the lamboidal suture.~5. Occipitomastoid suture distraction The head is directed to one side and both thumbs directed parallel to each other along occipitomastoid suture."
219072536|NCT07126197|PROCEDURE|lymphovenous bypass at diseased foot dorsum|A lymphovenous bypass procedure using a lymphangiography dye (Patent Blue V or indocyanine green), 0.2 mL was injected into the skin at the toe webspaces preoperatively. 8,13,14 The paths of lymphatic vessels were traced. On the foot dorsum of the affected limb, a horizontal incision of 2-3 cm was made close to the lymphatic vessel's pathway. Under the surgical microscope, suitable lymphatic and venous vessels were identified, usually located above the deep fascia (on the superficial side, ensuring that the extensor hallucis longus tendon remains unexposed). The coaptation between the lymphatic vessels and venules followed the same principles as those for vascular anastomosis by using higher magnification under the surgical microscope (approximately 20×), finer microsurgical instruments, and 11- or 12-0 nylon sutures.
219360410|NCT01306227|DRUG|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
219072537|NCT07126678|DRUG|zanubrutinib, bendamustine, and obinutuzumab|"Patients will receive combination therapy with zanubrutinib, bendamustine, and obinutuzumab over 6 cycles, with each cycle lasting 28 days. The specific dosing schedule is as follows: Bendamustine 70 mg/m²: administered intravenously on Days 2-3 of Cycle 1, and on Days 1-2 of Cycles 2-6. Obinutuzumab 1000 mg: administered intravenously on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 (every 28-day cycle). Zanubrutinib 160 mg orally twice daily (bid), continuously throughout Cycles 1-6.~Treatment is discontinued after 6 cycles, with no subsequent maintenance therapy."
219676577|NCT06224686|OTHER|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
219676578|NCT00098670|BIOLOGICAL|alemtuzumab|Given SC
219676579|NCT00098670|BIOLOGICAL|rituximab|Given IV
219676580|NCT00098670|DRUG|fludarabine phosphate|Given IV
219676581|NCT01187277|BEHAVIORAL|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
219676582|NCT01187277|DEVICE|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
219676583|NCT00232518|PROCEDURE|Infection with hookworm larvae|
219676584|NCT03290391|OTHER|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
219676585|NCT03290391|DRUG|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
219676586|NCT03290391|BEHAVIORAL|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
219676587|NCT03762681|DRUG|RO7239958|Solution for injection, subcutaneous use (SC).
219676588|NCT03762681|OTHER|Placebo|Sodium chloride solution for injection, SC
219676589|NCT02137226|DRUG|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
219676590|NCT02137226|DRUG|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
219676591|NCT03632070|BEHAVIORAL|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
219676592|NCT05462236|DRUG|Tinodasertib|MNK inhibitor
219676593|NCT05462236|DRUG|Pembrolizumab|PD-1 Inhibitor
219676594|NCT05462236|DRUG|Irinotecan|Topoisomerase inhibitor
219676595|NCT00882661|DEVICE|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
219676596|NCT00882661|DEVICE|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
219676597|NCT04270695|BEHAVIORAL|blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.
219676598|NCT04270695|BEHAVIORAL|sham blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
218982983|NCT01497457|PROCEDURE|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
218982984|NCT00087503|DRUG|Edotecarin|
218982985|NCT03329508|DRUG|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
218982986|NCT03329508|DRUG|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
218982987|NCT03329508|DRUG|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
218982988|NCT03329508|DRUG|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
218982989|NCT03666624|BEHAVIORAL|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
218982990|NCT00546559|DRUG|statins (simvastatin, pravastatin)|
218982991|NCT05384678|DRUG|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
218982992|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
218982993|NCT05384678|DRUG|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
218982994|NCT05384678|DRUG|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
218982995|NCT05384678|DRUG|Placebo|A Placebo (saline infusion) will be administered.
219676599|NCT02373137|PROCEDURE|DSAEK|
219676600|NCT02373137|PROCEDURE|DMEK|
219676601|NCT02373137|DEVICE|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
219676602|NCT02373137|DRUG|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
219676603|NCT02373137|DRUG|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
219676604|NCT02373137|DRUG|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
219676605|NCT02373137|DRUG|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
219072538|NCT07126366|OTHER|S-PRG Barrier coat|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession or temporary sensitivity due to whitening.
219676606|NCT02373137|DEVICE|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
219676607|NCT00003896|DRUG|cisplatin|
219676608|NCT00003896|DRUG|liposomal doxorubicin|
219676609|NCT00003896|DRUG|paclitaxel|
219676610|NCT00507988|BEHAVIORAL|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
219676611|NCT00507988|BEHAVIORAL|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
219676612|NCT01398358|BEHAVIORAL|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
219676613|NCT01398358|BEHAVIORAL|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
219676614|NCT00100152|DRUG|MK0752, (Notch Inhibitor)|
219676615|NCT02022735|DEVICE|Deep Brain Stimulator|DBS will provide brain stimulation.
219676616|NCT00985686|OTHER|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
219676617|NCT04692116|DEVICE|ExAblate treatment|Subthalamotomy using the ExAblate
219676618|NCT00748163|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219676619|NCT00748163|DRUG|sunitinib malate|
219676620|NCT02105519|BIOLOGICAL|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
219676621|NCT04127396|DRUG|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
219676622|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
219676623|NCT04127396|DRUG|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
219676624|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
219072539|NCT07126366|OTHER|S-PRG Prophylaxis paste|S-PRG Prophylaxis paste is a bioactive Giomer-based paste containing S-PRG particles that release six therapeutic ions-fluoride, strontium, borate, aluminum, sodium, and silicate each contributing to remineralization, antibacterial effects, and dentin sensitivity reduction.
219072540|NCT07128030|OTHER|Exercise|The experimental group completed a five-week supervised program combining moderate-intensity aerobic and resistance training (150 min/week). Intensity was monitored using the Borg and OMNI-Res scales after familiarization sessions. Adherence was encouraged through reminders, motivational messages, and follow-ups. Unlike prior studies, this intervention focused specifically on neurophysiological pain modulation. Sessions included step-based aerobic exercises and resistance training with elastic bands under safety protocols.
219072541|NCT07127965|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
219676625|NCT01670045|DRUG|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
219676626|NCT02494648|DEVICE|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
219676627|NCT02494648|OTHER|Control|
219676628|NCT02538406|OTHER|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
219676629|NCT04008888|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
219676630|NCT04008888|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
219676631|NCT04008888|DRUG|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
219676632|NCT04008888|DRUG|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
219676633|NCT04008888|DRUG|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
219676634|NCT04008888|DRUG|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
219676635|NCT00501137|BIOLOGICAL|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
219676636|NCT03092648|BIOLOGICAL|Bronchial basal cell|autologous bronchial basal cell transplantation
219676637|NCT00537290|DRUG|Rituximab|Rituximab 1000mg IV on Days 0 and 15
219676638|NCT02273128|GENETIC|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
219676639|NCT04326387|DIAGNOSTIC_TEST|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
219676640|NCT04326387|DIAGNOSTIC_TEST|Public Health England Gold Standard|Reverse Transcription PCR
219676641|NCT04326387|DIAGNOSTIC_TEST|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
219676642|NCT04326387|DIAGNOSTIC_TEST|Radiological Detection|Chest X-ray \& CT Scan detection of viral infection in the lungs
219676643|NCT00193557|DRUG|Bortezomib|
219676644|NCT01357005|OTHER|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
219676645|NCT00901082|BEHAVIORAL|Relaxation and information session|Relaxation and information session before the medial branch block
219676646|NCT02780271|BEHAVIORAL|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
219676647|NCT02780271|BEHAVIORAL|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
219676648|NCT02780271|BEHAVIORAL|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
218982996|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
218982997|NCT01555450|OTHER|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
219209383|NCT06750367|OTHER|Klapp method exercises|The researcher will administer Klapp method exercises to the participant for a period of 1 month (twice in a week for 50 min .The researcher will perform stretching of upper limb, neck and thoracic region to the participants as a baseline treatment. Klapps exercises program include four point walk followed by two point walk and back walk, breathing exercise from kneeling position, breathing exercise from quadrapedal position, simple bounce glide with simulanteos breathing, bunny hop greeting. Each exercise will be performed with 10 repetitions
219676649|NCT02559570|DRUG|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
219676650|NCT02559570|DRUG|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
219676651|NCT02559570|DRUG|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
218982998|NCT00569270|DRUG|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
218982999|NCT05646095|BEHAVIORAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
218983000|NCT03814083|DEVICE|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
219676652|NCT02559570|DRUG|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
219676653|NCT02559570|DRUG|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
219676654|NCT05022888|DEVICE|regional tissue saturation|tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
219676655|NCT02738229|DRUG|Valacyclovir|
219676656|NCT02738229|DRUG|placebo|
219676657|NCT00043849|DRUG|Quetiapine|
219676658|NCT03021629|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
219676659|NCT04685642|DRUG|Aspirin|Aspirin (100mg/day)
219676660|NCT04685642|DRUG|Atorvastatin|Atorvastatin (20mg/day)
219676661|NCT02264938|DIETARY_SUPPLEMENT|Antioxidant|Oral supplemmentation with antioxidants
219072542|NCT07126457|OTHER|RIS system|The RIS system based on the Internet of Things consists of three aspects: one-way output management of the large database of head and neck tumors, two-way interaction management of artificial intelligence applications, and popular science dissemination for the general public.
219072543|NCT07127848|PROCEDURE|Septoplasty with Mucotomy|Subtotal reconstruction of the nasal septum accompanied by radiofrequent nasal mucosal reduction of the inferior turbinates.
219072544|NCT07127848|PROCEDURE|Septoplasty with Turbinectomy|Subtotal reconstruction of the nasal septum accompanied by surgical resection of the inferior turbinates.
219072545|NCT07127848|PROCEDURE|Septoplasty with Valvuloplasty|Subtotal reconstruction of the nasal septum accompanied by surgical intervention by placing a flare sutture in the internal nasal valve area.
219072546|NCT07126730|DEVICE|EXOPULSE Mollii Suit + Exercise|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Once patients put on the EXOPULSE Mollii Suit and the stimulation begins, they will undergo a personalized exercise program including strengthening, balance, and gait training with scheduled rest intervals. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
219072547|NCT07126730|DEVICE|EXOPULSE Mollii Suit|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Patients will wear the suit and receive stimulation while resting for 60 minutes. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
219072548|NCT07126756|DEVICE|STAR S4 IR Excimer Laser System|LASIK with iDesign
219072549|NCT07126756|DEVICE|VisuMax 400 Surgical Laser|small incision lenticule extraction technique
219072550|NCT07126236|DRUG|Epcoritamab|Patients will receive 12 cycles of Epcoritamab monotherapy.
219072551|NCT07126236|DRUG|Epcoritamab, tafasitamab and lenalidomide|Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.
219072552|NCT07126613|BEHAVIORAL|Mobile Health Intervention to Reduce Alcohol Use Among Young Adults|"The mobile just-in-time adaptive intervention consists of 1) a digital participant dashboard and 2) tailored messages delivered to the participant's cellphone addressing the individual and ecological contexts of alcohol use.~The web-based intervention dashboard includes: 1) a drink counter for participants to log the number and type of drinks (e.g., beer, wine, mixed drink) they consume in a drinking occasion; 2) a calendar which summarizes the number of days on which a participant has consumed alcohol and the number of drinks consumed over the study period, broken out by drink type; 3) a log where participants can set drinking-related goals and update their progress on those goals; and 4) national and local substance use resources.~Participants will receive messages tailored to their drinking situation and ecological context during high-risk drinking times."
219072553|NCT07128251|PROCEDURE|TACE treatment|TACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted.
219072554|NCT07128251|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
219072555|NCT07128251|DRUG|Bevacizumab|Bevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
219072556|NCT07127653|OTHER|Retinol-Based Day Cream|A commercially available day cream containing retinol and moisturizing ingredients. Applied twice daily (morning and evening) to the full face for 4 weeks.
219676662|NCT05387694|OTHER|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
219676663|NCT04388176|DRUG|C21|C21 as first treatment
219676664|NCT04388176|DRUG|C21|C21 as second treatment
219676665|NCT04388176|DRUG|Placebo|Placebo as second treatment
219676666|NCT04388176|DRUG|Placebo|Placebo as first treatment
219676667|NCT04283253|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
219676668|NCT01289301|DRUG|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
219676669|NCT01289301|DRUG|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
219676670|NCT01215149|BIOLOGICAL|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
219676671|NCT01215149|BIOLOGICAL|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
219676672|NCT01215149|BIOLOGICAL|Placebo Control|Colorless 10mm Tris/HCl buffer
219676673|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
219072557|NCT07127653|OTHER|Lotion and Toner Bundle|A skincare regimen including a dermalift toner and a milky lotion. Applied twice daily (morning and evening) to the full face for 4 weeks.
219360411|NCT05644366|OTHER|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
219360412|NCT04475614|DIETARY_SUPPLEMENT|BioGaia Prodentis lozenges|oral probiotics
219676674|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
219676675|NCT01219192|DRUG|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
219676676|NCT01219192|DRUG|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
219676677|NCT02996890|BIOLOGICAL|MV-ZIKA|MV-Zika vaccine
219676678|NCT02996890|OTHER|Placebo|physiological saline
219676679|NCT01064362|DRUG|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
219676680|NCT01064362|DRUG|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
219676681|NCT00225108|DRUG|Tinzaparin|
219072558|NCT07126093|COMBINATION_PRODUCT|focal high-intensity focused ultrasound therapy combined with standard novel hormonal therapy|The participants in the intervention arm will receive HIFU combined with standard NHT. Depending on the location of the lesion, tumor load and the pathological conditions, hemicglandular ablation or focal ablation was selectively administered. The safe boundary was set at 3mm, with a power of 300W and a pulse width of 30ms. Novel endocrine therapy was given after HIFU treatment
219072559|NCT07126093|OTHER|Standard novel hormonal therapy only|Participants in the control arm will receive standard NHT.
219072560|NCT07126561|DRUG|Trastuzumab Deruxtecan|Do not substitute trastuzumab deruxtecan with trastuzumab or ado-trastuzumab emtansine. Do not administer as an intravenous push or bolus. Trastuzumab deruxtecan is not compatible with sodium chloride 0.9% solution for infusion. During treatment, patients should be observed for infusion-related reactions (IRRs). For additional information on the management of IRRs
219072561|NCT07127276|OTHER|Mobile application GERDCare|Features of GERDCare that support management of GERD
219072562|NCT07126782|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
219072563|NCT07127120|DIETARY_SUPPLEMENT|Prebiotic fiber blend|"Proprietary blend of 5 prebiotic fibers and normal bar excipients Product name: NeuroFiber Dosage form: Single bar/day~Storage conditions:~The Study Product delivered by Sorridi to patient/subject at the beginning of study. Any remainder will be collected by Sorridi at end of study.~Product is to be stored at room temperature in the patient's/subject's homes.~The bar will be produced and packaged at a licensed contract manufacturer experienced in producing nutritional supplements.~Labelling will be carried out by Sorridi Therapeutics."
219072564|NCT07127731|BEHAVIORAL|Patient Portal Messaging|Participants will receive weekly messages via their patient portal including feedback on their step counts and step count goals based on data from their FitBits
219072565|NCT07127731|BEHAVIORAL|FitBit EHR Linkage|Participants will receive FitBits and link this step count data with the Electronic Health Record (EHR)
219072566|NCT07126262|DRUG|Vosoritide|The vosoritide dose administered will be based on the participant's weight and will follow the weight-band dosing regimen approved for ACH
219072567|NCT07126262|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
219072568|NCT07126808|BEHAVIORAL|Simulation-Based CPR Workshop|A 4-hour, in-person simulation-based cardiopulmonary resuscitation (CPR) workshop designed for non-healthcare university students, following American Heart Association 2020 guidelines and the NLN Jeffries Simulation Framework. The training includes: (1) pre-briefing on OHCA and CPR importance; (2) instructor-led demonstration using manikins; (3) guided hands-on practice with real-time feedback; (4) scenario-based simulation with assigned team roles; and (5) structured debriefing for reflection and feedback. Skills practiced include scene safety, assessing responsiveness, high-quality chest compressions, rescue breathing, AED use, and team communication. Trainer-to-student ratio is approximately 1:6.
219072569|NCT07128108|OTHER|Visual Transient Elastography (ViTE) Examination|Post-marketing product (Mindray Hepatus 9 Ultrasound Diagnostic System) for visual transient elastography examination in patients with liver injury.
219072570|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 400IU|Low dose vitamin D (400 IU/day)
219072571|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 4000IU|Moderate dose vitamin D (4000 IU/day)
219072572|NCT07126210|BEHAVIORAL|Family engaged, enhanced Diet intervention|"The family component includes health education via books, lectures, and short videos, parenting skills training, regular monitoring of child growth, and behavior goal setting through the mobile health platform. Motivational interviewing via telephone provides tailored behavioral support.~Kindergartens assist in health education, supervise dietary intake and physical activity, monitor children's growth monthly, and maintain communication with families.~Hospitals provide targeted health counseling and facilitate clinic access as needed.~The mobile health platform integrates modules for health education, smart growth curve tracking, behavior goal management, and home-school-hospital collaboration."
219072573|NCT07127523|OTHER|Social Skin|This group receives a cleanser, serum, and cream.
219072574|NCT07127523|OTHER|Placebo|This group receives a cleanser, serum, and cream.
219072575|NCT07126314|OTHER|Competition based Education Format|Residents will be organized into 3 teams, each competing to amass points for critiquing articles presented during journal club, for a prize.
219072576|NCT06934876|DIAGNOSTIC_TEST|Colorimetric carbon dioxide (CO2) detection|"All patients will undergo colorimetric carbon dioxide (CO2) detection. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation: Is the color change consistent with a tube located in the trachea?"
219072577|NCT06934876|DIAGNOSTIC_TEST|Waveform capnography|"All patients will undergo waveform capnography. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation:  Is the waveform consistent with a tube located in the trachea?"
219676682|NCT02829385|DRUG|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
219676683|NCT01966302|DRUG|BPS-314d-MR|15-150 mcg po BID,
219072578|NCT06531356|BIOLOGICAL|autologous amniotic fluid|10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
219072579|NCT06531356|OTHER|No amniotic fluid injected in skin edges|conventional closure of skin
219072580|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
219072581|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
219072582|NCT06936709|DRUG|Colchicine 1.8 mg (loading dose) + Dextrose Oral Placebo|This intervention will be used for individuals in arm A of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, and will then be given placebo oral dextrose pills to take twice daily on postoperative days 1-3
219072583|NCT06936709|DRUG|Colchicine 1.8 mg + 0.6 mg|This intervention is will be given to patients in arm B of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, followed by a maintenance does of colchicine (0.6 mg) to be taken twice daily on postoperative days 1-3.
219072584|NCT06936709|DRUG|Dextrose Oral Placebo|This intervention will be for patients in arm C, the placebo arm. These patients will receive oral dextrose pills to be taken once on postoperative day 0, and twice daily on postoperative days 1-3.
219072585|NCT06940518|DRUG|Ivonescimab|Given by IV
219072586|NCT06167031|OTHER|chatbot facilitated teaching|"The experimental group will use chatbot to facilitate teaching."
219072587|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
219072588|NCT06947980|DRUG|Placebo Comparator|Placebo subcutaneous injection
219072589|NCT06947980|BIOLOGICAL|CM512|CM512 subcutaneous injection
219676684|NCT04626661|DEVICE|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
219676685|NCT01615978|DRUG|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
219072590|NCT06952049|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be randomized to listen to a three-minute recording about different pain management strategies (e.g., ice, rest) to promote overall well-being.
219072591|NCT06952049|BEHAVIORAL|Mindfulness without Psychoeducation|In the mindfulness without psychoeducation intervention, participants will be randomized to listen to a three-minute mindfulness practice consisting of 1 minute of mindful breathing, 1 minute of mindful mapping, and 1 minute of mindfulness of personal meaning.
219072592|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Pain Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Pain Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindful mapping.
219072593|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Meaning Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Meaning Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindfulness of personal meaning.
219072594|NCT06952049|BEHAVIORAL|2 Minutes of Psychoeducation with 1 Minute of Mindfulness|In the 2 Minutes of Psychoeducation with 1 Minute of Mindfulness intervention, participants will be randomized to listen to a 2 minute of psychoeducation about mindfulness and 1 minute of mindful breathing.
219072595|NCT06954818|BIOLOGICAL|A zoster mRNA vaccine SYS6017|SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.
219072596|NCT06954818|OTHER|Placebo|saline solution
219072597|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
219072598|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
219072599|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
219072600|NCT02639702|DRUG|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
219072601|NCT07126353|OTHER|prospective observational study (clinical, hormonal and auxological data)|We collect clinical, hormonal and auxological data and compare them between the two groups.
219072602|NCT06544642|DRUG|ASP5502|Oral
219072603|NCT06544642|DRUG|Placebo|Oral
219072604|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
219072605|NCT00738777|DRUG|Anastrozole|1 mg,QD,PO
219072606|NCT00738777|DRUG|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
219072607|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
219072608|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
219072609|NCT06280196|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
219072610|NCT06280196|DRUG|EU-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
219072611|NCT06280196|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
219072612|NCT06280196|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
219072613|NCT06280196|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
219072614|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
219072615|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
219360413|NCT04475614|PROCEDURE|low level laser treatment with Ga-Al-As laser|low level laser treatment
219676686|NCT01615978|DRUG|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
219676687|NCT01615978|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
219676688|NCT01337817|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
219676689|NCT01337817|OTHER|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
219676690|NCT00944632|DRUG|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
219676691|NCT00944632|DRUG|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
219676692|NCT03472001|OTHER|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
219676693|NCT03472001|OTHER|Lecture|Traditional didactic lecture which uses the same clinical cases
219676694|NCT04528329|DRUG|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
219676695|NCT04528329|DRUG|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
219072616|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
219072617|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
219072618|NCT03528538|OTHER|Placebo|rice flour in a vegetable/ cellulose capsule
219072619|NCT03214367|DRUG|LY900014|Administered SC
219072620|NCT03214367|DRUG|Insulin Lispro|Administered SC
219072621|NCT03214367|DRUG|Insulin Glargine|Administered SC
219072622|NCT03214367|DRUG|Insulin Degludec|Administered SC
219072623|NCT05564013|DEVICE|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
219072624|NCT03508843|BEHAVIORAL|interactive virtual presence|installing the car seat with advice via interactive virtual presence
219072625|NCT03527225|OTHER|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
219072626|NCT02421484|BIOLOGICAL|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
219676696|NCT00254215|BEHAVIORAL|high protein & low glycemic index diets|
219676697|NCT03076112|DRUG|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
219676698|NCT03076112|DRUG|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
219676699|NCT03972215|DRUG|Berberine Chloride|Traditional Chinese Medicine
219676700|NCT03972215|DRUG|Placebo|Placebo Control
219676701|NCT01715701|PROCEDURE|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
219676702|NCT01715701|PROCEDURE|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
219676703|NCT01715701|PROCEDURE|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
219676704|NCT01436487|BIOLOGICAL|MultiStem|single infusion 1-2 days following ischemic stroke
219676705|NCT01436487|BIOLOGICAL|Placebo|single infusion 1-2 days following ischemic stroke
219676706|NCT03114085|DRUG|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
219072627|NCT05597501|BEHAVIORAL|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy
219072628|NCT04592770|BEHAVIORAL|Nature based walk therapy|10 minutes stretching exercises followed by walk in nature for 50 minutes
219072629|NCT04592770|BEHAVIORAL|Sit in nature|Sit in nature for 60 minutes
219072630|NCT00765843|DEVICE|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
219072631|NCT01654432|OTHER|Paravertebral Blocks (PVB)|
219072632|NCT04278092|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, q21
219072633|NCT04278092|DRUG|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
219360414|NCT04475614|DIETARY_SUPPLEMENT|B vitamin injections (Neurobion, Merck, Darmstadt, Germany)|intra muscular vitamin injections
219676707|NCT03114085|DRUG|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
219676708|NCT04851366|BEHAVIORAL|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
219676709|NCT04851366|BEHAVIORAL|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
219676710|NCT04851366|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
219676711|NCT05686863|DRUG|Remimazolam|Remazolam for sedation in children undergoing bidirectional endoscopy
219676712|NCT05686863|DRUG|Esketamine|Esketamine
219676713|NCT05686863|DRUG|Propofol|Propofol
219676714|NCT05686863|DRUG|remifentanil|remifentanil
219676715|NCT05710146|DRUG|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
219676716|NCT05710146|DRUG|Placebo|1 injection of 100mL of normal saline
219676717|NCT00448214|DRUG|YM150|Oral
219676718|NCT00448214|DRUG|warfarin|Oral
219676719|NCT03944863|DRUG|Antibiotics|
219676720|NCT04560868|DEVICE|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
219072634|NCT03555396|BEHAVIORAL|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
219072635|NCT03555396|BEHAVIORAL|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
219072636|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
219072637|NCT03200938|DEVICE|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
219072638|NCT03200938|DEVICE|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
219072639|NCT05078190|OTHER|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
219072640|NCT06279182|BEHAVIORAL|Barre Stretching Intervention|The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
219676721|NCT04560868|DEVICE|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
219676722|NCT04560868|DRUG|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
219676723|NCT00279344|DRUG|Fentanyl (Matrifen)|
219676724|NCT01726465|DRUG|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
219676725|NCT01726465|DRUG|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
219676726|NCT02876861|PROCEDURE|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
219676727|NCT02876861|PROCEDURE|Distal ureterectomy|Distal ureterectomy.
219676728|NCT02876861|DRUG|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
219676729|NCT04811859|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
219676730|NCT04032795|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
219676731|NCT04032795|DIETARY_SUPPLEMENT|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
219072641|NCT00709280|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
219072642|NCT00709280|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
219072643|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
219072644|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
219072645|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Human Milk|Comparing formula and human milk
219072646|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Formula|Comparing formula and human milk
219072647|NCT02635815|PROCEDURE|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
219072648|NCT00243724|DRUG|Esomeprazole|
219072649|NCT01107574|DRUG|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
219072650|NCT01107574|PROCEDURE|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
219072651|NCT01107574|OTHER|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
219072652|NCT02747134|BEHAVIORAL|Emotion Regulation and Mindfulness skills|
219072653|NCT02014857|PROCEDURE|Gingival Crevicular Fluid Sampling|
219072654|NCT04256733|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
219072655|NCT04256733|BIOLOGICAL|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
219072656|NCT05959850|DRUG|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
219072657|NCT05959850|DRUG|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
219676732|NCT01302795|DRUG|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
219676733|NCT01310127|DRUG|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
219676734|NCT01310127|DRUG|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
219676735|NCT05704270|BEHAVIORAL|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
219676736|NCT05704270|BEHAVIORAL|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
219676737|NCT04120181|OTHER|There is no intervention.|There is no intervention.
219676738|NCT00005587|RADIATION|radiation therapy|
219676739|NCT05114187|OTHER|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. Ten selected multimedia e-learning lessons;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
219072658|NCT05579860|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
219072659|NCT05845229|DIETARY_SUPPLEMENT|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
219676740|NCT05114187|OTHER|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. One selected multimedia e-learning lesson;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
219676741|NCT03430908|OTHER|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
218983001|NCT03814083|DEVICE|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
218983002|NCT03814083|OTHER|Wait-list|No intervention
218983003|NCT03822182|DRUG|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
218983004|NCT03822182|DRUG|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
218983005|NCT00810355|BEHAVIORAL|Support Group|General support and problem solving for work activity
218983006|NCT00810355|BEHAVIORAL|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
218983007|NCT00810355|BEHAVIORAL|Cognitive Remediation|Computerized training to enhance cognitive functioning.
218983008|NCT01346579|OTHER|laboratory biomarker analysis|Correlative sciences
218983009|NCT01479023|DRUG|64Cu-DOTA-U3-1287|
218983010|NCT01479023|DRUG|U3-1287 (unlabeled)|
218983011|NCT03523130|DIAGNOSTIC_TEST|Imaging|Macrophage-specific inflammation
218983012|NCT00156897|DRUG|ATL-962|
218983013|NCT00156897|DRUG|Orlistat|
218983014|NCT05143281|DRUG|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
218983015|NCT06213246|BEHAVIORAL|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~* Maintain a consistent wake-up and bedtime schedule during workdays.~* Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~* Keep the bedroom temperature below 22°C.~* Avoid sources of light and noise in the bedroom.~* Use the bed only for sleeping, avoiding other activities before bedtime.~* Avoid daytime naps during workdays.~* Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~* Expose yourself to natural light in the morning and reduce artificial lights in the evening.~* Avoid consuming alcoholic beverages and caffeine in the afternoon.~* Have a moderately sized dinner at least 3 hours before bedtime."
218983016|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
218983017|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
219209384|NCT06750367|OTHER|At-Home exercise program|theywill begiven printed information on an at-home exercise program, such corrective exercises (Chin tuck, stretchingof neck extensormuscles andpectoral musclegroups instandingandsupinepositions) (16) ,posturecorrection exercises(Thisexerciseprogramconsistedof2strengthening(of thedeep cervical flexorsandshoulderretractors)(26) ,andbreathingexercises(Deep breathing is an exercise that can regulate breathing patterns and improve posture. The deep breathing that is done repeatedly can overcome stiffness in the thoracic cage and straighten the curve of thoracic kyphosis)(27).Theywillbeaskedtoperformtheperiodof1month twiceinaweekfor50minwith10repetitionsofeachexercise.
219676742|NCT03659123|BEHAVIORAL|standardized geriatric intervention|"Nutritional care is based on:~* A personalized evaluation of nutritional balance and nutritional needs of the patient~* A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~* 2 to 3 times a week: strength exercise~* 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~* 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
219676743|NCT00826566|DIETARY_SUPPLEMENT|Caffeine|2 times 250 mg caffeine per day
219676744|NCT00826566|DIETARY_SUPPLEMENT|placebo|2 times 250 mg per day
219676745|NCT00356109|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
219676746|NCT00356109|DRUG|Injectable insulin|patient specific dose, injected, before meals, 6 months
219676747|NCT00356109|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
219676748|NCT02640313|DRUG|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
219676749|NCT04835064|DRUG|Nab paclitaxel|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15
219676750|NCT04835064|DRUG|Gemcitabine|Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks
219072660|NCT05845229|DIETARY_SUPPLEMENT|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
219072661|NCT00270218|BIOLOGICAL|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
219072662|NCT00270218|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
219072663|NCT00270218|BIOLOGICAL|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
219072664|NCT00270218|BIOLOGICAL|PBS|phosphate buffered saline
219072665|NCT04289857|OTHER|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
219072666|NCT05795725|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
219072667|NCT05795725|PROCEDURE|Colonoscopy|Colonoscopy procedure
219072668|NCT01436903|DEVICE|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
219072669|NCT04542343|BEHAVIORAL|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
219209385|NCT05019027|DRUG|Beta blocker|"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol"
219676751|NCT04835064|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
219676752|NCT04824937|DRUG|Telaglenastat|Capsule, taken by mouth
219676753|NCT04824937|DRUG|Talazoparib|Capsule, taken by mouth
219676754|NCT04985227|OTHER|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
219676755|NCT02348697|BIOLOGICAL|NOVOCART 3D|Autologous Chondrocyte Implantation
219676756|NCT00741598|DRUG|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
219676757|NCT00741598|DRUG|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
219676758|NCT03269903|DEVICE|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
219676759|NCT01602705|OTHER|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
219676760|NCT01602705|OTHER|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
219676761|NCT01602705|OTHER|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
219676762|NCT05787743|OTHER|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
219676763|NCT05787743|OTHER|Base cream|Apply on the face twice a day
219676764|NCT00003367|DIETARY_SUPPLEMENT|green tea|
219072670|NCT02539342|DRUG|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
219072671|NCT02539342|DRUG|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
219072672|NCT02300753|DRUG|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
219072673|NCT06495775|DEVICE|quickfact|fecal sampling
219072674|NCT01369342|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
219072675|NCT01369342|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
219072676|NCT01369342|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
219072677|NCT01816594|DRUG|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
219072678|NCT01816594|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
219072679|NCT01816594|DRUG|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
219072680|NCT01816594|DRUG|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
219072681|NCT01951430|DRUG|Antibiotic and antifungal drugs|
219072682|NCT03722251|BEHAVIORAL|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
219072683|NCT01643694|BEHAVIORAL|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
219072684|NCT03905655|DRUG|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
219072685|NCT03905655|DRUG|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
219072686|NCT02566031|DRUG|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
219072687|NCT02566031|DRUG|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
219072688|NCT06388525|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|
219072689|NCT05118685|DRUG|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
219072690|NCT05118685|COMBINATION_PRODUCT|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
219072691|NCT06276192|OTHER|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
219360415|NCT04388306|OTHER|Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)|Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
219676765|NCT00003367|DIETARY_SUPPLEMENT|soy protein isolate|
219676766|NCT00003367|DIETARY_SUPPLEMENT|vitamin E|
219676767|NCT01899820|DRUG|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
219676768|NCT01899820|DRUG|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
219676769|NCT02488018|BIOLOGICAL|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
219676770|NCT02537665|OTHER|heating precondition|
219209386|NCT04270045|DEVICE|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
219676771|NCT02440048|DEVICE|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
219209387|NCT06762171|PROCEDURE|open wedge high tibial osteotomy|All procedures will be performed based on the technique recommended by the AO international knee expert group. Biplanar osteotomy, which comprises osteotomies in the axial and frontal planes, will be performed in all cases. Ascending frontal osteotomy, leaving the tibial tuberosity on the distal fragment, will be also performed. All osteotomies will be performed without the use of additional bone grafts, and the opening of the osteotomy was maintained with a Tomofix plate (Orthomed-E Co., Egypt). Wound closure will be performed in layers.
219676772|NCT02440048|DEVICE|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
219676773|NCT03571607|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
219676774|NCT04000126|DEVICE|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
219676775|NCT04000126|DEVICE|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
219676776|NCT04000126|DRUG|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
219676777|NCT04000126|DRUG|Placebo|100ml 0,9% NaCl iv 10min before intubation
219676778|NCT04000126|DEVICE|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
219676779|NCT04000126|DEVICE|HR|HR in beats/min will be measured by the electrocardiogram monitor
219676780|NCT04000126|DEVICE|BP|BP will be measured automatically by an occluding upper arm cuff
219676781|NCT00640419|DRUG|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
218983018|NCT03729466|OTHER|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
218983019|NCT02587884|PROCEDURE|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
218983020|NCT05929157|DRUG|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
218983021|NCT02837146|BIOLOGICAL|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
218983022|NCT02837146|DRUG|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
218983023|NCT00003487|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
218983024|NCT02807519|GENETIC|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
218983025|NCT01008176|BEHAVIORAL|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
218983026|NCT03098121|DRUG|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
218983027|NCT00951444|BIOLOGICAL|dalotuzumab|Given IV
218983028|NCT00951444|DRUG|carboplatin|Given IV
218983029|NCT00951444|DRUG|gemcitabine hydrochloride|Given IV
218983030|NCT02702453|BEHAVIORAL|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
218983031|NCT05475561|PROCEDURE|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
219209388|NCT06762171|PROCEDURE|Arthroscopic partial lateral patellar facetectomy|Diagnostic arthroscopy will be performed in all cases to assess Patellofemoral articular cartilage degeneration , assess the lateral compartment and exclude any other pathology. The knee is taken throughout a range of motion to directly visualize the impingement of the lateral patellar facet against the trochlea. Next, a radiofrequency probe is used to outline the area to be resected along the lateral patellar facet While maintaining the knee at 20 degrees of flexion, a 5.5-mm burr is introduced, and under arthroscopic visualization, the overhanging portion of the lateral patellar facet is carefully resected. Once the bony resection is complete, the knee is dynamically re-evaluated (through flexion and extension) for residual impingement and to assess for improvements in patellar mobility. Patellar tracking is assessed to verify that there is no catching in flexion and that patellar mobility is improved.
219072692|NCT06276192|OTHER|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
219072693|NCT01352338|DRUG|Lenalidomide, endoxan, prednisone|dose-finding
219072694|NCT01352338|DRUG|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
219072695|NCT04363801|DRUG|DKN-01 300mg|Administered by IV infusion
219072696|NCT04363801|DRUG|DKN-01 600mg|Administered by IV infusion
219072697|NCT04363801|DRUG|DKN-01 400mg|Administered by IV infusion
219072698|NCT04363801|DRUG|Tislelizumab 200mg|Administered by IV infusion
219072699|NCT04363801|DRUG|Tislelizumab 400mg|Administered by IV infusion
219072700|NCT04363801|DRUG|Oxaliplatin|Administered by IV infusion
219072701|NCT04363801|DRUG|Capecitabine 1000mg/ m2 BID|Administered orally
219209389|NCT06816199|OTHER|Hyperbaric oxygen exposure|Between 1 week and 3 months after the traumatic brain injury, participants will receive hyperbaric oxygen therapy on a 2.0 ATA protocol for 60 minutes once a day, five times a week.
219209390|NCT06818435|DEVICE|Myval THV series|Transcatheter Aortic Valve Implantation
219209391|NCT06751212|PROCEDURE|Radiofrequency ablation alone|Endoscopic radiofrequency ablation (RFA) consists of delivering a 465 KHz energy waveform to the diseased tissue through an array of bipolar electrodes. The electrodes are mounted externally to the balloon, on an articulating platform attached to the distal end of the endoscope, or on a flexible catheter that penetrates the scope. The principle of radiofrequency ablation is that the action of high-frequency alternating current (HFAC) induces the movement of charged particles within the tissue to generate heat, which results in evaporation of water inside and outside the cell, drying, and solidifying and shedding to the point of aseptic necrosis.RFA has been demonstrated to safely, effectively, and durably eradicate early stage tumors of Barrett's esophagus as well as gastric low-grade endoepithelial neoplasia, and is said by a consensus of experts to be capable of treating moderately severe atrophic enterocolitis that has not yet progressed to gastric low-grade intraepithelial neoplasi
219209392|NCT06780761|OTHER|simulation training|The author further demonstrated taking body temperature, heart rate and its characteristics, respiratory rate and saturation, blood pressure and pain assessment in line with previously created cases on the NOELLE® Maternal Birthing Simulator with Advanced Resuscitation Neonatal M-W45111 to the students deployed in the intervention group. Furthermore the students were allowed to work individually on the infant simulator, their questions were answered and feedback was given to them. Students were also offered free time to work on the infant simulator. One week after the training, before proceeding with the clinical practice, the students were individually assessed on measuring the vital signs by 2 different observers and were administered the post-tests.
219360416|NCT01430650|DRUG|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
219676782|NCT00640419|DRUG|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
219360417|NCT01430650|DRUG|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
219072702|NCT04363801|DRUG|Leucovorin Calcium|Administered by IV infusion
219072703|NCT04363801|DRUG|Fluorouracil|Administered by IV infusion
219072704|NCT03879720|PROCEDURE|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
219072705|NCT05278273|DEVICE|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
219072706|NCT06389604|OTHER|Heat acclimation|Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
219072707|NCT03669848|OTHER|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
219072708|NCT06062680|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
219072709|NCT00907673|DEVICE|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
219072710|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
219209393|NCT06780761|OTHER|Classical training|Before proceeding with the clinical practice, the students deployed in the control group were trained on how to measure the five vital signs, which tools to use and why, and normal and abnormal vital sign values by demonstration and explaining on a pediatric nursing manikin. Then, volunteering students were given the opportunity to develop their vital sign measurement skills on a pediatric nursing manikin and feedback was provided to them. One week after the training, all students were individually assessed on measuring the vital signs by 2 different independent observers on the simulator neonatal used in the intervention group and they were administered the post-tests.
219209394|NCT06413576|DIAGNOSTIC_TEST|homocysteine measurement|measuring the serum level of homocysteine
219360418|NCT02997592|DEVICE|SpinCare|The burn wound is treated using the SpinCare Systen
219676783|NCT04220801|DRUG|ZM-H1505R|Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
219676784|NCT04715191|GENETIC|CARE T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL0: 1x10\^7/m\^2 DL1: 3x10\^7/m\^2 DL2: 1x10\^8/m\^2 DL3: 3x10\^8/m\^2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219676785|NCT04715191|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
219676786|NCT04715191|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
219676787|NCT05840016|DRUG|AK112, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
219676788|NCT05840016|DRUG|Tislelizumab, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
219676789|NCT05830539|DRUG|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
219676790|NCT05830539|DRUG|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
219676791|NCT03161522|DRUG|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
219676792|NCT03161522|DRUG|Chemotherapy|Receive induction chemotherapy
219676793|NCT03161522|PROCEDURE|Conventional Surgery|Undergo surgery
219676794|NCT03161522|DRUG|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
219676795|NCT03161522|RADIATION|Radiation Therapy|Undergo RT
219676796|NCT02760524|BEHAVIORAL|NET Intervention|Neuro-emotional Technique
218983032|NCT05475561|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
218983033|NCT05475561|DRUG|Bupivacain|local anesthetic
218983034|NCT03404232|DEVICE|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
218983035|NCT00611507|DRUG|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
219072711|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
219072712|NCT04013815|PROCEDURE|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
218983036|NCT05263375|DEVICE|Innovalve TMVR system|Innovalve TMVR system
218983037|NCT02058173|DRUG|150 mg/daily chloroquine compare to placebo for 12 week|
218983038|NCT02058173|DRUG|Chloroquine|
218983039|NCT02058173|DRUG|placebo|
219676797|NCT06346418|GENETIC|WES analysis|"Whole-exome sequencing will be performed as the first approach in all the recruited patients. First, we will analyze different subsets of genes, belonging to:~1. Maternal effect genes as SCMC components and other related genes;~2. Genes essential in the maturation of the oocyte and zygote progression through the early phases of the embryogenesis or highly expressed at different stages of oocyte maturation;~3. Genes with known and potential roles in the establishment and control of genomic imprinting and involved in DNA methylation reactions.~Subsequently, variants with a high pathogenicity score will be analyzed, to identify any genes that may be associated with the phenomenon, but do not belong to the previously described categories of genes. Finally, we will conduct a whole genome sequencing (WGS) analysis on a selected subgroup of BWS mothers with peculiar clinical histories and negative WES analysis, to explore all the noncoding and regulatory regions not targeted by WES."
219676798|NCT06346418|GENETIC|whole-genome methylation analysis|A whole-genome methylation analysis will be performed to identify methylation changes in women with reproductive problems including those with offspring affected by BWS
219676799|NCT06126640|DRUG|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
219676800|NCT06126640|DRUG|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
219676801|NCT04831060|PROCEDURE|Periodontal or peri-implantitis treatment|"For Cases :~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal or peri-implantal treatment~* At 3 months = periodontal or peri-implantal reevaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* If periodontal or peri-implantal pockets greater than 5mm and bleeding persist: surgery and gingival explant sampling~* At 3 months post-surgery = periodontal or peri-implantal re-evaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* Maintenance"
219676802|NCT04831060|PROCEDURE|Control treatment|"For Controls:~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days"
219676803|NCT01713062|DEVICE|Vitelene|THA
219676804|NCT01713062|DEVICE|XLPE|THA
219676805|NCT04789681|DRUG|Canakinumab|Given SC
219676806|NCT04789681|OTHER|Quality-of-Life Assessment|Ancillary studies
219676807|NCT02234934|BIOLOGICAL|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell."
219676808|NCT06056830|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
219676809|NCT03192410|BEHAVIORAL|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
219676810|NCT03192410|BEHAVIORAL|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
219676811|NCT03192410|BIOLOGICAL|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
219676812|NCT03192410|BIOLOGICAL|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
219676813|NCT03192410|GENETIC|DNA|SNPs (GWAS)
219676814|NCT03192410|BIOLOGICAL|Mental well-being|Cognitive function; dispositional optimism; depression.
219072713|NCT04013815|PROCEDURE|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
219072714|NCT00413153|DRUG|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
219072715|NCT00413153|DRUG|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
219072716|NCT04333394|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
219072717|NCT04333394|OTHER|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
219072718|NCT03204279|DRUG|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
219072719|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
219072720|NCT03204279|DRUG|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
219676815|NCT02617134|BIOLOGICAL|anti-MUC1 CAR-T cells|
219676816|NCT03905681|DEVICE|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
219072721|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
219072722|NCT03898206|OTHER|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
219072723|NCT03898206|OTHER|Prolonged sitting|See Prolonged sitting arm description
219072724|NCT02277106|DRUG|SAGE-547|
219676817|NCT00123682|PROCEDURE|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
219676818|NCT00123682|PROCEDURE|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
219676819|NCT00123682|PROCEDURE|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
219676820|NCT00123682|PROCEDURE|Self-help|Project staff send out self-help materials for smoking cessation
219676821|NCT00869973|DRUG|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
219676822|NCT00869973|DRUG|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
219676823|NCT05446142|DRUG|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
219676824|NCT05446142|DRUG|Encorafenib first formulation|first formulation
219676825|NCT05446142|DRUG|Encorafenib second formulation|second formulation
219676826|NCT05446142|DRUG|Rabeprazole tablet|Proton-pump inhibitor
219072725|NCT02277106|DRUG|Placebo|
219072726|NCT01334801|PROCEDURE|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~1. BNP (Brain Natriuretic Peptide)~2. (PFA) Platelet Function Analyzer 100~3. von Willebrand Factor (vWF) antigen~4. (vWF) multimers~5. (vWF) \*activity by latex aggregation~6. Plasma stored for development of new testing approaches"
219072727|NCT01089972|DEVICE|22 gauge catheter|radial artery cannulation using 22 gauge catheter
219072728|NCT01089972|DEVICE|20 gauge catheter|radial artery cannulation using 20 gauge catheter
219072729|NCT06411457|DRUG|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
219072730|NCT01064739|DIETARY_SUPPLEMENT|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
219072731|NCT01064739|OTHER|Fixed Sodium Diet|Fixed sodium low monoamine diet
219072732|NCT06155968|PROCEDURE|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
219072733|NCT06155968|DRUG|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
219072734|NCT04639453|DIAGNOSTIC_TEST|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
219072735|NCT04639453|DIAGNOSTIC_TEST|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
219072736|NCT04639453|DIAGNOSTIC_TEST|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
219072737|NCT04639453|DIAGNOSTIC_TEST|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
219072738|NCT04639453|DIAGNOSTIC_TEST|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
219072739|NCT04639453|DIAGNOSTIC_TEST|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
219072740|NCT06333925|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)|10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)
219072741|NCT06333925|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)|inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)
219072742|NCT06333925|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
219072743|NCT03670316|DRUG|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
219072744|NCT03670316|OTHER|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
219072745|NCT02962687|BEHAVIORAL|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
219072746|NCT02962687|BEHAVIORAL|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
219072747|NCT02766751|BEHAVIORAL|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
219072748|NCT02766751|BEHAVIORAL|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
219072749|NCT05780203|BEHAVIORAL|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
219072750|NCT05780203|BEHAVIORAL|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
219676827|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219676828|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219676829|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219676830|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219072751|NCT05780203|BEHAVIORAL|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
219676831|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219676832|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
219676833|NCT05717205|DIAGNOSTIC_TEST|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
219676834|NCT01310582|DRUG|Desflurane|
219676835|NCT01310582|DRUG|Sevoflurane|
219676836|NCT04711694|BEHAVIORAL|Minfulness-based Intervention|"The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice."
219072752|NCT04287023|OTHER|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
219072753|NCT04287023|OTHER|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
219072754|NCT05762835|BEHAVIORAL|Virtual family-centered rounds (FCR)|"Parents will be given the option to join FCR virtually or in-person; this intervention is changing the behavior of how providers deliver healthcare and how parents engage in their child's care.~The NICU team members will use a computer with a speaker and pan-tilt-zoom camera, mounted on a stand with wheels to launch telehealth connections using the secure application called ExtendedCare. From within this telehealth connection, a NICU team member will send an electronic message (e.g. via text or email) to the subscribed parent(s) and wait for the parent to join the visit to establish a secure videoconference. The message to the parent includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. FCR will then proceed in usual fashion with the NICU team members and - if in attendance - parent(s)."
219072755|NCT06031701|BEHAVIORAL|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
219072756|NCT02479412|DRUG|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
219676837|NCT06164483|DIAGNOSTIC_TEST|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR"
219676838|NCT06164483|OTHER|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
219676839|NCT05942521|BEHAVIORAL|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
219676840|NCT05942521|BEHAVIORAL|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
219676841|NCT05942521|BEHAVIORAL|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
219072757|NCT02479412|DRUG|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
219072758|NCT02479412|DRUG|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
219072759|NCT02479412|DRUG|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
219072760|NCT02479412|DRUG|Salbutamol|Inhalation as needed
219072761|NCT00794612|DRUG|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
219072762|NCT02549898|DRUG|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
219072763|NCT02549898|DRUG|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
219072764|NCT02549898|OTHER|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
219676842|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
219676843|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
219676844|NCT04727593|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
219676845|NCT04727593|OTHER|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
219676846|NCT04793477|DEVICE|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
219072765|NCT02549898|OTHER|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
219072766|NCT01571362|DRUG|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
219072767|NCT01571362|DRUG|Placebo|oral placebo, divided into symmetric doses and administered twice daily
219072768|NCT00458328|DRUG|Z-338|
219072769|NCT00485485|DRUG|Imatinib Mesylate|400 mg by mouth daily
219072770|NCT00485485|DRUG|Docetaxel|60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
219072771|NCT05851365|DRUG|Hyperpolarized Bicarbonate (13C)|Given IV
219072772|NCT05851365|PROCEDURE|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
219072773|NCT05123508|DEVICE|2940nm and BBL treatment|2940nm and BBL treatment
219072774|NCT05123508|OTHER|Non-treatment side (Control)|No treatment
219072775|NCT03780764|OTHER|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
219072776|NCT03780764|OTHER|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
219072777|NCT01669629|DEVICE|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
219072778|NCT01669629|DEVICE|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
219072779|NCT05940532|DRUG|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
219072780|NCT02322957|DRUG|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
219072781|NCT03570294|DRUG|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
219072782|NCT05625048|OTHER|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
219072783|NCT00124904|BEHAVIORAL|Biofeedback|
219072784|NCT00124904|BEHAVIORAL|Kegel exercises|
219072785|NCT02324439|DRUG|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
219072786|NCT04117035|PROCEDURE|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
219072787|NCT04117035|PROCEDURE|GKRS standard care|Standard GKRS treatment
219072788|NCT03774628|BIOLOGICAL|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
219676847|NCT03382418|BIOLOGICAL|gp145 C.6980 Vaccine|Administered by intramuscular injection in the deltoid.
219676848|NCT03382418|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
219072789|NCT03774628|BIOLOGICAL|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
219676849|NCT03382418|BIOLOGICAL|Aluminum Hydroxide Adjuvant|Administered by intramuscular injection in the deltoid.
219676850|NCT02654158|DRUG|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
219209395|NCT06769230|OTHER|Core strengthening exercise|The participants will perform warm-up exercises including Cat and Camel, spinal movement (spinal flexion and extension cycles), and stretching exercises for the calf, hamstrings, quadriceps and lower back for about 5 minutes. After that, the women will be asked to perform core stability exercises including abdominal hollowing, bilateral knee raise, supine extension Bridge, straight leg rise from prone and alternate arm and leg raise from quadruped. Each exercise will be repeated for 10 times with 7-8 seconds hold and will be increased by four repetitions each week throughout the interventions. During each repetition for every exercise, the patient will be asked to contract her abdominal muscles and maintain this contraction while maintaining her normal breathing pattern.
219676851|NCT02654158|DRUG|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"
219676852|NCT02583022|DRUG|PAC-14028 cream 1.0%|Topical application
219676853|NCT02583022|DRUG|PAC-14028 cream vehicle|Topical application
219676854|NCT02583022|DRUG|Elidel cream 1%|Topical application
219676855|NCT05116371|DRUG|150 mcg levonorgestrel/30 mcg ethinyl estradiol|concurrent use of COC with Nexplanon
219676856|NCT03011177|DRUG|Teneligliptin|teneligliptin 20mg qd
219676857|NCT03011177|DRUG|Linagliptin|linagliptin 5mg qd
219676858|NCT04633226|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
219676859|NCT01151345|DRUG|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
219676860|NCT01151345|DRUG|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
219676861|NCT02536105|DRUG|Methylphenidate HCl ER tablets 1|
219676862|NCT02536105|DRUG|Placebo|
219676863|NCT02536105|DRUG|Methylphenidate HCl ER tablets 2|
219676864|NCT02536105|DRUG|Methylphenidate HCl ER for suspension|
219676865|NCT06333028|DEVICE|enVista Aspire EA IOLs|Subjects bilaterally implanted with enVista Aspire EA IOLs
219072790|NCT01221597|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
219072791|NCT01221597|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
219072792|NCT02504073|OTHER|No intervention|No intervention
219209396|NCT06769230|OTHER|sensory motor training|The participants will perform warm-up exercises including neck rotations, arm circles, ankle rotations, trunk rotations, trunk bending and extending for 5-10 mins. After warm up the women performs Bosu ball exercises including Bosu ball one Leg Bridge, Bosu Crunch, Bosu Sit ups, Bosu compressions, Bosu side crunch and Bosu bodyweight squat . Each exercise will be repeated for 6 repetitions in each set. At least 3 sets of each exercise are performed per session. Each exercise will be increased by five repetitions each week throughout the interventions.The total duration of each session is 45 minutes.
219209397|NCT06724016|DRUG|HM16390|HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
219072793|NCT06236022|DRUG|Sirolimus|at a dose of 2 mg once daily
219072794|NCT05271617|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
219676866|NCT04585243|DEVICE|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
219072795|NCT05020639|DRUG|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
219676867|NCT02950922|DRUG|RVT-501 0.2% ointment|
219676868|NCT02950922|DRUG|RVT-501 0.5% ointment|
219676869|NCT02950922|OTHER|Vehicle ointment|Placebo comparator
219676870|NCT06289777|PROCEDURE|TEVAR|minimally invasive endovascular intervention to treat aortic dissection
219676871|NCT01083992|DRUG|Galvus (vitagliptin)|Galvus (vitagliptin)
219676872|NCT01083992|DRUG|Galvus + vitamin D|Galvus + vitamin D
219676873|NCT04464408|DRUG|Favipiravir|1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
219676874|NCT04464408|DRUG|Placebo|(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
219676875|NCT05036798|DRUG|Tislelizumab|"Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD"
219676876|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
219676877|NCT02083302|BEHAVIORAL|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
219676878|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 4|Booster Session
219676879|NCT06253247|COMBINATION_PRODUCT|NanoChitosan impregnated Calcium Hydroxide|NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
219209398|NCT06308029|BEHAVIORAL|eHealth self-management support program|This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
219209399|NCT06308029|BEHAVIORAL|Face-to-face rehabilitation program|The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
219676880|NCT01630083|DRUG|epirubicin|Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
219676881|NCT01630083|DRUG|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
219676882|NCT01630083|DRUG|capecitabine|The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
219676883|NCT01630083|DRUG|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
218983040|NCT05209269|OTHER|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
218983041|NCT02109211|DEVICE|Intubation with Magill forceps|
218983042|NCT02109211|DEVICE|Intubation with altered Magill forceps|
218983043|NCT02201641|RADIATION|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
218983044|NCT02201641|RADIATION|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
218983045|NCT02201641|DEVICE|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
218983046|NCT02201641|DEVICE|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
218983047|NCT03475823|DIETARY_SUPPLEMENT|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
218983048|NCT03475823|DIETARY_SUPPLEMENT|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
218983049|NCT03475823|DIETARY_SUPPLEMENT|Placebo control|An inert encapsulated powder provided by Finzelberg.
218983050|NCT03558087|DRUG|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
218983051|NCT03558087|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.
218983052|NCT03558087|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.
218983053|NCT04437563|BEHAVIORAL|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
218983054|NCT04555421|DEVICE|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
218983055|NCT02617043|RADIATION|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
218983056|NCT03855228|DRUG|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
218983057|NCT03855228|DRUG|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
218983058|NCT03855228|DRUG|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
218983059|NCT03855228|DRUG|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
218983060|NCT00737243|DRUG|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
218983061|NCT00737243|DRUG|Carboplatin|AUC 6.0 IV Day 1
218983062|NCT00737243|DRUG|Bevacizumab|15 mg/kg IV infusion Day 1
219676884|NCT05471336|PROCEDURE|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
219676885|NCT00647036|DIETARY_SUPPLEMENT|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
219676886|NCT00647036|DRUG|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
219676887|NCT02450422|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
219676888|NCT02450422|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219676889|NCT01480817|DRUG|Sorafenib|Sorafenib 400mg po bid
219676890|NCT01480817|PROCEDURE|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
219676891|NCT03838029|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
219676892|NCT03838029|OTHER|Placebo|Placebo
219676893|NCT03749408|DRUG|bupivacaine plus mannitol|local anesthesia
219676894|NCT03749408|DRUG|bupivacaine alone|local anesthesia
219676895|NCT02394015|DRUG|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
219676896|NCT05535400|BEHAVIORAL|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
219676897|NCT05535400|DEVICE|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
218983063|NCT00737243|DRUG|Erlotinib|150 mg PO
218983064|NCT00737243|OTHER|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
218983065|NCT03529331|DRUG|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
219676898|NCT01343784|OTHER|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
219676899|NCT03581370|DRUG|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
219676900|NCT03581370|DRUG|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
219676901|NCT02439788|DRUG|cyclophosphamide|500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
219676902|NCT02439788|DRUG|Fludarabine|30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
219676903|NCT02439788|GENETIC|GINAKIT Cells|"* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
219676904|NCT02786706|DEVICE|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
219676905|NCT01348100|DRUG|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
219676906|NCT01348100|DRUG|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
219676907|NCT01348100|DRUG|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
218983066|NCT03529331|DRUG|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
218983067|NCT03529331|DRUG|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
218983068|NCT04275934|BEHAVIORAL|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
218983069|NCT04404205|DIAGNOSTIC_TEST|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
218983070|NCT00092573|DRUG|MK0653, ezetimibe|
218983071|NCT00092573|DRUG|Comparator: fenofibrate monotherapy|
218983072|NCT04534543|RADIATION|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
219072796|NCT03986112|BIOLOGICAL|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
219072797|NCT05526105|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
219072798|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
219072799|NCT00617760|BIOLOGICAL|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
219072800|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
219072801|NCT02969889|DEVICE|Airtraq|video laryngoscope with a channel
219072802|NCT02969889|DEVICE|ILMA|
219072803|NCT03667053|DRUG|dasiglucagon|glucagon analog
219072804|NCT03667053|DRUG|placebo|placebo for dasiglucagon
219072805|NCT03667053|DRUG|GlucaGen HypoKit|native glucagon
219072806|NCT04003116|DRUG|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
219072807|NCT03942250|BIOLOGICAL|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
219209400|NCT06890156|BEHAVIORAL|ENREACH child-parent-teacher triad|"Prior to enrolling study participants, we will conduct sensitization meetings with each selected government primary school. These meetings will be oriented toward community leaders, caregivers of children with or without disabilities, and school management committees to introduce them to the program, ensure the inclusion of all children, and address concerns related to gender, poverty, and disability.~A disability-inclusive module will be delivered to preschoolers in their regular pre-primary classrooms by trained pre-primary teachers. This module will cover foundational skills, the importance of play, communication, socio-emotional learning, and strategies for adapting the curriculum to accommodate children with disabilities.~ENREACH parent group school readiness intervention package will be provided to parents during monthly parent-teacher meetings, facilitated by trained preschool teachers."
219676908|NCT04292145|BEHAVIORAL|Relaxation Application|The use of an application for relaxation.
219072808|NCT02499874|DRUG|Efavirenz|oral Efavirenz 400mg
219072809|NCT02499874|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
219072810|NCT02499874|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
219072811|NCT02499874|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
219072812|NCT02202226|DRUG|Lu AF35700|
219072813|NCT02202226|DRUG|Placebo|
219072814|NCT00487162|PROCEDURE|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
219072815|NCT00487162|DRUG|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
219072816|NCT01877538|OTHER|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
219072817|NCT01495767|OTHER|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
219072818|NCT03229369|PROCEDURE|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
219072819|NCT03229369|PROCEDURE|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
219072820|NCT03432975|DRUG|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
219072821|NCT03432975|DRUG|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
219072822|NCT02739581|PROCEDURE|Endoscopic Variceal Ligation|
219072823|NCT02739581|DRUG|Non selective beta blocker|
219072824|NCT02739581|OTHER|Placebo|
219676909|NCT04292145|BEHAVIORAL|Relaxation Only|The individual's personal method to relax.
219676910|NCT04886245|OTHER|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound \[o\], the labial protrusion on the sound \[pu\] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
219676911|NCT03768921|OTHER|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
219676912|NCT03826966|DEVICE|reSET|reSET is a mobile app created by Pear Therapeutics, Inc., which has previously been approved by the FDA.
219676913|NCT02966756|DRUG|Venetoclax|Tablet; Oral
219676914|NCT00159107|DRUG|Acamprosate|Acamprosate
219676915|NCT00159107|BEHAVIORAL|Integrative behavior therapy|Integrative behavior therapy
219676916|NCT00159107|DRUG|Placebo|Placebo
219676917|NCT03953599|BIOLOGICAL|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
219676918|NCT03126253|DIAGNOSTIC_TEST|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
219676919|NCT01129804|BEHAVIORAL|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
219676920|NCT04442698|PROCEDURE|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
219676921|NCT03882957|BEHAVIORAL|Sustained attention|participants will complete a sustained attention task
219676922|NCT03882957|BEHAVIORAL|media multi-task|participants will complete multiple media tasks at the same time
219676923|NCT03882957|OTHER|Video|participants will watch a video of media tasks being completed
218983073|NCT06323057|DEVICE|Single pulse TMS to the frontal cortex|Single pulse TMS will be delivered to the left frontal cortex, and stimulation intensity will be at 110% of resting motor threshold.
218983074|NCT04108234|DRUG|HR071603|HR071603 monotherapy ,nasal spray
218983075|NCT04108234|DRUG|placebo|placebo,nasal spray
218983076|NCT00005865|DRUG|vinorelbine tartrate|
218983077|NCT03943160|DEVICE|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
218983078|NCT04882280|BEHAVIORAL|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
218983079|NCT05383521|DRUG|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
218983080|NCT05383521|DRUG|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
218983081|NCT02964975|PROCEDURE|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
218983082|NCT02964975|DRUG|Optimal medical therapy|Medical threatment according to guidelines
218983083|NCT04153604|DRUG|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
218983084|NCT03894800|DRUG|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
218983085|NCT03894800|DRUG|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
218983086|NCT03894800|DRUG|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
218983087|NCT03894800|DRUG|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
218983088|NCT04937946|DRUG|Fentanyl|Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
219209401|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
219676924|NCT02974803|DRUG|Dabrafenib|Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
219676925|NCT02974803|DRUG|Trametinib|Trametinib 2 mg once daily until progression or unaccepted toxicity.
219676926|NCT01608672|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
219676927|NCT05471427|DRUG|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
219676928|NCT04551768|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
219676929|NCT04551768|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
219072825|NCT02278328|DRUG|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
219072826|NCT02278328|DRUG|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
219072827|NCT02278328|DRUG|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
219209402|NCT06754514|DEVICE|liver retraction|A different way to lift the liver during bariatric surgery
219209403|NCT06755242|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
219676930|NCT02897466|OTHER|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
219676931|NCT00543673|OTHER|Milk based formula A|feed as per HCP directions
219676932|NCT00543673|OTHER|#2 Standard formula|Feed as per HCP directions
219676933|NCT00543673|OTHER|#3 Human Milk|Feed as per HCP directions
219676934|NCT00543673|OTHER|Milk based formula C|Feed as per HCP direction
219676935|NCT04233437|DRUG|MLC1501|MLC1501 capsules (4 capcules (2000 mg) twice a day)
219209404|NCT06768255|DRUG|Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT|Abiraterone Acetate（II）
219209405|NCT06768255|DRUG|Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT|Abiraterone acetate 1000 mg
219209406|NCT04478279|DRUG|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
219209407|NCT04478279|DRUG|Temozolomide|Temozolomide
219676936|NCT04233437|DRUG|CYP Cocktail|Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
219676937|NCT04233437|DRUG|Transporter Cocktail|Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
219676938|NCT01590316|DEVICE|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
219676939|NCT00226798|DRUG|Capecitabine (Xeloda)|
219676940|NCT02900664|BIOLOGICAL|PDR001|Powder for solution for infusion
219676941|NCT02900664|BIOLOGICAL|ACZ885|Solution for injection
219676942|NCT02900664|BIOLOGICAL|CJM112|Solution for infusion
219676943|NCT02900664|DRUG|TMT212|Tablets
219676944|NCT02900664|DRUG|EGF816|Tablets
219676945|NCT03326297|OTHER|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
219676946|NCT03326297|BEHAVIORAL|Measures to support and education to the family|Pedagogical intervention in parents and health education
219676947|NCT05212480|DIETARY_SUPPLEMENT|Zinc|For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
219676948|NCT05212480|DIETARY_SUPPLEMENT|Placebo|For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
219676949|NCT01119820|OTHER|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
219676950|NCT00039299|BIOLOGICAL|therapeutic autologous lymphocytes|
219072828|NCT04611503|DRUG|subretinal injection of rAAV.hPDE6A|"The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg)."
219072829|NCT04931927|BEHAVIORAL|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]
219072830|NCT04931927|BEHAVIORAL|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
219072831|NCT04955912|OTHER|music medicine|To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
219072832|NCT00598429|DRUG|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
219072833|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
219072834|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
219072835|NCT03847324|OTHER|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
219072836|NCT03847324|OTHER|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
219072837|NCT03847324|OTHER|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
219072838|NCT01097538|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
219072839|NCT01097538|OTHER|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
219072840|NCT02071173|DEVICE|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
219072841|NCT03834779|BEHAVIORAL|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
219072842|NCT01508468|DRUG|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
219072843|NCT01508468|DRUG|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
219072844|NCT04118348|BEHAVIORAL|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
219676951|NCT01379105|OTHER|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
219676952|NCT01379105|OTHER|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
219676953|NCT02303197|DRUG|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
219209408|NCT04478279|RADIATION|Radiation|Radiation
219676954|NCT05872061|OTHER|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
219676955|NCT03134911|DRUG|DOAC or VKA|6 months - 2 years
219676956|NCT03134911|DRUG|VKA|6 months - 2 years
219676957|NCT03143777|DEVICE|Sara Combilizer|Combined tilt table and stretcher chair
219676958|NCT05103800|BEHAVIORAL|invasive interventions|listening the white noise during the invasive interventions
219676959|NCT05019573|DIETARY_SUPPLEMENT|Black tea|Black tea twice a day for 4 weeks
219676960|NCT05019573|DIETARY_SUPPLEMENT|Placebo|Placebo tea twice a day for 4 weeks
219676961|NCT04646811|PROCEDURE|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
219676962|NCT04646811|OTHER|Best medical treatment|Best medical therapy alone
219676963|NCT04687189|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
219072845|NCT04118348|BEHAVIORAL|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
219072846|NCT01292928|DEVICE|Stent implantation|Stent implantation during the index procedure.
219676964|NCT02335385|PROCEDURE|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
219676965|NCT02335385|PROCEDURE|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
219072847|NCT02833168|OTHER|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
219072848|NCT02833168|DEVICE|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
219072849|NCT01708850|DRUG|Rivaroxaban|All specified in arm description. One arm study.
219072850|NCT03979573|DIAGNOSTIC_TEST|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
219072851|NCT03979573|DIAGNOSTIC_TEST|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
219209409|NCT06886399|DRUG|"AS-Probionorm"|"Phase II of the clinical trial of the medicine included 210 study subjects with identified clinical and/or microbiological signs of dysbiosis. 3 groups of 70 research subjects will be formed.~Group 1 - study subjects with an identified decrease in intestinal microflora activity; Group 2 - study subjects with an identified fungal (candidiasis) infection; Group 3 - study subjects with active pathogenic microflora.~Dosage regimen for first group - 1 sachet (1 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days. Dosage regimen for the second and third groups - 2 sachet (2 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days."
219676966|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.25 milliamps (mA)
219676967|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.5-1.0 mA
219676968|NCT00305565|DEVICE|VNS Therapy|Received output current of 1.0-1.5 mA
219676969|NCT02364076|DRUG|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
219676970|NCT02364076|DRUG|Epacadostat|100mg taken by mouth twice daily
219676971|NCT00420628|DRUG|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
219676972|NCT00420628|DRUG|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
219676973|NCT01830933|OTHER|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
219676974|NCT04786405|BEHAVIORAL|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
219676975|NCT04786405|BEHAVIORAL|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
219676976|NCT04690634|PROCEDURE|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
219676977|NCT03043963|BEHAVIORAL|Sleep Extension|Lengthen the duration of sleep time.
219676978|NCT03043963|BEHAVIORAL|Sleep Timing|Regularize the timing of the sleep period.
219676979|NCT00001338|DRUG|FLAC chemotherapy with GM-CSF|
219676980|NCT03307460|DRUG|68Ga-NOTA-AE105|PET/MRI scan
219676981|NCT02481752|OTHER|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
219676982|NCT02481752|OTHER|SHAM Training|
219676983|NCT00362661|DRUG|Cortisol|Cortisol 10 mg/d for 3 months
219676984|NCT00210886|DRUG|levofloxacin|
219676985|NCT04636411|DIETARY_SUPPLEMENT|Oral Magnesium Supplementation|250 mg of elemental magnesium daily for three months
219676986|NCT04636411|OTHER|Standard Care for diabetic patients|Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
219676987|NCT02009371|DEVICE|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
219676988|NCT02009371|DEVICE|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
219676989|NCT01643278|DRUG|Dasatinib|Given PO
219676990|NCT01643278|BIOLOGICAL|Ipilimumab|Given IV
219676991|NCT01643278|OTHER|Laboratory Biomarker Analysis|Correlative studies
219676992|NCT01643278|OTHER|Pharmacological Study|Correlative studies
219676993|NCT02969083|PROCEDURE|RNU|Radical surgical removal by open or laparoscopic access
219676994|NCT02969083|DRUG|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
219072852|NCT03979573|DIAGNOSTIC_TEST|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
219072853|NCT03979573|DIAGNOSTIC_TEST|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
219072854|NCT02043210|BEHAVIORAL|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
219072855|NCT02043210|BEHAVIORAL|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
219072856|NCT05845138|DRUG|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
219072857|NCT03691467|DEVICE|immediate dental implant|immediate dental implant placement in freshly extracted socket.
219072858|NCT03691467|DRUG|Hyaluronic Acid|topical application of hyaluronic acid
219072859|NCT00289354|DRUG|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
219072860|NCT00408473|DRUG|Flecainide|
219072861|NCT00944138|BEHAVIORAL|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
219072862|NCT03958370|OTHER|Fitbit|Fitbit use during physical therapy session
219072863|NCT01602887|DRUG|PD-0332991|isethionate hard capsule, 125 mg, single dose
219072864|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
219072865|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
219072866|NCT01602887|DRUG|PD-0332991|oral solution, 50 mg, single dose
219209410|NCT06769672|OTHER|active tDCS with dual-task training|participants receive three 20-minute active tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
219209411|NCT06769672|OTHER|sham tDCS with dual-task training|participants receive three 20-minute sham tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
219676995|NCT02969083|DRUG|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
219676996|NCT03472612|OTHER|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
219676997|NCT04966078|PROCEDURE|liposuction|suction-assisted liposuction
219072867|NCT02040116|DRUG|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
219072868|NCT00403832|DEVICE|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
219676998|NCT04966078|PROCEDURE|surgical excision|periareolar surgical excision
219676999|NCT01184170|BEHAVIORAL|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
219677000|NCT03523858|DRUG|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
219677001|NCT02860390|OTHER|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
219677002|NCT02860390|OTHER|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
219677003|NCT02867800|DRUG|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
219677004|NCT02867800|DRUG|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
219677005|NCT02867800|DRUG|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
219677006|NCT02867800|DRUG|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
219677007|NCT02867800|DRUG|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
219677008|NCT02867800|DRUG|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
219677009|NCT02867800|DRUG|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
219677010|NCT02867800|DRUG|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
219677011|NCT02867800|DRUG|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
219677012|NCT02867800|DRUG|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
219677013|NCT02867800|DRUG|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
219677014|NCT02867800|DRUG|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
219677015|NCT02867800|DRUG|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
219677016|NCT02867800|PROCEDURE|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
219677017|NCT02867800|DRUG|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
219677018|NCT02867800|DRUG|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
219677019|NCT03932916|DRUG|Donepezil Pamoate for Injection 17mg|A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
219677020|NCT03932916|DRUG|Donepezil Pamoate for Injection 34mg|A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
219677021|NCT03932916|DRUG|Donepezil Hydrochloride 5mg|A tablet of 5mg Donepezil Hydrochloride will be administered once.
219677022|NCT00463125|DRUG|Platelet Gel|
219677023|NCT00758134|DRUG|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
218983089|NCT05303181|DEVICE|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
219072869|NCT00568529|DRUG|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
219072870|NCT06061510|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
219072871|NCT06061510|DIETARY_SUPPLEMENT|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
219072872|NCT00127374|BEHAVIORAL|Dietary and physical activity modifications|
219072873|NCT00001048|DRUG|Filgrastim|
219072874|NCT00001048|DRUG|Cytarabine|
219677024|NCT00553527|PROCEDURE|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
219677025|NCT00429650|BEHAVIORAL|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
219677026|NCT00429650|BEHAVIORAL|diet|Use a prescribed diet to maintain weight loss
219677027|NCT00429650|BEHAVIORAL|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
219072875|NCT00001048|DRUG|Zidovudine|
219072876|NCT00001048|DRUG|Zalcitabine|
219072877|NCT00001048|DRUG|Didanosine|
219072878|NCT01738048|PROCEDURE|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
219677028|NCT05558800|PROCEDURE|Implant placement|Implant placement with different surface types
219677029|NCT02308371|DEVICE|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
219677030|NCT02420483|OTHER|Cardiopulmonary resuscitation chest compressions|
219677031|NCT00396383|DRUG|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
219677032|NCT00029861|DRUG|Rimonabant (SR141716)|
219677033|NCT03214549|PROCEDURE|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
219677034|NCT03214549|PROCEDURE|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
219677035|NCT03433859|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
219677036|NCT03433859|OTHER|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
219677037|NCT03075189|DIETARY_SUPPLEMENT|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
219677038|NCT02703376|DRUG|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
219677039|NCT00143468|BEHAVIORAL|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
219677040|NCT03927586|OTHER|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
219677041|NCT03927586|OTHER|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
218983090|NCT02429843|DRUG|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
218983091|NCT02028819|DRUG|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
218983092|NCT02028819|DRUG|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
218983093|NCT05705648|DIETARY_SUPPLEMENT|medium chain triglyceride oil|Medium chain triglyceride oil
218983094|NCT05705648|DIETARY_SUPPLEMENT|Safflower oil|Safflower oil
218983095|NCT06826924|BEHAVIORAL|Fasting|7 days of water-only fasting
218983096|NCT01757535|DRUG|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
218983097|NCT01757535|DRUG|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
218983098|NCT03439787|DRUG|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
218983099|NCT03439787|OTHER|Sodium Chloride 0.9 %|10 ml
218983100|NCT06668194|DEVICE|Light Force (150g Niti Coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (150g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
218983101|NCT06668194|DEVICE|Heavy Force (400 g Niti coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (400g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
218983102|NCT06668649|DIAGNOSTIC_TEST|Testing with Questionnaires|Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
219209412|NCT06746974|DEVICE|Shockwave|In the Shockwave group, will be applied focused shockwaves therapy of 1500 impulses at 0.01 mJ/mm2 over the painful area or the pathologic flexor tendon to each participant under the supervision of a physiatrist. The ESWT will be conducted once weekly for 4 weeks with a sham splint (DIP joint blocking splints) for at least 8 hours per day for 6 weeks.
218983103|NCT05764408|DEVICE|traxi® Panniculus Retractor|traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
218983104|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the SARS-pro navigation system|The SARS-pro navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the new navigation system group (patients with suspected lung cancer).
218983105|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the VBN navigation system|The VBN navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the old navigation system group (patients with suspected lung cancer).
218983106|NCT03919162|DRUG|PQ912|PQ912 150 mg tablets
218983107|NCT03919162|OTHER|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
218983108|NCT05730699|BIOLOGICAL|divozilimab|anti-CD20 monoclonal antibody
218983109|NCT02585622|BIOLOGICAL|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10\^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
218983110|NCT02585622|OTHER|Placebo|Volume total of fluid infused: 40 ml
218983111|NCT07011511|DRUG|MMV055 Dose 1|40mg
218983112|NCT07011511|DRUG|MMV055 Dose 2|100mg
218983113|NCT07011511|DRUG|MMV055 Dose 3|200mg
218983114|NCT07011511|DRUG|MMV055 Dose 4|400mg
218983115|NCT07011511|DRUG|MMV055 Dose 5|800mg
218983116|NCT07011511|DRUG|MMV055 Dose 6|TBCmg
218983117|NCT07011511|DRUG|Matching placebo Part A|Part A
218983118|NCT07011511|DRUG|Matching placebo Part B|Part B
218983119|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 1|Combination 1
218983120|NCT07011511|COMBINATION_PRODUCT|MMV055/MM371 Combo 2|Combination 2
218983121|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 3|Combination 3
218983122|NCT06680531|DRUG|YZJ-1139 tablets|YZJ-1139 tablets are administered orally single dose
218983123|NCT06680531|DRUG|Escitalopram oxalate tablets|•oral tablet, QD
218983124|NCT06680531|DRUG|YZJ-1139 simulated tablets|oral tablet, QD
218983125|NCT06680570|DIAGNOSTIC_TEST|Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing|"Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life."
218983126|NCT06681285|DRUG|Cadonilimab ;Anlotinib|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
218983127|NCT06190977|OTHER|Otago Exercise Program|Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes
218983128|NCT06190977|OTHER|General TKR pprotocol|Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
218983129|NCT05351905|DRUG|CBD oil ( MPL-001)|MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
218983130|NCT05351905|DRUG|CDB+THC oil (MPL-005)|MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
218983131|NCT05351905|DRUG|Placebo oil|The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
218983132|NCT06680739|DRUG|Durvalumab|Durvalumab 1500 mg IV every 4 weeks
218983133|NCT06680739|DRUG|Tremelimumab|Tremelimumab 300 mg IV as a single dose
218983134|NCT05041426|DRUG|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
218983135|NCT05041426|DRUG|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
218983136|NCT00391820|DRUG|TD-5108|
218983137|NCT06708780|BIOLOGICAL|Ex vivo Expanded Human Autologous Regulatory T Cells|Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
218983138|NCT06708780|OTHER|Routine Care|Routine care is provided to all participants according to clinical guidelines for T1DM.
218983139|NCT07054372|DIAGNOSTIC_TEST|Titres on conventional test tube method with different diluent|Titres on conventional test tube method with different diluent
218983140|NCT04639700|BEHAVIORAL|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
218983141|NCT06227546|DRUG|MGC018|Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle
218983142|NCT06934772|OTHER|M-TAPA|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
218983143|NCT06934772|OTHER|Subcostal TAP|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
218983144|NCT06169852|DEVICE|Unilateral dual-target (STN/GPi) DBS|Participants will be randomly assigned either DBS stimulation in the STN alone, GPi alone, or a combination of stimulation in the STN and GPi.
218983145|NCT06933251|DRUG|Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy|"1. Neoadjuvant Treatment 1.1 Short-Course Radiotherapy (SCRT) Total Dose: 25 Gy in 5 fractions over 5 days. Interval: 1-week rest before the next stage. 1.2 Chemotherapy and Immunotherapy Regimen: Start 1 week after SCRT with 6 cycles of CAPOX chemotherapy combined with PD-1 inhibitor immunotherapy (3 weeks per cycle).~   1.3 PCSK9 Inhibitor Administration: Subcutaneous injection every 4 weeks during neoadjuvant therapy (6 cycles total).~2. Multidisciplinary Team (MDT) Discussion Timing: 2 weeks after completing neoadjuvant therapy.~Approach:~Patients achieving clinical complete response (cCR): Watch-and-wait strategy. Others: Surgery based on MDT evaluation."
218983146|NCT03969511|PROCEDURE|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
218983147|NCT03969511|PROCEDURE|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
218983148|NCT05147428|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
218983149|NCT06067204|DEVICE|Automatic ventilation|"The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 500-600 ml."
218983150|NCT06067204|DEVICE|Manual ventilation|The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
218983151|NCT00060515|DRUG|RG2133 (2',3',5'-tri-O-acetyluridine)|
218983152|NCT06218563|OTHER|vibration-induced illusion of movement|Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
218983153|NCT02780375|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
218983154|NCT00239538|DRUG|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
218983155|NCT00239538|DRUG|valsartan combined with hydrochlorothiazide (160/12.5mg)|
218983156|NCT03971097|BEHAVIORAL|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
218983157|NCT03971097|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
218983158|NCT00106197|DRUG|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
218983159|NCT00804674|DRUG|bupivacain|
218983160|NCT00804674|DRUG|placebo|
218983161|NCT01998529|DRUG|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
218983162|NCT01998529|DRUG|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
218983163|NCT00527501|DRUG|Travoprost/brinzolamide|
218983164|NCT02704715|PROCEDURE|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
219209413|NCT06746974|DEVICE|Splint|In the splinting group, will be provided a PIP blocking splint at least 8 hours per day for 6 weeks with the sham shockwave (the patients close their eyes, extend their hand through a partition, apply shockwave device head with gel on the patient's finger, and play a mobile phone sound that mimics the sound of a real shockwave machine) once a week for 4 weeks.
218983165|NCT00217620|DRUG|sorafenib|800 mg per day, daily until progression
218983166|NCT05113420|DRUG|Detralex|Diosmin+ Hesperidin
218983167|NCT05113420|DRUG|Troxevasin|Troxerutin
218983168|NCT00784498|DRUG|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
218983169|NCT00784498|DRUG|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
218983170|NCT02077244|BEHAVIORAL|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
218983171|NCT00418015|PROCEDURE|Blood Draw|Blood for OPRM1 analysis
218983172|NCT03948698|OTHER|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
218983173|NCT00160485|DRUG|Glyburide|dosage required to obtain adequate glucose control
218983174|NCT00160485|DRUG|Insulin|variable dosage to obtain glucose control
218983175|NCT06007885|OTHER|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
218983176|NCT04307784|DIETARY_SUPPLEMENT|VD3|VD3 (50.000 IU/week) for 8 weeks
218983177|NCT04307784|DIETARY_SUPPLEMENT|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
218983178|NCT04307784|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
218983179|NCT04307784|OTHER|Control|No intervention is given
218983180|NCT05747820|OTHER|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
218983181|NCT03868020|PROCEDURE|Computed Tomography|Undergo PET/CT
218983182|NCT03868020|RADIATION|Fluciclovine F18|Given IV
218983183|NCT03868020|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
218983184|NCT04961307|DRUG|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
218983185|NCT00825682|OTHER|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
218983186|NCT00079248|BIOLOGICAL|therapeutic progesterone|
218983187|NCT00079248|DRUG|conjugated estrogens|
218983188|NCT06000332|DEVICE|InogenOne Rove 6 Portable Oxygen Concentrator|overnight use of Portable Oxygen Concentrator, 6 hours minimum
219072879|NCT03286374|BEHAVIORAL|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~1. Four weeks with an institutional stay at Muritunet (BL)~2. Follow-up;~   1. Eight weeks, telephone contact between therapist at Muritunet and the participant.~  2. 16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~  3. 28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~  4. 40 weeks, telephone contact between therapist at Muritunet and the participant.~  5. 52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
219072880|NCT04868266|OTHER|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
219072881|NCT02234531|DEVICE|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
219072882|NCT02234531|DEVICE|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
219072883|NCT03721991|DIETARY_SUPPLEMENT|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
219072884|NCT03721991|DIETARY_SUPPLEMENT|placebo|matching placebo
219072885|NCT02071004|DRUG|DS-1040b|IV of 6 mg given once over 30 minutes
219209414|NCT06829758|BEHAVIORAL|Compartiendo Salud|The intervention proposed (Compartiendo Salud) is a multicomponent intervention based on prevention and on promoting the health of older adults that live alone. The community-based intervention consists in five workshops that are carried out during a week (one day for each workshop). The sessions (which last 2.5 hours each) are designed in an expository and participatory way, using gaming dynamics that foster learning and social interaction. The content of the workshops is the same for all BHDs. Each workshop addresses risk factors that predispose the population to experiencing more unwanted loneliness and social isolation. The concepts corresponding to each of the five sessions that comprise the intervention are: Sleep hygiene, Healthy and sustainable eating habits, Physical activity and exercise, Memory and music therapy, Digital literacy
219209415|NCT06386692|BEHAVIORAL|FCHVs-led community based educational physical activity intervention|This intervention will be designed to promote physical activity among adults
219072886|NCT02071004|DRUG|Aspirin|Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
219072887|NCT02943148|OTHER|Davey score for striae gravidarum|
219209416|NCT06892782|OTHER|Hot Water Pack Application|A hot water pack heated to 40-42°C will be applied to the lumbar region of the patient for 20 minutes at three intervals per day during the first 48 hours post-surgery.
219209417|NCT06845098|PROCEDURE|Total thyroidectomy|Total thyroidectomy
219677042|NCT03116724|PROCEDURE|central venous catheterization through Rt. IJV|"* insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point"
219677043|NCT04086381|DIETARY_SUPPLEMENT|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
219677044|NCT04086381|DIETARY_SUPPLEMENT|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
219677045|NCT00453830|PROCEDURE|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
219072888|NCT03812796|DRUG|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
219209418|NCT06845098|PROCEDURE|Total thyroidectomy + RAIT|Total thyroidectomy + RAIT
219209419|NCT06845098|PROCEDURE|Thyroid one-sided lobe + isthmus resection|Thyroid one-sided lobe + isthmus resection
219677046|NCT01171469|BIOLOGICAL|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
219677047|NCT01171469|DRUG|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
219677048|NCT03182491|DIAGNOSTIC_TEST|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
219677049|NCT05111938|BEHAVIORAL|Friends, Family, and Food App (F3A-App)|
219677050|NCT01603199|DIETARY_SUPPLEMENT|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
219072889|NCT03812796|DRUG|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
219072890|NCT01210391|OTHER|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
219072891|NCT01210391|OTHER|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
219072892|NCT04760093|DIETARY_SUPPLEMENT|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
219209420|NCT06844097|BEHAVIORAL|Cervical Cancer Trans Inclusive Education (CC-TRAINED) Module|An online course designed to increase cervical cancer prevention clinical skills among medical students when working with Latinx transmasculine populations.
219209421|NCT06844097|BEHAVIORAL|Disaster Preparedness Course|An online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
219209422|NCT00650078|DRUG|MR prednisone|1 x 5 mg daily
219209423|NCT00650078|DRUG|Placebo|1x daily
219209424|NCT06796751|GENETIC|DNA/RNA sequencing and bioinformatic data analysis|"DNA will be extracted from peripheral blood or from somatic tissues. In some cases a skin biopsy will be performed to obtain fibroblasts for further analysis (DNA/RNA extraction and preparation of cell culture for high-throughput genomic and epigenomic technique (Hi-C).~LRS will be performed on extracted DNA using Oxford Nanopore Technology by two different approaches:~* Target, in samples with monoallelic alterations in genes related to autosomal recessive disease;~* Genomic in other cases.~Sequencing data will be analyzed through a dedicated bioinformatics pipeline, to reconstruct the tridimensional structure of chromatin and the regions"
219209425|NCT05672017|BEHAVIORAL|Dietary Instructions|Dietary Instructions
219072893|NCT04760093|DIETARY_SUPPLEMENT|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
219072894|NCT04694274|DEVICE|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
219072895|NCT04694274|PROCEDURE|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
219072896|NCT04694274|DEVICE|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
219072897|NCT00303966|DRUG|sorafenib tosylate|Given orally
219072898|NCT03280121|DEVICE|EsophyX ZR transoral device|TIF
219072899|NCT03806270|DRUG|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
219072900|NCT03806270|DRUG|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
219072901|NCT03552874|OTHER|The Performance of Upper Limb Questionnaire (PUL)|
219072902|NCT06579742|DIETARY_SUPPLEMENT|Live Conscious Beyond Collagen|Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
219209426|NCT05362474|DRUG|Montelukast|10mg orally once a day
219209427|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
219209428|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
219072903|NCT06579742|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
219072904|NCT01310387|BEHAVIORAL|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
219072905|NCT06634485|DEVICE|ultrasound, spirometry|"Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible."
219072906|NCT05913856|OTHER|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
219072907|NCT05913856|OTHER|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
219072908|NCT04321408|DRUG|Ziconotide Injection|Intrathecal analgesia with Ziconotide
219072909|NCT06434597|DRUG|SPH5030|SPH5030：Oral, QD, 600mg
219072910|NCT06290180|BEHAVIORAL|First Face for Mental Heatlh|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
219677051|NCT04910737|PROCEDURE|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
219677052|NCT04542811|OTHER|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
219677053|NCT05735405|BEHAVIORAL|Neuropsychological evaluation|Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.
219677054|NCT05735405|BIOLOGICAL|BDNF evaluation|During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).
219677055|NCT05735405|BEHAVIORAL|Pedaling as a moderate intensity aerobic exercise|During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.
219072911|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
219072912|NCT05267041|BIOLOGICAL|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
219072913|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
219072914|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire before second line treatment
219677056|NCT05735405|OTHER|Cognitive Training|During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.
219072915|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
219072916|NCT03435133|DRUG|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
219072917|NCT03435133|DRUG|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
219072918|NCT05909332|DRUG|Antivascular therapy|BP102 (anti VEGFR)
219072919|NCT05909332|DRUG|Chemotherapy|ddEC-P
219677057|NCT05735405|DIAGNOSTIC_TEST|VO2 assessment|"To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF."
219677058|NCT04618809|BEHAVIORAL|Didactic Session|This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
219072920|NCT05725005|DRUG|ASN51|Oral capsule
219072921|NCT05978843|BEHAVIORAL|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
219072922|NCT02945085|OTHER|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
219072923|NCT02945085|OTHER|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
219072924|NCT05875623|OTHER|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
219072925|NCT04029974|DEVICE|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
219072926|NCT06962137|DRUG|zolbetuximab|The investigational product, Zolbetuximab, is a sterile lyophilized powder preparation with the chimeric monoclonal antibody Zolbetuximab as the active pharmaceutical ingredient.
219072927|NCT06962137|OTHER|Retrospective cohort, no intervention|No intervention
219072928|NCT06962605|BEHAVIORAL|Moderate-intensity continuous running (MICE: 60% V̇O2max)|Participants run continuously for 40 minutes at moderate intensity (60-65% V̇O2max)
219072929|NCT06962605|BEHAVIORAL|5-minute interval running (5MIN)|Participants run for 40 minutes at average moderate intensity with 5-minutes slow and fast cycles where speed is increased and decreased by 20%.
219677059|NCT04618809|BEHAVIORAL|Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.|"* The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded."
219677060|NCT01330199|OTHER|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
219677061|NCT06443047|DEVICE|TTS suturing system|The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
219677062|NCT02008006|DRUG|BeEAM|"High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
219677063|NCT01270360|DEVICE|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
219677064|NCT03052348|OTHER|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
219677065|NCT03052348|OTHER|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
219677066|NCT05420831|PROCEDURE|Vaginal|Sacrospinous hysteropexy using the synthetic mesh
219677067|NCT05420831|PROCEDURE|Laparoscopic|Laparoscopic Sacrohysteropexy
219677068|NCT02461056|DRUG|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
219677069|NCT02461056|DRUG|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
219677070|NCT02614508|DRUG|Buparlisib|Given PO
219677071|NCT02614508|DRUG|Ibrutinib|Given PO
219677072|NCT02614508|BIOLOGICAL|Ofatumumab|Given IV
219677073|NCT06467539|DRUG|DAOIB plus AO|oral, for 24 weeks
219677074|NCT06467539|DRUG|DAOIB plus placebo|oral, for 24 weeks
219677075|NCT02698709|OTHER|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
218983189|NCT05032664|OTHER|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
218983190|NCT05032664|OTHER|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
218983191|NCT03680560|BIOLOGICAL|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
218983192|NCT03680560|DRUG|Trastuzumab|monoclonal antibody targeting HER2
218983193|NCT02557711|DEVICE|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
218983194|NCT05190588|OTHER|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
218983195|NCT01509365|DRUG|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
218983196|NCT01509365|DRUG|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
218983197|NCT01628978|OTHER|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
218983198|NCT01628978|OTHER|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
218983199|NCT04053439|OTHER|Blood test for determination of CHIP|Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
218983200|NCT01952925|PROCEDURE|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
218983201|NCT06057844|OTHER|Additional blood sampling|Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
218983202|NCT06202430|PROCEDURE|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
219209429|NCT06742450|OTHER|Constant current (CC) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.
219209430|NCT06742450|OTHER|Constant voltage (CV) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.
219072930|NCT06962605|BEHAVIORAL|2-minute interval running (2MIN)|Participants run for 40 minutes at average moderate intensity with 2-minutes slow and fast cycles where speed is increased and decreased by 20%.
219072931|NCT06962605|BEHAVIORAL|Resting control|Participants sit for 40 minutes in a comfortable position
219072932|NCT06961461|OTHER|AI-assisted quality control tool|"In this study, quality control personnel will be randomly divided into an experimental group and a control group, and will use artificial intelligence-assisted quality control and manual quality control to conduct quality control on the data collected from the epidemiological survey.~Experimental group: Quality control personnel will use the AI system to perform quality control on the questionnaire recordings.~Control group: The questionnaire content was checked by manually listening back to the recordings and errors were recorded manually."
219072933|NCT06961604|DRUG|NaF PET-CT|Following a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture
219072934|NCT06961721|BIOLOGICAL|Herpes Zoster Vaccine, Live|assigned to the vaccine group and placebo group in a 2:1 ratio.
219072935|NCT06961721|BIOLOGICAL|Placebo|assigned to the vaccine group and placebo group in a 2:1 ratio.
219072936|NCT06961942|OTHER|Training|A structured teaching module for fellows in training will be prepared and conducted at three university centres, namely University Hospitals Leuven, Ljubljana University Medical Centre, and CHU de Bordeaux. The training module will include short endoscopic videos (different from the pre- and post-training set), which participants will score in real-time using a polling application. This will be followed by a step-by-step demonstration of each scoring principle with explanations of the reasoning behind specific scores. Each scoring system will be reviewed in a short training video that provides a structured demonstration, highlights common pitfalls, and showcases typical IBD-associated endoscopic features. After the video training, participants will have the opportunity to ask questions to the experts.
219072937|NCT06961578|PROCEDURE|C1-2 instrumentation|"Surgical fracture stabilization with a posterior screw-rod system from C1-2 from a posterior approach.~The routine surgery commonly lasts approximately 100 minutes and requires a hospital stay of about 6 days. An additional external bracing in the postoperative setting is not required."
219072938|NCT06961578|OTHER|External immobilization with rigid cervical collar|External immobilization with a rigid cervical collar for 12 weeks. Compliance is monitored through patient diaries, recognizing the real-world challenges of consistent brace use. Lack of adherence is considered to reflect routine clinical practice. A typical drawback of the conservative intervention in daily practice is the absolute reliance on patient compliance to wear the collar continuously for at least 12 weeks, which poses a significant challenge to this treatment strategy.
219072939|NCT06288438|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
219072940|NCT06288438|OTHER|Physical Therapy Interventions|Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
219209431|NCT06741423|OTHER|Radiomics Algortihm|A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.
219209432|NCT04678427|OTHER|6 Minute Walk Functional Test|Complete 6-minute walk test
219209433|NCT04678427|BEHAVIORAL|Behavioral Intervention|Participate in walking and other activities
219072941|NCT06288438|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
219209434|NCT04678427|OTHER|Survey Administration|Complete survey
219209435|NCT04678427|BEHAVIORAL|Timed Get Up and Go Test|Complete timed get up and go test
219209436|NCT06627855|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
219209437|NCT06627855|PROCEDURE|Sham treatment|The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
219209438|NCT06837051|DEVICE|Conventional olfactory training device|"Four odorants are used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. Training patients will receive four glass vials. Each contains one odorant (5 mL, soaked in cotton pads to prevent spilling) and is labeled with the name of the odorant.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
219209439|NCT06837051|DEVICE|Modified olfactory training device|"The modified olfactory training device is based on the nasal bidirectional drug delivery system. The device uses breathing pressure to create positive pressure, significantly increasing the deposition rate of odors in the olfactory cleft area.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
219677076|NCT04129294|DRUG|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
219209440|NCT06837051|DRUG|Budesonide irrigation|Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects.
219677077|NCT03448172|DRUG|[14C]PF-05221304|a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
219677078|NCT03387657|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
219072942|NCT06288438|OTHER|Health Status Updates|Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
219072943|NCT06288438|OTHER|Physical Therapy Consult|Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
219072944|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
219072945|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
219072946|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
219072947|NCT04420221|BIOLOGICAL|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
219072948|NCT04420221|BIOLOGICAL|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
219072949|NCT04420221|BIOLOGICAL|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
219072950|NCT04420221|BIOLOGICAL|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
219072951|NCT04420221|BIOLOGICAL|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo Groups 1 to 3 (Dose-escalation epoch) and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo Group 4 (Dose-escalation epoch) and Group PoP: Placebo, administered intramuscularly.
219072952|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
219072953|NCT00511004|DRUG|Albendazole|Comparing 400 mg to 800 mg dose
219072954|NCT00511004|DRUG|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
219072955|NCT00990652|DRUG|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
219072956|NCT00990652|DRUG|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
219072957|NCT05795595|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
219072958|NCT02284438|DEVICE|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
219209441|NCT06795802|BEHAVIORAL|Evaluative conditioning|The evaluative conditioning procedure is a learning technique performed on a monitor. It consists of being exposed to the repeated association of an object (conditioned stimulus, in our case, Physical Activity or fruit and vegetables) to stimuli with a positive or negative valence (unconditioned stimulus, US). The total duration of the CE is approximately 15 minutes.
219209442|NCT02542683|OTHER|structured physical activity program|a structured modest physical activity program
219209443|NCT06418633|OTHER|60-minute walking test|Treadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up.
219677079|NCT03387657|DRUG|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
219677080|NCT04453410|OTHER|Questionnaire Quality-of-recovery 15 (QoR-15)|Children will use the questionnaire Quality-of-recovery 15 (QoR-15)
219677081|NCT04229771|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
219677082|NCT04229771|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
219677083|NCT02736708|DEVICE|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
219072959|NCT00517738|OTHER|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
219072960|NCT00517738|OTHER|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
219677084|NCT03070756|DEVICE|Minimal-Intervention - Specification of device settings|\- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
219677085|NCT06351085|BEHAVIORAL|Pre-Visit Planner|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process.
219677086|NCT06351085|BEHAVIORAL|Pre-Visit Planner + MyChart|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process as well as testing if watching educational videos about the Lung Cancer Screening (LCS) process prior to talking to an LVN will help with LCS uptake.
219677087|NCT00250809|PROCEDURE|Placement of a central venous catheter|Placement of a central venous catheter
219677088|NCT02787083|DRUG|Mirabegron|
219677089|NCT02787083|DRUG|Placebo|
219677090|NCT03812445|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8\*10\^9 Colony-Forming Units(CFU) \*2/d for 3 months.
219677091|NCT01454011|DRUG|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
219677092|NCT01454011|DRUG|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
219677093|NCT05123352|OTHER|collection of biological samples and clinical data|blood and feces samples
219072961|NCT04913753|PROCEDURE|CBEU|Patients in the control group will have bacterial culture and double J removal will be performed as usual. .
219072962|NCT04913753|PROCEDURE|No CBEU|Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
219072963|NCT04347681|OTHER|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
219072964|NCT03074630|DRUG|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
219072965|NCT03074630|DRUG|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
219072966|NCT01196338|BEHAVIORAL|Early weight-bearing and range of motion exercises|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
219072967|NCT01196338|BEHAVIORAL|non-weight bearing, no range of motion|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
219072968|NCT05040009|BEHAVIORAL|integrated foot care program|"1. Regular foot care and examination by an adequately trained professional: -~2. Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~1. Foot ulcers and their consequences~2. Preventative foot self-care behaviors~3. Wearing adequately protective footwear~4. Undergoing regular foot checks~5. Practicing proper foot hygiene~6. Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
219209444|NCT06418633|DIAGNOSTIC_TEST|Static blood test|33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test
219677094|NCT02710084|DRUG|Oxytocin|Intranasal oxytocin
219677095|NCT02710084|DRUG|Saline|Placebo
219677096|NCT03210051|DEVICE|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
219677097|NCT03210051|PROCEDURE|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
219677098|NCT05305989|DRUG|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
219677099|NCT05305989|DRUG|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
219677100|NCT05305989|DRUG|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
219677101|NCT00275665|DRUG|Valganciclovir|
219677102|NCT02305524|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
219677103|NCT02305524|DEVICE|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
219677104|NCT00182533|DRUG|Sertraline|25 - 200 mg/day x 16 weeks
219072969|NCT05932745|OTHER|E-liquid coolant (No WS-3) for non-menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
219072970|NCT05932745|OTHER|E-liquid coolant (No WS-3) for low menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
219072971|NCT05932745|OTHER|E-liquid coolant (No WS-3) for high menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
219072972|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for non-menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
219072973|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for low menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
219677105|NCT00182533|DRUG|Placebo|25 - 200 mg/day x 16 weeks
219677106|NCT00844662|DRUG|Fermagate|Film coated tablet 500mg
219677107|NCT00844662|DRUG|Sevelamer hydrochloride|Tablet 800mg
219677108|NCT03162328|DEVICE|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
219677109|NCT03162328|DEVICE|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
219677110|NCT03438864|DEVICE|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
219677111|NCT03438864|OTHER|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
219677112|NCT05132790|DRUG|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
219677113|NCT05132790|DRUG|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
219677114|NCT05132790|RADIATION|SBRT|radiation therapy for breast cance before surgery.
219677115|NCT00078910|DRUG|exisulind|
219072974|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for high menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
219072975|NCT05932745|OTHER|E-liquid coolant (High WS-3) for non-menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
219072976|NCT05932745|OTHER|E-liquid coolant (High WS-3) for low menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
219072977|NCT05932745|OTHER|E-liquid coolant (High WS-3) for high menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
219072978|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for non-menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
219072979|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for low menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
219072980|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for high menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
219072981|NCT05932745|OTHER|E-liquid coolant (High WS-23) for non-menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
219072982|NCT05932745|OTHER|E-liquid coolant (High WS-23) for low menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
219209445|NCT06418633|DIAGNOSTIC_TEST|Post-effort blood test|33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test.
219677116|NCT00078910|PROCEDURE|conventional surgery|
219677117|NCT00078910|PROCEDURE|neoadjuvant therapy|
219677118|NCT05916365|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
219677119|NCT06011824|OTHER|Blood draw|10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
219072983|NCT05932745|OTHER|E-liquid coolant (High WS-23) for high menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
219072984|NCT02085408|DRUG|Daunorubicin|Given IV
219072985|NCT02085408|DRUG|Cytarabine|Given IV
219072986|NCT02085408|DRUG|Clofarabine|Given IV
219072987|NCT02085408|DRUG|Decitabine|Given IV
219072988|NCT02085408|OTHER|Observation|Undergo clinical observation
219209446|NCT06418633|OTHER|Electrocardiogram|An electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery.
219209447|NCT06418633|OTHER|Blood pressure monitoring|Blood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery.
219677120|NCT06810167|DRUG|Tenapanor|CF patients with CFrC will ingest one 50 mg tablet of tenapanor twice daily for 4 weeks.
219677121|NCT06650566|DRUG|LM-299|Q2W/Q3W,Intravenous Drip
219677122|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
219677123|NCT05000866|BEHAVIORAL|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
219072989|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
219072990|NCT06125392|DIAGNOSTIC_TEST|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
219072991|NCT04578262|PROCEDURE|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
219072992|NCT04578262|PROCEDURE|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
219072993|NCT06189417|BEHAVIORAL|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
219072994|NCT06237972|PROCEDURE|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
219072995|NCT06237972|DEVICE|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
219072996|NCT01518868|DEVICE|Investigational contact lens|Worn on a daily wear basis for one week.
219072997|NCT01518868|DEVICE|PureVision contact lens|Worn on a daily wear basis for one week
219072998|NCT02774057|DRUG|Captafer®|"2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
219072999|NCT02774057|DRUG|Iron Sulfate|195 mg Iron supplement
219073000|NCT00373594|DRUG|Rituximab|
219073001|NCT00373594|DRUG|Fludarabine|
219073002|NCT02086357|PROCEDURE|SWUE|
219073003|NCT00934466|DRUG|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
219073004|NCT00934466|DRUG|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
219073005|NCT00934466|DRUG|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
219073006|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
219073007|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
219073008|NCT01556438|BIOLOGICAL|Tabalumab|Administered IV
219073009|NCT01556438|DRUG|Bortezomib IV|Administered IV
219073010|NCT01556438|DRUG|Bortezomib SC|Administered SC
219073011|NCT01556438|DRUG|Dexamethasone|Administered orally
219073012|NCT04622696|DIAGNOSTIC_TEST|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
219073013|NCT05428735|PROCEDURE|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
219073014|NCT02497573|OTHER|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
219677124|NCT05000866|BEHAVIORAL|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
219677125|NCT05849792|BEHAVIORAL|Exercise and psychological intervention|"Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive."
219677126|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
219677127|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
219677128|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
219209448|NCT06909279|BEHAVIORAL|The Hanen Centre's More Than Words® program|The Hanen Centre's More Than Words® program is a globally used, parent coaching intervention delivered by speech-language pathologists (SLPs) to parents of children who have social communication challenges, which includes children with a confirmed or suspected diagnosis of autism. The training program is designed to provide parents with the tools, strategies, and support they need to help their children reach their full communication and social interaction potential.
219209449|NCT06901635|OTHER|Dual Task|In our study, manual dexterity and cognitive task performance during a dual task will be evaluated. Box and Block Test was used to assess dexterity and 4 different cognitive functions were used as cognitive tasks. Previous studies used one or two cognitive tasks when examining the relationship between cognitive task and dexterity performance during a dual task. This study will examine the effect of different cognitive tasks such as attention, memory, executive functions and working memory on the motor task requiring dexterity during a dual task.
219677129|NCT00000841|DRUG|Indinavir sulfate|
219073015|NCT03695172|DRUG|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
219073016|NCT03695172|PROCEDURE|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
219073017|NCT03695172|BIOLOGICAL|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
219677130|NCT00000841|DRUG|Lamivudine|
219677131|NCT00000841|DRUG|Stavudine|
219073018|NCT03695172|PROCEDURE|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
219073019|NCT01494402|DRUG|D961S|Oral gelatine capsule
219073020|NCT01494402|DRUG|Esomeprazole|Oral HPMC capsule
219073021|NCT01494402|DRUG|Buffered acetylsalicylic acid|Tablet
219073022|NCT03778229|DRUG|osimertinib|osimertinib (80 mg oral OD).
219073023|NCT03778229|DRUG|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
219073024|NCT03778229|DRUG|placebo|placebo to osimertinib (oral OD)
219073025|NCT03726346|DEVICE|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
219209450|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
219209451|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
219209452|NCT02107573|PROCEDURE|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
219209453|NCT02107573|PROCEDURE|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
219073026|NCT02734212|BEHAVIORAL|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
219073027|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
219073028|NCT02319499|DIETARY_SUPPLEMENT|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
219073029|NCT02319499|DIETARY_SUPPLEMENT|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
219209454|NCT06905405|DIAGNOSTIC_TEST|Advanced imaging|Cardiac MRI scan Transthoracic ECHO
219073030|NCT02319499|DIETARY_SUPPLEMENT|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
219209455|NCT06905405|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor
219073031|NCT02319499|OTHER|Placebo|Placebo group received no minerals/vitamin
219073032|NCT00736372|DRUG|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
219073033|NCT03370653|DRUG|Odiparcil|Investigational product: odiparcil 250 mg tablets
219073034|NCT03370653|OTHER|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
219073035|NCT00021762|BIOLOGICAL|HIV-1 Immunogen|
219073036|NCT00021762|PROCEDURE|Structured Treatment Interruption|
219073037|NCT00177554|DRUG|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
219073038|NCT04006327|OTHER|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
219073039|NCT03664076|DIAGNOSTIC_TEST|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
219073040|NCT00421499|DRUG|dark chocolate|
219073041|NCT00909012|DIETARY_SUPPLEMENT|high oleic sunflower oil|placebo, which does not provide DHA
219209456|NCT06081426|OTHER|Non-ketogenic Diet|Consuming a non-ketogenic diet
219209457|NCT06081426|OTHER|Ketogenic Diet|Consuming a ketogenic diet
219209458|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
219677132|NCT00000841|DRUG|Zidovudine|
219677133|NCT03935334|BIOLOGICAL|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
219677134|NCT03935334|BIOLOGICAL|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
219677135|NCT01476306|OTHER|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
219677136|NCT01476306|OTHER|Usual care|Patients in this group will receive care as they usually do with the physician.
219677137|NCT00282152|DEVICE|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
219677138|NCT00282152|DRUG|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
219677139|NCT00585325|DRUG|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
219677140|NCT00585325|OTHER|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
219677141|NCT03301831|BEHAVIORAL|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
219677142|NCT01350375|DRUG|Botox|
219677143|NCT01350375|DRUG|Saline|
219677144|NCT03092791|BIOLOGICAL|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
219677145|NCT03092791|BIOLOGICAL|Reference IPV|Reference IPV intramuscular injection
219677146|NCT03092791|BIOLOGICAL|sIPV Placebo|sIPV placebo-matching intramuscular injection
219677147|NCT00614757|DRUG|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
219677148|NCT00614757|DRUG|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
219677149|NCT01124370|DEVICE|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
219677150|NCT03309514|BIOLOGICAL|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
219073042|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
219073043|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
219073044|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
219073045|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
219073046|NCT05088928|DRUG|Apixaban|Direct Acting Oral Anti coagulant
219073047|NCT05088928|DRUG|Rivaroxaban|Direct Acting Oral Anti coagulant
219073048|NCT00688636|DRUG|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
219073049|NCT00688636|DRUG|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
219073050|NCT00450827|BIOLOGICAL|bevacizumab|
219073051|NCT00450827|BIOLOGICAL|filgrastim|
219073052|NCT00450827|PROCEDURE|autologous hematopoietic stem cell transplantation|
219073053|NCT00450827|RADIATION|iodine I 131 monoclonal antibody 3F8|
219073054|NCT05432648|DIETARY_SUPPLEMENT|Green bean puree|Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
219073055|NCT06478784|OTHER|Resistance training|"The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
219073056|NCT06478784|OTHER|Low aerobic training|"Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
219073057|NCT06275204|DRUG|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
219073058|NCT06275204|DRUG|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
219073059|NCT06275204|DRUG|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
219209459|NCT06865287|OTHER|STR Group|"Both TPCT and STR groups will follow identical underwater rugby training sessions. Structure: Warm-up (15%): Land-based mobility (5 min) + in-water rondos (10 min). Small-Sided Games (30%): Tactical principles via modified scenarios. Full-Team Games (45%): 6v6, 5-min games with 3-min recovery. Cool-down (10%).~Training includes 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focus on tactical principles:~Containment (4v4, restricted defensive movement) → Defensive positioning, communication.~Recovery (5v6, interception-based) → Quick transitions, passing accuracy. Penetration (4v2, lane-based) → Offensive coordination, defensive pressure. Offensive Coverage (6v6, restricted movement) → Off-the-ball play, passing options.~Space (3v4, defenders in pairs) → Forward movement, spatial awareness."
219677151|NCT01538537|DRUG|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
219677152|NCT04869852|OTHER|Food|85g mango, 4x/week
219677153|NCT04697654|DRUG|TLC19|Hydroxychloroquine Liposome Inhalation Suspension
219073060|NCT06275204|DRUG|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
219073061|NCT04385953|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
219073062|NCT02361853|OTHER|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
219073063|NCT02361853|OTHER|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
219073064|NCT02361853|OTHER|Exposure: abundance of Immature monocytes counts in blood samples|
219073065|NCT02361853|OTHER|Exposure: abundance of Immature neutrophils counts in blood samples|
219073066|NCT00095264|DRUG|Darbepoetin Alfa|
219073067|NCT02020954|PROCEDURE|ECG, echocardiography, cardiac MRI, sera biomarkers|
219073068|NCT02741960|DRUG|metformin|500 mg metformin three times daily
219073069|NCT02741960|DRUG|placebo|500 mg placebo three times daily
219073070|NCT01360151|DRUG|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
219073071|NCT03734731|DEVICE|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
219073072|NCT03734731|DEVICE|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
219073073|NCT03734731|DRUG|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
219073074|NCT03734731|DRUG|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
219073075|NCT00333463|BEHAVIORAL|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
219073076|NCT00607555|DEVICE|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
219073077|NCT06198569|OTHER|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
219073078|NCT06198569|OTHER|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
219073079|NCT06216457|DEVICE|AI software for Stroke|AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
219073080|NCT05638867|DRUG|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
219073081|NCT05638867|DRUG|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
219073082|NCT00566267|DRUG|simvastatin 20 mg/ezetimibe|see protocol
219073083|NCT05627180|BEHAVIORAL|Tailored Health Literacy follow-up in cancer|"1. Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~2. Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~3. Telephone/digital conversations with the project every second month for a period of 9 months."
219073084|NCT01692340|OTHER|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
219073085|NCT01612403|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
219677154|NCT04697654|DRUG|TLC19 Vehicle|Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
219677155|NCT03831269|DRUG|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
219677156|NCT03831269|OTHER|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
219677157|NCT01179646|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
219677158|NCT04608890|DIAGNOSTIC_TEST|Eye-tracking video test|An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
219073086|NCT06028269|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
219073087|NCT03400891|BEHAVIORAL|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
219073088|NCT03521960|DRUG|Buspirone oral capsule|15 milligrams, three times daily
219073089|NCT03521960|DRUG|Placebo oral capsule|0 milligrams (placebo), three times daily
219073090|NCT03818412|PROCEDURE|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
219073091|NCT03185611|DRUG|Rifaximin|Antibiotics
219677159|NCT04468113|DEVICE|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
219677160|NCT00082095|DRUG|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
219677161|NCT00082095|DRUG|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
219677162|NCT02182830|DRUG|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
219677163|NCT02182830|DRUG|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
219677164|NCT02182830|DRUG|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
219677165|NCT00149032|PROCEDURE|DLI sensitized against antigens expressed by the host.|
219073092|NCT03185611|DRUG|Azathioprine|immunomodulator
219073093|NCT05991752|DIAGNOSTIC_TEST|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
219073094|NCT03543826|COMBINATION_PRODUCT|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
219073095|NCT01910129|DEVICE|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
219073096|NCT04938895|BEHAVIORAL|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
219073097|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
219073098|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
219073099|NCT02047019|DRUG|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
219073100|NCT02047019|DRUG|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
219073101|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
219073102|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
219073103|NCT00319098|BIOLOGICAL|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
219073104|NCT00319098|BIOLOGICAL|Fluarix|One intramuscular injection
219073105|NCT00319098|BIOLOGICAL|Placebo|One intramuscular injection
219073106|NCT01528189|OTHER|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
219073107|NCT01528189|OTHER|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
219073108|NCT05178082|BEHAVIORAL|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
219073109|NCT05178082|BEHAVIORAL|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
219073110|NCT02173977|OTHER|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
219073111|NCT02173977|OTHER|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
219073112|NCT05888597|DRUG|L-menthol|(Sigma-Aldrich, St. Louis, US)
219073113|NCT05888597|OTHER|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
219073114|NCT03193164|DEVICE|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
219073115|NCT03193164|OTHER|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
219073116|NCT02440958|DRUG|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
219073117|NCT02187991|DRUG|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
219073118|NCT02187991|DRUG|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
219073119|NCT01392560|DRUG|BI 10773|Oral once daily
219073120|NCT01994330|DRUG|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
219073121|NCT00408369|DRUG|DB289|
219073122|NCT02457572|PROCEDURE|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
219677166|NCT01738256|BEHAVIORAL|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
219073123|NCT02457572|OTHER|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
219073124|NCT04916223|OTHER|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
219073125|NCT04597320|DRUG|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
219677167|NCT01738256|BEHAVIORAL|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
219073126|NCT04597320|DRUG|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
219073127|NCT04597320|DRUG|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
219073128|NCT04029922|DRUG|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
219073129|NCT06196762|DRUG|XKH002 Injection|240 mg/4 mL/vial（60 mg/mL）
219073130|NCT01333124|RADIATION|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
219677168|NCT01738256|BEHAVIORAL|No intervention|No intervention
219677169|NCT00198809|DRUG|Biolean + Diet education|
219073131|NCT01333124|RADIATION|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
219073132|NCT02568527|DEVICE|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
219073133|NCT02638038|DRUG|INT131|INT- 131
219073134|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
219073135|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
219073136|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
219073137|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
219073138|NCT03715933|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
219073139|NCT03715933|DRUG|Carboplatin|Chemotherapy
219073140|NCT03715933|DRUG|Cisplatin|Chemotherapy
219073141|NCT03715933|DRUG|Pemetrexed|Chemotherapy
219677170|NCT00198809|DRUG|Biolean Free + Diet education|
219677171|NCT00198809|DRUG|Placebo + Diet education|
219677172|NCT02145637|DRUG|Afatinib plus Ruxolitinib combination therapy|
219677173|NCT02760121|DRUG|Acetazolamide|
219677174|NCT02760121|DRUG|Methazolamide|
219677175|NCT02760121|DRUG|Placebo|
219677176|NCT00154375|DRUG|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
219073142|NCT03715933|DRUG|5-fluorouracil|Chemotherapy
219073143|NCT03715933|DRUG|Irinotecan|Chemotherapy
219073144|NCT03715933|DRUG|Temozolomide|Chemotherapy
219073145|NCT05289362|DEVICE|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
219073146|NCT05289362|DEVICE|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
219073147|NCT04164992|DEVICE|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
219677177|NCT00154375|DRUG|Hydroxyurea|
219677178|NCT00489437|DEVICE|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
219677179|NCT00489437|PROCEDURE|Clinical Prediction Score-HIT Score Card|"1. clinical prediction rule~2. rapid immunoassay"
219677180|NCT05309330|OTHER|No Intervention|This is a non-interventional study.
219677181|NCT00797394|DIETARY_SUPPLEMENT|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
219677182|NCT00797394|DIETARY_SUPPLEMENT|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
219677183|NCT02348008|DRUG|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
219677184|NCT02348008|DRUG|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
219677185|NCT02348008|DRUG|MK-3475|Arm B: Phase II Treatment: 200mg IV
219677186|NCT02348008|DRUG|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
219209460|NCT06865287|OTHER|TPCT Group|"Both TPCT and STR groups followed identical underwater rugby training: Warm-up (15%), SSGs (30%), Full-Team Games (45%), Cool-down (10%). Training included 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focused on tactical principles:~Containment (4v4) → Defensive positioning, communication. Recovery (5v6) → Quick transitions, passing accuracy. Penetration (4v2) → Offensive coordination, defensive pressure. Offensive Coverage (6v6) → Off-the-ball play, passing options. Space (3v4) → Forward movement, spatial awareness. The TPCT group engaged in 10-min reflective discussions post-warm-up, SSGs, and games. Prompts included: What key moments defined the activity? How effective were our decisions? How well did we contain attackers? What hindered or helped recovery? How could we improve movement and space usage? Players progressively led discussions, enhancing tactical awareness."
219209461|NCT06761664|OTHER|Platysma Exercise Group|The participants in this group will perform a platysma exercise for 7 days following third molar extraction surgery.
219209462|NCT06761664|OTHER|Control (Standard treatment)|Participants in this group will receive routine treatment following third molar extraction.
219209463|NCT04710316|DIAGNOSTIC_TEST|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
219209464|NCT04710316|DIAGNOSTIC_TEST|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
219209465|NCT06783114|BIOLOGICAL|Recombinant Botulinum Toxin Type A for injection (YY001)|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).
219209466|NCT06783114|BIOLOGICAL|BOTOX®|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).
219209467|NCT06783114|BIOLOGICAL|Placebo|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
219209468|NCT06871059|BEHAVIORAL|Adapted Diabetes Prevention Program|Participants assigned to this group will participate in a group-based behavioural change program to improve diet and increase physical activity levels during 12 months.
219677187|NCT00616447|DEVICE|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
219677188|NCT00616447|DEVICE|placebo sham|Sham treatment will mimic active treatment mentioned above.
219677189|NCT06015919|BEHAVIORAL|dash diet|"* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
219677190|NCT06015919|DEVICE|Acupuncture|acupuncture
219677191|NCT06179043|BEHAVIORAL|Nutrient warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars"
219677192|NCT06179043|BEHAVIORAL|Text-only health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay"
219677193|NCT06179043|BEHAVIORAL|Graphic health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay"
219677194|NCT06179043|BEHAVIORAL|Control labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)"
219677195|NCT01909141|DRUG|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
219677196|NCT01909141|DRUG|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
219073148|NCT00987974|DRUG|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
219073149|NCT00987974|DRUG|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
219073150|NCT00987974|DRUG|placebo|placebo for 3 days.
219073151|NCT00987974|DRUG|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
219073152|NCT00987974|DRUG|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
219073153|NCT00987974|DRUG|placebo 7 days|placebo 7 days
219073154|NCT00626431|DRUG|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
219073155|NCT00626431|DRUG|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
219073156|NCT02199028|DRUG|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
219073157|NCT02199028|OTHER|Control|No hyaluronidase administered into insulin infusion set.
219073158|NCT01881126|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
219073159|NCT01881126|DRUG|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
219073160|NCT01881126|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
219073161|NCT01881126|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
219677197|NCT01909141|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of \> 18 mm or till day 20 of the cycle
219073162|NCT02791724|BEHAVIORAL|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
219073163|NCT02791724|OTHER|CAU|Care as Usual
219073164|NCT00522275|DRUG|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
219073165|NCT01371344|DRUG|Tacrolimus granules|oral
219073166|NCT01371344|DRUG|Tacrolimus capsules|oral
219073167|NCT00208416|PROCEDURE|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
219073168|NCT00208416|PROCEDURE|Conventional surgical technique|A conventional surgical technique used in total hip replacement
219073169|NCT02567084|DEVICE|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
219073170|NCT02351531|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
219073171|NCT02341417|DRUG|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
219073172|NCT00109538|DRUG|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
219073173|NCT00109538|OTHER|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
219073174|NCT04087538|DIAGNOSTIC_TEST|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
219073175|NCT04602533|DRUG|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
219073176|NCT04602533|DRUG|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
219073177|NCT04051346|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
219073178|NCT04051346|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
219073179|NCT04819269|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
219073180|NCT04819269|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
219073181|NCT05583591|DEVICE|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
219073182|NCT05583591|DEVICE|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
219073183|NCT06338696|OTHER|No intervention|No intervention
219073184|NCT06565507|DRUG|Oxfendazole single dose|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
219073185|NCT06565507|DRUG|Oxfendazole three doses|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
219073186|NCT06565507|DRUG|albendazole plus praziquantel regime|Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
219073187|NCT05388903|DRUG|DS-2325a|Subcutaneous injection (starting dose 30 mg)
219073188|NCT05388903|DRUG|DS-2325a|Intravenous infusion (starting dose 100 mg)
219677198|NCT01909141|OTHER|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
219073189|NCT05388903|DRUG|Placebo|Subcutaneous injection
219073190|NCT05388903|DRUG|Placebo|Intravenous infusion
219073191|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
219677199|NCT01909141|OTHER|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
219677200|NCT01909141|OTHER|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
219677201|NCT01909141|OTHER|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
219073192|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
219073193|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
219073194|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
219073195|NCT05665777|DRUG|Qingyan Lihou Decoction|Chinese medicine granules
219073196|NCT05665777|OTHER|Placebo|Placebo granules
219073197|NCT02726451|OTHER|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
219209469|NCT06871059|BEHAVIORAL|Usual Care|Participants assigned to this groups will receive usual care according to national guidelines
219209470|NCT06520371|DEVICE|Percutaneous radiofrequency|For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
219209471|NCT06520371|DEVICE|Conventional radiofrequency|For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
219209472|NCT05061719|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
219209473|NCT06894303|DEVICE|Target CI v1.5 remote programming|Use of the remote programming function of Target CI v1.5 and the AB remote support application
219209474|NCT06781515|OTHER|Peripheral and BM blood sample|Peripheral and BM blood samples will be analyzed with the ddPCR method
219209475|NCT06757855|DRUG|Olverembatinib|"induction therapy：40mg,QOD；~consolidation maintenance therapy: If patients with CMR are reduced to 30mg."
219677202|NCT01909141|OTHER|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
219677203|NCT01909141|OTHER|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
219677204|NCT06596876|DRUG|HRG2010; Sustained-release Carbidopa/Levodopa administered placebo|Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
219677205|NCT06596876|DRUG|Sustained-release Carbidopa/Levodopa; HRG2010 placebo|Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
219677206|NCT04672044|DEVICE|Active rTMS and exercise|active
219677207|NCT04672044|COMBINATION_PRODUCT|Sham rTMS+Exercise|sham
219073198|NCT02726451|OTHER|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
219073199|NCT06540443|DRUG|MPB-2043 of 0.5 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
219209476|NCT06757855|DRUG|Venetoclax|"induction therapy：leverl 0: 100mg d-2; 200mg d-1; 400mg d1-14~leverl -1: 100mg d-2; 200mg d-1; 400mg d1-7~leverl 1: 100mg d-2; 200mg d-1; 400mg d1-21~consolidation maintenance therapy: 400mg d1-7"
219073200|NCT06540443|DRUG|MPB-2043 of 1.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
219073201|NCT06540443|DRUG|MPB-2043 of 2.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
219073202|NCT06540443|DRUG|MPB-2043 of 3.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
219073203|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
219073204|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
219073205|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
219073206|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
219209477|NCT06757855|DRUG|Azacitidine|"induction therapy：75mg/m2/d, d1-7~consolidation maintenance therapy: 75mg/m2/d, d1-7"
219209478|NCT02650622|PROCEDURE|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
219209479|NCT05121051|PROCEDURE|Biospecimen Collection|Undergo collection of blood, buccal cell, and nasal epithelial cell samples
219209480|NCT05121051|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
219209481|NCT05121051|DRUG|Placebo Administration|Given PO
219209482|NCT05121051|OTHER|Questionnaire Administration|Ancillary studies
219209483|NCT04720625|BEHAVIORAL|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
219209484|NCT04720625|BEHAVIORAL|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
219677208|NCT06137820|DEVICE|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
219677209|NCT06137820|DEVICE|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
219677210|NCT02868736|DEVICE|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
219073207|NCT05758753|DEVICE|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
219073208|NCT05353283|BEHAVIORAL|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
219073209|NCT05353283|DEVICE|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
219073210|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
219073211|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
219073212|NCT06333678|DRUG|Durvalumab|10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
219073213|NCT06333678|DRUG|Sotorasib|960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
219073214|NCT06850389|DEVICE|ChitoCare® medical Wound Healing Gel|ChitoCare® medical Wound Healing Gel is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute and chronic wounds and other skin conditions, including partial thickness burn wounds.
219073215|NCT06850389|DEVICE|ChitoCare® medical Healing Spray|ChitoCare® medical Healing Spray is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute wounds and other skin conditions.
219073216|NCT05004324|BIOLOGICAL|FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
219073217|NCT05004324|BIOLOGICAL|Placebo|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
219073218|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.05%.
219073219|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.
219073220|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.
219073221|NCT05932693|OTHER|E-liquid coolant (WS-3, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
219073222|NCT05932693|OTHER|E-liquid coolant (WS-3, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.
219073223|NCT05932693|OTHER|E-liquid coolant (menthol, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.05%.
219073224|NCT05932693|OTHER|E-liquid coolant (menthol, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.
219073225|NCT05932693|OTHER|E-liquid coolant (menthol, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
219073226|NCT05932693|OTHER|E-liquid coolant (menthol, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.
219073227|NCT05932693|OTHER|E-liquid coolant (menthol, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.
219209485|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
219209486|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
219677211|NCT05887362|BEHAVIORAL|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
219677212|NCT03040349|BEHAVIORAL|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
219677213|NCT03040349|BEHAVIORAL|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
219209487|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
219073228|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.05%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.05%.
219073229|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.1%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.1%.
219073230|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.5%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.5%.
219073231|NCT05932693|OTHER|E-liquid coolant (WS-23, 1.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 1.0%.
219073232|NCT05932693|OTHER|E-liquid coolant (WS-23, 2.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 2.0%.
219073233|NCT05932693|OTHER|E-liquid coolant (WS-23, 4.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 4.0%.
219209488|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
219209489|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
219209490|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
219209491|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
219073234|NCT01808313|DRUG|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
219073235|NCT00733317|DRUG|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
219073236|NCT00733317|DRUG|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
219073237|NCT02759159|PROCEDURE|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
219073238|NCT02759159|PROCEDURE|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
219073239|NCT00251810|DEVICE|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
219073240|NCT02399579|OTHER|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
218983203|NCT06202430|PROCEDURE|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
219073241|NCT01289067|DRUG|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
219073242|NCT04656847|DRUG|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
219073243|NCT03506971|OTHER|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
219073244|NCT03506971|OTHER|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years"
219677214|NCT03040349|BEHAVIORAL|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
219677215|NCT03095352|BIOLOGICAL|Pembrolizumab|200 mg Given IV
219677216|NCT03095352|DRUG|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
219677217|NCT03095352|BIOLOGICAL|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
219677218|NCT06655441|DRUG|3% trehalose|ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
219209492|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
219209493|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
219209494|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
219209495|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
219677219|NCT00545935|DRUG|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
219677220|NCT00545935|DRUG|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
219677221|NCT00545935|DRUG|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
218983204|NCT05715697|PROCEDURE|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
218983205|NCT05715697|PROCEDURE|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
219073245|NCT03506971|OTHER|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months"
219073246|NCT01737580|DRUG|resiquimod|
219073247|NCT01737580|DRUG|placebo gel|
219073248|NCT03301051|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
219073249|NCT03301051|BIOLOGICAL|Placebo|Single dose of a Placebo
219073250|NCT02042235|BEHAVIORAL|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
219073251|NCT06463288|PROCEDURE|Jacobsons Breathing Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
219073252|NCT06463288|PROCEDURE|Pranayama Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
219073253|NCT00047879|BIOLOGICAL|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
219073254|NCT00047879|DRUG|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
219073255|NCT04251000|DEVICE|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
219073256|NCT05276466|DIAGNOSTIC_TEST|Polymerase Chain Reaction and Next-Generation DNA Sequencing|"The qPCR Rapid Screening Panel is a quantitative real-time PCR test for bacteria and fungi.~Next-Generation DNA Sequencing is the Comprehensive Sequencing test will detect virtually all microbial organisms and fungal pathogens that may be present in patient specimens."
219073257|NCT05725291|DRUG|AMT-116|Administered intravenously
219073258|NCT06015854|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
219073259|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
219073260|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
219073261|NCT00622167|DEVICE|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
219677222|NCT02169297|PROCEDURE|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
219677223|NCT02169297|PROCEDURE|PCA only|Patients received intravenous PCA post-operatively
219677224|NCT06240299|PROCEDURE|Neurofeedback|A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
219677225|NCT06988423|DRUG|CRS3123 200 mg capsule|CRS3123 200 mg capsule given as a single oral dose
219677226|NCT04741646|DRUG|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
219677227|NCT04741646|DRUG|Placebo|Placebo to match Ferric Citrate tablets
219677228|NCT06197646|DEVICE|Cartoon characters inhaler mask|Cartoon characters inhaler mask
219677229|NCT00781924|PROCEDURE|biopsy|ultrasound guided biopsy of tumors.
219677230|NCT05817214|DRUG|Cadonilimab|All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
219677231|NCT05817214|DRUG|Anlotinib|All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
219677232|NCT05817214|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
219677233|NCT03601572|OTHER|No intervention|No intervention
219677234|NCT05447767|DEVICE|KIT BMAC|intra-articular infiltration of BMAC
219073262|NCT00622167|DEVICE|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
219073263|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
219073264|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
219073265|NCT03219983|DRUG|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
219073266|NCT03219983|DRUG|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
219073267|NCT05915702|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
219073268|NCT05915702|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219677235|NCT05447767|DEVICE|KIT BMAC|intra-articular and intra-osseous infiltration of BMAC
219677236|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular infiltration of at-SVF
219677237|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular and intra-osseous infiltration of at-SVF
219073269|NCT05915702|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219073270|NCT05915702|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
219073271|NCT02357628|DEVICE|Wound treatment with RO-NPT|
219073272|NCT02357628|DEVICE|Wound Irrigation|
219073273|NCT02818881|OTHER|High-speed yoga|
219073274|NCT02818881|OTHER|Low-speed yoga|
219073275|NCT02683538|DEVICE|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
219073276|NCT02623673|DRUG|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
219073277|NCT05247151|OTHER|Oxytocin|Oxytocin nasal spray in a positive social setting.
219073278|NCT05247151|OTHER|Placebo|Placebo nasal spray in a positive social setting.
219073279|NCT06288984|DEVICE|active rTMS|The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks
219073280|NCT06288984|DEVICE|sham rTMS|The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
219073281|NCT05920369|OTHER|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
219073282|NCT05920369|OTHER|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
219073283|NCT05920369|OTHER|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
219073284|NCT04146714|OTHER|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
219073285|NCT04146714|OTHER|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
219073286|NCT03106818|DRUG|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
219073287|NCT03106818|DRUG|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
219073288|NCT03106818|DRUG|conventional|only conventional post operative analgesics will be used
219073289|NCT00572234|DRUG|bupropion SR|12 week course of bupropion SR 150 mg, BID
219073290|NCT06961734|BEHAVIORAL|follicular group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the late follicular phase of each cycle.
219073291|NCT06961734|BEHAVIORAL|luteal group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the mid- luteal phase of each cycle.
219073292|NCT06961734|BEHAVIORAL|Control group|Exercised at Fatmax intensity four times per week.
219073293|NCT05331261|PROCEDURE|Total diz replacement ameliyatı|Breath exercises
219073294|NCT06447064|OTHER|Cases & Controls|Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will only need to provide a photo ID and utility bill for ID verification, if the retailer cannot match participant details. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
219073295|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
219073296|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
219073297|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
219073298|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
219073299|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
219073300|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
219073301|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
219073302|NCT02983734|DRUG|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
219677238|NCT06608095|BEHAVIORAL|hypothermia group|Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.
219677239|NCT06608095|BEHAVIORAL|normothermia group|Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
219677240|NCT06609031|PROCEDURE|endoscopic mucosal resection|The SSLs less than 10mm in size in this group will be treated by EMR
219677241|NCT06609031|PROCEDURE|Cold snare polypectomy|The SSLs less than 10mm in size in this group will be treated by CSP
219677242|NCT00334295|DRUG|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
218983206|NCT05768217|BEHAVIORAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
218983207|NCT05768217|BEHAVIORAL|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
218983208|NCT05570292|DRUG|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
218983209|NCT05570292|DRUG|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
218983210|NCT06467461|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
218983211|NCT06467461|DIAGNOSTIC_TEST|Speech testing|Speech Testing to quantify evolving signs of 5-HT RBD
218983212|NCT06467461|DIAGNOSTIC_TEST|Ultra high field 7T MRI|7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
218983213|NCT02043171|DIETARY_SUPPLEMENT|Placebo|A Placebo comparator
218983214|NCT02043171|DRUG|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
218983215|NCT02043171|BEHAVIORAL|Non-Exercise|This group will not participate in 3 times per week strength training
218983216|NCT02043171|BEHAVIORAL|Exercise|This group will participate in a supervised 3 times per week strength training program
218983217|NCT01550289|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
218983218|NCT01550289|BIOLOGICAL|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
218983219|NCT03959943|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
218983220|NCT04962178|PROCEDURE|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
218983221|NCT04962178|OTHER|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
218983222|NCT02418702|DRUG|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
218983223|NCT02418702|OTHER|placebo|20 patients will randomly be assigned a placebo
218983224|NCT01929096|DRUG|Compound Edaravone Injection|
218983225|NCT01929096|DRUG|Edaravone Injection|
218983226|NCT05477693|BIOLOGICAL|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
218983227|NCT05477693|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
218983228|NCT02119481|BEHAVIORAL|Mindfulness-based stress reduction|
218983229|NCT02119481|BEHAVIORAL|Expressive writing condition|
218983230|NCT06963463|BEHAVIORAL|TranS-C|This intervention includes participants attending 6-8 sessions with a Sleep Therapist.
218983231|NCT06963463|BEHAVIORAL|Sleep Feedback|Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data.
218983232|NCT02092493|DEVICE|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
218983233|NCT06465290|DEVICE|Motor relearning training with wearable ankle robot|Ankle motor control relearning training under real-time feedback
218983234|NCT06465290|DEVICE|Passive stretching with wearable ankle robot|Passive stretching under intelligent robotic control
219073303|NCT02983734|DRUG|Placebos|Sugar pill
219073304|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
219677243|NCT06517550|OTHER|positive end-expiratory pressure while mechanical ventilation|a parameter in ventilator
219677244|NCT04207944|DRUG|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
219677245|NCT04207944|OTHER|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
219677246|NCT06658808|BEHAVIORAL|Promoting Community Conversations About Research to End Suicide|Promoting Community Conversations About Research to End Suicide (PC CARES) trains local community health workers to facilitate a series of five 3-hour Learning Circles (LCs) over \~6 months to develop a 'community of practice' (CoP), whereby trusted adults of youth (a) learn about SPBPs; (b) tailor the SPBPs to their culture and community; (c) build cross-sector relationships (parents, teachers, etc.), and (d) do more to prevent suicide. Each session shares evidence-based, actionable ways to enhance social support, reduce harm/risk, and promote help seeking, which participants adapt and apply in their daily interactions with youth.
219677247|NCT06670365|OTHER|Heat acclimation by warm-water immersion|Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
219677248|NCT05817721|DRUG|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
219677249|NCT05817721|DEVICE|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
219677250|NCT00743678|DRUG|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
219677251|NCT02152098|PROCEDURE|Acute Early onset of rehabilitation|Early onset of rehabilitation
219677252|NCT02152098|PROCEDURE|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
219677253|NCT02152098|PROCEDURE|Chronic Exercise|Exercise
219677254|NCT02152098|PROCEDURE|Chronic Control|Control
219677255|NCT03268005|DRUG|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
219073305|NCT01954017|OTHER|Control|Sterile Water
219073306|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
219073307|NCT02888405|OTHER|High-carbohydrate diet|
219073308|NCT02888405|OTHER|Low-carbohydrate diet|
219073309|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
219073310|NCT04679220|PROCEDURE|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
219073311|NCT02271386|BEHAVIORAL|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3\) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
219073312|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
219073313|NCT01235039|DRUG|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
219073314|NCT01235039|DRUG|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
219073315|NCT01235039|DRUG|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
219073316|NCT05505838|DRUG|Patisiran|Patisiran administered by intravenous (IV) infusion
219073317|NCT02030977|DIETARY_SUPPLEMENT|Resveratrol|
219073318|NCT02030977|OTHER|placebo|
219073319|NCT00006127|DRUG|amifostine|
219073320|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
219209496|NCT06774456|DEVICE|instrumented 3D serious game (BE API 3.0)|It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.
219677256|NCT03268005|DRUG|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
219677257|NCT03268005|DRUG|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
219677258|NCT03268005|DRUG|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
219073321|NCT00158743|OTHER|sodium chloride|
219073322|NCT01011010|DRUG|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
219073323|NCT01011010|DRUG|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
219209497|NCT06762912|OTHER|Passive application of BFR cuff|The first experimental session will start by conducting the one repetition maximum (1-RM) test of unilateral knee extension of the dominant leg, in which the dominant side was identified by asking the participants which side they will use to kick a ball. Before conducting the 1-RM test, 5 minutes warm-up on the cycle ergometer at 75W will be done. Calibration of the dynamometer will be done before operating the machine with each participant, then the participant will be positioned on the dynamometer seat comfortably with ensuring the back is supported and the knee is aligned with the axis of rotation. The participant will be asked to complete one successful repetition of knee extension through full range of motion (ROM), with increasing load until the participant can no longer complete full knee extension ROM, 3 minutes of rest will be allowed between attempts until the 1-RM is identified.
219677259|NCT03715452|DEVICE|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
219677260|NCT07002307|OTHER|Warm water at 35 oC|The placebo for the control group
219677261|NCT07002307|OTHER|Coffee|Instant coffee, Nescafé Gold Blend, manufactured by Nestlé Coffee Brand, Nestlé Global
219677262|NCT07002307|OTHER|Honey-sweetened coffee|Instant coffee plus raw dark amber honey produced by Apis mellifera adansonii
219677263|NCT07002307|OTHER|Green tea|Qualitea Natural Green Tea, packed by Qualitea Ceylon (PVT) LTD
219677264|NCT07002307|OTHER|Honey-sweetened green tea|Green tea plus honey
219677265|NCT07002307|OTHER|Black tea|Lipton Yellow Label Black Tea
219677266|NCT07002307|OTHER|Honey-sweetened black tea|Black tea plus honey
219677267|NCT06337292|DEVICE|Incisional Negative Pressure Wound Therapy (NPWT)|Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
219677268|NCT00792116|BEHAVIORAL|Gum Chewing|
219677269|NCT05171660|DRUG|Sintilimab|Sintilimab Injection: 200 mg, i.v., D1, Q3W
219677270|NCT05171660|DRUG|Bevacizumab|intravenous bevacizumab (7.5 mg/kg, day 1) in each 21-day cycle
219073324|NCT01011010|DRUG|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
219073325|NCT01011010|OTHER|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
219073326|NCT01011010|OTHER|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
219073327|NCT03701724|DEVICE|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
219073328|NCT03701724|DEVICE|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
219073329|NCT03701724|DEVICE|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
219073330|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
219677271|NCT05171660|DRUG|Oxaliplatin|intravenous oxaliplatin (130 mg/m2, day 1) in each 21-day cycle
219677272|NCT05171660|DRUG|Capecitabine|oral capecitabine (1 g/m2, days 1-14) in each 21-day cycle
218983235|NCT06465290|DEVICE|Gamed-based active movement training with wearable ankle robot|Active movement training through movement games with robotic assistance
218983236|NCT06465290|DEVICE|Passive movement with limited wearable ankle robot|Passive movement in the joint middle range of motion
218983237|NCT06465290|DEVICE|Active movement training with limited wearable ankle robot|Active movement training without robotic assistance
218983238|NCT06465290|DEVICE|Ankle torque and motion measurement with limited wearable ankle robot|Ankle torque and motion measurement with no real-time feedback
218983239|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
218983240|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
218983241|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
218983242|NCT05313555|DEVICE|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
218983243|NCT05313555|DEVICE|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
218983244|NCT03821155|OTHER|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
218983245|NCT03821155|DRUG|Corticosteroid|Prednisolone
218983246|NCT03274596|DRUG|Vitamin E|
218983247|NCT03274596|DRUG|Placebo|
218983248|NCT02173223|DRUG|Rho-Kinase Inhibitor|
218983249|NCT03663998|BIOLOGICAL|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
218983250|NCT03663998|BIOLOGICAL|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
218983251|NCT05084131|OTHER|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
218983252|NCT01897454|DRUG|Fluorouracil|Given IV
218983253|NCT01897454|DRUG|Gemcitabine Hydrochloride|Given IV
218983254|NCT01897454|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
218983255|NCT01897454|DRUG|Irinotecan Hydrochloride|Given IV
218983256|NCT01897454|DRUG|Leucovorin Calcium|Given IV
218983257|NCT01897454|DRUG|Oxaliplatin|Given IV
218983258|NCT03212924|BEHAVIORAL|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
218983259|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
218983260|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
218983261|NCT03212924|BEHAVIORAL|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
218983262|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
218983263|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
218983264|NCT01467726|DRUG|Velusetrag|Capsules
218983265|NCT01467726|DRUG|Velusetrag|Capsules
218983266|NCT01467726|DRUG|Placebo|Capsules
219209498|NCT06762912|OTHER|Resistance exercise with BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
219209499|NCT06762912|OTHER|Resistance exercise without BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
219209500|NCT06893445|PROCEDURE|Deep Tissue Massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
219209501|NCT06893445|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
219209502|NCT06747936|DRUG|AD-2281|PO, Once daily, 8weeks
219209503|NCT06747936|DRUG|AD-2282|PO, Once daily, 8weeks
219677273|NCT07021950|DRUG|AK112|AK112：20mg/kg，Q2W。Administered over 60 minutes (±10 minutes). For intolerable cases, infusion duration may extend up to 120 minutes. During treatment, dosing delays are allowed for up to 12 weeks (calculated from the last dose). AK112 may be resumed after 12 weeks under the following conditions: If treatment is paused due to glucocorticoid tapering for managing immune-related adverse events (irAEs);If treatment is paused due to adverse events unrelated or deemed unrelated to AK112; Resumption is permitted only if the investigator judges continued therapy beneficial, following discussion with relevant medical personnel.
219677274|NCT07021950|DRUG|FOLFIRI|FOLFIRI：Irinotecan, 180 mg/m² IV over 30-90 minutes (Day 1); Leucovorin (LV), 400 mg/m² IV over 2 hours (Day 1); 5-FU, 400mg/m²IV Day1, then 1200 mg/(m².d) ×2 days (total 2400 mg/m² ,IV over 46-48 hours).Q2W.
219677275|NCT07021950|DRUG|Bevacizumab|Bevacizumab：5 mg/kg，Q2W. The initial intravenous infusion should last approximately 90 minutes. If the first infusion is well tolerated, the duration of the second infusion can be reduced to approximately 60 minutes. Should the participant also tolerate the 60-minute infusion well, then all subsequent infusions may be administered over a period of approximately 30 minutes. Continuous monitoring for potential infusion-related reactions during the drip is required; if an infusion-related reaction occurs, the infusion rate should be promptly reduced or the infusion temporarily halted.
219677276|NCT07022236|DIAGNOSTIC_TEST|Thyroid profile|Thyroid dysfunction in patients undergoing hemogdialysis in sohag university hospital
219073331|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
219073332|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
219209504|NCT06747936|DRUG|Placebo of AD-2282|PO, Once daily, 8weeks
219209505|NCT02379351|DEVICE|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
219209506|NCT06909175|DEVICE|Transesophageal echocardiography|Portal vein velocities were measured using TEE and intraoperative doppler in patients undergoing living donor liver transplantation
219209507|NCT06423391|OTHER|NeuOst|As above
219209508|NCT06423391|OTHER|Control Intervention|As above
219209509|NCT06423391|OTHER|Usual Care|As above
219209510|NCT06942858|DEVICE|Deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC. A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The coil is an integrated coil for true and false stimulation loops. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
219073333|NCT03819335|DEVICE|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
219073334|NCT03819335|OTHER|Standard care|Face-to-face visits
219073335|NCT00714168|BEHAVIORAL|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
219073336|NCT00714168|BEHAVIORAL|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
219209511|NCT06942858|BEHAVIORAL|cognitive behavior therapy|Each patient receives 12 individual sessions of 50 minutes twice a week for 6 weeks.The CBT therapists are nationally registered psychotherapists with systematic professional training and uniform training in CBT for anorexia nervosa to ensure consistency. They are also supervised by a CBT supervisor at the end of each session.
219209512|NCT06942858|DEVICE|Sham deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field). A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
219073337|NCT04135053|BIOLOGICAL|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
219073338|NCT04358445|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
219677277|NCT07021924|OTHER|Fu's subcutaneous needling|"A single-use Fu's Subcutaneous Needling (FSN) device was employed. Participants were instructed to lie supine with the tested upper limb extended in a neutral position. After a 15-minute resting period, the FSN needle was fully inserted into the subcutaneous tissue layer at the acupoint Xialian (LI18) along the Large Intestine Meridian, with the needle tip oriented toward the radial styloid process.~The needle core was retracted into the soft tube, and the needle was then manipulated by swinging the handle left and right in a fan-shaped manner, with a sweep angle of approximately 60 degrees (30 degrees in each direction) relative to the insertion axis. The swaying movements was performed 50 times back and forth (100 cycles/min) over a duration of 2 minutes.~The needle was retained in place for 15 minutes before being removed. After needle removal, participants remained resting for 3 minutes before getting up, marking the end of the experimental procedure."
219677278|NCT07021924|OTHER|Acupuncture|"Participants were instructed to lie supine with the tested upper limb extended in a neutral position. According to WHO standard acupoint locations, the acupuncture needle was inserted at Xialian (LI18), located 4 cun below Quchi (LI11) on the line connecting Hegu (LI4) and Quchi (LI11). A 30-gauge, 1.5-inch acupuncture needle was used, and insertion continued until the Deqi sensation was achieved.~The needle was retained for 15 minutes before being removed. After a 3-minute post-removal rest period, participants were allowed to rise, completing the procedure."
219677279|NCT07022223|DRUG|orelabrutinib combined with rituximab regimen|"All participants will receive induction therapy with the orelabrutinib and rituximab regimen. The treatment cycle is 28 days, with a total of 6 cycles. The induction treatment period is as follows:~Cycle 1: Rituximab, 375 mg/m², on Day 1. Cycles 2-6:Orelabrutinib, 150 mg, once daily orally, from Day 1 to Day 28. Rituximab, 375 mg/m², on Day 1.~Patients who achieve a partial response (PR) or better will enter a 2-year maintenance period with orelabrutinib."
219677280|NCT07021521|DRUG|0 mg/kg Midazolam (Control Group)|"* Intravenous administration of volume-matched normal saline (0 mg/kg midazolam equivalent)~* Administered as single bolus prior to epidural anesthesia~* Served as active comparator for dose-response evaluation"
219677281|NCT07021521|DRUG|0.01 mg/kg Midazolam Group|"* Intravenous midazolam at 0.01 mg/kg (diluted in normal saline)~* Administered as single bolus over 2 minutes~* Manufacturer: Jiangsu Enhua Pharmaceutical Co., Ltd. (Approval H19990027)"
219073339|NCT06496152|OTHER|questionnaire|online form used to collect all information used in questionnaire
219073340|NCT02832323|BIOLOGICAL|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
219073341|NCT02283866|DRUG|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
219073342|NCT02283866|DRUG|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
219073343|NCT03456193|PROCEDURE|LA transplant|"The proposed study treatment will include three central components:~* Harvest of the left atrium and pulmonary veins from a suitable donor~* Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~* Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
219073344|NCT06193876|OTHER|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
219073345|NCT03655353|DIAGNOSTIC_TEST|ABY-PET|Diagnostic PET for HER2 expression
219073346|NCT01681589|DEVICE|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
219073347|NCT01681589|DEVICE|Control Group|This group will receive Sham TDCS
219073348|NCT01681589|OTHER|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
219073349|NCT02223234|BEHAVIORAL|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
219073350|NCT02223234|BEHAVIORAL|Control|Monthly emails on child health
219677282|NCT07021521|DRUG|0.02 mg/kg Midazolam Group|"* Intravenous midazolam at 0.02 mg/kg~* Identical administration protocol as 0.01 mg/kg group~* Primary focus: Intermediate dose efficacy/safety assessment"
219073351|NCT02223234|BEHAVIORAL|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
219209513|NCT06942858|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
219073352|NCT05725538|DEVICE|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
219073353|NCT05725538|OTHER|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
219073354|NCT01558154|DRUG|Chinese herbs|Chinese herbs special for depression
219073355|NCT01558154|PROCEDURE|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
219073356|NCT01558154|OTHER|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
219073357|NCT01558154|DEVICE|Transcranial magnetic stimulation|Give magnetic stimulation at head
219073358|NCT05989633|OTHER|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
219073359|NCT04402177|DRUG|Methyl Prednisolonate|Corticosteroid treatment
219073360|NCT00354874|DRUG|GW642444|drug
219073361|NCT00354874|DRUG|Placebo|placebo
219073362|NCT00354874|DRUG|salmeterol 50mcg|salmeterol
219073363|NCT02962713|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
219073364|NCT02962713|PROCEDURE|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
219677283|NCT07021521|DRUG|0.03 mg/kg Midazolam Group|"* Intravenous midazolam at 0.03 mg/kg (maximum tested dose)~* Special hemodynamic monitoring due to dose-dependent MAP effects~* Primary focus: Optimal dose determination"
219677284|NCT07022145|PROCEDURE|Endovascular repair|Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
219677285|NCT07023133|BEHAVIORAL|Weight loss|All participants will have self selected for bariatric surgery and their weight loss and mitochondrial function will be measured in this study.
219073365|NCT00919269|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219073366|NCT00919269|OTHER|Laboratory Biomarker Analysis|Correlative studies
219209514|NCT06953778|DEVICE|Zio XT® Patch|For participants randomized to be systematically screened, ambulatory ECG monitoring of up to 14 days will be performed using the Zio XT® Patch (iRhythm Inc, San Francisco, CA). The Zio XT® patch is a small, cutaneous ambulatory ECG recording device that provides cardiac rhythm monitoring for up to 14 consecutive days (significantly longer than the 48 hours of monitoring provided by a typical Holter Monitor). The device is approved by the Food and Drug Administration and is in routine clinical use, including in the VA system.
219677286|NCT07022444|DEVICE|IOL-MASTER 700|patients who were diagnosed cataract would go through tests with IOL-MASTER 700 to achieve ocular biometry parameters.
219073367|NCT03882684|DIAGNOSTIC_TEST|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
219073368|NCT03986853|PROCEDURE|Blood sampling|Blood sampling under general anesthesia
219073369|NCT00407446|DRUG|sildenafil|
219073370|NCT03413436|DRUG|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
219073371|NCT03413436|DRUG|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
219073372|NCT02289300|DRUG|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
219073373|NCT02289300|DRUG|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
219073374|NCT02289300|DRUG|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
219209515|NCT06796257|OTHER|radiotherapy planning|In this study, CT localization images from 32 patients were retrospectively used for radiotherapy treatment planning. Three radiotherapy plans were designed based on different K-value intervals of the Monaco-Serial biological function constraint for the heart. The dose-volume parameters of the organs at risk were compared.
219073375|NCT02804542|OTHER|Observational|
219073376|NCT02804542|OTHER|Retrospective review|
219073377|NCT00344123|DRUG|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
219073378|NCT00344123|DRUG|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
219073379|NCT06482372|DEVICE|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation at both cerebral hemisphere
219073380|NCT02653482|DRUG|Dapagliflozin|
219073381|NCT02653482|DRUG|Dapagliflozin matching placebo|
219073382|NCT01427075|PROCEDURE|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
219073383|NCT02786082|DRUG|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
219073384|NCT02786082|DRUG|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
219073385|NCT03969654|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
219073386|NCT03969654|DEVICE|Vanguard Total Knee|Primary Total Knee Arthroplasty
219073387|NCT03969654|DEVICE|NexGen Total Knee|Primary Total Knee Arthroplasty
219073388|NCT01771198|DRUG|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
219073389|NCT02191982|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
219073390|NCT03230916|DRUG|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
219073391|NCT04717804|OTHER|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
219073392|NCT04717804|OTHER|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
219073393|NCT02283060|DRUG|Stribild|To be administered orally, once daily with food.
219209516|NCT05933057|DRUG|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
219209517|NCT05933057|DRUG|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
219209518|NCT05720299|DRUG|Akkermansia muciniphila|one tablet of AKK
219073394|NCT02283060|DRUG|Atripla|To be administered orally, once daily at bedtime on an empty stomach
219073395|NCT04974164|BIOLOGICAL|Inactivated COVID-19 Vaccine|Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
219073396|NCT04532814|OTHER|Exercise|Cycling 60% VO2 max
219073397|NCT05322616|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
219073398|NCT05322616|DRUG|Matching Placebo|Vehicle control
219073399|NCT04370054|BIOLOGICAL|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
219073400|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
219073401|NCT02515136|BEHAVIORAL|Stimulus-response|See summary
219073402|NCT03375619|OTHER|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219073403|NCT05692024|DRUG|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
219073404|NCT05692024|DRUG|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
219073405|NCT03815721|DEVICE|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
219073406|NCT06227585|DEVICE|REVEAL 475 System|The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
219073407|NCT06227585|DRUG|Bevonescein|All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
219073408|NCT02300714|PROCEDURE|oblique view approach|
219073409|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
219073410|NCT02222220|DRUG|placebo|
219073411|NCT01371318|OTHER|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
219073412|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
219073413|NCT07119892|BEHAVIORAL|Lifestyle Modification (Exercise + Diet)|Participants received a 12-week supervised aerobic exercise program (5 sessions per week at 70% of age-predicted maximum heart rate) and dietary counseling with a calorie-restricted Mediterranean-style diet of 1,200 kcal/day. The intervention was culturally adapted, including modifications for Ramadan.
219073414|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 1 tablets and Placebo 2 tablets
219073415|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 2 tablets and Placebo 1 tablets
219073416|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 3 tablets and Placebo 0 tablets
219073417|NCT07123402|DRUG|Placebo|orally ;Take Placebo 3 tablets
219073418|NCT07126080|BEHAVIORAL|Incontinence Coping Training|"Intervention: Women in the experimental group will receive a four-week training program on managing urinary incontinence. The training will cover the following topics:~* Definition, types, and risk factors of urinary incontinence~* Treatment and prevention of urinary incontinence~* Symptoms of urinary incontinence and non-drug management strategies (addressing eating and toilet habits, such as limiting caffeinated beverages and cautioning spicy foods)~* The importance and implementation of Kegel exercises After the training, the experimental group will be reminded to practice Kegel exercises, and post-tests will be administered at 1 and 3 months. The control group will also receive post-tests at 1 and 3 months. Training will be conducted individually online."
219073419|NCT07126158|RADIATION|Stereotactic body radiotherapy|MRIdian and Ethos (adaptive radiation platforms)
219073420|NCT07126158|DRUG|Defactinib|Taken with 30 minutes of a meal
219073421|NCT07126158|DRUG|Avutometinib|Can be taken without regard to food.
219073422|NCT07127484|PROCEDURE|Hemoadsorption|Patients in intervention group will receive standard treatment plus hemoadsorption therapy administered once on days 1, 3, and 5 following enrollment.
219073423|NCT07127614|DIAGNOSTIC_TEST|MRI|pre-operative MRI scan
219073424|NCT07127614|DIAGNOSTIC_TEST|Histo-Pathological examination of the resected tumor tissues|histo-pathological examination of the resected tumor tissues with the lymph nodes involved to determine the pathological depth of invasion
219073425|NCT07126132|PROCEDURE|Coronary Angiography|Standard coronary angiography was performed via the radial or femoral approach on all participants to assess the presence and severity of coronary artery disease. Angiograms were used to determine coronary stenosis, which formed the basis for classifying participants into the CAD group (≥50% stenosis) or the control group (\<50% stenosis).
219073426|NCT07126132|DIAGNOSTIC_TEST|Hpx•apoB Product Measurement|Fasting blood samples were collected from all participants to measure the novel Hpx•apoB product. Plasma hemopexin (Hpx) was quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and apolipoprotein B (apoB) was measured using standard automated methods. This biomarker was the primary variable of interest for its association with CAD.
219073427|NCT07126275|DEVICE|Mirror App Journaling and Mood Tracking Study|Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. The Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries using unique, emotionally supportive features to help users identify and process emotions. Users can also complete free-form, unguided journaling, and can complete daily mood tracking and see changes/progress over time.
219073428|NCT07126067|PROCEDURE|Lung Ultrasound and PEEP Application|Application of Lung Ultrasound and PEEP After intubation, PEEP starts at 5 cmH2O. The first lung ultrasound (USG) is performed after 5 minutes. If the lung consolidation score is ≥2, PEEP increases by 2 cmH2O and is reassessed every 5 minutes until the score is \<2. If \<2, PEEP remains unchanged as the optimal level. This process is repeated after pneumoperitoneum, peritoneal deflation, and position changes. In Group U, PEEP is determined by USG, with a maximum of 20 cmH2O, a plateau pressure of 30 cmH2O, and a peak inspiratory pressure of 40 cmH2O.
219073429|NCT07126067|PROCEDURE|Application of PEEP with Dynamic Compliance|"Application of PEEP with Dynamic Compliance~* After endotracheal intubation, PEEP will be applied as 5 cmH2O.~* The first dynamic compliance (TV/Ppeak-PEEP) monitoring will be performed automatically by the ventilator (Mindray) 5 minutes after endotracheal intubation, and the PEEP value will be increased by 3 cmH2O. The obtained Cdyn value will be repeated after six respiratory cycles, and if there is an increase, the PEEP value will be increased by 2 cmH2O. When a decreasing trend is observed in the Cdyn value as a result of consecutive automatic measurements of 6 respiratory cycles, the PEEP value applied in the previous measurement will be determined as the most appropriate PEEP value for the participant."
219073430|NCT06273774|DRUG|MK-8189|Oral Tablet
219073431|NCT06273774|DRUG|Placebo|Oral Tablet
219073432|NCT06365580|DRUG|Kylo-0603 capsule|Administrated orally.
219073433|NCT06365580|DRUG|Placebo|Administrated orally.
219073434|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
219073435|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
219073436|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
219073437|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
219073438|NCT05163808|DRUG|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
219073439|NCT05163808|DRUG|Placebo|Placebo
219209519|NCT05720299|DRUG|Berberine|one tablet of Berberine
219209520|NCT05720299|DRUG|AKK Placebo|one tablet of AKK placebo
219209521|NCT05720299|DRUG|Berberine Placebo|one tablet of Berberine placebo
219073440|NCT04915794|OTHER|Simulation of preeclamptic pregnancy care|It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
219073441|NCT04298567|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg \[BID\])
219073442|NCT04298567|DRUG|Acetylsalicylic acid(ASA)|ASA (75mg \[QD\]; dose according to local label.
219677287|NCT07022080|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT Scan|The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivity is not less than 37MBq/mL; the solvent The residual amount of solvent complies with the regulations. Specification: 185\~1850 MBq/ml Characteristics Colourless and transparent, no visible particles. Physical half-life: 68 minutes for 68Ga. Stable for 3 half-lives from the time of labelling. Method of administration: Intravenous. Dose: 0.05Ci/kg, followed by a 5 mL saline flush.
219677288|NCT07022912|OTHER|educational healthcare intervention|This intervention will be applyed at the beginning of the study
219677289|NCT07022912|DIAGNOSTIC_TEST|Objective assessment of GI motility|Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.
219677290|NCT07022912|DIAGNOSTIC_TEST|Evaluation of GERD severity|Objective evaluation of GERD severity on PPI therapy will be performed.
219073443|NCT06819670|DRUG|Prednisolone|active drug
219073444|NCT06819670|DRUG|Famotidine|active drug
219073445|NCT06819670|DRUG|Placebo|non-active drug
219677291|NCT07022067|DEVICE|Telemonitoring app|periodic measurement of blood pressure and body weight
219073446|NCT03766971|BEHAVIORAL|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
219073447|NCT03766971|BEHAVIORAL|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
219073448|NCT03766971|DRUG|Cannabis|Participants will receive cannabis.
219073449|NCT06986525|PROCEDURE|CAF with PRF|Coronally advanced flap technique will be performed to reposition the gingival margin coronally. Platelet-rich fibrin (PRF) membranes will be placed over the exposed root surfaces and stabilized with sutures.
219073450|NCT06986525|PROCEDURE|Tunnel with PRF|A tunnel or subgingival pouch will be created using microsurgical instruments without vertical incisions. Platelet-rich fibrin (PRF) membranes will be inserted into the tunnel and the gingival tissue will be advanced coronally and sutured to cover the recession.
219073451|NCT00062933|PROCEDURE|Laparotomy|
219073452|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
219073453|NCT06660823|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablet
219073454|NCT06427668|DRUG|SPG302|synthetic small molecule
219073455|NCT06427668|DRUG|Placebo|Placebo
219073456|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
219073457|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
219073458|NCT00274053|DRUG|tiotropium|
219073459|NCT00214877|DRUG|Methylene Blue|
219073460|NCT06035601|DEVICE|EHR-integrated texting platform (Urotrust)|"* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI"
219073461|NCT06035601|OTHER|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
219073462|NCT04657822|DRUG|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
219209522|NCT05039021|DEVICE|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
219677292|NCT07021781|OTHER|MedQuest mobile application|Participants in this group will complete standardized questionnaires and scales using the MedQuest mobile application. Physicians will provide patients with a QR code, allowing them to access assigned digital questionnaires on their personal mobile devices or provided tablets. The application facilitates the digital input of patient responses. Following completion, the MedQuest application automatically processes the questionnaire data and utilizes an integrated artificial intelligence system (Claude 3.5 Sonnet, version from 22.10.2024) to generate recommended International Classification of Functioning, Disability and Health (ICF) codes. The application also provides an integrated calculator for questionnaire scores. This intervention aims to streamline the assessment process, reduce completion time, and enhance the efficiency and accuracy of ICF coding through AI integration.
219677293|NCT07021781|OTHER|Traditional Paper-Based Questionnaires|Participants in this group will complete all standardized questionnaires and scales (e.g. SF-36, Barthel Index, etc.) manually on printed paper forms. Physicians will complete the forms and patients will complete their responses with a pen or pencil. Subsequent evaluation and processing of these questionnaires will be performed by physicians via the Medquest application, followed by manual identification and recording of International Classification of Functioning, Disability, and Health (ICF) codes based on clinical judgment and established guidelines. This method represents the traditional approach to patient assessment and data collection.
219677294|NCT07022314|DEVICE|FIZE kUO®|FIZE kUO® is a commercially available, non-invasive device used for continuous, minute-by-minute real-time urine output monitoring in patients with an indwelling Foley catheter. In this observational study, the device is used during and after cardiac surgery as part of routine clinical care. Urine output data, along with additional clinical parameters, are collected throughout the study for research analysis.
219677295|NCT07021534|BIOLOGICAL|NKG2D CAR NK and NKG2D CAR T cells|"* NKG2D CAR-NK cells (hepatic artery infusion, D0 dose: 1×10⁹ cells,D1 dose: 1×10⁹ cells)~* NKG2D CAR-T cells (Over a two-day period, CAR-T cells are administered via intravenous infusion on two consecutive occasions.In the initial phase, rapid titration dose escalation was performed with 1 case per group.The initial dose is set at 1.5×10⁷/kg. If grade 2 or higher cytokine release syndrome (CRS) or related adverse events (AEs) occur, the 3+3 dose escalation protocol will be initiated. If not, the starting dose for escalation will be set at 3×10⁷/kg per administration of-T CAR cells, with subsequent escalations to 5×10⁷/kg per administration and 7×10⁷/kg per administration.)~Chemotherapy:~If you are treated with autologous CAR-NK cells, lymphodepleting chemotherapy with FC is usually not required. If you are treated with allogeneic NKG2D CAR-NK cells derived from umbilical cord blood of a healthy donor, the researchers will adjust the FC chemotherapy dosage or choose another appropriate"
219677296|NCT07022249|DEVICE|Intrasaccular Embolization Device|This is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.The intended therapeutic effect of this device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
219677297|NCT07021911|RADIATION|Radiotherapy|Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)
219677298|NCT06686654|BIOLOGICAL|Investigational hMPV/RSV vaccine|Investigational hMPV/RSV vaccine administered intramuscularly
219677299|NCT06686654|BIOLOGICAL|Investigational hMPV vaccine (monovalent)|Investigational hMPV vaccine (monovalent) administered intramuscularly
219677300|NCT06686654|BIOLOGICAL|Investigational RSV vaccine (monovalent)|Investigational RSV vaccine (monovalent) administered intramuscularly
219677301|NCT06686654|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV vaccine administered intramuscularly
219677302|NCT06686654|BIOLOGICAL|Placebo|Placebo administered intramuscularly
219677303|NCT06628453|DEVICE|CGM|Real-time continuous glucose monitoring
219677304|NCT07020572|BEHAVIORAL|Brief Interpersonal Psychotherapy - Adolescent Skills Training (B-IPT-AST)|This is an adolescent depression prevention program consisting of 6 sessions (4 group and 2 individual sessions).
219677305|NCT07020572|BEHAVIORAL|Services as usual (SAU)|Services as usual (SAU) involves any mental health services adolescents decide to receive in primary care or in the community. It is possible that adolescents in SAU may decide not to participate in any mental health services.
219677306|NCT07022873|OTHER|ACT-ED: Acceptance and Commitment Therapy based eating disorder prevention program|This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques. Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action.
219073463|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
219073464|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
219073465|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
219073466|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
219073467|NCT03207529|DRUG|Alpelisib|Given PO
219073468|NCT03207529|DRUG|Enzalutamide|Given PO
219073469|NCT05306327|DIAGNOSTIC_TEST|electroencephalography (EEG)|"1. brain cortical activity using full scalp~2. cerebral blood flow velocity~3. during the dying process following planned withdrawal of life sustaining measures (WLSM)"
219073470|NCT06669130|DEVICE|Xiangtong TM full degradation sinus drug stent system|use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus
219209523|NCT02118870|DRUG|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
219677307|NCT07022860|BIOLOGICAL|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is an autologous blood-derived material prepared by centrifuging the participant's venous blood without anticoagulants. The PRF clot is then compressed into a membrane and inserted into the extraction socket. It serves as a scaffold rich in platelets and growth factors to support bone regeneration and healing.
219073471|NCT06669130|DEVICE|nasopore|use nasopore to protect the post-operative sinus
219073472|NCT06669260|PROCEDURE|TEThA technique|Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
219073473|NCT06669858|OTHER|manual therapy|"In first session 6 techniques were applied to favorise fluids circulation, respiratory mecanism end equilibration of pressions (all were external soft tissue techniques, without manipulation): on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on liver and spleen organ, on lumbar fasciae.~In second session 6 techniques were applied in order to improve quality and quantity of legs and pelvis mobility (all were external sof tissue techniques, without manipulation) : on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on pubic symphysis, on legs and pelvis and on lumbar fasciae"
219073474|NCT06669858|OTHER|Sham|Wide ligth touch pressure applied with the 2 hand at day 2-4 and day 90
219073475|NCT05546281|OTHER|No intervention|No intervention
219073476|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
219073477|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single ascending dose
219073478|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
219073479|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
219073480|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
219073481|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
219073482|NCT06669429|DRUG|Placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
219073483|NCT05916196|DRUG|18F-Fluoroestradiol|18F-FES PET/CT
219073484|NCT03016871|DRUG|Carboplatin|Given IV
219073485|NCT03016871|DRUG|Etoposide|Given IV
219073486|NCT03016871|DRUG|Ifosfamide|Given IV
219209524|NCT02118870|DRUG|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
219209525|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
219677308|NCT07022522|DEVICE|5Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
219677309|NCT07022522|DEVICE|5Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
219209526|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
219073487|NCT03016871|OTHER|Laboratory Biomarker Analysis|Correlative studies
219073488|NCT03016871|BIOLOGICAL|Nivolumab|Given IV
219073489|NCT03958136|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
219073490|NCT03958136|BIOLOGICAL|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
219073491|NCT03958136|BEHAVIORAL|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
219073492|NCT05035901|OTHER|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
219073493|NCT06669936|DRUG|Fecal microbiota transplantation ± bezlotoxumab|Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
219073494|NCT06669052|DIETARY_SUPPLEMENT|30 mg liposomal iron, capsules|a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule
219073495|NCT06669000|DIAGNOSTIC_TEST|Standard X-Rays|\- Standard X-Rays: feet (Month 0)
219073496|NCT06669000|DIAGNOSTIC_TEST|Ultrasound|\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
219073497|NCT06669000|DIAGNOSTIC_TEST|DECT of feet|DECT of feet: in tophaceous patients only (Month 0, Month 24)
219073498|NCT06669000|BIOLOGICAL|DNA sample|DNA will be collected at Month 0
219073499|NCT06669000|BIOLOGICAL|Serum collection|\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
219073500|NCT06854601|DRUG|Mexidol|125 mg tablets
219073501|NCT06854601|DRUG|Placebo|Placebo tablets
219073502|NCT06854601|DRUG|Mexidol + Placebo|Combination of Mexidol and Placebo
219073503|NCT06770777|BEHAVIORAL|Tiered whole health support for people living with COPD|The website design allows study participants to choose the intervention tier(s) that meets their needs. There are three tiers from Tier 1: Information only, Tier 2 Reflective Writing, and Tier 3 LCSW Psychotherapeutic Intervention. Participants will also be able to choose multiple tiers if they are interested in continuing their participation. First Tier: The website offers standardized information about COPD care, healthcare navigation, and whole-person care. Information includes symptom management, disease progression and trajectory, healthcare navigation concepts, and directs people to the VA website with information about whole-person care. Second Tier: If participants choose, they can also select writing prompts with opportunities to reflect on their whole-person care and adjustment to illness. Third Tier: People living with COPD can also select to have asynchronous interaction with a licensed clinical social worker providing the narrative-based psychotherapeutic intervention.
219073504|NCT06384508|BEHAVIORAL|SHINE-VR|"The SHINE-VR takes place after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR, and is followed by the rest of the regular treatment. SHINE-VR consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR."
219073505|NCT03602417|DEVICE|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
219073506|NCT03602417|DEVICE|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
219073507|NCT02327754|DRUG|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
219073508|NCT02327754|DRUG|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
219073509|NCT00550485|DRUG|escitalopram|escitalopram 4 mg
219073510|NCT00252655|DRUG|Rapamune and Prograf|
219073511|NCT06073730|PROCEDURE|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
219073512|NCT06073730|PROCEDURE|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
219073513|NCT04073602|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
219073514|NCT00265369|DRUG|Spores of Bacillus Clausii Probiotic Strain|
219073515|NCT04935502|OTHER|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
219073516|NCT04935502|OTHER|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
219073517|NCT04769167|OTHER|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
219209527|NCT02422615|DRUG|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
219209528|NCT02422615|DRUG|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
219209529|NCT02422615|DRUG|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
219209530|NCT02034292|DRUG|Clopidogrel|
219209531|NCT02034292|DRUG|Aspirin|
219209532|NCT02034292|DRUG|APD791|
219209533|NCT02034292|DRUG|Placebo|
219209534|NCT00998413|BEHAVIORAL|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
219073518|NCT04769167|OTHER|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
219677310|NCT07022522|DEVICE|130Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
219677311|NCT07022522|DEVICE|130Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
219677312|NCT07022522|DEVICE|No stimulation|"In this control arm, Parkinson's disease patients will not receive active deep brain stimulation, with the DBS system maintained in an off state throughout the testing period."
219073519|NCT02807896|OTHER||This study is cohort.
219073520|NCT02062268|BEHAVIORAL|health education & law enforcement|
219073521|NCT01625897|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
219677313|NCT07021846|RADIATION|hypofractionated radiotherapy with tumor bed boost|hypofractionated radiotherapy with concomitant/simultaneous tumor bed boost
219677314|NCT07022431|OTHER|Interval strength training|"The intervention involves interval strength training with biofeedback and real-time decision-making for Alzheimer\&amp;amp;#39;s patients. Participants will complete 24 sessions, each including a circuit of strength exercises using rotational inertial devices (flywheels). Exercises, such as leg press, seated row, and bicep curl, will be randomly ordered, with load progression based on performance stability. Each session includes five sets per exercise, performed in a circuit, with a total of 15 sets over approximately 45 minutes. Real-time monitoring using a rotary encoder will track effort, and participants will continue each set until a 30% drop in average power is detected, ensuring consistent relative effort across sets.~Additionally, participants will engage in cognitively demanding tasks during training by verbally reporting the average power of the previous repetition while performing the next one. This dual-task approach aims to maximize both physical and cognitive engagement."
219677315|NCT07022808|OTHER|Synchronous Group exercise|Participants will participate in the TEEMS biweekly for 8 weeks (synchronous intervention). The synchronous group will attend sessions 2 times per week, with all sessions recorded. The sessions will be 60-minutes total, including 45-minutes of physical activity. Recorded sessions will be made available for participants to use on their own at the end of each week, building a video of 16 videos. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
219677316|NCT07022808|OTHER|Asynchronous exercise (Control)|Participants will participate in the TEEMS biweekly for 8 weeks (asynchronous video library). The asynchronous, control group will be provided with 2 recorded videos weekly that align with the synchronous group sessions, building a 16 video library as well. The sessions will be 60-minutes total, including 45-minutes of physical activity. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
219677317|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive on the day 0, 3, 7, 14 and 28, a total of 5 doses"
219073522|NCT01625897|DRUG|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
219073523|NCT06136390|OTHER|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
219073524|NCT06136390|OTHER|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
219073525|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
219073526|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
219073527|NCT02358603|DIAGNOSTIC_TEST|Chronotropic Incompetence Diagnostic Algorithm|
219073528|NCT01912612|DRUG|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
219073529|NCT04390737|DRUG|HH2853 Tablets|Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
219073530|NCT05071118|DRUG|Pregabalin 150mg|pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
219073531|NCT05071118|DRUG|Placebo|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
219073532|NCT01588184|DRUG|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
219073533|NCT03722186|DRUG|SHR-1603|SHR-1603 monotherapy
219073534|NCT05836766|DRUG|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
219209535|NCT01345422|OTHER|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
219073535|NCT05836766|DRUG|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
219073536|NCT06088940|DIETARY_SUPPLEMENT|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
219073537|NCT06088940|OTHER|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
219073538|NCT05197335|DEVICE|Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws|The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
219073539|NCT02640768|OTHER|educational training|implementation of a structured educational program for physicians and nurses
219073540|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with bupivacaine|"drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
219073541|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Ketamine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
218983267|NCT05661799|BEHAVIORAL|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
219073542|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Dexmedetomidine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
219073543|NCT00881387|BIOLOGICAL|rituximab|Given IV
219209536|NCT00800579|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
219209537|NCT00800579|DRUG|Placebo|Inhaled volume-matched placebo in sterile saline
219209538|NCT03575624|BEHAVIORAL|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
219209539|NCT03002259|DRUG|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
219209540|NCT01267370|DIETARY_SUPPLEMENT|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
219209541|NCT00995592|BEHAVIORAL|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
219209542|NCT01639131|DRUG|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
219209543|NCT01639131|DRUG|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
219209544|NCT01639131|DRUG|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
219209545|NCT00991549|BEHAVIORAL|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
219209546|NCT00166322|PROCEDURE|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
219073544|NCT00881387|DRUG|gemcitabine hydrochloride|Given IV
219073545|NCT00881387|DRUG|vinorelbine ditartrate|Given IV
219073546|NCT04380402|DRUG|Atorvastatin|Atorvastatin 40 mg tablet
219073547|NCT03939052|DIETARY_SUPPLEMENT|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
219073548|NCT04139070|DRUG|Bleomycin|Electroporation in combination with systemically administered bleomycin
219073549|NCT05552651|DRUG|Envafolimab|300mg,sc,d1,Q3W;
219073550|NCT05552651|DRUG|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
219677318|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive 2 doses on day 0, 1 dose on day 7 and day 21, a total of 4 doses."
219677319|NCT07022652|PROCEDURE|Esophageal cancer resection|Esophageal cancer resection
219677320|NCT07021677|DRUG|Daratumumab Injection|"Patients will receive intravenous daratumumab (16mg/kg per dose) once weekly for 2 doses. After 2 doses, they will undergo bone marrow examination for flow-cytometric MRD. Those who become MRD negative (less than 0.01% by flow-cytometry), will be off-study and continued on conventional treatment regimen as per institution policy. Hence, total duration in those who become MRD negative will be 3 weeks.~However, those who are still MRD positive (more than or equal to 0.01% by flowcytometry) after two doses, will be given two additional once weekly doses of intravenous daratumumab (16mg/kg per dose). In patients who receive two additional doses, bone marrow aspirate for MRD analysis will be done 7 days after fourth dose of daratumumab. Irrespective of MRD result after fourth dose, patients will be continued on conventional treatment regimen"
219677321|NCT07022834|DRUG|Dabrafenib or Trametinib and Clofarabine|"Drug: Dabrafenib or Trametinib Dabrafenib: 3-5 mg/kg/day; Trametinib: 0.025mg/kg/day~Drug: Clofarabine Consolidation therapy: 25 mg/m2/d, days 1-5 Maintenance therapy: 25 mg/m2/d, days 1-2"
219677322|NCT07022587|DEVICE|Sirolimus-eluting bioresorbable scaffolds|The Firesorb BRS (MicroPort Medical, Shanghai, China) is a balloon-expandable scaffold with a highly crystallized PLLA backbone, abluminally coated with a poly(D, L-lactide) (PDLLA) matrix incorporating sirolimus (4 μg/mm) through highly accurate and precise point spraying techniques. The scaffold thickness is 100 μm for devices with diameters of 2.5 and 2.75 mm, and 125 μm for those ranging from 3.0 to 4.0 mm in diameter. There are two radiopaque markers at each end of the scaffold, which can identify the position of the stent under X-ray monitoring and help to accurately locate the scaffold.
219677323|NCT07022587|DEVICE|Sirolimus-eluting stents|The Firehawk™ stent (MicroPort Medical, Shanghai, China) is a third-generation balloon-expandable L605 cobalt chromium stent with abluminal grooves containing a biodegradable polymer, which provides controlled release of the anti-proliferative medicinal substance sirolimus. The polymer is biodegradable, leaving only the metallic stent as a permanent implant. The stent is mounted on a rapid exchange delivery catheter system. The unique abluminal grooves are scored at the outer surface of the struts (total strut thickness: 86 μm), with an average sirolimus dosage of 3 µg/mm stent lengths.
219677324|NCT07023263|DEVICE|Schnider+ Mİnto|Patients assigned to the Standart TCI model Group would have Schnider + Minto models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
219677325|NCT07023263|DEVICE|Eleveld|Patients assigned to the Eleveld TCI model Group would have Eleveld+Eleveld models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
219677326|NCT07022496|DRUG|Caffeine (200 mg)|caffeine tablets
219677327|NCT07022496|DRUG|triptans|Sumatriptan
219677328|NCT07022496|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|Aspirin 250 mg, 81 mg, 75 mg
219677329|NCT07022496|DRUG|Paracetamol (acetaminophen)|Paracetamol 250 mg
219677330|NCT07021716|OTHER|No Interventions|No Interventions
219677331|NCT07021599|DIAGNOSTIC_TEST|Tailored AI echocardiogram analysis and reporting system|In the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized.
219073551|NCT05552651|DRUG|Carboplatin|AUC=5, iv,D1,Q3W
219073552|NCT04953390|DEVICE|Phonak Audeo hearing aid|Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3
219677332|NCT07022795|BEHAVIORAL|Educational video combined with daily surveys|Participants will receive the same educational intervention as those in the other arm and will also undergo an ecological momentary assessment (EMA) intervention. This will involve receiving multiple messages per day on their mobile phones, each linking to an online survey designed to capture real-time data on their current oral behaviors. The intervention aims to increase participants' awareness of these behaviors by prompting them to reflect on and report them throughout the day.
219677333|NCT07022795|BEHAVIORAL|Educational video only|"Participants will be provided with an educational video on recognizing and managing oral behaviors such as clenching, prolonged tooth contact, and keeping the jaw tense, etc.~The goal is to increase awareness and promote behavior change to reduce strain to the masticatory muscles and the temporomandibular joint."
219677334|NCT07023250|OTHER|manual dexterity and coordination skills|"The outcomes were assessed by the use of Bruininks-Oseretsky Test scale of motor proficiency (BOT-2) subtests (3,4\&7) for Manual Dexterity, Bilateral Coordination and Upper Limb Coordination respectively. The Bruininks-Oseretsky Examination of Motor Proficiency, Second Edition, evaluates motor performance in various areas such as Manual Dexterity, Bilateral Coordination and Upper Limb Coordination.~It utilizes subtests and complex structures to diagnose developmental and coordination issues among individuals aged four to twenty-one years old. The test is norm-referenced and purpose-oriented to assess motor abilities. The reliability and validity of the test were 0.78 and 0.84, respectively (Kosari et al., 2013; Ebrahimi et al., 2017; Yassin et al., 2020)."
219677335|NCT06698471|OTHER|Community worker training|Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy
219677336|NCT06698471|OTHER|Referral to Health System|Referral to Health System of Senegal
219073553|NCT04953390|DEVICE|Phonak hearing aid with multiple directionality settings, adjustable via a mobile app|Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
219073554|NCT02008890|BIOLOGICAL|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
219073555|NCT02008890|BIOLOGICAL|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
219073556|NCT02008890|BIOLOGICAL|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
219073557|NCT06022757|DRUG|XNW5004|XNW5004 an EZH2 inhibitor, BID, administered in continuous
219073558|NCT06022757|DRUG|KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection|KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
219073559|NCT02921529|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
219073560|NCT02921529|OTHER|false stimulation|Electrodes were attached to specific acupoints without electric current
219209547|NCT01645566|BEHAVIORAL|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
219677337|NCT03013413|PROCEDURE|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
219677338|NCT03013413|PROCEDURE|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
219677339|NCT03013413|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
219677340|NCT06877650|DRUG|JMT108|Intravenous (IV) administration every two weeks (D1, D15) in a 4-week cycle.
219677341|NCT06880874|DRUG|Enlicitide|Oral Tablet
219677342|NCT06171594|COMBINATION_PRODUCT|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
219073561|NCT06963060|DRUG|Gemcitabine nab-PaclitaxelLenvatinibTislelizumab|"Receive Gemcitabine (1000 mg/m² IV on Days 1 and 8) and nab-Paclitaxel (125 mg/m² IV on Days 1 and 8) every 3 weeks.~Take Lenvatinib (4-8 mg orally daily on Days 1-21).~Receive Tislelizumab (200 mg IV on Day 1) every 3 weeks."
219073562|NCT03626155|BEHAVIORAL|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
219073563|NCT03626155|BEHAVIORAL|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
219209548|NCT05049421|DIAGNOSTIC_TEST|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
219677343|NCT05644977|DRUG|Emraclidine|Oral tablets
219677344|NCT05644977|DRUG|Placebo|Oral tablets
219677345|NCT06474273|DRUG|Methylprednisolone|IV Methylprednisolone
219677346|NCT06474273|DRUG|Prednisone|Oral prednisone augmentation
219677347|NCT03207308|DIETARY_SUPPLEMENT|Vitamin A supplementation|200,000 IU of preformed vitamin A
219677348|NCT07023237|PROCEDURE|pulsed field ablation|"Pulsed electric fields refer to the generation of high-voltage electric fields with pulse widths ranging from milliseconds to microseconds or even nanoseconds. These fields release extremely high energy in a very short time, creating a large number of irreversible micropores in the cell membrane and even intracellular organelles such as the endoplasmic reticulum, mitochondria, and nucleus. This ultimately leads to apoptosis of the diseased cells, achieving the desired therapeutic effect.~By inserting a pulsed ablation catheter into the patient's body and reaching the target lesion, the pulsed energy is delivered to the ablation catheter via a cardiac pulsed field ablation device, thereby achieving the therapeutic goal of pulsed field ablation."
219073564|NCT02707354|DEVICE|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
219073565|NCT04567472|BEHAVIORAL|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
219677349|NCT06736899|DEVICE|Orbital Atherectomy System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.
219677350|NCT06736899|DEVICE|Balloon System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.
219677351|NCT00399295|DRUG|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
219677352|NCT06730984|OTHER|Endoscopy-Assisted Tracheal Intubation|Tracheal Intubation Under Endoscopic Guidance
219677353|NCT06730984|OTHER|Traditional Tracheal Intubation|Tracheal Intubation Under Video Laryngoscopy
219677354|NCT00980655|BIOLOGICAL|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
219677355|NCT00980655|BIOLOGICAL|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
219677356|NCT05861206|OTHER|GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
218983268|NCT05661799|BEHAVIORAL|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
218983269|NCT06203860|OTHER|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~* Lipid management~* Blood pressure management~* Antithrombotic therapy~* Glycemic targets~* Prevention of diabetes-related complications~* Treatment of vascular disease affecting the lower extremities~* Evaluation of cardioprotective drugs~* Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~* Guidance on vaccinations"
218983270|NCT06298409|DEVICE|CapScan collection capsule|The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
218983271|NCT00025272|DRUG|carboplatin|
218983272|NCT00025272|DRUG|etoposide|
218983273|NCT00025272|DRUG|topotecan hydrochloride|
218983274|NCT00025272|RADIATION|radiation therapy|
218983275|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
218983276|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
218983277|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
218983278|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
218983279|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
218983280|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
218983281|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
218983282|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
218983283|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
218983284|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
218983285|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
219073566|NCT05890443|BEHAVIORAL|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
219073567|NCT01577979|BEHAVIORAL|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
219073568|NCT01577979|BEHAVIORAL|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
219073569|NCT02478294|PROCEDURE|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
219073570|NCT02478294|DRUG|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
219073571|NCT02207816|PROCEDURE|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
219073572|NCT02207816|BIOLOGICAL|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
219073573|NCT02207816|BIOLOGICAL|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
219073574|NCT02207816|BIOLOGICAL|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
219073575|NCT02207816|BIOLOGICAL|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
219073576|NCT02207816|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
219073577|NCT05912400|DIAGNOSTIC_TEST|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
219073578|NCT05912400|OTHER|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
218983286|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
218983287|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
218983288|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
218983289|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
218983290|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
218983291|NCT02318875|DIETARY_SUPPLEMENT|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
218983292|NCT02318875|OTHER|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
218983293|NCT02057731|GENETIC|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
218983294|NCT05236400|DEVICE|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
218983295|NCT05236400|PROCEDURE|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
218983296|NCT02981017|DEVICE|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
218983297|NCT01839123|DEVICE|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
218983298|NCT01839123|DEVICE|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
218983299|NCT00462566|DEVICE|motor cortex stimulation|
218983300|NCT03095885|OTHER|Test Meal|
218983301|NCT02609204|DIAGNOSTIC_TEST|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
218983302|NCT03642457|DRUG|Bupivacaine|20 cc 0.5%
218983303|NCT03642457|DRUG|Bupivacaine liposome|133mg liposomal bupivacaine
218983304|NCT06377475|PROCEDURE|Jaw relation|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
218983305|NCT06377475|PROCEDURE|Questionnaire|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
218983306|NCT01392443|DRUG|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
219209549|NCT01681654|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
219677357|NCT05861206|OTHER|CHX-MW group (0.12% CHX, as a positive control group)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
219677358|NCT02514200|PROCEDURE|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
219677359|NCT02514200|PROCEDURE|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
219677360|NCT02514200|DRUG|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
219073579|NCT04377165|BEHAVIORAL|Gamification|This will provide the user with the newsfeed function and the addition of a gamification function
219073580|NCT04377165|BEHAVIORAL|Newsfeed function|This will provide the user with reliable accurate information on the pandemic.
219073581|NCT04997005|DEVICE|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
219073582|NCT01092338|DRUG|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
219073583|NCT03984799|PROCEDURE|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
219677361|NCT02514200|DEVICE|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
219677362|NCT01415726|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
219677363|NCT04439058|OTHER|ultrasound guided left stellate ganglion block|"Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
219677364|NCT06386159|OTHER|Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation|Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
219073584|NCT01454206|BEHAVIORAL|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
219209550|NCT01681654|BEHAVIORAL|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
219209551|NCT04157894|OTHER|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
219209552|NCT04157894|OTHER|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
219209553|NCT04157894|OTHER|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
219073585|NCT03114826|GENETIC|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
219073586|NCT05100082|DRUG|Cabozantinib|Cabozantinib tablets
219073587|NCT06094634|BEHAVIORAL|The Brief Alcohol Intervention (BAI): Behavioral|The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.
219073588|NCT05445284|BEHAVIORAL|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
219073589|NCT05445284|OTHER|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
219073590|NCT03044067|OTHER|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
219209554|NCT03172871|DRUG|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
219209555|NCT03172871|DRUG|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
219209556|NCT05004207|DIAGNOSTIC_TEST|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
219073591|NCT03044067|OTHER|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
219073592|NCT04226430|DEVICE|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
219209557|NCT03789071|DIAGNOSTIC_TEST|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
219209558|NCT02925988|DEVICE|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
219209559|NCT00084435|DRUG|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
219073593|NCT02980159|OTHER|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
219209560|NCT00084435|DRUG|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
219209561|NCT00084435|RADIATION|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
219209562|NCT02956109|DRUG|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
219073594|NCT02647112|OTHER|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
219073595|NCT03150472|DEVICE|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
219073596|NCT01200212|DRUG|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
219073597|NCT01200212|DRUG|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
219209563|NCT02956109|DRUG|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
219209564|NCT02956109|DRUG|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
219209565|NCT03194516|OTHER|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
219209566|NCT04541797|DRUG|Empagliflozin 10 MG|Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
219209567|NCT04541797|DRUG|Placebo|Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
219677365|NCT03057717|OTHER|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
219677366|NCT00552890|OTHER|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
219677367|NCT00552890|OTHER|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
219677368|NCT02992756|DRUG|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
219677369|NCT04692272|BEHAVIORAL|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
219677370|NCT02599064|DRUG|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
219677371|NCT03391804|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
219677372|NCT05194943|PROCEDURE|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
219677373|NCT01796275|BEHAVIORAL|Core intervention program|
219677374|NCT01796275|BEHAVIORAL|Booster session|
219677375|NCT01796275|BEHAVIORAL|Control only (Tea gathering)|
219677376|NCT01353391|DRUG|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
219677377|NCT01353391|DRUG|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
219677378|NCT03939533|DRUG|CUTAQUIG|Human normal immunoglobulin
219677379|NCT05140252|BEHAVIORAL|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
219677380|NCT00774072|DRUG|Tobramycin (Gernebcin®)|1 ml / day in each nostril
219677381|NCT06751446|OTHER|Scenario-based Simulation Skill Training|Scenario-based simulation is an educational approach that immerses students in realistic clinical scenarios, allowing them to practice decision-making and problem-solving in a safe, controlled environment. It challenges students to assess patient data, identify priorities, and implement interventions. Through guided debriefing sessions, students reflect on their actions, justify their decisions, and explore alternative strategies.
219677382|NCT06751446|OTHER|Traditional Skill Training|Traditional skill training in nursing education focuses on developing core technical skills through direct instruction, demonstrations, and hands-on practice. It emphasises mastery of essential tasks and conducting patient assessments. Students follow standardized protocols and procedures to ensure patient safety and accuracy in their practice
219677383|NCT01857804|DRUG|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
219677384|NCT01857804|DRUG|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
219677385|NCT01857804|DRUG|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
219677386|NCT03020628|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
219677387|NCT03020628|BIOLOGICAL|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
219677388|NCT05602740|DEVICE|Harmony|Passive recording of the head pulse
219677389|NCT03191565|OTHER|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
219677390|NCT03191565|DEVICE|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
219677391|NCT03232216|DIETARY_SUPPLEMENT|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
219073598|NCT02522494|BEHAVIORAL|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
219677392|NCT03232216|DIETARY_SUPPLEMENT|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
219677393|NCT00823758|BEHAVIORAL|Focus Groups|6 to 8 participants per group.
219073599|NCT02522494|BEHAVIORAL|Video|An educational intervention delivered prior to patients' visits with primary care providers.
219073600|NCT05854511|DRUG|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
219073601|NCT05688995|BIOLOGICAL|Naser Al-Husban|COVID-19 vaccines
219677394|NCT00823758|BEHAVIORAL|Personal Interviews|Conducted by phone and audiotaped.
219677395|NCT01472133|OTHER|Recording of 12 lead ECG|Recording of 12 lead ECG
219677396|NCT01472133|OTHER|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
219677397|NCT01472133|OTHER|Recording of chest wall movement|Recording of chest wall movement
219677398|NCT01472133|OTHER|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
219677399|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
219677400|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
219677401|NCT06305663|DEVICE|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
219677402|NCT06305663|DEVICE|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
219677403|NCT06840041|DIAGNOSTIC_TEST|Vaginal swab and culture|Participants will undergo vaginal swab collection both pre-operatively, immediately prior to the cesarean section, and post-operatively, within a defined timeframe after the procedure. The swabs will be collected using sterile swabs, following standardized procedures to ensure accurate sampling of the vaginal microbiota. The collected samples will then be sent to a designated laboratory for culture and analysis. This process will identify and characterize the bacterial composition of the vaginal microbiota, allowing researchers to investigate potential correlations between specific microbial profiles and the development of post-cesarean section wound infections
219677404|NCT06890143|DRUG|Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks|"①Dapagliflozin+Standard Treatment for 12 weeks. Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg Standard Treatment:standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.),This combined therapy will be administered for 12 weeks.~② Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Standard Treatment alone for an additional 12 weeks. To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
219073602|NCT01443481|DRUG|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
219677405|NCT06890143|DRUG|Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks|"①Standard Treatment for 12 weeks Standard Treatment:Standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy alone for 12 weeks.(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.)~②Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Dapagliflozin+Standard Treatment for 12 weeks Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg.This combined therapy will be administered for 12 weeks To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
219073603|NCT01764165|OTHER|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
219073604|NCT01764165|OTHER|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
219073605|NCT00176579|PROCEDURE|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
219073606|NCT03837652|OTHER|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
219073607|NCT00898118|GENETIC|polymerase chain reaction|
219073608|NCT00898118|OTHER|flow cytometry|
219073609|NCT00898118|OTHER|laboratory biomarker analysis|
219073610|NCT00898118|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219073611|NCT02288468|DEVICE|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
219073612|NCT03102814|BEHAVIORAL|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
219073613|NCT03102814|BEHAVIORAL|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
219073614|NCT06393049|OTHER|Hyperglycaemic clamp|"Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L."
219073615|NCT03248739|DEVICE|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
219073616|NCT03248739|DEVICE|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
219073617|NCT06635382|OTHER|Universal single bond adhesive|Will be applied and light cured for 20 seconds.
219209568|NCT04541797|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|Imaging: All patients will have stress CMR examinations at recruitment.
219209569|NCT02524769|DRUG|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
219073618|NCT06635382|OTHER|DMSO|DMSO application on tooth followed by active application of universal single bond adhesive and light cured for 20 seconds.
218983307|NCT05543967|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
218983308|NCT05543967|OTHER|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
218983309|NCT05543967|OTHER|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
218983310|NCT03307681|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
218983311|NCT03307681|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
218983312|NCT03307681|OTHER|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
218983313|NCT03307681|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
218983314|NCT03307681|OTHER|Meal skipping|No food given
218983315|NCT03041883|PROCEDURE|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
218983316|NCT03041883|PROCEDURE|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
218983317|NCT00917995|DEVICE|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
218983318|NCT01296217|PROCEDURE|lymph nod detection|
218983319|NCT01977794|DRUG|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
218983320|NCT01977794|DRUG|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
218983321|NCT01895062|DEVICE|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
218983322|NCT05817643|DRUG|BMS-984923|Oral capsule
218983323|NCT01100541|DEVICE|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
218983324|NCT02649465|DRUG|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
218983325|NCT02649465|DRUG|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
218983326|NCT00622817|DRUG|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
218983327|NCT00622817|DRUG|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
218983328|NCT05988008|DRUG|CCX168|Administered orally.
218983329|NCT05988008|DRUG|Placebo|Administered orally.
218983330|NCT05108662|PROCEDURE|Surgery method|Patients were subdivided into two groups according to their prostate volume
218983331|NCT04888468|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
218983332|NCT02680717|DRUG|Clobetasol|ointment, twice daily (alternating weeks)
218983333|NCT02680717|DRUG|Calcipotriene|ointment, twice daily
218983334|NCT02680717|DRUG|Tacrolimus|ointment, 0.1%, twice daily
218983335|NCT00297583|DRUG|Insulin Glulisine|
218983336|NCT06060743|OTHER|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
218983337|NCT02160535|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
218983338|NCT06327035|OTHER|Gait rehabilitation|"Assessment of gait and balance abilities after stroke during neurorehabilitation from the subacute phase of stroke to 6 months after stroke.~The assessments will be carried out on entrance to the neurological center, then at 1 ,3 and 6 months and on hospital discharge."
219073619|NCT00159211|DRUG|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
219073620|NCT00159211|DRUG|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
219073621|NCT06781723|BEHAVIORAL|Resistance Exercise|Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.
219073622|NCT06781723|DIETARY_SUPPLEMENT|Isolated Mixture|Participants will ingest isolated mixture of crystalized amino acids, maltodextrin, fiber and oil immediately after resistance exercise.
219073623|NCT06781723|OTHER|Rice and Beans|Participants will ingest cooked rice and beans meal immediately after resistance exercise.
219073624|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
219073625|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
219073626|NCT00254254|DRUG|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
219073627|NCT00254254|DRUG|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
219073628|NCT00254254|DRUG|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
219073629|NCT00293735|DRUG|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
219073630|NCT00293735|DRUG|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
218983339|NCT03019575|DRUG|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
218983340|NCT03019575|DRUG|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
219073631|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
219073632|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
219073633|NCT05596591|DEVICE|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
219073634|NCT05549401|DRUG|CKD-348(4) F1|QD, PQ
219677406|NCT06039501|BEHAVIORAL|Family Perspective Program|The program involves regular meetings between families and an ICU support counselor. The ICU support counselor is a trained expert in providing culturally competent emotional and/or spiritual support. The ICU support counselor will support families and also learn and summarize family perspectives in a standardized report. ICU care team members will be prompted to perspective take as they review reports prior to regular routine meetings between families and the ICU care team.
219073635|NCT05549401|DRUG|CKD-348(4) F2|QD, PQ
219073636|NCT05549401|DRUG|CKD-828, D097, D337|QD, PQ
219073637|NCT06041724|DRUG|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
219073638|NCT05451654|DRUG|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
219073639|NCT05451654|DRUG|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
219073640|NCT04376021|BEHAVIORAL|Babywearing|Increase mother-infant physical contact through babywearing
219073641|NCT03588533|DRUG|Trastuzumab|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"
219073642|NCT03588533|DRUG|Capecitabine|\- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
219073643|NCT03588533|DRUG|Cisplatin|\- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
219073644|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
219073645|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
219073646|NCT03461003|OTHER|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
219209570|NCT05437952|DIETARY_SUPPLEMENT|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
219677407|NCT06774807|OTHER|Saline infusion|Saline/NaCl (9mg/ml) intravenous infusion
218983341|NCT00794378|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
219677408|NCT06774807|OTHER|Saline injection|Saline/NaCl (9mg/ml) subcutaneous injection
219677409|NCT06774807|OTHER|1nmol antagonist infusion|GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min
218983342|NCT00794378|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
218983343|NCT00533897|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
219677410|NCT06774807|OTHER|4 nmol antagonist infusion|GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
219677411|NCT06774807|OTHER|Agonist injection|GLP-2(1-33) subcutaneous injection
219677412|NCT00305409|DRUG|Synbiotic (Synergy I / B.longum)|
219677413|NCT05225415|DRUG|CT1812|Orally administered CT1812
219677414|NCT06795243|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM|"PAIN NEUROSCIENCE EDUCATION~1\. Introduction to the knowledge of pain in the XXI century. Pain as an alarm system.~Types of pain. Differences between acute and chronic pain. 3. Chronic pain. Concepts of kinesiophobia, catastrophism and fear avoidance, self-determination and neuroplasticity.~4\. Main pain management tools based on scientific evidence. 5. . Transtheoretical model of change. Adherence to treatment, importance as a determinant in health.~6\. Messages for home. Strategies of active coping in the maintenance stage.~THERAPEUTIC EXERCISE PROGRAM 10-min warm-up. Joint mobility exercises with dual task or gamification. 30-min main part. Sequence of balance work between strength and body flexibility dosed according to the specific needs of each participant.~10-min cool down including breathing exercises and motor imagery. Home exercise program: walking (150 minutes in total, 3 days alternating with the face-to-face sessions)."
219677415|NCT06795243|PROCEDURE|USUAL CARE|"The treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients.~Conventional medical care is based on hormonal, pharmacological and/or surgical treatment and is carried out on an individualized basis depending on the severity of the disease and the patient's needs, especially in matters of desire to become pregnant. Surgical treatment is carried out when pharmacological therapy (hormonal or anti-inflammatory) is ineffective or involves adverse events."
219677416|NCT04091386|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
219677417|NCT06854185|BEHAVIORAL|Paso Program|The Paso Program is a behavioral weight loss program. It consists of a series of 16 one-hour-long semi-structured group counseling sessions led by a health educator every 1-2 weeks over 26 weeks. Each session has a curriculum with a counselor's guide and patient facing materials, covers specific topics (eating, physical activity, behavioral change strategies). Teaching methods include discussions, practice activities, demonstrations. The program is delivered to groups of 8 to 14 participants, classes are offered primarily in-person with the option of virtual attendance.
219677418|NCT01538849|DRUG|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
219677419|NCT01538849|DRUG|YH4808 A mg|1 tablet = YH4808 A mg
219677420|NCT01538849|DRUG|YH4808 B mg|1 tablet = YH4808 B mg
219677421|NCT01538849|DRUG|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
219677422|NCT00357890|DEVICE|Insulin pump therapy|CSII initiated within 1 month of diagnosis
219677423|NCT00357890|DRUG|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
219677424|NCT06843785|OTHER|Squat with knees over toes|Participants are instructed to stand comfortably with feet pelvis-width apart and approximately 15-30° to the side with arms extended in front of them. Participants are asked to squat to their most comfortable point, looking straight ahead, without heels leaving the floor, and to hold the position for 2 seconds before returning to the original standing position. The distance between the hips and the floor is measured vertically using a ruler for squat depth. Three trials are performed and the average of the three trials is used for further analysis.
219677425|NCT06843785|OTHER|Squat where the knee does not pass the toes|In the limited squat exercise, the position of the most anterior part of the knee is not allowed to extend beyond the toes. In the limited squat exercise, a wooden board is placed just distal to the first toe of each foot, and the 60 cm wide wooden board restricts knee movement. Participants are instructed to stand comfortably with their feet pelvis-width apart and approximately 15-30° to the side, and their arms extended in front of them. Participants are asked to squat to 90° of knee flexion, looking straight ahead, without the heels leaving the floor, and to hold the position for 2 seconds, then return to the original standing position. Squat depth is determined by measuring 90° of knee flexion using a goniometer placed on the knee and measured vertically between the hip and the floor using a ruler. Three trials are performed, and the average of the three trials is used for further analysis.
219677426|NCT06843785|OTHER|control|Participants will not be subjected to any intervention and will not be asked to perform any action.
218983344|NCT00533897|DRUG|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
218983345|NCT00426790|PROCEDURE|Positive end-expiratory pressure|
218983346|NCT03853408|PROCEDURE|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
218983347|NCT02171377|DEVICE|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
218983348|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
218983349|NCT02171377|DEVICE|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
218983350|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
218983351|NCT05451771|DRUG|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
219677427|NCT06880666|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|Conventional laparoscopic pull-through (CLP) surgery utilizes 3-5 small abdominal incisions for the placement of trocars, allowing the insertion of a laparoscopic camera and surgical instruments. After establishing pneumoperitoneum, the aganglionic segment is identified, and the colon is mobilized by dividing the lateral attachments using laparoscopic energy devices. The rectal dissection is performed circumferentially down to the level of the pelvic floor while preserving the mesenteric blood supply. A transanal approach is then used to complete the dissection, pull the mobilized bowel through the anus, and resect the aganglionic segment. A coloanal anastomosis is created, typically with absorbable sutures. Single-incision laparoscopic pull-through (SILS) follows the same principles but is performed through a single umbilical incision using a multi-port device; instruments and a camera are inserted through the same access point.
218983352|NCT05451771|DEVICE|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
218983353|NCT05451771|DRUG|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
218983354|NCT05451771|DRUG|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
219073647|NCT03461003|OTHER|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
219073648|NCT03461003|DRUG|Amlodipine|Calcium-channel blocker; antihypertensive
219073649|NCT03461003|DRUG|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
219073650|NCT03461003|DRUG|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
219073651|NCT03461003|DRUG|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
219073652|NCT03045666|OTHER|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
219209571|NCT05437952|OTHER|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
219209572|NCT05437952|DIETARY_SUPPLEMENT|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
218983355|NCT05451771|DRUG|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
219073653|NCT06395662|OTHER|Observational|Search for biomarkers
219073654|NCT03489304|DRUG|Zaleplon|non-benzodiazepine hypnotic agent
219073655|NCT03991611|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
219073656|NCT03991611|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
219209573|NCT05437952|OTHER|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
219209574|NCT03202992|DRUG|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
219677428|NCT06799078|OTHER|Observation while participants receive treatment by their primary care provider|Participants complete a consultation with a psychiatrist who makes some recommendations for the treatment of their depression. The participant's primary care provider decides whether to implement some of these recommendations.
219677429|NCT06745648|PROCEDURE|Arm A - Carotid Sinus Massage + Trendelenburg (CSM+T)|Manual stimulation of the carotid sinus area combined with head-down tilt positioning to activate baroreceptors for headache relief.
219677430|NCT06745648|PROCEDURE|Arm B - Sham CSM+T|Light neck contact, avoiding carotid sinus pressure, paired with identical body positioning to mimic the experimental intervention.
219677431|NCT00845676|DRUG|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
219677432|NCT01892904|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
218983356|NCT05451771|DRUG|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
218983357|NCT05451771|DRUG|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
218983358|NCT05451771|DRUG|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
218983359|NCT05451771|DRUG|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
218983360|NCT05451771|DRUG|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
218983361|NCT06078410|PROCEDURE|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
218983362|NCT06450080|OTHER|MRI and MRS acquisitions|All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
218983363|NCT06540027|PROCEDURE|rectal cacer surgery|minimally invasive surgery
218983364|NCT05600803|PROCEDURE|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
218983365|NCT03363269|DRUG|ID1201|
218983366|NCT05942560|BEHAVIORAL|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
218983367|NCT05942560|BEHAVIORAL|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
218983368|NCT03266731|DRUG|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
218983369|NCT05956691|DIETARY_SUPPLEMENT|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
218983370|NCT02472873|PROCEDURE|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
218983371|NCT02472873|PROCEDURE|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
218983372|NCT02472873|DRUG|Ethanol|
218983373|NCT02123342|BEHAVIORAL|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
218983374|NCT05490784|OTHER|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
218983375|NCT05490784|OTHER|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
218983376|NCT00227448|DRUG|intravenous saline|
218983377|NCT00227448|DRUG|intravenous phenylephrine|
218983378|NCT00227448|DRUG|intravenous levophed|
218983379|NCT00227448|DRUG|oral midodrine|
218983380|NCT04746248|OTHER|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
218983381|NCT04746248|OTHER|Inpatient labor induction|The participants are induced following standard inpatient care
218983382|NCT03228433|DRUG|TAK-418|TAK-418 Capsule.
218983383|NCT03228433|DRUG|TAK-418 Placebo|TAK-418 placebo-matching capsules.
219677433|NCT00472485|PROCEDURE|eye movement therapy|
219677434|NCT04135313|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14
219677435|NCT04135313|DRUG|Oxaliplatin|130 mg/m2 iv day 1
219677436|NCT04135313|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
219677437|NCT04135313|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
219677438|NCT04135313|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
219677439|NCT02675270|BEHAVIORAL|Phonological|This treatment involves picture viewing and word repetition.
219209575|NCT01606813|OTHER|Usual Care|Standard care
219209576|NCT01606813|BEHAVIORAL|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
219209577|NCT01606813|BEHAVIORAL|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
219677440|NCT02675270|BEHAVIORAL|Orthographic|This treatment involves picture viewing, reading, and writing.
219677441|NCT02675270|BEHAVIORAL|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
219677442|NCT02675270|BEHAVIORAL|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
218983384|NCT03268993|DIETARY_SUPPLEMENT|Avmacol|Avmacol is a dietary supplement available over the counter
218983385|NCT03677427|RADIATION|Radiation|Radiation in breast cancer
218983386|NCT03095339|OTHER|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
218983387|NCT02292121|PROCEDURE|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
218983388|NCT02292121|OTHER|a solution of mannitol and lactitol|
218983389|NCT04567498|OTHER|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
218983390|NCT00003805|DRUG|piperacillin sodium|
218983391|NCT00003805|DRUG|piperacillin-tazobactam|
218983392|NCT00003805|DRUG|tazobactam sodium|
218983393|NCT00003805|DRUG|vancomycin|
218983394|NCT06036823|DRUG|Insulin regular|Intravenous insulin
218983395|NCT06036823|DRUG|Dextrose 50|to be given to both arms
218983396|NCT06036823|DRUG|salbutamol|to be given to all patients
218983397|NCT06445296|OTHER|High-fat meal containing beef|High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.
218983398|NCT06445296|OTHER|High-fat meal containing Beyond Meat|High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
218983399|NCT03872154|OTHER|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
218983400|NCT01030536|DRUG|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
218983401|NCT01030536|DRUG|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
218983402|NCT01030536|DRUG|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
218983403|NCT01030536|DRUG|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
218983404|NCT01030536|DRUG|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
218983405|NCT03218644|OTHER|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
218983406|NCT03218644|OTHER|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
218983407|NCT03289858|DRUG|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
218983408|NCT03289858|DRUG|Sodium Chloride|Saline Injection
218983409|NCT05938062|PROCEDURE|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
218983410|NCT03154164|DEVICE|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
218983411|NCT06294782|RADIATION|STereotactic Arhythmia Radioablation (STAR)|STereotactic Arhythmia Radioablation (STAR)
218983412|NCT02577549|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
218983413|NCT02577549|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
219209578|NCT01606813|BEHAVIORAL|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
219209579|NCT05973240|OTHER|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
219677443|NCT02675270|BEHAVIORAL|Untrained|These words are not trained during the treatment phase.
219677444|NCT06842953|OTHER|Simulated indoor overheating|Older adults are exposed to a 10-hour simulated exposure
219073657|NCT03991611|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
219209580|NCT03653364|DRUG|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
219209581|NCT00299572|DRUG|alendronate (Fosamax)|
219209582|NCT02282709|DRUG|Daclatasvir|60 mg once daily
219209583|NCT02282709|DRUG|asunaprevir|100 mg BID
219677445|NCT06887777|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|The patients will orally take a dose of 200 mg/kg/day three times a day during meals: breakfast, lunch or afternoon snack and diner for 6 months.
219677446|NCT06559228|OTHER|ConnectedNest|Participants will receive a secure message to register and download ConnectedNest's patient app, EmpowerNest. They will be asked to complete a set of modules at baseline through ConnectedNest to understand their health related social needs and programs available to meet those needs. They will receive basic training on the functionality and services available within the app and asked to use the app to identify and connect with needed social and community services for 90 days. Participants will be directed to complete a survey at baseline, 30, 60, and 90 days to collect patient-reported outcomes.
219677447|NCT06559228|OTHER|Standard of care|Participants will be directed to complete a survey at baseline, 30, 60 and 90 days to collect patient-reported demographics, cancer characteristics and outcomes metrics
219073658|NCT03991611|OTHER|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
219073659|NCT03991611|OTHER|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
219073660|NCT01656551|DRUG|Gemcitabine|
219073661|NCT01656551|DRUG|Pemetrexed|500 mg/m2 day 1 every 3 weeks
219073662|NCT01656551|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks
219073663|NCT01227681|DRUG|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
219073664|NCT01227681|DRUG|Placebo|Sodium Chloride (NaCl) 0.9 %
219073665|NCT05129826|BEHAVIORAL|the association between periodontitis and malnutrition status|be determine the association between periodontitis and malnutrition status in older adult.
219073666|NCT02239679|DRUG|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
219073667|NCT02239679|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
219073668|NCT02239679|DEVICE|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
219073669|NCT02239679|PROCEDURE|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
219073670|NCT04572048|OTHER|Single-day NRP Training|NRP training course completed in one single day of 8 hours
219073671|NCT04572048|OTHER|longitudinal NRP training|NRP training course completed over one year by attending nine 30-minute modules.
219073672|NCT01898819|DRUG|Dexmedetomidine|
219073673|NCT01898819|DRUG|saline|
219209584|NCT03580551|BEHAVIORAL|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
219677448|NCT06843681|DRUG|Trastuzumab combined with taxane neoadjuvant therapy|Trastuzumab combined with taxane neoadjuvant therapy
219073674|NCT00228020|DRUG|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
219073675|NCT00228020|DRUG|MMF, cyclosporine, steroids|
219073676|NCT02278094|DEVICE|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
219073677|NCT02278094|DEVICE|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
219073678|NCT02278094|PROCEDURE|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
219073679|NCT02278094|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
219073680|NCT03583918|DEVICE|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
219209585|NCT03580551|BEHAVIORAL|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
219073681|NCT00002933|DRUG|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
219677449|NCT06178653|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
219677450|NCT06178653|OTHER|Trunk Control Training|Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
219073682|NCT00066248|DRUG|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
219073683|NCT00066248|DRUG|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
219073684|NCT00152776|DRUG|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
219073685|NCT05461222|DEVICE|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
219677451|NCT06408311|COMBINATION_PRODUCT|ENC-201-CED hPI|macro-encapsulated human primary islets
219677452|NCT05635097|BEHAVIORAL|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
219677453|NCT02559726|PROCEDURE|Echocardiography (TEE)|
219073686|NCT03857659|DIAGNOSTIC_TEST|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
219073687|NCT03857659|DIAGNOSTIC_TEST|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
219073688|NCT03857659|DIAGNOSTIC_TEST|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
219073689|NCT01815268|BIOLOGICAL|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
219073690|NCT01815268|BIOLOGICAL|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
219073691|NCT01815268|BIOLOGICAL|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
219073692|NCT01815268|BIOLOGICAL|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
219073693|NCT04879901|DIAGNOSTIC_TEST|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
219073694|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder|
219677454|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) with gadolinium enhancement|
219677455|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) without gadolinium enhancement|
219677456|NCT02559726|PROCEDURE|3D electrocardiographic mapping (ECM)|
219073695|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder (containing FeSO4), phytase|
219073696|NCT01991626|DIETARY_SUPPLEMENT|Iron pyrophosphate (FePP)|
219073697|NCT01991626|DIETARY_SUPPLEMENT|Iron sulphate|
219073698|NCT02047045|PROCEDURE|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
219073699|NCT02047045|DRUG|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
219073700|NCT03548298|PROCEDURE|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
219073701|NCT03565510|DIETARY_SUPPLEMENT|High-Protein Diet|The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
219073702|NCT02634411|DRUG|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
219073703|NCT02634411|DRUG|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
219073704|NCT04022200|DEVICE|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
219073705|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
219073706|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
219073707|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
219677457|NCT03386604|DIETARY_SUPPLEMENT|Whey protein|whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
219677458|NCT03386604|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin energy value 160 kcal.
219073708|NCT01569516|DRUG|Placebo|0mg, tid
219073709|NCT02451800|OTHER|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
219073710|NCT02451800|OTHER|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
219073711|NCT02451800|OTHER|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
219073712|NCT02564523|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
219073713|NCT02564523|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units)
219073714|NCT02564523|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline
219073715|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
219073716|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
219073717|NCT00373334|DRUG|placebo|placebo
219073718|NCT04862143|DRUG|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
219073719|NCT04862143|DRUG|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
219073720|NCT04862143|DRUG|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
219073721|NCT06215274|OTHER|Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.|The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
219073722|NCT04272268|DEVICE|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
219073723|NCT03174223|DRUG|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
219073724|NCT02123654|DRUG|Daclatasvir|
219073725|NCT02123654|DRUG|Asunaprevir|
219073726|NCT02123654|DRUG|DCV 3DAA|
219677459|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
219677460|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
219677461|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
219677462|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
219073727|NCT02123654|OTHER|Placebo for DCV 3DAA|
219677463|NCT01680653|DRUG|Mini-glucagon|Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age
219677464|NCT01680653|DEVICE|Remote monitoring|Provides real-time continuous glucose monitoring
219677465|NCT01680653|DIETARY_SUPPLEMENT|Carbohydrates|16 grams of carbohydrate
219677466|NCT02394236|OTHER|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
219677467|NCT00311454|DRUG|T.R.U.E.Test|
219677468|NCT06880549|BIOLOGICAL|mRNA-4106|Intramuscular Injection
219677469|NCT06880549|BIOLOGICAL|Nivolumab/Relatlimab|Intravenous infusion
219677470|NCT00162227|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
219677471|NCT00199576|DRUG|Methylprednisolone|
219677472|NCT06050330|DIAGNOSTIC_TEST|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
219677473|NCT03061240|DEVICE|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
219677474|NCT05367882|DIAGNOSTIC_TEST|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
219677475|NCT06268496|OTHER|serum formula 2039125 03|application twice a day of the tested product (in the morning and evening) to the face for 3 months
219677476|NCT00481767|BIOLOGICAL|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
219677477|NCT00481767|DRUG|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
219073728|NCT02123654|OTHER|Placebo for Daclatasvir|
219073729|NCT02123654|OTHER|Placebo for Asunaprevir|
219073730|NCT02828722|OTHER|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
219073731|NCT02828722|OTHER|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
219073732|NCT03031938|DRUG|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
219073733|NCT06388343|OTHER|Evaluation of Children's Listening and Processing Skills|The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
219209586|NCT00777894|RADIATION|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
219209587|NCT00777894|RADIATION|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
219209588|NCT00777894|RADIATION|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
219209589|NCT03998098|DIAGNOSTIC_TEST|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
219209590|NCT03998098|DIAGNOSTIC_TEST|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
219677478|NCT03601741|OTHER|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
219677479|NCT03601741|OTHER|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
219677480|NCT02358018|DRUG|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
219677481|NCT02778841|OTHER|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
219073734|NCT06388343|BEHAVIORAL|Multidisciplinary behavioral assessment|By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
219073735|NCT05981274|DIAGNOSTIC_TEST|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
219073736|NCT03984669|DIAGNOSTIC_TEST|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
219073737|NCT03984669|BIOLOGICAL|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
219073738|NCT01921439|BEHAVIORAL|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
219073739|NCT04566029|BIOLOGICAL|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
219073740|NCT04566029|BIOLOGICAL|Stool sample|The patients' stools will be collected at home
219073741|NCT04566029|OTHER|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
219073742|NCT03681626|PROCEDURE|no tracheal suction|No tracheal suctioning during extubation
219073743|NCT03681626|PROCEDURE|tracheal suction|tracheal suctioning during extubation
219073744|NCT01431625|OTHER|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. \- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
219073745|NCT03881735|DRUG|Enasidenib|Given PO
219073746|NCT03881735|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219073747|NCT02628054|BIOLOGICAL|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
219073748|NCT02628054|BIOLOGICAL|Placebo|Saline injection given 7 days apart
219073749|NCT00406835|PROCEDURE|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
219073750|NCT01815164|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
219073751|NCT01815164|BEHAVIORAL|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
219073752|NCT04022668|RADIATION|Coronary angiogram|Routine coronary angiogram, if indicated
219073753|NCT02468427|OTHER|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
219073754|NCT02468427|OTHER|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
219073755|NCT05095753|DEVICE|Earbud|In ear headphone with embedded infrasonic hemodynography technology
219073756|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
219073757|NCT01792011|DEVICE|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
219073758|NCT01491854|OTHER|Bloodsampling|Bloodsampling
219073759|NCT05496127|OTHER|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
219073760|NCT03404128|OTHER|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
219073761|NCT00121238|DRUG|cilengitide|Given IV
219073762|NCT02767115|DIETARY_SUPPLEMENT|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
219073763|NCT02767115|OTHER|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
219209591|NCT03998098|DIAGNOSTIC_TEST|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
219209592|NCT03998098|DIAGNOSTIC_TEST|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
219209593|NCT00405990|BEHAVIORAL|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
219209594|NCT00405990|BEHAVIORAL|VCT|HIV VCT for PMTCT
219677482|NCT05479838|PROCEDURE|Percutaneous coronary intervention|Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
219677483|NCT00000213|DRUG|Fluoxetine|
219677484|NCT00417638|DEVICE|Endovascular cooling by the Celsius Control System|
219073764|NCT02703350|DRUG|LY900014|Administered subcutaneously (SC)
219073765|NCT02703350|DRUG|Insulin Lispro|Administered SC
219073766|NCT06095726|BEHAVIORAL|Peppermint Inhalation|The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
219073767|NCT06095726|BEHAVIORAL|Swedish Massage|Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
219073768|NCT05771753|OTHER|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
219073769|NCT05771753|OTHER|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
219073770|NCT02077257|DRUG|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
219209595|NCT05789329|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|behavioral intervention aimed to reduce trauma-related guilt and shame
219209596|NCT05789329|BEHAVIORAL|Cognitive Processing Therapy|behavioral intervention aimed at reducing PTSD symptoms
219677485|NCT00417638|OTHER|Standard of care|
219677486|NCT02578459|DEVICE|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
219677487|NCT02578459|OTHER|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
219677488|NCT01941537|DRUG|ILV-094|IV infusion of ILV-094
219677489|NCT01941537|DRUG|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
219073771|NCT01026974|BIOLOGICAL|rMenB|
219209597|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
219677490|NCT00857961|DRUG|Testosterone MD-Lotion|Administered Topically
219677491|NCT04544553|OTHER|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
219677492|NCT04544553|OTHER|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
219677493|NCT03051373|DRUG|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
219677494|NCT03051373|DRUG|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
219677495|NCT03654391|DIETARY_SUPPLEMENT|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
219677496|NCT03654391|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
219677497|NCT04272957|DRUG|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
219073772|NCT01026974|BIOLOGICAL|rMenB+OMV NZ|
219073773|NCT03842657|COMBINATION_PRODUCT|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
219073774|NCT00325468|DRUG|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
219073775|NCT00845663|DRUG|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
219073776|NCT00845663|DRUG|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
219073777|NCT00622128|BEHAVIORAL|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
219073778|NCT06095570|DRUG|Ciprofol|For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
219073779|NCT06095570|DRUG|Remimazolam|For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
219073780|NCT00675389|BEHAVIORAL|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for \~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
219073781|NCT00675389|BEHAVIORAL|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
219073782|NCT04049630|DRUG|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
219209598|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
219209599|NCT05581498|BEHAVIORAL|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
219677498|NCT05635422|DIAGNOSTIC_TEST|isokinetism test|measure of muscular fatigability by isokinetism
219677499|NCT04293835|DIAGNOSTIC_TEST|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
219677500|NCT02557516|DRUG|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
219677501|NCT03865719|BEHAVIORAL|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
219209600|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
219677502|NCT02530918|DRUG|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
219073783|NCT04049630|DRUG|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
219073784|NCT04049630|DRUG|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
219073785|NCT04049630|DRUG|Placebo|5 tablets of placebo will be administrated to the participants.
219073786|NCT00262275|DRUG|Aspirin, Clopidogrel|
219073787|NCT01314118|DRUG|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
219073788|NCT02162420|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
219073789|NCT02162420|DRUG|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
219073790|NCT02162420|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
219073791|NCT02162420|RADIATION|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
219073792|NCT02162420|BIOLOGICAL|Stem Cell Transplant|Stem cell transplant on day 0.
219073793|NCT02162420|DRUG|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
219073794|NCT06582121|OTHER|Polysomnography|An overnight sleep study
219073795|NCT05545072|DRUG|Dupilumab|Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
219073796|NCT05545072|DRUG|Placebo|A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
219073797|NCT05545072|DRUG|Intranasal Corticosteroid Sprays (INCS)|All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will continue throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
219073798|NCT03592511|DIETARY_SUPPLEMENT|WGPF-burger|Volunteers consumed a WGPF-burger daily
219209601|NCT06764342|RADIATION|Full-mouth scaling combined with antimicrobial photodynamic therapy|After full-mouth scaling procedures antimicrobial photodynamic therapy was carried out using a laser-activated disinfection device with a red laser emission (wavelength: 630 nm, irradiance: 2000-4000 mW/cm², spot size at the probe tip: 8 mm diameter) and high-viscosity methylene blue gel (0.1 mg/mL) which was applied at six spots on the tongue dorsum. Antimicrobial photodynamic therapy was also applied iIn sites with altered periodontal pocket depth (≥ 4mm). The dye remained in the pockets for 10 minutes to ensure full absorption and its excess was rinsed with sterile saline after laser exposure.
219209602|NCT06764342|PROCEDURE|full-mouth scaling|Full-mouth scaling within 24 hours, divided into two sessions of ultrasonic instrumentation followed by manual supra- and subgingival scaling and root planing. Tongue cleaning was performed with a tongue scraper.
219677503|NCT02530918|DRUG|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
219677504|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart
219677505|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart
219677506|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart
219677507|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
219677508|NCT05202015|DRUG|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
219677509|NCT03280745|DRUG|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
219677510|NCT03280745|DRUG|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
219073799|NCT03592511|DIETARY_SUPPLEMENT|Control-burger|Volunteers consumed a Control-burger daily
219073800|NCT04583995|BIOLOGICAL|SARS-CoV-2 rS/Matrix M1-Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
219073801|NCT04583995|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
219073802|NCT04583995|BIOLOGICAL|Licensed seasonal influenza vaccine|Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
219073803|NCT04535401|PROCEDURE|Biopsy|Undergo tumor biopsy
219073804|NCT04535401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219073805|NCT04535401|PROCEDURE|Diagnostic Imaging|Undergo imaging
219073806|NCT04535401|DRUG|Elimusertib|Given PO
219073807|NCT04535401|DRUG|Fluorouracil|Given IV
219073808|NCT04535401|DRUG|Irinotecan Hydrochloride|Given IV
219073809|NCT04535401|DRUG|Leucovorin Calcium|Given IV
219073810|NCT04983615|DRUG|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
219073811|NCT04983615|DRUG|midazolam-based sedation|midazolam-based sedation
219073812|NCT05003349|OTHER|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
219073813|NCT05003349|OTHER|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
219073814|NCT05003349|OTHER|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
219073815|NCT05003349|OTHER|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
219073816|NCT05003349|OTHER|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
219073817|NCT05003349|OTHER|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
219073818|NCT00153764|DRUG|Cooper Complete One-A-Day Vitamin Supplement|
219073819|NCT05585307|DRUG|Bavtavirine|Administered orally
219073820|NCT05585307|DRUG|B/F/TAF|Administered orally
219073821|NCT05585307|DRUG|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
219073822|NCT05585307|DRUG|GS-1720|Administered orally
219073823|NCT05585307|DRUG|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
219209603|NCT06755476|OTHER|Psychological Counseling Program|"The Psychological Counseling Program consists of 8 sessions for caregivers of individuals diagnosed with Alzheimer's.~Aims of the sessions:~Session 1: Introduction, Collection of pretest data Session 2: It is aimed to inform Alzheimer's caregivers about the disease and its symptoms.~Session 3: It is aimed to strengthen caregivers' coping skills. Session 4: It is aimed to inform Alzheimer's patients about daily care practices.~Session 5: It is aimed to provide information to Alzheimer's caregivers about coping with stress.~Session 6: It is aimed to provide information about medical and financial support that individuals diagnosed with Alzheimer's and their relatives can receive in the region they live.~Session 7: It is aimed to conduct Q\&A sessions on the problems that caregivers bring.~Session 8: Collection of posttest data Sessions will be completed in 8 weeks, one day a week. Each session is planned to last approximately 60 minutes."
219209604|NCT06867406|DRUG|KPC000154 10mg Tablet Intervention|KPC000154 10mg Tablet administered orally in the morning once daily for 1 day
219073824|NCT05585307|DRUG|GS-6212|Administered orally
219073825|NCT05585307|DRUG|Standard of Care (Substudy 03)|Antiretroviral therapy, administered orally
219073826|NCT06787417|PROCEDURE|Restricted Kinematically-aligned Arthroplasty|Robot Assisted with Restricted Kinematically-Aligned TKA.
219073827|NCT06787417|PROCEDURE|Mechanically-Aligned Arthroplasty|Robot Assisted with Mechanically Aligned TKA.
219073828|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
219073829|NCT06240455|DRUG|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
219073830|NCT06240455|DRUG|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
219073831|NCT06240455|COMBINATION_PRODUCT|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
219073832|NCT04642638|DRUG|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
219073833|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
219073834|NCT04642638|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
219073835|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
219073836|NCT00054353|DRUG|fludarabine phosphate|Given IV
219073837|NCT00054353|DRUG|melphalan|Given IV
219073838|NCT00054353|RADIATION|total-body irradiation|Undergo TBI
219073839|NCT00054353|DRUG|mycophenolate mofetil|Given PO
219073840|NCT00054353|DRUG|cyclosporine|Given PO
219073841|NCT00054353|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
219677511|NCT03734445|DIETARY_SUPPLEMENT|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
219677512|NCT03734445|OTHER|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
219677513|NCT01623024|DRUG|Vitamin D|20.000 UI/week for 96 weeks
219677514|NCT01623024|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling for 96 weeks
219677515|NCT06922448|DRUG|BLU-808|BLU-808 tablets
219677516|NCT06922448|DRUG|Placebo|Placebo tablets
219677517|NCT06918132|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
219677518|NCT06918132|BIOLOGICAL|Cemiplimab|Given IV
219677519|NCT06918132|BIOLOGICAL|Fianlimab|Given IV
219677520|NCT06918132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219677521|NCT06918132|PROCEDURE|Surgical Procedure|Undergo SOC surgery
219677522|NCT06842732|BEHAVIORAL|Maternal Administered Malnutrition Monitoring System - Infant and Young Child Feeding (MAMMS IYCF) intervention|All caregivers randomized to the MAMMS-IYCF arm will be given two MUAC tapes after being trained by skilled study staff and their contact information will be entered into the online MAMMS-IYCF platform. The frequency of messages will be weekly. This will be a two-way SMS system, including health messages on age appropriate IYCF. These messages will also prompt caregivers to measure their child's MUAC, return the color outcome of the measurement to the clinic via the SMS system, and they will also be able to ask any health questions that they may have through the SMS. During follow-up, any caregiver who returns a MUAC measurement via SMS that suggests their child is wasted, will receive an SMS response asking them to come to the clinic with their child as soon as possible. At this visit, the wasting status of the child will be confirmed by a study staff, and if treatment is indicated they will be enrolled into nutritional care provided by MOH nutritionists.
219677523|NCT06842732|BEHAVIORAL|Standard of Care (SOC)|To promote high fidelity to current guidelines, all families randomized to the SOC arm will be enrolled into a one-way SMS service that will send them automated reminders before necessary routine EID or HIV care visits and research clinic appointments on day 90 and 180. During these routine clinic visits, study staff will ensure that the MUAC of SOC children are measured, and that treating clinicians (MOH nutritionists) are made aware if wasting is identified. Staff will ensure that SOC children are enrolled into nutritional care if they are wasted. This additional support means it is likely that SOC children in this study will receive care that is more adherent to current recommendations than is typical for many children. This enhanced SOC is necessary to ensure we are comparing the MAMMS-IYCF to current guidelines. The SMS messaging service will be free of cost to the caregivers as they will not incur any charges to send or receive messages while enrolled in the trial.
219677524|NCT04467983|DRUG|Denosumab Injection|Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
219677525|NCT04467983|DRUG|Abaloparatide|Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
219209605|NCT06867406|DRUG|KPC000154 30mg Tablet Intervention|KPC000154 30mg Tablet administered orally in the morning once daily for 1 day
219677526|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
219677527|NCT06954961|DRUG|D-0502|"* Dosage form: Tablet~* Administration route: Oral, once a day"
219677528|NCT06954961|DRUG|Fulvestrant|"* Dosage form: Injection~* Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose"
219677529|NCT00092963|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
219677530|NCT00092963|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
219677531|NCT04017715|OTHER|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
219073842|NCT00054353|PROCEDURE|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
219073843|NCT00054353|OTHER|laboratory biomarker analysis|Correlative studies
219073844|NCT04862793|DEVICE|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
219073845|NCT04862793|DEVICE|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
219073846|NCT02635880|DEVICE|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
219073847|NCT05256589|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
219073848|NCT00005076|BIOLOGICAL|cetuximab|
219073849|NCT00005076|DRUG|irinotecan hydrochloride|
219073850|NCT03438162|BEHAVIORAL|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
219073851|NCT03839953|BEHAVIORAL|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
219073852|NCT03839953|OTHER|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
219073853|NCT01988246|DRUG|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
219073854|NCT01988246|DRUG|Sham|Sham injection. No actual injection. No medication is used.
219073855|NCT04556708|OTHER|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
219073856|NCT04556708|OTHER|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
219073857|NCT04556708|OTHER|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
219209606|NCT06867406|DRUG|KPC000154 60mg Tablet Intervention|KPC000154 60mg Tablet administered orally in the morning once daily for 1 day
219209607|NCT06867406|DRUG|KPC000154 120mg Tablet Intervention|KPC000154 120mg Tablet administered orally in the morning once daily for 1 day
219209608|NCT06867406|DRUG|KPC000154 200mg Tablet Intervention|KPC000154 200mg Tablet administered orally in the morning once daily for 1 day
219209609|NCT06867406|DRUG|KPC000154 300mg Tablet Intervention|KPC000154 300mg Tablet administered orally in the morning once daily for 1 day
219073858|NCT03131518|BEHAVIORAL|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
219073859|NCT03131518|BEHAVIORAL|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
219073860|NCT03131518|BEHAVIORAL|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
219073861|NCT04053764|DRUG|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
219073862|NCT04053764|DRUG|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
219073863|NCT02935062|BEHAVIORAL|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
219209610|NCT06867406|DRUG|KPC000154 400mg Tablet Intervention|KPC000154 400mg Tablet administered orally in the morning once daily for 1 day
219677532|NCT04017715|OTHER|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
219073864|NCT02935062|BEHAVIORAL|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
219073865|NCT02935062|BEHAVIORAL|Placebo Therapy|No intervention to improve speech.
219073866|NCT01734681|DRUG|G-202|
219073867|NCT04657146|OTHER|Biorepository|"Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)"
219073868|NCT03872349|OTHER|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
219073869|NCT03872349|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
219073870|NCT05509296|DEVICE|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
219073871|NCT05509296|DEVICE|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
219073872|NCT02384954|BIOLOGICAL|Rituximab|Intravenous infusion 375 mg/m\^2.
219209611|NCT06867406|DRUG|KPC000154 80mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
219209612|NCT06867406|DRUG|KPC000154 120mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
219209613|NCT06867406|DRUG|KPC000154 40mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 120mg tablet administered orally in the morning for 14 days
219677533|NCT04017715|OTHER|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
219677534|NCT00003197|DIETARY_SUPPLEMENT|green tea extract|
219677535|NCT03374839|DRUG|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
219073873|NCT02384954|BIOLOGICAL|N-803|Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
219073874|NCT04291963|PROCEDURE|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
219073875|NCT04291963|PROCEDURE|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
219073876|NCT04732286|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
219073877|NCT04732286|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219073878|NCT00890955|DRUG|Amrubicin|"* Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
219073879|NCT00890955|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
219209614|NCT06867406|DRUG|Placebo-controlled（SAD）|A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.
219209615|NCT06867406|DRUG|Placebo-controlled（MAD）|A placebo used in a multiple-dose study where participants receive either the experimental drug or the placebo.
219209616|NCT06866249|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children. The test is designed to identify de"
219677536|NCT02422004|OTHER|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
219209617|NCT06866249|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|Test Of Sensory Functions In Infants (TSFI) provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old.
219209618|NCT06866249|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
219209619|NCT06862037|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication (LNF) is the most commonly performed anti-reflux surgery. LNF is performed in patients with GERD refractory to medication or those expected to require long-term medical treatment. During LNF, the fundus of the stomach is mobilized and wrapped 360 degrees around the lower esophagus to reinforce the lower esophageal sphincter (LES), preventing the reflux of gastric contents into the esophagus.
219209620|NCT06865547|BEHAVIORAL|The 4A ProActive Management Model|This model focuses on four key areas - Active Education, Active Prevention Strategies, Active Management, and Active Follow-up. Active Education involves providing patients with detailed information on treatment regimens, potential AEs, and self-care through verbal education, reminder cards, and direct counseling. Active Prevention Strategies aims to directly reduce risks through nursing care bundles that incorporate supportive medications, fall risk assessments, and dietary guidance. Active Management establishes robust protocols for early AE reporting, rapid treatment, and standardized order sets. Active Follow-up comprises additional outpatient visits, patient surveys, medication refill coordination, and pharmacist/nurse follow-up calls to closely monitor patient adherence and symptoms.
219209621|NCT02016924|DRUG|ATV|Capsules administered once daily according to dosing recommendations per product monograph
219073880|NCT03288662|OTHER|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
219209622|NCT02016924|DRUG|DRV|Tablets administered once daily according to dosing recommendations per product monograph
219209623|NCT02016924|DRUG|Cobicistat|Tablets administered orally once daily with food
219209624|NCT02016924|DRUG|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
219209625|NCT02016924|DRUG|F/TAF|Tablets administered orally once daily
219209626|NCT02016924|DRUG|LPV/r|Solution administered orally
219677537|NCT02422004|OTHER|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
219073881|NCT01557413|PROCEDURE|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
219073882|NCT01557413|PROCEDURE|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
219073883|NCT04027556|OTHER|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
219073884|NCT04027556|OTHER|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
219073885|NCT06344312|DRUG|Yangxue Qingnao Granules|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
219073886|NCT01474681|BIOLOGICAL|HSC835|
219073887|NCT05812651|OTHER|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
219073888|NCT00907829|DRUG|lidocaine|comparison of the effect of the drug to help improve finger function
219073889|NCT00907829|DEVICE|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
219209627|NCT02016924|DRUG|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
219209628|NCT02016924|DRUG|Cobicistat TOS|Tablets for oral suspension
219209629|NCT02016924|DRUG|F/TAF TOS|Tablets for oral suspension
219209630|NCT00673842|DEVICE|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)
219209631|NCT00673842|OTHER|Usual care|Usual post-MI care
219209632|NCT06811610|DIAGNOSTIC_TEST|Participants were tested for hearing using a new type of hearing detection device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
219209633|NCT06811610|DIAGNOSTIC_TEST|Participants' hearing was tested using a new portable pure tone audiometry device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
219209634|NCT05699408|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
219209635|NCT05699408|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
219209636|NCT05613894|DRUG|Cabozantinib|(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.
219209637|NCT05270525|DRUG|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
219677538|NCT02778022|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
219677539|NCT01684176|BEHAVIORAL|Complex tailored intervention|
219073890|NCT04656626|BEHAVIORAL|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
219073891|NCT04656626|BEHAVIORAL|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
219073892|NCT03359265|DEVICE|underpants|
219073893|NCT01850225|DEVICE|Auditory brainstem implant|
219073894|NCT02457039|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
219073895|NCT02457039|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
219073896|NCT02457039|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
219073897|NCT02457039|DRUG|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\]."
219073898|NCT04421781|OTHER|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
219073899|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
219073900|NCT01733056|BIOLOGICAL|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
219073901|NCT01408368|PROCEDURE|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
219677540|NCT01684176|BEHAVIORAL|Usual care|
219677541|NCT00328588|DRUG|YM155|IV
219677542|NCT04394702|OTHER|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
219677543|NCT04394702|OTHER|manual stainless steel K-file|sequential manual filing with stainless steel K-files
219677544|NCT03331263|DRUG|Chlorhexidine Gluconate|2% CHG
219677545|NCT03619655|PROCEDURE|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
219073902|NCT01408368|PROCEDURE|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
219073903|NCT01587664|DEVICE|NewBreez ILP|NewBreez ILP implantation
219073904|NCT04551170|DRUG|Theophylline|oral theophylline
219073905|NCT04551170|DRUG|Placebo|Placebo capsule or elixir
219073906|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
219073907|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
219073908|NCT01713413|DEVICE|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
219073909|NCT01713413|DEVICE|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
219073910|NCT03487835|OTHER|Kinesiotape|
219073911|NCT03487835|OTHER|No application|This group have no application during study time
219073912|NCT01126983|DEVICE|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
219073913|NCT01126983|DEVICE|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
219073914|NCT03699943|PROCEDURE|CaverStem|
219073915|NCT06963008|DRUG|inhaled BMD003(CFTR mRNA)|BMD003 is the world's first freeze-dried CFTR Mrna product (stored at 2-8 ℃), which is reconstituted with injection water before use, nebulized through a vibrating sieve atomizer, and inhaled into the lungs through the mouth and nose.
219073916|NCT00986167|DRUG|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
219073917|NCT05229289|OTHER|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
219073918|NCT05229289|OTHER|Fecal Microbiota Transplant|Fecal Microbiota Transplant
219073919|NCT02165150|OTHER|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
219677546|NCT03619655|DRUG|18F-DCFPyL PET/CT|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
219677547|NCT03619655|DRUG|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
219677548|NCT03619655|PROCEDURE|WB-MRI|Whole body MRI exam (total examination time \< 50 minutes)
219677549|NCT04485078|DIAGNOSTIC_TEST|Pressure pain threshold|The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
219073920|NCT06167187|PROCEDURE|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
219073921|NCT06167187|DRUG|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
219073922|NCT03719456|PROCEDURE|Retrograde Intrarenal Surgery|
219209638|NCT05270525|DRUG|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
219073923|NCT03095040|DRUG|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
219073924|NCT03095040|DRUG|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
219073925|NCT03095040|DRUG|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
219073926|NCT00604253|DRUG|insulin detemir|
219073927|NCT00604253|DRUG|insulin NPH|
219073928|NCT06110923|DRUG|CKD-846|once administration of Investigational Product
219073929|NCT06110923|DRUG|D091|once administration of Investigational Product per day
219677550|NCT04485078|DIAGNOSTIC_TEST|Temporal summation|TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
219677551|NCT04485078|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
219073930|NCT01968213|DRUG|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
219073931|NCT01968213|DRUG|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
219073932|NCT06496893|DIETARY_SUPPLEMENT|IP 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
219073933|NCT06496893|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
219073934|NCT01762046|DRUG|Glipizide|
219073935|NCT01762046|DRUG|Metformin|
219073936|NCT01762046|OTHER|Oral Glucose Tolerance Test|
219073937|NCT05381974|DRUG|Psilocybin|Open-Label
219073938|NCT03595904|BEHAVIORAL|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
219073939|NCT03595904|BEHAVIORAL|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
219073940|NCT03044301|COMBINATION_PRODUCT|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
219073941|NCT03044301|COMBINATION_PRODUCT|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
219073942|NCT03044301|COMBINATION_PRODUCT|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
219073943|NCT04303897|DEVICE|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
219073944|NCT00991354|BIOLOGICAL|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
219073945|NCT00991354|BIOLOGICAL|IL-12 DNA plasmids|Adjuvant for HIV vaccines
219073946|NCT03998787|OTHER|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
219073947|NCT04458948|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
219677552|NCT04485078|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
219073948|NCT04458948|DRUG|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
219073949|NCT02087163|DEVICE|Movement Enhancement Technique|Conventional Orthodontic treatment
219073950|NCT02087163|DEVICE|Clear Aligner|Orthodontic treatment with Clear Aligner
219073951|NCT05312775|PROCEDURE|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
219073952|NCT05312775|PROCEDURE|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
219073953|NCT03157713|BEHAVIORAL|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
219073954|NCT03157713|BEHAVIORAL|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
219677553|NCT04485078|OTHER|Bath Ankylosing Spondylitis Disease Activity Index|Standardized questionnaire to determine the level of disease activity in AxSpa patients
219677554|NCT04485078|OTHER|Ankylosing Spondylitis Quality of Life|Standardized questionnaire to investigate the quality of life in AxSpa patients
219677555|NCT04485078|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability
219677556|NCT04485078|OTHER|Beck Depression Inventory|Standardized questionnaire to investigate the depression
219677557|NCT04485078|OTHER|Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue
219677558|NCT04485078|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
219677559|NCT04485078|OTHER|Fibromyalgia Rapid Screening Tool|Standardized questionnaire to detect fibromyalgia
219677560|NCT04485078|OTHER|Visual analogue scale|global pain score on a 0 to 10
219677561|NCT01792765|OTHER|Ultrasound guidance|Patient will have intraoperative ultrasound .
219677562|NCT04214366|RADIATION|Carbon ion irradiation|22 x 3 Gy(RBE) Carbon Ions
219677563|NCT04214366|RADIATION|Bimodal irradiation|25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
219677564|NCT03639857|DEVICE|532nm laser|532nm laser will be used to treat the lesion in this study arm.
219677565|NCT03639857|DEVICE|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
219677566|NCT03639857|DRUG|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
219209639|NCT06748235|OTHER|Intensive Strength Training|Comprehensive Hand Repetitive Intensive Strength Training and Routine Physical Therapy 60 minutes per session, three sessions a week, at a total of 30 sessions per ten weeks. Comprehensive hand repetitive intensive strength training included treadmill training for the upper limb with body weight supporting the using upper limb. The posture of an arm swing was to maintain the joints of the elbows and wrist as much as possible, and the shoulder joint was allowed to be flexed by 160 degrees .The posture of the arm stance supported the weight using metacarpal heads, hands, and elbows, and the shoulder joints were allowed to be flexed by 90 degrees.
219209640|NCT06748235|OTHER|Routine Physical Therapy|Received 60 minutes per a session, three sessions a week, at a total of 30 sessions per 10 weeks by creating a home program, which consisted of a total of 8 exercises that enhanced the muscular strength of the upper limb including the triceps brachii and extensor carpi radialis, and conveyed an effect of reaching the muscles out. flexion and extension muscle strengthening with towel, hand grip and wrist extension muscle strengthening This exercise consisted of shoulder extension muscle, elbow flexion muscle, shoulder abduction muscle, and elbow extension muscle strengthening with a thera band, as well as hand grip, forearm with a velcro board, wrist extension muscle strengthening with sandbag and shoulder abduction-extension muscle strengthening with a thera band.
219677567|NCT02800369|BIOLOGICAL|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
219677568|NCT05603585|DIETARY_SUPPLEMENT|Optimal protein supplementation to achieve 80% protein adequacy.|Additional protein required and delivered by adding protein powder and given in bolus feeds
219677569|NCT01054495|DRUG|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
219677570|NCT01054495|DEVICE|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
219677571|NCT01054495|DEVICE|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
219677572|NCT06077162|OTHER|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
219677573|NCT06077162|OTHER|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
219677574|NCT05272553|OTHER|Narrative Exposure Therapy|NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
219677575|NCT02186158|DRUG|Vitamin C|
219677576|NCT02186158|DRUG|Placebo|
219677577|NCT01025284|DRUG|LY2523355|Administered intravenously as a 1-hour infusion
219677578|NCT01025284|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
219677579|NCT00905567|DRUG|Topiramate 2 x 25 mg tablet|
219677580|NCT00905567|DRUG|Topamax® Tablet 2 x 25 mg|
219677581|NCT03046771|BEHAVIORAL|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
219677582|NCT02542397|GENETIC|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
219677583|NCT04485663|DRUG|ALG-010133|Single or multiple doses of ALG-010133
219677584|NCT04485663|DRUG|Placebo|Single or multiple doses of Placebo
219677585|NCT01164150|RADIATION|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
219677586|NCT00389467|DEVICE|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
219677587|NCT05868681|DEVICE|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
219677588|NCT02133833|DEVICE|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
219073955|NCT03157713|BEHAVIORAL|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to \<2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to \<5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to \<5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
219073956|NCT04227782|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
219073957|NCT04227782|OTHER|Stable Isotope Study|Stable Isotope study
219073958|NCT04163302|BIOLOGICAL|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
219073959|NCT02429882|DRUG|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
219073960|NCT02429882|DRUG|Placebo|Placebo will be administered subcutaneously
219073961|NCT02797925|OTHER|Training|Long slow strength training of the tendon for 3 months to improve function
219073962|NCT04616157|BEHAVIORAL|ICBT-I|Cognitive-behavioral therapy for insomnia
219073963|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
219073964|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
219073965|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
219073966|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
219073967|NCT00868023|DRUG|Placebo|Placebo
219073968|NCT04520984|OTHER|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
219073969|NCT04520984|OTHER|Standard nephrology care|Standard nephrology care
219073970|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
219073971|NCT01899846|DRUG|Hydroxyprogesterone caproate 250 mg/ml|
219073972|NCT02101892|DRUG|Amitriptyline|per os, daily, evening
219073973|NCT02101892|DRUG|placebo|per os, daily, evening
219073974|NCT02469194|OTHER|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
219073975|NCT01968239|DRUG|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
219073976|NCT03882476|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for sepsis detection
219073977|NCT04210453|DRUG|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
219073978|NCT04210453|DRUG|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
219073979|NCT02039050|DRUG|Tiotropium|
219209641|NCT04908020|OTHER|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
219209642|NCT06642545|DRUG|Disitamab Vedotin|Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
219209643|NCT06642545|DRUG|RC148|20mg/kg, intravenous infusion, once every 2 weeks
219209644|NCT06642545|DRUG|Albumin-bound Paclitaxone|125 mg/m2,intravenous infusion, D1-8, every 3 weeks
219073980|NCT02039050|DRUG|Aclidinium|
219073981|NCT03580876|DRUG|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
219209645|NCT06642545|DRUG|Toripalimab|240mg,intravenous infusion, once every 3 weeks
219209646|NCT06763653|DEVICE|ULF therapy|ultra low frequency spinal cord stimulation
219209647|NCT06763653|OTHER|CMM|conventional medical management
219209648|NCT04739696|BEHAVIORAL|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
219209649|NCT04739696|BEHAVIORAL|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
219209650|NCT06692309|PROCEDURE|cardiovascular surgery|Heart bypass surgery; Heart valve replacement surgery
219209651|NCT07022704|DRUG|Doxapram|Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
219209652|NCT07023510|DIAGNOSTIC_TEST|AI-ECG driven echocardiography|The intervention utilizes a previously validated deep learning model based on 12-lead electrocardiogram (ECG) data to screen for moderate-to-severe valvular heart diseases (VHD). The model processes raw ECG signals and integrates age and sex to enhance prediction. (doi: 10.18632/aging.205835.) Participants identified as high-risk for any moderate-to-severe VHD by the algorithm of artificial intelligence-powered electrocardiogram (AI-ECG) in this intervention arm will receive transthoracic echocardiography to confirm diagnosis and guide further management.
219209653|NCT06696404|PROCEDURE|Combined Lumbar Plexus and Sacral Plexus Block|This intervention of Combined Lumbar Plexus and Sacral Plexus Block is assigned to Nerve block anesthesia group (NA group): A combined Lumbar Plexus Block (0.33% Ropivacaine 30ml) and Sacral Plexus Block (0.33% Ropivacaine 20ml) administered as a single injection.
219209654|NCT06696404|PROCEDURE|iliac fascial block|iliac fascial block administered as a single injection below the iliac fascial with 0.33% ropivacaine 30ml.
219209655|NCT06696404|PROCEDURE|spinal anesthesia|Spinal anesthesia was performed as a standard care of spinal anesthetic. The spinal puncture site is at L2-3 or L3-4. After the puncture needle reaches the subarachnoid space, 1% ropivacaine 0.8-2 ml, totaling 8-20mg, is injected. Depending on the center's practice, it may be replaced with an equivalent dose of bupivacaine .
219209656|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
219209657|NCT06699498|DRUG|Benmelstobart|1200mg, D1, IV,q3w
219209658|NCT06699498|DRUG|Anlotinib|10mg，D1-14，po，q3w
219209659|NCT06699498|DRUG|Cisplatin|60mg/m2， D1， IV，q3w
219209660|NCT06699498|DRUG|Paclitaxel for Injection （Albumin Bound）|260mg/m2，IVgtt ，D1，q3w
219209661|NCT04629599|BEHAVIORAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
219209662|NCT04629599|BEHAVIORAL|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
219209663|NCT06073431|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tumor samples
219209664|NCT06073431|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219209665|NCT06073431|OTHER|Electronic Medical Record|Review of medical record
219209666|NCT06073431|OTHER|Medical Device Usage and Evaluation|Wear actigraph
219209667|NCT06073431|OTHER|Physical Performance Testing|Undergo physical function tests
219209668|NCT06073431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219209669|NCT06073431|OTHER|Survey Administration|Complete surveys
219073982|NCT03580876|DRUG|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
219073983|NCT02081846|OTHER|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
219209670|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
219209671|NCT06711042|DIAGNOSTIC_TEST|functional tests and radiographic analysis|In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).
219677589|NCT04632459|DRUG|pembrolizumab plus ramucirumab|"Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles."
219073984|NCT02081846|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
219073985|NCT00680212|DIETARY_SUPPLEMENT|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
219073986|NCT00680212|DIETARY_SUPPLEMENT|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
219073987|NCT02657980|DEVICE|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219073988|NCT02657980|DEVICE|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219073989|NCT01211925|PROCEDURE|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
219073990|NCT01211925|DRUG|Aspirin|100 mg per day continuous
219073991|NCT03282227|DRUG|M207 Microneedle System|M207 Microneedle System 3.8 mg
219073992|NCT01952327|DEVICE|The pleurapump system|Implantation of the pleurapump system
219073993|NCT03850769|DRUG|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
219073994|NCT03782155|DRUG|glutamine supplementation|powder 14g
219073995|NCT03782155|DRUG|HMB|powder 3g
219073996|NCT03782155|DRUG|Placebo|powder 17g
219073997|NCT01390454|PROCEDURE|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
219073998|NCT01390454|PROCEDURE|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
219073999|NCT01390454|PROCEDURE|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
219074000|NCT04325750|PROCEDURE|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
219074001|NCT04325750|OTHER|Placebo|simulated TECAR Therapy (machine off)
219074002|NCT04019938|RADIATION|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
219074003|NCT06535048|DRUG|Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons|"Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks."
219074004|NCT04637412|OTHER|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
219074005|NCT04089033|PROCEDURE|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
219209672|NCT05233267|OTHER|Blood sample|Dosage of neopterin
219677590|NCT02022046|OTHER|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
219209673|NCT06878300|DEVICE|Over the counter hearing aid (Lexie)|The study will compare user perceptions of two over-the-counter (OTC) hearing aids, with the Lexie B3 Pro serving as the reference device. Participants will be fitted with each device for a predetermined period in a randomized order to ensure balanced exposure.
219209674|NCT06878300|DEVICE|Comparator over the counter hearing aid|The comparator OTC hearing aid will undergo the same evaluation process as the Lexie B3 Pro, ensuring an equivalent and unbiased comparison. Participants will be provided with the comparator device along with its standard user instructions, including any mobile applications or self-fitting guidance designed for independent setup.
219209675|NCT07038304|RADIATION|Metastasis directed radiotherapy|According to guidelines, in the case of oligoprogression next line systemic treatment is recommended. This study investigates the potential delay of NEST and rPFS by MDRT.
219209676|NCT07039097|PROCEDURE|Transcervical resection of septum|Transcervical resection of septum (TCRS) is divided into two categories: one is plasma hysteroscopic electrosurgical resection (actually TCIS), which uniformly uses a 7mm external diameter hysteroscopic electrosurgical resectoscope to reduce the difficulty of cervical dilation; the other is micro (5 or 7Fr) hysteroscopic cold knife incision, equipped with a 5Fr bipolar electrocoagulation stick for electrocoagulation and hemostasis.
219677591|NCT03999957|OTHER|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
219074006|NCT04089033|PROCEDURE|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
219074007|NCT02576678|DRUG|Apremilast|
219074008|NCT04582630|DIETARY_SUPPLEMENT|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
219074009|NCT03362905|DRUG|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
219074010|NCT03545854|PROCEDURE|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
219074011|NCT01926756|PROCEDURE|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
219074012|NCT01926756|PROCEDURE|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
219074013|NCT03600337|BEHAVIORAL|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
219074014|NCT05119959|OTHER|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
219074015|NCT05119959|OTHER|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
219074016|NCT02202473|DRUG|Lamivudine|
219074017|NCT02202473|DRUG|Lamivudine+Oxymatrine Capsules|
219074018|NCT00222651|DRUG|tenecteplase|
219074019|NCT04879914|DIETARY_SUPPLEMENT|Butyrate|3 cps/die 300 mg/cps
219677592|NCT06202703|DRUG|Pneumococcal Vaccine|vaccination with pneumococcal vaccine (PCV13)
219074020|NCT04879914|DIETARY_SUPPLEMENT|Placebo|3 cps/die 300 mg/cps
219074021|NCT03605095|DRUG|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
219677593|NCT04064203|OTHER|Oral glucose tolerance test|50 grams OGTT
219677594|NCT04064203|OTHER|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
219677595|NCT00000757|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219074022|NCT01158131|BEHAVIORAL|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
219074023|NCT00797654|BEHAVIORAL|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
219074024|NCT00797654|BEHAVIORAL|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
219074025|NCT06294301|BIOLOGICAL|LP-005 Dose 1 (Single)|A single dose of LP-005 (Dose 1) was administered intravenously.
219074026|NCT06294301|BIOLOGICAL|LP-005 Dose 2 (Single)|A single dose of LP-005 (Dose 2) was administered intravenously.
219074027|NCT06294301|BIOLOGICAL|LP-005 Dose 3 (Single)|A single dose of LP-005 (Dose 3) was administered intravenously.
219074028|NCT06294301|BIOLOGICAL|LP-005 Dose 4 (Single)|A single dose of LP-005 (Dose 4) was administered intravenously.
219074029|NCT06294301|BIOLOGICAL|LP-005 Dose 5 (Single)|A single dose of LP-005 (Dose 5) was administered intravenously.
219074030|NCT06294301|BIOLOGICAL|LP-005 Dose 6 (Single)|A single dose of LP-005 (Dose 6) was administered intravenously.
219074031|NCT06294301|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
219074032|NCT06294301|BIOLOGICAL|LP-005 Dose 7 (Multiple)|LP-005 (Dose 7) was administered multiple times intravenously.
219074033|NCT06294301|BIOLOGICAL|LP-005 Dose 8 (Multiple)|LP-005 (Dose 8) was administered multiple times intravenously.
219074034|NCT06294301|BIOLOGICAL|LP-005 Dose 9 (Multiple)|LP-005 (Dose 9) was administered multiple times intravenously.
219074035|NCT06294301|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times intravenously.
219074036|NCT00682734|DRUG|metoclopramide|metoclopramide 20 mg
219074037|NCT00682734|DRUG|metoclopramide|metoclopramide 40 mg
219074038|NCT00682734|DRUG|metoclopramide|metoclopramide 10 mg
219074039|NCT00682734|DRUG|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
219074040|NCT03310151|PROCEDURE|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
219074041|NCT05972096|BEHAVIORAL|Combination DBT, self-compassion and contextual-based skills|Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
219677596|NCT05216445|BEHAVIORAL|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
219074042|NCT02251990|DRUG|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
219074043|NCT02251990|DRUG|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
219074044|NCT01614665|DRUG|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
219074045|NCT01614665|DRUG|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
219074046|NCT05461625|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction
219074047|NCT05461625|OTHER|ALL anatomic|anatomic anterolateral ligament reconstruction
219074048|NCT05461625|OTHER|ALL tenodesis|anterolateral ligament teondesis
219074049|NCT01538381|DRUG|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
219074050|NCT01538381|OTHER|Observation|Observation
219074051|NCT04872764|OTHER|duration of hospitalization, mortality rate|duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
219074052|NCT05131048|OTHER|conventional group|this group will perform conventional therapy
219074053|NCT05131048|OTHER|experimental group|this group will perform home based exercises
219074054|NCT02368249|DRUG|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
219074055|NCT02368249|DRUG|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
219074056|NCT02558010|DRUG|Methadone|Perioperative IV methadone to be given
219074057|NCT02558010|OTHER|Normal Saline|control arm
219074058|NCT02558010|DRUG|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
219677597|NCT04464967|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
219074059|NCT05949762|PROCEDURE|Venetoclax in Combination With Azacitidine and HA Regimen|"Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
219074060|NCT04282135|DIAGNOSTIC_TEST|MCC IMS|Diagnosis by MCC IMS
219074061|NCT05774964|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
219074062|NCT05774964|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
219074063|NCT05774964|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
219074064|NCT05774964|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
219074065|NCT05774964|DRUG|Vitamin A|Vitamin A 5,000 units/time, qd
219074066|NCT05774964|DRUG|Folic acid|Folic acid 5 mg/time, qd
219074067|NCT00576069|DRUG|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
219074068|NCT00576069|DRUG|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
219677598|NCT04464967|DRUG|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
219677599|NCT04464967|DRUG|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
219677600|NCT02224612|DEVICE|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
219677601|NCT02224612|DEVICE|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
219677602|NCT05177640|DRUG|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
219677603|NCT02630563|DRUG|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
219677604|NCT02630563|DRUG|Cyclosporine|Cyclosporine will be administered as per center practice.
219677605|NCT02630563|DRUG|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
219677606|NCT04812184|DEVICE|Tape Face Mask|Adding tape to face mask
219677607|NCT02829658|BEHAVIORAL|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
219677608|NCT02829658|OTHER|No intervention|No intervention
219677609|NCT03575247|DRUG|Glucocorticoids|Long-term use of glucocorticoids
219074069|NCT00576069|DRUG|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
219074070|NCT00576069|DRUG|Prednisone|0-15 mg daily as needed
219074071|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
219074072|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
219074073|NCT00739349|DRUG|vehicle/placebo|vehicle/placebo
219074074|NCT05984953|DRUG|statin|40 mg of rosuvastatin daily for 8-12 weeks
219074075|NCT05984953|DRUG|evolocumab|140 mg evolocumab every 2 weeks (26 weeks)
219074076|NCT05475951|DIAGNOSTIC_TEST|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
219074077|NCT02698072|OTHER|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
219074078|NCT02698072|DEVICE|Dry needling|Dry needling needle AGUPUNT®
219074079|NCT02698072|DEVICE|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
219074080|NCT02218567|BEHAVIORAL|questionnaire qualilty of life|
219074081|NCT02218567|BEHAVIORAL|psychological interview|
219074082|NCT02218567|BEHAVIORAL|psychological tests|
219074083|NCT02218567|OTHER|Motor evaluation|
219074084|NCT02218567|BEHAVIORAL|Behavioral evaluation|
219074085|NCT02218567|BEHAVIORAL|cognitive tests|
219074086|NCT00856050|DRUG|letrozole|Taken orally once a day continuously
219074087|NCT02697253|DRUG|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
219074088|NCT02697253|DRUG|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
219074089|NCT00965432|DRUG|STX107|Single dose of an oral suspension
219074090|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
219074091|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
219074092|NCT00295750|DRUG|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
219074093|NCT00430768|BIOLOGICAL|rAAV1-CB-hAAT|
219074094|NCT05447117|PROCEDURE|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
219677610|NCT00621257|DIETARY_SUPPLEMENT|ergocalciferol|8000 units/ml
219677611|NCT00621257|DIETARY_SUPPLEMENT|Cholecalciferol|400 units per drop
219677612|NCT03419117|PROCEDURE|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
219677613|NCT03419117|PROCEDURE|Placebo|A sham ESP block will be performed before surgery in the placebo group
219677614|NCT01013714|PROCEDURE|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
219677615|NCT01013714|DRUG|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
219677616|NCT01255904|DRUG|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
219074095|NCT01566045|PROCEDURE|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
219074096|NCT01566045|PROCEDURE|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
219677617|NCT01255904|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
219677618|NCT01255904|OTHER|Oral placebo|Oral saline administered
219677619|NCT01255904|OTHER|Intranasal placebo|Intranasal saline administered
219677620|NCT06004271|OTHER|exercise|"Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching"
219677621|NCT06004271|OTHER|exercise and taping|When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
219677622|NCT06004271|OTHER|placebo|In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
219677623|NCT03607877|BEHAVIORAL|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
219677624|NCT03607877|BEHAVIORAL|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
219074097|NCT05323318|OTHER|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
219074098|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
219074099|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
219074100|NCT02439710|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
219074101|NCT01289912|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
219074102|NCT01289912|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
219074103|NCT00620841|OTHER|genotyping|Restriction fragment lenght polymorphisms
219074104|NCT03753165|OTHER|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
219074105|NCT00398008|DRUG|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
219074106|NCT00398008|DRUG|Naltrexone|Opioid antagonist medication to treat opiate dependence
219074107|NCT00398008|BEHAVIORAL|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
219677625|NCT03607877|BEHAVIORAL|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
219677626|NCT05006456|DEVICE|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
219677627|NCT02061813|DRUG|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
219074108|NCT01683864|DRUG|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
219074109|NCT00867217|DIETARY_SUPPLEMENT|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
219074110|NCT00867217|DIETARY_SUPPLEMENT|Placebo|Placebo comparator
219074111|NCT00867217|DIETARY_SUPPLEMENT|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
219074112|NCT00867217|DRUG|Letrozole 2.5mg|All subjects received letrozole as standard of care.
219074113|NCT03549650|DRUG|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
219677628|NCT02061813|DRUG|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
219677629|NCT02061813|DRUG|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
219074114|NCT03549650|DRUG|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
219074115|NCT04298138|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
219677630|NCT02061813|DRUG|Placebo|
219677631|NCT03002545|DIETARY_SUPPLEMENT|Magnesium citrate|
219677632|NCT03002545|DIETARY_SUPPLEMENT|Placebo|
219677633|NCT05048043|BEHAVIORAL|Computer-assisted Behavior Intervention|"The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands."
219677634|NCT05048043|BEHAVIORAL|Challenging Horizons Program|The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
219677635|NCT02427854|BEHAVIORAL|Education by animated training video|Training performed by watching an animated educational video.
219677636|NCT02427854|PROCEDURE|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
219677637|NCT00350077|DRUG|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
219677638|NCT00350077|DRUG|Vitamin C|IV vitamin C
219677639|NCT01156688|DRUG|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
219677640|NCT01156688|DRUG|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
219677641|NCT03783377|DRUG|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
219677642|NCT03783377|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
219677643|NCT00264485|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
219677644|NCT02992860|DRUG|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by \> 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
219677645|NCT02992860|PROCEDURE|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
219677646|NCT02992860|OTHER|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
219677647|NCT02992860|OTHER|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
219677648|NCT02992860|PROCEDURE|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
219677649|NCT02992860|GENETIC|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
219677650|NCT02992860|PROCEDURE|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
219677651|NCT02992860|PROCEDURE|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
219677652|NCT02992860|PROCEDURE|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
219074116|NCT03335462|OTHER|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
219677653|NCT00452660|DRUG|Exjade|
219677654|NCT05763914|BEHAVIORAL|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
219677655|NCT05763914|BEHAVIORAL|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
219677656|NCT05763914|BEHAVIORAL|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
219074117|NCT03335462|OTHER|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
219677657|NCT05763914|BEHAVIORAL|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
219677658|NCT05763914|BEHAVIORAL|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
219677659|NCT05763914|BEHAVIORAL|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
219677660|NCT00558012|DRUG|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
219677661|NCT00558012|DIETARY_SUPPLEMENT|Vitamin D 800 IU/daily|Daily divided dose
219677662|NCT00558012|DIETARY_SUPPLEMENT|Calcium 1200 mg/daily|supplement plus diet
219677663|NCT05470244|OTHER|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
219677664|NCT05470244|OTHER|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
219677665|NCT02431312|BIOLOGICAL|INO-1800|INO-1800 delivered by EP
219677666|NCT02431312|BIOLOGICAL|INO-9112|INO-9112 delivered by EP
219677667|NCT02431312|DRUG|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
219677668|NCT00496158|DRUG|Clevudine|
219677669|NCT00496158|DRUG|Adefovir|
219677670|NCT01705080|DEVICE|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
219677671|NCT04846270|DEVICE|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
219677672|NCT00206427|DRUG|GW572016|Lapatinib, 500 mg
219677673|NCT00206427|DRUG|lapatinib|Lapatinib 500 mg PO
219677674|NCT00003843|DRUG|irinotecan hydrochloride|
219677675|NCT00003843|GENETIC|mutation analysis|
219677676|NCT00003843|GENETIC|polymorphism analysis|
219677677|NCT02791529|PROCEDURE|Electrocautery|Skin incision performed by electrocautery
219677678|NCT02791529|PROCEDURE|Scalpel|Skin incision performed by scalpel
219677679|NCT01999985|DRUG|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
219677680|NCT01999985|DRUG|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
219677681|NCT01999985|DRUG|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
219677682|NCT01999985|DRUG|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
219677683|NCT03784391|DRUG|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
219677684|NCT06366646|OTHER|Competency-based intervention|90 head nurses and their assistants received the competency-based intervention program
219074118|NCT05224414|BEHAVIORAL|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
219074119|NCT05224414|BEHAVIORAL|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
219074120|NCT04060394|DRUG|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
219677685|NCT00828061|DRUG|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
219677686|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
219677687|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
219677688|NCT01824888|DRUG|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
219677689|NCT01824888|DRUG|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
219677690|NCT01400906|DRUG|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
219677691|NCT01400906|DRUG|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
219677692|NCT01400906|DRUG|lactose powder|lactose powder in dry powder device : placebo comparator
219677693|NCT03130959|BIOLOGICAL|Nivolumab|Specified dose on specified days
219677694|NCT03130959|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219677695|NCT02418793|DRUG|MOD-5014|Long Acting Factor VIIa
219677696|NCT04013295|OTHER|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
219677697|NCT01019460|PROCEDURE|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
219677698|NCT00437060|PROCEDURE|Cognitive Assessment|Ancillary studies
219677699|NCT00437060|PROCEDURE|Diffusion Tensor Imaging|Correlative studies
219677700|NCT00437060|OTHER|Laboratory Biomarker Analysis|Correlative studies
219677701|NCT00437060|OTHER|Pharmacological Study|Correlative studies
219677702|NCT00437060|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
219677703|NCT04053907|OTHER|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
219677704|NCT04053907|OTHER|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
219677705|NCT04053907|OTHER|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
219677706|NCT04053907|OTHER|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
219677707|NCT03601156|DEVICE|intraarterial chemoembolization|
219677708|NCT03601156|DEVICE|intravenous chemotherapy|
219677709|NCT06465771|BEHAVIORAL|Youth-led NCD risk reduction intervention|With the help of Youth (students of grades 9 and 10), their parents and other stakeholders, including teachers, headteachers, and canteen staff through qualitative interviews, we will develop an intervention focuses on NCD risk reduction among younger peers (students of grades 5 and 6). A nutritionist will train the youth on how to deliver the intervention among their younger peers.
219677710|NCT01960062|DEVICE|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
219677711|NCT01168609|PROCEDURE|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
219074121|NCT02964845|BEHAVIORAL|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
219074122|NCT02964845|OTHER|Enhanced Treatment as Usual|Linkage to Primary care.
219074123|NCT01047839|BIOLOGICAL|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
219074124|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
219074125|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
219074126|NCT06175065|DRUG|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
219074127|NCT06175065|DRUG|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
219074128|NCT06437769|OTHER|reiki|effect of reiki application to women who have been hospitalized by ceserean during the hospitlalization process on anxiety depression comfort and breastfeesing
219074129|NCT05414682|OTHER|MIND+SOUL Diet|The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
219074130|NCT01857531|DRUG|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
219677712|NCT02384538|BIOLOGICAL|ABT-981|ABT-981 administered by subcutaneous injection
219677713|NCT02384538|BIOLOGICAL|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
219677714|NCT01023347|DRUG|Paclitaxel (Genexol®)|
219677715|NCT01023347|DRUG|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
219677716|NCT03457324|DRUG|JCM-16021|This prescription with seven ingredients.
219677717|NCT03457324|DRUG|Placebo|Placebo
219677718|NCT02103023|DRUG|Imiquimod ointment|5% 250mg imiquimod ointment
219074131|NCT01857531|DRUG|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
219074132|NCT06966388|DRUG|Azelaic Acid|A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.
219074133|NCT05054023|DRUG|Soulagel®|topic gel
219074134|NCT05054023|DRUG|Arthrosyl®|topic gel
219074135|NCT02089672|DEVICE|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
219074136|NCT04987515|PROCEDURE|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
219074137|NCT06101199|OTHER|Acute Intermittent Hypercapnic Hypoxia|15 x \[1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia\];
219074138|NCT06101199|OTHER|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of \~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
219677719|NCT02103023|DRUG|Aqueous cream|aqueous cream
219677720|NCT02103023|BIOLOGICAL|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
219677721|NCT02103023|BIOLOGICAL|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
219677722|NCT01349530|OTHER|Evaluating of usual care|RESEARCH IN CURRENT CARE
219677723|NCT01349530|OTHER|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
219074139|NCT06101199|OTHER|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
219074140|NCT06101199|OTHER|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
219074141|NCT06495684|DEVICE|Anodal tDCS + Social Learning|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
219074142|NCT06495684|BEHAVIORAL|Placebo Anodal tDCS + Social Learning|Social learning tasks are completed on a computer and consist of viewing video modeling of social interactions, facial emotion detection practice, and videos for emotion and empathy learning.
219074143|NCT06961695|BEHAVIORAL|VR Mindfulness-Based Relaxation|"VR Mindfulness-Based Relaxation is a behavioral intervention that utilizes a VR application designed to reduce anxiety and promote relaxation. Participants in the experimental group will undergo a single VR session, scheduled on the day of hospital admission (one day prior to surgery).~The session lasts approximately 10 minutes and features an immersive beach environment combined with an audio-guided mindfulness exercise focused on breath awareness. Following the session, participants will engage in a brief, structured debriefing, during which they will reflect on what they felt, what they discovered, and how they can apply these insights during their hospital stay.~Participants will also be instructed to practice the 4-1-4 breathing technique three times per day during hospitalization. This technique involves inhaling for 4 seconds, holding the breath for 1 second, and exhaling for 4 seconds. It is intended to promote relaxation and support autonomic nervous system regulation."
219074144|NCT05784350|DRUG|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
219074145|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
219074146|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
219074147|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks.
219074148|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks.
219074149|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks.
219074150|NCT01785238|OTHER|renal echography|renal echography to analyse the kidney
219074151|NCT01785238|OTHER|Blood sampling|Blood sampling to analyse different parameters of renal function
219074152|NCT01785238|OTHER|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
219074153|NCT01785238|OTHER|Blood pressure measurement|
219074154|NCT05744687|DRUG|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
219074155|NCT05744687|DRUG|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
219074156|NCT00026273|DRUG|FOLFIRI regimen|
219074157|NCT00026273|DRUG|fluorouracil|
219074158|NCT00026273|DRUG|irinotecan hydrochloride|
219074159|NCT00026273|DRUG|leucovorin calcium|
219074160|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
219074161|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
219074162|NCT02672046|OTHER|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
219074163|NCT00035126|DRUG|epothilone b|
219074164|NCT05427279|DIETARY_SUPPLEMENT|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
219074165|NCT05427279|DIETARY_SUPPLEMENT|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
219074166|NCT05427279|DIETARY_SUPPLEMENT|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
219074167|NCT05427279|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
219074168|NCT06372275|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts related to physical activity once a day over four weeks.
219074169|NCT06372275|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the control group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to physical activity.
219074170|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
219074171|NCT02863640|DEVICE|Color retinography|
219074172|NCT02863640|DEVICE|Optical coherence tomography|
219074173|NCT02863640|DEVICE|Fundus autofluorescence imaging|
219074174|NCT00008853|BIOLOGICAL|GBS III-TT-SSI|
219074175|NCT00008853|BIOLOGICAL|GBS III-TT-MPHL|
219074176|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
219074177|NCT03143218|BIOLOGICAL|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
219074178|NCT03143218|BIOLOGICAL|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
219677724|NCT02872909|DEVICE|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
219677725|NCT02916953|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
219677726|NCT00179764|PROCEDURE|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
219677727|NCT00179764|PROCEDURE|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
219677728|NCT00179764|RADIATION|Central Nervous System (CNS) prophylaxis radiation|"* Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
219677729|NCT05689853|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
218983414|NCT02806245|OTHER|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
218983415|NCT04794309|OTHER|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
218983416|NCT04794309|DIETARY_SUPPLEMENT|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
218983417|NCT00731068|BIOLOGICAL|PRGF|injection of 6cc into injured area of tendon
218983418|NCT00731068|BIOLOGICAL|placebo|injection of 6 cc of saline into injured area
218983419|NCT03074955|DEVICE|leg wrapping with tension|"1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages."
218983420|NCT03074955|PROCEDURE|Trendelenburg position|"1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position"
218983421|NCT03074955|DEVICE|leg wrapping without tension|"1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages"
218983422|NCT03074955|PROCEDURE|supine position|1.maintain supine position
218983423|NCT04337801|OTHER|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
218983424|NCT04337801|OTHER|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
218983425|NCT05825339|DIAGNOSTIC_TEST|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
218983426|NCT02430623|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
218983427|NCT02430623|DEVICE|NanoKnife|
218983428|NCT05456269|DRUG|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
218983429|NCT05456269|DRUG|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
218983430|NCT05456269|DRUG|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
218983431|NCT05456269|DRUG|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
218983432|NCT01676571|DRUG|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
218983433|NCT05562414|BEHAVIORAL|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
218983434|NCT05562414|BEHAVIORAL|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
218983435|NCT01101880|BIOLOGICAL|filgrastim|Given SC
218983436|NCT01101880|DRUG|clofarabine|Given IV
218983437|NCT01101880|DRUG|cytarabine|Given IV
218983438|NCT02343679|DRUG|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
219074179|NCT03143218|DRUG|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
219074180|NCT03143218|DRUG|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
219074181|NCT00889213|PROCEDURE|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
219074182|NCT00889213|PROCEDURE|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
219074183|NCT02920905|DRUG|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
219074184|NCT02920905|DRUG|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
219074185|NCT02920905|DRUG|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
219074186|NCT06361082|PROCEDURE|ACL reconstruction|ACL reconstruction
219074187|NCT03690505|BEHAVIORAL|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
219074188|NCT00472095|OTHER|Fotonovela|
219074189|NCT00472095|OTHER|Placebo Fotonovela|
219209677|NCT07038408|PROCEDURE|Angioplasty with DCB (bail-out BRS)|"Angioplasty starts with lesion preparation in both arms with a PTCA balloon catheter.~The lesion is treated with the Mozec SEB through femoral or brachial artery. The DCB should be delivered to the target lesion within 120 seconds of insertion into the guide catheter. Under fluoroscopic visualization, the DCB is inflated at least 30 seconds (single inflation). If the results are insufficient, multiple inflation is permitted. If despite appropriate delivery and inflation of the DCB, the results remain insufficient bail-out BRS should be performed.~Bail-out BRS is performed through femoral or brachial artery. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, Optical Coherence Tomography (OCT) is performed, if available."
219074190|NCT03177304|OTHER|Web based IPT Training|
219074191|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
219074192|NCT04475744|DRUG|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
219074193|NCT04475744|PROCEDURE|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
219074194|NCT03081455|DIAGNOSTIC_TEST|Diagnostic Test|Genetic Diagnostic Testing
219074195|NCT02293187|DIETARY_SUPPLEMENT|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
219209678|NCT07038408|PROCEDURE|Angioplasty with BRS|Bail-out BRS is performed through femoral or brachial artery. BRS implantation is guided by OCT, if available. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, OCT is performed, if available.
219209679|NCT07039357|DEVICE|Near-infrared (spectroscopy) for non-invasive assessment of glycated keratin of nail|both interventions will be applied in both participant groups
219074196|NCT02293187|OTHER|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
219677730|NCT05689853|DRUG|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
219074197|NCT01752504|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
219074198|NCT04158947|DRUG|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
219074199|NCT04158947|DRUG|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
219074200|NCT01233791|DRUG|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
219074201|NCT01233791|DRUG|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
219074202|NCT05867446|BEHAVIORAL|pecha kucha|pecha kucha training
219074203|NCT04604587|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
219074204|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
219677731|NCT03259152|DRUG|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
219677732|NCT02617498|DEVICE|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
219677733|NCT02617498|DEVICE|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
219677734|NCT01014052|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
219677735|NCT04215796|DEVICE|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
219677736|NCT02966717|DRUG|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
219677737|NCT02966717|DRUG|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
219677738|NCT02966717|DRUG|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
219677739|NCT05971264|DIAGNOSTIC_TEST|Near infrared-spectroscopy|Comparison of regional intestinal oxygen saturation (measured with near infrared-spectroscopy) and indirect intraabdominal pressure measurement (bladder pressure) in muscle-relaxed, sedated patients compared to awake, non-sedated patients.
219677740|NCT04806321|OTHER|Project SOLVE|This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
219677741|NCT04806321|OTHER|Project SUCCESS|This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
219677742|NCT06479408|OTHER|progressive muscle relaxation (PMR) technique and vestibular rehabilitation exercises|A will be treated by progressive muscle relaxation (PMR) technique as a mean of stress relaxation and vestibular rehabilitation exercises for postural stability through Swiss ball, BOSU ball, balance board etc. Other components of vestibular rehab including gaze stability enhancement, improvement in vertigo and activities of daily living will also be focused.
219074205|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
219074206|NCT00744653|PROCEDURE|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
219074207|NCT04730297|DRUG|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
219074208|NCT04730297|DRUG|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
219074209|NCT04730297|DRUG|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
219074210|NCT01316926|DRUG|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
219074211|NCT01316926|DRUG|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
219074212|NCT03871647|DRUG|Beta blocker|perioperative beta blockers
219074213|NCT02696148|DRUG|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
219074214|NCT02696148|DRUG|placebo|For subcutaneous (s.c., under the skin) injection once daily.
219074215|NCT04764396|COMBINATION_PRODUCT|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
219677743|NCT06479408|OTHER|virtual reality (VR)|virtual reality (VR) based intervention program where three dimensional-3D environments will be used reduce stress and improve balance. A Simulator Sickness Questionnaire (SSQ) will be filled by participants before and after each session of VR to discriminate whether VR is provoking the symptoms or not.
219209680|NCT07039903|BEHAVIORAL|Cognitive behavioral therapy (CBT) + Functional Remediation (FR)|VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).
219209681|NCT07038044|DIETARY_SUPPLEMENT|Arginine-restricted diet|"Targeted Arginine Metabolism: The intervention zeroes in on arginine metabolism. As solid tumors often have arginine synthesis flaws and rely on external arginine, dietary restriction of arginine is a novel approach.~Dietary Intervention: The -Arg liquid diet in this study is precisely defined. Dosage is determined by patient weight, following 30 kcal/kg/day for energy and 1.5 g/kg/day for protein. A low - arginine food list is provided.~Study Design and Endpoints: It's a Phase I single - arm study. Its main goal is to evaluate the safety and tolerance of the combined treatment. Secondary and exploratory endpoints cover efficacy, nutritional state, and immune status."
219677744|NCT04252963|DRUG|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
219677745|NCT04252963|DRUG|Placebo|Placebo of MUCOLASE tablet
219074216|NCT04764396|DRUG|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
219074217|NCT05020223|OTHER|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
219074218|NCT05679492|BIOLOGICAL|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
219074219|NCT05679492|OTHER|Normal saline|Normal saline
219074220|NCT02115958|BIOLOGICAL|cancer stem cell vaccine|
219074221|NCT00074035|DRUG|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
219209682|NCT07038863|DIAGNOSTIC_TEST|Community screening for hepatitis B, C and delta in the Mongolian population living in France|"Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities.~During this screening visit, Rapid Diagnostic Orientation Test (RDOT) will be carried out to screen for HBV and HCV. If the RDOT is negative for both viruses, an information on transmission and prevention of viral infection will be given.~If the RDOT is positive, confirmation of these tests by blood sampling will be organized and complementary biology (ASAT, ALAT, GGT, PAL, bilirubin total, bilirubin conjugated). If HBV RDOT positive, additional tubes will be collected for centralized analysis at the end of the study (VHD DNA, VHD genotyping, fibrotest and LCR1/2 test).~Once these confirmatory tests have been carried out, the patient will be referred to a hepatology consultation."
219209683|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Gluten-containing shake vs gluten-containing cookie
219209684|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Half of participants will receive gluten-containing shake first, then gluten-containing cookie next, and vice versa
219074222|NCT00223418|DRUG|aripiprazole|
219074223|NCT00383448|DRUG|Clofarabine|days -7 through -3: 40 mg/m\^2 intravenously over 2 hours
219074224|NCT00383448|PROCEDURE|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
219074225|NCT00383448|DRUG|Melphalan|day -2: 140 mg/m\^2 intravenously over 30 minutes
219074226|NCT00383448|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
219074227|NCT00383448|DRUG|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
219074228|NCT00383448|DRUG|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR\<25 mL/minute corrected)
219074229|NCT00383448|DEVICE|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
219074230|NCT00383448|DRUG|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
219209685|NCT07038317|OTHER|Intervention|Intervention involves e-cigarette education messages tailored to participants' vaping status that will be sent out in SMS via text messaging three times per week over the course of 6 months.
219209686|NCT07038317|OTHER|Control|Participants will receive non-tobacco messages (messages about sun safety) three times per week over the course of 6 months.
219677746|NCT05149547|DIAGNOSTIC_TEST|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
219677747|NCT03756597|DEVICE|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
219677748|NCT03756597|DEVICE|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
219677749|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
219677750|NCT01075919|DIETARY_SUPPLEMENT|Placebo|1 g olive oil taken daily for 12 weeks
219677751|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
219074231|NCT00874861|BIOLOGICAL|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
219677752|NCT05206383|BEHAVIORAL|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
219677753|NCT05206383|BEHAVIORAL|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
219074232|NCT01257867|DIETARY_SUPPLEMENT|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
219074233|NCT01257867|DIETARY_SUPPLEMENT|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
219074234|NCT04654416|DRUG|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
219074235|NCT01943201|DEVICE|new bedsheet|sleeping 5 nights on the new bedsheet
219074236|NCT01943201|DEVICE|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
219074237|NCT00765193|OTHER|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
219074238|NCT00149253|DRUG|a single-dose of Etoricoxib before induction of anesthesia|
219074239|NCT04241861|OTHER|Respiratory support (High-flow oxygen therapy)|Noninvasive respiratory support respiratory support
219074240|NCT04241861|OTHER|Respiratory support (Helmet PSV)|Noninvasive respiratory support respiratory support
219074241|NCT04241861|OTHER|Respiratory support (Helmet CPAP)|Noninvasive respiratory support respiratory support
219074242|NCT01535716|BEHAVIORAL|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia"
219074243|NCT01535716|BEHAVIORAL|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia"
219074244|NCT01864564|OTHER|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
219074245|NCT05186623|DRUG|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
219209687|NCT07038018|DIAGNOSTIC_TEST|AI-ECG Algorithm|AI-ECG Algorithm to detect LVEF\<=40%
219209688|NCT07039513|OTHER|Blood sampling collection|Collection of an additional of 2.7mL citrate tube of blood for a D-dimer dosage.
219209689|NCT07038993|OTHER|Venous Pressure Monitoring|Measurement of venous pressure will be taken at dialysis machine pump speed set at 200ml/min, fistula needle gauge 16.
219677754|NCT05206383|BEHAVIORAL|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
219677755|NCT03124498|BIOLOGICAL|CIK Cell|Autologous cytokine-induced killer (CIK) cell
219074246|NCT04706468|DRUG|TG-1000|Capsules taken orally
219074247|NCT00105326|DRUG|paliperidone ER|
219074248|NCT02156713|BEHAVIORAL|CIMT Camp|
219074249|NCT02491008|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
219074250|NCT02491008|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
219209690|NCT07038993|OTHER|Color Doppler Ultrasound|Arteriovenous fistula (AVF) Access flow (QA) will be obtained using color Doppler ultrasound using the Mindray-M5 ultrasound system. AVF feeding arterial flow will be measured immediately proximal to the fistula. The QA volume will be obtained using the algorithm available on the system, which is based on the mean flow of two measurements.
219209691|NCT07038265|BEHAVIORAL|Personalised treatment|Patients going through a personalized intervention program
219209692|NCT07038265|OTHER|Usual Care|Usual cardiac rehabilitation program
219209693|NCT07038070|DRUG|Vaginal estrogen tablet|The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.
219677756|NCT03283332|OTHER|No intervention|
219677757|NCT06955039|OTHER|Sand Activites|Exercises included walking, jogging, striding, bounding, galloping, and short sprints.Exercise intensity (running speed) was controlled using a stopwatch and predefined running distances on the sand-based exercise court.
219209694|NCT07038070|DEVICE|Via Solv Wellness (Hyaluronic Acid Therapy)|The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.
219074251|NCT02065531|OTHER|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
219074252|NCT02065531|OTHER|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
219074253|NCT03077724|DRUG|Fish oil|Fish oil supplementation
219074254|NCT03077724|DRUG|Placebos|Olive Oil capsules
219074255|NCT01774565|DEVICE|Fully Automated Closed-Loop Insulin Delivery|
219209695|NCT07037888|DRUG|Ketorolac|IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0
219209696|NCT07037888|DRUG|Control (Standard treatment)|hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets
219209697|NCT07037888|DRUG|Control (Standard treatment)|indomethacin 75mg 1 tablet QD to start on POD0 10 tablets
219209698|NCT07037888|DRUG|Control (Standard treatment)|diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets
219209699|NCT07037888|DRUG|Omeprazole|20 mg qd
219209700|NCT07038889|DEVICE|C-Mill VR+ by Motek|Participants perform treadmill-assisted walking while interacting with non-immersive, game-like environments displayed on screens attached to the treadmill.
219209701|NCT07038889|DEVICE|Walk-over-Ground|This intervention utilizes the HTC VIVE Pro 2 system for a realistic, fully immersive VR-assisted overground gait therapy. The immersive VR environment is designed to mimic real-world scenarios and challenges, enhancing the rehabilitation process by engaging patients in naturalistic gait activities.
219209702|NCT07038148|PROCEDURE|Stapled reversal of gastric bypass to sleeve gastrectomy utilising stapling technique.|This research entails a single-stage laparoscopic conversion of gastric bypass to sleeve gastrectomy. The procedure entails the closure of the gastrojejunostomy with an endo-stapler and the reconstruction of the stomach by resecting along the greater curvature to create a sleeve gastrectomy. An intraoperative leak test will be conducted using methylene blue. Patients are monitored postoperatively for at least 24 hours, with subsequent assessments of nutritional status, weight, gastroesophageal reflux disease (GERD) symptoms, and quality of life at 3 and 6 months.
219209703|NCT07038629|DRUG|S1|PO, 40\~60mg，BID（d1-14，d22-35，two cycles)
219209704|NCT07038629|DRUG|Iparomlimab|IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)
219677758|NCT06955039|OTHER|Towel Curl Exercises|The experimental group will perform Towel Curl Exercises Sand .In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
219074256|NCT01774565|DEVICE|Conventional insulin therapy|
219074257|NCT02269670|DRUG|everolimus|Given PO
219074258|NCT02269670|DRUG|anastrozole|Given PO
219074259|NCT02269670|DRUG|letrozole|Given PO
219074260|NCT02269670|DRUG|tamoxifen citrate|Given PO
219074261|NCT02269670|DRUG|fulvestrant|Given IM or PO
219074262|NCT02269670|DRUG|megestrol acetate|Given PO
219074263|NCT05041673|DRUG|Metformin|Antidiabetic drugs
219074264|NCT00895401|DIETARY_SUPPLEMENT|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
219074265|NCT00895401|OTHER|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
219074266|NCT00789087|PROCEDURE|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
219209705|NCT07038629|RADIATION|Radiation|Concurrent Radiation, 1.8Gy/f, 28f;
219209706|NCT06751472|DIAGNOSTIC_TEST|VPS (Verbal Pain Score)|İt is a pain intensity determination system based on the system where there person tells a point between 0=(no pain) 10=( unbearable pain) and to describe their pain
219209707|NCT06751472|DIAGNOSTIC_TEST|WOMAC (Western Ontario and McMaster Universities Arthritis Index) scale|It includes 24 questions under three sub-headings as pain, stiffness and physical function
219209708|NCT06881147|BEHAVIORAL|Multimodal physiotherapy program|"Multimodal physiotherapy program of 6 weeks (3 times a week for 45 minutes), each session will include:~* Soft tissue mobilization of inoculated muscles;~* Stretching exercises of the inoculated muscles;~* Strengthening of antagonist muscles;~* Motor learning exercises (attentive strategies, feedback-based cervical active exercises).~Exercises will be progressively difficult (increase of active ROM) according to clinical improvements."
219209709|NCT06690788|BEHAVIORAL|Individual intervention condition (PreventT2)|PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
219360419|NCT02713568|OTHER|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
219074267|NCT00789087|PROCEDURE|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
219074268|NCT03584698|DRUG|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
219677759|NCT06955039|OTHER|(TCE)|The control group will only perform towel curl exercises In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
219677760|NCT03692923|OTHER|virtual community|
219677761|NCT00313586|DRUG|Azacitidine|Given SC
219677762|NCT00313586|DRUG|Entinostat|Given PO
219677763|NCT00313586|OTHER|Laboratory Biomarker Analysis|Correlative studies
219677764|NCT05916053|DIETARY_SUPPLEMENT|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
219677765|NCT05084976|BEHAVIORAL|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
219677766|NCT03076996|BEHAVIORAL|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
219677767|NCT06192238|PROCEDURE|adrenal venous sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
219677768|NCT03153800|BIOLOGICAL|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
219677769|NCT03117361|DRUG|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
218983439|NCT05789160|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
218983440|NCT04424888|OTHER|WB-011|WB-011 medical food product.
218983441|NCT04424888|OTHER|Placebo|Placebo Capsules identical to those containing WB-011.
218983442|NCT04424888|DEVICE|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
218983443|NCT05346874|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
218983444|NCT05346874|DRUG|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
218983445|NCT05346874|PROCEDURE|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
218983446|NCT06088875|DRUG|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
218983447|NCT06088875|DRUG|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
219677770|NCT03117361|DRUG|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
219677771|NCT03117361|DRUG|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
219677772|NCT01027468|DRUG|Bevacizumab|intraocular bevacizumab injection
219677773|NCT01999764|DRUG|QLT091001|QLT091001 administered orally at multiple time points.
219677774|NCT01999764|OTHER|Placebo|Placebo is administered orally at multiple time points.
218983448|NCT04400994|DRUG|Rituximab|"Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
218983449|NCT04400994|OTHER|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour"
219677775|NCT01869088|DRUG|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
219677776|NCT01869088|PROCEDURE|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
219677777|NCT00988000|OTHER|telephone consultation|alternative to face to face consultation for new referrals
219677778|NCT00988000|OTHER|No intervention|no alternative to face to face consultation
219677779|NCT04611139|DRUG|SP-2577|Daily oral doses
219677780|NCT04611139|DRUG|Pembrolizumab|200mg Q3W by IV infusion
219677781|NCT00701688|DRUG|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
219677782|NCT00095342|DRUG|TMI-005|
219677783|NCT06307834|BEHAVIORAL|Neurofeedback - based therapy|This intervention will include mental practice of various hand movements accompanied by guided visual feedback, aimed at regulating brain activation patterns to facilitate the restoration of hand movements. We will also incorporate EMG signals to control a hand exoskeleton.
219074269|NCT03584698|DRUG|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
219677784|NCT06307834|BEHAVIORAL|Standard hand exercise therapy|This intervention will include engaging in a set of particular hand exercises with the aim of enhancing hand movements.
219677785|NCT02957617|DRUG|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
219677786|NCT00898794|BIOLOGICAL|bevacizumab|
219677787|NCT00898794|OTHER|coagulation study|
219677788|NCT00898794|OTHER|laboratory biomarker analysis|
219677789|NCT00898794|OTHER|platelet aggregation test|
219677790|NCT03280056|BIOLOGICAL|NurOwn® (MSC-NTF cells)|"NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors"
219677791|NCT03280056|OTHER|Placebo|"One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection"
219677792|NCT03280056|OTHER|Bone Marrow aspiration|Bone Marrow aspiration
218983450|NCT01322659|DEVICE|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
218983451|NCT01322659|DEVICE|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
218983452|NCT03447704|DRUG|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
218983453|NCT03447704|OTHER|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
218983454|NCT04460937|DRUG|Adavosertib|Given PO
218983455|NCT04460937|RADIATION|Radiation Therapy|Undergo radiation therapy
218983456|NCT02750202|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
218983457|NCT02750202|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
218983458|NCT02586714|OTHER|No intervention|Observation only
219074270|NCT03877445|DEVICE|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
219074271|NCT00415987|PROCEDURE|Hematopoietic Stem Cell Transplantation|
219677793|NCT03235323|DEVICE|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
219677794|NCT02950116|DEVICE|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"* Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)"
219677795|NCT06452602|DRUG|Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f."
219677796|NCT06452602|DRUG|Induction immunochemotherapy followed by concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f."
219677797|NCT06344559|DEVICE|transcranial magnetic stimulation|"The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other."
219677798|NCT05485714|OTHER|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
219677799|NCT04659057|DRUG|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
219677800|NCT04659057|DRUG|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
219677801|NCT04659057|DRUG|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
219677802|NCT04659057|OTHER|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
219074272|NCT05023304|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
219074273|NCT05023304|DRUG|Topical prednisolone acetate|Standard of care topical drop regimen with four week taper
219677803|NCT04456400|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography (MSOT)|cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.
219677804|NCT00000173|DRUG|Donepezil|
219677805|NCT00000173|DRUG|Vitamin E|
219677806|NCT02144077|DRUG|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
219677807|NCT02144077|DRUG|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
219677808|NCT00610168|BIOLOGICAL|Boostrix TM|Single booster dose of vaccine
219677809|NCT01038102|OTHER|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
219677810|NCT01038102|OTHER|SFA diet|Diet high in saturated fat (15E%)
219677811|NCT00330694|OTHER|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
219677812|NCT00330694|OTHER|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
219074274|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
219074275|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
219074276|NCT03146520|DEVICE|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
219074277|NCT04657211|OTHER|Prospective observational cohort study|prospective observational cohort study
219074278|NCT05009992|DRUG|ONC201|Given orally (PO)
219074279|NCT05009992|RADIATION|Radiation Therapy|Undergo radiation therapy
219677813|NCT06142344|DEVICE|Quiremspheres™|The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
219677814|NCT04135755|OTHER|no drug intervention|no drug or treatment intervention
219677815|NCT06371690|OTHER|Web-Based Double-Eye Control Program|Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
219677816|NCT02494856|DRUG|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
219677817|NCT02494856|DRUG|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
219074280|NCT05009992|DRUG|Paxalisib|Given PO
219074281|NCT04731649|BEHAVIORAL|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
219074282|NCT06294704|OTHER|bariatric surgery|Having undergone bariatric surgery and on a closed-loop insulin pump after bariatric surgery
219074283|NCT05134454|DIAGNOSTIC_TEST|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
219074284|NCT02993068|OTHER|Educational Intervention|Watch genetic testing online educational video
219074285|NCT02993068|OTHER|Genetic Counseling|Receive post-telephone genetic counseling
219074286|NCT02993068|OTHER|Genetic Counseling|Receive pre-telephone genetic counseling
219074287|NCT02993068|OTHER|Laboratory Biomarker Analysis|Correlative studies
219074288|NCT02993068|OTHER|Questionnaire Administration|Ancillary studies
219677818|NCT06024811|BEHAVIORAL|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
219677819|NCT00943592|DRUG|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
219677820|NCT00943592|DRUG|Melphalan|Doses ranging from 100 to 140 mg/m2
219677821|NCT00943592|DRUG|Campath|20mg/d x5
219677822|NCT00943592|PROCEDURE|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
219677823|NCT00500734|PROCEDURE|Blood Sample|One time blood draw of 2 teaspoons.
219677824|NCT02215889|PROCEDURE|Liver transplantation|
219677825|NCT06432101|OTHER|Acupuncture combined with oral hydroxychloroquine sulfate tablets|Acupuncture combined with oral hydroxychloroquine sulfate tablets
219677826|NCT05779787|PROCEDURE|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
219677827|NCT05779787|PROCEDURE|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
219677828|NCT04026230|DRUG|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
219677829|NCT04026230|DRUG|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
219677830|NCT01247350|DRUG|LY3009104|Administered orally
219677831|NCT01247350|DRUG|Placebo|Administered orally
219677832|NCT05701540|DRUG|Tegoprazan|Tegoprazan 50mg tablet
219677833|NCT05701540|DRUG|Esomeprazole|"Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet"
219677834|NCT03118817|DRUG|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
219677835|NCT00169104|DRUG|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
219677836|NCT00169104|DRUG|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
219677837|NCT00169104|DRUG|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
219074289|NCT02693665|BEHAVIORAL|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
219074290|NCT03373604|DRUG|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
219074291|NCT03373604|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
219074292|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
219074293|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
219074294|NCT02322944|BEHAVIORAL|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
219074295|NCT02322944|BEHAVIORAL|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
219074296|NCT01496352|DRUG|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
219074297|NCT01496352|DRUG|Placebo|DFA-02 placebo
219677838|NCT00169104|DRUG|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
219677839|NCT00169104|DRUG|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
219677840|NCT01457417|DRUG|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
219677841|NCT00324662|DEVICE|Implantable cardioverter-defibrillator|
219677842|NCT03646968|DRUG|Anlotinib and Docetaxel|Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
219677843|NCT03246022|OTHER|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
219677844|NCT01540981|DEVICE|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
219677845|NCT01540981|OTHER|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
219074298|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219074299|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
219677846|NCT05624411|DEVICE|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
219074300|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
219677847|NCT05624411|DEVICE|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
219677848|NCT05082337|DEVICE|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
219677849|NCT01114009|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
219677850|NCT01114009|PROCEDURE|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
219677851|NCT01911754|BIOLOGICAL|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
219677852|NCT04697290|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
219677853|NCT02589509|BEHAVIORAL|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
219677854|NCT02589509|BEHAVIORAL|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
219074301|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
219074302|NCT02220972|DRUG|Perampanel|
219677855|NCT04849117|PROCEDURE|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
219677856|NCT01589367|DRUG|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
219677857|NCT01589367|DRUG|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
219074303|NCT02220972|DRUG|Placebo|
219074304|NCT02433353|DRUG|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
219677858|NCT04687111|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
219677859|NCT04687111|DRUG|Valsartan|Valsartan is an Angiotensin Receptor Blocker
219677860|NCT01224275|OTHER|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
219677861|NCT04951908|DIAGNOSTIC_TEST|MRI|MRI of TMJ
219677862|NCT03212859|BEHAVIORAL|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
219074305|NCT02433353|BEHAVIORAL|EMDR|psychotherapy
219074306|NCT02433353|DRUG|Placebo|Look-alike venlafaxine XR tablets containing no active drug
219074307|NCT03212105|BEHAVIORAL|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
219074308|NCT03212105|OTHER|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
219074309|NCT01431677|PROCEDURE|Muscle Biopsy|
219074310|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
219074311|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
219677863|NCT03212859|BEHAVIORAL|Usual Care|"Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context."
219677864|NCT05460949|OTHER|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
219677865|NCT05460949|OTHER|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
219677866|NCT02762071|DRUG|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
219677867|NCT02762071|DRUG|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
219677868|NCT00141518|DRUG|Levodopa-carbidopa intestinal gel (LCIG)|
219677869|NCT00141518|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219677870|NCT00141518|DEVICE|percutaneous endoscopic gastrostomy tube (PEG tube)|
219677871|NCT00141518|DEVICE|jejunal extension tube (J-tube)|
219677872|NCT02821429|OTHER|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
219677873|NCT00959465|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
219677874|NCT04361760|DEVICE|single-puls TMS|Medical Device (MD): MagPro X100
219677875|NCT04361760|DEVICE|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
219677876|NCT02816073|DEVICE|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
219677877|NCT01806168|DEVICE|rTMS|Magstim Super Rapid-2
219677878|NCT04335058|DRUG|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
219677879|NCT04335058|DRUG|Iron Supplement|Oral iron supplement alone
219677880|NCT02725658|DEVICE|DOSI|Breast tissue properties scanning
219074312|NCT03745664|DRUG|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
219074313|NCT03745664|DRUG|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
219074314|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
219074315|NCT01962493|OTHER|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
219074316|NCT01962493|DRUG|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
219074317|NCT04948203|DRUG|Sirolimus|Triangular-shaped tablet
219074318|NCT05343039|DEVICE|Non-invasive Transcutaneous Nerve Stimulation (tVNS)|Participants will engage in 25-minute tVNS sessions every day for 30 days.
219074319|NCT05343039|DEVICE|No Intervention|Participants will not receive any intervention.
219209710|NCT06690788|BEHAVIORAL|Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP)|PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
219677881|NCT01153217|DRUG|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
219677882|NCT02693262|DEVICE|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
219677883|NCT02693262|DEVICE|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
219209711|NCT06717425|DRUG|PF-07976016|Taken once daily
219209712|NCT06717425|DRUG|Placebo|Taken once daily
219209713|NCT07037797|DIAGNOSTIC_TEST|Order of the FAST echography|Randomisation of the order in which probes are used
219074320|NCT03311438|OTHER|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
219677884|NCT01861769|OTHER|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
219677885|NCT01861769|OTHER|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
219074321|NCT03156049|PROCEDURE|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
219074322|NCT03156049|PROCEDURE|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
219074323|NCT02245152|DIETARY_SUPPLEMENT|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
219074324|NCT02245152|BEHAVIORAL|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
219074325|NCT02245152|BEHAVIORAL|National policy well-baby visits|
219209714|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain tumor-associated antigens and HLA LOH.
219074326|NCT03776136|DRUG|lenvatinib|Administered orally once a day during each 21-day cycle.
219074327|NCT03776136|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
219074328|NCT03620942|DRUG|Phenylephrine|"Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
219074329|NCT03620942|DRUG|Ephedrine|"Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min."
219074330|NCT03620942|DEVICE|ADIVA System|"1. When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate \< 60 beats/min;~2. When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~3. When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~4. When SBP \< 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min."
219074331|NCT03620942|DEVICE|DIVA System|"DIVA system works as below:~1. When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate \< 60 beats/min."
219209715|NCT06715397|OTHER|No intervention|No intervention
219209716|NCT06886646|OTHER|Allogeneic Mesenchymal Stromal Cell Therapy|Patients in this arm will receive 4 injections of allogeneic mesenchymal stromal cells (CSM) derived from human umbilical cord. The doses will be 1.106 cells/kg administered intravenously at days 0, 7, 14, and 21. The injections are given after thawing, washing, resuspension, and adjusting the dose. The CSM treatment aims to control chronic active antibody-mediated rejection (cABMR), improve renal function, reduce proteinuria, and increase graft survival without changing the immunosuppressive regimen.
219209717|NCT06886646|OTHER|Placebo (NaCl 0.9%) Treatment|Patients in this arm will receive placebo treatments, which will consist of 150 mL of saline (NaCl 0.9%) administered intravenously at the same intervals as the CSM group (days 0, 7, 14, and 21). The placebo will be administered under the same conditions as the treatment, and the participants and investigators will remain blinded to the group allocation. Like the CSM group, no changes will be made to the patients' immunosuppressive regimen.
219209718|NCT07038460|DRUG|Limertinib+sintilimab+chemotherapy|Experimental group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, experimental group patients discontinue therapy for 1 week, then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
219209719|NCT07038460|DRUG|Limertinib+chemotherapy|Control group group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, control group patients receive Lilotinib for next 9 weeks + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
219074332|NCT07114692|BIOLOGICAL|Stromal vascular fraction transplantation|Subcutaneous fat was harvested from either the abdomen or the posterior inner thigh region and then digested with 600 U of collagenase (Shanghai Qiaoyuan Biological Pharmaceutical Co., Ltd, Shanghai, China) at 37°C and 150rpm for three hours. After enzymatic digestion, the lower aqueous phase liquid was aspirated to acquire the stromal vascular fraction (SVF). The SVF cell-pellet was washed and adjusted to 2×10\^6 cells/mL. Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
219074333|NCT07114692|BIOLOGICAL|Normal saline injection|Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml 0.9% normal saline were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
219074334|NCT04075435|DRUG|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
219074335|NCT07128290|DRUG|CISGEM + Rilvegostomig|"Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig~RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks~• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks~* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %~* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %"
219074336|NCT07126223|BEHAVIORAL|Hot water foot bath|A 20-minute hot foot bath therapy using a specially designed foot spa device (41°C) applied in the early postoperative period. Follow-up includes pain evaluation via Numeric Rating Scale (NRS) and monitoring of first flatus time.
219074337|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
219074338|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
219074339|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
219074340|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
219074341|NCT01823718|BIOLOGICAL|Injection of allogenic CTL EBV specific|
219074342|NCT01297933|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
219074343|NCT06736275|DRUG|SXRN|"SXRN is a naked plasmid DNA drug targeting miRNA. Accelerated titration and 3+3 dose escalation:In light of ethical considerations and with the aim of minimizing the number of patients possibly exposed to potentially ineffective doses, an accelerated titration strategy will be implemented in the early dose escalation phase (2 mg dose group) in this study, with only 1 subject enrolled. If no DLT occurs to the 3 subjects under the given dose in the DLT valuation window (the 1st cycle, 3 weeks), the study will proceed to the next dose (dose escalation in the same subject is not allowed); if one subject develops DLT, 3 additional subject s will be included to the current dose group; if ≥2 DLTs occur in the dose group with 3 or 6 subject s, the dose escalation will be stopped. The decision is made by discussion among the investigators whether to terminate the escalation or consider adjusting the dose for exploration."
219074344|NCT04787757|PROCEDURE|Percutaneous cardiac procedure|Collection and analysis of intraprocedural information to provide artificial intelligence algorithms
219209720|NCT07038460|PROCEDURE|surgery|The surgical procedure may involve minimally invasive surgery (video-assisted thoracoscopic surgery, robot-assisted surgery) or open thoracotomy. The surgical methods include lobectomy, combined lobectomy, pneumonectomy, sleeve resection, and ipsilateral systematic mediastinal lymph node dissection (for left-sided tumors, stations 4L, 5, 6, 7, and 9 should be included; for right-sided tumors, at least stations 2R, 3A, 4R, 7, and 9 should be included).
219677886|NCT05102669|OTHER|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
219677887|NCT05102669|DIAGNOSTIC_TEST|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
219209721|NCT07038460|DRUG|Osimertinib|Adjuvant treatment with Osimertinib for 2 years
219209722|NCT07038161|PROCEDURE|Modified Cattell-Warren duct-to-mucosa pancreaticojejunostomy|Technical modification of the original Cattell-Warren technique in all the stitches of both posterior and anterior duct-to-mucosa layer, taking the pancreatic duct with more than 5mm of pancreatic parenchyma adjacent to the duct and towards the jejunal side, taking more than 5 mm of full-thickness jejunum including mucosa.
219209723|NCT07038161|BEHAVIORAL|Institutional Prehabilitation Protocol|Routine perioperative incentive spirometry, four extremities exercise, and nutritional optimization with albumin and Total Parenteral Nutrition
219677888|NCT01029262|DRUG|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
219677889|NCT01029262|OTHER|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
219074345|NCT04414696|BEHAVIORAL|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
219074346|NCT05624775|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
219074347|NCT07127367|BEHAVIORAL|Memory Training|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
219074348|NCT07127068|DIETARY_SUPPLEMENT|Omega-3 Suplementation|The intervention group will receive a daily oral supplementation of 2000 mg omega-3, which will not be administered to the control group. Blood samples will be collected from all participants at baseline and at the end of the study to evaluate selected serum parameters. To minimize nutritional variability, individualized diets appropriate for coronary artery disease and chronic kidney disease were prescribed to both groups at the beginning of the study. Unlike many other intervention studies, this trial specifically targets end-stage renal disease patients and includes an evaluation of the intervention's impact in relation to dialysis initiation.
219074349|NCT07127068|OTHER|No intervention|Participants in the control group will not receive any dietary supplementation. Blood samples will be collected at baseline and at the end of the study to assess selected biochemical parameters. Standard dietary care appropriate for coronary artery disease and chronic kidney disease will be maintained throughout the study.
219074350|NCT07127627|DEVICE|PET/CT|positron emission tomography/computed tomography
219074351|NCT07126340|OTHER|Foot massage and cold application|The patient will receive both cold application and foot massage after total knee arthroplasty.
219074352|NCT07126340|OTHER|Cold application|After total knee arthroplasty, the patient will receive routine cold application.
219074353|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 1 (low gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 1. It will come in a ready to drink format for the participants.
219074354|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 2 (medium gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 2. It will come in a ready to drink format for the participants.
219074355|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 3 (high gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 3. It will come in a ready to drink format for the participants.
219074356|NCT07127198|OTHER|Control group (no gelation property)|The control product for this study is a drink containing protein and fiber. It will come in a ready to drink format for the participants.
219074357|NCT07126145|OTHER|Not applicable- observational study|no interventions were involved
219074358|NCT06675500|DRUG|Magnesium sulphate|Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate
219074359|NCT06675500|DRUG|Placebo|Intravenous infusion of Normal saline 0.9 followed by starch oral tablets
219074360|NCT03822858|DRUG|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
219074361|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
219074362|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
219074363|NCT06715605|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
219074364|NCT06715605|BIOLOGICAL|Standard-of-care|Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.
219074365|NCT06704399|OTHER|Acceptance and Commitment Therapy-Based Psychoeducation|Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
219074366|NCT06704399|OTHER|control group|No intervention will be applied to the control group.
219209724|NCT06884969|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months.
219209725|NCT06884969|BEHAVIORAL|Peabody Motor Development Scale-2|Peabody Motor Development Scale-2 was planned to be used to assess motor development. Peabody Motor Development Scale-2 was designed to determine developmental delays in children between 0-72 months.
219209726|NCT06882603|OTHER|hydrodissection|5 ml of 0.9% isotonic sodium chloride solution will be applied to the intracarpal area median nerve area once with the USG probe.
219209727|NCT06882603|OTHER|Steroid injection|1 ml of 3mg/ml betamethasone sodium phosphate or 3mg/ml betamethasone acetate solution will be applied with the USG probe.
219677890|NCT01753713|DRUG|dovitinib|Given PO
219677891|NCT01753713|OTHER|laboratory biomarker analysis|Correlative studies
219677892|NCT06166017|OTHER|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
219677893|NCT03410992|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
219677894|NCT03410992|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
219677895|NCT05722730|PROCEDURE|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
219677896|NCT02761018|BEHAVIORAL|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
219209728|NCT06882603|OTHER|Exercise|Performed with 6 different consecutive positions of the hand and wrist. 1- Wrist in neutral position, fingers and thumb in flexion 2- Wrist in neutral position, fingers and thumb in extension 3- Wrist and fingers in extension, thumb in neutral position 4- Wrist, fingers and thumb in extension 5- Forearm in supination, wrist and fingers in extension 6- Forearm in supination, wrist and fingers in extension, gentle stretching is applied to the thumb with the hand. Tendon gliding exercises: Performed to ensure isolated mobility of the flexor digitorum superficialis and profundus muscles in the canal. Tendon gliding exercises are performed in 5 different consecutive positions, respectively. 1- Fingers straight 2- Fingers in hook position 3- Fingers in fist position 4- Fingers in table shape position 5- Fingers in straight fist. The exercises will be asked to be done 10 times, once a day, every day for 3 weeks.
219074367|NCT07044557|OTHER|Withholding perioperative Dexamethasone|Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.
219074368|NCT07038642|BEHAVIORAL|Pharmacy Clinical Decision Support System for Asthma Management|A pharmacy clinical decision support system that generates individualized advice for asthma patients is provided to the pharmacist/RPht/assistant/student.
219074369|NCT07049783|BEHAVIORAL|Exercise|A single standardized, in-lab, 30-minute monitored treadmill exercise session
218983459|NCT06070311|COMBINATION_PRODUCT|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
219074370|NCT04722965|PROCEDURE|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
219074371|NCT04722965|PROCEDURE|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
219074372|NCT06758544|DRUG|Oncolytic virus VRT106|VRT106, IV
219677897|NCT02761018|BEHAVIORAL|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
219677898|NCT03810157|DEVICE|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
219677899|NCT03301987|OTHER|Therapeutic exercise|30 minutes per day of therapeutic exercise
219677900|NCT00336934|DIETARY_SUPPLEMENT|pomegranate juice|Given orally daily.
219677901|NCT00336934|OTHER|placebo|Given orally daily.
218983460|NCT03317340|OTHER|Background Sounds|Background music or sound of running water
218983461|NCT04390061|DRUG|Tofacitinib|Jak-1/3 inhibitor
218983462|NCT04390061|DRUG|Hydroxychloroquine|Standard Therapy
219677902|NCT00338091|DRUG|Benazepril|
219677903|NCT00338091|DRUG|Losartan|
219677904|NCT04637841|OTHER|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
219074373|NCT06758544|DRUG|Chemotherapy|21 days/cycle, administered up to 6 cycles
219074374|NCT07126886|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
219074375|NCT07126886|OTHER|XPURT + SOC|Participants will receive weekly applications of XPURT and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
219209729|NCT06889896|DIAGNOSTIC_TEST|After Blood samples collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau|The CLEAR-AD study is an ongoing population-based cross-sectional study, currently recruiting 400 participants in ten centers in China. The study includes cognitively normal controls, individuals with mild cognitive impairment (MCI) - categorized as amyloid-positive and amyloid-negative - as well as patients with dementia, also divided into amyloid-positive and amyloid-negative groups. All participants undergo amyloid PET scans using tracers such as AV1, AV45, and PIB. Blood samples are collected within three months prior to the PET scan or from existing samples collected after January 1, 2024, that meet quality standards. After collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau181/217. The detection technologies included single-molecule immunoassay, digital immunoassay chips, magnetic particle chemiluminescence, and flow cytometry fluorescence. The objective i
219209730|NCT06724432|DRUG|oral melatonin|Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
219209731|NCT06724432|DRUG|Placebo|Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
219209732|NCT06722534|DRUG|Celecoxib 400mg|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
219209733|NCT06722534|DRUG|Placebo|Participants in the control group receive identically appearing placebo twice daily for 6 months
219209734|NCT06889311|PROCEDURE|Subperiosteal hyaluronic acid injection overlay technique|using subperiosteal hyaluronic acid injection overlay technique showed promising results in treating lost interdental papilla which needs further assessment to its clinical effectiveness
219209735|NCT06889311|PROCEDURE|Tunneling with connective tissue graft.|Connective tissue graft base techniques have been for years the most predictable approach for treatment of interdental papillary defects. CTG can as a biological filler which enhances flap stability and wound strength. CTG also can promote coagulation cascade and protects the maturating fibrin clot (Tavelli et al. 2019). Moreover, CTG results in significant increase in gingival tissue thickness which positively improve tissue fill and soft tissue volume creeping which influence esthetic outcomes following periodontal regeneration
219209736|NCT06722807|PROCEDURE|sutureless, clampless partial nephrectomy|All subjects will undergo a clampless, sutureless robotic partial nephrectomy.
219677905|NCT04637841|OTHER|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
219677906|NCT01508247|BIOLOGICAL|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
219677907|NCT01508247|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
219677908|NCT00297700|BEHAVIORAL|Active referral|
219677909|NCT02438280|DEVICE|AcceleDent, Vibrational Device|20 minutes of vibration each day
219677910|NCT05869370|OTHER|High intensity resistance training|Twelve weeks of resistance training twice a week.
219677911|NCT05869370|OTHER|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
219209737|NCT06888674|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Neoantigen Therapeutics Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
219209738|NCT06888674|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m², administered intravenously over 30 minutes on Day 1 and Day 8; Capecitabine: 1650-2000 mg/(m²·day), divided into two daily oral doses from Day 1 to Day 14.~Treatment cycles repeat every 3 weeks for 8 cycles, with the actual number of cycles determined by the investigator based on comprehensive evaluation of the patient's physical status, disease progression, and adverse reactions."
219677912|NCT02260817|DRUG|11C-choline Injection|"1. Choline C11 Injection for PET/CT Imaging Protocol:~   * 15 - millicuries (mCi) 11C-choline IV Injection~  * PET images skull base to mid thigh with 3 min per bed position~  * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~  * Fusion of PET and CT images~2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~   * No IV contrast~  * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~  * Fusion of coronal and PET images"
219677913|NCT02048150|BIOLOGICAL|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
219677914|NCT02048150|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
219677915|NCT02048150|OTHER|diffuse optical imaging|Undergo IOOI
219677916|NCT02048150|OTHER|pharmacological study|Correlative studies
219677917|NCT02048150|OTHER|Laboratory Biomarker|Correlative studies
219677918|NCT02048150|OTHER|Questionnaire|Ancillary studies
219677919|NCT03299101|OTHER|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
219677920|NCT02485327|DRUG|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
219677921|NCT01100723|OTHER|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
219677922|NCT00347178|PROCEDURE|Laser Peripheral Iridotomy|
219677923|NCT05534828|DIAGNOSTIC_TEST|A consultation|A consultation at three months of discharge from the intensive care unit in the population of patients surviving a multivalent intensive care unit stay
219677924|NCT02027077|BEHAVIORAL|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
219074376|NCT07127796|OTHER|Dietary Supplement - Fish-derived Vitamin D|"Cholecalciferol (vitamin D3). Other components: polyunsaturated fatty acids (PUFA), arabic gum, maltodextrin, pea protein hydrolisate, hard gelatine capsules.~The fish derived vitamin D extract was obtained from sardines (Sardina pilchardus) waste ( whole fish) recovered by CNR-IRBIM (Centro Nazionale delle Ricerche-Istituto per le Risorse Biologiche e le Biotecnologie Marine) and sourced from a professional fishing fleet operating in the Adriatic Sea (Central Mediterranean). Fishes have been homogenized, freeze dried and extracted by using a Supercritical Fluid Extractor (SFE-CO2) in the laboratories of ENEA (Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile), then analyzed for the content of vitamin D3 and other bioactives by HPLC-DAD technique in the laboratories of University of Camerino and finally microencapsulated in the laboratories of University of Piemonte Orientale for the preparation of final supplement."
219074377|NCT07127796|OTHER|Dietary Supplement - Synthetic Vitamin D|Cholecalciferol (vitamin D3). Other components: medium-chain triglycerides, alfpha-tocopherol acetate, hard gelatin capsules.
219074378|NCT07126496|OTHER|Internet-Based Intervention|Receive information via online text
219074379|NCT07126496|OTHER|Questionnaire Administration|Ancillary studies
219074380|NCT07126496|OTHER|Virtual Technology Intervention|Receive information via ALEX Research Portal and vCHE
219074381|NCT00999258|DRUG|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
219074382|NCT05632510|DIAGNOSTIC_TEST|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
219074383|NCT04462861|DEVICE|Central venous access device (CVAD) Snuggie Securement Device|Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
219074384|NCT06012734|DRUG|LB-100|IV on day 1 and day 3
219074385|NCT06012734|DRUG|Atezolizumab|IV on day 1
219074386|NCT05542043|OTHER|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
219074387|NCT01551732|BEHAVIORAL|ACT|10 session manualized cognitive behavioral anger control therapy
219074388|NCT01551732|BEHAVIORAL|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
219074389|NCT04581525|DEVICE|transcranial direct current stimulation|
219074390|NCT04616508|BEHAVIORAL|motor control assessment|Basic science study of control of reaching movements
219074391|NCT00924287|DRUG|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
219074392|NCT00924287|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
219074393|NCT00924287|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219074394|NCT00924287|DRUG|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
219209739|NCT06888674|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
219209740|NCT06423300|DEVICE|LIFT Implant|The LIFT implant provides a less invasive option for treatment of patellofemoral cartilage degeneration in the knee. the LIFT implant unloads the patellofemoral joint by elevating the patellar tendon to unload the joint compartment and realign the kneecap toward healthier cartilage
219074395|NCT05884346|OTHER|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
219074396|NCT00275795|PROCEDURE|NAET Procedures|
219074397|NCT04367350|DIAGNOSTIC_TEST|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
219074398|NCT04367350|DIAGNOSTIC_TEST|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
219209741|NCT06423300|OTHER|Tibial Tubercle Osteotomy|Tibial Tubercle Osteotomy
219677925|NCT02027077|BEHAVIORAL|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
219074399|NCT03034642|PROCEDURE|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
219209742|NCT07039578|BIOLOGICAL|CM336 Injection(Low dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
219209743|NCT07039578|BIOLOGICAL|CM336 Injection(High dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
219677926|NCT02904083|BEHAVIORAL|self assessment of adherence|
219677927|NCT01985100|OTHER|hyperbaric oxygen chamber|
219677928|NCT00639262|DRUG|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
219677929|NCT00639262|DRUG|Temozolomide|For Cohort 2 - Gliomas only.
219677930|NCT00639262|RADIATION|Radiotherapy|Radiation Therapy (XRT)
219074400|NCT01785303|BEHAVIORAL|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
219074401|NCT01785303|PROCEDURE|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
219074402|NCT03457753|DRUG|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
219074403|NCT00783926|BIOLOGICAL|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
219074404|NCT02621931|DRUG|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
219074405|NCT02621931|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
219074406|NCT04969523|PROCEDURE|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
219074407|NCT00872352|PROCEDURE|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
219074408|NCT01744522|PROCEDURE|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
219074409|NCT02514629|DRUG|Placebo|
219074410|NCT02514629|DRUG|Metformin|
219074411|NCT02514629|DRUG|Testosterone Undecanoate|
219074412|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
219074413|NCT01354158|DRUG|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
219074414|NCT02811861|DRUG|Lenvatinib|
219074415|NCT02811861|DRUG|Everolimus|
219074416|NCT02811861|DRUG|Pembrolizumab|
219074417|NCT02811861|DRUG|Sunitinib|
219074418|NCT02394782|DEVICE|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
219074419|NCT02394782|DEVICE|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
219074420|NCT02925455|DEVICE|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
219074421|NCT02925455|DEVICE|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
219074422|NCT04912648|OTHER|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
219074423|NCT06151145|BEHAVIORAL|Usual care|Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.
219074424|NCT06151145|BEHAVIORAL|SELF|"The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages."
219074425|NCT06151145|BEHAVIORAL|STEP|The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
219074426|NCT00360308|DRUG|Placebo|
219074427|NCT00360308|DRUG|E2007|
219677931|NCT04470479|DRUG|Pilocarpine Hydrochloride|Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
219677932|NCT04470479|DRUG|Placebo|Placebo
219677933|NCT05361135|DIAGNOSTIC_TEST|PET/CT|Enhanced imaging with PET/CT
219677934|NCT01817166|DRUG|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
219074428|NCT00360308|DRUG|E2007|
219074429|NCT06470932|DIAGNOSTIC_TEST|Follow-up consult|Patients will be ask to participate to a follow-up consult
219074430|NCT04224077|DIAGNOSTIC_TEST|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
219074431|NCT02125175|RADIATION|Hypofractionated IMRT boost Radiotherapy|
219074432|NCT01889953|OTHER|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach"
219074433|NCT06326515|BEHAVIORAL|psychoeducation|"To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017)."
219074434|NCT06326515|BEHAVIORAL|Stigma Reduction and Relapse Management|"To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011)."
219074435|NCT02725632|DEVICE|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
219074436|NCT01217073|DRUG|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
219074437|NCT01217073|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
219074438|NCT01217073|DRUG|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
219074439|NCT01217073|DRUG|Metformin|Metformin 500 mg oral tablet administered once or twice daily
219074440|NCT01217073|DRUG|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
219074441|NCT02573974|OTHER|Samples|Blood samples, muscle biopsy and sample of hair
219074442|NCT01923259|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
219074443|NCT00276471|DEVICE|Implantable pulse generator and electrodes|
219074444|NCT03989466|BIOLOGICAL|Alemtuzumab|Given IV
219074445|NCT03989466|DRUG|Itacitinib|Given PO
219074446|NCT01469533|OTHER|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
219074447|NCT01469533|OTHER|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
219074448|NCT00042679|DRUG|Gemcitabine|
219074449|NCT00042679|DRUG|Carboplatin|
219074450|NCT00042679|DRUG|LY900003|
219074451|NCT03399760|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
219074452|NCT03399760|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
219074453|NCT03631186|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219074454|NCT00728819|DEVICE|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
219074455|NCT00728819|DEVICE|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
219074456|NCT04111081|OTHER|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
219074457|NCT04111081|OTHER|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
219074458|NCT05599529|OTHER|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
219074459|NCT06213025|BEHAVIORAL|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
219074460|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
219677935|NCT01817166|DRUG|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
219074461|NCT05005832|OTHER|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
219074462|NCT06530914|DRUG|MRG003 combined with Pucotenlimab|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
219074463|NCT06530914|DRUG|MRG003 combined with Pucotenlimab+Cisplatin|All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
219074464|NCT02019160|DRUG|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
219074465|NCT02019160|DRUG|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
219074466|NCT03019211|OTHER|Exercise|
219074467|NCT03725917|OTHER|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
219074468|NCT03591341|DIAGNOSTIC_TEST|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
219677936|NCT01817166|OTHER|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
219677937|NCT01817166|BIOLOGICAL|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
219209744|NCT07038759|DEVICE|the Motion Estimation and Motion Compensation|Motion Estimation and Motion Compensation (MEMC) is a video processing technology designed to enhance display quality by interpolating additional frames, thereby reducing motion blur and stuttering in fast-moving scenes. This is achieved by estimating motion between video frames and generating intermediate frames, effectively increasing the frame rate (e.g., from 30 FPS to 120 FPS) and display refresh rate (e.g., from 30 Hz to 120 Hz).
219209745|NCT07039799|BEHAVIORAL|Virtual Reality + Conventional Physiotherapy|This intervention involves the use of fully immersive virtual reality (VR) applications delivered through the Meta Quest 3 headset, integrated with hand-tracking technology. Participants engage in three custom-designed VR games aimed at improving shoulder, elbow, wrist, and hand functions. The games are tailored to individual functional levels and include progressive difficulty. Sessions are conducted twice per week for 8 weeks, each lasting approximately 40 minutes, under the supervision of a physiotherapist. This intervention is combined with conventional physiotherapy (excluding functional upper extremity exercises).
219209746|NCT07039799|BEHAVIORAL|Conventional Physiotherapy|This intervention consists of a standard physiotherapy program for individuals with Duchenne Muscular Dystrophy. It includes aerobic exercises, strengthening exercises, stretching routines, postural training, respiratory exercises, and functional upper extremity exercises. The sessions are delivered by a physiotherapist twice weekly for 8 weeks, with each session lasting approximately 40 minutes.
219209747|NCT06723899|OTHER|CanWork|CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.
219677938|NCT01817166|BIOLOGICAL|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
219677939|NCT01817166|BIOLOGICAL|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
219677940|NCT01440985|DRUG|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
219677941|NCT01440985|DRUG|Nicotine|Nicotine gum 4 mg, Lot number GC962A
219074469|NCT03885531|DEVICE|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
219074470|NCT01726192|PROCEDURE|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
219074471|NCT01726192|PROCEDURE|Placement of a femoral neurostimulating catheter|
219074472|NCT03771482|BEHAVIORAL|Quiztime modules|Text Messaging or Email system
219074473|NCT05194774|PROCEDURE|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
219074474|NCT03876652|DEVICE|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
219074475|NCT03627481|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
219074476|NCT00454051|DRUG|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
219074477|NCT00454051|DRUG|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
219074478|NCT02136277|DRUG|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
219074479|NCT06302166|OTHER|High Intensity Circuit training (HICT)|High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.
219677942|NCT01440985|DRUG|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
219677943|NCT05995587|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
219677944|NCT02091414|DRUG|mycophenolate mofetil (MMF)|1.0 g PO BID
219677945|NCT02091414|DRUG|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
219677946|NCT02091414|DRUG|corticosteroids|As per the practice of each participating center
219074480|NCT06302166|OTHER|Intermittent Fasting (IF)|Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.
219074481|NCT06302166|OTHER|Combination of HICT and IF|The participants will follow both HICT and IF for 8 weeks.
219074482|NCT02049073|DRUG|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
219074483|NCT02049073|DRUG|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
219074484|NCT04338100|PROCEDURE|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
219074485|NCT06442553|DEVICE|GRR laser|A total of 15 sessions were applied to each patient for three weeks, five times per week.
219074486|NCT06442553|DEVICE|Nd:YAG laser|A total of 10 sessions, five sessions per week, were applied
219074487|NCT00401570|DRUG|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
219074488|NCT00401570|DRUG|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
219074489|NCT06354101|DRUG|Tirzepatide|Once-weekly subcutaneous injectable
219074490|NCT06354101|DRUG|Semaglutide|Once-weekly subcutaneous injectable
219677947|NCT00435461|DRUG|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
219677948|NCT05335655|DRUG|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
219677949|NCT05335655|DRUG|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
218983463|NCT01103336|DRUG|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"* Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
218983464|NCT01229826|RADIATION|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
218983465|NCT02390908|BEHAVIORAL|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
218983466|NCT02390908|BEHAVIORAL|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
218983467|NCT00117455|DRUG|pegfilgrastim|
218983468|NCT00117455|DRUG|filgrastim|
218983469|NCT02829073|DEVICE|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
218983470|NCT02829073|DEVICE|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
218983471|NCT00003831|PROCEDURE|conventional surgery|
218983472|NCT05612711|DRUG|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
218983473|NCT02911220|GENETIC|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
218983474|NCT02579837|DEVICE|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
218983475|NCT02579837|DEVICE|Zeiss Cirrus|optical coherence tomographer (OCT)
218983476|NCT01964833|PROCEDURE|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
218983477|NCT01964833|PROCEDURE|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
218983478|NCT05832801|OTHER|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
218983479|NCT05832801|OTHER|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
218983480|NCT01781975|DRUG|Imatinib Mesylate|
218983481|NCT01781975|DRUG|Placebo (For imatinib mesylate)|
218983482|NCT00324792|DRUG|intensive insulin therapy|
218983483|NCT01940601|DRUG|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
218983484|NCT01940601|DRUG|Filgrastim|Filgrastim 5 μg/kg
218983485|NCT04710394|BEHAVIORAL|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
218983486|NCT02737397|DRUG|JMI-001 (SJP-304 and SJP-223)|
218983487|NCT02737397|DRUG|SJP-304|
218983488|NCT02737397|DRUG|SJP-223|
218983489|NCT02737397|DRUG|placebo|
218983490|NCT01164930|BEHAVIORAL|Acceptance and Commitment Therapy|8-week ACT group
219074491|NCT05319067|OTHER|Stool sampling|Stool sample taken at home 24 hours before hospital visit
219074492|NCT05484674|PROCEDURE|Deroofing and laser|Deroofing and laser to axilla
219677950|NCT00004057|DRUG|L-778,123|
219677951|NCT00004057|DRUG|paclitaxel|
219677952|NCT00868647|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
219074493|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
218983491|NCT06558591|DEVICE|Telerehabilitation intervention|"Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study."
218983492|NCT05618860|OTHER|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
218983493|NCT00069940|BIOLOGICAL|sargramostim|
218983494|NCT00069940|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
218983495|NCT02404220|DRUG|Entospletinib|
218983496|NCT02404220|DRUG|Vincristine|
218983497|NCT02404220|DRUG|Dexamethasone|
218983498|NCT02404220|DRUG|CNS Prophylaxis|
218983499|NCT01622231|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
218983500|NCT06557200|BEHAVIORAL|Digital Infant- parents support|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
218983501|NCT02627521|PROCEDURE|PRU guided CABG|Coronary Artery Bypass Surgery
218983502|NCT02627521|PROCEDURE|CABG per standard of care|Coronary Artery Bypass Surgery
218983503|NCT02627521|DEVICE|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
218983504|NCT02627521|DRUG|Ticagrelor|Ticagrelor administration prior to randomization
218983505|NCT01984411|PROCEDURE|Radial Technical|Vascular Access for cardiac catheterization
218983506|NCT01984411|PROCEDURE|Femoral Technical|Vascular Access for cardiac catheterization
218983507|NCT01984411|DRUG|Omnipaque|
218983508|NCT06257797|DIAGNOSTIC_TEST|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
218983509|NCT00242320|DRUG|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
218983510|NCT00242320|DRUG|Placebo|
218983511|NCT01005108|DRUG|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
218983512|NCT01015898|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
218983513|NCT03188315|GENETIC|HPV oncogenes|PCR and oncogenes detection
218983514|NCT05280782|DRUG|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
218983515|NCT03519620|OTHER|SWWSV|Behaviours to prevent child obesity
218983516|NCT04850521|OTHER|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
218983517|NCT06092385|OTHER|Data collection|"Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)"
218983518|NCT02589405|DRUG|Benzoyl Peroxide|
218983519|NCT02589405|OTHER|Dermotivin® Soft Liquid cleanser|
218983520|NCT02589405|OTHER|Cetaphil® Dermacontrol Moisturizer SPF30|
218983521|NCT00658008|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
218983522|NCT00658008|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
218983523|NCT00658008|DRUG|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
218983524|NCT00658008|DRUG|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
218983525|NCT00658008|DRUG|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
218983526|NCT06033612|DRUG|RV299|Oral Suspension
218983527|NCT06033612|DRUG|Placebo|matching placebo
218983528|NCT06033612|DRUG|Midazolam|pre-filled oral syringe
218983529|NCT02905149|PROCEDURE|Serrato|Serratus plane block.
218983530|NCT02905149|PROCEDURE|Control|Standard anesthesia
218983531|NCT02329080|DRUG|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
218983532|NCT02329080|DRUG|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
218983533|NCT02329080|DRUG|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
218983534|NCT02329080|DRUG|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
218983535|NCT02329080|DRUG|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
219677953|NCT05830890|PROCEDURE|Sentinel lymph node biopsy|After the total mesorectal excision, the indocyanine green was injected around the tumor via the anus. The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed and sent for rapid frozen pathological examination. Subsequently, a lateral lymph node dissection was performed.
218983536|NCT02329080|DRUG|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
218983537|NCT02329080|DRUG|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
218983538|NCT02329080|DRUG|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
218983539|NCT02329080|RADIATION|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
218983540|NCT03060733|OTHER|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
218983541|NCT04208997|DRUG|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
218983542|NCT00624234|BEHAVIORAL|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
218983543|NCT00624234|BEHAVIORAL|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
218983544|NCT05905900|COMBINATION_PRODUCT|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
218983545|NCT04612673|DRUG|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
218983546|NCT02424448|PROCEDURE|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
218983547|NCT00840892|OTHER|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
218983548|NCT06556979|RADIATION|Radiotherapy|Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
218983549|NCT05248581|PROCEDURE|Liver transplantation|living donor liver transplantation
218983550|NCT01655797|BEHAVIORAL|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
218983551|NCT02922855|BEHAVIORAL|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
218983552|NCT02922855|BEHAVIORAL|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
218983553|NCT02922855|BEHAVIORAL|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
218983554|NCT00881257|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
218983555|NCT02368197|DRUG|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
218983556|NCT02368197|DEVICE|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
219677954|NCT05830890|DRUG|Indocyanine green solution|Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
219677955|NCT05830890|DEVICE|fluorescence laparoscope|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node.
218983557|NCT03523234|DRUG|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
218983558|NCT03523234|PROCEDURE|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
218983559|NCT03523234|PROCEDURE|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
218983560|NCT03523234|DRUG|Chemotherapy|etoposide with cisplatin/carboplatin
218983561|NCT00348179|PROCEDURE|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
218983562|NCT03391310|OTHER|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
218983563|NCT04727931|BEHAVIORAL|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
219677956|NCT05830890|DIAGNOSTIC_TEST|pathological examination|The surgical specimens and sentinel lymph nodes were routinely examined for pathology.
219209748|NCT06395415|BEHAVIORAL|EQUIP|The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.
219209749|NCT06395415|BEHAVIORAL|Standard Care|Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.
219209750|NCT06716450|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
219209751|NCT06733597|PROCEDURE|Cement|The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.
219209752|NCT06733597|OTHER|Cementless|The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.
219209753|NCT06733597|PROCEDURE|Manual Surgery|The manual approach is the surgeon determining prosthetic placement using techniques developed during training.
219209754|NCT06733597|PROCEDURE|Robotic Surgery|The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.
219209755|NCT06737328|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
219209756|NCT06896110|DRUG|Nivolumab|Intrathecal nivolumab will be given at a flat dose of 40 mg
219209757|NCT06896110|DRUG|Azacitidine (AZA)|Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design.
219677957|NCT05830890|DIAGNOSTIC_TEST|rapid frozen pathological examination|The lateral green fluorescence imaging sentinel lymph nodes found during surgery was sent to make cryosections. And then a pathologist makes a rapid diagnosis under a microscope。
219677958|NCT05830890|PROCEDURE|total mesorectal excision|"1. Sharply dissect the vascular interface between the pelvic fascia parietal layer and the visceral layer around the mesentery under direct vision to ensure that the rectal mesentery of the resected specimen is intact and tearless.~2. For medium and low rectal cancer: the distal intestinal tube of the tumor should be resected ≥ 2 cm.~3. TME or mesenteric distal resection margin ≥ 5 cm away from the tumor."
219677959|NCT06411210|DRUG|Semaglutide Pen Injector|Escalated to 2.4mg or max tolerated dose
219677960|NCT06411210|DRUG|Placebo|Matched placebo.
219677961|NCT05534815|BEHAVIORAL|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
219677962|NCT05469620|DIETARY_SUPPLEMENT|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
219677963|NCT05469620|OTHER|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
219677964|NCT00552708|DRUG|COREG CR|
219677965|NCT00552708|DRUG|Lisinopril|
219677966|NCT01456143|DEVICE|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
219677967|NCT01456143|OTHER|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
219677968|NCT05391555|DRUG|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes.
219677969|NCT05391555|DEVICE|Pupillometry measurement|Pupillary measurements were taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
219677970|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
219677971|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
219677972|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
219209758|NCT06896110|PROCEDURE|lumbar puncture|Lumbar puncture for intrathecal delivery and collection of CSF
218983564|NCT01899664|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
218983565|NCT02143700|OTHER|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
219677973|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
219677974|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
219677975|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
219074494|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
219074495|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
219074496|NCT00209417|DRUG|Iodixanol 320-Arm 1|
219074497|NCT00209417|DRUG|Iopamidol 300-Arm 2|
219074498|NCT01621217|DRUG|Cetuximab|Will be given weekly intravenously during study treatment.
219074499|NCT01621217|DRUG|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
219074500|NCT01621217|DRUG|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
219074501|NCT01621217|RADIATION|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
219074502|NCT06162767|PROCEDURE|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
219074503|NCT06162767|PROCEDURE|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
219074504|NCT05278910|OTHER|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
219074505|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
219074506|NCT05278910|DIETARY_SUPPLEMENT|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
219074507|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
219074508|NCT05668117|DEVICE|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
219074509|NCT01788748|DEVICE|bipolar radiofrequency and infrared|
219074510|NCT01788748|DEVICE|fractional bipolar radiofrequency|
219074511|NCT01945606|DRUG|Placebo (treatment 1)|Oral administration of placebo tablets
219074512|NCT01945606|DRUG|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
219677976|NCT02238756|BIOLOGICAL|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
219677977|NCT02238756|BIOLOGICAL|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
219074513|NCT05183971|OTHER|Proprioceptive Functional Analysis System|Proprioceptive testing and Physical Performance Tests
219677978|NCT02238756|BIOLOGICAL|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
219074514|NCT03305120|OTHER|pain VAS evaluation|each patient has to answer to a questionnaire about pain
219074515|NCT04701398|OTHER|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
219074516|NCT02462746|DIETARY_SUPPLEMENT|L-Cysteine|The trade name is New Root Herbal Inc.
219074517|NCT02907021|DRUG|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
219074518|NCT02935335|DRUG|Menotrophin|
219074519|NCT01636882|BIOLOGICAL|CVA21|
219074520|NCT03496155|BEHAVIORAL|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
219074521|NCT00353717|DRUG|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
219074522|NCT02212574|DRUG|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
219074523|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
219074524|NCT02212574|DRUG|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
219074525|NCT02212574|DRUG|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
219074526|NCT02212574|DRUG|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
219074527|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
219677979|NCT00784589|DRUG|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
219677980|NCT00784589|DRUG|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
219677981|NCT04397549|OTHER|Cervical erector spinae plane block|Cervical erector spinae plane block will be administered before the surgery
219677982|NCT04397549|DEVICE|Intravenous morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
219677983|NCT03023267|BEHAVIORAL|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
219677984|NCT03023267|BEHAVIORAL|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
219677985|NCT02646319|OTHER|Laboratory Biomarker Analysis|Correlative studies
219677986|NCT02646319|DRUG|Nanoparticle Albumin-Bound Rapamycin|Given IV
219677987|NCT02646319|OTHER|Quality-of-Life Assessment|Ancillary studies
219677988|NCT02580253|DRUG|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
219677989|NCT02580253|DRUG|mFOLFOX6|Oxaliplatin,Fluorouracil
219677990|NCT01850394|DRUG|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
219677991|NCT01850394|DRUG|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
219677992|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
219677993|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 3T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
219677994|NCT00233584|PROCEDURE|Pulmicort (budesonide) pMDI|
219677995|NCT02587767|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
219677996|NCT02587767|DEVICE|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
219677997|NCT05261243|DIAGNOSTIC_TEST|EEG / questionnaires / working memory task|EEG resting state measurements and analysis of frequency bands (gamma, beta, alpha, theta), peak frequencies and connectivity measures / questionnaires for depression, anxiety, social activities, cognition, pain, sleep, fatigue / digitalized block-tapping task
219677998|NCT02447471|DEVICE|Nexfin|Nexfin cuff placed on finger to measure blood pressure
219677999|NCT00074815|DRUG|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
219074528|NCT05403008|OTHER|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
219074529|NCT01016210|DRUG|Leuveris|IV
219074530|NCT01016210|DRUG|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
219074531|NCT04700293|DIETARY_SUPPLEMENT|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
219074532|NCT02898974|BEHAVIORAL|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
219074533|NCT00001430|PROCEDURE|PBSC|
219074534|NCT00001430|DRUG|IL-2|
219074535|NCT00001430|DRUG|EPOCH II|
219074536|NCT02015676|DRUG|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
219074537|NCT02015676|DRUG|paclitaxel|60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
219074538|NCT02015676|DRUG|Myocet|40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
219074539|NCT02322671|DRUG|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
219074540|NCT02322671|DRUG|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
219074541|NCT02322671|DRUG|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
219074542|NCT01016769|DRUG|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
219678000|NCT00074815|BEHAVIORAL|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
219678001|NCT00074815|BEHAVIORAL|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
219678002|NCT05433545|OTHER|Questionnaire|Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
219678003|NCT06342115|DRUG|Ceftolozane-Tazobactam|In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
219678004|NCT06342115|DRUG|Meropenem|The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
219074543|NCT04301336|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
219074544|NCT04301336|DRUG|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
219074545|NCT04301336|DRUG|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
219209759|NCT06896110|DIAGNOSTIC_TEST|MRI Contrast|MRI Brain and full Spine (with and without contrast) will be performed prior to enrollment. During trial therapy, MRI Brain (with and without contrast) will be performed after cycle 1 and after that every 8 weeks (e.g. after cycle 3, cycle 5, etc…)
219209760|NCT06744894|DRUG|Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy|Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
219074546|NCT04301336|DRUG|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
219074547|NCT04301336|DRUG|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
219074548|NCT04301336|DRUG|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
219074549|NCT04301336|DRUG|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
219074550|NCT04301336|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
219074551|NCT04526366|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
219074552|NCT04526366|DEVICE|Polysomnography|Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
219074553|NCT03588208|OTHER|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
219074554|NCT03588208|OTHER|Educational Program|Structured education program were performed during one hour class once a week for five weeks
219074555|NCT03033823|DRUG|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
219074556|NCT03033823|DRUG|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
219074557|NCT05668728|OTHER|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
219209761|NCT06758258|DEVICE|Negative Pressure Wound Therapy|"Preparations for NPWT:~1. Impressions \& Model:~   Lower jaw impressions were taken with alginate and modified trays for optimal tissue recording.~   Dental plaster models were created.~2. Splint Fabrication \& Connection:~2mm hard splints were thermoformed and modified for vacuum. Intraoral splint fit was assessed, and soft acrylic ensured an airtight seal. The irrigation hose was connected to the splint via cyanoacrylate adhesive. 3. NPWT Application: The physiodispenser pump was operated in reverse at reduced power (10-20%). Three 1-hour NPWT sessions were performed."
219209762|NCT06758258|DEVICE|Sham Therapy|The same preparations will be conducted for the sham application arm, except that the peristaltic pump of the physiodispenser will remain inactive during application.
219209763|NCT06757894|DRUG|Zuberitamab|375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
219209764|NCT06757894|DRUG|Bendamustine|90 mg/m², administered on D1-2 of C1-C6
219209765|NCT06756867|OTHER|hand massage with violet oil|In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.
219678005|NCT00954525|DRUG|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
219678006|NCT00954525|DIETARY_SUPPLEMENT|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
219678007|NCT05762809|DIAGNOSTIC_TEST|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
219678008|NCT05762809|DIAGNOSTIC_TEST|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
219678009|NCT05762809|DIAGNOSTIC_TEST|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
219678010|NCT05762809|DIAGNOSTIC_TEST|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
219209766|NCT06756867|OTHER|hand massage with jojoba oil|Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
219209767|NCT06749665|DRUG|polidacanol 3%|Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany
219209768|NCT06749665|BIOLOGICAL|candida antigen|delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart
219209769|NCT06756269|BIOLOGICAL|Medium dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
219209770|NCT06756269|BIOLOGICAL|High dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
219678011|NCT05762809|DIAGNOSTIC_TEST|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
219678012|NCT05762809|DIAGNOSTIC_TEST|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
219678013|NCT05762809|DIAGNOSTIC_TEST|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
219678014|NCT05573256|BEHAVIORAL|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
219209771|NCT06756269|BIOLOGICAL|Placebo|Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
219209772|NCT06756269|BIOLOGICAL|9-HPV vaccine|Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
219209773|NCT06754800|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
218983566|NCT05868473|DIAGNOSTIC_TEST|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
218983567|NCT05868473|DIAGNOSTIC_TEST|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
218983568|NCT03404427|BEHAVIORAL|Normal sleep night|Usual hours of sleep
218983569|NCT03404427|BEHAVIORAL|Sleepless night|Total sleep deprivation the first night
218983570|NCT01481181|DIETARY_SUPPLEMENT|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
218983571|NCT04824976|DIETARY_SUPPLEMENT|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
218983572|NCT04824976|DIETARY_SUPPLEMENT|Placebo|matched powder maltodextrin twice daily = 60kcal
218983573|NCT03082261|DEVICE|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
218983574|NCT00549874|DRUG|Rosiglitazone|oral 8 mg/once daily for 6 months
218983575|NCT00549874|DRUG|Glyburide|20 mg/ once daily for 6 months
218983576|NCT01820156|DEVICE|Home Respiratory Polygraphy|
218983577|NCT01820156|DEVICE|Standard Polysomnography|
218983578|NCT02068027|DRUG|Clonidine Gel 0.1%|
218983579|NCT02068027|DRUG|Placebo|
218983580|NCT01704521|DRUG|PegInterferon|
218983581|NCT01704521|DRUG|Ribavirin|
218983582|NCT01704521|DRUG|Telaprevir|
218983583|NCT05473208|DEVICE|Exoskeleton|Lumbar assistive exoskeleton evaluation
218983584|NCT02173873|DRUG|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
218983585|NCT01032174|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
218983586|NCT01032174|DRUG|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
218983587|NCT04558684|DRUG|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
218983588|NCT04558684|DRUG|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
218983589|NCT04558684|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions)
219209774|NCT06751953|COMBINATION_PRODUCT|Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
219209775|NCT06751953|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219209776|NCT06757985|PROCEDURE|a clinically guided resuscitation protocol,|a clinically guided resuscitation protocol, derived from EGDT and modified to match with the latest survival sepsis campaign guidelines
219209777|NCT06757985|PROCEDURE|a transthoracic bedside focused echocardiographic assessment|a transthoracic bedside focused echocardiographic assessment of the patient will be done, as a baseline ECHO in a three-step approach to monitor hemodynamics using Logiq P7, S5-1 ECHO probe;
219209778|NCT06757387|DRUG|chidamide and golidocitinib|Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
219209779|NCT06753032|DIAGNOSTIC_TEST|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to positive defocus induced by +2.00 D spectacle lenses. The lenses are designed to create optical blur to evaluate the effects on contrast sensitivity and visual fatigue. Measurements will be conducted at baseline, 2 weeks, and 4 weeks after exposure to assess changes in visual function."
219209780|NCT06753032|DIAGNOSTIC_TEST|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to negative defocus induced by -2.00 D spectacle lenses. The induced defocus will allow for the evaluation of its impact on contrast sensitivity and visual fatigue. Assessments will be carried out at baseline, 2 weeks, and 4 weeks."
219209781|NCT06753032|COMBINATION_PRODUCT|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Non-Myopic Participants|"ntervention Description: This group will undergo positive defocus using +2.00 D spectacle lenses. The intervention aims to examine the effect of induced defocus on contrast sensitivity and visual fatigue in non-myopic participants. Data will be collected at baseline, 2 weeks, and 4 weeks."
219209782|NCT06753032|COMBINATION_PRODUCT|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Non-Myopic Participants|Intervention Description: This group will experience negative defocus induced by -2.00 D spectacle lenses. The purpose is to evaluate how negative lens-induced defocus affects contrast sensitivity and visual fatigue in non-myopic participants. Measurements will be taken at baseline, 2 weeks, and 4 weeks.
219209783|NCT06814353|PROCEDURE|Intraoperative assessment of the site of origin and growth pattern|The assessment of the epicenter and extension and therefore the assumed origin of tumor growth is conducted by an experienced pediatric neurosurgeon blinded to group allocation based on the intraoperative impression. The anatomical features and site of origin are systematically documented on the surgical form in all cases of this study.
219678015|NCT05573256|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
219678016|NCT05153083|PROCEDURE|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
218983590|NCT02651350|DRUG|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
218983591|NCT02651350|DRUG|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
218983592|NCT01845883|PROCEDURE|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
218983593|NCT02614651|PROCEDURE|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
218983594|NCT02614651|PROCEDURE|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
218983595|NCT02614651|PROCEDURE|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
219678017|NCT06382142|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219678018|NCT06382142|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
219678019|NCT06382142|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
219678020|NCT06382142|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
219678021|NCT06382142|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
219678022|NCT05964283|OTHER|Questionnaire|This questionnaire consists of (five) main parts. The first part is about personal information, the second part is about fluid administration in various settings (emergency room, operating room, and intensive care unit), the third part is about fluid administration behaviors, the fourth part is about workplace location, and the fifth part is about a case study. Filling out this questionnaire will take approximately 60 minutes of your time.
219678023|NCT04912479|DEVICE|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
219678024|NCT04513145|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
219678025|NCT04513145|DRUG|Saline Injection|Saline will be used as a placebo injection
219678026|NCT04513145|PROCEDURE|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
219678027|NCT04252547|OTHER|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
219678028|NCT04252547|OTHER|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
219678029|NCT02382809|DRUG|DC071|Mouthwash, twice daily
219678030|NCT02382809|DRUG|Placebo|Mouthwash, twice daily
219678031|NCT02895191|DRUG|ulinastatin|Patients will receive the study drugs for 7 to 14 days
219678032|NCT02895191|DRUG|placebo|Patients will receive the placebo for 7 to 14 days
219678033|NCT02255071|DEVICE|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
219678034|NCT02255071|DEVICE|Sham wristband|A wristband over wrist but no acupressure for seven days.
219678035|NCT05163938|DEVICE|REThink Therapeutic Game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
219678036|NCT05163938|DEVICE|Treatment as Usual|Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
219678037|NCT00547157|DRUG|Panitumumab|Arm 2 consists of panitmumab plus RT
219678038|NCT00547157|DRUG|Cisplatin|Cisplatin
219678039|NCT03517241|DIAGNOSTIC_TEST|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
218983596|NCT02614651|PROCEDURE|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
218983597|NCT02614651|DEVICE|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
218983598|NCT06238271|DEVICE|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
218983599|NCT02623478|DRUG|Insulin Lispro|Administered subcutaneously (SC)
218983600|NCT00702689|DRUG|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
218983601|NCT04645420|PROCEDURE|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
218983602|NCT02051842|DRUG|Metadoxine|
218983603|NCT01833988|DEVICE|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
218983604|NCT01833988|OTHER|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
218983605|NCT01281137|GENETIC|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
218983606|NCT01281137|OTHER|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
219209784|NCT06812039|DRUG|HAIC combined with sintilimab and donafenib|"HAIC: Two cycles, Q3W. The chemotherapy regimen consists of oxaliplatin 85 mg/m² over 2 hours and raltitrexed 2 mg/m² over 1 hour.~Donafenib: Treatment should begin the day after the completion of the first HAIC, with an initial dose of 0.1g bid p.o.. The investigator may increase the dose to 0.2g bid depending on the patient's condition.~Sintilimab: Administration may begin after the first HAIC, 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles."
219209785|NCT06812039|DRUG|Sintilimab and Donafenib|Donafenib: an initial dose of 0.1g bid p.o. The investigator may increase the dose to 0.2g bid depending on the patient's condition. Sintilimab: 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles.
219678040|NCT03517241|DIAGNOSTIC_TEST|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
219678041|NCT03517241|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
219678042|NCT03517241|DIAGNOSTIC_TEST|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
219678043|NCT03517241|DIAGNOSTIC_TEST|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
219678044|NCT05687721|DRUG|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
218983607|NCT01281137|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
219209786|NCT06812039|PROCEDURE|Surgery|After surgery, received sintilimab and donafenib for 6 cycles.
219209787|NCT06763861|OTHER|Biopsy|Biopsies from EAS
219209788|NCT06766994|OTHER|intrathecal morphine|Preoperatively, patients will be injected with 200 μg morphine intrathecally with a 27G pencil point spinal needle at the L4-L5 or L3-L4 intervertebral space in a sitting position.
219209789|NCT06766994|OTHER|Erector Spinae Plane Block|Preoperatively, patients will be placed in the prone position before the operation and an ESPB block will be applied bilaterally at the T9 vertebra level with the help of USG. 0.25% bupivacaine 20 ml will be used bilaterally as the blocking fluid.
219678045|NCT05687721|DRUG|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
219678046|NCT05431491|DEVICE|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
219678047|NCT05415462|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219678048|NCT05415462|BIOLOGICAL|Fluarix Tetra|Sterile suspension for injection
219678049|NCT00288444|DRUG|Lonafarnib|
219678050|NCT00288444|DRUG|Docetaxel|
219678051|NCT03621241|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometry
219678052|NCT04342013|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
219678053|NCT03616392|DRUG|D308, CKD-501|"1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg"
218983608|NCT01837407|PROCEDURE|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
218983609|NCT04550910|RADIATION|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
218983610|NCT02932423|OTHER|Control product E|Plain water
218983611|NCT02932423|OTHER|Test product A|Beverage with no sugar but sweetener
218983612|NCT02932423|OTHER|Test product B|Beverage with 22 g/L sugar and sweetener
218983613|NCT02932423|OTHER|Test product C|Beverage with 33 g/L sugar and sweetener
218983614|NCT02932423|OTHER|Test product D|Beverage with 47 g/L sugar and sweetener
218983615|NCT02932423|OTHER|Comparative product F|Beverage with 98 g/L sugar
218983616|NCT03697057|PROCEDURE|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
218983617|NCT03388437|DEVICE|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
218983618|NCT03388437|DEVICE|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
219074558|NCT05668728|OTHER|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
219678054|NCT06277713|BEHAVIORAL|Standing interruptions|A mobile sit-to-stand desk will be installed at the workplace and participants are instructed to alternate their working position every 30 minutes during two working days (8h).
219678055|NCT06277713|BEHAVIORAL|Exercise bout|Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
219678056|NCT06277713|BEHAVIORAL|Sedentary|Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
219678057|NCT02333422|OTHER|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
219074559|NCT05668728|OTHER|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
219074560|NCT02115555|BEHAVIORAL|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
219074561|NCT02115555|BEHAVIORAL|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
219074562|NCT02115555|BEHAVIORAL|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
219074563|NCT05735236|DEVICE|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
219074564|NCT06523673|RADIATION|Stereotactic Body Radiotherapy|The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
219074565|NCT06523673|DRUG|second-line systemic therapy|a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
219074566|NCT01360606|RADIATION|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
219074567|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
219074568|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
219074569|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
219074570|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
219074571|NCT06568705|RADIATION|Moderate hypofractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.
219678058|NCT04186221|DEVICE|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
219678059|NCT02259699|OTHER|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
219678060|NCT04932343|DIAGNOSTIC_TEST|cohort study|no intervention
219678061|NCT05624190|DRUG|Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)|The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
219678062|NCT05624190|OTHER|Best Medical Management|Best Medical Management
219209790|NCT06726941|OTHER|Physiotherapy and Rehabilitation Practices|It was planned to give the participants a routine stroke rehabilitation program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, balance exercises, walking training and 20 minutes of bicycle ergometry, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. It was planned to give passive bicycle ergometry to patients without voluntary muscle movement and muscle strength, and active bicycle ergometry to participants with voluntary muscle movement and muscle strength, with the bicycle rehabilitation. It was planned to apply the exercise program to the patients for 5 days a week and for a total of 30 sessions. It will be recommended that they continue the medical treatment they are using during the treatment program. Routine evaluations will be made by the physiatrist before the rehabilitation program starts and 2 tubes of venous blood will be taken from the patients by an experienced nurse
219678063|NCT02158377|DEVICE|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
219678064|NCT02158377|DEVICE|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
219678065|NCT00567424|DRUG|GW273225|
218983619|NCT03682887|PROCEDURE|Cryoballoon PV isolation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
218983620|NCT03682887|PROCEDURE|Cryoballoon PV isolation with Additional RA linear ablation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
218983621|NCT01581710|DRUG|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
218983622|NCT01581710|DRUG|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
218983623|NCT00853034|DIETARY_SUPPLEMENT|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
218983624|NCT00853034|DIETARY_SUPPLEMENT|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
218983625|NCT02761733|BEHAVIORAL|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
218983626|NCT00673946|OTHER|True saturation values displayed|Physicians will be presented with real saturations.
218983627|NCT00673946|OTHER|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
218983628|NCT01649388|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
218983629|NCT03561116|DIETARY_SUPPLEMENT|XAN|Daily intake of a sachet containing 12 mg of XAN
218983630|NCT03561116|DIETARY_SUPPLEMENT|Placebo|Daily intake of a sachet containing excipient
218983631|NCT01222884|DRUG|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
218983632|NCT01222884|DRUG|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
218983633|NCT01715935|DRUG|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
218983634|NCT00387803|DEVICE|Cardiac Resynchronization Therapy with Defibrillation|
218983635|NCT01986907|DRUG|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
218983636|NCT02380001|DRUG|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
218983637|NCT02380001|DRUG|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
219678066|NCT05185635|DIAGNOSTIC_TEST|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
218983638|NCT02842307|PROCEDURE|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
218983639|NCT02842307|PROCEDURE|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
218983640|NCT02842307|PROCEDURE|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
219074572|NCT06568705|RADIATION|Ultrafractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
219074573|NCT04863092|BEHAVIORAL|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
219074574|NCT05762302|DIAGNOSTIC_TEST|MeMed BV test|Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
219074575|NCT01345006|BIOLOGICAL|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
219074576|NCT06807047|OTHER|Epilepsy Management at School Mobile Health Application|Teachers who meet the inclusion criteria will use the EpiSchool
219074577|NCT06807047|OTHER|Digital Epilepsy Education Guide|Teachers who meet the inclusion criteria will use the EpiGuide
219074578|NCT05893914|PROCEDURE|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
219074579|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
219074580|NCT04515186|DRUG|Miltefosine|50 mg capsule
219074581|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
219074582|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
219074583|NCT05467553|DRUG|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
219074584|NCT05467553|DRUG|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
219074585|NCT05467553|DRUG|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
219074586|NCT01155947|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
219074587|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
219209791|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
219678067|NCT01134393|DRUG|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
218983641|NCT02725931|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
219074588|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
219074589|NCT04778033|OTHER|Sperm collection|Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.
219074590|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
219074591|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
219074592|NCT05799157|DRUG|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
219678068|NCT05042986|DRUG|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
219678069|NCT00013377|PROCEDURE|Low vision|
219074593|NCT05799157|DRUG|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
219074594|NCT05799157|DRUG|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
219074595|NCT04789668|DRUG|Bintrafusp Alfa|Given IV
219074596|NCT04789668|DRUG|Pimasertib|Given PO
219074597|NCT04789668|OTHER|Quality-of-Life Assessment|Ancillary studies
219074598|NCT06695637|RADIATION|active cTBS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique which employs magnetic fields to stimulate neural activity in the brain. cTBS is a specific TMS protocol, wherein bursts of high-frequency magnetic pulses are repeatedly applied in a rhythmic pattern, mimicking the theta rhythm of neural oscillations. Studies suggest that cTBS has the potential to modulate cortical excitability and synaptic plasticity, leading to alterations in targeted brain function.~Baseline measures will be collected to develop individualized targets for stimulation and also understand how brain structure and activity may change in response to cTBS."
219074599|NCT06695637|RADIATION|sham cTBS|The intervention group receives cTBS and the control group receives sham stimulation using the sham option in the coil that makes the same noise and feeling without delivering significant amount of magnetic energy into the brain. Both groups are exposed to drug and neutral pictures before and after receiving stimulation. People in the active group will receive cTBS with corrected individualized stimulation intensity to have 1 V/m in targeted brain regions while in the sham group people will only receive sham condition with a similar look, sound, and feel of active stimulation.
219074600|NCT02189798|DEVICE|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
219074601|NCT02189798|DEVICE|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
219074602|NCT03529604|OTHER|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
219074603|NCT03529604|DIAGNOSTIC_TEST|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
219074604|NCT03529604|DIAGNOSTIC_TEST|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
219074605|NCT04543110|DRUG|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
219074606|NCT04543110|RADIATION|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
219074607|NCT03902379|OTHER|Internet-Based Intervention|Receive CCI intervention
219074608|NCT03902379|OTHER|Quality-of-Life Assessment|Ancillary studies
219678070|NCT00652808|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
219074609|NCT03902379|OTHER|Questionnaire Administration|Ancillary studies
219074610|NCT03902379|OTHER|Survey Administration|Ancillary studies
219074611|NCT00578994|DEVICE|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
219074612|NCT03726034|BEHAVIORAL|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
219074613|NCT03726034|BEHAVIORAL|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
219074614|NCT02273141|DRUG|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
219074615|NCT02273141|DRUG|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
219074616|NCT02287935|PROCEDURE|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
219678071|NCT00652808|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
219678072|NCT01109134|DRUG|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
219678073|NCT01109134|DRUG|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
219678074|NCT03367234|BEHAVIORAL|Individual Therapy Sessions|One-on-one sessions with a counselor
219678075|NCT03367234|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
219678076|NCT03367234|BEHAVIORAL|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
219678077|NCT03367234|BEHAVIORAL|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
219074617|NCT02287935|PROCEDURE|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
219074618|NCT00529399|DRUG|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
219074619|NCT00529399|DRUG|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
219074620|NCT00529399|DRUG|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
219074621|NCT01703364|DRUG|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
219074622|NCT01374542|PROCEDURE|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
219074623|NCT02486328|DRUG|Midazolam|Dosage adjustment
219074624|NCT02486328|DRUG|Meperidine|Dosage adjustment
219074625|NCT02486328|DRUG|Remifentanil|Dosage adjustment
219074626|NCT02486328|DRUG|Propofol|Dosage adjustment
219074627|NCT06372470|OTHER|Zestril|N/A, this is an observational study.
219074628|NCT05672992|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
219074629|NCT02968784|DEVICE|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
219074630|NCT04084808|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
219074631|NCT04084808|BEHAVIORAL|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
219074632|NCT04084808|PROCEDURE|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS)."
219074633|NCT04084808|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
219074634|NCT04084808|PROCEDURE|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
219074635|NCT04084808|BEHAVIORAL|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
219074636|NCT04084808|BEHAVIORAL|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
219074637|NCT03461068|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
219074638|NCT03461068|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
219074639|NCT03998826|DRUG|Piroxicam|20mg piroxicam
219074640|NCT03998826|DRUG|Placebo|placebo
219074641|NCT01754831|DEVICE|Fluoride varnish|Topical application of fluoride varnish on present teeth
219360420|NCT02713568|OTHER|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031\*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
219360421|NCT00801866|DRUG|Bevacizumab|Intravitreal administration
219678078|NCT03367234|BEHAVIORAL|Group Therapy Sessions|Group therapy sessions
219678079|NCT03367234|BEHAVIORAL|Psychiatric Consultation|Access to psychiatric consultation
219074642|NCT02208180|BEHAVIORAL|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
219074643|NCT01048528|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
219074644|NCT03843229|DRUG|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
219074645|NCT03843229|PROCEDURE|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
219678080|NCT03367234|BEHAVIORAL|Contingency Management|Rewards for engagement in specified recovery behaviors
219678081|NCT00437372|DRUG|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
219074646|NCT03843229|DRUG|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
219074647|NCT02246517|DRUG|N2O|
219074648|NCT02246517|DRUG|Oxygen|
219074649|NCT02076152|DEVICE|FMISO PET|
219074650|NCT02076152|DEVICE|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
219074651|NCT02076152|DRUG|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
219074652|NCT02076152|DRUG|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
219074653|NCT03317977|BEHAVIORAL|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
219074654|NCT03317977|BEHAVIORAL|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
219074655|NCT00278434|DRUG|Zoledronate|
219074656|NCT00278434|OTHER|Placebo (Saline)|
219074657|NCT03346876|PROCEDURE|Nuss surgery|surgical correction for pectus excacatum
219074658|NCT03199625|BEHAVIORAL|Cognitive therapy|
219678082|NCT00437372|RADIATION|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
219678083|NCT00531947|DRUG|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
219074659|NCT03199625|BEHAVIORAL|Behavior therapy|
219074660|NCT03199625|DRUG|SSRI antidepressants|
219074661|NCT04313881|DRUG|Magrolimab|Administered intravenously
219074662|NCT04313881|DRUG|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
219074663|NCT04313881|DRUG|Placebo|Placebo to match magrolimab administered intravenously
219074664|NCT00496665|DRUG|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
219360422|NCT00801866|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation
219360423|NCT04001855|OTHER|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
219678084|NCT00531947|DRUG|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
219678085|NCT03775967|DIAGNOSTIC_TEST|sialic acid|sialic acid level estimation in salivary samples
219074665|NCT00496665|DRUG|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
219074666|NCT00496665|DRUG|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
219074667|NCT02882568|BIOLOGICAL|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
219074668|NCT05080400|DIETARY_SUPPLEMENT|White rice|Jasmine rice 179g of cooked weight
219074669|NCT05080400|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
219074670|NCT03680599|BEHAVIORAL|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
219678086|NCT03775967|DIAGNOSTIC_TEST|IL10|IL10 estimation in salivary samples
219209792|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
219209793|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
219209794|NCT05934292|DRUG|Enlicitide Decanoate|Oral dose
219074671|NCT03680599|BEHAVIORAL|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
219074672|NCT05595304|PROCEDURE|prosthetic refunctioning|Active treatment followed by regular interventions
219678087|NCT01800799|DRUG|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
219678088|NCT01800799|DRUG|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
218983642|NCT00969254|DRUG|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
219074673|NCT05595304|PROCEDURE|conventional prosthetic treatment|new prosthesis
219074674|NCT02145546|DRUG|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
219074675|NCT02145546|DRUG|Propafenone|150mg per 8 hours, 3 times per day
219074676|NCT02145546|DRUG|Sotalol|80mg twice per day.
219074677|NCT03061253|OTHER|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
219074678|NCT03061253|OTHER|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
219074679|NCT03061253|OTHER|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
219074680|NCT00242112|PROCEDURE|MRI Prostate|
219074681|NCT02573519|RADIATION|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
219074682|NCT02573519|DEVICE|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data"
219209795|NCT06361329|DRUG|Homoharringtonine|Intravenous infusion
219209796|NCT06361329|DRUG|venetoclax|Orally by mouth
219209797|NCT06361329|DRUG|Cytarabine|subcutaneous injection or Intravenous infusion
219209798|NCT06361329|DRUG|G-CSF|subcutaneous injection
219209799|NCT06361329|DRUG|Vindesine|Intravenous infusion
219678089|NCT03240276|OTHER|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
219678090|NCT03240276|DEVICE|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
219678091|NCT03240276|OTHER|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
218983643|NCT00969254|DRUG|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
218983644|NCT04335032|DRUG|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
218983645|NCT04335032|DRUG|Placebo|same as in arm/group description
218983646|NCT00625794|DRUG|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
218983647|NCT00625794|BEHAVIORAL|Smoking cessation counseling|8 weeks or counseling
218983648|NCT02149719|OTHER|Desensitisation using boiled peanut|
219678092|NCT03513783|OTHER|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~* A clinical exam is performed by the Physical Medicine \& Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~* Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~* The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
219678093|NCT00529178|DRUG|Pravastatin|
219678094|NCT04615078|DEVICE|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~* A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~* An organizational solution relying on a nurse call center."
219678095|NCT00282685|PROCEDURE|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
219678096|NCT02018302|DRUG|Triheptanoin|
219678097|NCT04529317|DIETARY_SUPPLEMENT|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
219678098|NCT02611765|DRUG|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
219678099|NCT02611765|DRUG|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
219678100|NCT02432209|OTHER|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
218983649|NCT02149719|OTHER|Desensitisation using boiled peanut (deferred start)|
218983650|NCT04193358|DIETARY_SUPPLEMENT|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
218983651|NCT04193358|OTHER|PLACEBO|Sugar pills
218983652|NCT03178331|OTHER|Study questionnaires|filled by parents, school nurse and teacher
218983653|NCT00245661|DRUG|Temazepam|
218983654|NCT04052282|DEVICE|Mobile Health App|There is no intervention
218983655|NCT00200642|DEVICE|Stretta® System|
218983656|NCT03010670|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
218983657|NCT03010670|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
218983658|NCT05109845|DIAGNOSTIC_TEST|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
218983659|NCT00000503|DRUG|nitroglycerin|
218983660|NCT00000503|DRUG|streptokinase|
218983661|NCT00000503|PROCEDURE|heart catheterization|
218983662|NCT03949439|PROCEDURE|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
219678101|NCT02432209|DRUG|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
219678102|NCT02432209|OTHER|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
219678103|NCT00311922|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
219678104|NCT00311922|BEHAVIORAL|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
219678105|NCT06222177|DIAGNOSTIC_TEST|Pathophysiologic evaluation|High-resolution manometry and pH study
219678106|NCT06099925|DRUG|Hetrombopag|All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
219678107|NCT05295199|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
219678108|NCT01486823|DRUG|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
219678109|NCT01486823|DRUG|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
219678110|NCT04035122|OTHER|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
219678111|NCT04035122|OTHER|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
219678112|NCT01720485|DRUG|Desloratadine + Prednisolone|1 tablet 3 times a day
219209800|NCT06361329|DRUG|Daunorubicin|Intravenous infusion
219678113|NCT01720485|DRUG|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
219678114|NCT01087203|BIOLOGICAL|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
218983663|NCT04295772|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
218983664|NCT04693117|OTHER|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
218983665|NCT01743417|BEHAVIORAL|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
218983666|NCT06319261|PROCEDURE|guided biofilm therapy|Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
218983667|NCT06319261|PROCEDURE|root surface debridement|Removing plaque and calculus by conventional root surface debridement
218983668|NCT01761175|PROCEDURE|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
218983669|NCT01761175|PROCEDURE|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
218983670|NCT03414320|OTHER|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
218983671|NCT05501223|OTHER|Medication review|30-60 minutes extra consultation regarding the patients drugs
218983672|NCT05501223|OTHER|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
218983673|NCT04801173|COMBINATION_PRODUCT|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
218983674|NCT04801173|BEHAVIORAL|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
218983675|NCT00784641|DEVICE|Novel Bausch & Lomb daily disposable contact lenses|Lenses to be worn and replaced daily for 2 weeks.
218983676|NCT00784641|DEVICE|Bausch & Lomb SofLens daily disposable contact lenses.|Lenses to be worn and replaced daily for 2 weeks.
218983677|NCT00784641|DEVICE|Johnson and Johnson 1-Day Acuvue Moist contact lenses|Lenses to be worn and replaced daily for 2 weeks.
218983678|NCT00496509|DRUG|ZD6474 (Zactima) 100mg|
218983679|NCT00496509|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
218983680|NCT00496509|PROCEDURE|Biomarker Draws|
218983681|NCT00496509|DRUG|ZD6474 (Zactima) 300mg|
218983682|NCT03014557|DEVICE|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
218983683|NCT04356742|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
218983684|NCT04356742|DRUG|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
218983685|NCT04356742|DRUG|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
218983686|NCT04356742|DRUG|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
218983687|NCT00764296|OTHER|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
218983688|NCT00764296|OTHER|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
218983689|NCT02759497|OTHER|serum amyloid A level|serum amyloid A level (SAA)
218983690|NCT01321060|PROCEDURE|Aspiration|
218983691|NCT01321060|PROCEDURE|Catheter drainage|
218983692|NCT01321060|DRUG|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
218983693|NCT06205823|DRUG|Immunotherapy|Immunotherapy
218983694|NCT01254071|DRUG|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
218983695|NCT02256371|BEHAVIORAL|Hypnosis sessions|1 session per week during 8 weeks
218983696|NCT02256371|BEHAVIORAL|Relaxation group|1 relaxation session per week during 8 weeks
218983697|NCT04718961|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
218983698|NCT04718961|DRUG|Placebo|Capsules matched to study drug minus active substance.
218983699|NCT05960942|DRUG|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
218983700|NCT05960942|DRUG|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
218983701|NCT02727842|DEVICE|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
218983702|NCT02727842|DEVICE|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
219074683|NCT02573519|DRUG|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
219074684|NCT02573519|DEVICE|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
219074685|NCT04027153|OTHER|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
219074686|NCT01027546|DRUG|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
219074687|NCT05688904|DRUG|Imipramine|Topical 4% Imipramine
219074688|NCT05688904|OTHER|Vehicle|Vehicle
219074689|NCT01572727|DRUG|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
219074690|NCT01572727|DRUG|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
219074691|NCT01572727|DRUG|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
219074692|NCT04313231|DIAGNOSTIC_TEST|Next Generation Sequencing|"Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%."
219074693|NCT04313231|DIAGNOSTIC_TEST|Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction|"Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit."
219074694|NCT04313231|DIAGNOSTIC_TEST|flow cytometry|A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
219074695|NCT04313231|DIAGNOSTIC_TEST|Metagenomics of stool samples|DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
219074696|NCT04313231|DIAGNOSTIC_TEST|Clinical/demographic data|Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
219074697|NCT04313231|OTHER|Elicitation of the HRQoL|Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
219074698|NCT00003951|DRUG|exatecan mesylate|
219074699|NCT04541238|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging
219074700|NCT02596815|PROCEDURE|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
219074701|NCT02596815|DEVICE|Goniometer|
219074702|NCT06041035|DRUG|QLS31905|Administered as an intravenous infusion.
219074703|NCT06041035|DRUG|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
219074704|NCT06041035|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
219074705|NCT06041035|DRUG|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
219074706|NCT06041035|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
219074707|NCT06041035|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
219074708|NCT01606449|PROCEDURE|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
219074709|NCT00517712|DRUG|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
219074710|NCT02184793|DEVICE|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
219678115|NCT01087203|BIOLOGICAL|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
219678116|NCT06272825|OTHER|Virtual reality|VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
219074711|NCT01856127|DRUG|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
219209801|NCT06361329|DRUG|cyclophosphamide|Intravenous infusion
219209802|NCT06361329|DRUG|Dexamethasone|Intravenous infusion or orally
219209803|NCT06361329|DRUG|L-ASP|subcutaneous injection
219209804|NCT04479787|DEVICE|Spinal Cord Stimulation|Utilization of BURSTDR stimulation
219209805|NCT04479787|OTHER|Conventional Medical Management|Assessing type of CMM, location and frequency.
219209806|NCT06744257|OTHER|Online Education tool|An online education tool that contains 4 modules
219209807|NCT06790667|DEVICE|Low Level Laser Therapy|Participants in this arm will receive Low-Level Laser Therapy (LLLT) using a Gallium Aluminum Arsenide (GaAlAs) semiconductor diode laser. The treatment involves a wavelength range of 650-808 nm with a power output of 775 mW. The therapy is administered by exposing tender points around the temporomandibular joint (TMJ) to the laser for 2 minutes per session. Each participant will receive treatment on alternate days (three sessions per week) over the course of three weeks. The goal is to assess the effectiveness of LLLT in reducing pain and improving mouth opening in patients with myofascial pain associated with Temporomandibular Disorders (TMD).
219209808|NCT06790667|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Participants in this arm will undergo Transcutaneous Electrical Nerve Stimulation (TENS), utilizing a four-electrode unit. The device will be set to deliver electrical impulses at a frequency of 150 Hz with a pulse width of 200 µs. Electrodes will be placed over the cutaneous region between the TMJ and coronoid process to stimulate the trigeminal and facial nerves. Each treatment session will last 15 minutes and occur on alternate days, three times a week for three weeks. This therapy aims to provide pain relief and improve jaw function for patients suffering from myofascial pain associated with TMD.
219209809|NCT06745544|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|The Rhythm- and Multitask-Based Activity (RYMA) program is a unique cognitive-motor exercise intervention designed for older adults with diabetes. It incorporates rhythm-based multitasking exercises, performed to improvised piano music, combined with Activities of Daily Living (ADL)-focused exercises. The intervention targets physical (strength, balance, and coordination) and cognitive (executive function, reaction time) components to reduce fall risk, improve bone health, and optimize cardiovascular outcomes. Delivered over 26 weeks, the program emphasizes social interaction to enhance adherence and long-term engagement.
219209810|NCT06744140|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|To Evaluate the breast Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma In Situ (DCIS) lesions among high-risk breast cancer patients while keeping the histopathology as a GOLD standard
219209811|NCT06766045|DIAGNOSTIC_TEST|Diaphragmatic Ultrasound|"Diaphragmatic ultrasound was performed bedside in the ICU with supine position. Diaphragmatic thickness was measured by placing the ultrasound on 8th-10th intercostal space between anterior and mid-axillary line with marker at 12 o'clock. B-mode ultrasound was used to measure the distance between thoracic and abdominal diaphragm which resulted in the diaphragmatic thickness at inspiration (DTi) and diaphragmatic thickness at expiration (DTe).~The ultrasound was then placed on the subcostal area between anterior and mid-axillary line with marker at 12 o'clock to observe the diaphragmatic motion on each side. Measurement of diaphragmatic excursion as well as recording and evaluation of diaphragmatic sliding and motion were performed during both inspiration and expiration using M-mode."
219209812|NCT06766045|DIAGNOSTIC_TEST|Fluoroscopy|Fluoroscopy test was conducted in cathlab with supine position and anteroposterior (AP) projection for at least 5 breathing cycles. The fluoroscopy recording was then expertised and interpreted by the pediatric cardiologist in charge.
219209813|NCT06792422|DRUG|Oral semaglutide|"Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)"
219209814|NCT06792422|DRUG|Placebo|"Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)"
219209815|NCT06832267|DRUG|Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)|Rituximab: 375 mg/m2 intravenously on day 3,7; Methotrexate: 1.5-3.5 g/m2 intravenously on day 1,14(≤65 ,3.5g/m2；\>65,1.5g/m2); Temozolomide 150 mg/m2 on days 3-7； Thiotepa:40 mg/m2 intravenously on day 17。 Treatment will be given for 4 cycles（28 days for each cycle）, and patients who achieve a CR or better can choose to undergo ASCT or WBRT(23.4Gy).
219209816|NCT06787339|DRUG|Capecitabine|Capecitabine 650mg/m2, bid, p.o for 1 year
219209817|NCT06791226|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 18F-FDG PET/CT|Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for diagnosis and staging.
219209818|NCT06767397|DIAGNOSTIC_TEST|general anesthesia|To evaluate the factors that affect the hemodynamic stability in patients undergoing spinal anesthesia and general anesthesia during pelvic surgery.
219209819|NCT06785766|BEHAVIORAL|Yoga-Based Exercise Program|This intervention is an 8-week yoga-based exercise program conducted with 60-minute sessions twice a week. The program aims to improve flexibility, mobility, and overall well-being. Each session consists of 5 minutes of warm-up, 5 minutes of breathing exercises, 40 minutes of yoga postures, 5 minutes of deep relaxation, and 5 minutes of meditation. The intervention adapts yoga postures based on participants' individual needs, offering a flexible approach. The difficulty of the yoga flows gradually increases over the 8 weeks. When necessary, postures are adapted using props like blocks, straps, blankets, and chairs. A physiotherapist guides participants, demonstrating correct techniques and providing verbal instructions. This program combines yoga, breathing exercises, and meditation to enhance physical and mental well-being, promoting long-term health benefits.
219209820|NCT06769074|BIOLOGICAL|Platelet Rich Plasma|PRP injection into the midurethra and its instillation into urinary bladder
219360424|NCT04001855|OTHER|Dilute bleach|Dilute bleach baths or gauze soaks
219074712|NCT01856127|DRUG|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
219074713|NCT01369862|BIOLOGICAL|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
219074714|NCT01369862|BIOLOGICAL|Placebo|SPGNH buffer
219360425|NCT04537689|BIOLOGICAL|Ixekizumab|Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
219360426|NCT04537689|DRUG|Methotrexate|Oral tablet up to 15mg per week
219678117|NCT06272825|OTHER|conventional rehabilitation|The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
219678118|NCT05720429|OTHER|Psychoeducational program|"A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art."
219678119|NCT00893529|DIETARY_SUPPLEMENT|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
219074715|NCT03998618|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
219074716|NCT03998618|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
219074717|NCT04051229|BEHAVIORAL|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
219074718|NCT04051229|BEHAVIORAL|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
219074719|NCT01478568|DRUG|mirabegron|oral
219074720|NCT01478568|DRUG|desipramine|oral
219074721|NCT04288908|OTHER|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
219074722|NCT05291208|COMBINATION_PRODUCT|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
219074723|NCT05291208|BEHAVIORAL|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
219074724|NCT04429308|PROCEDURE|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
219074725|NCT04429308|DRUG|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
219074726|NCT06448871|DIAGNOSTIC_TEST|Ultrasound assessment of the right lower extremity muscles|Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.
219074727|NCT06448871|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA) scan|skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
219074728|NCT01507870|PROCEDURE|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
219074729|NCT02025777|DEVICE|Capsule Endoscopy|
219074730|NCT01357798|DRUG|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
219360427|NCT04537689|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
219360428|NCT04537689|DRUG|Acitretin|Oral capsule up to 25mg per day
219074731|NCT01357798|DRUG|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
219209821|NCT06834529|GENETIC|CAR2219-T cells|"Genetic: CAR2219-T cells Each subject will be infused with single dose of CD2219-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 5×10\^5 /kg, the medium dose is 1×10\^6 /kg, and the high dose is 2×10\^6 /kg.~Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells."
219209822|NCT06767124|DIETARY_SUPPLEMENT|Ketogenic Supplement|Commercially available ketone ester drink
219074732|NCT03958344|DRUG|Prednisolone|Oral Tablet
219074733|NCT03958344|DRUG|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
219074734|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
219074735|NCT02834780|DRUG|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
219209823|NCT06767124|OTHER|Placebo Drink|Placebo drink containing sunflower oil.
219209824|NCT06765252|DRUG|Capecitabine-based chemotherapy|Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
219209825|NCT06765421|BEHAVIORAL|Intervention Group|"Intervention group activity involves three components:~1. Intervention group GPs will be provided with a long COVID 'toolkit'. The toolkit will be prepared by the study team in collaboration with expert clinicians and public and patient representatives as a resource for GPs to use in patient care.~2. GPs will attend an expert clinician / patient led long COVID educational session grounded in the findings of the toolkit.~3. Applying learnings to date, each GP will conduct case reviews of eight patients with long COVID attending their practice and provide patient care as appropriate."
219209826|NCT05351593|DRUG|Tafasitamab|Given IV
219209827|NCT05351593|DRUG|Lenalidomide|Given Orally
219209828|NCT06832917|DRUG|AK104 plus|SCRT followed by 6 cycles of cadonilimab (AK104) plus mFOLFOX6 as neoadjuvant therapy for patients
219209829|NCT06832917|DRUG|Chemo only|Short-course radiation (SCRT) followed by 6 cycles of mFOLFOX6 as neoadjuvant therapy for patients
219074736|NCT01716312|DRUG|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
219209830|NCT06768203|OTHER|umbilical vein catheterization|In our NICU, UVC placement is a sterile bedside procedure carried out by pediatric residents, neonatology fellows, and neonatology specialists, using polyurethane, single-lumen catheters sized according to the infant's weight: 3.5 Fr for those under 1500 g and 5 Fr for those over 1500 g. Catheter placement is performed using the Modified Shukla-Ferrara Formula
219209831|NCT06768203|OTHER|Control|No umbilical vein catheter was inserted in these infants.
219209832|NCT06768502|OTHER|Community Based Approach (CBA)|The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.
219074737|NCT02014714|DRUG|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
219209833|NCT06768723|OTHER|Warm-up (specifically, Post-Activation Performance Enhancement)|Assess which intervention delivered the best acute performance enhancements.
219678120|NCT00893529|DIETARY_SUPPLEMENT|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
219678121|NCT00614978|DRUG|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
219678122|NCT03731390|DRUG|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
219209834|NCT06791278|BEHAVIORAL|Exercise|After-school childcare educators will participate in a professional development course on delivering pedagogical and child-friendly exercise sessions. The children will receive 1-2 weekly sessions of 45-60 minutes of child-friendly exercise during after-school childcare programs. Duration: 1 year.
219209835|NCT03621813|BEHAVIORAL|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
219209836|NCT03621813|OTHER|Control|Participants are instructed to maintain current activity level and are monitored for changes.
219209837|NCT06788288|OTHER|Massage Chair session|The intervention is composed of a full-body relaxation massage offered by an automatic electric massage chair. The intervention will last for 3 months while the participant will change between massage and washout periods.
219209838|NCT06788288|OTHER|Washout period|During this phase, participants will spend on month without any intervention (massage) accounting for a washout period.
219360429|NCT03517631|BIOLOGICAL|shRNA-modified CD34+ cells|Infusion of CD34+ cells transduced with shRNAs.
219678123|NCT04285905|OTHER|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
219678124|NCT04285905|OTHER|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
219678125|NCT04285905|OTHER|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
219678126|NCT04285905|OTHER|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
219678127|NCT04285905|OTHER|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
219074738|NCT02014714|DRUG|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
219678128|NCT03397602|BEHAVIORAL|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
219678129|NCT03397602|BEHAVIORAL|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
219074739|NCT00637221|DRUG|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
219074740|NCT02755987|DRUG|ANG1005|
219074741|NCT00081367|BEHAVIORAL|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
219074742|NCT00081367|BEHAVIORAL|Standard care alone|Participants will receive standard care for suicide prevention.
219074743|NCT03104634|DRUG|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
219074744|NCT03104634|DRUG|Placebo|Placebo and delivery device matched to active intervention
219074745|NCT02415400|DRUG|Apixaban|
219074746|NCT02415400|DRUG|vitamin K antagonist|
219074747|NCT02415400|DRUG|Acetylsalicylic acid|
219074748|NCT02415400|OTHER|Acetylsalicylic acid placebo|
219074749|NCT02715128|DEVICE|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
219074750|NCT05027165|OTHER|Non-interventional|No intervention
219074751|NCT00062127|DRUG|irinotecan hydrochloride|Given IV
219074752|NCT00062127|DRUG|thalidomide|Given orally
219074753|NCT00062127|OTHER|pharmacological study|Correlative studies
219074754|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
219074755|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
219074756|NCT02270450|PROCEDURE|therapeutic conventional surgery|Undergo abdominal surgery
219074757|NCT02270450|PROCEDURE|gastrointestinal complications management/prevention|Undergo non-surgical management
219074758|NCT02270450|OTHER|quality-of-life assessment|Ancillary studies
219074759|NCT02363738|DRUG|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
219074760|NCT02363738|OTHER|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
219074761|NCT00601926|BIOLOGICAL|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
219678130|NCT00123994|BEHAVIORAL|Tai Chi classes|
219678131|NCT00123994|BEHAVIORAL|Hydrotherapy classes|
219678132|NCT03828214|DEVICE|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R\&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
219074762|NCT04097457|BEHAVIORAL|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
219074763|NCT05903001|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
219074764|NCT05903001|DIAGNOSTIC_TEST|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
219074765|NCT05903001|DIAGNOSTIC_TEST|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
219074766|NCT05903001|DIAGNOSTIC_TEST|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
219074767|NCT05903001|DIAGNOSTIC_TEST|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
219074768|NCT05903001|DIAGNOSTIC_TEST|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
219074769|NCT05903001|DIAGNOSTIC_TEST|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
219074770|NCT05903001|DIAGNOSTIC_TEST|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
219074771|NCT05903001|DIAGNOSTIC_TEST|6-minute walking distance|The maximum walking distance achieved in 6 minutes
219678133|NCT04721639|OTHER|Sphinx Yoga Therapy|Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
219074772|NCT05903001|DIAGNOSTIC_TEST|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
219074773|NCT05903001|DIAGNOSTIC_TEST|Electromyography|electromyography of the muscles of respiration via superficial electrodes
219074774|NCT05903001|DIAGNOSTIC_TEST|Lung Function|Measurement of lung function via body plethysmography
219074775|NCT05903001|DIAGNOSTIC_TEST|CAT-Questionnaire|COPD Assessment Test (CAT)
219074776|NCT05903001|DIAGNOSTIC_TEST|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
219074777|NCT01542918|DRUG|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
219074778|NCT01542918|DRUG|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
219074779|NCT03731689|DRUG|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
219074780|NCT03731689|DRUG|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
219074781|NCT01293448|DEVICE|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
219074782|NCT00519181|DRUG|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
219074783|NCT01567618|DRUG|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
219074784|NCT01567618|DRUG|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
219074785|NCT06343766|GENETIC|DNA collation and genotyping|"DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression."
219074786|NCT03146624|OTHER|attachment retained obturator|obturator which retained by attachment
219678134|NCT05708040|DEVICE|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
219678135|NCT05708040|DEVICE|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
219678136|NCT03056612|OTHER|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
219074787|NCT03146624|OTHER|clasp retained obturator|obturator which retained by clasp
219074788|NCT02937168|DRUG|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
219074789|NCT02937168|DRUG|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
219074790|NCT02937168|DRUG|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
219074791|NCT04290026|DRUG|metoclopramide versus granisetron|ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
219074792|NCT03392714|DRUG|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
219074793|NCT03265600|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
219074794|NCT03265600|BEHAVIORAL|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
219678137|NCT01372540|DRUG|Carfilzomib|Given IV
219678138|NCT01372540|DRUG|Filanesib|Given IV
219678139|NCT01372540|OTHER|Laboratory Biomarker Analysis|Correlative studies
219074795|NCT06454357|DRUG|B007|B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
219074796|NCT05767944|OTHER|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal \& distal phalanges
219074797|NCT05767944|OTHER|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks \& divisions
219074798|NCT04330638|OTHER|Usual Care|Usual Care
219678140|NCT01290575|DRUG|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
219678141|NCT01290575|DRUG|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
219678142|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
219678143|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
218983703|NCT03542123|DEVICE|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
218983704|NCT02908451|BIOLOGICAL|AbGn-107|Antibody Drug Conjugate
218983705|NCT03051750|OTHER|Complex Physical Therapy plus Pressotherapy|
218983706|NCT03051750|OTHER|Kinesio Taping|
218983707|NCT00446056|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
218983708|NCT00446056|DRUG|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
218983709|NCT01216748|OTHER|quiet breathing|Subjects were instructed to breath normally at room air.
218983710|NCT01216748|OTHER|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
218983711|NCT01216748|OTHER|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
218983712|NCT01216748|OTHER|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
218983713|NCT06205966|DIETARY_SUPPLEMENT|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
218983714|NCT06205966|OTHER|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
218983715|NCT02279446|OTHER|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
218983716|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
218983717|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
218983718|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
218983719|NCT00447005|DRUG|Axitinib (AG-013736)|AG-013736 5mg twice daily \[BID\]
218983720|NCT01595035|BEHAVIORAL|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
218983721|NCT05180617|BEHAVIORAL|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
218983722|NCT01942343|DRUG|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
218983723|NCT01484275|DRUG|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
218983724|NCT01484275|DRUG|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
218983725|NCT02293161|DRUG|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
218983726|NCT02293161|DRUG|Placebo|It is Sodium Chloride Intravenous Infusion
218983727|NCT02949531|DRUG|oxygen|
218983728|NCT05352711|DEVICE|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
218983729|NCT05352711|OTHER|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
218983730|NCT05446441|PROCEDURE|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
218983731|NCT03592654|BEHAVIORAL|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
218983732|NCT02021227|PROCEDURE|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for \> 1 hour
218983733|NCT03407625|OTHER|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
219074799|NCT04330638|DRUG|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
219074800|NCT04330638|DRUG|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
219074801|NCT04330638|DRUG|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
219074802|NCT03575273|BEHAVIORAL|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
219074803|NCT03575273|BEHAVIORAL|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
218983734|NCT03407625|OTHER|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
218983735|NCT02918201|DRUG|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
218983736|NCT02918201|DRUG|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
218983737|NCT02776865|DRUG|suprascapular nerve block|4ml 2% xylocaine
218983738|NCT02776865|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
218983739|NCT04154930|DEVICE|Restylane-L®|Intradermal injection.
218983740|NCT05654935|RADIATION|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
218983741|NCT05654935|RADIATION|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
218983742|NCT06259123|DRUG|[177Lu]Lu-PSMA I&T|2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
218983743|NCT05636059|OTHER|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
218983744|NCT05636059|OTHER|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
218983745|NCT05636059|OTHER|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
218983746|NCT05427929|DEVICE|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
218983747|NCT04032392|BIOLOGICAL|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
218983748|NCT03602430|DRUG|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
218983749|NCT03602430|DRUG|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
218983750|NCT04634890|BEHAVIORAL|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
218983751|NCT01888757|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
218983752|NCT01742000|DIETARY_SUPPLEMENT|Karinat|
218983753|NCT01742000|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
218983754|NCT03148314|DRUG|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
218983755|NCT03148314|DRUG|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
218983756|NCT01674114|PROCEDURE|TAP block|
218983757|NCT01674114|PROCEDURE|control|
218983758|NCT06026657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
218983759|NCT06026657|PROCEDURE|Computed Tomography|Undergo CT scan
218983760|NCT06026657|DRUG|Gemcitabine|Given IV
218983761|NCT06026657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218983762|NCT06026657|BIOLOGICAL|Naxitamab|Given IV
218983763|NCT06026657|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
218983764|NCT03104543|BEHAVIORAL|Education|30 minute education session; 15 minute booster session at 4 months
218983765|NCT03104543|BEHAVIORAL|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
218983766|NCT02714374|BIOLOGICAL|GL-ONC1|"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
218983767|NCT00966771|DRUG|Copper T380 IUD|copper T 380 IUD
218983768|NCT00966771|DRUG|Oral levonorgestrel|1.5 mg
218983769|NCT01828736|BIOLOGICAL|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
219360430|NCT03517631|DRUG|Low dose busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
219360431|NCT03517631|DRUG|Busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
219678144|NCT01290575|DRUG|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
218983770|NCT01828736|DRUG|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
218983771|NCT01828736|DRUG|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
218983772|NCT01828736|DRUG|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
218983773|NCT02130297|DEVICE|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
218983774|NCT01219673|OTHER|Placebo|1 by mouth twice a day.
218983775|NCT01219673|DRUG|Armodafinil|150 mg by mouth once a day.
218983776|NCT01219673|DRUG|Minocycline|100 mg by mouth twice a day.
218983777|NCT01219673|DRUG|Bupropion|100 mg by mouth twice a day.
218983778|NCT04596800|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
218983779|NCT04596800|OTHER|Enhanced Recovery After Surgery|ERAS
218983780|NCT05862142|OTHER|No intervention|No intervention
218983781|NCT01120535|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
218983782|NCT06253975|BIOLOGICAL|adipose tissue derived extracellular vesicles (AT-EVs)|Extracellular vesicles from patient's adipose tissue together with HA
218983783|NCT06253975|DRUG|Hyaluronic acid|Use HA only as a placebo
218983784|NCT03196856|BEHAVIORAL|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
218983785|NCT03196856|DIETARY_SUPPLEMENT|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
218983786|NCT03196856|DIETARY_SUPPLEMENT|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
218983787|NCT00551447|DRUG|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
218983788|NCT00551447|DRUG|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
218983789|NCT00551447|DRUG|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
218983790|NCT01647646|DRUG|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
218983791|NCT00806351|DRUG|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
218983792|NCT00806351|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
218983793|NCT00913380|RADIATION|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
218983794|NCT00913380|RADIATION|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
218983795|NCT00134030|DRUG|Cisplatin|Given IV
218983796|NCT00134030|DRUG|Doxorubicin Hydrochloride|Given IV
218983797|NCT00134030|DRUG|Etoposide|Given IV
218983798|NCT00134030|DRUG|Ifosfamide|Given IV
218983799|NCT00134030|DRUG|Methotrexate|Given IV
218983800|NCT00134030|BIOLOGICAL|Peginterferon Alfa-2b|Given subcutaneously
218983801|NCT00134030|OTHER|Quality-of-Life Assessment|Ancillary studies
218983802|NCT00134030|OTHER|Questionnaire Administration|Ancillary studies
218983803|NCT00134030|PROCEDURE|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
218983804|NCT04941859|BEHAVIORAL|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
218983805|NCT00601198|DRUG|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
218983806|NCT02261454|OTHER|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
218983807|NCT04111198|RADIATION|Cardiac MRI|Cardiac MRI
218983808|NCT01597401|DRUG|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
218983809|NCT01597401|DRUG|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
218983810|NCT01597401|DRUG|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
218983811|NCT01597401|DRUG|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
218983812|NCT01597401|DRUG|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
218983813|NCT03162588|DRUG|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
218983814|NCT05777746|BEHAVIORAL|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
218983815|NCT05777746|BEHAVIORAL|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
218983816|NCT03405584|DRUG|Esomeprazole|Proton pump inhibitor
219209839|NCT06769542|BEHAVIORAL|Experimental (micro teaching)|The experimental group was taught using the micro-teaching method for 8 weeks. Psychomotor skills for drug administration were performed on models. Video recordings were taken while the students were performing the skills. These videos were evaluated by the instructor and the students and the students were given the opportunity to see their own mistakes. During 8 weeks, each student was given the opportunity to perform the applications and evaluate themselves. In addition, activities for drug applications were carried out with students within the scope of small group work. Micro teaching with 4 groups of 8 students was applied for 8 weeks.
219209840|NCT06768606|BEHAVIORAL|EMPOWER Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context. The STEM Academy program will implement a shortened version of the social-emotional learning curriculum to meet their timelines.
219209841|NCT06768736|COMBINATION_PRODUCT|Personalised early warning system|Early warning system personalised forecasting messages
219209842|NCT06838884|OTHER|6 minutes step test and bicycle ergometer|Evaluation
219209843|NCT06793657|DIAGNOSTIC_TEST|computed tomography and poppy seed|comparison of both interventions
219074804|NCT03575273|BEHAVIORAL|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
219074805|NCT03575273|BEHAVIORAL|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
219074806|NCT03575273|PROCEDURE|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
219074807|NCT03575273|DIETARY_SUPPLEMENT|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
219074808|NCT03070613|DRUG|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
219074809|NCT02293538|DRUG|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
219074810|NCT02293538|DRUG|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
219074811|NCT02293538|DEVICE|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
219074812|NCT03576157|OTHER|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
219074813|NCT03813940|BIOLOGICAL|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
219074814|NCT03813940|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
219074815|NCT01414387|PROCEDURE|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
219074816|NCT01414387|PROCEDURE|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
219074817|NCT05315193|OTHER|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
219074818|NCT05315193|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
219074819|NCT00322348|DRUG|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
219074820|NCT00322348|DRUG|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
219074821|NCT02248298|DRUG|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
219678145|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
219678146|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
219678147|NCT01290575|DRUG|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
219678148|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
219678149|NCT03457623|OTHER|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
219678150|NCT01770821|OTHER|Dietary supplement and/or physical training|
219678151|NCT01324921|OTHER|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
219678152|NCT01324921|OTHER|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
218983817|NCT03405584|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
218983818|NCT03405584|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
218983819|NCT06319378|DRUG|psilocybin 25 mg sod|psilocybin 25 mg sod
218983820|NCT06319378|DRUG|psilocybin 1 mg sod|active placebo
218983821|NCT06558045|DRUG|Rivaroxaban 20 mg film-coated tablet|One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
218983822|NCT06558045|DRUG|Xarelto 20 mg film-coated tablet|One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
218983823|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
218983824|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
218983825|NCT02028143|PROCEDURE|Pulmonary vein isolation|
218983826|NCT02028143|PROCEDURE|ICE catheter placed through one of two existing 8F sheaths|
218983827|NCT00855673|DEVICE|Intermittent Mechanical Compression|FM220 device
218983828|NCT00855673|DRUG|Control|Standard medical treatment
218983829|NCT01932307|PROCEDURE|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
218983830|NCT05749107|DIAGNOSTIC_TEST|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
218983831|NCT05749107|COMBINATION_PRODUCT|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
218983832|NCT02842359|DRUG|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
218983833|NCT02842359|DRUG|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
218983834|NCT02842359|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
218983835|NCT02925520|DRUG|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
218983836|NCT06194630|DRUG|68Ga-A3|Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
218983837|NCT04690933|OTHER|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
218983838|NCT02643602|OTHER|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
218983839|NCT02643602|OTHER|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
218983840|NCT04775407|PROCEDURE|blood sampling|IgM og IgG analysis
218983841|NCT06210607|DRUG|HS-10511 Tablets|HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
218983842|NCT06210607|DRUG|HS-10511 Tablets Placebo|HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
218983843|NCT01765907|DEVICE|HIFU|
218983844|NCT00508755|DEVICE|Gait Robot|gait training with the use of a gait robot
218983845|NCT00508755|DEVICE|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
218983846|NCT03837860|DRUG|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
218983847|NCT03837860|DRUG|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
218983848|NCT03837860|DRUG|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
218983849|NCT06090396|DIAGNOSTIC_TEST|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
219074822|NCT02248298|DRUG|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
219074823|NCT02248298|DRUG|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
219074824|NCT03276351|DEVICE|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
219074825|NCT03276351|DEVICE|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
219074826|NCT00737126|DRUG|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
219074827|NCT00737126|DRUG|Placebo|Administration of an oral placebo pill
219074828|NCT01978613|DRUG|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
219074829|NCT01978613|DRUG|placebo|Tablets for one-daily oral administration.
219074830|NCT03568864|OTHER|Low nucleotide meal|The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
219074831|NCT03568864|OTHER|High nucleotide meal|The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
219074832|NCT02566954|OTHER|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
219074833|NCT03993769|OTHER|A19010-F|A snus product
219074834|NCT03993769|OTHER|B19010-F|A snus product
219074835|NCT03776513|BEHAVIORAL|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
219074836|NCT01298128|DRUG|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
219074837|NCT01298128|DRUG|marvelon|marvelon 21 daily
219074838|NCT01791933|DRUG|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
219074839|NCT01791933|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
219074840|NCT01791933|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10\~20 acupoints 1-2times a week for more than 2 months
219074841|NCT01791933|PROCEDURE|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
219074842|NCT04474236|OTHER|thoracic lung ultrasound|Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
219678153|NCT01324921|OTHER|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
219678154|NCT04633772|DRUG|Angiotensin-(1-7)|Intravenous supplementation of Angiotensin-(1-7)
219678155|NCT04633772|DRUG|Placebo|NaCl 0.9%
219678156|NCT02118259|OTHER|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
219678157|NCT00096759|BEHAVIORAL|Tai Chi Chih|
219678158|NCT00096759|BEHAVIORAL|Relaxation training|
219678159|NCT00040144|DRUG|ACH126, 433|
219678160|NCT00360009|PROCEDURE|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
219678161|NCT00360009|PROCEDURE|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
219678162|NCT04110886|DRUG|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
219678163|NCT04110886|DRUG|Placebo|Single dose, injection matching placebo
219678164|NCT03620383|PROCEDURE|Topical Heat|Warm heat pack applied topically in participant hand.
219074843|NCT03536806|DRUG|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
219074844|NCT03536806|DRUG|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
219074845|NCT04949373|DEVICE|High-intensity laser therapy (HILT)|"High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
219209844|NCT06737939|OTHER|intravenous ibuprofen|A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.
219209845|NCT06737939|OTHER|periprostatic nerve block|A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
219209846|NCT06797193|OTHER|Electronic Health Record Review|Ancillary studies
219209847|NCT06797193|PROCEDURE|Liver Biopsy|Undergo liver biopsy
219209848|NCT06797193|OTHER|Medical Device Usage and Evaluation|Undergo ultrasound with SHAPE technique
219209849|NCT06797193|DRUG|Perflutren Lipid Microspheres|Given IV
219209850|NCT06797193|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219209851|NCT06797011|BIOLOGICAL|High volume Plasma Exchange|High volume Plasma Exchange with minimum 3 sessions on alternate days
219209852|NCT06797011|OTHER|Standard Medical Treatment|Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
219209853|NCT06796465|OTHER|McKenzie with Progressive Postural Control Exercises|"The McKenzie Exercises focus on progressive spinal extension to alleviate back pain. Key steps include Extension in Standing, where patients lean backward and return to a neutral stance; Extension in Lying (Partial Range), involving partial pushups in a prone position; and Extension in Lying (Full Range), where patients fully extend their arms to achieve maximum spinal extension. Each movement is held for 1-2 seconds.~The PPCE program enhances core strength and stability through three stages. In the First Stage (2 weeks), core muscles are trained against gravity using movements like pelvic retroversion, crunches, and glute bridges. The Second Stage (3 weeks) incorporates a Swiss ball to challenge trunk muscles with instability. In the Third Stage (3 weeks), a Swiss ball, stretch bands, and a 5 kg sandbag are used to increase complexity on unstable surfaces. Each stage includes six movements, lasting 5 minutes each, for a total session duration of 30 minutes."
219209854|NCT06796465|OTHER|McKenzie without Progressive Postural Control Exercises|"Subject were treated with McKenzie exercises without the addition of Progressive Postural Control Exercises (PPCE).The exercises included the following:~Standing Extension Exercises: Patients leaned backward from a balanced standing position, arching their back before returning to a neutral stance.~Extension in Lying (Partial Range): Performed in a prone position with hands placed under the shoulders, patients lifted their upper torso in a motion similar to a push-up.~Extension in Lying (Full Range): Similar to the partial range extension, but with fully extended arms, aiming for the maximum tolerated extension. Each movement was sustained for 1-2 seconds."
219209855|NCT06796465|DEVICE|Hot Pack|for 10 to 15 minutes
219209856|NCT06737120|PROCEDURE|Mod-fgg|"Following an intrasulcular incision, 2 mm long horizontal incisions will be made on each side at the level of the gum line. From these incisions, divergent vertical release incisions will be made extending towards the alveolar mucosa. To prepare the recipient area, a thin partial thickness flap will be lifted and then removed. A foil template will be obtained by measuring the dimensions of the resulting area.~A horizontal incision will be made apical to the exposed root area of the target teeth at a distance corresponding to the height of the exposed root surface. Starting from the endpoints of this incision, two more slightly divergent incisions will be made in the coronal direction. Thus, a connective tissue pedicle flap will be formed and carefully separated from the periosteum. The pedicle graft will be turned over the exposed root surface and fixed with bioabsorbable sutures. The palatal graft will be sutured to cover the connective tissue."
219678165|NCT03328598|BEHAVIORAL|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
219678166|NCT03328598|BEHAVIORAL|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
219678167|NCT03328598|OTHER|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
219209857|NCT06737120|PROCEDURE|Fgg|The surgical procedures to be performed in this group will be the same as in the modified free gingival graft group, but no connective tissue pedicle flap will be performed.
219209858|NCT05453136|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
219209859|NCT05453136|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
219678168|NCT01319942|OTHER|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
219678169|NCT00007995|BIOLOGICAL|filgrastim|
219678170|NCT00007995|BIOLOGICAL|recombinant interferon alfa|
219678171|NCT00007995|BIOLOGICAL|sargramostim|
219678172|NCT00007995|DRUG|busulfan|
219678173|NCT00007995|DRUG|cyclophosphamide|
219678174|NCT00007995|DRUG|melphalan|
219678175|NCT00007995|PROCEDURE|autologous bone marrow transplantation|
219678176|NCT00007995|PROCEDURE|bone marrow ablation with stem cell support|
219678177|NCT00007995|PROCEDURE|peripheral blood stem cell transplantation|
219678178|NCT00205998|DEVICE|Locking Compression Plate 2,4mm|
219678179|NCT00205998|DEVICE|Locking Compression Plate 3,5mm|
219678180|NCT00561691|DRUG|nimotuzumab|monoclonal antibody
219678181|NCT04932135|DIAGNOSTIC_TEST|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
219678182|NCT02579317|BEHAVIORAL|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
219678183|NCT02579317|BEHAVIORAL|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
219678184|NCT02932813|BEHAVIORAL|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
219678185|NCT02009423|DRUG|Masitinib|
219678186|NCT02009423|DRUG|Placebo|
219678187|NCT06408779|PROCEDURE|mitral valve repair|coronary artery bypass grafting concomitant mitral valve repair
219678188|NCT03655600|OTHER|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
219678189|NCT01766908|OTHER|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
219678190|NCT01540513|DRUG|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
219678191|NCT01540513|DRUG|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
219074846|NCT04949373|DEVICE|Sham High-intensity laser therapy (sham HILT)|"Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
219074847|NCT00695669|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
219074848|NCT05045625|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
219074849|NCT02339961|RADIATION|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
219678192|NCT03327038|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
219074850|NCT00349453|DRUG|Deferiprone (L1)|50-100 mg/kg body weight daily
219074851|NCT00349453|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
219074852|NCT00349453|DRUG|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
219678193|NCT03327038|OTHER|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
219678194|NCT03327038|BEHAVIORAL|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
219074853|NCT04594161|DEVICE|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
219074854|NCT04594161|DEVICE|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
219074855|NCT02002169|OTHER|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
219074856|NCT02002169|OTHER|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
219074857|NCT02512575|DRUG|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
219074858|NCT02512575|DRUG|Placebo oral suspension/ Placebo capsule|Matching placebo
219074859|NCT02512575|DRUG|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
219074860|NCT04039672|PROCEDURE|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
219074861|NCT05263011|OTHER|Avocado|1 avocado as evening snack
219074862|NCT05263011|OTHER|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
219074863|NCT05263011|OTHER|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
219074864|NCT01750073|DRUG|Cyclophosphamide|Given IV
219074865|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
219074866|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
219074867|NCT01750073|DRUG|Paclitaxel|Given IV
219074868|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
219074869|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
219074870|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
219074871|NCT01022762|DRUG|repaglinide|Individually adjusted dose for 16 weeks
219074872|NCT01022762|DRUG|gliclazide|Individually adjusted dose for 16 weeks
219074873|NCT02808455|DRUG|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
219074874|NCT02808455|DRUG|(Treatment B)|A single 80-mg oral solution dose of pacritinib
219074875|NCT00679003|BEHAVIORAL|SLCBT|Social learning and cognitive behavioral therapy
219074876|NCT00679003|BEHAVIORAL|ES|Education and support (information about nutrition and gastrointestinal system)
219074877|NCT03273413|DRUG|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
219074878|NCT03273413|DRUG|Placebo|Inactive tablet
219074879|NCT06470529|DEVICE|drug eluting stents|different types of drug eluting stents
219074880|NCT06427226|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
219074881|NCT02748915|OTHER|Electrophysiological and psychoacoustic tests|
219074882|NCT05987683|PROCEDURE|Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture|Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
219074883|NCT03989804|BEHAVIORAL|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
219074884|NCT06124625|PROCEDURE|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
219074885|NCT06124625|PROCEDURE|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
219074886|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
219074887|NCT04385732|DEVICE|2D or 3D Melanoma Surveillance Photography|Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
219074888|NCT05094960|DIAGNOSTIC_TEST|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
219074889|NCT00435370|DRUG|Tropisetron|10 mg/day
219074890|NCT00435370|DRUG|Placebo|placebo
219074891|NCT00435370|DRUG|Risperidone|6mg/day
219074892|NCT05450874|PROCEDURE|hepatectomy|
219074893|NCT04584372|DIETARY_SUPPLEMENT|High-nitrate intervention|The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
219074894|NCT04584372|DIETARY_SUPPLEMENT|Low-nitrate intervention|The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
219074895|NCT01965834|DRUG|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
219074896|NCT01468402|PROCEDURE|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
219678195|NCT03327038|OTHER|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
219678196|NCT03327038|OTHER|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
219678197|NCT04030234|DRUG|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
219678198|NCT04030234|DRUG|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
219678199|NCT03541707|DEVICE|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
219678200|NCT01341093|BEHAVIORAL|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
219678201|NCT01341093|BEHAVIORAL|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
219678202|NCT04633499|BEHAVIORAL|Social Cognition Task|Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
219678203|NCT04633499|DEVICE|tDCS|tDCS either over the dmPFC or the rTPJ.
219678204|NCT01390571|DRUG|olaparib|
219678205|NCT01390571|DRUG|temozolomide|
219678206|NCT01390571|GENETIC|gene expression analysis|
219678207|NCT01390571|GENETIC|protein expression analysis|
219678208|NCT01390571|OTHER|laboratory biomarker analysis|
219678209|NCT01390571|OTHER|pharmacological study|
219678210|NCT01390571|PROCEDURE|diffusion-weighted magnetic resonance imaging|
219678211|NCT01390571|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219074897|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
219074898|NCT04936022|OTHER|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
219074899|NCT04936022|BEHAVIORAL|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
219074900|NCT00345774|DRUG|PRX-08066|
219074901|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
219074902|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
219074903|NCT02858739|DEVICE|BIOFREEDOM STENT|
219074904|NCT05282524|DEVICE|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
219678212|NCT01390571|PROCEDURE|therapeutic conventional surgery|
219678213|NCT02721498|PROCEDURE|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
219678214|NCT02721498|OTHER|Rest period|A 30-60 minute of resting
219678215|NCT03482908|BEHAVIORAL|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
219678216|NCT03482908|BEHAVIORAL|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
219678217|NCT03482908|BEHAVIORAL|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
219678218|NCT00502853|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
219678219|NCT00502853|DRUG|Methotrexate|10-25mg/week
219678220|NCT03145051|OTHER|Saline solution|a nasal irrigation care
219678221|NCT03145051|OTHER|Respimer Netiflow|a nasal irrigation care
219678222|NCT01634308|DRUG|Novosis(bongros/BMP-2)|
219678223|NCT01634308|DRUG|Bio-oss|
219678224|NCT05096962|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
219678225|NCT05096962|DIAGNOSTIC_TEST|Cellular immunity|Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
219678226|NCT03605472|OTHER|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
219678227|NCT04955613|DEVICE|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
219678228|NCT04955613|DEVICE|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
219678229|NCT04792307|OTHER|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
219678230|NCT01937585|BEHAVIORAL|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
219678231|NCT01937585|BEHAVIORAL|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
219678232|NCT01392456|PROCEDURE|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
219678233|NCT02485756|OTHER|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
219678234|NCT05061433|OTHER|Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support|MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
219074905|NCT02612402|DEVICE|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
219074906|NCT02612402|DEVICE|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
219074907|NCT03483636|DRUG|Lemborexant|Film-coated oral tablet
219678235|NCT02147392|DRUG|[11C]ER-176|
219678236|NCT04798872|OTHER|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
219678237|NCT03189069|DRUG|Apixaban|Treatment for NVAF patients
219678238|NCT03189069|DRUG|Dabigatran|Treatment for NVAF patients
219678239|NCT03189069|DRUG|Rivaroxaban|Treatment for NVAF patients
219678240|NCT03189069|DRUG|Warfarin|Treatment for NVAF patients
219678241|NCT04565821|DEVICE|IPD Probe via TNIT|A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
219678242|NCT02588664|OTHER|COMPASS Intervention|"* A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
219678243|NCT01315795|DRUG|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
219678244|NCT04400981|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
219678245|NCT04400981|OTHER|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
219678246|NCT00002823|DRUG|cisplatin|
219678247|NCT00002823|DRUG|etoposide|
219678248|NCT00002823|DRUG|vinblastine sulfate|
219678249|NCT00002823|DRUG|vindesine|
219678250|NCT00002823|DRUG|vinorelbine tartrate|
219678251|NCT00002823|RADIATION|radiation therapy|
219678252|NCT02720861|GENETIC|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
219678253|NCT04848753|COMBINATION_PRODUCT|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
219678254|NCT04848753|COMBINATION_PRODUCT|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
219678255|NCT01429298|DRUG|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
219678256|NCT01429298|DRUG|Usual care|Attending administers IV opioid of his choosing
219678257|NCT02852057|DRUG|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
219678258|NCT03592784|BEHAVIORAL|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
219678259|NCT03592784|BEHAVIORAL|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
219678260|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 1|Carbohydrate based food
219678261|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 2|Carbohydrate based food
219678262|NCT01734590|DIETARY_SUPPLEMENT|Control carbohydrate based food|Carbohydrate based food
219678263|NCT00619125|OTHER|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
219678264|NCT00696995|DRUG|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
219678265|NCT04839432|BEHAVIORAL|implementation of albumin solution in the priming of the cardiopulmonary bypass machine|In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
219678266|NCT04324515|PROCEDURE|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
219678267|NCT00002073|DRUG|Epoetin alfa|
219678268|NCT06004323|BEHAVIORAL|Digital health literacy intervention|Participants from the intervention group will be invited to join virtual or face-to-face training, watch short videos on social media, participate in virtual bi-weekly group discussion, and fill in questionnaires for five times during the course of the study
219678269|NCT02226263|DIETARY_SUPPLEMENT|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
219678270|NCT02983253|OTHER|blood sample|none, only laboratory tests on blood serum
219678271|NCT05709405|OTHER|Reading intervention|"The intervention will use a reading program called Lesing for alle (Reading for all) based on the research of Accessible Literacy Learning (ALL) which is an evidence-based approach, designed to teach reading skills to students with various intellectual disabilities, including autism spectrum disorders"
219209860|NCT05453136|DRUG|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
219209861|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
219678272|NCT06005090|PROCEDURE|Far Cortical Locking Technique|Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
219678273|NCT02903420|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
219678274|NCT02555085|BIOLOGICAL|BIIB063|Single ascending IV dose
219678275|NCT02555085|OTHER|Placebo|Single dose
219074908|NCT03483636|DRUG|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
219074909|NCT03483636|DRUG|Placebo|Film-coated oral tablet
219074910|NCT01735123|DIETARY_SUPPLEMENT|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
219074911|NCT03729219|BIOLOGICAL|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
219074912|NCT03729219|OTHER|Placebo|Oral suspension
219209862|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
219678276|NCT00227019|DRUG|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
219074913|NCT04587440|OTHER|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
219074914|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
219074915|NCT02205944|OTHER|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
219074916|NCT02239783|DEVICE|total hip arthroplasty implant|
219074917|NCT04775446|OTHER|Data collection|Data entered in a secure computer database
219209863|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
219209864|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219209865|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
219209866|NCT06325046|OTHER|Survey Administration|Ancillary studies
219209867|NCT06796088|OTHER|Treated zones exposed to Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219209868|NCT06796088|OTHER|Untreated zone exposed to Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219209869|NCT06794788|DEVICE|VR-The iWear|The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles
219209870|NCT05903352|OTHER|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
219074918|NCT03913585|BEHAVIORAL|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
219074919|NCT03985618|PROCEDURE|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
219209871|NCT05903352|DRUG|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
219209872|NCT06793813|DRUG|cadonilimab，bevacizumab，docetaxel|Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
219074920|NCT03985618|PROCEDURE|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
219074921|NCT00006154|DRUG|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
219074922|NCT00006154|DRUG|Ritonavir|100 mg liquid capsules equaling 400 mg daily
219074923|NCT00006154|DRUG|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
219209873|NCT06840236|BEHAVIORAL|Adapted Flu nudge messages|Adapted Flu nudge messages - digital health intervention aimed at improving influenza vaccination rates among adults with diabetes at Dario digital platform approach.
219209874|NCT06840236|BEHAVIORAL|Previously studied based on RCT|Previously studied flu nudge messages in RCT
219209875|NCT06370052|PROCEDURE|excision|excision of the affected area
219074924|NCT00006154|DRUG|Efavirenz|200 mg capsules equaling 600 mg daily
219074925|NCT00006154|DRUG|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
219209876|NCT06793007|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic resonance imaging cholangiopancreatography
219209877|NCT04878029|DRUG|Cabozantinib S-malate|Given PO
219209878|NCT04878029|DRUG|Enfortumab Vedotin|Given IV
219209879|NCT04878029|OTHER|Quality-of-Life Assessment|Ancillary studies
219209880|NCT04878029|OTHER|Questionnaire Administration|Ancillary studies
219209881|NCT04418778|BEHAVIORAL|BEAR|Building Empowerment and Resilience Therapy group
219209882|NCT03685461|OTHER|Electrocochleography|Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
219209883|NCT06837909|PROCEDURE|Transversus abdominis plane (TAP) block|A regional anesthesia technique in which a local anesthetic is injected into the transversus abdominis plane under ultrasound guidance to provide postoperative analgesia.
219209884|NCT06837909|PROCEDURE|Wound infiltration|A local anesthetic technique where bupivacaine with epinephrine is injected directly into the surgical wound sites to provide postoperative analgesia.
219209885|NCT06114212|DEVICE|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
219209886|NCT04899674|DRUG|Elontril|Tablet
219209887|NCT04899674|DRUG|BI 1358894|Film coated tablet
219209888|NCT06474533|DRUG|Fluorethyltyrosine (18-F)|Given intravenously (IV)
219209889|NCT06474533|PROCEDURE|Positron Emission Tomography (PET)|Undergo Imaging Procedure
219209890|NCT03774472|DRUG|Hydroxychloroquine|Given PO
219209891|NCT03774472|DRUG|Letrozole|Given PO
219074926|NCT00006154|DRUG|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
219209892|NCT03774472|DRUG|Palbociclib|Given PO
219209893|NCT05976945|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
219209894|NCT06846099|DRUG|RP903|Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle； Ib: RP903,RP2D,po qd for each 28-day cycle
219209895|NCT06847308|BEHAVIORAL|visual biofeedback through trans-perineal ultrasound|Trans-perineal ultrasound will be used to provide visual biofeedback during the active 2nd stage of labour, this for ten consecutive uterine contractions / pushing efforts
219209896|NCT06847490|OTHER|No intervention (observational study)|This is an observational study aimed at developing and validating a predictive model for perioperative blood transfusion. The study utilizes retrospective clinical data from surgical patients to identify key risk factors associated with transfusion requirements. No experimental intervention will be applied to participants, as the study solely focuses on data analysis and model development.
219209897|NCT06796348|PROCEDURE|Radiofrequency ablation alone|RFA of a cancer in the thyroid gland.
219209898|NCT06796348|PROCEDURE|Surgery|Hemithyroidectomy of the thyroid lobe with cancer
219209899|NCT06793826|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T combined vaccine|prefilled syringe injection intramuscular
219074927|NCT00006154|DRUG|Aldesleukin|Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
219209900|NCT05975593|OTHER|Tumor collection via biopsy|"Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence."
219209901|NCT05975593|OTHER|Blood collection|"Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence"
219209902|NCT05975593|DEVICE|Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)|"Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible."
219074928|NCT01432119|DEVICE|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
219209903|NCT06571240|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
219209904|NCT05109689|BEHAVIORAL|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
219209905|NCT05109689|BEHAVIORAL|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
219678277|NCT00227019|DRUG|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
219074929|NCT01432119|DRUG|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
219074930|NCT01432119|DRUG|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
219074931|NCT01432119|PROCEDURE|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
219074932|NCT05637138|DEVICE|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
219074933|NCT05637138|DEVICE|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
219074934|NCT05637138|DEVICE|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
219074935|NCT05637138|DEVICE|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
219074936|NCT06025331|PROCEDURE|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
219074937|NCT06025331|PROCEDURE|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
219074938|NCT03364205|BEHAVIORAL|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
219074939|NCT00001651|OTHER|[6,6-2H2]-glucose|\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
219074940|NCT02724943|BEHAVIORAL|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
219074941|NCT02724943|BEHAVIORAL|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
219074942|NCT02724943|BEHAVIORAL|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
219074943|NCT02724943|BEHAVIORAL|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
219074944|NCT02724943|BEHAVIORAL|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
219678278|NCT00227019|DRUG|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
219074945|NCT02599194|DRUG|18F-FSPG|Administered intravenously (IV)
219074946|NCT02599194|DRUG|18F-FDG|Administered intravenously (IV)
219074947|NCT05238935|OTHER|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
219074948|NCT00249951|DRUG|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
219074949|NCT03065894|OTHER|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
219074950|NCT03065894|OTHER|Current Care in Family Medicine|Patient education, medication management
219074951|NCT01087008|DRUG|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
219074952|NCT01087008|OTHER|No treatment control|Patients doesn't receive treatment
219209906|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
219209907|NCT05026125|DRUG|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
219209908|NCT05026125|DRUG|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
219074953|NCT05978765|DEVICE|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
219209909|NCT06315816|BEHAVIORAL|virtual reality glasses used during tooth extraction and extirpation treatment|The effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in 7-10 years old children
219209910|NCT06832904|DRUG|pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy|Receive four neoadjuvant cycles of oral pyrotinib (400 mg) once daily, plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) , nab-paclitaxel (260 mg/m2) and carboplatin（AUC=5）every 3 weeks.
219209911|NCT06735053|OTHER|Virtual Reality group|Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.
219678279|NCT00227019|DRUG|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
219678280|NCT00227019|DRUG|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
219678281|NCT03510897|DRUG|teprasiran|IV injection
219074954|NCT05978765|OTHER|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
219074955|NCT04894253|BIOLOGICAL|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
219074956|NCT00000129|PROCEDURE|Radial Keratotomy|
219074957|NCT01182753|RADIATION|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
219074958|NCT01182753|RADIATION|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
219074959|NCT03792113|PROCEDURE|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
219074960|NCT03792113|OTHER|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
219074961|NCT03792113|OTHER|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
219678282|NCT03510897|DRUG|Placebo|isotonic saline
219678283|NCT03786185|BEHAVIORAL|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
219209912|NCT06735053|OTHER|Placebo virtual reality group|The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
219209913|NCT04059406|DRUG|sapablursen|sapablursen administered subcutaneously
219209914|NCT06734377|DEVICE|Delta TMS|TMS will be administered at the frequency of delta oscillation (2.2Hz)
219209915|NCT06734377|DEVICE|Theta TMS|TMS will be administered at the frequency of theta oscillation (6.5Hz)
219678284|NCT03786185|BEHAVIORAL|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
219074962|NCT03334123|OTHER|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
219074963|NCT03334123|OTHER|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
219074964|NCT03826667|DEVICE|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~* HEALICOIL™ PK Preloaded Suture Anchors~* BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~* BIORAPTOR™ Knotless Suture Anchors~* MULTIFIX™ S Ultra Knotless Fixation System~* FOOTPRINT™ Ultra PK Suture Anchors~* TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~* SPEEDSCREW™ Knotless Fixation System~* SpeedLock Knotless Fixation Device"
219074965|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
219074966|NCT04313803|DEVICE|CGM|Dexcom CGM system
219074967|NCT00205569|BEHAVIORAL|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
219074968|NCT03755453|DEVICE|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
219074969|NCT01586143|DRUG|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
219074970|NCT01586143|DRUG|Placebo|
219074971|NCT03047668|DIETARY_SUPPLEMENT|diet with/without supplementation|diet with/without supplementation with PUFAs
219074972|NCT00911872|DEVICE|collagen (EVOLENCE)|injectable collagen
219074973|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
219074974|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
219074975|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
219074976|NCT02298192|DRUG|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
219074977|NCT00777725|DEVICE|FibroScan|Liver scan, similar to an ultrasound.
219074978|NCT04517266|RADIATION|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
219209916|NCT06734377|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency
219209917|NCT06837506|DRUG|Rectus sheath block|Patients will receive rectus sheath block (20 ml bilaterally, bupivacaine 0.25%) after induction of general anesthesia.
219209918|NCT06837506|DRUG|Intrathecal morphine|Patients will receive 150 µg intrathecal morphine after induction of general anesthesia.
219678285|NCT05078749|OTHER|Exercise training group|A regular advanced exercise program will be given and followed.
219678286|NCT05078749|OTHER|Control training group|Basic exercises will be given at the beginning and will do the same exercises
219678287|NCT02005900|DRUG|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
219678288|NCT01084213|DRUG|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
219678289|NCT01084213|DRUG|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
219074979|NCT04517266|RADIATION|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
219678290|NCT05398705|DRUG|Cepharanthine|Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
219678291|NCT05398705|DRUG|Placebo|"Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
219678292|NCT05398705|DRUG|Cepharanthine|"High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
219074980|NCT03386123|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
219074981|NCT03386123|BEHAVIORAL|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
219074982|NCT03386123|BEHAVIORAL|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
219074983|NCT03708939|DIETARY_SUPPLEMENT|Glucose|Daily consumption of 5g of glucose, for 14 days.
219074984|NCT03708939|DIETARY_SUPPLEMENT|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
219074985|NCT03708939|DIETARY_SUPPLEMENT|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
219074986|NCT03708939|DIETARY_SUPPLEMENT|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
219074987|NCT03708939|DIETARY_SUPPLEMENT|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
219074988|NCT03708939|OTHER|No Supplement|Follow up without any dietary supplementation.
219678293|NCT04093557|OTHER|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
219074989|NCT04537962|OTHER|Colgate Periogard® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
219074990|NCT04537962|OTHER|Colgate Peroxyl® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
219074991|NCT04537962|OTHER|Colgate Total® Mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
219074992|NCT04537962|OTHER|Toothpaste with sodium monofluorophosphate|Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
219074993|NCT04537962|OTHER|Toothpaste with sodium fluoride and zinc|Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
219074994|NCT04537962|OTHER|Toothpaste with tin fluoride|Patients will be submitted to brushing with toothpaste with tin fluoride
219074995|NCT05323526|DIAGNOSTIC_TEST|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
219074996|NCT05323526|DIAGNOSTIC_TEST|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
219074997|NCT02649868|PROCEDURE|Transarterial embolization (TAE)|Transarterial embolization
219074998|NCT02649868|DEVICE|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
219074999|NCT04748744|COMBINATION_PRODUCT|Butyrylcholinesterase|Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
219075000|NCT00864448|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
219075001|NCT00864448|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
219075002|NCT03094572|OTHER|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
219075003|NCT03684629|BEHAVIORAL|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
219075004|NCT02907346|BEHAVIORAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
219678294|NCT04093557|OTHER|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
219678295|NCT04649970|PROCEDURE|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
219678296|NCT04013880|DRUG|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
219678297|NCT04013880|DRUG|IDH-1 Inhibitor FT-2102|Given by mouth
219075005|NCT01846130|DIETARY_SUPPLEMENT|Leucine|
219075006|NCT01846130|BEHAVIORAL|Exercise|
219075007|NCT01846130|DIETARY_SUPPLEMENT|Whey protein|
219075008|NCT04625543|DRUG|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
219075009|NCT04625543|DRUG|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
219209919|NCT05155306|DRUG|BI 1358894, intended Commercial Formulation (iCF) (T)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning
219209920|NCT05155306|DRUG|BI 1358894, Trial Formulation 2 (TFII) (R)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning.
219209921|NCT06746090|BEHAVIORAL|Reminders|"Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated."
219209922|NCT06747533|OTHER|Standard Patient Education|"If participants are found to be eligible to take part in this study, participants will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups: the Standard Patient Education group or the Breathe Radiation Protocol Coaching group. This is done because no one knows if one study group is better, the same, or worse than the other group.~If participants are in the Standard Participants Education group, participants will receive standard of care participants education."
219209923|NCT06747533|OTHER|Breathe Radiation Protocol Coaching group|If participants are in the Breathe Radiation Protocol Coaching group, participants will have access to a video that helps guide participants through a relaxed breath hold for the radiation treatment and also access to a coach for questions about the breathing process during radiation. This coaching will take place in the week before participants undergo radiation planning.
219678298|NCT02151214|OTHER|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
219678299|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
218983850|NCT05306392|DEVICE|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
218983851|NCT05306392|DEVICE|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
218983852|NCT04623112|DEVICE|Hearing aid feature: Frequency Compression|FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
218983853|NCT03351933|BIOLOGICAL|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
219075010|NCT01445899|DRUG|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
219075011|NCT01445899|DRUG|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
219075012|NCT01445899|DRUG|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
219075013|NCT01913600|DEVICE|Resolute Integrity Stent|Drug eluting stent (DES)
219075014|NCT05071157|BEHAVIORAL|echocardiography|"* speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)"
219075015|NCT01872169|OTHER|Disordered eating screening questionnaire|
219075016|NCT05218005|DIAGNOSTIC_TEST|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
219075017|NCT02378168|OTHER|no intervention; retrospective study|
219075018|NCT00679939|DRUG|Rosiglitazone|up to 8mg/day
219075019|NCT00679939|DRUG|Metformin|up to 2000mg/day
219075020|NCT04885023|OTHER|Hippotherapy|The hippotherapy program for 10 weeks
219075021|NCT05624658|COMBINATION_PRODUCT|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
219075022|NCT01357967|DRUG|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
219075023|NCT01357967|DRUG|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime"
219075024|NCT01053208|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
219075025|NCT01875926|BIOLOGICAL|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
219075026|NCT01875926|BIOLOGICAL|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
219075027|NCT01875926|BIOLOGICAL|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
219678300|NCT03247881|OTHER|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
219075028|NCT03977220|DRUG|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
219075029|NCT01247129|PROCEDURE|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
219075030|NCT00596440|DRUG|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
219075031|NCT05717933|DIAGNOSTIC_TEST|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
219075032|NCT01029223|DRUG|ivabradine|
219075033|NCT01029223|DRUG|metoprolol|
219209924|NCT06823388|DEVICE|acupuncture|acupuncture
219209925|NCT06823388|DEVICE|pseudo-acupuncture|The pseudo-acupuncture device can simulate the sensation of acupuncture stimulation.
219209926|NCT04095260|OTHER|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
219678301|NCT03247881|OTHER|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
219678302|NCT01284751|OTHER|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
219678303|NCT03743844|BEHAVIORAL|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
219678304|NCT04539548|DRUG|Dextenza Ophthalmic Insert|0.4mg insert for intracanalicular use
219678305|NCT04539548|DRUG|Prednisolone acetate ophthalmic suspension USP 1%|"1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week"
219075034|NCT01029223|DRUG|placebo|
219075035|NCT05652062|DEVICE|Prizvalve® system|Transcatheter valve-in-valve replacement
219075036|NCT04597853|DIAGNOSTIC_TEST|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
219075037|NCT01913418|DRUG|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
219075038|NCT01913418|DRUG|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
219075039|NCT01373528|DRUG|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
219075040|NCT03784339|OTHER|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
219075041|NCT03784339|OTHER|Physiotherapy|Standard physiotherapy care
219075042|NCT01325168|DRUG|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
219075043|NCT01325168|DRUG|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
219075044|NCT04413890|DRUG|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
219075045|NCT00611013|DEVICE|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
219075046|NCT06104475|OTHER|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
219075047|NCT00229125|DRUG|Gabapentin|
219075048|NCT00229125|DRUG|Lorazepam|
219075049|NCT03166761|DRUG|Dexamethasone|Dexamethasone injection into the sacroiliac joint
219075050|NCT03166761|DRUG|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
219075051|NCT01097967|OTHER|CPAP|
219678306|NCT00104793|DRUG|carboplatin|
219075052|NCT01396967|DEVICE|surgery|cataract surgery
219075053|NCT04414982|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
219075054|NCT04414982|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
219075055|NCT06015321|DRUG|Enzalutamide|enzalutamide 160 mg PO daily
219075056|NCT03133975|DRUG|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
219678307|NCT00104793|DRUG|irinotecan hydrochloride|
219678308|NCT01860144|DRUG|Bevacizumab|
219678309|NCT06294444|OTHER|Constraint Induced Movement Therapy|Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.
219075057|NCT03133975|OTHER|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
219075058|NCT00827450|DIETARY_SUPPLEMENT|Ctl|Control, isocaloric diet; no coffee
219075059|NCT00827450|DIETARY_SUPPLEMENT|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
219678310|NCT06294444|OTHER|Mirror therapy|Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
219678311|NCT05168072|DEVICE|m-Health app|M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
219678312|NCT05168072|OTHER|conventional outpatient obesity management|Diet and exercise guidance
219678313|NCT02115061|DEVICE|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
219678314|NCT02115061|DEVICE|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
219678315|NCT03025347|OTHER|Control|Participants complete a resting control condition instead of a run.
219678316|NCT03025347|OTHER|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
219678317|NCT04532411|OTHER|Personal Protective Testing Booth|Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
219678318|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678319|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678320|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678321|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678322|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678323|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678324|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678325|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
219678326|NCT01181947|DEVICE|TEVAR|Thoracic endovascular aneurysm repair
219678327|NCT05211141|DEVICE|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
219678328|NCT06363448|PROCEDURE|Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia|Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
219075060|NCT00827450|DIETARY_SUPPLEMENT|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
219075061|NCT00827450|DIETARY_SUPPLEMENT|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
219075062|NCT00827450|DIETARY_SUPPLEMENT|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
219075063|NCT00788996|BEHAVIORAL|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
219678329|NCT07018791|DIAGNOSTIC_TEST|Standard TMD Assessment|This is the conventional diagnostic and management approach for TMD, focusing on physical evaluation and symptom tracking without the use of any visual or art-based tools. It serves as the baseline for comparison in this study.
219678330|NCT07018791|DIAGNOSTIC_TEST|Artistic Pain Exploration (APE) Method|This approach involves showing patients three expressive paintings and asking them to select the one that best resonates with them. A guided interview follows, using the artwork to explore the patient's pain characteristics, emotional impact, and functional limitations. This method aims to provide a richer, more personalized understanding of the patient's pain experience.
219678331|NCT07022327|DRUG|Ivacaftor 150 MG (milligrams)|Ivacaftor is a CFTR potentiator approved for the treatment of cystic fibrosis in patients with specific gating mutations. In this observational, single-patient study, Ivacaftor is being used off-label in an adolescent without a cystic fibrosis-associated CFTR mutation to evaluate its potential impact on chronic pancreatitis. The intervention is not assigned by the study team but is part of the participant's ongoing medical care. The study monitors clinical outcomes and wearable health data over a 12-month period.
219678332|NCT07021729|DRUG|Clarithromycin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
219678333|NCT07021729|DRUG|Levofloxacin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
219075064|NCT03459430|OTHER|Core stability training|Effect of different core stability programs using diverse training intensities
219075065|NCT05214872|DIAGNOSTIC_TEST|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~* hemoglobin (HGB) \[g/dl\];~* red blood count (RBC) \[10\^12/l\];~* hematocrit (HCT) \[l/l\];~* white blood cells (WBC) \[10\^9/l\];~* platelet count (PLT) \[10\^9/l\]"
219075066|NCT05214872|OTHER|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) \[kg/m\^2\] was calculated by dividing a person's weight (post-HD weight in HD group) \[kg\] by the squared their body height \[m\]
219209927|NCT06779357|OTHER|Artwork|d. A 3-arm randomized control trial will be used: one arm with Zentangle workshops, the other arm with Pastel Nagomi Art, while the control group will receive usual care. Data collection from each participant will be conducted at 3-time points, at baseline (T0) before the 4-week weekly Pastel Nagomi Art or Zentangle Art program, right after the program (T1), and one month after the program (T2).
219209928|NCT05812859|DEVICE|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
219209929|NCT06758492|DEVICE|Video laryngoscopy used to insert thin endotracheal catheter|Video laryngoscopy used to insert thin endotracheal catheter
219209930|NCT06758492|DEVICE|Direct laryngoscopy used to insert thin endotracheal catheter|Direct laryngoscopy used to insert thin endotracheal catheter
219209931|NCT06757790|OTHER|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
219209932|NCT06759480|PROCEDURE|Laparoscopic radical hysterectomy based on space anatomy|This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.
219209933|NCT06759480|PROCEDURE|Abdominal radical hysterectomy|This producre is a classic and traditional radical hysterectomy.
219209934|NCT06810219|DEVICE|Cognixion ONE|A wearable augmented reality brain computer interface with self contained computer and software to enable communication using the device input and output capabilities.
219209935|NCT06809803|DRUG|Extended-release sodium oxybate|Participants will take Extended-release sodium Oxybate (Lumryz) 4.5-9 g oral suspension in approximately ⅓ cup of water orally once a day before bedtime. Dosage of Lumryz will be the same as the equivalent total dose of the Non-Extended-release Oxybate (Xywav or Xyrem) that participants use before starting the study
219209936|NCT06809803|DRUG|Non-extended-release oxybates|Participants will take Non-Extended-release Oxybates (Xyrem oral solution or Xywav oral solution) 4.5-9 g orally per night (divided into two doses, once before bedtime and another dose 2-4 hours later) at the same dose of Xyrem or Xywav that participants use before starting the study will be continued to compare with Extended-release sodium Oxybate (Lumryz)
219209937|NCT06751264|PROCEDURE|Peritoneal combined with intrauterine water isolation|On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.
219209938|NCT06751264|PROCEDURE|Peritoneal water isolation|Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures
219678334|NCT07022691|DEVICE|Lafayette dynamometer:|Lafayette dynamometer will be used for assessment of muscle strength Flexible tape measurement will be used for assessment of WC and hip circumference.
219075067|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (1)|"Serum concentration of:~* advanced glycation ends products (AGE) \[µg/mg protein\];~* 3-nitrotyrosine (3-NT) \[µmol/mg protein\];~* advanced oxidation protein products (AOPP) \[µmol/mg protein\];~* carboxymethyle(lysine) (CML) \[µg/mg protein\]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
219075068|NCT05214872|DIAGNOSTIC_TEST|metalloproteinases|"metalloproteinases in the serum \[ng/ml\]:~* metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R\&D Systems, Canada;~* tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R\&D Systems, Canada;~* the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
219075069|NCT05214872|DIAGNOSTIC_TEST|parameters of lipids metabolism in the serum|"* total cholesterol (T-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* low-density lipoprotein cholesterol (LDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* high-density lipoprotein cholesterol (HDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* triglycerides (TG) \[mg/dl\] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C \[mg/dl\] = total cholesterol (T-C) \[mg/dl\]- HDL-C \[mg/dl\]- TG\[mg/dl\]/5)."
219209939|NCT06750380|OTHER|Tailored mat exercise program|The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.
219209940|NCT06750380|OTHER|McKenzie exercises|The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks.
219209941|NCT03987282|OTHER|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
219075070|NCT05214872|DIAGNOSTIC_TEST|parameters of iron metabolism|"* iron concentration \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* total iron-binding capacity (TIBC) \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* the unsaturated iron-binding capacity (UIBC) \[mg/dl\] was determined by an equation in which iron concentration in plasma is subtracted from TIBC \[mg/dl\];~* ferritin \[ng/ml\] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
219678335|NCT07021820|DIAGNOSTIC_TEST|MSOT|Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.
219678336|NCT07021768|DEVICE|Laser Auriculotherapy|French Laser Auriculotherapy using the ECCO REABILITY device and dual pen with red laser with 660 nm wavelength, both manufactured by Ecco Optical Fibers and Devices, using the ideal Nogier Frequency for each region with application of 2 J per point with 100 mW power. For the active group, a 120 mW active tip, red laser with 660 nm, pulse width of 1.2 milliseconds will be used.
219678337|NCT07023068|DIAGNOSTIC_TEST|68Ga-DPA PET/CT|Use 68Ga-DPA PET/CT in the diagnosis of lung cancer
219075071|NCT05214872|DIAGNOSTIC_TEST|selected inflammatory markers|"* high-sensitivity C-reactive protein (hsCRP) \[mg/l\] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~* neopterin \[nmol/l\] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~* interleukin 18 (IL-18) \[pg/ml\] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R\&D Inc., USA."
219075072|NCT05214872|DEVICE|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) \[mm\] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
219075073|NCT05214872|DEVICE|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) \[beats per minute \[bpm\]\]; ejection duration (ED) \[millisecons\]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) \[mm Hg\]; peripheral mean arterial pressure (pMAP) \[mm Hg\]; peripheral end-systolic pressure (pESP) \[mm Hg\]; central systolic (cSBP) and diastolic blood pressure (cDBP) \[mm Hg\]; central mean arterial pressure (cMAP) \[mm Hg\]; central augmented pressure (cAP) \[mmHg\]; central mean pressure of diastole (cMPD)\[mm Hg\]; central mean pressure of systole (cMPS) \[mm Hg\]; central end-systolic pressure (cESP) \[mm Hg\]."
219075074|NCT05214872|DEVICE|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~* reflection index (RI) \[in percentages \[%\]\];~* vascular stiffness index (SI) \[m/s\];~* peripheral pulse pressure (pPP) \[mm Hg\];~* central puls pressure (cPP) \[mm Hg\]~* peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
219075075|NCT05214872|OTHER|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
219075076|NCT05214872|DIAGNOSTIC_TEST|glucose (Glu)|glucose (Glu) \[mg/dl\] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
219075077|NCT05214872|DIAGNOSTIC_TEST|klotho|klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
219075078|NCT05214872|DIAGNOSTIC_TEST|fibroblast growth factor 23 (FGF-23)|FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
219075079|NCT05214872|DIAGNOSTIC_TEST|parameters of calcium and phosphate metabolism|"* total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
219075080|NCT05214872|DIAGNOSTIC_TEST|liver enzymes activity assessment|"activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
219075081|NCT05214872|DIAGNOSTIC_TEST|total protein and albumin|"* total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
219075082|NCT05214872|DIAGNOSTIC_TEST|creatinine and urea|"* creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
219209942|NCT03987282|BEHAVIORAL|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
219209943|NCT06824805|BEHAVIORAL|Exercise|aerobic exercise for 30 minutes at 40-60% HRres
219209944|NCT04445025|DRUG|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
219209945|NCT04445025|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
219075083|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.
219075084|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.
219678338|NCT07023159|OTHER|Demographics|The demographic profile of each patient was documented, including age and sex, to examine potential associations with survival and neurological outcomes.
219075085|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"* methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
219075086|NCT05214872|DIAGNOSTIC_TEST|selected electrolytes assessment|"* potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
219209946|NCT04445025|DIAGNOSTIC_TEST|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
219209947|NCT05375903|DRUG|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
219209948|NCT05375903|DRUG|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
219209949|NCT05375903|DRUG|Gemcitabine|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
219209950|NCT04222062|DRUG|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
219209951|NCT06884553|DEVICE|Robotic therapy (Gloreha Sinfonia system)|"Group A will receive rehabilitative treatment using the Gloreha Sinfonia system . The treatment regimen spans five weeks and encompasses a progressive series of exercises. Gloreha features an adaptable mechanical design developed for hand rehabilitation. Its activities involve grasping and releasing, facilitated through a lightweight and flexible orthosis. The device, comprising a robotic glove and mechanical arm, enables both finger mobility and upper limb support, facilitating semi-autonomous execution of motor tasks. Gloreha's versatility allows for exercises involving the entire upper limb, including motor-cognitive serious games utilizing virtual reality and interaction with real objects. Real-time feedback enhances patient self-assessment. Moreover, the robot incorporates an automated component interfacing with flexion sensors, gauging the patient's autonomous engagement in Occupational Therapy tasks and serious games."
219209952|NCT06884553|OTHER|Occupational therapy|"Occupational Therapy is also recommended in Stroke Rehabilitation Clinical Guidelines. However, its implementation in rehabilitation services in Italy is still limited, presumably due to regulatory factors. For stroke patients, the goal of occupational therapy is to enhance the ability to perform activities of daily living, often focusing on the use of the hand and upper limb in purposeful tasks. Strategies employed by occupational therapists include assessment, treatment, compensation strategies, assistive technologies, and environmental adaptations.~Occupational therapy appears to enhance performance in activities of daily living and reduce the likelihood of impairment in these abilities, although the evidence is of low quality. There is also limited and moderately quality evidence in the area of occupational therapy for addressing depressive and anxiety symptoms in hospital-based rehabilitation for physical disabilities."
219678339|NCT07023159|OTHER|Comorbidities|Data on pre-existing chronic conditions were recorded, such as hypertension, diabetes mellitus, coronary artery disease, chronic kidney disease, and malignancy, in order to assess their potential impact on prognosis following OHCA.
219678340|NCT07023159|OTHER|Prehospital Variables|Several prehospital factors were evaluated, including whether the cardiac arrest was witnessed, whether bystander CPR was performed, the time from collapse to the initiation of CPR, and the time from collapse to EMS arrival. Additionally, the durations of no-flow (i.e., time without any CPR) and low-flow (i.e., time with CPR but without ROSC) were noted. The initial cardiac rhythm was categorized as ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT), asystole, or pulseless electrical activity (PEA). Airway management methods used in the field were documented and classified as bag-valve-mask (BVM), supraglottic airway devices (SGAs), or endotracheal intubation (ETI). Other recorded interventions included prehospital defibrillation, administration of epinephrine (including total dosage), and use of mechanical chest compression devices. Whether ROSC was achieved prior to arrival at the emergency department was also noted.
219678341|NCT07023159|DIAGNOSTIC_TEST|Hematological Parameters|These included white blood cell count (WBC), hemoglobin level, platelet count, mean platelet volume (MPV), and differential counts such as neutrophils, monocytes, and eosinophils.
219678342|NCT07023159|DIAGNOSTIC_TEST|Biochemical Parameters|Measurements included creatinine, urea, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, potassium, chloride, calcium, and troponin-I levels.
219075087|NCT05214872|DIAGNOSTIC_TEST|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
219209953|NCT06884553|BEHAVIORAL|Control|Participants will be provided guidance by a skilled physiotherapist to follow a customized exercise regimen independently within the comfort of their homes. This program will specifically target the upper limb and will be tailored according to the evaluation performed at the initial assessment.
219678343|NCT07023159|DIAGNOSTIC_TEST|Arterial Blood Gas Parameters|The primary clinical outcomes recorded for each patient included return of spontaneous circulation (ROSC), 28-day survival or mortality, and neurological status, which was later assessed using the Cerebral Performance Category (CPC) scale.
219075088|NCT05214872|OTHER|estimated glomerular filtration rate (eGFR) calculation|eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.
219075089|NCT04364646|BEHAVIORAL|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
219075090|NCT05614297|DIAGNOSTIC_TEST|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
219075091|NCT00479011|PROCEDURE|fluid management based on arterial pulse pressure variation|
219075092|NCT00187018|BIOLOGICAL|Bone marrow transplant|
219075093|NCT05883813|PROCEDURE|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction \& maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
219075094|NCT05883813|PROCEDURE|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
219075095|NCT05883813|PROCEDURE|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
219075096|NCT04837066|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
219075097|NCT02048228|DRUG|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
219075098|NCT02048228|DRUG|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
219075099|NCT01060982|DEVICE|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
219075100|NCT03411967|DRUG|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
219075101|NCT03411967|DRUG|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
219678344|NCT07022509|OTHER|proceduder surgery|"The single-incision lateral sulcus mammoplasty is a breast-conserving surgical technique that involves making a single incision along the lateral aspect of the inframammary fold or within the natural skin crease of the lateral sulcus. This approach provides direct access to the lateral quadrants of the breast, which are commonly affected in breast carcinoma, allowing for effective tumor excision while preserving the breast contour.~In SILSM, the incision is carefully planned to align with natural anatomical lines, ensuring optimal cosmetic results and minimal visible scarring. Through this lateral access point, the surgeon performs both tumor resection and glandular reshaping. The technique often involves mobilization and rearrangement of the remaining breast tissue to fill the defect left by the tumor excision, thereby maintaining breast symmetry and volume.~This techn"
219678345|NCT07022509|OTHER|Technique surgery|"The matrix rotation flap is a versatile oncoplastic surgical technique employed in the reconstruction of partial breast defects following tumor excision. This method involves the creation of a rotational skin and glandular flap, mobilized from adjacent breast tissue, typically using an inferolateral or inferomedial pedicle. The flap is designed in a curvilinear or semicircular fashion, allowing it to rotate into the defect site while maintaining adequate vascular supply.~The MRF technique is particularly useful for defects in the lower quadrants of the breast, where direct tissue advancement may be limited. The surgeon carefully outlines a skin paddle adjacent to the resection cavity and undermines the surrounding breast parenchyma. The flap is then rotated and inset into the tumor bed to fill the defect, with the skin paddle contributing to both volume replacement and skin resurfacing if required.~This approach provides robust coverage of the surgical cavity, helps restore breast co"
219075102|NCT01327326|DRUG|Naltrexone|Oral, 50 mg, 1 Time Dose
219209954|NCT06743178|BEHAVIORAL|Photo of a person injecting drugs|Exposed to a photo of a person injecting drugs
219678346|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
219678347|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
219075103|NCT01327326|DRUG|Placebo|Oral, 1 Time Dose
219075104|NCT03083587|BEHAVIORAL|Normal lifestyle|Normal lifestyle
219075105|NCT03083587|BEHAVIORAL|Exercise|Mild exercise 3 min every half hour
219075106|NCT03083587|PROCEDURE|muscle and fat biopsy|Biopsy under local anesthesia
219075107|NCT03083587|DEVICE|Continuous glucose monitoring|Glucose concentrations during the study period
219075108|NCT03083587|DEVICE|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
219075109|NCT00941330|DRUG|Exemestane|25 mg daily by mouth for 6 to 12 months.
219075110|NCT00941330|DRUG|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
219075111|NCT00941330|DRUG|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
219075112|NCT05732233|DEVICE|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
219209955|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (White)|Exposed to a photo of EMS responding to an overdose (White)
219075113|NCT06362681|OTHER|Fluoride|Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
219209956|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (Black)|Exposed to a photo of EMS responding to an overdose (Black)
219075114|NCT02023970|DEVICE|Patients receiving animal-derived bioprosthetic heart valves.|
219075115|NCT02023970|OTHER|Echocardiography (1)|
219209957|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Jail)|Exposed to a photo of a person receiving treatment (Jail)
219209958|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Community)|Exposed to a photo of a person receiving treatment (Community)
219209959|NCT06743178|BEHAVIORAL|Photo of a person in recovery (White)|Exposed to a photo of a person in recovery (White)
219209960|NCT06743178|BEHAVIORAL|Photo of a person in recovery (Black)|Exposed to a photo of a person in recovery (Black)
219209961|NCT06743178|BEHAVIORAL|Photo of a family member of an overdose decedent|Exposed to a photo of a family member of an overdose decedent
219209962|NCT06890975|BEHAVIORAL|Lifestyle Coaching|"The schedule for the individual and group coaching sessions is summarized below:~* Individual Coaching: Six one-on-one online sessions with a trained dietician, starting with an initial 30-minute session at baseline, followed by sessions at one month and then every other month.~* Group Coaching: 60-minute group online sessions with up to 15 participants per group. Group sessions schedule: there will be a total of 13 group sessions. They will meet once a week for the first 4 weeks, twice monthly for the next 8 weeks of follow-up, and then monthly for the remaining follow-up until the 13th session."
219209963|NCT06892028|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
219209964|NCT06892028|DEVICE|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG). No stimulation is provided.
219209965|NCT06890715|DRUG|Test product (T): Ramelteon Modified-Release Tablets|Oral, take 1 tablet at a time, once a day.
219209966|NCT06890715|DRUG|Reference product (R): Ramelteon Tablets|Oral, take 1 tablet at a time, once a day.
219209967|NCT06749886|DRUG|Denosumab|Denosumab, 120 mg subcutaneous injection, every 21-28 days a cycle, given on the first day, a loading dose is given on d8 of the first cycle, and continued use
219678348|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
219678349|NCT07022977|BIOLOGICAL|MET233|For subcutaneous administration
219075116|NCT02023970|OTHER|Echocardiography (2)|
219075117|NCT02023970|OTHER|Echocardiography (3)|
219209968|NCT06749886|DRUG|tislelizumab|Tislelizumab, 200 mg intravenous infusion, every 21 days a cycle, given on the first day, and continued use
219209969|NCT06749886|DRUG|Docetaxel|Docetaxel, 60 mg/m2 intravenous infusion, every 21 days a cycle, given on the first day, and continued use.
219209970|NCT06894641|BEHAVIORAL|Cognitive Behavior Therapy for Older Adults (CBT-OA)|CBT-OA integrates modifications to standard CBT to consider age-related physical, cognitive and psychological changes. CBT-OA also integrates positive psychiatry principles for older adults to promote behavioural change and health attitude change.
219209971|NCT06750900|OTHER|NORMAL CONDITION|They perform 3 lumbar extensions until the onset of pain without virtual reality
219209972|NCT06750900|OTHER|UNDERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10%less than they are really moving.
219678350|NCT07022977|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration
219678351|NCT07021638|OTHER|EMMVIES program|Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health
219678352|NCT07021690|OTHER|High glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.
219678353|NCT07021690|OTHER|Low glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.
219678354|NCT06006377|OTHER|electrotherapy|hotpack electrotherapy ultrasound exercises
219678355|NCT06006377|OTHER|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
219678356|NCT00622492|OTHER|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
219678357|NCT00814723|DRUG|fluvastatin|80 mg MR, 12 weeks
219678358|NCT00814723|DRUG|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
219075118|NCT02023970|BIOLOGICAL|Blood sample (1)|
219075119|NCT02023970|BIOLOGICAL|Blood sample (2)|
219075120|NCT02023970|BIOLOGICAL|Blood sample (3)|
219209973|NCT06750900|OTHER|OVERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10% more than they are really moving.
219209974|NCT06891209|OTHER|Non-Interventional Study|Non-interventional study
219360432|NCT06436456|BEHAVIORAL|Online psychological intervention|The online intervention constitutes a psychological intervention rooted in therapeutic principals of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Comprising 7 obligatory modules and 4 optional modules, the intervention is facilitated through an online platform, offering a text-based self-help program. Patients receive written guidance from a psychologist at Steno Diabetes Center Odense (SDCO). While undergoing intervention, patients have the option to seek clarification or assistance from the psychologist if encountered with queries or difficulties. It is anticipated that patients will progress through approximately one module per week. Following completion of the intervention, patients retain access to the online intervention for a duration of 3 months.
219209975|NCT06892223|DRUG|Monalizumab (anti-NKG2A monoclonal antibody)|Monalizumab (humZ270 mAb, IPH2201) is a humanized IgG4 monoclonal antibody targeting the NKG2A receptor on NK cells. Administered intravenously at a dose of 1 mg/kg on days +30 and +44 after haploidentical stem cell transplantation with post-transplant cyclophosphamide (PT-Cy) as GVHD prophylaxis, Monalizumab aims to enhance NK cell activity by blocking NKG2A. This intervention is unique in its timing, as it is given during a period when CD94/NKG2A+ NK cells are abundant, and its two-dose regimen is designed to optimize NK cell reconstitution. It targets patients with hematologic malignancies, such as AML and MDS, to improve GVHD-free and progression-free survival by enhancing NK cell-mediated immunity. This approach differs from other therapies by focusing on NK cell alloreactivity in the post-transplant setting. Cyclophosphamide is used as part of the pre-transplant conditioning regimen and is part of the inclusion criteria, but it is not part of the protocol-specific intervention.
219209976|NCT06756568|DIAGNOSTIC_TEST|Reduced Morbidity|Early and accurate diagnosis using ultrasound minimizes delays in treatment initiation, thereby preventing complications such as chronic pain and abscess formation. By reducing the severity and duration of the disease, ultrasound contributes to improved patient well-being and a quicker recovery trajectory.
219209977|NCT06760377|DIETARY_SUPPLEMENT|Dietary supplement Group|Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.
219209978|NCT06759155|RADIATION|de-intensified radiation|Adjuvant radiation will be administered on a de-intensified schedule.
219209979|NCT06748781|PROCEDURE|Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.|2.5% Calcium Hypochlorite used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
219209980|NCT06748781|PROCEDURE|Pulpectomy using Saline as root canal irrigant|Saline used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
219209981|NCT06748118|OTHER|Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.|This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
219209982|NCT06761859|OTHER|Aromatherapy Inhalation in Psychiatric Nurses|Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The lavender essential oil to be used in the study will be dropped 3 drops onto a cotton handkerchief cut into a disc shape and fixed to the clothes of the psychiatric nurses, 20 cm away from their noses, and they will be asked to inhale it for 30 minutes.
219075121|NCT06397469|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
219075122|NCT06397469|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
219209983|NCT06755918|BEHAVIORAL|Control|Children will be monitored when fowler is in position during the use of nebulizers. In the Fowler position, the drug will be drained into the nebulizer chamber. Mask and nebulizer connections will be completed. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. Routine nursing care is applied during the use of nebulizer. During the use of a control group nebulizer, routine nebulizer will be used without video game and mask painting. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
219209984|NCT06755918|BEHAVIORAL|Video game|Children will be monitoring while the fowler position during the use of nebulizers. While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, the Water-Sorting Game will be introduced while the use of nebul will be introduced and you will be asked to play. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
219360433|NCT06436456|BEHAVIORAL|Individual psychological intervention|In the individual intervention, patients undergo personalized therapy administered by the assigned psychologist from SDCO. This treatment approach is grounded in the principles of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Delivery of treatment can occur through various modalities, including telephone, video conferencing, or in-person sessions, tailored to accommodate the preferences and requirements of the patient. A maximum of 10 treatment sessions are available for each patient.
219360434|NCT00876083|DRUG|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
219075123|NCT04195503|PROCEDURE|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
219075124|NCT05400798|DEVICE|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
219075125|NCT05400798|DEVICE|Corticosteroid|a single corticosteroid injection into the associated subacromial space
219075126|NCT03558867|DRUG|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
219075127|NCT03558867|DRUG|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
219075128|NCT03508453|BIOLOGICAL|IC14|Monoclonal antibody against CD14
219075129|NCT03508453|OTHER|Placebo|sterile normal saline for injection prepared to be identical to study drug
219678359|NCT06821087|DRUG|Ketamine only|Participants in this arm will receive four intramuscular (IM) ketamine injections over a two-week period. The initial dose will be 0.5 mg/kg during the first session, increasing to 0.65 mg/kg in the second session, and 0.75 mg/kg for the third and fourth sessions. Injections will be administered at least three days apart.
219678360|NCT03516708|DRUG|Epacadostat|Drug provided.
219678361|NCT03516708|RADIATION|Short-course radiation therapy|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
219678362|NCT03516708|DRUG|CAPOX chemotherapy|Standard of care
219678363|NCT03516708|DRUG|FOLFOX chemotherapy|Standard of care
219678364|NCT06766136|BEHAVIORAL|Asthma education program|An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.
219678365|NCT06929481|DEVICE|Cell free DNA (cfDNA) blood test|"The intervention is a novel blood test that evaluates circulating cell free tumor DNA (cfDNA) and detects colorectal cancer (CRC). Recently, the cfDNA test has been shown to have 83% sensitivity and 90% specificity for CRC detection, and 13% sensitivity for advanced polyp detection, heralding a new screening strategy postulated to be highly convenient and acceptable. The cfDNA test is made by Guardant Health, FDA approved for average risk colorectal cancer screening, and marketed with the brand name Shield. Patients opting for the cfDNA test will also be requested to complete an at home FIT."
219678366|NCT06929481|OTHER|At home Fecal Immunochemical Test (FIT) or Colonoscopy|The usual care group will be offered standard colorectal cancer screening options to choose from: at home FIT or colonoscopy.
219678367|NCT06618963|DRUG|Omalizumab Injection|Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.
219678368|NCT03300180|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
219075130|NCT01065961|DRUG|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
219075131|NCT01065961|DRUG|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
219075132|NCT02465593|DRUG|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
219075133|NCT02465593|DRUG|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
219075134|NCT02465593|DRUG|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
219075135|NCT02465593|PROCEDURE|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
219075136|NCT02465593|RADIATION|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
219075137|NCT05699434|BEHAVIORAL|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
219075138|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
219209985|NCT06755918|BEHAVIORAL|Mask painting|While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, mask painting process will be introduced while the use of nebul continues. For mask painting, six color paint will be given and the shapes and colors will be completely left to the child by leaving it to him. After the mask painting and receipt is finished, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
219678369|NCT03300180|OTHER|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
219678370|NCT01475032|DRUG|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
219678371|NCT01475032|DRUG|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
219678372|NCT01475032|DRUG|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
219209986|NCT06753318|DIAGNOSTIC_TEST|The assistance of the Joint-AI model|Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis
219209987|NCT06753318|DIAGNOSTIC_TEST|The assistance of the interpretable Joint-AI model|Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis
219360435|NCT02112500|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
219075139|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
219075140|NCT03701750|DRUG|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
219075141|NCT02860728|BEHAVIORAL|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
219075142|NCT04514159|DRUG|ZN-c5|ZN-c5 is the study drug.
219075143|NCT04514159|DRUG|Abemaciclib|Abemaciclib (VERZENIO®) is an approved drug.
219075144|NCT05626400|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
219075145|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
219075146|NCT01817413|PROCEDURE|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
219075147|NCT01817413|PROCEDURE|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
219075148|NCT07121569|DRUG|Oral lumbrokinase DLBS1033|DLBS1033: 490 mg, DISOLF film-coated tablet, Dexa Medica, 2 tabs t.i.d
219075149|NCT07121569|DRUG|Placebo|Placebo by Dexa Medica, 2 tabs t.i.d.
219075150|NCT07120269|DIAGNOSTIC_TEST|Nasal swab to collect material for RT-PCR SAA evaluation|Nasal swab for parallel identification of SARS-Cov2 and SAA expression
219075151|NCT07122349|DEVICE|Cannabis Impairment Test|Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.
219075152|NCT07126704|DRUG|FB-101|FB-101 10mg
219075153|NCT07126704|DRUG|Placebo for FB-101|Placebo for FB-101
219075154|NCT07127601|PROCEDURE|Ultrasound guided erector spinae plain block (ESPB).|Depending on the size of patient, either a 27 g 3 cm hypodermic needle or a 21 g 5 or 10 cm short bevel needle was used. All blocks were performed with the ultrasound guidance in the parasagittal position and with continuous in-plane needle visualization. The local anesthetic was deposited in the fascial plane deep to the erector spinae muscle superficial to the transverse processes, after confirming the correct tissue plane by hydro-dissection. protocols for choosing 0.25% bupivacaine with a dose of 0.5ml/kg was determined by the age and weight of the patient.
219075155|NCT07127172|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
219075156|NCT07127172|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
219075157|NCT07126964|OTHER|40-hour prone session (intervention)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
219075158|NCT07126964|OTHER|16-hour prone session (control)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
219075159|NCT07128264|BEHAVIORAL|Laughter Yoga|"Laughter eliminates feelings such as hopelessness, anger, and anxiety, thereby alleviating stress, depression, and anxiety, raising the pain threshold, reducing stress, accelerating blood circulation, strengthening immunity, improving quality of life, strengthening memory, reducing tension, and relaxing muscles. Based on these positive effects, laughter yoga is a complementary treatment method that combines humor and laughter. Laughter yoga sessions will be conducted online via Microsoft Teams in a quiet and peaceful environment at home.~The first 10-minute section consists of warm-up exercises (warming up and clapping). The second 10-minute section consists of deep breathing exercises that prepare the lungs for laughter. The third 10-minute section consists of childlike games that induce laughter without humor. The fourth and final 15-minute section consists of laughter exercises that enable laughter without any jokes, comedy, or humor."
219075160|NCT07128043|DEVICE|ultrasound therapy and cassava wax hot immersion|participants sat in a comfortable position with their hand placed on a pillow or cushion. Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm. Afterward, the hand was cleaned and immersed in cassava wax heated to 125°F (51.7°C). The affected hand was dipped into the wax for 3 seconds, then removed. This process was repeated for 10 cycles. The hand was then wrapped in a plastic bag and a towel for 15 minutes before the wax was removed and peeled off.
219075161|NCT07128043|DEVICE|ultrasound therapy|1\. ultrasound therapy Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm.
219075162|NCT07126743|OTHER|exposure to organic pollutant|Small samples of subcutaneous and visceral adipose tissue will be analyzed for the presence and concentration of specific organic pollutants using validated analytical chemistry methods, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).
219209988|NCT06754631|DRUG|Continuous Nebulization of Salbutamol|Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).
219209989|NCT06754631|DRUG|Intermittent Nebulization of Salbutamol|were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
219075163|NCT07127679|OTHER|Two minutes before the ROP examination, 2 mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As par|Data were collected using the premature infant information form, the premature infant vital signs record form, the Premature Infant Pain Profile (PIPP), and the Neonatal Stress Scale. Two minutes before the ROP examination, 2mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As part of routine care, all infants were swaddled and given a pacifier before the procedure. Video recording began 3 minutes prior to the ROP examination and continued until the infant stopped crying post-examination. Recordings were assessed by two independent observers to determine pain and stress scores, as well as parameters such as heart rate, oxygen saturation, perfusion index, and duration of crying.
219209990|NCT06761768|DRUG|Corticosteroids Triamcinolone Acetonide|ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
219678373|NCT03157726|PROCEDURE|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
219678374|NCT03157726|PROCEDURE|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
219678375|NCT00222222|PROCEDURE|vein puncture|comparison of different inflammatory markers in the blood of septic patients
219678376|NCT01486186|DRUG|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
219678377|NCT01486186|DRUG|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
219678378|NCT03922204|DRUG|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
219678379|NCT03922204|DRUG|Pembrolizumab (Keytruda)|Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
219678380|NCT00220233|DRUG|olmesartan medoxomil|
219678381|NCT00220233|DRUG|amlodipine|
219678382|NCT00220233|DRUG|hydrochlorothiazide|
219678383|NCT00461097|DRUG|Egg oral immunotherapy|Egg white solid powder
219678384|NCT00461097|DRUG|Control Group|Placebo for egg white solid
219678385|NCT03818776|DRUG|Durvalumab|Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
219678386|NCT03818776|RADIATION|Proton beam therapy RT|Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
219678387|NCT05977088|DEVICE|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group."
219678388|NCT06955585|DEVICE|Proluxx Artificial Tear Spray|Topical artificial tear spray applied to closed eyelids four times daily for 28 days.
219678389|NCT06954922|BEHAVIORAL|memory-based exercise and training intervention|The experimental group will be given memory-based exercises that will last approximately 15-20 minutes every day for 2 months. Four sessions of epilepsy training will be given, one session per week.
219678390|NCT06954922|BEHAVIORAL|educational initiative about epilepsy|This group will be given 4 sessions of epilepsy training, one session per week.
219678391|NCT06955897|OTHER|Observational|Observational
219678392|NCT03052569|DRUG|RXDX-105|Oral Capsules
219678393|NCT04052321|OTHER|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
219678394|NCT01142947|DRUG|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
219678395|NCT01681953|DRUG|Lamazym|ERT, i.v. infusions weekly
219678396|NCT01681953|DRUG|Placebo|Infusions weekly
219678397|NCT00734708|DRUG|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
219678398|NCT00734708|DRUG|Placebo|Control
219678399|NCT02477878|BIOLOGICAL|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
219678400|NCT02477878|DRUG|Rimiducid|Rimiducid administered to treat GVHD
219678401|NCT04378569|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
219678402|NCT04378569|DRUG|ARQ-252 cream 0.1%|ARQ-252 cream 0.1%
219678403|NCT04378569|DRUG|ARQ-252 Vehicle Cream|ARQ-252 Vehicle Cream
219678404|NCT02658266|BEHAVIORAL|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
219678405|NCT01140971|DRUG|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
219209991|NCT06761768|DEVICE|extracorporeal shockwave|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session)
219209992|NCT06761768|DEVICE|extracorporeal shockwave(minimum intensity)|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session)
219075164|NCT07127575|DEVICE|Resistance Breathing Device|The AIRpen is a multifunctional stress management tool that helps users engage in diaphragmatic breathing at differing resistance levels, as well as other common stress relieving behaviors such as fidgeting
219075165|NCT07127575|DEVICE|Electronic Resistance Breathing Device|The Smart AIRpen functions just as the original AIRpen device and has been augmented with sensors to measure use patterns to determine whether the AIRpen is being used for fidgeting or breathing.
219075166|NCT07127328|DEVICE|Patient with removable funcitonal appliance|Patients who have a malocclusion and/or a dysfunction treated by removable functional appliance
219075167|NCT06483373|DRUG|SPH7854|SPH7854： Orally, 50-3200mg
219075168|NCT06483373|DRUG|Placebo|Placebo：Orally；
219075169|NCT05237141|DRUG|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
219075170|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
219075171|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
219075172|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
219075173|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
219075174|NCT03630666|DRUG|IADT|Patient will receive one injection of IADT at randomization
219075175|NCT03630666|COMBINATION_PRODUCT|IADT + radiotherapy|Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
219075176|NCT04846608|OTHER|Observation|Observation
219075177|NCT06669988|DEVICE|VR|VR - Immersive instruction using virtual reality.
219075178|NCT06669988|DEVICE|Video|Video - Educational content presented through video.
219075179|NCT06669988|DEVICE|written materials|Written Materials - Instruction using text and images.
219209993|NCT06760325|BEHAVIORAL|Tidal Model Intervention|"The model emphasizes long-term developmental care, extending support from hospital to home after discharge. This approach equips individuals with skills to understand and address challenges, emphasizing therapeutic interventions and sustained support through professionals or community groups. By focusing on the chaos and tide concepts of the Tidal Model, psychosocial interventions aim to enhance independence, manage symptoms, and improve quality of life.~In this arm, Tidal Model-based approaches will be applied during home visits to COPD patients. Within the scope of the intervention, psychosocial needs of patients will be assessed, individualized care plans will be created and symptom management and independence will be promoted by focusing on the chaos and tide concepts of the Tidal Model."
219209994|NCT06760026|PROCEDURE|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision
219075180|NCT06669598|OTHER|Whole Body Electromyostimulation|The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
219075181|NCT06669598|BEHAVIORAL|control group|The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
219075182|NCT06996561|DRUG|Nalbuphine Injection|Anaesthesia induction will be done with propofol (2 mg/kg) nalbuphine (0.1mg/kg) and atracurium (0.6mg/kg) intravenously. Maintenance of anaesthesia will be achieved with oxygen (O2), nitrous oxide (N2O) in 1:2 ratio and isoflurane (0.8-1%). Intermittent top up of the study drug 1-2 ml boluses will be administered if either the patient's HR or BP increased to 20 % above baseline and when other causes of tachycardia and hypertension are excluded. Timing of analgesia will be recorded. Pain will be assessed for 24 hours postoperatively using verbal rating scale (VRS) with 0 = no pain and 10 = worst pain. Sedation will be assessed as 0=no sedation, 1= mild sedation, (eye-opening on verbal commands), 2= moderate sedation (eye-opening on painful stimulus), 3= deep sedation (not waking up on pain). All patients will be prescribed paracetamol one gram IV six hourly and nalbuphine 1-2 mg IV infusion in the first 24 hours post operatively.
219075183|NCT06996561|GENETIC|Next Generation Sequencing|5ml of blood samples by venipuncture will be obtained from the first 70 patients half an hour before extubation at the time of muscle closure. These blood samples will be processed for DNA analysis. Only the 15 samples where pain persisted despite nalbuphine administration, with a pain score remaining above 4, continuous use of rescue analgesia, or any documented opioid side effects (such as nausea, vomiting, or sedation), or the need for additional analgesia within 24 hours, will be sent for NGS analysis. These samples will undergo whole exome sequencing via NGS, based on patient parameters and pain scores, after being categorized as responders or non-responders to nalbuphine
219075184|NCT06996561|GENETIC|whole exome sequencing|Only the 15 samples will be sent for NGS based on patient parameters and pain scores after being categorized as responders or non-responders to nalbuphine
219075185|NCT06667453|DRUG|PGN-EDODM1|Administered by intravenous (IV) infusion
219075186|NCT06667453|OTHER|Placebo|Administered by intravenous (IV) infusion
219209995|NCT06760026|PROCEDURE|subdermal suture|wound closure with subdermal sutures using 2-0 nylon thread, under the same evaluation scheme
219209996|NCT03857646|DRUG|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
219678406|NCT01140971|DEVICE|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
219678407|NCT01962948|DRUG|paclitaxel|Given IV
219678408|NCT01962948|DRUG|ganetespib|Given IV
219678409|NCT01962948|OTHER|laboratory biomarker analysis|Correlative studies
219678410|NCT03606057|DRUG|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
219678411|NCT03606057|DRUG|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
219075187|NCT06266416|BEHAVIORAL|IMARA for Black Male Caregivers and Girls Empowerment|IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.
219075188|NCT06266416|BEHAVIORAL|Time-matched control program|FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (\~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
219075189|NCT05244356|BEHAVIORAL|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
219075190|NCT06670352|DRUG|Placebo|QD or BID, 24-weeks fixed dose.
219075191|NCT06670352|DRUG|HSK39297 50mgBID|24-weeks fixed dose.
219075192|NCT06670352|DRUG|HSK39297 100mgBID|24-weeks fixed dose.
219209997|NCT03857646|DRUG|Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
219209998|NCT06767150|DRUG|a second infusion of ZOL when crosslaps levels reach 300 pg/mL|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
219209999|NCT06767150|DRUG|a rescue second infusion at month-12 (standard traitment)|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
219210000|NCT06447532|PROCEDURE|Surgery (Mastectomy or quadrantectomy)|Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy
219210001|NCT06765837|DEVICE|biolase laser|after secondary cleft lip surgery to improve wound healing and prevent scar formation laser was used with group I and Gel was applied to Group II
219678412|NCT03606057|DRUG|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
219678413|NCT03606057|DRUG|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
219678414|NCT05419167|BEHAVIORAL|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
219210002|NCT06765837|DRUG|blue m gel|active oxygen releasing gel was used after the secondary cleft lip repair surgery
219678415|NCT03823820|OTHER|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
219678416|NCT01572714|BEHAVIORAL|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
219678417|NCT01572714|BEHAVIORAL|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
219075193|NCT06670352|DRUG|HSK39297 200mgQD|24-weeks fixed dose.
219075194|NCT07126379|BEHAVIORAL|Family Foundations|FF is an 8-session program for families of children aged 0-12 years targeting parent mental health and family conflict. It will be delivered via telehealth by an allied health professional (i.e., social work, psychology, counselling qualification) trained in FF. The 8 sessions can be delivered flexibly (1 or 2 sessions per week). The duration between sessions can vary as per the needs of the family. We are allowing up to 11 weeks from randomisation for FF to be completed. FF is a manualised program which provides instruction on discussion activities, skills practice, video and workbook exercises for every session. Sessions are based around the content areas of: emotion regulation, stress management, healthy communication, coparenting, conflict resolution, and problem solving.
219075195|NCT07126379|BEHAVIORAL|Family Life Check-In|Families allocated to Family Life Check In will receive this condition from a Clinical Research Nurse, employed at the Primary site (deakin University) with 2 weeks of randomisation. This brief intervention will be comparable to care typically provided to parents/caregivers seeking support for mental health difficulties and/or family/parent relationships issues from a community health service at intake. Family Life Check-In involves a brief (\~30 minute) telephone consultation involving: a) an assessment of the families' needs with one or all parents, b) referral to local services including GP to discuss a mental health care plan, c) provision of reputable Australian web-based resources about supporting children during crises (Raising Children Network, Phoenix Disaster Recovery), and (d) telephone and online support services (BeyondBlue; Lifeline, PANDA, MensLine, KidsLine, Parentline).
219075196|NCT07128160|OTHER|Clinical and Demographic Assessment|"1. Expanded Disability Status Scale (EDSS) (Kurtzke, 1983): This scale will be used for neurological disability assessment~2. Multiple Sclerosis Functional Composite (MSFC): This composite will be used for the assessment of functional performance in patients with MS. It includes: a) Timed 25-foot walk (T25FW), b) Nine-hole peg test (9HPT) for both hands, and c) Paced auditory serial addition test (PASAT).~3. Toronto Alexithymia Scale (TAS-20): This scale reports Alexithymia. It is a 20-item self-report questionnaire measuring three domains: Difficulty identifying feelings (DIF), Difficulty describing feelings (DDF), and externally oriented thinking (EOT). A score ≥ 61 indicates alexithymia (Bagby, Parker \& Taylor, 1994).~4. Montreal Cognitive Assessment (MoCA), (Nasreddine ZS et al, 2005): a 30-point tool that investigates visuospatial abilities, language, attention, memory, abstraction, and orientation, with scores \<26 suggestive of mild cognitive impairment"
219075197|NCT07128160|OTHER|Corticospinal Inhibition Assessment|"Corticospinal inhibition will be evaluated using Transcranial Magnetic Stimulation (TMS) (Ayache et al., 2022; Chalah et al., 2018). All TMS assessments will be conducted according to international safety guidelines. The following parameters will be measured:~1. Motor Evoked Potentials (MEPs) will be recorded from the abductor pollicis brevis muscle.~2. Cortical silent period (CSP) will be assessed to measure corticospinal excitability and inhibition.~3. The interhemispheric inhibition (IHI) is a parameter reflecting the transcallosal GABA-mediated inhibitory activity. It will be obtained at complete muscle rest using figure-of-eight coils (MC-B70; MagVenture), connected with a MagPro\_R20 (Medtronic Inc., USA) generator connected to a butterfly coil."
219210003|NCT06773702|OTHER|gastroenterology and otolaryngological evaluation|"* Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.~* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy."
219210004|NCT06754358|PROCEDURE|LenSx|Participants undergo FLACS using LenSx femtosecond laser system
219210005|NCT06754358|PROCEDURE|Z8|Participants undergo FLACS using Z8 femtosecond laser system
219210006|NCT06768554|OTHER|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)
219210007|NCT06756347|PROCEDURE|Patients receiving landmark-based brachial plexus blocks|The operator will visualize anatomical structures in real time, identify the brachial plexus (supraclavicular approach), and guide the needle to the injection site under direct ultrasound visualization
219210008|NCT06756347|PROCEDURE|Landmark-Based Brachial Plexus Block|The operator will identify anatomical landmarks (e.g., interscalene groove, supraclavicular fossa) using palpation and surface anatomy. The needle will be inserted based on these landmarks, with no direct visualization of internal structures.
219678418|NCT01572714|BEHAVIORAL|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
219678419|NCT02759094|DEVICE|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
219678420|NCT03092570|DEVICE|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
219075198|NCT07128160|OTHER|Radiological Assessment|"All patients will undergo brain and spinal cord Magnetic Resonance Imaging (MRI) using a 1.5T scanner. Brain MRI sequences include: T1-weighted, T2-weighted, FLAIR, and post-contrast sequences. Spinal MRI (cervical and thoracic) includes T2-weighted and STIR sequences. Radiological assessment focused on:~* Number and location of T2/FLAIR lesions~* Presence of contrast-enhancing lesions~* Degree of brain atrophy (qualitatively)~* Spinal cord lesion load A neuroradiologist will review MRI findings, blinded to the clinical and neuropsychological data"
219210009|NCT06756347|DRUG|Bupivacaine|injected in both group as local anesthetic agent ( at a standardized concentration and volume) to ensure comparability.
219210010|NCT06756022|DRUG|Dolasetron mesylate injection|"1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.~Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice."
219210011|NCT06749821|OTHER|Kinesio Tape|Kinesio tape (KT) is an elastic therapeutic tape used to treat sports injuries and various other disorders. It was first used by Dr. Kenzo Kase in 1979 to relieve pain and promote healing in soft tissues and is a method that is constantly being updated. The KT method is a therapeutic taping technique that relieves pain and facilitates lymphatic drainage by microscopically lifting the skin.
219210012|NCT06749821|OTHER|Placebo Tape (Arm 1)|In this application, taping was applied in the same way but with a plaster tape.
219210013|NCT06749821|OTHER|Control (no last irrigation)|No application was made.
219210014|NCT06755047|RADIATION|3D Ultrasound|3D placental volume and vascular indices
219210015|NCT06755047|RADIATION|2D ultrasound|2D placental criteria of invasion and color Doppler
219210016|NCT06756854|BIOLOGICAL|Biologic Agent: injectable platelet rich fibrin.|injection of I-PRF to thin gingival phenotype 3 times with 7 days interval between sessions.
219210017|NCT06756854|OTHER|injecable platelet rich fibrin, and low level laser therapy radiation.|injection of I-PRF+ exposure to LLLT to thin gingival phenotype 3 times with 7 days interval between sessions.
219075199|NCT07127042|DRUG|Low-dose BT-114143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a Low-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
219075200|NCT07127042|DRUG|High-dose BT-14143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a High-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
219075201|NCT07127042|DRUG|Tranexamic Acid (IV)|Intravenous infusion of TXA is started 10-15 minutes before skin incision at a dose of 20mg/kg, and intravenous infusion of TXA is initiated 3 hours (±10 minutes) after the end of the surgery at a dose of 1g.
219075202|NCT07127055|OTHER|No intervention|Control group will take standard diet
219075203|NCT07127055|OTHER|gluten free diet|This group received gluten free diet
219075204|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
219210018|NCT06764004|GENETIC|Stem Cell Product|Human umbilical cord stem cells and exosomes will be used.
219210019|NCT06764004|BIOLOGICAL|Bleeding and clots|Exosomes obtained from human umbilical cord stem cells will be used
219210020|NCT06762509|DRUG|Botulinum toxin type A|Local injection of botulinum toxin type A was given at the time of enrollment
219678421|NCT03092570|DEVICE|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
219678422|NCT05346237|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires, measuring maximum phonation and diadochokinesis
219678423|NCT06957548|DIAGNOSTIC_TEST|Cardiometabolic disease|Cardiometabolic disease screening
219678424|NCT05306717|OTHER|Questionnaire|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
219678425|NCT03864991|DEVICE|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
219678426|NCT03864991|BEHAVIORAL|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
219678427|NCT03864991|BEHAVIORAL|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
219210021|NCT06761521|DIAGNOSTIC_TEST|Peri-Implantitis and Peri-implant mucositis|peri-implant mucositis, peri-implantitis
219075205|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
219360436|NCT00749333|DRUG|AZD8566|solution. Specific dose will be selected by the safety review committee
219075206|NCT04146376|DRUG|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
219075207|NCT04146376|DRUG|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
219075208|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
219075209|NCT07128134|DEVICE|Low Level Laser Therapy|"Although low-level laser therapy has been applied in cases of periodontitis, there are only a limited number of studies investigating its additional benefits in implants with peri-implantitis. This study aims to contribute to the literature on this subject.~In addition to surgical periodontal treatment, low-level laser therapy (LLLT) was applied three times (on the same day as the initial treatment, on the third day, and on the seventh day) to the implants in the test group diagnosed with peri-implantitis. The 940 nm indium gallium arsenide phosphor diode laser (Epic Biolase, Irvine, CA, USA) will be applied perpendicular to the periodontal pocket for 20 seconds at a fixed distance of 15 mm and a continuous wavelength (3.41 J/cm2 application with a 1.76 cm2 spot and 0.3 W average output)."
219075210|NCT07128134|PROCEDURE|Non-surgical Periodontal Treatment|Peri-implantitis diagnosis will be made in the control group, and non-surgical periodontal treatment of implants will be performed using titanium curettes (Hu-Friedy, Chicago, IL, USA).
219075211|NCT07127913|DEVICE|Device: Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
219075212|NCT07127913|DEVICE|Device: Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
219075213|NCT07127913|DEVICE|Device: Stimulation -ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered with a fixed duty cycle
219075214|NCT07126717|DIETARY_SUPPLEMENT|Placebo|Food-grade maltodextrin
219075215|NCT07126717|DIETARY_SUPPLEMENT|Zynamite® S|Water-soluble mango leaf extract standardized to 60% of mangiferin
219075216|NCT06741202|BEHAVIORAL|Men's MST Group|see above
219075217|NCT06741202|BEHAVIORAL|Present-Centered Group Therapy|see above
219075218|NCT06183931|DRUG|ALXN2220|Participants will receive ALXN2220 via IV infusion.
219075219|NCT06183931|DRUG|Placebo|Participants will receive placebo via IV infusion.
219075220|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
219075221|NCT06750588|DRUG|Bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
219075222|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants twice daily for 7 days
219075223|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants three times daily for 7 days
219075224|NCT07059013|DEVICE|Chatbot|"The Chatbot will be designed using open-source conversational AI, such as GPT. The Chatbot will include three modules: individual strength, information, and Peer Networks.~1. Individual Strength Include eight positive psychology exercises: positive introduction, personal strengths, using strengths, three good things, gratitude letter/visit, hope and optimism, active/constructive responding, and savoring.~2. Information Include available healthcare services, parenting skills for children with ASD, the health information for ASD, the financial assistance provided by public and private funding, educational resources, and community resources.~3. Peer Networks Participants can share their experiences about adapting after their child's diagnosis and read others' sharing."
219075225|NCT07059117|OTHER|Hedonic mapping|During the first session, participants will be presented with risotto samples differing in MSG content and thus umami taste intensity, assigned based on Booth's method (Booth et al., 1983). Based on these individual ratings, umami taste intensities of the ad libitum test meals will be calculated per participant.
219075226|NCT07059117|OTHER|Ad libitum risotto test meal|During the ad libitum test meal, participants will be presented with 800 grams of risotto with either high-, low-, or optimum umami taste intensity.
219075227|NCT06598579|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a form of psychotherapy that combines principles of cognitive therapy with mindfulness practices focused on increasing non-judgemental awareness of the present moment. It was designed to help individuals, particularly those with depression, stop rumination and a cycle of negative thought patterns that lead to emotional distress including depression. It is a well established depression EBT. The Vietnamese version of the program (MBCT-VN) is a group treatment involving from five to ten participants (depending on how many participants are able to be recruited) per group.
219075228|NCT06598579|BEHAVIORAL|Treatment-as-usual involving Buddhist meditation|MBCT and other mindfulness interventions were originally derived from Buddhist meditation, modifed to be non-secular and focused on treatment of depression and other mental health and behavioral problems rather than on spiritual development. In the present study, a treatment-as-usual condition involving Buddhist meditation will be used. The project will assess the characteristics of the Buddhist meditation delivered for the control group participants at pagoda meditation retreats but will not influence this control condition in any way.
219075229|NCT06511921|BIOLOGICAL|early biologic therapy|biologic therapy for perforated Crohn's disease in the early postoperative period
219075230|NCT06511921|BIOLOGICAL|late biologic therapy|no biologic therapy for perforated Crohn's disease up to 2 to3 months in the post operative period
219075231|NCT01329029|DRUG|Roflumilast|500 µg, once daily
219075232|NCT01329029|DRUG|Placebo|once daily
219210022|NCT06757660|PROCEDURE|Furcation Repair|to evaluate the clinical and radiographic effects of chitosan and Naocl as an irrigation protocols applied during repair of furcation perforation.
219210023|NCT06761599|DIAGNOSTIC_TEST|group 1|To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.
219210024|NCT06761547|DRUG|magnsium sulfate|patients will take magnsium sulfate 15 mg/kg IV
219210025|NCT06761547|DRUG|Lidocaine (drug)|patients will take lidocaine2% 1 mg/kg
219210026|NCT06761547|DRUG|Saline|50 ml saline IV
219075233|NCT07066124|BEHAVIORAL|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks.|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks. After the first encounter, Pittsburgh Sleep Quality Index and Quality of Life Scale were re-administered to the pregnant women in the third and sixth weeks to evaluate their sleep and quality of life.
219075234|NCT07062042|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a short-term, trauma-focused intervention developed for individuals exposed to multiple traumatic events, including refugees and survivors of war and organized violence. It is grounded in principles of cognitive-behavioral therapy and testimonial therapy. NET helps adults reconstruct a coherent narrative of their life by integrating fragmented traumatic memories through structured exposure within a chronological autobiographical framework. Core components include lifeline construction, imaginal exposure to traumatic events, and reprocessing of emotional responses. The method emphasizes stabilization through therapeutic structure and is supported by evidence from randomized controlled trials showing reductions in PTSD symptoms. The approach is protocol-driven and applicable in low-resource settings under supervision, as outlined in the practice document.
219075235|NCT07084779|DEVICE|AI|"Following the completion of a pre-biopsy prostate MRI, the radiologist will interpret the MRI. Once interpreted by the radiologist alone, the radiologist will interpret the scan while aided by AI. A systematic biopsy in conjunction with radiologist-identified targets will be completed per standard of care, with the optional inclusion of up to 2 AI-detected targets.~When completing a biopsy per SOC, the prostate is divided into quadrants. In addition to noted targets, samples are taken systematically from each quadrant. If targets are detected by AI that were not identified by the physician when reviewing the MRI, these targets will be sampled. Sampling of these targets will not be in addition to the systematic sampling in each quadrant, but in place of up to two of the samples biopsied systematically"
219075236|NCT06535750|OTHER|Exercise|Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
219075237|NCT06904482|BIOLOGICAL|Haplo-Identical / Cord Blood Transplant|"Cord Blood Unit Selection Cord Blood Unit Selection should be consistent with published guidelines5 with the understanding that the goal cell dose is 1x105 CD34 cells/kg in this protocol. ABO matching and donor specific antibodies should be taken into account in the selection of the CB unit.~Haplo-Donor Selection Haplo-identical siblings and younger male donors are preferred. ABO matching, CMV compatibility, and donor specific antibodies should be taken into account in the selection of the donor."
219075238|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
219075239|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
219075240|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
219075241|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
219075242|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
219075243|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
219075244|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
219678428|NCT05643989|PROCEDURE|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
219678429|NCT05643989|PROCEDURE|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
219678430|NCT03287115|OTHER|Broccoli consumption|All subjects will eat broccoli on day 11
219678431|NCT00458315|DRUG|Cisplatin|
219678432|NCT00458315|DRUG|Paclitaxel|
219678433|NCT00458315|DRUG|Gemcitabine|
219678434|NCT00458315|DRUG|Avastin (Bevacizumab)|
219678435|NCT04074434|DEVICE|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
219075245|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
219075246|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
219075247|NCT07127887|OTHER|KM Resource - AI|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been AI translated using ChatGPT 4.0 into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
219075248|NCT07127887|OTHER|KM Resource - Professional|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been professionally translated into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
219075249|NCT07127237|DRUG|Bisacodyl 5 MG|On the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
219075250|NCT07127237|DRUG|Prucalopride 2mg|On the day prior to the procedure, the group receiving prucaloprida will take 1 tablet (2 mg) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
219075251|NCT07127497|BIOLOGICAL|Sintilimab combined with XELOX|Sintilimab (3 mg/kg, IV, qd for patients with body weight \< 60 kg; 200 mg, IV, qd for patients with body weight ≥ 60 kg) combined with XELOX (oxaliplatin 130 mg/m2, IV, qd + capecitabine 1000 mg/m2, bid, d1 - d14, q21d) for 2-4 courses
219075252|NCT07126665|DRUG|MHB088C for Injection|Intravenous administration
219075253|NCT07126665|DRUG|MHB039A for Injection|Intravenous administration
219075254|NCT07127666|OTHER|Structured Agenda-Setting Tool|We are testing a novel clinical visit agenda-setting intervention developed through participatory research methods for the pediatric inpatient environment. This structured agenda-setting (SAS) intervention will be co-designed to include structured discussion topic areas with the option for patients (when appropriate) and their care partners to consider and indicate their priority topic areas and take notes before, during, and after a clinical visit.
219210027|NCT05601882|DRUG|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection.
219678436|NCT01398852|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
219678437|NCT01398852|DEVICE|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
219678438|NCT03531723|OTHER|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
219678439|NCT01543568|DRUG|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
219075255|NCT07126249|DRUG|pimicotinib capsules|pimicotinib capsules
219075256|NCT06932341|OTHER|Non-interruptive|Non-interruptive BPA (appears as a visual cue but does not require clinicians to alter workflows) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
219210028|NCT05601882|DRUG|Upadacitinib|Extended-release tablet
219210029|NCT06826443|DRUG|Mosapride Citrate Tablets|Prokinetic Drug
219210030|NCT06826443|DRUG|Metoclopramide 10mg|Prokinetic Drug
219360437|NCT00749333|DRUG|Placebo|Single 10ml oral solution.
219360438|NCT01618292|PROCEDURE|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
219360439|NCT05376085|DRUG|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
219360440|NCT05376085|DRUG|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
219360441|NCT00727207|DRUG|everolimus|
219360442|NCT02429531|BIOLOGICAL|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
219075257|NCT06932341|OTHER|Interruptive|Interruptive BPA (requires clinicians to interact with the alert to continue the workflow) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
219075258|NCT00506493|DEVICE|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
219075259|NCT00506493|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
219075260|NCT06953076|DRUG|Relugolix/estradiol/norethisterone acetate|Oral therapy administered to patients with symptomatic uterine fibroids presenting with abnormal uterine bleeding
219075261|NCT06953674|DRUG|Normal Saline (0.9% NaCl)|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
219075262|NCT06953674|DRUG|balanced crystalloid|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
219678440|NCT03025113|DRUG|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
219678441|NCT03025113|DRUG|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
219678442|NCT05349019|OTHER|Observational|This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.
219678443|NCT00935077|OTHER|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
219678444|NCT00935077|OTHER|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
219678445|NCT00935077|OTHER|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
219678446|NCT02575378|DRUG|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
219678447|NCT02575378|DRUG|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
219678448|NCT04288882|DEVICE|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
219678449|NCT03159299|BEHAVIORAL|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
219678450|NCT00253006|PROCEDURE|Tissue examination for protein- and mRNA-expression of NO|
219678451|NCT02501161|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
219678452|NCT02501161|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
219678453|NCT00451113|DRUG|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
219075263|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
219678454|NCT05691777|DEVICE|Hand and shoulder task|"Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed."
219075264|NCT06100874|DRUG|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
219075265|NCT06100874|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
219678455|NCT00667992|DRUG|Budesonide HFA|standard daily inhaled dose
219678456|NCT00667992|DRUG|Budesonide CFC|standard daily inhaled dose
219678457|NCT04076852|OTHER|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~* Y-GTSS~* Y-BOCS or cY-BOCS"
219678458|NCT00696319|OTHER|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
219678459|NCT00696319|OTHER|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
219678460|NCT00000311|DRUG|Buprenorphine|Medication and Behavioral
219075266|NCT06100874|DRUG|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
219075267|NCT07126509|PROCEDURE|Partial Pleurectomy|A partial pleurectomy is a surgical procedure where part of the pleura, the lining of the lung cavity, is removed. This may be done to remove tumors, excess tissue, or to treat lung complications.
219075268|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
219075269|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
219075270|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
219075271|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219075272|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
219075273|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
219075274|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
219075275|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
219075276|NCT03854461|BEHAVIORAL|Personalised dietary advice and educational material|As within arm/group description
219075277|NCT03854461|BEHAVIORAL|Educational material|As within arm/group description
219075278|NCT01740674|OTHER|Electronic data collection|
219075279|NCT01704170|DEVICE|Kona Externally Focused Ultrasound Therapy|
219075280|NCT02414048|DRUG|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
219075281|NCT05800535|DRUG|Study of the adverse effects of long-term oncological treatments|Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
219075282|NCT05800535|BEHAVIORAL|Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients|Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
219075283|NCT02985866|DEVICE|Artificial Pancreas|Use of CTR at home for 3 months
219075284|NCT02985866|OTHER|Sensor Augmented Therapy|Use of personal pump with study CGM \& glucometer at home for 3 months
219075285|NCT05134181|DRUG|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
219075286|NCT04658303|DRUG|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
219075287|NCT06209879|DRUG|SYSTANE™ Hydration Lubricant Eye Drops|SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
219075288|NCT00508066|DRUG|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
219075289|NCT00508066|DRUG|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
219075290|NCT02580708|DRUG|Rociletinib|
219075291|NCT02580708|DRUG|Trametinib|
219075292|NCT06635525|BIOLOGICAL|Influenza vaccination|Single-dose
219075293|NCT06635525|BIOLOGICAL|SARS-CoV-2 vaccine|Single-dose
219075294|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
219075295|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
219678461|NCT00000311|DRUG|methadone|medication and behavioral
219075296|NCT00400010|BEHAVIORAL|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
219075297|NCT00007189|DRUG|Naproxen Sodium (Aleve)|
219678462|NCT00361608|DEVICE|EarlySense ES 16|
219075298|NCT00007189|DRUG|Celecoxib (Celebrex)|
219075299|NCT00064727|DRUG|Avandia (Rosiglitazone)|
219075300|NCT00064727|DRUG|Avanclia (Rosiqlitazone)|
219075301|NCT00127075|DRUG|nomegestrol acetate|10 mg/day
219075302|NCT00127075|DRUG|estradiol|75 mcg, once a week
219075303|NCT00127075|DRUG|placebo|matching placebo treatments
219678463|NCT04820296|OTHER|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
219678464|NCT00144560|DRUG|MRA(Tocilizumab)|
219075304|NCT01605513|DRUG|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
219075305|NCT00002574|BIOLOGICAL|recombinant interferon alfa|
219075306|NCT00002574|DRUG|omacetaxine mepesuccinate|
219075307|NCT05079074|DIAGNOSTIC_TEST|ctDNA testing|ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
219075308|NCT04066114|BIOLOGICAL|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
219075309|NCT04066114|BIOLOGICAL|antithymocyte globulin (rabbit)|Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
219075310|NCT04066114|DRUG|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
219075311|NCT04066114|BIOLOGICAL|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
219075312|NCT04066114|DRUG|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
219075313|NCT04066114|DRUG|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
219075314|NCT04066114|BIOLOGICAL|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
219075315|NCT04066114|DRUG|mycophenolate mofetil|mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
219075316|NCT04066114|DRUG|mycophenolic acid|mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
219075317|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
219075318|NCT01848873|DRUG|Amlodipine|amlodipine 5mg daily
219075319|NCT01848873|DRUG|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
219075320|NCT01848873|DRUG|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
219075321|NCT05510843|DRUG|THB001|100 mg capsules for oral administration
219075322|NCT05394870|OTHER|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
219075323|NCT05394870|OTHER|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
219075324|NCT02836808|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
219075325|NCT03886103|DRUG|14C labeled PXL770|Single administration
219075326|NCT03195257|OTHER|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
219075327|NCT03195257|OTHER|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
219075328|NCT03195257|OTHER|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
219360443|NCT02429531|BIOLOGICAL|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
219360444|NCT01485692|DRUG|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
219075329|NCT03529474|OTHER|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE"
219075330|NCT03529474|OTHER|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
219075331|NCT03117738|DRUG|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
219210031|NCT06828068|DEVICE|Ultrasound (Scolioscan system), and EOS radiography system|"Scolioscan ultrasound system was reported to be reliable and valid for spinal deformity assessment. The system composes of an ultrasound scanner with a linear probe of 10 cm width and frequency range of 4-10MHz, a frame structure and a spatial sensor attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using phantom to assure accuracy of spine image formation and subsequent angle measurement. Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process. The probe will be steered from L5 to C7 spinous process for scanning. SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral. Coronal Cobb angle measurement on EOS radiographs will be used as gold standard."
219075332|NCT03117738|OTHER|Placebo-Control|Saline with 30% auto-serum
219075333|NCT02264028|DRUG|[14C]-DK-AH 269 CL, solution for infusion|
219075334|NCT02264028|DRUG|[14C]-DK-AH 269 CL, drinking solution|
219075335|NCT01087853|DRUG|Crystalloid|2 litres intravenous infusion in 60 minutes
219075336|NCT01087853|DRUG|Colloid|1 litre intravenous infusion over 30 minutes
219075337|NCT03845348|OTHER|TD03|Shampoo TD 3 days
219075338|NCT03845348|OTHER|TD07|Shampoo TD 7 days
219075339|NCT03845348|DRUG|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
219075340|NCT01546896|DRUG|buspirone+alprazolam|day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
219075341|NCT01546896|DRUG|alprazolam|0.5mg/d
219075342|NCT04099810|DIAGNOSTIC_TEST|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
219210032|NCT06757608|OTHER|Assessment of postprandial metabolism after intake of different meat|30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
219210033|NCT05943041|DRUG|GB104(Level 1)|One capsule QD oral administration for 28 days
219210034|NCT05943041|DRUG|GB104(Level 2)|Three capsules QD oral administration for 28 days
219210035|NCT05943041|DRUG|GB104(Level 3)|Five capsules QD oral administration for 28 days
219210036|NCT06773338|BEHAVIORAL|Tetris|Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
219210037|NCT06773338|OTHER|No intervention|Participants do not receive any intervention.
219075343|NCT05314439|DRUG|ION904|ION904 will be administered by SC injection.
219075344|NCT05314439|DRUG|Placebo|Placebo will be administered by SC injection.
219075345|NCT04522518|DEVICE|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
219075346|NCT01835886|OTHER|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
219075347|NCT02355808|BEHAVIORAL|Tailored Leaflet|
219075348|NCT02355808|BEHAVIORAL|GP visit|
219075349|NCT01564550|DRUG|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
219210038|NCT06772493|DEVICE|ViewFlex X ICE System|Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System
219210039|NCT06770608|PROCEDURE|micro-needling with topical human actrapid insulin|Micro-needling with topical application of 2ml of human actrapid insulin once monthly for 4 months
219075350|NCT01564550|DRUG|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
219075351|NCT01564550|OTHER|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
219075352|NCT01564550|OTHER|no diet|The subjects will ingest a non-restricted diet prior to the study day.
219075353|NCT01695967|PROCEDURE|turbinate cauterization|
219075354|NCT00135148|PROCEDURE|Filling out a questionnaire on libido and possible partner relationship|
219075355|NCT00135148|PROCEDURE|Sex steroid analysis|
219075356|NCT03274843|OTHER|Activity of everyday life|Kitchen workshop
219075357|NCT04826354|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
219075358|NCT04826354|DRUG|Rosuvastatin|Rosuvastatin
219075359|NCT05180760|BEHAVIORAL|Smartphone app use|Smartphone app use in the active arm
219075360|NCT05180760|BEHAVIORAL|Standard of care|Standard of care
219075361|NCT04004611|DRUG|Mirikizumab|Administered IV and SC
219210040|NCT06770608|PROCEDURE|Micro-needling with topical Platelet rich plasma|Micro-needling with topical application of 2ml Platelet rich plasma once monthly for 4 months
219210041|NCT06773182|OTHER|Intermittent Fasting Intervention|A 14:10 intermittent fasting regimen, where participants fast for 14 hours and consume all meals within a 10-hour eating window daily.
219210042|NCT06773182|OTHER|Mediterranean Diet Intervention|A diet emphasizing whole grains, fruits, vegetables, olive oil, lean proteins, and minimizing processed foods.
219210043|NCT06773182|OTHER|Low FODMAP Diet Intervention|A diet limiting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols to manage gastrointestinal symptoms.
219210044|NCT06774222|DRUG|Fruquintinib|Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
219210045|NCT06773559|DIAGNOSTIC_TEST|plantar pressure, gait and static balance analysis|Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.
219210046|NCT06773559|DIAGNOSTIC_TEST|trunk posture analysis|Trunk posture analysis was performed using Diers Formetric 4D.
219210047|NCT06760000|DEVICE|Five seasons Sleep Tracking Mat|Non-contact mat monitoring sleep data through pulse wave detection
219210048|NCT06759324|DIETARY_SUPPLEMENT|Live kombucha (non filtered/ non pasteurized)|Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).
219210049|NCT06759324|DIETARY_SUPPLEMENT|Pasteurized kombucha (non filtered)|Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).
219210050|NCT06759324|OTHER|Control (sparkling water)|Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
219210051|NCT06759571|PROCEDURE|low level laser treatment|to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions
219210052|NCT06759467|DIAGNOSTIC_TEST|AI-Driven Virtual Biopsy for Diagnosis of Peritoneal Exfoliative Cytology-Positive Gastric Cance|"The intervention involves the use of an artificial intelligence (AI)-driven virtual biopsy technology for the non-invasive diagnosis of gastric cancer with positive peritoneal exfoliative cytology (PEC). Unlike traditional biopsy methods, which require invasive procedures to obtain tissue samples, this intervention utilizes AI algorithms to analyze non-invasive biomarkers derived from patient samples such as blood, urine, or peritoneal lavage fluid.~The AI model is designed to integrate various data types, including transcriptomic profiling, imaging data, and other biomarkers, to predict the presence of PEC-positive gastric cancer. This technology employs advanced machine learning techniques to identify molecular and cellular features indicative of peritoneal metastasis, providing a diagnostic tool that is potentially more sensitive and less invasive than conventional methods.~The intervention is unique in its ability to combine multi-omics data (such as gene expression and imaging."
219210053|NCT06758778|DIETARY_SUPPLEMENT|CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals]|Test product
219210054|NCT06758778|DIETARY_SUPPLEMENT|Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules|Reference product
219210055|NCT06758687|OTHER|Kinesiotape Application|"Before the appropriate taping is applied to the waist area, a small piece of kinesio tape will be attached to the participant's thigh area and an allergy test will be performed. If the participant does not have any complaints within 5-10 minutes, the participant will be taped. The tape to be used in this study will be waterproof, porous, breathable, 5 cm wide and 0.5 mm thick.~After the initial evaluation is completed, kinesio taping will be applied to the paravertebral muscles. First, the participant will be asked to perform trunk flexion while standing with their forearms supported by a table. While the participant is in this position, two I shaped tapes will be attached to the right and left sides of the spine (in the cranial direction) along the paravertebral muscle line without applying tension. Then, the field correction technique will be applied. While the participant is standing with their forearms supported on the table, four I tapes overlapping in"
219678465|NCT02121548|BEHAVIORAL|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
219678466|NCT02121548|BEHAVIORAL|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
219678467|NCT02307149|BIOLOGICAL|CAVATAK|CAVATAK is a preparation of CVA21
219678468|NCT02307149|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
219075362|NCT04420689|DRUG|Bevonescein|Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
219075363|NCT06382350|DEVICE|MiniMed 780 G|none, observational study
219075364|NCT02248792|DRUG|Methotrexate|
219075365|NCT02625103|PROCEDURE|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
219075366|NCT02625103|DRUG|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
219075367|NCT01575366|BEHAVIORAL|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
219075368|NCT06425354|DEVICE|Mechanical ventilation|Mechanical ventilatiom
219210056|NCT05755919|PROCEDURE|Epilepsy surgery|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
219210057|NCT06748248|OTHER|suspension Therapy|suspension therapy for individuals with Down syndrome is an approach that focuses on improving mobility and balance through different activities that will be conducted through universal exercise unit. This method involves organizing individuals with Down syndrome into two groups. Group A will perform Suspension Therapy in addition to routine physical therapy. These routine exercises will consist of stretching exercises (arm raises, chest stretch, leg swings, hamstring stretch, cat-cow poses, starfish stretch), strength and endurance training (like stepping, carrying light weights) and balance training (playing hopscotch and kicking a ball). The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. Suspension Therapy will consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. Repeated corrective movements will be performed.
219210058|NCT06748248|OTHER|Routine Treatment|"Group B will perform routine physical therapy (RPT) alone. These routine exercises will consist of stretching exercises (particularly upper and lower body stretches and full body stretches). Stretches will be gentle and avoid bouncing. Hold for each stretch will be 15-30 seconds. Balance and coordination exercises (Walking on balance beams, obstacle courses) will be performed as RPT. The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. These exercises will be carried out 5 days in a week for one hour daily.~Data will be assessed by assessor at baseline and at the end of 5th session of treatment (Pre and post)."
219210059|NCT06760845|DIAGNOSTIC_TEST|Imaging Time|Raman spectroscopy images of blood and urine
219210060|NCT06771752|OTHER|Questionnaire|The questionnaire will be made comprised of the questions taken from the Whole Day Matters Toolkit (WDMT) 24-hour movement questionnaire (The Canadian Society for Exercise Physiology, 2021), which is based on the official 24-hour movement guidelines (Ross et al., 2020) (see appendix). For diet quality, Mini-EAT, a short dietary screening tool will be used (Lara-Breitinger et al., 2023) (see appendix). The questionnaire will be open for two months during the football mid-season time period (January 15th to March 15th). The principal investigator will distribute the questionnaire digitally via Google Forms. It will be sent directly to sports staff professionals, individually and to football clubs and to universities to distribute to their cohort. Only people with the link will be able to access the questionnaire. Participants will answer the questionnaire, which will take roughly 10 minutes, completing the intervention.
219210061|NCT06775444|BEHAVIORAL|Breastfeeding Education Program Based on Planned Behavior Theory|"In addition to routine breastfeeding training at the hospital where the study is conducted, the intervention group will be given a 2-session Breastfeeding Training Program Based on Planned Behavior Theory.~Education Content:~The importance of breast milk, the benefits of breastfeeding, the dangers of artificial feeding, putting the baby to the breast, signs of hunger in the baby, the harms of bottle and pacifier, breastfeeding positions, breast-related problems, information sources about breastfeeding, birth and breastfeeding leave for working mothers, breastfeeding in the community, the importance of environmental and professional support during breastfeeding. Insufficient milk anxiety, increasing milk intake and production, situations where milk should be expressed, milk expression methods, storage conditions of breast milk, alternative feeding methods with expressed milk, methods to be applied to increase breast milk, differences between breast milk and formula milk."
219210062|NCT06775444|BEHAVIORAL|Routine Breastfeeding Training|The control group will receive routine breastfeeding education at the hospital where the study is conducted. Routine breastfeeding education includes the importance of breast milk and breastfeeding (benefits of breast milk and breastfeeding, correct breastfeeding technique and breastfeeding positions, time for the first feeding of the newborn, feeding method, expressing and storing breast milk, techniques for giving expressed breast milk as close as possible to breastfeeding, harms of bottle use, breast problems and coping methods). Pregnant women who give birth at the hospital where the study is conducted receive routine breastfeeding education from the breastfeeding nurse in the ward before being discharged.
219210063|NCT06775652|DRUG|Neoadjuvant Chemoradiotherapy|Patients assigned to the NCRT group received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles. Concurrently, they received intensity-modulated radiotherapy (IMRT) with a total of 20 sessions (CTV 40 Gy, GTV 44 Gy) five days per week. All radiotherapy plans were reviewed by designated radiation oncologists before treatment to ensure quality control. Patients were assessed 4 to 6 weeks after completing NCRT following RECIST 1.1 criteria.
219210064|NCT06775652|PROCEDURE|Adjuvant therapy|Patients in the AT group received surgery as soon as possible after randomization, followed by adjuvant therapy, postoperative adjuvant therapy based on pathological staging, as recommended by the NCCN Clinical Practice Guidelines for Esophageal and Esophagogastric Junction Cancers (2017 V4), starting one month post-surgery with either adjuvant chemotherapy or chemoradiotherapy. The adjuvant chemotherapy regimen was the same as the neoadjuvant chemotherapy regimen, and the adjuvant radiotherapy regimen and dose were administered according to guideline recommendations.
219210065|NCT06775652|PROCEDURE|Surgery|Surgery
219360445|NCT01485692|DRUG|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
219075369|NCT00089726|BIOLOGICAL|CG8123|
219075370|NCT00089726|DRUG|Cyclophosphamide|
219075371|NCT00441610|DRUG|Gimatecan|
219075372|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
219678469|NCT02408731|DRUG|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
219678470|NCT04655729|DRUG|Infliximab|Blood collection
219678471|NCT02136459|OTHER|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
219678472|NCT02136459|OTHER|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
219678473|NCT03161730|OTHER|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
219678474|NCT03161730|OTHER|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
219075373|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
219075374|NCT04049175|DRUG|Treatment A|Tablet of CHF 6532
219075375|NCT04049175|DRUG|Treatment B|Tablet of CHF 6532
219075376|NCT04049175|DRUG|Treatment C|Tablet of CHF 6532
219075377|NCT04049175|DRUG|Treatment D|Tablet of CHF 6532 placebo
219075378|NCT01055821|DRUG|pegylated interferon and ribavirin|48 weeks
219075379|NCT01055821|BIOLOGICAL|TG4040 + SOC|6 injections
219075380|NCT01055821|BIOLOGICAL|TG4040 + SOC|13 injections
219075381|NCT04315077|DIETARY_SUPPLEMENT|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
219075382|NCT04315077|OTHER|Resistance Training|5 days of supervised and programmed whole-body resistance training.
219075383|NCT04729257|DEVICE|Philips IntelliSpace Cognition (ISC).|Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
219210066|NCT06776822|OTHER|Dynamic neuromuscular stabilisation|"The nervous system establishes programs that control human posture, movement and gait. This 'motor control' is largely established during the first critical years of life. Therefore, the Prague School emphasizes neurodevelopmental aspects of motor control in order to assess and restore dysfunction of the locomotor system and associated syndromes."
219210067|NCT06775899|DEVICE|PC-Based Ultrasound Training Tool|An interactive, PowerPoint-based PC tool designed to simulate pathology recognition and ultrasound image optimization for medical students. It provides real ultrasound videos and images, allowing students to practice diagnostic interpretation and image acquisition in a structured training format.
219210068|NCT06775899|DEVICE|Traditional Ultrasound Simulator (VausSim)|A medium-cost ultrasound simulator used for hands-on training in thoracic and abdominal ultrasound. It allows medical students to practice probe handling, image acquisition, and pathology recognition in a controlled simulation environment.
219360446|NCT01485692|DRUG|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
219678475|NCT03161730|OTHER|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
219678476|NCT00568217|DRUG|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
219678477|NCT06501807|DRUG|Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
219678478|NCT00961779|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
219678479|NCT00961779|DRUG|Placebo|Normal saline infusion
219678480|NCT01557478|DRUG|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
219678481|NCT01557478|DRUG|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
219678482|NCT06053632|BEHAVIORAL|Low-load and high-velocity - lying prone - eccentric hamstring exercise|Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
219678483|NCT06458907|DEVICE|TricValve® Transcatheter Bicaval Valve System|TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.
219075384|NCT04729257|DIAGNOSTIC_TEST|Paper-Pencil Tests.|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
219075385|NCT00712868|DRUG|Lactic acid|Once a day
219075386|NCT00515502|DRUG|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
219075387|NCT00515502|DRUG|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
219075388|NCT04720079|PROCEDURE|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
219075389|NCT04720079|PROCEDURE|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
219075390|NCT00639873|DRUG|Artesunate|2 or 4 mg/kg/day for 7 days
219075391|NCT00639873|DRUG|quinine-doxycycline|quinine-doxycycline for 7 days
219075392|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
219075393|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
219075394|NCT03317002|DRUG|Placebo|Matching placebo (tablet)
219075395|NCT03939377|OTHER|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
219075396|NCT03058211|DIAGNOSTIC_TEST|Echocardiography|Standard protocols
219075397|NCT03058211|DIAGNOSTIC_TEST|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
219075398|NCT05588726|BEHAVIORAL|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
219075399|NCT05588726|BEHAVIORAL|Mindfulness|Once weekly coaching calls with advice on mindfulness
219210069|NCT06776523|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders."
219075400|NCT02645981|DRUG|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
219075401|NCT02645981|DRUG|Sorafenib|Control
219075402|NCT02732938|DRUG|PF-04136309|PF-04136309 oral dosing
219075403|NCT02732938|DRUG|Nab-paclitaxel|Nab-paclitaxel IV dosing
219075404|NCT02732938|DRUG|Gemcitabine|Gemcitabine IV dosing
219075405|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
219075406|NCT00636870|DRUG|Fexofenadine|
219075407|NCT00485290|BEHAVIORAL|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
219075408|NCT03927950|DRUG|escitalopram|escitalopram 10-20mg per day 12 weeks
219210070|NCT06768307|DRUG|First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC|"Cohort 1:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Concurrent Radiotherapy Phase: the fourth cycle will incorporate concurrent radiotherapy along with atezolizumab and chemotherapy.~Maintenance Phase: Atezolizumab monotherapy will be administered until disease progression or intolerance by the patient, with atezolizumab being administered for a maximum duration of 2 years.~Cohort 2:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Sequential Radiotherapy Phase: the fourth cycle will receive sequential radiotherapy in combination with atezolizumab.Final，Atezolizumab monotherapy will be continued until disease progression."
219210071|NCT06768632|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
219678484|NCT06458907|DRUG|Optimal medical therapy|Optimal medical therapy
219075409|NCT03927950|DRUG|bupropion|bupropion 150-300mg per day 6 weeks
219075410|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
219075411|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
219075412|NCT00436657|DRUG|CHPP of Cisplatin|Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
219075413|NCT00436657|PROCEDURE|Abdominal Surgery|Surgical removal of abdominal tumors.
219075414|NCT03783182|DRUG|Betamethason Sodium Phosphate|Glucocorticoid
219075415|NCT03783182|DRUG|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
219075416|NCT04530448|DRUG|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
219075417|NCT04530448|OTHER|Standard of Care|Standard of Care treatment
219075418|NCT02592382|DIETARY_SUPPLEMENT|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
219075419|NCT03214913|OTHER|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
219075420|NCT03214913|OTHER|Ruijin Strategy|"Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%."
219075421|NCT03928080|DIAGNOSTIC_TEST|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
219075422|NCT01613248|DRUG|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
219075423|NCT01613248|DRUG|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
219075424|NCT01613248|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded."
219075425|NCT03640260|BEHAVIORAL|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
219075426|NCT02799966|DEVICE|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
219210072|NCT06768632|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
219075427|NCT05758064|DRUG|Duphaston|10 mg tablet will be given twice
219075428|NCT05758064|DRUG|prolutex|subcutaneous injection daily
219075429|NCT03391674|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
219075430|NCT05034003|DEVICE|Zirconia crown|Esthetic crowns for capping primary incisor with caries
219075431|NCT05034003|DEVICE|composite strip crown|Esthetic resin restoration for primary incisor with caries
219075432|NCT05199818|DRUG|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
219075433|NCT05199818|DRUG|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
219075434|NCT03469323|DRUG|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
219075435|NCT03469323|DRUG|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
219075436|NCT01433354|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
219075437|NCT04875481|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219075438|NCT04875481|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
219075439|NCT01952496|OTHER|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months.~Arm: Force-measuring platform"
219075440|NCT02639260|DRUG|N-acetyl D-mannosamine|dose escalation
219075441|NCT01512862|DRUG|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
219075442|NCT01512862|DRUG|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
219075443|NCT01710176|DRUG|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
219075444|NCT01710176|DRUG|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
219075445|NCT01710176|DRUG|trabectedin 1.3 mg/m2|
219075446|NCT01710176|DRUG|high-dose ifosfamide 14 g/m2, given in in 14 days|
219075447|NCT01710176|DRUG|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
219075448|NCT01710176|DRUG|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
219075449|NCT05098054|DRUG|Soticlestat|Soticlestat tablets.
219075450|NCT05999955|DRUG|Neomycin/ Dexameythasone/Xylometazoline|The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
219075451|NCT05999955|COMBINATION_PRODUCT|Bacillus subtilis DSM32444|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/ PCBALA In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatmen.
219075452|NCT02571504|BEHAVIORAL|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
219075453|NCT00175851|DRUG|Seletracetam (ucb 44212)|
219075454|NCT03905200|DIAGNOSTIC_TEST|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
219210073|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
219075455|NCT01171326|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
219075456|NCT01426191|DRUG|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
219075457|NCT02039037|DEVICE|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
219075458|NCT02039037|DEVICE|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
219678485|NCT03412292|DRUG|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
219075459|NCT03788837|DRUG|ILOPROST|The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
219075460|NCT03788837|DRUG|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
219210074|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
219210075|NCT06772805|DRUG|Nemtabrutinib|Oral Tablet
219678486|NCT02168023|DEVICE|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
219678487|NCT02168023|DEVICE|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
219678488|NCT00975546|OTHER|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
219678489|NCT00975546|PROCEDURE|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
219678490|NCT04403555|DRUG|Ivermectin|Ivermectin treatment
219678491|NCT03162042|PROCEDURE|Tumor removal|Surgery
219678492|NCT06376708|OTHER|platelet rich fibrin|platelet rich fibrin
219678493|NCT06376708|OTHER|Polyether ether ketone|Polyether ether ketone
219678494|NCT01075997|DEVICE|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
219678495|NCT01075997|DEVICE|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
219075461|NCT02052505|PROCEDURE|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
219075462|NCT00004827|DRUG|docosahexaenoic acid|
219075463|NCT04161508|DRUG|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
219075464|NCT04161508|DRUG|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
219075465|NCT02871648|DRUG|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
219678496|NCT03630159|BIOLOGICAL|Tisagenlecleucel|Gene modified autologous T cells
219678497|NCT03630159|DRUG|Pembrolizumab|anti PD-1
219678498|NCT02749227|DRUG|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
219075466|NCT02871648|DRUG|Fludrocortisone|Fludrocortisone 0.1 mg
219075467|NCT02871648|DRUG|Eplerenone|Epleronone 100 mg
219075468|NCT02868060|DRUG|Romiplostim|
219678499|NCT02660437|OTHER|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
219678500|NCT03836157|DRUG|Mirvetuximab Soravtansine|The dose will not be recalculated unless the patient has ±10% weight change.
219678501|NCT03836157|DRUG|Bevacizumab|Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
219678502|NCT02364583|DRUG|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
219678503|NCT05495308|PROCEDURE|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
219678504|NCT00006329|PROCEDURE|Minimally invasive radioguided parathyroidectomy|
219678505|NCT04398810|PROCEDURE|robotic single port cholecystectomy|"1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity"
219678506|NCT02136901|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
219678507|NCT02136901|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
219678508|NCT02136901|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
219678509|NCT02136901|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
219075469|NCT00439868|DRUG|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
219075470|NCT00439868|DRUG|placebo|Matching placebo tablets to WELLBUTRIN XL.
219075471|NCT04827511|OTHER|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
219075472|NCT02013622|DRUG|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
219075473|NCT00432731|BIOLOGICAL|VARIVAX®|
219075474|NCT00432731|BIOLOGICAL|M-M-RTM II|
219075475|NCT05885672|BEHAVIORAL|Online psychoeducational lifestyle intervention|A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
219075476|NCT01763931|DRUG|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
219075477|NCT04650555|DRUG|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
219075478|NCT00889538|DRUG|placebo|50 mL of 1/2 normal saline IV
219678510|NCT01463943|OTHER|Probiotic|
219075479|NCT00889538|DRUG|glutathione|glutathione 600 mg IV
219075480|NCT00889538|DRUG|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
219075481|NCT03765866|PROCEDURE|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
219075482|NCT06009081|BEHAVIORAL|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
219075483|NCT06009081|BEHAVIORAL|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
219075484|NCT03776955|DRUG|Carvedilol|Oral tablet
219678511|NCT01463943|OTHER|Probiotic|
219678512|NCT01463943|OTHER|Probiotic|
219678513|NCT02962232|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
219678514|NCT02962232|DEVICE|PTA catheter|control group
219678515|NCT04070248|OTHER|No intervention|No intervention
219678516|NCT05978219|DRUG|Mirtazapine Tablets|Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
219678517|NCT00091468|DRUG|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
219678518|NCT00091468|DRUG|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
219678519|NCT00079651|BEHAVIORAL|Montessori-based dementia programming|
219678520|NCT02637310|DRUG|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
219678521|NCT02637310|DRUG|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
219678522|NCT00780780|DRUG|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
219678523|NCT00780780|DRUG|triamcinolone intravitreal injection|triamcinolone intravitreal injection
219678524|NCT01443741|OTHER|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
219678525|NCT01691417|DEVICE|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
219678526|NCT01957579|DRUG|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
219075485|NCT03206346|DRUG|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
219075486|NCT03206346|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
219075487|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
219075488|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
219075489|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
219075490|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
219075491|NCT04100200|DIETARY_SUPPLEMENT|Mixed berries|Strawberry and red raspberry
219075492|NCT04100200|DIETARY_SUPPLEMENT|FOS|Fructo-oligosaccharide
219075493|NCT04100200|DIETARY_SUPPLEMENT|Control|Placebo similar in color to mixed berry supplement without any polyphenols
219075494|NCT04100200|DIETARY_SUPPLEMENT|Combination|Mixed berry composite + FOS
219075495|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
219075496|NCT05043090|DRUG|savolitinib|Tablets : 3 × 200 mg tablets once daily
219075497|NCT05043090|DRUG|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
219075498|NCT05043090|DRUG|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
219075499|NCT06166225|BEHAVIORAL|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
219075500|NCT06166225|BEHAVIORAL|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
219678527|NCT00124891|DRUG|Double-blind investigational anti-arrhythmic|
219678528|NCT00124891|DRUG|GAP-486|
219075501|NCT06166225|BEHAVIORAL|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
219210076|NCT06771245|DRUG|SYH9056|PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
219678529|NCT02892617|OTHER|Bacteriological analysis of disc|
219678530|NCT01639144|BIOLOGICAL|PRP and PPP|Autogenous PRP and PPP
219678531|NCT00014612|PROCEDURE|axillary lymph node dissection|
219678532|NCT00014612|PROCEDURE|lymphoscintigraphy|
219678533|NCT00014612|PROCEDURE|therapeutic conventional surgery|
219678534|NCT00014612|RADIATION|radiation therapy|
219678535|NCT01589419|DRUG|veliparib|see arm description
219678536|NCT01589419|DRUG|capecitabine|see arm description
219678537|NCT01589419|RADIATION|radiation|see arm description
219678538|NCT00635934|DEVICE|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
219678539|NCT00652145|DRUG|mesalamine|Increase dose by 2.4gm per day over baseline dose
219678540|NCT01000974|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
219678541|NCT01000974|BIOLOGICAL|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
219678542|NCT01000974|BIOLOGICAL|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
219678543|NCT01000974|BIOLOGICAL|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
219678544|NCT01000974|BIOLOGICAL|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
219678545|NCT01000974|BIOLOGICAL|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
219075502|NCT05523284|DIAGNOSTIC_TEST|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
219075503|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
219075504|NCT06511232|DRUG|Intraosseous Morphine|More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the early postoperative period compared to the spine and adductor block alone.3 No study to date in the available literature has evaluated the efficacy of intraosseous morphine infusion in managing acute postoperative pain in patients undergoing ACL reconstruction with bone-patellar tendon-bone autograft, so that is the intended evaluation point with this project.
219075505|NCT06240442|OTHER|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
219075506|NCT06240442|OTHER|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
219075507|NCT03637205|PROCEDURE|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
219075508|NCT03637205|OTHER|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
219075509|NCT03175133|OTHER|Strength exercise|Strengthening exercises performed with physical therapist.
219075510|NCT04745611|DIAGNOSTIC_TEST|MRI|3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
219075511|NCT04745611|DIAGNOSTIC_TEST|Neuropsychological assessment|Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
219075512|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Patient|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) \& Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
219075513|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Family|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
219075514|NCT00908154|DRUG|Placebo|Tablets to match GSK1014802
219075515|NCT00908154|DRUG|GSK1014802|Sodium channel blocker
219075516|NCT01753687|OTHER|Ocular scattering of the tear film|
219075517|NCT01753687|OTHER|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
219075518|NCT01753687|OTHER|Measurement of tear film osmolarity|
219075519|NCT02824133|DRUG|AZD4547|80 mg bd (per os)
219075520|NCT06292156|DEVICE|Theta treatment group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks
219075521|NCT06292156|DEVICE|Alpha active control group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks
219075522|NCT06292156|DEVICE|Sham control group|Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).
219075523|NCT06268574|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
219075524|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
219075525|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
219075526|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
219075527|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
219075528|NCT02988973|DRUG|roxadustat|Oral administration
219075529|NCT02988973|DRUG|DA|Subcutaneous administration
219075530|NCT05631249|DRUG|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
219678546|NCT01000974|BIOLOGICAL|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
219075531|NCT06961812|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|"Next, the risk of falling will be assessed by a healthcare professional using a hetero-questionnaire and physical tests, as proposed in the algorithm for global recommendations (routine care).~These tests include a detailed characterisation of the history of falls, the Timed Up and Go, the Five Times Sit to Stand, the 4 m walking speed and the Short Physical Performance Battery."
219075532|NCT06961812|DIAGNOSTIC_TEST|Safe Self-Administered Questionnaire|"All people who agree to take part in the study will first complete the SAFE self-questionnaire (intervention).~the Self Assessment for Falls in the Elderly (SAFE), an auto-questionnaire that converts the binary items and performance tests of the 2022 World Guidelines for Falls Prevention and Management into visual analogue scales (100 mm each)."
219075533|NCT06962917|OTHER|Cross sectional study|This study is a cross-cultural study, not an intervention study. A total of 1,523 participants (484 from Germany, 548 from the United States, and 491 from Japan) were recruited.
219075534|NCT06961617|DRUG|LioCyx-M, HBV antigen-specific TCR-redirected T cells|Via intravenous (IV) infusion
219075535|NCT06962319|DRUG|dihydroartemisinin-piperaquine (DP)|Weight-based dosing of 3 (\<60kg), 4 (6-80kg) or 5 (\>80 kg) 40/320 mg tablets of dihydroartemisinin-piperaquine given once daily for 3 days
219075536|NCT06962319|DRUG|Pyronaridine-artesunate (PA)|Weight-based dosing of 2 (24-\<45 kg), 3 (45-\<65kg), or 4 (\>=65 kg) 180/60 mg tablets of pyronaridine-artesunate, once daily for 3 days.
219075537|NCT06962319|DRUG|Artemether-lumefantrine|1 x 80/480 or 4 x 20/120 mg tablets of artemether-lumefantrine, given twice daily, approximately 8 hours apart for 3 days
219075538|NCT06962670|OTHER|Biomaterial collection|All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
219075539|NCT06962670|OTHER|BayPass mobile application|"All subjects will be asked to use the study-specific mobile application BayPass to complete questionnaires and provide results from screening examinations over a course of 12 months."
219075540|NCT03921515|OTHER|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
219075541|NCT03921515|OTHER|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
219075542|NCT05081128|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
219678547|NCT01000974|BIOLOGICAL|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
219678548|NCT02554045|DRUG|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
219678549|NCT02554045|DRUG|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
219075543|NCT06634641|BIOLOGICAL|blood test|Only carrying out additional immunological assays during blood tests before initiation of treatment, six months after initiation of treatment and then one year after initiation of treatment.
219075544|NCT04034030|DEVICE|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
219075545|NCT00310219|PROCEDURE|computed tomography|
219075546|NCT00310219|PROCEDURE|positron emission tomography|
219075547|NCT05893758|DEVICE|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
219075548|NCT04769076|COMBINATION_PRODUCT|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
219075549|NCT00922454|PROCEDURE|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
219075550|NCT00922454|DEVICE|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
219075551|NCT00922454|DEVICE|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
219678550|NCT04346407|DRUG|Dronabinol 2.5mg Cap|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
219678551|NCT04346407|DRUG|Placebo|Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
219678552|NCT00064103|BIOLOGICAL|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
219678553|NCT00064103|OTHER|laboratory biomarker analysis|Correlative studies
219678554|NCT02750332|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
219210077|NCT06771245|DRUG|Levamlodipine|2.5mg PO once daily
219210078|NCT06771245|DRUG|Valsartan|80mg PO once daily
219678555|NCT04608916|PROCEDURE|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
219075552|NCT04166357|DIAGNOSTIC_TEST|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
219075553|NCT03257826|DEVICE|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
219075554|NCT04391023|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
219075555|NCT04391023|BEHAVIORAL|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
219075556|NCT04391023|DEVICE|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
219075557|NCT04391023|DEVICE|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
219075558|NCT01381692|DRUG|Bortezomib|Given IV or SC
219075559|NCT01381692|DRUG|Dexamethasone|Given PO
219075560|NCT01381692|OTHER|Laboratory Biomarker Analysis|Correlative studies
219075561|NCT01381692|OTHER|Quality-of-Life Assessment|Ancillary studies
219075562|NCT01381692|BIOLOGICAL|Rituximab|Given IV
219075563|NCT01381692|DRUG|Temsirolimus|Given IV
219075564|NCT06486922|BEHAVIORAL|StEP OUT|The details of program structure and content will evolve as the study progresses based on feedback from participants, interventionists, and the community advisory board. Initially, we will plan to have 5 formal sessions structured as groups with multiple participants receiving the session simultaneously, primarily via remote videoconference, though sessions may occur individually, based on participant schedule and preference. All sessions are designed to be supportive, educational, and interactive, with opportunities to practice skills and discuss feeding and parenting concerns.
219678556|NCT04608916|PROCEDURE|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
219075565|NCT06647095|DIETARY_SUPPLEMENT|D-Limonene Gelcaps|Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
219075566|NCT06647095|DIETARY_SUPPLEMENT|Fish Oil Concentrate, 1000 Mg Oral Capsule|Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
219075567|NCT06461039|DRUG|NNC0487-0111 A|NNC0487-0111 A will be administered subcutaneously.
219075568|NCT06461039|DRUG|NNC0487-0111 C|NNC0487-0111 C will be taken orally.
219075569|NCT06461039|DRUG|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
219075570|NCT06461039|DRUG|Acetaminophen - 500 mg/15 ml|Acetaminophen - 500 mg/15 ml will be taken orally.
219075571|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
219075572|NCT05140941|DRUG|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
219210079|NCT06771245|DRUG|SYH9056 placebo|PO once daily
219210080|NCT06771245|DRUG|Levamlodipine placebo|PO once daily
219210081|NCT06771245|DRUG|valsartan placebo|PO once daily
219210082|NCT06772428|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
219210083|NCT06772428|RADIATION|standard treatment|radiotherapy ± chemotherapy
219210084|NCT06771726|DEVICE|RedScar App|use of the RedScar© app on patients' smartphones. Patients will complete a brief health questionnaire and upload a wound photograph to the app, which will provide recommendations based on the risk of infection detected. Simultaneously, an in-person wound assessment will be conducted by the investigator to compare results.
219678557|NCT03717779|DIAGNOSTIC_TEST|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
219678558|NCT00160056|PROCEDURE|Hypoglycemia|
219678559|NCT02608996|DRUG|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
219678560|NCT02608996|DRUG|Placebo|For comparison to elucidate the true effect of nesiritide
219678561|NCT01751321|DRUG|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
219210085|NCT06772116|PROCEDURE|Focal Therapy|"Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).~Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed."
219210086|NCT06759844|BEHAVIORAL|Educational Booklet|A printed booklet containing general information on chronic disease management provided to participants for reference without interactive or digital features
219210087|NCT06759844|BEHAVIORAL|Mobile Health Application|A mobile health application that facilitates self-management of chronic conditions through daily education, personalized goal setting, and lifestyle monitoring. The intervention aims to improve participants' health behaviors and clinical outcomes by promoting active engagement with their health.
219210088|NCT06778590|PROCEDURE|Piezoelectric technique in third molar germectomy|Application of piezoelectric technique in third molar germectomy procedures
219678562|NCT03975504|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
219678563|NCT03975504|DEVICE|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
219075573|NCT03842995|BEHAVIORAL|Genetic Counselor|Standard of Care
219075574|NCT03842995|BEHAVIORAL|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
219075575|NCT01299246|PROCEDURE|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
219075576|NCT05406687|OTHER|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
219075577|NCT01143948|DRUG|Glargine & Glulisine|Basal Glargine \& bolus Glulisine
219075578|NCT01143948|DRUG|Regular insulin|Sliding scale regular insulin
219075579|NCT01143948|DRUG|NPH & regular insulin|Basal NPH \& bolus regular insulin
219075580|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
219075581|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
219075582|NCT00179023|DRUG|Pseudoephedrine|30mg tablet,VO. Single dose.
219075583|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
219075584|NCT00727272|DRUG|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
219075585|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
219075586|NCT00651664|DRUG|alisertib|Alisertib (MLN8237) capsules
219075587|NCT02992262|DEVICE|Point of care ocular ultrasound|
219075588|NCT03977519|PROCEDURE|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
219210089|NCT06778590|PROCEDURE|Traditional technique in third molar germectomy|Application of traditional technique in third molar germectomy procedures
219210090|NCT06778668|PROCEDURE|TAP block with bupivacaine only|Patients undergoing laparoscopic cholecystectomy will receive TAP block with bupivacaine only after induction and before the surgical procedure begins.
219210091|NCT06778668|PROCEDURE|TAP block with bupivacaine and fentanyl|Patients undergoing laparoscopic cholecystectomy will receive a TAP block with bupivacaine and fentanyl after induction and before the surgical procedure begins
219210092|NCT06763419|DEVICE|External low level laser therapy|Patients received 8 sessions of external diode laser (635 nm).
219210093|NCT06763419|DEVICE|Internal low level laser therapy|Patients received 8 diode laser (635 nm) sessions applied internally
219210094|NCT06842771|OTHER|Normal Saline (0.9% NaCl)|"Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL of saline (standard) at the end of the operation, prior to insufflation, release, and skin closure.~The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters).~All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'.~Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively."
219678564|NCT03975504|DIAGNOSTIC_TEST|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
219678565|NCT01060189|DRUG|Ulinastatin|
219678566|NCT01060189|DRUG|Tranexamic Acid|
219678567|NCT01060189|DRUG|Saline Solution|
219075589|NCT03977519|PROCEDURE|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
219075590|NCT04980053|OTHER|massage|Intervention group Control group
219075591|NCT00959517|DRUG|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
219075592|NCT00959517|DRUG|sulphadoxine-pyrimethamine (SP)|
219075593|NCT00959517|DRUG|Chloroquine (CQ)|
219075594|NCT00959517|DRUG|primaquine (PQ)|
219075595|NCT02159833|OTHER|Intranasal challenge with active substance (food protein)|
219075596|NCT02159833|OTHER|Intranasal challenge with placebo|
219075597|NCT01972516|DRUG|Tivozanib|
219075598|NCT02147548|DRUG|etifoxine|
219075599|NCT02147548|DRUG|lorazepam|
219075600|NCT02147548|DRUG|Placebo|
219075601|NCT05821738|DRUG|Avapritinib|administered orally
219075602|NCT00596765|BEHAVIORAL|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
219075603|NCT06405373|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
219075604|NCT06405373|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
219678568|NCT00983645|DRUG|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
219678569|NCT00983645|DRUG|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
219678570|NCT02397941|OTHER|Ultrasound|ultrasound measures
219678571|NCT02019342|OTHER|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
219678572|NCT02019342|OTHER|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
219678573|NCT01304134|DRUG|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
219360447|NCT01485692|DRUG|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
219360448|NCT01758757|PROCEDURE|Vitrectomy|
219678574|NCT01304134|DRUG|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
219678575|NCT06517498|OTHER|No Intervention|No Intervention will be conducted
219678576|NCT01520207|DRUG|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
219678577|NCT01520207|DRUG|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
219678578|NCT04203212|DRUG|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
219075605|NCT01744028|DEVICE|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
219075606|NCT01744028|OTHER|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
219075607|NCT02195986|DRUG|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
219075608|NCT02195986|DRUG|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
219075609|NCT02195986|DRUG|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
219075610|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
219360449|NCT02883244|DEVICE|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
219678579|NCT00423280|DRUG|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
219678580|NCT00473057|OTHER|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
219678581|NCT01882296|DRUG|AGSPT_10|AGSPT 10mg for 7days administration
219678582|NCT01882296|DRUG|AGSPT_20|AGSPT 20mg for 7days administration
219678583|NCT01882296|DRUG|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
219678584|NCT01882296|DRUG|Pantoprazole_20|Pantoprazole 20mg for 7days administration
219678585|NCT01882296|DRUG|Pantoprazole_40|Pantoprazole 40mg for 7days administration
219678586|NCT01706835|DRUG|aldoxorubicin|
219075611|NCT02571218|DEVICE|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
219075612|NCT02571218|DEVICE|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
219075613|NCT03332524|DRUG|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
219075614|NCT03332524|DRUG|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
219075615|NCT03332524|DRUG|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
219075616|NCT04404712|DRUG|[11C]MK-3168|One PET scan involving administration of PET ligand \[11C\]MK-3168
219075617|NCT06963073|OTHER|Diabetic DM|The intervention group will receive 45 minutes of diabetes education. Three telemonitoring sessions will be held 2 weeks, 1 month and 3 months after the education. During the monitoring, participants will be asked to monitor their blood sugar and HbA1C values, if any. Nothing will be done to the control group. The same monitoring will be held for the control group 3 months later.
219075618|NCT06961773|OTHER|Low energy availability|Participants follow 6 days of a low-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
219075619|NCT06961773|OTHER|High energy availability|Participants follow 6 days of a high-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
219075620|NCT06961903|OTHER|physiotherapy programme|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.
219075621|NCT06961903|OTHER|Functional Taping|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention. In addition, the taping method applied in this study can be defined as a Function-Oriented Taping Application to Preserve Extension: Lumbar Extension Taping, which was specifically designed to maintain lumbar extension."
219075622|NCT06961903|OTHER|Manual Therapy|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.Manual Therapy (MT), which literally means hands-on treatment, is an evidence-based therapeutic approach consisting of skilled hand movements and maneuvers applied to produce therapeutic effects and to treat musculoskeletal dysfunctions and pain. In addition to the standard program, manual therapy was also administered in this study."
219075623|NCT06961903|OTHER|Stereodynamic Interference Current|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.In addition, the stereodynamic interference current method was applied in this study. A 'Y' electrode was used during the application. Due to the rapid development of accommodation, the current intensity was frequently increased during the session. The average treatment duration was 15 minutes, and a frequency of 50-100 Hz was used to achieve analgesic effects.
219075624|NCT06962722|OTHER|Upper limb motor control training (uMCON)|The exercise program protocol was determined using elbow flexion (Biceps brachii) and elbow extension (Triceps) on a special platform developed for the arm. In this computer-based exercise, participants are asked to follow a small ball on the screen in different lines at certain percentages of maximum muscle strength (10%, 25%, 50%, and so on). Neuromuscular training will be worked on with this exercise.
219075625|NCT03449030|DRUG|TAK-164|TAK-164 intravenous infusion.
219075626|NCT03449030|DRUG|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
219075627|NCT01306773|DRUG|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
219075628|NCT01306773|DRUG|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
219075629|NCT06164626|PROCEDURE|Extraction|extraction: in all groups, extraction will be performed
219075630|NCT06164626|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
219075631|NCT06164626|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
219075632|NCT03335033|COMBINATION_PRODUCT|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
219360450|NCT02883244|DEVICE|Floss|Floss will be used once a day to clean interdental sites at home.
219075633|NCT03335033|DEVICE|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
219360451|NCT02435914|DRUG|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
219360452|NCT02435914|DRUG|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
219075634|NCT03335033|DEVICE|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
219075635|NCT05086133|DEVICE|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
219075636|NCT05086133|DEVICE|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
219075637|NCT00558311|DRUG|Clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h
219075638|NCT00558311|DRUG|Placebo|Placebo administered by continuous infusion matching clazosentan administration
219360453|NCT04148261|DRUG|Hydrocortisone Acetate (CORT)|Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
219075639|NCT04490486|BIOLOGICAL|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
219678587|NCT04819789|OTHER|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
219678588|NCT04819789|OTHER|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
219678589|NCT04819789|OTHER|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
219678590|NCT04819789|OTHER|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
219360454|NCT04148261|DRUG|Epinephrine Sulfate (EPI)|Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
219678591|NCT01684514|DEVICE|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
219360455|NCT04148261|DRUG|Placebo (PLB)|Participants will receive a placebo
219678592|NCT04330144|DRUG|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
219678593|NCT04330144|OTHER|Others(No intervention)|No treatment. Close monitoring and quarantine.
219678594|NCT01289327|DRUG|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
219678595|NCT04474808|OTHER|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
219678596|NCT04474808|OTHER|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
219678597|NCT02853526|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
219678598|NCT02853526|DRUG|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
219075640|NCT04490486|OTHER|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
219075641|NCT03369444|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
219075642|NCT04148443|OTHER|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
219075643|NCT04148443|OTHER|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
219075644|NCT03581721|DEVICE|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
219075645|NCT03351374|OTHER|Software|multi-module system of web software tools
219075646|NCT00153777|DRUG|Cellulose Sulfate gel (6%)|
219075647|NCT00785655|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
219075648|NCT01346748|DRUG|statin|Sinvastatin 80 mg per day - 21 days versus placebo
219075649|NCT01184287|DRUG|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
219075650|NCT05947877|PROCEDURE|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
219360456|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
219360457|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
219075651|NCT02628210|OTHER|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
219075652|NCT03232970|OTHER|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
219075653|NCT02405520|BIOLOGICAL|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
219075654|NCT02405520|BIOLOGICAL|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
219075655|NCT02405520|BIOLOGICAL|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
219210095|NCT06842771|DRUG|Marcaine hydrochloride without epinephrine 0.5%|Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% (the comparator) at the end of the operation, prior to insufflation, release, and skin closure. The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters). All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'. Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively.
219210096|NCT06791694|OTHER|Resins, Composite|Graduate students; healthy maxillary central teeth and color measurements will be performed with 4 different methods in at least 32 patients aged between 18-40 years. Firstly, students will be asked to make color measurements using the traditional method with two different color scales (Vita classical and Vita 3D master). As the third method; the enamel color of the teeth will be determined on digital photographs using the buton technique. Finally, tooth color will be measured on the buccal surface of the central teeth using a spectrophotometer.
219210097|NCT06738537|OTHER|Focus Groups/Quantitative Survey for Patients|5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.
219678599|NCT02853526|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
219678600|NCT02853526|DRUG|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
219075656|NCT02405520|BIOLOGICAL|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
219075657|NCT01993069|BEHAVIORAL|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
219075658|NCT03934398|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
219075659|NCT03934398|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
219075660|NCT03934398|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
219075661|NCT03934398|DIAGNOSTIC_TEST|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
219075662|NCT03863340|BEHAVIORAL|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch"
219075663|NCT00687648|DRUG|anastrozole|Given as previously prescribed
219075664|NCT00687648|DRUG|cyclophosphamide|Given by mouth
219075665|NCT00687648|DRUG|exemestane|Given as previously prescribed
219075666|NCT00687648|DRUG|letrozole|Given as previously prescribed
219678601|NCT03320265|DRUG|PC-mAb|Monthly treatment for 3 months (4 administrations)
219075667|NCT00687648|DRUG|methotrexate|Given by mouth
219075668|NCT00687648|DRUG|prednisolone|Given by mouth
219678602|NCT03320265|DRUG|Placebo|Monthly treatment for 3 months (4 administrations)
219678603|NCT00144443|BEHAVIORAL|Basic home repair|
219075669|NCT02491671|DEVICE|Hemopatch|
219075670|NCT02491671|PROCEDURE|standard preventive measures|
219075671|NCT03621644|RADIATION|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
219075672|NCT00002564|OTHER|educational intervention|
219075673|NCT00002564|PROCEDURE|therapeutic dietary intervention|
219075674|NCT05949723|DEVICE|Golf simulator device|The golf simulator can accurately predict the flight trajectory and landing point of the ball using high-speed moving object measurement technology, giving the user the impression that they are playing on a real golf course.
219075675|NCT06202521|DRUG|CX-4945 (SARS-CoV-2 domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
219075676|NCT06202521|DRUG|Placebo (SARS-CoV-2 domain)|The dosage and frequency is the same as active drug.
219678604|NCT00144443|BEHAVIORAL|Asthma Trigger Education|
219075677|NCT06202521|DRUG|CX-4945 (Influenza virus domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
219075678|NCT06202521|DRUG|Placebo (Influenza virus domain)|The dosage and frequency is the same as active drug.
219075679|NCT02654626|DRUG|KBP-7072|Drug Intervention
219075680|NCT02654626|OTHER|Placebo|
219678605|NCT03615261|BEHAVIORAL|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
219678606|NCT03100656|OTHER|A breakfast sandwich|A meat-based breakfast sandwich
219678607|NCT04583007|DRUG|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
219678608|NCT04583007|DRUG|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
219678609|NCT02154932|DRUG|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
219678610|NCT02154932|DRUG|single dose misoprostol|1 dose, 1 hours, prior surgery
219678611|NCT03446378|DEVICE|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
219678612|NCT03446378|BEHAVIORAL|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
219678613|NCT03446378|DEVICE|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
219678614|NCT03446378|DEVICE|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
219678615|NCT03289247|DEVICE|tissue adhesive (Leukosan®)|Tissue ahaesive
219678616|NCT00447525|BIOLOGICAL|REVAXIS®|
219678617|NCT00447525|BIOLOGICAL|DT-Polio®|
219678618|NCT01772927|DIETARY_SUPPLEMENT|Parenteral Nutrition|Protein and energy intakes
219678619|NCT05074134|DRUG|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
219678620|NCT02453880|BEHAVIORAL|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
219075681|NCT01398488|BEHAVIORAL|Patient education|Patient education by health care professional compared to education via tablet PC
219075682|NCT04166253|DRUG|Vitamin D|Alfacalcidol oral tablets once daily
219075683|NCT01342874|DIETARY_SUPPLEMENT|Inositol|inositol exposure in early GDM
219075684|NCT03337529|OTHER|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
219075685|NCT03337529|OTHER|Placebo|200 mg placebo will be given on daily basis for 8 weeks
219075686|NCT06443268|DIAGNOSTIC_TEST|questionnaire, hair samples, blood samples, clinical exam|The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
219075687|NCT00535730|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
219075688|NCT00535730|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
219075689|NCT00535730|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
219075690|NCT04176627|DEVICE|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
219075691|NCT04401384|DRUG|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
219075692|NCT04401384|DRUG|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
219075693|NCT04401384|DEVICE|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
219075694|NCT04401384|DEVICE|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
219075695|NCT05172765|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
219075696|NCT05187676|DEVICE|Oxygen saturation measurement using the IPAM device|Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
219075697|NCT05187676|DEVICE|Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device|Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
219075698|NCT04588350|DEVICE|i-SEP autotransfusion system|Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
219075699|NCT03816748|DEVICE|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
219075700|NCT05916690|DRUG|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
219075701|NCT03349450|BIOLOGICAL|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
219075702|NCT03349450|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
219075703|NCT03349450|DRUG|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
219075704|NCT01417299|DIETARY_SUPPLEMENT|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
219075705|NCT01417299|DIETARY_SUPPLEMENT|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
219075706|NCT00936858|DRUG|RAD001|
219075707|NCT02106299|DEVICE|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
219075708|NCT02106299|DEVICE|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
219075709|NCT06470854|DRUG|Nebulized Dexmedetomidine|Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
219075710|NCT06470854|PROCEDURE|Bilateral greater occipital nerve block|The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
219075711|NCT03734627|DRUG|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
219210098|NCT06738537|OTHER|Focus Group/Quantitative Survey for HCPs|5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.
219210099|NCT06738537|OTHER|Qualitative Focus Group|Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.
219075712|NCT03734627|DRUG|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
219075713|NCT03734627|DRUG|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
219075714|NCT03734627|DRUG|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
219075715|NCT03734627|DIAGNOSTIC_TEST|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
219210100|NCT04307615|COMBINATION_PRODUCT|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
219210101|NCT04307615|DRUG|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
219210102|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
219075716|NCT00303524|DRUG|Goserelin acetate|Injection 3.6 mg monthly
219075717|NCT00303524|DRUG|Goserelin acetate|injection 10.8 mg every 3 months
219210103|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally|0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
219210104|NCT05619783|DRUG|AMX0035|Combination of 3 g phenylbutyrate and 1 g taurursodiol
219210105|NCT06782737|OTHER|Dietetic interventión with mediterranean diet|Personalized dietary Mediterranean diet
219210106|NCT06843083|DIAGNOSTIC_TEST|CEM protocol|CEM combines low-energy mammography with high-energy contrast-enhanced imaging to highlight areas of neo-angiogenesis, which are indicative of malignancy. This intervention will be used to evaluate the diagnostic performance of CEM in detecting and characterizing breast lesions, especially in patients with dense breast tissue or inconclusive findings from routine mammography.
219210107|NCT06843083|DIAGNOSTIC_TEST|breast MRI|"MRI (Magnetic Resonance Imaging):~MRI will be used as an alternative imaging modality for breast lesion detection and characterization. MRI provides detailed soft tissue imaging and is widely used in the evaluation of high-risk patients or those with dense breast tissue. The results from MRI will be compared to CEM findings to determine which modality offers superior diagnostic accuracy and clinical impact."
219210108|NCT03869892|DRUG|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
219210109|NCT03869892|DRUG|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
219210110|NCT03869892|BIOLOGICAL|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
219210111|NCT03869892|BIOLOGICAL|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
219210112|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
219210113|NCT06823531|OTHER|Not applicable (Observational Study)|Not applicable (Observational Study)
219210114|NCT03991156|DEVICE|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
219678621|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
219678622|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
219678623|NCT01495052|DIETARY_SUPPLEMENT|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
219678624|NCT00892463|DRUG|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
219075718|NCT04321538|DEVICE|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
219075719|NCT04321538|DEVICE|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
219075720|NCT04321538|DIAGNOSTIC_TEST|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
219075721|NCT02739438|OTHER|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
219075722|NCT02739438|OTHER|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
219075723|NCT02739438|OTHER|Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
219075724|NCT03974542|BEHAVIORAL|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
219210115|NCT03991156|OTHER|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
219210116|NCT03991156|OTHER|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
219075725|NCT01279499|DRUG|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
219678625|NCT03291951|BEHAVIORAL|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
219678626|NCT06203535|OTHER|Aerobic training|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
219075726|NCT01279499|DRUG|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
219075727|NCT01279499|DRUG|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
219075728|NCT01279499|DRUG|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
219075729|NCT00862160|DEVICE|ROCsafeTM|using minimized perfusion circuit while CABG
219075730|NCT03556462|OTHER|Sleep Health Education|Parents and children receive sleep health education
219075731|NCT04878562|BEHAVIORAL|I-COPE|The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
219678627|NCT06251141|PROCEDURE|Gum Health gel|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel
219678628|NCT06251141|PROCEDURE|Gel foam|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
219075732|NCT00232492|DRUG|Placebo males|Intravenous saline bolus (Placebo-control) males
219075733|NCT00232492|DRUG|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
219075734|NCT00232492|DRUG|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
219210117|NCT03956680|DRUG|BMS-986301|Specified dose on specified days
219678629|NCT05411835|DIETARY_SUPPLEMENT|Nutritional Ketone Supplement|Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
219678630|NCT05411835|DIETARY_SUPPLEMENT|Isocaloric Placebo Supplement|Maltodextrin with flavors and stevia sweetener
219210118|NCT03956680|BIOLOGICAL|Nivolumab|Specified dose on specified days
219210119|NCT03956680|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219210120|NCT05139979|BEHAVIORAL|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
219210121|NCT05139979|OTHER|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
219210122|NCT06640010|OTHER|Non-Interventional Study|Non-interventional study
219210123|NCT06852508|BEHAVIORAL|TwySHE|Interpersonal support from trained peers to access and use PrEP and contraception.
219075735|NCT00232492|DRUG|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
219075736|NCT00232492|DRUG|Placebo females|Intravenous saline bolus (Placebo-control) females
219075737|NCT00232492|DRUG|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
219075738|NCT00232492|DRUG|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
219075739|NCT00232492|DRUG|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
219075740|NCT01953081|DRUG|TD-8954|
219075741|NCT01953081|DRUG|Metoclopramide|
219075742|NCT05525494|BEHAVIORAL|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219075743|NCT05525494|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
219075744|NCT05525494|BEHAVIORAL|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219210124|NCT04484636|DIAGNOSTIC_TEST|FoundationOne®CDx and FoundationOne®Liquid|FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient's cancer. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. FoundationOne®Liquid is a liquid biopsy test for solid tumors that analyzes circulating tumor DNA (ctDNA) in blood.
219210125|NCT05411640|OTHER|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
219210126|NCT05411640|OTHER|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
219360458|NCT05728294|PROCEDURE|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
219678631|NCT03762577|OTHER|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
219678632|NCT02632370|DRUG|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
219678633|NCT02632370|PROCEDURE|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
219678634|NCT00777166|DRUG|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
219678635|NCT00777166|DRUG|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
219075745|NCT05525494|BEHAVIORAL|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
219075746|NCT05525494|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
219075747|NCT00762320|DRUG|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
219075748|NCT00205283|DRUG|Nelfinavir|
219075749|NCT05737810|OTHER|No treatment given|No treatment given
219075750|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Sustain|Sustain improvements during QI collaborative focused on PCC
219075751|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Spread|Implement change package developed during QI Collaborative
219075752|NCT01840540|DRUG|Arterial infusion of autologous mesenchymal stem cells|
219075753|NCT03512665|DIETARY_SUPPLEMENT|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
219075754|NCT03512665|DIETARY_SUPPLEMENT|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
219075755|NCT03512665|OTHER|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
219075756|NCT05252767|BEHAVIORAL|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
219075757|NCT05252767|BEHAVIORAL|Educational Guide|Control participants will receive a brief educational guide about pain management.
219075758|NCT03119324|DEVICE|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
219075759|NCT03119324|DEVICE|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
219075760|NCT03119324|DRUG|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
219075761|NCT00003954|DRUG|melphalan|Given IV
219075762|NCT00003954|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
219075763|NCT00003954|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
219075764|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
219075765|NCT00003954|RADIATION|total-body irradiation|Undergo TBI
219075766|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo donor PBSCT
219075767|NCT00003954|DRUG|cyclosporine|Given IV and PO
219075768|NCT00003954|DRUG|mycophenolate mofetil|Given PO
219075769|NCT00003954|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
219075770|NCT06224452|DRUG|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
219075771|NCT01161316|DRUG|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
219075772|NCT01161316|DRUG|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
219678636|NCT02651870|DRUG|Candesartan 16mg|
219678637|NCT02651870|DRUG|Amlodipine 5mg|
219075773|NCT06135337|DEVICE|Thioderm Elate|Test Device
219075774|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
219075775|NCT00003857|DRUG|tamoxifen citrate|
219075776|NCT00003857|PROCEDURE|adjuvant therapy|
219075777|NCT00003857|RADIATION|radiation therapy|
219075778|NCT01355393|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
219075779|NCT01355393|BIOLOGICAL|sargramostim|Given ID
219075780|NCT01355393|DRUG|rintatolimod|Given ID
219075781|NCT03805724|OTHER|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
219075782|NCT05656950|PROCEDURE|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
219075783|NCT01726868|DEVICE|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
219075784|NCT00037219|DRUG|Anidulafungin, VER002|
219075785|NCT04802538|DEVICE|OstoRing®|Participants will use the OstoRing® along with their standard pouching equipment.
219075786|NCT01090453|BIOLOGICAL|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
219075787|NCT01090453|BIOLOGICAL|Prevenar 13®|3 co-administered doses
219075788|NCT01090453|BIOLOGICAL|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
219075789|NCT01090453|BIOLOGICAL|Menjugate®|3 co-administered doses
219075790|NCT01090453|BIOLOGICAL|Rotarix™|Oral, two doses
219678638|NCT02651870|DRUG|Amlodipine 10mg|
219678639|NCT03454087|OTHER|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
219678640|NCT03454087|OTHER|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
219678641|NCT01105104|DEVICE|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
219678642|NCT01105104|DEVICE|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
219678643|NCT01965002|DEVICE|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
219075791|NCT00149513|BEHAVIORAL|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
219075792|NCT00149513|BEHAVIORAL|Usual care|Participants will receive usual care.
219075793|NCT02859857|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
219075794|NCT04730050|DRUG|TT-01025-CL|Oral tablet
219210127|NCT05411640|OTHER|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
219210128|NCT06772792|DRUG|Alendronate|Oral administration
219075795|NCT06230289|PROCEDURE|Transabdominal plane block|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
219210129|NCT06772792|DRUG|Enlicitide Decanoate|Oral administration
219678644|NCT01965002|DRUG|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
219678645|NCT01965002|DRUG|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
219075796|NCT04072159|BEHAVIORAL|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
219075797|NCT02464449|BEHAVIORAL|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
219075798|NCT02464449|BEHAVIORAL|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
219075799|NCT01655030|DIETARY_SUPPLEMENT|creatine monohydrate|
219075800|NCT01655030|DIETARY_SUPPLEMENT|placebo|
219075801|NCT05956301|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
219075802|NCT05956301|DEVICE|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
219075803|NCT05956301|DEVICE|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
219075804|NCT01177904|OTHER|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
219075805|NCT01177904|OTHER|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
219075806|NCT03195192|OTHER|biomarker study|This is a biomarker study
219075807|NCT00832273|DEVICE|ELAD®|liver assist system
219075808|NCT02666950|DRUG|Cytarabine|Given SC
219075809|NCT02666950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219075810|NCT02666950|OTHER|Pharmacological Study|Correlative studies
219075811|NCT02666950|OTHER|Quality-of-Life Assessment|Ancillary studies
219075812|NCT02666950|OTHER|Questionnaire Administration|Ancillary studies
219075813|NCT02666950|DRUG|WEE1 Inhibitor AZD1775|Given PO
219075814|NCT06475612|OTHER|Death|Mortality group.
219075815|NCT06475612|OTHER|Survival|Survival group.
219075816|NCT04262544|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
219210130|NCT04158141|DRUG|Carboplatin|Intravenously
219210131|NCT04158141|DRUG|Cisplatin|Intravenously
219210132|NCT04158141|PROCEDURE|Decortication|Undergo decortication
219210133|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions
219210134|NCT04158141|DRUG|Pemetrexed|Intravenously
219210135|NCT04158141|DRUG|Pemetrexed Disodium|Intravenously
219210136|NCT04158141|RADIATION|Pencil beam scanning proton therapy|Daily fractions
219210137|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
219360459|NCT05728294|PROCEDURE|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
219360460|NCT01155700|DRUG|omalizumab|
219678646|NCT01724177|DRUG|Lenalidomide|25 mg of Lenalidomide administered orally once daily
219678647|NCT01773018|DRUG|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
219678648|NCT05063084|PROCEDURE|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
219678649|NCT05063084|PROCEDURE|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
219075817|NCT04262544|OTHER|Usual Care|Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
219075818|NCT02846974|DEVICE|Pulse oximeter|A pulse oximeter will be used for calibration
219075819|NCT02305927|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
219075820|NCT02305927|OTHER|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
219075821|NCT00887497|PROCEDURE|Angioembolization|Angioembolization
219075822|NCT04395105|DRUG|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
219075823|NCT06164717|BEHAVIORAL|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
219075824|NCT06164717|BEHAVIORAL|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
219075825|NCT06164717|OTHER|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
219075826|NCT02495051|PROCEDURE|esophageal biopsies|
219075827|NCT01746004|DRUG|[^14C]-LY2157299|\[\^14C\]-LY2157299 monohydrate administered as oral solution
219075828|NCT00989287|BIOLOGICAL|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
219075829|NCT00989287|BIOLOGICAL|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
219075830|NCT04250454|BEHAVIORAL|CONTRACT|"The intervention will consist of four elements:~1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~2. Home Activity Plan (HAP)~3. Home-based Feedback training~4. Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
219678650|NCT03592836|DRUG|Loop Diuretics|intravenous administration of diuretics
219075831|NCT00729833|DRUG|CP-751,871|CP-751,871 IV, every 3 weeks
219075832|NCT00729833|DRUG|Sunitinib|Sunitinib - daily dosing
219075833|NCT03102723|DRUG|Cangrelor|"1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
219075834|NCT01438502|DRUG|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
219075835|NCT02938598|BEHAVIORAL|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
219075836|NCT03598270|DRUG|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
219075837|NCT03598270|DRUG|Carboplatin|Intravenous. Day 1
219075838|NCT03598270|DRUG|Paclitaxel|175 mg/m². Intravenous. Day 1
219075839|NCT03598270|DRUG|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
219075840|NCT03598270|DRUG|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
219075841|NCT03598270|DRUG|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
219678651|NCT00581061|DRUG|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
219678652|NCT00370591|DRUG|Salmeterol/fluticasone propionate and fluticasone propionate|
219678653|NCT04226300|PROCEDURE|Laparoscopic|A transversus abdominis nerve block will be placed laparoscopically.
219678654|NCT04226300|PROCEDURE|Ultrasound|A transversus abdominis nerve block will be place by ultrasound
219678655|NCT00700375|DRUG|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
219678656|NCT00700375|DRUG|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
219678657|NCT02214940|DRUG|BI 11634|
219075842|NCT03598270|DRUG|Atezolizumab|1200 mg. Intravenous. Day 1
219075843|NCT00097331|DRUG|SB683699|
219075844|NCT00417079|DRUG|cabazitaxel (XRP6258) (RPR116258)|25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
219075845|NCT00417079|DRUG|mitoxantrone|12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
219075846|NCT00417079|DRUG|prednisone|10 mg daily administered by oral route
219075847|NCT00694603|DRUG|Cetuximab|Given intravenously once per week.
219075848|NCT01192438|PROCEDURE|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
219075849|NCT05234684|DRUG|Orelabrutinib + R-CHOP|The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
219075850|NCT05234684|DRUG|Placebo + R-CHOP|The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
219075851|NCT05110092|BEHAVIORAL|leg resistance combined with breathing exercise training|The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
219075852|NCT01862705|OTHER|Thoracic spine manipulation|TSM thrust or non-thrust
219075853|NCT01696487|DIETARY_SUPPLEMENT|High oral Fructose challenge (150g per day for 28 days)|
219075854|NCT03943030|OTHER|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
219075855|NCT05046184|DRUG|Ketamine Hydrochloride|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
219678658|NCT02214940|DRUG|Placebo|
219678659|NCT02999334|BEHAVIORAL|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
219678660|NCT06090968|PROCEDURE|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
219678661|NCT06090968|PROCEDURE|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
219678662|NCT01243918|OTHER|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
219678663|NCT05361967|DEVICE|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
219678664|NCT01443234|OTHER|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
219678665|NCT01443234|OTHER|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
219678666|NCT04565548|OTHER|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
219678667|NCT04565548|OTHER|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
219678668|NCT01005862|BIOLOGICAL|PF-04360365|10 mg/kg, single dose administered intravenously
219075856|NCT05046184|DRUG|Midazolam injection|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
219075857|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
219075858|NCT03152552|DRUG|LIK066|LIK066 was supplied in different doses as tablets taken orally.
219075859|NCT03152552|DRUG|Placebo|Placebo was supplied as tablets and capsules taken orally.
219075860|NCT03152552|DRUG|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
219075861|NCT03525366|OTHER|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
219075862|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
219075863|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
219360461|NCT04992416|PROCEDURE|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
219360462|NCT04992416|PROCEDURE|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
219678669|NCT01005862|DRUG|Placebo|Placebo
219678670|NCT00856791|DRUG|ON 01910.Na|
219075864|NCT05068817|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
219075865|NCT05068817|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
219075866|NCT05068817|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
219075867|NCT05925127|BIOLOGICAL|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
219075868|NCT05925127|BIOLOGICAL|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
219075869|NCT05925127|BIOLOGICAL|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
219075870|NCT05925127|BIOLOGICAL|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
219075871|NCT05925127|BIOLOGICAL|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
219075872|NCT05925127|BIOLOGICAL|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
219075873|NCT05925127|BIOLOGICAL|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
219075874|NCT00434382|DRUG|Sevoflurane|
219075875|NCT00434382|DRUG|Isoflurane|
219678671|NCT00329095|DRUG|travoprost, latanoprost, or bimatoprost|
219678672|NCT00329095|DRUG|Additional ocular hypotensive medication|
219075876|NCT00434382|DRUG|Desflurane|
219075877|NCT00434382|DRUG|Propofol|
219075878|NCT00434382|DRUG|Fentanyl|
219075879|NCT00434382|DRUG|Sufentanil|
219075880|NCT00434382|DRUG|Alfentanil|
219075881|NCT00434382|DRUG|Remifentanil|
219075882|NCT00434382|DEVICE|Midlatency auditory evoked potentials|
219075883|NCT04899349|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
219075884|NCT04899349|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
219075885|NCT04899349|DRUG|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
219075886|NCT04899349|DRUG|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
219075887|NCT04899349|DRUG|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
219075888|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
219075889|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
219678673|NCT00789607|DEVICE|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
219678674|NCT00789607|DEVICE|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
219678675|NCT00455000|BIOLOGICAL|PF-04360365|Monoclonal antibody
219678676|NCT00455000|DRUG|Placebo|Placebo
219678677|NCT02653157|OTHER|MDR-GNB|
219678678|NCT00281697|DRUG|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
219678679|NCT00281697|DRUG|Placebo|
219678680|NCT00281697|DRUG|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle."
219075890|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
219075891|NCT06072196|DRUG|Novel hormonal therapy|As provided in real-world setting
219075892|NCT06374212|DRUG|Anifrolumab|900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
219075893|NCT05935345|BEHAVIORAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
219075894|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
219075895|NCT03570619|DRUG|Nivolumab|"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
219075896|NCT03570619|DRUG|Ipilimumab|Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
219075897|NCT05054608|OTHER|No intervention|Observational study. No intervention.
219075898|NCT03154008|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
219075899|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
219678681|NCT00568737|DRUG|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
219678682|NCT00568737|DRUG|Placebo|0.9% sodium chloride
219678683|NCT06357520|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
219678684|NCT06357520|DRUG|Itraconazole|Itraconazole capsule will be administered orally.
219678685|NCT01861353|OTHER|Cranberry-lingonberry juice|
219678686|NCT01861353|OTHER|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
219678687|NCT00632125|DRUG|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
219678688|NCT04438408|OTHER|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
219678689|NCT05545423|OTHER|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
219678690|NCT05545423|OTHER|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
219678691|NCT00619372|DRUG|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
219678692|NCT00619372|DRUG|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
219678693|NCT00619372|DRUG|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
219678694|NCT00619372|DRUG|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
219678695|NCT00619372|DRUG|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
219678696|NCT00619372|DRUG|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
219678697|NCT00827788|DRUG|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
219678698|NCT00827788|DRUG|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
219678699|NCT02474134|DRUG|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
219678700|NCT04964336|OTHER|Analysis of B cells|B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
219678701|NCT03444259|PROCEDURE|Cardiac surgery|Open heart surgery
219678702|NCT04446429|DRUG|Proxalutamide|200 mg q.d.
219678703|NCT04446429|OTHER|Standard of Care|Standard of care as determined by the PI
219678704|NCT03061578|DIAGNOSTIC_TEST|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
219210138|NCT06094881|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
219210139|NCT06835140|DRUG|Donor-derived CD123-CD16 bispecific antibody-modified NK cells|Patients enrolled sequentially received varying doses of NK cell infusions. The first three patients received 1×10⁷ cells/kg, the next three received 2×10⁷ cells/kg, and the final three received 4×10⁷ cells/kg.
219210140|NCT06808594|DEVICE|APSI prosthesis implant|The adaptative proximal scaphoid implant (APSI) is a pyrocarbon partial scaphoid prosthesis, ovoid and unfixed, which replaces the proximal pole of the scaphoid and allows adaptative mobility in the movements of the first chain and restores the geometry of the carpus, thus preventing the evolution in SNAC (Scaphoid Non-union Advanced Collapse). Pyrocarbon has good compatibility with joint cartilage and bone, a modulus of elasticity similar to bone minimizing stress shielding effects and resorption. The implant is designed with two radii of curvature: in the frontal plane, the smaller radius of curvature corresponds to the scaphoid fossa, and the larger radius of curvature is directed anteroposteriorly to the transverse plane. When it's correctly positioned, the smallest radius of the curvature is visible in the anteroposterior view, whereas it's greater in the lateral view. These two axes of the implant make it adaptable to the kinematics of the wrist.
219210141|NCT06808035|OTHER|Activity-Based Recovery Training|ABRT uses task-specific training to improve neuromuscular capacity. ABRT will be tailored to participant presentation. Activity-Based Locomotor Training consists of stepping, standing, and sitting activities on a body weight support (BWS) treadmill using a harness and while overground. Therapists and trainers provide hands-on assistance for safety and kinematics. BWS is varied during sessions with a goal of optimal kinematics at the lowest BWS. Activities performed standing will focus on alignment incorporating static, active, and dynamic tasks. Activities performed during overground are based on neuromuscular capacity and appropriate developmental and functional levels. Principles of ABRT will be shared with parents/caregivers to foster activity in the home and community. Activity-Based Upper Extremity Training uses task-specific training of the trunk and upper extremities administered in sitting or standing via manual facilitation or support in a stander for best posture.
219210142|NCT06808035|DEVICE|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation (scTs) is a non-invasive stimulation administered over the skin using a modulated biphasic or monophasic waveform at 15-90Hz and a carrier frequency of 5-10kHz. Bouts of scTs at the cervical, thoracic, lumbar, and/or coccygeal level will be administered midline or just lateral to the spinous processes during activity-based recovery training.
219210143|NCT06276686|OTHER|Supervised Vigorous intensity aerobic interval exercise|11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
219210144|NCT06817915|BEHAVIORAL|AI assisted assessment of SD-OCT scans|AI 2nd opinion report on nAMD treatment planning
219678705|NCT03061578|DIAGNOSTIC_TEST|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
219678706|NCT01671137|OTHER|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
219678707|NCT01214993|DRUG|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
219678708|NCT01214993|DRUG|Placebo|Placebo is a tablet with no drug in it.
219075900|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
219678709|NCT01214993|DRUG|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
219678710|NCT01214993|DRUG|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
219678711|NCT04188886|OTHER|Practice survey|Practice survey on
219678712|NCT03839615|PROCEDURE|guided bone regenerations|"intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
219678713|NCT02706080|OTHER|emergency|
219678714|NCT05567471|BIOLOGICAL|BBV154 Intranasal Vaccine|Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route
219678715|NCT05567471|BIOLOGICAL|Intramuscular vaccine COVAXIN|Administered BBV152 vaccine via intramuscular route
219678716|NCT05567471|BIOLOGICAL|Covishield|Administered vaccine via intramuscular route
219678717|NCT01853683|PROCEDURE|Conservative Management|
219678718|NCT01853683|PROCEDURE|Operative Management|
219678719|NCT03090061|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
219678720|NCT03090061|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
219678721|NCT02727179|PROCEDURE|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
219678722|NCT00540644|DRUG|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
219678723|NCT00540644|DRUG|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
219678724|NCT00540644|DRUG|Prednisone|50 mg p.o. Q.O.D.
219678725|NCT03227731|DRUG|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
219678726|NCT02085265|DRUG|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
219075901|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
219075902|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
219075903|NCT02457221|DRUG|Tacrolimus capsules|oral
219075904|NCT02457221|DRUG|Cyclophosphamide injections|intravenous injection
219075905|NCT02457221|DRUG|Prednisone|oral
219075906|NCT00882947|DRUG|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
219075907|NCT00491049|DRUG|0.5% levofloxacin eye drops|
219075908|NCT05585424|OTHER|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
219075909|NCT03215797|DRUG|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
219075910|NCT03215797|DRUG|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
219075911|NCT01302119|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
219075912|NCT01302119|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
219075913|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
219678727|NCT02085265|DRUG|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
219678728|NCT01222208|DIETARY_SUPPLEMENT|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
219075914|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
219075915|NCT04084314|BIOLOGICAL|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
219075916|NCT02235493|BIOLOGICAL|Retrospective Case Only|
219075917|NCT01055769|DRUG|Linezolid|"1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG"
219075918|NCT01055769|DRUG|Linezolid|"1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG"
219075919|NCT06305338|OTHER|Optical Coherence Tomography|the study releated measurements will be performed: IOLMaster 700, Casia 2 and Pentacam HR.
219075920|NCT05576987|BEHAVIORAL|Education|Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
219075921|NCT04838899|RADIATION|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
219075922|NCT05152680|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
219075923|NCT02436148|OTHER|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
219075924|NCT06099626|OTHER|Different types of disease|Groups were observed according to disease type
219075925|NCT00000179|DRUG|Trazodone|
219075926|NCT00000179|DRUG|Haloperidol|
219075927|NCT01798329|DIETARY_SUPPLEMENT|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine"
219075928|NCT06427772|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty for neck femur fracture
219075929|NCT00802074|DRUG|Raltegravir|400mg BID
219075930|NCT00802074|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
219075931|NCT00802074|DRUG|Ritonavir|100 mg BID or QD
219075932|NCT01632748|DEVICE|Neurotech Vital Device|5 minute treatment
219075933|NCT01632748|DEVICE|Modified Neurotech Vital Device|5 minute stimulation
219075934|NCT05875948|DRUG|R2R01|Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
219075935|NCT05875948|DRUG|Terlipressin|"In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin."
219075936|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
219075937|NCT03049410|PROCEDURE|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
219075938|NCT03049410|PROCEDURE|Open Radical Cystectomy|Removal of bladder and adjacent organs
219075939|NCT02631798|DIETARY_SUPPLEMENT|Food grade dye mucosal staining|mucosal staining with food grade dye
219075940|NCT00160433|DRUG|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
219075941|NCT00160433|DRUG|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
219075942|NCT00160433|DRUG|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
219075943|NCT00160433|DRUG|Placebo|Tablet, oral Daily for 12 weeks
219075944|NCT01191489|DEVICE|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
219075945|NCT01191489|DEVICE|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
219075946|NCT01191489|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
219075947|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
219075948|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
219075949|NCT06647797|BEHAVIORAL|HOPE Clinical Communication Campaign|"* Patient-facing educational materials~* Provider counseling training and job aid"
219075950|NCT04086420|BEHAVIORAL|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
219075951|NCT04086420|BEHAVIORAL|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
219075952|NCT03463902|DEVICE|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
219075953|NCT03463902|DEVICE|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
219075954|NCT03463902|DEVICE|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
219075955|NCT03463902|DEVICE|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
219075956|NCT03463902|DEVICE|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
219075957|NCT05956119|DEVICE|dry needling + physiotherapy (standard/usual care)|same that arm descrption
219075958|NCT05956119|OTHER|sham dry needling + physiotherapy (standard/usual care)|same that arm description
219075959|NCT03336619|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
219075960|NCT03336619|DRUG|Placebo|Placebo administered orally twice daily for five days
219075961|NCT03743038|DRUG|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
219075962|NCT03743038|OTHER|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
219075963|NCT03671837|OTHER|Oxygen|15 L/min O2
219075964|NCT03671837|OTHER|Air|15 L/min air
219075965|NCT04083248|BEHAVIORAL|Feasibility group|Same as arm description
219678729|NCT01222208|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
219678730|NCT06453395|OTHER|Patients were grouped according to tumor location|Patients were grouped according to tumor location
219678731|NCT02752360|PROCEDURE|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
219678732|NCT02752360|PROCEDURE|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
219075966|NCT01300546|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
219075967|NCT01300546|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
219210145|NCT06816732|BEHAVIORAL|Nurse-led Modular Training|The intervention group participants filled out all the data collection tools in the first interview and three months later. They received modular training by phone 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the first interview.The modular training addressed (1) defining hypertension, (2) systemic effects of hypertension, (3) general effects of antihypertension drugs, (4) regular medication and blood pressure monitoring, and (5) eating a healthy diet and being active (what to do for a better heart health and a more stable blood pressure)
219210146|NCT06816615|PROCEDURE|Percutaneous cholangioscopic-assisted treatment|The intervention administered is a percutaneous colangioscopic assisted technique that uses endoscopic Spyglass system. The endoscopic Spyglass system is designed to provide direct viewing and to guide both optical devices and accessories for lithotripsy in case of litiasic pathology and is equipped with a suitable bioptic clamp in case of biopsy collection. The use of the digital Spyglass catheter involves the preliminary percutaneous puncture of the bile ducts with a right, left or combined approach, and the subsequent execution of a cholangiographic study. Additional treatment sessions may be performed every 15-20 days in case of residual lithiasis. At the end of each session, an internal-external transeptic percutaneous drainage (ptbd) of adequate caliber (8-14 fr) is left in place to monitor any complications and maintain a route of access for sequential treatments.
219678733|NCT04348097|DEVICE|Activator instrument|activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
219678734|NCT04348097|DEVICE|dry needle|By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
219678735|NCT00809094|DRUG|N-acetylcysteine (NAC)|
219678736|NCT00809094|DRUG|Placebo|
219678737|NCT02812589|OTHER|Diffusion tensor imaging (DTI) in Breast MRI|
219678738|NCT02956538|DRUG|Thalidomide|
219678739|NCT02956538|DRUG|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
219075968|NCT04584060|COMBINATION_PRODUCT|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
219075969|NCT04584060|COMBINATION_PRODUCT|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
219075970|NCT04584060|COMBINATION_PRODUCT|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
219075971|NCT01446458|DRUG|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
219075972|NCT01446458|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
219678740|NCT02794688|PROCEDURE|Ductal lavage therapy|"1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (\>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
219678741|NCT03731949|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography to assess placental volume
219678742|NCT04009304|BEHAVIORAL|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
219678743|NCT04799262|DRUG|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
219678744|NCT06238219|DRUG|Neuromuscular Blocking Agent|Administration of any neuromuscular blocking agent for surgery under general anesthesia
219678745|NCT05063578|DRUG|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
219678746|NCT01515098|DIETARY_SUPPLEMENT|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
219075973|NCT02580565|OTHER|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
219075974|NCT02820623|BEHAVIORAL|Self-report|
219075975|NCT02820623|BEHAVIORAL|Chart-Stimulated Recall|
219075976|NCT02820623|BEHAVIORAL|Behavioral Rehearsal|
219075977|NCT01163370|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
219075978|NCT01163370|OTHER|exercise training|resistance training twice a week for 24 weeks
219075979|NCT01163370|OTHER|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
219075980|NCT03936855|PROCEDURE|Direct composite resin|"For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal"
219075981|NCT06021301|OTHER|Platelet-Rich Fibrin and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
219075982|NCT04092374|PROCEDURE|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
219075983|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
219075984|NCT06562569|DEVICE|non-invasive cervical vagal nerve stimulation ncVNS|The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
219075985|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
219075986|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
219678747|NCT01515098|DIETARY_SUPPLEMENT|Dextrose Placebo|Placebo developed to closely match blueberry powder.
219678748|NCT00397189|DRUG|Circadin|Prolonged release melatonin 2 mg
219678749|NCT00397189|DRUG|placebo circadin|placebo circadin tablets
219678750|NCT03472937|PROCEDURE|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
219075987|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
219075988|NCT04647526|DRUG|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
219075989|NCT04647526|DRUG|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
219075990|NCT04647526|DRUG|Enzalutamide|Enzalutamide (160 mg orally qd)
219075991|NCT06490146|OTHER|No intervention|this is an observational study
219075992|NCT06147102|PROCEDURE|Surgery|Surgical treatment for the unruptured intracranial aneurysm
219075993|NCT06147102|PROCEDURE|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
219075994|NCT06649292|DRUG|SHR-A1904|SHR-A1904
219075995|NCT06649292|DRUG|Paclitaxel, Docetaxel, Irinotecan|Paclitaxel, Docetaxel, Irinotecan
219075996|NCT06412731|OTHER|Cera-bur|Dental caries removal using a low-speed handpiece and a ceramic bur and restoring the cavity with Glass ionomer filling material
219075997|NCT06412731|OTHER|Brix3000|Chemical-dissolving active dental caries and hand instrument used for removing the lesion then restoring with Glass ionomer filling material
219075998|NCT06412731|OTHER|E-SDF|Arresting the infected dentin and the demineralized lesion covered with Glass-ionomer filling
219075999|NCT06561529|DEVICE|Gastric Bypass Stent System|The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
219076000|NCT04568538|OTHER|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
219076001|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
219076002|NCT05504460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
219076003|NCT05504460|OTHER|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
219076004|NCT04867577|DIAGNOSTIC_TEST|CT scan of lung and spine|Dual energy CT scan of thorax and spine
219076005|NCT01308216|PROCEDURE|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
219678751|NCT00172445|PROCEDURE|blood sampling, neck lymph node biopsy|
219678752|NCT01535443|DRUG|Bromfenac|Drug: Bromfenac Other names: PRO-155
219678753|NCT02951026|OTHER|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
219678754|NCT02620683|DRUG|Lidocaine|See above
219678755|NCT03703752|DIAGNOSTIC_TEST|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
219678756|NCT05434663|DRUG|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
219678757|NCT05924659|OTHER|Cerabral training|1 week of cerebral training (neurofeedback or sham)
219678758|NCT00192972|PROCEDURE|Catheter ablation (pulmonary vein isolation)|
219678759|NCT05234268|OTHER|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
219678760|NCT05234268|OTHER|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
219678761|NCT05234268|OTHER|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
219678762|NCT03216707|DEVICE|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
219678763|NCT03216707|DEVICE|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
219678764|NCT03216707|DEVICE|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
219678765|NCT03216707|OTHER|Capsaicin cream|Capsaicin cream
219678766|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
219678767|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
219076006|NCT00670774|DRUG|Eculizumab|"* Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
219076007|NCT01022437|OTHER|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
219076008|NCT04273633|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
219076009|NCT04273633|DEVICE|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
219076010|NCT01808157|DRUG|CT327 ointment|
219076011|NCT01808157|DRUG|placebo|
219076012|NCT03341910|DRUG|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
219076013|NCT03341910|DRUG|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
219076014|NCT03341910|DRUG|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
219076015|NCT03341910|DRUG|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
219076016|NCT04744480|PROCEDURE|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
219076017|NCT02170168|OTHER|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
219076018|NCT02474927|DRUG|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
219076019|NCT04596254|OTHER|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
219076020|NCT05518929|DRUG|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
219076021|NCT05518929|DRUG|Propofol|The sedation of gastrointestinal endoscopy with Propofol
219076022|NCT01208454|DRUG|Isotretinoin|Given PO
219076023|NCT01208454|OTHER|Laboratory Biomarker Analysis|Correlative studies
219076024|NCT01208454|OTHER|Pharmacological Study|Correlative studies
219076025|NCT01208454|DRUG|Vorinostat|Given PO
219076026|NCT01763944|BEHAVIORAL|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
219076027|NCT05146674|DRUG|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
219076028|NCT04278053|DIETARY_SUPPLEMENT|inositol-stabilized arginine silicate|Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
219210147|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
219678768|NCT02997605|DRUG|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
219678769|NCT00232557|DEVICE|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
219076029|NCT00509847|DRUG|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
219076030|NCT06119100|DIAGNOSTIC_TEST|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
219076031|NCT02909972|DRUG|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
219076032|NCT02909972|DRUG|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
219076033|NCT06305572|DIAGNOSTIC_TEST|QFR|Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
219076034|NCT04805723|PROCEDURE|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
219678770|NCT00232557|DEVICE|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
219678771|NCT02170857|DRUG|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
219678772|NCT03629145|BEHAVIORAL|Live Music Therapy|Investigator will begin play live guitar and voice music.
219678773|NCT03629145|BEHAVIORAL|Recorded Music Therapy|Investigator will play recorded music.
219678774|NCT05013580|PROCEDURE|Guided bone regeneration (GBR)|Bone grafts will be placed in the patient's jawbone, along with a membrane to cover the bone grafts. A horizontal incision over the edentulous ridge crest will be made along with vertical incisions if indicated. Buccal and lingual full thickness mucoperiosteal flaps will be reflected to expose the alveolar bone. Intra-marrow penetration (decortication of the alveolar bone to increase vascular supply to the bone grafts) at the surgical site alveolar bone will be made with a high-speed hand piece and diamond bur. Bone allograft material will be placed to fill the alveolar bone defect. The bone graft will then be covered with a membrane and secured with sutures.
219076035|NCT04805723|PROCEDURE|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
219076036|NCT01371851|DRUG|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
219076037|NCT02967627|DEVICE|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
219076038|NCT02967627|DEVICE|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
219076039|NCT00833638|DRUG|Placebo|One tablet orally daily
219076040|NCT00833638|DRUG|Tadalafil|Orally once daily
219076041|NCT01055366|DRUG|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
219076042|NCT00307827|DRUG|Visilizumab|Visilizumab administered intravenously once per day for two days
219076043|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
219076044|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
219076045|NCT00689650|DEVICE|1540 nm fractional laser|
219076046|NCT02732925|DEVICE|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy"
219076047|NCT02732925|PROCEDURE|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy"
219076048|NCT01692535|PROCEDURE|Intubation|Intubation with one of the six videolaryngoscopes
219076049|NCT06129669|DRUG|Indocyanine green|Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
219076050|NCT04378348|BEHAVIORAL|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
219076051|NCT04378348|BEHAVIORAL|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
219076052|NCT04378348|BEHAVIORAL|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
219076053|NCT03317600|DEVICE|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
219076054|NCT03317600|DRUG|Placebo|"Intervention is a placebo nerve block with isotonic saline"
219076055|NCT01680328|OTHER|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
219076056|NCT01680328|DRUG|sodium chloride 0.9% solution|Solution for injection.
219076057|NCT04364958|OTHER|A web based-Patient Decision Aid (PtDA) (shown on the computer)|Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
219076058|NCT04364958|OTHER|A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.|Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
219076059|NCT01702753|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
219076060|NCT00229333|DRUG|Escitalopram|
219076061|NCT04817280|OTHER|Ice Swimming|The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
219678775|NCT05510414|BEHAVIORAL|psychological intervention based on psychological capital|Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
219678776|NCT04612283|OTHER|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
219076062|NCT03722368|BEHAVIORAL|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
219076063|NCT03722368|BEHAVIORAL|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
219076064|NCT03722368|OTHER|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
219076065|NCT01133652|DEVICE|Veinviewer|Veinviewer machine
219076066|NCT01133652|DEVICE|Ultrasound|Ultrasound
219076067|NCT01133652|OTHER|Conventional technique|Conventional IV placement by nurses
219076068|NCT03656133|RADIATION|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
219076069|NCT01953796|DRUG|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
219076070|NCT03760237|OTHER|observation only|No intervention, observational study only
219076071|NCT04439110|BIOLOGICAL|Trastuzumab Emtansine|Given IV
219678777|NCT04612283|OTHER|Placebo|A Placebo with no active ingredients
219678778|NCT05344222|DEVICE|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
219678779|NCT05344222|DEVICE|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
219678780|NCT01059773|DRUG|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
219678781|NCT01059773|DRUG|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
219678782|NCT04474262|BIOLOGICAL|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
219076072|NCT00651508|DRUG|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
219076073|NCT06670807|DIETARY_SUPPLEMENT|Probiotic Arm|Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.
219076074|NCT06670807|OTHER|Placebo|Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
219076075|NCT07127640|OTHER|Exercise|An aerobic exercise session on a recumbent exercise bike with a 5-minute warm-up period, followed by a 40-minute cool-down period and ending with a 5-minute cool-down at decreasing speed.
219076076|NCT07127029|DEVICE|Petrolatum coating of fast-absorbing gut suture|6-0 fast absorbing gut suture was coated with sterile petrolatum and a single interrupted suture was placed into the skin of the deltoid
219076077|NCT06670690|DRUG|Atenolol 50 MG|patients will be premedicated with atenolol (50mg)
219076078|NCT06670690|DRUG|Propranolol Pill|patients will be premedicated with propranolol (10mg)
219076079|NCT06670690|DRUG|Ivabradine|patients will be premedicated with Ivabradine (5mg)
219076080|NCT04797403|BEHAVIORAL|Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
219076081|NCT05394103|DRUG|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
219076082|NCT05394103|DRUG|KEYTRUDA® (pembrolizumab)|KEYTRUDA® (pembrolizumab) will be administered Q6W
219076083|NCT00016133|BIOLOGICAL|BCG vaccine|
219076084|NCT00016133|BIOLOGICAL|autologous tumor cell vaccine|
219076085|NCT00016133|DRUG|fluorouracil|
219076086|NCT00016133|DRUG|leucovorin calcium|
219076087|NCT00016133|PROCEDURE|adjuvant therapy|
219076088|NCT05245864|OTHER|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
219076089|NCT05245864|OTHER|physical therapy standard of care|the current standard of care after surgery for ACL repair.
219076090|NCT06680674|OTHER|Routine care for people with diabetes, with or without obesity, in the hospital setting|Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.
219076091|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
219076092|NCT06632041|DIAGNOSTIC_TEST|Complete blood count|Study haemtological disturbances in neonates with necrotizing enterocolities
219076093|NCT06632041|OTHER|Complete blood count|Haemtological disturbances in neonates with necrotizing enterocolities
219076094|NCT07026942|BIOLOGICAL|Universal donor derived CD33 CAR-NK|Universal donor derived CD38KO CD33 CAR-NK manuctured on-site. The NK cells are derived from the peripheral blood of universal donors with desirable HLA/KIR types and CMV status, modified by CRISPR/Cas9 targeting the CD38 locus, using AAV6 vector to insert a CD33-targeted CAR gene into the CD38 locus, and expanded in number.
219678783|NCT04474262|DRUG|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
219678784|NCT04474262|OTHER|Placebo|Placebo
219678785|NCT02356757|BEHAVIORAL|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
219678786|NCT02356757|BEHAVIORAL|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
219678787|NCT04308876|OTHER|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
219678788|NCT04308876|OTHER|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
219076095|NCT06025526|OTHER|aktivplan|"The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app."
219076096|NCT06025526|OTHER|Usual care|Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
219076097|NCT04936282|DRUG|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
219076098|NCT04936282|DRUG|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
219076099|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
219076100|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
219076101|NCT06695156|BEHAVIORAL|Meditation|The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly
219076102|NCT07075315|DRUG|Umbilical cord Mesenchymal stem cell|ucMSC 1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will then be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
219076103|NCT07075315|DRUG|Steroid|Prednisolone 40 mg once daily for 7 days as inpatients. After that Lille score will be calculated on day 7. Responders (Lille score \< 0.45) will be continued on steroids for a total of 4 weeks, followed by 2 weeks oftapering before stopping the therapy. In patients who were non responsive to steroids (Lille score \> 0.45) at day 7, steroids will be stopped at day 7 and will receive only SMT.
219076104|NCT07075315|OTHER|Standard Medical Treatment|All patients will receive the standard medical treatment.
219678789|NCT00004268|DRUG|midodrine|
219678790|NCT03866356|BEHAVIORAL|intervention group|The women in the intervention group were provided care according to SICP
219678791|NCT04530669|DEVICE|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
219678792|NCT04530669|OTHER|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
219678793|NCT05218200|OTHER|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
219678794|NCT01299883|OTHER|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
219076105|NCT07100392|DRUG|tauroursodeoxycholic acid (TUDCA)|TUDCA (250 mg, twice daily) will be administered orally until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219076106|NCT07100392|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg on day 1 of each 14 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219076107|NCT07100392|DRUG|Regorafenib|Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219076108|NCT06945718|PROCEDURE|beyond D2 regional lymph node dissection|dissect the lymph nodes outside the extent of D2 LN region.
219076109|NCT02097979|BEHAVIORAL|Glaucoma Educational Intervention|
219076110|NCT05009342|DEVICE|below-knee soft resin cast|Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
219076111|NCT05009342|DEVICE|Below-knee rigid resin cast|Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
219076112|NCT02119260|DRUG|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
219076113|NCT02119260|DRUG|GSK2798745 suspension|Aqueous suspension of GSK2798745 (\>=0.5 mg)
219076114|NCT02119260|DRUG|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)
219076115|NCT02119260|DRUG|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
219076116|NCT02119260|DRUG|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
219076117|NCT02119260|DRUG|Placebo capsule|Matching white opaque placebo blend filled capsule
219076118|NCT03849274|COMBINATION_PRODUCT|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
219076119|NCT03849274|DEVICE|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
219076120|NCT02145221|OTHER|Music Therapy|
219076121|NCT05981768|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
219076122|NCT00114868|DRUG|Vitamin A|
219076123|NCT05420155|PROCEDURE|Surgical resection|Surgical treatment of hepatic hydatidic cyst
219076124|NCT00857207|BEHAVIORAL|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
219076125|NCT00493818|DRUG|GSK690693|
219076126|NCT04443023|DEVICE|chosen TAVI valve|chosen TAVI valve
219076127|NCT06388668|DIAGNOSTIC_TEST|Lipid panel|Lipid panel measuring levels of LDL, non-HDL and apoB
219076128|NCT04461951|OTHER|Lifestyles (exposure)|no intervention
219076129|NCT01760239|BEHAVIORAL|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
219076130|NCT04886024|OTHER|Advanced Glycation End Products (AGEs)|Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
219076131|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
219076132|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
219076133|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
219076134|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
219076135|NCT05380648|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
219076136|NCT02077764|PROCEDURE|OCT and coronary angiography|
219076137|NCT02077764|PROCEDURE|Right heart cat.|
219076138|NCT02077764|RADIATION|PET|
219076139|NCT02077764|PROCEDURE|Echocardiography|
219076140|NCT02077764|PROCEDURE|exercise test|
219076141|NCT02077764|OTHER|blood samples|
219076142|NCT01189968|DRUG|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
219076143|NCT03035292|DIAGNOSTIC_TEST|Red-reflex assessment|The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
219076144|NCT03035292|DIAGNOSTIC_TEST|Infrared-reflex assessment|The infrared reflex was examined using a modified smart phone camera by a medical student examiner
219076145|NCT02974790|PROCEDURE|Echocardiography|Two-dimensional imaging echocardiography
219076146|NCT01384708|DRUG|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
219076147|NCT04274907|DRUG|Venetoclax|Tablet: Oral
219076148|NCT04274907|DRUG|Pembrolizumab|Intravenous (IV) Infusion
219076149|NCT00214357|BEHAVIORAL|Mindfulness-based stress reduction|
219076150|NCT01387880|DRUG|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
219076151|NCT01387880|DRUG|Everolimus|1.66 mg per day up to 7½ mg per day
219076152|NCT03675022|DRUG|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
219076153|NCT00974324|DRUG|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
219076154|NCT00226330|DRUG|Tesaglitazar|(0.5 or 1 mg)
219076155|NCT00226330|DRUG|Pioglitazone|(15, 30 or 45 mg)
219076156|NCT00440531|BIOLOGICAL|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
219076157|NCT00440531|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
219076158|NCT00440531|BIOLOGICAL|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
219076159|NCT00109291|DRUG|Placebo|
219076160|NCT00109291|DRUG|peginesatide|
219076161|NCT03709355|DRUG|Elpida®|Elpida® capsules, 20mg
219076162|NCT03709355|DRUG|Rifampin|Rifampin capsules, 150mg
219076163|NCT03709355|DRUG|Rifabutin|Rifabutin capsules, 150mg
219076164|NCT03709355|DRUG|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
219076165|NCT03709355|DRUG|Omeprazole|Omeprazole Film-coated tablets 20mg
219076166|NCT03709355|DRUG|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
219076167|NCT03709355|DRUG|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
219076168|NCT01229761|DRUG|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
219076169|NCT01229761|DRUG|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
219076170|NCT01229761|BEHAVIORAL|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
219076171|NCT01229761|BEHAVIORAL|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
219076172|NCT05382260|OTHER|Listening to music|After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
219076173|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
219076174|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
219076175|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
219076176|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
219076177|NCT01698684|DRUG|Placebo|One dose 15 minutes before attempting intercourse
219076178|NCT01698684|DRUG|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
219076179|NCT01698684|DRUG|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
219076180|NCT03236298|DEVICE|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
219678795|NCT01602991|PROCEDURE|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
219678796|NCT01602991|PROCEDURE|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
219678797|NCT02870192|PROCEDURE|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
219678798|NCT02720276|OTHER|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
219678799|NCT02842476|DEVICE|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
219678800|NCT02842476|DEVICE|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
219678801|NCT02842476|DEVICE|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
219678802|NCT00235573|DIETARY_SUPPLEMENT|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
219678803|NCT02871141|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy
219678804|NCT02871141|DRUG|Antidepressant|Antidepressant
219678805|NCT04642417|OTHER|dietary fiber literacy|education
219678806|NCT04642417|OTHER|routine care|routine care
219678807|NCT05474183|DRUG|Ketamine|drug
219076181|NCT02265302|DRUG|BIIL 284 oral solution|
219076182|NCT02265302|DRUG|BIIL 284 wetability improved formulation (WIF) tablets|
219076183|NCT02265302|DRUG|Placebo|
219076184|NCT04455789|PROCEDURE|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
219076185|NCT01928368|DRUG|AMG 282|Single dose either subcutaneously or intravenously on day 1.
219076186|NCT01928368|DRUG|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
219678808|NCT01787669|DRUG|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
219678809|NCT01787669|DRUG|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
219076187|NCT02668081|PROCEDURE|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
219076188|NCT02668081|PROCEDURE|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
219076189|NCT02172755|DRUG|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
219076190|NCT00686166|BIOLOGICAL|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78"
219076191|NCT00686166|DRUG|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)"
219076192|NCT00686166|DRUG|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78"
219076193|NCT00686166|PROCEDURE|therapeutic surgical procedure|Surgical resection
219076194|NCT00686166|RADIATION|radiation therapy|IMRT (intensity-modulated radiation therapy)
219076195|NCT01260220|PROCEDURE|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
219678810|NCT04635930|OTHER|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
219678811|NCT06300099|DRUG|Dexamethasone|Dexamethasone as adjunct to serratus anterior plane block.
219678812|NCT06300099|DRUG|Dexmedetomidine|Dexmedetomidine as adjunct to serratus anterior plane block.
219076196|NCT01260220|PROCEDURE|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
219076197|NCT05645354|BEHAVIORAL|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
219678813|NCT05888480|OTHER|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
219678814|NCT05888480|OTHER|Routine training activity|Routine training activities arranged by relevant departments in hospitals
219076198|NCT05645354|BEHAVIORAL|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
219076199|NCT02380092|DEVICE|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
219076200|NCT01983748|BIOLOGICAL|Autologous Dendritic Cells loaded with autologous Tumor RNA|
219076201|NCT02681913|DRUG|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
219076202|NCT06243146|OTHER|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
219076203|NCT06533228|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)|Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
219076204|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
219076205|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
219076206|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
219076207|NCT03244527|DIETARY_SUPPLEMENT|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
219076208|NCT03244527|OTHER|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
219076209|NCT01549613|DRUG|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
219076210|NCT01549613|DRUG|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
219076211|NCT03752229|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076212|NCT03752229|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076213|NCT03752229|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076214|NCT03752229|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076215|NCT03752229|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076216|NCT03752229|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076217|NCT03752229|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076218|NCT03752229|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219678815|NCT01427270|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
219678816|NCT01427270|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
219678817|NCT01427270|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
219678818|NCT02106780|DRUG|14C-labeled ASP1707|oral
219678819|NCT06135844|DRUG|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
219678820|NCT06135844|DRUG|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
219076219|NCT03752229|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076220|NCT03752229|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076221|NCT03752229|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076222|NCT03752229|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076223|NCT03752229|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076224|NCT03752229|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076225|NCT03752229|DEVICE|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076226|NCT03752229|DEVICE|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076227|NCT03752229|DEVICE|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076228|NCT03752229|DEVICE|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076229|NCT03752229|DEVICE|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076230|NCT03752229|DEVICE|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076231|NCT03752229|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076232|NCT03752229|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076233|NCT03752229|DEVICE|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076234|NCT03752229|DEVICE|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076235|NCT03752229|DEVICE|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076236|NCT03752229|DEVICE|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076237|NCT03752229|DEVICE|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076238|NCT03752229|DEVICE|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219678821|NCT06133998|DEVICE|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire."
219076239|NCT03752229|DEVICE|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076240|NCT03752229|DEVICE|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076241|NCT03752229|DEVICE|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076242|NCT03752229|DEVICE|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076243|NCT03752229|DEVICE|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076244|NCT03752229|DEVICE|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076245|NCT03752229|DEVICE|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076246|NCT03752229|DEVICE|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076247|NCT03752229|DEVICE|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076248|NCT03752229|DEVICE|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076249|NCT03752229|DEVICE|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076250|NCT03752229|DEVICE|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076251|NCT03752229|DEVICE|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076252|NCT03752229|DEVICE|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076253|NCT03752229|DEVICE|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076254|NCT03752229|DEVICE|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076255|NCT03752229|DEVICE|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076256|NCT03752229|DEVICE|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076257|NCT03752229|DEVICE|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076258|NCT03752229|DEVICE|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
219076259|NCT02216123|DRUG|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
219678822|NCT06133998|DEVICE|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap."
219678823|NCT01101750|BIOLOGICAL|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
219678824|NCT02768168|DRUG|dezocine|receive dezocine 0.1 mg/kg
219678825|NCT02768168|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
219678826|NCT00660296|OTHER|Air insufflation use in colonoscopy|Air insufflation for colonic distension
219678827|NCT00660296|OTHER|CO2 use in colonoscopy|Co2 insufflation for colonic distension
219678828|NCT05184348|RADIATION|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
219678829|NCT05184348|DRUG|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
219678830|NCT05184348|COMBINATION_PRODUCT|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
219678831|NCT02937181|DRUG|Ceftaroline|IV Ceftaroline will be given for 72 hours
219678832|NCT02104427|DRUG|TG-0054 combined with G-CSF|
219678833|NCT05961631|OTHER|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
219678834|NCT02134795|DEVICE|TNM Device|The noninvasive device is worn like a music headset and the patient lies back on a wedge pillow while the device is active. Each session lasts under 20 minutes.
219678835|NCT01300247|DRUG|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
219678836|NCT01300247|DRUG|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
219678837|NCT01300247|DRUG|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
219076260|NCT02216123|DRUG|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
219076261|NCT02216123|DRUG|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
219076262|NCT02216123|DRUG|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
219076263|NCT02216123|DRUG|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
219678838|NCT01300247|DRUG|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
219678839|NCT03147118|DIAGNOSTIC_TEST|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
219678840|NCT03478085|OTHER|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
219678841|NCT03707938|DRUG|Brigatinib|Given PO
219678842|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
219678843|NCT04802824|OTHER|PET/CT|18F-fluoropivalate PET/CT scan.
219678844|NCT03547037|DRUG|JNJ-63723283|JNJ-63723283 will be administered intravenously.
219678845|NCT03547037|DRUG|Erdafitinib|Erdafitinib will be administered orally.
219678846|NCT06248307|DIETARY_SUPPLEMENT|Barrita experimental|Nutritional advice, as well as administration of protein bars.
219678847|NCT06248307|DIETARY_SUPPLEMENT|Barrita Placebo|Nutritional advice, as well as administration of placebo bars.
219678848|NCT04120909|DEVICE|Cardiac resynchronization therapy|Biventricular pacing according to current standards.
219678849|NCT00371475|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
219678850|NCT00371475|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
219678851|NCT01750060|DRUG|Fentanyl|
219678852|NCT01750060|DRUG|Naltrexone|
219076264|NCT02131272|DRUG|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
219076265|NCT02131272|DRUG|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
219076266|NCT02131272|BEHAVIORAL|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
219076267|NCT04866316|OTHER|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
219076268|NCT00440648|DRUG|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
219076269|NCT00440648|DRUG|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
219210148|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
219210149|NCT06586021|DEVICE|Aortoseal Endostapling System|Aortoseal Endostapling System
219210150|NCT06857266|OTHER|Live Video-delivered Feedback|Feedback is delivered to students through a live video call.
219678853|NCT05359614|DEVICE|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
219678854|NCT05359614|DEVICE|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
219678855|NCT02364687|RADIATION|Computed tomography late enhancement imaging|
219678856|NCT05128591|DRUG|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
219678857|NCT05128591|DRUG|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
219678858|NCT02378948|DIETARY_SUPPLEMENT|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
219678859|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
219678860|NCT05385341|OTHER|Telerehabilitation (Tele RCV)|20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.
219678861|NCT05385341|OTHER|Rehabilitation (RCV)|20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
219678862|NCT03864003|BEHAVIORAL|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.
219678863|NCT04709497|PROCEDURE|viscotrabeculotomy (VT)|viscotrabeculotomy (VT)
219678864|NCT04709497|PROCEDURE|visco-circumferential-suture-trabeculotomy (VCST) .|visco-circumferential-suture-trabeculotomy (VCST)
219678865|NCT04709497|PROCEDURE|combined VT-Trabeculectomy with MMC (VT-Trab).|combined VT-Trabeculectomy with MMC (VT-Trab).
219678866|NCT06114771|OTHER|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
219678867|NCT06114771|OTHER|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
219678868|NCT00467207|DRUG|Botulinum Toxin A|
219678869|NCT00467207|BEHAVIORAL|Resistance training|
219678870|NCT01556932|DRUG|ABH gel|Given topically
219678871|NCT01556932|OTHER|placebo|Given topically
219678872|NCT06223308|DRUG|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
219678873|NCT06635252|DRUG|STA 4783|Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
219678874|NCT01882803|DRUG|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
219678875|NCT00502099|DRUG|Pegylated interferon alpha 2a|Injections: 180 ug once per week
219678876|NCT00502099|DRUG|Ribavirin|Tablets, 1000-1200 daily
219678877|NCT00502099|DRUG|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
219678878|NCT02990871|OTHER|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
219678879|NCT02990871|OTHER|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
219678880|NCT02434159|OTHER|Heart scan|
219678881|NCT00076401|DRUG|Motexafin gadolinium|
219678882|NCT01563913|DRUG|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
219678883|NCT01563913|DRUG|Placebo|Sugar Pill, taken for 1.5 years
219678884|NCT04388124|DRUG|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
219678885|NCT04388124|DRUG|Placebo|Placebo
219678886|NCT05552742|OTHER|Conservative rehabilitation|The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.
219678887|NCT05552742|DEVICE|Virtual Balance Training|Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
219678888|NCT03066778|BIOLOGICAL|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
219678889|NCT03066778|DRUG|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
219678890|NCT03066778|DRUG|Carboplatin|IV infusion on Day 1 of each cycle
219678891|NCT03066778|DRUG|Cisplatin|IV infusion on Day 1 of each cycle
219678892|NCT03066778|DRUG|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
219678893|NCT02328937|DEVICE|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
219678894|NCT02328937|DEVICE|lotrafilcon B|
219678895|NCT02328937|DEVICE|comfilcon A|
219678896|NCT00494429|DRUG|Morphine|Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
219678897|NCT00494429|DRUG|Morphine|Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
219678898|NCT02006199|BEHAVIORAL|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
219678899|NCT04039659|DEVICE|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
219678900|NCT01727362|OTHER|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
219678901|NCT01727362|OTHER|Usual care|Patients of this group receive usual care only
219076270|NCT05964478|OTHER|Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine|Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
219076271|NCT01118533|DEVICE|metal reusable blades MacIntosh|laryngoscope blades
219076272|NCT01118533|DEVICE|Single use plastic blades HEINE XP®|laryngoscope blades
219076273|NCT02077348|DRUG|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
219076274|NCT02077348|DRUG|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
219076275|NCT01104610|DEVICE|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
219076276|NCT02795273|DRUG|Grass-SPIRE|
219076277|NCT02795273|DRUG|Placebo|
219678902|NCT00057525|BIOLOGICAL|Anthrax|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
219678903|NCT00057525|BIOLOGICAL|Alhdryogel or PBS|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
219076278|NCT04681612|DIAGNOSTIC_TEST|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
219076279|NCT04681612|DIAGNOSTIC_TEST|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
219076280|NCT04681612|DIAGNOSTIC_TEST|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
219210151|NCT06857266|OTHER|In-Person Feedback|In-Person Feedback
219210152|NCT06857266|OTHER|Recorded Video-delivered feedback|Feedback is delivered via a personalized recorded video made by the instructor specific to the student's performance.
219076281|NCT04681612|DIAGNOSTIC_TEST|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
219210153|NCT04310644|OTHER|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
219678904|NCT00005069|DRUG|arsenic trioxide|
219678905|NCT02448745|DEVICE|Insecticide treated wall lining|Polypropylene non-woven fabric.
219678906|NCT04931771|DEVICE|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
219678907|NCT04931771|DEVICE|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
219678908|NCT03058471|DRUG|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
219678909|NCT03058471|DRUG|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
219678910|NCT03058471|DRUG|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
219678911|NCT01651754|BIOLOGICAL|Seasonal influenza vaccination|single dose of influenza vaccination
219076282|NCT04681612|DIAGNOSTIC_TEST|History, Lab, clinical and hemodynamic parameters|1\. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
219076283|NCT05055102|OTHER|Data collection|demographics co-morbidities risk factors operative, hospital and vascular follow-up data
219678912|NCT06078644|OTHER|respiratory exercise diary|Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
219678913|NCT03887585|PROCEDURE|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
219678914|NCT03665077|DIAGNOSTIC_TEST|Initial blood draw|At baseline, patients will undergo a blood draw.
219678915|NCT03665077|DIAGNOSTIC_TEST|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
219678916|NCT03665077|DIAGNOSTIC_TEST|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
219678917|NCT03665077|DIAGNOSTIC_TEST|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
219678918|NCT03665077|DIAGNOSTIC_TEST|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
219076284|NCT06213948|DRUG|Mirtazapine 15 MG|"Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)"
219076285|NCT04585932|DRUG|Apalutamide|Given PO
219076286|NCT04585932|DRUG|Degarelix|Given SC
219076287|NCT04585932|DRUG|Leuprolide Acetate|Given IM
219076288|NCT04585932|OTHER|Quality-of-Life Assessment|Ancillary studies
219210154|NCT03081403|DEVICE|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
219210155|NCT06771882|OTHER|BMOS technique|"The researcher obtained 5cc soaked in a 2cm×2 cm piece of sterilized gauze for every intervention administration.~* The preterm neonates were positioned in the supine position and the head turned to one side~* The gauze was placed near the head, 2cm away from the nose for 2 minutes before feeding to stimulate an olfactory sense of preterm neonates 3 times per day (11 am, 2 pm, and 5 pm)."
219678919|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
219678920|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
219678921|NCT00403026|DRUG|Bevacizumab ( Avastin)|
219678922|NCT02604030|OTHER|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
219678923|NCT00205660|OTHER|Stayers|Participants remain on their current antipsychotic.
219678924|NCT00205660|OTHER|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
219678925|NCT00558805|BEHAVIORAL|FISP + Usual Care|
219678926|NCT00558805|BEHAVIORAL|Usual Care|
219678927|NCT01643486|OTHER|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
219678928|NCT01643486|OTHER|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
219678929|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
219678930|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
219076289|NCT04585932|OTHER|Questionnaire Administration|Ancillary studies
219076290|NCT04585932|RADIATION|Radiation Therapy|Undergo RT
219076291|NCT06243705|DEVICE|Robot-Pet|The robot-pet makes sounds like a real cat and responds to touch and petting
219076292|NCT06243705|DEVICE|Virtual Reality Glasses|VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
219076293|NCT00852631|DRUG|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
219076294|NCT02130310|BIOLOGICAL|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
219076295|NCT02130310|OTHER|Placebo injection|Normal saline injected at each centimeter of ulcer bed
219076296|NCT03546894|DRUG|Brigatinib|Brigatinib tablets.
219076297|NCT03546894|DRUG|Alectinib|Alectinib capsules.
219076298|NCT03546894|DRUG|Ceritinib|Ceritinib capsules.
219076299|NCT03546894|DRUG|Lorlatinib|Lorlatinib capsules.
219076300|NCT03546894|DRUG|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
219076301|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
219076302|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
219678931|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
219678932|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
219678933|NCT02217670|DRUG|Metformin 1000 mg granules|
219678934|NCT02217670|DRUG|Metformin 1000 mg film-coated tablets|
219678935|NCT05631145|OTHER|MT Combined With XKSA|Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
219678936|NCT05631145|OTHER|MT|Morita therapy (MT) comprised bed rest and light work.
219678937|NCT01570257|PROCEDURE|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
219678938|NCT03910881|OTHER|Open-platform patient support system (PSS) app|The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
219678939|NCT01089010|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
219678940|NCT01089010|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
219678941|NCT01089010|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
219076303|NCT02204995|PROCEDURE|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
219076304|NCT02204995|PROCEDURE|Trapeziectomy|Trapeziectomy
219076305|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
219076306|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
219076307|NCT00223860|DRUG|Human chorionic gonadotropin (hCG)|
219678942|NCT02812082|OTHER|web-based patient education|
219678943|NCT02812082|BEHAVIORAL|questionnaire|
219678944|NCT02008136|DRUG|Botulinum Toxins|intramuscular injections
219678945|NCT06071741|PROCEDURE|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
219678946|NCT03642600|DIETARY_SUPPLEMENT|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
219678947|NCT03642600|DRUG|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
219678948|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
219076308|NCT00223860|DRUG|Luteinizing hormone releasing hormone (LHRH)|
219076309|NCT04110769|DIAGNOSTIC_TEST|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
219076310|NCT04110769|DIAGNOSTIC_TEST|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
219076311|NCT03125304|OTHER|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
219076312|NCT06188572|OTHER|Michigan Neuropathy Screening Instrument|A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
219076313|NCT06188572|OTHER|Numeric Pain Scale|"In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain."
219076314|NCT06188572|OTHER|Mandibular Function Disorder Questionnaire|This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
219076315|NCT06188572|OTHER|Fonseca Anamnestic Index|This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
219076316|NCT06188572|OTHER|Ferrans&Powers Quality of Life Index Diabetes Version|This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
219076317|NCT00982358|DRUG|Valsartan|
219076318|NCT00982358|OTHER|Placebo|
219678949|NCT03724045|DIETARY_SUPPLEMENT|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
219076319|NCT03203369|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
219678950|NCT06803043|BEHAVIORAL|SAH|"SAH is a group trauma informed intervention that uses motivational strategies and self-monitoring of one's thoughts and responses. It provides a unique fusion of interventions for trauma and IPV and consists of 12 two-hour weekly sessions. Throughout the program, group members complete in-session practice exercises and are provided practice assignments to consolidate and apply information learned in group."
219678951|NCT06803043|BEHAVIORAL|TAU|TAU is a court mandated 20 week, psychoeducational/directed program that emphasizes the sharing of power and control in relationships and personal accountability. Topics also focus on equality wheels, substance abuse impacts, culture and socialization impact on gender roles, defense mechanisms versus coping skills, triggers for stress and anger, and healthy versus unhealthy communication.
219076320|NCT05795582|DEVICE|POPMETRE® (Axelife , France)|Measurement with 2 devices
219076321|NCT02998281|DEVICE|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
219076322|NCT03443960|DRUG|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
219076323|NCT03443960|DRUG|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
219076324|NCT02836418|DRUG|ATYR1940|Concentrate for solution for infusion
219076325|NCT06395064|DRUG|Dimenhydrinate|Dimenhydrinate 50mg intravenously
219076326|NCT02931279|DEVICE|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
219076327|NCT06311695|DEVICE|Contrast Enhanced Mammography|Contrast Enhanced Mammography
219076328|NCT02540018|DEVICE|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
219076329|NCT02540018|DEVICE|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
219076330|NCT02244866|DRUG|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
219076331|NCT02244866|DRUG|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
219076332|NCT02750254|DRUG|Fludarabine|
219076333|NCT02750254|RADIATION|Fractionated total body irradiation|
219076334|NCT02750254|DRUG|Busulfan|
219076335|NCT02750254|DRUG|Cyclophosphamide|
219076336|NCT02750254|RADIATION|Single dose total body irradiation|
219076337|NCT02750254|DRUG|Melphalan|
219076338|NCT02750254|DRUG|Granulocyte-colony stimulating factor|
219076339|NCT02750254|PROCEDURE|Stem cell transplant|
219076340|NCT02750254|DRUG|Azacitidine|
219076341|NCT04799626|DRUG|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
219076342|NCT05346289|PROCEDURE|Elective surgery for intact AAA|Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
219076343|NCT01540851|BEHAVIORAL|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
219076344|NCT01540851|OTHER|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
219076345|NCT04447326|DRUG|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
219076346|NCT04447326|DRUG|IC＋CCRT|IC＋CCRT
219076347|NCT00273312|DRUG|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
219076348|NCT00395902|DRUG|Sensipar after Post Transplant|
219076349|NCT04020900|OTHER|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
219076350|NCT05138718|DIAGNOSTIC_TEST|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
219076351|NCT02238262|DRUG|Telmisartan|
219076352|NCT04434989|RADIATION|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
219076353|NCT04434989|PROCEDURE|radiofrequency ablation|RFA for perivascular HCC
219076354|NCT06241274|OTHER|Moxibustion|Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
219678952|NCT01592123|PROCEDURE|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
219678953|NCT01592123|BEHAVIORAL|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score \>5 is considered to be suggestive of significant sleep disturbance.
219678954|NCT01592123|BEHAVIORAL|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
219678955|NCT01592123|BEHAVIORAL|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
219678956|NCT02999841|DRUG|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
219678957|NCT02999841|DRUG|Vildagliptin|1-24 week: 50mg bid
219678958|NCT04687826|OTHER|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
219678959|NCT04687826|OTHER|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
219678960|NCT01639248|DRUG|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
219076355|NCT06241274|OTHER|Symptomatic supportive treatment|Symptomatic supportive treatment.
219076356|NCT00960466|BEHAVIORAL|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
219076357|NCT00960466|BEHAVIORAL|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
219076358|NCT02710799|OTHER|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
219076359|NCT02710799|OTHER|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
219076360|NCT04781374|DRUG|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
219076361|NCT01507220|DRUG|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
219076362|NCT01507220|DRUG|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
219678961|NCT02306850|DRUG|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
219678962|NCT01858415|DEVICE|TriPollar|
219678963|NCT00237692|BEHAVIORAL|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
219076363|NCT03768167|PROCEDURE|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
219076364|NCT04910893|DEVICE|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
219076365|NCT04910893|OTHER|Standard of Care|Standard intensive care of patients suffering septic shock
219678964|NCT00237692|BEHAVIORAL|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
219678965|NCT00237692|BEHAVIORAL|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral \& medication management
219678966|NCT02420262|DRUG|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
219678967|NCT02420262|DRUG|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
219678968|NCT02420262|DRUG|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
219678969|NCT05050448|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
219678970|NCT05050448|DRUG|1% Diclofenac Topical Gel|Topical pain-relief gel
219678971|NCT02378974|BIOLOGICAL|Cordstem-ST|
219678972|NCT02378974|BIOLOGICAL|Placebo|
219076366|NCT00315250|DRUG|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
219076367|NCT05909631|OTHER|Beetroot juice|250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
219076368|NCT05909631|OTHER|placebo|250 ml of a placebo
219076369|NCT05909631|OTHER|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
219678973|NCT04708899|BEHAVIORAL|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
219678974|NCT04708899|BEHAVIORAL|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
219678975|NCT00920413|DIETARY_SUPPLEMENT|Vitamin C|vitamin C 500mg orally once a day
219678976|NCT00920413|DIETARY_SUPPLEMENT|placebo|
219678977|NCT02540122|DEVICE|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
219678978|NCT02540122|DEVICE|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
219678979|NCT02540122|DEVICE|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
219678980|NCT02540122|DEVICE|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
219678981|NCT05937620|DIAGNOSTIC_TEST|99mTC nanocolloid albumin injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
219678982|NCT05937620|DIAGNOSTIC_TEST|ICG injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
219076370|NCT05909631|COMBINATION_PRODUCT|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD).
219076371|NCT03385928|DRUG|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
219076372|NCT03385928|DRUG|Normal saline|Placebo given within 2 hours of symptom onset
219076373|NCT05655754|DRUG|Methohexital|anesthesia during ECT
219076374|NCT05655754|DRUG|Ketofol|anesthesia during ECT
219076375|NCT06497452|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
219076376|NCT00224874|DRUG|Etanercept|Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
219678983|NCT00685360|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
219678984|NCT00685360|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
219678985|NCT00685360|DRUG|Placebo|Placebo tablets matching 50-mg tablets of delamanid
219678986|NCT01630018|DRUG|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
219678987|NCT01630018|DRUG|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
219678988|NCT01358786|PROCEDURE|quilting suture|"* quilting sutures and drains~* quilting sutures but no drains"
219678989|NCT06778525|OTHER|Exercise|Personalized neuromuscular exercises, according to the patient's specific needs.
219678990|NCT06778525|OTHER|SmartPose|Virtual reality application containing rehabilitative games developed for individuals in need of exercise.
219678991|NCT06347900|DIAGNOSTIC_TEST|Pentacam (corneal topographic changes detection), Polysymnography|Pentacam for recording corneal parameters in different stages of OSA patients. Polysymnography for for detction of hyponea, oxygen saturation and desaturation and staging of OSA in different patients.
219678992|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
219678993|NCT04865419|DRUG|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
219678994|NCT04865419|DRUG|Voriconazole|Voriconazole film-coated tablet will be administered orally.
219678995|NCT05192395|DRUG|DWJ1525|DWJ1525
219678996|NCT05192395|DRUG|DWP16001|DWP16001
219678997|NCT05192395|DRUG|DWC202101|DWC202101
219076377|NCT00224874|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
219076378|NCT00224874|DRUG|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
219076379|NCT00224874|DRUG|Pentostatin|Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
219076380|NCT06018480|OTHER|Creatine Monohydrate|The supplementation is the intervention.
219076381|NCT06018480|OTHER|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
219076382|NCT02519010|DRUG|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
219076383|NCT02519010|DRUG|Exforge|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
219076384|NCT01805492|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
219076385|NCT04357327|DIAGNOSTIC_TEST|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
219076386|NCT03528070|DRUG|Tranilast|Subjects will be treated with tranilast
219076387|NCT04991168|OTHER|Questionnaire|Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
219076388|NCT01353014|OTHER|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
219076389|NCT01353014|OTHER|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
219076390|NCT04940429|DEVICE|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
219076391|NCT04940429|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
219076392|NCT00056251|PROCEDURE|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
219076393|NCT03382496|OTHER|Non-Interventional|Non-Interventional
219076394|NCT02607995|BEHAVIORAL|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
219076395|NCT01638910|DRUG|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
219076396|NCT04913844|OTHER|Physical performance tests and observational assessments|There will be no interventions. Physical performance tests and observational assessments will be conducted.
219076397|NCT05449951|OTHER|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
219076398|NCT05449951|OTHER|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
219076399|NCT03764332|DEVICE|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
219076400|NCT02565043|DEVICE|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
219076401|NCT01257841|DRUG|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
219076402|NCT01257841|BEHAVIORAL|Fasting|Complete fasting, save for water and multivitamin, for four days.
219076403|NCT05377580|DRUG|Period 1 IBI112 Placebo|Intravenous Injection
219076404|NCT05377580|DRUG|Period 2 IBI112 dose 3|Subcutaneous injections
219076405|NCT05377580|DRUG|Period 1 IBI112 dose 1|Intravenous Injection
219076406|NCT05377580|DRUG|Period 1 IBI112 dose 2|Intravenous Injection
219076407|NCT05377580|DRUG|Period 2 IBI112 dose 4|Intravenous Injection
219076408|NCT05377580|DRUG|Period 2 IBI112 Placebo|Subcutaneous injections
219076409|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
219678998|NCT00261898|PROCEDURE|Increase sleep|
219678999|NCT04792060|PROCEDURE|Hook plate|We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
219679000|NCT02482883|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
219076410|NCT01191164|PROCEDURE|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
219679001|NCT05285059|BEHAVIORAL|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
219679002|NCT00015652|DRUG|Ribavirin|
219076411|NCT04332796|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
219076412|NCT04332796|DEVICE|ZnO-NPs socks|ZnO-NPs socks was given to patients for 4 weeks
219076413|NCT04332796|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
219076414|NCT06634576|DEVICE|Smooth pursuit neck torsion test|Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
219076415|NCT05301751|DRUG|AG-73305|AG-73305 Ophthalmic Solution
219076416|NCT00814294|DRUG|placebo|placebo capsule,0 units, quater in die (QID) for 18 weeks
219076417|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
219076418|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
219076419|NCT05891821|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
219076420|NCT02633137|DRUG|Lenalidomide|
219076421|NCT02633137|DRUG|R-CHOP|"* Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
219076422|NCT02633137|DRUG|high-dose cytarabine (HIDAC)|
219076423|NCT03314415|DEVICE|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
219076424|NCT04588961|PROCEDURE|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
219076425|NCT04588961|PROCEDURE|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
219076426|NCT03541759|DRUG|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.
219076427|NCT03541759|DRUG|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
219076428|NCT00439205|DEVICE|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
219076429|NCT00439205|DEVICE|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
219679003|NCT00015652|DRUG|Aldesleukin|
219076430|NCT01324271|DEVICE|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
219076431|NCT05130970|DRUG|Garadacimab|Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
219076432|NCT05130970|DRUG|Placebo|Participants received a matching placebo IV loading dose, followed by 3 SC doses.
219076433|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
219076434|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
219076435|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
219076436|NCT04907253|DRUG|Quercetin|500 mg twice daily
219076437|NCT04907253|DRUG|Placebo|twice daily
219076438|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
219076439|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
219076440|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
219679004|NCT00015652|DRUG|Peginterferon alfa-2b|
219679005|NCT01491867|DRUG|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
219679006|NCT03163719|DIAGNOSTIC_TEST|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
219679007|NCT02902042|DRUG|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
219679008|NCT02902042|DRUG|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
219679009|NCT02902042|DRUG|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
219679010|NCT02902042|DRUG|Pembrolizumab alone|200 mg q3w
219679011|NCT06525558|PROCEDURE|Intestinal resection|This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
219679012|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
219076441|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
219076442|NCT05109091|DRUG|ATH434 dose level 1|ATH434 taken BID
219076443|NCT05109091|DRUG|ATH434 dose level 2|ATH434 taken BID
219076444|NCT05109091|DRUG|Placebo|Placebo taken BID
219076445|NCT03996473|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
219076446|NCT03996473|DRUG|Pembrolizumab|200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
219076447|NCT06116591|BIOLOGICAL|mPnC candidate|monovalent pneumococcal conjugate candidate
219076448|NCT06116591|BIOLOGICAL|mPnC control|monovalent pneumococcal conjugate control
219076449|NCT05875181|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
219076450|NCT05875181|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
219076451|NCT06160947|OTHER|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
219076452|NCT06160947|OTHER|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
219679013|NCT06183424|PROCEDURE|Transcranial Direct Stimulation|2 mA, 20 min, 5 days
219679014|NCT01911702|OTHER|Standard fluidic resuscitation.|"Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE\> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
219679015|NCT01911702|OTHER|Volemic small treatment|"Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE\> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be \> 10-15 ml / kg / h an infusion of furosemide should be initiated"
219076453|NCT04769037|DIETARY_SUPPLEMENT|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
219076454|NCT04769037|DIETARY_SUPPLEMENT|Placebo|Lactose identical in appearance and taste to the active supplement
219076455|NCT01339585|DEVICE|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
219076456|NCT03855449|BEHAVIORAL|eDECIDE Web-based Intervention Group|"Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
219076457|NCT04620278|GENETIC|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
219679016|NCT04245618|DRUG|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
219679017|NCT05645107|DRUG|Xembify|SC infusion pump
219679018|NCT05645107|DRUG|Placebo|SC infusion pump
219679019|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
219679020|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
219076458|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
219076459|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
219076460|NCT06506435|BEHAVIORAL|Two Dimensional (2D) Informational Video|A 30-minute informational video. The two dimensional (2D) video provides information about the radiotherapy process. Participants will receive this one-time intervention in-person, prior to treatment.
219076461|NCT06506435|BEHAVIORAL|First-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a first-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
219076462|NCT06506435|BEHAVIORAL|Third-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a third-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
219076463|NCT05157971|DRUG|Cyclophosphamide|Given IV
219076464|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
219076465|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
219076466|NCT05157971|DRUG|Mercaptopurine|Given PO
219076467|NCT05157971|DRUG|Methotrexate|Given IT
219076468|NCT05157971|DRUG|Pegaspargase|Given IM or IV
219076469|NCT05157971|DRUG|Prednisone|Given PO
219076470|NCT05157971|DRUG|Venetoclax|Given PO
219076471|NCT05157971|DRUG|Vincristine Sulfate|Given IV
219679021|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
219076472|NCT06952114|DRUG|Stem Cells Lenses|Each subject will wear Stem Cells Lenses for four consecutive days. After a 4-day treatment period, a 14-day follow-up observation period will be conducted to monitor for potential adverse events.
219076473|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
219076474|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
219076475|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
219076476|NCT06962124|OTHER|serum sodium measurment|serum sodium measurment
219076477|NCT06962813|PROCEDURE|Radiofrequency V Eraser|standar of care sclerotherapy
219076478|NCT06961656|OTHER|Intervention Group-Jigsaw IV technique|Wound care training with the Jigsaw IV technique method
219076479|NCT06961656|OTHER|Control Group-Traditional methods|Wound care training with traditional methods
219679022|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
219679023|NCT02733341|DRUG|Cangrelor|
219679024|NCT02733341|DRUG|Ticagrelor|
219679025|NCT04819750|DEVICE|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
219679026|NCT04819750|DEVICE|Headphones with noise reduction|Headphones with noise reduction without music
219679027|NCT03463252|DRUG|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
219679028|NCT03463252|DEVICE|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
219679029|NCT03463252|DRUG|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
219679030|NCT01038154|DRUG|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
219679031|NCT03873311|DRUG|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
219679032|NCT03873311|DRUG|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
219679033|NCT03603561|DEVICE|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
219679034|NCT03603561|DEVICE|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
219076480|NCT06962527|BEHAVIORAL|Uncertainty-focused single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
219679035|NCT00355511|BEHAVIORAL|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
219679036|NCT02393235|OTHER|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
219679037|NCT01654263|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
219679038|NCT01904032|DRUG|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
219679039|NCT01904032|DRUG|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
219076481|NCT06962527|BEHAVIORAL|Maintaining a healthy lifestyle single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
219076482|NCT06962462|DRUG|Methyl Cellulose Placebo|Oral administration of inert methyl cellulose placebo tablets once daily for 3 months. Used as a comparator in healthy control participants to evaluate changes in Endothelin-1 and E-selectin serum levels.
219076483|NCT06962748|DIAGNOSTIC_TEST|cerebral blood flow measurment|measuring CO using cerebral blood flow
219076484|NCT06962748|DIAGNOSTIC_TEST|TTE CO measurment|measuring CO using TTE
219076485|NCT06962748|DIAGNOSTIC_TEST|ETCO2|measure the average ETCO2 over 30 minutes period
219076486|NCT06962072|PROCEDURE|Surgical resection with or without radiotherapy and/or chemotherapy|The surgical resection of STS serves as the primary treatment, aiming to completely remove the tumor with a wide margin of surrounding healthy tissue to minimize the risk of recurrence. Radiotherapy and/or chemotherapy may be incorporated depending on the tumor's type, stage, and grade.
219076487|NCT06962423|OTHER|AI system|Participants will complete the research task with the AI system developed by out team to perform automated biomedical research.
219076488|NCT05596045|DRUG|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
219076489|NCT05596045|DRUG|Placebo|Participants will be randomized to receive placebo
219076490|NCT06962709|OTHER|Warmed lidocaine|Lidocaine warmed to 98 F
219076491|NCT06962293|DEVICE|MAG-ESD assisted ESD|Flexible magnetic traction device would be used to assist the ESD procedure. Real time adjustment of traction could be achieved by controlling the EPM position and orientation anytime during the procedure.
219076492|NCT06962371|DEVICE|cerebral embolic protection|Use of Transverse Medical Inc. Point-Guard CEP device.
219076493|NCT06962228|PROCEDURE|Anal fistula surgery|Anal fistula incision, anal fistula excision, anal fistula hanging
219076494|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
219076495|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
219076496|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
219076497|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
219076498|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
219076499|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
219076500|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
219076501|NCT04897776|DEVICE|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
219076502|NCT04897776|DEVICE|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
219076503|NCT05754450|DRUG|AVTX-803|L-fucose crystalline powder
219076504|NCT05808101|OTHER|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
219076505|NCT05586230|DRUG|Pretomanid|Administered orally based on participant's weight
219076506|NCT05586230|DRUG|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
219076507|NCT06643351|OTHER|Standard Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
219076508|NCT06643351|OTHER|Liberalized Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
219076509|NCT05852015|BEHAVIORAL|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
219076510|NCT05852015|BEHAVIORAL|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
219076511|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
219076512|NCT06459921|DRUG|SOX+Sintilimab|Patients would be allocated to the SOX+Sintilimab group.
219076513|NCT06459921|DRUG|FLOT+Sintilimab|Patients would be allocated to the FLOT+Sintilimab group.
219076514|NCT05403762|OTHER|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
219076515|NCT05403762|OTHER|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
219076516|NCT06635317|DRUG|Aspirin|100 mg/day orally for 25 days
219076517|NCT06635317|DRUG|enoxaparin|40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
219076518|NCT06636461|PROCEDURE|microfragmented adipose tissue loaded on allograft|microfragmented adipose tissue loaded on allograft on ridge preservation
219076519|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
219076520|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
219076521|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
219076522|NCT04001673|BEHAVIORAL|Pharmacist's intervention|Information about bDMARDs management.
219076523|NCT06211205|DEVICE|Customized 3D printed nostril retainer combined with lip taping|the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments
219076524|NCT06211205|PROCEDURE|Lip taping|the infants will receive lip tape to approximate the labial and alveolar segments
219076525|NCT05698238|DRUG|CA9hu-1|Humanized monoclonal antibody to human carbonic anhydrase IX
219076526|NCT00193700|DRUG|Testosterone Gel (1%)|
219076527|NCT02701985|DRUG|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
219076528|NCT02701985|DRUG|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
219076529|NCT06733103|BEHAVIORAL|Stroke Cognitive Behavioural Therapy|This is the only intervention in this clinical (feasibility) study
219076530|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
219076531|NCT02034747|DRUG|Advagraf|oral
219076532|NCT02034747|DRUG|Corticosteroid|oral
219076533|NCT06421987|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS is a portable, non-invasive, brain imaging device.
219076534|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
219076535|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
219076536|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
219076537|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
219076538|NCT05642390|DEVICE|Breast implant|Patients operated for breast augmentation or reconstruction.
219076539|NCT04235036|DRUG|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
219076540|NCT04235036|DRUG|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
219076541|NCT05363813|DEVICE|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
219076542|NCT03761602|OTHER|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
219076543|NCT05721859|DEVICE|revision hip arthroplasty|revision hip arthroplasty
219076544|NCT03777098|DEVICE|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
219076545|NCT03913611|OTHER|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
219076546|NCT03913611|OTHER|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
219076547|NCT06309953|DRUG|Miebo|Miebo treatment
219076548|NCT01673932|BIOLOGICAL|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
219679040|NCT01340742|PROCEDURE|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
219679041|NCT01340742|PROCEDURE|Control|Cuff placed on arm uninflated for 30 minutes.
219076549|NCT01673932|PROCEDURE|surgery|
219076550|NCT03348748|OTHER|Laboratory Biomarker Analysis|Correlative studies
219076551|NCT03348748|OTHER|Quality-of-Life Assessment|Ancillary studies
219076552|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
219679042|NCT00147511|DRUG|linezolid|
219076553|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
219076554|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
219076555|NCT03348748|PROCEDURE|Thoracic Surgical Procedure|Undergo thoracic surgery
219076556|NCT01640808|DRUG|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
219076557|NCT01640808|DRUG|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
219076558|NCT06367621|DEVICE|iStatis Syphilis Antibody Test|1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
219076559|NCT00002109|DRUG|Thymopentin|
219076560|NCT00002109|DRUG|Stavudine|
219679043|NCT02635256|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
219679044|NCT00596050|DRUG|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
219679045|NCT00596050|DRUG|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
219679046|NCT04087369|OTHER|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
219679047|NCT02106741|BEHAVIORAL|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
219679048|NCT02106741|BEHAVIORAL|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
219076561|NCT00002109|DRUG|Zidovudine|
219076562|NCT00002109|DRUG|Zalcitabine|
219076563|NCT00002109|DRUG|Didanosine|
219076564|NCT06338982|PROCEDURE|Interoperative wisdom tooth removal in conjunction with BSSO|The objective of the present randomized controlled trial is to assess the fracture pattern, condylar segment positioning, frequency of complications, and PROMs following BSSO with or without impacted mandibular third molars. this is illustrated by the fact that the test group had their wisdom teeth removed in connection with the sagittal split of the mandible (the BSSO surgery). Subsequently, all outcome measures are compared with the control group, who had their wisdom teeth removed 6 months prior their BSSO surgery.
219076565|NCT02645734|DRUG|bevacizumab|1.25 mg of bevacizumab is injected
219076566|NCT02645734|DRUG|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
219076567|NCT02645734|DRUG|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
219076568|NCT02910622|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
219076569|NCT02683096|OTHER|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
219076570|NCT01869491|DRUG|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
219076571|NCT01869491|DRUG|Matching placebo tablets|2 tablets four times daily
219076572|NCT00493922|PROCEDURE|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
219679049|NCT04877418|PROCEDURE|TeleCIMT|Mode applied remotely, through the principles and components of the CIMT protocol.
219076573|NCT00493922|PROCEDURE|Microscopy|Microscopy for diagnosis of malaria
219076574|NCT00493922|PROCEDURE|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
219076575|NCT03786029|DRUG|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
219076576|NCT03786029|DRUG|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
219076577|NCT03786029|DRUG|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
219076578|NCT04237506|BEHAVIORAL|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
219076579|NCT04009291|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
219076580|NCT04009291|COMBINATION_PRODUCT|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
219076581|NCT05758337|DEVICE|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
219076582|NCT05191940|RADIATION|Particle-therapy using protons or carbon ions|According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
219076583|NCT05191940|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, after treatment and follow-up period.
219076584|NCT05191940|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
219076585|NCT05191940|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
219076586|NCT05191940|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For treatment planning as well as for follow-up radiological tumor assessment.
219076587|NCT05918705|PROCEDURE|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
219076588|NCT05092516|DEVICE|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
219076589|NCT05092516|DEVICE|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
219076590|NCT05279495|DEVICE|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
219679050|NCT00768287|BIOLOGICAL|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
219076591|NCT05279495|DEVICE|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
219076592|NCT05833737|DRUG|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
219076593|NCT04098133|OTHER|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
219076594|NCT04098133|OTHER|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
219076595|NCT04098133|OTHER|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
219076596|NCT04098133|OTHER|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
219679051|NCT00768287|BIOLOGICAL|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
219679052|NCT01462864|BEHAVIORAL|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
219679053|NCT06253910|OTHER|Patients selection|Patient selection were selected according to selected criteria.
219076597|NCT05110183|DEVICE|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
219076598|NCT05110183|OTHER|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
219076599|NCT05110183|OTHER|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
219210156|NCT06771999|OTHER|Educational intervention by a clinical pharmacist|All participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
219210157|NCT06863025|BEHAVIORAL|Neurofeedback training|Neurofeedback (NF) or electroencephalographic feedback (EEG) training refers to a type of computerized cognitive training that changes EEG patterns through operant conditioning. NF is a computerized rehabilitation technique but also a non-invasive neuromodulation approach, as it alters brain activity by delivering a stimulus. It is well-established for the treatment of conditions such as anxiety and ADHD. During NF rehabilitative training, the subject is provided with real-time EEG feedback, usually with a visual or auditory stimulus, with the aim of normalizing brain oscillations. Rehabilitation through NF training generally targets EEG frequencies that are affected and underlie the observed behavioral deficit (e.g., attentional dysfunctions).
219210158|NCT06863025|BEHAVIORAL|Standard cognitive therapy|This is the control intervention and it involves standard practice cognitive therapy in neurorehabilitation. Neuropsychologists and other clinicians test and train the patients' cognitive specific aspect (in this case, attention) with some validated tools and/or games
219679054|NCT06253910|OTHER|Recall visits|Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
219679055|NCT01816932|PROCEDURE|Home Visit|The intervention is the location of the insertion visit.
219679056|NCT01816932|PROCEDURE|Office visit|
219679057|NCT01504373|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
219679058|NCT04858867|RADIATION|rhTSH-stimulated I-124 dosimetry|"Preparation:~* Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~* Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~* Ingestion of capsule with 37±10% MBq I-124~* I-124 PET/CT at 24 and 96h post-ingestion~* Blood draws at 2, 24 and 96h post-ingestion~* Whole body counting at 2, 24 and 96h post-ingestion"
219679059|NCT04858867|RADIATION|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~* I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~* Blood draws at 2, 6, 24, 96 and 144h post-ingestion~* Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
219679060|NCT01789801|PROCEDURE|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
219679061|NCT01789801|PROCEDURE|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
219679062|NCT03163537|DEVICE|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
219679063|NCT02088892|DRUG|BCG SSI|Intradermal injection
219679064|NCT02088892|DRUG|BCG Tice|Intradermal injection
219679065|NCT00470561|DRUG|Aspirin|Two 325 mg doses of aspirin per day for 6 months
219679066|NCT00470561|DRUG|Placebo|Two placebo pills per day for 6 months
219679067|NCT00065273|DRUG|risperidone|
219679068|NCT00065273|DRUG|clozapine|
219679069|NCT00065273|DRUG|olanzapine|
219679070|NCT06048393|DRUG|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
219679071|NCT05450172|OTHER|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
219679072|NCT02748629|DEVICE|Covidien Parietex ProGrip Self-Fixating Mesh|
219679073|NCT02748629|DEVICE|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
219076600|NCT05704634|DRUG|Cemiplimab|Given by Injection under the skin every 2 weeks
219076601|NCT05704634|DRUG|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
219076602|NCT06479161|DRUG|Tranexamic acid|1.95 grams oral
219076603|NCT04821778|RADIATION|Radiotherapy|50-66Gy/1.8-2.2Gy/25-30f
219679074|NCT01547052|BEHAVIORAL|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
219076604|NCT04821778|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
219076605|NCT04821778|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
219076606|NCT04821778|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
219210159|NCT06862336|PROCEDURE|intra-dialytic exercise program associated with medical treatment|"* Stretch for pectorals and calf muscles: Two sets - 3 times/ set.~* Breathing exercises associated with upper limb movement.~* Resistive exercise for hip abductors, hip flexors, and calf muscles by using theraband.~* Sit to stand strengthening exercises: -"
219210160|NCT06862336|PROCEDURE|inter-dialytic combined exercise program with their medications|receive the inter-dialytic combined exercise program with their medications. Like the study group except for diaphragmatic breathing instead of breathing with upper limb exercise.
219210161|NCT06883877|OTHER|Multi-Modal Program (MMP)|MMP includes three modules: addressing psychological problems such as FCR; addressing problems related to breast cancer symptoms; and addressing tangible problems such as social support. Each module is divided into the chemotherapy period (hospitalization) and the chemotherapy interval (post-discharge). Each phase involves face-to-face, digital, and remote tools, with the intervention lasting 8 weeks. Each module has a different goal, and depending on the goal setting, the topic of the intervention is different. The goal of the information education stage is to improve patients' overall understanding of the disease and pay attention to the psychological problems of FCR. The goal of coping skills is that through the practice of coping skills, patients can learn to change thoughts, problem emotions, and behaviors. The objective of social support group interaction is to strengthen their social support networks.
219210162|NCT06883877|OTHER|Routine care|The control group will receive routine care.
219210163|NCT03655561|OTHER|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
219210164|NCT06626685|OTHER|Clinical and instrumental examination|Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.
219210165|NCT06889441|BEHAVIORAL|Test of sensory function in infants|It was planned to use the Test of sensory function in infants to evaluate the sensory development of infants. The test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months. It is used to determine whether an infant has a sensory processing problem and to what extent. It consists of 24 items. The test of sensory function in infants requires the infant to be stimulated and interacted with various materials. The total score varies between 0-49 and the test has normative values for different age groups. Although it is used from the fourth month onwards, the most reliable and valid results are obtained between 7-18 months.
219679075|NCT01547052|BEHAVIORAL|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
219679076|NCT02984644|DRUG|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
219679077|NCT02984644|DRUG|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
219679078|NCT02414217|BEHAVIORAL|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
219076607|NCT04821778|DRUG|5-FU Analog based chemotherapy|W1-5 qW or d1-14, q3W according to physician's preference
219076608|NCT04821778|DRUG|Nimotuzumab|200-400mg, d1,qW
219076609|NCT01380483|DRUG|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
219076610|NCT01380483|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
219076611|NCT04541134|DRUG|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
219076612|NCT04541134|DRUG|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
219076613|NCT02656797|DRUG|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
219076614|NCT05804565|PROCEDURE|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
219210166|NCT06889441|BEHAVIORAL|The Peabody Developmental Motor Scales-Second Edition|The Peabody Developmental Motor Scales-Second Edition is a standardized, norm-referenced assessment instrument designed to evaluate both gross and fine motor skills in children aged 0 to 71 months. It is frequently employed in clinical, educational, and research contexts to detect motor developmental delays, monitor developmental trajectories, and inform intervention strategies. Notably, higher scores on the scale reflect superior motor performance, indicating better developmental outcomes
219210167|NCT06889441|BEHAVIORAL|Infant/toddler sensory profile|"The infant/toddler sensory profile is a questionnaire filled out by the child's primary caregiver to collect information about sensory processing abilities. The test evaluates sensory processing in 6 different areas. These items consist of general, visual, auditory, vestibular, tactile and oral sensory processing. The caregiver evaluates the child's behavior on a 5-point scale. One point means almost always and five points means almost never. The caregiver's responses are summarized using standard scoring procedures and then interpreted in terms of the impact of a child's sensory processing abilities on the child and their family's lives. The scores are normative for age and are important in assessing sensory development."
219210168|NCT06752733|PROCEDURE|electrical cardioversion|synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation
219210169|NCT06669676|OTHER|acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
219210170|NCT06669676|OTHER|No acupuncture|patients will be given standard medical treatment to prevent ponv
219210171|NCT06761690|OTHER|hybrid simulated wound training|hybrid simulated wound training
219076615|NCT05804565|PROCEDURE|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
219076616|NCT05553808|DRUG|Docetaxel|Docetaxel was administered as IV infusion.
219076617|NCT05553808|DRUG|Feladilimab|Feladilimab was administered as IV infusion.
219076618|NCT01802372|BEHAVIORAL|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
219076619|NCT01802372|BEHAVIORAL|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
219076620|NCT01597544|PROCEDURE|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
219076621|NCT03936686|OTHER|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
219076622|NCT06242444|DRUG|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
219076623|NCT06242444|DRUG|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
219076624|NCT06242444|DRUG|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
219076625|NCT01303666|PROCEDURE|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
219076626|NCT01303666|PROCEDURE|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
219076627|NCT05790733|OTHER|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
219076628|NCT05790733|OTHER|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
219076629|NCT01820676|DEVICE|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
219076630|NCT01736228|DEVICE|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
219076631|NCT00402753|BEHAVIORAL|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
219076632|NCT03239119|BIOLOGICAL|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
219076633|NCT03239119|BIOLOGICAL|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
219076634|NCT03239119|BIOLOGICAL|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
219076635|NCT03239119|BIOLOGICAL|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
219076636|NCT05121753|DIETARY_SUPPLEMENT|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
219076637|NCT03725644|BEHAVIORAL|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
219076638|NCT03725644|BEHAVIORAL|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
219076639|NCT02102087|DEVICE|Initial Specimen Diversion Device (ISDD)|
219679079|NCT02414217|BEHAVIORAL|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
219679080|NCT03643302|DEVICE|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
219076640|NCT02102087|DEVICE|Lab standard practice (LSP)|
219076641|NCT03948568|COMBINATION_PRODUCT|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
219076642|NCT05475418|PROCEDURE|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
219076643|NCT05258825|DRUG|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
219076644|NCT04459026|PROCEDURE|combination|instillation and infiltration of ropivacaine
219076645|NCT04459026|PROCEDURE|infiltration|local infiltration ropivacaine
219076646|NCT04459026|PROCEDURE|instillation|intraperitoneal ropivacaine instillation
219679081|NCT04074330|DRUG|TAK-981|TAK-981 intravenous infusion.
219076647|NCT04790318|PROCEDURE|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
219076648|NCT04790318|PROCEDURE|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
219076649|NCT03205995|BIOLOGICAL|OMS721|Intravenous loading dose followed by daily subcutaneous injections
219076650|NCT00884429|PROCEDURE|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
219076651|NCT00884429|PROCEDURE|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
219076652|NCT00884429|PROCEDURE|3-Airway suction|Airway suction
219679082|NCT04074330|DRUG|Rituximab|Rituximab intravenous infusion.
219679083|NCT04288427|DRUG|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
219679084|NCT00184093|DRUG|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
219679085|NCT05056155|OTHER|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
219679086|NCT01903993|DRUG|Docetaxel|Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
219679087|NCT01903993|DRUG|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
219076653|NCT03793985|DRUG|T|CKD-391 40/10mg
219076654|NCT03793985|DRUG|R|D086 and D337 co-administration
219076655|NCT06128109|DEVICE|Thioderm Strong|Test Device
219076656|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
219076657|NCT02979262|BEHAVIORAL|Fathers for Change|
219076658|NCT02979262|BEHAVIORAL|Parent Education|
219679088|NCT00005802|BIOLOGICAL|aldesleukin|
219076659|NCT02160587|DRUG|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
219076660|NCT02160587|DRUG|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
219076661|NCT02160587|OTHER|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
219076662|NCT00000744|DRUG|Fluconazole|
219076663|NCT04956718|OTHER|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
219076664|NCT04956718|OTHER|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
219076665|NCT05903417|DRUG|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
219210172|NCT06748261|DIAGNOSTIC_TEST|CCTAI model|Using a derivative sub-cohort, the investigators aim to first develop an CCTA-based AI-assisted (CCTAI) screening model to distinguish patients with cardiac abnormalities from those normal controls. Second, the investigators target at developing a CCTAI diagnostic model with multi-classification output of cardiomyopathy diagnosis. Both models will be tested in internal validation cohort and external validation cohort.
219076666|NCT05903417|OTHER|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
219076667|NCT05404542|DRUG|Tavapadon|Oral tablets
219679089|NCT00005802|BIOLOGICAL|filgrastim|
219679090|NCT00005802|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219679091|NCT00005802|DRUG|cytarabine|
219679092|NCT00005802|DRUG|etoposide|
219679093|NCT00005802|DRUG|fludarabine phosphate|
219679094|NCT00005802|DRUG|methotrexate|
219679095|NCT00005802|DRUG|mitoxantrone hydrochloride|
219679096|NCT00005802|DRUG|therapeutic hydrocortisone|
219679097|NCT00005802|RADIATION|radiation therapy|
219679098|NCT05838911|OTHER|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
219076668|NCT03848533|DRUG|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
219076669|NCT03848533|DRUG|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
219076670|NCT03848533|DRUG|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
219076671|NCT01714128|DRUG|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
219076672|NCT03332368|OTHER|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
219076673|NCT02856464|OTHER|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
219076674|NCT02856464|OTHER|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
219076675|NCT06349369|DEVICE|transcranial direct current stimulation|tDCS is a non-invasive neuromodulation technique that has gained attention for its potential to influence neural activity and address cognitive and functional deficits in individuals with schizophrenia. It involves applying a weak direct electrical current to the scalp, which can increase or decrease the excitability of underlying brain regions.
219076676|NCT05887193|DEVICE|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
219076677|NCT05887193|DEVICE|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
219076678|NCT05887193|DEVICE|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
219076679|NCT05887193|DEVICE|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
219076680|NCT02263404|DEVICE|Deep Brain Stimulation|DBS Implant Stimulation
219076681|NCT00808808|BIOLOGICAL|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
219076682|NCT00808808|OTHER|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
219076683|NCT00808808|BIOLOGICAL|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
219210173|NCT05962489|OTHER|Clinically optimized deep brain stimulation|Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
219210174|NCT06782750|OTHER|Physiotherapy|Traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks.
219679099|NCT05838911|OTHER|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
219679100|NCT02130388|DIETARY_SUPPLEMENT|Zinc|
219679101|NCT05095311|DRUG|Cetirizine HCl|Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
219679102|NCT05095311|OTHER|Placebo|The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
219679103|NCT03941145|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training (REHIT)|REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
219679104|NCT01925976|BEHAVIORAL|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
219076684|NCT04405596|DRUG|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
219076685|NCT04405596|OTHER|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
219679105|NCT05859308|OTHER|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
219679106|NCT05859308|OTHER|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
219679107|NCT05451394|OTHER|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
219679108|NCT05451394|OTHER|Active Comparator|6 one-hour workshops on cognitive process
219679109|NCT02362737|BEHAVIORAL|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
219076686|NCT03591068|DRUG|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
219076687|NCT05216094|OTHER|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
219076688|NCT05216094|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
219679110|NCT05441553|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
219679111|NCT05219604|DRUG|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
219076689|NCT04554875|DIAGNOSTIC_TEST|A scoring system|The scoring system was used to rate score patients.
219076690|NCT03923413|OTHER|Blood samples|Blood samples for MP evaluation
219076691|NCT00615966|DRUG|Diannexin|single dose, 200 µg/kg IV
219076692|NCT00615966|DRUG|Placebo|Single dose, IV
219076693|NCT00615966|DRUG|Diannexin|Single dose, 400 µg/kg IV
219076694|NCT01356017|DRUG|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
219076695|NCT01356017|DRUG|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
219076696|NCT01694862|PROCEDURE|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
219076697|NCT00490646|DRUG|ixabepilone|"Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
219679112|NCT01998347|DRUG|Paclitaxel liposome|
219679113|NCT01998347|DRUG|Cisplatin|
219679114|NCT01998347|DRUG|5-fluorouracil|
219679115|NCT00311753|DRUG|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
219679116|NCT00311753|DRUG|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
219679117|NCT05858866|OTHER|Piper Fatigue Scale|The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
219679118|NCT00717652|DRUG|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
219679119|NCT00717652|DRUG|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
219679120|NCT01918657|DRUG|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
219679121|NCT01918657|DRUG|walnut powder|escalating doses of walnut powder
219679122|NCT00108290|DRUG|Chemotherapy|
219679123|NCT02509975|DEVICE|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
219679124|NCT00332306|DRUG|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients \<60kg, 400mg patients \> 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
219679125|NCT00332306|DRUG|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients \< 60kg, 400 mg OD patients \> 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
219076698|NCT00490646|DRUG|docetaxel|Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
219679126|NCT05030636|PROCEDURE|Acute moderate to vigorous exercise performed at a specific moment of the day|Treadmill (30 minutes) at 70% of maximal aerobic capacity
219679127|NCT02510612|DRUG|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
219679128|NCT02510612|DRUG|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
219679129|NCT00511485|DRUG|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
219679130|NCT00511485|DRUG|Etarfolatide|
219679131|NCT04411758|DIETARY_SUPPLEMENT|Propolis|Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
219679132|NCT04411758|DIETARY_SUPPLEMENT|Placebo|Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
219076699|NCT00490646|DRUG|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
219076700|NCT02756767|OTHER|Survey|
219076701|NCT00236548|DRUG|risperidone|
219076702|NCT06503211|BIOLOGICAL|UTAA09 injection|The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
219076703|NCT03079752|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
219076704|NCT03079752|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
219076705|NCT03079752|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
219076706|NCT03079752|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
219679133|NCT00972283|DRUG|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
219679134|NCT00972283|DRUG|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
219076707|NCT05608629|DEVICE|Transcutaneous Non-Invasive Vagus Nerve Stimulation|The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
219076708|NCT04388020|DEVICE|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
219076709|NCT04388020|DEVICE|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
219076710|NCT03838042|DRUG|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
219076711|NCT03834064|BEHAVIORAL|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
219076712|NCT01166633|DRUG|pitavastatin|pitavastatin 2mg per daily
219076713|NCT01166633|DRUG|atorvastatin|atorvastatin 10mg per daily
219679135|NCT00972283|DRUG|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
219679136|NCT02893046|OTHER|No intervention|
219679137|NCT00019357|BIOLOGICAL|aldesleukin|
219679138|NCT00019357|BIOLOGICAL|therapeutic autologous lymphocytes|
219679139|NCT00019357|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219679140|NCT02382315|BEHAVIORAL|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
219679141|NCT01738529|DEVICE|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
219679142|NCT05515510|OTHER|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
219679143|NCT05515510|OTHER|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
219210175|NCT06801080|OTHER|HealthySteps (https://www.zerotothree.org/our-work/healthysteps/)|Within the DoD, most elements of the civilian HS model copyrighted by ZeroToThree.org were implemented. However, there were some modifications to accommodate the unique environment of the military community. The pilot utilized the pre-existing Military Family Life Counseling Program (MFLC) staff to serve as HS Specialists at participating clinics. MFLCs were hired and trained in the HS model through the HS Institute provided by ZeroToThree.org. Although the DoD pilot offered all 3 tiers of targeted care standard for the HS model, note that the DoD pilot did not offer a 24-hour parent support line at tier 1. Also, the DoD pilot required participating pilot clinics to utilize a modified version of the Tufts Survey of Well-Being of Young Children (SWYC; https://www.tuftsmedicine.org/medical-professionals-trainees/academic-departments/department-pediatrics/survey-well-being-young-children) to provide augmented screenings for infants at all tiers of pilot service provision.
219210176|NCT06801080|OTHER|Treatment as Usual (TAU)|The comparison clinics included in this intervention were selected to represent pediatric care within military treatment facilities throughout the DHA medical system located at Army, Navy, Marine Corps, and Air Force facilities. There is variability in pediatric practice across military service branches. However, all clinics follow the American Academy of Pediatrics Bright Futures guidelines.
219076714|NCT01453595|DRUG|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
219076715|NCT00983073|DRUG|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
219076716|NCT03547089|DEVICE|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
219076717|NCT02047838|OTHER|Anti-mullerian hormone (AMH) level dosage.|
219076718|NCT02047838|OTHER|Follicle-stimulating hormone (FSH) level dosage.|
219210177|NCT04505722|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.
219210178|NCT04505722|OTHER|Placebo|Participants will receive Placebo.
219210179|NCT05505799|OTHER|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
219679144|NCT02516956|OTHER|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
219679145|NCT02516956|OTHER|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
219679146|NCT02516956|OTHER|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
219679147|NCT02516956|OTHER|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
219076719|NCT02047838|OTHER|Antral follicle count (AFC).|
219210180|NCT05505799|OTHER|Standard Care|Clinicians will intubate as per their usual practice
219210181|NCT06744842|OTHER|genicular nerve block|genicular nerve block
219210182|NCT06744842|OTHER|Exercise|isometric exercise
219210183|NCT06745375|DEVICE|contact lens wear|participants wear two different powered contact lenses (one with actual power, and one +/- 2.00Ds) contact lenses. No 2nd arm
219210184|NCT06766929|DRUG|VSA012|subcutaneous injection
219210185|NCT06766929|DRUG|Placebo|subcutaneous injection
219210186|NCT06791083|DRUG|Envafolimab|150mg/m2 , IH， d1；Q3W
219210187|NCT06791083|DRUG|Fruquintinib|5 mg ，po，QD，d1-d14；Q3W
219210188|NCT06786650|DRUG|Tenoxicam Injectable Product|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
219210189|NCT06786650|DRUG|ibuprofen|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
219210190|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
219210191|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
219210192|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
219210193|NCT06798051|DRUG|Roxithromycin tablets 150mg|Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
219679148|NCT02516956|OTHER|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
219210194|NCT06840158|DRUG|Miotox (Botulinum toxin type A is a hemagglutinin complex)|"During the study, patients were injected with the investigational drug Miotox® .~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
219210195|NCT06840158|DRUG|BOTOX®|"During the study, patients were injected with the investigational comparison drug Botox®.~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
219076720|NCT01237639|OTHER|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
219076721|NCT04392765|DEVICE|eXciteOSA|eXciteOSA transoral neurostimulation device
219076722|NCT05205265|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
219076723|NCT04484467|DIETARY_SUPPLEMENT|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
219076724|NCT04484467|OTHER|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
219076725|NCT02959996|DRUG|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
219076726|NCT02959996|DRUG|Placebo|placebo injection in the Pfannenstiel incision
219076727|NCT02906150|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
219076728|NCT02906150|DRUG|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
219076729|NCT02385344|DEVICE|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
219076730|NCT00058838|DRUG|sumanirole|
219076731|NCT05734794|DRUG|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
219076732|NCT05734794|DRUG|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
219076733|NCT02962908|BIOLOGICAL|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
219076734|NCT02962908|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
219076735|NCT02962908|BIOLOGICAL|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
219076736|NCT02962908|BIOLOGICAL|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
219076737|NCT01308242|DRUG|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
219076738|NCT00002803|DRUG|cyclophosphamide|
219076739|NCT00002803|DRUG|doxorubicin hydrochloride|
219076740|NCT00002803|DRUG|vincristine sulfate|
219076741|NCT00002803|PROCEDURE|conventional surgery|
219076742|NCT00083018|GENETIC|cytogenetic analysis|
219076743|NCT00083018|GENETIC|proteomic profiling|
219076744|NCT00083018|OTHER|cytology specimen collection procedure|
219076745|NCT00083018|OTHER|immunohistochemistry staining method|
219076746|NCT00083018|OTHER|laboratory biomarker analysis|
219076747|NCT00083018|PROCEDURE|breast duct lavage|
219076748|NCT02389972|DRUG|Dasatinib|
219076749|NCT03543254|DRUG|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
219076750|NCT01823848|DRUG|Sodium phosphate enema|Rectally administered medication to treat constipation
219076751|NCT01823848|DRUG|Normal saline enema|Rectally administered medication to treat constipation
219076752|NCT01823848|DRUG|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
219076753|NCT00072267|DRUG|7-hydroxystaurosporine|
219076754|NCT00072267|DRUG|topotecan hydrochloride|
219076755|NCT02283931|DEVICE|TTE / NICOM|
219679149|NCT01633099|DRUG|Decitabine|"1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,\>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,\>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,\>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,\>1h, on d1-3 of each 28day cycle)."
219679150|NCT02600611|DRUG|iclaprim|Experimental treatment
219679151|NCT02600611|DRUG|vancomycin|Active comparator
219679152|NCT00630201|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
219679153|NCT02317484|DRUG|Ipragliflozin (SGLT2 inhibitor)|
219679154|NCT03167255|DRUG|NS-065/NCNP-01|Received during weekly intravenous infusions
219679155|NCT02491970|DRUG|Fluticasone/Formoterol|
219679156|NCT02491970|DRUG|Fluticasone/Salmeterol|
219679157|NCT02589834|OTHER|Quran group|
219679158|NCT03679819|DEVICE|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
219679159|NCT03852498|GENETIC|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
219679160|NCT04030325|BEHAVIORAL|Sequential Personalized Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
219076756|NCT06064227|OTHER|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
219076757|NCT03932604|DEVICE|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
219076758|NCT01261338|DRUG|olestra|non-absorbable dietary fat
219076759|NCT01283412|DRUG|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
219076760|NCT01283412|DRUG|Dexmedetomidine|Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
219076761|NCT05545553|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
219076762|NCT05545553|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
219076763|NCT05714189|OTHER|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
219679161|NCT04030325|BEHAVIORAL|Simultaneous Personalized Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
219076764|NCT05714189|OTHER|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
219076765|NCT03195933|OTHER|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
219076766|NCT03195933|OTHER|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
219076767|NCT04360733|OTHER|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
219076768|NCT04982900|DRUG|furmonertinib|AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
219679162|NCT04030325|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking events
219076769|NCT04982900|DRUG|Placebo|The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
219076770|NCT06430450|DIAGNOSTIC_TEST|Clinical measurements and saliva samples collection|Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
219076771|NCT05210192|DRUG|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
219076772|NCT05210192|DRUG|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
219076773|NCT01544868|OTHER|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
219076774|NCT05983822|DEVICE|Technological Group|Specific rehabilitation for the recovery of hand function using the end-effector robot
219076775|NCT05983822|OTHER|Conventional Treatment|Conventional rehabilitation
219076776|NCT04216810|OTHER|muscle strengthening exercises|segmental stabilization exercises
219076777|NCT04216810|OTHER|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
219076778|NCT02313428|DEVICE|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
219076779|NCT00564122|DEVICE|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
219076780|NCT00564122|OTHER|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
219076781|NCT05374421|DEVICE|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
219076782|NCT05374421|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
219076783|NCT05768698|DIAGNOSTIC_TEST|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
219210196|NCT06798103|PROCEDURE|Erector Spinae Plane Block|Erector spinae plane block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved to a parasagittal plane to visualize skin and subcutaneous tissue layers, trapezius muscle, and lastly the erector spinae muscle just superficial to the transverse processes. The in-plane technique will be used, and the tip of the needle will be inserted in the fascial plane deep to the erector spinae muscle. After 2-3 mL of normal saline injection for hydro dissection to verify the correct needle tip placement, 30 mL of 0.25% bupivacaine will be injected deep to the erector spinae muscle. The same technique will be repeated on the contralateral side.
219679163|NCT01124292|PROCEDURE|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
219679164|NCT01124292|DEVICE|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
219679165|NCT04565899|OTHER|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
219076784|NCT05977894|OTHER|Reduced Environmental Stimulation Therapy|"During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation."
219076785|NCT05548101|PROCEDURE|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
219076786|NCT05440864|DRUG|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
219076787|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
219076788|NCT02899728|DRUG|Carboplatin|Given IV
219076789|NCT02899728|DRUG|Cediranib|Given PO
219076790|NCT02899728|DRUG|Cediranib Maleate|Given PO
219076791|NCT02899728|DRUG|Cisplatin|Given IV
219076792|NCT02899728|DRUG|Etoposide|Given IV
219076793|NCT02899728|DRUG|Olaparib|Given PO
219076794|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
219076795|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
219076796|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
219076797|NCT00208208|DRUG|Ziprasidone|
219076798|NCT02889991|OTHER|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
219076799|NCT02889991|OTHER|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
219076800|NCT02889991|OTHER|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
219076801|NCT02889991|OTHER|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling."
219076802|NCT05652517|PROCEDURE|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
219076803|NCT02157805|OTHER|beef meat|"Meat cooking conditions~1. st condition : beef meat cooked during 5 minutes at 55°C~2. nd condition : beef meat cooked during 30 minutes à 90°C"
219210197|NCT06798103|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved 3-5 cm laterally to identify the paravertebral space as the target injection site. After probe being rotated into transverse orientation, the needle will be inserted using the out-plane technique. Once the needle threads the internal intercostal membrane and arrives in the paravertebral space, 3 ml of normal saline will be injected firstly. If displacement sign of the pleura occurs, 25 ml of 0.25% bupivacaine will be then injected into the confirmed paravertebral space. The same technique will be repeated on the contralateral side.
219076804|NCT05214209|BEHAVIORAL|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
219076805|NCT05214209|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
219076806|NCT03789721|OTHER|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
219076807|NCT03789721|OTHER|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
219076808|NCT05557942|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
219076809|NCT03808675|BEHAVIORAL|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
219076810|NCT03808675|BEHAVIORAL|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
219076811|NCT06216002|DIAGNOSTIC_TEST|Train of four nerve stimulator|Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
219076812|NCT06218667|DRUG|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
219076813|NCT06218667|DRUG|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
219076814|NCT06218667|PROCEDURE|Radical Prostatectomy|Standard treatment
219679166|NCT00348036|BEHAVIORAL|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
219679167|NCT00348036|OTHER|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
219679168|NCT02893111|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
219679169|NCT03373461|DRUG|LNP023|LNP023 5, 25, 100 mg capsles
219076815|NCT02477618|DRUG|SAGE-547|
219076816|NCT02477618|DRUG|Placebo|Placebo
219076817|NCT03353818|BEHAVIORAL|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
219076818|NCT03353818|BEHAVIORAL|No intervention|Patients acting as controls will not be restricted in any ways.
219076819|NCT05283174|OTHER|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
219076820|NCT00433784|DRUG|Clopidogrel|
219076821|NCT00433784|PROCEDURE|Blood sampling - platelet aggregation|
219076822|NCT00433784|PROCEDURE|Blood sampling - genotyping|
219076823|NCT00371891|PROCEDURE|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
219076824|NCT01076569|OTHER|laboratory biomarker analysis|Correlative studies
219076825|NCT03961165|DRUG|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
219679170|NCT03373461|OTHER|Placebo|Matching placebo to LNP023
219679171|NCT01636089|DRUG|bicarbonates|sodium bicarbonates 1,4%
219679172|NCT01636089|DRUG|saline|sodium chloride 0,9%
219679173|NCT04298827|OTHER|Unimodal|Patients will receive physical therapy alone.
219076826|NCT03961165|DRUG|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
219076827|NCT02723838|BIOLOGICAL|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
219076828|NCT02723838|DRUG|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
219210198|NCT05035563|BEHAVIORAL|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. \- Training in communication to the health team~2. \- Written material~3. \- Family website~4. \- Standardized and daily telephone information~5. \- Health Team Support Strategy~6. \- Weekly multidisciplinary virtual meeting with the family~7. \- ICU diaries for family members"
219679174|NCT04298827|OTHER|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
219076829|NCT02723838|DRUG|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
219076830|NCT02680054|DRUG|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
219076831|NCT04036175|DEVICE|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%
219360463|NCT05659446|PROCEDURE|endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
219679175|NCT06955052|OTHER|"Minds In Motion The Maze"|"Minds in Motion the Maze is a program that combines physical activity with cognitive training. Research suggests that MIM can positively impact balance and gait in children with Down syndrome. Some potential benefits include:~* Improved balance and stability~* Enhanced gross motor skills~* Better coordination and overall physical function~* Increased confidence in physical abilities~The program's effectiveness may vary depending on individual needs and program implementation."
219679176|NCT06955052|OTHER|conventional treatment|"Document any specific motor challenges or deficits typical in children with down syndrome.~walk for 10 to 20 minutes warm up for 5 minutes cool down for 5 minutes rest period as per the subject convenience 6 stretching exercise performed during the warm and cool down period ,standing with feet together, standing with feet shoulder apart sitting with feet together ,sitting with feet shoulder width apart standing with only on leg extended , sitting with only one leg standing extended"
219679177|NCT06955078|OTHER|Visual Motor Integration|"The Beery Visual Motor Integration will be used to measure the integration of visual perception and motor skills as the participant children imitated and copied a developmentally sequential series of geometric forms using pencil and paper. As the task progressed, the levels of difficulty in geometric forms increased.~VP task will be used to measure an individual's visual abilities without the integration of fine motor skills. Children will be asked to point to the item in the array, which was identical to the target figure. The choices will be written on answer sheets by experimenters or children themselves. Elapsed time will be recorded beginning with Item 7, and the task discontinued after 3 minutes. Children will be told to connect dots and to draw within provided borders. Elapsed time was recorded beginning with Item 7 and the task ended up after 5 minutes."
219679178|NCT04892017|DRUG|Inlexisertib|Oral Tablet Formulation
219679179|NCT04892017|DRUG|Trametinib|Oral Tablet Formulation
219679180|NCT04892017|DRUG|Binimetinib|Oral Tablet Formulation
219679181|NCT04892017|DRUG|Sotorasib|Oral Tablet Formulation
219679182|NCT02480881|DRUG|BMS-663068|Investigational product
219679183|NCT02480881|DRUG|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
219679184|NCT02480881|DRUG|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
219679185|NCT06363019|BEHAVIORAL|Supporting at-risk Mothers Across perinatal period: a Randomized controlled Trial (SMART) mobile application|The intervention is delivered through the SMART mobile application. It contains educational information in audio, visual, article format; on parenting, pregnancy and managing emotional well-being. There is also a peer support feature where participants can speak to experienced mothers via the SMART app. There is also a forum feature where participants can interact with other mothers.
219679186|NCT00652847|DRUG|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
219679187|NCT00652847|DRUG|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
219076832|NCT06383975|PROCEDURE|Pulsed field ablation with posterior wall isolation|Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
219076833|NCT06383975|PROCEDURE|Radiofrequency ablation and vein of Marshall ethanolization|Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
219076834|NCT04800874|DRUG|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
219076835|NCT05568888|DRUG|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
219210199|NCT06832748|OTHER|VR neck training|VR intervention 8 weeks. A VR headset is used for assessment and training of sensorimotor functions of the neck. The VR headset has a built-in sensor which can measure movements and give objective test and training results. The results serve as a guide for tailored home-based training programs, also performed with the VR headset in the experimental group. The participant performs the training at home, 15-20 minutes/day 5 days/week, initiallay divided into 3 sessions of 5 minutes each, while progression may lead to longer but fewer sessions. The program is individually tailored to target specific sensorimotor disturbances, and progressed during the intervention to increase the challenge. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and every second week for the final 4 weeks. This can be adjusted to fit the participants needs. The VR is a novel technology, and this particular VR based training is not yet evaluated in research.
219210200|NCT06832748|OTHER|Endurance neck training|An 8-week traditional endurance neck training intervention. The training program consists of neck and shoulder exercises performed with body weight, rubber bands, and free weights. The training is carried out at home, 15-20 minutes per day, 5 days a week. The training is individualized and progressed during the intervention. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and then every second week for the final 4 weeks. This can be adjusted to fit the participants needs. This intervention is often used in the clinic and has been evaluated in several research studies with good results to reduce neck pain. However, its effects on sensorimotor functions have been less evaluated. Also, its effects compared to novel VR-training still needs to be evaluated.
219210201|NCT05417867|PROCEDURE|Biospecimen Collection|Undergo collection of stool and blood samples
219210202|NCT05417867|OTHER|Questionnaire Administration|Complete questionnaires
219076836|NCT05568888|DRUG|Placebo|Administered by IV infusion
219076837|NCT00003718|DRUG|temozolomide|
219076838|NCT04398277|BEHAVIORAL|Daily Coping Toolkit|"1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box."
219210203|NCT06785753|DRUG|Irrigation Solution|normal saline will be used as irrigation solution
219210204|NCT02544529|DRUG|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
219210205|NCT02544529|DRUG|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
219210206|NCT06780228|BEHAVIORAL|chatbot-assisted clinical learning|The participants will recevie a self-developed web-based chatbot platform which is accessible via smartphones. It provides real-time dialogue with the chatbot through texts, visual aids, and audio files. The intervention will be available throughout the 12-week study. the chatbot is characterized by a gender-neutral persona, assumes the role of a friendly and empathetic clinical mentor. Its communication style can be described as calm, tolerant, supportive, and appreciative. Participants will receive weekly SMS notifications to remind them to consult with the chatbot.
219210207|NCT06750679|OTHER|Compression bandage|A multicomponent inelastic compression bandage will be applied to the patient. Skin care and simple exercises will be added to intervention
219210208|NCT06750679|OTHER|Manual lymphatic drainage added to compression|Manual lymphatic drainage will be added to multicomponent inelastik compression bandage, skin care and simple exercises
219360464|NCT06061198|DEVICE|a virtual reality device|the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
219076839|NCT06585969|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtexan every three weeks
219076840|NCT06585969|DRUG|Ribociclib with ET|Ribociclib with endocrine therapy
219076841|NCT06585969|DRUG|Abemaciclib with ET|Abemaciclib with endocrine therapy
219076842|NCT06814002|DIETARY_SUPPLEMENT|Meal with 400 kilocalories|Meal with 400 kilocalories
219076843|NCT06814002|DIETARY_SUPPLEMENT|Meal without calories|Meal without calories
219076844|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
219076845|NCT03829215|DEVICE|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
219076846|NCT01839734|DRUG|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
219076847|NCT00655980|DRUG|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
219076848|NCT00655980|DRUG|Nitrous oxide and placebo|
219076849|NCT00655980|OTHER|standard of care|
219076850|NCT01146236|DEVICE|Sutures|Orthopedic surgical wounds closed with sutures
219076851|NCT01146236|DEVICE|Staples|Orthopedic surgical wounds closed with metallic staples
219076852|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
219076853|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
219076854|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
219076855|NCT02353923|DIETARY_SUPPLEMENT|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
219076856|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
219076857|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
219076858|NCT05202561|BIOLOGICAL|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
219076859|NCT05202561|BIOLOGICAL|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
219076860|NCT03007823|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
219076861|NCT06100627|DRUG|AP301|Orally administered
219076862|NCT06467006|OTHER|Use of IA for proximal humeral fracture prognosis|None (prognosis study)
219076863|NCT05540522|BIOLOGICAL|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
219076864|NCT05540522|BIOLOGICAL|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
219076865|NCT05555394|OTHER|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
219076866|NCT05555394|OTHER|Stretching Exercise|It consists in stretching movements of whole body
219076867|NCT02247505|DRUG|Harnal-D Cap. 0.2mg|
219076868|NCT02247505|DRUG|Cialis Tab. 5mg|
219076869|NCT03820661|DEVICE|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
219076870|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
219076871|NCT05435612|DEVICE|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
219076872|NCT03881345|DRUG|Anticoagulants|anticoagulation according to the main diagnosis
219076873|NCT03881345|PROCEDURE|Open surgery|removal of blood clots with open surgery
219076874|NCT03881345|PROCEDURE|Thrombolysis|removal of blood clots with thrombolysis
219076875|NCT03881345|PROCEDURE|Venous stenting|elimination of vein obstruction by stenting
219076876|NCT06669923|BEHAVIORAL|iSIPsmarter Program|web-based behavioral intervention to reduce sugary drink intake
219076877|NCT06669923|BEHAVIORAL|Patient Education|website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)
219076878|NCT06669065|DEVICE|extraoral versus intraoral scanning techniques|different data acquisition techniques for full-arch dental implants
219076879|NCT06670326|BEHAVIORAL|Imagery Rescripting|Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
219076880|NCT06669468|OTHER|PFME|All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
219076881|NCT06669468|OTHER|PFME + Anal ES|Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
219076882|NCT06669468|OTHER|PFME + Perineal ES|Perineal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
219076883|NCT03754803|OTHER|HIV symptom distress module (SDM) questionnaire|The SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
219076884|NCT03754803|OTHER|HIV treatment satisfaction questionnaire (TSQ)|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
219076885|NCT05933148|DEVICE|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
219076886|NCT05933148|DEVICE|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
219210209|NCT05754983|DRUG|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
219210210|NCT05081102|DRUG|FDC of oxycodone 5 mg/ibuprofen 400 mg|receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
219210211|NCT05081102|DRUG|Tylex|receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
219210212|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
219679188|NCT02475772|DRUG|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
219679189|NCT02475772|PROCEDURE|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
219076887|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
219076888|NCT00439907|PROCEDURE|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
219210213|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
219679190|NCT02252302|OTHER|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
219210214|NCT06821490|PROCEDURE|Targeted axillary dissection and subsequently a lymphadenectomy|Selective sentinel lymph node biopsy is performed, along with biopsy of the node marked at diagnosis. Subsequently, a lymphadenectomy is performed, with the three samples separated for pathological study during the same surgical procedure
219210215|NCT06809439|PROCEDURE|Non-Surgical Intervention|Oral hygiene instructions including tooth brushing, flossing, and interdental brushing were given to all patient groups before non-surgical periodontal treatment. In both periodontitis groups, scaling, and root surface smoothing were performed using ultrasonic instruments (Woodpecker Medicals Ins. Co., USA) and Gracey Curettes (Hu-Friedy, Chicago, IL, USA) under local anesthesia once a week for 4 weeks.
219210216|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (Baseline)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
219210217|NCT06809439|OTHER|Probing|Clinical and radiographic evaluations were performed by trained and calibrated examiners at Ankara University (SY) and Ataturk University (OT). Clinical parameters of probing depth (PPD), clinical attachment level CAL, plaque index PI, and bleeding on probing (BOP) were recorded from six tooth regions (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, middle lingual, and disto-lingual) using periodontal probe. Bone loss was assessed using panoramic radiographs, confirming the diagnosis of periodontitis.
219210218|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (After treatment)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
219210219|NCT06654167|OTHER|Low temperature (15℃) group|The exposure group will be exposed to low temperature (15℃) in a chamber for about 2 hours, resting during the whole period.
219679191|NCT02252302|OTHER|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
219679192|NCT02252302|DRUG|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
219076889|NCT00439907|PROCEDURE|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
219076890|NCT01951482|DRUG|Pemetrexed/Platinum|pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance every 3 weeks.
219076891|NCT01951482|DRUG|Bevacizumab and Pemetrexed/platinum|bevacizumab (7.5mg/kg, intravenously on day 1 of each 3-week cycle) plus pemetrexed-platinum chemotherapy (pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle) for four to six cycles, followed by bevacizumab plus pemetrexed maintenance every 3 weeks.
219076892|NCT05239039|DRUG|spesolimab|spesolimab
219076893|NCT06669637|DEVICE|Ablation|Ablation procedure for Atrial Fibrillation
219076894|NCT06670144|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan; Mediterranean diet)
219076895|NCT06670144|OTHER|Alcohol intake|(Frequency and intake of beer, wine, sherry, and spirits were collected by asking the number of specified units (pints, glasses or measures) of each type of alcoholic beverage (beer or cider, wine, sherry or fortified wines, and spirits) per week.)
219076896|NCT06670144|OTHER|Fruit and vegetables intake|(Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire)
219076897|NCT06670144|OTHER|Tea consumption|(Intake of tea from food frequency questionnaire)
219076898|NCT06670144|OTHER|Coffee consumption|(Intake of caffeinated coffee and decaffeinated coffee from food frequency questionnaire)
219076899|NCT06670144|OTHER|Fish intake|(Intake of fish from food frequency questionnaire)
219076900|NCT06670144|OTHER|Meat intake|(Intake of red meat, processed meat, and poultry from food frequency questionnaire)
219210220|NCT06654167|OTHER|Moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
219210221|NCT06656104|DEVICE|Reference strategy|Routine strategy based on the usual catheters and infusion systems used during the reference period
219210222|NCT06656104|DEVICE|Experimental strategy|EDELVAISS multi-infusion strategy as routine strategy during the experimental period
219210223|NCT00319696|DRUG|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
219210224|NCT00319696|DRUG|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
219210225|NCT06655753|OTHER|Reliability and Validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Temporomandibular Joint Disorders
219076901|NCT06670144|OTHER|Vitamin D intake|(Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake)
219076902|NCT06669390|DRUG|NG11-2|"NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution."
219076903|NCT06670898|DRUG|[14C] NS-580|Oral suspension
219076904|NCT05910736|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
219076905|NCT06613841|DRUG|Fluciclovine F18|To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
219076906|NCT06672718|DRUG|SPY002-091|Experimental
219076907|NCT06672718|OTHER|Placebo|Placebo
219076908|NCT05424068|BEHAVIORAL|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
219210226|NCT06854588|DIAGNOSTIC_TEST|Point-of-care ultrasound|POCUS screening will be conducted to measure the maximum diameters at end diastole of the aortic root, ascending aorta, aortic arch, and descending thoracic aorta.
219210227|NCT06853756|DEVICE|Ambu Auragain|Ambu Auragain was inserted after induction.
219076909|NCT05424068|BEHAVIORAL|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
219076910|NCT04951336|DIETARY_SUPPLEMENT|FoTv|Fomitopsis Officinalis and Trametes Versicolor
219076911|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
219076912|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
219076913|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
219076914|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
219076915|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
219076916|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
219076917|NCT00645398|DRUG|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
219076918|NCT00645398|DRUG|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
219076919|NCT00645398|DRUG|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
219076920|NCT00645398|DRUG|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
219076921|NCT06670430|DEVICE|experimental group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
219210228|NCT06853756|DEVICE|I-gel|The I-gel device was inserted after induction.
219210229|NCT06818058|DRUG|Brimonidine tartrate Gel|Once daily applications for 7 days
219210230|NCT06818058|DRUG|Placebo gel (no Brimonidine tartrate)|Once daily applications for 7 days
219360465|NCT03978559|DRUG|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
219360466|NCT03978559|DRUG|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
219360467|NCT03978559|DRUG|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
219076922|NCT06670430|DEVICE|control group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
219076923|NCT06670066|BEHAVIORAL|Let's Talk Birth Control|Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
219076924|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU +PD 1|Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
219076925|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU|Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
219076926|NCT06668974|OTHER|Mendelian Randomization|This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.
219076927|NCT06669273|OTHER|CEST MRI sequence at 3T|"The MRI will be performed at the Clermont Ferrand University Hospital on the 3T research MRI on a Siemens MRI system (MAGNETOM VIDA, Siemens Healthcare, Erlangen, Germany), the emission of the radiofrequency pulses and the reception of the signal will be done using a coil dedicated to the abdo-pelvic region. The images will be analyzed by the radiologist.~MRI is non-irradiating medical imaging. It is practiced according to good practices and the recommendations of the French Society of Radiology.~* Acquisition of morphological T1, T2 sequences for the identification of areas of interest on the pelvic area.~* Acquisition of the CEST MRI sequence (acquisition time 5 min)~* Acquisition of functional sequences, DWI diffusion-weighted images and dynamic DCE sequence after injection of a single dose of non-linear gadolinum.~The imaging report will reveal the presence or absence of tumor lesions in the prostate and their location. Data will then be compared to the histopathological analysis."
219076928|NCT07002216|DRUG|Brentuximab Vedotin|Participants will receive 1.8 mg/kg of Brentuximab Vedotin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076929|NCT07002216|DRUG|Etoposide|Participants will receive 150 mg/m\^2 of Etoposide intravenously (IV) for up to 60 minutes on Days 1-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076930|NCT07002216|DRUG|Cyclophosphamide|Participants will receive 1250 mg/m\^2 of Cyclophosphamide intravenously (IV) for up to 60 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076931|NCT07002216|DRUG|Doxorubicin|Participants will receive 40 mg/m\^2 of Doxorubicin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076932|NCT07002216|DRUG|Dacarbazine|Participants will receive 250 mg/m\^2 of Dacarbazine intravenously (IV) for up to 120 minutes on Days 2-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076933|NCT07002216|DRUG|Dexamethasone|Participants will self-administer 40 mg of Dexamethasone orally on Days 1-4 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
219076934|NCT00936390|DRUG|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
219679193|NCT02252302|DRUG|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
219679194|NCT02252302|OTHER|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
219076935|NCT00936390|DRUG|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
219076936|NCT00936390|DRUG|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
219076937|NCT00936390|RADIATION|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
219360468|NCT01405053|DRUG|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
219679195|NCT02252302|OTHER|Filtered air|Participants will be breathing filtered air
219679196|NCT00963976|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
219679197|NCT03413475|BEHAVIORAL|quality of life|
219679198|NCT03351088|PROCEDURE|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
219679199|NCT03576443|DRUG|Idelalisib|Idelalisib 150 mg x 2 p o
219679200|NCT03249168|DRUG|Duloxetine 60mg|tablet
219679201|NCT03249168|DRUG|Placebo|Tablet
219679202|NCT06487715|DRUG|albumin-bound paclitaxel (260 mg/m2, d1)|260 mg/m2, d1)
219679203|NCT06487715|DRUG|S-1|80 mg/m2, d1-14
219679204|NCT06487715|DRUG|sintilimab|200 mg, d1
219679205|NCT06487715|DRUG|bevacizumab|First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
219679206|NCT02627573|PROCEDURE|Unrelated allogeneic stem cell transplantation|
219679207|NCT02627573|DRUG|Busulfan|
219679208|NCT02627573|DRUG|Fludarabine monophosphate|
219076938|NCT06091189|BEHAVIORAL|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
219076939|NCT06091189|DRUG|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
219076940|NCT06091189|BEHAVIORAL|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
219076941|NCT06091189|BEHAVIORAL|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
219076942|NCT06091189|BEHAVIORAL|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
219076943|NCT06670742|DEVICE|running|Running 10 kilometers on a treadmill
219076944|NCT07126860|BEHAVIORAL|Structured combined resistance and aerobic training|"The 12-week intervention phase comprises the initial 12 weeks of a home-based combined resistance and aerobic training protocol for the intervention arm. Training will commence 8 weeks (when medically cleared, a reduction to minimally 4 weeks is possible) after RP or completion of EBRT, or any time for PC patients undergoing systemic treatment. As part of their visit for baseline testing, participants will be familiarized with the online platform incorporating the training program, including the correct execution of the exercises. In addition, the online platform includes demonstration videos of all exercises.~Detailed information about the training program will be available for patients and investigators via a website and smartphone application. Additionally, participants will receive a printed document explaining the training program, the repetitions in reserve (RIR) scale (Helms et al., 2016), and the online tool/app for tracking."
219076945|NCT07126860|BEHAVIORAL|Standard of Care|Participants randomized to the SOC arm will also be informed about the benefits of exercise and motivated to engage in exercise under their own management (self-directed exercise). They will receive a booklet with general information and guidelines about physical activity in prostate cancer patients, but without any specific exercise prescriptions.
219076946|NCT07127952|DEVICE|Video Capillaroscopy|A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.
219076947|NCT07126847|DIAGNOSTIC_TEST|Renal Ultrasonography|To investigate the primary and secondary signs of stones with ultrasound and to additionally use the Stone criteria in patients with suspected nephrolithiasis.
219076948|NCT04348604|BEHAVIORAL|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
219210231|NCT06820489|PROCEDURE|Conventional connective tissue graft after immediate implant placement|A pouch is made in the buccal mucosa extending 3 mm below the buccal bone crest. Thereupon, a free gingival graft is harvested from the palatal mucosa and de-epithelialized. The CTG is brought into the pouch and fixed with two single sutures onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
219210232|NCT06820489|PROCEDURE|Scarf connective tissue graft after immediate implant placement|No pouch is made in the recipient site. A free gingival graft is harvested from the palatal mucosa and de-epithelialized. The small CTG is fixed at the transmucosal aspect onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
219679209|NCT02627573|DRUG|Tacrolimus|
219679210|NCT02627573|DRUG|Mycophenolate mofetil|
219679211|NCT02627573|DRUG|Cyclophosphamide|
219679212|NCT02627573|DRUG|Thymoglobulin|
219679213|NCT03227393|BEHAVIORAL|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
219679214|NCT01008865|PROCEDURE|Studer Pouch orthotopic urinary diversion|
219679215|NCT01008865|PROCEDURE|T-Pouch orthotopic urinary diversion|
219679216|NCT06955312|BEHAVIORAL|Experimental|Description: After collecting the pre-test data, pregnant women in the experimental group will be informed about the paint-by-numbers activity, and the materials to be used will be introduced. Participants in the experimental group will be asked to choose one of the 40x50 cm paintings. They will then be instructed to complete the painting. Pregnant women will be asked to paint the selected canvas at their convenience over approximately five days. Once the paint-by-numbers activity is completed, participants will be asked to fill out the post-test questionnaires, and final data from the experimental group will be collected, marking the end of the data collection process. After data collection, participants will be gifted their completed paintings, which they can hang in their children's rooms.
219679217|NCT00006929|DRUG|suramin|Given IV
219679218|NCT00006929|DRUG|carboplatin|Given IV
219679219|NCT00006929|DRUG|paclitaxel|Given IV
219679220|NCT00006929|OTHER|pharmacological study|Correlative studies
219076949|NCT04348604|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
219076950|NCT02097108|DRUG|Raltegravir|
219076951|NCT06633640|COMBINATION_PRODUCT|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.|The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.
219076952|NCT02546583|DRUG|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
219076953|NCT02546583|DRUG|IV Chlorothiazide|
219076954|NCT04111445|DRUG|ADG116|IV infusion at Day 1 of each cycle
219679221|NCT00006929|OTHER|laboratory biomarker analysis|Correlative studies
219679222|NCT04940663|BEHAVIORAL|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
219679223|NCT04646018|OTHER|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
219679224|NCT04646018|OTHER|Sham Manipulation|Lumbar non-thrust manipulation without force applied
219679225|NCT04655781|PROCEDURE|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
219679226|NCT02939209|DRUG|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
219076955|NCT07127939|DIAGNOSTIC_TEST|AI-based Ocular Diagnosis Model for TCM Constitutions|AI-based Ocular Diagnosis Model for Identifying Traditional Chinese Medicine (TCM) Constitutions
219076956|NCT07128004|DEVICE|tDCS|would provide direct current for 40 minutes in 20 minute interval at 2 mA
219076957|NCT07128004|DEVICE|sound therapy|would provide acoustic ripples along with tDCS
219076958|NCT07127458|DRUG|Adolescent PCOS group receiving oral contraceptives|Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.
219076959|NCT06741449|PROCEDURE|keystone flap|facio-cutaneous flap used to cover the defect after removal of the disease
219076960|NCT06741449|PROCEDURE|lay open|after removal of the disease, the wound is left open to heal by granulation tissue
219076961|NCT06713603|BEHAVIORAL|TAMI Coach|The investigators address the problems of intrinsic motivation, Evidence Based Practice (EBP) education, and referral tailoring using a digital-coaching intervention that 1) promotes readiness to change, 2) educates and builds confidence about EBP's, and 3) creates a tailored quit plan sensitive to social obstacles and needs.
219076962|NCT06873360|OTHER|Clinical interviews with patients and Usability interviews and glove testing.|"Clinical interviews with patients: These will be conducted by nursing staff with an approximate total of 50 patients during their treatment at the Hospital. Each interview will last 15 minutes. Under no circumstances will the patient be required to answer any question.~Usability interviews and glove testing: 10 patients selected from the previous interviews will test different gloves with various textures and levels of stiffness. Additionally, other questions will be asked focusing on refining the design. This evaluation will help determine the most suitable materials for the device's manufacturing, achieving a balance between comfort, discretion and functionality."
219210233|NCT06820489|PROCEDURE|Dual zone concept after immediate implant placement|DBBM is applied and condensed up to the level of the buccal soft tissue margin. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Usually, sutures are not needed in this group, unless minimal papilla opening was required to extract the tooth. In that case, sutures will be removed after 1 week.
219210234|NCT06766149|BEHAVIORAL|CogniFit Computerized Cognitive Training|In the CogniFit Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory, attention, and inhibitory control, with automatic level advancement after each exercise.
219679227|NCT02939209|DRUG|Placebo|Patients may be randomized to placebo.
219679228|NCT05678712|DEVICE|Access to CGM data (Dexcom G6)|Acces to CGM data (not blinded CGM)
219679229|NCT05341050|DRUG|TKI|halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
219679230|NCT05606432|OTHER|Instructor-led, one-on-one M2M exercise group|Participants will attend 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. Each session will last from 25 to 50 minutes by increasing 5 to 10 minutes each week. The exercise program will focus on improving cardiorespiratory fitness using a series of movement patterns accompanied by music. The program will be tailored to individuals' abilities (e.g., use of arms only vs. truck movement together; slow vs. fast tempo music). The exercise will be prescribed at a moderate intensity level (working somewhat hard with increased heart rate and breathing rate). For the follow-up phase (weeks 25-36), participants will receive the recorded M2M exercise sessions between the M2M instructors and themselves to continue to exercise for the remaining 12 weeks.
219076963|NCT06887036|DRUG|Methylene Blue|"Subjects will be initially treated with an initial dose of 200mg/day for 8 weeks at which point the investigators will assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 400mg/day for the following 8 weeks and the investigators will then again assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 600mg/day for the following 8 weeks and the investigators will then assess the effect of the treatment."
219076964|NCT07074444|DRUG|Albendazole|Participants receive albendazole tablets orally at a total daily dose of 10 mg/kg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
219076965|NCT07074444|DRUG|Tribendimidine|Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.
219076966|NCT07074444|DRUG|praziquantel|Participants receive praziquantel tablets orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
219076967|NCT07086482|COMBINATION_PRODUCT|Cyanoacrylate tissue adhesive|Cyanoacrylate tissue adhesive is a chemical synthetic and hybrid tissue sealant possessing strong, rapid acting adhesive properties and is often used in general surgery. Recently, cyanoacrylate tissue adhesive has been effectively introduced into dentistry to close wounds and stop ischemic areas from forming in periodontal aesthetic surgeries. As well as in exposed membranes to preserve the bone graft after guided bone regeneration, in post-extraction sockets, and to seal any surgical flap. This material has strong hemostatic, bacteriostatic, and sealing qualities.
219076968|NCT07086482|DEVICE|Collagen sponge|Collagen sponge is an organic polymer that promotes the development of blood clots, and it resorbs quickly and completely over time. Collagen sponge create a matrix at the bleeding site, encourage platelet activation and aggregation, and engage the extrinsic coagulation pathway. Thus, it can be utilized as the first choice for wound healing.
219076969|NCT07086742|DEVICE|Smart Mask V1 System|PPG-based sensors integrated into a PAP-compatible face mask to measure SpO2 and PR.
219076970|NCT07085754|BEHAVIORAL|Sleep Deprivation|Sleep deprivation for up to 24 hours with no naps or other sleep periods
219076971|NCT07085000|OTHER|No Intervention - Observational Assessment|No intervention is applied. Preoperative cognitive status (MoCA) and physical frailty (CFS) are assessed as part of observational data collection. Postoperative follow-up includes decision satisfaction and adherence evaluations.
219076972|NCT06904079|OTHER|Gamified Digital Rehabilitation|The gamification intervention measures are as follows: Currently, the initial version of the community mental health rehabilitation interactive game mainly focuses on six dimensions of medication management, including the importance of taking medication, identifying and dealing with adverse reactions to antipsychotic drugs, learning self-management of medication, assessing the effectiveness of medication treatment, long-term management of medication treatment, and discussing issues related to medication effects with medical staff. Next, we will continue to design a series of games themed on symptom management and psychological rehabilitation, and implement game-based digital rehabilitation interventions for patients in the intervention group based on these games.
219076973|NCT06904079|BEHAVIORAL|Routine Care|Receive regular psychiatric medication treatment and regular community rehabilitation services, including regular follow-ups, rehabilitation guidance, and community education,etc.
219076974|NCT06888102|DRUG|Neoadjuvant Epigenetic Therapy|Participants will be assigned to receive one of the study interventions and will be monitored for safety and response. The duration of epigenetic therapy will be dependent on the treatment administered and will continue for the duration described in the cohort appendix for each respective combination, unless the participant: is no longer clinically benefiting (NLCB, as evidenced by symptomatic or radiographic disease progression and/or clinical deterioration); experiences any toxicity meeting specified discontinuation criteria (as described in the cohort appendix for each respective combination) or unacceptable toxicity in the best clinical discretion of the treating physician (i.e., Investigator discretion); reaches the maximum duration of study intervention; or withdraws consent.
219076975|NCT07082283|PROCEDURE|Pacing Protocol for Pacing Group|"At four standardized time points (H0: arrival in the ICU, H6, H12, H24), a transient pacing sequence at 70, 80, and 90 bpm is conducted, with each rate applied for 10 minutes to allow stabilization, followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a spontaneous rhythm between 50 and 69 bpm, measurements are taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a spontaneous rhythm between 70 and 79 bpm, measurements are taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a spontaneous rhythm between 80 and 89 bpm, measurements are taken at the spontaneous rate, then at 90 bpm~* If the patient has a spontaneous rhythm ≥ 90 bpm, measurements are taken at the spontaneous rate only"
219210235|NCT06766149|BEHAVIORAL|Cogmed Computerized Cognitive Training|In the Cogmed Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory and attentional control, with automatic level advancement after each exercise.
219210236|NCT06768905|DRUG|Iomab-B|single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.
219076976|NCT07082283|PROCEDURE|Pacing Protocol for Non-pacing Group|"At H0, H6, H12, and H24, they will undergo transient pacing at 70, 80, and 90 bpm, following the same measurement protocol (10 minutes per rate), followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a rhythm between 50 and 69 bpm, measurements will be taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a rhythm between 70 and 79 bpm, measurements will be taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a rhythm between 80 and 89 bpm, measurements will be taken at the spontaneous rate, then at 90 bpm~* If the patient has a rhythm ≥ 90 bpm, measurements will be taken at the spontaneous rate only~Outside the pacing periods at different rates, patients in the non-pacing group will remain on their spontaneous sinus rhythm."
219076977|NCT06144151|DEVICE|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
219076978|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
219076979|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
219076980|NCT07094386|PROCEDURE|External Oblique Intercostal Plain Block|The patient will be placed in the supine position. After sterilization of the skin, a high-frequency linear probe (6-13 MHz) will be placed obliquely medial to the anterior axillary line, the 6th and 7th ribs, skin, subcutaneous tissues, and external oblique muscle \[EOM\], intercostal muscles, pleura, and the lung will be identified. An 80 mm 22-gauge block needle (Stimuplex® D, BBraun, Germany) will be inserted in-plane to the US-probe in a craniocaudal direction directed under EOM. After confirmation of negative blood aspiration, 2-3 mL of normal saline will be injected for hydro-dissection to verify the correct needle tip placement then 30 mL of 0.25% bupivacaine will be injected between the EOM and intercostal muscles
219076981|NCT07094386|PROCEDURE|Quadratus Lumborum Block|Quadratus lumborum block will be performed. The patient will be placed in the lateral decubitus position After sterilization of the skin, a low frequency convex probe (5-8 MHz) will be positioned horizontally in the anterior axillary line half way between the subcostal margin and the iliac crest then will be advanced in the cranial direction to visualize the triple abdominal muscle layers and identifying the posterior border of the EO muscle (hook sign) with the underlying IO musclenforming a roof over the QL muscle. The QL muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. An 80 mm 22-gauge block needle will be inserted in-plane to the US-probe in an anterolateral to posteromedial direction. The needle tip will be placed between the middle layer of the thoracolumbar fascia and the QL muscle. After confirmation of negative blood aspiration, 30 mL of 0.25% bupivacaine will be injected.
219076982|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the External Oblique Intercostal Plain Block under ultrasound guidance, after confirming needle placement between the external oblique and intercostal muscles.
219076983|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the Quadratus Lumborum Block under ultrasound guidance, after confirming of correct needle placement and negative aspiration.
219076984|NCT06907615|DRUG|HLX43 DOSE 1 (2.0 mg/kg)|Dose 1; 2.0 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219076985|NCT06907615|DRUG|HLX43 DOSE 2 (2.5 mg/kg)|Dose 2; 2.5 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219076986|NCT07098260|BEHAVIORAL|DECIDE for MOM Provider Training|Participants will take an asynchronous online DECIDE for MOM provider training (approximately 3hours). DECIDE stands for Decide the problem; Explore the questions; Closed or open-ended questions; Identify the who, why, or how of the problem; Direct questions to your health care professional; Enjoy a shared solution. The 5 modules will cover shared decision-making, perspective-taking, patient activation, attributional errors, and being a responsive provider to perinatal individuals.
219076987|NCT07103057|DEVICE|Viz HCM|Viz HCM is a Software as a Medical Device (SaMD) intended to receive 12-lead ECG recordings collected as part of a routine clinical assessment and analyze them in parallel to the standard of care. The device uses a machine learning based algorithm to analyze 12-lead ECGs and identify ECGs with suspected HCM.
219076988|NCT07108205|DEVICE|Paired reading analysis|Paired side be side evaluation Each reader will assess- Image Quality (IQ) \& Diagnostic Confidence Ratings will be recorded using a 5-point Likert scale
219076989|NCT07116278|DEVICE|QuantalX DELPHI-MD (TMS-EEG)|Direct Electro-Physiological Imaging medical device (DELPHI-MD), developed by QuantalX Neuroscience, is a neurophysiological assessment system which utilizes a specific TMS-EEG protocol that automatically analyzes specific features of this brain response to reproduce numerical output measures. DELPHI-MD has previously shown to differentiate different healthy age groups, mild dementia and Parkinson's Disease (PD) from age matched healthy control. In addition, DELPHI-MD measures are correlated to white matter microstructural differences in post stroke and TBI patients. This multimodal approach allows for the evaluation of several neurophysiological mechanisms such as cortical reactivity, excitation and inhibition in local and distal regions, effective connectivity, and neural plasticity, characterized as modifications that outlast the stimulation period. The investigators predict that Delphi-MD has the potential to identify features of brain function altered in pain syndromes.
219076990|NCT07121153|DRUG|NNC0487-0111 A|Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
219076991|NCT07121153|DRUG|Placebo A|Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.
219076992|NCT02107209|PROCEDURE|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
219076993|NCT04274452|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
219076994|NCT04274452|OTHER|Placebo|Intravenous infusion of placebo
219210237|NCT06768905|DRUG|CAR-T cell|CAR-T cell therapy
219210238|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|\- Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester
219679231|NCT05606432|OTHER|Self-guided control with pre-recorded standard exercise videos|Participants will exercise for 36 weeks using pre-recorded exercise videos. The videos include warm-up, flexibility, muscular strength, aerobic endurance, balance, and cool-down.
219679232|NCT00707967|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
219679233|NCT00707967|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
219679234|NCT00707967|BIOLOGICAL|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
219679235|NCT02319252|DEVICE|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
219679236|NCT02319252|DEVICE|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
219679237|NCT03018275|BIOLOGICAL|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
219679238|NCT03117634|DRUG|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
219679239|NCT03117634|DRUG|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
219679240|NCT02245815|DIETARY_SUPPLEMENT|use probiotics boucardii|group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
219679241|NCT02245815|DIETARY_SUPPLEMENT|use probiotics Multi-species|Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
219679242|NCT01919164|DRUG|Sprifermin|Participants received Sprifermin as intra-articular injection.
219076995|NCT04560166|DRUG|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"* Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
219076996|NCT04010071|DRUG|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
219076997|NCT04826601|OTHER|essential oils|A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
219076998|NCT06020222|DEVICE|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
219679243|NCT01919164|DRUG|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
219679244|NCT01736735|DRUG|CLP|
219679245|NCT01736735|DRUG|placebo|
219679246|NCT04052607|DRUG|LH Suppression|Stimulation protocols
219679247|NCT00532909|DRUG|Vandetanib|100mg or 300mg By mouth every day continuous
219679248|NCT00532909|DRUG|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
219679249|NCT00532909|DRUG|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
219679250|NCT00532909|DRUG|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
219679251|NCT00435110|PROCEDURE|standard ventilatory settings|
219679252|NCT00435110|PROCEDURE|PEEP and FiO2|
219679253|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
219679254|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
219679255|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
219679256|NCT01686945|DRUG|placebo|Placebo semaglutide. For oral administration.
219679257|NCT01686945|DRUG|placebo|Placebo semaglutide with carrier. For oral administration.
219679258|NCT00588146|DRUG|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
219679259|NCT00588146|OTHER|Standard care|Standard care
219679260|NCT00302536|DRUG|Tacrolimus|Tacrolimus
219679261|NCT03902093|DIAGNOSTIC_TEST|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
219679262|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
219679263|NCT02823470|DRUG|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
219679264|NCT02823470|DEVICE|activated smart device|
219679265|NCT02823470|DEVICE|de-activated smart device|
219076999|NCT06020222|OTHER|education|Provide preventive CIPN education leaflets
219077000|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
219077001|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
219077002|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
219077003|NCT00432757|DRUG|Ketotifen with a Contact Lens (generic name not yet established)|
219077004|NCT03910413|DIAGNOSTIC_TEST|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
219210239|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester + Whey Protein (KET+PRO)|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
219210240|NCT06769100|DIETARY_SUPPLEMENT|Whey Protein (PRO)|"* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
219210241|NCT06769100|DIETARY_SUPPLEMENT|Flavour matched placebo (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
219210242|NCT06769100|OTHER|Resistance exercise|\- 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.
219210243|NCT06734884|DRUG|Benralizumab 30 MG/ML [Fasenra]|Subcutaneous injection 30 mg at day 2, week 4 and week 8.
219679266|NCT04356157|BEHAVIORAL|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
219679267|NCT03442725|DRUG|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
219679268|NCT00463801|DRUG|Daptomycin|
219679269|NCT00826098|BIOLOGICAL|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
219077005|NCT03230227|DRUG|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
219077006|NCT03230227|DRUG|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
219077007|NCT03143114|PROCEDURE|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
219077008|NCT00997087|DRUG|Flumazenil|Sublingual daily
219077009|NCT03786731|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
219077010|NCT03339674|BEHAVIORAL|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
219077011|NCT03339674|BEHAVIORAL|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
219679270|NCT02667314|BEHAVIORAL|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
219679271|NCT02667314|BEHAVIORAL|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
219679272|NCT04241913|BEHAVIORAL|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
219679273|NCT05077553|DIETARY_SUPPLEMENT|TCI999 probiotic sachet|Testing product
219679274|NCT05077553|DIETARY_SUPPLEMENT|Placebo sachet|Blank
219077012|NCT03877094|BEHAVIORAL|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
219077013|NCT03962387|OTHER|Not applicable(observational study)|Not applicable(observational study)
219210244|NCT06734884|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Subcutaneous injection at day 2, week 4 and week 8
219077014|NCT05453825|BIOLOGICAL|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
219077015|NCT05453825|BIOLOGICAL|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
219077016|NCT05453825|BIOLOGICAL|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
219077017|NCT04519840|OTHER|nill|nill
219077018|NCT05895032|OTHER|Exercise|12-week exercise intervention
219077019|NCT05895032|OTHER|Usual Care|usual care
219077020|NCT05518656|BEHAVIORAL|Experimental intervention|Daily lessons received by email to be completed the same day
219077021|NCT05518656|BEHAVIORAL|Comparison intervention|Daily lessons receive by email to be completed the same day
219077022|NCT03259633|DRUG|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
219077023|NCT00019916|BIOLOGICAL|aldesleukin|
219077024|NCT00019916|BIOLOGICAL|p53 peptide vaccine|
219077025|NCT00019916|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219077026|NCT02789280|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
219077027|NCT02789280|OTHER|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
219077028|NCT00955357|DRUG|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
219077029|NCT06263621|BEHAVIORAL|"Intervention Standard"|"The two cafes will offer entrees in two sizes, a smaller and larger size. In the intervention cafe, the smaller size will be labeled Standard during the intervention period, and Small during all other times. In the control cafe, the smaller size will always be labeled Small. The larger size will always be labeled Large for both cafes during the duration of the study."
219077030|NCT01258608|DRUG|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
219077031|NCT01258608|DRUG|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
219077032|NCT01258608|DRUG|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
219077033|NCT00000779|BIOLOGICAL|Aluminum hydroxide|
219077034|NCT00000779|BIOLOGICAL|MF59|
219077035|NCT00000779|BIOLOGICAL|rgp120/HIV-1IIIB|
219077036|NCT00000779|BIOLOGICAL|rgp120/HIV-1MN|
219077037|NCT00000779|BIOLOGICAL|rgp120/HIV-1 SF-2|
219077038|NCT00000779|BIOLOGICAL|Env 2-3|
219077039|NCT01719835|DRUG|Cyclophosphamide|750mg/m2 IV every 21 days
219077040|NCT01719835|DRUG|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
219077041|NCT01719835|DRUG|Doxorubicin|50mg/m2 IV every 21 days
219077042|NCT01719835|DRUG|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
219077043|NCT01719835|DRUG|Prednisolone|100mg PO Days 1-5 every 21 days
219077044|NCT01719835|DRUG|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
219077045|NCT01719835|DRUG|Cisplatin|100mg/m2 IV Day 15 every 28 days
219077046|NCT05670899|PROCEDURE|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
219077047|NCT03204253|DRUG|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
219077048|NCT03204253|DRUG|rFSH alone|32 women who were stimulated with recombinant FSH alone
219077049|NCT03853668|BEHAVIORAL|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
219077050|NCT01437826|DRUG|antioxidants|tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
219077051|NCT01437826|DRUG|placebo|placebo had an identical appearance as intervention
219077052|NCT01140217|DRUG|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
219077053|NCT04710810|OTHER|umbilical cord blood mononuclear stem cells|UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
219077054|NCT01532115|DRUG|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
219077055|NCT01532115|DRUG|Placebo|single-dose
219077056|NCT01532115|DRUG|moxifloxacin|400 mg moxifloxacin (single-dose)
219077057|NCT01726881|DEVICE|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel."
219077058|NCT01726881|DEVICE|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
219077059|NCT01726881|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
219077060|NCT05885152|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
219077061|NCT05638399|DRUG|Denosumab 60 mg/ml [Prolia]|60 mg subcutaneously per 6 month
219077062|NCT05638399|DRUG|Zoledronate|5mg, intravenous infusion once a year
219077063|NCT01835392|PROCEDURE|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
219077064|NCT01835392|OTHER|Control|Sham placement of blood pressure cuff without inflation
219077065|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
219077066|NCT01252823|DEVICE|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
219360469|NCT01405053|DRUG|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
219077067|NCT04928963|DIETARY_SUPPLEMENT|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
219679275|NCT02315664|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
219679276|NCT02315664|BEHAVIORAL|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
219679277|NCT01451099|BIOLOGICAL|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
219679278|NCT02922465|DRUG|K-877|
219679279|NCT02922465|DRUG|Clopidogrel|
219077068|NCT02943408|BEHAVIORAL|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
219077069|NCT02943408|BEHAVIORAL|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
219077070|NCT04275466|PROCEDURE|necrotic cavity lavage|"1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is \>100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is \>38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
219077071|NCT03263754|BEHAVIORAL|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
219077072|NCT03263754|BEHAVIORAL|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
219077073|NCT01241357|DEVICE|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
219077074|NCT04352179|BEHAVIORAL|Virtual Education Simulation|"The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~1. Fitness \& Nutrition~2. Smoking Cessation~3. Alcohol Use~4. Distress \& Anxiety"
219077075|NCT02396654|OTHER|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
219077076|NCT05678764|DEVICE|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
219077077|NCT02181803|DRUG|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
219077078|NCT02181803|DRUG|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
219077079|NCT02181803|DRUG|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
219210245|NCT06892405|DEVICE|SonoSite™ S Series ultrasound|"US measurements will be performed in the pre-operating room a~, patients are placed in supine position with the head in a sniffing position on a surgical pillow and using the 15 MHz linear array transducer of the SonoSite™ S Series ultrasound in transverse position. A scan is made from the skin surface of the floor of the mouth to the trachea exerting the minimum possible pressure to identify the structures correctly."
219679280|NCT05249387|DRUG|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
219679281|NCT05249387|DRUG|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
219679282|NCT05249387|DRUG|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
219679283|NCT05249387|DRUG|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
219679284|NCT03450408|PROCEDURE|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
219077080|NCT05113628|DIAGNOSTIC_TEST|methylene blue identification|"After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl."
219679285|NCT03843320|DEVICE|SAPIEN 3|Transcatheter aortic valve replacement
219077081|NCT03278938|DRUG|bupropion|FDA approved drug for treating depression
219679286|NCT03843320|DEVICE|SAPIEN XT|Transcatheter aortic valve replacement
219679287|NCT03843320|DEVICE|INSPIRIS RESILIA|Surgical aortic valve replacement
219679288|NCT03843320|DEVICE|EDWARDS INTUITY|Surgical aortic valve replacement
219679289|NCT03843320|DEVICE|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
219679290|NCT05695729|OTHER|PLYOMETRIC EXERCISE PROGRAM|"This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band"
219679291|NCT05695729|OTHER|CONVENTIONAL EXERCISE PROGRAM|"This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds"
219679292|NCT00399698|DRUG|Risperdal|
219679293|NCT01236625|PROCEDURE|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
219679294|NCT04023214|DIAGNOSTIC_TEST|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
219679295|NCT01718587|PROCEDURE|stem cell transplantation through interventional procedure|interventional procedure once
219679296|NCT01718587|DRUG|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
219679297|NCT01973517|DRUG|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
219077082|NCT03278938|DRUG|citalopram|FDA approved treatment for depression
219077083|NCT04945317|OTHER|ROSE (presence of cytotech) & liquid prep|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
219077084|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & liquid prep|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
219077085|NCT04945317|OTHER|ROSE (presence of cytotech) & tissue clot sample|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
219077086|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & tissue clot sample|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
219077087|NCT01620866|OTHER|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
219679298|NCT01973517|DRUG|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
219679299|NCT03750877|PROCEDURE|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
219679300|NCT03750877|PROCEDURE|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
219679301|NCT05418439|DIETARY_SUPPLEMENT|Drink Poppi Soda|Drink Poppi Vinager Soda
219679302|NCT03814902|DEVICE|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
219679303|NCT01222312|DRUG|Cisplatin|75 mg/m2, d1 every 3 weeks
219679304|NCT01222312|DRUG|Oxaliplatin|85 mg/m², d1 every 2 weeks
219679305|NCT01222312|DRUG|Docetaxel|75 mg/m2, d1 every 3 weeks
219679306|NCT01222312|DRUG|Docetaxel|50mg/m2, d1 every 2 weeks
219679307|NCT01431313|DRUG|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
219679308|NCT00301912|BIOLOGICAL|filgrastim|
219679309|NCT00301912|DRUG|busulfan|
219679310|NCT00301912|DRUG|fludarabine phosphate|
219679311|NCT00301912|DRUG|methotrexate|
219679312|NCT00301912|DRUG|tacrolimus|
219679313|NCT00301912|PROCEDURE|allogeneic bone marrow transplantation|
219077088|NCT05559034|BEHAVIORAL|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
219077089|NCT03162575|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
219077090|NCT03151005|DRUG|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
219077091|NCT03151005|DRUG|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
219077092|NCT01263951|DRUG|Everolimus|One 5 mg. tablet daily.
219679314|NCT00301912|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219679315|NCT00301912|PROCEDURE|peripheral blood stem cell transplantation|
219679316|NCT03604848|DRUG|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
219679317|NCT03604848|DRUG|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
219679318|NCT03604848|DRUG|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
219679319|NCT03604848|DRUG|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;"
219679320|NCT02748057|DRUG|Ezetimibe|
219077093|NCT01263951|DRUG|Sorafenib|200 mg. twice daily.
219077094|NCT03531047|PROCEDURE|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
219077095|NCT06635928|DEVICE|Bright light therapy|30min daily of 10.000 lux bright light therapy
219679321|NCT02748057|DRUG|Rosuvastatin|
219077096|NCT03496038|PROCEDURE|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
219077097|NCT03496038|PROCEDURE|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
219077098|NCT04786444|BIOLOGICAL|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
219077099|NCT02403726|PROCEDURE|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
219077100|NCT02403726|PROCEDURE|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
219679322|NCT03957486|OTHER|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
219679323|NCT03957486|OTHER|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
219077101|NCT06219746|DIAGNOSTIC_TEST|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
219077102|NCT04219748|BEHAVIORAL|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
219679324|NCT01990573|DRUG|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
219679325|NCT01990573|DRUG|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
219679326|NCT01990573|OTHER|control no methadone|The control group will not receive methadone.
219679327|NCT06106880|DRUG|Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
219077103|NCT01541228|DEVICE|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
219077104|NCT01541228|PROCEDURE|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
219077105|NCT05734118|DEVICE|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
219077106|NCT02486926|OTHER|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
219077107|NCT02486926|DRUG|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
219077108|NCT02486926|DRUG|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
219077109|NCT02486926|DRUG|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
219077110|NCT02486926|DRUG|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
219679328|NCT06106880|DRUG|Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
219077111|NCT05188573|DEVICE|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
219077112|NCT05188573|DEVICE|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
219077113|NCT00605800|OTHER|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
219077114|NCT00605800|OTHER|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
219077115|NCT05560672|OTHER|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
219077116|NCT02462876|DEVICE|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
219077117|NCT04474626|DRUG|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
219077118|NCT06204627|DEVICE|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
219077119|NCT06204627|DEVICE|Recognize (hand) - Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
219077120|NCT06204627|OTHER|Sham TDCS|TDCS sham: The device remains inactive for 20 minutes.
219077121|NCT06204627|OTHER|Landscape recognition|Image recognition training that does not refer to right/left discrimination.
219077122|NCT04320628|DEVICE|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
219077123|NCT04320628|OTHER|NSS|NSS
219077124|NCT04417023|OTHER|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
219077125|NCT01922115|DRUG|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
219077126|NCT01922115|DRUG|Placebo|
219077127|NCT03191318|OTHER|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
219077128|NCT03191318|OTHER|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
219077129|NCT04977050|DIAGNOSTIC_TEST|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
219679329|NCT06106880|DIETARY_SUPPLEMENT|Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
219679330|NCT06106880|OTHER|Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
219679331|NCT05182801|DIETARY_SUPPLEMENT|Placebo sachet|Blank
219679332|NCT05182801|DIETARY_SUPPLEMENT|Banana flower extract sachet|Happy Angel Banana Flower Extract sachet
219077130|NCT05082038|DEVICE|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
219077131|NCT05082038|DEVICE|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
219077132|NCT02552004|DEVICE|pCLE|Histological examination by pCLE technique preceding the frozen section
219077133|NCT02552004|DRUG|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
219077134|NCT05807451|PROCEDURE|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
219679333|NCT04854759|DRUG|Amantadine Hydrochloride|100 mg, capsule
219679334|NCT04854759|DRUG|Placebo|100 mg, capsule
219679335|NCT04945564|PROCEDURE|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
219679336|NCT04945564|DEVICE|Oxygen therapy|Patients receive oxygen therapy
219077135|NCT03280758|BEHAVIORAL|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
219077136|NCT02203474|DRUG|Tiotropium HFA BAI 5 mcg|
219077137|NCT02203474|DRUG|Tiotropium 18 mcg Capsule|
219077138|NCT02203474|DRUG|Placebo|Placebo
219077139|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
219077140|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
219077141|NCT01786512|DRUG|Placebo|Modified release tablets matching to omecamtiv mecarbil
219077142|NCT01786512|DRUG|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
219077143|NCT06013644|DEVICE|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
219077144|NCT06013644|DEVICE|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
219077145|NCT06013644|DRUG|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
219077146|NCT03025906|DRUG|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
219077147|NCT03025906|DRUG|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
219077148|NCT03464812|BEHAVIORAL|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
219077149|NCT00818857|BEHAVIORAL|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
219077150|NCT00818857|BEHAVIORAL|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
219077151|NCT03166618|DEVICE|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
219077152|NCT01954979|DRUG|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
219679337|NCT03112226|OTHER|GnRHant + E2|GnRH antagonist with estradiol add-back
219679338|NCT03112226|OTHER|GnRHant + Placebo|GnRH antagonist with placebo add-back
219679339|NCT01768065|DEVICE|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
219679340|NCT01768065|DEVICE|placebo sham|
219679341|NCT00447096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
219679342|NCT03958188|OTHER|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
219360470|NCT04218097|OTHER|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
219679343|NCT00886366|DRUG|AZD6714|Oral single doses a-h suspension
219679344|NCT00886366|DRUG|Placebo|Oral single doses suspension
219679345|NCT00886366|DRUG|AZD6714|Oral single doses a-d suspension
219679346|NCT00886366|DRUG|AZD6714|Oral single doses d and g suspension
219679347|NCT02403050|DEVICE|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
219077153|NCT04455672|DEVICE|splints|"* Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
219077154|NCT01925950|DRUG|orBec|
219077155|NCT01925950|DRUG|Placebo|
219077156|NCT05707533|PROCEDURE|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
219077157|NCT01795833|OTHER|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
219077158|NCT04546308|OTHER|Resistance exercise training|Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
219077159|NCT00522158|DRUG|simvastatin|
219077160|NCT00522158|DRUG|atorvastatin|
219077161|NCT00605293|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
219077162|NCT00605293|DRUG|Epoetin alfa|As prescribed
219077163|NCT04593433|OTHER|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
219077164|NCT00950066|DRUG|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
219077165|NCT00950066|DRUG|Amlodipine|Oral administration of Amlodipine 5mg once a day
219077166|NCT00950066|DRUG|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
219077167|NCT00950066|DRUG|Placebo|Oral administration of a placebo once a day
219077168|NCT03068338|DEVICE|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
219077169|NCT03068338|DEVICE|Intermittent pneumatic compression|Conventional device used by hospitals
219077170|NCT02353650|DIETARY_SUPPLEMENT|Q10|
219077171|NCT02353650|DIETARY_SUPPLEMENT|placebo|
219077172|NCT01891916|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
219077173|NCT04439526|DRUG|Guselkumab|Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
219077174|NCT00381940|DRUG|ifosfamide|Given IV
219077175|NCT00381940|DRUG|bortezomib|Given IV
219077176|NCT00381940|DRUG|vinorelbine tartrate|Given IV
219077177|NCT00381940|BIOLOGICAL|filgrastim|Given IV or SC
219077178|NCT05185310|PROCEDURE|Ablation|Ablation strategy during repeat AF ablation
219679348|NCT02588586|DRUG|3BNC117|3BNC117 infusions
219077179|NCT03154801|OTHER|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
219077180|NCT03162224|DRUG|MEDI0457|MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
219077181|NCT03162224|DEVICE|CELLECTRA®5P device|MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.
219077182|NCT03162224|DRUG|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
219360471|NCT05031741|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
219360472|NCT02642094|DRUG|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
219077183|NCT00798720|DRUG|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
219077184|NCT00798720|DRUG|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
219077185|NCT03137303|DEVICE|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
219077186|NCT03137303|DRUG|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
219077187|NCT03137303|DEVICE|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
219077188|NCT05931692|DIAGNOSTIC_TEST|Virtual reality|Virtual environment that triggers fear of falling
219077189|NCT05931692|DIAGNOSTIC_TEST|Electroencephalogram|Detect brain waves in response to fear of falling
219360473|NCT00273819|PROCEDURE|CT angiography|
219679349|NCT02588586|OTHER|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
219679350|NCT05554640|DEVICE|Acuvue® Oasys MAX 1-Day|TEST Lens
219679351|NCT05554640|DEVICE|Dailies Total 1|CONTROL Lens
219679352|NCT03089645|BIOLOGICAL|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
219077190|NCT05931692|DIAGNOSTIC_TEST|Electromyography|Measures muscle activity and response to fear of falling
219679353|NCT03089645|BIOLOGICAL|MEID5083 with Durvalumab or Tremelimumab|Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
219679354|NCT03089645|BIOLOGICAL|Medi5083 with Durvalumab and Docetaxel|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
219679355|NCT04587141|DRUG|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
219679356|NCT04587141|DRUG|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
219679357|NCT04587141|DRUG|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
219679358|NCT04541329|BIOLOGICAL|Tildrakizumab|IL-23 inhibitor
219679359|NCT00878579|DEVICE|PDS System|Percutaneous Dynamic Stabilization System
219679360|NCT00878579|DEVICE|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
219679361|NCT00638469|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
219679362|NCT00638469|OTHER|No treatment|no UV exposure
219679363|NCT03335813|DEVICE|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
219679364|NCT04497532|OTHER|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
219679365|NCT03476057|DIAGNOSTIC_TEST|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
219679366|NCT02210520|DEVICE|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
219679367|NCT02210520|DEVICE|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
219077191|NCT05931692|DIAGNOSTIC_TEST|Motion Capture system|Measures postural and gait responses to fear of falling
219077192|NCT05931692|DIAGNOSTIC_TEST|Polar H10 Heart Sensor|Heart rate monitor
219077193|NCT05931692|DIAGNOSTIC_TEST|Inertial measurement Unite|Measure Postural sway
219077194|NCT04110613|DIETARY_SUPPLEMENT|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
219077195|NCT02934490|DEVICE|Mesh|Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
219077196|NCT02170987|DRUG|Dabigatran etexilate low|
219679368|NCT02210520|DEVICE|laser|1 W/cm², 2 minutes in 6 points around the back spine
219679369|NCT01747096|DRUG|68-Ga-DOTANOC|
219679370|NCT03014271|BEHAVIORAL|Sources of Strength (SOS) Prevention Program|Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
219679371|NCT04323384|DEVICE|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
219679372|NCT03697941|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
219679373|NCT03697941|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
219679374|NCT00308516|DRUG|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
219679375|NCT00308516|DRUG|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
219679376|NCT00308516|PROCEDURE|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
219679377|NCT00308516|DRUG|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
219679378|NCT00308516|DRUG|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
219679379|NCT02982889|DRUG|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
219679380|NCT02982889|DRUG|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
219679381|NCT02982889|DRUG|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
219679382|NCT02982889|DRUG|0.5% bupivacaine hydrochoride|single subcutaneous injection
219679383|NCT06082310|OTHER|Exercise|Two HIIT modalities
219679384|NCT00176657|DRUG|HEMOBAG Assessment|
219679385|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
219679386|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
219077197|NCT02170987|DRUG|Dabigatran etexilate high|
219679387|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
219679388|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
219679389|NCT05136235|DIAGNOSTIC_TEST|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
219679390|NCT05136235|DIAGNOSTIC_TEST|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
219077198|NCT02170987|DRUG|Moxifloxacin|
219077199|NCT02170987|DRUG|Placebo|
219077200|NCT05959122|DIAGNOSTIC_TEST|CBC serum iron serum ferritin|"1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
219077201|NCT04530890|DIAGNOSTIC_TEST|Blood samples|Only blood samples at different times of treatment
219077202|NCT00717990|DRUG|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
219077203|NCT00717990|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
219077204|NCT00717990|DRUG|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
219077205|NCT05667220|DRUG|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
219077206|NCT05667220|DRUG|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
219077207|NCT02642250|DRUG|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
219077208|NCT02642250|DRUG|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
219077209|NCT02566018|PROCEDURE|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
219077210|NCT02566018|PROCEDURE|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
219077211|NCT01440400|PROCEDURE|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
219077212|NCT02858050|DEVICE|Portal-724 MEMs Cap|
219077213|NCT02943603|DRUG|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
219077214|NCT06034587|DIAGNOSTIC_TEST|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
219077215|NCT06034587|RADIATION|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
219077216|NCT00668954|DIETARY_SUPPLEMENT|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
219077217|NCT00668954|DIETARY_SUPPLEMENT|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
219679391|NCT03380871|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
219679392|NCT03380871|BIOLOGICAL|Pembrolizumab|monoclonal antibody against PDL1
219679393|NCT03380871|OTHER|Adjuvant|immune adjuvant
219679394|NCT03380871|DRUG|Carboplatin|chemotherapy
219679395|NCT03380871|DRUG|Pemetrexed|chemotherapy
219077218|NCT03663868|DIAGNOSTIC_TEST|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
219077219|NCT06096051|PROCEDURE|Use of fixed-dosed 4F-PCC|Determine if fixed-dose 4F-PCC is safe and effective in patients with DOAC-associated ICH when compared to weight-based dosing.
219679396|NCT01757860|DRUG|CARD-024|Comparison of different dosages of drug
219679397|NCT01757860|OTHER|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
219679398|NCT01795794|DRUG|omeprazole|
219679399|NCT05183334|DRUG|Sildenafil 50 mg|PD5I
219679400|NCT05183334|DRUG|Placebo|placebo
219679401|NCT05183334|DRUG|Tramadol Hydrochloride 100 MG|opiod
219679402|NCT04984122|PROCEDURE|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
219679403|NCT04747249|OTHER|Psychological support|Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
219679404|NCT06165237|DRUG|BR6001-1|One tablet administered alone, Once a day
219679405|NCT06165237|DRUG|BR6001-2|One tablet administered alone, Once a day
219077220|NCT03561090|DRUG|IW-3718|oral tablet
219077221|NCT03561090|DRUG|placebo|oral tablet
219679406|NCT02256917|BIOLOGICAL|Human cl rhFVIII|
219077222|NCT03561090|DRUG|Standard-dose PPIs QD|background therapy
219077223|NCT05225246|OTHER|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
219077224|NCT05090579|PROCEDURE|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
219077225|NCT05090579|PROCEDURE|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
219077226|NCT05090579|PROCEDURE|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
219077227|NCT00962195|DIETARY_SUPPLEMENT|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
219077228|NCT04162769|DRUG|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
219077229|NCT04162769|DRUG|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
219077230|NCT04162769|DRUG|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
219077231|NCT05334498|OTHER|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
219077232|NCT05334498|OTHER|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
219077233|NCT00033696|BIOLOGICAL|filgrastim|
219077234|NCT00033696|DRUG|carboplatin|
219077235|NCT00033696|DRUG|etoposide|
219077236|NCT00033696|DRUG|paclitaxel|
219077237|NCT00033696|DRUG|topotecan hydrochloride|
219077238|NCT00033696|RADIATION|radiation therapy|
219077239|NCT03663231|DEVICE|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
219679407|NCT06277570|OTHER|conventional physiotherapy|Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.
219077240|NCT03663231|DEVICE|Placebo|IND/IDE exempt device primarily water
219077241|NCT04909242|DRUG|DZD9008|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
219077242|NCT04909242|DRUG|Placebo|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
219077243|NCT04909242|DRUG|DZD9008|In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
219077244|NCT04909242|DRUG|DZD9008|Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
219077245|NCT06109792|PROCEDURE|implant supported mandibular overdenture|In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
219077246|NCT05805592|BEHAVIORAL|Screen-to-Move-Program (STEP)|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP)."
219679408|NCT06277570|OTHER|NMES|Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.
219679409|NCT06277570|OTHER|Superimposed NMES|Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
219679410|NCT00926341|DRUG|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
219679411|NCT00926341|DRUG|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
219077247|NCT00910923|DRUG|JNJ-38431055|
219077248|NCT04274920|OTHER|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
219077249|NCT04274920|OTHER|Light cured calcium hydroxide|Light cured calcium hydroxide
219077250|NCT05191758|DIETARY_SUPPLEMENT|FPP supplement|Participants will take the supplements per randomization
219360474|NCT00120458|DIETARY_SUPPLEMENT|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
219360475|NCT00779376|DRUG|Zidovudine 300mg tablets|
219679412|NCT00816127|DRUG|Desmopressin|intranasal desmopressin (300μg)
219679413|NCT00816127|BIOLOGICAL|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
219360476|NCT02639585|DRUG|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
219360477|NCT06474559|DEVICE|LMA Protector|LMA Protector will be inserted by a researcher after standard anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale.Mini bronchoalveolar lavage will be collected before the end of the procedure
219077251|NCT04731454|OTHER|Control Diet (CD)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
219077252|NCT04731454|OTHER|Healthy Nordic Diet (ND)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
219077253|NCT05699330|DEVICE|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
219077254|NCT00725452|BIOLOGICAL|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
219679414|NCT03868839|DRUG|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
219679415|NCT00715299|BEHAVIORAL|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
219679416|NCT02119078|OTHER|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
219679417|NCT02768402|DEVICE|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
219679418|NCT01707628|BIOLOGICAL|influenza vaccination with influenza vaccine|
219679419|NCT01788319|PROCEDURE|lasertrabeculoplasty|
219679420|NCT05915273|OTHER|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group
219077255|NCT00324870|DRUG|vorinostat|Given orally
219077256|NCT00324870|DRUG|bevacizumab|Given IV
219077257|NCT00620750|DRUG|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
219679421|NCT05915273|OTHER|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
219679422|NCT05915273|OTHER|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
219679423|NCT00872521|DRUG|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)"
219077258|NCT02178748|BIOLOGICAL|MVA85A|Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
219077259|NCT02935491|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
219077260|NCT02635854|OTHER|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
219077261|NCT02635854|OTHER|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
219679424|NCT03327389|DRUG|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
219679425|NCT03327389|DRUG|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
219679426|NCT03137277|PROCEDURE|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards."
219077262|NCT04710082|PROCEDURE|Photorefractive keratectomy (PRK)|Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
219077263|NCT03817996|OTHER|Fluid challenge|250ml of saline in Responders (those who increased \>10% their cardiac output after a passive leg raising maneuver).
219077264|NCT02163733|DRUG|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
219077265|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
219077266|NCT02163733|OTHER|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
219077267|NCT02163733|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
219077268|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
219077269|NCT04347551|OTHER|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
219077270|NCT00275197|DRUG|Sertraline and Elzasonan Combination|
219077271|NCT00275197|DRUG|Sertraline|
219679427|NCT06434675|OTHER|No intervention done|No intervention done
219679428|NCT03436017|OTHER|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
219679429|NCT01699334|BEHAVIORAL|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
219077272|NCT00275197|DRUG|Placebo|
219077273|NCT04477187|DEVICE|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
219077274|NCT00002587|DRUG|paclitaxel|
219077275|NCT00002587|DRUG|topotecan hydrochloride|
219077276|NCT03633968|PROCEDURE|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
219077277|NCT05047367|BEHAVIORAL|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
219077278|NCT04552964|OTHER|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
219077279|NCT06222515|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
219077280|NCT00480103|DEVICE|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
219077281|NCT05968001|DRUG|Obinutuzumab|obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
219077282|NCT02633800|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
219077283|NCT02633800|DRUG|Cetuximab|Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
219077284|NCT02633800|DRUG|Cisplatin|Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
219077285|NCT02633800|DRUG|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
219077286|NCT02633800|DRUG|Placebo|Placebo to match patritumab
219210246|NCT06735417|BEHAVIORAL|Indashyikirwa program|"Indashyikirwa training curriculum is delivered to heterosexual married couples in Syrian communities in Al-Hasakah governorate. The curriculum includes between 21 and 22 sessions, delivered to groups of up to 30 couples. Each week, participants will attend one session, lasting at least 3 hours.~Topics covered include: gender, power imbalance, triggers for GBV, conflict management, building healthy relationships, and coping mechanisms for managing GBV-related triggers.~The curriculum is designed to address both the wife and her husband and includes interactive exercises, take-home assignments, and reflections.~The sessions are delivered by trained facilitators."
219679430|NCT01699334|OTHER|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
219679431|NCT01918501|PROCEDURE|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
219679432|NCT02457195|DRUG|granisetron|Application granisetron transdermal patch preoperatively
219679433|NCT06459713|DIAGNOSTIC_TEST|multiplex respiratory polymerase chain reaction test|According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
219679434|NCT03163641|DEVICE|Acuvue Oasys|Bandage Contact Lens
219679435|NCT03163641|DEVICE|Ocular Bandage Gel|0.75% crosslinked HA
219679436|NCT06172231|PROCEDURE|Instrument Assisted Soft tissue mobilization|The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6\_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific. Frequency: 4 sessions in 4-week period. Duration: 15\_35 min each session.
219679437|NCT06172231|PROCEDURE|Conventional therapy|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15\_ 35 min each session.
219679438|NCT01896193|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219679439|NCT01896193|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219679440|NCT05104385|OTHER|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
219210247|NCT06760858|DRUG|Tislelizumab|Tislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles.
219210248|NCT06760858|DRUG|SOX|SOX: S-1 dosage based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 3 cycles.
219077287|NCT00526266|BEHAVIORAL|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
219077288|NCT00526266|BEHAVIORAL|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
219077289|NCT02176551|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
219077290|NCT02176551|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
219077291|NCT06068855|DRUG|BOTOX|Intramuscular Injections
219077292|NCT06068855|DRUG|Placebo|Intramuscular Injections
219077293|NCT04911790|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
219077294|NCT01578811|DRUG|Placebo|Dosage
219077295|NCT01578811|DRUG|SK-MS10|Dosage
219077296|NCT01578811|DRUG|SK-MS10|Dosage
219077297|NCT00746590|DRUG|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
219077298|NCT03222193|DEVICE|TRP|3 months of TRP tongue retraining
219077299|NCT01291498|DEVICE|High Intensity Focused Ultrasound|One or two HIFU sessions
219077300|NCT02256215|DRUG|Vitamin D|
219077301|NCT02486289|DRUG|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
219077302|NCT02486289|DRUG|Placebo|NBMI Placebo
219077303|NCT00464815|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
219077304|NCT00464815|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose
219077305|NCT01288482|DEVICE|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
219077306|NCT01288482|DEVICE|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
219679441|NCT02533700|DRUG|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
219077307|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
219077308|NCT00002153|DRUG|A-007|
219077309|NCT06451172|DRUG|ASO|Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
219077310|NCT03006250|DRUG|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
219077311|NCT03006250|DRUG|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
219077312|NCT00000392|DRUG|Peptide T|
219077313|NCT00000392|DRUG|Placebo|
219077314|NCT03671096|OTHER|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
219077315|NCT00517491|DRUG|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
219077316|NCT01270451|OTHER|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
219077317|NCT01362738|PROCEDURE|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
219077318|NCT01362738|PROCEDURE|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
219077319|NCT04402866|DRUG|TD-0903|Study Drug to be administered by inhalation
219077320|NCT04402866|DRUG|Placebo|Placebo to be administered by inhalation
219077321|NCT04091074|DRUG|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
219077322|NCT04091074|DRUG|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
219077323|NCT04091074|PROCEDURE|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
219077324|NCT02207920|BIOLOGICAL|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
219077325|NCT02207920|BIOLOGICAL|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
219077326|NCT02207920|BIOLOGICAL|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
219679442|NCT02533700|DRUG|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
219077327|NCT02207920|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
219077328|NCT06147895|BIOLOGICAL|CVI-HBV-002|Investigational Product
219077329|NCT00728390|DRUG|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
219077330|NCT02777151|DRUG|REGN3470-3471-3479|
219077331|NCT02777151|DRUG|Placebo|
219077332|NCT06356064|DEVICE|Extracorporeal shock wave therapy|Radİal ESWT and focus ESWT
219077333|NCT02621099|DEVICE|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
219077334|NCT02821273|OTHER|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
219077335|NCT02821273|OTHER|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
219077336|NCT04832503|BEHAVIORAL|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
219077337|NCT04832503|BEHAVIORAL|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
219077338|NCT02024906|DIETARY_SUPPLEMENT|soy protein isolate (SPI)|
219077339|NCT02024906|DIETARY_SUPPLEMENT|milk protein isolate (MPI)|
219077340|NCT03376581|PROCEDURE|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
219077341|NCT02125201|DRUG|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
219077342|NCT04608370|BEHAVIORAL|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
219077343|NCT04608370|BEHAVIORAL|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
219210249|NCT06760858|DEVICE|HIPEC|HIPEC: Docetaxel: 120mg, day 1, day 3.
219679443|NCT06435767|DRUG|Adjuvant chemotherapy|In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
219077344|NCT05817695|DEVICE|Leadless pacemaker|To observe the effect of pacemaker implantation at different sites on cardiac synchronization and tricuspid regurgitation
219077345|NCT04866550|OTHER|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
219077346|NCT01463748|OTHER|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
219077347|NCT01463748|OTHER|Placebo|starch
219077348|NCT04871789|DIAGNOSTIC_TEST|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
219077349|NCT04292626|DIAGNOSTIC_TEST|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
219077350|NCT00181948|DRUG|atomoxetine (Strattera)|
219077351|NCT04870216|OTHER|Questionnaire regarding intimate protections habit.|Questionnaire regarding intimate protections habit.
219077352|NCT04678492|DRUG|Esomeprazole|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
219077353|NCT04678492|DRUG|Amoxicillin|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
219077354|NCT04678492|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219077355|NCT04678492|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219077356|NCT04678492|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
219077357|NCT04678492|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
219077358|NCT06340620|DEVICE|Endoscopic ultrasound examination|Endoscopic ultrasound examination will be performed.
219077359|NCT05278455|BEHAVIORAL|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
219077360|NCT03430674|BEHAVIORAL|Exercise|Exercise, questionnaires and blood draws.
219077361|NCT00386880|OTHER|Sounds|
219077362|NCT02313467|DRUG|Topical application of 1.5% Butenyl ALA|
219077363|NCT02313467|DRUG|Topical application of sham control|
219077364|NCT01886924|BEHAVIORAL|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
219077365|NCT01886924|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
219077366|NCT05602714|OTHER|Collection Data|
219077367|NCT05437458|OTHER|Delirium (exposure)|No interventions.
219077368|NCT00408213|DRUG|mycophenolate mofetil [CellCept]|1g po bid
219077369|NCT00408213|DRUG|Placebo|po bid
219077370|NCT03545867|BEHAVIORAL|Seated control (CON)|Seated rest
219077371|NCT03545867|BEHAVIORAL|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
219077372|NCT03545867|BEHAVIORAL|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
219077373|NCT03545867|BEHAVIORAL|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
219077374|NCT03545867|OTHER|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
219077375|NCT05684081|BEHAVIORAL|Digital payment|The proposed intervention is designed to support the implementation of polio campaigns through digital payments
219077376|NCT05308173|PROCEDURE|Surgical Aortic Valve Replacement|Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
219077377|NCT05308173|PROCEDURE|Transcutenous Aortic Valve Implantation|Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
219077378|NCT05368779|BEHAVIORAL|The internet-based psychosocial intervention|Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
219077379|NCT00591474|DIETARY_SUPPLEMENT|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
219077380|NCT00591474|DIETARY_SUPPLEMENT|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
219077381|NCT00297154|BEHAVIORAL|Lifestyle Modification (diet, exercise, and behavior)|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
219360478|NCT06474559|DEVICE|Endotracheal tube|tracheal intubation will be perform after standard anaesthetic induction. Cormack Lehane will be recorded. Mini bronchoalveolar lavage will be collected before the end of the procedure
219679444|NCT04533789|OTHER|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
219679445|NCT00666107|BIOLOGICAL|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
219679446|NCT00738647|PROCEDURE|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
219679447|NCT03765060|PROCEDURE|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
219679448|NCT03765060|PROCEDURE|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
219679449|NCT05886114|BEHAVIORAL|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
219679450|NCT05886114|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
219679451|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, high Positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 5 cmH2O
219679452|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
219679453|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Zero support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
219679454|NCT01793038|DRUG|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
219077382|NCT02385305|DEVICE|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
219077383|NCT03882333|OTHER|Acute exercise|30 min acute exercise (bicycle at stationary cycle)
219077384|NCT02346305|DEVICE|Non-invasive ventilation|Home NIV installation
219077385|NCT03602131|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
219077386|NCT03602131|DRUG|Cladribine|6 mg/m2 intravenously once daily for 5 days
219077387|NCT03602131|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
219077388|NCT03602131|DRUG|Busulfan|3.2 mg/kg intravenously once daily for 4 days
219077389|NCT03602131|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
219077390|NCT03692533|DIAGNOSTIC_TEST|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
219077391|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
219077392|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
219077393|NCT02557841|DEVICE|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
219679455|NCT01793038|DRUG|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
219679456|NCT00126919|DEVICE|SonoPrep|
219679457|NCT04682899|DRUG|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
219679458|NCT04682899|DRUG|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
219679459|NCT00652912|DRUG|Clonazepam|ODT, 1 mg
219679460|NCT00652912|DRUG|Klonopin Wafers|ODT, 1 mg
219679461|NCT01558219|DRUG|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
219210250|NCT06774105|OTHER|Static Stretching|The protocol consisted in 2 sessions per week, each comprising 8 exercises of static stretching targeting all major muscle groups: 1) Hamstrings, 2) Knee Extensors, 3) Dorsal muscles, 4) Pectoralis muscles, 5) Elbow Flexors (biceps), 6) Elbow Extensors (triceps), 7) Adductors, and one day 8a) Spine Extensors while the second 8b) Spine Flexors. Each exercise involved 4 sets of 30 seconds of SS and 30 seconds of rest.
219679462|NCT02859350|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
219679463|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
219077394|NCT05152433|DEVICE|E-BRAiN therapy|The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
219077395|NCT05152433|BEHAVIORAL|Conventional therapy|Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
219077396|NCT02294890|PROCEDURE|Total knee arthroplasty|
219077397|NCT05077787|OTHER|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
219077398|NCT05077787|OTHER|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
219077399|NCT03686852|OTHER|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
219077400|NCT05350241|OTHER|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
219077401|NCT05350241|OTHER|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
219077402|NCT00868439|DRUG|patiromer|Active investigational drug
219077403|NCT00868439|DRUG|placebo|placebo
219077404|NCT00476476|DRUG|Erlotinib|Orally every day for about 4-6 weeks
219077405|NCT00344786|DRUG|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
219077406|NCT04149405|PROCEDURE|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
219077407|NCT04149405|DRUG|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
219077408|NCT04769427|DEVICE|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
219077409|NCT01494831|BEHAVIORAL|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
219077410|NCT00894231|DRUG|levocetirizine (Xyzal)|5mg po QD
219077411|NCT00894231|DRUG|placebo|sugar tablet
219077412|NCT03215836|PROCEDURE|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
219210251|NCT06765928|DRUG|selinexor in combination with venetoclax|After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
219210252|NCT06807710|OTHER|DNS Group|Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
219679464|NCT02859350|OTHER|Normal Saline|0.9% Sodium chloride
219679465|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
219679466|NCT05051046|PROCEDURE|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
219077413|NCT00520780|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
219077414|NCT00520780|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
219077415|NCT01189279|DRUG|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
219077416|NCT01189279|DRUG|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
219077417|NCT01189279|DRUG|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
219077418|NCT00971048|DEVICE|HP828-101|Topical test article applied once daily
219077419|NCT00971048|DEVICE|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
219077420|NCT01046305|BEHAVIORAL|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
219077421|NCT01046305|BEHAVIORAL|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
219077422|NCT01046305|BEHAVIORAL|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
219077423|NCT00195910|DRUG|Morphine|0.1 mg/kg IV morphine
219077424|NCT00195910|DRUG|Hydromorphone|0.015 mg/kg IV hydromorphone
219077425|NCT06088264|DRUG|BMS-986322|Specified dose on specified days.
219077426|NCT00243204|DRUG|talabostat mesylate|
219077427|NCT00243204|DRUG|docetaxel|
219077428|NCT02412930|PROCEDURE|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
219077429|NCT02412930|DRUG|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
219077430|NCT02412930|DRUG|Bupivacaine|
219077431|NCT02412930|DEVICE|Ultrasound|
219077432|NCT01015391|DRUG|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
219077433|NCT01015391|DRUG|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
219077434|NCT04109703|DEVICE|High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.|The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
219077435|NCT04109703|DEVICE|Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
219679467|NCT05598359|DIETARY_SUPPLEMENT|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
219077436|NCT04850300|PROCEDURE|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
219077437|NCT04850300|PROCEDURE|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
219077438|NCT05514353|DRUG|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
219077439|NCT05514353|DRUG|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
219077440|NCT00606372|PROCEDURE|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
219210253|NCT06807710|OTHER|Pilates Group|Reformer pilates exercises, focusing on core stability, flexibility, postural alignment, and breath control using a Reformer Pilates machine under the supervision of a physiotherapist.
219679468|NCT05598359|OTHER|Placebo|Inactive formulation
219679469|NCT03987308|DRUG|Beinaglutide|Beinaglutide (continuous subcutaneous infusion)
219679470|NCT03987308|DRUG|Insulin aspart|Insulin aspart (CSII)
219679471|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
219077441|NCT03321396|DEVICE|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
219077442|NCT01973933|DRUG|Metformin and Pyrimethamine|
219077443|NCT02167074|DEVICE|25G FNA needle|
219077444|NCT02167074|DEVICE|20G ProCore FNB needle|
219077445|NCT01944501|PROCEDURE|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
219077446|NCT01944501|PROCEDURE|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
219077447|NCT01487811|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
219077448|NCT04243317|BEHAVIORAL|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
219077449|NCT04243317|BEHAVIORAL|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
219077450|NCT03491865|BEHAVIORAL|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
219077451|NCT04024618|PROCEDURE|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
219077452|NCT03671668|OTHER|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
219077453|NCT01212367|BIOLOGICAL|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
219077454|NCT01212367|BIOLOGICAL|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
219077455|NCT02374905|DEVICE|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
219077456|NCT02374905|BEHAVIORAL|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
219077457|NCT00733538|DRUG|zometa|patients receiving treatment during their follow-up
219077458|NCT01654549|DRUG|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
219077459|NCT02301312|DEVICE|POSS-PCU vascular graft|New vascular access graft
219077460|NCT00937924|DRUG|Meperidine, Midazolam|
219077461|NCT00937924|DRUG|Diphenhydramine|
219077462|NCT00937924|DRUG|Promethazine|
219077463|NCT04230044|DRUG|Perampanel|Perampanel tablets.
219077464|NCT00430794|DRUG|Spironolactone|
219077465|NCT04478968|OTHER|presence of AVF|Functioning AVF may have cardiotoxic potential
219077466|NCT05985187|DRUG|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
219077467|NCT05985187|DRUG|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
219077468|NCT04460742|BEHAVIORAL|CAPABLE Transitions|The CAPABLE Transitions intervention group will receive an occupational therapy-led multidisciplinary in-home intervention in which the study occupational therapist (\<6 visits), registered nurse (\<5 visits), and handyman (\<2 visits) work with participants over 3-4 months. This intervention group also will receive home health agency care as usual services. CAPABLE Transitions in embedded within a home health agency and includes a care transitions emphasis.
219077469|NCT04460742|BEHAVIORAL|Home Health Agency Care|Both the CAPABLE Transitions intervention and care as usual treatment arms will receive home health agency care as usual services, which can include nursing, health aide, medical social work, and occupational, physical, and speech therapy services. Home health agency clinicians will determine the types and duration of CHHA services that the study participants receive; these services will be completely independent from the research study.
219077470|NCT03932851|OTHER|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
219077471|NCT00361543|DRUG|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
219077472|NCT00361543|OTHER|Lactose Capsules|1 tablet daily for 12 weeks
219077473|NCT02738268|DEVICE|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
219077474|NCT02738268|DEVICE|sham laser|
219077475|NCT06580132|DIETARY_SUPPLEMENT|Pectin|Pectin fibre (20g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
219077476|NCT06580132|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with pectin.
219077477|NCT05591508|DIETARY_SUPPLEMENT|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
219077478|NCT03999879|DIAGNOSTIC_TEST|Measure of OxPhos upregulation|OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
219077479|NCT03999879|DIAGNOSTIC_TEST|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
219077480|NCT05072080|BIOLOGICAL|CHIKV VLP/adjuvant|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
219077481|NCT05072080|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
219679472|NCT06235580|OTHER|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
219077482|NCT01961336|DRUG|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
219077483|NCT04335045|DRUG|Placebo|1\~8 Placebo capsule(s) corresponding to each PH100 dose
219077484|NCT04335045|DRUG|PH100 100mg|1 x 100 mg PH100 oral capsule
219077485|NCT04335045|DRUG|PH100 200mg|1 x 200 mg PH100 oral capsule
219077486|NCT04335045|DRUG|PH100 400mg|2 x 200 mg PH100 oral capsules
219077487|NCT04335045|DRUG|PH100 800mg|4 x 200 mg PH100 oral capsules
219077488|NCT04335045|DRUG|PH100 1200mg|6 x 200 mg PH100 oral capsules
219077489|NCT04335045|DRUG|PH100 1600mg|8 x 200 mg PH100 oral capsules
219077490|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.
219077491|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.
219077492|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
219077493|NCT02918110|DRUG|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
219077494|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
219077495|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
219077496|NCT04224155|DEVICE|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
219077497|NCT04224155|DEVICE|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
219077498|NCT04531046|DRUG|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
219077499|NCT03506958|PROCEDURE|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
219077500|NCT05597254|DIETARY_SUPPLEMENT|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
219077501|NCT05597254|DIETARY_SUPPLEMENT|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
219077502|NCT05597254|DIETARY_SUPPLEMENT|Placebo|1 capsule daily of placebo supplementation for 8 weeks
219077503|NCT01972841|DRUG|Solifenacin succinate|Oral tablet
219077504|NCT01972841|DRUG|Mirabegron|Oral tablet
219077505|NCT01972841|DRUG|Placebo to match solifenacin succinate|Oral tablet
219077506|NCT01972841|DRUG|Placebo to match mirabegron|Oral tablet
219077507|NCT03696017|OTHER|Multi-domain assessment battery|Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
219077508|NCT06961526|PROCEDURE|Esophageal band ligation|upper endoscopy will be performed within 6 months before starting atezolizumab-bevacizumab therapy in HCC patients. Esophageal band ligation for small non-risky varices before starting atezolizumab-bevacizumab therapy. Endoscopy will be repeated 3, 5, 9, 12 months after atezolizumab-bevacizumab therapy
219077509|NCT06962436|DEVICE|Robotic bronchoscopy system|Utilization of a robotic bronchoscopy system for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
219077510|NCT06962436|DEVICE|Ultrathin bronchoscope combined with virtual bronchoscopic navigation|Utilization of ultrathin bronchoscope combined with virtual bronchoscopic navigation for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
219210254|NCT06750770|DIAGNOSTIC_TEST|KDIGO CRITERIA|2012 KDIGO DIAGNOSTIC CRITERIA
219679473|NCT01977768|BIOLOGICAL|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
219679474|NCT01977768|BIOLOGICAL|Placebo|
219077511|NCT06962761|DRUG|Vit D|in this study we use a combination of vit d and probiotics
219077512|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
219077513|NCT04461301|PROCEDURE|Multimodal Prehabilitation|A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
219679475|NCT04544098|DRUG|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
219077514|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
219077515|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
219077516|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
219077517|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
219077518|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
219077519|NCT05830942|BEHAVIORAL|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
219077520|NCT05830942|DEVICE|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
219077521|NCT05830942|DEVICE|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
219077522|NCT04609891|DRUG|Avatrombopag|10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
219077523|NCT03282448|BEHAVIORAL|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
219077524|NCT00126412|DRUG|123I-mIBG (meta-iodobenzylguanidine)|
219077525|NCT05597969|BEHAVIORAL|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
219077526|NCT06292455|OTHER|Elastic resistance training|six-weeks elastic resistance training of upper limb. Three days per week. volume per session would be 10 repetitions and three sets. 2 minute rest interval between each set.
219077527|NCT06292455|OTHER|Conventional Resistance Training|players follow their routine exercise protocol
219077528|NCT02068807|DIETARY_SUPPLEMENT|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
219077529|NCT02068807|DIETARY_SUPPLEMENT|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
219077530|NCT03256162|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
219077531|NCT03256162|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
219077532|NCT04954118|PROCEDURE|Internal jugular vein cannulation|The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.
219077533|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
219077534|NCT05666453|BIOLOGICAL|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
219077535|NCT05666453|OTHER|No intervention|None of investigational drugs are administered to patients.
219077536|NCT01904448|DEVICE|Auditory Brainstem Implantation in Children|
219077537|NCT01015989|OTHER|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
219077538|NCT01015989|OTHER|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
219077539|NCT05713617|BEHAVIORAL|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
219077540|NCT04492254|DRUG|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
219210255|NCT06749873|OTHER|Background of different SP information|Sp was asked with the following baseline information: 1. 50 years of age and gender; 2. positive urea breath test; 3. asymptomatic; 4. family history of gastric cancer; 5. gastroscopy: atrophic gastritis; 6. untreated; and 7. no history of drug allergies.
219679476|NCT05196425|GENETIC|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
219679477|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
219679478|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
219679479|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
219679480|NCT04819438|DRUG|Riluzole 50 mg orodispersible film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
219679481|NCT04819438|DRUG|Rilutek® 50 mg riluzole tablets|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
219077541|NCT02510495|PROCEDURE|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219679482|NCT06154226|DRUG|Pantoprazole|Subjects will receive pantoprazole (40 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on post operative day 1 (POD 1) for a total of 4 doses over 2 days.
219679483|NCT06154226|DRUG|Famotidine|Subjects will receive famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days.
219077542|NCT02510495|PROCEDURE|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219679484|NCT05463861|DRUG|Lemborexant|Lemborexant tablet administered orally once daily.
219679485|NCT05463861|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily.
219077543|NCT02510495|PROCEDURE|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219077544|NCT02510495|PROCEDURE|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219077545|NCT01915134|DRUG|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
219679486|NCT03465709|DRUG|Pegcetacoplan|Study Drug
219679487|NCT02498977|GENETIC|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
219679488|NCT02498977|DRUG|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
219077546|NCT01915134|DRUG|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
219077547|NCT03819491|DIETARY_SUPPLEMENT|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
219679489|NCT02815033|DRUG|Enzalutamide|
219077548|NCT05111236|OTHER|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
219679490|NCT02815033|PROCEDURE|11C or 18F-Choline PET/CT|
219679491|NCT02815033|PROCEDURE|Whole body MRI|
219679492|NCT02815033|PROCEDURE|Bone scan|
219679493|NCT00243971|DRUG|SPM 962|
219679494|NCT05359952|BEHAVIORAL|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
219679495|NCT05359952|BEHAVIORAL|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
219679496|NCT01858207|PROCEDURE|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
219679497|NCT01858207|PROCEDURE|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
219210256|NCT06748573|DEVICE|SafeGuard FocusTM compression bandage|"If randomized to the study group, The study device was applied immediately after pocket closure using following steps:~* Preparation: cleaning wound and surrounding area.~* Placement: application of isobetadine gauze and transparent bandage. Study device placement at the level of the pocket.~* Applying compression: inflation of 60ml of air. If oozing persisted 5ml increments were added (maximum of 120ml) until oozing stopped.~The study device was gradually deflated by removal of 20ml of air every 2 hours. When oozing occurred 5ml increments were added until oozing stopped. When all air was deflated the study device was left in deflated mode and changed by conventional bandage at discharge."
219210257|NCT06748573|DEVICE|Conventional bandage|If randomized to the control group, compressive bandage was applied immediately after pocket closure. The bandage was removed after 6 hours and changed by conventional bandage.
219210258|NCT06764238|DRUG|Blinatumomab (Group A)|For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
219210259|NCT06764238|DRUG|Venetoclax (nonRand Group)|For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
219210260|NCT06764238|DRUG|Blinatumomab (Group B)|For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
219210261|NCT07039175|BEHAVIORAL|MINDSET|A behavior-change model informed mailed informational packet with tailored health information regarding the impacts of smoking/drinking on chronic disease and the benefits of stopping, followed by a brief motivational telephone booster call from a behavioral health provider.
219210262|NCT07039175|OTHER|Usual Care|All Veterans involved in this study will have a standard primary care (PC) appointment, which may include conversations/interventions related to drinking and smoking. This appointment is not controlled by the study team and we cannot comment on the extent to which smoking/drinking will or will not be discussed in the primary care appointment but we imagine this can range from no discussion/intervention at all to extensive conversations with the provision of medications, brief advice, etc.
219210263|NCT06777849|BEHAVIORAL|Right to Play-Plus (RTP-Plus)|"The comprehensive curriculum comprises of themes: Social and Emotional Development and Sexual and Reproductive Health will be delivered by school teachers who will receive training from Right to Play and Aahung. There will be 60 sessions for two years."
219210264|NCT06777849|OTHER|Control|There will be no intervention given to control arm during two years of cluster randomised control trial (cRCT). However, a delayed intervention having teachers' training, will be provided to the control arm after the completion of endline for the duration of 3-4 months.
219360479|NCT02851004|DRUG|Napabucasin|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
219077549|NCT05111236|OTHER|Traditional massage|Rehabilitation strategies in management of children with spastic CP
219077550|NCT00540280|RADIATION|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
219077551|NCT02672111|DRUG|CAM2038 q1w or q4w exposure to SL BPN/NX|
219077552|NCT02672111|DRUG|CAM2038 q1w or q4w new to BPN treatment|
219077553|NCT01909310|PROCEDURE|head extension|the lungs are ventilated with the patient´s head extended
219077554|NCT01909310|PROCEDURE|neutral position|the lungs are ventilated with the patient´s head in neutral position
219077555|NCT01909310|PROCEDURE|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
219077556|NCT04686903|PROCEDURE|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
219077557|NCT04686903|PROCEDURE|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
219077558|NCT04686903|PROCEDURE|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
219077559|NCT01839110|DRUG|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
219077560|NCT01839110|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
219077561|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
219077562|NCT00233077|BEHAVIORAL|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
219679498|NCT01858207|DRUG|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
219679499|NCT05919550|DRUG|search for a clozapine intake|search for a clozapine intake
219679500|NCT05384470|DRUG|Marihuana|Two doses of marijuana given.
219077563|NCT00233077|BEHAVIORAL|Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
219077564|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
219077565|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
219077566|NCT00384228|DRUG|Nilotinib|
219077567|NCT03378167|BIOLOGICAL|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
219077568|NCT03378167|BIOLOGICAL|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
219077569|NCT02308748|DRUG|Dofetilide|"* 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg"
219077570|NCT02308748|DRUG|Mexiletine|"* 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am"
219077571|NCT02308748|DRUG|Lidocaine|"* 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
219077572|NCT02308748|DRUG|Moxifloxacin|"* 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
219077573|NCT02308748|DRUG|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
219679501|NCT05384470|DEVICE|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
219679502|NCT04298606|OTHER|Quality-of-Life Assessment|Ancillary studies
219679503|NCT04298606|OTHER|Questionnaire Administration|Ancillary studies
219679504|NCT04298606|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
219679505|NCT04791332|DRUG|JNJ-67953964|JNJ-67953964 capsule will be administered orally.
219679506|NCT04791332|DRUG|Placebo|Matching placebo will be administered orally.
219679507|NCT06382129|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219679508|NCT06382129|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
219679509|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
219077574|NCT02308748|DRUG|Placebo|Placebo (#2 Gelcap or IV saline)
219077575|NCT06186752|BEHAVIORAL|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
219210265|NCT06769815|OTHER|Blood sample|For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.
219210266|NCT06769815|OTHER|Urine sample|For febrile children : 10 ml of urine
219210267|NCT06769815|OTHER|oropharyngeal sample|For febrile children : oropharyngeal swab sampling
219210268|NCT06769815|OTHER|Optionnal : stool sample|For febrile children (only as part of the care of the child) : 5g stool
219210269|NCT06769815|OTHER|Optionnal : cerebrospinal fluid|For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid
219210270|NCT06769815|OTHER|placental biopsy|For pregnant women : placental biopsy the size of 2 rice grains
219210271|NCT06069765|OTHER|TUPEX|"This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks."
219210272|NCT06846931|OTHER|Extracorporeal Shock Wave Therapy|By the same physiotherapist with more than 5 years of clinical experience, radial ESWT treatment with 2500 pulses, 10 Hz frequency, 2.5-3 bar pressure, is applied to the most painful point of the heel and surrounding soft tissues, plantar aponeurosis and Achilles tendon insertion area on the dorsum of the heel, once a week for a total of 3 sessions.
219210273|NCT06846931|OTHER|Low Intensity Laser|A total of 28j (5.6jx5 points) are applied to the plantar fascia at 5 points on the heel by the same physiotherapist for 3 weeks, a total of 9 sessions (every other day) with the patient lying face down.
219210274|NCT06846931|OTHER|EXERCİSE|Exercise therapy is carried out by the patient for 3 weeks. Plantar fascia stretching exercises (exercises to stretch the membrane on the sole of the foot), gastrocsoleus stretching exercises (exercises to stretch the calf muscles), foot intrinsic muscle strengthening exercises (exercises to strengthen the muscles on the sole of the foot) are taught to the patients by the doctor and they are asked to perform them 2 times a day 10 times for a total of 3 weeks.
219077576|NCT00435773|PROCEDURE|Single Leeching|
219077577|NCT00435773|PROCEDURE|Repeated Leeching after 4 weeks|
219077578|NCT00435773|PROCEDURE|Placebo Leeching|
219077579|NCT03451734|DRUG|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
219077580|NCT03451734|DRUG|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
219077581|NCT03451734|DRUG|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
219077582|NCT04513990|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
219210275|NCT06755723|OTHER|Rib fractures manangement|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients undergoing rib stabilization surgery as part of their routine clinical care. The exposure of interest includes surgical rib stabilization and its timing, combined with any related clinical and care procedures. The outcomes and clinical data collected reflect routine care practices.
219210276|NCT06812390|DRUG|Albumin infusion (25% albumin)|Albumin 25 gram infusion
219210277|NCT06812390|DRUG|Normal Saline (0.9% NaCl)|100 cc of normal saline
219077583|NCT04513990|OTHER|Questionnaire Administration|Demographic information, sample collection type preferences; clinical outcome information
219077584|NCT04762381|DRUG|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
219077585|NCT04762381|OTHER|Placebo|Saline
219077586|NCT06498765|OTHER|Pacifier Use|The newborns in the experimental group were given a pacifier, unlike the control group. The newborns were placed in a phototherapy incubator and each time they were placed in a phototherapy incubator, the newborns were given a pacifier for an average of 5 minutes. The researcher encouraged the babies to take the pacifier.
219077587|NCT01041638|BIOLOGICAL|Aldesleukin|Given IV
219077588|NCT01041638|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219077589|NCT01041638|BIOLOGICAL|Dinutuximab|Given IV
219077590|NCT01041638|DRUG|Isotretinoin|Given PO
219077591|NCT01041638|BIOLOGICAL|Sargramostim|Given IV or SC
219077592|NCT02541890|BEHAVIORAL|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
219210278|NCT06842641|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy
219210279|NCT06842043|OTHER|AI-assisted model|physicians will be authorized to access the AI model's predictions during patient care as an additional decision-making reference. These predictions will be generated in seconds and can help identify issues such as tube misplacement (e.g., nasogastric tube, endotracheal tube) and pneumothorax through AI analysis of CXRs, which will alert the physician to review the images.
219210280|NCT06843200|BEHAVIORAL|Parent Group Discussion|A 2-hour interactive parent group delivered to 5-10 parents via zoom; discuss weight bias and discrimination; brainstorm ways to respond in parent-child interactions involving health and appearance; and identify action steps.
219077593|NCT04930068|OTHER|low caloric diet|A low-calorie diet is a structured eating plan that restricts daily caloric intake, commonly for weight loss. Following a low-calorie diet typically means consuming around 1,200 to 1,500 calories per day, which creates a calorie deficit that can lead to weight loss. A low-calorie diet can be effective, but it requires a lot of discipline to work and be safe.
219077594|NCT00737165|BEHAVIORAL|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems"
219077595|NCT00737165|BEHAVIORAL|Suicide prevention program as usual|Usual suicide prevention program
219077596|NCT02275104|DEVICE|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
219077597|NCT02275104|DEVICE|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
219077598|NCT02275104|DEVICE|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
219077599|NCT02275104|DEVICE|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
219077600|NCT02275104|PROCEDURE|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
219077601|NCT01655290|OTHER|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
219077602|NCT03602651|OTHER|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
219360480|NCT02851004|DRUG|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
219360481|NCT05691855|DRUG|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
219360482|NCT00268242|DRUG|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
219360483|NCT00268242|DRUG|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
219679510|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
219679511|NCT01930916|DEVICE|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
219679512|NCT01930916|OTHER|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
219077603|NCT00970138|DRUG|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
219077604|NCT00999375|BEHAVIORAL|Education|
219077605|NCT00999375|BEHAVIORAL|Problem Solving|
219077606|NCT00999375|BEHAVIORAL|Social Learning|
219679513|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
219679514|NCT05653947|PROCEDURE|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
219679515|NCT00933985|DRUG|dexrazoxane hydrochloride|Given IV
219679516|NCT00933985|DRUG|doxorubicin hydrochloride|Given IV
219679517|NCT00933985|DRUG|obatoclax mesylate|Given IV
219679518|NCT00933985|DRUG|liposomal vincristine sulfate|Given IV
219679519|NCT00933985|OTHER|pharmacological study|Correlative studies
219679520|NCT00933985|OTHER|laboratory biomarker analysis|Correlative studies
219679521|NCT02811991|DRUG|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
219679522|NCT02811991|DRUG|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
219679523|NCT02811991|DRUG|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
219679524|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
219679525|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
219679526|NCT02021110|DRUG|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
219679527|NCT00000809|BIOLOGICAL|Aluminum hydroxide|
219679528|NCT00000809|BIOLOGICAL|QS-21|
219679529|NCT00000809|BIOLOGICAL|MN rsgp120/HIV-1|
219679530|NCT04730401|BIOLOGICAL|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
219077607|NCT00999375|BEHAVIORAL|Behavior Modification|
219077608|NCT04739501|PROCEDURE|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
219077609|NCT00003038|DRUG|doxorubicin hydrochloride|
219077610|NCT00003038|DRUG|suramin|
219077611|NCT00331747|DRUG|Glatiramer acetate|
219077612|NCT01687257|DRUG|SOF|SOF 400 mg tablet administered orally once daily
219077613|NCT01687257|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219077614|NCT00969501|DRUG|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
219679531|NCT04730401|BIOLOGICAL|Placebo|200mL saline
219679532|NCT01888250|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
219077615|NCT01652144|DRUG|AT7519M|
219077616|NCT01280279|OTHER|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
219077617|NCT05063838|OTHER|Pharmacogenomic optimisation of anaesthetic medications|Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
219077618|NCT00809887|DRUG|Micafungin lock therapy|
219077619|NCT06265428|DRUG|DB-1303/BNT323|Administered I.V.
219077620|NCT06265428|DRUG|T-DM1|Administered I.V.
219077621|NCT06545097|DRUG|Cebranopadol|Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).
219077622|NCT06545097|DRUG|Cebranopadol|Once daily on Day 2 (with Cebranopadol 400 ug)
219077623|NCT06545097|DRUG|Placebo|Once daily for 2 days
219077624|NCT01390467|DRUG|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
219077625|NCT05256173|OTHER|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
219077626|NCT05256173|OTHER|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
219077627|NCT05256173|DEVICE|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
219360484|NCT03881995|DRUG|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
219679533|NCT01543802|DRUG|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
219679534|NCT03243253|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
219679535|NCT03445403|OTHER|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
219679536|NCT00417521|BEHAVIORAL|Family-Based Treatment|
219679537|NCT01995344|DRUG|Cyclophosphamide|
219679538|NCT01995344|DRUG|Fludarabine|
219679539|NCT01995344|GENETIC|Tumour Infiltrating Lymphocytes|
219679540|NCT01995344|DRUG|Interleukin-2|
219679541|NCT03029455|DRUG|VX-659|
219679542|NCT03029455|DRUG|Tezacaftor|
219679543|NCT03029455|DRUG|Ivacaftor|
219679544|NCT03029455|DRUG|VX-659 Matching Placebo|
219679545|NCT03029455|DRUG|Triple Combination (TC) Matching Placebos|
219679546|NCT02237989|DRUG|paracetamol|1500 mg
219077628|NCT05256173|DEVICE|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
219077629|NCT04215042|DRUG|sodium chloride infusion|
219077630|NCT00239174|DRUG|SR147778|
219077631|NCT06398327|PROCEDURE|PULPOTOMY TREATMENT|During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
219077632|NCT02485210|PROCEDURE|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
219077633|NCT00990639|DRUG|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
219077634|NCT02437591|DRUG|fidaxomicin|oral
219077635|NCT01641250|DRUG|RO5429083|Multiple escalating doses
219077636|NCT01641250|DRUG|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
219077637|NCT02866565|DRUG|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
219077638|NCT06579378|DEVICE|VSail 3D|"The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life."
219077639|NCT06579378|OTHER|WEB-Health|The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
219679547|NCT02237989|DRUG|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
219077640|NCT02388802|PROCEDURE|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
219077641|NCT02388802|PROCEDURE|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
219077642|NCT02388802|PROCEDURE|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
219077643|NCT02388802|DRUG|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
219077644|NCT02388802|PROCEDURE|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
219077645|NCT02388802|PROCEDURE|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
219077646|NCT01019876|DRUG|Fludarabine|
219077647|NCT01019876|DRUG|Cyclophosphamide|
219077648|NCT01019876|DRUG|Busulfan|
219077649|NCT01019876|DRUG|Alemtuzumab|
219077650|NCT01019876|DRUG|Rabbit Anti-thymocyte Globulin|
219077651|NCT01019876|DRUG|Horse Anti-thymocyte Globulin|
219077652|NCT03846830|DEVICE|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
219077653|NCT03846830|BEHAVIORAL|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
219077654|NCT02445612|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
219360485|NCT03881995|DRUG|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
219679548|NCT01625442|DRUG|Saffron tablet|Saffron tablets 100 mg
219679549|NCT01625442|DRUG|Barberry tablet|Barberry tablets 200 mg
219679550|NCT01625442|DRUG|Placebo|Placebo tablets received daily for 45 days
219679551|NCT05777837|PROCEDURE|laparoscopic repair of cesarean scar niche|Intentional perforation of the niche will be done using uterine sound and excision of the fibrotic edges then suturing the uterine incision using 2-0 absorbable suture.
219360486|NCT00993928|BEHAVIORAL|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
219679552|NCT05777837|PROCEDURE|Combined hysteroscopic and laparoscopic repair of cesarean scar niche|Hysteroscopic resection of the niche under laparoscopic guide will be done to avoid perforation of the niche. After completion of the hysteroscopic approach, laparoscopic plication of the niche without opening it will be done using multiple interrupted 2-0 absorbable suture.
219679553|NCT05926843|PROCEDURE|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
219077655|NCT01565707|DRUG|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
219679554|NCT06251921|PROCEDURE|Restoration|with resin-based composite
219679555|NCT03426943|BIOLOGICAL|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
219679556|NCT03426943|BIOLOGICAL|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
219679557|NCT03426943|DEVICE|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
219679558|NCT03426943|DEVICE|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
219679559|NCT03850834|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
219679560|NCT03850834|DRUG|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
219679561|NCT03210012|DIAGNOSTIC_TEST|Transthoracic echocardiography|Diagnostic test done prior and after the dive
219679562|NCT03210012|DIAGNOSTIC_TEST|Blood samples|Diagnostic test done prior and after the dive
219679563|NCT03821766|DEVICE|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
219077656|NCT01565707|DRUG|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
219077657|NCT01565707|BEHAVIORAL|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
219077658|NCT05207813|DEVICE|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
219360487|NCT03225300|RADIATION|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
219360488|NCT04871711|DRUG|Delgocitinib cream|Cream for topical application
219679564|NCT03672344|DEVICE|Lookware TM|Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
219679565|NCT03672344|DEVICE|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
219679566|NCT05714540|DRUG|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
219679567|NCT03958110|DIAGNOSTIC_TEST|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
219679568|NCT00996034|BIOLOGICAL|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
219679569|NCT00996034|RADIATION|[123I]5-IA-85380|up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days
219679570|NCT00996034|DRUG|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
219077659|NCT03736434|BEHAVIORAL|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
219077660|NCT03736434|BEHAVIORAL|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
219210281|NCT06595329|PROCEDURE|Epidural analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned puncture. The epidural space will be identified at the level of the tenth thoracic intervertebral space using the loss of resistance technique and an 18G Tuohy epidural needle. After placing the epidural catheter, 4 ml of local anesthetic Levobupivacaine 0.25% will be administered into the epidural space. After inducing general anesthesia, an additional 4 ml of Levobupivacaine 0.25% will be administered before the surgical incision. Subjects in the control group will receive an infusion of 0.125% Levobupivacaine for 24 hours after the procedure.
219210282|NCT06595329|PROCEDURE|Intrathecal opioid analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned intrathecal puncture. Subsequently, at the selected site, the dura will be punctured using a spinal needle (25G Quincke spinal needle), and 0.3 mg of morphine will be administered to the patient. Following the intervention, the patient will be induced into general anesthesia.
219210283|NCT06878625|COMBINATION_PRODUCT|Sacituzumab Govitecan combined with Toripalimab|Sacituzumab Govitecan combined with Toripalimab
219210284|NCT06878625|COMBINATION_PRODUCT|Sacituzumab govitecan combined with anti-angiogenesis|Sacituzumab govitecan combined with anti-angiogenesis( Bevacizumab or Anlotinib Hydrochloride)
219077661|NCT05530135|OTHER|Exercise program|Exercise program
219077662|NCT05530135|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy
219210285|NCT04707937|OTHER|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
219679571|NCT01602497|DEVICE|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
219679572|NCT01602497|DEVICE|sham rTMS|Patients will undergo ten session of sham rTMS.
219679573|NCT00670722|DRUG|insulin aspart|Intervention at the discretion of the physician
219679574|NCT00670722|DRUG|insulin detemir|Intervention at the discretion of the physician
219679575|NCT00670722|DRUG|biphasic insulin aspart 30|Intervention at the discretion of the physician
219679576|NCT03508180|BEHAVIORAL|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
219679577|NCT03508180|OTHER|CONTROL|None intervention.
219679578|NCT02371902|DEVICE|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
219679579|NCT02371902|DEVICE|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
219679580|NCT03256357|BEHAVIORAL|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
219679581|NCT03256357|BEHAVIORAL|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
219679582|NCT03256357|BEHAVIORAL|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
219679583|NCT00158262|DRUG|Propranolol|Propranolol short-acting or long-acting capsule
219679584|NCT00158262|DRUG|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
219679585|NCT00156026|PROCEDURE|loop electrosurgical excision procedure (LEEP)|1\. loop electrosurgical excision procedure
219077663|NCT05530135|OTHER|Standard clinical care|Standard clinical care
219077664|NCT04628689|OTHER|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
219210286|NCT04707937|OTHER|Regular standard of care education|Access only to regular standard of care education
219210287|NCT06293651|DRUG|DA-4505|Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
219210288|NCT06293651|DRUG|DA-4505 + Pembrolizumab|Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
219210289|NCT06804369|BEHAVIORAL|Intensive psychodynamic therapy (PDT)|The KLIPP treatment unit (UPC KU Leuven, campus Kortenberg) provides intensive psychodynamic treatment (PDT) for patients with different types of PDs. There are three different programs that differ in treatment intensity: (1) inpatient treatment program (5 days a week), (2) day treatment program (4 days a week), and (3) a part-time outpatient treatment program of two half days per week. Patients attend one of these programs and stay in the program for at least 6 months (with an average duration of 8 months). The programs include individual and group psychodynamic psychotherapy as well as art, music and psychomotor therapy.
219210290|NCT06819683|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA. The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
219077665|NCT04988308|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
219077666|NCT04988308|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
219077667|NCT04988308|DRUG|Placebo|Placebo will be administered subcutaneously.
219077668|NCT01168492|DRUG|ketamine|0.5mg/kg ketamine iv
219077669|NCT00866840|DRUG|riluzole|100 mg orally twice daily
219077670|NCT06313762|DEVICE|Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet|They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
219077671|NCT06313762|BEHAVIORAL|Traditional Distractors|The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
219077672|NCT06313762|BIOLOGICAL|Triple Viral + Varicella Vaccine at 3 years of age|Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
219210291|NCT06895044|OTHER|ophtalmologic follow-up|alls exams included in ophtalmologic follow-up every 6 months for 5 years
219210292|NCT06895044|OTHER|ophtalmological follow-up|all exams included in ophtalmological follow-up including axial length mesurment every 6 moths
219210293|NCT06749782|RADIATION|TC|Radiation: Computed Tomography (CT)
219210294|NCT06744517|OTHER|Sprint Interval Training|6 sessions of sprint interval training over 2 weeks. Each session involves 4-6 x 30 second Wingate sprints with 4 minutes of recovery in between on a stationary bike
219210295|NCT06754553|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
219679586|NCT04785898|DIAGNOSTIC_TEST|ID Now™ COVID-19 Screening Test|"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
219679587|NCT05463497|DRUG|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
219679588|NCT05463497|DRUG|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
219679589|NCT05463497|DRUG|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
219679590|NCT05463497|DRUG|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
219077673|NCT06313762|BIOLOGICAL|Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.|Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
219077674|NCT03359980|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
219077675|NCT02243033|DEVICE|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
219077676|NCT06534398|DEVICE|Dental implant prosthesis with cantilever extension|A retrospective study on the radiographic and clinical findings of implant-supported dental prostheses with cantilever extensions in place and function for at least 10 years
219077677|NCT05366777|DRUG|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
219077678|NCT05366777|DRUG|Saline|100 ml of normal saline
219077679|NCT02625623|DRUG|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
219077680|NCT02625623|DRUG|Irinotecan|Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
219077681|NCT02625623|DRUG|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
219077682|NCT02625623|OTHER|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
219077683|NCT01012869|DEVICE|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
219360489|NCT04871711|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.
219077684|NCT05585723|BEHAVIORAL|Questionnaires completion|Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
219210296|NCT06754553|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
219679591|NCT05463497|DRUG|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
219679592|NCT01727817|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
219077685|NCT00115700|DRUG|Cyclophosphamide|1000 mg/m2 I.V. on day 1
219077686|NCT00115700|RADIATION|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
219077687|NCT00115700|DRUG|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
219679593|NCT05289388|DIAGNOSTIC_TEST|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
219679594|NCT02959918|DRUG|SEL-212|SEL-212, biologic
219679595|NCT02959918|DRUG|SEL-037|SEL-037, biologic
219679596|NCT02959918|DRUG|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
219679597|NCT03894709|BEHAVIORAL|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
219679598|NCT05691413|OTHER|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
219679599|NCT03541148|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
219679600|NCT04758195|PROCEDURE|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
219679601|NCT04758195|OTHER|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
219679602|NCT04538469|OTHER|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
219679603|NCT01048853|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
219077688|NCT00115700|DRUG|Prednisolone|50 mg/m2 orally daily for days 1 - 5
219077689|NCT00115700|DRUG|Rituximab|375 mg/m2 IV Infusion day 1
219077690|NCT04237662|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
219077691|NCT04237662|DEVICE|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
219077692|NCT01460329|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
219077693|NCT04357626|OTHER|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
219077694|NCT03578874|DRUG|Sorafenib|PO
219077695|NCT03578874|DRUG|Capecitabine|PO
219077696|NCT03578874|DRUG|Oxaliplatin|IV
219077697|NCT03926091|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
219077698|NCT03926091|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
219077699|NCT00493766|DRUG|LBH589|
219077700|NCT06161675|BEHAVIORAL|QuitAid|Participants will receive the QuitAid intervention, based on a medication adherence intervention, which addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician. Smokers not ready to quit will receive up to two sessions focused on using NRT to cut down cigarette use. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the full QuitAid intervention.
219077701|NCT06161675|BEHAVIORAL|SmokefreeTXT|All participants will receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment. For smokers not ready to quit, participants will receive two week-long pre-quit modules, Practice Quit and Daily Challenges. These modules will help the smoker become comfortable with not smoking for short periods of time and build skills before they attempt to quit. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the ready to quit treatment.
219210297|NCT06754553|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
219679604|NCT01048853|OTHER|Quality-of-Life Assessment|Ancillary studies
219679605|NCT01048853|PROCEDURE|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
219077702|NCT06161675|DRUG|Nicotine Replacement Therapy Patch|All participants will receive up to 8 weeks of NRT in the form of patch. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
219077703|NCT06161675|DRUG|Nicotine lozenge|All participants will receive up to 8 weeks of NRT in the form of lozenge. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
219077704|NCT02352948|DRUG|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
219077705|NCT02352948|DRUG|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
219077706|NCT02352948|DRUG|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
219210298|NCT06754553|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
219210299|NCT06754553|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
219210300|NCT06754553|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
219210301|NCT06754553|PROCEDURE|Cardiac monitoring|Electrocardiogram realized at day 0, 28 and 56.
219210302|NCT06758635|BEHAVIORAL|VRET-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session VR therapy
219210303|NCT06758635|BEHAVIORAL|Flash-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session EMDR Flash therapy
219679606|NCT01048853|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
219679607|NCT01048853|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
219679608|NCT04953143|BEHAVIORAL|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~\- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~* Therapeutic relationship~* Symptom management~* Coping with illness~* Prognostic awareness and illness understanding~* Treatment decision-making~* End-of-life care"
219679609|NCT05505695|OTHER|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
219679610|NCT05505695|OTHER|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
219679611|NCT05141318|OTHER|FROM-16 Questionnaire|A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life
219679612|NCT05141318|OTHER|Semi-structured two-part interview|A telephone/video interview to provide additional context to the FROM-16 responses
219679613|NCT04268758|DEVICE|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
219679614|NCT05141929|BEHAVIORAL|web based education|In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
219077707|NCT02352948|DRUG|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
219077708|NCT02352948|DRUG|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
219077709|NCT02352948|DRUG|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
219077710|NCT04879186|PROCEDURE|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
219077711|NCT01178086|DRUG|Rituximab|Rituximab IV
219077712|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
219077713|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
219077714|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
219077715|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
219077716|NCT01384994|DRUG|Panitumumab|6 mg/kg BW every 2 weeks
219210304|NCT06758635|BEHAVIORAL|PYSCHOEDU-O Group|Arm Description: the participants of this group will get 1 hour lasting online psychotherapy
219210305|NCT06765876|BIOLOGICAL|Autologous CAR123 T lymphocytes|Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)
219679615|NCT02264210|DRUG|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
219210306|NCT06767787|PROCEDURE|laparoscopic sleeve gastrectomy|Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.
219679616|NCT02585713|DRUG|Apixaban|Given PO
219679617|NCT02585713|DRUG|Dalteparin|Given SC
219679618|NCT02585713|OTHER|Questionnaire Administration|Ancillary studies
219679619|NCT00820287|PROCEDURE|Biopsy of testicular tumor|testicular biopsies performed through open surgery
219679620|NCT03160495|OTHER|All patients|All patients are scanned with PET/MR prior to surgery.
219679621|NCT02783313|DEVICE|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
219679622|NCT02783313|OTHER|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
219679623|NCT03956030|OTHER|Contraception Handout|Handout covering contraception options
219679624|NCT03956030|OTHER|Nutritional Handout|Handout covering nutrition
219077717|NCT01384994|DRUG|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
219077718|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
219077719|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
219077720|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
219077721|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
219077722|NCT03386370|DEVICE|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
219077723|NCT00990691|DRUG|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg."
219077724|NCT00990691|DRUG|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg."
219077725|NCT00990691|DRUG|Administration of a placebo|Administration of a daily dose of placebo
219077726|NCT02768961|DRUG|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
219077727|NCT02768961|DRUG|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
219077728|NCT01840267|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
219210307|NCT06767787|PROCEDURE|total knee arthroplasty|Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
219210308|NCT06758882|DRUG|Apalutamide|administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy
219210309|NCT06758882|DRUG|Androgen receptor (AR) inhibitor|administration of androgen deprivation therapy
219210310|NCT06762041|DRUG|Metformin treatment|Interested subjects with autism are treated with metformin with a standard dosage
219210311|NCT05527691|BEHAVIORAL|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
219210312|NCT06769867|RADIATION|PS-3D-DSA|undergo a PS-3D-DSA scan
219210313|NCT06769867|RADIATION|classic 3D-DSA|undergo a classic 3D-DSA scan
219210314|NCT06764017|DRUG|CHiR-DEL|Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
219210315|NCT06755021|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived Exosomes|WPMDE2 (Whey Protein Milk-Derived Exosomes 2) is an advanced nutritional supplement developed from natural milk components.
219210316|NCT06766513|OTHER|Actimetry|actimetry will be performed continuously during these 104 hours.
219210317|NCT06766513|OTHER|Subjective assessments|The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
219210318|NCT06766513|OTHER|questionnaire|MOCA : Montreal Cognitive Assessment
219210319|NCT06766513|OTHER|questionnaire|SF-36 The Short Form (36)
219210320|NCT06766513|OTHER|questionnaire|CRS-R (Coma Recovery Scale-Revised)
219210321|NCT06766513|OTHER|questionnaire|GOSE (Glasgow Outcome Scale-Extended)
219210322|NCT06766513|OTHER|questionnaire|GCS (Glasgow Coma Scale)
219210323|NCT06347601|OTHER|Without Intervention|Without Intervention
219210324|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
219210325|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
219210326|NCT03295773|DIAGNOSTIC_TEST|3DRA|
219210327|NCT05661682|DRUG|Tralement|Tralement with Manganese Sulfate
219679625|NCT01409187|DRUG|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
219679626|NCT01409187|DRUG|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
219077729|NCT01587534|DRUG|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
219077730|NCT05602636|DRUG|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
219077731|NCT00988312|BIOLOGICAL|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
219210328|NCT05661682|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
219210329|NCT06439823|DEVICE|ActiMyo®/Syde®|Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
219210330|NCT06491381|PROCEDURE|Cesarean delivery|The cesarean section will begin with a Pfannenstiel incision above the pubic bone, followed by blunt dissection to separate tissue layers and retracting the rectus muscles for peritoneal cavity access. A transverse or vertical peritoneal incision will expose the uterus, and a transverse incision on the lower uterine segment will be made for delivery. The baby will be delivered, the umbilical cord clamped and cut, and the baby handed to the pediatric team. The placenta will be detached and delivered, and the uterus will be closed with multiple layers of sutures. The abdominal layers will be closed with absorbable Polyglactin (Vicryl) sutures for the rectus sheath and subcutaneous tissue, and non-absorbable Polypropylene sutures for the skin. A sterile dressing will be applied to protect the wound and promote a clean healing environment, ensuring proper surgical technique, tissue handling, and minimizing post-operative complications.
219210331|NCT06282055|OTHER|No intervention|Observational prospective longitudinal data collection
219679627|NCT01409187|DRUG|Interleukin-2 (Aldesleukin)|9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
219679628|NCT04844008|DIETARY_SUPPLEMENT|Nanobubble drink|Commercially available sports drink
219679629|NCT02933398|PROCEDURE|Robotic Assisted Nephrectomy|Robotic (Davinci)
219679630|NCT02933398|PROCEDURE|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
219679631|NCT04682379|DIAGNOSTIC_TEST|Proprioceptive assessment|"1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test"
219077732|NCT01295554|OTHER|NCE MRA and CE MRA|"Each patient will receive on the same day:~* NCE MRA~* CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
219077733|NCT04666168|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
219077734|NCT04666168|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
219077735|NCT04666168|PROCEDURE|Leukapheresis|Leukapheresis
219077736|NCT00234065|DRUG|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
219077737|NCT00234065|DRUG|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
219679632|NCT02204345|DRUG|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
219679633|NCT02204345|DRUG|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
219679634|NCT02204345|DRUG|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
219077738|NCT00126438|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
219077739|NCT00000502|PROCEDURE|cardiopulmonary resuscitation|
219077740|NCT01521676|GENETIC|molecular alteration|research of molecular alteration
219077741|NCT02055131|DRUG|aspirin|
219210332|NCT05479006|DEVICE|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
219210333|NCT03976960|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
219360490|NCT00723164|DRUG|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
219679635|NCT00441870|DRUG|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
219077742|NCT05253872|OTHER|The MelaCare intervention|"The primary principles applied will be:~* Meta-cognitive strategies and normalization of emotions~* Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~* An educational booklet~* Doctor consultation to ensure correct SSE skills and compliance to the protocol~* 3-5 sessions with a experienced and specially trained melanoma nurse~* Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae."
219077743|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
219679636|NCT00441870|DRUG|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
219679637|NCT00597389|DRUG|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
219077744|NCT03254680|DIETARY_SUPPLEMENT|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
219077745|NCT05290558|DRUG|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
219077746|NCT05290558|DRUG|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
219077747|NCT06445491|OTHER|Control order|Participants will perform an initial baseline of tests, order of 1- 2- 3
219077748|NCT06445491|OTHER|Randomized sequence|the testing order will be randomized for follow up testing.
219077749|NCT03711773|OTHER|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
219077750|NCT03009526|DRUG|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
219077751|NCT03009526|DRUG|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
219077752|NCT05083247|DRUG|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
219077753|NCT05083247|RADIATION|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
219077754|NCT05083247|PROCEDURE|Surgery|Surgery
219077755|NCT02198027|DRUG|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
219077756|NCT02198027|OTHER|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
219077757|NCT00375687|DRUG|Triptorelin|
219077758|NCT06615531|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
219210334|NCT06471127|BEHAVIORAL|Pseudoword learning paradigm task|Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.
219210335|NCT06890871|RADIATION|Intensity-modulated radiotherapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
219679638|NCT02764476|OTHER|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
219679639|NCT02764476|OTHER|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
219679640|NCT04910581|PROCEDURE|rTMS|Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
219077759|NCT06669910|OTHER|only assesment|only assesment
219077760|NCT06670729|OTHER|Quran listening|listening to quran recitation via head phone
219077761|NCT06670729|OTHER|silent headphones group|headphones were silent, patient do not listen to any thing
219077762|NCT06507605|BIOLOGICAL|R21|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
219077763|NCT06507605|BIOLOGICAL|Pfs230D1-CRM197|Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
219077764|NCT06507605|BIOLOGICAL|Pfs230D1-EPA|Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
219077765|NCT06507605|OTHER|Matrix-M|Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
219210336|NCT06890871|DRUG|Immunotherapy Therapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
219360491|NCT00723164|DRUG|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
219360492|NCT00217815|DRUG|Mycograb, Docetaxel|
219360493|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|20 minutes exposure
219077766|NCT06293235|OTHER|Lifestyle and metabolic indicators|Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
219077767|NCT01818323|OTHER|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
219077768|NCT05501860|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
219077769|NCT05501860|DRUG|Placebo|Placebo Sterile Topical Ophthalmic Solution
219077770|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
219077771|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
219077772|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
219077773|NCT06628921|DRUG|Eptinezumab 100 or 300 mg ev|Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
219077774|NCT05705687|DRUG|BEP Protocol|anticancer therapy
219077775|NCT05705687|DRUG|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
219077776|NCT05705687|PROCEDURE|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
219077777|NCT02038673|DRUG|ASP5878|oral
219077778|NCT04201548|OTHER|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
219077779|NCT04201548|OTHER|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
219077780|NCT04201548|OTHER|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
219077781|NCT03555331|BEHAVIORAL|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
219077782|NCT03555331|BEHAVIORAL|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
219077783|NCT06925022|OTHER|Strength training session during Early Follicular Phase|"The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets.~This phase occurs at the beginning of the menstrual cycle (days 2-5 after the onset of menstruation)."
219360494|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|40 minutes exposure
219679641|NCT04910581|PROCEDURE|Sham stimulation|Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
219679642|NCT03173456|DRUG|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
219679643|NCT03173456|DRUG|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
219679644|NCT03173456|DRUG|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
219679645|NCT03173456|DRUG|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
219679646|NCT03173456|DRUG|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
219679647|NCT02450838|BIOLOGICAL|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
219679648|NCT02450838|BIOLOGICAL|Alhydrogel™|Aluminum hydroxide gel adjuvant
219679649|NCT02450838|BIOLOGICAL|Placebo|
219679650|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
219077784|NCT06925022|OTHER|Strength Training Protocol during Late Follicular Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs approximately between days 11-13 of the menstrual cycle.
219077785|NCT06925022|OTHER|Strength Training during Mid-Luteal Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs around days 19-28 of the menstrual cycle, following ovulation.
219077786|NCT07128017|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 4-week (30 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
219077787|NCT07128017|BEHAVIORAL|Progressive Muscle Relaxation (Internet-delivered)|A 4-week, unguided online progressive muscle relaxation (PMR) program adapted from Bernstein and Borkovec's protocol. The program included six sequential modules teaching systematic tensing and relaxing of major muscle groups, gradually reducing the number of groups until relaxation could be achieved through recall alone. Materials included audio recordings, written instructions, and automated reminder emails. No therapist guidance was provided.
219077788|NCT07128017|BEHAVIORAL|No Intervention - Waitlist Control|Participants in this arm received no active intervention during the 4-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered the choice to take part in either the online MBCT or PMR program.
219077789|NCT05565430|OTHER|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
219077790|NCT05565430|OTHER|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
219077791|NCT05565430|DRUG|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
219077792|NCT02725554|DEVICE|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
219077793|NCT06877715|OTHER|psychological and sensorial tests|children receive questionnaires and sensorial test
219077794|NCT06140121|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
219077795|NCT06140121|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
219077796|NCT03829254|DRUG|NUC-7738|NUC-7738
219077797|NCT03829254|DRUG|Pembrolizumab|Pembrolizumab
219077798|NCT07079241|OTHER|Naloxone-responder: A volunteer first responder system connected to emergency dispatch service and alerting overdose and first aid educated volunteers with naloxone to suspected opioid overdoses|The model is a smartphone-based alert system with an app which is connected to dispatcher centers. Volunteer first responders will be alerted in addition to standard emergency medical service (like ambulance) to suspected opioid overdoses and also cardiac arrests. The aim is to see if volunteers equipped with naloxone and with up-do-date knowledge of overdose treatment and first aid can arrive and reverse the condition safely prior to emergency service arrival.
219679651|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
219679652|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
219679653|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
219679654|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
219077799|NCT06822998|DRUG|HF50|HF50 is a liposomal T-cell engager with an unique design based on the lipid bilayer. It was also named a T cell Redirecting Antibody Fragment-anchored Liposomes (TRAFsome). The liposomal surface carries anti-CD3ε and anti-HER2 antibody-conjugated lipid molecules, enabling T-cell redirection and activation at HER2-positive or HER2-low tumor sites. In addition, the liposome internal space contains a TLR7/8 agonist Resiquimod (R848), which has been shown to help modulate the myeloid cells in the tumor micro-environement to complement the immune activation effects.
219360495|NCT03467646|PROCEDURE|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
219077800|NCT06573970|DRUG|Atomoxetine|Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
219077801|NCT06573970|DRUG|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
219077802|NCT05763420|DEVICE|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
219077803|NCT05763420|DEVICE|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
219077804|NCT06668350|OTHER|Smoking outcomes|Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide
219077805|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
219077806|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
219077807|NCT07109700|DRUG|HDM1005 1|administered SC, QW, 20 weeks
219077808|NCT07109700|DRUG|HDM1005 2|administered SC, QW, 20 weeks
219077809|NCT07109700|DRUG|HDM1005 3|administered SC, QW, 20 weeks
219077810|NCT07109700|DRUG|HDM1005 4|administered SC, QW, 20 weeks
219077811|NCT07109700|DRUG|Placebo|administered SC, QW, 20 weeks
219077812|NCT07109700|DRUG|Dulaglutide 1.5 MG|administered SC, QW, 20 weeks
219077813|NCT07111364|OTHER|observational diagnostic model development|observational diagnostic model development
219077814|NCT06932406|OTHER|Self-management intervention|"This intervention will implement a self-management protocol. It will consist in 5 strategy levels: educational concepts and dynamics, cognitive behavioural tools and processes, therapeutic exercise of the orofacial region, guidelines and strategies for lifestyle modification and mindbody tools.~Several of the above 5 strategies will be employed in each session. Education will include TMD concepts, pain neurophysiology, contextualisation of pain in terms of perceived stress, anxiety and others. Exercises will aim to train motor control, strength and mobility. Cognitive behavioural tools will be used to modulate pain relationship through behaviour modification. Processes such as cognitive distraction, gradual exposure to movement or the scheduling of self-care activities will be used. Mindbody strategies such as relaxation exercises and pain acceptance will seek to reduce the patient's frustration with pain. Structured guidelines will be included to achieve desirable lifestyle changes."
219210337|NCT06837649|BEHAVIORAL|The mindfulness-based Tai Chi Chuan|Studies have shown that compared with the Tai Chi Chuan, MTCC is more relaxing to practitioner. The Tai Chi Chuan section is based on the Yang's movements, which not only conform to the basic technical characteristics, such as the steps, stance, techniques, movement of the center of gravity, and the coordination of the whole body between the movements, but also are clear, smooth, simple, easy to learn, and beautiful. The mindfulness section is complemented by soothing, soft music to guide the practitioner to focus on himself and return to inner peace. The essence of the program is to help practitioners focus their attention and achieve inner peace during practice. Through the practice of MTCC, practitioners are encouraged to face the difficulties they encounter in reality and to develop a positive and open mind to deal with negative emotions and thoughts in daily life.
219210338|NCT06234631|DRUG|Epidiolex oral solution|"Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening."
219679655|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
219679656|NCT01651975|DIETARY_SUPPLEMENT|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
219210339|NCT06234631|OTHER|Placebo|Participants will be instructed to take one hour before or two hours after eating a meal.
219210340|NCT06755086|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
219210341|NCT05349006|DRUG|Azathioprine|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
219210342|NCT05349006|OTHER|Placebo|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
219360496|NCT03467646|PROCEDURE|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
219360497|NCT03467646|PROCEDURE|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
219360498|NCT04513431|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
219077815|NCT06932406|OTHER|Clinical Practice Guideline Intervention|"Following the guidelines, 5 sessions of education, cognitive behavioural tools, jaw exercises and manual therapy will be conducted.~The educational sessions will teach about TMD and basic pain concepts. A single type of cognitive behavioural tool will be employed. The aim will be to decrease bruxing and parafunctional activity during wakefulness. This will be done by training the jaw relaxation position, which will then be generalised to activities of daily living with the help of some conditioning through positive and negative reinforcement. Exercise activities will aim to train motor control, strength and mobility. Manual therapy will be carried out in the orofacial region by means of soft tissue techniques and joint mobilisation."
219077816|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
219077817|NCT03049046|DRUG|Placebos|Diluent
219077818|NCT03216876|DRUG|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
219077819|NCT02728388|DRUG|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
219077820|NCT01756950|BIOLOGICAL|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
219077821|NCT01756950|BIOLOGICAL|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
219077822|NCT01756950|BIOLOGICAL|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
219077823|NCT01756950|BIOLOGICAL|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
219077824|NCT01756950|BIOLOGICAL|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
219077825|NCT01756950|BIOLOGICAL|Placebo|administered as a single 2-hour intravenous infusion
219077826|NCT01990846|DRUG|Flufirvitide 3|
219077827|NCT01990846|DRUG|Placebo for Flufirvitide-3|
219077828|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, low dose
219077829|NCT00785408|DRUG|placebo|subcutaneous, twice daily, low dose
219077830|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, middle dose
219077831|NCT00785408|DRUG|placebo|subcutaneous, twice daily, middle dose
219077832|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, high dose
219077833|NCT00785408|DRUG|placebo|subcutaneous, twice daily, high dose
219077834|NCT05087082|OTHER|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
219077835|NCT06018792|DIAGNOSTIC_TEST|Molecular Culture|PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
219077836|NCT04861857|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement
219077837|NCT04861857|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement
219077838|NCT00998179|DEVICE|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
219077839|NCT00998179|DEVICE|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
219077840|NCT04081467|OTHER|Bed rest|10-day of complete bed rest
219077841|NCT02987075|OTHER|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
219077842|NCT02987075|OTHER|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
219077843|NCT00375154|DEVICE|Noninvasive Positive-Pressure Ventilation (NPPV)|
219077844|NCT02057874|DEVICE|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
219077845|NCT02057874|DRUG|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
219077846|NCT01738984|BEHAVIORAL|MomZing Web Program|Online web platform that is accessed via a television connected to internet
219077847|NCT01738984|BEHAVIORAL|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
219077848|NCT05390840|DRUG|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
219077849|NCT05390840|OTHER|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
219077850|NCT03031587|OTHER|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
219077851|NCT03031587|DEVICE|MRI|cardiac MRI
219077852|NCT01624038|DRUG|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
219077853|NCT01624038|DRUG|hydroxyurea, blood transfusion|* Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
219077854|NCT01592032|DRUG|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
219077855|NCT01592032|DRUG|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
219077856|NCT01592032|DRUG|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
219679657|NCT01651975|DIETARY_SUPPLEMENT|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
219679658|NCT01050322|DRUG|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
219679659|NCT01050322|DRUG|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
219679660|NCT01050322|DRUG|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
219679661|NCT03264612|BEHAVIORAL|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
219077857|NCT01592032|DRUG|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
219077858|NCT01592032|DRUG|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
219679662|NCT05075863|DRUG|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
219077859|NCT02159248|DRUG|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
219077860|NCT05225623|BEHAVIORAL|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
219077861|NCT05225623|BEHAVIORAL|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
219077862|NCT02297568|DRUG|Calciferol|Comparison 25OHD levels between calciferol and placebo
219077863|NCT02297568|DRUG|placebo|
219077864|NCT01770054|OTHER|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
219077865|NCT02245932|DIETARY_SUPPLEMENT|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
219077866|NCT02245932|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplementation (two doses per day)
219077867|NCT00240487|DRUG|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
219679663|NCT02297425|DRUG|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
219679664|NCT05903638|BEHAVIORAL|Mindfulness-Based Stress Reduction course|8-week, 26-hour, virtual mindfulness course
219679665|NCT01733121|DRUG|NBI-98854|25 mg capsule
219077868|NCT00240487|OTHER|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
219077869|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine low dose|50μg/dose
219077870|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine high dose|100μg/dose
219077871|NCT03280173|DRUG|tafamidis|bioavailability study
219077872|NCT04529668|DRUG|vitamin D supplementation|vitamin D supplementation
219679666|NCT01733121|DRUG|NBI-98854|50 mg capsule
219077873|NCT04529668|DRUG|usual therapy for nasal polyposis|steroids ( systemic and local )
219077874|NCT00487266|OTHER|Acupuncture|Acupuncture of low back and legs.
219077875|NCT05735067|OTHER|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
219077876|NCT02800850|BEHAVIORAL|Bright Light|
219679667|NCT01733121|DRUG|Placebo|
219679668|NCT03340038|OTHER|Non-ICU Specialty ward|
219077877|NCT02800850|BEHAVIORAL|Placebo Light|
219210343|NCT06806098|BEHAVIORAL|Truth Initiative Digital Cessation Program|Truth Initiative's digital cessation program is a multimodal evidence-based, digital tobacco cessation program. Accessible on any web-enabled device, it was developed with the Mayo Clinic around tobacco dependence treatment guidelines, Social Cognitive Theory, and the Mayo Clinic model for engaging tobacco users in cessation treatment. It includes a personalized quit plan with AI-driven content recommendations, interactive exercises, educational videos, and emails; a dynamically tailored, bidirectional text message program; the longest-running online community dedicated to tobacco cessation; synchronous live chat coaching (sponsored version only); and pharmacotherapy decision support and delivery (sponsored version only).
219210344|NCT06806098|BEHAVIORAL|Usual Care|Smokefree.gov is a web-based tobacco cessation platform run by the National Cancer Institute of the National Institutes of Health since 2003 and represents the current standard of care for digital tobacco cessation in the U.S. As of 2020, the SmokeFree.gov Initiative (SFGI) consisted of a multimodal suite of interventions - 6 mobile-optimized websites, 9 text messaging programs, 2 mobile apps, and social media platforms.
219679669|NCT04736069|OTHER|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
219679670|NCT03698539|BEHAVIORAL|hand gestures|We observe the use of spontaneous hand gestures in all the groups.
219679671|NCT04671394|PROCEDURE|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
219077878|NCT03031691|DRUG|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
219077879|NCT03031691|DRUG|trifluridine/tipiracil|
219077880|NCT01367873|DRUG|Placebo|Oral, matching number of placebo capsule(s) with active arm
219077881|NCT01367873|DRUG|VIA-3196|Oral, capsule(s)
219077882|NCT01898468|PROCEDURE|Pericostal Closure Technique|
219679672|NCT04671394|PROCEDURE|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
219679673|NCT02670421|BEHAVIORAL|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
219679674|NCT02670421|BEHAVIORAL|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
219679675|NCT02670421|BEHAVIORAL|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
219679676|NCT05399147|OTHER|fiberoptic intubation classic technique|classic fiberoptic intubation
219679677|NCT05399147|OTHER|fiberoptic intubation tube 1st technique|tube 1st technique
219679678|NCT02247739|BIOLOGICAL|Recombinant human C1 inhibitor|
219077883|NCT01898468|PROCEDURE|Intracostal Closure Technique|
219077884|NCT02427126|DRUG|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
219077885|NCT02427126|DRUG|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
219077886|NCT06509126|DRUG|Panitumumab|Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
219077887|NCT06509126|DRUG|Irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
219077888|NCT06509126|DRUG|5-fluorouracil|Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
219077889|NCT06509126|DRUG|L-folinic acid|Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
219077890|NCT02526732|OTHER|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
219077891|NCT01073423|BEHAVIORAL|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
219679679|NCT02247739|OTHER|Placebo|
219679680|NCT06549738|DEVICE|Intermittent pneumatic compression therapy|Lympha Press Optimal Plus is an advanced intermittent pneumatic compression therapy device. It is FDA cleared (K170658) for the indication of lipedema as well as for other indications for use.
219679681|NCT04501952|DRUG|RDV|Administered as an intravenous infusion
219077892|NCT01073423|BEHAVIORAL|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
219077893|NCT03952858|OTHER|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
219077894|NCT03827954|OTHER|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
219077895|NCT01835457|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
219679682|NCT04501952|DRUG|Placebo to Match RDV|Administered as an intravenous infusion
219077896|NCT01835457|BEHAVIORAL|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
219077897|NCT05203926|PROCEDURE|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
219077898|NCT01702727|DEVICE|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
219077899|NCT01702727|DEVICE|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
219077900|NCT01702727|DEVICE|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
219077901|NCT01205594|DEVICE|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
219077902|NCT01240174|BEHAVIORAL|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
219210345|NCT06704698|DRUG|Liposomal bupivacaine|Thoracic paravertebral block with liposomal bupivacaine.
219077903|NCT05119894|DRUG|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
219077904|NCT05119894|DRUG|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
219077905|NCT05119894|DRUG|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
219077906|NCT05119894|DRUG|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
219077907|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
219077908|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
219077909|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
219077910|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
219077911|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
219077912|NCT01499004|DRUG|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
219077913|NCT02002481|OTHER|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
219077914|NCT04592068|DEVICE|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
219077915|NCT04592068|OTHER|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
219077916|NCT02947126|DRUG|Hypertonic Saline|Inhaled 7% Hypertonic saline
219210346|NCT06704698|DRUG|Bupivacaine Hydrochloride|Epidural block with plane bupivacaine.
219210347|NCT06856148|BEHAVIORAL|Intervention: RPC Group|"The RPC model entails seven interrelated steps including a capacity building and collaboration phase. Throughout the implementation, researchers are provided direct access to intermediary support from our trained RPC fellows who facilitate RPC activity at each step coordinated by an implementation supervisor. Importantly, this model does not involve any lobbying. Consistent with NIH guidelines for grantees, the RPC instead aims to highlight and translate public health evidence…; conduct coalition building…; provide leadership and training, and foster safe and healthful environments. Specifically, implementation of the RPC model explicitly does not attempt to influence legislative actions, but instead facilitates honest brokerage in which researchers discuss evidence without indicating opinion or stance on how legislators should change specific policies, programs, or regulations."
219360499|NCT02052271|DEVICE|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
219679683|NCT01439984|DRUG|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
219077917|NCT02947126|DRUG|Isotonic Saline|Inhaled 0.9% Isotonic saline
219077918|NCT02947126|DRUG|Indium-DTPA|Inhaled Indium 111 DTPA
219077919|NCT02947126|DRUG|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
219077920|NCT02224768|DRUG|Ipilimumab|
219077921|NCT00990834|DRUG|simvastatin|simvastatin 80 mg PO daily for one to eight months.
219077922|NCT03100617|BEHAVIORAL|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
219679684|NCT04351880|OTHER|Medically Tailored Meals|Compare 2 and 4 weeks of meal delivery
219679685|NCT03061188|OTHER|Laboratory Biomarker Analysis|Correlative studies
219679686|NCT03061188|BIOLOGICAL|Nivolumab|Given IV
219679687|NCT03061188|OTHER|Pharmacological Study|Correlative studies
219679688|NCT03061188|DRUG|Veliparib|Given PO
219679689|NCT01400724|DIETARY_SUPPLEMENT|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
219679690|NCT00712894|DRUG|Diltiazem|Intracoronary Infusion 400-2000ug
219679691|NCT00712894|DRUG|Verapamil|Intracoronary Infusion 200-1000ug
219679692|NCT00712894|DRUG|Nitroglycerin|Intracoronary Infusion 200-1000ug
219679693|NCT04240561|DEVICE|High level of signal manipulation|Hearing aid will be programmed to a high level of signal manipulation.
219077923|NCT06248918|BEHAVIORAL|WATSOCPAP|Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
219077924|NCT01009931|DRUG|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
219077925|NCT01009931|DRUG|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
219077926|NCT01009931|DRUG|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
219077927|NCT03044483|OTHER|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
219077928|NCT02110641|BEHAVIORAL|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
219077929|NCT01297231|OTHER|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
219077930|NCT04354467|DIAGNOSTIC_TEST|urine neutrophil gelatinase -associated lipocalin|urine biomarker is measured and batched procesessed
219077931|NCT03532074|DIAGNOSTIC_TEST|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
219679694|NCT04240561|DEVICE|Low level of signal manipulation|Hearing aid will be programmed to a low level of signal manipulation.
219679695|NCT05945121|OTHER|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
219679696|NCT05762640|DRUG|Ruxolitinib|"Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT."
219679697|NCT04979533|DEVICE|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
219679698|NCT00986323|DEVICE|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
219210348|NCT06856148|BEHAVIORAL|Active Comparator: Control Group|"Control group participants will receive light touch research support, similar to previous work (e.g., an RPC associate will send publicly available research materials in response to research requests). This light touch control condition will increase responsiveness of state officials to survey follow up requests."
219360500|NCT00028912|DRUG|bortezomib|
219360501|NCT00028912|DRUG|carboplatin|
219679699|NCT00986323|DEVICE|Placebo TLA|Placebo TLA (without filtration and TLA function)
219679700|NCT00833404|DRUG|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
219679701|NCT01770808|DIETARY_SUPPLEMENT|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
219679702|NCT01770808|DIETARY_SUPPLEMENT|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
219679703|NCT01770808|DIETARY_SUPPLEMENT|Placebo|Subjects swallowed 4 capsules/day for six weeks.
219679704|NCT04957784|OTHER|questionnaire survey|Understand the current situation of hypertension management in a poor county in Shanxi Province through questionnaire surveys, and explore the factors that affect patients' blood pressure control based on local conditions
219679705|NCT05963932|DRUG|BMS-986419 DR Capsule|Specified dose on specified days
219679706|NCT05963932|DRUG|BMS-986419 IR Tablet|Specified dose on specified days
219679707|NCT06109350|OTHER|Supporting play exploration and early developmental intervention(SPEEDI)|SPEEDI will be performed by the parents
219679708|NCT06109350|OTHER|Standard care|Standard care will be performed by the parents
219679709|NCT00835835|OTHER|Body-weight supported treadmill training +/- Lokomat assistance|walking
219077932|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
219077933|NCT03532074|DIAGNOSTIC_TEST|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
219077934|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
219077935|NCT02319811|PROCEDURE|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
219077936|NCT03616548|DIAGNOSTIC_TEST|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
219077937|NCT04757987|OTHER|Pain|As above
219077938|NCT05389579|DEVICE|electric blanket|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
219077939|NCT01235390|DIETARY_SUPPLEMENT|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
219077940|NCT05786690|OTHER|Interventions|the temporospatial and kinematic gait characteristics
219077941|NCT00867438|PROCEDURE|Sigmoidoscopy|
219077942|NCT00908167|DRUG|Sorafenib|Please see detailed description.
219077943|NCT00908167|DRUG|Cytarabine|Please see Detailed Description.
219077944|NCT00908167|DRUG|Clofarabine|Please see Detailed Description.
219077945|NCT06423846|DRUG|Total intravenous anesthesia group|Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour
219077946|NCT06423846|DRUG|sevoflurane group|For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
219077947|NCT00981981|DIETARY_SUPPLEMENT|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
219210349|NCT04566250|COMBINATION_PRODUCT|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
219679710|NCT00835835|OTHER|Usual Care - no active intervention|No treatment used for comparison
219679711|NCT04262063|BEHAVIORAL|Tell play do technique|it apply the concept of learning by doing .children will enjoy playing with customized dental models
219360502|NCT04887493|DRUG|Misoprostol|Misoprostol 25µg will be used for both the study arms
219679712|NCT04262063|BEHAVIORAL|tell show do|Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
219679713|NCT00436826|DRUG|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
219679714|NCT00436826|DRUG|Placebo|Participants were administered with placebo orally.
219679715|NCT00436826|DRUG|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
219077948|NCT00981981|DIETARY_SUPPLEMENT|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
219077949|NCT00981981|DIETARY_SUPPLEMENT|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
219077950|NCT00981981|DIETARY_SUPPLEMENT|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
219077951|NCT00981981|DIETARY_SUPPLEMENT|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
219077952|NCT06380218|BEHAVIORAL|Nutrional and physical activity program|Nutritional prevention and physical activity workshops associated with a substitution of saturated and/or trans fatty acids by cis-unsaturated acids via the consumption of Primevère margarine to influence lifestyle habits, quality of life and improvement of the lipid profile of women with cardiovascular risk
219077953|NCT01106833|DRUG|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
219077954|NCT01106833|DRUG|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
219679716|NCT05689567|DEVICE|DEFOG glasses(peripheral focus-out glasses)|Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.
219077955|NCT05582720|BEHAVIORAL|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
219077956|NCT05582720|BEHAVIORAL|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
219077957|NCT05488392|PROCEDURE|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
219077958|NCT04376138|OTHER|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
219077959|NCT04376138|OTHER|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
219679717|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
219679718|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
219679719|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
219679720|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
219679721|NCT00784719|DRUG|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
219679722|NCT00784719|DRUG|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
219679723|NCT06822101|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
219679724|NCT04396899|BIOLOGICAL|EHM implantation|Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF \<35%).
219679725|NCT04892199|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
219679726|NCT04892199|DRUG|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
219679727|NCT04060797|DEVICE|endovascular denervation|Treating with endovascular denervation (EDN) at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
219679728|NCT04060797|DEVICE|PTA|Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
219679729|NCT02797509|BEHAVIORAL|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
219679730|NCT02594917|PROCEDURE|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
219679731|NCT02594917|OTHER|Blood draw|Test and control group will be asked to give 20 ml of blood samples
219679732|NCT01698944|DRUG|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
219679733|NCT01836146|DEVICE|EnligHTN™ Renal Artery Ablation Catheter|
219679734|NCT05464420|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219679735|NCT05464420|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219077960|NCT04000568|OTHER|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
219210350|NCT04977583|BEHAVIORAL|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
219360503|NCT04219423|BEHAVIORAL|Multimodal physical therapy|see description in arm/group description
219210351|NCT04977583|BEHAVIORAL|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
219210352|NCT04977583|BEHAVIORAL|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
219210353|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
219210354|NCT04047706|DRUG|Nivolumab|Given IV
219210355|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
219210356|NCT04047706|DRUG|Temozolomide|Given PO
219210357|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
219210358|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
219210359|NCT02134171|OTHER|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
219210360|NCT00002866|BIOLOGICAL|filgrastim|
219210361|NCT00002866|DRUG|docetaxel|
219210362|NCT00002866|DRUG|epirubicin hydrochloride|
219077961|NCT01621126|DEVICE|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
219077962|NCT00886340|BEHAVIORAL|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
219210363|NCT00070486|DRUG|carboplatin|given IV
219210364|NCT00070486|DRUG|celecoxib|given PO
219210365|NCT00070486|DRUG|gemcitabine hydrochloride|given IV
219210366|NCT00070486|DRUG|zileuton|given PO
219210367|NCT03676088|PROCEDURE|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
219210368|NCT02894554|DRUG|Telbivudine|
219210369|NCT02894554|DRUG|Lamivudine|
219210370|NCT03986840|OTHER|Exercise training|A multicomponent exercise program
219210371|NCT04047784|DEVICE|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
219077963|NCT00886340|BEHAVIORAL|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
219210372|NCT04975217|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
219210373|NCT04975217|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
219210374|NCT04975217|OTHER|Questionnaire Administration|Ancillary studies
219210375|NCT04975217|PROCEDURE|Resection|Undergo standard of care resection
219210376|NCT04975217|PROCEDURE|Therapeutic Colonoscopy|Undergo colonoscopy
219210377|NCT02260973|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
219210378|NCT03373916|BEHAVIORAL|Peer mentorship|The PREVAIL intervention will be delivered by a Certified Peer Support Specialist (CPSS) or Peer Recovery Coach. Participants will select a Peer to work with based on brief personal descriptions. Sessions may occur in-person (public place, the participant's home, or a research clinic space) or remotely (phone or video call). The first meeting will occur while the participant is hospitalized, and subsequent sessions will be scheduled per the participant's preferences, with a suggested frequency of twice weekly for weeks 1-2, weekly for weeks 3-8, and every other week for the last month. Sessions will last 1 hour on average and will consist of semi-structured conversations focused on protective factors such as hope, safety planning, and coping skills. Session structure and content are intentionally flexible to allow for general supportive listening, validation, sharing, and genuineness in the relationship, thereby increasing acceptability and implicit belongingness.
219210379|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
219360504|NCT05133011|PROCEDURE|Tongue base reduction surgery|Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
219360505|NCT03979274|DRUG|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
219360506|NCT03979274|DRUG|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
219077964|NCT02062359|BIOLOGICAL|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
219077965|NCT02062359|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219077966|NCT02062359|DRUG|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
219077967|NCT02062359|DRUG|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219077968|NCT03355417|OTHER|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
219077969|NCT04843033|DRUG|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
219077970|NCT01949311|DRUG|Dupilumab|
219077971|NCT00201084|BEHAVIORAL|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
219077972|NCT02939040|BEHAVIORAL|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
219077973|NCT03449810|PROCEDURE|DSE plus MET group A|"The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles."
219077974|NCT03449810|PROCEDURE|DSE alone group B|The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.
219077975|NCT03449810|PROCEDURE|Standard Physiotherapy treatment group C|In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
219077976|NCT02508467|DRUG|Fisogatinib (BLU-554)|
219077977|NCT03272633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
219077978|NCT03272633|BIOLOGICAL|Irradiated Allogeneic Cells|Correlative studies
219077979|NCT02672254|RADIATION|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
219077980|NCT00559650|DRUG|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
219077981|NCT00559650|DRUG|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
219077982|NCT03412682|DRUG|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
219077983|NCT03412682|DRUG|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
219077984|NCT03412682|DRUG|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
219077985|NCT03455374|DEVICE|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
219077986|NCT02120027|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
219077987|NCT02120027|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
219077988|NCT04106726|DRUG|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
219077989|NCT04106726|DRUG|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
219077990|NCT04106726|DRUG|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
219077991|NCT03192605|OTHER|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
219077992|NCT03192605|OTHER|Placebo|Placebo - matched for calories and fiber
219077993|NCT00875004|BIOLOGICAL|epoetin beta|
219077994|NCT00875004|DRUG|systemic chemotherapy|
219077995|NCT00875004|PROCEDURE|quality-of-life assessment|
219077996|NCT05549973|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219077997|NCT04222101|DIAGNOSTIC_TEST|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
219360507|NCT00671255|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
219360508|NCT00671255|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
219360509|NCT00671255|DRUG|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
219077998|NCT06495788|DEVICE|High-intensity laser therapy (HILT)|"* Pulsed high-intensity laser therapy (HILT) will be applied 3 sessions per week for 8 weeks with pulsed emission (1064 nm), very high peak power (3 kW), a short duration (120-150 ms), and low frequency (10-40 Hz).The probe is fixed vertically at 90° to the most painful points while the patients sit on a chair and wear safety eyewear.~* Conventional treatment ( 3 days per week for 8 weeks).: in the form of~* Hot pad: It will be used over the temporomandibular joint (TMJ) for 5 minutes at the beginning of each session.~* Ultrasound therapy (US): it will be applied over the TMJ with pulsed intensity of 1.0 W/cm2 at a 1MHz frequency for 5 min/session.~* TENS: one electrode is placed over the TMJ and the other just above the mandibular angle. it will be applied with a low frequency of 50 HZ, tolerable intensity for 15 minutes.~* Exercise therapy: anterior, medial and lateral glide of the mandible. Each glide will be done 10-15 repetitions, 5-6 times in a session, 10 minutes as a total."
219077999|NCT06495788|DEVICE|placebo high-intensity laser therapy|The same treatment procedure will be applied in the placebo group as in the experimental group, but the laser device is turned off during applications, in addition to the conventional treatment in the form of hot pad, US, TENS, and exercise therapy.
219078000|NCT02919800|BIOLOGICAL|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
219078001|NCT02919800|OTHER|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
219078002|NCT01002872|DRUG|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
219078003|NCT01002872|DRUG|placebo|Initial dose of placebo will be 1 pill three times a day
219078004|NCT02479568|DIETARY_SUPPLEMENT|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
219078005|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
219078006|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
219078007|NCT00414817|BEHAVIORAL|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
219078008|NCT05554068|DRUG|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
219078009|NCT01579591|OTHER|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
219078010|NCT01579591|OTHER|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
219078011|NCT05251051|BEHAVIORAL|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
219078012|NCT05251051|OTHER|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
219078013|NCT05703568|OTHER|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
219078014|NCT05703568|OTHER|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
219078015|NCT05774366|DRUG|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
219078016|NCT05774366|DRUG|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
219078017|NCT00447057|DRUG|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
219078018|NCT00447057|DRUG|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
219078019|NCT00447057|DRUG|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
219078020|NCT00447057|DRUG|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
219078021|NCT00900068|OTHER|immunoenzyme technique|
219078022|NCT00900068|OTHER|laboratory biomarker analysis|
219078023|NCT00900068|OTHER|medical chart review|
219078024|NCT02415426|BEHAVIORAL|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek \& Steffen Moritz, http://clinical-neuropsychology.de/metacognitive\_training\_for\_depression.html).
219360510|NCT00935558|BIOLOGICAL|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
219078025|NCT04487093|DRUG|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
219078026|NCT04487093|DRUG|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
219078027|NCT02073695|PROCEDURE|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
219078028|NCT02073695|DEVICE|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
219078029|NCT02073695|OTHER|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
219078030|NCT02073695|OTHER|Functional outcome forms filled in|
219078031|NCT02073695|OTHER|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
219078032|NCT02073695|OTHER|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
219078033|NCT05741580|PROCEDURE|Evolution of symptoms|percentage of patients with improvement in their symptoms
219078034|NCT00738946|DRUG|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
219078035|NCT01834066|BIOLOGICAL|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
219078036|NCT00981890|DRUG|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
219078037|NCT02468401|PROCEDURE|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
219078038|NCT03386903|DEVICE|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
219078039|NCT03386903|DEVICE|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
219078040|NCT05074628|DRUG|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
219078041|NCT01993225|DRUG|Androxal 12.5 mg/25 mg|
219078042|NCT01993225|DRUG|Placebo Capsules|
219078043|NCT01993225|DRUG|AndroGel 1.62%|
219078044|NCT01993225|DRUG|Placebo Gel|
219078045|NCT02940366|DRUG|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
219078046|NCT02940366|DRUG|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
219078047|NCT00484003|DRUG|Pimecrolimus cream 1%|
219078048|NCT06043739|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally
219078049|NCT06043739|DRUG|Filgotinib|Film-coated mini-tablets administered orally
219360511|NCT00935558|DRUG|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
219360512|NCT06424093|PROCEDURE|Virtual Reality Technology|To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
219078050|NCT01737957|DEVICE|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
219078051|NCT01737957|DEVICE|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
219078052|NCT01562210|DRUG|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
219078053|NCT01562210|DRUG|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
219078054|NCT01562210|RADIATION|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
219078055|NCT01843192|DEVICE|Endocutter|
219078056|NCT01471054|DRUG|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
219078057|NCT01471054|DRUG|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
219078058|NCT03509649|PROCEDURE|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
219078059|NCT04493216|DRUG|GSK3640254|GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
219078060|NCT04493216|DRUG|ABC/3TC|ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
219078061|NCT04493216|DRUG|FTC/TAF|FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
219078062|NCT04493216|DRUG|Dolutegravir|Dolutegravir was available as a 50 mg tablet to be administered via oral route.
219078063|NCT04493216|DRUG|Placebo|Placebo matching GSK3640254 was administered in the form of tablets via oral route.
219078064|NCT02672787|BEHAVIORAL|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
219078065|NCT02672787|BEHAVIORAL|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
219078066|NCT02269566|DRUG|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
219078067|NCT02269566|DRUG|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
219078068|NCT00083057|DRUG|gefitinib|
219078069|NCT00083057|DRUG|paclitaxel|
219078070|NCT00083057|RADIATION|radiation therapy|
219078071|NCT01559844|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
219078072|NCT01559844|DRUG|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219679736|NCT01383018|DEVICE|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
219679737|NCT01643447|DRUG|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
219679738|NCT01643447|DRUG|Diammonium glycyrrhizinate|
219679739|NCT00438204|BIOLOGICAL|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
219078073|NCT04917133|BEHAVIORAL|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
219078074|NCT04917133|OTHER|Control|classic 4-week rehabilitation program (standard care)
219078075|NCT04325438|OTHER|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~1. Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~2. Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
219078076|NCT00630110|DRUG|docetaxel|docetaxel (75 mg/m2)
219078077|NCT00630110|DRUG|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
219679740|NCT00438204|DRUG|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
219679741|NCT00438204|DRUG|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
219679742|NCT00558987|BEHAVIORAL|Discipline Video|"1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
219679743|NCT00558987|BEHAVIORAL|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
219078078|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
219078079|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
219078080|NCT03824379|DIETARY_SUPPLEMENT|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
219078081|NCT03824379|DRUG|Antidiabetic|insulin or oral hypoglycemics
219078082|NCT01514448|DRUG|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
219078083|NCT02881723|PROCEDURE|Surgery|
219078084|NCT02881723|RADIATION|Radio- chemotherapy|
219078085|NCT02314624|BEHAVIORAL|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
219078086|NCT02314624|BEHAVIORAL|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
219078087|NCT01180855|DRUG|Placebo|Placebo pill nightly for 42 nights.
219078088|NCT01180855|DRUG|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
219078089|NCT01180855|OTHER|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
219078090|NCT06469710|DEVICE|leukapheresis|Leukapheresis employs the density differential between leukocytes and other blood components to selectively separate leukocytes and return all other components of the blood to the patient. It can process multiple blood volumes in the body circulation, thereby enabling the concentration of nucleated cells to be significantly increased. The procedure is performed while maintaining no significant change in the patient's circulating blood volume, and it is a routine clinical procedure that is well tolerated and safe. CTC can be greatly enriched in a concentrated sample of leukocytes because it has a similar density to that of leukocytes and other nucleated cells. The density of CTCs is similar to that of nucleated cells, such as leukocytes, which enables their enrichment in single leukocyte concentrate samples.
219078091|NCT03065868|DRUG|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
219078092|NCT01436825|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
219679744|NCT04653259|OTHER|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
219679745|NCT03459508|DIAGNOSTIC_TEST|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
219679746|NCT05781087|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
219078093|NCT03676855|PROCEDURE|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
219078094|NCT05090709|OTHER|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
219210380|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume\_1 (PTV\_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV\_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV\_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
219210381|NCT04098575|DRUG|Empagliflozin|drug
219210382|NCT03367338|OTHER|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
219210383|NCT04540003|OTHER|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
219679747|NCT05781087|DIAGNOSTIC_TEST|Cardiac magnetic resonance angiogram|1.5T
219679748|NCT06620185|BIOLOGICAL|FLUENZ|LAIV (Intranasal Influenza Vaccine)
219679749|NCT06620185|BIOLOGICAL|Influenza challenge virus|Influenza challenge virus (H3N2 strain)
219679750|NCT03428399|OTHER|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
219679751|NCT02716922|PROCEDURE|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
219679752|NCT06308900|OTHER|Clinical simulation|Carrying out a total of 9 clinical simulation in three days, one day a week, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
219210384|NCT03568175|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
219679753|NCT00157001|PROCEDURE|Photopheresis Post Angioplasty|
219679754|NCT00285766|DRUG|Selegiline Transdermal System|
219679755|NCT00826150|BIOLOGICAL|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
219210385|NCT00418795|DRUG|recombinant human porphobilinogen deaminase (Porphozym)|
219210386|NCT03791996|PROCEDURE|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
219679756|NCT04962035|OTHER|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
219679757|NCT01085240|OTHER|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
219679758|NCT03381859|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
219679759|NCT03188783|DRUG|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
219679760|NCT03188783|DRUG|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
219078095|NCT05090709|OTHER|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
219078096|NCT01959451|DRUG|Prasugrel|see Arm description
219078097|NCT01959451|DRUG|Clopidogrel|see arm description
219210387|NCT04433637|DIETARY_SUPPLEMENT|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
219360513|NCT03719157|PROCEDURE|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
219210388|NCT04433637|OTHER|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
219210389|NCT00686595|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV infusion.
219210390|NCT00488566|DRUG|GSK drug|GSK drug
219210391|NCT00488566|OTHER|Placebo|Placebo
219210392|NCT00488566|OTHER|Lamictal|Positive control
219210393|NCT01752699|DRUG|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
219210394|NCT01752699|DRUG|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
219078098|NCT04855422|DIAGNOSTIC_TEST|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
219078099|NCT04855422|DIAGNOSTIC_TEST|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
219210395|NCT00195403|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
219210396|NCT01825850|DRUG|Gemigliptin|
219210397|NCT01825850|DRUG|Irbesartan|
219210398|NCT06003075|COMBINATION_PRODUCT|Nivolumab and Chemotherapy|3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
219078100|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
219078101|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment.
219078102|NCT03656601|DIAGNOSTIC_TEST|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
219078103|NCT04221997|DRUG|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
219078104|NCT03968913|DRUG|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
219078105|NCT03968913|PROCEDURE|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
219078106|NCT05240716|OTHER|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
219078107|NCT04651023|DIETARY_SUPPLEMENT|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
219078108|NCT05952180|DEVICE|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
219210399|NCT06003075|DRUG|Nivolumab|Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
219210400|NCT06003075|PROCEDURE|Post Induction Surgery|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
219210401|NCT06003075|RADIATION|Post Induction XRT|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
219210402|NCT05761626|OTHER|MP/Crs assessment < = 0.48 J/min/ml/cmH2O|Assessment of the ventilatory variables according to the MP/Crs value (\<= or \> 0.48 J/min/ml/cmH2O)
219210403|NCT06951308|DIETARY_SUPPLEMENT|Carbohydrate loading before surgery|Carbohydrate loading 2 hours before the surgery (400 ml of 12.5 maltodextrin and 400 ml of over-the-counter fruit-based lemonade)
219210404|NCT02956642|DEVICE|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
219210405|NCT02956642|DEVICE|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
219210406|NCT05288348|DRUG|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
219210407|NCT05288348|DRUG|standard care pain treatment|standard care pain treatment given in Emergency Department
219210408|NCT05182229|OTHER|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
219679761|NCT05340296|BEHAVIORAL|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
219078109|NCT05952180|OTHER|Standard cycloergometer|the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
219078110|NCT04195009|PROCEDURE|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
219078111|NCT05986175|OTHER|Motor Imagery Training|The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
219210409|NCT05182229|OTHER|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
219679762|NCT00700128|DRUG|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
219078112|NCT05986175|OTHER|Core Stabilization Exercises|Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
219078113|NCT04917523|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cell), Inactivated|0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
219078114|NCT02107118|BIOLOGICAL|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
219078115|NCT02107118|OTHER|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
219078116|NCT00986206|DIAGNOSTIC_TEST|Biomarker LPA and HE4|Non Interventional Trial
219078117|NCT02852551|DRUG|PAT-1251|
219078118|NCT02852551|DRUG|Placebo|
219078119|NCT05682053|DIAGNOSTIC_TEST|Multiparametic MRI|patients will have a Multiparametric MRI
219078120|NCT03604081|OTHER|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
219078121|NCT03604081|OTHER|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
219078122|NCT01204801|DEVICE|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
219078123|NCT01204801|DRUG|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
219078124|NCT00689767|DEVICE|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
219078125|NCT00689767|DEVICE|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
219078126|NCT01556373|OTHER|NA : non interventional study|NA : non interventional study
219078127|NCT03322969|DRUG|Paclitaxel/DDP|receiving the modified chemotherapy
219078128|NCT03322969|DRUG|XELOX/SOX|receiving the original chemotherapy
219078129|NCT05550116|OTHER|Giomer|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
219078130|NCT05550116|OTHER|Two composite resin sealants|Unfilled composite resin sealants
219078131|NCT05186870|OTHER|Outcome measures|Observational study
219078132|NCT00546585|BIOLOGICAL|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
219078133|NCT00546585|DRUG|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
219078134|NCT03210805|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
219078135|NCT00478348|PROCEDURE|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
219210410|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
219210411|NCT03053960|DEVICE|Computed Tomography|Undergo helical CT scan
219210412|NCT03053960|DEVICE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
219210413|NCT03053960|DEVICE|Cone-Beam Computed Tomography|Undergo CBCT scan
219210414|NCT03053960|DEVICE|Magnetic Resonance Imaging|Undergo MRI scan
219078136|NCT05455099|RADIATION|Carotid ultrasound examination 1|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.
219078137|NCT05455099|RADIATION|Carotid ultrasound examination 2|Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
219078138|NCT04082546|PROCEDURE|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
219078139|NCT00373399|DRUG|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
219078140|NCT00373399|DRUG|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
219210415|NCT03053960|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection of tumor
219078141|NCT00373399|DRUG|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
219078142|NCT01549431|DRUG|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"
219078143|NCT01549431|DRUG|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"
219078144|NCT01549431|DRUG|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
219078145|NCT06579482|DRUG|Aesculus hippocastanum, and associations|combination product
219078146|NCT06578962|OTHER|Phase 1: short intensive treatment phase|During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.
219078147|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with gentle balancing shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the gentle balancing shampoo RD1089O was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
219078148|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with neutral shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the neutral shampoo RD0057H was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
219078149|NCT06578962|OTHER|Phase 2 : neutral shampoo|"During maintenance phase (phase 2):~the neutral shampoo RD0057H was applied thrice a week for 8 weeks."
219078150|NCT05193591|OTHER|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
219078151|NCT06580288|DRUG|Finerenone|10mg or 20mg
219210416|NCT03053960|PROCEDURE|Histopathologic Examination|Correlative studies
219078152|NCT06580288|DRUG|Placebo|10mg or 20mg
219078153|NCT05441085|DEVICE|programed intermittent epidural bolus interval 90 (EI90)|programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
219078154|NCT05728723|DEVICE|Android Application|Android Application for 3 months
219078155|NCT05728723|BEHAVIORAL|Pharmacy education|Pharmacy education in hypertensive patients
219078156|NCT03362567|OTHER|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
219078157|NCT03362567|OTHER|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
219078158|NCT06431282|OTHER|CO2 laser + HA|Probands will be treated with a CO2 laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
219078159|NCT06431282|OTHER|Thulium laser + HA|Probands will be treated with a thulium laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
219078160|NCT02507518|PROCEDURE|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
219210417|NCT06156046|DIAGNOSTIC_TEST|skin prick test|Skin prick test for bee venom
219210418|NCT06156046|DIAGNOSTIC_TEST|Blood tests|IgE/G and T cell tolerance studies
219210419|NCT06274086|PROCEDURE|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
219210420|NCT03042039|OTHER|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
219679763|NCT00700128|DRUG|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
219679764|NCT00700128|DRUG|placebo|placebo
219360514|NCT03719157|PROCEDURE|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
219078161|NCT02489396|BEHAVIORAL|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal \& breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
219210421|NCT03380013|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
219210422|NCT02696161|OTHER|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
219210423|NCT02696161|OTHER|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
219078162|NCT02489396|BEHAVIORAL|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
219078163|NCT02489396|BEHAVIORAL|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
219078164|NCT02489396|BEHAVIORAL|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
219078165|NCT00713648|DRUG|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
219078166|NCT03607929|PROCEDURE|optimal|Physiological Saline Solution
219078167|NCT03607929|PROCEDURE|variability|Other solutions
219078168|NCT03603210|DEVICE|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
219078169|NCT03212157|OTHER|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
219078170|NCT03212157|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
219078171|NCT03212157|DIAGNOSTIC_TEST|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
219078172|NCT00082173|DRUG|Moxifloxacin|400mg daily for 8 weeks
219078173|NCT02771444|DEVICE|Tomo Assessment|A four-view tomosynthesis examination
219078174|NCT00644631|DRUG|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
219078175|NCT00644631|DRUG|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
219078176|NCT04602130|OTHER|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
219210424|NCT01866215|OTHER|exercise|cycling at 100W during 60 min
219210425|NCT01866215|DIETARY_SUPPLEMENT|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
219210426|NCT01866215|DIETARY_SUPPLEMENT|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
219210427|NCT03853161|OTHER|Vapotherm|A form of non invasive ventilation used in newborns
219210428|NCT03853161|OTHER|NIPPV|A form of non invasive ventilation used in newborns
219360515|NCT03719157|PROCEDURE|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
219210429|NCT04255212|OTHER|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
219679765|NCT00704977|PROCEDURE|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
219679766|NCT04130152|DRUG|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
219078177|NCT04602130|OTHER|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
219078178|NCT04602130|OTHER|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
219078179|NCT04602130|OTHER|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
219078180|NCT01733732|OTHER|SYSTANE® BALANCE Lubricant Eye Drops|
219078181|NCT01733732|OTHER|SYSTANE® Gel|
219078182|NCT05362890|DEVICE|DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE|The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
219078183|NCT00604526|RADIATION|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months."
219078184|NCT05154279|DRUG|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
219078185|NCT05586568|DRUG|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
219078186|NCT05586568|DRUG|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
219078187|NCT05586568|DRUG|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
219078188|NCT05283967|DIAGNOSTIC_TEST|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
219078189|NCT04342351|DRUG|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
219078190|NCT04342351|DRUG|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
219078191|NCT04342351|OTHER|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
219078192|NCT04342351|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
219078193|NCT01162681|DRUG|A-623|High dose given subcutaneously once a week for up to 52 weeks
219078194|NCT01162681|DRUG|A-623|Low dose given subcutaneously once a week for up to 52 weeks
219078195|NCT01162681|DRUG|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
219078196|NCT01162681|OTHER|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
219078197|NCT01738750|OTHER|Cost Information Included|
219078198|NCT01094925|DRUG|lactose|Single oral dose
219078199|NCT01094925|DRUG|Gabapentin 300mg|Single oral dose of 300mg gabapentin
219078200|NCT01094925|DRUG|Gabapentin 600mg|Single oral dose of 600mg gabapentin
219679767|NCT04130152|DRUG|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
219078201|NCT05387824|DEVICE|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
219078202|NCT05387824|DEVICE|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
219078203|NCT05387824|BEHAVIORAL|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
219078204|NCT03894852|DIAGNOSTIC_TEST|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
219078205|NCT04741308|BEHAVIORAL|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
219078206|NCT03907319|DEVICE|SIS System|Software technology for visualization of anatomical structures in the brain
219078207|NCT03979170|PROCEDURE|Lung tumor resection|lung tumor resection
219078208|NCT04206189|DIETARY_SUPPLEMENT|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
219078209|NCT04139564|DEVICE|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
219078210|NCT04139564|DEVICE|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
219078211|NCT02526654|DIAGNOSTIC_TEST|Heidelberg Edge Perimeter|HEP measures peripheral vision
219078212|NCT02526654|DIAGNOSTIC_TEST|Octopus Visual Field|OVF measures peripheral vision
219078213|NCT02526654|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
219078214|NCT06102941|DEVICE|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
219078215|NCT00002568|DRUG|cisplatin|
219078216|NCT00002568|DRUG|paclitaxel|
219078217|NCT00002568|PROCEDURE|conventional surgery|
219078218|NCT05400343|PROCEDURE|Standard care (control group)|"Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment."
219078219|NCT05400343|PROCEDURE|US-guided ﬂuid management (active group)|Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.
219078220|NCT05400343|OTHER|Standard ICU Care|All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
219078221|NCT00249106|BIOLOGICAL|ADVAX|
219078222|NCT05735873|OTHER|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
219078223|NCT04104581|OTHER|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
219078224|NCT04104581|OTHER|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
219078225|NCT04104581|OTHER|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
219078226|NCT04104581|OTHER|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
219078227|NCT04104581|OTHER|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
219078228|NCT03709368|OTHER|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
219078229|NCT03709368|BEHAVIORAL|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
219210430|NCT04255212|OTHER|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
219210431|NCT04255212|OTHER|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
219679768|NCT06144203|BEHAVIORAL|Exercise|Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.
219078230|NCT03709368|BEHAVIORAL|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
219078231|NCT03709368|BEHAVIORAL|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
219078232|NCT03709368|BEHAVIORAL|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
219078233|NCT03709368|OTHER|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
219078234|NCT05832450|OTHER|Red cell concentrate transfusion|Perioperative data of patient undergoing elective brain tumor resection with requirements of red cell concentrate transfusion.
219078235|NCT03137134|DRUG|Crizotinib|Crizotinib in a coated microsphere formulation
219078236|NCT03137134|DRUG|Esomeprazole|Proton pump inhibitor, esomeprazole
219078237|NCT04289818|OTHER|Health Coaching|Health Coaching as face to face with a coach
219078238|NCT00990158|DRUG|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
219078239|NCT00990158|DRUG|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
219078240|NCT02541708|DRUG|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
219078241|NCT02541708|DRUG|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
219078242|NCT02438618|PROCEDURE|Surgery for Ponto bone anchored hearing aids|
219078243|NCT06372769|DIAGNOSTIC_TEST|electromyograph and kinesiograph|"The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities."
219078244|NCT03298139|OTHER|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
219078245|NCT04092218|OTHER|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
219078246|NCT03583216|DIAGNOSTIC_TEST|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
219078247|NCT03583216|DIAGNOSTIC_TEST|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
219078248|NCT04386096|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
219078249|NCT04386096|OTHER|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
219078250|NCT00345241|DRUG|Systane Ocular Drops (OTC)|
219078251|NCT00345241|DRUG|Placebo - Saline Drops|
219078252|NCT03626948|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
219078253|NCT02025881|DRUG|Carboplatin + etoposide|"Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
219078254|NCT02025881|DRUG|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
219078255|NCT02025881|DRUG|Cyclophosphamide + Busilvex|"Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose."
219078256|NCT02025881|DRUG|Temozolimide + Irinotecan|"During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12"
219078257|NCT02025881|COMBINATION_PRODUCT|Etoposide + radiotherapy|"* Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)"
219078258|NCT02025881|DRUG|Temozolomide|150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
219078259|NCT00108095|DRUG|intravenous ondansetron|
219078260|NCT02376218|DRUG|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
219078261|NCT01260350|DRUG|SOF|Sofosbuvir (SOF) tablets administered orally once daily
219078262|NCT01260350|DRUG|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
219078263|NCT01260350|DRUG|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
219078264|NCT01260350|DRUG|LDV|Ledipasvir (LDV) tablets administered orally once daily
219078265|NCT01260350|DRUG|GS-9669|GS-9669 tablets administered orally once daily
219078266|NCT01260350|DRUG|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
219078267|NCT06113627|OTHER|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
219078268|NCT06143826|OTHER|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
219078269|NCT05641558|DRUG|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
219360516|NCT03719157|DRUG|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
219078270|NCT05641558|DRUG|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
219078271|NCT05641558|DRUG|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
219078272|NCT05641558|OTHER|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
219078273|NCT01936064|DIETARY_SUPPLEMENT|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
219078274|NCT01936064|DRUG|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
219078275|NCT02088268|OTHER|wound healing|wound healing
219078276|NCT03130400|PROCEDURE|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
219078277|NCT04644250|DRUG|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
219078278|NCT04644250|DRUG|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
219078279|NCT04644250|RADIATION|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
219078280|NCT05717868|OTHER|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
219078281|NCT05717868|OTHER|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
219078282|NCT01099904|DRUG|RO5024048|multiple oral doses for 5 days
219078283|NCT05457608|DEVICE|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
219078284|NCT05457608|DEVICE|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
219078285|NCT02884297|DRUG|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
219078286|NCT04319211|OTHER|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
219078287|NCT06385808|DRUG|MTBF regimen|"The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2."
219078288|NCT04439422|BEHAVIORAL|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
219360517|NCT03995290|OTHER|3D Hip Model from Pre-operative CT scan|A printed 3D model will be created based off of the patient's standard of care preoperative CT scan.
219360518|NCT02579655|BEHAVIORAL|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
219679769|NCT06110598|DRUG|Capecitabine|Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
219679770|NCT01744158|OTHER|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history"
219679771|NCT05320419|OTHER|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
219679772|NCT05320419|OTHER|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
219679773|NCT02980406|DIETARY_SUPPLEMENT|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
219679774|NCT02980406|DIETARY_SUPPLEMENT|Glucose (control)|Glucose is not a FODMAP.
219679775|NCT01616160|DRUG|mometasone furoate|2 sprays/nostril BID
219679776|NCT03109626|DIETARY_SUPPLEMENT|DHA|
219679777|NCT03034837|DRUG|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
219679778|NCT03034837|DRUG|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
219679779|NCT03327857|BIOLOGICAL|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
219679780|NCT01492192|DRUG|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
219679781|NCT03789097|DRUG|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
219078289|NCT04439422|OTHER|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
219078290|NCT02530307|DRUG|HT-3951|
219078291|NCT02530307|DRUG|Placebo|
219078292|NCT06473896|DRUG|Ketalar|a dissociative anesthetic used medically for induction and maintenance of anesthesia
219078293|NCT06473896|DRUG|Dexmedetomidine|an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
219078294|NCT06213766|DIAGNOSTIC_TEST|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
219078295|NCT06213766|OTHER|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities."
219078296|NCT06213766|DEVICE|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
219078297|NCT06213766|BIOLOGICAL|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
219078298|NCT00245895|DRUG|Aranesp|Aranesp
219078299|NCT05607693|DRUG|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
219078300|NCT05394246|DRUG|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
219078301|NCT01603069|DRUG|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
219078302|NCT01603069|DRUG|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
219078303|NCT01603069|DRUG|Placebo|Placebo to AZD3241 BID
219078304|NCT00454948|BEHAVIORAL|Home-based nutrition sessions and play group exercise|
219078305|NCT00454948|BEHAVIORAL|Group-based nutrition sessions and mail-out activities|
219078306|NCT04892355|DEVICE|Root canal irrigation|Devices used during root canal irrigation
219679782|NCT03789097|DRUG|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
219078307|NCT01049048|DIETARY_SUPPLEMENT|Vitamin D3|2500 IU Vitamin D3
219078308|NCT01049048|DIETARY_SUPPLEMENT|Placebo|No (0 IU) vitamin D3 added to cookie.
219078309|NCT01358968|DRUG|LY2603618|Administered intravenously as a 1-hour infusion.
219078310|NCT01358968|DRUG|Desipramine|Administered orally
219078311|NCT01358968|DRUG|Pemetrexed|Administered intravenously as a 10-minute infusion.
219679783|NCT03789097|RADIATION|Radiation|The target site will get 2 small treatments of radiation.
219679784|NCT03789097|DRUG|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
219679785|NCT02309957|DEVICE|BioMatrix CRD|
219679786|NCT02497508|DRUG|nivolumab|
219078312|NCT01358968|DRUG|Gemcitabine|Administered intravenously as a 30-minute infusion.
219210432|NCT04255212|OTHER|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
219078313|NCT03594669|OTHER|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
219078314|NCT00968682|BIOLOGICAL|trastuzumab|
219078315|NCT00968682|OTHER|laboratory biomarker analysis|
219679787|NCT00401518|DEVICE|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
219679788|NCT00401518|DEVICE|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
219679789|NCT00401518|DEVICE|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
219679790|NCT02601222|DRUG|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
219679791|NCT02601222|DRUG|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
219679792|NCT02601222|DRUG|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
219679793|NCT06319729|DRUG|CDD-2105|A Chinese herbal medicine formula containing four granular herbs.
219679794|NCT06319729|DRUG|Placebo|Placebo
219679795|NCT02858232|BIOLOGICAL|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
219078316|NCT00968682|PROCEDURE|assessment of therapy complications|
219679796|NCT01242241|DRUG|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
219679797|NCT01242241|DRUG|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
219679798|NCT03358381|PROCEDURE|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
219679799|NCT03358381|PROCEDURE|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
219679800|NCT03507985|OTHER|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
219078317|NCT03630874|OTHER|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
219078318|NCT06304259|DRUG|Saline|Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine
219078319|NCT06304259|DRUG|Saline|root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
219210433|NCT06225336|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
219210434|NCT01302600|DRUG|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
219078320|NCT05290350|OTHER|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
219078321|NCT01992380|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
219078322|NCT01992380|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
219078323|NCT01413568|DRUG|POL6326|
219078324|NCT01413568|PROCEDURE|Leukapheresis|
219078325|NCT01413568|PROCEDURE|PBSC Transplant|
219078326|NCT03438123|DEVICE|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
219078327|NCT06373757|OTHER|Nano-HAP/Chitosan hydrogel|The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
219078328|NCT02242864|DRUG|Micardis®|
219078329|NCT02242864|DRUG|MicardisPlus®|
219078330|NCT05022680|BEHAVIORAL|mhealth|the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
219078331|NCT01420055|DRUG|fingolimod|
219078332|NCT03474341|DIAGNOSTIC_TEST|MRI|"* Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
219078333|NCT03474341|DIAGNOSTIC_TEST|PET-CT|"* According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
219078334|NCT03474341|DIAGNOSTIC_TEST|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
219078335|NCT03474341|DIAGNOSTIC_TEST|Blood samples|"* Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT"
219078336|NCT06225765|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
219078337|NCT06225765|PROCEDURE|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
219078338|NCT00032695|DRUG|methionine|
219679801|NCT05552053|DEVICE|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
219679802|NCT05552053|DEVICE|MWSH|The Maternal Wellness Self Help (MWSH) app was created to help individuals to manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
219679803|NCT02282163|DRUG|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
219679804|NCT04231240|DEVICE|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
219679805|NCT04748952|DEVICE|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
219679806|NCT03895450|BEHAVIORAL|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
219679807|NCT03895450|BEHAVIORAL|Stretching Protocol|Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
219679808|NCT04203251|DEVICE|Caption Health Guidance Technology|
219679809|NCT01603407|DRUG|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
219078339|NCT04477252|DEVICE|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
219210435|NCT01302600|DRUG|Placebo|0.1ml/kg once a day with food at dinner.
219210436|NCT06157645|DEVICE|Prolene mesh|Application of mesh onlay post stoma closure
219210437|NCT00940069|DRUG|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
219210438|NCT01616537|OTHER|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
219210439|NCT05980247|DEVICE|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
219210440|NCT06431737|DRUG|Amoxicillin|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days
219679810|NCT01603407|DRUG|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
219078340|NCT04477252|OTHER|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
219210441|NCT00410423|DRUG|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
219210442|NCT00410423|DRUG|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
219210443|NCT00410423|DRUG|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
219679811|NCT01603407|DRUG|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
219679812|NCT05867225|PROCEDURE|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
219679813|NCT05615142|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.
219679814|NCT05615142|RADIATION|stereotactic body radiation therapy|Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.
219679815|NCT05615142|DRUG|PD-1 Inhibitors|Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.
219679816|NCT00574093|DRUG|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
219679817|NCT03648138|BEHAVIORAL|Sugary drink warning labels|This information appears in the description of the study arms.
219679818|NCT02500719|DEVICE|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
219679819|NCT03127709|BEHAVIORAL|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
219679820|NCT03127709|BEHAVIORAL|Brief Test of Attention|Assesses auditory working memory
219679821|NCT03127709|BEHAVIORAL|Symbol Span|Assesses visual working memory
219679822|NCT03127709|BEHAVIORAL|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
219679823|NCT03127709|BEHAVIORAL|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
219078341|NCT01814371|DRUG|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
219078342|NCT01814371|OTHER|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
219078343|NCT01814371|BEHAVIORAL|Hygiene Protocol|"Follow key hygiene tips:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors, brushes, or deodorant.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
219210444|NCT06996288|DEVICE|Transpulmonary pressure-guided individualized PEEP|Transpulmonary pressure-guided individualized PEEP group was an intraoperative ventilation strategy based on esophageal pressure (Pes) monitoring of transpulmonary pressure-guided ventilation, using a small tidal volume (6-8 ml/kg of ideal body weight), maintaining the transpulmonary pressure in the safe range of 5-15 cmH2O PEEP for Pes+1 cm H2O level.
219360519|NCT02579655|BEHAVIORAL|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
219679824|NCT03127709|BEHAVIORAL|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
219679825|NCT03127709|BEHAVIORAL|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
219679826|NCT03127709|BEHAVIORAL|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
219078344|NCT00961090|DRUG|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
219078345|NCT02794285|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
219078346|NCT02794285|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
219078347|NCT06241248|DIAGNOSTIC_TEST|Rapid sepsis diagnostic test|The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
219078348|NCT03252587|DRUG|BMS-986165|Specified dose on specified days
219078349|NCT03252587|OTHER|Placebo|Specified dose on specified days
219078350|NCT06231173|OTHER|Visual Feedback Therapy and Conventional Therapy|In experimental group individuals will receive visual feedback therapy and Conventional rehabilitation therapy. In visual feedback therapy, bilateral method is used to receive the visual feedback from the mirror. This visual feedback therapy consists of the following parts as the patient is asked to follow the involved hand that did the mimicking while the non-involved side will be performing wrist flexion, wrist extension, ulnar deviation, radial deviation, supination, pronation, and closing hand and opening hand.In conventional therapy, Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the noninvolved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
219078351|NCT06231173|OTHER|Conventional Therapy|In control group individuals will receive only conventional therapy. In conventional therapy, Patients are instructed to perform a sandbag and hand grip exercise with a resistive exercise for the non-involved side. At last, patients are instructed to perform a moving small object (ball of wool) and card flip operation to induce wrist and finger movements as functional activities. Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the non involved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. .This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
219078352|NCT04052204|DRUG|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
219078353|NCT04052204|DRUG|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
219078354|NCT04052204|DRUG|talazoparib|poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
219210445|NCT07007117|BIOLOGICAL|PHOX2B PC-CAR T Cells|The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.
219210446|NCT03971500|DRUG|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
219210447|NCT03971500|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
219679827|NCT03127709|DIAGNOSTIC_TEST|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
219679828|NCT03127709|DIAGNOSTIC_TEST|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
219679829|NCT03127709|BEHAVIORAL|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
219679830|NCT03074461|PROCEDURE|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
219679831|NCT03074461|PROCEDURE|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
219679832|NCT03125850|OTHER|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
219679833|NCT03125850|OTHER|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
219679834|NCT03746639|OTHER|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
219679835|NCT05178693|DRUG|ASTX727|Cedazuridine 100mg + 35mg decitabine
219679836|NCT05178693|RADIATION|Lutathera|Peptide receptor radionuclide therapy (PRRT)
219210448|NCT05322629|BEHAVIORAL|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
219210449|NCT05322629|BEHAVIORAL|Standard of care counseling|Adherence counseling based on self report and following national guidelines
219078355|NCT04052204|DRUG|enzalutamide|androgen receptor inhibitor
219078356|NCT02486484|DRUG|ziv-aflibercept|zaltrap injection
219679837|NCT04420117|OTHER|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
219679838|NCT01245153|OTHER|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
219078357|NCT02869087|DEVICE|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
219078358|NCT00095225|DRUG|Avastin (bevacizumab)|
219078359|NCT00095225|DRUG|Tarceva (erlotinib HCl)|
219078360|NCT00268294|DEVICE|Cardiac Resynchronization Therapy|
219078361|NCT04928820|PROCEDURE|Computed Tomography|Undergo PET/CT
219078362|NCT04928820|OTHER|Gallium Ga 68 Gozetotide|Given IV
219679839|NCT01245153|OTHER|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
219679840|NCT01473706|OTHER|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
219679841|NCT01990768|DRUG|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
219679842|NCT01990768|DRUG|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
219679843|NCT01990768|DRUG|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
219679844|NCT03418597|PROCEDURE|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
219679845|NCT03418597|PROCEDURE|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
219679846|NCT05393297|DIAGNOSTIC_TEST|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
219679847|NCT05393297|RADIATION|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
219679848|NCT05500014|OTHER|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
219679849|NCT00415324|DRUG|eribulin mesylate|Given IV
219679850|NCT00415324|DRUG|cisplatin|Given IV
219679851|NCT00415324|OTHER|laboratory biomarker analysis|correlative study
219679852|NCT00415324|OTHER|pharmacological study|correlative study
219078363|NCT04928820|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219210450|NCT06811168|OTHER|web based gamification|Kahoot gamificiation
219078364|NCT04415450|BEHAVIORAL|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
219078365|NCT00151307|DEVICE|INVOS cerebral oximeter|
219078366|NCT04437784|PROCEDURE|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
219078367|NCT04437784|PROCEDURE|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
219210451|NCT06809387|OTHER|Brain stimulation|Participants will be included in the real and sham rTMS. Participants will perform speech and reading tasks before and after stimulation.
219210452|NCT06122103|DEVICE|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
219078368|NCT04437784|PROCEDURE|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
219078369|NCT02362698|OTHER|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
219078370|NCT02362698|OTHER|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
219078371|NCT04833387|DRUG|PD-1 antibody|Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
219078372|NCT01515410|DRUG|DM-1992|72.5mg carbidopa/230mg levodopa
219679853|NCT00966732|BEHAVIORAL|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
219679854|NCT04029259|DIAGNOSTIC_TEST|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
219679855|NCT03538691|DRUG|Brexpiprazole|Administered as tablets.
219679856|NCT03538691|DRUG|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
219679857|NCT03915483|DEVICE|transcranial direct current stimulation (tDCS)|sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
219679858|NCT05424354|DEVICE|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
219679859|NCT05424354|OTHER|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
219679860|NCT06597084|DRUG|ESL 800 mg|800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
219679861|NCT06597084|DRUG|Placebo|Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
219679862|NCT04450914|BEHAVIORAL|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
219679863|NCT04450914|BEHAVIORAL|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
219679864|NCT01583283|DRUG|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
219679865|NCT01583283|DRUG|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
219078373|NCT01515410|DRUG|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
219078374|NCT04452708|DEVICE|HFNC|HFNV vs NIV vs conventional nasal cannula
219679866|NCT01583283|DRUG|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
219078375|NCT00802568|BIOLOGICAL|anti-thymocyte globulin|
219078376|NCT00802568|DRUG|busulfan|
219078377|NCT00802568|DRUG|fludarabine phosphate|
219078378|NCT00802568|PROCEDURE|allogeneic bone marrow transplantation|
219078379|NCT00802568|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219078380|NCT03876834|OTHER|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
219078381|NCT06495619|BEHAVIORAL|treatment-as-usual|life style modification intervention for weight loss
219078382|NCT06495619|BEHAVIORAL|combined TAU and guided self-help|combined TAU and guided self-help for improving eating behaviors
219078383|NCT06495619|BEHAVIORAL|combined TAU, GSH, and biofeedback|combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
219210453|NCT06122103|DEVICE|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
219210454|NCT03803969|DEVICE|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
219210455|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
219210456|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
219078384|NCT02683850|DIETARY_SUPPLEMENT|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
219078385|NCT05227001|BIOLOGICAL|PF-07852352 Influenza saRNA 1|Intramuscular injection
219078386|NCT05227001|BIOLOGICAL|PF-07836391 Influenza saRNA|Intramuscular injection
219078387|NCT05227001|BIOLOGICAL|PF-07836394 Influenza saRNA|Intramuscular injection
219210457|NCT06773195|DRUG|Ulixertinib|There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)
219679867|NCT05907187|BEHAVIORAL|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
219679868|NCT05542251|BEHAVIORAL|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
219078388|NCT05227001|BIOLOGICAL|PF-07836395 Influenza saRNA|Intramuscular injection
219210458|NCT06773195|DRUG|Ruxolitinib|Ruxolitinib for 28 day cycles.
219360520|NCT02704533|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
219360521|NCT02704533|BIOLOGICAL|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
219679869|NCT00696007|DRUG|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
219679870|NCT00696007|OTHER|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
219078389|NCT05227001|BIOLOGICAL|PF-07836396 Influenza saRNA|Intramuscular injection
219078390|NCT05227001|BIOLOGICAL|PF-07867246 Influenza saRNA|Intramuscular injection
219078391|NCT05227001|BIOLOGICAL|Placebo|Intramuscular injection
219360522|NCT02704533|BIOLOGICAL|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
219360523|NCT02704533|OTHER|Normal saline|0.9% sodium chloride
219679871|NCT04930614|OTHER|Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour|Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
219679872|NCT00431145|DRUG|Niacin|
219679873|NCT00431145|DRUG|Niacin+Statin|
219679874|NCT01403259|DRUG|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
219679875|NCT04329325|BIOLOGICAL|Blinatumomab|Please see detailed summary.
219679876|NCT04329325|DRUG|dasatinib|Please see detailed summary.
219679877|NCT04329325|DRUG|dexamethasone|Please see detailed summary.
219679878|NCT04329325|DRUG|methotrexate|Please see detailed summary.
219679879|NCT02185807|PROCEDURE|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
219679880|NCT02185807|PROCEDURE|control group|The control patients receive verbal information and discussion from their physicians.
219679881|NCT00768885|DEVICE|PureVision 1|Currently marketed PureVision soft contact lens.
219078392|NCT05227001|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
219679882|NCT00768885|DEVICE|PureVision 2|Alternate design soft contact lens.
219078393|NCT05227001|BIOLOGICAL|PF-07871987 Influenza saRNA|Intramuscular injection
219078394|NCT05227001|BIOLOGICAL|PF-07914705 Influenza saRNA|Intramuscular injection
219078395|NCT05227001|BIOLOGICAL|PF-07915048 Influenza saRNA|Intramuscular injection
219078396|NCT00676767|DIETARY_SUPPLEMENT|Resistant Starch Type 4|
219078397|NCT00676767|DIETARY_SUPPLEMENT|Dextrose|
219078398|NCT00676767|DIETARY_SUPPLEMENT|Puffed wheat|
219078399|NCT05782764|DRUG|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
219078400|NCT04216108|DEVICE|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
219078401|NCT04216108|DEVICE|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
219078402|NCT00011505|DRUG|G-CSF|
219078403|NCT00011505|PROCEDURE|Leukapheresis|
219078404|NCT06129773|PROCEDURE|antibiotic coated vicryl used for fascial closure|in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
219078405|NCT06224738|BIOLOGICAL|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
219078406|NCT01194960|DRUG|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
219078407|NCT01194960|DRUG|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
219078408|NCT00650832|DRUG|TMC114; darunavir; Prezista|
219078409|NCT00345982|DRUG|Serdolect|16 mg, 12 weeks
219078410|NCT00345982|DRUG|placebo|placebo
219078411|NCT04220164|OTHER|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
219078412|NCT01139307|OTHER|cell culture procedure|
219078413|NCT01139307|OTHER|laboratory biomarker analysis|
219078414|NCT01250977|DRUG|Donepezil|
219078415|NCT01250977|DRUG|Placebo|
219078416|NCT02964416|DRUG|Injection Tramadol|
219078417|NCT02964416|OTHER|placebo|0.9% Normal saline in 10 ml syringe
219078418|NCT04133233|DRUG|ILT101|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
219078419|NCT04133233|DRUG|Placebos|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
219078420|NCT06635707|DRUG|Urapidil|"1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
219078421|NCT06635707|DRUG|Urapidil and Esmolol|"1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
219078422|NCT02395042|DRUG|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
219078423|NCT02395042|DRUG|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
219078424|NCT04934423|DEVICE|Direct Current Transcranial Stimulation - tDCS|Active intervention
219360524|NCT06233526|OTHER|Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test|"1. Leukemia cells from newly diagnosed and relapsed children with AML were tested for high throughput in vitro drug sensitivity and resistance.~2. Combined with multi-omics sequencing technology such as whole exome and transcriptome, the data of drug sensitivity, drug resistance and genomic characteristics of children AML patients were integrated, and the internal rules between drug sensitivity or drug resistance and molecular characteristics such as gene fusion, gene mutation and abnormal gene expression of children AML patients were deeply analyzed, and the molecular characteristics of drug sensitivity in children AML were mapped"
219078425|NCT04934423|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
219078426|NCT00989768|DRUG|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
219078427|NCT00989768|DRUG|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
219078428|NCT00989768|DRUG|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
219078429|NCT02192502|DRUG|human albumin 5%|
219078430|NCT02192502|DRUG|HES 130/0.4 (Voluven)|
219078431|NCT06302751|DEVICE|Care 4 Today ® (Johnson and Johnson) mobile app|Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
219078432|NCT03390205|DIAGNOSTIC_TEST|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
219078433|NCT03883633|BEHAVIORAL|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
219078434|NCT05850832|DRUG|Esmolol|loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
219078435|NCT05850832|DRUG|Magnesium sulfate|loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
219078436|NCT06508281|OTHER|experimental group|. Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want
219078437|NCT05574660|DIETARY_SUPPLEMENT|High-Fat/High-Sugar (HF/HS) Diet|
219078438|NCT05574660|DIETARY_SUPPLEMENT|Low-Fat/Low-Sugar (LF/LS) Diet|
219078439|NCT01435083|DRUG|Desmopressin|120 µg, oral lyophilisate, sublingual use
219078440|NCT00508430|DRUG|ASP8825|oral
219078441|NCT00508430|DRUG|Placebo|oral
219078442|NCT06256133|PROCEDURE|Enhanced Recovery After Surgery protocol|Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
219078443|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
219078444|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
219078445|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
219078446|NCT01804452|OTHER|Observational Study|
219078447|NCT06283472|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
219078448|NCT06283472|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
219078449|NCT02837627|OTHER|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
219078450|NCT02967185|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
219078451|NCT00456638|DRUG|Depodur|Depodur vs. traditional management
219078452|NCT00003298|DRUG|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
219078453|NCT00003298|DRUG|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
219078454|NCT00003298|DRUG|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
219078455|NCT00003298|DRUG|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
219078456|NCT00003298|PROCEDURE|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
219210459|NCT06825143|PROCEDURE|Ischemic preconditioning|The objective of this Intervention is to show that ischemic preconditioning (IPC) protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of IPC in the opposite arm. IPC will be induced using a blood pressure cuff placed on the opposite upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two additional times taking about 30 minutest to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
219679883|NCT03762005|OTHER|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
219679884|NCT03762005|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
219679885|NCT00370097|DRUG|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
219679886|NCT00370097|DRUG|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
219679887|NCT01588405|DRUG|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
219679888|NCT00897871|DRUG|carboplatin|
219679889|NCT00897871|DRUG|cyclophosphamide|
219679890|NCT00897871|DRUG|etoposide phosphate|
219679891|NCT00897871|GENETIC|gene expression analysis|
219679892|NCT00897871|GENETIC|polymorphism analysis|
219679893|NCT00897871|OTHER|pharmacological study|
219679894|NCT01027377|DRUG|rFVIIIFc|Single dose
219078457|NCT00003298|RADIATION|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
219078458|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
219078459|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
219078460|NCT00105638|BEHAVIORAL|educational program, by telephone|
219078461|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
219210460|NCT06825143|DRUG|Intravenous lactate infusion|The objective of this Intervention is to show that an intravenous infusion of lactate protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After systemic lactate reaches \~3 mmol/L, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
219360525|NCT04159038|OTHER|Intervention Group|The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.
219360526|NCT04159038|OTHER|Control group|The control group will continue usual WIC care.
219679895|NCT01027377|DRUG|rFVIIIFc|Single dose
219679896|NCT02853045|DRUG|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
219679897|NCT02853045|DRUG|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
219679898|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
219679899|NCT06481124|DEVICE|electrical impedance tomography|Measurement of ventilation and perfusion during mechanical ventilation with different positive end-expiratory pressure by electrical impedance tomography
219078462|NCT05335317|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
219078463|NCT05335317|DRUG|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
219078464|NCT05335317|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
219078465|NCT05335317|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
219078466|NCT05335317|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
219078467|NCT05335317|DIAGNOSTIC_TEST|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
219078468|NCT05335317|DIAGNOSTIC_TEST|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
219078469|NCT05335317|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
219078470|NCT05335317|OTHER|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
219078471|NCT05335317|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
219078472|NCT05335317|DIAGNOSTIC_TEST|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
219078473|NCT05335317|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
219078474|NCT05335317|DIAGNOSTIC_TEST|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
219679900|NCT04215692|DIAGNOSTIC_TEST|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
219679901|NCT06612749|OTHER|Integrative medicine including manual and/or mind-body treatments|Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
219679902|NCT06612580|DRUG|68Ga-AAZTA-NI-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
219679903|NCT06612684|DEVICE|Piezoelectric syndesmotomy|Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
219679904|NCT06867926|OTHER|Cardiac rehabilitation|Individuals diagnosed with coronary artery disease will engage in a programme of cardiac rehabilitation.
219078475|NCT05335317|DIAGNOSTIC_TEST|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
219679905|NCT07022964|DRUG|CD5 CAR-T cells infusion|Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219679906|NCT03479944|PROCEDURE|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
219679907|NCT03479944|PROCEDURE|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
219679908|NCT03479944|DEVICE|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
219078476|NCT05335317|DIAGNOSTIC_TEST|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
219078477|NCT01290432|DIETARY_SUPPLEMENT|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
219078478|NCT00901693|DRUG|AL-46383A Ophthalmic Solution|
219078479|NCT00901693|DRUG|AL-46383A Ophthalmic Solution Vehicle|
219078480|NCT00850473|DIAGNOSTIC_TEST|PET/CT|Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
219078481|NCT00220298|DRUG|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
219078482|NCT02774070|RADIATION|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
219078483|NCT02774070|RADIATION|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
219078484|NCT01689064|PROCEDURE|Stamm Approach|
219078485|NCT01689064|PROCEDURE|Posterior Septectomy|
219078486|NCT04361929|DEVICE|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
219078487|NCT04434560|DRUG|Nivolumab|Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
219078488|NCT04434560|DRUG|Ipilimumab|Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
219360527|NCT01315262|DRUG|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
219679909|NCT03479944|DEVICE|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
219679910|NCT00729300|DRUG|placebo|0mg daily
219679911|NCT00729300|DRUG|disulfiram|250mg daily
219679912|NCT02870556|DEVICE|cervical epidural analgesia|
219679913|NCT06087705|DEVICE|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~* Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~* Check the integrity of the sterility protector.~* Take the syringe and remove the protective tip.~* Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~* Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~* A visual check of the attachment of the needle will be carried out.~* Remove the needle cap.~* Inject slowly."
219679914|NCT02963636|OTHER|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
219078489|NCT06174714|BEHAVIORAL|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
219078490|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
219078491|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
219078492|NCT03046459|BIOLOGICAL|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
219078493|NCT01603264|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
219078494|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
219078495|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
219078496|NCT05758844|PROCEDURE|safe-line technique|Safe-line approach
219078497|NCT02639130|DRUG|Exendin [9-39]|Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
219078498|NCT02639130|DRUG|Placebo|Placebo infusion as challenge agent
219078499|NCT00253591|DRUG|cisplatin|
219078500|NCT00253591|DRUG|vinorelbine tartrate|
219078501|NCT00253591|RADIATION|radiation therapy|
219078502|NCT03130751|BEHAVIORAL|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
219078503|NCT04369092|OTHER|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
219078504|NCT02191553|BEHAVIORAL|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
219078505|NCT02191553|BEHAVIORAL|Loving-kindness meditation|Following Kristin Neff protocol
219078506|NCT02191553|BEHAVIORAL|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
219078507|NCT02191553|BEHAVIORAL|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
219078508|NCT02958969|DRUG|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
219679915|NCT00819481|DEVICE|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
219679916|NCT05834127|OTHER|Aerobic exercise|"Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month"
219679917|NCT05834127|OTHER|Yoga Exercises|"Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose"
219679918|NCT06239181|BEHAVIORAL|Breathing Exercises|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
219679919|NCT06239181|OTHER|no intervention/routine procedure|Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
219679920|NCT04823390|DRUG|Midazolam-Fentanyl combination|Sedation is given to patients undergoing cataract surgery under local anesthesia
219679921|NCT04760535|DEVICE|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
219679922|NCT04760535|DEVICE|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
219078509|NCT05086367|OTHER|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
219078510|NCT05086367|OTHER|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
219078511|NCT03753061|DEVICE|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
219078512|NCT03753061|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
219078513|NCT04879550|DIAGNOSTIC_TEST|Antithrombin III|Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
219078514|NCT00584727|DEVICE|senofilcon A toric contact lens|contact lens
219679923|NCT01440634|OTHER|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
219679924|NCT02029274|DRUG|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
219679925|NCT02029274|DRUG|Placebo|Matching placebo to BAF312 as tablets for oral administration.
219078515|NCT00584727|DEVICE|alphafilcon A toric|contact lens
219078516|NCT00584727|DEVICE|etafilcon A sphere|contact lens
219078517|NCT04214704|DEVICE|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
219078518|NCT04214704|DEVICE|Conventional lancing device|Conventional lancing device
219078519|NCT05186948|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219210461|NCT06825143|PROCEDURE|No ischemic preconditioning (control)|The objective of this Intervention is to show that a control experiment without ischemic preconditioning does not provide protection against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of no upper arm occlusion in the opposite arm. To avoid upper arm occlusion, a blood pressure cuff will be placed on the upper arm and inflated to a low pressure of 20 mmHg pressure to not influence blood flow through the arm. This control procedure will be repeated two additional times taking about 30 minutes to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
219679926|NCT06877949|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET/CT is used regulary for a continuous, long term monitoring
219679927|NCT06877949|DIAGNOSTIC_TEST|CE-CT|CE-CT is used regulary for a continuous, long-term monitoring
219679928|NCT06880809|BEHAVIORAL|Bridge the Gap (BTG) - Black Youth Group|Participants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.
219679929|NCT06892990|DIAGNOSTIC_TEST|TXI mode vs. WLE mode|Experimental use of TXI mode compared to standard use of WLE to assess inflammatory activity in patients with IBD during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient.
219679930|NCT04758247|DEVICE|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
219679931|NCT05803759|DIETARY_SUPPLEMENT|Allicor|Each capsule contains 150 mg dried garlic powder
219078520|NCT06578923|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
219078521|NCT06578923|BEHAVIORAL|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
219078522|NCT04085783|PROCEDURE|PRP|Platelet Rich Plasma
219679932|NCT05803759|DRUG|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
219679933|NCT03678415|BEHAVIORAL|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
219078523|NCT01511848|DRUG|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
219360528|NCT00535925|DRUG|SoC therapy|the patients have to be treated according the standard good medical practice by any center
219679934|NCT05730855|DIAGNOSTIC_TEST|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
219679935|NCT02547896|DRUG|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
219679936|NCT02547896|DRUG|Diclofenac|The patients will receive only diclofenac
219679937|NCT05859282|BEHAVIORAL|Survey|A short 25-item tool was developed and can be applied in clinics to assess the awareness of pregnancy hypertension.
219078524|NCT01511848|DRUG|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
219078525|NCT06579651|DEVICE|Nailfold videocapillaroscopy (NVC)|Nailfold videocapillaroscopy (NVC) is the validated technique to assess SSc microvascular damage and is useful for the early diagnosis and follow-up of SSc micro- angiopathy.
219078526|NCT00627848|DRUG|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
219078527|NCT05884840|DIAGNOSTIC_TEST|HELENA|"The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients."
219078528|NCT05008666|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
219078529|NCT05008666|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
219078530|NCT05008666|DRUG|Azacitidine|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
219078531|NCT05008666|DRUG|L-DEP|L-DEP
219078532|NCT04380922|OTHER|Periodontal screening|Periodontal data collection (PPD, REC, CAL)
219078533|NCT02568241|OTHER|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
219078534|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
219078535|NCT06387901|DRUG|Paclitaxel Chemotherapy|Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
219078536|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
219078537|NCT01634126|BEHAVIORAL|1 FIT kit|Patient receives 1 FIT
219078538|NCT01634126|BEHAVIORAL|2 FIT kit|Patient receives 2 FIT kits
219078539|NCT05502432|DEVICE|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
219210462|NCT06825143|DRUG|Normal Saline Infusion (Placebo)|The objective of this Intervention is to show that a placebo intravenous infusion does not protect against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous infusion of normal saline that does not contain lactate will be delivered in the contralateral arm. After 20 minutes of the placebo infusion, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
219210463|NCT06825143|COMBINATION_PRODUCT|Ischemic preconditioning and intravenous lactate|The objective of this Intervention is to show that combining ischemic preconditioning (IPC) with an intravenous infusion of lactate provides the best protection against endothelial injury. First, baseline endothelial function to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After that investigators will administer IPC using a blood pressure cuff placed on the same upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two more times taking about 30 minutes to complete. The intravenous lactate infusion will be maintained. After a 10-minute rest phase and while lactate is still being infused, endothelial injury will be induced using a blood pressure cuff inflated to stop blood flow through the opposite arm (nondominant arm) for 20 minutes, followed by 15 minutes of cuff deflation. Endothelial function will be repeated.
219210464|NCT06890507|DRUG|N-Acetylcysteine (NAC)|The investigational product for this study is NAC 600 mg capsules. The NAC drug substance is sourced from a Good Manufacturing Practice (GMP)-certified supplier by Syntro Health Pty Ltd and tested on receipt
219360529|NCT00535925|DRUG|irbesartan|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
219360530|NCT00535925|DRUG|ramipril|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
219679938|NCT03027076|PROCEDURE|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
219679939|NCT03027076|PROCEDURE|Collect midstream urine samples|Collect midstream urine samples
219679940|NCT02735473|DRUG|Choline bitartrate|
219679941|NCT02735473|DRUG|Placebo|
219679942|NCT07022847|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Pleth Variability Index (PVI) and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
219679943|NCT02544958|DEVICE|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
219679944|NCT03545269|DRUG|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
219679945|NCT03545269|PROCEDURE|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
219679946|NCT02992184|DEVICE|HCV RNA detection with Genedrive assay|
219679947|NCT02992184|DEVICE|HCV RNA detection with RealTime HCV|
219679948|NCT00000356|DRUG|LAAM|
219679949|NCT04274309|DEVICE|EndoSWIR|Exposition of the respected tissues to the camera
219679950|NCT03009253|OTHER|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
219679951|NCT00401427|DRUG|trastuzumab|
219679952|NCT00401427|DRUG|vinorelbine|
219679953|NCT04651166|DRUG|Tranexamic acid|1g tranexamic acid mixed in 100mL saline or lactated ringer
219679954|NCT04651166|DRUG|Placebo|100mL saline or lactated ringers
219679955|NCT04437446|DIAGNOSTIC_TEST|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
219679956|NCT04437446|DIAGNOSTIC_TEST|Control Group|"The additional examinations correspond to:~* OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~* OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~* Visual field"
219679957|NCT02859519|DRUG|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
219679958|NCT02859519|DRUG|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
219679959|NCT00792714|DRUG|Mannitol|400mg twice daily for 7 days
219679960|NCT02007655|DRUG|Eliquis|
219679961|NCT05392777|DIAGNOSTIC_TEST|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
219679962|NCT00830583|PROCEDURE|blood test|There is only a blood test at the beginning.
219078540|NCT05502432|DEVICE|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
219679963|NCT01243177|DRUG|Lacosamide|"Lacosamide:~* Strengths: 50 mg / 100 mg~* Form: tablets~* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~* Duration: up to 118 weeks"
219679964|NCT01243177|DRUG|Carbamazepine-Controlled Release|"Carbamazepine-CR:~* Strengths: 200 mg~* Form: tablets~* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~* Duration: up to 118 weeks"
219078541|NCT01938612|DRUG|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
219679965|NCT02801981|DRUG|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
219679966|NCT02801981|DRUG|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
219679967|NCT06795100|OTHER|Pre-inclusion|Information and presentation of the proposed study to participants during the anesthesia consultation scheduled prior to surgery, including provision of the information document and consent form. Trial participants will have at least 2 days to decide whether or not to take part in the trial.
219679968|NCT06795100|OTHER|Inclusion|"Participants will be welcomed according to the usual process in the digestive, hepatic, urological, or gynecological surgery service. The inclusion visit will coincide with the pre-anesthesia visit during which the absence of contraindications for starting the study will be verified, particularly the occurrence of any health changes since the anesthesia visit that would contraindicate anesthesia or lidocaine administration. During this visit, participant consent will be obtained. The informed consent form must be signed no later than the morning of the intervention.~For women of childbearing age, the absence of current pregnancy will be verified orally for each participant included. A pregnancy test may be performed if the participant so wishes, but a systematic test is not justified."
219679969|NCT06795100|DRUG|Lidocaine|Induction of anesthesia will be at the discretion of the attending anesthesiologist, with a lidocaine bolus of 2 mg/kg administered over 1 minute, followed by a continuous IV infusion of 2 mg/kg/h.
219679970|NCT06795100|OTHER|Pharmacokinetic study of intravenous lidocaine|Blood samples of 3 mL will be collected in heparinized tubes without gel of 4 ml at 30, 60 and 120 minutes after the start of lidocaine infusion, then every two hours during surgery, and two finals samples at 15 and 60 minutes after the infusion stops.
219679971|NCT06795100|OTHER|Pain|. Maximal pain reported in the post-anesthesia care unit (PACU) and maximal pain at rest and with movement at 24 hours post-extubation will be recorded.
219679972|NCT06795100|OTHER|adverse effects/events|Any adverse effects/events will be documented from the start of lidocaine administration until 24 hours post-extubation,
219679973|NCT06795100|BIOLOGICAL|biological blood test|A biological blood test, not performed in routine practice, will be carried out to measure the following parameters: albumin, ASAT, ALAT, PAL, GammaGT, total and conjugated bilirubin, creatinine, with calculation of GFR.
219679974|NCT03663933|DRUG|Immunosuppression Only Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
219679975|NCT03663933|DRUG|Reduced Intensity Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
219078542|NCT01938612|DRUG|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
219078543|NCT01922076|DRUG|Adavosertib|Given PO
219679976|NCT03663933|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
219679977|NCT03663933|PROCEDURE|Allogeneic HSC|Stem cell transplant
219679978|NCT03191825|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
219679979|NCT03191825|OTHER|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
219679980|NCT03191825|OTHER|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
219679981|NCT06926738|OTHER|Upper Thoracic Manipulation|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will perform thoracic manipulation (screw thrust technique) at the selected segmental level/s. This maneuver will be repeated for a maximum of two attempts in case of no hearing of a pop sound. It will be performed by an experienced physiotherapist with more than 10-year experience."
219078544|NCT01922076|OTHER|Laboratory Biomarker Analysis|Correlative studies
219078545|NCT01922076|OTHER|Pharmacological Study|Correlative studies
219078546|NCT01922076|RADIATION|Radiation Therapy|Undergo radiation therapy
219078547|NCT00378989|BEHAVIORAL|Consultation at the occupational health services|Consultation at the occupational health services
219078548|NCT04311606|DRUG|Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
219078549|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
219078550|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) alone|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
219078551|NCT04853680|DEVICE|Anti-adhesion barrier (Collarbarrier)|Collagen derived anti-adhesion barrier
219078552|NCT01766622|DRUG|[18F]-CP18|7mCi, IV (in the vein) at baseline
219078553|NCT01766622|PROCEDURE|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third \[18F\]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
219078554|NCT01181050|DRUG|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
219078555|NCT01181050|DRUG|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
219078556|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
219078557|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
219078558|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
219078559|NCT05907382|DRUG|Placebo in Cohorts 1 to 5|oral once
219078560|NCT05907382|DRUG|Placebo in 2 Cohorts|oral once
219078561|NCT06962267|DRUG|TQB2916 Injection|A Phase II clinical study to evaluate the efficacy and safety of TQB2916 injection combined with gemcitabine and albumin-paclitaxel as first-line treatment for metastatic pancreatic cancer.
219078562|NCT06962267|DRUG|Chemotherapy|Chemotherapy is a systematic treatment.Chemotherapy drugs go into the body orally or intravenously, and they circulate throughout the body, and because of that, they can be used for advanced cancer, and they can also be effective against metastasized cancer cells.There are many chemotherapeutics, but the underlying mechanism is to kill fast growing cells.
219078563|NCT00403624|DRUG|OXALIPLATIN|
219078564|NCT01018394|DRUG|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
219078565|NCT01018394|DRUG|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
219078566|NCT00683644|DRUG|Zinc|Zinc taken once daily
219078567|NCT00683644|DRUG|Placebo oral capsule|Placebo capsules taken once daily
219679982|NCT06926738|OTHER|Sham Comparison|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will just the place the hands on the selected levels in the same hand placement of Thoracic manipulation group (screw thrust technique) without applying the manipulation. It will be performed by an experienced physiotherapist with more than 10-year experience."
219679983|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
219078568|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
219078569|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
219078570|NCT05808387|DIETARY_SUPPLEMENT|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
219078571|NCT05808387|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 90 days
219078572|NCT01650753|DIETARY_SUPPLEMENT|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)
219078573|NCT01650753|DIETARY_SUPPLEMENT|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
219078574|NCT06078904|DRUG|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
219078575|NCT06078904|DRUG|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
219078576|NCT06078904|DRUG|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
219078577|NCT06078904|DRUG|Placebo|Placebo, one pill a day, oral intake
219078578|NCT01592318|DRUG|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
219078579|NCT01592318|DRUG|danoprevir|Reference tablet, single oral dose
219078580|NCT01592318|DRUG|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
219078581|NCT01592318|DRUG|ritonavir|Reference tablet, single oral dose
219078582|NCT01669122|DRUG|nicotine|4 mg nicotine lozenge experimental
219078583|NCT03762473|DRUG|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
219078584|NCT03762473|DRUG|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
219078585|NCT04144842|BIOLOGICAL|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
219078586|NCT01542606|DEVICE|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
219078587|NCT05598190|DEVICE|Pro-Yellow laser 577|4 session for cases with digtal photo before and after sessions
219078588|NCT04824482|OTHER|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
219078589|NCT04824482|OTHER|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
219078590|NCT05855980|PROCEDURE|Wound closure|Wound is closed or left open to heal secondarily after amputation.
219078591|NCT05132699|DRUG|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
219078592|NCT05132699|DRUG|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
219078593|NCT05132699|BEHAVIORAL|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
219078594|NCT03533712|DIETARY_SUPPLEMENT|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~* Total energy: 250-500 kcal per daily serving~* Fat content: 10-60% of energy intake~* Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~* Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~* Trans Fats: \<1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
219078595|NCT03533712|DIETARY_SUPPLEMENT|Fe and folic acid supplement|Routine iron and folic acid supplementation.
219078596|NCT02421614|OTHER|high-protein low-carbohydrate diet with high olive oil|
219078597|NCT02421614|OTHER|high-protein low-carbohydrate diet with high sunflower oil|
219679984|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
219679985|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
219679986|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
219679987|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219679988|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
219679989|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
219679990|NCT06949709|BEHAVIORAL|Fasted-exercise|Breakfast intake before 30 min brisk walking on a treadmill
219679991|NCT06949709|BEHAVIORAL|Fed-exercise|30 min brisk walking on a treadmill before breakfast intake
219679992|NCT06955273|DEVICE|Corsano CardioWatch 287-2|Patients receive monitoring of their heart rhythm by the CardioWatch 287-2 next to monitoring of their heart rhythm by either a 24-48 holter or a short in-clinic 12-lead ECG monitoring.
219679993|NCT06955572|DIAGNOSTIC_TEST|Patients with colorectal cancer|Analysis of the lower fecal gene count (fGC) compared with the control group
219679994|NCT06955572|DIAGNOSTIC_TEST|Patients with Parkinson's disease|Analysis of the lower fecal gene count (fGC) compared with the control group
219679995|NCT06955572|DIAGNOSTIC_TEST|Patients with non-alcoholic steatohepatitis|Analysis of the lower fecal gene count (fGC) compared with the control group
219679996|NCT06955572|DIAGNOSTIC_TEST|Patients with obesity|Analysis of the lower fecal gene count (fGC) compared with the control group
219078598|NCT00786929|PROCEDURE|Catheter drainage|
219078599|NCT00786929|DRUG|Conservative treatment|
219078600|NCT00148967|DEVICE|Implantable Cardioverter Defibrillator|
219078601|NCT01437449|DRUG|Docetaxel|30 mg/m² by intravenous (IV) administration
219078602|NCT01437449|DRUG|Cisplatin|30 mg/m² by intravenous (IV) administration
219078603|NCT01437449|DRUG|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
219078604|NCT01437449|DRUG|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
219078605|NCT03880305|DIAGNOSTIC_TEST|complete blood count|complete blood count
219078606|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
219679997|NCT06955572|DIAGNOSTIC_TEST|Healthy volunteers|Determination of the number of bacterial faecal genes (fGC, fecal Gene Count) inferior reference
219679998|NCT06955026|OTHER|Hockey slideboard combined with BFR training|Hockey slideboard combined with BFR training
219679999|NCT06955026|OTHER|Hockey slideboard|Hockey slideboard
219680000|NCT06955663|BEHAVIORAL|Exercise training|12 week exercise intervention + cardiopulmonary exercise test (CPET) + wearable activity monitor
219078607|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
219078608|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
219078609|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
219078610|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
219078611|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
219680001|NCT06956131|DIETARY_SUPPLEMENT|Casein Protein Isolate Drink|30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water
219680002|NCT06956131|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water
219680003|NCT06956131|DIETARY_SUPPLEMENT|Soy Protein Isolate Drink|30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water
219680004|NCT06956131|DIETARY_SUPPLEMENT|Maltodextrin Drink|30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water
219680005|NCT06956092|BIOLOGICAL|Glofitamab treatment|eceive Glofitamab treatment as per the instructions in the package insert.
219680006|NCT06954844|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
219078612|NCT06370598|BIOLOGICAL|TP-122A|Bacteriophage cocktail targeting Psa
219078613|NCT01367262|DRUG|LY2886721|Administered orally
219680007|NCT06954844|DEVICE|Low intensity stimulation|The electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA, 1s ON, 30s OFF, 1 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
219078614|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
219078615|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
219078616|NCT03451838|DIAGNOSTIC_TEST|Ultrasound|Ultrasound will be done to every pregnant lady
219078617|NCT03451838|DIAGNOSTIC_TEST|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
219078618|NCT01204827|DEVICE|13C Methacetin Breath Test (BreathID)|
219078619|NCT02858895|DRUG|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
219078620|NCT02049086|BEHAVIORAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
219078621|NCT02049086|BEHAVIORAL|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
219078622|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
219680008|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
219078623|NCT06824480|BEHAVIORAL|debriefing group|Women who volunteered to participate in the study and met the participation criteria were informed about the study. The first session will be held face to face in the clinic for 40 minutes. Then, the second session will be held by phone within 4-6 weeks after birth, with a total of 2 meetings with each woman for approximately 40 minutes.
219078624|NCT06824480|BEHAVIORAL|control group|he women in the control group will be asked how the birth went within 12-24 hours after birth by the researcher as part of their routine care, but no detailed analysis or interpretation will be made.
219078625|NCT05602376|BEHAVIORAL|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
219078626|NCT05602376|BEHAVIORAL|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
219210465|NCT06890507|DRUG|Placebo|To ensure appropriate blinding and to match the physical characteristics of the NAC capsules, the placebo capsules will be filled with dicalcium phosphate (DCP). DCP has been selected over microcrystalline cellulose due to the weight requirements of the NAC formulation.
219210466|NCT06826781|DEVICE|Q30 Q-Collar|Participants will complete a series of tests (sit-to-stand, resistive breathing, and graded bike test) while wearing a Q-Collar.
219210467|NCT06826781|OTHER|Not wearing Q-Collar|Participants will undergo the same study procedures without wearing the Q-Collar.
219210468|NCT07032571|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants receive a 12-week core behavioral weight loss intervention consisting of the following: daily self-monitoring of weight; weekly behavioral lessons and action plans to promote healthy eating and physical activity; and tailored feedback. The intervention will be delivered remotely via email and/or text message.
219210469|NCT07032571|BEHAVIORAL|Limit Red Zone Foods|Participants randomized to receive this component are given a goal to limit their Red Zone Foods (i.e., foods high in calories and low in nutrition) and are instructed to self-monitor them daily.
219210470|NCT07032571|BEHAVIORAL|Limit Eating Window|Participants randomized to receive this component are given a goal to limit their eating windows (i.e., follow time-restricted eating) and are instructed to self-monitor them daily.
219210471|NCT07032571|BEHAVIORAL|Increase Protein|Participants randomized to receive this component are given a goal to increase their protein intake and are instructed to self-monitor it daily.
219210472|NCT07032571|BEHAVIORAL|Increase Fiber Intake|Participants randomized to receive this component are given a goal to increase their fiber intake and are instructed to self-monitor it daily.
219210473|NCT06881563|DRUG|Intrathecal Morphine|In this group, 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
219210474|NCT06881563|PROCEDURE|Epidural Analgesia|"Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery.~Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery."
219210475|NCT06882265|BEHAVIORAL|Group Monitoring|In the intervention group (IG), participants receive a HR and SPO2 monitor watch and a pulse oximeter and will be monitored every 15 days by a nurse to check for non-adherence and/or technical failure, and/or exacerbations, and monthly to apply questionnaires.
219680009|NCT05483075|BEHAVIORAL|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
219210476|NCT06882265|BEHAVIORAL|Control Group|In the control group (CG), participants receive only a pulse oximeter and will be monitored monthly by a nurse to administer the questionnaires.
219210477|NCT07029529|DRUG|Apremilast 60mg|Apremilast 60mg/day
219210478|NCT07029529|DRUG|Apremilast 90mg|Apremilast 90mg/day
219680010|NCT02546128|DEVICE|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
219680011|NCT02546128|OTHER|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
219210479|NCT07029529|OTHER|Placebo|Placebo
219680012|NCT04051541|OTHER|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
219680013|NCT03233815|DRUG|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
219680014|NCT03233815|DRUG|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
219210480|NCT07038421|OTHER|Cognitive level|The cognitive function was assessed with the Montreal Cognitive Assessment (MOCA). The total score ranges from 0 to 30, and scores of 21 and above indicate normal cognitive status
219210481|NCT07038421|OTHER|Gait|The Dynamic Gait Index (DGI) was assessed for gait. The maximum total score is 24, with a lower DGI score indicating greater impairment in functional mobility and gait
219680015|NCT02271217|DRUG|Placebo|
219680016|NCT02271217|DRUG|dalfampridine-ER 7.5mg|
219680017|NCT02271217|DRUG|dalfampridine-ER 10mg|
219680018|NCT01680809|DEVICE|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
219078627|NCT06600646|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in patients with refractory or unexplained chronic cough and healthy controls.
219680019|NCT01680809|DEVICE|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
219680020|NCT04854005|PROCEDURE|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
219680021|NCT01441869|DRUG|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
219680022|NCT01441869|DRUG|Diabex|Extended release oral tablets, 1000 mg, single dose
219680023|NCT01441869|DRUG|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
219680024|NCT01441869|DRUG|Diabex|Extended release oral tablets, 500 mg, single dose
219680025|NCT01441869|DRUG|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
219680026|NCT04609423|DIETARY_SUPPLEMENT|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
219078628|NCT03163758|DEVICE|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
219078629|NCT03163758|DEVICE|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
219078630|NCT06322108|DRUG|Botensilimab + Balstilimab|Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
219078631|NCT06331000|DRUG|elexacaftor-tezacaftor-ivacaftor treatment|Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
219078632|NCT06665763|OTHER|Sodium Lactate Solution|Infusion of sodium-lactate solution
219078633|NCT06665763|OTHER|Saline infusion (placebo)|NaCl solution
219078634|NCT06667921|DEVICE|Ultrasound|Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
219078635|NCT06670014|DEVICE|repeech|Participants in this group will use the repeech application for a period of 4 weeks, with recommended usage of 5 days per week for 30 to 60 minutes per session. A designated speech-language pathologist (SLP) will set individualized treatment goals and customize the content of the therapy sessions based on each participant's baseline assessment. The repeech intervention will be tailored to meet the specific needs of each participant to improve speech intelligibility and communication abilities.
219078636|NCT06670014|OTHER|Workbook|Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria, due to the lack of a standardized care protocol for this condition. The recommended usage is the same as the treatment group: 5 days per week, for 30 to 60 minutes per session over a period of 4 weeks. After each self-treatment session, participants will record their activities on a checklist to monitor adherence and ensure compliance with the study protocol.
219078637|NCT06669689|DEVICE|operating position|In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.
219078638|NCT06669689|DEVICE|pneumoperitoneum|Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.
219078639|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation|All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.
219078640|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation Sham|We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
219078641|NCT04907942|OTHER|EMA + EMA and FACE Stress|1 wk of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of EMA and FACE stress
219078642|NCT04907942|OTHER|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate ecological momentary affects.
219680027|NCT04609423|DIETARY_SUPPLEMENT|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
219680028|NCT02423811|DIETARY_SUPPLEMENT|Fursultiamine|Use of Fursultiamine in addition to CCRT
219680029|NCT03654729|DRUG|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
219680030|NCT03654729|DRUG|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
219680031|NCT03654729|DRUG|Placebo|Solution in 20 mL single dose glass vials
219680032|NCT06101186|OTHER|NPECP based on NSM|A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
219078643|NCT06669962|DIAGNOSTIC_TEST|Study of coronary microcirculation and biomarkers of microvascular dysfunction|Patients with tako-tsubo syndrome will undergo to coronary angiography, ventriculography and assessment of physiological indexes of coronary circulation as per clinical practice
219078644|NCT03408717|OTHER|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
219078645|NCT03408717|OTHER|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
219078646|NCT03408717|OTHER|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
219078647|NCT07127718|BIOLOGICAL|Prophylactic Plasma Transfusion|ABO/Rh-type compatible fresh frozen plasma (FPP) units will be thawed to 37° prior to administration. Plasma transfusion will be administered intravenously, 1 unit for 4 hours every 12 hours. There will be two consecutive days for the transfusion for a total of 4 units.
219078648|NCT07127718|DEVICE|Hemoperfusion|The hemoperfusion (HP) procedure will follow the standard procedure of National Kidney and Transplant Institute (NKTI) using Jafron HA330 hemoperfusion cartridge. First, an internal jugular catheter is attached to the patient. Alternatively, an arteriovenous fistula or arteriovenous graft may be placed on the patient. The patient will then be hooked to a hemodialysis machine. Blood pump speed will be set to 150-200mL/min, and HP will last for 2 to 2.5 hours. Whole blood will flow through the sorbent HA330 cartridge and back to the patient. Anticoagulation is not necessary due to the short treatment time. Hemoperfusion will be repeated after 12-24 hours for at least three days.
219078649|NCT07127718|DEVICE|Extracorporeal Membrane Oxygenation|"A veno-venous ECMO (VV ECMO) will be applied by aseptically inserting a venous cannula into the femoral veins. The patients will be hooked to an ECMO machine. Patients without significant bleeding or vascular intervention will be managed with an activated clotting time set at 140-180 sec by 800-1000 U/h of heparin. Otherwise, heparin will be titrated to maintain a partial thromboplastin time of 60-80 sec.~ECMO settings are as follows:~* Mean blood pressure of \>60 mm~* SaO2 at \>90% with a flow of 3.5-4.5 L/min~* Hematocrit at \>35%~* Platelets \>50000-100000/mL~* Transfusions will be done when necessary~Criteria for weaning:~* ABG:~  * pH 7.35-7.45~ * PaO2 \>80 mm Hg~ * PCO2 \<45 mm Hg~* Under the following conditions:~  * Gas blender FiO2 of 0.21~ * Sweep gas of 0 L/min at an ECMO flow of 2 L/min~ * Ventilator mode (if applicable):~    * FiO2 of 0.6~   * Tidal volume of 6 mL/kg~   * PEEP of 8 cmH2O~   * RR of 12-16/min for VV ECMO or 3 L/min of O2 via nasal prong with awakening ECMO patients"
219078650|NCT07127718|OTHER|Conventional therapy|Conventional therapy for leptospirosis includes antibiotics, fluids, inotropes, renal replacement therapy, ventilator support, and other treatment that the attending physician deems necessary.
219210482|NCT07038421|OTHER|Spasticity|Spasticity was assessed using the Modified Ashworth Scale (MAS). In the MAS, muscles were recorded as 0, 1, 1, 1+, 2, 3, and 4 according to the resistance they gave to passive movement.
219210483|NCT07038421|OTHER|Position sense|The position sense was measured using a dual digital inclinometer. The mean absolute error from three trials was recorded. As the mean absolute error increased, position sense deteriorated.
219360531|NCT00535925|DRUG|hydrochlorothiazide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
219680033|NCT00519467|DRUG|Chlorproguanil-dapsone-artesunate (CDA)|
219680034|NCT04947410|DEVICE|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
219680035|NCT04530838|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
219680036|NCT04530838|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
219680037|NCT05575739|DIAGNOSTIC_TEST|Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )|Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
219680038|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 16 weeks
219680039|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 8 weeks
219680040|NCT00920777|BEHAVIORAL|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
219680041|NCT05581823|DRUG|Tavapadon|Oral tablets
219680042|NCT05581823|DRUG|Carbamazepine|Extended-release oral tablets
219680043|NCT00803712|DRUG|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
219078651|NCT06630871|DRUG|Distitamab Vedotin in combination with Tislelizumab|On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
219078652|NCT05677087|BEHAVIORAL|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
219078653|NCT06713863|OTHER|BEtter AT LEarning (BEATLE)- Digital Care Pathway|"BEATLE is a digital care pathway consisting of ten episodes resembling an online course. The episodes are designed to be multimodal and immersive, incorporating text, recorded voice, pictures, cartoons, videos and peer support through given examples and case stories. Participants are encouraged to access BEATLE through a web browser on a computer, although it is also accessible through a mobile application. Participants have control over the pace of completing the BEATLE, but there must be a minimum five-day break between episodes. In other words, it is possible to complete the BEATLE in seven weeks.~All participants are referred to the BEATLE by a neuropsychologist and are strongly authenticated in the healthvillage.fi online platform. Each participant is assigned a designated neuropsychologist who tracks their progress in the BEATLE and to whom messages and questions can be sent by the participant."
219078654|NCT06730542|DRUG|Zanubrutinib|Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.
219078655|NCT06730542|DRUG|Methotrexate|Participants will receive Methotrexate as per standard of care (SOC).
219078656|NCT06730542|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin as per standard of care (SOC).
219078657|NCT06730542|DRUG|Rituximab|Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
219078658|NCT06730542|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
219078659|NCT06730542|DRUG|Doxorubicin|Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
219078660|NCT06730542|DRUG|Prednisone|Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
219078661|NCT06732817|DEVICE|Active rTMS was administered using a transcranial magnetic stimulator (Rapid2; MagStim).|Active rTMS was sequentially administered over the left DLPFC and left TPJ sites one hour apart, for 3 weeks (21 consecutive days), using a transcranial magnetic stimulator (Rapid2; MagStim) with a 70-mm air-cooled figure-of-eight coil. Stimulation at 20 Hz (2 seconds on, 28 seconds off) was applied over the left DLPFC with an intensity set at 100% of the individual resting motor threshold (RMT), delivering a total of 1,600 pulses daily. Continuous theta burst stimulation (cTBS) was applied over the left TPJ at either 100% of the individual RMT or at the highest intensity that the stimulator could deliver for this protocol (50% of maximum output). Three daily sessions of cTBS were administered, separated by two 15-minute breaks, delivering a total of 1,800 pulses daily. The coil was navigated in real-time using a frameless neuro-navigation system (Brainsight; Rogue Research, Montreal, Quebec, Canada).
219078662|NCT06732232|DRUG|CD19/CD20/BCMA CAR-T|CD19/CD20/BCMA CAR T therapy
219078663|NCT06776614|PROCEDURE|Decompressive Craniectomy|"The DC will be performed through a standard trauma incision, a retro-auricular C-shape or a Kempe incision and execute a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. There are multiple techniques for DC. The elected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal DC will be considered. The removed bone flap may be stored in an abdominal pouch in the right or left upper abdominal quadrants or by freezing in a bone or blood bank freezer."
219078664|NCT06776614|PROCEDURE|Expansion Craniotomy|"The EC will be performed through a retro-auricular C-shape incision and executing a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. The expansion craniotomy will be finished with a cranioplasty using a full set of 3-5 Rialto plates for bone graft closure. The selected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal EC will be considered."
219078665|NCT04630730|DRUG|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
219078666|NCT04630730|DRUG|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
219078667|NCT04630730|DRUG|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
219078668|NCT04630730|DRUG|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
219680044|NCT00803712|DRUG|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
219680045|NCT01834170|DRUG|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
219680046|NCT00052078|DRUG|Sertraline (SRT)|Participants were treated with sertraline.
219680047|NCT00052078|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
219680048|NCT00052078|DRUG|Placebo|Participants were treated with a placebo pill.
219078669|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
219078670|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
219078671|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
219078672|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
219078673|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
219078674|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
219078675|NCT06231693|DRUG|Trastuzumab deruxtecan|Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
219078676|NCT06938997|OTHER|Virtual clinical auditory hallucination solution combining AR/VR technology|"This study, titled Effectiveness of AR/VR-integrated OSCE on Psychiatric Nurses' Comprehensive Auditory Hallucination Care Ability: A Randomized Controlled Trial, involves both experimental and control groups watching videos. The control group views standard educational videos, while the experimental group uses AR/VR technology, virtual patient interaction platforms, and educational videos in a simulated clinical environment. Four scripts were developed: two for training and two for pre/post-testing. All scripts and OSCE checklists are researcher-developed, reviewed by experts, and pilot tested."
219078677|NCT06938997|OTHER|Auditory Hallucination Care Video|The videos include professional knowledge and skills related to auditory hallucinations.
219078678|NCT06951789|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 600 ml/min (two generators 300 ml/min each).
219078679|NCT06951789|OTHER|Placebo|Ambient air, flow rate 600 ml/min (two pumps 300 ml/min each).
219078680|NCT06432166|DRUG|2-hydroxybenzylamine acetate|2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
219078681|NCT06432166|OTHER|Placebo|Placebo taken three times per day for 16 weeks.
219078682|NCT05467176|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
219078683|NCT02277444|DRUG|Golimumab|Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
219078684|NCT02277444|DRUG|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
219078685|NCT02993445|OTHER|Alternate Nostril Breathing|
219078686|NCT02993445|DEVICE|Foot Reflexology|
219078687|NCT00844857|DRUG|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
219078688|NCT00844857|DRUG|Placebo|Orally, once daily in the evening for 8 weeks.
219078689|NCT06020092|PROCEDURE|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
219078690|NCT06020092|PROCEDURE|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
219078691|NCT01245465|OTHER|Profermin|Medical Food (food for special medical purposes)
219078692|NCT05213195|DRUG|NKG2D CAR-NK|NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
219078693|NCT01757834|DEVICE|SWUS Elastography|
219078694|NCT00791206|PROCEDURE|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
219078695|NCT00791206|PROCEDURE|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
219078696|NCT03464968|DRUG|Oxaliplatin,5FU, leucovorin|mFOLFOX
219078697|NCT03464968|DRUG|irinotecan,5FU, leucovorin|mFOLFIRI
219078698|NCT02646228|OTHER|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
219078699|NCT00877643|OTHER|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
219078700|NCT00877643|OTHER|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
219078701|NCT01762150|DRUG|Sorafenib|Sorafenib 400mg BID by oral until progressed;
219078702|NCT01762150|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
219210484|NCT07038421|OTHER|Plantar sense|Plantar sensation was evaluated with the Semmes-Weinstein monofilament test (SWMT). The smallest monofilament value felt and correctly identified was recorded as the patient's threshold for light touch and pressure sensation. As the value increases, the underfloor sensation worsens.
219360532|NCT00535925|DRUG|furosemide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
219078703|NCT01762150|DRUG|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
219078704|NCT02328833|OTHER|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
219078705|NCT02785341|OTHER|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
219078706|NCT02785341|OTHER|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
219078707|NCT02785341|OTHER|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
219210485|NCT07039279|BEHAVIORAL|Multicomponent Integrated Care Program|The multicomponent integrated care program is supported by a team of endocrinologist, dietitian, psychologist and research assistant with elements including medical therapy, cognitive behavioural therapy, e-care (TourHeart + platform), artificial intelligence chatbot, biofeedback, peer support
219210486|NCT07039279|OTHER|TourHeart + platform|TourHeart+ is a web-based program that provides mental health services that integrate both online and offline elements, opening up new possibilities for mental well-being. Participants will be introduced to the platform but the control group will not receive follow-up action. The platform is part of the multi-intervention care program and the participants in the intervention will receive follow-up action to engage their usage of the platform.
219210487|NCT07039474|DRUG|18F-G1|18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
219210488|NCT07037992|DRUG|injection of local anesthesia solution|Injection of 30 mL local anesthetic solution bupivacaine 0.25%
219078708|NCT03432923|DRUG|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
219210489|NCT07037992|DRUG|Injection of normal saline|Injection of 30 mL normal saline Natrium Chloride (NaCl) 0.9%
219210490|NCT07038772|OTHER|Orthodontic treatment|Undergoing orthodontic treatment
219210491|NCT07038499|OTHER||Participants are not assigned an intervention as part of the study.
219210492|NCT07039006|BEHAVIORAL|Training with EA feedback|Subjects will undergo reaching training that includes a 30-degree elbow flexion error 3 times in 1 week.
219210493|NCT07039006|BEHAVIORAL|Training without EA feedback|Subjects will undergo reaching training that does not include EA feedback 3 times in 1 week.
219210494|NCT07037914|BEHAVIORAL|Education and Counseling|"The researcher will inform the mothers (n=25) that the My Baby is Safe Educational Program will be delivered individually through distance education via Microsoft Teams at times convenient for them, and that the program will be completed over 5 days. The scheduling will ensure that all modules included in the My Baby is Safe Educational Program are completed within one week at the latest. Mothers will be informed that they can receive telephone counseling from the researcher until their infants reach two months of age, and the researcher's phone number will be provided to them. During this period, the researchers will send weekly reminder messages to the mothers' phones, encouraging them to read the provided educational booklet and to watch the educational videos.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this home visit, the researcher will assess the infant's sleep environment for safe sleep practices."
219680049|NCT05819372|PROCEDURE|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results"
219680050|NCT04380376|DRUG|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
219078709|NCT03432923|DRUG|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
219078710|NCT06367205|DRUG|Goal-Directed Fluid Therapy (GDFT)|Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
219078711|NCT06367205|DRUG|Regular Fluid Therapy|Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary
219078712|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
219210495|NCT07037914|OTHER|Leaflet|"No structured or planned education will be provided to the control group by the researchers during the study period. After the first assessment, the mothers in the control group will receive a brochure prepared by the researchers based on the literature, containing brief informational notes on SIDS and SBS.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this visit, the researcher will observe the home environment where the infant resides and evaluate the infant's sleep environment in terms of safe sleep practices.~After data collection from the intervention group has been completed, the same intervention (My Baby is Safe Educational Program) will also be delivered to the mothers in the control group."
219210496|NCT07038655|DIETARY_SUPPLEMENT|Randomised 20g Protein Supplement|Participants receive a 20g protein feed of their randomised blend over the course of five hours split into aliquots every twenty minutes. The drink also contains a top up of 13C2 leucine stable isotope tracer, as well as uniformly labelled 13C spirulina and 2H labelled free amino acids for quantification of digestibility.
219360533|NCT00535925|DRUG|amlodipine|"Therapy for hypertension~\- Step 3: amlodipine up to 10 mg/die"
219360534|NCT00535925|DRUG|atenolol|"Therapy for hypertension~\- Step 4: atenolol up to 100 mg/die"
219680051|NCT04380376|OTHER|Standard of care|the patients will receive only SOC (standard of care) treatment
219680052|NCT02672176|BEHAVIORAL|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
219680053|NCT02672176|BEHAVIORAL|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
219078713|NCT00868855|DRUG|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
219078714|NCT03078270|DRUG|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
219078715|NCT03078270|OTHER|Placebo|single treatment visit for 5 injections of normal saline
219078716|NCT04648189|DRUG|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
219078717|NCT04133155|DRUG|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
219078718|NCT03872921|DRUG|norUrsodeoxycholic Acid|oral treatment
219078719|NCT03531424|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
219078720|NCT03531424|PROCEDURE|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
219078721|NCT00383487|DRUG|Calcitriol|0.5 micrograms/kilogram q weekly
219078722|NCT00383487|DRUG|Naproxen-n-butyl nitrate|400 mg BID, oral
219078723|NCT01825629|OTHER|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
219078724|NCT01825629|OTHER|Placebo|
219078725|NCT00002426|DRUG|Adefovir dipivoxil|
219078726|NCT01544322|DRUG|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
219078727|NCT05540925|PROCEDURE|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups."
219078728|NCT03099993|OTHER|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
219680054|NCT02876796|DRUG|GS-0976|Capsule(s) administered orally
219078729|NCT04905394|PROCEDURE|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
219078730|NCT01409148|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
219078731|NCT03228056|DIAGNOSTIC_TEST|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
219078732|NCT01974167|DRUG|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
219078733|NCT01974167|DRUG|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
219078734|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
219078735|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
219078736|NCT05239130|DEVICE|Auralya|Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
219078737|NCT04245280|DRUG|Ropivacaine 0.5% Injectable Solution|ropivacaine 0.5% with epinephrine 2.5 mcg/ml
219078738|NCT04245280|DRUG|Saline Solution|normal saline solution (NaCl 0.9%)
219078739|NCT03468556|DRUG|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
219360535|NCT00535925|DRUG|doxazosin|"Therapy for hypertension~\- Step 5: doxazosin up to 4 mg/die"
219360536|NCT00535925|DRUG|clonidine|"Therapy for hypertension~\- Step 6: clonidine"
219078740|NCT03468556|DRUG|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
219078741|NCT05245929|DEVICE|Distalization|Distalizing the posterior maxillary segment
219078742|NCT04185805|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
219078743|NCT04185805|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
219078744|NCT02923804|DIETARY_SUPPLEMENT|Omega-3|3x 1g capsules taken daily for 6 months
219078745|NCT02923804|DIETARY_SUPPLEMENT|Olive oil|3x 1g capsules taken daily for 6 months
219680055|NCT02876796|DRUG|Placebo|Capsule(s) administered orally
219680056|NCT02876796|OTHER|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
219680057|NCT02876796|OTHER|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
219680058|NCT01010737|BIOLOGICAL|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
219680059|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
219078746|NCT00352482|DRUG|Sildenafil (50 mg)|
219078747|NCT00746122|PROCEDURE|Open repair|Standard treatment of emergency open surgery
219078748|NCT00746122|PROCEDURE|EVAR|Emergency endovascular aneurysm repair
219078749|NCT02539810|DEVICE|Renal artery Angioplasty plus stenting.|renal artery stenting
219078750|NCT02539810|DRUG|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
219078751|NCT02678130|DEVICE|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
219078752|NCT02678130|DEVICE|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
219078753|NCT06145243|OTHER|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
219078754|NCT06145243|OTHER|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
219078755|NCT06145243|OTHER|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
219078756|NCT03393000|DRUG|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
219078757|NCT03393000|OTHER|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
219078758|NCT03530930|DRUG|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
219078759|NCT01773070|DRUG|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
219078760|NCT01773070|DRUG|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
219078761|NCT01773070|DRUG|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
219078762|NCT02063334|DIETARY_SUPPLEMENT|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
219078763|NCT02063334|DIETARY_SUPPLEMENT|Placebo|
219078764|NCT06580262|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
219078765|NCT04499573|DRUG|CD19/CD22 CAR-T|"The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg"
219078766|NCT06485817|DRUG|Oxycodone|"3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
219360537|NCT00535925|DRUG|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c \<7):~\- insulin"
219680060|NCT01010737|BIOLOGICAL|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
219680061|NCT01010737|BIOLOGICAL|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
219680062|NCT01010737|BIOLOGICAL|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
219680063|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
219680064|NCT01010737|BIOLOGICAL|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
219680065|NCT02100839|DRUG|AEM-28|Solution for injection
219680066|NCT02100839|DRUG|Normal Saline|0.9% saline for injection
219680067|NCT04756622|DRUG|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
219680068|NCT02343367|BEHAVIORAL|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
219680069|NCT02343367|OTHER|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
219680070|NCT02343367|BEHAVIORAL|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
219078767|NCT06485817|DRUG|Placebo|"Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
219078768|NCT06485817|BEHAVIORAL|Stress State Induction|"ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting."
219078769|NCT06485817|BEHAVIORAL|Control State Induction|Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
219078770|NCT03643952|DRUG|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
219078771|NCT03731468|DRUG|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
219078772|NCT03731468|DRUG|Dexamethasone|dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
219078773|NCT04041960|OTHER|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
219078774|NCT04708444|DIAGNOSTIC_TEST|CD318|Flowcytometric marker
219078775|NCT00046358|DRUG|Lovostatin|
219078776|NCT00046358|DRUG|Ibuprofen|
219078777|NCT05622669|OTHER|Observational|Sensed and lived experience data from all groups without a specific behavioural or drug intervention
219078778|NCT04101305|DIAGNOSTIC_TEST|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
219078779|NCT02077179|BEHAVIORAL|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
219078780|NCT03098134|BEHAVIORAL|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
219078781|NCT03098134|OTHER|Health Education|Video based health education covering common myths and false believes about dental surgeries
219078782|NCT02535273|DRUG|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
219078783|NCT02535273|DRUG|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
219078784|NCT02535273|DRUG|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
219078785|NCT02535273|DRUG|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
219078786|NCT02535273|DRUG|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
219078787|NCT02535273|DRUG|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
219078788|NCT06064396|OTHER|Gong's Mobilization|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Gong's Mobilization.
219078789|NCT06064396|OTHER|Stecco Fascial Therapy|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with stecco fascial therapy.
219360538|NCT00535925|DRUG|simvastatin|"Therapy for hypercholesterolemia:~\- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die"
219680071|NCT02343367|BEHAVIORAL|Text messages|regularly scheduled cell phone text messages for 12 months
219680072|NCT02343367|BEHAVIORAL|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
219680073|NCT02343367|BEHAVIORAL|Newsletters|12 monthly newsletters mailed to participant homes
219680074|NCT00018824|DRUG|NALTREXONE|
219680075|NCT00018824|DRUG|Placebo|
219680076|NCT05702580|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
219078790|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
219078791|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
219078792|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
219078793|NCT04528069|DEVICE|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
219078794|NCT04528069|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
219078795|NCT03673254|DEVICE|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
219078796|NCT03966833|BEHAVIORAL|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
219078797|NCT03966833|BEHAVIORAL|Unconditional Cash Transfer|Lump sum cash transfer
219078798|NCT02436265|DRUG|Dexamethasone|IV dexamethasone
219078799|NCT02436265|DRUG|Ropivacaine|Ropivacaine only
219078800|NCT05853679|DEVICE|Lumoral Treatment|The device will be used 5 to 7 times per week according to the manufacturer's instructions.
219078801|NCT05853679|OTHER|Standard oral hygiene instructions according to the Finnish Dental Association|Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
219078802|NCT03584932|BEHAVIORAL|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
219078803|NCT03365024|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
219078804|NCT03365024|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
219078805|NCT05955703|BEHAVIORAL|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
219078806|NCT06025474|DRUG|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
219078807|NCT06025474|DRUG|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
219078808|NCT06025474|DRUG|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
219078809|NCT06025474|DRUG|Citalopram 20mg|Encapsulated citalopram tablets, once daily
219078810|NCT06025474|DRUG|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
219078811|NCT06025474|DRUG|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
219078812|NCT06025474|DRUG|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
219078813|NCT01616901|PROCEDURE|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
219078814|NCT02525874|DRUG|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
219078815|NCT04899830|DEVICE|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
219078816|NCT03901326|DIAGNOSTIC_TEST|CT-FFR assessment|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
219078817|NCT06005805|DIETARY_SUPPLEMENT|Mastic gum|Mastic gum 3g/pack daily for 21 days
219078818|NCT06005805|BEHAVIORAL|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
219078819|NCT00253968|DRUG|Eplivanserin|oral administration
219078820|NCT00253968|DRUG|placebo|oral administration
219078821|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro|
219078822|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro FreeD|
219680077|NCT01087164|BEHAVIORAL|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
219680078|NCT01087164|BEHAVIORAL|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
219680079|NCT03446092|BEHAVIORAL|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
219078823|NCT05830955|OTHER|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
219078824|NCT05830955|OTHER|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
219078825|NCT05830955|OTHER|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
219078826|NCT00006041|BIOLOGICAL|MUC1-KLH conjugate vaccine|
219078827|NCT00006041|BIOLOGICAL|MUC1-KLH vaccine/QS21|
219078828|NCT00006041|BIOLOGICAL|QS21|
219210497|NCT07038486|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
219078829|NCT04211038|DEVICE|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
219078830|NCT00446381|DRUG|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
219078831|NCT00446381|DRUG|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
219078832|NCT00006213|DRUG|BMS-214662|Given IV
219078833|NCT00006213|OTHER|pharmacological study|Correlative studies
219078834|NCT00006213|OTHER|laboratory biomarker analysis|Correlative studies
219078835|NCT05480150|DRUG|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
219078836|NCT05480150|DRUG|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
219078837|NCT05480150|DRUG|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
219078838|NCT01692782|DRUG|SEP-225289|SEP-225289 4mg once daily
219078839|NCT01692782|DRUG|SEP-225289|SEP-225289 8mg once daily
219078840|NCT01692782|DRUG|Placebo|Placebo once daily
219210498|NCT06578585|DRUG|Ubrogepant|Tablet
219210499|NCT06578585|DRUG|Lu AG09222|Solution for injection/infusion
219078841|NCT02846090|DRUG|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
219078842|NCT05612074|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
219078843|NCT02161133|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
219078844|NCT02161133|BEHAVIORAL|Health Education|Health Education provides didactic information about Gulf War Illness
219078845|NCT03220490|BEHAVIORAL|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
219078846|NCT03220490|BEHAVIORAL|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
219078847|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
219078848|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
219078849|NCT00696748|DRUG|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
219078850|NCT00696748|DRUG|Placebo|Placebo 4 mL intramuscular
219078851|NCT04158050|DRUG|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
219078852|NCT06580795|BEHAVIORAL|Student citizens' assembly|The intervention consists in participating in a deliberative mini-public, a student citizens' assembly whose mission is to to co-create a list of concrete proposals that would improve the access of USPN students to sustainable diets and physical activity
219078853|NCT03945188|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
219078854|NCT03945188|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
219078855|NCT02506842|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
219078856|NCT02506842|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
219078857|NCT02506842|DRUG|oxaliplatin|Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
219078858|NCT02506842|DRUG|folinic acid|Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
219078859|NCT02506842|DRUG|fluorouracil|Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
219078860|NCT05214833|BEHAVIORAL|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
219210500|NCT06578585|DRUG|Placebo|Solution for injection/infusion
219078861|NCT05214833|BEHAVIORAL|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
219680080|NCT02653365|DEVICE|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
219680081|NCT04515836|DRUG|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
219680082|NCT03565874|DEVICE|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
219680083|NCT00678847|DEVICE|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
219680084|NCT00678847|DEVICE|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
219680085|NCT00241007|DRUG|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
219680086|NCT05181098|PROCEDURE|Robotic-guided spine surgery|The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
219680087|NCT03967860|DIAGNOSTIC_TEST|CT scan|Post surgical standard CT Scan as predictor of complication
219680088|NCT06017401|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
219680089|NCT06017401|PROCEDURE|Transmuscular Quadratus Lumborum Block|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
219680090|NCT03440619|DEVICE|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
219680091|NCT03281746|PROCEDURE|Dental Procedure|Undergo dental examination
219078862|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
219078863|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
219078864|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
219078865|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
219078866|NCT01552850|DRUG|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
219078867|NCT04233476|DRUG|99mTc-3PRGD2 injection|A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
219078868|NCT03931148|DIAGNOSTIC_TEST|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
219078869|NCT03931148|DIAGNOSTIC_TEST|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
219078870|NCT03931148|DIAGNOSTIC_TEST|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
219078871|NCT03931148|OTHER|Qualitative interview|Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
219078872|NCT01982240|DRUG|Plecanatide|Plecanatide tablets QD for 12 weeks
219078873|NCT01982240|DRUG|Placebo|Matching placebo tablets QD for 12 weeks
219078874|NCT01982240|DRUG|Bisacodyl|Rescue medication
219078875|NCT05030402|PROCEDURE|Maitland|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
219078876|NCT05030402|PROCEDURE|Tens, exercise, SW|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
219078877|NCT05030402|PROCEDURE|Conventional physiotherapy|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
219078878|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
219078879|NCT04896489|OTHER|Placebo|Participants receive placebo
219078880|NCT04341116|DRUG|TJ003234|patients receive a single infusion
219210501|NCT06882174|DRUG|Scheduling of the time of pembrolizumab infusions|The intervention in this study is scheduling of the time of pembrolizumab infusions.
219078881|NCT04341116|DRUG|Placebo|patients receive a single infusion
219210502|NCT06730672|DRUG|Volonib combined with Everolimus Formation|Volonib 200mg once daily and Everolimus 5mg once daily
219680092|NCT03281746|OTHER|Educational Intervention (prevention education)|Receive prevention education
219680093|NCT03281746|OTHER|Interview|Ancillary studies
219680094|NCT03281746|OTHER|Survey Administration|Ancillary studies
219680095|NCT03281746|OTHER|Educational Intervention (one-on one education)|Receive one-on-one education
219680096|NCT03241576|BEHAVIORAL|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
219680097|NCT03241576|BEHAVIORAL|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
219680098|NCT03194178|OTHER|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)"
219680099|NCT00669318|BIOLOGICAL|alemtuzumab|
219680100|NCT00669318|BIOLOGICAL|rituximab|
219078882|NCT05019092|DIAGNOSTIC_TEST|Ultrasound examination of lower limb veins|Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
219078883|NCT03546881|PROCEDURE|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
219680101|NCT00669318|DRUG|pentostatin|
219680102|NCT00669318|DRUG|sargramostim|
219078884|NCT03546881|PROCEDURE|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
219078885|NCT03388567|OTHER|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
219078886|NCT04534231|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
219078887|NCT01845740|DRUG|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
219078888|NCT01845740|DRUG|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
219078889|NCT04154202|OTHER|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
219078890|NCT02219048|DRUG|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
219078891|NCT02219048|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
219078892|NCT02194270|DRUG|Ambroxol hydrochloride - soft pastille|
219078893|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - low dose|
219078894|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - high dose|
219078895|NCT00363675|BEHAVIORAL|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
219078896|NCT04592445|DEVICE|Satera GSN Ablation|The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
219078897|NCT04592445|DEVICE|Sham Control|The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
219680103|NCT04955795|BEHAVIORAL|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
219680104|NCT04955795|BEHAVIORAL|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
219680105|NCT01701544|DEVICE|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
219680106|NCT00844779|PROCEDURE|Bariatric surgery|Gastric bypass.
219078898|NCT01803074|DRUG|BMS-955176|BMS-955176
219078899|NCT01803074|DRUG|Placebo matching with BMS-955176|Placebo matching with BMS-955176
219078900|NCT01803074|DRUG|Atazanavir|Atazanavir
219078901|NCT01803074|DRUG|Ritonavir|Ritonavir
219078902|NCT01803074|DRUG|Tenofovir|Tenofovir
219210503|NCT06730958|DIAGNOSTIC_TEST|serum Follistatin-like protein 1|Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
219360539|NCT00535925|DRUG|fibrate|"Therapy for hypertriglyceridemia~\- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate"
219360540|NCT00535925|DRUG|erythropoietin|"Treatment of anaemia:~\- erythropoietin"
219078903|NCT01803074|DRUG|Emtricitabine|Emtricitabine
219078904|NCT02521090|BIOLOGICAL|EGFRBi-Armed Autologous T Cells|Given IT and IV
219078905|NCT02521090|OTHER|Laboratory Biomarker Analysis|Correlative studies
219078906|NCT02006082|DEVICE|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
219078907|NCT02081573|BEHAVIORAL|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
219078908|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation two days a week
219078909|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation three days a week
219078910|NCT00571454|BEHAVIORAL|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
219680107|NCT00844779|PROCEDURE|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
219078911|NCT05995028|BIOLOGICAL|Universal CD7-specific CAR gene-engineered T cells|Infusion of 4SCAR7U T cells
219078912|NCT03121157|BEHAVIORAL|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
219078913|NCT02073084|DRUG|K-877 Low Dose|K-877 Low Dose
219078914|NCT02073084|DRUG|Moxifloxacin|
219078915|NCT02073084|OTHER|Placebo|
219078916|NCT02073084|DRUG|K-877 High Dose|K-877 High Dose
219078917|NCT02352558|DRUG|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
219078918|NCT02352558|DRUG|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
219078919|NCT02352558|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
219078920|NCT02352558|DRUG|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
219078921|NCT02352558|DRUG|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
219078922|NCT02995772|DRUG|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
219680108|NCT01073163|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
219680109|NCT01073163|DRUG|Rituximab|Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
219680110|NCT05358899|DEVICE|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
219680111|NCT05358899|DEVICE|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
219680112|NCT00405015|DRUG|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
219078923|NCT02995772|DRUG|Tamoxifen|Comparison of efficacy with chemotherapy
219078924|NCT02995772|PROCEDURE|SOB|Comparison of efficacy with chemotherapy
219078925|NCT02995772|DRUG|FAC|Comparison of efficacy with hormonal therapy
219078926|NCT02995772|DRUG|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
219078927|NCT02995772|DRUG|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
219078928|NCT01618162|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
219078929|NCT01618162|DRUG|placebo|Injected subcutaneously (under the skin) once daily.
219078930|NCT05829161|BEHAVIORAL|no intervention|no intervention
219078931|NCT02901457|OTHER|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
219360541|NCT00535925|DRUG|aspirin|"Antiplatelet therapy (in all patients without contraindications):~\- aspirin up to 160 mg/die"
219680113|NCT03977987|DRUG|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
219680114|NCT06321185|PROCEDURE|Subcostal TAP block|"Subcostal TAP block will be applied after intubation and before surgery. A local anesthetic solution of 20 ml 0.25% bupivacaine for each side will be injected bilaterally between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
219680115|NCT06321185|OTHER|Port site local anesthetic infiltration|"After intubation and before port placements, a solution of 20 ml 0.25% bupivacaine will be infiltrated into the laparoscopic port sites. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
219680116|NCT06321185|OTHER|No intervention or local anesthetic administration|"There will not be an intervention or local anesthetic administration. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
219680117|NCT02706769|DRUG|Placebo|Study medication contains blinded placebo
219680118|NCT02706769|DRUG|Paracetamol|Study medication contains blinded paracetamol
219680119|NCT01677182|DRUG|Ramelteon|Ramelteon tablets for sublingual administration
219680120|NCT01677182|DRUG|Placebo|Ramelteon placebo-matching tablets for sublingual administration
219680121|NCT00995722|DRUG|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
219680122|NCT00995722|DRUG|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
219680123|NCT03206840|BEHAVIORAL|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
219680124|NCT03627078|OTHER|motor interference therapy|
219078932|NCT01189916|PROCEDURE|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
219078933|NCT01445925|PROCEDURE|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
219078934|NCT01445925|PROCEDURE|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
219078935|NCT01445925|DRUG|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
219078936|NCT05788757|DEVICE|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
219078937|NCT05253248|DIETARY_SUPPLEMENT|OMIS|This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
219078938|NCT02693275|DEVICE|Quotient® System iPad Test|See arm/group description
219078939|NCT04124926|DRUG|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
219078940|NCT04124926|DRUG|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
219360542|NCT04728490|OTHER|Allogenic transplantation transplantation|Haplo-identical transplantation with the use of Treosulfan, Thiotepa and Fludarabine in conditioning regimen.
219360543|NCT05664165|OTHER|dry needling|The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed
219680125|NCT03627078|OTHER|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
219680126|NCT02945735|BEHAVIORAL|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
219078941|NCT04603534|OTHER|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
219078942|NCT04618185|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
219078943|NCT01508039|OTHER|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
219078944|NCT03725683|DEVICE|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
219078945|NCT03725683|DEVICE|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
219078946|NCT00423176|DRUG|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
219078947|NCT00423176|DRUG|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
219078948|NCT00003260|DRUG|FOLFIRI regimen|
219078949|NCT00003260|DRUG|FOLFOX regimen|
219078950|NCT00003260|DRUG|fluorouracil|
219078951|NCT00003260|DRUG|irinotecan hydrochloride|
219078952|NCT00003260|DRUG|leucovorin calcium|
219078953|NCT00003260|DRUG|oxaliplatin|
219078954|NCT01919242|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
219078955|NCT01940042|BEHAVIORAL|CO2 was removed by means of trandelenburg positions|
219078956|NCT00898885|PROCEDURE|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
219078957|NCT03386279|DRUG|PF-04965842|one single dose of 600 mg by mouth
219078958|NCT03386279|DRUG|Moxifloxacin|one single dose of 400 mg by mouth
219078959|NCT03386279|DRUG|Placebo|one single dose by mouth
219078960|NCT01587508|DRUG|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
219078961|NCT01587508|DRUG|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
219078962|NCT01587508|DRUG|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
219078963|NCT03871595|DRUG|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
219078964|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in single sitting|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
219680127|NCT01288651|DRUG|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
219078965|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in two sittings|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
219680128|NCT05784376|BEHAVIORAL|Education-based|Nutrition education delivered via text messages through mobile applications (e.g. WhatsApp).
219680129|NCT05733845|OTHER|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
219680130|NCT05376761|DRUG|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
219078966|NCT03048851|DEVICE|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
219680131|NCT01952418|DEVICE|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
219680132|NCT00762762|DRUG|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
219680133|NCT00762762|DRUG|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
219078967|NCT03048851|DEVICE|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
219078968|NCT03048851|DEVICE|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
219078969|NCT03048851|DEVICE|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
219078970|NCT03048851|PROCEDURE|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
219078971|NCT02694705|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
219078972|NCT02694705|DEVICE|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
219078973|NCT02694705|DEVICE|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
219078974|NCT05640349|BIOLOGICAL|Positive blood culture|Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
219078975|NCT06579716|OTHER|Traditional balance exercise|All patients in both group received a traditional balance exercise program, 3 sessions per week, for 6 weeks. Each session of exercise comprised 10 min of warm-up, 40min of balance exercise, and 5min of cool down. Warm-up included treadmill walking. Balance exercise comprised two sets of sit to stand, one leg stance, tandem stance and 30 squats. The first set of exercises was performed on a stable surface, whereas the second set of exercises was performed on an unstable surface by using Thera band stability trainer. Each set of each exercise was performed for 3 min, with 1-2 min of rest in between the exercises. Cool-down included deep breathing, abdominal breathing, and mild stretching.
219078976|NCT06579716|OTHER|Resistance exercise|All patients in both group received a resistance exercise program, 3 sessions per week, for 6 weeks. Each patient was seated in sitting position and the weight sandbags was applied at the dorsum of the foot. The resistance was set to be around 40%-60% of the 1RM. The patient performed the exercise for 3 bouts, every bout 10 repetitions. The one repetition maximum (1RM) was established prior to the training period using the following equation: 1 RM = Weight (kg) X (1 + {0.033 X number of repetitions)}.
219078977|NCT06579716|OTHER|Whole-body vibration (WBV)|Patients were asked to stand barefoot on the vibratory platform with an even distribution of weight on both feet and familiarized with WBV at a lesser frequency and amplitude. Then, they were asked to bend their knee 30º to the vertical; thereafter, to obtain a greater muscular response, WBV training was performed at a frequency of 30 Hz and an amplitude of 2mm. The exercise comprised five bouts of a 30-sec vibration with a 1-min elapse between the bouts.
219078978|NCT06579716|OTHER|Kineso tape|Kineso tape was applied to dorsiflexors 24 hours a day and was replaced every 5 days for patients who were taped in accordance with Kenzo Kase's Kinesio taping Manual. For taping, each patient's leg was placed in a relaxed position while he sat on a taping table. The skin was to be free of oils and lotions, to avoid anything that might limit the acrylic adhesive's ability to adhere to the skin. So, the subject's skin was cleaned with alcohol prior to tape application. For the Tibialis anterior, tape was measured from the muscle origin to the insertion while the muscle was stretched. The base of the tape was applied to the origin at the lateral condyle and superior 2/3 of anterolateral surface of tibia. Then the subject was asked to stretch the foot into plantar flexion and eversion; taping was then finished toward the insertion at the medial and plantar surface of medial cuneiform and base of the first metatarsal.
219078979|NCT06580483|OTHER|amalgam restoration|An abutment tooth is restored on a side by amalgam plug
219680134|NCT06312384|PROCEDURE|3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.
219680135|NCT06312384|PROCEDURE|conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
219078980|NCT06580483|OTHER|nano-composite|An abutment tooth is restored on a side by nano-composite
219078981|NCT02099474|OTHER|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
219078982|NCT02960100|OTHER|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
219078983|NCT02960100|OTHER|Media Intervention|Receive targeted HPV vaccine narrative-style video
219078984|NCT02960100|OTHER|Survey Administration|Ancillary studies
219078985|NCT04957537|BEHAVIORAL|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
219078986|NCT03067038|DEVICE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
219078987|NCT03067038|DEVICE|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
219078988|NCT03960905|OTHER|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
219078989|NCT04777045|DRUG|Diltiazem Hydrochloride|"Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm."
219078990|NCT04777045|DRUG|Placebo|Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
219078991|NCT06635967|DEVICE|frequency-specific rTMS|Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
219680136|NCT04034212|OTHER|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
219680137|NCT02489448|DRUG|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
219680138|NCT01418911|OTHER|questionnaire|questionnaire only
219680139|NCT04063735|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
219680140|NCT04063735|DIETARY_SUPPLEMENT|Placebo|Placebo was given to participants.
219680141|NCT03308604|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
219680142|NCT03308604|RADIATION|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
219680143|NCT03308604|RADIATION|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
219680144|NCT03308604|DRUG|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
219680145|NCT03834025|BEHAVIORAL|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
219680146|NCT03834025|BEHAVIORAL|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
219078992|NCT06635967|DEVICE|1 Hz rTMS|Low-frequency rTMS will be performed at a frequency of 1Hz
219078993|NCT06636188|OTHER|Digi-Coach Chatbot|Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
219078994|NCT06635681|DRUG|combined chemotherapy|"Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease."
219078995|NCT01314274|DRUG|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
219078996|NCT01314274|DRUG|NaCl|10ml of 0.9% NaCl intranasal submucosal
219078997|NCT00922285|OTHER|psychosocial support for caregiver|6 weekly 60 minute sessions
219078998|NCT00922285|OTHER|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
219078999|NCT00922285|PROCEDURE|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
219079000|NCT00922285|PROCEDURE|stress management therapy|6 weekly 60 minute sessions
219079001|NCT03152526|DEVICE|Interventions|CliniMACS® CD3 and CD19 Reagent System
219079002|NCT04823377|OTHER|Usual care|Patients receiving systemic anticancer treatment in their last days of life
219079003|NCT04823377|OTHER|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
219079004|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Interscalene nerve block with 20 mL 0.5% bupivacaine.
219210504|NCT06758050|OTHER|Core strengthening exercises|By core strengthening exercise, could be improved pain, balance, and function in patients with patellofemoral pain syndrome. In that case, this will not only improve their postural stability and neuromuscular control, but we believe it will improve their overall functional, performance, and quality of life. Currently, limited evidence exists about the effectiveness of core strengthening exercises on pain, function and dynamic balance in patellofemoral pain syndrome. By addressing core strengthening exercise, physical therapists can advise new treatment methods for patellofemoral pain syndrome (Chevidikunnan et al., 2016)
219210505|NCT06758050|OTHER|Traditional treatment|hip and knee-focused exercises
219680147|NCT03834025|BEHAVIORAL|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
219680148|NCT03834025|BEHAVIORAL|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
219680149|NCT03834025|BEHAVIORAL|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
219680150|NCT03834025|BEHAVIORAL|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
219079005|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
219680151|NCT03834025|BEHAVIORAL|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
219680152|NCT00030966|DRUG|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
219680153|NCT00030966|DRUG|Placebo|Placebo monthly infusion for up to 116 weeks.
219680154|NCT04835961|OTHER|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
219079006|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
219210506|NCT06756464|DEVICE|ROHKEA: Virtual Reality Therapy|Using Interpretative Phenomenological Analysis (IPA): an exploration of the therapeutic benefits of a Virtual Reality enhanced Cognitive Behavioural Therapy (CBT) and movement (graded exposure) therapy 60-day chronic pain management programme (CPMP). Using the ROHKAE device and undertaking semi structures interviews, pain questionnaires and patient diaries to measure patient experience and pain management
219210509|NCT06734806|DIAGNOSTIC_TEST|Radiographic Imaging and Digital STL Analysis|This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.
219680155|NCT01084057|DRUG|vorinostat|Given orally
219680156|NCT01084057|DRUG|ixabepilone|Given IV
219079007|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
219079008|NCT05554237|DRUG|Placebo|Placebo
219079009|NCT05554237|DRUG|PF-07612577|PF-07612577
219079010|NCT05554237|DRUG|PF-06264006|PF-06264006
219079011|NCT06636877|DRUG|BR1019|One tablet administered alone
219079012|NCT06636877|DRUG|BR1019-2|One tablet administered alone
219079013|NCT06636877|DRUG|BR1019-3|One tablet administered alone
219079014|NCT06540339|OTHER|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
219079015|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
219079016|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
219079017|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
219079018|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
219079019|NCT04079621|DRUG|primaquine|Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
219079020|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
219079021|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
219079022|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
219079023|NCT02212704|OTHER|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
219079024|NCT02212704|OTHER|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
219079025|NCT02212704|OTHER|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
219680157|NCT01084057|OTHER|laboratory biomarker analysis|Correlative studies
219680158|NCT01084057|OTHER|pharmacological study|Correlative studies
219680159|NCT04235426|DRUG|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
219680160|NCT04235426|PROCEDURE|30 patients went to surgical procedure|30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
219680161|NCT04235426|OTHER|Injection|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
219680162|NCT03065686|GENETIC|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
219680163|NCT03516162|OTHER|There is no study-specific intervention|There is no study-specific intervention
219680164|NCT02705378|DRUG|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
219079026|NCT06099067|DRUG|Canagliflozin|Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
219079027|NCT06099067|DRUG|DPP4 inhibitor|DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
219079028|NCT06099067|DRUG|Liraglutide|Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
219079029|NCT06099067|DRUG|Saxagliptin|Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
219079030|NCT06099067|DRUG|2nd generation Sulfonylurea|2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
219079031|NCT04435366|DRUG|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
219079032|NCT04435366|DRUG|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
219079033|NCT06069206|OTHER|T2Bacteria® Panel (direct-from-blood testing)|Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.
219079034|NCT06069206|OTHER|Usual Care|Standard blood cultures.
219680165|NCT02705378|DRUG|naloxegol|Intervention would be given by OG or NG tube
219680166|NCT02871622|DEVICE|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
219680167|NCT02315144|DRUG|TV48108|TV48108 15, 60, 120 μg
219680168|NCT02315144|DRUG|Placebo|Placebo Comparator
219680169|NCT02752438|DEVICE|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
219680170|NCT04256564|PROCEDURE|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
219680171|NCT00752336|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
219680172|NCT00997347|DRUG|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
219680173|NCT04998214|DIAGNOSTIC_TEST|liver function , prothrombin time , INR , US .|analytic
219680174|NCT00494546|PROCEDURE|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
219680175|NCT02562586|DEVICE|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
219079035|NCT06079463|OTHER|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
219079036|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
219079037|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
219079038|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
219079039|NCT06962410|OTHER|Hybrid Closed-Loop Artificial Pancreas System|The pump was loaded with ultra-short-acting insulin (Manufacturer: Novo Nordisk A/S, Denmark; Approval Number: National Drug Approval No. J20050097; Specification: 3 mL: 300 U). The total daily insulin requirement was calculated at 0.2-0.4 U/(kg·d) based on the patient's weight. During operation, the system automatically adjusted the basal rate according to the blood glucose level. After the physician issued a large-dose order based on previous treatment experience and blood glucose conditions, the nurse manually entered the large-dose treatment instruction in the AAPS software.
219079040|NCT06961500|DRUG|Obinutuzumab|1000mg i.v., administered on Day 1/8/15 (D1/8/15) of Cycle 1 (C1), and D1 of C2-6
219079041|NCT06961500|DRUG|CHOP|a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4 mg/m2 i.v., administered on D1; d) Prednisone: 100mg/d po, administered on D1-5.
219079042|NCT06961500|DRUG|Bendamustine|90 mg/m2 i.v. drip, administered on D1-2.
219079043|NCT06962254|DRUG|Imatinib|"1. Imatinib is binding to the ATP-binding site of BCR-ABL, blocking its activity and preventing uncontrolled proliferation to target the BCR-ABL fusion protein in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It also inhibits PDGFR and c-KIT receptors, suppressing tumor growth and angiogenesis in gastrointestinal stromal tumors (GIST).~2. Preclinical studies have shown that imatinib combined with MEK inhibitors can suppress the growth of KRAS-mutated pancreatic adenocarcinoma."
219210510|NCT06734806|DIAGNOSTIC_TEST|FDI Criteria Evaluation and Plaque Index Measurement|This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
219210511|NCT06734429|OTHER|Urinary Artificial Sphincter|Urinary Artificial Sphincter is a device used for patients with urethral sphincter incompetence
219210512|NCT06746948|OTHER|dyadic psychological distress|There is no intervention among the cross-sectional study.
219210513|NCT05720468|OTHER|Exercise|Combined endurance and resistance exercise training
219210514|NCT05720468|OTHER|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
219210515|NCT06741605|OTHER||
219210516|NCT06742918|OTHER|Placebo|Placebo was given to the Group IV which was 2 grams of glucose.
219680176|NCT02063594|DRUG|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
219680177|NCT02063594|DRUG|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
219680178|NCT06153615|OTHER|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
219680179|NCT06153615|OTHER|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
219680180|NCT06153615|OTHER|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
219680181|NCT06153615|OTHER|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
219680182|NCT06105814|DEVICE|Rapid diagnostics|Sputum sampes will in addition to standard diagnostics be investigated using a rapid diagnostic plattform (FilmArray)
219680183|NCT00540397|DRUG|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
219680184|NCT01563198|BEHAVIORAL|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
219079044|NCT06962254|DRUG|Trametinib|Trametinib inhibits the MEK1 and MEK2 enzymes, preventing the downstream phosphorylation and activation of ERK1/2, which are crucial for the RAS-RAF-MEK-ERK signaling pathway. By blocking this pathway, trametinib reduces cell proliferation and induces apoptosis in tumor cells harboring pathway mutations.
219079045|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
219079046|NCT04054154|DEVICE|Shear Wave Elastography|Undergo shear wave elastography
219079047|NCT04054154|PROCEDURE|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
219079048|NCT06576362|PROCEDURE|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
219079049|NCT06574815|PROCEDURE|Early implant loading|Patients underwent definitive restoration at 6 weeks after implant surgery (early loading).
219079050|NCT06574815|PROCEDURE|Delayed implant loading|Patients underwent definitive restoration at 6 months after implant surgery (delayed loading).
219079051|NCT06574815|PROCEDURE|GBR using an SIS membrane|An small intestine submucosa (SIS) membrane was used in the guided bone regeneration (GBR) surgery.
219079052|NCT06574815|PROCEDURE|GBR using an Bio-Gide membrane|An Bio-Gide membrane was used in the guided bone regeneration (GBR) surgery.
219079053|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
219079054|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
219079055|NCT06731946|DEVICE|Flow diverting|Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
219079056|NCT05163574|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of peanut flour (300 mg peanut protein) mixed with well-tolerated fruit mousse.
219360544|NCT05664165|OTHER|cold spray and stretching|The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied.
219360545|NCT00321230|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
219360546|NCT04336761|DIAGNOSTIC_TEST|nasopharyngeal swab|Data collection and nasopharyngeal swab
219680185|NCT03959046|BEHAVIORAL|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
219680186|NCT04626609|OTHER|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
219680187|NCT04626609|OTHER|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
219680188|NCT04306497|DRUG|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
219680189|NCT03290118|OTHER|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
219680190|NCT03290118|OTHER|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
219680191|NCT03290118|OTHER|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
219680192|NCT03290118|DEVICE|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
219079057|NCT05163574|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of peanut flour (150 mg peanut protein) mixed with well-tolerated fruit mousse.
219079058|NCT02477111|DEVICE|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
219079059|NCT02579252|BIOLOGICAL|AADvac1|
219079060|NCT02579252|DRUG|Placebo|
219079061|NCT02921997|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
219680193|NCT06158217|PROCEDURE|ultrasound combined with microbubbles|IBC tumors were treated with microbubbles (MBs) stimulated by ultrasound
219680194|NCT05118035|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
219680195|NCT03787602|DRUG|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
219680196|NCT03787602|DRUG|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
219680197|NCT00610272|RADIATION|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
219680198|NCT00610272|RADIATION|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
219079062|NCT02921997|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
219680199|NCT00610272|RADIATION|Radiotherapy|8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
219680200|NCT00610272|RADIATION|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
219680201|NCT03060226|DIAGNOSTIC_TEST|blood sample|Search of blood predictive marker (s)
219680202|NCT02781818|DRUG|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
219680203|NCT02781818|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
219680204|NCT02781818|DRUG|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
219680205|NCT05118620|DRUG|Active bupivacaine 0.375% PENG block|A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
219680206|NCT05118620|DRUG|Placebo normal saline PENG block|A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
219680207|NCT01947842|DEVICE|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
219079063|NCT02921997|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
219079064|NCT03492281|DRUG|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
219079065|NCT03492281|DRUG|Vibegron placebo|placebo to match vibegron (experimental drug)
219079066|NCT03492281|DRUG|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
219079067|NCT03492281|DRUG|Tolterodine placebo|placebo to match tolterodine (active comparator)
219079068|NCT01506193|BIOLOGICAL|PriorixTetra™|One dose administered subcutaneously
219079069|NCT01506193|BIOLOGICAL|Meningitec|One dose administered intramuscularly
219079070|NCT03347968|BIOLOGICAL|MEDI0382|All participants will receive MEDI0382
219079071|NCT03347968|DRUG|Warfarin|All participants will receive Warfarin
219079072|NCT03347968|DRUG|Esmolol|All participants will receive Esmolol
219079073|NCT04100746|PROCEDURE|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
219079074|NCT04959370|DEVICE|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
219079075|NCT04959370|DEVICE|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
219079076|NCT04454866|DRUG|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
219680208|NCT01439646|OTHER|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
219680209|NCT04127877|DEVICE|NICAS|Electric regional bio impedance device
219079077|NCT04454866|DRUG|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
219079078|NCT04454866|DRUG|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
219079079|NCT02046980|PROCEDURE|Gufoni|
219079080|NCT02046980|PROCEDURE|Vibration|
219079081|NCT02046980|PROCEDURE|Sham|
219079082|NCT04575467|DRUG|CBL-514|CBL-514 will be administered via injection into the subcutaneous adipose layer.
219079083|NCT01367327|BEHAVIORAL|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
219079084|NCT01367327|BEHAVIORAL|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
219079085|NCT01320046|OTHER|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
219079086|NCT01328574|DRUG|TRC105|15 mg/kg intravenously
219079087|NCT04508439|DRUG|Enoxaparin|Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
219079088|NCT01483924|DRUG|Apo805K1|Sequential parallel dose escalation.
219079089|NCT05349344|OTHER|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
219079090|NCT05349344|OTHER|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
219079091|NCT03589898|DRUG|Gabapentin|Single dose of gabapentin 900 mg
219079092|NCT01930370|DRUG|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
219079093|NCT01930370|DRUG|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
219079094|NCT06060171|PROCEDURE|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
219079095|NCT04093622|GENETIC|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219079096|NCT05142267|DRUG|Placebo|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
219079097|NCT05142267|DRUG|Oxycodone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
219210517|NCT06741956|BEHAVIORAL|Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.|A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps\> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be r
219210518|NCT06741917|DRUG|Levofloxacin|single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
219210519|NCT06741917|DRUG|Cefmetazole (drug)|single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
219680210|NCT04478565|OTHER|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
219680211|NCT03464032|DRUG|BCD-135|Monoclonal anti-PD-L1 antibody
219680212|NCT00799084|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
219079098|NCT05142267|DRUG|Naloxone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
219680213|NCT00799084|BEHAVIORAL|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
219079099|NCT02219126|OTHER|Dietary intervention|
219079100|NCT03160027|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
219079101|NCT01002326|BEHAVIORAL|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
219079102|NCT01386528|DRUG|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
219079103|NCT05061251|DRUG|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
219079104|NCT00930293|BEHAVIORAL|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
219079105|NCT00930293|BEHAVIORAL|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
219079106|NCT00930293|DRUG|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
219079107|NCT04797247|DRUG|lerodalcibep|PCSK9 inhibitor
219079108|NCT03565887|DRUG|RVL-1201|RVL-1201 ophthalmic solution 0.1%
219079109|NCT03565887|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
219079110|NCT00695643|DRUG|Mesalazine|3 g per day
219079111|NCT00695643|DRUG|Placebo|0 g per day
219079112|NCT06171191|BEHAVIORAL|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
219079113|NCT05141669|DRUG|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
219079114|NCT01716429|BEHAVIORAL|Vegan diet|Vegan dietary approaches for weight loss
219079115|NCT01716429|BEHAVIORAL|Low calorie diet|Reduced calorie diet for weight loss
219079116|NCT00536003|DRUG|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
219079117|NCT00536003|DRUG|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
219079118|NCT04947800|DEVICE|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
219079119|NCT04947800|DEVICE|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
219079120|NCT04216316|DRUG|Berzosertib|Given IV
219079121|NCT04216316|PROCEDURE|Biospecimen Collection|Correlative studies
219079122|NCT04216316|DRUG|Carboplatin|Given IV
219079123|NCT04216316|PROCEDURE|Computed Tomography|Undergo CT
219079124|NCT04216316|DRUG|Gemcitabine Hydrochloride|Given IV
219079125|NCT04216316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219079126|NCT04216316|BIOLOGICAL|Pembrolizumab|Given IV
219079127|NCT00035529|DRUG|Placebo|Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
219079128|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.
219079129|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.
219079130|NCT05034523|RADIATION|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
219079131|NCT00022256|DRUG|motexafin gadolinium|
219079132|NCT00022256|RADIATION|radiation therapy|
219079133|NCT01994954|OTHER|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
219079134|NCT01397838|DRUG|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
219079135|NCT05305196|OTHER|Eccentric-focused exercises|"Three eccentric-focused exercises:~1. Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~2. Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~3. Shoulder abductor eccentric contraction in shoulder abduction 90 degree"
219079136|NCT05305196|OTHER|Stretching exercises|"1. Modified sleeper stretch~2. Modified cross-body stretch"
219079137|NCT05305196|OTHER|Hot pack|Hot pack application on shoulder region
219079138|NCT05305196|OTHER|Massage|Massage for upper trapezius
219680214|NCT00683488|BEHAVIORAL|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
219680215|NCT00683488|BEHAVIORAL|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~* Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~* Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~* Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
219680216|NCT00683488|BEHAVIORAL|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
219680217|NCT01594918|DRUG|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
219079139|NCT02270333|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
219079140|NCT02270333|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
219079141|NCT03516448|DRUG|Gan Fu Le Tablets|6 Tablets，tid,po
219079142|NCT03516448|DRUG|Tyroserleutide for injection|6mg/d, 5days,ivgtt
219079143|NCT03516448|DRUG|Placebo|0mg/d, 5days,ivgtt
219079144|NCT00528138|OTHER|Laboratory Test|CRP, white blood cell count, hepatic function tests
219079145|NCT00449176|DRUG|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
219079146|NCT00449176|DRUG|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
219680218|NCT01594918|DRUG|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
219680219|NCT01594918|DRUG|Prednisone|5 mg PO BID
219680220|NCT01594918|DRUG|Pegfilgrastim|6 mg, SC, once every 21 days
219680221|NCT01223404|DRUG|Placebo|Participants are administered a placebo patch and a placebo capsule
219680222|NCT01223404|DRUG|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
219680223|NCT01223404|DRUG|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
219680224|NCT04461548|BEHAVIORAL|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
219680225|NCT00707057|DRUG|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
219079147|NCT00449176|DRUG|placebo|matching placebo twice daily for 15 weeks
219079148|NCT01329367|BEHAVIORAL|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
219079149|NCT01329367|BEHAVIORAL|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
219079150|NCT01329367|BEHAVIORAL|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
219079151|NCT05978921|OTHER|Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
219079152|NCT05978921|OTHER|Normal life|Normal life and carry out all the activities they have been doing previously.
219079153|NCT04881201|PROCEDURE|blood sample|blood sample
219079154|NCT03632382|DIAGNOSTIC_TEST|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
219079155|NCT05363566|DEVICE|airway divice|inserted airway device
219079156|NCT01045746|DEVICE|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
219079157|NCT01045746|DEVICE|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
219079158|NCT06046274|BIOLOGICAL|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
219079159|NCT06046274|BIOLOGICAL|Acasunlimab|Acasunlimab IV infusion
219079160|NCT04901858|DIAGNOSTIC_TEST|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
219079161|NCT03595644|RADIATION|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
219079162|NCT03595644|DRUG|TKI|Received EGFR-TKI treatment
219680226|NCT00707057|DRUG|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
219680227|NCT04560556|DIAGNOSTIC_TEST|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
219680228|NCT04560556|DIAGNOSTIC_TEST|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
219680229|NCT04041596|DEVICE|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
219680230|NCT01646840|DRUG|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
219680231|NCT01646840|DRUG|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
219680232|NCT05535374|DEVICE|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
219680233|NCT05186584|OTHER|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
219680234|NCT05186584|OTHER|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
219079163|NCT00314197|BEHAVIORAL|Telephone Linked Care - Behavior Change Counseling System|
219079164|NCT00314197|BEHAVIORAL|Telephone-linked behavioral counseling|
219079165|NCT02265900|OTHER|Exercise|One type of exercise
219210520|NCT06743230|OTHER|Neuro athletic training|The neuroathletic training includes exercises that stimulate the visual, vestibular, and proprioceptive systems. The neuroathletic training includes 3 days per week for 8 weeks.
219210521|NCT06743230|OTHER|Conventional training|Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.
219210522|NCT06748521|DRUG|R-CHOP + X|Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
219210523|NCT06783075|OTHER|MILK|Drink containing amino acids in the composition of milk protein
219079166|NCT02265900|OTHER|Exercise|A different type of exercise
219079167|NCT03173040|DRUG|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
219079168|NCT00891267|DRUG|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
219210524|NCT06783075|OTHER|WHEAT|Drink containing amino acids in the composition of wheat protein
219210525|NCT06737146|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
219079169|NCT00891267|DRUG|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
219079170|NCT00891267|DRUG|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
219079171|NCT06440148|BIOLOGICAL|SCLEROSTIN|Pathogenesis of mastocytosis bone disease
219079172|NCT02330718|OTHER|No intervention|
219210526|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
219079173|NCT02369094|OTHER|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
219079174|NCT04597268|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mic/kg
219079175|NCT04597268|DRUG|Ketamine|ketamine 1mg/kg
219210527|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
219079176|NCT04597268|DRUG|Midazolam|midazolam 0.05 mg/kg
219079177|NCT06265077|DRUG|Placebo|Placebo
219079178|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
219079179|NCT02217930|DRUG|WCK 2349|
219079180|NCT02217930|DRUG|Placebo|
219079181|NCT02217930|DRUG|Moxifloxacin|
219079182|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
219079183|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
219079184|NCT02920827|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
219079185|NCT02920827|COMBINATION_PRODUCT|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
219210528|NCT06794060|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
219210529|NCT06794632|OTHER|HANDY occupational therapy intervention|The HANDY occupational therapy intervention is occupation-centred and follows the Occupational Therapy Intervention Process Model (OTIPM), specifying the steps of a problem-solving process focused on enabling performance of tasks in everyday life. The HANDY occupational therapy intervention consists of six mandatory sessions of 120 minutes representing a combination of individual and group sessions. Each group includes a maximum of eight participants with hand osteoarthritis, facilitated by two OTs.
219210530|NCT06844682|OTHER|intervention group|Following the removal of the mattresses, the patient was placed in the semi-fawler position.
219210531|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
219680235|NCT01688622|BEHAVIORAL|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
219680236|NCT03570775|DEVICE|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
219680237|NCT03570775|DEVICE|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
219680238|NCT06407219|DEVICE|Robot Assisted Gait Training|The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
219680239|NCT03880136|DRUG|CTP-543|Once daily dosing
219680240|NCT00121706|BEHAVIORAL|Condition A (see detailed summary)|
219680241|NCT00121706|BEHAVIORAL|Condition B (see detailed summary)|
219680242|NCT00121706|BEHAVIORAL|Condition C (see detailed summary)|
219079186|NCT00837174|DRUG|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
219079187|NCT02154763|DRUG|Ropivacaine|
219079188|NCT02154763|DRUG|Normal Saline|
219079189|NCT02901015|BEHAVIORAL|Assessment battery A|"Social cognition tests version A are administered to the patients"
219079190|NCT02901015|BEHAVIORAL|Assessment battery B|"Social cognition tests version B are administered to the patients"
219079191|NCT02059967|DRUG|Paclitaxel|Given IV
219079192|NCT02059967|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
219079193|NCT02059967|DRUG|carboplatin|Given IV
219079194|NCT00526123|DEVICE|Symmetric Tip Catheter|Dialysis catheter
219079195|NCT00526123|DEVICE|Conventional Split-tip Catheter|Dialysis Catheter
219079196|NCT00649194|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
219079197|NCT00649194|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
219079198|NCT00490893|DRUG|Detemir|
219210532|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
219210533|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
219680243|NCT03613714|OTHER|At-home Blood Pressure Monitoring|Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
219680244|NCT02089802|DRUG|Pazopanib|
219680245|NCT02380365|DEVICE|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
219680246|NCT01613261|DRUG|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
219680247|NCT01773083|DRUG|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
219680248|NCT01773083|DRUG|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
219680249|NCT00001577|PROCEDURE|double isolated limb perfusion with melphalan alone|
219079199|NCT06481748|OTHER|Batman|"The investigators foresee several teams engaged throughout the day to ensure greater variability, each team will consist of three students for the experimental condition (Batman; pregnant girl, observer) and two students for the control condition (pregnant girl and observer), plus the presence in both cases of a member of the research team. The 'pregnant girl' will be properly prepared and equipped with a sponge prosthesis to simulate pregnancy. In addition, the subject dressed as Batman must be prepared to play the role in a natural and non-invasive manner. During this phase, the student observers collaborating in the study will carefully record the behavior of the passengers in the underground."
219079200|NCT06533033|DRUG|Rapid Release Capsules Melatoni|"Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks."
219079201|NCT06533033|DRUG|Triamcinolone Acetonide ointment, Kenacort-A orabase|"Twenty-five will be given topical corticosteroid applied twice to three times daily.~Topical antifungal will be applied three to four times daily. This conventional treatment will be given to the patients for 8 weeks"
219680250|NCT04611542|BEHAVIORAL|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
219680251|NCT02813928|GENETIC|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
219680252|NCT03094884|RADIATION|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
219079202|NCT00088231|DRUG|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
219079203|NCT00088231|DRUG|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
219079204|NCT02045238|DRUG|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
219079205|NCT02045238|RADIATION|Chest X-Ray|
219079206|NCT02045238|OTHER|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
219079207|NCT05003089|DRUG|BAY1834845|Tablet, oral.
219079208|NCT05003089|DRUG|BAY1830839|Tablet, oral.
219079209|NCT05003089|DRUG|Prednisolone|Tablet, oral.
219079210|NCT05003089|DRUG|Placebo|Tablet, oral.
219079211|NCT03651089|DRUG|SP16|subcutaneous injection of experimental anti-inflammatory drug
219680253|NCT03094884|DRUG|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
219680254|NCT03094884|DRUG|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
219680255|NCT00320242|DEVICE|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
219680256|NCT04424147|COMBINATION_PRODUCT|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
219680257|NCT02548377|PROCEDURE|Remote ischemic preconditioning|
219680258|NCT02548377|PROCEDURE|Sham|
219680259|NCT04217460|BEHAVIORAL|Intervention for fluency difficulty|Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
219680260|NCT03202290|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
219680261|NCT05468216|OTHER|MovIn-Lessons group|The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
219680262|NCT02076386|DRUG|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
219680263|NCT01668056|DRUG|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
219680264|NCT01668056|PROCEDURE|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
219079212|NCT03651089|DRUG|Placebos|subcutaneous injection of sterile saline
219079213|NCT01568333|DRUG|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
219680265|NCT01668056|OTHER|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
219680266|NCT05409950|PROCEDURE|Immediate implant placement using socket shield technique|Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
219079214|NCT01454583|DRUG|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
219079215|NCT01454583|DRUG|ACE-I/ARB|
219079216|NCT01454583|DRUG|No RAS-inhibition|
219079217|NCT06335134|DRUG|XW003 injection|Administered subcutaneously
219079218|NCT06335134|DRUG|Metformin|Administered orally
219079219|NCT06335134|DRUG|Warfarin|Administered orally
219079220|NCT06335134|DRUG|Rosuvastatin|Administered orally
219079221|NCT06335134|DRUG|Digoxin|Administered orally
219079222|NCT05574569|BEHAVIORAL|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
219079223|NCT05574569|BEHAVIORAL|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
219079224|NCT05574569|BEHAVIORAL|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
219079225|NCT02656433|DEVICE|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
219210534|NCT05966636|PROCEDURE|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
219210535|NCT04233099|PROCEDURE|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
219210536|NCT06716840|DRUG|Remimazolam|participants in the remimazolam group received remimazolam besylate intravenously at an initial infusion rate of 0.2mg/kg/h and adjusted (maximum of 2 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale(RASS) score between - 2 and 0.If the maximum dose of remimazolam was insufficient to sedate, add rescue dexmedetomidine.
219210537|NCT06716840|DRUG|Propofol|participants in the propofol group received propofol intravenously at an initial infusion rate of 1 mg/kg/h and adjusted (maximum of 4 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale (RASS) score between - 2 and 0.If the maximum dose of propofol was insufficient to sedate, add rescue dexmedetomidine.
219079226|NCT02656433|OTHER|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
219079227|NCT03837912|BEHAVIORAL|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
219079228|NCT06063226|OTHER|Experimental|Orally administred probiotics with L. plantarum and L. rhamnosus
219079229|NCT06063226|OTHER|Negative control|Only routinary oral hygiene procedures
219079230|NCT06063226|OTHER|Positive control|Orally administred placebo without probiotics
219079231|NCT02677116|DRUG|Olaratumab|Olaratumab administered IV.
219079232|NCT02677116|DRUG|Doxorubicin|Doxorubicin administered IV.
219079233|NCT02677116|DRUG|Vincristine|Vincristine administered IV.
219079234|NCT02677116|DRUG|Irinotecan|Irinotecan administered IV.
219079235|NCT02677116|DRUG|Ifosfamide|Ifosfamide administered IV.
219680267|NCT03296969|PROCEDURE|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
219680268|NCT03296969|PROCEDURE|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
219680269|NCT01131559|DRUG|Lisdexamfetamine|Oral; 20-70mg/day
219680270|NCT01131559|DRUG|Placebo control|Oral; 20-70mg/day
219680271|NCT05856253|PROCEDURE|Enhanced recovery program|Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
219680272|NCT03477292|DRUG|Duration of antibiotic|Duration of antibiotic for treatment of VAP
219680273|NCT02801825|PROCEDURE|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
219680274|NCT02801825|PROCEDURE|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
219680275|NCT06148103|DRUG|Patients who received Dexmedetomodine|1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
219079236|NCT00290641|BIOLOGICAL|filgrastim|
219079237|NCT00290641|BIOLOGICAL|graft-versus-tumor induction therapy|
219079238|NCT00290641|DRUG|cyclophosphamide|
219079239|NCT00290641|DRUG|cyclosporine|
219079240|NCT00290641|DRUG|fludarabine phosphate|
219079241|NCT00290641|DRUG|mycophenolate mofetil|
219680276|NCT06148103|DRUG|patients who received propofol-fentanyl|Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
219079242|NCT00290641|PROCEDURE|umbilical cord blood transplantation|
219079243|NCT00290641|RADIATION|radiation therapy|
219079244|NCT03182868|DEVICE|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
219079245|NCT04183764|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
219079246|NCT04514848|DEVICE|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
219079247|NCT04514848|DEVICE|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
219079248|NCT03122418|BEHAVIORAL|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
219079249|NCT04632875|BEHAVIORAL|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
219079250|NCT04632875|BEHAVIORAL|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
219079251|NCT02363946|DRUG|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
219079252|NCT02363946|OTHER|Placebo|0.9 % normal saline
219079253|NCT02363946|DRUG|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
219210538|NCT06749769|BEHAVIORAL|simulation-based education|Patients will learn how to care for their stomata on a stoma simulator
219210539|NCT06748937|DRUG|Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD|Cohort 1 Arm 1
219210540|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD|Cohort 1 Arm 2
219079254|NCT03047200|BIOLOGICAL|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
219079255|NCT03905889|DRUG|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
219079256|NCT03905889|DRUG|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
219079257|NCT04453631|DEVICE|active tDCS|26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
219079258|NCT04453631|DEVICE|sham tDCS|tDCS is controlled in this intervention: sham mode.
219079259|NCT04453631|BEHAVIORAL|CBT-UP|15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
219079260|NCT04453631|BEHAVIORAL|Psychoeducation|To control for the cognitive-behavioral intervention we will use psychoeducation materials.
219079261|NCT04253743|OTHER|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
219079262|NCT01967732|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
219079263|NCT01967732|OTHER|CC|Single use of subject's own conventional cigarette (CC)
219079264|NCT01967732|OTHER|NNS|Single administration of 1 mg of nicotine
219079265|NCT06429254|OTHER|Experimental group|Life Scale will be administered as pre-tests to the EFT group. After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.
219079266|NCT03342638|DRUG|Cyclophosphamide|Potent immunosuppressive agent; an alkylating agent
219079267|NCT03342638|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
219079268|NCT03342638|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
219079269|NCT03342638|DRUG|Methylprednisolone|Steroid
219079270|NCT03342638|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
219079271|NCT03342638|BIOLOGICAL|IVIg|Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
219079272|NCT03342638|BIOLOGICAL|Autologous Stem Cells|Infusion of participant's own stem cells
219079273|NCT02211326|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
219079274|NCT02211326|BEHAVIORAL|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
219079275|NCT01584622|DEVICE|CADence System|Non-invasive detection of \> or equal to 50% stenosis in any of the major coronary arteries.
219079276|NCT03536000|DIAGNOSTIC_TEST|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
219210541|NCT06748937|DRUG|Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based|Active Comparator
219210542|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD|Cohort 2 Arm 4
219210543|NCT06751316|PROCEDURE|Conventional Pulpectomy|Removal of radicular pulp tissue, placing Zinc Oxide/Eugenol and covered by stainless steel crown
219210544|NCT06751316|PROCEDURE|MTA Pulpotomy|Removal of coronal pulp tissue, placing MTA and covered by stainless steel crown
219680277|NCT03145753|OTHER|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
219680278|NCT03145753|OTHER|HIV/HCV Education|Only education and support will be provided in this arm
219680279|NCT00102843|PROCEDURE|supplementation with folic acid and betaine|
219680280|NCT02915159|BIOLOGICAL|Abatacept|
219680281|NCT02915159|OTHER|Placebo|
219079277|NCT04936152|OTHER|mime therapy using tablet PC mirror application|"After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present."
219079278|NCT04936152|OTHER|the control intervention including the mime therapy|After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
219079279|NCT06115733|DRUG|Fruquintinib、Capecitabine Tablets|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3\) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4\) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
219079280|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079281|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079282|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079283|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079284|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079285|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
219079286|NCT02216058|DEVICE|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
219079287|NCT03327987|BIOLOGICAL|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
219079288|NCT00554970|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
219079289|NCT00554970|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
219079290|NCT00554970|DRUG|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
219079291|NCT00554970|DRUG|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
219079292|NCT03028974|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
219079293|NCT03028974|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
219079294|NCT02654808|DEVICE|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
219079295|NCT02654808|DEVICE|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
219079296|NCT00935376|BEHAVIORAL|Sleep Education Program|Treatment as usual.
219079297|NCT00935376|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
219079298|NCT00935376|BEHAVIORAL|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
219079299|NCT04279223|PROCEDURE|Laparoscopic cholecystectomy|Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
219079300|NCT00113568|DRUG|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
219079301|NCT00450086|DRUG|Budesonide|9 mg per day
219079302|NCT00450086|DRUG|Mesalazine|3 g per day
219079303|NCT00450086|DRUG|Placebo|0 g per day
219079304|NCT04728529|PROCEDURE|USSM protocol|"In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2"
219680282|NCT05407285|DRUG|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
219079305|NCT04728529|PROCEDURE|ACCM protocol|In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
219079306|NCT01292239|DRUG|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
219079307|NCT01292239|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
219079308|NCT01292239|DRUG|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
219079309|NCT01292239|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
219079310|NCT02712034|BEHAVIORAL|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
219079311|NCT02712034|OTHER|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
219079312|NCT01492075|DRUG|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
219079313|NCT00262821|DRUG|cisplatin|Given IV
219079314|NCT00262821|DRUG|tirapazamine|Given IV
219079315|NCT05712590|OTHER|dietary habit|As it is observational study, women that follow three different dietary patterns will be inlcuded .
219079316|NCT05181163|DIAGNOSTIC_TEST|swab|Swabs from site of infection will be taken
219210545|NCT06571422|DRUG|WJ47156|Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
219210546|NCT06571422|DRUG|JS001+Bevacizumab|Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
219210547|NCT06571422|DRUG|JS207|Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.
219210548|NCT06804863|BEHAVIORAL|Postoperative Regret Reduction through Immediate Quality of Life Intervention|Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.
219210549|NCT06805006|DEVICE|SSLF|Bilateral sacrospinous ligament fixation with i-Stitch device
219210550|NCT06805435|DEVICE|Continuous non-invasive blood pressure monitoring|A continuous non-invasive blood pressure monitoring cuff will be placed on the volunteers index finger (as intended) and 2nd toe (primary outcome).
219079317|NCT01509898|DEVICE|Water jet|use of water jet for a month
219210551|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
219079318|NCT03498833|OTHER|Test-retest reliability testing|Set of patient reported outcome measures
219079319|NCT00898469|GENETIC|polymorphism analysis|
219680283|NCT05407285|DRUG|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
219680284|NCT05407285|DRUG|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
219680285|NCT05407285|DRUG|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
219079320|NCT01489033|BIOLOGICAL|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
219079321|NCT04687891|DIAGNOSTIC_TEST|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
219079322|NCT02057900|BIOLOGICAL|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
219210552|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
219210553|NCT06577415|DRUG|RAY1225|Administered SC
219079323|NCT06307587|PROCEDURE|dry needling|The vastus intermedius will be approached with DN from the lateral aspect and the pincer approach will be followed. The Hong fast-in and fast out technique with multiple rapid needle insertions will be performed following previous recommendations (Chou, et al., 2014). The control group will receive the rehabilitation program alone. A headless 0.25 × 25-mm needle (Stainless steel, Agupunt A1038P, 158 Caspe, Barcelona, Spain) will be used. The penetration depth will be varied according to the patient. Hemostasis will be performed for 1 minutes. DN will be performed medial to the sartorius muscle limit to avoid saphenous nerve adverse effects during DN (Henry et al., 2016).
219079324|NCT01410773|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
219210554|NCT05413733|BEHAVIORAL|Digital care pathway|"Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals"
219210555|NCT05413733|BEHAVIORAL|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
219210556|NCT06811571|BEHAVIORAL|the mobile-based early intervention|The theoretical framework of the intervention was based on Cognitive Behavior Therapy (CBT). We designed three modules, which were the Gaming behavior management, the Gaming cognition establishment and the Early intervention on risk and protective factors. The interventions included self-monitoring questionnaires, scientific popular articles, and online lectures.
219210557|NCT06808971|DRUG|Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule|Adebrelimab combined with Nab-paclitaxel, Oxaliplatin andTegafur Gimeracil Oteracil Potassium Capsule
219210558|NCT05101096|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously (IV)
219210559|NCT05999721|PROCEDURE|superficial parasternal intercostal plane block|Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
219210560|NCT05999721|OTHER|Standard care|"Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered."
219210561|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
219210562|NCT06861946|DIAGNOSTIC_TEST|Corvis ST|"Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:~Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)"
219079325|NCT00785369|DEVICE|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
219210563|NCT06861946|DIAGNOSTIC_TEST|Conrneal endothelial cell density|"The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:~Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.~Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells)."
219210564|NCT06864091|OTHER|Rapid Manufacturing|The first intervention (I1) involves direct printing of the final prosthesis (rapid manufacturing, RM). The final prosthesis will be printed using a biocompatible rubber-like printable soft resin (Biomed Flex 80A resin, Formlabs, USA), and then will be colored and characterized to match the surrounding anatomy.
219210565|NCT06864091|OTHER|Direct Mould Making|In the second intervention (I2), the negative mold will be achieved directly, will be virtually designed based on an inverted STL file of prosthesis prototype/ pattern (direct mold making, DMM).
219079326|NCT03044379|DRUG|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
219079327|NCT03044379|OTHER|Universal HEC placebo gel|
219079328|NCT01867151|DIETARY_SUPPLEMENT|Gluten Free Diet|
219079329|NCT01867151|DIETARY_SUPPLEMENT|Normal Diet|
219079330|NCT01734304|BIOLOGICAL|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
219079331|NCT01988779|DRUG|oral levofloxacin|
219079332|NCT01988779|DRUG|nebulized levofloxacin|
219079333|NCT04504487|OTHER|Drain Removal|Abdominal drain placed during surgery removal
219079334|NCT02895087|OTHER|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
219079335|NCT02895087|OTHER|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
219079336|NCT03942133|PROCEDURE|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
219079337|NCT03942133|PROCEDURE|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
219079338|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
219079339|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
219079340|NCT01484548|BIOLOGICAL|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
219079341|NCT02293044|DEVICE|Crest® Sensi-Stop™ Strips|
219079342|NCT03273634|DRUG|Lansoprazole Pill|once daily at night time
219079343|NCT03273634|DRUG|Placebo|Placebo
219079344|NCT01789554|OTHER|MLS dispatch for bystander CPR|
219079345|NCT00377403|DRUG|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
219079346|NCT00377403|DRUG|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
219079347|NCT00377403|DRUG|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
219079348|NCT00377403|DRUG|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
219079349|NCT00377403|DRUG|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
219079350|NCT00377403|DRUG|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
219079351|NCT04756687|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
219079352|NCT06273098|BEHAVIORAL|Bladder Health Education|This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
219079353|NCT00219076|DRUG|aliskiren|
219079354|NCT00979836|DRUG|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
219079355|NCT05223985|DEVICE|Depth Coagulation Electrode|SEEG and thermocoagulation
219079356|NCT00736645|DIETARY_SUPPLEMENT|selenomethionine|Given orally
219079357|NCT00736645|DRUG|finasteride|Given orally
219079358|NCT00736645|OTHER|placebo|Given orally
219079359|NCT00824226|DIETARY_SUPPLEMENT|magnesium|magnesium 350 mg tablets once a day for 3 weeks
219079360|NCT00700921|DRUG|Lovastatin|40mg po once daily
219079361|NCT00700921|DRUG|Placebo|One capsule, once daily
219079362|NCT01049126|OTHER|ChemoFx|Chemoresponse Marker Assay
219079363|NCT01866228|OTHER|Consultation Recording|
219079364|NCT02955264|DIETARY_SUPPLEMENT|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
219079365|NCT00003214|DRUG|carboplatin|
219079366|NCT00003214|DRUG|cisplatin|
219079367|NCT00003214|DRUG|cyclophosphamide|
219079368|NCT00003214|DRUG|doxorubicin hydrochloride|
219079369|NCT00003214|DRUG|in vitro sensitivity-directed chemotherapy|
219079370|NCT00003214|DRUG|paclitaxel|
219079371|NCT03565081|DEVICE|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
219079372|NCT02080468|DRUG|lomitapide|20 mg
219079373|NCT02080468|DRUG|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
219079374|NCT06132880|DRUG|Human Urinary Kallidinogenase|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
219079375|NCT06132880|OTHER|Clinical Routine Treatment|Conventional therapy of acute ischemic stroke after based on Chinese guidelines
219079376|NCT00047801|DRUG|TLK286 in combination with docetaxel|
219079377|NCT03547843|BEHAVIORAL|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
219079378|NCT03547843|BEHAVIORAL|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
219079379|NCT03547843|OTHER|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
219079380|NCT00881179|DRUG|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
219079381|NCT00881179|DRUG|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
219079382|NCT00295022|DRUG|Placebo|"* Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use"
219079383|NCT00295022|DRUG|Montelukast|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use"
219079384|NCT00295022|DRUG|Levocetirizine|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use"
219079385|NCT00734630|DRUG|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
219079386|NCT00734630|DRUG|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
219079387|NCT03211286|DRUG|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
219079388|NCT03211286|DRUG|Saline Solution|saline solution 100 mL intravenous
219079389|NCT04489043|OTHER|Exercise and healthy lifestyle recommendations|In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
219079390|NCT04204629|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, PO
219210566|NCT06864091|OTHER|Indirect Mould Making|"the negative mold will be fabricated indirectly by printing the prosthesis prototype from resin for subsequent mold fabrication (indirect mold making, IMM). The printed prototype will be tried on the patient and adjusted in terms of shape, size and marginal fit.~After the try-in stage the prototype will be duplicated into wax by using silicone rubber molding and a conventional stone mold will be fabricated."
219210567|NCT06866067|DEVICE|PEEK clip|The overdentures were attached with PEEK clip . The retention of overdenture was assessed
219210568|NCT06866067|DEVICE|Nylon clip|The overdentures were attached with Nylon clip . The retention of overdenture was assessed
219210569|NCT06865716|DEVICE|Active noninvasive vagus nerve stimulation|The stimulation parameters include a 200µs stimulation width, at an intensity level of 10-50ma (adjusted for patient-comfort), at a frequency of 20Hz during 60min .
219210570|NCT06865716|OTHER|Chum electrode attached to patient's lower ear lobe|The clip stimulator is attached to the patient's lower ear lobe without stimulation.
219210571|NCT06867458|DEVICE|Antimicrobial photodynamic therapy (aPDT) nasal decolonization device|aPDT is a technique that employs a specific wavelength of light to activate a photosensitizer substance. Once activated, this photosensitizer reacts with surrounding molecules to produce radicals and reactive oxygen species. When activated in the presence of microorganisms, these molecules serve to disrupt membrane structure and protein cross-linking, leading to their death.
219210572|NCT06625957|DRUG|NTCB02-1|3 Days infusion
219210573|NCT06625957|DRUG|NTCB-C|3 Days infusion
219079391|NCT03742700|BEHAVIORAL|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
219079392|NCT03742700|BEHAVIORAL|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
219079393|NCT03742700|BEHAVIORAL|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
219079394|NCT05943457|DIETARY_SUPPLEMENT|Vitamin K2 or menaquinone-7|Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
219079395|NCT05943457|OTHER|Placebo|Placebo pills will be administered orally once daily for 6 months
219079396|NCT06497244|PROCEDURE|micro osteo-perforation|the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
219079397|NCT02701712|RADIATION|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
219079398|NCT04568135|OTHER|survey|survey
219210574|NCT03443492|DRUG|S-1|Intervention is administered to patients in this Arm.
219210575|NCT03443492|DRUG|Leucovorin(oral )|Intervention is administered to patients in this Arm.
219210576|NCT03443492|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
219210577|NCT03443492|DRUG|Oxaliplatin|Intervention is administered to patients in this Arm.
219210578|NCT03443492|DRUG|Irinotecan|Intervention is administered to patients in this Arm.
219210579|NCT03443492|DRUG|5-FU|Intervention is administered to patients in this Arm.
219210580|NCT03443492|DRUG|Leucovorin(IV)|Intervention is administered to patients in this Arm.
219210581|NCT06876129|DEVICE|TMS|Subjects will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device plus placebo.
219210582|NCT06876129|COMBINATION_PRODUCT|D-serine + TMS|"D-serine, 80 mg/kg, oral administration, will be advised to be taken 1-hour prior rTMS treatment day (Mon-Fri) for 6 weeks. Dosing is based on maximal plasticity at 80 mg/kg, and clinical dose-finding studies demonstrating that doses between 60 - 120 mg/kg were superior in clinical effectiveness to 30 mg/kg and were safe.~Subjects will not be randomized into their TMS group and will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device. Subjects will have their TMS protocol/treatment determined at the time of consultation according to clinical appropriateness as is the standard of care at the TMS clinic at McLean Hospital."
219079399|NCT05381155|BEHAVIORAL|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
219079400|NCT05695781|DRUG|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
219079401|NCT05695781|DRUG|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
219079402|NCT06275152|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219079403|NCT06275152|DEVICE|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219079404|NCT00010179|DRUG|lurtotecan liposome|
219210583|NCT06876467|OTHER|Evaluation of cellular response|detection of HBsAg-specific T lymphocytes by spectral cytometry
219210584|NCT06879470|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
219210585|NCT06885372|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
219210586|NCT06885372|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
219210587|NCT06747416|DRUG|KN057|KN057 will be administered subcutaneously once a week.
219210588|NCT06418269|OTHER|Therapeutic Play|"Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale."
219680286|NCT05407285|DRUG|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
219680287|NCT06076031|BEHAVIORAL|Streaming Media|The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
219079405|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
219680288|NCT02843464|OTHER|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
219680289|NCT01510964|BEHAVIORAL|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
219079406|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
219079407|NCT02060851|OTHER|standard PN|Group 1: a control group who received standard PN
219079408|NCT02060851|DRUG|Vifor|iron sucrose, 200 μg/kg per day, was given everyday with PN,
219680290|NCT01510964|BEHAVIORAL|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
219680291|NCT03446209|DRUG|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
219680292|NCT03446209|DRUG|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
219680293|NCT06274502|OTHER|YOLOv8|After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model.
219680294|NCT03005639|DRUG|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
219680295|NCT05314829|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
219680296|NCT01761643|DEVICE|SoC + iTab|Text messaging reminders to improve adherence to PrEP
219680297|NCT01839071|PROCEDURE|biopsy|
219680298|NCT02821416|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
219680299|NCT02821416|OTHER|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
219680300|NCT04059289|OTHER|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
219680301|NCT03903250|DIETARY_SUPPLEMENT|A-GPC|Taken orally in liquid form
219680302|NCT03903250|DIETARY_SUPPLEMENT|Sugar|Taken orally in liquid form
219680303|NCT03187184|DEVICE|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
219680304|NCT00137787|DRUG|ciprofloxacin|
219680305|NCT00137787|DRUG|cefepime|
219680306|NCT03784313|PROCEDURE|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
219680307|NCT03784313|PROCEDURE|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
219680308|NCT01533402|BEHAVIORAL|therapist support|Weekly therapist support without CBT-interventions
219680309|NCT01533402|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
219680310|NCT01666561|OTHER|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
219079409|NCT02060851|DRUG|Vifor and EPO|EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
219680311|NCT01666561|OTHER|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
219680312|NCT01666561|OTHER|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
219079410|NCT01850979|DRUG|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
219079411|NCT01850979|DRUG|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
219079412|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
219079413|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
219079414|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
219210589|NCT06892067|COMBINATION_PRODUCT|Cosmetic Products|To evaluate and analyze the safety of commonly used ingredients in over-the-counter personal care and cosmetic products.
219210590|NCT06741826|PROCEDURE|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
219079415|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
219079416|NCT06112756|DRUG|Elinzanetant|Oral
219079417|NCT06112756|OTHER|Placebo|Oral
219079418|NCT00173108|BEHAVIORAL|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
219079419|NCT02455648|PROCEDURE|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
219079420|NCT02455648|PROCEDURE|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
219079421|NCT00554879|PROCEDURE|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
219079422|NCT00554879|PROCEDURE|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
219210591|NCT06742775|OTHER|physiological signal acquisitions|"Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition."
219079423|NCT01176487|OTHER|questionnaire administration|
219680313|NCT01065571|DIETARY_SUPPLEMENT|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
219079424|NCT01176487|PROCEDURE|quality-of-life assessment|
219079425|NCT01176487|RADIATION|3-dimensional conformal radiation therapy|
219079426|NCT01176487|RADIATION|palliative radiation therapy|
219079427|NCT01176487|RADIATION|whole-brain radiation therapy|
219079428|NCT02238379|DRUG|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
219079429|NCT02238379|OTHER|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
219210594|NCT06740032|OTHER|Transcutaneous vagus nerve stimulation|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
219210595|NCT06740032|OTHER|Deep breath exercise|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
219210596|NCT06763822|BEHAVIORAL|close eyes|ask participants to close their eyes for rest
219079430|NCT02804568|DRUG|ALKS 3831|Oral capsule, daily administration
219079431|NCT04123067|DRUG|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
219079432|NCT04123067|DRUG|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
219079433|NCT02089256|DRUG|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
219079434|NCT06205667|PROCEDURE|Computer Guided Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
219210597|NCT06763822|BEHAVIORAL|cold compress|cold compress on participants' eyes for rest
219680314|NCT01065571|OTHER|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
219680315|NCT02244047|DRUG|Bifidobacterium breve|
219680316|NCT02244047|DRUG|Placebo (for Bifidobacterium breve)|
219680317|NCT03019029|OTHER|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
219680318|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
219680319|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
219079435|NCT06205667|PROCEDURE|Conventional Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
219079436|NCT01441102|DRUG|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
219079437|NCT05599828|DRUG|AMG 510|Oral Tablet
219079438|NCT05599828|DRUG|Omeprazole|Capsule
219079439|NCT05599828|DRUG|Famotidine|Tablet
219079440|NCT04893486|DRUG|PTX-022|QTORIN 3.9 % Sirolimus Topical Gel
219079441|NCT04893486|DRUG|Vehicle comparator|Vehicle comparator topical gel
219079442|NCT04571398|OTHER|ApricityRx mobile application|AE detection and monitoring software
219079443|NCT00005057|BIOLOGICAL|adenovirus RSV-TK|
219079444|NCT00005057|DRUG|ganciclovir|
219079445|NCT03152253|BEHAVIORAL|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
219079446|NCT03152253|BEHAVIORAL|Peer Support|A group chat room for peer support
219079447|NCT03152253|OTHER|Motivational Messages|Generic motivational messages not related to smoking cessation
219079448|NCT01775904|DRUG|LY2886721 in a Capsule|Administered orally.
219079449|NCT01775904|DRUG|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
219079450|NCT00518115|DRUG|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
219680320|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
219079451|NCT02234674|OTHER|Current intensive CDP|"Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging"
219079452|NCT02234674|OTHER|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
219680321|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
219680322|NCT00216528|DRUG|risperidone|
219680323|NCT04033406|DRUG|VIR-2482|VIR-2482 given by intramuscular injection
219680324|NCT04033406|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
219680325|NCT00570336|DRUG|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
219680326|NCT00570336|OTHER|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
219680327|NCT01773603|DEVICE|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
219079453|NCT04891419|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
219079454|NCT05426551|OTHER|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
219079455|NCT04443140|DIAGNOSTIC_TEST|PCR, lung ultrasound|PCR for Covid-19
219079456|NCT01845675|DRUG|temozolomide or dacarbazine-based chemotherapy, endostatin|
219079457|NCT05462665|BEHAVIORAL|theory training|theory training
219079458|NCT05462665|BEHAVIORAL|theory and simulation training|theory and simulation training
219079459|NCT02234869|DRUG|Interferon Beta|Subcutaneous injection
219079460|NCT02234869|DRUG|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
219079461|NCT00827918|DRUG|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
219079462|NCT00827918|DRUG|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
219079463|NCT00827918|DRUG|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
219079464|NCT02848248|DRUG|SGN-CD123A|Intravenous infusion in 3-week cycles
219079465|NCT05704075|PROCEDURE|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
219079466|NCT05704075|PROCEDURE|Conventional|Dressing + Negative Pressure Wound Therapy
219079467|NCT05283317|BIOLOGICAL|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
219079468|NCT05258110|DRUG|midazolam|midazolam
219079469|NCT05258110|DRUG|BI 425809|BI 425809
219079470|NCT02959489|BEHAVIORAL|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
219079471|NCT02959489|BEHAVIORAL|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
219079472|NCT03623087|DRUG|Cisplatin|SIMPLE
219079473|NCT03623087|DRUG|Gemcitabine|SIMPLE
219079474|NCT03623087|DRUG|Etoposide (VP-16)|SIMPLE
219079475|NCT03623087|DEVICE|Ifosfamide|SIMPLE
219079476|NCT03623087|DRUG|Dexamethasone|SIMPLE
219079477|NCT03623087|DRUG|L-asparaginase|SIMPLE
219210598|NCT06688357|DEVICE|Active NIR-PBM (MedX 1116, MCT502)|Near infrared light was delivered using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Dosing was based on a pilot study. This intervention was given 3 times/week for 2 weeks.
219210599|NCT06688357|DEVICE|Sham NIR-PBM (MedX 1116, MCT502)|The MedX sham intervention device is identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 2-week period, following the identical procedures described in the active condition.
219210600|NCT05717686|DRUG|AHB-137 injection|AHB-137 will be administered
219079478|NCT00115115|DRUG|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
219079479|NCT02961465|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
219079480|NCT04183270|OTHER|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
219079481|NCT01935817|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
219079482|NCT01935817|DRUG|Placebo|
219079483|NCT01761097|DEVICE|Endocuff attachment|Endocuff
219079484|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
219079485|NCT05260801|OTHER|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
219079486|NCT05260801|OTHER|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
219079487|NCT04101643|DRUG|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
219079488|NCT05789043|DRUG|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
219079489|NCT05789043|DRUG|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
219079490|NCT05789043|DRUG|camrelizumab|camrelizumab 200mg，q2w
219079491|NCT00843167|DIETARY_SUPPLEMENT|broccoli sprout extract|Given orally
219079492|NCT00843167|OTHER|placebo|Given orally
219210601|NCT05717686|DRUG|Placebo|Placebo will be administered
219210602|NCT06734546|OTHER|Exercise intervention|The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
219210603|NCT06746012|PROCEDURE|Discussion|Participate in think-aloud sessions
219210604|NCT06746012|OTHER|Educational Activity|Receive health coaching
219210605|NCT06746012|OTHER|Internet-Based Intervention|Use Healthy Buckeyes app
219210606|NCT06746012|OTHER|Internet-Based Intervention|Watch videos
219680328|NCT01001520|DRUG|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
219079493|NCT02291614|DRUG|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
219079494|NCT04231812|DEVICE|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
219079495|NCT00127101|DRUG|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
219210607|NCT06746012|OTHER|Interview|Complete semi-structured interview
219210608|NCT06746012|OTHER|Medical Device Usage and Evaluation|Wear Fitbiit and use exercise bands
219210609|NCT06746012|OTHER|Questionnaire Administration|Ancillary studies
219210610|NCT06746012|OTHER|Supportive Care|Receive caregiver support
219210611|NCT06746012|OTHER|Survey Administration|Complete surveys
219079496|NCT00127101|DRUG|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
219079497|NCT03030222|DRUG|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
219079498|NCT03030222|DRUG|Placebo Oral Tablet|Empagliflozin matching placebo
219079499|NCT02806375|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
219079500|NCT02806375|DRUG|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
219079501|NCT02806375|DRUG|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
219079502|NCT02806375|DRUG|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
219079503|NCT02806375|DRUG|Ruxolitinib|Days -8 through -2 15 mg tid
219079504|NCT02806375|DRUG|Ruxolitinib|Days +5 through +100: 7.5 mg bid
219079505|NCT05060328|OTHER|Medical Device Usage and Evaluation|"Use Google Translate Conversation Mode translation application."
219079506|NCT05060328|OTHER|Survey Administration|Complete survey
219079507|NCT00325611|BEHAVIORAL|Multidisciplinary palliative care team met with patient|
219079508|NCT03479320|DRUG|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
219079509|NCT03479320|DRUG|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
219079510|NCT06267053|DIAGNOSTIC_TEST|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
219079511|NCT06267053|DIAGNOSTIC_TEST|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
219079512|NCT06267053|DIAGNOSTIC_TEST|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
219210612|NCT06755788|DEVICE|RT-CGM|In the RT-CGM group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. RT-CGM monitoring will also be employed during surgery. A tablet in the operating room will be configured with low and high glucose alerts set at 3.9 mmol/L and 10.0 mmol/L, respectively. When an alarm is triggered, arterial blood gases will be rechecked, and glucose levels will be adjusted based on the arterial blood glucose results. If interstitial glucose values do not reach the intervention threshold, arterial blood gas measurements are recommended every 30 minutes.
219210613|NCT06755788|DEVICE|Control|In the control group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. CGM monitoring will also be employed during surgery, but the CGM interstitial glucose readings and alerts will be masked during the operation. The final intraoperative glucose management approach will be determined by the anesthesiologist, considering the patient's condition and surgical circumstances. The anesthesiologist can choose the intravenous insulin adjustment protocol we recommend.
219210614|NCT06752161|OTHER|Urine analysis|Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women
219210615|NCT00177268|OTHER|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
219680329|NCT01001520|DRUG|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
219680330|NCT00652704|DRUG|Doxycycline monohydrate|Capsules, 100 mg, fed
219680331|NCT00652704|DRUG|Monodox|Capsules, 100 mg, fed
219680332|NCT00652704|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, fasting
219680333|NCT03146338|OTHER|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
219680334|NCT02541422|DIETARY_SUPPLEMENT|N Acetyl Cysteine|
219680335|NCT02541422|OTHER|placebo|
219680336|NCT04272463|OTHER|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
219079513|NCT06267053|DIAGNOSTIC_TEST|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
219079514|NCT06291168|OTHER|Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)|"Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions."
219079515|NCT06291168|OTHER|Yoga-Based Exercise Program|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas."
219210616|NCT06755307|DIETARY_SUPPLEMENT|OMNiBiOTiC® Panda|Multistrain Probiotic OMNiBiOTiC® Panda containing: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactococcus lactis W58 and sunflower oil
219079516|NCT06291168|OTHER|Conventional Exercises|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
219079517|NCT03973008|RADIATION|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
219210617|NCT06755307|OTHER|Placebo|Placebo containing sunflower oil and maltodextrin
219210618|NCT06841250|PROCEDURE|intravitreal injection of anti-VEGF|Ranibizumab is injected into the vitreous under aseptic conditions as part of routine DME treatment
219210619|NCT06841757|BEHAVIORAL|Remote ischemic preconditioning|Patients will undergo Remote Ischemic Preconditioning using a blood pressure cuff inflated on the upper limb to induce ischemia and reperfusion, 40 mmHg above systolic pressure. The procedure will involve 3 cycles of inflation (5 minutes each) and deflation (5 minutes each) post intubation
219210620|NCT06841458|OTHER|Oral Supplement|Participants in the Active Comparator group will receive a dietary supplement designed to manage androgenetic alopecia (AGA). The intervention consists of one oral capsule per day for six months, containing active ingredients such as Saw Palmetto, Pumpkin Seed Oil, Pygeum africanum, L-Cystine, Oleanolic Acid, and Horsetail Extract.
219210621|NCT06813157|OTHER|MSC|The overall test process is as follows: screening period (V1): sign ICF, check the screening period, judge the criteria, record the baseline demographic information and the status of the subjects. Baseline period (V2): pre-transfusion assessment was performed to record the safety and other examinations of the subjects. During the treatment period (V3): according to the method and dose specified in the scheme, MSCs was treated for 5 times. Follow up period (V5): Safety and efficacy follow-up will be conducted at D14, M1, M2, M3, M6, M9, and M12 during the follow-up period.The subjects were followed up to M12 or those who met the withdrawal criteria withdrew early, whichever occurred first.
219210622|NCT01801709|GENETIC|intracerebral administration of AAVrh.10cuARSA|
219210623|NCT06842108|OTHER|Exercise tolerance test|"• The ETT will be performed using Bruce protocol. The Bruce protocol is a standardized treadmill exercise test used in Exercise Tolerance Testing (ETT) to evaluate cardiovascular fitness and diagnose heart conditions. This protocol is divided into seven stages, each stage duration is 3 minutes and date will be recorded at the end of the each stage. The recorded data will include heart Rate, Rate pressure product (∆RPP), HRR1 and Blood Pressure.~STEP 1:~Patient Preparation~STEP 2:~Consent and history:~STEP 3:~Start of ETT:~• Graded Exercise~STEP 4:~Parameters Recorded During ETT:~* Heart Rate: Monitoring heart rate response to exercise stress.~* Exercise induced changes in heart rate (∆HR) along with change in rate pressure product (∆RPP) due to excercise intensity.~STEP 5:~Cardiopulmonary Fitness Assessment VO2 Max"
219210624|NCT06842368|PROCEDURE|Hyaluronic Acid (HA)|"Hyaluronic acid is one of the essential components of extracellular matrix, which plays a predominant role in tissue morphogenesis, cell migration, differentiation, and adhesion. It has been recently reported that hyaluronic acid increases osteoblastic bone formation in vitro through increased mesenchymal cell differentiation and migration.~It has demonstrated that Hyaluronic acid not only acted as a carrier of growth factors and cell but also stimulated bone formation through chemotaxis, proliferation and differentiation of mesenchymal cells into osteoblasts.~Although Hyaluronic acid shares bone induction properties with growth factors as bone morphogenic protein 2 and osteopontin"
219079518|NCT03973008|DRUG|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
219210625|NCT06842368|PROCEDURE|Vitamin D|"It was shown that locally applied vitamin D3 in combination with bovine bone mineral matrix improved the bone formation and strengthened the site of the fracture in ovariectomized rats.~Local application of vitamin D3 also proved to be promising in promoting osteo- genesis and mineralization for restoration of bone defects. Grounding on this incites, it has been suggested that vitamin D3 might exert a positive local effect on alveolar bone regeneration"
219680337|NCT05004792|OTHER|DermLoop Learn|DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
219680338|NCT06164938|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
219680339|NCT00209950|DRUG|Gaboxadol|
219680340|NCT00968955|DRUG|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
219680341|NCT01967004|DEVICE|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
219079519|NCT06109987|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
219079520|NCT06489613|DIAGNOSTIC_TEST|M protein detection by iMS-LC Assay|"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput."
219079521|NCT02137369|DRUG|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
219079522|NCT02137369|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
219079523|NCT02137369|OTHER|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
219079524|NCT00781976|DRUG|AZD7295|700mg per day maximum
219079525|NCT00781976|DRUG|Placebo|matched placebo
219079526|NCT06303050|OTHER|Mental Imagery with task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. During each 45 minutes of session, the participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance. Regular breaks will give to the participants to avoid overexertion and fatigue during 45 minutes of continues practice. The 2 minutes rest period will provide to the partici-pants during each practice session
219079527|NCT06303050|OTHER|Task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will receive the Task oriented training for 25-30 minutes, 05 days a week for 06 weeks consisting of Warm up Period, Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
219079528|NCT01348867|OTHER|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
219079529|NCT01229540|GENETIC|genetic analyzer|
219680342|NCT00209391|DRUG|Gadodiamide Injection|
219680343|NCT01351090|DRUG|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
219680344|NCT01351090|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
219680345|NCT01351090|DRUG|Placebo|Intranasal
219680346|NCT03335319|OTHER|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or \> 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
219680347|NCT03335319|OTHER|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
219680348|NCT06542367|PROCEDURE|"Tympanoplasty performed under local anesthesia using fat graft and Tachosil."|"Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation"
219680349|NCT04199377|PROCEDURE|HIP KNEE REPLACEMENT|HIP KNEE REPLACEMENT
219680350|NCT06039072|DRUG|Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.|Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
219680351|NCT04165356|PROCEDURE|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
219680352|NCT04165356|PROCEDURE|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
219680353|NCT00202501|DEVICE|Nasal CPAP (Continuous Positive Airway Pressure)|
219680354|NCT02197585|PROCEDURE|Inguinal mesh hernioplasty|
219079530|NCT04447170|PROCEDURE|Simple repair or Graham technique|Simple suture with or without omental protective patch
219079531|NCT04014764|OTHER|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
219079532|NCT05566223|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
219079533|NCT05566223|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
219079534|NCT05566223|BIOLOGICAL|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
219079535|NCT05566223|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
219079536|NCT05566223|DRUG|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
219079537|NCT04341506|DEVICE|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
219079538|NCT01015157|PROCEDURE|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
219079539|NCT01567384|DRUG|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
219079540|NCT02320565|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
219079541|NCT02320565|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
219079542|NCT06286150|PROCEDURE|Surgical robot system|SHURUI Single-port surgical robot system
219079543|NCT05737082|DRUG|HCP2201|Take 2 tablets once per period
219079544|NCT05737082|DRUG|RLD2205|Take 2 tablets once per period
219079545|NCT05737082|DRUG|RLD2206|Take 1 tablet once per period
219079546|NCT05445648|DRUG|Tislelizumab Injection|After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
219079547|NCT05445648|PROCEDURE|Transurethral resection of bladder tumor|After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.
219079548|NCT05445648|RADIATION|Adjuvant radiotherapy|On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
219079549|NCT02393872|BEHAVIORAL|Feel4Diabetes-intervention|Community-based intervention.
219079550|NCT02741401|OTHER|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
219079551|NCT02741401|OTHER|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
219680355|NCT05136079|PROCEDURE|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
219680356|NCT03824717|DRUG|Dose of ropivacaine|Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
219680357|NCT03591601|OTHER|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
219680358|NCT03591601|OTHER|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
219079552|NCT03153579|DRUG|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
219680359|NCT03591601|OTHER|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
219680360|NCT03000985|BEHAVIORAL|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
219680361|NCT06316596|PROCEDURE|Spinal Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
219680362|NCT06316596|PROCEDURE|Epidural Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
219680363|NCT02807831|BEHAVIORAL|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
219680364|NCT02807831|BEHAVIORAL|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
219079553|NCT03153579|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
219079554|NCT04296695|DRUG|B/F/TAF|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
219079555|NCT04296695|DRUG|TDF/3TC/EFV|TDF/3TC/EFV
219079556|NCT05662384|OTHER|No intervention is planned|Observational study, no intervention
219680365|NCT02807831|OTHER|Regular school curriculum|Ministry of Education national school curriculum.
219680366|NCT00254059|PROCEDURE|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
219079557|NCT05668169|OTHER|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
219079558|NCT01912924|DEVICE|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
219079559|NCT06311279|PROCEDURE|Anterior resection of Rectal cancer|Anterior resection of cancer rectum and type of anastomosis (End to end or side to end)
219079560|NCT02160314|DEVICE|pessary|disposable, single-use pessary
219079561|NCT02160314|DEVICE|Absorbent pad|
219079562|NCT01751126|DRUG|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
219079563|NCT01751126|DRUG|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
219079564|NCT00654719|DIETARY_SUPPLEMENT|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
219079565|NCT00654719|DIETARY_SUPPLEMENT|Placebo|Nutritional supplementation containing only 12 kcal/day
219079566|NCT06282679|DRUG|Botulinum Toxin Type A Injection [Botox]|you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
219079567|NCT04979559|DEVICE|Mobile health apps|Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
219079568|NCT04979559|OTHER|Standard care|Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
219079569|NCT04246983|DIAGNOSTIC_TEST|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
219210626|NCT06865755|DEVICE|integrated medication monitoring (MM) system|We have created a new integrated medication monitoring (MM) system consisting of baseline, 3-month, and 6-month surveys, smartphone-based ecological momentary assessment via an application installed on a smartphone (Digital Trails based on the UVA Sensus app), a wireless medication event monitoring system device (MEMS; Wisepill), and a wearable sensor (Fitbit), and data collected passively from smartphone sensors using the Digital Trails app. These sources of information will be used to understand predictors of medication taking behaviors and, after two months of monitoring, to deploy appropriate interventions which will be delivered via the Digital Trails app platform.
219210627|NCT06886061|DIETARY_SUPPLEMENT|The capsules contain Ergothioneine.|Take one 30 mg Ergothioneine capsule orally every day for a period of eight weeks.
219680367|NCT04254081|DRUG|Buprenorphine 0.15 MG|Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
219680368|NCT04254081|DRUG|Lidocaine 1% Injectable Solution|20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
219680369|NCT00002182|DRUG|Megestrol acetate|
219079570|NCT02657616|DRUG|vitamin-k-antagonists|
219079571|NCT02657616|DRUG|Novel oral anticoagulants|
219079572|NCT02093767|DIETARY_SUPPLEMENT|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
219079573|NCT03297515|DIETARY_SUPPLEMENT|Madeos|Arm 1: Omega 3
219079574|NCT03297515|DIETARY_SUPPLEMENT|Placebo|Arm 2 : Placebo
219079575|NCT00593567|DRUG|gentamicin-collagen sponge|Inserted daily into open ulcer
219079576|NCT00593567|DRUG|Levofloxacin|750mg oral levofloxacin daily
219079577|NCT06154343|DRUG|GQ1005|an antibody drug conjugate
219079578|NCT03664479|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
219210628|NCT06886061|DIETARY_SUPPLEMENT|The capsules do not contain Ergothioneine.|Take one capsule devoid of Ergothioneine orally every day for a period of eight weeks.
219210629|NCT06882837|BEHAVIORAL|BUMP app|Participants in the experimental group will have access to the BUMP app, which aims to support them to control the amount and rate of weight gain during pregnancy, from baseline (early or mid-pregnancy) until they give birth. The app will prompt participants to regularly self-monitor their weight gain during pregnancy, and will provide access to a weight gain chart for tracking. Participants will receive feedback notifications about their weight gain trajectory, and will have access to information and tips on weight management during pregnancy.
219210630|NCT06885983|PROCEDURE|implant placement|Late implant placement without regenerative therapy
219680370|NCT06480136|DRUG|SHR-A1921 injection and adebrelimab injection|The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
219680371|NCT02210507|OTHER|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
219680372|NCT02210507|OTHER|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
219680373|NCT02210507|OTHER|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
219079579|NCT00061802|DRUG|risperidone, quetiapine|
219079580|NCT00785291|BIOLOGICAL|Bevacizumab|Given IV
219079581|NCT00785291|DRUG|Ixabepilone|Given IV
219079582|NCT00785291|OTHER|Laboratory Biomarker Analysis|Correlative studies
219079583|NCT00785291|DRUG|Nab-paclitaxel|Given IV
219079584|NCT00785291|DRUG|Paclitaxel|Given IV
219079585|NCT00785291|OTHER|Questionnaire Administration|Ancillary studies
219079586|NCT05864664|PROCEDURE|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed"
219079587|NCT00137930|BIOLOGICAL|Live attenuated rotavirus vaccine|
219079588|NCT05538962|DIAGNOSTIC_TEST|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
219079589|NCT03110341|DRUG|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
219079590|NCT03110341|DRUG|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
219079591|NCT05543291|BEHAVIORAL|renal function|levels of eGFR
219079592|NCT02877511|DRUG|BAY987517|Applied liberally to the skin (Formulation: Y73-161
219079593|NCT02877511|DRUG|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
219079594|NCT04967768|OTHER|Questionnaire about impact of the COVID-19 pandemic on orthopaedic resident training|Answers were collected for the effects of the COVID-19 pandemic on the real-life experiences of orthopaedic residents
219079595|NCT00235092|DEVICE|Cypher Sirolimus-Eluting Stent|
219079596|NCT00235092|DEVICE|Taxus Paclitaxel-Eluting Stent|
219079597|NCT06064084|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test 50g
219079598|NCT06064084|OTHER|Intravenous isoglycaemic glucose clamp|Intravenous isoglycaemic glucose clamp
219079599|NCT06064084|OTHER|Liquid Mixed meal test|Liquid Mixed meal test 520 kcal
219079600|NCT00570674|DRUG|Abraxane|
219079601|NCT00570674|DRUG|Erbitux|
219079602|NCT00570674|DRUG|Carboplatin|
219079603|NCT00570674|RADIATION|Intensity Modulated Radiation Therapy|
219079604|NCT03151980|PROCEDURE|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
219079605|NCT03151980|OTHER|Untreated skin and sun exposure|Skin that will not receive Hamam.
219079606|NCT03103243|BEHAVIORAL|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
219079607|NCT03578003|OTHER|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
219079608|NCT03519750|DRUG|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
219079609|NCT01928420|DRUG|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
219079610|NCT01928420|DRUG|Placebo|Subjects with Alzheimer's Disease placebo comparator
219079611|NCT05877443|PROCEDURE|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
219079612|NCT05877443|PROCEDURE|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
219079613|NCT05877443|PROCEDURE|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
219079614|NCT00005801|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219210631|NCT06885983|PROCEDURE|Guided bone regeneration|Application of collagen membrane after implant placement.
219210632|NCT06745453|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
219079615|NCT00005801|PROCEDURE|peripheral blood stem cell transplantation|
219079616|NCT00005801|RADIATION|radiation therapy|
219079617|NCT00244790|BEHAVIORAL|Diet|crossover low vs high protein diet before and after weight loss
219079618|NCT02979639|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
219079619|NCT04837300|OTHER|Resisted Sprint Traininig|The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
219079620|NCT03672838|BEHAVIORAL|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
219079621|NCT02344043|DEVICE|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
219079622|NCT00817180|OTHER|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
219079623|NCT00817180|OTHER|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
219079624|NCT01477125|BEHAVIORAL|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
219079625|NCT00799292|DRUG|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
219079626|NCT04584034|DRUG|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
219079627|NCT04584034|DRUG|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
219210633|NCT06745453|PROCEDURE|Sham Procedure|Sham Procedure
219079628|NCT04080804|DRUG|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
219210634|NCT06764368|DRUG|Adebrelimab + Apatinib|"Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons."
219210635|NCT06764069|DEVICE|Sensor Lead|The Glucotrack Sensor Lead will be inserted into the subclavian vein, using a Seldinger technique, where it will continuously measure blood glucose levels.
219210636|NCT06762847|DEVICE|Use of Conventional Silicone Prosthetic Liner|At this stage participant who will be fitted with a standard silicone liner typically used for transtibial prosthetics. Over a set duration, we will assess the liner's performance, particularly in terms of durability, comfort, skin health, and fit stability. Acting as the control group, this cohort will provide essential baseline data for comparison with the innovative prosthetic liner.
219210637|NCT06762951|OTHER|Pilates mat exercices|Pilates mat exercise which consists of (single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions.
219210638|NCT06762951|OTHER|Segmental control exercises|Segmental control exercise which consists of (Segmental control over primary stabilizers, Exercises in closed chain, and Exercises in open chain)
219680374|NCT06392152|DRUG|Focal Mass Drug Administration with Primaquine|"A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year."
219079629|NCT04080804|DRUG|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
219079630|NCT04080804|DRUG|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
219079631|NCT06450132|DRUG|Atropine Ophthalmic|0.05% atropine ophthalmic solution
219079632|NCT06450132|DEVICE|MiSight 1-day disposable contact lenses|soft multifocal contact lenses
219079633|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
219079634|NCT06169514|OTHER|No intervention|No intervention
219079635|NCT03676426|OTHER|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
219079636|NCT03676426|OTHER|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
219079637|NCT01394965|PROCEDURE|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
219079638|NCT01834105|DRUG|Liuwei Dihuang Pills|
219079639|NCT03348579|OTHER|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
219079640|NCT03348579|OTHER|Targeted experience feedback|"Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi"
219079641|NCT05437133|DEVICE|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
219079642|NCT05582564|OTHER|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
219079643|NCT06135103|DRUG|talfirastide|TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
219079644|NCT06135103|DRUG|Placebo|Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
219079645|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
219079646|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
219079647|NCT00698594|BIOLOGICAL|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
219079648|NCT02683564|DRUG|BOW015|monoclonal antibody against TNF-alpha
219079649|NCT02683564|DRUG|Remicade|monoclonal antibody against TNF-alpha
219079650|NCT05824065|DRUG|OMA102|1 mg
219079651|NCT05824065|DRUG|OMA102|2 mg
219079652|NCT05824065|DRUG|Placebo|OMA102 - Placebo
219079653|NCT04050865|DRUG|Dexamethasone, 0.4mg|Ophthalmic Insert
219079654|NCT04050865|DEVICE|Placebo plug with no drug|Ophthalmic Insert
219079655|NCT01466985|DRUG|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
219079656|NCT01466985|DRUG|Placebo|Placebo tablets once daily for 7 days.
219079657|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
219079658|NCT06105073|PROCEDURE|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
219210639|NCT06762951|OTHER|Traditional physical therapy|Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
219210640|NCT06790927|DRUG|Usual Care|The doctor prescribes medication for patients and follow-up every 3 months
219210641|NCT06790927|DRUG|Standard Medical Therapy|The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
219210642|NCT06782594|DRUG|Mosapride Citrate Injection(high)|Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days
219210643|NCT06782594|DRUG|Mosapride Citrate Injection(low)|Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days
219210644|NCT06782594|DRUG|Placebo|Placebo, iv, bid, for 3 to 5 days
219210645|NCT06769373|DEVICE|Whirlpool Bath|This group of participants will receive an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, whirlpool bath (32-38 °C) 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
219210646|NCT06769373|DEVICE|Contrast Bath|This group of participants will recieve an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, contrast bath therapy which consist of 4 minutes hot water (38°C) followed by 1 minute cold water (10°C) periods for 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
219210647|NCT06768541|PROCEDURE|THA using a short stem|Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
219210648|NCT06287671|PROCEDURE|Colorectal resection or stoma closure|Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
219680375|NCT01080092|BEHAVIORAL|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
219680376|NCT01080092|BEHAVIORAL|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
219680377|NCT00878800|DRUG|PXD101|Administered in combination with doxorubicin (BelDox)
219680378|NCT00878800|DRUG|Doxorubicin|Administered in combination with PXD101 (BelDox)
219680379|NCT00613821|DRUG|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
219680380|NCT00613821|DRUG|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
219680381|NCT04091737|BIOLOGICAL|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"* Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200"
219079659|NCT03500614|BEHAVIORAL|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
219079660|NCT03500614|BEHAVIORAL|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
219079661|NCT02541552|DRUG|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
219680382|NCT03363867|DRUG|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
219079662|NCT04450537|BEHAVIORAL|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
219079663|NCT05338723|DRUG|Rosuvastatin 20mg|20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
219079664|NCT04205630|DRUG|SYD985|SYD985 powder for concentrate for solution for infusion
219079665|NCT00676182|OTHER|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
219210649|NCT03872284|OTHER|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
219079666|NCT05017922|PROCEDURE|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
219079667|NCT01677273|DIETARY_SUPPLEMENT|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
219079668|NCT01677273|DIETARY_SUPPLEMENT|Intact casein|30 g protein/supplement, 4 supplements/visit
219079669|NCT01677273|DIETARY_SUPPLEMENT|Intact whey protein|30 g protein/supplement, 4 supplements/visit
219079670|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
219079671|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
219079672|NCT00476216|DRUG|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
219079673|NCT05049759|BEHAVIORAL|Confident, Active and Happy Youth|The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
219079674|NCT00640627|DRUG|Celecoxib|200 mg oral capsule once daily for 6 weeks
219079675|NCT00640627|DRUG|Placebo|Matched oral placebo for 6 weeks
219079676|NCT05031364|BEHAVIORAL|Behavioral Interventions for Anxiety in Children with Autism (BIACA)|In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
219210650|NCT06751979|DIETARY_SUPPLEMENT|Probiotic treatment|Daily intake of a lozenge containing the probiotic strain S. salivarius M18.
219210651|NCT06751979|DIETARY_SUPPLEMENT|Placebo|Placebo
219210652|NCT06758947|DRUG|Upadacitinib 15 MG|oral tablet upadacitinib
219210653|NCT06758947|DEVICE|Cellcept Oral Product|active control group 2000mg MMF daily
219210654|NCT06757400|OTHER|Mobilization|Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.
219210655|NCT06757400|OTHER|manipulation|Manipulation will be conducted on an examination table with the subject in right lateral decubitus. It will be a rotary manipulation to the most hypomobile lumbar spine segment after assessment.
219210656|NCT06768086|PROCEDURE|Hysteroscopic myomectomy|"The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as failed procedures and were subsequently excluded from the study."
219210657|NCT06761729|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
219210658|NCT06458322|OTHER|Home dialysis or In-Center dialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
219210659|NCT04704219|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
219210660|NCT04704219|DRUG|Lenvatinib|Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
219210661|NCT06203041|DIETARY_SUPPLEMENT|Vitamin D|Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
219680383|NCT03363867|DRUG|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
219079677|NCT05031364|BEHAVIORAL|Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)|Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
219079678|NCT05759416|DRUG|Melatonin2%gel|Intra-pocket application of 2% Melatonin gel
219079679|NCT05759416|DRUG|PLACEBO|placebo intra-pocket application
219079680|NCT00107003|DRUG|lapatinib ditosylate|
219680384|NCT03363867|DRUG|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
219680385|NCT02302846|DRUG|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
219680386|NCT05555277|OTHER|No interventions - retrospective data collection|The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
219079681|NCT00107003|PROCEDURE|Adjuvant therapy|
219079682|NCT00107003|PROCEDURE|Conventional surgery|
219680387|NCT04994561|DRUG|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
219680388|NCT04135482|OTHER|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
219680389|NCT01468454|DRUG|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
219680390|NCT00242697|PROCEDURE|spinal analgesia and anesthesia for coronary artery surgery|
219680391|NCT00003494|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219079683|NCT00107003|PROCEDURE|Neoadjuvant therapy|
219079684|NCT00258258|DRUG|paricalcitol|
219079685|NCT00258258|DRUG|zoledronic acid|
219079686|NCT03944525|DEVICE|High flow nasal cannula|Oxygen-therapy via HFNC
219079687|NCT03944525|DEVICE|Continuous positive airway pressure|Non-invasive CPAP ventilation
219079688|NCT05590780|OTHER|Clinical Attachment level|1-year
219079689|NCT04040660|DRUG|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
219079690|NCT05506787|DRUG|Esketamine|Esketamine
219079691|NCT05506787|DRUG|Placebo|Placebo
219079692|NCT01402141|DIETARY_SUPPLEMENT|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
219079693|NCT01402141|DIETARY_SUPPLEMENT|Placebo|Placebo(35g/day) for 12 weeks
219079694|NCT04976738|DRUG|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
219079695|NCT01164995|DRUG|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
219079696|NCT03549910|PROCEDURE|APRVplus protocol|Physiology-driven APRVplus protocol
219079697|NCT03549910|PROCEDURE|Low tidal volume ventilation|Low tidal volume lung protective ventilation
219079698|NCT03903133|DRUG|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
219079699|NCT00158938|DEVICE|EASYTRAK 3 left ventricular pacing lead|
219079700|NCT03411655|DEVICE|Ambu Aura GainTM|Time and success rate
219079701|NCT03411655|DEVICE|Ambu® Aura-ITM|Time and success rate
219079702|NCT00249925|BEHAVIORAL|Home-Based Intervention|
219079703|NCT00249925|BEHAVIORAL|Multi-component home-based intervention|
219079704|NCT06532214|DIAGNOSTIC_TEST|International Study Group for Liver Surgery (ISGLS)|According to the ISGLS criteria, the patient was judged to have liver failure and further analysis
219079705|NCT03434951|DRUG|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
219079706|NCT03434951|DRUG|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
219079707|NCT03434951|DRUG|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
219680392|NCT00317746|DRUG|Citalopram|
219680393|NCT00317746|DRUG|Placebos|
219680394|NCT04435808|DRUG|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
219680395|NCT02620787|DRUG|Tedizolid|
219079708|NCT01844804|BIOLOGICAL|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
219079709|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
219079710|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
219680396|NCT02620787|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
219079711|NCT06273423|OTHER|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
219079712|NCT00541515|DEVICE|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
219079713|NCT06477575|DEVICE|neurocognitive therapy based on new technologies|"The cognitive neurorehabilitation program is based on gaming through the use of the Nintendo Switch device. The following games have been chosen: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder, since they are games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Hardware: Nintendo Switch Software: 60 in 1 game Games: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder. Therapy time: 30 minutes effective. Number of Sessions: 2 per week / Number of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
219079714|NCT06477575|OTHER|conventional neurocognitive therapy|"The cognitive neurorehabilitation program for group active comparator is based on playing more conventional board games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Traditional games and token book. Games: Dobble, Lynx, Crazy cups, Jungle speed, animalea, ghost. Card: Stimulate and learn level 3 and 4. Therapy time: 30 minutes effective. No. of sessions: 2 per week / No. of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
219079715|NCT01745432|DEVICE|ADBLOCK|Laparoscopic surgery
219079716|NCT00249535|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
219079717|NCT04460118|PROCEDURE|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
219079718|NCT04460118|PROCEDURE|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
219680397|NCT05821387|DRUG|Lucid-21-302|A small molecule inhibitor of hypercitrullination
219680398|NCT05821387|DRUG|Placebo|Product containing excipients with no active ingredients
219680399|NCT01333423|DRUG|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
219079719|NCT01490996|DRUG|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
219079720|NCT01490996|DRUG|Chemotherapy only|Standard care chemotherapy
219079721|NCT04199858|BEHAVIORAL|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
219079722|NCT04199858|BEHAVIORAL|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
219079723|NCT04199858|BEHAVIORAL|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
219079724|NCT04199858|OTHER|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
219079725|NCT05245669|BIOLOGICAL|ENZ215|healthy volunteers receive ENZ215 (60mg) once
219680400|NCT01333423|DRUG|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
219680401|NCT00164138|PROCEDURE|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
219680402|NCT03744897|BEHAVIORAL|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
219079726|NCT05245669|BIOLOGICAL|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
219079727|NCT05245669|BIOLOGICAL|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
219079728|NCT03886818|DEVICE|Standard dressings|Standard dressings will be used from surgery to wound healing
219079729|NCT03886818|DEVICE|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
219079730|NCT01597050|DRUG|R932333|R393233 6% (60 mg/g), bid
219079731|NCT01597050|DRUG|Placebo|Placebo, bid
219079732|NCT03602170|BEHAVIORAL|High-Intensity Interval Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.
219079733|NCT03602170|BEHAVIORAL|Moderate-Intensity Continuous Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
219079734|NCT00483184|BIOLOGICAL|Veldona,|Very low dose oral natural human interferon alpha lozenges
219079735|NCT01936584|PROCEDURE|TAPP repair for inguinal hernias|
219079736|NCT01936584|PROCEDURE|TEP repair for inguinal hernia|
219079737|NCT01936584|OTHER|EuraHS-QoL questionnaire|questionnaire administration
219079738|NCT01936584|OTHER|Carolina Comfort Scale|questionnaire administration
219079739|NCT00558428|DRUG|fixed dose combination of telmisartan+amlodipine|
219079740|NCT00558428|DRUG|amlodipine|
219680403|NCT03744897|DEVICE|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
219680404|NCT03744897|OTHER|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
219210662|NCT06746558|COMBINATION_PRODUCT|Potassium Nitrate Gel and Diode Laser Therapy|Participants in the experimental group receive treatment combining a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to affected teeth and diode laser therapy (980 nm). The laser is used with specific power settings (0.3W, 0.5W, 0.7W) for 20 seconds at each setting, followed by a second application of the gel and irradiation. The treatment aims to reduce dentinal hypersensitivity by occluding dentinal tubules and altering neural responses.
219210663|NCT06746558|DRUG|Potassium Nitrate Gel Alone|Participants in the control group receive treatment with a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to the teeth. The gel is applied twice using a microbrush in a rubbing motion for 2 minutes each time. No diode laser therapy is administered. This intervention aims to evaluate the standalone efficacy of the gel in reducing dentinal hypersensitivity.
219210664|NCT06754202|OTHER|Social activities with cognitive stimulation|"The nine-month program will include social activities following the Montessori action in the context of the agricultural multifunctionality such as horticulture, pet therapy, occupational therapy, sensory labs, physical activity held three days a week for five hours each day."
219210665|NCT06784661|DRUG|Lipid-Based Artificial Tear|This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
219210666|NCT06784661|DRUG|Non-Lipid Artificial Tear|This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
219210667|NCT06762431|DRUG|Lenalidomide|Dose Level 1
219210668|NCT06762431|DRUG|Lenalidomide|Dose Level 2
219210669|NCT06812689|DIETARY_SUPPLEMENT|Flavanol|Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
219210670|NCT06812689|DIETARY_SUPPLEMENT|Placebo|Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
219210671|NCT06812689|OTHER|Sugar water|250 mL of hot water with 6 g of sugar
219210672|NCT06321536|DRUG|Allogeneic Microbiota in Glycerol (9%) (AMG)|Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
219210673|NCT06835166|PROCEDURE|12-lead electrocardiography measurement|"Intraoperative 12-lead electrocardiography (EKG) measurement during laparoscopic sleeve gastrectomy in morbidly obese patients:~In all patients, pneumoperitoneum CO₂ intraabdominal pressure will be studied as 15 cmH₂O.~Intraoperatively, 12-lead ECG will be obtained at five position measurement points:~Procedure1. Supine-monitored; Procedure 2. After induction; Procedure 3. Under general anesthesia-Supine-abdominal inflated; Procedure 4. Abdominal inflated-(30% vertical) Reverse Trendelenburg; Procedure 5. Abdominal deflated-(30% vertical) Reverse Trendelenburg.~Hemodynamic monitoring \[systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate \] was recorded at 5 simultaneous measurement points.~All hemodynamic measurements and ECG recordings will be performed 3 minutes after the position change to ensure standardization, to allow the response to settle after the position change, and to prevent the possibility of exaggerated-incorrect data."
219210674|NCT06786299|BIOLOGICAL|RD-IIT-001|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
219210675|NCT06786299|DRUG|CD84-CART|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
219680405|NCT03744897|DEVICE|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
219680406|NCT01735318|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
219079741|NCT01785966|BEHAVIORAL|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
219210676|NCT06793878|BEHAVIORAL|Living in Families With Emotions|This is an 8-week group-based psychosocial intervention teaching adolescents how to recognize their feelings, manage them, and talk about emotions through group discussions, live exercises, and games. The adolescents' caregivers are also provided with the same information, through two live sessions.
219680407|NCT01735318|DRUG|Lisinopril|40 mg tablet once a day
219680408|NCT00967577|DRUG|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
219079742|NCT00615043|PROCEDURE|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
219079743|NCT02308384|BEHAVIORAL|Intervention|CME, Start-package and status mail
219079744|NCT01375348|DRUG|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
219680409|NCT03929263|BEHAVIORAL|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
219680410|NCT01200706|DRUG|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
219680411|NCT05549583|DRUG|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
219680412|NCT06538987|PROCEDURE|percutaneous epicardial ablation|Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.
219079745|NCT03229954|DRUG|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
219079746|NCT03229954|DRUG|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
219079747|NCT02766530|OTHER|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
219079748|NCT04677972|DRUG|Ebselen|Glutathione peroxidase mimetic
219079749|NCT04677972|DRUG|Placebo|Matching placebo containing excipients
219079750|NCT01918410|DEVICE|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
219079751|NCT01918410|DEVICE|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
219079752|NCT02614716|DRUG|LY3090106|Administered SC
219079753|NCT02614716|DRUG|Placebo|Administered SC
219079754|NCT03386968|BEHAVIORAL|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
219079755|NCT03386968|BEHAVIORAL|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
219079756|NCT03671005|BEHAVIORAL|Mindfulness-based group therapy|see above
219079757|NCT03671005|OTHER|Treatment as usual|see above
219079758|NCT05111795|DEVICE|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
219079759|NCT01147224|DRUG|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
219079760|NCT01130948|OTHER|altitude exposure|exposure to 490m, 1700m and 2590m
219079761|NCT00425048|PROCEDURE|wearing gloves|
219079762|NCT00815295|DRUG|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
219079763|NCT00815295|DRUG|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
219079764|NCT00530855|DRUG|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
219079765|NCT03972111|DRUG|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
219210677|NCT06795295|PROCEDURE|Implant retained mandibular overdenture|Participants received dental implants to retain mandibular overdentures.
219079766|NCT02054767|DRUG|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
219079767|NCT02816151|DRUG|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
219079768|NCT02816151|DRUG|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
219079769|NCT00473798|BEHAVIORAL|Questionnaire|Questionnaire
219079770|NCT05422326|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
219079771|NCT05422326|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
219079772|NCT05422326|BIOLOGICAL|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
219079773|NCT05224050|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
219079774|NCT05224050|BIOLOGICAL|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
219079775|NCT05224050|DRUG|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
219079776|NCT01292876|DEVICE|Extracellular Matrix|Extracellular Matrix
219079777|NCT04960111|DEVICE|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
219079778|NCT05156918|OTHER|Exercise|Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
219079779|NCT05156918|OTHER|Non Exercise|There are no modifications to regular diet or exercise habits for 30 days.
219079780|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
219079781|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
219079782|NCT03907124|DRUG|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
219079783|NCT03907124|DRUG|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
219079784|NCT04783467|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
219079785|NCT04238806|DRUG|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
219079786|NCT01627327|DRUG|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
219079787|NCT01627327|DRUG|tiotropium bromide 18mcg|inhalation powder
219079788|NCT04003168|DRUG|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
219079789|NCT01848080|BEHAVIORAL|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
219079790|NCT02692326|PROCEDURE|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
219079791|NCT06124209|DRUG|TachoSil|TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
219079792|NCT02115594|DRUG|Fulvestrant|
219079793|NCT02115594|DRUG|Entinostat|
219079794|NCT02115594|DRUG|Placebo|
219079795|NCT05450315|BEHAVIORAL|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
219079796|NCT05450315|BEHAVIORAL|Canadian Physical Activity Guidelines|
219079797|NCT03435874|BIOLOGICAL|ChAd63 RH5|Vaccine
219079798|NCT03435874|BIOLOGICAL|MVA RH5|Vaccine
219079799|NCT03435874|BIOLOGICAL|Rabies Vaccine|Vaccine
219079800|NCT01081093|PROCEDURE|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
219079801|NCT05156190|OTHER|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
219079802|NCT03797768|BEHAVIORAL|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
219079803|NCT05615298|RADIATION|Mammography|FFDM (Full-Field Digital mammography)
219079804|NCT01012830|DRUG|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
219079805|NCT04294966|DRUG|Dextrose|Administering dextrose to healthy volunteers for our placebo group
219079806|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
219079807|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
219680413|NCT03549598|DRUG|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
219079808|NCT01175850|DEVICE|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
219079809|NCT01175850|DEVICE|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
219079810|NCT06242626|OTHER|observation|analysis of clinical, laboratory and haemodynamics parameters
219079811|NCT04432987|DRUG|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
219079812|NCT05475054|PROCEDURE|Minimally invasive liver resection|A liver resection performed by minimally invasive (keyhole) surgery
219079813|NCT03546517|OTHER|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
219079814|NCT03546517|OTHER|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
219079815|NCT00083408|DRUG|Pamidronate|
219079816|NCT00083408|DRUG|Thalidomide|
219079817|NCT03270449|OTHER|Multidisciplinary intervention|10 week multidisciplinary education and exercise
219079818|NCT04184063|DRUG|NBMI|NBMI active treatment
219079819|NCT04184063|OTHER|Placebo|Placebo for comparison
219079820|NCT01851148|OTHER|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
219079821|NCT01851148|OTHER|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
219079822|NCT01851148|DRUG|triptans|administration of triptans drug treatment according to international guidelines
219079823|NCT01838798|OTHER|Baseline activities|Initial consent procedures and baseline data collection.
219210678|NCT06797843|OTHER|"SPRG-based Resin Composite : (BEAUTIFIL II, Shofu Inc. Kyoto, Japan)."|A fluoride releasing, highly aesthetic dental material that is S-PRG (Surface Pre-reacted Glass Ionomer) based , has the ability to recharge fluoride and appropriate for patients with a high caries index.
219210679|NCT06797843|OTHER|Alkasite based restoration : Cention N|Cention N offers tooth-coloured esthetics together with high flexural strength. The new filling material belongs to the materials group of Alkasites. The patented alkaline filler increases the release of hydroxide ions to regulate the pH value during acid attacks. As a result, demineralization can be prevented. Moreover, the release of large numbers of fluoride and calcium ions forms a sound basis for the remineralization of dental enamel. The initiator system enables good chemical self-curing.
219210680|NCT06797843|OTHER|provisional Resin modified glass ionomer followed by Nanohybrid composite|"GC Fuji IX GP® EXTRA is the fastest setting glass ionomer on the market.The faster final set saves valuable chair time which provides improved stability against water, an important feature in challenging oral environments. This product contains a next generation glass filler which elicits higher translucency, fluoride release, reactivity and a faster setting time.~Then followed by Conventional Nano hybrid composite restoration(Neo Spectra® ST LV, Dentsply Sirona) which is nano-ceramic, light-cured, radiopaque, universal composite with novel SphereTEC filler technology."
219210681|NCT06795607|DIETARY_SUPPLEMENT|Probiotic|The experimental product is a dietary supplement manufactured by Cerbios-Pharma S.A, Each stick contains probiotic live cultures of Enterococcus lactis SF68® at a concentration of 10\^9 CFU, phytosterols, 6S-5MeTHF, maltose and silicon dioxide. Study participants will be given N°3 packs each containing 30 stick packs of 1.7 g each, in granulated form in sufficient quantity for the entire duration of the study (12 weeks). Subjects will be required to consume N°1 stick pack of the supplement daily after dinner for 12 continuous weeks. The product should be placed directly on the tongue and should be taken without water. After taking the product, the subject should drink half a glass of water to promote solubilization and transit. The supplement should be stored in a cool, dry place, away from light, moisture and direct heat sources to ensure the viability of the probiotic strain until the expiration date.
219210682|NCT06795607|DIETARY_SUPPLEMENT|Placebo|N°1 stick/day of placebo food supplement (i.e., stick without added probiotics), with the same intake modalities as probiotic.
219210683|NCT04121741|OTHER|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
219210684|NCT04121741|OTHER|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
219210685|NCT04121741|OTHER|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
219210686|NCT04100135|DEVICE|Actual device PFO closure|Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
219210687|NCT04100135|DRUG|Thienopyridine (clopidogrel or prasugrel)|Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
219680414|NCT03549598|DRUG|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
219079824|NCT01838798|OTHER|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire"
219079825|NCT01838798|OTHER|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts"
219680415|NCT03549598|DRUG|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
219079826|NCT01838798|OTHER|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress"
219680416|NCT05969990|OTHER|tryptophan metabolites in plasma|we will investigate the tryptophan metabolites in plasma of children with migraine
219680417|NCT01885832|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction|
219079827|NCT01982149|GENETIC|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
219079828|NCT01982149|GENETIC|Group 2|Correlate gene expression data from nasal and bronchial epithelium
219079829|NCT01982149|GENETIC|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
219079830|NCT00745810|OTHER|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
219079831|NCT01137474|DRUG|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
219079832|NCT01137474|DRUG|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
219079833|NCT03540654|OTHER|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
219079834|NCT03833882|DEVICE|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
219079835|NCT03833882|OTHER|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
219079836|NCT00498719|BEHAVIORAL|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
219079837|NCT00498719|OTHER|Control Group|Standard educational support.
219079838|NCT04983550|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
219079839|NCT04983550|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
219079840|NCT00003006|GENETIC|reverse transcriptase-polymerase chain reaction|
219079841|NCT00003006|OTHER|immunohistochemistry staining method|
219079842|NCT04794803|DRUG|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
219079843|NCT04794803|DRUG|Standard of care|Standard of care
219079844|NCT00911534|DRUG|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
219079845|NCT00911534|DRUG|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
219079846|NCT06191627|DIAGNOSTIC_TEST|Patch testing|Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.
219079847|NCT05013450|DRUG|Dupilumab|three q3w cycles
219079848|NCT05013450|DRUG|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
219079849|NCT05013450|DRUG|Anakinra|100 mg daily injection for Three q3w cycles
219210688|NCT04100135|DEVICE|Sham device PFO closure|Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
219210689|NCT01084863|DRUG|CT-P6|CT-P6: administered every 3 weeks
219079850|NCT05300425|OTHER|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
219079851|NCT05300425|OTHER|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
219079852|NCT04040751|BEHAVIORAL|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
219079853|NCT04040751|BEHAVIORAL|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
219079854|NCT04118530|OTHER|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
219079855|NCT04737460|GENETIC|AAV9/CLN7|Enrollees will receive gene therapy via a viral vector
219079856|NCT06297486|GENETIC|SPK-8011|Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.
219079857|NCT03609112|OTHER|The WISC-V|The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
219079858|NCT03609112|OTHER|The NEPSY-II|The NEPSY-II (Korkman et al., 2012). The Narrative Memory subtest is designed to assess verbal memory using organised language material.
219210690|NCT01084863|DRUG|Herceptin|Herceptin: administered every 3 weeks
219210691|NCT01084863|DRUG|Paclitaxel|Paclitaxel: administered every 3 weeks
219210692|NCT03473223|BIOLOGICAL|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration
219210693|NCT03473223|OTHER|Placebo|25% albumin solution diluted to 4.4%
219210694|NCT06838949|DRUG|herombopag olamine tablets|The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week.
219210695|NCT02845596|DRUG|cyclosporine|cyclosporine
219210696|NCT02845596|PROCEDURE|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
219079859|NCT03609112|OTHER|The Child Executive Function Evaluation Battery CEF|The Child Executive Function Evaluation Battery CEF (Roy et al., 2021), which aims to evaluate the four main components of executive function (inhibition, working memory, flexibility and planning).
219079860|NCT03609112|OTHER|"The CONNERS 3 long version"|"The  CONNERS 3 long version  (Conners, 2008), which assesses attentional skills by means of a questionnaire to be completed by parents."
219079861|NCT03609112|OTHER|"The BRIEF"|The 'BRIEF' (Gioia et al., 2013; parent version, teacher version), which is a behavioural evaluation inventory of executive functions completed by parents and teachers and which makes it possible to determine whether the child has, for example, difficulties with organisation, planning or behavioural regulation.
219079862|NCT03609112|OTHER|"The PEDS-QL quality of life"|"The PEDS-QL quality of life (Tessier et al., 2009) that will be completed by the parents and the patient concerns the day to- day functioning of the child (in school, relationships to others, physical abilities and emotional state)."
219079863|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort) which assesses fatigue in everyday life.
219079864|NCT03609112|OTHER|The Family Functioning Inventory FAD)|The Family Functioning Inventory FAD (Speranza et al., 2006) is used to assess the family functioning of the child and his/her family. The short version is used as an indicator of general functioning.
219079865|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
219079866|NCT03488901|OTHER|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
219079867|NCT00006136|DRUG|arginine butyrate|
219079868|NCT00006136|DRUG|epoetin alfa|
219079869|NCT03298009|DRUG|Canagliflozin 100mg|2-week intervention
219079870|NCT03298009|DRUG|Placebo oral capsule|2-week intervention
219079871|NCT03298009|RADIATION|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
219079872|NCT03896035|BEHAVIORAL|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
219079873|NCT06530862|OTHER|ESWT+stretching exercises|Participants in this group will receive ESWT treatment
219079874|NCT06530862|OTHER|Dry needling+stretching exercises|Participants in this group will receive Dry needling treatment
219079875|NCT04939129|DIAGNOSTIC_TEST|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
219079876|NCT02526264|OTHER|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
219079877|NCT05579353|OTHER|nothing|nothing
219079878|NCT03479372|DRUG|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
219079879|NCT05441072|DEVICE|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
219079880|NCT02243553|DRUG|Tipranavir capsule|
219079881|NCT02243553|DRUG|Tipranavir solution|
219079882|NCT02243553|DRUG|Ritonavir capsule|
219079883|NCT02243553|DRUG|Caffeine|
219079884|NCT02243553|DRUG|Warfarin sodium|
219079885|NCT02243553|DRUG|Vitamin K|
219079886|NCT02243553|DRUG|Omeprazole|
219079887|NCT02243553|DRUG|Dextromethorphan hydrobromide|
219079888|NCT02243553|DRUG|Midazolam injection|
219079889|NCT02243553|DRUG|Midazolam oral solution|
219079890|NCT02243553|DRUG|Digoxin tablet|
219079891|NCT02243553|DRUG|Digoxin injection|
219079892|NCT03343236|RADIATION|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
219079893|NCT01388816|DRUG|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
219210697|NCT02845596|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
219210698|NCT02845596|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
219079894|NCT04749719|DEVICE|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
219079895|NCT01915615|OTHER|None - this is an observational study|None - this is an observational study
219079896|NCT00001020|BIOLOGICAL|rgp120/HIV-1IIIB|
219079897|NCT00001020|BIOLOGICAL|rgp120/HIV-1MN|
219079898|NCT04789538|OTHER|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
219210699|NCT02845596|DRUG|methotrexate|methotrexate
219210700|NCT02845596|DRUG|fludarabine|fludarabine
219210701|NCT02845596|DRUG|cyclophosphamide|cyclophosphamide
219210702|NCT02845596|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
219210703|NCT02845596|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
219210704|NCT06212453|PROCEDURE|Targeted Microwave Ablation|3D ultrasound-guided focal thermal ablation of the prostate transition zone
219210705|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype AA|
219210706|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype BB|
219210707|NCT02377622|DEVICE|FX CorDiax 80 Dialyzer|
219210708|NCT02377622|DEVICE|FX CorDiax 800 Dialyzer|
219210709|NCT06811350|PROCEDURE|post-implementation cohort|Patients recieved a structured early mobilization pathway was introduced. The pathway included standardized assessments for patient stability and phased rehabilitation, progressing from passive to active mobilization.
219210710|NCT06812416|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+
219079899|NCT02257268|BEHAVIORAL|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
219210711|NCT06812416|DIETARY_SUPPLEMENT|Rice Flour Placebo|Rice Flour Placebo
219680418|NCT03869762|DRUG|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
219680419|NCT03869762|DRUG|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
219210712|NCT06810908|PROCEDURE|Internal fixation or bracing|Adult patients with humeral shaft fractures have been treated either with internal fixation or functional bracing according to the discretion of the treating surgeon.
219210713|NCT06873815|DRUG|Fluorescein Sodium|Patients will receive IV fluorescein sodium in the operating room before the vulvectomy procedure.
219210714|NCT06745570|BEHAVIORAL|Lifestyle Modification and Sleep Intervention|This study is being performed to develop, refine, and test the effects of a group lifestyle modification intervention augmented with a sleep intervention on weight loss, eating behaviors, and sleep outcomes. Results from this study will inform future studies to test the efficacy of this intervention. This intervention is being offered as part of a research study within Drexel University's WELL Center. Participants will receive remote, group-based, weekly weight loss and sleep coaching (90 minutes per coaching session) for 16 weeks.
219210715|NCT02848625|OTHER|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
219210716|NCT03907826|DRUG|PD-1 blocking antibody|Toripalimab 240mg, D1, every 3 weeks per cycle
219079900|NCT00743366|DRUG|Marijuana|0,6.2% THC
219079901|NCT00743366|DRUG|Quetiapine|200 mg/day
219079902|NCT00743366|DRUG|Placebo oral capsule|
219079903|NCT05946811|DRUG|Macitentan 10mg|Macitentan 10 mg oral once daily for 3 months. vs placebo
219210717|NCT03907826|DRUG|GP|Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
219210718|NCT03907826|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
219210719|NCT06045351|DRUG|Vitamin D|"Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day"
219210720|NCT06045351|OTHER|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued"
219210721|NCT05991908|DRUG|Fludarabine, busulfan and melphalan|FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
219210722|NCT05991908|DRUG|Fludarabine and Busulfan|FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
219210723|NCT03817229|BEHAVIORAL|Education microlearning sessions|mHealth education microlearning sessions
219210724|NCT03817229|BEHAVIORAL|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
219079904|NCT04884438|BEHAVIORAL|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~1. Psychoeducation about gratitude and its effects on health (both physical and psychological).~2. Gratitude towards life:~   1. Gratitude walk~  2. Three positive things~  3. Sharing gratitude~3. Social gratitude:~   1. Daily thanks to others~  2. Gratitude letter~  3. Proof of gratitude~4. Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~   1. Gratitude for the things I do to take care of my physical health.~  2. Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~  3. Gratitude for what I do to take care of others."
219079905|NCT03206203|DRUG|Atezolizumab|Given by vein
219079906|NCT03206203|DRUG|Carboplatin|Given by vein
219079907|NCT03206203|OTHER|Laboratory Biomarker|Correlative study
219079908|NCT03206203|OTHER|Quality-of-Life Assessment|Ancillary studies
219079909|NCT03548740|BIOLOGICAL|Human Papillomavirus|women with high-risk Human Papillomavirus or not
219079910|NCT02459873|BEHAVIORAL|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
219079911|NCT02478619|OTHER|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
219079912|NCT02478619|OTHER|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
219079913|NCT03006523|PROCEDURE|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
219079914|NCT00030719|BIOLOGICAL|filgrastim|
219079915|NCT00030719|BIOLOGICAL|monoclonal antibody Ch14.18|
219079916|NCT00030719|DRUG|busulfan|
219079917|NCT00030719|DRUG|carboplatin|
219079918|NCT00030719|DRUG|cyclophosphamide|
219079919|NCT00030719|DRUG|etoposide|
219079920|NCT00030719|DRUG|isotretinoin|
219079921|NCT00030719|DRUG|melphalan|
219079922|NCT00030719|DRUG|vincristine sulfate|
219079923|NCT00030719|PROCEDURE|bone marrow ablation with stem cell support|
219079924|NCT00030719|PROCEDURE|conventional surgery|
219079925|NCT00030719|PROCEDURE|peripheral blood stem cell transplantation|
219079926|NCT00030719|RADIATION|radiation therapy|
219680420|NCT02862938|DRUG|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
219079927|NCT04775680|BIOLOGICAL|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
219079928|NCT04775680|BIOLOGICAL|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
219079929|NCT03963726|RADIATION|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
219079930|NCT03963726|OTHER|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
219079931|NCT05686057|DEVICE|percutanous coronary angiography with stenting|Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
219079932|NCT05105295|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
219079933|NCT06187753|DIAGNOSTIC_TEST|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
219079934|NCT01107184|PROCEDURE|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
219079935|NCT01107184|PROCEDURE|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
219079936|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR and PVI|
219079937|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR|
219079938|NCT05888636|OTHER|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
219079939|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
219079940|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
219210725|NCT03817229|BEHAVIORAL|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
219680421|NCT02862938|OTHER|Sham|Sham surgery
219210726|NCT03817229|BEHAVIORAL|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
219210727|NCT03524092|DRUG|Mirikizumab SC|Administered SC
219210728|NCT03524092|DRUG|Mirikizumab IV|Administered IV
219680422|NCT04094779|OTHER|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
219680423|NCT04094779|OTHER|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
219079941|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
219079942|NCT01235208|OTHER|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
219079943|NCT02166008|DRUG|Repamipide|
219079944|NCT02166008|DRUG|Placebo|
219079945|NCT04973865|OTHER|Validation & reliability|Translated version of IPAQ(SF) validation \& Reliability
219079946|NCT01152580|DIETARY_SUPPLEMENT|melatonin|3mg p.o. at bedtime daily
219079947|NCT01152580|DIETARY_SUPPLEMENT|sugar pill|lactose p.o. at bedtime daily
219079948|NCT01437748|DRUG|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
219079949|NCT01437748|DRUG|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
219079950|NCT05594979|DIETARY_SUPPLEMENT|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
219079951|NCT03950765|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
219079952|NCT03424824|DRUG|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
219079953|NCT03424824|DRUG|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
219079954|NCT03424824|DRUG|Placebo|Tablet, once daily oral administration
219079955|NCT03424824|DRUG|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
219079956|NCT01570829|DRUG|Dietressa|Oral administration.
219210729|NCT03524092|DRUG|Placebo SC|Administered SC
219210730|NCT06770920|OTHER|use of an observer tool when not role-playing|Observers will use an observer tool (based on technical skills and specifically related to airway management during BLS) when they will be not role role-playing.
219210731|NCT06781671|BEHAVIORAL|ComfortTheory|"Structured nursing interventions based on the Comfort Theory were applied to patients in the intervention group.~Patients were mobilized at least once during the day. Auxiliary materials believed to increase patient comfort, such as tablet computers, wired headphones, sleep headphones, and sleep masks, were provided.~Patients had face-to-face meetings with their families during the day and video calls in the evening.~Care interventions were minimized as much as possible for patients between 24:00-07:00 at night, and treatments were carefully planned around these hours.~Blood sampling was performed at 23:00 at night, and X-rays were taken at 07:00 in the morning.~The Patient Identification Form, General Comfort Scale, and Intensive Care Unit Environmental Stressor Scale were administered face-to-face by the researcher 48 hours after the patient\&amp;amp;amp;#39;s admission to the intensive care unit."
219210732|NCT06678217|OTHER|Stroop task|The Stroop task will be used as a mild, acute stressor since it has effects on anxiety and autonomic response. In each Stroop task condition, four coloured visual stimuli will be presented on a computer screen for 3 s with 7 s inter-stimulus interval. The stimuli will be coloured words naming the colour of the ink in the nonconflict task condition (e.g. GREEN written in green ink) and a different colour in the conflict task condition (e.g. GREEN written in red ink). The participants were asked to name the colour of the stimuli. The test will be administered using the online version of PsyToolKit (Stoet, 2021).
219210733|NCT06678217|OTHER|Cold pressor test|The participant lowers their hand in icy water to induce temporary tonic pain
219079957|NCT01570829|DRUG|Placebo|Oral administration.
219680424|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
219079958|NCT02073396|DIAGNOSTIC_TEST|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
219079959|NCT05289726|DRUG|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
219079960|NCT05289726|DRUG|Placebo|he control group received placebo granules mixed with dextrin and food coloring
219079961|NCT00323596|BEHAVIORAL|physical activity program of strength and balance retraining|
219079962|NCT03364751|OTHER|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
219079963|NCT03364751|OTHER|Cigarette|Patients will continue to smoke cigarettes ad libitum.
219079964|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
219079965|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
219079966|NCT01475968|OTHER|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
219079967|NCT01475968|OTHER|Filtered Air|Filtered Air
219079968|NCT02496624|OTHER|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
219079969|NCT02636634|OTHER|imaging|
219079970|NCT00715546|PROCEDURE|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
219079971|NCT06449833|DRUG|Henagliflozein and Metformin|The experimental group will be treated with 10mg Henagliflozein and Metformin.
219079972|NCT06449833|DRUG|Linagliptin and Metformin|The control group will be treated with 5mg Linagliptin and Metformin.
219210734|NCT06339788|DRUG|HD-P023|Single dose administration of HD-P023
219079973|NCT00413387|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
219079974|NCT00413387|DRUG|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
219079975|NCT04468438|DIAGNOSTIC_TEST|serum estrogen and urinary albumin creatinine ratio|serum estrogen and urinary albumin creatinine ratio
219079976|NCT04396067|DRUG|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
219079977|NCT04396067|DRUG|Aerosolized All trans retinoic acid|The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
219079978|NCT04396067|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
219079979|NCT04654338|RADIATION|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
219079980|NCT02829853|GENETIC|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
219079981|NCT00362518|DIETARY_SUPPLEMENT|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
219079982|NCT00362518|DIETARY_SUPPLEMENT|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
219079983|NCT00362518|DIETARY_SUPPLEMENT|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
219079984|NCT00362518|DIETARY_SUPPLEMENT|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
219079985|NCT04067466|DIETARY_SUPPLEMENT|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
219079986|NCT04067466|DIETARY_SUPPLEMENT|Control product|Placebo product with maltodextrin and plum powder
219079987|NCT01964170|DRUG|degarelix|subcutaneous
219079988|NCT01964170|DRUG|Goserelin|subcutaneous
219210735|NCT06339788|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
219210736|NCT06339788|DRUG|Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
219210737|NCT06030635|DEVICE|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
219210738|NCT06813066|BEHAVIORAL|High Levels of Common Therapeutic Factors|The therapist large language model (LLM) is designed to show high levels of empathy, warmth, and genuineness. This setup aims to create a supportive and trusting therapeutic environment to improve patient engagement. High levels of these positive factors are linked to better psychotherapy outcomes and a stronger therapist-patient relationship.
219079989|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
219079990|NCT05371184|DRUG|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
219079991|NCT05371184|OTHER|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
219079992|NCT04270214|DRUG|Dysport Injectable Product|Dysport injections optimized using kinematics
219079993|NCT02557152|DEVICE|GentleWave System Treatment|
219079994|NCT03809481|DRUG|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
219079995|NCT03809481|DRUG|Argatroban|Synthetic direct thrombin inhibitor
219210739|NCT06813066|BEHAVIORAL|Low Levels of Common Therapeutic Factors|The therapist LLM for this group is designed to show low levels of empathy, warmth, and genuineness. This setup aims to examine how a less supportive and empathetic therapist affects psychotherapy sessions. Lower levels of these positive behaviors can lead to reduced patient engagement and a weaker therapist-patient relationship, potentially hindering therapy outcomes.
219210740|NCT06813066|BEHAVIORAL|Standard motivational interviewing|Motivational interviewing techniques as applied during the sessions on which the transcripts are based.
219210741|NCT06811766|OTHER|Strain-counterstrain|This is a technique that uses gentle body positioning passively to treat muscles and joints pain. So, this can be effective for neck pain in patients with CGH
219210742|NCT06811766|OTHER|Muscle energy techniques|This technique uses patient's own muscles to treat muscles and joint restrictions. So, this technique can be prove affective for neck pain and limited range in patients with CGH
219210743|NCT06812065|DRUG|Hydrogen Peroxide 3 % Topical Solution|"Dressing: Like the Local Hyperthermia Group, use a cotton ball soaked in 3% hydrogen peroxide.~Irradiation: For seven sessions in three weeks, use simulated infrared light (without heat) with the same frequency as the Local Hyperthermia Group.~Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
219210744|NCT06812065|DEVICE|Local Hyperthermia at 44℃|"(Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) An infrared hyperthermia device was used to apply local hyperthermia at 44°C to the largest wart. The device includes a heating source, an infrared temperature monitor, an adjusting arm, a control circuit for temperature stabilization, and a display. It uses a tungsten-halogen lamp (wavelength: 760-2300 nm, peak at 1200 nm) to maintain the temperature of a 0.5\*0.5 cm skin area within ±0.1°C using a non-contact infrared feedback system.Hyperthermia: Conduct 44-degree Celsius, 30-minute sessions. Do it daily for the first 3 days, then 2 sessions every 7 days for 3 weeks, for a total of 7 sessions.~Dressing: Apply a cotton ball soaked in 0.9% saline to the warts, wrap it with plastic film for 1 hour, and do this once a day for 6 weeks. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
219210745|NCT06657612|OTHER|No intervention|No intervention
219210746|NCT06813391|OTHER|Patient Reported Outcome (PRO)|after enrollment, patient will answer to several PRO to assess their pain and overall well-being after their stroke
219210747|NCT06806670|BEHAVIORAL|lifestyle intervention|exercise and dietary counselling
219210748|NCT06819644|DRUG|high flow oxygen therapy rate adjusted of lung volumes measured|Use of a technique based on non-contact measurement of lung volumes by depth camera in order to optimise the use of hihg flow oxygen therapy, with adaptation of the flow rate.
219210749|NCT04969146|BEHAVIORAL|Dyadic Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
219210750|NCT04969146|BEHAVIORAL|Patient Only Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
219210751|NCT06745336|DRUG|CS-001|CS-001 Topical Treatment
219210752|NCT06745336|DRUG|Placebo Topical Solution|Placebo Topical Solution
219079996|NCT03222648|OTHER|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
219079997|NCT03222648|OTHER|Usual Care|Continuation of usual care
219079998|NCT06141148|DIAGNOSTIC_TEST|sputum analysis|sputum analysis to diagnose tuberculosis
219079999|NCT06141148|DIAGNOSTIC_TEST|lymph node biobsy|to diagnose tuberculous lymphadenitis
219080000|NCT05717634|DIAGNOSTIC_TEST|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
219210753|NCT06891898|DEVICE|iLet Dosing Decision Software|Interoperable alternate glycemic controller
219210754|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146|BID for 36 weeks orally
219210755|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146 Placebo|BID for 36 weeks orally
219210756|NCT06761586|DRUG|AUR104|Once or twice a day
219210757|NCT06760559|PROCEDURE|Intra-articular corticosteroid injection|Intra-articular hip injections with and without local anastesia and questionnaire about pain and anxiety related to the procedure was administered before and after the injection to the study and control groups.
219210758|NCT06762093|PROCEDURE|surgical repaire|"* Primary closure of lacerations~* Eyelid margin repair~* Eyelid crease reconstruction~* Eyelid transposition flaps or grafts~* Tarsorrhaphy"
219210759|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)
219210760|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.
219360547|NCT01403337|OTHER|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP \> 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
219080001|NCT03215732|DIAGNOSTIC_TEST|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
219080002|NCT04299672|PROCEDURE|Postural reconstruction|Interventions are described in group descriptions
219080003|NCT01632605|DRUG|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
219680425|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
219680426|NCT00807612|DRUG|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
219680427|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
219680428|NCT00807612|DRUG|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
219680429|NCT05817188|OTHER|No intervention|No intervention was applied
219080004|NCT05755308|PROCEDURE|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
219080005|NCT05755308|PROCEDURE|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
219080006|NCT01625221|DEVICE|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
219080007|NCT04180618|OTHER|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
219080008|NCT06496633|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
219080009|NCT03541070|DEVICE|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
219080010|NCT05163366|DRUG|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
219080011|NCT05163366|DRUG|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
219080012|NCT00001587|PROCEDURE|Isolated hepatic portal and arterial perfusion|
219080013|NCT00001587|DRUG|Melphalan|
219080014|NCT06580236|DRUG|B11-FC|Infusion
219080015|NCT06580236|DRUG|Botulinum neurotoxin type A|Infusion
219080016|NCT06580236|OTHER|Placebo|Infusion
219080017|NCT01206998|DRUG|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
219080018|NCT01206998|DRUG|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
219080019|NCT02275065|DRUG|Bictegravir|Bictegravir tablet(s) administered orally once daily
219360548|NCT01403337|OTHER|Control|A Blood Pressure cuff inflated to 40-50 mmHg
219360549|NCT06304454|OTHER|Board game intervention|5 weeks / 2 sessions each week / 1 hour each session
219680430|NCT05819879|PROCEDURE|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
219080020|NCT02275065|DRUG|Placebo|Placebo to match bictegravir administered orally once daily
219080021|NCT01473667|PROCEDURE|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
219080022|NCT01473667|PROCEDURE|Local site infiltration|Local site infiltration using 2% lidocaine
219080023|NCT00599612|DRUG|GW856553|A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
219080024|NCT02219022|OTHER|Control group|
219080025|NCT02219022|OTHER|Experimental group|
219080026|NCT01981733|DEVICE|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
219080027|NCT04606355|DIAGNOSTIC_TEST|Visual Acuity|autostereoscopic, monocular dynamic force choice test
219080028|NCT04606355|DIAGNOSTIC_TEST|stereopsis|autostereoscopic dynamic forced-choice depth perception test
219080029|NCT04606355|DIAGNOSTIC_TEST|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
219080030|NCT06102265|PROCEDURE|sterilization|the use of sterilization methods and the reuse of gowns
219080031|NCT03015402|DRUG|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
219080032|NCT03015402|DRUG|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
219080033|NCT04775914|PROCEDURE|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
219080034|NCT04775914|PROCEDURE|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
219080035|NCT00312793|DEVICE|stimulation of the quadriceps muscle with Myospare|
219080036|NCT04169308|DRUG|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
219080037|NCT03213158|DRUG|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
219210761|NCT06773156|DRUG|Adebrelimab + Apatinib|"Adebrelimab: Administered by intravenous infusion at a fixed dose of 1200 mg. The infusion should be completed within 30-60 minutes, with a maximum duration of 2 hours. The first dose is given on Day 1, with subsequent doses repeated every 3 weeks. Dose adjustments (either up or down) are not allowed during the study. A maximum delay of 9 weeks for treatment is allowed, or treatment may be terminated.~Apatinib: 250 mg, taken orally after meals, once daily, continuously. The investigator may temporarily pause the dose or adjust the administration schedule based on symptomatic treatment, such as changing to an every-other-day (qod) schedule or a 5-day-on, 2-day-off regimen. Once toxicity resolves, treatment may resume at the original dose.~The combined treatment of Adebrelimab + Apatinib for consolidation therapy should not exceed 24 months in total."
219680431|NCT05819879|PROCEDURE|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
219680432|NCT01878695|DRUG|IV/oral n-acetylcysteine|
219680433|NCT05612217|OTHER|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
219680434|NCT06517745|PROCEDURE|Prone positioning|Prone positioning sessions: at least one session per day proning duration: 2 hours at least per session
219680435|NCT00225186|DRUG|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
219680436|NCT04227418|DEVICE|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
219680437|NCT04227418|DEVICE|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
219080038|NCT02335073|OTHER|Venous blood|
219080039|NCT04576468|PROCEDURE|Open flap debridement|Surgical intevention
219080040|NCT04576468|PROCEDURE|perforated membrane|surgical intervention
219080041|NCT04576468|PROCEDURE|leucocyte - platelet rich fibrin|surgical intervention
219080042|NCT00466518|DRUG|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
219080043|NCT01684748|DRUG|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
219080044|NCT00712361|DEVICE|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
219080045|NCT01995461|DRUG|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
219360550|NCT04741269|DIAGNOSTIC_TEST|Find a link between lack of knee flexion and meniscal posterior luxation fixed|"Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift."
219360551|NCT01767883|OTHER|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation~* Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
219680438|NCT04227418|DEVICE|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
219680439|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
219680440|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
219680441|NCT02258659|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219680442|NCT02258659|DRUG|carboplatin|Given IV
219680443|NCT02258659|RADIATION|radiation therapy|Undergo radiation therapy
219080046|NCT03434938|BEHAVIORAL|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
219080047|NCT04873648|BEHAVIORAL|caloric reduced -intermitted fasting diet|obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
219080048|NCT04873648|BEHAVIORAL|Daily calorie restriction|obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
219080049|NCT04873648|BEHAVIORAL|Control group|obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
219080050|NCT00134979|DRUG|Formoterol|
219080051|NCT05717556|PROCEDURE|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
219080052|NCT04763057|DRUG|NeoPUTTY MTA|NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
219080053|NCT04763057|DRUG|calcium hydroxide|Calcium hydroxide the gold standard for IPT
219080054|NCT03372200|DRUG|FYU-981|Oral daily dosing for 14 weeks
219080055|NCT03372200|DRUG|Febuxostat|Oral daily dosing for 14 weeks
219080056|NCT00202202|PROCEDURE|consultation format|
219080057|NCT00369330|DEVICE|external electrical cardioversion|
219080058|NCT01201057|DRUG|0.5% SPL7013 Gel|Vaginal gel
219080059|NCT01201057|DRUG|1.0% SPL7013 Gel|Vaginal gel
219080060|NCT01201057|DRUG|3.0% SPL7013 Gel|Vaginal gel
219080061|NCT01201057|OTHER|Placebo Gel|Vaginal gel
219080062|NCT03084666|DEVICE|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
219680444|NCT02258659|DRUG|paclitaxel|Given IV
219680445|NCT02258659|DRUG|fluorouracil|Given IV
219680446|NCT02258659|DRUG|hydroxyurea|Given PO
219680447|NCT02258659|DRUG|cisplatin|Given IV
219680448|NCT02258659|OTHER|laboratory biomarker analysis|Correlative studies
219680449|NCT02258659|PROCEDURE|quality-of-life assessment|Ancillary studies
219680450|NCT04437914|DIAGNOSTIC_TEST|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
219680451|NCT04892446|DRUG|Magrolimab|Administered IV
219680452|NCT04892446|DRUG|Daratumumab|Administered either SC or IV
219680453|NCT04892446|DRUG|Pomalidomide|Administered orally
219680454|NCT04892446|DRUG|Dexamethasone|Administered orally
219680455|NCT04892446|DRUG|Bortezomib|Administered either SC or IV
219080063|NCT04259086|DRUG|DaxibotulinumtoxinA for injection|Intramuscular injection
219080064|NCT05318794|DRUG|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
219210764|NCT06773104|PROCEDURE|immediate implant and grafting with autogenous tooth bone graft|"In autogenous tooth bone graft group:~Any restorations, caries, cementum, periodontal ligament and pulp tissue will be removed .The tooth will be grinded using dental bone mill and bone crusher Tooth particles will be sieved to particles size 300 to 1200 microns. The sorted particles will be immersed in 70 % ethanol and 5% Peracetic acid\* in a sterile container for 10 minutes to remove any soft tissue remnants, bacteria and smear layer (defatting and sterilization).~Tooth particles will be demineralized using 2% HNO3‡ for 20 minutes to expose the dentine organic matrix.~The bacteria-free particulate dentin will be washed with phosphate buffered saline‡ twice for 5 minutes to restore the PH balance to 7.4. In the same setting, after atraumatic extraction immediate implant will be inserted with graft"
219210765|NCT06773104|PROCEDURE|immediate implant with allogenic bone graft|after atraumatic extraction immediate implant will be inserted with allogenic bone graft
219360552|NCT01767883|OTHER|Clinical Decision Support Only|"* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms"
219360553|NCT02420873|DRUG|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
219360554|NCT03594890|BIOLOGICAL|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
219680456|NCT04892446|DRUG|Carfilzomib|Administered IV
219680457|NCT00272844|DRUG|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
219680458|NCT00096187|DRUG|pemetrexed disodium|
219080065|NCT05094531|OTHER|Primary prevention programm|This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).
219080066|NCT03240692|DEVICE|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
219080067|NCT02300220|DRUG|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
219680459|NCT05463588|OTHER|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
219080068|NCT02300220|DRUG|Placebo|One capsule, twice daily for 1 week
219080069|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
219080070|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
219680460|NCT01116752|OTHER|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
219680461|NCT05495386|DEVICE|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant."
219680462|NCT04783233|BIOLOGICAL|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
219680463|NCT04783233|BIOLOGICAL|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
219680464|NCT00718094|DRUG|Polyphenon E®|Oral capsules
219680465|NCT00718094|DRUG|Placebo Oral Tablet|Oral tablet: placebo
219680466|NCT00005032|BIOLOGICAL|oblimersen sodium|
219680467|NCT00005032|DRUG|paclitaxel|
219680468|NCT06218771|DRUG|TQB3454 Tablets|TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
219680469|NCT02983175|OTHER|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA."
219680470|NCT02954328|DEVICE|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
219680471|NCT01664702|DIETARY_SUPPLEMENT|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
219680472|NCT01664702|DIETARY_SUPPLEMENT|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
219680473|NCT05398796|BIOLOGICAL|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
219680474|NCT04953741|DRUG|Fluticasone propionate inhaled aerosol|The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
219680475|NCT03139136|DRUG|MBS2320|As described in the arm descriptions
219680476|NCT03139136|DRUG|Placebo|As described in the arm descriptions
219680477|NCT02090387|OTHER|ONS without AN777|2 servings a day
219080071|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
219080072|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
219080073|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
219080074|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
219680478|NCT02090387|OTHER|ONS containing AN777|2 servings a day
219680479|NCT00579332|DIETARY_SUPPLEMENT|brassica intervention|diet and phyto-chemical intervention
219680480|NCT00871364|DRUG|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
219680481|NCT00871364|DRUG|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
219680482|NCT06002659|BIOLOGICAL|CAR20(NAP)-T|Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
219680483|NCT06002659|DRUG|Cyclophosphamide|pre-conditioning chemotherapy
219080075|NCT01027000|BIOLOGICAL|rituximab|
219680484|NCT06002659|DRUG|Fludarabine|pre-conditioning chemotherapy
219080076|NCT01027000|DRUG|busulfan|
219080077|NCT01027000|DRUG|cyclophosphamide|
219080078|NCT01027000|DRUG|fludarabine phosphate|
219080079|NCT01027000|DRUG|methotrexate|
219080080|NCT01027000|DRUG|sirolimus|
219080081|NCT01027000|DRUG|tacrolimus|
219080082|NCT01027000|PROCEDURE|allogeneic stem cell transplant|
219080083|NCT03119467|DRUG|RP4010|Escalating doses starting at 25 mg
219080084|NCT01835951|OTHER|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
219080085|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
219080086|NCT00009828|DRUG|leucovorin calcium|
219080087|NCT00009828|DRUG|paclitaxel|
219080088|NCT00009828|DRUG|tegafur-uracil|
219080089|NCT00441090|DRUG|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
219080090|NCT00441090|DRUG|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
219210766|NCT06773585|DIAGNOSTIC_TEST|Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI|"This study is a minimal-risk study involving non-invasive, non-pharmacological interventions. Participants will continue receiving their usual medication or counseling treatments as part of their routine care during the study.~When participants come to the hospital for assessments, they will engage in clinical assessments and complete questionnaires over a period of 1-2 hours, undergo MRI scans, and participate in virtual environment-based behavioral assessments. They will have the option to take breaks during the assessments and can withdraw from the study at any time without providing a reason."
219210767|NCT06818786|OTHER|Branded pack with new PHWs covering 50% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 50% of the pack, without quitline information.
219210768|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, without quitline information.
219210769|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
219210770|NCT06818786|OTHER|Plain pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a plain cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
219210771|NCT06818786|OTHER|Branded pack with the current set of PHWs covering 50% of the pack without quitline information|Participants received and were required to view 6 images depicting a branded cigarette pack with a current set of 6 pictorial health warnings covering 50% of cigarette packs without quitline information (It is the current pictorial health warnings implemented in Vietnam)
219210772|NCT06772974|DRUG|Doxylamine Succinate USP|Tab. Doxylamine Succinate
219080091|NCT00410033|DRUG|soluble human insulin|
219080092|NCT00410033|DRUG|isophane human insulin|
219080093|NCT00410033|DRUG|insulin aspart|
219080094|NCT06170541|DEVICE|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
219080095|NCT06170541|DEVICE|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
219080096|NCT04389450|BIOLOGICAL|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
219080097|NCT04389450|BIOLOGICAL|Placebo|Placebo solution for injection
219080098|NCT06504615|DRUG|nivolumab + chemotherapy|As prescribed by the treating clinician, as per product label
219080099|NCT03085485|DRUG|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
219080100|NCT03085485|DRUG|Placebo|placebo pills
219080101|NCT03746366|RADIATION|[C-11]|Radiolabel
219210773|NCT06772974|DIETARY_SUPPLEMENT|Ginger|Ginger (zingiber officinale)
219080102|NCT03746366|DRUG|Pittsburgh Compound B|Tracer
219210774|NCT06779006|BEHAVIORAL|Self-help acceptance and commitment therapy with behavioral activation|Internet-based self-help acceptance and commitment therapy with behavioral activation
219210775|NCT06775392|DRUG|bromelain-quercetin gel|bromelain-quercetin gel is prepared from capsules in laboratory
219210776|NCT06775392|DRUG|chlorhexidine gel|chlorhexidine gel is prepared in laboratory
219210777|NCT06775392|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
219210778|NCT05972876|BEHAVIORAL|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
219210779|NCT05972876|BEHAVIORAL|Resistance training|Resistance training will be performed without any blood flow restriction
219210780|NCT06757725|DIAGNOSTIC_TEST|colour doppler of the renal artery and measurement of resistive index|using colour doppler to asses vascular resistance and resistive index
219210781|NCT05720507|BEHAVIORAL|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
219210782|NCT03834740|DRUG|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
219080103|NCT00605280|DRUG|Standard of Care|Clinicians decision to use optional laser therapy.
219080104|NCT00605280|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
219080105|NCT04986176|DRUG|HC-1119|oral
219080106|NCT04986176|DRUG|Placebo|oral
219080107|NCT06221566|OTHER|Muscle Energy Technique|"Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
219080108|NCT06221566|OTHER|Stretching Exercises|"Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
219080109|NCT04663048|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
219080110|NCT01710072|DRUG|aspirin|
219080111|NCT01662882|DRUG|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
219080112|NCT05729763|OTHER|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
219080113|NCT05729763|OTHER|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
219080114|NCT02466022|DRUG|Dexmedetomidine|Bolus dose prior to spinal anesthetic
219080115|NCT02466022|DRUG|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
219210783|NCT03834740|DRUG|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
219210784|NCT06781060|DEVICE|Faradic Nerve Stimulation Therapy+Standard Physiotherapy|This is electrical nerve stimulation with faradic type current to the injured nerve for conservative treatment of post injection sciatic nerve injury.
219210785|NCT06781060|DEVICE|Physiotherapy Standard Treatment with TENS machine therapy|The control group in which Standard Physiotherapy + TENS therapy will be provided to the participants.
219210786|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
219210787|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
219210788|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
219210789|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
219680485|NCT05376072|OTHER|Electromyographic Biofeedback|"The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial."
219680486|NCT02036684|BEHAVIORAL|Prehabilitation (PREHAB)|
219680487|NCT00560482|DRUG|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
219680488|NCT00560482|DRUG|Placebo|Identical appearing gelatin capsules containing placebo
219680489|NCT05265832|PROCEDURE|Phacoemulsification|Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
219680490|NCT06265909|DEVICE|AmDTx|AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
219680491|NCT02044562|DIETARY_SUPPLEMENT|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
219680492|NCT02044562|DIETARY_SUPPLEMENT|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
219680493|NCT00705341|DRUG|fluticasone|Inhaled corticosteroid approved for treatment of asthma
219680494|NCT03942887|DRUG|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
219680495|NCT03942887|DRUG|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
219680496|NCT03942887|DRUG|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
219080116|NCT02466022|DRUG|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
219080117|NCT02466022|DRUG|Fentanyl|Intrathecal Fentanyl 10ug
219080118|NCT02466022|DRUG|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
219210790|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
219210791|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
219210792|NCT06247124|BEHAVIORAL|multi-channel communication campaign to promote HPV vaccination|High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
219210793|NCT06846047|DEVICE|electrical vestibular stimulation (EVS)|EVS involves electrically activating the vestibular nerves by passing small electrical currents through electrodes placed on the mastoid processes (behind the ears) via battery powered, constant current isolated stimulators.
219210794|NCT06846047|DEVICE|Sham Comparator|No current is applied during EVS treatment
219210795|NCT06796270|RADIATION|Hypofractionated radiotherapy|The patients with nasopharyngeal carcinoma were given the dose of large segmentation radiotherapy, 2.64Gy/ time, 5 times/week, a total of 25 times, a total of 66Gy/5 weeks.
219360555|NCT03594890|BIOLOGICAL|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
219360556|NCT03594890|BIOLOGICAL|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
219360557|NCT03594890|BIOLOGICAL|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
219210796|NCT06741722|DRUG|Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF|"The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles."
219210797|NCT06817876|DEVICE|Care Buddy|Care Buddy mobile intervention will be a one-stop solution for caregivers of dementia patients and help them in their care-giving journey by providing them solutions to manage behavioural problems, physical conditions of their loved one. The app will be multi-component and will provide tools for the caregiver to manage their stress and burden. It will provide information on dementia, list of service providers, information on grief, financial support. This app will provide a platform for all enrolled caregivers to chat with each other and provide social support.
219210798|NCT06741748|OTHER|Direct Warming Method|This intervention involves thawing vitrified blastocysts using a simplified, one-step direct warming method. The blastocyst is placed in a pre-warmed embryo culture medium for approximately one minute, then transferred directly into the embryo culture medium within a time-lapse system until ready for uterine transfer. The total thawing process takes approximately three minutes, reducing the duration and complexity of the procedure compared to conventional methods.
219210799|NCT06741748|OTHER|Conventional Multi-step Thawing Method|This intervention involves thawing vitrified blastocysts using a standard, multi-step process. The procedure includes sequential exposure of the blastocyst to different thawing solutions containing varying concentrations of cryoprotectants, followed by its transfer into an embryo culture medium in a time-lapse system. The overall process takes approximately 10-30 minutes.
219210800|NCT06744023|OTHER|To examine the effect of the improved environment according to Watsons Human Care Theory on sleep quality, anxiety, and depression in patients undergoing open heart surgery.|"The patients who underwent open heart surgery and who were in the experimental group were admitted to the ward from the postoperative intensive care unit and the environment was improved for three days based on the improved environment of Watson's HCT, and on the morning of the fourth day in the clinic, the patients were interviewed face to face and the Personal Information Form, RSCQ and HAD Scale were completed. The following improvements were implemented within the scope of environmental improvement:~* Considering the seasonal conditions, the patient room was ensured to have appropriate temperature (18-26 °C) and humidity values (30-60%), and the temperature and humidity were gradually reduced and maintained in the appropriate range by monitoring at 21:00, 22:00, and 23:00 (Days 1, 2, and 3)~* In line with the environmental arrangements, the brightness of the light in the patient room was gradually reduced at 21:00, 22:00, and 23:00 using the Light Meter LM-3000 (Days 1, 2, and 3)"
219210801|NCT06760416|OTHER|Nursing Education|5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit
219210802|NCT05651594|PROCEDURE|Biopsy|Undergo tissue collection
219210803|NCT05651594|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219210804|NCT05651594|PROCEDURE|Computed Tomography|Undergo CT scans
219210805|NCT05651594|DRUG|Fluorouracil|Given IV
219080119|NCT04091139|BEHAVIORAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
219080120|NCT04091139|BEHAVIORAL|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
219080121|NCT01428648|BEHAVIORAL|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
219080122|NCT06360939|RADIATION|SBRT|Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
219080123|NCT06360939|PROCEDURE|CA|CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
219080124|NCT03417167|OTHER|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
219080125|NCT04866173|OTHER|Dog|Subjection to standardised stress situations in the presence of a dog and a person
219080126|NCT04866173|OTHER|No Dog|Subjection to standardised stress situations in the presence of a person
219080127|NCT00127244|PROCEDURE|Periodontal Treatment|
219080128|NCT03712644|DEVICE|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
219080129|NCT05243758|DEVICE|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
219210806|NCT05651594|DRUG|Leucovorin|Given IV
219080130|NCT05243758|DEVICE|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
219210807|NCT05651594|DRUG|Oxaliplatin|Given IV
219210808|NCT05651594|BIOLOGICAL|Pembrolizumab|Given IV
219210809|NCT05651594|DRUG|Propranolol Hydrochloride|Given PO
219210810|NCT05651594|OTHER|Questionnaire Administration|Perceived Stress Scale
219210811|NCT06772558|DRUG|Desflurane Inhalation|Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
219210812|NCT06772558|DEVICE|mechanical ventilation (MV)|Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
219210813|NCT06496724|BIOLOGICAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
219210814|NCT06850844|DEVICE|electrical impedance tomography|The individualized high PEEP with RMs group commences with a PEEP of 5 cm H2O and undergo an RM followed by a decremental PEEP trial. Pressure-controlled ventilation mode is set with a respiratory rate of 16 breaths per minute and ΔP=15 (ΔP is calculated by subtracting PEEP from the plateau pressure (Pplat). In intervals of 5 breaths, PEEP is incrementally increased by 5 cm H2O, starting at 5 cm H2O and reaching up to 20 cm H2O. The decremental PEEP trial is immediately performed following the first RM, beginning at a PEEP of 20 cm H2O with a respiratory rate of 15 breaths per minute. Every 30 seconds, PEEP is decreased by increments of 2 cm H2O until it reaches a minimum of 6 cm H2O. This decremental PEEP trial is succeeded by a second RM, after which the individualized PEEP level will be established as determined by the decremental PEEP trial and sustained until the completion of ventilation.
219210815|NCT06850844|DEVICE|Conventional Ventilation|Ventilation is set in volume-controlled mode with a tidal volume of 7 ml/kg predicted body weight (PBW), the respiratory rate is adjusted to target normocapnia (end-tidal carbon dioxide partial pressure between 35 and 45 mmH), an inspiratory to expiratory ratio of 1:2, and a PEEP of 5 cmH2O.
219210816|NCT06640868|BEHAVIORAL|MyChart nurse message|Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination
219210817|NCT06640868|BEHAVIORAL|SMFM video|Receipt of SMFM video around 34 weeks encouraging RSV vaccination
219210818|NCT06640868|BEHAVIORAL|Visual aid|Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
219210819|NCT06853873|BEHAVIORAL|The Counselling for Alcohol Problems in Pregnancy (CAP-Pre) intervention|"Five structured 60-minute counseling sessions (weekly, CHW-delivered).~Key components:~Motivational interviewing (MI) to enhance behavior change. Cognitive-behavioral strategies (CBT) for managing alcohol cravings. Goal-setting and self-monitoring for tracking progress. Problem-solving techniques and social support enhancement."
219080131|NCT05243758|DEVICE|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
219080132|NCT05243758|DEVICE|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH \&Co. KG, Tuttlingen, Germany)
219080133|NCT05050201|DEVICE|Sleepio|Digital CBT application for insomnia
219080134|NCT02119351|DEVICE|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
219210820|NCT06810661|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females with cardiovascular disease.
219210821|NCT06744348|PROCEDURE|ENTİRE PAPİLLA PRESERVATİON|"The EPP technique is a tunnel-like approach of the defect-associated inter-dental papilla. Surgical loupes (3.3× magnification) with LED light illumination were used to increase visibility of the surgical site. Following a buccal intra-crevicular incision, a bevelled vertical releasing incision was performed in the buccal gingiva of the neighbouring inter-dental space and extended just beyond the mucogingival line to provide appropriate mechanical access to the intrabony defect."
219210822|NCT06892145|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
219210823|NCT06761326|PROCEDURE|Ultrasound guided right infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
219360558|NCT01407783|BEHAVIORAL|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
219360559|NCT06296732|PROCEDURE|Duration of surgery intervention|Intraoperative- duration from the beginning of the skin incision to skin suture (min)
219360560|NCT02841371|RADIATION|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
219080135|NCT02119351|DEVICE|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
219210824|NCT06761326|PROCEDURE|Ultrasound guided left infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
219210825|NCT04643574|BIOLOGICAL|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
219210826|NCT04643574|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219210827|NCT04643574|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219210828|NCT04643574|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
219080136|NCT04010994|PROCEDURE|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
219080137|NCT01662310|DRUG|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
219080138|NCT01662310|DRUG|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
219080139|NCT03577210|PROCEDURE|augmentation genioplasty|augmentation genioplasty with patient-specific PEEK implant
219080140|NCT03088826|DRUG|Morphine Sulfate|15mg PO morphine sulfate
219080141|NCT03088826|DRUG|Oxycodone|10mg Oxycodone
219080142|NCT03088826|DRUG|Acetaminophen|650 mg Acetaminophen
219080143|NCT03051503|DRUG|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
219080144|NCT03051503|DEVICE|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
219080145|NCT02462707|DRUG|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
219080146|NCT05085587|DRUG|Test|2 inhalations of Test and Reference product in each study period
219080147|NCT05085587|DRUG|Reference|2 inhalations of Test and Reference product in each study period
219080148|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
219080149|NCT00683826|OTHER|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
219080150|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
219080151|NCT01619202|BEHAVIORAL|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
219080152|NCT00994838|OTHER|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
219080153|NCT03282318|DRUG|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
219080154|NCT03282318|DRUG|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
219080155|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
219080156|NCT01825213|DEVICE|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
219080157|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
219080158|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
219210829|NCT04643574|RADIATION|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
219360561|NCT05467722|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
219360562|NCT05223361|DRUG|Six percent hydroxy ethyl starch 130/0.4|6% HES 130/0.4 additive to ringer lactate as prime solution
219210830|NCT06752148|COMBINATION_PRODUCT|neurofeedback intervention training game|"1. Issuance of training equipment and training in its use: For subjects randomly assigned to the intervention group, a volunteer who has received adequate training in the use of the equipment will issue the EEG monitoring electrodes (model: HXD-1) and paired PADs, and will provide an activated account for the use of the subject only and training in its use. Subjects will be provided with a short tutorial on how to use the APP, which is very user-friendly and suitable for elderly novices. An initial training session will consist of 3 training components and will be completed with a volunteer.~2. Training programme and supervision: The closed-loop neurofeedback training will consist of 3 parts, namely Digital Meditation, Brain Training and Sleep Induction. The brain training will consist of three games: Idea Chase, Idea Magic Ball and Focused Archery. The control subjects lived a normal life before the surgery, and all subjects underwent the surgery as planned."
219210831|NCT06812208|BEHAVIORAL|Teleultrasound with Philips Lumify ultrasound probes and Reacts software|"Clinicians at hospitals randomized to Arm 1 will be provided with Reacts licenses and trained to use Reacts with Philips Lumify devices immediately following the baseline training. Each hospital will be assigned to 2-3 radiologist supervisors (typically 1 Rwandan, 1 U.S.-based), with at least one available on each designated U/S clinic day to provide real-time teleultrasound mentorship. Clinician trainees scan the breast, document their independent findings and management plan in the study REDCap database, and then call the supervisor using Reacts. Reacts permits supervisor and trainee to see each other virtually; the supervisor can also view live U/S images and the trainee's probe and hand position to provide real-time feedback."
219360563|NCT05223361|DRUG|Ringer lactate|Ringer lactate as prime solution
219680497|NCT03942887|DRUG|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
219080159|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
219080160|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
219080161|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
219080162|NCT06543446|PROCEDURE|ICD implantation|Surgical implant of ICD device
219080163|NCT06134349|OTHER|Lithium MR imaging|After obtaining written informed consent and within four weeks of reaching a stable therapeutic serum lithium concentration, lithium MR imaging will be performed using a 7 Tesla MR system (Achieva, Philips Medical Systems, Eindhoven, The Netherlands) with a dual-tuned 7Li/1H volume head coil (RAPID Biomedical GmbH, Rimpar, Germany). Various approaches, including whole-brain, voxel-wise, parcellation, mean, and regions of interest, will be applied to measure lithium concentrations.
219080164|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
219080165|NCT06052410|OTHER|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
219080166|NCT06052410|OTHER|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
219080167|NCT05101239|DEVICE|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
219080168|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
219080169|NCT06534567|OTHER|Physical activity|Physical activity level
219080170|NCT02342067|DRUG|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
219080171|NCT02342067|DRUG|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
219080172|NCT06239168|DIETARY_SUPPLEMENT|Citrus extract|As described in experimental arm
219080173|NCT06239168|DIETARY_SUPPLEMENT|Maltodextrin|As described in comparator arm
219080174|NCT04365660|DRUG|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
219080175|NCT00297752|DRUG|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
219080176|NCT00297752|DRUG|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
219080177|NCT04259268|OTHER|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
219080178|NCT04259268|OTHER|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
219080179|NCT00497302|BEHAVIORAL|RBT|Contingency management and behavioral counseling including motivational interviewing
219080180|NCT00497302|BEHAVIORAL|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
219080181|NCT00734227|PROCEDURE|Emergency portacaval shunt|
219080182|NCT00734227|OTHER|Emergency TIPS|
219080183|NCT01765634|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.
219210832|NCT06812208|BEHAVIORAL|Asynchronous virtual feedback|Clinicians at Arm 2 hospitals will save static images, with or without video at clinicians' discretion, onto the Philips Lumify tablets. These will be uploaded to a secure internet-based folder with case descriptions, and assigned U.S.- and Rwanda-based experts will be notified that images are available. Experts will review images within 24 hours and email feedback to trainees on imaging quality/ technique and management; trainees can also email questions.
219210833|NCT06811051|BIOLOGICAL|Menthol lozenge|Patients in the menthol group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
219210834|NCT06811051|BIOLOGICAL|Clove lozenge|Patients in the clove group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
219080184|NCT01765634|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
219080185|NCT03013114|DRUG|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
219080186|NCT01811550|OTHER|Glycemic Control|
219080187|NCT04302350|PROCEDURE|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
219080188|NCT00048516|DRUG|paricalcitol capsule|
219360564|NCT05789017|DRUG|Prednisone and Mycophenolate Mofetil|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.
219360565|NCT05789017|DRUG|Mycophenolate Mofetil|Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
219680498|NCT04569604|DIAGNOSTIC_TEST|MRI scans|Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
219680499|NCT04569604|DIAGNOSTIC_TEST|Neuro cognitive tests|Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
219680500|NCT04569604|DIAGNOSTIC_TEST|Questionnaires on Quality of Life|SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
219680501|NCT04569604|DIAGNOSTIC_TEST|Blood samples|Markers of calcium homeostasis, inflammatory markers and hematology.
219680502|NCT04569604|DIAGNOSTIC_TEST|24 hr urine samples|24 hr urine content of calcium, phosphate, magnesium, and creatinine.
219680503|NCT03070275|BIOLOGICAL|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
219680504|NCT03070275|PROCEDURE|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
219680505|NCT00005083|PROCEDURE|conventional surgery|
219680506|NCT00005083|PROCEDURE|magnetic resonance imaging|
219080189|NCT03024073|PROCEDURE|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
219080190|NCT02118220|OTHER|Concussion Questionnaire|
219080191|NCT02768896|BEHAVIORAL|Baseline|Patients will walk naturally with EEG measuring brain waves
219080192|NCT02768896|BEHAVIORAL|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
219080193|NCT02768896|BEHAVIORAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
219080194|NCT02768896|BEHAVIORAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
219080195|NCT04994457|DEVICE|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
219080196|NCT04994457|DIAGNOSTIC_TEST|Standard Automated Perimetry|Standard of care perimeter
219680507|NCT00005083|PROCEDURE|magnetic resonance spectroscopic imaging|
219680508|NCT00845273|DRUG|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
219080197|NCT04659655|PROCEDURE|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
219080198|NCT03584451|BEHAVIORAL|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
219080199|NCT00149058|DRUG|Erythropoietin|
219080200|NCT03306212|DRUG|Botulinum toxin A|
219080201|NCT03306212|OTHER|Occupational Therapy|
219080202|NCT03306212|OTHER|Intermittent serial casting|
219080203|NCT04464928|OTHER|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
219210835|NCT06811051|OTHER|None-placebo|Before routine clinical procedures after surgery, the patients in the control group will fill out the Patient introduction form, Patient follow-up form, and Numerical pain scale. After 60 minutes after extubation; clinical procedures do not include any procedures or interventions and the patient follow-up form and Numerical pain scale will be evaluated. After 120 minutes after extubation; the patient follow-up form and numerical pain scale will be evaluated.
219210836|NCT06753812|OTHER|constraint induced movement therapy|Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.
219680509|NCT02412397|PROCEDURE|Total Shoulder Arthroplasty|
219210837|NCT06753812|OTHER|Control (Standard treatment)|Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.
219210838|NCT06812351|DRUG|Osteon III collagen|Hydroxyapatite and tricalcium phosphate particles embeded in bovine collagen
219210839|NCT06812351|BIOLOGICAL|Blood clot|Induction of bleeding from apical papilla
219210840|NCT06819800|OTHER|Transparent Waterproof Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Ulcer Risk Assessment Scale' were applied to the patients in the transparent waterproof flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a transparent waterproof flaster was applied. The transparent waterproof flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
219210841|NCT06819800|OTHER|Medical Silk Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were applied to the patients in the medical silk flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a medical silk flaster was applied. The medical silk flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
219360566|NCT05789017|DRUG|Leflunomide|Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
219080204|NCT04464928|OTHER|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
219360567|NCT00023387|DRUG|Rifapentine|
219360568|NCT00023387|DRUG|25-desacetyl Rifapentine|
219360569|NCT00023387|DRUG|Isoniazid|
219360570|NCT04751162|DEVICE|Actigraphy device (wearable) and mobile application|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
219680510|NCT05783947|DIAGNOSTIC_TEST|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
219680511|NCT00791700|DRUG|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
219080205|NCT03694639|OTHER|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
219080206|NCT05175755|OTHER|Patients|The procedure involves taking a total of 12 ml of blood.
219080207|NCT00313404|BIOLOGICAL|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
219080208|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
219080209|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
219080210|NCT00435604|DRUG|Hylenex|
219080211|NCT03487250|DEVICE|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
219080212|NCT03516331|DRUG|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
219080213|NCT04408573|OTHER|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
219080214|NCT03524040|DEVICE|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
219080215|NCT06085248|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
219080216|NCT06085248|BEHAVIORAL|Active walking|walking without RAS cue
219080217|NCT04074980|DIAGNOSTIC_TEST|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
219080218|NCT04074980|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to collect blood samples from subjects
219210842|NCT06819800|OTHER|Elastic Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were administered to the patients in the control group, which was in the elastic flaster group. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, an elastic flaster was applied. The elastic flaster was prepared using the preparation of the nose by the pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
219210843|NCT06809738|PROCEDURE|reconstructive technique|"1. Analysis and limitation of the tissue injury. Bilateral testicular and spermatic cord dissection.~2. Formation of cutaneous flaps and bilateral inguinal neocavity.~3. Perineal-scrotal reconstruction with fascial facing and cutaneous flaps"
219680512|NCT06494592|BEHAVIORAL|Aerobic Exercise|Participants in the aerobic exercise intervention group will engage in a virtual aerobic exercise intervention three times a week for 12 weeks for a 30-minute session (5 minute warm up, 20 minutes of aerobic exercise, 5 minutes cooldown) and will receive information about the session prior to their appointment. Sessions have a goal of reaching at least 20 minutes of supervised exercise performed at 80% of the heart rate at symptom threshold.
219680513|NCT06494592|BEHAVIORAL|Balance Exercise|Participants in the balance exercise intervention group will participate in a staff-led virtual session three times a week for 12 weeks for a 30-minute session and will receive information about the session prior to their appointment. This group will focus on improving balance, with some additional work on flexibility and strength.
219680514|NCT05007626|OTHER|axial length and refractive error|Comparing the correlation between heterophoria and refraction, even after age adjustment.
219680515|NCT05024656|OTHER|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
219080219|NCT03234426|OTHER|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
219080220|NCT03234426|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
219080221|NCT05153980|DEVICE|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
219080222|NCT05153980|OTHER|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
219080223|NCT00374322|DRUG|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
219080224|NCT00374322|OTHER|placebo|6 tablets daily for 12 months
219080225|NCT00364429|DRUG|[123]I-CNS 1261|Study Drug
219080226|NCT00364429|DRUG|Lorazepam|Study Drug
219080227|NCT00364429|DRUG|Risperidone|Study Drug
219080228|NCT02012491|DRUG|Misoprostol|
219080229|NCT02012491|DRUG|Mifepristone|
219080230|NCT03278418|PROCEDURE|Tricuspid Valve Repair|It will be performed according to the surgeon preference
219080231|NCT03278418|PROCEDURE|Left-sided valve surgery|It will be performed according to the surgeon preference
219080232|NCT00450411|RADIATION|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
219080233|NCT00450411|RADIATION|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
219080234|NCT03283904|OTHER|Multicomponent physical activity intervention|School-based multicomponent intervention
219080235|NCT06447857|OTHER|Cardiac MRI|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
219080236|NCT00688818|DRUG|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
219080237|NCT00688818|DRUG|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
219080238|NCT00912548|DRUG|goserelin|"1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
219080239|NCT00912548|DRUG|tamoxifen|"1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
219080240|NCT03249519|RADIATION|Radiation|50.4 Gy
219080241|NCT03249519|RADIATION|brachytherapy|35-40 Gy
219080242|NCT03249519|DRUG|Cisplatin|weekly 40 mg/m\^2 (6cycles)
219080243|NCT03249519|OTHER|Hyperthermia|10 times
219080244|NCT02430194|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
219080245|NCT02430194|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
219080246|NCT02430194|DRUG|Pegylated interferon-alfa-2a|immunomodulator
219080247|NCT03298646|DRUG|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
219080248|NCT03298646|DRUG|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
219080249|NCT03105310|DRUG|Pegylated interferon alfa|Pegylated interferon alfa
219080250|NCT03105310|DRUG|Ezetimibe|Ezetimibe
219080251|NCT06059495|DRUG|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
219080252|NCT01188434|BEHAVIORAL|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
219080253|NCT01188434|BEHAVIORAL|Services as Usual|Services as usual referred by child welfare
219080254|NCT03969719|DRUG|Placebo|Placebo
219680516|NCT05024656|OTHER|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
219680517|NCT01472822|DIETARY_SUPPLEMENT|Omija extract.|Omija extract 1.2g/day for 12weeks
219680518|NCT01472822|DIETARY_SUPPLEMENT|Placebo|Placebo 1.2g/day for 12weeks
219680519|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
219680520|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
219680521|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
219680522|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
219680523|NCT04873635|OTHER|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
219680524|NCT01720524|DRUG|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
219680525|NCT01720524|DRUG|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
219080255|NCT03969719|DRUG|PF-06835919|150 mg once daily
219080256|NCT03969719|DRUG|PF-06835919|300 mg once daily
219080257|NCT04750746|OTHER|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
219080258|NCT04750746|OTHER|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
219080259|NCT05188001|OTHER|Not an Interventional Study|Not an interventional Study
219080260|NCT04184791|DEVICE|Deep Brain Stimulation|Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
219080261|NCT04847869|DEVICE|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
219080262|NCT05918926|BEHAVIORAL|Exercise|Individualised remote exercise intervention
219080263|NCT00726726|DRUG|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
219080264|NCT00726726|DRUG|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
219080265|NCT00726726|DRUG|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
219080266|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
219080267|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
219680526|NCT02493452|DRUG|Plecanatide|
219680527|NCT02493452|DRUG|Placebo|
219680528|NCT02332941|DRUG|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
219680529|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
219680530|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
219680531|NCT03628378|DEVICE|Verasense|Ligamentous balancing device
219680532|NCT00182741|DIETARY_SUPPLEMENT|calcitriol|
219680533|NCT00182741|DRUG|mitoxantrone hydrochloride|
219680534|NCT00182741|DRUG|prednisone|
219210844|NCT04855370|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
219210845|NCT06824714|DRUG|glucocorticoid, immunosuppressants, targeted therapy|Drug intervention protocol will be determined by clinicians
219210846|NCT06819046|DRUG|Rocklatan|netarsudil and latanoprost ophthalmic solution 0.02%/0.005%
219210847|NCT06819046|DRUG|Systane Ultra|artificial tears
219210848|NCT06818110|OTHER|Exercise|The supervised exercise-training sessions will last \<1 hour, and exercise-training intensities will be individually tailored to each participant using the results from their CPET. Participants will be screened prior to each session to ensure that it is safe to perform exercise. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high-intensity (50%∆) for a predetermined amount of time. Five minutes of freewheel cycling will be performed at the start and end of the protocol for a warm-up and cool-down. Exercise sessions can be terminated by the participant at any time. Participants will have continuous ECG and SpO2 monitoring throughout the training session. Vital signs will be taken before (some during) and after each training session.
219210849|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
219210850|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle"
219210851|NCT06768814|BEHAVIORAL|Sub-acute stabilization|The sub-acute stabilization center (SASC) is for people who have had or are at risk for having an opioid overdose and have an encounter with Seattle Fire Department emergency medical services (EMS) in Seattle, WA. Those transported to the SASC are the intervention participants and two comparison groups will be utilized: eligible Seattle EMS patients who opt not to go to the SASC and King County residents, outside of Seattle, who meet the same eligibility criteria. A comparative interrupted time series analysis is planned to study the main effectiveness outcomes. Seattle Fire EMS will assess, refer, and arrange transport participants to the SASC. The SASC will offer an array of services including post-overdose monitoring, utilization of buprenorphine and methadone for the treatment opioid use disorder and opioid withdrawal, linkage to ongoing care for OUD, and provision of harm reduction services and supplies. The length of stay in the SASC will be limited to less than 24 hours.
219210852|NCT06769295|DRUG|AK112|non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
219210853|NCT06782555|DRUG|Evofosfamide|Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
219210854|NCT06782555|DRUG|Zalifrelimab|Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
219210855|NCT06782555|DRUG|Balstilimab|Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
219680535|NCT04769232|DEVICE|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
219680536|NCT02383901|DRUG|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
219680537|NCT02105285|DRUG|OPC-1085EL ophthalmic solution|
219680538|NCT02105285|DRUG|Carteolol long-acting ophthalmic solution|
219680539|NCT01779063|BEHAVIORAL|web based multimedia intervention|cognitive therapy based web intervention
219680540|NCT01779063|OTHER|educational booklet|patient education booklet
219680541|NCT06152380|OTHER|Knee Care @Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
219680542|NCT04716374|OTHER|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
219680543|NCT01421641|DRUG|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
219680544|NCT01421641|DRUG|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
219210856|NCT04028973|OTHER|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
219080268|NCT01639885|BIOLOGICAL|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
219080269|NCT03580733|DRUG|caspofungin antifungal therapy|caspofungin
219080270|NCT03580733|OTHER|placebo|placebo
219080271|NCT02058615|BEHAVIORAL|Male Spouse Transition Toolkit|
219080272|NCT02644187|DEVICE|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
219080273|NCT02644187|DEVICE|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
219080274|NCT02644187|DRUG|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
219080275|NCT04999813|COMBINATION_PRODUCT|Comprehensive intensive intervention|"* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance."
219210857|NCT04028973|OTHER|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
219210858|NCT06767904|DEVICE|Continous Oxygen by Bottles|Oxygen delivery by bottles giving a continous flow.
219210859|NCT06767904|DEVICE|Demand oxygen by Portable Concentrator|Oxygen delivery by consentrators, giving oxygen only when inhaling.
219080276|NCT03686046|OTHER|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
219210860|NCT06793501|OTHER|Reablement intervention|Reablement's implementation in this study is characterized by a comprehensive assessment of the older person's everyday activities, both current and past. This is done through a person-centered interview using the Canadian Occupational Performance Measure (COPM). The COPM is based on the assumptions described in the theoretical framework of CMOP-E. Based on the assessment, the older adult selects a personal activity goal, which consists of an activity they consider meaningful and wish to improve. In collaboration with the older adult and staff, a goal-oriented support plan, also referred to as a training program, is developed to achieve the goal. Nursing assistant staff support the older persons in performing defined training activities and receive supervision from rehabilitation staff. The support plan and progress toward the activity goal are evaluated through regular reassessments during a fixed intervention period of eight weeks.
219210861|NCT06793501|OTHER|Control group|TAU includes a general approach where all activities that the older adult engages in during everyday life are considered rehabilitative. The staff are encouraged to motivate the older adult to do as much as possible independently, in order to prevent loss of function and maintain the ability to perform activities. The approach does not involve any direction toward specific activities where there is a rehabilitative need. It does not include any formulated goals or follow-up. Additionally, there is no specific education offered to the nursing assistants on how to encourage the older adult or how to follow-up up on the extent to which the approach is applied.
219210862|NCT06719544|DRUG|lithium carbonate|Oral capsule
219680545|NCT01881607|BEHAVIORAL|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
219210863|NCT06719544|DRUG|enlicitide|Oral tablet
219210864|NCT06359782|DRUG|C1 Esterase Inhibitor Injection [Cinryze]|C1 Esterase Inhibitor Injection \[Cinryze\]
219080277|NCT01417026|DRUG|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
219080278|NCT01190592|OTHER|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
219080279|NCT04674124|BEHAVIORAL|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
219210865|NCT06359782|DRUG|Placebo|Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
219080280|NCT02130193|DRUG|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
219680546|NCT05221697|DEVICE|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
219080281|NCT02130193|DRUG|Placebo|Subjects will receive danirixin matching placebo
219080282|NCT01918735|DRUG|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
219080283|NCT01918735|DRUG|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
219080284|NCT01421576|DIETARY_SUPPLEMENT|High fat meal|offer high fat-meal in the morning before drug intake.
219080285|NCT01297959|DRUG|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
219080286|NCT01297959|DRUG|Saline solution|Saline solution matched to E-101
219080287|NCT02127424|PROCEDURE|Nurse-driven HIV targeted screening|
219080288|NCT02127424|PROCEDURE|Current practice|
219080289|NCT01667432|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
219080290|NCT02464189|OTHER|Q-Kap|
219080291|NCT02077166|DRUG|Ibrutinib|
219080292|NCT02077166|DRUG|Lenalidomide|
219080293|NCT02077166|DRUG|Rituximab|
219080294|NCT00707031|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219080295|NCT00707031|DEVICE|Pen auto-injector|
219080296|NCT00707031|DRUG|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
219080297|NCT00707031|DEVICE|Prefilled pen injector|
219080298|NCT00707031|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
219080299|NCT01821261|DEVICE|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
219080300|NCT01821261|DRUG|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
219080301|NCT01821261|DRUG|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
219680547|NCT00883415|DRUG|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
219680548|NCT04002726|OTHER|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
219680549|NCT04530929|DIETARY_SUPPLEMENT|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
219680550|NCT04530929|DIETARY_SUPPLEMENT|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
219080302|NCT00815282|OTHER|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
219080303|NCT02568748|BIOLOGICAL|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
219080304|NCT02568748|PROCEDURE|TACE|Trans-arterial chemoembolization
219080305|NCT01299948|DRUG|Prednisolone|5 mg prednisolone orally per day
219080306|NCT04567108|BEHAVIORAL|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
219080307|NCT04567108|BEHAVIORAL|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
219080308|NCT04567108|BEHAVIORAL|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
219080309|NCT04567108|BEHAVIORAL|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
219080310|NCT03502382|DIAGNOSTIC_TEST|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
219080311|NCT02479230|BIOLOGICAL|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
219080312|NCT02479230|DRUG|gemcitabine hydrochloride|Given IV
219080313|NCT01779726|RADIATION|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
219080314|NCT01779726|RADIATION|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
219080315|NCT01735890|DRUG|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
219080316|NCT04133727|BEHAVIORAL|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
219080317|NCT04133727|OTHER|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
219210866|NCT06259929|DRUG|Abemaciclib 150 MG + Giredestrant 30 MG|Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
219210867|NCT04299191|DRUG|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
219210868|NCT06835660|DEVICE|procedure of DCB implantation|Patients assigned to the DCB group (study group) will receive DCB inflation(s) at the level of the lesions according the DCB instructions for use (120 seconds inflation minimum). One or several DCBs will be inflated at the level of the lesions depending on lesions' lengths. The DCB diameter(s) will be the one(s) of the index diameter of the artery. Overlaps between zones that will receive DCB inflations will be of 10 mm to avoid any geographic miss.
219210869|NCT06835660|DEVICE|procedure of SEDES implantation|"SEDES implantation wille be performed according to the SEDES instructions for use. Stent(s) oversizing will be of 1 mm maximum. Overlaps between stents will be of 10 mm.~Completion angiogram will assess the technical success of the procedure (see endpoints definitions). The physician may then decide to add a bailout SEBMS because of flow limiting dissection and/or a new stenosis \>30%."
219210870|NCT06796933|OTHER|Silicon based products (silicon gel)|The participants will be treated with cosmetic creams such as Silicone-based products (silicone gels twice a day) for one month.
219210871|NCT06796933|DEVICE|Bioptron (polarized light therapy)|The participants will be treated by polarized light therapy (Bioptron) for 15 minutes, 3 sessions per week, for one month.
219210872|NCT06844981|BEHAVIORAL|Latin Dance|Latin Dance intervention
219210873|NCT06845709|OTHER|gaze stabilization exercise|Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment
219210874|NCT06845709|OTHER|otago exercise|group B patients will receive Otago Exercises with conventional baseline treatment
219210875|NCT06845085|PROCEDURE|Intervention|pulmonary vein re-isolation plus Vein of Marshall ethanol ablation in combination with block of mitral and tricuspid isthmuses and dome line
219210876|NCT06845085|PROCEDURE|Control|pulmonary vein re-isolation
219210877|NCT06845267|BEHAVIORAL|Chronotherapy|This study utilize and test different combinations of three types of interventions (zeitgebers) to entrain the circadian rhythm: 1) Light being the primary photic zeitgebers that directly entrain the SCN, 2) physical activity and 3) timing of eating) being non-photic zeitgebers that drive peripheral rhythms.
219210878|NCT06845267|BEHAVIORAL|Control|Control condition
219210879|NCT06815562|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth.
219210880|NCT01001364|DRUG|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
219680551|NCT04691219|DIETARY_SUPPLEMENT|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
219080318|NCT03372122|DRUG|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
219080319|NCT03372122|COMBINATION_PRODUCT|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
219080320|NCT02813070|DRUG|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
219080321|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo lower dose platelet transfusion
219080322|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo higher dose platelet transfusion
219080323|NCT01284465|BEHAVIORAL|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
219080324|NCT01284465|BEHAVIORAL|Control group|Group education sessions at baseline, 3 and 6 months
219680552|NCT04691219|BEHAVIORAL|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
219680553|NCT01945346|DRUG|PRX167700|Oral capsule
219680554|NCT01945346|DRUG|Placebo|Oral capsule
219680555|NCT01057667|DRUG|RO5024048|1000mg bid po, 24 weeks
219680556|NCT01057667|DRUG|Ribavirin [Copegus]|1000mg or 1200mg po daily
219080325|NCT03710915|DRUG|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
219080326|NCT05411458|OTHER|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
219680557|NCT01057667|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
219080327|NCT06021717|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
219080328|NCT06021717|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
219080329|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
219080330|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
219080331|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
219080332|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
219080333|NCT03375944|OTHER|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
219080334|NCT00428350|DRUG|Quetiapine Fumarate (Seroquel)|
219080335|NCT00696254|BEHAVIORAL|Nerve excitability measurement|
219080336|NCT05598216|DIAGNOSTIC_TEST|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
219080337|NCT02626780|DEVICE|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
219080338|NCT03080129|DIETARY_SUPPLEMENT|Fresubin energy|dietary protein energy supplement
219080339|NCT03456700|DRUG|Auranofin|Given PO
219080340|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
219080341|NCT03456700|DRUG|Sirolimus|Given PO
219080342|NCT04154787|DRUG|LNP023|Investigation of LNP023
219680558|NCT03860298|DEVICE|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
219080343|NCT04154787|DRUG|Rituximab|Comparison of rituximab dose
219080344|NCT06772155|PROCEDURE|Ventriculostomy|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is a common procedure performed in this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
219080345|NCT06772155|PROCEDURE|Ventriculostomy + Locking Device|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is an alternative procedure performed for this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. During the insertion, a locking device is attached and secured at the burr hole defect. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
219080346|NCT01530217|DRUG|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
219080347|NCT00000279|DRUG|Clonidine|
219080348|NCT00246116|PROCEDURE|Functional Imaging of Treatment Effects|PET \& VQ Scans
219080349|NCT00815867|DRUG|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
219080350|NCT03123146|BEHAVIORAL|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
219080351|NCT03553004|DRUG|Niraparib Treatment|Niraparib treatment by mouth (oral)
219080352|NCT01074398|GENETIC|gene expression analysis|
219080353|NCT01074398|GENETIC|polymorphism analysis|
219080354|NCT01074398|GENETIC|protein expression analysis|
219080355|NCT01074398|OTHER|immunohistochemistry staining method|
219210881|NCT01001364|DRUG|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
219680559|NCT00672607|DRUG|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
219680560|NCT00672607|DRUG|Placebo|Placebo
219680561|NCT04294199|OTHER|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
219080356|NCT01074398|OTHER|laboratory biomarker analysis|
219080357|NCT01575353|DEVICE|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
219210882|NCT06833385|DIAGNOSTIC_TEST|Intraoral Scanning|Participants will first undergo intraoral scanning using a digital scanner to capture a 3D image of their dental arches. The procedure is non-invasive and requires no impression material. After one week, the same participants will undergo a polyvinyl siloxane (PVS) impression using conventional impression trays and materials
219080358|NCT01575353|DEVICE|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
219080359|NCT04257266|DEVICE|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
219080360|NCT03811184|DIAGNOSTIC_TEST|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
219080361|NCT04209816|DIAGNOSTIC_TEST|Lipoprotein kinetics|Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
219080362|NCT00883506|DRUG|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
219080363|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fasting conditions.|
219080364|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fed conditions.|
219080365|NCT03878732|DIAGNOSTIC_TEST|Bindex measurement|One time bone density measurement with ultrasound device
219080366|NCT01635608|DRUG|Acetaminophen|administration of 500 mg paracetamol
219080367|NCT01635608|DRUG|Talinolol|administration of 50 mg talinolol
219080368|NCT01635608|DRUG|Amoxicillin|administration of 500 mg amoxicillin
219210883|NCT06833385|DIAGNOSTIC_TEST|PVS Impression|Participants will first undergo a polyvinyl siloxane (PVS) impression, where an impression tray filled with PVS material is used to capture the shape of their dental arches. After one week, the same participants will undergo intraoral scanning using a digital scanner for a 3D image of their dentition.
219680562|NCT00178217|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
219680563|NCT03025269|DRUG|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
219680564|NCT04649086|OTHER|Rehabilitation by Eccentric exercises|Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
219680565|NCT04649086|OTHER|Rehabilitation by Concentric exercises|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
219680566|NCT04442087|BIOLOGICAL|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
219680567|NCT04442087|BEHAVIORAL|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
219680568|NCT04444765|OTHER|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
219680569|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
219680570|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract|Take 4 tablets with warm water twice a day
219080369|NCT01635608|OTHER|non-caloric water|administration of 240 ml water
219080370|NCT01635608|OTHER|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
219080371|NCT02464813|DRUG|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
219080372|NCT02464813|DRUG|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
219080373|NCT02464813|DRUG|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
219080374|NCT05182567|DRUG|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
219080375|NCT05182567|DRUG|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
219080376|NCT05182567|DRUG|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
219080377|NCT05182567|DRUG|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
219080378|NCT03426384|BEHAVIORAL|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
219080379|NCT06444906|DEVICE|Dermacyte Matrix|The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
219080380|NCT06444906|OTHER|Standard of Care (SOC)|SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
219080381|NCT03921125|DEVICE|Massimo for Pleth variability index|To assess fluid response
219080382|NCT04171102|DEVICE|ProFlor Hernia implant|Inguinal hernia repair
219080383|NCT05040555|COMBINATION_PRODUCT|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
219080384|NCT00003508|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219080385|NCT05228548|OTHER|Perioperative blood transfusion|Perioperative blood transfusion
219080386|NCT01925664|BEHAVIORAL|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
219080387|NCT04918784|DEVICE|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
219080388|NCT04918784|DEVICE|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
219080389|NCT02773550|DRUG|Bortezomib|Low dose of bortezomib
219680571|NCT05497765|DIETARY_SUPPLEMENT|Placebo|Take 4 tablets with warm water twice a day
219680572|NCT00537186|DRUG|Iron oligosaccharide|
219680573|NCT01139346|DRUG|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
219680574|NCT02609984|BIOLOGICAL|CMB305|A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
219680575|NCT02609984|BIOLOGICAL|atezolizumab|IV Infusion
219680576|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
219680577|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
219680578|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
219680579|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
219080390|NCT02773550|DRUG|Melphalan|
219080391|NCT02773550|DRUG|Prednisone|
219080392|NCT03113292|OTHER|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
219080393|NCT03113292|OTHER|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
219080394|NCT03217448|DRUG|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
219080395|NCT03217448|DRUG|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
219080396|NCT01834885|DRUG|QVA149|QVA149 via inhaler twice a day
219080397|NCT01834885|DRUG|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
219080398|NCT04498130|BEHAVIORAL|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
219080399|NCT04498130|BEHAVIORAL|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
219680580|NCT03404388|BEHAVIORAL|Balance Training|4 days of a challenging balance training task
219680581|NCT05974228|DEVICE|Bioactive glass wound dressing|Bioactive glass wound dressing is a dressing covered on the wound bed
219080400|NCT05952635|PROCEDURE|Tip bendable suction ureteral access sheath|Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
219080401|NCT05682092|DIETARY_SUPPLEMENT|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
219080402|NCT05682092|DIETARY_SUPPLEMENT|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
219080403|NCT02219893|DRUG|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
219080404|NCT01712009|DRUG|Naproxen|
219080405|NCT01712009|DRUG|Loratadine|
219080406|NCT01712009|BIOLOGICAL|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
219680582|NCT03141515|DEVICE|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
219680583|NCT01758614|PROCEDURE|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
219680584|NCT01758614|DRUG|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
219680585|NCT01758614|DRUG|Clopidogrel|
219680586|NCT01210222|BIOLOGICAL|Trebananib|Given IV
219680587|NCT02797860|DRUG|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
219680588|NCT00973284|BIOLOGICAL|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
219680589|NCT00973284|BIOLOGICAL|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
219680590|NCT00973284|BIOLOGICAL|Norwalk virus|Norwalk virus solution
219680591|NCT03569826|OTHER|Observational; no intervention|Observational; no intervention
219080407|NCT01712009|DRUG|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
219080408|NCT03625401|DRUG|AD-35 60mg group|AD-35 60mg QD
219680592|NCT04832451|BEHAVIORAL|Interpersonal Relational Role Analysis|"Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps."
219680593|NCT01322087|DIETARY_SUPPLEMENT|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
219680594|NCT02959333|BIOLOGICAL|hAEC|hAEC: human amniotic epithelial cells
219680595|NCT00941304|DRUG|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
219680596|NCT00941304|DRUG|Buprenorphine|Single-dose of buprenorphine HCl buccal film
219680597|NCT00941304|DRUG|Placebo Film|Single-dose of placebo buccal film
219680598|NCT00941304|DRUG|Placebo Capsule|Single-dose of oral placebo capsule
219680599|NCT03293394|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219680600|NCT03293394|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219680601|NCT00086450|PROCEDURE|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
219680602|NCT00086450|DEVICE|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
219680603|NCT04978337|DRUG|Rilematovir|Rilematovir 250 mg will be administered orally.
219680604|NCT04978337|DRUG|Placebo|Placebo matching to rilematovir will be administered orally.
219080409|NCT03625401|DRUG|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
219080410|NCT02685722|BIOLOGICAL|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
219080411|NCT02685722|OTHER|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
219080412|NCT01377480|DRUG|Posaconazole|POS 40 mg/mL oral suspension
219080413|NCT01377480|DRUG|Placebo for posaconazole|Placebo oral suspension
219080414|NCT01377480|DRUG|Benznidazole|BNZ 100 mg oral tablet
219080415|NCT00739375|PROCEDURE|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
219210884|NCT04003857|BIOLOGICAL|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)
219210885|NCT04003857|BIOLOGICAL|normal saline|A single intratracheal administration of normal saline
219680605|NCT01504672|OTHER|Medication review|"In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs"
219080416|NCT06463444|DRUG|HAIC + Tislelizumab +lenvatinib|"All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later."
219080417|NCT05024851|OTHER|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
219080418|NCT02837640|DRUG|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
219080419|NCT01946542|DRUG|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
219210886|NCT06725862|PROCEDURE|Retrolaminar Block (RLB)|This intervention involves administering 0.25% bupivacaine (0.1 mL/kg) into the retrolaminar space at the L4 vertebral level using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
219210887|NCT06725862|PROCEDURE|Caudal Block (CB)|This intervention involves administering 0.125% bupivacaine (1 mL/kg, maximum 20 mL) into the sacral canal using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
219210888|NCT06815315|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation|The multiple micronutrient supplementation composition follows the United Nations International Multiple Micronutrient Antenatal Preparation. Each MMS tablet contains 15 micronutrients, including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg) and is consumed daily.
219210889|NCT06815315|DIETARY_SUPPLEMENT|Iron Folic Acid Supplementation|One IFAS tablet contains Iron (60 mg) and Folic Acid (2800 μg) and is taken weekly.
219210890|NCT06815315|BEHAVIORAL|Adolescent Nutrition Curriculum|The Adolescent Nutrition Curriculum includes five modules focused on promoting healthy behaviors to enhance nutrition, with an emphasis on consuming iron-rich foods.
219210891|NCT06747897|DEVICE|MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)|Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.
219210892|NCT05899153|DEVICE|Biomotum Spark: Robotic ankle resistance|Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.
219210893|NCT05899153|DEVICE|Audiovisual Biofeedback|Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
219210894|NCT05899153|PROCEDURE|Multilevel Orthopedic Surgery|Musculoskeletal surgeries to address alignment, contracture, and other lower-extremity impairments. This study does not impact surgical decision making but evaluates changes in gait before and after surgery.
219210895|NCT06849141|OTHER|Role Performance Strenghthening Program|This intervention was developed by the researcher within the scope of her doctoral dissertation. The intervention is an individual psychoeducation program; it was written and structured within the framework of cognitive behavioral therapy, based on the Roy Adaptation Model. The intervention was structured on the idea of empowering nurses working in pandemic units.
219210896|NCT00743951|BEHAVIORAL|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
219210897|NCT00743951|BEHAVIORAL|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
219080420|NCT01946542|OTHER|placebo|
219080421|NCT01826240|BEHAVIORAL|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
219080422|NCT03940599|DEVICE|step counter|Fitbit
219080423|NCT03940599|DEVICE|weight scale|BodyTrace weight scale
219080424|NCT03940599|DEVICE|step counter with screen covered|Fitbit with screen covered
219080425|NCT00871689|BIOLOGICAL|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
219080426|NCT00871689|DRUG|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
219080427|NCT00871689|DRUG|fludarabine phosphate|25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
219080428|NCT00871689|PROCEDURE|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
219080429|NCT00871689|RADIATION|total-body irradiation|administered on days -5 through -2; 330 cGy daily
219080430|NCT01127880|DRUG|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
219080431|NCT01127880|DRUG|Placebo|.9% Normal Saline as a placebo
219080432|NCT05592054|PROCEDURE|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
219080433|NCT05592054|PROCEDURE|Standard guide catheter|MT procedure with standard guide catheter
219210898|NCT03275285|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219210899|NCT03275285|DRUG|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219210900|NCT03275285|DRUG|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
219210901|NCT03621670|BIOLOGICAL|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
219680606|NCT01408901|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
219210902|NCT03621670|BIOLOGICAL|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210903|NCT03621670|BIOLOGICAL|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210904|NCT03621670|BIOLOGICAL|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210905|NCT03621670|BIOLOGICAL|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210906|NCT03621670|BIOLOGICAL|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210907|NCT03621670|BIOLOGICAL|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
219210908|NCT03621670|BIOLOGICAL|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
219210909|NCT03621670|BIOLOGICAL|Prevnar 20|Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
219210910|NCT04996134|DRUG|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
219210911|NCT06393725|BEHAVIORAL|Asynchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered asynchronously via a private Facebook group led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
219210912|NCT06393725|BEHAVIORAL|Synchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered synchronously via weekly videoconference group meetings led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
219210913|NCT00115934|PROCEDURE|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
219210914|NCT00115934|PROCEDURE|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
219210915|NCT03646292|DRUG|Pioglitazone|The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
219080434|NCT02244905|BEHAVIORAL|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
219210916|NCT03646292|DRUG|Empagliflozin|The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
219210917|NCT03646292|DRUG|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
219680607|NCT01408901|OTHER|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
219680608|NCT01408901|DRUG|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
219080435|NCT02244905|OTHER|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
219080436|NCT03576768|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
219080437|NCT03576768|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219210918|NCT04699747|DRUG|F-18 3F4AP|Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
219360571|NCT05713643|PROCEDURE|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
219210919|NCT06803303|DEVICE|sonoelastography|"Sonoelastography examination\[10,11\] will be performed using (GE logiqs8,) device system with a high-frequency (a 5-12 MHz linearMHz) linear probe. The procedure will be carried out by a radiologist , who is blinded to the MRI results.~Magnetic resonance imaging (MRI) \[12\] will be performed on the patients in our radiology department using a Philips Achieva 1.5 Tesla superconducting magnet (The Netherlands), shoulder joint MRI protocol included several imaging sequences, included coronal oblique T1 and T2 weighted fast spin-echo, coronal oblique proton density fat suppressed, oblique sagittal T2-weighted spin-echo and axial T1-weighted spin-echo Image evaluation will be conducted by experienced musculoskeletal radiologist, Then we correlate results of sonoelastography to that of MRI ."
219080438|NCT03576768|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
219080439|NCT03576768|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
219080440|NCT00590902|DRUG|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
219080441|NCT02342522|DEVICE|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
219080442|NCT02342522|DEVICE|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
219080443|NCT03888339|PROCEDURE|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
219080444|NCT03888339|PROCEDURE|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
219680609|NCT06155474|DIETARY_SUPPLEMENT|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
219080445|NCT02489955|DRUG|Amikacin|
219080446|NCT02489955|DRUG|Tobramycin|
219080447|NCT02489955|DRUG|Colomycin|
219080448|NCT00915031|DEVICE|UroCool|Hypothermia Endorectal Device
219080449|NCT03924479|DEVICE|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
219080450|NCT01037855|OTHER|Non-intervention observational study|Non-intervention observational study
219080451|NCT04821479|BIOLOGICAL|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
219080452|NCT01253525|BIOLOGICAL|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
219080453|NCT01253525|DRUG|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
219080454|NCT05307380|DIAGNOSTIC_TEST|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
219080455|NCT05202925|OTHER|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
219080456|NCT02422602|DRUG|Xarelto|Taking conventional charge
219080457|NCT02422602|OTHER|Experimental: Personalized information intervention|
219080458|NCT01986881|DRUG|Ertugliflozin|Oral, once daily, for up to approximately 6 years
219080459|NCT01986881|DRUG|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
219080460|NCT01986881|DRUG|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
219080461|NCT05261893|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
219080462|NCT05261893|OTHER|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
219080463|NCT02709668|DIETARY_SUPPLEMENT|Enlyte|gel cap of reduced B vitamins
219080464|NCT02709668|OTHER|placebo|identical to Enlyte
219210920|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)|"DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include:~* Education on cancer and cancer treatments, including clinical trials~* An exercise to identify perceived barriers and benefits to treatment options~* An exercise to clarify personal goals for treatment that align with life goals~* Resources to support communication with the oncology health care team"
219210921|NCT03710928|OTHER|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
219210922|NCT03710928|OTHER|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
219680610|NCT06155474|DIETARY_SUPPLEMENT|Starch Only|The Starch Solution is a low-fat diet.
219210923|NCT06850532|OTHER|IGF-1|The effects of NMES coupled with HIIT and MICT on IGF-1 and substrate metabolism has not been studied earlier.
219210924|NCT06846190|OTHER|mCIMT|mCIMT+ Hot pack will be applied and unaffected hand will be immobilized by a volar resting splint extending from finger tips to the proximal forearm. Use splint every day for at least 5 waking hours daily for 4 weeks and perform daily activities. Program of mCIMT every other day, 3 times per week during a 4-week period.
219210925|NCT06846190|OTHER|VR|VR+ Hot pack will be applied. 25 minutes of VR program, every other day, 3 times per week for 4 weeks. Each VR session continued for 10 minutes then 5 minutes rest after that again 10 minutes VR session will do.
219680611|NCT06155474|DIETARY_SUPPLEMENT|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
219680612|NCT00222638|DRUG|Influenza vaccination|
219680613|NCT00725907|BIOLOGICAL|PGRF|injection of 6cc into injured area
219680614|NCT00725907|BIOLOGICAL|placebo saline|injection of 6cc into injured area
219680615|NCT00606749|DRUG|KC706|300 mg once daily (QD) for 12 weeks.
219210926|NCT06152237|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
219210927|NCT06844747|OTHER|erector spinae plane block(ESPB)|ESPB group received US-guided plane block, WI group received local anaesthetic wound infiltration
219210928|NCT06846021|OTHER|Disease status|According to the disease status, patients are divided into four groups including healthy donors, initial patients with high activity, patients with deformities and patients with clinical remission
219080465|NCT05144932|DEVICE|Stroke Alarm|The patients are in this clinical trial instructed to use the device continuously for 1 month.
219080466|NCT05183022|DEVICE|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
219210929|NCT06846502|PROCEDURE|Pulmonary vein isolation|Compared to conventional radiofrequency (RF) ablation, which is performed with a power set of 30-40 Watt for a duration of 20-30 seconds, ablation with higher power and shorter duration (vHPSD, 90W/4sec) may result in more continuous and more durable ablation lesions with a similar safety profile, while reducing procedure duration.
219210930|NCT06818955|DRUG|Orlistat 120 mg|Orlistat 120 mg po tid
219680616|NCT03509181|BEHAVIORAL|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
219680617|NCT03509181|BEHAVIORAL|Symptom Tracking|smartphone delivered self-monitoring of anxiety and depression symptoms
219680618|NCT06039137|DRUG|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
219680619|NCT06039137|DRUG|Clemastine IV|Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
219680620|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
219680621|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
219680622|NCT01436227|OTHER|Laboratory Biomarker Analysis|Correlative studies
219680623|NCT01436227|DRUG|Pazopanib Hydrochloride|Given PO
219680624|NCT03465761|DEVICE|ExAblate|Bilateral side treatment of Essential Tremor
219680625|NCT03971591|BEHAVIORAL|Immediate Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
219080467|NCT04159974|DRUG|Durvalumab 50 MG/ML|IV Infusion
219080468|NCT04159974|DRUG|Tremelimumab|IV Infusion, Combination with Durvalumab
219080469|NCT01331057|OTHER|NEEL test|An assessment for children in French with items extracted from the NEEL test
219080470|NCT01331057|OTHER|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
219080471|NCT01331057|OTHER|Interview|For parents of children include in the study: A semi -structured interview
219080472|NCT01741376|DRUG|Progesterone|Progesterone 200 mg twice daily
219210931|NCT06802484|OTHER|Experimental: Pre-Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
219680626|NCT06039319|OTHER|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
219680627|NCT01860716|DRUG|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
219680628|NCT01860716|DRUG|Placebo|
219680629|NCT06117254|BEHAVIORAL|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
219680630|NCT06117254|DEVICE|Hearing Aids|Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.
219680631|NCT06117254|DEVICE|Remote Microphones|Remote microphone systems will be provided for use with hearing aids.
219680632|NCT05190666|BEHAVIORAL|PACE Weight Loss program|12 month phone-based behavioral weight loss program
219680633|NCT05190666|BEHAVIORAL|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
219680634|NCT03648918|OTHER|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
219680635|NCT04225013|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
219680636|NCT04225013|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
219680637|NCT06234098|DRUG|AT-1965 Liposome Injection|AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
219680638|NCT05658172|DIAGNOSTIC_TEST|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
219680639|NCT05658172|DIAGNOSTIC_TEST|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
219680640|NCT05658172|DIAGNOSTIC_TEST|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
219680641|NCT05658172|OTHER|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
219680642|NCT06462898|DIETARY_SUPPLEMENT|Omega-3 Fortified Protein Smoothie|Omega-3 powder and protein supplementation.
219080473|NCT01741376|DRUG|Placebo|
219210932|NCT06802484|OTHER|Experimental: Post- Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
219080474|NCT00290862|DEVICE|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
219080475|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
219080476|NCT06052696|DRUG|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
219210933|NCT04040764|PROCEDURE|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
219210934|NCT06802614|DEVICE|BLEACHING GEL A|Carbomer 940 hydrogel + 6% Hydrogen Peroxide
219210935|NCT06802614|DEVICE|5% NF_TiO2|Bioactive nanoparticles
219210936|NCT06802614|DEVICE|BLEACHING GEL B|Hyaluronic Acid hydrogel + 6% Hydrogen Peroxide
219210937|NCT06802614|RADIATION|VISIBLE LIGHT IRRADIATION|Low intensity visible light irradiation (405 nm)
219210938|NCT06802614|DEVICE|Whiteness HP 35%|Commercially available bleaching gel
219210939|NCT06802614|DEVICE|Whiteness HP Automixx 6%|Commercially available bleaching gel
219210940|NCT06459388|OTHER|Stabilizing Reversals and Rhythmic Stabilization|3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.
219210941|NCT06459388|OTHER|Pelvic Proprioceptive Neuromuscular Facilitation|The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
219680643|NCT06462898|DIETARY_SUPPLEMENT|Non-Fortified Protein Smoothie|Protein without omega-3 powder supplementation.
219680644|NCT04504565|DIAGNOSTIC_TEST|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
219680645|NCT05826340|BEHAVIORAL|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
219680646|NCT05826340|BEHAVIORAL|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
219210942|NCT06267924|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband Experimental device to determine effectiveness in providing temporary relief to symptoms of vertigo.
219210943|NCT06267924|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband Sham device to determine effectiveness in providing temporary relief to symptoms of vertigo.
219210944|NCT06804174|OTHER|use of gonadotropins|Comparison of endometrial proteome during the window of implantation between stimulated and spontaneous cycles.
219210945|NCT05599048|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
219210946|NCT05599048|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
219210947|NCT05599048|DRUG|13C,15N-Urea|Given IV
219210948|NCT06827574|OTHER|Sciatic nerve flossing technique|Group A 16 subjects were treated with Sciatic Nerve Flossing Technique. Subjects were in sitting position. Nerve Flossing Technique was performed actively with the participant sitting on a chair. The participant was flex the knee of the target lower extremity backwards beside the chair, as far back as possible and flex the neck at the same time, holding both the flexed knee and neck in this position for 10 seconds. The participant in turn will extend the neck and the knee of the target lower extremity, abduct and then flex the hip until pain is felt and do not push beyond that point. This extended position was maintained for 10 seconds. The above procedure of Nerve Flossing Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the nerve becomes less sensitive, the participant can increase the stretching effect by dorsiflexion the ankle and extending the toes of the foot upward towards the shin.
219210949|NCT06827574|OTHER|Active Release Technique|Group B 16 subjects were treated with Active Release Technique. Subjects were in prone position. ART was performed actively by the participant lying on a bed. The participant was dorsiflex the foot of the target lower extremity, holding the dorsiflexion foot in this position for 10 seconds. The participant in turn was plantar-flexed the foot of the target lower extremity. This dorsiflexion position was maintained for 10 seconds. The above procedure of Active Release Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the muscles becomes more flexible, the participant can increase the flexibility effect by plantar flexing the foot.
219210950|NCT06854120|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
219210951|NCT06826352|BEHAVIORAL|Active Distraction|The video games will be played by children during the procedure.
219680647|NCT04004260|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
219680648|NCT03774888|PROCEDURE|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
219680649|NCT03774888|PROCEDURE|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
219680650|NCT03774888|PROCEDURE|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
219080477|NCT06052696|DRUG|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
219080478|NCT02922348|DRUG|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
219210952|NCT06826352|BEHAVIORAL|Passive Distraction|The cartoons will be selected by the children related to their interests. The cartoons are included Pepee, Niloya, Tom and Jerry, Masha and The Bear and others.
219210953|NCT06877013|OTHER|Placebo challenge|2 sachets per day over 7-day challenge
219210954|NCT06877013|OTHER|Fiber's mix (among 4 doses) - intervention phase 1|2 sachets per day over 7-day challenge
219210955|NCT06877013|OTHER|Best fiber's mix - intervention phase 2|2 sachets per day over 7-day challenge
219210956|NCT06713447|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
219210957|NCT06866704|PROCEDURE|catheter ablation|In the experimental group, patients receive pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI), circumferential BOX ablation around bilateral pulmonary veins, and mitral isthmus ablation. In the control group, anhydrous alcohol is first injected into the Marshall vein, followed by radiofrequency catheter ablation to complete PVI, BOX lesion sets, and mitral isthmus ablation.
219210958|NCT06863519|PROCEDURE|Endoscopic treatment|After the patient is enrolled, HVPG testing is performed, and appropriate endoscopic treatment is selected as a secondary prevention method. HVPG testing is performed again after regular endoscopic treatment.
219210959|NCT06753422|DIETARY_SUPPLEMENT|Kefir|"200 ml/day kefir~The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota."
219210960|NCT06744114|DIAGNOSTIC_TEST|Consciousness in the Emergency Department|To determine the common and definitive etiologies of altered level of consciousness in emergency department.
219210961|NCT06740981|OTHER|Food diary|A food and beverage diary will be collected for five days starting from the initiation of noninvasive ventilation, with caloric and protein intake quantified by a Nutrition Physician Specialist.
219210962|NCT05338632|DRUG|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
219210963|NCT05338632|DRUG|Naloxone Hydrochloride|Naloxone 0.4mg/mL
219210964|NCT05338632|DRUG|Nalmefene HCl injection|Nalmefene 1 ng/mL
219210965|NCT06892886|DEVICE|Virtual Reality|Four tasks, uni and bi-manuals, will be proposed for the treatment of the patient's paretic upper limb in virtual-apartment for improving the relevance and the transferability of the movements requested.
219210966|NCT06892951|DRUG|Caspofungin Acetate 50 MG|The experimental treatment will be administered once daily for up to seven days, through the nebulization route by the means of a disposable vibrating mesh Aeroneb solo® nebulizer with the valved mask (Galway, Ireland). Before generating aerosol, resuspension of the caspofungin powder will be carried out in the same manner than for the IV route, into 10.5 mL saline serum. Preparation of the experimental drug (re-suspension) will be unblindly carried out in a distinct medical office by a nurse neither involved in the healthcare of the included patients, nor in the other parts of the study, data recording or outcome assessment. Once reconstituted, the suspension is expected to be limpid, with neither odour nor foam. Thereafter, its administration will be blindly completed by the clinical staff in charge of the enrolled patient.
219210967|NCT06892951|DRUG|Physiologic saline|Procedures will be exactly the same than those described above for the experimental group, but caspofungin will be replaced during the seven days of intervention by 10mL of 0.9% saline nebulized in the control group for a 15 minute-long process of nebulization (from d-1 to d-7).
219210968|NCT06748612|BIOLOGICAL|Pentavalent vaccine|Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate
219210969|NCT06748612|BIOLOGICAL|Hexavalent vaccine|Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3
219080479|NCT02922348|DRUG|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
219080480|NCT02306070|DRUG|Metformin|metformin treatment + standard of care dietary and exercise advice
219080481|NCT02306070|DRUG|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
219080482|NCT01760889|DRUG|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once-daily for 4 weeks; then,~* 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~* if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
219210970|NCT06748612|BIOLOGICAL|Inactivated poliovirus vaccine (IPV)|one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3
219210971|NCT06748612|BIOLOGICAL|Bivalent oral polio vaccine (bOPV)|Contain two poliovirus types: type 1 and 3
219210972|NCT06748612|BIOLOGICAL|Fractional IPV( fIPV)|The dose of fIPV is 0.1 mL or 1/5th of a full dose
219080483|NCT01760889|DRUG|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once daily for 1 week; then~* 120 mg capsule once-daily for 1 week, then,~* 140 mg capsule once-daily for 2 weeks, then~* 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~* if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
219080484|NCT01760889|DRUG|Placebo|One capsule a day for 26 weeks
219210973|NCT06748482|BEHAVIORAL|Counseling|a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
219210974|NCT06742658|OTHER|Rapid Move|A short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.
219210975|NCT06766331|OTHER|Integrated care|Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment.
219210976|NCT06760117|DRUG|Irinotecan (CPT-11)|Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
219210977|NCT06760117|DRUG|Temozolomide (TMZ)|TMZ：100mg/m2/d，d1-5
219210978|NCT06760117|DRUG|Vincristine|VCR: 1.5mg/m2/d(≯2mg), d1
219210979|NCT06766409|BEHAVIORAL|A community group-based demonstration counseling method|At the community level, a perinatal woman in the intervention arm will get individual family planning counseling along with group-based counseling that includes a planned demonstration of all possible techniques.
219210980|NCT06766409|BEHAVIORAL|An individual family planning counseling|The control group's pregnant and postpartum women will simply get standard individual FP counseling in accordance with Ethiopian national recommendations.
219210981|NCT04943172|DEVICE|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
219210982|NCT05691972|DEVICE|Restylane Contour|a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
219080485|NCT00392405|DRUG|3 amps of sodium bicarbonate mixed in one liter of D5W|
219210983|NCT06766448|OTHER|robotic training|continuous passive mobilization and robotic therapy on armeo sping
219680651|NCT04293484|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219680652|NCT04293484|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219680653|NCT03608813|OTHER|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
219680654|NCT03003169|OTHER|Medical questionnaire|"* quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)"
219210984|NCT06766448|OTHER|conventionnal rehabilitation|rehabilitation sessions with a physiotherapist
219680655|NCT03101384|OTHER|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
219680656|NCT06038500|OTHER|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
219080486|NCT00265980|DRUG|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
219080487|NCT00265980|DRUG|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
219080488|NCT04007458|BEHAVIORAL|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
219080489|NCT04007458|BEHAVIORAL|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
219210985|NCT06768216|OTHER|Indianized version of Mediterranean Diet|Indo Mediterranean diet will have Carbohydrates 40-45%, fats 30-35% and proteins 15-20%. Mediterranean diet, it will be specified to use Mustard oil, use of specific fruits like orange, apple, mosambi (avoid high glycemic fruits), use more of green leafy vegetables, Use of multigrain atta (Home made- 10 kg of multigrain atta will have - 8 kg of wheat + 500g each of Ragi+Bajra+ Jowar + Chana dal flour).
219210986|NCT06768216|OTHER|Low Fat Diet|Low fat diet will have 50-60% carbohydrate, 20-30% fat (with \<10% saturated fat), and 20% protein. In the Low Fat Diet group, there will be only be restriction of total fat content to less than \<30%. They can use whichever household oil, consume any fruit or vegetables, any atta and no restriction on diary or non-vegetarian diet. Along with this, both groups will be given a list of do's and dont's. In the list of Do's , it will be mentioned to Eat plenty of vegetables, Fruits, Nuts, Whole grains, Screen time of less \<2 hrs /day (According to American academy of pediatrics) and Average hours of sleep in a day for age 8-18 = 8-9 hrs (According to American academy of sleep medicine). In the dont's list, it will be mentioned to avoid Sugar, Soda, Beverages, cold drinks, processed juices, processed food, junk foods, Maida, Ice cream, Creamy Desserts, Biscuit, chips and cake.
219080490|NCT01816750|DEVICE|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
219080491|NCT01273233|BIOLOGICAL|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
219080492|NCT01273233|OTHER|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
219080493|NCT04382105|OTHER|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
219080494|NCT04163887|PROCEDURE|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
219080495|NCT02281799|DRUG|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
219080496|NCT04381520|OTHER|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
219080497|NCT04381520|DRUG|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
219080498|NCT05042778|OTHER|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
219080499|NCT03640702|OTHER|Protocol change|To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
219080500|NCT03176420|PROCEDURE|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
219080501|NCT05699733|DEVICE|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
219080502|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
219080503|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
219080504|NCT04378322|BEHAVIORAL|Nutrition education tool|Participants will be asked to review nutrition education materials online.
219210987|NCT06768216|OTHER|Physical Activity|At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
219210988|NCT06770062|DIAGNOSTIC_TEST|Cardiac MRI|Each subject will receive two cardiac MRI scans (with and without contrast), one preoperative and another 6-12 months after. The duration of each MRI is approximately 45-60 minutes
219680657|NCT05828368|PROCEDURE|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
219680658|NCT02077309|DRUG|Linagliptin|
219680659|NCT02077309|DRUG|Placebo|
219680660|NCT02719002|DEVICE|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
219680661|NCT01158742|OTHER|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
219680662|NCT01158742|OTHER|Glomerular Filtration Rate with Iohexol|used to determine kidney function
219680663|NCT03383224|OTHER|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
219680664|NCT03383224|DRUG|Nicotine patch|
219680665|NCT03383224|BEHAVIORAL|Smoking cessation counseling|
219680666|NCT03021317|DRUG|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
219680667|NCT04527042|DRUG|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
219680668|NCT02279615|DRUG|Mirabegron|50mg of mirabegron per day will be given.
219680669|NCT02279615|DRUG|Tamsulosin|0.4mg of flomax per day.
219680670|NCT01765569|DRUG|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
219680671|NCT01765569|DRUG|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
219680672|NCT05460858|DRUG|N-acetyl cysteine|One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
219680673|NCT05460858|DRUG|placebo|placebo
219210989|NCT06763757|BEHAVIORAL|Art Therapy Program|The Art Therapy Program consists of 12 weekly group sessions, each lasting 90 minutes, designed to improve emotional well-being and quality of life in solitary older adults. Participants engage in structured activities that include creating art (e.g., drawing and painting), observing and interpreting art pieces, and reflective discussions to explore personal emotions and experiences. The sessions are led by trained facilitators under the supervision of licensed occupational therapists. This intervention follows a thematic progression: initial sessions focus on building trust and self-expression, mid-sessions deepen emotional awareness, and final sessions culminate in a creative project reflecting the participant's personal growth. Unlike other interventions, this program is tailored specifically for older adults living alone, addressing their unique challenges of isolation and reduced social interaction.
219210990|NCT06751849|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
219080505|NCT02729181|DEVICE|DRX9000|
219080506|NCT05032209|OTHER|follow-up of children with severe asthma in adulthood|follow-up of children with severe asthma in adulthood
219080507|NCT00178425|PROCEDURE|Serial blood sampling as described in protocol|
219080508|NCT00178425|PROCEDURE|Estimation of Creatinine Clearance at regular intervals|
219080509|NCT03642925|DIETARY_SUPPLEMENT|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
219080510|NCT02330432|BIOLOGICAL|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
219210991|NCT06751849|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
219210992|NCT06751849|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219210993|NCT06755268|OTHER|listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music|Listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music during the angiography procedure.
219080511|NCT02330432|OTHER|Best standard care|Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
219210994|NCT06753292|PROCEDURE|active gas aspiration|surgeon will be instructed to actively aspirate the intraperitoneal CO2 gas
219680674|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
219680675|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
219680676|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
219680677|NCT04226014|PROCEDURE|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
219680678|NCT00650338|DRUG|DE-104 ophthalmic solution, low concentration|Topical ocular application
219680679|NCT00650338|DRUG|DE-104 ophthalmic solution, medium concentration|Topical ocular application
219680680|NCT00650338|DRUG|DE-104 ophthalmic solution, high concentration|Topical ocular application
219680681|NCT00650338|DRUG|Placebo|placebo
219080512|NCT04768400|DRUG|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
219680682|NCT00650338|DRUG|0.005% latanoprost|Topical ocular application
219680683|NCT03460873|PROCEDURE|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
219080513|NCT04924283|BEHAVIORAL|Tetris and Assessments|Participants will complete assessments on their phone to rate cravings for alcohol. Participants will complete a visual cognitive interference task (i.e., play Tetris on their phone) after endorsing a alcohol craving, and then re-rate craving after the task.
219080514|NCT04924283|OTHER|Assessment Only|Participants will complete assessments on their phone to rate cravings for alcohol.
219080515|NCT05769985|OTHER|Caregiver's responses and patient satisfaction|Interaction between caregivers' responses and patient satisfaction about those responses
219080516|NCT00225654|DEVICE|coronary stent|
219680684|NCT03414229|DRUG|Epacadostat|100mg bid days 1-21
219680685|NCT03414229|DRUG|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
219080517|NCT03801785|OTHER|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
219080518|NCT01047592|DRUG|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
219080519|NCT01047592|DRUG|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
219080520|NCT01047592|DRUG|placebo|placebo,oral, for 12 weeks
219080521|NCT05104528|DEVICE|OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3|Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
219210995|NCT06753292|PROCEDURE|pulmonary recruitment maneuver|patients will receive the PRM which consisted of five manual pulmonary inflations, where each positive pressure inflation will be done for 5 s at a maximum pressure of 30 cm H2O, manually by using the APL valve in the anesthesia machine. The patient will be in a Trendelenburg position (30°). The fifth positive pressure inflation lasted for approximately 5 s. During that time, the patient will be closely monitored, while the anesthesiologist performed PRM
219210996|NCT06777095|OTHER|Routine Treatment + I Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, I taping (a total of 5 times every 3 days) was performed. Two I-shaped kinesio tapings were applied on the paraspinal muscles from the posterior superior iliac spine to the T12 level. 50% tension was applied to the area of the tapes outside the anchor points.
219210997|NCT06777095|OTHER|Routine Treatment + Star Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, star taping (a total of 5 times every 3 days) was performed. Four I tapes, one vertical, one horizontal and two at a 45° angle to the vertical tape, were applied to the point of maximum pain in the lumbar region. 25% tension was applied to the midpoint of the tapes except for the ends.
219210998|NCT06777095|OTHER|Routine Treatment|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. No taping was applied.
219210999|NCT03860792|BEHAVIORAL|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
219211000|NCT03860792|BEHAVIORAL|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
219211001|NCT05720065|DRUG|Botulinum toxin type A|Randomized double-blind administration
219211002|NCT05720065|DRUG|Isotonic saline 0,9%|Randomized double-blind administration
219211003|NCT06750120|DIETARY_SUPPLEMENT|Family food ration|Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day
219211004|NCT06750120|BEHAVIORAL|Optimal weight counseling|Counseling on health gestational weight gain and post partum weight loss
219211005|NCT06750120|OTHER|Enhanced Usual Care|"Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost."
219211006|NCT06755567|DIAGNOSTIC_TEST|MRI-based radiomics-clinical model|Response to NACI was predicted using MRI-based radiomics-clinical model.
219211007|NCT06095960|BEHAVIORAL|Telehealth MOM|Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
219680686|NCT03576924|BEHAVIORAL|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
219680687|NCT03576924|BEHAVIORAL|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
219211008|NCT06095960|OTHER|Enhanced Standard of Care|Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
219211009|NCT06847581|DEVICE|JAME|JAME is a wearable device able to monitor movements of the upper limbs and, through an ad-hoc algorithm based on machine learning, can recognize tremor and suppress it through TENS
219211010|NCT06894667|DRUG|Antioxidant gel|An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing
219211011|NCT06894667|DRUG|Antimicrobial gel|An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing
219211012|NCT05917522|BIOLOGICAL|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
219211013|NCT05917522|PROCEDURE|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
219211014|NCT06410547|OTHER|LLM|A LLM-based comparison between treatment and guideline.
219080522|NCT05104528|DEVICE|Fujifilm Sonosite M-Turbo C Ultrasound system|A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
219080523|NCT05256108|DRUG|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
219080524|NCT05256108|DRUG|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
219080525|NCT05256108|DRUG|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
219080526|NCT05256108|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
219211015|NCT05747599|BEHAVIORAL|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
219211016|NCT05395663|BEHAVIORAL|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
219211017|NCT06618703|RADIATION|Blood sample, urine sample, osteodensitometry|Blood sample, urine sample, osteodensitometry
219211018|NCT05018611|BEHAVIORAL|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
219211019|NCT06569992|OTHER|VIS, TIES|The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
219211020|NCT06199349|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
219080527|NCT05256108|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
219080528|NCT01459432|OTHER|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
219080529|NCT04149925|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
219080530|NCT04149925|DEVICE|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
219080531|NCT01452633|DRUG|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
219080532|NCT01452633|DRUG|Saline will be injected at the study port site prior to incision|Injection will precede incision
219080533|NCT01452633|DRUG|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
219080534|NCT01452633|DRUG|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
219080535|NCT02586025|DRUG|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
219080536|NCT02586025|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
219211021|NCT06199349|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
219211022|NCT06890533|DRUG|Experimental: YZJ-4729|Loading dose + demand dose
219211023|NCT06890533|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
219211024|NCT06890533|DRUG|Active Comparator: Morphine|Loading dose + demand dose
219211025|NCT06843993|BIOLOGICAL|MK-2060|Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization.
219211026|NCT06843993|BIOLOGICAL|Placebo|Single doses of placebo administered via IV infusion on Day 1 according to randomization.
219080537|NCT02586025|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
219211027|NCT01207336|DEVICE|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
219211028|NCT06792305|PROCEDURE|Starting by anterior ring fixation in vertical shear pelvic ring injuries|The procedure will involve addressing the pelvic ring anteriorly with open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate. The goal isto achieve anatomical reduction and stable fixation to restore the integrity of the pelvic ring. Fixation of the posterior ring will be achieved using a single sacroiliac screw in S1. The goal of posterior fixation is to achieve stability and alignment of the posterior pelvic structures.
219211029|NCT06792305|PROCEDURE|Starting by posterior ring fixation in vertical shear pelvic ring injuries|the procedure will involve fixation of the posterior ring which will be achieved by using a single sacroiliac screw in S1. Then open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate.
219211030|NCT06885346|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
219211031|NCT06885346|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
219211032|NCT06782711|PROCEDURE|cranioplasty|In this pivotal study of a medical device, patients with bone loss undergo a computed tomography scan, which is used to create a three-dimensional model of the lesion. After validation, the model is printed using PEEK material, and subsequently, the skull is repaired through cranial reconstruction (cranioplasty).
219211033|NCT06782711|DEVICE|customized skull implants made of polyetheretheretherketone (PEEK) using 3D printing|customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty
219680688|NCT03576924|BEHAVIORAL|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
219211034|NCT06790797|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
219211035|NCT06791720|BEHAVIORAL|music-based cognitive-motor dual-task training/exercise|Participants is engaged in 4 sessions for each training, including rhythmic marching, singing familiar songs, dance workout with elastic bands and stretching exercise with relaxing music. This combination of physical and cognitive activities aims to improve overall well-being by integrating music and movement, making the exercise both enjoyable and beneficial for mental and physical health. Rhythmic aerobic exercises to music focuses on rhythm and movement accuracy. Listening and singing familiar songs is cognitively stimulating. Dance workout allows strength and endurance training with music. Stretching exercise with relaxing music improves the range of movement in major muscle and tendon groups.
219680689|NCT04533438|DEVICE|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
219680690|NCT04533438|DEVICE|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
219680691|NCT04963725|DRUG|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
219680692|NCT06585280|OTHER|No intervention|No intervention
219080538|NCT02586025|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
219080539|NCT02586025|DRUG|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
219080540|NCT02586025|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
219080541|NCT01175525|DRUG|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
219680693|NCT00271219|DRUG|Methadone|daily oral dosing 20-140 mg
219680694|NCT00271219|DRUG|Buprenorphine|sl daily 2-32 mg
219211036|NCT06791720|BEHAVIORAL|Social Gatherings|Participants in the social control group will have a social gathering at the participating center once weekly over the 16 weeks. They will also continue to receive the usual care offered by the centers, such as social support, and health education.
219080542|NCT01175525|DRUG|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
219080543|NCT06384586|DIETARY_SUPPLEMENT|Placebo shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
219211037|NCT04557423|BEHAVIORAL|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
219211038|NCT04557423|BEHAVIORAL|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
219211039|NCT04557423|BEHAVIORAL|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
219211040|NCT06832319|BEHAVIORAL|PERSONALIZED FEEDBACK|Students in the study group will be asked to intervene in a simulated situation in the management of bleeding during pregnancy. It will be filmed with a camera so that students can see their own mistakes after the simulated scenario. After the scenarios are completed by the students in the control group, the mistakes in the clinical situations will be analyzed by the researchers and students in the form of questions and answers and the necessary feedback will be given to them.
219211041|NCT05827068|BIOLOGICAL|mRNA-1011.1|Sterile liquid for injection
219080544|NCT06384586|DIETARY_SUPPLEMENT|Functional energy shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
219080545|NCT03493243|OTHER|Questionnaires|2-hour clinical observation
219080546|NCT03104764|DEVICE|Scalpel|Labial frenulum removed by scalpel
219211042|NCT05827068|BIOLOGICAL|mRNA-1011.2|Sterile liquid for injection
219211043|NCT05827068|BIOLOGICAL|mRNA-1012.1|Sterile liquid for injection
219211044|NCT05827068|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219211045|NCT05827068|BIOLOGICAL|mRNA-1010.2|Sterile liquid for injection
219211046|NCT05827068|BIOLOGICAL|mRNA-1010.3|Sterile liquid for injection
219211047|NCT06842979|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure measured and adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
219211048|NCT06842979|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
219211049|NCT06770075|OTHER|Observational|Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.
219211050|NCT06827366|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'
219211051|NCT06766383|BEHAVIORAL|GPT-simulated patients|GPT-simulated patients
219211052|NCT06766383|BEHAVIORAL|traditional role-playing|traditional role-playing
219360572|NCT05713643|PROCEDURE|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
219680695|NCT05138055|OTHER|No intervention|No intervention
219680696|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
219680697|NCT06015230|BIOLOGICAL|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
219680698|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
219080547|NCT03104764|DEVICE|Er:YAG laser|Labial frenulum removed by Er:YAG laser
219680699|NCT06015230|BIOLOGICAL|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
219680700|NCT06015230|BIOLOGICAL|Placebo in phase Ⅱ|Placebo
219080548|NCT00175825|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
219080549|NCT00175825|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
219080550|NCT02478411|PROCEDURE|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
219080551|NCT02478411|PROCEDURE|Conventional physiotherapy|30 minutes of conventional physiotherapy
219080552|NCT01981694|DRUG|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
219680701|NCT06342401|DIAGNOSTIC_TEST|ENCODE|A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.
219680702|NCT06329687|DRUG|Tyrvaya Nasal Pump|Tyrvaya Nasal Pump with Silicone Lubricant
219680703|NCT04704609|OTHER|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
219080553|NCT01981694|DRUG|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
219080554|NCT05129319|DRUG|prabotulinumtoxinA|Injection of glabellar rhytids
219080555|NCT06005766|BEHAVIORAL|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
219080556|NCT06005766|OTHER|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
219080557|NCT00004122|BIOLOGICAL|BCG vaccine|
219080558|NCT00004122|BIOLOGICAL|recombinant interferon alfa|
219080559|NCT02030015|DRUG|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
219080560|NCT02030015|OTHER|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
219080561|NCT00365391|BIOLOGICAL|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
219080562|NCT00365391|DRUG|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
219080563|NCT00608010|PROCEDURE|Vitrification|Embryos were vitrified according to a previously described technique
219080564|NCT00608010|PROCEDURE|Slow freezing|Embryos were frozen with slow freezing technique
219080565|NCT00977353|DRUG|citalopram|20-60 mg/day, oral, for 6 weeks
219080566|NCT00977353|DRUG|sarcosine|500-1500 mg/day, oral, for 6 weeks
219080567|NCT01429129|DRUG|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
219080568|NCT01039051|BEHAVIORAL|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
219080569|NCT00608582|DEVICE|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
219080570|NCT02070055|OTHER|No intervention|
219080571|NCT01406626|BEHAVIORAL|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
219080572|NCT03199222|DEVICE|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
219080573|NCT02538731|PROCEDURE|dilation-assisted stone extraction|
219080574|NCT02538731|DEVICE|Spyglass Guided Laser Lithotrips|
219080575|NCT01263808|DRUG|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
219080576|NCT01263808|DRUG|Indacaterol 300 µg|QD via SDDPI
219080577|NCT01263808|DRUG|Indacaterol 600 µg|QD via SDDPI
219080578|NCT01263808|DRUG|Placebo|QD via SDDPI
219080579|NCT01263808|DRUG|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
219080580|NCT00745745|DEVICE|Device Implantation|ICD lead implantation
219680704|NCT04061746|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
219680705|NCT04061746|OTHER|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
219680706|NCT04667715|DEVICE|Exablate BBBD|Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
219680707|NCT03143270|DRUG|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
219080581|NCT01096992|DRUG|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
219080582|NCT01096992|DRUG|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
219080583|NCT01096992|DRUG|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
219080584|NCT04167501|OTHER|biological sample analysis|HPV Prevalence analysis
219080585|NCT03382964|BIOLOGICAL|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
219080586|NCT04047043|DIAGNOSTIC_TEST|serum taurine|blood sample for serum taurine level
219080587|NCT01936480|DRUG|Moxifloxacin 400mg once time|
219080588|NCT01093118|DRUG|TMI-358|Micro implant monthly x 3
219080589|NCT01093118|DRUG|MMI-467|Micro implant monthly x 3
219211053|NCT06155695|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
219211054|NCT06155695|BEHAVIORAL|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
219211055|NCT06779370|DRUG|Calcium Silicate|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
219211056|NCT06779370|DRUG|Calcium hydroxide|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
219211057|NCT06812104|DRUG|KK2845_1|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
219680708|NCT03143270|DRUG|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
219080590|NCT04959058|DEVICE|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
219080591|NCT05603468|DRUG|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
219680709|NCT05568797|BIOLOGICAL|RSVPreF3 OA vaccine|One dose of RSVPreF3 OA vaccine administered intramuscularly.
219680710|NCT05568797|BIOLOGICAL|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
219080592|NCT05603468|DRUG|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
219080593|NCT05603468|DRUG|Normal saline|Normal saline
219080594|NCT02594748|BEHAVIORAL|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
219080595|NCT02594748|BEHAVIORAL|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
219080596|NCT00155389|DRUG|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
219080597|NCT06443619|PROCEDURE|unilateral USG-deep SAPB with glucose|patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
219080598|NCT06443619|PROCEDURE|unilateral USG-deep SAPB without glucose|will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
219080599|NCT00173901|DRUG|ceftazidime|
219080600|NCT04526535|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
219080601|NCT06071962|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219080602|NCT06071962|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
219080603|NCT01247402|DEVICE|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
219080604|NCT01247402|DEVICE|standard balloon angioplasty|standard balloon angioplasty
219080605|NCT06162650|RADIATION|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
219080606|NCT06162650|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
219080607|NCT03774901|DRUG|Avelumab|intravenous 10 mg/kg every 2 weeks
219080608|NCT04250727|DEVICE|ZYN|30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
219080609|NCT04358172|OTHER|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
219080610|NCT05005780|DEVICE|Negative peak triggered 100 Hz triplet burst TMS|MagVenture MagPro X100: Ipsilesional negative peak triggered 100 Hz triplet burst TMS.
219080611|NCT05005780|DEVICE|1 Hz rTMS|MagVenture MagPro X100: Contralesional 1 Hz rTMS.
219080612|NCT01393782|DRUG|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
219080613|NCT06096493|PROCEDURE|curative surgery for cancer rectum|Curative surgery for cancer rectum.
219080614|NCT01829438|BEHAVIORAL|Listening to fast music|
219080615|NCT01829438|BEHAVIORAL|Listening to preferred music|
219080616|NCT01829438|BEHAVIORAL|Listening to slow music|
219080617|NCT00379522|DRUG|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
219080618|NCT00379522|DRUG|Saline placebo|Placebo for arginine vasopressin
219080619|NCT00433901|BEHAVIORAL|Targeted parental instruction for positive lifestyle change with follow-up calls.|
219080620|NCT04039399|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
219080621|NCT04039399|PROCEDURE|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
219080622|NCT02698124|DRUG|Decitabine|
219080623|NCT00587327|DRUG|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
219080624|NCT00587327|DRUG|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
219080625|NCT00587327|DRUG|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
219080626|NCT01911403|PROCEDURE|Manual compression|Closure procedure by Manual compression
219080627|NCT01911403|DEVICE|Angio-Seal|Closure procedure by angio-Seal
219080628|NCT01605929|PROCEDURE|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
219080629|NCT02200718|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
219080630|NCT02200718|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
219080631|NCT00863252|DRUG|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
219080632|NCT00863252|DRUG|angiotensin blockade|Continuation of angiotensin blockade
219080633|NCT03281148|DEVICE|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
219080634|NCT03281148|DEVICE|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
219080635|NCT04279314|DRUG|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
219080636|NCT03638895|DEVICE|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
219080637|NCT03638895|BEHAVIORAL|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
219080638|NCT04573465|BEHAVIORAL|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
219080639|NCT04573465|BEHAVIORAL|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
219080640|NCT04573465|BEHAVIORAL|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
219080641|NCT03064516|PROCEDURE|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
219080642|NCT03064516|PROCEDURE|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
219080643|NCT03251625|DRUG|Probiotic Formula Capsule|
219080644|NCT02668523|DEVICE|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
219080645|NCT00160680|DRUG|Levocetirizine|"* Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use"
219080646|NCT02877043|PROCEDURE|resection pulmonaire|
219211058|NCT06812104|DRUG|KK2845_2|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
219680711|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
219680712|NCT05680142|DRUG|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
219080647|NCT04244890|DEVICE|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
219680713|NCT05680142|DRUG|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
219680714|NCT03184129|DEVICE|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
219680715|NCT03184129|DEVICE|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
219080648|NCT02001857|DRUG|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
219211059|NCT06812104|DRUG|KK2845_3|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
219680716|NCT04178616|DIAGNOSTIC_TEST|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
219211060|NCT06812104|DRUG|KK2845_4|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
219211061|NCT02254746|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
219211062|NCT06435312|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants
219211063|NCT05277519|DEVICE|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
219211064|NCT06516627|BEHAVIORAL|Positive Labels|"Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best)."
219680717|NCT03881202|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
219080649|NCT03697902|DIAGNOSTIC_TEST|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
219080650|NCT04375748|DIAGNOSTIC_TEST|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
219080651|NCT04375748|DIAGNOSTIC_TEST|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
219080652|NCT02577666|BEHAVIORAL|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
219080653|NCT02577666|BEHAVIORAL|Housing Only|receives 3 months of project supported rental assistance
219080654|NCT02577666|BEHAVIORAL|Treatment as Usual|receives services as normally offered within the community
219080655|NCT03086304|DEVICE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
219080656|NCT03086304|DEVICE|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
219080657|NCT01777659|DEVICE|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
219080658|NCT04899882|OTHER|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
219080659|NCT03484975|DEVICE|Observation group|Collect coronary images with a hybrid IVUS OCT system.
219080660|NCT01313702|DRUG|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
219080661|NCT01313702|DRUG|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
219080662|NCT01313702|DRUG|usual care|the drugs used in clinical practice, defined by physician
219080663|NCT02348450|DRUG|Irinotecan|40mg
219080664|NCT02348450|DRUG|Etoposide|5ml：0.1g
219080665|NCT02348450|DRUG|Cisplatin|6ml：30mg
219080666|NCT01808950|DRUG|0.06% Resiquimod Gel - A|single 60mg dose
219080667|NCT01808950|DRUG|0.06% Resiquimod Gel - B|single 100mg dose
219211065|NCT06516627|BEHAVIORAL|Spectrum Labels|"All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best)."
219211066|NCT06516627|BEHAVIORAL|FDA High In Labels|Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.
219680718|NCT00679224|DRUG|ambrisentan|ambrisentan
219680719|NCT03315494|DRUG|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
219080668|NCT01808950|DRUG|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
219080669|NCT00854633|DRUG|Talactoferrin|Enteral, 150 mg/kg twice per day
219080670|NCT00854633|DRUG|Placebo|Oral, twice per day
219080671|NCT01459510|BEHAVIORAL|Play Nicely Program|Multi media educational intervention
219080672|NCT04203693|DRUG|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
219080673|NCT00142779|DRUG|Fluoxetine|
219080674|NCT04323813|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
219080675|NCT03202706|PROCEDURE|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
219080676|NCT05182879|DIAGNOSTIC_TEST|Assessement with GERONTOPOLE scale|"The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)"
219080677|NCT04857931|DRUG|Colchicine|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
219080678|NCT04857931|DRUG|Placebo|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
219080679|NCT01104194|DIETARY_SUPPLEMENT|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
219080680|NCT01104194|DIETARY_SUPPLEMENT|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
219211067|NCT06516627|BEHAVIORAL|FDA Traffic Light Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red."
219211068|NCT06766227|BEHAVIORAL|iEndSmokin App|Mobile Health App that includes educational material and psychological programs based on CBT.
219211069|NCT06766227|BEHAVIORAL|Educational Session|It will include lectures and distribution of educational material about smoking health risks and strategies to quit.
219211070|NCT06276621|BEHAVIORAL|Family Bridge Program|The Family Bridge Program consists of 7 components, delivered by a trained lay navigator, the Guide. The program includes: (1) orientation to the hospital, unit, room, and hospital resources (e.g., toiletries, loaner phone chargers); (2)unmet social needs assessment, followed by connection to appropriate resources (e.g., food vouchers, community-based transportation); (3)communication and cultural preference assessment (eg, preferred language, comfort asking questions, and health-related cultural beliefs), which is communicated to the medical team and documented in the electronic health record;(4)communication coaching for parents/caregivers to help them clarify and practice asking questions of the medical team; (5)emotional support via daily check-ins during the hospital stay; (6)assistance with logistics ; and (7)one follow-up phone call, 2 days post-discharge, to address remaining questions and connect families to ongoing services if needed.
219211071|NCT06276621|BEHAVIORAL|Care as usual - resources only|Families randomized to the control arm will receive FBP written resources, which the Guide (and interpreter, as needed) will review with them over \~5-15 minutes one time. This includes information on hospital services (e.g., cafeteria coupons), community resources (e.g., food and housing support), the structure and roles of the medical team, and the daily hospital schedule. Parents will be informed that their child's nurse is available to help them.
219211072|NCT05613413|DRUG|Cabozantinib 40 MG|Cabozantinib is taken my mouth
219211073|NCT05613413|DRUG|Pembrolizumab 200mg|Pembrolizumab is given intravenously
219211074|NCT05613413|DRUG|Pembrolizumab 400mg|Pembrolizumab is given intravenously
219680720|NCT03315494|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
219680721|NCT05284903|OTHER|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
219680722|NCT05284903|OTHER|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
219080681|NCT06525324|PROCEDURE|Immediate implant surgery with T-PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
219211075|NCT04586478|BIOLOGICAL|single dose of CNCT19|Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
219080682|NCT06525324|PROCEDURE|Immediate implant surgery with PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
219211076|NCT06022107|BEHAVIORAL|LDART|LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
219080683|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
219080684|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule at recommended dose orally.
219080685|NCT00259532|PROCEDURE|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
219080686|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
219680723|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
219680724|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
219680725|NCT05628857|DRUG|RC108|RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
219080687|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
219080688|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
219080689|NCT01353352|OTHER|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
219080690|NCT00380848|PROCEDURE|Hemodiafiltration|
219080691|NCT06333054|DRUG|Pyrethrum Extract|Treatment with Goldgeist® Forte
219080692|NCT06333054|DEVICE|Silcap Shampoo|Treatment with Silcap Shampoo
219080693|NCT03595579|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks.
219080694|NCT03595579|DRUG|Bupropion|Bupropion taken twice daily for 6 weeks.
219080695|NCT03977675|DRUG|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
219080696|NCT03235167|DRUG|CpG DNA|CpG DNA concentrate
219080697|NCT03235167|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
219080698|NCT03235167|DRUG|Placebo - Concentrate|CpG DNA vehicle
219080699|NCT04134156|PROCEDURE|sleeve gastrectomy|5-port sleeve gastrectomy
219080700|NCT04134156|PROCEDURE|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
219080701|NCT02450331|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
219080702|NCT02178605|PROCEDURE|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
219080703|NCT06056375|BEHAVIORAL|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
219080704|NCT05719454|DEVICE|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
219080705|NCT06580691|PROCEDURE|Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads|"Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision."
219080706|NCT05211388|PROCEDURE|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
219211077|NCT06408428|DEVICE|PANAXIUM MicroECoG|The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
219080707|NCT05211388|PROCEDURE|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
219080708|NCT02324218|OTHER|Data collection|Data extraction from CPRD database of UK.
219080709|NCT00254033|DRUG|Dextroamphetamine|
219080710|NCT00254033|DRUG|Methylphenidate|
219080711|NCT02612987|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|
219080712|NCT03823781|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo.
219080713|NCT03823781|DRUG|Normal saline|The study intervention is an intravenous infusion of milrinone or placebo.
219080714|NCT04406948|DRUG|MGCND00EP1|Patients will take cannabis oil during the study
219080715|NCT04406948|DRUG|Placebo|Patient will take carrier oil during the study
219080716|NCT04406948|DIAGNOSTIC_TEST|ECG|"A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results."
219080717|NCT04406948|DIAGNOSTIC_TEST|EEG|An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
219080718|NCT04406948|DIAGNOSTIC_TEST|Blood and urine collection|safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
219080719|NCT02723864|DRUG|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
219080720|NCT02744222|BIOLOGICAL|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
219211078|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
219080721|NCT02744222|BIOLOGICAL|Avonex®|30 mcg intramuscularly once a week
219080722|NCT02744222|BIOLOGICAL|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
219080723|NCT02744222|OTHER|Placebo|intramuscularly once a week (0,5 ml)
219211079|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
219080724|NCT00112268|BEHAVIORAL|QuitLink (office support system for quit line referral)|
219080725|NCT03148470|DEVICE|Sham iTBS|Placebo stimulation for the iTBS group
219080726|NCT03148470|DEVICE|Sham cTBS|Placebo stimulation for the cTBS group
219080727|NCT03148470|DEVICE|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
219080728|NCT03148470|DEVICE|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
219080729|NCT02191696|DEVICE|IMED-4 recording|
219080730|NCT03346720|OTHER|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
219080731|NCT03346720|OTHER|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
219211080|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
219080732|NCT03232983|DRUG|LY900014 (SC)|Administered SC
219080733|NCT03232983|DRUG|LY900014 (IV)|Administered IV
219080734|NCT00405626|DRUG|Bellis Perenis ,Arnica montana|
219080735|NCT03346226|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
219080736|NCT03346226|DRUG|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
219080737|NCT02606903|DRUG|BI 695501 prefilled syringe|
219080738|NCT02606903|DRUG|BI 695501 autoinjector|
219080739|NCT01633879|BEHAVIORAL|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
219080740|NCT01633879|BEHAVIORAL|health and success parent and school|Parenting education and school intervention
219080741|NCT00906841|DRUG|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
219080742|NCT03656705|BIOLOGICAL|CCCR-NK92 cells|CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
219080743|NCT03881306|DRUG|D-TACE|D-TACE with CalliSpheres-Oxaliplatin
219080744|NCT04051164|OTHER|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
219080745|NCT04051164|OTHER|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
219080746|NCT02548455|DEVICE|Quartet 1457Q LV Lead|
219211081|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
219211082|NCT06892743|PROCEDURE|US-guided external oblique intercostal plane block (EOIPB)|US Guided external oblique intercostal plane block (EOIPB) or Posterior TAP Block:
219211083|NCT06758141|OTHER|3D printed educational model|3D Printed Advanced Cardiac Model
219211084|NCT06758141|OTHER|Slide-based presentation|Slide-based presentation
219211085|NCT06000787|RADIATION|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
219080747|NCT05228899|DRUG|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
219080748|NCT05228899|OTHER|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
219080749|NCT05872373|BEHAVIORAL|Snakebite prevention and first aid|The study will offer a communication strategy to develop an effective narrative by using a mix-media campaign, where IEC materials would be chiefly localized.
219080750|NCT03764839|BEHAVIORAL|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
219680726|NCT05443074|OTHER|Face to face intervention group|"Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI)."
219680727|NCT05443074|OTHER|Remote intervention group|"Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI."
219680728|NCT05443074|OTHER|Control group|Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
219680729|NCT05341791|OTHER|Cartoon video describing study information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
219680730|NCT00544908|DRUG|dasatinib|
219080751|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
219080752|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
219080753|NCT01030861|DRUG|Teplizumab|intravenous infusions
219080754|NCT01030861|DRUG|Placebo infusion|Placebo for Teplizumab
219080755|NCT04480294|DRUG|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
219080756|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
219080757|NCT03360708|OTHER|Laboratory Biomarker Analysis|Correlative studies
219080758|NCT03360708|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
219080759|NCT04339231|PROCEDURE|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
219080760|NCT01925716|OTHER|Corn oil|corn oil 56 g/day for 21 days
219080761|NCT01925716|OTHER|Olive oil|olive oil 56 g /day for 21 days
219080762|NCT05571631|OTHER|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
219080763|NCT03046212|DEVICE|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
219080764|NCT03046212|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
219080765|NCT06131866|OTHER|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
219080766|NCT01509729|PROCEDURE|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
219080767|NCT01509729|PROCEDURE|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
219211086|NCT06000787|RADIATION|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
219680731|NCT00544908|OTHER|immunoenzyme technique|
219680732|NCT00544908|OTHER|immunohistochemistry staining method|
219080768|NCT02261493|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
219080769|NCT02261493|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
219080770|NCT05836493|PROCEDURE|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
219080771|NCT05836493|PROCEDURE|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
219080772|NCT04315168|DEVICE|FRED and FRED JR|Intracranial aneurysm treatment
219080773|NCT01335204|DRUG|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
219080774|NCT03637946|OTHER|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
219080775|NCT03886532|OTHER|Medical Marijuana|registry and blood samples
219080776|NCT00141427|DRUG|Pregabalin|
219080777|NCT00108602|DRUG|acetazolamide|
219680733|NCT00544908|OTHER|laboratory biomarker analysis|
219680734|NCT00544908|PROCEDURE|quality-of-life assessment|
219680735|NCT05521113|BEHAVIORAL|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
219680736|NCT05521113|BEHAVIORAL|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
219680737|NCT03538704|DRUG|Metformin|Metformin is given to patients 1-1.5g/d.
219680738|NCT01135043|BEHAVIORAL|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
219080778|NCT06335433|OTHER|Exercise Training (Isometric Handgrip Exercise)|Participants allocated to the exercise groups will complete 6 weeks of isometric handgrip exercise training (IHGT) using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong) for either 2 or 4 sessions per week. Each exercise session will consist of 4 x 2-minute isometric contractions at 30% MVC with 1 minute rest periods between contractions. The first bout will be performed on the dominant arm and then the arm will be alternated for each subsequent two-minute bout. Participants will be instructed to try keep the contraction tension as close as possible to the set tension of 30% MVC using visual feedback from the dynamometer's electronic display.
219080779|NCT00713440|OTHER|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
219080780|NCT05108792|OTHER|NO INTERVENTION|observational study, no intervention performed
219680739|NCT01135043|BEHAVIORAL|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
219680740|NCT00778349|DRUG|Metformin solution 100 mg/mL|
219680741|NCT04875780|BEHAVIORAL|Digital diabetes prevention app intervention|"16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
219080781|NCT02425332|DEVICE|Lokomat gait trainer|
219080782|NCT05895266|DRUG|ABBV-903|Oral Tablet
219080783|NCT05895266|DRUG|Midazolam|Oral Liquid
219080784|NCT02825082|PROCEDURE|Abdominal emergency surgery|all abdominal emergency surgery procedures
219080785|NCT02436330|BEHAVIORAL|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
219080786|NCT02436330|BEHAVIORAL|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
219080787|NCT00174525|DRUG|AAB-001|
219080788|NCT02162784|DRUG|Budesonide/Procaterol, 180/10mcg X1|one puff
219080789|NCT02162784|DRUG|Budesonide/procaterol 180/10 mcg X 2|2 puffs
219080790|NCT02162784|DRUG|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
219080791|NCT06525948|DRUG|rhTPO|rhTPO
219680742|NCT04875780|BEHAVIORAL|Digital weight loss tracking app intervention|"All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
219680743|NCT04875780|BEHAVIORAL|Wait-list control (usual care)|Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
219080792|NCT06525948|DRUG|Cyclosporin A|cyclosporine A
219080793|NCT03112018|BEHAVIORAL|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
219211087|NCT06778317|DIAGNOSTIC_TEST|Circulating mSEPT9 Biomarker Testing|"This intervention involves the analysis of the circulating epigenetic biomarker mSEPT9 through plasma samples collected from patients with cirrhosis. The mSEPT9 test evaluates the methylation status of the SEPT9 gene promoter using a triplicate assay. A switch in the test status, defined as a transition from triple-negative (no methylation detected in any triplicate) to at least one positive triplicate, is being investigated as a prognostic marker for the development of hepatocellular carcinoma (HCC).~The mSEPT9 test is conducted on plasma samples collected during routine blood draws at each of the 11 scheduled study visits. Samples are processed and analyzed in batches using specialized high-throughput equipment provided by Epigenomics/New Day Diagnostics. Results of the mSEPT9 test are not shared with clinicians during the study period to avoid influencing patient management, ensuring the test is purely investigational in this context."
219211088|NCT03416530|DRUG|Dordaviprone (ONC201)|Dordaviprone is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
219211089|NCT06302530|PROCEDURE|Stayer|"In group A, the intervention involves using the Strayer technique, an echo-guided recession of the gastrocnemius tendon, with local anesthesia and sedation as needed. The patient can be in a prone or supine position. Ultrasound will identify the sural nerve and blood vessels to prevent damage. The entry point is 2-3 cm distal to the medial head of the gastrocnemius. Local anesthetic is infiltrated, and blunt dissection creates a working space. V-shaped curettes widen the entry point without harming noble structures.~Under direct ultrasound control, a curved scalpel is inserted until reaching the medial border of the gastrocnemius tendon. Transection occurs progressively from medial to lateral while flexing the foot. Verification of complete tendon transection is done with a blunt dissector. Finally, a dressing with adhesive strips and an elastic bandage is applied, eliminating the need for sutures."
219211090|NCT06302530|PROCEDURE|Plantar transection|In group B, an echo-guided transection of the plantar tendon will be performed. Local anesthesia and sedation will be used as needed. The patient will be in prone or supine position. The plantar tendon will be identified ultrasonographically on the medial aspect of the gastrocnemius distal to the myotendinous junction. Local anesthetic will be infiltrated at that point to isolate the plantar tendon. An ultrasound-guided retrograde hook is introduced until the plantar tendon is engaged. Then proceed to retrograde transection of the tendon from lateral to medial, verifying complete section. At the end, a dressing with adhesive strips and elastic bandage, without sutures, will be performed.
219211091|NCT06302530|PROCEDURE|Baumann|It consists of an ultrasound-guided recession of the anterior gastrocnemius aponeurosis. Under local anesthesia, the myotendinous junction is accessed 3 cm proximal to the myotendinous junction, using saline for hydrodissection. Under ultrasound guidance, the entry portal is enlarged and a scalpel is introduced for transection of the aponeurosis and plantar tendon. The procedure is verified with a buttoned probe and does not require sutures. The patient wears a Walker boot for 4 weeks and follows a stretching protocol.
219211092|NCT06302530|PROCEDURE|Gastro-Soleus|This technique adapts the Strayer technique to include the soleus. Under local anesthesia, access is gained 4-5 cm distal to the medial head of the gastrocnemius. Transection of the gastrocnemius aponeurosis and a superficial section of the soleus tendon are performed, all under ultrasound guidance. Without the need for sutures, the patient wears a Walker boot for 4 weeks and follows a progressive rehabilitation protocol.
219211093|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
219211094|NCT03424525|DRUG|11C-Trimethoprim|\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
219680744|NCT03338504|DIAGNOSTIC_TEST|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
219080794|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
219080795|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
219080796|NCT03112018|BEHAVIORAL|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
219080797|NCT03112018|BEHAVIORAL|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
219080798|NCT00003132|DRUG|bryostatin 1|
219080799|NCT00003132|DRUG|cisplatin|
219080800|NCT04321239|BEHAVIORAL|Positive STEPS|Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
219680745|NCT03338504|RADIATION|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
219680746|NCT03338504|DIAGNOSTIC_TEST|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
219680747|NCT00000267|DRUG|Risperidone|
219680748|NCT03131687|DRUG|tirzepatide|Administered SC
219680749|NCT03131687|DRUG|Dulaglutide|Administered SC
219680750|NCT03131687|DRUG|Placebo|Administered SC
219680751|NCT02651337|DEVICE|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
219680752|NCT04555707|DRUG|Apremilast 30mg|30mg PO BID started within 10 days of baseline
219680753|NCT04555707|DRUG|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
219680754|NCT00869128|DRUG|Circadin|2 mg prolonged-release melatonin
219680755|NCT00869128|DRUG|Placebo|
219680756|NCT05137002|DRUG|CIN-107|CIN-107 tablets by mouth once daily
219680757|NCT05137002|DRUG|Placebo|Placebo tablets by mouth once daily
219680758|NCT02998996|BIOLOGICAL|15 µg HA/strain and 1% Endocine™|intranasal administration
219080801|NCT01146496|DEVICE|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
219080802|NCT03270605|PROCEDURE|Myomectomy|Surgical removal of uterine fibroid
219080803|NCT02599415|DEVICE|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
219080804|NCT05718375|DRUG|CU01-1001|CU01-1001
219080805|NCT05718375|DRUG|Placebo|Placebo
219080806|NCT04851483|DRUG|BAY2328065|Solid Form, Oral administration.
219080807|NCT04851483|DRUG|Placebo|Matching placebo of BAY2328065.
219080808|NCT04665635|PROCEDURE|Rectosigmoid resection|Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
219080809|NCT05971719|DIAGNOSTIC_TEST|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
219080810|NCT01795430|DRUG|etoposide|Given IV
219080811|NCT01795430|DRUG|ifosfamide|Given IV
219080812|NCT01795430|RADIATION|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
219080813|NCT01795430|DRUG|topotecan hydrochloride|Given IV
219080814|NCT01795430|DRUG|busulfan|Given IV
219080815|NCT01795430|DRUG|melphalan|Given IV
219080816|NCT01795430|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
219680759|NCT02998996|BIOLOGICAL|15 µg HA/strain and 2% Endocine™|intranasal administration
219680760|NCT02998996|BIOLOGICAL|15 µg HA/strain|intranasal administration
219680761|NCT02998996|BIOLOGICAL|intramuscular comparator|intramuscular administration
219680762|NCT02998996|BIOLOGICAL|intranasal comparator|intranasal administration
219080817|NCT01795430|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
219080818|NCT01795430|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
219080819|NCT00998608|DRUG|risperidone|risperidone 4mg/d
219080820|NCT04512521|DRUG|Mepolizumab|Mepolizumab therapy
219211095|NCT06770595|BEHAVIORAL|breastfeeding positions and attachment practice.|Breastfeeding clinical demonstration is a method of presentation of skills that shows how a particular procedure is performed in position and attachment breastfeeding. Respondents in this group will receive education provided face-to-face once with a duration of 40 minutes, with the following details: first, 25 minutes of education about breastfeeding position and attachment. In this case, the lactation counselor first explains the correct position and attachment for breastfeeding. Respondents were asked to carry out a practical simulation regarding the correct breastfeeding position and attachment using a doll, in this case, the lactation counselor will assess how the mother is positioned and attached. second, 10 minutes of education about swollen breasts and how to deal with them. third, a 10-minute question and answer session related to the educational material provided.
219211096|NCT06830434|PROCEDURE|Crown lengthening surgery|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a single operator. After anesthesia, the distance from the gingival margin to the cementoenamel junction will be measured, and these values will be transferred to the gingival tissue to guide the procedure. Excess gingival tissue will be excised, and, when necessary, an osteotomy will be performed to re-establish the supracrestal attachment tissues.
219211097|NCT05862324|BIOLOGICAL|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
219211098|NCT05663346|OTHER|Cannabis & Cancer digital educational intervention|The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
219211099|NCT05663346|OTHER|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
219211100|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
219211101|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
219211102|NCT05065281|OTHER|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
219211103|NCT06818721|DRUG|Intravitreal topotecan|Patients who meet all inclusion criteria and none of the exclusion criteria will receive intravitreal topotecan (8 µg in 0.05 mL). The treatment will be administered within one week before retinal detachment surgery (pneumatic retinopexy, pars plana vitrectomy, and/or scleral buckling) and one week after surgery, for a total of two injections.
219211104|NCT06818721|PROCEDURE|Retinal detachment surgery|Standard retinal detachment surgery (pneumatic retinopexy, three-port pars plana vitrectomy, and/or scleral buckling).
219211105|NCT06889558|PROCEDURE|tenting titanium technique|technique used to increase bone augmentation and increase bone volume
219211106|NCT06889558|PROCEDURE|tenting titanium screw|technique used for increase bone voliume
219211107|NCT06763718|OTHER|Modified Qigong Breathing Exercise|"The exercise is recommended to be performed standing, or modified standing with trunk leaning forward and bilateral upper extremities support on countertop. Initial position: Stand up with feet shoulder-width apart, hands down along the body, or put palms on the abdomen. Take a deep breath, squaring shoulders, and pull in belly at the same time. Hold breath for 3 to 4 seconds, while keeping abdomen retracted with maximally contracting abdominal muscles. Exhale, so the shoulders go back to the starting position, while chest and abdominal muscles relax. Repeat this exercise 10 times. Note. If the stomach is difficult to draw in a standing position, it is possible to perform the exercise with both hands resting on support.~Duration: 30 minutes, 3 days/ week for 8 weeks"
219211108|NCT06763718|OTHER|Control|No exercise will be given to the participants in the control group
219211109|NCT06834958|PROCEDURE|Appendectomy|Open surgery for appendix which is inflamed
219211110|NCT00353496|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
219680763|NCT02998996|BIOLOGICAL|Placebo, Saline|intranasal administration
219680764|NCT01136564|DRUG|Zemplar|2 capsules of 1 microgram daily
219080821|NCT00109616|BEHAVIORAL|Newborn skin cleansing with 0.25% chlorhexidine solution|
219080822|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with soap and water solution|
219080823|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with 4% chlorhexidine|
219080824|NCT00146575|DEVICE|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
219080825|NCT00146575|DEVICE|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
219080826|NCT00162370|DRUG|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
219080827|NCT00606775|DRUG|Carvedilol|2.5-5mg/day
219080828|NCT03154216|BEHAVIORAL|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
219211111|NCT00353496|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
219211112|NCT06818630|OTHER|SkinCeuticals combination skin care products|"1. CE Ferulic Serum,~2. Discoloration Defense (3% Tranexamic Acid),~3. Triple Lipid Restore 2:4:2"
219211113|NCT06818630|OTHER|Regular skin care procedure|"1. Regular moisturizing product (Phyto Corrective Gel),~2. sunscreen (Advanced Brightening UV Defense SPF50 PA++++)"
219680765|NCT01136564|DRUG|Placebo|2 capsules daily
219680766|NCT02447913|BEHAVIORAL|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
219680767|NCT01118663|DRUG|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
219080829|NCT03154216|OTHER|Drink|Beverage to be consumed after exercise
219080830|NCT00877331|BEHAVIORAL|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
219211114|NCT05892055|OTHER|MRI Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
219211115|NCT06773624|OTHER|PET/CT-enterography with 68Ga-DOTATOC|Patients underwent to PET/CT-enterography with 68Ga-DOTATOC
219211116|NCT06575595|BIOLOGICAL|Tulisokibart|single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
219080831|NCT03683485|PROCEDURE|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
219080832|NCT03683485|PROCEDURE|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
219080833|NCT01115257|PROCEDURE|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
219211117|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group|Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.
219211118|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Lower dose group|The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.
219211119|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for higher dose group|The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
219211120|NCT06842784|OTHER|Ambient heat stress|3-hour ambient heating in 44°C and 20% relative humidity
219211121|NCT01746849|BIOLOGICAL|Palifermin|
219211122|NCT01746849|BIOLOGICAL|Lupron|
219211123|NCT01746849|PROCEDURE|peripheral blood stem cell transplantation|
219211124|NCT01746849|RADIATION|Total-Body Irradiation (TBI)|
219211125|NCT01746849|DRUG|Thiotepa|
219211126|NCT01746849|DRUG|Cyclophosphamide|
219680768|NCT01118663|DRUG|Acetadote|Acetadote \[old formulation\] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
219680769|NCT03338283|OTHER|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
219080834|NCT01115257|PROCEDURE|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
219080835|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
219080836|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
219211127|NCT01746849|DRUG|Degarelix|
219211128|NCT01906853|BIOLOGICAL|BCG|
219211129|NCT06746714|BEHAVIORAL|Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)|The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.
219211130|NCT06746714|BEHAVIORAL|Usual care, after system-side dissemination of HOAP|Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.
219211131|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
219211132|NCT05186636|OTHER|KPI reports|Quarterly
219211133|NCT05186636|OTHER|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
219211134|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
219211135|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
219211136|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
219080837|NCT00000602|DRUG|hydroxyurea|
219080838|NCT00095524|DRUG|Aripiprazole|
219080839|NCT03624504|DEVICE|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
219080840|NCT03341390|DRUG|Aspirin|1 x 325 mg tablet of aspirin administered once daily
219080841|NCT03341390|DRUG|BMS-986177|200 mg of BMS-986177 administered twice daily
219080842|NCT03341390|DRUG|Placebo|200 mg of Placebo administered twice daily
219080843|NCT06066060|DRUG|JMKX000623|JMKX000623, administered orally ;
219080844|NCT06066060|DRUG|Metformin|Metformin,administered orally
219080845|NCT04822220|OTHER|Fatigue Self-management Programme|Fatigue Self-management Programme
219080846|NCT04298593|DEVICE|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
219080847|NCT00611143|DRUG|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
219080848|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
219080849|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
219080850|NCT01505023|DIETARY_SUPPLEMENT|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
219211137|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
219211138|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
219211139|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
219211140|NCT05935644|BEHAVIORAL|ORCHID|The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
219080851|NCT02862457|DRUG|Epacadostat 25 mg|Oral administration
219080852|NCT02862457|DRUG|Epacadostat 100 mg|Oral administration
219080853|NCT02862457|BIOLOGICAL|pembrolizumab 200 mg|Intravenous (IV) infusion
219080854|NCT02862457|DRUG|Cisplatin 75 mg/m^2|IV infusion
219080855|NCT02862457|DRUG|Carboplatin Area Under the Curve (AUC) 5|IV infusion
219211141|NCT06336655|DEVICE|IABP|LV unloading via intra-aortic balloon pump (IABP)
219211142|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
219080856|NCT02862457|DRUG|Pemetrexed 500 mg/m^2|IV infusion
219080857|NCT02862457|DRUG|Paclitaxel 200 mg/m^2|IV infusion
219080858|NCT02862457|DRUG|Carboplatin AUC 6|IV infusion
219211143|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
219211144|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219211145|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
219211146|NCT06928389|DRUG|Ivonescimab, docetaxel|Patients will receive ivonescimab and docetaxel as an IV injection
219080859|NCT01782066|BIOLOGICAL|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
219080860|NCT04496219|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy
219080861|NCT04496219|BIOLOGICAL|BCG Solution|Given by intravesical injection
219211147|NCT06928389|DRUG|Placebo, docetaxel|Patients will receive placebo and docetaxel as an IV injection
219211148|NCT01470144|DRUG|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
219080862|NCT04496219|OTHER|Best Practice|Receive standard of care symptom management
219080863|NCT04496219|OTHER|Quality-of-Life Assessment|Ancillary studies
219080864|NCT04496219|OTHER|Questionnaire Administration|Ancillary studies
219080865|NCT04752423|OTHER|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
219080866|NCT04013711|DIAGNOSTIC_TEST|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
219080867|NCT02859792|DRUG|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
219080868|NCT02859792|DRUG|Placebo|placebo capsules 25 or 50 mg
219080869|NCT02859792|BIOLOGICAL|Blood Samples|v1;v2;v3;v4
219080870|NCT02554968|OTHER|Questionnaires|
219080871|NCT05590819|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
219080872|NCT05590819|DEVICE|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
219080873|NCT05590819|DEVICE|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
219080874|NCT00672074|DRUG|Ipamorelin|IV
219211149|NCT03871036|DRUG|Tremelimumab|See experimental arm description for more details.
219211150|NCT03871036|DRUG|Durvalumab|See experimental arm description for more details.
219211151|NCT03871036|DRUG|Paclitaxel|See experimental arm description for more details.
219211152|NCT06935994|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
219680770|NCT03338283|OTHER|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
219211153|NCT06935994|DRUG|Placebo|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
219211154|NCT01663363|DEVICE|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
219211155|NCT06788795|DEVICE|Device with Phone App|This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app
219211156|NCT06788795|DEVICE|Device without Phone App|This is the intervention where the patients will receive the device alone
219211157|NCT06737315|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
219211158|NCT06789874|PROCEDURE|Intralesional Saline|Intralesional Saline injected in scars
219211159|NCT06789874|PROCEDURE|35% trichloracetic acid peel|35%Trichloracetic acid peel was applied to scars monthly for 3 months
219211160|NCT06890286|DRUG|BR3006|One tablet administered alone
219211161|NCT06890286|DRUG|BR3006A|One tablet administered alone
219211162|NCT06890286|DRUG|BR3006B|One tablet administered alone
219680771|NCT01566422|DRUG|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
219080875|NCT00672074|DRUG|placebo|IV
219211163|NCT06890286|DRUG|BR3006C|One tablet administered alone
219211164|NCT06936124|PROCEDURE|Deep Brain Stimulation of the Pedunculopontine Nucleus|The DBS implantation procedure targeting the PPN involves a neurosurgical operation performed under general anesthesia. During the procedure, thin electrodes are implanted in the PPN with the aid of advanced pre-operative imaging (MRI and CT scan) to confirm precise targeting. This device generates and transmits electrical impulses to the PPN, which can be adjusted to optimize therapeutic outcomes.
219211165|NCT06777238|DRUG|GZR18|Administered SC
219211166|NCT06777238|DRUG|Placebo|Administered SC
219211167|NCT06798194|DIAGNOSTIC_TEST|Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.|"This study developed an AI model that can provide optimal highly conformal ablation thermal field for HCC patients using ultrasound and MRI. Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.~The patients were divided into:~1. Actual ablation zone of the tumor was consistent with the highly conformal ablation thermal field (consistent group);~2. Actual ablation zone of the tumor was inconsistent with the highly conformal ablation thermal field (inconsistent group)."
219680772|NCT02419391|BIOLOGICAL|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
219080876|NCT04070924|OTHER|Bandaid|Bandaid dressing
219680773|NCT02419391|OTHER|Placebo|Tris Buffered Saline, sterile
219680774|NCT04663243|BEHAVIORAL|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
219211168|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
219211169|NCT06952413|DRUG|Rituximab(Genetical Recombination)|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
219211170|NCT06952413|DRUG|Placebo|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
219211171|NCT03580655|DRUG|Avapritinib|Avapritinib tablet
219080877|NCT04070924|OTHER|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
219080878|NCT06265350|DRUG|Cadonilimab|Cadonilimab, 375mg，Q3W， IV
219080879|NCT06265350|DRUG|Bevacizumab|Bevacizumab, 7.5mg/kg，Q3W， IV
219080880|NCT06265350|PROCEDURE|Cryoablation|Patients accepted Cryoablation of pulmanary metastases
219080881|NCT00562887|BIOLOGICAL|Placebo|every 4 weeks, IV
219211172|NCT06291233|BEHAVIORAL|Virtual Interview Training (VIT)|Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
219211173|NCT06291233|BEHAVIORAL|Services-as-usual|Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
219211174|NCT05605613|DRUG|PD-1 Antibody|PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
219211175|NCT05605613|DEVICE|BACE|Bronchial Arterial Chemoembolization
219211176|NCT04668729|OTHER|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
219211177|NCT01577524|DRUG|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
219211178|NCT01577524|DRUG|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
219211179|NCT02325466|DRUG|Aspirin|Aspirin 81mg
219080882|NCT00562887|BIOLOGICAL|ABT-874|400 mg IV every 4 weeks
219080883|NCT00562887|BIOLOGICAL|ABT-874|700 mg IV every 4 weeks
219211180|NCT02325466|DRUG|Ticagrelor|ticagrelor 90 mg
219211181|NCT02325466|DRUG|Aspirin Placebo|
219211182|NCT02325466|DRUG|Ticagrelor Placebo|
219211183|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression|In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
219680775|NCT05039125|RADIATION|ultrasonic cavitation|"* From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
219680776|NCT01468571|DRUG|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
219680777|NCT01468571|DRUG|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
219080884|NCT03923348|DEVICE|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
219080885|NCT00001926|DRUG|O15|
219080886|NCT00001926|DEVICE|Cadwell rTMS|
219080887|NCT04080050|DRUG|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
219080888|NCT02087631|DRUG|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
219080889|NCT06136975|DEVICE|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
219080890|NCT04840810|PROCEDURE|In-plane Axis|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
219080891|NCT04840810|PROCEDURE|Out of plane Axis|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
219080892|NCT02471196|DRUG|ORM-12741|ORM-12741 low dose twice a day
219080893|NCT02471196|DRUG|ORM-12741|ORM-12741 high dose twice a day
219080894|NCT02471196|DRUG|Placebo|Placebo twice a day
219080895|NCT06580873|DRUG|DOVATO|HIV-1 medication
219080896|NCT02853890|OTHER|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
219080897|NCT03457519|DEVICE|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
219080898|NCT05970627|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
219211184|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + lateral skin incision|Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
219211185|NCT06454474|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states.
219211186|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
219080899|NCT05970627|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
219080900|NCT05970627|DRUG|S1|S-1 orally intake as perioperative chemotherapy
219080901|NCT06347302|BIOLOGICAL|Blood sampling|Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
219080902|NCT06347302|OTHER|vitreous sampling|Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
219211187|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
219211188|NCT02867982|PROCEDURE|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
219211189|NCT02867982|PROCEDURE|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
219211190|NCT02867982|DRUG|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
219211191|NCT02867982|DEVICE|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
219680778|NCT06076122|DIETARY_SUPPLEMENT|Food supplement based on Salicornia extracts|Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.
219680779|NCT06076122|DIETARY_SUPPLEMENT|Placebo|Placebo capsules physically equal to the Salicornia extracts capsules
219211192|NCT02867982|RADIATION|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
219080903|NCT06347302|OTHER|Sub-retinal fluid sampling|Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.
219080904|NCT06347302|OTHER|Retinal tissue sampling|cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
219080905|NCT04160325|DIETARY_SUPPLEMENT|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
219080906|NCT04160325|DRUG|azathioprine|azathioprine
219080907|NCT04160325|OTHER|normal diet|normal diet
219080908|NCT01025440|DEVICE|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
219080909|NCT01328080|RADIATION|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
219080910|NCT00285142|DRUG|rosiglitazone|
219080911|NCT01319266|DRUG|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
219080912|NCT00862134|DRUG|PR104|770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
219080913|NCT00862134|DRUG|docetaxel|75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
219080914|NCT00862134|DRUG|docetaxel|60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
219080915|NCT00862134|DRUG|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
219080916|NCT06236750|DEVICE|EPIFIX|EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
219080917|NCT02414542|DEVICE|MINIMA stem|
219080918|NCT05776173|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
219080919|NCT04967235|OTHER|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
219080920|NCT04967235|OTHER|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
219080921|NCT01871831|DEVICE|6 blood glucose monitoring systems for self-testing|
219080922|NCT02191267|RADIATION|[F18]-T807|\[F18\]-T807 PET Scan to measure tau deposition in the brain.
219080923|NCT02191267|RADIATION|[F18]-Florbetapir|\[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
219080924|NCT02191267|DEVICE|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
219080925|NCT02191267|GENETIC|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
219080926|NCT06262568|OTHER|assess the nurse knowledge and practices.|assess the nurse knowledge and practices.
219080927|NCT00765674|DRUG|Aliskiren|150 and 300 mg tablets
219080928|NCT00765674|DRUG|Amlodipine|5 and 10 mg capsules
219080929|NCT00765674|DRUG|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
219080930|NCT00765674|DRUG|Placebo|tablet
219080931|NCT00765674|DRUG|Placebo|capsules
219080932|NCT02560948|BIOLOGICAL|Placebo solution|4 x 2 injections over 21 days
219080933|NCT02560948|BIOLOGICAL|gpASIT+TM|4 x 2 injections over 21 days
219080934|NCT00360438|DRUG|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
219080935|NCT01813474|DRUG|olaparib|tablet oral
219080936|NCT02186210|DEVICE|prewarming|recovery slope StO2
219080937|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
219080938|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
219080939|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
219080940|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
219080941|NCT00316082|DRUG|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
219080942|NCT00316082|DRUG|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
219080943|NCT01011829|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
219080944|NCT01011829|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
219080945|NCT00528775|DRUG|HPPH|4 mg/m2 IV
219080946|NCT00528775|PROCEDURE|endoscopic procedure|Treatment with 150 joules from laser
219080947|NCT05361226|OTHER|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
219080948|NCT04605796|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
219080949|NCT01121068|OTHER|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
219211193|NCT01818180|DIETARY_SUPPLEMENT|URELL|
219211194|NCT01818180|OTHER|Placebo|
219080950|NCT05117138|BIOLOGICAL|AMT-116 CAR-T cells|"1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled."
219080951|NCT05117138|BIOLOGICAL|AMT-253 CAR-T cells|"1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum)."
219080952|NCT01826812|OTHER|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
219080953|NCT01826812|OTHER|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
219080954|NCT05435274|DRUG|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
219211195|NCT05456932|DRUG|Intravenous iron|Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
219211196|NCT05456932|DRUG|Ferric maltol|Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
219211197|NCT05456932|DRUG|Ferrous fumarate|Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
219211198|NCT05044598|OTHER|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
219211199|NCT06450587|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP)
219211200|NCT06450587|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
219211201|NCT06450587|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
219211202|NCT06450587|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
219211203|NCT06231472|PROCEDURE|preoperative inferior vena cava measurement|preoperative inferior vena cava measurement
219211204|NCT05971875|PROCEDURE|vNOTES vs Vaginal Hysterectomy|Comparison of vNOTES vs VH
219211205|NCT05971875|PROCEDURE|vNOTES vs Laparoscopic Hysterectomy|Comparison of vNOTES vs LH
219211206|NCT01288443|DRUG|Alirocumab|Two SC injections in the abdomen only.
219211207|NCT01288443|DRUG|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
219080955|NCT00276640|DRUG|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
219080956|NCT00276640|DRUG|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
219080957|NCT00276640|RADIATION|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
219080958|NCT01955954|DEVICE|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
219080959|NCT04901650|DIAGNOSTIC_TEST|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
219211208|NCT01288443|DRUG|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
219211209|NCT01596972|DEVICE|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
219211210|NCT04327843|BEHAVIORAL|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
219680780|NCT04594109|BEHAVIORAL|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
219680781|NCT04594109|BEHAVIORAL|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
219680782|NCT01321632|DRUG|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
219080960|NCT03185533|BEHAVIORAL|Quality improvement (QI) interventions|"1\. The ED admissions exhibited prolonged length of stay.~2\. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3\. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting."
219080961|NCT03356379|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
219080962|NCT01744652|DRUG|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
219080963|NCT01744652|DRUG|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
219080964|NCT01207102|DRUG|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
219080965|NCT01207102|DRUG|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
219080966|NCT01560039|DEVICE|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
219080967|NCT01560039|OTHER|Neurofeedback|EEG neurofeedback based on the primary motor cortex
219080968|NCT01560039|OTHER|Sham neurofeedback|Sham EEG neurofeedback
219080969|NCT05140928|OTHER|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
219080970|NCT05140928|OTHER|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
219080971|NCT02982005|DRUG|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
219080972|NCT02982005|DRUG|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
219080973|NCT04667312|DRUG|Durvalumab|Durvalumab
219080974|NCT01239030|DRUG|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
219211211|NCT04327843|DRUG|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
219211212|NCT01623908|DRUG|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
219211213|NCT00263549|BIOLOGICAL|House dust mite Novo Helisen Depot|
219211214|NCT02745249|BEHAVIORAL|Maternal Nutrition Behavior change|
219680783|NCT02716584|BEHAVIORAL|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
219080975|NCT01239030|DRUG|Placebo|Placebo capsules
219080976|NCT06457828|PROCEDURE|Non-corticosteroid injection|no infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
219080977|NCT06457828|DRUG|Corticosteroid injection|infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
219080978|NCT04136886|DRUG|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
219080979|NCT04136886|RADIATION|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
219080980|NCT05584891|PROCEDURE|mastoidectomy and mastoid oblitration|Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
219080981|NCT00990990|DRUG|PNU-100480|100 mg BID for 14 days
219080982|NCT00990990|DRUG|Placebo|to match 100 mg BID for 14 days
219080983|NCT00990990|DRUG|PNU-100480|300 mg BID for 14 days
219080984|NCT00990990|DRUG|Placebo|to match 300 mg BID for 14 days
219080985|NCT00990990|DRUG|PNU-100480|600 mg BID for 14 days
219080986|NCT00990990|DRUG|Placebo|to match 600 mg BID for 14 days
219080987|NCT00990990|DRUG|PNU-100480|1200 mg QD for 14 days
219080988|NCT00990990|DRUG|Placebo|to match 1200 mg QD for 14 days
219080989|NCT00990990|DRUG|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
219080990|NCT00990990|DRUG|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
219080991|NCT00990990|DRUG|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
219080992|NCT00990990|DRUG|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
219080993|NCT00990990|DRUG|Linezolid|300 mg QD for 4 days (open label)
219211215|NCT05792956|BEHAVIORAL|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
219211216|NCT04946682|DIAGNOSTIC_TEST|Types of etiological diagnostic methods|In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.
219211217|NCT03656211|OTHER|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
219211218|NCT05967858|OTHER|observation|no intervention
219211219|NCT02029469|DEVICE|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
219680784|NCT02716584|BEHAVIORAL|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
219680785|NCT04291118|PROCEDURE|Private system endoscopic sinus surgery|Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
219680786|NCT04291118|PROCEDURE|Public system endoscopic sinus surgery|Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
219680787|NCT04291118|DRUG|Budesonide|Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
219680788|NCT01423929|DRUG|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
219680789|NCT01423929|DEVICE|Room air|Fitting of Oxymask TM
219680790|NCT03578133|DIAGNOSTIC_TEST|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
219680791|NCT05642104|DRUG|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
219080994|NCT05618795|OTHER|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
219080995|NCT03494387|DRUG|Oxygen|80% versus 30% inspiratory oxygen concentration
219080996|NCT03494387|DRUG|Antioxidants|Antioxidants versus placebo
219080997|NCT02495272|DRUG|Oxytocin|Oxytocin 10IU Administered intramuscularly.
219080998|NCT00829387|BEHAVIORAL|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
219080999|NCT00829387|BEHAVIORAL|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
219081000|NCT00796081|DRUG|ER OROS paliperidone, paliperidone ER|
219081001|NCT05257096|BEHAVIORAL|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
219081002|NCT03157609|DEVICE|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
219081003|NCT04575636|DIAGNOSTIC_TEST|Magnetic Resonance Lymphography|Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system
219680792|NCT03466723|GENETIC|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
219680793|NCT02555917|PROCEDURE|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
219680794|NCT03635762|BEHAVIORAL|Be In Charge|comparison of pre and post-program weight and calorie intake
219081004|NCT00100685|DRUG|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
219081005|NCT04807465|DEVICE|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
219211220|NCT05274321|DEVICE|Nanodropper|Device used for administering eye drops
219211221|NCT05274321|DEVICE|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
219211222|NCT01223924|OTHER|placebo|placebo
219211223|NCT01223924|DRUG|M2ES|M2ES IV 7.5mg-90mg
219211224|NCT04630509|PROCEDURE|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
219211225|NCT06112600|PROCEDURE|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
219211226|NCT06112600|PROCEDURE|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
219211227|NCT04738201|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
219211228|NCT01356524|DRUG|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
219211229|NCT01105975|DRUG|LY2484595|Administered daily by mouth for 12 weeks
219680795|NCT04356287|BIOLOGICAL|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
219680796|NCT04356287|OTHER|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
219081006|NCT04807465|DEVICE|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
219081007|NCT04807465|DEVICE|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
219081008|NCT01464541|PROCEDURE|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
219081009|NCT01464541|PROCEDURE|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
219211230|NCT01105975|DRUG|Atorvastatin|Administered daily by mouth for 12 weeks
219680797|NCT02787122|BEHAVIORAL|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
219680798|NCT02787122|BEHAVIORAL|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
219680799|NCT05279131|DRUG|Tirbanibulin ointment 1%|Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
219680800|NCT04350047|PROCEDURE|Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy|The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
219680801|NCT04855331|PROCEDURE|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
219680802|NCT04855331|PROCEDURE|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
219680803|NCT01564992|OTHER|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
219680804|NCT03682029|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
219680805|NCT03682029|OTHER|Placebo|Placebo
219680806|NCT05988346|PROCEDURE|abdominal plastic intervention|According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
219680807|NCT00821197|PROCEDURE|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
219680808|NCT00821197|PROCEDURE|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
219680809|NCT06955676|OTHER|treadmill exercise|Intervention consists of exercises only. Participants in this group will walk on a treadmill. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
219680810|NCT06955676|OTHER|cycle ergometer exercise|Intervention consists of exercises only. Participants in this group will cycle on an ergometer. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
219680811|NCT01940640|DIETARY_SUPPLEMENT|DHA|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
219081010|NCT01767558|OTHER|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
219081011|NCT05874765|DIAGNOSTIC_TEST|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5)|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5) , will be used to diagnose and classify the Tics among all included patients
219081012|NCT03735264|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
219081013|NCT04636970|OTHER|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
219211231|NCT01105975|DRUG|Simvastatin|Administered daily by mouth for 12 weeks
219211232|NCT01105975|DRUG|Rosuvastatin|Administered daily by mouth for 12 weeks
219081014|NCT02341430|DEVICE|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
219081015|NCT01417689|OTHER|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
219211233|NCT01105975|DRUG|Placebo for LY2484595|Administered daily by mouth for 12 weeks
219211234|NCT01105975|DRUG|Placebo for Statins|Administered daily by mouth for 12 weeks
219211235|NCT00902213|BEHAVIORAL|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
219680812|NCT01940640|DIETARY_SUPPLEMENT|control|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
219680813|NCT02250456|PROCEDURE|Echo doppler|vascular ultrasound explorations
219680814|NCT00159770|DRUG|ziprasidone versus olanzapine , risperidone or quetiapine|
219680815|NCT00159770|BEHAVIORAL|Panss , CGI-C, UKU-SERS-Pa|
219680816|NCT00159770|PROCEDURE|Blood tests|
219081016|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
219081017|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Medical management
219081018|NCT01944865|OTHER|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
219081019|NCT01944865|OTHER|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
219081020|NCT02128464|PROCEDURE|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
219081021|NCT02128464|PROCEDURE|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
219081022|NCT04740489|BEHAVIORAL|Phase 3 Cardiac rehabilitation|Phase 3 CR is a comprehensive outpatient programme, considered the core rehabilitation phase, in which participants receive structured exercise, health education, risk factor modification and psychological support. Upon discharge from clinically supervised phase 3 CR participants are generally signposted to long-term community-based exercise classes (phase 4). The current study will take place within a core phase 3 CR programme in the UK.
219081023|NCT04462666|DRUG|Huzhang granule|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
219081024|NCT04462666|DRUG|Etoricoxib|take one capsule per day in the morning, at approximately 30 minutes after the meal.
219081025|NCT04462666|DRUG|Huzhang granule Placebo|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
219081026|NCT04462666|DRUG|Etoricoxib Placebo|take one capsule per day in the morning, at approximately 30 minutes after the meal.
219081027|NCT01385072|BIOLOGICAL|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
219081028|NCT03778879|DRUG|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
219081029|NCT05738993|DRUG|BCD-178|A single intravenous (IV) infusion at a dose of 420 mg
219081030|NCT05738993|DRUG|Perjeta|A single intravenous (IV) infusion at a dose of 420 mg
219081031|NCT00282022|DRUG|laromustine|
219081032|NCT04062357|DRUG|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
219081033|NCT04062357|OTHER|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
219081034|NCT01963325|DRUG|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
219081035|NCT04470245|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI)|Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
219211236|NCT00902213|BEHAVIORAL|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
219680817|NCT00331539|DEVICE|Cochlear Implant|
219680818|NCT06298955|DRUG|OMS906 study drug|OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
219680819|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
219680820|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
219680821|NCT06294535|DEVICE|reconstruction of orbital walls|under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap.
219680822|NCT04047732|BIOLOGICAL|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
219081036|NCT00818753|DRUG|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
219680823|NCT02546869|DRUG|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
219680824|NCT02546869|DEVICE|Prefilled Syringes|
219081037|NCT00818753|DRUG|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
219081038|NCT00818753|DRUG|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
219081039|NCT05450965|DRUG|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
219081040|NCT03565445|DRUG|ASP1948|Intravenously (IV)
219081041|NCT03565445|DRUG|nivolumab|Intravenously (IV)
219081042|NCT03565445|DRUG|pembrolizumab|Intravenously (IV)
219081043|NCT04770025|DEVICE|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
219081044|NCT04770025|DEVICE|Sham stimulation|High-density electrode configuration with sham stimulation
219081045|NCT04770025|BEHAVIORAL|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
219081046|NCT05295498|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
219081047|NCT05295498|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
219081048|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
219081049|NCT06440915|DRUG|Isavuconazole|Isavuconazole
219081050|NCT02504658|BEHAVIORAL|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
219081051|NCT02504658|BEHAVIORAL|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
219081052|NCT02289391|DRUG|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
219081053|NCT02289391|DRUG|Anesthesia maintenance|"* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60."
219081054|NCT02289391|DRUG|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
219081055|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
219081056|NCT02245958|OTHER|No Intervention|No treatment (intervention) was administered.
219081057|NCT02357251|OTHER|Enhanced recovery protocol|
219081058|NCT04304833|OTHER|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
219081059|NCT04304833|BEHAVIORAL|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
219081060|NCT03253224|DRUG|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
219081061|NCT03253224|DRUG|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
219081062|NCT01951625|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
219081063|NCT01951625|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
219081064|NCT01951625|DRUG|Placebo|
219081065|NCT02703675|DEVICE|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
219211237|NCT05909449|OTHER|exercises|participants will be given a structured home exercise program
219211238|NCT06062641|DRUG|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
219211239|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
219081066|NCT00057668|BEHAVIORAL|Multi-Setting Early Intervention|
219081067|NCT00057668|BEHAVIORAL|Community Intervention|
219081068|NCT02470546|DRUG|Metformin|Metformin 1000mg twice a day
219081069|NCT02470546|DRUG|Placebo|Placebo 1000mg twice a day
219081070|NCT06670820|DEVICE|Active rTMS|iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions
219081071|NCT06670820|DEVICE|Sham rTMS|sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
219211240|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
219081072|NCT06670612|OTHER|nature based music concert|It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
219081073|NCT06669481|OTHER|Semiquantitative 131I-MIBG Scintigraphy Assessment|Patients received thyroid blockade using solution of potassium iodide before the examination. After intravenous administration of 111 MBq of 131I-MIBG, whole body planar images were acquired at 24 hours (Day 1) and 48 hours (Day 2), respectively.
219081074|NCT03129828|DRUG|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
219081075|NCT03171298|PROCEDURE|Laparoscopic Assisted Transanal Total Mesorectal Excision|"* Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally"
219211241|NCT00389194|DRUG|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
219211242|NCT00179751|DRUG|CC-5013|
219081076|NCT06669793|DEVICE|biolimus-coated balloon|238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.
219211243|NCT00179751|DRUG|gemcitabine|
219211244|NCT03562338|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
219211245|NCT03562338|OTHER|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
219211246|NCT05889299|DRUG|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
219211247|NCT04761042|OTHER|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
219081077|NCT06669793|DEVICE|paclitaxel-coated balloon|237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
219211248|NCT04761042|OTHER|WAYA-Holiday|"An attention control group (information in Detailed description)"
219081078|NCT05815329|OTHER|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
219211249|NCT06433713|DRUG|Lidocaine IV|They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
219680825|NCT02843815|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
219081079|NCT01296451|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
219081080|NCT01296451|BIOLOGICAL|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
219081081|NCT01296451|BIOLOGICAL|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
219081082|NCT05780346|OTHER|TGNB-CARE (Connecting and Reflecting Experience)|12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
219211250|NCT06433713|DRUG|Placebo|0.9% normal saline infusion
219680826|NCT02843815|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
219680827|NCT06247839|DRUG|Psilocybin|COMP360 (Brand name of psilocybin to be used)
219680828|NCT05022459|DRUG|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
219211251|NCT00000119|DEVICE|Heparin Surface-Modified Intraocular Lens|
219211252|NCT02132455|PROCEDURE|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
219211253|NCT02348632|DRUG|JZP-110|
219211254|NCT01158417|DRUG|Placebo|oral
219211255|NCT01158417|DRUG|Resveratrol 40 mg oral three times a day|Drug
219081083|NCT06668311|OTHER|play dough|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
219081084|NCT06668311|OTHER|picture book reading|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
219081085|NCT02459574|PROCEDURE|AVATAR-AF ablation|Experimental ablation protocol
219081086|NCT02459574|DRUG|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
219081087|NCT02459574|PROCEDURE|Conventional AF ablation|Conventional ablation procedure
219081088|NCT05924126|OTHER|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
219081089|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
219081090|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
219081091|NCT00251745|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
219081092|NCT06626191|PROCEDURE|Interscalene brachial plexus block|"Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219081093|NCT06626191|PROCEDURE|Serratus posterior superior intercostal plane block|"Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219081094|NCT06626191|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
219081095|NCT00636649|DRUG|Escitalopram|10-20 mg
219081096|NCT00636649|DRUG|Placebo|Placebo
219680829|NCT05022459|DRUG|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
219680830|NCT06958393|DRUG|Dexmedetomidine|Continuous infusion at 0.5-1.0 μg/kg/h during surgery
219680831|NCT06958393|DRUG|Esketamine|Induction dose 0.3-0.5 mg/kg; maintenance 0.2-0.5 mg/kg/h; 0.02 mg/kg at closure; PCIA: 1.5 mg/kg in 100 mL saline
219081097|NCT04839679|BEHAVIORAL|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
219081098|NCT04839679|BEHAVIORAL|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
219081099|NCT04866017|DRUG|Tislelizumab|200 mg intravenously every three weeks
219081100|NCT04866017|DRUG|Durvalumab|10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
219081101|NCT04866017|DRUG|Ociperlimab|900 milligrams (mg) intravenously every three weeks
219211256|NCT01158417|DRUG|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
219211257|NCT05609734|OTHER|no intervention, only observational retrospective study|no intervention, only observational retrospective study
219680832|NCT06958393|DRUG|Esmolol|Maintenance 20-100 μg/kg/min during surgery
219680833|NCT06958393|DRUG|Sufentanil|0.3-0.5 μg/kg induction; 0.15 μg/kg at closure; 2 μg/kg in 100 mL for PCIA
219211258|NCT00412646|DRUG|TMC125|
219211259|NCT05427305|DRUG|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
219211260|NCT05427305|DRUG|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
219211261|NCT01189149|PROCEDURE|IV fluids|Infants will be allocated to IV fluids
219211262|NCT01189149|PROCEDURE|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
219211263|NCT05899699|DRUG|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
219211264|NCT05899699|DRUG|Adapalene .1% gel|Adapalene .1% gel
219211265|NCT02284113|DEVICE|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
219211266|NCT02284113|DEVICE|iovera° Sham|iovera° device used for sham treatment
219211267|NCT03006367|DRUG|NFC-1 100 mg|
219211268|NCT03006367|DRUG|NFC-1 200 mg|
219211269|NCT03006367|DRUG|NFC-1 400 mg|
219211270|NCT03006367|DRUG|NFC-1 800 mg|
219680834|NCT06958393|DRUG|Remifentanil|0.2-1.0 μg/kg/min maintenance
219680835|NCT06359262|OTHER|Hope@School|A digital platform aimed at promoting student mental health in schools
219680836|NCT06359262|OTHER|Treatment as usual|Regular student health care in schools
219081102|NCT04866017|DRUG|Chemotherapy|"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
219081103|NCT04866017|RADIATION|Radiotherapy|All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
219680837|NCT05178823|DRUG|Chlorhexidine mouthwash|Comparison of oral rinses
219081104|NCT01475136|DRUG|LY2140023|
219081105|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
219081106|NCT06733727|DRUG|Letrozole|Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage
219081107|NCT06733727|DRUG|Mifepristone|Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
219081108|NCT06731920|DIAGNOSTIC_TEST|cervical medial branch block|ultrasound-guided cervical medial branch block with fluoroscopic control and digital subtraction angiography
219081109|NCT06733233|DRUG|T-DXd combined with immune checkpoint inhibitor|Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses.
219081110|NCT06732310|BEHAVIORAL|Pregnant Moms' Empowerment Program|Women who receive the PMEP complete a structured set of sessions delivered over the course of 5 weeks, each session lasts 2 hours in duration: (1) becoming a group \& safety planning, (2) identifying and understanding sources of stress, (3) strategies to build resilience and resolve conflict, (4) perinatal health and infant care, and (5) positive parenting.
219081111|NCT06732310|BEHAVIORAL|Reminiscing and Emotion Training|Each of the 5 RET sessions are 1 hour in duration. The program is manualized and each session includes teaching/review of skills, instructions/activity with rationale, reminiscing practice, and immediate video feedback by a family coach.
219081112|NCT06732310|BEHAVIORAL|Pregnancy - Active Control|Women who are not randomized to the PMEP participate in a contact-equivalent, nondirective social support group.
219081113|NCT06732310|BEHAVIORAL|Enhanced Case Management|Families randomized to this attentional control condition will receive enhanced case management. They will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials (e.g., Adventures in Parenting curriculum developed by NICHD) that were selected to not overlap with RET content (e.g., reading together, fitness, etc.). Using mothers' responses regarding access to resources on the Family Resource Scale (Dunst \& Leet, 1987), which is completed during the baseline visit, mothers will also receive referrals to community resources for items rated as inadequate.
219081114|NCT03355326|DRUG|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
219081115|NCT06359769|BEHAVIORAL|Group Cognitive Evolutionary Therapy|In-person therapy group. Delivery method: in-person groups. Number of sessions: 2. Duration of each session: 8 hours. Topics to be covered in the sessions are informed by the answers to the Fitness Evaluation Scale, following an adapted protocol of Cognitive Therapy for Depression.
219081116|NCT05622305|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
219081117|NCT05986578|DEVICE|TMS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dmPFC, approximately 25% of the nasion-inion distance or Talairah coordinates X 0 Y+60 Z+60 will be measured. The first session will begin with the acquisition of the resting motor threshold (rMT) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last \~3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
219211271|NCT03756896|DRUG|Carfilzomib|Given IV
219211272|NCT03756896|DRUG|Dexamethasone|Given PO
219680838|NCT04780815|OTHER|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
219680839|NCT04780815|OTHER|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
219081118|NCT05986578|DEVICE|TMS to dlPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dlPFC, position F3 will be measured, using probabilistic EEG placement. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last 3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
219081119|NCT05986578|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
219081120|NCT06831864|DRUG|HFrEF Polypill|"The heart failure with reduced ejection fraction (HFrEF) polypill will include 4 guideline recommended medications used to treat HFrEF patients. The dose of initiation and titration will be at the investigator's discretion.~HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 3: bisoprolol 10 mg + losartan 100 + eplerenone 50 mg + dapagliflozin 10 mg"
219081121|NCT06831864|OTHER|Comparator Arm|Participants in the comparator control group will receive usual care by their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines.
219081122|NCT04854291|OTHER|Administration of donor FMT|Intracaecal infusion of FMT
219081123|NCT04854291|OTHER|Administration of placebo|Intracaecal infusion of carrier solution
219081124|NCT05451251|DEVICE|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine lesion
219081125|NCT06931262|DRUG|Dichloroacetate (DCA)|Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL) Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens: EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA.
219081126|NCT05477745|PROCEDURE|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
219081127|NCT05665699|DRUG|D-0120|increasing dose of D-0120
219081128|NCT05665699|DRUG|Allopurinol|standard dosing
219081129|NCT06952712|DRUG|Aspirin 100mg|Aspirin 100mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
219081130|NCT06952712|DRUG|Aspirin 150mg|Aspirin 150mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
219081131|NCT05892328|OTHER|Watermelon Flesh Dose 1|1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
219081132|NCT05892328|OTHER|Watermelon Flesh Dose 2|2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
219081133|NCT05892328|OTHER|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
219081134|NCT06225167|BEHAVIORAL|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
219081135|NCT01965405|DRUG|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
219081136|NCT01965405|BEHAVIORAL|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
219081137|NCT01965405|BEHAVIORAL|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
219081138|NCT01965405|BEHAVIORAL|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
219081139|NCT01965405|BEHAVIORAL|No additional treatment|No additional treatment will be given.
219081140|NCT01965405|BEHAVIORAL|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
219081141|NCT01965405|BEHAVIORAL|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
219081142|NCT02142647|BEHAVIORAL|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
219081143|NCT02142647|BEHAVIORAL|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
219081144|NCT00388310|PROCEDURE|Culture|Culture
219081145|NCT04536311|PROCEDURE|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
219081146|NCT05634239|BEHAVIORAL|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
219081147|NCT06526403|DEVICE|Zero-fluoroscopy ASD closure|Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
219081148|NCT00238030|DRUG|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
219081149|NCT00238030|DRUG|iv thryoxine|thyroxine 2 mcg/kg iv
219081150|NCT04274270|DRUG|Endostar|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
219081151|NCT02273284|DEVICE|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
219081152|NCT04604002|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
219081153|NCT04604002|DEVICE|Color Fundus Photography|Non-contact white light photography
219081154|NCT04604002|DEVICE|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
219081155|NCT03160989|OTHER|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
219081156|NCT04649866|DIAGNOSTIC_TEST|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline"
219211273|NCT03756896|DRUG|Pomalidomide|Given PO
219680840|NCT05236907|DRUG|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
219081157|NCT04333420|DRUG|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
219081158|NCT04333420|DRUG|BSC|Phase II study part: BSC
219081159|NCT04333420|DRUG|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
219081160|NCT04333420|DRUG|Placebo + SOC|Phase III study part: Placebo + SOC
219081161|NCT03664466|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin capsules 12 mg twice daily
219081162|NCT03664466|OTHER|Placebo|placebo capsules twice daily
219081163|NCT06550336|DRUG|Chidamide|20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
219081164|NCT03672773|DRUG|Talazoparib|Given PO
219081165|NCT03672773|DRUG|Temozolomide|Given PO
219081166|NCT03362333|OTHER|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
219081167|NCT03362333|OTHER|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
219081168|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 2 weeks
219081169|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 4 weeks
219081170|NCT00610116|DEVICE|Electronic Repositioning|Change of pacing vectors for CRT pacing
219081171|NCT02792361|PROCEDURE|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
219081172|NCT05819814|GENETIC|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
219211274|NCT00144287|DRUG|Tipranavir/Ritonavir|
219211275|NCT03809416|DEVICE|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
219211276|NCT03809416|OTHER|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
219211277|NCT03809416|COMBINATION_PRODUCT|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
219211278|NCT02901522|OTHER|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
219211279|NCT02901522|OTHER|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
219680841|NCT05236907|OTHER|No intervention|No intervention was used.
219680842|NCT05236907|DRUG|Midazolam|7.5 mg of Midazolam orally.
219680843|NCT05914818|DEVICE|EXPLORER V2|4 sessions of use of the exoskeleton, 1 in a laboratory of gait analysis and 3 in the home and the community of the participants
219211280|NCT02901522|OTHER|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
219211281|NCT02901522|OTHER|Teleconsultation|The general practioner received phone call to asthma care.
219081173|NCT02801994|DEVICE|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
219680844|NCT01427010|RADIATION|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
219680845|NCT01058291|DRUG|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
219680846|NCT01058291|DRUG|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
219680847|NCT01935986|DIETARY_SUPPLEMENT|probiotic|
219680848|NCT01935986|DIETARY_SUPPLEMENT|placebo|
219680849|NCT03272347|DRUG|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
219680850|NCT03272347|DRUG|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
219680851|NCT03272347|DRUG|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
219081174|NCT02776332|PROCEDURE|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
219081175|NCT01746693|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
219081176|NCT01746693|OTHER|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
219081177|NCT01746693|DEVICE|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
219081178|NCT01746693|OTHER|Pattern electroretinography|inner retinal function
219081179|NCT01746693|OTHER|Fourier domain optical coherence tomography|Blood flow in retina.
219081180|NCT02647606|PROCEDURE|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
219081181|NCT02647606|DEVICE|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
219081182|NCT02647606|DEVICE|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
219081183|NCT02647606|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
219081184|NCT02525848|DRUG|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
219081185|NCT02525848|DRUG|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
219081186|NCT02525848|DRUG|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
219680852|NCT03272347|DRUG|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
219680853|NCT03272347|DRUG|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
219680854|NCT03272347|DRUG|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
219680855|NCT03272347|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
219680856|NCT03272347|DRUG|Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
219680857|NCT03272347|DRUG|Doravirine/Islatravir|Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
219680858|NCT00703677|DRUG|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
219081187|NCT01533701|OTHER|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
219081188|NCT00400907|OTHER|clinical observation|
219081189|NCT00400907|PROCEDURE|management of therapy complications|
219081190|NCT02699502|OTHER|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
219081191|NCT03771014|OTHER|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
219680859|NCT03103256|DRUG|YHP1701|PO, Once daily (QD), 8 weeks
219081192|NCT04573621|PROCEDURE|Pelvic drain|A pelvic drain is placed
219211282|NCT05410106|DEVICE|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
219211283|NCT05410106|DEVICE|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
219211284|NCT02779478|PROCEDURE|Bronchoscopy|
219211285|NCT04503395|DEVICE|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
219211286|NCT04503395|DEVICE|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
219211287|NCT06461910|DRUG|Serplulimab|200 mg, i.v., D1, Q3W
219211288|NCT06461910|DRUG|thymalfasin|4.8mg,sc,biw
219211289|NCT06461910|DRUG|Oxaliplatin|130 mg/m2, i.v., D1, Q3W
219211290|NCT06461910|DRUG|Tegafur|oral administration: body surface area \< 1.25, 40 mg each time; body surface area ≥ 1.25 to \< 1.5, 50 mg each time; body surface area ≥ 1.5, 60 mg each time, twice daily for each treatment cycle at D1-D14
219680860|NCT03103256|DRUG|YHR1703|PO, Once daily (QD), 8 weeks
219680861|NCT03103256|DRUG|YHR1704|PO, Once daily (QD), 8 weeks
219680862|NCT05201326|DRUG|Bevacizumab，Irinotecan and Re-radiotherapy|All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
219680863|NCT01450514|DRUG|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
219680864|NCT01450514|DRUG|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
219081193|NCT04573621|OTHER|No pelvic drain is placed|A pelvic drain is not placed
219081194|NCT06221202|OTHER|Stories in the Moment Dance Program - Online|Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.
219081195|NCT00744770|DRUG|TMC278|
219211291|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
219211292|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
219211293|NCT06288854|OTHER|weight gain each group|weight gain after 12 Weeks
219211294|NCT04436250|DRUG|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
219680865|NCT02383069|OTHER|Intervention Group|Aerobic training
219680866|NCT02383069|OTHER|Control Group|Chest physiotherapy: Flutter and muscle stretching
219680867|NCT04389528|OTHER|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
219081196|NCT00006155|DRUG|SU5416 and carboplatin|
219081197|NCT00644462|DEVICE|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
219211295|NCT04436250|DRUG|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
219211296|NCT04436250|DRUG|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
219680868|NCT02809352|BIOLOGICAL|Human papillomavirus genotyping|
219680869|NCT05930171|PROCEDURE|Ultrasound guided L-ESPB and PENG block using Bupivacaine|Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
219680870|NCT05930171|DRUG|Postoperative conventional analgesia in form of Acetaminophen|Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
219081198|NCT03111056|BEHAVIORAL|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
219081199|NCT03428425|DRUG|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
219680871|NCT03885323|DEVICE|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
219680872|NCT03885323|DEVICE|Control placebo with no RF|Placebo control, with no RF
219081200|NCT04177680|DRUG|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
219081201|NCT04177680|DRUG|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
219081202|NCT03364322|OTHER|Observation|Observation
219680873|NCT05133583|OTHER|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
219680874|NCT01085422|DRUG|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
219680875|NCT01085422|DRUG|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
219680876|NCT00940888|DEVICE|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
219680877|NCT03688347|PROCEDURE|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
219680878|NCT03688347|PROCEDURE|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
219680879|NCT03688347|OTHER|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
219680880|NCT03688347|GENETIC|Microbiome analysis|Study of microbial communities found in and on the human body.
219680881|NCT03688347|GENETIC|DNA Banking|Secure, long term storage of an individual's genetic material.
219680882|NCT03688347|PROCEDURE|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
219680883|NCT05497297|DRUG|HSK7653 tablets|HSK7653, tablet, oral
219680884|NCT03923777|OTHER|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is \>3 cm in size or the VDT decreases to \<400 days.
219081203|NCT04499807|OTHER|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
219081204|NCT01830114|BEHAVIORAL|Web app|The Checkup and Choices web application
219081205|NCT05796856|DEVICE|repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)|crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.
219081206|NCT03254082|OTHER|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
219081207|NCT03254082|OTHER|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
219081208|NCT03254082|OTHER|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
219081209|NCT03254082|OTHER|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
219081210|NCT03254082|OTHER|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
219211297|NCT06179992|DEVICE|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
219211298|NCT04844879|DEVICE|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
219211299|NCT01315132|DEVICE|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
219211300|NCT03260569|DRUG|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
219211301|NCT03260569|DRUG|Placebo|Nitrogen plus oxygen
219680885|NCT01082679|DRUG|Methadone|daily for 12 months
219680886|NCT01082679|DRUG|buprenorphine (Suboxone)|daily for 12 months
219081211|NCT00642512|DRUG|dronabinol|10 - 20 mg
219081212|NCT00642512|DRUG|ondansetron|8 - 16 mg
219081213|NCT00642512|DRUG|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
219081214|NCT00642512|DRUG|placebo|placebo
219081215|NCT05721131|DEVICE|NC° Thermometer (Gen 3)|The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
219081216|NCT04888390|BEHAVIORAL|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
219081217|NCT04888390|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
219081218|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
219081219|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
219211302|NCT05770895|BIOLOGICAL|GS-2829|Administered intramuscularly
219211303|NCT05770895|BIOLOGICAL|GS-6779|Administered intramuscularly
219211304|NCT05770895|BIOLOGICAL|Placebo for GS-2829|Administered intramuscularly
219211305|NCT05770895|BIOLOGICAL|Placebo for GS-6779|Administered intramuscularly
219680887|NCT00578279|DRUG|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
219680888|NCT01535469|DRUG|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
219680889|NCT03215875|DRUG|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
219680890|NCT03215875|DRUG|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
219680891|NCT03003702|DEVICE|Nonin|
219680892|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
219680893|NCT04441788|DRUG|Placebo|Placebo administered by oral inhalation
219081220|NCT03014674|BIOLOGICAL|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
219211306|NCT05718791|DIAGNOSTIC_TEST|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
219081221|NCT03014674|BIOLOGICAL|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
219081222|NCT03014674|DEVICE|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
219081223|NCT03014674|DEVICE|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
219081224|NCT05164575|BEHAVIORAL|progressive resistance exercise|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
219081225|NCT05164575|BEHAVIORAL|self-management strategies|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
219081226|NCT03834233|DRUG|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
219081227|NCT04336735|OTHER|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
219211307|NCT02711332|OTHER|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
219211308|NCT02711332|OTHER|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
219211309|NCT06521151|DIETARY_SUPPLEMENT|egg based diet|egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
219211310|NCT02731599|PROCEDURE|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
219211311|NCT03840902|DRUG|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
219211312|NCT03840902|DRUG|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
219211313|NCT03840902|DRUG|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
219680894|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
219680895|NCT01963559|DRUG|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
219680896|NCT03161041|PROCEDURE|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
219081228|NCT00047476|DRUG|dexmethylphenidate(d-mph)|
219081229|NCT05446324|DRUG|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
219081230|NCT00059644|DRUG|Ecraprost in lipid emulsion|
219081231|NCT05745142|DRUG|Sunitinib|as provided in real world practice
219680897|NCT03161041|DRUG|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
219680898|NCT02415192|DRUG|Levacalm|
219680899|NCT02415192|DRUG|Valsartan/amlodipine|
219680900|NCT00753298|DEVICE|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
219680901|NCT00753298|DEVICE|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
219680902|NCT00921258|PROCEDURE|prostate biopsy|"patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years"
219680903|NCT06079996|OTHER|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
219680904|NCT03547258|GENETIC|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
219680905|NCT01344694|OTHER|patient with liver fat|30 patient with liver fat
219680906|NCT01344694|OTHER|pts. with excess of visceral fat|pts. with excess of visceral fat
219081232|NCT05656599|DRUG|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
219081233|NCT02784483|DRUG|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
219081234|NCT00002411|DRUG|Nelfinavir mesylate|
219081235|NCT00002411|DRUG|Lamivudine|
219081236|NCT00002411|DRUG|Stavudine|
219081237|NCT00002411|DRUG|Zidovudine|
219081238|NCT00002411|DRUG|Didanosine|
219081239|NCT03722927|DRUG|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
219081240|NCT03722927|DRUG|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
219081241|NCT00444808|DRUG|Intranasal calcitonin|
219081242|NCT04125368|BEHAVIORAL|Health Facility Interventions|"1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
219081243|NCT04125368|BEHAVIORAL|Community Interventions|"1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
219081244|NCT04125368|BEHAVIORAL|Health System Interventions|"1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T."
219081245|NCT02937961|BIOLOGICAL|Early SLED|withing 6 to 12 hours
219081246|NCT02937961|BIOLOGICAL|Late SLED|when absolute indications will meet
219081247|NCT05843916|DRUG|Recombinant human alpha galactosidase A (agalsidase beta)|All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks
219081248|NCT05843916|DRUG|Recombinant human alpha-galactosidase A (agalsidase beta)|All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
219211314|NCT03840902|DRUG|Etoposide|Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
219680907|NCT01344694|OTHER|control|30 control subjects
219680908|NCT01228656|DRUG|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
219680909|NCT01228656|DRUG|Mometasone furoate|Dermatologic ointment applied once a day
219680910|NCT01196377|DRUG|Albuterol|Nebulized albuterol
219081249|NCT03224182|DRUG|Qapzola|Qapzola administered by the intravesical route.
219081250|NCT03224182|DRUG|Placebo|Qapzole-matching placebo administered by the intravesical route.
219081251|NCT02822222|DRUG|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
219081252|NCT02822222|DRUG|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
219211315|NCT03840902|DRUG|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
219211316|NCT03840902|DRUG|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
219211317|NCT03840902|DRUG|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
219680911|NCT04739592|DRUG|alendronate sodium vitamin D3 tablets|once per week for one year
219680912|NCT04739592|DRUG|Placebo|once per week for one year
219680913|NCT03088228|DIAGNOSTIC_TEST|gingival crevicular fluid collection|
219680914|NCT03859648|DEVICE|BONEBRIDGE|Bone Conduction Implant
219081253|NCT03665610|DRUG|ozanimod|ozanimod
219680915|NCT04416919|OTHER|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
219680916|NCT03758768|OTHER|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
219680917|NCT03758768|OTHER|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
219680918|NCT05013502|DRUG|Empagliflozin 10 MG|empagliflozin 10mg PO once daily
219081254|NCT01248273|BIOLOGICAL|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
219680919|NCT03313531|DIAGNOSTIC_TEST|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
219680920|NCT03313531|DRUG|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
219680921|NCT06321120|DRUG|variability-based lenvatinib regimen|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
219680922|NCT01018745|DRUG|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
219680923|NCT03198429|BEHAVIORAL|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
219680924|NCT03198429|BEHAVIORAL|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
219081255|NCT02481310|DRUG|Cyclophosphamide|Given IV
219081256|NCT02481310|DRUG|Cytarabine|Given IT or intraventricularly
219081257|NCT02481310|DRUG|Doxorubicin Hydrochloride|Given IV
219081258|NCT02481310|DRUG|Etoposide|Given IV
219081259|NCT02481310|DRUG|Ixazomib Citrate|Given PO
219081260|NCT02481310|OTHER|Laboratory Biomarker Analysis|Correlative studies
219081261|NCT02481310|DRUG|Methotrexate|Given IT or intraventricularly
219081262|NCT02481310|DRUG|Prednisone|Given PO
219081263|NCT02481310|BIOLOGICAL|Rituximab|Given IV
219081264|NCT02481310|DRUG|Therapeutic Hydrocortisone|Given IT or intraventricularly
219081265|NCT02481310|DRUG|Vincristine Sulfate|Given IV
219081266|NCT01958632|PROCEDURE|Nerve reconstruction|
219081267|NCT06449040|DRUG|Liposomal amphotericin B (AmBisome®)|Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
219081268|NCT05407454|OTHER|Questionnaire|The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.
219081269|NCT02675387|DEVICE|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
219081270|NCT02675387|DRUG|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
219081271|NCT00833560|DRUG|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
219081272|NCT00833560|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
219081273|NCT00833560|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
219081274|NCT06111651|BEHAVIORAL|Parenting Intervention|parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
219081275|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
219081276|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
219081277|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
219081278|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
219081279|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
219081280|NCT00643916|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
219081281|NCT00708240|DRUG|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
219081282|NCT00004070|BIOLOGICAL|IL-12|
219081283|NCT00499031|BIOLOGICAL|Cetuximab|Given IV
219081284|NCT02579954|BEHAVIORAL|Rehabilitation|
219081285|NCT04779970|OTHER|Cessation of ongoing treatment|Cessation of ongoing treatment
219081286|NCT06121154|DIAGNOSTIC_TEST|SARC-F questionnaire|"The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia."
219081287|NCT06121154|DIAGNOSTIC_TEST|Gait speed|Low gait speed was defined as walking below than 0.8 meters per second.
219081288|NCT06121154|DIAGNOSTIC_TEST|The chair rise test|the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
219081289|NCT06121154|DIAGNOSTIC_TEST|Grip strength|Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
219081290|NCT06121154|DIAGNOSTIC_TEST|Visual analog scale|The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
219081291|NCT04547010|DIETARY_SUPPLEMENT|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
219081292|NCT00477230|DEVICE|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
219081293|NCT00477230|DRUG|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
219081294|NCT01259050|DRUG|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
219081295|NCT03780348|DIAGNOSTIC_TEST|New Method|A 'new' WHZ tool will be used to assess children.
219081296|NCT03780348|DIAGNOSTIC_TEST|Existing Method|'Existing' WHZ tools will be used to assess children
219081297|NCT03971682|BEHAVIORAL|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
219081298|NCT03971682|OTHER|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
219081299|NCT00643058|BIOLOGICAL|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
219081300|NCT01143688|DRUG|albuterol|
219081301|NCT01143688|DRUG|placebo inhaler|
219081302|NCT01143688|PROCEDURE|placebo acupuncture|
219081303|NCT01785680|OTHER|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC\>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
219081304|NCT01785680|OTHER|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
219081305|NCT00970879|DRUG|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
219081306|NCT00970879|DRUG|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
219081307|NCT05047055|DRUG|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
219081308|NCT05047055|DRUG|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
219081309|NCT05047055|DRUG|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
219081310|NCT05047055|DRUG|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
219211318|NCT03840902|DRUG|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
219211319|NCT03840902|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
219081311|NCT05047055|DRUG|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
219081312|NCT05236686|PROCEDURE|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
219081313|NCT03839264|DIAGNOSTIC_TEST|Graft stenosis and thrombosis|
219211320|NCT03244813|OTHER|Personalized activity program|Targeted physical activity
219081314|NCT03523468|PROCEDURE|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
219680925|NCT06172738|PROCEDURE|the left atrial appendage closure through surgery.|Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
219081315|NCT03523468|PROCEDURE|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
219081316|NCT03105674|DRUG|Multi-drug local anesthetics (Combination)|"1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
219081317|NCT03105674|DRUG|Standard local anesthetics (Combination)|Marcaine and Lidocaine
219081318|NCT05527379|DEVICE|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
219081319|NCT00004549|PROCEDURE|Magnetic resonance imaging|
219081320|NCT03687567|PROCEDURE|Preimplantation genetic diagnosis|
219081321|NCT05805995|PROCEDURE|vertebral derotation|"* Incentive spirometer (Mediciser): Used for breathing exercises.~* Cycle ergometer ( Mijnhardt , St. Paul, MN): Used for lower limb exercise."
219081322|NCT00184548|DRUG|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
219081323|NCT00184548|DRUG|placebo|placebo
219081324|NCT02606279|DRUG|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
219081325|NCT02606279|OTHER|Placebo|
219081326|NCT02925910|DEVICE|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
219081327|NCT02184611|DRUG|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
219081328|NCT02184611|DRUG|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
219081329|NCT01900938|PROCEDURE|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
219081330|NCT01900938|PROCEDURE|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
219081331|NCT01900938|DRUG|Midazolam|
219081332|NCT01900938|DRUG|Propofol|
219081333|NCT06202833|DEVICE|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
219081334|NCT06202833|DEVICE|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
219081335|NCT06083025|DEVICE|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
219081336|NCT06221189|BEHAVIORAL|ACT-CSP|The ACT treatment will consist of three 45 to 60-min weekly sessions to be delivered to the caregiver in an individual format via online videoconferencing application e.g. ZOOM or WhatsApp within 3 weeks. The ACT-CSP can be delivered via face-to-face on request. Each session has a specific content with pre-planned materials and mindfulness exercises and metaphors. Psychological-based homework will be assigned at the end of each session. The components of ACT process will be emphasized in the intervention programme, which include perspective taking, self-as-context and defusion (i.e. recognizing worry thoughts as thoughts only), identifying values and acceptance of present-moment experience with respect to the values, and committed action.
219081337|NCT01792479|DRUG|BIND-014|
219081338|NCT01907191|DRUG|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy
219081339|NCT01907191|DRUG|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
219211321|NCT00003593|DRUG|asparaginase|Given IV
219680926|NCT00765739|OTHER|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
219680927|NCT00765739|OTHER|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
219680928|NCT03868189|OTHER|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
219680929|NCT03868189|OTHER|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
219680930|NCT00929487|DEVICE|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
219680931|NCT00929487|OTHER|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
219680932|NCT00929487|DEVICE|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
219081340|NCT05527366|OTHER|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
219081341|NCT05527366|OTHER|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
219081342|NCT00985725|DRUG|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
219081343|NCT00985725|DRUG|Matching placebo|oral, once daily
219081344|NCT02292017|DEVICE|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
219081345|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
219081346|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219081347|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219081348|NCT02331381|DEVICE|Magnetic resonance imaging|
219081349|NCT03326505|BIOLOGICAL|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
219081350|NCT03326505|OTHER|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
219081351|NCT00003125|BIOLOGICAL|ALVAC-CEA vaccine|
219081352|NCT00003125|BIOLOGICAL|aldesleukin|
219081353|NCT00003125|BIOLOGICAL|sargramostim|
219081354|NCT00003125|BIOLOGICAL|vaccinia-CEA vaccine|
219081355|NCT03019354|DEVICE|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
219081356|NCT03019354|DEVICE|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
219081357|NCT06413251|OTHER|Boxing Training|The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.
219680933|NCT06260917|DIAGNOSTIC_TEST|position of urination|effect of position on uroflowmetry parameters
219081358|NCT06413251|OTHER|Control flexibility|The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
219081359|NCT02583425|DRUG|DFN-11 Injection|
219081360|NCT01718028|OTHER|Propylene glycol 0.6% ocular emulsion|
219081361|NCT01718028|OTHER|Sodium chloride 0.9% saline solution|
219081362|NCT04477642|DRUG|Abatacept|10mg/kg intravenously administered on Day 1
219081363|NCT01460550|PROCEDURE|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
219081364|NCT01460550|PROCEDURE|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
219081365|NCT04150679|PROCEDURE|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
219081366|NCT04150679|PROCEDURE|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
219081367|NCT00591890|DRUG|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
219081368|NCT02428296|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
219211322|NCT00003593|DRUG|cytarabine|Given IT
219211323|NCT00003593|DRUG|daunorubicin hydrochloride|Given IV
219211324|NCT00003593|DRUG|methotrexate|Given IV
219211325|NCT00003593|DRUG|therapeutic hydrocortisone|Given IT
219211326|NCT00003593|DRUG|thioguanine|Given IV
219081369|NCT06185257|DEVICE|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
219081370|NCT00402181|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
219081371|NCT00402181|DRUG|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
219081372|NCT03919136|DEVICE|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
219081373|NCT00487409|PROCEDURE|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
219081374|NCT00487409|PROCEDURE|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
219081375|NCT01261702|DRUG|Placebo|Normal saline IV
219081376|NCT01261702|DRUG|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
219081377|NCT02340741|PROCEDURE|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
219081378|NCT02340741|PROCEDURE|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
219081379|NCT02340741|PROCEDURE|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
219081380|NCT00104169|DRUG|Epoetin Alfa|
219081381|NCT00372281|DRUG|Cliavist|Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
219081382|NCT02769286|DRUG|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
219081383|NCT04150003|BEHAVIORAL|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
219081384|NCT04150003|OTHER|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
219081385|NCT00096694|DEVICE|Levonorgestrel-releasing intrauterine device (IUD)|
219081386|NCT05830994|PROCEDURE|G-POEM|An Endoscopic submucosal tunnel is formed and extended to the first part of the duodenum, followed by a pyloromyotomy, beginning approximately two centimetres proximal to the pylorus and ending in the first part of duodenum.
219081387|NCT05830994|PROCEDURE|Sham|Endoscopy is performed and tissue samples are collected from fundus and antrum as part of the Sham procedure
219081388|NCT04010630|DRUG|Sodium bicarbonate infusion|"Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion."
219081389|NCT00163579|DRUG|Bryophyllum|
219081390|NCT00163579|OTHER|Placebo|
219081391|NCT03610295|PROCEDURE|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
219081392|NCT03610295|PROCEDURE|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
219081393|NCT00768820|DRUG|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
219081394|NCT02608398|OTHER|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
219081395|NCT01523054|DRUG|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
219081396|NCT01523054|DRUG|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
219081397|NCT06490562|DRUG|PDCy|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
219081398|NCT06490562|DRUG|Non Cy|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
219081399|NCT02230956|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
219081400|NCT02230956|DRUG|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
219081401|NCT00338884|DRUG|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
219081402|NCT05196464|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
219211327|NCT01170624|DEVICE|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
219680934|NCT03559283|DIAGNOSTIC_TEST|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
219680935|NCT05275465|DRUG|HH-006|Different dose levels of HH-006
219680936|NCT05275465|DRUG|Placebo|Different dose levels of placebo
219680937|NCT04423133|BEHAVIORAL|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
219680938|NCT02097511|DRUG|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
219081403|NCT05196464|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
219081404|NCT06117280|OTHER|Paraxanthine 200 mg|For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
219081405|NCT06117280|OTHER|Paraxanthine 300 mg|For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
219081406|NCT06117280|OTHER|Placebo|The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
219081407|NCT02396745|DEVICE|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
219081408|NCT06126354|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
219081409|NCT06126354|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
219081410|NCT06126354|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
219081411|NCT06126354|DRUG|Human Growth Hormone|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
219081412|NCT06126354|DRUG|Dexamethasone Oral|Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
219081413|NCT06126354|OTHER|[6,6-2H2] D-glucose|"Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)"
219081414|NCT06126354|DRUG|20% D-glucose (aq)|"20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)"
219081415|NCT06126354|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)"
219081416|NCT06126354|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|"Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)"
219081417|NCT06126354|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|"Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)"
219081418|NCT06126354|OTHER|Normal saline|Normal saline (0.9% NaCl, aq), variable rate (as needed)
219081419|NCT06126354|OTHER|Human albumin|Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
219680939|NCT02097511|DRUG|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
219680940|NCT02097511|DRUG|Metoprolol|Metoprolol Tartrate 100 mg once a day
219680941|NCT00075452|DRUG|gemcitabine hydrochloride|
219680942|NCT00075452|DRUG|oxaliplatin|
219081420|NCT05103020|DRUG|intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
219081421|NCT05103020|DRUG|IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
219081422|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
219081423|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
219081424|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
219211328|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
219680943|NCT02010905|DRUG|Losartan|
219680944|NCT02010905|DRUG|Placebo|
219680945|NCT00391872|DRUG|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
219680946|NCT00391872|DRUG|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
219081425|NCT04766762|PROCEDURE|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
219081426|NCT04766762|PROCEDURE|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
219081427|NCT01982357|DEVICE|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
219081428|NCT01371214|BEHAVIORAL|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
219081429|NCT01970982|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
219081430|NCT01970982|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
219081431|NCT01970982|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
219081432|NCT01066325|BEHAVIORAL|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
219081433|NCT01066325|OTHER|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
219081434|NCT05032001|DRUG|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
219081435|NCT02923843|OTHER|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
219081436|NCT06165783|OTHER|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
219680947|NCT04407039|DEVICE|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
219680948|NCT02484092|BIOLOGICAL|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
219680949|NCT02411279|OTHER|Equiped group with telemedicine systems|
219680950|NCT02335879|BIOLOGICAL|Gonal-F|
219680951|NCT05332041|OTHER|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
219680952|NCT00242411|DRUG|Budesonide/Formoterol Turbuhaler|
219680953|NCT00242411|DRUG|Conventional Best Asthma Therapy|
219680954|NCT02966132|BEHAVIORAL|iMD|Interactive video education delivered on a tablet computer
219680955|NCT02966132|BEHAVIORAL|NPA|
219680956|NCT01766531|DEVICE|body bioelectrical impedance|
219680957|NCT01672268|OTHER|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
219680958|NCT00356161|DEVICE|interventionally implanted hepatic arterial port catheter|
219680959|NCT02861664|OTHER|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
219680960|NCT02861664|OTHER|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
219680961|NCT01239394|DRUG|ofatumumab|Weekly infusion for 8 weeks
219680962|NCT01476267|DRUG|dalcetrapib|Single oral radiolabeled dose
219680963|NCT02229799|DRUG|Actilyse|
219680964|NCT01137487|PROCEDURE|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
219680965|NCT01137487|PROCEDURE|not monitoring of residual gastric volume|no measurements of residual gastric volume
219680966|NCT00002125|DRUG|Foscarnet sodium|
219680967|NCT00901615|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
219680968|NCT01268657|BEHAVIORAL|Education|Learning about anxiety
219680969|NCT01268657|BEHAVIORAL|Relaxation Training|Learning skills to reduce tension
219680970|NCT01268657|BEHAVIORAL|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
219680971|NCT01268657|BEHAVIORAL|Behavioral Activation|Learning to initiate healthy activity
219680972|NCT01268657|BEHAVIORAL|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
219680973|NCT00905632|DRUG|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
219680974|NCT00905632|DRUG|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
219680975|NCT00905632|DRUG|Placebo + SOC|Placebo tid +SOC
219680976|NCT00905632|DRUG|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
219211329|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
219211330|NCT03660930|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
219211331|NCT03660930|DRUG|Pazopanib hydrochloride|Given PO
219211332|NCT05813795|DRUG|Ecnoglutide Low Dosage|Subcutaneous Injection
219081437|NCT03148223|DEVICE|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
219081438|NCT04685902|DEVICE|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
219081439|NCT04475549|DRUG|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
219081440|NCT05711641|DRUG|Lidocaine 10 MG/ML|Application of 10% topical lidocaine in the external auditory canal of tinnitus patients.
219081441|NCT05711641|DRUG|Distilled water|Application of distilled water in the external auditory canal of tinnitus patients.
219081442|NCT04262362|PROCEDURE|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
219081443|NCT06579118|OTHER|Laughter yoga|The women in the experimental group were given laughter yoga sessions by the researcher.
219081444|NCT02503748|OTHER|Online tutorial|website informing about treatment options in localized prostate cancer
219081445|NCT01698294|OTHER|Clinical Observation|Participants maintain usual diet and undergo clinical observation
219081446|NCT01698294|DIETARY_SUPPLEMENT|Flaxseed|Given PO
219081447|NCT01698294|OTHER|Laboratory Biomarker Analysis|Correlative studies
219081448|NCT01698294|OTHER|Questionnaire Administration|Ancillary studies
219081449|NCT05431075|DRUG|Amoxicillin|Included in quadruple eradication medication.
219081450|NCT05431075|DRUG|Tetracycline tid|Included in quadruple eradication medication.
219081451|NCT05431075|DRUG|Tetracycline qid|Included in quadruple eradication medication.
219081452|NCT05431075|DRUG|Bismuth Potassium Citrate|Included in quadruple eradication medication.
219081453|NCT05431075|DRUG|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
219081454|NCT05431075|DRUG|Esomeprazole 20mg|Included in quadruple eradication medication.
219081455|NCT04303949|OTHER|Behavioral:|Facilitating couples reduce anxiety, depression and grief through e-book education.
219081456|NCT00465413|DEVICE|Small volume spacer and/or Rinsing the mouth with water|
219081457|NCT01183676|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
219081458|NCT01183676|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
219081459|NCT00507000|DRUG|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
219081460|NCT00507000|DRUG|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
219211333|NCT05813795|DRUG|Ecnoglutide Medium Dosage|Subcutaneous Injection
219211334|NCT05813795|DRUG|Ecnoglutide High Dosage|Subcutaneous Injection
219211335|NCT05813795|DRUG|Placebo|Subcutaneous Injection with matched volume
219211336|NCT04100538|BEHAVIORAL|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
219211337|NCT03433794|BEHAVIORAL|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
219680977|NCT03832270|BEHAVIORAL|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
219680978|NCT03832270|BEHAVIORAL|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
219680979|NCT01278602|DRUG|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
219680980|NCT06420037|DEVICE|Hearing aid feature adjustment (frequency compression) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely frequency compression turned off, to the basic setting.
219081462|NCT03508648|DRUG|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
219081463|NCT03508648|DRUG|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
219081464|NCT03018405|BIOLOGICAL|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
219081465|NCT04171466|OTHER|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
219081466|NCT04171466|OTHER|SH-DS01|SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
219081467|NCT04171466|OTHER|Placebo|Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
219081468|NCT05918068|DRUG|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
219081469|NCT05918068|COMBINATION_PRODUCT|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
219081470|NCT05918068|OTHER|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
219081471|NCT00210795|DRUG|epoetin alfa|
219081472|NCT02017340|DRUG|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
219081473|NCT02017340|DRUG|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
219081474|NCT00951483|DRUG|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
219081475|NCT03291574|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
219081476|NCT03291574|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
219081477|NCT02423187|OTHER|No Intervention|
219081478|NCT03583554|DRUG|Placebo|Single dose of 4 placebo oral capsules
219081479|NCT03583554|DRUG|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
219081480|NCT03583554|DRUG|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
219081481|NCT03178266|DEVICE|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
219081482|NCT05001100|OTHER|rehabilitation|rehabilitation
219081483|NCT00796770|BIOLOGICAL|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
219081484|NCT04582474|OTHER|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
219081485|NCT05417880|DRUG|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
219081486|NCT05417880|DRUG|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
219211338|NCT03433794|BEHAVIORAL|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
219081487|NCT05417880|DRUG|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
219081488|NCT02342886|DRUG|Moxifloxacin|Oral
219081489|NCT02342886|DRUG|PA-824|Oral
219081490|NCT02342886|DRUG|Pyrazinamide|Oral
219081491|NCT02342886|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
219680981|NCT06420037|DEVICE|Hearing aid feature adjustment (noise reduction) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely noise reduction turned off, to the basic setting.
219680982|NCT06420037|BEHAVIORAL|Cognitive screening and vision screening|The Dutch Montreal Cognitive Assessment will be assessed. The Snellen Eye Test will be used to screen for normal or corrected-to-normal vision.
219680983|NCT06420037|BEHAVIORAL|Audiological Assessment|Three audiological tests are included: 1) Tympanometry to assess the middle ear status, 2) Pure-tone audiometry with headphone to evaluate the hearing thresholds, 3) Speech audiometry in free field to assess the ability to understand spoken sentences in quiet and in the presence of background noise.
219680984|NCT06420037|BEHAVIORAL|Questionnaires|"Three questionnaires are included:~1. The HAVICOP questionnaire to assess the hearing-related quality of life (Ceuleers, D., Baudonck, N., Keppler, H., Kestens, K., Dhooge, I., \& Degeest, S. (2023). Development of the hearing-related quality of life questionnaire for auditory-visual, cognitive and psychosocial functioning (hAVICOP). Journal of communication disorders, 101, 106291.)~2. the FAS (fatigue assessment scale) to assess how you usually feel~3. the EEAS (extended effort assessment scale) to assess how you experience listening in everyday life."
219680985|NCT06420037|BEHAVIORAL|Cognition|Four cognitive functions, important for speech understanding, will be assessed both audibly and visually: divided attention, working memory, processing speed, and cognitive flexibility and inhibition.
219680986|NCT06420037|OTHER|Real ear measurement|This test will give an objective assessment of the hearing aids' configuration.
219680987|NCT02793219|BIOLOGICAL|Sipuleucel-T|
219680988|NCT02793219|DRUG|Docetaxel|
219680989|NCT00148044|PROCEDURE|Blood sampling for determination of uremic toxins|
219680990|NCT00938665|DEVICE|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
219680991|NCT02762435|OTHER|sham|light touch at established points on hand and wrist
219680992|NCT02762435|OTHER|control|no contact with the subject
219680993|NCT02762435|OTHER|acupressure|moderate pressure at established points on hand and wrist
219680994|NCT01557673|DIETARY_SUPPLEMENT|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
219680995|NCT01557673|DIETARY_SUPPLEMENT|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
219680996|NCT06326086|DRUG|Chemotherapy drug|Chemotherapy drug as prescribed by primary treating physician
219680997|NCT06326086|DRUG|Targeted Agent|Targeted agents as prescribed by primary treating physician
219680998|NCT06326086|DRUG|Immunotherapy|Immunotherapy as prescribed by primary treating physician
219081492|NCT02342886|DRUG|HR (rifampicin plus isoniazid combination tablets)|Oral
219081493|NCT05072873|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
219680999|NCT05630443|PROCEDURE|prone position|Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
219081494|NCT05072873|OTHER|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
219081495|NCT02426788|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
219081496|NCT00156793|PROCEDURE|AI-700 contrast-enhanced echocardiography|
219681000|NCT02778035|DEVICE|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
219681001|NCT02603211|DEVICE|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
219681002|NCT04617119|DEVICE|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
219681003|NCT04617119|OTHER|Conventional physical therapy|daily
219681004|NCT01405495|PROCEDURE|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
219681005|NCT04349540|OTHER|no intervention|no intervention
219681006|NCT01229969|OTHER|Wii Fit Balance Games|Ski Slaloms and Table Tilt
219681007|NCT01229969|OTHER|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
219681008|NCT03822156|OTHER|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
219081497|NCT01732068|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
219081498|NCT01732068|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
219081499|NCT01732068|DRUG|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
219081500|NCT01509222|BEHAVIORAL|Personalized nutrition counseling|
219081501|NCT05959993|BEHAVIORAL|Human Care Model Based Nursing Interventions|The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
219081502|NCT00417352|DEVICE|Brace|
219081503|NCT00417352|DEVICE|Added mass|
219081504|NCT01383733|DRUG|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
219081505|NCT00587964|RADIATION|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
219081506|NCT05321680|OTHER|Treatment withdrawal|Tapering or suspension of antidementia drugs
219081507|NCT00540124|DRUG|Tadalafil|5 mg once a day
219081508|NCT00540124|DRUG|Placebo|once a day
219081509|NCT00540124|DRUG|Tamsulosin|0.2 mg once a day
219081510|NCT01538732|DRUG|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
219081511|NCT02671032|DEVICE|Nucleus CI532 cochlear implant|
219081512|NCT02763800|DRUG|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
219081513|NCT02763800|DRUG|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
219081514|NCT01403896|DRUG|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
219081515|NCT01403896|DRUG|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
219081516|NCT00914329|DRUG|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
219081517|NCT00914329|DRUG|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
219081518|NCT00914329|DRUG|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
219081519|NCT04508595|DIAGNOSTIC_TEST|RestEaze|Wearable band to detect leg movements of sleep
219081520|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
219081521|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
219081522|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
219081523|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
219081524|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
219081525|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
219081526|NCT01163097|DRUG|Palifermin|40 µg/kg IV bolus injections for three consecutive days
219081527|NCT01163097|DRUG|Heparin|Heparin continuous IV infusion
219081528|NCT05965687|PROCEDURE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
219081529|NCT05965687|PROCEDURE|Nasal oxygen|For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
219081530|NCT05965687|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
219081531|NCT01245010|OTHER|Water|Water and education will be provided
219081532|NCT01245010|OTHER|Education|Education
219081533|NCT06079905|OTHER|Nonoperative treatment|Nonoperative treatment
219081534|NCT06079905|OTHER|Operative treatment|Operative treatment
219081535|NCT05637840|OTHER|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
219081536|NCT05637840|OTHER|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
219081537|NCT01921296|DRUG|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
219081538|NCT00208143|DRUG|Quetiapine|
219081539|NCT00208143|DRUG|Risperidone|
219081540|NCT02959632|BEHAVIORAL|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
219081541|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
219081542|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Posterior TAP Block|
219081543|NCT01429480|DRUG|Patient controlled analgesia|
219081544|NCT03031964|DEVICE|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
219081545|NCT01569438|DRUG|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
219081546|NCT01569438|DRUG|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
219081547|NCT00331643|DRUG|ixabepilone|Given IV
219081548|NCT00796302|DRUG|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
219081549|NCT00796302|DRUG|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
219081550|NCT00796302|BEHAVIORAL|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
219081551|NCT00796302|DRUG|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
219081552|NCT00775710|DEVICE|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
219081553|NCT01337895|OTHER|Low dairy|No more than 1 serving per day
219081554|NCT01337895|OTHER|High dairy|4 or more servings per day
219081555|NCT04629703|DRUG|Fostamatinib|Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
219081556|NCT04629703|DRUG|Placebo|Placebo (twice daily) for 14 days and Standard of Care
219081557|NCT03278262|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
219081558|NCT03076255|PROCEDURE|Computed Tomography|Undergo CT simulation
219081559|NCT03076255|DEVICE|Medical Device|Given thermoplastic mask
219081560|NCT03076255|DEVICE|Medical Device|Given MID
219211339|NCT03433794|BEHAVIORAL|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
219211340|NCT06447389|OTHER|retraction cordu (SURE-CORD®PLUS)|The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
219211341|NCT03432338|OTHER|inquiries|Inquires reported to clinician.
219681009|NCT05171114|DIAGNOSTIC_TEST|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
219081561|NCT03076255|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT imaging
219081562|NCT04791501|DEVICE|Mechanical ventilation|Ventilatory support
219081563|NCT02083016|DEVICE|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
219081564|NCT02083016|DEVICE|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
219081565|NCT01777854|DRUG|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
219081566|NCT03651167|OTHER|Survey|Participants will complete a survey online
219081567|NCT05697094|BEHAVIORAL|Meditation to Remove Stress and Create A Proper System in Mind|Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.
219081568|NCT06200454|DEVICE|neuromuscular ultrasound of cranial nerves|neuromuscular ultrasound of cranial nerves.
219211342|NCT01289314|PROCEDURE|TLH|Total laparoscopic hysterectomy (TLH)
219681010|NCT03166501|DRUG|Lanicemine|Three 60 min parenteral infusions over a 5 day period
219681011|NCT03166501|DRUG|Placebo|Three 60 min parenteral infusions over a 5 day period
219081569|NCT00452387|DRUG|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
219211343|NCT01289314|PROCEDURE|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
219211344|NCT05681234|RADIATION|18F-RD2|Patients will receive 5-10 mCi 18F-RD2
219211345|NCT06251674|OTHER|long-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
219081570|NCT00452387|DRUG|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
219081571|NCT00452387|DRUG|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
219081572|NCT03649230|DRUG|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
219081573|NCT05047198|PROCEDURE|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
219081574|NCT05047198|PROCEDURE|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
219081575|NCT02652481|DEVICE|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~\* May only be used internationally outside the US"
219081576|NCT01803308|DRUG|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
219081577|NCT01803308|DRUG|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
219081578|NCT01803308|DRUG|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
219081579|NCT00579280|DRUG|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
219081580|NCT00579280|DRUG|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
219081581|NCT00579280|DRUG|placebo|placebo
219081582|NCT03407599|DRUG|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
219081583|NCT03407599|DRUG|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
219081584|NCT01693068|DRUG|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
219681012|NCT05225025|BEHAVIORAL|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
219681013|NCT05225025|OTHER|Standard of Care|Usual hospital care with no behavioral intervention
219681014|NCT06336317|BIOLOGICAL|Influenza vaccine|VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02
219681015|NCT06336317|BIOLOGICAL|Placebo|Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
219681016|NCT04284683|OTHER|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
219681017|NCT01307891|DRUG|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
219081585|NCT01693068|DRUG|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
219081586|NCT05478655|OTHER|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
219081587|NCT01624675|DRUG|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.
219081588|NCT01624675|DRUG|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
219081589|NCT02605629|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
219081590|NCT02605629|OTHER|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
219081591|NCT00474695|DRUG|Lucentis|0.05 mg intravitreal injection
219081592|NCT00811876|OTHER|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
219081593|NCT04684121|DRUG|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
219081594|NCT04684121|DRUG|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
219081595|NCT02379182|BEHAVIORAL|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
219081596|NCT02379182|DEVICE|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
219081597|NCT02379182|DEVICE|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
219081598|NCT05029765|DIETARY_SUPPLEMENT|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
219081599|NCT05029765|DIETARY_SUPPLEMENT|Healthy diet (WHO recommendations)|Recommendations according to WHO
219081600|NCT05029765|DIETARY_SUPPLEMENT|Placebo|Placebo
219081601|NCT05029765|DIETARY_SUPPLEMENT|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
219081602|NCT03260166|DRUG|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
219681018|NCT01307891|DRUG|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
219681019|NCT03128450|BIOLOGICAL|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
219681020|NCT00527137|DRUG|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
219681021|NCT00527137|DRUG|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
219081603|NCT00710138|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
219081604|NCT00956566|BEHAVIORAL|dietary intervention|dietary counseling, group teaching
219081605|NCT02510144|DRUG|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
219081606|NCT02510144|DRUG|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
219081607|NCT04126408|DEVICE|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
219081608|NCT05604625|DEVICE|Van-Beek activator and a headgear|12 patients will receive Van-Beek activator and a headgear
219081609|NCT05604625|DEVICE|Andresen activator|12 patients will receive Andresen activator.
219081610|NCT02322008|BIOLOGICAL|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
219081611|NCT01922492|PROCEDURE|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
219081612|NCT01922492|DRUG|Oral anti-diabetic drugs|"* Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
219081613|NCT02782338|DRUG|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
219081614|NCT00694005|PROCEDURE|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
219081615|NCT00694005|PROCEDURE|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
219081616|NCT02330133|BEHAVIORAL|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
219081617|NCT02330133|BEHAVIORAL|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
219081618|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
219081619|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
219211346|NCT06251674|OTHER|short-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
219681022|NCT02937740|DRUG|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
219081620|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
219081621|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
219081622|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
219081623|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
219081624|NCT05012800|BIOLOGICAL|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
219081625|NCT01931280|BEHAVIORAL|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
219211347|NCT06302842|DIETARY_SUPPLEMENT|Bioritmon Immuno Defend|Bioritmon Immuno Defend daily oral preparation for 24 days.
219081626|NCT00406003|DRUG|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
219081627|NCT01551199|BEHAVIORAL|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
219081628|NCT01185444|PROCEDURE|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
219081629|NCT01185444|PROCEDURE|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
219081630|NCT01408355|DRUG|PF-06273588|Intravenous, 50 microgram, single dose
219081631|NCT01408355|DRUG|PF-06273588|Oral solution, 50 microgram, single dose
219211348|NCT06486532|BEHAVIORAL|HeartBeet Clinic|16 weeks of group based lifestyle medicine coaching covering the six pillars of lifestyle medicine. The six pillars of lifestyle medicine include regular physical activity; a whole-food plant-based diet; restorative sleep; limiting substance use (e.g., tobacco and alcohol use); having meaningful social connections; and stress management. Groups will be led by clinician or health coach expert.
219211349|NCT06486532|BEHAVIORAL|Self-paced education|Self-paced course and workbook with no contact with study clinician or health coach expert
219211350|NCT06613490|BIOLOGICAL|anti CD19 CAR NK cells|This study is a single-arm, open-label and single-center exploratory clinical study to evaluate the safety and effectiveness of anti CD19 CAR NK cells in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA). All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by Anti-CD19 CAR NK cells infusion.
219211351|NCT07038122|PROCEDURE|Laparoscopic resection|Laparoscopic resection of bowel and corresponding mesentery.
219211352|NCT07038122|OTHER|Neoadjuvant Therapy|Neoadjuvant Therapy aims to downstage the tumor including different chemotherapy, targeted therapy and immunotherapy.
219081632|NCT05204225|OTHER|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
219681023|NCT04683796|DRUG|100% Autologous platelet rich plasma|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
219081633|NCT05204225|OTHER|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
219081634|NCT05161299|PROCEDURE|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
219681024|NCT04683796|DRUG|100% Autologous serum|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
219681025|NCT03018314|OTHER|Blood sample|Serum analysis
219681026|NCT01737307|DRUG|Fluoride varnish|Fluoride Varnish (NaF 5%)
219681027|NCT01737307|OTHER|Oral Hygiene|Oral hygiene followed.
219681028|NCT01737307|DRUG|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
219681029|NCT02288702|DEVICE|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
219681030|NCT00214617|DRUG|Rosuvastatin at 5 mg/day and 40 mg/day|
219081635|NCT02624362|BEHAVIORAL|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
219211353|NCT06733428|DEVICE|Pachymeter|Measure the thickness of the cornea
219211354|NCT06729892|DRUG|Esketamine at low dose|Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
219211355|NCT06729892|DEVICE|new BIS baseline|Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.
219681031|NCT05704855|BEHAVIORAL|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
219681032|NCT05704855|BEHAVIORAL|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
219681033|NCT03062215|BEHAVIORAL|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
219081636|NCT02624362|BEHAVIORAL|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
219081637|NCT02624362|OTHER|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
219081638|NCT03433989|DIAGNOSTIC_TEST|telephone interview|questionnaire PDEQ et IES-R
219211356|NCT06729892|DRUG|an equivalent dose of saline|An equivalent dose of saline was given and closed-loop control stared.
219211357|NCT06729892|DEVICE|original BIS baseline|Drug dosage was adjused under close-loop control based on original BIS baseline.
219081639|NCT04569630|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
219081640|NCT01925833|PROCEDURE|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
219081641|NCT01925833|PROCEDURE|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
219081642|NCT00328432|DRUG|celecoxib 400 mg bid|
219081643|NCT02119507|DEVICE|Curodont Repair|Single application on Day 0
219081644|NCT02119507|OTHER|No treatment - control|
219081645|NCT04733287|OTHER|High Intensity Interval Training of the Knee Extensors|"Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at \~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at \~80% of maximum aerobic power. Recovery of 4 minutes at \~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity."
219211358|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
219681034|NCT01546051|DRUG|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
219681035|NCT01546051|DRUG|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
219681036|NCT01546051|DRUG|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
219681037|NCT01546051|DRUG|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
219681038|NCT02812641|DRUG|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
219681039|NCT02812641|DRUG|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
219681040|NCT02812641|DRUG|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
219681041|NCT03952572|DRUG|Cyclophosphamide|750mg/m² ivgtt on day 1
219681042|NCT03952572|DRUG|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
219681043|NCT03952572|DRUG|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
219681044|NCT03952572|DRUG|Prednisone|Prednisone100mg/m² po on day1-5
219681045|NCT03952572|DRUG|Doxorubicin|50mg/m² ivgtt on day 1
219681046|NCT04745741|RADIATION|IB-positive group|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
219681047|NCT00230789|DRUG|Tolterodine ER 4 mg QD|
219681048|NCT00230789|BEHAVIORAL|OAB Patient Behavioral Training Material|
219681049|NCT03397121|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
219681050|NCT03397121|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
219681051|NCT05761418|DRUG|Dinoprostone|prostaglandin (PG) E2 analog
219681052|NCT05761418|DRUG|Misoprostol|prostaglandin (PG) E1 analog
219681053|NCT03939442|PROCEDURE|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
219681054|NCT00305227|DRUG|Lactin-V|
219681055|NCT00305227|DRUG|Placebo|
219681056|NCT01605864|DRUG|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
219681057|NCT05237115|DRUG|Clostridium butyricum capsule|Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
219681058|NCT05237115|DRUG|esomeprazole|Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
219681059|NCT05237115|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
219211359|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
219211360|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
219211361|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
219211362|NCT06732284|OTHER|Psychomotor vigilance task|Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.
219211363|NCT06732284|OTHER|Video-polysomnography|Performed overnight as part of routine care (11 p.m. to 7 a.m.).
219211364|NCT06732284|OTHER|Sleep and activity monitoring|Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.
219211365|NCT06738901|BIOLOGICAL|SKP-0141|Human plasma-derived coagulation factor VIII concentrate
219211366|NCT06887179|PROCEDURE|HF focused POCUS|"* POCUS findings guide diuretic therapy adjustments by treating physicians~* POCUS is performed with handheld device Vscan air SL® or Vscan extend®, GE Healthcare.~* Sector probe and abdominal preset are used. Only B-mode is used.~* The image depth is 15 cm or more to evaluate the structures sufficiently.~* Patient position is supine or semirecumbent. For the pleural effusion exam, the preferred position is sitting.~  1. Lungs: Assessment of B-lines in midclavicular and midaxillary zones.~ 2. Pleural Effusion~ 3. Inferior Vena Cava~ 4. Ascites"
219681060|NCT05237115|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
219211367|NCT06887179|PROCEDURE|Standard Care (in control arm)|Standard care assessment with NT-proBNP on every scheduled visit.
219211368|NCT06889233|BEHAVIORAL|measuring cognitive functions, severity of autism , gross and fine motor skills|measuring cognitive functions by RAVEN measuring severity by CARS measuring fine and gross motor functions by BOT2
219211369|NCT02652052|OTHER|Standard of Care - Observation Only|Control Arm - Observation only
219211370|NCT02652052|DRUG|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
219211371|NCT02652052|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
219211372|NCT00326677|BEHAVIORAL|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
219681061|NCT05237115|DRUG|Bacillus clotting|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
219681062|NCT05237115|DRUG|Bismuth|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
219681063|NCT03069235|BEHAVIORAL|Family member / peer support|supplemental individualized counselling
219681064|NCT03069235|BEHAVIORAL|Enhanced intervention with counselor support|"hands on EBF demonstrations"
219681065|NCT03069235|BEHAVIORAL|standard of care|one on one and in-group counselling
219681066|NCT05447143|OTHER|Fatigue Severity Scale|Evaluation for severity of fatigue
219681067|NCT05447143|OTHER|Berg Balance Test|Evaluation of balance
219681068|NCT05447143|OTHER|Time up and go- 25 steps walking test|Evaluation for walking
219681069|NCT05447143|OTHER|Multiple Sclerosis Quality of Life|Evaluation of quality of life
219681070|NCT05447143|OTHER|Brief International Cognitive Assessment for MS (BICAMS)|Evaluation of cognitive functions
219681071|NCT05447143|OTHER|Beck Depression and Anxiety Scale|Evaluation of depression and anxiety
219211373|NCT00326677|BEHAVIORAL|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
219211374|NCT06735768|DEVICE|rTMS treatment|Brightmind.AI´s rTMS protocol is applied
219211375|NCT06735768|DEVICE|Determination of motor hotspot and motor treshold|Determination of motor hotspot and motor treshold
219211376|NCT06734949|OTHER|AI-guided patient classification|The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.
219211377|NCT06735066|PROCEDURE|Ascending urethrocystography|"It will be performed after instructing the patient to evacuate the bladder. A contrast agent will be infused through the urethra under fluoroscopy, using a urethral catheter or Knutson's clamp at the external urethral meatus. When the bladder is full, an anteroposterior film and two oblique films will be taken. Voiding cystourethrography will be performed as a part of this imaging examination. From this procedure, the following findings may be diagnosed:~* Upper urinary tract: Vesicoureteral reflux (VUR); laterality and degrees of VUR will be defined.~* Bladder: Capacity (defunctionalized, Small-sized or contracted bladder), neurogenic bladder, bladder diverticulum, filling defects, etc.~* Urethra: Stricture and filling defects."
219211378|NCT06810297|PROCEDURE|Therapeutic Exercise|It will consist of an 8-week intervention divided into 2 weekly sessions, in which functional exercise will be combined with aerobic exercise. A progressive protocol will be carried out.The sessions will last approximately 60 minutes divided into a first aerobic part which will serve as a warm-up for the functional part, then a main part with approximately 6 exercises and, finally, a cool-down of 3 to 5 minutes with relaxation exercises and stretching.
219211379|NCT06810297|COMBINATION_PRODUCT|Therapeutic exercise and sexual education|"The sexual education part will consist of a 4-week intervention divided into 1 session every two weeks in an online format, in which topics related to the pathology and self-knowledge will be addressed. The sessions will last approximately 60 minutes, divided into a first part of reception and welcome of the group (lasting approximately 5-10 minutes), then the main content will be divided differently in each session (the explicit content of each session will be detailed later) and will end with a farewell and closing of the online session (lasting approximately 5-10 minutes) together with the explanation of the homework.~In addition, they will also carry out the therapeutic exercise protocol."
219681072|NCT02632006|BIOLOGICAL|PIK-PD-1 cells|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10\*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
219681073|NCT02632006|BIOLOGICAL|DC-PMAT|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10\*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
219681074|NCT03407001|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219681075|NCT03407001|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
219681076|NCT03407001|PROCEDURE|Ultrasound|Undergo non-contrast US
219681077|NCT01852123|DEVICE|High-sensitivity troponin I assay|
219681078|NCT03395626|DIETARY_SUPPLEMENT|ID-JPL934|probiotics
219681079|NCT03395626|DIETARY_SUPPLEMENT|Placebo|corn starch
219681080|NCT02851459|BEHAVIORAL|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
219681081|NCT02851459|BEHAVIORAL|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
219681082|NCT02851459|BEHAVIORAL|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
219681083|NCT02851459|BEHAVIORAL|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
219681084|NCT02851459|BEHAVIORAL|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
219681085|NCT02851459|BEHAVIORAL|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
219681086|NCT04085601|DRUG|APL-2|Complement (C3) Inhibitor
219681087|NCT00429832|DRUG|Ondansetron|
219681088|NCT00429832|DRUG|promethazine|
219681089|NCT06293274|PROCEDURE|Discharge training|What is motherhood blues? Why does it occur? What are its symptoms? How to deal with it? What is postpartum depression? What causes postpartum depression? Information is provided on this topic.
219681090|NCT03492437|DRUG|Dabigatran Etexilate|Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
219681091|NCT03492437|DRUG|Tepotinib|Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
219681092|NCT04559477|OTHER|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
219681093|NCT04559477|OTHER|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
219681094|NCT02418234|OTHER|mutation detection|
219681095|NCT02418234|OTHER|ARMS and ddPCR|
219681096|NCT02418234|GENETIC|ctDNA analysis|
219681097|NCT04534517|DEVICE|JJV Investigational Multifocal Contact Lens|TEST Lens
219681098|NCT04534517|DEVICE|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
219681099|NCT00612911|OTHER|Cell therapy|bone marrow mononuclear cell
219081646|NCT04733287|OTHER|Muscle Heat Therapy|Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to \~39C, a similar temperature induced by exercise.
219211380|NCT06744088|COMBINATION_PRODUCT|Del Nido cardioplegia|To assess the clinical outcomes of modified Del Nido cardioplegia in cardiac surgeries across different age groups,
219211381|NCT06743893|OTHER|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups
219681100|NCT01299350|OTHER|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
219681101|NCT04407676|OTHER|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
219681102|NCT05515133|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
219081647|NCT04733287|OTHER|Muscle Disuse|Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.
219681103|NCT03363607|PROCEDURE|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
219681104|NCT03363607|PROCEDURE|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
219681105|NCT03363607|PROCEDURE|Intraoral scanning|Intraoral Scanning of the bonded brackets
219681106|NCT03363607|PROCEDURE|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
219681107|NCT03872843|DRUG|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
219681108|NCT03872843|DRUG|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
219681109|NCT00938353|DRUG|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
219681110|NCT00938353|DRUG|Placebo solution for nebulisation 2 ml|single dose: 4 ml
219081648|NCT04733287|OTHER|Sham Heat Therapy|Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
219081649|NCT05412641|OTHER|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
219081650|NCT05668533|DIAGNOSTIC_TEST|Interscalene versus PENG Block|"1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."
219081651|NCT04459390|DIAGNOSTIC_TEST|realtime PCR|Detection of SARS-CoV-2 genes by realtime PCR
219081652|NCT00977665|DRUG|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
219081653|NCT00977665|DRUG|placebo|placebo tablet for 48 weeks
219081654|NCT00404365|OTHER|counseling intervention|
219081655|NCT00404365|OTHER|screening questionnaire administration|
219081656|NCT00404365|OTHER|study of socioeconomic and demographic variables|
219081657|NCT00404365|PROCEDURE|psychosocial assessment and care|
219081658|NCT00668902|DRUG|[13C]Pantoprazole|\[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
219081659|NCT02316964|DRUG|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
219081660|NCT02316964|BIOLOGICAL|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
219081661|NCT02316964|BIOLOGICAL|aldesleukin|Given SC
219081662|NCT02316964|OTHER|laboratory biomarker analysis|Correlative studies
219081663|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
219081664|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
219081665|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
219081666|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
219081667|NCT01221987|PROCEDURE|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
219081668|NCT01221987|OTHER|Data collection|Questionnaire completion
219081669|NCT04262518|DEVICE|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
219081670|NCT01159054|DRUG|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
219211382|NCT06737393|PROCEDURE|Backfill|Participants undergoing laparoscopic hysterectomy have the bladder filled with 200 mL saline prior to Foley removal at the end of surgery.
219211383|NCT06894927|DIAGNOSTIC_TEST|Screening HHIA questionnaire|"Completion of the abbreviated (screening) version of the standardized HHIA questionnaire (Czech version)."
219081671|NCT04560257|DEVICE|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
219211384|NCT06894927|DIAGNOSTIC_TEST|Whispered voice test|Whispered voice test conducted following the standardized protocol.
219681111|NCT03100409|OTHER|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
219681112|NCT04828031|DRUG|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
219681113|NCT04088162|DEVICE|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
219681114|NCT02155192|DRUG|No Intervention|
219681115|NCT00823264|DRUG|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
219081672|NCT00905918|DIETARY_SUPPLEMENT|vitamin E|Given orally
219081673|NCT00905918|OTHER|laboratory biomarker analysis|All patients undergo biomarker analyses
219081674|NCT02382198|DRUG|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
219081675|NCT02382198|DRUG|Placebo|
219081676|NCT00808275|DIETARY_SUPPLEMENT|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
219081677|NCT02036489|DRUG|Vincristine|
219081678|NCT02036489|DRUG|Daunorubicin|
219081679|NCT02036489|DRUG|Prednisone|
219081680|NCT02036489|DRUG|L-asparaginase|
219081681|NCT02036489|DRUG|Ciclophosphamide|
219081682|NCT02036489|DRUG|Metotrexate|
219081683|NCT02036489|DRUG|ARA-C|
219081684|NCT02036489|DRUG|Hidrocortisone|
219081685|NCT02036489|DRUG|Mercaptopurine|
219081686|NCT02036489|DRUG|VP-16|
219081687|NCT02036489|DRUG|Dexametasone|
219081688|NCT00305799|PROCEDURE|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
219681116|NCT05133323|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm.
219681117|NCT05133323|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
219081689|NCT00381069|BEHAVIORAL|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
219081690|NCT05258786|BEHAVIORAL|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"1. Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~2. The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~3. A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~4. Finally, the provider will turn the screen again from the patient and repeat the first stage."
219081691|NCT01774513|DEVICE|Procore-Needle|
219081692|NCT01356355|DRUG|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
219081693|NCT01356355|DRUG|Placebo|One capsule twice a day daily till ureteral stent in situ
219081694|NCT01356355|DRUG|Tolterodine|One capsule twice a day daily till ureteral stent in situ
219081695|NCT02158676|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharides
219081696|NCT02158676|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
219081697|NCT02158676|OTHER|Placebo|Maltodextrin
219081698|NCT01769300|BEHAVIORAL|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
219081699|NCT03097705|DIAGNOSTIC_TEST|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
219211385|NCT06894927|DIAGNOSTIC_TEST|Screening pure tone audiometry|Screening pure-tone audiometry at a level of 35 dB at the frequencies: 500, 1000, 2000, and 4000 Hz.
219211386|NCT06894927|DIAGNOSTIC_TEST|Pure Tone Audiometry|Clinical Pure Tone Audiometry
219211387|NCT06894927|DIAGNOSTIC_TEST|Tympanometry|Clinical Tympanometry
219211388|NCT06894459|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
219211389|NCT06894459|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
219211390|NCT06894459|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
219211391|NCT06893588|DEVICE|NEVA VS|cerebral artery dilation device
219081700|NCT01825681|BEHAVIORAL|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
219081701|NCT05902832|BEHAVIORAL|EmotiPlay|EmotiPlay is a computer-based intervention program, designed to enhance emotion recognition (ER) by addressing multiple modalities of emotional cues (facial expressions, tone of voice, body language),
219081702|NCT02432105|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
219081703|NCT02432105|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
219081704|NCT01947465|BIOLOGICAL|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
219081705|NCT04718428|DIAGNOSTIC_TEST|Nail Ultrasonography|The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
219081706|NCT06560047|PROCEDURE|Catheter ablation|Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
219081707|NCT01005940|DEVICE|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
219081708|NCT02674893|DRUG|Liraglutide|
219081709|NCT02674893|OTHER|Observation alone|
219081710|NCT03860857|RADIATION|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
219081711|NCT03860857|DRUG|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
219081712|NCT03860857|BEHAVIORAL|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
219081713|NCT03860857|OTHER|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
219081714|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
219081715|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
219211392|NCT06894485|OTHER|Conventional therapy|"* Conventional range of motion (ROM) exercises~* Muscle strengthening exercises~* Fine motor skill exercises~* Functional rehabilitation exercises"
219681118|NCT00113295|DRUG|Continued Paroxetine CR|
219211393|NCT06894485|OTHER|Sensory Training|"* Desensitization training (exposure to various textures and stimuli to improve sensory tolerance)~* Proprioceptive exercises (closed-eye position sense training, weight transfer exercises)~* Tactile stimulation"
219681119|NCT00113295|DRUG|Quetiapine|
219681120|NCT00113295|DRUG|Placebo|
219681121|NCT01714544|DRUG|Cloderm Cream|
219081716|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
219081717|NCT02228265|OTHER|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
219081718|NCT02228265|DRUG|Enzalutamide|Given PO
219081719|NCT02228265|OTHER|Laboratory Biomarker Analysis|Correlative studies
219081720|NCT06470321|BEHAVIORAL|Flexiquit Computerized Smoking Cessation Program|Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
219081721|NCT00233922|DEVICE|Osteosheet(r)|
219081722|NCT00000154|PROCEDURE|Vitrectomy|
219211394|NCT06894797|RADIATION|Concurrent Chemoradiotherapy（Radiation + Capecitabine）|Capecitabine 825 mg/m\^2 Po BlD, Monday-Friday, on days of radiation treatment only, throughout the duration of RT Radiation：45-50Gy/25fractions/5 weeks，5fractions/week
219211395|NCT06894797|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
219211396|NCT06894797|DRUG|Oxaliplatin|Oxaliplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
219081723|NCT01400503|DRUG|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
219081724|NCT00058123|DRUG|poly ICLC|
219081725|NCT01525732|PROCEDURE|Per Oral Endoscopic Myotomy|
219681122|NCT06474156|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
219681123|NCT02697214|DEVICE|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
219681124|NCT02697214|DEVICE|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
219681125|NCT02697214|DEVICE|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
219681126|NCT02697214|DEVICE|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
219681127|NCT01179607|DRUG|M0002|
219681128|NCT01179607|DRUG|Placebo|
219681129|NCT02459197|BEHAVIORAL|Heat Pain Stimuli A|
219681130|NCT02459197|BEHAVIORAL|Heat Pain Stimuli B|
219681131|NCT02459197|BEHAVIORAL|Positive Video|
219681132|NCT02459197|BEHAVIORAL|Neutral Video|
219681133|NCT02459197|DRUG|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
219681134|NCT02459197|DRUG|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
219081726|NCT01936025|DRUG|Dextromethorphan|
219081727|NCT01936025|DRUG|Sitagliptin|
219211397|NCT06894797|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by intravenous infusion on 46h in a 2-week treatment cycle.
219211398|NCT06747819|DIAGNOSTIC_TEST|Cervical Epidural Steroid Injection (CESI)|Participants in this group received CESI to reduce inflammation and alleviate pain in the cervical nerve roots.
219211399|NCT06747819|COMBINATION_PRODUCT|Neural Mobilization (NM)|Participants in this group underwent NM exercises aimed at improving nerve mobility and reducing symptoms related to nerve compression.
219211400|NCT06785246|OTHER|Grasshopper dashboard|Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record
219211401|NCT06740279|OTHER|Assessment of upper limb function|Observational study of the changes in upper limb after SCI paralysis
219211402|NCT05018143|BEHAVIORAL|STARS|This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
219211403|NCT05018143|BEHAVIORAL|Control condition|In this intervention, participants will receive the safety planning intervention.
219211404|NCT05270109|PROCEDURE|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
219211405|NCT05270109|PROCEDURE|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
219211406|NCT06846567|DRUG|BM2216 Extended-Release tablets（5.5mg）|5.5mg BM2216 Extended-Release ,test drug
219081728|NCT01936025|DRUG|Placebo|
219081729|NCT04682496|PROCEDURE|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
219081730|NCT01767740|DEVICE|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
219081731|NCT01767740|DEVICE|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
219081732|NCT01212770|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
219081733|NCT01212770|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
219081734|NCT01212770|DRUG|Placebo|
219211407|NCT06846567|DRUG|Mirogabalin Besilate Tablets|15mg of Mirogabalin Besilate Tablets,reference drug
219211408|NCT06846567|DRUG|BM2216 Extended-Release Tablets(11mg)|11mg of BM2216 Extended-Release,test drug
219211409|NCT06846567|DRUG|BM2216 Extended-Release Tablets(16.5mg)|16.5mg of BM2216 Extended-Release Tablets,test drug
219211410|NCT06835309|OTHER|Pelvic floor muscles exercises|The exercises for strengthening the PFM were 10 contractions of 5 seconds, 15 contractions of 3 seconds, 20 contractions of 2 seconds, 20 contractions of 1 second (equal rest time between contractions), and 5 repetitions of maximum contractions while coughing (1-minute interval).25 The level of difficulty of the exercises throughout the 20 sessions was determined by the patient's position, starting in a supine position, then progressing to a sitting position and, finally, to a standing position
219681135|NCT00041197|DRUG|imatinib mesylate|Given orally (PO)
219681136|NCT00041197|OTHER|placebo|Given PO
219681137|NCT00041197|OTHER|laboratory biomarker analysis|Correlative studies
219681138|NCT05102071|DRUG|empagliflozin|empagliflozin
219681139|NCT05102071|DRUG|metformin|metformin
219681140|NCT05102071|DRUG|sulfonylurea|sulfonylurea
219681141|NCT00577772|DRUG|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
219681142|NCT00577772|DEVICE|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
219681143|NCT00577772|PROCEDURE|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
219681144|NCT02012400|OTHER|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
219681145|NCT00572455|DRUG|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
219681146|NCT00572455|DRUG|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
219681147|NCT00572455|DRUG|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
219681148|NCT00572455|DRUG|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
219681149|NCT00572455|DRUG|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
219681150|NCT00572455|DRUG|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
219681151|NCT00572455|DRUG|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
219681152|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
219081735|NCT06285877|PROCEDURE|Conventional therapy sessions|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
219081736|NCT06285877|PROCEDURE|Conventional therapy sessions plus Nintendo Switch|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
219081737|NCT02243943|DRUG|Sugammadex|
219081738|NCT02243943|DRUG|Neostigmine|
219081739|NCT04728321|BIOLOGICAL|AK104 lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
219081740|NCT04728321|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
219081741|NCT05242328|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
219081742|NCT05242328|PROCEDURE|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
219081743|NCT04440566|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219081744|NCT01970826|PROCEDURE|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
219081745|NCT01970826|PROCEDURE|Sterilized Aseptic|Operatory room will be prepared totally aseptic
219081746|NCT01970826|PROCEDURE|Sterilized Clean|Operatory room will be prepared clean but not aseptic
219081747|NCT01970826|PROCEDURE|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
219081748|NCT01970826|PROCEDURE|Partial Rehabilitation|two or more implants to support partial rehabilitation
219081749|NCT01970826|PROCEDURE|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
219081750|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
219081751|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
219081752|NCT03581812|DIETARY_SUPPLEMENT|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
219081753|NCT03717961|DRUG|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
219081754|NCT03717961|DRUG|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
219081755|NCT02483169|DRUG|cilostazol|Cilostazol 100mg bid
219081756|NCT02483169|DRUG|Probucol|Probucol 250mg bid
219081757|NCT02483169|DRUG|Aspirin|Aspirin 100mg qd
219081758|NCT02483169|DRUG|placebo of cilostazol|same shape and size of active cilostazol
219081759|NCT02483169|DRUG|Placebo of aspirin|same size and shape of active aspirin 100mg
219081760|NCT02483169|DEVICE|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
219081761|NCT02019368|DIETARY_SUPPLEMENT|Placebo|
219081762|NCT02019368|DIETARY_SUPPLEMENT|Aged garlic extract|
219081763|NCT01248338|DRUG|metoprolol succinate|once daily 50 or 100 mg for one year
219081764|NCT01248338|DRUG|Nebivolol|once daily 5 mg capsule for one year
219081765|NCT02235948|DRUG|folic acid supplementation|0.8mg folic acid/day
219081766|NCT01142206|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
219081767|NCT01142206|BEHAVIORAL|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
219081768|NCT01142206|BEHAVIORAL|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
219081769|NCT02950246|PROCEDURE|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
219081770|NCT02950246|DRUG|2% alcoholic chlorhexidine|
219081771|NCT02950246|DRUG|povidon iodine|
219681153|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
219681154|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
219211411|NCT06835309|OTHER|Pelvic floor muscles exercises and isokinetic strengthening of hip muscles|The hip muscle strengthening exercise was executed on Biodex multi-joint system isokinetic dynamometer. Muscle tension of the lower limbs was relieved by executing 5-minute warm-up exercises using a cycle ergometer before execution of the isokinetic exercise For each hip muscle group, eight repetitions per set for 4 sets were carried out for a single exercise with a 30 second break between each set. The patient's position were the same positions used in the testing procedure. The exercises were carried out 3 times a week and the hip muscles strength evaluation was conducted after the end of the program intervention
219211412|NCT00897702|OTHER|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
219211413|NCT00897702|OTHER|immunoenzyme technique|
219211414|NCT00897702|PROCEDURE|biopsy|
219681155|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
219681156|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
219211415|NCT00897702|PROCEDURE|histopathologic examination|
219211416|NCT06671574|OTHER|Emotional intelligence and Relaxation techniques|In each session, participants will engage in exercises aimed at recognizing, understanding, and regulating their emotions. These interactive activities will foster personal reflection and group discussion, helping individuals identify emotions in various situations and their impact on behavior. This approach will enhance emotional awareness and equip participants with practical tools for managing stress and anxiety. Various relaxation techniques will also be introduced. Deep breathing exercises will teach participants to calm their minds and bodies, reducing tension. Guided meditation will help them focus inward, promoting mental peace and deep relaxation. Additionally, visualization exercises will encourage imagining calming scenarios, alleviating anxiety and improving overall well-being.
219211417|NCT06754475|OTHER|Low-volume, high-intensity interval training|Low-volume, high-intensity interval training with an arm ergometer will be given two days a week for a total of eight weeks.
219211418|NCT06754475|DRUG|Standart medical treatment|Standart medical teatment
219211419|NCT02879318|DRUG|Gemcitabine|
219211420|NCT02879318|DRUG|Nab-paclitaxel|
219211421|NCT02879318|DRUG|Durvalumab|
219211422|NCT02879318|DRUG|Tremelimumab|
219211423|NCT06751875|DRUG|Lithium|Patients are randomized to either receive lithium or not.
219211424|NCT06766591|DRUG|Ivonescimab combined with chemotherapy|Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
219211425|NCT06790459|DEVICE|UlfTens (Ultra-low-frequencies Transcutaneous electrical nervous stimulation)|ULFTENS device will be administered in the experimental group for 15 minutes
219211426|NCT06769464|BEHAVIORAL|odor|present odor
219211427|NCT06790771|DIETARY_SUPPLEMENT|High Dose Supplement|Participants in this intervention receive approximately 10 grams of the supplement, containing 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. The supplement is consumed in powdered form after an 8-hour fasting period. Following a 60-minute rest, participants eat an ad libitum meal to assess the supplement's effect on hunger and food intake. Blood samples are collected at eight specific time points to measure metabolic markers, including GLP-1 levels, while hunger is tracked using a 7-point satiety scale. This intervention aims to determine the effects of a high dose of the supplement on appetite suppression and metabolic responses.
219211428|NCT06790771|DIETARY_SUPPLEMENT|Low Dose Supplement|In this intervention, participants consume approximately 5 grams of the supplement, which contains 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. The protocol mirrors that of the high-dose intervention: participants arrive after fasting for 8 hours, consume the supplement, rest for 60 minutes, and eat the standardized ad libitum meal. Blood samples are taken at the same eight time points to assess metabolic responses, and hunger levels are measured using the same satiety scale. This intervention investigates whether a lower dose of the supplement can still significantly affect hunger and GLP-1 secretion.
219211429|NCT06790771|DIETARY_SUPPLEMENT|Placebo|The placebo intervention involves participants consuming a \~5 g inert powder with no active ingredients. Participants follow the same protocol as the other two interventions, including fasting, baseline blood collection, supplement (placebo) consumption, a 60-minute rest, and an ad libitum meal. Blood samples are collected at eight time points, and hunger levels are assessed with the 7-point scale. This intervention serves as a control, helping to determine whether observed effects in the other two interventions are attributable to the active supplement ingredients.
219211430|NCT06767670|OTHER|stainless steel crown|familiar method of managing multi-surface carious lesions in primary teeth
219211431|NCT06767670|OTHER|bioflex crown|aesthetic preformed pediatric crowns that offer the properties of both stainless steel and zirconia crowns
219211432|NCT05067478|DRUG|Vibegron|Vibegron to be administered.
219211433|NCT06845124|DRUG|Cannabidiol capsules|800mg (trial arm 1) or 1200mg (trial arm 2) Cannabidiol capsules will be administered daily over the course of 14 days.
219211434|NCT06845124|DRUG|Naltrexone (drug)|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study.
219211435|NCT06845124|DRUG|Placebo|Placebo capsules matching the cannabidiol capsules will be administered daily.
219681157|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
219681158|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
219681159|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
219681160|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
219681161|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
219681162|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
219681163|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
219681164|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
219081772|NCT00277667|DRUG|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
219681165|NCT00572455|DRUG|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
219681166|NCT06484296|OTHER|Education|"Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test."
219681167|NCT06105606|DEVICE|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
219681168|NCT00334412|DRUG|Ambisome|
219681169|NCT00334412|DRUG|caspofungin|
219681170|NCT04302207|BEHAVIORAL|De-implementation Strategy for Bronchiolitis|De-implementation strategy to reduce over-use of treatments for patients with bronchiolitis
219681171|NCT00484471|DRUG|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
219681172|NCT00484471|DRUG|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
219681173|NCT00484471|DRUG|placebo|placebo to aripiprazole, 22 weeks
219681174|NCT02955953|DRUG|LY2963016|Administered SC
219681175|NCT02453464|DRUG|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
219681176|NCT02453464|DRUG|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
219681177|NCT02453464|DRUG|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
219681178|NCT02453464|DRUG|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
219081773|NCT05449834|DRUG|Fibrinogen Concentrate|3g Fibrinogen Concentrate
219081774|NCT05449834|OTHER|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
219081775|NCT02069444|PROCEDURE|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
219081776|NCT02069444|PROCEDURE|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
219081777|NCT03381495|DRUG|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
219081778|NCT05378633|RADIATION|SRS|Stereotactic Radiotherapy (SRS)
219081779|NCT05378633|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
219081780|NCT03662204|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
219081781|NCT06009341|OTHER|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
219081782|NCT05245344|PROCEDURE|Peripheral blood withdrawal|25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
219081783|NCT03526822|BIOLOGICAL|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
219081784|NCT03526822|BIOLOGICAL|Tumor sample|One tumor sample in operative period
219081785|NCT01923155|PROCEDURE|Colonoscopy|
219681179|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus plantarum strain 299v|Given PO
219681180|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus acidophilus probiotic|Given PO
219681181|NCT01644097|DIETARY_SUPPLEMENT|placebo|Given PO
219681182|NCT01644097|OTHER|laboratory biomarker analysis|Correlative studies
219681183|NCT01644097|OTHER|questionnaire administration|Ancillary studies
219681184|NCT01644097|PROCEDURE|quality-of-life assessment|Ancillary studies
219681185|NCT01644097|DIETARY_SUPPLEMENT|Bifidobacterium lactis probiotic supplement|Given PO
219681186|NCT03310242|BEHAVIORAL|Sunlight Exposure|"* Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~* Completing a Sun Diary after sunlight exposure"
219681187|NCT03310242|DIETARY_SUPPLEMENT|Vitamin D Supplementation|\- Supplementation of vitamin D3 500 IU/day for 8 weeks
219681188|NCT03310242|OTHER|Placebo|\- Intake of placebo for 8 weeks
219681189|NCT00117169|PROCEDURE|multi-detector helical computed tomography|
219681190|NCT00004244|BIOLOGICAL|recombinant interferon alfa|
219681191|NCT00004244|BIOLOGICAL|recombinant interleukin-12|
219681192|NCT00245024|DRUG|sulindac|
219681193|NCT00245024|OTHER|laboratory biomarker analysis|
219681194|NCT02824224|DRUG|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
219681195|NCT02824224|DRUG|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
219681196|NCT06959667|OTHER|Observational study, no intervention|Observational study, no intervention
219681197|NCT04494269|DRUG|Tegoprazan 50mg|Oral administration once daily
219681198|NCT01912859|BEHAVIORAL|Nutrition/physical activity intervention|Nutrition/physical activity intervention
219681199|NCT01296854|OTHER|Spa therapy|3 weeks of spa therapy
219681200|NCT02047435|BEHAVIORAL|Information, event and workshops at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~   * A guided tour at the museum~  * A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~  * The museum serves a refreshment and offer participants a season pass to the museum.~   And~2. Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
219081786|NCT02339831|DEVICE|CAMOPED|Camoped given after surgery
219081787|NCT02339831|DEVICE|CPM passive motion device|passive motion device given after surgery
219081788|NCT03036163|DRUG|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
219081789|NCT03036163|DRUG|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
219081790|NCT03036163|DRUG|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
219081791|NCT03036163|DRUG|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
219081792|NCT03036163|DRUG|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
219081793|NCT03036163|DRUG|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
219081794|NCT03036163|DRUG|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
219081795|NCT05415735|BEHAVIORAL|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
219081796|NCT05189730|DRUG|Tirelizumab|Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
219081797|NCT05189730|DRUG|Paclitaxel|Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
219081798|NCT05189730|DRUG|Carboplatin|Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
219081799|NCT05189730|RADIATION|Neoadiuvant radiotherapy|Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
219081800|NCT02668224|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
219081801|NCT02668224|OTHER|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
219081802|NCT06089811|DIETARY_SUPPLEMENT|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
219081803|NCT06089811|DIETARY_SUPPLEMENT|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
219081804|NCT06089811|DIETARY_SUPPLEMENT|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
219081805|NCT03519854|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
219081806|NCT03519854|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
219081807|NCT03519854|DRUG|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
219081808|NCT00182754|DRUG|octreotide acetate|Given subcutaneously
219081809|NCT00182754|OTHER|placebo|Given subcutaneously
219081810|NCT03356925|DIAGNOSTIC_TEST|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
219081811|NCT01458197|DRUG|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
219081812|NCT01458197|DRUG|Placebo|Capsule, qd, 12 weeks
219081813|NCT01458197|DRUG|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
219081814|NCT01667601|OTHER|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
219081815|NCT01667601|BEHAVIORAL|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
219081816|NCT01667601|BEHAVIORAL|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
219081817|NCT01763710|DRUG|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
219081818|NCT01763710|DRUG|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
219081819|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
219081820|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
219081821|NCT03876405|DEVICE|smartskin non-invasive sensory feedback|"The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket."
219081822|NCT05777226|DRUG|Epalrestat|Patients in the treatment group are intervened with Epalrestat tablets.
219081823|NCT04881006|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
219081824|NCT04881006|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
219081825|NCT04364373|PROCEDURE|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
219081826|NCT04364373|PROCEDURE|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
219081827|NCT04364373|PROCEDURE|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
219081828|NCT02535104|DRUG|Ranpirnase|Topical application by subject
219081829|NCT02535104|DRUG|Vehicle|Vehicle control
219081830|NCT02297022|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
219081831|NCT00236873|DRUG|topiramate|
219081832|NCT01054768|DRUG|alpha-lipoic acid and acetyl-L-carnitine|none to report
219081833|NCT01054768|DRUG|Control|none to report
219081834|NCT04786158|DRUG|Apomorphine|Reporting the effects of subcutaneous apomorphine on pain and on quality of life
219081835|NCT05433870|OTHER|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
219081836|NCT01053182|PROCEDURE|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
219081837|NCT01053182|PROCEDURE|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
219081838|NCT01232608|BEHAVIORAL|Exercise|12 months of exercise training
219081839|NCT05222282|OTHER|Sexual Health|Prevention of sexual dysfunction
219081840|NCT02603081|DRUG|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
219081841|NCT06011590|OTHER|No intervention.|No intervention.
219081842|NCT02122133|DEVICE|PC 400|
219081843|NCT05744648|PROCEDURE|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
219081844|NCT05744648|PROCEDURE|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
219081845|NCT05627102|OTHER|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
219681201|NCT02047435|BEHAVIORAL|Information and event at a cartoon museum|"1\. An event at the Storm P. Museum consisting of:~* A guided tour at the museum~* A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~* The museum serves a refreshment and offer participants a season pass to the museum."
219081846|NCT05627102|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
219081847|NCT02575885|OTHER|Electronic Cigarette|Receive different type of ENDS product at each visit
219081848|NCT02575885|OTHER|Electronic Cigarette|Receive BLU e-cigarette ENDS product
219081849|NCT02575885|OTHER|Laboratory Biomarker Analysis|Correlative studies
219081850|NCT02575885|OTHER|Pharmacological Study|Correlative studies
219081851|NCT02575885|OTHER|Questionnaire Administration|Ancillary studies
219081852|NCT02747238|DEVICE|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
219081853|NCT02747238|PROCEDURE|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
219081854|NCT02747238|PROCEDURE|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
219081855|NCT02471651|DRUG|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
219081856|NCT02471651|DRUG|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
219081857|NCT03758170|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
219081858|NCT05069090|BEHAVIORAL|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
219081859|NCT01571505|BIOLOGICAL|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
219081860|NCT01944904|DIETARY_SUPPLEMENT|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
219081861|NCT01944904|DIETARY_SUPPLEMENT|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
219081862|NCT05665933|BEHAVIORAL|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
219081863|NCT02085252|DRUG|Leuprorelin|Solution for injection
219681202|NCT00629031|DRUG|Paromomycin|11 mg/kg for 14 days
219681203|NCT00629031|DRUG|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
219681204|NCT02533583|DEVICE|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
219681205|NCT03180957|DRUG|Adalimumab|
219681206|NCT03180957|DRUG|Saline|
219081864|NCT02085252|DRUG|Bicalutamide|Bicalutamide tablets
219081865|NCT02767258|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
219081866|NCT02767258|DEVICE|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
219081867|NCT03606330|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT."
219081868|NCT03606330|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
219081869|NCT06323733|OTHER|Exercise Intervention|The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
219081870|NCT02616874|DRUG|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
219081871|NCT02616874|DRUG|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
219081872|NCT05944965|DRUG|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
219081873|NCT05944965|DRUG|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
219081874|NCT05944965|DRUG|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
219681207|NCT02403583|BEHAVIORAL|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
219681208|NCT01773629|OTHER|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
219681209|NCT01773629|OTHER|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
219681210|NCT04037514|DRUG|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
219681211|NCT04037514|DRUG|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
219081875|NCT00951275|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
219081876|NCT00951275|DRUG|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
219081877|NCT04477928|DIAGNOSTIC_TEST|Sera and whole blood sampling|"* Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
219081878|NCT04477928|DIAGNOSTIC_TEST|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
219081879|NCT04072510|BEHAVIORAL|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
219081880|NCT04072510|BEHAVIORAL|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
219081881|NCT01460940|DRUG|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
219081882|NCT01460940|DRUG|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
219211436|NCT02739477|DRUG|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
219211437|NCT03311451|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
219081883|NCT05327881|DIAGNOSTIC_TEST|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
219081884|NCT04405518|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
219081885|NCT01420848|OTHER|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
219081886|NCT01420848|OTHER|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
219211438|NCT06758167|DRUG|XingpiJieyu formula|XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
219081887|NCT02271958|DRUG|Mifepristone|
219081888|NCT02271958|DRUG|PLACEBO|
219211439|NCT06758167|DRUG|Placebo|Placebo, no therapeutic effect.
219211440|NCT06758167|DRUG|Escitalopram|A commonly used drug in MDD treatment.
219081889|NCT01760096|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
219081890|NCT01760096|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
219081891|NCT01760096|DRUG|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
219211441|NCT06758609|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy
219211442|NCT06758609|DRUG|4°C saline infusion|Patients received a total of 350 ml of 4°C saline infusion in addition to mechanical thrombectomy (MT).
219211443|NCT06758609|DRUG|Normothermic saline infusion|Patients received a total of 350 ml of roomtemperature saline infusion in addition to mechanical thrombectomy (MT).
219211444|NCT06768034|PROCEDURE|Intervention Group|Patients being referred to an internist or cardiologist after myocardial injury after noncardiac surgery
219211445|NCT06809868|GENETIC|RNA and DNA Sequencing|DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.
219081892|NCT01254123|DRUG|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
219211446|NCT06761651|DRUG|TAVO412|Biologic
219211447|NCT06163092|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
219211448|NCT05791396|BIOLOGICAL|Donor - FMT|this intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
219081893|NCT01254123|DRUG|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
219081894|NCT02446301|DRUG|Bain®|Nalbuphine HCl 20mg, IM injection
219081895|NCT02446301|DRUG|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
219081896|NCT03295890|PROCEDURE|Dry Needing|Dry Needling
219081897|NCT01826864|BIOLOGICAL|sargramostim|Given SC
219081898|NCT01826864|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
219081899|NCT01826864|OTHER|laboratory biomarker analysis|Correlative studies
219081900|NCT01826864|OTHER|hypertonic saline|Given SC
219081901|NCT05483504|DRUG|F61 injection|Colorless or slightly yellow liquid, may be slightly opalescent
219211449|NCT05791396|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through colonoscopy
219211450|NCT06600789|DRUG|CT7439 Capsules (0.5 mg, 1mg, 3mg)|CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed.
219211451|NCT06405984|DEVICE|Fetal Oxygenation Measurements|The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.
219081902|NCT05483504|DRUG|F61 Placebo|Colorless or slightly yellow liquid, may be slightly opalescent
219081903|NCT06294496|PROCEDURE|CEA/CAS|carotid endarterectomy (CEA) and carotid artery stenting (CAS)
219081904|NCT04359472|DEVICE|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
219081905|NCT04621110|DRUG|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
219081906|NCT04621110|DRUG|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
219081907|NCT04621110|DRUG|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
219081908|NCT04621110|DRUG|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
219081909|NCT04304664|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
219081910|NCT03283774|OTHER|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
219081911|NCT05944523|PROCEDURE|Erector Spina Plan Block|Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
219081912|NCT04253327|OTHER|questionnaire|"Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email.."
219081913|NCT05748548|OTHER|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
219211452|NCT06883851|OTHER|Structured pelvic floor rehabilitation|"The classic DDVAP therapy will be administered by the pediatric urologist. The classic urotherapy training recommended for enuresis will be provided by the physiotherapist. In addition, structured pelvic floor muscle rehabilitation (SPFMR) will be provided by the physiotherapist for 10 weeks. Each session is planned to last approximately 60 minutes.~SPFMR will include multiple interventions combined. Below is information about the brief interventions.~* Diaphragmatic Breathing Training~* Pelvic Floor Training with Biofeedback~* Core Stabilization Exercises~* Squat Exercises~* External Rotator Strengthing~* Adductor Strengthing~* Balance Training~* Home Exercises"
219211453|NCT06734052|BEHAVIORAL|CAPPA|See CAPPA arm description.
219211454|NCT06734052|BEHAVIORAL|Health education|See health education arm description
219211455|NCT06758024|DRUG|Infliximab|IFX therapeutic drug monitoring before the second and third infusion and subsequent dashboard-guided dosing regimes suggested to attending gastroenterologists based on clinical and pharmacokinetics data
219211456|NCT06758024|DRUG|Infliximab|No IFX therapeutic drug monitoring before the second and third infusion and subsequent dosing regimes based on clinical data
219081914|NCT05748548|OTHER|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
219081915|NCT05748548|OTHER|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
219081916|NCT00036881|DIETARY_SUPPLEMENT|zinc sulfate|
219211457|NCT06757621|RADIATION|Regional Nodal Irradiation|Patients will receive chest wall / breast radiation with or without regional nodal irradiation
219211458|NCT06891508|OTHER|Venous blood sampling|Venous blood sampling (3 mL) via venipuncture from the antecubital fossa at the time of delivery
219211459|NCT06891508|OTHER|Tissues sampling|Sampling of the placenta and amniochorionic membranes (hAM) at delivery
219211460|NCT06891508|OTHER|Umbilical cord blood sampling|Umbilical cord blood sampling from the residual cord attached to the placenta immediately after clamping.
219081917|NCT00036881|OTHER|placebo|
219081918|NCT06122714|DRUG|AZD4144 Part A|Part A: Participants will be administered a single oral dose on Day 1.
219081919|NCT06122714|DRUG|AZD4144 Part B|Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
219081920|NCT06122714|DRUG|Placebo Part A|Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
219081921|NCT06122714|DRUG|Placebo Part B|Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
219081922|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
219681212|NCT06492447|DRUG|Against HER 2-ADC Drug|Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
219681213|NCT01005017|PROCEDURE|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
219681214|NCT03579121|OTHER|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
219681215|NCT03579121|OTHER|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
219681216|NCT04257396|DEVICE|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
219681217|NCT04152083|DRUG|Eptinezumab|Injection for IV administration
219681218|NCT04152083|DRUG|Placebo|Injection for IV administration
219681219|NCT03792542|DRUG|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
219681220|NCT06958510|DEVICE|3D-Modified Anatomical-Mesh.|3D-Modified Anatomical-Mesh.
219681221|NCT06958510|DEVICE|conventional orbital rim miniplates and orbital mesh configuration|conventional orbital rim miniplates and orbital mesh configuration
219681222|NCT06165198|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
219681223|NCT00215891|DRUG|PEG-Interferon a-2b + Ribavirin|
219681224|NCT06059937|OTHER|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
219681225|NCT04870632|OTHER|Education|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.
219681226|NCT04870632|OTHER|Video-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
219681227|NCT04870632|OTHER|Booklet-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
219681228|NCT04512963|DRUG|Progerinin|100 mg/g nano-suspension for oral use
219681229|NCT04512963|DRUG|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
219681230|NCT05084183|DEVICE|PermeaDerm®|Wound Management Device
219681231|NCT05084183|DEVICE|Mepilex Ag|Wound Dressing
219681232|NCT06391359|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
219081923|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
219081924|NCT06218017|DEVICE|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
219681233|NCT06391359|OTHER|Watchful waiting|Watchful waiting
219681234|NCT04366154|OTHER|Questionnaire|delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
219681235|NCT05010213|OTHER|Educational intervention|Educational intervention
219681236|NCT00856999|DRUG|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
219081925|NCT06218017|DEVICE|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
219681237|NCT01427543|BEHAVIORAL|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
219681238|NCT03557918|DRUG|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
219081926|NCT04365582|DRUG|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
219681239|NCT01341015|OTHER|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
219681240|NCT06958133|OTHER|Standard Postoperative Rehabilitation|Standard rehabilitation protocol after surgical fixation of Weber type B ankle fractures without Kinesio taping.
219681241|NCT06958133|OTHER|Kinesio Taping|Kinesio taping applied over the surgical ankle to assist in reducing postoperative pain, swelling, and improving range of motion.
219681242|NCT06959433|DRUG|Lu-177 PSMA-617|Included patients will receive 4 cycles of 7.4GBq Lu-177 PSMa therapy every 6 weeks. If any toxicity develops after the first cycle, dose reduction will be performed for the other cycles. At 1. And 4. Cycles of therapy, whole body planar and SPECT/CT imaging will be performed at 4. And 24. Hours and any time at 4-7.days of injection. On these images , kindey, liver and salivary gland doses will be calculated. Mean tumor dose will also be calculated by measurinf the tumoral uptake. In the follow up, patients will be controlled at 9. And 24. Weeks and every 12 months then after.
219681243|NCT00626652|DRUG|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
219681244|NCT04164368|DRUG|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
219681245|NCT06959147|DRUG|High-Voltage Long-Duration Pulsed Radiofrequency plus Liposomal Bupivacaine group|High-Voltage Long-Duration Pulsed Radiofrequency Combined with Liposomal Bupivacaine Subcutaneous Block
219681246|NCT06959147|OTHER|High-Voltage Long-Duration Pulsed Radiofrequency|High-Voltage Long-Duration Pulsed Radiofrequency
219681247|NCT06958185|DEVICE|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
219681248|NCT03350490|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
219681249|NCT03350490|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
219681250|NCT06958965|OTHER|Resistance exercise training|The total duration of the training was 12 weeks, with a frequency of two sessions per week. Each session lasted approximately 90 to 120 minutes. The exercise intensity was set at 40-70% of the participants' one-repetition maximum (1RM), or adjusted based on the Modified Borg Rating of Perceived Exertion (RPE), targeting a moderate intensity level (approximately a score of 3).
219681251|NCT06958705|DRUG|Venetoclax combined with Ibrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using ibrutinib. After the completion of combination therapy, patients will stop both the ibrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and ibrutinib will continue for an additional 12 cycles. Venetoclax and ibrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Ibrutinib is intended to be admistratered orally 420mg once daily."
219681252|NCT06958705|DRUG|Venetoclax combined with Zanubrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using zanubrutinib. After the completion of combination therapy, patients will stop both the zanubrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and zanubrutinib will continue for an additional 12 cycles. Venetoclax and zanubrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Zanubrutinib is intended to be admistratered orally 160mg twice daily."
219681253|NCT06958705|DRUG|Venetoclax combined with Acalabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using acalabrutinib. After the completion of combination therapy, patients will stop both the acalabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and acalabrutinib will continue for an additional 12 cycles. Venetoclax and acalabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Acalabrutinib is intended to be admistratered orally 100mg twice daily."
219681254|NCT06958705|DRUG|Venetoclax combined with Orelabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using orelabrutinib. After the completion of combination therapy, patients will stop both the orelabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and orelabrutinib will continue for an additional 12 cycles. Venetoclax and orelabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Orelabrutinib is intended to be admistratered orally 150mg once daily."
219681255|NCT01695382|BEHAVIORAL|Navigation|As per Arm description
219681256|NCT06959485|BIOLOGICAL|Oxygen Therapy|"1. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on proteinuria in patients with diabetic kidney disease.~2. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on glycated haemoglobin in patients with diabetic kidney disease.~3. Comparing the effects of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask), early morning air exposure, and standard care on kidney function"
219681257|NCT04575090|DRUG|Simvastatin|Simvastatin 40 mg daily.
219681258|NCT02702362|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
219081927|NCT04365582|DRUG|Hydroxychloroquine|200 mg x 3/day for 10 days
219081928|NCT04365582|DRUG|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
219081929|NCT05558657|OTHER|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
219081930|NCT05558657|OTHER|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
219081931|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
219081932|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
219681259|NCT02465437|DRUG|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
219081933|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
219081934|NCT06647550|DRUG|HD-6277 100mg|PO, QD
219081935|NCT06647550|DRUG|HD-6277 50mg|PO, QD
219081936|NCT06647550|DRUG|HD-6277 25mg|PO, QD
219081937|NCT06647550|DRUG|Placebo|PO, QD
219081938|NCT00225433|DRUG|follitropin beta|Follitropin beta
219081939|NCT00225433|DRUG|ganirelix acetate|Ganirelix acetate
219081940|NCT06483750|DEVICE|Systane iLux Treatment|The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
219681260|NCT02465437|DRUG|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
219681261|NCT02465437|DRUG|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
219081941|NCT00778765|DRUG|400 mg Gabapentin Capsules|
219081942|NCT05066464|OTHER|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
219081943|NCT03053050|DRUG|SEL|Tablets administered orally once daily
219081944|NCT03053050|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
219081945|NCT03053050|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
219081946|NCT03703466|DRUG|Abemaciclib|Administered orally.
219081947|NCT06665607|PROCEDURE|Intrinsic Mucle Training|Conventional physiotherapy treatment and the intrinisc foot muscles strengthening program for 8 weeks.
219081948|NCT06667115|OTHER|PNF exercise|Foundational PNF D2 shoulder flexion exercise incorporating shoulder flexion, abduction, and external rotation. This exercise was performed at a metronome-guided pace of 14 beats per minute to establish a consistent baseline.
219681262|NCT03128853|DEVICE|Rad-67 and DCI Mini Sensor|
219681263|NCT05680662|COMBINATION_PRODUCT|quercetin, EGCG, metformin , zinc|this intervention target many mechanisms at tumorigenesis, metastasis autophagy, apoptosis, interleukin 6, cathepsin L, and also epigenetic DNA methylation
219211461|NCT06891534|OTHER|Continuous Feeding|Participants will receive 24-hour continuous feeds through an NG tube
219211462|NCT06891534|OTHER|Intermittent feeding|Participants will receive 3 boluses of feeding per day at regular meal times through an NG tube to mimic normal meals.
219211463|NCT06760169|DEVICE|Surgery with ELIOS laser|This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
219211464|NCT06895564|RADIATION|Spinal Proton SBRT|Patients will be treated with spinal proton SBRT over 5 fractions, with a prescription dose of 6 Gray equivalent (GyE) per fraction to the planning target volume.
219211465|NCT05383495|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg \[100 mcg/mL (max 200 mcg or 2 mL)
219211466|NCT05383495|DRUG|Midazolam Nasal Spray|Intranasal midazolam 0.4 mg/kg \[5 mg/mL (max 10 mg or 2 mL)
219211467|NCT05383495|DRUG|Nitrous oxide|50% nitrous oxide in 50% oxygen by face mask
219211468|NCT06764108|BEHAVIORAL|Self-monitoring|Self-monitoring will involve completing one brief smartphone-based survey (at a fixed time) per day on suicidal thoughts and related affect states and experiences over the past day during the four weeks after psychiatric hospitalization.
219211469|NCT06764108|BEHAVIORAL|JITAI|The JITAI will involve prompts to complete additional randomly timed self-monitoring surveys throughout the day. When suicidal thoughts are reported on any self-monitoring survey, random assignment to receive or not receive a series of automated smartphone-based messages that recommend using specific coping strategies from either a personalized safety plan or general evidence-based coping strategies that others tend to find helpful.
219081949|NCT06667115|OTHER|PNF exercise with virtual reality gaming|Combined the PNF D2 shoulder flexion exercise with a virtual reality motion capture game (the U-Ball game).
219081950|NCT06667115|OTHER|PNF with concurrent feedback|"PNF exercise with the addition of auditory concurrent feedback (Sword) which referenced the action of unsheathing a sword in a diagonal upward direction."
219081951|NCT06610617|DEVICE|transcranial direct current stimulation (tDCS)|tDCS designed to facilitate the excitability of the left dlPFC or sham stimulation on separate visits separated by at least one week in random order, using a double-blinded, within-subject crossover design. Electrode placement and current parameters will be optimized to each participant with the goal of generating an average electric field of 0.25 V/m within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA using the Stimweaver algorithm. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort
219081952|NCT06610617|DEVICE|Sham tDCS|Active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention delivers currents and mimics the sensations induced by tDCS, but does not significantly influence cortical tissue.
219081953|NCT06669650|OTHER|PGx guided personalized post-operative pain management|Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.
219081954|NCT06669650|DRUG|Oxycodone|oxycodone
219081955|NCT06669650|DRUG|Hydromorphone|hydromorphone
219081956|NCT06670157|OTHER|Detachable Clip|After the varicose vessels basically disappeared under the endoscope, the removable titanium clamp was removed
219081957|NCT06670989|BEHAVIORAL|Fixation training|Training (adapting) microsaccades during fixation
219081958|NCT06669299|PROCEDURE|Re-Do ventricular tachycardia ablation|1\. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.
219081959|NCT06669299|DRUG|Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)|The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
219211470|NCT06764108|BEHAVIORAL|Self-guided SSI|The brief (10-12 minute) online self-guided SSI will help individuals identify and address barriers to using coping strategies for suicidal thoughts. It may be delivered up to three times during the four weeks after hospitalization for those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions.
219211471|NCT06764108|BEHAVIORAL|Clinician-delivered SSI|The clinician-delivered SSI will consist of a brief (30-minute) Zoom or phone meeting in which a study clinician will help individuals identify and address barriers to using coping strategies for suicidal thoughts. Those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions may receive up to three clinician-delivered SSIs during the four weeks after hospitalization.
219211472|NCT06764537|PROCEDURE|Blood collection|Blood collection (40 mL) in glioblastoma patients
219681264|NCT05999591|PROCEDURE|Intrauterine insemination|Transfer of sperm into the fallopian tube through a specialised cannula
219081960|NCT05338333|DEVICE|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
219081961|NCT05338333|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
219081962|NCT05338333|DEVICE|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
219081963|NCT06670248|PROCEDURE|Debridement Surgery|Surgical debridement of burn wounds involving ≥ 20% of the TBSA, including debrided and donor sites.
219081964|NCT06670248|DIAGNOSTIC_TEST|Sdc-1 Level Measurement|"Measurement of plasma sdc-1 levels in different situations to assess endothelial glycocalyx damage using an enzyme-linked immunosorbent assay (ELISA):~Preoperatively:~* Upon admission to the Burn Unit.~* 24 hours after admission to the Burn Unit.~* Prior to the start of surgery, after anesthetic induction.~* If surgery is performed after the fifth day following the burn, an additional sdc-1 measurement will be taken on the fifth day of hospital admission.~Postoperatively:~* 6 hours after surgery.~* 24 hours after surgery.~* 48 hours after surgery."
219081965|NCT06669559|OTHER|DROM-Test|DROM test: a tool for assessing the ability to decide on returning home
219081966|NCT00254202|DRUG|Iloperidone|
219081967|NCT00254202|DRUG|Ziprasidone|
219081968|NCT00254202|DRUG|Placebo|
219081969|NCT06120907|OTHER|Data collection|The data include phenotypic data, treatments administered, response to treatment, Three-dimensional total body images, biopsies and blood plasma.
219081970|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
219081971|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
219081972|NCT06723951|OTHER|QUALAS survey|Participants will be asked to complete the surveys at one (controls) and two (patients) timepoints.
219081973|NCT06733779|OTHER|observation|cross-sectional study
219081974|NCT06732219|BEHAVIORAL|Functional Communication Training|Functional Communication Training (FCT) focuses on teaching an appropriate functional communicative response (FCR) to access the reinforcer maintaining severe problem behavior (SPB). This procedure involves selecting an appropriate topography for the FCR (e.g., touching a card, exchanging a picture) and using a backward chaining approach. The training will progress from full physical prompts to partial prompts and eventually to independent, unprompted responses, all within a trial-based format.
219081975|NCT06732219|BEHAVIORAL|Extinction-Correlated Stimuli|A distinct extinction-correlated stimulus (e.g., a laminated picture card) will be used in all treatment sessions where severe problem behavior (SPB) is subject to extinction contingencies. This stimulus will also be present during relapse challenges (described below). The selection of the stimulus will be individualized for each participant to ensure it has no prior association with treatment-related contexts, minimizing the influence of pre-existing learning histories.
219081976|NCT06732219|BEHAVIORAL|Caregiver Fading|"Behavioral Skills Training (BST) will be used to teach caregivers to (1) implement the behavioral intervention package (i.e., differential reinforcement of alternative behavior with extinction) in a controlled setting with confederates and (2) transition into behavioral sessions with the participant while gradually phasing out the clinical therapist.~Caregivers will begin by implementing mastered intervention components alongside the therapist during sessions with the participant, where the therapist will provide in-situ feedback. Once the caregiver demonstrates at least 80% treatment integrity across two consecutive sessions, the therapist will systematically increase their distance by 3 meters each session (maintaining at least 80% integrity) until they are fully removed from the treatment area."
219081977|NCT06732219|BEHAVIORAL|Structured-Probe Schedule Thinning|"Once a clinically significant decrease in severe problem behavior (SPB) is achieved (defined as an 80% reduction from the baseline mean rate), schedule thinning will be implemented. This process involves reducing the density of reinforcement by introducing a multiple schedule with alternating periods where reinforcement for the functional communication response (FCR) is available and unavailable.~Schedule thinning will begin immediately at the terminal schedule, with an 80% reduction in reinforcer density from treatment. Specifically, the FCR will be placed on extinction for 540 seconds and reinforced for 60 seconds during each session. This schedule was selected based on prior analyses of effective reductions in reinforcer density. If the treatment effect remains strong (defined as maintaining at least an 80% reduction in SPB relative to baseline), schedule thinning will proceed at this step until three consecutive sessions show consistent results."
219081978|NCT06732219|BEHAVIORAL|Multiple-Context Generalization Training|In multiple-context training, treatment will be implemented at the terminal schedule (i.e., after completing schedule thinning) in new contexts, including unique locations and with different individuals, distinct from the setting used during the initial treatment phase.
219081979|NCT06732336|DIAGNOSTIC_TEST|89Zr-trastuzumab|Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.
219081980|NCT06732024|PROCEDURE|Vaccum assisted closure|close skin and SC tissue by vaccum device
219081981|NCT06732024|PROCEDURE|primary wound closure|close skin and SC tissue by primary closure
219081982|NCT04915183|OTHER|Placebo|Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
219081983|NCT04915183|DRUG|Atorvastatin|Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
219081984|NCT06535061|OTHER|white noise|The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
219681265|NCT03403881|BEHAVIORAL|Physical activity promotion + TAU|"Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual"
219681266|NCT03403881|BEHAVIORAL|Control|Weekly call on general health aspects + treatment as usual
219681267|NCT02104245|DRUG|Ciprofloxacin dispersion for inhalation|
219681268|NCT02104245|DRUG|Placebo|
219081985|NCT06902571|DEVICE|Intermittent theta burst stimulation (iTBS)|600 pulses (3 pulses × 10 bursts × 20 trains = 600 pulses) will be delivered each session with reference to a 3-minute protocol developed by Huang, et al. (2005). Before, during and after iTBS, both fNIRS and fMRI measurements will be conducted simultaneously.
219081986|NCT06495710|OTHER|Blood pressure treatment algorithm|Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
219081987|NCT01602536|BEHAVIORAL|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
219081988|NCT01602536|BEHAVIORAL|Twitter|Twitter quit-smoking group
219081989|NCT04021810|DEVICE|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
219081990|NCT04021810|DEVICE|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
219081991|NCT05596370|DIAGNOSTIC_TEST|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
219081992|NCT03195868|DEVICE|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
219081993|NCT00510094|BEHAVIORAL|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
219081994|NCT00510094|BEHAVIORAL|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
219081995|NCT05374226|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
219081996|NCT03409666|DEVICE|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
219081997|NCT03409666|DEVICE|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
219081998|NCT00733603|OTHER|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
219081999|NCT00733603|OTHER|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
219082000|NCT03462732|DEVICE|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
219082001|NCT03462732|DEVICE|Nelaton catheter|plus nelaton catheter
219082002|NCT01791725|DRUG|ELND005|
219211473|NCT06767631|DIAGNOSTIC_TEST|threedimensional freehand ultrasound and instrumented spasticity assessment|To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
219681269|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
219681270|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
219681271|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
219681272|NCT01874626|DRUG|Placebo|Placebo cream
219681273|NCT01874626|DRUG|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
219082003|NCT01791725|DRUG|Placebo|
219082004|NCT05715996|DEVICE|mixed reality guided localization|In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
219082005|NCT05545982|PROCEDURE|Video laryngoscope with Miller approach|Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
219082006|NCT00512148|DEVICE|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
219082007|NCT01686789|DRUG|Pegylated interferon alpha-2a|
219211474|NCT06751667|DEVICE|Urinary biomarkers|In a bid to reduce or replace surveillance cystoscopies multiple urinary biomarkers have been evaluated for the follow-up of the bladder cancer patients. These device will reduce the number of cystoscopies
219681274|NCT00001919|DRUG|Hypericum (LI-160)|
219681275|NCT00003483|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
219681276|NCT03967067|PROCEDURE|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
219681277|NCT01348685|OTHER|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
219681278|NCT01348685|OTHER|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
219681279|NCT01348685|OTHER|The effect of solid vs. liquid forms of whey protein on food intake|
219082008|NCT06413836|DEVICE|aPDT|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC THERAPY/EC, Sao Carlos, Brazil) will be used to shine light at a wavelength of 660nm, 100 mW (miliWatts) and irradiation time of 3 min. CaOH (calcium hydroxide) paste will be applied at the root canals canals as a long-term dressing for endodontic treatment..
219082009|NCT06413836|PROCEDURE|Endodontic treatment|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC, THERAPY/EC, Sao Carlos, Brazil) will be used with an aluminium foil at the tip of the equipment to block light and use during 3 min as study group. CaOH (calcium hydroxide) will be applied at the root canals as a long-term dressing for endodontic treatment.
219082010|NCT00221442|DRUG|Zonegran|zonegran (zonisamide)
219082011|NCT00221442|DRUG|sugar pill|fake pill
219082012|NCT00822133|DRUG|lidocaine|lidocaine 5%
219082013|NCT00822133|DRUG|ketamine|ketamine cream
219082014|NCT00822133|DRUG|non-active drug cream|will be put on the skin
219082015|NCT02904408|BEHAVIORAL|psychotherapy|Group psychotherapy
219082016|NCT02926248|DRUG|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
219082017|NCT02926248|OTHER|Placebo|
219082018|NCT01223157|BIOLOGICAL|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
219082019|NCT03705208|OTHER|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
219082020|NCT05482048|OTHER|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
219082021|NCT06580535|OTHER|blood sample|Blood sample taking from patient for tissue culture
219082022|NCT00780858|DRUG|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
219082023|NCT01444157|OTHER|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
219082024|NCT05065489|OTHER|No intervention|No intervention
219082025|NCT00811343|BIOLOGICAL|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
219082026|NCT00677833|DRUG|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
219681280|NCT04579432|OTHER|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
219082027|NCT00677833|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
219681281|NCT01957423|DIETARY_SUPPLEMENT|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
219082028|NCT03948750|PROCEDURE|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
219082029|NCT02978755|DRUG|GM102|GM102 escalating doses (phase1)
219082030|NCT02978755|DRUG|GM102 escalating doses|GM102 escalating doses combined with paclitaxel and carboplatin
219082031|NCT02978755|DRUG|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
219082032|NCT02975570|DRUG|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
219082033|NCT02975570|DRUG|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
219082034|NCT02975570|DRUG|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
219082035|NCT02975570|DRUG|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
219681282|NCT01957423|DIETARY_SUPPLEMENT|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
219681283|NCT03944213|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
219082036|NCT02975570|DRUG|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
219082037|NCT01168193|OTHER|No intervention|
219211475|NCT06753968|PROCEDURE|Laparoscopic Right Hemicolectomy With Transrectal/transvaginal Specimen Extraction (NOSES)|Transvaginal extraction, begins with the irrigation and disinfection of the vagina, followed by a transverse incision in the posterior fornix. The assistant then utilizes oval forceps to carefully extract the specimen bag through the incision, which is subsequently closed with continuous full-thickness sutures, using barbed sutures to ensure secure closure. Similarly, transrectal extraction begins with irrigation of the rectum using a dilute iodine solution, followed by a longitudinal incision along the anterior wall of the upper rectum. The specimen, along with the protective sleeve, is then removed using oval forceps, and the incision is closed with a continuous full-layer running suture once the specimen has been completely extracted.
219681284|NCT02033044|OTHER|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
219681285|NCT02033044|OTHER|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
219681286|NCT02710019|OTHER|Back to Reality Series Video Games|Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
219681287|NCT02710019|OTHER|Control Video Game|The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
219681288|NCT00789620|DRUG|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
219681289|NCT00789620|DRUG|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
219681290|NCT05929742|BEHAVIORAL|virtual reality training|The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
219681291|NCT05929742|BEHAVIORAL|early rehabilitation|Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
219681292|NCT06433843|BEHAVIORAL|Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)|12 weeks inpatient disorder specific psychotherapy
219681293|NCT05115539|OTHER|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) \* 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
219681294|NCT05174156|DRUG|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
219681295|NCT04694976|BIOLOGICAL|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
219681296|NCT04420169|OTHER|Questionnaire|A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
219082038|NCT05072457|DEVICE|Roger On microphone|Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids
219082039|NCT05072457|DEVICE|Roger Select microphone|Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
219082040|NCT04575168|DIAGNOSTIC_TEST|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
219082041|NCT03852563|DRUG|BAY207543 (Bepanthol)|Product is applied to one hemiface.
219082042|NCT03852563|OTHER|Semisolid vaseline|Product is applied to one hemiface.
219082043|NCT02001194|BEHAVIORAL|Individual Incentives|
219082044|NCT02001194|BEHAVIORAL|Team Incentives|
219082045|NCT02001194|BEHAVIORAL|Individual plus Team Incentives|
219082046|NCT03075579|DRUG|Medication Other|medication of atomoxetine
219082047|NCT03075579|DEVICE|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
219082048|NCT02037048|DRUG|oxaliplatin|Given IV
219082049|NCT02037048|DRUG|leucovorin calcium|Given IV
219082050|NCT02037048|DRUG|fluorouracil|Given IV
219082051|NCT02037048|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
219082052|NCT02037048|RADIATION|radiation therapy|Undergo radiation therapy
219082053|NCT02037048|DRUG|carboplatin|Given IV
219082054|NCT02037048|DRUG|paclitaxel|Given IV
219211476|NCT06753968|PROCEDURE|Totally laparoscopic right hemicolectomy (TLRH)|Totally laparoscopic right hemicolectomy (TLRH), which involves performing intracorporeal anastomosis and specimen extraction through a small abdominal incision, further enhances the benefits of minimally invasive surgery. In the TLRH group, following the stapled side-to-side anastomosis, a small horizontal incision is made about 2 to 3 cm above the symphysis pubis, at the junction of the pubic hairline, to allow for specimen removal.
219082055|NCT01579604|PROCEDURE|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
219082056|NCT02690974|DRUG|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
219082057|NCT01091155|DEVICE|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
219082058|NCT03791164|BEHAVIORAL|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
219082059|NCT03791164|BEHAVIORAL|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
219082060|NCT03925701|DRUG|Vildagliptin|vildagliptin twice daily
219082061|NCT03925701|DRUG|vildagliptin\metformin|vildagliptin\\metformin twice daily
219082062|NCT05025657|BEHAVIORAL|ALLY|ALLY is a universal, school-based prevention program that takes place during the school day with individual students over 6 weeks.
219082063|NCT00678314|DRUG|Ropivacaine 0.2%|10 ml
219082064|NCT00678314|DRUG|Ropivacaine 0.75%|3 ml
219082065|NCT00678314|DRUG|Normal saline|10 ml
219082066|NCT01355588|DRUG|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
219082067|NCT01355588|DRUG|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
219082068|NCT01355588|DRUG|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
219082069|NCT01355588|DRUG|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
219211477|NCT06766630|DEVICE|Silk fibroin surgical mesh|This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
219082070|NCT00002481|DRUG|cisplatin|
219082071|NCT00002481|DRUG|cyclophosphamide|
219082072|NCT00002481|DRUG|cytarabine|
219082073|NCT00002481|DRUG|dexamethasone|
219082074|NCT00002481|DRUG|etoposide|
219082075|NCT00002481|PROCEDURE|autologous bone marrow transplantation|
219082076|NCT00002481|RADIATION|radiation therapy|
219082077|NCT03201016|DIAGNOSTIC_TEST|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
219082078|NCT02686580|BIOLOGICAL|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
219082079|NCT02126501|OTHER|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
219082080|NCT06150651|OTHER|CAR T-cell therapy|1x10\^6 cells/kg CD-19 CAR-T cells
219082081|NCT02187913|DIETARY_SUPPLEMENT|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
219082082|NCT00522301|DRUG|sorafenib tosylate|
219082083|NCT00522301|OTHER|immunoenzyme technique|
219082084|NCT00522301|OTHER|immunohistochemistry staining method|
219082085|NCT00522301|OTHER|laboratory biomarker analysis|
219082086|NCT00522301|OTHER|pharmacological study|
219082087|NCT04646655|DRUG|Enoxaparin|subcutaneous injections
219211478|NCT06610344|DIETARY_SUPPLEMENT|R-1,3-Butanediol|R-1,3-Butanediol 35 mL
219082088|NCT01666951|DRUG|LCP-Tacro tablets|Tacrolimus
219082089|NCT01666951|DRUG|Prograf|Tacrolimus
219082090|NCT00772785|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
219082091|NCT04613908|DEVICE|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
219082092|NCT04613908|OTHER|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance."
219082093|NCT04613908|OTHER|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
219082094|NCT02885987|DEVICE|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
219082095|NCT05654896|DRUG|Ceftriaxone Sodium|Antibiotic will be administered prophylactically for TACE
219211479|NCT06821386|DIAGNOSTIC_TEST|Genetic study with nanopore sequencing|The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.
219211480|NCT06768684|BEHAVIORAL|Brief behavioral counseling|Participants receive a two-session phone-based alcohol risk reduction intervention based on principles of harm reduction. Participants receive personalized feedback regarding how alcohol use may impact their health. Following a motivational enhancement exercise, participants are advised to reduce alcohol intake to within recommended limits. Evidence-based strategies are discussed (e.g., goal setting, self-monitoring, identifying and avoiding triggers, dealing with urges, pacing and spacing drinks, managing high risk situations, finding alternatives to alcohol, developing refusal skills, and enlisting social support). Educational materials addressing methods for cutting down are also provided, along with information about other available resources to support their efforts.
219211481|NCT06766097|DIETARY_SUPPLEMENT|mastic toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
219211482|NCT06766097|DIETARY_SUPPLEMENT|Placebo toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
219211483|NCT06757842|BEHAVIORAL|Mindfulness in Students|The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.
219211484|NCT06756971|DRUG|Propofol|Propofol will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
219211485|NCT06756971|DRUG|Dexmedetomidine|Dexmedetomidine will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
219211486|NCT06756659|OTHER|Center-based exercise training|All participants will undergo a spot jogging cardiopulmonary exercise test and a six-minute walking test. The outpatient center-based cardiac rehabilitation group will perform moderate-intensity stationary biking or treadmill exercise for 30 minutes, twice a week, under the supervision of a physical therapist in the outpatient cardiac rehabilitation room.
219211487|NCT06756659|OTHER|Home-based spot jogging|The home-based spot jogging cardiac rehabilitation group will receive exercise intensity guidance in the outpatient cardiac rehabilitation room for 30 minutes of spot jogging and treadmill exercise during the first, fourth, and seventh weeks. They will then perform moderate-intensity spot jogging at home for 30 minutes, twice a week, at a perceived exertion level of 13 out of 20 on the RPE scale.
219211488|NCT06758037|DRUG|Drug therapy|"All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W"
219211489|NCT06757751|DIETARY_SUPPLEMENT|EVOO diet supplement|For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).
219211490|NCT06750354|PROCEDURE|papworth technique|For Group A: The Papworth breathing technique consists of a series of diaphragmatic breathing and relaxation exercises, and teaches patients which muscles to use when breathing and how to avoid breathing too or too fast by emphasizing nose breathing. The technique is altered to suit activity; this allows the technique to be integrated by patients into their everyday lives with subsequent improvements in quality of life.
219211491|NCT06750354|PROCEDURE|aerobic training|"Aerobic training exercises are any activities that raise heart rate and make breathing somewhat harder. The activity you are doing must be constant and continuous. Examples of aerobic activities are~Walking or hiking Jogging or running Biking Swimming Rowing In-line skating Cross-country skiing Exercising on a stair-climber or elliptical machine"
219211492|NCT04099823|OTHER|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
219681297|NCT04020536|DRUG|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
219681298|NCT06064058|DIETARY_SUPPLEMENT|Ghazwan program|6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
219681299|NCT06064058|DRUG|Standard management|Standard care with NSAIDs and acetaminophen for pain management
219681300|NCT01176786|OTHER|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
219681301|NCT03028675|OTHER|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
219082096|NCT05461976|BEHAVIORAL|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
219082097|NCT02443948|OTHER|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
219082098|NCT06078605|OTHER|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
219082099|NCT06078605|OTHER|Placebo|Placebo
219082100|NCT03704155|DRUG|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
219082101|NCT03704155|OTHER|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
219082102|NCT05339048|GENETIC|Genetic risk variants|Exposure: Genetic predisposition to complex diseases.
219082103|NCT05339048|OTHER|Diet|Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.
219082104|NCT05339048|BEHAVIORAL|Physical activity|Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.
219082105|NCT05339048|OTHER|Socio-economic conditions|Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
219082106|NCT04272580|DRUG|Control group|No preload was given before spinal anesthesia.
219082107|NCT04272580|DRUG|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
219082108|NCT04272580|DRUG|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
219082109|NCT04272580|DRUG|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
219082110|NCT03043079|DIAGNOSTIC_TEST|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
219082111|NCT02430402|OTHER|Rehabilitation in warm climate|
219082112|NCT02366910|DEVICE|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
219211493|NCT04099823|DIAGNOSTIC_TEST|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
219681302|NCT04491981|PROCEDURE|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
219681303|NCT04491981|PROCEDURE|Composite resin|Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
219681304|NCT03285035|DEVICE|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
219082113|NCT02366910|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
219211494|NCT04099823|DIAGNOSTIC_TEST|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
219211495|NCT06762015|BEHAVIORAL|Positive Nursing Practice Environments Promotion Program|A multi-component intervention program aimed at promoting positive nursing practice environments.
219211496|NCT03280030|DRUG|Midostaurin|Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
219681305|NCT01369745|DRUG|Prednisolone|Prednisolone 2.7 mg daily
219681306|NCT01369745|DRUG|dipyridamole|dipyridamole 360 mg daily
219681307|NCT01369745|DRUG|Prednisone|Prednisone 5 mg daily
219082114|NCT03331718|DRUG|PGA felt reinforcement|During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.
219681308|NCT01369745|DRUG|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
219681309|NCT01369745|OTHER|placebo|
219681310|NCT00006114|DRUG|mitoxantrone hydrochloride|
219681311|NCT00006114|DRUG|vinorelbine tartrate|
219082115|NCT01843426|DRUG|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
219082116|NCT02897713|OTHER|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
219082117|NCT02897713|OTHER|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
219082118|NCT05276830|DRUG|BXCL501|Sublingual film containing 40 Micrograms BXCL501
219082119|NCT05276830|DRUG|BXCL501|Sublingual film containing 60 Micrograms BXCL501
219082120|NCT05276830|DRUG|Placebo film|Matching Sublingual Placebo film
219082121|NCT05530213|DEVICE|3D gait analysis on the GRAIL|3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)
219082122|NCT05530213|OTHER|Weight and height|The subject's body weight and height will be assessed
219082123|NCT01196455|DRUG|Capecitabine and Mitomycin C|"* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~* Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
219082124|NCT02623322|DRUG|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
219082125|NCT02623322|DRUG|Placebo|Placebo will be administered as a single dose by IV administration.
219082126|NCT04962555|PROCEDURE|Meniscus Suture|Patients with knee joint meniscus injury undergoing meniscus suture
219082127|NCT04962555|PROCEDURE|Partial meniscus resection|Patients with knee joint meniscus injury undergoing partial meniscus resection
219082128|NCT04962555|PROCEDURE|Subtotal meniscus resection|Patients with knee joint meniscus injury undergoing subtotal meniscus resection
219082129|NCT04962555|PROCEDURE|Complete meniscectomy|Patients with knee joint meniscus injury undergoing complete meniscectomy
219082130|NCT00743769|DRUG|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
219082131|NCT00743769|OTHER|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
219211497|NCT03280030|DRUG|Placebo|Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
219211498|NCT06764745|DEVICE|PC Ventilation Modes|Following induction, Group I patients received mechanical ventilation using the PC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
219082132|NCT02942602|DRUG|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
219082133|NCT02942602|DRUG|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
219681312|NCT02565602|OTHER|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
219082134|NCT02942602|DRUG|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
219082135|NCT02942602|DRUG|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
219082136|NCT02942602|BEHAVIORAL|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
219082137|NCT04012996|DEVICE|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
219082138|NCT04012996|DEVICE|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
219082139|NCT05861362|RADIATION|Curative radiotherapy|Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist
219082140|NCT05861362|BEHAVIORAL|5:2 intermittent fasting|Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
219082141|NCT06459947|PROCEDURE|Free gingival graft procedure|The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.
219082142|NCT04796441|BIOLOGICAL|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
219082143|NCT05941754|DIETARY_SUPPLEMENT|omega-3|supplement in the market
219082144|NCT05941754|DIETARY_SUPPLEMENT|placebo|corn oil
219082145|NCT03775200|DRUG|Psilocybin|Dose-finding
219082146|NCT04586725|OTHER|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
219082147|NCT04586725|OTHER|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
219082148|NCT02834156|OTHER|LP in a seated position then LP in a lying position|
219082149|NCT02834156|OTHER|LP in a lying position then LP in a seated position|
219082150|NCT03037632|BEHAVIORAL|Family Heart Talk Booklet|
219211499|NCT06764745|DEVICE|VC Ventilation Modes|Following induction, Group II patients received mechanical ventilation using the VC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
219211500|NCT06764745|DEVICE|PRVC Ventilation Modes|Following induction, Group III patients received mechanical ventilation using the PRVC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
219082151|NCT00292435|DRUG|Read vine leaf extract (AS 195)|
219082152|NCT02623465|DRUG|Insulin Lispro|Administered subcutaneously (SC)
219082153|NCT05686239|DRUG|RL-007 (Inidascamine)|investigational study drug
219082154|NCT05686239|DRUG|Placebo|placebo capsules matching the appearance and size of the active drug
219082155|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1|Participants wear a VR headset which plays VR content/material pre- endoscopy only.
219082156|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1&2|Participants wear a VR headset which plays VR content/material pre- endoscopy and during endoscopy.
219082157|NCT00005855|DRUG|carmustine|
219082158|NCT00005855|DRUG|efaproxiral|
219082159|NCT04467385|OTHER|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~* Coconut ShootersVR - 5 min/day~* Ninja flipVR - 5 min/day.~* Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~* Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~* Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~* Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~* Conventional exercises include:~  * passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
219082160|NCT04467385|OTHER|VR training + conventional therapy|"After the baseline assessment,~* The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~* Coconut ShootersVR - 8 min/day~* Ninja flipVR - 8 min/day~* Conventional Therapy - 20 min per day~  * Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
219082161|NCT04460144|DIAGNOSTIC_TEST|Mass spectrometry|Proteomic analysis
219082162|NCT01690130|DEVICE|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
219211501|NCT06767839|OTHER|Transcutaneous Electrical Nerve Stimulation|The current parameters for the TENS to be applied in the study were determined as 100 Hz, 100 microsecond pulse duration, and asymmetric biphasic waveform. The current intensity will be increased until the person feels a tingling sensation and will be applied for a total of 20 minutes. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
219082163|NCT01690130|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
219082164|NCT02035800|DRUG|Adalimumab|Patient will received medication as standard of care
219082165|NCT03731273|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
219082166|NCT02073799|PROCEDURE|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
219082167|NCT04466748|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
219082168|NCT04466748|DRUG|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
219082169|NCT02823951|DRUG|Rebif|
219681313|NCT02565602|OTHER|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
219082170|NCT02823951|DRUG|Tecfidera|
219082171|NCT01642680|OTHER|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
219082172|NCT01642680|OTHER|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
219211502|NCT06767839|OTHER|High Voltage Pulsed Galvanic Stimulation|YVKGS is a monophasic waveform current with double peaks, short pulse duration and a voltage higher than 100 Volts, the frequency of which can be adjusted optionally. In the study, the current parameters of YVKGS were determined as a frequency of 100 Hz, continuous pulse, double peak monophasic waveform. The current intensity will be applied for 20 minutes at the voltage at which the person feels a tingling sensation. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
219211503|NCT06767839|OTHER|Sham TENS|The current will be applied to the sham TENS group with the same parameters as the TENS group, and will be reduced and turned off after a while. In TENS application, people normally report that they no longer feel tingling after a few minutes of starting the application. Therefore, it will be explained to the sham TENS group that this situation is normal, and that they no longer feel tingling because they have become accustomed to the applied current.
219211504|NCT06768424|DEVICE|Guided biofilm therapy|Use of Airflow Plus powder subgingivally on teeth with deep periodeontal pockets
219082173|NCT04719780|BEHAVIORAL|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
219211505|NCT06768424|PROCEDURE|Platelet Rich Fibrin|Pack Platelet Rich Fibrin chops into the intrabony periodontla defect
219211506|NCT06768424|PROCEDURE|Minimally Invasive Surgical Technique|Periodontal intrabony defect is treated by minimally invasive surgical intervention
219211507|NCT00878319|PROCEDURE|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
219211508|NCT00878319|OTHER|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
219211509|NCT06827041|BIOLOGICAL|Phage (Cytophage Technologies)|"Our phage is a new type of investigational treatment for bacterial infections. Our lytic, monophage preparation was provided by Cytophage Technologies and underwent rigorous testing to ensure final product potency (7 x 10\^9 PFU/dose), purity, fidelity, and safety; laboratory tests demonstrate phage in vitro efficacy against the S. epidermidis strain.~Phage prepared in injection-grade saline will be given via two routes: a) intravenously twice daily, and concomitantly, b) intraarticularly twice daily, for a total duration of 14 days."
219082174|NCT04719780|BEHAVIORAL|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
219082175|NCT03436329|PROCEDURE|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
219082176|NCT03436329|PROCEDURE|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
219082177|NCT00269490|BEHAVIORAL|Yoga Nidra|
219082178|NCT05271864|DEVICE|Apple Watch|Apple Watch
219082179|NCT01404520|OTHER|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
219211510|NCT03741790|PROCEDURE|Ventilation|The difficult mask ventilation is defined as A) It is not possible for unassisted anesthesiologist to maintain the SpO2 \> 90% using 100% oxygen and positive pressure mask ventilation in a patient whose SpO2 \> 90% before anesthetic intervention; and/or B) It is not possible for unassisted anesthesiologist to prevent or reverse signs of inadequate ventilation during positive mask ventilation.
219211511|NCT03741790|PROCEDURE|Intubation|"The difficult endotracheal intubation is defined as  It is not possible to visualize any portion of the vocal cords with conventional laryngoscopy or when proper insertion of the endotracheal tube with conventional laryngoscopy requires more than three attempts or more than ten minutes."
219211512|NCT03936933|DRUG|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
219211513|NCT03936933|DRUG|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
219211514|NCT06832852|OTHER|Stepped care|During the first education session, participants will be provided with information pertaining to painful area, basic pain science, injury specific advice on load management, pain and activity management, lifestyle factors and physical activity. A general physical activity will be recommended (150-300 minutes of moderate-intensity activity per week). Then, participants will be directed to a website developed by the research team and patient partners. The website includes explanations of the various topics discussed during the session , explanatory videos, and summarized information. During the second educational session, the participant's condition will be reviewed, and their understanding of the topics covered in the first session and on the website will be assessed. A follow-up on the website will also be conducted. The physiotherapist will then answer the participant's questions and provide personalized advice based on their condition, along with long-term recommendations.
219681314|NCT02565602|DIETARY_SUPPLEMENT|Vitamin D|One tablet daily (400IU per tablet)
219681315|NCT02861963|PROCEDURE|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
219681316|NCT02861963|PROCEDURE|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
219681317|NCT03953521|DEVICE|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
219681318|NCT00003205|DRUG|bryostatin 1|
219082180|NCT05159622|BEHAVIORAL|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety \& affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
219082181|NCT04052672|OTHER|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
219082182|NCT02368808|BEHAVIORAL|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
219211515|NCT06832852|OTHER|Rehabilitation Care|The pragmatic rehabilitation program will include exercises aimed at improving strength, endurance, flexibility, capacity to sustain mechanical load and dynamic control. Manual therapy may be provided during the sessions, based on pragmatic clinical decision-making. Participants will also receive information pertaining to the painful area and advice on pain and load management, and on activity modification, integrated across the sessions.
219211516|NCT06832852|OTHER|Medical Care|The pragmatic medical intervention may include pharmacological management, education, physiotherapy referral or referral to a specialist as deemed necessary.
219211517|NCT06774898|DEVICE|Custom-molded lumbar-sacral orthosis|A custom-molded lumbar-sacral orthosis made according to the Vésinet method associated with measures designed to enhance adherence based on goal-setting techniques (i.e. personalized advice, self-determination of the wearing time, hotline) techniques and monitoring of adherence using a temperature sensor chip to provide feedbacks to participants on the wearing time at follow-up visits, and usual care (i.e. a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises).
219211518|NCT06774898|OTHER|Usual Care|Usual care consisting in a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises
219211519|NCT06774261|DRUG|Phenserine|"Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed."
219211520|NCT06774261|DRUG|Donepezil (Aricept®)|"The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards."
219211521|NCT06774183|OTHER|Near vision glasses for presbyopia correction|Provision of near vision glasses for presbyopia correction to individuals who did not previously have glasses and have correctable presbyopia
219211522|NCT06775093|DRUG|GLP-1 receptor agonist|3 months
219211523|NCT06775093|DRUG|Metformin|3 months
219211524|NCT06775093|BEHAVIORAL|healthy lifestyle education|3 months
219211525|NCT06770478|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT Scan|The imaging agent 68Ga-MY6349 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
219211526|NCT06771050|PROCEDURE|Debridement and Implant Retention (DAIR)|"Intervention 1: DAIR- cleaning of infected joint including irrigation, debridement and exchange of modular components (those not fixed to bone) with implant retention.~Intervention 2: Single stage revision - cleaning of infected joint including irrigation, removal and placement of definitive new components which could be primary or revision components."
219211527|NCT06771050|DRUG|Antibiotic Choice|"No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines."
219211528|NCT06771050|DRUG|Antibiotic duration Part A - Single stage revision|"Intervention Arm: Short course 6-week (42 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.~Intervention Arm: Long course 12- week (84 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors."
219082183|NCT03646799|DRUG|CKD-387|test drug
219082184|NCT03646799|DRUG|D484|reference drug
219082185|NCT02231827|OTHER|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
219082186|NCT02139722|BEHAVIORAL|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
219082187|NCT03318523|DRUG|Placebo|Administered as specified in the treatment arm
219211529|NCT06771050|DRUG|Antibiotic Duration Part B - Two stage revision|"Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability."
219211530|NCT06774950|BEHAVIORAL|Physician-patient quality circle|"Intervention: (To be compared with standard care)~1. Interprofessionnal meeting per neighbourhood: (beforehand) Therapeutic patient education (TPE) training for healthcare professionals~2. Physician-patient quality circle t0 Group sessions (n= 3 to 6 patients) with doctor and therapeutic patient education specialist Clinical measurements - CM (incl. HbA1c, body composition, blood pressure). PROM evaluation questionnaires (EQ5D\&DIABQ)~3. Development of individualised T2D programme: with case manager~4. Quarterly follow-up: t3, t6, t9 months PROM follow-up (DIABQ\&PHQ9) +CM.~5. Evaluation of experience: t12 \& t18 months PREM\&PROM evaluation questionnaire +CM"
219211531|NCT06772948|OTHER|Asynchronised group|Health workers with musculoskeletal system disorders will be given pilates exercises asynchronously using the YouTube application.
219211532|NCT06772948|OTHER|Synchronized group|Using the Zoom application, healthcare workers with musculoskeletal disorders will perform pilates exercises synchronously.
219211533|NCT06772909|OTHER|No intervention (observational study)|no intervention
219211534|NCT06771063|DRUG|WXSH0102/placebo|Administer WXSH0102 tablets/placebo orally.
219211535|NCT06771063|DRUG|fluconazole capsules/placebo|Administer fluconazole capsules/placebo orally
219211536|NCT06770725|BEHAVIORAL|Temporal Adaptation Intervention|The research on temporal adaptation intervention will be conducted through activities and individual sessions within the framework of temporal adaptation intervention. The activities included in the temporal adaptation intervention used in our research have been adapted for ADHD by referencing temporal adaptation training models in the literature.
219211537|NCT06770725|BEHAVIORAL|Conventional Occupational Therapy|The control group will be given a 10-week-long conventional occupational therapy intervention by the investigator (Fatma Temizkan). The intervention will consist of occupational therapy approaches such as; obstacle courses, sensory integration, motor skills training, cognitive skills training, sequenced activities and so on.
219211538|NCT06775756|RADIATION|IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation|For N0 disease, only cover bilateral RPN and level II. For N1 disease, cover ipsilateral involved level plus subsequent level downword, and cover contralateral level RPN and level II. For N2 disease, cover ipsilateral involved level plus subsequent level downword. For N3 disease, cover ipsilateral involved level plus subsequent level downword, and ensuring a 2cm margin below GTVn if GTVn reach or near the sternoclavicular joint. Notably, for unilateral N3, the contralateral neck would only include RPN and level II. Prescribing dose for CTVn2 was 50Gy/33Fx.
219211539|NCT06310343|DRUG|Alemtuzumab|Licensed dose
219082188|NCT03318523|DRUG|BIIB054|Administered as specified in the treatment arm.
219082189|NCT05632146|PROCEDURE|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
219082190|NCT05632146|PROCEDURE|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
219082191|NCT01000168|OTHER|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
219082192|NCT05190250|DIAGNOSTIC_TEST|Pipelle biopsy|Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
219082193|NCT00361374|DIETARY_SUPPLEMENT|eicosapentaenoic acid|1 gram/day
219082194|NCT00361374|DIETARY_SUPPLEMENT|docosahexaenoic acid|1 gram/day
219082195|NCT00361374|DRUG|Placebo|980 milligram/day
219211540|NCT06777966|DRUG|nebulized tranexamic acid|patients will receive a preoperative nebulizer session of 500 mg of tranexamic acid. To ensure the blinding of the participating anesthetist and patient, patients in this group will receive an intravenous drip of 100 ml of 0.9% normal saline.
219211541|NCT06777966|DRUG|intravenous tranexamic acid|patients will receive a preoperative intravenous drip of TXA at a dose of 15 mg/kg in 100 ml of normal saline. To ensure blinding this group patients will receive 5 ml of 0.9% normal saline nebulizer session.
219082196|NCT03581981|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)
219082197|NCT03581981|BEHAVIORAL|Treatment as Usual|Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
219082198|NCT02080871|DEVICE|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
219082199|NCT05201573|OTHER|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
219082200|NCT02696655|BEHAVIORAL|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
219082201|NCT06106386|OTHER|cryotherapy|Cooling of irrigation
219082202|NCT05263752|DEVICE|ERCP with NvisionVLE® Imaging Low Profile System|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
219082203|NCT00234052|BIOLOGICAL|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
219082204|NCT00234052|DRUG|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
219082205|NCT00234052|DRUG|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
219082206|NCT04326270|DEVICE|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
219082207|NCT04481295|OTHER|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
219211542|NCT06764199|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT), a relatively new psychotherapy, incorporates psychopathological hypotheses and interventions based on contextual behavioral sciences and Relational Frame Theory.
219211543|NCT06782464|PROCEDURE|Treatment|Treatment
219211544|NCT05500417|DRUG|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
219681319|NCT00874315|OTHER|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
219082208|NCT04481295|OTHER|Low SpO2|Low SpO2
219082209|NCT01410474|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
219082210|NCT06579521|OTHER|Alcohol|A standard dose of alcohol will be administered (volume calculated with regard to age, sex assigned at birth, height, and weight) in the form of vodka and combined with mixer at a 1:4 ratio to reach a target breath alcohol concentration of .08%.
219082211|NCT06579066|DRUG|Probiotic Blend Capsule|Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
219082212|NCT06579066|DRUG|Activated Charcoal|Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
219082213|NCT06457074|DRUG|Finerenone Oral Tablet|Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
219082214|NCT06457074|DRUG|Spironolactone Oral Tablet|Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
219082215|NCT03603080|DRUG|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
219082216|NCT04525495|DRUG|Dopamine|Dopamine treatment
219082217|NCT04701151|DRUG|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
219082218|NCT03105414|DEVICE|Mechanical ventilation|Mechanical ventilation
219082219|NCT00505245|OTHER|Interview|Complete interview
219082220|NCT00505245|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
219082221|NCT00505245|OTHER|Questionnaire Administration|Complete questionnaires
219082222|NCT03384173|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
219082223|NCT04632602|OTHER|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
219082224|NCT00002974|DRUG|carboplatin|
219082225|NCT00002974|DRUG|etoposide|
219082226|NCT00002974|DRUG|ifosfamide|
219082227|NCT00002974|PROCEDURE|hyperthermia treatment|
219211545|NCT05500417|BIOLOGICAL|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
219681320|NCT00874315|DRUG|busulfan|0.8 mg/kg/dose for total of 8 doses.
219681321|NCT00874315|DRUG|cyclosporine|1.5 mg/kg/dose every 12 hours.
219681322|NCT00874315|DRUG|fludarabine phosphate|30 mg/m2/day for 5 days.
219681323|NCT00874315|DRUG|mycophenolate mofetil|15 mg/kg/dose every 8 hours
219681324|NCT00874315|DRUG|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
219681325|NCT00874315|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
219082228|NCT05267392|DRUG|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
219211546|NCT02616666|DRUG|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
219082229|NCT05267392|OTHER|standard of care RT/RCT|standard of care RT/RCT
219082230|NCT03355638|DRUG|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
219082231|NCT03355638|DRUG|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
219082232|NCT03355638|DRUG|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
219082233|NCT03840590|DEVICE|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
219082234|NCT03840590|DEVICE|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
219082235|NCT05617690|DRUG|Cyclopol|Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h
219082236|NCT05617690|DRUG|Propofol|Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
219082237|NCT05807243|OTHER|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
219082238|NCT00446810|DRUG|Benfotiamine|
219082239|NCT00446810|DRUG|Placebo|
219082240|NCT00828984|DRUG|macrogol 3350-based oral osmotic laxative|Given PO
219082241|NCT00828984|OTHER|Placebo|Given PO
219082242|NCT00828984|OTHER|Laboratory Biomarker Analysis|Correlative studies
219082243|NCT05904951|DEVICE|INVADER™ PTCA Balloon Dilatation Catheter|INVADER™ PTCA Balloon Dilatation Catheter is a single use, EO sterilized, monorail rapid exchange (RX) coronary angioplasty balloon dilatation catheter. The INVADER™ PTCA has been designed to dilate the stenotic atherosclerotic lesions in coronary arteries or bypass grafts. The INVADER™ PTCA is an interventional, non-surgical device, and considered minimally invasive.
219082244|NCT03509974|DEVICE|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
219082245|NCT04232514|DRUG|HEC74647|Administered HEC74647 200 mg orally once daily in fed state
219082246|NCT04232514|DRUG|HEC110114|Administered HEC110114 800 mg orally once daily in fed state
219082247|NCT02710279|BEHAVIORAL|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
219082248|NCT02710279|DEVICE|smartphone|
219082249|NCT02230202|OTHER|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
219082250|NCT02230202|OTHER|single blood draw|single blood draw of approximately 45 mL.
219082251|NCT01210833|DEVICE|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
219082252|NCT00464646|DRUG|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
219082253|NCT00464646|DRUG|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
219082254|NCT00464646|DRUG|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
219082255|NCT00464646|DRUG|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
219082256|NCT00464646|DRUG|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
219082257|NCT01174420|DEVICE|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
219082258|NCT01174420|DRUG|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
219211547|NCT02616666|DRUG|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
219211548|NCT05338008|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
219211549|NCT06826534|BEHAVIORAL|Cardio-oncology rehabilitation|Least 60 minutes of physical activity each day including vigorous-intensity and strengthening activities at least 3 days per week
219211550|NCT06878742|DRUG|Intravenous dobutamine 5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 5 mcg/kg/min.
219211551|NCT06878742|DRUG|Intravenous dobutamine 7.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 7.5 mcg/kg/min.
219211552|NCT06878742|DRUG|Intravenous dobutamine 10 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 10 mcg/kg/min.
219211553|NCT06878742|DRUG|Intravenous dobutamine 12.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 12.5 mcg/kg/min.
219211554|NCT06878742|DRUG|Intravenous dobutamine 15 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 15 mcg/kg/min.
219211555|NCT06242873|OTHER|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
219211556|NCT04656340|OTHER|non-medication, non-interventional therapies|non-medication, non-interventional therapies
219211557|NCT06742476|DEVICE|nasal cannula|In the apneic oxygenation group, nasal cannula will be employed to administer continuous oxygenation, utilizing a flow rate of 0.2 L/kg, during the apneic phase while tracheal intubation is performed. Successful intubation will be confirmed by auscultation and the appearance of a square wave capnogragh.
219211558|NCT06618976|DRUG|Sotagliflozin|Sotagliflozin 400 mg, P.O. once daily for 1 month.
219211559|NCT06618976|DRUG|Empagliflozin|Empagliflozin 10 mg, P.O. once daily for 1 month.
219211560|NCT06700980|OTHER|Focus Group|Dutch-speaking patients, Dutch- and/or French-speaking general practitioners and Dutch- and/or French-speaking representatives from pertinent organizational and policy sectors will be questioned in heterogeneous focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
219211561|NCT06878976|DRUG|Solriamfetol 75mg, 150 mg, or 300 mg|Taken once daily.
219211562|NCT06740591|DEVICE|HD-tDCS|The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
219211563|NCT06740591|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation(sham HD-tDCS)|The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
219211564|NCT06284941|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
219211565|NCT05841927|DIETARY_SUPPLEMENT|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
219211566|NCT05841927|DIETARY_SUPPLEMENT|ASD placebo|ASD placebo
219082259|NCT04043923|DRUG|Norketotifen|Oral capsule
219082260|NCT04043923|DRUG|Placebo|Oral capsule
219082261|NCT05423925|PROCEDURE|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
219082262|NCT05423925|PROCEDURE|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
219082263|NCT03820856|PROCEDURE|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
219082264|NCT03820856|PROCEDURE|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
219082265|NCT01615328|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
219082266|NCT01615328|DEVICE|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
219082267|NCT05439798|DRUG|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
219082268|NCT05439798|DRUG|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
219082269|NCT05439798|DRUG|Dexamethasone|Dexamethasone
219082270|NCT00177060|DRUG|hydromorphone|
219082271|NCT01090570|DRUG|PLX3397|Once-daily oral capsules
219082272|NCT02022579|PROCEDURE|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
219082273|NCT03338894|BEHAVIORAL|Yoga|1 Hour yoga class
219681326|NCT02651844|DRUG|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
219211567|NCT06829927|BEHAVIORAL|e-book|Patients with pilot application will not be included in the study. Patients who agree to participate in the study will be informed by the researcher about the purpose and process of the study, and their written and verbal informed consent will be obtained. Patients will be informed that the decision on whether or not to participate in the study is entirely their own, that no money will be deducted from their health insurance or any money will be paid to them, that the data to be collected from this study will only be used within the scope of the research, and that confidentiality will be strictly ensured. Pretests (Personal Information Form, Urinary Catheter Self-Efficacy Scale and Comfort Scale) will be administered to the patients whose consent is obtained.
219211568|NCT06827899|DRUG|veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)|Specified dose on specified days
219082274|NCT01543243|DEVICE|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
219211569|NCT05071482|DRUG|Flumatinib|Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
219211570|NCT05071482|DRUG|Imatinib|Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
219082275|NCT01543243|DEVICE|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
219082276|NCT04900129|COMBINATION_PRODUCT|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
219082277|NCT00863655|DRUG|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
219082278|NCT00863655|DRUG|Exemestane|Exemestane 25 mg orally daily.
219082279|NCT00863655|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
219082280|NCT02538185|DEVICE|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
219082281|NCT02538185|DEVICE|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
219211571|NCT04671771|DEVICE|InnAVasc Arteriovenous Graft (IG) surgical implant|The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
219211572|NCT02819882|OTHER|No intervention|
219211573|NCT04252235|DEVICE|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
219211574|NCT04252235|DEVICE|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
219211575|NCT06759064|DRUG|zoledronic acid plus Sintilimab intraperitoneal injection|At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
219681327|NCT03564769|BEHAVIORAL|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
219681328|NCT03564769|OTHER|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
219681329|NCT01252407|OTHER|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
219681330|NCT00292708|DRUG|Cefmetazole (drug)|
219681331|NCT04019717|DRUG|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
219082282|NCT02538185|DEVICE|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
219082283|NCT02538185|DRUG|Vaccin rabique Pasteur®|
219082284|NCT02538185|DRUG|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
219082285|NCT04465357|DRUG|Erenumab-Aooe 140 MG/ML [Aimovig]|140 mg/mL administered subcutaneously
219082286|NCT01040858|BEHAVIORAL|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
219082287|NCT01040858|OTHER|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
219082288|NCT02157779|BEHAVIORAL|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
219082289|NCT02157779|BEHAVIORAL|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
219082290|NCT02445313|DEVICE|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
219082291|NCT04351503|OTHER|Study A|Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
219082292|NCT04351503|OTHER|Study B|Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
219082293|NCT04351503|OTHER|Study C|Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.
219082294|NCT04351503|OTHER|Study D|"Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting)."
219082295|NCT02855307|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
219082296|NCT02855307|DEVICE|Insulin pump|Patient's insulin pump will be used to infuse insulin.
219082297|NCT02855307|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
219082298|NCT02855307|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
219082299|NCT02855307|OTHER|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
219082300|NCT00778583|DRUG|Nitrofurantoin 100 mg capsules|
219082301|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
219082302|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
219082303|NCT01787448|DRUG|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
219082304|NCT01787448|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
219082305|NCT05801211|PROCEDURE|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
219082306|NCT04000841|BEHAVIORAL|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~* Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~* User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~* Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~* User-customized reminders to do specific meditations and display personally selected images or messages."
219082307|NCT01826227|PROCEDURE|Positron Emission Tomography|
219082308|NCT01826227|RADIATION|18F-Fluoro-2-deoxy-D-lucose|
219082309|NCT01826227|PROCEDURE|Cytoreductive surgery|
219082310|NCT05287555|OTHER|Telemonitoring Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, SpO2 sensor and modems.
219082311|NCT05287555|OTHER|Standard Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, and modems
219082312|NCT03021356|DEVICE|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
219681332|NCT04019717|DRUG|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
219681333|NCT06400901|OTHER|No interventions|No interventions were given to patients except for the deep brain stimulation surgery they originally planned to take
219681334|NCT04089254|BEHAVIORAL|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
219082313|NCT03294330|DRUG|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
219082314|NCT06532318|BIOLOGICAL|Platelet rich plasma|Freshly prepared autologus platelet rich plasma
219082315|NCT06532318|DRUG|Pfizer Depo-medrol|Methylprednisolone acetate 20mg/ml injection
219082316|NCT01911039|BIOLOGICAL|Regulatory T Cells|
219082317|NCT02813187|BIOLOGICAL|cellular and tissue based therapy|
219211576|NCT06791759|OTHER|The course on technology use in nursing|Students attended in the course technology use in nursing. The course consisted of 2 hours per week over 14 weeks. The course aims to provide students with an understanding of fundamental technological developments in nursing, highlighting the importance and impact of technology in nursing education and practice.Theoretical lessons were delivered by two nurse educators over 8 weeks through PowerPoint presentations and interactive discussions. For the remaining five weeks, students were given some assignments to increase their interaction with digital technological tools. Three assignments were planned for each of the students. In this context, microsoft teams, canva, microsoft powerpoint, kahoot, mentimeter, quizlet, ed-puzzle, capcut, mobile health applications, google classroom, discord and artificial intelligence applications were used for assignments.
219211577|NCT06738212|OTHER|Group A aerobic exercises|"Group A will perform the aerobic exercises (such as bicycling, treadmill and running) Aerobic exercises 15min/session for each exercise, 2 times/week. Frequency: 2 times /week Intensity: Easy to moderate about 60 to 75% of maximum heart rate Type: treadmill, bicycling, running Time: 45min/session~Bicycling:~15~\- Start with gentle, low-intensity cycling and gradually increase as comfort allows - Aim for regular, consistent cycling sessions (e.g., 2-3 times a week,15min/session) - Consider incorporating other exercises, like stretching or yoga, to complement cycling.~Running~To get started with running for dysmenorrhea:~1. Start with short distances and gradually increase as comfort allows~2. Aim for regular, consistent running sessions (e.g., 2-3 times a week,15 minute/session)~3. Consider incorporating other exercises, like stretching or yoga, to complement running."
219211578|NCT06738212|OTHER|Group B Aviva exercises|"Group B will perform the Aviva exercises in 18 different movements. Aviva exercise intervention method is based on a carefully structured, mild-to-moderate intensity series of 18 movement sequences and aerobic exercises 30min/session, 2 times/week (20)~Aviva Methods of exercises:~These exercises are a carefully structured, intense, and methodical series of movement sequences, including a 5 min warm-up exercise at the beginning and 5 min cooling-down exercises at the end of the session. These exercises are performed in Standing, Sitting, Supine lying, prone lying"
219211579|NCT06758674|OTHER|education|Prepared in clear language and supported with visuals in line with guidelines and studies (Kottner et al. 2019, Orhan 2017, APUPA 2011, EPUAP and NPUAP 2009, EPUAP 2019, Arıkan and vanGiersbergen 2019, Arslantaş et al. 2018) training will be given to prevent pressure ulcers. Training content will be sent to expert opinion for content validity. In the content of the training, the definition of pressure ulcers, how they develop, high-risk areas for wound formation, identification of risks, evaluation of the skin, skin care, lying positions and position changes, supporting bone protrusions with pillows, lying on a support surface, nutritional status and content, fluid intake will be discussed.
219211580|NCT05113862|BIOLOGICAL|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
219082318|NCT02813187|PROCEDURE|debridement|
219082319|NCT02813187|PROCEDURE|advanced wound therapy|
219082320|NCT02813187|DIETARY_SUPPLEMENT|Nutritional screening|
219082321|NCT06491771|DEVICE|TargetCool|The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
219082322|NCT02249819|DEVICE|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
219082323|NCT05849779|DRUG|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
219082324|NCT05849779|DRUG|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
219082325|NCT06468774|PROCEDURE|Laparoscopic surgery|"The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression.~In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior mesenteric artery or both will be performed.~For operative treatment will be performed in general anaethesia whereas the endovacular treatment with PTA with stent for CMI will be performed in local anaethesia."
219082326|NCT00002558|BIOLOGICAL|filgrastim|
219082327|NCT00002558|DRUG|carboplatin|
219082328|NCT00002558|DRUG|etoposide|
219082329|NCT00002558|DRUG|ifosfamide|
219082330|NCT00002558|DRUG|paclitaxel|
219082331|NCT00002558|PROCEDURE|peripheral blood stem cell transplantation|
219082332|NCT02295514|BIOLOGICAL|PTP1B dosage|PTP1B sampled and dosed during sepsis
219082333|NCT06038760|PROCEDURE|Resection|Patients undergo a resection from a lesion, and give 40mL of blood
219082334|NCT04085848|OTHER|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
219082335|NCT04818580|PROCEDURE|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
219082336|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219082337|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219211581|NCT05113862|BIOLOGICAL|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
219211582|NCT05113862|BIOLOGICAL|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
219082338|NCT05538624|DRUG|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
219211583|NCT05113862|BIOLOGICAL|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
219211584|NCT06717373|DEVICE|AutoAS|AutoAS is an artificial intelligence algorithm that will be tested retrospectively on the images acquired as part of the study
219211585|NCT06708962|OTHER|Mulligan's mobilization|Mulligan mobilization isthe concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient.
219211586|NCT06708962|OTHER|corticosteroid injection for rotator cuff tendinopathy|corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches
219211587|NCT06361173|OTHER|BMT4me|Caregivers will pilot test a Spanish version of the BMT4me app at a single time point.
219211588|NCT06822465|OTHER|P. aeruginosa using in vitro and in vivo assays|This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The investigators also plan to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
219211589|NCT06613867|OTHER|Wakobotikodro|Wakobotikodro : an intervention combining (i) training matrons to identify and monitor high-risk pregnancies, (ii) integrating them into the healthcare system and (iii) using a digital decision-support application installed on a smartphone and adapted to their profile, could improve the identification and monitoring of high-risk pregnancies.
219211590|NCT06822140|DEVICE|transcutaneous auricular vagus nerve stimulation|"Stimulation parameters:~* Stimulating side: ipsilateral to the infarcted brain hemisphere~* Location of pStimulation: Cymba conchae~* Impulse shape: bi-phasic~* Impulse intensity: at least 0.5 mA (max. 2.0 mA).~* Impulse duration: 28 sec on, 32 sec off~* Impulse frequency: 20-30 Hz."
219211591|NCT06822140|DEVICE|sham-stimulation|An electrode is only attached to the ear without applying electrical impulses.
219211592|NCT06591715|OTHER|Home exercise program|The home exercise program routinely given to individuals with knee OA in addition to their medical treatment will consist of exercises routinely used in the BETY innovation.
219211593|NCT06728215|DEVICE|CRET 1|Fisiowarm 7.0 and the new capacitive/resistive electrode, for 15' at a frequency of 300 KHz (Treated Group).
219211594|NCT06728215|DEVICE|CRET 2|Classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
219211595|NCT06183645|DEVICE|Actimyo|Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219211596|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
219211597|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
219211598|NCT03999983|OTHER|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
219211599|NCT06761820|DEVICE|Echocardiogram|Echo : for evaluation anatomical and functional alteration LV and diastolic dysfunction and myocardial reserve measure by LVEF by M-mode before the study and follow up echo assessment 3 months after glycemic control
219211600|NCT06762522|OTHER|Nonlinear dynamical neurofeedback (NLD)|NeurOptimal nonlinear dynamical (NLD) neurofeedback brain training works as a detection and monitoring system of changes in cortical patterns within the brain, mirroring the brain activity that can be undermining optimal brain function, providing the brain with the information it needs to make its own adjustments which over time results in the brain functioning more efficiently and effectively. Two scalp sensors at C3 \& C4 and two earclips at tops of ears (reference) and one on the earlobe (ground) are used to read EEG activity which is analyzed by the NeurOptimal software. As participants listen to music through earbuds, information is fed back to the individual by slight interruptions in the music. One session lasts 33.5 minutes.
219211601|NCT06762522|OTHER|Low energy neurofeedback system (LENS)|Low energy neurofeedback system (LENS) therapy is an EEG-based direct neurofeedback system that stimulates the brain to reset itself and achieve optimal performance. Therapy consists of delivery of a tiny electromagnetic field carrying the feedback signal down the electrode wires for only one second at each of the chosen electrode sites during every session. Generally, between one and seven of the ordinary electrode sites are utilized during each session. Therapy is adapted to the participant's reactivity/sensitivity and the response of their nervous system.
219082339|NCT05538624|DRUG|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
219082340|NCT02362529|DRUG|Minocycline|50 mg and 100 mg capsule, oral administration
219211602|NCT06762522|OTHER|Brain Music|Chen Medimo Corp (CMC) Brain Music neurofeedback analyzes an individual's EEG brainwave patterns and translates them into orchestral music. Listening to this personalized brain music allows the individual to gain self-awareness and rewire and alter their own mental states. The Brain Music protocol requires regular in-person follow-ups for optimal results. Generally, the number of sessions varies based on individual needs and the progress made in response to the CMC Brain Music. A minimum of once a week in-person sessions is recommended for qEEG model updating to accurately track progress. Each session may last 30 minutes. Additionally, participants are advised to listen to their personalised music at least once a day, with a minimum of two listens per session. In general, participants may start to detect a change in their neurodevelopmental or cognitive function in 4-6 weeks.
219211603|NCT06762522|OTHER|Usual Care|The Usual Care control group will be followed in the Memory clinic at intervals determined by their clinician. Usual Care for individuals with mild cognitive impairment (MCI) at the The Memory Clinic consists of inter-professional assessment, diagnosis and recommendations. There are currently no drugs approved to treat MCI. Therapy is aimed at managing treatable causes and contributors including medication side effects, thyroid problems, sleep apnea, vitabim B deficiency, depression, anxiety, and unrecognized or untreated difficulties with hearing or vision. Neurofeedback is not a component of the standard of care.
219211604|NCT06761235|DIAGNOSTIC_TEST|Standard BP intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure.
219211605|NCT06761235|DIAGNOSTIC_TEST|EVA intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure. In contrast to BP arm, EVA arm will additionally reciuve counseling about vascular age.
219211606|NCT06761482|PROCEDURE|monitoring by dd-cfDNA|monitoring by dd-cfDNA
219211607|NCT06761482|PROCEDURE|monitoring by T-Vis|monitoring by T-Vis
219211608|NCT06761482|PROCEDURE|monitoring by dd-cfDNA+ T-Vis|monitoring by dd-cfDNA+ T-Vis
219211609|NCT06569914|BEHAVIORAL|Humanized care|(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
219211610|NCT06570577|PROCEDURE|Inter-semispinalis Plane Block|A nerve block targeting the dorsal rami of the cervical spinal nerves can help alleviate postoperative incisional pain.
219211611|NCT06570577|DRUG|Opioids|Routine Pain Management
219211612|NCT06740799|DRUG|Quizartinib|Participants will receive a single oral dose of 30 mg
219211613|NCT06889506|PROCEDURE|skin biopsy and serum sample|skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control
219211614|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
219211615|NCT05629689|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
219211616|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
219211617|NCT05629689|DIAGNOSTIC_TEST|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
219211618|NCT06832709|OTHER|a program of rehabilitation|physical activities, health education, psychosocial and motivational support
219211619|NCT06779643|DEVICE|General Anesthesia (GA)|Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
219681335|NCT04089254|BEHAVIORAL|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
219681336|NCT05036941|DEVICE|Acteev™ Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
219681337|NCT05036941|DEVICE|Comparison Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
219082341|NCT02362529|DRUG|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
219082342|NCT02362529|DRUG|Celecoxib|100 mg and 200 mg capsules, oral administration.
219082343|NCT00447148|PROCEDURE|3-dimensional coronary angiography|3-dimensional coronary angiography
219082344|NCT04989959|DRUG|[18F]PT2385|\[18F\]PT2385 infusion
219082345|NCT04989959|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after \[18F\]PT2385 infusion
219082346|NCT04989959|PROCEDURE|Biopsy|CT-guided tumor biopsy
219082347|NCT02166424|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
219082348|NCT02166424|DIETARY_SUPPLEMENT|Olive oil|
219082349|NCT05214274|OTHER|No intervention would be taken|No intervention would be taken
219082350|NCT02045394|OTHER|Chest X-ray|
219082351|NCT02045394|OTHER|computed tomography of the chest|
219082352|NCT02045394|PROCEDURE|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
219082353|NCT02660710|DRUG|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
219082354|NCT02065336|DRUG|ARC-520|
219082355|NCT02065336|DRUG|Placebo|
219082356|NCT02065336|DRUG|entecavir|
219082357|NCT02065336|DRUG|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
219082358|NCT05418036|DRUG|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
219082359|NCT03978234|DRUG|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
219082360|NCT03118583|DIETARY_SUPPLEMENT|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
219082361|NCT02965950|DRUG|Cyclophosphamide|I.v. infusion
219082362|NCT00626028|DRUG|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
219082363|NCT00626028|DRUG|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
219082364|NCT00626028|DRUG|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
219082365|NCT03657433|DIETARY_SUPPLEMENT|Ferrous sulfate 325mg|Oral tablets supplied for home use
219082366|NCT03657433|DRUG|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
219082367|NCT04496180|DEVICE|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
219082368|NCT02144064|DRUG|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
219082369|NCT04880564|DRUG|CN1, 0.5mg/kg and CN401, 400mg|CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
219082370|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 600mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
219082371|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 800mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
219082372|NCT04880564|DRUG|CN1, 3mg/kg and CN401, 800mg|CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
219082373|NCT04880564|DRUG|CN1, 10mg/kg and CN401, 800mg|CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
219082374|NCT06381089|DEVICE|Robotic Rehabilitation|Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.
219082375|NCT06381089|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.
219082376|NCT01320007|DRUG|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
219082377|NCT01320007|OTHER|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
219082378|NCT00831779|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
219082379|NCT00831779|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
219082380|NCT00511017|DRUG|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
219082381|NCT04269499|DEVICE|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
219082382|NCT02235350|OTHER|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
219082383|NCT02235350|OTHER|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
219082384|NCT03689335|PROCEDURE|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
219082385|NCT03689335|DEVICE|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
219082386|NCT02311530|DRUG|Felodipine|Extended Release Tablets, 10mg
219082387|NCT02311530|DRUG|Felodipine (Plendil®)|
219211620|NCT06779643|DEVICE|Continuous Brachial Plexus Block|Patients were positioned supine with the head slightly turned to the contralateral side to expose the supraclavicular fossa. The injection site was prepared using standard aseptic techniques. Under ultrasound guidance, a needle was advanced to the vicinity of the brachial plexus. Aspiration was performed to confirm the absence of blood return before the slow, incremental injection of either liposomal bupivacaine \[adult dose: 133 mg (10 mL) to 266 mg (20 mL)\] or ropivacaine \[adult dose: 20 mL of 0.5% ropivacaine, administered via continuous infusion at a rate of 5-10 mL/h; pediatric dose: 0.1% ropivacaine at 0.1-0.2 mL/kg, administered via continuous infusion at 0.05-0.15 mL/kg/h\]. Patient responses were closely monitored throughout the procedure.
219211621|NCT06738953|BEHAVIORAL|Cognitive-Behavioral Intervention to increase Self Efficacy|Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
219681338|NCT03761485|OTHER|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
219082388|NCT03758963|DEVICE|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
219082389|NCT04483310|BEHAVIORAL|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
219082390|NCT04483310|BEHAVIORAL|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
219082391|NCT00526643|DRUG|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
219082392|NCT00526643|DRUG|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
219082393|NCT02804087|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
219681339|NCT03444805|PROCEDURE|Autologous HSCT|1st AHSCT
219681340|NCT06355375|BEHAVIORAL|exercise in pregnancy|aerobic exercise
219082394|NCT02804087|OTHER|Sham Implantation|Sham Implantation
219082395|NCT03965156|PROCEDURE|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
219082396|NCT03965156|PROCEDURE|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
219082397|NCT02133534|DRUG|Atorvastatin|
219082398|NCT01984684|DRUG|delafloxacin|
219082399|NCT01984684|DRUG|vancomycin|
219082400|NCT01984684|DRUG|aztreonam|
219082401|NCT01375114|DRUG|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
219082402|NCT01375114|DIETARY_SUPPLEMENT|Placebo|Placebo by mouth twice daily for 4 weeks.
219082403|NCT01375114|BEHAVIORAL|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
219082404|NCT05163418|DEVICE|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
219082405|NCT05163418|DEVICE|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
219082406|NCT01368367|OTHER|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
219082407|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
219082408|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
219082409|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
219082410|NCT01039701|DRUG|AZD1446|capsules, oral, 3 times daily
219082411|NCT01039701|DRUG|Placebo|capsules, oral, 3 times daily, 4 weeks
219082412|NCT01817179|OTHER|FES neuroprosthesis to dorsiflexors on affected leg|
219082413|NCT06097312|OTHER|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
219082414|NCT00223834|BEHAVIORAL|single session of Motivational Interviewing|
219082415|NCT03963908|BEHAVIORAL|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
219082416|NCT03963908|BEHAVIORAL|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
219082417|NCT02610348|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
219082418|NCT02610348|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
219082419|NCT02302443|BIOLOGICAL|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
219082420|NCT02302443|BIOLOGICAL|Active comparator|Single dose subcutaneous administration of active comparator
219082421|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
219082422|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
219082423|NCT03240848|PROCEDURE|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
219082424|NCT03240848|PROCEDURE|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
219082425|NCT03240848|PROCEDURE|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
219082426|NCT02615574|BIOLOGICAL|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
219082427|NCT02615574|DRUG|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
219082428|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
219082429|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
219082430|NCT04050826|DRUG|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
219082431|NCT04050826|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
219211622|NCT06738953|BEHAVIORAL|Placebo: Weekly Recap and Group Discussion on Psychological Experiments|Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
219211623|NCT02500576|BIOLOGICAL|Aldesleukin|Given IV or SC
219082432|NCT04050826|PROCEDURE|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
219082433|NCT00006352|BIOLOGICAL|BCG vaccine|
219082434|NCT00006352|BIOLOGICAL|monoclonal antibody BEC2|
219082435|NCT01398150|DIETARY_SUPPLEMENT|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
219211624|NCT02500576|DRUG|Cyclophosphamide|Given IV
219082436|NCT01398150|DIETARY_SUPPLEMENT|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
219082437|NCT01846182|DRUG|Duloxetine|serotonin norepinephrine reuptake inhibitor
219082438|NCT01846182|DRUG|Pregabalin|alpha-2-alpha subunit calcium channel ligand
219082439|NCT01846182|DRUG|Placebo|Placebo
219082440|NCT02794376|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|
219082441|NCT02794376|BEHAVIORAL|Waiting Period|
219082442|NCT00241579|DRUG|Smoked Cannabis|
219082443|NCT06134830|DRUG|RAI|Radioactive iodine
219082444|NCT05314036|OTHER|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
219211625|NCT02500576|DRUG|Fludarabine Phosphate|Given IVPB
219211626|NCT02500576|OTHER|Laboratory Biomarker Analysis|Correlative studies
219211627|NCT02500576|BIOLOGICAL|Pembrolizumab|Given IV
219211628|NCT02500576|OTHER|Quality-of-Life Assessment|Ancillary studies
219211629|NCT02500576|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
219211630|NCT06766370|PROCEDURE|Ultrasound-guided nerve hydrodissection treatment|Under ultrasound guidance, a mixed solution of corticosteroids and local anesthetics is injected around the nerve, followed by release of the transverse carpal ligament.
219211631|NCT06109090|OTHER|Neuropsychological testing|"In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis."
219211632|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
219211633|NCT06524804|RADIATION|palliative radiotherapy|Undergo palliative radiotherapy
219211634|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
219082445|NCT02930733|DRUG|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
219082446|NCT02930733|DRUG|Saline|2 ml saline subcutaneously bilaterally
219082447|NCT02291731|DRUG|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
219082448|NCT06010082|BEHAVIORAL|Music Therapy|Music Therapy intervention will be delivered through instructed participants to empty their bladder and then listen to music for 30 min in a semi-fowler's position with their head and shoulders raised 30° in a quiet and dim environment, listening to the music of symphonic music.
219082449|NCT03118024|DRUG|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
219082450|NCT03118024|DRUG|Catecholamines|catecholamine restrictive anesthesia protocol
219082451|NCT05035472|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
219082452|NCT05035472|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
219082453|NCT03311373|DRUG|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
219082454|NCT03311373|DRUG|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
219082455|NCT03311373|DRUG|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
219082456|NCT03311373|DRUG|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
219082457|NCT03768258|DRUG|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
219082458|NCT06122740|OTHER|Turkish Validity and Reliability of The MAM-36 Scale|The aim of this study is to adapt the Manual Ability Measure-36 (MAM-36) scale to Turkish society and to make its validity and reliability in Turkish.
219082459|NCT01758354|OTHER|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
219082460|NCT05536362|DRUG|TCI Propofol Injection|To decrease postoperative pain after cancer colon surgery
219082461|NCT00112879|DRUG|arsenic trioxide|
219082462|NCT00112879|DRUG|ascorbic acid|
219082463|NCT00112879|DRUG|dexamethasone|
219082464|NCT00112879|DRUG|thalidomide|
219211635|NCT06524804|RADIATION|curative radiotherapy|Undergo curative radiotherapy
219211636|NCT06134453|OTHER|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
219082465|NCT00112879|PROCEDURE|anti-cytokine therapy|
219211637|NCT06841978|DRUG|Intravenous Thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
219211638|NCT06848673|OTHER|Office-Based Vergence/Accommodative Therapy with Movement (OBVAM)|Head and body movements are incorporated into some therapy procedures in Phases 3 and 4. Additional details are provided in the Overall Program Narrative. Participants undergoing office-based VAM therapy will be prescribed home therapy procedures including the HTS2 Home Vision Therapy System (https://htsvision.com/) thrice weekly to support their in-office VAM therapy. This software progressively increases fusional convergence and divergence demands, offers instant user feedback, and will allow us to track participants' usage and progress. Basic procedures like free-space fusion cards and Brock String will also be prescribed for home therapy.
219211639|NCT06229106|DEVICE|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
219211640|NCT06229106|DEVICE|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
219211641|NCT06816706|PROCEDURE|Modified high flow tracheal oxygen-40L/min|Modified high-flow tracheal oxygen with a flow rate of 40L/min will be performed.
219082466|NCT00112879|PROCEDURE|antiangiogenesis therapy|
219082467|NCT00112879|PROCEDURE|biological therapy|
219082468|NCT00112879|PROCEDURE|chemotherapy|
219082469|NCT00112879|PROCEDURE|drug resistance inhibition|
219082470|NCT00112879|PROCEDURE|growth factor antagonist therapy|
219082471|NCT00112879|PROCEDURE|non-specific immune-modulator therapy|
219082472|NCT01256567|BIOLOGICAL|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
219082473|NCT01256567|DRUG|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
219082474|NCT00004339|DRUG|tetrathiomolybdate|
219082475|NCT00004339|DRUG|trientine|
219082476|NCT06559501|BEHAVIORAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
219082477|NCT05850091|DRUG|Rosuvastatin|Pharmacotherapy for reduction in LDL cholesterol level
219082478|NCT05850091|DRUG|Colchicine|Pharmacotherapy for inflammation inhibition
219211642|NCT06816706|PROCEDURE|Standard high flow tracheal oxygen-40L/min|Standard high-flow tracheal oxygen with a flow rate of 40 L/min will be performed.
219211643|NCT06816706|PROCEDURE|T-piece|T-piece will be performed.
219211644|NCT06816706|PROCEDURE|Modified high-flow tracheal oxygen-60L/min|Modified high-flow tracheal oxygen with a flow rate of 60L/min will be performed.
219211645|NCT06816706|PROCEDURE|Standard high-flow tracheal oxygen-60 L/min|Standard high-flow tracheal oxygen with a flow rate of 60 L/min will be performed.
219211646|NCT06873230|OTHER|The study will utilize the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy.|This cross-sectional observational study utilizes the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy, distinguishing itself as the first of its kind to be conducted among Dental Hygiene students and interns in Saudi Arabia. The unique focus on this specific population in the Saudi context sets this research apart from previous studies in the field.
219211647|NCT03399500|BEHAVIORAL|In-Person Case Management at Homeless Recovery Program|In-Person Case Management at Homeless Recovery Program
219211648|NCT03399500|BEHAVIORAL|Unlimited Smartphone|Smartphone with unlimited calls, texts, and data plan
219211649|NCT03399500|BEHAVIORAL|Smartphone Based Case Management (SPCM) app|Smartphone Based Case Management app
219082479|NCT05850091|DRUG|Placebo|Capsule with sugar pill that mimics active study drugs
219082480|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
219082481|NCT02450318|OTHER|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
219082482|NCT05675657|OTHER|No Block|The patients will receive general anesthesia.
219082483|NCT05675657|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
219082484|NCT05675657|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
219082485|NCT02112981|DEVICE|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
219082486|NCT02112981|DEVICE|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
219082487|NCT00572741|DIETARY_SUPPLEMENT|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
219082488|NCT00572741|DIETARY_SUPPLEMENT|Placebo|cellulose
219082489|NCT00572741|DIETARY_SUPPLEMENT|folate|Folinic acid: Dose: 400 µg twice a day (BID)
219082490|NCT00572741|DIETARY_SUPPLEMENT|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
219211650|NCT06818136|DIAGNOSTIC_TEST|Bladder EpiCheck|The participant will provide a voided urine sample, which will be tested using the Bladder EpiCheck test. The clinical care team and the participant will not be informed of the result, and the standard of care will not change.
219211651|NCT06875648|OTHER|Not applicable (observational study)|Retrospective analysis of gut microbiota in CRC patients vs. healthy controls. No interventions were administered; data were collected from archived samples and medical records.
219211652|NCT06735924|DIETARY_SUPPLEMENT|Low-oxalate fixed diet|Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
219211653|NCT06744478|DEVICE|Misight 1 Day Contact Lens|Misight 1 Day Contact Lens wearing for myopia control
219211654|NCT06745505|PROCEDURE|Bowel Preparation|Group A received bowel preparation and Group B did not.
219211655|NCT03691493|DRUG|Anastrozole|Given PO
219211656|NCT03691493|DRUG|Exemestane|Given PO
219211657|NCT03691493|DRUG|Fulvestrant|Given IM
219211658|NCT03691493|DRUG|Letrozole|Given PO
219211659|NCT03691493|DRUG|Palbociclib|Given PO
219211660|NCT03691493|RADIATION|Radiation Therapy|Undergo radiation therapy
219211661|NCT03691493|DRUG|Tamoxifen|Given PO
219211662|NCT06820047|PROCEDURE|Laparoscopic sleeve gastrectomy|"Patients underwent SG, involving longitudinal resection of approximately 75% of the stomach along its greater curvature, with excision of the fundus and part of the body and antrum, preserving a portion of the latter and the pylorus itself. This results in a vertical tube-shaped gastric tube sleeve. After surgery, patients followed a free diet. Patients were evaluated at baseline and at 1, 3, 6, 9, and 12 months after starting the intervention."
219211663|NCT06820047|OTHER|Obesity pharmacotherapy|Patients underwent 1 month of a very low calorie diet (VLCD) with 813 kcal/day, followed by a low calorie diet (LCD) for 11 months together with intensive physical exercise (30 min/day of brisk walking plus at least 3 h/week of aerobic exercise) with 2.4 mg/week of semaglutide (Ozempic®), given once weekly as subcutaneous injections. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months after starting the interventions.
219211664|NCT06791811|OTHER|OFA|"Prior to the induction of anesthesia the patients in OFA group will receive Dexmedetomidine loading dose 1 μg/kg i.v. infusion, and Lidocaine loading dose 1.5 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine will be prepared in a 20 ml syringe and infused over 10 minutes prior to induction.~Then after induction maintenance drugs will be infused as follow:~Dexmedetomidine 0.25-0.5 μg/kg/h (200 micogram in 50cc syrige with infusion rate 0.125-0.250ml/kg/h), and Lidocaine 2mg/kg/h (400mg in 20cc syringe with infusion rate 0.1 ml/kg/h)"
219211665|NCT06791811|OTHER|OA|In the opioid anaesthesia group patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h (200 micograms in 50 cc syringe with infusion rate 0.125-0.250ml/kg/h).Placebo (saline infusion) in 20 cc syringe with rate infusion rate 0.1 ml/kg/h.
219211666|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
219211667|NCT05197530|DRUG|Indocyanine green|A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
219211668|NCT05197530|DEVICE|MultiSpectral Imaging System|Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
219211669|NCT06785493|DRUG|Optimized Treatment (OPT)|After the first sufficient intravenous infusion of UST (6 mg/kg), the patient's response was assessed based on PRO2 at week 8, and an individualized treatment plan was developed. At week 8, the patients with incomplete response of PRO2 (a decline of PRO2 was less than 50% from baseline or still in moderate to severe active phase of PRO2) were given one or more UST intravenous re-induction (6 mg/kg) every 4 or 6 weeks.
219211670|NCT03373552|DIAGNOSTIC_TEST|Platelet function assay|Platelet function assay
219211671|NCT02806570|DEVICE|Mitral valve repair|
219211672|NCT06780462|DRUG|Corticosteroids + Rivaroxaban|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban
219082491|NCT00572741|DIETARY_SUPPLEMENT|vitamin C|Vitamin C 500 mg
219082492|NCT00572741|DIETARY_SUPPLEMENT|cod liver oil|Cod liver oil 1/2 teaspoon
219082493|NCT00572741|DIETARY_SUPPLEMENT|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
219211673|NCT06780462|DRUG|Corticosteroids alone|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
219211674|NCT06787300|BEHAVIORAL|Stories that Empowered Mother|this intervention is made by resercher for this research.
219211675|NCT06786858|DEVICE|HandMate|HandMate device is used for 20 hours in 4 weeks. Device is then used in the home for 3 months at discretion of participant.
219211676|NCT06789822|DEVICE|Invitation to wear the smartwatch|During a consultation with the psychiatrist, and after verifying the eligibility criteria, the patient will receive oral information about the study from the psychiatrist.
219211677|NCT06718192|OTHER|Bleomycin injection|Wart injection (0.2 mL \<5 mm; 0.5 mL 5-10 mm; 1ml for \>10 mm) were injected at a depth of 1.5mm, diluted with normal saline at a concentration of 3u/ml=3mg/ml, and the maximum amount of each wart was 1ml until the wart turned white
219211678|NCT06718192|OTHER|Cryotherapy|The wart was frozen by liquid nitrogen until a circle of frozen tissue appeared around the wart for about 10s, with an interval of 30s, for a total of 2 times
219211679|NCT06788301|PROCEDURE|Inferior Alveolar Nerve Block|local anesthesia administration (inferior alveolar nerve block)
219082494|NCT00572741|DIETARY_SUPPLEMENT|carnitine|Acetyl L-Carnitine Dose: 250 mg
219082495|NCT01764737|DRUG|VX15/2503|single dose intravenous administration
219082496|NCT01764737|DRUG|Placebo|single dose intravenous administration
219082497|NCT06100133|DIETARY_SUPPLEMENT|Ketone ester|Up to 100g ketone ester daily for 56 days
219082498|NCT01249248|DEVICE|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
219082499|NCT02925676|DEVICE|hyposafe H02|hypoglycaemia notification device
219082500|NCT03260868|DRUG|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
219082501|NCT03260868|DRUG|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
219082502|NCT02417818|DEVICE|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
219082503|NCT02417818|DEVICE|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
219082504|NCT04629482|OTHER|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
219082505|NCT00541450|DRUG|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
219082506|NCT00541450|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
219082507|NCT00541450|DRUG|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
219082508|NCT00541450|DRUG|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
219082509|NCT00541450|DRUG|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
219082510|NCT00541450|DRUG|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
219211680|NCT06788301|DEVICE|VR eyeglasses|VR eyeglasses was used to distarct patients from dental environment during inferior alveolar nerve block.
219211681|NCT06788301|DEVICE|Buzzy device|Buzzy device was used to distarct patients from dental environment during inferior alveolar nerve block.
219211682|NCT06794346|DRUG|Transdermal testosterone|women will receive 300mcg of transdermal testosterone in cream daily for six months
219211683|NCT06794346|DRUG|Vaginal testosterone gel|women will receive 300mcg of vaginal gel testosterone daily for six months
219211684|NCT06794346|DEVICE|Placebo group|women will receive both vaginal gel and transdermal cream placebo for six months
219211685|NCT05733494|OTHER|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
219082511|NCT05929469|BEHAVIORAL|App|Participants will receive an mHealth program.
219082512|NCT05929469|BEHAVIORAL|Fully Automated Kick-Off|As an orientation to the study, participants will receive a fully automated kick-off session.
219082513|NCT05929469|BEHAVIORAL|Human-Enhanced Kick-Off|As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.
219082514|NCT05929469|BEHAVIORAL|Check-In|Participants will receive a check-in with a study interventionist.
219082515|NCT05929469|BEHAVIORAL|Counseling|Participants will receive counseling from a study interventionist.
219211686|NCT06809712|DRUG|Busulfan (Busulfex)|Myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d); Reduced intensity conditioning: Busulfan (Bu，3.2 mg/kg/d IV -7d\~-5d);
219082516|NCT01975896|BEHAVIORAL|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
219082517|NCT01298999|DRUG|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
219082518|NCT01298999|DRUG|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
219082519|NCT01394900|BEHAVIORAL|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
219082520|NCT01394900|BEHAVIORAL|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
219082521|NCT00826306|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
219082522|NCT03138148|OTHER|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
219082523|NCT03757000|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
219082524|NCT04510805|DEVICE|NextDose (nextdose.org)|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
219082525|NCT05934968|OTHER|Mad Dog cooking class series|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
219211687|NCT06809712|DRUG|Cyclophosphamide (CTX)|Myeloablative conditioning: Cyclophosphamide (Cy，1.8g/m2, -5d, -4d) Cyclophosphamide is not used for reduced intensity conditioning
219211688|NCT06809712|DRUG|Fludarabine (Fludara)|Myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d); Reduced intensity conditioning: Fludarabine (Flu，30mg/m2 /d IV -10d\~-5d);
219211689|NCT06809712|DRUG|Semustine (MeccNU)|"For both myeloablative and reduced intensity conditioning:~Semustine (MeCCNU: 250 mg/m2 orally-3d)"
219211690|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
219211691|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
219211692|NCT05599412|DRUG|Lorviqua|As provided in real world practice
219211693|NCT06805695|OTHER|No Intervention|No Intervention
219211694|NCT06750757|BIOLOGICAL|Bone marrow aspirate concentrate|145cc of BMAC/PRP/PPP injection.
219211695|NCT06750757|PROCEDURE|Hip arthroscopy|Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
219211696|NCT03867201|BIOLOGICAL|Erenumab|Administered by pre-filled syringe
219211697|NCT03867201|OTHER|Placebo|Administered by pre-filled syringe
219211698|NCT06772779|DRUG|Warfarin|single oral dose
219211699|NCT06772779|DRUG|Enlicitide Decanoate|single oral dose
219211700|NCT06772779|DRUG|Lisinopril|single oral dose
219211701|NCT06762665|PROCEDURE|Spinal injection|Patients underwent a spinal injection procedure under CT scan
219211702|NCT06762665|OTHER|pre-operative consultation|Pre-operative consultation, in person or by teleconsultation, consists of an interview about the patient's history and symptoms. This is followed by a clinical examination and consultation of the patient's imaging file, to confirm the request for paraspinal infiltration and its location. In addition, the radiologist explains the procedure to the patient, supplementing the explanatory documents already provided at the time of the appointment, and outlines the results that may be expected and any complications.
219211703|NCT06848426|DRUG|Xingbaiji Formula|"Patients were randomized into two groups:~Control Group:~Non-squamous NSCLC: Sintilimab (200 mg) combined with pemetrexed + cisplatin/carboplatin, administered intravenously (IV) every 3 weeks (Q3W) for 4 cycles. After 4 cycles, maintenance therapy with sintilimab (200 mg Q3W, up to 24 months) + pemetrexed Q3W continued until disease progression, intolerable toxicity, death, or voluntary withdrawal.~Squamous NSCLC: Sintilimab (200 mg) combined with gemcitabine + cisplatin/carboplatin, IV Q3W for 4-6 cycles. Post-induction, sintilimab (200 mg Q3W) maintenance continued until progression, intolerance, or ≤2 years of treatment.~Experimental Group:~The control regimen plus Xingbaiji Formula:~Xingbaiji Granule 1: 10 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals.~Xingbaiji Granule 2: 5 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals."
219211704|NCT06750198|OTHER|Hip focused|"Group A will be treated with hip focused exercises and standard rehabilitation protocol.~Hip focused exercises will be comprised of following exercises in phase 1 will be Side lying hip abduction, Hip abduction in standing, Hip extension from prone, Single leg bridge, Side lying clam with resistance while exercises in phase 2 will be same with more repetitions in addition to Side lunges, Forward lunges"
219082526|NCT04719689|OTHER|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
219082527|NCT04719689|OTHER|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
219082528|NCT03993548|BEHAVIORAL|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
219082529|NCT03993548|BEHAVIORAL|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
219082530|NCT03993548|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
219082531|NCT03993548|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
219082532|NCT03993548|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
219082533|NCT03993548|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
219211705|NCT06750198|OTHER|Standard rehabilitation|Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
219211706|NCT06749951|OTHER|Cognitive Behavioural Therapy for insomnia (CBT-I)|Five 60-90 minutes weekly sessions delivered by an appropriately trained cardiac nurse at a cardiology department. The CBT-I intervention will follow a manualized treatment protocol developed by Espie and colleagues (Espie et al. 2001, 2007, 2008) and evaluated in a number of published RCTs using CBT-I. The key components of this intervention include sleep hygiene advice, stimulus control, sleep restriction, relaxation training, and cognitive restructuring.
219211707|NCT06749951|OTHER|Sleep Hygiene Advice|"Sleep well is a 16-page written brochure developed by the Directorate of Health in Norway for dissemination to patients with sleep problems including insomnia. It covers general sleep hygiene advice (setting a regular bed-time, avoiding stimulants, alcohol and exercise in the evening, sleeping in a quiet bedroom, advice of practicing relaxation technique and postpone worries)."
219211708|NCT05557045|DRUG|JZP815|JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
219211709|NCT01983683|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
219211710|NCT01983683|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
219211711|NCT01983683|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
219211712|NCT01983683|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
219211713|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
219211714|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
219082534|NCT03993548|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
219082535|NCT01381796|DRUG|NP101|comparison of NP101 with minor patch modifications
219082536|NCT01381796|DRUG|sumatriptan succinate|tablet, 100 mg
219082537|NCT01169675|DRUG|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
219211715|NCT05954585|BEHAVIORAL|Treatment as usual|Emergency department treatment as usual
219211716|NCT05954585|BEHAVIORAL|Family Navigator|Family Navigator will speak with families about individual and systemic issues for linkage to mental health care biweekly for 3 months or until the youth's first mental health appt has been attended, whichever comes first.
219211717|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
219211718|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
219211719|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
219211720|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
219082538|NCT01169675|DRUG|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
219082539|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219211721|NCT06749574|DIAGNOSTIC_TEST|stability ball exercises|articipants in the first group performed stability ball exercises designed to enhance balance, core stability, they were introduced to the stability ball with instructions on maintaining proper posture, alignment, and safety to prevent injuries. The program included exercises such as the Stability ball bridging, stability ball bird dog and stability ball pelvic tilts were included to activate the lower abdominal muscles and glutes through gentle, controlled movements
219082540|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219082541|NCT01169675|DRUG|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
219082542|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219082543|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219082544|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219211722|NCT06749574|DIAGNOSTIC_TEST|dead bug exercise|The second group focused on dead bug exercises, Participants performed exercises such as extending one arm and the opposite leg while lying on their backs, ensuring their spine remained neutral and their lower back stayed pressed into the floor. Variations included alternating opposite arm and leg movements and holding the extended position to increase the challenge and enhance core stability. These exercises were performed slowly to maintain control and improve movement precision over the eight-week period
219211723|NCT06749574|COMBINATION_PRODUCT|Combined Groupo|The third group combined stability ball and dead bug exercises for a comprehensive training approach targeting both core stability and balance. Participants alternated between dead bug exercises, which required controlled arm and leg extensions while lying on their backs, and stability ball exercises such as the ball with bridging and bird dog. Throughout the eight weeks, participants were encouraged to maintain proper posture, alignment, and a neutral spine during all activities to ensure safety and effectiveness
219211724|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
219082545|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
219211725|NCT06756516|OTHER|Feldenkrais Method and Core stabilization|Balance exercises from supine lying position using Feldenkrais style, plus core stabilization exercises.
219211726|NCT06756516|OTHER|Core stability exercises|trunk deep muscles activation and engaging using exercises as bridging, side bridging, plank, side plank and McGill Abdominal
219211727|NCT06751940|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
219211728|NCT06751940|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219211729|NCT03274297|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
219211730|NCT03274297|DRUG|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
219211731|NCT06776198|DRUG|Chemotherapy|Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
219082546|NCT01169675|DRUG|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
219082547|NCT01169675|DRUG|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
219082548|NCT01169675|DRUG|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
219082549|NCT01550458|DRUG|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
219082550|NCT01550458|OTHER|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
219082551|NCT00803452|DRUG|doxycycline|Oral doxycycline 100mg bid
219082552|NCT00803452|DRUG|azithromycin|topical 1% azithromycin daily to eye
219082553|NCT01818479|BIOLOGICAL|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
219082554|NCT01818479|PROCEDURE|Stem cell transplant|
219082555|NCT06304766|PROCEDURE|Laparoscopic ablation|Heat-based ablation modality performed by laparoscopy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
219082556|NCT06304766|PROCEDURE|Open ablation|Heat-based ablation modality performed by laparotomy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
219082557|NCT01340469|BIOLOGICAL|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
219082558|NCT05207514|DRUG|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
219082559|NCT05207514|DRUG|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
219082560|NCT05207514|DRUG|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
219082561|NCT05207514|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
219082562|NCT04839965|BIOLOGICAL|Ampion|Ampion administered via intravenous infusion
219082563|NCT04839965|OTHER|Saline|Placebo administered via intravenous infusion
219082564|NCT00936442|DRUG|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
219082565|NCT00936442|OTHER|Educational materials|Reception of educational material on regular basis.
219082566|NCT02816138|DRUG|Nicotine|Open-label transdermal nicotine patch
219211732|NCT06758297|OTHER|AI-Powered Motivational Speech|"It is known that patients with knee prosthesis have difficulty in the first standing process due to fears of falling, not being able to walk again, and recurrence of their disease. For this purpose, a speech text that will motivate patients was prepared with the support of ChatGPT. Expert opinions were obtained from 2 orthopedic specialists and 2 specialist psychiatric nurses for this speech text. Later, the speech text was converted into an audio video with the ElevenLabs application. Thus, it was planned to make it easier for patients to listen to it again. Patients will listen to this motivational speech in their own patient rooms and using their own headphones."
219211733|NCT06755931|BEHAVIORAL|quilling set|After the intervention group is determined in randomization, half an hour before the cardiac catheterization and angiography procedure, without premedication treatment, the researcher will be asked to choose 2 animal and plant figures, samples of which have been previously made, through a quilling set, in cooperation with the researcher. It will be done with the child in a 15-20 minute period, accompanied by the researcher, with 2 figures chosen by the child. With the opportunity for the child to choose the color and figure he/she wants, the child will be at the center of the work. The figure will be given as a gift to the child and the survey forms will be filled out again 5 minutes after the application, before the premedication treatment. In order to prevent bias in the research, the descriptive information form and fear and anxiety scales will be taken by the evaluation of three people: the researcher, the parent and the child.
219211734|NCT06755931|BEHAVIORAL|Control|Before the procedure, while the child is in the patient room, the details of the research will be explained, their consent will be obtained and the Introductory Information Form will be filled in by the parent, and the Fear Scale and State Anxiety Scale will be filled in by the child and the parent. After the control group is determined in randomization, the researcher will apply the posttest without premedication treatment half an hour before the cardiac catheterization and angiography procedure. No separate intervention will be applied. In accordance with ethical principles, after the procedure, 2 Quilling figures chosen by the control group and the child will be prepared with the help of the researcher, and the prepared figures will be gifted to the child.
219211735|NCT06812546|DRUG|Vericiguat|Patients enrolled in the experimental group will receive 26 weeks of oral vericiguat on top of the standard treatment, with vericiguat at a dose of 2.5 mg once a day, doubled every fortnight to a maximum dose of 10 mg once a day at the end of week 6 of the visit, which will be maintained for the duration of the treatment.
219211736|NCT04447209|OTHER|2-weekly Food baskets|2 weekly Food basket containing fresh foods or minimally processed foods.
219082567|NCT00180726|PROCEDURE|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
219082568|NCT05268679|OTHER|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
219082569|NCT05268679|OTHER|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
219082570|NCT05268679|OTHER|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
219082571|NCT03829124|DRUG|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
219082572|NCT03829124|DRUG|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
219082573|NCT01190696|PROCEDURE|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
219082574|NCT01190696|DEVICE|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
219082575|NCT02365519|BIOLOGICAL|LME636 ophthalmic solution|
219082576|NCT02365519|BIOLOGICAL|LME636 Vehicle|Inactive ingredients used as a placebo comparator
219082577|NCT01814969|RADIATION|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
219082578|NCT01814969|RADIATION|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
219082579|NCT03375983|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
219082580|NCT05387941|DRUG|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
219082581|NCT02291679|DRUG|Linaclotide|
219082582|NCT02291679|DRUG|Matching Placebo|
219082583|NCT04398212|DIAGNOSTIC_TEST|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
219082584|NCT01695564|DEVICE|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
219082585|NCT01695564|DEVICE|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
219082586|NCT00981084|DRUG|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
219082587|NCT05166941|BEHAVIORAL|creative drama|In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
219082588|NCT03994068|DIAGNOSTIC_TEST|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
219082589|NCT03004794|OTHER|medical records review|
219082590|NCT00737555|DRUG|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
219211737|NCT06173063|DEVICE|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
219211738|NCT06828536|OTHER|Gynecology consultation|Gynecology consultation M0 - M3 - M6 - M12
219211739|NCT06828536|OTHER|Transvaginal ultrasound|Transvaginal ultrasound
219211740|NCT06828536|OTHER|PCR Schistosoma spp|PCR Schistosoma spp Colposcopy Cervical biopsy Cervical smear
219211741|NCT06779513|DIAGNOSTIC_TEST|Echocardiohraphy|Transthoracal echocardiography for diastolic function assessment
219211742|NCT06778655|DIETARY_SUPPLEMENT|5% propolis gel|5% propolis gel (prepared according to Joshy et al. 2018) Joshy A, Doggalli N, Patil K, Kulkarni PK. To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial. Contemp Clin Dent. 2018 Jan-Mar;9(1):65-71.
219211743|NCT06778655|OTHER|Placebo gel|placebo mucoadhesive gel having the same flavor, consistency, and color as the propolis.
219211744|NCT06779305|PROCEDURE|Minimally invasive surgical application of Calcanail®|The procedure involves making small incisions to insert a specialized nail into the bone to realign and stabilize the fracture. This approach minimizes damage to surrounding tissues, reduces the risk of wound complications, and allows for quicker recovery compared to traditional open surgery. after surgery, the patient will benefit from an immobilisation with a plaster boot without support for 3 weeks, followed by immobilisation with a removable walking boot for 3 weeks with partial support depending on the patient's pain.
219211745|NCT06779305|PROCEDURE|Immobilisation by cast boot|The patient will be immobilised in a plaster cast without support for 3 weeks, followed by immobilisation in a removable walking boot for 3 weeks with partial support depending on the pain.
219211746|NCT06778564|DRUG|CBD 100 mg/mL Oral Solution|Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
219211747|NCT06778564|OTHER|Placebo|5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
219211748|NCT06830382|DIAGNOSTIC_TEST|Positron emission tomografy with [68Ga]Ga-ABY-025|Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)
219211749|NCT06828497|PROCEDURE|Technique of posterior quadratus lumborum block (QL 2 block):|The patient was in the lateral position, and the US probe was placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe was placed in the midaxillary line, and at this juncture, the layers of abdominal layers started to taper. When the probe was placed in the posterior axillary line as per the posterior approach, sonoanatomy showed first the transversus abdominis disappearing, then the internal oblique and external oblique forming aponeurosis, and the appearance of the QL muscle was noticed. The posterior aspect of the QL muscle was confirmed, and a 22-G block needle was guided, in plane, and the needle tip was inserted into this aspect of the QL muscle. Following aspiration, the local anesthetic was injected into the lift behind the QL muscle. The same procedure was performed bilaterally
219082591|NCT04064879|OTHER|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
219082592|NCT04011774|OTHER|PLANI-REV|Cognitive remediation program.
219082593|NCT04011774|OTHER|RELAXATION|Stimulation with no cognitive remediation.
219082594|NCT03583749|DRUG|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
219082595|NCT03583749|DRUG|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
219082596|NCT00331981|DRUG|Amisulpride|
219082597|NCT02048072|DRUG|Gilenya|Autonomic testing during first dose administration of Gilenya.
219082598|NCT03830593|PROCEDURE|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
219082599|NCT00363519|DRUG|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
219082600|NCT00363519|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
219082601|NCT03909126|BIOLOGICAL|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
219082602|NCT03909126|BIOLOGICAL|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
219082603|NCT00551252|DRUG|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
219082604|NCT05081869|OTHER|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
219082605|NCT05081869|OTHER|Education Program|There will be video training on the subject for both groups.
219082606|NCT05711979|BEHAVIORAL|AARC|There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
219082607|NCT04932876|BIOLOGICAL|SARS - COV 2 VACCINE|Vaccination for SARS - COV 2
219082608|NCT00002292|DRUG|Pentamidine isethionate|
219211750|NCT06828497|PROCEDURE|Technique of erector spinae plane block:|The patient will be placed in a sitting position. Under aseptic conditions, a high-frequency linear transducer will be placed on the spinous process at the T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the in-plane technique, the needle was advanced between the transverse process and erector spinae muscle. The correct location was confirmed, and local anesthetic was injected between the muscle and transverse process. The same procedure was performed bilaterally
219211751|NCT06833346|OTHER|Hip belt squat exercise|Hip belt squat exercise performed twice per week for 12 weeks
219211752|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
219082609|NCT05539092|OTHER|changing angle of bed|Before the cardiac catheterization procedure: patients' demographic characteristics and health relevant data will be collected on the first day of admission. the researcher will change angle of bed from 15° to 45°.
219082610|NCT00604032|DRUG|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
219082611|NCT05676632|OTHER|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
219082612|NCT04457557|OTHER|Reduced concentration of local anesthetic (ropivacaine)|Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
219211753|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
219211754|NCT06654141|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement at 2 different time intervals (3 and 6 months)
219211755|NCT06838585|PROCEDURE|infusion therapy|Monitoring patients with fluid overload and fluid accumulation
219082613|NCT04457557|OTHER|Usual concentration of local anesthetic (ropivacaine)|0.5% ropivacaine 15ml
219082614|NCT03249155|BEHAVIORAL|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif\_example)
219082615|NCT03249155|BEHAVIORAL|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
219082616|NCT03900702|BEHAVIORAL|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
219082617|NCT00842140|DRUG|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
219082618|NCT00842140|DRUG|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
219082619|NCT00842140|DRUG|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
219082620|NCT01543061|DEVICE|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
219082621|NCT01543061|PROCEDURE|No treatment|One month of contact lens wear with no eye drop use
219082622|NCT01543061|DEVICE|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
219681341|NCT03972384|BEHAVIORAL|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
219082623|NCT04548063|OTHER|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
219082624|NCT04548063|OTHER|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
219082625|NCT04548063|OTHER|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
219082626|NCT00653640|PROCEDURE|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
219082627|NCT00653640|PROCEDURE|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
219082628|NCT04431466|DRUG|Ivermectin|SOC plus different dosing regimens of Ivermectin
219082629|NCT04431466|OTHER|Standard of Care|Standard treatment for COVID-19
219211756|NCT06760520|DRUG|Ivonescimab (SMT112 or AK112) Injection|Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
219211757|NCT06886347|DRUG|Penplimab Injection|"Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.~Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.~Gemcitabine injection: Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles."
219211758|NCT06886347|DRUG|Antitinib Hydrochloride Capsules|10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.
219211759|NCT06886347|DRUG|Gemcitabine|Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.
219211760|NCT05556746|DRUG|Bedaquiline|Daily therapy for 12 weeks
219211761|NCT05556746|DRUG|Clofazimine|Daily therapy for 12 weeks
219211762|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 12 weeks
219211763|NCT05556746|DRUG|Delamanid|Daily therapy for 12 weeks
219211764|NCT05556746|DRUG|Rifampin|Daily therapy for 26 weeks
219681342|NCT02575196|DEVICE|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
219681343|NCT01266824|DRUG|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
219681344|NCT05156996|DEVICE|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
219082630|NCT00725296|BIOLOGICAL|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
219082631|NCT05432076|DEVICE|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~* Being extubated~* A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~* Baby dreams of boredom~* Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
219082632|NCT00772226|DEVICE|music pillow|according to randomisation patients will receive with/without music.
219082633|NCT00772226|DEVICE|pillow without music|According to randomisation patients will receive a pillow with/without music
219082634|NCT02136940|DRUG|AMA0076|
219082635|NCT02136940|DRUG|Placebo|
219082636|NCT04339192|PROCEDURE|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
219082637|NCT01456026|DIETARY_SUPPLEMENT|Glycated beta-lactoglobulins.|oral, 20 g, single administration
219082638|NCT01456026|DIETARY_SUPPLEMENT|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
219082639|NCT01031810|DRUG|tranylcypromine|MAO-Inhibitor 60mg-120mg
219211765|NCT05556746|DRUG|Isoniazid|Daily therapy for 26 weeks
219211766|NCT05556746|DRUG|Ethambutol|Daily therapy for 8 weeks
219211767|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 8 weeks
219211768|NCT03400150|DEVICE|balloon|balloon implantation
219211769|NCT03400150|OTHER|Control|Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention
219211770|NCT06892457|OTHER|TMS-EEG|Evoked brain activity is measured with the help of TMS-EEG in epilepsy patients OFF and ON medication.
219211771|NCT05943522|OTHER|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
219211772|NCT06740903|DRUG|inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
219211773|NCT06740903|DRUG|inj. lignocaine infusion @1-2 mg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
219211774|NCT06790446|OTHER|Eccentric training group (ECC)|"The first, preparatory phase, lasts two weeks, aiming at making the participant familiar with the principles of eccentric training. Participants first experience the muscle recruitment patterns (during two sessions), then are prepared to induce protective response from the plantar flexors, conditioning these muscles for higher subsequent eccentric intensities.~The aim of the second, training phase per se, which lasts six weeks, is to induce muscular and neurological adaptations through a steady increase in work intensity to stimulate muscle plasticity until the end of the program - varying volume, load and speed.~Perceived exertion is quantified using Borg's scale (expected rating between 3 and 6) to ensure sufficient work intensity and prevent excessive fatigue. Musculoskeletal pain is assessed before and after each session through a Visual Analog Scale (0-10). Verbal encouragements and advising on correct exercise execution are provided by the therapist along each session."
219082640|NCT02200731|BEHAVIORAL|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
219082641|NCT00253669|OTHER|laboratory biomarker analysis|
219082642|NCT00253669|OTHER|physiologic testing|
219082643|NCT00253669|PROCEDURE|management of therapy complications|
219082644|NCT03089437|BEHAVIORAL|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
219082645|NCT03089437|BEHAVIORAL|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
219082646|NCT03961789|OTHER|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
219211775|NCT06790446|OTHER|Conventional therapy|The participant visits a physiotherapist depending on the prescription, as in current practice
219681345|NCT05156996|PROCEDURE|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
219681346|NCT06312397|OTHER|Acupressure|"For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity The symmetry of the three selected different points will also be applied to the other extremity.~After coronary angiography, acupressure will be applied for a total of 15 minutes."
219681347|NCT06312397|OTHER|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
219681348|NCT02790918|OTHER|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
219082647|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
219082648|NCT03083899|OTHER|Out-patient clinic on demand (patient-initiated)|Free use of any resources in the out-patient clinic
219082649|NCT03083899|OTHER|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
219082650|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
219082651|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
219082652|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
219082653|NCT00817362|DRUG|IPI-504|IPI-504 IV infusion 300 mg/m2
219082654|NCT00817362|DRUG|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
219082655|NCT03289234|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
219082656|NCT02992990|PROCEDURE|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
219082657|NCT04680455|OTHER|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
219082658|NCT03862157|DRUG|Azacitidine|Given IV or SC
219082659|NCT03862157|DRUG|Pevonedistat|Given IV
219082660|NCT03862157|DRUG|Venetoclax|Given PO
219082661|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
219082662|NCT01592370|BIOLOGICAL|Nivolumab|Administered by intravenous (IV) infusion
219082663|NCT01592370|BIOLOGICAL|Ipilimumab|Administered by IV infusion
219082664|NCT01592370|BIOLOGICAL|Lirilumab|Administered by IV infusion
219082665|NCT01592370|BIOLOGICAL|Daratumumab|Administered by IV infusion
219082666|NCT01592370|DRUG|Pomalidomide|Administered PO
219082667|NCT01592370|DRUG|Dexamethasone|Administered PO and by IV infusion
219082668|NCT06597019|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
219082669|NCT06597019|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
219082670|NCT01775228|BEHAVIORAL|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
219082671|NCT06172972|BEHAVIORAL|Atraumatic nursing care|Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
219082672|NCT06669195|DEVICE|Intravascular lithotripsy group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Intravascular lithotripsy group.
219082673|NCT06669195|DEVICE|high-pressure balloon group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of high-pressure balloon group.
219082674|NCT06669026|DIETARY_SUPPLEMENT|vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel|Scaling and root debridement then inject gel in the pocket
219082675|NCT06669026|DIETARY_SUPPLEMENT|vitamin D3 gel (regular non-nanoparticle form)|Scaling and root debridement then inject gel in the pocket
219082676|NCT06669026|OTHER|Poly lactic-co-glycolic acid nanoparticles placebo gel|Scaling and root debridement then inject gel in the pocket
219082677|NCT06669026|PROCEDURE|only mechanical debridement|Scaling and root debridement
219082678|NCT06670950|DRUG|SYT-510|Oral formulation A fasted
219082679|NCT06670950|DRUG|SYT-510|Oral formulation B fasted
219082680|NCT06670950|DRUG|SYT-510|Oral formulation A fed
219082681|NCT06670950|DRUG|Placebo|Oral formulation
219082682|NCT06669741|DEVICE|Placebo|One group will receive placebo therapy (identical shoulder brace and arm sleeve absent of semiconductor fabric)
219082683|NCT06669741|DEVICE|Shoulder Sleeve|One group will receive active therapy (active semiconductor embedded shoulder brace and arm sleeve)
219082684|NCT06670235|BEHAVIORAL|Upright Birthing Position|This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.
219082685|NCT06670235|BEHAVIORAL|Lithotomy Birthing Position|Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
219082686|NCT06669169|DRUG|Jia Shen Tablet Placebo|Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
219082687|NCT06669169|DRUG|Low dose Jia Shen Tablet|Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
219082688|NCT06669169|DRUG|High dose Jia Shen Tablet|High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
219082689|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
219082690|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
219082691|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
219082692|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
219082693|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
219082694|NCT06586255|RADIATION|Concurrent Immunotherapy and Radiation Therapy|Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
219082695|NCT06595108|RADIATION|Stereotactic body radiotherapy|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
219211776|NCT06812455|DRUG|Rivaroxaban|Patients with RAO that will receive p.o. tabs Rivaroxaban 20 mg q.d.
219211777|NCT06880081|DRUG|PN20 treatment|Three dose cohorts, single dose, subcutaneous injections
219211778|NCT06767176|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|7 doses, taken daily, 70 ml shots, consumed in the morning before the start of fasting
219082696|NCT06140199|PROCEDURE|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
219082697|NCT06140199|PROCEDURE|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
219082698|NCT06670209|DRUG|GZR18 and metformin|GZR18: 3 mg-18 mg Metformin: 500 mg
219082699|NCT06670703|DIAGNOSTIC_TEST|Obesity|diagnosis as obese patients
219082700|NCT06670183|OTHER|Dietary patterns|Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.
219082701|NCT06670183|OTHER|Food groups and Nutrients|Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.
219082702|NCT06670183|OTHER|Alcohol intake|Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.
219082703|NCT06670183|OTHER|Vitamin D status|Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
219082704|NCT06672471|OTHER|No Post Operative Antibiotics for intervention group|No Post Operative Antibiotics in patients going clean contaminated head and neck surgery
219082705|NCT06672471|OTHER|Post Operative Antibiotics for one day|Control group will receive perioperative as well as post operative antibiotics for one day
219082706|NCT05460325|DRUG|Lanadelumab|Lanadelumab subcutaneous injection
219082707|NCT03800823|BEHAVIORAL|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
219082708|NCT03800823|BEHAVIORAL|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
219082709|NCT03800823|BEHAVIORAL|Standard care|Standard care for overweight and obesity.
219082710|NCT04278287|RADIATION|Radiotherapy|59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.
219082711|NCT04278287|DRUG|Albumin-Bound Paclitaxel|100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
219082712|NCT04278287|DRUG|Cisplatin|25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
219082713|NCT05261178|OTHER|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
219082714|NCT06669286|PROCEDURE|implant placement using navigated surgery near alveolar nerve|Dental implant placement in proximity of alveolar nerve (within 2 mm) using navigated surgery.
219082715|NCT06670846|DEVICE|Lollipop|Distraction using a Lollipop 15 minutes before anesthesia
219082716|NCT06670846|DRUG|distraction using intranasal Midazolam|Distraction using intranasal Midazolam 15 minutes before anesthesia
219082717|NCT06670300|DRUG|cardonilimab|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
219082718|NCT05505656|DIAGNOSTIC_TEST|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
219082719|NCT06678178|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
219681349|NCT02790918|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
219681350|NCT06180434|RADIATION|proton therapy|Radiotherapy delivered with protons
219681351|NCT06180434|RADIATION|photon therapy|Radiotherapy delivered with photons
219681352|NCT00171626|DRUG|Diclofenac Topical Sodium Gel 1%|
219681353|NCT00417144|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
219681354|NCT00417144|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
219082720|NCT06678178|BEHAVIORAL|Warning High Climate Impact Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
219082721|NCT06678178|BEHAVIORAL|Traffic Light Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
219082722|NCT06678178|BEHAVIORAL|Climate Grade Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
219082723|NCT06678178|BEHAVIORAL|Numeric Carbon Footprint Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
219211779|NCT05410860|DRUG|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
219211780|NCT05410860|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
219082724|NCT05073133|GENETIC|OAV101|A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
219082725|NCT01356875|DRUG|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
219082726|NCT01356875|DRUG|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
219082727|NCT06669143|DRUG|Zanubrutinib|160 mg bid, po, day 1-21, a maximum of 2 years.
219082728|NCT06669143|DRUG|Lenalidomide|25 mg qd, po, day 1-10, a maximum of 2 years.
219082729|NCT02434809|PROCEDURE|Bronchoscopic Implantation|Calypso transponders
219082730|NCT02434809|DEVICE|Cone-Beam CT-Guided|
219082731|NCT02434809|RADIATION|stereotactic body radiation treatments|
219082732|NCT05878197|BEHAVIORAL|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
219082733|NCT05878197|BEHAVIORAL|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
219082734|NCT05878197|BEHAVIORAL|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
219082735|NCT02611466|DRUG|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
219082736|NCT02611466|DRUG|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
219082737|NCT02611466|DRUG|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
219082738|NCT04427202|BEHAVIORAL|Referral to harm reduction services|Participants are referred to harm reduction services
219082739|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
219211781|NCT06811012|DRUG|Contezolid|"This study intends to enroll 24 patients with bone and joint tuberculosis, who will be randomly divided into two groups: the contezolid monotherapy group and the linezolid monotherapy group. Patients will receive oral contezolid or linezolid monotherapy for 14 consecutive days, and data on treatment safety, pharmacokinetics, and preliminary efficacy will be collected before and after administration.~Study Medications:~Contezolid 800mg QD for 14 days; Linezolid 600mg QD for 14 days."
219211782|NCT06811012|DRUG|Linezolid (LZD)|Linezolid 600mg QD for 14 days.
219211783|NCT06840730|DRUG|Botulinum Toxin A (Botox )|TX-A will be injected into the masseter and temporalis muscles (30 and 15 units per side, respectively) following a standardized protocol.
219211784|NCT06747962|PROCEDURE|A1 pulley release and pull out tenolysis|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley under direct vision. Flexor digitorum superficialis and flexor digitorum profundus tendons or flexor pollicis longus tendon (for the thumb) will be gently pulled out of the wound with two mosquito forceps to break any adhesions. The wound will be closed primarily with sutures. The patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
219211785|NCT06747962|PROCEDURE|Simple A1 pulley release|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley vision. After release, the patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
219211786|NCT06623357|OTHER|Pilot Training Protocol|The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
219211787|NCT06623357|OTHER|Standard Training Protocol|The standard training protocol uses the caregiver training methods that are currently used in our clinics.
219211788|NCT06790199|BEHAVIORAL|"Incredible Years® Helping Preschool Children with Autism program (IY-HPCA)"|The IY-HPCA® program is a face-to-face 6-session group-based intervention for preschool teachers of children aged 2-5 with ASD or language and communication difficulties. Sessions last 3 hours, are delivered weekly, and are led by two trained co-leaders who have experience working with children on the autism spectrum. The program covers three main topics: (1) language development, (2) social interactions, and (3) emotion literacy and self-regulation. Teachers learn about coaching language, imitation, sensory routines, social communication, use of pretend and puppet play, and self-regulation skills. Visual supports such as picture schedules, choice cards, command and feelings cards are used, and practices are tailored to children's communication and play level stages. The intervention is structured and includes role-playing techniques and video visualization.
219211789|NCT05981664|DEVICE|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
219211790|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
219211791|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
219211792|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
219211793|NCT06894706|BEHAVIORAL|Control （CON） group|Both groups were given arthroscopy and meniscoplasty. After operation, the control group received active knee flexion and extension exercise, ankle pump training, quadriceps muscle training and other routine rehabilitation training.
219211794|NCT06894706|BEHAVIORAL|Functional exercise training (FET) group|Patients in the observation group were supplemented with neuromuscular training on the basis of routine rehabilitation training, and received rehabilitation education before training. The patients were informed of the specific content, frequency, expected effect and importance of training in various forms such as on-site demonstration combined with publicity brochures and playing videos, so as to improve patient cooperation.
219211795|NCT05807321|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
219681355|NCT02274597|DEVICE|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
219082740|NCT06624137|DRUG|Placebo|Matched Placebo
219082741|NCT05399953|OTHER|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
219082742|NCT05399953|OTHER|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
219082743|NCT05399953|OTHER|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
219082744|NCT04675138|OTHER|No intervention will be provided to the subject|No intervention will be provided to the subject
219082745|NCT01538550|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
219082746|NCT01538550|PROCEDURE|iFOBT|Biennial screening with iFOBT
219082747|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
219082748|NCT06701539|DRUG|Liposome bupivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.
219082749|NCT06701539|DRUG|Ropivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
219082750|NCT06693479|DEVICE|Shoulder watch load (SWL) feedback|During week 2 and 3 after randomization, the experimental group will undergo the intervention using the SWL, designed to monitor workers' physical work demands. During this time, the SWL will provide real-time feedback based on parameters set via Ergowatchapp. A workplace visit by a physiotherapist will be conducted to establish and adjust the feedback thresholds in week 2, after the education intervention. If necessary, a second remote meeting will take place in week 3 to explain how participants can modify the thresholds themselves. The initial feedback thresholds will be set based on the physical work demands measured during week 1 and will be adjusted after one week of feedback use. These thresholds will be collaboratively determined by a physiotherapist and the workers. Only the experimental group will receive feedback from the SWL during the study period.
219082751|NCT06693479|OTHER|Education|Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place preferentially at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.
219082752|NCT06414070|BEHAVIORAL|Jenga Dada|Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
219082753|NCT06877078|BEHAVIORAL|Constipation information via Podcast|"The podcast is 30 minutes long, and includes information on constipation explained by a gastroenterologist specialised in defecation disorders, as well as patients' experience with constipation after surgery.~The podcast is developed in collaboration with Silkeborg Regional Hospital and the Central Denmark Region's Centre for Competence Development.~Patients will get access to the podcast after randomisation, and will be able to listen to it throughout the study period."
219082754|NCT06720051|PROCEDURE|Intraosseous dexamethasone injection after 3rd molar surgery|In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
219082755|NCT06720051|PROCEDURE|Submucosal dexamethasone injection after 3rd molar surgery|In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
219082756|NCT06883162|DRUG|Varenicline|Participants will be randomized 1:1 to varenicline or matched placebo. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1 mg b.i.d. starting on Day 8. Dosing of 2 mg per day will be maintained for the next 11 weeks.
219082757|NCT06883162|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at weekly visits. Weekly counseling sessions will include discussion of online intervention modules, while providing skills-based strategies focused on enlisting social support, recognizing triggers, managing craving/withdrawal/stress, etc. Staff will use motivational enhancement techniques to address tobacco cessation, cannabis reduction or abstinence, and medication adherence.
219082758|NCT06883162|BEHAVIORAL|Psychosocial modules|Participants will have access to online modules addressing tobacco and cannabis co-use to support cessation and/or reduction. Content includes 12 virtual modules combining cognitive behavioral therapy (CBT) and motivational enhancement (MET) to address tobacco, cannabis, and their co-use.
219082759|NCT04948099|DRUG|VIB1116|VIB1116
219082760|NCT04948099|DRUG|Placebo|Placebo
219211796|NCT06811506|PROCEDURE|Anatomical size patella component|After the patella was resurfaced, surgeon evaluated the symmetry through haptic feedback and assessed the thickness by measuring the distance from the anterior to posterior center of the patella. An inset, single pegged patella component was cemented after milling the patella. The patella was medialized as the patella bone would allow. Synovium laying on top of the femoral component with the knee in extension was routinely excised. Lateral facetectomy and restoration of native patella thickness were performed in all knees. In the control group, anatomically sized patella components were used.
219211797|NCT06811506|PROCEDURE|Reduced size patella component|The same procedure of patella resurfacing as control group was done, then 3 mm reduced size patella component was used in the intervention group.
219211798|NCT06894121|OTHER|Greater Occipital Nerve Pulsed Radiofrequency (Unilateral)|Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.
219681356|NCT02004938|DEVICE|Sonosite Titan Ultrasound Machine|
219681357|NCT00411450|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
219211799|NCT06894121|OTHER|Bilateral GON PRF Treatment:|"Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.~Bilater"
219211800|NCT05417321|DRUG|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
219211801|NCT05501600|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
219211802|NCT05501600|DRUG|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
219211803|NCT06851299|DRUG|trop2-ADC|Accept ADC monotherapy
219211804|NCT06851299|DRUG|ADC +anti-angiogenic drug|Accept ADC combined with anti-angiogenic drug
219211805|NCT06851299|DRUG|ADC + PD1 monoclonal antibody +anti-angiogenic drug|ADC combined with PD1 monoclonal antibody and anti-angiogenic drug
219211806|NCT06275217|BEHAVIORAL|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
219211807|NCT06275217|OTHER|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
219211808|NCT06888479|BIOLOGICAL|hepatitis B vaccine|Three doses of hepatitis B vaccine
219211809|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
219082761|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
219082762|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
219082763|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
219211810|NCT06734325|BEHAVIORAL|Mobile Oral Health Intervention|46 messages delivered over a 3-month period (12 weeks) via WhatsApp
219211811|NCT06423157|OTHER|Intervention|The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises.
219211812|NCT05147909|DIETARY_SUPPLEMENT|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
219211813|NCT05147909|DIETARY_SUPPLEMENT|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
219211814|NCT06777342|BEHAVIORAL|Cognitive behavioral therapy intervention|The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.
219211815|NCT06777342|DIETARY_SUPPLEMENT|Melatonin intervention|Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).
219681358|NCT00411450|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
219681359|NCT01617239|BIOLOGICAL|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
219681360|NCT00760721|BEHAVIORAL|Educational Small Group Session|1 hour small group health-related discussion
219082764|NCT06724068|OTHER|Diabetes，Insulin resistance，Control|This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
219082765|NCT06722482|DEVICE|FDBA|Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
219082766|NCT06722482|DEVICE|CEBX|Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
219082767|NCT06723366|DRUG|Angong Niuhuang Pill (ANP)|Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
219082768|NCT06723366|OTHER|Control (Standard treatment)|Blank control
219211816|NCT06777342|OTHER|Placebo intervention|Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
219211817|NCT06759402|BEHAVIORAL|Family based treatment|FBT is an intensive, manualized therapy in which the parents of those affected are closely involved in a resource-oriented manner by FBT-certified therapists. FBT takes place in 3 phases: in phase 1, the parents take responsibility for their child's weight gain. Phase 2 involves the gradual transfer of responsibility for eating back to the patient. Phase 3 focuses on individual issues of the children and adolescents, e.g. catching up on important developmental steps missed due to the illness.
219211818|NCT06759402|BEHAVIORAL|Inpatient multimodal therapy|comprehensive, patient-oriented and multidisciplinary approach to address eating disorders following the S3 joint German treatment guidelines in specialized hospitals. Includes individual psychotherapy, family sessions, body-oriented therapy, nutritional counseling, group therapy sessions, relaxation techniques, mindfulness practices, and skills training. Targeted weight gain per week is at least 500g.
219211819|NCT05589831|DEVICE|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
219211820|NCT06513663|BEHAVIORAL|Exercise Intervention|"Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands.~All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session."
219681361|NCT01716663|DEVICE|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
219082769|NCT06723678|PROCEDURE|Two distally inclined 45-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.
219082770|NCT06723678|PROCEDURE|Two distally inclined 30-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
219082771|NCT06717685|DRUG|Adenosine|Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
219082772|NCT06717685|DRUG|Verapamil Injection|Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.
219082773|NCT05227833|DRUG|Vonoprazan fumarate (Vonaspire)|Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.
219082774|NCT05227833|DRUG|Pantoprazole 40mg|Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.
219082775|NCT05227833|OTHER|Placebo|No Intervention
219082776|NCT04219033|OTHER|EEG(Electroencephalogram) change|patients are found to have characteristic EEG change
219082777|NCT06723873|OTHER|Kinesiology Taping|The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.
219082778|NCT06723873|OTHER|Placebo Kinesio Taping|In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
219082779|NCT06722976|OTHER|Multicomponent exercise programs|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each session.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
219082780|NCT06733064|DIETARY_SUPPLEMENT|Supplementation of vitamin D3|Supplementation of vitamin d3 at a dose of 4000 iu / day
219082781|NCT06733064|DIETARY_SUPPLEMENT|Placebo|Vegetable oil as a placebo
219082782|NCT06732570|DEVICE|high intensity laser|the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.
219082783|NCT06732570|OTHER|manual therapy|manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
219082784|NCT06732570|OTHER|exercise therapy|therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
219082785|NCT06733948|DEVICE|Dental stent|Dental stent is personalised device for tongue depressing and immobilisation during RT. The aims are to reduce unnecessary RT doses to adjacent non-target healthy tissue, including the tongue, adjacent oral mucosa, parotid glands/ submandibular glands, and temporomandibular joints. Dentists will take impression of the teeth on moulds, and measure the height to raise the bite, the stent is then fabricated as methyl methacrylate resin in the dental laboratory. The resin base extends to the tongue and a flat plate depresses the tongue. This device will be placed before each RT fraction.
219082786|NCT06733948|OTHER|No dental stent|No dental stent used during chemoradiation treatment
219082787|NCT06732765|OTHER|Pilates exercise program|Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
219082788|NCT06732765|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
219082789|NCT06732128|OTHER|nature-based virtual reality applications and videos|Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
219082790|NCT06732128|OTHER|nature-based videos|Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
219082791|NCT06732934|OTHER|exercise (Basic Body Awareness Therapy|"Body Awareness Therapy is a patient-centered physiotherapy approach that also includes mental health, focusing on movement awareness training. This therapy primarily consists of exercises aimed at improving postural disorders, balance, and muscle tension. It aims to help individuals experience and accept bodily responses while increasing coping strategies.~The therapy includes body scanning, integration of sound and movement, stretching exercises, and exercises focusing on body alignment and midline orientation.~Floor exercises: body scanning, stretching, strength accumulation, sound resonance.~Seated exercises: body alignment, trunk rotation, head and neck movements. Standing exercises: support surface perception, midline elevation and lowering, bilateral arm movements, rotation, one-legged balance, voice exercises, and group movements."
219082792|NCT06732934|OTHER|exercise (aerobic exercise)|"The continuous exercise protocol specified by the American College of Sports Medicine (ACSM) will be applied under supervision on a treadmill. The exercise duration will follow ACSM recommendations, starting at 30 minutes in the first week and increasing to 45 minutes by the 12th week.~Exercise intensity will be assessed using the target heart rate method (220 - age). The intensity of aerobic exercise will be set at a moderate level (64-77% HRmax), according to ACSM guidelines.~During exercise, heart rate will be monitored through a heart rate monitoring device. A 5-minute warm-up and a 5-minute cool-down exercise will be performed before and after each session, with an intensity of 50-60% of the maximum heart rate."
219082793|NCT04506970|DIAGNOSTIC_TEST|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
219082794|NCT04506970|OTHER|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
219082795|NCT06732622|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
219082796|NCT06732622|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
219082797|NCT06732622|DEVICE|Sham laser acupuncture|"Patients in the laser acupuncture group (Sham group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
219082798|NCT06733714|DEVICE|Transcranial Alternating Current Stimulation|An alternate eletric current of 1.6mA in theta frequency is applied in the scalp, using two eletrodes (5x5cm). The eletrodes are located aiming for the left dorsolateral prefrontal Cortex area.
219082799|NCT06733714|DEVICE|Digital Cognitive Training|Using a tablet, the participant will do exercises that were designed to stimulate cognitive domains, especially attention and memory. In this case, we use the BrainHQ platform.
219082800|NCT06888986|BEHAVIORAL|VR Dementia Prevention Health Education Module|A virtual reality (VR) cognitive health education program designed to enhance knowledge related to dementia, improve health literacy, boost self-efficacy, and shape attitudes towards dementia. Participants engage with 360-degree immersive VR modules using VR headsets that simulate real-world scenarios related to dementia. The intervention comprises five interactive VR sessions, each addressing important topics in dementia prevention and management. Trained research staff will guide participants to ensure safe and effective interaction with the VR system.
219082801|NCT06891040|DRUG|VC005 Placebo group|VC005 Placebo group with Local topical application
219082802|NCT06891040|DRUG|VC005 groups|VC005 group with Local topical application
219082803|NCT06723275|OTHER|Standardized assessments, guided tumor biopsy and biobanking|"Standardized assessment of Scores~* Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
219082804|NCT06723275|OTHER|Standardized assessments and biobanking|"* Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
219082805|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
219082806|NCT04711889|DRUG|Blank control|Blank control
219082807|NCT06750731|DEVICE|Tappt|"Tappt is a web-based system designed to record participants medication taking behavior and bowel symptoms. Participants will be assigned smart labels for their specific vedolizumab regimen, which will be used by participants to record their vedolizumab use. Participants will be shipped smart labels to be affixed to an IV card for the first three infusions and for subsequent infusions or injections. At the time of a vedolizumab dose, participants will scan the smart label by tapping it with their mobile device to verify that they are taking the medication. Each day that vedolizumab is due, patients will receive a reminder through SMS message. If participants fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message reminder. Participants will also complete a patient reported outcome assessment at baseline, weekly for 6 weeks, and then monthly for the entire 22 weeks of the study triggered by the system."
219082808|NCT06777758|DRUG|Remimazolam|Remimazolam
219082809|NCT06777758|DRUG|Propofol|Propofol dose reduction ratio
219082810|NCT07090668|DEVICE|taVNS device|"Sparrow Link taVNS device from Spark Biomedical, a non-invasive, adhesive earpiece placed on the tragus of the ear to deliver vagal nerve stimulation. The stimulation level is titrated by the investigator to a perceptible but comfortable intensity. Patients cannot adjust the settings themselves, though adjustments can be made upon request.~The device consists of a disposable earpiece connected by a cable to a battery-powered controller (3 AAA batteries). It emits a biphasic, rectangular waveform with a 100 µs interphase and a maximum output of 95V."
219082811|NCT07094347|DEVICE|inspiratory muscle training|Powerbreathe® threshold resistance loading device (POWERbreathe, HaB International) will be used for this training program that strengthens the inspiratory muscles. The PowerBreathe® device is a threshold device that creates resistance to inspiration. This resistance is created by the spring tension in the device mechanism. The device has a mechanism that is adjusted according to 9 different levels in its mechanism specific to the individuals using it.
219082812|NCT07093320|OTHER|No intervention|No intervention
219082813|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
219082814|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
219082815|NCT03902054|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
219082816|NCT03902054|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
219082817|NCT03902054|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
219082818|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
219082819|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
219082820|NCT06914167|BEHAVIORAL|Slow Breathing Exercises|Participants will perform slow breathing (6 breaths/min) for 3 minutes daily before bedtime
219082821|NCT06914167|BEHAVIORAL|Lavender Essential Oil Inhalation|inhalation of 3 drops of lavender essential oil on a towel,
219082822|NCT06914167|BEHAVIORAL|linalyl acetate essential oil Inhalation|inhalation of 3 drops of linalyl acetate essential oil on a towel.
219082823|NCT06914167|BEHAVIORAL|linalool essential oil Inhalation|inhalation of 3 drops of linalool essential oil on a towel.
219082824|NCT02651766|PROCEDURE|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
219082825|NCT01516047|DRUG|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
219082826|NCT01516047|DRUG|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
219082827|NCT06388694|OTHER|Pharmacist Care|Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
219082828|NCT06388694|OTHER|Primary Care Physician Care|Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
219082829|NCT06190301|DRUG|Rituximab|Intralesional Rituximab Injection
219082830|NCT06190301|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
219082831|NCT01046539|DRUG|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
219082832|NCT01046539|DRUG|Placebo|0 mg
219082833|NCT05911503|DRUG|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
219082834|NCT06950619|GENETIC|Whole Genome Sequencing|Genetic testing will be performed to find variants in genes involving congenital cataract and/or ocular diseases (keratitis, keratoconus, corneal dystrophies, ectopia lentis, glaucoma, retinitis pigmentosa, coloboma and aniridia) and dental anomalies (tooth agenesis, supernumerary teeth, Hutchinson teeth, mulberry molars). Cutaneous appendage anomalies will be also evaluated in clinical history for ascertaining ectodermal diplasia.
219082835|NCT06950619|OTHER|Cephalometric tracing|Cephalometric tracing will be performed on lateral cephalometric radiographs if present and not taken on purpose for the study
219082836|NCT00230828|DRUG|bifeprunox|
219082837|NCT04514341|OTHER|Short Message Service (SMS)|Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.
219082838|NCT04514341|OTHER|Remote Patient Navigation|Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
219082839|NCT04295005|DRUG|Empagliflozin|film coated tablet
219082840|NCT04295005|DRUG|DPP-4i|film coated tablets, specifically Sitagliptin
219082841|NCT04295005|DRUG|GLP-1-RA|subcutaneous injection or tablet
219082842|NCT03169387|BEHAVIORAL|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
219082843|NCT03169387|BEHAVIORAL|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
219082844|NCT06234293|DEVICE|near-infrared light device|Nurses will have to find the vein for the PIVC using the near-infrared light device.
219082845|NCT02880592|OTHER|Affinity Allograft|fresh hypothermically stored human amniotic membrane
219082846|NCT02880592|OTHER|Standard of care|offloading, debridement, infection management using appropriate dressings
219082847|NCT05584852|OTHER||no intervention
219082848|NCT01518855|DRUG|Nifedipine (Adalat, BAYA1040)|
219082849|NCT01518855|DRUG|Amlodipine (Norvasc)|
219082850|NCT01518855|DRUG|Diovan|
219082851|NCT04318184|PROCEDURE|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
219082852|NCT01834755|OTHER|Evaluation of psychological phenotype|
219082853|NCT06366204|OTHER|Dietary Lysine Intakes|Participants consume 8 hourly meals that contain the assigned test lysine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 x Resting Energy Expenditure (REE) and adequate protein at 1.5 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and nitrogenous free cookies.
219082854|NCT03912493|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
219082855|NCT03912493|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
219082856|NCT00289887|DRUG|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
219082857|NCT00289887|DRUG|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
219082858|NCT02879266|BIOLOGICAL|TetraVax-DV TV005|Contains 10\^3 plaque-forming units (PFUs) of rDEN1Δ30, 10\^4 PFUs of rDEN2/4Δ30(ME), 10\^3 PFUs of rDEN3Δ30/31-7164, and 10\^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
219082859|NCT02879266|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
219082860|NCT01266850|BIOLOGICAL|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
219082861|NCT01266850|BIOLOGICAL|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
219082862|NCT01584180|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
219082863|NCT01584180|DEVICE|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
219082864|NCT05419648|BIOLOGICAL|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
219082865|NCT01695824|DEVICE|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
219082866|NCT01695824|PROCEDURE|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
219082867|NCT01695824|DRUG|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
219082868|NCT01862952|OTHER|starting of anti-epileptic drug treatment|
219082869|NCT03115294|DRUG|Theophylline|iv injection
219082870|NCT03115294|PROCEDURE|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
219082871|NCT03115294|DEVICE|Videorecording|Myocardial movement videorecording
219082872|NCT04883307|BEHAVIORAL|Coaching|Professional development coaching based on a curriculum of positive psychology principles and coaching principles.
219082873|NCT04883307|BEHAVIORAL|Wellness resources|Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
219082874|NCT00707265|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
219082875|NCT00707265|DEVICE|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
219082876|NCT00437645|DRUG|Valsartan 160 mg capsules|
219082877|NCT00437645|DRUG|Amlodipine 5 mg capsules|
219082878|NCT00437645|DRUG|placebo|capsules
219082879|NCT00412048|PROCEDURE|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
219082880|NCT02614495|DRUG|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
219082881|NCT05282797|DRUG|ANEB-001|Experimental Treatment
219082882|NCT05282797|DRUG|Placebo|Placebo comparator
219082883|NCT06146491|DRUG|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
219211821|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
219211822|NCT04663061|BEHAVIORAL|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
219211823|NCT04663061|BEHAVIORAL|Diabetes education|Participants will receive standard of care diabetes education
219211824|NCT04663061|BEHAVIORAL|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
219211825|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
219211826|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
219082884|NCT05011968|DIETARY_SUPPLEMENT|Lettuce with not biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
219082885|NCT05011968|DIETARY_SUPPLEMENT|Lettuce biofortificated with Iodine|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
219082886|NCT02295839|BEHAVIORAL|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
219082887|NCT03350568|OTHER|Total dietary NEAC assessed at baseline|
219082888|NCT02559336|OTHER|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
219082889|NCT03089684|OTHER|No intervention|No intervention
219082890|NCT04835818|DIAGNOSTIC_TEST|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
219082891|NCT00003617|DRUG|chlorambucil|
219082892|NCT00003617|DRUG|clarithromycin|
219082893|NCT00003617|DRUG|omeprazole|
219082894|NCT00003617|DRUG|tinidazole|
219082895|NCT05858697|OTHER|Declining participation in the Aarhus intervention|Each year a fraction of the children invited into the Aarhus intervention decline to participated.
219082896|NCT05858697|BEHAVIORAL|Participation in the Aarhus intervention|A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
219082897|NCT03751631|DRUG|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
219082898|NCT03751631|DRUG|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
219082899|NCT03751631|DRUG|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
219082900|NCT04238026|PROCEDURE|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
219082901|NCT03949166|OTHER|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
219082902|NCT03159520|BEHAVIORAL|Advice sheet|Advice on management of post orthodontic pain
219082903|NCT03073148|DEVICE|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
219082904|NCT03073148|OTHER|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
219211827|NCT05694715|DRUG|Niraparib|Given orally
219211828|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
219082905|NCT00140504|OTHER|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
219082906|NCT00370630|DRUG|Avastin (Bevacizumab) and triamcinolone|
219211829|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
219082907|NCT00879138|DRUG|VA106483|
219082908|NCT00879138|DRUG|Sugar pill|
219082909|NCT01610427|PROCEDURE|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
219211830|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
219211831|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
219211832|NCT05169112|DRUG|Lupron Depot|Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
219082910|NCT00444691|DEVICE|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
219082911|NCT02250105|DRUG|ARI-3037MO|Lipid lowering
219082912|NCT02250105|DRUG|Placebo|Inactive
219211833|NCT06892353|DIAGNOSTIC_TEST|AI-powered fundus camera screening|All the participants will undertake an AI-powered fundus camera screening, physician/optometrist consultation, survey with questionnaires and a phone interview three months after their baseline assessment.
219211834|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
219082913|NCT03382782|BEHAVIORAL|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
219082914|NCT03382782|BEHAVIORAL|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI \& Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
219082915|NCT03382782|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
219082916|NCT04186013|DRUG|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
219082917|NCT04186013|RADIATION|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
219082918|NCT01316510|DIETARY_SUPPLEMENT|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
219082919|NCT01316510|OTHER|Placebo|Dilute Nutramigen formula
219082920|NCT03974620|BEHAVIORAL|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
219082921|NCT03974620|BEHAVIORAL|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
219082922|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
219082923|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
219082924|NCT00135369|DRUG|stavudine extended-release, lamivudine, efavirenz|
219082925|NCT02377154|DEVICE|Slit lamp|Examination of cornea
219082926|NCT02377154|DEVICE|Autorefractor|Measurement of refraction
219082927|NCT02377154|DEVICE|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
219082928|NCT02377154|DEVICE|Pentacam HR|Measurement of white-to-white distance; Keratometry
219082929|NCT02377154|DEVICE|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
219082930|NCT02377154|DEVICE|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
219082931|NCT03233243|DRUG|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
219082932|NCT04852874|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
219082933|NCT00428090|DRUG|Rosiglitazone|XR (extended release) oral tablets
219082934|NCT03912454|OTHER|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
219082935|NCT04553341|DEVICE|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
219082936|NCT01380951|DRUG|telbivudine|telbivudine 600mg/d 96 weeks
219082937|NCT01315093|DRUG|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
219082938|NCT01315093|DRUG|no heparin|
219082939|NCT03205397|OTHER|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
219082940|NCT03205397|OTHER|usual care|Usual care
219082941|NCT04818294|DEVICE|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
219082942|NCT00361140|DRUG|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
219082943|NCT00361140|DRUG|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
219082944|NCT06174584|DRUG|Hypertonic saline|Hypertonic saline
219082945|NCT06174584|OTHER|Cow Milk|Cow Milk
219082946|NCT03191487|OTHER|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
219082947|NCT03191487|OTHER|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
219082948|NCT05732441|DRUG|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
219082949|NCT02969720|DIETARY_SUPPLEMENT|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
219082950|NCT02969720|DIETARY_SUPPLEMENT|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
219082951|NCT02159131|DRUG|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
219082952|NCT02159131|DRUG|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
219082953|NCT02159131|DRUG|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
219082954|NCT01034267|DRUG|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
219082955|NCT00003780|BIOLOGICAL|tumor infiltrating lymphocyte therapy|
219082956|NCT00003780|DRUG|gemcitabine hydrochloride|
219082957|NCT04051268|BIOLOGICAL|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
219082958|NCT04051268|BIOLOGICAL|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
219082959|NCT04051268|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Active Comparator
219082960|NCT03255824|DRUG|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
219082961|NCT03255824|DRUG|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
219082962|NCT03967431|OTHER|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
219082963|NCT00279292|PROCEDURE|Celiac Plexus Neurolysis|
219082964|NCT02859610|OTHER|research on interactions between portal hypertension and microparticles|
219082965|NCT06020690|DEVICE|bioabsorbable steroid-releasing stent|The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
219082966|NCT03515928|OTHER|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
219082967|NCT03515928|DIAGNOSTIC_TEST|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
219082968|NCT03500055|PROCEDURE|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
219082969|NCT06206967|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
219082970|NCT06206967|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
219082971|NCT04299880|DRUG|Napabucasin|Oral
219082972|NCT04299880|DRUG|Nab-paclitaxel|Intravenous
219082973|NCT04299880|DRUG|Gemcitabine|Intravenous
219082974|NCT04299880|DRUG|Nivolumab|Intravenous
219082975|NCT04299880|DRUG|Paclitaxel|Intravenous
219082976|NCT04299880|DRUG|Irinotecan|Intravenous
219082977|NCT04299880|DRUG|Leucovorin|Intravenous
219082978|NCT04299880|DRUG|5Fluorouracil|Intravenous
219082979|NCT04299880|DRUG|Bevacizumab|Intravenous
219082980|NCT01866943|DRUG|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
219082981|NCT01866943|DRUG|Normal Saline Solution|
219082982|NCT03977090|DRUG|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
219082983|NCT03977090|DRUG|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
219082984|NCT04646239|DIAGNOSTIC_TEST|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
219082985|NCT04646239|DIAGNOSTIC_TEST|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
219082986|NCT04401514|DEVICE|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
219082987|NCT00617578|DEVICE|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
219082988|NCT00617578|DEVICE|ATP One Shot OFF|Standard defibrillation shock delivery
219082989|NCT00337272|DRUG|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
219082990|NCT00337272|DRUG|Ramelteon|8 mgs daily for days 1-28 of treatment period
219082991|NCT06490757|DRUG|Baricitinib|An ancillary study will be performed in a subgroup of 12 patients to assess the variation of the results of PET-CT with 18FDG from baseline to 3 months. The variation of tumor features assessed by PET-CT with 18FDG after three months of treatment, will be assessed. The median value of the SUV max and tumor to non-tumor ratio of the SUV max value for each HCA lesion between the PET CT with 18FDG performed at baseline and after 3 months of treatment will be assessed.
219082992|NCT00993655|DRUG|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
219082993|NCT00993655|DRUG|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
219082994|NCT00993655|DRUG|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
219082995|NCT01082094|BIOLOGICAL|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
219082996|NCT05795530|PROCEDURE|cochlear implantation|surgery for bilateral hearing loss
219082997|NCT02408575|DEVICE|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
219082998|NCT02408575|DEVICE|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
219082999|NCT01278355|DEVICE|Ear acupuncture|Ear acupuncture
219083000|NCT01953393|OTHER|Low-dose TNF-alpha|
219083001|NCT01828580|DEVICE|active laparoscope positioner (AutoLap)|
219083002|NCT03235505|DRUG|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
219083003|NCT03235505|DRUG|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
219083004|NCT03235505|BEHAVIORAL|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
219083005|NCT05595668|BEHAVIORAL|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
219083006|NCT05595668|OTHER|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
219083007|NCT00005041|DRUG|tipifarnib|
219083008|NCT00002611|BIOLOGICAL|dactinomycin|
219083009|NCT00002611|BIOLOGICAL|filgrastim|
219083010|NCT00002611|DRUG|cyclophosphamide|
219211835|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
219211836|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
219211837|NCT06736587|DRUG|DWP212525 10mg|DWP212525 10mg
219083011|NCT00002611|DRUG|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
219083012|NCT00002611|DRUG|etoposide|
219083013|NCT00002611|DRUG|vincristine sulfate|
219083014|NCT00002611|PROCEDURE|conventional surgery|
219083015|NCT00002611|RADIATION|radiation therapy|
219083016|NCT05100290|DIAGNOSTIC_TEST|Hyperventilation Provocation Test (HPTest)|"During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate."
219083017|NCT06182306|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
219083018|NCT06385743|OTHER|Neuromuscular Training-based Exercise Program|Neuromuscular training has been accepted as an effective treatment modality to improve the neurophysiological states of the joints for coordinated work. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility). All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
219083019|NCT06385743|OTHER|''Thrower's Ten'' Exercise Program|"''Thrower's Ten'' Exercise Program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added. All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks."
219083020|NCT01568099|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
219083021|NCT01568099|OTHER|Control|Untreated control
219083022|NCT02465281|OTHER|Device: 3T scanner with MRI-compatible robot|
219083023|NCT01169714|DRUG|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
219083024|NCT01169714|DRUG|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
219083025|NCT01169714|DRUG|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
219083026|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
219083027|NCT01169714|DRUG|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
219083028|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
219083029|NCT03313518|DEVICE|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
219083030|NCT03313518|DEVICE|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
219083031|NCT04605978|DRUG|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
219083032|NCT04605978|DRUG|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
219083033|NCT02660723|OTHER|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
219083034|NCT05562479|BIOLOGICAL|Sars Cov 2 infection|Donors recovered from Sars Cov 2 Infection
219083035|NCT05562479|BIOLOGICAL|Sars Cov 2 vaccination|Egg Donors vaccinated
219083036|NCT02003079|BEHAVIORAL|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
219083037|NCT03813238|DRUG|TEV-50717|Dosage ranging from 6 mg to 48 mg.
219083038|NCT03813238|DRUG|Placebo|Dosage ranging from 6 mg to 48 mg.
219083039|NCT02484157|DEVICE|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
219083040|NCT02484157|DEVICE|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
219083041|NCT06057623|OTHER|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
219083042|NCT06956963|OTHER|Partial Sleep Deprivation|30% reduction in habitual time in bed
219083043|NCT06788184|DEVICE|Virtual Reality (VR) Game for Auditory Processing|"The Virtual Reality (VR) Game is a novel auditory rehabilitation tool designed to enhance central auditory processing skills in children with cochlear implants. This intervention features a restaurant simulation environment where participants perform auditory tasks such as identifying verbal orders, recognizing speech in noisy environments, and matching auditory cues to visual inputs.~Dosage Form: Virtual reality sessions conducted through a VR headset (Oculus Meta Quest 3).~Frequency: Once per week. Duration per Session: 30 minutes per session. Total Duration: Four weeks (4 sessions). Complexity Levels: Tasks increase in complexity over time, starting with simple auditory cues in quiet environments and progressing to more challenging scenarios involving background noise and multitasking.~The VR game is specifically designed to replicate real-world auditory challenges in a controlled and engaging virtual environment, providing participants with tailored tasks to improve auditory atten"
219211838|NCT06736587|DRUG|DWP212525 30mg|DWP212525 30mg
219211839|NCT06736587|DRUG|DWP212525 50mg|DWP212525 50mg
219211840|NCT06736587|DRUG|DWP212525 100mg|DWP212525 100mg
219083044|NCT06788184|BEHAVIORAL|Traditional Auditory Rehabilitation|"Name: Traditional Auditory Rehabilitation~Description:~Participants will continue the standard auditory rehabilitation program they currently receive at their registered rehabilitation center and will focus on improving auditory processing skills. This program includes:~Session Length: 30 minutes per session Frequency: Once a week Total Duration: 4 weeks (4 sessions total)~Components:~Improve speech understanding in noise"
219083045|NCT06958315|OTHER|Inclisiran|This is an observational study, there is no treatment allocation.
219083046|NCT01484639|OTHER|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
219083047|NCT01484639|OTHER|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
219083048|NCT06791473|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, imaging data, and genetic information, to predict the risk of cancer. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of cancer risks. By analyzing historical health data, the model aims to predict potential cancer developments, improving early detection and treatment outcomes.
219083049|NCT02096328|DRUG|POL7080|Intravenous infusion
219083050|NCT01644734|DRUG|Spiriva HandiHaler|
219083051|NCT03188848|DRUG|BPI-3016|Single-dose subcutaneous injection of BPI-3016
219083052|NCT03188848|DRUG|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
219083053|NCT02976441|RADIATION|Radiation therapy|
219083054|NCT02976441|DRUG|Temozolomide|
219083055|NCT02976441|PROCEDURE|Stem cell collection|
219083056|NCT02976441|PROCEDURE|Stem cell infusion|
219083057|NCT01930357|BIOLOGICAL|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
219211841|NCT06736587|DRUG|DWP212525 200mg|DWP212525 200mg
219211842|NCT06736587|DRUG|DWP212525 400mg|DWP212525 400mg
219211843|NCT06736587|DRUG|DWP212525 placebo|DWP212525 placebo
219211844|NCT06877468|BEHAVIORAL|Associative conditioning|Child is offered a vegetable to taste with a palatable dip, over 8 occasions. Vegetable is served at home by parent/caregiver following standard script.
219211845|NCT06877468|BEHAVIORAL|Modeling|Child is offered a vegetable to taste while their parent/caregiver also tastes it and models enjoying it, over 8 occasions. Vegetable is served at home with parent/caregiver following standard scripting.
219211846|NCT06787846|OTHER|Experimental: Group TP|Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day
219211847|NCT06787846|DRUG|Active Comparator: Group HQ: Hydroquinone 4%|Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
219211848|NCT06885801|DEVICE|use of an anatomically designed nasal conformer|this study will evaluate the use of a nasal conformer that has been designed to match the internal airway anatomy of the anterior nose rather than the standard hollow, conical conformer currently available on the market
219211849|NCT06893289|OTHER|Exercise|Balance and proprioceptive exercises
219211850|NCT06893289|OTHER|Muscle strengthening|Strengthening of the lower limb muscles
219211851|NCT06791967|BEHAVIORAL|home-based walking program|The home-based walking intervention involves five walking sessions per week over 12 weeks, with a target of 3,000 additional steps per session beyond daily activities. In the first week, participants in the experimental group will wear a smart wristband upon waking to record their average daily steps, which will guide their walking goals. By the 7th week, participants are expected to achieve at least 3,000 extra steps per session, completed in 30 continuous minutes. The wristband, synced via Bluetooth to its companion app, can store up to one month of walking data. Weekly phone follow-ups will record participants' daily step counts. No additional cloud uploads of personal data are required.
219211852|NCT06745635|OTHER|Usual Care|Usual care for immunizations.
219211853|NCT06745635|OTHER|Multifaceted intervention|The multifaceted quality improvement intervention includes: video-based training on vaccine management in SUS, an optimized Cold Chain Manual schema, technical documents on proper vaccine handling and immunization schedules, and checklists for managing post-vaccination errors and corrective procedures. Videos will focus on six key points (right person, vaccine, dose, time, route, and documentation), with each lasting about 2 minutes and accessible on-demand. The Cold Chain schema will cover storage, monitoring, transport, conservation, and handling, with checklists for each category. Standardized technical documents will align with video themes, ensuring protocol adherence. An error identification and management schema will address issues like improper vaccine administration, cold chain violations, and incorrect dosages. This schema will be reviewed by staff and made available in health units.
219083058|NCT01930357|BIOLOGICAL|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
219083059|NCT00005791|DRUG|cisplatin|
219083060|NCT00005791|DRUG|fluorouracil|
219083061|NCT00005791|DRUG|irinotecan hydrochloride|
219083062|NCT05095272|BIOLOGICAL|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
219211854|NCT06773455|DRUG|tralokinumab|600mg at week 0 followed by 300mg Q2W for 24 weeks
219211855|NCT06858384|OTHER|Control (Standard treatment)|Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions. At the end of the 6-month period, the educational materials provided to the intervention group will be offered to the control group.
219083063|NCT04467554|DEVICE|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
219083064|NCT02370433|DRUG|Intravenous Neostigmine and Glycopyrrolate|
219083065|NCT02370433|DRUG|Transdermal Neostigmine and Glycopyrrolate|
219083066|NCT01875380|DRUG|Regorafenib|
219083067|NCT01063101|OTHER|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
219083068|NCT01063101|OTHER|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
219083069|NCT03386201|DRUG|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
219083070|NCT00489385|DRUG|Albinterferon|
219083071|NCT00489385|DRUG|Ribavirin|
219083072|NCT00489385|DRUG|Albuferon|
219083073|NCT05241704|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
219083074|NCT05241704|PROCEDURE|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
219083075|NCT04969484|OTHER|Telehealth visit|ImPACTT Telehealth visit with the PC provider
219083076|NCT01786486|DEVICE|Amplatzer Cardiac Plug|
219083077|NCT03994458|BEHAVIORAL|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
219083078|NCT03994458|BEHAVIORAL|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
219083079|NCT01855217|DRUG|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
219083080|NCT01855217|DRUG|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
219083081|NCT01855217|DRUG|Placebo|0,9% NaCl
219083082|NCT04834791|DRUG|Letrozole 2.5mg|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
219083083|NCT04834791|DRUG|Gonadotropin|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
219083084|NCT01342224|BIOLOGICAL|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
219083085|NCT03226964|DEVICE|high flow nasal oxygen|humidified high flow nasal oxygen
219083086|NCT03471663|DRUG|D-0502|oral tablets
219083087|NCT03471663|DRUG|palbociclib|standard dose of palbociclib
219083088|NCT04969237|DIAGNOSTIC_TEST|Vitamine D in blood samples|vitamine D values
219083089|NCT03489590|DRUG|PFP|"* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
219083090|NCT01712100|DRUG|Irbesartan|
219083091|NCT01712100|DRUG|Avapro|
219083092|NCT00881491|DRUG|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
219083093|NCT00881491|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
219083094|NCT00881491|DRUG|Mineral Trioxide Aggregate|standard material providing an apical barrier
219083095|NCT00533377|DRUG|CP-533, 536|Active study drug
219083096|NCT00533377|DRUG|Placebo|Placebo vehicle
219083097|NCT00533377|PROCEDURE|Standard of Care|Standard surgical procedure
219083098|NCT00533377|DRUG|CP-533,536|Active study drug
219083099|NCT00533377|DRUG|CP-533,536|Active study drug
219083100|NCT00533377|DRUG|CP-533,536|Active study drug
219083101|NCT03368820|OTHER|No intervention|Treatment left at the discretion of the participant
219083102|NCT06647836|OTHER|Efficacy observation|Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
219083103|NCT01859481|DRUG|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
219083104|NCT01859481|DRUG|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
219211856|NCT06858384|OTHER|Pharmacist-Led Educational Intervention|Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.
219211857|NCT03422432|PROCEDURE|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
219211858|NCT06801600|DRUG|Weight-based dosing|Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight \> 15 kg
219083105|NCT01859481|DRUG|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
219083106|NCT03422874|DRUG|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
219083107|NCT03422874|DRUG|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
219083108|NCT05794542|DEVICE|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
219083109|NCT04393441|DRUG|011516X (New Artificial Tear Formulation)|Topical eye drops
219083110|NCT04393441|DRUG|Systane Ultra Multidose|Topical eye drops
219083111|NCT04393441|DRUG|REFRESH PLUS®|Topical eye drops
219083112|NCT06359938|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
219083113|NCT06359938|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
219083114|NCT03756103|DRUG|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
219083115|NCT03756103|DRUG|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
219083116|NCT03756103|DRUG|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
219083117|NCT03756103|DRUG|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
219083118|NCT01688700|DRUG|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
219083119|NCT01432548|PROCEDURE|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
219083120|NCT05642481|DIAGNOSTIC_TEST|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
219083121|NCT03558048|DIAGNOSTIC_TEST|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
219083122|NCT02316795|PROCEDURE|Sentinel lymph node biopsy|
219083123|NCT02316795|DEVICE|Goggle-based device with light-emitting diodes (LED)|
219083124|NCT02316795|DRUG|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
219083125|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
219083126|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
219083127|NCT05198466|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
219083128|NCT05198466|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
219083129|NCT01452750|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
219083130|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
219211859|NCT06801600|DRUG|Age-based dosing|Hyperbaric bupivacaine 0.5% will be administered at the dose of age divided by 5 (in ml). The age in months after the completion of a year was noted and considered as the next age if it is more than 6 months and the same age if it is ≤ 6 months.
219211860|NCT01968109|BIOLOGICAL|Relatlimab|
219211861|NCT01968109|BIOLOGICAL|Nivolumab|
219083131|NCT01452750|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
219083132|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
219211862|NCT01968109|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab
219211863|NCT06723522|DEVICE|HD-tDCS|2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days, each stimulation lasted for 20 min, with 30 s of ramp-up and ramp-down before and after the 20-min stimulation, respectively.
219211864|NCT06723522|DEVICE|Sham (No Treatment)|Received 1 min of ramping up/down without experiencing 2 mA HD-tDCS stimulation lasted for 20 min.
219211865|NCT06725017|DRUG|Live SK08 powder|SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.
219083133|NCT01452750|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
219083134|NCT01452750|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
219083135|NCT00538135|BEHAVIORAL|Cognitive Behavioural Therapy|
219083136|NCT00538135|OTHER|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
219083137|NCT02472964|BIOLOGICAL|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
219083138|NCT02472964|BIOLOGICAL|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
219083139|NCT02472964|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
219083140|NCT02472964|DRUG|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
219083141|NCT03141320|OTHER|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
219083142|NCT01725828|DEVICE|Ultrasound|Using the Ultrasound to determine the location of the CTM.
219083143|NCT01725828|OTHER|External Palpation|Using External Palpation to identify cricothyoid membrane
219083144|NCT01215292|DRUG|Acyline|300 mcg/kg on Day 1
219083145|NCT01215292|DRUG|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
219083146|NCT01215292|DRUG|ketoconazole 400|400 mg PO daily, Days 3-10
219083147|NCT01215292|DRUG|Ketoconazole 800|800 mg PO daily, Day 3-10
219083148|NCT01215292|DRUG|Dutasteride|2.5 mg PO daily, Day 3-10
219211866|NCT06725017|DRUG|Placebo|Placebo
219211867|NCT04039113|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
219211868|NCT04039113|OTHER|Placebo|Placebo subcutaneous injection
219211869|NCT06886490|OTHER|Mediterranean diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Mediterranean diet: Animal : vegetable protein ratio - 70:30.
219211870|NCT06886490|OTHER|Planetary diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Planetary diet: Reduce consumption of red meat, moderate consumption of poultry, fish and seafood and their products, and eggs and dairy. Animal : vegetable protein ratio - 50:50
219211871|NCT06886490|OTHER|Lactovegetarian diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Lactovegetarian diet: Reduce consumption of meat, fish and seafood and their preparations, and eggs and dairy products. Animal : vegetable protein ratio - 30:70.
219083149|NCT01215292|DRUG|Anastrozole|1 mg PO daily, Day 3-10
219083150|NCT01215292|DRUG|Placebo ketoconazole|placebo to mimic ketoconazole
219083151|NCT02543034|DEVICE|Betafoam Wound Dressing|Foam dressing including Betadine iodine
219083152|NCT02543034|DEVICE|Petrolatum Gauze|Gauze dressing
219083153|NCT02543034|DEVICE|Allevyn Wound Dressing|Foam dressing
219083154|NCT00403416|DRUG|AEB071|
219083155|NCT00403416|DRUG|Mycophenolic Acid|
219083156|NCT04099108|COMBINATION_PRODUCT|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
219083157|NCT00244296|DRUG|Duloxetine hydrochloride|
219083158|NCT00244296|DRUG|placebo|
219083159|NCT04941040|DRUG|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h"
219083160|NCT04941040|DRUG|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
219083161|NCT00689221|DRUG|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
219083162|NCT00689221|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
219083163|NCT00689221|RADIATION|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
219083164|NCT04355351|OTHER|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
219083165|NCT04355351|OTHER|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
219083166|NCT02766569|DEVICE|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
219083167|NCT04534374|BEHAVIORAL|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
219083168|NCT04534374|BEHAVIORAL|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
219083169|NCT06171542|DEVICE|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
219083170|NCT04994834|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
219083171|NCT01749982|OTHER|Placebo|
219083172|NCT01749982|DRUG|Choline bitartrate|
219083173|NCT01749982|DRUG|Betaine|
219083174|NCT01749982|DRUG|Choline bitartrate + Betaine|
219083175|NCT02444455|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
219083176|NCT03189017|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
219083177|NCT03189017|DRUG|Placebos|The placebo is a white, round, uncoated tablet.
219083178|NCT05817851|DRUG|Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)|in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
219083179|NCT05817851|DRUG|standard treatment|no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
219083180|NCT01812655|DEVICE|Virtual Reality|
219083181|NCT01812655|OTHER|Passive Distraction|
219083182|NCT04822038|DIETARY_SUPPLEMENT|Vitamin D3|5000 UI Vitamin D3 daily by 4 weeks
219083183|NCT04822038|OTHER|Dietary recommendations|Dietary recommendations based on food rich in 25 (OH) vitamin D
219083184|NCT04647149|BEHAVIORAL|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
219083185|NCT04950374|OTHER|Moisturizer Body Lotion|The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
219083186|NCT04950374|OTHER|Lip Moisturizer|The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
219083187|NCT00036569|PROCEDURE|adjuvant therapy|
219083188|NCT00036569|BIOLOGICAL|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
219083189|NCT01596582|BEHAVIORAL|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
219083190|NCT01187693|OTHER|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
219083191|NCT03608930|DEVICE|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
219083192|NCT05242991|DEVICE|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
219083193|NCT00442143|PROCEDURE|Stem cell implantation|
219083194|NCT04814329|OTHER|genetic characteristic|the underlying genetic characteristics that prodicting response
219083195|NCT01274195|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
219083196|NCT05798195|OTHER|conventional western medicine treatment|conventional western medicine treatment only
219083197|NCT05798195|DRUG|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
219083198|NCT05798195|OTHER|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
219083199|NCT03390439|DEVICE|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
219211872|NCT06886490|OTHER|Vegan diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Vegan diet: Excludes all animal and animal-derived products (meat, fish, seafood, dairy, eggs, honey).
219083200|NCT03390439|DEVICE|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
219083201|NCT00204048|BEHAVIORAL|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
219083202|NCT01986465|DRUG|Depomedrol|
219083203|NCT01986465|DRUG|Placebo|
219083204|NCT06191718|DEVICE|Mitral Valve Replacement|Foldax Mitral Valve Replacement
219083205|NCT04635553|DRUG|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
219083206|NCT04808804|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
219083207|NCT05356858|DRUG|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
219083208|NCT04672941|DRUG|Tiotropium bromide plus Olodaterol|Tiotropium bromide plus Olodaterol
219083209|NCT04435665|DRUG|NFX-179 Gel|gel for topical administration
219083210|NCT04435665|DRUG|Vehicle Gel|vehicle gel for topical administration
219083211|NCT01263834|DRUG|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
219083212|NCT01263834|DRUG|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
219083213|NCT00765388|DEVICE|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
219083214|NCT00765388|DEVICE|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
219083215|NCT03923933|DRUG|Chlorthalidone|Chlorthalidone
219083216|NCT03923933|DRUG|Bumetanide|Bumetanide
219083217|NCT01435538|BEHAVIORAL|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
219083218|NCT06268158|BEHAVIORAL|Eye patch|The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
219083219|NCT04073238|DEVICE|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
219083220|NCT00419263|DRUG|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
219083221|NCT00419263|DRUG|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
219083222|NCT00419263|DRUG|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
219083223|NCT05480475|DRUG|Dabigatran etexilate|On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
219083224|NCT05480475|DRUG|Rosuvastatin|On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
219083225|NCT05480475|DRUG|Daridorexant|On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
219083226|NCT00343928|OTHER|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
219083227|NCT01395381|DRUG|Placebo|placebo given once
219083228|NCT01395381|DRUG|Albendazole|single dose albendazole given at the time of enrollment
219083229|NCT00400335|DRUG|Nanomilled testosterone|
219083230|NCT00400335|DRUG|commercially available dutasteride|
219083231|NCT00400335|DRUG|Nanomilled dutasteride|
219083232|NCT01372306|DRUG|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
219083233|NCT06246604|DIAGNOSTIC_TEST|Ultrasound screening for lower limbs DVT|Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.
219083234|NCT06246604|DIAGNOSTIC_TEST|Standard-of-care|Ultrasound examination of lower limbs is performed according to clinical risk of DVT
219083235|NCT00274638|DRUG|Telmisartan & Hydrochlorothiazide|
219083236|NCT00274638|DRUG|Losartan & Hydrochlorothiazide|
219083237|NCT00274638|PROCEDURE|ABPM|
219083238|NCT06470165|PROCEDURE|Priority-matching correction technique in DLS|"For Type 1 global coronal malalignment (GCM), TL/L curve makes the primary contri- bution on C7PL shifting. First, inserting pedicle screws bilaterally. Second, aggressively decreasing the magnitude of TL/L curve. Third, moderately leveling L4 endplate to pull the fusion segments to the middle line with hand pressure on the convexity of TL/L curve. If the correctability of the key curve was limited, the correction of the minor curve would be con- vergent.~For Type 2 GCM, LS curve makes the primary contribution on C7PL shifting. First, releasing LS curve from the concave side using facetectomy after screws inserted. Second, performing L4-5 or L5-S1 trans- foraminal lumbar interbody fusion (TLIF) from the con- vexity of the fractional curve, with cages inserted at the concave side to assist deformity correction. Third, compressing the convexity of LS to horizontalize L4 endplate, followed by moderate manipulative reduction of TL/L curve to adjust intraoperative coronal balance."
219083239|NCT06470165|PROCEDURE|Traditional correction technique in DLS|"In concave coronal malalignment (CM), the correction of the main curve improves the CM, thus we can talk about convergent corrective objectives. The ability to correct the CM depends on the correctability of the main curve. The need of three-column osteotomies in order to obtain correction of CM depends on the location and flexibility of the main curve.~The correction of convex CM depends on the correction of the lumbosacral curve. The correction strategy will depend on many factors including the driver of the deformity, which should always be fused, but also the degeneration and stiffness of the compensatory curve which can lead to more extended fusion. The need of three-column osteotomies depends mainly on the stiffness of the lumbosacral curve."
219083240|NCT05304169|DRUG|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
219211873|NCT06886490|OTHER|Control diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Control diet: Reduce consumption of red meat, consumption of poultry, fish and seafood and their products, regular consumption of eggs and dairy products.
219083241|NCT00002258|DRUG|Interleukin-3|
219211874|NCT05634005|BEHAVIORAL|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
219083242|NCT02044185|DRUG|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
219211875|NCT06790108|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
219211876|NCT06793683|DRUG|Bladder chemodenervation (Botox)|BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).
219211877|NCT06793683|PROCEDURE|Bladder Sham (Saline) Injection Procedure|20mL placebo (saline only), will be injected into the detrusor (bladder wall muscle).
219211878|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
219211879|NCT06909227|PROCEDURE|surgery under general anesthesia|Only in children, \< 1 year old non-cardiac surgery
219211880|NCT02666898|DRUG|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD \>10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
219211881|NCT02666898|DRUG|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~* patients in CR with BM MRD \< 10-4 : Ibrutinib alone 420mg daily~* patients with BM MRD \>10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
219083243|NCT00561210|DIETARY_SUPPLEMENT|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
219083244|NCT00561210|DIETARY_SUPPLEMENT|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
219083245|NCT01696201|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
219211882|NCT02666898|DRUG|Cyclophosphamide|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
219211883|NCT02666898|DRUG|Fludarabine|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
219083246|NCT00975312|DRUG|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
219083247|NCT00975312|DRUG|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
219083248|NCT04540874|DRUG|BI 894416|BI 894416
219211884|NCT05252390|DRUG|NUV-868|NUV-868 is an investigational drug for oral dosing.
219211885|NCT05252390|DRUG|Olaparib|Olaparib
219211886|NCT05252390|DRUG|Enzalutamide|Enzalutamide
219211887|NCT05353257|DRUG|HLX10|"Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
219083249|NCT04540874|DRUG|Placebo|Placebo
219083250|NCT03115892|DRUG|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
219083251|NCT03115892|DRUG|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
219211888|NCT05353257|DRUG|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
219211889|NCT05353257|RADIATION|Thoracic radiotherapy|Standard Thoracic Radiotherapy
219211890|NCT05353257|DRUG|Placebo|Placebo Q3W
219211891|NCT05353257|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
219211892|NCT03997474|BIOLOGICAL|ATL001|ATL001 infusion
219211893|NCT03997474|DRUG|Checkpoint Inhibitor|Nivolumab
219211894|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
219211895|NCT06215469|DEVICE|Amma Portable Scalp Cooling System (PSCS)|The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.
219211896|NCT06215469|OTHER|Questionnaires|Quality of Life (QoL) and device usage questionnaires
219211897|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
219083252|NCT06405503|OTHER|NO INTERVENTION|NO INTERVENTION - OBSERVATIONAL ONLY
219211898|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
219083253|NCT02451527|DRUG|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
219083254|NCT02451527|DRUG|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
219083255|NCT04407390|DIETARY_SUPPLEMENT|Nicotinamide riboside|The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.
219083256|NCT04407390|DIETARY_SUPPLEMENT|Placebo|Placebo
219083257|NCT02029079|DIETARY_SUPPLEMENT|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
219083258|NCT03208023|PROCEDURE|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
219083259|NCT03208023|OTHER|No intervention|No intervention
219083260|NCT04924231|BEHAVIORAL|astigmatism|astigamatism at least 1 month after the cataract surgery
219083261|NCT05046054|DEVICE|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
219083262|NCT05046054|DEVICE|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
219083263|NCT03223974|DEVICE|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for \>30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
219083264|NCT03223974|DEVICE|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
219083265|NCT00349479|BEHAVIORAL|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
219211899|NCT06864507|DRUG|HS-10561|Single and multiple doses of HS-10561 orally
219211900|NCT06864507|DRUG|Placebo|Placebo
219211901|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
219211902|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
219211903|NCT06774924|DEVICE|Echoscopy examination using the echOpen probe|"In addition to standard care, each patient will have a systematic 4-point echoscopy examination using the echOpen probe: liver, spleen, lymph nodes, thyroid and, depending on symptoms, lung, kidney, bladder, abdomen.~The echOpen probe is CE marked. It will be used for all indications except certain areas of the body (thyroid, lymph nodes, bladder, liver, spleen, kidney, bladder and lymph nodes).~In addition to echoscopy with the echOpen probe, patient and physician satisfaction questionnaires will be used as part of this study."
219083266|NCT03917368|OTHER|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
219083267|NCT02115633|DEVICE|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
219083268|NCT02115633|DEVICE|Walkasins OFF|Subjects will be wearing a device that is turned off.
219083269|NCT01786967|DRUG|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
219083270|NCT04653766|DRUG|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
219083271|NCT04653766|DRUG|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
219083272|NCT04653766|DRUG|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
219083273|NCT04653766|DRUG|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
219083274|NCT04653766|DRUG|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
219083275|NCT01563536|DRUG|ABT-267|Tablet
219083276|NCT01563536|DRUG|ABT-450|Tablet
219083277|NCT01563536|DRUG|ABT-333|Tablet
219083278|NCT01563536|DRUG|Ritonavir|Capsule
219083279|NCT01563536|DRUG|Ribavirin|Tablet
219211904|NCT06752252|PROCEDURE|ultrasound guided paravertebral block|after sterilization and identifying the level of T10 ,linear ultrasound probe will be placed in the midline over the spinous process at the chosen level, then the probe will be moved laterally to view the lamina and hyperechoic transverse process ,the pleural should be visible as a bright white line .The needle should be inserted in -plane from lateral to medial and the needle tip should end in a hypoechoic triangular space. Correct needle placement should be confirmed by anterior displacement of pleura with injection of small volume of saline then 0.5 ml/kg of a mixture of 0.25 ℅ bupivacaine and 1℅ lidocaine (1:1) will be injected
219211905|NCT06752252|PROCEDURE|Ultrasound guided erector spinae plane block|After sterilization, the linear ultrasound probe will be placed over transverse process of T10 ,after optimizing the image in sagittal or transverse scanning ,A 50 mm 22-G needle will be placed under the erector spinae muscle in -in plane orientation until it contacted T8 transverse process in the cranial caudal direction ,after hydro dissection and confirmation that the tip of the needle is between the transverse process and the fascia of the erector spinae muscle group, 0.5 ml/kg of a mixture of 0.25 ℅bupivacaine and 1℅ lidocaine (1:1) will be injected
219083280|NCT03156660|BEHAVIORAL|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps"
219083281|NCT03156660|BEHAVIORAL|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps"
219083282|NCT03156660|BEHAVIORAL|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale"
219211906|NCT06752252|PROCEDURE|control group C|will receive standard general anesthesia with pain management protocol without regional block.
219211907|NCT06734637|DRUG|Peginterferon α-2b injection|Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
219083283|NCT05232695|DIAGNOSTIC_TEST|metabolically healthy obese|Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
219083284|NCT01270126|DEVICE|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
219083285|NCT00538590|DEVICE|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
219083286|NCT00538590|DRUG|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
219083287|NCT06059222|DRUG|Romosozumab|Romosozumab 210 mg/2.34 ml from baseline to month 11
219083288|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 12
219083289|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
219083290|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 6
219083291|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5
219211908|NCT06181500|OTHER|Home-based multicomponent exercise intervention program|A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
219211909|NCT06825455|DRUG|Fludarabine|Intravenous infusion group:30mg/m2 x 3 days (Day-4\~-2)
219211910|NCT06825455|DRUG|Cyclophosphamide|Intravenous infusion group:500mg/m2 x 3 days (Day-4\~-2)
219083292|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 5 and month 18
219083293|NCT04240366|PROCEDURE|Control intervention|patients treated with balloon-based ablation of AF by PVI
219083294|NCT04240366|PROCEDURE|Experimental intervention|patients treated with balloon-based ablation of AF by PVI
219083295|NCT06333587|PROCEDURE|image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
219083296|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
219211911|NCT06825455|BIOLOGICAL|B7H3 CAR-γδT cells|A single infusion of 6.0×107 CAR+ cells, 2.0×108CAR+ cells, and 6.0×108CAR+ cells
219211912|NCT06864260|OTHER|Built Environment|Built environment modifications include sidewalks, sidewalk cuts, traffic-calming devices, crosswalks, transit improvements, green space, street trees, beautification, signage, lighting, wellness van
219211913|NCT06864260|OTHER|Social Environment|Neighborhood coalition, Community Leadership Academy (LHSA), community-led events, community health workers
219211914|NCT06883370|COMBINATION_PRODUCT|ultrasound-guided transversals fascia plane block with ropivacaine|using 0.375% ropivacaine of 0.4mls/kg
219083297|NCT03136445|DRUG|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
219083298|NCT03136445|DRUG|Placebo|IV (saline) or oral placebo tablets
219211915|NCT06818604|DEVICE|CPAP|Participants randomized to this group will receive auto-CPAP therapy. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre. Settings will be adjusted to achieve a device efficacy index \< 5 events per hour.
219211916|NCT06818604|DEVICE|BiPAP|Participants will receive BiPAP S mode therapy for 4 weeks. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre with initial settings of IPAP 8 cmH2O and EPAP 3 cmH2O. Settings will be modified to a maximum tolerated level to achieve a tidal volume of 8 mL/kg ideal body weight and SpO2 \> 95%. Overnight oximetry will be performed to ensure at least 4 hours of device use, and settings will be adjusted to achieve a DEI \< 5 events per hour.
219211917|NCT06870045|OTHER|Physical examination|The physical examination will included Timed Up and Go Test (TUG), Walking speed, Wong-Baker FACES Pain Scale, Pediatric balance scale and CHAQ (Childhood Health Assessment Questionnaire).
219211918|NCT06870045|OTHER|Dynamic Gait Index|The DGI, whose validity and reliability will be investigated, consists of 8 items: walking on level ground, walking with changing speed, walking with sideways head turns, walking with vertical head turns, walking with pivot turns, walking over obstacles, going around obstacles, and climbing stairs. Performance on each item is rated on a 4-point scale ranging from 0 (severe impairment) to 3 (normal walking ability without a walking aid). The total score is 24. Scores below 19 indicate a risk of falling, while scores above 22 define safe ambulation.
219083299|NCT06974591|OTHER|Dental splints|Each participant will receive six custom-made dental splints to incrementally increase their VDO. These splints will alter the VDO in increments from 5 to 30 mm, specifically: 5, 10, 15, 20, 25, and 30 mm.
219083300|NCT06974591|OTHER|Dentures|Participants in this group will participate in balance and gait testing both with and without their dentures to examine how the presence or absence of dentures affects postural stability and movement.
219083301|NCT05625191|DIAGNOSTIC_TEST|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
219083302|NCT05625191|DIAGNOSTIC_TEST|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
219083303|NCT04526795|DRUG|Cytarabine|Given IV
219083304|NCT04526795|DRUG|Fludarabine|Given IV
219083305|NCT04526795|DRUG|Pegcrisantaspase|Given IV
219083306|NCT03772067|DEVICE|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
219211919|NCT06885099|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
219083307|NCT03772067|DIAGNOSTIC_TEST|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
219083308|NCT03772067|DIAGNOSTIC_TEST|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
219083309|NCT03772067|DIAGNOSTIC_TEST|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
219211920|NCT06860802|DRUG|Cefoxitin|Cefoxitin 2000 mg Bolus Injection
219211921|NCT06864429|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency (RF) catheter ablation is a minimally invasive procedure that targets and eliminates certain types of cardiac arrhythmias. RF became effective as the first-line treatment for ventricular arrhythmias in some circumstances.
219211922|NCT04670536|DEVICE|PASS LP implants|Thoraco lumbar arthrodesis
219211923|NCT04670536|DEVICE|PASS DEGEN|Thoraco lumbar arthrodesis
219083310|NCT03772067|DIAGNOSTIC_TEST|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
219083311|NCT03772067|DIAGNOSTIC_TEST|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
219083312|NCT03772067|DIAGNOSTIC_TEST|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
219211924|NCT04670536|DEVICE|PASS TULIP PRIME|Thoraco lumbar arthrodesis
219681362|NCT02661230|DEVICE|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
219681363|NCT01342575|PROCEDURE|Intra-operative exposure maneuvers|"* Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
219681364|NCT03049228|DIAGNOSTIC_TEST|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
219681365|NCT03049228|DIAGNOSTIC_TEST|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
219681366|NCT03049228|DIAGNOSTIC_TEST|Blood analysis|To determine blood glucose metabolism and renal function.
219681367|NCT03049228|DIAGNOSTIC_TEST|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
219211925|NCT03263546|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
219083313|NCT03772067|DIAGNOSTIC_TEST|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
219083314|NCT03772067|DIAGNOSTIC_TEST|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
219083315|NCT03772067|OTHER|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
219083316|NCT03772067|DIAGNOSTIC_TEST|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
219083317|NCT05411965|DRUG|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
219083318|NCT05411965|DRUG|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
219083319|NCT05411965|DRUG|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
219083320|NCT06200766|DRUG|Mometasone furoate as a nasal spray|Subjects received 2 presses in each side nostrils at the same time point (± 1h).
219211926|NCT03263546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
219211927|NCT06748820|BEHAVIORAL|Remote Therapeutic Patient Education (e-TPE)|TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers
219211928|NCT06827288|BEHAVIORAL|SUN|The SUN helps patients initiate buprenorphine treatment in the hospital, connects patients to follow-up care by facilitating appointments at outpatient clinics, addresses barriers to care, and serves as a resource for patients and clinicians. The SUN also advocates for a harm-reduction culture, models respectful interactions with people who use drugs and provides technical assistance to hospital staff to reduce stigma and discrimination.
219211929|NCT06827288|BEHAVIORAL|SUN + Telebridge|TeleBridge consists of an immediate telehealth connection to a buprenorphine provider affiliated with the CA Bridge program who has expertise facilitating pharmacotherapy with individuals with OUD. TeleBridge addresses barriers to initiation of buprenorphine by reducing long wait times and the inability of the outpatient setting to initiate treatment on demand. TeleBridge also eliminates the need for patients to meet system-level requirements (e.g. on time for appointments during working hours while wearing appropriate attire) to obtain follow-up care. TeleBridge is a more resource-intensive form of care because it involves developing formalized relationships with outpatient providers and implementing telehealth protocols. TeleBridge is feasible based on the increased use of telehealth to expand post-ED care pathways.
219211930|NCT06827288|BEHAVIORAL|ED-ITT|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report nonadherence to the prescribed BUP are considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment by an ED-based interim treatment team (ED-ITT), the SUN and Site PI (an ED physician with expertise in addiction medicine) will meet weekly to review the SUN's caseload, using a patient registry that has been modified for the trial. The registry: 1) prompts/documents proactive SUN outreach up to 3 additional months for non-responders, with an emphasis on prioritizing subsequent outreach to patients who have not yet engaged with outpatient care, or who are at risk of dropping out if the patient have transitioned; and 2) documents when the ED provider prescribes transitional BUP and when the patient would be due for a new prescription.
219211931|NCT06827288|BEHAVIORAL|ED-ITT + BHS|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report to the SUN nonadherence to the prescribed BUP will be considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment from the ED-ITT+BHS, Behavioral Health Support (BHS) will be added to ED-ITT and include a weekly caseload review with an externally-affiliated psychiatrist with expertise in addiction medicine who will make mental health and substance use treatment recommendations, both pharmacological and behavioral, to the ED provider and SUN for up to 3 months. The consultant may also ask the SUN to do a more detailed behavioral health assessment, if insufficient information is available to make treatment recommendations. All prescriptions will be written by the ED provider.
219211932|NCT06757114|OTHER|High altitude|High altitude is defined as a long-term residence with an altitude of 1500m and above
219211933|NCT06741592|DEVICE|EDDY Group|The EDDY activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
219211934|NCT06741592|DEVICE|PUI Group|The passive ultrasonic activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
219211935|NCT06775795|DIETARY_SUPPLEMENT|Oat milk|Participants will consume one portion of plant-based milk alternative (oat) which will provide approximately 200 µg of iodine
219211936|NCT06775795|DIETARY_SUPPLEMENT|Soya milk|Participants will consume one portion of plant-based milk alternative (soya) which will provide approximately 200 µg of iodine
219211937|NCT06775795|DIETARY_SUPPLEMENT|Cow's milk|Participants will consume one portion of semi-skimmed cow's milk which will provide approximately 200 µg of iodine
219211938|NCT06747169|DRUG|Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin|All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
219083321|NCT04656834|PROCEDURE|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
219083322|NCT04656834|PROCEDURE|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
219083323|NCT03292250|DRUG|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
219083324|NCT03292250|DRUG|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
219083325|NCT03292250|DRUG|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
219083326|NCT03292250|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
219083327|NCT03292250|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
219211939|NCT05652400|OTHER|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
219211940|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
219211941|NCT06788925|DEVICE|Patients support with survival coverage|"Following calls to emergency medical services, handled by the ground SMUR/SAMU or the air SMUR (HéliSMUR), the operator collects essential information on the nature of the incident and the apparent condition of the injured. A medical team is thus mobilized on site. It takes over from the rescue team (e.g. the SDIS fi refi ghters) who are generally the fi rst to arrive on the scene.~Eligible patients will be randomly assigned consecutively to one of two groups: control (use of the survival blanket) and experimental (use of the Therm'Up breastplate).~Any traumatized person at risk of hypothermia or in hypothermia in a pre-hospital environment, having given verbal consent to participate in the study and meeting the inclusion criteria"
219083328|NCT05040451|DEVICE|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~* An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~* A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
219083329|NCT05308329|DEVICE|Intra-coronary imaging device|Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
219083330|NCT05308329|BEHAVIORAL|PCI procedural characteristics|Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
219083331|NCT05330065|DRUG|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
219083332|NCT01352598|RADIATION|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
219083333|NCT04023240|DRUG|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
219083334|NCT04023240|PROCEDURE|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
219083335|NCT04023240|PROCEDURE|Positron Emission Tomography (PET) scan|PET images will be acquired.
219211942|NCT06788925|DEVICE|Patients support with active thermic jacket|The intervention Description is exactly the same, except that the patient will be given a ThermUp jacket
219211943|NCT06746142|RADIATION|Deep inspiration breath hold radiotherapy|Participants will be trained for 2-3 days for obtaining the desired breathing cycle by trained technologists. No extra equipment will be needed. At first, they will be assured and asked to relax. Then instructed to breath in and out twice followed by a slow, deep breath in to a comfortable higher level than normal and to hold it for at least 20 seconds then again breath normally. Once they are ready with expected breath holding, simulation will be done. Treatment will also be given in this breath holding position.
219211944|NCT06746142|RADIATION|Free breathing radiotherapy|Patient will be advised for free breathing during simulation and treatment.
219681368|NCT03049228|DIAGNOSTIC_TEST|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
219681369|NCT01301261|DRUG|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
219083336|NCT00327626|DRUG|ISIS 113715|
219083337|NCT05725317|DEVICE|LID220365 contact lens|Investigational delefilcon A spherical contact lens made with a modified manufacturing process
219083338|NCT05725317|DEVICE|LID006961 contact lens|Commercially available delefilcon A spherical contact lens
219083339|NCT05568433|DIAGNOSTIC_TEST|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
219083340|NCT02096523|OTHER|Blood collection for platelet protein samples|
219083341|NCT05945433|DEVICE|anovo™ Surgical System|The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
219083342|NCT04414267|BIOLOGICAL|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
219083343|NCT04414267|BIOLOGICAL|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
219083344|NCT06313580|OTHER|Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
219083345|NCT06313580|OTHER|Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
219083346|NCT03661411|DRUG|Aspirin|100mg qd
219083347|NCT03661411|DRUG|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
219083348|NCT03661411|DRUG|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
219681370|NCT01301261|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
219681371|NCT01301261|DRUG|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
219083349|NCT03691116|BEHAVIORAL|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
219083350|NCT03691116|BEHAVIORAL|Treatment as usual|Ordinary psychological assessment and counseling.
219211945|NCT04980300|BEHAVIORAL|Intervention|Participants in the Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
219211946|NCT04980300|BEHAVIORAL|Control|Participants in the Control arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
219211947|NCT06740188|DRUG|5-hydroxytryptamine balanced antidepressants trazodone|The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
219211948|NCT06740188|DRUG|Citalopram hydrobromide combined with zolpidem|the control group was given citalopram hydrobromide combined with zolpidem
219211949|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
219211950|NCT04248335|DRUG|Pantoprazole|single-dose administration
219211951|NCT04248335|DRUG|Midazolam injection|single-dose administration
219211952|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
219211953|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
219211954|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
219211955|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
219083351|NCT04115111|DRUG|Durvalumab|Durvalumab in monotherapy as second line treatment
219211956|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
219211957|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
219211958|NCT04972292|DRUG|FDC of codeine 30 mg/dipyrone 500 mg|Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
219211959|NCT04972292|DRUG|Tylex|Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
219211960|NCT06733740|PROCEDURE|ultrasound-guided thermal ablation|ultrasound-guided thermal ablation to treat tumor
219211961|NCT06819748|DRUG|The cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone|The patient receive the cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone as incision local anesthesia at the end of surgery
219211962|NCT06819748|DRUG|0.5% ropivacaine|The patient receive 0.5% ropivacaine as incision local anesthesia at the end of surgery
219211963|NCT06827730|DIAGNOSTIC_TEST|Point of care ultrasound|The investigator uses PoCUS to investigate thoracic or abdominal pain after anamnesis and clinical examination. The investigator reports the anamnesis, clinical examination, and PoCUS results in the patient's medical file. PoCUS images are recorded according to the procedures of the study centers and the capacities of the ultrasound machines.
219083352|NCT00005600|PROCEDURE|management of therapy complications|
219083353|NCT03610126|PROCEDURE|volume controlled ventilation|the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
219083354|NCT03610126|PROCEDURE|pressure controlled ventilation|the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
219083355|NCT01235468|BIOLOGICAL|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
219083356|NCT00501254|DRUG|Slow release acetyl salicylic acid|
219211964|NCT06778603|DRUG|a targeted probe B7H3-IRDye800CW|B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
219211965|NCT06802952|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
219211966|NCT06918340|DRUG|Diclofenac|Group II: 5-6 puffs of topical 1% diclofenac spray will be applied before radial artery blood gas sampling.
219681372|NCT05618015|PROCEDURE|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
219681373|NCT05618015|PROCEDURE|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
219083357|NCT00501254|BEHAVIORAL|Antithrombotic effect|
219083358|NCT03682718|DEVICE|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
219083359|NCT03682718|DRUG|Misoprostol|Misoprstol inserted vaginally for induction of labor
219211967|NCT06918340|DRUG|Lidocaine spray|Group I: 5-6 puffs of topical 10% lidocaine spray will be applied before radial artery blood gas sampling.
219211968|NCT06918340|OTHER|Placebo|Group III: 5-6 puffs of topical 70% alcohol solution spray will be applied before radial artery blood gas sampling.
219211969|NCT06931717|DRUG|Cemiplimab|Cemiplimab, 350 mg i.v., every 3 weeks (±3 days), for 4 cycles, followed by 700 mg i.v., every 6 weeks (±1 week) for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first.
219211970|NCT05364762|DRUG|Cyclophosphamide|Given IV
219211971|NCT05364762|DRUG|Itacitinib|Given PO
219211972|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
219211973|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
219211974|NCT05364762|DRUG|Tacrolimus|Given IV or PO
219211975|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
219211976|NCT06786715|DEVICE|Retrograde intrarenal surgery using DISS|Retrograde intrarenal surgery using Direct in scope suction for renal stone up to 3 cm
219211977|NCT06786715|DEVICE|Retrograde intrarenal surgery using FANS|Retrograde intrarenal surgery using Flexible and navigable suction for renal stone up to 3 cm
219211978|NCT05774002|BEHAVIORAL|Aims to Decrease Anxiety and Pain Treatment (ADAPT)|One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
219681374|NCT03556969|OTHER|Observation|no intervention
219681375|NCT03816553|DRUG|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
219681376|NCT03816553|DRUG|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
219681377|NCT04531748|DRUG|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
219681378|NCT04531748|DRUG|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
219681379|NCT04531748|OTHER|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
219681380|NCT04552600|DRUG|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
219681381|NCT04552600|OTHER|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
219681382|NCT00614874|DRUG|rosiglitazone|2mg, 4mg, 8mg
219681383|NCT04071782|DEVICE|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
219681384|NCT04488913|OTHER|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
219681385|NCT04488913|OTHER|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
219681386|NCT03019900|PROCEDURE|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
219681387|NCT04584515|DRUG|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
219681388|NCT04584515|DRUG|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
219681389|NCT00026247|PROCEDURE|pain therapy|
219681390|NCT00026247|PROCEDURE|radiofrequency ablation|
219681391|NCT04996966|BIOLOGICAL|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
219681392|NCT04996966|OTHER|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
219681393|NCT02993835|OTHER|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
219681394|NCT02993835|OTHER|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
219681395|NCT02993835|OTHER|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
219681396|NCT05090202|DIAGNOSTIC_TEST|hbA1C|hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
219211979|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
219681397|NCT06011694|OTHER|MERCURY test, health questionnaires and annual routine physical exams|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
219681398|NCT05610488|DRUG|FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]|Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
219681399|NCT02233699|DRUG|XEN-D0501|
219681400|NCT02233699|DRUG|Placebo|
219681401|NCT00372632|DRUG|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
219681402|NCT00372632|DRUG|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
219681403|NCT02597309|DRUG|Canagliflozin|
219681404|NCT05699512|BEHAVIORAL|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
219681405|NCT05604365|BEHAVIORAL|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
219211980|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
219083360|NCT03337646|DRUG|Lisdexamfetamine Dimesylate|Medication to treat ADHD
219083361|NCT00671931|DRUG|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
219083362|NCT00671931|DRUG|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
219083363|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
219083364|NCT00671931|DRUG|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
219211981|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
219211982|NCT05452941|DIAGNOSTIC_TEST|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
219211983|NCT02377700|DEVICE|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
219211984|NCT06324240|BIOLOGICAL|Ipilimumab|Given IV
219211985|NCT06324240|BIOLOGICAL|Pembrolizumab|Given IV
219211986|NCT06324240|BIOLOGICAL|Vaccine Therapy|Given TMV vaccine ID
219211987|NCT01078909|BIOLOGICAL|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
219211988|NCT05152849|DRUG|AXA1125|AXA1125 administered BID with or without food
219211989|NCT05152849|DRUG|Placebo|Matching Placebo administered BID with or without food
219083365|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
219083366|NCT06270654|PROCEDURE|Erector spinae plane block|"After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side."
219211990|NCT03140670|DRUG|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
219211991|NCT00569634|PROCEDURE|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
219681406|NCT02909790|DEVICE|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
219681407|NCT03165773|OTHER|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
219083367|NCT06270654|PROCEDURE|Skin infiltration LA|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
219083368|NCT04369014|DRUG|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
219083369|NCT04369014|DRUG|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
219083370|NCT02251327|DEVICE|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
219083371|NCT04419948|OTHER|White bread|White bread (120g) containing 54 g CHO
219211992|NCT00792337|DRUG|simvastatin|10 mg per oral once daily for 8 weeks
219211993|NCT00792337|DRUG|B1-6-12|1 table per day for 8 weeks
219681408|NCT03165773|OTHER|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
219681409|NCT03582384|DRUG|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
219083372|NCT04419948|OTHER|Butter|Butter 39 g
219083373|NCT04419948|OTHER|Refined olive oil|Refined olive oil (40 ml).
219083374|NCT04419948|OTHER|EVOO with 250 mg/kg oleocanthal|Extra virgin olive oil containing 250 mg/kg oleocanthal.
219083375|NCT04419948|OTHER|EVOO with 500 mg/kg oleocanthal|Extra virgin olive oil containing 500 mg/kg oleocanthal.
219083376|NCT04419948|OTHER|Ibuprofen|Ibuprofen 400 mg
219083377|NCT02118129|BEHAVIORAL|an educational video|
219083378|NCT02118129|OTHER|wait listed|
219083379|NCT02460692|DRUG|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
219083380|NCT02460692|DRUG|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
219083381|NCT02460692|DRUG|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
219083382|NCT00816881|DEVICE|flutter mucus clearance device|five minutes every session, four sessions per day
219083383|NCT03619460|PROCEDURE|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
219083384|NCT03619460|PROCEDURE|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
219083385|NCT03084926|DRUG|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
219211994|NCT02377193|DRUG|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
219211995|NCT02377193|DRUG|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
219211996|NCT00220805|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
219211997|NCT00220805|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
219211998|NCT01355172|BIOLOGICAL|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
219211999|NCT03351400|BIOLOGICAL|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
219212000|NCT02984345|OTHER|Mycoprotein beverage|Mycoprotein protein beverage
219212001|NCT02984345|OTHER|Milk protein beverage|Milk protein beverage
219212002|NCT06453174|OTHER|Adherence to the first prescribed antipsychotic medication|We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
219212003|NCT05370378|OTHER|Hold Relax with Agonist Contraction|"1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
219083386|NCT04437940|DIAGNOSTIC_TEST|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
219083387|NCT04616261|BEHAVIORAL|Training|6 weeks of training
219083388|NCT04616261|DRUG|Formoterol|inhalation of 54 microg formoterol
219083389|NCT04616261|DRUG|Placebo|inhalation of placebo
219681410|NCT05758896|DRUG|Isuzinaxib (APX-115)|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
219681411|NCT05758896|DRUG|Placebo|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
219681412|NCT03722082|BEHAVIORAL|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
219681413|NCT03722082|BEHAVIORAL|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
219681414|NCT06171854|DRUG|Cabozantinib|cabozantinib in patients with refractory mCRC
219681415|NCT04583605|DEVICE|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
219681416|NCT06386380|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.
219083390|NCT00003500|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219083391|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
219083392|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
219681417|NCT06386380|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30
219681418|NCT06386380|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.
219681419|NCT06386380|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
219212004|NCT05370378|OTHER|Active Release Therapy|"1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
219212005|NCT05320094|DRUG|Mavacamten|Specified dose on specified days
219212006|NCT05320094|DRUG|Activated Charcoal with Sorbitol|Specified dose on specified days
219212007|NCT05142215|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
219212008|NCT05142215|PROCEDURE|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
219212009|NCT06579157|OTHER|Pressure-Sensing Mattresses|using ballistocardiography (BCG) for monitoring respiration and heart rate in neonates
219212010|NCT00387452|BEHAVIORAL|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
219212011|NCT00387452|BEHAVIORAL|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
219212012|NCT04029909|DRUG|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
219212013|NCT04029909|DRUG|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
219212014|NCT04029909|DRUG|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
219212015|NCT05611060|BEHAVIORAL|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
219212016|NCT04657172|DRUG|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
219212017|NCT04657172|DRUG|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
219212018|NCT01321164|DEVICE|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
219212019|NCT01321164|DRUG|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
219212020|NCT00168415|BIOLOGICAL|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
219083393|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
219083394|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
219083395|NCT06217367|DRUG|50 mg Diphenhydramine|Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
219083396|NCT06217367|DRUG|10 mg Loratadine|Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
219083397|NCT06217367|DRUG|5 mg Desloratadine|Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
219083398|NCT06217367|OTHER|Placebo (Sugar Pill)|Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
219083399|NCT00455065|BEHAVIORAL|Whole Grain Foods|
219083400|NCT04845048|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
219083401|NCT02507648|DRUG|Oseltamivir|1 tablet contains 75 mg oseltamivir
219083402|NCT02507648|DRUG|Tamiflu®|1 tablet contains 75 mg oseltamivir
219083403|NCT02151266|BEHAVIORAL|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
219083404|NCT02151266|BEHAVIORAL|Exercise Only|
219083405|NCT02151266|BEHAVIORAL|Stretching and Flexibility|
219083406|NCT03511755|DEVICE|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
219083407|NCT01723722|DRUG|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
219083408|NCT01723722|DRUG|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
219083409|NCT02771743|DRUG|Cisplatin|
219083410|NCT02771743|DRUG|Doxorubicin|
219083411|NCT02771743|DRUG|Etoposide|
219083412|NCT02771743|DRUG|Cyclophosphamide|
219083413|NCT02771743|DRUG|Ifosfamide|
219083414|NCT02771743|DRUG|Carboplatin|
219083415|NCT02771743|PROCEDURE|Tandem HDCT/auto-SCT|
219083416|NCT02771743|RADIATION|Radiotherapy|
219083417|NCT02771743|DRUG|Interleukin-2|
219083418|NCT02771743|DRUG|Isotretinoin|
219083419|NCT02771743|RADIATION|MIBG|
219212021|NCT04139005|BEHAVIORAL|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
219083420|NCT03816774|DRUG|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
219083421|NCT03439774|DEVICE|Topcon CT-800|tonometer
219083422|NCT03439774|DEVICE|Topcon TRK-2P|tonometer, pachymeter
219212022|NCT04139005|BEHAVIORAL|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
219212023|NCT04139005|BEHAVIORAL|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
219212024|NCT00220675|DRUG|Erythropoietin infusion|
219212025|NCT02203500|DRUG|Lacidipine|
219212026|NCT02203500|DRUG|Telmisartan|
219212027|NCT00042731|DIETARY_SUPPLEMENT|Lycopene|Daily administration as outlined in treatment arm(s)
219212028|NCT00042731|DIETARY_SUPPLEMENT|Multivitamin|Daily administration as outlined in treatment arm(s)
219212029|NCT00042731|DIETARY_SUPPLEMENT|Soy isoflavones|Daily administration as outlined in treatment arm(s)
219212030|NCT00283205|BEHAVIORAL|Yoga|
219212031|NCT02201888|BEHAVIORAL|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
219212032|NCT02201888|OTHER|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
219212033|NCT02201888|OTHER|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
219212034|NCT03985774|PROCEDURE|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
219212035|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
219212036|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
219212037|NCT04502381|DRUG|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
219083423|NCT02262533|DRUG|Apixaban|
219212038|NCT04502381|DRUG|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
219212039|NCT00176800|DRUG|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
219212040|NCT00176800|PROCEDURE|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
219212041|NCT00176800|PROCEDURE|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
219212042|NCT04633941|OTHER|Standard Care|Standard Care
219212043|NCT02446145|DRUG|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
219212044|NCT02446145|DRUG|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
219681420|NCT06386380|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.
219083424|NCT02262533|DRUG|Atenolol|
219083425|NCT03123965|DRUG|glecaprevir|Glecaprevir will be administered orally.
219083426|NCT03123965|DRUG|pibrentasvir|Pibrentasvir will be administered orally.
219083427|NCT03011632|DRUG|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
219083428|NCT03011632|DRUG|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
219212045|NCT06367023|BEHAVIORAL|Rajyoga Meditation Practice|The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
219083429|NCT05812001|BEHAVIORAL|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
219212046|NCT04801706|DIAGNOSTIC_TEST|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
219212047|NCT01964300|BIOLOGICAL|peginterferon alfa-2b|Given subcutaneously (SC)
219083430|NCT05812001|BEHAVIORAL|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
219083431|NCT02354664|OTHER|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
219083432|NCT02354664|OTHER|Spirometry|Upright forced vital capacity (FVC)
219083433|NCT02354664|OTHER|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
219083434|NCT02354664|OTHER|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
219083435|NCT02354664|OTHER|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
219083436|NCT02354664|OTHER|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
219083437|NCT03987841|BEHAVIORAL|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
219083438|NCT05197894|DEVICE|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
219083439|NCT01763879|OTHER|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
219083440|NCT01763879|OTHER|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
219083441|NCT03875027|PROCEDURE|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
219083442|NCT00098969|DRUG|resveratrol|
219083443|NCT03757221|COMBINATION_PRODUCT|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
219083444|NCT00137566|DRUG|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
219083445|NCT00137566|OTHER|Placebo|
219083446|NCT01105611|DRUG|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
219083447|NCT01105611|DRUG|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
219083448|NCT04896268|DEVICE|Radiofrequency|Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
219083449|NCT04896268|DEVICE|Arterial ligation then recto-anal repair with Doppler|"The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return."
219083450|NCT01265355|DIETARY_SUPPLEMENT|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
219083451|NCT01265355|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 1 gm daily
219083452|NCT02635802|DRUG|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
219212048|NCT01964300|OTHER|laboratory biomarker analysis|Correlative studies
219083453|NCT02635802|DRUG|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
219083454|NCT02635802|DRUG|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
219083455|NCT02635802|DRUG|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
219083456|NCT04823260|DRUG|Nicotinamide Mononucleotide|Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
219212049|NCT06210659|BEHAVIORAL|Theory of Planned Behavior Based Training Program|"Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles."
219212050|NCT04495426|OTHER|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
219212051|NCT00186784|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
219212052|NCT03592797|OTHER|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
219212053|NCT03592797|OTHER|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
219212054|NCT04484675|DRUG|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
219212055|NCT04484675|DRUG|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
219212056|NCT03753932|DEVICE|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
219212057|NCT00926354|DRUG|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
219212058|NCT01032668|DRUG|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
219212059|NCT05561231|PROCEDURE|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
219212060|NCT05561231|PROCEDURE|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
219212061|NCT03183050|BEHAVIORAL|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
219212062|NCT01692769|DRUG|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
219212063|NCT01692769|DRUG|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
219212064|NCT01281657|DRUG|fingolimod|
219083457|NCT04823260|OTHER|Placebo|Rice flour in white capsule resembling NMN
219083458|NCT02355028|DRUG|LHA510 ophthalmic suspension|
219083459|NCT02355028|DRUG|LHA510 vehicle|Inactive ingredients used as a placebo comparator
219083460|NCT02355028|DRUG|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
219083461|NCT02276222|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
219083462|NCT02276222|DRUG|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
219083463|NCT03948191|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
219212065|NCT01215747|DRUG|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
219212066|NCT01215747|DRUG|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
219212067|NCT02705976|OTHER|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
219212068|NCT02705976|OTHER|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
219681421|NCT06386380|OTHER|Brief Resilient Coping Scale|The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.
219083464|NCT03948191|DRUG|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
219083465|NCT05290831|DEVICE|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
219212069|NCT06951646|DRUG|Ivonescimab plus docetaxel|"For ctDNA-positive patients, escalation treatment will be administrated~1. Ivonescimab: Intravenous infusion (IV), 20 mg/kg, Day 1, every 3 weeks (Q3W);~2. Docetaxel: IV, 75 mg/m², Day 1, Q3W (The investigator may adjust the chemotherapy dose and schedule based on the patient's tolerance during treatment.)~All enrolled participants will continue treatment until one of the following occurs, whichever comes first:~* The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status)~* Unacceptable toxicity~* Completion of 24 months of treatment~* Other discontinuation criteria specified in the protocol are met."
219212070|NCT06951646|OTHER|Standard Treatment|"For ctDNA-positive patients, continuing the original immunotherapy maintenance or immunotherapy combined with chemotherapy~• In the event of clinical progression, consider switching to treatment with Ivonescimab plus docetaxel, administered every 3 weeks."
219212071|NCT05994131|DRUG|IN10018|orally taken once daily
219212072|NCT05994131|DRUG|Furmonertinib|orally taken once daily
219212073|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
219083466|NCT03668587|OTHER|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
219083467|NCT06324266|DRUG|Cyclophosphamide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
219083468|NCT06324266|DRUG|Lenalidomide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
219083469|NCT03655795|BIOLOGICAL|Bronchial basal cells|Autologous transplantation of bronchial basal cells
219083470|NCT02115880|BEHAVIORAL|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
219212074|NCT00754065|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
219212075|NCT00754065|DRUG|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
219212076|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
219212077|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
219212078|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
219681422|NCT06386380|GENETIC|Expression of CDKN2A /p16INK4a|CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.
219681423|NCT06386380|OTHER|Immunophenotype of leukocyte subpopulations|CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).
219681424|NCT06386380|GENETIC|Telomere length|The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.
219681425|NCT06386380|OTHER|Cellular senescence|Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
219681426|NCT06231134|DEVICE|Conventional surgery|an implant will be exposed using the conventional surgical exposure techniques with a tissue punch, the cover screw will be removed, and the healing abutment placed
219083471|NCT05982457|BEHAVIORAL|virtual reality group|"Before the training, the Descriptive Information Form and the State and Trait Anxiety Inventory as a pre-test will be applied by face interview method. They will study for two hours. After the introduction and information, the lens and pupil distances of the virtual reality Glasses will be adjusted according to each student and students are expected to wear their vision. The application is the same for every student. Students will be introduced through the images projected to the computer simultaneously while in the application. Cervical dilation and effacement application will be monitored using virtual reality glasses. Next, the students will be asked to touch the woman's perineum with their hands to make her image transparent and we ask them to watch the cervix structures again. After the application, Learning Satisfaction and Self-Confidence in Learning Scale and State and Trait Anxiety Inventory will be applied as a post-test."
219083472|NCT06495931|DRUG|HRS-1780 tablets|HRS-1780 tablets, three times
219083473|NCT06495931|DRUG|HR20033 tablets|HR20033 tablets, nine times
219083474|NCT06495931|DRUG|HRS-7535 tablets|HRS-7535 tablets ，three times or nine times
219083475|NCT04530292|BEHAVIORAL|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
219083476|NCT01168284|BEHAVIORAL|Coping Effectiveness Training|
219083477|NCT01024426|PROCEDURE|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
219083478|NCT01024426|OTHER|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
219083479|NCT03285139|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
219083480|NCT04107922|DIETARY_SUPPLEMENT|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
219083481|NCT04107922|OTHER|Placebo|Patients will take placebo
219083482|NCT04887025|BIOLOGICAL|RGV004|a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
219083483|NCT06113601|OTHER|There is no intervention.|There is no intervention in the study.
219083484|NCT05166044|BIOLOGICAL|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
219083485|NCT03076099|DRUG|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
219083486|NCT03076099|OTHER|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
219083487|NCT02650050|RADIATION|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
219212079|NCT06637111|PROCEDURE|Ultrasound guided office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
219212080|NCT06637111|PROCEDURE|Conventional office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
219212081|NCT03658616|DRUG|WO3970|Application of cream to each axilla
219212082|NCT03658616|DRUG|Placebo (WO3988)|Application of cream to each axilla
219212083|NCT00832169|DRUG|AZD1386|1 dose of oral solution
219212084|NCT03279224|BIOLOGICAL|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
219681427|NCT06231134|DEVICE|Diode laser 940 nm|implant will be uncovered using a diode laser (940nm) in contact type with a continuous mode at a power of 1.5 watts, the laser tip will be used in a circular motion to create a small opening which will be increased till large enough to expose and remove the cover screw and place the healing abutments.
219681428|NCT06231134|DEVICE|Electrosurgical|the monopolar electrosurgical device will be used in the same way as the laser tip with additional care avoiding contacting the implants during exposure.
219083488|NCT04719091|DEVICE|Lubricity|Oral spray
219083489|NCT01826474|DRUG|PRO045, 0.15 mg/kg/week|Subcutaneous injection
219083490|NCT01826474|DRUG|PRO045, 1.0 mg/kg/week|Subcutaneous injection
219083491|NCT01826474|DRUG|PRO045, 3.0 mg/kg/week|Subcutaneous injection
219083492|NCT01826474|DRUG|PRO045, 6.0 mg/kg/week|Subcutaneous injection
219083493|NCT01826474|DRUG|PRO045, 9.0 mg/kg/week|Subcutaneous injection
219083494|NCT01826474|DRUG|PRO045, selected dose|Subcutaneous injection
219083495|NCT01180348|DRUG|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
219083496|NCT01180348|DRUG|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
219681429|NCT06444334|RADIATION|low level Diode Laser|Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device
219083497|NCT05056779|DRUG|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
219083498|NCT05056779|DRUG|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
219083499|NCT02613104|OTHER|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
219212085|NCT03279224|BIOLOGICAL|Autologous FMT|"1\. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
219212086|NCT01053325|DRUG|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
219212087|NCT01053325|DRUG|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
219212088|NCT05260398|BEHAVIORAL|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
219212089|NCT05416827|PROCEDURE|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
219212090|NCT02094560|DRUG|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
219083500|NCT02613104|OTHER|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
219083501|NCT02613104|OTHER|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
219083502|NCT02613104|OTHER|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
219212091|NCT01074294|DRUG|OPDC-34712|OPDC-34712 tablets, daily, Orally.
219212092|NCT01074294|DRUG|Placebo|Matching-placebo tablets, daily, Orally.
219212093|NCT01074294|DRUG|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
219212094|NCT04185181|OTHER|virtual reality|wii video game based exercise
219212095|NCT04185181|OTHER|proprioceptive neuromuscular facilitation|PNF with breathing
219212096|NCT04185181|OTHER|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
219212097|NCT02109575|DIAGNOSTIC_TEST|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
219212098|NCT00623194|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
219212099|NCT00623194|DRUG|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
219212100|NCT06798545|DEVICE|endoscopic ultrasound with navigation system|Use of the EZ-EUS navigation system during the procedure
219212101|NCT03502369|PROCEDURE|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
219083503|NCT00002155|DRUG|Indinavir sulfate|
219083504|NCT00002155|DRUG|Lamivudine|
219083505|NCT00002155|DRUG|Zidovudine|
219083506|NCT02323984|OTHER|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
219083507|NCT01971723|OTHER|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (\>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
219212102|NCT01231438|DRUG|Renvela|800mg t.i.d. over 2 weeks
219212103|NCT01231438|DRUG|Etalpha|0.25ug o.d. for 2 weeks
219212104|NCT01260896|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
219212105|NCT01260896|DRUG|Effexor® XR|150 mg Extended-Release Capsule
219212106|NCT01746706|DEVICE|PET amyloid tracer (Florbetapir F18 AV45 F18|
219212107|NCT05661708|DRUG|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
219083508|NCT01971723|OTHER|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
219083509|NCT00551798|PROCEDURE|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
219083510|NCT05899686|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
219083511|NCT04932629|BIOLOGICAL|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10\*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
219083512|NCT04852016|BEHAVIORAL|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
219083513|NCT04852016|BEHAVIORAL|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
219083514|NCT04717726|DIETARY_SUPPLEMENT|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
219083515|NCT04717726|DIETARY_SUPPLEMENT|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
219083516|NCT04717726|BEHAVIORAL|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
219083517|NCT04717726|DIETARY_SUPPLEMENT|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
219083518|NCT05038384|OTHER|Survey Administration|Complete survey
219212108|NCT02572700|OTHER|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
219212109|NCT01925144|DRUG|Baricitinib|Administered orally
219212110|NCT01925144|DRUG|Omeprazole|Administered orally
219212111|NCT03197649|PROCEDURE|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
219212112|NCT02043041|OTHER|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
219212113|NCT00312208|DRUG|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
219212114|NCT00312208|DRUG|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
219212115|NCT01094626|DRUG|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
219083519|NCT02840357|OTHER|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
219083520|NCT02840357|OTHER|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
219083521|NCT02883738|OTHER|tremor|evaluation of the intensity of the tremor
219083522|NCT00618254|DRUG|Granisetron|
219083523|NCT00568048|BIOLOGICAL|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
219083524|NCT00568048|DRUG|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
219083525|NCT00377325|DRUG|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
219083526|NCT03144713|DRUG|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
219083527|NCT03144713|DRUG|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
219083528|NCT03144713|DRUG|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
219083529|NCT03968432|BEHAVIORAL|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS\&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
219083530|NCT03968432|BEHAVIORAL|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
219083531|NCT04028986|DRUG|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
219083532|NCT04639674|DRUG|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
219083533|NCT02716948|OTHER|Laboratory Biomarker Analysis|Correlative studies
219083534|NCT02716948|BIOLOGICAL|Nivolumab|Given IV
219083535|NCT02716948|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
219083536|NCT03155789|PROCEDURE|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion"
219083537|NCT01012232|DRUG|20 mL ropivacaine 5 mg/mL|
219083538|NCT01012232|DRUG|10 mL ropivacaine 10 mg/mL|
219083539|NCT03645759|BEHAVIORAL|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
219083540|NCT03645759|OTHER|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
219083541|NCT03126825|DEVICE|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
219083542|NCT03126825|DEVICE|CP910/CP920|The approved CP910 or CP920 Sound Processor.
219083543|NCT04109014|OTHER|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
219083544|NCT01873430|DRUG|Melatonin|
219083545|NCT05751122|OTHER|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
219083546|NCT05751122|OTHER|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
219083547|NCT01648270|DRUG|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
219083548|NCT05341258|DIAGNOSTIC_TEST|EtCO2|EtCO2
219083549|NCT05341258|DIAGNOSTIC_TEST|PaCO2|PaCO2
219083550|NCT00466882|DEVICE|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
219212116|NCT02098837|DRUG|Dolutegravir|Dolutegravir 50mg once daily
219212117|NCT01488656|DIETARY_SUPPLEMENT|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
219212118|NCT01488656|DIETARY_SUPPLEMENT|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
219212119|NCT06116929|OTHER|Morphological and functional magnetic resonance imaging (MRI)|"Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI."
219212120|NCT06116929|OTHER|Neuropsychological assessment|"3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once."
219212121|NCT02955563|OTHER|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
219212122|NCT00612209|DRUG|ARQ 197|Treatment with ARQ 197
219212123|NCT03907306|PROCEDURE|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
219212124|NCT02624141|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
219212125|NCT05570305|DRUG|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
219212126|NCT05570305|DRUG|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
219212127|NCT05570305|DRUG|Placebo|Matching placebo.
219212128|NCT05570305|DRUG|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
219681430|NCT06444334|PROCEDURE|PRF platelet rich fibrin|The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
219083551|NCT01389193|DRUG|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
219681431|NCT00080015|DRUG|Diflomotecan (BN80915)|
219083552|NCT01389193|DRUG|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
219083553|NCT02064543|OTHER|GAITRite|mobility test assessing gait parameters
219681432|NCT04293705|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
219083554|NCT02064543|OTHER|ADPM|mobility test assessing gait parameters
219083555|NCT04706702|BEHAVIORAL|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
219083556|NCT02199236|RADIATION|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
219083557|NCT02199236|DRUG|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
219083558|NCT02199236|BEHAVIORAL|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
219083559|NCT06249932|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
219083560|NCT06249932|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
219083561|NCT03994302|DRUG|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
219083562|NCT02953301|DRUG|resminostat|
219212129|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
219212130|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
219212131|NCT03541525|OTHER|Biological sampling|Biological samples including blood, surgical remainder, urine,...
219212132|NCT03032458|DRUG|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
219212133|NCT03032458|DRUG|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
219212134|NCT03032458|DRUG|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
219212135|NCT04165564|OTHER|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
219212136|NCT04165564|OTHER|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
219212137|NCT00570466|BEHAVIORAL|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
219212138|NCT00570466|BEHAVIORAL|Web and DVD knowledge|Web and DVD based knowledge games
219212139|NCT00982644|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219212140|NCT00982644|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219212141|NCT02023346|BEHAVIORAL|surveys and cognitive tests|
219681433|NCT05565170|BEHAVIORAL|Structured ICT-assisted multimodal lifestyle intervention|The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.
219083563|NCT02953301|DRUG|Placebo|
219083564|NCT05477732|DIETARY_SUPPLEMENT|Bifidobacterium longum OLP-01|Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
219212142|NCT02695134|OTHER|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
219212143|NCT00571298|PROCEDURE|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
219212144|NCT00571298|DRUG|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
219212145|NCT00571298|DRUG|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
219212146|NCT00571298|DRUG|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
219212147|NCT00571298|DRUG|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
219212148|NCT00571298|PROCEDURE|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
219212149|NCT00909649|PROCEDURE|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
219212150|NCT04994795|OTHER|Predictive models (data collection)|Machine learning predictive models
219083565|NCT05477732|OTHER|Placebo|Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
219083566|NCT04858919|DIAGNOSTIC_TEST|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
219212151|NCT03997994|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
219212152|NCT00051298|DRUG|Olanzapine|
219212153|NCT00051298|DRUG|Placebo|
219212154|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
219212155|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management|Routine nutrition management for 12 weeks.
219212156|NCT00943917|OTHER|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
219083567|NCT04858919|DIAGNOSTIC_TEST|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
219083568|NCT04858919|DIAGNOSTIC_TEST|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
219083569|NCT01430260|DRUG|Ciclesonide|200 ㎍ once daily
219083570|NCT01430260|DRUG|Levocetirizine|5mg once daily
219083571|NCT01430260|DRUG|Ciclesonide & Levocetirizine|"* Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily"
219083572|NCT05570955|BEHAVIORAL|Text reminder|weekly text to remind use of drug
219083573|NCT03677713|PROCEDURE|No nasal packing.|No nasal packing at the end of the surgery
219083574|NCT03677713|PROCEDURE|Nasal Packing|Patients will have nasal packing at the end of the surgery
219083575|NCT01643590|BIOLOGICAL|JVS-100 15 mg dose Injection|Intramyocardial Injection
219083576|NCT01643590|BIOLOGICAL|Placebo Injection|Intramyocardial Injection
219083577|NCT01643590|BIOLOGICAL|JVS-100 30 mg dose injection|Intramyocardial Injection
219083578|NCT01285583|DRUG|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
219083579|NCT06276595|BEHAVIORAL|Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)|The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.
219083580|NCT06276595|BEHAVIORAL|Control condition - 3 Monthly Group Activities in the Community|The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
219083581|NCT00902694|BEHAVIORAL|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
219083582|NCT00902694|OTHER|Control|group health classes quarterly with topics not related to weight
219212157|NCT00943917|DRUG|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
219212158|NCT00943917|OTHER|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
219212159|NCT05599815|DRUG|ADX-629|ADX-629 (250 milligrams) administered twice daily
219212160|NCT06133530|DIETARY_SUPPLEMENT|Human milk oligosaccharides|Prebiotic
219681434|NCT05565170|BEHAVIORAL|Self-guided multimodal lifestyle intervention|Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
219083583|NCT01731236|DIETARY_SUPPLEMENT|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
219083584|NCT01731236|DIETARY_SUPPLEMENT|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
219083585|NCT01731236|DRUG|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
219083586|NCT01731236|DRUG|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
219083587|NCT01731236|DRUG|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
219212161|NCT06133530|DIETARY_SUPPLEMENT|Maltose|Control
219212162|NCT05150873|OTHER|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
219212163|NCT05028933|DRUG|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
219681435|NCT02912221|OTHER|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
219681436|NCT00334087|BEHAVIORAL|feeding habits|
219681437|NCT05684289|DRUG|BMS-986278|Specified dose on specified days
219681438|NCT05684289|DRUG|Sildenafil|Specified dose on specified days
219681439|NCT05684289|DRUG|Placebo|Specified dose on specified days
219212164|NCT05443464|BIOLOGICAL|OSSM-001|Direct IV infusion of OSSM-001
219212165|NCT06570629|DEVICE|Oronasal CPAP|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
219212166|NCT06570629|DEVICE|Nasal CPAP plus Chinstrap|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
219212167|NCT05563766|DRUG|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
219212168|NCT04612244|DEVICE|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
219212169|NCT04612244|DEVICE|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
219083588|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
219083589|NCT06566131|BEHAVIORAL|Gamified mobile health app|Participants will receive visualized instructions about the PW use (e.g., search and download the app on App Store, navigate and understand key features, play puzzle games, and track step counts). During the 6-week intervention period, participants will receive reminders on wearing the accelerometer, using the app for potential incentives, and engaging in regular physical activities for health promotion.
219083590|NCT06679751|BEHAVIORAL|ID-TOUCH|ID TOUCH is a multi-pronged intervention to increase HIV testing and PrEP linkage that includes jail-based HIV care process improvements with post-incarceration outreach and linkage to community services.
219083591|NCT04658667|BIOLOGICAL|IHV01|IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
219212170|NCT04991831|DEVICE|Unilateral thalamotomy|Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
219212171|NCT05613296|DRUG|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
219212172|NCT06239831|DEVICE|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
219212173|NCT04086849|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
219212174|NCT00649805|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
219212175|NCT00649805|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
219212176|NCT02804074|OTHER|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
219212177|NCT02804074|OTHER|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
219212178|NCT04042532|DEVICE|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
219083592|NCT04658667|BIOLOGICAL|A244|A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
219212179|NCT06251869|PROCEDURE|total hip arthroplasty with electrocoagulation|using normal technique
219212180|NCT06251869|PROCEDURE|total hip arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
219212181|NCT06251869|PROCEDURE|total knee arthroplasty with electrocoagulation|using normal technique
219212182|NCT06251869|PROCEDURE|total knee arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
219212183|NCT04580888|PROCEDURE|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
219212184|NCT04580888|PROCEDURE|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
219212185|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
219212186|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
219212187|NCT03049072|RADIATION|Protons and Carbon Ions|
219212188|NCT06153628|OTHER|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
219212189|NCT06456723|DRUG|[18F]-FET-βAG-TOCA|Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA). Patients will receive a maximum injected dose of 370MBq and will subsequently undergo PET/CT imaging.
219212190|NCT05783869|DEVICE|Echocardiography|echocardiographic study of both groups
219681440|NCT04213391|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane take 2550mg once a day.
219681441|NCT04213391|DIETARY_SUPPLEMENT|Placebo|Placebo take 2550mg once a day.
219212191|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
219212192|NCT06673511|PROCEDURE|Lymph node visualization|Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
219212193|NCT06673511|PROCEDURE|No visualization of lymph nodes|Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
219212194|NCT06997640|DIAGNOSTIC_TEST|Dynamic Stretching Protocol|Participants assigned to Group A will undergo a structured dynamic stretching protocol, designed to enhance lumbar flexibility, core muscle activation, and postural alignment, specifically targeting the pelvic inclination associated with radicular low back pain (RLBP). The intervention will be administered three times per week under the direct supervision of a qualified physiotherapist. Each session will last for 30 minutes, beginning with a 5-minute warm-up involving light aerobic activity such as marching or gentle trunk rotations to prepare the body for movement. This will be followed by 20 minutes of dynamic stretching exercises, focusing on the major muscle groups that influence pelvic and lumbar mobility.
219212195|NCT06997640|COMBINATION_PRODUCT|Neural Mobilization Technique Protoco|Participants in Group B will receive a standardized neural mobilization intervention, targeting the sciatic nerve and lumbar plexus, known to contribute to pain and restricted mobility in radicular low back pain (RLBP). The treatment will be conducted three times per week, with each session lasting 30 minutes under the guidance of an experienced physiotherapist trained in neurodynamic techniques. The session will begin with a 5-minute preparatory phase to position the participant comfortably and explain the sequence of movements. This will be followed by 20 minutes of gentle neural mobilization techniques, including nerve sliders and tensioners, performed through movements such as the Straight Leg Raise (SLR) sliders and the Seated Slump mobilization technique.
219212196|NCT06454604|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
219212197|NCT00104741|DRUG|flutamide|
219083593|NCT04658667|BIOLOGICAL|ALFQ|ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
219083594|NCT04658667|OTHER|Placebo|Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
219212198|NCT00104741|DRUG|triptorelin|
219212199|NCT00104741|RADIATION|radiation therapy|
219212200|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
219212201|NCT03357952|DRUG|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
219681442|NCT03050177|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
219681443|NCT03050177|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
219083595|NCT03743649|DRUG|Haloperidol|Given IV
219083596|NCT03743649|DRUG|Lorazepam|Given IV
219083597|NCT03743649|OTHER|Placebo|Given IV
219083598|NCT03743649|OTHER|Quality-of-Life Assessment|Ancillary studies
219083599|NCT03743649|OTHER|Questionnaire Administration|Ancillary studies
219083600|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
219212202|NCT03357952|DRUG|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
219212203|NCT06867731|PROCEDURE|Endosonographic Elastography|The patient will undergo a standard-of-care endoscopic ultrasound with liver biopsy. At the time, elastography of the liver and spleen will be performed while using the echoendoscope. Different degrees of pressure will be applied while performing elastography of the left and right lobes of the liver as well as the spleen. The E values and VsN values will be recorded and then compared to liver histology.
219681444|NCT05805683|DRUG|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
219681445|NCT05805683|DRUG|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
219681446|NCT02028507|DRUG|Palbociclib|
219681447|NCT02028507|DRUG|Capecitabine|
219681448|NCT02028507|DRUG|Exemestane|
219681449|NCT02028507|DRUG|Fulvestrant|
219681450|NCT06957990|OTHER|Music|Music of the participant's selected genre will be played through headphones according to the arm assigned.
219681451|NCT06308393|DRUG|RSS0393 ointment；Placebo|RSS0393 ointment；RSS0393 ointment placebo
219681452|NCT05709912|BEHAVIORAL|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
219681453|NCT05709912|BEHAVIORAL|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
219681454|NCT00525473|DRUG|Azathioprine|azathioprine usual dosage 100mg per day
219083601|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
219083602|NCT04314557|DEVICE|Renal denervation|Spyral device. Bilateral renal denervation.
219083603|NCT04058652|DEVICE|transcutaneous electrical nerve stimulation (TENS) unit|The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
219083604|NCT04625712|PROCEDURE|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
219083605|NCT05572138|DIAGNOSTIC_TEST|Body Impedance Analysis|Body Impedance Analysis
219083606|NCT04450108|DIAGNOSTIC_TEST|Vivatmo pro FeNO Test|Breath gas analysis
219083607|NCT01461876|DRUG|antiretroviral therapy|Standard of care antiretroviral therapy
219083608|NCT01959724|OTHER|Vitrectomy|
219083609|NCT01257906|DRUG|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
219083610|NCT01257906|DRUG|ZIANA®|Topical Gel applied in the evening for 84 days
219083611|NCT01257906|DRUG|Vehicle Control|Topical Gel applied in the evening for 84 days.
219083612|NCT03657277|DEVICE|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
219083613|NCT02693743|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
219083614|NCT01394393|BEHAVIORAL|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
219083615|NCT01394393|BEHAVIORAL|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
219083616|NCT01394393|DIETARY_SUPPLEMENT|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
219083617|NCT04960865|OTHER|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
219083618|NCT04960865|OTHER|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
219083619|NCT04960865|OTHER|Rigid Taping|Rigid Taping will be applied.
219083620|NCT04521855|OTHER|Questionnaire|Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
219083621|NCT01024608|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
219083622|NCT01024608|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
219083623|NCT05225064|BEHAVIORAL|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
219083624|NCT05225064|DEVICE|Mask|Individuals are given cloth masks
219083625|NCT05225064|BEHAVIORAL|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
219083626|NCT05225064|BEHAVIORAL|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
219083627|NCT05225064|BEHAVIORAL|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
219083628|NCT04549363|DRUG|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
219083629|NCT04606966|OTHER|Therapeutic Horseback Riding|Horse therapy
219083630|NCT04606966|OTHER|Barn Activity|Horsemanship group
219083631|NCT04606966|OTHER|Hybrid|Ground and riding activities
219083632|NCT01806987|BEHAVIORAL|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
219083633|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
219083634|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
219083635|NCT03856879|BEHAVIORAL|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
219083636|NCT01009268|PROCEDURE|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
219083637|NCT01774149|DEVICE|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
219083638|NCT01774149|DEVICE|Diastat|Users get the Few Touch Application with Diastat module activated.
219212204|NCT06867731|DIAGNOSTIC_TEST|Endosonographic shear wave elastography|The patient will undergo an upper endoscopic ultrasound procedure. During this procedure, the patient will be put to sleep and a trained endosonographer physician will insert an echo-endoscope through the mouth and guide it down to the stomach and the duodenum. This endoscope is equipped with technology that uses sound waves to assess the stiffness of the liver and spleen. For research purposes, the doctor will also press on these organs in order to take the additional measurements.
219212205|NCT03786237|DRUG|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
219212206|NCT02533973|DRUG|Xamiol® gel|
219212207|NCT02533973|DRUG|Daivonex® scalp solution|
219212208|NCT06827067|BEHAVIORAL|Simulation application with standard patient|Before the encounter with the standard patient (SH), a preliminary interview was held with the nurses in the briefing room, where the content and purpose of the application were explained to the nurses, and the story of the SH was told to the nurses in line with the prepared scenario. Three nurses were interviewed for each scenario. The nurses communicated with the SH for 10-15 minutes and each interview was conducted using video recordings. Those who finished the interview with the SH watched the scenario of the other group as observers, and at the end of each 3 scenarios, the debriefing phase was carried out for an average of 60-90 minutes.
219212209|NCT06827067|BEHAVIORAL|Theoretical training|The trainings, each of which lasted 40-45 minutes on average, were conducted in a total of 7 sessions.
219212210|NCT01371994|DRUG|solifenacin succinate|oral
219212211|NCT01371994|DRUG|Placebo|oral
219212212|NCT06827587|DRUG|Efgartigimod + Telitacicept (1-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 25 weeks (Week 5 to Week 29)"
219212213|NCT06827587|DRUG|Efgartigimod + Telitacicept (2-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 24 weeks (Week 6 to Week 29)"
219212214|NCT06827587|DRUG|Telitacicept-only group|Drug: Telitacicept Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 30 weeks (Week 0 to Week 29)
219212215|NCT05689073|DEVICE|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
219681455|NCT04917354|DEVICE|Superb-Microvascular imaging|Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
219681456|NCT00247520|DRUG|topical nasal rEV131|
219681457|NCT04701450|OTHER|digital consent|the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
219681458|NCT06382116|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219681459|NCT06382116|DRUG|Pemetrexed+Cisplatin or Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
219083639|NCT06979492|BIOLOGICAL|Prophylactic Transfusion Intervention group: Transfusion|"For participants randomized to the prophylactic transfusion intervention group, the first RBC transfusion will occur within 3 weeks of randomization. All transfusions will be managed per SOC.~SOC prophylactic RBC transfusion management is as follows: transfusions are performed at 3-6 week intervals with the intent to maintain a pre-transfusion hemoglobin S level at \<30%. All participants will have a complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH, ferritin, and type/screen at baseline and within 3 days of all monthly transfusions. All RBC transfusions must be compatible between the recipient and the donor and antigen matched for Rh (D/Cc/Ee) and Kell antigens at a minimum. For participants with a previous history of RBC alloimmunization, extended matched RBCs will be provided (Rh, Kell, Duffy, Kidd, S/s) per NHLBI/ASH guidelines to minimize further alloimmunization."
219083640|NCT06979492|OTHER|Control group|"Participants randomized to the control group will be followed per SOC. SOC management for pregnant women with SCD includes but is not limited to~* Clinic appointments with an SCD provider every 2 months~* Lab draws - complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH and ferritin."
219212216|NCT05689073|OTHER|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
219083641|NCT00657618|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
219083642|NCT06191913|DEVICE|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
219083643|NCT03389542|PROCEDURE|Surgery|Early mitral valve repair
219083644|NCT03389542|OTHER|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
219083645|NCT04110405|BEHAVIORAL|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
219083646|NCT04110405|BEHAVIORAL|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
219212217|NCT06819137|OTHER|Gingival visibility exceeding 3 mm during smiling|Obtaining gummy smile photographs in accordance with the inclusion criteria specified in the study's materials and methods section.
219212218|NCT03151798|BEHAVIORAL|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
219083647|NCT06815640|OTHER|recovery|Fatigue protocol
219083648|NCT02610738|BEHAVIORAL|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
219083649|NCT06656299|DEVICE|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block
219083650|NCT06656299|DRUG|Bupivacaine injection|5 ml local anesthetic for each trocar sides
219083651|NCT06656299|DRUG|paracetamol, tramadol, and ondansetron|"As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic"
219212219|NCT03151798|BEHAVIORAL|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
219212220|NCT03151798|OTHER|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
219212221|NCT06699550|OTHER|Haptonomy|The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.
219212222|NCT06699550|OTHER|Mindfulness-Based Stress Reduction Program|Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
219212223|NCT06880107|BIOLOGICAL|blood withdrawal|blood withdrawal
219212224|NCT03623295|OTHER|Blood sample|Blood withdrawal.
219212225|NCT03623295|OTHER|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
219212226|NCT03623295|OTHER|MRI-imaging|MRI imaging of joints.
219212227|NCT03623295|OTHER|Physical examination|Physical examination of joint status.
219681460|NCT05171270|OTHER|Questionnaire|PsAID questionnaire
219681461|NCT04663165|PROCEDURE|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
219083652|NCT06977802|BEHAVIORAL|Digital Nutrition Education Mobile App for Healthy and Sustainable Eating|"This intervention is uniquely characterized by:~Dual Health-Sustainability Focus - Unlike most nutrition apps targeting weight loss, this integrates planetary health metrics (e.g., carbon/water footprints) alongside dietary guidance.~Psychobehavioral Personalization - Content is tailored to four predefined user profiles (e.g., Convenience-Seeker, Health-Conscious) identified through baseline questionnaires, adapting messaging strategies (e.g., time-saving tips vs. environmental appeals).~Biomarker-Validated Outcomes - Unlike apps relying solely on self-reports, efficacy is assessed via objective measures (urinary LC-MS metabolomics, fecal microbiota analysis).~Academic Development - Designed by nutrition scientists + AI engineers (University of Parma), with recipes aligned to Mediterranean/Planetary Diet standards"
219083653|NCT00642187|DRUG|budesonide|
219083654|NCT00642187|DRUG|Placebo|
219083655|NCT01083251|DRUG|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
219083656|NCT01083251|DRUG|Peginterferon|180 mcg/week
219083657|NCT01083251|DRUG|Sebivo|Telbivudine 600 mg daily
219212228|NCT07038031|BEHAVIORAL|Promotion a food habits|They develop the service learning project to promote a healthy food habits in diferent social organitzations of the territory. It consists to do an interview to identify nutritional educational needs, and do 3 nutritional workshops to participants from this organitzations. Each workshop has 1 hour, and is addreced to a small group of participants (8-15 maximum), always with the supervision of the professional of the social organitzation.
219212229|NCT06888583|PROCEDURE|Transpedicular fixation|Patients underwent transpedicular sacral fixation.
219212230|NCT06778161|PROCEDURE|nerve block|Nerve block for providing analgesia after thoracotomy
219212231|NCT06737796|BEHAVIORAL|Finger Feeding|feeding method
219212232|NCT06737796|BEHAVIORAL|syringe feeding|feeding method
219083658|NCT01083251|DRUG|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
219083659|NCT04608487|DRUG|Fludarabine|Intravenous infusion
219083660|NCT04608487|DRUG|Cyclophosphamide|Intravenous infusion
219083661|NCT04608487|BIOLOGICAL|Axicabtagene Ciloleucel|Intravenous infusion
219083662|NCT01880723|DRUG|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
219083663|NCT01880723|DRUG|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
219083664|NCT00326131|DRUG|Oral Taxane|
219083665|NCT00863174|DRUG|SPARC147709|SPARC147709 injection
219083666|NCT00863174|DRUG|Reference147709|Reference147709 injection
219083667|NCT02821403|DEVICE|clear lens with regular coating|
219083668|NCT02821403|DEVICE|regular coating lens with yellow tint|
219083669|NCT02821403|DEVICE|clear lens with blue-light blocking coating|
219083670|NCT02444065|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
219083671|NCT02444065|BEHAVIORAL|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter \& Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
219083672|NCT03846648|DRUG|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
219083673|NCT02434133|PROCEDURE|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
219083674|NCT04915573|DIAGNOSTIC_TEST|Specimen|Sputum will be collected in clean disposable containers
219083675|NCT04247672|DEVICE|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
219212233|NCT05942911|DRUG|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
219212234|NCT05942911|DRUG|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
219212235|NCT05942911|DRUG|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
219212236|NCT05942911|DRUG|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
219212237|NCT06673368|DRUG|NRCT-101SR, NRCT-202XR|NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
219212238|NCT06826547|DRUG|Adjustment of insulin doses DAR|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12), biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) DAR Group: Insulin will be adjusted per DAR 2021 guidelines. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
219083676|NCT06820658|DIAGNOSTIC_TEST|Neuromuscular Test|"To measure neuromuscular connectivity, Transcranial Magnetic Stimulation (TMS) will be used to stimulate regions of the cerebral cortex known to control specific muscles.~Electromyography (EMG) activity will then be measured from the following muscle groups: deltoid, biceps, extensor digitorum communis, abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscle."
219083677|NCT06820658|DIAGNOSTIC_TEST|DEXA|The DEXA test uses X-rays to measure how many grams of calcium and other bone minerals are packed into a segment of bone. The test also measures the amount of fat-free mass, and fat mass.
219083678|NCT06820658|DIAGNOSTIC_TEST|Mixed Meal Tolerance Test|Fasting blood will be collected for glucose, insulin, and c-peptide. Participants will be provided with a milkshake with a fixed amount of protein, carbohydrates, and fat. Glucose, insulin, and c-peptide will be measured at multiple time points (every 10 minutes) until four hours after consumption (50% Fat, 30% Carbohydrate HO, 20% Protein). Approximately 70mls of blood will be drawn during this time
219083679|NCT06820658|DIAGNOSTIC_TEST|Strength Test|Knee extensor strength will be tested by gradually increasing the workload on a pneumatic Keiser knee extension machine. The test will begin with a warm-up of 4-5 reps with one leg at 30-50 psi. Then the participant will increase the workload at self-selected intervals ranging from 5-20psi until a maximum effort is achieved. If a rep is failed, then the workload will be reduced by 5psi until a successful rep is performed or a workload is reached in which a successful rep had been previously achieved. Handgrip strength will be tested using a handheld dynamometer (Baseline® standard hydraulic hand dynamometer). The test is performed with the participant seated with the elbow unsupported and flexed at 90 degrees, forearm neutral, wrist held between 0-15 degrees of ulnar deviation (Horowitz, 1997). Maximum grip is the average of three 3-5 second trials.
219212239|NCT06826547|DRUG|Adjustment of insulin doses CFT|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12) and biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) .~CFT Group: Insulin adjusted after a Carbohydrate Fasting Test. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
219212240|NCT04990921|COMBINATION_PRODUCT|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
219212241|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
219212242|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
219212243|NCT06753097|DEVICE|Continuous finger-cuff arterial pressure monitoring|Arterial pressure will be monitored using continuous non-invasive finger-cuff arterial pressure monitoring.
219212244|NCT02044497|DRUG|oral oxycodone|
219212245|NCT06892171|BIOLOGICAL|Blood sample|blood sample for genetic analysis
219212246|NCT06742697|BEHAVIORAL|Flexibility, Resistance, Aerobic, Movement Execution training|"Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.~Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.~Movement execution training: gait training according to motor learning principles.~Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurothrophic factors)."
219212247|NCT04921449|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
219212248|NCT04921449|OTHER|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
219083680|NCT06668246|DEVICE|Vision-S™ 700, an immersive and compact phoropter with a tunable-focus lens, and Vision-R™ 800, a phoropter with a tunable-focus lens without immersion, with cycloplegic refraction serving as the gold|As of today, no published clinical studies have been conducted with the Vision-S™ 700 neither Vision R 800
219083681|NCT04491448|BEHAVIORAL|Social needs screening|Interview and referral for non-medical health-related social needs
219083682|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
219083683|NCT06626412|DIAGNOSTIC_TEST|Diagnostic Test: 18F-SynVesT-1 PET|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
219212249|NCT06896474|BEHAVIORAL|Shared Decision-Making Training and Decision Aid|The intervention includes training surgeons in shared decision making techniques and providing eligible participants with a tailored breast cancer treatment decision aid prior to the initial surgical consultation.
219212250|NCT06045507|DRUG|MK-8527|MK-8527 capsule
219212251|NCT06045507|DRUG|Placebo to MK-8527|Placebo capsule matched to MK-8527
219212252|NCT06738524|BEHAVIORAL|Fighting with Digital Addiction|The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.
219083684|NCT06626412|DIAGNOSTIC_TEST|Volumetric MRI|Magnetic resonance imaging of brain volume.
219083685|NCT06320860|DEVICE|Kidney Stone Retrieval|Using FlexStone Basket aimability to retrieve kidney stones
219083686|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
219083687|NCT04913363|OTHER|Green space|Green space in which activities take place
219083688|NCT03577587|DIETARY_SUPPLEMENT|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
219083689|NCT03577587|DIETARY_SUPPLEMENT|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
219083690|NCT06732700|OTHER|Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.|INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed
219083691|NCT07064824|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
219083692|NCT07064824|BEHAVIORAL|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
219083693|NCT07064824|BEHAVIORAL|Automated Text Reminders|Scheduled text reminder to take medication
219083694|NCT07081984|BIOLOGICAL|therapeutic tumor vaccine|TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.
219083695|NCT07092787|BEHAVIORAL|Smartphone-based behavioral intervention|The proposed study will use a behavioral smartphone-based intervention in a 12-week RCT among clinically diagnosed ADHD adolescents in Hong Kong. Guided by a conceptual framework on SO in ADHD, we will implement specific strategies that counter the potentially addictive qualities of smartphones using built-in smartphone functions that have been previously shown to be effective.
219212253|NCT06736938|DRUG|Propofol 1%|Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
219212254|NCT06736938|DRUG|Midazolam|Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
219212255|NCT06736938|DRUG|Pethidine|Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
219212256|NCT06738511|DIAGNOSTIC_TEST|blood sampling|Molecular signature using plasma sample
219212257|NCT06738511|OTHER|stool sampling|Stool sampling (by the participant)
219212258|NCT06738511|OTHER|colonoscopy|Colonoscopy will be performed in the course of a screening programme
219212259|NCT05578846|DRUG|Treatment A|Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
219083696|NCT07092787|OTHER|Self-monitoring of smartphone use|Participants will receive information about the known benefits and risks of SO and activate their smartphones' screentime monitoring setting. They will receive weekly reminders to submit their smartphone usage data.
219083697|NCT06940232|DIAGNOSTIC_TEST|Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers|All groups will have blood drawn per standard of care. Blood samples will be analyzed using Traumatic Brain Injury (TBI) cartridges for iSTAT Alinity device.
219083698|NCT04922554|DRUG|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
219083699|NCT04922554|DRUG|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
219083700|NCT01128803|PROCEDURE|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration \> 2mm
219083701|NCT06176261|DRUG|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
219083702|NCT00596843|BEHAVIORAL|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
219083703|NCT00596843|BEHAVIORAL|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
219083704|NCT03502486|OTHER|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
219083705|NCT03502486|OTHER|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
219083706|NCT03502486|OTHER|Reading|20 minutes of seated reading
219083707|NCT02259179|DRUG|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
219083708|NCT02259179|DRUG|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
219083709|NCT05095805|BEHAVIORAL|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
219083710|NCT05095805|BEHAVIORAL|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
219212260|NCT05578846|DRUG|Treatment B|Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
219212261|NCT05578846|DRUG|Treatment C|Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
219212262|NCT06405295|OTHER|no intervention|Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
219681462|NCT04663165|PROCEDURE|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
219212263|NCT06734091|DIAGNOSTIC_TEST|PrestoCHILL|PrestoCHILL (Milestone Medical Technologies, Inc.MI 49009, USA)which by reducing the tissue freezing time to less than 60 seconds should eliminate freezing artefacts and improve the quality of sections for morphological and IHC examination. In selected cases and according to the diagnostic algorithm required for the diagnosis of specific neoplasms, rapid IHC analysis will be performed with the Benchmark ULTRA® immunostainer (Ventana Medical Systems), which is already in place to confirm or exclude the suspected neoplasm, as well as to confirm the histotype. For the latter purpose, commercially available antibody panels for routine examinations will be used (Ventana/Roche,Ventana Medical Systems, USA).
219212264|NCT06747832|DRUG|iNK cells|Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
219212265|NCT06753552|OTHER|Underwater US|7 min per session with an intensity of 0.9 W/cm2 for 20 sessions
219212266|NCT06753552|DEVICE|CFO|Custom made orthotics
219212267|NCT06843096|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|"The intervention in this study involves Contrast-Enhanced Mammography (CEM), a specialized imaging technique that combines standard mammography with contrast-enhanced imaging to detect neo-angiogenesis, which is a characteristic of malignancy. Unlike traditional mammography, CEM utilizes both low-energy and high-energy images to provide enhanced visualization of tissue vascularity, aiding in the identification of occult primary tumors, particularly in patients with Cancer of Unknown Primary (CUP) syndrome.~Patients who present with CUP syndrome, suspected of having a primary breast malignancy, will undergo CEM as part of their diagnostic workup. The CEM findings will be compared with other conventional imaging modalities, including ultrasound and MRI, to assess the diagnostic accuracy of CEM in detecting primary breast tumors. The intervention will also involve correlating the imaging results with histopathological findings from biopsy or surgical specimens.~This study aims to demons"
219212268|NCT06646107|DEVICE|MInimed 780G|Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
219681463|NCT00232206|DRUG|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
219681464|NCT03925181|BEHAVIORAL|Counselling Group|All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
219681465|NCT02033278|DRUG|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
219083711|NCT05794438|BEHAVIORAL|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
219083712|NCT05794438|BEHAVIORAL|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
219083713|NCT05100264|OTHER|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
219083714|NCT05100264|OTHER|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
219083715|NCT05166538|DRUG|Ticagrelor|direct-acting oral P2Y12-receptor antagonist
219083716|NCT05166538|DRUG|Clopidogrel|platelet aggregation inhibitor
219083717|NCT05049408|DIAGNOSTIC_TEST|MMP-1 Enzyme Linked Immunosorbent assay (ELISA)|The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
219681466|NCT02033278|DRUG|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
219681467|NCT06066255|DRUG|Thymoglobulin Injectable Product|single intravenous injection of thymoglobulin
219681468|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with radiofrequency|The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.
219681469|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with pulsed field ablation|The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.
219083718|NCT00169000|DRUG|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
219083719|NCT00169000|DRUG|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
219083720|NCT04123925|DRUG|Nivolumab|Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
219083721|NCT02611739|DEVICE|Medi-Port|Treatment
219212269|NCT06810739|DIAGNOSTIC_TEST|Cervical Cancer Screen-Triage-Treat Care Cascade|Cervical Cancer Screen-Triage-Treat Care Cascade: After providing informed consent, the study clinician will open a Case Report Form (CRF) for each patient which starts with a brief questionnaire, which will include the participant's demographic information and medical history, including HIV viral load and cluster of differentiation 4 (CD4) counts, previous cervical cancer screening results if previously screened, and result of rapid pregnancy test performed that day. Each participant will then be accompanied to a private location where the study nurse will provide counseling and instruction on how to appropriately perform the self-collection vaginal swab technique.
219212270|NCT06763367|OTHER|Face mask containing Centella sinensis|A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica
219681470|NCT06351553|PROCEDURE|Combined pulmonary vein isolation|"The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group."
219681471|NCT04525209|OTHER|No intervention|No intervention
219083722|NCT02611739|DEVICE|Medi-Port|Control
219083723|NCT03502655|OTHER|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
219083724|NCT03502655|OTHER|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
219083725|NCT03502655|OTHER|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
219083726|NCT03502655|OTHER|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
219681472|NCT03613792|DRUG|Remifentanil|Opioid analgesic
219681473|NCT03613792|DRUG|Fentanyl|Opioid analgesic
219681474|NCT03613792|DRUG|Midazolam|Benzodiazepine
219681475|NCT03613792|DRUG|Ketamine|Analgesic
219083727|NCT06732739|OTHER|percussions with teach-back breathing exercise|"patient will receive Teach Back Breathing Exercises like pursed lip breathing, DE breathing and diaphragmatic breathing Teach-back breathing exercises refer to a method of instructing individuals in breathing techniques and then having them demonstrate or teach back the instructions to ensure comprehension and mastery. This educational approach is commonly used in healthcare settings, particularly when teaching patients how to perform various breathing exercises for therapeutic purposes. Patients were informed about the importance of regular chest percussion I will use the clapping technique which provided by cupped hand for 3 minutes in 5 positions of drainage (upper lobes-apical and posterior segment, apical and anterior segment, right upper lobe-posterior segment, left upper lobe-posterior segment, lower lobes- apical segment) with assisted suction three times/shift for four days, and then each patient will be observed."
219681476|NCT06073509|DIAGNOSTIC_TEST|Screening for atrial fibrillation and other cardiac arrhythmias and diseases|"In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~* connected smartwatches for atrial fibrillation screening~* complete ECG for other cardiac arrhythmias~* echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)"
219681477|NCT01384747|DRUG|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
219083728|NCT06732739|OTHER|PERCUSSION|similar to Group A, each patient underwent individual interviews. Patients were educated on the significance of regular chest percussion. The clapping technique, executed with cupped hands, was applied for 3 minutes in five drainage positions (upper lobes - apical and posterior segment, apical and anterior segment, right upper lobe - posterior segment, left upper lobe - posterior segment, lower lobes - apical segment). This procedure, including assisted suction three times per shift, was administered for four consecutive days.
219212271|NCT06763562|OTHER|Carbohydrate-first meal|Rice eaten first (150 grams), followed by edamame (150 grams) and butter (10 grams)
219212272|NCT06763562|OTHER|Carbohydrate-last meal|Edamame (150 grams) and butter (10 grams) eaten first, followed by rice (150 grams)
219212273|NCT06763978|DEVICE|Transcatheter PDA closure|Transcatheter PDA closure
219083729|NCT05452655|BEHAVIORAL|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
219083730|NCT05452655|BEHAVIORAL|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
219083731|NCT02221401|DRUG|Linagliptin/Metformin FDC|
219083732|NCT02221401|DRUG|Linagliptin|
219083733|NCT02221401|DRUG|Metformin|
219083734|NCT01708330|DRUG|Lidocaine|2% Lidocaine gel
219083735|NCT01708330|DRUG|Placebo gel|odorless, colorless gel will be used as a placebo
219083736|NCT02546830|DEVICE|FreeO2 v2.2 active|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
219083737|NCT02546830|DEVICE|FreeO2 v2.2 with manual oxygenation|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
219083738|NCT03404492|OTHER|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
219212274|NCT06819826|DRUG|SC0062 strength 10mg|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
219212275|NCT06819826|DRUG|Placebo matched to SC0062|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
219681478|NCT01384747|DRUG|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
219681479|NCT01514110|DRUG|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
219681480|NCT01466413|DEVICE|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
219083739|NCT01730885|OTHER|Comparison of different Blood Glucose Meters|
219083740|NCT03432364|GENETIC|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
219083741|NCT03288610|DIAGNOSTIC_TEST|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
219083742|NCT03544346|OTHER|Exploratory brain and general health assessment|Exploratory brain and general health assessment
219083743|NCT05179967|DEVICE|WeFlow-JAAA Stent Graft System|WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.
219083744|NCT00538551|OTHER|Database|Database
219083745|NCT00770107|DRUG|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
219083746|NCT00770107|DRUG|Placebo|Placebo, once daily, for a duration of 4 weeks
219212276|NCT06767332|OTHER|eye movement desensitization and reprocessing (EMDR)|"EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxiety disorders (e.g. fear of illness and specific phobia) (Logie \& de Jongh, 2014) and somatic complaints such as post-operative pain, medically unexplained symptoms and seizure-related post-traumatic stress (Dautovic, de Roos, van Rood, Dommerholt, \& Rodenburg, 2016; van Rood \& de Roos, 2009; Maroufi, Zamani, Izadikhah, Marofi, \& O'Connor, 2016).~With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology including physical symptoms and fear of future catastrophes (Balkom van et al., 2013)."
219212277|NCT06766032|DEVICE|CELL-Saver|The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
219212278|NCT06766032|DEVICE|SAME|The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
219212279|NCT06739148|DEVICE|Low Level Laser Therapy|Low-level laser therapy can increase cellular energy production, making it useful as a pre-conditioning treatment to prevent muscle contraction fatigue or as a post-contraction therapy to accelerate fatigue recovery.
219212280|NCT06739148|DEVICE|blood flow restriction|Its advantage is that during training, it can surpass the \&#34;overload principle,\&#34; allowing for effective muscle cross-sectional area growth with relatively light weight training (20%-50% of 1RM or 20%-40% of MVC).
219212281|NCT06739148|DEVICE|Neuromuscular Electrical Stimulation|It is a strength training method that uses electrical currents to stimulate nerve and muscle activation, helping to maintain muscle mass, increase blood flow, and slow down or prevent muscle atrophy.
219212282|NCT06837779|DRUG|Fluoride Iontophoresis with Acidulated Phosphate Fluoride|Application of fluoride gel and activated with Iontophoresis electrical pole
219212283|NCT06837779|DRUG|Remineralization with sodium fluoride varnish|CASIN PHOSPHOPEPTIDE AMORPHOUS CALCIUM PHOSPHATE
219212284|NCT06794645|DRUG|Pembrolizumab|pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle
219212285|NCT06794645|DRUG|Pemetrexed Phase 2|pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
219212286|NCT06740422|DRUG|Xuanhuang Runtong Tablet|A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
219212287|NCT06740422|DRUG|Xuanhuang Runtong Tablet Simulator|Xuanhuang Runtong Tablet Simulator
219083747|NCT03488368|OTHER|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
219083748|NCT00900874|DRUG|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
219083749|NCT00900874|DRUG|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
219083750|NCT02808936|PROCEDURE|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
219083751|NCT02808936|PROCEDURE|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
219083752|NCT01199484|OTHER|Cow's milk|
219083753|NCT03983187|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
219083754|NCT03320018|DRUG|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
219083755|NCT03320018|DRUG|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
219083756|NCT03320018|OTHER|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
219083757|NCT03320018|OTHER|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
219083758|NCT02858141|OTHER|Data collection|
219212288|NCT06765200|BEHAVIORAL|Self-administered psychosocial intervention delivered via smartphone.|The treatment includes a smartphone-based psychosocial program designed to improve the quality of life of adolescents with chronic pain.
219212289|NCT06763523|PROCEDURE|arthroereisis of the subtalar joint|arthroereisis alone versus arthroereisis combined with corrective osteotomies
219681481|NCT00868478|DRUG|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
219083759|NCT06514144|DRUG|BGF|budesonide/glycopyrrolate/formoterol fumarate
219083760|NCT04657744|DRUG|Sphingomod|1 capsule contains 0.5 mg Fingolimod
219083761|NCT04657744|DRUG|Gilenya|1 capsule contains 0.5 mg Fingolimod
219083762|NCT04147039|BEHAVIORAL|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
219083763|NCT02313857|BIOLOGICAL|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
219083764|NCT00969384|BEHAVIORAL|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
219083765|NCT04984707|DRUG|KX0826|AR antagonist
219083766|NCT04984707|OTHER|Placebo|Placebo of KX-826
219083767|NCT04629677|OTHER|Electronic Health Record Review|Review of medical records
219212290|NCT06762704|OTHER|Video recording|Videos of rotating the blastocysts will be recorded during the preparation stage of trophectoderm (TE) biopsy. The focal plane starts from the middle plane of the blastocyst. and then moves downwards until individual TE cells and inner cell mass (ICM) are clearly visible. A biopsy micropipette is used to gently push the blastocyst and rotate the blastocyst each time by a small angle, for instance, smaller than 35° such that more than 10 images can be captured for the entire 360° rotation to achieve high-accuracy measurement. After the first 360° rotation, the second one will be conducted around the axis perpendicular to the previous axis to ensure the whole surface of the blastocyst is captured. The entire rotation process will be video recoded.
219681482|NCT03063736|DRUG|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
219212291|NCT05933941|OTHER|Virtual reality|"This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility."
219212292|NCT05933941|OTHER|Exercises|The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
219212293|NCT06771232|PROCEDURE|Subdural pressure measurement|Subdural intracranial pressure (SDIP) will observed during an alveolar recruitment maneuver and best PEEP titatration. SDIP will be measured while mechanical ventilation is maintained using the identified best PEEP.
219083768|NCT04629677|OTHER|Quality-of-Life Assessment|Ancillary studies
219083769|NCT04629677|OTHER|Questionnaire Administration|Complete questionnaires
219083770|NCT03284788|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
219083771|NCT04828564|DRUG|Ribavirin Capsules|Ribavirin 200 mg capsules
219083772|NCT04828564|DRUG|Favipiravir|Favipiravir 200 mg tablets
219083773|NCT01572064|PROCEDURE|Blood sample|1 fasted blood sample taken for metabolomics
219083774|NCT01572064|OTHER|MRI Scan|1 single visit for MRI and MRS
219083775|NCT05399225|DIAGNOSTIC_TEST|Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio and procalcitonin in sepsis
219083776|NCT06525844|PROCEDURE|regenerative endodontic therapy using I-PRF|Blood will be taken from medial cubital vein
219083777|NCT06525844|PROCEDURE|blood clot|Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
219083778|NCT06174311|BEHAVIORAL|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
219083779|NCT02899325|DRUG|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
219083780|NCT03958084|DIAGNOSTIC_TEST|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
219083781|NCT05052086|DIAGNOSTIC_TEST|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
219083782|NCT02002026|PROCEDURE|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
219212294|NCT06775600|PROCEDURE|Hip Replacement|Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.
219212295|NCT05120232|BEHAVIORAL|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
219083783|NCT03026790|OTHER|Medication management|Individualized management of medications for pain
219083784|NCT03026790|OTHER|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
219083785|NCT03026790|DRUG|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
219083786|NCT00198484|DRUG|Vitrase|
219083787|NCT04209478|DRUG|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
219083788|NCT04596202|BEHAVIORAL|Supine position|After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
219083789|NCT04596202|BEHAVIORAL|Prone position|After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
219681483|NCT03063736|BIOLOGICAL|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
219083790|NCT04596202|BEHAVIORAL|Lateral position|After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
219212296|NCT05120232|BEHAVIORAL|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
219212297|NCT05301842|DRUG|Tremelimumab|Tremelimumab IV (intravenous)
219212298|NCT05301842|DRUG|Durvalumab|Durvalumab IV (intravenous)
219212299|NCT05301842|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
219212300|NCT05301842|DRUG|Lenvatinib|Lenvatinib (oral)
219212301|NCT06775054|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat depression, particularly in patients who have not responded to traditional treatments such as selective serotonin reuptake inhibitors (SSRIs) or psychotherapy. The most common target area is the dorsolateral prefrontal cortex, which is often underactive in individuals with depression. TMS devices, such as the FDA-approved Magventure system, deliver magnetic pulses to stimulate or inhibit brain activity in the targeted region. This process is believed to help reset or normalize patterns of neural activity associated with depression and other psychiatric disorders. TMS offers a promising alternative for individuals struggling with depression, providing a non-invasive approach with relatively few side effects and notable potential benefits.
219212302|NCT06774118|OTHER|Data collection|Data collection
219212303|NCT06770894|DRUG|Sitagliptin 100 mg|The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)
219212304|NCT06770894|DRUG|Placebo Tablets|Placebo tablets 1 a day, provided in identical blisters.
219212305|NCT06770374|PROCEDURE|Control group: silicone adhesive sutureless fixation device|"The standard care consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and silicone adhesive sutureless fixation device (3300MWA Grip-Lok®)."
219212306|NCT06770374|PROCEDURE|Intervention Group: zinc oxide sutureless fixation device|"Alternative care consisted of:~* Application of haemostasis at the insertion site for 2 minutes post-puncture or until cessation of bleeding.~* Fixation with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and zinc oxide sutureless fixation device (2200NUZA Grip-Lok®)."
219212307|NCT06770374|DEVICE|PICC|"The PICC lines used in the study will all be third-generation polyurethane and of the commercial brands:~* PowerPICC™ 4, 5 and 6 Fr from BD~* Maxflo expert™ 5 and 6 Fr from Vygon"
219212308|NCT06770374|DEVICE|Midline|"The midline lines used in the study will be second or third generation polyurethane and of the commercial brands:~* PowerMidline™ 4 Fr from BD~* Arrow® Midline 4Fr from Arrow"
219212309|NCT06770374|OTHER|Ultrasound scanner|All punctures will be performed under ultrasound guidance.
219212310|NCT05175404|DIAGNOSTIC_TEST|PET/CT scan F18-PSMA-11|PET/CT scan with F18-PSMA-11
219212311|NCT06777680|DIETARY_SUPPLEMENT|co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)|oral suspension, 10 ml twice a day (every 12 hours) for 7 days
219212312|NCT06777680|OTHER|Placebo|oral suspension,10 ml twice a day (every 12 hours) for 7 days
219212313|NCT06777680|PROCEDURE|Thrombectomy|Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
219083791|NCT03182699|DIAGNOSTIC_TEST|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
219212314|NCT03222609|DRUG|Ruxolitinib|Tablet; Oral
219212315|NCT03222609|DRUG|Navitoclax|Film-coated tablet; Oral
219212316|NCT06777550|OTHER|SimucaseTM|experiment group - who will receive the clinical learning method using SimucaseTM
219212317|NCT06777550|OTHER|Conventional Clinical Learning|Problem-based learning case-study case studies
219212318|NCT06762119|DRUG|CAR-T cell|CAR-T cell
219212319|NCT06760780|OTHER|Experimental|The experimental group will first be given a theoretical lesson prepared in line with the current literature on osteoporosis. At the end of the lesson, a prepared scenario example on osteoporosis will be covered.
219212320|NCT06760780|OTHER|Control|The control group will only be given a theoretical lesson prepared in line with the current literature on osteoporosis. No other intervention will be made.
219212321|NCT06768567|PROCEDURE|effect of hemostasis time on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required and time taken to achieve hemostasis will be recorded using stop watch. Teeth in which bleeding will be controlled within 6 mins will be placed in Group A, while those in which it gets controlled between 7 to 12 mins will be included in Group B. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 12 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
219212322|NCT06767592|DIETARY_SUPPLEMENT|Bio-Kult Advanced|Bio-Kult Advanced will be provided as capsules and can be stored at room temperature. Participants will be instructed to swallow two capsules in the morning and two capsules in the evening, with food.
219681484|NCT02738359|PROCEDURE|optical colonoscopy|optical colonoscopy
219681485|NCT02738359|PROCEDURE|colon capsule endoscopy|colon capsule endoscopy
219681486|NCT02738359|DIAGNOSTIC_TEST|fecal immunological test (FIT)|fecal immunological test (FIT)
219212323|NCT06781047|OTHER|Trunk Focused Rehabilitation (TFR)|"Abdominal stabilization progression for TFR is applied with simultaneous breathing exercise for 3 days a week, 45 minutes a day, 8 weeks (24 sessions in total)(8).~1. Basic Abdominal Stabilization Training, Task-Focused Exercises (without spinal diagonal and rotational components)(8,12).~   Warm-up: 5 minutes, Global Stretching and Relaxation(9,10,11). Extremity load, elastic band, and unstable surface are added as stabilization is achieved in neurodevelopmental positions. Task-oriented exercises(12).~   Cooling Down: Warm-up exercises are repeated.~2. General Posture and Asymmetry Training Brochure (includes adolescent, family, and team members)(13-17).~The exercise starts with 3 seconds and gradually progresses to 10 seconds, 10 repetitions, and 3 sets.~The TFR group also receives Conventional Treatment 2 days a week, 40 minutes per day, for 8 weeks. The same treatment protocol is applied as the control group). Routine physiotherapists apply conventional treatment."
219212324|NCT06781047|OTHER|Conventional Rehabilitation (CR)|"Conventional treatment is applied to the group, 2 days a week, 40 minutes each session, for 8 weeks. It is an intervention performed by a physiotherapist who regularly follows up in a special education and rehabilitation center.~1. Normal Joint Movement (NEH)~2. Stretching for the lower, and upper extremities and around the hips~3. Lying activities~4. Curl up (assisted, unaided)~5. Bridging exercise, cat camel exercise, posterior pelvic tilt exercise~6. Walking training~7. Climbing and descending stairs~8. Weight transfer exercises at standing, sitting"
219083792|NCT03182699|DIAGNOSTIC_TEST|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
219083793|NCT03182699|DIAGNOSTIC_TEST|Laboratory tests|drawing blood from dialysis machine
219083794|NCT03182699|DIAGNOSTIC_TEST|Body composition monitoring|Measurement with BCM (Fresenius) machine
219083795|NCT03182699|DIAGNOSTIC_TEST|lung ultrasound|ultrasound
219083796|NCT00772590|DRUG|Raltegravir|Tablets, 400mg, twice daily
219083797|NCT00772590|DRUG|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
219083798|NCT00772590|OTHER|raltegravir placebo|One tablet, twice daily
219083799|NCT00772590|OTHER|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
219083800|NCT00772590|DRUG|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
219083801|NCT05100186|DRUG|Dexamethasone 0.4 MG [Dextenza]|Dextenza
219083802|NCT01367028|DRUG|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
219083803|NCT01367028|DRUG|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
219083804|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
219083805|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
219212325|NCT06820372|OTHER|Electronic Drug Dosing and Decision Support Kidney (eDoseCKD) Tool|Thirty evidence, expert informed and validated computerized drug decision support algorithms of high risk medications will be utilized by community pharmacists for individuals with an eGFR \< 60 ml/min who are on one of the 30 target algorithms. The will be followed up to 3 months to assess effectivess, safety and whether the dose change was maintained.
219083806|NCT01843998|DRUG|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
219083807|NCT01855854|DRUG|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
219083808|NCT01176721|DEVICE|t-VNS verum|Active stimulation of the left auricle by t-VNS
219083809|NCT01176721|DEVICE|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
219083810|NCT02079662|OTHER|Behavioral, Psychological or Informational Intervention|Undergo IO intervention
219083811|NCT02079662|OTHER|Best Practice|Undergo standard of care
219083812|NCT02079662|OTHER|Cognitive Intervention|Undergo IO intervention
219212326|NCT06776744|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).
219212327|NCT06832384|PROCEDURE|intensive physiotherapy|"the dosing of the intensive physiotherapy is of 2 sessions a day, lasting 45 minutes each, administered 5 days a week, for a period of 4 weeks.~the physiotherapy is mainly addressed to the improvement of gross motor movement and balance and the training is designed according to the specific need of the subject recruited. it is not allowed the use of technological devices, excepted treadmill training."
219212328|NCT06380166|DIAGNOSTIC_TEST|Hepatitis C core antigen|Semi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.
219212329|NCT06767982|DRUG|Bacillus Calmette-Guerin (BCG)|In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
219212330|NCT06819215|DRUG|VB15010|Oral PARP1 inhibitor
219681487|NCT05203601|BIOLOGICAL|SIBP-03|"Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study."
219083813|NCT02079662|OTHER|Computer-Assisted Intervention|Undergo IO intervention
219083814|NCT02079662|OTHER|Counseling|Undergo counseling
219083815|NCT02079662|BEHAVIORAL|Exercise Intervention|Undergo IO intervention
219083816|NCT02079662|OTHER|Laboratory Biomarker Analysis|Correlative studies
219083817|NCT02079662|OTHER|Quality-of-Life Assessment|Ancillary studies
219083818|NCT02079662|OTHER|Questionnaire Administration|Ancillary studies
219083819|NCT00687999|DRUG|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
219083820|NCT02775292|BIOLOGICAL|Aldesleukin|Given SC
219083821|NCT02775292|DRUG|Cyclophosphamide|Given IV
219083822|NCT02775292|DRUG|Fludarabine Phosphate|Given IV
219083823|NCT02775292|OTHER|Laboratory Biomarker Analysis|Correlative studies
219083824|NCT02775292|BIOLOGICAL|Nivolumab|Given IV
219083825|NCT02775292|BIOLOGICAL|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
219083826|NCT02775292|BIOLOGICAL|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
219083827|NCT02775292|PROCEDURE|Positron Emission Tomography|Correlative studies
219083828|NCT00199615|PROCEDURE|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
219083829|NCT03104699|DRUG|AGEN2034|Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody
219083830|NCT04329065|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
219083831|NCT04329065|DRUG|Paclitaxel|Given via infusion
219083832|NCT04329065|BIOLOGICAL|Trastuzumab|Given IV
219083833|NCT04329065|BIOLOGICAL|Pertuzumab|Given IV
219083834|NCT04329065|DRUG|Docetaxel|Given IV
219083835|NCT04329065|DRUG|Carboplatin|Given IV
219083836|NCT04329065|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
219083837|NCT04329065|PROCEDURE|Biopsy Procedure|Undergo biopsy
219083838|NCT04329065|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219083839|NCT05365321|DRUG|WP1122|Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
219083840|NCT05687968|BEHAVIORAL|Real-Time Personalized Dietary Feedback (via AI and Nutritionist)|"* Behavioral: 3D/AR MetaFood Portion Size and Nutrition Education~* Behavioral: Nutrition and Physical Activity Educational Videos"
219083841|NCT05687968|BEHAVIORAL|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
219083842|NCT00378001|DRUG|FSH-IBSA|
219083843|NCT00378001|DRUG|GONAL-F|
219083844|NCT00152464|DRUG|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
219083845|NCT00152464|DRUG|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
219083846|NCT06845046|DIETARY_SUPPLEMENT|w-3 fatty acid|omega-3 fatty acid supplement
219083847|NCT06845046|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine supplement
219083848|NCT06845046|OTHER|Control Diet|Control Diet high in unsaturated fat
219083849|NCT02398929|DRUG|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
219083850|NCT02398929|DRUG|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
219083851|NCT01088139|DIETARY_SUPPLEMENT|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
219083852|NCT06201338|PROCEDURE|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
219083853|NCT01421433|DRUG|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
219083854|NCT01421433|DRUG|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
219083855|NCT00616187|DRUG|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
219083856|NCT00616187|DRUG|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
219083857|NCT00501176|PROCEDURE|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
219083858|NCT03440749|OTHER|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
219083859|NCT05360082|OTHER|[11C]UCB-J PET|11C-labeled SV2A binding PET radioligand
219083860|NCT05360082|OTHER|[18F]SynVest-1 PET|18F-labeled SV2A binding PET radioligand
219083861|NCT00236301|DRUG|CLIMASTON (drug)|CLIMASTON(drug)
219083862|NCT00236301|DRUG|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
219083863|NCT00236301|DRUG|placebo|placebo
219083864|NCT03211364|OTHER|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
219083865|NCT03211364|OTHER|Scapular mobilization|
219083866|NCT01487317|DRUG|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped
219083867|NCT01487317|DRUG|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
219083868|NCT04653402|DEVICE|Hydrocelectomy surgery|The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
219083869|NCT01973660|DRUG|Lapatinib|
219083870|NCT01973660|DRUG|Trastuzumab|
219083871|NCT01973660|DRUG|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
219083872|NCT01973660|DRUG|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
219083873|NCT00001507|DRUG|Monoclonal Antibody 3A1|
219083874|NCT00001507|DRUG|Monoclonal Antibody 95-5-49|
219083875|NCT00001507|DRUG|Monoclonal Antibody 95-6-22|
219083876|NCT00001507|DEVICE|Baxter Isolex 3001 Stem Cell Selection System|
219083877|NCT00001507|DEVICE|Ceprate SC|
219083878|NCT00420199|DRUG|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
219361793|NCT02028195|OTHER|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
219083879|NCT00420199|DRUG|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
219083880|NCT06449131|DRUG|Platelet-Rich Plasma and Fibrin Glue|"Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution."
219083881|NCT01328301|OTHER|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
219083882|NCT01328301|OTHER|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
219083883|NCT02445040|DEVICE|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
219083884|NCT03676179|PROCEDURE|patella denervation|patella denervation
219083885|NCT03676179|PROCEDURE|patella non-denervation|patella non-denervation
219083886|NCT06397599|OTHER|denture adhesive|use of adhesive for completely edentulous
219212331|NCT06770829|BEHAVIORAL|DiaFOOTCare Program|The DiaFOOTCare Program includes initiatives to support diabetic foot self-management. An e-booklet on type 2 diabetes management and preventive foot care will be shared via WhatsApp or email, along with audio modules for convenient access. An interactive video featuring a simulated patient will visually demonstrate preventive foot care practices and will also be shared digitally. A 25-30-minute face-to-face training session will provide personalized education using a tablet. Goal-tracking cards will be introduced to collaboratively set three-month behavioral goals, with patients documenting their progress during the follow-up. SMS reminders will be sent three times weekly to reinforce adherence. Patients will have digital access to all DiaFOOTCare resources, including the e-booklet, audio modules, and video, for 12 weeks, ensuring accessibility via WhatsApp or email. These measures aim to enhance knowledge, behavior, and self-management practices in preventive diabetic foot care.
219212332|NCT06770829|BEHAVIORAL|Ministry of Health and Education|The active control group will receive routine outpatient follow-ups and a diabetic foot care brochure from the Ministry of Health, explained by the researcher and shared via WhatsApp or email for reference. Goal-tracking cards from the DiaFOOTCare program will be used to set individual diabetic foot self-management behavioral goals collaboratively during the initial interview. Patients will be instructed on how to complete the cards and maintain them over a three-month period. At the end of the follow-up, post-tests will assess outcomes using the Glycemic Control Form, Goal-Tracking Card, Diabetic Foot Knowledge Scale, Foot Care Behavior Scale, Nottingham Functional Foot Care Diagnostic Form, Diabetic Foot Development Follow-up Form, and Diabetic Foot Self-Management Scale. Educational resources, including the e-booklet, audio modules, and video developed in DiaFOOTCare, will also be shared via WhatsApp or email to provide additional support and enhance diabetic foot self-management.
219212333|NCT06859125|DEVICE|Endo-Wing™ (Shangxian Minimal Invasive Inc, China)|Endo-Wing™ (Shangxian Minimal Invasive Inc, China) is a medical-grade soft silicone rubber device that is attached at the end of a colonoscope. It has 6 soft wing-like projections that are bendable and pliable, giving the endoscopist a superior visualization directly from its action of flattening the colonic folds and maintaining the central view of the colonoscope during withdrawal. This can improve the endoscopist's ADR.
219212334|NCT06859125|DEVICE|Standard Colonoscopy|Colonoscopies performed using Olympus Evis Exera III 90 series or Olympus Evis Lucera 260 series colonoscopes without Endo-Wing attached at the tip of the colonoscope
219212335|NCT06744868|DRUG|THDBH120 injection (SAD)|Participants received escalating single doses of THDBH120 by subcutaneous injection.
219212336|NCT06744868|DRUG|Placebo of THDBH120 injection (SAD)|Participants received single dose of placebo by subcutaneous injection.
219212337|NCT06744868|DRUG|THDBH120 injection (MAD)|Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
219212338|NCT06744868|DRUG|Placebo of THDBH120 injection (MAD)|Participants received placebo once weekly for four weeks by subcutaneous injection.
219212339|NCT03125954|OTHER|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
219212340|NCT05530421|DRUG|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
219212341|NCT05530421|DRUG|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
219681488|NCT03961763|DIETARY_SUPPLEMENT|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
219681489|NCT03961763|OTHER|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
219681490|NCT02412202|OTHER|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
219681491|NCT00516100|DRUG|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
219681492|NCT02018432|DRUG|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
219681493|NCT02018432|DRUG|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
219083887|NCT00430248|DRUG|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
219083888|NCT00430248|DRUG|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
219083889|NCT00430248|DRUG|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
219083890|NCT04434807|PROCEDURE|Minimally invasive hematoma evacuation|Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
219212342|NCT05530421|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
219212343|NCT03307382|DEVICE|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
219212344|NCT06753084|PROCEDURE|Alloderm|the study is done to patient who lacks of keratinized mucosa width by apically positioned flap and using of FGG as gold standard and Mucoderm as compartive group
219212345|NCT03253835|DIAGNOSTIC_TEST|Single Group Assignment|
219361794|NCT01535079|DRUG|Placebo|Single administration
219361795|NCT01535079|DRUG|Ibuprofen 35 mg|Single administration
219681494|NCT02834858|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
219681495|NCT02834858|BIOLOGICAL|saline|
219681496|NCT05475899|DEVICE|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
219083891|NCT01939704|OTHER|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
219083892|NCT01939704|OTHER|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
219083893|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
219083894|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
219083895|NCT00002402|BIOLOGICAL|Aluminum hydroxide|
219083896|NCT05892315|PROCEDURE|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
219083897|NCT05892315|PROCEDURE|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
219083898|NCT05775588|PROCEDURE|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
219083899|NCT04497792|DRUG|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
219083900|NCT04497792|DRUG|hypoglycemic therapy|hypoglycemic therapy.
219083901|NCT02133599|DRUG|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
219083902|NCT03351855|BIOLOGICAL|HPV-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
219083903|NCT01291914|DRUG|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
219083904|NCT01291914|DRUG|Placebo 1 (Carrier)|Single intra-articular injection
219083905|NCT01291914|DRUG|Placebo 2 (Diluent)|Single intra-articular injection
219083906|NCT04069598|DIAGNOSTIC_TEST|Statin intolerance test|Statin intolerance test
219083907|NCT03918863|OTHER|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
219083908|NCT03918863|OTHER|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
219212346|NCT06745349|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria. The Sleep Course is four lessons long and is offered with once weekly therapist support for 8 weeks where clients are encouraged to email the assigned therapist for support each week. The therapist reviews client progress in the Course and emails clients once per week on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
219212347|NCT06744270|OTHER|i-PRF group|"In the i-PRF group, 10 ml of venous blood taken from the patient immediately after the SDG operation will be transferred to a tube that does not contain any anticoagulant. The collected venous blood will be centrifuged for 3 minutes at 2300 rpm in a centrifuge device and two layers will be obtained: the lower layer is red blood cells and the upper layer is i-PRF. 20-25 minutes will be waited for polymerization. After polymerization, the polymerized i-PRF will be applied to the wound surface in the donor area. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days and their photographs will be taken and the following parameters will be evaluated.~* Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using the Image program from patient photographs~* Edema and erythema scores will be assessed visually."
219361796|NCT01535079|DRUG|Ibuprofen 25 mg|Single administration
219361797|NCT01535079|DRUG|Ibuprofen 15 mg|Single administration
219361798|NCT01535079|DRUG|Strefen|Single administration
219083909|NCT03980444|DEVICE|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
219083910|NCT03980444|PROCEDURE|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
219083911|NCT02745821|DEVICE|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
219083912|NCT03387579|DRUG|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
219083913|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
219083914|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
219083915|NCT01546961|DRUG|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
219083916|NCT04769726|DIETARY_SUPPLEMENT|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
219083917|NCT04295954|OTHER|Yoga Intervention|"It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards."
219083918|NCT03605433|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
219083919|NCT00314925|DRUG|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
219212348|NCT06744270|OTHER|low-dose laser group|"In the laser group, low-dose laser will be applied to the palatal donor area immediately after SDG surgery, on the 3rd, 5th, 7th and 14th days. A GaAlAs diode laser (CHEESETM, GIGAA Laser, Wuhan Gigaa Optronics Technology Co., Ltd., China) with a wavelength of 810 nm and a low-dose diode laser application tip with a fiber diameter of 950 µm will be used. A low-dose diode laser will be applied to the surgical operation area in accordance with the manufacturer's instructions, with a non-contact regional 0.3 W power and an intensity of 4 J/cm2 in continuous mode for 1 min. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days, and their photographs will be taken and the following parameters will be evaluated. • Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using Image program from patient photographs~* Edema and erythema scores will be assessed visually."
219212349|NCT06745700|BEHAVIORAL|Brief Behavioural Activation|"Behavioral: Brief Behavioral Activation.~A five-session telephone-based brief behavioral activation treatment.~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log.~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week.~Session 3-4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned. with life goals and values; creating a a maintenance plan.~Other group: care as usual."
219212350|NCT06745700|OTHER|Care as usual|Care as usual provided by Region Västamanland,
219212351|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 2 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days."
219212352|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 1 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation."
219212353|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation"
219212354|NCT06669572|DRUG|Pembrolizumab|"Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks."
219212355|NCT06669572|DRUG|Lenvatinib|Lenvatinib will be taken once daily, with or without food, at the same time each day.
219212356|NCT06784700|OTHER|Massage|Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.
219212357|NCT06784700|OTHER|No intervention|Subjects will not receive any massage program; instead, they will be rested for 30 minutes on an automatic switch-off electric massage chair and subsequently lay down for an additional 30 minutes on a proper double bed;
219212358|NCT06790615|DRUG|methyl prednisolone acetate|methyl prednisolone acetate was injected after the aspiration
219212359|NCT06790615|OTHER|Silk suture|The silk suture was used for threading technique
219212360|NCT06767033|DEVICE|Ultrasound Guided Inferior Vena Cava Collapsibility Index Assessment|Before spinal anaesthesia, inferior vena cava collapsibility index was measured for all patients using Ultrasound device.
219212361|NCT06822946|DRUG|zhibitai capsule|2 capsule of Zhibitai capsule/time, 2 times/day, oral
219681497|NCT02122315|OTHER|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
219083920|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
219681498|NCT02122315|OTHER|Physical therapy|Best-evidence physical therapy intervention
219681499|NCT01266005|DRUG|Clevudine|30mg,QD
219681500|NCT01266005|DRUG|Entecavir|0.5mg QD
219681501|NCT03213392|DRUG|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
219681502|NCT01808261|DRUG|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
219083921|NCT06019195|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
219212362|NCT06822946|DRUG|zhibitai capsule|(1 capsule of Zhibitai capsules+1 capsule of Zhibitai capsule simulant)/time, 2 times/day, oral
219212363|NCT06655272|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
219212364|NCT06655272|DRUG|Placebo|Matching placebo.
219212365|NCT06654401|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard assessment of the parameters of the left atrium: size, volume, volume indices
219212366|NCT06654401|DIAGNOSTIC_TEST|24-hour ECG Monitor|Assessment of cardiac arrhythmias according to 24-hour monitoring data
219212367|NCT06654401|PROCEDURE|Electroanatomic mapping|Intraoperative assessment of low voltage areas (potential fibrosis zones)
219083922|NCT04921631|BEHAVIORAL|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
219083923|NCT01682980|OTHER|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
219083924|NCT01682980|OTHER|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
219083925|NCT04852653|PROCEDURE|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
219083926|NCT01821742|OTHER|Ultrasound cardiac output measurement|
219083927|NCT05143827|OTHER|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
219083928|NCT05143827|OTHER|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
219083929|NCT05410938|DRUG|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
219083930|NCT05100888|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
219083931|NCT05979753|OTHER|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
219083932|NCT02363556|PROCEDURE|Misoprostol administered vaginally|
219083933|NCT02363556|PROCEDURE|Misoprostol administered buccally|
219083934|NCT02363556|PROCEDURE|Misoprostol administered vaginally with Dilapan|
219083935|NCT02363556|PROCEDURE|Misoprostol administered buccally with Dilapan|
219083936|NCT03351972|DRUG|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
219083937|NCT03351972|OTHER|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
219083938|NCT02104622|DEVICE|ReWalk Rehabilitation 2.0|
219212368|NCT06655610|DEVICE|External Trigeminal Nerve Stimulation|Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.
219212369|NCT06655610|DEVICE|Sham device|The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
219212370|NCT06655714|OTHER|No intervention|No intervention
219212371|NCT06631586|BIOLOGICAL|MTP-101C|MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
219212372|NCT06631586|BIOLOGICAL|MTP-101S|MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
219212373|NCT06856031|DRUG|Optimized Treatment (OPT)|After induction therapy with intravenous vedolizumab (300 mg) at weeks 0, 2, and 6, PRO2 was assessed to determine the patient's response and an individualized treatment plan was formulated: vedolizumab was reinfused intravenously (300 mg) every 4 weeks if PRO2 was reduced by \<50% from baseline or was still in the moderately-severe active phase of PRO2.
219681503|NCT01808261|DRUG|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
219083939|NCT03912844|PROCEDURE|SIRT followed by liver resection or liver transplantation|The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
219083940|NCT02979938|OTHER|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
219083941|NCT01754467|BEHAVIORAL|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
219083942|NCT00335218|DRUG|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
219083943|NCT00335218|DRUG|Placebo|1 tablet daily
219083944|NCT03078348|OTHER|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
219083945|NCT03078348|BEHAVIORAL|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
219083946|NCT03078348|BEHAVIORAL|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
219212374|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file.
219212375|NCT06893263|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the canine and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth. A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology.This stage was repeated in 2 different treatment sessions, blue rubber dam was preferred in one of the appointments and black rubber dam was preferred in the other.
219212376|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
219212377|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
219083947|NCT00049374|BIOLOGICAL|oblimersen sodium|
219083948|NCT00049374|DRUG|dexamethasone|
219083949|NCT00049374|DRUG|thalidomide|
219083950|NCT01970462|DRUG|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
219083951|NCT01970462|DRUG|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
219681504|NCT03709147|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
219681505|NCT03709147|DRUG|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
219083952|NCT03311412|DRUG|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
219083953|NCT03311412|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
219083954|NCT03311412|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
219083955|NCT05439902|DRUG|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
219212378|NCT06751888|OTHER|Controlled CO2 delivery|The use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension
219083956|NCT05439902|DRUG|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
219083957|NCT04538326|BEHAVIORAL|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
219083958|NCT04746573|DEVICE|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
219083959|NCT03964597|DIAGNOSTIC_TEST|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
219083960|NCT00144274|DRUG|Ambroxol Lozenge|
219083961|NCT03094780|BEHAVIORAL|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
219083962|NCT03094780|OTHER|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
219083963|NCT04208516|PROCEDURE|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
219083964|NCT04208516|PROCEDURE|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
219083965|NCT04208516|PROCEDURE|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
219083966|NCT04208516|PROCEDURE|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
219083967|NCT04208516|DRUG|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
219083968|NCT04208516|DRUG|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
219083969|NCT04208516|DRUG|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
219083970|NCT04208516|DRUG|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
219083971|NCT04208516|DRUG|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
219083972|NCT04020341|DRUG|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
219083973|NCT04020341|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
219083974|NCT04020341|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
219083975|NCT04020341|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
219083976|NCT03756792|BEHAVIORAL|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
219083977|NCT03756792|BEHAVIORAL|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
219212379|NCT06751888|DEVICE|Controlled CO2 delivery (Sham)|For this intervention, we will be using this device set at 0% CO2 for our sham comparison.
219212380|NCT06762288|DEVICE|Ultrasound|Sedation and local anesthesia to the surgical field will be applied as standard procedure and unilateral USG-guided TAP block will be performed to the patients who will undergo TAVİ.
219212381|NCT06762288|PROCEDURE|Local anesthesia and sedation|Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
219212382|NCT06762223|DRUG|Henagliflozin 10 mg daily|Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.
219083978|NCT05763628|DEVICE|Control Lens (stenfilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
219083979|NCT05763628|DEVICE|Test Lens (senofilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
219083980|NCT05574725|DEVICE|Smartphone|review of the smartphone video on patients phone by general neurologist and epileptogist each separately with comment on onquality of video using videoquality scale(10), semiology, seizure diagnosis
219083981|NCT02361320|PROCEDURE|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
219083982|NCT02361320|BEHAVIORAL|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
219083983|NCT02351219|DRUG|FOLFOXIRI|
219083984|NCT04830826|PROCEDURE|Surgeries|Surgeries
219083985|NCT02098980|DIETARY_SUPPLEMENT|Vitamin D|
219083986|NCT04683926|DRUG|Desmetramadol|Analgesic
219083987|NCT00346021|BEHAVIORAL|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
219681506|NCT03709147|DRUG|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
219212383|NCT06762223|DRUG|Metformin 1700 mg daily|The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
219212384|NCT06762223|OTHER|Placebo of Henagliflozin|The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.
219212385|NCT06773351|DRUG|Sevoflurane 0 + different doses of ciprofol|Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg/kg, respectively.
219212386|NCT06773351|DRUG|Sevoflurane 0.7% + different doses of ciprofol|Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg/kg, respectively.
219212387|NCT06773351|DRUG|Sevoflurane 1.0% + different doses of ciprofol 0.05|Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
219212388|NCT06773351|DRUG|Sevoflurane 1.5% + differnet doses of ciprofol|Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
219212389|NCT06773351|DRUG|Sevoflurane 2.0% + different doses of ciprofol|Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
219212390|NCT06773351|DRUG|Sevoflurane 2.5% + different doses of ciprofol|Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
219212391|NCT06773351|DRUG|Ciprofol 0 + different end-expiratory concentration of sevoflurane|Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.
219212392|NCT06773351|DRUG|Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.05 mg/kg combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5 %, respectively.
219212393|NCT06773351|DRUG|Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.1mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
219212394|NCT06773351|DRUG|Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.2 mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
219083988|NCT02753049|BEHAVIORAL|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
219083989|NCT00003796|DRUG|irofulven|
219083990|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Bread with Yeast|Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
219083991|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Sourdough Bread|Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
219212395|NCT06773351|DRUG|Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.3 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
219083992|NCT00617981|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
219083993|NCT00617981|DRUG|5% Dextrose Solution|Single 30 minute intravenous infusion
219083994|NCT02281669|DRUG|Pentostam|Intralesional injection of Pentostam
219083995|NCT02123108|DRUG|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
219083996|NCT02123108|DRUG|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) \< 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
219083997|NCT02123108|DRUG|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
219212396|NCT06773351|DRUG|Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.4 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
219083998|NCT02123108|DRUG|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
219083999|NCT02241122|PROCEDURE|prostate biopsy|
219084000|NCT02450266|DEVICE|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
219084001|NCT02450266|DEVICE|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
219084002|NCT05039372|BEHAVIORAL|TRAINING AND CONSULTANCY|TRAINING AND CONSULTANCY
219084003|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
219084004|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
219084005|NCT00716092|DRUG|Sitagliptin|100 mg once daily for 28 days
219084006|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
219084007|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
219084008|NCT00716092|DRUG|Linagliptin|5mg once daily for 28 days
219084009|NCT01208948|DRUG|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
219084010|NCT03956472|PROCEDURE|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
219084011|NCT03956472|DEVICE|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
219084012|NCT03956472|OTHER|Fake Osteopathic protocol|Placebo intervention
219084013|NCT03956472|OTHER|PEEP-Sham|PEEP 0 cmH2O (hidden)
219212397|NCT06773572|PROCEDURE|Autologous Exososomes procedure obtained from the patients' own platelets.|Intraovarian injection (into the ovarian cortex) was performed over four cycles, once a month in each ovary on days 7, 8, or 9 of the menstrual cycle. Blood was drawn using the selected PRP kit; in this case, all the PRP was placed into two 20 cc syringes, and the exosomes were filtered using the EXOSMAT kit for autologous platelet exosomes. A total of 5 to 6 cc of liquid composed exclusively of platelet-derived exosomes was obtained, with a concentration of 5 to 6 trillion exosomes per milliliter. Finally, 2 to 3 cc were administered to each ovary via the transvaginal route.
219084014|NCT00578955|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
219084015|NCT00578955|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
219084016|NCT00578955|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
219084017|NCT00122226|DRUG|Lopinavir/ritonavir + zidovudine + lamivudine|
219084018|NCT00122226|DRUG|Lopinavir/ritonavir + nevirapine|
219084019|NCT02713802|DRUG|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
219084020|NCT02713802|DRUG|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
219084021|NCT01132326|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
219084022|NCT03888664|DRUG|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
219084023|NCT05933759|BEHAVIORAL|Telemedical coaching|Individual telemedical coaching delivered by a nutritional consultant
219084024|NCT05933759|BEHAVIORAL|Low-Insulin-Method|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
219084025|NCT00677235|DEVICE|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
219084026|NCT00677235|PROCEDURE|PTA|Treatment of stenoses with PTA only
219084027|NCT00952367|OTHER|Nasopharyngeal swab|Nasopharyngeal swab
219084028|NCT03016767|PROCEDURE|Manual oral stimulation protocol|
219212398|NCT06773572|PROCEDURE|Patient group for activated platelet growth factors|the plasma was placed in two 5 cc injectors to place 2 to 3 cc in each ovary (in the ovarian cortex) with the patient sedated. The PRP was placed transvaginally and using a follicular aspiration needle for the PRP group. All biostimulations were performed in early follicular phase (day 7, 8 or 9) in all groups according to their assigned technique.
219212399|NCT06773572|PROCEDURE|the control group|Finally, the control group received 2 to 3 cc of physiological solution in each ovarian cortex for 4 cycles as the two previous groups. All these procedures were performed transvaginally under controlled surgical sedation with follicular aspiration needle in the ovarian cortex and guided by transvaginal echosonogram
219212400|NCT06773884|OTHER|"Observational Analysis of Primary Hip Fracture Surgery Outcomes"|This study examines outcomes following standard primary hip fracture surgery by analyzing retrospective data from national health registries. The focus is on identifying perioperative and patient-related risk factors that influence outcomes such as reoperation rates, mortality, and secondary fractures within one year of surgery. No experimental or new intervention is introduced in this study.
219212401|NCT06774560|OTHER|CAD/Cam milled onlays|"The digital workflow in dentistry has proven in the past decades to be a time-efficient, multifunctional, effortless, and accessible approach. The inherited shortages milling machines represented by the incapability to produce accurate complex hollow structures may give preference to modern 3D ceramic printing.~Computer-aided-design/computer-aided-manufacturing (CAD/CAM) in dentistry is a digital subtractive approach for manufacturing indirect restorations. Nevertheless, waste materials and milling burs wearing are considered as key disadvantages of CAD/CAM technology, and are the main drive to improve 3D printing technology (additive manufacturing) as the latter has shown considerable efficiency in minimising wasted materials."
219084029|NCT03521726|DRUG|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
219084030|NCT03521726|DRUG|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
219084031|NCT03414801|OTHER|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
219084032|NCT01040260|OTHER|Counseling|Smoking cessation counseling
219084033|NCT01040260|BEHAVIORAL|Contingency management|Use of tangible rewards for abstinence from smoking
219084034|NCT01040260|DRUG|Nicotine patches|Nicotine patches
219084035|NCT00264420|DRUG|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
219084036|NCT06215014|OTHER|Isometric handgrip training|Participants will train three days per week at home for 1 month using a reliable and validated digital handgrip dynamometer (DynX, MD System, Inc., Westerville, USA) in a seated position. The isometric handgrip training protocol will consist of four sets (2 for each hand) of two-min sustained contractions starting at 30% of maximum voluntary contraction (MVC) interspersed by 1-min resting periods (a total of 12-min). All training sessions will be remotely supervised via Zoom or phone call by a research team member to ensure compliance with the exercise prescription. Before each training session, MVCs will be re-assessed over three repetitions, each separated by 30-s, to ensure an accurate exercise prescription. The highest value will be used to determine the target intensity of the session
219084037|NCT04504331|DRUG|Infigratinib|Oral dose
219084038|NCT04504331|DRUG|Tamoxifen|Oral Dose
219084039|NCT04504331|DRUG|Omnipaque 350|IV contrast agent
219084040|NCT04504331|DRUG|Iopamidol|IV contrast agent
219084041|NCT04504331|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
219084042|NCT01732848|DRUG|BMS-986094/INX-08189|
219084043|NCT01732848|DRUG|Placebo matching BMS-986094/INX-08189|
219084044|NCT05741684|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
219212402|NCT06774560|OTHER|3D printed onlays|"3D printing technologies are developing more intensively in dentistry as this technology has the capacity to produce shapes or models with high accuracy and in a short time. This method of fabrication takes less time and money and saves on materials compared to CAD/CAM.~Although it seems that digital manufacturing technology has made great changes in the restorative dentistry field, this technology is still not fully in use. This is possibly because of the lack of studies and research on this technology, particularly in terms of clinical performance and patient-centred outcomes. 3D printing technologies are novel technologies with a lack of research; therefore, the processing of 3D printing materials is still controversial."
219212403|NCT06773416|COMBINATION_PRODUCT|CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 1 will receive CPAP therapy immediately upon enrollment alongside web-based sleep education through the Brain Health Pro (BHP) platform. The CPAP intervention includes a study-provided auto-titrating device, in-person mask fitting, and ongoing support from a study sleep technologist. Adherence will be monitored via remote data uploads. The BHP platform is a 45-week web-based formal educational program program designed to increase dementia literacy, foster engagement, and convey best available evidence for lifestyle changes that can mitigate dementia risk. This combined approach ensures simultaneous initiation of CPAP and educational reinforcement to optimize adherence and cognitive outcomes.
219212404|NCT06773416|COMBINATION_PRODUCT|Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 2 will begin with 4 months of BHP web-based sleep education before adding CPAP therapy for the remaining 4 months. CPAP setup and support are identical to the Early CPAP group. Participants in Group 2 will experience procedure similar to current clinical practices.
219212405|NCT06712940|BEHAVIORAL|Motivational Interviewing and Firearm Safety Training, with Case Management|"The basic principles of MI as applied to violence risk reduction in victims of gun violence are as follows: Express Empathy, Develop Discrepancy, Roll with Resistance, and Support Self-Determination/Self- Efficacy. MI practitioners offer themselves as a consultant while respecting the participant as the real expert in their own life. MI also affirms the patient's ability to make changes and communicates trust in the patient's judgments about readiness and plans for change. Motivational interviewing sessions will occur once a month, for six months with a licensed clinical social worker (LCSW).~The LCSW will additionally provide case management over the course of the six month study, and a one time firearm safety training that covers safe storage methods. At the end of the firearm safety training, the participant will be offered a biometric lock box for free."
219212406|NCT03981380|DRUG|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
219212407|NCT06765018|DEVICE|Tongue Brush (Orabrush)|Patients in this group uses the Tongue Brush (Orabrush) 2 times a day for a duration for 3-5 days until the follow-up-screening takes place.
219084045|NCT05741684|BEHAVIORAL|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
219084046|NCT02753855|DRUG|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
219084047|NCT04759690|BEHAVIORAL|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
219084048|NCT04759690|BEHAVIORAL|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
219084049|NCT01451879|DRUG|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
219084050|NCT01451879|DRUG|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
219084051|NCT05018884|PROCEDURE|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
219084052|NCT03659448|DRUG|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
219084053|NCT01509781|PROCEDURE|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
219084054|NCT01509781|PROCEDURE|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
219084055|NCT04679181|OTHER|Telemedecine|telemedical consultation
219084056|NCT03129854|DEVICE|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
219084057|NCT00228072|PROCEDURE|Suction-curettage|
219084058|NCT04570436|DRUG|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
219084059|NCT04570436|DRUG|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
219084060|NCT04570436|DRUG|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
219084061|NCT04570436|DRUG|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
219084062|NCT04570436|OTHER|placebo|participants will receive an oral dose of placebo
219084063|NCT00023153|DRUG|Adefovir Dipivoxil|
219212408|NCT06749158|PROCEDURE|spontaneous bone regeneration|"stage 1 surgery:~1. after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml + adrenaline 0.017 mg/1.7 ml injectable solution), sulcular incision will be done , extending two teeth beyond the area of interest followed by two oblique incisions on either side of the flap~2. after flap elevation, enucleation of the cystic lesion and extraction of the non-restorable teeth related to the lesion will be done.~3. titanium mesh will be tailored with 3 mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws.~This will be followed by:~* proper decompression of soft tissue to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(after 6 months):~  1. titanium mesh and screws will be removed.~ 2. core biopsy will be obtained for histological assessment~ 3. implant/s placement."
219084064|NCT05727410|DRUG|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
219084065|NCT01635257|OTHER|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
219212409|NCT06749158|PROCEDURE|guided bone regeneration|"stage 1 surgery after cyst enucleation and extraction of the non-restorable teeth related to the lesion, The intra-bony defect will be filled with Deproteinized Bovine Bone.~* Titanium mesh will be tailored with 3mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws. This will be followed by:~* proper decompression of soft tissue will be applied to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(6 months later) :~  1. titanium mesh will be removed.~ 2. core biopsy will be obtained for histological assessment.~ 3. implant/s placement."
219084066|NCT05817448|DIAGNOSTIC_TEST|HIF 1α and LC3B expression and MMP-9 level|"5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression"
219212410|NCT06748326|PROCEDURE|Laparoscopy|Intussusception reduction by laparoscopy in children in failed non surgical procedures and in recurrence
219212411|NCT06749522|RADIATION|high resolution ultrasonography|to compare high resolution ultrasonography finings with other imaging modalities(CT and MRI)
219212412|NCT06749691|DRUG|Liposomal Irinotecan and Apatinib|Liposomal Irinotecan in Combination With Apatinib
219212413|NCT06748859|OTHER|Counterstrain technique|In this group, participants will receive counterstrain technique on the Psoas major muscle and exercise training within two weeks.
219212414|NCT06748859|OTHER|Exercise therapy|participants who will assign to this group will receive exercise therapy within two weeks.
219212415|NCT06762743|DRUG|Brivaracetam Oral Solution (Test Formulation)|The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
219084067|NCT00781391|DRUG|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
219084068|NCT00781391|DRUG|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
219084069|NCT00781391|DRUG|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
219084070|NCT00781391|DRUG|placebo warfarin|placebo warfarin
219084071|NCT00781391|DRUG|placebo edoxaban|placebo edoxaban
219084072|NCT04745481|DEVICE|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
219084073|NCT04745481|DEVICE|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
219084074|NCT04444167|BIOLOGICAL|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
219084075|NCT04444167|DRUG|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
219084076|NCT03574064|OTHER|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
219084077|NCT03574064|OTHER|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
219212416|NCT06762743|DRUG|Brivaracetam Oral Solution (Reference Formulation)|The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
219212417|NCT06769698|DRUG|FDC fianlimab+cemiplimab|Fixed-Dose Combination (FDC) Administered per the protocol
219084078|NCT03574064|OTHER|GLP-2+GIP|GLP-2+GIP injection.
219084079|NCT03574064|OTHER|Placebo|Placebo injection.
219084080|NCT03616184|DRUG|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
219084081|NCT06439355|BIOLOGICAL|Fasting blood test|metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
219212418|NCT06769698|DRUG|Cemiplimab|Administered per the protocol
219084082|NCT06439355|OTHER|Subject interview|socio-demographic data, medical and family history, treatment taken
219212419|NCT06769698|DRUG|Placebo|Administered per the protocol
219212420|NCT06769828|DRUG|Ga-68-FAPI-46|Ga-68-FAPI-46 PET scan in colorectal cancer
219212421|NCT06764823|OTHER|Cryotherapy|In the cryotherapy group, after completing the biomechanical preparation, the root canals will be irrigated with 5 mL of 0.9% physiological saline solution at 2.5°C for 5 minutes; the solution will be stored in the refrigerator until use.
219212422|NCT06764823|OTHER|Control|In the control group, the final irrigation will be performed using 5 mL of 0.9% physiological saline solution at room temperature for 5 minutes.
219212423|NCT06762587|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.
219212424|NCT06762587|DRUG|Oseltamivir|Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
219212425|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_L|subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain
219212426|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_L|subject will receive a low-dosage (300mg/d) of resveratrol
219212427|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_M|subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain
219084083|NCT06439355|OTHER|Motor assessment|MDS-UPDRS scale PART III
219084084|NCT06439355|OTHER|Neurocognitive assessment|MoCA and MMSE scales
219212428|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_H|subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain
219212429|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_H|subject will receive a low-dosage (600mg/d) of resveratrol
219212430|NCT06779214|OTHER|placebo_Bif|subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)
219212431|NCT06779214|OTHER|placebo_resveratrol|subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)
219212432|NCT06772467|BEHAVIORAL|Intervention (Reiki)|Reiki was applied to this group twice a week for 4 weeks by a researcher who had a Reiki application certificate. Reiki sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Reiki is applied to the seven major chakras and many minor chakras in the body. The chakras are located in the centre of the body, on a vertical line, in the front and back of the body. In this study, Reiki was applied to the patients twice a week for 4 weeks. Reiki sessions were performed before haemodialysis and each session lasted approximately 35-40 minutes. The vital signs of the patients were measured and recorded 3 times: before each Reiki session, after the Reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale.
219212433|NCT06772467|BEHAVIORAL|EFT|"Emotional Freedom Technique (EFT) is a method that helps people manage their emotions and disturbing thoughts, helping to reduce their stress and anxiety. EFT is also called tapping.~EFT sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Patients received 8 sessions of EFT. The vital signs of the patients were measured and recorded 3 times: before each EFT session, after the reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale."
219212434|NCT05616260|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
219212435|NCT05616260|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
219212436|NCT05616260|DEVICE|Continuous Positive Airway Pressure|Standard CPAP device
219212437|NCT06806839|PROCEDURE|dual plating|surgical fixation of the distal femur using two plates to enhance stability and fracture healing.
219212438|NCT06806839|PROCEDURE|single plating|surgical fixation of the distal femur using a single plate according to standard fixation protocols.
219212439|NCT06733766|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radiofrequency ablation, laser ablation
219084085|NCT06439355|OTHER|Nutritional assessment|anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
219084086|NCT06439355|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
219681507|NCT03709147|DRUG|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
219681508|NCT03709147|DIETARY_SUPPLEMENT|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
219681509|NCT03709147|DRUG|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
219681510|NCT00939614|DRUG|Lamotrigine|
219681511|NCT00573872|RADIATION|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
219681512|NCT03128619|PROCEDURE|Biopsy of Breast|Undergo biopsy
219681513|NCT03128619|DRUG|Copanlisib|Given IV
219681514|NCT03128619|OTHER|Laboratory Biomarker Analysis|Correlative studies
219681515|NCT03128619|DRUG|Letrozole|Given PO
219681516|NCT03128619|DRUG|Palbociclib|Given PO
219681517|NCT03128619|OTHER|Pharmacological Study|Correlative studies
219681518|NCT05358990|OTHER|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
219681519|NCT05358990|OTHER|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
219681520|NCT00812032|DRUG|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
219212440|NCT06756152|DRUG|Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150|The most significant adverse events limiting the use of HSCT from an unrelated donor are graft-versus-host disease (GVHD) and prolonged immunodeficiency associated with the development of severe infectious complications. The use of post-transplant cyclophosphamide for the prevention of GVHD during allogeneic HSCT from unrelated and haploidentical donors has reduced the incidence of acute clinically significant GVHD in children to 25%, chronic GVHD to 12-30%, but the issue of GVHD control still remains extremely relevant. Emerging data on the use of abatacept, a selective blocker of the costimulatory signal from an antigen-presenting cell, in the prevention of intestinal GVHD and data on the effectiveness of Janus-kinase type 1/2 inhibitors (JAK-1/2) in the treatment and prevention of acute GVHD allow us to justify the use of these drugs in combination with post-transplant cyclophosphamide as a promising pharmacological platform for the prevention of GVHD.
219212441|NCT06860737|DEVICE|Novel plano spectacle lenses|Use of novel plano spectacle lenses for at least 8 hours a day with objective wearing time measured by smart frame and objective outdoor time measured by smart bracelet.
219212442|NCT06832865|DRUG|elranatamab|"Subcutaneously injected study drug, usually into the abdomen or lower stomach. Each vial of elranatamab contains a sufficient amount of product to ensure an extractable volume of 1.9 mL at a concentration of 40 mg/mL. The dosing is as follows:~* Cycle 1 Day 1: 12 mg/0.3 mL~* Cycle 1 Day 4: 32 mg/0.8 mL~* Cycle 1 Day 8, 15, 22: 76 mg/1.9 mL~* Cycles 2-6, Day 1 and 15: 76 mg/1.9 mL~* Cycles 7+, Day 1: 76 mg/1.9 mL"
219212443|NCT06832865|DRUG|Isatuximab SC|"Isatuximab (SAR650984) is an IgG1 derived monoclonal antibody binding selectively the human CD38 membrane protein. Subcutaneously (SC) injected study drug with each vial containing 140 mg/mL (1400 mg/10mL) isatuximab. Isatuximab SC will be injected using the investigational OBDS and in the following doses:~* Cycles 2-6, Day 1 and 15: 1400 mg/10 mL~* Cycles 7+ Day 1: 1400 mg/10 mL"
219681521|NCT00812032|DRUG|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
219084087|NCT03458455|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
219084088|NCT03458455|RADIATION|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
219084089|NCT03458455|DRUG|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
219084090|NCT04413630|OTHER|family workshop|The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
219084091|NCT04111757|DEVICE|Technolas® TENEO 317 Model 2|LASIK eye surgery
219084092|NCT00929162|DRUG|ZD4054 Zibotentan|10 mg oral tablets once daily
219084093|NCT00929162|DRUG|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
219084094|NCT00929162|DRUG|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
219084095|NCT00929162|DRUG|Placebo|matching placebo for ZD4054 10 mg
219084096|NCT00107250|DRUG|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
219084097|NCT00107250|DRUG|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
219084098|NCT00107250|DRUG|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
219084099|NCT00107250|DRUG|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
219084100|NCT01429636|BEHAVIORAL|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
219084101|NCT01429636|BEHAVIORAL|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
219084102|NCT04506957|DEVICE|Pulse CO-Oximetry Hemoglobin measurement transcutaneous|this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
219084103|NCT05079022|DRUG|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
219084104|NCT01535820|DRUG|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
219084105|NCT01535820|DRUG|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
219084106|NCT05508230|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
219084107|NCT02891720|DEVICE|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
219084108|NCT00762944|DEVICE|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
219084109|NCT04202939|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
219084110|NCT02495480|DEVICE|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
219084111|NCT01822587|DRUG|Propranolol, 40 mg|
219084112|NCT01822587|DRUG|Propranolol, 80 mg|
219084113|NCT01822587|DRUG|Placebo|
219681522|NCT03965520|BEHAVIORAL|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
219084114|NCT05353998|OTHER|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
219084115|NCT05353998|OTHER|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
219084116|NCT01274182|BIOLOGICAL|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
219212444|NCT06832865|DEVICE|Isatuximab SC-OBDS|The On Body Delivery System (OBDS) also called Isatuximab SC Wearable Injection System, is a sterile, single-use, disposable, elastomeric, user-filled investigational medical device. The OBDD has a reservoir for the drug product (isatuximab). A self-contained, integrated needle (with manual insertion and automatic retraction mechanism) is provided within the OBDS. The OBDS will be used to inject isatuximab each time the participant receives isatuximab in this study. Study drug administration will be done by trained medical professionals in the clinic. The OBDS device will be prepared by the medical professional, placed on the abdomen using the adhesive (sticky) pads that are on the device, the study drug (isatuximab) will be injected, and then the device will be removed.
219212445|NCT06854744|PROCEDURE|lesion sterlization and tissue repair|evaluate and compare the clinical and radiographic effect of zinc oxide-ozonated olive oil (ZnO-OO) versus Modified Triple Antibiotic Paste (MTAP) as a Lesion Sterilization and Tissue Repair Technique in Primary Molars.
219212446|NCT06854744|OTHER|Zinc Oxide Ozonated Oil|Zinc Oxide Ozonated Oil
219212447|NCT06854744|OTHER|Modified Triple Antibiotic Paste|Modified Triple Antibiotic Paste
219212448|NCT06745830|OTHER|No intervention|No intervention
219212449|NCT04305327|DRUG|Brodalumab|Solution for subcutaneous injection.
219212450|NCT04305327|DRUG|Ustekinumab|Solution for subcutaneous injection.
219212451|NCT04305327|DRUG|Placebo|The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
219212452|NCT06778395|DRUG|Dexlansoprazole 60 mg|once daily for 8 weeks
219212453|NCT06778395|DRUG|Vonoprazan 20 mg bid|twice daily for 8 weeks
219212454|NCT06884696|OTHER|Blood samples for inflammatory markers|Blood sampling
219212455|NCT06884696|OTHER|Placental Extract|Placental sampling after caesarean section
219084117|NCT01274182|BIOLOGICAL|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
219212456|NCT06883539|DRUG|LXP1788 is administered intravenously via Port-A|LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.
219212457|NCT06752226|OTHER|action observation trainingAOT refers to an observational practice that has been used extensively for the goal of motor programming and enhances motor learning and performance|In AOT, motor-related information can be available through the visual function by encoding into the mental representation of the memory to organize the intended action
219212458|NCT06747104|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
219212459|NCT06747104|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
219212460|NCT06750575|DIAGNOSTIC_TEST|Invasive measurements|Blood and urine samples will be collected during the study.
219212461|NCT06842550|BEHAVIORAL|MAintAin Activity with Arthritis|Participants will receive up to five health coaching sessions led by a trained provider. The aim is to motivate people to meet their physical activity goals, look at their options, make choices and plans, identify challenges, and help them through these changes related to their physical activity and maintenance. Session 1: One to one session with a physical activity coach Session 2-5: Group sessions with approx. 8-10 other people living with arthritis. In the sessions participants will: • Set, reflect and adapt your activity goals • Learn to problem solve • Develop action plans to build new habits. • Learn about opportunities such as walking groups, aqua aerobics and yoga classes are available in your community • Have the support of peers in the group. Please note that these sessions are not exercise classes.
219212462|NCT06845540|DRUG|Metformin|Participants received oral metformin tablets for the treatment of melasma. The initial dose was 500 mg once daily for four weeks. At week 4, participants who tolerated the medication well increased their dose to 500 mg twice daily for the remaining eight weeks of the study. Participants were instructed to avoid other melasma treatments during the trial and to use sunscreen (SPF 30 or higher) daily.
219212463|NCT06849570|OTHER|Minimal distension|Patients receive tidal volume (VT) of 6 mL/kg and conservative positive end-expiratory pressure (PEEP) setting.
219212464|NCT06849570|OTHER|Maximal Recruitment|Patients receive tidal volume adjusted to limit plateau pressure (∆P) to 14 cmH2O and the highest possible PEEP while maintaining plateau pressure (PPLAT) ≤ 27 cmH2O.
219084118|NCT01274182|BIOLOGICAL|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
219084119|NCT02355002|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
219084120|NCT04594031|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)
219084121|NCT03371810|BEHAVIORAL|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
219212465|NCT06849570|OTHER|Prone position + early NMBAs|NMBAs given as soon as possible after randomization
219212466|NCT06849570|OTHER|Prone position + rescue NMBAs|NMBAs given only as a rescue
219212467|NCT06798818|DEVICE|Ultra-rapid therapeutic hypothermia induction by total liquid ventilation|Vent2Cool System is a targeted temperature management device used to induce ultra-rapid therapeutic hypothermia by total liquid ventilation.
219212468|NCT06845917|DEVICE|Remote Patient Monitoring system|"RMS consists of an initial assessment visit and system installation: A nurse trained by the EPOCA team will conduct a comprehensive assessment of the patient's needs during a home visit within 48 hours of enrollment. This includes collecting biometric measurements, socio-economic profile, and completing a questionnaire with the patient. The initial visit also includes a consultation with a physician. All the information is transmitted to a digital platform accordingly a personalized care plan (PCP) will be defined. The nurse installs a telemonitoring kit for the patient and gives them instructions on how to use it.~The PCP manager will be responsible for implementing and overseeing the patient care plan, including informing the relevant stakeholders. Patients will be monitored via regular data feedback from the connected devices, the physician and the PCP manager. The PCP manager will treat any identified anomalies or abnormalities and implement the necessary changes on the PCP."
219084122|NCT03371810|BEHAVIORAL|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
219212469|NCT05763966|OTHER|No intervention|Observational study where participants are followed over time
219212470|NCT03656718|BIOLOGICAL|nivolumab|(Subcutaneous) Specified dose on specified days
219212471|NCT03656718|DRUG|rHuPH20|Specified dose on specified days Permeation enhancer
219212472|NCT03656718|BIOLOGICAL|nivolumab|(IV) Specified Dose on Specified Days
219212473|NCT05838846|DRUG|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
219084123|NCT03533426|PROCEDURE|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
219084124|NCT03533426|PROCEDURE|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
219084125|NCT05569746|DRUG|INM004|Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
219084126|NCT05569746|OTHER|SoC|Standard of care
219084127|NCT03132428|DRUG|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
219084128|NCT03879746|DRUG|Tamsulosin|drug will be used in treatment of premature ejaculation
219084129|NCT03879746|DRUG|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
219084130|NCT03879746|OTHER|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
219084131|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
219084132|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
219084133|NCT00708916|DRUG|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
219084134|NCT02444390|PROCEDURE|Biopsy|biopsy of a metastasis
219212474|NCT05838846|DRUG|IV Milrinone|Patients will receive intravenous milrinone infusion at dosage of 0.3 - 0.75 mcg/kg/min with loading dose of 50 mcg/kg over 10 min. After cross clamp off and temperature of 32 degree, Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
219212475|NCT06792903|DRUG|CG101 high dose + artificial tear|Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
219212476|NCT06792903|DRUG|CG101 low dose + artificial tear|Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
219212477|NCT06792903|DRUG|placebo + artificial tear|Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
219212478|NCT00214708|PROCEDURE|Screening for Tuberculosis|
219212479|NCT06748651|DRUG|Allocetra|Intra-articular injection of Allocetra performed once on Day 1 of the study
219212480|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
219212481|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
219212482|NCT03211247|BIOLOGICAL|Part A Placebo|Placebo patch, once daily
219212483|NCT03211247|BIOLOGICAL|Part B Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
219212484|NCT03211247|BIOLOGICAL|Part B Placebo|Placebo patch, once daily
219212485|NCT06815887|DRUG|Bupivacaine|Patients received the combined pectoralis nerve block II (PECS II) (20 mL) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) without magnesium sulfate.
219212486|NCT06815887|DRUG|Bupivacaine + Magnesium sulfate|Patients received the combined (20 mL) pectoralis nerve block II (PECS II) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) mixed with 2.5 mL magnesium sulfate (10%), i.e., 250 mg.
219212487|NCT06854991|OTHER|Active VR-PAT|Virtual Reality Pain Alleviation Tool (VR-PAT) hosted on a Pico Neo 3 Pro Eye headset. Both engagement and immersion.
219212488|NCT06854991|OTHER|Passive VR-PAT|VR-PAT hosted on a Pico Neo 3 Pro Eye headset, with the active game participation removed. Immersion with engagement removed.
219212489|NCT06854991|OTHER|iPad|VR-PAT hosted on an Apple iPad. Engagement with immersion removed.
219212490|NCT06743724|DEVICE|repeated transcranial magnetic stimulation treatment|Patients with low score of Maternal Care Rating Scale received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 2 week.
219212491|NCT06773923|DEVICE|PCL Scaffold|patients with their jaw/maxilla in which the 3D scaffold with PCL will be inserted.
219212492|NCT06773923|DEVICE|PTFE + Bio-Oss®|patients with jaw/maxilla which will be regenerated using the conventional technique using a titanium reinforced polytetrafluoroethylene (PTFE) membrane (Cytoplast® brand) and filling the space with Bio-Oss xenograft (Geistlich
219212493|NCT04352166|DRUG|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
219084135|NCT04020848|OTHER|Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.|Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
219084136|NCT04020848|OTHER|The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire|Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
219084137|NCT02200796|OTHER|Control Meal|High carbohydrate meal
219084138|NCT02200796|OTHER|Low Protein Meal|Omelet with 15 g of protein
219084139|NCT02200796|OTHER|Moderate Protein Meal|Omelet with 30 g of protein
219212494|NCT04352166|DRUG|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
219212495|NCT06725173|GENETIC|Targeted Long-read sequencing|All patient's will undergo targeted long-read sequencing to resolve genomic and epigenomic signatures of the RB1 gene
219084140|NCT02200796|OTHER|High Protein Meal|Omelet with 45 g of protein
219212496|NCT06891482|BEHAVIORAL|Telerehabilitation|Intervention: Each enrolled participant within the telerehabilitation + usual care rehabilitation part will be provided a Fitbit® Charge 5 tracker, connected with the smartphone application Fitbit on the participant\&#39;s smartphone by creating a Fitbit user account, and the tracker will be configured for each participant. A smartphone will be provided if the participant does not have a smartphone. Participants will be asked to continue wearing their tracker on their non-access arm at all times, other than bathing, for the 3-months study duration. Each week during this telerehabilitation phase, the physiotherapist (PT) will follow-up the participants' step counts during hemodialysis. Participants will receive feedback on their activity level and will be motivated by the PT, along with specific step goals for the upcoming week. The PT gives advise on how to incorporate more walking into participants' daily routine with specific attention for shared decision making during this feedback
219212497|NCT00898365|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219212498|NCT00898365|OTHER|Laboratory Biomarker Analysis|Correlative studies
219212499|NCT05169697|DRUG|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
219212500|NCT05169697|DRUG|B:YH002+YH001|YH002 and YH001 on same day,Q3W
219212501|NCT05169697|DRUG|YH002+YH001|A traditional 3+3 dose escalation algorithm
219212502|NCT06763458|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
219084141|NCT02483897|DRUG|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
219084142|NCT02483897|DRUG|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
219212503|NCT06866782|DIAGNOSTIC_TEST|Imaging|Imaging will be done according to local protocols and/or guidelines of EAU
219361799|NCT01949363|DRUG|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
219084143|NCT04195308|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
219084144|NCT04195308|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219084145|NCT04195308|DEVICE|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
219084146|NCT04563468|PROCEDURE|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
219084147|NCT04563468|PROCEDURE|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
219084148|NCT01358695|BIOLOGICAL|ANT-1207|The interventions differ by dose of investigational product applied.
219084149|NCT01358695|BIOLOGICAL|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
219084150|NCT01358695|BIOLOGICAL|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
219084151|NCT04934579|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
219084152|NCT04934579|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
219084153|NCT04934579|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
219084154|NCT05263466|DIAGNOSTIC_TEST|PET-MRI|For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
219212504|NCT06791876|BEHAVIORAL|Nurture and Play (NnP)|"The NnP group Intervention is a group-based, manualized parenting intervention initiated during pregnancy and continued into the postnatal period until infant age seven months. The program is designed to enhance parenting abilities focusing on three domains: Emotional availability, parental reflective functioning, and the ability to regulate own emotions. During NnP, the parents are supported in enhancing their emotional availability through caring and playing activities.~The intervention has been developed in Finland by Dr. Saara Salo and colleagues and tested in a randomized controlled trial among pregnant women with depression and it is now being implemented in Finland. The results from the study showed that mothers in the intervention group showed more emotional availability and higher levels of reflective functioning and experienced fewer depressive symptoms compared to mothers in the control group."
219212505|NCT06763016|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"The sessions focused on various topics, such as sexuality, sexual health, gender roles, and sexual violence. Participants were encouraged to engage in group discussions and complete weekly tasks, which allowed them to interact and reflect on the material presented. The intervention aimed to address and challenge prevalent sexual myths, encourage open discussions about sexuality, and foster healthier sexual attitudes through evidence-based counseling.~The content of the digital interventions was structured on the basis of a semi-structured interactive group counseling. It was supported by sharing content on Instagram, one of the most widely used social media tools of the generation representing.~For three days a week over six weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous consultation session was held once a week. The participants were connected to the live broadcast of the research team."
219681523|NCT03791762|PROCEDURE|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
219681524|NCT03791762|PROCEDURE|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
219681525|NCT03791762|PROCEDURE|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
219084155|NCT05263466|PROCEDURE|Brain tumour biopsy|All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
219084156|NCT04899050|DRUG|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
219084157|NCT02934152|DRUG|H pylori eradication|H pylori eradication
219084158|NCT02934152|OTHER|H pylori eradication timing|Early or late eradication
219084159|NCT01758835|OTHER|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
219681526|NCT01840592|DRUG|Sorafenib|
219681527|NCT01840592|DRUG|Doxorubicin|
219681528|NCT02102347|OTHER|exercise|
219681529|NCT02102347|OTHER|Phototherapy|
219212506|NCT06675019|OTHER|Manual therapy|Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.
219084160|NCT01758835|OTHER|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
219084161|NCT01758835|OTHER|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
219212507|NCT06675019|OTHER|Kinesio taping|Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.
219212508|NCT06675019|OTHER|Control (Standard treatment)|The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
219212509|NCT06734819|BEHAVIORAL|Storytelling Video|The Living Donation Storytelling Project (LDSP) is an online video library of living donation first-person narratives aiming to inspire more people to consider LDKT (https://livingdonationstories.org/).17 As of 2020, the library has 118 stories from living donors and kidney recipients sharing their experiences with the pursuit, challenges and outcomes of transplant.18,19 Four videos were selected from the LDSP and edited to standardized duration and thematic content. Videos were cut to three minutes in length and covered the topics of 1) challenges faced when seeking LDKT, 2) life after LDKT and 3) advice for other patients considering LDKT.
219212510|NCT06734819|BEHAVIORAL|Standard Patient Education|Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.
219212511|NCT06850519|GENETIC|Exome Sequencing and Sanger Sequencing|Exome Sequencing and Sanger Sequencing
219212512|NCT06867263|PROCEDURE|Fulguration|Posterior urethral valve fulguration
219212513|NCT00129038|DRUG|modified-release dipyridamole/aspirin|
219212514|NCT00129038|DRUG|aspirin|
219212515|NCT06854445|DRUG|TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection|"Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection;~Other Name:~Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen~TQB2825 injection is Cluster of Differentiation 3 (CD3) and and Cluster of Differentiation 20 (CD20) bispecific antibody; Gemcitabine hydrochloride for injection is a cell cycle-specific antimetabolite; Oxaliplatin for Injection is a platinum chemotherapy drug."
219212516|NCT06767085|DRUG|Lidocaine-Prilocaine Topical|lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure
219212517|NCT06767085|DRUG|Saline spray|saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
219212518|NCT02110004|PROCEDURE|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
219212519|NCT02110004|DEVICE|Picasso NAV Catheter|
219212520|NCT05001087|OTHER|Observation|Not applicable-Observational study
219212521|NCT05315206|DIETARY_SUPPLEMENT|Citicoline|"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."
219084162|NCT01269996|DRUG|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
219084163|NCT01269996|DRUG|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
219212522|NCT05315206|DIETARY_SUPPLEMENT|Placebo|The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
219212523|NCT06024473|DEVICE|rTMS|Transcranial Magnetic Stimulation
219212524|NCT06024473|DEVICE|rTMS+iVCT|Transcranial Magnetic Stimulation and immersive virtual reality
219212525|NCT06902051|DEVICE|Lateral Decubitus position|Lateral Decubitus position with a special device
219212526|NCT06902051|DEVICE|Lateral Decubitus device|Lateral Decubitus postion with a special device
219681530|NCT05201677|PROCEDURE|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
219681531|NCT03997097|DRUG|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
219084164|NCT05011474|BIOLOGICAL|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
219212527|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
219212528|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
219084165|NCT02470130|BEHAVIORAL|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
219084166|NCT01265602|DRUG|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
219084167|NCT01265602|DRUG|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
219084168|NCT01265602|DRUG|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
219084169|NCT02403882|BEHAVIORAL|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
219084170|NCT02403882|BEHAVIORAL|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
219084171|NCT02403882|BEHAVIORAL|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
219084172|NCT02403882|BEHAVIORAL|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
219084173|NCT02403882|BEHAVIORAL|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
219084174|NCT04031482|OTHER|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts"
219084175|NCT02915848|DEVICE|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
219084176|NCT04322604|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
219084177|NCT04322604|OTHER|Placebo|Placebo
219212529|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
219212530|NCT05111600|DRUG|Transplantation|Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
219212531|NCT06429228|PROCEDURE|Catheter removal after surgery|Removal of catheter placed during the procedure in first or second post-surgical days.
219212532|NCT06931054|OTHER|Acupuncture|"The principle of traditional acupuncture and auricular acupressure is to alleviate withdrawal symptoms. Acupuncture therapy for smoking cessation is generally considered safe, but some people may experience mild side effects. These can include soreness, bruising, or bleeding at the needle insertion sites, dizziness, fatigue, or lightheadedness after treatment. Occasionally, individuals may feel nausea or discomfort during or after the session. In rare cases, infections can occur if proper hygiene protocols are not followed. Overall, most side effects are temporary and resolve shortly after treatment.~Primary Acupoints The selection of body acupuncture points follows specific guidelines\[11-12\], including three head points (Baihui, Shenting, Yintang ), three hand points (Neiguan, Kongzui, Lieque), and three foot points (Zusanli, Sanyinjiao, Taichong). For auricular acupoints, selection is based on corresponding areas (Mouth), syndrome differentiation of zang-fu organs and meridians (Hea"
219681532|NCT03997097|DRUG|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
219084178|NCT00850889|DEVICE|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
219084179|NCT00850889|DEVICE|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
219084180|NCT05543850|DEVICE|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
219084181|NCT05543850|DEVICE|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
219084182|NCT01238055|DRUG|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks"
219084183|NCT01238055|DRUG|Docetaxel only|Docetaxel 60 mg/m2 iv
219084184|NCT03945838|OTHER|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
219212533|NCT06931054|DRUG|Nicotine Replacement therapy|Each eligible participant will be prescribed a two-week supply of NRT by a registered smoking cessation nurse following the initial counseling session. The nurse will determine the appropriate type and dosage of NRT based on the participant's level of nicotine dependence and lifestyle habits, and provide instructions on how to use the medication. NRT can cause some potential side effects such as nausea, headaches, dizziness, and insomnia, with vivid dreams being common for those using patches. Method-specific side effects include skin irritation from patches, mouth or throat irritation from gums or lozenges, and nasal or throat discomfort from inhalers and sprays. These symptoms usually lessen as the body adjusts, but persistent or worsening side effects may require medical attention. According to current smoking cessation medication guidelines from the Department of Health\[10\], participants who smoke 20 or more cigarettes per day will be prescribed 4 mg nicotine gum (or lozenges) or 2
219212534|NCT06931054|BEHAVIORAL|Smoking cessation counseling|The first step for smoking cessation nurses is to assess each participant's smoking behavior using a baseline questionnaire. In the second step, informed consent will be obtained from the participants. The third step involves smoking cessation counseling using the 5A (Ask, Advise, Assess, Assist, Arrange) and 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) frameworks as outlined in the smoking cessation manual published by the Department of Health. During this step, the nurse will also assess the type and dosage of NRT suitable for the participant. In the fourth step, participants will be introduced to TCM therapies, and arrangements will be made for consultations with a TCM practitioner.
219212535|NCT06931054|OTHER|Auricular acupressure|First, one ear will be routinely disinfected with 75% medical ethanol. In the experimental group, the auricular acupressure tape contains Semen Vaccariae. Using forceps or tweezers, an auricular acupressure tape will be applied to specific acupoints on one ear for participants in the experimental group, followed by pressing the tape for 1 minute. The auricular tape will remain in place for two days, and participants will be instructed to self-press the acupoints 3 to 5 times daily, for 1 minute per acupoint each time. During the use of the auricular acupressure, if withdrawal symptoms occur, participants can immediately press the acupoints. The pressure applied should be tolerable, and the pressing duration should last until the withdrawal symptoms subside. Participants will also record the number of presses each day.
219361800|NCT06498934|DEVICE|deep brain stimulation|Stimulation of the dentate nucleus that is paired with upper limb rehabilitation movements.
219361801|NCT06498934|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
219084185|NCT02456402|DEVICE|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
219084186|NCT02456402|DEVICE|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
219084187|NCT00420992|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
219084188|NCT00420992|DRUG|Placebo|capsules, bid
219084189|NCT00740961|BEHAVIORAL|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
219084190|NCT00740961|DRUG|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
219084191|NCT00740961|OTHER|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
219084192|NCT00740961|OTHER|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
219084193|NCT00740961|OTHER|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
219084194|NCT00740961|PROCEDURE|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
219084195|NCT00740961|PROCEDURE|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
219084196|NCT05038280|BEHAVIORAL|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
219212536|NCT06931054|OTHER|Sham acupressure|"The sham tape resembles the genuine auricular acupressure tape with Semen Vaccariae but is a regular adhesive tape designed to minimize stimulation of the acupoints.~The sham auricular tape will be applied to non-smoking cessation acupoints, including:~* Elbow Acupoint located in the third section of the triangular fossa between the middle cartilage and the rim cartilage of the ear, primarily used for treating elbow pain.~* Ankle Acupoint located near the apex of the superior crus of the antihelix, used for treating arthritis.~* Urethra Acupoint located on the helix above the rectum acupoint, used for treating symptoms such as frequent urination or painful urination."
219212537|NCT06931054|OTHER|Sham acupuncture|"The TCM practitioner will perform needle insertion 2-3 mm beside the selected acupoints (at non-specific sham points) using normal needling techniques but without manipulating the needles, in order to minimize any physiological effects."
219212538|NCT06761963|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
219212539|NCT06761963|OTHER|Rehabilitation|Pulmonary rehabilitation program.
219212540|NCT06779812|PROCEDURE|Carpal Tunnel Surgery|Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
219212541|NCT06779812|OTHER|real auricolothery|3 days before the intervention, patients will have an auriculotherapy session with an experimental group
219212542|NCT06779812|OTHER|sham auriculotherapy|3 days before the intervention, patients will have an auriculotherapy session with an sham group
219212543|NCT04787341|DRUG|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
219212544|NCT04787341|DRUG|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
219212545|NCT06775990|OTHER|Blood sample|Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.
219084197|NCT05767684|BIOLOGICAL|Dendritic Cell Vaccine|Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
219084198|NCT05767684|DRUG|Lenvatinib|Lenvatinib 10mg/day on day 43-77
219084199|NCT05767684|DRUG|Nivolumab|Nivolumab 3mg/kg on day 43, 57 and 71.
219084200|NCT03234153|DRUG|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
219212546|NCT06765408|OTHER|facial yoga exercise program|An exercise programme consisting of basic yoga movements such as swan neck exercise, fist exercise, hand to head exercise, jowl drawer exercise, tongue and palate exercise, lip curling exercise, ceiling kissing exercise, namaste exercise, balloon inflation, spider and fish exercise, lip spray, Chinese moustache, binocular exercise, gaze exercises and lion pose was applied. Each session was approximately 30 minutes and all exercises were accompanied by breathing exercises on the basis of exercising all facial muscles. The exercise programme was performed for 8 weeks, 2 days a week face-to-face and 5 days at home, for a total of 16 sessions face-to-face and 40 sessions at home. Participants were given verbal, written and video explanations and instructions about the exercise protocol. Every day in a WhatsApp group where all participants take part, Assist. Prof. Dr. Hazel Çelik Güzel provided information and reminders and ensured the continuity of the exercises. Participants were al
219212547|NCT06750991|DRUG|CDR-CHOP|Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
219212548|NCT06532396|DRUG|QRL-101|Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
219212549|NCT06532396|DRUG|Placebo|Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
219212550|NCT06756555|DIAGNOSTIC_TEST|efficacy of Incentive spirometer|The main objective of this research is to check the efficacy of Incentive spirometer on pulmonary complication after bariatric surgrey
219212551|NCT06756919|BEHAVIORAL|Music intervention|Music therapy ( nature sounds) during the endoscopy procedure
219212552|NCT06756334|DRUG|[18F]AlF-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
219212553|NCT06756334|DRUG|[18F]F-DCFPyL|Each subject receive a single intravenous injection of \[18F\]F-DCFPyL, and undergo PET/CT imaging within the specificed time.
219212554|NCT06760221|RADIATION|stereotactic body raiotherapy|Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.
219212555|NCT06766734|PROCEDURE|Tendon Dry Needling|Tendon dry needling procedure is that repetitively passing the needle though the area of supraspinatus tendon. Tendon dry needling was performed under sterile conditions with real-time imaging guidance using an ultrasound probe. The supraspinatus tendon was scanned from anterior to posterior, and tendon dry needling was applied to the identified lesion (tendinozis or partial tear) area. This treatment method was applied twice, with a one-month interval between sessions.
219212556|NCT06766734|PROCEDURE|Sham Tendon Dry Needling|In this treatment subcutaneous sham tendon dry needling was performed by randomly holding the ultrasound probe in the area corresponding to the same anatomical localization. Sham tendon dry needling performed to subcutaneus tissue not tendon.
219212557|NCT06767384|RADIATION|X-ray|To determine diagnostic accuracy of x-ray KUB in diagnostic renal and ureter calculi keeping CT scan KUB as a gold standard.
219212558|NCT06780774|DIETARY_SUPPLEMENT|Caffeine, Vitamins, Minerals and Botanical Blend|"Blend containing 120mg of caffeine, vitamins, minerals and botanical extracts in capsule form.~Other Names: Active Treatment"
219212559|NCT06780774|DIETARY_SUPPLEMENT|Placebo|Blend containing 17mg Marigold Extract and Brown rice flour. Other Names: Placebo Treatment
219212560|NCT06619327|BEHAVIORAL|Resilient Together for Dementia|RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.
219212561|NCT06619327|BEHAVIORAL|MEUC|The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.
219681533|NCT04387409|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
219681534|NCT04387409|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
219681535|NCT04964167|COMBINATION_PRODUCT|Plant extract|Natural plant extract
219681536|NCT01861002|DRUG|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
219681537|NCT01861002|DRUG|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
219681538|NCT01861002|DRUG|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
219681539|NCT01861002|DRUG|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~* Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~2. \- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~   * 3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
219084201|NCT03234153|DRUG|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
219084202|NCT00825422|DRUG|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
219084203|NCT03105284|PROCEDURE|Liposuction|Fat harvest by liposuction (Colemans method)
219084204|NCT03249610|BEHAVIORAL|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
219084205|NCT01969019|DRUG|methylprednisolone, prednisone|
219084206|NCT05908214|OTHER|wide pulse high frequency neuromuscular electrical stimulation training|Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
219212562|NCT06137638|DRUG|ENA-001|ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
219212563|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
219212564|NCT05239793|DRUG|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
219212565|NCT05958030|DEVICE|Placebo|The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
219212566|NCT05958030|DEVICE|GyroGlove|GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
219212567|NCT04007796|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
219212568|NCT04007796|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
219212569|NCT04153890|BEHAVIORAL|FamPALcare|Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care.
219212570|NCT06782828|OTHER|observe results of FNAC|observe results of FNAC and compare it with results of histopathological examination to detect accuracy of FNAC in diagnosis of thyroid nodules.
219212571|NCT06745258|OTHER|External Facilitation|Multi-component facilitation strategy to address identified implementation needs
219212572|NCT06748027|OTHER|Fasting|Long-term fasting (\&gt;3d)
219212573|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine|NAC capsules
219212574|NCT05986318|DRUG|Dexamethasone Oral|Dexamethasone tablets
219212575|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine Placebo|Matching placebo for NAC capsules
219212576|NCT05986318|DRUG|Dexamethasone Placebo|Matching placebo for dexamethasone tablets
219212577|NCT05986318|RADIATION|Radiation Therapy|All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
219212578|NCT06889181|OTHER|Plasma Rich in Growth Factors (PRGF)|using prgf with closing primary cleft palate - isolated cleft palate Minutes before the surgery, 10-20 ml of venous blood from each patient. -The blood is centrifuged to obtain PRGF. -Fixed between nasal and palatal mucosa
219212579|NCT06889181|OTHER|Placebo|primary closing cleft palate-isolated cleft palate
219212580|NCT00627432|DRUG|gemcitabine hydrochloride|
219212581|NCT00627432|DRUG|oxaliplatin|
219212582|NCT06851208|OTHER|Emotional intervention|Emotional intervention Description: The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
219212583|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
219212584|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
219084207|NCT03261128|OTHER|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
219084208|NCT00053989|BIOLOGICAL|anti-thymocyte globulin|iv
219084209|NCT00053989|BIOLOGICAL|graft-versus-tumor induction therapy|iv
219084210|NCT00053989|BIOLOGICAL|sargramostim|iv
219084211|NCT00053989|BIOLOGICAL|therapeutic allogeneic lymphocytes|iv
219084212|NCT00053989|DRUG|cyclophosphamide|injection
219084213|NCT00053989|DRUG|fludarabine phosphate|iv
219084214|NCT00053989|DRUG|methylprednisolone|oral
219084215|NCT00053989|DRUG|mycophenolate mofetil|oral
219084216|NCT00053989|DRUG|tacrolimus|oral
219084217|NCT00053989|PROCEDURE|allogeneic bone marrow transplantation|iv
219084218|NCT00053989|PROCEDURE|peripheral blood stem cell transplantation|iv
219084219|NCT00053989|PROCEDURE|umbilical cord blood transplantation|iv
219212585|NCT02298348|DRUG|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
219212586|NCT02298348|DRUG|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
219212587|NCT02298348|DRUG|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
219212588|NCT06085300|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
219212589|NCT06748014|DRUG|Aescin in Horse Chestnut|Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
219212590|NCT06748014|DRUG|MPFF|MPFF 3000 mg 7 day then 1000 mg 2 months
219212591|NCT06750952|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.
219084220|NCT05094401|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
219212592|NCT06431113|COMBINATION_PRODUCT|Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )|treatment for 4 months and then cross over to the other therapy
219212593|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
219212594|NCT05786612|DEVICE|Biatain® Silicone|Wound care dressing
219084221|NCT03114280|DRUG|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
219212595|NCT05786612|DEVICE|Mepilex Border with Aquacel Extra Hydrofiber|Wound care dressing
219212596|NCT04926740|OTHER|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
219212597|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
219084222|NCT03114280|OTHER|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
219084223|NCT02679040|PROCEDURE|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
219084224|NCT02679040|DRUG|Chemotherapy|Chemotherapy treatment
219212598|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
219212599|NCT06762938|BEHAVIORAL|ShotBlocker|Apply ShotBlocker
219212600|NCT06764043|OTHER|Clinical evaluation|In this study, it was aimed to measure the levels of MMP-8, MMP-20, and TGF-β1 in GCF together with the volume of GCF to investigate the effect of MIH on oral hygiene, and gingival health, and also to evaluate the relationship between MIH, and various biomarkers.
219212601|NCT06765603|DRUG|Atropine 0.025%|Atropine 0.025%
219212602|NCT06765603|DEVICE|Multizonal contact lens|Multizonal CL
219084225|NCT02679040|RADIATION|Radiation therapy|Radiation therapy
219084226|NCT05769738|DRUG|Furosemide|40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
219084227|NCT05769738|DRUG|Normal saline|4ml of normal saline to be nebulized 3 times daily for 3 days
219084228|NCT00382824|DIETARY_SUPPLEMENT|Coenzyme Q10|active drug
219084229|NCT00382824|OTHER|Placebo|Placebo
219084230|NCT02850432|PROCEDURE|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
219084231|NCT02850432|OTHER|Conservative treatment|rehabilitation with medical therapy
219084232|NCT01146301|DRUG|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
219084233|NCT01137188|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
219084234|NCT03205371|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
219084235|NCT03205371|BIOLOGICAL|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
219084236|NCT03205371|BIOLOGICAL|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
219084237|NCT03205371|BIOLOGICAL|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
219212603|NCT06765603|DRUG|Placebo|Placebo
219212604|NCT06765603|DEVICE|Single vision Contact lens|Single vision contact lens
219212605|NCT06764212|DIAGNOSTIC_TEST|Ultrasound|M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.
219212606|NCT06359314|BEHAVIORAL|ALDER|The ALDER skills are delivered over approximately 5 weeks. A week consists of learning at least one skill and then applying that skill(s) in daily home practice throughout the week. Skill lessons and daily home practice exercises are housed on the ALDER website. Participants have the option to share their home practice responses with fellow participants by posting them to the discussion board, where they can like and comment on each other's posts.
219212607|NCT04538352|DRUG|Semaglutide|Medication for type 2 diabetes management
219212608|NCT04538352|DRUG|Insulin Degludec|Medication for type 2 diabetes management
219212609|NCT04538352|DRUG|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
219212610|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
219212611|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
219212612|NCT02427724|DRUG|placebo vehicle|
219212613|NCT02427724|DEVICE|Q-switched 532nm Laser|
219212614|NCT06801405|DRUG|antibiotic prophylaxis|Antibiotic prophylaxis before percutaneous nephrostomy
219084238|NCT03205371|BIOLOGICAL|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
219084239|NCT02486601|DRUG|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
219084240|NCT02486601|DRUG|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
219084241|NCT04038528|BEHAVIORAL|telemonitoring of T2DM|"Baseline record of:~* Weight~* Height~* BMI~* Abdominal circumference~* Winsor Index~* ECG~* Retinography~* Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~* Blood sugar (two measurements per week).~* Body weight (weekly)~* Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
219084242|NCT03882879|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
219084243|NCT03882879|BEHAVIORAL|Pre-Intervention Study Visit|At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
219084244|NCT03882879|BEHAVIORAL|Bimonthly Online Survey|All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
219084245|NCT03882879|BEHAVIORAL|6-month Study Visit|All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
219084246|NCT03882879|BEHAVIORAL|12-month Study Visit|At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
219084247|NCT01851174|DRUG|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion
219084248|NCT01851174|DRUG|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
219084249|NCT01641393|DRUG|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
219084250|NCT01641393|DRUG|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
219084251|NCT04426643|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
219084252|NCT04426643|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
219084253|NCT00298922|DRUG|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
219084254|NCT00298922|DRUG|Placebo|tablet orally thrice weekly for 24 weeks
219084255|NCT00959543|OTHER|MRI|MRI and clinical investigation
219681540|NCT01861002|DRUG|Intrathecal Methotrexate (IT MTX)|"* Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. \- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. \- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
219681541|NCT05101759|PROCEDURE|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
219681542|NCT02400619|DEVICE|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
219681543|NCT02400619|DRUG|Botulinum Toxin Type A|Botulinum toxin type A Botox
219681544|NCT00848029|BIOLOGICAL|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
219681545|NCT00028626|DRUG|embolization therapy|
219681546|NCT04693078|DEVICE|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
219681547|NCT02567175|DRUG|Domperidone|
219681548|NCT03046953|DRUG|Avelumab|anti-PDL1 antibody
219681549|NCT04039204|DRUG|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
219681550|NCT04039204|DRUG|Ortho Cyclen|Oral contraceptive prescribed by physician.
219681551|NCT01199887|DRUG|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
219212615|NCT06829680|OTHER|Pilates|"The participants were given a total of 12 sessions of Pilates training, applied twice a week for 6 weeks, and each session lasted approximately 60 minutes. The 60-min session consisted of warm up and cool down (5 min each) and the main active phase (50 min).~In the main active phase; One leg stretch, Double leg stretch, One leg circle, Heels together toes apart, Shoulder bridge, The hundreds, Chest lift, Criss cross, Clam, Side bend, Arm opening, Cobra, Breast stroke, Swimming, Modified push-up, Plank, Leg pull prone and Squat exercises were performed. The exercises were applied with 10 repetitions in the first 3 weeks and with 20 repetitions in the last 3 weeks."
219212616|NCT06829680|OTHER|Whole Body Vibration|"The participants were given a total of 12 sessions of WBV training, applied twice a week for 6 weeks.~The vibration parameters were set as frequency: 20 Hz, amplitude: 2-3 mm, duration: 30-60 s and rest period: 60 s. The application time of the WBV training was 30 s for the first two weeks, 45 s for the next two weeks and 60 s for the last two weeks.~The individuals were asked to maintain squat, shoulder bridge and quadruped positions statically for the first two weeks. Starting from the third week, they were asked to perform reciprocal upper extremity flexion and extension movements during the positions. The application was repeated 3 times in each position."
219212617|NCT06790225|OTHER|Glucose-dependent Insulinotropic Polypeptide (GIP)|Recombinant human GIP (1-42)
219681552|NCT01363284|DRUG|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
219681553|NCT01189461|DRUG|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
219681554|NCT02938338|PROCEDURE|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
219681555|NCT02924233|DRUG|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
219681556|NCT02924233|DRUG|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
219681557|NCT00585338|DEVICE|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
219681558|NCT00006390|BIOLOGICAL|alemtuzumab|
219681559|NCT00006390|BIOLOGICAL|filgrastim|
219681560|NCT00006390|DRUG|cyclophosphamide|
219681561|NCT00006390|PROCEDURE|peripheral blood stem cell transplantation|
219681562|NCT00006390|RADIATION|radiation therapy|
219681563|NCT02566499|DEVICE|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
219681564|NCT05355077|DRUG|JT001 200mg Bid|JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
219681565|NCT05355077|DRUG|JT001 400mg Bid|JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
219084256|NCT06068621|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
219084257|NCT06068621|DRUG|"3+7"|"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
219084258|NCT05493592|BIOLOGICAL|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
219084259|NCT01175603|BEHAVIORAL|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
219084260|NCT03142048|OTHER|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
219084261|NCT03404570|DRUG|Dexmecamylamine HCl|Investigational drug
219084262|NCT03404570|OTHER|Placebo|Oral tablet containing no active drug.
219084263|NCT02448251|DRUG|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
219084264|NCT05414591|DRUG|DWP16001 drug A|1 tablet, Oral, once daily single dose
219084265|NCT05414591|DRUG|DWP16001 drug B|3 tablet, Oral, once daily single dose
219681566|NCT05355077|DRUG|JT001 600mg Bid|JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
219681567|NCT01712139|DRUG|Irbesartan and Hydrochlorothiazide|
219681568|NCT01712139|DRUG|Avalide|
219212618|NCT06639425|DIETARY_SUPPLEMENT|Lactobacillus paracasei LC19 supplementation|Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
219212619|NCT06639425|DIETARY_SUPPLEMENT|Placebo probiotic milk powder|Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
219212620|NCT06637969|BEHAVIORAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
219212621|NCT06777732|DRUG|Keverprazan|Potassium-competitive acid blocker
219212622|NCT06777732|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219212623|NCT06777732|DRUG|Furazolidone|Antibiotic for H. pylori eradication
219212624|NCT06777732|DRUG|Colloidal Bismuth Pectin|Gastric mucosal protectant
219212625|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
219212626|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
219212627|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
219212628|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
219681569|NCT03112486|PROCEDURE|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
219212629|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
219212630|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
219212631|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
219212632|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
219084266|NCT04584164|DEVICE|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
219084267|NCT03227679|OTHER|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
219084268|NCT03227679|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
219084269|NCT03227679|DRUG|Bupropion|FDA-approved smoking cessation pharmacotherapy
219212633|NCT06299020|BEHAVIORAL|intermittent fasting|fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
219212634|NCT05781360|DRUG|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
219084270|NCT03227679|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
219212635|NCT05709860|BEHAVIORAL|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
219212636|NCT05709860|BEHAVIORAL|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
219212637|NCT05691192|BEHAVIORAL|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
219212638|NCT06828367|BEHAVIORAL|Online family educational intervention and cooking workshop|Registration for the educational platform will be open for 3 months from the start of the school year. Over the first 2-3 months, the contents of each topic will be activated weekly, and family participation will be encouraged through reminders. In the following 3 months, the platform will remain open, allowing families who did not follow the weekly content to catch up. Participation reminders will continue. From the 3rd to 6th month, the cooking workshop will be held in person. Throughout the intervention, activities will promote participation, and a Q\&A channel with an expert (nutritionist) will remain open. Total intervention time: 6 months.
219212639|NCT06799039|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
219681570|NCT06361186|DRUG|Proximod|Single and multiple-dose to establish the safety and PK profile
219681571|NCT06361186|DRUG|Placebo|Placebo controlled
219681572|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
219084271|NCT03143725|DRUG|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
219084272|NCT03340402|RADIATION|Accelerated Partial Breast Irradiation|Proton radiation
219084273|NCT03340402|DEVICE|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
219084274|NCT01463956|DRUG|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
219212640|NCT06758765|PROCEDURE|Erector Spinae Plane Block|ESPB was applied to the patients in a sitting position. A high-frequency linear probe was used. Under sterile conditions, the USG probe was placed longitudinally approximately 2 cm lateral to the T4 spinous process. Skin, subcutaneous fat tissue, m. trapezius, rhomboid muscles, erector group muscles, transverse process, intercostal muscles, pleura and lung movements were visualized from superficial to deep structures. 1 ml of 2% lidocaine was injected into the estimated needle entry area. Then, with the block needle the m. trapezius, mm. rhomboidei and erector spinae muscles were passed in order with the in-plane method and the needle was brought into contact with the transverse process. Fascial separation was confirmed with 1-2 ml of saline solution and the block was performed by injecting 20 ml of 0.375% bupivacaine. The distribution of the drug was confirmed by observing it with USG.
219212641|NCT06758765|PROCEDURE|Pectoral Nerve Block|"The PECSI and PECSII blocks were applied concurrently.~In patients who will undergo PECS II, sterile conditions were prepared with the arm on the side to be operated on in the supine position and 90 degrees of abduction. The lateral and pectoral branches of the thoracoacromial artery were visualized between the PM and Pm muscles at the level of the 4th rib under USG guidance. The blocking needle was directed between the PM and Pm muscles for PECS I, 1-2 ml of saline was injected to verify fascial spread, and 10 ml of 0.375% bupivacaine was applied. Afterwards, fascial spread was confirmed by injecting 1-2 ml of saline between the pectoralis minor muscle and the serratur anterior muscle, and PECS II was performed by injecting 10 ml of 0.375% concentration bupivacaine. The distribution of the drug was confirmed by observing it with USG."
219212642|NCT06759766|COMBINATION_PRODUCT|Garlic-Lemon Extract irrigant|"garlic (Allium sativum) Shows a wide range of therapeutic effects due to the presence of allicin, ajoene \& other thiosulfinates. It has antibacterial effect against wide range of gram-positive and gram-negative bacteria, anti-inflammatory, antioxidant, antiviral, antifungal, antitumor, immunomodulatory effects and tissue-dissolving capacity (Siddique, et al., 2020). According to (Elheeny., 2019) Allium sativum extract can be used efficiently as an irrigant for pulpectomy of primary molar root canals.~Lemon (Citrus Limon) as well has curative properties such as, antibacterial, antiviral, antifungal, anti-inflammatory, anti-cancerous activities and removal of the smear layer as well. Due to presence of ascorbic acid, phenolic acids, polyphenols, and dietary fibers.~the combination of Garlic-Lemon has been tested in adult teeth as an irrigant and showed an effective result equal to NaOCl (Siddique, et al., 2020)."
219212643|NCT06759766|OTHER|physiological saline|Normal saline solution exhibits no adverse effects on the developing successors; Serves primarily to facilitate root canal cleaning during the irrigation process, in comparison to other commercial synthetic irrigants such as Sodium hypochlorite (NaOCl), Chlorhexidine (CHX), Ethylenediamine tetra acetic acid (EDTA) which exhibit potential side effects and cytotoxic reactions (Sayadizadeh et al., 2019).
219681573|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
219681574|NCT00656175|DRUG|raltegravir|raltegravir
219681575|NCT05003284|DEVICE|acupressure wristband|acupressure after surgery
219681576|NCT05003284|DEVICE|placebo wristband|acupressure after surgery
219681577|NCT05941624|DEVICE|Ha-330 Hemoperfusion Filter Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
219681578|NCT05941624|DEVICE|Conventional Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
219681579|NCT00994227|PROCEDURE|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
219681580|NCT05955144|DEVICE|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
219681581|NCT01818973|DRUG|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
219681582|NCT01818973|DRUG|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
219681583|NCT01818973|DRUG|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
219681584|NCT01818973|RADIATION|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
219681585|NCT01818973|PROCEDURE|surgery|Total Mesorectal Excision (TME)
219084275|NCT01463956|BIOLOGICAL|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
219084276|NCT01463956|DRUG|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
219084277|NCT02246335|DEVICE|Cemented total hip arthroplasty|
219681586|NCT04839666|DRUG|Propofol|Perioperatively propofol administration
219084278|NCT02246335|DEVICE|Cemented hemiarthroplasty|
219084279|NCT04777812|DIAGNOSTIC_TEST|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
219084280|NCT02835339|DRUG|Magnesium sulfate 4g loading dose, 1g/hr infusion|
219212644|NCT06839833|DIAGNOSTIC_TEST|APOL1 Genotyping|The APOL1 Genotyping CTA will identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2). The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
219212645|NCT06891378|OTHER|Intrevention group (mHealth group)|"1. Receive a customized rehabilitation exercise program after surgery and perform rehabilitation exercises while watching videos~2. Check recovery of shoulder joint range of motion~3. Write an exercise diary (check exercise schedule and post-exercise condition)~4. Check activity level through step count collection~5. Check exercise records and contact to confirm reason if exercise was not performed"
219212646|NCT06891378|OTHER|control group (usual care)|"This group performs home rehabilitation exercises using in-hospital educational materials.~Control group data are retrospectively collected and matched using propensity score methods."
219212647|NCT06764420|DIETARY_SUPPLEMENT|Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. This control intervention serves to compare the effects of glutamine alone with the combined arginine and glutamine treatment. In addition to the glutamine suspension, patients in this group will receive general measures and analgesic drugs according to the WHO scale to manage symptoms of mucositis.
219212648|NCT06764420|DIETARY_SUPPLEMENT|Arginine and Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of arginine and 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. The swish and swallow technique involves patients swishing the solution around the oral mucosa to ensure even distribution before swallowing. This intervention aims to evaluate the combined effect of arginine and glutamine on reducing the severity of radiation-induced mucositis, improving mucosal healing, and providing symptomatic relief.
219212649|NCT06791837|BEHAVIORAL|EXERCISE|each group will undergo a max test and a submaximal exercise test
219212650|NCT06839014|OTHER|Exercise|Perform 30 minutes of TENS unit exercise muscle stimulation each day for 3 days a week for the duration of cancer treatment.
219212651|NCT06430684|DRUG|Empagliflozin 10 MG|Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
219212652|NCT06565442|DEVICE|NeuraSignal transcranial doppler robot|measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
219212653|NCT06611111|DRUG|Ceftriaxone (Rocephin®)|Slightly yellow liquid.
219212654|NCT06611111|DRUG|Dextrose 5% (D5W)|Colorless liquid
219212655|NCT02278185|DRUG|Enzalutamide|Given PO
219212656|NCT02278185|DRUG|leuprolide acetate|Given SC or IM
219212657|NCT02278185|DRUG|goserelin acetate|Given SC or IM
219212658|NCT02278185|DRUG|histrelin acetate|Given SC or IM
219212659|NCT02278185|DRUG|triptorelin|Given SC or IM
219212660|NCT02278185|DRUG|degarelix|Given SC or IM
219084281|NCT02835339|DRUG|Magnesium sulfate 6g loading dose, 2g/hr infusion|
219084282|NCT01498432|DRUG|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
219084283|NCT01498432|DRUG|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
219084284|NCT02401581|OTHER|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
219084285|NCT00435279|DRUG|Eszopiclone|Eszopiclone 3 mg
219084286|NCT00435279|DRUG|Placebo|Placebo
219084287|NCT00435279|DRUG|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
219212661|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
219361802|NCT06194357|OTHER|Mindfulness-based Health Qigong Intervention|Participants are introduced the practice of the most essential skills, particularly mindfulness, the basic movements of Qigong and the use of the resources package. Following the initial session, participants will kick off 8 bi-weekly online sessions of Mindfulness-based interventions approximately two hours each via the Mobile App. Afterwards, participants will be asked to practice Qigong for 30 minutes per day with five days weekly for another 8 weeks. Follow-up sessions will be conducted by an experienced coach via the Mobile App. After the first 16-week intervention, booster sessions will be provided every 3 months to revise the interventions and follow-up assessments will be completed every 6 months for 2 years.
219361803|NCT02870361|DRUG|intranasal insulin|
219361804|NCT02870361|DRUG|Placebo|
219084288|NCT06629363|OTHER|biobank|"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"
219084289|NCT00508443|RADIATION|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
219084290|NCT05968651|DRUG|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
219084291|NCT01077544|DRUG|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
219084292|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
219084293|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
219084294|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
219084295|NCT06087510|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
219084296|NCT04341623|OTHER|Cetaphil Pro Eczema moisturizer|All 30 patients to receive
219084297|NCT04341623|BEHAVIORAL|Electronic interaction|10 patients to electronic surveys about moisturizer use
219084298|NCT04341623|BEHAVIORAL|GPSkin|Measuring moisture in the skin
219084299|NCT03923959|DRUG|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
219084300|NCT03923959|OTHER|Placebo|100 cc normal saline
219084301|NCT04918147|DRUG|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
219084302|NCT04918147|DRUG|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
219084303|NCT04918147|DRUG|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
219084304|NCT04918147|DRUG|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
219084305|NCT04918147|DRUG|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
219084306|NCT04918147|DRUG|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
219084307|NCT04918147|DRUG|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
219084308|NCT04409119|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
219084309|NCT04409119|DEVICE|LV pacing|LV lead in a CS branch
219084310|NCT00664937|DRUG|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
219084311|NCT00664937|DRUG|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
219084312|NCT06488521|BIOLOGICAL|Complarate|Complarate solution, a subcutaneous injection at a single dose of 162 mg.
219084313|NCT06488521|BIOLOGICAL|Actemra®|Actemra® solution, subcutaneous injection at a single dose of 162 mg.
219084314|NCT06488664|BIOLOGICAL|GNR-068|GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
219084315|NCT06488664|BIOLOGICAL|Stelara®|Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
219084316|NCT05806229|PROCEDURE|Mid transverse process to pleura block (MTP)|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
219084317|NCT05806229|PROCEDURE|Mid transverse process to pleura Sham block|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
219361805|NCT02998723|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
219361806|NCT02998723|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
219361807|NCT01891331|DRUG|VT-1161|
219361808|NCT01891331|DRUG|Fluconazole|
219084318|NCT04273139|DRUG|IBRUTINIB|Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
219361809|NCT00939692|DRUG|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
219084319|NCT04273139|DRUG|Venetoclax|Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
219361810|NCT02218918|BEHAVIORAL|Ground walk training|3 times a week and 6 weeks
219212662|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
219212663|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
219212664|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
219212665|NCT06758648|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|"Dynamic retinal vessel analysis (DVA) is an established, non-invasive technique for evaluating the responsiveness of retinal vessels to flickering light stimuli. This technique allows for the measurement of changes in retinal vessel diameter in response to changes in blood flow, providing insight into the microcirculatory function of the retina. In the case of DVA, patients will asked to focus on a needle, and one arteriole and venule diameter were automatically and continuously recorded. Arteriole and venule segments between 0.5 to 1 mm will be analyzed approximately 2-disc diameters away from the optic nerve in a lower-temporal direction. The baseline recording will be 50 seconds, followed by a flickering phase of 20 seconds and then a recovery period of 80 seconds. Three of these cycles were performed.~Based on this, we will calculate the percentage of maximum arteriolar (aFID) and venular dilation (vFID) to baseline."
219212666|NCT06758648|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Collection of blood samples from participants for the purpose of performing clinical chemistry analysis. Peripheral blood mononuclear cells (PBMCs) will be isolated from the collected blood samples using standard techniques, such as density gradient centrifugation, and will be analyzed using fluorescence-activated cell sorting (FACS)
219212667|NCT06758648|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|This study involves a comprehensive evaluation of life quality, pain, and gastrointestinal (GI) symptoms using a set of established and validated questionnaires. The tools employed include the SF-36 (Short Form-36 Health Survey) to assess overall health-related quality of life across multiple domains, the COMPASS-31 (Composite Autonomic Symptom Score) to evaluate autonomic dysfunction symptoms, and the Brief Pain Inventory (BPI) to measure pain severity and its impact on daily activities. Additionally, the Gastrointestinal Symptom Rating Scale (GSRS) is used to quantify the severity and frequency of GI symptoms, covering dimensions such as reflux, abdominal pain, indigestion, diarrhea, and constipation. Together, these questionnaires provide a multidimensional assessment of the patient's physical, emotional, and symptomatic experiences, allowing for a robust understanding of their health status and quality of life.
219361811|NCT02218918|BEHAVIORAL|Supervised Treadmill Walk training|3 times a week and 6 weeks
219361812|NCT00097357|DRUG|Apixaban|Tablets, Oral, 12 +/- 2 days
219361813|NCT00097357|DRUG|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
219084320|NCT04496726|OTHER|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
219084321|NCT03227354|DEVICE|Vittamed 205|non-invasive Intracranial Pressure measurement
219084322|NCT05934812|DRUG|Oxytocin nasal spray|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
219084323|NCT05934812|DRUG|Placebo|Placebo liquid nasal spray administered twice-daily
219084324|NCT05391854|DIETARY_SUPPLEMENT|Pep2dia|700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner
219084325|NCT05391854|DIETARY_SUPPLEMENT|Placebo|700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
219084326|NCT01525316|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
219084327|NCT01525316|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
219084328|NCT02954354|DRUG|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
219084329|NCT02954354|DRUG|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
219361814|NCT00097357|DRUG|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
219084330|NCT02954354|DRUG|Oseltamivir|75 mg capsules taken orally
219084331|NCT02954354|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
219084332|NCT05208281|DRUG|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
219084333|NCT05208281|DRUG|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
219084334|NCT05208281|DRUG|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
219084335|NCT05590247|BEHAVIORAL|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
219084336|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
219084337|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
219084338|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
219084339|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
219084340|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
219084341|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
219084342|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
219212668|NCT06758648|DIAGNOSTIC_TEST|Cardio MRI|Cardiovascular magnetic resonance imaging (CMR or cardio MRI) will be utilized in patients with Fabry disease. This imaging technique will enable detailed assessment and monitoring of key cardiac abnormalities, including thickening of the heart walls, left ventricular hypertrophy, and decreased blood flow in the coronary vessels. Additionally, T1 relaxation time measurement will be conducted, offering a non-invasive means to detect myocardial tissue abnormalities such as fibrosis and sphingolipid accumulation, which are hallmarks of Fabry disease. Together, these measures provide a comprehensive evaluation of cardiac structure, function, and tissue characteristics in affected patients.
219084343|NCT06959992|BEHAVIORAL|Metaverse group|The activities will be conducted in a Metaverse platform with immersive features. Each session is divided into two parts (\~2 hours duration). First, a specific social context will be represented (environmental features and static avatars) and a microaggression scenario (adapted for the chosen context) will be described. Participants are engaged in the conversation by the moderator in order to identify various psychological manifestations regarding the context (according to the SORC model) and to come up with solutions for the main, model avatar (part of the research team). Second, the debriefing part of the session will allow participants to talk about their own experiences alongside specific self-compassionate exercises. Repeated measurements will be required: pre-intervention, mid-intervention, post-intervention and at follow-up (after 3 months).
219084344|NCT06959992|BEHAVIORAL|Online asynchronously|The activities will be conducted asynchronously in an online platform where participants will be guided by the moderator through the same type of activities. First, a social context with specific microaggressions will be presented in a text format followed by the same requirements for participants (identifying various psychological manifestations regarding the context and coming up with solutions for the problematic situation). Second, participants will have the transcripts of several self-compassionate exercises to be done independently. A discussion forum will also require their active engagement. Repeated measurements will be required pre-interventions, mid-intervention, post-intervention and at follow-up (3 months).
219084345|NCT06411288|DRUG|AOC 1001 (del-desiran)|Del-desiran will be administered by intravenous (IV) infusion.
219084346|NCT06411288|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
219084347|NCT03556111|PROCEDURE|Sticky bone augmentation|"1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement"
219084348|NCT03716609|DIETARY_SUPPLEMENT|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
219084349|NCT03716609|OTHER|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
219084350|NCT03716609|OTHER|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
219084351|NCT03453398|OTHER|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
219084352|NCT00742092|DRUG|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
219084353|NCT00742092|DRUG|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
219084354|NCT05508503|DIAGNOSTIC_TEST|Test of methylated NTMT1 and MAP3K14-AS1|A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
219084355|NCT05508503|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test（optional）
219084356|NCT05867654|DRUG|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
219084357|NCT05867654|DRUG|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
219084358|NCT05867654|DRUG|Levofloxacin 750mg QID|Oral antibiotic used based on indication
219084359|NCT05092321|BEHAVIORAL|Aquatic Occupational Therapy|Group of 4-8 children, paired with a swim buddy. Intervention techniques including discrete teaching, motor shaping, behavioral management, therapeutic relationship and individualized goals.
219361815|NCT00097357|DRUG|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
219361816|NCT00097357|DRUG|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
219681587|NCT04693299|DIAGNOSTIC_TEST|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
219681588|NCT03086005|DRUG|Metformin|
219361817|NCT02502760|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
219681589|NCT04949282|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
219681590|NCT04949282|DEVICE|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
219681591|NCT06553963|OTHER|Control group|The control group maintained their regular diet and training without additional nutritional support.
219681592|NCT06553963|OTHER|Experimental group|Biochemical Monitoring and Nutritional Support
219212669|NCT06758648|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive, high-resolution imaging technique that utilizes low-coherence light to capture cross-sectional images of the ocular fundus. Based on the principle of interferometry, OCT employs low-coherence light, which is scattered by the tissue, to produce detailed, high-resolution images of the retina and its layers. This technology enables precise visualization of the different retinal layers, including the nerve fiber layer, the ganglion cell layer, and the inner and outer plexiform layers. Additionally, OCT can be used to detect and monitor subtle structural changes in the retina, offering critical insights into retinal microarchitecture and potential manifestations of systemic diseases such as Fabry disease.
219212670|NCT06758648|DIAGNOSTIC_TEST|Echocardiography|Detection of signs of left ventricular hypertrophy, diastolic dysfunction, and valvular disease, which are common cardiac complications associated with Fabry disease, will be a key focus of the assessment. These abnormalities are indicative of the progressive cardiac involvement characteristic of the disease. Left ventricular hypertrophy reflects the thickening of the heart muscle, often caused by sphingolipid accumulation, while diastolic dysfunction highlights impaired relaxation and filling of the left ventricle. Valvular disease, including regurgitation or stenosis, further contributes to the cardiac burden in Fabry disease. Identifying and monitoring these conditions are essential for timely intervention and effective management of cardiac manifestations in affected patients.
219212671|NCT06758648|DIAGNOSTIC_TEST|24 hour pulse wave analysis|Pulse wave analysis (PWA) is a non-invasive method used to assess the cardiovascular system. It uses a sensor to measure the pressure waves generated by the heart's contraction and the subsequent blood flow through the peripheral vessels. By analyzing these pressure waves, PWA can provide information about the elasticity of the arterial walls, the blood flow in the peripheral vessels, the blood pressure, and the arterial stiffness.
219212672|NCT06758648|DIAGNOSTIC_TEST|24-hour blood pressure measurement|Blood pressure measurement to asses cardiovascular risk.
219212673|NCT06758648|DIAGNOSTIC_TEST|1 hour ECG|One hour ECG to asses autonomic dysfunction in patients with Fabry disease.
219212674|NCT06758648|DIAGNOSTIC_TEST|Ophthalmological consultation|Evaluation and monitoring of ocular manifestations of Fabry disease.
219212675|NCT06758648|DIAGNOSTIC_TEST|Static retinal vessel analysis (SVA)|"Comparable to DVA, SVA is a non-invasive and quick tool to examine the retinal microvasculature. SVA pictures will be analyzed using Vesselmap 2® (IMEDOS Systems GmbH, Jena, Germany). One eye will be examined, and three images will be taken with a focus on the optic disc at an angle of 50°. Roughly one disc diameter away from the optic disc, retinal veins and arterioles segments will be semi-automatically labeled. The Paar-Hubbard formula averages the central retinal arteriolar (CRAE) and central venular (CRVE) equivalents.~The arteriolar-venular ratio will be calculated as CRAE/CRVE."
219212676|NCT06886620|DRUG|Cilostazol 200 mg|Provided as 1# placebo tablet in the morning and 1# PMR 200 mg/tablet in the evening, orally, for 24 weeks.
219212677|NCT06886620|DRUG|Cilostazol 100 mg|Provided as 1# Pletaal® 100 mg/tablet, orally twice a day, for 24 weeks.
219212678|NCT04107233|BEHAVIORAL|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
219212679|NCT06259097|DRUG|Misoprostol|25 mcg vaginally every 6 hours
219212680|NCT06259097|DRUG|Pitocin|3-6 mL intravenously every hour
219212681|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
219212682|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
219212683|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
219681593|NCT05297890|DRUG|Lorlatinib|Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
219681594|NCT04712864|BIOLOGICAL|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
219681595|NCT02145208|DEVICE|TIND System|An implant
219681596|NCT06302049|DRUG|Esomeprazole|esomeprazole 20 mg once daily
219681597|NCT06302049|DRUG|Placebo|Placebo once daily
219681598|NCT02677597|DRUG|Cisplatin Combined With S-1|
219681599|NCT02677597|DRUG|Cisplatin Combined With Paclitaxel|
219681600|NCT00256009|DRUG|Cytotec|
219212684|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
219212685|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
219212686|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
219084364|NCT06393322|OTHER|Depression e-Learning A|"Participants in Depression e-Learning A will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
219084365|NCT06393322|OTHER|Depression e-Learning B|"Participants in Depression e-Learning B will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
219084366|NCT06393322|OTHER|Anxiety e-Learning A|"Participants in Anxiety e-Learning A will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
219212687|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
219212688|NCT05747794|BIOLOGICAL|eftilagimod alpha|APC activator, MHC II agonist
219084367|NCT06393322|OTHER|Anxiety e-Learning B|"Participants in Anxiety e-Learning B will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
219084368|NCT02470650|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
219084369|NCT02470650|DRUG|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
219212689|NCT05747794|DRUG|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
219212690|NCT05747794|OTHER|placebo|placebo matching eftilagimod alpha
219212691|NCT06938984|DEVICE|Sham Comparator|Massaging the quadriceps with one of the Human TECAR probes with the device turned off for 10 minutes
219212692|NCT06938984|DEVICE|Capacitive mode before|Capacitive mode applied to the quadriceps for 10 minutes
219212693|NCT06938984|DEVICE|Resistive mode before|Resistive mode applied to the quadriceps for 10 minutes
219212694|NCT06938984|DEVICE|Capacitive mode after|Capacitive mode applied to the quadriceps for 10 minutes
219212695|NCT06938984|DEVICE|Resistive mode after|Resistive mode applied to the quadriceps for 10 minutes
219212696|NCT06401759|BEHAVIORAL|Podcast|Routine maintenance will be applied.
219212697|NCT06890585|DRUG|ZCR-CHOP|Zanubrutinib, Chidamide, and Rituximab Induction Therapy Sequentially Combined With or Without CHOP
219212698|NCT06890585|DRUG|R-CHOP|R-CHOP
219681601|NCT01388712|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).
219084370|NCT02470650|DRUG|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
219084371|NCT02470650|DRUG|Ritonavir|Ritonavir 100 mg recovered tablet once a day
219084372|NCT02470650|DRUG|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
219084373|NCT02470650|DRUG|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
219084374|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
219084375|NCT03338829|BEHAVIORAL|Positive incentive|Compensation is paid for each glucose test completed
219084376|NCT03338829|BEHAVIORAL|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
219084377|NCT05115825|BEHAVIORAL|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
219084378|NCT05115825|OTHER|Quality-of-Life Assessment|Ancillary studies
219084379|NCT05115825|OTHER|Questionnaire Administration|Ancillary studies
219212699|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
219212700|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
219212701|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
219212702|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
219212703|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
219212704|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
219681602|NCT01388712|DIETARY_SUPPLEMENT|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
219681603|NCT00443157|BIOLOGICAL|Meningococcal B Vaccine NZ|
219361818|NCT02502760|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
219361819|NCT02502760|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
219361820|NCT02287987|PROCEDURE|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
219361821|NCT02287987|PROCEDURE|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
219084380|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
219084381|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
219084382|NCT06032559|OTHER|TAU|TAU only
219084383|NCT06118372|DRUG|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
219212705|NCT06941753|OTHER|Off-script diagnosis & differential diagnosis (D&D) training|"1. Training Timeline: Must be completed within 72 hours post-randomization; Requires standardized structured off-script D\&D analysis.~2. Structured Analysis Framework: 1)Epidemiology: Incidence, mortality, and disability rates; 2) Etiologic Classification: TOAST classification system; 3) Vascular Mechanisms: Culprit vessel, vascular territory, pathophysiology; 4) Differential Diagnosis: Stroke mimics and stroke subtype differentiation; 5) Acute Management: Hyperacute interventions (thrombolysis/EVT), secondary prevention strategies, and evidence-based case analysis; 6) Patient Education: Stroke prevention education for patients/public; 7) Research Gaps: Current limitations and future directions.~3. Presentation Requirements: 1)Mandatory off-script delivery (no prepared text); 2) Time limit: 15+3 minutes for complete analysis."
219212706|NCT06773468|BEHAVIORAL|stress management|These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.
219212707|NCT06767527|DRUG|AK112|AK112 via intravenous (IV) infusion
219212708|NCT06767527|DRUG|Nab-paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
219212709|NCT06767527|DRUG|Placebo|Placebo via IV infusion
219212710|NCT05372549|OTHER|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
219212711|NCT05372549|OTHER|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
219212712|NCT05372549|OTHER|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
219212713|NCT05271331|DRUG|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
219212714|NCT05271331|DRUG|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
219212715|NCT05271331|DRUG|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
219212716|NCT05271331|DRUG|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
219212717|NCT03911466|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
219212718|NCT03911466|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
219212719|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
219212720|NCT06940180|DRUG|Toripalimab|An anti-PD-1 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
219212721|NCT06940180|DRUG|Carboplatin|An antineoplastic agent, multi-dose vials, via intravenous (into the vein) infusion per standard of care.
219212722|NCT06940180|DRUG|Docetaxel|A taxoid antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
219212723|NCT06940180|RADIATION|Radiation Therapy|per standard of care
219084384|NCT05535478|BEHAVIORAL|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
219212724|NCT06940180|DRUG|Cisplatin|An antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
219212725|NCT05028881|OTHER|blood sampling|blood sampling for determining antibody responses
219212726|NCT06944899|DEVICE|NO Sensor|NO sensor measuring wound characteristic data in wound bed
219212727|NCT06793293|DEVICE|High level laser|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) in addition to High level laser for 5 minutes on days 1 st , 2 nd , and 3 rd , after cesarean section (3 sessions)
219212728|NCT06793293|DRUG|Non-steroidal anti- inflammatory drugs and antibiotics|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
219212729|NCT06797323|BEHAVIORAL|Web-Based Application for Pelvic Floor Health|A user-friendly web application designed to provide educational resources, exercises, and interactive tools aimed at improving pelvic floor health in pregnant women.
219212730|NCT06796413|PROCEDURE|Loop Resection or Cold-cup biopsy|Loop Resection or cold-cup biopsy of bladder tumor base - thus after the tumor has been resected and the deep muscle specimen needed to be obtained, the Loop Cautery or Lowsley Forceps (for cold-cup biopsy) was used to obtain the deep muscle specimen
219361822|NCT02849756|OTHER|older in intensive care unit|It is an observational study with no intervention.
219361823|NCT00002953|DRUG|cyclophosphamide|
219361824|NCT00002953|DRUG|epirubicin hydrochloride|
219361825|NCT00002953|DRUG|paclitaxel|
219361826|NCT06312787|DRUG|VX-118|Tablets and Suspension for Oral Administration
219361827|NCT01286857|DEVICE|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
219212731|NCT06795308|OTHER|Bed Position and Head Elevation|The first group will remain in the supine position for 6 hours after the Angiography procedure, and the treated leg will be kept straight and immobile. Patients will not move their legs during this period. A sandbag weighing approximately 4 kg will be placed over the catheter dressing for 6 hours to prevent bleeding and subcutaneous blood accumulation. For the first two hours, the patient will lie on his back and on a flat surface with his legs extended straight. During the remaining 4 hours, investigators will monitor the patient's bed head by raising it 15 degrees intermittently under the supervision of the doctor, and at the end of the 6th hour, the sandbag on the leg will be removed. Blood pressure, pulse rate, respiratory rate, body temperature, as well as pain level will be measured every two hours.
219212732|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
219212733|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
219212734|NCT05664243|BIOLOGICAL|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
219084385|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
219084386|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
219084387|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
219084388|NCT06496048|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
219084389|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
219084390|NCT06496048|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
219084391|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
219084392|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
219084393|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
219212735|NCT05664243|BIOLOGICAL|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
219212736|NCT05836025|DRUG|Rapamycin|5mg/week of rapamycin orally for 12 weeks
219212737|NCT05836025|OTHER|Placebo|5mg/week of placebo orally for 12 weeks
219084394|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
219084395|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
219084396|NCT03575325|DRUG|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
219084397|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
219084398|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
219084399|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
219084400|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
219084401|NCT04576091|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219212738|NCT06947317|PROCEDURE|Arthroscopic anterior talofibular ligament repair|This intervention involves an isolated all-inside arthroscopic repair of the anterior talofibular ligament (ATFL) without addressing the coexisting osteochondral lesion of the talus. It is intended for patients with chronic ankle instability and a concomitant talar osteochondral lesion, where only the ligamentous injury is treated. Patients follow a standard rehabilitation protocol with return to sports allowed after 3 months.
219212739|NCT06947317|PROCEDURE|Talar chondral lesion treatment using microfracture technique|This intervention consists of an arthroscopic debridement and microfracture of a symptomatic osteochondral lesion of the talus. Postoperative rehabilitation is extended due to the cartilage procedure, delaying return to sports until 4 months.
219212740|NCT04692181|BIOLOGICAL|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
219212741|NCT06946602|PROCEDURE|Bu/Flu/Cy/ATG|The Bu/Flu/Cy/ATG conditioning regimen consists of the following components: Ara-C (2 g/m²/day, injected i.v.) on days-10 and-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Flu (30 mg/m²/day, injected i.v.) from day-6 to day-2; Cy (1.0 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
219084402|NCT04576091|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT scan
219084403|NCT04576091|DRUG|Elimusertib|Given PO
219084404|NCT04576091|BIOLOGICAL|Pembrolizumab|Given IV
219084405|NCT04576091|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
219084406|NCT04576091|OTHER|Quality-of-Life Assessment|Ancillary studies
219084407|NCT04576091|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219084408|NCT01882322|DRUG|Prograf|oral
219084409|NCT01882322|DRUG|Advagraf|oral
219084410|NCT00959933|DRUG|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
219084411|NCT00959933|DRUG|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
219084412|NCT03589079|GENETIC|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
219084413|NCT05073757|DEVICE|Custom-made guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with custom-made guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
219212742|NCT06946602|PROCEDURE|Bu/Cy/ATG|The Bu/Cy/ATG conditioning regimen consists of the following components: Ara-C (4 g/m²/day, injected i.v.) on day-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Cy (1.8 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
219212743|NCT04599036|DEVICE|MARK|EMG controlled arm orthosis
219212744|NCT06950801|BEHAVIORAL|outdoor-horticultural therapy|Students are randomly assigned to the Outdoor Horticultural Therapy group, where they will receive outdoor horticultural therapy for eight weeks
219212745|NCT06950801|BEHAVIORAL|indoor-Horticultural Therapy group|Students are randomly assigned to the indoor horticultural therapy group, where they will receive indoor horticultural therapy for 8 weeks
219212746|NCT06950801|BEHAVIORAL|General Psychological Group Counselling Team|Students were randomly assigned to general group groups to participate in an 8-week mental health group activity
219212747|NCT06950723|OTHER|Chest Physical Therapy (CPT) modalities , Medical Treatment|Chest Physical Therapy (CPT) modalities in the form of postural drainage, percussion and vibration.
219084414|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
219084415|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
219084416|NCT05676255|BEHAVIORAL|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
219084417|NCT00135005|DRUG|AMN107, STI571|
219084418|NCT01952184|DEVICE|CBSvit HS device|closed vitrification with closed storage
219084419|NCT01952184|DEVICE|Cryotop SC device|open vitrification with closed storage
219212748|NCT06950138|DRUG|Triticum aestivum|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
219212749|NCT06950138|DRUG|calcined magnesia|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
219212750|NCT06950203|DIETARY_SUPPLEMENT|Very Long Chain Polyunsaturated Fatty Acids|Fish oil with DHA and VLCPUFA
219212751|NCT06950203|DIETARY_SUPPLEMENT|Comparator arm (DHA)|Oil containing equal DHA content to active arm
219212752|NCT06880965|DIAGNOSTIC_TEST|testing implant stability|testing implant stability by using the periotest device
219212753|NCT06880965|DRUG|use concentrated growth factor.|short implants assisted over denture in combination with concentrated growth factor.
219212754|NCT06880965|RADIATION|marginal bone loss calculation|marginal bone loss calculation by digitized periapical radiograph
219361828|NCT01392807|DRUG|NKTR-118|25 mg Oral tablets, single dose
219084420|NCT06803355|DIAGNOSTIC_TEST|complete blood count, CRP, blood smear test, blood culture, chest X- ray|Inflammation markers obtained from all cases will be evaluated and used to differentiate between transient tachypnea of the newborn and congenital pneumonia.
219084421|NCT06052241|DRUG|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
219084422|NCT00146835|BIOLOGICAL|Pediarix|1 or more injections
219084423|NCT00146835|BIOLOGICAL|Licensed DTPa containing vaccine|1 or more injections
219084424|NCT00146835|BIOLOGICAL|Prevnar®: (Wyeth)|Concomitant vaccination
219084425|NCT02968420|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
219084426|NCT02618967|BIOLOGICAL|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
219084427|NCT02618967|BIOLOGICAL|AMG 570 Matching Placebo|Placebo administered as single dose subcutaneous in healthy volunteers.
219084428|NCT01368965|DEVICE|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
219084429|NCT06304818|DRUG|SCTB14|SCTB14,IV
219084430|NCT06041984|DRUG|Glycopyrrolate|Intravenous injection of glycopyrrolate 0.2mg
219084431|NCT06041984|OTHER|Placebo|Intravenous injection of saline 1ml
219084432|NCT05560048|DIETARY_SUPPLEMENT|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
219084433|NCT05560048|DIETARY_SUPPLEMENT|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
219084434|NCT00502255|DEVICE|Health Buddy system|Patients are followed on distance by the Health Buddy system.
219084435|NCT00502255|DEVICE|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
219084436|NCT05522725|OTHER|Single-use wipes installed at the bedside|
219084437|NCT05770999|OTHER|Lavender application|Lavender application
219084438|NCT04658147|DRUG|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
219084439|NCT04658147|DRUG|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
219084440|NCT03225664|BIOLOGICAL|Pembrolizumab|Given IV
219084441|NCT03225664|OTHER|Pharmacokinetic Study|Correlative studies
219084442|NCT03225664|DRUG|Trametinib|Given PO
219084443|NCT05773768|DEVICE|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
219084444|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
219084445|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
219084446|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
219084447|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
219084448|NCT04672551|BEHAVIORAL|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
219212755|NCT06954688|OTHER|dry needling|Dry Needling: The puncture is intramuscular and is performed with a non-beveled, filiform, solid needle, similar to those used in acupuncture, which has been shown to produce less damage at the muscle level. It does not infiltrate any substance. As many entries as necessary are made until the local twitch response (LTR) is exhausted.
219361829|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the morning (AM) for 7 days
219084449|NCT05616988|OTHER|psychological-clinical intervention with three days of expressive writing by Pennebaker|"The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~* Emotions and expectations related to the breast reconstruction process.~* Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~* Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days)."
219084450|NCT00957476|DIETARY_SUPPLEMENT|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
219084451|NCT05360056|DEVICE|DexCom G6|Wearable continuous glucose monitor
219084452|NCT04041362|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion plus standard ART
219084453|NCT04041362|OTHER|Antiretroviral Therapy (ART)|Standard ART
219084454|NCT05304338|DRUG|Chlorhexidine|Gargling with 10 mL 0.2% Chlorhexidine
219084455|NCT05304338|OTHER|Oil Pulling|In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
219084456|NCT05304338|OTHER|Distilled Water|Gargling with 10 mL distilled water
219084457|NCT02742168|RADIATION|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
219084458|NCT01371331|DRUG|Tacrolimus granules|oral
219084459|NCT00330083|BIOLOGICAL|ALK Ragweed Tablet|
219361830|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD AM for 7 days
219361831|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to study eye, QD AM for 7 days
219084460|NCT00514735|PROCEDURE|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
219084461|NCT00514735|DRUG|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
219084462|NCT02802800|OTHER|Plyometric training|Plyometric exercises
219084463|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
219084464|NCT04217681|BEHAVIORAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
219084465|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
219084466|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
219084467|NCT02264704|OTHER|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
219084468|NCT02264704|OTHER|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
219084469|NCT04210206|OTHER|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
219084470|NCT00194558|BEHAVIORAL|Internet co-management module|
219084471|NCT01064232|DRUG|Risperidone|Risperidone Tablets 1 mg
219084472|NCT04763902|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
219084473|NCT05303779|OTHER|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
219084474|NCT05303779|DRUG|Medication and eye glasses|medication and eye glasses used post strabismus surgery
219084475|NCT01278134|DRUG|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
219084476|NCT01278134|DRUG|RO5024048|1000 mg bid orally, up to 24 weeks
219084477|NCT01278134|DRUG|danoprevir|100 mg bid orally, up to 24 weeks
219084478|NCT01278134|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
219084479|NCT01278134|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
219084480|NCT01278134|DRUG|ritonavir|100 mg bid orally, up to 24 weeks
219084481|NCT05217342|DRUG|Diuretic therapy|Standard diuretic therapy according to the current guidelines
219084482|NCT06217757|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
219084483|NCT06217757|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219084484|NCT06217757|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
219084485|NCT06217757|DRUG|Sugemalimab|Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
219084486|NCT06217757|DRUG|Olaparib|Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
219361832|NCT01528787|OTHER|AR-13324 Ophthalmic Solution Vehicle|Administered to study eye, QD AM for 7 days
219361833|NCT03163381|DRUG|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
219084487|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
219084488|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
219084489|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
219084490|NCT00586911|DRUG|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
219084491|NCT00586911|DRUG|Identical Placebo|Placebo
219084492|NCT03640650|COMBINATION_PRODUCT|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
219084493|NCT03640650|DRUG|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
219212756|NCT06952725|BEHAVIORAL|online quit-smoking support group with intelligent chatbot|In the intervention arm (N=60), each quit-smoking peer support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). This chatbot will monitor all posts in the group and seek to comprehend these posts using the training it has been provided. If a group member makes a post and no one responds with about 10 seconds, the chatbot will respond using one of its 25 response libraries created from knowledge bases, which contain over 1k responses in total. In effect, the intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so.
219212757|NCT06952725|BEHAVIORAL|online quit-smoking support group with unintelligent bot|In the control arm (N=60), the support groups will be connected to our original automated message-posting bot running on our secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot; it will not respond to posts if no human group member does but, instead, remain silent. However, it will post the same daily discussion topic, and at the same time of day, as the intelligent chatbot.
219084494|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
219084495|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
219084496|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
219084497|NCT02549469|DRUG|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
219084498|NCT02380547|OTHER|Sonographic diaphragmatic measurements|
219084499|NCT03275025|DRUG|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
219084500|NCT03275025|DRUG|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
219084501|NCT03275025|DRUG|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
219084502|NCT03275025|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
219084503|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
219212758|NCT06952621|DRUG|3 cycles (Toripalimab + chemotherapy)|Toripalimab: 240mg, intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Nab-paclitaxel: 125mg/m², intravenous infusion, on Day 1 and Day 8, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 75mg/m², intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment;
219212759|NCT06952621|DRUG|3 cycles（DCF）|Docetaxel: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; 5-FU (5-fluorouracil): 750mg/m², intravenous infusion, on day 1 to day 5, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment
219212760|NCT06955819|OTHER|Placebo Intervention|Subjects will be given a blank matrix powder with the same appearance as the products in the experimental groups, which does not contain probiotics or herbal powder. The dosage, frequency, and administration method are exactly the same as those in Experimental Group. Intervention duration will be 12 weeks, carried out synchronously with the experimental groups to ensure the consistency of research conditions.
219212761|NCT06955819|DIETARY_SUPPLEMENT|Probiotic Intervention|Subjects will take Zhigu Zhijian (QingzhiningTM) probiotic powder, 2g per sachet, twice a day, one sachet after breakfast and one after dinner, taken with lukewarm water (water temperature ≤ 30℃). Intervention duration will also be 12 weeks, for parallel comparison with other groups.
219212762|NCT06955819|DIETARY_SUPPLEMENT|Probiotic with Herbal Powder Intervention|Subjects in this group will be given Zhigu Zhijian (QingzhiningTM) probiotic powder and Zhigu Zhijian (QingzhiningTM) herbal powder. The probiotic powder is 2g per sachet, taken twice a day, one sachet after breakfast and one after dinner, and should be taken with lukewarm water (water temperature ≤ 30℃). The herbal powder is 15g per sachet, taken once every other day before breakfast, and should be taken after being brewed with boiling water. Intervention duration will be last for 12 weeks to ensure sufficient time to observe the long - term effects on defecation and gut microbiota.
219212763|NCT06953869|DRUG|Tasimelteon Oral Suspension|Single daily dose, weight-based liquid suspension formulation.
219212764|NCT06953869|DRUG|Placebo|Placebo comparator.
219212765|NCT06953830|DEVICE|Vibration-controlled transient elastography|Liver and spleen stiffness measurements using vibration-controlled transient elastography
219084504|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
219084505|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
219084506|NCT06019117|DIETARY_SUPPLEMENT|Probiotic K10|clinical trial using 90 days of probiotic K10
219084507|NCT06019117|DRUG|Placebo|clinical trial using 90 days of placebo controlled
219084508|NCT02693990|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
219084509|NCT03491761|BIOLOGICAL|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
219084510|NCT03491761|BIOLOGICAL|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
219084511|NCT00680511|BEHAVIORAL|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
219084512|NCT00680511|BEHAVIORAL|Functional Family Therapy (FFT)|FFT
219084513|NCT01894295|DIETARY_SUPPLEMENT|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
219084514|NCT01894295|DIETARY_SUPPLEMENT|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
219212766|NCT06951451|BEHAVIORAL|smartphone application (MED-AD)|"1. Medication Reminders: The oral medication list of the patient (names, doses, times, and frequency of administration) will be entered manually in the application by the RA in agreement with the patient during the medication prescription refill. This application will then send reminders, as notifications and voice notes, to take medications. An example of the reminder is take lisinopril, one tablet, 10 mg at 9:00 am. The reminders will be categorized as normal, urgent \& critical. Normal is a reminder sent on the normal medication timing. An urgent reminder is when the patient misses confirming a reminder more than once, which will be set as an alert on the phone. Critical reminder is when the patient misses confirming a reminder multiple times, which will be as an alert or an alarm on the phone. In addition, the application will notify a family member in case of urgent and critical reminders.~2. Medication Adherence Report: The application will generate a weekly report on medication"
219084515|NCT00091481|DRUG|Zemplar|
219084516|NCT05979909|DRUG|Mitomycin C|Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
219212767|NCT06951451|BEHAVIORAL|Short Text-message Reminders|"Participants will receive short text message (SMS) reminders to remind them to take medications as prescribed ONCE daily. However, the SMS will be general and not specify taking particular medicine compared to the application reminders. An example of the SMS message will be Remember to take your medicines of the day? The research team will pilot the MED-AD application on the same population and modify it before the implementation of the study."
219084517|NCT03062969|PROCEDURE|Cleavage stage biopsy group|"* intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer"
219084518|NCT03062969|PROCEDURE|Trophectoderm biopsy group|"* ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer"
219084519|NCT01839929|DRUG|Prograf|oral
219084520|NCT01839929|DRUG|Advagraf|oral
219084521|NCT02660632|OTHER|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
219084522|NCT02660632|OTHER|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
219084523|NCT00142441|DEVICE|Pulsed dye laser|
219084524|NCT02063126|DIETARY_SUPPLEMENT|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
219084525|NCT02063126|DIETARY_SUPPLEMENT|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
219084526|NCT05230173|OTHER|Pragmatic|"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
219084527|NCT02910648|BEHAVIORAL|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
219084528|NCT05081453|DEVICE|pavlik harness|The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
219084529|NCT00291967|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
219084530|NCT02889653|DRUG|Any oral antithrombotics (antiplatelets or anticoagulants)|
219084531|NCT01494168|PROCEDURE|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
219084532|NCT01972958|OTHER|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
219084533|NCT02190539|OTHER|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
219084534|NCT00003334|DRUG|paclitaxel|
219084535|NCT00003334|DRUG|pegylated liposomal doxorubicin hydrochloride|
219084536|NCT05238233|DRUG|Tropicamide|One drop will be given to participants
219084537|NCT05238233|DRUG|1% Pilocarpine|One drop will be given to participants
219084538|NCT05238233|DRUG|Proparacaine Hydrochloride|One drop will be given to participants
219084539|NCT05238233|DEVICE|Tono pen AVIA|Participant intraocular pressures measured
219084540|NCT05238233|DEVICE|VG4 Gonio|Participant iridocorneal angle measured
219084541|NCT05238233|DEVICE|Reichert phoropter|Participant screened for hyperopia \>+1 diopter
219084542|NCT04337814|DRUG|EMLA Cream|Topical anaesthetic cream
219084543|NCT04337814|DRUG|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
219084544|NCT04337814|DRUG|Placebo syrup|Placebo syrup similar to Ibuprofen
219212768|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
219212769|NCT05370612|DEVICE|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
219212770|NCT05370612|OTHER|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
219212771|NCT05854212|BEHAVIORAL|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
219212772|NCT06360133|DRUG|VVN001 Ophthalmic Solution, 5%|VVN001 Ophthalmic Solution, 5%
219212773|NCT06360133|DRUG|VVN001 Ophthalmic Solution, Vehicle|VVN001 Ophthalmic Solution, Vehicle
219212774|NCT01203722|DRUG|Fludarabine|Fludarabine 30 mg/m2/day
219212775|NCT01203722|DRUG|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
219212776|NCT01203722|RADIATION|Total Body Irradiation|400 cGy TBI administered in a single fraction
219212777|NCT01203722|PROCEDURE|Allogeneic Blood or Marrow Transplant|
219084545|NCT04337814|DRUG|Placebo cream|Placebo cream similar to EMLA
219084546|NCT01345721|BIOLOGICAL|MenACWY-CRM|
219084547|NCT00506064|DRUG|Melatonin|0.15 mg/kg by mouth (PO) Daily
219084548|NCT00506064|DRUG|Placebo|Two, three, or four starch tablet or capsules before bed
219084549|NCT00506064|BEHAVIORAL|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
219084550|NCT00553696|DRUG|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
219084551|NCT00553696|DRUG|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
219084552|NCT00553696|DRUG|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
219084553|NCT05087381|DRUG|FluvoxaMINE Maleate 50 MG|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
219084554|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Bromhexine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
219084555|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Cyproheptadine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
219212778|NCT01203722|PROCEDURE|Peripheral Blood Stem Cell Transplant|
219212779|NCT01203722|DRUG|Mycophenolate Mofetil|15mg/kg by mouth three times daily
219212780|NCT01203722|DRUG|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
219212781|NCT01203722|DRUG|Tacrolimus|Tacrolimus 1mg intravenously, daily
219212782|NCT06275464|COMBINATION_PRODUCT|BT-600|NaviCap device containing liquid formulation of Tofacitinib
219212783|NCT06275464|COMBINATION_PRODUCT|BT-600 Placebo|NaviCap device containing placebo formulation
219212784|NCT06060977|DRUG|IMG-007|Intravenous Infusion
219212785|NCT03572803|OTHER|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
219212786|NCT03572803|OTHER|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
219212787|NCT03572803|OTHER|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
219212788|NCT00146172|DRUG|neratinib|HKI-272
219212789|NCT01902914|PROCEDURE|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
219361834|NCT05193565|DRUG|Sirolimus|Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
219361835|NCT05193565|DRUG|Mycophenolate mofetil|Up to 1g BID(total 2g daily), PO
219084556|NCT05087381|DRUG|Niclosamide Pill|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
219212790|NCT05786378|BIOLOGICAL|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
219212791|NCT05786378|DRUG|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
219212792|NCT05786378|PROCEDURE|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
219212793|NCT05766202|OTHER|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
219212794|NCT06951178|DEVICE|TMJ Total Arthroplasty System (TMJ System)|All patients treated or to be treated with the TMJ Total Arthroplasty System for TMJ reconstruction. The TMJ Total Arthroplasty System (TMJ System) is a medical device intended to restore the TMJ. It comprises two articulating components: a temporal component and a mandibular component. The TMJ System is patient-specific based on the patient's anatomy and surgical treatment. Different shape designs are possible depending on the patient's anatomy and the type of surgery performed.
219361836|NCT06086847|OTHER|progressive resistant exercises|"Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3\. Progressive Resistance exercises:~1. Leg press :( dual leg press): Leg press target the~   Quadriceps or quads .but they also work your Hamstrings.~2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4\. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
219361837|NCT02416557|PROCEDURE|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
219681604|NCT02118779|BEHAVIORAL|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
219681605|NCT05892250|BEHAVIORAL|Conventional physical therapy|Manual techniques and therapeutic exercise
219681606|NCT05892250|BEHAVIORAL|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
219681607|NCT02273362|DRUG|Erlotinib|Given PO
219681608|NCT02273362|DRUG|Erlotinib Hydrochloride|Given PO
219681609|NCT02273362|OTHER|Laboratory Biomarker Analysis|Correlative studies
219681610|NCT02273362|OTHER|Quality-of-Life Assessment|Ancillary studies
219681611|NCT01719991|OTHER|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
219681612|NCT01973426|DEVICE|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
219681613|NCT02954549|DIETARY_SUPPLEMENT|Vitamin D3|As in Arms
219681614|NCT02966821|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
219681615|NCT00990509|DRUG|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
219681616|NCT00990509|DRUG|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
219681617|NCT00990509|PROCEDURE|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)"
219681618|NCT00716768|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
219681619|NCT00716768|PROCEDURE|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
219681620|NCT02927574|DEVICE|DCB|
219681621|NCT02927574|DEVICE|POBA|
219084557|NCT05087381|COMBINATION_PRODUCT|Niclosamide, Bromhexine|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
219084558|NCT01507805|DEVICE|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
219084559|NCT01507805|DEVICE|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
219084560|NCT05382182|DRUG|androgen deprivation therapy|outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
219084561|NCT05382182|RADIATION|external beam radiotherapy|outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
219084562|NCT00243880|DRUG|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
219084563|NCT00686881|BIOLOGICAL|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
219084564|NCT00686881|DRUG|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
219084565|NCT04846452|DRUG|Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin|Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
219084566|NCT04846452|DRUG|Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin|Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
219084567|NCT06221579|OTHER|No intervention, interviews with MCI patients as part of the development phase|No intervention, interviews with MCI patients as part of the development phase
219084568|NCT03303157|OTHER|no intervention|not relevant
219084569|NCT02908373|OTHER|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
219084570|NCT05845320|OTHER|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
219084571|NCT03511833|DRUG|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg
219084572|NCT03511833|DRUG|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
219084573|NCT04292249|OTHER|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP\>20 mg/L a regular CRP-measurement will be performed.
219084574|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
219681622|NCT06613308|DRUG|Neoadjuvant immunotherapy combined with chemotherapy|The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
219084575|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
219084576|NCT02680548|DRUG|0.9% saline|
219084577|NCT02680548|DRUG|0.25% bupivacaine hydrochloride injectable suspension USP|
219084578|NCT02680548|DRUG|4mg/cc methylprednisolone acetate injectable suspension USP|
219361838|NCT00259480|BEHAVIORAL|Home Based Intervention|occupational therapy
219084579|NCT00838955|DRUG|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
219084580|NCT05176275|DIAGNOSTIC_TEST|68Ga-NOTA-RP25|The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
219084581|NCT06128668|BEHAVIORAL|Yoga|Yoga will be applied
219084582|NCT00255957|DRUG|HES administration|
219084583|NCT00255957|DRUG|Hydroxy Ethyl Starch administration to stroke patients|
219084584|NCT03285425|OTHER|Natural history|Parent interview
219084585|NCT02264522|OTHER|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
219084586|NCT02264522|OTHER|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
219084587|NCT02264522|OTHER|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
219361839|NCT04924855|OTHER|Blood sampling (4 per year)|Blood sampling (4 per year)
219212795|NCT06950515|PROCEDURE|Peripheral EBUS under Concious sedation|In the conscious sedation group, the procedure will be performed through the nose or mouth at the discretion of the endoscopist. The patient will remain breathing spontaneously throughout the procedure and will be administered oxygen through a nasal cannula at an initial flow rate of 2L/min. A combination of propofol, fentanyl and midazolam boluses will be used to maintain moderate sedation. At IUCPQ-UL, fentanyl and midazolam will be used as in our routine practice. The boluses will be prescribed by a doctor experienced in conscious sedation (anesthesiologist, intensivist or pulmonologist) according to the patient's state of wakefulness assessed by the Richmond Agitation-Sedation Scale (RAS) .Centers will decide, prior to initiating recruitment locally, the drug combination used to sedate patients and they will maintain the use of the same drug combination throughout the study
219212796|NCT06950515|PROCEDURE|Peripheral EBUS under General Anesthesia|In the general anesthesia group, an endotracheal tube larger than 7 will be used. The patient will be kept non-arousable to non-nociceptive stimulation (RAS = -5) by a perfusion including, at the anesthesiologist's discretion: fentanyl, sufentanyl, remifentanyl, midazolam or propofol. The sedation of this group will not be protocolized given the wide variety of practices in the participating centers, but the targeted level of sedation will be and the medication administered will be adjusted according to this target. The RAS will be evaluated every 5 minutes, or earlier if signs of arousal are present, to ensure that the intended target is maintained and adjustments to the rate of infusions as well as boluses may be made/administered by the anesthesiologist to maintain the targeted level of sedation. Patients may be paralyzed at the discretion of the anesthesiologit. The ventilatory parameters will be standardized according to the VESPA protocol
219212797|NCT03684590|DEVICE|ANI-guided opioid administration|Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)
219212798|NCT03684590|OTHER|Standard opioid administration|Intraoperative opioid will be administered according to standard practice during surgery.
219212799|NCT03876457|DEVICE|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
219212800|NCT03876457|OTHER|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
219681623|NCT06613308|DRUG|Neoadjuvant chemotherapy|"A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments."
219681624|NCT00865657|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
219681625|NCT00865657|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
219084588|NCT02264522|OTHER|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
219084589|NCT03652974|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
219084590|NCT03652974|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
219084591|NCT03652974|DRUG|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
219084592|NCT03652974|DRUG|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
219084593|NCT03918746|BEHAVIORAL|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
219084594|NCT02170025|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
219084595|NCT02170025|DRUG|Placebo|Participants received matching placebo tid.
219084596|NCT00572195|DEVICE|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
219084597|NCT03677011|DIAGNOSTIC_TEST|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
219084598|NCT06485076|OTHER|Early Palliative Care|see previous description
219084599|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
219212801|NCT01036724|DEVICE|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
219212802|NCT03718013|DEVICE|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
219212803|NCT03718013|DEVICE|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
219212804|NCT02863315|DEVICE|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
219212805|NCT01048476|DIETARY_SUPPLEMENT|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
219212806|NCT01048476|DIETARY_SUPPLEMENT|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
219212807|NCT01048476|DIETARY_SUPPLEMENT|placebo|Dietary Supplement: placebo; daily supplementation one year
219212808|NCT01048476|DRUG|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
219212809|NCT01617369|DEVICE|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
219212810|NCT03555175|OTHER|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
219212811|NCT03555175|OTHER|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
219084600|NCT02412137|OTHER|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
219084601|NCT06700915|DIETARY_SUPPLEMENT|Diaberine|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
219084602|NCT06700915|DIETARY_SUPPLEMENT|Placebo Capsule|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
219084603|NCT06698887|DRUG|Idecabtagene vicleucel|As per CA089-1043 study protocol
219084604|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
219084605|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
219084606|NCT06719505|OTHER|ME|Exercises selected with a focus on the major muscle groups. There will be one protocol for the first 3 months and a second protocol for months 4-6, with the number of repetitions for each exercise varying from 3 sets of 8 to 10 repetitions, totaling 18 exercises.
219084607|NCT06719505|OTHER|PE|The stretching and strengthening exercises will target the major muscle groups, and at the end of each session (lasting approximately 60 minutes), the instructor will guide the participant through a relaxation exercise using an EVA foam roller. The exercises were selected to improve overall muscle strength, as traditionally applied in Pilates. There will be one protocol for the first 3 months and a second protocol for months 4-6, with 17 exercises in each protocol, varying from 3 sets of 8 to 10 repetitions.
219084608|NCT06720662|DIETARY_SUPPLEMENT|Icosapent-ethyl ester capsules|Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.
219212812|NCT03555175|OTHER|Control group|Any exercise
219212813|NCT06232681|BEHAVIORAL|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
219212814|NCT01887275|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
219212815|NCT01887275|DRUG|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
219212816|NCT00557284|DRUG|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
219212817|NCT00557284|DRUG|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
219212818|NCT03001440|OTHER|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
219212819|NCT04826822|DRUG|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
219212820|NCT04826822|DRUG|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
219212821|NCT04129203|DEVICE|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
219212822|NCT03871439|DRUG|PF-05221304 Formulation A|50mg
219212823|NCT03871439|DRUG|PF-05221304 Formulation B|50mg
219212824|NCT05429164|OTHER|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
219212825|NCT05429164|OTHER|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
219212826|NCT05429164|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
219212827|NCT05995795|DEVICE|ARTHROSCOY|arthroscopy
219212828|NCT04255316|PROCEDURE|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
219212829|NCT04255316|PROCEDURE|Standard method of eversion carotid endarterectomy|standard eversion technic
219212830|NCT02432300|BEHAVIORAL|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
219212831|NCT06094166|DIAGNOSTIC_TEST|MRI|Quantitative imaging MR parameters
219212832|NCT05136066|OTHER|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
219212833|NCT03827200|DRUG|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
219212834|NCT05106049|DIAGNOSTIC_TEST|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
219084609|NCT06720662|DIETARY_SUPPLEMENT|Corn oil Control|Corn oil twice a day (2.0 g/day x 2) for six months.
219084610|NCT06721026|OTHER|Continuous intravenous stable isotope amino acid tracer infusion|During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.
219084611|NCT06721026|OTHER|Amino acid infusion|In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.
219212835|NCT05106842|OTHER|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
219212836|NCT05106842|OTHER|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
219212837|NCT01006772|OTHER|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
219212838|NCT01266369|DRUG|masitinib|
219212839|NCT01211106|BEHAVIORAL|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
219212840|NCT01211106|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
219212841|NCT01792557|DRUG|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
219681626|NCT04162795|DRUG|Loratadine (Claritin, BAY76-2211)|Chewable tablet, oral, single dose
219681627|NCT04171362|OTHER|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
219681628|NCT04171362|OTHER|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
219212842|NCT01792557|PROCEDURE|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
219681629|NCT01406184|OTHER|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
219681630|NCT03519113|BIOLOGICAL|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
219681631|NCT03519113|BIOLOGICAL|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
219084612|NCT06722222|PROCEDURE|Gao's triple eversion carotid endarterectomy|The carotid sheath is dissected in front of the sternocleidomastoid muscle to expose sufficient lengths of the CCA, ECA, and ICA. After raising the systolic blood pressure to 180 mmHg and intravenously injecting 1 mg/kg heparin, the superior thyroid artery is lapped and severed, and the CCA is occluded proximally to the CCA plaque, based on the plaque location shown by preoperative CTA and by intraoperative arterial exploration. Subsequently, the ECA and ICA are blocked individually. The ICA is cut diagonally at the CCA fork and the ECA is transected approximately 5 mm above its beginning. The plaque is removed with tweezers after eversion of the ICA. This process is repeated for the ECA. Finally, the long segment of plaque in the CCA is stripped proximally, followed by thorough removal of the debris on the peeling surface using heparin irrigation.
219084613|NCT06722261|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
219084614|NCT06732492|DRUG|RD13-02 cell infusion|CAR-T cells
219681632|NCT03519113|BIOLOGICAL|I.V HBIG|human anti-hepatitis B Immunoglobulin
219212843|NCT01792557|PROCEDURE|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
219084615|NCT06732973|DRUG|JS005|JS005：The drug was administered by a single subcutaneous injection
219084616|NCT01323530|DRUG|Eribulin mesylate|Intravenous (IV) bolus or infusion.
219212844|NCT01792557|PROCEDURE|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
219212845|NCT02906657|OTHER|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
219212846|NCT02387606|DRUG|Placebo|Participants will receive placebo once daily.
219212847|NCT02387606|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
219681633|NCT04551365|BEHAVIORAL|Lifestyle changes|Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
219681634|NCT04551365|DIETARY_SUPPLEMENT|Chitosan|Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
219681635|NCT04551365|OTHER|Placebo|Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
219681636|NCT05373563|PROCEDURE|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
219681637|NCT01899105|DRUG|lumacaftor|
219681638|NCT01899105|DRUG|ivacaftor|
219681639|NCT02107950|BIOLOGICAL|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
219084617|NCT01323530|DRUG|Capecitabine|Oral film-coated tablets.
219084618|NCT03716310|DIAGNOSTIC_TEST|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
219084619|NCT05604924|OTHER|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
219212848|NCT05362942|DRUG|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
219212849|NCT06314932|OTHER|MD high in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
219212850|NCT06314932|OTHER|MD low in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
219681640|NCT02107950|DRUG|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
219212851|NCT04425980|OTHER|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
219212852|NCT00395759|DRUG|Optiva artificial tear by Allergan|
219212853|NCT00557492|DRUG|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
219212854|NCT00557492|DRUG|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
219212855|NCT00557492|RADIATION|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
219084620|NCT04608175|OTHER|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
219084621|NCT01314989|DRUG|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
219084622|NCT01314989|DRUG|Sugar pill|liquid placebo
219084623|NCT00253344|DRUG|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
219084624|NCT00253344|DRUG|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
219084625|NCT00953134|DIETARY_SUPPLEMENT|Ferrous fumarate (iron)|60 mg of ferrous fumarate
219084626|NCT00953134|DIETARY_SUPPLEMENT|folic acid|400 mcg folic acid
219084627|NCT05961852|DEVICE|Angioplasty|Angioplasty with cutting and drug-coated balloon
219084628|NCT02138045|DRUG|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
219084629|NCT02138045|DRUG|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
219212856|NCT01884805|DEVICE|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
219212857|NCT05025813|DRUG|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
219212858|NCT04213807|BIOLOGICAL|MAA868 Cohort 1|Subcutaneous injection: low dose
219212859|NCT04213807|BIOLOGICAL|MAA868 Cohort 2|Subcutaneous injection: high dose
219212860|NCT04213807|BIOLOGICAL|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
219212861|NCT04213807|OTHER|Placebo|Subcutaneous injection: Placebo
219212862|NCT03142672|PROCEDURE|pulpotomy|vital endodontic procedure
219212863|NCT03142672|PROCEDURE|tooth filling|tooth filling
219084630|NCT03046615|DEVICE|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
219084631|NCT03046615|DEVICE|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
219084632|NCT01615874|DRUG|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
219084633|NCT01615874|DRUG|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
219084634|NCT01615874|DRUG|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
219084635|NCT01615874|DRUG|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
219084636|NCT01615874|DRUG|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
219084637|NCT01615874|DRUG|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
219084638|NCT01615874|DRUG|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
219084639|NCT05519280|BEHAVIORAL|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
219084640|NCT01885728|DIETARY_SUPPLEMENT|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
219084641|NCT01735201|DRUG|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
219084642|NCT01735201|DRUG|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
219084643|NCT01735201|DRUG|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
219084644|NCT01735201|DRUG|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
219084645|NCT02643576|BEHAVIORAL|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
219212864|NCT01574716|DRUG|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
219212865|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
219212866|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
219212867|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
219212868|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
219212869|NCT01574716|DRUG|Placebo|
219212870|NCT04394897|COMBINATION_PRODUCT|Remifentanil-Propofol admixture|
219212871|NCT02208596|DRUG|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
219212872|NCT02208596|DRUG|propofol|
219212873|NCT02208596|DRUG|Etomidate|
219681641|NCT06956001|DRUG|Firmonertinib Mesilate Tablets|Usage and dosage: oral, 240mg, QD。 Medication duration: 21 days as a cycle, until intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
219681642|NCT06956001|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: 500mg/m2, intravenous infusion. Medication duration: 21 days as a cycle, D1 administration, until the occurrence of intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
219681643|NCT06956001|DRUG|Cisplatin for injection|Usage and dosage: 75 mg/m2, i.v. Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles.
219681644|NCT06956001|DRUG|Carboplatin Injection|"Usage and dosage: give the drug according to AUC 5 mg/ml, intravenous drip.~Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles."
219681645|NCT01060423|DRUG|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
219212874|NCT02438137|DRUG|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
219212875|NCT02438137|DRUG|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
219212876|NCT01645124|DRUG|Hydroxyurea|
219212877|NCT01645124|PROCEDURE|Phlebotomy|
219212878|NCT02802488|PROCEDURE|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
219212879|NCT03447496|PROCEDURE|Closed reduction|The children were treated with closed reduction.
219084646|NCT02643576|BEHAVIORAL|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
219084647|NCT02643576|BEHAVIORAL|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
219084648|NCT01553318|DRUG|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
219084649|NCT01553318|DRUG|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
219084650|NCT00892502|DRUG|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
219084651|NCT00892502|DRUG|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
219084652|NCT04219852|OTHER|data collection|data collection
219084653|NCT03362463|OTHER|Non-Interventional Study|Non-Interventional Study
219681646|NCT01060423|DRUG|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
219681647|NCT01060423|DEVICE|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
219084654|NCT00176163|BEHAVIORAL|Operant behavioral treatment; Drug: THC|
219084655|NCT00209573|DRUG|fospropofol disodium|
219084656|NCT01976065|DRUG|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
219084657|NCT01976065|OTHER|Standard Treatment|Standard Treatment no use of study drug
219084658|NCT02218827|DRUG|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
219084659|NCT04156490|OTHER|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
219084660|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
219084661|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
219212880|NCT03447496|PROCEDURE|Open reduction|The children were treated with Open reduction.
219212881|NCT05420480|PROCEDURE|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
219212882|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
219212883|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
219681648|NCT05259163|DEVICE|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
219681649|NCT05259163|DEVICE|Traditional phoropter (SOC)|Standard unit for evaluating visual refractive state of the patient
219681650|NCT03031340|DRUG|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
219681651|NCT03031340|OTHER|placebo|placebo
219681652|NCT05502627|DRUG|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
219681653|NCT06725277|DRUG|Spravato|Intranasal esketamine
219681654|NCT06725277|DRUG|IV Ketamine|IV ketamine
219681655|NCT06259214|OTHER|15% HCl gel|Icon , DMG, Hamburg, Germany
219681656|NCT06259214|OTHER|H3PO4 gel|Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
219681657|NCT06259214|OTHER|Er:YAG laser|Fotona AT Fidelis III, Ljubljana, Slovenia
219212884|NCT01411137|DRUG|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
219212885|NCT01678079|DIETARY_SUPPLEMENT|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
219212886|NCT01678079|DIETARY_SUPPLEMENT|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
219084662|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
219084663|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
219084664|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
219084665|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
219084666|NCT04876794|DEVICE|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
219084667|NCT05981118|DRUG|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
219084668|NCT05981118|DRUG|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
219084669|NCT01139190|DRUG|PL3100|Oral administration
219084670|NCT01139190|DRUG|Naproxen|Oral administration
219084671|NCT00718822|OTHER|oxygen concentration in the culture atmosphere|
219084672|NCT03603223|BIOLOGICAL|Pembrolizumab|Given IV
219084673|NCT03896009|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
219084674|NCT03896009|DRUG|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
219212887|NCT01558908|BIOLOGICAL|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
219212888|NCT00936416|PROCEDURE|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
219212889|NCT05917015|DIETARY_SUPPLEMENT|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
219212890|NCT05917015|OTHER|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
219212891|NCT04327752|OTHER|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
219084675|NCT03896009|DRUG|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
219084676|NCT03896009|DRUG|Placebo|Placebo taken once upon onset of a qualifying migraine.
219084677|NCT05618548|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
219084678|NCT02127372|DRUG|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~* Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~* Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~* Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~* Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~* Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~* Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
219084679|NCT02127372|DRUG|Docetaxel|
219084680|NCT02127372|DRUG|Cisplatin|
219084681|NCT03597568|DIETARY_SUPPLEMENT|Resveratrol|Oral supplementation for 6 weeks
219212892|NCT01637402|DRUG|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
219212893|NCT01637402|DRUG|Prednisone|5 mg, twice daily, oral administration
219084682|NCT03597568|OTHER|Placebo|Oral supplementation for 6 weeks
219212894|NCT02436174|DEVICE|novel device|novel device being used to measure shivering
219212895|NCT00359606|DRUG|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
219212896|NCT00359606|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219212897|NCT00359606|OTHER|Pharmacological Study|Correlative Studies
219212898|NCT00359606|DRUG|Tetrahydrouridine (THU)|Given PO and IV
219212899|NCT00202436|PROCEDURE|Phlebotomy|Removal of 500 ml whole blood
219212900|NCT00202436|PROCEDURE|Erythrocytapheresis|machinal removal of erythrocytes
219681658|NCT01381926|DRUG|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
219681659|NCT01381926|DRUG|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
219084683|NCT00498979|BIOLOGICAL|recombinant interferon alfa-2b|recombinant interferon alfa-2b
219084684|NCT00498979|DRUG|cisplatin|recombinant interferon alfa-2b
219084685|NCT00498979|DRUG|sodium stibogluconate|sodium stibogluconate
219084686|NCT00498979|DRUG|dacarbazine|dacarbazine
219084687|NCT00498979|DRUG|vinblastine|vinblastine
219084688|NCT04618874|DIAGNOSTIC_TEST|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
219084689|NCT01799564|PROCEDURE|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
219084690|NCT06049264|OTHER|Thoracic spine manual traction with mobilization protocol.|The therapist will perform one 30-second bout of grade I or II central posterior-anterior mobilization at the T3 spinous process as described by Maitland et al. After the 30-second bout, the therapist proceeded to T4 and performed the same technique. This process was continued sequentially in a caudal direction to T8, for an overall intervention time of approximately 3 minutes. In addition to mobilization, thoracic spine traction will be also given in sitting position.
219084691|NCT06049264|OTHER|Thoracic manipulation protocol|To perform the manipulation, the stabilizing hand will be placed at the level immediately caudal to the restricted segment using a ''pistol grip''. Once the pre manipulative position will be achieved the patient will be instructed to take a deep inhalation and exhale. During the exhalation the treating clinician performed a high velocity, small amplitude thrust in a direction to facilitate relative closing or opening of the respective facet joint as indicated by the segmental examination.
219084692|NCT05399745|OTHER|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
219084693|NCT03247790|DRUG|Lasmiditan|Administered orally
219084694|NCT01490502|DRUG|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
219084695|NCT02281448|DRUG|BIA 2-093|
219084696|NCT02281448|DRUG|Contraceptives, Oral, Combined|
219212901|NCT02285270|DEVICE|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
219212902|NCT00862706|DRUG|Telbivudine/LDT600A|Oral once daily
219212903|NCT02512250|OTHER|Registry|
219212904|NCT02111096|DRUG|LY2409021|Administered orally
219212905|NCT02111096|DRUG|Sitagliptin|Administered orally
219212906|NCT02111096|DRUG|Placebo|Administered orally
219212907|NCT02111096|DRUG|Metformin|Administered orally
219212908|NCT02111096|DRUG|Sulfonylurea|Administered orally
219212909|NCT02035605|DRUG|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
219212910|NCT02035605|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219084697|NCT04827485|OTHER|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
219084698|NCT04827485|OTHER|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
219084699|NCT05148325|DRUG|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
219084700|NCT05465057|BEHAVIORAL|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
219212911|NCT05708365|OTHER|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
219212912|NCT05708365|OTHER|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
219212913|NCT00913289|BIOLOGICAL|adipose tissue derived stromal cells|dosage
219212914|NCT01780649|PROCEDURE|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
219212915|NCT01780649|PROCEDURE|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
219212916|NCT02307396|DRUG|Olanzapine|
219212917|NCT02307396|DRUG|Amisulpride|
219212918|NCT02307396|DRUG|Risperidone|
219212919|NCT02307396|DRUG|Haloperidol|
219212920|NCT02307396|DRUG|Quetiapine|
219212921|NCT02307396|DRUG|Perphenazine|
219212922|NCT02307396|DRUG|Sulpiride|
219212923|NCT02307396|DRUG|bromperidol|
219212924|NCT02307396|DRUG|Zuclopenthixol|
219212925|NCT02307396|DRUG|Thioridazine|
219212926|NCT02307396|DRUG|Paliperidone|
219212927|NCT02307396|DRUG|Ziprasidone|
219212928|NCT02307396|DRUG|Benperidol|
219212929|NCT02307396|DRUG|Fluspirilene|
219212930|NCT02307396|DRUG|Pimozide|
219212931|NCT02307396|DRUG|Perazine|
219212932|NCT02307396|DRUG|Fluphenazine|
219212933|NCT02307396|DRUG|Flupentixole|
219212934|NCT02307396|DRUG|Sertindole|
219212935|NCT00936182|DRUG|Fluconazole|Fluconazole daily for 30 days
219212936|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
219212937|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
219212938|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
219212939|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
219212940|NCT00692120|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule once daily for 12 months
219212941|NCT03709706|DRUG|Lete-cel|lete-cel will be administered to eligible participants.
219212942|NCT03709706|DRUG|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
219084701|NCT05465057|BEHAVIORAL|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
219084702|NCT00003163|BIOLOGICAL|filgrastim|
219084703|NCT00003163|BIOLOGICAL|sargramostim|
219084704|NCT00003163|DRUG|cyclophosphamide|
219084705|NCT00003163|DRUG|melphalan|
219084706|NCT00003163|PROCEDURE|autologous bone marrow transplantation|
219084707|NCT00003163|PROCEDURE|peripheral blood stem cell transplantation|
219084708|NCT00003163|RADIATION|radiation therapy|
219084709|NCT05098470|DRUG|Metformin|1500-2000 mg per day for 8 weeks
219084710|NCT05098470|DRUG|Insulin Glargine|Long-acting insulin for 8 weeks
219084711|NCT05098470|DRUG|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
219084712|NCT02565914|DRUG|TEZ/IVA|Fixed dose tablet for oral administration.
219084713|NCT02565914|DRUG|IVA|Tablet for oral administration.
219084714|NCT05154383|BIOLOGICAL|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
219084715|NCT05154383|BIOLOGICAL|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
219084716|NCT06578910|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
219084717|NCT06578910|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
219084718|NCT00663325|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
219084719|NCT01977300|DRUG|Valproate|serum level of 50 to 125 ug/L
219084720|NCT01977300|DRUG|Lithium|serum levels of 0.6 to 1.2 mmol/L
219084721|NCT01977300|DRUG|Risperidone|1 to 6 mg/day
219084722|NCT01977300|DRUG|Olanzapine|5 to 25 mg/day
219084723|NCT01977300|OTHER|Placebo|manufactured to mimic risperidone and olanzapine
219084724|NCT04669730|OTHER|usual care|Routine care
219084725|NCT04669730|BEHAVIORAL|Walk|Walk 30mins
219084726|NCT04669730|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
219084727|NCT04669730|BEHAVIORAL|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
219084728|NCT02258139|DEVICE|B&L Investigational Contact Lens|The lens used in this study will be supplied by the Sponsor. All subjects will wear a -3.00D lens.
219084729|NCT06048731|DEVICE|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
219084730|NCT04493931|DRUG|Gepotidacin|Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
219084731|NCT04493931|DRUG|Cimetidine|Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
219084732|NCT04493931|DRUG|Rifampicin|Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
219084733|NCT04493931|DRUG|Midazolam|Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
219084734|NCT04493931|DRUG|Digoxin|Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
219084735|NCT04493931|OTHER|Placebo matching to gepotidacin|Placebo matching to gepotidacin tablets will be administered orally.
219084736|NCT06296095|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
219084737|NCT02138630|DIETARY_SUPPLEMENT|Capsaicin|
219084738|NCT02138630|DIETARY_SUPPLEMENT|Placebo|Sugar capsule
219084739|NCT01391520|DRUG|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
219084740|NCT01391520|DRUG|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
219084741|NCT00123032|BEHAVIORAL|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
219212943|NCT06397196|OTHER|Laser guided proprioceptive exercises|Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
219212944|NCT06397196|OTHER|Routine Physical therapy|Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
219084742|NCT00123032|PROCEDURE|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
219084743|NCT00892112|DRUG|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
219084744|NCT00892112|DRUG|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
219084745|NCT04372836|PROCEDURE|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
219084746|NCT00814424|DEVICE|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
219084747|NCT00814424|DEVICE|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
219084748|NCT04750967|DRUG|Lidocaine 1% Injectable Solution|Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
219084749|NCT04750967|DRUG|Amitriptyline|Amitriptyline 25 mg daily
219084750|NCT02015494|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine delivered IM
219084751|NCT05838807|DEVICE|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
219084752|NCT05838807|DEVICE|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
219084753|NCT05838807|DEVICE|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
219084754|NCT05838807|DEVICE|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
219084755|NCT00919074|PROCEDURE|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
219212945|NCT00442637|DRUG|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
219212946|NCT00442637|OTHER|observation|observation after induction treatment
219212947|NCT00649272|DRUG|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
219212948|NCT00649272|DRUG|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
219212949|NCT01575015|DEVICE|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
219212950|NCT01575015|PROCEDURE|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
219084756|NCT00919074|PROCEDURE|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
219084757|NCT04111003|PROCEDURE|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
219084758|NCT04111003|PROCEDURE|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
219084759|NCT04111003|PROCEDURE|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
219084760|NCT06225856|DRUG|YY201|Oral administration under fasting state.
219084761|NCT02864225|DEVICE|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
219084762|NCT02864225|DEVICE|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
219212951|NCT04868617|DEVICE|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
219212952|NCT03222934|DEVICE|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
219212953|NCT03779672|DRUG|Memantine Hydrochloride 10 mg|"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
219212954|NCT04163237|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
219212955|NCT04163237|DRUG|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
219212956|NCT04132167|PROCEDURE|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
219212957|NCT05145205|PROCEDURE|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
219212958|NCT05145205|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
219681660|NCT05095194|PROCEDURE|Cataract surgery with IOL implantation and with/without capsular tension ring implatation|Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation
219084763|NCT02864225|DEVICE|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
219084764|NCT02857530|DRUG|rhTPO|rhTPO
219084765|NCT02857530|DRUG|placebo|without rhTPO
219084766|NCT00378352|DRUG|Epoetin alfa|Randomized
219084767|NCT01738620|BEHAVIORAL|psychological counseling|
219084768|NCT01738620|BEHAVIORAL|prevention of sleep disorders in ICU|
219084769|NCT04721379|BEHAVIORAL|Meditation|"1. Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~2. Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
219084770|NCT03300791|OTHER|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
219084771|NCT04317508|DRUG|Topicale GelPatch (Benzocaine 18%)|Intervention group
219084772|NCT04317508|DRUG|Benzocaine oral gel 20%|control group
219084773|NCT05032365|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
219084774|NCT05032365|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
219084775|NCT04433364|OTHER|biological samples, questionnaires and interviews|"Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth."
219212959|NCT00505336|DRUG|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
219084776|NCT04419090|OTHER|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
219084777|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
219084778|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
219084779|NCT02264184|DRUG|Tamsulosin|
219084780|NCT02264184|DRUG|Paroxetine|
219084781|NCT01197508|DRUG|TC-5214|Twice daily for 8 weeks.
219084782|NCT01197508|DRUG|Placebo|Twice daily for 8 weeks.
219084783|NCT03610464|DRUG|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
219084784|NCT05200130|OTHER|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
219084785|NCT05200130|OTHER|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
219084786|NCT05200130|OTHER|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
219084787|NCT05589870|OTHER|Multi-drug analysis of polypharmacy treatment|Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
219084788|NCT01588626|DRUG|AZD6140|tablet
219084789|NCT05477758|BEHAVIORAL|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
219084790|NCT05477758|OTHER|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
219084791|NCT05477758|BEHAVIORAL|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
219084792|NCT04749589|DIAGNOSTIC_TEST|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
219084793|NCT00995982|BIOLOGICAL|VRC-FLUDNA056-00VP|
219084794|NCT01873170|DRUG|levonorgestrel exposure|
219212960|NCT00505336|OTHER|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
219212961|NCT00505336|DRUG|Atorvastatin|oral Atorvastatin 40mg
219212962|NCT01627561|BIOLOGICAL|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
219084795|NCT01873170|DRUG|DMPA exposure|
219084796|NCT01873170|DRUG|etonogestrel exposure|
219212963|NCT01627561|BIOLOGICAL|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
219212964|NCT01627561|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
219212965|NCT00856700|DRUG|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
219212966|NCT03661463|DRUG|Aspirin|Drug
219212967|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 60mj|
219212968|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 120mj|
219212969|NCT02358005|PROCEDURE|non extracorporeal shock wave therapy|
219212970|NCT04221659|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
219212971|NCT00382941|DEVICE|Red and near infrared LED phototherapy device|
219212972|NCT05892562|OTHER|No intervention|As this study is purely observational, no intervention is involved.
219084797|NCT01873170|DEVICE|IUD insertion|
219084798|NCT01873170|DEVICE|subdermal contraceptive implant insertion|
219084799|NCT03170011|BEHAVIORAL|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
219084800|NCT05672979|DRUG|Brolucizumab Injection [Beovu]|brolucizumab 6mg intravitreal injection
219084801|NCT03536910|OTHER|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
219084802|NCT00266825|DRUG|DHA|600 mg DHA
219084803|NCT00266825|OTHER|Placebo capsule|Placebo capsule
219084804|NCT04688424|DEVICE|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
219084805|NCT04688424|OTHER|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
219084806|NCT05122390|OTHER|Contraction Coper|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.
219084807|NCT05122390|OTHER|Contraction Coper Plus|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
219084808|NCT04285450|DIETARY_SUPPLEMENT|Vitamin K|1mg
219084809|NCT04285450|OTHER|Placebo|Lactose
219084810|NCT01514526|DRUG|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
219212973|NCT03472352|BIOLOGICAL|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
219212974|NCT05357677|DRUG|SR419|SR419 capsule
219212975|NCT00259792|DRUG|Budesonide/formoterol Turbuhaler|
219212976|NCT01023698|PROCEDURE|laser photocoagulation|Laser photocoagulation
219212977|NCT01579318|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
219212978|NCT01579318|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
219084811|NCT04452292|OTHER|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
219084812|NCT04452292|OTHER|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
219212979|NCT02797132|DRUG|LUM/IVA|
219212980|NCT03388840|BIOLOGICAL|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
219212981|NCT03388840|BIOLOGICAL|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
219212982|NCT01970007|DEVICE|Zilver Vena Venous Self-Expanding Stent|stenting
219212983|NCT03878979|DRUG|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
219212984|NCT04559633|OTHER|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
219212985|NCT01816971|DRUG|dexamethasone|Given IV or PO
219212986|NCT01816971|DRUG|carfilzomib|Given IV
219212987|NCT01816971|DRUG|lenalidomide|Given PO
219212988|NCT01816971|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
219212989|NCT01816971|OTHER|laboratory biomarker analysis|Correlative studies
219212990|NCT00436631|BEHAVIORAL|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
219212991|NCT00477893|DRUG|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
219212992|NCT00477893|DRUG|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
219212993|NCT05283408|DRUG|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
219084813|NCT05736562|DIETARY_SUPPLEMENT|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
219212994|NCT05283408|DRUG|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
219212995|NCT05283408|DRUG|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
219212996|NCT02766296|BEHAVIORAL|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
219084814|NCT05736562|DIETARY_SUPPLEMENT|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
219084815|NCT02834702|DEVICE|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
219084816|NCT02834702|DEVICE|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
219084817|NCT05009108|DIAGNOSTIC_TEST|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
219084818|NCT01301391|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
219084819|NCT04184726|BEHAVIORAL|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
219084820|NCT02920697|DRUG|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
219084821|NCT01782443|DRUG|Ziv-aflibercept|
219084822|NCT00153998|DRUG|Cetuximab|
219084823|NCT00153998|PROCEDURE|Liver resection|
219084824|NCT00153998|DRUG|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
219084825|NCT00153998|DRUG|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
219212997|NCT02766296|BEHAVIORAL|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
219212998|NCT05538494|OTHER|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
219084826|NCT03671174|DRUG|Prednisone|10mg once daily orally
219084827|NCT03671174|DRUG|Hydroxychloroquine|100mg to 200mg twice daily orally
219084828|NCT03671174|DRUG|Aspirin|50mg once daily orally
219084829|NCT03671174|DRUG|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
219084830|NCT02448940|DIETARY_SUPPLEMENT|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
219084831|NCT02448940|DIETARY_SUPPLEMENT|lactose|2 capsule a day containing lactose
219084832|NCT04128644|BEHAVIORAL|Thoughts & health|12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
219084833|NCT04128644|OTHER|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
219212999|NCT05538494|OTHER|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM."
219213000|NCT00068458|DIETARY_SUPPLEMENT|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
219213001|NCT00068458|OTHER|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
219213002|NCT00068458|OTHER|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
219084834|NCT02430467|BEHAVIORAL|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
219084835|NCT02430467|BEHAVIORAL|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
219084836|NCT03608280|PROCEDURE|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
219084837|NCT03608280|PROCEDURE|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
219084838|NCT00717639|PROCEDURE|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
219084839|NCT03600584|PROCEDURE|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
219084840|NCT03600584|PROCEDURE|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
219084841|NCT03088592|DEVICE|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
219084842|NCT02629991|DRUG|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
219084843|NCT02629991|OTHER|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
219084844|NCT00306033|DRUG|Intravenous ImmuneGlobulin|
219084845|NCT03887338|OTHER|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
219213003|NCT01171976|DRUG|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
219084846|NCT03718689|DEVICE|Laser etching|Acid etching
219084847|NCT01122082|BEHAVIORAL|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
219084848|NCT03754179|DRUG|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
219084849|NCT03754179|DRUG|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
219213004|NCT00288288|PROCEDURE|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
219213005|NCT00288288|PROCEDURE|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
219681661|NCT04398602|BEHAVIORAL|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
219681662|NCT02437994|BEHAVIORAL|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
219681663|NCT04585490|DRUG|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
219681664|NCT04585490|DRUG|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
219681665|NCT04585490|DRUG|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
219681666|NCT04585490|DRUG|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
219681667|NCT04585490|DRUG|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
219084850|NCT03754179|DRUG|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
219213006|NCT05093062|OTHER|Tian Jiu Therapy|
219084851|NCT01257776|DRUG|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
219084852|NCT01557387|OTHER|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
219084853|NCT02799784|DRUG|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
219084854|NCT02799784|DRUG|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
219084855|NCT02799784|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
219084856|NCT03695302|BEHAVIORAL|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
219084857|NCT04636372|DEVICE|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
219084858|NCT04636372|OTHER|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
219084859|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
219084860|NCT00822081|DRUG|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
219084861|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
219084862|NCT00822081|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
219084863|NCT03748290|DRUG|Pregabalin|Pregabalin 75 mg for 12 weeks
219213007|NCT01241526|OTHER|Disease Management|"* Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring"
219213008|NCT01241526|OTHER|Usual site management|"* Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring"
219213009|NCT04473703|DRUG|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
219213010|NCT04030585|DEVICE|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
219213011|NCT04030585|OTHER|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
219213012|NCT04640584|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
219681668|NCT04585490|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
219681669|NCT04585490|DRUG|Tremelimumab|not to exceed 75mg IV on Day 1 of every 21-day cycle
219681670|NCT06262633|DEVICE|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation|Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.
219084864|NCT03748290|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219084865|NCT01624948|DRUG|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
219084866|NCT01624948|DRUG|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
219084867|NCT04237805|DRUG|SAF-189s|20mg，40mg，80mg，120mg，160mg，210mg，once daily
219084868|NCT00372008|DRUG|Testosterone|
219084869|NCT05592795|OTHER|Whether ERCP or EST is carried out|This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.
219084870|NCT00003835|DRUG|leucovorin calcium|Given IV
219084871|NCT00003835|DRUG|fluorouracil|Given IV
219084872|NCT00003835|DRUG|irinotecan hydrochloride|Given IV
219084873|NCT00003835|OTHER|laboratory biomarker analysis|Correlative studies
219084874|NCT01629914|BEHAVIORAL|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
219084875|NCT05635578|BEHAVIORAL|sleep|reiki
219084876|NCT00466635|DRUG|GT267-004 (tolevamer potassium sodium)|
219084877|NCT01129388|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
219084878|NCT01129388|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
219084879|NCT01129388|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
219084880|NCT05873374|BIOLOGICAL|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
219084881|NCT05873374|OTHER|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
219084882|NCT03426202|DRUG|Modafinil Oral Tablet|modafinil 200mg
219084883|NCT03426202|DRUG|Placebo Oral Tablet|placebo 200mg
219084884|NCT03769402|DRUG|Citric acid|Citric acid ph1, 50% concentration solution
219084885|NCT03769402|DRUG|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
219084886|NCT03042455|DEVICE|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
219084887|NCT03042455|DEVICE|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
219213013|NCT04740944|BEHAVIORAL|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
219213014|NCT01693822|DRUG|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
219213015|NCT03948542|OTHER|Outcome|"Nerve Recovery~* NCV~* Funcional assessment"
219213016|NCT02844439|DRUG|Tesevatinib|
219213017|NCT03041155|BEHAVIORAL|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
219213018|NCT06311396|GENETIC|genetic model|Create a complete molecular-level description of the heterogeneous population of cells that are capable of giving rise to tumor transformation in the liver.
219213019|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
219213020|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
219213021|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
219213022|NCT04614454|DEVICE|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
219213023|NCT04614454|DEVICE|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
219213024|NCT05378347|DEVICE|Medtronic Endurant II or Endurant IIs Stent Graft System|EVAR treatment with Medtronic Endurant II/IIs Stent Graft System
219213025|NCT05378347|DEVICE|Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis|EVAR treatment with Excluder / Excluder Conformable Stent Graft System
219213026|NCT06298253|BEHAVIORAL|Behavioral economics-enhanced SWAP implementation|Intervention will include behavioral nudges at baseline and over 12 months to promote use of the SWAP nutrition program for pantries.
219213027|NCT06298253|BEHAVIORAL|Basic SWAP implementation|Intervention will include basic information about the SWAP program and encouragement to obtain SWAP toolkits.
219213028|NCT06355063|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
219213029|NCT00317720|DRUG|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
219213030|NCT00317720|DRUG|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
219681671|NCT05438342|BIOLOGICAL|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
219681672|NCT05438342|DEVICE|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
219681673|NCT05438342|DRUG|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
219681674|NCT03060369|DEVICE|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
219213031|NCT05103345|DRUG|SGN1|SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
219213032|NCT06405841|OTHER|Survey|All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
219213033|NCT06405841|OTHER|Pain management|All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
219213034|NCT03357926|DIAGNOSTIC_TEST|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
219213035|NCT04259047|BEHAVIORAL|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
219213036|NCT04259047|BEHAVIORAL|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
219213037|NCT06066268|DIAGNOSTIC_TEST|Critical limb ischemia: analysis of RNAs|analysis of miRNA expression levels
219213038|NCT06066268|DIAGNOSTIC_TEST|Controls: analysis of RNAs|analysis of miRNAs expression levels
219213039|NCT06478667|DRUG|levosemindan|inotropic agent
219213040|NCT04199338|OTHER|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
219084888|NCT03042455|OTHER|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
219084889|NCT03909984|DEVICE|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
219084890|NCT04068350|OTHER|Pain questionnaire|Pain questionnaire, 3 months after surgery
219084891|NCT03458884|OTHER|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
219084892|NCT03466086|DEVICE|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
219084893|NCT03466086|DEVICE|Control Eye Drops|Systane® BALANCE eye drops
219213041|NCT00137800|DRUG|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
219213042|NCT05985499|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
219213043|NCT05985499|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
219213044|NCT04531800|PROCEDURE|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
219084894|NCT00595504|DRUG|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
219213045|NCT04531800|PROCEDURE|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
219213046|NCT01934036|DIETARY_SUPPLEMENT|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
219213047|NCT01934036|DRUG|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
219213048|NCT01785446|DRUG|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
219213049|NCT01785446|DRUG|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
219213050|NCT06440226|BEHAVIORAL|Eye Movement Technique|Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.
219084895|NCT00595504|DRUG|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
219084896|NCT02235246|DRUG|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
219084897|NCT02235246|DRUG|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
219084898|NCT02994914|OTHER|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
219084899|NCT03039595|OTHER|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
219213051|NCT06440226|BEHAVIORAL|Memory Recall of Previous Night's Thoughts|Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.
219213052|NCT06440226|BEHAVIORAL|Recall of Previous Lucid Dreams|Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
219213053|NCT02748226|PROCEDURE|endovascular treatment|endovascular treatment
219213054|NCT06091995|BEHAVIORAL|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
219213055|NCT05615623|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
219084900|NCT02098213|OTHER|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
219084901|NCT02098213|OTHER|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
219084902|NCT01949870|DRUG|Cisplatin|day1 and day8 at each cycle
219084903|NCT01949870|DRUG|Gemcitabine|day1 and day8 at each cycle
219084904|NCT01949870|DRUG|Selumetinib|25mg/day, 50mg/day and 75mg/day
219084905|NCT06086379|BEHAVIORAL|Compensatory Cognitive Training for COVID-19|CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
219084906|NCT06086379|BEHAVIORAL|Holistic Cognitive Education|HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
219084907|NCT01291784|BIOLOGICAL|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
219084908|NCT05851859|OTHER|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
219084909|NCT00027001|BEHAVIORAL|Aerobic and Resistance Exercises|
219084910|NCT00027001|BEHAVIORAL|Qigong|
219084911|NCT03062722|PROCEDURE|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
219084912|NCT00075062|PROCEDURE|Flexible Sigmoidoscopy|
219084913|NCT00075062|PROCEDURE|Rectal Biopsy|
219213056|NCT05615623|DRUG|Doxorubicin|Doxorubicin infusion
219213057|NCT03170648|DEVICE|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
219213058|NCT03509909|BEHAVIORAL|Hatha yoga|Manualized hatha yoga
219213059|NCT03509909|BEHAVIORAL|Supportive physical activity|Manualized stretching and strengthening
219213060|NCT03831334|DRUG|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
219213061|NCT04410146|DEVICE|SQUID Embolization|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent
219213062|NCT04410146|DEVICE|SQUID Embolization and Surgical Evacuation|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma
219213063|NCT04410146|PROCEDURE|Surgical Evacuation|Surgical evacuation of the sub-dural hematoma
219213064|NCT04410146|OTHER|Other: Medical Management|Standard
219213065|NCT06008301|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
219213066|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
219213067|NCT00789542|DEVICE|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
219213068|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
219213069|NCT02238769|DEVICE|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
219213070|NCT03500549|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219213071|NCT03500549|DRUG|Soliris|Complement (C5) Inhibitor
219213072|NCT04522570|DEVICE|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
219213073|NCT04522570|DEVICE|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
219084914|NCT00345449|BEHAVIORAL|Decision Aid|
219084915|NCT01292954|DIETARY_SUPPLEMENT|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
219213074|NCT04522570|DEVICE|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
219213075|NCT02371512|DEVICE|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
219213076|NCT02371512|PROCEDURE|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
219084916|NCT03475550|OTHER|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
219084917|NCT01067170|DEVICE|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
219084918|NCT02570126|BIOLOGICAL|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
219084919|NCT02570126|BIOLOGICAL|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
219084920|NCT02154633|BEHAVIORAL|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
219084921|NCT02154633|BEHAVIORAL|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
219084922|NCT05649111|DRUG|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
219084923|NCT00048464|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
219084924|NCT06202326|DEVICE|renal artery doppler|doppler ultrasound follow up
219084925|NCT01379872|OTHER|Non-Interventional Study|This is a non-interventional study
219084926|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
219084927|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
219084928|NCT05311800|OTHER|Physical activity|Comparison of HIIT mode (running vs cycling)
219213077|NCT00404742|DRUG|Placebo|PO BID
219213078|NCT00404742|DRUG|LX211|0.2 mg/kg, twice a day (BID)
219213079|NCT00404742|DRUG|LX211|0.4 mg/kg, twice a day (BID)
219213080|NCT00404742|DRUG|LX211|0.6 mg/kg, twice a day (BID)
219213081|NCT05425953|OTHER|No intervention other than obtaining biopsies|Biopsies will be obtained.
219213082|NCT02754596|DRUG|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
219213083|NCT02754596|DRUG|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
219213084|NCT02754596|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
219213085|NCT04888104|PROCEDURE|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
219213086|NCT02961868|OTHER|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
219213087|NCT02961868|GENETIC|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
219213088|NCT02961868|OTHER|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
219084929|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
219084930|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
219084931|NCT00754338|DRUG|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
219084932|NCT05724979|OTHER|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
219213089|NCT02961868|OTHER|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
219213090|NCT03778515|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
219213091|NCT02107261|DRUG|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
219084933|NCT00677352|DRUG|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
219084934|NCT00677352|DRUG|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
219084935|NCT01841346|PROCEDURE|Procedure: PCI|
219084936|NCT00932776|DEVICE|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
219213092|NCT02107261|DRUG|Placebo|matching placebo
219213093|NCT05461235|DRUG|Pembrolizumab|2mg/kg or 200mg,iv,q3w
219213094|NCT05461235|DRUG|Nivolumab|3mg/kg or 240mg,iv,q2w
219213095|NCT05461235|DRUG|Sintilimab|200mg,iv,q3w
219213096|NCT05461235|DRUG|Toripalimab|3mg/kg or 240mg,iv,q2w
219213097|NCT05461235|DRUG|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
219213098|NCT05461235|DRUG|Tislelizumab|200mg,iv,q3w
219213099|NCT05461235|BIOLOGICAL|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
219213100|NCT02137616|DRUG|risperidone|Risperdal tablets
219213101|NCT02137616|DRUG|olanzapine|olanzapine tablets
219084937|NCT00932776|DEVICE|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
219084938|NCT03339323|OTHER|Exercise|TKA patients do the exercise intervention
219084939|NCT04791280|PROCEDURE|Faeces collection|"* faeces collection at inclusion~* follow-up visit 6 months after inclusion"
219084940|NCT02351804|DRUG|Ropivacaine + dexamethasone|Adductor canal block, single bolus
219084941|NCT02351804|DRUG|Ropivacaine + placebo|Adductor canal block, single bolus
219084942|NCT04329754|DEVICE|Cataract surgery|Cataract surgery with implantation of an intraocular lens (IOL)
219084943|NCT02892812|BIOLOGICAL|Pneumococcal conjugate vaccine|
219084944|NCT03594565|DRUG|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
219084945|NCT02872701|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
219084946|NCT02872701|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
219084947|NCT02872701|PROCEDURE|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
219084948|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
219213102|NCT02137616|DRUG|Quetiapine|quetiapine tablets
219213103|NCT02137616|DRUG|Aripiprazole|Aripiprazole tablets
219213104|NCT05297214|DIAGNOSTIC_TEST|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
219213105|NCT02431273|DRUG|TDF IVR|
219213106|NCT02431273|DRUG|TDF-FTC IVR|
219213107|NCT02431273|DRUG|TDF-FTC-MVC IVR|
219213108|NCT04337931|DRUG|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
219213109|NCT06140732|DRUG|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
219213110|NCT04436289|BEHAVIORAL|Home Link|In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
219213111|NCT05443945|DEVICE|Nasal Spray|3 sprays in each nostril 3 times per day
219213112|NCT06819449|DRUG|Dapsone|To evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.
219213113|NCT06306924|RADIATION|Radiation therapy|Subjects with metastatic cancer receive radiation therapy.
219213114|NCT06893250|BIOLOGICAL|PRP injection|Platelet rich plasma, blood from the patient that is centrifuged.
219213115|NCT06893250|BIOLOGICAL|ADSTEM Inj. (Adult human mesenchymal stem cells)|Adipose tissue stem cells, from abdominal fat.
219084949|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
219084950|NCT03963674|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
219084951|NCT02182973|DIETARY_SUPPLEMENT|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
219084952|NCT03854968|OTHER|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
219084953|NCT00941993|DEVICE|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
219084954|NCT02200913|OTHER|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
219084955|NCT02200913|OTHER|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
219084956|NCT04385368|DRUG|Durvalumab + SoC chemotherapy|Experimental Treatment
219084957|NCT04385368|OTHER|Placebo + SoC chemotherapy|Placebo Comparator
219213116|NCT06893250|BIOLOGICAL|Injection|PRP + adipose tissue stem cells
219213117|NCT06893250|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|Sterile saline injection.
219213118|NCT06888531|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma|Toripalimab: intravenous infusion, 240mg, D1, Q3W, for 2 consecutive doses; or Envorimab: subcutaneous injection, 400mg, D1, Q3W, for 2 consecutive doses. Albumin-bound paclitaxel: intravenous infusion, 50mg/m2, D1, QW, for 5 consecutive doses. Carboplatin: intravenous infusion, AUC=2, D1, QW, for 5 consecutive doses. Radiotherapy: 41.4Gy/1.8Gy/23F, D1-5, 5 times per week.
219213119|NCT06893601|DRUG|Parasternal block|A block containing 0.9% NaCl solution was applied to the Saline group just before the sternum was closed by the surgeon, while a bilateral parasternal block using 0.25% bupivacaine was applied to the bupivacaine group. The solutions used for the parasternal block were colorless and indistinguishable to ensure blinding.
219213120|NCT06741566|DRUG|intranasal saline group|3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
219213121|NCT06741566|DRUG|intranasal insulin|20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
219681675|NCT03734523|COMBINATION_PRODUCT|Flourish Vaginal Care System|This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
219681676|NCT00826410|DEVICE|Redon drain|subcutaneous suction drain after laparotomy for two days
219681677|NCT05820243|OTHER|Moderate Intensity Aerobic Exercise|Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
219681678|NCT01932749|DEVICE|Transcranial Magnetic stimulation|
219681679|NCT02953015|BEHAVIORAL|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
219084958|NCT01235546|DRUG|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
219084959|NCT01235546|DRUG|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
219084960|NCT01197196|BEHAVIORAL|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
219084961|NCT01197196|OTHER|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
219084962|NCT01123382|DEVICE|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
219084963|NCT01123382|OTHER|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
219084964|NCT04704518|DRUG|Sodium Hyaluronate Ophthalmic 0.4%|Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
219084965|NCT04704518|DRUG|Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%|Topical ophthalmic administration of one drop of Thealoz® Duo QID.
219084966|NCT01631084|OTHER|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
219084967|NCT01631084|OTHER|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
219084968|NCT00885196|DRUG|Placebo|
219084969|NCT00885196|DRUG|AEB071|
219084970|NCT05886400|OTHER|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
219084971|NCT05886400|OTHER|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
219084972|NCT01256411|DRUG|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
219084973|NCT01256411|DRUG|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
219213122|NCT06741566|DRUG|Intranasal dexmedetomidine|1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
219213123|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.
219213124|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
219213125|NCT06894693|BIOLOGICAL|RS001 injection|CD19-CAR-mbIL15-DNT Cells.
219213126|NCT05642936|BEHAVIORAL|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
219213127|NCT05642936|BEHAVIORAL|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
219213128|NCT06754488|PROCEDURE|Posterior Reconstruction|"Reconstruct the bladder neck using the inverted tennis racket method to narrow the bladder neck opening and lengthen the posterior bladder wall. Measure the length of the extended part."
219213129|NCT06754488|PROCEDURE|anterior suspension|The anterior wall of the bladder was continuously sutured and fixed onto the muscular membrane of the lower margin of the symphysis pubis using a 3-0 barb suture.
219213130|NCT06312514|BEHAVIORAL|LAFIYA|The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
219213131|NCT06831292|DIETARY_SUPPLEMENT|Diet intervention NMR|Participants will receive groceries to their homes with planned recipes. The recipes are planned by using the Nordic nutrition councils recommendations.
219213132|NCT06831487|DEVICE|Line-Field Confocal Optical Coherence Tomography (LC-OCT)|Analysis of Line-Field Confocal Optical Coherence Tomography (LC-OCT) in separate groups of patients with gingivitis, periodontitis and healthy patients
219213133|NCT02636569|DRUG|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
219084974|NCT01256411|DRUG|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
219681680|NCT02953015|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
219681681|NCT02953015|DRUG|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
219084975|NCT00134550|DRUG|Atorvastatin (10 mg or 80 mg)|
219084976|NCT02740049|DRUG|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
219084977|NCT04042155|DRUG|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
219084978|NCT04102202|DRUG|BOL-DP-o-05|BOL-DP-o-05
219084979|NCT04102202|DRUG|Placebo|Placebo
219084980|NCT06580522|OTHER|Prone Position Group|After the children in the prone position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were prone positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
219084981|NCT06580522|OTHER|Supine Position Group|After the children in the supine position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were supine positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
219084982|NCT01989026|BIOLOGICAL|BCG|
219084983|NCT03443882|DIETARY_SUPPLEMENT|Astaxanthin|an oral dose form
219084984|NCT04431193|DRUG|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
219084985|NCT06579456|OTHER|Surgical Training Intervention|Validation of a Formaldehyde-Free embalmed cadavers for recreate with more precision the experience of learning surgical endoscopy
219084986|NCT06579456|OTHER|Positive Control|training in models that emulate the rigidity, structure, dimensions, and haptic feedback of the anatomical structures to be treated.
219084987|NCT06579456|OTHER|Negative Control|Training proceeded in the rigid described skills acquisition platform, adding suture training using a perforable MMA-type woven fabric
219084988|NCT06580977|BEHAVIORAL|cardiovascular training|Cardiovascular training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. The training is performed on a cycle ergometer at 60% of peak power output (Wmax) for 30 min (i.e., 5 min warm-up, 20 min at 60% Wmax, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (max. 55 min) and 5% of intensity (in Watt) every two weeks. If participants report a too low (i.e., Borg scale ≤ 11) or too high (i.e., Borg scale ≥ 16) subjective rate of perceived exertion (RPE; Borg scale 6-20) intensity will be increased or decreased until the target levels are met (i.e., Borg scale 12-15). During training, heart rate, intensity (in Watt) and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
219213134|NCT02636569|DRUG|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
219213135|NCT04457284|DRUG|Temozolomide (TMZ)|"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"
219084989|NCT06580977|BEHAVIORAL|stretching|The stretching training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. Stretching training consists of lying, seated, and standing flexibility exercises (according to the recommendations of the American Parkinson´s Disease Foundation and the Parkinson Society Canada) for 30 min (i.e., 5 min warm-up, 20 min main part, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (i.e., adding additional repetitions and exercises; max. 55 min) every two weeks. Intensity of stretching exercises will be assessed by subjective rate of perceived muscle tension on a visual analog scale (VAS) from 0 to 10 and will be moderate defined as 5 to 7 on the VAS. During training VAS, heart rate, and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
219084990|NCT06579924|PROCEDURE|Disposable mini-PCNL|Mini-PCNL carried out using disposable scope
219084991|NCT06579924|PROCEDURE|Re-usable mini-PCNL|Mini-PCNL carried out using re-usable scope
219084992|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
219084993|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
219084994|NCT02310529|BEHAVIORAL|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
219084995|NCT00758238|OTHER|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
219084996|NCT02545777|DRUG|diclofenac sodium enteric-coated|
219084997|NCT02545777|DRUG|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
219084998|NCT02545777|DRUG|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
219084999|NCT02545777|DRUG|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
219085000|NCT05088070|DRUG|SPH 3348|2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
219085001|NCT05088070|DRUG|SPH 3348|1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
219085002|NCT05088070|DRUG|SPH 3348|2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
219085003|NCT05088070|DRUG|SPH 3348|4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
219085004|NCT05088070|DRUG|SPH 3348|6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
219213136|NCT04457284|DRUG|Cisplatin|Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
219213137|NCT04457284|DRUG|Nivolumab|Nivolumab 480 mg Q4W IV infusion Cycle 1 +
219213138|NCT04875078|DEVICE|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
219213139|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
219085005|NCT05088070|DRUG|SPH 3348|8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
219085006|NCT00189215|DEVICE|cardiac stabilizer instead of cardiopulmonary bypass|
219213140|NCT06153485|DEVICE|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the participant's immediate needs.
219213141|NCT06153485|OTHER|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
219213142|NCT06873386|DEVICE|Valera & Minaya protocol|"Valera \& Minaya protocol:~US-guided PNM with the conventional frequency of the Valera Minaya protocol, with localised location on the peripheral nerve. Stimulation of the upper gluteal nerve and lower gluteal nerve will be performed, with 10 stimulations, with 10 seconds of stimulation and 10 seconds of rest, at a frequency of 10 Hz, with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
219085007|NCT02270151|DEVICE|MyDiagnostick|Diagnostick strategy with MyDiagnostick
219085008|NCT04905615|OTHER|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
219213143|NCT06873386|DEVICE|High-frequency US-guided PNM|"High-frequency US-guided PNM with localised peripheral nerve location. Ten 10-second stimulations of the upper gluteal nerve and lower gluteal nerve will be performed, with frequency sweeps of 20Hz -100Hz with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction, with 10 seconds of rest between each stimulation.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
219361840|NCT04528121|OTHER|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
219085009|NCT02316769|PROCEDURE|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
219681682|NCT02090686|DEVICE|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
219085010|NCT02316769|PROCEDURE|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
219085011|NCT00954148|PROCEDURE|PET/CT|5 visits with PET/CT as only testing
219085012|NCT00954148|PROCEDURE|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
219085013|NCT03532802|DRUG|Metoprolol Succinate|"1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week."
219085014|NCT03532802|DRUG|Placebo oral capsule|"1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week"
219085015|NCT00500877|BEHAVIORAL|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
219085016|NCT02228070|DEVICE|strabismus video goggles|
219085017|NCT04721925|BEHAVIORAL|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
219085018|NCT03324893|DIAGNOSTIC_TEST|[F-18]-FCH PET/MRI|Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
219085019|NCT01443819|OTHER|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
219085020|NCT01443819|OTHER|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
219085021|NCT01443819|OTHER|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
219085022|NCT01463722|OTHER|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
219085023|NCT05025969|OTHER|Glioma data collection|Glioma data collection
219085024|NCT05025969|OTHER|Brain metastasis data collection|Brain metastasis data collection
219085025|NCT05373355|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
219085026|NCT04550988|OTHER|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
219085027|NCT04437238|OTHER|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
219085028|NCT04437238|OTHER|Control - Usual care|Participants allocated to the control condition will receive care as usual.
219085029|NCT01926730|OTHER|Restriction diet|Selected food items will be limited in the participants diet
219085030|NCT01016080|DRUG|glutathione|250 mg capsules, twice daily, orally
219085031|NCT01016080|DRUG|placebo|250 mg capsules, twice daily, orally
219085032|NCT05288010|COMBINATION_PRODUCT|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
219213144|NCT06874088|PROCEDURE|Pulpotomy with Calcium Silicate-Based Bioceramics in Permanent Teeth|This intervention involves performing pulpotomy using calcium silicate-based bioceramic materials, MTA and Biodentine™, in both mature and immature permanent teeth diagnosed with reversible or irreversible pulpitis. The study uniquely evaluates the long-term clinical and radiographic success of these materials by assessing pulp healing, dentin bridge formation, and periapical healing over a 24-month follow-up period. Additionally, this study compares clinical survival rates between mature and immature teeth, contributing to the growing body of evidence on the efficacy of pulpotomy in cases traditionally considered for root canal treatment. Unlike conventional pulpotomy studies, this research incorporates retrospective data analysis to align with international standards, addressing gaps in existing literature.
219213145|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
219213146|NCT06764862|DRUG|HSK44459 dose 1|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
219213147|NCT06764862|DRUG|HSK44459 dose 2|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
219213148|NCT06764862|DRUG|Placebo|Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
219213149|NCT06767189|DIAGNOSTIC_TEST|ECG monitoring|R-test or ECG patch for up to 28 days
219213150|NCT06784232|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
219213151|NCT06784232|PROCEDURE|Modified Periosteal Inhibition Technique|Cortical lamina stabilized with human fibrin glue to preserve the buccal wall of the socket. The socket was then filled with collagen.
219213152|NCT06792123|OTHER|pre-op VR application group|VR application group during preoperative process
219213153|NCT06792123|OTHER|intra-op VR application group|VR application group during intraoperative process
219213154|NCT06772142|DEVICE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation
219213155|NCT06769087|DEVICE|Immediate urinary catheter removal|A urinary catheter is removed immediately after surgery and before general anesthesia wears off in the operating room.
219213156|NCT06769087|DEVICE|urinary catheter removal within postoperative 1day|The urethral catheter will be removed in the ward within 1 day after surgery (within 24 hours after surgery).
219213157|NCT06768762|BEHAVIORAL|Phone Coaching|Participants will receive 11 coaching calls with a health coach. Calls will occur weekly during the first month, twice/month during months 2-3, and once/month during months 4-6. Each call is expected to last 10-15 minutes.
219213158|NCT06768762|BEHAVIORAL|Progress reports to providers|Progress reports on physical activity and program adherence will be sent to participants providers at 3 and 6 months.
219213159|NCT06768762|BEHAVIORAL|'Hear from Others' Videos|Participants will receive monthly 'Hear From Others' videos. The videos will include other adults with knee replacement discussing the challenges they have faced and strategies to overcome barriers to activity.
219681683|NCT02090686|DEVICE|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
219085033|NCT04949659|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
219085034|NCT05120115|OTHER|Weight belt|Wearing belt around waist with various weights attached.
219085035|NCT06525493|PROCEDURE|Regional Anesthesia|The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
219085036|NCT01911728|DRUG|MDV3100|Oral
219085037|NCT01911728|DRUG|Pioglitazone|Oral
219681684|NCT02800005|DEVICE|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
219085038|NCT01911728|DRUG|Warfarin|Oral
219085039|NCT01911728|DRUG|Omeprazole|Oral
219085040|NCT01911728|DRUG|Midazolam|Oral
219085041|NCT02456766|DEVICE|FibroTouch|
219085042|NCT02456766|PROCEDURE|Liver Biopsy|
219213160|NCT06768762|BEHAVIORAL|Individualized Feedback|Participants will receive individualized feedback from a coach via email. The feedback will specifically focus on participant responses to the 'Apply Your Knowledge' activities and will correspond with the video lessons. Feedback will be weekly during months 1-3 and monthly during months 4-6.
219213161|NCT06768762|BEHAVIORAL|Online exercise program|MOST Energized! Online Exercise Program
219213162|NCT02112214|DRUG|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
219213163|NCT02112214|OTHER|Placebo|Placebo for bismuth-based quadruple therapy
219361841|NCT04528121|OTHER|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
219085043|NCT02213562|DIETARY_SUPPLEMENT|200 mg of chrysanthemum flower oil|
219085044|NCT02213562|DIETARY_SUPPLEMENT|300 mg of chrysanthemum flower oil|
219085045|NCT02213562|DIETARY_SUPPLEMENT|400 mg of chrysanthemum flower oil|
219085046|NCT00480701|DRUG|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
219085047|NCT04557072|DRUG|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
219085048|NCT04557072|DRUG|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
219213164|NCT06768294|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.
219213165|NCT06768294|DRUG|Methylprednisolone (Corticosteroid)|The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.
219213166|NCT06768294|DRUG|Colchicine 1 MG Oral Tablet|1 or ½ tablet (depending on individual tolerance) daily after breakfast
219213167|NCT06768294|DRUG|Hydroxychloroquine 200 mg|1 tablet daily after lunch
219213168|NCT06768294|COMBINATION_PRODUCT|Methotrexate + Folic Acid|MTX 2.5 mg tablets, from 2 to 4 tablets (5-10mg), depending on disease severity, to be administered once weekly after dinner, always in the same day of the week. One tablet of folic acid (folina 5 mg) will be administered the day after MTX administration, after breakfast, to reduce and prevent the common side effects of MTX.
219681685|NCT02800005|OTHER|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
219681686|NCT03726073|DEVICE|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
219681687|NCT03726073|OTHER|Usual care|Patients in this group only receive usual care developed by the study hospital
219085049|NCT06313801|DRUG|Docetaxel|Docetaxel 50 mg/m2 intravenously on day 1
219085050|NCT06313801|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 on Day 1
219085051|NCT06313801|DRUG|Calcium folinate|200 mg/m2 2-hour intravenous infusion on day 1
219085052|NCT06313801|DRUG|Fluorouracil|2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
219085053|NCT06313801|PROCEDURE|Diagnostic laparoscopy|Access to the abdominal cavity by Hassen (3 trocars). Carboxyperitoneum - 12 mm of water column - stable pressure maintenance throughout the operation. Revision. Photo recording of 4 quadrants of the abdominal cavity from the paraumbilical port. The evaluation of the PCI index. The evaluation of other distant dissemination. Standard peritoneal lavage of 300 ml Sol. NaCl 0.9 % (37 ºС), with the exposure of 3-5 minutes (with Trendelenburg and Fowler position alternately) and the lavage aspiration, the transfer of the lavage for the cytological examination. Biopsy of perioneal lessions if needed.The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
219085054|NCT06313801|COMBINATION_PRODUCT|dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).|Diagnostic laparoscopy described earlier and PIPAC session. The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml. The rate of administration is 30 ml per minute. The maximum pressure in the injector system is 250 PSI. After the spray stage, the exposure is 30 minutes while maintaining the declared intraperitoneal pressure. After the exposure stage, only gas is removed from the abdominal cavity. The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
219085055|NCT00325364|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
219085056|NCT00325364|DRUG|Injectable insulin|patient specific dose, injectable, before meals, 24 months
219085057|NCT04843787|DRUG|SLV213|SLV213 oral capsule (200mg) BID
219085058|NCT04843787|DRUG|SLV213|SLV213 oral capsule (400mg) BID
219085059|NCT04843787|DRUG|SLV213|SLV213 oral capsule (800mg) QD
219085060|NCT04843787|DRUG|Placebo|Placebo oral capsule (200mg) BID
219085061|NCT04843787|DRUG|Placebo|Placebo oral capsule (400mg) BID
219085062|NCT04843787|DRUG|Placebo|Placebo oral capsule (800mg) QD
219681688|NCT06380205|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
219681689|NCT06380205|DRUG|Levonorgestrel/Ethinyl estradiol|Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
219085063|NCT06370026|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
219085064|NCT01144026|BIOLOGICAL|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
219085065|NCT01144026|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
219085066|NCT03913598|OTHER|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
219085067|NCT03388749|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
219085068|NCT02613819|RADIATION|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
219085069|NCT00288483|DRUG|Policosanol|
219213169|NCT06831032|RADIATION|Adaptive radiotherapy using SBRT|Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)
219361842|NCT04409873|DRUG|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
219681690|NCT00058071|DRUG|amifostine trihydrate|
219085070|NCT04032665|DIAGNOSTIC_TEST|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
219085071|NCT03390699|DIAGNOSTIC_TEST|Microbial profile|microbiological testing
219213170|NCT05702281|DEVICE|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
219213171|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
219213172|NCT06838390|DEVICE|Microcurrent Therapy|The study uses a four-channel microcurrent therapy device to treat pressure ulcers. The treatment involves applying four electrodes to the area around the ulcer, ensuring microcurrent passage throughout the wound bed. The treatment is done three times a day, lasting 35-40 minutes. The microcurrents are delivered in a monophasic, pulsed, square-form wave pulse with a voltage of 21 mV, an intensity of 42 µA, and a current density of 4.2 µA/cm.
219213173|NCT06838390|DEVICE|Transcutaneous electrical nerve stimulation|The study aimed to treat ulcers with TENS using a two-channel device, delivered three times a day, for 8 weeks. The device induced peripheral vasodilation and activate local blood flow, potentially promoting wound healing. The treatment was delivered using a pulse train duration of 300 ms, with an internal frequency of 100 Hz and a burst frequency of 2 Hz.
219213174|NCT06838390|OTHER|physical therapy program|The physiotherapy program included circulatory circulatory exercises, stretching exercises, and ROM exercises.
219213175|NCT06838390|DRUG|medial treatment|patients was given their drugs from their physicians
219213176|NCT06785701|PROCEDURE|Upper Gastrointestinal Endoscopy|After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
219213177|NCT06762249|OTHER|CIMT + Brunnstrom therapy + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks.
219213178|NCT06762249|OTHER|CIMT + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks
219213179|NCT06749093|OTHER|Filtered Air (FA)|Exposure to HEPA filtered air, as a control
219213180|NCT06749093|OTHER|Wood Smoke (WS)|Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
219213181|NCT06749093|OTHER|Diesel Exhaust (DE)|Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
219213182|NCT06749093|OTHER|Diesel Exhaust and Wood Smoke (DEWS)|Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
219213183|NCT06762197|OTHER|Conventional treatment|Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.
219213184|NCT06762197|DEVICE|shockwave therapy|Shockwave therapy is a non-invasive alternative treatment for muscle disorders like sports and traumatic injuries, as it reduces pain and promotes soft tissue repair. In a study, patients in group A were treated with three sessions of Storz Medical Shock Wave MP100, each consisting of 2000 pulses with a total energy dose of 1080 mJ / mm. The study aimed to determine the location of the piriformis muscle in the prone position.
219213185|NCT06762197|DEVICE|low level laser therapy|Low Level Laser Therapy, also known as Photo-biomodulation, is a low-intensity light therapy that triggers biochemical changes within cells, similar to photosynthesis in plants. It can treat nociceptive and neuropathic pain, but central pain has not been proven responsive to low level laser therapy.
219213186|NCT06778850|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
219213187|NCT06778850|DRUG|palcebo|Administered orally placebo
219213188|NCT06775977|DIAGNOSTIC_TEST|Contrast Enhanced Ultrasound (CEUS)|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
219213189|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
219213190|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
219213191|NCT06778213|BIOLOGICAL|NovoHelisen Depot|allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
219213192|NCT06776094|OTHER|One-legged-knee extensor exercise|1 hour of one-legged-knee-extensor exercise followed by 4 hours of rest
219213193|NCT06776094|PROCEDURE|Insulin infusion|"The hyperinsulinemic-euglycemic clamp is a well-established and recognized method for determining glucose uptake at a specific insulin infusion rate. It is a technique with which we have 25 years of uncomplicated experience. During the clamp, insulin (human recombinant insulin) is infused (1.42 mU/kg/min) into an arm vein (antecubital vein), while glucose (20% solution) is administered in an amount adjusted to maintain blood glucose (plasma glucose concentration) at basal levels.~The amount of insulin administered raises the participant's plasma insulin concentration (blood concentration) to approximately 100 μU/mL, which is considered within the physiological range. Blood samples are collected and analyzed continuously for glucose content, allowing for the determination of glucose uptake at the whole-body level and across the legs.~Later, these blood samples will also be analyzed for relevant metabolites and proteins, including insulin, to assess the metabolism of these substances."
219361843|NCT04409873|DRUG|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
219361844|NCT04409873|DRUG|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
219361845|NCT04409873|DRUG|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
219361846|NCT04409873|DRUG|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
219085072|NCT04309045|BEHAVIORAL|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
219085073|NCT04309045|BEHAVIORAL|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
219085074|NCT04309045|OTHER|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
219085075|NCT04535947|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
219085076|NCT04535947|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
219085077|NCT05241964|BIOLOGICAL|PRP|4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
219085078|NCT06063798|OTHER|General anesthesia for laryngotracheal surgery|Patients undergoing general anesthesia and mechanical ventilation.
219085079|NCT06063798|OTHER|Mechanical ventilation by FCV|Mechanical ventilation is assured by Flow-controlled ventilation mode.
219085080|NCT06063798|OTHER|Mechanical ventilation by HFJV|Mechanical ventilation is assured by High frequency jet ventilation mode.
219213194|NCT06776094|PROCEDURE|Muscle Biopsy Medication: Lidocaine|"During supine rest, the skin on the outer thigh, approximately 15 cm above the knee, is disinfected with chlorhexidine alcohol. Subsequently, 3-4 mL of local anesthetic (lidocaine 20 mg/mL) is administered into the skin, subcutaneous tissue, and the upper portion of the muscle using a very thin needle. A pinprick test is performed after a few minutes to ensure the anesthetic is effective.~A small incision is then made in the skin and subcutaneous tissue to allow the biopsy needle to pass through to the muscle. Using the biopsy needle, a small sample of muscle tissue (approximately 150 mg) is collected. This may cause some discomfort but is very brief (\~1-2 seconds). The needle is removed, a sterile dressing is applied, and the participant can leave the facility after completing the study.~The biopsy may result in mild muscle soreness for 2-3 days, similar to a minor muscle bruise. Regular physical activities can be resumed after the biopsy. However, it is advised to avoid swimming."
219213195|NCT06776094|OTHER|Exercise|The participants' maximal oxygen uptake is determined through a test on a cycle ergometer before the start of the experiment. The test begins with a 20-minute warm-up at two different low workloads, after which the workload is gradually increased until the predetermined cadence can no longer be maintained, or the participant indicates exhaustion. During the test, the participant's exhaled air is collected. After completing the warm-up, it typically takes between 4 and 7 minutes to complete the test.
219213196|NCT06775873|PROCEDURE|Modified diaphragmatic plication|Modified diaphragm plication (MDP) using a cutting stapler consists of four steps: clamping and lifting, depressing and resecting, cutting and verifying, and hemostasis and reinforcement.
219213197|NCT06776536|DIAGNOSTIC_TEST|Transrectal ultrasound of the bowel endometriosis during operation|"This is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (TRUS) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (DIE). The study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and MRI, and scheduled for bowel resection.~Preoperative evaluations will include pelvic examination, imaging (TVUS and MRI), and pain assessment using a visual analog scale (VAS). During surgery, TRUS will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative MRI results."
219213198|NCT05139992|BIOLOGICAL|COVID-19 Vaccine|Vaccination against SARS-CoV-2 administered as part of standard of care
219085081|NCT05416957|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
219085082|NCT01185626|OTHER|SCP care|
219085083|NCT03802123|DRUG|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
219085084|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
219085085|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
219085086|NCT04636658|OTHER|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
219085087|NCT04636658|OTHER|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
219085088|NCT04225533|DRUG|SP16|All patients will receive a single dose of SP16
219085089|NCT06579560|DIAGNOSTIC_TEST|Audiovestibular assessment in Patients with Fibromyalgia|Audiovestibular assessment in Patients with Fibromyalgia
219085090|NCT04052464|OTHER|endometrium biopsy|All patients will have endometrium biopsy.
219085091|NCT04052464|OTHER|endometrium lavage|In some selected cases biopsy is preceded by endometrium lavage.
219085092|NCT04052464|OTHER|repeated endometrium lavage|Endometrium lavage is repeated during the same cycle.
219085093|NCT01290406|DRUG|BEZ235|
219085094|NCT03732118|DEVICE|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
219085095|NCT04426448|BEHAVIORAL|Brief Relaxation, Education And Trauma HEaling|A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
219085096|NCT06542458|BEHAVIORAL|Assessments|Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record
219085097|NCT06542458|OTHER|Neuroimaging volumetric measures|Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.
219213199|NCT01208974|PROCEDURE|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
219213200|NCT01208974|PROCEDURE|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
219213201|NCT01208974|PROCEDURE|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
219213202|NCT01208974|RADIATION|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
219213203|NCT06511726|DRUG|Cadonilimab|Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
219213204|NCT05091632|PROCEDURE|Electroencephalography|Undergo EEG
219213205|NCT05091632|OTHER|Questionnaire Administration|Complete questionnaires
219213206|NCT06739616|BEHAVIORAL|AUTOSIB across time|Intervention will be in place across increasing time frames.
219213207|NCT06739616|BEHAVIORAL|AUTOSIB diminished reinforcement|Intervention will be in place with decreasing levels of reinforcement
219213208|NCT06737276|OTHER|Interactive fiction activities|The case studies were prepared using interactive fiction through Twine. Each case simulated a nursing consultation with a patient requiring dietary advice, and the patient's evolution depended on the students' choices. All cases created had similar structures, durations, and difficulties to avoid complexity-related bias. For each circumstance, three possible dietary advice options were offered to the patient: one option that would be ideal, one suitable option, and one unsuitable option.
219213209|NCT06737276|OTHER|Role-play simulation|Role-play activity of the nursing consultation on dietary advice according to Nemec et al. (2021) recommendations. Ten case studies of a nursing consultation on dietary advice involving a nurse and a patient were designed with the consensus of a group of nursing professionals with expertise in food and nutrition, health literacy, and communication. Each student was assigned a role and provided with the necessary information to play their character or understand their patient's context. The information provided was different according to the role assigned. They had to perform a simulation of eight minutes, similar to the time available in the student's primary care consultations in the referral health system. Thus, the patient and the family member had to explain the situation or health problem, the professional would analyse it, and together, they would try to reach a therapeutic agreement. After the consultation, a debriefing was carried out.
219213210|NCT05521516|DEVICE|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
219213211|NCT05521516|DEVICE|Sham Treatment|Application of 5 days of a nonfunctional sham device
219213212|NCT06771986|OTHER|Observation|sRAGE levels were studied in three different groups
219213213|NCT06866873|BIOLOGICAL|CAR-T|CAR-T cell (CHXCART01) infusion intravenously once at a dose of 0.2-2 million cells/kg recipient body weight
219213214|NCT06870721|PROCEDURE|arthroscopic dynamic anterior stabilization for recurrent anterior shoulder dislocation|arthroscopic dynamic anterior stabilization transferring long head of biceps to the anterior glenoid in patients with recurrent anterior shoulder dislocation
219213215|NCT06893848|OTHER|Culture Care program|"The Culture Care program modernizes the in-hospital environment by including art and culture proposed in the form of an individualized pathway. It will be offered primarily to hospitalized patients, but also available to families, caregivers and healthcare professionals. It will aim to create a new hospital experience, different from the one we've always known.~The Culture Care program will display posters illustrating works of art (paintings, drawings, photographs, etc.) along the hallways. These posters will be interactive, so that a QR code can be scanned to access musical content and audio podcasts (interviews and documentaries) accessible via bone-conduction headphones.~The Culture Care program is likely to reduce the sedentary behavior of hospitalized patients, by providing an attractive in-hospital environment that is likely to produce both physical and psychological benefits."
219361847|NCT06351930|BEHAVIORAL|CBT-I + UC group|Refer to the arm description
219681691|NCT03493438|OTHER|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
219085098|NCT06542458|OTHER|Biofluid samples|Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
219085099|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
219085100|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
219085101|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
219085102|NCT05323539|OTHER|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
219213216|NCT06745739|BEHAVIORAL|Life Skills Training Workplace Prevention Program|A workplace health promotion intervention for youth age 16-24, adapted from the school-based Life Skills Training program. The program teaches participants the skills necessary to be productive in work and personal settings while also promoting healthy behaviors and preventing or reducing health risk behaviors. Program content focuses on goal-setting and problem-solving skills, stress and anger management skills, effective communication and conflict management skills, time and financial management, substance use risk reduction, and how to contribute to a healthy, safe, and drug-free workplace.
219213217|NCT06745557|BIOLOGICAL|denovoSkin(TM)|Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area
219213218|NCT06745557|OTHER|STSG|Transplantation of autologous split-thickness skin to the control area
219085103|NCT04495179|DRUG|AZD4635|Subjects will receive AZD4635 orally daily
219213219|NCT06754826|OTHER|AI-generated questions and feedback as a spaced repetition|Participants in the intervention group will undergo structured learning sessions consisted of AI-generated questions and feedback as a spaced repetition.
219213220|NCT06809569|DRUG|Allyl Isothiocyanate (AITC)|Topical administration
219213221|NCT06809569|DRUG|Capsaicin|Intradermal administration
219213222|NCT06809569|OTHER|Vehicle for AITC|Topical administration
219213223|NCT06809569|OTHER|Vehicle for Capsaicin|Intradermal administration
219213224|NCT05198960|DRUG|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
219213225|NCT05198960|DRUG|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
219213226|NCT06748898|OTHER|TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the upper area 1 and 2 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. The electrodes were placed close to the skin and connected with TENStem eco basic (Wuxi Jiajian Medical Device Co., Ltd.). Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis.Upper area 1 is between the ulnar border on the little finger side and the flexor carpi ulnaris tendon.Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reachthe maximum tolerable level without causing pain, continuous stimulation until the end of surgery.
219213227|NCT06748898|OTHER|non TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the same position without current stimulation.
219213228|NCT03778944|PROCEDURE|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
219213229|NCT03778944|PROCEDURE|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
219213230|NCT03778944|PROCEDURE|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
219213231|NCT06860139|BEHAVIORAL|Health literacy intervention|The intervention will be developed in co-creation with patients and nurses in the clinic, based on their needs.
219213232|NCT06754774|DIAGNOSTIC_TEST|Shoulder Endurance Test|Each patient receive the same intervention, the Shoulder Endurance Test (SET). The Shoulder Endurance Test assesses the endurance of the shoulder muscles in an open kinetic chain.
219213233|NCT06755801|DRUG|Nevibolol|Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg
219213234|NCT06755801|DRUG|Placebo|Placebo
219213235|NCT06617923|DRUG|Senaparib|Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
219213236|NCT06617923|DRUG|Temozolomide|Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
219085104|NCT04495179|DRUG|Durvalumab|Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
219681692|NCT00610181|PROCEDURE|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
219085105|NCT04495179|DRUG|Cabazitaxel|Subjects will receive intravenous cabazitaxel every 3 weeks
219085106|NCT06236165|DRUG|N-acetylcysteine|Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
219681693|NCT04334525|BEHAVIORAL|Choice architecture + repeated exposure|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
219681694|NCT03456843|DRUG|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
219085107|NCT03465280|PROCEDURE|Microdebrider|Removal of lesions via microdebrider
219085108|NCT03465280|PROCEDURE|Cold-steel surgery (forceps)|Removal of lesions via forceps
219085109|NCT03465280|PROCEDURE|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
219085110|NCT03465280|PROCEDURE|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
219085111|NCT03465280|PROCEDURE|Pulsed dye laser|Removal of lesions via pulsed dye laser
219085112|NCT03465280|PROCEDURE|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
219085113|NCT03465280|PROCEDURE|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
219085114|NCT03465280|PROCEDURE|Plasma coagulation|Removal of lesions via plasma coagulation
219213237|NCT06764082|DIETARY_SUPPLEMENT|high MCT formula|"Energy Intake: The tube-feeding formula was a special medical-purpose formula food with high MCT and deep hydrolyzed milk protein (Alfare, Nestlé, Switzerland), which contained hydrolyzed whey protein, maltodextrin, vegetable oil, and MCT, etc. At a high-calorie concentration, each 1000 mL could provide 800 kcal, 15.8 g MCT, and 21.5 g protein (osmotic pressure 227 mOsm/kg).~Feeding Procedure: On the basis of 130 - 150% DRI, a high-calorie formula feeding amount of 160 ml/kg/d could provide 2.7 g/kg/d MCT. After the operation, starting from when oral nutrition was feasible, the amount gradually increased from the initial amount until the expected amount was reached, and this continued until 6 months after the operation. The difference between the estimated feeding amount and the actual feeding amount could be selectively supplemented with enteral nutrition (nasogastric tube)."
219085115|NCT03465280|PROCEDURE|Other|Removal of lesions via other methods
219085116|NCT03465280|OTHER|Adjuvant therapies|All adjuvant therapies
219213238|NCT06764082|DIETARY_SUPPLEMENT|normal oral intake of the traditional formula|For the children in the control group, there were no special restrictions before the operation. After they were able to have a normal diet postoperatively, they were encouraged to have a normal oral intake of the traditional formula. The recommended energy input for the formula was 130 - 150% of the reference intake (DRI) based on age and gender as per the World Health Organization (WHO). The final dosage and schedule were determined by the children and their parents or caregivers. The feeding route and the schedule for complementary feeding were the same as those in the experimental group.
219213239|NCT06763276|OTHER|Virtual Reality Group|In the study, a 400-gram virtual reality (VR) headset with an anti-reflective lens system was used, compatible with all earphones with screens ranging from 4.5 to 7.0 inches. The virtual reality (VR) headset, which was lightweight enough for children to wear, was supported on three sides to fit securely on the children's heads and was disinfected after each use. For the experimental group, the compartment at the front of the virtual reality (VR) headset was removed. The earphone was placed into the removed compartment, which was then reinserted. Subsequently, the YouTube virtual reality (VR) feature was activated on the phone, making it ready for viewing.
219213240|NCT06763731|DRUG|Systane COMPLETE|Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
219213241|NCT06765135|BEHAVIORAL|Clinician Survey|At the conclusion of the intervention period, practice stakeholders, including survey providers and practice managers in the intervention sites will be surveyed to identify their degree of satisfaction with the intervention and suggestions for improvement.
219213242|NCT06765135|BEHAVIORAL|Focus Group|Prior to installing the device in each primary care practice, trained moderators will conduct focus groups with clinicians and practice staff to to elicit provider perceptions of POC testing for respiratory pathogens, including feasibility and acceptability of integration of testing into routine workflows.
219213243|NCT06765135|DIAGNOSTIC_TEST|Biofire Spotfire Respiratory (R) panel|Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.
219213244|NCT06765135|BEHAVIORAL|Patient Survey|During the intervention period, patients who undergo POC RPP testing will be surveyed soon after their visit to elicit their opinions about the test.
219085117|NCT02625896|BEHAVIORAL|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
219085118|NCT03328299|DRUG|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
219085119|NCT03328299|DRUG|bupivacaine|20 ml of 0.5 % bupivacaine
219085120|NCT00673309|PROCEDURE|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
219085121|NCT00673309|DRUG|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
219085122|NCT00673309|DRUG|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
219085123|NCT00673309|DRUG|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
219085124|NCT00673309|DRUG|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
219085125|NCT00673309|DRUG|Insulin Low Dose|Insulin administered IV until 95% wound healing
219085126|NCT00673309|DRUG|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
219085127|NCT00673309|DRUG|Itraconazole|Itraconazole administered until 95% wound healing
219085128|NCT00673309|DRUG|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
219085129|NCT00673309|DRUG|Oxandrolone and Propranolol|Oxandrolone and Propranolol
219085130|NCT00673309|DRUG|Placebo or Control|Administration of Placebo or Control until 95% wound healing
219085131|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
219085132|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） High Dose|
219085133|NCT01512901|DRUG|Sham|
219085134|NCT02355743|DRUG|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
219085135|NCT04131608|DIAGNOSTIC_TEST|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
219085136|NCT02007642|PROCEDURE|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
219085137|NCT04212091|BIOLOGICAL|PGT121.414.LS|Administered via IV infusion or SC infusion, depending on the arm
219213245|NCT06766786|DRUG|Magnesium Sulfate high dose|Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
219213246|NCT06763172|DRUG|Caffeine (200 mg)|Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
219213247|NCT06763172|DRUG|Placebo|Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
219213248|NCT06765577|OTHER|Finger Blood Pressure Measurement|Finger Blood Pressure Measurement were taken from three digits: the thumb (F1), the middle finger (F2), and the little finger (F3) from both arms.
219213249|NCT06774508|OTHER|HIFE+cog|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Simultaneous cognitive exercises are added to static and dynamic balance exercises. Relative exercise intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
219213250|NCT06774508|OTHER|HIFE|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Relative exercises intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
219213251|NCT06766903|BEHAVIORAL|Exercise training|"All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions.~The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume."
219085138|NCT04212091|BIOLOGICAL|VRC07-523LS|Administered via IV infusion or SC infusion, depending on the arm
219085139|NCT02563457|OTHER|periodontal manual treatment|periodontal manual treatment
219085140|NCT02563457|OTHER|no periodontal manual treatment|blood sampling
219085141|NCT03300947|DRUG|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
219085142|NCT03300947|DRUG|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
219213252|NCT06765239|DIETARY_SUPPLEMENT|Hayfever Care|"Powdered natural food supplement provided as a decoction, to be taken twice daily.~Personalized Diet and Nutrition Guidance along with Lifestyle Advice"
219213253|NCT06765239|OTHER|Wait-list Control|Personalized Diet and Lifestyle Advice
219213254|NCT05296187|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
219085143|NCT03300947|DRUG|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
219085144|NCT04796818|PROCEDURE|Diffusion Weighted Imaging|Undergo IVIM DWI
219085145|NCT06506578|RADIATION|Radiation|Radiation
219085146|NCT05339529|DRUG|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
219085147|NCT05339529|DRUG|Blank control|Blank control
219085148|NCT05315349|OTHER|Complete ophthalmological check-up|Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)
219085149|NCT05315349|BIOLOGICAL|Blood sampling|Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
219213255|NCT06752525|DRUG|Bupivacaine|patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).
219213256|NCT06752525|DRUG|Magnesium Sulphate 500 mg|patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).
219085150|NCT05341349|BIOLOGICAL|Ipilimumab|Given IV
219085151|NCT05341349|BIOLOGICAL|Nivolumab|Given IV
219085152|NCT05341349|BIOLOGICAL|Pembrolizumab|Given IV
219085153|NCT05341349|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219085154|NCT05341349|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTFields
219085155|NCT04865627|DEVICE|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
219085156|NCT05630547|DRUG|SAR443820|Tablet by oral administration
219085157|NCT05630547|OTHER|Placebo|Tablet by oral administration
219085158|NCT00715429|DRUG|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
219085159|NCT00715429|DRUG|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
219213257|NCT06766617|OTHER|75 gr Glucose|75g of anhydrous glucose dissolved in 375 ml of water (Vittel) mixed with 150mg of U-13C\]-glucose (stable isotope from Eurisotope, France). will be orally taken
219085160|NCT03681158|DRUG|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
219085161|NCT01409538|OTHER|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
219085162|NCT01409538|OTHER|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
219085163|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
219085164|NCT03543930|DEVICE|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
219681695|NCT03456843|DRUG|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
219681696|NCT03456843|OTHER|Laboratory Biomarker Analysis|Correlative studies
219085165|NCT00618553|OTHER|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
219681697|NCT03456843|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219681698|NCT03456843|OTHER|Questionnaire Administration|Ancillary studies
219681699|NCT03456843|PROCEDURE|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
219085166|NCT00618553|BEHAVIORAL|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
219085167|NCT03845153|DRUG|Metformin Retard 850 mg|tablet
219681700|NCT02624947|BIOLOGICAL|RSV F vaccine with adjuvant|
219085168|NCT03845153|OTHER|Placebo|placebo tablet
219085169|NCT00185185|DRUG|Olmesartan medoxomil|
219085170|NCT00185185|DRUG|Atenolol|
219085171|NCT00185185|DRUG|Hydrochlorothiazide|tablets
219085172|NCT00185185|DRUG|olmesartan medoxomil|tablets
219085173|NCT00185185|DRUG|atenolol|tablets
219085174|NCT06537154|PROCEDURE|Active Surveillance|Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.
219085175|NCT06537154|PROCEDURE|Control arm - Definitive bladder treatment|Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
219085176|NCT02998073|BEHAVIORAL|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
219085177|NCT04085328|DEVICE|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
219085178|NCT04085328|DEVICE|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
219085179|NCT04518878|DRUG|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
219085180|NCT04518878|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
219085181|NCT00744484|BEHAVIORAL|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
219085182|NCT00744484|BEHAVIORAL|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
219085183|NCT03768492|DRUG|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
219213258|NCT06755541|DRUG|Fenofibrate in Combination With Ursodeoxycholic Acid|Experimental: Fenofibrate 200 mg Capsules
219213259|NCT06775210|OTHER|supportive sleep care|sleep bundle
219213260|NCT06775210|OTHER|care bundle|sleep bundle
219681701|NCT02624947|BIOLOGICAL|Formulation buffer|
219681702|NCT02604537|DRUG|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
219681703|NCT02604537|DRUG|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
219681704|NCT01550510|DRUG|Ascorbic Acid|3x a week for 9 weeks
219681705|NCT01550510|DRUG|Irinotecan|350mg/m2 once a week every 3 weeks
219681706|NCT05787860|DRUG|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
219681707|NCT06952517|DRUG|Clascoterone Cream 1%|Clascoterone 1% cream
219681708|NCT04991792|OTHER|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
219213261|NCT06771310|OTHER|Endurance exercise|"The exercise-training program will be consisted of 10 minutes warming up, 30 minutes of treadmill walking, and 10 min cooling down three times per week.~Warming up: It will be in the form of stretching of muscle groups for 10 minutes (3-5 stretch for the key muscle group (iliopsoas muscle, gluteus maximus ,quadriceps ,tibialis anterior , calf muscle, hold for 20-30 seconds), before the actual aerobic training session.~Actual session: Participants will receive aerobic exercises in the form of Moderate aerobic exercise training in the form of 30 min of treadmill walking and corresponding to a target heart rate of 65% to 75% of HR max (Maximum HR = 220 - Age ) to be gradually achieved and maintained throughout the training program.~Cooling down: It will be in the form of a treadmill walking at very slow speed for ten minutes."
219085184|NCT03768492|OTHER|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
219085185|NCT05591339|BIOLOGICAL|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
219085186|NCT05591339|BIOLOGICAL|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
219085187|NCT01920451|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
219213262|NCT06771310|OTHER|Kinesiotaping|"The participants will be asked to assume standing position then to flex back to reach its maximum point.~* Two bands, 1 on each side of the lumbar spine, will be applied vertically from the lower posterior iliac crest region to the upper twelfth rib region, with inhibition technique.~* The remaining 2 bands will be attached horizontally, with space correction technique.~* All 4 bands will be placed to allow for 50% longitudinal stretching. The stretching directions for the vertical and horizontal applications were bottom-up and sideways, respectively."
219213263|NCT02962973|DEVICE|CARMAT TAH|
219213264|NCT02962973|PROCEDURE|Surgical intervention|
219213265|NCT06767735|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
219213266|NCT06767735|DRUG|Insulin Glargine U100|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
219213267|NCT06780605|GENETIC|niPGT-A|"After being thawed following the standard lab practice, any donated blastocyst usable for the study will be washed individually to remove any trace of cumulus DNA and will be transferred to a new culture dish with a drop of 10-15µl. Day-5 blastocysts with proper re-expansion after thawing, will be cultured overnight (≈24 hours) before media collection and TE/ICM biopsies. Day-6 blastocysts will be cultured a total of 8 hours after thawing, before media collection and TE/ICM biopsies.~On day 6/7, the embryos' media will be collected with an automatic pipette for niPGT-A and additional genetic analysis. The same protocol will be used to analyze SBM and blastocyst biopsies."
219213268|NCT06780605|GENETIC|Multifocal TE biopsies and ICM biopsy|"For biopsy, blastocysts will be transferred to the biopsy dish and multi-focal TE biopsies will be performed in three locations related to the position of the ICM. ICM biopsies will be performed following a published protocol provided to the participant centers. ICM and TE sections will be aspirated with the use of micropipettes adapted to a micromanipulation and laser microscope system.~For the genetic study of the samples, the same protocol will be used to analyze embryo biopsies and SBM."
219213269|NCT06654947|DRUG|Surufatinib+Toripalimab+GEMOX|Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
219213270|NCT06771271|DRUG|RO7200220|RO7200220 was administered as IVT injection.
219213271|NCT06771271|DRUG|Ranibizumab|Ranibizumab was administered as IVT injection.
219213272|NCT06775119|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|"Baseline measurements of neuromuscular function and hemodynamic responses will be done. Investigators will then assess the mechanoreflex activation using the experimental technique of passive leg movement (PLM).~Following the PLM and the neuromuscular function baseline assessments, participants will perform four consecutive blocks, each consisting of a fatigue task followed by post-exercise circulatory occlusion (PECO). Neuromuscular function, assessed through maximal voluntary contraction (MVC) and quadriceps twitch techniques, will be measured before the fatigue task and after PECO in each block. Participants will perform 2-minutes isometric quadriceps sustained contraction at 20% MVC to induce exercise-induced neuromuscular fatigue. Hemodynamic responses will be measured during the PECO to isolate to the metaboreflex by inflating a cuff over the right thigh for a 2 minutes duration. After the PECO, the thigh cuff will be deflated, and neuromuscular function will be reassessed."
219213273|NCT06852573|BIOLOGICAL|ZM001 Injection|ZM001 injection, 2.5× 10\^7 CAR-T cells, 5× 10\^7 CAR-T cells, 1× 10\^8 CAR-T cells and 2× 10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
219213274|NCT00747565|DEVICE|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
219213275|NCT00747565|DEVICE|CeeOn 911A monofocal IOL|Monofocal Control IOL
219213276|NCT06851520|PROCEDURE|Anterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected anterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
219213277|NCT06851520|PROCEDURE|Posterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected posterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
219213278|NCT05008276|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
219213279|NCT05008276|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
219213280|NCT05008276|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size and selectivity
219213281|NCT05755204|DRUG|LA-CAB|Intramuscular LA-CAB for PrEP
219213282|NCT05755204|DRUG|TDF/FTC|Oral TDF/FTC for PrEP
219213283|NCT06797427|DRUG|DPH001|100 mg
219085188|NCT03602118|DRUG|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
219085189|NCT03878810|BEHAVIORAL|Exergaming|A video game-based physical activity training applied using a commercial game console.
219213284|NCT06797427|DRUG|Nexavar (Sorafenib)|200 mg
219213285|NCT05077748|OTHER||
219213286|NCT03777657|DRUG|Tislelizumab|200 mg intravenously (IV) on Day 1 of each 21-day cycle
219213287|NCT03777657|DRUG|Placebo|Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
219213288|NCT03777657|DRUG|Cisplatin|80 mg/m² IV on Day 1 of each 21-day cycle
219213289|NCT03777657|DRUG|Oxaliplatin|130 mg/m² IV on Day 1 of each 21-day cycle
219213290|NCT03777657|DRUG|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
219213291|NCT03777657|DRUG|5-Fluorouracil|800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle
219213292|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
219213293|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
219213294|NCT06809218|DRUG|Inhaled isoflurane administered by Sedaconda ACD-S|Intervention: isoflurane
219213295|NCT06809218|DRUG|Intravenous infusion of propofol|Intervention: propofol
219213296|NCT06704464|OTHER|Manual Dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT, 9-HPT, ABILHAND, and JTHFT.
219213297|NCT06704464|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
219213298|NCT06704464|OTHER|disability level|Individuals who meet the inclusion criteria will be evaluated for disability level using EDSS
219213299|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219213300|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219213301|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219213302|NCT06831097|BEHAVIORAL|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)"|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)~Description: Arm Description: Comidas Para Salud (Food for Health), will focus on assisting young children to learn skills in healthy eating. The Bienestar Preschool Curriculum is home-based and directed to both the primary caregivers as well as the child participants. The Pasos Para Salud (Steps for Health), which will use IVG/exergaming to increase children's physical activity level and reduce their sedentary behavior. Jardines Para Salud (Gardens for Health), will involve planting gardens in the HS settings and supervised home gardening projects for the preschool participants and their parents/guardians. This will instill the value of gardening and gardening skills in promoting a healthy lifestyle."
219213303|NCT06129942|DEVICE|Bright light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
219213304|NCT06129942|DEVICE|Dim Light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
219213305|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
219213306|NCT06262776|BIOLOGICAL|Recombinant zoster vaccine adjuvanted (SHINGRIX)|2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
219213307|NCT06802068|DIETARY_SUPPLEMENT|whole salmon oil|A minimally processed whole salmon oil
219213308|NCT06802068|DIETARY_SUPPLEMENT|Cod liver oil|Standard, processed omega-3 cod liver oil
219213309|NCT03665922|DIETARY_SUPPLEMENT|BroccoMax®|Nutraceutical neoadjuvant
219213310|NCT03665922|OTHER|Placebo|control
219213311|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
219213312|NCT06294990|DRUG|Testosterone gel|Two years treatment with testosterone
219213313|NCT06294990|OTHER|Placebo|Two years treatment with placebo
219213314|NCT02998164|BEHAVIORAL|augmentative and alternative communication technology|
219213315|NCT02998164|BEHAVIORAL|Usual Care|No change to the therapy care received
219213316|NCT05785221|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
219213317|NCT05785221|BEHAVIORAL|Personalized nutritional and lifestyle weight reduction intervention|Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
219213318|NCT06463015|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
219213319|NCT05014178|DIAGNOSTIC_TEST|Sodium-23 MRI|Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
219213320|NCT06071130|BEHAVIORAL|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
219213321|NCT06333457|DEVICE|VR Cue-Exposure Therapy|Standard VR Cue Exposure Therapy (VR-CET) for the treatment of alcohol dependence
219213322|NCT06822673|BEHAVIORAL|Mindfulness Based Intervention|The Mindfulness-Based Intervention will include techniques derived from the Mindfulness Matters Program protocol (for Children and Adolescents, 2019). It will consist of both formal and informal practices, which participants will engage in during sessions and at home. These practices will encompass body scan meditation, mindful eating, mindful sitting, walking exercises, attention-focusing activities, and more. The intervention will be delivered over eight weekly sessions, following a skill-building, educational approach.
219213323|NCT06821672|PROCEDURE|Chronobiological Group|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
219213324|NCT05275686|DRUG|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
219213325|NCT05275686|OTHER|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
219213326|NCT05802264|COMBINATION_PRODUCT|ABCI|Subjects will receive ABCI via oral inhalation
219213327|NCT05802264|COMBINATION_PRODUCT|Placebo|Subjects will receive ABCI via oral inhalation
219213328|NCT05162352|DRUG|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
219085190|NCT05417620|BEHAVIORAL|Social Media Campaign|PrEP social influence campaign, which will use online approaches to promote PrEP within communities in addition to the standard of care activities. Messaging crafted with community input will be geographically targeted to women, parents/mentors, and male partners on Facebook, Instagram, and Whatsapp, all with the intention to promote PrEP for women at high risk of HIV infection and change community norms and influence around PrEP. A combination of static imagery and brief videos will be used to engage these groups via social media platforms. A Facebook page will be created and maintained that can be accessed by anyone anywhere, but will only be advertised/promoted in the intervention districts.
219085191|NCT05417620|BEHAVIORAL|PrEP Champions|Within venues served by the FSW and AGYW programs, the team will identify and train 1 venue-based PrEP champion per venue who will receive supplies (e.g. a hat, pin and posters, flyers, IEC material) to wear to promote PrEP, facilitate linkage between women interested in PrEP and the TB HIV Care PrEP programme. PrEP champions will be either peers with experience taking PrEP, venue managers or local influencers (e.g. women running shops next to the mobile serving AGYW) that have repeated contact with the women the programme is intended to serve. The final selection of PrEP champions will be made in consultation with the Community Advisory Groups, venues and by the programme who works closely with each of the sites.
219085192|NCT05417620|BEHAVIORAL|Community Mobilization|A PrEP community mobilization team (2 peers, including one woman and one man) will be recruited within each ward to promote PrEP. The team will present information about PrEP and the PrEP programme at the ward councilors meeting, at Learning Support Agent meetings with parents/guardians, at local events/fairs, community meetings and through engaging men, women and parents across the community through informal conversations. Teams will be wearing branded material and will focus on presenting factual information and decreasing PrEP stigma. Each team will focus on promoting PrEP within their own ward over the 6-month period.
219085193|NCT05417620|OTHER|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
219085194|NCT03821168|DRUG|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
219085195|NCT03821168|DRUG|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
219085196|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with sublingual sprayable microemulsion.|Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.
219085197|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with oil droplets|Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.
219085198|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with capsules|Participants received capsules of vitamin D3 4000 IU daily for 30 days.
219085199|NCT05989100|BEHAVIORAL|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
219085200|NCT05989100|BEHAVIORAL|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
219085201|NCT05989100|BEHAVIORAL|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
219085202|NCT03969862|DEVICE|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
219085203|NCT01786928|OTHER|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
219085204|NCT03346629|DRUG|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
219213329|NCT06812845|OTHER|eye investigations|BY data entry ,measuring the visual acuity ,measuring IOP, doing refraction and recording eye investigations results to reach the final diagnosis
219213330|NCT06762067|OTHER|mirror therapy|Participants will undergo physiotherapy exercises in a mirror alongside post-surgery care. The program includes palming exercises, eye exercises, pencil push-ups, Brock string exercises, thumb exercises, and proprioceptive neuromuscular facilitation exercises. The first exercise warms up extra ocular muscles, the second improves eye coordination, the third motivates the lazy eye, the fourth strengthens eye muscles, and the fifth involves a near-distance jump for oblique muscles.
219213331|NCT06762067|OTHER|traditional therapy|The patients within the control group will receive traditional care post-strabismus operation as eye glasses and eye drops and regular exercise
219213332|NCT06753019|OTHER|survey assessment tools|Functional and psychological status and the level of somatosensory amplification in patients with knee osteoarthritis will be evaluated with questionnaires.
219213333|NCT06764433|PROCEDURE|GONPRF|GON PRF treatment, which we apply by imaging the target nerve and surrounding structures with the proximal technique (at C2 level) under USG guidance in patients who do not respond to conservative treatments for cervicogenic headache.
219213334|NCT06764433|PROCEDURE|Proximal GONPRF|Ultrasound-guided pulsed radiofrequency treatment of the greater occipital nerve at the C2 level
219213335|NCT06734273|DRUG|Mounjaro|In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
219213336|NCT06734273|PROCEDURE|Sleeve Gastrectomy|Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
219213337|NCT06764667|PROCEDURE|Spinal anesthesia adjuvant|Patients in this arm will receive 10 mg 0.5% hyperbaric Bupivacaine, 100 mcg Morphine, 100 mcg Sulfas Atropine, and 0.9% normal saline to total volume of 4 ml before induction of anesthesia.
219213338|NCT06764667|PROCEDURE|Quadratus Lumborum Block (QLB)|Patients in this arm will receive quadratus lumborum block with 20-30 ml of 0.25% Bupivacaine after induction of anesthesia and after operation.
219085205|NCT03560427|DRUG|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
219085206|NCT03560427|DRUG|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
219213339|NCT06764667|PROCEDURE|General Anesthesia|The subject will undergo preoxygenation with 100% oxygen for 3 minutes. Following preoxygenation, anesthesia induction will be performed using lidocaine at a dose of 1.5 mg/kg, fentanyl at 1.5 mcg/kg, and propofol at 2.0 mg/kg. Once the subject is adequately sedated, baseline neuromuscular monitoring using the train-of-four (TOF) technique will be conducted, followed by the administration of rocuronium at a dose of 0.8 mg/kg. Endotracheal intubation will be performed using direct laryngoscopy once the TOF value reaches 0, utilizing an appropriately sized endotracheal tube (ETT). Ten milligrams of intravenous dexamethasone is administered after induction.
219213340|NCT05687292|DEVICE|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
219213341|NCT05857397|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
219085207|NCT00673972|RADIATION|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
219085208|NCT00579566|OTHER|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
219085209|NCT01559298|DRUG|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
219085210|NCT01559298|DRUG|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
219085211|NCT02106988|RADIATION|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
219085212|NCT02106988|DRUG|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
219085213|NCT02106988|DRUG|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
219085214|NCT02106988|DRUG|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
219085215|NCT02106988|DRUG|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
219085216|NCT02106988|DRUG|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
219085217|NCT02413580|BIOLOGICAL|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
219085218|NCT02347020|BEHAVIORAL|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
219085219|NCT02347020|BEHAVIORAL|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
219085220|NCT02347020|BEHAVIORAL|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
219213342|NCT04779697|DRUG|GLP-1 analogue - semaglutide|GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
219213343|NCT04779697|OTHER|Placebo|Placebo - administered once weekly for a total of 12 weeks
219213344|NCT06238908|DRUG|NGGT003|Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
219213345|NCT06791512|DRUG|mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody|Participants in the experimental group will receive the neoadjuvant therapy regimen of mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody. And the first five doses received the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous), and the sixth dose received the same regimen of mFOLFOX6 and PD-1 monoclonal antibody but not plus bevacizumab, in order to allow sufficient withdrawal time of Bevacizumab for surgery.
219213346|NCT06791512|DRUG|mFOLFOX6|Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
219213347|NCT03417336|RADIATION|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
219213348|NCT06759896|DEVICE|Protraction facemask|Patients assigned to intervention 1 will utilize the Petit protraction facemask, in conjunction with a rapid maxillary expansion (RME). This facemask consists of a forehead pad and chin pad linked by a sturdy steel support rod.
219213349|NCT06759896|DEVICE|Upper partial fixed appliance|Upper partial fixed appliance / 2 by 4 appliance will be used in this study by using bracket set (119-142 Unitek™ Gemini Bracket MBT™ U/L 5x5 0T-Cuspid 3Hk) with molar bands (3M™ Victory Series™ First Molar Bands) or buccal tubes (3M™ Victory Series™ Superior Fit Buccal Tubes) and upper nickel titanium archwires (3M™ Unitek™ Nitinol Heat-activated Archwire) and upper stainless steel archwires (3M™ Unitek™ Permachrome Standard Archwire) .
219213350|NCT06840678|DEVICE|Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. The investigators will use a cylindrical neodymium magnet of 60 mm diameter and 30 mm of thickness (MAG60r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the supplementary motor area (SMA) using an ergonomic helmet (MAGsv1.1, Neurek SL, Toledo, Spain).
219213351|NCT04895956|PROCEDURE|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
219085221|NCT02347020|BEHAVIORAL|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
219085222|NCT00067015|DRUG|bicalutamide|
219085223|NCT00067015|DRUG|goserelin acetate|
219085224|NCT00067015|PROCEDURE|assessment of therapy complications|
219085225|NCT00067015|PROCEDURE|quality-of-life assessment|
219085226|NCT00067015|RADIATION|radiation therapy|
219085227|NCT02328885|DRUG|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
219085228|NCT04591522|OTHER|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
219085229|NCT00765232|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
219085230|NCT00765232|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
219085231|NCT06639061|DEVICE|Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)|"We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation."
219085232|NCT06639061|DEVICE|Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)|We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
219085233|NCT03804710|DRUG|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
219085234|NCT03804710|DRUG|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
219085235|NCT03804710|OTHER|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
219085236|NCT01268748|PROCEDURE|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
219085237|NCT01268748|PROCEDURE|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
219085238|NCT04542018|OTHER|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
219085239|NCT04357262|OTHER|StreaMD|Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
219213352|NCT04895956|PROCEDURE|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
219213353|NCT04895956|DEVICE|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
219213354|NCT00545545|BIOLOGICAL|Imprime PGG 2 mg/kg|Infusion of 2mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
219213355|NCT00545545|BIOLOGICAL|Imprime PGG 4 mg/kg|Infusion of 4mg/kg on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
219213356|NCT00545545|BIOLOGICAL|Cetuximab|Infusion 400 mg/m2 over 2 hours on Day 1, then 250 mg/m2 over 1 hour on Days 8, 15, 22, 29, and 36 of each 6-week treatment cycle;
219213357|NCT00545545|DRUG|Irinotecan|Infusion 125 mg/m2 i.v. over 1.5 hours on Days 1, 8, 15, and 22 of each 6-week treatment cycle
219213358|NCT00545545|BIOLOGICAL|Imprime PGG 6mg/kg|Infusion of 6mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
219213359|NCT06836297|DEVICE|Transcranial Magnetic Stimulation Sham|Participants will be asked to perform various behavioral tasks involving the use of action observation or motor imagery. During these tasks, transcranial magnetic stimulation will be used.
219213360|NCT05375851|OTHER|Digital Interventions|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management."
219213361|NCT05375851|DRUG|Treatment as Usual|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
219213362|NCT06793761|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
219213363|NCT06793761|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
219213364|NCT06793761|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
219213365|NCT06426329|BEHAVIORAL|Therapeutic Touch|Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
219213366|NCT06744153|PROCEDURE|Space Maintainer|Fabrication of KOS\&MET functional space maintainer and its cementation.
219213367|NCT04338399|DRUG|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
219213368|NCT06772935|BEHAVIORAL|Electro-acupuncture|A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
219213369|NCT06891079|DIAGNOSTIC_TEST|Videodensitometric guided|"In the experimental arm, a TAVI device is implanted according to the local practice. Immediately after implantation, aortography is performed to quantitatively assess the aortic regurgitation (qAR). The aortography is analyzed using CAAS A-Valve (Pie-Medical, Maastricht, The Netherlands).~•If qAR is \>17%, we recommend that corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed and angiography is repeated for the assessment of aortic regurgitation. If the qAR ≤17%, whether corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed is left to the discretion of the operators. Inform operators of the results of qAR and the threshold criteria. Continuous qAR was stratified into categorical variables according to the following pre-determined threshold criteria: (1) none or trace (qAR \<6%); (2) mild (6% to ≤17%); and (3) moderate or severe (\>17%).~At discharge, all the patients will undergo Cardiac magnetic resonance, the Car"
219361848|NCT03433781|DRUG|Vitamin C|All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).
219681709|NCT04991792|OTHER|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
219681710|NCT04991792|OTHER|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
219085240|NCT04358003|DEVICE|Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)|"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician."
219085241|NCT03399032|DRUG|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
219085242|NCT01273454|DRUG|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
219085243|NCT04787601|OTHER|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
219085244|NCT04787601|OTHER|Classic Training|Classic match preparation training
219085245|NCT06372821|DRUG|NIO752|Antisense oligonucleotide
219085246|NCT06372821|OTHER|Placebo|Saline
219085247|NCT00421551|DRUG|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
219085248|NCT00421551|DRUG|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
219085249|NCT03869398|DIETARY_SUPPLEMENT|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
219085250|NCT03869398|DIETARY_SUPPLEMENT|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
219213370|NCT06891079|DIAGNOSTIC_TEST|Stand of care guided|"In the control arm, a TAVI device is implanted according to local practice. Immediately after implantation, TEE/TTE or aortography is performed as a part of usual practice.~* The requirement of post-dilatation or any additional procedure is left to the discretion of the operator.~* The operator judges the sufficient procedural outcome to end the procedure according to local practice.~At discharge, all the patients will undergo Cardiac magnetic resonance, the Cardiac magnetic resonance-derived regurgitation fraction (CMR-RF) will be analyzed as the primary endpoint."
219213371|NCT06832774|PROCEDURE|Local treatment|For bone lesions, radiotherapy or orthopedic surgery may be selected. For lymph node lesions, radiotherapy or high-energy focused ultrasound (HIFU) maybe selected. The specific treatment plan will be determined by the researcher and based on the patient's clinical condition.
219213372|NCT06832774|DRUG|Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).|"The intervention contains gonadotropin releasing hormone analog (GnRHa) and novel hormone therapy. For GnRHa, there are 3 options available. 1. Leuprorelin/Prostap or Staladex. 2. Goserelin/Zoladex. 3. Triptorelin /LiverTox. For novel hormone therapy, there are also 3 options available. 1. Abiraterone/ ZYTIGA®. 2. Apalutamide/ERLEADA®. 3. Rezvilutamide/ARIANE®. The specific treatment plan will be designed according to patients' clinical conditions based on EAU guidelines."
219213373|NCT06752486|DRUG|Giving post photorefractive keratectomy for pain relief|We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
219213374|NCT05120856|BEHAVIORAL|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
219213375|NCT05120856|BEHAVIORAL|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
219213376|NCT06302452|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma Centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
219213377|NCT06747520|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
219361849|NCT02856165|DEVICE|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F\&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 \> 94%.
219361850|NCT02856165|DEVICE|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 \> 94% (up to a maximum of 2l/min).
219681711|NCT06785090|DRUG|Bromfenac|Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.
219085251|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
219085252|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
219085253|NCT01311960|DRUG|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
219085254|NCT01311960|DRUG|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
219085255|NCT05554952|COMBINATION_PRODUCT|MTA|Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
219085256|NCT05748912|PROCEDURE|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
219085257|NCT06307015|RADIATION|De-escalation|Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
219085258|NCT06307015|RADIATION|Standard of care|Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
219085259|NCT05916326|BIOLOGICAL|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
219085260|NCT05916326|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
219085261|NCT02652988|OTHER|Active-tDCS|Active home-based tDCS applied at home.
219085262|NCT02652988|OTHER|Sham-tDCS|Sham home-based tDCS applied at home.
219085263|NCT01428076|DRUG|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
219085264|NCT01896570|PROCEDURE|Catheter ablation of subsequent atrial tachycardia|
219085265|NCT01834131|BEHAVIORAL|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
219085266|NCT01087892|DIETARY_SUPPLEMENT|Probiotic drink containing the live strain|Probiotic drink contains no strain
219085267|NCT01087892|DIETARY_SUPPLEMENT|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
219213378|NCT06618950|BEHAVIORAL|physical activity|The key factor that distinguishes this study from others is its comprehensive examination of the effects of regular physical activity on late adolescents, not only in terms of physical health but also regarding healthy lifestyle behaviors, self-esteem, and psychological well-being. While other studies typically focus on the benefits of physical activity for physical health, this research considers the broader psychological and social development of adolescents, offering a wider perspective. Additionally, its emphasis on the sustainability of a planned and structured physical activity regimen, along with its approach to transforming physical activity into a lifestyle, represents a significant difference.
219213379|NCT03133195|DRUG|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
219213380|NCT03133195|DRUG|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
219085268|NCT04598724|OTHER|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
219213381|NCT03133195|DIETARY_SUPPLEMENT|Calcium supplement|1000 mg/day of elemental calcium
219085269|NCT04088019|DRUG|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
219085270|NCT03907995|BEHAVIORAL|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
219085271|NCT04351867|DRUG|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
219085272|NCT04351867|DRUG|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
219085273|NCT04688242|OTHER|Anal dilatation per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
219085274|NCT04688242|DRUG|administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
219085275|NCT03167307|DRUG|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
219085276|NCT03167307|DRUG|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
219085277|NCT02454101|PROCEDURE|cord milking|milking of the cord 5 times toward the neonate
219085278|NCT02454101|PROCEDURE|delayed cord clamping|delay clamping of the cord for 120 seconds
219085279|NCT04602312|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
219085280|NCT05307848|OTHER|No intervention|No intervention
219085281|NCT05031546|DRUG|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
219085282|NCT03467867|DRUG|Venetoclax|Venetoclax will be administered as described in the reporting arm.
219085283|NCT03467867|DRUG|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
219213382|NCT03133195|DIETARY_SUPPLEMENT|Vitamin D|20,000 IU/week of vitamin D2
219213383|NCT06770114|DRUG|Cetylpyridinium Chloride and Zinc Lactate Mouthwash|0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate
219213384|NCT06770114|DRUG|PhosFlur Mouthwash|0 .044 % sodium fluoride
219213385|NCT06763185|OTHER|Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
219213386|NCT06763185|OTHER|Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
219361851|NCT01356004|DRUG|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
219361852|NCT01356004|DRUG|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
219361853|NCT05264220|BEHAVIORAL|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
219681712|NCT06785090|DRUG|Moxifloxacin 0.5% ophthalmic solution|antibiotic, standard postoperative care regimen
219085284|NCT03467867|DRUG|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
219085285|NCT03037450|PROCEDURE|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
219085286|NCT05969171|DRUG|Surufatinib, gemcitabine, nab-paclitaxel|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks for a treatment cycle, did not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks for a treatment cycle. Surufatinib: 250mg, qd, po, every 3 weeks for a treatment cycle. Surufatinib and gemcitabine was continued until disease progression (PD, RECIST 1.1) or death (while the patient was on treatment) or toxicity became intolerant or other criteria for discontinuation of study therapy were met in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
219213387|NCT06759285|BEHAVIORAL|Experimental (cradle position)|The newborn in cot bed was swaddled freely with the help of a thin blanket during feeding. Then, the nurse, wearing a box apron, took the baby in her arms and gave it a cradle position. The baby's physiological parameters and Comfort Scale were filled in before feeding began. The baby was kept in a cradle position on the researcher's lap during feeding. Immediately after feeding, without changing the baby's position, the physiological parameters and Comfort Scale were evaluated a second time, and again 15 minutes after feeding, without changing the position, the physiological parameters and Comfort Scale were evaluated a third time and recorded. Then, the baby was gently and slowly laid down on the denim bed as usual (right lateral).
219213388|NCT05268237|DRUG|Liraglutide|Sublingual or subcutaneous liraglutide
219213389|NCT05268237|DRUG|Placebo|Sublingual placebo
219213390|NCT06747221|OTHER|Systems Analysis and Improvement Approach (SAIA)|"SAIA is a 5-step implementation strategy that is repeated every 4-6 weeks for continuous quality improvement. It will be implemented by Kenyan public health workforce and frontline clinical care personnel to systematically identify and address bottlenecks to develop and implement solutions to delivery of HIV Testing Services during emergency department (ED) interactions.~Step 1: Understanding the cascade of ED patient flow from triage through care conclusion with focus on HTS opportunities. This will support identification of bottlenecks where patients are missed and provides data on potential increases in efficiency if misses are addressed.~Step 2: Use process mapping to identify modifiable bottlenecks.~Step 3: Define and implement workflow adaptations to mitigate modifiable bottlenecks.~Step 4: Monitor changes in performance.~Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
219213391|NCT06849362|DRUG|Bevacizumab|"Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody used in combination with chemotherapy or immunotherapy for the treatment of metastatic colorectal cancer (CRC). In this study, bevacizumab is administered as part of combination therapy in certain patient groups to assess its impact on treatment efficacy in MSS/MSI-L/pMMR advanced colorectal cancer.~Patients receiving bevacizumab will be evaluated for treatment response, survival outcomes, and potential biomarkers predictive of therapeutic efficacy. The study will compare the clinical benefits of immunotherapy alone, immunotherapy + bevacizumab, and immunotherapy + chemotherapy + bevacizumab to determine the optimal treatment strategy.~The dose and administration schedule of bevacizumab will follow standard clinical guidelines as per institutional protocols."
219213392|NCT06866223|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax
219213393|NCT06667661|BEHAVIORAL|Shining Star mHealth App|The Shining Star mHealth App Intervention is a 12-week mobile health program designed to improve adherence to the 24-Hour Movement Guidelines (physical activity, screen time, and sleep) among preschool-aged children (3-4 years old). The intervention delivers weekly behavior-related goals and educational lessons to parents through a mobile app, including concise messages (\&lt;500 characters) and links to additional resources. The app also includes gamification features, behavior trackers, and a \&#34;Kids Corner\&#34; for child-friendly content. Parents receive reminders and can engage with other participants through an optional chat forum.
219681713|NCT06785090|DRUG|Dexamethasone phosphate 0.1%|steroid, standard postoperative care regimen
219681714|NCT02404402|OTHER|LED|Low Level Light Therapy
219085287|NCT05969171|DRUG|Nab-paclitaxel, gemcitabine|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks as a treatment cycle, should not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks as a treatment cycle, treatment until toxicity intolerance or disease progression, death, or other criteria for termination of study therapy as specified in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
219085288|NCT02216773|PROCEDURE|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
219085289|NCT02216773|PROCEDURE|Portal vein embolization (PVE)|
219085290|NCT04274894|DRUG|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
219085291|NCT03061565|DRUG|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
219085292|NCT03061565|DRUG|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
219085293|NCT05491148|OTHER|work conditions|an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
219085294|NCT06309108|OTHER|Education Booklet|The education group was given training with a education booklet
219085295|NCT06309108|OTHER|Augmented Reality Group|The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
219085296|NCT02164877|DRUG|pectin|Patients allocated to experiment group will receive 15g pectin each day
219681715|NCT02404402|OTHER|sham LED|Inactive (sham) LED treatment
219213394|NCT05310786|OTHER|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
219085297|NCT01936857|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
219085298|NCT01936857|DRUG|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
219085299|NCT00134290|DRUG|metformin|
219085300|NCT00134290|BEHAVIORAL|"standard diet advice"|
219085301|NCT00134290|BEHAVIORAL|"personal diet advice"|
219085302|NCT02279043|BEHAVIORAL|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
219085303|NCT02279043|BEHAVIORAL|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
219085304|NCT02124265|DRUG|CeraLyte 90|"1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5\. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used."
219085305|NCT01795365|OTHER|Active surveillance|
219085306|NCT02067260|DEVICE|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
219085307|NCT02067260|DEVICE|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
219085308|NCT05608850|OTHER|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
219085309|NCT05608850|OTHER|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
219085310|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Energy|Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine
219085311|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Sleep|Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine
219085312|NCT06524674|DIETARY_SUPPLEMENT|Energy Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine
219085313|NCT06524674|OTHER|Sleep Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
219085314|NCT00490282|RADIATION|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
219085315|NCT00490282|RADIATION|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
219085316|NCT06524466|DRUG|Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab|"SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT."
219085317|NCT04474743|OTHER|No intervention - cross-sectional observational only|No intervention - cross-sectional observational only
219085318|NCT04266379|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
219085319|NCT04266379|DEVICE|Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring|Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
219085320|NCT00353587|DRUG|MBX-102|MBX-102 200 mg once daily for 16 weeks
219085321|NCT00353587|DRUG|MBX-102|MBX-102 400 mg once daily for 16 weeks
219085322|NCT00353587|DRUG|MBX-102|MBX-102 600 mg once daily for 16 weeks
219213395|NCT04032106|OTHER|Best Practice|Receive standard information about HPV and HPV vaccine
219213396|NCT04032106|OTHER|Informational Intervention|Receive Outsmart HPV intervention
219213397|NCT04032106|OTHER|Questionnaire Administration|Ancillary studies
219213398|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
219213399|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive interactive text message vaccine reminders
219213400|NCT05464732|DEVICE|Vivity IOL emmetropia|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to bilateral emmetropia.
219213401|NCT05464732|DEVICE|Vivity IOL monovision|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to emmetropia in the dominant eye and -0.50 in the non-dominant eye.
219085323|NCT00353587|DRUG|Placebo|MBX-102 Placebo once daily for 16 weeks
219085324|NCT00353587|DRUG|Actos|Actos 30 mg once daily for 16 weeks
219085325|NCT01270269|BEHAVIORAL|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
219085326|NCT01270269|BEHAVIORAL|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
219085327|NCT00303199|DRUG|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
219213402|NCT06885398|OTHER|treatment|"* Endotracheal Tube Ventilation with an endotracheal tub~* Laryngeal tube Ventilation with a laryngeal tube~* Laryngeal mask Ventilation with a laryngeal mask~* I-Gel-Laryngeal Mask Ventilation with an I-Gel-laryngeal mask"
219213403|NCT03682172|DRUG|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
219213404|NCT03682172|DRUG|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
219213405|NCT03682172|DRUG|Placebo|Four hour intravenous infusion with saline water
219213406|NCT06768450|BEHAVIORAL|Online mindfulness meditation|"The mindfulness meditation program is adapted from the Breathwork Mindfulness for Stress program. However, it uses shorter meditations designed for individuals who cannot sit for 40 minutes. The mindfulness meditation program encourages greater self-acceptance, kindness, and compassion toward oneself. It builds on this concept by helping participants find pleasure in life despite suffering, fostering kindness and compassion toward others, and increasing social connections to counteract the social isolation common among individuals with chronic and long-term illnesses.~The program will be led by a well-trained Breathwork mindfulness instructor and conducted remotely via Microsoft Teams once a week for 8 weeks. Each session will last 2 to 2.5 hours and consist of body scans, mindful movements, and various meditations, introducing new ideas every week."
219213407|NCT06847321|DRUG|LHP588|25 mg
219213408|NCT06847321|DRUG|LHP588|50 mg
219085328|NCT02361515|RADIATION|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
219213409|NCT06847321|DRUG|Placebo Drug|Placebo
219213410|NCT00902044|GENETIC|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
219213411|NCT00902044|DRUG|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes"
219213412|NCT00902044|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes"
219213413|NCT00902044|GENETIC|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
219213414|NCT06766526|BEHAVIORAL|Internet-based cognitive behavioral therapy|An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.
219213415|NCT06766526|BEHAVIORAL|Non-directive support|Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.
219213416|NCT06765629|DEVICE|Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group|After obtaining informed consent from the subjects, the researchers screen the subjects based on the inclusion and exclusion criteria. The wearable non-invasive percutaneous tibial nerve stimulator is placed on the area where the tibial nerve runs at the medial malleolus of the subjects. Once the wearable stimulator is properly fitted, stimulation parameter programming and treatment record management are conducted through the programming software running on the mobile phone.
219213417|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
219213418|NCT06736964|DEVICE|Giomer|based on Pre-reacted glass ionomer (PRG)
219361854|NCT04351139|OTHER|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
219085329|NCT02361515|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
219085330|NCT04132843|DRUG|Gadobenate Dimeglumine|Given IV
219085331|NCT04132843|DRUG|Gadobutrol|Given IV
219085332|NCT04132843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219085333|NCT05613738|DRUG|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
219213419|NCT06782984|OTHER|Organoid-based drug sensitivity test|"The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis.~The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis."
219085334|NCT05613738|DRUG|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
219085335|NCT05613738|DRUG|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
219085336|NCT04805255|RADIATION|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
219085337|NCT04510675|DEVICE|Test Article|Omeza Collagen Matrix
219213420|NCT06734962|PROCEDURE|Apical surgery procedure using A-PRF|Participants will undergo an apical surgery procedure using A-PRF. Before the surgery and at follow-ups, patients will undergo comprehensive evaluation using clinical, radiological, and ultrasonographic techniques.
219213421|NCT06734962|PROCEDURE|Apical surgery without using A-PRF|Participants will undergo an apical surgery procedure without using A-PRF. Patients will undergo comprehensive evaluation before the surgery and at follow-ups using clinical, radiological, and ultrasonographic techniques.
219213422|NCT06792383|DIAGNOSTIC_TEST|quality of life|"The following assessment tools will be proposed to patients:~* Quality of Life in Epilepsy (QOLIE-31)26~* Dissociative Experience Scale (DES)27~* Symptom Checklist-90 (SCL-90)28~* Irritability Questionnaire (I-EPI)29~* Beck Depression Inventory II (BDI-II)30~* State-Trait Anxiety Inventory Y-1 e Y-2 (STAI)31~* Epilepsy Stigma Scale modificata32 These assessment tools are validated and used universally, and will allow the collection of information on the psychological and psychiatric functioning of the patients."
219213423|NCT06868160|BEHAVIORAL|Rehabilitation|"Two cycles of dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises.~Three 1-hour sessions per week for 6 weeks. Cycle repeated after 8-week washout period."
219213424|NCT06868160|DEVICE|SHAM tDCS|SHAM stimulation will be performed using the same montage used for transcranial and spinal stimulation, however an initial current is delivered and programmed to fade off in a brief period of time.
219213425|NCT06868160|DEVICE|tDCS|Anodic tDCS with the anode placed on the of the left DorsoLateral Prefrontal Cortex. Patients will undergo 30 minutes tDCS session preceding rehabilitation
219213426|NCT06868160|DEVICE|tsDCS (first cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the first cycle (6 weeks)
219213427|NCT06868160|DEVICE|tsDCS (second cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
219213428|NCT06868160|DEVICE|SHAM tsDCS (first cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the first cycle (6 weeks)
219213429|NCT06868160|DEVICE|SHAM tsDCS (second cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
219213430|NCT06868160|DEVICE|SHAM tsDCS|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation
219213431|NCT06892262|OTHER|Athletes|The group was included in strength assessment using an isokinetic dynamometer and postural stability evaluation. (high level training group)
219213432|NCT06619574|DEVICE|3D Analysis Group|Dental Compass and Dental Compass software used for therapeutic splint fabrication
219213433|NCT06619574|OTHER|Manual Analysis Cohort|Manual methods used for therapeutic splint fabrication
219085338|NCT04510675|OTHER|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
219085339|NCT04501510|DIAGNOSTIC_TEST|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
219085340|NCT05204810|OTHER|Anticoagulation strategy|For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant
219085341|NCT05204810|OTHER|Blood sampling|During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
219085342|NCT05204810|OTHER|Scanning of hemodialyzer with micro-computed tomography|After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
219085343|NCT05310474|DEVICE|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
219085344|NCT01479387|DRUG|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
219085345|NCT03034616|DEVICE|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
219085346|NCT02317393|OTHER|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
219085347|NCT02317393|OTHER|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
219085348|NCT05177458|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.
219085349|NCT05177458|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
219085350|NCT04198805|DIETARY_SUPPLEMENT|Vitamin E [(all-rac)-α-tocopheryl acetate]|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
219085351|NCT04198805|DIETARY_SUPPLEMENT|Omega-3 fatty acid (DHA EE)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
219085352|NCT04198805|COMBINATION_PRODUCT|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
219085353|NCT04198805|OTHER|Placebo|Matching soybean placebo (3 capsules) of all arms daily for 6 months.
219085354|NCT01330433|DEVICE|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing \>10kg will receive 2-4ml of CoSeal"
219085355|NCT06378892|DRUG|Lorlatinib|Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
219085356|NCT01499082|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
219085357|NCT01499082|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
219085358|NCT05686005|DRUG|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
219085359|NCT05686005|DRUG|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
219085360|NCT01457911|DRUG|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
219085361|NCT01457911|DRUG|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
219213434|NCT06758102|BEHAVIORAL|Dance Program|A 12-week, virtual dance program consisting of seated and standing choreography and contemporary style elements will be taught by a certified dance instructor. Sessions will be conducted by the HIPAA-compliant, video-conferencing platform, Zoom.
219361691|NCT06001944|OTHER|Multimodal rehabilitation|"Patients with LDT will be informed that the condition will be gradually resolved with adequate rest and time.~Exercise Training will consist of 3 phases.The goal is to protect the injured tissue from stress during the first phase of rehabilitation during the protective phase but not to restrict its function. In this phase, the use of counterforce breys, cold application, cyriax physiotherapy, Mill's manipulation, elbow mobilization and stretching to the wrist extensors will be applied. The program will be created taking into account the principle of proximal stability for distal mobility during the reinforcement phase. The rotator manchet will be added to the program. It will be active first in the exercise and then progresses resistantly according to the condition of the patient. After distal strengthening, the dress will be transferred to stabilization exercises where flexion and extension reveal simultaneous contraction."
219085362|NCT03599349|DEVICE|Microfocused ultrasound w/ visualization|
219085363|NCT06439563|DRUG|JP-1366 10 mg|JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
219085364|NCT06439563|DRUG|Lanston Capsule 15 mg|Lanston Capsule 15 mg orally once a day for up to 24 weeks
219085365|NCT06439563|DRUG|JP-1366 10 mg placebo|JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
219085366|NCT06439563|DRUG|Lanston Capsule 15 mg placebo|Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
219085367|NCT05617755|BIOLOGICAL|AB-1015|autologous T cell therapy
219085368|NCT01527929|DRUG|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
219085369|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
219085370|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
219085371|NCT00222833|DRUG|Aripiprazole|
219085372|NCT04197843|DEVICE|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
219085373|NCT04557930|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
219085374|NCT01830127|DRUG|Ribavirin|24 Weeks
219085375|NCT01830127|DRUG|BI 207127 high dose|24 Weeks
219085376|NCT01830127|DRUG|Faldaprevir|24 Weeks
219085377|NCT01830127|DRUG|Ribavirin|24 Weeks
219085378|NCT01830127|DRUG|BI 207127 low dose|24 Weeks
219085379|NCT01830127|DRUG|Faldaprevir|24 Weeks
219085380|NCT01584765|DRUG|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
219085381|NCT05840432|DEVICE|Postoperative hypotension prediction index|Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
219085382|NCT02899494|OTHER|Antenatal classes|
219085383|NCT02899494|OTHER|Physical and psychic preparation|
219085384|NCT04216030|OTHER|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
219085385|NCT04216030|OTHER|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
219085386|NCT00844025|BEHAVIORAL|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
219085387|NCT02563496|DRUG|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
219085388|NCT02563496|DRUG|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
219085389|NCT03717896|DRUG|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
219213435|NCT06623370|DRUG|methylprednisolone|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
219085390|NCT03717896|DRUG|Placebo|50mL 0.9% saline
219085391|NCT00567190|DRUG|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
219085392|NCT00567190|DRUG|Placebo|Placebo (matching pertuzumab) was administered intravenously.
219085393|NCT00567190|DRUG|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
219085394|NCT00567190|DRUG|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
219085395|NCT06031883|DRUG|Ketamine|Total intravenous anesthesia in craniotomy
219085396|NCT04288505|DIAGNOSTIC_TEST|VIRTUAL REALITY application|application on virtual reality headset
219085397|NCT06264479|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
219085398|NCT00233558|DRUG|adalimumab (up to 9 months exposure)|
219085399|NCT00233558|DRUG|methotrexate|
219085400|NCT05258162|OTHER|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
219085401|NCT05258162|OTHER|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks."
219361692|NCT06217120|DRUG|Colchicine|Colchicine 0.5 mg daily
219361693|NCT06217120|DRUG|Placebo|Placebo once daily
219085402|NCT01522417|DRUG|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
219085403|NCT01522417|DRUG|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
219085404|NCT01522417|DRUG|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
219213436|NCT06623370|OTHER|Saline (NaCl 0,9 %) (placebo)|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
219213437|NCT06854575|DIETARY_SUPPLEMENT|Dietary Supplement|Oral dietary supplement
219213438|NCT06854575|OTHER|Placebo|Placebo pill
219213439|NCT06089915|BEHAVIORAL|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
219213440|NCT06089915|DEVICE|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
219213441|NCT06785857|OTHER|mHealth Supportive Care Program|On the basis of monthly home visits in the control group, a weekly mHealth supportive care intervention program was added through the medium of Xiamen iHealth, with one supportive care item every two weeks for 12 weeks, for a total of 12 online interventions, as well as the provision of online consulting and booking services for caregivers at any time.
219213442|NCT06785857|OTHER|Offline supportive care|"This was done routinely in accordance with the requirements of public health services for chronic diseases in the community elderly. In addition, health education on diabetes mellitus and dementia was provided to the caregivers during their monthly home visits.~① the content of diabetes health education: the researcher gave the caregivers education and training on the care of diabetes patients: the main points of care in diet, sleep, exercise, etc.~② The content of dementia health education: the researcher gave the caregivers education and training related to the care of dementia patients: instructing the caregivers in the basic life care skills of patients' diet, sleep, exercise, etc."
219213443|NCT06783777|DEVICE|Esophageal pressure monitoring|Esophageal pressure and Tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
219213444|NCT06783777|DEVICE|Tracheotomy tip pressure|Esophageal pressure and tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
219213445|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
219213446|NCT02405169|DEVICE|4 vs 6 implant treatment in the maxilla|
219213447|NCT06893367|DEVICE|IMU and RealSense Cameras|Each participant will perform the FMA-sens, with their most affected hand, followed by the FMA-sens with the less affected hand.
219361855|NCT04244344|OTHER|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
219361856|NCT02881034|DRUG|Triple therapy|
219361857|NCT01286246|DRUG|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
219085405|NCT04406493|DIAGNOSTIC_TEST|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
219085406|NCT04801550|DEVICE|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
219085407|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
219085408|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
219085409|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
219085410|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
219085411|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
219085412|NCT00093834|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
219085413|NCT00093834|DRUG|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
219085414|NCT00093834|DRUG|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
219085415|NCT04788550|COMBINATION_PRODUCT|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
219085416|NCT04788550|COMBINATION_PRODUCT|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
219085417|NCT04788550|COMBINATION_PRODUCT|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
219213448|NCT06887855|PROCEDURE|Neuromuscular Electrical Stimulation|NMES is a modality for stimulating muscles through electrical pulses, is used widely in the rehabilitation of stroke patients with pharyngeal dysphagia. It reinforces the strength of the muscles for swallowing and smooths the swallowing reflex through sensory stimulation. Clinically, NMES is applied to depolarize nerve fibers at the point of engagement, involving muscle contraction (Park et al. 2019). NMES includes the placement of electrical stimuli to the skin around the face and neck through surface electrodes. Stimulation intensity can be diverse depending on the treatment objectives. Low-intensity (sensory) NMES lets patients feel the tingling sensation on the skin, whereas high-intensity (motor) NMES can stimulate muscle contractions (Cheng et al. 2022).
219213449|NCT06887855|PROCEDURE|Neuromuscular Taping|NMT is similar to kinesiology taping but specifically focuses on neuromuscular re-education and it is a commonly used therapy approach for various neuromuscular problems. The neuromuscular tape can be easily applied to skeletal muscles to induce or inhibit muscle activity and to support the stabilization of structures such as joints and ligaments. The elasticity and adhesion properties of NMT can be used to restrain the anterior-upward movement of the hyolaryngeal complex during spontaneous swallowing. This effect increases the load on the suprahyoid muscles and consequently, the patient spends more effort to overcome this movement while swallowing. Resistance exercises provided with NMT activate the suprahyoid muscle and contractions for the muscles of the tongue.
219213450|NCT06887855|PROCEDURE|Swallowing exercise (Expiratory Muscle Strength Training)|IN EMST the patients blow into a one-way spring-loaded apparatus calibrated to a percentage of maximum expiratory pressure until the valve opens with adequate effort. Four to eight weeks of EMST exercises increased the maximum expiratory pressure (MEP), maximum hyoid displacement, suprahyoid muscle action, and swallowing safety in patients with amyotrophic lateral sclerosis, stroke, and neck cancer.
219213451|NCT06887855|PROCEDURE|Swallowing exercise (Chin Tuck Against Resistance)|CTAR exercise is performed by an inflatable 12 cm rubber ball. The patients are directed to sit upright on a chair and hold the rubber ball between the base of the chin and the manubrium sterna. This exercise is composed of isometric and isotonic movements. The isometric movement will be performed for 10 seconds, whereas the isokinetic movement will be successively repeated 10 times to strengthen the suprahyoid and infrahyoid muscles (Kagaya \& Inamoto, 2022).
219213452|NCT06688903|BEHAVIORAL|App-based diabetes management and community-based health coaching|All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
219213453|NCT06751303|OTHER|Patients that are HRP are given a decision aid for PARPi use|Study created patient decision aid if the first for HRD tested Ovarian Cancer patients
219213454|NCT06687941|DRUG|AST-201|AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
219213455|NCT06889519|BEHAVIORAL|MBT Lighthouse Parenting Program|Lighthouse Parenting Programme, a 12-week intervention for parents, focusing on enhancing mentalizing abilities. It includes weekly group sessions (2hrs) led by 3 trained MBT psychotherapists for 8-12 parents, and fortnightly individual parenting sessions (1hr) with a practitioner. The programme, rooted in Mentalization-Based Treatment (MBT) skills, explores parents mentalizing and their childrens mentalizing and attachment styles through a variety of interactive methods, including multimedia resources and creative activities to stimulate mentalizing. Central to the programme is the metaphor of the parent as a lighthouse, guiding their child. Training for practitioners spanned 4 days, covering MBT and Lighthouse Parenting skills, with an emphasis on experiential learning and self-reflection. Ongoing weekly group supervision will ensure the quality and fidelity of the intervention. Delivered in person at University Diego Portales.
219213456|NCT06889519|BEHAVIORAL|Psychoeducational cards|They will receive weekly information on parenting in the first 3 years of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
219085418|NCT03538470|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool"
219085419|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
219085420|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
219085421|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
219085422|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
219085423|NCT02732366|BEHAVIORAL|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
219213457|NCT00319020|DRUG|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
219085424|NCT02732366|OTHER|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
219213458|NCT06819059|BEHAVIORAL|Pediatric Cardiac Telerehabilitation|The program was entirely virtual except for pre and post program cardiopulmonary exercise testing. Patients were provided a stationary bicycle, hand weights, and resistance training bands. They exercised over zoom with a physical therapist or exercise physiologist weekly and were also asked to exercise independently 2x per week. Electrocardiograms (ECGs) were provided to the patients as a single lead monitor and results were shared with the study team after each session or during sessions if the patient reported symptoms. Compliance and activity data were recorded using Fitbit activity trackers.
219213459|NCT06819059|BEHAVIORAL|Fitness Tracker Only|Control participants were provided fitness trackers and weekly text messaging from the study team to synch their devises but no formal exercise training. They were allowed to enroll in the exercise training after completing 3 months as a control.
219213460|NCT06877559|OTHER|balloon-assisted enteroscopic treatment for phytobezoar|The endoscopists applied balloon-assisted enteroscopy for the treatment of the phytobezoar
219213461|NCT06893120|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
219085425|NCT05279170|OTHER|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
219213462|NCT06769880|OTHER|Ultrasound and Educational Intervention|This will include the educational intervention combined with a point-of-care ultrasound
219213463|NCT06769880|OTHER|Educational Intervention Alone|This will include only the educational intervention (without ultrasound)
219213464|NCT06769191|BIOLOGICAL|CD7 CAR-T cells injection|Intravenous infusion, single dose
219213465|NCT06769191|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
219085426|NCT04524468|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
219085427|NCT05228600|DRUG|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
219085428|NCT04609033|DRUG|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
219085429|NCT04609033|DRUG|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
219085430|NCT04609033|DRUG|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
219085431|NCT04609033|DRUG|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
219085432|NCT05525273|DRUG|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
219085433|NCT03131557|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
219085434|NCT03131557|DEVICE|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
219085435|NCT03520764|DIETARY_SUPPLEMENT|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
219085436|NCT03520764|DIETARY_SUPPLEMENT|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
219085437|NCT05579418|DRUG|Evolocumab|Evolocumab is an injection for management of dyslipidemia
219085438|NCT00000727|DRUG|Pentamidine isethionate|
219085439|NCT00000727|DRUG|Pyrimethamine|
219085440|NCT00000727|DRUG|Sulfamethoxazole/Trimethoprim|
219085441|NCT00000727|DRUG|Sulfadoxine/Pyrimethamine|
219085442|NCT00000727|DRUG|Zidovudine|
219213466|NCT06769191|PROCEDURE|Kidney Transplantation|Kidney Transplantation
219213467|NCT00227266|DRUG|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
219085443|NCT03781752|DRUG|Methylphenidate|study to determine dose
219085444|NCT00344461|DRUG|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
219085445|NCT04189562|OTHER|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
219085446|NCT01229930|DRUG|carboplatin|
219085447|NCT01229930|DRUG|cediranib maleate|
219085448|NCT01229930|DRUG|paclitaxel|
219085449|NCT01229930|OTHER|laboratory biomarker analysis|
219085450|NCT01229930|OTHER|pharmacological study|
219085451|NCT01229930|PROCEDURE|quality-of-life assessment|
219085452|NCT06171607|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219085453|NCT06171607|DRUG|Perflutren Lipid Microspheres|Given IV
219213468|NCT00227266|DRUG|Placebo|
219213469|NCT04584983|DRUG|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
219213470|NCT04584983|DRUG|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
219213471|NCT06782477|DRUG|STAR-0310|STAR-0310 will be administered as a subcutaneous bolus injection.
219213472|NCT06782477|DRUG|Placebo|Placebo will be administered as a subcutaneous bolus injection.
219213473|NCT05971602|DRUG|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
219085454|NCT06171607|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
219085455|NCT04584229|OTHER|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
219085456|NCT03063294|OTHER|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
219085457|NCT03063294|OTHER|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
219085458|NCT00000126|PROCEDURE|Surgery|
219085459|NCT04760418|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
219085460|NCT00646477|DEVICE|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
219085461|NCT00636610|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
219085462|NCT00636610|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
219085463|NCT00636610|DRUG|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
219085464|NCT00636610|DRUG|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
219213474|NCT05971602|DRUG|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
219213475|NCT05971602|DRUG|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
219213476|NCT05971602|DRUG|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
219213477|NCT05971602|DRUG|Isoniazid and Rifampicin (HR)|Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
219213478|NCT06776042|OTHER|Nasal brushing of the olfactory cleft|Nasal brushing of the olfactory cleft
219213479|NCT06776042|OTHER|Smell testing|Smell testing using the Sniffin' Sticks Test
219213480|NCT06454669|DRUG|Dronabinol|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
219213481|NCT06454669|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
219213482|NCT06736834|OTHER|Babao Congee and Youtiao(deep-fried dough sticks) with different cooking conditions|Babao Congee and deep-fried dough sticks with different cooking conditions
219213483|NCT06210243|BIOLOGICAL|C752|C752 will be administered on Day 0
219213484|NCT06117111|DEVICE|PaMo monitoring device|Comparison of the device to standard monitoring
219085465|NCT00636610|DRUG|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
219213485|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
219213486|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
219213487|NCT04452097|BIOLOGICAL|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
219213488|NCT04452097|OTHER|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
219361858|NCT01286246|DRUG|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
219085466|NCT06731959|DRUG|Flexlamose|Fexlamose solution via nebulizer for 28 days
219085467|NCT06731959|DRUG|Placebo|Placebo solution via nebulizer for 28 days
219085468|NCT06733883|OTHER|psychotherapy|Music therapy
219213489|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
219213490|NCT06894940|BEHAVIORAL|Active Comparator #1|task oriented rehabilitation
219213491|NCT06894940|BEHAVIORAL|Placebo|passive rehabilitation
219213492|NCT06894940|BEHAVIORAL|Experimental|rehabilitation with virtual reality
219085469|NCT00478712|OTHER|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
219085470|NCT07087665|DEVICE|Wavelight Plus|"The WaveLight EX500 laser system, in conjunction with INNOVEYES Sightmap, is indicated for use in INNOVEYES Laser Assisted In-Situ Keratomileusis (wavelight plus1 LASIK) treatments:~* or the reduction or elimination of myopia or myopia with astigmatism, in eyes with spherical equivalent (SE) more than -1.00 and up to -9.00 diopters (D), with up to -8.00 D of spherical component (in minus cylinder format) and up to -3.00 D of astigmatic component at the spectacle plane, based on the INNOVEYES Sightmap Measured Refraction,~* in patients with magnitude of the spherical equivalent (SE) difference between the Manifest Refraction (MRSE) and the Sightmap measured refraction SE being less than 0.75D,~* in patients who are 18 years of age or older, and~* for patients with documentation of a stable manifest refraction defined as 0.5 D preoperative spherical equivalent shift over one year prior to surgery."
219085471|NCT07089186|DRUG|Meropenem and Pralurbactam|3g，q8h，180min infusion，Dose adjustments are available for participants with eGFR(mL/min)
219085472|NCT07089186|DRUG|Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)|The main therapeutic agents anticipated for use, either in combination or as monotherapy, commonly include colistin, meropenem, tigecycline, amikacin, and ceftazidime-avibactam.
219085473|NCT06058832|DEVICE|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
219085474|NCT06058832|OTHER|Kegel Exercises|"* The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening"
219213493|NCT03959423|DEVICE|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
219213494|NCT06341647|DRUG|AB-201|NK Cell Therapy
219213495|NCT06341647|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219085475|NCT04168554|DEVICE|Telemedicine|Patient is examined using telemedicine
219085476|NCT06944704|DRUG|Pentoxifylline|Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
219085477|NCT02929355|OTHER|carotid assesment by duplex ultrasonography|
219085478|NCT02532179|BIOLOGICAL|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
219213496|NCT06341647|DRUG|Fludarabine|Lymphodepleting chemotherapy
219213497|NCT06786000|DEVICE|Anodal tDCS combined with mCIMT|20 minutes of anodal tDCS followed by 1 hour of the mCIMT program. The anodal electrode will be placed over the ipsilesional M1 (primary motor cortex, C3 or C4 according to EEG 10/20 system), and the cathodal electrode over the contralateral supraorbital area (Fp1 or Fp2) ). Leading to subthreshold depolarization to promote cortical excitation. And twelve different oriented tasks will be used during the 1-hour training period.
219085479|NCT03648112|DIETARY_SUPPLEMENT|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
219085480|NCT03648112|DIETARY_SUPPLEMENT|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
219213498|NCT06786000|DEVICE|Cathodal tDCS combined with mCIMT|20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the contralesional M1, and the anodal electrode over the contralateral supraorbital area (Fp1 or Fp2). leading to subthreshold polarization to promote cortical inhibition. And twelve different oriented tasks will be used during the 1-hour training period.
219361859|NCT03404999|OTHER|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
219085481|NCT03648112|DIETARY_SUPPLEMENT|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
219213499|NCT06786000|DEVICE|Bihemispheric tDCS combined with mCIMT|20 minutes of Bihemispheric tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the primary motor cortex (M1) of the contralesional hemisphere and the anodal electrode will be placed above the ipsilateral M1 position (C3 or C4 positions, according to the 10/20 EEG system). And twelve different oriented tasks will be used during the 1-hour training period.
219213500|NCT06786000|DEVICE|Sham tDCS combined with mCIMT|20 minutes of sham tDCS followed by 1 hour of the mCIMT program. the same stimulation place and parameters will be used as in the anodal group. However, after 30 seconds of stimulation, the stimulator will switch off. This provides the participants with the experience of the initial itchy sensation that occurs during tDCS, which is required for efficient masking. And twelve different oriented tasks will be used during the 1-hour training period.
219213501|NCT06744075|OTHER|Blood assessment|ctDNA collection (venous blood draw) will occur at baseline, mid-treatment, and at the end of treatment
219213502|NCT04731558|DRUG|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
219213503|NCT04731558|DRUG|No intervention|No preoperative thromboprophylaxis.
219213504|NCT03184922|PROCEDURE|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
219213505|NCT06662123|DRUG|Anifrolumab|Participants will receive a single SC or IV dose of anifrolumab at day 1
219213506|NCT06498661|PROCEDURE|Biospecimen Collection|Undergo collection of cervical samples by clinician
219213507|NCT06498661|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
219213508|NCT06498661|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
219213509|NCT06498661|OTHER|Electronic Health Record Review|Ancillary studies
219213510|NCT06498661|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
219213511|NCT06498661|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
219213512|NCT06498661|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal samples
219213513|NCT06498661|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
219085482|NCT03648112|DIETARY_SUPPLEMENT|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
219085483|NCT03648112|DIETARY_SUPPLEMENT|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
219085484|NCT02681848|DRUG|Varenicline|Smoking cessation medication
219085485|NCT02681848|DRUG|Nicotine replacement therapy|
219085486|NCT04715516|BEHAVIORAL|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
219213514|NCT06498661|OTHER|Questionnaire Administration|Ancillary studies
219213515|NCT06498661|OTHER|Survey Administration|Ancillary studies
219213516|NCT06894823|OTHER|Creation of a laboratory network|Creation of a laboratory network in Central-Southern Italy capable of performing complex genomic analyses.
219213517|NCT06894823|OTHER|Mapping of genomic alterations|Mapping of genomic alterations aimed at precision medicine and personalized diagnostic and therapeutic approaches.
219213518|NCT06894823|OTHER|Creation of a bioinformatics network among the participating institutions.|Creation of a bioinformatics network among the participating institutions.
219213519|NCT06894823|OTHER|Development of a platform for the collection of clinicopathological and genetic-molecular data.|Development of a platform for the collection of clinicopathological and genetic-molecular data.
219213520|NCT06894823|OTHER|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.
219213521|NCT06762834|COMBINATION_PRODUCT|Ginger tea|determine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects.
219213522|NCT06762834|COMBINATION_PRODUCT|self administred Ginger tea|To identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments.
219213523|NCT06111872|DRUG|Ketamine|Administration described in arm/ group description
219213524|NCT06111872|DRUG|Midazolam|Administration described in arm/ group description
219213525|NCT06111872|DRUG|Pethidin|Administration described in arm/ group description
219213526|NCT06596317|PROCEDURE|Chromoendoscopy|Patients will undergo chromoendoscopy with spraying indigo carmine.
219213527|NCT06596317|PROCEDURE|Conventional colonoscopy|Patients will undergo conventional colonoscopy.
219085487|NCT04715516|BEHAVIORAL|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
219213528|NCT06114498|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
219213529|NCT06114498|DIAGNOSTIC_TEST|Bioimpedance|Bioelectrical impedance analysis research
219085488|NCT03646032|BEHAVIORAL|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
219085489|NCT03646032|BEHAVIORAL|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
219213530|NCT06114498|DIAGNOSTIC_TEST|Immunoassay|Enzyme immunoassay of heat shock proteins in blood serum
219213531|NCT06114498|DIAGNOSTIC_TEST|Routine biochemistry|Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
219213532|NCT05818319|OTHER|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
219213533|NCT05818319|OTHER|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
219213534|NCT05818319|OTHER|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
219213535|NCT02549352|DRUG|LEO43204 gel|
219213536|NCT02549352|DRUG|Vehicle gel|
219213537|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
219213538|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
219213539|NCT06801964|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
219213540|NCT06801964|DIETARY_SUPPLEMENT|Protein and Fish Oil|milk/carbohydrate mixture and supplementation of 3.5g of EPA+DHA (7g of fish oil)
219213541|NCT06801964|DIETARY_SUPPLEMENT|Protein and Olive Oil|milk/carbohydrate mixture with olive oil
219213542|NCT06801964|DIETARY_SUPPLEMENT|Carbohydrate and Olive Oil|carbohydrate mixture with olive oil
219085490|NCT03348072|PROCEDURE|Cardiac surgery|Cardiac surgery
219085491|NCT05639179|BIOLOGICAL|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
219085492|NCT02395861|OTHER|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
219085493|NCT04386434|BEHAVIORAL|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
219213543|NCT06767137|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a gold-standard, evidence-based treatment combining techniques to improve the clinical symptomatology of insomnia. Delivered in six 90-minute group sessions over six weeks, it includes: sleep education (i.e. understanding sleep mechanisms and influencing factors), bedtime restriction (i.e. aligning bedtimes with reported sleep duration), stimulus control (i.e. getting out of bed when unable to sleep), cognitive therapy (i.e. addressing dysfunctional sleep beliefs), relaxation techniques (i.e. using methods like progressive muscle relaxation).
219085494|NCT00889057|DRUG|sorafenib|400 mg bid until progression or inacceptable toxicity
219213544|NCT06767137|BEHAVIORAL|Bedtime restriction (BRT)|"Bedtime Restriction Therapy (BRT): A behavioral intervention aimed at improving the clinical symptomatology of insomnia by aligning time spent in bed with reported sleep duration. Participants attend four 60-minute group therapy sessions over six weeks. The intervention includes: setting individualized sleep windows based on sleep diaries, regular adjustment of sleep schedules to enhance sleep pressure, group discussions to address implementation challenges and maintain motivation.~BRT focuses exclusively on bed time restriction without additional cognitive or relaxation components, making it a simplified, resource-efficient approach to treating insomnia."
219213545|NCT06778629|PROCEDURE|Transversalis Fascia Plane Block|After the wound closure is completed and the patient is still under general anesthesia the TFPB will be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed longitudinally, 2-3 cm laterally, just above the iliac crest at the mid-axillary line. After the external oblique, internal oblique, and transversus abdominis muscles are distinguished, the common aponeurosis of the transversus abdominis and the internal oblique muscle will be found. The block needle will be directed from anterior to posterior, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine, Polifarma ®) will be applied between the transversus abdominis muscle and transversalis fascia.
219085495|NCT00876915|DRUG|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
219085496|NCT03952702|PROCEDURE|Myopic overcorrection|Myopic overcorrection
219085497|NCT05600049|DEVICE|Prototypes (815-v1 001) to (815-v1 050)|"Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
219085498|NCT05600049|DEVICE|Prototype (815-v1 051) to (815-v1 100)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
219085499|NCT05600049|DEVICE|Prototypes (815-v1 101) to (815-v1 150)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
219213546|NCT06778629|PROCEDURE|Post Operative Pain Management|Acetaminophen 1 gr (Paracerol, Polifarma®) intravenous (IV), and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be administered to all patients 30 minutes before wound closure. After surgery, Acetaminophen (Paracerol, Polifarma®) 1 gr IV, and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be given three times a day. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV pethidine (Aldolan, Liba Laboratory ®) 0,5 mg/kg will be given as a rescue analgesic.
219213547|NCT06778629|PROCEDURE|Port Site Infiltration|A total of 20 ml of 0.25% bupivacaine ( (Buvicaine, Polifarma ®) will be applied to the trocar entry points by the surgeon at the beginning of the operation, before entering the trocars.
219213548|NCT05681156|OTHER|N/A- There is no intervention.|There is no intervention.
219213549|NCT06750419|DRUG|89Zr-TLX250 PET/CT|"89Zr-TLX250, is a chimeric monoclonal antibody (INN name: girentuximab) with specificity for the CAIX (carbonic anhydrase 9) antigen, radiolabelled with the positron emitting radiometal zirconium- 89. Girentuximab has a CAS number of 916138-87-9. The chemical formula, without the 89Zr and the desferrioxamine, is C6460H1006N1718O2018S48 with a molecular mass of 146.5 kg/mol.~89Zr-TLX250 is formulated as a solution for IV administration in glass vials at the nominal dosage strength of 37 MBq (±10%) for single IV use. The mass dose of 89Zr-TLX250 to be used in this Phase 3 study will be 10 mg, labelled with 37 MBq (±10%) 89Zr per dose."
219213550|NCT04483115|DRUG|TPN171H|Tablets; Oral; Single dose
219213551|NCT04483115|DRUG|Placebo|Tablets; Oral; Single dose
219213552|NCT04483115|DRUG|Tadalafil|Tablets; Oral; Single dose
219213553|NCT05985850|DRUG|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
219213554|NCT05985850|DRUG|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
219213555|NCT06827301|DEVICE|Non Invasive vagus nerve stimulation|Transcutaneous Auricular Vagus Nerve Stimulation
219213556|NCT04559581|DRUG|Nintedanib|Capsules
219213557|NCT04214210|OTHER|Adapted Family Gene Toolkit|Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
219213558|NCT04214210|OTHER|Targeted intervention|The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
219213559|NCT06827223|DEVICE|computer-controlled Starpen Automatic Injection Device|using computer-controlled Starpen Automatic Injection Device during inferior alveolar nerve block anesthesia and extraction of mandibular primary molars
219213560|NCT06827223|DEVICE|Traditional Syringe|nerve block anesthesia and extraction of mandibular primary molars using Traditional Syringe
219213561|NCT04579952|DEVICE|transcranial Direct Current Stimulation|The current stimulation will be applied using 35 squares cm wide sponge electrodes
219213562|NCT05044845|BEHAVIORAL|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
219213563|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
219213564|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
219213565|NCT02754583|DRUG|Azithromycin|20mg/kg
219085500|NCT05600049|DEVICE|Prototypes (815-v1 151) to (815-v1 200)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
219085501|NCT06308679|DRUG|Empagliflozin 10 mg tablets|Empagliflozin 10 mg tablets (test drug)
219085502|NCT06308679|DRUG|JARDIANCE®|Empagliflozin 10 mg tablets (reference drug)
219213566|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
219213567|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
219213568|NCT02334865|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
219213569|NCT02334865|OTHER|Laboratory Biomarker Analysis|Correlative studies
219213570|NCT02334865|DRUG|Lenalidomide|Given PO
219213571|NCT02334865|BIOLOGICAL|Sargramostim|Given SC
219213572|NCT02334865|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
219213573|NCT06688409|DIAGNOSTIC_TEST|awake ABPM|Comparison of a BP measured with the home BP devices and the average awake ABPM performed immediately after
219213574|NCT04728295|DEVICE|Exablate 4000|Exablate Pallidothalamic Tractotomy
219213575|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
219213576|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
219213577|NCT06808945|OTHER|Prehabilitation program|Participants will be subjected to an eight week home-based multimodal prehabilitaiton program. The program consists of an exercise program, nutritional support, smoking cessation and psychological counselling.
219213578|NCT05662397|DRUG|HST-1011|HST-1011 given orally
219213579|NCT05662397|BIOLOGICAL|Cemiplimab|Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
219213580|NCT05954481|OTHER|Stress echocardiography|After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
219213581|NCT06920433|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
219213582|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
219213583|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
219213584|NCT06769009|BEHAVIORAL|Educational intervention measures on iodine, iodine deficiency and iodine intake|The intervention consist of an educational intervention which will educate the young women on the importance of iodine, the consequences of iodine deficiency, dietary iodine sources and the iodine in pregnancy. The educational intervention consist of four intervention components: an iodine feedback tool, and educational iodine conversation with a healthcare professional, an iodine factsheet and an iodine video. The healthcare professionals who carry out the educational conversation will receive a specially designed training program.
219213585|NCT06781372|BIOLOGICAL|Development and characterization of PDOs|An amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.
219361860|NCT05369819|DRUG|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
219085503|NCT01865708|DRUG|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
219085504|NCT02238925|DRUG|CPX-351|
219085505|NCT03499522|OTHER|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\]."
219085506|NCT02357004|DRUG|Carvedilol|CR 40 mg daily in addition to normal BP medications
219085507|NCT02357004|DRUG|Chlorthalidone|12.5 mg daily in addition to normal BP medications
219085508|NCT02565901|DRUG|Carboplatin|Given IV
219085509|NCT02565901|DRUG|Docetaxel|Given IV
219085510|NCT02565901|OTHER|Laboratory Biomarker Analysis|Correlative studies
219213586|NCT06781372|BIOLOGICAL|Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs|PDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, the investigators will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), the investigators will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
219213587|NCT00593840|RADIATION|Intensity modulated radiation therapy|
219213588|NCT06752759|DRUG|nebulized ketamine|The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
219213589|NCT05496829|BEHAVIORAL|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
219213590|NCT05496829|OTHER|Usual Care|Receipt of usual care from providers
219213591|NCT06789497|DRUG|Lovastatin 60 MG|Participants were given lovastatin 60 mg/day for three consecutive days.
219213592|NCT06789497|DRUG|Placebo|Participants were given placebo 60 mg/day for three consecutive days.
219213593|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
219213594|NCT06936475|DRUG|Povidone-Iodine|5% povidone iodine
219213595|NCT06936475|DRUG|Chlorhexidine Gluconate|0.5% chlorhexidine
219213596|NCT06940297|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219213597|NCT06940297|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219213598|NCT06940297|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219213599|NCT06940297|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219085511|NCT02565901|DRUG|Sirolimus|Given PO
219085512|NCT03177668|DRUG|YS110|Intravenous administration
219085513|NCT02042079|PROCEDURE|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
219085514|NCT01946022|DRUG|randomization between the two GnRH analogues (agonist and antagonist)|
219085515|NCT04563221|DEVICE|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
219085516|NCT06165406|PROCEDURE|Distal radial access|Distal radial access for coronary procedures
219213600|NCT06940297|BIOLOGICAL|Ciltacabtagene Autoleucel|Given IV
219213601|NCT06940297|PROCEDURE|Computed Tomography|Undergo CT scan
219213602|NCT06940297|DRUG|Cyclophosphamide|Given IV
219213603|NCT06940297|DRUG|Dasatinib|Given PO
219213604|NCT06940297|DRUG|Fludarabine|Given IV
219213605|NCT06940297|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219213606|NCT06940297|DRUG|Quercetin|Given PO
219085517|NCT02318043|DRUG|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
219085518|NCT00154206|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219213607|NCT06048380|DRUG|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
219213608|NCT06048380|OTHER|Placebo|Saline eye drops
219213609|NCT06948643|OTHER|Play the Oculus Quest 2|Every three to four days (roughly 72 to 96 18 19 hours), a session was held. Students were required to use the Oculus Quest 2 and touch controllers to play immersive exergames for thirty minutes during each session. In each session, they were asked to play the games Dance Central (https://www.dancecentral.com/ ) and CREED: Rise to Glory (which the researchers loaded into the Oculus Quest 2) via the Meta Quest Gaming platform (https://www.meta.com/tr-tr/experiences/creed-rise-to27 glory-championship-edition/2366245336750543/ ).
219085519|NCT04547088|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
219085520|NCT04547088|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
219085521|NCT04128293|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
219085522|NCT04128293|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
219085523|NCT02965222|DEVICE|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
219085524|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
219085525|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
219085526|NCT03019510|BEHAVIORAL|No exercise|No exercise will be done on the day of the study night to be tested
219085527|NCT03019510|BEHAVIORAL|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
219085528|NCT03019510|BEHAVIORAL|Evening exercise|Evening exercise will be done on the day of the study night to be tested
219085529|NCT03178786|BEHAVIORAL|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
219085530|NCT05542940|OTHER|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
219085531|NCT03496779|DRUG|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
219085532|NCT03496779|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
219085533|NCT03496779|DRUG|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
219213610|NCT06952920|DEVICE|electroacupuncture|The acupuncturist applied needles at four acupoints: Zusanli (ST36), Neiguan (PC6), Hegu (LI4), and Zhaohai (KI6), with insertion depths of approximately 20 mm, 15 mm, 20 mm, and 5 mm respectively. Electrical stimulation was delivered in continuous wave mode at 2 Hz frequency with current intensity ≤10 mA (adjusted according to patient tolerance), administered for 30 minutes per session.
219213611|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3.
219085534|NCT03496779|PROCEDURE|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
219085535|NCT05924542|BEHAVIORAL|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
219085536|NCT05596643|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
219085537|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
219085538|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
219213612|NCT06952920|DEVICE|sham electroacupuncture|The same acupoints as the electroacupuncture group were referenced, but with sham acupuncture (minimal insertion at non-acupoint locations) and sham electrical stimulation, while maintaining the same treatment duration and course as the electroacupuncture group.
219213613|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3. All the antiemetic drugs used are the same as those in the true acupuncture group.
219213614|NCT06952556|DRUG|ACB|15 mL of 0.25% Bupivacaine block of the saphenous nerve injected under ultrasound guidance via adductor canal.
219213615|NCT06952556|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
219085539|NCT05596643|DIAGNOSTIC_TEST|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
219085540|NCT05596643|DIAGNOSTIC_TEST|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
219213616|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-enriched milk fat globule membrane supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil), supplemented with a whey protein-enriched milk fat globule membrane (providing \~5 g of milk polar lipids) powdered ingredient. The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
219213617|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-based supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil) supplemented with a whey protein-based powdered ingredient without milk fat globule membrane (placebo) The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
219213618|NCT06953700|DIAGNOSTIC_TEST|Test of hearing function|These are measurements of hearing acuity and spatial hearing.
219213619|NCT06952946|OTHER|0.5 lt/dk fresh gas flow|Fresh gas flow will be set to 0.5 l/min in the low flow anesthesia group.
219681716|NCT04143659|BIOLOGICAL|levonorgestrel butanoate (LB) injection|"The initial formulation of the investigational product (IP) is LB Injectable Suspension at a concentration of 40 mg/2 mL (20 mg/mL). Each vial contains 2 mL at 20mg/mL for a total of 40 mg. This formulation will only be used for dosing groups A and B with the injections completed as 40 mg IM (2 mL) or 40 mg SQ (2 mL).~The second formulation of the investigational product (IP) is LB Injectable Suspension is a concentration of 140 mg/2 mL (70 mg/mL). Each vial contains 2 mL at 70 mg/mL for a total of 140 mg. This formulation will only be used for dosing groups B2, C, and D with the injections completed as 40 mg SQ (0.57 mL), 50 mg SQ (0.71 mL), and 60 mg SQ (0.86 mL)."
219681717|NCT02201589|DEVICE|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
219681718|NCT04416997|PROCEDURE|Blood and serum samples|The blood and serum samples will taken from RA patients
219681719|NCT01065558|DRUG|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
219681720|NCT01237288|DRUG|Z-521|
219085541|NCT05596643|DIAGNOSTIC_TEST|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
219085542|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to standing|clinical test to detect sympathetic dysfunction
219085543|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
219085544|NCT05596643|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
219085545|NCT05596643|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
219085546|NCT05596643|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
219085547|NCT05596643|OTHER|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
219213620|NCT06952946|OTHER|2 lt/dk fresh gas flow|Fresh gas flow will be set to 2 lt/min in the medium flow anesthesia group.
219213621|NCT06952946|OTHER|4 lt/dk fresh gas flow|Fresh gas flow will be set to 4 lt/min in the high flow anesthesia group.
219213622|NCT06949163|OTHER|Homemade formula|Patients will receive enteral feeding with a polymeric formula made from blended natural foods (apple, chayote, cookie, chicken and olive oil), adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
219213623|NCT06949163|DIETARY_SUPPLEMENT|Commercial formula|Patients will receive enteral feeding with a commercial polymeric formula, adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
219213624|NCT06952075|DRUG|GR1803|D1 given at a dose of 10ug/kg, D4 given at a dose of 30ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
219213625|NCT06951607|OTHER|Coban wrap|A Coban bandage or wrap is a self-adhering elastic wrap that sticks to itself but not to skin or clothing. It is commonly used as a wrap on limbs due to its ability to adhere to itself and not loosen. Coban is often used as a compression bandage
219085548|NCT05596643|OTHER|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
219085549|NCT00000192|DRUG|Lamotrigine|
219085550|NCT01037842|DRUG|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
219085551|NCT01037842|DRUG|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
219085552|NCT04444037|DEVICE|OCT-guided PCI|using optical coherence tomography imaging to help PCI procedure
219085553|NCT03008967|OTHER|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
219085554|NCT03728829|DRUG|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
219085555|NCT01357616|DRUG|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
219085556|NCT01357616|DRUG|Brinzolamide 1% ophthalmic suspension|
219085557|NCT01357616|DRUG|Timolol 0.5% ophthalmic solution|
219085558|NCT01418274|DRUG|danoprevir|oral doses of danoprevir
219085559|NCT01418274|DRUG|escitalopram|oral doses of escitalopram
219085560|NCT01418274|DRUG|ritonavir|oral doses of ritonavir
219085561|NCT00726206|OTHER|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
219085562|NCT05194904|DRUG|Dexmedetomidine|This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children
219085563|NCT04439643|DEVICE|vascuCAP|time to event and phenotype classification model
219085564|NCT04186780|OTHER|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
219085565|NCT01699022|DRUG|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
219085566|NCT02052310|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
219085567|NCT02052310|DRUG|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
219085568|NCT04469647|DIAGNOSTIC_TEST|Serology Test|"Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test."
219085569|NCT02650219|GENETIC|genetic analyses|
219085570|NCT02066402|DRUG|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
219085571|NCT02066402|DRUG|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
219681721|NCT00832988|OTHER|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
219681722|NCT06099730|DEVICE|Pulsed Field Ablation (PFA)|PFA using Irreversible Electroporation (IRE) Ablation System
219681723|NCT00203658|DRUG|Tinzaparin sodium|
219681724|NCT00858806|DRUG|Imatinib|"Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
219085572|NCT02066402|DRUG|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
219085573|NCT02066402|DRUG|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
219085574|NCT05035914|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
219085575|NCT02380625|DRUG|Azithromycin|Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
219085576|NCT02380625|DRUG|Sunitinib and Erlotinib|Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days
219085577|NCT02380625|DRUG|Atorvastatin and Irbesartan|Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.
219085578|NCT02380625|OTHER|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
219085579|NCT05703100|OTHER|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
219085580|NCT05703100|OTHER|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
219085581|NCT05703100|OTHER|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
219681725|NCT01923675|OTHER|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
219681726|NCT01923675|OTHER|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
219213626|NCT06951607|OTHER|Neoprene sleeve|Neoprene sleeve is an innovative treatment approach, it consists of a synthetic rubber-like material used to provide compressive support. Neoprene sleeves can provide protection, light compression and mild extension support while allowing full finger flexion.
219213627|NCT05551507|DRUG|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
219213628|NCT03561818|OTHER|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
219213629|NCT03561818|OTHER|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
219085582|NCT03001297|BIOLOGICAL|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
219085583|NCT03001297|BIOLOGICAL|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
219085584|NCT03001297|BIOLOGICAL|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
219085585|NCT03001297|BIOLOGICAL|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
219085586|NCT03001297|BIOLOGICAL|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
219085587|NCT01312870|DIETARY_SUPPLEMENT|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
219085588|NCT01312870|OTHER|standard hospital diet|standard hospital diet
219085589|NCT03434327|OTHER|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
219085590|NCT03434327|OTHER|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
219085591|NCT02203240|OTHER|Cocoa|
219085592|NCT02203240|OTHER|Placebo|
219085593|NCT02656810|DRUG|Teriparatide|Single subcutaneous injection
219085594|NCT01505387|DIETARY_SUPPLEMENT|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
219085595|NCT01505387|DIETARY_SUPPLEMENT|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
219085596|NCT01941732|DRUG|Sildenafil|
219085597|NCT04756557|OTHER|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P\&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
219085598|NCT04756557|OTHER|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P\&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
219085599|NCT04290351|PROCEDURE|band ligation|"Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
219085600|NCT04290351|DRUG|oral 450 mg diosmin+50 mg hesperidin|"450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
219085601|NCT04749732|BEHAVIORAL|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
219213630|NCT04036812|PROCEDURE|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
219213631|NCT04036812|OTHER|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
219213632|NCT04557501|DIAGNOSTIC_TEST|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
219213633|NCT04557501|OTHER|Control Arm|Control - Treatment without PSMA PET/CT
219213634|NCT05246709|DEVICE|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
219085602|NCT04749732|BEHAVIORAL|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
219213635|NCT05246709|DEVICE|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
219085603|NCT04749732|BEHAVIORAL|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
219085604|NCT01232010|DRUG|Mirodenafil|50mg Single Oral Dose of
219085605|NCT02216266|DRUG|Physostigmine|
219085606|NCT02216266|OTHER|Sodium Chloride solution|
219085607|NCT00679328|DEVICE|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
219085608|NCT05127525|DRUG|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
219085609|NCT05127525|DRUG|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
219085610|NCT02732379|PROCEDURE|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
219085611|NCT02732379|PROCEDURE|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
219085612|NCT02732379|PROCEDURE|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
219085613|NCT02732379|PROCEDURE|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
219085614|NCT01755702|DRUG|Placebo|Placebo
219085615|NCT01755702|DRUG|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
219085616|NCT01755702|DRUG|ibuprofen marketed formulation|ibuprofen marketed formulation
219085617|NCT01755702|DRUG|Paracetamol marketed formulation|Paracetamol marketed formulation
219085618|NCT06016010|DRUG|USL|500mg of Achyranthis Radix Extract
219085619|NCT06016010|DRUG|USL Placebo|USL Placebo
219085620|NCT04519086|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI \>30
219085621|NCT04519086|PROCEDURE|Laparoscopic appendectomy|All patients with BMI \>30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
219085622|NCT03692338|BEHAVIORAL|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
219085623|NCT00541918|DRUG|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
219085624|NCT00541918|DRUG|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
219085625|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
219085626|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
219085627|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
219213636|NCT06342973|DEVICE|Xenograft and allograft|For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
219213637|NCT05458258|DEVICE|Bioelectrical Impedence Analysis Device|A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.
219085628|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
219085629|NCT02392325|BIOLOGICAL|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)
219085630|NCT02392325|BIOLOGICAL|Placebo|Administered subcutaneously in 0.5 mL
219085631|NCT02392325|BIOLOGICAL|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
219361861|NCT05369819|DRUG|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
219681727|NCT01923675|OTHER|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
219085632|NCT02960399|BIOLOGICAL|Zostavax®|Zostavax® immunization
219085633|NCT02361125|DRUG|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
219085634|NCT02361125|BEHAVIORAL|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
219085635|NCT04735744|OTHER|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
219085636|NCT01260844|DRUG|briakinumab|single dose briakinumab and 2 doses of CYP substrates
219213638|NCT05458258|OTHER|6 Minute Walk Test|Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.
219213639|NCT05458258|DIAGNOSTIC_TEST|Computed Tomography Scans to Measure Skeletal Muscular Index|Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).
219213640|NCT05458258|DIAGNOSTIC_TEST|Blood Test/Blood Draw|Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.
219213641|NCT05458258|OTHER|Hand Grip Strength Test|Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.
219213642|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
219213643|NCT00683670|DRUG|cyclophosphamide|
219213644|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
219213645|NCT05787054|OTHER|Third trimester ultrasound|Single scan versus Longitudinal scan
219213646|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219213647|NCT04530487|DRUG|Cyclosporine|Given IV and PO
219213648|NCT04530487|DRUG|Etoposide|Given IV
219213649|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
219213650|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
219213651|NCT04530487|DRUG|Melphalan|Given IV
219213652|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
219213653|NCT04530487|DRUG|Tacrolimus|Given IV and PO
219213654|NCT04530487|DRUG|Thiotepa|Given IV
219213655|NCT06432998|OTHER|Perineal massage|The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.
219213656|NCT06432998|OTHER|Standard treatment|The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
219213657|NCT04926324|DRUG|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
219681728|NCT01923675|OTHER|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
219681729|NCT01695005|DRUG|LY3039478|Administered orally
219085637|NCT03536286|BEHAVIORAL|Encouragement|Households will be visited and encouraged to enroll in Asili
219085638|NCT00594854|DRUG|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
219085639|NCT00594854|DRUG|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
219085640|NCT01187979|BEHAVIORAL|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
219085641|NCT01187979|BEHAVIORAL|Life skills curriculum|Standard department of education lifeskills curriculum
219085642|NCT04732091|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
219085643|NCT06201130|DIAGNOSTIC_TEST|Suctioning of artificial airway|Collection of tracheal aspirates in either the PICU or NICU will occur. We will instill 1 mL of normal saline, then perform bag ventilation, and then suction out aspirate. Suctioning is routinely performed for tracheostomy and endotracheal tube hygiene - for instance, it is performed on tracheostomies by caregivers at home. The aspirates that will be collected will be clinically indicated and otherwise would be discarded. If the patients weren't enrolled in this research, the aspirates would have been collected anyways.
219085644|NCT03144414|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy
219085645|NCT03309839|OTHER|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
219213658|NCT04926324|DRUG|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
219213659|NCT04926324|RADIATION|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
219213660|NCT05023434|PROCEDURE|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
219213661|NCT04356729|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
219213662|NCT04356729|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
219213663|NCT01595451|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
219681730|NCT01695005|DRUG|Prednisone|Administered orally
219213664|NCT06326788|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus pushups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till 60-70% of their maximum heart rate is achieved and maintained."
219085646|NCT03172702|DRUG|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
219085647|NCT05343416|PROCEDURE|Open abdomen procedure|All patients underwent to open abdomen procedure
219085648|NCT05458375|DRUG|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
219085649|NCT03118921|DEVICE|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
219213665|NCT06326788|BEHAVIORAL|SUSTAINED SOLEUS PUSH-UPS|"Participants will start soles push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum 4-minute break time after every 90 mins intervention. In the meantime, their blood sample will be collected."
219213666|NCT00655499|DRUG|Panitumumab|6 mg/kg
219213667|NCT00655499|DRUG|Irinotecan hydrochloride|180 mg/kg
219213668|NCT00655499|GENETIC|Chromogenic in situ hybridization|
219213669|NCT00655499|GENETIC|Fluorescence in situ hybridization|
219213670|NCT00655499|GENETIC|Gene expression analysis|
219213671|NCT00655499|OTHER|Laboratory biomarker analysis|
219213672|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
219213673|NCT06074744|OTHER|SSNB + IPACK|already included in arm/group description
219213674|NCT06074744|OTHER|FNB + IPACK|already included in arm/group description
219213675|NCT06098105|PROCEDURE|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
219213676|NCT06098105|PROCEDURE|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
219213677|NCT06098105|PROCEDURE|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
219213678|NCT06098105|DRUG|Bupivacaine|bupivacaine
219213679|NCT06519617|DRUG|Yi Qi Yang Yin Decoction|The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
219213680|NCT06519617|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
219213681|NCT06091449|OTHER|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
219213682|NCT06091449|OTHER|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
219213683|NCT06411041|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT) and yoga|The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
219213684|NCT00838461|DRUG|HSD-016|
219213685|NCT00838461|DRUG|placebo|
219213686|NCT00772044|DEVICE|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
219085650|NCT05807581|OTHER|physical activity|treadmill running 3 times weekly
219085651|NCT05807581|OTHER|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
219085652|NCT02967614|DRUG|[A]|One eye drop(about 40ul) / Day1 \~ Day8 / BID
219085653|NCT02967614|DRUG|[B]|One eye drop(about 40ul) / Day1 \~ Day92 / BID
219085654|NCT02967614|DRUG|[A]+[B](1)|One eye drop(about 40ul) / Day9 \~ Day100 / BID
219085655|NCT02967614|DRUG|[A]+[B](2)|One eye drop(about 40ul) / Day93 \~ Day100 / BID
219085656|NCT03786952|BEHAVIORAL|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
219213687|NCT00772044|DEVICE|Sham Device|Sham device will be applied
219681731|NCT03284034|DEVICE|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
219085657|NCT03786952|BEHAVIORAL|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
219213688|NCT06950307|RADIATION|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer patients|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer will be treated with 20x3 Gray (Gy), 5 days/week
219213689|NCT06950307|RADIATION|Hypofractionated radiotherapy for high-risk prostate cancer patients|Hypofractionated radiotherapy for high-risk prostate cancer will be treated with 20x3.1 Gy, 5 days/week
219213690|NCT05677269|PROCEDURE|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
219213691|NCT05677269|PROCEDURE|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
219213692|NCT04421365|DEVICE|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
219213693|NCT00990808|DRUG|anacetrapib|\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
219213694|NCT00990808|DRUG|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
219213695|NCT00990808|DRUG|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
219213696|NCT00990808|DRUG|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
219213697|NCT01184326|DRUG|pazopanib|
219213698|NCT01184326|DRUG|everolimus|
219213699|NCT01739244|DRUG|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
219213700|NCT01739244|DRUG|Placebo|Ocular topical administration of placebo for 14 consecutive days
219085658|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
219213701|NCT03755752|PROCEDURE|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
219213702|NCT04689178|OTHER|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
219213703|NCT04689178|OTHER|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
219213704|NCT04480385|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
219213705|NCT06461585|OTHER|Sprint interval training|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes. Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
219213706|NCT02549807|DEVICE|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
219213707|NCT00083967|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
219213708|NCT03621735|DEVICE|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
219213709|NCT03621735|DEVICE|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
219361694|NCT02965079|DEVICE|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
219361695|NCT03792074|DRUG|SCT510|SCT510 Injection
219361696|NCT03792074|DRUG|Bevacizumab|Bevacizumab Injection
219361697|NCT03792074|DRUG|Paclitaxel|Paclitaxel Injection
219085659|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
219085660|NCT03786952|BEHAVIORAL|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
219085661|NCT03786952|BEHAVIORAL|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
219085662|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
219085663|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
219085664|NCT03320616|DRUG|EYP001a|Oral EYP001a capsules - 100 mg strength
219085665|NCT03113123|DRUG|PrEP with Truvada®|"Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
219085666|NCT05290857|OTHER|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
219085667|NCT05290857|OTHER|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
219085668|NCT01682993|OTHER|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
219085669|NCT01682993|OTHER|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
219085670|NCT02084459|BEHAVIORAL|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
219085671|NCT03683147|OTHER|Laboratory Biomarker Analysis|Correlative studies
219085672|NCT03683147|BEHAVIORAL|Meditation-Based Stress Reduction Program|Participate in 6-week online program
219085673|NCT03683147|OTHER|Quality-of-Life Assessment|Ancillary studies
219085674|NCT03683147|OTHER|Questionnaire Administration|Ancillary studies
219085675|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
219085676|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
219085677|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
219085678|NCT05518383|DRUG|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
219085679|NCT03468933|DRUG|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
219085680|NCT03468933|PROCEDURE|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
219085681|NCT05534022|DEVICE|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
219085682|NCT06433531|DRUG|TQH2929 Injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
219085683|NCT05088889|DRUG|Nivolumab|Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
219085684|NCT05088889|DRUG|ipilimumab|Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
219085685|NCT05088889|RADIATION|Stereotactic body radiation therapy|Three fractions of 8 Gy, treated on alternate days
219085686|NCT05088889|RADIATION|Low dose irradiation|a single fraction of 2Gy will be given to the metastatic lesions at first progression
219085687|NCT01186029|DRUG|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
219085688|NCT05275192|DEVICE|Videoscope-assisted periodontal regeneration minimally invasive surgery|Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
219085689|NCT05275192|PROCEDURE|Periodontal regeneration minimally invasive surgery|Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
219213710|NCT06458179|PROCEDURE|Ultrasound-guided proximal greater occipital nerve radiofrequency ablation|In the prone position with the head slightly flexed and the US probe was placed in the neck transversely and then was located the bifid spinous process of C2 and the probe was lateralized (toward the affected side). At this level, the GON is located above the obliquus capitis inferior muscle and deeper than the semispinalis capitis muscle. The in-plane approach from medial to lateral was employed to treat the nerve with a 21 G 5-mm active tip radiofrequency needle. Sensory stimulation was administered at 50 Hz for 1 ms to induce paresthesia, pain, or irritation. A motor stimulus was applied at 2 Hz for 1 ms and up to 2 volts to see if fasciculation was absent. Then 1 mL of 2% lidocaine was administered through the RF cannulas to alleviate procedure related pain. Conventional RFA was conducted for 60 seconds at a temperature of 60 degrees. Following the procedure, 2 mg of dexamethasone was administered per lesion site.
219213711|NCT01521169|OTHER|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
219213712|NCT01521169|OTHER|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
219213713|NCT01521169|OTHER|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
219213714|NCT06026800|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
219213715|NCT00143130|DRUG|Pregabalin|Pregabalin
219361698|NCT03792074|DRUG|Carboplatin|Carboplatin injection
219361699|NCT02312947|DEVICE|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
219361700|NCT02312947|DEVICE|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
219085690|NCT05275192|PROCEDURE|Guided tissue regeneration surgery|Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
219085691|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
219085692|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
219085693|NCT06134180|BEHAVIORAL|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
219085694|NCT06254469|DRUG|[F-18]Flornaptitril|All participants will receive a single dose of F-18 FNT during an imaging visit.
219085695|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
219085696|NCT02152982|OTHER|Laboratory Biomarker Analysis|Correlative studies
219085697|NCT02152982|OTHER|Placebo Administration|Given PO
219085698|NCT02152982|OTHER|Quality-of-Life Assessment|Ancillary studies
219085699|NCT02152982|DRUG|Temozolomide|Given PO
219085700|NCT02152982|DRUG|Veliparib|Given PO
219085701|NCT04377555|DRUG|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
219085702|NCT04219670|DIAGNOSTIC_TEST|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
219085703|NCT04697576|BIOLOGICAL|Ipilimumab|immune checkpoint inhibitor
219085704|NCT04697576|BIOLOGICAL|Nivolumab|immune checkpoint inhibitor
219085705|NCT04697576|BIOLOGICAL|Pembrolizumab|immune checkpoint inhibitor
219361701|NCT00576173|DRUG|tramadol hydrochloride; acetaminophen|
219085706|NCT04697576|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
219085707|NCT04697576|PROCEDURE|Resection|Undergo surgical resection
219213716|NCT04039906|DEVICE|Removal of needle with using ANDYs|"1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
219213717|NCT04805736|PROCEDURE|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
219213718|NCT04805736|DRUG|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
219085708|NCT04697576|BIOLOGICAL|Nivolumab + Relatlimab|immune checkpoint inhibitor
219085709|NCT02141763|DRUG|UCB4940 40 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219085710|NCT02141763|DRUG|UCB4940 80 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219213719|NCT04805736|PROCEDURE|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
219213720|NCT00575016|BIOLOGICAL|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor
219213721|NCT00575016|BIOLOGICAL|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
219213722|NCT00575016|BIOLOGICAL|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
219213723|NCT00575016|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
219213724|NCT01149759|DRUG|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
219213725|NCT02350400|DEVICE|DEBIRI|DEBIRI TACE
219213726|NCT04775810|DEVICE|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
219213727|NCT04242212|BEHAVIORAL|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
219213728|NCT04242212|BEHAVIORAL|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
219213729|NCT00192218|BIOLOGICAL|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
219213730|NCT03422549|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
219213731|NCT04898569|DRUG|Ferinject|Ferric carboxymaltose injection
219213732|NCT04898569|DRUG|Normal Saline Flush|placebo
219213733|NCT05694832|BEHAVIORAL|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
219213734|NCT03234374|COMBINATION_PRODUCT|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
219213735|NCT03234374|DRUG|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
219213736|NCT05031923|PROCEDURE|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
219213737|NCT05031923|PROCEDURE|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
219085711|NCT02141763|DRUG|UCB4940 160 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219085712|NCT02141763|DRUG|UCB4940 240 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219213738|NCT03294967|DIETARY_SUPPLEMENT|Caffeine|As in group descriptions
219213739|NCT03294967|DIETARY_SUPPLEMENT|Vitamin E|As in group descriptions
219213740|NCT03455985|OTHER|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
219213741|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
219361702|NCT06528886|PROCEDURE|hysterectomy by V-NOTES|V-notes is like laparoscopy via the vaginal route.
219085713|NCT02141763|DRUG|UCB4940 320 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219681732|NCT03284034|DRUG|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
219681733|NCT03612466|DRUG|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
219085714|NCT02141763|DRUG|UCB4940 560 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
219085715|NCT02141763|OTHER|Placebo|"* Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous"
219085716|NCT05771337|DIAGNOSTIC_TEST|blood sample|blood sample
219085717|NCT05374954|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
219085718|NCT05374954|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
219085719|NCT01870193|DIETARY_SUPPLEMENT|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
219085720|NCT06191419|OTHER|Odorants|Each smoker is assigned a CPAP nose mask. Odor sample bags are attached to the mask. Smokers open the valve, inhale once through the nose, close the valve, remove the bag from the mask and report on the odor.
219085721|NCT03892993|OTHER|Decision Aid|Use decision aid
219085722|NCT03892993|OTHER|Questionnaire Administration|Ancillary studies
219085723|NCT00432250|PROCEDURE|Cervical length ultrasound|
219085724|NCT03065387|DRUG|Everolimus|Given PO
219681734|NCT03612466|RADIATION|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
219681735|NCT03612466|DRUG|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
219681736|NCT03612466|DRUG|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
219681737|NCT03612466|DRUG|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
219681738|NCT04206345|OTHER|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
219085725|NCT03065387|DRUG|Neratinib|Given PO
219085726|NCT03065387|DRUG|Palbociclib|Given PO
219085727|NCT03065387|DRUG|Trametinib|Given PO
219085728|NCT06561178|DIAGNOSTIC_TEST|molecular residual disease detection|ctDNA detection
219085729|NCT06412653|DRUG|Zinc Acetate Dihydrate|In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
219085730|NCT03586661|DRUG|Copanlisib|Given IV
219085731|NCT03586661|DRUG|Niraparib|Given PO
219681739|NCT04206345|OTHER|exercise|Elbow bending exercises
219085732|NCT05917652|BEHAVIORAL|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
219085733|NCT04026295|BEHAVIORAL|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
219085734|NCT04026295|BEHAVIORAL|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of \< 6/10.
219213742|NCT06498817|BEHAVIORAL|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
219085735|NCT05141019|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
219085736|NCT04345393|BEHAVIORAL|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
219085737|NCT04889573|GENETIC|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
219085738|NCT06250270|DIETARY_SUPPLEMENT|protein or placebo|casein protein (30g) or placebo (maltodextrin, 30g)
219085739|NCT06231355|DRUG|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
219085740|NCT06231355|DRUG|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
219085741|NCT01409161|DRUG|Arsenic Trioxide|Given IV
219085742|NCT01409161|DRUG|Gemtuzumab Ozogamicin|Given IV
219085743|NCT01409161|OTHER|Laboratory Biomarker Analysis|Correlative studies
219085744|NCT01409161|DRUG|Tretinoin|Given PO
219085745|NCT05617313|DRUG|Pembrolizumab|200 mg intravenously on Day 1 of cycle.
219085746|NCT05617313|DRUG|GT103|10mg/kg taken intravenously on Day 1 of cycle.
219085747|NCT06464653|DEVICE|Forel's Field H-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy. The targets used in this study is Forel's Field H. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
219085748|NCT05046301|PROCEDURE|Biospecimen Collection|Correlative studies
219085749|NCT05046301|OTHER|Contrast Agent|Given IV
219085750|NCT05046301|PROCEDURE|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
219213743|NCT06498817|BEHAVIORAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
219213744|NCT05161000|OTHER|Oral Nutritional Supplement|ONS plus dietary counseling
219213745|NCT05161000|OTHER|Dietary counseling|dietary counseling
219213746|NCT02435485|DEVICE|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
219213747|NCT02435485|OTHER|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
219213748|NCT04239768|DEVICE|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
219213749|NCT03239704|BEHAVIORAL|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
219213750|NCT03239704|OTHER|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
219361703|NCT06503445|OTHER|education video|"the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video."
219085751|NCT05046301|OTHER|Questionnaire Administration|Ancillary studies
219085752|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
219085753|NCT04628442|PROCEDURE|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
219213751|NCT03239704|BEHAVIORAL|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
219213752|NCT02347332|DRUG|Vinflunine|
219213753|NCT02347332|DRUG|Methotrexate|
219213754|NCT00253266|DRUG|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
219213755|NCT00253266|DRUG|Quetiapine|Quetiapine up to 200 mg/d for four weeks
219213756|NCT04574466|BEHAVIORAL|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
219213757|NCT04996407|DEVICE|survival thermal blanket|patients were given a thermal blanket
219213758|NCT04996407|DEVICE|draping fabric|Patients were given a draping fabric
219213759|NCT03941106|DEVICE|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
219085754|NCT04628442|PROCEDURE|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
219085755|NCT04628442|PROCEDURE|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
219085756|NCT04153227|DIAGNOSTIC_TEST|Bone mineral density (BMD)|Bone mineral density (BMD) is measured by Dual-energy X-ray absorptiometry (DXA). BMD provides a measure of bone mass.
219085757|NCT04153227|DIAGNOSTIC_TEST|Trabecular bone score (TBS)|The Trabecular Bone Score (TBS) is a novel gray-level texture measurement that can be extracted from DXA images. TBS provides a measure of bone quality (bone microarchitecture).
219085758|NCT04153227|DIAGNOSTIC_TEST|Fracture risk Assessment Tool (FRAX)|The Fracture risk Assessment Tool (FRAX) is a fracture risk calculator that estimates an individual's 10-year probability of incurring a hip or other major osteoporotic fracture.
219085759|NCT06013878|OTHER|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
219085760|NCT05809635|OTHER|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
219085761|NCT03844620|OTHER|Best Practice|Receive SOC
219085762|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
219085763|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
219085764|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
219085765|NCT03844620|DRUG|Regorafenib|Given by mouth
219085766|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
219085767|NCT05338658|DRUG|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
219085768|NCT03131908|DRUG|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
219213760|NCT04813991|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
219213761|NCT04813991|DRUG|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
219213762|NCT05643521|OTHER|Dietary composition of macronutrients and calories|Carbohydrate restriction
219213763|NCT04569188|BIOLOGICAL|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
219213764|NCT04890938|COMBINATION_PRODUCT|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
219213765|NCT04890938|OTHER|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
219361704|NCT04668859|DRUG|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
219085769|NCT03131908|DRUG|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
219085770|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
219085771|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
219085772|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
219085773|NCT06577623|BEHAVIORAL|MINDful TIME|Group-based psychoeducational mindfulness-based intervention.
219085774|NCT03482479|DRUG|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
219085775|NCT03482479|OTHER|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
219085776|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
219085777|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
219085778|NCT04895475|BEHAVIORAL|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
219085779|NCT04671784|OTHER|EUS-E|EUS-E
219085780|NCT03703856|DRUG|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
219085781|NCT03703856|DRUG|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
219085782|NCT05493774|OTHER|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
219085783|NCT05493774|OTHER|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
219085784|NCT00812786|DRUG|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
219085785|NCT05337514|BEHAVIORAL|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
219085786|NCT05337514|BEHAVIORAL|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
219085787|NCT06335719|PROCEDURE|BES|Nerve biopsies during surgery + brief electrical stimulation therapy
219085788|NCT06335719|PROCEDURE|Standard of Care surgery|Nerve biopsies during surgery - no brief electrical stimulation therapy
219085789|NCT06430424|BIOLOGICAL|Relapsed glioblastoma|Paired tumor samples diagnosis/relapse
219085790|NCT02727296|DRUG|sevoflurane|General anesthesia with sevoflurane
219085791|NCT02727296|DRUG|propofol|General anesthesia with propofol
219085792|NCT03579316|DRUG|Adavosertib|Given PO
219085793|NCT03579316|DRUG|Olaparib|Given PO
219085794|NCT03579316|DRUG|Ceralasertib|Given PO
219085795|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
219085796|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
219085797|NCT06258018|DRUG|Temodal|given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
219213766|NCT06199115|PROCEDURE|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
219213767|NCT00362960|DRUG|Olmesartan medoxomil|
219085798|NCT06258018|DRUG|Niraparib|given orally in continous
219085799|NCT02650648|DRUG|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
219085800|NCT02650648|BIOLOGICAL|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10\^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
219213768|NCT00362960|DRUG|Losartan|
219085801|NCT02650648|BIOLOGICAL|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over \~30-90 minutes
219085802|NCT02650648|DRUG|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10\^5 U/m\^2/day.
219085803|NCT06024538|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
219085804|NCT06199258|DIAGNOSTIC_TEST|pulmonary function test|pulmonary function testing
219085805|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
219085806|NCT04112641|DRUG|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
219085807|NCT04112641|DRUG|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
219085808|NCT01146509|DRUG|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
219085809|NCT00853814|BEHAVIORAL|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
219085810|NCT06198465|DRUG|adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil|adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
219085811|NCT04189718|PROCEDURE|osseodensification protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
219085812|NCT04189718|PROCEDURE|conventional implant site preparation protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
219085813|NCT02676375|DRUG|Combination Bupropion + NRTs|
219085814|NCT02676375|OTHER|Extended Treatment|
219085815|NCT02676375|OTHER|Home Visits & Calls|
219085816|NCT02676375|DRUG|Monotherapy|
219681740|NCT03783117|DEVICE|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
219681741|NCT03539276|BEHAVIORAL|Knowledge exchange|OptimaMed
219085817|NCT00569582|DRUG|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
219681742|NCT00335517|DRUG|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
219085818|NCT04674241|DRUG|Dexmedetomidine|Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
219085819|NCT04674241|DRUG|0.9% saline|0.9% saline is administered with the same volume at the same speed as the other group.
219085820|NCT05586152|DRUG|INV-102|INV-102 Ophthalmic Solution
219085821|NCT05586152|DRUG|Vehicle|Vehicle Ophthalmic Solution
219085822|NCT00464802|DRUG|MOA-728|
219085823|NCT00487617|PROCEDURE|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
219213769|NCT01847456|DRUG|human insulin as nasal spray|
219213770|NCT01847456|DRUG|Placebo|
219213771|NCT01331499|DEVICE|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
219213772|NCT01331499|PROCEDURE|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
219213773|NCT03078205|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
219213774|NCT03078205|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
219213775|NCT04416321|DEVICE|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
219213776|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
219213777|NCT00110552|DRUG|Salvia officinalis (sage)|oral dosage
219213778|NCT00435318|PROCEDURE|Iontophoresis|
219213779|NCT05845515|PROCEDURE|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
219213780|NCT03910855|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
219085824|NCT05688748|OTHER|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
219213781|NCT03910855|OTHER|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
219085825|NCT03230773|DEVICE|Defibrillator model|Comparison of the performance of different public access defibrillators
219213782|NCT05551286|OTHER|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
219213783|NCT04544982|OTHER|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
219681743|NCT01162044|OTHER|Computer game|Playing with specially designed computer game while in emergency room
219681744|NCT06428266|DEVICE|Bicanalicular intubation|Placement of the bicanalicular intubation set at each lacrimal point and fixed by means of its flaps at the level of the opening of the lacrimal sac.
219085826|NCT01011621|DRUG|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
219085827|NCT01011621|DRUG|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
219085828|NCT00762450|DRUG|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
219085829|NCT00762450|DRUG|fluoride|Rinse 3 times daily with assigned toothpaste slurry
219085830|NCT00762450|DRUG|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
219085831|NCT03905330|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
219085832|NCT03905330|OTHER|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
219085833|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
219085834|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
219085835|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
219085836|NCT04433884|DEVICE|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
219085837|NCT02502201|OTHER|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
219085838|NCT02502201|OTHER|six-minute walk study outdoors|Performance of a six-minute walk test.
219085839|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System|
219213784|NCT04544982|OTHER|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
219213785|NCT00802126|DRUG|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
219213786|NCT04678375|DIAGNOSTIC_TEST|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
219213787|NCT00002381|DRUG|Nelfinavir mesylate|
219213788|NCT00002381|DRUG|Nevirapine|
219213789|NCT00002381|DRUG|Stavudine|
219681745|NCT06428266|PROCEDURE|Closed dacryointubation|Placement of dacryointubation tube through the canaliculus until it reaches the medial wall of the lacrimal sac and then passed the nasolacrimal duct until it empties out at the level of the inferior meatus.
219681746|NCT03720925|PROCEDURE|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
219681747|NCT05630482|BEHAVIORAL|Healthy Family Foundations|Healthy Family Foundations Curriculum
219681748|NCT05630482|OTHER|Standard of Care|Standard of Care
219085840|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System.|
219085841|NCT06491472|DRUG|Ivonescimab|20mg/kg,IV,d1,Q3W
219213790|NCT06515678|DRUG|arm A - angiotensin converting enzyme inhibitors (ACEi)|"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"
219213791|NCT06515678|DRUG|arm B - calcium channel blockers (CCBs)|"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"
219213792|NCT06515678|DRUG|arm R - angiotensin receptor blockers ARB|"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."
219213793|NCT00954668|PROCEDURE|immediate angiography and revascularization|immediate angiography \< 2 hours after randomization
219085842|NCT06491472|DRUG|Gemcitabine|1000mg/m2, IV, d1/8, Q3W
219085843|NCT06491472|DRUG|Nab paclitaxel|125mg/m2, IV, d1/8, Q3W
219085844|NCT06491472|RADIATION|SBRT|5Gy \*5 F
219085845|NCT02001766|BEHAVIORAL|Exercise training|
219085846|NCT06024226|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
219085847|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
219085848|NCT05694741|DRUG|AZD0186|Subjects will receive AZD0186 orally.
219085849|NCT05694741|DRUG|Placebo|Subjects will receive placebo orally.
219085850|NCT04989075|OTHER|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
219085851|NCT05759078|DRUG|Ferinject|The first dose of either FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7). If safety criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
219085852|NCT05759078|DRUG|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7).
219085853|NCT05261152|DRUG|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
219085854|NCT01508429|OTHER|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
219085855|NCT01508429|DRUG|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
219085856|NCT06078462|OTHER|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
219213794|NCT00954668|PROCEDURE|early invasive angiography|early invasive angiography 12-72 h after randomization
219213795|NCT03484910|OTHER|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
219213796|NCT00557596|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
219213797|NCT06398600|PROCEDURE|Caudal|In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
219085857|NCT03087071|OTHER|Laboratory Biomarker Analysis|Correlative studies
219085858|NCT03087071|BIOLOGICAL|Panitumumab|Given IV
219085859|NCT03087071|DRUG|Trametinib|Given PO
219085860|NCT02652741|DRUG|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
219085861|NCT02782169|DRUG|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
219085862|NCT02782169|DRUG|Placebo|Matching placebo capsule with excipient to match Pregabalin
219085863|NCT02975973|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
219213798|NCT06398600|PROCEDURE|Quadratus lumborum plane block|The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
219361705|NCT04668859|DRUG|Methylcellulose|Placebo will consist of inert methylcellulose
219213799|NCT02362139|DRUG|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
219213800|NCT06562907|DRUG|GS-4571|Administered orally
219085864|NCT04220177|DEVICE|SETA LATECBA Stent Grafts|ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
219213801|NCT06562907|DRUG|Placebo|Administered orally
219213802|NCT06562907|DRUG|Omeprazole|Administered orally
219085865|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 100 ug/kg
219085866|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 300 ug/kg
219085867|NCT00771810|DRUG|Placebo|Once daily subcutaneous injection of placebo
219085868|NCT00989248|OTHER|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
219085869|NCT02942108|PROCEDURE|piezo surgery|
219085870|NCT02942108|PROCEDURE|conventional surgery|
219085871|NCT05524974|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
219085872|NCT05524974|DRUG|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
219085873|NCT05524974|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
219085874|NCT05524974|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
219085875|NCT05524974|DRUG|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
219085876|NCT01900782|BIOLOGICAL|Intervention A|Prefilled syringe.
219085877|NCT01900782|BIOLOGICAL|Intervention B|Prefilled syringe.
219085878|NCT01900782|BIOLOGICAL|Placebo|Prefilled syringe to match experimental drug and active comparator.
219085879|NCT01953848|DRUG|EC905|Oral
219085880|NCT04640532|DRUG|KRT-232|KRT-232, administered by mouth
219085881|NCT04640532|DRUG|TL-895|TL-895, administered by mouth
219085882|NCT01489995|DRUG|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
219085883|NCT01489995|DRUG|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
219085884|NCT01489995|DRUG|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
219085885|NCT01489995|DRUG|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
219085886|NCT01489995|DRUG|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
219085887|NCT01832116|DRUG|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
219085888|NCT05916651|BEHAVIORAL|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
219085889|NCT05916651|BEHAVIORAL|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
219085890|NCT01727739|DEVICE|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
219085891|NCT01727739|DEVICE|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
219085892|NCT04802941|DEVICE|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
219213803|NCT01834846|PROCEDURE|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
219213804|NCT01834846|PROCEDURE|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
219213805|NCT00874536|DIETARY_SUPPLEMENT|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
219213806|NCT00874536|DIETARY_SUPPLEMENT|Placebo|
219085893|NCT04802941|DRUG|General practice|General practice
219085894|NCT05275257|DEVICE|Use of Uricap Female, a New Urine Collecting Device|The uridome is changed daily by trained staff
219213807|NCT05435794|DEVICE|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
219213808|NCT05435794|DEVICE|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
219213809|NCT02839395|OTHER|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
219213810|NCT02839395|OTHER|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
219213811|NCT02839395|OTHER|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
219213812|NCT00112359|DRUG|AZLI 75 mg three times a day (TID)|
219213813|NCT00112359|DRUG|Placebo three times a day (TID)|
219213814|NCT05652075|PROCEDURE|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
219085895|NCT04779138|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
219213815|NCT05652075|PROCEDURE|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
219085896|NCT03043508|OTHER|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
219085897|NCT03043508|BEHAVIORAL|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
219085898|NCT06104033|DEVICE|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
219085899|NCT06104033|DEVICE|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
219085900|NCT05721534|OTHER|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
219085901|NCT00255931|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
219085902|NCT00255931|BEHAVIORAL|Attention Placebo|Untrained relaxation
219213816|NCT02576275|DRUG|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
219213817|NCT02576275|DRUG|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
219085903|NCT01127867|DIETARY_SUPPLEMENT|dietary intervention|dietary intervention
219085904|NCT01579734|DRUG|Tamoxifen|1 tablet, 5 mg / day for 5 years
219085905|NCT01579734|DRUG|Placebo|1 tablet day for 5 years
219085906|NCT04732455|DRUG|Lidocaine in Saline|Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
219085907|NCT04732455|DRUG|Duloxetine 30 MG|Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
219085908|NCT04732455|DRUG|Normal saline|200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
219085909|NCT00100451|PROCEDURE|exercise|
219213818|NCT02576275|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
219213819|NCT02576275|DRUG|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
219213820|NCT01467128|OTHER|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
219213821|NCT01467128|OTHER|No Intervention|Normal hospital pharmaceutical care
219085910|NCT02660827|DEVICE|Insulin Pump|Closed Loop Algorithm
219213822|NCT02530190|DEVICE|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
219213823|NCT02530190|PROCEDURE|massage|20 minutes of massage to lower extremities
219213824|NCT05985408|DEVICE|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
219213825|NCT05985408|DEVICE|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
219213826|NCT05566444|DEVICE|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
219213827|NCT05430087|DRUG|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
219085911|NCT01833338|DEVICE|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
219085912|NCT01792180|BEHAVIORAL|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
219085913|NCT03071055|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection
219085914|NCT02679261|DRUG|Atorvastatin|Oral administration atorvastatin 20 mg per day
219085915|NCT02679261|DRUG|Placebo|Oral administration placebo
219085916|NCT05938985|DIAGNOSTIC_TEST|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
219085917|NCT05099042|OTHER|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
219085918|NCT04823429|BEHAVIORAL|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
219085919|NCT04823429|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
219085920|NCT02373800|DEVICE|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
219085921|NCT01832428|OTHER|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
219085922|NCT00566683|DRUG|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
219213828|NCT01988402|DRUG|allopurinol|
219213829|NCT01988402|DRUG|Placebo (sugar pill)|
219213830|NCT01961609|BIOLOGICAL|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
219213831|NCT04755504|DIAGNOSTIC_TEST|EEG behind the ear|2 additional electrodes behind each ear will record EEG
219213832|NCT03402854|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
219213833|NCT03402854|BEHAVIORAL|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
219213834|NCT02766946|DEVICE|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
219213835|NCT02766946|DEVICE|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
219213836|NCT02766946|OTHER|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
219213837|NCT02766946|OTHER|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
219213838|NCT01262339|DRUG|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
219213839|NCT03132688|DRUG|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
219213840|NCT00571649|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
219213841|NCT00571649|DRUG|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
219213842|NCT00571649|DRUG|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
219213843|NCT00571649|DRUG|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
219213844|NCT03664882|DRUG|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
219213845|NCT03664882|DRUG|Placebo|Pharmaceutical form: tablet Route of administration: oral
219213846|NCT00582972|DRUG|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
219213847|NCT02206815|DRUG|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
219213848|NCT02206815|DRUG|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
219085923|NCT00566683|DRUG|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
219213849|NCT05305391|OTHER|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
219213850|NCT00588406|DRUG|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
219085924|NCT00520858|OTHER|Resistance Exercise (RE)|
219085925|NCT00520858|OTHER|Aerobic Exercise (AE)|
219085926|NCT00520858|OTHER|Resistance and Aerobic Exercise (RAE)|
219085927|NCT01647490|PROCEDURE|Permanent Cardiac Pacemaker Implantation|
219085928|NCT05566600|BIOLOGICAL|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
219085929|NCT02336334|DEVICE|Positioning measurement|Logging of posturing informations
219085930|NCT02336334|DEVICE|Patient feedback|Evaluation of patients questionary
219085931|NCT02336334|PROCEDURE|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
219085932|NCT02336334|DEVICE|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
219085933|NCT04274673|DEVICE|measuring cotinine level|Measuring of the cotinine levels
219085934|NCT00611000|DIETARY_SUPPLEMENT|folic acid|
219085935|NCT00611000|GENETIC|DNA methylation analysis|
219085936|NCT00611000|GENETIC|gene expression analysis|
219085937|NCT00611000|GENETIC|microarray analysis|
219213851|NCT00588406|DRUG|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
219213852|NCT00588406|DRUG|Ipratropium bromide|2.5 mg, one dose
219213853|NCT00588406|DRUG|Prednisone|60mg PO
219213854|NCT03342820|PROCEDURE|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
219213855|NCT01566890|DRUG|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
219213856|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
219213857|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
219213858|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
219213859|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
219213860|NCT03983434|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
219085938|NCT00611000|GENETIC|polymorphism analysis|
219085939|NCT00611000|OTHER|laboratory biomarker analysis|
219085940|NCT02953938|BIOLOGICAL|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
219085941|NCT02953938|RADIATION|Grid&Direct short pulse laser photocoagulation|Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
219085942|NCT05735574|OTHER|IPG infections|Infected IPGs
219085943|NCT04137692|OTHER|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
219085944|NCT02142933|OTHER|vagino-perineal swab|
219085945|NCT01220700|OTHER|Triclosane|Triclosane coated suture material
219085946|NCT01220700|OTHER|Control|Ordinary suture material
219085947|NCT05810168|OTHER|Dietary modifications|TDA and low FODMAP diet
219085948|NCT00262587|DRUG|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
219085949|NCT00262587|DRUG|Placebo|Inhaled sugar powder in a placebo inhaler
219213861|NCT06387576|BEHAVIORAL|Behaviorally informed pre-discharge iPad video scheduling|The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
219213862|NCT03934528|DEVICE|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
219213863|NCT05559801|DRUG|Bone marrow-derived mesenchymal stromal cells (MSCs)|Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
219213864|NCT05780762|OTHER|IMPACT Program|"care at 3 levels:~(1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and with the team caring for him or her, and incorporating evidence-based measurement tools."
219213865|NCT05780762|OTHER|usal care|usual management with a Nurse in Advanced Practice.
219085950|NCT01903850|DEVICE|spray cryotherapy|spray cryotherapy
219085951|NCT02038894|DRUG|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
219085952|NCT02038894|DRUG|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
219085953|NCT02038894|DRUG|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
219085954|NCT02038894|DRUG|Propofol|
219085955|NCT05828966|DRUG|human chorionic gonadotropin (hCG)|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
219085956|NCT05828966|DRUG|Magnesium sulfate|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
219085957|NCT01492023|BEHAVIORAL|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
219085958|NCT03381755|DRUG|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
219085959|NCT03381755|DRUG|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
219085960|NCT03613675|DEVICE|Video games|"The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
219085961|NCT00665574|OTHER|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
219085962|NCT00549588|OTHER|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
219085963|NCT00549588|OTHER|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
219085964|NCT00549588|OTHER|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
219085965|NCT00549588|OTHER|Intervention: none (only UV)|
219085966|NCT02980055|PROCEDURE|collagen matrix|Surgical procedure for root coverage using collagen matrix
219085967|NCT02980055|PROCEDURE|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
219085968|NCT04637334|PROCEDURE|Superior vena cava reconstruction|Endovascular therapy with percutaneous transluminal angioplasty (PTA) and, in recent years, with stenting of the SVC, has been performed with increasing frequency. An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because long-term durability of this treatment method remains to be assessed.
219085969|NCT03577639|OTHER||
219085970|NCT00491803|DRUG|Sildenafil|sildenafil 20 mg orally
219085971|NCT00491803|DRUG|Sildenafil|sildenafil 40 mg orally
219085972|NCT00387673|BEHAVIORAL|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
219085973|NCT03158883|DRUG|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).
219213866|NCT04004325|DRUG|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
219213867|NCT04004325|DRUG|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
219213868|NCT04004325|OTHER|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
219213869|NCT03589625|OTHER|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
219213870|NCT01970553|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
219213871|NCT01970553|DRUG|Gemcitabine|1000 mg vial, powder for injectable solution
219213872|NCT01357512|DEVICE|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
219213873|NCT05088798|DRUG|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
219213874|NCT05325541|DEVICE|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
219213875|NCT05325541|BEHAVIORAL|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
219213876|NCT03117582|OTHER|Stool specimen|"The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor"
219213877|NCT05605925|DRUG|Artemether/lumefantrine|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
219085974|NCT03158883|RADIATION|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
219085975|NCT03065270|OTHER|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
219085976|NCT03065270|OTHER|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
219085977|NCT03326531|OTHER|Not applicable for this study|Not applicable for this study
219085978|NCT05125575|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the Test (T) product was administered orally with 240 mL of water.
219085979|NCT05125575|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets|One tablet of the Reference (R) product was administered orally with 240 mL of water.
219085980|NCT00045305|DRUG|Cyclosporine|Immunosuppressant
219085981|NCT00045305|DRUG|Methotrexate|Antimetabolite
219085982|NCT00045305|DRUG|Photopheresis|Psoralens
219085983|NCT00045305|DRUG|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
219085984|NCT00045305|DRUG|Pentostatin|Purine analogue
219085985|NCT00045305|PROCEDURE|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
219085986|NCT00045305|PROCEDURE|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
219085987|NCT00045305|RADIATION|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
219085988|NCT01033357|DEVICE|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
219085989|NCT01033357|DEVICE|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
219213878|NCT05605925|DRUG|Ivermectin|IVN 600 mcg/kg/day for 3 days
219213879|NCT05246943|DIAGNOSTIC_TEST|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
219213880|NCT04491201|OTHER|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
219213881|NCT01211184|DIETARY_SUPPLEMENT|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
219213882|NCT01211184|DIETARY_SUPPLEMENT|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
219213883|NCT01211184|BEHAVIORAL|Fasting.|The patient is fasting from midnight before the surgery.
219213884|NCT06150833|BIOLOGICAL|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
219213885|NCT04291027|OTHER|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
219213886|NCT04291027|OTHER|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
219213887|NCT01421667|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
219213888|NCT01421667|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion
219085990|NCT04492579|OTHER|Gentle-UHT donor human milk supplementation|Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born \>36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
219085991|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 150:500 EE EU|
219085992|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 500:200 EE EU|
219085993|NCT02763514|DIETARY_SUPPLEMENT|3 g Placebo|
219213889|NCT03765658|DRUG|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
219085994|NCT01440491|OTHER|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
219085995|NCT00910442|DIETARY_SUPPLEMENT|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
219085996|NCT00955669|BIOLOGICAL|Symptoms and Objective Examination|5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
219213890|NCT03765658|DRUG|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
219213891|NCT02999763|DEVICE|SlimShape|SlimShape radiofrequency treatment to the abdomen
219213892|NCT02192242|OTHER|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
219213893|NCT04060212|OTHER|Tuna fish|Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
219213894|NCT04060212|DIETARY_SUPPLEMENT|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
219213895|NCT03617315|DRUG|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
219213896|NCT05374642|BEHAVIORAL|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
219213897|NCT05374642|BEHAVIORAL|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
219085997|NCT03323333|BEHAVIORAL|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
219085998|NCT00005810|BIOLOGICAL|filgrastim|
219085999|NCT00005810|DRUG|carboplatin|
219213898|NCT01009424|DRUG|R7103|escalating inhaled dose
219086000|NCT00005810|DRUG|docetaxel|
219086001|NCT00005810|DRUG|estramustine phosphate sodium|
219086002|NCT02635048|PROCEDURE|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
219213899|NCT01074359|DRUG|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
219213900|NCT01074359|DRUG|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
219213901|NCT00231504|PROCEDURE|Blood samples|Blood samples
219213902|NCT04881409|DEVICE|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
219213903|NCT04881409|DEVICE|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
219213904|NCT02356055|BEHAVIORAL|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
219086003|NCT02635048|PROCEDURE|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
219086004|NCT04830072|BEHAVIORAL|Brief AWARD advice and active referral to somking cessation services|The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.
219086005|NCT04830072|BEHAVIORAL|Chat-based support through Instant Messaging apps|Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.
219086006|NCT04830072|OTHER|Leaflet|Leaflet on harms of smoking
219086007|NCT04830072|BEHAVIORAL|AR images|AR images of the harms of smoking and the benefit of abstinence.
219213905|NCT06622057|DRUG|D07001-Softgel Capsules|D07001-softgel capsule is an oral gemcitabine.
219213906|NCT06622057|DRUG|Placebo|Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
219213907|NCT06622057|COMBINATION_PRODUCT|Capecitabine|Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.
219213908|NCT04027439|DRUG|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
219213909|NCT04027439|DRUG|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
219213910|NCT04027439|DRUG|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
219213911|NCT03664011|DRUG|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
219213912|NCT03598946|DEVICE|Urinary test|Women use a home urinary test themselves
219681749|NCT04248946|OTHER|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
219361706|NCT03555266|DEVICE|NSS-2 Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
219086008|NCT03138096|BIOLOGICAL|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
219086009|NCT03138096|OTHER|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
219361707|NCT03555266|DEVICE|Sham NSS-2 BRIDGE|NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
219361708|NCT00137917|BIOLOGICAL|Meningococcal serogroup B vaccine|
219213913|NCT03450460|BEHAVIORAL|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
219213914|NCT02631668|DRUG|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
219213915|NCT02631668|DRUG|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
219213916|NCT02631668|DRUG|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
219361709|NCT02167945|DRUG|ABT-450/r/ABT-267|Tablet for oral use
219086010|NCT03977038|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
219086011|NCT02536365|BEHAVIORAL|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
219086012|NCT02536365|BEHAVIORAL|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
219086013|NCT02159599|DRUG|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
219086014|NCT02159599|DRUG|Lamivudine|Lamivudine (300mg) : QD
219086015|NCT02159599|DRUG|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
219086016|NCT03848403|BIOLOGICAL|Ixekizumab|Administered SC
219086017|NCT02475122|OTHER|azygos blood flow measurements by MRI|
219086018|NCT05011994|BEHAVIORAL|Maintenance intervention|"The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity"
219086019|NCT01939548|DRUG|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
219086020|NCT01939548|DRUG|Placebo|Placebo BID until the Week 12 visit
219086021|NCT01939548|DRUG|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
219086022|NCT00534131|PROCEDURE|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
219086023|NCT00534131|PROCEDURE|APPEAR Procedure|Perineal incision to reach the distal rectum
219213917|NCT06298266|BIOLOGICAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219213918|NCT01077700|DRUG|ABT-288 Low Dose|
219213919|NCT01077700|DRUG|Placebo|inactive substance
219213920|NCT01077700|DRUG|ABT-288 High Dose|
219213921|NCT06424652|OTHER|Blood draws|After passing the screening, participation in the research study will be approximately three weeks. The participant will have seven study visits all at the Pennington Center. On five occasions, the participant will have a five-hour visit in the inpatient unit. At the study visit blood will be drawn. The total amount of blood drawn during the study is approximately 12 fluid ounces.
219213922|NCT06424652|OTHER|Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test|This procedure measures how the body responds to insulin. Insulin is normally produced by the body during meals and helps the body use sugar. There will be two IV lines, one in the participant's arm and one in the participant's hand on the opposite side. Small amounts of glucose and insulin will be infused into the participant's arm. The participant's blood sugar level will be checked every 5-10 minutes from the IV in the hand to determine how much glucose the participant should have to keep blood sugar at a normal level. The participant's hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During the IV procedure, a small amount of the participant's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.
219086024|NCT00534131|PROCEDURE|Proctectomy|standard rectal excision which does not preserve the anal canal
219086025|NCT00760149|DRUG|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
219086026|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation On
219086027|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation Off
219086028|NCT02386995|DEVICE|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
219086029|NCT02386995|DEVICE|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
219086030|NCT01414621|OTHER|atrial tissue sample|atrial tissue sample from CABG patient
219086031|NCT03234205|DEVICE|MRI scan|"MRI standard protocol with addition of:~* a second clinical respiratory belt besides belt usually installed for clinical examination~* a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~* 12 sequences during free respiration are added lasting supplementary 15 minutes~* Use of cardiac antennae usually used for cardiac MRI scans"
219086032|NCT00877825|PROCEDURE|dairy food control diet and high- and low- isoflavone soyfood diets|
219086033|NCT02601989|DRUG|Tadalafil|
219086034|NCT02601989|DRUG|Placebo|Per oral intake of placebo for six weeks
219086035|NCT05316285|OTHER|Yoga exercise|Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
219086036|NCT06562361|DRUG|[68Ga]Ga-DOTA-Cys-ATH001|Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
219086037|NCT00976352|DRUG|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
219086038|NCT00976352|OTHER|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
219086039|NCT00500942|BEHAVIORAL|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
219086040|NCT02114151|DRUG|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
219086041|NCT02114151|DRUG|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
219086042|NCT04738526|OTHER|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
219086043|NCT04738526|OTHER|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
219086044|NCT04738526|OTHER|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
219086045|NCT01494584|DRUG|ezogabine/retigabine|ezogabine dose escalation
219213923|NCT06424652|OTHER|Resting Metabolic Rate (RMR)|After the participant rests for 30 minutes, a clear plastic hood will be placed over the participant's head and chest area. The hood is ventilated with fresh air. The participant's oxygen intake and carbon dioxide output will be measured for 30 minutes to determine how many calories the participant burns during the time they are being tested.
219361710|NCT02167945|DRUG|ABT-333|Tablet for oral use
219361862|NCT04539093|OTHER|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
219361863|NCT01791608|DIETARY_SUPPLEMENT|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
219213924|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
219213925|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
219213926|NCT03960099|BEHAVIORAL|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
219213927|NCT05690945|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
219681750|NCT05527795|OTHER|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"* Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
219086046|NCT03220243|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
219086047|NCT01666808|DRUG|FACBC|FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
219086048|NCT01666808|RADIATION|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
219086049|NCT02624544|DRUG|esomeprazole|esomex 40 mg twice daily
219086050|NCT02624544|DRUG|desonide|topical corticosteroid desonid 0,1% b.i.d
219086051|NCT03179644|OTHER|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
219086052|NCT00859079|DRUG|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
219086053|NCT00859079|DRUG|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
219086054|NCT05678205|DRUG|AB-201|NK Cell Therapy
219086055|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219086056|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
219086057|NCT00009802|DIETARY_SUPPLEMENT|calcitriol|
219086058|NCT00009802|DRUG|paclitaxel|
219086059|NCT03442712|OTHER|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
219086060|NCT03442712|OTHER|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
219086061|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
219086062|NCT04861987|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
219086063|NCT05378581|DEVICE|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
219086064|NCT05378581|OTHER|control arm|usual process
219086065|NCT06437990|PROCEDURE|Arteriovenous loop graft|Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
219086066|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
219213928|NCT05690945|DRUG|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
219361864|NCT01791608|DIETARY_SUPPLEMENT|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
219361865|NCT01791608|DIETARY_SUPPLEMENT|Milk without fortification without zinc|Milk without fortification
219213929|NCT05884164|PROCEDURE|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
219086067|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
219086068|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
219086069|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
219086070|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
219213930|NCT05884164|PROCEDURE|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
219086071|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
219086072|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
219086073|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
219086074|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
219086075|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
219086076|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
219086077|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
219086078|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
219086079|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
219213931|NCT06166836|DRUG|D1553|D1553 orally taken，600mg twice a day
219213932|NCT06166836|DRUG|IN10018（Ifebemtinib）|IN10018 orally taken once daily at approximately the same time each day
219213933|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
219361866|NCT00408694|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219361867|NCT00408694|BIOLOGICAL|Bevacizumab|Given IV
219361868|NCT00408694|DRUG|Cisplatin|Given IV
219086080|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
219086081|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
219086082|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
219086083|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
219213934|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
219213935|NCT05779761|BEHAVIORAL|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
219086084|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
219086085|NCT01832948|DRUG|Endostar|
219213936|NCT02787005|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219213937|NCT01231971|DRUG|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
219086086|NCT01832948|DRUG|Oxaliplatin|
219086087|NCT01832948|DRUG|Folinic acid|
219086088|NCT01832948|DRUG|5-FU|
219086089|NCT04209075|DIETARY_SUPPLEMENT|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
219086090|NCT04209075|DRUG|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
219086091|NCT04209075|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
219086092|NCT02149251|GENETIC|Pre-genetic diagnosis|
219086093|NCT02271256|DEVICE|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
219086094|NCT02638948|DRUG|BMS-986142|BMS986142 specific dose on specific days
219213938|NCT01231971|DRUG|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
219213939|NCT04817020|OTHER|%2 Klorheksidin|Effect on phlebitis
219213940|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
219213941|NCT05176392|DEVICE|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
219213942|NCT05176392|BEHAVIORAL|Headache Management Therapy|Therapy will be provided on headache management.
219361869|NCT00408694|DRUG|Fluorouracil|Given IV
219086095|NCT02638948|DRUG|Placebo|Placebo of BMS-986142 specific dose on specific days
219086096|NCT02638948|DRUG|Methotrexate|Methotrexate specific dose on specific days
219361870|NCT00408694|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219086097|NCT06472466|BEHAVIORAL|Sleep/eating virtual reality self-help exposure-based intervention|"Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties."
219086098|NCT06472466|BEHAVIORAL|Sleep/eating self-help written materials.|Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
219086099|NCT00141154|DRUG|Celecoxib|
219086100|NCT00141154|DRUG|Placebo|
219086101|NCT00141154|DRUG|Loxoprofen|
219086102|NCT00764920|DEVICE|non-invasive imaging modalities for assessment of skin|skin imaging
219086103|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
219086104|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
219086105|NCT04920864|DEVICE|rTMS|Repetitive transcranial magnetic stimulation
219086106|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M6, and M12
219086107|NCT02411565|DRUG|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
219086108|NCT02411565|DRUG|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
219086109|NCT02411565|OTHER|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
219086110|NCT02411565|OTHER|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
219213943|NCT05176392|DEVICE|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
219213944|NCT05176392|BEHAVIORAL|Headache Education Control|In the control, educational sessions on headaches will be provided.
219213945|NCT05784194|PROCEDURE|Intervention for correct discharge medication list|As above
219213946|NCT04116372|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
219213947|NCT00516477|BIOLOGICAL|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
219213948|NCT04896736|OTHER|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
219213949|NCT04896736|OTHER|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
219213950|NCT02246075|DRUG|EVP-6124|
219213951|NCT01387516|BEHAVIORAL|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
219213952|NCT01387516|BEHAVIORAL|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
219213953|NCT01387516|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
219086111|NCT02963974|DEVICE|Cochlear implant|Implantation
219086112|NCT00810264|DEVICE|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
219086113|NCT04814836|PROCEDURE|Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)|35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
219086114|NCT04814836|PROCEDURE|Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)|35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
219086115|NCT04814836|PROCEDURE|Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)|the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.
219086116|NCT04814836|PROCEDURE|Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).|The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
219213954|NCT01387516|BEHAVIORAL|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
219213955|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's Parent Toolkit 2.0|Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.
219213956|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's General Health Guide|General Health Guide provides information to parents on how to promote health in their families.
219086117|NCT04814836|PROCEDURE|Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)|Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
219086118|NCT02569580|DEVICE|Topically|"use the No More medical device as anti lice treatment"
219086119|NCT06030674|OTHER|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
219086120|NCT00778479|DEVICE|Sepraspray|Max. 10g of Sepraspray
219086121|NCT00365443|BIOLOGICAL|V502|
219086122|NCT02131779|BEHAVIORAL|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
219086123|NCT02131779|BEHAVIORAL|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
219086124|NCT06213701|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
219086125|NCT06213701|OTHER|Psychoeducation app|Psychoeducation app
219086126|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
219086127|NCT05914064|DEVICE|Gravitas FT and Gravitas FT Monitor guidance|FT placed with guidance from the Gravitas FT system
219086128|NCT05914064|DEVICE|Gravitas FT System without placement guidance|SOC placement
219086129|NCT06576726|OTHER|This study involves no intervention.|This study involves no intervention.
219213957|NCT06032377|BEHAVIORAL|cognitive behavioral therapy for sleep, anxiety, and depression|This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
219361871|NCT02984592|BEHAVIORAL|physical exercise|regular exercise programs in the previous 6 months.
219086130|NCT03266783|DRUG|Apixaban|Refer to Apixaban group
219086131|NCT03266783|DRUG|Rivaroxaban|Refer to Rivaroxaban group
219086132|NCT00995072|DRUG|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
219086133|NCT00995072|DRUG|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
219086134|NCT02226913|DRUG|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
219086135|NCT02226913|DRUG|sodium bicarbonate|8.4% sodium bicarbonate
219086136|NCT02226913|DRUG|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
219086137|NCT04776980|DIAGNOSTIC_TEST|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
219086138|NCT04696666|DEVICE|INSTYLAN (Sodium Hyaluronate 80mg/50ml)|The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
219213958|NCT06032377|BEHAVIORAL|education about healthy nutrition habits and communication in older age|This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
219213959|NCT04694365|DRUG|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
219213960|NCT03249142|DRUG|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
219213961|NCT03249142|DRUG|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
219213962|NCT04755920|DRUG|SGM-101|Fluorescence-guided surgery
219213963|NCT03736564|COMBINATION_PRODUCT|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
219213964|NCT06648265|DRUG|Tranexamic Acid (Topical)|Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture
219213965|NCT06648265|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Arm infiltration with traditional Klein\&#39;s tumescent solution
219213966|NCT04068506|DRUG|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
219213967|NCT06279793|DRUG|Fish Oil|"Omegaven® is a 10% fish oil emulsion with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe: Day -1: 0.20 g fish oil/kg BW/d (the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion); intraoperative day 0: no dose; postoperative day 0: 0.20 g fish oil/kg BW/d; postoperative days 1 to max. 7): 0.20 g fish oil/kg BW/d"
219086139|NCT02658864|DRUG|lafutidine|comparison of different doses, sex and medication conditions
219086140|NCT01037348|DRUG|ranibizumab 0.5mg|
219086141|NCT05911204|OTHER|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
219086142|NCT01751828|DRUG|Sertraline|
219086143|NCT02306759|DRUG|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
219086144|NCT02306759|DRUG|Placebo|Normal saline 50ml, administered over 15 minutes
219086145|NCT05646667|OTHER|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
219086146|NCT05646667|OTHER|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
219213968|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d) provided at the same timepoints as the intervention.
219361872|NCT02427048|BEHAVIORAL|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
219361873|NCT02024516|OTHER|50 gr concentrated pomegranate juice|
219681751|NCT05527795|OTHER|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
219681752|NCT05527795|OTHER|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
219086147|NCT00624299|DRUG|Botox|Botox injection (100 ius) per muscle
219086148|NCT00624299|OTHER|Saline|Saline injection
219086149|NCT02666547|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
219086150|NCT02666547|RADIATION|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
219086151|NCT02666547|RADIATION|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
219086152|NCT04830475|DEVICE|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
219086153|NCT04830475|DEVICE|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
219086154|NCT05420103|OTHER|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
219086155|NCT02329054|DRUG|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
219086156|NCT02535910|DIETARY_SUPPLEMENT|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
219086157|NCT02535910|DIETARY_SUPPLEMENT|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
219213969|NCT04793100|OTHER|Ophthalmologic exam at inclusion and 12 months after CRVO|"As part of routine care : OCT-B (Optical coherence tomography-B), OCT-angiography (Optical coherence tomography and fluorescein angiography after pupillary dilatation (at inclusion only)~Added by the study :~* Assessment of best corrected visual acuity in letters read and validated using the ETDRS scale ;~* The shooting of a 10 second infrared movie by the Heidelberg Spectralis device centered on the head of the optic nerve (at inclusion only)~* A measurement of the eye tension with an air tonometer (at inclusion only)~* A blood pressure measurement (diastolic and systolic) and pulse measurement (at inclusion only)~* A color retinophotography (Optos) with autofluorescence images~* A color Doppler ultrasound of the optic nerve of both eyes will be performed, for patients treated at the Foundation A de Rothschild Hospital only."
219681753|NCT05527795|OTHER|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
219681754|NCT05527795|OTHER|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
219086158|NCT02535910|DIETARY_SUPPLEMENT|Control|Subjects are asked to consume a breakfast without vitamin D
219086159|NCT02170740|DRUG|BIBR 1048 MS - low dose|
219086160|NCT02170740|DRUG|BIBR 1048 MS - high dose|
219086161|NCT02170740|DRUG|BIBR 1048 MS + Pantoprazole|
219086162|NCT02183987|OTHER|Active Knowledge Translation Intervention|"1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (\>3 months) starting dialysis early (eGFR \>10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up."
219086163|NCT02495025|BEHAVIORAL|Telephone-based developmental screening and care coordination|
219086164|NCT00512395|DRUG|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
219086165|NCT04753372|DRUG|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
219086166|NCT02395939|PROCEDURE|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
219086167|NCT02395939|PROCEDURE|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
219086168|NCT03341793|DIAGNOSTIC_TEST|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
219086169|NCT03818672|DRUG|Rifaximin|Rifaximin 550 MG BID
219086170|NCT03505112|OTHER|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
219086171|NCT02275676|OTHER|bioelectrical impedance analysis|
219086172|NCT02275676|OTHER|indirect calorimetry|
219086173|NCT05917795|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
219086174|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Medicine Diet|Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
219086175|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Diet|Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
219681755|NCT05527795|OTHER|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
219681756|NCT04643327|DRUG|Levetiracetam|Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
219681757|NCT04643327|DRUG|Placebo|Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
219086176|NCT02815462|OTHER|FAMFACESG|\- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
219086177|NCT02815462|OTHER|Control|\- Usual hospital Care
219086178|NCT02815462|OTHER|FAMFACESG|\- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
219086179|NCT02815462|OTHER|FAMFACESG|"* For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator."
219086180|NCT02815462|OTHER|FAMFACESG|\- For low risk patients, PNs will continue usual hospital care.
219086181|NCT05646186|DIETARY_SUPPLEMENT|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
219086182|NCT05646186|DIETARY_SUPPLEMENT|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
219086183|NCT00313820|DRUG|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
219086184|NCT00313820|DRUG|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
219086185|NCT03827122|DRUG|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
219086186|NCT00336674|BIOLOGICAL|Intranasal insulin|440IU Insulin
219086187|NCT00336674|OTHER|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
219086188|NCT04072094|PROCEDURE|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
219086189|NCT04072094|PROCEDURE|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
219086190|NCT01417572|DRUG|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
219213970|NCT04793100|DRUG|Treatment standardization with aflibercept|For patients requiring intravitreal injection
219213971|NCT06463977|OTHER|Survey|The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
219213972|NCT01858285|GENETIC|Exome and/or whole genome sequencing|
219213973|NCT02496325|PROCEDURE|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
219213974|NCT06623305|DEVICE|Photobiomodulation|Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
219361874|NCT04447885|DEVICE|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
219681758|NCT05524766|DEVICE|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
219213975|NCT03956628|BEHAVIORAL|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
219213976|NCT03335397|DEVICE|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
219213977|NCT03335397|OTHER|Traditional learning process|Traditional content available in university library.
219213978|NCT05461313|OTHER|Constrained Liner|Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
219213979|NCT05461313|OTHER|Dual Mobility|Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
219086191|NCT03248258|OTHER|Qualitative Interview or Focus group discussions|"The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial)."
219213980|NCT00979121|DRUG|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
219213981|NCT00979121|DRUG|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
219213982|NCT00933257|DRUG|LACTIC ACID(ND)|Treatment duration 5 weeks
219213983|NCT01039155|DRUG|Azacitidine|Given IV
219086192|NCT02721082|BEHAVIORAL|Opt Out Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
219086193|NCT02721082|DRUG|Nicotine Replacement Therapy|Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
219086194|NCT02721082|BEHAVIORAL|Opt In Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
219213984|NCT01039155|OTHER|Laboratory Biomarker Analysis|Correlative studies
219213985|NCT01039155|DRUG|Oxaliplatin|Given IV
219213986|NCT01039155|OTHER|Pharmacological Study|Correlative studies
219213987|NCT03920592|BEHAVIORAL|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings"
219213988|NCT03836222|DRUG|PCS499|MR tablet
219086195|NCT02721082|DRUG|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
219086196|NCT01751438|OTHER|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
219086197|NCT01751438|OTHER|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
219086198|NCT01751438|BEHAVIORAL|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
219086199|NCT01751438|OTHER|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
219213989|NCT03836222|DRUG|Trental|comparator tablet
219213990|NCT00359658|DRUG|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
219213991|NCT00359658|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
219213992|NCT00359658|DRUG|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
219213993|NCT05599282|DRUG|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
219213994|NCT05599282|OTHER|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
219213995|NCT01435252|DRUG|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
219213996|NCT03323203|DEVICE|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
219213997|NCT01511159|DRUG|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
219213998|NCT01511159|DRUG|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
219213999|NCT01511159|DRUG|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
219681759|NCT05227443|PROCEDURE|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
219086200|NCT00251862|BEHAVIORAL|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
219086201|NCT00251862|BEHAVIORAL|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
219086202|NCT00251862|BEHAVIORAL|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
219086203|NCT00265889|BIOLOGICAL|filgrastim|480 mcg beginning day +5
219086204|NCT00265889|DRUG|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
219086205|NCT00265889|DRUG|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
219086206|NCT00265889|DRUG|etoposide|60 mg/kg, IV
219086207|NCT00265889|DRUG|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
219086208|NCT00265889|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
219214000|NCT01511159|DRUG|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
219086209|NCT00265889|RADIATION|radiation therapy|radiation therapy
219086210|NCT02134587|OTHER|Multifaceted educational intervention|"1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
219086211|NCT04373876|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|Patients implanted with a totally subcutaneous defibrillator system
219214001|NCT01511159|DRUG|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
219086212|NCT03133026|DEVICE|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
219086213|NCT03503266|DRUG|[14C] MT-7117|14-C MT-7117
219086214|NCT00211705|BEHAVIORAL|Diet|
219086215|NCT00211705|DRUG|Diet+pravastatin|
219086216|NCT01952626|DRUG|Ondansetron|intravenous injection
219214002|NCT01511159|DRUG|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
219214003|NCT01511159|DRUG|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
219214004|NCT03137836|BEHAVIORAL|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
219086217|NCT01952626|DRUG|Palonosetron|intravenous injection
219086218|NCT01625351|DRUG|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
219086219|NCT01625351|DRUG|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
219086220|NCT01625351|DRUG|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
219214005|NCT02928172|DEVICE|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
219086221|NCT01625351|DRUG|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
219086222|NCT01625351|DRUG|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
219086223|NCT01625351|BIOLOGICAL|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
219086224|NCT01625351|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219086225|NCT01831622|DRUG|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
219086226|NCT01831622|DRUG|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
219086227|NCT03096405|DIAGNOSTIC_TEST|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
219086228|NCT00860379|DRUG|Selenium1|2 ug/kg
219086229|NCT00860379|DRUG|Selenium2|4 ug/kg
219086230|NCT00860379|DRUG|Placebo|IV saline as placebo
219086231|NCT01515748|DRUG|Docetaxel (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
219214006|NCT02928172|DEVICE|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
219214007|NCT03468634|DIAGNOSTIC_TEST|endoscopy|Oesophageal endoscopy with biopsy
219214008|NCT03611088|OTHER|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
219214009|NCT05827796|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
219214010|NCT05827796|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
219214011|NCT05827796|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
219214012|NCT05827796|DRUG|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
219214013|NCT05835570|DIAGNOSTIC_TEST|PET/CT scans|Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.
219214014|NCT04177147|OTHER|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
219214015|NCT03492866|DRUG|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
219214016|NCT06048588|DRUG|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
219214017|NCT06048588|DRUG|Placebo for YN001|The injection solution to mimic the YN001
219214018|NCT06048588|DRUG|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
219214019|NCT06648837|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.
219214020|NCT06648837|OTHER|Collection of relevant information|Collect relevant information to ensure potential participant meets all inclusion/exclusion criteria.
219214021|NCT03664635|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
219214022|NCT06610162|OTHER|Eucalaloric feeding|Participants will complete a 3-day diet run-in followed by an 24-hr in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 1.3 x REE (\~30% fat, 55% carbohydrate, and 15% protein at each meal). Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
219214023|NCT06610162|OTHER|Acute Fasting|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. Participants will complete a 24 hour fast while in the calorimeter. They will be permitted to consume non-caloric beverages (i.e., water, non-caloric and non-caffeinated soft drinks, caffeine-free tea, or decaffeinated coffee) but refrain from consuming any caloric food or beverages. Upon exiting the calorimeter, participants will be provided a meal from the University of Colorado Hospital Patient Kitchen.
219214024|NCT06610162|OTHER|Acute Overfeeding|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 200% of energy requirements, based on EE measured during the eucaloric condition. Macronutrient intake will be 3% protein, 51% carbohydrate, and 46% fat. Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
219361711|NCT02167945|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
219361875|NCT00503204|DRUG|Cediranib|oral tablet
219086232|NCT01515748|DRUG|Oxaliplatin (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
219086233|NCT01515748|DRUG|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
219086234|NCT02215122|DRUG|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
219086235|NCT02215122|DRUG|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
219086236|NCT02215122|DRUG|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
219086237|NCT03917667|DIAGNOSTIC_TEST|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
219086238|NCT03345498|DRUG|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
219086239|NCT03535935|DRUG|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
219086240|NCT03535935|OTHER|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
219086241|NCT02400138|OTHER|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
219086242|NCT02400138|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
219086243|NCT01711203|OTHER|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
219214025|NCT03224481|OTHER|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
219214026|NCT05743205|BEHAVIORAL|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
219214027|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
219214028|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 2
219214029|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 3
219214030|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 4
219214031|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
219214032|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks
219214033|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks
219214034|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
219214035|NCT06048055|OTHER|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
219214036|NCT06048055|OTHER|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
219086244|NCT01711203|OTHER|General Strengthening|General abdominal and lower quarter musculature strengthening
219086245|NCT04873570|DRUG|Moxifloxacin 400mg|Moxifloxacin 400mg IR tablet
219086246|NCT00006231|PROCEDURE|quality-of-life assessment|
219086247|NCT00006231|PROCEDURE|standard follow-up care|
219086248|NCT00006231|RADIATION|radiation therapy|
219086249|NCT00416182|DRUG|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
219086250|NCT00416182|DRUG|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
219086251|NCT03371875|BEHAVIORAL|Automated transition care reminders|The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
219086252|NCT06289075|OTHER|Intensive Care Unit (ICU) treatment|ICU treatment
219086253|NCT00460187|DEVICE|Percutaneous intervention of the carotid artery|
219214037|NCT00859781|DRUG|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
219214038|NCT00859781|DRUG|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
219681760|NCT05227443|PROCEDURE|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
219681761|NCT03289013|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
219681762|NCT03289013|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
219681763|NCT03289013|OTHER|LT-2|Newly developed adhesive
219681764|NCT03289013|OTHER|LT-21|Newly developed adhesive
219681765|NCT03289013|OTHER|LT-25|Newly developed adhesive
219681766|NCT03289013|OTHER|33-20|Newly developed adhesive
219681767|NCT04076436|OTHER|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
219086254|NCT00071617|BEHAVIORAL|Youth-Nominated Support Team|
219086255|NCT05185531|COMBINATION_PRODUCT|PD-1 plus stereotactic body radiotherapy|neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
219086256|NCT03288116|DIAGNOSTIC_TEST|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
219086257|NCT04952506|DRUG|CKD-349 F1 Tab.|1T Single does
219086258|NCT04952506|DRUG|CKD-349 F2 Tab.|1T Single does
219086259|NCT04952506|DRUG|D113 Tab.|1T Single does
219214039|NCT00859781|DRUG|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
219086260|NCT00014638|DRUG|letrozole|
219086261|NCT03001284|OTHER|NO intervention|
219214040|NCT00859781|DRUG|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
219086262|NCT03221387|DEVICE|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
219086263|NCT02571517|DRUG|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
219214041|NCT01219790|RADIATION|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
219086264|NCT02571517|OTHER|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
219086265|NCT05917639|DEVICE|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
219214042|NCT01219790|DRUG|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
219214043|NCT03759678|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
219214044|NCT02016872|DRUG|18F-FMISO|
219214045|NCT02016872|OTHER|PET/CT|
219214046|NCT06696599|PROCEDURE|Serum and corporal irisin|measure serum and corporal irisin
219214047|NCT06698848|DRUG|ketamin|Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
219214048|NCT06698978|OTHER|Simplified protocol (PS)/Conventional protocol (PC)|Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
219214049|NCT06698978|OTHER|Conventional protocol (PC)/Simplified protocol (PS)|Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
219214050|NCT06753409|DEVICE|Processed electroencephalography (pEEG) Guided General Anesthesia|"Processed electroencephalography (pEEG) can guide the optimization of anesthesia depth, potentially preventing overly deep anesthesia and, in turn, reducing the incidence of IOH and the need for vasopressors .~Depth of anesthesia will be managed based on pEEG monitoring using Entropy with a target range of 40-60."
219214051|NCT06753409|DEVICE|Non-pEEG-Guided General Anesthesia (with blinded pEEG monitoring)|Depth of anesthesia will be managed based on clinical judgment, informed by clinical perception and vital signs.
219214052|NCT04532970|BEHAVIORAL|Cessation Counseling|Two different types of smoking cessation counseling
219214053|NCT06755398|OTHER|Exercise|During the exercises based on the protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) following anterior cruciate ligament (ACL) surgery, additional cognitive tasks will be assigned to the patients.
219214054|NCT06755398|OTHER|Exercise|The protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) will be applied following anterior cruciate ligament (ACL) surgery.
219214055|NCT06767826|BEHAVIORAL|Salutogenesis Models|On the basis of the Salutogenesis Model, this study is based on the development of individuals' internal and external resources for game addictions and strengthening their sense of integrity. It has been determined that digital game addiction and problematic internet use in adolescents form the basis of seven problems. These problems have been identified as mental health, vision, pain, sleep and rest patterns, nutrition, social contact and physical activity. Encouraging behavioral changes regarding internet use and teaching adolescents how to deal with these problems becomes a necessity in today's technology. In the literature, counseling has been provided for families and adolescents to prevent digital game addiction in adolescents.
219214056|NCT05337826|DEVICE|Continuous Glucose Monitor|Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
219214057|NCT06816160|PROCEDURE|tru-cut biopsy|needle biopsy from the tumor
219086266|NCT05917639|DEVICE|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
219086267|NCT05917639|DEVICE|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
219086268|NCT03352791|BEHAVIORAL|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
219086269|NCT03352791|BEHAVIORAL|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
219214058|NCT06844799|DRUG|HS-20137|HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.
219214059|NCT06844799|DRUG|Placebo&HS-20137|Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter
219214060|NCT06846177|OTHER|Graded Activity Training|"4 types of progressive activities of 2 hour session two times/week with resting periods of 30 mins. Activities consist of treadmill walk ,walk on floor, core muscles exercises ,home tasks .~To ensure the proper heart rate and loads during the exercises, measurements of individual heart rate and muscle strength are taken during the first session (baseline) with HR Tracking portable device and also during the session to continuously monitor HR of the Patient. To withdraw or adjust the training intensity for each patient Borg's Scale of Perceived Exertion is used throughout the session for monitoring Training intensity of endurance, muscle training, individual's effort and exertion level."
219361876|NCT00503204|DRUG|Lomustine|oral capsule
219214061|NCT06846177|OTHER|Task-Oriented Training|4 task oriented physical fitness activities which include walk on floor, walk on inclined surface using treadmill ,sit to stand , stair climbing and descending for duration of 2 hour session with frequent breaks. Each treatment session began with 10 minutes of warm-up exercise, which consisted of passive stretching of the calf muscles, hamstring, and hip adductors. The level of difficulty and frequency for each task were gradually increased during the 6 weeks with the patients consent.10 minutes of cool down at the end of each treatment session.
219086270|NCT03959462|DEVICE|real anodal transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
219086271|NCT03959462|DEVICE|sham transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
219086272|NCT04944641|BEHAVIORAL|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
219086273|NCT04944641|DRUG|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
219086274|NCT01474733|OTHER|educational intervention|series of lectures and workshops on health literacy
219086275|NCT04127838|BEHAVIORAL|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
219086276|NCT02622854|PROCEDURE|plasma exchange|see arm description
219086277|NCT02622854|DRUG|conservative treatment|see arm description
219086278|NCT01811082|DRUG|Coenzyme A|Coenzyme A 400mg per day.
219086279|NCT01811082|DRUG|Pantethine|Pantethine 600mg per day.
219086280|NCT03610087|BEHAVIORAL|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
219086281|NCT03610087|BEHAVIORAL|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
219086282|NCT04979975|OTHER|Placebo|PBO- placebo matching to UB-621
219214062|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
219214063|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
219214064|NCT06838052|OTHER|Strong Woman, Safe Life Training Program Supported by Laughter Yoga|The training program consists of 8 modules, each module consists of two sessions. A session will last 45 minutes. The program includes the following topics: Self-Awareness and Importance of Communication (Module 1), Stress and Coping Techniques (Module 2), Gender (Module 3), Women's Empowerment (Module 4), Violence and Its Effects on Women's Health (Module 5), Non-Violent Communication (Module 6), Combating Violence (Module 7), Psychological Health (Module 8). In addition, a laughter yoga session will be held in the second session of each module.
219214065|NCT06037980|DRUG|Gemcitabine|◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
219214066|NCT06037980|DRUG|Nab paclitaxel|◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
219214067|NCT06037980|DRUG|Cisplatin|◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
219214068|NCT06037980|PROCEDURE|Curative Surgery|Curative surgery on primary tumor
219214069|NCT06037980|DRUG|Capecitabine|1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
219681768|NCT04076436|OTHER|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
219681769|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
219681770|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
219086283|NCT04979975|BIOLOGICAL|UB-621 low-dose|fully human anti-HSV mAb
219086284|NCT04979975|BIOLOGICAL|UB-621 high-dose|fully human anti-HSV mAb
219086285|NCT01485042|DRUG|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
219086286|NCT00059358|DRUG|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
219681771|NCT05771454|PROCEDURE|Histopathological confirmation|After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
219681772|NCT03082027|DIAGNOSTIC_TEST|ultrasonography|ultrasonography of median nerve
219086287|NCT00059358|DRUG|Ribavirin|Oral tablet taken daily
219086288|NCT00059358|DRUG|Peginterferon alfa-2b|Subcutaneous injection
219086289|NCT03406728|OTHER|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
219086290|NCT03406728|OTHER|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
219086291|NCT03406728|DEVICE|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
219214070|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
219214071|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
219086292|NCT00790283|DEVICE|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
219086293|NCT03407794|OTHER|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
219214072|NCT06837610|PROCEDURE|Inverted T trabeculectomy|"* Fornix-based conjunctival incision along with the opening of Tenon's capsule and dissection along the area of the potential bleb.~* A 4 x 4 mm limbal-based scleral flap was fashioned using a crescent knife. Dissection was carried out up to the clear cornea.~* A longitudinal tunnel was made through the scleral bed, starting from the limbus and extending 1 mm beyond the end of the scleral flap. Afterwards, the horizontal limb of the Inverted T was created. (Figure 2)~* A paracentesis was made using an MVR blade.~* The anterior chamber was entered using an MVR blade. Kelly's punch was used to excise 1.5 x 1.5 mm of scleral bed at the limbus at the base of the vertical limb of the figure (T), and then a peripheral iridectomy was performed using Vannas scissors.~* The scleral flap was then closed using two fixed 10/0 Nylon sutures, one at each corner."
219086294|NCT03407794|OTHER|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
219086295|NCT00990080|BIOLOGICAL|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
219086296|NCT03213275|OTHER|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
219086297|NCT01529125|DRUG|zidovudine, lamivudine, nevirapine|
219086298|NCT02075879|BEHAVIORAL|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
219086299|NCT02075879|OTHER|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
219086300|NCT04558255|DIAGNOSTIC_TEST|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
219086301|NCT04102579|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219086302|NCT04102579|DRUG|Placebo|non-active dosage form
219086303|NCT01269879|DEVICE|Flexi-Bar vibration device only|daily vibration training 10min twice
219086304|NCT01269879|DEVICE|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group"
219086305|NCT05350943|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
219214073|NCT02235857|DEVICE|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
219214074|NCT04110340|DRUG|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
219681773|NCT01563731|DRUG|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
219086306|NCT05350943|DRUG|Gemcitabine|1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W
219086307|NCT05350943|DRUG|Oxaliplatin|85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W
219086308|NCT05350943|DRUG|Toripalimab|3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W
219086309|NCT05350943|DRUG|Donafenib|0.2mg. P.O, BID, continuously
219086310|NCT02185625|DEVICE|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
219086311|NCT04021303|DIETARY_SUPPLEMENT|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
219086312|NCT04021303|DIETARY_SUPPLEMENT|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
219086313|NCT01901107|DRUG|Kiklin capsules|oral
219086314|NCT01407081|BEHAVIORAL|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
219086315|NCT04668196|DEVICE|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
219086316|NCT04668196|DEVICE|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
219086317|NCT04668196|DEVICE|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
219086318|NCT01638325|DRUG|Insulin Lispro|Administered SC
219086319|NCT01638325|DRUG|BC106 insulin lispro|Administered SC
219086320|NCT01525602|DRUG|PLX3397|PLX3397 tablets, 200mg
219086321|NCT01525602|DRUG|Paclitaxel|Paclitaxel IV
219086322|NCT06124040|BEHAVIORAL|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
219086323|NCT05316441|BEHAVIORAL|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
219086324|NCT05684406|GENETIC|Genotyping|Genotyping by Real Time PCR
219681774|NCT02758288|OTHER|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
219681775|NCT02758288|OTHER|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
219681776|NCT00492700|DRUG|rosiglitazone|
219681777|NCT05339815|DEVICE|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
219086325|NCT04349280|DRUG|Bintrafusp alfa|Participants will receive bintrafusp alfa.
219086326|NCT03794622|OTHER|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
219086327|NCT03794622|OTHER|intramedullary nail fixation|intramedullary nail fixation only
219086328|NCT06732661|PROCEDURE|Preserve pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
219086329|NCT06732661|PROCEDURE|Dissect pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
219086330|NCT05655026|DEVICE|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
219086331|NCT05970822|DRUG|BC3402|Escalating of BC3402 will be administered IV(intravenous)
219086332|NCT05970822|DRUG|Azacitidine|Azacitidine will be administered daily
219086333|NCT00824096|PROCEDURE|Bronchoscopy|The patients in our ICU intubated for \> 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1\~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3\~4 days even with CLV \<24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
219086334|NCT04413591|BEHAVIORAL|Community based combination HIV prevention package|The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
219086335|NCT05887505|OTHER|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
219086336|NCT05887505|OTHER|Placebo|Oral supplementation of placebo in 3 consecutive days.
219086337|NCT01105026|DEVICE|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
219086338|NCT02335008|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
219086339|NCT02335008|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
219086340|NCT01452997|DRUG|NSAI treatment|Ibuprofen 5% gel
219086341|NCT01452997|DRUG|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
219361712|NCT05299385|BEHAVIORAL|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~* method of the conventional rehabilitation treatment~* intensity for aerobic exercise and anaerobic exercise"
219681778|NCT02052427|DEVICE|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
219681779|NCT02052427|DEVICE|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
219086342|NCT00656279|BEHAVIORAL|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
219086343|NCT00965926|DRUG|YM178|oral
219086344|NCT04469686|COMBINATION_PRODUCT|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
219214075|NCT04110340|DRUG|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
219214076|NCT04110340|DRUG|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
219214077|NCT06850311|DRUG|herbal ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks
219214078|NCT06850311|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks.
219214079|NCT03936790|OTHER|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
219214080|NCT03936790|OTHER|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
219214081|NCT05537142|DRUG|BV100|Rifabutin for Infusion
219086345|NCT04469686|COMBINATION_PRODUCT|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
219214082|NCT06891339|OTHER|mobile application|The aim is to evaluate whether a patient-centered mobile application with smartphone-based systematic follow-up assessment during the perioperative period can improve surgery-related anxiety, complications, comfort, and patient satisfaction compared to standard care. This thesis will be one of the pioneering studies in this field.
219086346|NCT04469686|COMBINATION_PRODUCT|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
219214083|NCT06744569|DRUG|CU-10101|0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
219214084|NCT06752720|DRUG|Stem cell Transplantation|Manufactured autologous mescenchymal stem cell (HUNS001-01) in our cell processing center will be injected into the brain, totally 4 x 10\^7 cells, in 2 brain sites.
219214085|NCT06758817|OTHER|MedDiet+ intervention|Study arm will consume a Mediterranean like style diet enriched in fermented foods for 12 weeks
219214086|NCT06758817|OTHER|General dietary recommendations|Study arm will be given general healthy eating advice at baseline.
219214087|NCT06758466|PROCEDURE|Prostate surgery|Prostate removal
219214088|NCT06753006|DEVICE|Neurorehabilitation simulator|The participant must complete a mental task - imagine the movement of his arm. If successful, the robotic simulator moves the paralyzed limb.
219214089|NCT06753006|PROCEDURE|Standard course|The participant receives a standard course of intervention as prescribed by the attending physician in accordance
219214090|NCT06753513|OTHER|99mTc-FDPH46 SPECT/CT Imaging|99mTc-FDPH46 SPECT/CT Imaging
219214091|NCT06775223|OTHER|Cardiac implantable electronic devices|validity and reliability study
219086347|NCT03577067|PROCEDURE|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
219086348|NCT00129922|DRUG|paclitaxel|
219214092|NCT03654716|DRUG|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
219086349|NCT00129922|DRUG|Fluorouracil|
219086350|NCT00129922|DRUG|Epirubicin|
219086351|NCT00129922|DRUG|Cyclophosphamide|
219086352|NCT05351996|DEVICE|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
219086353|NCT05351996|DEVICE|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
219214093|NCT03654716|DRUG|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
219214094|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum Aminopeptidase 1 and 2|endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
219214095|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
219214096|NCT03574493|PROCEDURE|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
219214097|NCT06805526|BEHAVIORAL|Intermittent Islamic fasting with lifestyle modification|"Both groups followed a healthy lifestyle for 6 months including:~Diet: The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men .~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week .~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day. Followed Intermittent Islamic fasting which meant fasting two days per week (Monday and Thursday) with fasting (13, 14, 15) middle of lunar months. (during Intermittent Islamic fasting caloric requirement was distributed as 30-40~For Group I (intervention group) only, Followed Intermittent Islamic fasting wh"
219361713|NCT05299385|DEVICE|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
219361877|NCT04663178|OTHER|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
219086354|NCT05351996|OTHER|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
219086355|NCT05139667|DRUG|Corticosteroid Topical|topical tacrolimus and corticosteroids
219086356|NCT04904770|DEVICE|Scoop stretcher|Already included in arm/group description
219086357|NCT04904770|DEVICE|Vacuum mattress|Already included in arm/group description
219086358|NCT01194570|DRUG|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
219086359|NCT01194570|OTHER|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
219086360|NCT03060655|BIOLOGICAL|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
219086361|NCT03060655|BIOLOGICAL|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
219086362|NCT00806234|DRUG|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
219086363|NCT00806234|DRUG|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
219086364|NCT00806234|DRUG|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
219086365|NCT06009601|DIAGNOSTIC_TEST|Pectus Study Form|"Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives."
219086366|NCT06009601|DIAGNOSTIC_TEST|Adams Test|Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
219086367|NCT06009601|DIAGNOSTIC_TEST|Scoliosis Graphy|"ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs."
219086368|NCT06009601|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes."
219086369|NCT01337674|DRUG|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
219214098|NCT06805526|BEHAVIORAL|Lifestyle modification only|"The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. For men, the formula is: BMR = 66.4730 + 13.7516 × weight (kg) + 5.0033 × height (cm) - 6.7550 × age (years). For women, the formula is: BMR = 655.0955 + 9.5634 × weight (kg) + 1.8496 × height (cm) - 4.6756 × age (years) \[27\]. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men \[28\].~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week \[29\].~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day."
219214099|NCT05184504|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
219086370|NCT01337674|DRUG|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
219214100|NCT06774833|BEHAVIORAL|Self-initiated perturbation-based balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be required to recover their balance upon self-initiated perturbation.
219214101|NCT06774833|BEHAVIORAL|Conventional balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be instructed to perform balance and strength training. The same training duration and format will be used as the Self-initiated perturbation-based balance training group.
219214102|NCT06783257|DRUG|Vonorasan fumarate injection1|40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days
219214103|NCT06783257|DRUG|Vonorasan fumarate injection2|40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days
219214104|NCT06783257|DRUG|Esomeprazole sodium for injection|80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h
219214105|NCT06797492|DIAGNOSTIC_TEST|Shoulder Physical Examination|shoulder physical examination is conducted to assess the patient's musculoskeletal condition and to track progress throughout the rehabilitation phases
219214106|NCT06797492|PROCEDURE|Shoulder Rehabilitation in a Virtual Environment|The rehabilitation protocol for shoulder disorders is executed using a Virtual Reality (VR) system, where patients perform customized exercises tailored to their physical characteristics.
219086371|NCT01337674|DRUG|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
219086372|NCT01337674|DRUG|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
219086373|NCT03662932|OTHER|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
219086374|NCT00006364|DRUG|omacetaxine mepesuccinate|Given IV or SC
219086375|NCT00006364|OTHER|pharmacological study|Correlative studies
219086376|NCT00006364|OTHER|laboratory biomarker analysis|Correlative studies
219086377|NCT04922151|DRUG|601|intravitreal recombinant humanized anti-VEGF monoclonal antibody
219086378|NCT04922151|DRUG|Ranibizumab|intravitreal recombinant humanized anti-VEGF monoclonal antibody
219086379|NCT04123678|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
219086380|NCT00003979|DRUG|CHS 828|
219214107|NCT06797492|OTHER|Usability assessment and presence and co-presence evaluation|The usability of the VR system, along with the sense of presence and co-presence during rehabilitation, is assessed using validated scales
219086381|NCT05347264|OTHER|gun massager|15 to 20 minutes along with hot pack.
219086382|NCT05347264|OTHER|transverse friction massage|15 to 20 minutes along with hot pack.
219086383|NCT03076970|DRUG|lasmiditan 200 mg|drug including single placebo tablet
219086384|NCT03076970|DRUG|Sumatriptan|drug including single placebo tablet
219086385|NCT03076970|DRUG|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
219214108|NCT06795789|DIETARY_SUPPLEMENT|Vitals+ (combined multivitamin and polyphenol supplement)|Multivitamin with 19 essential nutrients combined with Bilberry polyphenols
219214109|NCT06712901|BEHAVIORAL|Median Ranked Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
219214110|NCT06712901|BEHAVIORAL|Overall Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
219214111|NCT06712901|BEHAVIORAL|Black American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
219214112|NCT06712901|BEHAVIORAL|White American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
219086386|NCT03893721|DIAGNOSTIC_TEST|arsenic exposure|analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
219086387|NCT03688984|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
219086388|NCT05807113|OTHER|Atopi intensive care BNO 3731|Crem twice daily
219086389|NCT05807113|OTHER|Benchmark product|Crem twice daily
219214113|NCT06712901|BEHAVIORAL|Control|There will be no message content of cancer screening and sharing intentions in this arm.
219086390|NCT05980208|DRUG|Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
219086391|NCT01007864|DRUG|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
219086392|NCT01007864|DRUG|pramipexole or ropinirole|continuation of pre-study treatment regimen
219086393|NCT03790995|PROCEDURE|Robot assisted laparoscopic prostatectomy|
219086394|NCT02673398|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
219086395|NCT02673398|OTHER|Laboratory Biomarker Analysis|Correlative studies
219086396|NCT02673398|DRUG|Neratinib|Given PO
219086397|NCT02673398|OTHER|Pharmacological Study|Correlative studies
219086398|NCT05181852|DRUG|IP2015, dose 1|Active
219086399|NCT05181852|DRUG|IP2015, dose 2|Active
219086400|NCT05181852|DRUG|Placebo|Placebo
219086401|NCT05181852|DRUG|Pregabalin|Comparator
219086402|NCT01236079|BEHAVIORAL|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
219086403|NCT04679402|OTHER|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
219086404|NCT03917940|DIETARY_SUPPLEMENT|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
219086405|NCT03917940|DRUG|Glimepiride|glimepiride 2 mg or 3 mg per day oral
219086406|NCT00048230|DRUG|bortezomib|
219086407|NCT05308550|DIAGNOSTIC_TEST|rapid RT-LAMP test to detect SARS-COV-2 RNA|rapid RT-LAMP test to detect SARS-COV-2 RNA
219086408|NCT01321554|DRUG|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
219086409|NCT01321554|DRUG|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
219086410|NCT01321554|DRUG|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
219086411|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
219086412|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
219086413|NCT03033654|OTHER|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
219086414|NCT05593757|DRUG|Quinidine|Oral quinidine
219086415|NCT05593757|DRUG|Verapamil|Oral verapamil
219086416|NCT05265663|RADIATION|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
219086417|NCT04968691|OTHER|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
219086418|NCT04968691|OTHER|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
219214114|NCT06828458|OTHER|Biological sampling|"Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites)~At day 0, day 3, day 7, day 14, day 21"
219214115|NCT06760494|DIAGNOSTIC_TEST|the MAPUSE model|Using the MAPUSE model to predict MVI status before surgical resection for HCC patients
219214116|NCT06890962|DIETARY_SUPPLEMENT|Energy drink consumption|Participants will consume an energy drink (or placebo) and then undergo experimental testing after a 40 minute rest period following drink consumption.
219086419|NCT00752843|DRUG|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
219086420|NCT02943850|BIOLOGICAL|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
219086421|NCT02943850|DEVICE|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
219086422|NCT02355067|BEHAVIORAL|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
219086423|NCT02355067|BEHAVIORAL|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
219086424|NCT02063230|DRUG|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
219086425|NCT02063230|DRUG|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
219086426|NCT05797922|DRUG|DWP16001|DWP16001 0.3mg
219086427|NCT04676425|DRUG|MK-8189|Administered at a dose of 4 mg via oral tablet
219086428|NCT02350712|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
219086429|NCT02350712|DRUG|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
219086430|NCT02350712|DRUG|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
219086431|NCT02350712|DRUG|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
219214117|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted.
219214118|NCT05507970|DRUG|Placebo|Single Dose dispersed in sterile water, fasted.
219086432|NCT03391609|DRUG|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
219086433|NCT03391609|DRUG|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
219086434|NCT03753451|PROCEDURE|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
219086435|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
219086436|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
219086437|NCT02130934|PROCEDURE|Cardiac 3D MRI|
219086438|NCT05217186|DIAGNOSTIC_TEST|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
219086439|NCT01410058|DIETARY_SUPPLEMENT|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
219086440|NCT01410058|DRUG|Efavirenz 600mg|Efavirenz 600mg based regimen
219086441|NCT01410058|DRUG|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
219086442|NCT00389883|DRUG|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
219086443|NCT06524076|PROCEDURE|Partial Pulpotomy|After removing caries high-speed handpiece with water coolant using a round diamond bur. Once there is an exposure, the bur is changed with another sterile one with which the superficially inflamed pulp tissue will be gently removed to a depth of 1-3 mm beneath the pinpoint pulp exposure that occurred at the end of caries removal. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
219086444|NCT06524076|PROCEDURE|Complete pulpotomy|After removing caries with a large round bur, the access cavity will be opened. Excavation of inflamed coronal pulp tissues will be done using a sharp excavator. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
219086445|NCT04829721|OTHER|Educational Intervention with video|Women randomized to an educational video workshop group.
219086446|NCT02607982|DRUG|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
219086447|NCT02607982|DRUG|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
219086448|NCT02607982|RADIATION|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
219214119|NCT05507970|DRUG|MMV367 (Fed 440mg)|Single dose dispersed in sterile water with a high fat meal.
219214120|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
219214121|NCT05507970|DRUG|Placebo|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
219214122|NCT05507970|DRUG|MMV367 (Fasted 440mg)|Single dose dispersed in sterile water fasted.
219214123|NCT05956795|DIAGNOSTIC_TEST|Ultrasound|Sonographic imaging will be performed of lymph node basins
219214124|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag|Clinicians seeing patients at elevated predicted risk will see a flag on the EHR 'storyboard' during in person or telephone encounters indicating the patient is at elevated predicted risk of opioid overdose. The clinician will have the option of including this information into their decision-making process when providing care. There will be no best practice alerts/behavioral nudges in this arm.
219361878|NCT03261531|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
219086449|NCT02153801|PROCEDURE|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
219086450|NCT06414486|DIETARY_SUPPLEMENT|Dietary supplement group|One tablet per day for 3 weeks consumed for subjects randomized in the Dietary supplementation group. This will lead to an intake of 200mg per day of Red Panax Ginseng (corresponding to 22.4mg of ginsenosides and 20.2mg of rare ginsenosides).
219086451|NCT06414486|OTHER|Placebo group|One tablet per day consumed for 3 weeks for subjects randomized in the Control group. The product is composed of rice flour (50mg) and brown sugar (150mg).
219214125|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag with Behavioral Nudges|"Clinicians seeing patients at elevated predicted risk for opioid overdose will see a flag on the EHR storyboard indicating that the patient is at elevated predicted risk.~Clinicians will also receive up to 4 best practice alerts/behavioral nudges during an in-person or telephone primary care encounter with elevated risk patients when certain requirements are met: 1) if the patient does not have an active naloxone prescription on their medication list, the clinicians will receive an active choice alert during any medication ordering to encourage naloxone prescription; 2) if the patient's opioid dosage is \>50 MME, OR they are ordered a new opioid prescription, OR they have an overlapping opioid and benzodiazepine prescription order, the clinicians will receive an accountable justification alert when the relevant order is entered."
219214126|NCT06806163|BEHAVIORAL|Usual Care|Patients in the practices randomized to the Usual Care arm will receive standard care practice without change.
219214127|NCT06810700|DEVICE|MiniMed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
219214128|NCT06806059|BEHAVIORAL|Physical Activity|The intervention group will engage in increased physical activity, aiming for a daily step count of at least 8,000, with a target of 10,000 steps, over a four-week preoperative period. Weekly supervised phone consultations will be conducted to provide guidance and support.
219214129|NCT06804408|BEHAVIORAL|Qigong|12-week training of Baduanjin (or named Eight-Section Brocades), with two sessions per week. Each session lasts for 60 min.
219214130|NCT06804408|BEHAVIORAL|Mindfulness-based training|12-week training of mindfulness-based breathing, walking, and stretching practices, with two sessions per week. Each session lasts for 60 min.
219214131|NCT06804408|BEHAVIORAL|Low-to-moderate intensity physical exercise|12-week training of stretching, flexibility exercise, and balance exercise, with two sessions per week. Each session lasts for 60 min.
219214132|NCT06843187|DRUG|Lemborexant|Dayvigo (lemborexant compound) is an orexin antagonist that acts on the arousal and sleep neural networks of the brain to regulate sleep-wake cycles and is used in the treatment of insomnia characterized by difficulties with sleep.
219214133|NCT06843187|OTHER|Placebo|The placebo is an inactive sugar pill that looks and tastes identical to the lemborexant pill.
219214134|NCT06750887|OTHER|Normal condition|The normal condition IS measured as a lumbar extension without VR until the onset of pain.
219086452|NCT00402701|BEHAVIORAL|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
219086453|NCT05808738|BEHAVIORAL|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
219086454|NCT02737800|PROCEDURE|endometrioma aspiration|Transvaginal ultrasound guided aspiration
219086455|NCT02737800|DRUG|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
219086456|NCT02737800|PROCEDURE|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
219086457|NCT01953614|OTHER|Chiropractic adjustment|
219086458|NCT01953614|OTHER|Sham adjustment|
219086459|NCT05559502|DEVICE|HFNO group|HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.
219214135|NCT06750887|OTHER|Understated condition|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% less movement in the VR (understated visual feedback)
219214136|NCT06750887|OTHER|OVERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% more movement in the VR (understated visual feedback)
219214137|NCT06808178|DEVICE|Low Level Laser Therapy|"The device has the following treatment parametes :~* Maximum average power \> 500 milli watts~* Wave length combined (904-808) nm~* Maximum repition rate (1-2000) Hz~* Energy density : 4:6 J per cm per session"
219214138|NCT06808178|OTHER|kinesio taping|"* the material used is 100%acrylic,latex free and heat activated with 10-15% stretch.~* It is made of 100% cotton to allow quickening of the drying process.~* Ability to stretch to 120-140% of its original length~* Recoil back to the anchor that is applied without stretch~* Heat-activated adhesive~* Hypoallergenic dyes that make the tape safe for most users~* Latex-free~* Drying time after being wet is about 5-10 minutes~* Can be worn for several days"
219361879|NCT00363038|DRUG|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
219086460|NCT05559502|DEVICE|ET group|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
219086461|NCT02497898|BIOLOGICAL|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
219086462|NCT06448325|OTHER|Hip arthroplasty|Surgical treatment of the hip after osteoporosis fracture. The focus of the study is the prediction of further fractures (and therefore further surgical procedures) after the first one.
219086463|NCT05256030|OTHER|Speed-based relearning training|Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
219086464|NCT05256030|OTHER|Neurodevelopmental Therapy|Neurodevelopmental Therapy
219086465|NCT03857503|DIAGNOSTIC_TEST|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures."
219086466|NCT01203930|DRUG|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
219086467|NCT01203930|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
219086468|NCT01645826|DRUG|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
219086469|NCT01645826|DRUG|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
219086470|NCT02178059|DRUG|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
219086471|NCT02178059|DRUG|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
219086472|NCT05988021|DRUG|CCX168|Administered orally.
219086473|NCT04957017|BEHAVIORAL|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
219086474|NCT05178121|BEHAVIORAL|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
219086475|NCT04569110|OTHER|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
219214139|NCT06739512|PROCEDURE|Extensive Electro-Anatomical Guided Ablation|Ablation using PFA. Combination of anatomical and electrogram-guided ablation techniques.
219086476|NCT01835262|DRUG|Morphine|Morphine: 0.1 mg /kg given as IVP
219086477|NCT01835262|DRUG|Ketamine|Ketamine:0.3 mg/given as IVP
219214140|NCT06739512|PROCEDURE|Anatomical Guided Ablation|Ablation using PFA. Guided by anatomical landmarks without potential mapping
219214141|NCT06739512|PROCEDURE|Electrogram Guided Ablation|Ablation using PFA. Guided by real-time electrogram characteristics from a multi-electrode catheter.
219214142|NCT06763315|DRUG|Selumetinib|Use of the internationally recommended standard dose and low dose of the same drug
219214143|NCT06637800|DEVICE|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)|The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
219214144|NCT06763159|DRUG|HS-20124 (Phase Ia：Dose escalation )|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
219214145|NCT06763159|DRUG|HS-20124 (Phase Ib: Dose expansion)|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
219214146|NCT06208904|OTHER|Intravenous infusion of GIPRA|Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min during experimental days
219214147|NCT06208904|OTHER|Intravenous infusion of saline|Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin during experimental days
219214148|NCT06776900|PROCEDURE|Supine position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
219214149|NCT06776900|PROCEDURE|Lateral position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
219214150|NCT06756958|OTHER|No intervention (observational study)|No intervention (observational study: The study participants were inpatient and were given robot-assisted gait training routinely.)
219214151|NCT06894264|BEHAVIORAL|Emotion regulation|The intervention is an adapted version of skills training that stems from DBT. The text has been simplified, and illustrations have been added to facilitate learning. In addition, metaphors have been removed, making it more user-friendly for the targeted populations. It consists of 12 modules that are delivered during 12 weeks, one module per week. A licensed psychologist are responsible for each individual treatment. Care givers or relatives are encouraged to participate and help the study participant to complete their homework assignments.
219214152|NCT04632810|OTHER|Ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
219214153|NCT04632810|OTHER|non-ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
219214154|NCT05742269|DIAGNOSTIC_TEST|89Zr-atezolizumab PET/CT|All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
219214155|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
219361880|NCT00363038|DRUG|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
219214156|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on nature|Reading journalistic posts and articles, published on social media, regarding nature.
219214157|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on deaths by suicide|Reading journalistic posts and articles, published on social media, regarding deaths by suicide.
219214158|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on traffic-related deaths|Reading journalistic posts and articles, published on social media, regarding traffic-related deaths
219214159|NCT06750978|BEHAVIORAL|Self-reflection|Participants will be guided to identify goals of daily PSU reduction. o Participants will be guided to actively review their smartphone usage data each day.
219214160|NCT06750978|BEHAVIORAL|Self-reflection + Alternative activity engagement|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will be guided to develop a plan for alternative activity engagement and confirm their engagement in the alternative activities as planned.
219214161|NCT06750978|BEHAVIORAL|Self-reflection + Contingency management|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will receive an incentive ($8) if they meet the daily PSU reduction goal.
219214162|NCT06836934|DEVICE|soft knee brace|A commercially available soft brace (orthomedics ser. number 86) plus traditional physiotherapy
219214163|NCT06836934|DEVICE|lateral wedge foot insole|Wearing Lateral wedge insole 5mm for 8 weeks Standardized non-customized laterally wedged insoles were evaluated. Insoles were made of high-density ethyl vinyl acetate, were wedged approximately 5°
219214164|NCT06836934|PROCEDURE|convential physical therapy program|"Strengthening Exercises:~* Quadriceps Strengthening: Exercises like straight leg raises, quadriceps sets, and seated knee extensions help strengthen the quadriceps muscle, which supports the knee joint.~* Hamstring Strengthening: Hamstring curls and bridges target the hamstrings to enhance stability and support for the knee.~* Hip Strengthening: Exercises such as hip abductions, adductions, and clamshells strengthen the hip muscles (each 3 sets, 10 reps). (Deyle et al ., 2005)~Flexibility Exercises:~* Hamstring Stretch: Gentle stretching of the hamstrings can alleviate tension around the knee.~* Quadriceps Stretch: Stretches like the standing quadriceps stretch help maintain flexibility in the front of the thigh.~* Calf Stretch: Stretching the calf muscles can prevent tightness (J. D. Deyle et al 2005) TENS (Transcutaneous Electrical Nerve Stimulation): Helps manage pain by sending electrical impulses to the affected area."
219214165|NCT06435663|OTHER|Different methods of efficacy evaluation|When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
219214166|NCT06829212|DEVICE|WRS|WRS is a minimally invasive, wireless brain-machine interface system, consisting of a wireless implanted neural signal collector(Model: WRS64), data energy transmitter(Model: DTC01/02), and a brain function information management platform software(Model: SW01).
219214167|NCT06789055|OTHER|Cold Spray|Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
219214168|NCT06789055|OTHER|Placebo|Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
219214169|NCT05424055|BEHAVIORAL|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
219214170|NCT05489289|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
219214171|NCT05489289|BIOLOGICAL|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
219361881|NCT00363038|DRUG|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
219361882|NCT00363038|DRUG|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
219361883|NCT00416988|OTHER|educational intervention|
219086478|NCT04495439|DEVICE|Augmentation with the ISS Study System|Augmentation with the ISS Study System
219086479|NCT04495439|OTHER|Augmentation with PMMA|Augmentation with PMMA (standard)
219086480|NCT03324438|BEHAVIORAL|Home Telehealth T1D C2oYoT1-HR|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
219086481|NCT03324438|BEHAVIORAL|Personalized Behavioral Health|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
219086482|NCT03324438|BEHAVIORAL|Personalized Adherence Feedback|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
219086483|NCT01718002|BEHAVIORAL|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
219086484|NCT03717402|BEHAVIORAL|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
219086485|NCT04395573|DEVICE|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
219086486|NCT04395573|DEVICE|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
219086487|NCT02244801|DRUG|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
219086488|NCT01704625|PROCEDURE|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
219086489|NCT01704625|PROCEDURE|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
219086490|NCT01900262|OTHER|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
219214172|NCT06584682|OTHER|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
219214173|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
219214174|NCT04466150|DRUG|Ocrelizumab|open label biomarker study
219214175|NCT06808490|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the moderate intensity exercise condition will complete a 30 min session on a motor driven treadmill. Participants will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as the goal of participants staying within a target zone of 50-70% AAMHR while briskly walking and/or jogging depending on current fitness status.
219214176|NCT06808490|BEHAVIORAL|Light Intensity Stretching|Participants randomized into the light stretching condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a series of seated arm, torso, leg, knee and shoulder stretches on a yoga mat. Participants will be monitored throughout the stretching session by a trained research assistant, and HR and perceived exertion will also be measured throughout. The research assistant may make modifications to the poses in real-time to ensure that AAMHR is kept below 40%.
219086491|NCT01900262|OTHER|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
219214177|NCT06808490|BEHAVIORAL|Seated Meditation|Participants randomized into the meditation condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a seated guided meditation on a yoga mat. This includes a series of breathing, visualization, and body awareness exercises. Participants will be monitored throughout the meditation session by a trained research assistant, and HR and perceived exertion will also be measured throughout, to ensure that AAMHR is kept below 30%.
219214178|NCT06628843|OTHER|cesarean section rate|Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
219681780|NCT05505383|OTHER|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
219681781|NCT04099238|DRUG|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
219681782|NCT04553614|BEHAVIORAL|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
219086492|NCT01900262|OTHER|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
219086493|NCT03147235|BEHAVIORAL|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
219681783|NCT04553614|OTHER|Control|Usual exercise referral scheme procedure.
219086494|NCT02909348|DRUG|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
219086495|NCT01914094|BEHAVIORAL|Prehab|
219086496|NCT04550325|BIOLOGICAL|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
219086497|NCT05239988|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
219086498|NCT04494438|DRUG|Rituximab|
219086499|NCT00242528|DRUG|Zoledronic acid|
219086500|NCT01436968|BIOLOGICAL|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
219214179|NCT03005652|BEHAVIORAL|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
219214180|NCT03005652|BEHAVIORAL|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
219214181|NCT06809920|PROCEDURE|Group 1 ACL reconstruction with quadruple flexor tendons and conventional physiotherapy|Group 1 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus). All the participants will receive conventional physiotherapy.
219214182|NCT06809920|PROCEDURE|Group 2 ACL reconstruction with quadruple flexor tendons + ALL reconstruction|Group 2 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus) + ALL reconstruction. All the participants will receive conventional physiotherapy.
219681784|NCT03336814|DRUG|Terlipressin|Administration of terlipressine
219681785|NCT03336814|OTHER|Placebo|Administration of placebo
219681786|NCT00351689|BEHAVIORAL|dietary supplement|
219086501|NCT01436968|BIOLOGICAL|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
219086502|NCT03760601|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
219086503|NCT04202926|DEVICE|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
219086504|NCT04202926|DEVICE|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
219086505|NCT03248765|OTHER|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2\) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
219086506|NCT03456037|OTHER|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
219086507|NCT05994144|OTHER|VIDEO OBSERVED THERAPY|Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
219086508|NCT00662857|DRUG|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
219086509|NCT00662857|DRUG|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
219086510|NCT00662857|DRUG|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
219086511|NCT05995314|DIETARY_SUPPLEMENT|PLACEBO|3 mg/kg of cellulose (0 mg/kg of caffeine)
219086512|NCT05995314|DIETARY_SUPPLEMENT|3 mg/kg of caffeine|Ingestion of 3 mg/kg of body mass of caffeine
219086513|NCT05995314|DIETARY_SUPPLEMENT|6 mg/kg of caffeine|Ingestion of 6 mg/kg of body mass of caffeine
219086514|NCT02544464|DRUG|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
219086515|NCT02544464|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
219086516|NCT03966053|DRUG|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
219086517|NCT04524143|OTHER|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
219086518|NCT04524143|OTHER|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
219681787|NCT03701542|DIAGNOSTIC_TEST|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
219086519|NCT03966222|DEVICE|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
219086520|NCT03966222|OTHER|Open vein harvest|Open vein harvest
219086521|NCT04407013|OTHER|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
219086522|NCT04407013|OTHER|Control group with usual care|Control group will receive usual care (symptom monitoring only)
219086523|NCT03397680|DIAGNOSTIC_TEST|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
219086524|NCT00005954|DRUG|temozolomide|
219086525|NCT00989092|BIOLOGICAL|darbepoetin alfa|Administered subcutaneously.
219361884|NCT01265771|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
219681788|NCT03701542|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
219681789|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
219086526|NCT05750186|OTHER|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
219681790|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50
219086527|NCT00002864|DRUG|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
219086528|NCT00002864|DRUG|tamoxifen citrate|20 mg PO for 5 years
219086529|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
219086530|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
219086531|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
219086532|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
219086533|NCT01010425|DRUG|Placebo|Placebo, s.c., single-dose
219214183|NCT06888128|DRUG|Psilocybin 15mg|Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant.
219214184|NCT06888128|DRUG|Psilocybin 25mg|The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session.
219214185|NCT06765720|OTHER|Intermittent feeding method with nasogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
219214186|NCT06765720|OTHER|Intermittent feeding method with orogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
219214187|NCT06762860|DRUG|Dexmedetomidine|label sticker
219214188|NCT06762860|DRUG|Granisetron|label sticker
219214189|NCT06762860|OTHER|Placebo|label sticker
219214190|NCT06787183|RADIATION|Short course radiotherapy|CTV 25Gy/5Fx.
219214191|NCT06787183|DRUG|Capecitabine|1000mg/m2, d1-14，bid, q3w, 2 cycles.
219214192|NCT06787183|DRUG|Oxaliplatin|130mg/m2, d1, q3w, 2 cycles
219214193|NCT06787183|DRUG|QL1706|5.0 mg/kg, q3w
219214194|NCT06780280|OTHER|Overground Walking|Overground walking with an exoskeleton
219214195|NCT06866639|BEHAVIORAL|Cognitive behavioral therapy|The CBT is based on the treatment manual written by Fennell (1997). The patients receiving CBT will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
219214196|NCT06866639|BEHAVIORAL|Metacognitive therapy|The meta-cognitive treatment program is based on Wells's metacognitive therapy (Wells, 2013). The patients receiving meta-cognitive therapy will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
219214197|NCT06879704|OTHER|Imaging assessment|The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
219214198|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
219361885|NCT01265771|DEVICE|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
219086534|NCT01010425|DRUG|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
219086535|NCT05850039|OTHER|Sampling|Sample collection: a small fragment of atrial wall will be collected
219086536|NCT01869790|OTHER|Different fat types|Saturated, monounsaturated fats
219086537|NCT00990964|DEVICE|Attain Success Lead|Attain Success Lead
219086538|NCT03895164|BEHAVIORAL|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
219086539|NCT03895164|BEHAVIORAL|Standard NE|Standard nutrition education package from primary health care
219086540|NCT06184711|DEVICE|Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
219086541|NCT06184711|DEVICE|Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
219086542|NCT06184711|DEVICE|Transcranial Magnetic Stimulation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
219086543|NCT00375362|DRUG|Nitroderm patch|
219086544|NCT04932499|OTHER|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
219214199|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
219214200|NCT04882917|DRUG|M4076|M4076 was administered orally.
219086545|NCT04932499|OTHER|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
219086546|NCT04551599|DRUG|Danicopan|A single dose of danicopan (200 milligrams) will be administered orally.
219086547|NCT04199780|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
219086548|NCT04199780|BEHAVIORAL|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
219086549|NCT06110884|BEHAVIORAL|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
219086550|NCT06110884|BEHAVIORAL|speech therapy|receive only traditional language therapy
219086551|NCT05888506|DIETARY_SUPPLEMENT|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
219086552|NCT05888506|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
219086553|NCT03974659|COMBINATION_PRODUCT|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
219086554|NCT01590290|OTHER|financial compensation|financial monetary reimbursement
219086555|NCT04378192|DEVICE|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
219086556|NCT04378192|DEVICE|face mask|use of face mask before intubation of a morbidly obese patient
219086557|NCT06519994|DRUG|Artesunate vaginal inserts|Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
219086558|NCT06519994|DRUG|Placebo vaginal inserts|Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
219086559|NCT03329898|PROCEDURE|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
219086560|NCT03329898|DEVICE|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
219086561|NCT03329898|DRUG|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
219086562|NCT03329898|DRUG|dydrogesterone Tablets|oral dydrogesterone Tablets
219086563|NCT02191072|DRUG|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
219086564|NCT04636554|OTHER|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
219214201|NCT06836336|BEHAVIORAL|Hybrid therapy|Hybrid intervention that combined face-to-face educational sessions with the integration of technological advancements. They attended weekly 40-minute interactive educational sessions over the course of a month. The educational materials encompass information regarding the components of a healthy balanced diet and an active lifestyle.Throughout the intervention, participants were provided with a range of behavior change techniques to support participants in applying the educational content to improve their dietary and lifestyle habits. The employed behavior change techniques were SMART (specific, measurable, achievable, relevant, time-bound) goal setting, reviewing behavioral goals, problem-solving and environmental restructuring. The technological support for this intervention included the use of a smartphone diet tracker app called MyFitneesPal as well as communication with the interventionists via WhatsApp.
219214202|NCT06836336|BEHAVIORAL|Fully digital|Fully digital intervention, where they received the same educational materials through WhatsApp twice a week over the course of one month. The educational materials were presented through easily understandable posters, brief videos, and followed by short quizzes to reinforce the acquired knowledge. Additionally, the digital intervention incorporated the same behavior change strategies that were utilized in the hybrid group. Participants were also introduced to MyFittnessPal application in order to help them track their dietary habits and monitor their progress since it is considered a tool for self-monitoring and promoting healthy dietary behaviors throughout the intervention period.
219361886|NCT05455957|OTHER|exercise|neuromuscular and vestibulo-ocular training
219361887|NCT00151671|DRUG|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
219361888|NCT00151671|DRUG|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
219086565|NCT06815497|DRUG|Telmisartan|Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg
219086566|NCT02886806|OTHER|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
219086567|NCT02886806|OTHER|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
219214203|NCT06892912|OTHER|Diaphragmatic ultrasound|"Sample:~Given the observational nature of the study, a convenience sample will be obtained from all patients admitted to the emergency services and/or ICU with respiratory failure over the course of 1 year.~Inclusion Criteria:~* Age ≥ 18 years~* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)~* Need for NIMV and/or HFNC.~Exclusion Criteria:~* Neuromuscular disease~* Pregnancy~* Tracheostomy~* Rib fractures~* Cervical injuries~* Diaphragmatic paralysis~* Diaphragmatic malformations~* Hemodynamic instability~* Morbid obesity (BMI \> 35)~* Use of sedation and neuromuscular relaxants~* Pneumothorax or pneumomediastinum~* Poor acoustic window~* Critically ill patients with a prognosis of less than 24 hours of life~* Patients receiving palliative interventions."
219086568|NCT04271943|BEHAVIORAL|Computer Based Exercises|For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises
219086569|NCT04271943|DIETARY_SUPPLEMENT|Aerobic Exercises|For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
219086570|NCT03962244|DEVICE|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
219086571|NCT03962244|DEVICE|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
219086572|NCT05194306|DRUG|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
219086573|NCT01332227|DRUG|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
219086574|NCT01332227|DRUG|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
219086575|NCT01332227|DRUG|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
219086576|NCT01332227|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
219086577|NCT00514943|DRUG|BIBW 2992|experimental drug taken once daily orally
219086578|NCT00514943|DRUG|Cetuximab|active comparator administered weekly intravenously
219086579|NCT04839029|PROCEDURE|Bipolar En bloc TURBT|patients subjected to Bipolar resection of bladder tumor by Collins loop
219086580|NCT04839029|PROCEDURE|Monopolar En bloc TURBT|patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
219086581|NCT03406819|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
219086582|NCT03406819|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
219214204|NCT06865469|DRUG|Dexmedetomidine|dexmedetomidine will be administered by i.v. infusion at 0.4 μg/kg/h
219214205|NCT06865469|DRUG|Lidocaine Hydrochloride 2%|lidocaine hydrochloride 2% (400 mg/20 mL) 1.5 mg/kg/h by i.v. infusion.
219214206|NCT06752291|DEVICE|water flosser|A water flosser will be provided for use throughout the study, with participants instructed to use it once daily, specifically at the end of the day before bedtime.
219086583|NCT03406819|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
219086584|NCT01100255|DRUG|Ketamine infusion|0.5mg/kg IV over 40 minutes
219086585|NCT01100255|OTHER|Saline|saline infusion
219086586|NCT02073916|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
219086587|NCT02073916|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
219086588|NCT02073916|DRUG|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
219086589|NCT02173548|DRUG|Anakinra|
219086590|NCT02173548|DRUG|Placebo|
219086591|NCT01580072|OTHER|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
219086592|NCT01580072|OTHER|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
219086593|NCT04535674|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
219086594|NCT05810181|OTHER|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
219086595|NCT06393348|DRUG|HRS-7535|HRS-7535
219086596|NCT06393348|DRUG|Placebo|Placebo
219086597|NCT01295645|DRUG|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
219086598|NCT01295645|OTHER|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
219086599|NCT00792896|BEHAVIORAL|family conference|family conference
219214207|NCT06070857|DRUG|LV232|Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
219214208|NCT06070857|DRUG|Placebo|Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
219214209|NCT06747728|DRUG|Bevacizumab|Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
219361889|NCT00004914|BIOLOGICAL|epoetin alfa|
219361890|NCT00004914|PROCEDURE|physical therapy|
219086600|NCT02239393|BIOLOGICAL|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
219086601|NCT00455975|DRUG|Bevacizumab|Bevacizumab
219086602|NCT04350710|OTHER|PEEP trial|Measurement of Recruitment-to-Inflation Ratio
219086603|NCT01086748|DRUG|Risperidone|Administered orally.
219086604|NCT01086748|DRUG|Placebo|Administered orally.
219086605|NCT01086748|DRUG|LY2140023|Administered orally.
219086606|NCT02961023|OTHER|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
219086607|NCT01389830|BEHAVIORAL|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
219086608|NCT04424862|DRUG|Prednisone, ciclosporin and mycophenolate mofetil|Multitarget Therapy
219086609|NCT04424862|DRUG|Ponticelli Regimen|Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
219086610|NCT03658564|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
219214210|NCT06750029|OTHER|Medical clown visits|The intervention is 15-minute visits from MCs twice daily during the first two days of admission. The clowns use various techniques to relax the patients (e.g. music, singing, playing, humor, guided imagination) and helpe encourage children to begin drinking and eating on their own.
219214211|NCT06111248|OTHER|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
219214212|NCT02678689|BIOLOGICAL|BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
219214213|NCT02678689|DEVICE|Intracerebroventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
219214214|NCT06777199|PROCEDURE|Microscopic Selective Dorsal Neurectomy (SDN)|"Selective dorsal neurectomy (SDN) involves microsurgical dissection and partial transection of the dorsal penile nerves to reduce glans sensitivity.~The procedure is performed under spinal anesthesia or local anesthesia with 1% lidocaine.~A midline or dorsal sub-coronal incision is made 1 cm proximal to the coronal sulcus.~The skin is retracted, exposing the Dartos fascia and Buck's fascia to reach the neurovascular bundle (two dorsal penile nerves lateral to two dorsal penile arteries).~Every other nerve on either side of the corpora cavernosa is transected to damage approximately 50% of the nerve supply to the glans.~Suturing is done using 7-0 or 8-0 prolene sutures, and the incision is closed. Patients are evaluated at 1 month and 3 months post-procedure for IELT, AIPE, and PEDT scores to determine success."
219214215|NCT06777199|PROCEDURE|Pulsed Radiofrequency (PRF) Nerve Ablation|"Pulsed radiofrequency (PRF) nerve ablation aims to reduce sensitivity of the dorsal penile nerves using low-energy radiofrequency pulses.~Under sterile conditions, a 22-gauge RF cannula (5-cm-long, 10-mm active tip) is inserted into the flaccid penile skin at the 1-o'clock position for the right dorsal penile nerve.~Sensory stimulation testing is performed at 50 Hz to identify the point of maximum glans sensitivity.~Pulsed radiofrequency is applied at an energy output of 45 V for 180 seconds at 42°C (using the NeuroTherm generator).~The procedure is repeated at the 11-o'clock position for the left dorsal penile nerve, ensuring both sides are treated.~The goal is to ablate sensation over as large an area of the glans as possible without causing permanent nerve damage.~Post-procedure, patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores."
219214216|NCT06777199|PROCEDURE|Intraglanular Hyaluronic Acid (HA) Injection|"Intraglanular hyaluronic acid (HA) injection involves administering HA gel into the glans penis to reduce its sensitivity.~The circumference of the glans penis is divided into three circles (1 cm apart, starting from the base), and each circle is further divided into quarter circles.~Topical anesthetic cream (Emla®, lidocaine 25 mg + prilocaine 25 mg) is applied for 30 minutes to numb the glans.~Using two prefilled syringes of HA gel (Hyabell Ultra® 24 mg/ml with 0.3% lidocaine), 12 injections are administered into the deep dermis of the glans using a 27-G needle.~Each injection site receives 0.25 ml of HA gel following the multiple puncture technique.~Patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores to assess efficacy."
219214217|NCT06774170|BEHAVIORAL|structured follow-up intervention|"The intervention has been created in light of the studies including type 1 and type 2 diabetes patients and experiences of the project team with patients after PD. Theoretical background of the intervention is based on the interventions developed for glucose management in type 1 and type 2 diabetes patients and the effect of the intervention will be evaluated by using the plan-do-check-act model."
219086611|NCT03982602|OTHER|Ketogenic diet|Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
219086612|NCT00810836|DRUG|BG00012|oral
219214218|NCT06564454|OTHER|No intervention|Assessment of knowledge, attitude and practice of green Dentistry
219214219|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
219214220|NCT05019742|DRUG|Placebo|Placebo
219086613|NCT00810836|DRUG|BG00012|Oral
219086614|NCT00810836|DRUG|placebo|oral placebo
219214221|NCT06411132|OTHER|observational study|observational study
219214222|NCT02761187|OTHER|No Intervention|As this was an observational study, no intervention was administered.
219214223|NCT01297166|DRUG|LEO 27989 ointment|once daily application, 3weeks
219214224|NCT01297166|DRUG|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
219086615|NCT02609880|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
219086616|NCT02609880|BEHAVIORAL|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
219086617|NCT03205540|PROCEDURE|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
219086618|NCT03205540|PROCEDURE|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
219086619|NCT04285008|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
219086620|NCT06075797|BEHAVIORAL|PediQUEST ResPOND|"PPC teams will have access to feedback reports and the PQ-ResPOND checklist (standardized framework to diagnosis and treatment of recurrent pain behaviors in children with severe neurologic impairment).~Integration of the PPC team into care will be achieved through (i) initial consultation (goals: identify treatment goals, and address recurrent pain), and (ii) follow-up: the team will contact or visit the family in response to feedback reports or for treatment monitoring purposes."
219086621|NCT03040713|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose
219086622|NCT03040713|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
219214225|NCT01297166|DRUG|Calcipotriol ointment|once daily application, 3weeks
219214226|NCT01297166|DRUG|Vehicle ointment|once daily application, 3weeks
219214227|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
219214228|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
219214229|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
219214230|NCT05472753|OTHER|Control Treatment|Control group will receive a placebo (product loading substance)
219214231|NCT05979116|OTHER|myofascial release|MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
219214232|NCT06806969|DEVICE|Decision support|Patients will digitally fill out forms, which will go into the decision support tool integrated in the electronic health record journal, which predicts outcome of surgery for the patient, to inform shared decision making.
219214233|NCT06814015|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
219214234|NCT06758154|DEVICE|"TXJN electro-acupuncture"|Firstly, EA treatment will be administered at the Neiguan (PC6, bilateral), Shenting(GV23), Yingxiang(LI20, bilateral), Yintang(GV29) acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensations of achiness, heaviness, and numbness (known as de qi) at all above-mentioned acupoints. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at PC6, GV23, LI20, GV29, with a dilatational wave of 5 Hz and a current intensity of 2 \~ 4 mA depending on the patient's tolerance. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
219361891|NCT03543410|DRUG|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
219361892|NCT03543410|DRUG|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
219086623|NCT02723942|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
219086624|NCT01224301|BEHAVIORAL|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
219086625|NCT01224301|BEHAVIORAL|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
219086626|NCT03263884|DEVICE|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
219086627|NCT03263884|DEVICE|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
219361893|NCT03543410|DRUG|Placebo|Placebo (supplied in two tablets/day)
219361894|NCT03895125|BEHAVIORAL|[year1] dual-task training with task priority strategy|postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
219681791|NCT00366782|BIOLOGICAL|Placebo|Placebo for rB/HPIV3 vaccine
219681792|NCT02128659|BEHAVIORAL|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
219214235|NCT06758154|DEVICE|sham acupuncture|Firstly, EA treatment will be administered at the non-acupoints near above-mentioned real acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will take the needle into the acupoints without the sensations of de qi. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at non-acupoints without the current. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
219086628|NCT04789265|OTHER|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
219086629|NCT05134766|OTHER|Observation only|Based on type of SOC applied and the type of CAM products by subject's own decison
219086630|NCT01519531|DRUG|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
219086631|NCT01519531|DRUG|VIA-3196|Oral, daily dosing for 14 days
219086632|NCT01788865|DEVICE|cSEMS(Covered self-expandable dual-layered metal stent) implant|
219086633|NCT05021510|OTHER|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
219086634|NCT05021510|OTHER|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
219214236|NCT04827615|BEHAVIORAL|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
219086635|NCT03895411|DRUG|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
219086636|NCT03895411|DRUG|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
219681793|NCT02358265|DRUG|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
219681794|NCT02358265|DRUG|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
219681795|NCT02358265|DRUG|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
219681796|NCT02358265|DRUG|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
219681797|NCT01971567|DEVICE|HIRREM|
219681798|NCT00115206|DRUG|Neulasta® (pegfilgrastim)|
219681799|NCT01580826|OTHER|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
219681800|NCT00118989|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
219086637|NCT03895411|DRUG|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
219086638|NCT03613311|DIAGNOSTIC_TEST|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
219086639|NCT04042857|DEVICE|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
219086640|NCT01055730|OTHER|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
219086641|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
219086642|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
219214237|NCT00463983|DRUG|octreotide|
219214238|NCT04160507|OTHER|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
219214239|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
219086643|NCT04737564|BEHAVIORAL|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
219086644|NCT00778128|DRUG|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
219086645|NCT00778128|DRUG|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
219086646|NCT03448445|OTHER|Usual care setting|usual care settings without any intervention
219086647|NCT04178057|BIOLOGICAL|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
219086648|NCT04178057|BIOLOGICAL|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
219086649|NCT04178057|BIOLOGICAL|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
219214240|NCT06749626|OTHER|progressive relaxation exercise|Relaxation exercises CD developed by the Turkish Psychologists Association; It consists of muscle exercises, rhythmic breathing and music recital. The CD content, which includes relaxation exercises accompanied by music, was prepared by Psychologist Elif Kabak and voiced by Tülay Bursa. The CD, which includes deep breathing and muscle relaxation exercises, consists of three parts. The first section includes the definition of deep relaxation, the purpose of relaxation exercises and the rules to be considered in exercise practice. In the second part; There are relaxation exercises with audio instructions accompanied by streaming sounds. The third part contains relaxation music without instructions. After the information in the first part of the CD is explained to the patients in the experimental group, the second part, which lasts only approximately 30 minutes, will be administered under the supervision of the researcher. However, since the patients have undergone abdominal surgery, the
219214241|NCT04056013|DEVICE|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
219214242|NCT06757803|PROCEDURE|rertrolaminar block|"Positioning~The patient is positioned in a lateral decubitus position with the affected side up. The patient's arm on the affected side is placed behind the head. The patient's spine is aligned and the shoulder is elevated to expose the paravertebral space.~\*Ultrasound imaging~A high-frequency linear ultrasound probe (5-12 MHz) is placed in a paramedian sagittal plane at the desired level of block. The probe is oriented so that the transverse processes are visualized on the lateral side of the screen and the vertebral laminae are visualized on the medial side of the screen. The interlaminar space is visualized as a hypoechoic region between the laminae.~\*Needle insertion~A short bevel block needle (20-22 G) is inserted through the skin at the caudal end of the ultrasound probe, aiming cephalad. The needle is advanced under real-time ultrasound guidance until the tip of the needle contacts the lamina. The needle is then slightly withdrawn and the local anesthetic is injected into t"
219086650|NCT04178057|BIOLOGICAL|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
219086651|NCT00006048|DRUG|cisplatin|
219086652|NCT00006048|DRUG|gefitinib|
219086653|NCT00006048|DRUG|gemcitabine hydrochloride|
219086654|NCT04539821|OTHER|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
219361895|NCT03895125|BEHAVIORAL|[year2-3] dual-task training with internal and external focus|internal focus: focus mainly on body movements external focus: focus mainly on object in the environment
219361896|NCT06536400|DRUG|HSK42360|Oral administration, QD
219361897|NCT04428177|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
219681801|NCT02137148|DEVICE|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
219086655|NCT01720290|DRUG|repaglinide|Dose individually adjusted
219086656|NCT01720290|DRUG|metformin|Dose individually adjusted
219086657|NCT01720290|DRUG|metformin|Dose at 1000 mg/day
219086658|NCT04980664|OTHER|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
219086659|NCT05078151|DIAGNOSTIC_TEST|Whole-Body Diffusion Weighted MRI|MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
219214243|NCT06757803|PROCEDURE|paravertebral block|"* Patient Preparation~* Place the patient in the lateral decubitus position with the side of the block facing up.~* Position the patient's arm so that it is resting comfortably on the operating table.~* Prepare the skin over the block site with an antiseptic solution.~* Sterilely drape the area.~* Ultrasound Imaging~* Place the ultrasound probe in a transverse plane at the level of the desired block.~* Identify the following anatomical landmarks:~* Vertebral body~* Transverse process~* Pleura~* Intercostal space~* Needle Insertion~Use a sterile ultrasound-guided needle. Insert the needle in-plane from a lateral to medial direction, aiming for the apex of the paravertebral space.~The needle should be advanced until it is just beyond the transverse process.~\*Test Aspiration~Aspirate to ensure that the needle is not in a blood vessel.~* Local Anesthetic Injection~* Inject the local anesthetic slowly, aspirating frequently.~* The local anesthetic should be injected int"
219214244|NCT06754072|OTHER|Virtual Keyboard (VK) System|Participants underwent a 4-week training program comprising 12 one-hour sessions to enhance finger individuation and motor control using a virtual reality platform.
219214245|NCT06762821|PROCEDURE|Single-visit revascularization|Revascularization protocol will be performed in single visit
219214246|NCT06762821|PROCEDURE|Multiple-visit revascularization|Revascularization protocol will be performed in multiple visit
219214247|NCT02307682|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection
219214248|NCT02307682|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection
219214249|NCT06766578|RADIATION|Neoadjuvant Therapy(5×3Gy radiotherapy)|Radiotherapy: 5×3Gy. The preoperative radiotherapy target was outlined by radiotherapy physicians according to the NCCN Guidelines for Gastric/esophagogastric Junction Tumor 2024 edition and the surgeon's opinions. The first and third cycles were 5×3Gy.
219214250|NCT06766578|DRUG|Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)|The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
219214251|NCT06766578|PROCEDURE|Surgical treatment|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
219086660|NCT01439607|OTHER|Bone marrow and blood sampling|Bone marrow and blood sampling
219086661|NCT03859414|DRUG|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
219086662|NCT03859414|DRUG|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
219086663|NCT03859414|DRUG|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
219086664|NCT03859414|DRUG|Placebo|CHF 5993 placebo pMDI
219086665|NCT01840553|DRUG|oral sodium phosphate tablets|
219086666|NCT01840553|DRUG|polyethylene glycol|
219086667|NCT00309530|DRUG|5-fluorouracil, levamisol, interferon|
219086668|NCT02641392|DRUG|GED-0301|Mongersen
219086669|NCT02641392|OTHER|Placebo|Placebo
219681802|NCT05122624|OTHER|PredicTB score|"This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score."
219086670|NCT00168545|BIOLOGICAL|Measles vaccine|
219086671|NCT00402480|DRUG|Hydroxyurea|
219086672|NCT02691182|DRUG|SPN-810|
219086673|NCT04167241|DIAGNOSTIC_TEST|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
219086674|NCT03197012|DRUG|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
219086675|NCT03197012|DRUG|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
219086676|NCT02333214|OTHER|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
219086677|NCT02333214|OTHER|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
219086678|NCT02525757|DRUG|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
219681803|NCT00215644|DRUG|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
219086679|NCT02525757|DRUG|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
219086680|NCT02525757|DRUG|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
219086681|NCT02525757|RADIATION|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
219086682|NCT01550198|DEVICE|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
219086683|NCT02434094|BEHAVIORAL|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
219086684|NCT04152902|OTHER|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
219086685|NCT04152902|OTHER|Quality of life|SF-36 Questionnaire
219214252|NCT06766578|DRUG|Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
219086686|NCT02256670|BEHAVIORAL|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
219086687|NCT05531279|DRUG|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
219086688|NCT04635579|DEVICE|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
219086689|NCT03075384|PROCEDURE|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
219086690|NCT00845884|DRUG|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"* Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
219086691|NCT04839263|PROCEDURE|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op"
219214253|NCT04272827|PROCEDURE|Liposuction|"Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions."
219086692|NCT04116749|OTHER|Water|Drink water freely until 2 hours before anesthesia.
219086693|NCT04897984|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
219086694|NCT01053195|BEHAVIORAL|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
219086695|NCT01694784|BEHAVIORAL|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
219086696|NCT01694784|BEHAVIORAL|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
219214254|NCT06828146|OTHER|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.
219214255|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
219214256|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
219214257|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
219214258|NCT06028334|BEHAVIORAL|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
219681804|NCT00215644|DRUG|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
219681805|NCT00215644|DRUG|Cisplatin|Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
219681806|NCT00215644|DRUG|Capecitabine|Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
219681807|NCT01745562|DRUG|Alprazolam 0.5 mg|Reference product
219681808|NCT01745562|DRUG|Alprazolam 0.5 mg|Test product
219681809|NCT00125060|DRUG|Simvastatin (20mg versus 80mg/day)|
219681810|NCT03671655|DEVICE|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
219086697|NCT01694784|BEHAVIORAL|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
219086698|NCT01694784|BEHAVIORAL|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
219086699|NCT02531178|BIOLOGICAL|ABBV-257|subcutaneous injection
219086700|NCT02531178|BIOLOGICAL|Placebo|Placebo for ABBV-257
219086701|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
219086702|NCT04122248|DEVICE|cervical total disc replacement|Artificial disc replacement (ADR) in the cervical spine is a minimally invasive procedure that involves removing diseased disc tissue and replacing it with an artificial disc. The artificial disc is designed to preserve the spine\&#39;s natural motion while remaining securely attached to the surrounding vertebral bones. The goal of ADR is to help preserve the motion of the cervical spine or spinal segment after surgery, which can improve the quality of life for patients.
219086703|NCT02563002|DRUG|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
219086704|NCT02563002|DRUG|FOLFIRI|Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
219086705|NCT02563002|BIOLOGICAL|Pembrolizumab|IV infusion
219086706|NCT02563002|BIOLOGICAL|Bevacizumab|IV infusion
219086707|NCT02563002|BIOLOGICAL|Cetuximab|IV infusion
219214259|NCT06028334|BEHAVIORAL|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
219214260|NCT06305364|DEVICE|Gixam|Participants will be required to extend their tongue in the Gixam device. Six images will be obtained and analyzed by the artificial intelligence (AI) model generating a prediction score for the presence of colorectal adenoma.
219214261|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
219214262|NCT04909268|DIAGNOSTIC_TEST|HIV testing|serology for HIV testing
219214263|NCT06861205|OTHER|This is an observational study|This is an observational study
219214264|NCT06615505|OTHER|VIA Disc NP|Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).
219681811|NCT03671655|DEVICE|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
219681812|NCT01967680|PROCEDURE|Non-sedation for intubated, mechanically ventilated patients|
219681813|NCT01967680|PROCEDURE|Controlgroup, sedation with daily wake-up trial|
219086708|NCT06839092|PROCEDURE|oxaliplatin-based PIPAC|"Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6 weeks apart).~Each PIPAC session will include exploration laparoscopy (with PCI score), peritoneal lavage for cytology and biopsies of healthy peritoneum of the four quadrants + Douglas + omentum), and oxaliplatin-based PIPAC."
219086709|NCT06839092|PROCEDURE|Control (Standard treatment)|Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy, followed by exploration laparoscopy (including 300ml peritoneal lavage for cytology and seven punch peritoneal biopsies in the four quadrants of the abdomen, Douglas and omentum, as well as peritonectomy of 1 cm2) at 6 months after index surgery before entering a standard surveillance program.
219214265|NCT06615505|OTHER|Sham Injection|"Participants will receive the sham procedure at 1 or 2 levels.~The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc."
219214266|NCT06487572|DRUG|Risankizumab|Intravenous (IV) Infusion
219214267|NCT06487572|DRUG|Risankizumab|Subcutaneous (SC) Injection
219214268|NCT04683250|DRUG|TAS0953/HM06|Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
219214269|NCT04683250|DRUG|TAS0953/HM06|Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
219214270|NCT06770621|DIAGNOSTIC_TEST|Insulin-induced hypoglycemia test|For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.
219681814|NCT06283953|BEHAVIORAL|Trach Plus|The Trach Plus program includes education, social support, and outreach to outpatient care team.
219681815|NCT06283953|BEHAVIORAL|Trach Me Home|The Trach Me Home discharge program includes caregiver education, skills training and case management.
219086710|NCT05008029|PROCEDURE|In situ immobilization|Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
219086711|NCT05008029|PROCEDURE|Reduction under general anesthesia|The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
219214271|NCT06770621|DIAGNOSTIC_TEST|Glucagon profile|The subject must fast before the consultation and follow a specific diet the day before; after an initial blood draw (P1), the patient will have breakfast and take any required insulin, followed by two additional blood draws 1.5 hours after breakfast (P2) and 1.5 hours after P2 (P3)
219214272|NCT06770621|OTHER|Biological sample once|The exome of each patient will then be analyzed from the blood sample taken beforehand.
219214273|NCT06770621|OTHER|Observation-questionnaire|only the answer to a questionnaire
219214274|NCT06783855|PROCEDURE|suspension uretheroileal technique|The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra
219214275|NCT06783855|PROCEDURE|conventional radical cystectomy and ileal neobladder|After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra, including the mucosa and muscularis of the neobladder neck, ensuring mucosa-to-mucosa anastomosis
219214276|NCT06791200|DIAGNOSTIC_TEST|biochemical indices|some biochemical indices for prediction of Acute kidney Injury
219214277|NCT06740084|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the EUC plus the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised Guidance and Counselling Coordinators (GCC) at schools in 6 sessions. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the GCC helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
219214278|NCT06740084|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC): Guidance and counselling coordinators in the schools provide some counselling to students who need it. Building on the existing structure, enhanced usual care in the Y-mind programme, will be enhanced in three ways: 1) Teaching staff will receive basic training on common mental health conditions affecting youth in Ghana with an emphasis on depression and suicidal symptoms and treatment. The WHO guidelines for school health services will form the basis for the training for teachers. 2) Nurses in all schools and other relevant local health care professionals will be trained in mental health, substance-use and self-harm including guidelines on when and where to refer young people for psychiatric care. The World Health Organization (WHO) Mental Health Gap intervention guide (mhGAP) will be used for training of nurses and other health care professionals . 3) The study team will provide a letter for the Guidance and Counselling Coordinators for the participant.
219086712|NCT01800773|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
219086713|NCT01800773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
219086714|NCT05682911|DRUG|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
219086715|NCT05682911|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
219086716|NCT05362981|OTHER|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
219086717|NCT00676286|PROCEDURE|3T MR Imaging|3TR Imaging
219086718|NCT00676286|PROCEDURE|C-Choline PET Scanning|C-Choline PET Scanning
219086719|NCT00676286|PROCEDURE|Gene Rearrangement|Gene Rearrangement
219086720|NCT02123602|OTHER|core stabilization|
219086721|NCT02123602|OTHER|lower extremity training only|
219086722|NCT05852132|PROCEDURE|pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
219086723|NCT05852132|PROCEDURE|Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
219086724|NCT05852132|PROCEDURE|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
219086725|NCT04874402|PROCEDURE|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
219086726|NCT04874402|PROCEDURE|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
219086727|NCT02745665|OTHER|flow mediated dilation (endothelial function)|
219086728|NCT02745665|OTHER|ABPI|
219086729|NCT02745665|OTHER|Pulse wave velocity and augmentation index|
219214279|NCT06889259|BEHAVIORAL|CBT based digital therapeutics|The mobile-based digital therapeutic intervention integrated video education, thought record sheets, and sound therapy. This comprehensive treatment was administered five times weekly. The program consisted of a total of 30 sessions.
219214280|NCT06889259|BEHAVIORAL|Conventional CBT|The cognitive behavioral therapy program for tinnitus, based on a paper manual, was administered five times per week. The treatment regimen consisted of a total of 30 sessions,.
219214281|NCT04328532|DEVICE|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
219214282|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
219214283|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
219214284|NCT06807320|DRUG|MTA pulp dressing material|MTA powder ( ProRoot; Dentsply ⁄ Tulsa Dental, Tulsa, OK,USA) was added to sterile water. The mixture was left to achieve a sandy consistency for about thirty seconds. Then, the material was applied to the cavity using a ball condenser.
219214285|NCT06807320|DRUG|Calcium Hydroxide (Ca(OH)2)|For Group I patients, Calcium hydroxide (Dycal\_ Ivory,Dentsply Caulk, Dentsply, L.D. Caulk, Milford, DE,USA ) was used. The catalyst and paste were mixed as per the manufacturer's recommendations.
219214286|NCT06867393|DRUG|HL-003 tablet Placeco|100mg、250mg、500mg、1000mg、1500mg，SAD
219214287|NCT06867393|DRUG|HL-003 tablet|25mg、100mg、250mg、500mg、1000mg、1500mg，SAD
219214288|NCT06862102|BIOLOGICAL|HPV vaccine|vaccine administration
219214289|NCT06877338|OTHER|Loaded breathing on stable and unstable surfaces|Participants will be instructed to perform 10 loaded breaths via a threshold inspiratory load device on both a stable surface (sitting on a chair, Protocol 1) and an unstable surface (sitting on a soft pad, Protocol 2) in random order. The inspiratory load/resistance will be set at 50% of the maximum inspiratory pressure (MIP).
219214290|NCT06863506|DRUG|befotertinib|Befotertinib will be administered orally at an initial dose of 75 mg once daily for 21 days, with escalation to 100 mg if tolerated. Treatment continues until disease progression, unacceptable toxicity, or withdrawal.
219214291|NCT04588038|BIOLOGICAL|Efineptakin alfa|Given via intramuscular injection
219214292|NCT06839352|DRUG|Vitamin K1|10 mg intravenous infusion daily for three days
219086730|NCT02745665|OTHER|blood pressure|
219086731|NCT02745665|OTHER|ramp test|
219214293|NCT04725110|DRUG|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
219086732|NCT04748081|PROCEDURE|hepatectomy|hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
219086733|NCT05700084|DRUG|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
219086734|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
219086735|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
219086736|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
219086737|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
219086738|NCT05700084|DRUG|Capecitabine|1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
219214294|NCT04725110|OTHER|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
219214295|NCT06817200|DRUG|Amantadine (100mg) as add on therapy.|Amantadine will be administered at the dose of 100 mg t.i.d or b.i.d. (if t.i.d. is not tolerated) over 12 weeks, after a period of 3 weeks of titration.T he study treatment will be stopped after a dose decrease of 100 mg / day every 3 days.
219214296|NCT06817200|DRUG|Placebo|Placebo tablets will be also administered b.i.d. or t.i.d over 12 weeks after a period of 3 weeks of titration. Placebo tablets will be indistinguishable from amantadine ones.
219214297|NCT06740786|DRUG|Dapagliflozin Treatment Group|"This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day)."
219214298|NCT02125149|OTHER|Exercise Intervention|
219214299|NCT06778707|PROCEDURE|External Oblique Intercostal Block|In group E, a needle will be used to pierce the skin, subcutaneous tissue then external oblique muscle to hydrodissect the fascial plane between external oblique muscle and intercostal muscles with 25 ml bupivacaine 0.25 % and 4 mg dexamethasone added to it.
219214300|NCT06778707|PROCEDURE|Subcostal Transversus Abdominis Plane Block|In group T, a needle will be used to pierce the skin, subcutaneous tissue then rectus muscle and 25 ml of 0.25 % bupivacaine with 4 mg dexamethasone will be injected between rectus muscle and transversus abdominis muscle.
219214301|NCT06830824|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
219214302|NCT06830824|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
219214303|NCT06760286|DIETARY_SUPPLEMENT|Lung Care Solution|"Participants in the Breathe-Easy group received the food supplement solution designed to improve lung health and respiratory function. The supplement includes natural ingredients known for their potential to reduce inflammation, improve oxygen utilization, and support overall lung capacity.~Participants used 1 teaspoon of the supplement, prepared as a tea decoction, twice daily."
219214304|NCT06760286|OTHER|Support treatment|Participants in this group engaged in guided lifestyle modifications aimed at improving respiratory health. This included dietary recommendations as part of clinical practice.
219214305|NCT06808412|DRUG|sintilimab combined with bevacizumab and XELOX|Patients with locally advanced low rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvant regimen during the perioperative period.
219214306|NCT06771349|PROCEDURE|sigmoidopexy|"Both Sigmoidectomy and sigmoidopexy can be used for the treatment of sigmoid volvulus. The former is the treatment of sigmoid volvulus by removing a portion of the sigmoid colon, and depending on the patient's condition, a bowel reconstruction or anastomosis may be performed to reattach the healthy bowel segment. The procedure may result in long-term bowel changes and may even require an stomy. sigmoidopexy is a procedure that immobilizes the sigmoid colon to the abdominal wall or pelvic structure, preventing it from twisting again.~The goal of sigmoidectomy is primarily to remove damaged or necrotic portions of the sigmoid colon and to treat complications resulting from sigmoid volvulus, especially when the volvulus results in intestinal necrosis, ischemia, or other serious complications. The goal of sigmoidopexy is to prevent the sigmoid from re-twisting by immobilizing the sigmoid, and it is suitable for those cases of sigmoid torsion without severe ischemia or necrosis."
219214307|NCT06666439|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)|Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.
219086739|NCT05700084|DRUG|Utidelone Capsule (Part 3)|Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.
219086740|NCT01889173|DRUG|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
219214308|NCT06773312|BIOLOGICAL|BC001+Sintilimab+XELOX|patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg（body weight\<60kg）or 200mg（body weight≥60kg）intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.
219214309|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
219214310|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
219214311|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
219214312|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
219214313|NCT06235905|DRUG|NV-5138|NV-5138 is a novel , orally bioavailable, activator of mTORC1
219361898|NCT04428177|DEVICE|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
219681816|NCT00954122|DRUG|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
219361899|NCT00666926|DRUG|PF00562271|125 mg twice daily \[BID\] with food, tablet
219681817|NCT05911126|DRUG|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
219681818|NCT02981199|PROCEDURE|stem cell transplantation|conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
219681819|NCT01030016|DRUG|atenolol|25 mg/day, twice a day for 6 weeks
219086741|NCT01889173|DRUG|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
219086742|NCT01889173|DRUG|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
219086743|NCT01889173|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
219214314|NCT04568473|OTHER|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
219214315|NCT04568473|OTHER|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
219086744|NCT06423755|OTHER|Swimming programme|A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.
219086745|NCT06423755|OTHER|Standard Physiotherapy care|Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
219086746|NCT03191695|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
219086747|NCT01649830|RADIATION|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
219086748|NCT01649830|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
219086749|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
219086750|NCT02139098|DRUG|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
219086751|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
219086752|NCT02139098|DRUG|Placebo|Placebo
219086753|NCT05273125|BEHAVIORAL|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
219086754|NCT06491849|OTHER|Peri-implant Condition Evaluation|This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
219086755|NCT04077619|BEHAVIORAL|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
219214316|NCT05630833|DRUG|Gepotidacin|Gepotidacin will be administered.
219214317|NCT05630833|DRUG|Nitrofurantoin|Nitrofurantoin will be administered.
219214318|NCT05630833|DRUG|Placebo|Placebo will be administered.
219214319|NCT06620276|BEHAVIORAL|Acceptance and Commitment Therapy|8 sessions of one hour of Acceptance and Commitment Therapy delivered one on one by a licensed psychologist with experience and training in this intervention.
219214320|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
219214321|NCT06323460|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219214322|NCT06323460|DRUG|Carboplatin|Given IV
219214323|NCT06323460|DRUG|Cisplatin|Given IV
219214324|NCT06323460|PROCEDURE|Computed Tomography|Undergo PET/CT
219681820|NCT06067867|OTHER|Data extraction from medical files|Data extraction from medical files
219681821|NCT03438084|DIETARY_SUPPLEMENT|Interesterified fat|50 g fat provided as commercially available interesterified fat.
219214325|NCT06323460|RADIATION|External Beam Radiation Therapy|Undergo external beam radiotherapy
219214326|NCT06323460|DRUG|Paclitaxel|Given IV
219214327|NCT06323460|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219214328|NCT06323460|OTHER|Questionnaire Administration|Ancillary studies
219681822|NCT03438084|DIETARY_SUPPLEMENT|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
219681823|NCT03438084|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
219681824|NCT03438084|DIETARY_SUPPLEMENT|Butter|50g fat provided as commercially available spreadable butter
219681825|NCT01416545|BEHAVIORAL|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
219086756|NCT04077619|BEHAVIORAL|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
219086757|NCT05097846|DRUG|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
219086758|NCT05097846|DRUG|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
219086759|NCT05097846|DRUG|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
219214329|NCT06826469|DEVICE|Temporal Interference Stimulation|During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA.
219214330|NCT05567692|DIAGNOSTIC_TEST|OGTT|Oral Glucose Tolerance Test
219214331|NCT05567692|OTHER|HbA1c|HbA1c measurement
219214332|NCT05567692|OTHER|Questionnaire|Follow-up questionnaire
219214333|NCT03905694|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
219681826|NCT01416545|BEHAVIORAL|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
219681827|NCT03559504|DRUG|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
219086760|NCT05097846|DRUG|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
219086761|NCT01862822|OTHER|upright position|
219086762|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
219086763|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
219086764|NCT03447080|OTHER|Ricebran soybean milk|White Bread with rice bran soybean milk
219086765|NCT03447080|OTHER|Soybean milk|White Bread with soybean milk
219086766|NCT03953235|BIOLOGICAL|GRT-C903|a shared neoantigen cancer vaccine prime
219086767|NCT03953235|BIOLOGICAL|GRT-R904|a shared neoantigen cancer vaccine boost
219086768|NCT03953235|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
219086769|NCT03953235|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
219086770|NCT04465019|DEVICE|Exoskeleton Rehabilitation|The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
219086771|NCT00412100|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
219086772|NCT06087341|OTHER|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
219086773|NCT04620291|BIOLOGICAL|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
219086774|NCT00319748|DRUG|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
219086775|NCT04354987|DRUG|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
219086776|NCT04354987|DRUG|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
219086777|NCT00306982|BIOLOGICAL|Fluarix|
219086778|NCT03116048|OTHER|Chronic pain evaluation|Chronic pain assessment with study questionnaire
219214334|NCT06833489|OTHER|ARN extraction from muscle biopsies|"There will be no visits from participants, so we will be using samples already in the Biological Resources Centre (CRB).~RNA will be extracted from muscle biopsies taken as part of the treatment. RNAseq libraries will be sequenced by the Genomics and Bioinformatics Platform (GBiM) at Marseille Medical Genetics (MMG, U1251, AMU). Sequencing will be performed in paired-end (2\*100 bp) on Illumina's Novaseq 6000 system (50 million clusters per sample, 100 M paired-end reads) and then analysed by bioinformatics."
219214335|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
219214336|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
219214337|NCT06379750|OTHER|Nurse-delivered care using WelTel check-ins and BCC SMS|Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS
219214338|NCT06379750|OTHER|Community-based peer-support model|Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring
219214339|NCT06817616|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 2.5X10 cells/0.5mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   \- High dose: 5X10 cells/1mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
219214340|NCT05061316|DIETARY_SUPPLEMENT|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
219214341|NCT06759038|DEVICE|C-MAC blade D video laryngoscope|C-MAC blade D Video Laryngoscope is used for difficult intubation and for better glottic view
219214342|NCT06759038|DEVICE|Macintosh Laryngoscope|Macintosh Laryngoscope is conventional laryngoscope used generally for intubations
219214343|NCT05783908|COMBINATION_PRODUCT|With non-magnetic screen|Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
219086779|NCT01179204|PROCEDURE|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
219086780|NCT05305287|DRUG|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
219086781|NCT05305287|OTHER|Placebo|Placebo for pioglitazone
219086782|NCT03087565|PROCEDURE|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
219086783|NCT03087565|PROCEDURE|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing."
219086784|NCT06374446|OTHER|Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.
219086785|NCT06374446|OTHER|Virtual Reality Combined with Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
219086786|NCT06374446|OTHER|Virtual Reality|Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
219086787|NCT06374446|OTHER|Control Group|This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
219086788|NCT03985891|DRUG|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
219086789|NCT03985891|DRUG|Chemotherapy|Folfox
219214344|NCT05661136|DEVICE|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
219214345|NCT05661136|OTHER|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
219214346|NCT06739707|DRUG|MD-18|MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
219214347|NCT04789070|DRUG|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
219214348|NCT04789070|DRUG|Placebo|Placebo
219214349|NCT06779552|DEVICE|CardioMEMS HF System|PA Pressure Sensor
219086790|NCT04334265|DRUG|Anluohuaxian|6g each time, twice a day
219361900|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
219086791|NCT01659190|OTHER|Oiled-limestone liniment|
219086792|NCT01474096|OTHER|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
219086793|NCT02054806|BIOLOGICAL|Pembrolizumab|IV infusion
219086794|NCT00034255|DRUG|INGAP Peptide|
219086795|NCT02781402|PROCEDURE|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
219086796|NCT00885092|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
219086797|NCT00885092|DEVICE|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
219086798|NCT00885092|DEVICE|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
219086799|NCT00885092|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
219086800|NCT00946439|DEVICE|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
219086801|NCT06103214|OTHER|acute normovolemic hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
219086802|NCT06103214|OTHER|acute hypervolemic hemodilution (AHH)|The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
219086803|NCT03627884|DRUG|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
219086804|NCT03627884|DRUG|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
219214350|NCT06038032|BEHAVIORAL|Digital wellness platform|A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
219214351|NCT06038032|BEHAVIORAL|Online healthcare professional support|Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
219214352|NCT06798415|DRUG|Metronidazole|"Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia will be added. The solutions will be injected intralesionally and not subcutaneously."
219214353|NCT06829654|OTHER|Step 1|Cryopreservation of ovarian tissue
219214354|NCT06829654|OTHER|Step 2|Analysis of tumor markers in the primary tumor
219214355|NCT06829654|OTHER|Step 3|Search for neoplastic cells in cryopreserved ovarian tissue
219214356|NCT06829654|OTHER|Step 4|Cryopreserved ovarian tissue autotransplantation
219214357|NCT06813898|PROCEDURE|Computed Tomography|Undergo PET/CT
219214358|NCT06813898|OTHER|Electronic Health Record Review|Ancillary studies
219214359|NCT06813898|OTHER|Flotufolastat F-18 Gallium|Given IV
219214360|NCT06813898|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219214361|NCT06774287|BEHAVIORAL|Karman Line memory strategy training|The memory strategy training consists of six weekly face-to-face treatment sessions. After sessions 3-5, the participant will play 8 levels in total of the Karman Line memory game on their computer or mobile device. In these levels they practice the strategies that are introduced in the face-to-face treatment in a safe digital environment. Also, the Karman Line memory app is provided.
219214362|NCT06774287|BEHAVIORAL|Treatment as usual|Treatment as usual contains ten sessions, with nine obligatory sessions supplemented with 1 (of five) non-obligatory sessions. Which non-obligatory sessions is chosen is dependent on the patients treatment goals.
219214363|NCT06811311|BEHAVIORAL|Ericksonian Hypnotherapy|Ericksonian hypnotherapy is a therapeutic approach that utilizes indirect suggestion, storytelling, and metaphorical language to induce a trance state and facilitate psychological change. This intervention aims to reduce anxiety symptoms, improve emotional regulation, and alter neurophysiological responses as measured by EEG. Participants will undergo 12 individual sessions, each lasting 90 minutes, over a period of 12 weeks.
219214364|NCT05856396|BIOLOGICAL|Triaxis® (Pertussis-containing vaccine)|"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."
219214365|NCT05856396|BIOLOGICAL|Vaxelis® (Pertussis-containing vaccine)|Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
219214366|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
219214367|NCT06780124|DRUG|ZE63-0302 or placebo|The participants will receive ZE63-0302 or placebo
219086805|NCT01113502|DRUG|Eltrombopag|Oral formulation taken daily
219214368|NCT06773650|OTHER|Completion of online survey|The online survey aims to reach a representative sample of the Italian population to identify their knowledge regarding LI
219214369|NCT06780631|OTHER|Web-based diabetic foot education based on health promotion model|The first group can access the training at any time and repeat the training thanks to web-based training.
219361901|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
219086806|NCT04620967|DRUG|Insulin aspart|Insulin aspart (Iasp) in insulin pump
219086807|NCT04620967|DRUG|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
219086808|NCT04782557|DIAGNOSTIC_TEST|EUS-guided portal vein and hepatic vein aspiration|EUS-guided portal vein and hepatic vein aspiration
219361902|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
219214370|NCT06780631|OTHER|Face to face diabetic foot education based on health promotion model|Individuals with Type 2 diabetes in the face-to-face training group will receive face-to-face diabetic foot training in line with the training booklet for approximately 45 minutes, one by one.
219086809|NCT03466424|RADIATION|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
219086810|NCT02238002|PROCEDURE|cataract surgery|The patients of both groups underwent cataract surgery
219086811|NCT04010240|OTHER|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
219086812|NCT03520595|DRUG|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
219086813|NCT03520595|DRUG|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
219086814|NCT03520595|DRUG|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
219086815|NCT00212381|DRUG|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
219086816|NCT00212381|DIETARY_SUPPLEMENT|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
219086817|NCT04996615|OTHER|no intervention|no intervention
219086818|NCT01161979|DRUG|Zonisamide|Zonisamide capsules 100 mg
219086819|NCT01161979|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
219086820|NCT00995501|DRUG|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
219086821|NCT00995501|DRUG|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
219086822|NCT00995501|DRUG|anesthesia management|Light anesthesia to maintain BIS about 55
219086823|NCT00995501|OTHER|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
219086824|NCT00995501|OTHER|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
219086825|NCT00995501|OTHER|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
219086826|NCT03002610|OTHER|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
219086827|NCT03002610|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
219086828|NCT03002610|OTHER|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
219086829|NCT01017354|DRUG|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
219086830|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|60000 vitamin D3 orally and once per month
219086831|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
219086832|NCT06229002|PROCEDURE|Transcranial alternative current stimulation (tACS) at alpha frequency|Single session of tACS
219214371|NCT06059651|PROCEDURE|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
219214372|NCT06827977|DRUG|PRIM-DJ2727|"For oral administration, each dose will contain the number of capsules needed to deliver the lyophilized intestinal bacteria powder derived after lyophilization of 60 g of filtered stool in 300 mL 0.85% NaCl and 2% mannitol. Participants will take the capsules (5-6 capsules twice weekly) from week 2 through week 10. Capsules will be taken over a period of up to one hour to maximize tolerance and ensure the capsules are not expelled by vomiting.~For administration via retention enema, which will be done at baseline and week 11, 50 g of filtered, frozen stool in 250 mL of 0.85% sodium chloride (NaCl) will be used."
219214373|NCT06827977|DRUG|Placebo|Placebo will be administered as capsules from week 2-10 and as enema at baseline and week 11.
219214374|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
219214375|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
219214376|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
219214377|NCT06775418|PROCEDURE|Ultrasound erector spinae plane block|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group U (15 patients):will receive bilateral US guided single shot ESPB, 30 ml of bupivacaine 0.25% on each side after induction of anesthesia."
219086833|NCT06229002|PROCEDURE|Sham stimulation|Single session of tACS sham stimulation
219086834|NCT04878835|BIOLOGICAL|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
219086835|NCT06291610|BEHAVIORAL|Clinical trial decision support intervention|"1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention."
219086836|NCT02454192|BEHAVIORAL|CHAMPS|
219086837|NCT02253355|DEVICE|Deep Brain Stimulation|
219086838|NCT05521425|DEVICE|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
219086839|NCT03865602|BEHAVIORAL|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
219086840|NCT03865602|BEHAVIORAL|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
219086841|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
219086842|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
219086843|NCT01701414|DRUG|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
219086844|NCT01701414|DRUG|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
219086845|NCT05280418|BIOLOGICAL|Tezepelumab|Monoclonal antibody designed for the treatment asthma.
219086846|NCT05280418|BIOLOGICAL|Placebo|Matched placebo.
219086847|NCT00149305|OTHER|Genetic analyses|
219086848|NCT00149305|OTHER|Genetic analyses|
219086849|NCT03617744|PROCEDURE|Sleeve gastrectomy|Open sleeve gastrectomy
219086850|NCT05514912|DRUG|Cisplatin|Given IV
219086851|NCT05514912|DRUG|Gemcitabine Hydrochloride|Given IV
219214378|NCT06775418|PROCEDURE|dexamedotomidine infusion after induction of anesthesia|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group D (15 patients):will receive the study drug infusion (Dexmedetomidine) after induction of anesthesia."
219214379|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
219086852|NCT05514912|DRUG|Infigratinib Phosphate|Given PO
219086853|NCT05514912|DRUG|Nab-paclitaxel|Given IV
219086854|NCT01531166|DRUG|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
219086855|NCT06029101|PROCEDURE|posterior fossa craniectomy with or without duraplasty|craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
219086856|NCT04547374|OTHER|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
219086857|NCT01362439|DRUG|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
219086858|NCT03233802|BEHAVIORAL|Individualized Assess & Treatment (IATP)|See previous description
219086859|NCT03233802|BEHAVIORAL|Packaged Cognitive-Behavioral (PCBT)|See previous description
219086860|NCT03233802|BEHAVIORAL|Case Management (CaseM)|See previous description
219214380|NCT06758713|BIOLOGICAL|CAR-T|CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.
219214381|NCT06812559|DRUG|Progesterone|compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.
219214382|NCT06812559|DRUG|GnRH antagonist (Cetrorelix)|Subcutaneous injection
219214383|NCT06779227|BEHAVIORAL|Hospital family transitional nursing intervention|The intervention group received a transitional care intervention mainly focused on the transitional care model (TCM).
219214384|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
219361903|NCT01180803|DEVICE|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
219086861|NCT00114179|DRUG|capecitabine|Given orally
219086862|NCT00114179|RADIATION|radiation therapy|Undergo radiotherapy
219086863|NCT00114179|BIOLOGICAL|bevacizumab|Given IV
219086864|NCT00114179|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219086865|NCT00114179|DRUG|gemcitabine hydrochloride|Given IV
219086866|NCT04108455|OTHER|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
219086867|NCT05273632|DRUG|Oxytocin|trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
219086868|NCT04710745|DIAGNOSTIC_TEST|Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.|Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
219086869|NCT04710745|DIAGNOSTIC_TEST|Echocardiography|"ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index"
219086870|NCT04710745|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives an ECG Holter for a 7-day monitoring.
219214385|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
219214386|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
219214387|NCT06767878|BEHAVIORAL|PORTiSOFIE|"This treatment is based on the Clark and Wells model of social phobia, and it is constituted by 9 modules:~1. Introduction of the program and overview of social anxiety disorder and symptoms~2. Negative automatic thoughts~3. Challenging negative automatic thoughts~4. Behavioral experiments~5. Exposure~6. Exposure and self-focus attention~7. Exposure and get closer to fears~8. Social skill training~9. Maintenance plan"
219086871|NCT04710745|DIAGNOSTIC_TEST|Standardized Mini-Mental Status Exam (SMMSE)|A screening test for evaluating cognitive performance of patients done in the clinician's office.
219086872|NCT00063284|DEVICE|Magstim Rapid Magnetic Stimulator|
219086873|NCT00777374|DRUG|Patch|epicutaneous application of allergen patch
219214388|NCT06775106|OTHER|There is no intervention in this observational study|No direct intervention will be done to patients eligible for the study. There will be a shunt placed to divert 5-15% of exhaled breath into a collection tube. This will not affect the patient's existing standard medical care.
219086874|NCT00777374|DRUG|Placebo patch|epicutanoeus application of a placebo patch
219086875|NCT04609267|DIAGNOSTIC_TEST|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
219086876|NCT00047775|DRUG|BiDil|
219086877|NCT03116984|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
219086878|NCT03116984|RADIATION|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
219086879|NCT04851548|PROCEDURE|hyaluronic acid|after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
219086880|NCT01133158|DRUG|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
219086881|NCT05777798|DEVICE|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
219086882|NCT00115141|DRUG|Resiquimod|
219086883|NCT00831064|PROCEDURE|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
219086884|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
219086885|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
219086886|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
219086887|NCT04890535|DRUG|TBAJ-587|oral suspension
219086888|NCT04890535|DRUG|Placebo|matching placebo oral suspension for TBAJ-587
219086889|NCT01127282|DRUG|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
219086890|NCT01127282|DRUG|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
219086891|NCT05333354|OTHER|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
219086892|NCT01281644|DEVICE|Diode Laser|810 nm diode laser
219086893|NCT03404310|DIETARY_SUPPLEMENT|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
219086894|NCT03404310|OTHER|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
219086895|NCT00065585|PROCEDURE|Accupuncture|
219086896|NCT01497522|DRUG|Vildagliptin|vildagliptin 50 mg twice daily
219086897|NCT01497522|DRUG|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
219086898|NCT04006561|RADIATION|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
219086899|NCT06259422|DRUG|Iohexol|Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
219086900|NCT06259422|DIAGNOSTIC_TEST|125I-iothalamate and 131I-hippuran|Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
219214389|NCT06795776|DRUG|Eschscholzia tablets|"The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material."
219086901|NCT04879290|OTHER|FiO2 0.5|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 0.5 (50%)
219086902|NCT04879290|OTHER|FiO2 1|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 1 (100%)
219086903|NCT00614081|DEVICE|Contrast-enhanced dynamic MRI|
219214390|NCT06795776|DRUG|Placebo Tablets|A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.
219086904|NCT04920357|DRUG|Vaccination|Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
219086905|NCT02132845|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
219086906|NCT02132845|DRUG|targeted therapy|Receive target-directed therapy
219086907|NCT02132845|PROCEDURE|therapeutic procedure|Receive standard of care therapy
219086908|NCT02132845|OTHER|laboratory biomarker analysis|Correlative studies
219086909|NCT03083314|PROCEDURE|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
219086910|NCT03083314|PROCEDURE|COMPLETE AXILLARY DISSECTION (ALND)|
219086911|NCT03006484|OTHER|No intervention|No intervention will be needed.
219086912|NCT00877279|DEVICE|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
219086913|NCT00877279|DEVICE|Belotero Soft|Dermal Filler
219086914|NCT05294796|COMBINATION_PRODUCT|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
219214391|NCT05397457|DEVICE|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
219214392|NCT05701150|OTHER|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
219214393|NCT05701150|OTHER|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
219214394|NCT06758570|DIETARY_SUPPLEMENT|Pectin dosages|15 individuals were provided with increasing doses of pectin: 5g for 2 weeks 10g for 2 weeks 15 for 2 weeks
219681828|NCT02511041|DRUG|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
219681829|NCT02511041|DRUG|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
219681830|NCT01684852|OTHER|Medical device, drug-like|
219681831|NCT03365934|DEVICE|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
219681832|NCT03365934|DEVICE|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
219086915|NCT05294796|COMBINATION_PRODUCT|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
219086916|NCT03638206|BIOLOGICAL|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
219086917|NCT02598986|DIETARY_SUPPLEMENT|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
219086918|NCT01325285|DEVICE|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
219086919|NCT03514602|BEHAVIORAL|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
219086920|NCT03514602|BEHAVIORAL|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
219214395|NCT06742203|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived EVs|WPMDE1 - Whey Protein Milk-Derived EVs, is a white powder obtained by filtration, concentration, and dehydrating whey solution, with the addition of sweeteners and flavorings to balance the taste. The WPMDE1 contains a known concentration of EVs (also known as milk exosomes).
219361904|NCT01180803|DEVICE|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
219086921|NCT02681614|DEVICE|Uronav guided biopsy|"All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.~Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum."
219086922|NCT02681614|DEVICE|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
219086923|NCT00691938|DRUG|LBH589|
219086924|NCT00691938|DRUG|Decitabine|
219086925|NCT04842578|OTHER|Cross- Section of CT Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
219086926|NCT04842578|OTHER|3D simulation Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
219086927|NCT04667299|DRUG|Rabeprazole|20mg bid
219086928|NCT04667299|DRUG|Bismuth potassium citrate|0.6g bid
219086929|NCT04667299|DRUG|Metronidazole|0.4g qid
219086930|NCT04667299|DRUG|Amoxicillin|1g bid
219086931|NCT04390984|DRUG|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
219086932|NCT02003352|PROCEDURE|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
219086933|NCT04860518|DRUG|IFN beta-1a|Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
219086934|NCT04860518|DRUG|Dexamethasone|Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
219086935|NCT00452686|BIOLOGICAL|Boostrix|
219086936|NCT00452686|BIOLOGICAL|Chinese DT vaccine|
219086937|NCT04807985|DEVICE|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
219086938|NCT04886479|OTHER|Control|No lens
219086939|NCT04886479|DEVICE|Test Lens|Low Dk HEMA contact lens worn for 3 hours
219086940|NCT01965782|DRUG|[^14C]-LY3023703|Administered orally
219086941|NCT01673763|DEVICE|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
219086942|NCT03776825|DEVICE|Permacol Paste|Permacol Paste Injection
219086943|NCT02028026|DRUG|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
219086944|NCT02028026|DRUG|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
219086945|NCT02753309|DRUG|Sirolimus|
219086946|NCT02756754|DEVICE|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
219086947|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
219086948|NCT01534325|DEVICE|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
219086949|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
219086950|NCT01372657|OTHER|biometry calculation|
219086951|NCT02521662|DRUG|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
219086952|NCT02521662|DEVICE|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
219086953|NCT02521662|DRUG|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
219086954|NCT02521662|BEHAVIORAL|Behavioural support|Withdrawal-oriented behavioural support
219086955|NCT01844284|DEVICE|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
219086956|NCT01844284|DEVICE|Absorb™ BVS|Subjects receiving Absorb™ BVS
219086957|NCT03017430|DRUG|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
219214396|NCT06771778|OTHER|Survey using a questionnaire.|A Qualtrics link was provided for current and former NICU RDNs to complete a 10-minute online survey that provided an optional gift card for completion. Part 1 of the survey had eight questions, and part 2 had eleven additional questions.
219086958|NCT03017430|DRUG|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
219086959|NCT03017430|DRUG|Doxylamin|
219086960|NCT03017430|DRUG|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
219086961|NCT00611858|DRUG|Cetuximab|
219086962|NCT00611858|DRUG|5-Fluorouracil|
219214397|NCT06935799|PROCEDURE|One minute intercostal nerves cryoanalgesia|One-minute cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
219214398|NCT06935799|PROCEDURE|Two minutes intercostal nerves cryoanalgesia|Two-minutes cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
219214399|NCT06939842|OTHER|Menthol ice|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and menthol ice will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, menthol ice will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
219214400|NCT06939842|OTHER|Frozen saline|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and frozen saline will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, frozen saline will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
219214401|NCT06939842|OTHER|No Interventions|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Introduction Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with Numerical Pain Scale(NPS) will be evaluated. Patients in the control group will be waited for approximately 10 minutes, taking into account the application times in the intervention groups. No intervention will be applied during the waiting period. After 10 minutes of waiting time, thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes. Considering the 2nd application time in the intervention groups, it will be waited again for approximately 10 minutes without any intervention. After the waiting period, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
219214402|NCT06836895|BEHAVIORAL|HIIT and IMT|The HIIT protocol involved four intervals, each lasting 4 minutes, beginning at 70% of maximum power and building to a target intensity of at least 85% HRmax. The IMT sessions included 2-3 sets of 30 breaths (totaling 60-90 breaths per session), with a two-minute rest between sets, three days per week starting with 30% of PImax and reaching 60% of PImax.
219214403|NCT06836895|OTHER|walking|30-min walking
219086963|NCT00611858|RADIATION|Radiation|
219086964|NCT04701463|DIETARY_SUPPLEMENT|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate|2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
219086965|NCT04701463|COMBINATION_PRODUCT|Placebo|Isocaloric formula
219086966|NCT04085302|DEVICE|Digital Behaviour Change Intervention|14 days
219086967|NCT01058304|OTHER|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
219086968|NCT01058304|OTHER|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
219086969|NCT02317939|OTHER|instruction|online instruction tutorials at followup visits
219086970|NCT02317939|OTHER|standard baseline instruction|self-guidance at followup visits
219086971|NCT04344639|OTHER|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
219086972|NCT01820559|DRUG|Placebo|Tablets
219086973|NCT01820559|DRUG|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
219086974|NCT01820559|DRUG|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
219086975|NCT02755597|DRUG|Venetoclax|Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
219086976|NCT02755597|DRUG|Bortezomib|Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.
219086977|NCT02755597|DRUG|Dexamethasone|Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
219086978|NCT02755597|DRUG|Placebo for venetoclax|Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
219086979|NCT05782725|OTHER|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
219086980|NCT04496102|DEVICE|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
219086981|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
219086982|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
219086983|NCT05642468|DRUG|Ritivixibat|10mg tablet A3907 administered orally
219086984|NCT04642898|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
219086985|NCT04642898|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
219086986|NCT04642898|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
219086987|NCT03574597|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
219086988|NCT03574597|DRUG|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
219086989|NCT01952223|DRUG|Cabazitaxel|Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
219086990|NCT01952223|RADIATION|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
219086991|NCT01952223|RADIATION|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
219086992|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
219086993|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
219086994|NCT03434678|PROCEDURE|Open Pancreaticoduodenectomy|Whipple' Procedure
219086995|NCT04654377|OTHER|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
219086996|NCT04064489|OTHER|TRIPscore|TRIPcast score calculation
219361905|NCT05481866|OTHER|Oropharyngeal administration of colostrum|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.
219681833|NCT03365934|DEVICE|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
219681834|NCT03365934|DEVICE|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
219361906|NCT05481866|OTHER|Oropharyngeal administration of sterile water|The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
219681835|NCT03365934|OTHER|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
219681836|NCT03365934|OTHER|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
219681837|NCT03106883|BEHAVIORAL|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
219681838|NCT03106883|BEHAVIORAL|Sham training|3 sessions of sham attention training using non-affective stimuli
219086997|NCT01446081|BEHAVIORAL|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
219086998|NCT06060457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219086999|NCT06060457|BIOLOGICAL|mRNA-1345|Suspension for injection
219087000|NCT06060457|BIOLOGICAL|Fluzone HD|Suspension for injection
219087001|NCT03468010|RADIATION|chemoradiation|radiation with concurrent ciplatin
219087002|NCT03468010|DRUG|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
219087003|NCT02061202|DRUG|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
219087004|NCT02061202|DRUG|Placebo|placebo training inhaler with the same instructions as the experimental group.
219087005|NCT04803981|OTHER|SpoonfulONE|SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
219087006|NCT03509740|DRUG|tramadol|100 mg tramadol in 100 ml saline with slow infusion
219087007|NCT03509740|DRUG|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
219087008|NCT01528384|DRUG|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
219214404|NCT06766279|PROCEDURE|Osteopathic Manipulative Treatment|"The OMT intervention in this study will be comprised of an occipitoatlantal (OA) decompression and treatment of the nasal Chapman point. The OA decompression will be applied for 2 minutes with 12N of pressure as this pressure has been determined to produce the greatest effect. Treatment at this level reduces congestion of nasal mucosa. The suboccipital decompression technique is generally considered to bear minimal risks and is perceived by most patients as a pleasant experience. This technique is considered to be a basic skill among osteopathic physicians. It is usually taught within the first semester of the first year at Colleges of Osteopathic Medicine.~The other intervention technique will be addressing the nasal Chapman points that are found at the tip of the transverse process of C1 and the costochondral junction of the first rib on each side. Both techniques are performed while the subject is supine."
219214405|NCT06766279|PROCEDURE|Sham treatment|The sham intervention will consist of the subject lying supine with the investigator's hands resting gently on both sides of subject's neck for 5 minutes.
219214406|NCT06847737|DIAGNOSTIC_TEST|perfusion index|To compare the incidence of hypotension after spinal anesthesia and the values of perfusion index, pleth variability index, tissue oxygen saturation and tissue hemoglobin index between those who developed hypotension and those who did not develop hypotension over time.
219214407|NCT06954207|DEVICE|Non interventional. Data collection concerns routine procedures and monitoring devices|Non interventional. Physiological parameters under general anesthesia are collected (arterial pressure, heart rhythm, bispectral index, NOL index, temperature, total dose of remifentanil infusion, analgesic drugs infusions). After surgery, pain scores (NRS), motor function and time to ambulation are also collected.
219214408|NCT06953856|OTHER|occlusal reduction|Occlusal reduction is a procedure that applied patients for different aims. One of these aims is pain relief after endodontic treatment and there are some studies about this topic however, there is no consensus about it. This discrepency could be related to differences of the inclusion criteria for this reason this study aimed to get a reliable result.
219087009|NCT06239870|DRUG|Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy|Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
219087010|NCT02863484|OTHER|surgery|pealing of the outer layer of the cavernous sinus
219087011|NCT01992679|BEHAVIORAL|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
219087012|NCT04560491|DIAGNOSTIC_TEST|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
219087013|NCT04503525|OTHER|Nutritional assessment|Nutritional assessment in COVID patients
219087014|NCT01534026|DRUG|Aspirin|Current dose
219087015|NCT01534026|OTHER|withdrawal of aspirin|Stopping current dose of aspirin
219087016|NCT02317926|DRUG|Levothyroxine|
219087017|NCT02317926|DRUG|Levothyroxine Plus Liothyronine|
219087018|NCT02317926|DRUG|Desiccated Thyroid Extract|
219087019|NCT05189951|OTHER|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
219087020|NCT05189951|OTHER|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
219087021|NCT05189951|OTHER|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
219087022|NCT05288426|OTHER|No intervention|This is an observational study, with no intervention.
219087023|NCT04885556|DEVICE|Tampon-like device for absorption of sexual fluids|Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
219087024|NCT03419364|DRUG|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
219087025|NCT02073461|DRUG|CD1579 2.5%|
219087026|NCT02073461|DRUG|CD1579 5%|
219087027|NCT02073461|DRUG|Vehicle|
219087028|NCT03120754|PROCEDURE|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
219087029|NCT03120754|PROCEDURE|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
219087030|NCT04900623|DEVICE|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
219087031|NCT04900623|RADIATION|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
219087032|NCT04900623|DRUG|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
219087033|NCT05484388|DEVICE|SN2|Investigational device absorption level Normal
219087034|NCT05484388|DEVICE|SP3|Investigational device absorption level Plus
219214409|NCT06953193|PROCEDURE|General Anesthesia|"Patients will undergo balanced general anesthesia for pancreatoduodenectomy. Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~Anesthesia maintenance will be achieved with sevoflurane (variable concentration as per anesthesiologist discretion) and continuous fentanyl infusion according to the attending anesthesiologist's judgment.~No epidural catheter will be placed."
219214410|NCT06953193|PROCEDURE|Combined General Anesthesia (Thoracic Epidural)|"Patients will undergo combined general anesthesia (thoracic epidural) for pancreatoduodenectomy.~Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~A thoracic epidural catheter will be placed at the best palpable intervertebral space between T6-T9 by the attending anesthesiologist.~Anesthesia maintenance will include sevoflurane (variable concentration), fentanyl infusion at the anesthesiologist's discretion, and continuous infusion of 0.25% bupivacaine via the epidural catheter throughout the surgery."
219087035|NCT01338025|DRUG|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
219087036|NCT01338025|DRUG|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
219087037|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
219087038|NCT02381522|OTHER|Remote Ischemic Pre-conditioning|
219087039|NCT02381522|OTHER|Sham RIPC|
219214411|NCT06953999|DRUG|Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
219214412|NCT06953999|DRUG|Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
219361907|NCT04586829|OTHER|Diet|\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
219361908|NCT00402441|DRUG|Risedronate (HMR4003)|
219087040|NCT05884216|DEVICE|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
219087041|NCT05884216|DEVICE|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
219087042|NCT05547295|OTHER|Numeric prevention|Numeric information for prevention of pressure sores thgrough digital tool MEDIASCREEN
219087043|NCT05547295|OTHER|Paper prevention|Information for prevention of pressure sores in classic way with paper
219087044|NCT06088277|BEHAVIORAL|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
219087045|NCT06088277|BEHAVIORAL|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
219087046|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
219087047|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
219087048|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
219087049|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
219087050|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 10|Subjects will consume 10 grams of fructan
219087051|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
219087052|NCT00988403|DIETARY_SUPPLEMENT|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
219087053|NCT05576584|DRUG|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
219087054|NCT05576584|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
219087055|NCT06423326|PROCEDURE|Biopsy|Undergo biopsy
219087056|NCT06423326|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219087057|NCT06423326|DRUG|Cisplatin|Given IV
219087058|NCT06423326|PROCEDURE|Computed Tomography|Undergo CT
219087059|NCT06423326|DRUG|Gemcitabine|Given IV
219087060|NCT06423326|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219087061|NCT06423326|DRUG|Nab-paclitaxel|Given IV
219087062|NCT06423326|PROCEDURE|Pancreatic Surgical Procedure|Undergo surgical resection
219087063|NCT06981299|DRUG|PROT-001|Orally bioavailable small molecule kinetic stabilizer of lambda light chains (λLCs).
219087064|NCT06602193|DRUG|BIIB122 225 mg|Administered as specified in the treatment arm
219087065|NCT06602193|OTHER|BIIB122-Matching Placebo|Administered as specified in the treatment arm
219087066|NCT03175770|PROCEDURE|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
219087067|NCT06233279|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
219087068|NCT06233279|DEVICE|Sham Stimulation|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
219087069|NCT05610852|PROCEDURE|Transvesical Single Port Robotic Partial Prostatectomy|A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
219087070|NCT05610852|PROCEDURE|High-intensity focused ultrasound (HIFU)|Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
219087071|NCT01999166|RADIATION|radiography (X-ray)|
219087072|NCT01999166|GENETIC|DNA sampling|
219214413|NCT06953999|DRUG|Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
219087073|NCT05420636|DRUG|Iadademstat|Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
219087074|NCT05420636|DRUG|Paclitaxel|Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
219087075|NCT06623396|BIOLOGICAL|M28z1XXPD1DNR CAR|Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
219087076|NCT07010289|OTHER|Prepared Meals|Participants will receive the intervention of weekly home meal delivery, consecutively for 4 weeks, delivered to their home. The meals will be provided by Providence Community Kitchen, which is a program of Second Harvest Food Bank of Northwest NC. During the 4 weeks of meal provisions, participants will receive 7 family style frozen dinners delivered to the participant's home weekly. Meals are frozen, have minimal preparation time, and can be heated by oven.
219087077|NCT07010289|OTHER|Grocery Gift Cards|Participants will receive weekly grocery store gift cards, consecutively for 4 weeks. During the 4 weeks of gift card provisions, participants will receive (1) $40.00 grocery store gift card weekly, mailed to participants' home address by study staff.
219214414|NCT06765148|OTHER|Retrospective radiologic study|Retrospective radiologic study
219214415|NCT06766825|DRUG|Plitidepsin 1.5 mg/day|"Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
219214416|NCT06766825|DRUG|Placebo|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
219214417|NCT06766825|DRUG|Placebo and Plitidepsin 1.5mg/day|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
219214418|NCT06954155|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
219214419|NCT06954155|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
219214420|NCT06953349|PROCEDURE|Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis|The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
219214421|NCT06953271|DRUG|Methenamine Hippurate|Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.
219214422|NCT06953271|DRUG|Typically prescribed oral antibiotic prophylaxis|Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.
219361909|NCT03840330|OTHER|Experimental: High-intensity interval training group|16 weeks of High-intensity interval training
219361910|NCT03840330|OTHER|Experimental: Moderate-intensity interval training group|16 weeks of Moderate-intensity interval training
219214423|NCT06953037|OTHER|acupressure|The application will be made to the women in the acupressure group after applying the data collection forms (Personal Information Form, STAI-1 and Physiological Parameters and Fetal Heart Rate Chart) 1 hour before the cesarean section. The application will be made to the women in the acupressure group by manually pressing the SP6 and HT7 points with the index or middle finger for 5 seconds to a depth of 1-1.5 cm in the order determined by lot, then resting for 2 seconds and continuing the application for 2 minutes. Anxiety, physiological parameters and fhr will be measured again 40 minutes after the application. The data collection forms (descriptive characteristics form, loss, physiological parameters, fhr) will be applied to the women in the control group 1 hour before the cesarean section. No intervention will be made to the women in the control group. Anxiety, physiological parameters and fhr will be measured again 40 minutes later.
219214424|NCT06954389|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
219214425|NCT06954389|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
219087078|NCT07010289|OTHER|Standard of Care|Participants will receive the current standard for care for families endorsing inpatient food insecurity during a hospitalization, which include provision of printed and electronic food access resources. Currently, all families with positive food insecurity screening are met by a community health worker in the hospital who reviews current food access status with families (including enrollment in federal nutrition programs) and provides them with printed and electronic resources of nearby food pantries and other food access resources available to them at time of discharge from the hospital.
219087079|NCT06209320|DRUG|Lower dose atropine sulfate eye drops|administer to eyes
219087080|NCT06209320|DRUG|Low dose atropine sulfate eye drops|administer to eyes
219087081|NCT06209320|DRUG|placebo|administer to eyes
219087082|NCT04120233|DRUG|Placebo|Matched placebo administered orally
219087083|NCT04120233|DRUG|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
219087084|NCT04120233|DRUG|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
219087085|NCT04120233|DRUG|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
219087086|NCT04120233|DRUG|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
219087087|NCT04120233|DRUG|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
219087088|NCT05725928|BEHAVIORAL|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
219214426|NCT06946511|DRUG|Peptide PMS-001 Intravenous Injection|Participants will receive intravenous injections of PMS-001.
219214427|NCT06946511|DRUG|Placebo|The control group will receive a placebo, which is the blank excipient (mannitol) of the injectable PMS-001.
219214428|NCT06950437|DEVICE|active iTBS|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
219087089|NCT06688578|DEVICE|Subperceptual Stimulus|For each test participants will be stimulated using a subperceptual electric signal that is optimized to improve their gait.
219214429|NCT06950437|DEVICE|Sham iTBS|Participants will undergo three sham iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
219214430|NCT06950437|BEHAVIORAL|speech therapy|Speech therapy will be delivered between iTBS/sham sessions. Two 30-minutes trainings every day.
219214431|NCT06953024|DIAGNOSTIC_TEST|INSTI HIV/syphilis Point of Care Self-Test Administration|The INSTI Human Immunodeficiency Virus (HIV)/syphilis POCT is a rapid, single-use, flow-through immunoassay that is Health Canada-approved as a screening test for detecting antibodies to HIV1/2 and syphilis using a fingerstick blood sample.
219214432|NCT06954649|DIETARY_SUPPLEMENT|Plant based extract rich in phytosterols and phytostanols resveratrol and hydroxytyrosol.|Individuals will take two capsules daily of the phytosterol-rich extract for 56 days. Two capsules will be taken daily in the evening, after dinner
219214433|NCT06954649|OTHER|Placebo|Individuals will take two capsules daily of the placebo capsule for 56 days. Two capsules will be taken daily in the evening, after dinner
219087090|NCT06688578|DEVICE|Sham Comparator|During intervention trial, sham comparator will consist of same stimulation device but no actual electrical stimulation will be provided by device during intervention trial.
219087091|NCT00099892|DRUG|vildagliptin|
219087092|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
219087093|NCT07030595|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.1g to 9.1g
219087094|NCT07030595|DRUG|Sevelamer carbonate (Renvela®)|Three times a day, administered orally with three meals at a daily dose level from 2.4g to 9.6g
219087095|NCT07030595|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level of 0.375g.
219087096|NCT03779906|DRUG|Isovue|Isovue will be given to all subjects per the standard of clinical care.
219087097|NCT06269757|BEHAVIORAL|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report."
219214434|NCT06953531|DEVICE|Cold Application (Local Skin Cooling Device)|Immediately before the blood collection procedure, cold application will be made to the area with a local skin cooling device.
219214435|NCT06953531|BEHAVIORAL|Distraction Method (Bubble Machine)|A bubble machine will be used to distract children during the blood collection process.
219214436|NCT06953531|BEHAVIORAL|Distraction Method (Simulative Toy)|A simulative toy will be used to distract children during the blood collection process.
219214437|NCT03610971|DRUG|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
219214438|NCT03610971|DRUG|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
219214439|NCT02755896|RADIATION|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
219087098|NCT06269757|BEHAVIORAL|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
219087099|NCT07034183|DRUG|PRD001|PRD001 capsules will be provided for oral administration
219087100|NCT07034183|DRUG|Placebo|Placebo capsules will be provided for oral administration
219087101|NCT06732908|DIETARY_SUPPLEMENT|LipoMicel Berberine|Berberine powder in a LipoMicel matrix encapsulated in soft gel.
219087102|NCT06732908|OTHER|Placebo|microcrystalline cellulose
219087103|NCT06722053|OTHER|virtual reality and digital education|Breastfeeding education through virtual reality and digital education
219087104|NCT06722053|OTHER|virtual reality and digital education and lemon scent|virtual reality and digital education and lemon scent inhalation
219087105|NCT06732297|BEHAVIORAL|dyadic art therapy intervention for parent-child relationship in vulnerable families|The Stronger Family Through Art Therapy (SFAT) is a dyadic art therapy intervention developed to improve the parent-child relationship in vulnerable families. Service users of the SFAT programme will receive a progressive support from workshops, dyad art therapy, and an innovative art-based self-care tool developed with a multidisciplinary team to meet the needs of enhancing family communication and strengthening emotional bonding.
219087106|NCT07050238|BEHAVIORAL|Life Force|5-session, group-based, skills training program tailored specifically for active-duty Soldiers aimed at mitigating harmful and high-risk behaviors and promote Mental Toughness
219087107|NCT03520322|DEVICE|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
219087108|NCT03520322|DEVICE|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
219087109|NCT06733246|DEVICE|Aspiration 0|Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
219087110|NCT06732050|DEVICE|nociception guided treatment|For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
219214440|NCT02755896|RADIATION|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
219214441|NCT06524089|OTHER|Pilate training|Pilates based training exercises group will perform Pilates divided into two levels (beginner and intermediate). Each level will last for six sessions.
219214442|NCT06524089|OTHER|eccentric training|eccentric trunk training exercises group:The course of the intervention period is 12 sessions total, exercises performed for two to three sets with 10 to 15 repetitions each set and 2 min rest between each set
219214443|NCT05458323|DEVICE|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
219214444|NCT05804032|DRUG|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
219214445|NCT05804032|DRUG|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
219214446|NCT05804032|DRUG|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
219214447|NCT05804032|DRUG|Bortezomib|Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
219214448|NCT05804032|DRUG|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
219681839|NCT04194489|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
219681840|NCT05242302|PROCEDURE|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
219681841|NCT00490347|DEVICE|VentrAssist Left Ventricular Assist Device|
219681842|NCT05191719|PROCEDURE|Botox injection|Comparator, current gold standard
219681843|NCT05191719|PROCEDURE|Neurotomy|Surgical procedure
219681844|NCT00002168|DRUG|Indinavir sulfate|
219681845|NCT00002168|DRUG|Lamivudine|
219681846|NCT00002168|DRUG|Stavudine|
219681847|NCT00002168|DRUG|Zidovudine|
219681848|NCT00002168|DRUG|Didanosine|
219214449|NCT05699564|OTHER|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
219214450|NCT03672058|OTHER|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
219214451|NCT03672058|OTHER|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
219214452|NCT03801434|DRUG|Ruxolitinib|Given PO
219214453|NCT05551104|DRUG|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
219214454|NCT05551104|DRUG|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
219214455|NCT03955991|BEHAVIORAL|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
219214456|NCT03955991|BIOLOGICAL|Influenza vaccine|Standard of care Influenza vaccine for that given year.
219214457|NCT05278104|DRUG|Zentiva®|Zentiva®
219214458|NCT05278104|DRUG|Placebo|Placebo
219214459|NCT03674372|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).
219214460|NCT06352632|DRUG|Standard-dose intravenous tenecteplase|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
219214461|NCT06352632|DRUG|Low-dose intravenous tenecteplase|Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
219214462|NCT06352632|OTHER|No intravenous tenecteplase|No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
219214463|NCT06352632|OTHER|Conservative Blood Pressure Control|No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
219214464|NCT06352632|OTHER|Moderate Blood Pressure Control|SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
219087111|NCT06732635|PROCEDURE|Enhanced recovery after surgery (ERAS)|Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
219214465|NCT06352632|OTHER|Intensive Blood Pressure Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
219214466|NCT06352632|OTHER|Placebo|100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.
219214467|NCT06352632|DRUG|NoNO-42|NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
219214468|NCT06352632|OTHER|No deferoxamine mesylate and no colchicine|No deferoxamine mesylate and no colchicine
219214469|NCT06352632|DRUG|Deferoxamine mesylate only|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
219214470|NCT06352632|DRUG|Colchicine only|0.5mg of oral colchicine daily for 30 days
219214471|NCT06352632|DRUG|Both deferoxamine mesylate and colchicine|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
219214472|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
219214473|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
219087112|NCT06733805|BEHAVIORAL|Portrait + Therapeutics Letter|"In the context of audit and feedback interventions, Portrait is a document produced by the physician organization Therapeutics Initiative that provides personalized prescribing feedback for BC clinicians. Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual prescriber's prescribing practice, benchmarks or targets, a succinct review of the best-available evidence on the topic, and recommendations for future action.~The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and provide reference for the data presented in the Portraits."
219214474|NCT01630902|DRUG|Torrent's Felodipine Extended-Release Tablets|
219087113|NCT06732869|BEHAVIORAL|eHealth physical activity coaching intervention|Patients will attend a PR program and in week 5 of PR will receive an eHealth PA coaching intervention until 6 months after end of PR. The PA goals will be prescribed through a phone call and the personalisation of goal prescription will be based on an algorithm considering patient's performance in the previous week, perceived easiness of achieving the previous goal and confidence to change it. If patient does not achieve the goal, reasons, barriers to PA and strategies to overcome them will be identified. Patients will receive a daily notification about their goal achievements, at 6PM every day, giving them the possibility to increase their PA to achieve the goal, if they have not reached it yet. Patients will also receive personalized notifications sent manually by the researcher whenever appropriate. PA goals will be prescribed on a weekly basis.
219087114|NCT06732869|BEHAVIORAL|pulmonary rehabilitation|Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.
219087115|NCT07051187|DRUG|WGc0201|Wgc0201 will be administered by intramuscular route, with a total of 9 doses.
219087116|NCT06865651|DRUG|Remibrutinib|tablets
219087117|NCT06865651|DRUG|Placebo|tablets
219087118|NCT07059546|DRUG|Adrenomedullin|The participants will receive continuous intravenous infusion of 20 mL of 19.9 pmol/kg/min adrenomedullin over 20 minutes.
219087119|NCT07059546|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
219087120|NCT03830151|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219087121|NCT03830151|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219087122|NCT07079761|BEHAVIORAL|Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
219087123|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 1, a 1.7 mcg/kg dose of IV Allo will be administered over 5 minutes at the completion of extinction training to raise resting plasma Allo plus pregnanolone (PA) levels by 1500 pg/ml. This will be followed by a 4-5-hour continuous infusion of IV Allo at 2.6 mcg/kg/hr to maintain resting plasma Allo levels at the target level.
219087124|NCT07079761|BEHAVIORAL|Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
219087125|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 1, participants randomized to placebo will receive IV matching placebo over 5 minutes at the completion of extinction training followed by a continuous infusion of matching placebo over the next 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
219214475|NCT02896907|DRUG|Oxaliplatin|Given IV
219214476|NCT02896907|DRUG|Irinotecan Hydrochloride|Given IV
219214477|NCT02896907|DRUG|Leucovorin Calcium|Given IV
219214478|NCT02896907|DRUG|Fluorouracil|Given IV
219214479|NCT02896907|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
219214480|NCT03933371|DEVICE|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
219214481|NCT03737487|PROCEDURE|Multidisciplinary fall risk and geriatric comprehensive assessment|"* Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~* Calculation of BMI~* A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~* A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~* A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~* A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~* A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
219214482|NCT05935969|PROCEDURE|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
219214483|NCT00091689|DRUG|852A|
219214484|NCT06030258|DRUG|IN10018|orally taken once daily
219214485|NCT06030258|DRUG|Tislelizumab|200mg D1, Q3W, intravenously
219087126|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
219087127|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 2, a 28 mcg/kg dose of IV Allo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over 4-5 hours.
219087128|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
219087129|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 2, matching IV placebo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over the 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
219087130|NCT07088601|DRUG|Oral ondansetron strips|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip.
219087131|NCT07088601|OTHER|Placebo (oral peppermint strip)|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip.
219087132|NCT07081971|OTHER|Bioheat Patch|Bioheat Patch for pain relif
219087133|NCT07081971|OTHER|Placebo Patch|placebo Patch
219087134|NCT07092774|DEVICE|Ablation|Ablation procedure using the Thermocool Smarttouch SF
219087135|NCT07093086|DRUG|Triple-targeted CAR-T Therapy|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
219087136|NCT04021017|DRUG|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
219214486|NCT06030258|DRUG|Carboplatin|AUC 5 mg/ml/min, D1, Q3W, intravenously
219214487|NCT06030258|DRUG|Etoposide|Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
219214488|NCT05562427|BEHAVIORAL|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
219214489|NCT01078285|BEHAVIORAL|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
219214490|NCT01078285|BEHAVIORAL|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
219214491|NCT05866536|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
219214492|NCT05866536|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
219214493|NCT00003867|DRUG|capecitabine|
219214494|NCT00003867|DRUG|irinotecan hydrochloride|
219214495|NCT00955162|DRUG|Buprenorphine (Subutex)|Sublingual tablet
219214496|NCT00955162|DRUG|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
219214497|NCT00945321|DRUG|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
219214498|NCT00945321|DRUG|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
219214499|NCT00945321|DRUG|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
219087137|NCT04805060|DRUG|TQB2858 injection|TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
219087138|NCT06370364|OTHER|Nurses' Practice of Safe Blood Transfusion|Nurses' Practice of Safe Blood Transfusion
219214500|NCT00945321|DRUG|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
219214501|NCT02633215|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
219214502|NCT03784170|DEVICE|FemPulse System|Device therapy with the FemPulse System
219214503|NCT02969759|OTHER|Skin Biopsy|
219214504|NCT00279981|DEVICE|Diagnostic|
219214505|NCT03658915|DEVICE|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
219087139|NCT02697279|PROCEDURE|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.
219087140|NCT02697279|PROCEDURE|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
219087141|NCT00503022|DRUG|ACZ885|
219087142|NCT04649502|COMBINATION_PRODUCT|Metformin|Metformin in combination with doxycycline
219087143|NCT05654792|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
219214506|NCT02809755|DRUG|4% Lidocaine|
219214507|NCT02809755|OTHER|Saline|
219214508|NCT02503397|DEVICE|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
219214509|NCT04017611|DEVICE|INVSENSOR00038|Noninvasive regional oximeter
219214510|NCT00692913|DRUG|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
219214511|NCT00692913|DIETARY_SUPPLEMENT|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
219214512|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
219214513|NCT05673109|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
219214514|NCT05891405|PROCEDURE|Cardiac surgery|Operations for congenital heart diseases
219214515|NCT02291913|DRUG|Everolimus|
219214516|NCT02291913|DRUG|Exemestane|Anti-estrogen therapy
219214517|NCT02291913|DRUG|Tamoxifen|Anti-estrogen therapy
219214518|NCT02291913|DRUG|Fulvestrant|Anti-estrogen therapy
219214519|NCT02291913|DRUG|Anastrozole|Anti-estrogen therapy
219214520|NCT02291913|DRUG|Letrozole|Anti-estrogen therapy
219214521|NCT02291913|DRUG|Toremifine|Anti-estrogen therapy
219214522|NCT03987243|BEHAVIORAL|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
219214523|NCT03987243|OTHER|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
219214524|NCT04703283|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
219681849|NCT04300712|BEHAVIORAL|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
219087144|NCT03571958|BEHAVIORAL|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
219087145|NCT03866941|BEHAVIORAL|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
219087146|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
219087147|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
219087148|NCT02543658|DRUG|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
219087149|NCT02543658|COMBINATION_PRODUCT|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
219087150|NCT00034957|DRUG|Investigational drug|
219087151|NCT03552133|DEVICE|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
219087152|NCT00789815|DEVICE|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3\~12 mg/kg/hour) to maintain BIS around 65\~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
219214525|NCT02246946|DEVICE|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
219214526|NCT02246946|OTHER|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
219087153|NCT00789815|DRUG|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S\* 2\~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S\* 2\~3 or if intolerance of procedure. Alfentanil as study arm.~\*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
219087154|NCT01343602|BEHAVIORAL|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
219087155|NCT01343602|OTHER|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
219087156|NCT04436263|BEHAVIORAL|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
219087157|NCT04436263|BEHAVIORAL|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
219087158|NCT05115344|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
219214527|NCT02246946|PROCEDURE|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
219214528|NCT05835375|OTHER|EQ-778|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
219214529|NCT05835375|OTHER|Placebo|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
219214530|NCT04095884|PROCEDURE|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
219214531|NCT02866942|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
219214532|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol - duration 3 weeks|Standard metabolic integrated rehabilitation protocol
219214533|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks|Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
219214534|NCT04463875|DIETARY_SUPPLEMENT|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
219214535|NCT06330298|BEHAVIORAL|Treatment social cognition and emotion regulation (T-ScEmo)|T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
219214536|NCT03513692|DEVICE|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
219214537|NCT03287713|DRUG|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
219214538|NCT00000234|DRUG|Buprenorphine|
219214539|NCT02917512|DRUG|HU00701|Cyclosporine 0.01% + 3% trehalose
219214540|NCT02917512|DRUG|HU007|Cyclosporine 0.02% + 3% trehalose
219214541|NCT02917512|DRUG|Restasis|Cyclosporine 0.05%
219214542|NCT02917512|DRUG|Placebo|Vehicle
219214543|NCT01268306|DEVICE|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
219214544|NCT00294736|DRUG|Tarceva|Dose Escalation: 150-350+ mg/day
219214545|NCT04334317|DRUG|TAK-071|TAK-071 tablet.
219087159|NCT05115344|DRUG|flonoltinib 50mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
219087160|NCT05115344|DRUG|flonoltinib 100mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
219087161|NCT05115344|DRUG|flonoltinib 150mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
219087162|NCT05115344|DRUG|flonoltinib 225mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
219214546|NCT04334317|DRUG|Placebo|TAK-071 placebo-matching tablet.
219087163|NCT05115344|DRUG|flonoltinib 325mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
219087164|NCT02617875|OTHER|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
219087165|NCT02617875|OTHER|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
219087166|NCT05189626|OTHER|Muscle energy technique|Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
219087167|NCT05189626|OTHER|Kaltonborn mobilizations|Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
219087168|NCT02644590|DRUG|Melatonin|Detailed in arm description
219087169|NCT02758353|DRUG|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
219087170|NCT03139422|DRUG|Tranexamic Acid 500 MG|oral tablets
219087171|NCT03139422|DRUG|Calcium Dobesilate|oral tablets
219214547|NCT02993211|DEVICE|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
219087172|NCT02368106|RADIATION|Radiation Therapy|targeted radiation treatment
219214548|NCT02993211|DEVICE|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
219214549|NCT03035084|DRUG|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
219681850|NCT01726062|BEHAVIORAL|Motivational Interviewing plus Incentives|"1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
219681851|NCT01726062|BEHAVIORAL|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
219681852|NCT03897569|OTHER|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
219681853|NCT05127564|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
219681854|NCT01000987|DRUG|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
219087173|NCT01906684|DRUG|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
219087174|NCT03190551|OTHER|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
219087175|NCT03190551|OTHER|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
219087176|NCT06070402|DEVICE|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
219087177|NCT02802163|DRUG|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
219681855|NCT01000987|DRUG|placebo|placebo
219681856|NCT00798941|BEHAVIORAL|mouth care|mouth spray, mouth swab, moisturizer
219087178|NCT02802163|DRUG|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
219087179|NCT02802163|DRUG|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
219087180|NCT02802163|DRUG|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
219087181|NCT00962351|PROCEDURE|Total Hip Replacement|
219087182|NCT06119984|BEHAVIORAL|Community mobilization|The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
219087183|NCT02119143|DIETARY_SUPPLEMENT|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
219087184|NCT02119143|DIETARY_SUPPLEMENT|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
219087185|NCT00432874|PROCEDURE|wound hydration method|Anterior vs lateral wound hydration
219214550|NCT03035084|DRUG|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
219214551|NCT03035084|DRUG|Placebo oral capsule|Placebo oral capsule
219214552|NCT00147719|DRUG|Colesevelam hydrochloride|
219214553|NCT02747394|OTHER|Working Memory Training|
219214554|NCT05804994|DEVICE|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
219214555|NCT00724399|BEHAVIORAL|Survey on womens health Issues.|Cardiovascular health.
219681857|NCT00798941|BEHAVIORAL|pain intervention|music and massage
219681858|NCT01570140|BEHAVIORAL|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
219681859|NCT01991964|OTHER|laryngeal ultrasound|
219214556|NCT00990600|OTHER|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
219214557|NCT04752072|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
219214558|NCT04752072|BEHAVIORAL|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
219681860|NCT02598739|OTHER|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
219681861|NCT02598739|OTHER|Waiting list for the exercises|
219681862|NCT03642535|DRUG|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
219681863|NCT03590171|DRUG|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
219681864|NCT04853823|DRUG|PDC-APB|PDC-APB Intra-muscular Injection
219681865|NCT04853823|OTHER|Placebo|Vehicle
219681866|NCT03752476|PROCEDURE|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
219087186|NCT00908492|BEHAVIORAL|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
219087187|NCT00908492|BEHAVIORAL|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
219214559|NCT03600844|BEHAVIORAL|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
219214560|NCT00862043|DRUG|Sildenafil Citrate|40 mg t.i.d.
219214561|NCT00862043|DRUG|Placebo|Placebo t.i.d.
219214562|NCT02085772|OTHER|Blood samples at 37-38 Weeks of amenorrhea|
219681867|NCT05377112|DRUG|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
219681868|NCT05377112|OTHER|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
219681869|NCT06394583|PROCEDURE|Lung ultrasound|We will perform a LU at birth to all infants, before the first dose of surfactant.
219087188|NCT06013943|DRUG|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
219087189|NCT05810246|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
219087190|NCT01308606|DRUG|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
219087191|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
219087192|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
219214563|NCT02085772|OTHER|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
219214564|NCT02085772|OTHER|Blood samples at the time of delivery|
219214565|NCT02523170|DEVICE|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
219214566|NCT03420196|OTHER|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
219681870|NCT01571141|DEVICE|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
219681871|NCT05995834|OTHER|Research questions|"Stage 1: Secondary analysis of a previous international survey to identify items~Stage 2: Cognitive debriefing interviews with about 10 people living with iMCD to assess the content validity of the items~Stage 3: Completion of questionnaire to finalise scale~Stage 4a: Re-administering of follow-up questionnaire to Stage 3 patients to assess minimally important clinical difference. Test-retest will be calculated only in patients exhibiting no change.~Stage 4b: Qualitative interviews with a subset of participants from Stages and 4 to help with interpretation of meaningful difference from their perspective"
219087193|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
219087194|NCT01308606|DRUG|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
219087195|NCT04846088|OTHER|Product A|A 4mg nicotine pouch product
219087196|NCT04846088|OTHER|Product B|A 7mg nicotine pouch product
219087197|NCT04846088|OTHER|Product C|A 7mg nicotine pouch product
219087198|NCT04846088|OTHER|Product D|A 7mg nicotine pouch product
219087199|NCT04846088|OTHER|Product E|A 7mg nicotine pouch product
219087200|NCT04846088|OTHER|Product F|A 7mg nicotine pouch product
219087201|NCT04846088|OTHER|Product G|A 7mg nicotine pouch product
219087202|NCT04846088|OTHER|Product H|A 7mg nicotine pouch product
219087203|NCT04846088|OTHER|Product I|A 7mg nicotine pouch product
219087204|NCT00800839|DRUG|Busulfan|Starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
219087205|NCT00800839|DRUG|Fludarabine|Dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
219087206|NCT00800839|DRUG|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
219087207|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except friday|
219087208|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except thursday and friday|
219087209|NCT02489786|DRUG|patients take 0.125 mg of digoxin daily|
219087210|NCT02489786|DRUG|digoxin dose is calculated using Jusko-Koup method and given daily|
219087211|NCT01184599|DRUG|aliskiren|150 mg/day p.o.
219214567|NCT03420196|OTHER|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
219214568|NCT03614663|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
219214569|NCT03614663|OTHER|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
219214570|NCT02084420|DRUG|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
219214571|NCT02084420|DRUG|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
219214572|NCT00002236|DRUG|Indinavir sulfate|
219087212|NCT03340480|DRUG|NVP-1402|Oral
219087213|NCT00939484|OTHER|Pharmacological Study|Correlative studies
219087214|NCT00939484|DRUG|Vismodegib|Given PO
219214573|NCT00002236|DRUG|Delavirdine mesylate|
219214574|NCT00002236|DRUG|Zidovudine|
219214575|NCT01128595|DRUG|FF/GW642444M|
219214576|NCT01128595|DRUG|GW642444M|
219214577|NCT01128595|DRUG|Fluticasone Furoate|
219214578|NCT01128595|DRUG|Placebo|
219214579|NCT00605306|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
219214580|NCT00605306|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
219087215|NCT05947214|OTHER|Myofascial Decompression Therapy|Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
219087216|NCT05947214|OTHER|positional Release Therapy|Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
219087217|NCT06398483|PROCEDURE|surgical fixation of acute bony mallet finger|"surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire"
219087218|NCT04036071|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
219087219|NCT01957917|OTHER|NAC (Nutritional Assessment and Counseling)|
219087220|NCT01957917|OTHER|Cash Transfer|
219087221|NCT01957917|OTHER|Food Assistance|
219087222|NCT05217095|DEVICE|Convergence Dialyzer|The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
219087223|NCT01224925|PROCEDURE|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
219087224|NCT01224925|PROCEDURE|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
219214581|NCT04359017|DRUG|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
219214582|NCT05604755|DRUG|HQP1351( Olverembatinib dimesylate)|HQP1351 was initiated at a dose of 40mg every two days
219214583|NCT06275659|DEVICE|CT-100-004-A|Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
219214584|NCT06275659|DEVICE|CT-100-004-B|The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
219087225|NCT03122561|DRUG|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
219087226|NCT03122561|DRUG|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
219087227|NCT03122561|DRUG|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
219214585|NCT03980613|OTHER|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
219681872|NCT02114619|DRUG|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
219087228|NCT03381001|PROCEDURE|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
219087229|NCT03381001|PROCEDURE|embryo transfer with no culture|embryos will be transfer with no culture after thaw
219681873|NCT02114619|DRUG|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
219681874|NCT02114619|DRUG|High dose|We will administer 200 micro currie of iodine per thyroid gram
219681875|NCT00260013|PROCEDURE|program of care delivery|
219681876|NCT01851655|BEHAVIORAL|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
219087230|NCT00791843|DRUG|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
219087231|NCT00647101|DRUG|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
219087232|NCT01720732|BEHAVIORAL|Lifeline NET|Short Version of Narrative Exposure Therapy
219087233|NCT06170775|OTHER|Pulp therapy|Pulp capping material
219087234|NCT06170775|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
219087235|NCT06170775|OTHER|MTA|MTA
219087236|NCT01439061|DEVICE|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
219087237|NCT03019146|OTHER|HIIT|
219087238|NCT03019146|OTHER|HOLD|
219087239|NCT03019146|OTHER|HUG|
219087240|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
219087241|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
219087242|NCT03014765|OTHER|EDOP|no intervention
219087243|NCT00621608|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
219087244|NCT00621608|PROCEDURE|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
219087245|NCT05848921|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
219087246|NCT05848921|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
219087247|NCT00245102|DRUG|sorafenib tosylate|Given orally
219087248|NCT01788696|RADIATION|Group A - Early Imaging|Total of 3 scans
219087249|NCT01788696|RADIATION|Group B - Delayed Imaging|Total of 2 scans
219087250|NCT01371773|PROCEDURE|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
219087251|NCT03501433|DIETARY_SUPPLEMENT|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
219087252|NCT03501433|DIETARY_SUPPLEMENT|Placebo|2x/day for 7 days
219087253|NCT06216522|OTHER|Topical Sesame Oil|5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
219087254|NCT06216522|OTHER|Liquid paraffin oil|5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
219087255|NCT01231529|DRUG|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
219087256|NCT03310073|BIOLOGICAL|bOPV|Batch Number: 2042015
219087257|NCT03310073|BIOLOGICAL|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
219087258|NCT03310073|BIOLOGICAL|IPV|The vaccine shall be given intramuscularly.
219087259|NCT04000867|DEVICE|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
219681877|NCT04576650|DEVICE|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
219087260|NCT05307770|DIETARY_SUPPLEMENT|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
219087261|NCT05307770|DIETARY_SUPPLEMENT|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
219087262|NCT04392466|OTHER|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
219087263|NCT03362450|OTHER|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
219087264|NCT00253201|DRUG|galantamine hydrobromide|
219087265|NCT01716143|PROCEDURE|radiofrequency catheter ablation|
219087266|NCT03287739|BEHAVIORAL|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
219087267|NCT02000739|GENETIC|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
219087268|NCT06065878|PROCEDURE|IPACK + Genicular Nerve Block|IPACK and Genicular Nerve block were applied with the same total volume of local anesthetic as the control group.
219087269|NCT06342089|OTHER|Type I diabetes milletus|the exposure is type I diabetes milletus
219087270|NCT05646394|DRUG|Dual antiplatelet therapy|Aspirin plus any of clopidogrel, ticagrelor or prasugrel
219681878|NCT03151447|RADIATION|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
219087271|NCT05646394|DRUG|Combined antithrombotic therapy|Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.
219087272|NCT05646394|DRUG|Vitamin K antagonist standard intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
219087273|NCT05646394|DRUG|Vitamin K antagonist high intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
219087274|NCT03109821|OTHER|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
219214586|NCT06444984|OTHER|Fasting Trial|Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
219214587|NCT06444984|OTHER|Fed Trial|Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
219214588|NCT05854446|OTHER|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
219214589|NCT00372775|DRUG|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
219087275|NCT00233441|DRUG|CELIVARONE (SSR149744C)|
219087276|NCT03227016|DRUG|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
219087277|NCT03227016|DRUG|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
219087278|NCT00231673|DRUG|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
219087279|NCT05074355|DRUG|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
219087280|NCT05074355|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
219087281|NCT03963661|BEHAVIORAL|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
219214590|NCT01970410|DRUG|teriflunomide|14 mg oral teriflunomide daily
219214591|NCT04257487|DRUG|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
219214592|NCT04257487|DRUG|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
219214593|NCT04257487|DRUG|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
219214594|NCT03443700|DEVICE|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
219214595|NCT03443700|PROCEDURE|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
219214596|NCT05953363|DEVICE|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
219214597|NCT00733811|DRUG|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
219681879|NCT04378686|OTHER|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
219214598|NCT00733811|DRUG|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
219214599|NCT02568215|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
219214600|NCT02568215|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
219214601|NCT02691169|DRUG|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
219214602|NCT02132559|DRUG|DHEA|
219681880|NCT01815658|DEVICE|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
219681881|NCT00416819|BIOLOGICAL|filgrastim|
219681882|NCT00416819|BIOLOGICAL|rituximab|
219681883|NCT00416819|DRUG|cytarabine|
219681884|NCT00416819|DRUG|etoposide phosphate|
219681885|NCT00416819|DRUG|leucovorin calcium|
219681886|NCT00416819|DRUG|methotrexate|
219681887|NCT00416819|DRUG|temozolomide|
219087282|NCT02687321|OTHER|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
219087283|NCT03540511|DIAGNOSTIC_TEST|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
219087284|NCT06453122|OTHER|Oral care|The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
219087285|NCT02035332|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
219087286|NCT02452684|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
219087287|NCT04418934|DEVICE|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
219087288|NCT03554993|DRUG|CC-99677|CC-99677
219087289|NCT03554993|OTHER|Placebo|Placebo
219087290|NCT04465279|DEVICE|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
219087291|NCT06510452|DRUG|2000 mg of Cefazolin|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
219087292|NCT06510452|DRUG|500 mg of Metronidazole IV|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
219087293|NCT06510452|DRUG|NACL 0.9% 100 ml|receive 100 ml NACL0.9% without any antibiotics in it.
219087294|NCT00082394|DRUG|Trizivir|
219087295|NCT00082394|DRUG|atazanavir|
219214603|NCT02403375|DEVICE|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
219214604|NCT00201149|BEHAVIORAL|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
219214605|NCT04147637|COMBINATION_PRODUCT|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
219214606|NCT04147637|DEVICE|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
219087296|NCT00082394|DRUG|Combivir|
219087297|NCT01539876|PROCEDURE|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
219087298|NCT00838682|DRUG|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
219087299|NCT00838682|DRUG|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
219087300|NCT01861886|DEVICE|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
219087301|NCT01827826|BEHAVIORAL|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
219681888|NCT01285661|DRUG|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
219681889|NCT02104076|DEVICE|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
219681890|NCT04552561|BEHAVIORAL|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
219087302|NCT02124889|BEHAVIORAL|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
219087303|NCT03166943|PROCEDURE|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:"
219087304|NCT03166943|PROCEDURE|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities."
219087305|NCT02026856|DRUG|sodium selenite pentahydrate|
219087306|NCT02026856|OTHER|placebo - continuous saline NaCl 50 ml|
219087307|NCT04684225|OTHER|Hand Therapy via Telerehabilitation|Hand Therapy via Telerehabilitation
219087308|NCT04684225|OTHER|Hand Therapy via home-exercises|Hand Therapy via home-exercises
219214607|NCT01841671|BIOLOGICAL|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
219214608|NCT01841671|BIOLOGICAL|bOPV|As indicated
219214609|NCT01841671|BIOLOGICAL|mOPV type 2|Administered at 28 weeks of age to all study participants
219214610|NCT01841671|BIOLOGICAL|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
219087309|NCT00292175|PROCEDURE|Narrow Band Imaging|
219087310|NCT00292175|PROCEDURE|colonoscopy|
219087311|NCT04793919|DRUG|Mylotarg|See the protocol
219087312|NCT04793919|DRUG|Arsenic Trioxide|See the protocol
219087313|NCT04793919|DRUG|All-trans retinoic acid|See the protocol
219087314|NCT01756664|OTHER|Sunscreen|
219087315|NCT01756664|OTHER|Vaseline|
219087316|NCT01487278|DRUG|misprostol|600 mcg misoprostol oral
219087317|NCT01487278|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
219087318|NCT00003578|DRUG|CHOP regimen|
219087319|NCT00003578|DRUG|carmustine|
219087320|NCT00003578|DRUG|cyclophosphamide|
219087321|NCT00003578|DRUG|cytarabine|
219087322|NCT00003578|DRUG|doxorubicin hydrochloride|
219087323|NCT00003578|DRUG|etoposide|
219087324|NCT00003578|DRUG|melphalan|
219087325|NCT00003578|DRUG|prednisone|
219087326|NCT00003578|DRUG|vincristine sulfate|
219087327|NCT00003578|PROCEDURE|autologous bone marrow transplantation|
219087328|NCT00003578|PROCEDURE|peripheral blood stem cell transplantation|
219087329|NCT02565238|DEVICE|BioMonitor 2|Implantation of BioMonitor 2
219087330|NCT02424084|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
219087331|NCT00823784|PROCEDURE|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
219087332|NCT00823784|PROCEDURE|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
219087333|NCT01667913|OTHER|6 minutes walking test|
219087334|NCT00003092|DRUG|paclitaxel|
219087335|NCT06200337|PROCEDURE|Fine needle acupuncture|All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
219087336|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
219087337|NCT02104362|RADIATION|exclusive single-fraction irradiation|
219087338|NCT01175915|OTHER|Western therapy|"1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~3. No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
219087339|NCT01175915|OTHER|Reduning Injection|"1. Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~2. Reduning Injection, 0.5\~15ml, depending on patient's condition, IV per day, or according to the instruction;~3. Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
219087340|NCT01175915|OTHER|Reduning Injection plus western therapy|"1. General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~2. Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~3. Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
219087341|NCT04344041|DRUG|cholecalciferol 200,000 IU|Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
219087342|NCT04344041|DRUG|cholecalciferol 50,000 IU|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
219087343|NCT03202472|DEVICE|Implanted Medical Device|Radiofrequency tag
219087344|NCT03202472|PROCEDURE|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
219087345|NCT03202472|OTHER|Questionnaire Administration|Ancillary studies
219087346|NCT03202472|PROCEDURE|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
219087347|NCT03202472|PROCEDURE|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
219214611|NCT03085433|DEVICE|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
219087348|NCT03675451|DRUG|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
219087349|NCT03675451|DRUG|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
219087350|NCT04098406|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
219214612|NCT03085433|PROCEDURE|in vitro fertilization|ivf/icsi
219214613|NCT04900467|BIOLOGICAL|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
219214614|NCT04900467|BIOLOGICAL|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
219214615|NCT05220111|PROCEDURE|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
219214616|NCT02987218|DRUG|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
219214617|NCT02987218|DRUG|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
219214618|NCT03406169|DRUG|Sildenafil 25 MG Oral Tablet|twice a day dosing
219214619|NCT03406169|DRUG|Pentoxifylline|400mg twice a day
219214620|NCT03406169|OTHER|Placebo|placebo twice a day
219214621|NCT00635869|BEHAVIORAL|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
219214622|NCT00635869|BEHAVIORAL|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
219214623|NCT00635869|BEHAVIORAL|Placebo|didactic education sessions on physical assessment
219214624|NCT05141136|PROCEDURE|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
219214625|NCT05141136|PROCEDURE|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
219214626|NCT06151301|DIAGNOSTIC_TEST|serum procalcitonin|predicting the severity of intoxication
219214627|NCT06151301|DIAGNOSTIC_TEST|C-reactive protein|predicting the severity of intoxication
219214628|NCT00073372|DRUG|Abciximab|
219214629|NCT01064999|DRUG|Oxaliplatin|CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
219214630|NCT01064999|DRUG|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
219214631|NCT01064999|RADIATION|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
219214632|NCT01064999|PROCEDURE|Surgery|Lower anterior resection or abdominoperineal resection
219214633|NCT04720612|BIOLOGICAL|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
219214634|NCT04720612|OTHER|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
219214635|NCT01319838|DRUG|Isotretinoin|\>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
219214636|NCT04155905|PROCEDURE|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
219214637|NCT04155905|PROCEDURE|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
219214638|NCT00336505|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
219214639|NCT00336505|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
219087351|NCT04098406|DRUG|Placebo|Placebo was liquid with identical color and taste
219087352|NCT03817892|OTHER|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
219087353|NCT03817892|OTHER|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
219087354|NCT02385734|OTHER|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
219087355|NCT02385734|PROCEDURE|Coronally Advanced Flap|Periodontal plastic surgery technique
219087356|NCT04422613|DIAGNOSTIC_TEST|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
219087357|NCT06574009|BEHAVIORAL|Multimodal pain care|Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
219087358|NCT06574009|DRUG|Medication optimization|Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
219087359|NCT06574009|DEVICE|Buprenorphine rotation|Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
219087360|NCT06574009|OTHER|Opioid tapering|Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
219087361|NCT03274635|BEHAVIORAL|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
219087362|NCT01132625|DRUG|AUY922|
219087363|NCT05100225|BIOLOGICAL|PTP-001|Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
219087364|NCT05100225|OTHER|Placebo control|The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
219087365|NCT02088151|DEVICE|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
219087366|NCT05001880|BIOLOGICAL|Atezolizumab|Given IV
219087367|NCT05001880|BIOLOGICAL|Bevacizumab|Given IV
219087368|NCT05001880|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219087369|NCT05001880|DRUG|Carboplatin|Given IV
219087370|NCT05001880|PROCEDURE|Computed Tomography|Undergo CT scan
219087371|NCT05001880|PROCEDURE|Cytoreductive Surgery|Undergo surgery
219087372|NCT05001880|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
219087373|NCT05001880|DRUG|Pemetrexed|Given IV
219087374|NCT05001880|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219087375|NCT03764449|DRUG|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
219087376|NCT03764449|DRUG|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
219087377|NCT00580658|DEVICE|Medtronic Activa Gpi|Activa Therapy, Gpi
219087378|NCT06956417|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy (CBT) is delivered by a psychologist over 10 individual (1:1) manualized videoconference sessions. The goal of this therapy is for participants to use their memory more normally (i.e., reduce avoidance and safety behaviors) and view memory lapses as less threatening.
219087379|NCT06956417|BEHAVIORAL|Cognitive rehabilitation|Cognitive compensatory strategy training (CCST), a traditional cognitive rehabilitation intervention, is delivered by a Occupational Therapist over 10 individual (1:1) manualized videoconference sessions. Participants optimize their use of current compensatory strategies and/or learn new ones suited to their needs and lifestyle. The goal is to minimize memory lapses in daily life.
219087380|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219087381|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219087382|NCT05782543|PROCEDURE|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
219087383|NCT00150579|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
219087384|NCT02878174|PROCEDURE|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
219087385|NCT02662725|DRUG|IPILIMUMAB|
219087386|NCT02662725|RADIATION|Stereotactic radiosurgery|
219087387|NCT03010839|PROCEDURE|Modified Remote Ischemic Preconditioning|mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
219087388|NCT03010839|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
219087389|NCT05284825|RADIATION|12 Gy in 6 daily fractions|12 Gy in 6 daily fractions
219087390|NCT01075932|DIETARY_SUPPLEMENT|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
219087391|NCT01075932|DIETARY_SUPPLEMENT|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
219087392|NCT03705195|DRUG|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
219087393|NCT02278068|DEVICE|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
219087394|NCT00800969|PROCEDURE|FDG-PET-CT|Radiologic standard procedure
219087395|NCT01783418|BEHAVIORAL|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
219087396|NCT06228521|OTHER|Liquid nitrogen sprayed|Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.
219087397|NCT06228521|OTHER|980nm diode laser applied|980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
219087398|NCT06267456|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
219087399|NCT06267456|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
219087400|NCT06267456|DIAGNOSTIC_TEST|Upper Quarter Y Balance Test|The Upper Extremity Y Balance Test was created using three rulers placed on the ground in the medial, inferolateral, and superolateral directions. The rulers in the superolateral and inferolateral directions were positioned at a 90° angle to each other, while the ruler in the medial direction was placed at a 135° angle with respect to these two directions. In this test, both arms started in a push-up position with shoulder-width apart. The athlete was then instructed to touch, using their non-dominant hand, the maximum reachable point in the medial, inferolateral, and superolateral directions.
219087401|NCT00687570|DIETARY_SUPPLEMENT|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery
219087402|NCT00687570|DRUG|Laxabon®|Laxabon® 4 litres starting the day before surgery
219214640|NCT05909670|BEHAVIORAL|Family Advice and Support Text and Telephone (FASTT) program|The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
219214641|NCT01624493|DRUG|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
219214642|NCT01624493|DRUG|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
219214643|NCT01624493|DRUG|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
219087403|NCT01886911|OTHER|Attention Training Intervention Game|
219087404|NCT01886911|OTHER|Prosocial Training Intervention Game|
219087405|NCT01886911|OTHER|Control for Attention Intervention|
219087406|NCT01886911|OTHER|Control for Prosocial Intervention|
219087407|NCT05599009|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
219087408|NCT05599009|PROCEDURE|sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
219087409|NCT03548207|BIOLOGICAL|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
219087410|NCT01613638|OTHER|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
219087411|NCT05270681|OTHER|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
219087412|NCT06048510|DIAGNOSTIC_TEST|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
219087413|NCT00415610|DRUG|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
219087414|NCT01184365|BEHAVIORAL|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
219087415|NCT01184365|BEHAVIORAL|Energy Management Program|The goal of the EnMP-2 is to control for group effects
219087416|NCT00310232|DRUG|Epoetin Alfa|
219087417|NCT00945464|OTHER|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
219087418|NCT05473754|BEHAVIORAL|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
219087419|NCT02555540|BIOLOGICAL|Boostrix|Randomised assignment
219087420|NCT02555540|BIOLOGICAL|Placebo (Saline)|Randomised assignment
219087421|NCT00999466|DRUG|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
219681891|NCT04192721|BEHAVIORAL|Cognitive Behavioral Therapy-Based Group Counseling|"* Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents"
219681892|NCT00370773|DEVICE|Precision Spinal Cord Stimulation System|
219681893|NCT01649882|PROCEDURE|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
219681894|NCT02478515|DRUG|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
219681895|NCT00379561|DRUG|PSA-Activated PSA-PAH1|
219681896|NCT03175614|OTHER|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
219681897|NCT03175614|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
219681898|NCT04081675|DEVICE|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
219214644|NCT01624493|DRUG|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
219214645|NCT01624493|DRUG|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
219214646|NCT01939691|DRUG|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
219214647|NCT01939691|DRUG|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
219214648|NCT01939691|DRUG|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
219214649|NCT01185041|DIETARY_SUPPLEMENT|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
219214650|NCT05535959|DRUG|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
219214651|NCT03067857|BIOLOGICAL|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
219214652|NCT02005159|OTHER|Microbiological studies|
219214653|NCT02105259|BEHAVIORAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
219087422|NCT00999466|DRUG|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
219087423|NCT05700500|PROCEDURE|shockwave therapy, barbotage and infiltration|ultrasound guided interventions
219214654|NCT02105259|OTHER|Waiting list|Waiting list, where participants wait for delayed treatment
219087424|NCT01494337|PROCEDURE|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
219214655|NCT00199056|DRUG|Dexamethasone / Prednisolone|
219214656|NCT00199056|DRUG|Cyclophosphamide|
219214657|NCT00199056|DRUG|Methotrexate|
219214658|NCT00199056|DRUG|Vincristine / Vindesine|
219087425|NCT01494337|PROCEDURE|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
219087426|NCT05199779|BEHAVIORAL|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
219087427|NCT05199779|BEHAVIORAL|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
219214659|NCT00199056|DRUG|Daunorubicin|
219214660|NCT00199056|DRUG|Asparaginase|
219214661|NCT00199056|DRUG|G-CSF|
219214662|NCT00199056|DRUG|Cytarabine|
219214663|NCT00199056|DRUG|6-Mercaptopurine|
219214664|NCT00199056|DRUG|VP16|
219214665|NCT00199056|DRUG|Adriamycin|
219214666|NCT00199056|DRUG|Thioguanine|
219214667|NCT00199056|DRUG|VM26|
219214668|NCT00199056|DRUG|Idarubicin|
219214669|NCT00199056|DRUG|Fludarabine|
219214670|NCT00199056|DRUG|Ifosfamide|
219214671|NCT00199056|PROCEDURE|CNS irradiation|
219214672|NCT00199056|PROCEDURE|Mediastinal irradiation (if residual tumor)|
219214673|NCT00199056|PROCEDURE|stem cell transplantation|
219087428|NCT06490107|DRUG|Durvalumab combined with S-1|"The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles"
219214674|NCT04169256|DRUG|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
219214675|NCT04169256|DRUG|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
219214676|NCT04169256|OTHER|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
219214677|NCT02379000|DRUG|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
219214678|NCT02379000|PROCEDURE|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
219214679|NCT00547066|BIOLOGICAL|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
219214680|NCT03648190|DIAGNOSTIC_TEST|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
219214681|NCT02221505|DRUG|LOP628|
219214682|NCT05706246|DIAGNOSTIC_TEST|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
219214683|NCT01561300|OTHER|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
219214684|NCT01561300|OTHER|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
219087429|NCT00877084|OTHER|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
219087430|NCT00877084|OTHER|Usual care|usual care according to clinical pathway for COPD, No training
219087431|NCT01843543|OTHER|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
219087432|NCT03120962|DRUG|Oxycodone|Oxycodone 20mg/day, for 4 weeks
219087433|NCT03120962|DRUG|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
219087434|NCT03120962|DRUG|Famciclovir|Famciclovir 500mg three-times daily for 7 days
219087435|NCT01742377|PROCEDURE|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
219087436|NCT01742377|PROCEDURE|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
219087437|NCT01742377|PROCEDURE|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
219087438|NCT01825668|OTHER|Plant Sterols|
219087439|NCT01825668|OTHER|High cholesterol|
219087440|NCT01825668|OTHER|Placebo|
219087441|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE)|"Spinal stabilization exercises (SSE) including bridging, planks and tummy tuck-in will be performed. Each participant received a total 7 session thrice a week sessions in two weeks, . Each session had lasted for 30-40 minutes. Spinal stabilization exercises were repeated 5-15 times depending on the endurance of patients.~Home exercise plan will also be given e.g. postural care, precautions in lifting and carrying weights etc."
219087442|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|In experimental group in addition SSE group interventions, participants will receive the latissimus dorsi stretching (LDS). Each participant received a total 7 session thrice a week sessions in two weeks. Each session had lasted for 30-40 minutes. each stretch of latissimus dorsi was of 20-30 seconds with 10-20 repetitions in each session.
219087443|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
219087444|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
219087445|NCT06276270|DEVICE|Mucopad HA|The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
219087446|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
219214685|NCT00018096|BIOLOGICAL|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
219214686|NCT01943305|BIOLOGICAL|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
219214687|NCT01943305|BIOLOGICAL|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
219214688|NCT00246805|DEVICE|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
219214689|NCT02620449|OTHER|Diet|Participants will be fed a low-additive diet as the primary intervention
219214690|NCT05923190|DRUG|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
219214691|NCT05923190|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
219214692|NCT06250868|DEVICE|Kerato-Refracto Tonometer|measures pressure inside the eye and thickness of the cornea.
219214693|NCT05121142|DRUG|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
219214694|NCT03454113|DEVICE|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
219214695|NCT00609869|DRUG|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
219087447|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
219087448|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
219087449|NCT03814798|BIOLOGICAL|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
219214696|NCT00609869|DRUG|Rituximab|Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
219087450|NCT00835848|DRUG|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
219087451|NCT00835848|DRUG|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
219087452|NCT03399643|DRUG|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
219087453|NCT02526043|PROCEDURE|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
219087454|NCT02526043|PROCEDURE|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
219087455|NCT02845401|OTHER|Stop NA therapy|Cases will stop antiviral therapy
219087456|NCT00122642|PROCEDURE|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
219087457|NCT00122642|DRUG|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
219087458|NCT02158117|DRUG|nasal naloxone|one puff in one nostril with the subject is lying down
219087459|NCT03258216|DIAGNOSTIC_TEST|panendoscopy|panendoscopy
219214697|NCT03588832|DIAGNOSTIC_TEST|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
219214698|NCT04936386|BEHAVIORAL|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
219214699|NCT01099566|DRUG|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
219214700|NCT01099566|DRUG|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
219214701|NCT03516370|DRUG|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
219087460|NCT03258216|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
219087461|NCT01980238|DEVICE|cannula ileostomy|
219087462|NCT01980238|DEVICE|loop ileostomy|
219087463|NCT01980238|DEVICE|LAR|
219087464|NCT01916005|DEVICE|18F-FDG PET/CT|
219087465|NCT05374902|OTHER|Providing procedural informational animation video|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
219087466|NCT05374902|DEVICE|Buzzy|Buzzy® was placed on the injection site and it was turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
219087467|NCT05374902|COMBINATION_PRODUCT|Multiple interventions|Watching procedural informational animation video prior to venipuncture, and Buzzy application during venipuncture
219087468|NCT03013023|BEHAVIORAL|BS|NNS, FT, positional support, and oral sucrose feeding
219087469|NCT03013023|BEHAVIORAL|Routine care|Routine NICU care
219087470|NCT03013023|BEHAVIORAL|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
219087471|NCT03013023|BEHAVIORAL|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
219087472|NCT06509256|DRUG|Tranexamic acid injection|work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
219087473|NCT03059901|OTHER|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
219087474|NCT06193265|PROCEDURE|Discectomy|Discectomy is total or more often partial intervertebral disc surgical removal
219087475|NCT02708875|OTHER|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
219087476|NCT02708875|OTHER|Glucose Challenge|Glucose drink (50g glucose)
219087477|NCT00645164|OTHER|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
219087478|NCT00645164|DRUG|Xenaderm|20 mg under Finn chambers
219087479|NCT05413980|OTHER|Moxifloxacin hydrochloride ophthalmic solution|Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
219087480|NCT05245578|DRUG|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
219087481|NCT05245578|DRUG|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
219087482|NCT02346396|DEVICE|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
219087483|NCT01744886|PROCEDURE|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
219087484|NCT02240433|DRUG|LY2157299|LY2157299 administered orally
219087485|NCT02240433|DRUG|Sorafenib|Sorafenib administered orally
219087486|NCT03343223|BEHAVIORAL|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
219087487|NCT03595332|OTHER|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
219087488|NCT02493400|OTHER|No intervention in the follow up study.|
219214702|NCT06371456|PROCEDURE|epidural catheter placement|after sterilization of the back, local anesthesia injection (xylocaine 5 ml) at lumbar 4-5 level, then advancing the epidural needle till loss of resistance by air occurs and the epidural catheter inserted then aspiration through the catheter will be done to confirm that no accidental cerebrospinal fluid or blood are aspirated and to observe the dew sign inside the outer portion of the epidural catheter near the back of the patient
219214703|NCT03194659|DIETARY_SUPPLEMENT|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
219214704|NCT00890591|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
219214705|NCT04773145|PROCEDURE|Hemiarthroplasty with hydroaxyapatite coated stem|Hemiarthroplasty with non cemented femoral stem, using the hydroxyapatite-coated femoral stem Pharo
219214706|NCT00914641|DRUG|Apixaban IR|immediate release tablet, 10 mg, single dose
219214707|NCT00914641|DRUG|Apixaban MR1|modified release tablet 1, 10 mg, single dose
219214708|NCT00914641|DRUG|Apixaban MR2|modified release tablet 2, 10 mg, single dose
219214709|NCT00914641|DRUG|Apixaban MR3|modified release tablet 3, 10 mg, single dose
219214710|NCT00724126|DRUG|Rifaximin|
219214711|NCT00724126|DRUG|Placebo|
219214712|NCT02867956|DRUG|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
219214713|NCT02867956|DRUG|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
219214714|NCT06372340|PROCEDURE|Personalized pelvic floor rehabilitation program generated by the intelligent diagnosis and treatment system.|Utilizing machine learning to process and analyze vast amounts of previously collected data, the investigators will establish an intelligent system that can generate personalized pelvic floor exercise prescription by matching factors such as general clinical information and pelvic floor muscle strength data. The experimental group will receive tailored program, including pelvic floor muscle training with diverse intensity and frequency, electrical stimulation, magnetic stimulation, biofeedback and other treatments. The results will ultimately be compared with those taking standardized pelvic floor muscle training only.
219214715|NCT06372340|PROCEDURE|Standard pelvic floor muscle training(PFMT) program|Participants will be given handbooks with detailed training program: the basic regimen consists of 3 sets of 8 to 12 contractions sustained for 8 to 10 sec each, performed 3 times a day. Patients should try to do this every day and continue for at least 15 to 20 weeks.
219214716|NCT04869605|DIAGNOSTIC_TEST|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
219214717|NCT01929291|BIOLOGICAL|Boostrix|Single intramuscular injection
219087489|NCT04110002|BEHAVIORAL|Injury Prevention Program|
219087490|NCT04906525|BEHAVIORAL|Resistance training|Participants will undergo 6 weeks of supervised resistance training
219087491|NCT04906525|OTHER|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
219087492|NCT03257332|PROCEDURE|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
219087493|NCT03786861|PROCEDURE|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
219087494|NCT03786861|PROCEDURE|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
219087495|NCT01019538|OTHER|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
219087496|NCT02718703|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
219087497|NCT00117676|DRUG|TDF|300 mg tablet administered orally once daily
219087498|NCT00117676|DRUG|ADV|10 mg tablet administered orally once daily
219087499|NCT00117676|DRUG|TDF placebo|Tablet administered orally once daily
219087500|NCT00117676|DRUG|ADV placebo|Tablet administered orally once daily
219087501|NCT00117676|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
219087502|NCT00952822|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
219087503|NCT01715974|DRUG|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
219214718|NCT01929291|OTHER|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
219214719|NCT04353050|PROCEDURE|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
219214720|NCT02977832|DIETARY_SUPPLEMENT|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
219214721|NCT02977832|DRUG|Alfuzosin|10Mg Oral Tablet, Extended Release
219214722|NCT02502526|DEVICE|Centurion® Vision System, 45° Balanced Tip|
219214723|NCT02502526|DEVICE|Centurion® Vision System, 45° MFK Tip|
219087504|NCT01715974|DRUG|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
219087505|NCT02643862|DRUG|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
219681899|NCT03934008|OTHER|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
219087506|NCT02643862|DRUG|Placebo|Placebo
219087507|NCT03721575|PROCEDURE|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
219087508|NCT03721575|PROCEDURE|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
219087509|NCT00195026|DEVICE|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
219087510|NCT06222216|OTHER|Chilled Needle|Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
219087511|NCT06222216|OTHER|Control Group|SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.
219087512|NCT00975845|OTHER|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
219087513|NCT04284449|OTHER|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment \& supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
219087514|NCT03264651|DRUG|enobosarm|Oral combination therapy of enobosarm and anastrozole
219087515|NCT00000379|DRUG|Fluoxetine|
219087516|NCT00000379|BEHAVIORAL|EMDR|
219214724|NCT02502526|DEVICE|lnfiniti® Vision System, 45° MFK Tip|
219214725|NCT02502526|DEVICE|INTREPID® Ultra infusion sleeve|
219214726|NCT02502526|DEVICE|Ultra infusion sleeve|
219214727|NCT03604809|OTHER|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
219214728|NCT03267537|BEHAVIORAL|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
219087517|NCT05809206|OTHER|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
219087518|NCT05809206|OTHER|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
219681900|NCT05390008|OTHER|Pelvic Floor Muscle Training|"In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased."
219681901|NCT05390008|OTHER|Modified Pilates Exercise|"Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching."
219087519|NCT05809206|OTHER|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
219087520|NCT05809206|DEVICE|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
219087521|NCT05742828|BEHAVIORAL|Virtual Seating Coach|Power wheelchair intervention
219087522|NCT01040702|DRUG|methylphenidate|a single doses of 10-20 mg in each one of two visits
219087523|NCT01040702|DIETARY_SUPPLEMENT|sweetener pill|a capsule containing a sweetener pill
219087524|NCT02621580|DEVICE|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
219087525|NCT02577055|PROCEDURE|myomectomy|Surgical ablation of all fibroids
219087526|NCT02577055|PROCEDURE|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of \>500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
219087527|NCT03072940|OTHER|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
219087528|NCT01296022|DEVICE|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
219087529|NCT01296022|DEVICE|Implantation of transvenous ICD|Implantation of transvenous ICD
219087530|NCT04332510|OTHER|Intact formula|600 ml of infant formula with intact protein
219087531|NCT04332510|OTHER|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
219087532|NCT04332510|OTHER|High protein formula|600 ml of infant formula with high protein level
219087533|NCT04332510|OTHER|Human breast milk|600 ml of breast milk, safe for human consumption
219087534|NCT05547425|DEVICE|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
219087535|NCT05547425|DEVICE|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
219087536|NCT05547425|DEVICE|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
219087537|NCT05547425|DEVICE|Raw images|No editing is performed on images.
219087538|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
219087539|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
219087540|NCT01319799|OTHER|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
219214729|NCT03267537|BEHAVIORAL|Conventional office-based CBT-I|Conventional office-based CBT-I
219214730|NCT00278928|DRUG|Liposyn III 20% (lipid infusion)|
219214731|NCT00278928|DRUG|Intralipid 20% (lipid infusion)|
219087541|NCT00783380|BIOLOGICAL|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
219087542|NCT00783380|BIOLOGICAL|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
219087543|NCT01473693|OTHER|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
219087544|NCT01473693|OTHER|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
219087545|NCT00186316|BIOLOGICAL|Idiotype-pulsed allogeneic dendritic cells|
219087546|NCT05227755|DIETARY_SUPPLEMENT|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
219087547|NCT05227755|DIETARY_SUPPLEMENT|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
219087548|NCT01250535|DRUG|Warfarin|10 mg, po, single dose on day 7
219087549|NCT01250535|DRUG|Placebo|po, once a day, days 1 through 14
219087550|NCT01250535|DRUG|Lovastatin|40 mg, po, once a day, days 1 through 14
219214732|NCT06700720|DRUG|Dose 1 YN001|Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
219214733|NCT06700720|DRUG|Dose 2 YN001|Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
219214734|NCT06700720|DRUG|Evolocumab|Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
219087551|NCT05322070|DRUG|Fluocinolone Acetonide Intravitreal Implant 0.18 mg|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
219087552|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
219087553|NCT05003102|DRUG|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
219087554|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
219087555|NCT00004408|DRUG|poloxamer 188|
219087556|NCT04623073|PROCEDURE|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
219087557|NCT03951038|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
219214735|NCT04261309|OTHER|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
219214736|NCT05692817|DEVICE|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
219214737|NCT06196749|PROCEDURE|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
219214738|NCT06196749|PROCEDURE|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
219214739|NCT01462799|BEHAVIORAL|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
219214740|NCT01462799|BEHAVIORAL|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
219087558|NCT03951038|PROCEDURE|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
219087559|NCT05306366|DRUG|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
219087560|NCT04555096|DRUG|GC4419|180 Minute IV Infusion
219087561|NCT04555096|DRUG|Placebo|180 Minute IV Infusion
219214741|NCT05100797|DEVICE|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
219214742|NCT04373694|PROCEDURE|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
219214743|NCT04373694|PROCEDURE|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
219214744|NCT00588471|DRUG|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
219214745|NCT00588471|DRUG|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
219214746|NCT03575936|DEVICE|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
219214747|NCT03575936|PROCEDURE|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
219214748|NCT02476435|DEVICE|Active rTMS|Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
219214749|NCT02476435|DEVICE|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
219214750|NCT02920710|DRUG|Repository Corticotropin Injection|"* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
219214751|NCT00293397|DEVICE|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
219214752|NCT03058445|DEVICE|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
219214753|NCT03058445|DEVICE|CVC|Injection of 5 ml of saline
219087562|NCT00295763|DRUG|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
219087563|NCT04175795|BEHAVIORAL|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
219214754|NCT02540824|DRUG|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
219214755|NCT02189174|DRUG|CLR457|
219214756|NCT01611493|DEVICE|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
219214757|NCT01611493|DEVICE|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
219214758|NCT04688060|DIAGNOSTIC_TEST|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
219087564|NCT03263832|DIAGNOSTIC_TEST|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
219087565|NCT00904514|GENETIC|gene expression analysis|
219087566|NCT00904514|GENETIC|microarray analysis|
219087567|NCT00904514|GENETIC|mutation analysis|
219087568|NCT00904514|GENETIC|polymerase chain reaction|
219087569|NCT00904514|OTHER|flow cytometry|
219087570|NCT00904514|OTHER|immunoenzyme technique|
219087571|NCT00904514|OTHER|laboratory biomarker analysis|
219087572|NCT05608096|DEVICE|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
219087573|NCT02685644|PROCEDURE|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
219087574|NCT04182763|OTHER|CoA-Z|People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
219087575|NCT04182763|OTHER|Placebo|The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
219214759|NCT00674752|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
219214760|NCT00674752|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
219214761|NCT00674752|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
219214762|NCT03830567|OTHER|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
219214763|NCT03830567|OTHER|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
219214764|NCT04017793|BEHAVIORAL|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
219214765|NCT04017793|BEHAVIORAL|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
219214766|NCT00698113|PROCEDURE|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
219214767|NCT00698113|OTHER|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
219214768|NCT04623489|BEHAVIORAL|¡Vivir Mi Vida! Lifestyle Intervention|
219214769|NCT06299670|DRUG|Thalidomide|Patients will get only Thalidomide
219214770|NCT06299670|DRUG|Hydroxy Urea|Patients will get only Hydroxyurea
219214771|NCT06299670|DRUG|Combinations|Combination Of Thalidomide \& Hydroxyurea
219214772|NCT00822120|BIOLOGICAL|bleomycin sulfate|
219214773|NCT00822120|BIOLOGICAL|filgrastim|
219214774|NCT00822120|DRUG|ABVD regimen|
219214775|NCT00822120|DRUG|BEACOPP regimen|
219214776|NCT00822120|DRUG|cyclophosphamide|
219087576|NCT06579339|OTHER|xylitol chewing gum|Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
219087577|NCT01250990|DRUG|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
219087578|NCT01250990|OTHER|Placebo|Placebo
219087579|NCT04995679|PROCEDURE|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
219087580|NCT05321355|DEVICE|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
219087581|NCT02341001|OTHER|Daily text message of support|
219087582|NCT00004670|PROCEDURE|pallidotomy|
219087583|NCT00942617|DRUG|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
219087584|NCT01468298|OTHER|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
219214777|NCT00822120|DRUG|dacarbazine|
219214778|NCT00822120|DRUG|doxorubicin hydrochloride|
219214779|NCT00822120|DRUG|etoposide|
219214780|NCT00822120|DRUG|prednisone|
219214781|NCT00822120|DRUG|procarbazine hydrochloride|
219214782|NCT00822120|DRUG|vinblastine sulfate|
219214783|NCT00822120|DRUG|vincristine sulfate|
219214784|NCT03491540|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
219214785|NCT03491540|DRUG|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
219214786|NCT03491540|DRUG|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
219214787|NCT03491540|DRUG|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
219214788|NCT03491540|DRUG|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
219214789|NCT00503906|DRUG|Avastin|
219214790|NCT00503906|DRUG|Gemcitabine|
219214791|NCT00503906|DRUG|Abraxane|
219214792|NCT05462067|DEVICE|AT LARA IOL|EDOF IOL for treatment of cataract
219214793|NCT05462067|DEVICE|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
219214794|NCT06461390|DRUG|Norepinephrine|NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
219214795|NCT06461390|DRUG|Ringer's Lactate|Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
219214796|NCT00291954|BIOLOGICAL|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
219214797|NCT00291954|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
219087585|NCT01468298|OTHER|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
219087586|NCT00046501|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
219214798|NCT01324310|DRUG|Romidepsin|Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
219214799|NCT01324310|DRUG|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
219214800|NCT02582424|OTHER|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
219214801|NCT02582424|OTHER|placebo|placebo
219214802|NCT00255307|DRUG|CVT-E002 ginseng extract|
219214803|NCT00137098|DRUG|Caffeine|
219214804|NCT00008242|DRUG|dexamethasone|
219214805|NCT00008242|DRUG|doxorubicin hydrochloride|
219214806|NCT00008242|DRUG|thalidomide|
219214807|NCT01951807|BEHAVIORAL|Psychotherapy|
219214808|NCT06162702|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
219087587|NCT00046501|DRUG|Humulin N|
219087588|NCT00046501|DRUG|Humulin L|
219087589|NCT00046501|DRUG|Lispro|
219087590|NCT03814733|DRUG|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087591|NCT03814733|DRUG|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087592|NCT03814733|DRUG|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087593|NCT03814733|DRUG|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087594|NCT03814733|DRUG|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087595|NCT03814733|DRUG|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
219087596|NCT00523159|DRUG|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
219087597|NCT00523159|DRUG|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
219087598|NCT03641313|DRUG|Berzosertib|Given IV
219087599|NCT03641313|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
219087600|NCT03641313|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
219087601|NCT03641313|DRUG|Irinotecan|Given IV
219087602|NCT03641313|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219087603|NCT05735587|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
219214809|NCT03095872|DEVICE|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
219214810|NCT03095872|DRUG|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
219214811|NCT03095872|DRUG|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
219214812|NCT02505191|DRUG|St. John's wort prolonged-release tablet 500 mg|
219214813|NCT02505191|DRUG|St. John's wort film coated tablets 250 mg|
219214814|NCT03954275|OTHER|no intervention|no intervention
219214815|NCT03447457|DEVICE|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
219214816|NCT03447457|DEVICE|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
219214817|NCT00708045|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
219214818|NCT00115011|DRUG|Escitalopram|
219214819|NCT01974843|DRUG|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
219214820|NCT01974843|DRUG|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
219087604|NCT05735587|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
219087605|NCT03744793|DRUG|Avelumab|Given IV
219087606|NCT03744793|DRUG|Pemetrexed|Given IV
219214821|NCT05489913|OTHER|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
219214822|NCT03959813|OTHER|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~* A questionnaire, based on the physical experience,~* The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
219214823|NCT05282966|DIAGNOSTIC_TEST|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
219214824|NCT02540369|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
219214825|NCT05680857|OTHER|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
219214826|NCT05680857|OTHER|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
219214827|NCT02614911|OTHER|Biological sampling|Biological sampling including blood, feces, biopsies...
219214828|NCT03865004|DRUG|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
219214829|NCT03865004|DRUG|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
219214830|NCT03865004|DRUG|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
219214831|NCT05729503|DRUG|Lidocaine 2% Injectable Solution|Cotton tip applicator pre-soaked with lidocaine
219214832|NCT05729503|DRUG|Placebo|Cotton tip applicator pre-soaked with saline
219214833|NCT03960359|OTHER|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
219214834|NCT03738709|BEHAVIORAL|Falls prevention and education giving a demonstration of the usage of technical assistance.|"* Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
219214835|NCT04023175|OTHER|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
219214836|NCT04023175|OTHER|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
219214837|NCT06843824|DEVICE|a custom-made graphene therapy cap|The GFII involved the use of a custom-made graphene therapy cap. The cap consisted of 3 parts: the main body of the cap, the thermostat and the power adapter. One end of the thermostat was connected to the main body of the cap, and the other end was connected to the power adapter; the adapter was plugged into a 220 V household power outlet. This turned on the cap, and the temperature could be adjusted. The light energy conversion rate of the graphene coating material used in the cap reached 90%, generating a temperature of 40 °C. Five caregivers were responsible for providing care for the elderly individuals. We will provided standardized training on the GFII to their caregivers. Each caregiver was responsible for assisting with the intervention of the elderly individuals that they usually cared for.
219214838|NCT06843824|DEVICE|A regular cap that generates heat|The rest of the procedure is the same as the GFII group, but the cap used is a regular cap that can heat up to 40°C.
219681902|NCT02076204|BEHAVIORAL|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
219681903|NCT00409981|DEVICE|paclitaxel coated balloon catheter (device with drug)|
219087607|NCT00994981|DRUG|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
219087608|NCT00994981|DRUG|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
219087609|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
219214839|NCT04717544|BEHAVIORAL|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
219087610|NCT06462508|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
219087611|NCT06462508|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
219087612|NCT03798938|OTHER|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
219087613|NCT06220955|OTHER|centric relation registration|centric relation registration using conventional and digital methods
219087614|NCT06220955|OTHER|maximum intercuspation registration|maximum intercuspation registration
219214840|NCT02402569|DEVICE|32 channels Deep Brain Stimulator|
219214841|NCT02029235|DRUG|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
219214842|NCT02029235|DRUG|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
219214843|NCT02911441|BEHAVIORAL|Cognitive Behavioral Therapy|
219214844|NCT05948449|DRUG|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
219214845|NCT01715194|DEVICE|Telemedicine intervention|Patients undergoing telemedicine intervention
219214846|NCT05784259|BEHAVIORAL|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
219214847|NCT05960539|PROCEDURE|surgical training|surgical residency focussed on visceral robotic procedures
219214848|NCT06509529|OTHER|Motivational Interviewing Based on the COM-B Model|Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
219214849|NCT05931627|PROCEDURE|Patients undergoing ACL reconstruction with or without a tourniquet|Patients undergoing ACL reconstruction with or without a tourniquet
219214850|NCT04251442|DEVICE|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
219214851|NCT00756067|BIOLOGICAL|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
219214852|NCT00756067|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
219087615|NCT01743079|DRUG|Telbivudine|LdT 600mg QD
219214853|NCT01208116|OTHER|Cardiovascular events|"* Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death"
219214854|NCT01913314|DRUG|[^14C]-LY2835219|Administered as oral solution
219214855|NCT03874819|DEVICE|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
219214856|NCT03874819|DEVICE|High-flux dialyzer|Treatment using a high-flux dialyzer
219214857|NCT01138254|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
219214858|NCT01138254|OTHER|no intervention|no intervention
219214859|NCT01738438|DRUG|Cabozantinib|
219087616|NCT01743079|DRUG|Lamivudine|LAM 100mg QD
219087617|NCT03755830|OTHER|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
219087618|NCT03224013|PROCEDURE|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
219214860|NCT04437641|OTHER|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
219214861|NCT02673216|OTHER|No intervention|
219214862|NCT05751161|OTHER|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
219214863|NCT05769413|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
219214864|NCT00111683|DRUG|MK0457|
219214865|NCT02282657|DEVICE|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
219087619|NCT04832828|DIAGNOSTIC_TEST|Roth´s Test|Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
219087620|NCT01533493|DRUG|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
219087621|NCT01533493|DRUG|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
219087622|NCT01533493|DRUG|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
219087623|NCT02433743|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
219214866|NCT02282657|OTHER|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
219214867|NCT02282657|DEVICE|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
219214868|NCT02282657|OTHER|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
219214869|NCT02282657|OTHER|Respiratory Rate|RR will be kept what it was at baseline
219214870|NCT02282657|OTHER|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
219214871|NCT02282657|OTHER|Ventilation will be adapted|If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
219214872|NCT02282657|OTHER|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
219214873|NCT03484949|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
219214874|NCT02961634|DEVICE|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
219214875|NCT02961634|DRUG|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
219214876|NCT04066075|BEHAVIORAL|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
219214877|NCT00327119|DRUG|ABX-EGF (panitumumab)|
219214878|NCT00309166|BIOLOGICAL|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
219214879|NCT00309166|BIOLOGICAL|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
219214880|NCT04310514|DIETARY_SUPPLEMENT|Fructose/glucose/xylitol/saccharose|"1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
219214881|NCT04861805|DEVICE|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
219214882|NCT06698692|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib Combined chemoradiotherapy
219214883|NCT05966064|DRUG|Denosumab 120 Mg/1.7 Ml Inj|Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
219681904|NCT03793569|BEHAVIORAL|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
219214884|NCT05966064|DRUG|Placebo|placebo randomized at baseline and after 3 months
219214885|NCT06798025|PROCEDURE|Punctal dilation|Patients were treated with punctal dilatation only.
219681905|NCT00498680|DRUG|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
219214886|NCT06798025|DRUG|Punctal dilation and topical medication|Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
219214887|NCT06798025|DRUG|Triamcinolone acetonide|Patients were treated with a peri-punctual injection of Triamcinolone acetonide.
219214888|NCT06698588|DIETARY_SUPPLEMENT|Omega 3 Fish Oil supplements|Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).
219214889|NCT06698588|DIETARY_SUPPLEMENT|Placebo|Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
219214890|NCT06146556|PROCEDURE|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
219214891|NCT03029286|BEHAVIORAL|Usual Care Arm|Health information provided by the American Cancer Society Website
219087624|NCT01136122|DEVICE|CPAP Treatment|Effective CPAP treatment for one month
219087625|NCT00525525|DRUG|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
219087626|NCT00525525|DRUG|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
219087627|NCT00525525|DRUG|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
219087628|NCT06350253|DIAGNOSTIC_TEST|Metabolic cart|RMR measurement via metabolic cart
219087629|NCT06350253|DIAGNOSTIC_TEST|MedGem|RMR measurement via MedGem
219214892|NCT03029286|BEHAVIORAL|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
219214893|NCT06773715|DEVICE|KindVR Aqua Program|For this study, patients will be introduced to a virtual reality software program called Aqua, created by the company KindVR. This software program was designed specifically for use in pediatric patients. The software has been programmed into the Pico Neo 3 headset and provides an immersive 3D experience during which the patients explore a virtual underwater world inside a submarine with a goal of providing more color to treasure and different sea animals that they will engage with along their journey. The VR experience itself lasts approximately 15 minutes
219214894|NCT06789250|BEHAVIORAL|Internet-based cognitive behavior therapy|The intervention within this study is based on cognitive behavioral therapy principles and adapted to target harmful alcohol use and mild to moderate alcohol use disorder co-occuring with psychological symptoms of depression, anxiety, stress and/or sleeping disorder. The 10 weeks of individually tailored treatment include psycho-educational texts as well as examples and exercises supported by a therapist.
219214895|NCT06829823|DRUG|N-803 and BCG|Combination therapy N-803 plus BCG
219214896|NCT06829823|DRUG|N-803 and Gemcitabine|Combination therapy N-803 plus Gemcitabine
219214897|NCT06879067|DRUG|Placebo|Placebo nasal spray
219214898|NCT06879067|DRUG|Foralumab Nasal|foralumab nasal spray
219214899|NCT04823650|DEVICE|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
219214900|NCT04823650|DEVICE|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
219214901|NCT06772350|PROCEDURE|examinations|Echo-Doppler and blood samples
219214902|NCT06850441|OTHER|Psychoeducation|"The education is a group psychoeducation. Education methods such as role-play, discussion, demonstration, and narration will be applied. The education will be held once a week and will be completed in 7 weeks.~Psychoeducation topics include adaptation to stigma in type 1 diabetes, coping, diabetes management, social life, self-esteem, roles in life and impact on life. Concepts such as stigma, blame, judgment, discrimination, shame and stereotyped thoughts will be included."
219214903|NCT06738225|DIAGNOSTIC_TEST|certain serum MicroRNA biomarkers (miR-15b and miR-21)|miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
219214904|NCT06765473|DRUG|Misoprostol|preoperative vaginal and postoperative sublingual administration of misoprostol (800 μg) to reducing the amount of blood loss during and 24 hours after CS to determine the optimum time for drug administration.
219214905|NCT06817122|BEHAVIORAL|Let's Talk Tech|Let's Talk Tech is a self-administered dyadic education and communication tool delivered as a web application to support shared decision making about technology use.
219214906|NCT06825182|DRUG|Outpatient newly diagnosed type 2 diabetes subjects|Outpatient newly diagnosed type 2 diabetes subjects, who have signed the informed consent form, meet the inclusion and exclusion criteria, and have their demographic data collected, including height, weight, systolic and diastolic blood pressure, and calculation of the body mass index (BMI) = weight/height\^2 (kg/m\^2). Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is performed, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested, with eGFR calculated. Type 2 diabetes patients are treated with GLP-1RA for three months, and then the aforementioned indicators are retested to complete the study.
219681906|NCT00498680|DRUG|Sildenafil|100mg
219681907|NCT00498680|DRUG|Vardenafil|20mg
219681908|NCT00498680|DRUG|Sildenafil & Vardenafil|50mg \& 10 mg
219087630|NCT06350253|DIAGNOSTIC_TEST|BIA|RMR estimation from BIA analysis
219214907|NCT06825182|DRUG|Inpatient newly diagnosed type 2 diabetes subjects|Demographic data are collected. Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is conducted, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested. During hospitalization, if hypoglycemic symptoms occur or peripheral blood glucose or continuous glucose monitoring is ≤3.9 mmol/L, immediate venous blood is drawn for glucose, GCG, adrenocorticotropic hormone (ACTH), cortisol (Cor), growth hormone (GH), and Cp testing. Patients are treated with GLP-1RA for three months, then the aforementioned indicators are retested to complete the study and hypoglycemia (including hypoglycemic clamp and hypoglycemia tests) is assessed for glucose and GCG, with additional tests for ACTH, Cor, GH, and Cp if conditions permit, to complete the study.
219214908|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
219214909|NCT06745596|PROCEDURE|cataract surgery 1|Cataract with limited anterior pars plana vitrectomy
219214910|NCT06745596|PROCEDURE|cataract surgery 2|cataract without limited anterior pars plana vitrectomy
219087631|NCT05019261|OTHER|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
219087632|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
219087633|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
219087634|NCT05094466|BEHAVIORAL|Behavioral Intervention|Receive peer support sessions
219214911|NCT06777927|OTHER|Exercise|The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
219214912|NCT06777927|OTHER|Exercise|The subjects would be doing treadmill training within moderate intensity target heart rate.
219214913|NCT06777927|OTHER|No intervention|The subjects would not be given any intervention and would be used as controls.
219087635|NCT05094466|OTHER|Counseling|Receive health coaching sessions
219087636|NCT05094466|PROCEDURE|Discussion|Attend focus groups
219087637|NCT05094466|OTHER|Educational Intervention|Receive handbook
219214914|NCT05561673|COMBINATION_PRODUCT|GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide|Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
219214915|NCT05561673|BIOLOGICAL|GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system|Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
219214916|NCT05561673|BIOLOGICAL|GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system|Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
219214917|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
219214918|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
219214919|NCT06750705|OTHER|PechaKucha|The PechaKucha format consists of 20 slides, each displayed for 20 seconds, focusing on vital signs measurement skills. The method emphasizes a fast-paced, engaging, and visual learning experience designed to enhance retention and improve students' practical knowledge and skills in measuring vital signs.
219087638|NCT05094466|OTHER|Informational Intervention|Receive navigation sessions
219087639|NCT05094466|OTHER|Interview|Participate in interview
219087640|NCT04532606|DRUG|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
219087641|NCT04532606|DRUG|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
219087642|NCT06058624|BEHAVIORAL|Veteran ACT for Chronic Pain (VACT-CP)|"Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting."
219214920|NCT06750705|OTHER|PowerPoint|The PowerPoint presentation will cover the same vital signs measurement content but in a more conventional, linear format. The intervention will aim to reinforce students' understanding of vital signs through text and images, with a slower pace compared to the PechaKucha method.
219214921|NCT04057820|OTHER|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
219087643|NCT06058624|BEHAVIORAL|Online Pain School|"Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox."
219087644|NCT00030693|BIOLOGICAL|recombinant fowlpox-B7.1 vaccine|Given intratumorally
219087645|NCT00030693|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
219087646|NCT00030693|OTHER|laboratory biomarker analysis|Correlative studies
219087647|NCT00030693|PROCEDURE|quality-of-life assessment|Ancillary studies
219087648|NCT01124760|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
219087649|NCT01124760|DRUG|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
219087650|NCT01124760|DRUG|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
219087651|NCT04181203|DRUG|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
219087652|NCT04181203|RADIATION|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
219214922|NCT04057820|OTHER|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
219214923|NCT03593226|DRUG|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
219214924|NCT06754748|OTHER|Caffeinated coffee|11 g caffeinated coffee made with 200 ml water was given to participants.
219214925|NCT06754748|OTHER|Decaffeinated coffee|11 g decaffeinated coffee made with 200 ml water was given to participants.
219214926|NCT06754748|OTHER|Water|200 ml water was given to participants.
219214927|NCT06775366|DRUG|Remimazolam|Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.
219681909|NCT01999647|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
219087653|NCT04181203|DRUG|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
219087654|NCT04885062|DEVICE|Belun Ring|The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.
219087655|NCT04885062|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
219087656|NCT03899753|DEVICE|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
219087657|NCT03899753|DEVICE|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
219087658|NCT03585582|OTHER|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
219214928|NCT06775366|DRUG|propofol|Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
219214929|NCT06809348|BEHAVIORAL|PRECISE|"PRECISE includes aspects of several evidence-based approaches, such as Safety Planning and DBT to manage and reduce suicide risk. During the initial visit, staff train participants how to complete EMAs. Participants then complete two weeks of five-times per day EMAs regarding their emotions, emotion regulation strategies as well as SITBs. Following an initial learning period, participant data is analyzed via GIMME to determine the within-person correlates of SITBs. Data is processed through a real-time pre-programmed data cleaning and analysis script. Coaches then teach a selection of skills in collaboration with the client."
219214930|NCT06810921|PROCEDURE|lateral sinus lift|"A rectangular shaped osteotomy was performed using a low-speed surgical handpiece and round diamond bur, with copious cooled normal saline irrigation.~The Schneiderian membrane (SM) was gently elevatated using Frios Sinus Set elevators for implant placement"
219214931|NCT04517435|DRUG|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
219214932|NCT04517435|DRUG|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
219214933|NCT04517435|DRUG|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
219214934|NCT04517435|DRUG|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
219214935|NCT04517435|DRUG|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
219087659|NCT04862182|DIAGNOSTIC_TEST|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
219087660|NCT00063050|BEHAVIORAL|Physical activity and nutrition intervention|
219087661|NCT00796692|DRUG|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
219214936|NCT04517435|DRUG|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
219214937|NCT06814158|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab 20mg/kg + CT Q3W, 3cycles
219214938|NCT06754306|OTHER|normal diet (100% energy)|Daily intake of 100% energy requirements, adjusted individually based on each participant's basal metabolic rate (BMR).
219214939|NCT06754306|OTHER|16+8 time-restricted eating group (100% energy)|Participants will consume 100% energy within an 8-hour eating window and fast for the remaining 16 hours.
219214940|NCT06754306|OTHER|16+8 time-restricted eating group (75% energy)|Participants will consume 75% of their energy requirements within the 8-hour eating window.
219214941|NCT06754306|OTHER|Alternate-day fasting group (75% energy)|"Participants alternate between feeding days (125% energy requirements) and fasting days (25% energy requirements)."
219214942|NCT06754306|OTHER|5+2 intermittent fasting group (75% energy)|Participants consume 95% energy requirements for 5 consecutive days and 25% energy requirements for 2 fasting days.
219214943|NCT06754306|OTHER|Low-calorie diet group (75% energy)|Participants will reduce daily caloric intake to 75% of energy requirements, consumed evenly across three meals.
219214944|NCT06754306|OTHER|Very low-calorie diet group (45% energy)|Participants will reduce daily caloric intake to 45% of energy requirements (\~800 kcal/day)
219214945|NCT06753773|DEVICE|Repeated Low-Level Red-Light|All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.
219214946|NCT06754540|DRUG|Azacitidine (AZA)|Azacitidine 32mg/m2
219681910|NCT01999647|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
219681911|NCT01999647|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
219214947|NCT06818149|DIAGNOSTIC_TEST|Biomarker Analysis for Severity Assessment|Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury biomarkers, iron metabolism-related biomarkers, and immunological biomarkers will be tested.
219214948|NCT06816251|DRUG|HRS-1893|HRS-1893 tablet.
219214949|NCT06816251|DRUG|HRS-1893 placebo|HRS-1893 tablet placebo.
219214950|NCT06868745|DRUG|Experimental: melatonin treatment group|Each participant received melatonin 5 mg for a period of 30 days
219681912|NCT01999647|PROCEDURE|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
219681913|NCT01999647|DRUG|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
219087662|NCT00796692|DRUG|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
219087663|NCT02657031|DRUG|Prochlorperazine|prochlorperazine 10 mg IV
219087664|NCT02657031|DRUG|Ketamine|Ketamine 0.3 mg/kg IV
219087665|NCT02657031|DRUG|Diphenhydramine|Diphenhydromine 25 mg IV
219087666|NCT02657031|DRUG|Ondansetron|Ondansetron 4 mg IV
219087667|NCT02657031|DRUG|Normal Saline|Normal Saline 500 cc IV Bolus
219087668|NCT03440684|OTHER|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
219087669|NCT01561001|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
219087670|NCT01245946|PROCEDURE|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
219087671|NCT01245946|DRUG|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
219214951|NCT06868745|DRUG|Placebo comparator: placebo treatment group|Each participant received placebo for a period of 30 days
219087672|NCT00512512|PROCEDURE|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
219087673|NCT03912558|PROCEDURE|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
219087674|NCT04118244|DIAGNOSTIC_TEST|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
219087675|NCT04716348|PROCEDURE|muscle energy technique|muscle energy technique for suboccipital muscles
219087676|NCT04997954|DRUG|MediCabilis CBD oil|"The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~* Cannabis sativa L. dry extract~* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~* 50 mg of Cannabidiol (CBD+CBDA)~* Less than 2 mg tetrahydrocannabinol (THC)~* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut"
219087677|NCT02748187|OTHER|CBASP|Interpersonal psychotherapy for chronic depression
219087678|NCT05114655|OTHER|Herbaceous Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
219087679|NCT05114655|OTHER|Citrus Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
219214952|NCT04968964|DEVICE|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
219214953|NCT04968964|OTHER|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
219214954|NCT06783400|BEHAVIORAL|SASA! Together|"SASA! Together is a community mobilisation approach that engages communities to create positive and sustainable changes around norms and behaviors that perpetuate violence against women. Some new features in this revision of SASA! include a distinct focus on IPV, including sexual decision-making; three strategies aligned to the socio-ecological model that reach across the whole community (individuals, groups, and institutions); and more support to get organisations and communities started and to sustain change.~The evidence- and theory-based SASA! approach is grounded in: (1) benefits-based activism, (2) a gender-power analysis, (3) four phases of change (start, awareness, support, action) according to the stages of behaviour change, (4) holistic community engagement, (5) local activism, (6) community leadership, and (7) institutional strengthening."
219214955|NCT03767348|BIOLOGICAL|RP1|Genetically modified herpes simplex type 1 virus
219214956|NCT03767348|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
219087680|NCT05114655|OTHER|Inert Oil|Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
219087681|NCT03797521|DRUG|SXC-2023|SXC-2023 oral capsules
219087682|NCT03797521|DRUG|Placebo|Matching Placebo oral capsules
219087683|NCT03953339|PROCEDURE|Release or no release of the suprascapular nerve|
219214957|NCT06763887|OTHER|No Interventions|No intervention
219214958|NCT06767930|BEHAVIORAL|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities|The HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) program is an intensive rehabilitation therapy designed to improve motor functions and promote functional independence. Participants in this arm will engage in 6.5 hours of structured activities per day for two weeks (10 days). The therapy focuses on bimanual coordination combined with constant stimulation of the trunk and/or lower extremities, using task-oriented exercises tailored to individual goals. Each participant will be supported by one or two therapists and supervised by a trained team to ensure the program is delivered effectively and safely. The therapy emphasizes engaging, play-based activities to maximize motivation and active participation.
219087684|NCT03078816|DEVICE|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087685|NCT03078816|DEVICE|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219214959|NCT06767930|BEHAVIORAL|Conventional intervention|Participants in the control group will continue their usual care, which includes conventional physical and occupational therapy, for a duration of two weeks. They will follow their regular therapy schedules without any changes to their routines or treatment habits. This approach ensures that the control group reflects standard rehabilitation practices, allowing for a direct comparison with the intervention group.
219214960|NCT06793345|OTHER|Moderate intensity intermittent walking training|The intensity of the training is 60 to 80% of 6MWTdistance.
219214961|NCT06846801|PROCEDURE|Balloon Dilation Under Portable X-ray System|"* All the esophageal dilation procedures will be performed using rigid hypopharyngoscope and / or oesophagoscope with endotracheal intubation under general anesthesia by experienced surgical and anesthesia team.~* The rigid hypopharyngoscope / oesophagoscope (Storz, germany) will be introduced through the mouth to whole through examination to localize the site of the stenosis then a contrast material will be injected via the endoscope and picture taken with X-DR portable x-ray system.~* After that a guide wire 0.035mm will be passed through the endoscope till the stomach. The guide wire site will be confirmed by with X-DR portable x-ray system and then a suitable size balloon catheter will be passed over the guide wire (Boston Scientific, Cork, Ireland), then the balloon catheter will be advanced through the stricture confirmed by taking a photo by the x-ray system. The balloon will be inflated with radiopaque contrast solution using EncoreTM 26 inflation device."
219087686|NCT03078816|DEVICE|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219214962|NCT06447272|OTHER|sham inspiratory muscle training|This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)
219214963|NCT06447272|OTHER|target inspiratory muscle training|This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).
219214964|NCT06593392|DRUG|Difelikefalin|The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
219214965|NCT06754410|DRUG|Tamsulosin|group A take tamsulosin once daily
219214966|NCT06754410|DRUG|Cetirizine|give cetirizine once dailly
219214967|NCT06754410|COMBINATION_PRODUCT|Cetirizine + Tamsulosin|both once daily
219214968|NCT06754410|OTHER|Placebo|once dailly
219214969|NCT06751277|DRUG|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
219214970|NCT06752564|BEHAVIORAL|Goal-Oriented Care Model|"The experimental group : Goal-Oriented Care (GOC) The concept of Goal-Oriented Care (GOC) was first introduced by Mold et al. in 1991, addressing the limitations of problem-oriented care, which focuses on eradicating diseases and preventing death. GOC is defined as a process of reaching a consensus on health-related goals between the healthcare team and the patient (Vermunt et al., 2017). It is based on patients' core values and priorities within a clinical context, guiding medical interventions and specific treatment decisions (Secunda et al., 2020).~Healthcare professionals using GOC aim to help patients achieve their maximum personal health potential, aligning care with individual goals. The clear direction provided by GOC fosters teamwork and interdisciplinary collaboration (Gray et al., 2020). When establishing long-term goals with patients, it is crucial to revisit and adjust these goals, considering realistic survival timelines, as time plays a vital role in goal-setting."
219681914|NCT00522548|DRUG|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
219087687|NCT03078816|DEVICE|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087688|NCT03078816|DEVICE|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087689|NCT03078816|DEVICE|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087690|NCT03078816|DEVICE|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087691|NCT03078816|DEVICE|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087692|NCT03078816|DEVICE|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
219087693|NCT00543595|DRUG|MK0916|
219214971|NCT06752564|BEHAVIORAL|standard health education|The control group received standard health education. The content of the standard health education included verbal instructions provided by nurses during the general hospital stay, as well as the distribution of educational pamphlets. These instructions covered topics such as the frequency of dialysis and dietary control. The standard health education was generic, without a specific schedule or structured content.
219087694|NCT04450602|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
219681915|NCT00522548|DRUG|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
219087695|NCT04450602|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219087696|NCT04450602|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219087697|NCT04450602|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
219087698|NCT04450602|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
219087699|NCT04450602|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219087700|NCT04450602|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
219087701|NCT04450602|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
219087702|NCT05766917|BEHAVIORAL|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
219087703|NCT04766268|OTHER|Prostate artery embolization|Prostate artery embolization (PAE) is a safe and effective minimally invasive interventional radiology procedure in which intraprostatic vessels are embolized to shrink the size of the prostate gland. LUTS is mainly categorized into irritative, obstructive, and mixed types. This has a variable impact on patients' quality of life by interfering with sleep, activities of daily living, anxiety, mobility, leisure, and effect on sexual activities. This trial aims to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
219087704|NCT00180635|DRUG|Aminoguanidine|500mg
219087705|NCT00180635|DRUG|Placebos|2ml
219087706|NCT05899842|DRUG|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
219087707|NCT00145015|BEHAVIORAL|Increased dietary intake of salmon or cod|
219087708|NCT05724355|DRUG|Dalpiciclib Isetionate Tablets, Camrelizumab|Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
219087709|NCT05977426|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
219087710|NCT02375295|DRUG|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
219087711|NCT00669786|DRUG|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
219087712|NCT03325543|OTHER|Visual observation|Verbal instructions about the anatomy, function and how to perform the pelvic floor muscle contraction
219214972|NCT06751771|OTHER|comprehensive correcting exercise program|Group A will be treated with comprehensive correcting exercise program (three times a week for 6 weeks) into 3 phases with different intensity and frequency
219087713|NCT03325543|OTHER|Vaginal palpation (bidigital touch)|The physiotherapist touched the patients' perineal region (vulva, tendinous centre of the perineum and external region of the anal canal) with a spatula and asked them to identify the pointed region; and with the digital palpation, the physiotherapist touched the tendinous centre of the perineum, pressing it in the cranial direction, and instructed the patients to contract the pelvic floor muscle
219087714|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
219087715|NCT04410068|DEVICE|WARMTAC|Randomization to one of the arms previous to surgery.
219087716|NCT04410068|DEVICE|3M Bair Hugger|Randomization to one of the arms previous to surgery.
219087717|NCT00603577|DRUG|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
219087718|NCT00603577|DRUG|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
219087719|NCT05505474|DEVICE|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
219087720|NCT02706860|DRUG|Atorvastatin|
219087721|NCT00293683|DEVICE|Insorb absorbable skin staple|
219087722|NCT03777267|DEVICE|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
219087723|NCT06472596|DIAGNOSTIC_TEST|CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha|compare results of investigations in asthmatics and non asthmatics
219087724|NCT05129943|DEVICE|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
219087725|NCT05129943|DEVICE|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
219087726|NCT04679090|OTHER|Exercise Program|Participants will exercise twice a week for twelve weeks total.
219087727|NCT00145093|DRUG|Baker's yeast (Bio Chromium)|
219087728|NCT02707835|OTHER|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
219087729|NCT02707835|OTHER|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
219087730|NCT02707835|OTHER|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
219087731|NCT04305314|OTHER|PRI (Enhanced Recovery after surgery protocol)|Standard use of Spanish perioperative guidelines (PRI)
219087732|NCT01889433|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
219087733|NCT01889433|DRUG|Pegasys|180 µg subcutaneously, once a week
219087734|NCT00103766|DRUG|Alteplase|
219681916|NCT00977912|DIETARY_SUPPLEMENT|Probiotic supplementation|one capsule containing probiotics per day added to milk
219087735|NCT04300894|DEVICE|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
219087736|NCT04300894|OTHER|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
219087737|NCT02768363|BIOLOGICAL|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
219087738|NCT02768363|BIOLOGICAL|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
219087739|NCT02768363|DRUG|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
219087740|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
219681917|NCT00977912|DIETARY_SUPPLEMENT|Milk containing placebo|one capsule containing placebo per day added to milk
219681918|NCT03272243|PROCEDURE|short segment posterior spine fixation|
219681919|NCT03272243|PROCEDURE|long segment posterior spine fixation|
219087741|NCT04016090|OTHER|Placebo|Placebo capsule
219087742|NCT06095297|BEHAVIORAL|Processing Speed Training|"Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to rapidly distinguish targets from decoys, which trains how rapidly the player processes information received through their senses."
219087743|NCT06095297|BEHAVIORAL|In-lab Instrumental Activities of Daily Living Training|Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
219087744|NCT06095297|BEHAVIORAL|In-lab Brain Health Training|Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
219087745|NCT06095297|BEHAVIORAL|Transfer Package|"The Transfer Package was designed to try and bridge the gap between what is trained in the lab and what the participant does outside of the treatment setting. This components includes negotiation of a behavioral contract with participants at the outset of treatment regarding the responsibilities of the participant, family caregivers, if available, and the treatment team, self-monitoring, assignment of homework, review of homework by the trainer, and support of problem-solving by the participant."
219087746|NCT06095297|BEHAVIORAL|Follow Up Phone Calls|After completing training, participants will receive four follow up phone calls in the first month of training. Each call will separated by about a week. The focus of the calls will incorporating the lessons learnt during treatment into daily life.
219087747|NCT06095297|BEHAVIORAL|Vocational Rehabilitation|In partnership with the Alabama Department of Rehabilitation Services (ADRS), participants who are eligible may receive vocational rehabilitation. Participants will receive typical services offered by the ADRS. These could include career counseling, guidance regarding job retention or return-to-work, and guidance regarding workplace accommodations.
219087748|NCT06095297|BEHAVIORAL|Peer Mentoring|Participants who are eligible for vocational rehabilitation, and agree will also have a peer mentor, a co-worker that will be trained by our team, to reinforce strategies the participant learned during training, and to help the participant problem solve issues that may arise on the job during the first month after treatment. Peer mentors will meet with trainers during the month after treatment to make sure procedures are being followed and address any issues that may arise.
219087749|NCT06095297|BEHAVIORAL|Reaction Time Training|"Reaction time training involves trainer-guided practice of computer-based video games. Several different games will be featured that train how rapidly players react to threats and train eye-hand coordination."
219087750|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: High Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of at least 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
219087751|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: Low Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of less than 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
219087752|NCT05007392|DRUG|Dotinurad|Dotinurad oral tablets.
219087753|NCT05007392|DRUG|Febuxostat|Febuxostat oral tablets.
219087754|NCT05007392|OTHER|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
219087755|NCT05007392|OTHER|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
219087756|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
219087757|NCT06559163|DRUG|Placebo|Placebo
219087758|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
219087759|NCT01218126|DRUG|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
219087760|NCT01218126|DRUG|placebo|placebo comparison with active
219214973|NCT06751771|OTHER|McKenzie's method of exercises|Group B will receive the McKenzie's method of exercises that include Deep neck flexor (chin tucks), Shoulders shrug McKenzie exercise for neck, Repeated shoulder flexion/Extension, Neck flexion McKenzie exercises
219087761|NCT04835155|PROCEDURE|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
219087762|NCT02241941|DRUG|Daptomycin|
219087763|NCT02254447|DRUG|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
219087764|NCT02254447|DRUG|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
219087765|NCT02254447|DRUG|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
219087766|NCT04064151|BEHAVIORAL|My Guide|12-week long health promotion Smartphone application
219087767|NCT01019044|PROCEDURE|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
219087768|NCT06296576|PROCEDURE|arterial ultrasound scan|An arterial ultrasound scan of the lower limbs with pulsed Doppler analysis of arterial flow spectra over the abdominal aorta, dorsal artery of the foot and lateral plantar artery, bilaterally
219087769|NCT05977231|PROCEDURE|BT|A program of BT (including exercise and muscle training)
219087770|NCT05977231|PROCEDURE|bPFMT|A bPFMT program at home
219087771|NCT05977231|PROCEDURE|iVES|An iVES program at home
219087772|NCT05977231|PROCEDURE|BT + bPFMT|Combination of BT and bPFMT
219087773|NCT05977231|PROCEDURE|BT + iVES|Combination of BT and iVES
219087774|NCT05977231|PROCEDURE|bPFMT + iVES|Combination of bPFMT and iVES
219087775|NCT06379919|PROCEDURE|Irrisept Irrigation|Irrisept Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device. Irrisept contains 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United Staes Pharmacopeia (USP). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle.
219087776|NCT06379919|PROCEDURE|Saline Irrigation Solution Delivery|Normal saline is isotonic and the most commonly used wound irrigation solution due to safety (lowest toxicity) and physiologic factors.
219087777|NCT00453986|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
219087778|NCT00453986|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose
219087779|NCT00453986|BIOLOGICAL|Fluarix™|One intramuscular dose
219087780|NCT02925611|DRUG|Isoflurane|
219087781|NCT02925611|DRUG|Desflurane|
219087782|NCT02622165|BEHAVIORAL|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
219087783|NCT00522626|DEVICE|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
219087784|NCT05437081|BEHAVIORAL|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
219214974|NCT04566887|DRUG|Acalabrutinib|Administered as 100mg tablets.
219214975|NCT04566887|DRUG|R-CHOP chemotherapy|R-CHOP chemotherapy
219214976|NCT06588673|OTHER|Art Thrapy|Art therapy at Art Therapy Studio, a well-established recommended art therapy leader since 1967 with extensive experience in virtual therapy for patients with medical needs. Cheryl Pete, MA ATR-BC, a board-certified art therapist and the Clinical Director will complete the art therapy sessions. The art therapy will be a 1-hour sessions, once a week for a total of 8 weeks (or 8 sessions). Cheryl Pete's role will solely involve providing a service. Chery will complete the Art Therapy according to her standard practices. Cheryl's Art Therapy will not be altered in any way as a part of this research study. Cheryl will not collect any research data. As research participants are referred to Cheryl for the Art Therapy, the research participant's name and contact information will be shared.
219087785|NCT04848428|BEHAVIORAL|Online mindfulness-based cognitive therapy|The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
219087786|NCT04848428|BEHAVIORAL|Online standardized education|One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
219214977|NCT06754436|BIOLOGICAL|Determination of blood drug concentration|Collecting blood samples from patients and determining blood drug concentrations. Patients were intravenously titrated after 3 doses of maintenance dose titration of L-AmB. The time points of sample collecting were 30 minutes before and 1, 2, 3, 6, 9, 12, 16, 20, 24 hours after administration. Then, the blood concentrations were determined according to the established method.
219214978|NCT06776055|BIOLOGICAL|HPV-16/18 vaccine|Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)
219214979|NCT06776055|BIOLOGICAL|Placebo|Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.
219087787|NCT06184672|OTHER|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
219087788|NCT00553930|DRUG|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
219087789|NCT00553930|DRUG|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA\_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
219214980|NCT06776354|BEHAVIORAL|GPT-based training|GPT-based training whether could improve the ability of students to develop effective hypertension management plans
219214981|NCT06776354|BEHAVIORAL|traditional training|traditional teaching methods
219214982|NCT06826586|DIAGNOSTIC_TEST|Measuring the microplastics|Measuring the type, nature, and abundance of microplastics in stomach, liver, feces, and blood
219214983|NCT06829225|DRUG|Tulisokibart|SC Injection or IV Infusion
219214984|NCT06829225|DRUG|Placebo|Tulisokibart-matched Placebo SC Injection or IV Infusion
219214985|NCT05139225|DRUG|TTI-622|"(-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions."
219214986|NCT05139225|DRUG|Daratumumab Hyaluronidase-fihj|Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
219214987|NCT06773091|BIOLOGICAL|NK042|NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors and enriched with NKR+ NK cells.
219214988|NCT06773091|DRUG|Fludarabine (FLU)|Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.
219214989|NCT06773091|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.
219214990|NCT06770907|OTHER|Blood, stool and saliva collection|Blood, stool and saliva collection
219214991|NCT06770907|OTHER|Questionnaire completion|"Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale"
219214992|NCT06770907|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) and Breath test|MRI scans and breath test samples collected after drink test with sucrose
219681920|NCT05704400|DRUG|Rituximab Biosimilar ABP 798|Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
219087790|NCT00066482|BIOLOGICAL|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
219087791|NCT00066482|BIOLOGICAL|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC \> 5,000/uL
219214993|NCT05305664|DRUG|Pelacarsen (TQJ230) 80 mg s.c.|Pelacarsen (TQJ230) 80 mg s.c. Q4W
219214994|NCT05305664|DRUG|Corresponding Placebo|Placebo to Pelacarsen
219087792|NCT00066482|DRUG|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
219087793|NCT00066482|DRUG|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
219087794|NCT00066482|DRUG|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
219214995|NCT06604364|DEVICE|hypno VR|pre-surgery sedation using virtual reality headset
219214996|NCT06792045|OTHER|Physiotherapist assessment|"* Tongue motor skills (Tongue pressures and tongue mobility, assessed through the Iowa Oral Performance Instrument and the Motricité Bucco-Linguo-Faciale tongue subscore, respectively)~* Tongue restriction of mobility due to its frenulum (assessed through the Quick Tongue-Tie assessment tool)~* Breathing Pattern (questionnaire from Abreu RR, Rocha RL, Lamounier JA, Guerra AF. Etiology, clinical manifestations and concurrent findings in mouth-breathing children. J Pediatr (Rio J). 2008;84(6):529-535.)."
219214997|NCT06792045|OTHER|ENT assessment|Data from the ENT appointment will be collected (e.g., sex, height, weight)
219214998|NCT06792045|DIAGNOSTIC_TEST|Drug-Induced Sleep Endoscopy|A Drug-Induced Sleep Endoscopy will be performed, recorded, and evaluated by two blinded raters using the IPSES scale.
219214999|NCT04516720|OTHER|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
219087795|NCT00066482|PROCEDURE|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
219087796|NCT00066482|BIOLOGICAL|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
219215000|NCT03987009|DEVICE|Without RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
219681921|NCT05704400|DRUG|Daratumumab|Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
219681922|NCT00478270|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
219087797|NCT04697277|DRUG|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
219087798|NCT05941130|DRUG|Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory"
219087799|NCT05941130|DRUG|Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory"
219087800|NCT00413270|DRUG|nilotinib|
219087801|NCT04322123|DRUG|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
219087802|NCT04322123|DRUG|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
219087803|NCT03740308|DEVICE|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
219087804|NCT03740308|DEVICE|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
219087805|NCT05925933|OTHER|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
219087806|NCT05365776|BEHAVIORAL|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
219087807|NCT05365776|BEHAVIORAL|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
219087808|NCT05365776|OTHER|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
219087809|NCT05571280|DIETARY_SUPPLEMENT|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
219087810|NCT05571280|BEHAVIORAL|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
219215001|NCT03987009|DEVICE|With RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
219215002|NCT03987009|DEVICE|Without RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
219215003|NCT03987009|DEVICE|With RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
219215004|NCT03789110|DRUG|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
219681923|NCT01703390|DRUG|FOLFIRI + Cetuximab|
219681924|NCT01703390|DRUG|modifiedFOLFOX6 + Cetuximab|
219681925|NCT05200377|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
219087811|NCT05571280|BEHAVIORAL|Standard intervention|"The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
219087812|NCT06676280|DRUG|Aspirin|Patients will take aspirin 100 mg/day.
219087813|NCT06676280|DRUG|High-intensity statin|Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
219087814|NCT06676280|DRUG|Guideline-directed statin therapy|as 2018 Cholesterol Clinical Practice Guidelines.
219087815|NCT06122727|PROCEDURE|total knee arthroplasty|In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
219087816|NCT06689553|DEVICE|Automated Continual Fluid Removal System|The intraperitoneal device is percutaneously implanted via mini laparotomy, under local anaesthesia and sedation, and connected to the wearable rechargeable pump through extracorporeal tubing. The device aims to remove excess fluids in heart failure patients with diuretic resistance
219087817|NCT05047185|DRUG|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
219087818|NCT05047185|DRUG|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
219087819|NCT05047185|DRUG|Placebo|Matching placebo capsules for oral use
219087820|NCT06627270|DRUG|Metronidazole|Participants will receive metronidazole (500 mg t.i.d. x 10 days)
219087821|NCT06627270|OTHER|Chlorhexidine|Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
219087822|NCT01750138|DRUG|Glutamine|
219087823|NCT01750138|DRUG|Dextrose powder|
219087824|NCT07022886|PROCEDURE|achalasia treatments|esophageal achalasia treatments
219215005|NCT03789110|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
219087825|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
219215006|NCT06265740|OTHER|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If the participant accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
219215007|NCT06821789|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
219215008|NCT06821789|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
219215009|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
219215010|NCT03912194|BEHAVIORAL|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
219215011|NCT03912194|BEHAVIORAL|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
219215012|NCT03912194|BEHAVIORAL|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
219215013|NCT05786157|OTHER|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
219215014|NCT06748560|OTHER|Neurodynamics|Following Castellote-Caballero et al., the neurodynamic sliding technique (NST) was applied to the dominant leg's sciatic nerve in the NST and ETNST groups. The technique involves alternating stress proximally and distally to promote nerve sliding. Participants performed two sets of movements-cervical flexion with knee and ankle flexion, and cervical extension with knee and ankle extension-repeated actively for 60 seconds, five times per session. Over six weeks, both groups underwent three supervised sessions per week led by an experienced researcher.
219215015|NCT06748560|OTHER|Eccentric training|The Nordic exercise served as the foundation for the intervention, focusing on eccentric loading as participants resisted falling forward. To minimize DOMS and ensure adherence, a two-week preparatory phase of mixed concentric/eccentric leg curls using a stability ball was implemented. Following this, the gradual progression outlined by Mjolsnes et al. led to a four-week Nordic hamstring curl regimen. Weekly supervision ensured proper technique and compliance throughout the program.
219215016|NCT06747702|OTHER|Injury prevention workout|The injury prevention workout consisted on engaging on a prevention program from 1 day to 8 weeks where the participants will develop functional sport exercises to prevent shoulder injuries or pain in overhead sports.
219215017|NCT06761222|OTHER|The use of ultrasound in central blocks|Ultrasonography was conducted using a convex probe in the paramedian and transverse planes.
219215018|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
219215019|NCT06757335|DRUG|HP568|In the I/II stage: HP568 administered QD or BID for 28 day cycles.
219087826|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
219087827|NCT01165775|DEVICE|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
219087828|NCT07031518|DEVICE|Syde|Actimyo/Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219087829|NCT07031518|DIAGNOSTIC_TEST|The Self-Paced 40-meter Walk Test (SPWT)|Assesses walking speed over a fixed distance by having participants walk as quickly and safely as possible, but without running, along a 40-meter course.
219087830|NCT07031518|DIAGNOSTIC_TEST|30-second chair stand test (30s-CST)|It is a simple assessment of lower body strength and endurance. Participants are instructed to stand up and sit down from a chair as many times as possible in 30 seconds.
219087831|NCT07031518|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
219087832|NCT07031518|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC 3.1)|The WOMAC is a widely used self-administered health status measure for evaluating pain, stiffness, and function in patients with osteoarthritis of the hip or knee. The WOMAC measures three separate dimensions: pain (5 questions), stiffness (2 questions) and function (17 questions).
219087833|NCT07031518|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S)|"The PGI-S is a patient-reported measure that evaluates the perceived severity of a condition based on a standardized scale, ranging from none to very severe."
219087834|NCT07031518|OTHER|Pain Level Diary|Patients will record their specific OAK average pain level during the day using the VAS scale of 0-10 points for one week at the beginning of each month of recording.
219215020|NCT06757335|DRUG|HP568 in combination with palbociclib|In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
219087835|NCT07031518|OTHER|Qualitative Interview|This interview is designed to better understand the patient's perspective on the impact of osteoarthritis of the knee on their motor function and to inform the selection of digital tools in upcoming clinical studies.
219087836|NCT06877026|DEVICE|FibroScan|Day 1 = 5 FibroScan examinations Day 2 = 4 FibroScan examinations
219087837|NCT06877026|OTHER|Liver Enzymes|Day = 1 blood collection for liver enzymes. Day 2= 1 blood collection for liver enzymes.
219087838|NCT04909970|OTHER|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
219087839|NCT04909970|OTHER|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
219087840|NCT06717191|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
219087841|NCT06711770|BIOLOGICAL|Blood sample|Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
219087842|NCT06732076|BEHAVIORAL|web based education|web based education
219087843|NCT06732544|OTHER|snoezelen room|During the travail, projectors, starry ceiling visuals and blue light LEDs will be used for visual stimuli, speakers will be used as auditory stimuli, diffusers will be used for olfactory stimuli, and therapy dough will be used for touch stimuli.
219087844|NCT06732544|OTHER|routine delivery room|General practice
219087845|NCT06733402|DRUG|Trifarotene Cream 0.005%|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
219087846|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
219087847|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
219087848|NCT06733402|DRUG|Placebo|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
219087849|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Oral administration
219087850|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Oral administration
219087851|NCT06733818|OTHER|Functional assessment of physical performance|Functional assessment of physical performance was performed with the Alusti test. This 10-question test was developed to assess physical performance in the geriatric population 13 and has been validated in Turkish 14. This test evaluates limb range of motion and muscle strength, ability to move from supine to sitting position, sitting balance, ability to stand up from sitting position, standing, walking, walking distance, ability to stand on tandem and single leg with eyes closed. The results of this test, which is scored out of 100, indicate the level of activity. 0-30, interpreted as totally dependent; 31-40, highly dependent; 41-50, moderately dependent; 51-60, slightly dependent; 61-75, good activity; 76-90, very good activity; and 91-100, excellent activity.
219087852|NCT06732583|BIOLOGICAL|Tuberculosis (TB) vaccine (Ad5-105K)|1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth
219087853|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
219087854|NCT06732583|BIOLOGICAL|Ad5-105K|1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH
219215021|NCT03328663|OTHER|CARE|Promote effective coping and reduce caregiving burden.
219215022|NCT03328663|OTHER|Standard Transplant Care|Standard cared administered by the hospital.
219215023|NCT06753344|BEHAVIORAL|Intervention app|The app-based intervention, co-designed with the V-YAC, aims to introduce life skills and self-management skills to promote general mental well-being and resilience among Vietnamese youth. With this app, youth users will have a fun and safe space to learn and practice six life skills areas (Problem-solving, Social Media and Well-being, Communication and Interpersonal Skills, Realistic Thinking, Coping with Emotions and Stress, and Goal Setting). Lessons (in the form of short texts) and activities (ex. multiple choice activities, blank worksheets, reflection questions) were adapted from evidence-based interventions developed in other contexts to be culturally appropriate to the Vietnamese youth context. Youth users are free to explore the app at their own pace. Gamification features will also allow youth users to collect points in the app for completing each lesson, activity, or challenge.
219215024|NCT06772844|DIAGNOSTIC_TEST|fecal DNA methylation testing|Three rounds of screening were performed. In the first year, colonoscopy was conducted along with concurrent fecal DNA testing performed prior to the colonoscopy. In the second year, fecal DNA testing was performed only if no polyps were detected during the colonoscopy in the first year; otherwise, both colonoscopy and fecal DNA testing were conducted. In the third year, a colonoscopy was performed with concurrent fecal DNA testing conducted before the procedure
219215025|NCT06742528|DRUG|Ferrous sulfate|ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
219215026|NCT06742528|DRUG|Iron Polymaltose Complex|Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
219215027|NCT06747143|DIETARY_SUPPLEMENT|Lactobacillus casei DN-114001|Probiotic
219215028|NCT06685744|DEVICE|Telerehabilitation_TRsA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach.
219215029|NCT06685744|BEHAVIORAL|Educational treatment|Home rehabilitation indications according to a conventional approach, customized according to the disease.
219215030|NCT06685744|DEVICE|Telerehabilitation_TRcA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: a combination of exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach together with exercises aimed at recovering muscle strength (resistance) and improving endurance (endurance) using an Impairment-oriented approach.
219215031|NCT03219879|BEHAVIORAL|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
219215032|NCT03219879|OTHER|Usual care|Usual care without any study-related intervention
219087855|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
219087856|NCT06732063|DEVICE|endodontic retreatment|Re-treatment of previously failed root canal treatments
219087857|NCT06733662|BEHAVIORAL|Experimental: Education-based motivational interviewing Group|The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
219087858|NCT02553460|DRUG|ITMHA|Given intrathecally (IT).
219087859|NCT02553460|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
219087860|NCT02553460|DRUG|Mitoxantrone|Given IV.
219215033|NCT06668402|DEVICE|Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.|Employing a smartwatch to monitor steps, sleep quality, intense physical activity, and vital signs in persons undergoing treatment for rectal carcinoma.
219215034|NCT06758739|DRUG|Curcumin (Turmeric)|Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.
219215035|NCT06758739|DRUG|Intralesional Steroid Injection|Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
219215036|NCT06843603|BEHAVIORAL|culturally informed care coordination intervention|Culturally Informed Care Coordination Strategies
219087861|NCT02553460|DRUG|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
219087862|NCT02553460|DRUG|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
219087863|NCT02553460|DRUG|Bortezomib|Given IV.
219087864|NCT02553460|DRUG|Vorinostat|Taken PO or NG.
219087865|NCT02553460|DRUG|Cyclophosphamide|Given IV.
219087866|NCT02553460|DRUG|Mercaptopurine|Given PO or NG.
219087867|NCT02553460|DRUG|Methotrexate|Given IV, IM or PO.
219087868|NCT02553460|DRUG|Leucovorin Calcium|Leucovorin rescue PO or IV.
219087869|NCT02553460|DRUG|Cytarabine|Given IV.
219087870|NCT02553460|DRUG|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
219087871|NCT02553460|DRUG|Vincristine|Given IV.
219087872|NCT07057037|DRUG|NEMO-103 Injection|15mL(at least 12mL), solution for Intravenous injection, single dose
219087873|NCT07058064|PROCEDURE|Electrocardiogram|"All participants receive a standard 12-lead ECG when they present for follow-up 1 year after completion of anthracycline-based therapy. All participants will also record a 6-lead Kardia (AliveCor, Mountain View, CA, USA) and 1-lead Apple Watch (Apple, Cupertino, CA, USA) ECG with Mayo-owned or participant-owned devices.~Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs."
219087874|NCT07058064|PROCEDURE|Echocardiogram|All participants will have an echocardiogram as part of standard of care when they present for their follow-up 1 year after completion of anthracycline-based therapy.
219087875|NCT07058064|PROCEDURE|LVEF echocardiogram|Participants will undergo a limited LVEF echocardiogram at the 6-month post therapy visit.
219087876|NCT07058064|OTHER|Apple Watch|"Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs.~Longitudinal participants will be asked to transmit weekly cardio fitness (estimates of peak VO2) from baseline to 1-year post therapy."
219087877|NCT07058064|PROCEDURE|Biospecimen collection|Undergo blood draw
219215037|NCT06843603|OTHER|No Intervention - Usual Care Group|No Intervention - Usual Care Group
219215038|NCT06495372|DRUG|Experimenta group (standard of care + Methoxyflurane).|standard of care + Methoxyflurane
219215039|NCT06495372|DRUG|control group (standard of care + placebo).|standard of care + placebo
219215040|NCT06828250|DEVICE|intradermal needle therapy|In addition to conventional treatment, patients in the treatment group received intradermal needle therapy after returning to the ward safely. Bilateral Hegu (LI4) and Zusanli (ST36) acupoints were selected for this therapy. Patients were positioned in a supine position, and after locating the acupoints, the skin of the acupoint areas was sterilized with 75% ethanol using a medical cotton swab. The intradermal needle was then removed along with the adhesive tape, inserted into the acupoints, and pressed every 4 hours for approximately 60 presses each time, excluding nighttime sleep. The pressure was applied until an acid, swelling, or numb sensation was felt at each acupoint. The intradermal needle therapy was administered only once and continuously pressed for 3 days.
219215041|NCT05554510|OTHER|Observational|No interventions planned. Observational data collection only.
219215042|NCT06757517|DRUG|Oxytocin nasal spray|Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
219215043|NCT06757517|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline intranasal placebo comparator
219215044|NCT02898610|DRUG|Colchicine|
219087878|NCT07058064|OTHER|Questionnaires|Participants fill out 2 questionnaires: 1) the Kansas City Cardiomyopathy-12 (KCCQ-12) Questionnaire, and 2) the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ore 30 (EORTC QLQ-C30) to evaluate health related quality of life and heart failure symptoms.
219215045|NCT06786026|DRUG|bevacizumab|bevacizumab
219215046|NCT06786026|DRUG|QL1706|Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
219215047|NCT06786026|DRUG|Nab paclitaxel|albumin-bound paclitaxel
219215048|NCT06789146|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219681926|NCT00218478|BEHAVIORAL|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
219087879|NCT07058064|OTHER|Cardio-pulmonary exercise test|Undergo CPET to assess the response of heart and lungs to exercise.
219215049|NCT06789146|PROCEDURE|Thoracic Paravertebral Block|"Thoracic paravertebral block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219215050|NCT04846881|DRUG|Iclepertin|Iclepertin
219215051|NCT04846881|DRUG|Placebo|Placebo
219215052|NCT06734442|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
219215053|NCT06745817|DIAGNOSTIC_TEST|Assessement of nutritional status|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
219215054|NCT06745817|DIAGNOSTIC_TEST|Dermis density and thickness|Dermis density and thickness will be measured using ultrasonography with Cortex DermaLab 20 MHz US probe.
219215055|NCT06745817|DIAGNOSTIC_TEST|Skin elasticity|Skin elasticity will be measured using Cortex DermaLab elasticity probe.
219215056|NCT06745817|DIAGNOSTIC_TEST|Body composition measurement|Body composition will be measured using Biostat Multiscan 5000.
219215057|NCT06745817|DIAGNOSTIC_TEST|Screening questionnaire|Screening questionnaire: assessment of socio-demographic parameters, use of food supplements, health status, dietary habits
219215058|NCT06735599|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
219215059|NCT06735599|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
219681927|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
219087880|NCT07058064|OTHER|6 minute walk test|Complete a 6MWT, to see how far participants can walk on a hard, flat surface for 6 minutes
219087881|NCT07058064|OTHER|Grip strength test|A hand-held device called a dynamometer will be used to measure the muscle strength in hand/forearm
219087882|NCT06838832|BIOLOGICAL|Allogenic CD19-CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6× 10\^6 cells/kg); Phase 2 : dose of RP2D.
219087883|NCT06838832|DRUG|Fludarabine|"Intravenous fludarabine 30\~50 mg/m\^2/day on days~-5, -4, and -3."
219087884|NCT06838832|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/ day on days -5, -4, and -3.
219087885|NCT06865521|DIETARY_SUPPLEMENT|Akkermansia Probiotics|After enrollment, patients will receive anti-PD-1 monoclonal antibody + Tyrosine kinase inhibitor (TKI, e.g., regorafenib, fruquintinib) treatment or anti-PD-1 monoclonal antibody ± chemotherapy (etc., CAPEOX \[oxaliplatin+capecitabine \], XELIRI \[irinotecan+capecitabine \]) ± Bevacizumab treatment (anti-PD-1 monoclonal antibody, chemotherapy, and bevacizumab every 3 weeks, TKI every 4 weeks), along with daily continuous administration of Akkermansia probiotics (Songke, dose: 1 capsule/day, taken with breakfast), until disease progression, intolerable toxicity, or patient withdrawal from the study.
219215060|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
219087886|NCT06105021|DRUG|AFNT-211|Engineered TCR T-Cell
219087887|NCT07065448|OTHER|physical performance tests|All participants underwent the 4-meter Gait Speed Test, the Short Physical Performance Battery (SPPB), the Timed Up and Go (TUG) test, and the Elbow Performance Test twice, with a 7-10-day interval between sessions. In the Elbow Performance Test, a 1-kilogram sandbag was fixed to the distal forearm of the dominant arm, and participants were asked to perform 30 consecutive elbow flexion-extension movements.
219087888|NCT06829862|OTHER|Own Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the internet-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their specialist doctor.
219215061|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
219215062|NCT06740864|DEVICE|Sham Transcranial alternating current stimulation|Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
219215063|NCT05972772|DRUG|Doxycyclin|100-mg film-coated tablets; Pfizer
219215064|NCT05972772|DRUG|Azithromycin|250-mg capsules; Pfizer
219087889|NCT06829862|OTHER|Unknown Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same intervention, but in this case supported by audiovisual instructions given by a doctor outside the patient.
219215065|NCT04363827|DRUG|Hydroxychloroquine|Hydroxychloroquine
219215066|NCT06766760|DEVICE|Da Vinci SP Surgical System, Model SP1098|The da Vinci SP Surgical System is intended to assist in the accurate control of the da Vinci SP endoscope and instruments during minimally invasive endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, and breast surgical procedures. The system is indicated for adult use. It is intended to be used by trained physicians in an operating room environment.
219215067|NCT06844591|OTHER|Conditioning Exercises/ Aerobic Interval Training|Aerobic interval training (AIT), which included rest intervals in between sessions of aerobic activity on a stationary bike and treadmill, was administered to the control group. A 10-minute warm-up, or a maximum of 50% to 60% of HR, preceded the program. The next activity round consisted of six x six-minute intervals of cycling and walking/uphill running on a treadmill at 60% to 85% of THR, separated by three minutes of rest/recovery. A ten-to fifteen-minute cool- down period followed the session.
219215068|NCT06844591|OTHER|Resistance Interval Training|Resistance interval training for post-coronary artery bypass grafting (CABG) patients requires careful consideration and should be conducted under the supervision of healthcare professionals, such as cardiac rehabilitation specialists or physiotherapists. Exercise programs for individuals recovering from cardiac surgery must be tailored to their specific needs, taking into account their overall health, medical history, and current fitness level. Before beginning any exercise program, it's essential to obtain clearance from a healthcare provider. The workout lasted thirty to forty minutes in total. To fit the training load, resistance and intensity were gradually raised. For six weeks, this supervised training program was adhered to three times a week on alternate days
219215069|NCT06766565|DRUG|QYJD Compound Preparation|The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
219215070|NCT06765460|BEHAVIORAL|Medical prescription of exercise|MPE consists of dedicating a specific time to establish a specific and individualized exercise plan for the patient, with the premises of fully assessing their physical fitness, motivation, adaptability to change and the possibility of exercising within their social environment, as well as the achievement of specific objectives within an agreed follow-up period
219215071|NCT06765460|BEHAVIORAL|Health Advice|HA consists of providing the patient with information and motivation in line with general international recommendations to try to increase PA levels in their daily life. This advice can be given in a short period of time (up to three minutes) during any medical consultation
219215072|NCT04109950|DRUG|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
219087890|NCT06646835|BEHAVIORAL|Stress Ball Intervention|The stress ball is a simple and effective tool for reducing anxiety and relaxation as a non-pharmacological method (Yanes et al., 2018). Due to the limited pharmacological options available for pregnant women to reduce anxiety during cesarean section, alternative, complementary or supportive non-pharmacological methods and low-risk approaches are needed (Baltacı \& Başer, 2020). It is thought that squeezing the stress ball may be advantageous in reducing anxiety.
219087891|NCT07068763|RADIATION|Lymph-node-sparing short-course radiotherapy|Three-dimensional conformal or intensity-modulated radiotherapy targeting only the primary tumor bed (no regional lymph nodes), delivering a total dose of 25 Gy in 5 Gy fractions over five consecutive days.
219087892|NCT07068763|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m² administered twice daily on Days 1-14 of each 21-day cycle, for a total of four cycles.
219087893|NCT07068763|DRUG|PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)|Intravenous PD-1/CTLA-4 bispecific monoclonal antibody at 5 mg/kg every 3 weeks for four cycles, starting on Day 8 after completion of radiotherapy.
219087894|NCT06901193|BEHAVIORAL|Virtual Reality Mindfulness intervention|Mindfulness will be offered via a virtual reality headset; participants will use the virtual reality mindfulness program 3 times per week (15 minutes at a time) for 8 weeks.
219087895|NCT06812143|BEHAVIORAL|Strength training|This intervention involves strength training with lighter loads and higher repetitions.
219087896|NCT06812143|BEHAVIORAL|Strength training|This intervention involves conventional strength training with higher loads and moderate repetitions.
219087897|NCT06854419|DIETARY_SUPPLEMENT|Placebo Drink|Take one bottle of the product every morning on an empty stomach
219087898|NCT06854419|DIETARY_SUPPLEMENT|Blood Peach Extract Drink|Take one bottle of the product every morning on an empty stomach
219087899|NCT06854419|DIETARY_SUPPLEMENT|Rose Apple Extract Drink|Take one bottle of the product every morning on an empty stomach
219087900|NCT06866925|DEVICE|Transcranial stimulation|A randomized, 2-arm, sham-controlled study, patients with Down syndrome presenting with major depressive episode (DSM5) with catatonic features will be randomly allocated to receive 15 sessions of either active (20 min, 2mA, ramp up/down 30 sec) or sham tDCS (20 min, ramp up/down 30 sec at the beginning and at the end of each stimulation session), thrice daily. Each stimulation session will be spaced at least two hours apart. The anode will be placed over the left DLPFC, the cathode over the right DLPFC using the Beam F3 algorithm in order to individualize target location based on head circumference, tragus to tragus and inion to nasion distances.
219215073|NCT04950764|DRUG|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
219215074|NCT04950764|DRUG|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
219215075|NCT05611632|DEVICE|Multi-cancer early detection test (Galleri test)|Blood collection and multi cancer early detection testing with return of positive test results.
219215076|NCT06192615|DRUG|Intravenous Dexmedetomidine|Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
219215077|NCT06192615|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine (120 μg)
219215078|NCT06192615|DRUG|Intravenous Placebo|Intravenous placebo of 0.9% saline administered over 40 minutes
219215079|NCT06192615|DRUG|Sublingual Placebo|Inert sublingual film
219215080|NCT06769360|PROCEDURE|PMI-targeted PSV setting|The pressure support is adjusted according to PMI between 0 and 2 cmH2O. After application of PSV mode in mechanically ventilated patients, the initial PS level was first set based on respiratory rate (RR) \<35 beats/min and 6-8 ml/Kg tidal volume (Vt) per predict body weight (PBW), and then modified according to PMI at a frequency of twice a day (morning and afternoon bedside rounds)# 1) Perform three end- inspiratory occlusions, with at least 1 minute between each measurement, and calculate the mean PMI. 2) Determine whether the PMI is within the target range (0≤PMI≤2cmH2O). 3) If the PMI is not within the target range, adjust the PS level up or down by 1-3 cmH2O and balance for 3-5 minutes. 4) Repeat the above steps until PMI reaches the target. 5) Additional: During PS adjustment, if Vt≤4ml/Kg, respiratory acidosis, respiratory distress, Vt≥8ml/Kg, respiratory alkalosis occurs, return to the safe PS level before adjustment and optimize other treatments.
219215081|NCT06769360|PROCEDURE|VT/RR-targeted PSV setting|Standard of care: the pressure support is adjusted to obtain a VT between 6 and 8 ml/kg PBW and RR between 20 and 35 breaths/min.
219215082|NCT06765213|DIAGNOSTIC_TEST|Open Ended Oral Food Challenge|Allergens determined to be sensitized will be brought in for an oral challenge to that food.
219087901|NCT06848244|BEHAVIORAL|Appetite Awareness Training (AAT)|Partcipants will receive the AAT delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
219087902|NCT06848244|BEHAVIORAL|Diabetes Prevention Program (DPP)|Partcipants will receive the DPP delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
219087903|NCT07075068|DIAGNOSTIC_TEST|Behavioral and Functional Performance Assessment Battery|This study will include only observational functional assessments. No active intervention will be performed.This observational protocol will involve standardized assessments of lower extremity coordination (LEMOCOT), movement speed (30-meter sprint), and smoking-related behavioral patterns (Fagerström Test for Nicotine Dependence). These tools will be used to evaluate the potential impact of cigarette addiction on physical performance in young adults. No therapeutic or pharmacological intervention will be applied.
219087904|NCT07078045|OTHER|Arterial pressure monitoring|We will perform oscillometric arterial pressure measurements at different limb sites.
219087905|NCT07076446|BIOLOGICAL|IgPro|IgPro20 is a solution for infusion for subcutaneous administration.
219215083|NCT06765213|OTHER|Early Introduction|Infants that are not sensitized will have the food introduced to their diet at regular intervals.
219215084|NCT04081428|RADIATION|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
219215085|NCT04040452|DRUG|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
219087906|NCT07081386|OTHER|Laparoscopic Training using the LAPARO Analytic simulator|Participants in the experimental group will undergo a 3-hour in-person laparoscopic training session using the LAPARO Analytic simulator. The session will be supervised by an experienced General Surgery tutor and will include real-time performance analytics to guide skill acquisition relevant to laparoscopic appendicectomy.
219087907|NCT07081386|OTHER|Laparoscopic Training using a classic Box Trainer|Participants will receive a single, 3-hour in-person laparoscopic training session using a Classic Box Trainer. Training will be supervised by an experienced General Surgery tutor and focused on key technical skills required for laparoscopic appendicectomy.
219087908|NCT07081672|PROCEDURE|Ultrasound-guided interscalene brachial plexus block (ISB)|The intervention consisted of an ultrasound-guided interscalene brachial plexus block (ISB) administered to patients in Group B prior to general anesthesia. The block was performed using a posterior in-plane approach with real-time ultrasound visualization. A total of 20 mL of 0.125% bupivacaine was injected around the C5-C6 nerve roots under sterile conditions by experienced anesthesiologists.
219087909|NCT07081672|PROCEDURE|General Anesthesia (control group)|General anesthesia without regional block
219087910|NCT07080255|PROCEDURE|Adams-Berger Reconstruction|The Adams-Berger procedure involves anatomical reconstruction of the distal radioulnar joint (DRUJ) ligaments using a palmaris longus tendon graft. Bone tunnels are drilled in the radius and ulna, and the graft is passed through these tunnels to reconstruct the dorsal and palmar radioulnar ligaments. This technique is designed to restore stability in patients with chronic post-traumatic DRUJ instability.
219215086|NCT03499691|DEVICE|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
219215087|NCT03499691|DEVICE|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
219215088|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
219215089|NCT02994459|OTHER|Weight Loss|Diet-induced weight loss (obese only)
219087911|NCT07080255|DEVICE|TightRope®-Augmented Adams-Berger Reconstruction|This intervention combines the standard Adams-Berger procedure with the addition of the TightRope® (Double Loop Lift System) device to provide dynamic stabilization of the DRUJ. The TightRope® system consists of a FiberWire suture passed through 2.7 mm bone tunnels in the radius and ulna and secured with cortical metal buttons. It allows for early mobilization and enhanced postoperative joint stability.
219087912|NCT07080151|OTHER|Cardiac imaging|Patients who underwent CTA or CAG, with or without other cardiac imaging modelities (OCT, IVUS, or CMR) will be enrolled in this registry.
219087913|NCT04458610|BIOLOGICAL|Rituximab|Given IV
219087914|NCT04458610|DRUG|Zanubrutinib|Given PO
219087915|NCT06767800|DRUG|TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody
219087916|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody
219087917|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy|TQB2102 for injection is an antibody-coupled drug
219087918|NCT07082673|DIETARY_SUPPLEMENT|Sea Buckthorn (Hippophae rhamnoides L.) botanical extract 500 mg.|Dietary supplement based on sea buckthorn extract (Hippophae rhamnoides L.) at a dose of 500 mg - DOSE A (1 capsule of supplement + 2 capsules of placebo).
219087919|NCT07082673|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophae rhamnoides L.) 1500 mg.|Dietary supplement based on sea buckthorn (Hippophae rhamnoides L.), at a dose of 1500 mg - DOSE B (3 capsules of supplement).
219087920|NCT07082673|DIETARY_SUPPLEMENT|Placebo|Placebo (3 capsules of placebo).
219087921|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.075%finasteride
219087922|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.1%finasteride
219087923|NCT07076706|DRUG|Placebo foam|Topical placebo foam
219087924|NCT04312867|BEHAVIORAL|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
219087925|NCT04312867|BEHAVIORAL|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
219087926|NCT07087171|OTHER|Artificial intelligence-Machine learning report with accurate personalized probabilities of having a live birth rate|Patients included in the prospective arm will receive the Univfy® PreIVF Report with their accurate personalized probabilities of having a live birth rate (Univfy®) together with a medical explanation by their physician
219215090|NCT06651567|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
219215091|NCT06651567|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
219215092|NCT06702124|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
219215093|NCT06702124|DRUG|Placebo|Placebo administration for 24 weeks
219362047|NCT06162208|OTHER|Standard exercise program based on telerehabilitation|Exercises included in a standard exercise program based on telerehabilitation; Week 0-3 Patellar mobilization Isometric quadriceps femoris exercise Terminal extension exercise Active assisted knee flexion Straight leg lift Active hip abduction Active assisted knee flexion in sitting SAFTE Cold pack application Week 3-6 Straight leg raises with weights Hip abduction in weighted side lying Knee flexion in the prone position Knee extension in weight-bearing sitting Sliding forward in the chair to increase the knee flexion angle Standing weighted hip abduction Standing knee flexion with weight Squat Walking Climbing stairs Action observation therapy will be practiced by watching videos of all exercises with a focus on close-up action.
219362048|NCT01831960|DRUG|cortexolone 17α-propionate|
219087927|NCT07085637|OTHER|intravenous infusion of hydrogen nanobubbles (HNB) administered twice weekly over a 5-week period|"This study investigated a novel intervention using intravenous hydrogen nanobubbles (HNBs), which are microscopic hydrogen gas bubbles encapsulated in liquid, offering enhanced stability, deep tissue penetration, and sustained antioxidant and anti-inflammatory effects. Unlike other hydrogen therapies (such as inhalation or hydrogen-rich water), this method delivers HNBs directly into the bloodstream.~Participants were randomized into six groups: one control group receiving saline and five intervention groups receiving escalating doses of HNBs (5-25 mL) over 10 intravenous infusions in 5 weeks. This intervention is distinct for its dose-response design, intravenous delivery, and combined evaluation of cardiovascular function and quality of life (SF-36)-a patient-centered approach not commonly found in similar studies."
219087928|NCT07086885|BEHAVIORAL|Resistance band training|Four-week resistance band training intervention (15 mins 3x per week). Written and video instructions on the exercises were provided inlcuding guidance on increasing resistance over the weeks.
219087929|NCT06905652|DRUG|R-3,4-methylenedioxymethamphetamine|A dose of 300mg enantiomeric R-MDMA will be administered.
219087930|NCT06905652|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 100mg enantiomeric S-MDMA will be administered.
219087931|NCT06905652|OTHER|Placebo|Placebo (Mannitol)
219087932|NCT06777316|DRUG|CGT4859|CGT4859 is a selective FGFR2/3 inhibitor
219087933|NCT07089056|PROCEDURE|transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
219087934|NCT07089056|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead for 20 minutes. However, there will be current only during the first 10 seconds and the last 10 seconds.
219215094|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel vehicle|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX® oral gel vehicle) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
219215095|NCT06731777|PROCEDURE|Scaling and root planing plus 0.12% chlorhexidine oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (0.12% chlorhexidine oral gel) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
219215096|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX®) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
219681928|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
219681929|NCT04361799|DEVICE|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
219681930|NCT04361799|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
219087935|NCT07089056|PROCEDURE|immobilization|The researchers will use an upper limb fixation splint to fix the right upper limb of the participants, with the elbow joint flexed at 90 degrees, to ensure that all movements of the wrist, metacarpophalangeal joints, proximal interphalangeal joints, and interphalangeal joints are completely restricted. To avoid discomfort caused by the splint, soft bandages will be wrapped around the hand, and the splint will be adjusted to fit the shape of the hand. Ensure that the fingertips are visible to ensure good blood circulation. The subjects need to wear the upper limb fixation splint for 16 hours. Instruct the subjects to minimize movement and use of the right upper limb as much as possible. During the immobilization process, pay attention to checking if the participants have numbness or other discomfort, as well as whether the blood flow is good. If any adverse symptoms occur, the immobilization will be immediately terminated.
219087936|NCT07088419|DRUG|Tinidazole|2 grams orally on day one followed by 500mg orally twice daily on days 2-10
219215097|NCT06644196|DEVICE|Acquisition of images/videos of the bilateral fundus with the holographic doppler laser|Acquisition of images/videos of the bilateral fundus with the holographic Doppler laser
219087937|NCT07088276|PROCEDURE|microneedling with topical crisaborole|From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
219087938|NCT07088510|PROCEDURE|Hysteroscopic resection|Participants will undergo a hysteroscopy where a camera is placed on the inside of the uterus. Then a resector will be used to remove the pregnancy loss under direct visualization.
219087939|NCT07088510|PROCEDURE|Manual Vacuum Aspiration|Participants will undergo a manual vacuum aspiration with ultrasound guidance for treatment of early pregnancy loss. This is when pregnancy loss is suctioned by a machine from the uterus.
219087940|NCT02047591|OTHER|Relaxing-touch method|
219087941|NCT04814368|BIOLOGICAL|canakinumab|Canakinumab 600 mg single intra-articular injection (into the knee) on Day 1
219087942|NCT04814368|BIOLOGICAL|LNA043|LNA043 40 mg intra-articular injection (into the knee) every 4 weeks, on Days 15, 43 and 71
219087943|NCT04814368|OTHER|Placebo to canakinumab|Placebo to canakinumab single intra-articular injection (into the knee) on Day 1
219087944|NCT07093424|OTHER|scoring|magnesium depletion score calculation
219087945|NCT07093216|BEHAVIORAL|Exercise|6 month exercise intervention
219215098|NCT06662136|BEHAVIORAL|motivasional intereview|No application will be made to the participants in the control group
219215099|NCT06791603|OTHER|Standardized chemotherapy education + video|Videos will be provided with patients and they will watch videos during the visit. The information regarding the prevention and management of side effects and further instructions when to visit hospital. Patients will have access to videos and watch videos after leaving the hospital for the entire treatment course
219215100|NCT06749262|OTHER|walking on incline or walking at increasing speed for 36 visits|Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.
219215101|NCT06820229|PROCEDURE|Enucleation|The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium
219215102|NCT06820229|PROCEDURE|cyst enucleation|"The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium.~Using coarse round surgical carbide burs under copious normal saline irrigation, peripheral ostectomy was done for all bony walls to remove any microscopic daughter cyst, with isolation, retraction, and preservation of the lingual and inferior alveolar bundle. The bony septa were removed using rotary Lindemann fissure burs in case of multilocular lesions.~After enucleation and peripheral ostectomy a sterile radiopaque gauze coated with 5-fluorouracil cream 5% and put into the surgical cavity."
219215103|NCT05240924|BEHAVIORAL|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
219362049|NCT03961360|DRUG|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
219087946|NCT07092644|DEVICE|UltraSonic Cardiac Output Monitor (USCOM®)|Using USCOM, the haemodynamic evaluation will be performed at the time of diagnosis of congenital heart desease and then every two weeks until delivery. A further evaluation will be performed immediately after delivery (within 72 hours).
219087947|NCT07094880|DRUG|Tab. Methotrexate 25mg/week|Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week
219087948|NCT07094880|DRUG|Inj. Methotrexate 25mg/week|Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm
219087949|NCT07093762|DRUG|Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel|Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.
219087950|NCT07093944|DRUG|N-Acetylcysteine (NAC) Treatment|Parkinson's disease patients receive NAC (1200 mg/day) for one year.
219087951|NCT07093944|DRUG|Placebo|Parkinson's disease patients receive Placebo similar to the real drug, with no active ingredient
219087952|NCT07093450|OTHER|Educational Quality Improvement Intervention|The intervention will be delivered at the cluster level. It will include an initiation visit, when educational sessions and an operations manual will be delivered to the ICU. These will consist of cognitive aids for antimicrobial initiation and duration decision-making, based on recent recommendations from guidelines, societies and regulatory authorities. In this visit, an assessment of barriers and facilitators for implementation of the behavioral change will be done, so that local adaptations can be done by the clinicians championing the implementation. Additionally, monthly, one-day audits will be done, which will be used to provide feedback to the ICU during the intervention phase regarding the suggested recommendations for antimicrobial decision-making.
219087953|NCT07093112|DIETARY_SUPPLEMENT|Psychobiotic supplement|"The psychobiotic supplement consists of Bifidobacterium lactis CCT 7858 and Lactobacillus rhamnosus CCT 7863, at a final concentration of 1 x 10\^10 CFU/g (GABBIA® Biotechnology, Santa Catarina, Brazil).~The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase."
219087954|NCT07093112|DIETARY_SUPPLEMENT|Placebo|The placebo consists of maltodextrin. The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase.
219087955|NCT07094581|DIAGNOSTIC_TEST|USG|Masseter Muscle Thickness and Internal Echogenic Bands Assessed by Ultrasonography
219087956|NCT07092943|DEVICE|Lung protective ventilation|The patient in this group will receive tidal volume at 6-8 ml/kg of ideal body weight with PEEP of 5 cm of H2O and plateau pressure will be kept less than 30cm of H2O.
219087957|NCT07092943|DEVICE|Driving pressure guided ventilation|They will receive tidal volume of 6-8 ml/kg of ideal body weight and initial PEEP of 5 cm of water. Principal investigator will then incrementally increase PEEP by 2 cm of water till a value 15 cm of water PEEP is reached or Plateau pressure becomes equal to 30 cm of water or driving pressure starts to increase or there is change in any hemodynamics. Each incremental PEEP will last for 3 respiratory cycles before moving on to next value. PEEP value with lowest driving pressure will then be selected for the duration of surgical procedure
219087958|NCT07094529|BEHAVIORAL|Recumbent Exercise Bike to induce mild hypoglycemia|"The participant rides the recumbent exercise bike at their preferred speed and records the distance travelled until there is onset of mild hypoglycemia, determined by capillary blood glucose test result 3.0 to 3.8 mmmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
219087959|NCT07094529|BEHAVIORAL|Delaying food to induce mild hypoglycemia,|"At the study visit, in front of the study nurse, the participant takes their usual clinical care dose of sulfonylurea or basal insulin. If the participant's usual clinical care includes insulin with a rapid-acting component, then its dose is reduced based on the study protocol.~No food intake (water is allowed) until there is onset of mild hypoglycemia, determined by a capillary blood glucose test result 3.0 to 3.8 mmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
219087960|NCT07093229|OTHER|Ultrasound exam of quadriceps muscles (left/right) and gait analysis|"Ultrasound exam (initial and after 3 months) - with SonoScape S9Pro; the investigators exam the thickness of the quadriceps muscle group between the superficial fat-muscle interface and the cortex of the femur and calculate the quadriceps muscle index as sum of both muscle thickness RT and LT cm/height2 (m2). The exam is conducted by a qualified sonographer. The examination is carried out on a one-on-one basis in a private setting where only the participant and the sonographer are present.~Gait analysis with wireless system - BTS G-WALK; the investigators consider four gait parameters: Timed Up-and-Go (TUG) test, Symmetry index, Six Minutes Walking Test (6 MWT), and Walk cadence or average cadence (steps/min)."
219087961|NCT07093229|OTHER|Electrotherapy measures: transcutaneous nerve stimulation, ultrasound and low intensity laser; each one daily , applied on both lower limbs, for 10 days. Kinetic measures daily|The gait training is the distinguish aspect in rehabilitation program. Usually, KOA training include only kinetic measures, without gait control training
219087962|NCT07093229|OTHER|Gait training|This type of special kinetic training includes Frenkel exercises for lower limb muscles and virtual / mirror exercises for different types of gait
219087963|NCT07094295|OTHER|perioperative blood transfusion|The PBT group received the red blood cell concentrate units during surgery and up to one month postoperatively.
219215104|NCT05240924|OTHER|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
219215105|NCT06795464|DEVICE|Immersive Virtual Reality|"Participants in the experimental group will follow a treatment program that combines standard care with an immersive virtual reality (IVR) intervention. During the first 4 weeks, participants will undergo the IVR intervention, followed by the same standard treatment as the control group for the subsequent 8 weeks.~IVR Intervention Protocol:~Sessions and Equipment: Participants will attend up to 12 IVR sessions using a head-mounted device (HMD), the Meta Quest III, equipped with a hand-tracking system (Meta VR, Facebook, California) to enable interaction with the therapeutic software Dynamics PainRehab (Dynamics VR Rehab, Seville, Spain). The Meta Quest III HMD is chosen for its commercial availability, widespread use, minimal visual latency, and user-friendly interface. The software application, Hombro PainRehab, features multisensory inputs (vision and sound), high-quality graphics, head and hand tracking, and provides a highly immersive experience. The IVR intervention incorporate"
219681931|NCT05978518|DEVICE|CPM Device + Monitoring|Daily device use \& data monitoring leading to symptomology assessment and notification to provider.
219681932|NCT05978518|DRUG|CPM Device|Daily device use
219087964|NCT07093671|OTHER|MBT + NBCI|The MBT for CHR-P intervention consists of 24 weekly individual psychotherapy sessions, supplemented by monthly mentalization-based family therapy sessions. Both patient and family sessions will last 50 minutes. These psychotherapeutic sessions will complement those received though NBCI by strengthening mentalizing abilities aiming to reduce or prevent detrimental outcomes, by prohibiting or restricting some usual techniques in NBCI treatment (e.g., interpretation, cognitive challenge and Socratic dialogue) and by emphasizing certain techniques (e.g., empathic validation, active management of emotional arousal) which are only sporadically and irregularly used during NBCI treatment. Overall, the program is designed to improve patients' capacity to understand their own and others' mental states and, within interpersonal settings, how these patterns contribute to conflict and psychological distress.
219087965|NCT07093788|DEVICE|super high-pressure balloon|preparation strategy for calcified lesions after unsatisfactory dilation
219087966|NCT07093788|DEVICE|intravascular lithotripsy (IVL)|preparation strategy for calcified lesions after unsatisfactory dilation
219087967|NCT07093645|DEVICE|SEL4@ll|SEL4@ll is a school-based digital intervention targeting students aged 10-16 (Primary and Secondary Education). It combines: (1) a serious game with five missions promoting SEL skills (1/week), playable online at home or school; (2) a digital teacher handbook with classroom activities used 1-2 times per week; and (3) online surveys to assess impact. The program lasts 8 weeks: 2 weeks for pre/post assessments and 6 weeks of gameplay and classroom sessions. Surveys are administered online (3 waves), and optional focus groups are conducted with a subsample of students. Teachers complete an online evaluation after implementation.
219087968|NCT07092891|PROCEDURE|Ultrasound-Guided Supraclavicular Block|Ultrasound-guided supraclavicular brachial plexus block using a high-frequency linear ultrasound probe-real-time visualization of the brachial plexus for precise anesthetic delivery.
219087969|NCT07092891|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|30 mL used for supraclavicular brachial plexus block
219087970|NCT07092891|DEVICE|Ultrasound|Imaging for block placement
219087971|NCT07092891|DEVICE|Infrared Thermography Camera|Skin temperature monitoring
219215106|NCT06795464|PROCEDURE|Exercise|Participants assigned to the control group will receive standard treatment for rotator cuff-related shoulder pain. This will consist of standardized therapeutic exercise performed for 25 minutes, 3 times per week, over a 12-week period. The exercise regimen will be individualized based on intensity, utilizing the Rate of Perceived Exertion (RPE) scale, with the goal of achieving intensity levels of 6-8 on a scale of 0 to 10.
219215107|NCT06764290|OTHER|pedal walking|Pedal walking is a challenging walking task that can be used as a form of physical therapy for stroke participants.
219215108|NCT06764290|OTHER|visual occlusion|Walking with eyes-covered is a challenging walking task that can be used as a form of physical therapy for stroke participants.
219215109|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
219215110|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
219215111|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
219087972|NCT07092891|DEVICE|Pulse Oximeter|Perfusion Index monitoring
219215112|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
219215113|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
219215114|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
219681933|NCT01781104|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
219681934|NCT01781104|DRUG|Placebo|Placebo delivered subcutaneously once daily for 14 days.
219087973|NCT07094165|DRUG|Dexmedetomidine|Following 2 hours of bilateral muscle compression, rats in the dexmedetomidine group underwent a 1-hour period including both laparotomy and continuous intravenous dexmedetomidine infusion.
219681935|NCT00141414|DRUG|Pregabalin|
219681936|NCT02077686|BEHAVIORAL|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
219681937|NCT04956471|OTHER|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
219087974|NCT07094165|DRUG|Remifentanil|Following 2 hours of bilateral muscle compression, rats in the remifentanil group underwent a 1-hour period including both laparotomy and continuous intravenous remifentanil infusion.
219087975|NCT07094165|PROCEDURE|Laparotomy|A standardized laparotomy was carried out for 1 hour, during which the abdominal cavity was opened and subsequently closed. This procedure aimed to mimic the physiological impact of a one-hour surgical operation.
219087976|NCT07094165|PROCEDURE|Compression|Bilateral compression was applied to the gastrocnemius muscles for a duration of 2 hours.
219087977|NCT07094867|OTHER|customized Z shaped miniplate|Planning was done using Mimics Innovation Suite 15.0 software for surgical planning, surgical simulation, and modeling of a custom-made Z-pattern plate installed on a standard personal computer system. The milling of a plate design on a titanium block was be done.
219215115|NCT06734247|DIAGNOSTIC_TEST|Coronary computer tomography angiography (CCTA)|Use of standard equipment for usual care
219215116|NCT06734247|OTHER|Photoplethysmography (PPG) and single-lead ECG|Physiological data acquisition equipment
219215117|NCT06734247|DEVICE|Brachial single cuff-based arterial stiffness|Use of standard equipment
219215118|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Administer 0.5ml of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) separately at different locations upon enrollment. Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
219215119|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Vaccination with 15-Valent Pneumococcal Conjugate Vaccine with a 7-day interval (+15 day window period) followed by vaccination with Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed). Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
219215120|NCT06817187|BIOLOGICAL|Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Only administer the Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) and according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
219215121|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
219215122|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
219215123|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
219215124|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
219215125|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
219215126|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
219215127|NCT06827444|OTHER|Placebo|Participants will be provided with a chest strap for heart rate measurement (the strap will be washed and disinfected after each session), connected to the Polar Beat app downloaded by the researcher. Subsequently, each participant will perform an initial 10-minute baseline warm-up session (a cadence of 70-80 RPM will be requested). From the cycle ergometer display, values for watts (the amount of work done per second), power (the amount of work done over a certain period of time), and speed (expressed in kilometers per hour) will also be extracted. During the test, no visual or verbal feedback will be provided. Participants will be blind to the cycle ergometer screen, so the data will not influence their behavior. Heart rate will be continuously recorded throughout the exercise period and during the participant's recovery. Participants will then be randomized to one of the following manipulations.
219215128|NCT06459973|DRUG|intravenous (IV) infusion|YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
219215129|NCT03384238|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
219215130|NCT03384238|BIOLOGICAL|Panitumumab|Given IV
219215131|NCT03384238|DRUG|Panitumumab-IRDye800|Given IV
219215132|NCT06575530|DRUG|Remimazolam Besylate|patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if remimazolam fails to achieve a satisfactory RASS score (0 to -2 points) within its upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
219362050|NCT03961360|DRUG|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
219087978|NCT07094867|OTHER|conventional two miniplates|Mobilization of the fracture, removal of any soft tissue entrapped within the fracture line, and management of teeth in the fracture line, either by extraction or preservation. Followed by bone reduction into proper anatomical occlusion. Then conventional two miniplates was used according to Champy's osteosynthesis lines
219087979|NCT01901068|DEVICE|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
219087980|NCT07092605|DRUG|GLP-1|Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
219087981|NCT07092605|DRUG|Placebo|Sublingual Placebo (weekly) for up to 6 months
219087982|NCT07093710|DRUG|Golidocitinib|"Cohort1: 150mg, po, qd;~Cohort2: 150mg, po, qod and 150mg, po, qd (phase Ib); RP2D (II study)"
219087983|NCT07093710|DRUG|Mitoxantrone Hydrochloride Liposome|Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)
219087984|NCT07093710|DRUG|GemOx|Cohort 2: Gemcitabine：1g/m2，IV，D1; Oxaliplatin：100mg/m2, IV，D1
219087985|NCT07092618|DRUG|Metformin|Increasing doses from 500mg/d to 2000mg/d metformin
219087986|NCT07092618|DRUG|Rapamycin|Increasing doses from 1mg/wk to 6mg/wk rapamycin
219087987|NCT07092618|DRUG|Naltrexone|Increasing doses from 1.5mg b.i.d. to 4.5mg b.i.d. low-dose naltrexone
219087988|NCT07092618|DIETARY_SUPPLEMENT|Vitamin C|Placebo control - increasing doses from 250mg/d to 1000mg/d vitamin C (ascorbic acid)
219087989|NCT07094633|PROCEDURE|Kegel Exercise Group|The patient was positioned in a supine lying position, with the therapist standing beside them for guidance. They were instructed to engage and contract their pelvic floor muscles for 3 to 5 seconds, followed by a relaxation phase of 3 to 5 seconds.
219087990|NCT07094633|PROCEDURE|Clamshell Exercise Group|The patient was positioned in a side-lying posture with both knees flexed at 90 degrees. One hand was placed on the hip for stability, while the other supported the head. The therapist, standing nearby, instructed the patient to lift the top knee as high as comfortably possible while keeping the feet together. The position was held for 3 to 5 seconds, after which the knee was slowly lowered back to the starting position.
219087991|NCT05514210|BEHAVIORAL|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
219087992|NCT07093047|OTHER|Questionnaire administration|Participants are required to complete a survey collecting anonymous data
219087993|NCT06944509|DEVICE|treatment with the Azurion system with Xres5|treatment with the Azurion system with Xres5
219087994|NCT06944509|OTHER|Azurion with Clairy IQ|Azurion system with the standard of care (ClarityIQ/Xres4)
219087995|NCT06942494|DRUG|conventional medical treatment (TAU)|In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD in children and adolescents. The drugs used in this study are commonly used in clinical practice and have a good safety profile. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual, or the maximum dosage tolerated by the patients.
219087996|NCT06942494|BEHAVIORAL|Family-Based Self-help Book for Adolescents with Obsessive-Compulsive Disorder|The self-help book used in this study was independently developed by members of our research team. Its content is based on Exposure and Response Prevention (ERP). Adolescent patients with OCD will be instructed to read one chapter of the self-help book each week and complete the corresponding exercises. This 12-week intervention will involve self-guided practice conducted by the adolescent and their family members.Throughout the intervention period, adolescents and their caregivers may contact the therapist via WeChat to ask questions and upload records of their completed exercises. The therapist will respond to any questions within 48 hours by sending written messages via WeChat, with each family receiving no more than 30 minutes of such written guidance per week. All therapists will be required to keep a weekly log of the time spent providing guidance to each participating family.If a participating family does not initiate contact, the therapist will not provide proactive guidance.
219215133|NCT06575530|DRUG|Dexmedetomidine Hydrochloride|patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if dexmedetomidine fails to achieve a satisfactory RASS score (0 to -2 points) within the upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
219215134|NCT04384367|DRUG|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
219215135|NCT04384367|DRUG|Maxalt 10Mg Tablet|oral - single dose
219215136|NCT04384367|DRUG|Flanax 550mg|oral - single dose
219215137|NCT04384367|DRUG|Placebo oral tablet|oral - single dose
219215138|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
219215139|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
219215140|NCT06821217|DEVICE|NALU Endo Flow App|NALU Endo Flow App is a mobile application for women with endometriosis. The App provides educational information through videos, audios, and texts. Women learn about endometriosis in general with its symptoms, diagnosis, and therapy options such as lifestyle and mindset modification, endometriosis-specific diets, physical and mindfulness exercises. The App includes a diary to track the menstrual cycle and symptoms. Furthermore, access to a WhatsApp community of people with endometriosis is provided and a peer-group call is performed once monthly, as well as one additional monthly Q\&A (Question\&Answer) call moderated by certified health coaches.
219215141|NCT06831214|OTHER|(pericardial) collagen membrane|bone gain following composite graft rehabilitation of horizontal maxilla atrophy with sausage technique utilizing (pericardial) collagen membrane
219215142|NCT06831214|OTHER|periosteal Membrane harvested from anterior iliac bone|The choice of comparators in clinical studies involving guided bone regeneration (GBR) often includes both nonresorbable and resorbable membranes. Resorbable membranes have demonstrated better soft tissue compatibility compared to nonresorbable options, making them a preferred choice in many cases. For instance, studies have shown that using an organic bovine bone-derived mineral (ABBM) in conjunction with a rapidly resorbing natural collagen membrane is effective for horizontal ridge augmentation, as evidenced by positive histologic outcomes.
219215143|NCT03680456|DRUG|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
219215144|NCT03680456|DRUG|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
219215145|NCT05843786|DRUG|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
219215146|NCT05843786|DRUG|Placebo|Placebo during 5 days
219362051|NCT02541773|DEVICE|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
219362052|NCT00006247|DRUG|semaxanib|
219362053|NCT03542201|OTHER|PLS|Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)
219087997|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
219087998|NCT05062486|DRUG|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
219087999|NCT05062486|DRUG|Curcumin|1000 mg curcumin BID
219088000|NCT05673070|DIETARY_SUPPLEMENT|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
219088001|NCT05673070|DIETARY_SUPPLEMENT|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
219088002|NCT05151068|BEHAVIORAL|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
219088003|NCT05151068|BEHAVIORAL|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
219088004|NCT05838261|PROCEDURE|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
219088005|NCT00089089|DRUG|decitabine|Given IV
219088006|NCT00089089|OTHER|pharmacological study|Correlative studies
219088007|NCT00089089|OTHER|laboratory biomarker analysis|Correlative studies
219088008|NCT01592903|GENETIC|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"* Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality."
219088009|NCT05385458|BEHAVIORAL|ACT Intervention|Acceptance and Commitment Therapy
219088010|NCT05385458|OTHER|Usual Care|Usual Care Services
219088011|NCT03329287|BEHAVIORAL|SCBT|SCBT, one hour per session.
219088012|NCT03329287|DRUG|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
219088013|NCT03329287|BEHAVIORAL|Psychological Placebo|Supportive and relaxation therapy, one our per session.
219088014|NCT02733809|DRUG|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
219088015|NCT01953003|DRUG|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
219088016|NCT01953003|DRUG|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
219088017|NCT06230458|DIAGNOSTIC_TEST|FeNO-test|Fractional Exhaled Nitric Oxide (FeNO)- test
219088018|NCT04099602|OTHER|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
219088019|NCT00979823|OTHER|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
219088020|NCT00979823|OTHER|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
219088021|NCT01043016|PROCEDURE|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
219088022|NCT04806295|OTHER|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
219088023|NCT00291759|DRUG|Tamoxifen|
219088024|NCT00291759|DRUG|Anastrozole|
219088025|NCT02558582|BEHAVIORAL|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
219088026|NCT02558582|BEHAVIORAL|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
219088027|NCT02512679|DRUG|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
219088028|NCT02512679|DRUG|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
219088029|NCT02512679|DRUG|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
219088030|NCT02512679|DRUG|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
219088031|NCT05312567|DRUG|FP-101|daily oral tablet administration (b.i.d.)
219215147|NCT06891586|DIAGNOSTIC_TEST|echocardiographic evaluation and blood phoenixin-14 level|For participants who provide consent, blood samples will be collected at 6 hours postpartum. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.
219088032|NCT01599390|OTHER|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
219088033|NCT03503539|PROCEDURE|Mini percutaneous nephrolithotomy|
219215148|NCT06065800|DEVICE|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
219088034|NCT03503539|PROCEDURE|Retrograde intrarenal surgery|
219088035|NCT05698134|DIAGNOSTIC_TEST|ROTEM|ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.
219088036|NCT05698134|OTHER|Standard of care|Standard of care
219088037|NCT00751764|DRUG|Moxidectin|
219088038|NCT03511911|DIAGNOSTIC_TEST|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
219088039|NCT03511911|DIAGNOSTIC_TEST|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
219088040|NCT06511336|DRUG|Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt|children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
219088041|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
219088042|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
219215149|NCT06534710|DEVICE|electronic moxibustion apparatus|The experimental group used the electronic moxibustion instrument every day on the basis of the control group
219215150|NCT06793735|DEVICE|Telerehabilitation with Virtual Reality|Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile. These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises. NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities. The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets. Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol. This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv
219362054|NCT03542201|OTHER|Blogshot|Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
219088043|NCT00192062|DRUG|gemcitabine|
219088044|NCT00192062|DRUG|vinorelbine|
219088045|NCT04791761|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219088046|NCT04791761|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219088047|NCT04791761|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219088048|NCT04791761|OTHER|Opioid disposal pouch|Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
219088049|NCT04791761|OTHER|Opioid disposal education|An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
219088050|NCT01756352|DRUG|18F-FET|Radiotracer, surrogate marker for protein synthesis
219215151|NCT06793735|OTHER|Traditional Cognitive Rehabilitation|Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises. This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities. The intervention also spans six weeks, with participants completing three 30-minute sessions per week. During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home. Therapists will provide weekly remote support via phone or video to track progress and address any concerns. This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
219215152|NCT05211115|PROCEDURE|Split thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
219215153|NCT05211115|PROCEDURE|Full thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
219215154|NCT05211115|PROCEDURE|Autogenous sub epithelial connective tissue graft|Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
219215155|NCT05211115|PROCEDURE|Volume stable collagen matrix|Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
219088051|NCT00010855|BEHAVIORAL|Self-hypnotic relaxation|
219215156|NCT06358612|OTHER|Stress Balls|Patients in the experimental arm will receive a foam stress ball to squeeze during their biopsy procedure.
219215157|NCT05319496|DEVICE|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
219215158|NCT05319496|BEHAVIORAL|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
219215159|NCT02622581|OTHER|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
219215160|NCT06824610|DEVICE|capnography|measurment of end-tidal carbon dioxide
219215161|NCT04318717|DRUG|Pembrolizumab|Pembrolizumab is commercially available
219215162|NCT04318717|RADIATION|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
219215163|NCT06751004|OTHER|BALLISTIC SIX EXERCISES|Ballistic six exercises will be given to group A and exercises of 3 sets of 10-20 repetitions will be completed, with each series offering 30-60 seconds of rest. The ballistic Six exercise uses resistance-band latex tube and fitness balls.
219215164|NCT06751004|OTHER|RESISTANCE-BAND EXERCISES|Resistance-band exercises will be given to group B and the duration of training sessions will be 3 sets of 10-20 repetitions
219215165|NCT06831721|BEHAVIORAL|Unstable Strength Training|Sixty-two participants were divided into an experimental group and a control group. 31 participants in the experimental group were in an unstable condition, with the help of unstable equipment such as BOSU balls, balance capsules and Swiss balls. The training program was designed according to the actual situation and characteristics of the participants to meet the characteristics of the volleyball sport. The remaining 31 participants in the control group underwent a conventional strength training routine.
219681938|NCT04360460|OTHER|Immersive virtual reality + related functional translation into real-life|The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.
219088052|NCT06093906|BEHAVIORAL|Positive Processes and Transition to Health|See arm/group description for details regarding this intervention
219088053|NCT06093906|BEHAVIORAL|Progressive Muscle Relaxation|See arm/group description for details regarding this intervention
219088054|NCT01728519|DRUG|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
219215166|NCT05843708|DRUG|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
219215167|NCT05843708|DRUG|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
219215168|NCT05843708|DRUG|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
219215169|NCT06779656|DEVICE|General Anesthesia (GA)|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
219215170|NCT06779656|PROCEDURE|Paravertebral Block (PVB)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe (6-13 MHz) will be used to visualize the transverse processes, ribs, and pleura adjacent to the thoracic transverse processes on the operative side. Under ultrasound guidance, a needle will be inserted from posterior to anterior, advancing just superior to the tip of the transverse process, 1-2 mm, avoiding the pleura, and entering the paravertebral space. For ropivacaine, either 0.375% or 0.5% will be administered at a dose of 3-5 mL per segment, according to the patient's height and the extent of surgery. The block will target the T2-T6 nerve distribution, with a total dose not exceeding 20 mL. Alternatively, for liposomal bupivacaine (10-26.6 mg/mL), the dose will be determined based on the patient's weight and surgical extent, typically a total dose of 100-200 mg, diluted with normal saline to a total injection volume of 10-20 mL.
219215171|NCT06779656|PROCEDURE|Rhomboid Intercostal and Subserratus Plane Block (RISS)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe will be used to locate the medial border of the scapula and identify the rhomboid, intercostal, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the rhomboid and intercostal muscles, or the plane between the intercostal and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 15-20 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 15-20 mL.
219215172|NCT06779656|PROCEDURE|Pectoral Nerves Block II (PECS II)|The patient will be placed in the supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the pectoralis major, pectoralis minor, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the pectoralis minor and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
219215173|NCT06779656|PROCEDURE|Intercostal Nerve Block (INB)|The patient will be positioned in the lateral decubitus or supine position. A high-frequency ultrasound probe will be used to locate the ribs and intercostal muscles. Under ultrasound guidance, the needle will be advanced to the inferior margin of the rib, in the intercostal muscle plane. Ropivacaine 0.25% will be administered at a dose of 2-5 mL per intercostal space, typically targeting 3-5 intercostal spaces. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered at a dose of 2-5 mL per intercostal space, with a total dose not exceeding 200 mg, and a total injection volume of 5-20 mL.
219088055|NCT01728519|DRUG|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
219362055|NCT03863626|OTHER|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
219681939|NCT04360460|OTHER|Immersive virtual reality + non-related translation into real-life|The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
219681940|NCT00338546|DRUG|Cocaine hydrochloride|
219681941|NCT00338546|DRUG|Dexmedetomidine|
219681942|NCT00338546|PROCEDURE|Microneurography|
219681943|NCT00338546|PROCEDURE|Laser doppler velocimetry|
219681944|NCT02635919|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
219088056|NCT01728519|DRUG|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
219088057|NCT01728519|DRUG|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
219088058|NCT01256853|DRUG|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
219088059|NCT02529826|PROCEDURE|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
219088060|NCT03315143|DRUG|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
219088061|NCT03315143|DRUG|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
219088062|NCT01280838|BEHAVIORAL|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
219088063|NCT01280838|BEHAVIORAL|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
219088064|NCT00111670|DRUG|DPP-IV Inhibitor|Escalating doses po bid or qd
219088065|NCT00111670|DRUG|Placebo|po bid or qd
219088066|NCT00549757|DRUG|Aliskiren|Aliskiren 150 mg film-coated tablets
219088067|NCT00549757|DRUG|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
219088068|NCT01981525|DRUG|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
219088069|NCT04860960|DRUG|Hydroxypropyl-beta-cyclodextrin|Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
219088070|NCT04860960|DRUG|Placebo|0.5N saline provided every 2 weeks intravenously
219088071|NCT03891121|DEVICE|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
219215174|NCT06779656|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The patient will be positioned in the lateral decubitus or supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the serratus anterior muscle. Under ultrasound guidance, the needle will be advanced either superficial or deep to the serratus anterior muscle. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
219215175|NCT06779656|PROCEDURE|Epidural Block|The patient will be positioned in the sitting or lateral decubitus position. The area will be prepped and draped using standard aseptic technique. Either the thoracic or lumbar region will be selected, with the T4-T5 level often chosen. An epidural needle will be inserted into the epidural space, and an epidural catheter will be placed, using standard epidural techniques. Ropivacaine 0.1% or 0.083% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. Alternatively, bupivacaine 0.1% or 0.0625% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. These can be used in combination with opioid medications such as fentanyl or sufentanil to enhance analgesia.
219215176|NCT04261855|DRUG|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
219215177|NCT04261855|RADIATION|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
219215178|NCT04261855|RADIATION|Lutetium-177 (177Lu)-DOTATATE|"Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart.~This treatment arm is now closed to recruitment."
219088072|NCT03891121|DRUG|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
219215179|NCT04041050|DRUG|Navitoclax|Tablet; Oral
219215180|NCT04041050|DRUG|Ruxolitinib|Tablet; Oral
219215181|NCT04041050|DRUG|Celecoxib|Capsule; Oral
219215182|NCT06765278|OTHER|Interscalene brachial plexus block|Patients will receive an Interscalene brachial plexus block.
219088073|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
219215183|NCT06765278|OTHER|Anterior glenoid nerve block|Patients will receive an anterior glenoid nerve block.
219215184|NCT06765278|OTHER|Pericapsular nerve group block|Patients will receive a pericapsular nerve group (PENG) block.
219215185|NCT06773988|DIAGNOSTIC_TEST|Monitoring of NIV at home|Monitoring of NIV at home
219215186|NCT06746584|BEHAVIORAL|benson relaxation exercise|BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.
219215187|NCT06757738|DRUG|TRX-100|CEN inhibitor, dosage form - capsules, dosing regimen - QD
219215188|NCT06757738|DRUG|Placebo|Placebo, dosage form - capsules, dosing regimen - QD
219215189|NCT03170349|DEVICE|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
219088074|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
219088075|NCT01431001|DEVICE|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
219088076|NCT02676401|DRUG|MT-3995 Low|
219088077|NCT02676401|DRUG|MT-3995 Middle|
219088078|NCT02676401|DRUG|MT-3995 High|
219088079|NCT00250913|BEHAVIORAL|Telephone-based physical activity counseling program|
219215190|NCT04013152|OTHER|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
219215191|NCT06477536|DRUG|HB0034|300mg, i.v. Q4W
219088080|NCT03919786|PROCEDURE|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
219088081|NCT06156722|PROCEDURE|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
219215192|NCT06117436|DRUG|Cilostazol|Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
219215193|NCT06117436|DRUG|Selenium|Selenium 200 mcg oral tablet once daily
219215194|NCT06636487|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
219215195|NCT06636487|BEHAVIORAL|Home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
219215196|NCT06636487|BEHAVIORAL|Control|Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
219215197|NCT04233190|DRUG|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg|one inhalation, twice daily
219215198|NCT06830421|DRUG|R-MP and Procarbazine maintenance|Firstline systemic treatment with conventinal immunochemotherapy (3 cycles of Rituximab-MTX-Procarbazine) followed by Procarbazine maintenance
219215199|NCT06830421|DRUG|R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT|Firstline systemic treatment with age-adjusted MTX based induction (2 cycles of Rituximab-Methotrexate-Cytarabin) followed by consolidating aged-adapted high-dose chemotherapy and autologous stem cell transplantation
219215200|NCT06830512|PROCEDURE|Echocardiography-guided percutaneous radiofrequency ablation for cardiac tumors|In the parasternal long-axis section, the cardiac puncture guide line was used to locate the puncture, and the best puncture path through the chest wall was selected. The coaxial biopsy needle was punctured through the guide frame, and then through the skin and subcutaneous tissue into the heart tumor tissue to take 2-10 biopsy samples, which were sent for pathological examination. The biopsy needle was extracted, and the radiofrequency electrode needle was punctured along the coaxial sheath to the planned ablation site of the heart tumor. The radiofrequency ablation device was started and the ablation treatment was performed.
219215201|NCT06830486|OTHER|No intervention|No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
219215202|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
219215203|NCT03750331|OTHER|Ap'Telecare|an internet application on a computer, tablet or smartphone
219215204|NCT03750331|OTHER|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
219088082|NCT06156722|PROCEDURE|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
219215205|NCT03086421|BEHAVIORAL|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
219215206|NCT06827639|PROCEDURE|blood collection|Blood sampling is performed during Scrrening / visit 1 for patients enrolled in cohort 1, cohort 2 and cohort 3
219215207|NCT06827639|PROCEDURE|tissue specimen collection|In Cohort 1- patients with solid tumor undergoing surgery, fresh tissue specimen is collected during surgery
219088083|NCT03293576|BEHAVIORAL|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
219088084|NCT06495567|DIETARY_SUPPLEMENT|Creatine|For 7 days, participants will take a 20mg creatine supplement each day.
219215208|NCT05429138|OTHER|biological sampling|Biological sampling: blood and semen
219215209|NCT06827821|DRUG|18F-CP6A|For pharmacokinetics, healthy volunteers underwent PET imaging targeting α-synuclein. Blood samples were collected at before and 2 ± 1, 5 ± 2, 10 ± 2, 30 ± 5, 60 ± 5, 90 ± 5, and 120 ± 10 min after imaging agent injection, and urine specimens were collected at before and 0-1.5, and 1.5-3 h after injection to measure radioactivity in blood and urine. PET/MR and PET/CT scans were performed at 0 ± 10, 30 ± 10, 60 ± 10, and 100 ± 10 min after injection to understand distribution for healthy volunteers and synucleinopathy patients. A separate 10-minute PET scan of the brain is required of each acquisition. Blood tests, liver and kidney function, and other biochemical markers must be performed one week prior to and after imaging.
219215210|NCT06550934|PROCEDURE|Fracture stabilization|isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
219215211|NCT03868943|DRUG|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
219215212|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
219215213|NCT06425900|DRUG|Winlevi (Clascoterone) cream 1%|Dosed twice daily (BID)
219215214|NCT03516942|OTHER|Quality-of-Life Assessment|Ancillary studies
219215215|NCT03516942|OTHER|Questionnaire Administration|Ancillary studies
219215216|NCT00833742|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
219088085|NCT06495567|DIETARY_SUPPLEMENT|Dietary methionine tracer and protein intake|On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
219088086|NCT05083325|DRUG|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
219088087|NCT05083325|DRUG|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
219088088|NCT01501708|DRUG|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
219088089|NCT04751201|BEHAVIORAL|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
219088090|NCT02150018|OTHER|non invasive ventilation|
219088091|NCT04203043|DRUG|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
219088092|NCT04203043|OTHER|Placebo|Placebo
219088093|NCT01686555|DRUG|ABT-199|Tablet
219088094|NCT01686555|OTHER|Placebo|Tablet
219088095|NCT00293267|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
219088096|NCT00293267|DRUG|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
219215217|NCT04957342|DEVICE|amnion-chorion membrane|allograft to be placed on palate
219215218|NCT04957342|PROCEDURE|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
219215219|NCT06830070|OTHER|subjective pain score assessment|a questionnaire assessing subjective pain during surgery, using the Visual Analogue Scale with values from 0 to 10
219215220|NCT05236699|COMBINATION_PRODUCT|DEB-TACE combined with Surufatinib and Camrelizumab|"1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
219215221|NCT06222099|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
219215222|NCT06222099|OTHER|Standard care|RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
219215223|NCT06222099|DEVICE|Heartfelt-guided care|Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
219088097|NCT00994357|DEVICE|Real-time CGM|See previous description.
219088098|NCT00994357|OTHER|Standard care|See text.
219088099|NCT00602056|OTHER|Redesigned immunization card|A low cost nad simplified redesigned immunization card
219088100|NCT00602056|OTHER|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
219088101|NCT00602056|OTHER|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
219088102|NCT05195931|DIAGNOSTIC_TEST|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
219088103|NCT05195931|DIAGNOSTIC_TEST|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
219088104|NCT05195931|DIAGNOSTIC_TEST|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
219215224|NCT06222099|OTHER|Questionnaires|Patients were presented with one or more optional questionnaires (some validated, some bespoke)
219215225|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
219215226|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
219088105|NCT02331862|DRUG|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
219088106|NCT01477853|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally daily
219088107|NCT01477853|DRUG|Atorvastatin|Atorvastatin 80 mg tablet orally daily
219088108|NCT01477853|OTHER|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
219088109|NCT01477853|OTHER|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
219088110|NCT01477853|DRUG|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
219088111|NCT01477853|DRUG|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
219088112|NCT01477853|DRUG|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
219088113|NCT01477853|DRUG|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
219088114|NCT03659604|BEHAVIORAL|'SmartLife' with tailored feedback|'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
219088115|NCT03659604|BEHAVIORAL|'SmartLife' without tailored feedback|'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
219215227|NCT06284252|OTHER|Virtual Gaming Simulation|Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
219215228|NCT06257537|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
219215229|NCT06257537|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
219215230|NCT06257537|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
219215231|NCT06257537|OTHER|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
219215232|NCT04782232|OTHER|No intervention|No intervention due to observational design
219088116|NCT03659604|BEHAVIORAL|No game|Passive control: School classes will be asked to continue their daily life as usual.
219088117|NCT04009369|OTHER|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
219215233|NCT06826885|RADIATION|Postoperative radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed. A tumor bed boost will be provided to patients with high-risk factors following breast-conserving surgery, at the discretion of the radiation oncologist. The tumor bed boost regimen may consist of a sequential boost of 10-16 Gy (RBE) in 5-8 fractions, or 10-13.35 Gy (RBE) in 4-5 fractions or 10.4 Gy (RBE) in 2 fractions, or a simultaneous integrated boost of 48-49.5 Gy (RBE) in 15-16 fractions.
219088118|NCT01050816|PROCEDURE|Chondron(autologous chondrocyte) Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
219088119|NCT03086330|DRUG|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
219088120|NCT03086330|DRUG|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
219088121|NCT00248781|DEVICE|Telecommunications system|
219088122|NCT00248781|DEVICE|attention control|health education
219088123|NCT01102244|DRUG|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
219088124|NCT01102244|DRUG|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
219215234|NCT06826885|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed.
219215235|NCT06826885|RADIATION|Definitive Radiotherapy|Radiotherapy was delivered using IMPT or IMRT. The target volume encompassed the ipsilateral whole breast and regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions was preferred. Alternatively, a conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions was permitted. Dose escalation was applied in high-risk areas, resulting in a total prescribed dose exceeding 66 Gy (RBE) when calculated as equivalent doses in 2-Gy fractions (EQD2), with an α/β ratio of 4.
219215236|NCT05662371|DEVICE|Nociception Level monitor (NOL)|NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuously monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics, and avoiding overdose or underuse of these drugs. The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation).
219215237|NCT05662371|DEVICE|Standard care|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
219215238|NCT06338293|DRUG|Inclisiran sodium|The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
219215239|NCT06338293|DRUG|Rosuvastatin|Rosuvastatin
219215240|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
219215241|NCT06831045|PROCEDURE|Bikini Incision|Participants will receive the bikini incision in person during THA. A one-time incision will be made along the groin line before standard of care THA surgery. The surgery takes approximately two hours.
219088125|NCT05454150|DEVICE|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
219088126|NCT05454150|DEVICE|self-expanding valve|Evolut R/Pro, Medtronic©
219088127|NCT01107860|DEVICE|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
219088128|NCT01107860|DEVICE|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
219088129|NCT02360319|DRUG|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
219088130|NCT02360319|DRUG|aripiprazole long acting injectable formulation|
219088131|NCT05410600|OTHER|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
219088132|NCT02132364|OTHER|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
219088133|NCT03074227|OTHER|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
219215242|NCT06831045|PROCEDURE|Longitudinal Incision|Participants will receive the longitudinal incision in person during THA. A one-time linear incision will be made along the thigh before standard-of-care THA surgery. The surgery takes approximately two hours.
219215243|NCT05630183|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
219215244|NCT05630183|DRUG|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
219215245|NCT05630183|DRUG|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
219215246|NCT04372914|DIETARY_SUPPLEMENT|BRB Lozenges|Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to \~5 black raspberries) in the form of a dissolvable slow-release lozenge.
219215247|NCT06922279|RADIATION|Radiation Therapy + standard sistemic therapy (chemoteraphy)|Standard systemic therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist considers most useful) + combination of RT on the primary gastroesophageal Gross Tumor Volume (GTV) + SBRT on each of the distal lesions for oligometastatic or limited metastatic spread patients (to be delivered prior to initiation of systemic therapy).
219215248|NCT06922279|DRUG|Standard systemic therapy (chemotherapy)|The patients will go to standard therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful.) without RT/SBRT combination
219215249|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
219215250|NCT06813794|BEHAVIORAL|Gain- Framed Messages|Patients will be recruited to whatsapp group based on gain framing about diabetic foot care skills. Gain framing messages and videos will be delivered to patients via whatsapp 3 times a week for 3 months.
219215251|NCT06813794|BEHAVIORAL|Lost Framed Messages|Patients will be included in whatsapp group based on Lost framing about diabetic foot care skills. Patients will receive loss framing messages and videos 3 times a week for 3 months via whatsapp.
219215252|NCT06778473|DEVICE|Active Intradermal Acupuncture|"Depending on acupoints' location, φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Insert the Active IA vertically into the acupoint and retain it in the skin.~Active IA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be required to press the Active IA 4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours."
219088134|NCT03074227|OTHER|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
219215253|NCT06778473|DEVICE|Sham Intradermal Acupuncture|Sham intradermal acupuncture will be attached to the acupoints and retained for 72 hours with a day's rest after removal. During the period of sham needle retention,pressing times and frequencies are identical to those in the active intradermal acupuncture group.
219215254|NCT06778473|OTHER|Guided self-rehabilitation management program|Self-rehabilitation techniques are taught in individual sessions of about 40 minutes at each outpatient clinic visit, as detailed below: Analysis of the problem, Education, Massage, Facial muscles exercise,Synkinesis or spasticity management, Homework. Participants are requested to perform daily facial muscle exercises as prescribed by the therapist and keep the written diary on a daily basis. The therapists retrieve and evaluate the diaries at each visit.
219215255|NCT06778473|OTHER|Health Education|Health education knowledge about the disease such as etiology, pathology,clinical symptoms of Bell's palsy, Bell's palsy diagnosis and role of medical tests;medication education;complications and sequelae,etc
219215256|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
219215257|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
219215258|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
219088135|NCT04387630|DRUG|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
219215259|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
219215260|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
219088136|NCT04387630|DRUG|Placebo oral tablet|Simethicone 60 mg three times daily.
219088137|NCT05120089|OTHER|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
219088138|NCT02036203|DEVICE|SCu300A IUB|Spherical copper contraceptive
219215261|NCT05995860|BEHAVIORAL|Intervention group triads|The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter. Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs. As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.
219088139|NCT02036203|DEVICE|TCu380A IUD|T-shaped copper IUD
219088140|NCT03036358|OTHER|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
219088141|NCT03036358|OTHER|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
219088142|NCT05165342|DEVICE|Rexon-eye|a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
219088143|NCT01186445|DRUG|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
219215262|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
219088144|NCT01186445|DRUG|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
219215263|NCT06954519|OTHER|Mental imagery|The principle of guided mental imagery and helping students to mentally represent the key stages of a process, using an animated slideshow full of evocative elements, which we created specifically for this study. The mental imagery will be repeated by the students several times independently until the evaluation simulation at 6 months based on reminders via messages from investigators.
219215264|NCT06954519|OTHER|Cognitive aid reading|Participants of the control group will only read the cognitive aid on neonatal resuscitation at the same intervalls than the experimentation group
219215265|NCT06954363|PROCEDURE|Mulligan Mobilization|Mulligan Mobilization involves manual tibial glides (medial and lateral) using a mobilization belt. The patient lies supine with the knee flexed between 30°-45°. The therapist applies a sustained glide while the patient actively moves the knee into flexion and extension. The treatment is delivered in 3 sets of 10 repetitions per session, 5 days per week for 3 weeks, along with a conventional physical therapy protocol.
219215266|NCT06954363|PROCEDURE|Muscle Energy Technique (MET)|Muscle Energy Technique involves the application of post-isometric relaxation targeting hamstring muscles. The therapist applies a 10-second isometric contraction at the resistance barrier, followed by a 20-second passive stretch, progressing into a new range of motion. This technique is applied 3 times per session, 5 days per week for 3 weeks, in combination with a conventional physical therapy protocol.
219088145|NCT01532128|DRUG|rasagiline|1 mg rasagiline (single-dose)
219215267|NCT06950970|BEHAVIORAL|Tion-Emo therapy and technique for depression and anxiety Improvement|From 10 a 12 sessions once a week and one hour each session , for a positive result and development it is necessary to practice the technique
219215268|NCT06954129|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic used to treat infections caused by Gram-positive bacteria, including those due to methicillin-resistant Staphylococcus aureus. Dosing of vancomycin will follow standard of care procedures, including the use of individualized dosing regimens developed in consultation with clinical pharmacists, based on participant body weight and renal function, and dosage titration guided by therapeutic drug monitoring. Vancomycin is administered via intermittent intravenous infusions of 60-90 minutes.
219215269|NCT06954129|DRUG|Piperacillin-tazobactam|Piperacillin-tazobactam is an anti-pseudomonal penicillin with a dose range of 2.25 g or 4.5 g and frequency of every 6 or 8 hours based on a participant's body weight, renal function, and clinician discretion. Piperacillin-tazobactam is administered via extended-duration (4 hours) intravenous infusions
219088146|NCT01532128|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
219088147|NCT04992351|PROCEDURE|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
219088148|NCT01718327|DRUG|Sunitinib|sunitinib dose :37.5mg/day
219088149|NCT05195073|BIOLOGICAL|Laparoscopy|3 D laparoscopy
219088150|NCT04866615|DIAGNOSTIC_TEST|Optvue OCT|Optical coherence tomography
219088151|NCT05375474|DRUG|Oral anticoagulation therapy|Vitamin-K antagonists (warfarin)
219088152|NCT05375474|DRUG|Single antiplatelet therapy|Aspirin
219088153|NCT05016154|BEHAVIORAL|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
219088154|NCT05016154|BEHAVIORAL|SilverCloud guided|Group of participants make use of the SilverCloud guided app
219088155|NCT05016154|BEHAVIORAL|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
219088156|NCT05016154|BEHAVIORAL|Mood Flow|Group of participants make use of the Mood Flow app
219088157|NCT02953743|DRUG|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
219088158|NCT06472401|OTHER|Integrated Learning Support System|"Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session"
219088159|NCT06472401|OTHER|Standard Learning Model|"Students will receive standard simulation preparation consisting of:~\- Expository and dialogued theoretical class."
219088160|NCT05085119|PROCEDURE|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
219088161|NCT05471648|DRUG|420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
219088162|NCT05471648|DRUG|Perjeta (EU origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
219088163|NCT05471648|DRUG|Perjeta (US origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
219088164|NCT04069000|BEHAVIORAL|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
219215270|NCT06954129|DRUG|Cefepime|Cefepime is an anti-pseudomonal cephalosporin with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 8, 12, or 24 hours based on a participant's body weight, renal function, and clinician discretion. Cefepime is administered via extended-duration (4 hours) intravenous infusions
219088165|NCT04069000|BEHAVIORAL|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
219088166|NCT00948974|BEHAVIORAL|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
219215271|NCT06950632|DIETARY_SUPPLEMENT|Pepppermint oil inhalation|Participants in the experimental group will inhale five drops of 100% pure peppermint essential oil placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the chemotherapy infusion.
219215272|NCT06950632|DIETARY_SUPPLEMENT|Placebo|The control group will follow the same procedure using five drops of distilled water placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the infusion
219215273|NCT06950580|OTHER|abdominal massage|In addition to routine physiotherapy, abdominal massage will be applied by the physiotherapist. The patient is positioned supine. The abdominal muscles are stroked three times, followed by colon stroking performed three times, and colon kneading performed three times. The massage is concluded by repeating the colon and abdominal stroking techniques in the same manner. Patients hospitalized in the intensive care unit will routinely receive abdominal massage twice daily by the physiotherapist
219215274|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
219215275|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
219215276|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
219215277|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
219215278|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
219215279|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
219215280|NCT05820711|DRUG|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)"
219215281|NCT05419726|DRUG|Semaglutide Injectable Product (not provided by the study)|"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
219215282|NCT06525129|OTHER|Cerebellar stimulation group (CbSG)|Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.
219215283|NCT06525129|OTHER|Cerebral (M1) Stimulation group (MSG)|In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.
219362056|NCT03863626|OTHER|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
219362057|NCT00426894|PROCEDURE|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
219088167|NCT00948974|BEHAVIORAL|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
219088168|NCT04983758|OTHER|Oral Rehabilitation with dental implants|Patients have been treated with oral dental implants supporting fixed dental prostheses
219088169|NCT03833297|DRUG|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
219088170|NCT01302470|PROCEDURE|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
219088171|NCT01302470|PROCEDURE|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
219215284|NCT06525129|OTHER|Sham Stimulation group (SSG)|In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
219215285|NCT04550169|OTHER|Intensive Care Coordination|"Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable"
219215286|NCT04207736|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
219215287|NCT04207736|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
219215288|NCT01823406|PROCEDURE|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
219215289|NCT01823406|PROCEDURE|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
219215290|NCT00773500|OTHER|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
219088172|NCT03627039|DRUG|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
219088173|NCT03627039|DRUG|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
219088174|NCT03940820|BIOLOGICAL|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
219088175|NCT04886882|OTHER|placebo comparator|solution containing 0.9 % sodium chlorine
219215291|NCT03956095|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
219088176|NCT04886882|OTHER|sham comparator|vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
219215292|NCT03956095|OTHER|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
219088177|NCT04886882|OTHER|Experimental drug 1|A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
219088178|NCT04886882|OTHER|Experimental drug 2|A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
219088179|NCT04886882|DRUG|Centella asiatica|A cream containing Centella asiatica
219088180|NCT03941275|DIAGNOSTIC_TEST|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
219088181|NCT00386503|DRUG|Artesunate + Amodiaquine|
219088182|NCT01394354|DRUG|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
219088183|NCT01394354|DRUG|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
219215293|NCT04094519|DRUG|enzalutamide|oral
219215294|NCT04094519|DRUG|enzalutamide Placebo|oral
219215295|NCT04094519|DRUG|digoxin|oral
219215296|NCT04094519|DRUG|rosuvastatin|oral
219088184|NCT01394354|DRUG|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
219088185|NCT01394354|DRUG|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
219088186|NCT03440931|DIAGNOSTIC_TEST|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
219088187|NCT00238433|BIOLOGICAL|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC\> 1500 for 2 consecutive days.
219088188|NCT00238433|DRUG|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
219088189|NCT00238433|DRUG|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
219088190|NCT00238433|DRUG|thiotepa|250 mg/m2/day/iv on days -3 and -2
219088191|NCT00238433|PROCEDURE|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
219088192|NCT00238433|PROCEDURE|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
219088193|NCT04218448|OTHER|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
219088194|NCT02481544|BEHAVIORAL|Gratitude Journaling Plus SOC|
219088195|NCT02481544|BEHAVIORAL|Memorable Events Journaling Plus SOC|
219088196|NCT02695030|DEVICE|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
219088197|NCT06580366|DRUG|Sennosid A+B|Bowel Preparation
219088198|NCT06580366|DRUG|Sodium Picosulfate/Magnesium Oxide/Citric Acid|Bowel Preparation
219088199|NCT06579703|DRUG|Ketorolac|"Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)"
219088200|NCT00580814|DRUG|Experimental: methylphenidate treatment|subjects received mehtylphenidate treatment for 12 months
219088201|NCT02548767|OTHER|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
219088202|NCT02548767|OTHER|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
219088203|NCT02548767|OTHER|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
219088204|NCT02548767|OTHER|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
219088205|NCT06579976|OTHER|No intervention|This is an observational study, no intervention will be implemented.
219088206|NCT05019664|DEVICE|Affixus Natural Nail System|Intramedullary nailing designed for fixation and stabilization of fractures or osteotomies of the humerus. Nails are comprised of proximal and antegrade/retrograde.
219088207|NCT05854225|DRUG|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
219215297|NCT04515667|BEHAVIORAL|Mindfulness|Participants will view a brief mindfulness video
219215298|NCT04515667|BEHAVIORAL|Video|Participants will view a control video
219215299|NCT05724966|DEVICE|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
219215300|NCT01419808|PROCEDURE|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
219215301|NCT01419808|PROCEDURE|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
219215302|NCT05188066|DIAGNOSTIC_TEST|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
219215303|NCT04357158|DEVICE|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with \>2 weeks in between).
219215304|NCT06952309|DRUG|Intracheal dexmedetomidine|Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
219215305|NCT06952309|DRUG|Intravenous lidocaine|Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
219215306|NCT06952309|DRUG|Intravenous lidocaine combined with intracheal dexmedetomidine|Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
219215307|NCT06952309|DRUG|Saline (NaCl 0,9 %) (placebo)|Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
219088208|NCT02274389|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
219088209|NCT01814748|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
219088210|NCT01814748|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
219088211|NCT01814748|DRUG|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
219088212|NCT03520166|OTHER|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
219088213|NCT03520166|OTHER|No treatment|No treatment
219088214|NCT06579729|BEHAVIORAL|Dietary intervention for low free sugars|After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.
219088215|NCT06462911|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
219088216|NCT06578975|DIAGNOSTIC_TEST|HT-ENDO-MOS-A13|Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
219088217|NCT06578975|OTHER|Normal diagnosis|Standard diagnosis for endocrine hypertension
219088218|NCT06580379|PROCEDURE|Spine surgery|Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
219088219|NCT06579274|DRUG|Parecoxib|Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
219088220|NCT06579274|DRUG|Placebo|Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
219088221|NCT03901196|DIAGNOSTIC_TEST|Elemental analysis|LIBS multi elemental analysis of the specimen
219215308|NCT06566339|DEVICE|Robotically Aligned Eye Imaging System|Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
219215309|NCT01675063|DEVICE|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
219215310|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) food introduction-1st|1 serving size of food proven to induce histologic and clinical symptoms in EoE
219215311|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (E0E) food introduction-2nd|Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
219215312|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) Food introduction-3rd dose|Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1
219215313|NCT05247866|DRUG|Dupilumab|"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
219088222|NCT04044456|BEHAVIORAL|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
219088223|NCT04044456|BEHAVIORAL|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
219215314|NCT00130546|DEVICE|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
219215315|NCT00130546|DEVICE|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
219215316|NCT06197217|DRUG|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
219215317|NCT06197217|DRUG|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
219215318|NCT00206986|DRUG|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
219215319|NCT00206986|DRUG|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
219215320|NCT03238261|RADIATION|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
219215321|NCT03363529|DEVICE|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
219088224|NCT04044456|BEHAVIORAL|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
219088225|NCT04044456|BEHAVIORAL|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
219088226|NCT01344668|OTHER|Enhanced Diabetes Education|Provide enhanced diabetes education
219088227|NCT01344668|OTHER|Standard Diabetes Education|Provide Standard Diabetes Education
219088228|NCT01972529|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
219088229|NCT01972529|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
219088230|NCT01972529|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
219215322|NCT03363529|DEVICE|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
219088231|NCT01972529|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
219088232|NCT03262610|DRUG|Setmelanotide|daily subcutaneous injection
219088233|NCT01844271|DEVICE|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
219215323|NCT02795754|DRUG|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
219215324|NCT02795754|DRUG|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
219215325|NCT02795754|DRUG|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
219215326|NCT02795754|DRUG|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
219215327|NCT02795754|DRUG|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
219215328|NCT01532310|DRUG|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
219088234|NCT01872533|OTHER|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at \~ 15% O2 (ca. 2400 m elevation).
219088235|NCT00268827|DRUG|Kaletra soft-gel capsules switched to Kaletra tablets|
219088236|NCT00268827|DEVICE|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
219088237|NCT03393195|BEHAVIORAL|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
219088238|NCT03393195|BEHAVIORAL|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
219088239|NCT00783731|DRUG|Low dose midazolam|
219088240|NCT02274857|PROCEDURE|Standard PVI Ablation|Standard PVI procedure without FIRMap.
219088241|NCT02274857|PROCEDURE|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
219215329|NCT02967458|DRUG|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
219215330|NCT01505712|GENETIC|gene expression analysis|
219088242|NCT01606527|DRUG|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
219088243|NCT04894201|RADIATION|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
219215331|NCT01505712|OTHER|laboratory biomarker analysis|
219215332|NCT06515873|DEVICE|Virtual Reality Headset|The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
219215333|NCT06135922|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
219215334|NCT01501617|BIOLOGICAL|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
219215335|NCT01501617|DEVICE|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
219215336|NCT02186509|RADIATION|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
219215337|NCT02186509|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
219215338|NCT02186509|DRUG|Alisertib|Given PO
219215339|NCT02186509|PROCEDURE|Quality-of-life assessment|Ancillary studies
219088244|NCT02999828|BIOLOGICAL|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
219088245|NCT00948298|DRUG|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
219088246|NCT00948298|DRUG|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
219088247|NCT03871179|DIAGNOSTIC_TEST|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
219088248|NCT06072534|DRUG|"Mivacurium Chloride"|emergence modified sequence intubation
219088249|NCT00939874|DRUG|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
219088250|NCT00330174|DRUG|Acamprosate|2 333mg tablets three times daily
219088251|NCT05019833|DEVICE|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
219088252|NCT05199610|DRUG|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
219088253|NCT05295966|OTHER|Cognitive therapy|Cognitive therapy
219215340|NCT01163981|OTHER|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
219215341|NCT03500822|PROCEDURE|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
219215342|NCT03500822|PROCEDURE|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
219088254|NCT05295966|BEHAVIORAL|Physiocognitive Integration|Physiocognitive Integration
219088255|NCT03470779|OTHER|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
219088256|NCT03470779|OTHER|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
219088257|NCT04606277|OTHER|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
219088258|NCT02749357|DEVICE|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
219215343|NCT04715269|DRUG|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
219088259|NCT02749357|DEVICE|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
219088260|NCT01520818|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
219088261|NCT01520818|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
219088262|NCT01520818|DRUG|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
219088263|NCT03810625|DRUG|D-0502|D-0502 oral tablets
219215344|NCT04715269|OTHER|Placebo|Empty capsule
219088264|NCT00627484|PROCEDURE|Gastric bypass|NOTE: the surgery is not paid for by the study
219088265|NCT00627484|PROCEDURE|Gastric banding|NOTE: the surgery is not paid for by the study
219088266|NCT00627484|PROCEDURE|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
219088267|NCT00627484|BEHAVIORAL|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
219088268|NCT00546780|DRUG|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
219088269|NCT00546780|DRUG|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
219088270|NCT01032733|BEHAVIORAL|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
219088271|NCT01032733|OTHER|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
219088272|NCT06116565|BIOLOGICAL|CM310|CM310, subcutaneous injection
219215345|NCT02482701|DEVICE|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
219215346|NCT06407804|OTHER|Thrower's Ten Exercise Program|No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
219215347|NCT06407804|OTHER|Routine physical therapy.|"In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)"
219215348|NCT03039296|PROCEDURE|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
219215349|NCT00895609|DRUG|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
219215350|NCT04235998|DIAGNOSTIC_TEST|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
219215351|NCT00325767|DRUG|nebulized albuterol (2.5 mg/3ml/dose)|
219088273|NCT05421455|DRUG|Group A|treat participants with biologics
219088274|NCT05421455|PROCEDURE|Group B|treat participants with surgery
219088275|NCT01595893|DRUG|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
219088276|NCT01595893|DRUG|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
219088277|NCT01506895|DRUG|darapladib|Experimental compound 160 mg dose
219088278|NCT01506895|DRUG|placebo|Placebo to match
219088279|NCT02726802|OTHER|physical therapy vs. primary care interventions|Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
219088280|NCT05950425|OTHER|Aspiration training|"Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge."
219088281|NCT02955472|DRUG|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
219088282|NCT02955472|DRUG|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
219088283|NCT06274814|PROCEDURE|U/S guided Type 2 Pectoral Nerve Block|20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles
219088284|NCT06274814|PROCEDURE|U/S guided RIB combined with the sub-serratus plane block (RISS)|he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
219088285|NCT04667975|DRUG|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
219215352|NCT00325767|DRUG|nebulized levalbuterol (1.25 mg/3ml/dose)|
219215353|NCT00325767|DRUG|nebulized placebo (3ml/dose)|
219215354|NCT02261805|DRUG|Ganetespib|
219215355|NCT02261805|DRUG|Doxorubicin|
219215356|NCT01292863|OTHER|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
219088286|NCT05347979|DRUG|Dabigatran Etexilate|Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
219088287|NCT05347979|DRUG|Relacorilant|Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
219088288|NCT01567332|DEVICE|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
219215357|NCT01292863|OTHER|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
219215358|NCT00963092|GENETIC|DNA analysis|
219215359|NCT00963092|GENETIC|RNA analysis|
219215360|NCT00963092|GENETIC|microarray analysis|
219215361|NCT00963092|GENETIC|protein analysis|
219215362|NCT00963092|OTHER|cytology specimen collection procedure|
219215363|NCT00963092|OTHER|laboratory biomarker analysis|
219215364|NCT00963092|OTHER|questionnaire administration|
219088289|NCT01567332|DEVICE|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
219088290|NCT02413060|OTHER|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
219088291|NCT02413060|BEHAVIORAL|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
219088292|NCT04995185|RADIATION|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
219088293|NCT04469881|BEHAVIORAL|VR|"Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
219088294|NCT04731779|DRUG|cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
219088295|NCT04731779|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
219088296|NCT00409682|BIOLOGICAL|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
219215365|NCT01389921|OTHER|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
219215366|NCT05328258|DRUG|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
219215367|NCT05328258|DRUG|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
219215368|NCT06162182|DIAGNOSTIC_TEST|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
219215369|NCT06162182|DIAGNOSTIC_TEST|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
219215370|NCT04553549|DEVICE|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
219215371|NCT01296100|BEHAVIORAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
219215372|NCT01296100|BEHAVIORAL|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
219215373|NCT05538000|OTHER|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment."
219088297|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
219088298|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
219215374|NCT02113826|DRUG|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
219215375|NCT06509828|BIOLOGICAL|AVB-114|AVB-114 is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.
219215376|NCT00701259|DRUG|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
219088299|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and human counseling|
219088300|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and computer counseling|
219088301|NCT00200304|BEHAVIORAL|Internet weight loss program with SlimFast|
219088302|NCT03581084|DRUG|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
219088303|NCT00990717|BIOLOGICAL|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2"
219088304|NCT01361425|DRUG|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
219088305|NCT01361425|DRUG|placebo|placebo 500mg 8/8h, orally
219088306|NCT05807659|DRUG|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
219088307|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
219088308|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
219088309|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
219088310|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
219088311|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
219088312|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
219088313|NCT00428467|PROCEDURE|LV Apex Compression|
219088314|NCT01944202|BEHAVIORAL|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
219088315|NCT03358056|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
219088316|NCT02782702|DRUG|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
219088317|NCT02403180|DEVICE|DACP MF|Nelfilcon A multifocal contact lenses
219088318|NCT02403180|DEVICE|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
219088319|NCT00041782|DRUG|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
219088320|NCT05711537|DEVICE|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
219088321|NCT01876290|DRUG|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
219088322|NCT01876290|DRUG|Placebo|Placebo
219088323|NCT03831243|RADIATION|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
219088324|NCT03831243|RADIATION|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
219088325|NCT00232830|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
219088326|NCT00232830|DEVICE|bare-metal stent|any bare-metal stent brand
219088327|NCT01876316|DRUG|Moxifloxacin|single oral administration of 400mg of moxifloxacin
219088328|NCT01876316|DRUG|Placebo|single oral administration of 400mg of placebo
219088329|NCT01304030|BEHAVIORAL|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
219088330|NCT01304030|BEHAVIORAL|Residency Training as usual|Residents will receive their typical didactic and clinical education
219215377|NCT00701259|DRUG|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
219215378|NCT00701259|DRUG|placebo|
219088331|NCT05135416|PROCEDURE|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
219088332|NCT05135416|PROCEDURE|Control group|control of consciousness listening to bowel sounds assessment of pain
219088333|NCT06089356|DRUG|zolmitriptanee|zolmitriptane tablet daily
219088334|NCT06089356|DRUG|topiramate|topiramate once daily
219088335|NCT06089356|DRUG|Valproate|valproate once daily
219088336|NCT04194567|OTHER|Black Ragi|Pancakes made out of the dark ragi
219088337|NCT04194567|OTHER|White Ragi|Pancakes made out of the white ragi
219088338|NCT00834106|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
219088339|NCT00834106|BIOLOGICAL|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
219088340|NCT03364855|OTHER|Star excursion balance test|Star excursion balance test,
219088341|NCT03364855|OTHER|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
219088342|NCT03364855|OTHER|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
219088343|NCT02365675|DEVICE|Cotton gauze with petrolatum|
219088344|NCT02365675|DEVICE|Cellulose acetate with petrolatum|
219088345|NCT02365675|DEVICE|Nanocrystalline silver (Acticoat)|
219088346|NCT02365675|DEVICE|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
219088347|NCT01450748|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
219088348|NCT01450748|DRUG|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
219088349|NCT05001360|DRUG|XBI-302 + Nivolumab|After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
219088350|NCT02958592|OTHER|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
219088351|NCT00330915|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
219088352|NCT03022201|DRUG|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
219088353|NCT03022201|DRUG|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
219088354|NCT03022201|DRUG|Placebo domperidone|
219088355|NCT03022201|DRUG|Placebo DA-9701|
219088356|NCT02428322|DIETARY_SUPPLEMENT|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
219088357|NCT02428322|DIETARY_SUPPLEMENT|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
219088358|NCT00801801|DRUG|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
219215379|NCT00290537|DRUG|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
219215380|NCT00290537|DRUG|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
219215381|NCT00290537|DRUG|Paclitaxel|200 mg/m\^2 IV Over 3 Hours On Day 1
219215382|NCT02593760|OTHER|Placebo|Placebo will be administered PO QD for up to 48 weeks.
219215383|NCT02593760|DRUG|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
219215384|NCT02593760|DRUG|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
219215385|NCT03067974|DRUG|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
219215386|NCT06402552|DIAGNOSTIC_TEST|bp-MRI prostate|Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.
219215387|NCT06402552|DIAGNOSTIC_TEST|mp-MRI prostate|Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
219215388|NCT00065182|DRUG|Topotecan/Docetaxel combination|
219088359|NCT00118716|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
219088360|NCT00118716|DRUG|Fluticasone Propionate|Fluticasone Propionate
219088361|NCT03665844|DEVICE|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
219088362|NCT03665844|DEVICE|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
219088363|NCT04436666|DEVICE|motivational video production through virtual reality glasses|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
219088364|NCT04436666|OTHER|Ice Application|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
219088365|NCT01445652|DEVICE|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
219088366|NCT01445652|OTHER|Spectacles|Spectacles per current prescription
219088367|NCT06097754|DIETARY_SUPPLEMENT|Ketone ester|"Ketone ester: A total of 300g ketone ester supplementation will be provided in one of the 72h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
219088368|NCT06097754|DIETARY_SUPPLEMENT|Placebo|"Placebo: Water, 5% sucralose (w/w), octaacetate (1 mM)~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
219088369|NCT02708979|OTHER|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
219088370|NCT02708979|OTHER|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
219088371|NCT01398670|BIOLOGICAL|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
219088372|NCT01398670|BIOLOGICAL|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
219088373|NCT02436811|BEHAVIORAL|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
219088374|NCT02436811|BEHAVIORAL|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
219088375|NCT02436811|BEHAVIORAL|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
219088376|NCT02471092|OTHER|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
219088377|NCT02227875|DRUG|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
219088378|NCT02227875|DRUG|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
219088379|NCT00656604|GENETIC|proteomic profiling|at the time of each procedure.
219088380|NCT00656604|PROCEDURE|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
219088381|NCT00656604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
219088382|NCT00656604|PROCEDURE|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
219088383|NCT00656604|PROCEDURE|magnetic resonance spectroscopy|Prior to initiation of treatment
219088384|NCT04209725|DRUG|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
219088385|NCT04209725|DRUG|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
219088386|NCT04833764|DRUG|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
219088387|NCT01804101|OTHER|Laboratory Biomarker Analysis|Correlative studies
219215389|NCT00065182|DRUG|Docetaxel|
219215390|NCT04684095|BEHAVIORAL|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
219215391|NCT04707807|DIAGNOSTIC_TEST|IIEF-5|IIEF-15 form will be filled out by all participants
219215392|NCT06130228|DIETARY_SUPPLEMENT|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
219215393|NCT06130228|DIETARY_SUPPLEMENT|Placebo (PLA)|Supplementation with inactive placebo
219215394|NCT05097638|DIAGNOSTIC_TEST|spirometry|Patient do spirometry
219215395|NCT01911156|DRUG|Continue NA treatment|Prescribed NA during the 72 week study period
219088388|NCT01804101|DRUG|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
219215396|NCT01911156|DRUG|Discontinue NA Treatment|Discontinue NA Treatment
219215397|NCT02097381|DRUG|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
219215398|NCT05596331|OTHER|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
219088389|NCT02019628|DIETARY_SUPPLEMENT|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
219088390|NCT03741101|DRUG|Trametinib|treatment
219088391|NCT02393287|OTHER|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
219088392|NCT03402256|BEHAVIORAL|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
219088393|NCT06508047|DEVICE|Informed Vital Core App|Informed Vital Core App will be initiated by the study staff to take a measurement, which takes 60 seconds to calculate and report a breathing rate value.
219088394|NCT03673306|OTHER|Clinical outcomes|Clinical outcomes
219088395|NCT02202746|DRUG|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
219088396|NCT04723823|OTHER|Motor or sensory imagery with fMRI|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
219088397|NCT06441565|DRUG|Fruquintinib|A treatment cycle of 4 weeks, with 5 mg orally once daily for 3 weeks, followed by a 1-week break
219088398|NCT06441565|DRUG|Fluorouracil|2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
219215399|NCT03117426|DEVICE|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
219215400|NCT03117426|DEVICE|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
219215401|NCT00754325|DRUG|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
219215402|NCT00754325|DRUG|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
219215403|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
219215404|NCT01768793|BEHAVIORAL|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
219215405|NCT01768793|BEHAVIORAL|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
219215406|NCT00351299|DRUG|Dexmedetomidine|dexmedetomidine infusion titrated to effect
219215407|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
219215408|NCT04876417|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
219215409|NCT04876417|DEVICE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
219215410|NCT03394534|OTHER|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
219215411|NCT03155113|OTHER|blood drawing|Before starting therapy a blood sample will be collected from any subject.
219215412|NCT01441284|DRUG|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
219215413|NCT01441284|DRUG|placebo|placebo
219215414|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
219215415|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
219215416|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
219215417|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
219215418|NCT05359536|BEHAVIORAL|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
219215419|NCT02127749|DRUG|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
219215420|NCT02127749|DRUG|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
219215421|NCT01143142|BEHAVIORAL|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
219215422|NCT00439270|DRUG|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
219088399|NCT06441565|DRUG|Oxaliplatin|85 mg/m² given every 2 weeks through hepatic arterial infusion
219088400|NCT02744833|DRUG|GMI-1271|
219088401|NCT02744833|DRUG|Enoxaparin Sodium (Lovenox®)|
219088402|NCT01456299|DRUG|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
219088403|NCT01456299|DRUG|Control|The control group, which received an infusion of normal saline
219088404|NCT01456299|DRUG|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
219088405|NCT03569384|COMBINATION_PRODUCT|Tele Rehab|The intervention group will obtain telerehabilitation
219215423|NCT00439270|DRUG|Docetaxel|Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
219215424|NCT06031116|PROCEDURE|depigmentation|gingival depigmentation
219215425|NCT00862030|PROCEDURE|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
219215426|NCT00001968|DRUG|Amprenavir|
219215427|NCT00001968|DRUG|Ritonavir|
219088406|NCT02020525|PROCEDURE|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
219088407|NCT02020525|PROCEDURE|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
219088408|NCT02913664|DRUG|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
219088409|NCT02913664|BEHAVIORAL|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
219088410|NCT02913664|OTHER|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
219215428|NCT00001968|DRUG|Abacavir|
219215429|NCT00001968|DRUG|Lamivudine|
219215430|NCT04316936|DRUG|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
219215431|NCT04316936|DRUG|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
219215432|NCT04316936|DRUG|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
219215433|NCT04316936|DRUG|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
219215434|NCT00804219|BIOLOGICAL|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
219088411|NCT02913664|BEHAVIORAL|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
219088412|NCT03877458|OTHER|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
219088413|NCT03877458|OTHER|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
219088414|NCT03877458|OTHER|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
219215435|NCT02854241|PROCEDURE|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
219215436|NCT02854241|PROCEDURE|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
219215437|NCT02854241|PROCEDURE|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
219215438|NCT01290003|DRUG|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
219215439|NCT00188045|DRUG|Propranolol - Spironolactone|
219215440|NCT00145587|PROCEDURE|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
219215441|NCT00145587|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
219215442|NCT00145587|DRUG|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
219215443|NCT01750684|DRUG|AC105|
219215444|NCT01750684|OTHER|Placebo|
219088415|NCT06213532|BEHAVIORAL|Smoking Cessation Intervention|Multimedia program administered either remotely or in person
219088416|NCT06213532|OTHER|Saliva Collection|Saliva samples will be collected from each participant
219088417|NCT06213532|OTHER|Survey Administration|Ancillary studies
219088418|NCT05571293|DRUG|Botensilimab|Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
219088419|NCT05571293|DRUG|Balstilimab|Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
219088420|NCT06205342|DRUG|Mesenchymal Stem Cells|Autologous bone marrow derived MSCs
219088421|NCT06205342|OTHER|Other: Placebo|Control
219215445|NCT00702884|DRUG|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
219215446|NCT02185794|DRUG|Voxilaprevir|Voxilaprevir tablets administered orally once daily
219215447|NCT02185794|DRUG|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
219215448|NCT02185794|DRUG|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
219088422|NCT04639388|BEHAVIORAL|neuropsychological testing, questionnaires and experimental tasks|Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
219088423|NCT03628287|OTHER|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
219088424|NCT03628287|OTHER|Original Care Coordination Program|Original Care Coordination
219088425|NCT04237753|BEHAVIORAL|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
219088426|NCT04237753|BEHAVIORAL|MyHealtheBladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
219088427|NCT05130359|DIETARY_SUPPLEMENT|Placebo|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
219215449|NCT04407884|DEVICE|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
219215450|NCT00428805|BEHAVIORAL|classroom curriculum|"classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
219215451|NCT00428805|BEHAVIORAL|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
219215452|NCT00428805|BEHAVIORAL|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
219088428|NCT05130359|DIETARY_SUPPLEMENT|Banana peel extract|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
219215453|NCT00428805|BEHAVIORAL|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
219215454|NCT00428805|BEHAVIORAL|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
219215455|NCT00428805|BEHAVIORAL|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
219215456|NCT00428805|BEHAVIORAL|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
219215457|NCT01092416|DEVICE|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
219088429|NCT05905302|OTHER|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
219088430|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
219215458|NCT02877641|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219215459|NCT02877641|OTHER|Laboratory Biomarker Analysis|Correlative studies
219215460|NCT02877641|DIETARY_SUPPLEMENT|Multivitamin|Given PO
219215461|NCT02877641|OTHER|Placebo|Given PO
219215462|NCT02877641|OTHER|Questionnaire Administration|Ancillary studies
219215463|NCT05465018|DEVICE|Happy Flow / Baseline|Baseline (without make-up or mask)
219215464|NCT05465018|DEVICE|Make-up|To test device on participant who is wearing facial make-up
219215465|NCT05465018|DEVICE|Sunglasses|To test device on participant who is wearing sunglasses
219088431|NCT06246396|DRUG|Placebo|Placebo
219088432|NCT05830162|DRUG|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
219088433|NCT05830162|DRUG|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
219088434|NCT00934284|OTHER|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
219088435|NCT00934284|OTHER|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
219088436|NCT03587662|DRUG|Doxorubicin|Given IV
219215466|NCT05465018|DEVICE|Face mask|To test device on participant who is wearing a facial mask
219215467|NCT05465018|DEVICE|Minimum requirements camera|To test the minimum requirements of the camera
219088437|NCT03587662|DRUG|Doxorubicin Hydrochloride|Given IV
219088438|NCT03587662|DRUG|Gemcitabine|Given IV
219088439|NCT03587662|DRUG|Gemcitabine Hydrochloride|Given IV
219215468|NCT05465018|DEVICE|Worst case hardware|To test if software still works with an older smartphone
219215469|NCT05465018|DEVICE|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
219215470|NCT05465018|DEVICE|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
219215471|NCT04046159|DRUG|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
219088440|NCT03587662|DRUG|Ixazomib|Given PO
219088441|NCT03587662|DRUG|Ixazomib Citrate|Given PO
219088442|NCT05163522|DRUG|VH4004280|VH4004280 will be administered.
219088443|NCT05163522|DRUG|Placebo|Placebo will be administered.
219088444|NCT05163522|DRUG|Midazolam|Midazolam will be administered
219088445|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
219088446|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
219215472|NCT04046159|RADIATION|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
219215473|NCT03916341|OTHER|EC with nicotine|Use an EC with nicotine for up to 30 minutes
219215474|NCT03916341|OTHER|EC without nicotine|Use an EC without nicotine for up to 30 minutes
219215475|NCT03916341|OTHER|control|sham control
219215476|NCT03916341|OTHER|TC with nicotine (own brand)|smoke a TC
219215477|NCT03916341|OTHER|research TC with very low level nicotine|smoke a research TC with very low level nicotine
219215478|NCT04214756|PROCEDURE|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
219215479|NCT00570388|DRUG|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
219215480|NCT02326181|DEVICE|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
219088447|NCT05365490|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
219088448|NCT01853891|OTHER|dim light at night|
219088449|NCT03599752|DRUG|Chemotherapy|Receive chemotherapy
219088450|NCT03599752|PROCEDURE|Metastasectomy|Undergo pulmonary metastasectomy
219088451|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
219088452|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
219088453|NCT06492278|BEHAVIORAL|SMART-3RP|The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
219088454|NCT06492278|BEHAVIORAL|Health Education Program|This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
219215481|NCT02326181|DEVICE|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
219215482|NCT00366249|DRUG|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
219215483|NCT00366249|DRUG|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
219215484|NCT04383067|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
219215485|NCT04383067|DRUG|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
219215486|NCT03188341|OTHER|vascular surgery procedure|"* an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
219215487|NCT05600387|DRUG|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
219215488|NCT03239301|PROCEDURE|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
219215489|NCT03239301|PROCEDURE|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
219215490|NCT00777049|DRUG|Panobinostat|Hard gelatine capsule - 5mg and 20mg
219215491|NCT00051584|DRUG|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
219215492|NCT00051584|DRUG|Gemzar (Gemcitabine)|
219088455|NCT05091268|BEHAVIORAL|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
219088456|NCT06017219|DIETARY_SUPPLEMENT|spermidine|spermidine
219088457|NCT06437782|OTHER|Questionnaire completion|HLQ (Health Literacy questionnaire) will be completed by all included patients once.
219215493|NCT02765594|DRUG|Hydroxychloroquine Sulfate|200mg bid
219215494|NCT02765594|DRUG|Valsartan|160mg qd
219215495|NCT01912300|BEHAVIORAL|experimental condition: Passvice Video game; Avtive Video game; Exercise|
219215496|NCT01310166|DRUG|Fingolimod|
219215497|NCT00009932|DRUG|cisplatin|
219215498|NCT00009932|DRUG|fenretinide|
219215499|NCT00009932|DRUG|paclitaxel|
219215500|NCT01185600|BIOLOGICAL|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
219215501|NCT01185600|BIOLOGICAL|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
219215502|NCT03673566|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
219215503|NCT05749224|DIAGNOSTIC_TEST|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
219215504|NCT05089266|DRUG|CAR T cells|αPD1-MSLN-CAR T Cells
219215505|NCT04955951|DEVICE|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
219215506|NCT04955951|DRUG|Topical corticosteroid ointment|corticosteroid 1 %.
219215507|NCT03281603|DEVICE|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
219215508|NCT01540500|DRUG|Tasimelteon|5.66 mg dose on Day 1 and Day 8
219088458|NCT03818087|BEHAVIORAL|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
219088459|NCT03412396|DRUG|Apalutamide|Given PO
219088460|NCT03412396|OTHER|Quality-of-Life Assessment|Ancillary studies
219215509|NCT01540500|DRUG|Fluvoxamine|50 mg Dose on Days 2-8
219215510|NCT00739934|DRUG|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
219088461|NCT03412396|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219088462|NCT06164639|BEHAVIORAL|aspiration|Based on whether the patient meets the diagnosis of aspiration pneumonia.
219088463|NCT06164639|DIAGNOSTIC_TEST|bronchial alveolar fluid|Performing bronchoscopy.
219215511|NCT03577106|DEVICE|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
219088464|NCT06164639|DEVICE|EIT V/Q test|Local pulmonary ventilation and perfusion are measured by electrical impedance tomography (EIT). For perfusion imaging, 10 ml of 5% saline is injected as a central venous bolus. The matching of ventilation and perfusion reveals intrapulmonary shunting.
219088465|NCT06164639|OTHER|Nitric oxide inhalation|According to the physician's judgment and the family members' consent, the patient is administered nitric oxide inhalation at a dosage of 20-30 parts per million (ppm).
219088466|NCT05950646|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
219088467|NCT05950646|DRUG|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
219088468|NCT05950646|DRUG|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
219088469|NCT05921227|BEHAVIORAL|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
219088470|NCT05166304|DRUG|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
219088471|NCT05166304|DRUG|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
219088472|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
219088473|NCT06142656|DRUG|Metformin Hydrochloride tablet|Metformin Hydrochloride 850 mg oral tablet
219215512|NCT06017700|BEHAVIORAL|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
219215513|NCT06017700|BEHAVIORAL|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
219215514|NCT00635700|DRUG|ziprasidone|20-160 mg/d
219215515|NCT00635700|DRUG|placebo|placebo
219215516|NCT02315118|DRUG|T-cell therapy + Rituximab + IL-2|"* T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients"
219215517|NCT00278135|DIETARY_SUPPLEMENT|DHA (nutritional supplement) or placebo|oral 900mg/day
219215518|NCT06822933|DEVICE|Urika|Self-management application for patients with gout receiving urate lowering therapy. The 'Urika'-app includes films and written information about gout and gout management, reminders for blood-tests and medication, a visualisation of serum urate level over time, and an algorithm to calculate the medication drug-dose escalation. The app also includes a chat function and a secure web-platform for remote monitoring and communication between the participant and nurse. The study nurse will log into the web-platform on weekdays to check patient-reported side effects, adherence to medication, the current dose, and the need for a renewal of urate lowering therapy prescription.
219215519|NCT06822933|OTHER|Nurse-led follow-up with telephone consultations.|Nurse-led follow-up in specialist healthcare with monthly blood tests and telephone consultations until the treatment target is reached.
219215520|NCT03918096|OTHER|Questionnaire|Questionnaire to the parents after the hospital discharge
219215521|NCT02191670|DRUG|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
219215522|NCT01806207|DEVICE|Durolane injection|
219215523|NCT01806207|OTHER|Saline injection|
219215524|NCT00347061|DRUG|afuzosin|
219215525|NCT00893698|PROCEDURE|bilateral allotransplantation|bilateral allotransplantation of upper limbs
219088474|NCT06142656|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG oral tablets
219088475|NCT05488626|DEVICE|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
219088476|NCT05488626|DEVICE|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
219088477|NCT05488626|DRUG|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
219088478|NCT05488626|DRUG|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
219088479|NCT00542438|BEHAVIORAL|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
219088480|NCT00542438|BEHAVIORAL|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
219088481|NCT01371630|BIOLOGICAL|Blinatumomab|Given CIVI
219088482|NCT01371630|DRUG|Cyclophosphamide|Given IV
219088483|NCT01371630|DRUG|Cytarabine|Given IT and IV
219088484|NCT01371630|DRUG|Dexamethasone|Given IV or PO
219088485|NCT01371630|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219088486|NCT01371630|OTHER|Laboratory Biomarker Analysis|Correlative studies
219088487|NCT01371630|DRUG|Mercaptopurine|Given PO
219088488|NCT01371630|DRUG|Methotrexate|Given IT, IV, and PO
219215526|NCT05197127|DEVICE|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
219215527|NCT06517914|DRUG|YH35995|Oral administration of YH35995
219215528|NCT06517914|DRUG|Placebo|Oral administration of Placebo
219215529|NCT01567787|RADIATION|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
219088489|NCT01371630|DRUG|Prednisone|Given PO
219088490|NCT01371630|BIOLOGICAL|Rituximab|Given IV
219088491|NCT01371630|DRUG|Vincristine|Given IV
219088492|NCT00796380|DRUG|Xingnaojing|injection
219088493|NCT00406133|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
219215530|NCT01567787|RADIATION|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
219215531|NCT05625230|BEHAVIORAL|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
219215532|NCT05625230|BEHAVIORAL|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
219215533|NCT04237857|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
219215534|NCT06073184|DRUG|Mounjaro|Weekly subcutaneous injection of 2.5mg tirzepatide at baseline with dose escalation by 2.5mg every 4 weeks to reach 15mg or the maximum tolerated dose, by Week 20
219215535|NCT06073184|DRUG|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
219215536|NCT04551651|DEVICE|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
219215537|NCT04551651|DEVICE|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
219215538|NCT06432790|BEHAVIORAL|CHAMPION|The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).
219215539|NCT06633926|BEHAVIORAL|Nutrition Education|Given nutrition education
219088494|NCT05288660|DRUG|ALXN1210|All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
219088495|NCT05288660|DRUG|Placebo|All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
219088496|NCT04899245|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
219088497|NCT04880395|DRUG|Intervention Arm: dolutegravir/lamivudine|1 pill QD
219088498|NCT04880395|DRUG|Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)|1 pill of each QD
219088499|NCT01087554|DRUG|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
219088500|NCT01087554|DRUG|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
219088501|NCT01087554|DRUG|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
219088502|NCT01087554|DRUG|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
219088503|NCT05082090|PROCEDURE|Spinal Surgery|Implanted with Orthofix Spinal products
219088504|NCT03088267|DRUG|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
219088505|NCT03088267|DRUG|Placebo extended-release oral suspension|6, 7 or 8 mL PO
219088506|NCT03744273|PROCEDURE|breast capsule biopsy|
219088507|NCT01895972|DRUG|Latanoprostene bunod|
219215540|NCT06633926|BEHAVIORAL|Lifestyle Counseling|Given lifestyle recommendations
219215541|NCT06633926|OTHER|Yoga|Participate in yoga
219215542|NCT06633926|PROCEDURE|Marma therapy|Participate in marma therapeutic touch
219215543|NCT06633926|OTHER|Educational Intervention|Attend online HEI sessions
219215544|NCT06633926|OTHER|Quality of Life Questionnaire Administration|Self-reported questionnaires are given to participants to complete
219215545|NCT05775757|RADIATION|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
219215546|NCT06202378|DRUG|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
219215547|NCT06202378|DRUG|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
219088508|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
219215548|NCT06202378|DRUG|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
219088509|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
219088510|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
219215549|NCT04825379|DEVICE|bioactive composite|Cention N
219215550|NCT04825379|DEVICE|posterior composite|G-ænial Posterior
219215551|NCT03703440|OTHER|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
219215552|NCT03703440|OTHER|Control arm|Usual diabetes care, every 3-month for 12 months
219215553|NCT06117085|DEVICE|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
219215554|NCT05402384|DRUG|AVTX-801|"Medical grade D-galactose~dosage:2.0 g/kg/day"
219215555|NCT05402384|DRUG|Placebo|Matching placebo
219215556|NCT06797999|BIOLOGICAL|Antibody-drug conjugate (ADC)|ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
219088511|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
219088512|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
219088513|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
219088514|NCT06450834|DEVICE|Ostene|Soluble Bone Hemostasis Implant Material
219088515|NCT05893927|OTHER|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
219088516|NCT06061497|OTHER|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
219088517|NCT06061497|BEHAVIORAL|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
219088518|NCT05750628|DRUG|INE963|oral INE963
219088519|NCT05750628|DRUG|KAE609 (Cipargamin)|oral KAE609 (Cipargamin)
219088520|NCT05750628|DRUG|SoC (Coartem)|SoC (Coartem)
219215557|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
219215558|NCT05695196|BIOLOGICAL|nasal microbiota transplant (NMT)|nasal microbiota transplant
219215559|NCT05695196|BIOLOGICAL|Placebo|Placebo sterile saline
219215560|NCT06397118|BEHAVIORAL|Maternal Nutrition Education|Community Health Worker delivered Maternal Nutrition Education
219215561|NCT06397118|BEHAVIORAL|Standard Care|Standard care in the sickle cell disease (SCD) clinic
219088521|NCT05750628|DRUG|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
219088522|NCT05718544|DRUG|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
219088523|NCT05718544|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
219088524|NCT05718544|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
219088525|NCT03664869|DRUG|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
219088526|NCT03664869|DRUG|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
219088527|NCT04631263|DEVICE|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
219215562|NCT04801823|OTHER|Home introduction|Cautious, graded introduction of individual tree nuts
219088528|NCT03057353|DEVICE|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
219088529|NCT04414449|OTHER|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
219088530|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
219215563|NCT04801823|OTHER|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
219088531|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
219088532|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
219088533|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
219088534|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
219088535|NCT01570868|DRUG|Ponatinib|Starting dose: 45 mg by mouth once daily.
219088536|NCT02453581|DRUG|OZ439|OZ439 Powder for Oral Suspension
219088537|NCT04856722|PROCEDURE|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
219088538|NCT04856722|PROCEDURE|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
219088539|NCT04856722|PROCEDURE|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
219088540|NCT06231862|DIAGNOSTIC_TEST|SeptiCyte (various)|mRNA expression scores
219088541|NCT01217931|DRUG|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
219088542|NCT01217931|DRUG|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
219088543|NCT01217931|DRUG|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
219088544|NCT02021838|OTHER|Lethality Assessment Program|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services.
219088545|NCT02021838|OTHER|Domestic Violence High Risk Team|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services and a team who monitors the clinical and criminal justice progress.
219088546|NCT04895865|BEHAVIORAL|RPE-based load and repetition number selection|Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
219088547|NCT04895865|BEHAVIORAL|Predetermined load and number of repetitions|Trainees predetermine the load and perform ten repetitions per set and exercise
219088548|NCT05872568|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|The recommended dose range is 360 to 720mg,bid
219088549|NCT01072461|BEHAVIORAL|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
219215564|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
219215565|NCT03241940|DRUG|Cyclophosphamide|Given IV
219088550|NCT01072461|BEHAVIORAL|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
219088551|NCT01072461|BEHAVIORAL|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
219088552|NCT05822115|DEVICE|Reduction of breast hypertrophy by means of laparoscopic|"The research procedure is a breast reduction performed by means of laparoscopic surgery.~The project consists of removing a disc from the breast at the level of the base, thus causing peripheral skin slackening of 2 to 3 cm but circular. Both breasts are usually operated on at the same time. In case of asymmetry, only one side will be treated."
219088553|NCT01156948|DRUG|misoprostol|400ug vaginally the day before surgery
219088554|NCT01156948|DRUG|oral misoprostol|400ug misoprostol orally the day before the surgery
219088555|NCT04321226|DEVICE|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
219215566|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
219215567|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
219215568|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
219215569|NCT06639035|OTHER|External oblique intercostal plane block|The external oblique intercostal plane block is applied to the patients at the end of the surgery.
219215570|NCT06639035|OTHER|intavenous tramadol|Intravenous tramadol will be administered with patient-controlled analgesia
219215571|NCT05065957|DRUG|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
219215572|NCT05065957|DRUG|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
219362058|NCT04448990|DEVICE|TENS eco 2 Transauricular vagal nerve stimulation|"Auricular electrical stimulation will be applied bilaterally using Transcutaneous Electrical Nerve Stimulation device TENS eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany).~tVNS will be applied bilaterally using electrical square impulses delivered in blocks of 9 impulses with a frequency of 100 Hz and a pulse width of 200 μs emitted twice per second resulting in mixed frequency pattern of 100 Hz/2 Hz with the current intensity, that will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved."
219362059|NCT04448990|DEVICE|Sham TENS eco 2|Sham
219088556|NCT00003532|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219088557|NCT02515279|DRUG|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
219088558|NCT02515279|DRUG|Ribavirin|1000-1600 mg day orally for 48 weeks.
219088559|NCT02429765|DRUG|ACL/FOR|
219088560|NCT02429765|DRUG|Placebo|
219215573|NCT05945849|BIOLOGICAL|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
219215574|NCT06457971|DEVICE|Robotic Ventral Hernia Repair|The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
219215575|NCT01342367|DRUG|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
219215576|NCT01342367|DRUG|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
219215577|NCT01342367|DRUG|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
219215578|NCT01342367|RADIATION|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
219215579|NCT03822988|OTHER|no intervention, only complete a survey|we will ask patients to answer to a survey
219215580|NCT03484988|DIETARY_SUPPLEMENT|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219215581|NCT03484988|DIETARY_SUPPLEMENT|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219215582|NCT03484988|DIETARY_SUPPLEMENT|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219215583|NCT03971851|OTHER|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
219215584|NCT05484648|DRUG|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
219362060|NCT01653041|DRUG|Everolimus|
219362061|NCT00654498|DRUG|Pramipexole|
219362062|NCT00654498|DRUG|Placebo|
219362063|NCT02795078|DRUG|conservative treatment|
219088561|NCT01417429|DRUG|Galantamine|8mg/a day or placebo
219088562|NCT01417429|DRUG|IV Nicotine|1.0 mg/70 kg of nicotine against saline
219088563|NCT03528018|DEVICE|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
219362064|NCT02795078|PROCEDURE|Aneurysms clipping|
219088564|NCT03528018|OTHER|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
219088565|NCT00226239|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
219088566|NCT00226239|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
219088567|NCT00226239|DRUG|Cetuximab|Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
219088568|NCT00226239|PROCEDURE|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
219088569|NCT02808624|DRUG|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
219088570|NCT03756428|PROCEDURE|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
219088571|NCT03756428|PROCEDURE|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
219088572|NCT01800968|DRUG|Liraglutide|Active Drug
219088573|NCT01800968|DRUG|Placebo|Placebo
219088574|NCT02865720|DRUG|CINRYZE 500 U|IV infusion administered twice weekly
219088575|NCT02865720|DRUG|CINRYZE 1000 U|IV infusion administered twice weekly
219215585|NCT05484648|DRUG|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
219215586|NCT00002156|DRUG|Fomivirsen sodium|
219215587|NCT00002156|DRUG|Ganciclovir|
219215588|NCT03035851|BEHAVIORAL|Aerobic exercise|
219215589|NCT03035851|BEHAVIORAL|Stretch and Strength|
219215590|NCT05766319|DEVICE|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)"
219215591|NCT05766319|DEVICE|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
219215592|NCT05766319|DEVICE|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
219215593|NCT05869617|OTHER|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
219215594|NCT05869617|OTHER|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
219215595|NCT04699058|DIAGNOSTIC_TEST|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
219215596|NCT00515814|DEVICE|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
219215597|NCT05403476|DRUG|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
219215598|NCT05403476|DRUG|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
219215599|NCT06108024|DRUG|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
219215600|NCT06108024|DRUG|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
219215601|NCT02840929|PROCEDURE|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
219215602|NCT02840929|DRUG|Esomeprazole|
219215603|NCT04670887|PROCEDURE|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
219215604|NCT04670887|PROCEDURE|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
219215605|NCT01300975|DRUG|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
219088576|NCT05362565|BIOLOGICAL|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
219088577|NCT03144895|PROCEDURE|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
219088578|NCT03403868|DIAGNOSTIC_TEST|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
219088579|NCT03749564|BEHAVIORAL|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
219088580|NCT03749564|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
219088581|NCT03749564|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
219088582|NCT03749564|BEHAVIORAL|Extended SMT|Additional 6 SMT sessions provided
219088583|NCT04834466|BEHAVIORAL|Pain Level experience during orthodontic treatment|A questionnaire was given to patients who have started their orthodontic treatment to assess their pain level experience
219088584|NCT05502705|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
219088585|NCT05502705|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
219088586|NCT06057376|OTHER|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
219088587|NCT06057376|OTHER|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
219088588|NCT06496217|DRUG|MBX 2109|Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)
219215606|NCT01300975|PROCEDURE|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
219088589|NCT06496217|DRUG|MBX 2109|Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)
219088590|NCT06496217|DRUG|MBX 2109|Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis
219088591|NCT06496217|DRUG|MBX 2109|Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
219088592|NCT02085148|DRUG|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
219215607|NCT01300975|DRUG|placebo cream|topical emollient crean 3 times a day during 21 days
219215608|NCT00640159|DRUG|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
219215609|NCT00076648|DRUG|Poly SFH-P Injection|
219215610|NCT00212251|BEHAVIORAL|moderate exercise and healthy, low-fat diet|
219215611|NCT01500200|DRUG|ALKS 5461|Two active tablets, given daily
219088593|NCT02085148|DRUG|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
219215612|NCT01500200|DRUG|Placebo|Two placebo tablets, given daily
219215613|NCT03053505|BIOLOGICAL|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
219215614|NCT03053505|DRUG|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
219215615|NCT03205072|DEVICE|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
219215616|NCT01718600|BEHAVIORAL|Neuropsychological testing|
219215617|NCT00621673|DRUG|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
219362065|NCT02795078|PROCEDURE|Interventional embolization forAneurysms|
219362066|NCT02795078|PROCEDURE|stenting for stenosis|
219362067|NCT04830267|DRUG|Camrelizumab|Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
219215618|NCT04037813|PROCEDURE|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
219215619|NCT04860505|DRUG|Doxycycline|Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
219215620|NCT04860505|DRUG|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
219215621|NCT04441775|OTHER|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
219215622|NCT02741505|DEVICE|Actigraph|Participants will be asked to wear an actigraph
219215623|NCT04812249|OTHER|Clinical assessment|Clinical assessment and follow up of oral feeding ability
219215624|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 40 mg every other week, subcutaneous
219215625|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 80 mg every other week, subcutaneous
219215626|NCT02340013|DRUG|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
219215627|NCT03547102|DIETARY_SUPPLEMENT|Cherry concentrate|
219215628|NCT03547102|DIETARY_SUPPLEMENT|Placebo concentrate|
219215629|NCT00198419|DRUG|Vitrase|
219215630|NCT02491489|OTHER|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
219215631|NCT01940107|OTHER|evaluations|Only evaluations
219215632|NCT01940107|PROCEDURE|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
219215633|NCT03066609|DRUG|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
219215634|NCT03066609|DRUG|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
219215635|NCT03066609|DRUG|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
219215636|NCT02551237|RADIATION|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
219215637|NCT02551237|DRUG|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
219215638|NCT02551237|RADIATION|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
219215639|NCT02568306|DRUG|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
219215640|NCT02568306|DRUG|placebo|Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
219215641|NCT01465152|DRUG|metformin|Adminstered orally during the three main meals for 24 weeks
219215642|NCT01465152|DRUG|repaglinide|Administered orally before the three main meals for 24 weeks
219215643|NCT04004494|OTHER|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
219215644|NCT06085729|DRUG|ADI-PEG 20|Given by Injection
219215645|NCT06085729|DRUG|Cabazitaxel|Given by IV (vein)
219215646|NCT06085729|DRUG|Carboplatin|Given by IV (vein)
219215647|NCT03855293|PROCEDURE|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
219215648|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
219215649|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
219215650|NCT04968886|DIAGNOSTIC_TEST|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
219215651|NCT06000202|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.
219215652|NCT06000202|DEVICE|Sham|Er:YAG laser is applied with sham handpiece.
219215653|NCT04512456|BEHAVIORAL|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
219215654|NCT00135200|DRUG|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
219215655|NCT02389855|PROCEDURE|NeuroBlate® System Therapy|
219215656|NCT01404585|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
219215657|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
219215658|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
219215659|NCT05715502|RADIATION|brachytherapy|Radiation: focal low dose rate or high dose rate brachytherapy for the lesion with appropriate margin, defined in magnetic resonance or positron emission tomography All recruited participants will be treated with interstitial brachytherapy for local recurrence of prostate cancer. The low dose rate of brachytherapy is used with a total dose of 145 Gy in the clinical target volume for participants after hypofractionated radiotherapy, a high dose rate brachytherapy as monotherapy or boost with external beam radiotherapy The high dose rate brachytherapy with two fractions of 13 Gy in the clinical target volume with a 3 to 14 days break is used after primary low dose rate brachytherapy or external beam radiotherapy alone.
219215660|NCT05357911|DRUG|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
219215661|NCT06518772|OTHER|hot application|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.
219215662|NCT00115089|DRUG|R926112|
219215663|NCT00115089|DRUG|Beclomethasone dipropionate|
219215664|NCT01595789|DRUG|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
219215665|NCT01595789|DRUG|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
219088594|NCT02085148|DRUG|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
219088595|NCT05808049|OTHER|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
219088596|NCT05808049|OTHER|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
219088597|NCT04864574|OTHER|Garden installation|"Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis."
219088598|NCT02899780|DEVICE|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
219088599|NCT05440370|DEVICE|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
219088600|NCT05440370|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
219215666|NCT02099123|DRUG|Atorvastatin|Atorvastatin 20 mg tablet
219215667|NCT02099123|DRUG|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
219215668|NCT03477305|BEHAVIORAL|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
219215669|NCT05783791|DIAGNOSTIC_TEST|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
219215670|NCT00409799|DRUG|I-0401 (a new bone graft substitute)|1 time application
219215671|NCT02379936|DEVICE|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
219215672|NCT02379936|PROCEDURE|Traditional evaluation|Traditional way of evaluation
219215673|NCT02379936|DEVICE|iPhone 4S|
219215674|NCT02477514|DRUG|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
219215675|NCT02477514|DRUG|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
219215676|NCT02477514|DRUG|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
219362068|NCT04830267|RADIATION|Stereotactic body radiotherapy|Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).
219362069|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection before vitrectomy
219088601|NCT03019926|BIOLOGICAL|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
219088602|NCT03044964|DRUG|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
219088603|NCT03044964|DRUG|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
219088604|NCT01422408|DRUG|Fluocinonide Cream|Given topically
219088605|NCT01422408|PROCEDURE|Management of Therapy Complications|Receive fluocinonide cream
219088606|NCT01422408|OTHER|Questionnaire Administration|Ancillary studies
219215677|NCT05216796|BEHAVIORAL|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
219088607|NCT03185481|DRUG|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
219088608|NCT03185481|DRUG|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
219088609|NCT03185481|DRUG|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
219088610|NCT03185481|DRUG|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
219088611|NCT03185481|DRUG|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
219088612|NCT03185481|DRUG|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
219215678|NCT01854151|OTHER|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
219215679|NCT01089335|PROCEDURE|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
219215680|NCT05529420|OTHER|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
219215681|NCT04845386|DEVICE|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
219215682|NCT04845386|DEVICE|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
219215683|NCT04845386|DEVICE|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
219215684|NCT04845386|DEVICE|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
219215685|NCT04845386|DEVICE|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
219088613|NCT03185481|DRUG|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
219088614|NCT03185481|DRUG|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
219088615|NCT04540705|BIOLOGICAL|Nivolumab|Specified dose on specified days
219088616|NCT04540705|DRUG|Axitinib|Specified dose on specified days
219088617|NCT04540705|DRUG|Cabozantinib|Specified dose on specified days
219088618|NCT03051971|DEVICE|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
219088619|NCT03051971|DEVICE|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
219088620|NCT04492527|BEHAVIORAL|Telehealth coaching sessions|Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
219088621|NCT03598413|DIETARY_SUPPLEMENT|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
219215686|NCT04244058|DRUG|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
219215687|NCT04244058|DRUG|NMDA blocker|NMDA blocker
219215688|NCT00930306|DRUG|AZD2066|12 doses, Given as capsule, 2 mg \& 8 mg
219215689|NCT00930306|DRUG|Caffeine|2 doses, Given as Tablet, 2x50 mg
219215690|NCT00930306|DRUG|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
219215691|NCT00930306|DRUG|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
219215692|NCT00930306|DRUG|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
219215693|NCT05142046|DRUG|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
219215694|NCT05769244|OTHER|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
219215695|NCT03717467|DRUG|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
219215696|NCT03717467|DRUG|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
219088622|NCT02561494|DRUG|Nefopam|
219088623|NCT02561494|DRUG|Saline|
219088624|NCT05684627|DIETARY_SUPPLEMENT|Fast mimicking diet group|Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.
219088625|NCT05684627|PROCEDURE|Normal diet group|Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
219088626|NCT01950949|OTHER|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
219088627|NCT01398280|DRUG|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
219088628|NCT01398280|DRUG|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
219088629|NCT05170165|OTHER|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
219088630|NCT00057551|BEHAVIORAL|Brief Supportive Psychotherapy|brief supportive psychotherapy
219088631|NCT00057551|BEHAVIORAL|CBASP|psychotherapy developed for chronic depression
219088632|NCT00057551|DRUG|Medication Only|antidepressant medication
219215697|NCT04124432|DRUG|Cannabis|Cannabis will be smoked
219215698|NCT04124432|DRUG|Nicotine|Nicotine will be smoked or vaporized
219215699|NCT01237067|DRUG|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
219088633|NCT00801008|BEHAVIORAL|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
219088634|NCT00204295|DRUG|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
219088635|NCT04037501|OTHER|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
219088636|NCT02680873|OTHER|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
219088637|NCT03221621|PROCEDURE|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
219088638|NCT03221621|DRUG|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
219215700|NCT01237067|DRUG|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
219215701|NCT02311452|DEVICE|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
219215702|NCT00523419|DRUG|Pemetrexed|500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
219215703|NCT05719519|PROCEDURE|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
219215704|NCT02876016|DEVICE|functional MRI|locate the cerebral bases in functional imaging
219215705|NCT02162225|DRUG|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
219215706|NCT02379260|OTHER|Interview with a sociologist|
219215707|NCT06054841|BEHAVIORAL|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
219215708|NCT06054841|OTHER|Control|No deviation from standard discharge education
219215709|NCT01218009|DRUG|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
219215710|NCT01218009|DRUG|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
219215711|NCT04929106|DEVICE|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
219215712|NCT01630824|OTHER|Structured education program|structured education program after kidney transplantation
219215713|NCT05850975|OTHER|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
219215714|NCT05850975|OTHER|reading about anxiety|Participants are given an educational text to read about anxiety.
219215715|NCT02040363|PROCEDURE|Muscular biopsy|
219215716|NCT02040363|OTHER|5-10 weeks sport training|
219215717|NCT02492412|DRUG|HE 10|
219088639|NCT03330223|DEVICE|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
219088640|NCT02813837|BIOLOGICAL|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
219088641|NCT03531320|DRUG|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
219088642|NCT01846793|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
219215718|NCT02492412|DRUG|Restasis|
219215719|NCT03003286|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
219215720|NCT03003286|BEHAVIORAL|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
219215721|NCT02095717|DRUG|Curcumin|
219215722|NCT02095717|DRUG|Placebo|
219215723|NCT02095717|DRUG|Taxotere|
219215724|NCT06512181|OTHER|Conservative/Expectant Management|At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
219215725|NCT02540031|DRUG|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
219215726|NCT02540031|DRUG|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
219215727|NCT02631369|DEVICE|Heidelberg Spectralis OCT device|
219088643|NCT05099926|BEHAVIORAL|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
219088644|NCT02362048|DRUG|ACP-196|
219088645|NCT02362048|DRUG|ACP-196 in combination with pembrolizumab|
219088646|NCT00644397|DEVICE|95-degree Angled Blade Plate|
219088647|NCT00644397|DEVICE|4.5mm Condylar Locking Plate|
219088648|NCT03609567|OTHER|Aromatherapy|Aromatherapy using essential oils
219215728|NCT00336349|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
219215729|NCT04661306|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
219215730|NCT03930940|DEVICE|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
219215731|NCT03930940|OTHER|Regular treatment|Regular treatment is based on associated guidelines for ICH.
219215732|NCT03170882|DRUG|Ixazomib|Ixazomib capsules
219215733|NCT03170882|DRUG|Pomalidomide|Pomalidomide capsules
219215734|NCT03170882|DRUG|Dexamethasone|Dexamethasone tablets
219088649|NCT03609567|OTHER|Placebo|Aromatherapy using odorless placebo oil
219088650|NCT00269035|DRUG|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
219088651|NCT00269035|DRUG|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
219088652|NCT01896882|OTHER|Sodium restriction|
219088653|NCT04365595|OTHER|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
219088654|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
219088655|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
219088656|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
219088657|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
219088658|NCT00724152|BEHAVIORAL|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
219088659|NCT00724152|BEHAVIORAL|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
219088660|NCT01417507|PROCEDURE|cognitive assessment|Undergo neurocognitive assessment
219215735|NCT02715518|DEVICE|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm"
219215736|NCT05911867|OTHER|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
219215737|NCT05911867|OTHER|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
219215738|NCT05911867|OTHER|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
219362070|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection after vitrectomy
219362071|NCT02058602|OTHER|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
219362072|NCT00168610|DRUG|Vitamin A|
219362073|NCT02004002|BEHAVIORAL|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
219362074|NCT02004002|BEHAVIORAL|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
219088661|NCT01417507|PROCEDURE|magnetic resonance imaging|Undergo MRI
219088662|NCT01417507|OTHER|laboratory biomarker analysis|Correlative studies
219088663|NCT01417507|OTHER|questionnaire administration|Ancillary studies
219088664|NCT01417507|PROCEDURE|quality-of-life assessment|Ancillary studies
219088665|NCT01426971|DRUG|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
219088666|NCT01426971|DRUG|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
219088667|NCT00050180|DRUG|Midazolam|
219088668|NCT00050180|DRUG|Indinavir|
219088669|NCT00050180|DRUG|Saquinavir|
219088670|NCT01753921|OTHER|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
219088671|NCT01753921|OTHER|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
219088672|NCT01753921|DEVICE|MRI|MRI study of the brain will be performed at t=3months.
219215739|NCT00949364|DRUG|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
219215740|NCT06308406|DRUG|Bevacizumab； HRS-1167|Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
219088673|NCT00227617|BIOLOGICAL|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
219088674|NCT00227617|DRUG|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
219088675|NCT00227617|DRUG|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
219088676|NCT00227617|DRUG|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
219215741|NCT00622700|DRUG|Teriflunomide|Film-coated tablet Oral administration
219088677|NCT05089617|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
219088678|NCT03266770|DEVICE|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
219088679|NCT04370925|PROCEDURE|Radical colectomy|Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
219088680|NCT04370925|PROCEDURE|HIPEC|HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.
219088681|NCT04370925|DRUG|Systemic chemotherapy|"Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable."
219088682|NCT00281710|DRUG|Methylprednisolone|
219088683|NCT04130568|DIAGNOSTIC_TEST|INO survey|Garvin's Learning organisation tool
219088684|NCT03663686|DRUG|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
219088685|NCT05938257|PROCEDURE|TMJ discopexy|Arthroscopic versus open TMJ discopexy
219088686|NCT02609165|DRUG|rhNGF 180 µg/ml eye drops solution|eye drops
219088687|NCT02609165|DRUG|vehicle eye drops|placebo
219088688|NCT05554601|BEHAVIORAL|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration
219215742|NCT00622700|DRUG|Placebo|Film-coated tablet Oral administration
219088689|NCT05554601|BEHAVIORAL|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
219088690|NCT05609084|PROCEDURE|Speech therapy|Patients will connect on an interface to pratice speech therapy
219088691|NCT05609084|PROCEDURE|Speech therapy assessment|Patients will be followed by an speech therapist
219088692|NCT04360525|OTHER|Reasons|Causes of sigmoid volvulus
219088693|NCT05741216|OTHER|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
219088694|NCT05741216|OTHER|Ocular Lubricant|Commercially available ocular lubricant
219088695|NCT04062890|DRUG|Vigabatrin Pill|Oral Vigabatrin Pill
219088696|NCT04062890|DRUG|Placebo oral tablet|Oral Placebo Pill
219088697|NCT05708755|DEVICE|Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)|Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
219215743|NCT06246890|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
219088698|NCT05708755|DIAGNOSTIC_TEST|Donor-Derived Cell-Free DNA (dd-cfDNA) Assay|Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
219088699|NCT05708755|DRUG|Valganciclovir|Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
219088700|NCT02698254|BIOLOGICAL|Bevacizumab|
219215744|NCT05508854|GENETIC|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
219088701|NCT02698254|OTHER|Quality-of-Life Assessment|Ancillary studies
219215745|NCT03766191|BEHAVIORAL|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
219215746|NCT03766191|OTHER|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
219215747|NCT04867824|DIETARY_SUPPLEMENT|Case (use of inhaled vanilla essential oil)|Use of inhaled vanilla essential oil during frenotomy for a tongue-tie
219215748|NCT04867824|DIETARY_SUPPLEMENT|Control (use of inhaled lavender essential oil)|Use of inhaled lavender essential oil during frenotomy for a tongue-tie
219215749|NCT02646618|BEHAVIORAL|Get Social|Online-delivered weight loss intervention
219215750|NCT02646618|BEHAVIORAL|Traditional|Group-delivered weight loss intervention
219215751|NCT02646618|DEVICE|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
219215752|NCT05503368|PROCEDURE|surgical treatment of vitiligo using NCES|NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
219215753|NCT00898352|PROCEDURE|regional lymph node dissection|
219215754|NCT00898352|RADIATION|radiation therapy|
219215755|NCT03896659|DRUG|Hydrocortisone Oral|Hydrocortisone 160 mg tablet
219215756|NCT03896659|DRUG|Placebo Oral Tablet|Hydrocortisone-matched Placebo tablet
219215757|NCT01299194|DRUG|ATORVASTATIN|80mg once daily for 3 months
219215758|NCT06343493|DRUG|Normal saline heated up to 50 °C|Saline heated up to 50 °C used for irrigation
219215759|NCT00236535|DRUG|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
219088702|NCT02698254|RADIATION|Radiation Therapy|Undergo radiation therapy with conventional fractionation
219215760|NCT05697705|OTHER|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
219215761|NCT05697705|OTHER|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
219215762|NCT05697705|OTHER|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
219215763|NCT05697705|OTHER|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
219215764|NCT01753999|DEVICE|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
219215765|NCT01753999|DEVICE|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
219215766|NCT00948168|DRUG|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
219215767|NCT02313675|DRUG|Acetaminophen|
219215768|NCT02313675|DRUG|Ketorolac Tromethamine|
219215769|NCT02313675|DRUG|Saline|
219215770|NCT00112034|DRUG|Methotrexate|
219088703|NCT05390970|PROCEDURE|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
219088704|NCT02935361|DRUG|Atezolizumab|Given IV
219088705|NCT02935361|DRUG|Guadecitabine|Given SC
219215771|NCT00112034|DRUG|IV methylprednisolone|
219215772|NCT06615232|BEHAVIORAL|Vaginal washing cessation|Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
219215773|NCT02190149|BIOLOGICAL|ADVATE (Antihemophilic Factor [Recombinant])|
219215774|NCT02190149|BIOLOGICAL|RIXUBIS (Coagulation Factor IX [Recombinant])|
219215775|NCT05916768|OTHER|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
219215776|NCT05916768|OTHER|usual care|symptomatic treatments
219215777|NCT00928824|DIETARY_SUPPLEMENT|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
219215778|NCT05296772|BIOLOGICAL|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
219215779|NCT05296772|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
219215780|NCT05973279|OTHER|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
219362075|NCT01032148|DRUG|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
219362076|NCT01397578|DRUG|MABT5102A|Repeating subcutaneous injection
219362077|NCT01397578|DRUG|MABT5102A|Repeating intravenous infusion
219362078|NCT01397578|DRUG|placebo|Repeating subcutaneous injection
219088706|NCT04226027|BEHAVIORAL|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
219088707|NCT02525965|PROCEDURE|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin \>1cm
219088708|NCT02525965|PROCEDURE|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin \<1cm
219088709|NCT03927469|OTHER|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
219088710|NCT00818116|DEVICE|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
219088711|NCT00913484|DRUG|Disulfiram|Disulfiram 250 mg per day
219088712|NCT00913484|DRUG|Placebo|Placebo daily
219088713|NCT00980070|DEVICE|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
219088714|NCT00980070|DEVICE|Lumbar Puncture Device|Lumbar Puncture positioner
219088715|NCT00980070|OTHER|Standard of Care|Lumbar Puncture positioner
219088716|NCT03732183|BEHAVIORAL|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
219215781|NCT05973279|OTHER|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
219215782|NCT05973279|OTHER|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
219215783|NCT02867072|PROCEDURE|Open appendectomy|
219215784|NCT02867072|PROCEDURE|Laparoscopic appendectomy|
219215785|NCT01222442|DRUG|AZD3199|Single dose, oral inhalation
219215786|NCT01222442|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
219215787|NCT01222442|OTHER|Placebo comparator|Single dose, oral inhalation
219088717|NCT00942214|DRUG|Natalizumab|300mg, IV, every 4 weeks
219088718|NCT06584864|DIAGNOSTIC_TEST|bedside ultrasound examination of the lumbar spinal canal|The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
219088719|NCT04716179|DIAGNOSTIC_TEST|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
219088720|NCT04716179|DIAGNOSTIC_TEST|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
219215788|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 100 mg/day
219088721|NCT04716179|DIAGNOSTIC_TEST|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
219088722|NCT04716179|OTHER|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
219088723|NCT01860703|DRUG|Deferiprone|Ferriprox 500 mg tablets
219088724|NCT01860703|DRUG|deferiprone matching placebo tablets|deferiprone matching placebo tablets
219088725|NCT01860703|DRUG|moxifloxacin|Active control
219088726|NCT01860703|DRUG|placebo|moxifloxacin-matching placebo
219088727|NCT06580639|OTHER|No intervention.|Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.
219088728|NCT03825783|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
219088729|NCT03726255|PROCEDURE|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
219088730|NCT01423630|DIETARY_SUPPLEMENT|Probiotics and fruit fibre|probiotics and fruit fibre
219215789|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 150 mg/kg/ twice daily
219088731|NCT01188109|DRUG|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
219088732|NCT01188109|DRUG|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
219215790|NCT01821989|DIETARY_SUPPLEMENT|Placebo|in form of distilled water
219088733|NCT00530595|DRUG|candesartan or valsartan or losartan|
219088734|NCT01494844|DEVICE|Respiratory monitor patient interface.|Wear each interface for 20 minutes
219088735|NCT05168826|DEVICE|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
219088736|NCT05405959|DEVICE|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
219088737|NCT05405959|DEVICE|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
219088738|NCT06050226|DRUG|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
219088739|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
219088740|NCT06227247|BEHAVIORAL|Meals4Moms Intervention|A community-based, healthy living program including continued gestational diabetes (GDM) education, physical activity level monitoring, and delivery of medically-tailored GDM meals for the management of gestational diabetes in pregnant people.
219215791|NCT04210037|DRUG|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
219681945|NCT05089578|OTHER|focus interview|"The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes."
219088741|NCT04180657|GENETIC|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
219088742|NCT04188977|OTHER|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
219088743|NCT04188977|OTHER|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
219088744|NCT02446158|DRUG|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
219088745|NCT02453685|DRUG|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
219088746|NCT02453685|DRUG|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
219088747|NCT02453685|DRUG|insulin aspart|Injected s.c./subcutaneously once daily.
219088748|NCT00303862|DRUG|cediranib maleate|Given orally
219088749|NCT00303862|OTHER|laboratory biomarker analysis|Correlative studies
219088750|NCT02778100|DRUG|Nasal Glucagon|Administered intranasally.
219088751|NCT02778100|DRUG|Oxymetazoline|Administered intranasally.
219088752|NCT01001052|DRUG|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
219088753|NCT00825266|DRUG|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
219088754|NCT00825266|DRUG|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
219215792|NCT04210037|DRUG|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
219215793|NCT03024034|DRUG|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
219215794|NCT00694889|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
219215795|NCT00694889|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
219215796|NCT06321952|DEVICE|ROSA robotic assist TKA|total knee replacement with ROSA robotic assist
219215797|NCT06321952|PROCEDURE|iassist TKA|total knee replacement with iassist
219215798|NCT03486600|OTHER|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
219088755|NCT03152383|BEHAVIORAL|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
219088756|NCT03152383|BEHAVIORAL|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
219088757|NCT03152383|BEHAVIORAL|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
219088758|NCT03152383|BEHAVIORAL|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
219088759|NCT01459861|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
219088760|NCT01459861|PROCEDURE|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
219088761|NCT03295487|PROCEDURE|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
219088762|NCT00147680|DRUG|Paclitaxel, Carboplatin|
219088763|NCT03479697|DEVICE|HIRREM|Technology
219088764|NCT03479697|OTHER|Continued Current Care|Continue their current clinical care.
219088765|NCT03460028|BEHAVIORAL|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
219088766|NCT03634124|BIOLOGICAL|Blood test|Additional blood test of 4,5 ml of venous blood
219088767|NCT03634124|OTHER|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
219088768|NCT03375502|DRUG|Varicella Vaccine|The subject will receive investigational product or comparator.
219215799|NCT00402259|DRUG|Esomeprazole IV|
219215800|NCT00402259|DRUG|Omeprazole IV|
219215801|NCT01180231|DRUG|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
219088769|NCT06244277|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
219215802|NCT01180231|OTHER|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
219215803|NCT06829732|DEVICE|closed-loop oxygen control (CLOC)|HAMILTON-C6 (Hamilton Medical, Bonaduz, Switzerland) ventilators will be used. It allows for O2 Assist software, that will be installed on all C6 ventilators before the start of this study. Automatic Oxygen management sets the Oxygen control according to the patient's measured SpO2 and the operator-set SpO2 target range. The Oxygenation controller will be activated for 4h and adjusts the Oxygen according to patient's measured SpO2.
219215804|NCT06829732|DEVICE|2. manual oxygen titration (MOT)|O2 will be manually set according to SpO2 target during a 4h period.
219215805|NCT03477175|DRUG|E7080|Oral Administration.
219215806|NCT03477175|DRUG|Comparator Drug|Per parent study.
219215807|NCT03477175|DRUG|Comparator Drug: Sorafenib|Per parent study.
219215808|NCT06777381|PROCEDURE|single visit root canal treatment using ProTaper Universal rotary system|single visit endodontic treatment will be performed using ProTaper Universal rotary system for root canal preparation.
219215809|NCT06777381|PROCEDURE|single visit root canal treatment using M-Pro rotary system|single visit endodontic treatment will be performed using MPro rotary systems for root canal preparation.
219215810|NCT06775457|OTHER|sample collection|Blood samples and fecal samples will be taken from patients during evaluation visits. Blood samples will be analyzed for the study of HERVs. While fecal samples will be analyzed for the characterization of gut microbiota.
219362079|NCT01397578|DRUG|placebo|Repeating intravenous infusion
219362080|NCT02528240|PROCEDURE|EMS|
219681946|NCT05722262|DRUG|K-001|K-877-ER and CSG452 combination tablet
219681947|NCT05722262|DRUG|K-877-ER|K-877-ER tablet
219362081|NCT02528240|DEVICE|+ occlusive membrane|
219362082|NCT02528240|DEVICE|conebeam CT|
219681948|NCT05722262|DRUG|CSG452|CSG452 tablet
219088770|NCT06244277|DRUG|Zolpidem|Zolpidem 10Mg Tab 10mg tablet once daily
219088771|NCT06328530|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
219088772|NCT06328530|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
219088773|NCT05667467|PROCEDURE|Care Bundle Implementation|"In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses."
219088774|NCT04962425|DRUG|Trastuzumab|Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
219088775|NCT02432872|DRUG|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
219088776|NCT02432872|DRUG|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
219088777|NCT01118364|OTHER|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
219088778|NCT01118364|OTHER|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
219088779|NCT02659761|DRUG|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
219088780|NCT02464800|PROCEDURE|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
219088781|NCT03055143|DRUG|SPARC-08-038|2 mg/ml intravenous infusion
219088782|NCT03055143|DRUG|Ref-08-038|2 mg/ml intravenous infusion
219088783|NCT03322280|PROCEDURE|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
219088784|NCT03322280|PROCEDURE|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
219215811|NCT06776939|DEVICE|Oxygen therapy|All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.
219215812|NCT06775821|DEVICE|Ultrasound or CT of the abdominal aorta|Patient underwent ultrasound or CT of the abdominal aorta
219215813|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
219215814|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
219215815|NCT06759922|DRUG|Tab Metformin + Tab Glimepiride|Tab Metformin 500mg+ Tab Glimepiride 2mg (FDC) once per orally for 90 days.
219088785|NCT01547897|DRUG|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
219088786|NCT01367509|DRUG|Methylnaltrexone (MNTX)|
219088787|NCT02475785|DEVICE|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
219215816|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.
219215817|NCT06759922|DRUG|Tab Metformin +Tab Sitagliptin|Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.
219215818|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin + Tab Sitagliptin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.
219215819|NCT06729255|DEVICE|EpiZact-assisted epidural placement|The standard epidural kit used with the EpiZact device to place a midline epidural using the landmark technique between the L2 and L5 vertebral bodies. The patient's back will be sterilized with a 2% chlorhexidine/70% isopropyl alcohol applicator. The epidural will be placed with a 17-gauge 3.5-inch Tuohy needle. Once the Tuohy needle is appreciated to be engaged in ligament the EpiZact device will be filled with sterile and attached to the Tuohy via a Luer connector. The green button on the EpiZact device will then be pressed to prime the device. The EpiZact device and Tuohy needle will be advanced as a unit in continuous fashion or with intermittent advancement. Upon sensing a loss of resistance, the EpiZact device will provide a visual and tactile signal, halting needle advancement and signaling that the epidural catheter should be threaded through the Tuohy needle.
219215820|NCT04194424|OTHER|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
219088788|NCT02475785|DEVICE|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
219088789|NCT00552084|DRUG|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
219088790|NCT00552084|DRUG|Placebo|Placebo supplements will be taken daily for 24 weeks.
219088791|NCT00316810|DRUG|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
219088792|NCT00316810|DRUG|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
219088793|NCT03403322|OTHER|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
219088794|NCT03403322|OTHER|Without taping|Children performed functional activities without tape
219088795|NCT00489333|DRUG|ProAlgaZyme|
219088796|NCT05435352|PROCEDURE|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
219088797|NCT06022328|BIOLOGICAL|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
219215821|NCT04194424|OTHER|Standard Care|General lifestyle tips
219088798|NCT04823884|PROCEDURE|open distal chevron osteotomy|Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.
219088799|NCT04823884|PROCEDURE|minimally invasive distal chevron osteotomy|The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
219088800|NCT06989164|OTHER|Post prandial testing|A variety of foods, supplements, and short prescriptive exercise will be tested to see which one helps mitigate the rise is postprandial glucose after eating carbohydrate containing foods.
219088801|NCT05614947|DIETARY_SUPPLEMENT|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
219088802|NCT05614947|DIETARY_SUPPLEMENT|Placebo|500 mg colored cornstarch per capsule
219088803|NCT06439914|DRUG|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
219088804|NCT06859541|BEHAVIORAL|Culturally Adapted Play-Based Behavioural Intervention|The Culturally Adapted Play-Based Behavioural Intervention (PPBI) integrates traditional Tamil games and folk storytelling to enhance social, emotional, and communication skills in children with Autism Spectrum Disorder (ASD). This 12-week structured program focuses on engagement, motor development, language, emotional regulation, social interaction, and real-world skill application, making it a culturally relevant and accessible intervention for improving adaptive behaviours.
219088805|NCT06859541|BEHAVIORAL|Applied Behaviour Analysis|The ABA-based program utilized structured techniques focused on positive reinforcement, imitation training, guided communication, and step-by-step skill-building. The primary goal was to reduce problem behaviors while reinforcing desirable social and communication skills. Parents and teachers were provided with structured training on how to apply ABA strategies consistently at home and school.
219088806|NCT06669624|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
219088807|NCT06669624|OTHER|Waitlist with 4-month delay, then ABC|A 4-month waitlist period, after which they will also receive the home-based ABC program (same as Intervention group).
219088808|NCT06993064|DIETARY_SUPPLEMENT|4000 IU of Vitamin D3|Vitamin D supplementation in Mexican subjects with Type 2 Diabetes Mellitus
219088809|NCT00684437|BEHAVIORAL|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
219088810|NCT00684437|BEHAVIORAL|Questionnaire|Questionnaires taking 15-30 minutes to complete.
219088811|NCT06671548|DRUG|Relugolix|"* Relugolix (40 mg) tablet administered orally once daily；~* megestrol acetate (1 mg) administered orally once daily；~* medroxyprogesterone acetate (2 mg) administered orally once daily"
219088812|NCT06671548|DRUG|Relugolix placebo|"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."
219088813|NCT01387139|DRUG|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
219088814|NCT01387139|DRUG|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
219088815|NCT05251454|PROCEDURE|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
219088816|NCT07009171|DRUG|KDS2010|KDS2010 will be administered orally once daily, three tablets per day, for 12 weeks. Dosage will be either 120 mg or 180 mg depending on the assigned group.
219088817|NCT07009171|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, three tablets per day, for 12 weeks.
219215822|NCT04194424|DRUG|Metformin Hcl 850Mg Tab|1 tablet, twice daily
219215823|NCT06849518|DIAGNOSTIC_TEST|Circulogene liquid biopsy testing|A Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.
219215824|NCT06850142|PROCEDURE|Discopexy to external ear cartilage|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to external ear cartilage
219215825|NCT06850142|PROCEDURE|Discopexy to temporal fascia|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to temporal fascia
219215826|NCT06844786|OTHER|Physical activity program|SCORE! Club is offered twice a week for enrolled participants. Modules will include soccer, arts and health, Sportball, and nature-based activities.
219088818|NCT07014020|GENETIC|RB001|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
219088819|NCT07014202|COMBINATION_PRODUCT|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
219088820|NCT07014202|DRUG|Immunotherapy (with or without chemotherapy) maintenance therapy|Immunotherapy (with or without chemotherapy) maintenance therapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
219088821|NCT07016815|DEVICE|Wearable wrist heart rate and activity monitor|A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.
219088822|NCT07016815|DEVICE|Bluetooth enabled body weight scale with bioimpedance analysis|An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.
219088823|NCT07016815|DEVICE|Bluetooth enabled electronic blood pressure device|An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.
219088824|NCT07016815|DEVICE|mobile application|a mobile Application through which data from remote monitoring and wearables will be incorporated, and instruction for medication titration and education on heart failure management will be provided to the patients.
219088825|NCT06627933|OTHER|No intervention|No intervention
219088826|NCT03205657|PROCEDURE|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
219088827|NCT01878929|DRUG|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
219088828|NCT02785640|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
219088829|NCT05271058|OTHER|Control group|23 eyes that didn't receive any intraoperative steroids
219088830|NCT05271058|DRUG|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
219215827|NCT06844786|OTHER|Navigation|Participants will have access to a navigator from the study team who will help them access resources relating to recreation and physical activity in their communities. For example, the navigator will help direct families with low income to the recreation assistance program if they are interested in such a service.
219088831|NCT05271058|DRUG|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
219088832|NCT00501189|BIOLOGICAL|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
219088833|NCT05395988|DEVICE|Digital hand washing instructions|Tablet displaying animated hand washing instructions
219088834|NCT05395988|DEVICE|Digital hand washing reward|Tablet displaying animated hand washing instructions and animated animals as reward
219088835|NCT01561859|BEHAVIORAL|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
219088836|NCT01561859|BEHAVIORAL|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
219215828|NCT06844786|OTHER|Health promotion|Health promotion messaging will be provided to participants via social media and other physical methods (i.e., flyers). Topics will include diet, sleep, physical activity, and other related items.
219088837|NCT05897567|OTHER|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
219088838|NCT05897567|OTHER|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
219088839|NCT05897567|OTHER|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
219088840|NCT05284864|PROCEDURE|Stoma closure|Stoma closure after rectal surgery
219088841|NCT00780650|DRUG|Atomoxetine|80 mg oral dose, once per day for 6 weeks
219088842|NCT00780650|DRUG|Placebo|80 mg dose once per day for 6 weeks
219215829|NCT01173341|DIAGNOSTIC_TEST|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
219088843|NCT06470074|DEVICE|Transcranial electrical stimulation|Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
219088844|NCT01257464|DRUG|Sitagliptin|100mg po one dose
219088845|NCT01257464|DRUG|Placebo|Sugar pill po one dose
219088846|NCT00819364|BEHAVIORAL|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
219088847|NCT00819364|BEHAVIORAL|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
219088848|NCT06325137|DIAGNOSTIC_TEST|Transcriptome analyses|A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
219088849|NCT02681575|BEHAVIORAL|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
219088850|NCT02243644|DRUG|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
219088851|NCT02243644|DRUG|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
219088852|NCT01857882|OTHER|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
219088853|NCT04190628|DRUG|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
219088854|NCT04190628|DRUG|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
219088855|NCT02898779|DRUG|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
219088856|NCT00004401|DRUG|botulism immune globulin|
219088857|NCT00940238|DRUG|Citalopram Hydrobromide|
219215830|NCT01173341|OTHER|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
219215831|NCT01173341|OTHER|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
219215832|NCT05376462|DIAGNOSTIC_TEST|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
219088858|NCT03701295|DRUG|Azacitidine|Given IV or SC
219215833|NCT06384976|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
219215834|NCT06384976|DRUG|Standard lymphodepletion regimen|CYC/FLU
219215835|NCT06384976|DRUG|Anti-CD20 mAB|Anti-CD20 mAB
219215836|NCT06405113|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
219215837|NCT05958940|PROCEDURE|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
219088859|NCT03701295|DRUG|Pinometostat|Given IV
219088860|NCT05751174|OTHER|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
219088861|NCT04947371|DRUG|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
219088862|NCT00403897|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
219215838|NCT05958940|DEVICE|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
219215839|NCT06850740|DRUG|Ondansetron 8mg|Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)
219215840|NCT06850740|DRUG|Normal Saline|Patients will be managed by administering 100 ml of normal saline solution as placebo
219215841|NCT03875144|PROCEDURE|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
219088863|NCT04639193|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
219088864|NCT04639193|DRUG|Eszopiclone|Eszopiclone tablet (encapsulated)
219088865|NCT04639193|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
219088866|NCT04639193|DRUG|Venlafaxine|Venlafaxine capsule
219088867|NCT01023568|DEVICE|Macintosh blade|Intubation with Macintosh blade laryngoscope
219088868|NCT01023568|DEVICE|Glidescope|Intubation with Glidescope laryngoscope.
219215842|NCT03875144|DRUG|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
219215843|NCT03875144|DRUG|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
219215844|NCT02415127|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
219215845|NCT02415127|DRUG|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
219215846|NCT06840665|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
219215847|NCT06840665|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219088869|NCT01023568|DEVICE|Truview PCD|Intubation with Truview PCD laryngoscope.
219088870|NCT04331535|DIAGNOSTIC_TEST|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
219088871|NCT00224770|DRUG|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
219088872|NCT00224770|PROCEDURE|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
219088873|NCT01106430|DRUG|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
219088874|NCT01106430|DRUG|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
219215848|NCT06840665|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
219215849|NCT06811974|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most frequently performed procedures in maxillofacial surgery is impacted wisdom tooth surgery. An impacted tooth is defined as a tooth that is not fully or partially erupted and is blocked from eruption by another tooth, bone, or soft tissue, and thus has a low probability of eruption. The tooth is blocked from eruption by adjacent hard or soft tissue, including bone or dense soft tissue. The most common complications after impacted wisdom tooth surgery are pain, edema, trismus, and alveolar osteitis.
219215850|NCT06811220|DRUG|Hespiridin and Diosmin|Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)
219215851|NCT06842030|DIAGNOSTIC_TEST|Darwin OncoTarget and OncoTreat|Darwin OncoTarget and OncoTreat predict potential drugs with early markers of efficacy in early human clinical trials. Specifically, OncoTarget identifies high-affinity inhibitors of master regulator proteins, while OncoTreat identifies tumor-checkpoint module inhibitors that modulate the transcriptional activity of hyper-connected master regulators. These tests are now commercially available with Clinical Laboratory Improvement Amendments (CLIA) approval through Columbia Presbyterian Medical Center.
219215852|NCT06855173|DEVICE|Active external rewarming device|Electrical heating blanket
219215853|NCT06855173|DEVICE|Active external rewarming device 2|Electrical heating blanket
219215854|NCT06855173|DEVICE|Active external rewarming device 3|Electric heating blanket
219215855|NCT06855173|DEVICE|Active external rewarming device 4|Electric heating blanket
219088875|NCT01341977|DEVICE|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
219088876|NCT01341977|DEVICE|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
219088877|NCT04557839|OTHER|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
219215856|NCT05085886|BEHAVIORAL|DepCare|Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.
219215857|NCT05085886|BEHAVIORAL|Enhanced Usual Care|Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
219681949|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
219088878|NCT04557839|OTHER|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~* eyes open firm surfaces~* Eyes open soft surfaces~* Eyes closed firm surfaces~* Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~* These exercise will perform with turning the head side to side ad up and down~* Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
219088879|NCT00861614|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
219088880|NCT00861614|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
219088881|NCT05083195|OTHER|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
219088882|NCT05083195|OTHER|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
219088883|NCT04227080|DRUG|BH4|oral administration of 20 mg/kg KUVAN (BH4)
219215858|NCT06072703|DEVICE|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
219088884|NCT04426396|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, CT-FFR computed by coronary CT angiography
219088885|NCT02331797|DEVICE|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
219215859|NCT06740734|BEHAVIORAL|Stress ball|Sterile Stress ball for pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands.
219215860|NCT06740734|BEHAVIORAL|Expressive touch applications|During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes
219215861|NCT06743555|OTHER|Observation without surgery|Patients randomized to this arm will forego standard-of-care thoracic surgery and will undergo strict surveillance based on serial radiological follow-up and ctDNA monitoring
219215862|NCT06743555|PROCEDURE|Standard-of-care surgery|Patients randomized to this arm will undergo standard-of-care thoracic surgery and undergo post-operative surveillance with serial radiological follow-up and ctDNA monitoring
219215863|NCT05308121|OTHER|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
219215864|NCT05308121|OTHER|Evaluation of foot characteristics|The mobility of foot, morphological changes of foot and foot posture will be evaluated
219215865|NCT06745895|BEHAVIORAL|MATCHES|"Participants will be asked to complete a survey with specific topics including Hepatitis C (HCV) and Colorectal (CRC) knowledge and health beliefs, screening intentions and demographic characteristics.~Participants will be provided with education intervention materials (for example, a booklet) either in-person or via mail, access to free stool-based CRC screening, and access to free HCV screening.~Approximately 1-2 weeks after receiving the education materials, participants will be asked to complete a post-intervention survey about the same specific topics (for example, HCV and CRC knowledge, HCV and CRC health beliefs, HCV and CRC screening intentions, healthcare experiences, perceptions of the educational materials) over the phone with a trained study staff.~Participants with a positive HCV screening and/or CRC screening result will be navigated to follow-up care as needed."
219088886|NCT02331797|DEVICE|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
219088887|NCT00551070|OTHER|Laboratory Biomarker Analysis|Correlative studies
219088888|NCT00551070|OTHER|Pharmacological Study|Correlative studies
219088889|NCT00551070|DRUG|Selumetinib|Given PO
219088890|NCT00551070|DRUG|Selumetinib Sulfate|Given PO
219681950|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 472 mg QD|SFC 118 mg capsules will be given to the patients as 472 mg QD
219681951|NCT04020653|DRUG|Artemisinin-based combination (ACT)|Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
219681952|NCT04020653|DRUG|Placebo|Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
219681953|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
219681954|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 236 mg BID|SFC 118 mg capsules will be given to the patients as 236 mg BID
219088891|NCT05324969|BEHAVIORAL|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
219088892|NCT05324969|OTHER|healthy education|9 health education emails will be sent to participating parents in the control group
219088893|NCT02782390|OTHER|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).
219088894|NCT02782390|OTHER|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
219088895|NCT00992953|BEHAVIORAL|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
219088896|NCT00992953|BEHAVIORAL|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
219088897|NCT00113282|DRUG|Interleukin-2 (IL-2)|
219088898|NCT00622011|DRUG|Risperidone and Zotepine for delirium|try risperidone or zotepine in the treatment of delirium
219088899|NCT00845338|DRUG|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
219088900|NCT06347094|OTHER|Personalized Dietary Plan|Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet
219215866|NCT03291522|PROCEDURE|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
219215867|NCT06889792|OTHER|Theory of planned behaviour|This theory holds that an intention to engage in a health-related behaviour is determined by the proximal factors of attitudes, subjective norms, and perceived behavioural control. Attitudes represent individuals perceived likelihood of performing and appraisal of the consequences of performing a health-promoting behaviour. Subjective norms are the social pressure perceptions to either perform or not perform a health-promoting behaviour. Finally, perceived behavioural control is an individual's perception of control regarding performing the behaviour.
219215868|NCT06889792|OTHER|Foot-in-the-door technique|The foot-in-the-door technique, which was introduced by Freeman and Fraser, emphasises the notion that individuals who initially comply with a small, easy request are more likely to later comply with a larger request. Compliance with the first request or target increases the individual's confidence and alters their self-perceived capability and willingness regarding further requests or targets. This technique can facilitate the recruitment process and enhance compliance.
219215869|NCT06889792|OTHER|Self-determination theory|"According to self-determination theory, behavioural regulation is more autonomous when it is internalised, as opposed to being regulated by external factors. Compared with external regulation, autonomous regulation is associated with increased self-efficacy, greater behavioural persistence, longer-term behavioural changes and more positive health behaviour. Autonomy is another influential determinant of behaviour that is emphasised by freedom of choice. There is some evidence that people who have greater autonomy demonstrating greater competence and self-efficacy in achieving behavioural change compared with those with less autonomy. As a result, increased autonomy will facilitate a gradual change in risky behaviours.~Our intervention aims to first change the participants' attitudes and their subjective norms through risk communication. Using foot-in-the-door technique and self-determination theory, it will then increase participants' willingness to adopt a healthy lifestyle."
219215870|NCT06889792|OTHER|Follow-up booster intervention|Staff will send WhatsApp/WeChat messages approximately once a week to remind the participants to adhere to their desired health-related lifestyle for the first 6 months. In addition, during the first week, the RA will send participants a link via WhatsApp/WeChat to a 1-minute video developed by the research team comprising content relevant to their selected health-related lifestyle. Four separate 1-minute videos will be compiled, each focusing on a different healthy lifestyle. These videos will indicate the health hazards of continuing this health risk behaviour and the benefits of adopting a healthy lifestyle. Moreover, the RA will encourage the participants to watch the video and ask any questions regarding the video content via WhatsApp/WeChat.
219215871|NCT06889792|OTHER|Practical Resource Hub for Healthy Life leaflet|The participants will be provided a Practical Resource Hub for Healthy Life leaflet containing information on various applications, including (i) 'Move Your Body', (ii) 'Eat Healthy', (iii) 'Live Alcohol Free', and (iv) 'Stay Away from Tobacco', which were developed by the Hong Kong Department of Health
219681955|NCT04244617|BEHAVIORAL|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
219088901|NCT06347094|DIETARY_SUPPLEMENT|Oral (Poly)phenol Challenge Test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
219088902|NCT06347094|OTHER|General Dietary Advice|Prescription of balanced dietary plans
219088903|NCT02020122|DRUG|Duloxetine|duloxetine 60mg
219088904|NCT02020122|DRUG|Pregabalin|pregabalin 150mg
219088905|NCT02020122|DRUG|Placebo|non active placebo
219088906|NCT03704584|DRUG|Treatment Group: Corticosteroid injection|Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.
219088907|NCT03704584|DRUG|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
219088908|NCT03704584|DRUG|Treatment Group: Lidocaine|Subjects will receive an injection of lidocaine (1% lidocaine HCl).
219215872|NCT06889792|OTHER|a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model|The participants will receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model : (1) Ask about and assess health-risk behaviours; (2) Warn about the high morbidity and mortality risks associated with health-risk behaviours; (3) Advise on adopting healthy lifestyles to improve the participant's health; (4) Refer to hotline services, such as those for smoking cessation and alcohol treatment or the nearest district health centre to follow up their health status; and (5) Do it again if participants have not adopted a healthy lifestyle at follow-ups.
219088909|NCT03987126|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
219088910|NCT03987126|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
219088911|NCT03439189|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
219088912|NCT03439189|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
219088913|NCT03439189|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
219088914|NCT03881280|BEHAVIORAL|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~* Fill in a registration questionnaire, which will tailor recommendations.~* Receive information and video content recommendations.~* Set goals related to their child's lifestyle and tracking progress.~* Earn points by watching the contents.~* Invite children to play a serious game.~* Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
219088915|NCT04670133|DIETARY_SUPPLEMENT|Inulin|Supplementation with a prebiotic, specifically inulin.
219088916|NCT04670133|DIETARY_SUPPLEMENT|Maltodextrin|Supplementation with maltodextrin (placebo)
219088917|NCT04483154|DEVICE|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
219088918|NCT02579564|DRUG|Gemcitabine|
219088919|NCT02579564|DRUG|Vinorelbine|
219088920|NCT02579564|DRUG|Paclitaxel|
219088921|NCT02579564|DRUG|Pemetrexed|
219088922|NCT02579564|DRUG|Oncorine|
219088923|NCT02579564|DRUG|Endostar|
219088924|NCT02579564|DRUG|Cisplatin|
219088925|NCT01641796|DRUG|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
219088926|NCT05274932|OTHER|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
219088927|NCT04069325|DRUG|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
219088928|NCT04069325|DRUG|placebo|pills, 6g twice daily (BID), oral, 12 weeks
219088929|NCT04069325|DRUG|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
219088930|NCT01450722|PROCEDURE|bypass surgery, stent placement|bypass surgery, stent placement
219088931|NCT01450722|PROCEDURE|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
219088932|NCT00485225|DRUG|EN3270|Transdermal Therapeutic System
219088933|NCT04372628|DRUG|Lopinavir/Ritonavir 400 mg/100 mg|Lopinavir/Ritonavir tablets
219088934|NCT04372628|OTHER|Placebo|Unmatched placebo
219088935|NCT00194688|DRUG|H. pylori treatment|
219088936|NCT01512771|OTHER|CPAP|6 weeks of CPAP
219088937|NCT05445154|DRUG|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
219088938|NCT02088203|DIETARY_SUPPLEMENT|Dose 1|Russian Tarragon Nutrasorb 0.3 g
219088939|NCT02088203|DIETARY_SUPPLEMENT|Dose 2|Russian Tarragon Nutrasorb 1 g
219088940|NCT02088203|DIETARY_SUPPLEMENT|Dose 0|Placebo
219088941|NCT02088203|DIETARY_SUPPLEMENT|Dose 3|Russian Tarragon Nutrasorb 3 g
219088942|NCT02088203|DIETARY_SUPPLEMENT|Dose 4|Russian Tarragon Nutrasorb 10 g
219088943|NCT02088203|DIETARY_SUPPLEMENT|Dose 5|Russian Tarragon Nutrasorb 20 g
219215873|NCT06751160|OTHER|Dry Needling|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Dry Needling will be given to group A along with baseline treatment through following protocol:~Patient will be in prone lying. Sterilized disposable dry needles of 0.25\*60mm will be used. Dry needling will be performed on three points on Hamstring muscle for one minute each. We considered a line between ischial tuberosity and head of fibula to target long head of bicep femoris (60% of line) and short head of bicep femoris (30% of line). Semitendinosus and Semi Membranosus were targeted at a point of 60% of line from ischial tuberosity to medial epicondyl of femur.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
219215874|NCT06751160|OTHER|Soft Tissue Mobilization|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Soft Tissue Mobilization will be given to Group B along with Baseline treatment.~Subject will be in prone lying position with knee bent at 30 to 60 degrees. Soft tissue mobilization will be applied on hamstring muscle through Graston technique. Massage cream will be applied on hamstring muscle and Graston Instrument will be rubbed from gluteal line to politeal fossa 30 times for 60 seconds.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
219215875|NCT06748404|DRUG|Tricalm Hydrogel|TriCalm Hydrogel® is a topical gel that allows rapid administration to areas of the skin. TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.
219215876|NCT06748404|DRUG|Triamcinolone acetonide 0.1% cream|Triamcinolone acetonide 0.1% cream is a topical steroid cream that will be applied directly to the skin.
219215877|NCT06742060|DIAGNOSTIC_TEST|serum copeptin levels|For children who met the entry criteria, the blood samples were collected preoperatively (T0), 1h postoperatively (T1), 1 day postoperatively (T2), 2 days postoperatively (T3), 3 days postoperatively (T4), 4 days postoperatively (T5), 5 days postoperatively (T6) to test serum and peptide levels.
219215878|NCT06741982|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
219215879|NCT06741982|DRUG|Tislelizumab|200mg IV Q3W
219215880|NCT06741982|DRUG|Afatinib|30mg PO QD
219215881|NCT02423629|DEVICE|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
219681956|NCT06132334|OTHER|Upper extremity aerobic exercise training|"Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points.~Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of \>300 mg/dL will not be allowed to exercise that day."
219681957|NCT06132334|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
219681958|NCT01945879|DRUG|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
219681959|NCT01151306|DRUG|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
219681960|NCT01151306|DRUG|Lactose tablet|One tablet taken each evening for 6 weeks
219681961|NCT04861844|BEHAVIORAL|mindfulness training|phone based mindfulness training on 4 consecutive days
219088944|NCT02088203|DIETARY_SUPPLEMENT|Dose 6|Russian Tarragon Nutrasorb 30 g
219088945|NCT03362359|DRUG|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
219088946|NCT05709990|DRUG|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
219088947|NCT05709990|DRUG|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
219088948|NCT05709990|BEHAVIORAL|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
219088949|NCT00107055|DRUG|REN-1654|
219088950|NCT04224324|PROCEDURE|Tonsillectomy and Adeniodectomy|pediatric patients undergoing tonsillectomy and adenoidectomy
219215882|NCT06743386|DEVICE|Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)|It will be performed under general anesthesia with intubation, using a sectorial probe echoendoscope to target pancreatic tumors. Prophylactic measures, including intrarectal Diclofenac and antibiotics, are used to prevent complications. A high-frequency monopolar electrode needle is inserted into the lesion under ultrasound guidance, avoiding critical structures like pancreatic and biliary ducts. Energy is delivered until specific safety parameters are met, with multiple applications to maximize tumor coverage. RFA sessions are scheduled before, midway, and after chemotherapy cycles, and progress is monitored with routine imaging. Post-procedure care includes fasting, pain management, and standard blood tests. Patients are typically discharged the day after the procedure if no complications occur. Further treatment plans, including continuation or modification of chemotherapy and RFA, are determined based on disease progression observed in follow-up scans.
219215883|NCT06766240|DEVICE|MRI on lumbosacral spine|MRI imaging on lumbosacral spine using Philips Achieva1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea1.5T MRI device (Siemens Healthineers, Germany). the sequences used are Axial T2W; Sagittal T1W, T2W, Sagittal STIR, Coronal STIR and post gadolinium if needed.
219215884|NCT06502418|OTHER|Acupuncture therapy|7 acupuncture points will be used to managed pain and improved patient's experience
219215885|NCT06550687|OTHER|Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis|Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
219681962|NCT04861844|BEHAVIORAL|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
219681963|NCT02121795|DRUG|FTC/TDF|200/300 mg FDC tablets administered orally once daily
219088951|NCT03087344|DEVICE|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
219088952|NCT03087344|DEVICE|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
219088953|NCT03087344|DEVICE|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
219088954|NCT05435222|BEHAVIORAL|Male-specific psychotherapeutic program (MSPP)|The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
219088955|NCT05435222|BEHAVIORAL|Cognitive beahvioral therapy (CBT)|This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.
219088956|NCT05428605|OTHER|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
219088957|NCT04030858|BEHAVIORAL|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
219088958|NCT05455905|DIAGNOSTIC_TEST|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
219088959|NCT05455905|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
219088960|NCT05455905|DIAGNOSTIC_TEST|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
219088961|NCT05455905|DIAGNOSTIC_TEST|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
219088962|NCT03373526|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
219088963|NCT03373526|OTHER|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
219088964|NCT06496191|BIOLOGICAL|FMT|\- Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4
219088965|NCT06496191|OTHER|SMT|Baclofen + AUD counselling
219088966|NCT06496191|OTHER|Placebo|Placebo identical to the FMT arm.
219088967|NCT06083870|DRUG|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
219681964|NCT02121795|DRUG|F/TAF|Tablets administered orally once daily
219215886|NCT06855966|OTHER|250 ml crystalloid bolus infusion|In thoracic surgical setting, restrictive fluid replacement is widely accepted. However, goal directed fluid therapies can provide a more precise and tailored fluid replacement for each patient. Although ERAS protocols emphasize otherwise, patients still arrive in the operating room with certain deficite, due to prolonged fasting or advanced age. PLR is used as a reversible fluid challenge since the blood which is pooled in the lower extremities as well as splancnic area. End tidal carbon dioxide is monitorized at each patient per American Society of Anesthesia Guideline. In this study, we aimed to assess the feasibility of end tidal carbondioxide changes as a response to passive leg raise maneuer (PLR) for preload optimization in thoracic surgical practice.
219215887|NCT06753526|DRUG|NSAID|For 1st group of patients
219215888|NCT06753526|DRUG|L-Arginine, 500 Mg Oral Capsule|group 2by twice dose
219215889|NCT06753526|DRUG|Tamsulosin 0.4 mg QD|group 3 by once per day
219215890|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
219215891|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
219215892|NCT06740513|PROCEDURE|Endovascular Treatment|Medical Therapy plus Stent/Balloon Angioplasty
219215893|NCT06789263|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|Dissolved in flavoured water, single dose, 10 g
219088968|NCT01559948|BEHAVIORAL|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
219088969|NCT01559948|DEVICE|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
219088970|NCT00508261|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection
219088971|NCT00508261|BIOLOGICAL|Infanrix™ hexa|Single dose intramuscular injection
219088972|NCT00508261|BIOLOGICAL|Meningitec™|Single dose intramuscular injection
219088973|NCT02231866|BIOLOGICAL|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
219088974|NCT02231866|BIOLOGICAL|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
219088975|NCT00972348|OTHER|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
219088976|NCT00972348|OTHER|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
219088977|NCT00180479|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219088978|NCT00180479|DEVICE|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219088979|NCT01423682|BEHAVIORAL|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
219088980|NCT03056482|DRUG|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
219088981|NCT03056482|DRUG|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
219088982|NCT03056482|DRUG|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
219215894|NCT06789263|OTHER|Placebo|Single dose
219215895|NCT06764329|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
219215896|NCT06764329|OTHER|0.9 % saline|0.9% Saline as placebo
219215897|NCT06780345|DRUG|Placebo|Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
219215898|NCT06780345|DRUG|Vitamin C|Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
219215899|NCT06832839|PROCEDURE|Revascularization|Revascularization
219681965|NCT02121795|DRUG|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
219681966|NCT02121795|DRUG|FTC/TDF Placebo|Tablets administered orally once daily
219681967|NCT02121795|DRUG|F/TAF Placebo|Tablets administered orally once daily
219681968|NCT00849069|BIOLOGICAL|GSK2231395A|3 doses intramuscular injections
219681969|NCT00849069|BIOLOGICAL|TwinrixTM|3 doses intramuscular injections
219681970|NCT05544591|DRUG|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
219088983|NCT02336243|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
219088984|NCT02336243|DIETARY_SUPPLEMENT|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
219088985|NCT05346003|PROCEDURE|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
219088986|NCT01222169|DRUG|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
219088987|NCT03652779|DRUG|Tecarfarin 10mg|Tecarfarin 10mg tablets
219215900|NCT06759636|DRUG|Romiplostim N01|3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
219215901|NCT06759636|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|25-50μg/kg, subcutaneous injection, once a day
219215902|NCT06716333|OTHER|Experimental Group (12-Week Wrestling Training)|The intervention consists of a structured 12-week intensive wrestling training program designed specifically for male wrestlers aged 12-14 years. This program was conducted at athlete training centers equipped with international standard facilities, and led by professional coaches. The training included 5 sessions per week, each lasting approximately 80 minutes, with a total weekly duration of 400 minutes. Each session consisted of 20 minutes of gymnastic warm-up, 50 minutes of basic technical and strength exercises (e.g., squats, push-ups, deadlifts), and 10 minutes of stretching.
219215903|NCT04686877|PROCEDURE|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
219215904|NCT04300023|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
219088988|NCT03652779|DRUG|Tecarfarin 20mg|two tecarfarin 10mg tablets
219088989|NCT03652779|DRUG|Tecarfarin 30mg|three tecarfarin 10mg tablets
219088990|NCT03652779|DRUG|Tecarfarin 40mg|four tecarfarin 10mg tablets
219088991|NCT03626779|OTHER|Prf|Take 10cc blood from patient and gain prf blug
219088992|NCT01267292|DRUG|Buspirone|\[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]
219088993|NCT01267292|DRUG|Placebo for Buspirone|\[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]
219088994|NCT01267292|DRUG|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
219088995|NCT01267292|DRUG|Placebo for Methylphenidate|\[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
219088996|NCT03238898|DRUG|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
219088997|NCT03238898|OTHER|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
219215905|NCT01855750|DRUG|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
219088998|NCT06282614|DEVICE|Mucogyne Ovule|At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
219088999|NCT01945905|OTHER|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
219215906|NCT01855750|DRUG|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
219215907|NCT01855750|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
219089000|NCT01945905|OTHER|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
219089001|NCT04074421|DRUG|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
219089002|NCT04074421|DRUG|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
219215908|NCT01855750|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
219215909|NCT01855750|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
219215910|NCT01855750|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
219089003|NCT04074421|DRUG|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
219089004|NCT01478009|DIETARY_SUPPLEMENT|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
219089005|NCT01478009|DIETARY_SUPPLEMENT|Placebo|Placebo (3.0g/day) for 12 weeks
219089006|NCT00598026|OTHER|Tele- follow-up|Remote transmission to the implantation centre every 3 months
219089007|NCT00598026|OTHER|Conventional follow-up|Visits at the implantation centre every 3 months
219089008|NCT00766233|OTHER|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
219089009|NCT03026023|DRUG|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
219089010|NCT05541055|DEVICE|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
219215911|NCT01855750|DRUG|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
219215912|NCT06776445|DRUG|minocycline combined with hydroxychloroquine|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
219215913|NCT06776445|DRUG|gabapentin 300mg bid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
219215914|NCT06776445|DRUG|gabapentin 300mg tid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
219215915|NCT04435756|OTHER|Biomarker Analysis|Correlative study
219215916|NCT04435756|PROCEDURE|Blood Product Collection|Undergo collection of blood
219215917|NCT04965155|DRUG|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
219215918|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
219215919|NCT05525572|DEVICE|Shockwave Therapy (SWT)|"Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions."
219215920|NCT05525572|DRUG|Autologous Platelet-Rich Plasma (PRP)|"Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval."
219215921|NCT01181544|PROCEDURE|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
219215922|NCT06247254|BEHAVIORAL|Intensive Clinic Management|Blood pressure management at in-person follow-up visits occurring every 2 months when systolic blood pressures are at target (i.e., \< 130 mmHg), and monthly when systolic blood pressure is ≥ 130 mmHg. Participants will also receive low-touch health promotion messaging via text messaging, with reminders focused on medication adherence, healthy diet, and physical activity and a tailored Blood Pressure Care Plan for managing stroke recovery. Participants will be encouraged to monitor their blood pressure at home and record values in logs.
219215923|NCT06247254|BEHAVIORAL|Intensive Tailored Telehealth Management|Tailored Blood Pressure Care Plan and health coaching contracted through INTERVENT.
219215924|NCT06746701|DRUG|Peg-IFNα-2b combined with NA|From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
219215925|NCT06746701|DRUG|Nucleotide Analogues|Starting from the first day of enrollment, take NA orally once a day.
219681971|NCT05544591|DRUG|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
219089011|NCT05541055|OTHER|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
219089012|NCT05758831|DRUG|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
219089013|NCT05758831|DRUG|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
219089014|NCT00440869|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg po bid
219089015|NCT00440869|DIETARY_SUPPLEMENT|placebo|bid oral dosing
219089016|NCT01711762|DRUG|GDC-0973|Single oral dose of \[14C\]-GDC-0973
219089017|NCT05001724|BIOLOGICAL|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
219089018|NCT05001724|DRUG|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
219089019|NCT05001724|DRUG|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
219089020|NCT03631446|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
219089021|NCT01746095|DRUG|Vancomycin hydrochloride inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
219089022|NCT01746095|DRUG|Placebo inhalation powder|
219089023|NCT05388721|OTHER|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
219089024|NCT00526630|DRUG|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
219089025|NCT00526630|DRUG|Placebo|Participants will be given placebo instead of active MPD.
219089026|NCT02944084|DIETARY_SUPPLEMENT|Rice bran extract|
219089027|NCT02944084|DIETARY_SUPPLEMENT|Porridge in water|
219089028|NCT02944084|DIETARY_SUPPLEMENT|Porridge in milk|
219089029|NCT03012464|OTHER|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
219089030|NCT04088201|DEVICE|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
219089031|NCT06187740|RADIATION|thoracic radiotherapy|"Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy."
219089032|NCT03979196|OTHER|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
219089033|NCT03979196|OTHER|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
219089034|NCT02459262|BIOLOGICAL|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
219089035|NCT01656330|DRUG|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
219089036|NCT01656330|DRUG|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
219089037|NCT01656330|DRUG|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
219089038|NCT01656330|DRUG|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
219089039|NCT01656330|OTHER|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
219089040|NCT03107078|DRUG|Glucocorticoids|Intravenous Glucocorticoids (GCs)
219089041|NCT00181571|DRUG|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
219089042|NCT00181571|DRUG|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
219215926|NCT04057131|DRUG|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
219215927|NCT06762535|DEVICE|repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
219215928|NCT06762535|DEVICE|Sham repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session).But there's no real pulse output,Just set the same conditions.
219089043|NCT01094132|DEVICE|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
219089044|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
219089045|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
219089046|NCT01242748|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
219089047|NCT01242748|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
219089048|NCT05542810|COMBINATION_PRODUCT|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
219089049|NCT05386667|DRUG|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
219089050|NCT05386667|OTHER|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
219089051|NCT05386667|OTHER|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
219089052|NCT05386667|PROCEDURE|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
219215929|NCT06815419|OTHER|spiritual care education program|The spiritual care education program to improve nurses ability to provide spiritual care. Education includes; Program orientation, an introduction to spiritual care, the concepts of spiritual care, the significance of spiritual care, the theoretical underpinnings of spirituality in mental health, practical strategies for integrating spiritual care in psychiatric nursing, reflective practice, and self-care for enhancing personal spirituality were all covered in the program's weekly two-hour sessions.
219215930|NCT06889103|OTHER|Observation|observation during eating
219215931|NCT06726993|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty (TKA) is a common orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic
219215932|NCT06856525|DRUG|Hyperpolarized Xe129|Determine the impact of e-cigarette use on pulmonary gas exchange capacity in interstitial tissues and capillaries using hyperpolarized xenon-129 MRI.
219215933|NCT06856525|DIAGNOSTIC_TEST|Cardiopulmonary Stress Test|Exercise stress test to evaluate cardiac and pulmonary fitness.
219215934|NCT06856525|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard clinic pulmonary function test to evaluate lung function
219215935|NCT06856525|DIAGNOSTIC_TEST|Chest CT|Clinical standard chest computer tomography to evaluate any lung tissue scars or air movement.
219215936|NCT06750874|BEHAVIORAL|Acceptance and Commitment Therapy|One day workshop + telephone booster
219215937|NCT06774599|DEVICE|music combined with lavender essential oil group|listening of 30 mins ocean wave music, aromatherapy of lavender essential oil, and eye masks and earplugs.
219215938|NCT06765538|OTHER|Video consultation|Preanaesthetic videoconsultation
219215939|NCT03160885|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
219215940|NCT03160885|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
219215941|NCT03404778|DEVICE|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
219215942|NCT06619600|DRUG|Dapagliflozin|Dapagliflozin 10 mg qd
219215943|NCT06619600|DRUG|Placebo|Matched placebo qd
219681972|NCT05544591|DRUG|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
219681973|NCT02379013|PROCEDURE|Volunteer with MRI|functional MRI
219681974|NCT00346749|DRUG|Salmeterol|
219681975|NCT00346749|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
219681976|NCT06084702|OTHER|Rehydration with plain water|Plain water without calories, sweetener, or electolytes
219089053|NCT03767166|DEVICE|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
219089054|NCT03724487|BEHAVIORAL|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
219089055|NCT03724487|BEHAVIORAL|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
219089056|NCT01007656|DIETARY_SUPPLEMENT|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
219089057|NCT00464451|DRUG|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
219089058|NCT00464451|DRUG|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
219089059|NCT05008952|OTHER|High-fat shake|All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
219089060|NCT04696913|DIAGNOSTIC_TEST|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
219089061|NCT04696913|DIAGNOSTIC_TEST|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
219089062|NCT04111068|DEVICE|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
219215944|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
219215945|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
219215946|NCT03425682|OTHER|ViBone|Viable Bone Allograft
219215947|NCT03117946|OTHER|Biological samples|blood and tumor tissue sample
219089063|NCT04111068|DEVICE|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
219089064|NCT00320775|DRUG|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
219089065|NCT05987306|BEHAVIORAL|Weight loss plus self-compassion|A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
219089066|NCT06497218|DIAGNOSTIC_TEST|Blinklab diagnostic device|Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
219089067|NCT04955834|DRUG|Insulin degludec injection|long-acting insulin
219089068|NCT04955834|DRUG|Tresiba®|long-acting insulin
219089069|NCT02107794|OTHER|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
219089070|NCT03674554|PROCEDURE|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
219089071|NCT03674554|PROCEDURE|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
219089072|NCT02437656|DRUG|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
219089073|NCT05130125|DRUG|rFSH|rFSH or HP-hMG or rFSH and HP-hMG
219089074|NCT03320798|OTHER|Data record|
219089075|NCT06370910|OTHER|Low-Level Laser Therapy|The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.
219089076|NCT03962296|DRUG|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
219089077|NCT03962296|DRUG|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
219215948|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
219089078|NCT03962296|DRUG|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
219089079|NCT02856425|DRUG|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
219089080|NCT02856425|DRUG|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
219089081|NCT04500496|DRUG|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
219089082|NCT04500496|DRUG|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
219089083|NCT03311282|DEVICE|infants bottles|"* angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat"
219089084|NCT03311282|DEVICE|Infants Bottles|"* large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat"
219089085|NCT03311282|DEVICE|Infants Bottles|"* teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat"
219089086|NCT03518125|BIOLOGICAL|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
219089087|NCT03518125|BIOLOGICAL|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
219089088|NCT03518125|DRUG|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
219089089|NCT06491836|DIETARY_SUPPLEMENT|oligoantigenic diet|Oligoantigenic diet that will cover recommended daily allowance (RDA) of macronutrients and micronutrients according patients' ages according to our available sources of food in our culture and the diet consists typically of meat (e.g. chicken and lamb), carbohydrate sources (e.g., potatoes and rice), fruits (e.g., bananas, pears and apples), vegetables (e.g., cucumbers, carrot, lettuce, cauliflower, turnips, cabbage and broccoli)
219089090|NCT06491836|OTHER|Food regimen without food restrictions.|Food regimen that will cover recommended daily allowance (RDA) for macronutrients and micronutrients according patients' ages without any food restriction
219089091|NCT02416492|BIOLOGICAL|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
219089092|NCT02416492|PROCEDURE|Sham Control|Sham Surgery
219089093|NCT03730285|DEVICE|Telemedicine|Installation of videotelephone with broadband in patient's home
219089094|NCT04626739|DRUG|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
219215949|NCT06768333|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
219089095|NCT04626739|DRUG|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
219089096|NCT04626739|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
219089097|NCT04626739|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
219089098|NCT04626739|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
219089099|NCT02514018|BIOLOGICAL|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
219089100|NCT00260143|DRUG|Testosterone enanthate|
219089101|NCT00260143|DRUG|Placebo|
219089102|NCT01791920|DRUG|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
219089103|NCT01791920|DRUG|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
219089104|NCT05197361|DIAGNOSTIC_TEST|Invasive coronary physiology|Estimation of guide-wire coronary physiology parameters
219089105|NCT02417779|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
219215950|NCT06768333|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) of the Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
219681977|NCT06084702|OTHER|Rehydration Drink|Roaring Water. An electrolyte drink with low Carbohydrate content
219681978|NCT03523195|BEHAVIORAL|Exercise Intervention|Complete exercise program
219681979|NCT03523195|OTHER|Informational Intervention|Receive written information on healthy exercise and diet recommendations
219089106|NCT02417779|DEVICE|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
219089107|NCT00426608|DRUG|metyrapone|Metyrapone will be available as 250 mg dose capsule.
219089108|NCT00426608|DRUG|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
219089109|NCT00426608|DRUG|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
219089110|NCT00426608|DRUG|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
219089111|NCT03286751|DRUG|LY900014|Administered SC
219089112|NCT03286751|DRUG|Insulin Lispro|Administered SC
219089113|NCT03261284|DIAGNOSTIC_TEST|D-dimer-guided adjustment stratege|D-dimer-guided adjustment stratege
219089114|NCT03261284|DIAGNOSTIC_TEST|Thepeautic-heparin therapy|0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
219089115|NCT01573936|OTHER|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
219089116|NCT00648128|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
219089117|NCT00648128|DRUG|Clarithromycin|single-dose 500 mg immediate-release oral dose'
219089118|NCT00626730|PROCEDURE|adjuvant therapy|
219215951|NCT06768333|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) of the SIS Go Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
219215952|NCT05972525|BEHAVIORAL|Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee|The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
219215953|NCT06817421|BIOLOGICAL|Pneumococcal conjugate vaccine|10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.
219089119|NCT00626730|RADIATION|radiation therapy|
219215954|NCT06817421|BIOLOGICAL|Typhoid conjugate vaccine|Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.
219215955|NCT06044324|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
219215956|NCT06837441|PROCEDURE|Atrial Fibrillation Termination|Pursuing Atrial Fibrillation Termination as a Procedural Endpoint
219215957|NCT06837441|PROCEDURE|Prespecified Ablation|Prespecified Ablation Strategy Followed by Cardioversion
219215958|NCT04015700|BIOLOGICAL|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
219215959|NCT04015700|DEVICE|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
219215960|NCT04015700|DRUG|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
219089120|NCT01839006|PROCEDURE|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
219215961|NCT06750744|RADIATION|chest x ray|chest X ray identify severity of pneumonia
219215962|NCT06750744|RADIATION|chest X ray|chest radiological evaluation via x ray
219215963|NCT06750744|DRUG|Tigecycline (Tygacil)|selective antibiogram
219215964|NCT06817655|BEHAVIORAL|PaRole OncO France : Individual peer support|"Following the development of the peer support program PaRole OncO France, we are now proceeding with its implementation and evaluation through a pilot study. This study aims to derive both implementation-related and clinically relevant results.~Prior to their assignment, all peer helpers undergo a comprehensive training course to ensure they are well-equipped for their role.~Patients receive individual peer support during their treatment visits, providing real-time assistance and support within the clinical setting.~The study incorporates three key measurement time points:~1. Baseline measurement (before the intervention)~2. After the intervention~3. Follow-up measurement (1months after the first intervention)~4. Follow-up measurement (6 months after the first intervention)~At each time points, participants will complete a set of standardized questionnaires. These instruments are designed to capture relevant outcomes and experiences related to the peer support intervention."
219215965|NCT05927350|OTHER|Survey|Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
219215966|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
219215967|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
219215968|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
219215969|NCT02673476|DRUG|Placebo|Identical placebo tablets
219215970|NCT06587659|DEVICE|Transcranial Magnetic Stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
219215971|NCT06587659|DEVICE|Robotic Arm|This robotic system is based on a commercially available collaborative robot. The robot is mounted on a cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
219681980|NCT03523195|OTHER|Laboratory Biomarker Analysis|Blood tests
219681981|NCT03523195|DEVICE|Monitoring Device|Wear Fitbit
219681982|NCT03523195|OTHER|Questionnaire Administration|Ancillary studies
219089121|NCT03154489|OTHER|acenocoumarol|medication review with follow-up in acenocoumarol treatment
219089122|NCT03154489|OTHER|control|group
219089123|NCT03220399|DRUG|NVP-1603-1 (P)|1capsule, single oral dosing
219089124|NCT03220399|DRUG|NVP-1603-2 (T)|1tablet, single oral dosing
219089125|NCT03220399|DRUG|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
219089126|NCT04406480|GENETIC|CGH-array and exome sequencing|A blood sample will be used for CGH-array and exome sequencing
219681983|NCT03523195|OTHER|Physical Performance Testing|Performance of physical tests
219089127|NCT01438125|OTHER|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
219089128|NCT01438125|OTHER|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
219089129|NCT02389257|DEVICE|MINIMAG / MEG|
219089130|NCT02389257|DEVICE|MINIMAG / ECG|
219089131|NCT03559101|OTHER|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
219089132|NCT03559101|OTHER|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
219089133|NCT03559101|OTHER|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
219089134|NCT03559101|OTHER|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
219089135|NCT03559101|OTHER|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
219089136|NCT02116348|DRUG|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
219089137|NCT01346319|DRUG|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
219089138|NCT01346319|DRUG|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
219089139|NCT04547725|OTHER|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
219089140|NCT05651854|OTHER|pranayama breathing|Bhramari and sheetali pranayama breathing
219089141|NCT04591028|DRUG|Indocyanine green|A one time injection of IDC prior to the day of scheduled surgery.
219089142|NCT02423681|DEVICE|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
219215972|NCT06854705|OTHER|Continuity of Midwifery care model|The intervention group will receive a continuity of midwifery care model organized by a team of qualified midwives. In this model, antenatal, intrapartum, and postnatal care will be provided by a named (or primary) midwife, who works within a small team (4-8) of CoMC midwives to their cohort of women and will refer or consult an obstetrician in case of complications that requires specialized care. Each named midwife will be backed up by a partner midwife and other team colleagues. The CoMC team comprises 8 whole-time equivalent midwives, including an experienced senior midwife, who leads the team. Following a training needs assessment by the team leader, midwives will receive specialist training, provided by a team of clinical experts and educators, on how to work in midwife continuity models. Pregnant women receive their entire antenatal, intrapartum, and postnatal care from one of the participating CoMC midwives.
219215973|NCT06854705|OTHER|Standard care model|Pregnant women who receive antenatal, intrapartum, and postnatal care following standard practice in Ethiopia will be assigned to the control group. An established practice followed the shared model of care in which responsibility is shared among different staff members, including midwives, nurses, health officers, and medical doctors. Midwives and other health care providers worked conventional eight-hour shifts and handed over care to the next health care provider coming on duty during the next shift. In this model of care, each unit of care had its staff working independently. Besides, the health care provider assigned to the postnatal ward will be responsible for immediate postnatal care. After discharge, each woman in this group become the responsibility of a different group of healthcare providers (usually midwives or nurses) in the family planning and immunization room.
219215974|NCT05551754|DIETARY_SUPPLEMENT|Ketone Supplement|Drink a single dose of ketone supplement 25g
219215975|NCT05551754|OTHER|Alcohol Beverage|Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
219215976|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
219089143|NCT02423681|DEVICE|Without ThermoSmart|ThermoSmart is switched off
219089144|NCT04432701|BEHAVIORAL|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
219089145|NCT05002205|OTHER|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
219089146|NCT05002205|OTHER|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
219089147|NCT05002205|OTHER|ECG|During two study visits, the presence of arrhythmia will be explored.
219089148|NCT05002205|OTHER|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
219089149|NCT05002205|OTHER|Vital parameters|blood pressure, pulse, weight
219089150|NCT00908401|OTHER|Breastmilk|Breastmilk: 0.2 ml
219089151|NCT00908401|OTHER|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
219089152|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
219089153|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
219089154|NCT06214286|DEVICE|Shockwave|Shockwave therapy
219089155|NCT06214286|OTHER|Kinesio taping|Kinesio taping application
219089156|NCT06214286|OTHER|conventional physical therapy|conventional physical therapy
219089157|NCT03737201|OTHER|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
219089158|NCT03737201|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
219089159|NCT03737201|OTHER|Control|without any cavity disinfectant
219089160|NCT01621880|DRUG|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
219089161|NCT01621880|DRUG|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
219089162|NCT01127646|DRUG|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
219089163|NCT01127646|DRUG|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
219089164|NCT01127646|DRUG|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
219089165|NCT02887430|OTHER|foot reflexology therapy|standard care and foot reflexology
219089166|NCT00714376|DRUG|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
219089167|NCT03921814|DEVICE|Treatment with IPL device|Exposure of body parts to the IPL device
219089168|NCT03924778|BEHAVIORAL|DASH diet|brief description
219089169|NCT03924778|BEHAVIORAL|standard American diet|describe
219089170|NCT01568268|DRUG|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
219089171|NCT01568268|DRUG|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
219089172|NCT03566459|OTHER|CBOC offering Tele-MOUD to Veterans|CBOC offering medications for opioid use disorder (MOUD) using telemedicine
219089173|NCT03566459|OTHER|CBOC not offering Tele-MOUD to Veterans|CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
219215977|NCT06098118|BEHAVIORAL|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
219215978|NCT06822114|DRUG|Methoxyethyl Etomidate Hydrochloride|The dose is 50 μCi/48 mg，in the fasting state, a single intravenous injection was given slowly
219215979|NCT06828614|DRUG|Chemotherapy|"The present approved ethics committee includes the conduct of two studies. In the first one, a cross-sectional study, breast cancer patients will be distributed in the study groups according to the moment of their chemotherapy treatment (group 1: pre-chemotherapy, group 2: during chemotherapy, group 3: post-chemotherapy). Each patient will undergo a single evaluation session, which will include the variables detailed in the following section.~In the second, a longitudinal study, patients from the previous study in group 1 (pre-chemotherapy) will be followed up. Patients will receive three assessments of the variables detailed in the following section: 1) during the time prior to the start of chemotherapy (assessment that will coincide with study 1), 2) assessment during chemotherapy treatment and, 3) assessment after the end of chemotherapy treatment."
219215980|NCT04046692|OTHER|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
219215981|NCT04046692|OTHER|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
219089174|NCT00582257|BEHAVIORAL|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
219089175|NCT04963205|DEVICE|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
219089176|NCT04963205|OTHER|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
219089177|NCT01725269|DRUG|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
219089178|NCT03454165|COMBINATION_PRODUCT|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
219089179|NCT03454165|COMBINATION_PRODUCT|Ibrutinib|A novel BTK inhibitor.
219089180|NCT03793725|DRUG|SHR1210|Anti-PD-1 Antibody
219089181|NCT03793725|DRUG|Apatinib|Anti-angiogenic drugs
219089182|NCT01914835|BEHAVIORAL|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
219089183|NCT04067401|BEHAVIORAL|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
219215982|NCT04046692|OTHER|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
219215983|NCT04046692|OTHER|Hospital School Experience, point of view of parents|Operators interview parents
219089184|NCT04067401|BEHAVIORAL|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
219089185|NCT04675450|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
219215984|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
219089186|NCT04675450|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
219089187|NCT06108401|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
219089188|NCT06108401|DIETARY_SUPPLEMENT|Cow milk-based infant formula|Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
219215985|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
219215986|NCT03436992|OTHER|Placebo|placebo
219215987|NCT06812130|OTHER|This is a non-interventional study.|This is a non-interventional study.
219215988|NCT02778425|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
219215989|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219215990|NCT02778425|PROCEDURE|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
219215991|NCT02778425|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
219215992|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219215993|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
219215994|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
219215995|NCT05704725|DRUG|ABP 938|IVT injection
219215996|NCT05704725|DRUG|Aflibercept|IVT injection
219215997|NCT05902325|DRUG|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
219215998|NCT06826573|DIAGNOSTIC_TEST|Intraocular pressure|Intraocular pressure will be measured and recorded at 1 day, 1 week, 1 month, 3 months, 6 months postoperatively, and before silicone oil removal.
219215999|NCT06826573|DIAGNOSTIC_TEST|retinal recovery status|Measure and record the retinal recovery status 1 day, 1 week, 1 month, 3 months, 6 months after surgery and before silicone oil removal.
219089189|NCT02579876|DRUG|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
219089190|NCT02579876|DRUG|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
219089191|NCT02081625|DRUG|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
219089192|NCT05226182|OTHER|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
219089193|NCT04077957|DRUG|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
219089194|NCT04077957|DRUG|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
219089195|NCT04077957|DRUG|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
219089196|NCT04077957|DRUG|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
219089197|NCT04077957|DRUG|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
219089198|NCT04077957|DRUG|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
219089199|NCT01933035|OTHER|Immune Thrombocytopenics|Full blood count with extended platelet parameters
219089200|NCT01933035|OTHER|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
219089201|NCT01933035|OTHER|Control Population|Full blood count with extended platelet parameters
219089202|NCT00738686|DEVICE|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
219089203|NCT05080062|BEHAVIORAL|Requirements and functional Schedule|An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
219089204|NCT05080062|BEHAVIORAL|No intervention|a pain rehabilitation-program
219089205|NCT05287308|DRUG|doxorubicin|doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
219089206|NCT05287308|DRUG|epirubicin|epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
219089207|NCT05287308|DRUG|pirarubicin|pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
219089208|NCT05287308|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
219089209|NCT05287308|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
219681984|NCT04891666|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 12 weeks
219681985|NCT04891666|DIETARY_SUPPLEMENT|Placebo|1 sachet of placebo per day for 12 weeks
219681986|NCT00666211|OTHER|educational intervention|Participants will be educated on pain management.
219681987|NCT00666211|OTHER|Titrated pain management|Pain will be Monitored and Medication Titrated
219681988|NCT00666211|OTHER|questionnaire administration|Participants will be given questionnaires to complete.
219089210|NCT05287308|DRUG|paclitaxel|paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
219089211|NCT05287308|DRUG|docetaxel|docetaxel 80\~100mg/m2, i.v., d1, q3w.
219089212|NCT01555788|DEVICE|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
219089213|NCT06319417|DIETARY_SUPPLEMENT|HT treatment|Total consumption of 60 mg/day of HT
219089214|NCT06319417|DIETARY_SUPPLEMENT|Placebo treatment|Consumption of placebo treatment of 4 caramels/day
219089215|NCT01551602|DRUG|AK159|transdermal administration of teriparatide acetate
219089216|NCT01551602|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
219089217|NCT01551602|DRUG|Placebo|Multiple administration of placebo AK159
219089218|NCT06448429|OTHER|Usual care|Participants will have the usual diabetes care at the Grady Diabetes Clinic.
219089219|NCT06448429|OTHER|Collaborative care model (CoCM)|"Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care."
219089220|NCT00639730|DIETARY_SUPPLEMENT|modified Atkins diet|High fat, low carbohydrate diet
219089221|NCT03577860|DRUG|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
219089222|NCT03577860|DRUG|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
219681989|NCT05030116|DRUG|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
219681990|NCT05030116|DRUG|Domperidone suspension|Domperidone suspension
219681991|NCT06029881|DEVICE|Movesense MD|This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
219089223|NCT00548730|PROCEDURE|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
219089224|NCT03917004|DRUG|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
219089225|NCT00227526|BEHAVIORAL|Prehabilitation|
219089226|NCT02877602|DEVICE|MRI|
219089227|NCT02877602|DEVICE|Transient Elastography|
219089228|NCT01662063|DRUG|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
219089229|NCT02496338|OTHER|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
219089230|NCT01547026|BEHAVIORAL|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
219089231|NCT04782934|DEVICE|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
219089232|NCT03717090|OTHER|No intervention|Sample collection study Sample collection and collection of laboratory values
219089233|NCT03369275|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
219089234|NCT03369275|OTHER|Placebo|Placebo, with excipients, will be administered intravenously.
219216000|NCT04180267|DEVICE|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
219216001|NCT06826872|DRUG|SPC 1001 Mid2|low-dose combination therapy
219216002|NCT06826872|DRUG|SPC 2002|low-dose combination therapy
219216003|NCT06826872|DRUG|SPC 2003|low-dose combination therapy
219216004|NCT06826872|DRUG|SPC 2004|low-dose combination therapy
219216005|NCT06757296|PROCEDURE|Endoscopic SASI|Endoscopic conversion to sleeve gastrectomy to SASI
219216006|NCT06763926|DRUG|Subcutaneous Triptorelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection."
219216007|NCT06763926|DRUG|Intranasal nafarelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection."
219216008|NCT03227861|DRUG|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
219216009|NCT03078010|DRUG|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
219216010|NCT03078010|DRUG|cefepime|(2 gm IV q 8 hrs)
219216011|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
219216012|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
219216013|NCT06808243|PROCEDURE|connective tissue graft|10 patients received mVIP-CTG
219216014|NCT06808243|DEVICE|xenogenic collagen membrane|10 patients received XCM
219216015|NCT06780618|OTHER|RICE|150 g of brown rice from Aek Sibundong variant at once
219216016|NCT06780618|OTHER|rice wheat (placebo)|150 g of white rice from Setra Ramos variant at once
219216017|NCT06891287|COMBINATION_PRODUCT|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity.
219216018|NCT06891287|DRUG|PG-102|PG-102 is a drug for the treatment of obesity.
219089235|NCT00969397|DRUG|Topical Antiangiogenic|Topical Antiangiogenic
219089236|NCT00969397|DEVICE|Pulsed Dye Laser|Pulsed Dye Laser
219089237|NCT01681108|BEHAVIORAL|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
219089238|NCT03487536|OTHER|Nutritional assessment|BMI and cholesterol levels evaluation
219089239|NCT02897479|DRUG|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
219089240|NCT01905930|DEVICE|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
219216019|NCT06891287|OTHER|Placebo|The placebo is the RaniPill with saline instead of a drug.
219089241|NCT01905930|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
219089242|NCT04791072|OTHER|Exercise|Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
219089243|NCT00048672|DRUG|Gleevec|Starting dose of 400 mg orally daily.
219089244|NCT01359670|DRUG|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
219089245|NCT01359670|DRUG|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
219089246|NCT01293058|DRUG|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
219216020|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
219216021|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
219089247|NCT01293058|DRUG|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
219216022|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
219216023|NCT06917703|OTHER|E-learning|in experience group
219216024|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
219216025|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
219216026|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
219216027|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
219216028|NCT04888338|OTHER|Data Capture|Treatment related data is collected
219216029|NCT04888338|OTHER|Electronic Medical Record|Medical records are reviewed
219216030|NCT05182008|OTHER|Decision aid|Online interactive decision aid on method of early abortion
219089248|NCT06425380|OTHER|Resistant Potato Starch|Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations.
219089249|NCT01537302|DEVICE|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
219089250|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
219089251|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
219089252|NCT04543006|DIAGNOSTIC_TEST|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
219089253|NCT00106184|DRUG|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
219089254|NCT00106184|DRUG|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
219089255|NCT02313909|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
219089256|NCT02313909|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
219089257|NCT02313909|OTHER|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
219089258|NCT02313909|OTHER|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
219089259|NCT02082925|OTHER|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
219089260|NCT02799615|DRUG|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
219216031|NCT05182008|OTHER|Usual care|Patients will be directed to the abortion clinic website
219216032|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
219216033|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
219216034|NCT06759818|DEVICE|transcutaneous vagus nerve stimulation|①The first adjustment requires electrical stimulation to break through the skin barrier. The first intervention is the day before the operation. The initial electrical stimulation frequency is 30Hz and the pulse width is 300μs. The frequency and pulse width are adjusted according to the individual feelings of the subject until they are tolerated by the subject. Maximum current stimulation without discomfort and lasting for 30 minutes; ② second time For the intervention, the subject is connected to the monitor after entering the surgery room. After observing that the subject\&#39;s vital signs are within the normal range, the same stimulation frequency as the first time is immediately given for 30 minutes; ③ The third intervention is after the subject\&#39;s surgery is completed. The same stimulation frequency was given in the resuscitation room until the patient was extubated and resuscitated.
219216035|NCT06759818|DEVICE|Sham stimulation group|① The first intervention is also the day before the operation. The frequency and pulse width are adjusted three times without turning on the machine, and the subject is asked if they have any feelings. After adjusting the frequency three times, no operation is performed for 30 minutes; ② The second intervention For the first intervention, after the monitor is connected in the operating room, the frequency and pulse width are not set, and it lasts for 30 minutes before being taken out; ③ For the third intervention, after the subject\&#39;s surgery, earplugs are inserted in the recovery room, and the frequency and pulse width are not set. Remove the earplugs after extubation resuscitation is completed.
219216036|NCT06864130|DRUG|Alendronate 70mg weekly|The intervention is discontinuation of Alendronate
219089261|NCT05180266|OTHER|Therapeutic Touch|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
219216039|NCT06516497|OTHER|Group using traditional method in long bone deformity correction|Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.
219216040|NCT06516497|DEVICE|Group using computer-aided sensors in long bone deformity correction|After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
219089262|NCT05180266|OTHER|Music Listening Group|Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again
219089263|NCT05180266|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
219089264|NCT00314561|DRUG|Pioglitazone, Rosiglitazone|
219089265|NCT00169559|DRUG|GW590735|1µg to 20µg daily doses of GW590735
219216041|NCT06759012|OTHER|EyeTeacher|Participants randomized to the intervention group will receive access to the EyeTeacher system, along with their username, password, and a user manual, one week before the start of the course. They will follow instructions on the website and complete a quiz before and after each course. After completing the EyeTeacher curriculum, they will take the first examination (Examination 1) and complete a set of questionnaires. A classroom will be provided for study purposes, but no restrictions will be imposed on the study location. Following the EyeTeacher section, participants will attend the ophthalmology course in the regular training program, with support from the EyeTeacher system. They will be evaluated according to the ophthalmology posting's evaluation criteria (Examination 2).
219216042|NCT01371045|OTHER|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
219216043|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
219216044|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
219216045|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
219216046|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
219216047|NCT05859750|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
219216048|NCT05859750|DRUG|Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin|oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
219089266|NCT00169559|DRUG|fenofibrate|Marketed Drug
219089267|NCT06063720|DEVICE|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
219089268|NCT04325113|DRUG|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
219216049|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
219216050|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
219216051|NCT01638533|OTHER|Pharmacological Study|Correlative studies
219216052|NCT01638533|DRUG|Romidepsin|Given IV
219216053|NCT06024785|PROCEDURE|Vertebropexy|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side. Additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
219216054|NCT06751901|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
219089269|NCT02789384|OTHER|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
219089270|NCT01583686|DRUG|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219089271|NCT01583686|BIOLOGICAL|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
219216055|NCT06751901|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
219216056|NCT06751901|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219216057|NCT05486507|DIETARY_SUPPLEMENT|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
219216058|NCT05486507|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
219216059|NCT04895917|DRUG|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
219216060|NCT06773234|OTHER|Questionnaire|DREEM Tool
219216061|NCT06776497|DEVICE|VIRTUAL REALITY GLASSES (VRG)|Individuals who met the inclusion criteria and signed the informed consent form were assigned to the study groups based on a list which was numbered and generated in the computer environment before the arteriovenous fistula (AVF) procedure. According to the results given by the computer programme, the individuals were assigned to the control group and the virtual realitiy group (VRG)group. While the control group included patients who underwent AVF procedure with the standard method, the virtual reality headset group included patients who underwent AVF procedure during the VRG application.
219216062|NCT06775483|DRUG|JSKN016|Administered intravenously according to protocol.
219216063|NCT06775483|DRUG|Docetaxel|Administered intravenously according to protocol.
219216064|NCT06775197|PROCEDURE|partial meniscal replacement with Spongioflex®|for any surgical procedure, the patient receives an antibiotic shot NIMP) just before surgery. The patient will be arthroscopically treated via the arthroscopic portal with implantation of a demineralized bone block (IMP: Spongioflex ®, appropriate size (DIZG gGmbH, Berlin, Germany)) as a partial meniscus substitute. The block will be adapted to the defect size and secured with 2-4 inside-out sutures (Etibond 0, Ethicon, Somerville, NJ). No dosing, the IMP has no systemic effect. The surgery (Intervention) will last between 60-90 minutes. The hospital stay is between 2-3 days after surgery. Follow-up visits: at the end of the hospital stay, after 6 weeks, after 6, 12 and 24 months and after 5 years for the operated group.
219216065|NCT04551066|DRUG|parsaclisib|parsaclisib will be administered QD orally
219216066|NCT04551066|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
219216067|NCT04551066|DRUG|placebo|placebo will be administered QD orally
219681992|NCT02299440|OTHER|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
219216068|NCT05529992|DRUG|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
219216069|NCT06945783|DEVICE|Kinesiology Taping|Kinesiology taping was applied to the lumbar area of the participants in the intervention group. The taping aimed to improve posture, reduce pain, and enhance balance and functional performance.
219216070|NCT06945783|OTHER|Physiotherapy|The physiotherapy program included therapeutic exercises and physical modalities (such as stretching, strengthening, and posture training) tailored for individuals with nonspecific low back pain.
219216071|NCT06949475|DIAGNOSTIC_TEST|Single Task (Box and Block Test)|The test requires a wooden box divided into two compartments and 150 blocks (2.5 cm tall). When administering the test, the evaluator should be aware of whether the child's fingertips move from one compartment to the other. The number of blocks passed from one side of the box to the other in one minute determines the level of the skill. It is done separately for right and left hand. The number of cubes thrown in 1 minute gives the score.
219681993|NCT02299440|DRUG|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
219089272|NCT01583686|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
219089273|NCT01583686|DRUG|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219089274|NCT03859258|DEVICE|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
219089275|NCT05016726|DEVICE|Intravascular Lithotripsy|Intravascular Lithotripsy and/or Rotational Atherectomy and/or Orbital Atherectomy to the target vessel prior to placing a coronary stent.
219089276|NCT02560662|BEHAVIORAL|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
219089277|NCT04005534|DRUG|Standard group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
219089278|NCT04005534|DRUG|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
219089279|NCT01249469|OTHER|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
219089280|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0008%|
219089281|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.001%|
219216072|NCT06949475|DIAGNOSTIC_TEST|Single Task (Nine Hole Peg Test)|The 9-hole peg test is a standardized test that measures fine dexterity against time. It is simple to administer and is a valid and reliable method of assessment. Both hands are tested in the assessment. The child is first asked to place 9 sticks of 3.2 cm in length into the holes on the platform as quickly as possible with the dominant hand and the time from the start command until the last stick is placed is recorded. Then, with the same hand, he/she is asked to pick up the sticks in order and the time to remove all the sticks is recorded in seconds. The same procedure is repeated with the other hand.
219089282|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0012%|
219089283|NCT00637130|DRUG|TRAVATAN|
219089284|NCT00637130|OTHER|Vehicle|
219089285|NCT01218880|DRUG|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
219089286|NCT01218880|DRUG|M2ES 15mg|M2ES Dosage：15mg/m2
219216073|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Kognitif Task)|Box Block Test-for the cognitive task assessment, the individual will be asked to count animal names while performing the test.
219216074|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Kognitif Task)|9 Hole Peg Test-for the cognitive task assessment, the individual will be asked to count backwards from 20 one by one while performing the test
219216075|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Motor Task)|For the Box Block Test-motor task assessment, the individual will be asked to keep a rhythm by tapping the table with the fingers on the other side while performing the test. The number of blocks passed from one side to the other side of the box divided into two in one minute will be determined and recorded.
219216076|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Motor Task)|9 Hole Peg Test-for motor task assessment, the individual will be asked to bend and unbend the other elbow while performing the test.
219216077|NCT06949475|DIAGNOSTIC_TEST|ABILHAND-Kids|The Abilhand Kids Hand-Related Ability Scale will be used to assess the use of upper extremities in Activities of Daily Living (ADL). The scale includes 21 sub-items. Sub-items are scored as 0; cannot do, 1; has difficulty in doing and 2; can easily do. The questions are usually answered by the parent, but can also be answered by the child if the child is old enough and cognitive level is appropriate.
219089287|NCT01218880|DRUG|M2ES 30mg|M2ES Dosage：30mg/m2
219089288|NCT01218880|DRUG|M2ES 45mg|M2ES Dosage：45mg/m2
219216078|NCT06949475|DIAGNOSTIC_TEST|Functional Mobility Scale (FMS)|The child's walking ability is assessed at 3 different distances (5 meters (home), 50 meters (school), 500 meters (community)). The assessment at all three distances is graded on a scale of 1-6, with wheelchair mobilization 1 and independent ambulation 6. It is indicated as (C) if the distance can be covered by crawling and (N) if the distance cannot be covered by any other means. The assessment is done through an interview with the family. The child is not observed.
219681994|NCT02299440|DRUG|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
219089289|NCT04367558|PROCEDURE|Minimally invasive, in-office, RF reduction of the affected area|Usage of RF needle to treat one or more of the affected areas
219089290|NCT03629418|DRUG|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
219089291|NCT03629418|DRUG|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
219089292|NCT04667364|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
219089293|NCT06384950|BEHAVIORAL|ChatGPT|Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
219216079|NCT06949475|DIAGNOSTIC_TEST|Myelomeningocele Functional Classification System (MMFC)|The Myelomeningocele Functional Classification System (MMFC) is a 4-level system that classifies individuals with myelomeningocele according to their functional capacity. The functional status of children in Level 1 is more inadequate than in other levels. Functional status improves as the level increases.
219089294|NCT06384950|BEHAVIORAL|patient education with traditional methods.|Patients receive standard traditional education procedures.
219089295|NCT03202043|OTHER|High dose vegetable juice|High dose (13 fl oz) vegetable juice
219089296|NCT03202043|OTHER|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
219089297|NCT03202043|OTHER|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
219089298|NCT03202043|OTHER|Control bottled water|Control (12 fl oz) bottled water
219089299|NCT06427655|DEVICE|SALAD intubation|SALAD suction during intubation
219089300|NCT04230057|DIETARY_SUPPLEMENT|Antitumor B|Single dose 2400 mg
219089301|NCT06579352|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)|Umbilical cord-derived mesenchymal stem cells administered intravenously.
219089302|NCT05408806|OTHER|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
219089303|NCT05860127|BEHAVIORAL|Referral for Cognitive Stimulation Therapy|Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
219089304|NCT05860127|OTHER|No change to Standard of Care|Participants will not receive referral from a physician. They will continue with standard of care at their site.
219089305|NCT04334473|PROCEDURE|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
219089306|NCT04334473|DIAGNOSTIC_TEST|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
219216080|NCT06949475|DIAGNOSTIC_TEST|Modified Mini Mental Test (MMMT)|The Modified Mini Mental Test (MMMT) is used to screen for cognitive dysfunctions in children, to assess the severity of impairments and to determine changes over time. It has been reported that the test is a suitable tool for examining cognitive functions in children from the age of 4 and can be easily included in general neurological examinations of children. The test, which takes 5 to 10 minutes to administer, assesses 5 cognitive domains, including orientation, memory, concentration, language function and measures of structural ability. The total score in this test reaches a plateau at approximately 9-10 years of age. In children over 10 years of age, scores below 27 out of a total of 35 points are indicative of mental retardation.
219089307|NCT02231177|DRUG|BI 1744 CL|
219089308|NCT02231177|DRUG|BI 1744 CL/Tiotropium FDC|
219216081|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
219216082|NCT06953011|OTHER|music application|Patients were met within 1 hour preoperatively. Vital signs, pain score, blood glucose were checked and state anxiety scale was applied. Music was played through headphones and speakers for at least 20 minutes according to the type of music preferred by the patients and the preferred way of listening to music, and the state anxiety scale was applied again. Patients' questions were answered and they were encouraged to share any concerns. Patients were prepared for surgery and transferred to the operating room. Considering the patient's recovery from anesthesia, patients were visited again the day after surgery, vital signs, pain score, blood glucose were checked and the perianesthesia comfort questionnaire (PCQ) was applied.
219089309|NCT02231177|DRUG|Tiotropium|
219089310|NCT00087958|DRUG|XRP9881|
219089311|NCT05718843|DRUG|BI 425809|BI 425809
219089312|NCT01954355|DRUG|LDE225|400, 600 and 800 mg OD
219089313|NCT01954355|DRUG|Paclitaxel|80 mg/m2 (days 1, 8, 15)
219089314|NCT06379191|BEHAVIORAL|Nutrition intervention model based on WeChat applets|"We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group."
219089315|NCT03475082|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (\>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
219089316|NCT03375281|PROCEDURE|RFA|thermal ablation using radiofrequency for HCC
219089317|NCT01087268|OTHER|questionnaire administration|
219089318|NCT01087268|PROCEDURE|gastrointestinal complications management/prevention|
219089319|NCT01087268|PROCEDURE|quality-of-life assessment|
219089320|NCT01896869|DRUG|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
219089321|NCT01896869|BIOLOGICAL|Vaccine|5x10\^8 cells administered in 6 intradermal injections
219089322|NCT01896869|DRUG|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
219089323|NCT02367755|DRUG|Propofol|Propofol use during therapeutic hypothermia
219089324|NCT02367755|DRUG|Lorazepam|Lorazepam use during therapeutic hypothermia
219089325|NCT04670692|OTHER|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
219089326|NCT04670692|OTHER|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
219089327|NCT02260453|OTHER|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
219089328|NCT02260453|OTHER|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
219089329|NCT03058341|DRUG|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
219089330|NCT03058341|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
219089331|NCT01919203|DRUG|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
219089332|NCT05291780|RADIATION|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
219089333|NCT02221167|OTHER|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
219089334|NCT01287130|DRUG|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
219089335|NCT01287130|DRUG|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
219089336|NCT04235335|BEHAVIORAL|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
219089337|NCT06437379|BEHAVIORAL|Infection control|To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.
219089338|NCT00286117|DRUG|Anastrozole|oral
219089339|NCT00286117|DRUG|Tamoxifen|oral
219089340|NCT01387555|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
219089341|NCT01387555|OTHER|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
219089342|NCT04857203|DIAGNOSTIC_TEST|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
219216083|NCT06765746|PROCEDURE|Ventricular tachycardia ablation|"All ventricular tachycardia (VT) ablation procedures will be performed under general anesthesia. An epicardial approach will be performed, if clinically needed, when a detailed endocardial mapping during VT fails to reveal the complete VT critical isthmus. In case of epicardial mapping, the pericardium will be accessed percutaneously using the method described by Sosa et al.~VT activation mapping will be performed and the critical isthmus will be defined as the diastolic pathway.~Ablation will be performed at 50 W (temperature limit of 43 °C) using an irrigated ablation catheter (TactiFlex, Abbott, MN). Ablation will be aimed at VT isthmus transection. Substrate modification will be added if the patient is still inducible or in the absence of any inducible/tolerated VT. Substrate ablation will be performed based on sinus rhythm mapping, aiming at non-inducibility of any VT. At the end of procedure, programmed ventricular stimulation will be repeated."
219089343|NCT03496519|DRUG|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
219089344|NCT03496519|DRUG|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
219089345|NCT02826200|DRUG|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
219089346|NCT02826200|OTHER|Standard of care|Standard of care
219089347|NCT03019874|DIETARY_SUPPLEMENT|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
219089348|NCT03462615|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
219089349|NCT04951674|OTHER|High fiber diet|30 grams of fiber per day
219089350|NCT04951674|OTHER|Control diet|No diet education and change in diet
219089351|NCT03956290|BEHAVIORAL|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
219089352|NCT03865966|OTHER||No intervention
219089353|NCT00430053|GENETIC|gene rearrangement analysis|
219089354|NCT00430053|GENETIC|polymerase chain reaction|
219089355|NCT00430053|GENETIC|proteomic profiling|
219089356|NCT00430053|OTHER|flow cytometry|
219089357|NCT00430053|OTHER|immunohistochemistry staining method|
219089358|NCT00430053|PROCEDURE|biopsy|
219216084|NCT06953102|OTHER|Survey using a questionnaire.|Survey was conducted to collect their responses to PSQI and BAI questionnaires.
219216085|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Virtual Network|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Virtual Newtwork arm will primarily receive these interventions online."
219216086|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Integrated Network activities|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Integrated Network arm will primarily receive these interventions face-to-face and active online activities."
219216087|NCT06950268|DEVICE|ICAMS Splinting Protocol|The ICAMS protocol consisted of a daytime yoke splint maintaining the injured finger in 20° more extension than adjacent fingers, combined with a nocturnal static splint in the intrinsic plus position. The splinting was applied for 4 weeks following extensor tendon tenorrhaphy.
219216088|NCT06950268|DEVICE|Classic Plaster Immobilization|Participants received a classic plaster splint in the intrinsic plus position worn continuously for 4 weeks following extensor tendon tenorrhaphy.
219216089|NCT03301467|DRUG|Avacopan|Orally administered
219216090|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
219089359|NCT00314314|DRUG|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
219089360|NCT00314314|DRUG|Diluent|Intranasal spray; 8 weeks
219089361|NCT00146250|DRUG|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
219089362|NCT02787707|DRUG|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
219089363|NCT02787707|DRUG|lactose|2.7 grams Lactose every 8 hour
219089364|NCT00024492|DRUG|Liposome Encapsulated Mitoxantrone (LEM)|
219216091|NCT02631733|DRUG|Ferumoxytol|Given IV
219089365|NCT05725252|DRUG|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
219089366|NCT05725252|DRUG|NVP-2203-R|administration of active comparator
219089367|NCT01410955|DIETARY_SUPPLEMENT|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
219089368|NCT01410955|DIETARY_SUPPLEMENT|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
219089369|NCT02695355|DRUG|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
219089370|NCT03474302|BEHAVIORAL|Physical Activity|Aerobic, strength training, balance, flexibility
219089371|NCT03474302|OTHER|Successful Aging|Healthy aging education
219089372|NCT01273025|DIETARY_SUPPLEMENT|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
219089373|NCT00454571|DRUG|pazopanib hydrochloride|Given PO
219089374|NCT00454571|DRUG|leuprolide acetate|
219089375|NCT00454571|DRUG|goserelin acetate|
219089376|NCT03431402|DRUG|Hyperbaric oxygen|\- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
219089377|NCT04336748|DRUG|Hydroxychloroquine|low dose (200mg) Hydroxychloroquine once daily for 4 weeks
219089378|NCT04336748|DRUG|Placebo|Placebo
219216092|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
219216093|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
219216094|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219216095|NCT02631733|DRUG|Veliparib|Given PO
219216096|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
219089379|NCT04770064|DRUG|High-dose/short-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
219089380|NCT04770064|DRUG|Low-dose/sustained-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
219089381|NCT04770064|OTHER|Oral placebo capsule|Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
219089382|NCT05939921|DRUG|Metformin|T2DM patients will be provided with metformin in a specified dose
219089383|NCT03389152|DEVICE|Elastography|liver stiffness measurements by shear wave-based elastography
219089384|NCT00816465|DIETARY_SUPPLEMENT|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
219089385|NCT00816465|OTHER|Placebo|PO Placebo pill
219089386|NCT06320886|DIAGNOSTIC_TEST|Diagnostic Test|Use both ultrasonography and Computed tomography scan to diagnose the causes of Acute Abdominal Pain in Adults.
219089387|NCT01092403|DRUG|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
219089388|NCT01092403|DRUG|Placebo|Placebo once daily by inhalation
219089389|NCT02657317|BEHAVIORAL|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
219089390|NCT02657317|OTHER|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
219089391|NCT01201811|DRUG|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
219089392|NCT01089374|RADIATION|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
219089393|NCT02856113|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets.
219089394|NCT02856113|DRUG|Placebo|Alogliptin placebo-matching tablets.
219089395|NCT04367038|OTHER|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
219089396|NCT03494166|BEHAVIORAL|Start with SMSH+TIPC|See arm/group descriptions
219089397|NCT03494166|BEHAVIORAL|Start with SMSH alone|See arm/group descriptions
219089398|NCT06579495|OTHER|Peer involvement in Two player mode(peer involvement) in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
219089399|NCT06579495|OTHER|Single player mode in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
219216097|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
219216098|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
219089400|NCT06579495|OTHER|Children did not engage in any Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
219216099|NCT02798471|DRUG|Edoxaban|15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
219089401|NCT03376815|DIAGNOSTIC_TEST|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
219089402|NCT03782311|BEHAVIORAL|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
219089403|NCT05462535|DRUG|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
219089404|NCT00408148|DRUG|Placebo|Undistinguishable placebo tablets
219089405|NCT00408148|DRUG|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
219089406|NCT03792854|OTHER|EORTC QLQ C30|standardized questionaire
219089407|NCT03792854|OTHER|EORTC QLQ CR29|standardized questionaire
219089408|NCT00615186|DRUG|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
219089409|NCT00615186|DRUG|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
219089410|NCT03477279|BEHAVIORAL|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
219089411|NCT04304352|DRUG|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
219089412|NCT04304352|DRUG|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
219089413|NCT04304352|DRUG|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
219089414|NCT00156143|PROCEDURE|Blood sample|
219089415|NCT00156143|PROCEDURE|Radiography|
219089416|NCT03721640|OTHER|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
219089417|NCT04176341|OTHER|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
219216100|NCT02798471|DRUG|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
219216101|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.
219216102|NCT03626857|OTHER|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
219681995|NCT02299440|OTHER|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
219681996|NCT02299440|DRUG|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
219681997|NCT02299440|DRUG|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
219681998|NCT03627793|OTHER|resistance training|Moving muscles against loads with the purpose of increasing strength.
219681999|NCT05882929|OTHER|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
219682000|NCT05882929|OTHER|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
219089418|NCT01097252|RADIATION|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
219089419|NCT01097252|DRUG|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
219089420|NCT01097252|DRUG|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
219089421|NCT05003050|OTHER|Meditation|Holistic natural therapy
219089422|NCT05003050|OTHER|Pranic Healing|Energy therapy
219089423|NCT03128996|DRUG|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
219089424|NCT03128996|DRUG|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
219089425|NCT02790723|DRUG|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
219089426|NCT06141330|DIETARY_SUPPLEMENT|D Max Drops|Vitamin D
219089427|NCT06141330|DRUG|Azithromycin 250 milligram Oral Capsule|Anti Biotic
219089428|NCT06141330|DRUG|Adapalene|Retinoid
219089429|NCT05292859|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
219089430|NCT05728255|DIAGNOSTIC_TEST|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
219089431|NCT05384028|OTHER|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
219089432|NCT05384028|OTHER|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
219089433|NCT01842113|DRUG|Rifaximin|Rifaximin 550mg by mouth twice a day
219089434|NCT01842113|DRUG|Lactulose|Lactulose 30ml by mouth three times a day
219089435|NCT01842113|DRUG|Lactulose Placebo|Lactulose Placebo 30ml three times a day
219216103|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
219216104|NCT03626857|OTHER|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
219216105|NCT06817408|OTHER|Observation|One additional blood draw in the Emergency Department as part of their standard of care visit.
219216106|NCT05879068|DRUG|PM8002|IV infusion
219216107|NCT05879068|DRUG|Paclitaxel|IV infusion
219216108|NCT06063746|DRUG|Vidutolimod|
219216109|NCT05293717|DRUG|Ruxolitinib|1.5% Ruxolitinib cream
219216110|NCT05036291|DRUG|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
219216111|NCT05848674|OTHER|CArdiac Brief INtervention (CABIN)|CABIN is designed as a brief intervention with a facilitated discussion between a patient and a nurse, with the provision of a short leaflet that summarises information and acts as an aide memoir. The discussion takes place in a quiet area and is intended to last 15-20 minutes. CABIN involves a nurse listening to the patient and recognising any concerns he / she may have and / or identifying erroneous beliefs. It also provides the patient with personalised education on coronary artery disease and cardiac rehabilitation (i.e., information about stenting, stent placement, medication, and purpose / potential benefits of cardiac rehabilitation), along with facilitating psychological and emotional support discussions with a nurse (i.e., explaining causes of a STEMI, discussing support / treatment options, and exploring methods of improving health).
219682001|NCT03671876|DEVICE|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
219682002|NCT06958874|PROCEDURE|Non-surgical periodontal therapy + sub-gingival air polishing|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments, combined with sub-gingival air polishing using erythritol powder. The treatment is applied to periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth.
219682003|NCT06958874|PROCEDURE|Non-surgical periodontal therapy alone|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments.
219089436|NCT01842113|DRUG|Rifaximin Placebo|Rifaximin Placebo twice a day
219089437|NCT04426864|OTHER|Supervised Aerobic Plus Stretching Exercises|An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
219216112|NCT05848674|OTHER|Refined version of CABIN|Participants of the control group will receive a refined version of CABIN, which excludes psychological and emotional support discussions with a nurse and details some standard discharge information (information about coronary artery disease and stenting / stent placement).
219216113|NCT02731612|DRUG|lurasidone|Atypical Antipsychotic
219216114|NCT02731612|OTHER|Placebo|Inactive substance
219216115|NCT05549661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219216116|NCT05549661|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219216117|NCT05549661|DRUG|Onvansertib|Given PO
219089438|NCT04426864|OTHER|Supervised Resistance Plus Stretching Exercises Group|According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.
219089439|NCT04426864|OTHER|Home-based Stretching Exercises Group|Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
219089440|NCT03210662|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219089441|NCT03210662|BIOLOGICAL|Pembrolizumab|Given IV
219089442|NCT03773393|BIOLOGICAL|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
219089443|NCT05298150|OTHER|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
219216118|NCT05549661|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
219216119|NCT05741112|DEVICE|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
219216120|NCT01162096|DEVICE|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
219216121|NCT03485287|DRUG|Midomafetamine HCl|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
219216122|NCT03485287|BEHAVIORAL|Manualized therapy|Non-directive therapy
219216123|NCT03158818|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
219682004|NCT03695146|BEHAVIORAL|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
219682005|NCT03695146|BEHAVIORAL|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
219682006|NCT06958991|DEVICE|Histolog Scanner|The clinical performance study is collecting data from the use of a CE mark product used within the scope of its intended purpose to intraoperatively visualize tissue specimen. The subjects are not submitted to invasive and burdensome procedures compared to the standard of care surgical practices and regular use of the CE mark product.
219682007|NCT02990403|DRUG|Aspirin|
219682008|NCT02990403|DRUG|Heparin|
219682009|NCT02990403|DRUG|Prednisone|
219682010|NCT02990403|DRUG|Immunoglobulin|
219682011|NCT02990403|DRUG|Dydrogesterone|
219216124|NCT05413798|OTHER|Urine HPV testing|Human papillomavirus (HPV) testing in urine sample.
219216125|NCT05413798|OTHER|Self-collected cervicovaginal specimen|Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
219089444|NCT05298150|OTHER|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
219089445|NCT06211660|BEHAVIORAL|AI-based AR training system|Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
219216126|NCT05413798|OTHER|Provider-collected cervical samples|Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
219216127|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
219216128|NCT04477200|DRUG|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
219216129|NCT04477200|RADIATION|Radiation Therapy|40.5 Gy in 15 fractions
219216130|NCT04477200|PROCEDURE|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
219682012|NCT05094414|DRUG|Valacyclovir|oral valacyclovir 500 mg twice per day for 4 weeks
219682013|NCT04054817|DEVICE|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
219682014|NCT03001947|OTHER|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
219682015|NCT00346762|BEHAVIORAL|Education|HIV prevention education and risk reduction counselig
219682016|NCT03352492|PROCEDURE|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
219089446|NCT06211660|BEHAVIORAL|Hand scanner and Video training|Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
219089447|NCT00501826|DRUG|Cyclophosphamide|Given IV
219089448|NCT00501826|DRUG|Cytarabine|Given IV
219089449|NCT00501826|DRUG|Dexamethasone|Given IV or PO
219089450|NCT00501826|DRUG|Doxorubicin Hydrochloride|Given IV
219089451|NCT00501826|DRUG|Mercaptopurine|Given PO
219089452|NCT00501826|DRUG|Methotrexate|Given IV and PO
219089453|NCT00501826|DRUG|Nelarabine|Given IV
219089454|NCT00501826|DRUG|Pegaspargase|Given IV
219089455|NCT00501826|DRUG|Prednisone|Given PO
219089456|NCT00501826|DRUG|Venetoclax|Given PO
219089457|NCT00501826|DRUG|Vincristine Sulfate|Given IV
219089458|NCT05139875|DRUG|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
219089459|NCT05139875|DRUG|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
219089460|NCT04994158|COMBINATION_PRODUCT|Drugs, procedures|standard of care only. non interventional registry.
219089461|NCT02288754|DIAGNOSTIC_TEST|Blood test|No intervention except to collect blood for diagnostic test development
219682017|NCT03352492|PROCEDURE|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
219089462|NCT04471155|PROCEDURE|Holep|laser enucleation of the gland versus open enucleation
219089463|NCT05685459|OTHER|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
219089464|NCT03033225|PROCEDURE|Endoscopic Ultrasound|Undergo EUS-guided PDT
219089465|NCT03033225|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
219089466|NCT03033225|DRUG|Photodynamic Therapy|Undergo EUS-guided PDT
219089467|NCT03033225|OTHER|Quality-of-Life Assessment|Ancillary studies
219089468|NCT03033225|OTHER|Questionnaire Administration|Ancillary studies
219089469|NCT03033225|DRUG|Verteporfin|Given IV
219089470|NCT00423384|DRUG|Placebo|Placebo
219089471|NCT00423384|DRUG|Ibandronate|I.v.
219089472|NCT05864781|BEHAVIORAL|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
219089473|NCT01510431|DRUG|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
219089474|NCT04481737|BEHAVIORAL|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
219089475|NCT04481737|BEHAVIORAL|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
219089476|NCT05780489|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
219089477|NCT03897257|DRUG|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
219089478|NCT03897257|DRUG|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
219089479|NCT03897257|DRUG|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
219089480|NCT03897257|DRUG|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).
219089481|NCT03897257|DRUG|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
219089482|NCT04348305|DRUG|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
219089483|NCT04348305|DRUG|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
219089484|NCT03611348|DRUG|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
219216131|NCT04477200|DRUG|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
219682018|NCT03015298|DEVICE|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
219682019|NCT03015298|DEVICE|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
219682020|NCT00287456|DEVICE|Insulin Pump|
219682021|NCT00287456|DRUG|Insulin|0
219682022|NCT00287456|PROCEDURE|Oral Glucose Tolerance Test|0
219682023|NCT00287456|PROCEDURE|Whole body Protein Turnover|0
219216132|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
219216133|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
219216134|NCT04477200|RADIATION|Radiation Therapy|60 Gy in 30 fractions
219216135|NCT04479696|OTHER|Educational Intervention|Receive standard of care verbal and written education materials
219216136|NCT04479696|OTHER|Questionnaire Administration|Ancillary studies
219216137|NCT04479696|OTHER|Survey Administration|Complete optional survey
219216138|NCT04479696|OTHER|Video|Watch NIRS video
219216139|NCT05030493|DRUG|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219216140|NCT05030493|DRUG|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219216141|NCT06699771|DRUG|GCC2005|CAR-NK Cell Therapy
219216142|NCT06699771|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219089485|NCT03611348|DEVICE|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
219089486|NCT03670667|OTHER|Non-Interventional|Non-Interventional
219089487|NCT03670667|OTHER|Non-Interventional|Non-Interventional
219216143|NCT06699771|DRUG|Fludarabine|Lymphodepleting chemotherapy
219216144|NCT05721573|DRUG|ABC008|Given by subcutaneous injection
219089488|NCT03670667|OTHER|Non-Interventional|Non-Interventional
219216145|NCT05301101|RADIATION|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
219216146|NCT05377060|BEHAVIORAL|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
219216147|NCT05377060|BEHAVIORAL|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
219216148|NCT03762850|DRUG|sparsentan|Target dose of 400 mg daily
219216149|NCT03762850|DRUG|irbesartan|Target dose of 300 mg daily
219216150|NCT03762850|DRUG|Dapagliflozin|Target dose of 10 mg daily
219216151|NCT02398786|OTHER|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
219089489|NCT05349825|DIAGNOSTIC_TEST|Genetic analysis and Losartan plazma level measurement|20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
219089490|NCT05095610|DEVICE|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
219089491|NCT01105923|OTHER|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
219089492|NCT01868295|BEHAVIORAL|Sleeping with denture|Sleeping with denture at night
219089493|NCT01071564|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219089494|NCT01071564|OTHER|Laboratory Biomarker Analysis|Correlative studies
219216152|NCT05606614|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
219216153|NCT03083366|DEVICE|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
219216154|NCT05570617|BEHAVIORAL|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
219216155|NCT05570617|BEHAVIORAL|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
219682024|NCT06959654|DIAGNOSTIC_TEST|ELISA test|ELISA test to evaulate serum oncostatin M and galactin 3 in two group of patientsL
219682025|NCT00202020|DRUG|Cilostazol 200mg/day Oral|
219682026|NCT00202020|DRUG|Aspirin 100mg/day Oral|
219682027|NCT01401946|DRUG|soy isoflavones|
219682028|NCT01401946|DRUG|Placebo|
219216156|NCT05810363|DRUG|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
219089495|NCT01071564|OTHER|Pharmacogenomic Study|Correlative studies
219089496|NCT01071564|OTHER|Pharmacological Study|Correlative studies
219089497|NCT01071564|DRUG|Vismodegib|Given PO
219089498|NCT04999878|DRUG|Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
219089499|NCT00257140|DRUG|levofloxacin|
219089500|NCT01222325|PROCEDURE|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
219089501|NCT01201148|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
219089502|NCT03371940|BEHAVIORAL|Program ACTIVE Exercise|Please see the Exercise arm description above.
219089503|NCT03371940|BEHAVIORAL|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
219089504|NCT03371940|BEHAVIORAL|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
219089505|NCT03371940|BEHAVIORAL|Usual Care - No intervention|Please see the Usual Care arm description above.
219089506|NCT01496833|DEVICE|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
219089507|NCT03353064|OTHER|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
219089508|NCT03353064|OTHER|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
219089509|NCT01636180|DRUG|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
219089510|NCT01636180|DRUG|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
219089511|NCT04983381|OTHER|Multimedia education video|The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
219089512|NCT04523896|RADIATION|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"\- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~\- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
219089513|NCT01751555|DRUG|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
219089514|NCT03069092|BEHAVIORAL|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
219089515|NCT03069092|BEHAVIORAL|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
219089516|NCT03069092|BEHAVIORAL|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
219089517|NCT02080429|PROCEDURE|Passive Descent|
219089518|NCT02080429|PROCEDURE|Pushing|
219089519|NCT06070155|OTHER|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
219216157|NCT05810363|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
219216158|NCT05841706|BIOLOGICAL|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb \< 7 g/dL)
219216159|NCT05841706|BIOLOGICAL|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb \< 9 g/dL)
219216160|NCT05841706|PROCEDURE|Computed Tomography|Undergo CT scan
219216161|NCT05841706|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219089520|NCT04137848|PROCEDURE|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
219089521|NCT04137848|PROCEDURE|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
219089522|NCT00329329|DRUG|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
219089523|NCT02764034|DEVICE|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
219089524|NCT00404664|BEHAVIORAL|influenza vaccine, reminders letters, raffle prize|
219089525|NCT01160848|DRUG|Area cleaned with saline water and occluded with Tegaderm|
219089526|NCT01160848|DRUG|Area cleaned with saline water|
219089527|NCT01160848|DRUG|Area cleaned with Ethyl alcohol solution|
219089528|NCT01160848|DRUG|Visonac left on the skin for 24 hours in facial area one|
219089529|NCT01160848|DRUG|Visonac wiped off after one hour|
219089530|NCT01160848|DRUG|Visonac left on the skin 24 hours in facial area two|
219089531|NCT03859882|OTHER|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
219089532|NCT02240095|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
219089533|NCT02240095|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
219089534|NCT02240095|BEHAVIORAL|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
219089535|NCT00637208|PROCEDURE|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
219089536|NCT06442618|OTHER|Extracorporeal Shockwave Treatment (Group A)|Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol
219089537|NCT06442618|OTHER|Nutraceutical Supplementation (Group B)|Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.
219216162|NCT05841706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219089538|NCT06442618|OTHER|Combined Treatment (Group C)|Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
219089539|NCT00031486|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
219089540|NCT00031486|DRUG|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
219089541|NCT03403348|DRUG|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
219089542|NCT03403348|DRUG|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
219089543|NCT03685591|DRUG|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
219089544|NCT03685591|DRUG|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
219089545|NCT02021175|BEHAVIORAL|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
219089546|NCT02021175|OTHER|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
219089547|NCT04726020|OTHER|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
219216163|NCT05841706|OTHER|Survey Administration|Ancillary studies
219216164|NCT05841706|PROCEDURE|Pancreatectomy|surgical removal of all or part of pancreas
219089548|NCT04726020|OTHER|Standard monitoring|standard monitoring of adverse event reaction
219216165|NCT03668899|PROCEDURE|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
219216166|NCT05490732|BIOLOGICAL|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
219216167|NCT06416072|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
219216168|NCT05464368|DRUG|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
219216169|NCT05464368|DRUG|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
219216170|NCT05464368|DRUG|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
219089549|NCT04767867|OTHER|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
219089550|NCT02220894|BIOLOGICAL|pembrolizumab|
219089551|NCT02220894|DRUG|carboplatin|
219089552|NCT02220894|DRUG|paclitaxel|
219089553|NCT02220894|DRUG|pemetrexed|
219089554|NCT03365076|OTHER|Physical activity|Aerobic physical activity as stated in Arm A
219089555|NCT03230708|OTHER|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
219089556|NCT03230708|DRUG|convention drugs|according to usage method of drugs
219089557|NCT04780373|OTHER|data collection|clinical data collection
219216171|NCT05517265|DRUG|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
219216172|NCT05517265|DRUG|Calquence|acalabrutinib according to Calquence® SmPC.
219216173|NCT04919811|DRUG|Taletrectinib|400mg or 600mg QD
219216174|NCT06148740|OTHER|Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C|Skin serum containing propolis, vitamin C, and manuka honey.
219216175|NCT06290570|DIAGNOSTIC_TEST|12-Lead ECG|A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.
219216176|NCT06290570|DIAGNOSTIC_TEST|Apple Smart Watch Single Lead ECG|A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.
219216177|NCT06290570|DIAGNOSTIC_TEST|AliveCor KardiaMobile 6-Lead ECG|A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
219089558|NCT00529490|DRUG|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
219089559|NCT00529490|DRUG|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
219089560|NCT00500903|DRUG|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
219089561|NCT02447822|DRUG|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
219089562|NCT04373538|BEHAVIORAL|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
219089563|NCT05096156|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
219089564|NCT02510430|BEHAVIORAL|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
219089565|NCT02510430|BEHAVIORAL|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
219089566|NCT02510430|BEHAVIORAL|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
219089567|NCT00529750|DRUG|IRBESARTAN|Tablets
219089568|NCT00529750|DRUG|Atenolol|Tablets
219089569|NCT04445636|DRUG|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
219089570|NCT04445636|DRUG|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
219089571|NCT02532556|DEVICE|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
219089572|NCT00696410|DRUG|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
219089573|NCT01844752|DRUG|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
219216178|NCT06379932|OTHER|Surveys completion|"A questionnaire (including the NRS) will be given to the patient on the day of the procedure, immediately after the biopsy, in the treatment room and without staff intervention (responses will be analyzed by two study investigators at a later date).~The patient health questionnaire (PHQ-9) will also be provided at the same time as the self-report questionnaire, for the assessment of depressive symptoms.~Assessment of the participant's frailty using the Clinical Frailty Scale (CFS) will be carried out prior to the procedure.~Further data will be collected by telephone by a study investigator 15 +/- 2 days after the biopsy and 30 +/- 2 days after the biopsy."
219216179|NCT00979459|DRUG|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
219216180|NCT00979459|DRUG|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
219216181|NCT00083590|DRUG|Huperzine A|
219089574|NCT01844752|DRUG|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
219089575|NCT01844752|DRUG|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
219089576|NCT06048770|BIOLOGICAL|RBI-4000|RBI-4000 intramuscular injection.
219216182|NCT04555668|OTHER|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
219216183|NCT04555668|OTHER|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
219216184|NCT06253299|OTHER|marble stone|"Marble stones with dimensions of 4x5 cm will be used for cold application. When placed in the freezer compartment of the refrigerator at -10°C (Celsius) for 4 minutes, they cool down to 11°C. Subsequently, in 1 minute, the temperature rises to 12°C when held in the palm. After being placed on a table at room temperature, it reaches 18°C in 5 minutes."
219216185|NCT06033105|DEVICE|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
219216186|NCT05747014|DEVICE|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
219216187|NCT04503681|OTHER|Enhanced compassion video|"Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion."
219216188|NCT04503681|OTHER|Standard introduction video|Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
219216189|NCT02961075|OTHER|local surface anesthesia|Airway anesthesia for Bronchoscopy
219216190|NCT02961075|DEVICE|Laryngeal tube|
219216191|NCT01782846|DRUG|Ixprim®|
219216192|NCT01782846|DRUG|Dafalgan-Codeine®|
219216193|NCT04359069|OTHER|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
219216194|NCT04359069|OTHER|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
219089577|NCT06048770|BIOLOGICAL|RabAvert|RabAvert intramuscular injection.
219089578|NCT03344224|DIAGNOSTIC_TEST|laboratory test|laboratory test
219089579|NCT06969456|PROCEDURE|Exercise|Structured treatment sessions, each lasting 30 minutes, will be organized into distinct blocks. In the initial phases, participants will engage in exercises emphasizing core stabilization and general strength training, with a particular focus on forced expiration as a technique to ensure the proper activation of the transversus abdominis muscle. This methodology aims to mitigate adverse effects associated with increased intra-abdominal pressure. To optimize the activation of the transversus abdominis, patients will be instructed to perform a forced expiration while concurrently drawing the navel inward and upward toward the spine, maintaining the lumbar spine in a neutral position. During the initial exercises, ultrasound imaging of the transversus abdominis will be employed as visual feedback, enabling patients to observe muscle thickening during forced expiration. This visual feedback enhances the accuracy of muscle activation and exercise technique. Exercises will be progressively s
219216195|NCT03986359|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
219216196|NCT00028548|DRUG|R(+)XK469|
219216197|NCT00753337|DEVICE|Assurant® Cobalt Iliac Stent System|Iliac Stenting
219216198|NCT05902845|DRUG|RD13-02 cell infusion|CAR-T cells
219216199|NCT05716113|DRUG|RD13-02 cell infusion|CAR-T cells
219089580|NCT06969456|PROCEDURE|TDCS|The transcranial direct current stimulation (tDCS) protocol will involve the application of a continuous current for 30 minutes, with an intensity ranging from 1 to 1.5 mA, targeting the left dorsolateral prefrontal cortex (DLPFC) during each session. Two saline-soaked sponge electrodes, each measuring 35 cm², will be employed to ensure adequate skin contact. In accordance with the international 10-20 EEG electrode placement system, the anodal electrode will be positioned at the F3 location, specifically targeting the left DLPFC. The reference electrode will be placed above the left eye to facilitate efficient current flow through the prefrontal region of the brain. To enhance both safety and efficacy, a 30-second ramp-up and ramp-down period will be incorporated at the commencement and conclusion of the stimulation session. This methodology is intended to minimize potential adverse effects and ensure an optimal stimulation experience for participants.
219089581|NCT06969456|PROCEDURE|ShamTDCS|The device will be configured to produce an upward gradient for 30 seconds, identical to that used in the experimental group, followed by a downward gradient for another 30 seconds. Consequently, the control group will feel a similar tingling on their scalp as the experimental group. This stimulation will occur for a total of 60 seconds, which is insufficient to induce changes in cortical excitability. Studies have demonstrated that this approach effectively ensures patient blinding.
219089582|NCT06971588|OTHER|Music intervention|The intervention will involve patient-chosen music.
219089583|NCT05340855|BEHAVIORAL|Wiidookaage'win Facebook Group|A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
219089584|NCT04791982|BEHAVIORAL|Educational sessions|Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
219089585|NCT00033358|DRUG|medroxyprogesterone|Given intramuscularly
219089586|NCT00033358|DRUG|ethinyl estradiol|Given orally
219089587|NCT00033358|DRUG|norgestrel|Given orally
219089588|NCT00033358|OTHER|laboratory biomarker analysis|Correlative studies
219089589|NCT01811212|DRUG|Cabozantinib S-malate|Given PO
219089590|NCT01811212|OTHER|Laboratory Biomarker Analysis|Correlative studies
219089591|NCT04648540|DRUG|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
219089592|NCT04648540|DRUG|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
219089593|NCT05900726|DIAGNOSTIC_TEST|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
219682029|NCT06959589|DRUG|IBI351, cetuximab β combined with FOLFIRI|"Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for metastatic colorectal cancer with KRAS G12C mutations; Twenty untreated patients with advanced colorectal cancer with KRAS G12C mutation are proposed to be enrolled and treated with the first-line IBI351+ cetuximab β injection +FOLFIRI regimen. The historical reference is expected to be around 40-50%, and it is expected to increase to around 75%. Therefore, among the 20 patients, if ≥15 patients achieve remission, it is considered that the efficacy of the trial protocol is statistically significant.~Cohort B - To evaluate the efficacy and safety of BI351 and cetuximab β as second-line treatment for metastatic colorectal cancer with KRAS G12C mutations.~It is proposed to enrolled 30 patients with advanced colorectal cancer with KRAS G12C mutation who have progressed after first-line treatment, and evaluate IBI351+ cetuximab β injection for second-line treatment. The hi"
219682030|NCT06054945|PROCEDURE|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
219682031|NCT06054945|OTHER|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
219682032|NCT06054945|DEVICE|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
219682033|NCT01953042|BEHAVIORAL|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
219682034|NCT02363387|BEHAVIORAL|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
219682035|NCT02363387|BEHAVIORAL|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
219682036|NCT02609386|BIOLOGICAL|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
219682037|NCT02609386|DRUG|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
219682038|NCT02609386|DRUG|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
219682039|NCT02609386|DIETARY_SUPPLEMENT|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
219089594|NCT05900726|DIAGNOSTIC_TEST|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
219089595|NCT05900726|OTHER|Bowel diary|A daily diary to assess episodes of faecal incontinence
219089596|NCT05900726|OTHER|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
219089597|NCT05900726|OTHER|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
219089598|NCT05900726|OTHER|FISI|Questionnaire to assess the severity of faecal incontinence
219089599|NCT05900726|OTHER|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
219216200|NCT03865199|BEHAVIORAL|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
219089600|NCT05900726|OTHER|St Mark's incontinence score|A score of incontinence
219089601|NCT03684486|BEHAVIORAL|rehabilitation by effort|
219089602|NCT01942681|DRUG|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
219089603|NCT00421720|DRUG|Sufentanil|
219089604|NCT00421720|DRUG|Remifentanil|
219089605|NCT03163355|OTHER|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
219089606|NCT00032279|DRUG|Visilizumab|
219216201|NCT06514391|PROCEDURE|compressive single piece dental implant|4 inter-foraminal single piece compressive dental implants were placed in the mandible via flapless protocol by the aid of stereolithographic surgical guide
219216202|NCT03259269|OTHER|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
219216203|NCT02760654|DEVICE|Proactive Self Management Program for Effects of Cancer Treatment|
219216204|NCT00210106|DEVICE|Ablathermy|
219216205|NCT00224432|DRUG|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
219682040|NCT02609386|DRUG|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
219682041|NCT04142671|OTHER|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
219682042|NCT04567004|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
219682043|NCT04567004|OTHER|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
219682044|NCT04567004|OTHER|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
219089607|NCT01080508|OTHER|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
219089608|NCT01080508|OTHER|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
219089609|NCT04523155|DIETARY_SUPPLEMENT|Medically tailored meals|10 meals per week for 3 months
219089610|NCT05606757|DRUG|BOTOX Dose A|Injection; intramuscular
219089611|NCT05606757|DRUG|Placebo for BOTOX|Placebo
219216206|NCT00825344|DRUG|Etanercept|50 mg subcutaenous preoperatively
219216207|NCT00825344|DRUG|Saline|Given subcutaneously preoperatively
219216208|NCT04515992|BEHAVIORAL|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
219089612|NCT05606757|DRUG|BOTOX Dose B|Injection; intramuscular
219089613|NCT05606757|DRUG|BOTOX Dose C|Injection; intramuscular
219089614|NCT00724581|DRUG|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
219089615|NCT00451165|PROCEDURE|laparoscopic colorectal surgery|laparoscopic colorectal surgery
219089616|NCT04417686|PROCEDURE|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
219089617|NCT00282893|PROCEDURE|transluminal ballooning|
219089618|NCT00282893|OTHER|currently existing therapies for the treatment of vasospasm|
219089619|NCT03642041|BEHAVIORAL|smoking|smoking behavior
219089620|NCT01298505|DRUG|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
219089621|NCT01298505|DRUG|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
219089622|NCT01298505|DRUG|placebo|placebo given twice daily for 7 days
219089623|NCT03256825|DIAGNOSTIC_TEST|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
219089624|NCT03256825|OTHER|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration"
219089625|NCT02154984|BEHAVIORAL|behavioral dietary intervention|Follow tRD
219089626|NCT02154984|BEHAVIORAL|telephone-based intervention|Receive coaching calls
219089627|NCT02154984|OTHER|laboratory biomarker analysis|Correlative studies
219089628|NCT05140330|BEHAVIORAL|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
219089629|NCT05140330|BEHAVIORAL|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
219089630|NCT03659422|OTHER|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
219089631|NCT00820937|PROCEDURE|Single photon emission computed tomography and Magnetic Resonance Imaging|
219089632|NCT05159089|BEHAVIORAL|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
219089633|NCT05159089|BEHAVIORAL|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
219089634|NCT03017079|DIETARY_SUPPLEMENT|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
219089635|NCT03017079|OTHER|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
219089636|NCT06456632|OTHER|Intervention Su Jok Therapy|Su Jok Therapy
219089637|NCT03512652|DEVICE|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
219089638|NCT06220357|DIAGNOSTIC_TEST|Indocyanine Green|The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
219089639|NCT02964676|PROCEDURE|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
219089640|NCT02964676|PROCEDURE|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
219089641|NCT04504656|OTHER|observation of postoperative leak, stenosis, mortality|detect complications in both groups
219089642|NCT06545981|OTHER|Lumbar puncture and administration of medication|Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
219089643|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
219089644|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
219216209|NCT00609050|BEHAVIORAL|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
219089645|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
219089646|NCT06999213|OTHER|Assist|The device will provide assistive torques to support either ankle, knee, and/or hip movements.
219089647|NCT06999213|OTHER|Resist|The device will apply resistive torques to exaggerate gait asymmetries, facilitating error augmentation.
219089648|NCT06999213|OTHER|Slack|The device will be worn but will not generate any torque.
219216210|NCT00609050|BEHAVIORAL|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
219216211|NCT00609050|BEHAVIORAL|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
219216212|NCT04886505|DEVICE|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
219089649|NCT06670872|DRUG|Eravacycline combination therapy group|"Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines."
219089650|NCT02697851|DRUG|Microgynon 30®|
219089651|NCT02697851|DRUG|Evotaz®|
219089652|NCT07002762|DIETARY_SUPPLEMENT|Burdock ( Arctium lappa L.) root extract in a form of a nutritional additive|Gastric soluble capsules each containing: 750 mg of burdock ( Arctium lappa L.) root extract in the form of a nutritional additive
219089653|NCT07002762|OTHER|Placebo|Gastric soluble capsules each containing: Maltodextrin, silicon dioxide, calcium stearate, food colourants
219089654|NCT06621238|BEHAVIORAL|Music|Listen to Music
219089655|NCT04839354|DRUG|L-Arginine Hydrochloride|A one-time L-arginine hydrochloride loading dose of 200 mg/kg will be administered intravenously (IV) followed by a standard dose of 100 mg/kg given by IV three times per day (TID).
219089656|NCT04839354|OTHER|Normal saline|A placebo of normal saline will be administered by IV with a loading dose of 2ml/kg followed by 1ml/kg given by IV three times per day (TID).
219089657|NCT05879627|DRUG|BAT8007 for injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
219089658|NCT03389568|BEHAVIORAL|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
219089659|NCT05613790|DEVICE|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
219089660|NCT05613790|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
219089661|NCT01747564|DRUG|YM178 (mirabegron)|oral
219089662|NCT05467579|DEVICE|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
219089663|NCT00969475|DEVICE|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
219089664|NCT00385411|DRUG|valproate microgranules|20 to 30 mg/kg/day
219216213|NCT01354782|DRUG|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
219216214|NCT01240707|OTHER|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
219216215|NCT00564421|DRUG|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
219089665|NCT04606784|BIOLOGICAL|Ampion|Ampion, nebulized for inhalation
219089666|NCT04606784|OTHER|Standard of Care|Standard of Care
219089667|NCT04700501|OTHER|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
219089668|NCT00820274|PROCEDURE|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
219089669|NCT05323617|DRUG|Romiplostim|Administered as a subcutaneous injection.
219089670|NCT05323617|DRUG|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
219089671|NCT05323617|DRUG|Cyclosporine A|Administered orally.
219089672|NCT05773560|DEVICE|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
219089673|NCT02044627|DRUG|[14C-ETC-1002]|
219089674|NCT01048892|BIOLOGICAL|Seneca Valley virus-001|
219089675|NCT01048892|DRUG|cyclophosphamide|
219089676|NCT01048892|OTHER|laboratory biomarker analysis|
219089677|NCT01048892|OTHER|pharmacological study|
219089678|NCT01331460|BEHAVIORAL|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
219216216|NCT00564421|OTHER|placebo nasal spray|2 sprays in each nostril, dosed twice a day
219216217|NCT00564421|DRUG|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
219216218|NCT00564421|DRUG|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
219216219|NCT00564421|DRUG|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
219216220|NCT01946594|OTHER|Acetaminophen|
219216221|NCT01946594|OTHER|Placebo|
219216222|NCT01608568|DEVICE|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
219682045|NCT04567004|OTHER|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
219089679|NCT01331460|OTHER|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
219089680|NCT03610763|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
219089681|NCT03610763|BEHAVIORAL|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
219089682|NCT05513326|OTHER|Exercises and education|"Exercises: 3 training sessions per week that will last for 30 minutes. Sessions will start with 5 minutes of activation (walking on a treadmill or cycling). Then, participants will be asked to complete 5 exercises targeting lower limb strengthening (time: 18 minutes) followed by 2 exercises designed to improve balance and 3 stretching exercises for the lower limb (time: 7 minutes).~Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions."
219089683|NCT05513326|OTHER|Education alone|Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions.
219089684|NCT06325423|COMBINATION_PRODUCT|neoadjuvant chemotherapy|platinum-based chemotherapy before radical cystectomy or bladder preservation
219089685|NCT06495203|DRUG|anti-VEGF treatment|Follow clinical practice/administration
219089686|NCT06038955|BEHAVIORAL|Virtual reality Based Cognitive Remediation|The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
219089687|NCT06038955|BEHAVIORAL|Virtual reality control training|The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
219089688|NCT04813380|OTHER|Sublingual immunotherapy|Sublingual immunotherapy give to allergic rhinitis patients for treatment
219089689|NCT02240108|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
219089690|NCT02240108|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
219089691|NCT04799379|DRUG|microporous polysaccharide hemospheres (MPH) agent in rectal surgery|Use of microporous polysaccharide hemospheres (MPH) agent in patients after rectal surgery to avoid pelvic collections and the use of any drain
219089692|NCT01345630|DRUG|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
219089693|NCT01345630|DRUG|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
219089694|NCT01345630|DRUG|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
219089695|NCT01345630|DRUG|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
219089696|NCT01345630|DRUG|placebo for maraviroc|placebo for maraviroc
219089697|NCT04414579|DRUG|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
219089698|NCT01573806|DRUG|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
219089699|NCT01573806|DRUG|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
219089700|NCT02310555|PROCEDURE|Gastric bypass|
219089701|NCT02310555|PROCEDURE|Modified gastric bypass.|
219089702|NCT02310555|PROCEDURE|Slevee Gastrectomy|
219089703|NCT03041779|DRUG|Diclofenac Sodium 50Mg Suppository|
219089704|NCT03041779|DRUG|Paracetamol 500Mg Suppository|
219089705|NCT03808779|PROCEDURE|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
219216223|NCT05343494|BEHAVIORAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
218983854|NCT06429488|OTHER|no intervention, questionnaires were used|"The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD)."
219089706|NCT03808779|PROCEDURE|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
219089707|NCT00533104|PROCEDURE|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
219216224|NCT03964740|OTHER|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
219216225|NCT01146522|DRUG|LCQ908|
219216226|NCT01146522|DRUG|Placebo|
219216227|NCT02359929|BIOLOGICAL|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
219216228|NCT03901989|DEVICE|zeolite|given for a period of 12 months
219216229|NCT03901989|DEVICE|cellulose|given for a period of 12 months
219216230|NCT06337058|BEHAVIORAL|Experimental group (motivational interview)|"For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group."
219216231|NCT02672891|DEVICE|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
219682046|NCT04630782|DIAGNOSTIC_TEST|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
219682047|NCT04124380|BEHAVIORAL|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
218983855|NCT03975036|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules
219216232|NCT05001659|OTHER|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
218983856|NCT03975036|DRUG|pd-1 antibody|Pembrolizumabinjection
218983857|NCT04640857|DEVICE|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
218983858|NCT02421471|DRUG|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
219216233|NCT00470314|DRUG|L-Ornithine L-Aspartate|
219216234|NCT03311360|DEVICE|drug-coated balloon|Orchid and Dahlia DCB
219216235|NCT03311360|DEVICE|bare metal stent|any type of bare metal stent
219216236|NCT03793413|PROCEDURE|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
219682048|NCT04124380|BEHAVIORAL|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
219216237|NCT03478969|DEVICE|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
219216238|NCT03478969|DEVICE|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
219216239|NCT03478969|OTHER|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
219216240|NCT04325217|DRUG|Nintedanib|Capsules
219216241|NCT01164488|DRUG|danoprevir|Repeated daily doses
219216242|NCT01164488|DRUG|ketoconazole|Repeated daily doses
219216243|NCT01164488|DRUG|ritonavir|Repeated daily doses
218983859|NCT01435603|BEHAVIORAL|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
218983860|NCT01435603|BEHAVIORAL|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
218983861|NCT05247775|PROCEDURE|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
218983862|NCT04512014|DIAGNOSTIC_TEST|serum lactate|perioperative measurement of lactate levels
218983863|NCT04207021|DIETARY_SUPPLEMENT|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
218983864|NCT04207021|DIETARY_SUPPLEMENT|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
218983865|NCT02846831|OTHER|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
218983866|NCT02846831|OTHER|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
218983867|NCT02846831|DEVICE|Insulin pump|Tandem Diabetes Care
218983868|NCT02846831|DEVICE|Continuous glucose monitoring system|Dexcom G5 Platinum
218983869|NCT02846831|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
218983870|NCT05879679|BEHAVIORAL|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
218983871|NCT01468675|OTHER|Intervention|risk assessment survey; decision support for providers for prevention based on risk
218983872|NCT01784445|DRUG|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
219216244|NCT04246866|BIOLOGICAL|GEM103|GEM103
218983873|NCT06129175|BIOLOGICAL|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
218983874|NCT06129175|OTHER|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
218983875|NCT04352569|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
218983876|NCT03690531|DEVICE|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
218983877|NCT03690531|DEVICE|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
218983878|NCT04336293|DEVICE|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
218983879|NCT04336293|DEVICE|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
218983880|NCT00821483|DRUG|Frovatriptan|2.5mg, qd
218983881|NCT03734042|BIOLOGICAL|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
218983882|NCT03734042|BIOLOGICAL|Normal saline|Intrauterine infusion of normal saline at day 11
218983883|NCT02004522|DRUG|Duvelisib|PI3K Inhibitor
218983884|NCT02004522|DRUG|Ofatumumab|monoclonal antibody
218983885|NCT05509036|OTHER|No interventions|No interventions
218983886|NCT01787331|DRUG|Itraconazole|Given PO
218983887|NCT01787331|OTHER|Laboratory Biomarker Analysis|Correlative studies
218983888|NCT01787331|OTHER|Pharmacological Study|Correlative studies
219216245|NCT04638738|DEVICE|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
219216246|NCT05886972|BEHAVIORAL|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
219216247|NCT02146469|BIOLOGICAL|2 doses with an 3 months interval|varicella vaccination
219216248|NCT02146469|BIOLOGICAL|A second dose with an 1 year interval|varicella vaccine
219216249|NCT02146469|BIOLOGICAL|A second dose with an 3 year interval|varicella vaccine
219216250|NCT02146469|BIOLOGICAL|A second dose with an 5 year interval|varicella vaccine
219216251|NCT02146469|BIOLOGICAL|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
219216252|NCT02146469|BIOLOGICAL|1 dose MMR|MMR
219216253|NCT02941549|OTHER|Placebo capsules|
219216254|NCT02941549|DRUG|Epeleuton|
219216255|NCT02994407|DRUG|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
219216256|NCT01436175|DRUG|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
219216257|NCT01214759|DRUG|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
219216258|NCT01214759|DRUG|Raltegravir|Raltegravir 400mg twice a day
219216259|NCT00661336|DRUG|buthionine sulfoximine|
219216260|NCT00661336|DRUG|melphalan|
219216261|NCT00661336|GENETIC|microarray analysis|
219216262|NCT00661336|OTHER|high performance liquid chromatography|
219216263|NCT00661336|OTHER|laboratory biomarker analysis|
219216264|NCT00661336|OTHER|pharmacological study|
219216265|NCT00661336|PROCEDURE|biopsy|
219216266|NCT05179265|DRUG|recombinant human serum albumin|10 g/bottle (20%, 50 mL)
219216267|NCT05179265|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
219216268|NCT05405244|DRUG|Placebo|2 capsules, orally administered once
219216269|NCT05405244|DRUG|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
219216270|NCT05981352|PROCEDURE|mineral trioxide aggregate pulpotomy|"* After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
219216271|NCT05981352|PROCEDURE|Dehydrated amniotic membrane pulpotomy|"* After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
219216272|NCT05981352|PROCEDURE|Hyaluronic acid pulpotomy|"* After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
219216273|NCT01410409|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
219216274|NCT01410409|DRUG|Paracetamol|1 g x 4/day
218983889|NCT04090866|OTHER|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
218983890|NCT01186536|DIETARY_SUPPLEMENT|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
218983891|NCT01186536|DIETARY_SUPPLEMENT|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
218983892|NCT01186536|DIETARY_SUPPLEMENT|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
219216275|NCT01410409|DRUG|Burana|400 mg x 3/day for three weeks
219216276|NCT01410409|DRUG|Pantoprazol|20mg x 1/day for three weeks
219216277|NCT01410409|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
219216278|NCT01410409|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
219216279|NCT01410409|PROCEDURE|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
219216280|NCT01410409|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
219216281|NCT05201599|DEVICE|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
219216282|NCT05206981|DEVICE|IlluminOss Device|Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.
219216283|NCT01702376|DRUG|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
218983893|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
218983894|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
219216284|NCT01702376|DRUG|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
219216285|NCT01702376|DRUG|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
219216286|NCT01702376|DRUG|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
219216287|NCT00055991|DRUG|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
219216288|NCT03856619|DRUG|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
219216289|NCT03418922|DRUG|Lenvatinib|Specified doses will be administered orally on specified days.
219216290|NCT03418922|DRUG|Nivolumab|Specified doses will be administered intravenously on specified days.
219216291|NCT03451422|DRUG|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
219216292|NCT03451422|DRUG|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
219216293|NCT03158506|DRUG|HMS5552|\[14C\]-labelled HMS5552
219216294|NCT03148652|OTHER|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
219216295|NCT01584466|DRUG|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
219216296|NCT03387540|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
219216297|NCT04132154|PROCEDURE|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
219216298|NCT03213028|OTHER|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
219216299|NCT05267769|DRUG|AP707|Preparation of Cannabis flowers (Cannabis flos)
219216300|NCT01788371|DRUG|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
219216301|NCT01788371|DRUG|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
219216302|NCT00010088|DRUG|fluorouracil|
219216303|NCT00010088|DRUG|gemcitabine hydrochloride|
219216304|NCT00010088|DRUG|leucovorin calcium|
219216305|NCT00010088|PROCEDURE|conventional surgery|
219216306|NCT00010088|RADIATION|radiation therapy|
219216307|NCT00653172|DRUG|NXL103|600mg orally twice daily
219216308|NCT00653172|DRUG|comparator|comparator twice daily
219216309|NCT00653172|DRUG|NXL103|500mg orally twice daily
219216310|NCT04495140|DRUG|[14C]PF-06882961, 50 mg|A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
218983895|NCT05327426|BIOLOGICAL|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
218983896|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
218983897|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
218983898|NCT01682954|BEHAVIORAL|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
218983899|NCT00354861|BIOLOGICAL|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
218983900|NCT00354861|BIOLOGICAL|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
218983901|NCT00354861|BIOLOGICAL|Engerix B|20 µg hepatitis B antigen absorbed on alum
218983902|NCT00667875|DRUG|Placebo|placebo
218983903|NCT00667875|DRUG|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
218983904|NCT00667875|DRUG|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
218983905|NCT03777488|DRUG|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
218983906|NCT03777488|DRUG|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
218983907|NCT03777488|DRUG|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
218983908|NCT02426944|DRUG|NOAC|Medical arm, patients will be treated by NOAC.
218983909|NCT02426944|DEVICE|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
218983910|NCT05577780|PROCEDURE|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
218983911|NCT04789083|OTHER|Propholis extrate|Plassebo
218983912|NCT00450255|BIOLOGICAL|ziv-aflibercept|Given IV
218983913|NCT00450255|OTHER|pharmacological study|Correlative studies
218983914|NCT03247751|DEVICE|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
218983915|NCT01613534|DRUG|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
218983916|NCT01613534|DRUG|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
219216311|NCT04495140|DRUG|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
219216312|NCT03601715|OTHER|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
219216313|NCT03601715|OTHER|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
219216314|NCT03601715|OTHER|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
219216315|NCT00123409|BEHAVIORAL|Telephone disease management|Telephone based care management
219216316|NCT00123409|BEHAVIORAL|Usual Care|Usual care
219216317|NCT05153681|OTHER|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
219216318|NCT00918333|DRUG|panobinostat|Given PO
219216319|NCT00918333|DRUG|everolimus|Given PO
219216320|NCT00918333|OTHER|laboratory biomarker analysis|Correlative studies
219216321|NCT00918333|OTHER|pharmacological study|Correlative studies
218983917|NCT02944032|OTHER|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
218983918|NCT02944032|OTHER|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
218983919|NCT02231008|DRUG|tasimelteon|
219216322|NCT03135782|OTHER|Communication Skills Training|Undergo motivational interviewing training
219216323|NCT03135782|OTHER|Medical Chart Review|Undergo medical chart review
218983920|NCT02231008|DRUG|placebo|
218983921|NCT02530359|DRUG|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
218983922|NCT02530359|DRUG|Placebo equivalent|Placebo equivalent per mouth
218983923|NCT03709446|DRUG|Leflunomide|Single agent leflunomide
218983924|NCT01696071|DRUG|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
218983925|NCT01696071|DRUG|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
218983926|NCT01275820|DIETARY_SUPPLEMENT|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
218983927|NCT02183142|DRUG|Mobic, China, 7.5 mg|
218983928|NCT02183142|DRUG|Mobic, Germany, 7.5 mg|
218983929|NCT03685695|OTHER|Laboratory Biomarker Analysis|Correlative studies
218983930|NCT03685695|DEVICE|Monitoring Device|Wear Fitbit Charge 2
218983931|NCT03685695|OTHER|Physical Activity|Complete aimed walking steps
218983932|NCT03685695|OTHER|Quality-of-Life Assessment|Ancillary studies
218983933|NCT03685695|OTHER|Questionnaire Administration|Ancillary studies
218983934|NCT02255903|OTHER|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
218983935|NCT02587793|OTHER|not interventional study|
218983936|NCT00437983|DIETARY_SUPPLEMENT|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
218983937|NCT00437983|DIETARY_SUPPLEMENT|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
219089708|NCT00533104|PROCEDURE|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
219089709|NCT03994042|DEVICE|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
219089710|NCT04585659|OTHER|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
219089711|NCT00744094|DIETARY_SUPPLEMENT|protein drink|250 ml protein hydrolysate solution
219089712|NCT00744094|BEHAVIORAL|Resistance training|12 weeks resistance training, 3 days per week
219089713|NCT01201603|DIETARY_SUPPLEMENT|orange juice|250ml of orange juice or a sugars matched orange drink
219089714|NCT00148226|BEHAVIORAL|Decision Aid|
219089715|NCT00000822|DRUG|Ritonavir|
219089716|NCT00000822|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219089717|NCT00000822|DRUG|Stavudine|
219089718|NCT00000822|DRUG|Didanosine|
219089719|NCT04960605|PROCEDURE|Dental implants|Treatment of the toothless regions with dental implants
219089720|NCT04112225|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
219216324|NCT03135782|OTHER|Questionnaire Administration|Ancillary studies
219216325|NCT03135782|OTHER|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
219216326|NCT01313884|DRUG|Irinotecan|50 mg/m2/day x 5 days
218983938|NCT02972671|DEVICE|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
218983939|NCT02972671|DEVICE|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
218983940|NCT01163331|OTHER|Singing Therapy|Singing therapy as a way to improve voice quality
218983941|NCT00670150|DRUG|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
218983942|NCT00670150|DRUG|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
218983943|NCT01721993|DRUG|T121|
218983944|NCT01721993|DRUG|Zoledronic acid|
218983945|NCT03966144|DEVICE|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
218983946|NCT05510440|DIETARY_SUPPLEMENT|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
218983947|NCT03233607|PROCEDURE|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
218983948|NCT02138682|DRUG|l-123 Ioflupane|5 millicuries of Ioflupane
218983949|NCT00678080|DRUG|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
218983950|NCT00678080|DRUG|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
218983951|NCT06464003|OTHER|Questionnaire|Malocclusion impact questionnaire
218983952|NCT06485947|BIOLOGICAL|Dinutuximab beta|Combination of immunotherapy with standard chemotherapy
218983953|NCT06485947|DRUG|chemotherapy treatment called GPOH|chemotherapy treatment called GPOH
218983954|NCT06485947|DRUG|chemotherapy treatment called rapid COJEC|chemotherapy treatment called rapid COJEC
218983955|NCT06655285|OTHER|This was a retrospective study and no patient intervention was performed.|This was a retrospective study and no patient intervention was performed.
218983956|NCT01690585|DRUG|Ferinject 1000 mg|
218983957|NCT01690585|DRUG|Sodium chlorure 0,9 %|
218983958|NCT06681168|DEVICE|transcutaneous auricular vagal nerve stimulation|"Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20)."
218983959|NCT06681168|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
219089721|NCT05739669|DEVICE|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
219089722|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
219089723|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
219089724|NCT00463827|DRUG|Atorvastatin|
219089725|NCT00463827|DRUG|atorvastatin|atorvastatin 40mg
219089726|NCT00463827|DRUG|matched placebo|Matched placebo
219216327|NCT01313884|DRUG|Vincristine|2 mg/m2 to a maximum of 2 mg
219089727|NCT02222480|DRUG|Fimasartan|
219089728|NCT02222480|DRUG|Hydrochlorothiazide|
219089729|NCT02222480|DRUG|Placebo|
219089730|NCT04612855|OTHER|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
219089731|NCT06303154|DEVICE|Mobiderm Intimate Bra group|At the conclusion of the surgical operation, MOBIDERM Intimate bra will be placed on the patient by the medical team. It will be recommended for the patients to wear MOBIDERM Intimate Bra during day and night for 3 weeks after the surgery, and as much time as the patients tolerate the device during the rest of the study, until 6 months after radiotherapy
219089732|NCT02573480|BEHAVIORAL|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
219089733|NCT00048880|DRUG|HeFi-1 Monoclonal Antibody|
219089734|NCT04437420|DRUG|injection of BEP 800|injection of BEP 800
219089735|NCT04437420|OTHER|Control|no injection of BEP 800
219089736|NCT00673062|DRUG|SCH 900538|(4X50mg Capsules)
219089737|NCT00673062|DRUG|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
219089738|NCT00673062|DRUG|Placebo Capsules|Placebo
219089739|NCT02481284|DEVICE|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
219089740|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
219089741|NCT05450263|BEHAVIORAL|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
219216328|NCT01313884|DRUG|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
219216329|NCT01313884|DRUG|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
219216330|NCT01313884|DRUG|Cytoxan|1200 mg/m2
219089742|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
219089743|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
219089744|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
219089745|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
219089746|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
219089747|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
219216331|NCT01313884|DRUG|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
219216332|NCT00263757|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
219089748|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
219089749|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
219089750|NCT03938454|DRUG|Crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
219089751|NCT06196736|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
219089752|NCT06196736|DRUG|Chemotherapy|75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
219089753|NCT01090310|DRUG|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
219089754|NCT01090310|DRUG|Placebo|Matching placebo to AIN457
219089755|NCT06116838|DEVICE|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
219216333|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
219216334|NCT04092322|DEVICE|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
219216335|NCT04092322|OTHER|PASE|Physical Activity Scale for Elderly
219216336|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
219216337|NCT04269694|DRUG|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
219216338|NCT04269694|DEVICE|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
219216339|NCT03461666|BEHAVIORAL|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
219216340|NCT03461666|BEHAVIORAL|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
219089756|NCT06116838|DEVICE|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
219216341|NCT03461666|BEHAVIORAL|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
218983960|NCT06681116|DIETARY_SUPPLEMENT|structured nano-water|Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
218983961|NCT06681116|DRUG|Hydrochlorothiazide (HCTZ)|hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
218983962|NCT06681116|OTHER|ordinary bottled drinking water|Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
218983963|NCT06680180|DIAGNOSTIC_TEST|Viscoelastometric assessment of fibrinolysis|Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.
218983964|NCT06680609|DRUG|Nefopam 20 MG/ML|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
218983965|NCT06680609|DRUG|Placebo|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
218983966|NCT06680986|OTHER|Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements)|The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).
218983967|NCT05065528|DIETARY_SUPPLEMENT|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
218983968|NCT05065528|DRUG|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
218983969|NCT03913468|DRUG|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
219089757|NCT00877578|DIETARY_SUPPLEMENT|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
219089758|NCT00877578|DIETARY_SUPPLEMENT|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
219089759|NCT06053814|DRUG|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
219089760|NCT06053814|DRUG|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
219089761|NCT02542839|DEVICE|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
219089762|NCT02542839|DEVICE|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
219089763|NCT02542839|OTHER|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
219089764|NCT02542839|OTHER|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
219089765|NCT02542839|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
219089766|NCT02542839|PROCEDURE|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
219089767|NCT06247202|OTHER|Smart Phone Education (mhealth)|Nutrition and Health Education module delivered through m-health approach (smart phones)
219089768|NCT06247202|OTHER|Paper Education (conventional)|Nutrition and Health Education module delivered through conventional approach (paper)
219089769|NCT02018445|PROCEDURE|Posterolateral Fusion|
219089770|NCT02888717|PROCEDURE|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~* Slices A and C are sent OSNA analysis~* Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~* Free (-): \<250 copies~* Micrometastatic (+): 250 ≤ - \<5,000 copies,~* Macrometastatic (++): ≥ 5000 copies."
219089771|NCT06147518|DRUG|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
219089772|NCT06147518|DRUG|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%
219089773|NCT06147518|DRUG|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%
219089774|NCT00949884|DRUG|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
219089775|NCT00949884|DRUG|Placebo|placebo oral tablets once daily for two weeks
219089776|NCT00949884|DRUG|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
219089777|NCT02463201|BEHAVIORAL|Weight loss|
219089778|NCT04083716|DRUG|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
219216342|NCT03461666|BEHAVIORAL|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
219216343|NCT03225625|PROCEDURE|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
219089779|NCT04083716|DRUG|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
219089780|NCT05614414|PROCEDURE|tracheal intubation by Videolaryngoscope|The investigators performed laryngoscopy using a McGrath video-laryngoscope with a number 4 blade.
219216344|NCT03225625|PROCEDURE|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
219216345|NCT03225625|PROCEDURE|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
219216346|NCT04700410|DEVICE|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
219216347|NCT06226441|PROCEDURE|Continuous Renal Replacement Therapy|CRRT
219089781|NCT05614414|PROCEDURE|tracheal intubation by direct laryngoscope|The investigators performed laryngoscopy using either a Macintosh laryngoscope using a number 4 blade.
219089782|NCT03092375|DRUG|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
219089783|NCT03092375|DRUG|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
219089784|NCT04945421|DRUG|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
219089785|NCT04945421|DRUG|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
219089786|NCT01104740|OTHER|Biological sample collection|Blood (serum) sample collection
219089787|NCT03175627|DEVICE|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
219089788|NCT03175627|DEVICE|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
219089789|NCT01985620|BEHAVIORAL|Educational intervention|
219089790|NCT05458596|BEHAVIORAL|Screen-based simulation|In the research, training will be given to the sample group on intimate partner violence against women through screen-based simulation.
219089791|NCT06175585|OTHER|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
219089792|NCT06175585|OTHER|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
219089793|NCT01255592|DRUG|AZD5069|Oral dose bid
219089794|NCT01255592|DRUG|Placebo|Oral dose bid
219089795|NCT03133104|OTHER|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
219089796|NCT01083641|DRUG|Estradiol|10mg oral three times daily
219089797|NCT04500860|DRUG|Low dose tadalafil 5 mg|Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
219089798|NCT04500860|DRUG|Tolterodine 4 Mg Oral Capsule, Extended Release|To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
219089799|NCT04500860|DRUG|Placebo|Placebo drugs
219089800|NCT01777321|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
219089801|NCT03484676|DEVICE|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
219089802|NCT04158414|DIAGNOSTIC_TEST|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
219216348|NCT05840185|DEVICE|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
219216349|NCT04887337|PROCEDURE|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
219682049|NCT04124380|BEHAVIORAL|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
219682050|NCT05498597|DRUG|AMT-151|Administered intravenously
219682051|NCT05409716|PROCEDURE|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
219216350|NCT04887337|OTHER|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
218983970|NCT06689917|DRUG|JY231 Injection|"This study employs two pretreatment regimens:~In the lymphodepletion regimen, upon enrollment, subjects undergo leukapheresis followed by 3-5 days of lymphodepleting therapy with fludarabine and cyclophosphamide, culminating in intravenous infusion of JY231 and autologous patient PBMCs via a double-lumen catheter; in the non-lymphodepletion regimen, subjects receive direct intravenous injection of the JY231 preparation immediately after enrollment."
218983971|NCT07050121|DRUG|Ciwujia capsules|Ciwujia capsules for oral use，2-3 capsules per dose, three times daily. 28 days constitute one treatment course; efficacy and safety will be assessed over two courses. Dosage adjustments should follow the physician's instructions.
218983972|NCT07053202|COMBINATION_PRODUCT|Nivolumab|hepatic artery infusion therapy with nivolumab was performed
218983973|NCT07053202|PROCEDURE|Transarterial Chemoembolization (TACE)|Seldinger technique for femoral artery puncture. Catheterization to celiac trunk/hepatic artery. Infusion of a mixture of idarubicin, raltitrexed, iodized oil, and contrast agent (approx. 8 mL). Embolization with microspheres (300-500 μm and 500-700 μm).
218983974|NCT07054346|DRUG|177 Lutetium Prostate-Specific Membrane Antigen 617|Given intravenously (IV) or intra-arterially (IA)
218983975|NCT07054346|DRUG|Actinium-225 Prostate-Specific Membrane Antigen 617|Given IV or IA
218983976|NCT07054346|PROCEDURE|Non-investigational, Prostatectomy|Undergo non-investigational surgical procedure to remove prostate.
218983977|NCT07054346|PROCEDURE|Prostate Tissue Collection|Whole prostate tissue will be collected for correlative research at time of prostatectomy.
218983978|NCT07054346|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Imaging procedure
218983979|NCT07054346|PROCEDURE|Blood Sample Collection|Blood samples will be obtained for research purposes
218983980|NCT07054567|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
218983981|NCT07054567|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
218983982|NCT07054567|DRUG|Bevacizumab|Administration for a cycle of 3 weeks.
218983983|NCT07054944|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Lymphatic mapping
218983984|NCT00014937|DRUG|lopinavir/ritonavir|
218983985|NCT00014937|DRUG|lamivudine/zidovudine|
218983986|NCT00014937|DRUG|efavirenz|
218983987|NCT00014937|DRUG|lamivudine|
218983988|NCT00014937|DRUG|stavudine|
218983989|NCT00014937|DRUG|zidovudine|
218983990|NCT00014937|DRUG|didanosine|
218983991|NCT06681311|OTHER|Exercises|During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
218983992|NCT03730012|DRUG|gilteritinib|Oral tablet
218983993|NCT03730012|DRUG|atezolizumab|Intravenous infusion
218983994|NCT05471557|PROCEDURE|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
218983995|NCT03395210|DRUG|Rilzabrutinib|BTK inhibitor
218983996|NCT05679427|RADIATION|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
218983997|NCT05241912|DRUG|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
218983998|NCT05736497|OTHER|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
218983999|NCT03320057|DRUG|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
218984000|NCT03320057|OTHER|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
218984001|NCT01367002|DRUG|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
218984002|NCT01367002|DRUG|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
218984003|NCT02027883|DEVICE|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
219216351|NCT06950814|PROCEDURE|postoperative adjuvant therapy|Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
219216352|NCT06261710|OTHER|Sonography in labour|Using intrapartum sonography parameters in labour
219216353|NCT05374889|OTHER|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
219216354|NCT02352675|OTHER|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
218984004|NCT02027883|DEVICE|Educated T shock setting|Experimental Parameter Set 2 Programming Values
218984005|NCT05575531|OTHER|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
218984006|NCT02655640|OTHER|Questionnaires|Questionnaires will be provided to patients
218984007|NCT03047915|OTHER|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
218984008|NCT00841646|BIOLOGICAL|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
218984009|NCT02614092|BEHAVIORAL|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
219089803|NCT01924611|PROCEDURE|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
219089804|NCT01924611|PROCEDURE|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
219089805|NCT04332523|DRUG|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
219089806|NCT02032160|BIOLOGICAL|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
219089807|NCT02032160|BIOLOGICAL|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
218984010|NCT00717093|DRUG|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
218984011|NCT00717093|DRUG|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
218984012|NCT02428270|DRUG|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
218984013|NCT02428270|DRUG|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
218984014|NCT04546061|BEHAVIORAL|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
218984015|NCT00354536|DRUG|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
218984016|NCT00354536|BIOLOGICAL|placebo injection|placebo injection
218984017|NCT05557708|DRUG|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
218984018|NCT05557708|DIAGNOSTIC_TEST|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
218984019|NCT02684916|PROCEDURE|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
218984020|NCT02684916|PROCEDURE|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
218984021|NCT06248801|DRUG|Vildagliptin and Metformin-Test product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
218984022|NCT06248801|DRUG|Vildagliptin and Metformin-Reference product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
218984023|NCT03035604|OTHER|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
219089808|NCT05655676|DRUG|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
219089809|NCT01519388|OTHER|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
219089810|NCT01519388|DEVICE|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
219089811|NCT05850780|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain."
219089812|NCT05850780|DRUG|MTA|Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
219089813|NCT05767528|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
219089814|NCT01207570|PROCEDURE|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
219089815|NCT01207570|PROCEDURE|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
219089816|NCT01972633|PROCEDURE|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
219089817|NCT01972633|PROCEDURE|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
219216355|NCT04449835|PROCEDURE|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
219216356|NCT01446497|DRUG|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
219216357|NCT01446497|DRUG|Timolol|Twice per day, 1 drop at each time
219216358|NCT01693211|DEVICE|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
219216359|NCT01693211|DEVICE|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
219216360|NCT06435650|COMBINATION_PRODUCT|Cannabis suppositories and mindful-compassion for anal pain|This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain
219216361|NCT06435650|BEHAVIORAL|Mindful-compassion|Mindful-compassion
219216362|NCT04248998|DIETARY_SUPPLEMENT|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
219216363|NCT04248998|DRUG|Metformin|Metformin 850 mg twice a day
219216364|NCT04248998|DRUG|Preoperative chemotherapy|"Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
219089818|NCT00089141|DRUG|mycophenolate mofetil|Given orally
219089819|NCT00089141|DRUG|placebo|Given orally
219216365|NCT01236846|DIETARY_SUPPLEMENT|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
219216366|NCT01236846|DIETARY_SUPPLEMENT|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
219216367|NCT04621435|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
219216368|NCT04621435|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
219216369|NCT04621435|DRUG|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
219216370|NCT06379516|OTHER|Moisturising Cream (5%)|This intervention is a moisturiging cream of concentration 5% for topical application to the respective test sites.
219216371|NCT06379516|OTHER|Moisturising Cream (10%)|This intervention is a moisturiging cream of concentration 10% for topical application to the respective test sites.
219216372|NCT06379516|OTHER|Coconut Oil|This intervention is a 100% pure coconut oil product (Parachute Pure Coconut Oil) for topical application to the respective test sites.
218984024|NCT02023567|DRUG|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
218984025|NCT01516437|PROCEDURE|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
218984026|NCT01516437|PROCEDURE|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
218984027|NCT01516437|PROCEDURE|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
218984028|NCT06373627|OTHER|Hypnosis|"A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient."
219216373|NCT02097069|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 mcg/day
219216374|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol|myo-inositol 2000 mg twice a day
219216375|NCT02097069|DIETARY_SUPPLEMENT|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
219216376|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
219216377|NCT02796729|PROCEDURE|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
219216378|NCT02796729|DRUG|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
219089820|NCT03026218|OTHER|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
219089821|NCT03026218|OTHER|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
219216379|NCT02796729|DRUG|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
219216380|NCT02325349|DRUG|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
219216381|NCT04218383|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
219216382|NCT01638975|BEHAVIORAL|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
219216383|NCT00402428|DRUG|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
219216384|NCT00402428|DRUG|peginterferon alfa-2a|180 mcg once a week for 48 weeks
219216385|NCT00402428|DRUG|Ribavirin|"1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)"
219216386|NCT01560494|OTHER|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
219216387|NCT02964741|DEVICE|Active Comparator|non-invasive brain stimulation (active protocol)
219216388|NCT02964741|DEVICE|Sham Comparator|non-invasive brain stimulation (sham protocol)
219216389|NCT01332175|DEVICE|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
219216390|NCT01332175|DEVICE|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
219216391|NCT01332175|PROCEDURE|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
219216392|NCT04674995|PROCEDURE|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
219216393|NCT00455650|DRUG|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
219216394|NCT00455650|DRUG|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
219216395|NCT00455650|DRUG|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
219216396|NCT02412033|DRUG|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
219216397|NCT02412033|DRUG|Placebo|This group will receive placebo
218984029|NCT06373627|DRUG|Conventional medications used for sedation-analgesia|MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
218984030|NCT06373627|DRUG|Medications used in addition to hypnosis|MEOPA + intravenous ketamine (0.3 mg/kg)
218984031|NCT05981898|DEVICE|OPTIVF dosage|Dosage predicted by Opt-IVf
219089822|NCT03418116|DEVICE|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
219089823|NCT01888393|DRUG|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
219216398|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
219216399|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
219216400|NCT00606333|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
219216401|NCT00606333|DEVICE|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
218984032|NCT05981898|DEVICE|traditional Dosage|Dosage used traditionally by doctors
218984033|NCT03613844|DRUG|DHA|DHA supplementation
218984034|NCT03613844|DRUG|Placebo|Placebo for DHA
218984035|NCT01650844|OTHER|School-Based Telemedicine Enhanced Asthma Management|
218984036|NCT01650844|OTHER|Enhanced Usual Care|
219216402|NCT05419466|DIETARY_SUPPLEMENT|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
219216403|NCT03781349|DEVICE|MENS|
219216404|NCT03781349|DEVICE|TENS|
219216405|NCT06303674|BEHAVIORAL|Physical activity with engaging cognitively|"This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams."
219216406|NCT06303674|BEHAVIORAL|Physical activity without engaging cognitively|This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
219216407|NCT01905800|DEVICE|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
219216408|NCT03001206|DEVICE|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
219216409|NCT01209195|DRUG|MM-121|increasing doses of MM-121 IV QW
219089824|NCT00873418|BEHAVIORAL|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
219089825|NCT06181864|OTHER|NAO intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. the children are guided by the voice of the robot Nao. The robot guides them in carrying out practical and relaxation activities. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
219089826|NCT06181864|OTHER|Traditional intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. The children are guided by the instructions of the operator who guides them in carrying out practical and relaxation activities. Consequently, the operator will provide feedback, to return information to the subject regarding the accuracy of the response.
219089827|NCT04577677|DEVICE|brain stimulation|tDCS and peripheral nerve stimulation
219089828|NCT02780232|BEHAVIORAL|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~1. What is 'CUIDA TU ÁNIMO': Description and definition of the program~2. Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~3. How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~4. Forums.~5. Blog.~6. Appointment (Chat or Phone call).~7. Contact."
219089829|NCT02391636|DRUG|Carbetocin|at delivery of anterior shoulder
219089830|NCT02391636|DRUG|Oxytocin|at delivery of anterior shoulder
219089831|NCT01479998|OTHER|standard care|standard care plus nicotine replacement therapy
219089832|NCT01479998|OTHER|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
219216410|NCT01209195|DRUG|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
219216411|NCT03471585|DRUG|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
219216412|NCT03471585|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
219216413|NCT01212744|DRUG|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
219216414|NCT01749319|DRUG|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
219216415|NCT01749319|DRUG|Intervenous baclofen|
219216416|NCT06274203|DRUG|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.
219216417|NCT02588313|DIETARY_SUPPLEMENT|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
219216418|NCT02167451|DRUG|Maraviroc|
219216419|NCT05237999|BEHAVIORAL|KopOpOuders-PTSD|See arm description
219216420|NCT01935063|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
219089833|NCT02984657|PROCEDURE|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
219089834|NCT02984657|PROCEDURE|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
219089835|NCT05131165|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
219089836|NCT05131165|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to draw a prize if they take their medication within +/- one hour of the stated existing routine to which pill-taking is anchored on at least 70% of days between recruitment and the 3-month study visit.
219089837|NCT02300857|BEHAVIORAL|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
219089838|NCT02300857|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
219089839|NCT02300857|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
219089840|NCT04930692|DIAGNOSTIC_TEST|Contrast-enhanced CT lymphography with the periareolar injection of iopamidol|"Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator."
219089841|NCT05897723|DEVICE|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
219216421|NCT01935063|OTHER|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
219216422|NCT03510416|DRUG|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
219216423|NCT03510416|RADIATION|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
219216424|NCT03297138|PROCEDURE|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
219216425|NCT01218659|DRUG|migalastat hydrochloride|150-mg capsule administered orally QOD
219216426|NCT01218659|BIOLOGICAL|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
219216427|NCT02631655|OTHER|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
219216428|NCT01440166|DRUG|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
219216429|NCT01440166|OTHER|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
219216430|NCT05770492|DIAGNOSTIC_TEST|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
219216431|NCT04796792|DEVICE|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
219216432|NCT02555306|DRUG|0.5 mg of DE-122|DE-122 Injectable Solution
219216433|NCT02555306|DRUG|1.0 mg of DE-122|DE-122 Injectable Solution
219216434|NCT02555306|DRUG|2.0 mg of DE-122|DE-122 Injectable Solution
219216435|NCT02555306|DRUG|4.0 mg of DE-122|DE-122 Injectable Solution
219216436|NCT04650191|OTHER|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
219216437|NCT04497337|PROCEDURE|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
219089842|NCT05181293|BEHAVIORAL|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
219089843|NCT02298361|OTHER|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
219089844|NCT01798394|DRUG|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
219089845|NCT01798394|OTHER|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
219089846|NCT02520167|BEHAVIORAL|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
219089847|NCT00116896|DRUG|OSI-7904L|
219089848|NCT00116896|DRUG|Cisplatin|
219089849|NCT02234544|DRUG|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
219089850|NCT02234544|DRUG|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
219089851|NCT02234544|OTHER|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
219089852|NCT04107831|OTHER|Pulmonary rehabilitation|Pre-post test design
219089853|NCT06185998|DEVICE|low pressure tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
219089854|NCT06185998|DEVICE|plated balloon tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
219089855|NCT05168579|BEHAVIORAL|Deliberate practice|As above
219089856|NCT01934803|DIETARY_SUPPLEMENT|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
219216438|NCT02298166|DRUG|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
219216439|NCT02298166|DRUG|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
219089857|NCT01934803|DIETARY_SUPPLEMENT|Placebo|
219089858|NCT05747963|DEVICE|software-delivered CBT-I|The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
219089859|NCT05747963|OTHER|online PE|Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
219089860|NCT02167763|DEVICE|VeraCept Intrauterine Copper Contraceptive|
219089861|NCT02167763|DEVICE|TCu380 IUD|
219089862|NCT02094443|DRUG|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
219089863|NCT02094443|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
219089864|NCT05280769|OTHER|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
219089865|NCT05280769|OTHER|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
219089866|NCT05280769|OTHER|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
219089867|NCT05280769|OTHER|Smokeless tobacco|Participant's typical brand of smokeless tobacco
219089868|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
219089869|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
219089870|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
219089871|NCT06276933|DRUG|Camrelizumab + chemotherapy+Thalidomide|"Camrelizumab + chemotherapy+Thalidomide Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: Thalidomide Thalidomide 100mg，po qd； Other Name: Thalidomide~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
219216440|NCT02298166|DRUG|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
219089872|NCT06276933|DRUG|Camrelizumab + chemotherapy+placebo|"Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: placebo 100mg placebo 100mg，po qd；~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
219089873|NCT02754102|OTHER|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
219089874|NCT01424930|DRUG|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
219216441|NCT02298166|OTHER|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
219216442|NCT01617707|DRUG|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
219216443|NCT01617707|DRUG|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
219216444|NCT02534285|DEVICE|hearing protection|Attenuation of hearing during surgery
219216445|NCT04191824|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed APOL1 return of results
219216446|NCT00909324|DRUG|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
219216447|NCT00909324|DRUG|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
219216448|NCT04428710|OTHER|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
219216449|NCT04305821|OTHER|Dosage of S100β protein|Dosage of S100β protein
219216450|NCT01378416|DRUG|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
219216451|NCT06270524|PROCEDURE|Blood sampling|Blood sampling will be taken for further analysis
219216452|NCT01760382|DEVICE|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
219216453|NCT00415649|BIOLOGICAL|VRC-HIVDNA016-00-VP|
218984037|NCT06343740|BEHAVIORAL|COMET-Y|Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
218984038|NCT02281201|BIOLOGICAL|BE1116 (Prothrombin Complex Concentrate)|
218984039|NCT06484738|OTHER|transcriptomic analysis|to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
218984040|NCT04437186|BEHAVIORAL|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
219089875|NCT01424930|DRUG|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
219089876|NCT02449668|DEVICE|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
219089877|NCT02449668|DEVICE|Sham Acupuncture|
219089878|NCT00872040|OTHER|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
219089879|NCT04119895|OTHER|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
219089880|NCT04119895|OTHER|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
219089881|NCT02608866|RADIATION|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
219089882|NCT02608866|RADIATION|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
219089883|NCT02913066|OTHER|S-1 concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.
219089884|NCT02913066|OTHER|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
219089885|NCT02982525|DIETARY_SUPPLEMENT|No Mussels|Habitual diet only
219089886|NCT02982525|DIETARY_SUPPLEMENT|One mussel portion|1 x 75g mussel portions provided per week
218984041|NCT05501275|BEHAVIORAL|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
219089887|NCT02982525|DIETARY_SUPPLEMENT|Two mussel portions|2 x 75g mussel portions provided per week
219089888|NCT02982525|DIETARY_SUPPLEMENT|Three mussel portions|3 x 75g mussel portions provided per week
219089889|NCT05461703|BEHAVIORAL|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
219089890|NCT01691833|DIETARY_SUPPLEMENT|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
218984042|NCT00316719|DRUG|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
218984043|NCT00316719|DRUG|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
218984044|NCT03493399|BEHAVIORAL|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
218984045|NCT01542320|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
218984046|NCT01542320|OTHER|Placebo|Solution without active Lactobacillus reuteri
218984047|NCT04453371|DRUG|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
218984048|NCT04453371|DRUG|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
218984049|NCT00134459|DRUG|Bifeprunox|
218984050|NCT00134459|DRUG|Placebo|
218984051|NCT01559467|OTHER|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
218984052|NCT01559467|OTHER|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
219089891|NCT01691833|DIETARY_SUPPLEMENT|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
219216454|NCT00415649|BIOLOGICAL|VRC-HIVADV014-00-VP|
219216455|NCT00415649|BIOLOGICAL|Vaccine placebo|Placebo comparator
219216456|NCT06494566|DIETARY_SUPPLEMENT|Omega-3|Omega-3 capsule
219216457|NCT06494566|DIETARY_SUPPLEMENT|Mineral Oil|Mineral Oil Capsule
219216458|NCT03496545|DRUG|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
219216459|NCT03496545|DRUG|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
219216460|NCT04729855|DIAGNOSTIC_TEST|PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample, normal and CRC tissue
219089892|NCT01080222|DRUG|telaprevir|tablet, 1125-mg, twice daily
219089893|NCT01080222|DRUG|VX-222|capsule, 100-mg, twice daily
219089894|NCT01080222|DRUG|ribavirin|tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
219089895|NCT01080222|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
219089896|NCT01080222|DRUG|VX-222|capsule, 400-mg, twice daily
219089897|NCT02826122|DEVICE|Pai APP|Prescription: Target 100 PAI Points per week
219216461|NCT03247842|PROCEDURE|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
219216462|NCT01437319|DEVICE|lotrafilcon A|To be used during run-in phase only.
219216463|NCT01437319|DEVICE|comfilcon A|To be assigned at randomization at phase 2 only.
219216464|NCT01437319|DEVICE|balafilcon A|To be assigned at randomization during phase 2 only.
219216465|NCT01437319|OTHER|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
219216466|NCT01499849|DRUG|Rolapitant|(4 X 50 mg capsules) 200 mg PO
219216467|NCT01499849|DRUG|Granisetron|10 mcg/kg IV
219216468|NCT01499849|DRUG|dexamethasone|20 mg PO and 8 mg PO
219216469|NCT01499849|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
219216470|NCT03282045|DRUG|Lysobact Complete Sprey|Inhaling spray
219216471|NCT03282045|DRUG|Tantum Verde® Spray|Inhaling spray
219216472|NCT03282045|DRUG|Pharyngal® Oromucosal Spray|Inhaling spray
219216473|NCT03282045|DRUG|Placebo|Inhaling spray
219089898|NCT02826122|DEVICE|FitBit APP|Prescription: Target daily 10.000 steps
219089899|NCT00846105|OTHER|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
219089900|NCT00779389|DRUG|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
219089901|NCT00779389|DRUG|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
219089902|NCT00779389|DRUG|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
219089903|NCT00779389|DRUG|Placebo|Placebo for 14-21 days.
219089904|NCT00779389|DRUG|Erlotinib|Erlotinib 150 mg for 14-21 days.
219089905|NCT04150991|OTHER|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
219216474|NCT00174252|DRUG|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
219216475|NCT05298371|BEHAVIORAL|Corrected Sitting postures|Change after being in Corrected Sitting postures
219216476|NCT05298371|BEHAVIORAL|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
219216477|NCT05298371|BEHAVIORAL|Corrected Standing posture|Change after being in Corrected Standing posture
219216478|NCT05298371|BEHAVIORAL|Natural / relaxed standing postures|Change after being in relaxed standing postures
219216479|NCT06395571|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
219216480|NCT06395571|DIETARY_SUPPLEMENT|Cow's milk-based infant formula|Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
219216481|NCT04737291|DEVICE|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
219216482|NCT04544319|DRUG|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
219216483|NCT04544319|DRUG|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
219216484|NCT05823818|DEVICE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
219216485|NCT01233934|DRUG|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
219216486|NCT01233934|DRUG|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
219216487|NCT00154115|DRUG|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
219216488|NCT00154115|DRUG|placebo|Placebo
219216489|NCT00811941|DRUG|Placebo|as-needed use, tablets, orally, 52 weeks
219216490|NCT00811941|DRUG|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
219216491|NCT04056702|DRUG|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
219216492|NCT02061124|DRUG|Sevelamer 1600 mg TID for 7 days|
219216493|NCT02061124|DRUG|Placebo 1600 mg TID for 7 days|
219216494|NCT05562102|BIOLOGICAL|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
219216495|NCT02958800|OTHER|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
219089906|NCT04150991|OTHER|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
219089907|NCT00983632|PROCEDURE|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
219089908|NCT00983632|DEVICE|selective vagus nerve stimulation|electrical vagus stimulation
219089909|NCT00218881|PROCEDURE|HIV educational video|
219089910|NCT05691257|DRUG|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
219089911|NCT05691257|DRUG|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
219089912|NCT00311038|DRUG|ONO-1101|
219089913|NCT01694732|DRUG|Varenicline|
219089914|NCT01694732|DRUG|placebo|
219089915|NCT02857426|DRUG|Nivolumab|
219089916|NCT01645748|DRUG|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
219216496|NCT03802994|DRUG|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
219216497|NCT03802994|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
219216498|NCT03802994|OTHER|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
219216499|NCT02620306|DRUG|Fimsartan 60mg~120mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
219089917|NCT01645748|DRUG|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
219216500|NCT02620306|DRUG|Fimsartan 60mg~120mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
219216501|NCT02620306|DRUG|Losartan 50mg~100mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
219216502|NCT02620306|DRUG|Losartan 50mg~100mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
219216503|NCT03042741|BIOLOGICAL|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
219216504|NCT03042741|BIOLOGICAL|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
219216505|NCT01201772|DRUG|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
219216506|NCT05909072|DRUG|Hyaluronic acid combined with tranexamic acid microneedling|1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
219216507|NCT05909072|DRUG|tranexamic acid microneedling|On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
219682052|NCT05409716|PROCEDURE|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
218984053|NCT01212523|DRUG|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
218984054|NCT04336306|OTHER|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
219089918|NCT01645748|DRUG|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
219089919|NCT01733108|DRUG|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
219089920|NCT01733108|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
219089921|NCT01155154|DRUG|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
219089922|NCT01155154|DRUG|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
219089923|NCT01155154|DRUG|placebo|Two placebo capsules every 6 hours for 7 days
219089924|NCT05602051|DEVICE|virtual reality device|mindfulness combined with virtual reality
219089925|NCT03761303|DEVICE|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude\> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
219089926|NCT03761303|DEVICE|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
219089927|NCT04093674|PROCEDURE|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
219089928|NCT04788901|OTHER|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
219216508|NCT05206240|OTHER|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
218984055|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 1
218984056|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 2
218984057|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 3
218984058|NCT02092831|DRUG|GDC-0941|Single dose Phase 2 tablet formulation
218984059|NCT00005073|DRUG|zoledronic acid|
218984060|NCT06349330|DEVICE|Test: 3D intra-oral scanner|"3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush."
218984061|NCT06349330|OTHER|Control: Standard oral hygiene|Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
218984062|NCT02099578|DIETARY_SUPPLEMENT|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
218984063|NCT02099578|DIETARY_SUPPLEMENT|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
218984064|NCT02099578|DIETARY_SUPPLEMENT|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
219089929|NCT05453968|DRUG|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
219089930|NCT05634044|DEVICE|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
219089931|NCT05024669|COMBINATION_PRODUCT|Gluma desensitiser|Gluma desensitiser was used before restoration.
219089932|NCT05024669|COMBINATION_PRODUCT|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
219089933|NCT05024669|COMBINATION_PRODUCT|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
219089934|NCT02110901|DRUG|PRT-201|
219089935|NCT02110901|DRUG|Placebo|
219089936|NCT02522143|BEHAVIORAL|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
219089937|NCT02522143|BEHAVIORAL|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
219089938|NCT06173375|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
219089939|NCT06173375|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
219089940|NCT05103163|OTHER|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
219089941|NCT01238640|DRUG|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
219089942|NCT01238640|DRUG|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
219089943|NCT01238640|DRUG|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
219089944|NCT06347510|DIAGNOSTIC_TEST|Suppression of tumorigenicity 2 (ST2)|Suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 (IL-1) receptor family. The ligand and soluble versions are its two isoforms. It was first isolated in 1989. It was found to function as an IL-33 ligand in 2005. The IL-33-ST2L ligand complex\&#39;s creation offers protection against heart fibrosis and hypertrophy. The formation of this complex is inhibited by soluble ST2, which removes the cardioprotective effect. Unlike NT pro BNP, it is unaffected by age, body mass index, creatinine, hemoglobin, and albumin levels, according to studies performed on individuals. with heart failure.
219089945|NCT00326586|DRUG|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
219089946|NCT02223884|DRUG|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
219089947|NCT02223884|DRUG|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
219089948|NCT01780935|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
219089949|NCT00855595|DRUG|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
219216509|NCT01341132|PROCEDURE|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
219216510|NCT03418610|DRUG|Azelaic Acid foam 15%|mild to moderate rosacea
219216511|NCT03938337|DRUG|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
219216512|NCT03938337|DRUG|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
219216513|NCT04777383|DRUG|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
219216514|NCT04777383|DRUG|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
219216515|NCT04777383|DRUG|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
219089950|NCT00855595|DRUG|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
219089951|NCT00855595|DRUG|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
219089952|NCT02831257|DRUG|AZD2014|
219089953|NCT03962725|DRUG|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
219089954|NCT03962725|DRUG|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
219089955|NCT02621346|BEHAVIORAL|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
219089956|NCT02621346|BEHAVIORAL|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
219089957|NCT02621346|BEHAVIORAL|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
219089958|NCT05163613|OTHER|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
219216516|NCT04777383|DRUG|Atropine|Iontophoretic administration of 5 different concentrations of atropine
219216517|NCT04777383|DRUG|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
219216518|NCT04777383|DRUG|Sterile water|Iontophoretic administration of sterile water
219216519|NCT01961076|OTHER|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
219216520|NCT05480540|BEHAVIORAL|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
219216521|NCT01602185|DRUG|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
219216522|NCT01602185|DRUG|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
219216523|NCT01602185|DRUG|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
219216524|NCT05314049|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
219216525|NCT05314049|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
219089959|NCT05163613|OTHER|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
219089960|NCT01824615|DRUG|Sunitinib|37.5mg everyday from D1-D28
219089961|NCT02666287|DRUG|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
219089962|NCT02666287|DRUG|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
219089963|NCT02666287|DRUG|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
219089964|NCT02666287|DRUG|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
219089965|NCT02666287|DRUG|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
219089966|NCT06162143|DEVICE|Gelsectan®|Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
219089967|NCT02571270|OTHER|Combined aerobic and resistance physical training program|
219089968|NCT00571766|DRUG|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
219089969|NCT00571766|DRUG|Placebo|Placebo 2 g twice a day for 14 weeks
219089970|NCT00166296|DRUG|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
219089971|NCT00166296|DRUG|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
219089972|NCT02604290|DEVICE|Kinesio Taping method|"The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
219089973|NCT02604290|DEVICE|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
218984065|NCT01925534|DEVICE|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
218984066|NCT01925534|DEVICE|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
218984067|NCT02086292|PROCEDURE|2 ml 1% Lidocaine|
218984068|NCT02086292|PROCEDURE|1 ml 2% Lidocaine|
218984069|NCT02903355|DRUG|D-methionine|D-methionine, oral liquid suspension
218984070|NCT02903355|DRUG|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
218984071|NCT02468674|DRUG|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
218984072|NCT02468674|DRUG|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
218984073|NCT02738060|DIETARY_SUPPLEMENT|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
218984074|NCT05689476|DEVICE|NAVA GROUP|NAVA ventilation: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
218984075|NCT02318147|PROCEDURE|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
218984076|NCT02318147|DRUG|The traditional treatment|the traditional treatments according to associated guidelines
218984077|NCT03712956|DRUG|Caelyx®|Caelyx® every two weeks for 8 courses
218984078|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
218984079|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|
218984080|NCT01644565|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|
218984081|NCT03478332|DRUG|Yangxinshi pill|0.6g/tablet
218984082|NCT03478332|DRUG|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
218984083|NCT03478332|DRUG|Placebos|Yangxinshi simulant
218984084|NCT05984056|BEHAVIORAL|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
218984085|NCT01952405|BEHAVIORAL|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
218984086|NCT03323541|DRUG|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
218984087|NCT02036697|DRUG|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
218984088|NCT02036697|DRUG|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
218984089|NCT02036697|DRUG|Morphine|morphine 150 mcg.
218984090|NCT02036697|DRUG|Fentanyl|15 mcg
219089974|NCT04035200|DRUG|V117957 tablets|V117957 tablets taken orally at bedtime
219089975|NCT04035200|DRUG|Placebo|Tablets to match V117957
219089976|NCT05108649|OTHER|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
219089977|NCT05108649|OTHER|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
219089978|NCT05917977|BEHAVIORAL|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
219089979|NCT05917977|OTHER|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
219089980|NCT02961530|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
219089981|NCT02961530|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
219089982|NCT03627013|DRUG|Custodiol-N Solution|Perfusion
219089983|NCT03627013|DRUG|Custodiol HTK Solution|Perfusion
219089984|NCT06256614|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT for T1DM.
219089985|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
219089986|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
219089987|NCT04086329|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
219089988|NCT04176848|DRUG|CFI-400945|CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
219089989|NCT04176848|DRUG|Durvalumab|Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
219089990|NCT02272049|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
219089991|NCT06368115|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
219089992|NCT00623090|BEHAVIORAL|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
219089993|NCT00623090|BEHAVIORAL|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
218984091|NCT00875875|DRUG|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
218984092|NCT01910857|BEHAVIORAL|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
218984093|NCT04667481|OTHER|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
218984094|NCT04667481|OTHER|Resistance Exercise Intervention|Participate in resistance exercise intervention
218984095|NCT04667481|OTHER|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
218984096|NCT04667481|OTHER|Questionnaire Administration|Ancillary studies
218984097|NCT04667481|OTHER|Quality-of-Life Assessment|Ancillary studies
218984098|NCT00094172|DRUG|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
218984099|NCT00094172|DRUG|Placebo|tablet form
218984100|NCT00261274|BIOLOGICAL|A-ECO|
218984101|NCT00261274|BIOLOGICAL|Saline|
218984102|NCT00725374|DRUG|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
218984103|NCT00725374|DRUG|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
218984104|NCT02363842|DEVICE|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
218984105|NCT02363842|OTHER|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
218984106|NCT05231304|PROCEDURE|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
218984107|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
218984108|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
218984109|NCT05231304|PROCEDURE|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
219089994|NCT00623090|BEHAVIORAL|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
219216526|NCT05314049|DEVICE|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
219089995|NCT02303184|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
219089996|NCT02303184|DRUG|Sham|suprachoroidal sham procedure
219089997|NCT02303184|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
219216527|NCT05314049|DEVICE|Heat Therapy|superficial heating for 20 minutes
219216528|NCT00861003|DEVICE|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
219216529|NCT00284752|DRUG|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
219216530|NCT01199315|DRUG|AZD1446|oral capsule, Moderate Release
219216531|NCT01199315|DRUG|Placebo|oral capsule
218984110|NCT03476993|BIOLOGICAL|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
218984111|NCT04923061|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
218984112|NCT04923061|OTHER|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
219089998|NCT06383585|DEVICE|oZTEo|An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
219089999|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
219090000|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
219216532|NCT03611556|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
219216533|NCT03611556|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
219216534|NCT03611556|DRUG|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
219216535|NCT03611556|DRUG|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
219216536|NCT03611556|DRUG|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
219216537|NCT03611556|DRUG|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
219216538|NCT03611556|DRUG|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
219216539|NCT03068988|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
219216540|NCT03068988|PROCEDURE|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
219216541|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
219216542|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
219216543|NCT04845321|DRUG|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
219216544|NCT04845321|DRUG|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
218984113|NCT03076320|COMBINATION_PRODUCT|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
218984114|NCT03076320|COMBINATION_PRODUCT|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
218984115|NCT06061536|DRUG|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
218984116|NCT06061536|DRUG|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
219090001|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
219216545|NCT04035447|BEHAVIORAL|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
219216546|NCT05907603|DRUG|RD13-02 cell infusion|CAR-T cells
219216547|NCT05609929|DRUG|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
219216548|NCT04564443|OTHER|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
219682053|NCT01784276|BEHAVIORAL|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
219090002|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
219090003|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
219090004|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
219090005|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
219090006|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
219090007|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
219090008|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
219090009|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
219090010|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
219090011|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
219090012|NCT03023592|DRUG|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
219216549|NCT04564443|OTHER|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
219216550|NCT04564443|OTHER|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
219216551|NCT04564443|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
219216552|NCT04564443|OTHER|Fibracol Wound Dressing|Application of a collagen alginate dressing
219216553|NCT05628064|DEVICE|1C70|Investigational energy storage and return prosthetic foot with using novel elastic elements.
219216554|NCT05628064|DEVICE|Pro-Flex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
219682054|NCT00198263|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
219682055|NCT02454348|DRUG|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
219090013|NCT03209323|DEVICE|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
219090014|NCT03209323|DEVICE|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
219090015|NCT03209323|DEVICE|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
219090016|NCT03209323|DEVICE|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
219090017|NCT00960180|DRUG|MR1817|
219090018|NCT00960180|DRUG|Placebo|
219090019|NCT04502576|DEVICE|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
219090020|NCT00279669|PROCEDURE|Ultrasound examination|contact ultrasound examination
219090021|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
219090022|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
219090023|NCT04605562|DRUG|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219216555|NCT06402422|DEVICE|Theta-burst stimulation|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). Concurrent iTBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
219216556|NCT06110468|OTHER|CoreDISTParticipation|CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
219216557|NCT03304587|DIAGNOSTIC_TEST|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
219090024|NCT04605562|DRUG|Palbociclib|Administered orally
219216558|NCT03304587|DIAGNOSTIC_TEST|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
219216559|NCT03304587|OTHER|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
219216560|NCT03304587|OTHER|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
219216561|NCT03304587|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
219362083|NCT04044833|BEHAVIORAL|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
219682056|NCT02454348|DRUG|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
219682057|NCT00196703|DRUG|memantine|
219682058|NCT00196703|PROCEDURE|constraint-induced language therapy|
219090025|NCT04605562|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
219090026|NCT04605562|DRUG|PD-1 blocking antibody|Administered every 3 weeks
219090027|NCT04605562|DRUG|Galunisertib|Administered orally
219090028|NCT03365154|DEVICE|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
219090029|NCT03365154|DEVICE|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
219090030|NCT03209804|PROCEDURE|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
219090031|NCT03124979|DEVICE|LNCS DBI Sensor|Noninvasive Measurement of SpO2
219090032|NCT00386022|DRUG|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
219090033|NCT00386022|DRUG|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
219090034|NCT00386022|DRUG|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
219090035|NCT00276692|DRUG|irinotecan hydrochloride|
219090036|NCT04590534|DRUG|Chromax|Treatment of BPH by Chromax for 3 Months
219216562|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|"8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
219216563|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|"8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
219216564|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|"8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
219216565|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|"8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
219216566|NCT03304587|OTHER|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
219216567|NCT03304587|OTHER|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
219216568|NCT03304587|OTHER|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
219216569|NCT03304587|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
219362084|NCT00212147|DRUG|General anesthesia with nitrous oxide|
219362085|NCT00212147|DRUG|General anesthesia without nitrous oxide|
219682059|NCT04330417|DEVICE|Robot-Assisted Hand Training|Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles
219682060|NCT04330417|OTHER|Standard Hand Therapy|Stretching, Strengthening, Hand Functional Training
219090037|NCT04590534|DRUG|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
219090038|NCT04590534|OTHER|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
219090039|NCT04928105|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
219090040|NCT04371146|DRUG|Methylphenidate|35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
219090041|NCT04371146|DRUG|Reboxetine|8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
219090042|NCT04371146|DRUG|Placebos|A placebo pill is administered once using a randomized placebo-controlled between subject's design
219090043|NCT06451900|DRUG|Fenofibrate|full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
219090044|NCT06451900|OTHER|placebo|ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
219090045|NCT06393621|DIETARY_SUPPLEMENT|KEFPEP®|Twice daily (one pack before breakfast and the other before dinner)
219090046|NCT06393621|OTHER|Placebo|Twice daily (one pack before breakfast and the other before dinner)
219090047|NCT01085838|DRUG|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
219090048|NCT02440633|DRUG|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
219090049|NCT03427684|RADIATION|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction \>2Gy .
219090050|NCT03427684|DRUG|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
219090051|NCT02493296|OTHER|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
219090052|NCT03346603|OTHER|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
219090053|NCT00095706|DRUG|Bevacizumab (drug), Herceptin (drug)|
219090054|NCT05660200|DIETARY_SUPPLEMENT|IBSA Iron ODF|IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
219090055|NCT05660200|DIETARY_SUPPLEMENT|SiderAL® FORTE|Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
219090056|NCT05753150|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
219090057|NCT05753150|DRUG|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
219090058|NCT05753150|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
219090059|NCT04029129|OTHER|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
219090060|NCT06180304|OTHER|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
219090061|NCT02296554|PROCEDURE|SLAP Repair|SLAP repair for SLAP tear
219090062|NCT02296554|PROCEDURE|Biceps Tenodesis|Biceps tenodesis for SLAP tear
219090063|NCT01172002|DRUG|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
219090064|NCT01172002|DRUG|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
219090065|NCT01637103|BEHAVIORAL|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
219090066|NCT01637103|BEHAVIORAL|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
219090067|NCT00168038|BIOLOGICAL|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
219090068|NCT05016583|OTHER|Paula Method|12 weeks of Paula Method of Exercises
219090069|NCT05085626|DRUG|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
219090070|NCT05085626|DRUG|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
219090071|NCT04499651|BEHAVIORAL|Navigation|Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
219090072|NCT05586594|DIAGNOSTIC_TEST|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
219090073|NCT01151800|OTHER|Using IVR to maintain ACS patients on best practice guidelines|
219090074|NCT01274052|OTHER|Meal test|Liquid meal test
219090075|NCT01938248|DRUG|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
219090076|NCT01938248|DRUG|aspirin|aspirin 81 mg once daily
219090077|NCT02855931|PROCEDURE|Middle turbinate resection|
219090078|NCT01714804|DEVICE|Accell Evo3 Prospective Use|
219090079|NCT01685138|DRUG|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
219090080|NCT02283281|DRUG|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
219090081|NCT02283281|DRUG|Dummy oromucosal|drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
219090082|NCT01210430|DRUG|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
219090083|NCT01210430|DRUG|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
219216570|NCT03304587|OTHER|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
219216571|NCT05880108|BEHAVIORAL|12-weeks of Weight Loss|Participants will be asked to participate in a 1x/week center-based or tele-health nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for \~12 weeks.
219216572|NCT05880108|BEHAVIORAL|12-weeks of Weight Stability|Participants will be asked to participate in a 1x/week center-based or tele-health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for \~12 weeks.
219216573|NCT04515238|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
219216574|NCT04515238|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
219216575|NCT04515238|BIOLOGICAL|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
219216576|NCT04515238|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
219216577|NCT04289324|PROCEDURE|regular lung recruitment|stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
219216578|NCT04187573|DEVICE|Neqstent|Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.
219216579|NCT06044441|BEHAVIORAL|ENABLE-SG model|Patients and caregivers will receive individual structured psycho-educational sessions with a health coach. These sessions will be primarily delivered over the phone. Patient and caregiver dyads will have different health coaches. Patients will have six sessions on the topics of maintaining positivity, self-care, coping with stress, managing symptoms, exploring what matters most, and life review. Caregivers will have four sessions on the topics of maintaining positivity, self-care, coping with stress, and managing symptoms. All sessions will begin with screening for distress using the Distress Thermometer and Problem List culturally adapted from the National Comprehensive Cancer Network. From screening results, the health coach can flexibly change the order of the topics to address specific problems. It will take approximately three months to complete all sessions.
219216580|NCT06044441|OTHER|Wait-list control|"* 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model"
219216581|NCT06799962|OTHER|Enhanced Body-Swap for Anorexia Nervosa|The protocol begins with a baseline session, where participants familiarize themselves with their virtual body and provide anamnesis and therapeutic efficacy baseline data. The treatment phase includes 12 bi-weekly sessions where participants embody a virtual avatar in a VR environment. During each session, the Body Mass Index (BMI) of the virtual body is incrementally increased toward a target BMI approximating normal weight (18.5). Follow-ups are conducted at 4, 8, and 12 weeks to assess long-term effects.
219362086|NCT00935389|DRUG|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
218984117|NCT06061536|DRUG|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
218984118|NCT06061536|DRUG|DTG|DTG +3TC + TDF（once daily）.
218984119|NCT01259128|DRUG|SER120 Nasal Spray 500 ng/day|SER120 Level 1
218984120|NCT01259128|DRUG|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
218984121|NCT01948297|DRUG|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
218984122|NCT04862819|DRUG|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
218984123|NCT04862819|PROCEDURE|scaling root planing|In the second group, on one side of the dental arch srp will be performed
218984124|NCT03689530|BEHAVIORAL|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
218984125|NCT03689530|BEHAVIORAL|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
218984126|NCT03240965|DIAGNOSTIC_TEST|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
218984127|NCT03240965|OTHER|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
218984128|NCT03240965|DIAGNOSTIC_TEST|Taste-/smell-test|Taste-/smell-test
218984129|NCT03240965|DIAGNOSTIC_TEST|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
219090084|NCT01210430|DRUG|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
219090085|NCT00975910|DRUG|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
219090086|NCT00975910|DRUG|saline|Saline arm: infused at the same rate as lidocaine
219216582|NCT06799962|OTHER|Emotional Rescripting for Bulimia Nervosa|The protocol starts with an assessment phase (1 session), gathering anamnesis and baseline therapeutic efficacy data. This is followed by an evaluation phase (2 sessions), where participants rate craving responses for virtual foods and environments in immersive VR, with physiological data collected via biosensors. Using this data, a personalized exposure hierarchy is created, combining the most craving-inducing foods and environments into 40 interactive 3D scenarios. The treatment phase involves 9 VR sessions focusing on emotional regulation and craving management. Follow-ups at 4, 8, and 12 weeks evaluate progress.
219216583|NCT06799962|OTHER|Standard Therapy for Anorexia Nervosa (Control)|Participants follow a similar structure with a baseline session to collect anamnesis and baseline data, but without VR immersion. The treatment phase consists of 12 bi-weekly sessions of standard cognitive-behavioral therapy (CBT), focusing on addressing maladaptive thought patterns, promoting healthy eating behaviors, and reducing body image disturbances. Follow-ups are conducted at 4, 8, and 12 weeks to monitor progress. No VR or AI technologies are integrated.
219216584|NCT06799962|OTHER|Standard Therapy for Bulimia Nervosa (Control)|Participants undergo an assessment phase (1 session) to collect baseline data and an evaluation phase (2 sessions) using standard craving questionnaires without VR immersion or biosensors. The treatment phase includes 9 sessions of traditional CBT targeting binge-purge cycles and emotional triggers. Follow-ups at 4, 8, and 12 weeks monitor progress without the integration of VR or AI technologies.
219216585|NCT06803134|OTHER|Selected physical therapy program|Both groups will receive a selected physical therapy program in the form of trans-cutaneous electrical nerve stimulation (TENS), moist hot pack, posture education, and strengthening exercises for deep neck flexors, for 30 minutes, 3 sessions per week, for 8 weeks.
219216586|NCT06803134|OTHER|Kinetic control retraining|"Each patient in the experimental group will receive kinetic control retraining for 30 minutes, 3 sessions per week, for 8 weeks. Each session is based on the progression on the motor control rating scale (MCRS) related to kinetic control management frame. For each movement direction, specific control tests will be conducted. The direction and site of the uncontrolled movement will be evaluated using special tests in accordance with the pain history of the patient. The tests will be chosen according to the patients symptoms; screening of all patients will be done through at least three tests in each direction according to the patients symptoms."
219216587|NCT06494189|BIOLOGICAL|Tislelizumab|200mg IV Q3W
219216588|NCT06494189|DRUG|Afatinib|30mg PO QD
219216589|NCT06494189|RADIATION|Low dose radiotherapy|The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.
219216590|NCT04589598|DEVICE|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
219216591|NCT04589598|DEVICE|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
219216592|NCT06088758|DEVICE|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
219090087|NCT04841941|DEVICE|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
219216593|NCT05840887|PROCEDURE|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
219216594|NCT05840887|PROCEDURE|Knee osteotomy|Knee osteotomy
219216595|NCT01458366|DRUG|Bendamustine|"Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
219090088|NCT00490256|PROCEDURE|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
219090089|NCT06218225|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
219216596|NCT01458366|DRUG|Ofatumumab|"Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1"
219216597|NCT01458366|DRUG|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
219216598|NCT01458366|DRUG|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
219216599|NCT01458366|PROCEDURE|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
219216600|NCT01458366|PROCEDURE|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
219216601|NCT01458366|GENETIC|Stem Cell Transplant (STC)|"For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
219216602|NCT05615051|DEVICE|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
219216603|NCT04540588|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219216604|NCT02397096|DRUG|Doravirine, Tenofovir, Lamivudine|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
219216605|NCT02397096|DRUG|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
219216606|NCT02397096|DRUG|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
219090090|NCT06218225|DIETARY_SUPPLEMENT|Placebo|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
219090091|NCT05773118|DEVICE|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
219090092|NCT05773118|DEVICE|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
219090093|NCT05773118|DEVICE|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
219090094|NCT02472210|DRUG|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
219090095|NCT01542957|BEHAVIORAL|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
219090096|NCT01542957|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
219090097|NCT02827006|PROCEDURE|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
219090098|NCT03687801|BEHAVIORAL|Online hearing support|The intervention group will follow an online hearing support for five weeks
219216607|NCT02397096|DRUG|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
219216608|NCT02397096|DRUG|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
219216609|NCT01705886|PROCEDURE|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
219216610|NCT01705886|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
219216611|NCT01705886|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
219216612|NCT01705886|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
219216613|NCT01705886|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
219216614|NCT05321992|BEHAVIORAL|eCHEC program|The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
219216615|NCT06228573|PROCEDURE|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
219216616|NCT06418334|DIAGNOSTIC_TEST|Thoracal hyperkyphosis study form|Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
219362087|NCT06145893|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
219682061|NCT00459771|DRUG|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
219682062|NCT00459771|DRUG|Placebo|Placebo, 32 mg, oral QD
219090099|NCT03687801|BEHAVIORAL|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
219682063|NCT00002692|DRUG|fluorouracil|
219682064|NCT00002692|DRUG|isolated perfusion|
219682065|NCT00002692|DRUG|leucovorin calcium|
219682066|NCT00815997|PROCEDURE|PCI (percutaneous coronary intervention)|PCI will be performed via the radial artery.
219682067|NCT02299388|DRUG|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
219682068|NCT06199427|DRUG|Cyclophosphamide|Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
219682069|NCT06199427|DRUG|Ruxolitinib|Ruxolitinib 7 mg/m2 from day +5 after HSCT
219216617|NCT06418334|DIAGNOSTIC_TEST|Scoliosis graphy|Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
219090100|NCT06435104|OTHER|neoadjuvant chemotherapy|The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
219090101|NCT06435104|OTHER|aromatherapy|Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
219090102|NCT04430751|BEHAVIORAL|Medical QiGong training|"The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization."
219090103|NCT02432989|BEHAVIORAL|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
219090104|NCT04461743|OTHER|No intervention|No intervention, regular therapy
219216618|NCT06418334|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
219090105|NCT05559957|BEHAVIORAL|observation of delivery and neonatal outcomes|MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
219090106|NCT05582005|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children 3 year old and younger, scheduled for elective MRI, that are not intubated or require higher oxygen support and with no parents/guardians refusal will be placed on an electrocardiogram during post-anesthesia recovery. The NIPE monitor will be connected to the patients monitor in the PACU. Values will be recorded from the time of patient awaking until the patient meets the discharge criteria from PACU not before 1 hour.
219090107|NCT02068495|DRUG|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
219090108|NCT05365243|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
219216619|NCT06418334|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
219216620|NCT05805826|BIOLOGICAL|C. difficile vaccine (previously studied formulation).|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
218984130|NCT05487144|BEHAVIORAL|Learning in a Virtual Environment (LIVE)|Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
218984131|NCT00187577|DRUG|Latanoprost (Xalatan)|
218984132|NCT00187577|DRUG|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
218984133|NCT00187577|DRUG|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
218984134|NCT02299830|PROCEDURE|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
218984135|NCT02299830|PROCEDURE|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
218984136|NCT02299830|PROCEDURE|stent placement|use stent placement to open the airway compressed by out neoplasm
218984137|NCT02299830|PROCEDURE|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
218984138|NCT02646137|DRUG|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
218984139|NCT02646137|PROCEDURE|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
219090109|NCT00736307|PROCEDURE|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
219090110|NCT03076268|BEHAVIORAL|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
219090111|NCT01032655|DRUG|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid"
219090112|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|50μg/dose
219090113|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent High dose|100μg/dose
219090114|NCT05547243|DRUG|Placebo|Saline solution
219090115|NCT00018135|DRUG|calcium acetate|
219216621|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 1.|C. difficile vaccine formulation 1 given as an intramuscular injection
219216622|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 2.|C. difficile vaccine formulation 2 given as an intramuscular injection
219216623|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 3.|C. difficile vaccine formulation 3 given as an intramuscular injection
219216624|NCT05805826|OTHER|Saline Placebo.|0.9% sodium chloride solution given as an intramuscular injection
219216625|NCT05580003|DRUG|PF-07817883|Oral suspension or solid oral formulation(s)
219216626|NCT05580003|DRUG|Placebo|Placebo suspension
219090116|NCT00018135|DRUG|aluminum hydroxide|
219090117|NCT00018135|DRUG|Sevelamer|
219090118|NCT06252103|DRUG|Ferrous Gluconate 300 MG|iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
219090119|NCT06252103|DRUG|ferrous gluconate with lactoferrin|Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
219090120|NCT03733405|BEHAVIORAL|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
219090121|NCT03733405|BEHAVIORAL|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
219216627|NCT05580003|DRUG|Midazolam|midazolam oral solution
219090122|NCT02693938|DEVICE|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
219090123|NCT02693938|DEVICE|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
219216628|NCT05580003|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet
219090124|NCT04663451|RADIATION|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
219090125|NCT03819140|DRUG|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
219090126|NCT01299519|BEHAVIORAL|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
219090127|NCT01299519|BEHAVIORAL|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
219090128|NCT00929825|DEVICE|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
219090129|NCT00929825|PROCEDURE|TENS|transcutaneous electrical stimulation
219090130|NCT00689026|DRUG|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
219090131|NCT00689026|OTHER|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
219090132|NCT01600664|BEHAVIORAL|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
219090133|NCT01600664|BEHAVIORAL|Convertible PC|Participants will be using the convertible PC without the interactive computer game
219216629|NCT00495976|OTHER|A commercially produced cordial drink|
219216630|NCT02392234|DRUG|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
219216631|NCT02392234|DRUG|Ivacaftor|Tablet, oral use
219216632|NCT02392234|DRUG|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
219216633|NCT02392234|DRUG|Placebo matched to Ivacaftor|Tablet, oral use
219216634|NCT02052440|DRUG|Baclofen|Treatment arm: baclofen 10mg tid
219216635|NCT02052440|DRUG|Placebo|Sugar pill by mouth three times daily
219216636|NCT00697060|DRUG|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
219216637|NCT00328692|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
219216638|NCT00328692|DRUG|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
219216639|NCT04124887|DRUG|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
219216640|NCT04124887|DRUG|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
219216641|NCT04124887|DRUG|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
219216642|NCT04124887|DRUG|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
219216643|NCT05492604|OTHER|Clinical examination|Cinical examination carried out during a consultation for the follow-up of the patient
219362088|NCT06145893|DRUG|Hemay005|Hemay005 tables 45mg bid p.o;
219216644|NCT05492604|OTHER|Functional scales|The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
219090134|NCT06214845|PROCEDURE|Red blood cell EXchange (REX)|A single automated REX will be performed, as soon as possible after randomization.
219090135|NCT01155752|DRUG|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
219090136|NCT01155752|DRUG|placebo|identical placebo
219090137|NCT01383265|PROCEDURE|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
219090138|NCT01383265|PROCEDURE|Water method|Control method will use plain water with water method for screening colonoscopy
219090139|NCT05311202|BEHAVIORAL|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
219216645|NCT05492604|DIAGNOSTIC_TEST|Walking test|Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
219216646|NCT02130557|DRUG|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
219216647|NCT02130557|DRUG|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
219216648|NCT01183767|DRUG|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
219216649|NCT01183767|DRUG|Placebo|
219216650|NCT05738369|DIETARY_SUPPLEMENT|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
219216651|NCT05738369|DIETARY_SUPPLEMENT|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
219216652|NCT04411888|OTHER|observation|observation
219216653|NCT02408887|PROCEDURE|Total Thyroidectomy (TT)|Total removal of thyroid
219216654|NCT02408887|PROCEDURE|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
219216655|NCT02134262|DRUG|Cyclophosphamide or Bendamustine|Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
219090140|NCT05311202|BEHAVIORAL|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
219090141|NCT05311202|BEHAVIORAL|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
219090142|NCT05311202|BEHAVIORAL|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
219090143|NCT05311202|BEHAVIORAL|Control group|Reading a book related to cognitive function \& exercise for 40 minutes
219216656|NCT02134262|GENETIC|Dose Level -1|CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
219216657|NCT02134262|GENETIC|Dose Level 1|CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
219216658|NCT02134262|GENETIC|Dose Level 2|CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
219216659|NCT02134262|GENETIC|Dose Level 3|CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
219216660|NCT03333109|BIOLOGICAL|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
219216661|NCT03333109|OTHER|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
219216662|NCT04474496|OTHER|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
219216663|NCT03959384|DRUG|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
219216664|NCT03959384|OTHER|Ambient Air|Ambient air aspirated in sterile syringes
219216665|NCT04453332|DRUG|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
219216666|NCT04453332|DRUG|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
219216667|NCT01447706|DRUG|MM-121|MM-121 (SAR256212) (IV)
219216668|NCT01447706|DRUG|Paclitaxel|Standard dosing Paclitaxel (IV)
219216669|NCT00918203|BIOLOGICAL|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
219216670|NCT00918203|DRUG|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
219362089|NCT06145893|DRUG|Placebo|placebo to Hemay005 tables bid p.o
219090144|NCT00308256|BEHAVIORAL|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
219090145|NCT00136786|DRUG|Memantine|
219090146|NCT01038388|DRUG|Bortezomib|1.3mg/m² given IV or subcutaneously
219090147|NCT01038388|DRUG|Lenalidomide|25 mg given PO
219090148|NCT01038388|DRUG|Dexamethasone|20 mg given PO
219090149|NCT01038388|DRUG|Vorinostat|100, 200, or 300 mg given PO
219090150|NCT05794048|BIOLOGICAL|Hepatocellular carcinoma|Tumor and liver biopsy
219090151|NCT05794048|BIOLOGICAL|Pancreatic adenocarcinoma|Tumor and pancreatic biopsy
219090152|NCT05794048|BIOLOGICAL|Pancreatic neuroendocrine tumor|Tumor and pancreatic biopsy
219216671|NCT00918203|DRUG|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
219216672|NCT00369109|OTHER|biologic sample preservation procedure|
219216673|NCT00369109|OTHER|immunohistochemistry staining method|
219216674|NCT00369109|OTHER|laboratory biomarker analysis|
219216675|NCT00369109|PROCEDURE|biopsy|
219216676|NCT06132594|PROCEDURE|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
219216677|NCT06132594|PROCEDURE|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
219216678|NCT02788019|DRUG|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
219216679|NCT01870830|OTHER|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
219216680|NCT04694014|BEHAVIORAL|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
219216681|NCT04694014|BEHAVIORAL|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
219216682|NCT04694014|BEHAVIORAL|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
219216683|NCT06137898|BIOLOGICAL|biological check-up|Blood sampling
219216684|NCT02928250|DIETARY_SUPPLEMENT|Carnosine|Patients in intervention group received carnosine capsules orally daily
219090153|NCT00041730|BIOLOGICAL|Id-KLH|
219090154|NCT01819246|PROCEDURE|Aphersis Treatment Arm|
219090155|NCT01819246|OTHER|Control Arm|
219090156|NCT00944047|DRUG|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
219216685|NCT02928250|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
219216686|NCT02957799|BEHAVIORAL|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
219216687|NCT02957799|BEHAVIORAL|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
219216688|NCT01645046|DRUG|Coenzyme A|Coenzyme A 200mg per day.
219090157|NCT00944047|DRUG|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
219090158|NCT00944047|DRUG|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
219090159|NCT00944047|DRUG|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
219090160|NCT00944047|BIOLOGICAL|Growth Factor Support|"* All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
219090161|NCT00944047|PROCEDURE|Surgery|"* After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
219090162|NCT04069130|DRUG|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
219216689|NCT01645046|DRUG|Coenzyme A|Coenzyme A 400mg per day.
219216690|NCT01645046|DRUG|Placebo|Capsule without coenzyme A.
219090163|NCT05734963|GENETIC|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
219090164|NCT02415179|DRUG|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
219090165|NCT02415179|DRUG|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
219090166|NCT00892489|DRUG|ER OROS Paliperidone|
219090167|NCT03258749|DRUG|Tiotropium|inhaled Tiotropium(18μg, qd)
219090168|NCT03258749|DRUG|Formoterol|inhaled formoterol(4.5μg, bid)
219090169|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
219090170|NCT03701984|DRUG|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
219090171|NCT03701984|DRUG|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
219090172|NCT03701984|DRUG|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
219090173|NCT02870140|DEVICE|SUPRAFLEX|Percutaneous Coronary Intervention
219090174|NCT02870140|DEVICE|XIENCE|Percutaneous Coronary Intervention
219090175|NCT01273948|DRUG|Bavituximab|"1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
219090176|NCT01273948|DRUG|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
219090177|NCT04639128|DEVICE|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
219090178|NCT06448923|DRUG|Cannabidiol|25 mg of CBD tablets twice daily
219090179|NCT06448923|DRUG|Cannabidiol|50 mg of CBD tablets twice daily
219090180|NCT06448923|DRUG|Placebo|Matching placebo tablets twice daily
219090181|NCT06850987|PROCEDURE|non surgical periodontal therapy|All participants will have their non-surgical periodontal treatments completed after samples are taken and periodontal measurements are taken at the beginning.
219090182|NCT06850987|OTHER|measurement of periodontal clinical parameters|Periodontal measurements will be taken from all participants at baseline, 1 month, 3 months and 6 months
219090183|NCT06850987|OTHER|Gingival crevicular fluid samples will be collected|Gingival crevicular fluid samples will be collected from all participants at baseline, 1 month, 3 months and 6 months
219090184|NCT06228001|DEVICE|Actimyo|Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219090185|NCT06577571|OTHER|CKM-EMPOWER|CKM-EMPOWER is a series of 11 just-in-time educational videos on topics related to caring for patients who opt for CKM: CKM overview, dysgeusia, fatigue, restless leg syndrome, uremic pruiritis, cramping, pain, volume overload, electrolyte abnormalities, anticipatory grief, and actively dying patient. Videos are approximately 5-10 minutes in length and intended to provide learners with a brief overiew on the definition of each issue, impact of the issue on a patient, assessment of the issue, and approaches to addressing the issue. Videos conclude with references to additional resources on each topic for more in-depth self-study. CKM-EMPOWER was created by a team comprised of a health educator, the principal investigator (nephrologist), a geriatrician and a physician dually trained in nephrology and palliative care and with feedback from a geriatric pharmacist and members of a national professional interest workgroup in kidney palliative care.
219090186|NCT00006257|DRUG|paclitaxel|
219090187|NCT00006257|DRUG|semaxanib|
219090188|NCT01752673|OTHER|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
219090189|NCT01752673|OTHER|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
219090190|NCT02703922|OTHER|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
219090191|NCT03157518|DIETARY_SUPPLEMENT|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
219090192|NCT03934736|DRUG|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
219216691|NCT00993174|PROCEDURE|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
219216692|NCT00993174|PROCEDURE|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
219362090|NCT04722211|DIETARY_SUPPLEMENT|PS128|daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
219090193|NCT00944502|DRUG|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
219090194|NCT03856710|DEVICE|self-gripping mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
219090195|NCT03856710|DEVICE|Stapled mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
219090196|NCT02108379|DEVICE|Rhinix Nasal Filters|
219090197|NCT00114010|DRUG|AMA1/Alhydrogel|
219090198|NCT04838990|OTHER|EDSS|Neurological Exam - EDSS (Expanded Disability Status Scale)
219090199|NCT04838990|OTHER|Discussion of symptoms, Patient reported outcome (MSIS)|Patients will be asked about their wellbeing
219090200|NCT03868865|BEHAVIORAL|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
219090201|NCT00394355|DRUG|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
219090202|NCT00394355|DRUG|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
219216693|NCT04801199|DRUG|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
219216694|NCT04801199|DRUG|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
219216695|NCT05853861|BEHAVIORAL|JASPER|JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.
219216696|NCT05853861|BEHAVIORAL|Babble Bootcamp|Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
219216697|NCT03989388|BEHAVIORAL|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
219090203|NCT00394355|DRUG|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
219216698|NCT03989388|BEHAVIORAL|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
219216699|NCT03989388|BEHAVIORAL|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
219216700|NCT02859844|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|
219216701|NCT06403540|DIAGNOSTIC_TEST|ultrasonography|Using ultrasonography to measure diaphragm thickness
219216702|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
219090204|NCT00394355|DRUG|montelukast|10 mg given once daily in the evening by mouth for 1 year.
219090205|NCT00575926|DRUG|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
219090206|NCT02053818|DRUG|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
219090207|NCT02053818|DRUG|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
219090208|NCT04141527|PROCEDURE|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
219090209|NCT01527734|DRUG|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
219090210|NCT01527734|DRUG|placebo|1ml once or twice a day for 1 or 2 days.
219216703|NCT06453577|DRUG|Recompensation (guideline directed medical therapy)|Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
219216704|NCT00225407|DRUG|Smoking of cannabis cigarettes (different strength)|
219216705|NCT00138541|DRUG|vildagliptin|
219216706|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
219216707|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
219216708|NCT01155206|DRUG|glucagon|glucagon 3ng/kg/min
219216709|NCT00589875|BIOLOGICAL|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
219682070|NCT03464084|DRUG|placebo|Capsules containing microcrystalline cellulose
219682071|NCT03464084|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
219090211|NCT00286845|DRUG|Standard Chemotherapy|physician determined
219090212|NCT06578988|PROCEDURE|Mammography Images|Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
219090213|NCT02119910|BEHAVIORAL|Technology Supported Manual|
219090214|NCT00627380|BEHAVIORAL|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
219090215|NCT00627380|OTHER|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
219090216|NCT00070902|PROCEDURE|Lumbar side-posture spinal adjusting|
219090217|NCT02731248|OTHER|Prospective screening study|Prospective screening study in newborns
219090218|NCT02813148|DRUG|Naloxegol|Non-interventional study of drug utilization
219090219|NCT04211064|DIAGNOSTIC_TEST|Ultrasonographic measurement of optic nerve sheath diameter|Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
219216710|NCT00589875|DRUG|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
219216711|NCT00589875|DRUG|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
219216712|NCT00589875|RADIATION|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
219216713|NCT05786352|PROCEDURE|ERAS protocol|The combination of interventions explained in arm descriptions.
219216714|NCT06813027|BIOLOGICAL|EV|"Extracellular secretomes ( extracellular vesicles EV) derived from mesenchymal stroma cells (MSCs)"
219216715|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
219216716|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
219216717|NCT03488719|DRUG|Metoprolol Succinate 25 MG|A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
219216718|NCT03488719|DRUG|Metoprolol Succinate 50 MG|A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
218984140|NCT02646137|PROCEDURE|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
218984141|NCT04218825|DRUG|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
218984142|NCT02079545|DRUG|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
218984143|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
219090220|NCT04211064|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
219090221|NCT04211064|PROCEDURE|Moderate neuromuscular block|Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
219090222|NCT04284527|OTHER|Observational study|a reliability - validity study
219090223|NCT02452723|BIOLOGICAL|ISC-hpNSC|
218984144|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
219090224|NCT00072761|PROCEDURE|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
219090225|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
219090226|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
219216719|NCT03488719|DRUG|Metoprolol Succinate 100 MG|A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
219216720|NCT06842537|DRUG|SYH2062 injection|SYH2062 for sc injection
218984145|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
218984146|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
218984147|NCT00713323|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219090227|NCT00753792|DRUG|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
219090228|NCT01892059|PROCEDURE|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
219090229|NCT01892059|PROCEDURE|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
219090230|NCT01648348|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
219090231|NCT01648348|BIOLOGICAL|Bevacizumab|Given IV
219090232|NCT01648348|OTHER|Laboratory Biomarker Analysis|Correlative studies
219090233|NCT01648348|OTHER|Pharmacological Study|Correlative studies
219090234|NCT01648348|OTHER|Quality-of-Life Assessment|Ancillary studies
219090235|NCT03249051|OTHER|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
219090236|NCT04196426|BEHAVIORAL|Nutrition education intervention about osteoporosis and calcium|The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
219090237|NCT06350890|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
219090238|NCT06350890|DRUG|Placebo|Matching placebo administered orally BID as four capsules
219090239|NCT00002538|PROCEDURE|laparoscopic surgery|
219090240|NCT01951638|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
219090241|NCT01951638|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
219090242|NCT01951638|DRUG|Placebo|
219090243|NCT01185067|DRUG|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
219090244|NCT06139757|DEVICE|Oura ring|Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
219090245|NCT02080780|DRUG|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
219090246|NCT02080780|DRUG|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
219090247|NCT02382068|DRUG|Dexamethasone|Given via intratympanic injection
219090248|NCT02382068|OTHER|Placebo|Given via intratympanic injection
219090249|NCT02382068|DRUG|Cisplatin|"Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum"
219090250|NCT04923113|DIAGNOSTIC_TEST|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
219090251|NCT04923113|DRUG|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
219090252|NCT06336616|BEHAVIORAL|Behavior Activation|Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
219090253|NCT04451122|OTHER|cleansing the eyelid margins|using eyelid cleaning wipes to cleansing the eyelid margins
219090254|NCT05563194|DEVICE|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
219090255|NCT05563194|DEVICE|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
219090256|NCT05563194|DEVICE|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
218984148|NCT01925677|DEVICE|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
218984149|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
219090257|NCT00459342|DRUG|dasatinib|Given orally
219090258|NCT02686034|DEVICE|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
218984150|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
219216721|NCT06842537|DRUG|SYH2062-Matching placebo|Normal saline matching volume of SYH2062 doses will be administered
219216722|NCT06598553|BEHAVIORAL|Projet Jeune Leader Comprehensive Sexual Education|PJL provides trained educators to deliver a 22 week comprehensive sexual education (CSE) curriculum in participating middle schools. All adolescents enrolled in the school receive the CSE program.
219361714|NCT04196660|BEHAVIORAL|Labor Dance|The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
219361715|NCT00132730|DRUG|MK-0873 2.5 mg|
218984151|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
218984152|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
218984153|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
218984154|NCT00631995|DIETARY_SUPPLEMENT|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
218984155|NCT06383221|COMBINATION_PRODUCT|"Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care"|Simple and scientific advice
219216723|NCT06978296|RADIATION|Stereotactic body radiotherapy (SBRT)|"The acceptable regimens are:~* 27 Gy / 3 fractions / 3 fractions per week~* 35 Gy / 5 fractions / 3 fractions per week An interval of at least 24 hours should be kept between two consecutive fractions.~Prescription must be defined on 80% isodose or higher, maximum dose up to 130% of the isodose prescription. At least 90% of the Planning Target Volume should receive the prescribed dose. A coverage of \<90% of the Planning Target Volume will be considered as acceptable deviation, and coverage of \<80% of the target volume as an Unacceptable Deviation. At least 90% of the Gross Tumoral Volume should receive the prescribed dose.~Only a part of the Gross Tumoral Volume\_Total could be considered for radiation, depending on the ratio with Bone Marrow Reserve. High-risk and/or symptomatic metastases will be prioritized over other metastases.~Anatomic bone marrow reserve (BMR) will be first determined for each patient:~BMR = Total trabecular bone - (Total trabecular bone ∩ GTV\_Total)"
219216724|NCT04321603|BEHAVIORAL|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
219216725|NCT05567497|PROCEDURE|trigeminal nerve block|ultrasound guided trigeminal nerve block
219216726|NCT06824155|DRUG|177Lu-RAD202|177Lu-RAD202 administered at Imaging (im) and Treatment (tr) doses
219216727|NCT06952218|PROCEDURE|Injection of cross linked hyaluronic acid filler|Injection of cross linked hyaluronic acid filler
219216728|NCT00585156|DRUG|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
219216729|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
219216730|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
219216731|NCT01118754|DRUG|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
219216732|NCT06590064|DEVICE|Non-invasive Blood Pressure Measurement|Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
219216733|NCT06861335|OTHER|Exercise|For each participant included in the exercise group, an individualized pelvic floor muscle exercise program will be created based on the results of digital palpation and the PERFECT assessment system. The first exercise session will be conducted with the physiotherapist, and the participant will be provided with a home-based program. During pregnancy check-ups, the pelvic floor muscles will be re-evaluated, and the exercise program will be updated according to the new evaluation results. To monitor the home-based program, participants will be given an exercise tracking chart that they will be asked to fill out daily
219216734|NCT06861335|BEHAVIORAL|Control|Participants in the control group of our study will receive standard pregnancy care and check-ups. Within this scope, the general health status of the pregnant women will be evaluated during routine antenatal follow-up visits, check-ups appropriate to their gestational weeks will be performed, and necessary medical interventions will be carried out. Additionally, participants will receive detailed education about pelvic floor anatomy, the functions of the pelvic floor muscles, and the changes that occur in these muscles during pregnancy. Within the scope of general health education, information will be provided about nutrition, hygiene, exercise, and other lifestyle recommendations during pregnancy. The participants in the control group will not be given the specific pelvic floor muscle training program applied in the experimental arm of the study; they will only receive standard pregnancy care and general information
219216735|NCT06416839|BEHAVIORAL|VR exercise|Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
219216736|NCT03534726|DEVICE|7 T CMR|7 tesla MRI device
219216737|NCT06677710|DRUG|IDP-023|NK cell therapy
219216738|NCT06677710|DRUG|Ocrelizumab|Anti-CD20 antibody therapy
219216739|NCT06677710|DRUG|Interleukin-2|Immune cytokine
219216740|NCT06677710|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219216741|NCT06677710|DRUG|Fludarabine|Lymphodepleting chemotherapy
219216742|NCT06677710|DRUG|Mesna|Chemoprotectant
219216743|NCT06699459|DRUG|Irinotecan Liposome|②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
219216744|NCT06699459|DRUG|Capecitabine|① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
219216745|NCT06714552|DIETARY_SUPPLEMENT|Galacto-Oligosaccharide|24.0 g Oligomate® in 100 mL water
219216746|NCT06714552|OTHER|Glucose|17.8 g glucose in 100 mL water
219216747|NCT06444451|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
219216748|NCT06444451|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
219216749|NCT06925620|OTHER|Multimodal Information Technology-based Hand Hygiene Strategies|The intervention, adapted from the WHO's multimodal strategy, incorporated IT-based components to enhance hand hygiene compliance. A one-time, 1-hour online education session via Google Meet covered the WHO's Five Moments and seven-step handwashing technique, with real-time feedback using fluorescent dye and UV light. Post-session videos were available on tablets for review. Visual reminders, such as screensavers and digital posters, reinforced learning. Smart sanitizer dispensers with seven-step lights and a 20-second countdown were installed at five key sites, RFID-linked to staff badges for automatic tracking. Monthly performance data were shared via bulletin boards and LINE, with SMS feedback to top and bottom performers. Daily audio reminders played at 9 a.m. and 5 p.m., and high performers were recognized in monthly meetings.
219216750|NCT06922526|DEVICE|Pacemaker implantation|Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing
218984156|NCT01911078|PROCEDURE|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
218984157|NCT01911078|DEVICE|EnligHTN™ Renal Denervation System.|
219361716|NCT00132730|DRUG|MK-0873 1.25 mg|
219361717|NCT00132730|DRUG|MK-0873 0.75 mg|
219361718|NCT00132730|DRUG|Placebo to MK-0873|
219361719|NCT00132730|DRUG|Usual Care|
219361720|NCT05215366|DIAGNOSTIC_TEST|copeptin biomarker in children with febrile seizures|biomarkers increase in children with febrile seizures
219682072|NCT03464084|OTHER|bright light|room light will be bright
219682073|NCT03464084|OTHER|dim light|room light will be dim
219682074|NCT02429102|DRUG|MT-8554|
219682075|NCT02429102|DRUG|Placebo|
219090259|NCT02686034|DEVICE|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
219090260|NCT01440426|PROCEDURE|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
219090261|NCT01440426|DEVICE|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
219090262|NCT00468221|DRUG|Ozone Exposure|Low dose ozone exposure in chamber
219216751|NCT06763848|DEVICE|Protein A immunoadsorption|The experimental group was treated with a combination of protein A immunoadsorption and intravenous methylprednisolone. The methylprednisolone was administered following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day. Protein A immunoadsorption was conducted every other day, unless a physician determined that the patient's condition was unsuitable for treatment, in which case treatment was administered according to medical advice. A total of 5 treatments were given, with each session involving the regeneration of plasma at 1 to 3 times the plasma volume.
219216752|NCT06763848|DRUG|intravenous methylprednisolone|The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.
219216753|NCT06838364|OTHER|Infrared peripheral venous technique|use a infrared device for venous peripheral visualisation and catheter insertion
219216754|NCT06838364|OTHER|Ultrasound-guided peripheral venous technique|Use the ultrasound-guided technique for venous peripheral visualisation and catheter insertion
219216755|NCT06838364|OTHER|Landmark technique|the gold standard technique with observationnal and palpation
219090263|NCT03846102|DRUG|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
219090264|NCT03846102|DRUG|Placebo|Sodium Chloride 0,9% for injection/infusion.
219090265|NCT03846102|DRUG|Acetaminophen|Acetaminophen 500 milligram tablet
219090266|NCT03846102|DRUG|Morphine|Morphine 1 mg/ml solution for infusion.
219090267|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
219090268|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
219090269|NCT04578327|DEVICE|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
219090270|NCT04578327|PROCEDURE|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
219090271|NCT01216930|OTHER|Observation|Observation
219090272|NCT02775955|DRUG|RX0041|Active
219090273|NCT04490746|OTHER|with no intervention, Collect samples|only with observation,there is no need to intervene
219090274|NCT00566579|PROCEDURE|Cryotherapy|Double freezing technique
219090275|NCT02863679|DRUG|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
219090276|NCT05391828|DEVICE|Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design|TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
219090277|NCT05391828|DEVICE|Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design|TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
219090278|NCT04549155|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
219090279|NCT03678935|OTHER|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
219090280|NCT04964219|DRUG|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
219090281|NCT04964219|DRUG|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
219216756|NCT06855485|DEVICE|HANAROSTEN® HOT Plumber™ with Z-EUSIT™|An electrocautery-enhanced lumen-apposing metal stent designed for the drainage of pancreatic pseudocysts. The stent is delivered using a system that allows for single-step deployment without the need for guidewire exchanges or tract dilation.
219216757|NCT06875921|OTHER|McKenzie Exercise Group|"The intervention will last 7 minutes and will consist of the following exercises:~* Four Extension Exercises: Lying Face Down, Lying Face Down in Extension, Repeated Lumbar Extension in Lying, Repeated Lumbar Extension in Standing.~* Two Flexion Exercises: Repeated Lumbar Flexion in Lying, Repeated Lumbar Flexion in Sitting."
219216758|NCT06875921|OTHER|Pilates Exercise Group|The intervention will last 20 minutes and will include Pilates exercises focused on mobility and strengthening.
219361721|NCT04318405|DRUG|Iron isomaltoside 1000|Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000
219090282|NCT04350892|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|"This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass."
219090283|NCT04350892|PROCEDURE|Sleeve Gastrectomy (SG)|"Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy."
219361722|NCT05957172|DEVICE|ZOLL Arrhythmia Management System|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)
219361723|NCT06547970|OTHER|Educational intervension|an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
219361724|NCT01554579|DRUG|Gefapixant|BID
219361725|NCT01554579|DRUG|Sugar Pill|Placebo
219362091|NCT04722211|DIETARY_SUPPLEMENT|placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
218984158|NCT04264091|OTHER|Observational|Observational
218984159|NCT01402414|RADIATION|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
218984160|NCT01402414|RADIATION|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
218984161|NCT01402414|RADIATION|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
218984162|NCT05455697|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
218984163|NCT05455697|DRUG|Cyclophosphamide|Given IV
218984164|NCT05455697|DRUG|Doxorubicin|Given IV
218984165|NCT05455697|DRUG|Prednisone|Given PO
218984166|NCT05455697|BIOLOGICAL|Retifanlimab|Given IV
218984167|NCT05455697|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
218984168|NCT05455697|BIOLOGICAL|Tafasitamab|Given IV
218984169|NCT05455697|DRUG|Vincristine|Given vincristine
218984170|NCT05455697|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
218984171|NCT05455697|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
218984172|NCT05455697|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
218984173|NCT05455697|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
218984174|NCT05455697|PROCEDURE|Computed Tomography|Undergo FDG-CT
218984175|NCT05455697|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
218984176|NCT05455697|DRUG|Polatuzumab Vedotin|Given IV
218984177|NCT06113744|BIOLOGICAL|Placebo|saline
218984178|NCT06113744|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
218984179|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
218984180|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
218984181|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
218984182|NCT02981121|BEHAVIORAL|Exercise and Diet remedies|
218984183|NCT02981121|DRUG|Metformin|
218984184|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
218984185|NCT06498154|RADIATION|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
218984186|NCT00281307|DRUG|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
218984187|NCT03591185|OTHER|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
218984188|NCT03869983|OTHER|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
218984189|NCT03869983|OTHER|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
218984190|NCT00437177|DRUG|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
218984191|NCT00437177|DRUG|[(123)I] iodobenzamide|\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
218984192|NCT02398578|DEVICE|Amphora OAB Device|Cystoscopic procedure to treat OAB
218984193|NCT02478632|DRUG|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
218984194|NCT02958514|DEVICE|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
219216759|NCT06879301|DRUG|Intravitreal injection of aflibercept 8 mg|"Preoperative preparation: Patients were prepared by applying topical fluoroquinolone eye drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) 4 times daily for three days before injection.~Procedure: The intravitreal injection was carried out in the operating room under complete aseptic techniques with an operating microscope. After the topical application of anaesthetic drops (benoxinate hydrochloride 0.4%, Benox, Epico, Egypt) to the ocular surface followed by the topical application of 10% povidone-iodine (Betadine) to the periocular area, lids and eye lashes, 5% povidone iodine was administered inside the conjunctival sac for three minutes before the intravitreal injection. 0.07 ml of aflibercept (8 mg) was injected into the vitreous cavity in the inferotemporal quadrant of the globe using a 30-gauge needle 4 mm from the limbus.~Postoperative care: After injection, topical antibiotic drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) were applied, and the eye was"
219216760|NCT06762314|DRUG|Insulin|Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
219216761|NCT06762314|DRUG|Semaglutide|Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days
219216762|NCT06762314|DRUG|Empagliflozin|Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
219216763|NCT05771844|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
219216764|NCT06765967|OTHER|displaying virtual reality images|Patients were shown content filmed in 4K resolution through the glasses.
219216765|NCT06765967|OTHER|music playback|With the permission of the Turkish Music Research and Promotion Group (TÜMATA), 'Acemaşiran Makamı' was played.
218984195|NCT02958514|DRUG|Tobramycin and Dexamethasone Ophthalmic Ointment|
218984196|NCT06446011|PROCEDURE|root canal treatment in Ckd patients|root canal treatment in teeth with apical periodontitis to observe periapical healing , and change in eGFR ,blood urea and creatinine and HSCRP
218984197|NCT06446011|PROCEDURE|root canal treatment in healthy patients|root canal treatment in teeth with apical periodontitis to observe periapical healing and change in HSCRP
218984198|NCT03494543|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
218984199|NCT05700617|DRUG|1:1 Randomization to receive milrinone|Randomized to receive either inotropic agent: milrinone or no agent
218984200|NCT05196646|DEVICE|Respiratory Acoustic Sensors|Wireless sensor that contains a dual microphone and an inertial measurement unit (IMU) will capture the breathing sound and respiratory effect. Two wireless sensors will be used, with one placed on the suprasternal notch and the other placed on the right upper chest of the infant, in order to determine the sensor placement yielding the best respiratory signal. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller (ISP1807, Insight SIP) and stored on the same device for future analysis.
218984201|NCT05196646|DEVICE|Nasal thermistor|The nasal temperature probe that detects changes in temperature between inhaled and exhaled gases allows for the surrogate measure of airflow. It will be placed in one naris and secured with tape at the upper lip or cheek. The nasal temperature signal will be acquired using the Power Lab analog-digital acquisition system and stored for later analysis.
218984202|NCT05196646|DEVICE|Respiratory Inductive Plethysmography|Two respiratory bands will be placed circumferentially around the infant's chest (at the level of nipple line) and around the abdomen (just above the level of the umbilicus) in order to measure chest and abdominal wall movements, respectively. These movements will be recorded using Respiratory Inductive Plethysmography (Respitrace QDC®, Viasys® Healthcare, USA). The Respitrace® signals will be acquired using the Power Lab data acquisition system and stored for later analysis.
218984203|NCT05196646|DEVICE|Pneumotachometer|The pneumotachometer is a pressure-differential based flow sensor that is used to measure respiratory flow. It will be connected to a standard face mask that is gently applied to cover the infant's mouth and nose. The face mask will be similar to the masks used as part of standard of care in the NICU for infants who require continuous positive pressure, with or without ventilation. The flow measurements will be recorded using the Power Lab data acquisition system and stored for later analysis.
218984204|NCT05287126|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
218984205|NCT04949464|PROCEDURE|Computed Tomography|Undergo LDCT
218984206|NCT04949464|BEHAVIORAL|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
218984207|NCT05408117|DEVICE|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
218984208|NCT05408117|DEVICE|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
218984209|NCT05676099|PROCEDURE|Phlebotomy|Participants may elect to submit a blood sample to the Biosample Repository.
218984210|NCT05676099|PROCEDURE|Buccal (cheek) swab|Participants may elect to submit a buccal swab sample to the Biosample Repository.
218984211|NCT05676099|GENETIC|Genetic Testing|Biosamples may be processed and analyzed for genetic variants using whole genome sequencing (WGS) or other sequencing methods. Participants whose samples are processed in this manner may be contacted and provided the option to receive TSC1 or TSC2 genetic variant results by opting in using Consent to Return of Genetic Results Form. Participants will be offered a one-time genetic counseling session to review their results, free of charge. CLIA-certified, TSC1 or TSC2 genetic variant results will be returned to participants who opt in to receive such results. Additionally, negative results and results not able to be clinically certified will also be offered to participants with a one-time genetic counseling session to review their results, free of charge using the Return of Genetic Research Results Template Letter. CSS will be responsible for informing clinic participants that their samples have been sequenced and offer to connect participant to the TSC Alliance for further information.
218984212|NCT05676099|OTHER|Tissue donation after routine clinical procedure|Participants may elect to submit a tissue sample to the Biosample Repository following a medical procedure.
218984213|NCT05849129|DRUG|Ascorbic acid|High dose ascorbic acid delivered intravenously
218984214|NCT05849129|OTHER|Normal Saline|0.9% NaCl solution
219216766|NCT06812429|DRUG|Dapagliflozin (DAPA)|Participants will receive 10mg of Dapagliflozin per day for three days.
219216767|NCT06765369|OTHER|Mediterranean diet|The MD is characterized by increased consumption of legumes, whole grains, vegetables, fruits, nuts, seeds and olive oil, moderate consumption of fish, poultry and dairy foods, with low consumption of processed foods and red meat. The nutritional profile of the MD intervention will consist of 46% carbohydrates, 17% protein, and 35% fat. A significant focus on dietary fat consumption with maintaining an omega 6:3 ratio of approximately 3:1 or lower. The MD will provide fibre-rich foods to meet the fibre recommendations for Canadians (males: 30 grams/day, females: 21 grams/day)
219216768|NCT06765369|OTHER|Westernized Diet|The WD is characterized by increased consumption of highly processed foods, refined grains, red meats, processed meats, added sugars, added salt, high intake of omega-6 PUFA, accompanied by a reduction in fibre, fruits and vegetables, whole grains, fish, as well as nuts and seeds.The nutrition composition of the WD intervention will consist of 46% of calories derived from refined carbohydrates and added sugars, 17% protein (sourced from red and processed meats) and 35% fat. The fatty acid profile will be characterized by higher amounts of n-6 PUFAs while lacking in n-3 PUFAs and MUFAs, with a omega 6:3 ratio of 15-20:1.
219216769|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus.|Minimally invasive procedures for the Hallux Abductus Valgus
219216770|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
219216771|NCT06751420|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging Time Of Flight Angiography
219216772|NCT06750159|OTHER|No intervention (observational study)|no intervention(observational study)
219216773|NCT06748456|BEHAVIORAL|Podcast|A pre-recorded podcast with a urologist and a GP discussing the theme to promote preparatory reflections among the GPs before the cluster meeting
219216774|NCT06748456|BEHAVIORAL|Cluster meeting|A two-hour meeting facilitated by either the GPs cluster coordinator, another GP from the cluster or a facilitator outside the cluster chosen by the cluster itself with specific slides about PSA in general, guidelines, expert videos, data from the clinics, cases, and group discussions
219216775|NCT06748456|BEHAVIORAL|Hand-out material 1|Hand-outs of the main take-home messages to facilitate further discussion in their respective GP offices
219216776|NCT06748456|BEHAVIORAL|Hand-out material 2|Hand-outs to be used by GP and patients to facilitate communication about the relevance of taking a PSA-test
218984215|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
218984216|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
218984217|NCT06582225|BEHAVIORAL|Internet-delivered exposure and response prevention (I-ERP)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks."
218984218|NCT06582225|BEHAVIORAL|Internet-delivered stress management (I-SM)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks."
218984219|NCT05488171|DRUG|Methylone|Single oral dose of 200 mg of methylone.
218984220|NCT05488171|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
218984221|NCT05488171|DRUG|Placebo|Single oral dose of placebo.
218984222|NCT02202187|DRUG|GSK2140944|Investigational Study Drug
218984223|NCT02202187|OTHER|Placebo|Placebo
218984224|NCT05589766|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
218984225|NCT05589766|OTHER|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
218984226|NCT02130232|BEHAVIORAL|Lifestyle Intervention|
218984227|NCT02130232|OTHER|Usual Care|
218984228|NCT04062708|DRUG|Durvalumab|"Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
218984229|NCT04062708|PROCEDURE|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
219216777|NCT06549049|BEHAVIORAL|TranS-C for PTSD|The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.
219216778|NCT06549049|BEHAVIORAL|Sleep Psychoeducation Control|Participants will receive psychoeducation about sleep.
219216779|NCT06753617|PROCEDURE|Cryoablation of brain neoplasm|The procedure begins with standard surgical exposure of the tumor, followed by a biopsy. Next, one or more cryoprobes will be positioned directly into the tumor for ablation. Once positioned, the cryoablation process will commence. A maximum of 2x10 minutes cryoablation cycles will be established followed by active thawing. Following ablation, resection of the tumor will be performed, after which patients will receive standard treatment and follow-up care. Ice formation around the cryoprobes will be monitored using intraoperative ultrasound to optimize the ablation process.
219216780|NCT06756217|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT|68Ga-grazytracer is designed to target granzyme B, and showed excellent in vivo metabolic stability and favorable targeting efficiency during immune responses. 68Ga-grazytracer PET/CT could directly display the killing effect of CD8+T cells on tumor. All enrolled patients underwent the same 68Ga-grazytracer PET/CT imaging.
219216781|NCT06754085|DRUG|Florastamin[18F] Injection|The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
219216782|NCT06754267|DRUG|Venetoclax|BCL-2 inhibotor
219216783|NCT06754267|DRUG|Olverembatinib|Tyrosine kinase inhibitor
219216784|NCT06754267|DRUG|Predinisone|Glucocorticoids
219216785|NCT06751641|OTHER|patient participating in a clinical trial incorporating decentralized elements.|participating in a clinical trial incorporating decentralized elements.
219216786|NCT06764355|DRUG|Tislelizumab|200 mg, 1h-IVF, Q3W on day 1 for 2 cycles
219216787|NCT06764355|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, 3h-IVF, Q3W on day 1 for 2 cycles
219216788|NCT06764355|DRUG|Cisplatin|Cisplatin 75 mg/m2, 2h-IVF, Q3W on day 1 for 2 cycles
219216789|NCT06764355|RADIATION|Chemoradiotherapy|"Chemoradiotherapy~* Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8,15, 22, and 29;~* Cisplatin 30 mg/m2,1h-IVF, on days 1, 8,15, 22, and 29;~* RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
219216790|NCT06763510|DRUG|Chirocaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Isobaric levobupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
218984230|NCT04062708|RADIATION|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
218984231|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
218984232|NCT05594290|DRUG|Retifanlimab|Retifanlimab i.v. 500 mg day 1
218984233|NCT05594290|DRUG|Cisplatin|Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
218984234|NCT05594290|DRUG|Etoposide|Etoposide 100 mg/sqm iv. day 1, 2, 3
218984235|NCT03698201|OTHER|Non-interventional|Translational, observational study
218984236|NCT05299606|DEVICE|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
218984237|NCT00935090|DEVICE|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
218984238|NCT04811378|OTHER|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
218984239|NCT06079658|BEHAVIORAL|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
218984240|NCT04622306|DEVICE|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
218984241|NCT00443027|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
218984242|NCT02043314|DRUG|Isoniazida|
218984243|NCT02499276|DEVICE|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
218984244|NCT03897023|BIOLOGICAL|Gut Microbiota|Status of microbiota
218984245|NCT06000397|OTHER|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
219216791|NCT06763510|DRUG|Bupivacaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Hyperbaric bupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
219216792|NCT06768697|BIOLOGICAL|KFD1(0µg )|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(0µg + 80µg)
219216793|NCT06768697|BIOLOGICAL|KFD1(20µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(20µg + 80µg)
218984246|NCT06000397|OTHER|Standard CANImmunize notifications|"Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date"
218984247|NCT00864721|DRUG|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
218984248|NCT04689269|OTHER|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
218984249|NCT04689269|OTHER|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
218984250|NCT04689269|DEVICE|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
218984251|NCT04689269|DEVICE|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
218984252|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Colonic-Delivery capsule)|250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
218984253|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Regular Administration capsule)|250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
218984254|NCT06097182|OTHER|Placebo|250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
218984255|NCT05825781|DRUG|Pertuzumab|i.v.
218984256|NCT05825781|DRUG|Perjeta®|i.v.
218984257|NCT05661110|OTHER|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
218984258|NCT04521374|BEHAVIORAL|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
218984259|NCT01050855|DRUG|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
218984260|NCT01050855|DRUG|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
218984261|NCT01050855|DRUG|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
218984262|NCT00282100|DRUG|Gefetinib (Iressa)|
218984263|NCT00223015|DRUG|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
218984264|NCT03128827|DEVICE|RAM sensor|Acoustic Respiration Monitor
218984265|NCT05768074|OTHER|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
218984266|NCT02154737|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
218984267|NCT02154737|DRUG|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
218984268|NCT04752683|OTHER|MyBuddy Employee Wellbeing App|"The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data)."
218984269|NCT04763668|OTHER|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
218984270|NCT04763668|OTHER|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
218984271|NCT00003970|DRUG|irinotecan hydrochloride|Given IV
218984272|NCT00736944|DRUG|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
218984273|NCT00736944|DRUG|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
218984274|NCT00736944|DRUG|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
218984275|NCT00736944|DRUG|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
218984276|NCT00736944|DRUG|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
218984277|NCT00736944|RADIATION|Radiation (Post induction)|Monday-Friday, weeks 1-7
218984278|NCT00736944|DRUG|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
219216794|NCT06768697|BIOLOGICAL|KFD1(40µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(40µg + 80µg)
219216795|NCT06768697|BIOLOGICAL|KFD1(80µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(80µg + 80µg)
219216796|NCT06761495|PROCEDURE|Baseball Suturing Technique|(Baseball Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and running baseball stitch pattern was started. The suturing pattern was performed by taking bites from the inside out through the upper and lower lips of the wound at approximately 1 cm intervals with a 1 cm margin from the wound edges
219216797|NCT06761495|PROCEDURE|Single-Layer Locked Continuous Suturing Technique|(Single-Layer Locked Continuous Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and single-layer-locked continuous suturing was started. The suturing pattern was performed by taking bites from outside to inside through the lower lip and inside to outside through the upper lip of the wound. Each time, a lock was formed by passing through the loop formed by the previous suture. The suturing was performed at approximately 1 cm intervals with a 1 cm margin from the wound edges
219216798|NCT06761495|PROCEDURE|Single-Layer Unlocked Continuous Suturing Technique|(Single-Layer Unlocked Continuous Suturing Technique): The uterotomy line was closed in a single-layer continuous suturing pattern that is explained above as group 2 but without passing the needle through the loop formed by the previous sutu
219090284|NCT04350892|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
219090285|NCT04114734|BEHAVIORAL|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
219090286|NCT06665386|PROCEDURE|hypothermia|"Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL"
219090287|NCT05963607|OTHER|Weighted blanket|A blanket sewn with extra weight in it.
219090288|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
219090289|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
219090290|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
219090291|NCT04838041|DRUG|Asciminib 40 MG|40 mg by mouth (PO) when used with imatinib.
219090292|NCT04838041|DRUG|Asciminib 40 MG Twice Daily|40 mg twice daily when used with nilotinib.
219090293|NCT04838041|DRUG|Asciminib 80 MG daily|80 mg daily when used with dasatinib or taken alone.
219090294|NCT04838041|DRUG|Imatinib|Maximum dose of 400 mg PO once daily.
219090295|NCT04838041|DRUG|Nilotinib|Maximum dose of 300 mg twice daily.
219216799|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
218984279|NCT00736944|DRUG|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
218984280|NCT00876057|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy
218984281|NCT00876057|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
219090296|NCT04838041|DRUG|Dasatinib|Maximum dose of 100 mg PO once daily.
219090297|NCT06606574|OTHER|Titration protocol|A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
219090298|NCT06984003|OTHER|stretching exercises|a brief explanation, by a trained physical therapist, of stretching exercise program and of how to practice these active stretching exercises as a home program 3 times per week for 4 weeks.
219090299|NCT05560854|BEHAVIORAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
219090300|NCT01855776|DEVICE|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
219361726|NCT02623335|OTHER|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
219361727|NCT05319236|DEVICE|Gabi System|See arm description
219361728|NCT01665963|DEVICE|TopClosure(c) System|
219216800|NCT06773247|OTHER|I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy|"The cupping procedure was performed as follows: Massage oil was applied over the area first to improve contact and makes it easier to move the cup's position. double-walled glass cups (6 glasses with diameters from 75 to 100 mm) were held inverted, after which each glass was placed on an afflicted area overlying the low back muscle (acupoint: BL23).~Myofascial Release Technique Vertical stroking technique was performed in lumbar region to quadratus lumborum. AIt was performed as follow; Quadratus lumborum is palpated in prone and side lying for trigger points. The technique is applied by the patient positioned in side lying with a pillow under waist to exaggerate stretch of the muscle. The therapist stands at level of patient's hip posterior and counter pre"
219361729|NCT01665963|DEVICE|Pressure Bandage|
218984282|NCT04521660|DEVICE|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
219361730|NCT03739528|DRUG|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
219361731|NCT03739528|DRUG|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
219361732|NCT04355598|DRUG|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
218984283|NCT06303908|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
218984284|NCT00002854|BIOLOGICAL|filgrastim|
218984285|NCT00002854|DRUG|carboplatin|
218984286|NCT00002854|DRUG|cisplatin|
218984287|NCT00002854|DRUG|cyclophosphamide|
218984288|NCT00002854|DRUG|etoposide|
218984289|NCT00002854|DRUG|ifosfamide|
218984290|NCT00002854|DRUG|mesna|
218984291|NCT00002854|DRUG|paclitaxel|
218984292|NCT00002854|PROCEDURE|peripheral blood stem cell transplantation|
218984293|NCT06487416|DRUG|Tiotropium Bromide Inhalation Powder|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
218984294|NCT06487416|DRUG|Spiriva®Handihaler®|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
218984295|NCT00446862|DRUG|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
218984296|NCT04085393|DRUG|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
218984297|NCT05350410|BEHAVIORAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
218984298|NCT01601132|DRUG|theophylline|300mg (80mg/15ml elixir)
218984299|NCT01601132|DRUG|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
218984300|NCT05274061|BEHAVIORAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
218984301|NCT01902823|BEHAVIORAL|Services from a Nurse Navigator|Services from a Nurse Navigator
218984302|NCT01139983|GENETIC|DNA analysis|
218984303|NCT01139983|GENETIC|RNA analysis|
218984304|NCT01139983|GENETIC|fluorescence in situ hybridization|
218984305|NCT01139983|GENETIC|microarray analysis|
218984306|NCT01139983|GENETIC|polymerase chain reaction|
218984307|NCT01139983|GENETIC|reverse transcriptase-polymerase chain reaction|
218984308|NCT01139983|OTHER|laboratory biomarker analysis|
218984309|NCT03629431|PROCEDURE|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
218984310|NCT03629431|PROCEDURE|postoperative standard care|Standard care received postoperatively
218984311|NCT02678975|DRUG|Disulfiram|Disulfiram 400 mg daily
218984312|NCT02678975|DIETARY_SUPPLEMENT|Copper|nutritional supplement with copper, 2 mg daily
218984313|NCT02678975|DRUG|Alkylating Agents|Alkylating antineoplastic agent
218984314|NCT04996043|DIETARY_SUPPLEMENT|Collagen Peptide Drink|Testing product
218984315|NCT04996043|DIETARY_SUPPLEMENT|Placebo drink|Blank
218984316|NCT04185311|BIOLOGICAL|Ipilimumab|Given IV
219090301|NCT01855776|BEHAVIORAL|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
219090302|NCT01855776|BEHAVIORAL|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
219090303|NCT01855776|OTHER|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
219090304|NCT04704063|DRUG|Tocotrienols / Vitamin E|Palm Tocotrienols complex
219090305|NCT04704063|DRUG|Placebo control|Placebo matching Tocovid Suprabio
219090306|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation"
219090307|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App"
219090308|NCT03538951|DRUG|10% VDA-1102|200 mg twice-daily for 12 weeks
219090309|NCT03538951|DRUG|20% VDA-1102|200 mg once-daily for 12 weeks
219090310|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
219090311|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
219090312|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
219090313|NCT06668376|DEVICE|Leg Sleeve|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
219090314|NCT06668376|DEVICE|Placebo|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
219090315|NCT05601869|DEVICE|RECOVER Prosthetic Ankle-Feet System|The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
219090316|NCT06987786|OTHER|Massage|"Soft tissue mobilization (STM), also known as massage, is a form of manual therapy. STM consists of many different categories of treatment, but all involve a hand's on application. During the session, the Dr. Cook will use techniques such as kneading, stretching, and deep tissue manipulation to target the affected areas. The total time of application will be 30 minutes. This hands-on approach is theorized to reduce muscle tension, improve blood circulation, and promote relaxation. STM stimulates the release of endorphins and serotonin, which are natural painkillers and mood enhancers."
219216801|NCT06770192|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
219216802|NCT06770192|OTHER|Plyometric|: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
219216803|NCT06770192|OTHER|Control|compare with other groups
219216804|NCT06771141|BEHAVIORAL|Virtual Reality Video Session|This intervention involves a 10-minute virtual reality (VR) video session designed to reduce pre-procedural anxiety and promote relaxation in pediatric patients. The video immerses participants in a calming virtual environment with interactive and visually engaging content tailored for children. It is administered prior to the endoscopy procedure to help manage anxiety and stabilize vital signs, such as blood pressure, heart rate, and oxygen saturation. The VR session serves as a non-pharmacological approach to anxiety management during medical procedures.
218984317|NCT04185311|BIOLOGICAL|Nivolumab|Given IV
218984318|NCT04185311|BIOLOGICAL|Talimogene Laherparepvec|Given intratumorally
218984319|NCT03949309|OTHER|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
218984320|NCT02170194|BEHAVIORAL|Resilience Enhancement Training via Smart Phone|
218984321|NCT02170194|BEHAVIORAL|Daily Text Messages|
218984322|NCT01699490|DRUG|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
218984323|NCT01699490|DRUG|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
218984324|NCT00362557|DEVICE|MRI|Magnetic resonance imaging
218984325|NCT01788488|OTHER|Use of procalcitonin as biomarker to guide therapy|
218984326|NCT05429060|PROCEDURE|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
219361733|NCT04355598|DRUG|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
219090317|NCT06987786|OTHER|Talk-based therapy|Talk based therapy includes an innovative, evidence-based psychosocial therapy designed to provide rapid and effective pain management for individuals suffering from chronic pain. This single-session, intervention equips patients with essential pain relief skills through a combination of cognitive behavioral therapy (CBT) techniques, mindfulness principles, and pain neuroscience education. The program focuses on teaching patients how to identify and reframe distressing thoughts, practice relaxation techniques, and develop personalized pain management plans.
219090318|NCT06670664|OTHER|No intervention|No intervention. This is a single-group study.
219090319|NCT01582191|DRUG|Everolimus|Given PO
219090320|NCT01582191|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218984327|NCT00543010|DRUG|MK0767|
219090321|NCT01582191|OTHER|Pharmacological Study|Optional correlative studies
219090322|NCT01582191|DRUG|Vandetanib|Given PO
219090323|NCT06991101|DRUG|Ruxolitinib|"During Radiation Therapy phase: 20 mg ruxolitinib will be self-administered orally (PO) twice every day (BID), starting on Day 1 for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Ruxolitinib 20 mg will be self-administered PO BID, starting on Day 1 in consecutive 28-day cycles.~Either phase:~Aside from the 30-day break, ruxolitinib will be continued daily until disease progression or treatment intolerance. Ruxolitinib should be administered at approximately the same time each day. The tablets should be swallowed whole with water and should not be opened, broken, or chewed. The dose may be reduced in the case of certain adverse events."
219090324|NCT06991101|DRUG|Temozolomide|"During Radiation Therapy phase: 75 mg/m\^2 will be self-administered PO once every day, starting on Day 1, for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Temozolomide 150-200 mg/m\^2 will be self-administered PO BID, starting on Day 1 to Day 5 of each cycle for six cycles.~Either phase:~The dose may be reduced in the case of certain adverse events."
219090325|NCT06991101|RADIATION|Radiation Therapy|Radiation will be administered every weekday (Monday to Friday) in 2 Gy fractions for 30 fractions during a 6-week period (60 Gy total).
219090326|NCT02630134|OTHER|These patients receive the Baeta device and take it home|
219090327|NCT04665154|DRUG|MAS825|single dose i.v. and s.c.
219090328|NCT04665154|DRUG|Placebo|single dose i.v. and s.c.
219090329|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels + fibroblasts|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours.
219090330|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest.
219090331|NCT06733090|DRUG|0.12% chlorhexidine glucanate solution|The superiority of two different solutions over each other will be examined with a standard maintenance.
219090332|NCT06733090|DRUG|0.2% chlorhexidine glucanate solution|0.2% chlorhexidine glucanate solution
219090333|NCT06731972|OTHER|Exercises|Classical massage, stretching, functional exercises, electrical modalities, thermal agents, home exercises, etc., plus home exercises.
219090334|NCT06731972|DEVICE|Mobile game|mobile application games (such as Temple Run, Flappy Bird, Angry Birds, etc., or games the patient is already playing) as part of their home exercise program.
219090335|NCT06733857|BEHAVIORAL|VEG2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
218984328|NCT00142935|BEHAVIORAL|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
218984329|NCT00142935|BEHAVIORAL|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
218984330|NCT00142935|BEHAVIORAL|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
219090336|NCT06733857|BEHAVIORAL|OMNI2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
219090337|NCT06733168|DEVICE|electrical impedance tomography|"Before initiating recruitment maneuver, all patients were placed on mechanical ventilation set according to the ARDSnetwork strategy for 10 minutes, ensuring SpO2 of 88-95%, PaO2 of 55-80 mmHg, and a mean arterial pressure (MAP) ≥ 65 mmHg.~* PEEP was incrementally increased by 5 cmH2O every minute: from 10 to 15, to 20, and finally to 25 cmH2O, with a maximum pressure limit of 40 cmH2O.~* Following recruitment maneuver at the final PEEP level, the process of identifying the optimal PEEP was initiated.~* Then, PEEP will be set to 20 cmH2O and was gradually decreased by 2 cmH2O every 30 seconds until it reached 6 cmH2O or SpO2 dropped to ≤ 80%.~* Selection of optimal PEEP: The optimal PEEP was defined as the intersection point between the alveolar overdistension and collapse curves as measured by the EIT system."
219090338|NCT06733168|OTHER|Non-EIT|Patients will have PEEP set using the low FiO2-PEEP table, based on the ARDSnet protocol
219090339|NCT06732557|OTHER|Traditional treatments|Isometric exercise for deep neck flexors and sub occipital release
219216805|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
219090340|NCT06732557|OTHER|muscle energy technique|Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
219090341|NCT06732557|OTHER|Mulligan Mobilization|Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
219090342|NCT06733961|DIAGNOSTIC_TEST|SCUBE-1 and VAP-1|There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
219090343|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using NuSmile Zirconia crowns|Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect. These crowns have high flexural strength, allowing them to resist crack propagation. The additional benefits of these crowns are the ability to replace metals due to extremely high strength and toughness, higher resistance to chemicals, and superior erosion resistance
219090344|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using BioFlx crowns|The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns. The Bioflex crown may provide a promising result in terms of the clinician's and parental satisfaction as aesthetic is a prime concern for parents and children in this era. The limitations of the studies on this type of crowns will require more studies with more detailed clinical observation and larger sample size to provide more rigorous results.
219216806|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
219216807|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
219216808|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
219216809|NCT03747133|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
219216810|NCT04520217|DRUG|4% Imipramine Cream|4% Imipramine Cream
219216811|NCT04520217|DRUG|Base Cream|Base Cream
219216812|NCT06547827|OTHER|robotic rehabilitation|"Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
219216813|NCT06547827|OTHER|traditional rehabilitation|"A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
219216814|NCT06533436|PROCEDURE|Corded tube care|The caregiver cut a 6 cm strip of Tensoplast® and wrapped it around the intubation probe at the level of the prescribed fixation mark at the corner of the mouth. The cord strands are placed around the patient's head, tightened, and a double knot is tied at the patient's cheek. Compresses are placed over the ears to protect them from possible lesions caused by the cords.
219216815|NCT06533436|DEVICE|Tube care attached by AnchorFast|"Shaving is recommended for patients with beards, and prior family consent is required for patients with beards.~AnchorFast is Suitable for intubation probes from 5 to 10 mm in diameter, it adapts to different morphologies thanks to hydrocolloid dressings bonded to the face and an adjustable cord around the neck. Due to its rigidity, this device is not recommended for patients whose condition requires them to be positioned in the ventral decubitus (VD) or lateral decubitus position."
219361734|NCT04355598|DRUG|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
219361735|NCT03038646|DRUG|MIN-101|
219361736|NCT06070948|DRUG|Venetoclax|Oral; Tablet
219216816|NCT06533436|OTHER|Caregiver's evaluation on each tube fixation|The caregivers who performs the interventions according to the study will fill question form to assess the worload and the confort of the tube care for each intervention type The caregivers are both a research actor and a study population. One of the secondary aims of this study is to evaluate the two types of tube-fixing with regard to caregiver workload and comfort in performing care. Caregivers will complete identical questionnaires assessing their satisfaction with the two types of tube fixation studied in arms 1 and 2.
219216817|NCT05189496|BEHAVIORAL|hyperbaric oxygen therapy|hyperbaric oxygen therapy
219216818|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
219216819|NCT05423145|BEHAVIORAL|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
219216820|NCT02659293|DRUG|Lenalidomide|"* Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21"
219216821|NCT02659293|DRUG|Carfilzomib|"* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
219090345|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using Digital VITA ENAMIC crowns (CAD/CAM blanks)|is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
219090346|NCT06732206|OTHER|Short Solution Focused Approach Program|It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.
219090347|NCT06733870|PROCEDURE|guided immediate implant surgery|fully guided immediate implant placement and loading
219090348|NCT06209281|DRUG|Lower dose atropine sulfate eye drops|Administer to eyes
219090349|NCT06209281|DRUG|Low dose atropine sulfate eye drops|Administer to eyes
219090350|NCT06209281|DRUG|placebo|Administer to eyes
219090351|NCT06735651|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
219090352|NCT06735651|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks
219090353|NCT06473584|DIAGNOSTIC_TEST|Diabetes detection|Fasting glycemia on blood sample
219090354|NCT01265199|DRUG|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
219090355|NCT07073521|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss|The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.
219216822|NCT02659293|DRUG|Dexamethasone|"* Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
219216823|NCT02659293|DRUG|Lenalidomide (Control)|"* Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28"
219361737|NCT06112041|DRUG|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
219682076|NCT03446976|BIOLOGICAL|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
219090356|NCT07066228|DEVICE|tissue-engineered bone|Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro
219090357|NCT06901388|PROCEDURE|Non-surgical peri-implant therapy|Standardized non-surgical therapy consisting of mechanical debridement of peri-implant sites using ultrasonic instruments, combined with personalized oral hygiene instruction. The intervention is delivered in a single session. No adjunctive antimicrobials are used. Follow-up is scheduled 3 months after therapy for clinical and psychometric re-evaluation.
219090358|NCT07076797|OTHER|EXERCISE TRAINING|PHYSIOTHERAPY PROGRAM
219090359|NCT07076797|OTHER|NMES|PHYSIOTHERAPY PROGRAM
219090360|NCT07093346|DIETARY_SUPPLEMENT|Pectin|15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.
219090361|NCT07093346|OTHER|Cocoa Powder|10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.
219090362|NCT07093346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.
219090363|NCT07093138|COMBINATION_PRODUCT|Canvert-M (Produced by Alasht Pharmed co. Iran)|Canvert-M is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. At the onset of a migraine attack, an adequate amount of Canvert-M roll-on should be applied to the areas of the forehead, temporal, behind the ears, and the base of the neck. If the patient's headache persists after 30 minutes, a second dose can be used.
219090364|NCT07093164|BEHAVIORAL|Virtual visit|Patients will be provided an initial virtual health or telehealth visit instead of an in person visit.
219090365|NCT07093190|DIETARY_SUPPLEMENT|exercise following Rg1 consumption|The effect of Rg1 on exercised skeletal muscle in older women
219090366|NCT07093190|DIETARY_SUPPLEMENT|Placebo|Resistance exercise performed 1 hour following placebo consumption
219090367|NCT07093879|OTHER|STATIC HAMSTRING STRETCH|For the static stretching technique, individuals lay supine in a straight posture on the treatment table and relaxed. Then, the pelvis and thighs opposite to the lower limb to which the stretching technique was to be applied were tied with Velcro straps. With the knees extended, the foot in neutral position and the hip joint bent as much as possible within its range, the hip joints were bent more until the hamstring muscle was stretched with light, tolerable pain, and kept there for 30 seconds
219216824|NCT06749509|OTHER|Face-to-face musculoskeletal rehabilitation|Kela's rehabilitation course for those with MSD includes two 5-day periods and one 3-day period of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation center over a 9-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation course is group-based and provided free of charge. The 9-month rehabilitation period also includes calls to the participants before and after rehabilitation. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A medical statement is required when applying for the rehabilitation course.
219216825|NCT06749509|OTHER|Musculoskeletal telerehabilitation|Kela´s MSD telerehabilitation course is arranged entirely as telerehabilitation, and it includes videoconferencing, online rehabilitation, and group-based rehabilitation days implemented by a multidisciplinary team of rehabilitation experts. Participation does not require particular IT skills, but appropriate equipment (e.g., mobile phone, laptop, tablet computer) is needed. The rehabilitation course is free of charge, and the total duration, including the calls before and after rehabilitation, is approximately 7 months. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A physiotherapist's recommendation is required when applying for the telerehabilitation course
219216826|NCT06749509|OTHER|Controls|The control participants have an MSD diagnosis and musculoskeletal symptoms. Based on an occupational physiotherapist's brief evaluation they are eligible to apply for Kela's musculoskeletal rehabilitation (the interventions below). By them own choice, however, they will not participate in these rehabilitation programs in the near future. The controls are recruited via two occupational health care producers in the private sector.
219216827|NCT06777277|OTHER|Cognitive-behavioral therapy|The intervention will be delivered in 16, 60-minute sessions (1st session 90 mins). The treatment manual was informed by a 12-session (75 min each) CBCT developed by our team for genito-pelvic pain. The SIAD manual focuses on empirically supported interpersonal factors relevant to SIAD, informed by the Interpersonal Emotion Regulation Model of women's sexual dysfunction. The goals of the CBCT are to: (1) re-conceptualize low sexual desire/arousal as multidimensional in which both partners affect and are affected by the SIAD symptoms (2) modify and/or accept those factors that are associated with low sexual desire/arousal to increase adaptive coping, facilitate sexual desire/arousal, and reduce sexual distress, (3) as per our theoretical model, improve couple interactions related to sexuality (e.g., communication, intimacy) via enhanced emotion regulation, and (4) consolidate skills.
219361738|NCT05091320|DRUG|Mechanical thrombectomy|Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
219090368|NCT07092878|DIETARY_SUPPLEMENT|Chamomile (Matricaria recutita)|Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.
219090369|NCT07092878|DIETARY_SUPPLEMENT|Chamomile|A chamomile-flavored beverage
219090370|NCT07092488|PROCEDURE|Advanced Platelet-Rich Fibrin Plus (A-PRF+) Revascularization Procedure|The intervention consists of the advanced platelet-rich fibrin plus (A-PRF+) revascularization protocol. It includes minimal mechanical instrumentation of the root canal, disinfection using sodium hypochlorite irrigation, and intracanal medicaments-initially calcium hydroxide followed by triple antibiotic paste. Peripheral venous blood was drawn from each participant into anticoagulant-free sterile tubes. The blood was immediately centrifuged at 1300 rpm for 8 minutes to obtain the A-PRF+ clot, which was then used as the scaffold material, extending through the root canal into the coronal cavity. The cavity was permanently sealed with glass ionomer cement. This protocol aims to promote regenerative healing and continued root development in necrotic immature permanent teeth.
219090371|NCT07093658|OTHER|High fall injury group|High fall injury group
219090372|NCT07094178|PROCEDURE|Corticosteroid Injection|This intervention consists of a single injection of corticosteroids administered directly into the affected tendon of the shoulder. Corticosteroids are anti-inflammatory drugs used to rapidly reduce inflammation and pain associated with tendinopathy. The injection is performed under aseptic conditions by a trained physician. The aim is to provide quick pain relief and improve shoulder function, although effects may be temporary.
219090373|NCT07094178|PROCEDURE|platelet-rich plasma injection|This intervention involves a single injection of Platelet-Rich Plasma (PRP), which is prepared from the patient's own blood through a process of centrifugation to concentrate platelets. PRP contains growth factors that may promote tissue healing and regeneration. The injection is administered under aseptic conditions into the affected shoulder tendon by a trained physician. The goal is to enhance long-term recovery of tendon function and reduce pain.
219090374|NCT07092722|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast with water for 12 Weeks
219090375|NCT07092722|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast with water for 12 Weeks
219090376|NCT07094659|BEHAVIORAL|Task-Specific Balance Training|Participants in the intervention groups will receive 8 weeks of task-specific balance training that includes both functional tasks and predictable perturbations specific to slips and trips. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
219090377|NCT07094659|BEHAVIORAL|Treadmill Perturbation Training|Participants in the treadmill perturbation training group will receive 8 weeks of training that includes exposure to slip-like and trip-like perturbations delivered via motorized treadmill. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
219090378|NCT07094659|BEHAVIORAL|Conventional Balance Training|Participants in the conventional balance training group will receive 8 weeks of training that includes conventional exercises designed to improve balance control. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
219090379|NCT07093697|DRUG|DW5121|Participants receive DW5121, 2 tablets orally, DW51211 Placebo, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
219090380|NCT07093697|DRUG|DW51211|Participants receive DW5121 placebo, 2 tablets orally, DW51211, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
219090381|NCT07093697|DRUG|DW51212|Participants receive DW5121 placebo, 2 tablets orally, DW51211 placebo, 2 tablets orally, DW51212 , 1 tablets orally, 3 times a day after meals for 7 days
219090382|NCT07093840|DEVICE|AmblyoPlay Digital Visual Therapy|AmblyoPlay is a home-based, app-delivered multimodal visual therapy program designed for children with amblyopia. The therapy consisted of 30-minute sessions, performed 5 days per week over a 6-month period. Exercises included gamified visual tasks targeting oculomotor control, visual acuity, stereopsis, visual-motor integration, and postural coordination. The software automatically adjusted task difficulty based on individual performance. Therapy was performed on a tablet or computer with red-green anaglyph glasses provided to participants
219090383|NCT07093840|OTHER|control group|Participants in this group were healthy children who did not receive any therapeutic intervention during the 6-month study period. They were age- and gender-matched with participants in the intervention group to ensure baseline comparability. Assessments were performed only at baseline and at the 6-month follow-up and included measurements of visual acuity, oculomotor function, stereopsis, visual-motor integration, and postural control.
219090384|NCT07094191|DIETARY_SUPPLEMENT|Chicory Coffee (Caffeine-free, polyphenol-rich beverage from roasted chicory root)|"A single oral dose of 180 mL chicory coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added.~Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL."
219090385|NCT07094191|DIETARY_SUPPLEMENT|arabica coffee|A single oral dose of 180 mL Arabica coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
219090386|NCT07094191|DIETARY_SUPPLEMENT|no beverage control|Participants underwent the shuttle run exercise protocol in a fasted state, without consuming any food or beverages prior to the test. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
219090387|NCT07093827|PROCEDURE|Posterior decompression surgery|\*\*Posterior decompression for thoracolumbar fractures involves a midline incision and subperiosteal exposure of the posterior spinal elements, followed by laminectomy or laminotomy to relieve neural compression. Pedicle screw-rod instrumentation is then applied above and below the fractured level under fluoroscopic guidance to restore stability, often supplemented by posterolateral fusion using bone graft. The procedure concludes with layered wound closure, providing direct neural decompression, rigid fixation for early mobilization, and reduced morbidity compared to anterior approaches in select cases. This technique is indicated for unstable fractures (e.g., AO Type B/C) or neurological deficits with posterior canal compromise, with variations based on fracture severity and surgical judgment.\*\*
219090388|NCT07093827|PROCEDURE|unilateral open-door laminoplasty|Posterior cervical expansive open-door laminoplasty (also known as unilateral open-door laminoplasty) is a surgical technique used to decompress the spinal cord in cervical myelopathy or spinal cord injury. The procedure involves a midline posterior cervical incision, followed by exposure of the laminae. A high-speed burr is used to create a hinged trough on one side (preserving the inner cortex) and a complete trough on the contralateral side, allowing the lamina to be gently elevated like an opening door. The opened lamina is then stabilized using sutures, miniplates, or spacers to maintain the expanded canal diameter. This approach effectively increases spinal canal space while preserving posterior elements, reducing cord compression while minimizing instability risks compared to laminectomy. It is particularly indicated for multilevel cervical stenosis with preserved cervical alignment.
219090389|NCT07093827|PROCEDURE|Posterior lumbar discectomy with fusion|Posterior lumbar discectomy with fusion (PLDF) is a standard surgical treatment for lumbar disc herniation with instability or recurrent symptoms. The procedure involves a midline posterior approach to expose the affected vertebral level, followed by laminotomy or partial laminectomy to access the neural elements. The herniated disc material is carefully removed to decompress the nerve roots, after which pedicle screws and rods are inserted for segmental stabilization. Interbody fusion (via posterior lumbar interbody fusion \[PLIF\] or transforaminal lumbar interbody fusion \[TLIF\]) is often performed by placing a bone graft or cage in the disc space to promote bony union. The combination of neural decompression, rigid instrumentation, and interbody fusion aims to relieve radicular pain while restoring spinal stability and alignment.
219216828|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
219216829|NCT05637177|BEHAVIORAL|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
219090390|NCT07093827|PROCEDURE|Surgical resection of spinal tumors|Surgical resection of spinal tumors involves a tailored approach based on tumor location, type (primary/metastatic), and spinal stability. For posteriorly accessible lesions, a midline incision exposes the affected vertebrae, followed by laminectomy to access the epidural space and decompress neural elements. Tumor resection is performed using meticulous dissection, with intraoperative neuromonitoring to minimize neurological risk. In cases requiring vertebral body involvement, a posterolateral (costotransversectomy) or combined anterior-posterior approach may be used for en bloc or piecemeal excision. Reconstruction typically involves spinal instrumentation (pedicle screws/rods) and structural support (cages/allografts) to restore stability. The goal is maximal safe resection while preserving neurological function, often supplemented by adjuvant therapies (radiation/chemotherapy) for malignant tumors.
219090391|NCT07093827|DRUG|Conservative management of ankylosing spondylitis|Conservative management of ankylosing spondylitis (AS) focuses on symptom relief, functional preservation, and slowing disease progression through a multidisciplinary approach. First-line pharmacotherapy includes NSAIDs (e.g., celecoxib) for pain and inflammation control, supplemented by TNF-α inhibitors (e.g., adalimumab) or IL-17 inhibitors for refractory cases. Physical therapy emphasizes daily spinal extension exercises, postural training, and deep breathing to maintain mobility and prevent kyphotic deformity. Patient education on ergonomic adjustments (sleeping positions, workplace modifications) and low-impact aerobic exercise (swimming, yoga) is integral. Smoking cessation is strongly advocated due to its association with worse outcomes. Regular monitoring with inflammatory markers (CRP/ESR) and imaging (MRI for early sacroiliitis) guides therapeutic adjustments, while comorbidities (uveitis, osteoporosis) require coordinated care.
219090392|NCT07093827|PROCEDURE|anterior cervical discectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
219090393|NCT07093827|PROCEDURE|anterior cervical corpectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
219216830|NCT05637177|BEHAVIORAL|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
219216831|NCT05637177|BEHAVIORAL|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
219216832|NCT05637177|BEHAVIORAL|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
219216833|NCT05637177|BEHAVIORAL|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
219216834|NCT04440735|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
219216835|NCT04440735|BIOLOGICAL|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
219216836|NCT06778408|RADIATION|Hybrid Palliative Radiation Therapy|Hybrid Palliative Radiation Therapy will be administered to all patients.
219216837|NCT06767163|DEVICE|iBalance|"Participants will engage in the device test, clinical assessment tests. The whole test will last twelve months, and the outcome will be assessed pre- and post-implementation for comparison and validation.~The intervention results are used to compared with traditional tests and clinical diagnosis, to identify whether the sensor provides a higher accuracy in predicting fall risk, and to explore the feasibility of the sensor in clinical scenarios."
219216838|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
219216839|NCT06841588|OTHER|Mulligan's Mobilization with Movement and Dry Needling|"the intervention group 1 was treated using Mulligan Mobilization with Movements and Dry Needling (DN\&MWM) for soft tissue trigger points, (N=15).~The treatment duration was 6 sessions, 3 sessions per week ( day after day)."
219216840|NCT06841588|OTHER|Dry Needling (DN)|The intervention group 2 was treated using Dry Needling (DN) for soft tissue trigger points, (N=15). The treatment duration was 6 sessions, 3 sessions per week ( day after day).
219216841|NCT06838455|OTHER|Spinopelvic mobility exercise|Participants will complete a 15-20 min session of therapeutic exercises performed by patients with assistance of a pre-recorded video. The exercise regimen has been developed by the investigators of this study to incorporate exercises to increase a patient's spinopelvic mobility. Study staff that has been properly trained will be present to guide the patient through the exercise regimen and ensure the exercises are being performed accurately.
219216842|NCT06392958|OTHER|Traditional Chinese Medicine exercises - Baduanjin|According to the four steps of the cross-theoretical model, the behavior stage (pre-intention stage, intention stage, preparation stage, action stage and maintenance stage) and the family empowerment (clarify the problem, express the emotion, formulate the plan, implement the plan, and evaluate the effect). Combined with the characteristics of elderly patients after PCI, the cardiac rehabilitation management plan was designed focusing on the timing of cardiac rehabilitation, the way of health guidance, safety and compliance management.
219216843|NCT06618755|OTHER|Experimental group : PSH (usual care) with motivational interviewing|The experimental group will begin follow-up after the 1st inclusion visit, during hospitalisation for withdrawal. The first motivational interview will take place 1 to 4 days before discharge from full hospitalisation. The following 10 motivational interviews will be held 2 weeks apart and will follow a framework based on the following objectives: to create a relationship of trust and an effective and lasting therapeutic alliance from the first interview; to create personalised objectives for the user, in line with their addictive pathology; to support the user as they modify, 'fail' and 'succeed' in achieving these objectives; to encourage the emergence and maintenance of the user's desire to change.
219216844|NCT06761079|PROCEDURE|Thoracolumbar interfascial plane block|Ultrasound-guild bilateral Thoracolumbar interfascial plane block with a total 40 ml, 0.25% bupivacaine by anesthesiologist
219216845|NCT06761079|PROCEDURE|Local anesthetic infiltration|0.25%bupivacaine infiltration at surgical wound site by orthopedic surgeon
219216846|NCT06752798|DRUG|Trilaciclib + Cisplatin|Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
219216847|NCT02868970|BIOLOGICAL|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
219216848|NCT02868970|BIOLOGICAL|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
219216849|NCT02868970|BIOLOGICAL|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
219216850|NCT02868970|BIOLOGICAL|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
219216851|NCT02868970|BIOLOGICAL|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
219216852|NCT02868970|BIOLOGICAL|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
219090394|NCT07093827|DRUG|Conservative management of lumbar spinal stenosis|Conservative management of lumbar spinal stenosis (LSS) focuses on symptom alleviation and functional improvement through a multimodal approach. First-line interventions include NSAIDs or acetaminophen for neurogenic claudication pain, with consideration of epidural steroid injections for refractory radicular symptoms. Supervised physical therapy emphasizes flexion-based exercises, core stabilization, and aquatic therapy to reduce mechanical stress on neural structures. Activity modification strategies (e.g., avoiding prolonged standing) combined with assistive devices (walking frames) improve mobility. Adjuvant therapies such as gabapentinoids may be trialed for neuropathic pain, while cardiovascular conditioning (stationary cycling) counters deconditioning. Patient education on weight management and posture optimization is integral, with surgical evaluation reserved for progressive neurological deficits or failure of 3-6 months structured conservative care.
219090395|NCT07093827|PROCEDURE|decompression surgery for caudal plexus disorder|Surgical intervention for caudal plexus disorders is indicated in cases of structural compression, trauma, or refractory symptoms unresponsive to conservative measures. The approach involves meticulous exposure of the lumbosacral plexus through a retroperitoneal or transabdominal route, depending on lesion location. For compressive pathologies, microsurgical decompression with intraoperative neurophysiological monitoring (IONM) is performed to minimize iatrogenic injury. In traumatic avulsions or sharp injuries, direct nerve repair, grafting, or neurolysis may be attempted to restore function. For chronic pain syndromes, dorsal root entry zone (DREZ) ablation or nerve decompression may be considered. Surgical success depends on etiology, timing of intervention, and extent of neural damage, with optimal outcomes achieved in early decompression of compressive lesions or precise repair of focal injuries.
219090396|NCT07094360|OTHER|Land-based exercise program|Land-based exercise program
219090397|NCT07094360|OTHER|Hydrotherapy besides Land-based exercise program|Hydrotherapy besides Land-based exercise program
219090398|NCT07093970|DRUG|MRG006A|Administrated intravenously
219090399|NCT07094009|PROCEDURE|received transverse needling|received transverse needling of high-frequency microneedles
219216853|NCT03906292|DRUG|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
219216854|NCT03906292|DRUG|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
219216855|NCT03906292|DRUG|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
219216856|NCT03906292|DRUG|Asciminib|Asciminib 80 mg QD Monotherapy
219090400|NCT07094009|PROCEDURE|received vertical needling|received vertical needling of high-frequency microneedles
219090401|NCT07094009|PROCEDURE|received mixed needling|received mixed needling of high-frequency microneedles
219216857|NCT06816784|DRUG|Autologous serum therapy|5 ml of blood will be collected and centrifuged at 3000 r.p.m for 10 min to obtain serum,2 ml of the serum will be injected into the gluteus muscle. We will give the patients 9 injections of Autologous Serum intramuscularly once a week
219216858|NCT06816784|DRUG|Oral levocetirizine|Group B will receive oral levocetirizine 5mg 1 tablet HS.
219216859|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
219216860|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
219216861|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
219216862|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
219216863|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
219216864|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
219361739|NCT05091320|DRUG|medical treatment|medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
219361740|NCT05941819|DEVICE|ARC-IM Thoracic System implantation|Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
219090402|NCT07093775|OTHER|Tumor grade (I or II vs. III)|We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
219216865|NCT05637970|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
219216866|NCT05637970|DEVICE|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
219216867|NCT05668819|DEVICE|TH-001|TH001 is a software program intended to treat adults with prediabetes.
219090403|NCT07093736|DEVICE|FW-200|Non-invasive, home-use neurostimulation device delivering transcranial fixed output, alternating current stimulation
219090404|NCT07093632|PROCEDURE|Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.|This study concerns adult subjects with symptomatic lower limb arterial disease who have undergone arterial bypass surgery and are included in the study cohort. Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.
219090405|NCT07092813|DRUG|sulopenem etzadroxil and probenecid|single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet.
219090406|NCT07094802|DRUG|Intrathecal morphine with bupivacaine|Participants will receive 100 mcg intrathecal morphine along with 2.2ml of 0.5% hyperbaric bupivacaine
219216868|NCT06766708|OTHER|self-management lymphedema (SML) education program|The content of the booklet was prepared based on literature review.. In addition to the above intervention methods, the phone number of each patient was taken and the patients were followed up by phone for 12 months. For this purpose, the patient was asked to fill in the compliance chart prepared in order to monitor the patient's compliance and was checked by the researcher every two weeks by phone call. By phone call; compliance with skin care, SLD, compression garments and exercise practices included in the SMLEP were evaluated and recorded. Within the scope of the SMLEP, the patients were asked to do exercises and SLD at least 3 days a week and 2 times a day (morning and evening) for 12 months. It was recommended to wear compression garments, especially during exercises and throughout the day.
219216869|NCT06763835|DIAGNOSTIC_TEST|Blood is drawn to test for specific biomarkers|After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.
219090407|NCT07094802|DRUG|Hyperbaric Bupivicaine|0.5% hyperbaric Bupivacaine 2.2 ml
219216870|NCT06812741|DRUG|Transversus abdominis plane (TAP) block with 0.25 % bupivacaine|The probe was placed in a plane transverse to the lateral abdominal wall in the mid-axillary line immediately cephalad to the iliac crest. The needle was advanced immediately anterior to the probe using the in-plane needle-probe orientation and advanced posteriorly until the needle was observed to penetrate the interface between the internal oblique and transversus abdominis muscles. Thereafter, a local anesthetic (0.2 mL/kg of 0.25 % bupivacaine) was injected incrementally, and the spread was observed within the plane.
219682077|NCT03446976|BIOLOGICAL|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
219090408|NCT07093515|OTHER|No intervention|No intervention
219090409|NCT07094750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219090410|NCT07094750|PROCEDURE|Bone Marrow Collection|Undergo bone marrow assessment
219090411|NCT07094750|OTHER|Electronic Health Record Review|Ancillary studies
219090412|NCT07094750|OTHER|Questionnaire Administration|Ancillary studies
219090413|NCT07094464|DRUG|Maintenance Therapy with Selinexor and Azacitidine|"1. Selinexor: Oral administration in 4 cycles:~   \- Dose Escalation Phase: Cohort 1: Selinexor, 20 mg, twice a week for 2 weeks Cohort 2: Selinexor, 40 mg, twice a week for 2 weeks Cohort 3: Selinexor, 60 mg, twice a week for 2 weeks~   \- Dose Expansion: MTD/RP2D will be determined based on safety.~2. Azacitidine: 35 mg/m² for 5 days."
219090414|NCT07092748|DRUG|HS387|HS387 tablets will be given orally
219090415|NCT07093853|OTHER|Four Locator Attachments, Four Bar Attachment System|"This study retrospectively evaluated two types of implant-retained mandibular overdenture attachment systems placed in edentulous patients over a 10-year period. All patients received four dental implants placed in the interforaminal region (lateral incisor and first premolar areas).~In the Locator group, each implant was restored with an individual Locator attachment, allowing for independent retention and easier hygiene access.~In the Bar group, the four implants were splinted together with a rigid metal bar, and the overdenture was attached using clips that engaged the bar, offering splinted support and enhanced load distribution.~Both interventions were designed to support mandibular overdentures and were compared in terms of their long-term effects on posterior mandibular ridge resorption, marginal bone loss around implants, and anterior maxillary ridge resorption."
219090416|NCT07089836|DEVICE|ALPCO Syphilis-T|Detection of antibodies to Treponema pallidum in human serum and plasma
219090417|NCT07089836|DEVICE|ALPCO Syphilis-NT CLIA Kits|Detection of antibodies to lipoidal antigens in human serum and plasma
219090418|NCT07093723|DIAGNOSTIC_TEST|S100B Protein|Serum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
219090419|NCT07093723|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes ratio|Neutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.
219090420|NCT07092657|OTHER|Nursing Education Intervention|Four standardized sessions. With a duration of 40 to 60 minutes each session, once a week for a period of one month and a follow-up one month after the end of the intervention. Interventions are carried out at different times depending on the availability of the nursing professionals.
219090421|NCT07094763|DRUG|TNK plus standard medical treatment|Patients in the TNK treatment group will receive TNK intravenous thrombolysis and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg.
219090422|NCT07094763|DRUG|standard medical management|standard medical management
219216871|NCT06812741|DRUG|Ilioinguinal/iliohypogastric Nerve Block with 0.25 % bupivacaine|The ultrasound probe was placed immediately medial and slightly cephalad to the upper aspect of the anterior superior iliac spine to obtain a short-axis view of the nerves situated between the two abdominal muscles (internal oblique and transversus abdominis), A 22 G needle tip \~1 cm caudal to the probe surface was introduced and was advanced until a characteristic 'tenting' of the interface between the two muscles was seen and was then further advanced deep to this interface until a pop was felt and then the injectate (0.2 mL/kg of 0.25 % bupivacaine) was observed spreading between these two layers.
219216872|NCT06837584|OTHER|Questionnaire and Physical Exam|Questionnaire and Physical Exam
219216873|NCT06800859|DRUG|Supplement fluids|To ensure optimal recovery and manage potential complications, patients are advised to supplement fluids by increasing their oral intake or receiving intravenous fluids as necessary. Bed rest is recommended to reduce physical strain and promote healing. Additionally, a blood patch procedure may be performed to alleviate symptoms such as headaches that can occur after certain medical procedures, particularly spinal taps. This involves injecting a small amount of the patient's own blood into the epidural space to seal any leaks of cerebrospinal fluid, thereby providing relief and aiding in recovery. Proper monitoring and follow-up care are essential to ensure the effectiveness of these interventions
219216874|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
219216875|NCT06786559|BEHAVIORAL|Assistive Device and health Education|After discharge they will be assessed and followed by RA nurses through home visit and tele services for 2 months. The nurses will contact the patients periodically over telephone, and follow up their regular self-care activities, adjustment to devices, exercise and adaptive behavior.
219216876|NCT05021562|DRUG|Niraparib|Niraparib capsules
219216877|NCT06814782|OTHER|Action Observation Training|Action Observation Training (AOT) consists of patients observing videos of specific movements, followed by practice of those movements
219216878|NCT06814782|OTHER|Action Observation and Motor Imagery|Action Observation and Motor Imagery (AOMI) consists of patients observing videos of specific movements, followed by mental rehearsal of those movements
219216879|NCT06814782|OTHER|Exercise|After watching a landscape video, patients will have to perform specific postural and balance exercises
219216880|NCT05080504|DEVICE|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
219216881|NCT06811831|DRUG|Macitentan 10 mg tablet, once daily.|After the patient signed an informed consent form, Macitentan was given as an oral medication (10 mg once daily) for a period of 4 weeks
219216882|NCT06752655|OTHER|Curcumin with photodynamic thearpy|root canals will irrigated with final irrigation procedure: curcumin+photodynamic therapy. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
219216883|NCT06752655|OTHER|Control group|root canals will irrigated with routine root canal final irrigation with NaOCl and EDTA. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
219216884|NCT06765187|BIOLOGICAL|RIV3|intramuscular injection
219216885|NCT06763679|OTHER|mobilization|"Acromioclavicular joint mobilization:~* The patient is placed in the supine position and the upper limb is placed in a physiological position with the patient's arm clinging to the body and the hand on the abdomen, which causes the capsule to stretch less and the technique to be less painful.~* The therapist placed the tips of his both thumbs on the anterior surface of the clavicle adjacent to the ACJ and spread his other fingers out for stability and his forearm was situated in line with the posterior movement at the ACJ.~* ACJ mobilization was performed in up to 30-minute individual sessions by a single trained therapist.~* The treatment techniques were anterior to posterior passive accessory glides of the distal end of the clavicle categorized from Grade III~* Grade III is used at a large amplitude from the middle of the joint ROM to the start of the constraint. Grade III will apply for stimulating a stretching to relieve joint stiffness in a shorter tissue"
219216886|NCT06763679|OTHER|traditional physical therapy|"Spencer technique:~* The patient was resting on their side, with the affected shoulder raised.~* In 7 separate movements, the therapist used the proximal hand to stabilize the shoulder girdle, while the distal hand applied force to the restrictive barrier of the shoulder.~* Shoulder extension, circumduction with compression, shoulder flexion, circumduction with distraction, abduction, adduction with internal rotation, and glenohumeral pump were the exercises performed.~* The patients were advised to employ their muscle energy technique against the small resistance provided by the therapist for 3-5 seconds throughout each movement.~* Over the course 5 days a week, the exercise was repeated 3-5 times per session, with rest breaks."
219216887|NCT06831370|DRUG|Brentuximab Vedotin|Brentuximab Vedotin IV infusion
219216888|NCT06831370|DRUG|Doxorubicin|Doxorubicin IV infusion
219216889|NCT06831370|DRUG|Vinblastine|Vinblastine IV infusion
219216890|NCT06831370|DRUG|Dacarbazine|Dacarbazine IV infusion
219216891|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
219216892|NCT06749171|PROCEDURE|coronary artery bypass grafting|ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)
219090423|NCT07094438|PROCEDURE|Deep Brain Stimulation, DBS|Deep brain stimulation (DBS) is performed after preoperative MRI and CT images are fused in a planning system to determine the target and trajectory. Under general anesthesia, electrodes are precisely implanted into the fornix or nucleus basalis of Meynert using a stereotactic frame or neurosurgical robot. The electrodes are inserted through a burr hole in the patient's skull and connected to a pulse generator placed subcutaneously in the chest. Optimal stimulation parameters for Alzheimer's disease are not yet established. For fornix targets, settings are typically 3-3.5 V, \~130 Hz, 90 μs; for nucleus basalis targets, 2-4.5 V, 10-20 Hz, 90-150 μs, adjusted according to anatomical features and intraoperative responses.
219090424|NCT07094438|PROCEDURE|Deep cervical lymphatic-venous anastomosis, LVA|Cervical deep lymphaticovenous anastomosis (LVA) microsurgically connects deep cervical lymphatic vessels to adjacent veins, promoting drainage of brain-derived amyloid-β and tau into the venous system and potentially alleviating Alzheimer's disease symptoms. The minimally invasive neck procedure involves small incisions and high-magnification suturing of lymphatics and veins with ultra-fine (11-0 or 12-0) sutures, creating multiple anastomoses to enhance brain lymphatic outflow.
219216893|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
219216894|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
219216895|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
219216896|NCT06696352|BEHAVIORAL|Partners4Pain|This is a group program that will teach participants about different things they can do to manage their pain. They will watch educational videos and do workbook activities. They will learn and practice different exercises and mind-body strategies for pain including back and neck exercises (like strengthening and stretching), mind-body exercises (like meditation, relaxed breathing, guided imagery, and muscle relaxation), problem solving, and how to communicate with others about your pain. They will also have an opportunity to take part in discussions with other group members. The program will be delivered via weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
219216897|NCT06696352|BEHAVIORAL|Keys to Wellbeing|This is a group program that will teach participants about different things they can do to improve their health and wellbeing. Participants will watch educational videos and do workbook activities. They will learn different back and neck exercises (like strengthening and stretching) and be introduced to different health-related topics including information and tips about health, pain and wellbeing; keeping active and well; the importance of rest and relaxation; and working with meaning and purpose in your life. They will also have an opportunity to take part in discussions with other group members. The program will be delivered in weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
219216898|NCT06827600|BEHAVIORAL|Structured breastfeeding education and follow-up|"Breastfeeding education was provided face-to-face to mothers assigned to the experimental group. The authors developed a breastfeeding education program and prepared a booklet. This booklets were distributed to experimental group.Follow-up were carried out on the 3rd day and at the 1st, 3rd, and 6th months postpartum. each follow-up session, the educational program's core components were reinforced through a standardized summary, ensuring continuity and clarity in the information provided.~Training Content~* Significance of Breastfeeding~* Advantages of Breastfeeding~* Overview of Colostrum~* Duration for Breastfeeding~* Breastfeeding Positions~* Strategies for Enhancing Breast Milk Production~* Increasing Breast Milk Supply~* Techniques for Placing the Baby on the Breast~* Implications of Improper Baby Positioning~* Indicators of Sufficient Breast Milk for the Infant~* Expressing Breast Milk~* Recommendations for Storing Expressed Milk"
219216899|NCT06583070|RADIATION|Radiation therapy|Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy
219216900|NCT06583070|DRUG|Targeted and immunotherapy|Targeted and immunotherapy
219216901|NCT06456515|DRUG|Regorafenib and Sintilimab in combination with electroacupuncture|Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
219216902|NCT06319170|DRUG|Olanzapine Extended Release|Powder and vehicle for injectable suspension
219216903|NCT06319170|DRUG|Olanzapine|IntraMuscular Injection
219216904|NCT05613907|OTHER|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI. Patients are assessed and imaged, and undergo elective revascularization procedures if appropriate
219216905|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
219216906|NCT06827093|OTHER|Skill Building Dyadic Intervention|The focal point of skill-building interventions contains some strategies that facilitate problem-solving, goal setting, communicating with care experts, stress management, hands-on training in such skills (lifting and mobility techniques and assistance with activities of daily living), and modification of communication according to the needs of stroke survivors.
219216907|NCT03626571|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
219216908|NCT06077461|BEHAVIORAL|mandala painting|Patients in this group will be subjected to mandala painting.
219216909|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
219090425|NCT07094438|DRUG|Recognized pharmacological treatments for AD.|Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.
219090426|NCT07093866|DRUG|Disitamab Vedotin (RC48)|Disitamab Vedotin 2mg/kg is administered intravenously once every 2 weeks (1 cycle)
219090427|NCT07093866|DRUG|Abiraterone + prednisone|Abiraterone 1000mg is administered orally once a day，and prednisone 5mg is administered orally twice a day.
219090428|NCT07092709|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
219090429|NCT07092709|DRUG|Placebo|Matched placebo is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
219090430|NCT07092956|BEHAVIORAL|Financial Literacy Education|A structured financial literacy training program delivered by an expert in economics. The training includes topics such as budgeting, saving, opportunity cost, financial planning, and investment tools. It was provided to the experimental group over a single session, and outcomes were assessed three weeks later.
219090431|NCT07093060|DRUG|Oxytocin lower dose (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1 puffs (4IU per puff) of spray on and under the tongue)
219090432|NCT07093060|DRUG|Oxytocin higher dose (48IU)|48IU oxytocin administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on or under the tongue)
219090433|NCT07093060|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
219090434|NCT07093060|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1 ml sprays one and under the tongue. Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and atosiban interventions
219090435|NCT07092982|PROCEDURE|Ultrasound Guided Suprainguinal Fascia Iliaca Block|Ultrasound Guided Suprainguinal Fascia Iliaca Block, 30 ml Bupivacain %0,25
219090436|NCT07092982|PROCEDURE|Ultrasound Guided Adductor Canal Block|Ultrasound Guided Adductor Canal Block, 15ml Bupivacain %0,25
219090437|NCT07092982|PROCEDURE|Ultrasound Guided iPACK Block|Ultrasound Guided iPACK Block, 15ml Bupivacain %0,25
219090438|NCT07093372|DEVICE|Laryngeal Mask Airway|A supraglottic airway device (i-gel) used to deliver oxygen and assist ventilation during electroconvulsive therapy (ECT) in obese patients. The device is inserted after induction of general anesthesia and removed after spontaneous respiration is restored.
219090439|NCT07093372|DEVICE|High-Flow Nasal Cannula|A heated and humidified oxygen delivery system that provides high flow oxygen through nasal prongs. In this study, it is used throughout the ECT procedure to maintain oxygenation in obese patients without the need for invasive airway insertion.
219090440|NCT07092839|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
219090441|NCT07092930|DIETARY_SUPPLEMENT|BA and SB supplementation|"Assigned Interventions:~* Beta-alanine (BA)~* Sodium bicarbonate (SB)~Description:~• Participants receive beta-alanine and sodium bicarbonate~Intervention list \& supplementation details:~1. Beta-alanine (BA)~   * Form: Gelatin capsules~  * Substance: Pure beta-alanine~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the combined effects of BA and SB"
219216910|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
219216911|NCT05696561|DEVICE|Canaloplasty Device|Canaloplasty
219216912|NCT05812183|DEVICE|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
219361741|NCT04982081|BIOLOGICAL|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
219090442|NCT07092930|DIETARY_SUPPLEMENT|BA and PL2 supplementation|"Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol.~* Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days.~* PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals.~This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB"
219090443|NCT07092930|DIETARY_SUPPLEMENT|PL1 and SB supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Sodium bicarbonate (SB)~Description:~• Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the isolated effects of SB"
219216913|NCT05812183|DRUG|Medical weight loss|The medical weight loss intervention will follow UCLA's RFO standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very low caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins. Some patients may recieve adjuvant drug therapy including Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), Naltrexone-bupropion (Contrave), Liraglutide (Saxenda), Semaglutide (Wegovy), Tirzepatide (Zepbound) or Setmelanotide (Imcivree).
219216914|NCT06586645|BEHAVIORAL|Safety Planning|Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.
219216915|NCT06586645|BEHAVIORAL|Give to Others Module|"The Give to Others Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief phone follow-up."
219216916|NCT06826651|PROCEDURE|laparoscopic appendectomy|By using laparoscopy, after achieving conclusive identification of the mesoappendix
219216917|NCT06826651|PROCEDURE|bipolar diathermy|the mesoappendix coagulated using bipolar diathermy, then cut with scissor.
219216918|NCT06826651|PROCEDURE|clips closure|mesoappendix will be divided between 3 clips, two placed distally and one proximally. The mesoappendix will be cut in between the clips.
219216919|NCT04160455|BIOLOGICAL|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
219216920|NCT05787795|OTHER|biological samples|blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
219216921|NCT06504979|OTHER|Telehealth follow-up of post-intensive care syndrome|Using a telehealth platform for the detection of the emotional, neuropsychological and physical PICS-related sequelae along 12 months in ICU survivors
219216922|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
219216923|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
219216924|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
219216925|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
218984331|NCT04808544|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
218984332|NCT04808544|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
218984333|NCT05049616|DRUG|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
218984334|NCT05049616|DRUG|NIFEdipine ER|Extended release nifedipine
218984335|NCT06095804|DEVICE|Percutaneous Ultrasound Jejunostomy|Placement of a jejunostomy tube using the PUMA-J System
218984336|NCT01737320|DRUG|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
218984337|NCT01737320|DRUG|accepted prolonged antibiotic treatment|
218984338|NCT04988139|OTHER|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
218984339|NCT02489162|DEVICE|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
218984340|NCT02489162|DEVICE|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
218984341|NCT03144947|BIOLOGICAL|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
218984342|NCT03144947|BIOLOGICAL|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
218984343|NCT03144947|BIOLOGICAL|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
218984344|NCT03144947|DRUG|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
218984345|NCT03055156|DEVICE|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
218984346|NCT03055156|DEVICE|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
218984347|NCT02765269|DEVICE|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
219216926|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
219216927|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
219216928|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
219216929|NCT06757309|BEHAVIORAL|Mediterranean Diet|Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes
219216930|NCT06747546|PROCEDURE|"goal-directed treatment strategy based on oxygen supply and consumption balance"|"The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3. A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing oxygen consumption (VO2) after CPB is compensated by increasing oxygen delivery (DO2) to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB."
219216931|NCT06747546|PROCEDURE|Conventional Treatment group|Ventilation support is adjusted to maintain arterial oxygen partial pressure and oxygen saturation. Appropriate fluid infusion to stabilize central venous pressure and ensure preload; Combined use of vasoactive drugs to maintain heart rate and blood pressure; Appropriate diuresis can improve urine output and reduce cardiac afterload. Blood transfusion is used to improve coagulation function and maintain appropriate hematocrit.
219216932|NCT06007053|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
219216933|NCT06007053|BEHAVIORAL|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
219216934|NCT06828081|OTHER|Range of Motion Exercises|Will get standard shoulder muscle exercises, including rigid and stretchy ones with bands that offer resistance.
219216935|NCT06828081|OTHER|Strengthening exercises with theraband|They will go through the GRASP method, which involves special workouts just for them, teaching them about their health and ways to deal with pain.
219216936|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
219216937|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
219216938|NCT06508450|BEHAVIORAL|Just Do You|Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
219090444|NCT07092930|DIETARY_SUPPLEMENT|PL1 and PL2 supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Placebo matched to SB (PL2)~Description:~• Participants receive two matched placebos.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Placebo matched to SB (PL2)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and timing to SB~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This serves as the control group for comparison with all active intervention arms."
219090445|NCT07093385|DRUG|Faricimab Injection|Faricimab (6 mg/0.05 mL) for three months (loading dose) in a sterile environment,
219216939|NCT06508450|BEHAVIORAL|Component A|Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
219216940|NCT06508450|BEHAVIORAL|Component B|Content addresses identity-based motivations for on-going engagement with services and hope for the future.
219216941|NCT06508450|BEHAVIORAL|Component C|Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
219216942|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
219216943|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
219216944|NCT06727448|OTHER|SRQ questionnaire|SRQ questionnaire administered at inclusion visit and 14 days after inclusion
219216945|NCT04257994|DIAGNOSTIC_TEST|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
219216946|NCT06828575|OTHER|predictions|predictions of learning language models
219216947|NCT06140290|DRUG|Etrasimod Immediate Release (IR)|An immediate release tablet
219216948|NCT06745869|BEHAVIORAL|Diaphragmatic breathing exercise training|"At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise."
219216949|NCT06745869|BEHAVIORAL|Aerobic exercise training|The intensity of the aerobic exercise program will be calculated for each participant using the Karvonen formula. Accordingly, each participant will be given a brisk walking program on a suitable surface, which will be created specifically for the individual to reach the target heart rate range within the scope of the aerobic exercise program; they will apply a 45-minute session, 3 days a week, for 8 weeks.
219216950|NCT04243226|DEVICE|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
219216951|NCT06744010|PROCEDURE|Sub sartorial canal block and popliteal block in ankle surgeries|"All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
219361742|NCT02945956|DRUG|Entecavir|The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
219361743|NCT02945956|DRUG|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
219361744|NCT05049603|DRUG|Atorvastatin 20mg|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
219361745|NCT05049603|OTHER|Placebo|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
219361746|NCT02710409|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
218984348|NCT06395545|DEVICE|Electronic injector|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
218984349|NCT06273462|DRUG|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
218984350|NCT06273462|OTHER|placebo|visually identical placebo capsule
218984351|NCT01613300|DRUG|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
218984352|NCT03609879|DEVICE|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
218984353|NCT03609879|DEVICE|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
218984354|NCT03609879|DEVICE|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
218984355|NCT03609879|DEVICE|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
218984356|NCT03609879|DEVICE|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
218984357|NCT04812899|BEHAVIORAL|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
218984358|NCT03847246|DRUG|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
218984359|NCT03847246|DRUG|Entecavir tablets,1.0 mg|oral,once,under fasting condition
219361747|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
219090446|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
218984360|NCT04036903|RADIATION|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
219090447|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
219090448|NCT07094516|OTHER|Placebo|Solution for infusion
219090449|NCT07094841|DEVICE|3D PRINTED herbst appliance|participants will receive treatment with herbst appliance for 4 to 5 months
219090450|NCT07094841|DEVICE|3d printed mara|participants will receive treatment with mara appliance for 4 to 5 months
219090451|NCT07093242|BEHAVIORAL|Personalized Nutritional Follow-Up|Participants in the experimental arm will receive a individual nutritional follow-up based on their epigenetic hair analysis results. This includes dietary guidance, recommendations tailored to genetic markers, and periodic consultations with a nutritionist over 4 weeks and continuous availability to clarify doubts via email . The aim is to evaluate changes in genetic expression or health biomarkers after the intervention period.
219090452|NCT07092852|OTHER|Cheek swab for PGx testing|Pharmacogenetic test kits will be provided to each CPU residence. An order will be issued to obtain samples for the study - a cheek swab - to be collected by residence direct care providers or nursing staff, trained in the procedure for obtaining the sample, and preparing and submitting it for transport. Failures to collect and submit valid samples, the number of samples submitted that cannot be processed, and the reasons for failure, will be recorded. If a submitted sample cannot be processed, another sample can be obtained and submitted.
219090453|NCT07092852|OTHER|Medication safety review|A medication reconciliation will be performed by a GalenusRx pharmacist on all included residents. Medication data for enrolled participants will be collected by the GalenusRx pharmacist from the unique pharmacy provider and/or the medication records from the facility and a medication reconciliation will be conducted with the nurse of the residents' facility. GalenusRx pharmacists will apply a CDSS to patients' medication regimens, screening for drug interactions, assess medication related risks, and consider pharmacogenomic type and phenoconversion results in recommending appropriate drug selection and dosage to prescribing clinicians.
218984361|NCT00528177|DRUG|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
218984362|NCT05845736|DRUG|Antihypertensive Agents|number of hypertensive drugs
218984363|NCT01512342|BEHAVIORAL|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
218984364|NCT01512342|BEHAVIORAL|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
218984365|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation A
218984366|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
218984367|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
218984368|NCT05898360|COMBINATION_PRODUCT|Time Restricted Eating|time restricted eating
218984369|NCT05898360|OTHER|normal diet|normal diet
218984370|NCT02234232|BEHAVIORAL|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
218984371|NCT01330030|DRUG|Selegiline|6mg/24 hrs for 8 weeks
218984372|NCT01330030|OTHER|matching placebo|placebo/24hrs for 8 weeks
218984373|NCT00132652|DRUG|Lamivudine|
218984374|NCT00132652|DRUG|Telbivudine|
219090454|NCT07094477|DRUG|CD22/CD19 CAR-T cell immunotherapy|targeted CD22/CD19 CAR-T cell immunotherapy
219090455|NCT07093177|BEHAVIORAL|Telerehabilitation Unit|Telerehabilitation is the use of information and communication technology (ICT) to deliver rehabilitation services remotely in participants' homes or other settings. A telerehab unit consists of a touchscreen tablet, a portable bike, elastic bands, and a pulse oximeter. A mobile Wi-Fi hotspot device will be provided for participants who have limited or no internet connection for the duration of the study. The telerehab unit is designed to work in areas with limited internet connectivity as all multimedia materials are stored locally on the tablet.
219090456|NCT07094854|OTHER|Cention Forte alkasite bioactive restorative material|Cention forte material will be used as a final restoration for pulpotomized second primary molars
219090457|NCT07094854|OTHER|Stainless steel crown|The control group using the gold standard stainless steel crown (SSC) as a final restoration for pulpotomized second primary molars
219090458|NCT07094451|DEVICE|Virtual Reality|Meta Quest 2 virtual reality headset. The VR experience includes an interactive, immersive environment with classical music and wrist-controlled movement to match floating visual cues to a beat. The experience is designed to be soothing and require minimal movement.
219090459|NCT07094451|PROCEDURE|Ultrasound|Ultrasound-guided (US-Guided) procedure
219090460|NCT07093554|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219090461|NCT07093554|DRUG|Ciltacabtagene Autoleucel|Ciltacabtagene Autoleucel will be administered intravenously.
219090462|NCT06924788|BEHAVIORAL|Video-Conferenced Stress Management and Relaxation Training (VSMART)|10 week stress management group discussions
219090463|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
219090464|NCT06941831|OTHER|Digital Dashboard-Supported Sugira Muryango Implementation|Arm investigating technology-supported delivery of Sugira Muryango, specifically, the use of a Digital Dashboard tool developed in partnership with the University of Rwanda. Developed using co-design and user interface/user experience techniques, the Dashboard (a) streamlines collection of data on evidence-based intervention quality and reach; (b) improves visibility and searchability of implementation data by region; (c) facilitates caregiver mental health and social services referrals and follow up, and (d) serves as a training platform with resources to enhance lay worker fidelity (content-specific skills) and competence (cross-cutting skills) in evidence-based intervention delivery.
219090465|NCT06941831|OTHER|Usual Care - Sugira Muryango Implementation|Sugira Muryango intervention is delivered using traditional supervision, data entry, and quality monitoring tools.
219090466|NCT05797103|DEVICE|A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands|Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
219090467|NCT01797679|OTHER|Strength Training|
219216952|NCT06744010|PROCEDURE|femoral block and popliteal block in ankle surgeries|"* All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
219216953|NCT06760793|OTHER|manual static stretching exercises on plantar flexors|A manual static stretching exercises was performed on the plantar flexors in both knee extension and flexion. The stretch was applied while the participant was in a prone position
219216954|NCT06760793|OTHER|deep friction massage on plantar flexors|Deep Friction Massage was applied to both the gastrocnemius muscle and the Achilles tendon. Participants were positioned in a prone posture for both applications
219090468|NCT01797679|OTHER|Aerobic Exercise|
219090469|NCT00791323|DRUG|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
219216955|NCT04042402|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
219216956|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
219090470|NCT00791323|DRUG|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
219090471|NCT00207584|DRUG|Doxycycline treatment|
219090472|NCT02235545|DEVICE|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
219090473|NCT04073563|DEVICE|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
219090474|NCT04073563|DEVICE|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
219090475|NCT06431503|OTHER|Tok-Sen Massage|Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.
219090476|NCT06431503|OTHER|Pressure Massage|Press the wedge: the strength for pressing the wedge is 1500g±50g,
219090477|NCT01546467|BEHAVIORAL|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
219090478|NCT03502863|DEVICE|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
219090479|NCT03502863|OTHER|Manual Refraction|Manual refraction and ETDRS chart
219090480|NCT00914004|DRUG|Desipramine HCl 50 mg Tablets Cord Laboratories|
219090481|NCT00914004|DRUG|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
219090482|NCT05030779|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
219090483|NCT01641263|BEHAVIORAL|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
219216957|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
219361748|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
219090484|NCT01641263|BEHAVIORAL|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
219090485|NCT05438030|DIAGNOSTIC_TEST|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
219090486|NCT05438030|DIAGNOSTIC_TEST|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
219090487|NCT06326710|BEHAVIORAL|mHealth|"Participants receive 4 sessions of face-to-face or online delivered workshop on how to use the mobile app Outdoor Rehab-Fit to support their daily PA level. In addition to the workshop, participants have to go to public parks to practice what they have learnt from the mobile app."
219090488|NCT06326710|BEHAVIORAL|Health Talk|Participants receive 4 sessions of face-to-face or online delivered health talks on the benefits different types of modified exercises for frail older adults (chair yoga, seated eight-section brocades, Otago and seated multi-component exercise). Each talk has an experiential session.
219090489|NCT01142388|BIOLOGICAL|Cixutumumab|Given IV
219090490|NCT01142388|OTHER|Laboratory Biomarker Analysis|Correlative studies
219090491|NCT01142388|DRUG|Paclitaxel|Given IV
219090492|NCT01142388|OTHER|Pharmacological Study|Correlative studies
219090493|NCT06051539|DEVICE|MR-001|MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
219090494|NCT00695786|DRUG|Lenalidomide|Given PO
219216958|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
219216959|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
219216960|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
219216961|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|Parents receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
219216962|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|After the postintervention data collection, parents in the waitlist group receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
219090495|NCT00695786|BIOLOGICAL|Rituximab|Given IV
219090496|NCT06492980|PROCEDURE|triple-branched stent graft|a triple-branched stent graft for aortic arch repairement during surgery
219090497|NCT01471132|DRUG|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
219090498|NCT01471132|DRUG|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
219090499|NCT01960595|PROCEDURE|IV fentanyl PCA|
219090500|NCT01960595|PROCEDURE|local bupivacaine infiltration and post-OP IV fentanyl PCA|
219090501|NCT01960595|PROCEDURE|Nerve Blocks and post-OP IV fentanyl PCA|
219090502|NCT03027414|DRUG|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
219090503|NCT03027414|DEVICE|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
219090504|NCT01364922|DRUG|hydrocodone/acetaminophen extended release|
219090505|NCT01364922|DRUG|Placebo|
219090506|NCT02200263|DIETARY_SUPPLEMENT|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
219090507|NCT02200263|DIETARY_SUPPLEMENT|Placebo|two softgels once-daily with a meal
219090508|NCT00651235|DRUG|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
219090509|NCT00651235|DRUG|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
219090510|NCT03727009|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
219216963|NCT06950424|DIETARY_SUPPLEMENT|black cumin seed oil|500mg of black cumin seed oil standardized for 3% thymoquinone)
219090511|NCT04244396|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
219090512|NCT04133103|PROCEDURE|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
219090513|NCT02775318|PROCEDURE|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
219090514|NCT02775318|DRUG|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
219090515|NCT02775318|PROCEDURE|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
219090516|NCT02775318|PROCEDURE|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
219090517|NCT01787097|DRUG|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
219090518|NCT01787097|DRUG|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
219090519|NCT01787097|DRUG|Formoterol 24ug|Turbuhaler
219090520|NCT01787097|DRUG|BUD total dose 800ug|Turbuhaler
219090521|NCT03810534|BEHAVIORAL|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
219090522|NCT02629835|OTHER|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
219090523|NCT02629835|OTHER|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
219090524|NCT05286944|OTHER|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
219216964|NCT06951256|DRUG|Scalp block with bupivacaine alone|In Group SB: (LA) was done by 20ml of Bupivacaine 0.25%. maximal dose of Bupivacaine did not exceed (2.5 mg/kg) Scalp nerve block will be done by anesthesiologist who is blind to the drug being injected and under complete septic condition where local infiltration of local anesthetic (LA) will be done guided by bony superficial landmarks to block the supraorbital, supratrochlear, auriculotemporal, occipital, and post auricular branches of the greater auricular nerves
219216965|NCT06951256|DRUG|Scalp block by adding dexmedetomidine as an adjuvant to bupivacaine|local infiltration of total volume 20ml which include (Bupivacaine 0.25%. + Dexmedetomidine 1mcg/kg) was done Dexmedetomidine preparation was done by 2ml (200 mcg) diluted by 18 ml normal saline in 20 ml syringe as 1ml was contain 10 mcg and injected at same points as above
219216966|NCT06951087|DRUG|Dexamethasone sodium phosphate|In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.
219216967|NCT06950359|DEVICE|Gelatin Sponge Dressing (Cutanplast®)|Absorbable gelatin-based hemostatic sponge used for all study groups as a wound contact dressing.
219216968|NCT06950359|DEVICE|Cyanoacrylate Tissue Adhesive (PeriAcryl®)|High-viscosity N-Butyl Cyanoacrylate/2-Octyl Cyanoacrylate adhesive applied as a topical barrier to the palatal wound site in the Cyanoacrylate Group.
219216969|NCT06950359|DEVICE|Polyglycolic Acid Sheet (Neoveil®)|Bioresorbable PGA sheet placed over the gelatin sponge in the Polyglycolic Acid Group to enhance wound protection and healing.
219216970|NCT06953544|BEHAVIORAL|Father-Sensitive Education|he father-sensitive education program preserves the basic structure of the Childbirth Preparation Education program, but has been enriched with original content that supports the active emotional and functional participation of fathers-to-be in the birth process.
219090525|NCT02448667|DIETARY_SUPPLEMENT|FAXE Kondi|Sucrose and glucose containing softdrink
219216971|NCT06953544|BEHAVIORAL|Standardized birth education|The control group received a total of 12 hours of standard childbirth preparation training, consisting of four three-hour sessions.
219216972|NCT06954012|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|ice every 2 waking hours during the first 24 to 48 hours,a brace early in rehabilitation , strain counters strain technique
219216973|NCT06954012|OTHER|Exercise|RICE, anterior-to-posterior talar mobilization, orthoses
219216974|NCT06951776|BEHAVIORAL|Morning administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
219216975|NCT06951776|BEHAVIORAL|Evening administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
219216976|NCT06954558|DRUG|GK01 Injection|Autologous tumor-reactive T cells injection
219090526|NCT02448667|DIETARY_SUPPLEMENT|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
219090527|NCT05009524|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
219090528|NCT05009524|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
219090529|NCT00553501|BIOLOGICAL|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV
219090530|NCT00553501|BIOLOGICAL|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV
219090531|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
219090532|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
219216977|NCT06952322|OTHER|Questionnaire and Physical Exam|Questionnaire results of groups will be compared.
219216978|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
219216979|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
219090533|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
219090534|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
219090535|NCT02293395|DRUG|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
219090536|NCT02293395|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
219090537|NCT02293395|DRUG|Clopidogrel|Clopidogrel 75 mg once daily orally.
219090538|NCT02293395|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily orally.
219090539|NCT03305874|OTHER|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
219090540|NCT01677221|DEVICE|Acleara Acne Treatment System|
219090541|NCT02816034|BEHAVIORAL|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
219090542|NCT02816034|BEHAVIORAL|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
219090543|NCT02300012|PROCEDURE|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
219090544|NCT01478711|OTHER|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
219090545|NCT03391765|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
219090546|NCT03391765|DRUG|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
219090547|NCT02212444|DEVICE|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
219090548|NCT02212444|DEVICE|Off -the-shelf triplanar orthoses|
219216980|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
219216981|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
219090549|NCT01056588|BEHAVIORAL|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
219090550|NCT01056588|BEHAVIORAL|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
219090551|NCT00944658|DRUG|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
219090552|NCT00944658|DRUG|Placebo (sugar pill)|twice a day
219090553|NCT01272960|DEVICE|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
219090554|NCT01272960|DEVICE|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
219216982|NCT05017532|BEHAVIORAL|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
219216983|NCT04297605|DRUG|Pembrolizumab|Pembrolizumab 200 mg
219216984|NCT04297605|OTHER|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
219216985|NCT04297605|OTHER|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
219216986|NCT04091295|DRUG|DNG64|Intravenous infusions of DNG64 for treatment of advanced pancreatic cancer, sarcoma and carcinoma of breast
219090555|NCT05297474|OTHER|MRI|No intervention was performed in this study.
219216987|NCT06441149|OTHER|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
219090556|NCT01837329|DRUG|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
219090557|NCT04698317|PROCEDURE|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
219090558|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
219090559|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
219090560|NCT03312153|DRUG|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
219090561|NCT03312153|DRUG|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
219090562|NCT00963911|OTHER|Geriatric screening tests|"The G-8 consists of eight items: patient age (\>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment."
219216988|NCT06441149|OTHER|Standard informed consent|Standard informed consent
219216989|NCT06084416|DRUG|Sovilnesib|Sovilnesib tablets will be given orally.
219216990|NCT05536076|OTHER|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
219216991|NCT05971342|DRUG|Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)|The experimental group
219216992|NCT05971342|DRUG|Gelatin sponge only （Kuaikang®)|The positive control group
219216993|NCT03220074|DRUG|Oral Tablet|study drug given and monitored for efficacy and tolerability
219216994|NCT05276297|DRUG|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
219216995|NCT05276297|BIOLOGICAL|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~* 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~* 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~* 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
219216996|NCT05276297|DRUG|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
219216997|NCT02475343|DEVICE|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
219216998|NCT02475343|DEVICE|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
219216999|NCT02475343|DEVICE|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
219217000|NCT02475343|DEVICE|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
219090563|NCT00963911|OTHER|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
219090564|NCT05616364|DRUG|Dexmedetomidine injection|Dexmedetomidine intravenous
219090565|NCT05616364|DRUG|Tramadol|Tramadol intravenous
219090566|NCT01038258|PROCEDURE|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
219217001|NCT02475343|DEVICE|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
219217002|NCT02475343|DEVICE|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
219217003|NCT06950736|DIETARY_SUPPLEMENT|NR|600 mg/d of oral NR for two months
219217004|NCT06950736|DIETARY_SUPPLEMENT|Vit E|200 mg/d of oral Vitamin E for two months
219217005|NCT04966858|OTHER|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
219217006|NCT04966858|OTHER|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
219217007|NCT06782165|PROCEDURE|Arthroscopy & saline irrigation alone|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly
219217008|NCT06782165|PROCEDURE|Discectomy|Discectomy refers to open temporomandibular joint surgery where the joint disc is completely removed without being replaced.
219217009|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
219217010|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
219217011|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
219090567|NCT00297115|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
219217012|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
219217013|NCT06782191|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
219217014|NCT06782191|PROCEDURE|Operative arthroscopy|Operative arthroscopy refers to an arthroscopic procedure where the temporomandibular joint is accessed via two ports of entry. The joint is rinsed with saline solution and the anterior disc attachment is released with cold ablation where after the posterior attachment is sclerosed with the coagulation mode on the coblator.
219217015|NCT02036970|DRUG|Bardoxolone methyl|
219217016|NCT02036970|DRUG|Placebo|
219217017|NCT02266654|OTHER|IV fluids|Normal Saline 0.9%
219217018|NCT02266654|OTHER|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
219090568|NCT00297115|DRUG|Placebo|once daily
219090569|NCT05381298|PROCEDURE|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
219090570|NCT05381298|PROCEDURE|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
219090571|NCT02352597|DRUG|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
219090572|NCT02352597|DRUG|estradiol valerate|2mg from cycle day 7 to day 11
219217019|NCT02298842|DEVICE|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
219217020|NCT02298842|DEVICE|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
219217021|NCT06699628|DRUG|IRL757|IRL757 capsules
219217022|NCT02386098|DRUG|BMS-955176|HIV Maturation Inhibitor
219217023|NCT02386098|DRUG|Atazanavir (ATV)|Atazanavir
219217024|NCT02386098|DRUG|Ritonavir (RTV)|Ritonavir
219217025|NCT02386098|DRUG|Dolutegravir (DTG)|Dolutegravir
219217026|NCT02386098|DRUG|Tenofovir (TDF)|Tenofovir
219090573|NCT02352597|DRUG|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
219090574|NCT00336739|DRUG|cinacalcet|
219090575|NCT04978974|BEHAVIORAL|Stress Management Program|Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
219090576|NCT02832622|DEVICE|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
219090577|NCT02832622|DEVICE|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
219090578|NCT02816190|PROCEDURE|prone position|
219090579|NCT05011643|OTHER|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
219090580|NCT02243280|DRUG|ABT-493|Tablet
219217027|NCT03287232|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
219217028|NCT03287232|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
219217029|NCT05955040|DRUG|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
219217030|NCT05955040|DRUG|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
219217031|NCT04826159|DRUG|IMB-1018972|Modified release tablet for oral administration
219090581|NCT02243280|DRUG|ABT-530|Tablet
219090582|NCT01058538|DRUG|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
219090583|NCT05001438|PROCEDURE|Hidro|Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
219090584|NCT05001438|PROCEDURE|MUA|Movilization under anesthesia
219217032|NCT05013216|DRUG|Cohort A: Patients at high risk of developing pancreatic cancer.|"1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
219217033|NCT05013216|DRUG|Cohort B: Patients must have evidence of a pancreatic cystic neoplasm|Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
219217034|NCT04280718|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
219217035|NCT06518551|DRUG|Elotuzumab|Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
219682078|NCT02741648|DEVICE|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
219682079|NCT00054223|PROCEDURE|psychosocial assessment and care|
219682080|NCT03925129|DEVICE|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
219090585|NCT00605514|DRUG|VRC-EBODNA023-00-VP|
219090586|NCT00605514|DRUG|VRC-MARDNA025-00-VP|
219090587|NCT02472652|DRUG|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
219090588|NCT01053260|BEHAVIORAL|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
219090589|NCT01053260|BEHAVIORAL|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
219217036|NCT06518551|DRUG|Iberdomide|A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
219217037|NCT06518551|DRUG|Dexamethasone|Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
219217038|NCT04539704|DEVICE|magnet and sham|In same subject some areas will have magnet and others will have sham
219217039|NCT04682288|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
219217040|NCT05861570|DRUG|normal saline|Ultrasound guided injection using 3ml normal saline
219217041|NCT05861570|DRUG|(Sodium Hyaluronate (Hyruan One , LG)|Ultrasound guided injection using 3ml of Sodium Hyaluronate
219217042|NCT05861570|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
219217043|NCT05861570|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
219217044|NCT06219434|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
219217045|NCT06219434|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
219217046|NCT06219434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219217047|NCT06219434|OTHER|Questionnaire Administration|Ancillary studies
219217048|NCT02394054|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
219217049|NCT02394054|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
219090590|NCT02713711|RADIATION|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
219090591|NCT02713711|PROCEDURE|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
219090592|NCT02713711|PROCEDURE|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
219217050|NCT06523478|PROCEDURE|Intratonsillar immunotherapy (ITIT)|During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.
219217051|NCT06523478|PROCEDURE|Subcutaneous immunotherapy (SCIT)|Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
219217052|NCT02305511|DEVICE|Peripheral venous catheterization|Cannulation using standard method
219217053|NCT02305511|DEVICE|Jamshidi|intraosseous access using the Jamshidi device
219217054|NCT02305511|DEVICE|BIG|intraosseous access using the BIG device
219217055|NCT02305511|DEVICE|Cook|intraosseous access using the Cook device
219217056|NCT02305511|DEVICE|EZIO|intraosseous access using the EZIO device
219217057|NCT05047458|DRUG|ALXN2050|Powder-in-capsule (PIC).
219217058|NCT05047458|DRUG|Placebo|PIC.
219217059|NCT01262963|DRUG|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
219217060|NCT03496558|OTHER|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
219217061|NCT00357916|DRUG|PEP005 Topical Gel (0.01% concentration)|
219217062|NCT01961466|OTHER|psychological and social self-administered questionnaires|
219217063|NCT02053298|DRUG|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
219217064|NCT03223688|BEHAVIORAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
219217065|NCT03223688|BEHAVIORAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
219217066|NCT03223688|BEHAVIORAL|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
219217067|NCT06387810|DRUG|irinotecan liposome II combined with 5-FU/LV and oxaliplatin|"irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs."
219090593|NCT00001790|DRUG|FK463|
219090594|NCT00998400|BEHAVIORAL|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
219217068|NCT03965949|DRUG|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
219217069|NCT03965949|DRUG|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
219217070|NCT00235937|DRUG|Anastrozole and goserelin|
219217071|NCT05333367|OTHER|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
219217072|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet non-colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate before colonization
219217073|NCT03752684|DIETARY_SUPPLEMENT|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
219217074|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate after colonization
219217075|NCT01596231|DIETARY_SUPPLEMENT|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
219217076|NCT01596231|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
219217077|NCT04720794|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
219217078|NCT03790215|DRUG|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
219217079|NCT03352713|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
219217080|NCT01214031|DEVICE|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
219217081|NCT04300244|BIOLOGICAL|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
219217082|NCT04300244|BIOLOGICAL|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
219217083|NCT04300244|BIOLOGICAL|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
219217084|NCT01812759|DRUG|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
219217085|NCT01812759|DRUG|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
219217086|NCT01812759|OTHER|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
219217087|NCT03260452|PROCEDURE|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
219217088|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
219217089|NCT02819999|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
219217090|NCT02819999|DRUG|Cisplatin|
219217091|NCT02819999|DRUG|Etoposide|
219217092|NCT03301870|DRUG|ATx201 Gel 2%|2% active gel
219217093|NCT03301870|DRUG|ATx201 Gel 4%|4% active gel
219090595|NCT03460457|DRUG|TQB2450|Pharmacokinetics/Dynamics Study
219090596|NCT03766841|BEHAVIORAL|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
219090597|NCT03185832|DEVICE|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
219090598|NCT03185832|DEVICE|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
219090599|NCT03185832|DEVICE|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
219090600|NCT03185832|OTHER|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
219090601|NCT00004935|DRUG|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
219090602|NCT00004935|DRUG|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
219090603|NCT02127619|DEVICE|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
219217094|NCT03301870|DRUG|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
219217095|NCT03301870|DRUG|Negative Control|Water for Injection, USP
219217096|NCT03301870|DRUG|ATx201 Placebo|matching placebo gel
219682081|NCT03925129|DEVICE|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
219090604|NCT04563325|DRUG|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
219090605|NCT04563325|DRUG|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
219090606|NCT05502419|PROCEDURE|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
219090607|NCT05502419|PROCEDURE|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
219361749|NCT05275569|PROCEDURE|True acupuncture + standard antiemetic treatment|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy."
219090608|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
219090609|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
219090610|NCT05233202|DRUG|Levosimendan|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
219090611|NCT05233202|DRUG|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
219090612|NCT06070584|PROCEDURE|aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
219090613|NCT04234724|OTHER|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
219090614|NCT02352441|OTHER|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
219090615|NCT00003084|DRUG|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
219090616|NCT00003084|DRUG|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
219090617|NCT00003084|DRUG|Etoposide|Oral etoposide twice daily on days 1-14.
219090618|NCT00003084|DRUG|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
219090619|NCT00003084|DRUG|Paclitaxel|IV over 1 hour on day 2.
219090620|NCT00003084|DRUG|Vinblastine|IV on days 8, 22, and 36.
219090621|NCT01750762|DRUG|Lenalidomide|
219090622|NCT02421562|PROCEDURE|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
219090623|NCT02955030|BIOLOGICAL|NSV0001|sublingual
219090624|NCT02955030|BIOLOGICAL|"Influenza HA vaccine Biken HA"|subcutaneous
219090625|NCT02955030|BIOLOGICAL|Placebo|sublingual
219682082|NCT04391179|DRUG|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
219682083|NCT04391179|DRUG|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
219682084|NCT01562652|DEVICE|AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)|
219090626|NCT04995562|DRUG|129Xe|Inhaled contrast for MRI
219090627|NCT00087360|OTHER|counseling intervention|
219090628|NCT00087360|OTHER|physiologic testing|
219090629|NCT00087360|PROCEDURE|evaluation of cancer risk factors|
219090630|NCT01900600|OTHER|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
219090631|NCT01900600|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
219090632|NCT01329354|BIOLOGICAL|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
219090633|NCT01807156|DRUG|Tivozanib|Oral medication given daily. No placebo.
219090634|NCT05753865|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
219090635|NCT05753865|DRUG|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m\^2
219090636|NCT05412888|DIETARY_SUPPLEMENT|CoQ10 supplementation|Young men training endurance running will be supplemented with CoQ10
219090637|NCT05412888|PROCEDURE|Ischemic preconditioning training|Young men training endurance running will undergo IPC training
219682085|NCT01146015|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
219682086|NCT03334188|BEHAVIORAL|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
219682087|NCT03334188|BEHAVIORAL|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
219682088|NCT04218279|OTHER|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
219090638|NCT05412888|DIETARY_SUPPLEMENT|IPC training combined with CoQ10 supplementation|Young men training endurance running will undergo IPC training combined with CoQ10 supplementation
219090639|NCT05412888|DIETARY_SUPPLEMENT|Sham IPC combined with placebo|Young men training endurance running will undergo sham IPC training combined with placebo supplementation
219090640|NCT01480947|DRUG|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
219090641|NCT02483286|BEHAVIORAL|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
219090642|NCT02483286|BEHAVIORAL|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
219090643|NCT02483286|BEHAVIORAL|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
219090644|NCT04377230|PROCEDURE|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
219090645|NCT04377230|PROCEDURE|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
219090646|NCT03276637|GENETIC|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
219090647|NCT03464279|BEHAVIORAL|Nudge using Behavioral Economic Interventions|
219090648|NCT03464279|BEHAVIORAL|Standard Practices to Reduce Health System Antibiotic Prescription|
219217097|NCT00716170|BIOLOGICAL|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
219217098|NCT01413659|BIOLOGICAL|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
219217099|NCT06179446|BIOLOGICAL|pdmFlu vaccine|Intramuscular injection
219217100|NCT06179446|BIOLOGICAL|Placebo|Intramuscular injection
219217101|NCT06179446|BIOLOGICAL|Licensed influenza vaccine|Intramuscular injection
219217102|NCT03179046|DIAGNOSTIC_TEST|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
219217103|NCT03835559|PROCEDURE|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
219217104|NCT03835559|PROCEDURE|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
219217105|NCT00536120|BIOLOGICAL|BG00002 (natalizumab)|
219217106|NCT00536120|BIOLOGICAL|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
219217107|NCT00536120|BIOLOGICAL|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
219217108|NCT01015872|DEVICE|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
219217109|NCT01038934|PROCEDURE|samples collected by buccal cytobrush|
219217110|NCT02722434|OTHER|Laboratory Biomarker Analysis|Correlative studies
219217111|NCT02722434|OTHER|MC5-A Scrambler Therapy|Undergo Scrambler therapy
219090649|NCT04680325|DIETARY_SUPPLEMENT|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
219090650|NCT04508452|DRUG|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
219090651|NCT06329726|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
219090652|NCT01731743|DEVICE|AT LISA tri 839MP|
219090653|NCT00005993|DRUG|aldesleukin|
219090654|NCT00005993|DRUG|filgrastim|
219090655|NCT00005993|DRUG|recombinant human stem cell factor|
219217112|NCT02722434|OTHER|Questionnaire Administration|Ancillary studies
219217113|NCT02722434|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
219217114|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
219090656|NCT00005993|PROCEDURE|peripheral blood stem cell transplantation|
219090657|NCT02056860|PROCEDURE|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
219090658|NCT02056860|PROCEDURE|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
219090659|NCT02056860|PROCEDURE|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
219090660|NCT02056860|PROCEDURE|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
219090661|NCT02056860|PROCEDURE|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
219090662|NCT00122590|DRUG|nelfinavir|
219090663|NCT00122590|DRUG|lopinavir/r|
219090664|NCT00122590|DRUG|indinavir|
219090665|NCT00122590|DRUG|ritonavir|
219090666|NCT05596084|PROCEDURE|maxillary sinus augmentation and implant placement|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
219090667|NCT05596084|PROCEDURE|Maxillary sinus augmentation with bovine bone graft|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
219090668|NCT05748210|OTHER|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
219090669|NCT05748210|OTHER|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
219090670|NCT03122119|DRUG|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
219090671|NCT00699439|OTHER|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
219090672|NCT04728308|DRUG|Bupivacain|Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
219090673|NCT00970216|DRUG|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
219090674|NCT04361344|BIOLOGICAL|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
219217115|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
219217116|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
219217117|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
219217118|NCT06070961|DIAGNOSTIC_TEST|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
219217119|NCT06070961|DIAGNOSTIC_TEST|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
219682089|NCT03373760|BIOLOGICAL|Durvalumab|Given IV
219682090|NCT03373760|OTHER|Laboratory Biomarker Analysis|Correlative studies
219682091|NCT03373760|BIOLOGICAL|Tremelimumab|Given IV
219217120|NCT06070961|DIAGNOSTIC_TEST|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
219217121|NCT01252420|DRUG|Enoxaparin|1.5mg/kg daily for 2 weeks
219217122|NCT00360269|DRUG|Atomoxetine|25 to 100 mg daily
219217123|NCT00360269|PROCEDURE|Motivational enhancement therapy|Three sessions
219217124|NCT00360269|DRUG|Placebo|25 to 100 mg daily
219217125|NCT02378922|BIOLOGICAL|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
219217126|NCT02378922|OTHER|Laboratory Biomarker Analysis|Correlative studies
219217127|NCT02378922|OTHER|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
219217128|NCT02704052|DRUG|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
219217129|NCT02704052|DRUG|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
219217130|NCT02351791|OTHER|Patch 1|Patch 1:standard adhesive with own feces in sleeve
219217131|NCT02351791|OTHER|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
219217132|NCT02351791|OTHER|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
219090675|NCT05742425|DRUG|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
219090676|NCT02552290|OTHER|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
219090677|NCT02552290|OTHER|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
219090678|NCT02552290|OTHER|No intervention|Wait
219090679|NCT04970199|DEVICE|laser application on acupoints|laser acupuncture
219217133|NCT02351791|OTHER|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
219550225|NCT04681391|DEVICE|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
219217134|NCT02351791|OTHER|Patch 5|Patch 5:standard adhesive with buffer in sleeve
219217135|NCT02351791|OTHER|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
219217136|NCT03450642|OTHER|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
219217137|NCT01726998|OTHER|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
219217138|NCT01726998|OTHER|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
219217139|NCT02720432|OTHER|CIMT|Constraint-induced movement therapy
219217140|NCT02720432|OTHER|HABIT|hand-arm bimanual intensive training
219217141|NCT02720432|OTHER|baby-massage|instructions for baby-massage
219217142|NCT00048932|DRUG|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
219217143|NCT00048932|DRUG|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
219217144|NCT00048932|DRUG|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
219217145|NCT01444690|DRUG|Dimiracetam|Capsules for oral administration twice daily
219217146|NCT01444690|DRUG|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
219090680|NCT01631890|PROCEDURE|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
219090681|NCT01631890|PROCEDURE|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
219090682|NCT05566808|OTHER|Autologous Costal Cartilage Graft|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
219090683|NCT05566808|OTHER|Costal Cartilage Allograft.|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
219090684|NCT03181802|DRUG|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
219090685|NCT03181802|DRUG|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
219217147|NCT02822703|DEVICE|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
219090686|NCT04070625|OTHER|Communication book group|Communication book
219090687|NCT04070625|OTHER|Control group|Simple speech therapy
219090688|NCT01003522|OTHER|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
219090689|NCT01003522|OTHER|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
219090690|NCT01003522|PROCEDURE|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
219090691|NCT01003522|PROCEDURE|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
219090692|NCT01003522|OTHER|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
219090693|NCT01003522|OTHER|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
219550226|NCT05644392|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
219550227|NCT05644392|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
219550228|NCT05244863|OTHER|Test|Measurements
219550229|NCT00835081|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
219090694|NCT01003522|OTHER|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
219217148|NCT02822703|DEVICE|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
219090695|NCT00131339|BEHAVIORAL|Cognitive behavioral therapy|
219090696|NCT00131339|DRUG|D-cycloserine|
219090697|NCT05716230|OTHER|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
219090698|NCT01500330|PROCEDURE|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
219217149|NCT05291403|OTHER|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
219090699|NCT01500330|PROCEDURE|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
219217150|NCT05291403|OTHER|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
219217151|NCT05291403|OTHER|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
219217152|NCT03733574|DRUG|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
219217153|NCT03733574|DRUG|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
219217154|NCT03849937|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
219217155|NCT05615337|BEHAVIORAL|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
219217156|NCT05615337|BEHAVIORAL|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
219217157|NCT00300404|DRUG|daraprim|
219217158|NCT00300404|DRUG|pyrimethamine|
219217159|NCT00300404|DRUG|folinic acid|
219217160|NCT06352905|OTHER|Whole body vibration (WBV)|WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.
219217161|NCT06352905|OTHER|Control|Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
219090700|NCT06789484|OTHER|Probiotic|Given daily from enrollement to 28 days of life
219090701|NCT06789484|DIETARY_SUPPLEMENT|Placebo|Given daily from enrollement to 28 days of life
219090702|NCT06446505|OTHER|Deep Brain Stimulation Decision Aid|An online decision support tool that provides education about deep brain stimulation and the alternatives, and includes value clarification exercise.
219090703|NCT05127148|OTHER|Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.|Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
219090704|NCT01493687|DRUG|CD5024|CD5024 1% Cream, once daily
219090705|NCT01493687|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
219217162|NCT05160779|OTHER|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
219217163|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
219550230|NCT00835081|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
219217164|NCT04926597|DIETARY_SUPPLEMENT|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
219217165|NCT04926597|OTHER|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
219217166|NCT04926597|OTHER|general nutritional information|general information about health food behavior upon hospital discharge
219217167|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
219217168|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
219217169|NCT04284878|GENETIC|PCR-RFLP|PCR-Restriction fragment length polymorphism
219217170|NCT04655833|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
219217171|NCT04999007|OTHER|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
219217172|NCT04989816|DRUG|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
219217173|NCT03437733|DEVICE|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
219090706|NCT05809713|OTHER|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
219090707|NCT05809713|OTHER|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
219090708|NCT05067439|DRUG|Abrocitinib|200 mg once daily (QD)
219090709|NCT05067439|DRUG|Omeprazole|single doses of 10 mg
219090710|NCT05067439|DRUG|Caffeine|single dose of 100 mg
219090711|NCT05067439|DRUG|Efavirenz|single doses of 50 mg
219090712|NCT02282397|DEVICE|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
219090713|NCT04121884|BEHAVIORAL|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
219090714|NCT06373484|BEHAVIORAL|Behavioral Parent Training|Two 15-session multi-component cognitive-behavioral group treatments for children with disruptive behavior and their parents (i.e., one program for children aged 6-8 years and their parents and another for children aged 9-12 years and their parents. The programs have a child and parent group that are implemented concurrently).
219090715|NCT00705133|DRUG|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
219090716|NCT04368650|DRUG|BMP-2|lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.
219090717|NCT04368650|PROCEDURE|PRF|For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
219090718|NCT00453011|DEVICE|posterior chamber intraocular lens|
219090719|NCT00453011|DEVICE|anterior chamber intraocular lens|
219217174|NCT05982522|DRUG|IN10018|orally taken once daily
219217175|NCT05982522|DRUG|Nab-paclitaxel|125 mg/m2 D1, 8 Q3W, Intravenously
219217176|NCT05982522|DRUG|Tislelizumab|200mg Q3W, Intravenously
219217177|NCT04956887|BEHAVIORAL|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
219217178|NCT04956887|OTHER|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
219217179|NCT03407144|BIOLOGICAL|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
219217180|NCT03407144|DRUG|doxorubicin|"25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
219550231|NCT00421304|BIOLOGICAL|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
219090720|NCT03135535|DEVICE|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
219090721|NCT02857439|OTHER|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
219217181|NCT03407144|DRUG|vinblastine|"6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
219217182|NCT03407144|DRUG|dacarbazine|"375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
219217183|NCT03407144|DRUG|cyclophosphamide|500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
219217184|NCT03407144|DRUG|vincristine|"1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
219090722|NCT02364180|DIAGNOSTIC_TEST|Electromyography (EMG)|
219090723|NCT01903421|DRUG|Spinal anesthesia group: bupivacaine 10-15mg|
219090724|NCT01903421|DRUG|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
219090725|NCT01903421|GENETIC|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
219090726|NCT01903421|OTHER|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
219090727|NCT01903421|BEHAVIORAL|Montreal Cognitive Assessment (MOCA) and MMSE|
219090728|NCT02755064|DRUG|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
219090729|NCT02755064|DRUG|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
219090730|NCT02755064|DRUG|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
219090731|NCT02755064|DRUG|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
219090732|NCT02755064|DRUG|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
219090733|NCT02323646|DRUG|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
219090734|NCT02323646|DRUG|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
219090735|NCT05810207|PROCEDURE|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
219090736|NCT02731664|BIOLOGICAL|GLP-1|Intravenous infusion of GLP-1
219090737|NCT02731664|BIOLOGICAL|Intravenous saline|Control
219090738|NCT01299155|DEVICE|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
219090739|NCT01299155|DEVICE|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
219090740|NCT03073564|DIAGNOSTIC_TEST|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
219217185|NCT03407144|DRUG|prednisone/prednisolone|"60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
219217186|NCT03407144|DRUG|bleomycin|10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
219090741|NCT03073564|DIAGNOSTIC_TEST|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
219090742|NCT02106130|DRUG|Rebamipide|oral administration, 3 times/day
219090743|NCT02106130|DRUG|Mosapride citrate|oral administration, 3 times/day
219217187|NCT03407144|DRUG|etoposide|125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
219217188|NCT03407144|RADIATION|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
219090744|NCT03263689|DRUG|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
219090745|NCT00521144|DRUG|obatoclax mesylate|Given IV
219090746|NCT00521144|DRUG|topotecan hydrochloride|Given IV
219090747|NCT00521144|OTHER|laboratory biomarker analysis|Correlative studies
219090748|NCT01592149|OTHER|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
219090749|NCT01037439|DEVICE|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
219217189|NCT01982682|RADIATION|Total-Body Irradiation (TBI)|Undergo TBI
219217190|NCT01982682|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
219217191|NCT01982682|DRUG|Cyclophosphamide|Given IV
219217192|NCT01982682|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
219217193|NCT01982682|DRUG|Mycophenolate mofetil|Given IV
219090750|NCT01370525|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
219090751|NCT04664725|DRUG|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
219090752|NCT02614443|OTHER|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
219090753|NCT02614443|OTHER|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
219090754|NCT02614443|OTHER|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
219090755|NCT00804492|BEHAVIORAL|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
219090756|NCT05799326|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
219090757|NCT05799326|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.
219090758|NCT04416893|DIAGNOSTIC_TEST|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
219090759|NCT04416893|DIAGNOSTIC_TEST|Sars-Cov2 serology|A microsample of blood will be taken for serology
219090760|NCT03844022|DIAGNOSTIC_TEST|MRI|magnetic resonance imaging
219090761|NCT03376867|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
219090762|NCT03128424|DEVICE|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
219217194|NCT05930197|DRUG|Bismuth subsalicylate|BSS is a commonly used, widely available, OTC medication for a variety of gastrointestinal GI symptoms. It is available in the generic form, but also under the more commonly known brands: Bismatrol; Diotame; Geri-Pectate; Kao-Tin; Peptic Relief; Pepto-Bismol; Pink Bismuth and Stomach Relief. It received approval by the US Food and Drug Administration (FDA) in 1939.
219217195|NCT05788965|DRUG|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
219217196|NCT05485532|DEVICE|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
219090763|NCT00214305|BEHAVIORAL|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
219090764|NCT00214305|BEHAVIORAL|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
219090765|NCT01705496|RADIATION|[124I]FIAU|This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
219090766|NCT05033782|OTHER|questionnaire|"Each included patient will be given a paper questionnaire, with the following questions:~* Zip code of patient's iterative residences since 2018, as well as the zip code of residence at the time of the 2 confinements~* Occupational status~* Occurrence of COVID infection/date needed for hospitalization~* During the COVID-19 outbreak, did the patient: avoid seeing a doctor, avoid going to health care facilities, stop background treatment for MS. If yes to any of the questions, the reason, date and duration of the cessation will be asked.~Other sources of data will be used together:~Clinical data from the OFSEP registry Pollution data from approved air quality monitoring associations Data on the circulation of influenza and gastroenteritis, produced by Santé Publique France"
219090767|NCT03653455|BEHAVIORAL|Email reminders|Patients will receive email reminders until their PROs are completed.
219090768|NCT03653455|BEHAVIORAL|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
219090769|NCT03653455|BEHAVIORAL|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
219090770|NCT04280653|DEVICE|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
219090771|NCT00314548|DRUG|PGE1 (prostacyclin)|alprostadil nebulization
219090772|NCT00314548|DRUG|normal saline|nebulize for 30 mins
219090773|NCT06395610|DRUG|CHF6001 DPI|Single dose of CHF6001
219090774|NCT06395610|DRUG|Erythromycin|Repeated doses of oral Erythromycin
219217197|NCT06074679|PROCEDURE|Open cholecystectomy|The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
219217198|NCT00277914|DRUG|Flibanserin|flibanserin flexible dosing
219217199|NCT03786211|PROCEDURE|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
219217200|NCT03786211|PROCEDURE|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
219217201|NCT05662436|OTHER|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
219217202|NCT02490956|BIOLOGICAL|Verorab® (PVRV; Purified Vero Cell Vaccine)|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
219217203|NCT04593238|DRUG|Double Antibiotic paste|Metronidazole and Ciprofloxacin
219550232|NCT00421304|OTHER|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
219217204|NCT04593238|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
219217205|NCT03056313|BEHAVIORAL|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
219217206|NCT03056313|BEHAVIORAL|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
219217207|NCT00005921|DRUG|L-743,872|
219090775|NCT06171334|DEVICE|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
219090776|NCT06219564|PROCEDURE|Peripartum total abdominal hysterectomy (p-TAH)|"Peripartum total abdominal hysterectomy (cesarean hysterectomy) refers to a surgical procedure in which a woman undergoes both a cesarean section (C-section) and a hysterectomy simultaneously.~Placenta Accreta, Increta, or Percreta: These are conditions where the placenta attaches too deeply to the uterine wall. In cases of severe attachment, it may be difficult to remove the placenta without causing excessive bleeding, and a hysterectomy may be required.~Cesarean hysterectomy is a major surgical procedure involving significant medical expertise and coordination among healthcare professionals, including obstetricians and surgeons. The decision to perform a cesarean hysterectomy is usually made in emergency situations to address life-threatening complications."
219090777|NCT06219564|PROCEDURE|Cesarean Section (C/S)|"A cesarean section (C/S) involves making an incision in the abdominal wall and uterus to deliver a baby when a vaginal delivery is not feasible or safe.~Total placenta previa refers to a condition where the placenta completely covers the opening of the cervix in the uterus. This condition can pose significant risks during pregnancy and childbirth, and it often necessitates a planned cesarean section (C/S) for delivery."
219090778|NCT06219564|OTHER|Neonatal mortality|"Neonatal mortality refers to the death of a newborn within the first 28 days of life. This period is divided into early neonatal mortality, which covers the first seven days of life, and late neonatal mortality, which extends from the eighth to the 28th day. Neonatal mortality is a critical measure of the health and well-being of infants and is often used to assess a population's overall health and healthcare systems.~To reduce neonatal mortality, efforts are made to improve maternal healthcare, access to prenatal care, skilled attendance during childbirth, and the availability of neonatal healthcare services. Tracking and addressing factors contributing to neonatal mortality are crucial for improving the chances of survival of newborns and overall health outcomes."
219090779|NCT01719822|DEVICE|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
219090780|NCT04028349|DRUG|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
219090781|NCT00964834|DRUG|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
219090782|NCT00964834|DRUG|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
219090783|NCT00964834|DRUG|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
219090784|NCT03067454|PROCEDURE|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
219090785|NCT03067454|PROCEDURE|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
219217208|NCT05901532|DRUG|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
219217209|NCT05901532|DRUG|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
219217210|NCT05458466|OTHER|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
219550233|NCT05870332|DEVICE|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
219217211|NCT04881305|DIAGNOSTIC_TEST|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
219090786|NCT05936931|BEHAVIORAL|Changes in CRC screening awareness and intentions|Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
219090787|NCT03948984|BEHAVIORAL|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
219090788|NCT05279781|PROCEDURE|Non surgical root canal treatment|Complete root canal treatment will be performed followed by direct restoration
219090789|NCT05279781|PROCEDURE|Pulpotomy|Full pulpotomy followed by direct restoration
219090790|NCT04692402|DEVICE|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
219217212|NCT01267643|DRUG|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
219217213|NCT06837259|DRUG|PF-07328948|single oral dose day 1 and day 12 (Part A) and day 4 (part B)
219217214|NCT06837259|DRUG|cyclosporine|600 mg capsule day 12 (Part A)
219217215|NCT06837259|DRUG|clarithromycin|500 mg tablets twice daily day 1 to day 6 (Part B)
219217216|NCT04056754|DRUG|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
219217217|NCT04056754|DRUG|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
219217218|NCT04056754|DRUG|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
219090791|NCT02101229|DRUG|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
219090792|NCT02546934|DRUG|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
219090793|NCT02546934|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
219217219|NCT06506175|DRUG|HRS9531 tablets|HRS9531 tablets
219090794|NCT04302831|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
219090795|NCT04302831|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
219090796|NCT04302831|BEHAVIORAL|Flexibility training|stretches to improve flexibility
219090797|NCT04302831|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
219090798|NCT04302831|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
219090799|NCT03960229|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
219090800|NCT03960229|OTHER|Gradient-Density Centrifugation|sperm selection of IVF treatment
219217220|NCT05626374|BEHAVIORAL|Basic Case Management|Usual case management support during 12-week training program
219217221|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool|Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
219090801|NCT01103310|DRUG|BAY94-9392|
219090802|NCT00953264|BEHAVIORAL|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
219090803|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
219217222|NCT05626374|BEHAVIORAL|Basic Case Management plus rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
219090804|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
219090805|NCT02560870|DRUG|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
219090806|NCT02560870|DRUG|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
219217223|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
219217224|NCT01584167|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
219217225|NCT01584167|DEVICE|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
219217226|NCT05483985|DEVICE|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
219217227|NCT06476769|OTHER|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
219217228|NCT06476769|OTHER|percussion|Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
219217229|NCT00315185|DRUG|Cetuximab|
219217230|NCT01384890|RADIATION|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
219217231|NCT01384890|RADIATION|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
219217232|NCT03739658|OTHER|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
219090807|NCT03372330|DRUG|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
219090808|NCT03372330|DRUG|Standard care for sepsis|The standard care for the patient with sepsis.
219090809|NCT04536246|PROCEDURE|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
219090810|NCT04536246|PROCEDURE|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
219090811|NCT03233568|DIAGNOSTIC_TEST|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
219090812|NCT04978714|PROCEDURE|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
219217233|NCT05808205|DEVICE|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips."
219217234|NCT00857766|DRUG|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
219217235|NCT00857766|OTHER|Placebo|COPD subjects-Placebo DISKUS
219217236|NCT03072888|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
219217237|NCT03537326|DRUG|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
219217238|NCT02455765|OTHER|Rice and Amino Acid mixtures|Rice and amino acid mixture
219550234|NCT03196284|DRUG|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
219550235|NCT03196284|DRUG|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
219682092|NCT05950880|OTHER|High intensity shoulder exercise|Exercises that target the rotator cuff muscles using 90% of one repetition maximum only for 5 repetitions
219090813|NCT01302431|OTHER|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
219090814|NCT00303056|DRUG|HOE140 Icatibant|
219090815|NCT06363422|PROCEDURE|Epicanthoplasty|Patients with unsatisfied blepharoplasty underwent epicanthoplasty in our center
219090816|NCT05760157|OTHER|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
219090817|NCT00335452|DRUG|Clopidogrel|oral administration
219090818|NCT00335452|DRUG|acetylsalicyclic acid (ASA)|oral administration
219090819|NCT06096480|PROCEDURE|gabapentin + bilateral spine erector block|preoperative, ultrasound-guided, bilateral ESP block (administration of a local anesthetic mixture of ropivacaine 0.375% and lidocaine 1%) and a 100mg dose of oral gabapentin 4 nights daily before surgery and 2 weeks postoperatively.
219090820|NCT01969422|PROCEDURE|observation|intervention is the contact with online question answering serice ad subseudd
219090821|NCT02031367|DRUG|Triamcinolone Acetonide|Corticosteroid arm
219090822|NCT02031367|OTHER|Platelet Rich Plasma|Platelet Rich Plasma
219217239|NCT06511089|PROCEDURE|carotid artery stenting during EVT|"Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)."
219217240|NCT06511089|OTHER|no carotid artery stenting during EVT|A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
219217241|NCT00131274|DRUG|Imatinib Mesylate (Gleevec)|
219217242|NCT01640951|DRUG|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
219217243|NCT01640951|DRUG|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
219217244|NCT01640951|DRUG|Placebo|
219217245|NCT06327282|BEHAVIORAL|education on pain and related knowledge|Before surgery, pain related knowledge was educated.
219217246|NCT02776982|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
219217247|NCT02776982|PROCEDURE|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
219090823|NCT03486028|OTHER|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
219090824|NCT03486028|OTHER|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
219090825|NCT03088709|DRUG|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
219090826|NCT03088709|DRUG|Tacrolimus|IV medication given for prevention of graft versus host disease.
219090827|NCT03088709|DRUG|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
219090828|NCT03088709|OTHER|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
219090829|NCT03933475|DEVICE|Virtual reality game|Use of virtual reality games on television screens
219090830|NCT01904864|DRUG|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
219090831|NCT01904864|DRUG|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
219090832|NCT01152775|OTHER|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
219090833|NCT01152775|OTHER|No Media|This group will not be exposed to multimedia
219090834|NCT01163643|DRUG|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
219090835|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
219090836|NCT01163643|DRUG|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
219090837|NCT01163643|DRUG|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
219090838|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
219217248|NCT02776982|PROCEDURE|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
219090839|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
219090840|NCT05272891|OTHER|experimental group|audio book app
219090841|NCT03880630|OTHER|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
219090842|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
219090843|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
219090844|NCT00959101|DRUG|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
219090845|NCT00959101|DRUG|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
219090846|NCT01719107|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
219090847|NCT01719107|DIETARY_SUPPLEMENT|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
219090848|NCT00691808|DRUG|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
219090849|NCT00691808|DRUG|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
219090850|NCT00691808|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
219090851|NCT06171230|OTHER|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
219217249|NCT02776982|PROCEDURE|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
219217250|NCT02564705|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|
219217251|NCT02564705|PROCEDURE|Posterior Fusion|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
219090852|NCT06171230|OTHER|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
219090853|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
219090854|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
219090855|NCT03687190|BEHAVIORAL|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
219090856|NCT03687190|DRUG|conventional medicine|participants without Tai chi training still received routine conventional medicine
219090857|NCT02714855|DRUG|Apixaban|
219090858|NCT05516277|BEHAVIORAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.
219090859|NCT03685838|OTHER|Compression Stockings|Class II above knee compression stockings
219090860|NCT02115867|DIETARY_SUPPLEMENT|Probiotic|Symprove probiotic
219090861|NCT03168568|DRUG|Valsartan/Sacubitril or placebo|tablet (double dummy)
219090862|NCT03168568|DRUG|Valsartan or placebo|tablet (double dummy)
219090863|NCT01928966|OTHER|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
219090864|NCT00715650|BEHAVIORAL|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
219217252|NCT03355573|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
219090865|NCT00715650|BEHAVIORAL|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
219217253|NCT04730206|DRUG|Camostat|100 milligram tablets
219217254|NCT04730206|DRUG|Placebo|oral tablets, identical in size and shape
219090866|NCT01750879|DRUG|Peanut Flour|Peanut Flour
219090867|NCT01750879|DRUG|Oat Flour|Oat Flour
219090868|NCT00809692|PROCEDURE|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
219090869|NCT00809692|PROCEDURE|new technique for histamine response|laser Dopper technique and genotyping
219090870|NCT05993702|DRUG|regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
219090871|NCT05993702|DRUG|fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; or Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
219090872|NCT00019058|DRUG|chemotherapy|
219090873|NCT00019058|DRUG|hydroxyurea|
219090874|NCT00019058|DRUG|pentoxifylline|
219090875|NCT00019058|RADIATION|radiation therapy|
219090876|NCT01548430|DRUG|TTP4000|
219090877|NCT01548430|DRUG|Placebo|
219090878|NCT00001785|DRUG|Recombinant human interferon beta-1a|
219090879|NCT02421666|BEHAVIORAL|PNMI|Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
219090880|NCT01230255|PROCEDURE|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
219090881|NCT00455585|DRUG|nevirapine, stavudine, lamivudine|
219090882|NCT04976803|OTHER|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
219090883|NCT05877950|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
219090884|NCT05877950|OTHER|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
219090885|NCT04647032|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
219090886|NCT00317889|PROCEDURE|Bone preparation technique: compaction|
219090887|NCT00317889|PROCEDURE|Bone preparation technique: broaching|
219090888|NCT06153043|OTHER|Women patients with classical congenital adrenal hyperplasia|The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
219217255|NCT04730206|DRUG|Molnupiravir|200 milligram tablets
219217256|NCT01025167|DIETARY_SUPPLEMENT|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
219217257|NCT01025167|DIETARY_SUPPLEMENT|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
219217258|NCT01567605|DRUG|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
219217259|NCT01567605|OTHER|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
219217260|NCT00059826|BIOLOGICAL|interferon-alfa-2b|IV
219217261|NCT00059826|DRUG|cisplatin|IV
219090889|NCT01041014|BEHAVIORAL|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
219090890|NCT00290602|DRUG|Methylprednisolone sodium succinate|
219090891|NCT05968222|OTHER|Vibration exercise|Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
219090892|NCT01288339|DRUG|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
219090893|NCT01288339|DRUG|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
219090894|NCT04424784|BIOLOGICAL|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
219090895|NCT03708588|DRUG|Ticagrelor|Chewed
219090896|NCT03708588|DRUG|Ticagrelor|Integral
219090897|NCT02946840|DEVICE|FNA with 25 G Beacon needle|
219090898|NCT01722760|PROCEDURE|measurements|
219090899|NCT01936701|PROCEDURE|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
219090900|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
219090901|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
219090902|NCT04009590|OTHER|Educational Intervention|Read educational booklet
219090903|NCT04009590|OTHER|Questionnaire Administration|Ancillary studies
219090904|NCT04009590|BEHAVIORAL|Smoking Cessation Intervention|Utilize Quit4Health
219090905|NCT00239564|DRUG|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
219090906|NCT00239564|DRUG|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
219090907|NCT00239564|DRUG|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
219090908|NCT00239564|DRUG|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
219090909|NCT00239564|DRUG|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
219090910|NCT06233643|DRUG|Phloroglucinol|The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
219090911|NCT06233643|COMBINATION_PRODUCT|Acupuncture Combined Intradermal Sterile Water|Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
219090912|NCT06130878|OTHER|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
219090913|NCT04204369|OTHER|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~* An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~* A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
219090914|NCT06386003|DRUG|Psilocybin|Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
219090915|NCT00508404|DRUG|Panitumumab|Administered by intravenous infusion
219090916|NCT00508404|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
219090917|NCT03662074|DRUG|Gemcitabine|Given IV
219090918|NCT03662074|BIOLOGICAL|Nivolumab|Given IV
219090919|NCT02781948|DEVICE|Optical Coherence Tomography|
219090920|NCT05692622|OTHER|Whole-body exercise and respiratory exercise|The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
219090921|NCT03156933|OTHER|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
219090922|NCT00161590|DRUG|CHOP and alemtuzumab|
219090923|NCT06335420|DIETARY_SUPPLEMENT|Carrot juice from Yellowstone carrots cultivars|Consumption of 100 ml of carrot juice daily for 1 year
219090924|NCT06335420|DIETARY_SUPPLEMENT|Placebo juice|Consumption of 100 ml of placebo juice daily for 1 year
219090925|NCT00846638|BEHAVIORAL|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
219090926|NCT00846638|BEHAVIORAL|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
219090927|NCT01566331|DEVICE|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
219090928|NCT06246500|OTHER|No intervention|No intervention
219090929|NCT02908308|PROCEDURE|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
219090930|NCT02908308|PROCEDURE|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
219090931|NCT05029752|DEVICE|Vendys II Device|Using the device
219090932|NCT03090867|OTHER|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
219090933|NCT03090867|OTHER|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
219090934|NCT01597830|OTHER|Mobility shoe|flat, specialized shoe
219090935|NCT01597830|OTHER|control shoe|control shoe
219090936|NCT06378853|OTHER|no intervention|no intervention
219090937|NCT06362980|DRUG|BPI-1178|200 or 300 mg, oral, QD
219217262|NCT00059826|DRUG|5-fluorouracil|IV
219217263|NCT00059826|RADIATION|radiation therapy|
219217264|NCT01536093|OTHER|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
219217265|NCT01536093|OTHER|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
219217266|NCT06463145|DIETARY_SUPPLEMENT|Vanizem|Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
219217267|NCT06463145|DIETARY_SUPPLEMENT|Placebo|Food grade Maltodextrin 12
219217268|NCT05891132|DRUG|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
219217269|NCT05891132|DRUG|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
219217270|NCT02209246|OTHER|PROMIS CAT Pain Interference|
219217271|NCT02209246|OTHER|PROMIS CAT Pain Behavior|
219217272|NCT02209246|OTHER|PROMIS CAT Physical Function|
219217273|NCT02209246|OTHER|MISS-21|
219217274|NCT01023542|DRUG|delayed, low-dose CNI|immunosuppression
219217275|NCT01023542|DRUG|BU-CNI|Immunosuppression
219217276|NCT01023542|DRUG|BU-Everolimus|Immunosuppression
219090938|NCT06362980|DRUG|Osimertinib|80mg, oral, QD
219090939|NCT00797979|DEVICE|Skull Grip bone fixation|Skull Grip bone fixation
219090940|NCT00797979|DEVICE|sutures|Standard skull bon flap fixation, sutures
219090941|NCT03325244|OTHER|EEG monitor|sleep patterns will be monitored using EEG monitor
219090942|NCT03325244|OTHER|FitBit|activity levels will be monitored
219090943|NCT03685396|BIOLOGICAL|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
219090944|NCT03685396|DRUG|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
219090945|NCT02157025|DEVICE|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
219090946|NCT02157025|OTHER|Usual Care procedures during Humphrey perimetry for children|
219217277|NCT04592185|DEVICE|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
219217278|NCT04769596|DEVICE|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
219217279|NCT04769596|DEVICE|Sham Device|A Sham device will be used in the nasal cavity
219217280|NCT05459350|DIAGNOSTIC_TEST|Safe Discharge Classification|Safe Discharge Classification
219217281|NCT02008669|PROCEDURE|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
219217282|NCT02008669|OTHER|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
219090947|NCT05340959|DEVICE|Devices: Osstell®, Periotest® and AnyCheck®.|"1. Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~2. Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~3. AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
219090948|NCT05177445|COMBINATION_PRODUCT|Phototherapy|"Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention."
219090949|NCT05177445|COMBINATION_PRODUCT|OT+Corticosteroids|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
219090950|NCT01059643|DRUG|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
219090951|NCT01059643|DRUG|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
219090952|NCT00886028|DRUG|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
219090953|NCT00886028|DRUG|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
219090954|NCT06425731|OTHER|Fasting|Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
219090955|NCT06425731|OTHER|No Intervention|No Intervention
219090956|NCT06770491|DRUG|Y-3 for injection|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
219090957|NCT06770491|DRUG|Placebo|"The placebo consists of two parts: placebo (lyophilized powder) and Solvent for Y-3 for injection(concentrated solution).~Name: Placebo Strength: 0 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Solvent for Y-3 for injection Strength: 3 mL (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
219217283|NCT02008669|OTHER|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep"
219217284|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 50 mg
219217285|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 300 mg
219217286|NCT01411566|BEHAVIORAL|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
219217287|NCT01411566|BEHAVIORAL|regular treatment|regular treatment
219217288|NCT03746938|DEVICE|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
219217289|NCT03710252|DRUG|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
219217290|NCT03794219|OTHER|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
219682093|NCT05950880|OTHER|Conventional physical therapy|Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises
219217291|NCT03794219|DRUG|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
219217292|NCT00942266|DRUG|fluorouracil|Given IV
219217293|NCT00942266|DRUG|leucovorin calcium|Given IV
219217294|NCT00942266|DRUG|vorinostat|Given orally
219217295|NCT00942266|OTHER|pharmacological study|Correlative study
219217296|NCT02506452|OTHER|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
219090958|NCT01422135|DRUG|AG200-15|A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
219090959|NCT02295566|DRUG|Nitric Oxide|Not required
219090960|NCT02295566|DRUG|Control|Not required
219090961|NCT02819102|DRUG|BCX7353 and probes|
219090962|NCT02162680|DRUG|1% lidocaine|
219090963|NCT02162680|DRUG|bacteriostatic normal saline (BNS)|
219090964|NCT02600884|BEHAVIORAL|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
219090965|NCT02600884|BEHAVIORAL|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
219090966|NCT04538365|DRUG|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
219217297|NCT02506452|OTHER|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
219217298|NCT04567459|DIETARY_SUPPLEMENT|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
219217299|NCT00482911|DRUG|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
219217300|NCT00482911|DRUG|lenalidomide|10 mg by mouth once daily on days 1-28.
219217301|NCT00482911|DRUG|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
219217302|NCT00584675|DEVICE|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
219217303|NCT00833313|PROCEDURE|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
219217304|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
219217305|NCT02139436|OTHER|FES-row-training|
219217306|NCT02139436|OTHER|Arms-only-row training|
219090967|NCT04538365|DRUG|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
219090968|NCT02809144|PROCEDURE|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
219090969|NCT05627063|DRUG|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
219090970|NCT00643123|DRUG|Allopurinol|300-600 mg/day over a 6 week period
219090971|NCT00643123|OTHER|Placebo|Inactive substance
219090972|NCT03631225|DIAGNOSTIC_TEST|Vectra|Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
219090973|NCT02150720|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
219090974|NCT02150720|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
219090975|NCT02150720|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
219090976|NCT05929443|OTHER|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
219090977|NCT03819582|DEVICE|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
219090978|NCT06381323|DRUG|Finerenone|All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
219090979|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
219090980|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
219217307|NCT02139436|OTHER|Time Control|
219217308|NCT05910203|OTHER|The effectiveness of education|Training will be provided on smoking cessation.
219217309|NCT02550951|PROCEDURE|lymphangiography|
219217310|NCT00257881|DRUG|CMD-193|
219217311|NCT05162560|OTHER|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
219217312|NCT00317395|DRUG|Otamixaban (XRP0673)|intravenous administration
219090981|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
219090982|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
219090983|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
219090984|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
219090985|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
219090986|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
219090987|NCT04323956|DRUG|Cyclophosphamide|Given IV
219090988|NCT04323956|DRUG|Doxorubicin Hydrochloride|Given IV
219090989|NCT04323956|DRUG|Parsaclisib|Given PO
219090990|NCT04323956|BIOLOGICAL|Pegfilgrastim|Given SC
219090991|NCT04323956|DRUG|Polatuzumab Vedotin|Given IV
219090992|NCT04323956|DRUG|Prednisone|Given PO
219090993|NCT04323956|BIOLOGICAL|Rituximab|Given IV
219090994|NCT04323956|DRUG|Vincristine Sulfate|Given IV
219217313|NCT00317395|DRUG|unfractionated heparin|intravenous administration
219217314|NCT00317395|DRUG|eptifibatide|intravenous administration
219217315|NCT03317652|OTHER|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
219217316|NCT03317652|OTHER|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
219217317|NCT03317652|DRUG|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
219217318|NCT01697891|DEVICE|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
219550236|NCT05244876|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
219090995|NCT04313959|DRUG|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
219090996|NCT04313959|DRUG|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
219090997|NCT02701335|DEVICE|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
219090998|NCT02701335|DEVICE|Gloreha device|Robotic assisted passive mobilization.
219090999|NCT02701335|DEVICE|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
219091000|NCT02179502|DRUG|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
219091001|NCT02179502|DRUG|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
219091002|NCT02179502|DRUG|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
219091003|NCT02179502|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
219091004|NCT02929433|OTHER|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
219091005|NCT03471169|DRUG|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
219091006|NCT03471169|DRUG|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
219091007|NCT03297203|BEHAVIORAL|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
219217319|NCT02230046|DRUG|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
219217320|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
219217321|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
219217322|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
219217323|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
219091008|NCT06412627|PROCEDURE|4°C frozen normal saline gauze|Soak two 4x4 gauze pads in 15 ml of normal saline, refrigerate at 4°C, and then apply in the oral cavity for 15 minutes before removal.
219091009|NCT03526601|DIAGNOSTIC_TEST|NT-proBNP, echocardiography|screening
219091010|NCT00243542|DRUG|ACZONE Gel, 5%|
219091011|NCT00243542|DRUG|Vehicle|
219091012|NCT02573402|DEVICE|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
219217324|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
219217325|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
219217326|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
219217327|NCT00756574|DEVICE|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
219217328|NCT00756574|DEVICE|N95 mask|N95 mask worn for patients with febrile respiratory illness
219217329|NCT03605901|DRUG|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
219217330|NCT03605901|DRUG|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
219217331|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
219217332|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
219217333|NCT05777200|BEHAVIORAL|Supportive psychotherapy|Counselling patients, providing supportive psychotherapy to help them detox their illicit drug usage, and help them rehabilitate again into society.
219217334|NCT03842085|DRUG|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
219217335|NCT05517655|DRUG|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
219217336|NCT05263830|OTHER|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
219217337|NCT05384223|BEHAVIORAL|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
219217338|NCT05384223|BEHAVIORAL|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
219217339|NCT05760248|DRUG|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
219217340|NCT05760248|DRUG|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
219217341|NCT04572906|COMBINATION_PRODUCT|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
219217342|NCT05933733|OTHER|Salvage treatment (surgery and/or radiation therapy)|Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.
219217343|NCT02610426|OTHER|Laboratory Biomarker Analysis|Correlative studies
219217344|NCT04524247|DEVICE|Physician Modified Endografts|"Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs"
219091013|NCT02573402|DEVICE|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
219091014|NCT00883038|OTHER|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
219091015|NCT00883038|OTHER|low-fat vegetarian diet|The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
219091016|NCT00796250|BIOLOGICAL|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
219091017|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
219091018|NCT00796250|DRUG|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
219091019|NCT00796250|DRUG|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
219091020|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
219091021|NCT00796250|BIOLOGICAL|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
219091022|NCT05147610|DIAGNOSTIC_TEST|Intraocular pression|"First, measurement of the eye pressure by air-puff tonometry and estimation of the pachymetries with the TONOREF III.~Secondly, measurement of the eye pressure by GAT. Thirdly, measurement of the eye pressure by Icare 200."
219091023|NCT06579053|DRUG|Spironolactone Tablets (Test)|Take one test tablet each period
219091024|NCT06579053|DRUG|Spironolactone Tablets (Reference)|Take one reference tablet each period
219091025|NCT01591382|DRUG|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
219091026|NCT01591382|DRUG|Placebo|Patients who received ketamine-matching placebo were given saline infusions
219091027|NCT01591382|DRUG|Hydromorphone PCA|Intravenous hydromorphone PCA
219091028|NCT05506748|OTHER|pantients undergoing pancreaticoduodenectomy|The study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.
219091029|NCT00053495|BIOLOGICAL|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
219091030|NCT00053495|BIOLOGICAL|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
219091031|NCT03550833|BEHAVIORAL|Questionnaire|Questionnaire
219091032|NCT03550833|BIOLOGICAL|blood sample|7 ml whole blood for Peripheral blood
219091033|NCT01670981|BIOLOGICAL|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
219091034|NCT01670981|OTHER|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
219091035|NCT01166516|DEVICE|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
219091036|NCT03483987|DRUG|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
219091037|NCT03483987|DRUG|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
219091038|NCT03483987|DRUG|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
219091039|NCT03483987|DRUG|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
219091040|NCT03483987|DRUG|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
219091041|NCT03483987|DRUG|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
219091042|NCT03630822|BEHAVIORAL|Psychiatric Advanced Directive|The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
219091043|NCT03630822|BEHAVIORAL|Standard care|standardized maintenance with the patient
219091044|NCT03262740|DRUG|BMS-986195|Oral administration of specified dose on specified days
219091045|NCT03262740|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
219091046|NCT06384248|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
219091047|NCT05354843|DRUG|ET0038|ET0038 for oral administration
219091048|NCT03513406|DRUG|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
219091049|NCT03513406|DRUG|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
219091050|NCT03513406|DRUG|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
219091051|NCT00109044|DRUG|Escitalopram|
219091052|NCT06403579|DEVICE|virtula reality goggles|no intervention
219550237|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
219550238|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every week
219217345|NCT04326140|DEVICE|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
219091053|NCT04610931|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
219091054|NCT04610931|BEHAVIORAL|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
219091055|NCT03319537|DRUG|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
219091056|NCT03319537|DRUG|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
219091057|NCT04307706|BEHAVIORAL|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
219091058|NCT04413292|DIAGNOSTIC_TEST|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
219217346|NCT04326140|DEVICE|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
219217347|NCT04326140|DEVICE|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
219550239|NCT00501735|DRUG|Forodesine 200 mg|2 x 100mg tablets once daily
219550240|NCT01912807|DRUG|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
219550241|NCT01912807|DRUG|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
219550242|NCT04334863|DRUG|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
219550243|NCT04806035|BIOLOGICAL|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
219550244|NCT04806035|BIOLOGICAL|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
219550245|NCT02489864|DRUG|Terlipressin|
219550246|NCT04667390|OTHER|total knee arthroplasty|total knee arthroplasty
219550247|NCT01262235|DRUG|TKM-080301|Repeat dose IV infusion.
219550248|NCT03018925|DRUG|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
219550249|NCT02756858|DRUG|ANAVEX2-73|
219550250|NCT01137864|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
219550251|NCT00922896|DRUG|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"* Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
219550252|NCT03503435|BEHAVIORAL|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
219550253|NCT05583162|BEHAVIORAL|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
219550254|NCT01126762|BEHAVIORAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
219550255|NCT01126762|BEHAVIORAL|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
219550256|NCT01368380|BEHAVIORAL|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
219550257|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
219550258|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
219550259|NCT02407548|DIETARY_SUPPLEMENT|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
219217348|NCT01379482|DRUG|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
219217349|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received one drain.|patients who underwent two level lumbar decompression with BESS procedure received one drain.
219217350|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received two drain.|patients who underwent two level lumbar decompression with BESS procedure received two drains
219217351|NCT03660618|DEVICE|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
219217352|NCT04415307|OTHER|Acupuncture|Acupuncture over acupoints.
219217353|NCT04415307|OTHER|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
219217354|NCT04415307|OTHER|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
219217355|NCT04415307|OTHER|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
219217356|NCT05859659|DIAGNOSTIC_TEST|This study does not intervene in this process.|This study does not intervene in this process.
219217357|NCT04006834|OTHER|No intervention involved|No intervention involved
219217358|NCT04010136|OTHER|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
219217359|NCT02707666|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
219217360|NCT02707666|DRUG|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
219217361|NCT03699410|RADIATION|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
219217362|NCT03699410|DRUG|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
219091059|NCT02091479|DRUG|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
219091060|NCT02091479|DRUG|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
219217363|NCT03699410|PROCEDURE|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
219217364|NCT00228475|DRUG|Pulmicort (budesonide) Turbuhaler|
219217365|NCT04646733|OTHER|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
219217366|NCT04646733|OTHER|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
219217367|NCT04200287|BEHAVIORAL|Online decision aid tool|The decision aid intervention will be presented via a website
219217368|NCT00163046|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
219217369|NCT00163046|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
219217370|NCT05759260|OTHER|Observation|Observation
219217371|NCT01297894|DRUG|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
219217372|NCT01297894|DRUG|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
219217373|NCT01084941|BEHAVIORAL|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
219217374|NCT01084941|BEHAVIORAL|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
219217375|NCT01647932|DRUG|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
219217376|NCT01647932|DRUG|Placebo|Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
219091061|NCT03883815|OTHER|Active Video Games Therapy|"Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills."
219091062|NCT00855062|DRUG|minocycline|100 mg capsule every 12 hours by mouth
219091063|NCT00855062|DRUG|minocycline placebo capsule|1 capsule every 12 hours by mouth
219091064|NCT03357614|DRUG|Sulopenem|Antibiotic therapy for complicated UTI
219091065|NCT03357614|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
219091066|NCT03357614|DRUG|Ertapenem|Antibiotic therapy for complicated UTI
219091067|NCT03357614|DRUG|Ciprofloxacin|Antibiotic therapy for complicated UTI
219091068|NCT03357614|DRUG|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
219091069|NCT01116492|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
219091070|NCT01116492|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
219091071|NCT03738202|BEHAVIORAL|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan"
219091072|NCT01893385|DRUG|Vitamin D (drug)|
219091073|NCT00868465|DRUG|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
219217377|NCT05677451|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
219217378|NCT05677451|DRUG|placebo|matching active drug
219217379|NCT06892691|PROCEDURE|Pleuroscopy first|Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.
219217380|NCT06892691|PROCEDURE|Thoracentesis first|Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.
219217381|NCT06778772|BEHAVIORAL|transition pathway to adult care services for epilepsy patients.|This proposal aims to create a coordinated and shared transition pathway between pediatric and adult epilepsy services, addressing the needs of patients with chronic conditions. The primary objective is to assess the readiness of both patients and their caregivers for the transition, by comparing the Transition Readiness Assessment (TRAQ) questionnaire results between the last pediatric neuropsychiatric visit and the first adult neurology visit. Secondary objectives include evaluating changes in emotional-behavioral issues and quality of life, using the CBCL, YSR, and PedsQoL questionnaires. Assessments will be conducted at both pediatric and adult epilepsy services. The ultimate goal of the transition protocol is to improve care and outcomes for adolescents and young adults during the transition, focusing on emotional-behavioral and psychosocial aspects, and to develop a best-practice model that could influence future guidelines.
219217382|NCT06775080|DRUG|propranolol (beta-blocker used treat high blood pressure)|Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
219217383|NCT00972621|DEVICE|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
219091074|NCT00868465|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
219091075|NCT03406546|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
219091076|NCT03406546|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
219091077|NCT03406546|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
219091078|NCT00433303|BEHAVIORAL|Correlation between early delivery and coital activity|
219217384|NCT00972621|DEVICE|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
219217385|NCT06769061|PROCEDURE|Acupuncture|Patients will receive 6 weeks of electroacupuncture, 2 sessions per week, 30 min per session Stainless steel, single-use, sterile, and disposable needles will be used. We will use the bilateral acupoints LI4 (He-Gu), TE5 (Wai-Guan), LI11 (Qu-Chi), and LU5 (Chi-Ze) for upper limbs. For lower limb numbness, we will use the bilateral acupoints of LV3 (Tai-Chong), ST41 (Jie-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan) for the numbness of back of feet, or the bilateral acupoints of KI1 (Yong-Quan), KI3 (Tai-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan). After skin disinfection, sterile adhesive pads will be placed on bilateral LI4 (Hegu), TE5 (Waiguan), LI11 (Quchi), and LU5 (Chize). Following each needle insertion, acupuncturists will perform equal manipulations of twirling, lifting, and thrusting on the needle by acupuncturists to achieve the de qi sensation. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be electrically stimulated for 30 min.
219217386|NCT06769061|DEVICE|sham acupuncture|Patients will receive 6 weeks of sham acupuncture, 2 sessions per week, 30 min per session. The Streitberger sham acupuncture needle designed specifically for sham acupuncture trials will be used. Patients will feel the needle on the skin, but the needle actually will not puncture the skin. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be connected to the electrical stimulation device KWD-808I MULTI-PURPOSE Health device (Great Wall Company), but not stimulated. The needle will remain for 30 minutes. without stimulating the acupoints. The sham acupuncture will be used within the trocar. The trocar will be fixed by a base on the skin with sticker. The trocar-base-sticker will be used for both acupuncture group and sham acupuncture control group, so they are exactly the same in appearance. Patients cannot see if there is acupuncture or sham acupuncture within the trocar.
219217387|NCT06769451|RADIATION|Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy|STAR with a single dose of 25Gy(RBE) Proton Therapy
219217388|NCT06649149|OTHER|Genially|In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
219217389|NCT06649149|OTHER|Education|In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
219217390|NCT05468320|DRUG|Caplacizumab|Lyophilized powder for solution for injection.
219217391|NCT05468320|DRUG|Corticosteroids|Solution for injection or Tablet
219217392|NCT05468320|BIOLOGICAL|anti-CD20 antibody|Solution for injection
219217393|NCT06768528|DIAGNOSTIC_TEST|Galectin-3 dosage|Peripheral blood sample will be collected in the 24h before CABG
219217394|NCT06769477|OTHER|Experimental Group|individuals will receive diabetes education with motivational interviewing technique based on health belief model
219217395|NCT06761430|DEVICE|ClearPlasma|ClearPlasmais an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasmaTM is a non-pyrogenic, sterile, single-use medical device.
219091079|NCT01258192|DRUG|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
219091080|NCT05580848|PROCEDURE|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
219091081|NCT04601558|BEHAVIORAL|The letters with the Cochrane abstracts in the form of blog-shots|"The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
219091082|NCT04601558|BEHAVIORAL|The letters with remainder on cardiovascular risk factors|"The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
219091083|NCT02605564|OTHER|Gluten Free Diet|Gluten Free Diet
219091084|NCT02605564|OTHER|Placebo|Placebo No intervention, standard T1DM diet
219091085|NCT05969457|DRUG|Naropeine|Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
219091086|NCT05969457|OTHER|questionnaires|Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4
219091087|NCT05969457|OTHER|Placebo|Injection of 20 mL of NaCl
219091088|NCT04605848|DIAGNOSTIC_TEST|Infrared themrography|measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
219091089|NCT06006988|COMBINATION_PRODUCT|myoton pro|MyotonPRO is a mobile, removable handheld myotonometer. This tool is noninvasive and provides a quantitative assessment of a muscle's viscoelastic properties. These properties are characterized by various parameters such as hardness, tone and elasticity. The probe of MyotonPRO delivers a short (15 ms), low intensity (0.58 N) mechanical impact/impact on the skin on the muscle. The response of the touch then generates a recorded signal and an internal software program generates an acceleration graph. Measurements of various viscoelastic muscle properties such as stiffness, tone and elasticity are then extracted from this graph.
219091090|NCT02390726|BIOLOGICAL|Fecal Microbiota Transplant|
219091091|NCT02390726|BIOLOGICAL|Placebo|
219091092|NCT02551523|DRUG|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
219091093|NCT02551523|DRUG|Standard of care combinational antiretroviral therapy|
219217396|NCT06762132|BIOLOGICAL|CD33 CAR T-cells|Each subject receive CD33 CAR T-cells by intravenous infusion
219091094|NCT01960725|BIOLOGICAL|RV5 (Pentavalent Rotavirus Vaccine)|
219091095|NCT01487980|PROCEDURE|Cord clamping|Early vs Delayed
219091096|NCT00487058|DRUG|Gimatecan|
219091097|NCT03098940|DRUG|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
219091098|NCT02770651|DEVICE|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
219091099|NCT02770651|DEVICE|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
219091100|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt + Vitamin D|cheese \& yogurt with added 420 IU cholecalciferol
219091101|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt|Cheese \& yogurt without added vitamin D
219091102|NCT03771430|BEHAVIORAL|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results"
219091103|NCT03771430|PROCEDURE|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
219091104|NCT03367507|BEHAVIORAL|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
219091105|NCT04889001|OTHER|Simulation enhanced HBB training|Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
219091106|NCT04995848|OTHER|Telepalliation|Telepalliation platform Telepal.dk
219091107|NCT02524392|OTHER|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
219091108|NCT05009303|DEVICE|OneStep Smartphone App and C-Mill Treadmill|OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
219091109|NCT00448890|DRUG|GSK729327|Tablets
219217397|NCT06760650|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography
219217398|NCT06761456|OTHER|Providing training models|The experimental group was trained using the Clinical Education Module on 3 Parenteral Interventions in the Nursing Fundamentals laboratory.
219217399|NCT06761456|OTHER|Control|The control group was trained using standard training models.
219217400|NCT06767865|OTHER|online support programe|Individuals in the experimental group received online training and were subsequently provided with continuous follow-up, counseling, motivation and informative message support for three months. In addition, patients were given a target board containing a daily diabetes management program and were asked to use it for three months.
219217401|NCT06791161|DRUG|Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor|BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
219217402|NCT05709574|DRUG|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
219217403|NCT06720961|PROCEDURE|Collection of surgical specimen|Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
219091110|NCT00448890|DRUG|Placebo|GSK729327 Matching placebo - Tablets
219091111|NCT05414539|OTHER|OptiCogs Online|A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
219091112|NCT00758459|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
219091113|NCT00758459|DRUG|Placebo|Dosing to match AZD1236
219091114|NCT04069780|PROCEDURE|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
219091115|NCT04069780|PROCEDURE|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
219217404|NCT06720961|PROCEDURE|Collection of stool sample|One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
219217405|NCT04043494|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
219091116|NCT04069780|PROCEDURE|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
219091117|NCT02489110|BEHAVIORAL|Webnovela|
219217406|NCT04043494|DRUG|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
219217407|NCT04043494|DRUG|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
219091118|NCT02489110|BEHAVIORAL|Information|
219091119|NCT02415699|DRUG|Fluorouracil|
219091120|NCT02415699|DRUG|Oxaliplatin|
219091121|NCT02415699|DRUG|Leucovorin|
219091122|NCT02415699|BIOLOGICAL|DC-CIK|
219217408|NCT04043494|DRUG|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
219217409|NCT04043494|DRUG|Doxorubicin|Part of standard chemotherapy
219217410|NCT04043494|DRUG|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
219217411|NCT04043494|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
219217412|NCT04043494|DRUG|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
219217413|NCT04043494|DRUG|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib\* (Randomization R2)
219217414|NCT04043494|DRUG|Prednisone|Part of standard chemotherapy
219217415|NCT04043494|DRUG|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
219217416|NCT04043494|DRUG|Thioguanine|Part of standard chemotherapy
219217417|NCT04043494|DRUG|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
219217418|NCT04043494|DRUG|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
219217419|NCT06770868|DEVICE|Patient specific reconstruction plate for patients suffering from mandibular segmental defects|Patients with mandibular segmental defect including coronoidectomy managed with patient specific reconstruction plate with custom made temporalis tendon enthesis
219217420|NCT04550377|DRUG|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
219682094|NCT04407702|OTHER|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
219091123|NCT00892125|DRUG|paliperidone ER; Carbamazepine|
219091124|NCT05999786|BEHAVIORAL|early rehabiliation swallowing program|not receiving early rehabilitation swallowing program from before and after surgery
219091125|NCT05999786|BEHAVIORAL|not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
219091126|NCT00004410|DRUG|tauroursodeoxycholic acid|
219091127|NCT02533869|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
219091128|NCT02533869|PROCEDURE|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
219091129|NCT02693821|DRUG|Gabapentin|gabapentin 300 mg per day, orally during 30 days
219091130|NCT02693821|DRUG|Placebo|Placebo 300 mg per day, orally during 30 days
219091131|NCT00262795|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
219091132|NCT00262795|DRUG|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
219091133|NCT01726855|PROCEDURE|vascularized finger dorsal fascial flap|
219091134|NCT01860469|PROCEDURE|vancomycin-soaked mesh|
219217421|NCT04550377|DRUG|Placebo|non-active medication
219217422|NCT06770504|BIOLOGICAL|YTS109|In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.
219091135|NCT01860469|PROCEDURE|plain mesh|
219091136|NCT05374044|DIAGNOSTIC_TEST|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
219091137|NCT00916461|DRUG|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
219091138|NCT00916461|DRUG|Placebo|Placebo + treatment as usual.
219091139|NCT01281202|DRUG|Vigabatrin|Tablets
219091140|NCT01281202|DRUG|Matching Placebo|Tablets
219091141|NCT02252432|DRUG|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
219091142|NCT02252432|DRUG|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
219217423|NCT06771713|BEHAVIORAL|Brief Pain Reprocessing Therapy (BPRT)|"Participants will have three 90-minute behavioral intervention sessions over a 3-week period, completing 35 days of brief daily assessments, and one additional set of questionnaires.~Participants will also complete study questionnaires at 1, 2, 3, and 6 months after attending the 3 behavioral intervention sessions."
219217424|NCT06774716|BEHAVIORAL|Internet-based cognitive behavioural treatment and relapse prevention|A self help program consisting of 12 modules and access to therapist guidance through messages. Including three video session.
219682095|NCT04407702|PROCEDURE|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
219091143|NCT02252432|DRUG|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
219091144|NCT03224221|DRUG|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
219091145|NCT03224221|DRUG|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
219091146|NCT06082245|PROCEDURE|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~* patients received general anesthesia"
219091147|NCT06082245|PROCEDURE|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~* patients received general anesthesia"
219091148|NCT06082245|PROCEDURE|Lidocaine injection|"* patients received general anesthesia~* the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
219091149|NCT00894673|BIOLOGICAL|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
219091150|NCT00894673|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
219091151|NCT02969837|DRUG|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
219091152|NCT02969837|DRUG|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
219091153|NCT02969837|DRUG|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
219091154|NCT02969837|DRUG|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
219091155|NCT04252742|DRUG|Erenumab|140 mg, 2 consecutive injections of 70 mg
219682096|NCT04407702|RADIATION|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
219091156|NCT04252742|DRUG|Placebo|2 consecutive injections
219091157|NCT06304389|OTHER|electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration|Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
219217425|NCT06774716|BEHAVIORAL|Face-to-face cognitive behavioural treatment or short-term psycodynamic therapy with relapse prevention|Face-to-face therapy with a licenced psychologist or licenced psychotherapist, including 10-15 sessions.
219217426|NCT06775275|DRUG|Adebellizumab|adebrelimab
219217427|NCT06775275|DRUG|Bevacizumab|bevacizumab
219217428|NCT06775275|DRUG|Platinum-based chemotherapy|paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
219217429|NCT06775470|DIAGNOSTIC_TEST|Patients must have been diagnosed with ovarian cancer and be BRCA positive|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
219091158|NCT06304389|OTHER|transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration|Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
219091159|NCT06644560|BEHAVIORAL|Prehabilitation Intervention|The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
219091160|NCT05370781|BEHAVIORAL|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
219091161|NCT05370781|BEHAVIORAL|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
219091162|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
219091163|NCT04417595|DRUG|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
219091164|NCT04417595|DRUG|Olive Oil|Olive Oil Supplement
219091165|NCT06636565|OTHER|No intervention|No intervention
219091166|NCT06796764|DEVICE|the COMBO Endoscopy Oropharyngeal Airway Group|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
219217430|NCT06775470|DIAGNOSTIC_TEST|BRCA1 and BRCA2 positive, and be affected by Ovarian Cancer|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
219217431|NCT06778993|OTHER|Breastfeeding Education Program Accompanied by a Wearable (Hybrid) Simulator|This training is conducted in both theoretical and practical formats. The theoretical training consists of two sessions, each lasting 25 minutes, with a 10-minute break in between, totaling 60 minutes. Following the theoretical training, simulation-based skill training is conducted. This phase also comprises two sessions of 25 minutes each, with a 10-minute break, making a total duration of 60 minutes.
219091167|NCT06796764|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
219091168|NCT03459287|DEVICE|INTERCEPT|Pathogen reduced RBCs
219091169|NCT03459287|DEVICE|Control|Conventional RBCs
219091170|NCT01784068|DRUG|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
219091171|NCT04685590|DRUG|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
219091172|NCT04685590|OTHER|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
219217432|NCT06770465|DRUG|Different categories of antibiotics|Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
219091173|NCT00743561|DEVICE|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
219217433|NCT06771089|OTHER|Manual therapy and bandaging|The MTG group received an intervention based on anterior-posterior mobilizations of the talus and fibula and taping, both based on Mulligan® techniques Individually, participants received Grade IV passive mobilizations lasting approximately 30 seconds, totalling 12 active mobilizations performed by the participant. Furthermore, a tape was applied, placed on the anterior part of the talus with a posterior and caudal direction, with its ends anchored near the heel. Due to its placement, this taping maintained a sustained posterior force on the talus throughout the training session. This intervention was conducted on the affected limb(s) with DF deficits.
219682097|NCT02616198|OTHER|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
219682098|NCT02616198|OTHER|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
219217434|NCT06771089|OTHER|Therapeutic exercise|"Therapeutic exercise protocol lasting approximately 5-10 minutes, performed before regular training sessions. It included 2 exercises, each performed in 3 sets of 10 repetitions with 1-minute rest intervals.~Exercise 1: Weighted DF in a kneeling position. From this position, ankle DF is performed with the front leg, on which the weight of the arms and the torso is placed to force the movement.~Exercise 2: Ankle lunge with band resistance at the ankle. The player performs ankle DF with a medium-resistance green Theraband® providing a posterior force vector on the talus.~This intervention was applied to the affected limb(s) with ankle DF limitations and was supervised by a physiotherapist. It was performed before training session at each club's facilities."
219217435|NCT06771089|OTHER|No specific treatment|The Control group received no specific treatment; they only participated in the current training sessions.
219217436|NCT06777836|DEVICE|Personalised Discharge training|Discharge education also contributes to the empowerment of diabetic surgery patients in diabetes management. During the training process, patients will be informed about blood glucose control, diet, exercise and medication management.
219217437|NCT06799546|DRUG|HSK39297 tablets|200mg QD for 24 weeks
219217438|NCT06799546|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
219217439|NCT06752460|DEVICE|EF192B|EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
219217440|NCT06264362|BEHAVIORAL|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
219217441|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
219217442|NCT06162338|BIOLOGICAL|LY-M001 Injection|With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
219217443|NCT06709404|OTHER|Telemedicine|Receive telehealth navigation intervention
219217444|NCT06709404|OTHER|Survey administration|Ancillary studies
219091174|NCT00743561|DEVICE|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
219091175|NCT05133050|DRUG|Ramipril|We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
219217445|NCT06709404|OTHER|Electronic health record review|Ancillary studies
219682099|NCT02616198|OTHER|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
219091176|NCT00946296|DRUG|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
219091177|NCT04283448|BEHAVIORAL|Dietary Lentil|Participants in the Lentil arm of the study will consume midday meals containing 0.66 cups of lentils seven days per week for 12 weeks.
219091178|NCT04283448|BEHAVIORAL|Control|Participants in the Control arm of the study will consume midday meals containing 0.00 cups of lentils seven days per week for 12 weeks.
219091179|NCT05902234|BEHAVIORAL|interdiciplinary treatment|Normal interdiciplinary treatment path
219091180|NCT05535049|PROCEDURE|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
219217446|NCT06709404|OTHER|Best Practice|Receive standard caregiving experience
219217447|NCT06186973|OTHER|Monitoring with Neobeat heart rate meter|"At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.~In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization."
219217448|NCT06186973|OTHER|Maternal arterial blood gases|Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.
219217449|NCT06186973|OTHER|Amniotic fluid lactate|Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.
219091181|NCT02137525|DRUG|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
219091182|NCT02137525|DRUG|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
219091183|NCT02137525|DRUG|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
219091184|NCT02137525|DRUG|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
219091185|NCT02137525|DRUG|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
219091186|NCT02137525|DRUG|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
219091187|NCT01704469|PROCEDURE|The local anesthetic injection|
219091188|NCT06190795|OTHER|AMPLIFY Smartphone Application|AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform
219091189|NCT06190795|OTHER|Hardcopy Manual|Hardcopy Manual
219091190|NCT06432686|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is a safe, relatively cheap, and non-painful stimulation of the peripheral sensory and motor nerves. The stimulator is easy to operate and pwMS can apply the stimulation themselves at home. This makes TENS an interesting tool to augment sensory input. A high frequency and long pulse duration is used.
219091191|NCT06432686|BEHAVIORAL|Movement|Participants are instructed to perform plantar- and dorsi-flexion contraction in a relatively slow tempo. The movement of the ankle is measured by an MRI-compatible potentiometer and participants receive feedback of this movement on the screen inside the scanner.
219091192|NCT03809273|DRUG|Yangxinshi|Yangxinshi pill 3 pills /tid
219091193|NCT03809273|DRUG|Trimetazidine|Trimetazidine 20mg/tid
219091194|NCT03809273|DRUG|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
219091195|NCT03809273|DRUG|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
219091196|NCT05038930|DEVICE|Mobilisation using the Sara Combilizer|The mobilisation with the Sara Combilizer, will be done one time either 24 or 48 hours after stable intracranial pressure
219091197|NCT04273542|OTHER|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
219091198|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
219091199|NCT05861674|BIOLOGICAL|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
219091200|NCT05861674|BIOLOGICAL|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
219091201|NCT05861674|DRUG|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
219091202|NCT05995821|OTHER|Collection of biological specimens|Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
219091203|NCT03652259|GENETIC|SRP-9003|SRP-9003 will be administered through a single systemic injection.
219091204|NCT01849263|DRUG|Ibrutinib|Given PO
219091205|NCT01849263|OTHER|Laboratory Biomarker Analysis|Correlative studies
219091206|NCT05721235|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
219091207|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
219091208|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
219091209|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
219091210|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|Injection in the muscle
219091211|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|Injection in the muscle
219091212|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose|injection in the muscle
219091213|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose|Injection in the muscle
219091214|NCT06156423|OTHER|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
219091215|NCT06156423|OTHER|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
219682100|NCT02616198|OTHER|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
219682101|NCT02419599|OTHER|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
219091216|NCT02718274|DEVICE|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
219682102|NCT02419599|OTHER|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
219091217|NCT02718274|OTHER|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
219091218|NCT03401684|BEHAVIORAL|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
219091219|NCT00701038|DEVICE|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
219091220|NCT00439712|DRUG|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
219091221|NCT00439712|DRUG|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
219091222|NCT03079154|OTHER|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
219091223|NCT03079154|OTHER|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
219091224|NCT00038051|DRUG|Hum-195/rGel|Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
219091225|NCT00473070|DRUG|Tobradex AF|
219091226|NCT04547608|OTHER|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
219091227|NCT05000567|OTHER|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
219091228|NCT03873948|OTHER|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
219091229|NCT02469948|DRUG|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
219091230|NCT06011941|PROCEDURE|Modified laparoscopic transcystic biliary drainage|First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
219091231|NCT03094260|DEVICE|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
219091232|NCT03094260|DEVICE|Low intensity light therapy|"Treatment with light therapy in low intensity (\<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
219091233|NCT03246282|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
219091234|NCT03246282|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
219091235|NCT03246282|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
219091236|NCT06542536|DRUG|Monlunabant|Oral monlunabant
219091237|NCT06542536|DRUG|Placebo (monlunabant)|Oral placebo (monlunabant)
219091238|NCT03737838|DEVICE|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
219217450|NCT04099992|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
219217451|NCT04099992|BEHAVIORAL|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
219682103|NCT01710397|OTHER|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
219091239|NCT03661138|DRUG|Upadacitinib|Upadacitinib is administered orally.
219091240|NCT03661138|DRUG|Placebo for upadacitinib|Placebo is administered orally.
219091241|NCT03661138|DRUG|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
219091242|NCT01295450|DRUG|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
219091243|NCT01295450|DRUG|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
219091244|NCT01292551|DRUG|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
219091245|NCT01292551|DRUG|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
219091246|NCT05488132|DRUG|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
219217452|NCT04099992|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer tVNS twice per day for 8 weeks. tVNS is delivered using a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
219091247|NCT06580431|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
219217453|NCT04099992|DEVICE|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer sham-tVNS twice per day for 8 weeks. Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
219217454|NCT01675492|DEVICE|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
219217455|NCT06893770|BEHAVIORAL|Quran recital|standard treatment and care
219217456|NCT06893770|OTHER|standard treatment and care|standard treatment and care
219217457|NCT06842342|PROCEDURE|Lumber plexus block|LPB Group: All members of this group will receive ipsilateral lumber plexus after induction of general anesthesia. The LPB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
219217458|NCT06842342|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|ESB Group: All members of this group will receive ipsilateral sacral erector spinae block after induction of general anesthesia. The ESB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
219217459|NCT06842342|PROCEDURE|PENG Block|PENG block: All members of this group will receive PENG block in the supine position after general anesthesia, The PENG will be performed by using 40 ml mixture of, 20 mL of 0.5 bupivacaine,10 mL of 2% lidocaine, and 10 mL of normal saline.
219217460|NCT06847386|PROCEDURE|Hysterocopic metroplasty|If the uterine cavity is normal during intraoperative hysteroscopy, the operation will be finished and embryo transfer will be scheduled in 1 month after the operation; if the uterine cavity is narrowed or the uterine wall is coalesced, hysteroscopic metroplasty and IUD placement will be performed, and a second hysteroscopy with IUD retrieval will be performed after 2-month postoperative estrogen-progesterone treatment, then embryo transfer will be scheduled after 1-month estrogen-progesterone treatment.
219091248|NCT06579131|BEHAVIORAL|sitting position|The participants' seating positions will be assessed, and evaluations will be made based on this.
219091249|NCT03818282|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
219091250|NCT06144866|DRUG|Dabigatran, rivaroxaban, apixaban, edoxaban|For patients who received direct oral anticoagulants (DOAC) before ischemic stroke or intracranial hemorrhage, the DOAC level upon hospital arrival will be measured.
219091251|NCT06579898|OTHER|Progressive resistance exercise training|A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.
219217461|NCT06752889|OTHER|Group( 1): Control Group (pulpectomy using zic oxide eugenol based sealer Zical):|Zinc oxide eugenol based sealer (Zical) will be mixed into a thick paste and packed into the pulp chamber to fill the canal.
219217462|NCT06752889|OTHER|Group ( 2) Experimental group modified 3-MIX-TATIN):|Modified 3Mix-tatin will be prepared by mixing three commercially available antibiotics with simvastatin. This powder will be mixed with zinc oxide eugenol based sealer called Zical which will act as a carrier or vehicle to form a creamy paste of 3Mixtatin at the time of application
219217463|NCT06774092|OTHER|Data collection|Data collection
219091252|NCT03371082|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
219217464|NCT02510625|PROCEDURE|Anatomic Glenoid Reconstruction|Distal tibia bone graft
219217465|NCT02510625|PROCEDURE|Arthroscopic bankart Repair|Arthroscopic bankart Repair
219217466|NCT06828627|PROCEDURE|TLSA|"TLSA surgery procedure. (A) On the greater curvature of the stomach, the gastrocolic ligament is incised along the avascular area between the left and right gastric omentum vessels, and the gastric fundus is separated upward to the cardia to protect the vagus nerve.~(B) The cardia, lower esophagus, and diaphragm is exposed, and the confluence of the left and right crus of the diaphragm is revealed.~The retroperitoneum at the left and right crus of the diaphragm is incised, and the lower esophagus is dissociated for about 3-5 cm. The gastric fundus and the posterior wall of the esophagus are fully dissociated from the upper spleen. (C) Non-absorbable thread is used to intermittently suture the left and right crus of diaphragm in order to reconstruct the esophagus hiatus with a diameter of about 1.5 cm. (D) Then, the surgeon inserts the patch and fixes it on the crus of diaphragm if the hiatal hernia is larger than 5 cm or the diaphragm on both sides is weak. (E) A small incisio"
219091253|NCT03371082|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
219091254|NCT01064297|DRUG|Lamotrigine monotherapy|Lamotrigine monotherapy
219091255|NCT01064297|DRUG|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
219091256|NCT01064297|DRUG|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
219091257|NCT01229631|DIETARY_SUPPLEMENT|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
219091258|NCT01229631|DIETARY_SUPPLEMENT|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
219091259|NCT01722942|PROCEDURE|ICD implantation|ventricular ICD implantation
219091260|NCT01722942|DRUG|amiodarone hydrochloride|amiodarone prescription
219091261|NCT02615964|RADIATION|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
219091262|NCT02803554|OTHER|Plasma|Blood plasma from donors aged 25 years or younger
219091263|NCT00986076|DRUG|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
219091264|NCT00986076|DRUG|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
219091265|NCT02578979|DEVICE|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
219091266|NCT02578979|DEVICE|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
219091267|NCT03027648|PROCEDURE|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
219091268|NCT06185933|DRUG|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
219091269|NCT06185933|DRUG|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
219091270|NCT02161302|DEVICE|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
219091271|NCT02161302|DEVICE|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
219217467|NCT06828627|PROCEDURE|TBSA|Traditional bilateral surgical approach (TBSA) surgery procedure. (A) Separation is initiated from the avascular area of the lesser omentum, and the hepatic branch of vagus nerve is preserved as far as possible. Careful separation is performed upward to expose the right crus of diaphragm. (B) At the greater curvature of the stomach, two to three short gastric vessels are cut off to expose the left crus of diaphragm, and the space between the anterior and posterior of esophagus is dissociated. (C) The diaphragmatic esophageal membrane is incised and the lower part of the esophagus is dissociated about 4-5 cm, then the gastroesophageal valve flap is reformed and the His angle is restored. During the operation, it mainly protects the anterior and posterior trunk of the vagus nerve. The anterior and posterior trunk of the vagus nerve are mainly protected during the operation. (D) Both sides of the crus of the diaphragm are intermittently sutured with non-absorbable thread to reconst
219217468|NCT04699786|OTHER|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A \& C participants will receive their risk estimate about two weeks after consent is signed and Arms B\& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing \& demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A \& C will have extra surveys at twenty-four months post disclosure.
219217469|NCT06765486|OTHER|Lower limb resistance training|Exercise intervention with leg extensions on the dominant quadriceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
219091272|NCT03943784|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
219091273|NCT03943784|DRUG|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
219091274|NCT05964608|BEHAVIORAL|Behavioral Therapy|"Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
219091275|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
219217470|NCT06765486|OTHER|Upper limb resistance training|Exercise intervention with brachial biceps curl on the dominant brachial biceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
219217471|NCT06206252|OTHER|Medical Cannabis|Participants will be restricted to specific medical cannabis products from Ethos Dispensary. They will be randomized to one medical cannabis formulation (tincture or vaporization) for the duration of the study. Each month for three months, they will purchase a different composition (predominantly THC, predominantly CBD, or balanced products) of their designated formulation. The order of compositions will be randomized and double-blinded, so participants and the research team will not know which compositions of medical cannabis they are using each month.
219217472|NCT03718364|PROCEDURE|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
219217473|NCT05360849|BEHAVIORAL|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
219091276|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
219091277|NCT01276925|DEVICE|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
219091278|NCT01276925|PROCEDURE|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
219091279|NCT01276925|DRUG|Saline|Isotonic. 10 ml for the femoral nerve.
219091280|NCT01276925|PROCEDURE|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
219091281|NCT01276925|DRUG|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
219091282|NCT00032474|DRUG|Ginkgo biloba extract|
219091283|NCT01134146|RADIATION|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
219091284|NCT02428465|BEHAVIORAL|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
219091285|NCT03189784|OTHER|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
219091286|NCT05741957|BEHAVIORAL|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
219091287|NCT05741957|BEHAVIORAL|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
219091288|NCT05741957|OTHER|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
219091289|NCT04475432|DRUG|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
219091290|NCT04475432|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
219091291|NCT03369379|DRUG|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
219091292|NCT03369379|OTHER|Placebo|Placebo pill
219091293|NCT01353781|DRUG|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
219217474|NCT06822244|BEHAVIORAL|Pranayama exercise|"The people in the pranayama experimental group were first informed about the practice (At the deepest point of the breath, the left nostril is closed with the index finger of the right hand and exhaled through the right nostril. When it reaches the deepest point, close the nostril with the thumb and exhale through the left nostril. At least 3 more rounds are continued in this way.~one Pranayama session (approximately 30 minutes). The people in the experimental group were taught pranayama exercises during the application and were given a brochure with written instructions on home application and were info"
219217475|NCT06822244|BEHAVIORAL|normal breathing|normal breathing 20 breath per min
219217476|NCT06812195|DEVICE|Plate and nail|spinal anesthesia in supine position, lateral approach to the femur is used to do corrective osteotomies and introduction of nail according to preoperative plan. After that, plate is applied to lateral border to the femoral shaft
219217477|NCT06466798|DRUG|Nivolumab|Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
219217478|NCT06466798|DRUG|Methotrexate|2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
219091294|NCT05947929|OTHER|Aerobic excise|the treadmill exercises three times a week for 12 weeks) based on the Following protocol: Intensity exercise: determined by karvonen formula: Exercise heart rate = \[(A-B) × desired intensity\] + B \[A represents maximum heart rate (220-age) and B for resting heart rate (average of three measurements)\]. The desired intensity will be at 50- 70%. Heart rate was measured by pulse-meter to detect pulse rate before exercise (Resting HR)\].
219091295|NCT05947929|OTHER|acupuncture|the acupuncture needles will be inserted through the adhesive pads. The acupuncture needles used in the study are 40 mm in length and 0.30 mm in diameter and manufactured by Suzhou Hwato Medical Instruments Co. Ltd (Suzhou, China). The following acupoints will be used: DU20 (Baihui), ST36 (Zusanli), ST37 (Shangjuxu), SP6 (Sanyinjiao), ST25 (Tianshu), and LR3 (Taichong).
219091296|NCT07093905|PROCEDURE|arthroscopy of the shoulder rotator cuff|minimally invasive surgical procedure in which a camera (arthroscope) is inserted into the shoulder joint
219091297|NCT07093151|OTHER|Target SBP <160mmHg|For subjects assigned to the SBP \<160 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<160 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
219091298|NCT07093151|OTHER|Target SBP <140 mmHg|For subjects assigned to the SBP \<140 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<140 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
219091299|NCT07087990|DEVICE|Virtual Reality Glasses|articipants in the VR group used virtual reality glasses during coronary angiography to reduce anxiety and pain and improve satisfaction.
219091300|NCT07087990|OTHER|Stress Ball|articipants in the stress ball group used a stress ball during coronary angiography to evaluate its effects on anxiety, pain, and satisfaction.
219091301|NCT07094282|OTHER|Acupuncture|Integrative Medicine: Acupuncture treatment
219091302|NCT07094282|OTHER|myofascial therapy|Integrative Medicine: myofascial therapy to include transverse abdominus teaching, rectus abdominus release, functional neuromyofascial techniques, cupping, gua sha, active needling.
219091303|NCT07094282|OTHER|microcurrent therapy|Integrative Medicine: Microcurrent
219091304|NCT07094282|OTHER|LASER|Integrative Medicine: LASER
219091305|NCT07094282|OTHER|extracorporeal shockwave therapy|Integrative Medicine: Extracorporeal shockwave therapy
219091306|NCT07094282|OTHER|Pulsed electromagnetic therapies|Integrative Medicine: Pulsed electromagnetic therapies
219091307|NCT07094282|OTHER|Miscellaneous integrative medicine|other integrative medicine modalities
219091308|NCT07094100|DEVICE|Tissue engineered cartilage|Cartilage constructed by autologous bone marrow mesenchymal stem cells
219091309|NCT05303493|BIOLOGICAL|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
219091310|NCT06931652|DRUG|Epcoritamab|Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase.
219091311|NCT00766675|DRUG|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
219091312|NCT00766675|DRUG|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
219091313|NCT05795413|PROCEDURE|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
219217479|NCT06466798|DRUG|5-Azacytidine|10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
219091314|NCT05795413|DRUG|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
219091315|NCT05673239|DRUG|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
219091316|NCT03099330|DRUG|TQ-B3139|TQ-B3139 p.o. qd
219091317|NCT01974115|DEVICE|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
219217480|NCT06822582|BEHAVIORAL|Pelvic Health Module|Telerehabilitation program involving pelvic floor exercises, education and counselling.
219217481|NCT06881927|DRUG|Hydrocortisone Hemisuccinate: 200 mg per day.|The hydrocortisone hemisuccinate is a powder and solvent for injectable solution at 100 mg. The powder must be dissolved in the solvent to ensure final isotonicity. The solution must be used within 24 hours. The injection is performed as a slow direct IV injection, either via an electric syringe pump or as a bolus of 50 mg every 6 hours
219217482|NCT06881927|OTHER|reduction of the level of immunosuppression|"In this arm, the usual immunosuppressive treatment of the patients will be discontinued.~Patients will receive hydrocortisone hemisuccinate 200 mg per day (slow direct intraveinous injection of 50 mg four times a day, or through an electric syringe pump)."
219217483|NCT06810050|DRUG|CGB-500 with 0.5% tofacitinib|CGB-500 is a proprietary ointment formulation
219217484|NCT06810050|DRUG|CGB-500 Ointment with 1% tofacitinib|CGB-500 is a proprietary ointment formulation
219217485|NCT06810050|DRUG|Vehicle (placebo)|placebo ointment
219217486|NCT06750926|DIAGNOSTIC_TEST|video image through laryngeal mask specific channel|patients placed SaCoVLM will be checked the proper position of placement by native camera through specific video channel and fiberoptic endoscopy through ventilation channel perspectively
219682104|NCT05827692|BEHAVIORAL|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
219091318|NCT04660422|OTHER|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
219091319|NCT04660422|OTHER|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
219091320|NCT04660422|OTHER|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
219091321|NCT04660422|OTHER|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
219091322|NCT00150774|DRUG|Levetiracetam|
219091323|NCT02163590|OTHER|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
219091324|NCT02163590|OTHER|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
219091325|NCT02163590|OTHER|Placebo|Intervention that mimics the experimental procedures
219091326|NCT01514214|DEVICE|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
219091327|NCT01514214|DEVICE|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
219091328|NCT06240052|BEHAVIORAL|Conditioning and active avoidance paradigm (CAAP)|On day 1 subjects will undergo image viewing, fear conditioning, and avoidance learning. Subjects will be instructed to passively view the images from 3 categories on the screen, with 2 of the 3 categories being paired with a mild shock to the subjects' foot. Then they will see a picture of a button on the screen together with all three categories. If they press the button, they may prevent the shock from occurring. Pressing the button for one of the conditioned categories will prevent the shock from happening. Pressing the button to the other conditioned cue will not prevent the shock .Pressing the button to the third category does nothing. On day 2, subjects will be given $5 and will be told that they can press a button to avoid a shock. The number of times the button was pressed will be counted and if it is less than the number by another randomly selected participant then the participant will get to keep the money.
219091329|NCT06219889|BEHAVIORAL|Frequency of neurochecks|the frequency with which a patient is awakened to perform serial examinations
219091330|NCT05177510|DRUG|Mifepristone|Progestin Antagonist
219091331|NCT05177510|DRUG|Placebo|Placebo
219217487|NCT05025384|OTHER|Acupressure|"Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation."
219217488|NCT06235411|DRUG|Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
219217489|NCT06235411|DRUG|Inactive Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
219217490|NCT06235411|OTHER|Electroencephalogram|"* Rest EEG prior to first treatment administration~* EEG during first treatment administration~* Rest EEG during integration session after second treatment administration"
219217491|NCT06235411|OTHER|Blood samples for the analysis of immune and inflammatory profiles|Three 7ml EDTA tubes will be taken in the morning on an empty stomach at day 0 and at 3 weeks.
219682105|NCT01093586|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo transplantation
219217492|NCT06235411|OTHER|stool samples|Stool sampling at day 0 and 3 weeks Analysis of intestinal microbiota is carried out on a stool sample, which is stored at -20°C for a maximum of 24 hours. The sample is then transferred cold to the CRB of the Nîmes University Hospital, where it is stored at -80°C until the microbiology laboratory can perform a group analysis.
219217493|NCT06235411|OTHER|MRI functional and cerebral|MRI functional and cerebral at day 0 and 3 weeks
219091332|NCT06229457|BEHAVIORAL|Girls PLAY program|Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
219091333|NCT06487091|DIAGNOSTIC_TEST|Analysis of platelet function|Blood withdrawal, platelet separation and analysis of the expression levels of markers of platelet function
219091334|NCT05954156|OTHER|Injectable restorative resin composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
219091335|NCT05954156|OTHER|Dual cured resin cement|Resin cements are widely used due to their strong adhesion, and compatibility with various restorative materials, including ceramics and zirconia. They bond to enamel and dentin through functional monomers such as MDP, and 4-META, forming a stable hybrid layer. Based on their bonding mechanism, resin cements are classified as adhesive or self-adhesive, while their polymerization method -chemical, light, or dual-cure-allows for versatility in clinical applications
219091336|NCT03592225|BEHAVIORAL|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
219091337|NCT00286000|DRUG|Administration of high dose simplified folfiri|
219091338|NCT05064787|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
219091339|NCT03007784|DEVICE|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
219217494|NCT05961553|BEHAVIORAL|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
219217495|NCT05961553|OTHER|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
219217496|NCT06619613|BIOLOGICAL|Alzheimer Disease (AD)|CM383 injection
219217497|NCT06619613|OTHER|Placebo|Matched placebo
219217498|NCT05575752|OTHER|high temperature (32℃) group|The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
219217499|NCT05575752|OTHER|moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
219217500|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
219217501|NCT06471504|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
219217502|NCT02781857|OTHER|No intervention|
219217503|NCT05431946|BEHAVIORAL|Advance Care Planning and the consequent actions|"The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities"
219217504|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
219682106|NCT01093586|OTHER|cytogenetic analysis|Correlative studies
219682107|NCT01093586|PROCEDURE|bone marrow aspiration|Correlative studies
219682108|NCT01093586|OTHER|fluorescence in situ hybridization|Correlative studies
219682109|NCT01093586|DRUG|busulfan|Given orally
219217505|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
219217506|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
219682110|NCT01093586|DRUG|cyclophosphamide|Given IV
219682111|NCT01093586|DRUG|anti-thymocyte globulin|Given IV
219217507|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
219217508|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
219217509|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
219217510|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
219217511|NCT02045381|PROCEDURE|MRI Group|A single research MRI
219217512|NCT03312920|DEVICE|active anodal tDCS|active anodal tDCS with memory task
219217513|NCT03312920|DEVICE|sham tDCS|sham tDCS with memory task
219217514|NCT03312920|DEVICE|active cathodal tDCS|active cathodal tDCS with memory task
219217515|NCT06214819|DEVICE|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
219217516|NCT06214819|DEVICE|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
219217517|NCT06749340|OTHER|Assigned Interventions|"Psychometric Hepatic Encephalopathy Scoring (PHES) Test~* Digit Symbol Test~* Number Combination Test-A~* Number Combination Test-B~* Serial Punctuation Test~* Line Drawing Test~  6 Minute Walk Test~  5 Times Sit and Stand Test~Manual Muscle Test~Hand Grip Strength Test~Quadriceps muscle thickness measurement with ultrasonography~All evaluations will be repeated 5 times."
219217518|NCT06749340|OTHER|Face-to-face Exercise|Participants will undergo exercise sessions 3 days a week for 12 weeks. Sessions will include a warm-up, upper and lower extremity strengthening (1/3 set - 8/12 repetitions) and cool-down program. Theraband will be used in strengthening exercises. Theraband offers different resistance levels with its different colors. In order from lightest to heaviest; skin color, yellow, red, green, blue, black, grey, gold. Exercises (theraband color, intensity, number of sets and repetitions) will be made into a personalized program according to the tolerance level of the participants in the first session. Exercise intensity will be determined using the OMNI - Resistance Exercise Scale (OMNI - RES). The warm-up and cool-down periods in the exercise program will be carried out at levels 9 - 12 according to the Borg Scale.
219217519|NCT06749340|OTHER|Home-based Exercise|Participants will follow the same program as in the face-to-face exercise group. The first meeting with the participants will be held face to face and the details of the study will be explained. Home-based exercises will be carried out with the Fiziu (Fiziu Sağlık Hizmetleri Teknoloji A.Ş., Istanbul, Türkiye) program and the exercise program will be delivered to the participants through this program. Therabands with which the participants will do their exercises will be provided by the researchers. The progression program will be determined in line with the difficulty and effort felt by the participants through weekly meetings.
219217520|NCT06749340|OTHER|Control|Participants assigned to the control group will have the same evaluation sessions as participants assigned to the experimental groups. The first evaluation will be made at the beginning of the study, the second evaluation after the 8-week period, the third evaluation after the 12-week period, the fourth evaluation after the 6-month follow-up, and the fifth evaluation after the 12-month follow-up. Participants who will not be included in any study sessions during this process will be included in the study program that appears to be effective as a result of the study. Participants in this group will be offered the program recommended by the US Office of Disease Prevention and Health Promotion and used in individuals who have previously had a liver transplant. This program consists of aerobic exercises (walking, cycling, etc.) starting from 60-65% of the maximum heart rate and progressing to 75-80%.
219217521|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
219217522|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
219682112|NCT01093586|DRUG|methylprednisolone|Given IV
219682113|NCT01093586|DRUG|cyclosporine|Given IV
219682114|NCT01093586|DRUG|mycophenolate mofetil|Given orally or IV
219682115|NCT01093586|OTHER|flow cytometry|Correlative studies
219682116|NCT01093586|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
219682117|NCT01867320|DRUG|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
219682118|NCT02949882|DIETARY_SUPPLEMENT|Yakult|Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
219682119|NCT02949882|DIETARY_SUPPLEMENT|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
219682120|NCT05873270|OTHER|Wrist and ankle acupuncture|Patients in the intervention arm started the wrist and ankle acupuncture treatment 1 day before the surgery. Take up and down 1,2 area as a needle point, use hua tuo brand sterile acupuncture needle (specification: 0.25mm 25mm), into the skin disinfection into the needle, keep 30 subcutaneous needle and skin, when the operator under the needle, patients without acid swelling, pain, close to the skin dermis, to about 1.5 inches, give tape fixed 24h, left under the skin, until postoperative 3 day.
219682121|NCT06117722|OTHER|Eplerenone torasemide in chronic heart failure|Heart Failure patients treated with eplerenone and torasemide
219217523|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
219217524|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
219217525|NCT06754007|PROCEDURE|ROPES Training Programme|ROPES is a training programme that involves resistance training, whole-body exercises and HIIT aerobic sessions with each session lasting no longer than 45 minutes.
219217526|NCT06809374|DRUG|gemcitabine|neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel
219217527|NCT06465576|DRUG|Solifenacin|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
219091340|NCT04117269|DEVICE|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
219091341|NCT06178783|DRUG|Brensocatib|Brensocatib oral solutions will be expectorated following the tasting.
219091342|NCT01936896|DRUG|Alpha 1-Antitrypsin|
219091343|NCT02597907|DRUG|aprepitant|aprepitant 80 mg is given to all patients before surgery
219091344|NCT02597907|DRUG|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
219091345|NCT02597907|DRUG|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
219091346|NCT06063122|DEVICE|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
219091347|NCT01303120|DRUG|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
219217528|NCT06465576|DRUG|Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
219217529|NCT06465576|DRUG|Solifenacin + Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
219217530|NCT06777563|BEHAVIORAL|Brief psychological counselling and health education|This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
219217531|NCT06777563|BEHAVIORAL|2 Weeks of Ecological Momentary Assessment (EMA)|The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.
219217532|NCT06777563|BEHAVIORAL|10 weeks of mobile health psychological support|A total of 20 regular instant messages (e.g., via WhatsApp) personalised by baseline demographic characteristics (current pregnancy details, history of postpartum mental illness) and results of EMA will be sent to the participants in multi-media formats.
219217533|NCT06777563|BEHAVIORAL|CBT-guided telephone counselling booster|A 45-minute telephone counselling based on CBT.
219217534|NCT06649500|OTHER|Treadmill|The Walker View system is a treadmill equipped with a loaded cell sensor belt and a 3D camera that allows you to detect every single angular movement of the subject. Furthermore, thanks to the two optics, a classic one for 2D shooting in high resolution, and a revolutionary one for infrared rays, it is possible to reconstruct the position of the subject in space in three-dimensional mode and in real time. The reflected image reconstructed by the system helps to improve movement through the \&#34;continuous feedback system\&#34; method.
219217535|NCT06649500|OTHER|conventional therapy|Conventional therapy intervention will follow the usual treatment according to current clinical practice. This treatment will be delivered to patients in a group session in order the balance disorders.
219217536|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
219682122|NCT01560026|PROCEDURE|surgery|endometrial cancer with or without oophorectomy
219091348|NCT01303120|DRUG|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
219091349|NCT01303120|DRUG|Patient-controlled analgesia|Patient controlled analgesia with morphine
219091350|NCT06397274|BIOLOGICAL|Stemchymal|Patients will receive Stemchymal® through intravenous infusion
219091351|NCT06397274|BIOLOGICAL|Placebo|Patients will receive Placebo through intravenous infusion
219091352|NCT05194189|DRUG|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
219091353|NCT05194189|DRUG|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
219091354|NCT04872244|DEVICE|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
219091355|NCT04872244|DRUG|Levonorgestrel Drug Implant Product|intrauterine administration
219091356|NCT02063100|DRUG|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
219091357|NCT02063100|DRUG|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
219091358|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
219091359|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
219091360|NCT02063100|DRUG|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
219091361|NCT02060591|DRUG|Exparel|
219091362|NCT02060591|DRUG|Marcaine|
219091363|NCT01879423|DRUG|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
219091364|NCT01879423|DRUG|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
219091365|NCT04458584|PROCEDURE|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
219091366|NCT04458584|PROCEDURE|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
219091367|NCT04458584|PROCEDURE|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
219217537|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
219217538|NCT05908955|PROCEDURE|PVI|pulmonary vein isolation
219217539|NCT05908955|PROCEDURE|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
219550260|NCT02535923|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
219091368|NCT05464381|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
219091369|NCT05464381|DRUG|Placebo|Placebo
219091370|NCT03897062|DRUG|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
219091371|NCT03897062|OTHER|placebo|Placebo controlled double blind suvorexant vs placebo
219091372|NCT04962399|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
219091373|NCT02357030|DRUG|Methyl-P plus GWI Nutrient Formula|"Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily"
219091374|NCT00926510|BEHAVIORAL|Language toolkit|Simple toolkit of interactive things to stimulate language.
219091375|NCT00926510|BEHAVIORAL|Safety counseling|Smoke detector and general safety counseling
219091376|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
219091377|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
219091378|NCT06491251|PROCEDURE|Bilateral Subinguinal microscopic varicocelectomy|Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
219091379|NCT03784690|OTHER|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
219217540|NCT06205550|DRUG|Flecainide|Flecainide monotherapy
219217541|NCT06205550|DRUG|Flecainide + beta-blocker|Flecainide + beta-blocker
219217542|NCT06832124|PROCEDURE|Sham alpha-tACS|A sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with in-phase stimulation at parieto-occipital brain areas and anti-phase stimulation in frontal brain areas. The stimulation will involve a 10s ramp-up, followed by an immediate 10s ramp-down (no stimulation afterwards).
219217543|NCT06832124|PROCEDURE|alpha-tACS|Active tACS with a sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with a 10s ramp-up and 10s ramp-down after stimulation. In-phase stimulation will be applied to parieto-occipital brain areas and anti-phase stimulation will be applied to frontal brain areas
219091380|NCT03784690|OTHER|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
219091381|NCT00101127|BIOLOGICAL|filgrastim|
219091382|NCT00101127|BIOLOGICAL|pegfilgrastim|
219091383|NCT00101127|DRUG|docetaxel|
219091384|NCT00101127|DRUG|gemcitabine hydrochloride|
219091385|NCT05153460|DEVICE|Telemetry and manual monitoring vs Contactless monitoring devices|"All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
219091386|NCT02235467|BEHAVIORAL|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
219091387|NCT04916119|DRUG|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
219091388|NCT02427789|OTHER|Physical Exercise|physical exercise
219091389|NCT02789683|OTHER|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
219091390|NCT02789683|OTHER|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
219091391|NCT02789683|OTHER|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
219217544|NCT06776770|DRUG|Adebrelimab|"Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14."
219217545|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
219217546|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait parameters.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure the gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
219682123|NCT03442088|DRUG|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
219682124|NCT00105989|DRUG|Duloxetine|
219682125|NCT00105989|DRUG|placebo|
219682126|NCT05926141|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
219682127|NCT00817388|OTHER|No intervention|No intervention
219682128|NCT00357877|DRUG|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
219682129|NCT00357877|OTHER|Placebo|
219091392|NCT01560325|DRUG|CKD-516 inj.|CKD-516: 3.3\~13mg/m2/day
219091393|NCT03586583|DEVICE|FBP|Old processing
219091394|NCT03586583|DEVICE|ISR|New processing
219091395|NCT01073670|DRUG|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
219091396|NCT01073670|DRUG|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
219091397|NCT01073670|DRUG|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
219091398|NCT04479033|OTHER|Multidisciplinary collaborative model of community care management|An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
219091399|NCT05050578|DEVICE|Lehfilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
219091400|NCT05050578|DEVICE|Senofilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
219091401|NCT05050578|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
219091402|NCT01558310|DRUG|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
219091403|NCT01558310|DRUG|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
219091404|NCT04607655|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
219091405|NCT04607655|DRUG|Placebo|Placebo is administered as inhalation once a day
219091406|NCT00172354|DRUG|Hydrocortisone|
219091407|NCT04682119|DRUG|LY3526318|Administered orally.
219217547|NCT06759181|DRUG|anti-BCMA/FcRL5 CAR T|"anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:"
219217548|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
219217549|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
219217550|NCT06747923|DRUG|SB17170|Taking SB17170 orally once a day
219217551|NCT06747923|DRUG|Placebo|Taking Placebo orally once a day
219217552|NCT05885763|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
219217553|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
219217554|NCT06446284|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
219217555|NCT06446284|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
219217556|NCT05360329|PROCEDURE|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
219217557|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
219217558|NCT05578976|DRUG|Epcoritamab|Subcutaneous Injection (SC)
219217559|NCT05578976|DRUG|Cyclophosphamide|Intravenous (IV) Injection
219217560|NCT05578976|DRUG|Rituximab|IV Infusion
219217561|NCT05578976|DRUG|Vincristine|IV Infusion
219682130|NCT05678439|DIETARY_SUPPLEMENT|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
219091408|NCT04682119|DRUG|Placebo|Administered orally.
219091409|NCT01073904|DRUG|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
219091410|NCT01073904|DRUG|Postinor 2|Single dose of 1.5 mg tablet
219091411|NCT03386032|DRUG|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
219217562|NCT05578976|DRUG|Doxorubicin|IV Infusion
219217563|NCT05578976|DRUG|Prednisone|Oral; Tablet
219217564|NCT03011541|PROCEDURE|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
219217565|NCT06778694|OTHER|Motor control exercises|Bridging Dead bug Plank Pelvic tilts Squatting and lunges
219217566|NCT06778694|OTHER|Isolated strengthening lumbar exercises|Child pose Mckenzie Lat pull down Russian twist
219217567|NCT06778980|OTHER|The chin tuck posture|A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
219217568|NCT06772272|DRUG|Roxadustat|Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
219091412|NCT03386032|DRUG|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
219091413|NCT03386032|OTHER|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
219091414|NCT01003457|OTHER|ultrasonography|transvaginal ultrasonography of bladder wall thickness
219091415|NCT03753295|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
219091416|NCT05362552|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
219091417|NCT03364348|DRUG|Utomilumab|Given IV
219091418|NCT03364348|DRUG|Trastuzumab|Given IV
219091419|NCT03364348|DRUG|Ado-Trastuzumab Emtansine|Given IV
219091420|NCT00004884|DRUG|cisplatin|
219091421|NCT00004884|DRUG|docetaxel|
219091422|NCT00004884|DRUG|gemcitabine hydrochloride|
219091423|NCT06212648|DRUG|SPC1001 High|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091424|NCT06212648|DRUG|SPC1001 Mid1|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091425|NCT06212648|DRUG|SPC1001 Mid2|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091426|NCT06212648|DRUG|SPC1001 Low|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091427|NCT06212648|DRUG|SPC3001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091428|NCT06212648|DRUG|SPC4001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091429|NCT06212648|DRUG|SPC4002|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091430|NCT06212648|DRUG|Placebo|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
219091431|NCT04532723|DEVICE|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
219091432|NCT01768832|BEHAVIORAL|Treadmill|
219091433|NCT01768832|BEHAVIORAL|Tango|
219091434|NCT01768832|BEHAVIORAL|Stretching|
219091435|NCT05917704|OTHER|Guitar then physical therapy|See arm/group descriptions
219091436|NCT05917704|OTHER|Physical therapy then guitar|See arm/group descriptions
219091437|NCT00336843|DRUG|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
219091438|NCT03710525|OTHER|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
219091439|NCT03710525|OTHER|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
219091440|NCT02581332|BEHAVIORAL|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
219091441|NCT02145325|DRUG|Expanded Tregs|
219091442|NCT03319511|OTHER|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
219091443|NCT03319511|OTHER|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
219091444|NCT03852238|OTHER|Blood test and self-administrated questionnaires|
219091445|NCT03323619|PROCEDURE|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
219091446|NCT03873220|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
219091447|NCT03873220|DEVICE|Sleep Monitor|Remote Sensor
219217569|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
219217570|NCT06800781|PROCEDURE|Prolonged treatment with posterior pericardial chest tube plus standard care|Prolonged treatment with posterior pericardial chest tube plus standard care All patients will receive chest tubes based on each surgeon's preference. Usually, 1 or 2 tubes are inserted in the mediastinum, and 1 is inserted into each open pleural cavity. Patients in the intervention arm will receive an additional posterior 20Ch chest tube. In cases where the surgeon routinely inserts 2 mediastinal chest tubes, they will use 1-2 anterior mediastinal tubes in the intervention group, based on their preference. The posterior chest tube will be positioned between the inferior aspect of the heart and the pericardium and connected to an active suction system per routine. Once the remaining chest tubes are extracted, the posterior chest tube will remain positioned in the pericardium and be reconnected from active suction to a collection bag for passive drainage. The chest tube will be removed on postoperative Day 3 or when chest tube output is \<50 mL/24 h.
219091448|NCT03873220|DEVICE|Polysomnography|Sleep Monitor
219217571|NCT05881265|DRUG|Chidamide+venetoclax|Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
219091449|NCT03873220|DEVICE|Videography|Thermal Camera
219091450|NCT01170338|DRUG|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
219091451|NCT01170338|DRUG|control|this is the placebo that will help us maintain a blinded study
219091452|NCT01910623|OTHER|Health Related Quality of Life (HRQOL) measures|
219091453|NCT04358692|DEVICE|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
219091454|NCT00146614|DRUG|Sirolimus|
219091455|NCT00146614|DRUG|Tacrolimus|
219091456|NCT00146614|DRUG|Methotrexate|
219091457|NCT00146614|PROCEDURE|Stem Cell Transplantation|
219091458|NCT06423963|BEHAVIORAL|Physical Activity|Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.
219217572|NCT03054831|DRUG|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
219217573|NCT06239896|BEHAVIORAL|Facilitated Group ACP Session|Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
219217574|NCT06239896|BEHAVIORAL|Facilitated one-on-one ACP visits|Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
219217575|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
219091459|NCT06423963|BEHAVIORAL|Nutrition Counseling|Participants will receive nutritional counseling with a registered dietician.
219091460|NCT06423963|BEHAVIORAL|Resistance Training|Participants will engage in progressive, full-body resistance training based on American College of Sports Medicine (ACSM) guidelines.
219091461|NCT02128646|DRUG|EXPAREL|
219091462|NCT02128646|DRUG|Ketorolac|
219091463|NCT02128646|PROCEDURE|laparoscopic abdominal hernia repair|
219091464|NCT02128646|PROCEDURE|an open surgery for abdominal hernia repair|
219091465|NCT06472076|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219091466|NCT06472076|BIOLOGICAL|Belrestotug|Belrestotug will be administered.
219091467|NCT06472076|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
219091468|NCT06472076|DRUG|Placebo|Placebo will be administered.
219091469|NCT02347644|BEHAVIORAL|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action"
219091470|NCT04029701|DRUG|Ruyizhenbao Pill|Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
219091471|NCT04029701|DRUG|Placebo of Ruyizhenbao Pill|Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
219091472|NCT00664898|DRUG|bortezomib|Escalating intravenous repeating dose
219091473|NCT00664898|DRUG|SGN-40|Escalating intravenous repeating dose
219091474|NCT04894526|OTHER|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
219091475|NCT04894526|OTHER|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
219217576|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
219217577|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
219091476|NCT01410370|RADIATION|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
219091477|NCT01410370|DRUG|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
219091478|NCT02943941|OTHER|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
219091479|NCT05320055|PROCEDURE|robotic repair|robotic assisted retromuscular hernia repair
219091480|NCT02103621|BEHAVIORAL|Unified Protocol (UP)|
219091481|NCT02103621|BEHAVIORAL|Taper and Monitoring (TAP-M)|
219091482|NCT00182962|BEHAVIORAL|Geriatric Resources for Assessment & Care of Elders (GRACE)|
219091483|NCT00267410|BEHAVIORAL|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
219091484|NCT04563650|BIOLOGICAL|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
219217578|NCT06829134|PROCEDURE|laparoscopic renal artery perivascular nerve blockade|"1. When only the main renal artery is present: The complete dissection of the renal artery should be performed in the distal 2/3 portion, close to the renal hilum. The connective tissue and nerve tissue within a 1 cm radius from the center of the renal artery lumen must be completely separated (using instruments such as an ultrasonic scalpel or monopolar hook, etc.). The length of the dissected renal artery should be at least 0.5 cm, forming a dissection ring.~2. When accessory renal arteries are present: In addition to the main renal artery meeting the aforementioned standards, the accessory renal arteries must also be dissected. The radius of the dissection ring should be 0.7 cm, with a length ranging from 0.3 to 0.5 cm.~3. When renal polar arteries are present: Dissection may be performed appropriately based on the surgical conditions.~4. The prerequisite is to ensure the safety of the surgery, specifically the safe resection of the primary lesion."
219217579|NCT06829134|PROCEDURE|surgery related to the primary disease|The surgeries related to the primary disease include laparoscopic partial nephrectomy, laparoscopic adrenalectomy, and other similar procedures.
219217580|NCT05829824|BEHAVIORAL|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
219217581|NCT05829824|OTHER|AutoReach|Phone call / SMS Text
219217582|NCT05829824|PROCEDURE|Biospecimen samples|Optional saliva sample
219217583|NCT06320041|DRUG|Low dose oxelidine group|Analgesic dose
219217584|NCT06320041|DRUG|High dose oxelidine group|Analgesic dose
219217585|NCT06320041|DRUG|Hydromorphone group|Analgesic dose
219217586|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants A|Peer participants in group A will self select a peer coach and will be contacted weekly by peer coaches.
219217587|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants B|Peer participants in group B will self select a peer coach and will be contacted bi-weekly by peer coaches.
219217588|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants C|Peer participants in group C will be matched with a peer coach and will be contacted weekly by peer coaches.
219217589|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants D|Peer participants in group D will be matched with a peer coach and will be contacted bi-weekly by peer coaches.
219091485|NCT04035213|BEHAVIORAL|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
219217590|NCT05127161|BEHAVIORAL|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
219682131|NCT05678439|OTHER|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
219091486|NCT00500864|DRUG|Magnesium Sulfate 2 grams|
219091487|NCT03960632|DIAGNOSTIC_TEST|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
219091488|NCT03183102|DIETARY_SUPPLEMENT|Flaxseed|2 months of dietary flaxseed supplementation
219091489|NCT01402596|DRUG|Midazolam|0,4 mg per kg - intranasal midazolam - once
219091490|NCT01402596|DRUG|Chloral Hydrate|50 mg per kg, rectal
219091491|NCT05751031|DRUG|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
219091492|NCT06738368|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
219091493|NCT06738368|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219091494|NCT06738368|PROCEDURE|Bone Marrow Collection|Undergo bone marrow sample collection
219091495|NCT06738368|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219091496|NCT06738368|DRUG|Cyclophosphamide|Given IV
219091497|NCT06738368|DRUG|Doxorubicin|Given CIV
219091498|NCT06738368|DRUG|Etoposide|Given CIV
219217591|NCT06839898|DEVICE|EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm|The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
219091499|NCT06738368|BIOLOGICAL|Filgrastim|Given SC
219091500|NCT06738368|BIOLOGICAL|Pegfilgrastim|Given SC
219091501|NCT06738368|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219091502|NCT06738368|DRUG|Prednisone|Given PO
219091503|NCT06738368|BIOLOGICAL|Rituximab|Given IV
219091504|NCT06738368|DRUG|Vincristine|Given CIV
219091505|NCT00111748|DRUG|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
219217592|NCT06839898|DEVICE|Visian® Toric ICL Treatment Arm|The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
219217593|NCT03268421|BEHAVIORAL|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
219217594|NCT03268421|BEHAVIORAL|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
219091506|NCT00654810|BEHAVIORAL|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
219091507|NCT02301351|OTHER|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
219091508|NCT02301351|OTHER|Text Warning Label|All packs provided will include standard text warning labels
219217595|NCT03268421|BEHAVIORAL|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
219091509|NCT05273970|OTHER|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
219091510|NCT01774747|DRUG|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
219091511|NCT01774747|DRUG|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
219091512|NCT00832767|PROCEDURE|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
219091513|NCT00832767|PROCEDURE|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
219091514|NCT05177406|OTHER|Aimovig|patients newly initiating Aimovig therapy
219091515|NCT02940574|DRUG|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
219217596|NCT00667121|DRUG|citalopram hydrobromide|
219217597|NCT00667121|DRUG|escitalopram oxalate|
219217598|NCT00667121|DRUG|gabapentin|
219091516|NCT02940574|OTHER|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
219091517|NCT02798510|RADIATION|Concurrent Chemoradiotherapy|
219091518|NCT02798510|DRUG|capecitabine|
219091519|NCT02798510|DRUG|gemcitabine|
219091520|NCT06132555|OTHER|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
219217599|NCT00667121|DRUG|sertraline hydrochloride|
219217600|NCT00667121|DRUG|tamoxifen citrate|
219217601|NCT00667121|DRUG|venlafaxine|
219217602|NCT00667121|GENETIC|molecular genetic technique|
219217603|NCT00667121|OTHER|high performance liquid chromatography|
219217604|NCT00667121|OTHER|laboratory biomarker analysis|
219217605|NCT00667121|OTHER|pharmacological study|
219217606|NCT00667121|PROCEDURE|adjuvant therapy|
219091521|NCT06132555|OTHER|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
219091522|NCT06132555|OTHER|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
219217607|NCT06831123|BEHAVIORAL|L2B|a 6-session, group-based intervention that helps youth develop mindfulness skills
219217608|NCT06831123|BEHAVIORAL|L2B + App|the Learning to Breathe plus App condition, the 6-session L2B intervention augmented by a mobile application designed to support the use of mindfulness skills in daily life
219217609|NCT06831123|BEHAVIORAL|skills for success|a 6-session life skills intervention designed to support decision making and healthy relationships
219217610|NCT05038709|DEVICE|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
219217611|NCT06812949|DIAGNOSTIC_TEST|PEEP Titration with Echocardiographic, Hemodynamic, and Ventilatory Measurements|This intervention consists of clinical recruitment maneuvers performed in mechanically ventilated patients by adjusting positive end-expiratory pressure (PEEP) at two levels: low PEEP (5 cmH₂O) and high PEEP (15 cmH₂O). Throughout these maneuvers, echocardiographic imaging, hemodynamic assessments, and ventilatory measurements are performed to evaluate the cardiorespiratory effects of PEEP adjustments. Transthoracic echocardiography (TTE) is used to assess right ventricular function, pulmonary pressures, and venous congestion, while mechanical ventilator parameters are recorded to monitor lung mechanics and compliance.
219217612|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
219217613|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
219217614|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
219682132|NCT04668209|DRUG|Silmitasertib|Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
219682133|NCT00738855|OTHER|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
219682134|NCT00738855|OTHER|Nothing per os|A nasogastric tube
219682135|NCT03147950|PROCEDURE|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
219682136|NCT03147950|PROCEDURE|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
219091523|NCT00387894|DRUG|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
219217615|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
219217616|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
219217617|NCT06823921|OTHER|Exercise|HIIT will include aerobic, strength, and balance exercises and boxing
219217618|NCT06797284|DEVICE|Transcranial Magnetic Stimulation|repetitive transcranial magnetic stimulation, or transcranial direct current stimulation, or daytime timed bright light exposure
219091524|NCT03268239|DEVICE|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~* 3D T1 GRE after injection (Gradient-Recalled Echo)~* 3D T1 TSE before injection (Turbo Spin Echo)~* 3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
219091525|NCT06330584|DRUG|Placebo Nasal Spray 0 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound"
219091526|NCT06330584|DRUG|Midazolam Nasal Spray 0.45 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg"
219091527|NCT06330584|DRUG|Midazolam Nasal Spray 0.9 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg"
219091528|NCT05639543|DRUG|INT-787|Blinded Study Drug
219091529|NCT05639543|DRUG|Placebo|Placebo
219091530|NCT01493505|DRUG|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
219091531|NCT01493505|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
219091532|NCT01493505|DRUG|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
219091533|NCT01493505|DRUG|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
219091534|NCT06221423|DRUG|Fruquintinib Combined With TAS-102|Fruquintinib Combined With TAS-102
219091535|NCT00794638|DRUG|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
219091536|NCT00794638|DRUG|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
219091537|NCT05057689|DRUG|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
219091538|NCT05057689|DRUG|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
219091539|NCT05057689|DRUG|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
219091540|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
219091541|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
219091542|NCT00714922|PROCEDURE|PRK|Laser refractive surgery
219091543|NCT00714922|PROCEDURE|SBK|Laser refractive surgery
219091544|NCT04360850|BEHAVIORAL|online survey|A brief survey for therapists to fill out
219217619|NCT04049890|OTHER|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
219217620|NCT04049890|OTHER|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
219217621|NCT04049890|OTHER|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
219091545|NCT03525548|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
219217622|NCT06830564|DRUG|we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of nalbuphine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using paediatric anaesthesia Emergence delirium scale (PAEDS)
219217623|NCT06830564|DRUG|we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of dexmedetomidine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using pediatric anesthesia Emergence delirium scale (PAEDS) .
219217624|NCT06814821|OTHER|Web-based rehabilitation|Participants perform their rehabilitation independently with the instructions from the web-based platform.
219217625|NCT06814821|OTHER|Standard rehabilitation|Participants attend physical visits at the clinic to get instructions and support in their rehabilitation. Written and verbal instructions will be given.
219217626|NCT05310734|DRUG|Spinosad Topical|A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
219217627|NCT06667817|BEHAVIORAL|Exercise|16 weeks of exercise training (Exercise Group) will be prescribed via a smart phone application. Results from this group will be compared to results of the sedentary control group.
219217628|NCT05913752|DRUG|CMND-100|The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
219217629|NCT06831500|DRUG|Administration of Carbidopa/levodopa|Participants will perform beat-by-beat orthostatic tests (Schellong tests) before and after intake of single doses of carbidopa:levodopa combinations at 3 different ratios
219217630|NCT06828315|OTHER|Reflexology|Reflexology is a practice based on the fact that the organs in the body are connected to the reflex areas in the hands and feet.
219217631|NCT06826937|BEHAVIORAL|Reconsolidation based short term therapy|This is a behavioral intervention that uses imaginal and in vivo exposure in daily meetings.
219217632|NCT04238715|DRUG|E7090|E7090 tablets orally.
219091546|NCT03525548|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
219091547|NCT03525548|DRUG|IVA|Participants received IVA orally once daily in the evening.
219091548|NCT03525548|DRUG|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
219217633|NCT06075732|BEHAVIORAL|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
219217634|NCT06824428|OTHER|Pain perception threshold|The patients' pressure pain threshold will be evaluated with a manual pressure algometer (Baseline Dolorimtre®).The patients' pain perception thresholds will be measured bilaterally in the midfrontal region, the midpoint of the trapezius muscle, the lateral epicondyle, the midpoint of the web between the 1st and 2nd fingers, the greater trochanter, and the medial crease of the knee.
219217635|NCT06828354|DRUG|SHR-A1811|SHR-A1811.
219217636|NCT06828354|DRUG|Paclitaxel Injection|Paclitaxel Injection.
219217637|NCT06828354|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection.
219217638|NCT06828354|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
219217639|NCT06828354|DRUG|Topotecan Hydrochloride for Injection|Topotecan Hydrochloride for Injection.
219217640|NCT04728711|DRUG|ADX-629|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
219217641|NCT04728711|DRUG|Placebo|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
219217642|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
219217643|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
219217644|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
219091549|NCT03525548|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
219091550|NCT05246449|OTHER|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
219091551|NCT04441281|PROCEDURE|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
219091552|NCT02032212|OTHER|EVP unflavoured|
219091553|NCT02032212|OTHER|EVP flavoured|
219091554|NCT02032212|OTHER|Nicotine inhalator|15 mg nicotine Nicorette
219091555|NCT02032212|OTHER|Conventional cigarette|
219091556|NCT03404102|DEVICE|Cu-IUD|Copper Intra-uterine device used as contraceptive method
219091557|NCT06443242|DEVICE|Low-Dose Laser Acupuncture (LLA)|The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
219091558|NCT06443242|DEVICE|Sham Laser Acupuncture (SLA)|Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
219091559|NCT00148382|DRUG|ATL-962|
219091560|NCT06162832|COMBINATION_PRODUCT|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
219091561|NCT06162832|COMBINATION_PRODUCT|Allograft and Saline solution|This will be used as the control group
219091562|NCT04836221|BEHAVIORAL|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
219091563|NCT03379623|OTHER|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
219091564|NCT06437236|DRUG|ondansetron|"Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
219091565|NCT06437236|DRUG|granisetron|"Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
219091566|NCT00705302|BEHAVIORAL|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
219091567|NCT00705302|BEHAVIORAL|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
219091568|NCT03889626|DRUG|Apatinib|Apatinib: 500mg qd po, q4w
219091569|NCT03889626|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
219091570|NCT02834637|DRUG|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
219091571|NCT02834637|DRUG|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
219091572|NCT05343338|DRUG|Sivelestat sodium|After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
219091573|NCT05889806|OTHER|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
219217645|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
219217646|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
219217647|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
219682137|NCT01687634|BEHAVIORAL|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
219682138|NCT01687634|BEHAVIORAL|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
219682139|NCT03327285|BIOLOGICAL|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
219682140|NCT03301077|OTHER|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
219091574|NCT02291523|BIOLOGICAL|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
219217648|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
219217649|NCT06253585|OTHER|Algorithm Alarm- Crystalloids|"The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution)."
219682141|NCT01863290|OTHER|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
219091575|NCT03117595|DRUG|Bupivacaine-fentanyl|Dosages as previously written
219091576|NCT03117595|DRUG|Bupivacaine-fentanyl morphine|Dosage as previously written
219091577|NCT04800419|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
219091578|NCT01403025|DRUG|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
219217650|NCT06253585|OTHER|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
219217651|NCT05483517|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
219217652|NCT05483517|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
219217653|NCT05483517|BEHAVIORAL|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
219091579|NCT06328166|PROCEDURE|Sono-guided injection with ES135|Sono-guided injection with ES135 between carpal tunnel and median nerve
219091580|NCT06328166|PROCEDURE|Sono-guided injection with placebo|Sono-guided injection with placebo between carpal tunnel and median nerve
219091581|NCT02923739|BIOLOGICAL|Bevacizumab|Given IV
219091582|NCT02923739|BIOLOGICAL|Emactuzumab|Given IV
219091583|NCT02923739|OTHER|Laboratory Biomarker Analysis|Correlative studies
219091584|NCT02923739|DRUG|Paclitaxel|Given IV
219091585|NCT02923739|OTHER|Pharmacological Study|Correlative studies
219091586|NCT06152042|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
219091587|NCT03683797|OTHER|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
219091588|NCT06094556|DRUG|SHR-1826|dose is calculated based on the subjects' baseline weight.
219091589|NCT01416870|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
219091590|NCT01416870|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
219091591|NCT02623855|BEHAVIORAL|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
219091592|NCT02623855|BEHAVIORAL|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
219091593|NCT02623855|DEVICE|Pedometry|Participants will record their daily pedometry.
219091594|NCT02623855|BEHAVIORAL|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
219217654|NCT06359821|DRUG|ZA-001|Study drug ZA-001 administered via intravenous injection.
219217655|NCT05580978|BEHAVIORAL|GEM|The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
219217656|NCT05580978|OTHER|Routine Care|Participant's current prediabetes treatment.
219217657|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
219217658|NCT03936101|DIAGNOSTIC_TEST|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
219217659|NCT06056570|DRUG|dontinurad|dotinurad alone
219091595|NCT02009670|DIETARY_SUPPLEMENT|13C inulin|Oral 13C inulin
219091596|NCT02009670|OTHER|Placebo|Oral maltodextrin
219091597|NCT02153138|DEVICE|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~1. The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~2. The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
219091598|NCT02153138|DEVICE|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
219217660|NCT06056570|DRUG|dotinurad + allopurinol|dotinurad + allopurinol 300mg
219682142|NCT00534872|DRUG|SB-649868|10 mg
219091599|NCT02153138|DEVICE|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
219091600|NCT05633875|OTHER|MRI|Patients will undergo MRI without contrast agent
219091601|NCT03996057|DRUG|Methenamine Hippurate 1000 MG|Discussed in arm/group description
219091602|NCT03996057|DRUG|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
219091603|NCT03996057|DIETARY_SUPPLEMENT|D-mannose|Powder or tablet, depending on what patient is already using.
219091604|NCT06578884|DEVICE|877PTY|IOL implantation with 6-month follow-up period Monocular UDVA/CDVA Manifest Refraction (SPH, CYL, SEQ) Optical Biometry, Keratometry (K1, K2, AXL, ACD) IOL axis orientation determination Visual function questionnaire Glistening evaluation Tonometry Slit-Lamp examination Fundus visualization
219091605|NCT00369538|DRUG|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
219091606|NCT00369538|DRUG|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
219091607|NCT01945749|DRUG|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
219091608|NCT01945749|DRUG|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
219091609|NCT01945749|OTHER|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
219091610|NCT06273943|DRUG|Cabotegravir Tablets, for oral use.|Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
219091611|NCT06273943|DRUG|Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.|Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
219091612|NCT06273943|DRUG|Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use|"* Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
219217661|NCT06056570|DRUG|allopurinol|allopurinol 300 mg alone
219217662|NCT06738290|BEHAVIORAL|Targeted home-based touchscreen training|Participants will practice the Swipe-Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants perform different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 min. per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. Feedback will be provided during the rest periods.
219217663|NCT04402151|DRUG|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
219217664|NCT04402151|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
219682143|NCT05618288|BEHAVIORAL|mobile Health Breastfeeding Counseling|a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
219091613|NCT06273943|PROCEDURE|Rectal Biopsies|"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
219091614|NCT00365586|DRUG|Ketoprofen Topical Patch , 20%|
219091615|NCT02634788|DRUG|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
219091616|NCT02634788|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
219091617|NCT03076372|DRUG|MM-310|MM-310
219091618|NCT03057743|DEVICE|Positron emission tomography (PET/CT) imaging|
219091619|NCT03057743|DEVICE|radiotracer [18F]ISO-1|
219091620|NCT02415348|DEVICE|Fibroscan|
219682144|NCT05618288|BEHAVIORAL|Standard of care breastfeeding counseling|The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
219091621|NCT04402463|OTHER|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
219091622|NCT04402463|OTHER|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
219091623|NCT03760770|PROCEDURE|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
219217665|NCT06763471|DEVICE|Neuropixels recording intraoperatively during planned neurosurgery|"The SUNAN study is a basic science study involving a procedure to record single-unit neurophysiological activity with human participants who are already undergoing a transcranial neurosurgical procedure on the brain.~As part of the surgery, a region of cerebral cortex on the convexity of the brain will be:~* Resected e.g., as removal of part of a tumour or epilepsy focused. Or~* Transgressed as part of the surgical approach to reach a deeper target e.g., resection of a deep tumour or cavernoma.~Or~• Transgressed by the passage of a surgical implant e.g., a ventriculoperitoneal shunt catheter or deep brain stimulation electrode.~Within this region of the brain that is going to be resected or transgressed, the research team will undertake a single-unit resolution neurophysiological recording (NR) using a digital neural probe (Neuropixels) for a maximum of 15 minutes."
219217666|NCT06723080|DRUG|VC005 low dose group|VC005 low dose group repeat administration
219217667|NCT06723080|DRUG|VC005 high dose group|VC005 high dose group repeat administration
219217668|NCT06723080|DRUG|VC005 Placebo group|VC005 Placebo group repeat administration
219217669|NCT06575621|BEHAVIORAL|Support program|education, medical navigation, exercise
219091624|NCT03467932|DRUG|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
219217670|NCT05485805|DRUG|Naproxen sodium and caffeine (BAY2880376)|Tablet, oral use, single dose
219217671|NCT05485805|DRUG|Naproxen sodium (Aleve)|Tablet, oral use, single dose
219217672|NCT05485805|DRUG|Caffeine|Tablet, oral use, single dose
219091625|NCT03467932|DRUG|Placebo oral capsule|Placebo provided QHS, BID, TID
219091626|NCT03467932|DRUG|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
219091627|NCT02788630|BEHAVIORAL|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
219091628|NCT05863130|DRUG|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
219091629|NCT05863130|DRUG|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
219091630|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period"
219091631|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period"
219091632|NCT06306014|DRUG|Placebo|"Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period"
219217673|NCT05485805|DRUG|Placebo|Tablet, oral use, single dose
219217674|NCT04218357|DRUG|Probenecid or placebo single administration|study drug administration with alcohol in the laboratory
219217675|NCT06446154|DRUG|Fruquintinib|Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
219217676|NCT06019377|BEHAVIORAL|Stronger Youth Networks and Coping (SYNC)|SYNC is a 8-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
219217677|NCT05349838|DRUG|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
219217678|NCT05348577|DRUG|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
219217679|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
219217680|NCT05348577|OTHER|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
219217681|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
219217682|NCT05411484|DRUG|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
219091633|NCT03360630|BIOLOGICAL|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
219091634|NCT03360630|BIOLOGICAL|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
219091635|NCT00723099|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
219091636|NCT00723099|DRUG|Cyclophosphamide|Given IV
219091637|NCT00723099|DRUG|Cyclosporine|Given IV
219091638|NCT00723099|DRUG|Fludarabine Phosphate|Given IV
219217683|NCT05411484|DEVICE|CO2 Ablative Fractional Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
219217684|NCT05943197|DIAGNOSTIC_TEST|dental prosthetics, biofilm response and oral microbiota|microbiota, biofilm, oral mucosa
219682145|NCT00767221|DRUG|Budesonide|8 mg PL-56 once daily for six months
219682146|NCT05834218|OTHER|split body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
219682147|NCT05834218|OTHER|full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
219682148|NCT00608751|RADIATION|IMRT|
219682149|NCT03559543|DIETARY_SUPPLEMENT|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
219682150|NCT05258253|OTHER|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
219682151|NCT05258253|OTHER|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
219682152|NCT02959216|OTHER|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
219682153|NCT02959216|OTHER|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
219682154|NCT05323877|DEVICE|Test Device (PerQseal+)|Percutaneous arterial closure device
219682155|NCT05128266|PROCEDURE|Endodontical Retreatment|"1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
219682156|NCT02311608|DRUG|Terlipressin|administered as a first-line medicine or as salvage
219682157|NCT02311608|DRUG|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
219682158|NCT02311608|DRUG|High Dose Somatostatin/Octreotide|administered as salvage
219682159|NCT03735082|DRUG|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
219682160|NCT03735082|DRUG|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
219682161|NCT03735082|DRUG|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
219682162|NCT01718392|BEHAVIORAL|Training|
219682163|NCT05964985|DRUG|Normal saline|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
219682164|NCT05964985|DRUG|Ropivacaine|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
219682165|NCT05964985|DRUG|Compound lidocaine|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
219682166|NCT05964985|DRUG|Esketamine|After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
219682167|NCT02988739|BIOLOGICAL|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
219682168|NCT02988739|DEVICE|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
219682169|NCT03620149|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
219091639|NCT00723099|OTHER|Laboratory Biomarker Analysis|Correlative studies
219091640|NCT00723099|DRUG|Mycophenolate Mofetil|Given IV or PO
219091641|NCT00723099|RADIATION|Total-Body Irradiation|Undergo TBI
219217685|NCT06922240|DRUG|Riociguat|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc., continue oral administration of riociguat for treatment.
219217686|NCT06922240|DRUG|Routine Treatment|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc, and stop taking riociguat
219217687|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
219217688|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
219217689|NCT06745232|DEVICE|FAST MAP|Patients with complete arch restorations loaded immediately with a full digital workflow using stereophotogrammetry Intraoral impression
219217690|NCT05662098|DRUG|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
219217691|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
219217692|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
219091642|NCT00723099|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
219091643|NCT00500721|DRUG|HCV-796|HCV-796 500mg BID x 14 days
219091644|NCT00500721|DRUG|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
219091645|NCT04018248|DRUG|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
219091646|NCT04018248|DRUG|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
219091647|NCT02496767|DRUG|Tirasemtiv|
219091648|NCT02496767|DRUG|Placebo tablets|
219091649|NCT02203708|OTHER|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
219091650|NCT03041844|DEVICE|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)
219091651|NCT03041844|DEVICE|Sham Applicator|Sham ultrasound applicator
219091652|NCT01939886|DRUG|Mefloquine - Artesunate|
219091653|NCT01939886|DRUG|Artemether-lumefantrine combination|
219091654|NCT00325325|DRUG|everolimus and tacrolimus|
219091655|NCT04345159|OTHER|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
219091656|NCT04513613|DEVICE|Procedure/Surgery: Robotic-PVI|Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
219091657|NCT05680454|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
219091658|NCT05680454|BIOLOGICAL|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
219091659|NCT05174481|OTHER|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
219091660|NCT02712125|DRUG|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
219091661|NCT02712125|DRUG|Placebo|placebo vaginal tablets once daily until delivery
219091662|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
219091663|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
219217693|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
219217694|NCT01958021|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
219217695|NCT01958021|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
219217696|NCT01958021|DRUG|Placebo|Placebo (hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
219217697|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
219091664|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
219091665|NCT01984580|DRUG|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
219091666|NCT05207930|DEVICE|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
219091667|NCT05207930|DEVICE|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
219091668|NCT04888091|PROCEDURE|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
219091669|NCT04888091|PROCEDURE|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
219091670|NCT02481492|DEVICE|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
219091671|NCT02481492|DEVICE|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
219091672|NCT02277990|DEVICE|TYRX™ Absorbable Antibacterial Envelope|
219091673|NCT00170222|DRUG|doxycycline|
219091674|NCT03991117|BEHAVIORAL|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
219091675|NCT00405457|DRUG|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
219217698|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
219091676|NCT04711603|DRUG|MR13A9|Intravenous administration
219091677|NCT04711603|DRUG|Placebo|Intravenous administration
219091678|NCT03203109|BEHAVIORAL|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
219091679|NCT01587352|OTHER|Laboratory Biomarker Analysis|Correlative studies
219091680|NCT01587352|DRUG|Vorinostat|Given PO
219091681|NCT05541510|BIOLOGICAL|AD17002 + Formulation buffer|Intranasal innate immune modulator
219091682|NCT05541510|BIOLOGICAL|Placebo|Formulation buffer
219091683|NCT06500559|PROCEDURE|PRP injection|PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides
219217699|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
219217700|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
219217701|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
219217702|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
219217703|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
219217704|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
219217705|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
219217706|NCT02625441|DRUG|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
219217707|NCT02625441|DRUG|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
219217708|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
219217709|NCT04677153|OTHER|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
219217710|NCT04677153|OTHER|Usual care|Participants are referred to another location for HCV treatment.
219217711|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
219217712|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
219217713|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
219217714|NCT06795672|BEHAVIORAL|Telerehabilitation|Three hours of cognitive rehabilitation per week, performed remotely and independently, using a computerized device, which is pre-programmed based on the patient's needs.
219217715|NCT06795672|BEHAVIORAL|Traditional in-person rehabilitation.|Three hours of in-person cognitive rehabilitation per week using a computerized device.
219091684|NCT06500559|PROCEDURE|Combined decortication and PRP injection|Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
219091685|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
219091686|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
219091687|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
219091688|NCT01351909|DRUG|Cyclophosphamide|Given PO
219091689|NCT01351909|OTHER|Laboratory Biomarker Analysis|Correlative studies
219217716|NCT06791915|PROCEDURE|Radiofrequency Ablation with FCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).
219217717|NCT06791915|PROCEDURE|Radiofrequency Ablation with VCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).
219091690|NCT01351909|DRUG|Veliparib|Given PO
219091691|NCT06319846|DRUG|Tirofiban|Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
219091692|NCT06319846|DRUG|Placebo|Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
219091693|NCT05539729|DRUG|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
219091694|NCT05539729|DRUG|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
219091695|NCT04026529|OTHER|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope."
219091696|NCT05646485|DIAGNOSTIC_TEST|Urinalysis|"Urine analysis (every 6 months for 2 years); Patients with \<3 red blood cells (RBCs) per high-powered field (HPF) will repeat screening at 6-month intervals for an average of 2 years.~If RBCs are 3-25 RBSc/HPF- subjects will undergo- \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\].~If \>25 RBCs, subjects will get - \[cystoscopy + Upper tract imaging\]."
219091697|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
219091698|NCT05982873|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219217718|NCT02577185|DRUG|Botulinum Toxin Type A|
219217719|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
219217720|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
219217721|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
219217722|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
219217723|NCT03254914|PROCEDURE|Home Blood Pressure|Measure Home Blood Pressure
219091699|NCT02514681|DRUG|Trastuzumab|
219091700|NCT02514681|DRUG|Pertuzumab|
219091701|NCT02514681|DRUG|Docetaxel|
219091702|NCT02514681|DRUG|Paclitaxel|
219091703|NCT02514681|DRUG|Nab-paclitaxel|
219091704|NCT02514681|DRUG|Vinorelbine|
219091705|NCT02514681|DRUG|Eribulin|
219091706|NCT02514681|DRUG|Capecitabine|
219091707|NCT02514681|DRUG|Gemcitabine|
219091708|NCT04938817|BIOLOGICAL|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
219091709|NCT04938817|DRUG|lenvatinib|Oral administration
219091710|NCT04938817|BIOLOGICAL|MK-4830|IV infusion
219091711|NCT04938817|BIOLOGICAL|coformulation favezelimab/pembrolizumab|IV infusion
219091712|NCT04938817|BIOLOGICAL|R-DXd|IV Infusion
219091713|NCT02956499|DRUG|APX001 single dose 1|
219091714|NCT02956499|DRUG|APX001 single dose 2|
219091715|NCT02956499|DRUG|APX001 single dose 3|
219091716|NCT02956499|DRUG|APX001 single dose 4|
219091717|NCT02956499|DRUG|APX001 single dose 5|
219091718|NCT02956499|DRUG|APX001 single dose 6|
219091719|NCT02956499|DRUG|APX001 multiple dose 1|
219091720|NCT02956499|DRUG|APX001 multiple dose 2|
219091721|NCT02956499|DRUG|APX001 multiple dose 3|
219091722|NCT02956499|DRUG|APX001 multiple dose 4|
219091723|NCT02956499|DRUG|Matching Placebo|
219091724|NCT06200155|DRUG|Psilocybin|Given by PO
219091725|NCT06200155|OTHER|Niacin|Given by PO
219091726|NCT02098538|DRUG|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
219091727|NCT05400005|OTHER|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
219091728|NCT06527183|DIAGNOSTIC_TEST|Skin punch biopsy to demonstrate small fiber neuropathy|Skin punch biopsy to assess intrapidermal nerve fiber density
219091729|NCT05867160|OTHER|ASM as adjunctive therapy|ASM approved as adjunctive therapy
219091730|NCT01364051|DRUG|Cediranib|Given PO
219091731|NCT01364051|DRUG|Cediranib Maleate|Given PO
219091732|NCT01364051|OTHER|Laboratory Biomarker Analysis|Correlative studies
219091733|NCT01364051|OTHER|Pharmacological Study|Correlative studies
219091734|NCT01364051|DRUG|Selumetinib|Given PO
219091735|NCT01364051|DRUG|Selumetinib Sulfate|Given PO
219091736|NCT05997407|BEHAVIORAL|Organic Conceptions mindset management program|"Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group."
219091737|NCT06398652|BIOLOGICAL|CMAB015|Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
219091738|NCT06398652|BIOLOGICAL|Secukinumab|Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
219091739|NCT05297448|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
219091740|NCT05297448|DRUG|Placebo|Placebo Twice Daily
219091741|NCT04121026|OTHER|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~* history of contact~* suggestive TB symptoms~* tachycardia~* chest radiography~* abdominal ultrasound~* Xpert MTB/RIF Ultra.~A score of \>100 is highly predictive of TB. In children with a score \>100, anti-TB treatment will be initiated immediately. In children with a score of \<100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
219091742|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
219217724|NCT04840134|BEHAVIORAL|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in three consecutive phases:~1. Intensive Intervention Phase (weeks 1 to 6), consisting of 6 weekly group sessions and 4 one-on-one coaching sessions to navigate financial resources.~2. Intermediate Phase (weeks 7 to 12), consisting of 3 biweekly group sessions, and either 3 biweekly or 2 monthly one-on-one coaching sessions, based on participant preference.~3. Follow up Phase (weeks 13 to 24), consisting of 3 monthly group sessions, and either 3 monthly or 6 biweekly one-on-one coaching sessions based on participant preference.~Key intervention components:~1. Peer-led group sessions~2. Individual peer coaching sessions to complement group sessions"
219091743|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
219217725|NCT02655575|BEHAVIORAL|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
219217726|NCT02655575|BEHAVIORAL|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
219217727|NCT06756399|OTHER|Questionnare, hand grip and respiratory muscle strength|Upper extremity strength will be assessed using the Jamar hand dynamometer to measure hand grip strength. For lower extremity muscle strength, participants will undergo the five-repetition sit-to-stand test. Respiratory muscle strength, both inspiratory and expiratory, will be measured through mouth pressure assessments. Additionally, participants will complete a questionnaire addressing components related to sarcopenia diagnosis, including questions on strength, assistance with walking, rising from a chair, climbing stairs, and incidence of falls.
219217728|NCT02767999|DRUG|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
219217729|NCT02767999|DRUG|Placebo|cellulose placebo per day from D0 to D90
219217730|NCT02767999|RADIATION|fMRI|functional resting state MRI
219217731|NCT06043791|RADIATION|1.5 Tesla magnet MR arthrography|MR arthrogram is an invasive procedure where the patient's joint is injected with a mixture of dilute gadolinium, iodinated contrast medium, local anesthetic, and saline solution followed by imaging with 1.5 Tesla MRI.
219217732|NCT06043791|RADIATION|3 Tesla magnet non-contrast MRI|3T MRI uses very powerful magnets that produce a 3-tesla magnetic field. A 3-tesla magnetic field is twice as powerful as the fields used in conventional high-field MRI scanners, and as much as 15 times stronger than low-field or open MRI scanners. This results in a clearer and more complete image. Studies have shown that it is highly sensitive and specific in detecting labral and cartilage pathology
219217733|NCT06934798|DRUG|Vasopressin intravenous infusion|Vasopressin will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 0.12 U/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 0.01 to 0.06 U/min). The target is to reach and maintain mean arterial pressure (MAP) ≥65 mmHg. If this is not achieved, open-label norepinephrine may be added. Hemodynamic and echocardiographic parameters will be measured before and after the target MAP is reached.
219217734|NCT06934798|DRUG|Norepinephrine intravenous infusion|Norepinephrine will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 120 µg/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 10 to 60 µg/min). The goal is to reach and maintain MAP ≥65 mmHg. If the MAP target is not reached, open-label norepinephrine may be initiated. Clinical and hemodynamic parameters will be collected at baseline and after MAP stabilization.
219217735|NCT06766396|DEVICE|Postpartum Intrauterine Contraceptive Device (PPIUCD).|Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery. For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure. All insertions will be performed by trained healthcare professionals
219217736|NCT06748807|PROCEDURE|APRVplus|Early Pathophysiology-driven Airway Pressure Release Ventilation (APRVplus)
219217737|NCT06748807|PROCEDURE|TCAV|Time-Controlled Adaptive Ventilation (TCAV)
219217738|NCT02488408|DRUG|Bemcentinib|
219217739|NCT02488408|DRUG|Cytarabine|
219217740|NCT02488408|DRUG|Decitabine|
219217741|NCT06714578|OTHER|Questionnaire and Physical Exam|The investigators use questionnaire to assess biological factors (sleep quality, externalizing problem behavior, prosocial tendencies, sensation seeking, and hedonic hunger), psychological factors (risk awareness of drug misusing, indulgence of drug misusing, self-efficacy of drug misusing, and ACEs), and social factors (whether work in a special place, whether have drug-addicts around, cognition of traditional drug types, and cognition of NPS types) and demographic data
219217742|NCT06755112|OTHER|Placebo cream|Placebo cream application
219217743|NCT06755112|OTHER|active cream|Active cream application
219217744|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
219091744|NCT06517563|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
219091745|NCT06517563|DRUG|Rivaroxaban|FXa Inhibitor
219091746|NCT06517563|DRUG|UFH|Unfractionated Heparin
219091747|NCT06517563|DRUG|Enoxaparin|Low Molecular Weight Heparin
219217745|NCT04161755|DRUG|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
219217746|NCT04161755|BIOLOGICAL|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
219217747|NCT04161755|DRUG|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
219217748|NCT03110575|DRUG|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
219217749|NCT05886777|BIOLOGICAL|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
219217750|NCT05886777|BIOLOGICAL|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
219217751|NCT05886777|BIOLOGICAL|RSVpreF|RSVpreF given as an intramuscular injection
219217752|NCT05886777|BIOLOGICAL|QIV|Licensed QIV given as an intramuscular injection
219217753|NCT05886777|BIOLOGICAL|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
219217754|NCT06840795|OTHER|conventional physiotherapy|Conventional physiotherapy methods will be applied. Pain relief, electrotherapy, hot applications, ultrasound etc.
219217755|NCT06840795|OTHER|Vibration Massage Therapy|The device-assisted massage therapy will be applied by the physiotherapist with its gun-shaped form that massages through vibration.
219217756|NCT03884543|PROCEDURE|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
219217757|NCT06310681|BEHAVIORAL|"Encompass group programme"|"* Groups will take place over ten modules~* They will take place in-person at a local community venue~* The groups will be two hours long, with a break for refreshments in the middle. They will take place every fortnight in term-time only over approximately 6 months.~* The groups predominantly follow a participatory learning approach and although the facilitators have manuals, the activities tend to include some imparting of information, key points for discussion, examples from other settings and activities for the group to practice.~* They are run by two facilitators - one parent with lived experience and one healthcare professional"
219217758|NCT06724926|DRUG|Azeliragon|"Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion."
219217759|NCT06724926|PROCEDURE|CSI|Patients will receive CSI.
219217760|NCT06875453|OTHER|Exercise|The Schroth Best Practice program, which is widely used in the conservative treatment of scoliosis, consists of 6 modules including physiological exercises to correct the sagittal plane, activities of daily living, 3D correction techniques, powerful Schroth exercises, de-tethering exercises and gait rehabilitation. Detethering exercises in this program will be performed in this study.
219217761|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
219217762|NCT01009177|DRUG|Placebo|Placebo
219217763|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
219217764|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
219091748|NCT06020014|DRUG|AZD4604|AZD4604
219091749|NCT06020014|OTHER|Placebo|Placebo
219091750|NCT05107960|DRUG|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
219091751|NCT06262997|OTHER|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
219091752|NCT06262997|OTHER|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
219091753|NCT06199934|BIOLOGICAL|Vaccination|BNT162b2 vaccination
219091754|NCT03182075|BEHAVIORAL|Computerized Training|OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
219091755|NCT04270747|DRUG|ABP 938|Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
219091756|NCT04270747|DRUG|Aflibercept|Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
219091757|NCT06239519|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
219091758|NCT04862676|DRUG|Hyperbaric oxygen|The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
219091759|NCT06771388|DIETARY_SUPPLEMENT|Liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
219091760|NCT06771388|DIETARY_SUPPLEMENT|Non-liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
219091761|NCT06771388|DIETARY_SUPPLEMENT|Placebo drink|consume 50 g liquid drink daily for 8 consecutive weeks
219091762|NCT03672539|DRUG|Gemtuzumab Ozogamicin|Given IV
219091763|NCT03672539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219091764|NCT03672539|OTHER|Quality-of-Life Assessment|Ancillary studies
219091765|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
219091766|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
219091767|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
219091768|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
219091769|NCT06207630|DEVICE|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
219091770|NCT04578678|OTHER|Steering|Fine tuning of the STN-DBS settings
219091771|NCT04138277|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
219091772|NCT04138277|BIOLOGICAL|ATB200|Enzyme Replacement Therapy via intravenous infusion
219091773|NCT04189354|DEVICE|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
219091774|NCT02417584|DEVICE|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
219091775|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
219091776|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
219091777|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
219091778|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
219091779|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
219091780|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
219091781|NCT03178552|DRUG|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
219091782|NCT03178552|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
219091783|NCT03178552|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
219091784|NCT03178552|DRUG|Cisplatin|Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
219091785|NCT03178552|DRUG|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
219091786|NCT03178552|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
219091787|NCT03178552|DRUG|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
219217765|NCT06936020|OTHER|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
219217766|NCT06936111|DIAGNOSTIC_TEST|Assessment of residual cholesterol and inflammatory risk factors|The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)
219217767|NCT00872729|DRUG|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
219091788|NCT03178552|DRUG|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
219091789|NCT03178552|DRUG|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
219091790|NCT03178552|DRUG|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
219091791|NCT03178552|DRUG|Divarasib|Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
219091792|NCT03178552|DRUG|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
219091793|NCT06079203|BEHAVIORAL|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
219091794|NCT06079203|BEHAVIORAL|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
219217768|NCT00872729|DRUG|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
219217769|NCT06939725|OTHER|Transversus abdominis plane (TAP) block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversus abdominis plane block was applied to this group
219091795|NCT06079203|BEHAVIORAL|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
219091796|NCT02974725|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
219091797|NCT02974725|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
219091798|NCT02974725|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
219091799|NCT02974725|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
219091800|NCT00520390|DRUG|EZN-2208|
219091801|NCT05845814|BIOLOGICAL|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
219091802|NCT05845814|BIOLOGICAL|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
219091803|NCT05845814|COMBINATION_PRODUCT|EV|1.25 mg/kg IV infusion
219091804|NCT05845814|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
219091805|NCT04108052|RADIATION|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
219091806|NCT04108052|RADIATION|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index\>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
219091807|NCT01908465|DRUG|Ebastine|
219091808|NCT01908465|DRUG|Placebo|
219091809|NCT06455371|OTHER|Decision support tool|Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
219091810|NCT03726788|DRUG|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
219091811|NCT03726788|DRUG|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
219091812|NCT03726788|DRUG|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
219091813|NCT00344058|DRUG|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
219091814|NCT05434858|OTHER|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
219091815|NCT06571448|DRUG|SR750 tablet|SR750 high dose BID orally for 6 weeks
219091816|NCT06571448|DRUG|SR750 tablet|SR750 low dose BID orally for 6 weeks
219091817|NCT06571448|DRUG|Placebo|Placebo
219217770|NCT06939725|OTHER|Transversalis Fascia Plane Block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversalis Fascia Plane Block was applied to this group
219217771|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
219091818|NCT06100419|PROCEDURE|serratus posterior superior intercostal plane block|With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
219091819|NCT05810493|OTHER|Observation|Follow-up of disease, therapeutics and evolution
219091820|NCT00209924|DRUG|Gaboxadol|
219091821|NCT01864239|OTHER|Medicines Advice Service|"The intervention consists of:~1. Telephone consultations with a pharmacist~2. Follow-up tailored written information~3. A medicine reminder chart"
219091822|NCT04367584|OTHER|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
219091823|NCT01348750|OTHER|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
219091824|NCT05855226|OTHER|OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)|The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
219217772|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
219217773|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
219217774|NCT06935513|BEHAVIORAL|Wearable Devices|Participants utilize wearable devices (smart wristbands) 24 hours a day for 6 months. Wearable devices can provide medication reminders for each use and heart rate monitoring.
219217775|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
219217776|NCT06941766|DRUG|QL1706|5 mg/kg, IV infusion, Q3W (D1)
219217777|NCT06941766|DRUG|Chemotherapy|FAEV, EMA/EP, EMA/CO, or TP/TE.
219217778|NCT05754593|BIOLOGICAL|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
219217779|NCT05754593|OTHER|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
219217780|NCT05754593|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
219091825|NCT05034432|PROCEDURE|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
219091826|NCT05034432|OTHER|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
219091827|NCT04290130|OTHER|Measurement of brain activity using electrodes.|We will present audiovisual speech and record neural responses.
219091828|NCT04605731|BIOLOGICAL|Durvalumab|Given IV
219091829|NCT04605731|BIOLOGICAL|Tremelimumab|Given IV
219091830|NCT05614089|DRUG|Insulin Glargine|"Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)~Duration of therapy: 12 months"
219091831|NCT05614089|DRUG|NPH or premixed 70/30 (human insulin)|"Formulation: Available as a liquid in a glass cartridge (3ml=300IU) or as liquid in a prefilled, disposable pen (3ml=300IU).~Route: Bangladesh = reusable pens; Tanzania = disposable pens~Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician)~Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months"
219091832|NCT05587712|DRUG|Sotatercept|SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
219091833|NCT05656040|BIOLOGICAL|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
219091834|NCT05656040|DRUG|Placebo|Normal saline administered subcutaneously
219091835|NCT06356220|OTHER|Gluten-Free Diet Education|The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
219091836|NCT01712477|DRUG|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
219091837|NCT01712477|DRUG|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
219091838|NCT04875286|OTHER|Electronic Health Record Review|Medical records reviewed
219091839|NCT04875286|OTHER|Questionnaire Administration|Complete questionnaires
219091840|NCT06370481|OTHER|Telemedicine|Routine care administered via telemedicine
219091841|NCT06370481|OTHER|Standard of care|Standard of care, as received in HIV clinic settings
219091842|NCT05183672|PROCEDURE|Telecare consultation|Using Zoom to communicate with patients
219091843|NCT05183672|PROCEDURE|Usual face-to-face consultation|Face-to-face communication with patients
219091846|NCT06340217|OTHER|washed microbiota transplantation|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.
219091847|NCT06340217|OTHER|placebo|A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
219091848|NCT04130802|DRUG|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
219091849|NCT04130802|DRUG|Placebo|Vehicle eye drops
219091850|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
219091851|NCT06851481|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
219091852|NCT02044991|DRUG|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
219091853|NCT02044991|DRUG|Placebo Injection|A placebo injection
219091854|NCT02954523|DRUG|Dasatinib|oral every day
219091855|NCT02954523|DRUG|Osimertinib|oral every day
219091856|NCT02259738|DRUG|Human Urinary Kallidinogenase|
219091857|NCT02259738|DRUG|Shuxuening injection|
219091858|NCT02701894|DIETARY_SUPPLEMENT|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
219091859|NCT01303081|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
219091860|NCT01303081|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
219217781|NCT06942507|DRUG|Zanubrutinib|zanubrutinib 160mg po bid d1-28
219091861|NCT01303081|BEHAVIORAL|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
219091862|NCT01303081|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
219091863|NCT01303081|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
219091864|NCT05385120|PROCEDURE|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
219091865|NCT00438880|DRUG|Agatolimod Sodium|Given IV
219091866|NCT00438880|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
219091867|NCT00438880|OTHER|Laboratory Biomarker Analysis|Correlative study
219091868|NCT00438880|PROCEDURE|Radionuclide Imaging|Undergo imaging scans
219091869|NCT00438880|BIOLOGICAL|Rituximab|Given IV
219091870|NCT00438880|PROCEDURE|Single Photon Emission Computed Tomography|Undergo imaging scans
219091871|NCT00438880|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
219091872|NCT05815654|DEVICE|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
219091873|NCT02475252|PROCEDURE|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
219091874|NCT00002180|DRUG|Tenofovir|
219091875|NCT05203484|DEVICE|Multielecotrde Mapping|Multielectrode Mapping with Pentaray/Octaray
219091876|NCT05203484|DEVICE|Point-by-point mapping|Point-by-point mapping with QDot
219091877|NCT01857401|OTHER|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
219091878|NCT04992546|DRUG|PRN473 (SAR444727)|White to off-white gel suspension
219091879|NCT04992546|DRUG|Placebo|White to off-white gel suspension
219091880|NCT06821997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219091881|NCT06821997|PROCEDURE|Computed Tomography|Undergo CT
219091882|NCT06821997|DRUG|Fluorouracil|Given IV
219091883|NCT06821997|DRUG|Irinotecan Sucrosofate|Given IV
219091884|NCT06821997|DRUG|Leucovorin Calcium|Given IV
219091885|NCT06821997|DRUG|Oxaliplatin|Given IV
219091886|NCT06821997|PROCEDURE|Surgical Procedure|Undergo surgical resection
219091887|NCT04044222|BIOLOGICAL|Sintilimab|IV
219091888|NCT04044222|DRUG|Carboplatin|IV
219217782|NCT06942507|DRUG|Bendamustine + Rituximab|bendamustine 70-90mg/m2 ivgtt d1-2, rituximab 375mg/m2 ivgtt d1
219091889|NCT04044222|DRUG|Etoposide|IV
219091890|NCT04044222|DRUG|Ifosfamide|IV
219091891|NCT04044222|DRUG|Placebo|IV
219091892|NCT04044222|DRUG|Carboplatin|IV
219091893|NCT04044222|DRUG|Etoposide|IV
219217783|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
219091894|NCT04044222|DRUG|Ifosfamide|IV
219217784|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
219091895|NCT04671979|DIAGNOSTIC_TEST|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
219091896|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
219091897|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
219091898|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
219091899|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
219091900|NCT02674217|PROCEDURE|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
219091901|NCT04716699|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor samples
219091902|NCT04716699|DRUG|Lidocaine|Given IV
219091903|NCT04716699|PROCEDURE|Resection|Undergo surgical resection per standard of care
219091904|NCT04230421|DEVICE|The Monsenso system with feedback|See description under intervention
219091905|NCT04230421|DEVICE|The Monsenso system without feedback|See description under intervention
219091906|NCT04230421|DEVICE|CAG Bipola and mood monitoring only|See description under intervention
219091907|NCT03125005|DEVICE|Rainbow Universal Pulse Oximeter Sensor|
219217785|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
219217786|NCT06180486|OTHER|Mindfulness Meditation Intervention|The mindfulness intervention is a scripted, \~12min audio recording based on core tenets of mindfulness meditation and contextualized for patients undergoing total knee arthroplasty. It teaches sustained attention on the present, body awareness, acceptance of the body's current state, and transformational strategies to cope with emotional or physical stimuli as they arise. It has been created by the study team based on the teachings of Jon Kabat Zinn (founder of mindfulness meditation) and the PI's history teaching yoga and meditation. Patients will be encouraged to review the audio recording once a week.
219091908|NCT04876040|DEVICE|SSO2 Downstream System|60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
219091909|NCT04876040|PROCEDURE|PCI + Impella|Standard of Care Intervention
219091910|NCT04387864|DEVICE|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
219217787|NCT06761625|DIETARY_SUPPLEMENT|SanProbi® Barrier capsules|The probiotic group received SanProbi® Barrier capsules
219217788|NCT06761625|OTHER|Placebo|The placebo group received capsules filled mainly with maize starch and maltodextrins.
219217789|NCT06043609|OTHER|This is an observational cohort study|This is an observational cohort study
219217790|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
219217791|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
219217792|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel, S-1|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
219217793|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
219217794|NCT06484517|DEVICE|Hugemed Videolaryngoscope|After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
219217795|NCT05911230|DIAGNOSTIC_TEST|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
219217796|NCT06949371|OTHER|Morning chronotype|All assessment measurements determined for individuals with morning chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
219217797|NCT06949371|OTHER|Evening chronotype|All assessment measurements determined for individuals with evening chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
219217798|NCT06951334|DRUG|Vildagliptin 50 mg bid|Vildagliptin 50 mg bid for 12months
219217799|NCT06951074|BIOLOGICAL|Insulin producing stem cells infusion|"1. Liposuction of the anterior abdominal subcutaneous fat layer of participant~2. Characterization and Identification of mesenchymal stem cells~3. Differentiation of mesenchymal stem cells into insulin producing stem cells~4. In vitro detection of Insulin and c-peptide in differentiated MSC (Confirmatory tests for the insulin producing cells)~5. In vitro Insulin and c-peptide release detection in differentiated MSC in response to increasing glucose concentrations Differentiated MSCs injection in human subjects~6. Followup"
219217800|NCT06952127|OTHER|Rehabilitation program|"* 5-minute warm-up including easy global exercises~* 5 resistance training exercises targeting upper and lower muscle groups~* 30 secondes break between sets~* Cooldown with breathing and stretching exercises"
219091911|NCT01445405|DRUG|Bortezomib (Velcade, PS-341)|
219091912|NCT01445405|DRUG|Cetuximab|
219091913|NCT01445405|DRUG|Cisplatin|
219091914|NCT01445405|PROCEDURE|Radiation Therapy|
219091915|NCT06256289|DRUG|Canagliflozin 100mg Tab|Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
219091916|NCT06256289|DRUG|Metformin Hydrochloride|Metformin 1000mg twice daily
219091917|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
219091918|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
219091919|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
219091920|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
219091921|NCT05458648|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
219091922|NCT05311033|OTHER|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
219091923|NCT06084858|OTHER|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
219091924|NCT02414191|BEHAVIORAL|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
219091925|NCT02414191|BEHAVIORAL|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
219217801|NCT06950463|OTHER|Group A (control group): It will be consisted of twenty two post menopausal women who will receive daily dosage of vitamin D3 supplement (600 IU/day) (Schleicher et al., 2016), for 6 week|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
219217802|NCT06950463|DEVICE|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl fo|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
219217803|NCT06749353|DEVICE|Virtual reality|We will use a virtual reality glasses with the 'Lending Moments' program, where patients can experience a sunset on a paradise beach while listening to a soothing voice that guides them through the experience with relaxation and meditation techniques. During this time, we will proceed with the surgical intervention.
219217804|NCT06952582|BEHAVIORAL|The IMB model-based safer sexual dual protection educational intervention|The IMB model based safe sexual dual protection education was designed to provide factual information about sexual risks of STI/HIV and unwanted pregnancy and the benefits of safer sexual dual protection behaviors including abstinence and dual protection use, enhance motivation to practice primary sexual abstinence for sexually inexperienced youth and dual protection use for sexually experienced young women, and teach specific behavioral skills required for practicing abstinence and/or negotiate safer sex with partners to use condoms/dual protection for simultaneous prevention of both risks of STI/HIV and unwanted pregnancy among youth at risk.
219217805|NCT06954415|OTHER|No intervention (observational study)|Questionnaire without intervention
219217806|NCT06953115|OTHER|Vagal stimulation physiotherapy with trigger point release|"The patient will be instructed to remain in a seated position, with the knee slightly ahead of the feet and the feet firmly planted on the floor, with the hips higher than the knees. The therapist will stand behind the patient. Myofascial release will be performed on the upper trapezius (UT) while the patient slowly turns their head from side to side and lets it drop forward. The therapist will then apply pressure on the opposite side of the rotation.~* Therapist's position: Behind the patient.~* Patient's position: Seated with the spine in a neutral position."
219217807|NCT06953115|OTHER|Positional Release Therapy|"A 30-minute session of positional release therapy will be provided every two weeks, in addition to personalized antihypertensive treatment, from the start of treatment (T0) until the final measurement (days 28 to 35 after obstetric resolution).~Keeping the cervical spine in a neutral position, the participant will be asked to lie down in a relaxed supine position. The therapist will progressively apply more pressure to the trigger points identified with their thumb. In the next step, the therapist will move to a more comfortable position that exerts less stress. The therapist will passively hold the patient's upper limbs in an abducted position, with a rest period between each repetition.~* Therapist's position: On the side of the patient.~* Patient's position: Supine."
219217808|NCT06952959|OTHER|Acupuncture|Cosmetic acupuncture
219217809|NCT06953765|OTHER|PSQI|Prospective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \<7).
219217810|NCT06953765|OTHER|PQSI|PQSI-Sleep quality assessment scale
219217811|NCT06953401|OTHER|Muscle contraction protocol for electromyographic assessment|Participants will perform a set of standardized lower limb muscle contractions (isometric, concentric, and eccentric) involving the gastrocnemius and soleus muscles while lying on an examination table and in standing position both static and dynamic as well as walking. Surface electromyography (mDurance® sEMG system) will be used to record muscle activation during each phase. The task is designed for physiological measurement only and does not constitute a therapeutic intervention. Protocol includes 3 trials per muscle and side, using standardized test conditions.
219682170|NCT04883151|BEHAVIORAL|SOFUS pilot program|"The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered."
219682171|NCT03610074|OTHER|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
219682172|NCT03610074|PROCEDURE|Blood test|Additional blood test 5 min after mint ice cubes application
219682173|NCT03610074|OTHER|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
219682174|NCT05454995|OTHER|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
219682175|NCT03341845|DRUG|Axitinib|axitinib in combination with avelumab
219682176|NCT03341845|DRUG|Avelumab|axitinib in combination with avelumab
219682177|NCT05748574|DIETARY_SUPPLEMENT|Sleep Well Sachet|Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
219682178|NCT02884739|OTHER|Data collection|
219091926|NCT00717860|DRUG|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
219091927|NCT00717860|DRUG|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
219091928|NCT02917707|OTHER|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
219091929|NCT06013254|DIETARY_SUPPLEMENT|sour liquid|applying lemon juice
219091930|NCT04866212|BEHAVIORAL|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
219217812|NCT06953596|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Eight rTMS sessions will be administer per day at 60-minute intervals for 5 consecutive days.~Each rTMS session will consist of 600 pulses of theta-burst stimulation (iTBS), a pattern of 3 TMS pulses every 200 milliseconds for 2 seconds (i.e., 3 x 50 Hz bursts repeated at 5 Hz) for 3 minutes at 100% of resting motor threshold. The left dorsomedial prefrontal cortex (DMPFC) will be targeted via the Fz EEG site (30% of the nasion-inion distance posteriorly along the nasion-inion line)."
219217813|NCT06954701|DEVICE|Novel Personalizable Pessary|Novel personalizable pessary.
219217814|NCT06954506|BEHAVIORAL|Reiki Group|Patients were informed about the application, and a Reiki application video prepared/selected by the researchers was shared with the patients. Patients were asked to perform Reiki every day for a week following each chemotherapy session for 4 cycles. A reminder message was sent to the patients the day before each cycle for the Reiki application. The level of hopelessness was reassessed at the end of each week.
219217815|NCT06952842|DRUG|ZVS203e|ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 (rAAV8) vector that expresses humanized SauriCas9 protein and single guide RNA (sgRNA) targeting specific mutations in the RHO gene.
219217816|NCT06954090|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide will be introduced at a dose of 0.25 mg/week subcutaneous injection, escalated to 0.5 and 1.0 mg/week after 4 and 8 weeks if tolerated.
219217817|NCT06954090|DRUG|Finerenone Oral Tablet|Finerenone will be introduced at a dose of 10 mg/day in patients with a serum potassium level \< 4.8 mmol/l and eGFR \< 60 ml/min/1.73 m2 and escalated to 20 mg/day after 4 weeks if the serum potassium level is still \< 4.8 mmol/l. Starting dose is 20 mg/day if eGFR ≥ 60 ml/min/1.73 m2. The dosage will be reduced or discontinued in patients who develop hyperkalemia (serum potassium \> 5.5 mmol/l).
219217818|NCT06954090|DRUG|Dapagliflozin (DAPA)|Dapagliflozin will be introduced at a dose of 10 mg/day. The dose can be reduced at any time during the trial if required by the subject's tolerance to the product.
219091931|NCT04866212|BEHAVIORAL|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
219091932|NCT04866212|DIAGNOSTIC_TEST|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
219091933|NCT03538015|DRUG|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
219091934|NCT03538015|DRUG|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
219091935|NCT03538015|DRUG|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
219091936|NCT04058353|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
219091937|NCT04058353|DRUG|IVA|Mono-tablet for oral administration.
219091938|NCT04058353|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219091939|NCT05663424|OTHER|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
219682179|NCT00028262|DRUG|Cystagon|
219682180|NCT01869777|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
219682181|NCT01588158|DRUG|Acetaminophen|325 mg
219682182|NCT01588158|DRUG|Vicodin|Vicodin 5/325 mg
219682183|NCT00018564|DRUG|treatments for essential tremor|
219682184|NCT03866421|DIAGNOSTIC_TEST|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
219682185|NCT03866421|DIAGNOSTIC_TEST|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
219682186|NCT03866421|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
219682187|NCT03866421|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
219682188|NCT03866421|DIAGNOSTIC_TEST|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
219682189|NCT03866421|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
219682190|NCT03866421|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
219682191|NCT03866421|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
219682192|NCT05293522|COMBINATION_PRODUCT|NTX-001|2 solutions plus a delivery device; one time use surgical product
219682193|NCT04644120|DRUG|ABBV-47D11|Intravenous (IV) infusion.
219682194|NCT04644120|DRUG|Placebo for ABBV-47D11|Intravenous (IV) infusion.
219682195|NCT04644120|DRUG|ABBV-2B04|Intervenous (IV) Infusion
219682196|NCT04644120|DRUG|Placebo for ABBV-2B04|Intervenous (IV) Infusion
219682197|NCT00613366|DRUG|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
219682198|NCT00613366|DIETARY_SUPPLEMENT|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
219682199|NCT02966847|PROCEDURE|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
219682200|NCT02966847|PROCEDURE|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
219091940|NCT05663424|OTHER|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (\>2hr)
219091941|NCT05663424|OTHER|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
219091942|NCT00698646|DRUG|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
219217819|NCT06765824|DEVICE|Repetitive Transcranial Magnetic Stimulation|The protocol will be applied with the MagVenture R30 stimulation device and the cool-B70 coil for active treatment. The protocol will consist of two sessions per day, with a 50-minute break between sessions, every day of the week (Monday to Friday) for three and a half weeks (a total of 36 sessions). Each session will consist of the application of a 1Hz protocol (2000 pulses at 120% of the motor threshold) in the right dorsolateral prefrontal cortex (F4) followed by an intermittent theta-burst protocol (1800 pulses at 90% of the motor threshold) in the left dorsolateral prefrontal cortex (F3). The cortical target localization will be performed using the beam-F3/F4 technique that combines different electroencephalographic positioning parameters and measurements to accurately locate said cortical targets. The motor threshold of each patient will be calculated at the beginning of each week of treatment using an electromyography system.
219091943|NCT00698646|DRUG|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
219091944|NCT00698646|DRUG|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
219091945|NCT05844813|DRUG|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
219091946|NCT05844813|PROCEDURE|Radical Surgery|Radical sarcoma resectional surgery
219091947|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
219091948|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
219091949|NCT05550142|DRUG|Placebo|Saline solution
219091950|NCT01814592|PROCEDURE|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
219091951|NCT01814592|PROCEDURE|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
219091952|NCT04642508|PROCEDURE|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
219091953|NCT05907824|OTHER|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
219091954|NCT03651648|DEVICE|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
219091955|NCT03651648|DEVICE|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
219091956|NCT02739282|OTHER|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
219091957|NCT04956302|DRUG|Bortezomib|Given SC
219091958|NCT04956302|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
219091959|NCT04956302|DRUG|Dexamethasone|Given PO or IV
219091960|NCT04956302|DRUG|Panobinostat Lactate|Given PO
219091961|NCT02808364|BIOLOGICAL|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
219091962|NCT03381768|BIOLOGICAL|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
219091963|NCT03381768|BIOLOGICAL|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
219091964|NCT00319540|BEHAVIORAL|Control with depression course (CWD)|
219091965|NCT04000295|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
219091966|NCT04000295|DRUG|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
219217820|NCT06765824|DEVICE|Transcranial Magnetic Stimulation Sham|The same protocol described in the intervention group will be carried out in the control group. The device used is the same, the difference is the coil that maintains the same appearance and generates the same sound as the active treatment coil, but unlike the latter, it does not produce an effective magnetization to depolarize the cerebral cortex on which we act.
219217821|NCT01318486|OTHER|Heparin free dialysis technique|Saline flushes or predilution
219217822|NCT01318486|DEVICE|Evodial|Evodial dialyer
219217823|NCT06765616|DRUG|Adebrelimab Injection combined with radiotherapy and chemotherapy|"Radiotherapy regimen: SCRT short-term radiotherapy of 5 × 5Gy Immunotherapy regimen: Adebrelimab Injection 1200 mg or 20 mg/kg, iv., followed by administration on the 1st day of each subsequent chemotherapy cycle.~Chemotherapy regimen: CAPOX regimen (chemotherapy cycle d1, to chemotherapy cycle d14):~Oxaliplatin 130 mg/m2 iv d1~Capecitabine 1000 mg/m2 po bid d1\~14~Repeat every 3 weeks for 6 cycles~After completing 6 cycles of chemotherapy, the patient underwent TME surgery 2-3 weeks later."
219217824|NCT06737263|DEVICE|BioHPP abutment|Patients in the test group receive abutments made of BioHPP
219217825|NCT06737263|DEVICE|Titanium abutment|Patients in the control group receive abutments made of titanium
219217826|NCT06737263|DEVICE|Zirconia abutment|Patients in the control group receive abutments made of zirconia
219217827|NCT06767241|DEVICE|Non-invasive auricular vagus nerve stimulation|Non-invasive transcranial direct current auricular vagus nerve stimulation (tDC-aVNS)
219217828|NCT06767241|OTHER|Standard Medical Therapy|Standard of care treatment for moderate to severe COVID-19
219217829|NCT06765655|DRUG|Insulin Lispro Injection|point-of-care glucose monitoring via fingerstick perioperatively
219091967|NCT04000295|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
219091968|NCT04663022|OTHER|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
219091969|NCT01531452|DRUG|Oxaliplatin|130mg/m2 d1,repeated q21d
219091970|NCT01531452|DRUG|s1|80mg/m2/d, d1-14,repeated q21d
219217830|NCT06765655|DIAGNOSTIC_TEST|glucose testing|POCT glucose testing via fingerstick
219217831|NCT06766318|DEVICE|group A will receive cryo-ultrasound therapy combined with conventional physical therapy for two months|Cryo-ultrasound therapy combines two therapeutic methods: cryotherapy (using cold) and ultrasound (using sound waves). The ultrasound component provides a therapeutic heating effect, improving blood circulation and tissue flexibility, while the cold component reduces pain and inflammation
219217832|NCT06766318|DEVICE|LASER therapy|group B will receive LASER therapy combined with conventional physical therapy.
219217833|NCT06952543|DIAGNOSTIC_TEST|Ultrasound Imaging|"Non-invasive ultrasound will be performed using Angio Flow Reactivity Analysis (AFRA)~The ultrasound probe will be attached to the subject's calf muscle and a pressure cuff will be secured around thigh. Ultrasound data will be collected for 1 minute.~The cuff will then be induced to a tolerable pressure of no more than 160 mm Hg, and ultrasound data will be collected for 3 minutes while cuff is inflated.~The cuff pressure will be released, and ultrasound data will be collected for 2 minutes after the release.~Subject will be asked to perform 1 minute plantar flexion exercise, and ultrasound data will be collected for two minutes after the completion of exercise"
219217834|NCT06771440|OTHER|EPR search|A stored query in the EPR, that checks for re-exposure to the culprit antibiotic or class-member, from the date of AAL registration to the date of patient inclusion
219091971|NCT00279201|DRUG|Insulin glargine|Subcutaneous injection daily
219091972|NCT00279201|DRUG|Lispro Low Mix|Subcutaneous injection twice daily.
219091973|NCT00279201|DRUG|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
219091974|NCT00279201|DRUG|Lispro|Lispro subcutaneous injection 3 times daily.
219091975|NCT01391221|DRUG|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
219091976|NCT00680927|OTHER|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
219217835|NCT06834750|OTHER|Experimental Group|"The application methods of kinesiology tape for the experimental group are as follows:~1. Promoting supraspinatus muscle: Use an I-shaped tape (with natural tension).~2. Promoting the anterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~4. Fixing the shoulder joint: Use an I-shaped tape (with moderate tension).~5. Inhibiting biceps brachii muscle / promoting triceps brachii muscle (depending on the patient's recovery stage and different functional impairments, different taping methods are used).~6. Promoting wrist extensor muscles / inhibiting wrist flexor muscles (depending on the patient's recovery stage and different functional impairments, different taping methods are used)"
219217836|NCT06834750|OTHER|Control group (placebo)|The control group was pasted with sports white tape (the pasting method was the same as above, replaced with sports white tape).
219217837|NCT06443008|DEVICE|Observation Group|On the basis of myoelectric biofeedback treatment in the control group, the control group was trained alternately in each muscle group (triangle muscle, triceps brachii muscle group and forearm extensor muscle group). For example,After disinfection of the triangular, triceps and extensor muscles of the patient, the feedback electrode was attached to the area. The stimulation frequency was set at 50 Hz and the stimulation pulse width was set at 200 μs.During treatment, the patient is instructed to listen carefully to the device's password, drive the affected limb according to the specific password, and then perform tension and relaxation training.For each muscle group, the training time of each muscle group is about 0.5 h, 1 / d.In the later stage of treatment, the training intensity can be increased appropriately, so that the patient can carry out weight lifting during the feedback treatment, and listen to the password issued by the device to carry out muscle strength exercise.
219217838|NCT05374785|DRUG|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
219217839|NCT05374785|OTHER|Placebo|Tablets without CPL409116 as an active substance
219217840|NCT06454617|OTHER|Phantom|The patients will be simultaneously scanned with a QCT phantom
219217841|NCT05671510|DRUG|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
219217842|NCT05671510|DRUG|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
219217843|NCT05652218|DEVICE|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
219217844|NCT05652218|DEVICE|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
219091977|NCT02413164|OTHER|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
219217845|NCT06307938|DIAGNOSTIC_TEST|liquid biopsy|based on a panel of circulating tumor DNA markers
219091978|NCT01444859|DIETARY_SUPPLEMENT|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
219091979|NCT01444859|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 10 weeks
219217846|NCT06057974|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
219217847|NCT06000956|DRUG|Jitongning tablets|The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
219217848|NCT06000956|DRUG|a simulated agent of Jitongning tablets|The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
219091980|NCT01717781|PROCEDURE|Thunderbeat technology|
219091981|NCT01717781|PROCEDURE|Standard bipolar electrosurgery|
219091982|NCT04598867|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
219091983|NCT04598867|DRUG|Placebo|Placebo capsules
219091984|NCT04598867|DRUG|Afobazol|Afobazol 10 mg tabletes
219091985|NCT03281473|OTHER|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
219091986|NCT03281473|OTHER|Strategy 2|PEEP titration according to chest wall elastance measurement
219091987|NCT04980118|BEHAVIORAL|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
219091988|NCT04980118|BEHAVIORAL|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
219091989|NCT00162695|DRUG|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
219091990|NCT06166693|DEVICE|"MINDLiNG Digital Mental Health Intervention"|The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
219091991|NCT03113474|OTHER|Food palatability|Food palatability is modulated
219091992|NCT00316173|DRUG|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
219091993|NCT00316173|DRUG|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
219091994|NCT05857787|DEVICE|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
219217849|NCT06129838|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
219217850|NCT06792994|OTHER|Observational|The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
219217851|NCT02388828|BIOLOGICAL|lentiviral-based CART meso therapy|
219217852|NCT06296992|BEHAVIORAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
219217853|NCT05897294|DRUG|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
219217854|NCT04000750|OTHER|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
219217855|NCT04000750|OTHER|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
219217856|NCT04000750|OTHER|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
219217857|NCT04000750|DIETARY_SUPPLEMENT|Whey Protein|Consumed on all exercise days.
219217858|NCT05020496|DRUG|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
219217859|NCT03065049|BEHAVIORAL|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
219217860|NCT03065049|BEHAVIORAL|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
219217861|NCT01492049|BEHAVIORAL|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
219217862|NCT01492049|BEHAVIORAL|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
219217863|NCT01492049|BEHAVIORAL|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
219217864|NCT00506844|DRUG|Cetuximab, Irinotecan, Capecitabine|
219217865|NCT04277156|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
219217866|NCT04277156|DIETARY_SUPPLEMENT|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
219217867|NCT04382313|PROCEDURE|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
219217868|NCT02243800|OTHER|cholecalciferol versus placebo|
219217869|NCT02919787|DRUG|5-FU|Neoadjuvant treatment
219217870|NCT02919787|DRUG|Oxaliplatine|Neoadjuvant treatment
219217871|NCT02919787|DRUG|Irinotecan|Neoadjuvant treatment
219217872|NCT02919787|PROCEDURE|Pancreatic surgery|All patients
219217873|NCT02919787|DRUG|5-FU|Adjuvant treatment
219217874|NCT02919787|DRUG|Oxaliplatine|Adjuvant treatment
219217875|NCT02919787|DRUG|Irinotecan|Adjuvant treatment
219217876|NCT03270709|DRUG|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
219217877|NCT02232737|OTHER|Very low nicotine content cigarettes|
219217878|NCT04559698|BEHAVIORAL|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
219217879|NCT03971539|DRUG|BI 894416|BI 894416 film-coated tablet.
219217880|NCT03971539|DRUG|Placebo|Placebo film-coated tablet matching BI 894416.
219217881|NCT01147757|DRUG|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
219217882|NCT03507504|OTHER|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
219217883|NCT05600114|DRUG|Cannabidiol oral solution|CBD 150 mg BID
219217884|NCT05600114|DRUG|Cannabidiol oral solution|CBD 300 mg BID
219217885|NCT05600114|DRUG|Placebo|Placebo BID
219217886|NCT06385002|DRUG|Remimazolam|After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
219217887|NCT05943795|DRUG|SI-B001|Administration by intravenous infusion
219217888|NCT05943795|DRUG|Docetaxel|Administration by intravenous infusion
219217889|NCT06385262|DRUG|Alirocumab|300 mg subcutaneously every 4 weeks prior to surgery
219217890|NCT06385262|DRUG|Cemiplimab|350mg IV every 3 weeks prior to surgery
219217891|NCT06385262|DRUG|Chemotherapy|Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
219091995|NCT05857787|DEVICE|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
219091996|NCT03497455|DEVICE|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
219091997|NCT03497455|DEVICE|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
219091998|NCT03497455|OTHER|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
219091999|NCT02792465|DRUG|CFI-402257|
219092000|NCT02792465|DRUG|Fulvestrant|
219092001|NCT05260996|OTHER|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
219092002|NCT04207827|BEHAVIORAL|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
219092003|NCT04207827|BEHAVIORAL|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
219092004|NCT04207827|OTHER|Usual Care|Usual postnatal care
219092005|NCT01172769|BIOLOGICAL|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
219092006|NCT02390531|DRUG|Bevacizumab|Varying dosages in 10µl
219092007|NCT01911377|DRUG|Botulinum Toxin Type A|
219092008|NCT01911377|DRUG|Normal Saline for Injection|
219092009|NCT00511875|DRUG|doxycycline monohydrate|50mg once daily for 24 months
219092010|NCT00511875|DRUG|placebo|placebo taken once daily for 24 months
219217892|NCT00715351|DRUG|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
219682201|NCT05208827|DRUG|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
219682202|NCT05208827|DRUG|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
219092011|NCT00221910|PROCEDURE|Ultrasound|
219092012|NCT01536132|DRUG|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
219092013|NCT01536132|DRUG|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
219092014|NCT05322148|DRUG|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
219092015|NCT00784394|DRUG|diindolylmethane|Given PO
219092016|NCT00784394|OTHER|placebo|Given PO
219092017|NCT00784394|OTHER|pharmacological study|Correlative studies
219092018|NCT00784394|OTHER|laboratory biomarker analysis|Correlative studies
219092019|NCT00784394|OTHER|quality-of-life assessment|Ancillary studies
219092020|NCT06272422|PROCEDURE|hip arthroplasty|resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
219092021|NCT03861910|DIETARY_SUPPLEMENT|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
219092022|NCT02618616|DRUG|ZPL-3893787|
219092023|NCT02618616|DRUG|Placebo|
219092024|NCT05089838|BIOLOGICAL|CMV-TCR-T cells|Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
219092025|NCT01349920|DRUG|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
219092026|NCT04167605|OTHER|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
219092027|NCT04167605|OTHER|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
219092028|NCT01458470|DRUG|Memantine|oral tablet, 1 BID, 24 weeks
219092029|NCT01458470|OTHER|Placebo|oral tablet, 1 BID, 24 weeks
219217893|NCT00715351|DRUG|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
219217894|NCT01872494|OTHER|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
219217895|NCT01872494|OTHER|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
219217896|NCT01872494|DRUG|0.33% ropivacaine 250ml|
219217897|NCT01872494|DRUG|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
219217898|NCT00786864|OTHER|exercise programme|Specific low back pain exercise programme for children
219217899|NCT00368394|DRUG|Insulin glulisine|
219217900|NCT05249153|DRUG|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
219217901|NCT05249153|DRUG|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
219217902|NCT03102853|OTHER|Nordic diet|
219217903|NCT03102853|OTHER|Control diet|
219217904|NCT03987581|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
219217905|NCT03987581|BEHAVIORAL|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
219092030|NCT04049318|OTHER|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
219217906|NCT03987581|BEHAVIORAL|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
219092031|NCT04656379|PROCEDURE|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
219092032|NCT04445480|PROCEDURE|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
219092033|NCT04445480|OTHER|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
219092034|NCT01552564|PROCEDURE|Index of microvascular resistance|
219217907|NCT01087359|DRUG|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
219217908|NCT00416858|DRUG|cisplatin|
219217909|NCT00416858|DRUG|fluorouracil|
219092035|NCT01552564|OTHER|Cardiac magnetic resonance|
219092036|NCT01552564|OTHER|Blood markers|
219092037|NCT04272502|DRUG|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
219092038|NCT02568631|OTHER|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
219092039|NCT02568631|OTHER|control video game|The patients will play 6 sessions of one hour with the control video game
219092040|NCT01005342|OTHER|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
219092041|NCT01005342|OTHER|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
219092042|NCT01005342|OTHER|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
219092043|NCT01005342|OTHER|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
219092044|NCT01005342|OTHER|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
219092045|NCT01005342|OTHER|Control|No fiber was added to control meal (250 g black-currant beverage)
219217910|NCT00416858|PROCEDURE|adjuvant therapy|
219217911|NCT00416858|PROCEDURE|conventional surgery|
219217912|NCT00416858|PROCEDURE|neoadjuvant therapy|
219217913|NCT00416858|RADIATION|radiation therapy|
219682203|NCT02392026|DRUG|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
219217914|NCT02746926|DRUG|tafamidis|
219217915|NCT03595969|DIAGNOSTIC_TEST|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
219217916|NCT02387658|PROCEDURE|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
219217917|NCT02359448|DRUG|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
219217918|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
219217919|NCT02310152|BEHAVIORAL|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
219217920|NCT02310152|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
219217921|NCT03322995|DRUG|First-line Chemotherapy|The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
219217922|NCT03322995|DRUG|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
219217923|NCT03322995|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
219217924|NCT03594305|BEHAVIORAL|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
219217925|NCT06148441|DIAGNOSTIC_TEST|bone morphogenetic protein-2 (BMP-2)|novel biomarkers associated with in-stent restenosis after percutaneous coronary intervention
219682204|NCT02235181|DEVICE|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
219682205|NCT03583879|OTHER|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
219092046|NCT01996579|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
219092047|NCT01996579|OTHER|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
219092048|NCT06358157|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
219092049|NCT00895986|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
219092050|NCT00895986|BEHAVIORAL|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
219092051|NCT00002832|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
219092052|NCT00002832|DRUG|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
219092053|NCT00002832|DRUG|Decitabine|IV for 6 hours every 12 hr for 5 days.
219092054|NCT00002832|PROCEDURE|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
219092055|NCT00002832|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
219092056|NCT04063774|DIAGNOSTIC_TEST|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
219682206|NCT03583879|OTHER|Standard exercise|Functional exercise without a robotic exoskeleton
219682207|NCT03583879|OTHER|No treatment|Wait-list control
219682208|NCT01146535|DRUG|Interferon-alpha|150 IU lozenges bid for 5 days
219682209|NCT01146535|DRUG|Oseltamivir|75 mg capsules bid for 5 days
219682210|NCT01146535|OTHER|maltose|200 mg maltose lozenges bid for 5 days
219682211|NCT00766597|DRUG|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
219682212|NCT01992250|DEVICE|Visica 2 Treatment System|Cryoablation
219682213|NCT01653145|OTHER|Diet A|Dietary
219682214|NCT01653145|OTHER|Diet B|Dietary
219682215|NCT01653145|OTHER|Diet C|Dietary
219092057|NCT03660579|OTHER|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
219092058|NCT03660579|OTHER|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
219092059|NCT03660579|OTHER|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
219092060|NCT03660579|OTHER|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
219092061|NCT03034343|BEHAVIORAL|Mindfulness|
219092062|NCT04849286|DRUG|HTL0016878|Oral solution
219092063|NCT00542880|DRUG|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
219092064|NCT00542880|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
219092065|NCT04310553|PROCEDURE|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
219217926|NCT04762914|OTHER|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
219092066|NCT01778348|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
219092067|NCT01778348|DEVICE|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
219092068|NCT03497650|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
219217927|NCT03026920|PROCEDURE|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
219092069|NCT03497650|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
219217928|NCT01083732|DRUG|dabigatran etexilate|Experimental dose chosen based on age and weight
219217929|NCT02893800|DEVICE|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
219217930|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
219217931|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
219217932|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
219217933|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
219217934|NCT00788541|OTHER|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
219217935|NCT02430766|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
219217936|NCT02430766|DEVICE|NanoKnife|
219217937|NCT04093609|GENETIC|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
219217938|NCT02852252|DRUG|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
219217939|NCT02852252|DRUG|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
219217940|NCT04307056|PROCEDURE|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
219217941|NCT04307056|PROCEDURE|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
219217942|NCT02455427|DEVICE|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
219217943|NCT02455427|OTHER|Physical Therapy|Physical therapy will be administered for 60 minutes
219217944|NCT02455427|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
219217945|NCT02433782|OTHER|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
219217946|NCT01199185|BEHAVIORAL|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
219362092|NCT04230863|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
219092070|NCT01690091|DRUG|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
219092071|NCT01690091|DRUG|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
219092072|NCT05101525|PROCEDURE|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
219092073|NCT01445808|BEHAVIORAL|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
219092074|NCT01445808|BEHAVIORAL|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
219217947|NCT01199185|BEHAVIORAL|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
219217948|NCT00978016|DRUG|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
219217949|NCT00978016|DRUG|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
219217950|NCT00978016|DRUG|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
219217951|NCT00978016|DRUG|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
219217952|NCT00978016|DRUG|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
219092075|NCT01445808|OTHER|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
219092076|NCT02642198|DEVICE|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
219092077|NCT00696384|DRUG|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
219092078|NCT00696384|DRUG|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
219092079|NCT00696384|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
219092080|NCT04984057|DRUG|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
219092081|NCT04984057|DRUG|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
219217953|NCT00978016|DRUG|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
219092082|NCT03117348|OTHER|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
219092083|NCT04552743|DRUG|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
219092084|NCT04552743|DRUG|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
219217954|NCT00545519|DRUG|thymoglobulin|
219217955|NCT03442777|DEVICE|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
219092085|NCT03544892|OTHER|Low carbohydrate diet|60-80 g total carbohydrate per day
219092086|NCT03544892|OTHER|Standard of care diet|\> 150 g total carbohydrate per day
219217956|NCT03442777|DEVICE|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
219217957|NCT04580459|BEHAVIORAL|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
219217958|NCT04580459|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
219217959|NCT05437770|OTHER|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
219217960|NCT05437770|OTHER|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
219217961|NCT00139165|DRUG|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
219217962|NCT00139165|PROCEDURE|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
219217963|NCT03551600|PROCEDURE|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
219217964|NCT06389890|PROCEDURE|Pancreatic resection procedure|Pancreatic resection procedure
219217965|NCT02458924|BIOLOGICAL|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
219217966|NCT03167944|DEVICE|Low thermal electrosurgery system|PEAK Plasmablade
219217967|NCT03167944|DEVICE|Conventional Electrocautery|Conventional Electrocautery
219092087|NCT02129101|DRUG|Azacitidine|Given SC or IV
219092088|NCT02129101|DRUG|Decitabine|Given IV
219092089|NCT02129101|OTHER|Laboratory Biomarker Analysis|Correlative studies
219092090|NCT02129101|OTHER|Quality-of-Life Assessment|Ancillary studies
219092091|NCT02129101|DRUG|Sonidegib|Given PO
219092092|NCT02027402|PROCEDURE|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
219092093|NCT05692505|DIAGNOSTIC_TEST|QuadQuik|Invitro diagnostic device
219092094|NCT04945148|DRUG|Metformin|Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
219092095|NCT04945148|RADIATION|Radiation IMRT|2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
219092096|NCT04945148|DRUG|Temozolomide|75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
219092097|NCT02513069|OTHER|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
219217968|NCT01611545|GENETIC|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
219217969|NCT06274099|OTHER|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
219217970|NCT03484741|BIOLOGICAL|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
219217971|NCT05485818|DRUG|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
219217972|NCT05485818|DRUG|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
219092098|NCT02513069|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
219092099|NCT02513069|BEHAVIORAL|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
219092100|NCT02513069|OTHER|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
219092101|NCT02513069|OTHER|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
219217973|NCT05485818|DRUG|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
219217974|NCT05485818|OTHER|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
219217975|NCT04149132|DEVICE|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
219217976|NCT04149132|DIAGNOSTIC_TEST|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
219217977|NCT04939909|DRUG|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
219217978|NCT05224024|PROCEDURE|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
219217979|NCT04325711|DRUG|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
219217980|NCT01641900|DRUG|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
219217981|NCT01641900|DRUG|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
219217982|NCT04789759|DEVICE|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
219217983|NCT04789759|PROCEDURE|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
219217984|NCT02810600|OTHER|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
219217985|NCT01005849|DIETARY_SUPPLEMENT|Protecflor|1 Capsule to be taken once a day during the entire study period
219217986|NCT01005849|DIETARY_SUPPLEMENT|Placebo|1 Capsule to be taken once a day during the entire study period
219217987|NCT03209700|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
219217988|NCT04790331|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
219092102|NCT02513069|OTHER|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
219092103|NCT02513069|OTHER|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
219217989|NCT04790331|DRUG|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
219217990|NCT04790331|DRUG|Placebo|Placebo oral tablet
219217991|NCT03723031|DRUG|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
219217992|NCT02330588|BEHAVIORAL|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
219217993|NCT02330588|BEHAVIORAL|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
219092104|NCT03513757|DRUG|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
219092105|NCT03513757|DRUG|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
219092106|NCT03513757|DRUG|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
219092107|NCT03513757|DRUG|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
219092108|NCT03513757|DRUG|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
219092109|NCT03513757|DRUG|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
219092110|NCT01767168|OTHER|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
219092111|NCT01949779|DEVICE|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
219092112|NCT02859402|DRUG|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
219217994|NCT02330588|BEHAVIORAL|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
219092113|NCT02859402|DRUG|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
219092114|NCT00002892|BIOLOGICAL|recombinant interferon alfa|
219092115|NCT05174663|OTHER|Almond-enriched diet - 1.5 oz|Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
219092116|NCT05174663|OTHER|Almond-enriched diet - 2.5 oz|Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
219092117|NCT05174663|OTHER|Control snack|Participants will receive a control snack daily for 16 weeks.
219092118|NCT03169218|OTHER|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
219092119|NCT03169218|OTHER|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
219217995|NCT04051333|DEVICE|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
219217996|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
219217997|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
219092120|NCT00661739|DRUG|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
219092121|NCT01048814|OTHER|ChemoFx|Chemoresponse Marker Assay
219092122|NCT02252419|DRUG|Dexamethasone|Dexamethasone will be administered.
219092123|NCT02252419|DRUG|Paracetamol|Paracetamol will be administered.
219092124|NCT05369715|OTHER|Exercise|Aerobic exercise
219092125|NCT02832206|PROCEDURE|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
219092126|NCT01865955|PROCEDURE|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
219092127|NCT01865955|DEVICE|The spinal needle|
219092128|NCT03688061|BIOLOGICAL|ChAd3-hliNSmut|Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV
219092129|NCT03688061|BIOLOGICAL|MVA-hliNSmut|Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
219092130|NCT03018964|PROCEDURE|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
219092131|NCT03018964|PROCEDURE|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
219092132|NCT04092725|DRUG|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
219092133|NCT04092725|DRUG|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
219092134|NCT02660814|OTHER|Non-surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
219092135|NCT02660814|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
219217998|NCT03220724|BIOLOGICAL|CH505TF|Administered by intramuscular (IM) injection in the thigh
219217999|NCT03220724|BIOLOGICAL|CH505w53|Administered by IM injection in the thigh
219218000|NCT03220724|BIOLOGICAL|CH505w78|Administered by IM injection in the thigh
219218001|NCT03220724|BIOLOGICAL|CH505 M5|Administered by IM injection in the thigh
219218002|NCT03220724|BIOLOGICAL|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
219218003|NCT03220724|BIOLOGICAL|Placebo|Administered by IM injection in the thigh
219218004|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
219218005|NCT00743574|DRUG|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
219092136|NCT03450902|COMBINATION_PRODUCT|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
219092137|NCT03450902|COMBINATION_PRODUCT|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
219092138|NCT03450902|COMBINATION_PRODUCT|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
219218006|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
219218007|NCT00743574|DIETARY_SUPPLEMENT|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
219218008|NCT00449774|DRUG|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
219218009|NCT00449774|DRUG|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
219218010|NCT03022968|DRUG|[18F]T807 PET|Imaging with \[18F\]T807 PET
219218011|NCT05085535|OTHER|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
219218012|NCT05085535|OTHER|Exercise|Exercises for body mobility and muscle toning, Sophrology
219218013|NCT04383184|PROCEDURE|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
219092139|NCT03450902|OTHER|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
219092140|NCT04251884|PROCEDURE|Local anesthetic (ropivacaine)|Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
219218014|NCT01507506|RADIATION|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
219218015|NCT01507506|RADIATION|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
219218016|NCT03378791|DRUG|Iron bisglycinate Oral Tablet|
219218017|NCT03378791|DRUG|Ferrous Fumarate Oral Tablet|
219218018|NCT00232375|DRUG|Insulin|
219218019|NCT05421117|PROCEDURE|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
219218020|NCT03529305|DEVICE|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
219218021|NCT03529305|OTHER|Physical therapy|Receive physical therapy
219218022|NCT03204032|DRUG|Tegafur|Tegafur 40-60mg po bid(d1-d14);
219218023|NCT03204032|DRUG|Temozolomide|200mg po qd(d10-d14)
219218024|NCT03204032|DRUG|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
219218025|NCT05969899|DRUG|FOLFIRI+Bevacizumab|irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
219218026|NCT04819698|OTHER|Troponin I (cTnI ) monitoring|cTnI will be measured at baseline prior to surgery, as well as on 1h,12h, 24h and 72h after surgery for each patient in study B.
219218027|NCT01664741|DRUG|Nicotine patch - transdermal|21 mg patch
219218028|NCT01664741|DRUG|placebo|
219218029|NCT05316259|DRUG|BPI-16350|Administered orally
219218030|NCT04535856|DRUG|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"
219092141|NCT02268695|DRUG|Cisplatin|
219218031|NCT04535856|OTHER|Placebo|Control group (placebo)
219218032|NCT02448069|DRUG|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
219218033|NCT05132049|DRUG|DA-5211|single dose administration (DA-5211 one tablet once a day)
219218034|NCT05132049|DRUG|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
219218035|NCT03212885|DEVICE|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
219218036|NCT05211232|DRUG|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
219218037|NCT05211232|DRUG|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
219092142|NCT02268695|DRUG|5-Fluorouracile|
219092143|NCT02268695|DRUG|Docetaxel|
219092144|NCT02268695|DRUG|Cetuximab|
219218038|NCT01809457|OTHER|educational poster|educational poster for dental trauma
219218039|NCT05511545|OTHER|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
219092145|NCT02268695|DRUG|granulocyte colony-stimulating factor (G-CSF)|
219092146|NCT04179721|BEHAVIORAL|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
219092147|NCT04179721|BEHAVIORAL|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
219092148|NCT01989143|DRUG|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
219092149|NCT01989143|DRUG|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
219218040|NCT04243200|OTHER|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
219092150|NCT01989143|DRUG|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
219092151|NCT01989143|DRUG|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
219092152|NCT01989143|DRUG|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
219092153|NCT01989143|DRUG|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
219092154|NCT03613805|DEVICE|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
219092155|NCT03613805|DEVICE|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
219092156|NCT01405625|OTHER|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
219092157|NCT01405625|OTHER|AAAAI standard of care written action plan|
219092158|NCT01696448|DIETARY_SUPPLEMENT|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
219092159|NCT01696448|OTHER|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
219218041|NCT01026805|DEVICE|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
219218042|NCT00442104|DRUG|Ganaxolone|
219092160|NCT01738880|DRUG|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
219092161|NCT01738880|DRUG|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
219092162|NCT00256958|PROCEDURE|total knee replacement|
219092163|NCT03637244|BEHAVIORAL|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
219092164|NCT04225988|DRUG|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
219092165|NCT04225988|DRUG|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
219092166|NCT04327141|BEHAVIORAL|P-IF|Protein pacing and intermittent fasting
219092167|NCT04327141|BEHAVIORAL|HH|Heart Healthy
219218043|NCT00830856|DRUG|Fluconazole|Fluconazole 800mg po qday
219218044|NCT00830856|DRUG|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
219218045|NCT00830856|DRUG|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
219218046|NCT03268135|DIAGNOSTIC_TEST|measurement of RNAs|
219092168|NCT00265135|DRUG|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
219092169|NCT05752799|DRUG|Opioid Free Anaesthesia|"* 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
219092170|NCT05752799|DRUG|Opioid based anesthesia|"* 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
219092171|NCT05403099|OTHER|Hyaluronic acid|immediate placement of dental implant after topical application of hyaluronic acid on implant surface
219092172|NCT05403099|OTHER|conventional implant placement|immediate placement of dental implant without application of hyaluronic acid on implant surface
219218047|NCT03044652|DEVICE|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
219218048|NCT03044652|DRUG|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
219218049|NCT02142309|DRUG|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
219218050|NCT02142309|DRUG|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
219218051|NCT02142309|DRUG|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
219218052|NCT02142309|DRUG|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
219218053|NCT01857076|PROCEDURE|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
219218054|NCT01857076|PROCEDURE|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
219218055|NCT01857076|OTHER|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
219218056|NCT02576691|DEVICE|percutaneous coronary intervention|
219218057|NCT03578978|OTHER|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
219218058|NCT02798653|DRUG|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
219218059|NCT02798653|DRUG|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
219218060|NCT02798653|DRUG|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
219218061|NCT06850792|BEHAVIORAL|Telemedicine-Based Adherence Support|The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.
219218062|NCT06125197|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
219218063|NCT06125197|BIOLOGICAL|KEYTRUDA®|pembrolizumab, a monoclonal antibody binding PD-1
219218064|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
219218065|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
219218066|NCT00987272|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
219218067|NCT00987272|DRUG|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
219218068|NCT03328364|DRUG|enzalutamide|oral
219218069|NCT03328364|DRUG|docetaxel|intravenous infusion
219218070|NCT05995262|OTHER|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
219218071|NCT06950749|PROCEDURE|Robotic Gloves assisted Task-oriented mirror therapy|"Robotic gloves assissted task-oriented Mirror therapy along with conventional therapy.~Conventional therapy consists of stretching exercises,active assisted and active ROMS of shoulder along with weight bearing and reaching activities.~Robotic gloves assisted task-oriented Mirror therapy will be delivered by syrebo robotic hand rehabilitation device.~it has different training modes including Mirror mode and task-oriented training.~5 sessions per week will be provided for 8 weeks exercises: 30 minutes (3 sets of 10 reps)~* In mirror training mode: Synchronized flexion and extension training with both hands."
219218072|NCT06950749|PROCEDURE|Task-Oriented Mirror Therapy|"Interventional group (B) will receive Task-Oriented Mirror Therapy along with conventional therapy.~To perform Task-Oriented Mirror Therapy both the extremities of the subject will be placed on the table and the mirror (40×60 cm) will be placed in the patients' mid-sagittal plane. Mirror will be placed in such a way that the reflection of the non-affected arm can be seen. The subjects will be instructed to perform the movement bilaterally. The movement on the impaired limb will be performed. Affected arm is involved in exercise therapy either through patients trying to move themselves or with a therapist in assisting movement.~5 sessions per week will be provided for 8 weeks.~* Task-Oriented Mirror therapy exercises: 30 minutes. (3 sets of 10 reps)~* Hand flexion and extension through the tennis ball.~* Grasping and releasing (cylindrical grasp, spherical grasp, hook grasp, pincer grasp)~* Task oriented activities: positioning the cup upright, carrying a woode"
219218073|NCT04584658|DIAGNOSTIC_TEST|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
219092173|NCT02624739|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
219092174|NCT04602884|DIAGNOSTIC_TEST|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
219092175|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
219092176|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
219092177|NCT00419822|PROCEDURE|Acupuncture|6 Acupuncture visits
219092178|NCT00419822|PROCEDURE|Sham Acupuncture|6 Acupuncture visits with sham procedure
219092179|NCT00419822|OTHER|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
219092180|NCT00158665|BIOLOGICAL|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
219092181|NCT05361655|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
219092182|NCT05361655|DRUG|Aromatase inhibitor|Aromatase inhibitor therapy
219092183|NCT04119388|OTHER|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
219092184|NCT00693251|PROCEDURE|Crush technique|Crush technique
219092185|NCT00693251|PROCEDURE|provisional T stenting|Provisional T stenting
219092186|NCT00379132|DRUG|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
219092187|NCT05901038|DEVICE|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
219092188|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
219092189|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
219092190|NCT06673394|DRUG|Complement protein C5 inhibitor|Investigational arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline). Terminal complement complex inhibition by eculizumab predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Meningococcal vaccination will not be effective in this timeframe; instead, all enrolled patients will receive antibiotic prophylaxis against N meningitidis from the time of the first dose of the study drug to 8 weeks after the last administration.
219092191|NCT06673394|DRUG|IVMP|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
219092192|NCT03444376|DRUG|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
219092193|NCT03444376|DRUG|KEYTRUDA®|pembrolizumab(100mg/4mL/vial), Intravenous administration
219092194|NCT07061080|DRUG|Tarlatamab|Tarlatamab as a standalone treatment through intravenous infusion at 10 mg dose every 14 days (i.e. 2 weeks)
219092195|NCT07061080|DRUG|standard of care second-line chemotherapy (FOLFIRI)|FOLFIRI:: irinotecan intravenously 180 mg/m2 on day 1, followed by 400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion, a 10-min bolus of 400 mg/m2 5-FU, and 2400 mg/m2 5-FU over 46 hours; every 14 days).
219092196|NCT07061509|OTHER|Battery of Physical and Psychological Assessments|Participants in this observational study will not receive any therapeutic intervention. Instead, all individuals will undergo a series of standardized non-invasive assessments for data collection purposes. These include the Exercise Dependence Scale-21 (EDS-21) to classify exercise addiction status, the Drive for Muscularity Scale (DMS) to evaluate body image and muscle-related attitudes, and the Extended Nordic Musculoskeletal Questionnaire to determine the presence and severity of musculoskeletal symptoms. Cardiovascular risk will be assessed using the SCORE Risk Assessment System, which incorporates blood pressure, cholesterol, blood glucose, smoking status, and demographic data. Additional measurements will include oxygen saturation and heart rate using pulse oximetry, and blood pressure using a sphygmomanometer. These evaluations are intended solely for comparative analysis between exercise-dependent and non-dependent groups.
219218074|NCT04584658|DIAGNOSTIC_TEST|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
219218075|NCT04584658|OTHER|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
219218076|NCT04584658|OTHER|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
219218077|NCT04732000|DRUG|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
219218078|NCT04732000|OTHER|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
219218079|NCT06145984|BEHAVIORAL|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
219362093|NCT05911646|OTHER|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe \>81."
219092197|NCT07094620|RADIATION|Non-surgical rhinoplasty|Non-surgical rhinoplasty using hyaluronic acid at baseline consultation.
219092198|NCT07094698|OTHER|sacral stimulation|A low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.
219092199|NCT07094828|OTHER|AOMI with D-Wall|"The intervention group will follow routine rehabilitative activity in the morning and will perform one hour of Action Observation and Motor Imagery training with augmented visual feedback (D-Wall) in the afternoon, three times a week.~Each session will be conducted as follows: first AO (Action Observation), then MI (Motor Imagery). During the MI phase, participants will be asked to imagine the motor tasks and then perform them, receiving real-time augmented visual feedback provided by the digital mirror."
219092200|NCT07094828|OTHER|Routine physiotherapy with D-Wall|The control group will also follow routine rehabilitative activity in the morning, while in the afternoon they will perform motor training of the same duration, without Action Observation and Motor Imagery, but solely with augmented visual feedback (D-Wall), with the same weekly frequency.
219092201|NCT07094048|DRUG|Target trough IgG level of 8-10 g/L|Target trough IgG level of 8-10 g/L
219092202|NCT07094048|DRUG|Target trough IgG level 4-6 g/L|Target trough IgG level of 4-6 g/L
219092203|NCT07094048|DRUG|No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L|If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B
219092204|NCT07088315|DEVICE|TECAR therapy|TECAR therapy was applied to the lower limbs of patients diagnosed with lipedema using the BTL-6000 TR-Therapy PRO device (BTL, Turkiye). All treatment sessions were performed by a physiotherapist with specific experience in TECAR therapy. The device operated at a frequency of approximately 500 kHz and employed three types of electrodes: active, neutral, and static application electrodes. Two types of active electrodes -capacitive and resistive- were utilized and applied directly to the treatment area. The neutral electrode, serving as a reference point, was placed in proximity to the target region to ensure effective energy transfer.
219092205|NCT07088315|OTHER|compression|All participants were provided with individually fitted compression garments (either pantyhose-type or thigh-high models, in class I \[18-21 mmHg\] or class II \[23-32mmHg\] depending on symptom severity and tolerance), and were instructed to wear them during waking hours for a minimum of 8 hours per day. Adherence to garment usage was monitored through patient diaries and reinforced at follow-up visits.
219092206|NCT07088315|OTHER|Exercise|All patients were advised to engage in a structured walking program, consisting of moderate-intensity walking (perceived exertion level 11-13 on the Borg scale), for at least 20 minutes per session, three times per week.
219092207|NCT07093931|DRUG|lobaplatin|30mg / m2 i.v. q3w
219092208|NCT07093931|DRUG|carboplatin|AUC 5-6 i.v. q3w
219092209|NCT07093931|DRUG|Docetaxel or albumin paclitaxel|Docetaxel ( 75 mg / m2 i.v. d1, q3w ) or albumin paclitaxel ( 260 mg / m2 i.v. d1, q3w )
219092210|NCT07093931|DRUG|Trastuzumab|6 cycles of treatment, according to the instructions recommended dosage.
219092211|NCT07093931|DRUG|pertuzumab|6 cycles of treatment, according to the instructions recommended dosage.
219092212|NCT07093099|BEHAVIORAL|Enhanced Education Package for Bowel Preparation|"a multifaceted intervention was designed to improve mechanical bowel preparation (MBP) in patients undergoing colonoscopy. It included:~Structured face-to-face counseling on the importance of bowel prep, potential complications of poor prep, and how to follow instructions.~A 6-minute instructional video explaining step-by-step dietary and medication instructions.~A printed booklet with visual aids summarizing key steps.~A mobile phone app delivering interactive reminders, tracking tools, and preparation guidance.~All participants used the same polyethylene glycol-based bowel cleansing agent."
219092213|NCT07093099|OTHER|Standard Education Leaflet|Participants in this arm received a standard hospital-issued bowel preparation instruction leaflet. The document provided written instructions on dietary modifications, timing and dosage of the bowel cleansing agent, and day-of-procedure guidance. No personalized counseling, video support, or reminder tools were provided. This reflects the routine care practice at the study hospitals.
219092214|NCT07093918|OTHER|V-echo|Imaging system
219092215|NCT07093918|OTHER|L-echo|Imaging system
219092216|NCT07092696|DRUG|Toripalimab|"Induction chemo-immunotherapy (platinum-based tri-weekly regimen)~* Paclitaxel 175 mg/m² IV on day 1~* Cisplatin 50 mg/m² IV on day 1 or carboplatin AUC 4-5 IV on day 1~* Toripalimab 240 mg IV on day 1, administered immediately before each chemotherapy infusion Cycle length: every 3 weeks Number of cycles: 2 Concurrent chemoradiotherapy (weekly regimen)~* Radiation therapy delivered according to institutional protocol~* Cisplatin 40 mg/m² IV once weekly~* Toripalimab 240 mg IV on day 1 of every 3-week cycle, given before chemotherapy Cycle length: every 3 weeks during radiotherapy~Maintenance immunotherapy~• Toripalimab 240 mg IV on day 1 every 3 weeks (Q3W) Duration: 1 year (total 13 cycles)"
219092217|NCT07092696|RADIATION|Pelvic External-Beam Radiotherapy (EBRT)|"* PTV: 6 MV photons, 1.80 Gy per fraction × 28 fractions = 50.4 Gy.~* PGTVnd: 6 MV photons, 2.14 Gy per fraction × 28 fractions = 59.92 Gy. Brachytherapy:Dose prescriptions~* Dose: 7.00 Gy per fraction × 4 fractions = 28.0 Gy."
219092218|NCT07093996|PROCEDURE|Endoscopic pancreatic duct stent placement|Endoscopic pancreatic duct stent placement will be performed with a 5Fr Boston Scientific pancreatic stent (3-4 cm in length) within 24 hours from the randomization procedure. The stent will be removed on the 5th day after installation.
219092219|NCT07093996|DRUG|Conventional treatment of acute pancreatitis in early phase|Infusion therapy, pain relief, nutritional support and surgical procedure if needed
219092220|NCT07093255|DRUG|FLQ-101|"The invervention comprises 3 Groups:~* Group 1: Low Dose~* Group 2: Middle Dose~* Group 3: High Dose"
219092221|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
219092222|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
219092223|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
219092224|NCT07092683|OTHER|anemia|preoperative anemia
219092225|NCT07092683|OTHER|nonanemia|preoperative nonanemia
219092226|NCT06920186|PROCEDURE|Analgesia|1-Adductor canal block + surgical infiltration
219092227|NCT06920186|PROCEDURE|Analgesia|2-Adductor canal block + femoral-cutaneous block + obturator block + IPACK block
219218080|NCT06145984|BEHAVIORAL|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
219218081|NCT03230643|DEVICE|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
219218082|NCT03106922|DRUG|PMF104|"Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
219092228|NCT05550064|OTHER|Structured contraceptive counseling|"1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
219092229|NCT06932783|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. The top electrode will be placed at ST36 (via acupuncture point) and the electrode patch will be placed vertically.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)."
219092230|NCT06932783|DEVICE|Sham Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply sham TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. Sham TEA will be performed via one point on the leg and not on any meridian or acupoints that were used in previous gastrointestinal studies and did not yield any significant effects.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)"
219092231|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
219092232|NCT06104956|DRUG|HFNO Standard of care|Weaning methods will be left to the free choice of the practitioner.
219092233|NCT06932809|DRUG|18F-JSS20-183A PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 18F-JSS20-183A.
219092234|NCT06932809|DIAGNOSTIC_TEST|Brain MRI|MRI scan of the brain.
219092235|NCT06932809|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB.
219092236|NCT06932809|BEHAVIORAL|Neurological Assessments|Neurological assessments, including a video interview.
219092237|NCT06936241|OTHER|Circuit weight training|"The Circuit Training protocol will be performed as follows:~wall push-up, bridge on floor, single leg bridge, bird dog, windshield wiper, march in place, ball squat, squat with an overhead press, reverse pendulum, jumping rope, and spinal twist, 30-35 minutes, 3 times a week for 8 weeks"
219092238|NCT06936241|OTHER|Traditional physical therapy program|The participants will receive traditional physical therapy program in the form of therapeutic exercises to keep daily living activity by restoring the strength of flexors and abductors of the shoulder joint using the shoulder wheel and ladder. It will be performed 3 times per week for eight weeks
219092239|NCT07093593|OTHER|Mandatory biological samples (blood and sell)|"At cycle 1 and Cycle 3 :~* Stool sample collection~* Blood sample collection (5 EDTA tubes)"
219092240|NCT07094308|BEHAVIORAL|Learn Intestinal Failure Tele-ECHO Program|LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a virtual tele-education program designed to improve the knowledge and clinical decision-making of non-specialist clinicians managing patients with chronic intestinal failure (CIF) on parenteral nutrition (PN). The intervention consists of eight 60-90-minute sessions delivered over 2-4 months. Each session includes the presentation of anonymized real-world CIF cases and a didactic lecture by an expert in intestinal rehabilitation. Participating physicians may also complete baseline and follow-up surveys, and optionally participate in focus groups or appreciative inquiry workshops.
219092241|NCT07094308|BEHAVIORAL|Standard of Care|Participants will receive routine clinical care for chronic intestinal failure from their usual providers. No additional educational programming or intervention is delivered during this period.
219092242|NCT07092761|DEVICE|GS3 CGM|Wearing CGM for a consecutive 14 days
219092243|NCT04499859|DRUG|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
219092244|NCT04499859|DRUG|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
219092245|NCT07164235|OTHER|Patients diagnosed with spondylodiscitis|Patients admitted to the Infectious Diseases Department of the University Hospital of Alessandria between January 1, 2017, and December 31, 2024, who were diagnosed with spondylodiscitis
219092246|NCT06249828|DEVICE|MegaCarti^®|MegaCarti® application after microfracture through athroscopic or incision surgery
219218083|NCT03106922|DRUG|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
219218084|NCT01238146|DRUG|bendamustine hydrochloride|Given IV
219218085|NCT01238146|DRUG|obatoclax mesylate|Given IV
219218086|NCT01238146|BIOLOGICAL|rituximab|Given IV
219218087|NCT05533658|DIETARY_SUPPLEMENT|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
219218088|NCT05533658|DIETARY_SUPPLEMENT|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
219218089|NCT00790413|DRUG|iodine I 131 metaiodobenzylguanidine|
219092247|NCT06249828|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
219092248|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
219092249|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
219092250|NCT00658437|DRUG|CY-503|solution for subcutaneous injection, 350 ng twice weekly
219092251|NCT01984697|BIOLOGICAL|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
219092252|NCT03070496|BIOLOGICAL|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
219092253|NCT03070496|PROCEDURE|ECG|ECG will be performed at 6 months after myocardial infarction
219092254|NCT03070496|DEVICE|MRI|MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
219092255|NCT03070496|OTHER|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
219092256|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
219092257|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
219092258|NCT03308825|BIOLOGICAL|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
219092259|NCT05763641|PROCEDURE|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
219092260|NCT00001579|DRUG|5-Fluorouracil|
219092261|NCT00001579|DRUG|Ethynyluracil|
219092262|NCT00001579|DRUG|Leucovorin|
219092263|NCT03178279|OTHER|Physical Health Plan|Use of a Physical Health Plan by service users
219092264|NCT01313143|DRUG|AOP200704|Comparison of AOP200704 with Esmolol
219092265|NCT01313143|DRUG|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
219092266|NCT06320626|OTHER|Emicizumab - PK-guided dose reduction|PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
219092267|NCT06320626|OTHER|Emicizumab - Dosis continuation group|Continue on their current dose regimen
219218090|NCT00790413|DRUG|Fludarabine|
219218091|NCT00790413|DRUG|Thiotepa|
219218092|NCT00790413|PROCEDURE|T-cell depletion|
219218093|NCT00790413|PROCEDURE|Haploidentical stem cell transplantation|
219218094|NCT00790413|PROCEDURE|Donor Lymphocyte Infusion|
219218095|NCT00790413|DRUG|Rituximab|
219218096|NCT00790413|PROCEDURE|Co-transplantation of mesenchymal stem cells|
219218097|NCT06152640|DEVICE|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
219218098|NCT06152640|DEVICE|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given."
219218099|NCT06152640|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
219218100|NCT00885313|DRUG|DHA250|DHA 250 mg/kg/d
219218101|NCT00885313|DRUG|DHA500|DHA 500 mg/kg/d
219218102|NCT00885313|DRUG|PLACEBO|placebo
219218103|NCT00885313|BEHAVIORAL|Lifestyle intervention|lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
219218104|NCT03551379|DEVICE|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
219218105|NCT05493644|OTHER|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
219218106|NCT05493644|OTHER|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
219218107|NCT05493644|OTHER|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
219218108|NCT05493644|OTHER|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
219218109|NCT05408624|PROCEDURE|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
219218110|NCT05408624|PROCEDURE|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
219218111|NCT02463448|BIOLOGICAL|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
219218112|NCT01307085|PROCEDURE|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
219218113|NCT01650896|OTHER|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
219218114|NCT05166590|BEHAVIORAL|Sleep Restriction|Sleep Deprivation
219218115|NCT01911767|DRUG|Dimethyl fumarate|Administered as specified in treatment arm.
219218116|NCT01911767|DRUG|Peginterferon beta-1a|Administered as specified in treatment arm.
219218117|NCT03562325|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
219218118|NCT02479672|DEVICE|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
219218119|NCT02479672|PROCEDURE|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
219218120|NCT02479672|DEVICE|VividTrac®|
219218121|NCT05838781|DIAGNOSTIC_TEST|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
219218122|NCT05838781|DIAGNOSTIC_TEST|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
219218123|NCT03789734|BIOLOGICAL|BLS-M22|BLS-M22 250mg/capsule
219218124|NCT03789734|OTHER|Placebo|BLS-M22 placebo 250mg/capsule
219218125|NCT05623436|BEHAVIORAL|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
219218126|NCT06195813|DIETARY_SUPPLEMENT|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
219218127|NCT06195813|OTHER|Placebo capsule|Placebo capsule is categorized as other.
219218128|NCT00610558|DEVICE|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
219218129|NCT00610558|DEVICE|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
219218130|NCT00610558|DEVICE|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
219218131|NCT05645068|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
219218132|NCT05645068|OTHER|multidisciplinary care program|multidisciplinary care program including sports activity
219218133|NCT01557036|DEVICE|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
219092268|NCT06320626|OTHER|Emicizumab - Dose adjustment group|Adjusted in dosing regimen according to local protocol
219218134|NCT01291628|DEVICE|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
219218135|NCT04639869|DRUG|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
219218136|NCT04639869|DRUG|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
219092269|NCT00000844|DRUG|Interferon alfa-n3|
219092270|NCT00000844|DRUG|Interferon alfa-n1|
219092271|NCT03265054|BIOLOGICAL|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
219092272|NCT01332396|DRUG|Lapatinib|
219092273|NCT00847405|DRUG|Sumatriptan Succinate|100 mg Tablets
219092274|NCT00847405|DRUG|Imitrex®|100 mg Tablet
219092275|NCT04614883|DEVICE|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
219092276|NCT04614883|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
219092277|NCT02359643|DRUG|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
219218137|NCT04802018|DEVICE|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
219218138|NCT04718610|OTHER|Osteopathic intervention|Nerve vagus stimulation
219218139|NCT04718610|BIOLOGICAL|CRP assessment|Blood CRP will be assessed during trial
219218140|NCT04718610|BEHAVIORAL|QLQ-C30 questionnaire|Completion of QLQ-C30
219218141|NCT03253367|OTHER|Blood is obtained, mostly during routine venipuncture|
219218142|NCT06457516|COMBINATION_PRODUCT|Mirror Therapy|A mirror is used to create a reflective illusion of an affected limb in order to trick the brain into thinking movement has occurred without pain, or to create positive visual feedback of a limb movement. It involves placing the affected limb behind a mirror.
219218143|NCT06457516|OTHER|Music Therapy|Music therapy, an allied health profession, the clinical and evidence-based use of music interventions to accomplish individualized goals
219218144|NCT02809599|BEHAVIORAL|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
219218145|NCT00463229|OTHER|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
219092278|NCT02962856|DRUG|BAY987517|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
219092279|NCT02962856|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
219092280|NCT02294825|PROCEDURE|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
219092281|NCT05432908|BEHAVIORAL|Orofacial exercises and oropharyngeal functions|Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
219092282|NCT02422719|DRUG|Radotinib|Radotinib 400mg bid
219218146|NCT00982436|DRUG|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
219218147|NCT00982436|RADIATION|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
219092283|NCT04737109|DRUG|Ipatasertib|Ipatasertib
219092284|NCT04737109|DRUG|Darolutamide|Darolutamide
219092285|NCT04737109|DRUG|Androgen Deprivation Therapy|ADT per institutional standards
219092286|NCT04959630|BEHAVIORAL|Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)|Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
219092287|NCT00949715|DEVICE|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
219092288|NCT00949715|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
219092289|NCT00844740|DRUG|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
219092290|NCT03853356|DEVICE|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
219092291|NCT06349018|OTHER|Dietary Supplement: High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
219092292|NCT06349018|OTHER|Dietary Supplement: No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
219092293|NCT05963152|BEHAVIORAL|Habitual Physical Activity|Participants will be asked to maintain their normal activity levels
219092294|NCT05963152|BEHAVIORAL|Morning Exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
219092295|NCT05963152|BEHAVIORAL|Afternoon Exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
219218148|NCT00982436|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
219218149|NCT05090631|GENETIC|DNA analysis|GWAS
219218150|NCT04478487|DIETARY_SUPPLEMENT|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
219218151|NCT03452254|DEVICE|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
219092296|NCT01166490|DRUG|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
219092297|NCT02287350|DRUG|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
219218152|NCT03452254|DEVICE|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
219218153|NCT03452254|OTHER|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
219218154|NCT01932970|DRUG|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
219218155|NCT01594957|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
219218156|NCT04228913|OTHER|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
219218157|NCT01150656|GENETIC|gene expression analysis|
219218158|NCT01150656|GENETIC|microarray analysis|
219218159|NCT01150656|GENETIC|protein expression analysis|
219218160|NCT01150656|GENETIC|reverse transcriptase-polymerase chain reaction|
219218161|NCT01150656|GENETIC|western blotting|
219218162|NCT01150656|OTHER|laboratory biomarker analysis|
219218163|NCT01150656|OTHER|pharmacological study|
219092298|NCT05636150|DRUG|Fruquintinib in Combination with S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
219092299|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
219092300|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
219092301|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
219092302|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
219218164|NCT00609297|OTHER|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
219218165|NCT00609297|OTHER|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
219218166|NCT00609297|OTHER|survey administration|Given to patient and caregivers throughout the study
219218167|NCT00144040|BEHAVIORAL|Physician & patient education on appropriate antibiotic use|
219092303|NCT05699122|OTHER|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
219092304|NCT05699122|OTHER|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
219092305|NCT02198495|DRUG|Supplementation of ferric carboxymaltose|
219092306|NCT02198495|DRUG|Supplementation of iron sucrose|
219092307|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
219092308|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
219092309|NCT02675478|DRUG|AC220|
219092310|NCT05890625|OTHER|On going treatment|No additional attempts will be made by the investigator on the cases in the control group. These cases will only benefit from the services in the clinic.
219218168|NCT00144040|PROCEDURE|Rapid C-reactive protein testing to guide antibiotic treatment|
219218169|NCT00978588|DRUG|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
219218170|NCT01362075|PROCEDURE|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
219218171|NCT01362075|PROCEDURE|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
219218172|NCT03380494|OTHER|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
219218173|NCT03380494|OTHER|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
219218174|NCT03177590|OTHER|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
219092311|NCT05890625|OTHER|InT-mAp|InT-mAp, the content of which will be created as a result of the evaluation of the nursing needs of infertile women, consists of a web-based training and online consultancy platform. The treatment plan specific to each participant will be entered into the web base individually, and the participants will be able to follow and manage the treatment protocols and appointments under their own control. InT-mAp is a guide that helps breakers about the intended use, effects, side effects of the drugs under treatment and how to self-administer, especially for women.
219092312|NCT02259517|DRUG|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
219092313|NCT02259517|DRUG|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
219092314|NCT06197555|OTHER|Sodium Monofluorophosphate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
219092315|NCT06197555|OTHER|Stannous Fluoride|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
219092316|NCT06197555|OTHER|Nano-Hydroxyapatite|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
219092317|NCT06197555|OTHER|8% Arginine & Calcium Carbonate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
219092318|NCT01807806|BEHAVIORAL|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
219092319|NCT03657498|PROCEDURE|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
219092320|NCT03657498|PROCEDURE|Standard orthodontic treatment|treatment with standard orthodontic procedures
219218175|NCT01767467|BIOLOGICAL|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
219218176|NCT01767467|DRUG|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
219218177|NCT03504904|BEHAVIORAL|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
219218178|NCT03958773|DEVICE|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
219092321|NCT02540694|DEVICE|Endosonography|
219092322|NCT01352585|DRUG|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
219092323|NCT00605202|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
219092324|NCT00605202|DIETARY_SUPPLEMENT|Licorice|Licorice candy 32 grams a day for 14 days.
219092325|NCT01126827|BEHAVIORAL|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
219092326|NCT06452056|DEVICE|Rapid Antigen Screening Test|A point-of-care Rapid Antigen Screening Test (RAST) using a lateral flow immunoassay platform with our partner, BioMedomics Inc. The BioMedomics RAST is a lateral flow immunoassay that detects the nucleocapsid protein (NP) antigen of SARS-CoV-2 using a double antibody sandwich assay. The test cassette contains one detection line (T) fixed with anti-SARS-CoV-2 NP antibody and one quality control line (C) fixed with control antibody. When the test sample is treated with lysis buffer and added to the sample well of the test cassette, the fluid will move forward along the test strip via capillary action. If the sample contains NP antigen at levels higher than the limit of detection, the antigen will bind to the NP capture antibody as well as the immobilized detection antibody on the membrane forming a red T line, indicating a positive result. A positive signal at C line provides assurance that the fluid containing the sample material has moved laterally in an appropriate fashion.
219092327|NCT02276066|DIAGNOSTIC_TEST|GFR by Iohexol|Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
219092328|NCT02276066|DIAGNOSTIC_TEST|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
219092329|NCT02276066|DIAGNOSTIC_TEST|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
219092330|NCT03644901|PROCEDURE|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
219092331|NCT03401892|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
219092332|NCT03401892|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
219092333|NCT03401892|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
219092334|NCT01870752|PROCEDURE|Transplantation of previously cryopreserved ovarian tissu|
219218179|NCT00569387|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
219218180|NCT04160936|DRUG|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
219682216|NCT02820870|BEHAVIORAL|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
219682217|NCT03042351|DEVICE|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
219092335|NCT05519384|DRUG|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
219092336|NCT03928028|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
219092337|NCT03928028|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
219092338|NCT04379193|BEHAVIORAL|Neuroproprioceptive facilitation and inhibition physical therapy|All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).
219092339|NCT02239497|PROCEDURE|Femoral block by ultrasound and neurostimulation|
219092340|NCT02239497|DRUG|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
219092341|NCT03895554|PROCEDURE|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
219092342|NCT02710292|DEVICE|Delefilcon A contact lenses|
219092343|NCT02710292|DEVICE|Narafilcon A contact lenses|
219092344|NCT01074892|DRUG|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
219092345|NCT01074892|DRUG|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
219092346|NCT01074892|DEVICE|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
219092347|NCT02016404|OTHER|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
219218181|NCT03872063|OTHER|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
219682218|NCT02754518|DRUG|Entresto|
219682219|NCT00459719|DRUG|Tacrolimus modified-release|oral
219682220|NCT00459719|DRUG|Prograf|oral
219682221|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
219682222|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
219092348|NCT02016404|OTHER|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
219092349|NCT03594539|OTHER|Withholding standard phosphate binder|In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
219092350|NCT05485363|DIAGNOSTIC_TEST|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
219092351|NCT04525547|DRUG|Nintedanib|Nintedanib
219092352|NCT02628002|DEVICE|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
219092353|NCT02628002|DEVICE|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
219092354|NCT06395155|DRUG|DHP2306R1|100mg per capsule, BID
219092355|NCT06395155|DRUG|DHP2306R2|75mg per Tab, BID
219092356|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
219092357|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
219092358|NCT06100302|OTHER|no-intervention|no-intervention
219092359|NCT02531763|BEHAVIORAL|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
219218182|NCT03872063|OTHER|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
219218183|NCT02565966|OTHER|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
219218184|NCT01760226|DRUG|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
219218185|NCT01760226|DRUG|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
219218186|NCT01760226|DRUG|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
219218187|NCT01760226|DRUG|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
219218188|NCT01760226|DRUG|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
219218189|NCT01760226|DRUG|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
219092360|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
219092361|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
219092362|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
219092363|NCT00518635|DRUG|Nutropin|Nutropin 0.1 mg/day self-administered once a day
219092364|NCT05411432|DRUG|68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans
219092365|NCT04803448|BEHAVIORAL|Benefit statement|"The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in \>30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis."
219092366|NCT04803448|BEHAVIORAL|Risk Statement|"The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis."
219218190|NCT01760226|DRUG|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
219218191|NCT01760226|DRUG|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
219218192|NCT01760226|DRUG|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
219218193|NCT05240794|DEVICE|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
219092367|NCT04803448|BEHAVIORAL|Privacy Statement|"The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
219092368|NCT04803448|BEHAVIORAL|Benefit + Privacy|"The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
219092369|NCT04803448|BEHAVIORAL|Risk + Privacy|"The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
219092370|NCT00800202|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
219092371|NCT00800202|DRUG|carboplatin|AUC6 iv every 3 weeks for 6 cycles
219092372|NCT00800202|DRUG|erlotinib [Tarceva]|150mg/day po
219092373|NCT00800202|DRUG|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
219092374|NCT04425902|DRUG|GSK3640254 200 mg|GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
219092375|NCT04425902|DRUG|Caffeine 200 mg|Caffeine will be available as oral tablets at unit dose strength of 200 mg.
219092376|NCT04425902|DRUG|Metoprolol 100 mg|Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
219092377|NCT04425902|DRUG|Montelukast 10 mg|Montelukast will be available as oral tablets at unit dose strength of 10 mg.
219092378|NCT04425902|DRUG|Flurbiprofen 100 mg|Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
219218194|NCT05240794|DEVICE|Digital Control|Placebo control for ABM-01
219218195|NCT06175299|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
219218196|NCT00690404|DRUG|AZD2066|single oral dose
219092379|NCT04425902|DRUG|Omeprazole 40 mg|Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
219092380|NCT04425902|DRUG|Midazolam 5 mg (2.5 mL)|Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
219092381|NCT04425902|DRUG|Digoxin 0.25 mg|Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
219092382|NCT04425902|DRUG|Pravastatin 40 mg|Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
219092383|NCT01920282|DRUG|Nebivolol|
219092384|NCT01920282|OTHER|Lifestyle Modification|
219092385|NCT01920282|OTHER|Nebivolol plus Lifestyle Modification|
219092386|NCT02966145|OTHER|Observational Study|
219092387|NCT02803125|BEHAVIORAL|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
219218197|NCT04804566|OTHER|This is a non-interventional study|This is a non-interventional study
219218198|NCT05437666|OTHER|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
219218199|NCT05437666|OTHER|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
219682223|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
219682224|NCT03317717|DRUG|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
219682225|NCT03317717|DRUG|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
219682226|NCT00002034|DRUG|Zidovudine|
219682227|NCT00002034|DRUG|Ganciclovir|
219682228|NCT02044003|DEVICE|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
219682229|NCT04286620|DEVICE|LASIK|Correcting errors of refraction
219682230|NCT00311688|DRUG|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
219682231|NCT03318003|DEVICE|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
219092388|NCT02803125|BEHAVIORAL|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
219092389|NCT00027924|DRUG|busulfan|
219092390|NCT00027924|DRUG|cyclosporine|
219092391|NCT00027924|DRUG|fludarabine phosphate|
219092392|NCT00027924|DRUG|methotrexate|
219092393|NCT00027924|PROCEDURE|peripheral blood stem cell transplantation|
219218200|NCT03113409|DRUG|Buprenorphine|Buprenorphine will be administered daily
219218201|NCT03113409|DRUG|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
219218202|NCT03113409|DRUG|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
219218203|NCT05555901|DRUG|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
219218204|NCT05555901|DRUG|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
219218205|NCT02170259|OTHER|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
219218206|NCT02170259|OTHER|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
219218207|NCT02170259|OTHER|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
219218208|NCT02785159|DRUG|IDP-118 Lotion|Lotion
219218209|NCT02785159|DRUG|Tazorac Cream|Cream
219218210|NCT02785159|DRUG|IDP-118 Vehicle Lotion|Lotion
219218211|NCT02785159|DRUG|IDP-118 Vehicle Cream|Cream
219218212|NCT01487837|DRUG|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
219092394|NCT02584348|DEVICE|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
219218213|NCT01544907|DEVICE|Conventional PTA|Use of conventional balloon for angioplasty only
219218214|NCT01544907|DEVICE|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
219218215|NCT03578965|DRUG|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
219218216|NCT01787032|DRUG|BI 113608|tablet
219218217|NCT01787032|DRUG|BI 113608|tablet
219218218|NCT01787032|DRUG|BI 113608|tablet
219218219|NCT01787032|DRUG|Ketoconazole|tablet
219218220|NCT01787032|DRUG|Voriconazole|tablet
219092395|NCT02916602|DRUG|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
219092396|NCT02916602|DRUG|HCP0605|amlodipine, Losartan FDC
219092397|NCT04943198|DRUG|Vemurafenib|20 mg/kg/day
219092398|NCT02564679|PROCEDURE|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
219218221|NCT00776009|DRUG|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
219218222|NCT00776009|DRUG|Placebo|Placebo Comparator
219218223|NCT06021275|OTHER|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
219218224|NCT06021275|OTHER|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
219218225|NCT02401932|OTHER|Hemophagocytosis|Best supportive care and immunosuppressive treatments
219218226|NCT04378413|OTHER|exercise|exercise for low back pain
219218227|NCT01611337|OTHER|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
219218228|NCT00877019|DEVICE|Sonicare elite medium brush head|
219218229|NCT00877019|DEVICE|Sonicare elite mini brushhead|
219218230|NCT00877019|DEVICE|GABA Elmex sensitive extra soft toothbrush|
219092399|NCT02564679|BEHAVIORAL|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
219092400|NCT01461382|OTHER|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
219092401|NCT01461382|OTHER|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
219092402|NCT01875354|DIETARY_SUPPLEMENT|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
219218231|NCT00877019|DEVICE|ADA reference toothbrush|
219218232|NCT05335044|DRUG|CKD-331|QD, PO
219218233|NCT05335044|DRUG|EX5619|QD, PO
219218234|NCT00775892|DEVICE|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
219218235|NCT00630357|DRUG|Levetiracetam (Keppra)|
219218236|NCT02851134|GENETIC|genetic analysis|genetic (Whole Exome Sequencing )
219218237|NCT02851134|BIOLOGICAL|blood and stools samples|biological collection
219218238|NCT00463502|DRUG|Metformin|
219218239|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
219218240|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
219218241|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
219218242|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
219218243|NCT04971733|DRUG|E2814|E2814 intravenous infusion.
219218244|NCT03911271|DRUG|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
219218245|NCT03911271|DRUG|0.01% atropine|0.01% atropine for 24 months
219218246|NCT03911271|DRUG|0.9% Sodium-chloride|Placebo for 24 months
219218247|NCT06015308|DRUG|Amlitelimab|Subcutaneous injection in abdomen, outer thigh, or upper arm
219218248|NCT06015308|DRUG|Placebo|Subcutaneous injection in abdomen, outer thigh, or upper arm
219092403|NCT01875354|DIETARY_SUPPLEMENT|Placebo and Low Fat Eating Plan|
219092404|NCT03559088|OTHER|Migraine App|Smart phone app used to report migraine burden to the EHR.
219092405|NCT00204984|DRUG|oral hydralazine and intravenous nesiritide|vasodilators
219092406|NCT00462254|DRUG|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
219092407|NCT00462254|DRUG|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
219092408|NCT03326960|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
219092409|NCT03326960|DRUG|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
219092410|NCT03326960|DRUG|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
219092411|NCT01124721|BEHAVIORAL|Cognitive training|Cognitive computerized training for several days per week.
219092412|NCT01124721|BEHAVIORAL|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
219218249|NCT06015308|BIOLOGICAL|Tdap vaccine|Intramuscular (IM) injection into the deltoid muscle of the upper arm
219218250|NCT06015308|BIOLOGICAL|PPS vaccine|Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
219218251|NCT03904069|DRUG|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
219218252|NCT03666468|OTHER|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
219218253|NCT03666468|OTHER|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
219218254|NCT03666468|OTHER|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
219218255|NCT06124573|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
219218256|NCT02406092|DRUG|Rituximab|Rituximab SC 1400 mg
219218257|NCT02406092|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
219218258|NCT02406092|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice.
219218259|NCT02406092|DRUG|Vincristine|Vincristine will be administered as per standard local practice.
219218260|NCT02406092|DRUG|Prednisone|Prednisone will be administered as per standard local practice.
219218261|NCT02406092|DRUG|Fludarabine|Fludarabine will be administered as per standard local practice.
219218262|NCT06143501|DIAGNOSTIC_TEST|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
219218263|NCT06143501|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
219218264|NCT06143501|DIAGNOSTIC_TEST|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
219218265|NCT04074096|RADIATION|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).
219218266|NCT04074096|DRUG|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
219682232|NCT03943914|COMBINATION_PRODUCT|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.
219092413|NCT03117725|DRUG|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
219092414|NCT03117725|DRUG|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
219092415|NCT00958763|BEHAVIORAL|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
219092416|NCT00958763|BEHAVIORAL|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
219092417|NCT00958763|OTHER|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
219092418|NCT06835725|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|prostate stereotactic ablative radiotherapy
219092419|NCT00122564|BIOLOGICAL|HIV-1 gp 160|
219092420|NCT00122564|BIOLOGICAL|DC-Chol|
219092421|NCT04589468|OTHER|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
219092422|NCT06802601|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
219092423|NCT06802601|OTHER|Manual Therapy, Exercise and Visio-Vestibular Exercise|Manual Therapy, Exercise and Visio-Vestibular Exercise
219092424|NCT05435924|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
219092425|NCT06029855|OTHER|Kabat Therapy|The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.
219092426|NCT06029855|OTHER|Mime Therapy|The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.
219092427|NCT05842213|BIOLOGICAL|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
219092428|NCT05842213|BIOLOGICAL|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
219092429|NCT01713543|OTHER|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
219092430|NCT03462329|DRUG|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
219092431|NCT04903314|DRUG|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
219092432|NCT03339479|DIAGNOSTIC_TEST|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
219092433|NCT03339479|DIAGNOSTIC_TEST|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
219092434|NCT03339479|DIAGNOSTIC_TEST|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
219092435|NCT02417103|DRUG|GLP-1 (Liraglutide)|GLP-1 Analogon
219092436|NCT02417103|DRUG|Placebo|Placebo
219092437|NCT05199363|OTHER|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
219218267|NCT04074096|DRUG|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
219218268|NCT04074096|DRUG|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
219218269|NCT00587275|DRUG|AST-120|Oral, sachet, 2 grams daily for 4 weeks
219092438|NCT05199363|OTHER|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
219092439|NCT05199363|OTHER|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
219092440|NCT03394066|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
219092441|NCT04035837|DRUG|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
219092442|NCT05408728|PROCEDURE|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
219092443|NCT02901626|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~1. Nulliparous 65 mm, 32 mm~2. Multiparous 70 mm, 32 mm~3. Alternative 70 mm, 35 mm"
219092444|NCT03504098|BEHAVIORAL|nutrition consult|Post-lung cancer operation diet pattern
219092445|NCT04562961|OTHER|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
219092446|NCT00331344|DRUG|mitoxantrone hydrochloride|Given IV
219092447|NCT00331344|DRUG|ixabepilone|Given IV
219092448|NCT00331344|DRUG|prednisone|Given orally
219092449|NCT03396029|BEHAVIORAL|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
219092450|NCT03396029|BEHAVIORAL|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
219092451|NCT05378984|OTHER|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
219092452|NCT05378984|OTHER|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
219092453|NCT04565171|DRUG|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
219092454|NCT02462902|DRUG|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
219218270|NCT00587275|DRUG|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
219218271|NCT01065649|DRUG|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
219218272|NCT01065649|DRUG|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
219218273|NCT01082900|OTHER|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
219218274|NCT03631407|DRUG|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
219218275|NCT03631407|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
219218276|NCT00002945|BIOLOGICAL|aldesleukin|IV
219218277|NCT00002945|BIOLOGICAL|filgrastim|IV
219218278|NCT00002945|DRUG|cyclophosphamide|IV
219218279|NCT00002945|DRUG|cytarabine|IV
219218280|NCT00002945|DRUG|etoposide|IV
219218281|NCT00002945|DRUG|idarubicin|IV
219218282|NCT00002945|DRUG|melphalan|IV
219218283|NCT00002945|PROCEDURE|peripheral blood stem cell transplantation|IV
219218284|NCT00002945|RADIATION|radiation therapy|delivered to the cancer cells
219218285|NCT00156208|DRUG|Asoprisnil|10mg Tablet, oral Daily for 18 months
219218286|NCT00156208|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 18 months
219218287|NCT01182649|DEVICE|coronary stent|coronary angioplasty with stent implantation
219218288|NCT01182649|DEVICE|stent|coronary angioplasty with stent implantation
219218289|NCT06274060|BEHAVIORAL|Case management|Participants will receive case management delivered by a peer with PrEP experience/success for seven months, with the goal of improving self-efficacy to take PrEP. The intention of this intervention is to help participants to develop individualized strategies to address and overcome barriers to PrEP use, as well as develop disclosure strategies. This strategy includes weekly face-to-face support with the case manager for the first month of the trial, followed by monthly face-to-face support for the remainder of the trial follow up period. The strategy will also include client-initiated on-demand phone consultation with the case manager and mental health/substance use screening and referrals. Participants randomized to this strategy may also opt into daily timed PrEP pill-taking reminders via short message service (SMS).
219218290|NCT06274060|BEHAVIORAL|Food vouchers|Participants will be given food vouchers with a value of 200 South African Rand at the time of PrEP initiation and at 1- and 4-month standard of care visits at which clinical checkups and PrEP refills are provided. The goal of these vouchers is to improve participants' capacity to persist on PrEP. While PrEP can be taken without food, some experience increased side effects or prefer to take pills with food, making adherence difficult if they cannot afford food at times.
219218291|NCT06274060|BEHAVIORAL|PrEP support buddy|Participants will identify a person in their network (such as a friend, partner, parent) that they wish to support them in their PrEP usage, with the goal of improving participants' motivation and self-efficacy to persist on PrEP and providing social support to facilitate ongoing PrEP use. Support buddies selected by FSW and AGYW randomized to this intervention will receive a one-time training session on PrEP and support strategies as well as informational materials and text reminders to assist them in providing ongoing PrEP support.
219218292|NCT06274060|BEHAVIORAL|Community-based PrEP pickup points|Participants will be able to pick up PrEP from alternative pick-up points within the community that are convenient for them, with the goal of making PrEP more accessible to participants. Ten pickup points will be established at existing Hubs of Hope throughout the subdistricts served by the TB HIV Care programme. Hubs of Hope are based in the War Rooms within subdistricts, where the TB HIV Care programme operates, and serve as meeting places for service users to receive support searching for jobs, completing online courses, and other personal development activities to support a multi-sectoral approach to health. A TB HIV Care ambassador is based at each Hub of Hope to coordinate activities and provide support to service users. Participants who choose to use pick-up points will have the option of either completing an HIV self-test or testing with the on-site TB HIV Care staff to confirm HIV-negative status prior to receipt of PrEP refills.
219218293|NCT04000516|BEHAVIORAL|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
219218294|NCT02955719|DRUG|Sertraline|
219092455|NCT02462902|DRUG|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
219092456|NCT03850652|DIETARY_SUPPLEMENT|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
219218295|NCT02955719|DRUG|Venlafaxine|
219218296|NCT02955719|OTHER|CBT/Psychological Therapy|
219218297|NCT02955719|OTHER|Psychiatric Consultation|
219218298|NCT02955719|OTHER|Lifestyle Intervention Resources|
219218299|NCT00211549|DRUG|IDEA-033|
219218300|NCT05841407|DIETARY_SUPPLEMENT|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
219218301|NCT05841407|DIETARY_SUPPLEMENT|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
219218302|NCT02503722|OTHER|Laboratory Biomarker Analysis|Correlative studies
219218303|NCT02503722|DRUG|Osimertinib|Given PO
219218304|NCT02503722|OTHER|Pharmacological Study|Correlative studies
219218305|NCT02503722|DRUG|Sapanisertib|Given PO
219218306|NCT04706754|OTHER|Questionnaires|Participants will complete the survey(s) at the initial visit and every 3 months and/or whenever there is an update in their treatment protocol. Patients may also choose to opt out of the surveys and only consent to primary data collection at the site.
219218307|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219218308|NCT05806515|DRUG|Carboplatin|Given IV
219682233|NCT03943914|COMBINATION_PRODUCT|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
219682234|NCT02051790|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
219682235|NCT03844425|DEVICE|Conventional VFR|Conventional retainers
219682236|NCT03844425|DEVICE|VFR from SLA|SLA has better finishing compared to FDM but it is more expensive.
219682237|NCT03844425|DEVICE|VFR from FDM|FDM has poorer finishing compared to SLA but it is cheaper.
219682238|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
219682239|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
219682240|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
219682241|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
219682242|NCT05503459|OTHER|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
219682243|NCT05503459|OTHER|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
219218309|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
219218310|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
219218311|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219092457|NCT03850652|DIETARY_SUPPLEMENT|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
219682244|NCT01936363|DRUG|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
219682245|NCT01936363|DRUG|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
219682246|NCT01936363|DRUG|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
219092458|NCT01373931|DRUG|LY2216684|Administered orally
219092459|NCT01373931|DRUG|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
219682247|NCT01936363|DRUG|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
219682248|NCT01936363|DRUG|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
219092460|NCT01373931|DRUG|Placebo|Administered orally
219092461|NCT04857034|DRUG|Deucravacitinib|Specified dose on specified days
219092462|NCT04857034|DRUG|Placebo|Specified dose on specified days
219092463|NCT03580590|DRUG|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
219682249|NCT03514719|DIAGNOSTIC_TEST|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
219682250|NCT03514719|DRUG|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
219682251|NCT03044847|OTHER|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
219682252|NCT02644278|DRUG|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
219092464|NCT03580590|DRUG|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
219092465|NCT03580590|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219092466|NCT06785181|DIAGNOSTIC_TEST|Active standing|a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos
219092467|NCT00659490|DRUG|AZD1940|800ug oral administration
219092468|NCT00659490|DRUG|Naproxen|500mg oral administration
219682253|NCT02644278|DRUG|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
219092469|NCT00659490|DRUG|Placebo|Placebo given pre-surgery
219092470|NCT02341508|BIOLOGICAL|0.5 mg/kg Lpathomab|
219092471|NCT02341508|BIOLOGICAL|1.0 mg/kg Lpathomab|
219092472|NCT02341508|BIOLOGICAL|3.0 mg/kg Lpathomab|
219092473|NCT02341508|BIOLOGICAL|10 mg/kg Lpathomab|
219092474|NCT02341508|BIOLOGICAL|20 mg/kg Lpathomab|
219092475|NCT02341508|OTHER|Saline solution for intravenous infusion|
219092476|NCT01375270|PROCEDURE|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
219092477|NCT01375270|PROCEDURE|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
219092478|NCT04719039|BEHAVIORAL|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
219092479|NCT00827541|DRUG|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
219092480|NCT01649232|DEVICE|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
219092481|NCT06782919|OTHER|Trunk control training|Four sessions of biofeedback trunk movement training, provided once per week.
219218312|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
219218313|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
219218314|NCT06243770|DRUG|mRNA-0184|Intravenous infusion
219218315|NCT06545344|OTHER|Best Practice|Receive usual care
219218316|NCT06545344|PROCEDURE|Palliative Care Consultation|Attend a palliative care visit
219218317|NCT06545344|OTHER|Survey Administration|Ancillary studies
219218318|NCT06545344|OTHER|Tumor Board Review|Undergo evaluation by tumor board
219218319|NCT04204941|DRUG|Tazemetostat|400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
219092482|NCT05891626|BEHAVIORAL|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~1. missed opportunities and doubts/hesitancy about immunization as a whole;~2. specific questions with regard to specific vaccines;~3. health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~4. challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
219092483|NCT02228967|BEHAVIORAL|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
219092484|NCT04141631|DRUG|EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"
219092485|NCT05318924|DRUG|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
219218320|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
219218321|NCT04204941|DRUG|Tazemetostat|800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
219218322|NCT04204941|DRUG|Placebo|Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
219218323|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
219218324|NCT04240613|DEVICE|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
219218325|NCT04958798|BEHAVIORAL|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
219218326|NCT01855516|DRUG|Heparin|
219218327|NCT04895696|DRUG|Afimetoran|Specified dose on specified days
219218328|NCT04895696|OTHER|Placebo|Specified dose on specified days
219092486|NCT05318924|OTHER|Placebo|Participants will receive a saline infusion as the placebo control condition.
219092487|NCT05476055|GENETIC|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
219218329|NCT03980418|PROCEDURE|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
219218330|NCT06561841|DRUG|HSK39297|HSK39297 tablets for 24 weeks
219218331|NCT04764175|BEHAVIORAL|Telephone All Nations Breath of Life|Same as described above.
219218332|NCT04764175|BEHAVIORAL|Comparison Program|Same as described above.
219218333|NCT04719936|PROCEDURE|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
219218334|NCT04719936|PROCEDURE|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
219218335|NCT01858012|BEHAVIORAL|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
219092488|NCT00001444|DRUG|7-hydroxystaurosporine (UCN-01)|
219092489|NCT03017417|OTHER|Exercise Intervention|Various exercise tests
219092490|NCT03017417|OTHER|standard of care|standard treatment
219092491|NCT00407199|DRUG|quetiapine|
219218336|NCT03821506|DEVICE|Dynamic Light|Dynamic Lighting system
219218337|NCT03821506|DEVICE|Usual care|Standard lighting system
219218338|NCT06971042|RADIATION|Lung Ultrasound|Patients were examined in supine position, using a portable ultrasound machine equipped with a curvilinear transducer (5-3 MHz)
219218339|NCT06421285|BEHAVIORAL|Aerobic exercise, Strength training, Flexibility exercise|"Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement~* Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise~* Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation"
219218340|NCT05616754|BIOLOGICAL|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
219218341|NCT05616754|BIOLOGICAL|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
219218342|NCT03882450|PROCEDURE|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
219092492|NCT05374499|DRUG|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
219092493|NCT05374499|DRUG|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
219092494|NCT05236946|RADIATION|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
219092495|NCT05236946|DRUG|Tyrosine kinase inhibitor|TKI
219092496|NCT02671201|OTHER|Education|Different methods in education of emergency ultrasound
219218343|NCT03882450|PROCEDURE|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
219218344|NCT01368744|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System"
219218345|NCT00423020|DRUG|Erythropoietin|
219218346|NCT06221215|PROCEDURE|trauma|The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
219092497|NCT03600675|OTHER|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
219092498|NCT03440502|PROCEDURE|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
219092499|NCT03826290|OTHER|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
219218347|NCT00679770|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
219218348|NCT00679770|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
219218349|NCT00679770|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
219218350|NCT00679770|DRUG|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
219218351|NCT05843240|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
219218352|NCT05843240|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
219218353|NCT00837954|DEVICE|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
219682254|NCT02644278|DRUG|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
219092500|NCT01964326|DRUG|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
219092501|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
219092502|NCT02347657|DRUG|Ivacaftor|Tablet, oral use
219092503|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
219092504|NCT02347657|DRUG|Ivacaftor placebo|Tablet, oral use
219092505|NCT05764343|OTHER|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
219092506|NCT02564302|DEVICE|MUSE Headband|MUSE Headband will help patients with mindfulness.
219092507|NCT05356754|DEVICE|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
219218354|NCT00837954|DEVICE|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
219218355|NCT00837954|PROCEDURE|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
219218356|NCT04611373|DRUG|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
219218357|NCT05777304|DEVICE|wearable device|IMU sensors and EMG sensors
219218358|NCT01588951|DRUG|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
219218359|NCT01588951|DRUG|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
219218360|NCT00736463|DRUG|Simvastatin|One arm of randomized crossover
219218361|NCT00736463|DRUG|Atorvastatin 80 mg|Second arm of randomized crossover
219218362|NCT03919721|BEHAVIORAL|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
219218363|NCT02727634|OTHER|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
219218364|NCT01830049|OTHER|Take blood|
219218365|NCT01917994|BEHAVIORAL|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
219218366|NCT01917994|BEHAVIORAL|Appointment Reminders|
219218367|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
219218368|NCT06510790|DEVICE|Double J stent|Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
219218369|NCT01595282|DRUG|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
219218370|NCT01595282|DRUG|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
219218371|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
219218372|NCT02794363|BIOLOGICAL|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
219092508|NCT06452953|DRUG|suanzaoren decoction|The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver
219092509|NCT06452953|DRUG|Eszopiclone 1 mg|Eszopiclone is used in the treatment of various types of insomnia.
219092510|NCT03417947|DIETARY_SUPPLEMENT|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
219092511|NCT03417947|DIETARY_SUPPLEMENT|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
219092514|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
219092515|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
219092516|NCT06573671|DIAGNOSTIC_TEST|scanning electron microscope with energy-dispersive X-ray spectroscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
219092517|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
219092518|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
219092519|NCT00261495|DRUG|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
219092520|NCT00261495|DRUG|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
219092521|NCT03953898|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219092522|NCT03953898|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219092523|NCT03953898|DRUG|Olaparib|Given PO
219092524|NCT04034108|PROCEDURE|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
219092525|NCT06250491|DEVICE|Deep active rTMS with Hesed coil|This brain neurostimulation method targets the motor cortex bilaterally
219092526|NCT06250491|DEVICE|Sham rTMS with Hesed coil|This brain sham neurostimulation method targets the motor cortex bilaterally
219092527|NCT06202222|OTHER|rehabilitation|The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
219092528|NCT04023864|DIETARY_SUPPLEMENT|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
219092529|NCT04023864|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
219218373|NCT02227706|BIOLOGICAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
219092530|NCT00234650|PROCEDURE|Colonoscopy|
219092531|NCT05911568|PROCEDURE|Endovascular Stroke Treatment|Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke
219218374|NCT02227706|DEVICE|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
219218375|NCT02628626|DRUG|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
219218376|NCT02628626|DRUG|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
219218377|NCT02628626|OTHER|Placebo|Placebo will be identical in appearance to the active drug.
219218378|NCT04932018|BEHAVIORAL|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
219218379|NCT04932018|BEHAVIORAL|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
219218380|NCT02792907|DEVICE|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
219218381|NCT01534091|BEHAVIORAL|Pedometer with supervision|
219218382|NCT01534091|BEHAVIORAL|Pedometer without supervision|
219218383|NCT02848560|DRUG|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
219218384|NCT01593020|DRUG|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
219218385|NCT01593020|DRUG|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
219218386|NCT01593020|DRUG|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
219092532|NCT05911568|OTHER|Medical Management|Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
219218387|NCT01593020|DRUG|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
219218388|NCT01593020|DRUG|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
219218389|NCT01593020|DRUG|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
219218390|NCT00900900|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
219218391|NCT00900900|DIETARY_SUPPLEMENT|pregnenolone|one-time 400mg oral dose of pregnenolone
219218392|NCT00900900|DRUG|Placebo|one-time dose oral dose
219218393|NCT04231279|DRUG|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
219218394|NCT06035809|BEHAVIORAL|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
219092533|NCT04617548|COMBINATION_PRODUCT|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
219218395|NCT06163391|DRUG|SOT201|intravenous infusion
219218396|NCT04197648|DEVICE|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
219218397|NCT04857983|DRUG|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
219218398|NCT04857983|DRUG|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
219218399|NCT03186326|DRUG|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
219218400|NCT03186326|DRUG|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
219218401|NCT03186326|DRUG|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
219218402|NCT03186326|DRUG|Panitumumab|Administered at 6 mg/Kg
219218403|NCT03186326|DRUG|Cetuximab|Administered at 500 mg/m²
219218404|NCT03186326|DRUG|Bevacizumab|Administered at 5 mg/Kg
219218405|NCT03186326|DRUG|Aflibercept|Administered at 4 mg/Kg
219218406|NCT04958317|OTHER|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
219218407|NCT04958317|OTHER|Late exercise|Participants will exercise for 30 minutes after an evening meal.
219218408|NCT04144868|DEVICE|Oxygen storage face masks and nasal catheter|Giving high-flow mask oxygen via oxygen storage face masks (100% O2, flow rate 8 L/min, 1 hour, four times daily, and 2 L/min via nasal catheter during intermittent periods, for 7 days) immediately at admission.
219218409|NCT04144868|DEVICE|Nasal catheter|Giving 2 L/min flow of 100% O2 via nasal catheter at admission for 24 hours daily for 7 days.
219218410|NCT02440672|DEVICE|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
219218411|NCT04203394|OTHER|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
219218412|NCT04203394|OTHER|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
219218413|NCT05051982|DEVICE|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
219218414|NCT00348751|DEVICE|CholGate|
219218415|NCT05423119|BEHAVIORAL|conventional therapy|upper limb rehabilitation with and without technologies
219218416|NCT06482632|PROCEDURE|Discectomy of Omohyoid|Will be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
219218417|NCT06482632|PROCEDURE|Control group no discectomy of Omohyoid|Will not be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
219218418|NCT05587699|DRUG|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
219218419|NCT05587699|DRUG|CKD-843 A 45mg|Single Injection
219218420|NCT05587699|DRUG|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
219218421|NCT05587699|DRUG|CKD-843 A 55mg|Single Injection
219218422|NCT05587699|DRUG|CKD-843-R|0.5mg/day, 9 Month
219218423|NCT03190603|DRUG|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
219218424|NCT04190108|DIAGNOSTIC_TEST|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
219218425|NCT06102616|DIAGNOSTIC_TEST|measure Osteocalcin level|in gingival crevicular fluid before and during orthodontic tooth movement
219218426|NCT00575419|DRUG|N-acetylcysteine|"* Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day"
219218427|NCT06425250|OTHER|Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
219218428|NCT06425250|OTHER|Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.|"Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection"
219218429|NCT04570358|OTHER|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
219092534|NCT06181110|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
219092535|NCT05254184|DRUG|Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides|administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
219092536|NCT03128866|PROCEDURE|Hemipelvectomy|Undergo hemipelvectomy
219092537|NCT03128866|DRUG|Tranexamic Acid|Given IV
219092538|NCT04786314|OTHER|Hot Water Application|Pregnant women will apply hot water to their legs before going to sleep for a week.
219092539|NCT04786314|OTHER|Cold Water Application|Pregnant women will apply cold water to their legs before going to sleep for a week.
219092540|NCT00947726|DRUG|CeraVe|Using OTC cream on foot twice daily for two weeks.
219092541|NCT03762343|DRUG|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
219092542|NCT03762343|DRUG|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
219682255|NCT02644278|DRUG|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
219682256|NCT03545945|PROCEDURE|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
219682257|NCT03545945|PROCEDURE|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
219682258|NCT04691128|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
219682259|NCT04691128|DRUG|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
219682260|NCT00627562|DEVICE|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
219682261|NCT06069739|BEHAVIORAL|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
219682262|NCT06069739|BEHAVIORAL|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
219682263|NCT06369558|OTHER|PLYOMETRIC TRAINING|A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
219682264|NCT06369558|OTHER|CLASSIC PHYSIOTHERAPY PROGRAM|HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
219682265|NCT05743153|BEHAVIORAL|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
219682266|NCT00511810|DRUG|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
219682267|NCT00511810|DRUG|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
219682268|NCT05648903|OTHER|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
219682269|NCT05648903|OTHER|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
219218430|NCT04570358|OTHER|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
219218431|NCT02645942|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
219218432|NCT02645942|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
219218433|NCT00732966|DRUG|losartan|with losartan 50 mg once daily for one month
219218434|NCT00732966|DRUG|valsartan|valsartan 160 mg once daily
219218435|NCT01732120|PROCEDURE|Off-clamp partial nephrectomy|
219218436|NCT06321224|OTHER|Breathing exercises|Breathing exercises will be performed 3 days a week during 2 menstrual periods.
219218437|NCT06321224|OTHER|Control|No intervention will be made to the control group and they will be asked to continue their routine lives.
219218438|NCT00645359|PROCEDURE|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
219218439|NCT00575549|OTHER|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
219218440|NCT02595346|DRUG|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
219218441|NCT02595346|DRUG|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
219218442|NCT02660294|BIOLOGICAL|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
219218443|NCT00180934|PROCEDURE|Reirradiation with concomitant chemotherapy|
219218444|NCT00429338|PROCEDURE|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
219092543|NCT05951088|PROCEDURE|Cardio2U follow-up|During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
219092544|NCT04387981|DRUG|[14C]-orvepitant|Oral solution of \[14C\]-orvepitant
219682270|NCT05648903|OTHER|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
219092545|NCT05596890|DRUG|Paclitaxel-albumin|260mg/m2, ivdrip, d1
219092546|NCT05596890|DRUG|Cisplatin|60mg/m2, ivdrip, d1
219092547|NCT05596890|DRUG|Carboplatin|AUC=4-6, ivdrip, d1
219092548|NCT05596890|DRUG|Tislelizumab|200mg, ivdrip, d1
219092549|NCT05596890|RADIATION|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
219092550|NCT05596890|PROCEDURE|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
219092551|NCT01538472|DRUG|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
219092552|NCT01538472|DRUG|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
219092553|NCT01538472|DRUG|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
219092554|NCT01538472|DRUG|BCNU|300 mg/m2 by vein on Day -6.
219092555|NCT01538472|DRUG|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
219092556|NCT01538472|DRUG|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
219092557|NCT01538472|DRUG|Melphalan|140 mg/m2 by vein on Day -1.
219092558|NCT01538472|PROCEDURE|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
219092559|NCT01538472|DRUG|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
219092560|NCT04918368|BEHAVIORAL|Behavioral scales were used|Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
219218445|NCT00429338|PROCEDURE|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
219218446|NCT00370942|DRUG|GW823093C A|A=45 mg
219218447|NCT00370942|DRUG|GW823093C B|B=30 mg
219218448|NCT00370942|DRUG|GW823093C C|C=25 mg
219218449|NCT00023920|BIOLOGICAL|bevacizumab|Given IV
219218450|NCT00023920|DRUG|idarubicin|Given IV
219218451|NCT00023920|DRUG|cytarabine|Given SC
219218452|NCT06514183|OTHER|Clinical diagnosis of recurrence|Clinical diagnosis of recurrence
219092561|NCT02732613|DEVICE|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
219092562|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
219092563|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
219092564|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
219092565|NCT03881319|DRUG|Conventional gynecologic treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
219092566|NCT03881319|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
219218453|NCT02143375|DEVICE|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
219218454|NCT00032435|DRUG|PAL-40 Active|
219218455|NCT00032435|DRUG|PAL-40 Placebo|
219218456|NCT02766517|DRUG|Capsaicin|Administered topically
219218457|NCT02080585|BEHAVIORAL|Physical Activity advice.|Subjects receive advice regarding physical activities.
219218458|NCT03329612|PROCEDURE|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
219218459|NCT02190708|DRUG|PQ912|from day2 up to day6 twice daily oral dose of PQ912
219218460|NCT02190708|DRUG|Midazolam|single oral dose on day1 and day 6
219218461|NCT02190708|DRUG|Omeprazole|single oral dose on day1 and day6
219092567|NCT03881319|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
219218462|NCT04379375|BEHAVIORAL|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
219218463|NCT00401869|DRUG|Epoetin alfa|
219218464|NCT01232959|DEVICE|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
219218465|NCT01333800|DRUG|Beclomethasone|200 to 400 mcg per day for 6 months
219218466|NCT01333800|DRUG|Ciclesonide|80 to 160 mcg per day for 6 months
219682271|NCT04936503|DIAGNOSTIC_TEST|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
219092568|NCT06409221|OTHER|Non-interventional study, Observational only|Observational study only, there are no planned interventions.
219092569|NCT05046496|DIAGNOSTIC_TEST|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
219092570|NCT02905383|OTHER|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
219218467|NCT05113810|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
219218468|NCT05113810|OTHER|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
219218469|NCT02378649|DRUG|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
219218470|NCT02378649|DRUG|Placebo|Placebo comparator concomitant with best practice usual care
219218471|NCT00754000|OTHER|Observation|AE monitoring and EPIC QOL survey
219218472|NCT01662154|DEVICE|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
219218473|NCT01662154|DEVICE|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
219218474|NCT02063659|DRUG|Telotristat etiprate|Telotristat etiprate tablets
219218475|NCT02063659|DRUG|Placebo|Placebo-matching telotristat etiprate tablets
219218476|NCT02972359|DRUG|Neridronic acid|Neridronic acid administered as intravenous infusion.
219218477|NCT06033040|OTHER|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
219218478|NCT03366506|OTHER|Observation|
219218479|NCT01541059|DRUG|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
219218480|NCT01541059|DRUG|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
219218481|NCT02072499|PROCEDURE|KTP Green Light Prostatectomy|
219218482|NCT02072499|DEVICE|Green Light|
219218483|NCT02072499|PROCEDURE|Open prostatectomy|
219218484|NCT00528320|DEVICE|Ovatio CRT|
219682272|NCT04936503|DIAGNOSTIC_TEST|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
219682273|NCT04936503|DIAGNOSTIC_TEST|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
219682274|NCT04936503|DIAGNOSTIC_TEST|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
219682275|NCT04936503|OTHER|Questionnaire|To determine the rhythmic risk of athletes
219092571|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
219092572|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
219092573|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
219092574|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
219092575|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
219092576|NCT06177158|BEHAVIORAL|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
219218485|NCT05733559|DEVICE|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
219218486|NCT02355041|BEHAVIORAL|Meal Replacement-based Weight Loss Diet|
219218487|NCT02355041|BEHAVIORAL|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
219218488|NCT04979715|PROCEDURE|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
219218489|NCT04979715|OTHER|control|no intervention; preoperative patient informaiton and information leaflet
219218490|NCT05225376|OTHER|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
219218491|NCT01939288|DEVICE|Neuromuscular stimulation, followed by intermittent pneumatic compression|
219218492|NCT01939288|DEVICE|Intermittent pneumatic compression, followed by neuromuscular stimulation|
219218493|NCT06812754|DRUG|Fezolinetant|oral
219218494|NCT06812754|DRUG|Placebo|oral
219092577|NCT05184322|DRUG|T2026|Once daily for 15 days.
219218495|NCT06981208|OTHER|ChatGPT-generated patient education|This is created by entering the patient's age, medical history, social history, and case-specific details into Washington University ChatGPT Beta (HIPAA and FERPA compliant) by a study team member.
219218496|NCT06981208|OTHER|Usual patient education|Usual patient education will include description of breast reconstruction options, with further elaboration on which option are more suitable to the patient. This include also review of risk of complications and expected recovery after surgery.
219218497|NCT04724759|DRUG|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
219218498|NCT06856733|BEHAVIORAL|Person-centred team-based approach|"Phase 1 (investigation and assessment, week 1-3):~* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.~* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.~* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.~* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.~* A visit to a care manager~Phase 2 (treatment plan, week 3-4):~\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.~Phase 3 (treatment and follow-up, week 4-24):~* Implementation of the individualized rehabilitation plan.~* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.~* A second team consultation half-way"
219218499|NCT06864546|BEHAVIORAL|Physical activity intervention|"In the first week, patients will be asked to maintain their normal sedentary life, spending most of the waking day sitting. During the second week, participants will be asked to take at least 10,000 steps/day, with sitting replaced by standing and light-intensity walking.~See doi: 10.1007/s00125-016-4161-7"
219218500|NCT07013812|DRUG|Tranexamic Acid (IV)|One gram (10 ml) intravenous injection
219218501|NCT07013812|DRUG|Dextrose 5% (D5W)|5% dextrose water intravenously
219218502|NCT07012590|DRUG|Morphine|Patients received erector spinae plane block with morphine 2 mg as an adjuvant to bupivacaine 30 ml 0.25%.
219218503|NCT07012590|DRUG|Dexmedetomidine|Patients received erector spinae plane block with dexmedetomidine 100 µg as an adjuvant to bupivacaine 30 ml 0.25%.
219092578|NCT05184322|DRUG|Placebo|Once daily for 15 days.
219092579|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 6 weeks.
219092580|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily and titrated up in concentration to once every week during maintenance period.
219092581|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
219218504|NCT07012590|OTHER|Erector spinae plane block|Patients received erector spinae plane block with bupivacaine 30 ml 0.25% only.
219218505|NCT07013435|OTHER|Health Education Program|8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.
219092582|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
219218506|NCT07013435|OTHER|SMART3RP-Lymphoma|The SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.
219218507|NCT07012044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219218508|NCT07012044|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219218509|NCT07012044|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219218510|NCT07012044|DRUG|Decitabine|Given PO
219218511|NCT07012044|DRUG|Decitabine and Cedazuridine|Given PO
219218512|NCT07012044|BIOLOGICAL|Filgrastim|Given SC or IV
219218513|NCT07012044|PROCEDURE|Imaging Procedure|Undergo diagnostic imaging
219218514|NCT07012044|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219218515|NCT03373968|DRUG|Givinostat|suspension of givinostat (10 mg/mL)
219092583|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
219092584|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
219092585|NCT05184322|DRUG|T2026|Once daily for 6 weeks.
219092586|NCT05184322|DRUG|Placebo|Once daily for 6 weeks.
219092587|NCT05184322|DRUG|T2026|Once daily to once weekly for 12 weeks.
219092588|NCT05184322|DRUG|Placebo|Once daily to once weekly for 12 weeks.
219092589|NCT01059630|DRUG|Obinutuzumab|IV infusion.
219092590|NCT01059630|DRUG|Bendamustine|IV infusion.
219092591|NCT02017054|OTHER|Cath|No intervention - registry
219218516|NCT06688370|DEVICE|Petit Drill|Day 1: 2-4 doses, including one of the daily doses taken at bedtime. Days 2 and 3: 3 to 4 doses on days 2 and 3, including one of the daily doses taken at bedtime.
219218517|NCT04934995|OTHER|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
219218518|NCT06697132|PROCEDURE|laparoscopic dismembered pyeloplasty|Modified antegrade stenting in laparoscopic pediatric pyeloplasty
219218519|NCT06698874|OTHER|ds-MCE and EGD examinations|Sequentially performing ds-MCE and EGD examinations on enrolled participants.
219218520|NCT03598907|OTHER|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
219218521|NCT06705582|OTHER|Fortified Bread|Intervention group will be supplied with fortified bread delivering 10 -15 μg (400-600 IU) vitamin D3 in a daily portion and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
219218522|NCT06705582|OTHER|Unfortified bread|Placebo control group will be supplied with unfortified bread and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
219218523|NCT06714461|DRUG|Leflunomide|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
219092592|NCT03170375|BEHAVIORAL|Performance of WHEELS-I in promoting DASH/SRD adoption|All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.
219092593|NCT03587246|DIAGNOSTIC_TEST|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
219092594|NCT03221855|DRUG|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
219092595|NCT03221855|DRUG|Placebo|Capsules 10mg orally each 8 hours for 7 days.
219092596|NCT04040309|BIOLOGICAL|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
219092597|NCT04040309|DRUG|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
219682276|NCT04936503|DEVICE|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~* 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~* 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
219682277|NCT04936503|BIOLOGICAL|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
219092598|NCT03797482|PROCEDURE|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
219092599|NCT01572779|DEVICE|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
219218524|NCT07043543|RADIATION|Adaptive radiotherapy|"Patient will be treated by concomitant:~* adaptive radiotherapy 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
219218525|NCT07043543|RADIATION|standard radiotherapy|"Patient will be treated by concomitant:~* standard 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
219218526|NCT07043764|OTHER|Caring Contacts Text Messages|Caring Contacts are brief, hopeful, supportive text messages.
219218527|NCT07043842|OTHER|Shoulder circumference exercises|They are strengthening and stretching exercises that support the range of motion of the shoulder joint.
219218528|NCT07043842|OTHER|Scapular stabilization exercises|Changes in the biomechanics of the scapula affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the scapula.
219218529|NCT07043842|OTHER|Thoracic mobility exercises|Changes in the biomechanics of the thoracic spine affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the thoracic spine.
219218530|NCT07044258|PROCEDURE|trans-tarsal stair-step lateral extension of the transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
219218531|NCT07044258|PROCEDURE|transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
219218532|NCT07042789|OTHER|Material source: AI generated ads vs existing ads by health agency|Each participant evaluated 50 ads in random order, of which 25 were AI-generated through youth co-design process, and 25 were existing ads from official health agencies.
219092600|NCT01572779|DEVICE|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
219092601|NCT05515419|BIOLOGICAL|Allogeneic cord blood treatment|Allogeneic cord blood treatment
219092602|NCT01227603|DRUG|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
219092603|NCT01227603|DRUG|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
219092604|NCT01227603|DRUG|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
219092605|NCT01550484|DRUG|18F-AV-133|222 MBq (6 mCi)
219092606|NCT02637934|DRUG|[18F]FluorThanatrace|
219092607|NCT02637934|RADIATION|PET/CT imaging sessions|
219092608|NCT00763958|DRUG|Placebo|Placebo to match buprenorphine administered for 3 months
219092609|NCT00763958|DRUG|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
219092610|NCT03203655|BEHAVIORAL|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
219092611|NCT03203655|BEHAVIORAL|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
219092612|NCT03043001|DRUG|Memantine|All the subjects will receive add-on memantine for 12 week
219092613|NCT00530062|DRUG|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
219092614|NCT00530062|DRUG|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
219092615|NCT01522534|DRUG|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
219092616|NCT01522534|DRUG|Morphine|Morphine alone with a placebo nerve block
219092617|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
219092618|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
219092619|NCT01320332|DRUG|ASP3291|Oral tablets
219218533|NCT07042789|OTHER|source labelling conditions: control condition, AI condition, health agency condition, combined condition|"Participants were randomly assigned to one of four source labelling conditions: (1) Control (ads presented without any source labelling), (2) AI condition (ads labelled with the text Made with AI), (3) Health agency condition (ads labelled with the text Made by the World Health Organization (WHO)), and (4) Combined condition (ads labelled with the text Made with AI, by the World Health Organization (WHO))."
219092620|NCT01320332|DRUG|Placebo|Oral tablets
219092621|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
219092622|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
219092623|NCT03050502|DEVICE|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
219092624|NCT03050502|OTHER|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
219092625|NCT01376323|DRUG|GSK256073 1mg|GSK256073 1mg capsule
219092626|NCT01376323|DRUG|GSK256073 5mg|GSK256073 5mg capsule
219092627|NCT01376323|DRUG|GSK256073 10mg|GSK256073 10mg capsule
219092628|NCT01376323|DRUG|GSK256073 25mg|GSK256073 25mg capsule
219092629|NCT01376323|DRUG|Placebo|placebo capsule
219092630|NCT01376323|DRUG|Sitagliptin 100mg|Sitagliptin 100mg capsule
219092631|NCT04681729|DRUG|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219092632|NCT04681729|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219092633|NCT04681729|DRUG|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
219092634|NCT01209637|BEHAVIORAL|exercise training|exercise training min. 4 times a day for at least 30 min
219092635|NCT01209637|BEHAVIORAL|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
219092636|NCT05671640|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
219092637|NCT00006825|BIOLOGICAL|trastuzumab|
219092638|NCT00006825|DRUG|pegylated liposomal doxorubicin hydrochloride|
219092639|NCT03306901|PROCEDURE|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
219092640|NCT03306901|DRUG|5-fluorouracil|3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
219218534|NCT06741293|OTHER|No intervention: observational study|No intervention: observational study
219218535|NCT06811857|DEVICE|hyperbaric oxygen therapy and povidone-iodine wet compresses|The hyperbaric oxygen group receives 30-40 sessions of hyperbaric oxygen therapy (100% oxygen at a pressure of 2.0 ATA) and povidone-iodine wet compresses.
219218536|NCT06811857|OTHER|wet compresses of povidone-iodine|wet compresses of povidone-iodine
219218537|NCT06823635|DEVICE|Transcatheter device closure of perimembranous ventricular septal defects (PmVSDs)|Transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using an occluder device either specifically designed for this purpose or used off-label.
219218538|NCT06810817|COMBINATION_PRODUCT|tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
219218539|NCT06810817|BEHAVIORAL|sham tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of sham-tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
219218540|NCT06810817|BEHAVIORAL|physical training|Participants will have physical training at home for 8 weeks.
219218541|NCT02404870|DRUG|Placebo|Placebo
219218542|NCT02404870|DRUG|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
219218543|NCT06888544|BEHAVIORAL|HIIT program for 24 weeks with a frequency of 2 times per week.|Participants will receive a 24-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 37 to 40 minutes with progression of training. Each HIIT section will include six high-impact weight-bearing exercise. For Weeks 1-4, the HIIT section will include 12 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 11 intervals of 60 seconds of active recovery. To ensure the subjects' safety, a chair will be used for assistance during training in the first month. Additionally, a 3 kg weight will be incorporated for the training in the final two months.
219218544|NCT06888544|BEHAVIORAL|Non-exercise control|Workshop participants in the non-exercise control group will receive a series of workshops related to daily recreation.
219092641|NCT03306901|DRUG|Cisplatin|45\~60mg intravenously over 1 hour on day 1
219092642|NCT03306901|RADIATION|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
219092643|NCT03978325|OTHER|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
219092644|NCT03978325|OTHER|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
219092645|NCT04772846|DRUG|Oral tablet|Oral 250mg chloroquine tablets
219092646|NCT04772846|DRUG|Placebo|Oral placebo tablets
219092647|NCT02470494|DEVICE|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
219092648|NCT03092284|BIOLOGICAL|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC\_ASC
219092649|NCT03092284|BIOLOGICAL|Placebo|Saline
219092650|NCT03834103|BEHAVIORAL|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
219218545|NCT06785298|DRUG|Levodopa/carbidopa|A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
219218546|NCT06785298|DRUG|Fexofenadine|Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
219218547|NCT05605496|DRUG|NP137|IV infusion, 14mg/kg, Q3W
219092651|NCT05392023|OTHER|Relaxation Exercises and Scapular Stabilization exercise program|Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
219092652|NCT05392023|OTHER|Relaxation Exercises of cervico- scapular region|Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
219092653|NCT06484270|OTHER|Simulation based safety mobilization program|"Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured."
219218548|NCT05605496|DRUG|anti-PD-1/PD-L1|IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
219218549|NCT06764641|DIAGNOSTIC_TEST|Breath test|Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant (i.e. upper/lower gastrointestinal endoscopy, CT/MRI/ultrasound ± histological/cytology)
219218550|NCT00521846|DEVICE|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
219218551|NCT03381300|PROCEDURE|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
219218552|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
219218553|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
219218554|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
219218555|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
219092654|NCT02535364|BIOLOGICAL|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
219092655|NCT04792125|BEHAVIORAL|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
219092656|NCT04792125|BEHAVIORAL|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
219092657|NCT04792125|BEHAVIORAL|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
219092658|NCT02121678|OTHER|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
219218556|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
219218557|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
219218558|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
219218559|NCT03480698|DRUG|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
219218560|NCT06763549|DEVICE|SUBPROTOCOL A|A 30-minute COR ECG recording will be performed, including 15 minutes of continuous sitting data used for clinical indication analysis through CardioMIND software. Data collection can occur in-clinic, via PHS, or using a shipped device with telehealth support. Sleep, HRV, and AFIB risk analysis will not be included.
219218561|NCT06763549|DEVICE|SUBPROTOCOL B|Subjects will undergo 24 hours of COR ECG recording, which must include at least one 15-minute unsupervised sitting session. Data analysis will include sleep patterns, HRV, and AFIB risk. ECG acquisition may take place in-clinic, via Patient Home Setup (PHS), or with a shipped device.
219218562|NCT06763549|DEVICE|SUBPROTOCOL C|COR 1.0 ECG recordings will be conducted over 2 to 7 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants subjects will also wear a cleared wrist or finger device to track SpO2 during sleep. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
219092659|NCT02121678|OTHER|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
219218563|NCT06763549|DEVICE|SUBPROTOCOL D|COR 2.0 (CORMDX) recordings will be conducted over 2 to 14 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants will also wear a cleared wrist or finger device to track SpO2 during sleep nights. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
219218564|NCT06763549|DEVICE|SUBPROTOCOL E|Subjects will complete a 30-minute CORMDx (COR 2.0) ECG recording, with 15 minutes of continuous sitting data used for clinical indication analysis. Sleep, HRV, and AFIB risk analysis will not be performed.
219218565|NCT06763549|DEVICE|SUBPROTOCOL F|A 30-minute COR 2.0 ECG recording will be completed, along with a 12-lead resting ECG using an FDA-cleared reference device. Sleep, HRV, and AFIB analysis will not be performed.
219218566|NCT06763549|DEVICE|SUBPROTOCOL G|A 40-minute COR 2.0 recording will be conducted in two phases: 15 minutes of upright sitting and 15 minutes in a supine position. Hemodynamic monitoring, including blood pressure, cardiac output, and stroke volume variation, will be conducted using an FDA-cleared reference device. No sleep, HRV, or AFIB analysis will be performed.
219218567|NCT06763549|DEVICE|SUBPROTOCOL H|Subjects will undergo a 40-minute COR 2.0 recording, followed by a 40-minute COR 1.0 recording. Hemodynamic monitoring using an FDA-cleared reference device will be performed during both sessions. The transition between devices must occur within 60 minutes if the same adhesive is reused. Sleep, HRV, and AFIB analysis will not be performed.
219092660|NCT03184584|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
219092661|NCT05357014|DIAGNOSTIC_TEST|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
219092662|NCT01078857|OTHER|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
219092663|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
219092664|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
219092665|NCT00284063|PROCEDURE|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
219092666|NCT02464683|DIETARY_SUPPLEMENT|VitaminD|200 International Units (oral dose) daily of 60 days
219092667|NCT05927974|DIAGNOSTIC_TEST|Passive testing|Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.
219092668|NCT05927974|DIAGNOSTIC_TEST|Active testing|"Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications."
219092669|NCT03737786|OTHER|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
219092670|NCT06029556|OTHER|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
219092671|NCT06029556|OTHER|Ergometry in Bed|Ankle pumps (5\*2), knee extension (5\*2), breathing exercises with elbow flexion and extension(5\*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
219092672|NCT06479616|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
219092673|NCT01846000|PROCEDURE|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
219218568|NCT06753253|BEHAVIORAL|Cycling Exercise|Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.
219092674|NCT03540875|DEVICE|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
219092675|NCT03540875|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
219218569|NCT04148495|DRUG|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
219218570|NCT04148495|DRUG|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
219218571|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
219218572|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
219218573|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
219218574|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
219218575|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
219218576|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
219218577|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
219218578|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
219218579|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
219218580|NCT04332471|OTHER|Home therapy|Stretching and ice massage
219682278|NCT04868669|BEHAVIORAL|In-home, intensive nutrition counseling|"* Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress"
219682279|NCT02635308|BEHAVIORAL|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
219682280|NCT02050334|DRUG|CC100|CC100 reconstituted in diluent
219092676|NCT03540875|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
219092677|NCT02293746|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
219092678|NCT00735865|PROCEDURE|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin \& tarsal/inferior fornix conjunctiva obtained \& plated according to protocol
219218581|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
219218582|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
219218583|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
219218584|NCT06646692|BEHAVIORAL|Mindful Self Compassion|(MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities, we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.
219682281|NCT02050334|DRUG|Placebo|Diluent. Amount to match CC100 dose.
219218585|NCT06646692|BEHAVIORAL|Treatment as Usual (TAU)|"Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials."
219092679|NCT00735865|PROCEDURE|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin \& conjunctiva/inferior fornix of BOTH eyes"
219092680|NCT00735865|PROCEDURE|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
219092681|NCT00735865|OTHER|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
219092682|NCT01572025|DRUG|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
219092683|NCT01572025|DRUG|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
219092684|NCT03279835|OTHER|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
219092685|NCT03279835|OTHER|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
219092686|NCT02660801|PROCEDURE|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
219092687|NCT02660801|PROCEDURE|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
219092688|NCT04766086|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
219092689|NCT04766086|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
219092690|NCT04766086|BIOLOGICAL|Placebo|Saline control
219092691|NCT03390530|DRUG|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
219092692|NCT03390530|DRUG|Placebo|Placebo
219092693|NCT04903171|OTHER|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
219092694|NCT05285462|BEHAVIORAL|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
219092695|NCT05285462|BEHAVIORAL|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
219092696|NCT05892666|OTHER|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
219092697|NCT05892666|OTHER|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
219092698|NCT05892666|OTHER|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
219092699|NCT00000986|DRUG|Zidovudine|
219092700|NCT00000986|DRUG|Aldesleukin|
219092701|NCT02565719|DRUG|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
219092702|NCT02565719|DRUG|Pegasys|immunotherapy
219092703|NCT02565719|DRUG|Viread|HBV RT polymerase inhibitor
219092704|NCT02565719|DRUG|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
219092705|NCT05685992|OTHER|no intervention|no intervention
219092706|NCT03140501|DEVICE|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
219092707|NCT03163914|DRUG|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
219092708|NCT03163914|DRUG|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
219092709|NCT03163914|DRUG|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
219092710|NCT03163914|DRUG|Saline|saline infusion will apply till the end of the surgery
219092711|NCT01069081|DRUG|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
219092712|NCT01069081|DRUG|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
219092713|NCT01069081|DRUG|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
219092714|NCT05326763|DRUG|Platelet Rich Plasma|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
219092715|NCT05326763|DRUG|Dextrose 50%|The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
219092716|NCT04045821|DRUG|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
219092717|NCT04045821|DRUG|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
219092718|NCT04045821|PROCEDURE|dilation and curettage|all participants will undergo routine D\&C procedure
219092719|NCT00052676|DRUG|patent blue V dye|
219092720|NCT00052676|PROCEDURE|radionuclide imaging|
219092721|NCT00052676|PROCEDURE|sentinel lymph node biopsy|
219092722|NCT00052676|RADIATION|technetium Tc 99m sulfur colloid|
219092723|NCT04988802|DIETARY_SUPPLEMENT|Prenatal Nutrients Solgar|Patients will take dietary supplement Prenatal Nutrients from Solgar
219092724|NCT04988802|OTHER|Placebo|Placebo capsules based on starch.
219092725|NCT02450630|BEHAVIORAL|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
219092726|NCT01241383|DRUG|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
219092727|NCT02889133|DRUG|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
219092728|NCT02889133|DRUG|Saline|Salt water IV - 500 mL, one pint normal saline.
219092729|NCT02889133|PROCEDURE|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
219092730|NCT02889133|PROCEDURE|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
219092731|NCT00521703|DRUG|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
219092732|NCT00521703|DRUG|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
219092733|NCT02265614|GENETIC|PGS|
219092734|NCT01488565|DRUG|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
219092735|NCT06296823|BEHAVIORAL|Simulated jetlag protocol|16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
219092736|NCT00133536|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
219092737|NCT00133536|DRUG|Placebo|Normal saline administered intramuscularly.
219092738|NCT01154478|OTHER|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
219092739|NCT01154478|OTHER|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
219092740|NCT01154478|OTHER|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
219092741|NCT01154478|OTHER|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
219682282|NCT04789525|OTHER|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
219092742|NCT01555801|DEVICE|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
219092743|NCT01555801|DEVICE|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
219092744|NCT02276924|DEVICE|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
219092745|NCT02087436|DEVICE|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
219092746|NCT02087436|DEVICE|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
219092747|NCT03044522|OTHER|Opioid Education|
219092748|NCT01440686|DRUG|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
219092749|NCT01440686|DRUG|Placebo|Tablets, oral administrations
219092750|NCT02659917|OTHER|Glass ionomer|Application of preventive agent
219092751|NCT02659917|OTHER|Glass ionomer cement|Application of preventive agent
219092752|NCT02659917|OTHER|-Glass ionomer-|Atraumatic Restorative Treatment
219092753|NCT02659917|OTHER|-Glass ionomer cement-|Atraumatic Restorative Treatment
219092754|NCT05278052|RADIATION|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
219092755|NCT05278052|DRUG|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
219092756|NCT05024474|OTHER|Inspiratory muscle training (IMT)|Inspiratory muscle training (IMT) at 20-50 % of maximal inspiratory pressure (MIP), 2 x 30 repetitions, twice a day for 8 weeks.
219092757|NCT05024474|OTHER|Physical exercise|A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.
219092758|NCT00179790|PROCEDURE|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
219682283|NCT05748964|PROCEDURE|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
219682284|NCT01583413|PROCEDURE|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
219682285|NCT04518618|DRUG|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
219682286|NCT04518618|DRUG|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
219092759|NCT03488693|RADIATION|Radiation|Radiotherapy given
219092760|NCT03488693|OTHER|No Radiation|No radiotherapy given
219092761|NCT02124148|DRUG|Prexasertib|Administered IV
219092762|NCT02124148|DRUG|Cisplatin|Administered IV
219092763|NCT02124148|DRUG|Cetuximab|Administered IV
219092764|NCT02124148|DRUG|G-CSF|Administered SC
219092765|NCT02124148|DRUG|Pemetrexed|Administered IV
219092766|NCT02124148|DRUG|Fluorouracil|Administered IV
219092767|NCT02124148|DRUG|LY3023414|Administered PO
219092768|NCT02124148|DRUG|Leucovorin|Administered IV
219092769|NCT06222372|DRUG|Rifampin|antibiotic
219092770|NCT03763643|DRUG|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
219092771|NCT03763643|PROCEDURE|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
219092772|NCT05451004|OTHER|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
219092773|NCT05451004|RADIATION|Ipsilateral and Contralateral Neck|Radiotherapy
219092774|NCT03351738|DRUG|MEDI5884|Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
219092775|NCT03351738|DRUG|Placebo|Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
219092776|NCT04191447|DRUG|Flamboyant 200/12|Flamboyant 200/12 capsule
219092777|NCT04191447|DRUG|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
219092778|NCT04191447|OTHER|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
219092779|NCT04191447|OTHER|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
219092780|NCT03997513|BEHAVIORAL|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
219092781|NCT02322541|OTHER|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
219092782|NCT06427122|BEHAVIORAL|EMD Protocol for Urge|During the EMD-U sessions, the patient is asked to focus on the spot on his/her skin where the urge to scratch is highest. The patient is asked to rate the level of urge to scratch this spot on a 10-point scale and to imagine that they scratch this spot as they would like. At the same time eye movements are offered for 30 seconds. This procedure is repeated until the level of urge to scratch has become nihil. This procedure is repeated for all other skin parts where the patient experiences an urge to scratch, until there are no skin parts left. As a homework assignment straight after the first session, the patient is instructed and encouraged to practice the same intervention at home. The two EMD-U sessions and two phone calls, take place in the first three weeks of the study. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home.
219092783|NCT06427122|OTHER|Care as Usual|Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
219218586|NCT06320262|PROCEDURE|Wet cupping therapy (WCT)|"Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking.~Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas.~After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done."
219218587|NCT02215928|GENETIC|mutation analysis|Correlative studies
219218588|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
219218589|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
219218590|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
219218591|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
219218592|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
219218593|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
219218594|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
219682287|NCT04486508|DRUG|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
219682288|NCT04486508|DRUG|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
219682289|NCT04486508|DRUG|Atorvastatin 20mg|Statin
219682290|NCT04486508|DRUG|Matched placebo|Matched placebo to atorvastatin 20 mg
219682291|NCT03509168|DRUG|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
219092784|NCT01375205|OTHER|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
219092785|NCT01375205|OTHER|Standard of Care|Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
219092786|NCT06251739|DRUG|Ivermectin 6 Mg Oral Tablet|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
219092787|NCT06251739|DRUG|Miltefosine Oral Capsule|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
219092788|NCT01120158|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
219092789|NCT01120158|DRUG|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
219092790|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
219092791|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
219218595|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
219218596|NCT06828289|DRUG|Rivastigmine Mini-Tablet|Treatment group: Rivastigmine Mini-Tablet
219218597|NCT06828289|DRUG|Donepezil Hydrochloride|Control group: Donepezil Hydrochloride
219218598|NCT05336344|BEHAVIORAL|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
219218599|NCT04686266|BEHAVIORAL|Health Information + Health Coaching|Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
219218600|NCT06827665|BIOLOGICAL|DDA|: demineralized dentin allografts (DDA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
219218601|NCT06827665|BIOLOGICAL|WTA|whole tooth allografts (WTA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
219218602|NCT05908331|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
219218603|NCT05908331|DEVICE|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
219218604|NCT03697304|DRUG|BI 754091|Solution for infusion
219218605|NCT03697304|DRUG|BI 754111|Solution for infusion
219218606|NCT03697304|DRUG|BI 836880|Solution for infusion
219218607|NCT05579730|DRUG|Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%|combination ophthalmic solution
219218608|NCT05579730|DRUG|Brimonidine Tartrate 0.025%|ophthalmic Solution
219218609|NCT05579730|DRUG|Ketotifen Fumarate 0.035%|ophthalmic Solution
219218610|NCT05579730|DRUG|Vehicle|ophthalmic Solution
219218611|NCT06831630|OTHER|Holmich protocol exercise|The treatment consisted of exercise therapy (ET) protocol suggested by Holmich et al and was started under the supervision of a trained sport physiotherapist who ensured that the exercise was carried out correctly and adhered to the original protocol. No treatment other than ET was applied. Although the ET protocol exactly mirrored the randomised clinical trial of Holmich et al, details such as the perceived resistance or weights (in exercise 3 in module 2) and the rest period between the exercise sets and repetitions, which were not defined in the Holmich study, were explained here for the athletes' benefit (tables 1 and 2). Treatment was administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions. Although adductor muscle stretching was for
219218612|NCT06831630|OTHER|Joint Mobilization|"Focus of treatment was on reducing hip joint pain using joint mobilization techniques provided by the physical therapist and exercises performed in the HEP. Based on published literature, we developed a standard set of mobilizations to target hip joint motion limitations, defined as stiffness or pain that limited joint range of motion. Joint mobilization techniques were prioritized based on patient-specific tasks and the motion used during those tasks, followed by the hip motion limitations. The choice of joint mobilization techniques and grade used was based on direction of hip motion limitation and the relationship of pain and stiffness during hip motion assessment. The HEP included commonly used joint motion and stretching exercises to complement techniques performed during supervised sessions.~The exercises will be conducted over a period of 12 weeks, which is explained below Techniques will be prioritized based on restrictions noted on baseline examination.~1. Caudal glide~2. Lat"
219218613|NCT06832930|PROCEDURE|unicorn robotic bronchoscopy system|cryobiopsy with the help of robotic bronchoscopy system
219218614|NCT06832930|PROCEDURE|Conventional navigation bronchoscopy|cryobiopsy with the help of Conventional navigation bronchoscopy
219218615|NCT06827925|OTHER|Distance Digital Learning|receiving Distance Digital Learning of Flipped Education
219682292|NCT03509168|OTHER|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
219092792|NCT04024631|OTHER|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
219092793|NCT04024631|OTHER|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
219218616|NCT06829940|OTHER|Baduanjin exercise training (BET)|Baduanjin Exercise Training (BET) is a traditional Chinese exercise focused on improving physical health, flexibility, balance, and mental well-being. It involves a 10-minute warm-up, a 40-minute core session practicing eight distinct postures, and a 10-minute cool-down. The postures, based on the Baduanjin form, target different body parts and promote strength, flexibility, and circulation. The exercises are synchronized with deep breathing to enhance relaxation and stress reduction. BET is especially beneficial for joint health, mobility, and mental clarity, making it suitable for individuals of all ages and fitness levels
219092794|NCT05995717|DIETARY_SUPPLEMENT|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
219218617|NCT06138340|DRUG|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
219218618|NCT06138340|DRUG|Propofol|Participants will be sedated and maintained by propofol during the surgery.
219218619|NCT06138340|DRUG|Remimazolam Injection|Participants will be sedated and maintained by remimazolam during the surgery.
219218620|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
219218621|NCT04306367|DRUG|Olaparib|300 mg given orally.
219218622|NCT06823063|BIOLOGICAL|MSC|a single injection dose i.v.
219218623|NCT06758700|DRUG|Teniposide administration|Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.
219218624|NCT06763094|DRUG|Calcium dobesilate (Doxium)|This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.
219218625|NCT06763094|DRUG|Tranexamic Acid|Tranexamic Acid stands out due to its non-hormonal action in managing menorrhagia, providing an alternative for women who are contraindicated for hormonal treatments or prefer non-hormonal solutions. Unlike other hormonal treatments, Tranexamic Acid does not impact fertility or have significant endocrine effects.
219218626|NCT04665297|BEHAVIORAL|International Guide for Monitoring Child Development|Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
219218627|NCT06487819|PROCEDURE|Application of a rubber dam during dental treatments for varying durations.|Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
219218628|NCT04108351|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
219218629|NCT04108351|OTHER|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
219218630|NCT04108351|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
219218631|NCT06828341|BIOLOGICAL|CAR-T|allogeneic CAR-T targeting CD70 that cultured from heathy adults.
219218632|NCT05124041|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
219218633|NCT06453018|DEVICE|Positional device, Rematee Bumper Belt or Night Shift|Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
219218634|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
219218635|NCT06382818|RADIATION|COHORT A|"IMRT radiotherapy on whole breast according to the investigator's decision among:~* Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable.~* Extreme whole breast hypofractionated RT according to :~  * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks~ * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days"
219218636|NCT06382818|RADIATION|COHORT B|"Breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable."
219218637|NCT06382818|RADIATION|COHORT C|"Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions)."
219218638|NCT06382818|RADIATION|COHORT D|"Breast radiotherapy based on available clinical trials:~\- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered."
219092795|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
219092796|NCT02260128|OTHER|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
219092797|NCT03821337|DEVICE|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
219092798|NCT03821337|DEVICE|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
219092799|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
219218639|NCT06531018|DRUG|Eltrombopag 25 MG|Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
219218640|NCT06531018|DRUG|Prednisolone|Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
219218641|NCT03044158|DEVICE|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
219218642|NCT03044158|BEHAVIORAL|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
219218643|NCT03044158|OTHER|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
219218644|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology Co., Ltd., administered in the deltoid area of lateral arm by intramuscular injection.
219218645|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine, Live|0.5ml for each dose, manufactured by Chengdu Institute of Biological Products Co., Ltd., administered subcutaneously in the lower part of the deltoid area of lateral arm.
219218646|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the GDM Group (Experimental Arm)|"Gestational Diabetes Diagnosis: The intervention for this group involves the diagnostic procedure of the 100-gram oral glucose tolerance test (OGTT) after an initial glucose challenge test (GCT) with a result equal to or greater than 140 mg/dL. The test assesses fasting plasma glucose and post-glucose consumption plasma glucose levels at 1 hour and 2 hours, which is used to diagnose GDM.~Biomarker Analysis: The albumin to high-sensitivity C-reactive protein (hsCRP) ratio is measured as a biomarker to explore its potential role in GDM diagnosis and related pregnancy outcomes."
219218647|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the Control Group|"Glucose Challenge Test (GCT): The control group participants are exposed to the glucose challenge test (GCT), where plasma glucose levels are measured one hour after the consumption of 50 grams of glucose. If their glucose levels are below 140 mg/dL, they are categorized as not having GDM.~Biomarker Analysis: Similar to the GDM group, the albumin to hsCRP ratio is measured for participants in the control group to compare the biomarker levels between those with and without GDM."
219218648|NCT06742905|DIAGNOSTIC_TEST|Robot-guided echo|This echo will be performed by a remote sonographer, though a robot
219218649|NCT06742905|DIAGNOSTIC_TEST|Standard echocardiogram|Echocardiogram acquired by a sonographer at the patient's bedside
219218650|NCT06832969|PROCEDURE|cryoablation|Lung cancer patients undergo treatment for peripheral malignant lung tumors using cryoablation technology under the guidance of bronchoscopy.
219218651|NCT05794009|OTHER|Immersive Virtual Reality Exercise (IVRE)|The IVRE program will include aerobic exercise, muscle strengthening exercise, balance and flexibility exercise.
219218652|NCT05794009|OTHER|Home Exercise|Aerobic exercise, muscle strengthening exercise, balance and flexibility exercise at home.
219218653|NCT03013946|BEHAVIORAL|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
219218654|NCT05426785|DEVICE|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
219218655|NCT06826521|PROCEDURE|Single construct versus dual constructs will give satisfactory radiological and functional outcomes|Single construct like cephalomedullary nail or long DHS in fixation of both neck and shaft fractures, dual constructs like DHS or cannulated screws and retrograde nail or DHS or cannulated screws and dymanic compression plate in fixation of both fractures.
219092800|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
219092801|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
219218656|NCT06829121|DIAGNOSTIC_TEST|Ultrasound|The thickness of the psoas muscle and the musculus quadriceps femoris will be measured by ultrasound
219218657|NCT03391921|BIOLOGICAL|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
219218658|NCT02401815|DRUG|CGT9486|CGT9486 will be administered per dose and schedule specified in the arm.
219218659|NCT02401815|DRUG|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
219218660|NCT02401815|DRUG|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
219218661|NCT06832215|DIAGNOSTIC_TEST|Blood and urine samples collection|Blood and urine were collected at a single time point for all participants, from the tree study groups. Fasting for blood collection and the first urine in the morning were required.
219092802|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
219092803|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
219092804|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
219092805|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
219092806|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
219092807|NCT01750736|OTHER|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
219092808|NCT01750736|OTHER|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
219092809|NCT05887908|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
219092810|NCT05887908|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
219092811|NCT05887908|DRUG|imipenem/cilastatin|1 g imipenem/1 g cilastatin
219092812|NCT05369052|DRUG|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
219092813|NCT05369052|DRUG|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
219092814|NCT06384261|DRUG|Cusatuzumab|CD70 monoclonal antibody
219092815|NCT06384261|DRUG|Venetoclax|BCL-2 inhibitor
219092816|NCT06384261|DRUG|Azacitidine|Hypomethylating agent
219092817|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
219092818|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
219218662|NCT05427487|BIOLOGICAL|IVX037|Bioselected oncolytic RNA virus
219218663|NCT05427487|BIOLOGICAL|Sintilimab|An immune checkpoint inhibitor
219682293|NCT06107647|DEVICE|COVIDIEN WarmTouch|"COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia."
219682294|NCT00532545|DRUG|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
219682295|NCT05201846|DEVICE|DIA:CONN G8 insulin pump|Subjects on continuous subcutaneous insulin infusion system with CGM
219682296|NCT05201846|OTHER|Multiple daily insulin injection|Subjects on multiple daily insulin injection with CGM
219682297|NCT00627497|PROCEDURE|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
219682298|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
219682299|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
219092819|NCT03604406|OTHER|Placebo Injection|Saline solution injection
219092820|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
219092821|NCT02747888|GENETIC|•Referral to Genetic Counselor, if indicated|
219092822|NCT04490785|PROCEDURE|MRI|1 MRI 5 days after surgery (-1; +4 days), with intravenous administration of gadolinium
219092823|NCT04490785|BIOLOGICAL|Postoperative dosage of released troponin|Dosage of troponin I Hs H4, H8, H12, H24, H48, and H72 after the aortic cross-unclamping.
219218664|NCT05203237|BIOLOGICAL|VK2735|Administered SC
219218665|NCT05203237|BIOLOGICAL|Placebo|Administered SC
219682300|NCT00627497|DEVICE|Fusion|Posterolateral Interbody Fusion
219218666|NCT05203237|DRUG|VK2735 Placebo|Administered orally
219218667|NCT05203237|DRUG|VK2735 Drug|Administered orally
219218668|NCT06329856|BEHAVIORAL|Administering of artificial hydration|Administering of artificial hydration to terminal cancer patients
219218669|NCT05949593|DRUG|Tinlarebant|5 mg tablet taken orally once a day
219682301|NCT01625871|DRUG|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
219682302|NCT03768778|PROCEDURE|Debridement and dural repair|
219682303|NCT01372046|BEHAVIORAL|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
219682304|NCT01372046|BEHAVIORAL|Training|memorandums, staff meetings
219682305|NCT04868019|DRUG|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
219092824|NCT06461338|PROCEDURE|acupuncture|Acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
219092825|NCT06461338|PROCEDURE|Sham acupuncture|Sham acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with sham electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
219092826|NCT03871088|DIETARY_SUPPLEMENT|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
219092827|NCT05479604|DEVICE|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
219092828|NCT05479604|DEVICE|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
219092829|NCT03723343|DRUG|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
219218670|NCT05949593|DRUG|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly.
219218671|NCT06762405|RADIATION|radiotherapy|short course of radiotherapy (5 grays × 5 days)
219218672|NCT06762405|DRUG|Dostarlimab|dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)
219218673|NCT06762405|BIOLOGICAL|Biological study on circulating tumor DNA (optional for the patient)|"* Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses"
219218674|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
219218675|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
219218676|NCT06748768|DIAGNOSTIC_TEST|group 1|To determine the optimal treatment for dry eyes in term of cost effectiveness and time efficiency by comparing omega 3 supplements versus warm compression
219218677|NCT06828107|DEVICE|SENSE device|The SENSE Device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage and/or cerebral edema.
219218678|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
219218679|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
219682306|NCT01416077|OTHER|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase \> 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI \> 2,5.~4. If despite CI \> 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
219682307|NCT04854070|DEVICE|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
219682308|NCT04854070|DEVICE|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
219682309|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
219682310|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
219218680|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
219218681|NCT06118138|COMBINATION_PRODUCT|Hyperbaric oxygen therapy (HBOT)|"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."
219218682|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
219682311|NCT00402792|DRUG|Placebo|2 tablets q 12 hours
219218683|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
219218684|NCT05071430|DRUG|Placebo|HB-1 matched placebo
219218685|NCT06768866|BEHAVIORAL|Gruop 1|To determine factors influencing Postsurgical acute pain
219218686|NCT06951230|DRUG|Fentanyl injection|Fentanyl 1mcg/kg will be given before skin incision and Mayfield placement and followed up by fentanyl 1mcg/kg/hr, along the operation.
219682312|NCT01502033|DEVICE|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
219682313|NCT01664507|DRUG|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
219682314|NCT01664507|DRUG|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
219682315|NCT02308449|DRUG|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
219682316|NCT02308449|DRUG|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
219682317|NCT02548663|OTHER|Sport therapy|"Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises."
219218687|NCT06951230|PROCEDURE|scalp block|The scalp block procedure is performed with the patient in the supine position, utilizing surface landmarks for guidance. The local anesthetic is injected into the nerves after careful aspiration and under strict aseptic technique. The nerves that are typically injected include the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, as well as the lesser and greater occipital nerves, with or without the inclusion of the third occipital nerve. The volume of 0.5% bupivacaine injected should not exceed 2 ml at each site.
219218688|NCT06951204|PROCEDURE|Adductor Canal Block (ACB) Only|All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound
219218689|NCT06951204|PROCEDURE|Adductor canal block (ACB) combined with Genicular nerve block (GNB)|All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves,2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration
219218690|NCT06952101|PROCEDURE|Sparing Approach|Accurate staging with Pelvic MRI, CT scan, PET total body have to be performed before local excision in order to exclude false positive mesorectal lymph nodes. Subsequent Wait and See (W\&S) approach could be proposed.
219218691|NCT06952101|PROCEDURE|experimental chemoradiotherapy|Participants with cT2N0 rectal tumors are typically candidates for upfront surgical resection. The investigators propose an alternative approach based on experimental chemoradiotherapy (spCRT). Literature suggests that pathologic complete response (pCR) rates after CRT are significantly higher than the 25% described for intermediate-advanced tumors. The investigators will assess clinical complete response (cCR) or complete metabolic response (cMR) through a multidisciplinary restaging process, including MRI, PET, thorax-abdomen CT scan, ERUS, and rectoscopy. In participants achieving cCR or cMR, a Watch and Wait (W\&S) strategy or Local Excision/Transanal Minimally Invasive Surgery (LE/TAMIS) may be proposed to avoid the physical and psychological consequences of major surgery, followed by a rigorous surveillance program.
219218692|NCT06952101|PROCEDURE|Standard Chemotherapy|Tumors will be initially treated with standard CRT (stCRT). Patients who reach cCR-cMR at restaging they are already candidates to sparing approaches with W\&S/LE/TAMIS according to Multicentric Resarch Study Protocol
219218693|NCT06951503|DRUG|AK112|iv, q2w
219218694|NCT06951503|DRUG|Oxaliplatin|iv, q2w
219218695|NCT06951503|DRUG|Irinotecan|iv, q2w
219218696|NCT06951503|DRUG|Leucovorin and 5-FU|iv, q2w
219218697|NCT06951503|DRUG|Bevacizumab|iv, q2w
219218698|NCT06950164|OTHER|observation group|in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)
219218699|NCT06950164|OTHER|control group|in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)
219218700|NCT06953557|DIAGNOSTIC_TEST|To compare the effect of salivary glycine , proline , lysine and alanine concentration between participants with high caries activity and participants with negative caries activity|The investigators will measure Salivary-free amino acids by using reverse phase high performance liquid chromatography
219218701|NCT06766877|OTHER|core stability exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
219218702|NCT06766877|OTHER|foot-ankle strengthening exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
219218703|NCT06745622|DRUG|HSK39297 tablets|HSK39297 tablets until the end of treatment
219218704|NCT06951841|DRUG|Liposome Irinotecan|Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
219218705|NCT06951841|DRUG|Platinum|Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
219218706|NCT06951841|DRUG|Tislelizumab|Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
219218707|NCT06951841|DRUG|Anlotinib|Anlotinib (8mg) will be administered orally in a 3-week treatment cycle, once a day from day 1 to day 14 of each cycle
219218708|NCT04542031|OTHER|Questionnaire|Questionnaire to be completed at 6 and 12 months
219092830|NCT03723343|DRUG|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
219092831|NCT05108207|OTHER|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
219092832|NCT05108207|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
219092833|NCT05108207|OTHER|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
219092834|NCT04062552|OTHER|Behavioral, Psychological or Informational Intervention|Receive ENABLE palliative care information
219092835|NCT04062552|OTHER|Educational Intervention|Participate in VLC group-based learning sessions
219092836|NCT04062552|OTHER|Educational Intervention|Participate in consultation with ENABLE/TA expert
219218709|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
219218710|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
219218711|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
219218712|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
219218713|NCT06554509|DRUG|SHR-1819 injection|SHR-1819 injection
219092837|NCT04062552|PROCEDURE|Medical Examination Assessment|Undergo palliative care assessment
219092838|NCT04062552|OTHER|Quality-of-Life Assessment|Ancillary studies
219092839|NCT04062552|OTHER|Survey Administration|Complete surveys
219092840|NCT04062552|BEHAVIORAL|Telephone-Based Intervention|Receive monthly phone calls
219092841|NCT02557490|DRUG|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
219092842|NCT05889689|BEHAVIORAL|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
219092843|NCT05889689|BEHAVIORAL|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
219092844|NCT05889689|BEHAVIORAL|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
219092845|NCT03653546|DRUG|AZD3759|AZD3759 200mg PO BID.
219092846|NCT03653546|DRUG|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
219092847|NCT03653546|DRUG|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
219092848|NCT06376760|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of intravenous anesthetic drug during digestive endoscopy between insomnia group and normal sleep group.
219092849|NCT06960070|DEVICE|Saremco print resin|The teeth were restored with Saremco print resin via Asiga Max printer according to the manufacturer's instructions.
219092850|NCT06960070|DEVICE|Varseosmile Crownplus resin|The teeth were restored with Varseosmile Crownplus resin via Asiga Max printer according to the manufacturer's instructions.
219218714|NCT06554509|DRUG|Placebo|placebo
219218715|NCT04257747|OTHER|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
219218716|NCT04257747|OTHER|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
219218717|NCT06566950|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
219218718|NCT06566950|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
219218719|NCT06566950|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as stairs, single leg squat, and single leg deadlift.
219218720|NCT03762395|DRUG|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
219218721|NCT03762395|DRUG|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
219218722|NCT06314672|PROCEDURE|Accrual|Participate in AEP
219218723|NCT06314672|PROCEDURE|Discussion|Participate in implementation discussions
219218724|NCT06314672|OTHER|Educational Activity|Participate in educational sessions/activities
219218725|NCT06314672|OTHER|Interview|Undergo interview
219218726|NCT06314672|OTHER|Review|Undergo data capture review
219218727|NCT06314672|OTHER|Survey Administration|Ancillary studies
219218728|NCT02465307|BEHAVIORAL|Confusion Assessment Method|Confusion Assessment Method (CAM) score
219218729|NCT02465307|DEVICE|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
219092851|NCT06960070|DEVICE|Varseosmile TriniQ resin|The teeth were restored with Varseosmile TriniQ resin via Asiga MAx printer according to the manufacturer' instructions
219218730|NCT02465307|DEVICE|Commercially available camera|As part of facial recognition video system
219218731|NCT02465307|DEVICE|Internet Pod (iPod)|Monitors noise levels in the room
219092852|NCT06160986|BEHAVIORAL|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
219092853|NCT06834113|PROCEDURE|Dorsogluteal intramuscular injection|"The injection is carried out on the dorsogluteal intramuscular site, without virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, without virtual reality headset~The injection is carried out on the dorsogluteal intramuscular site, with virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, with virtual reality headset"
219092854|NCT03138733|DRUG|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
219218732|NCT02465307|DIAGNOSTIC_TEST|Cortisol Swab|Cortisol level collected through self administered salivary swab
219218733|NCT04398095|RADIATION|Hypofractionated radiotherapy|Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
219218734|NCT04398095|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
219218735|NCT04398095|RADIATION|Hypofractionated radiotherapy with boost|"Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification."
219218736|NCT02303392|DRUG|Selinexor|Given PO
219218737|NCT02303392|DRUG|Ibrutinib|Given PO
219092855|NCT03138733|DRUG|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
219218738|NCT02303392|OTHER|Pharmacological Study|Correlative studies
219218739|NCT02303392|OTHER|Laboratory Biomarker Analysis|Correlative studies
219218740|NCT03937713|DRUG|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
219218741|NCT03937713|BEHAVIORAL|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
219218742|NCT03876288|DEVICE|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
219218743|NCT03876288|DRUG|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
219218744|NCT03876288|PROCEDURE|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
219682318|NCT02548663|OTHER|Osteopathic treatment|Frequency: 60 min weekly
219682319|NCT00613379|DRUG|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
219682320|NCT00613379|DRUG|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
219682321|NCT00613379|DRUG|Placebo|PBO, one IV dose (N=10)
219682322|NCT05476354|DRUG|Irbesartan/Amlodipine low|Irbesartan/Amlodipine low once daily for 8 weeks
219682323|NCT05476354|DRUG|Irbesartan/Amlodipine high|Irbesartan/Amlodipine high once daily for 8 weeks
219682324|NCT05476354|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
219682325|NCT02080364|DRUG|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
219682326|NCT02080364|DRUG|Placebo|Placebo administered orally, once daily for 18 months
219682327|NCT00635544|OTHER|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
219682328|NCT00635544|OTHER|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
219092856|NCT06502665|OTHER|Women having had second ovulation induction after failed oocyte pick-up|IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes
219092857|NCT05335928|DRUG|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
219218745|NCT00092534|BIOLOGICAL|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
219218746|NCT00092534|BIOLOGICAL|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
219218747|NCT05746429|BEHAVIORAL|Cognitive Behavior Therapy|Receive mobile CBT
219218748|NCT05746429|DEVICE|Transcranial Direct Current Stimulation|Undergo active tDCS
219218749|NCT05746429|OTHER|Interview|Attend virtual meetings and focus groups
219092858|NCT05335928|DRUG|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
219092860|NCT05688059|OTHER|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
219092861|NCT06048081|DRUG|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
219092862|NCT05950945|DRUG|Trastuzumab Deruxtecan|Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
219092863|NCT05887947|DEVICE|Electronic Cigarette with 5% Nicotine Concentration|Electronic cigarette in 5% nicotine concentration (Vuse Alto), provided for free.
219092864|NCT05887947|DEVICE|Electronic Cigarette with 1.8% Nicotine Concentration|Electronic cigarette in 1.8% nicotine concentration (Vuse Alto), provided for free.
219218750|NCT05746429|DRUG|Placebo Administration|Undergo sham tDCS
219218751|NCT05746429|OTHER|Questionnaire Administration|Ancillary studies
219092865|NCT05800743|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
219092866|NCT05800743|DEVICE|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
219682329|NCT03126461|RADIATION|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
219092867|NCT05800743|PROCEDURE|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
219092868|NCT01861314|DRUG|Bortezomib|Given SC
219682330|NCT03126461|DRUG|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
219682331|NCT03126461|DRUG|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
219092869|NCT01861314|DRUG|Decitabine|Given IV
219092870|NCT01861314|OTHER|Laboratory Biomarker Analysis|Correlative studies
219092871|NCT01861314|OTHER|Pharmacological Study|Correlative studies
219092872|NCT01861314|DRUG|Sorafenib Tosylate|Given PO
219682332|NCT00921206|BIOLOGICAL|VAX102|1 ug i.m. compared to 2 ug s.c.
219682333|NCT05754671|OTHER|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
219682334|NCT05754671|OTHER|voice recording|voice recording
219682335|NCT05038449|DRUG|Colchicine Tablets|Colchicine Tablets (Each tablet contains colchicine 0.5mg)
219092873|NCT06014502|DRUG|IMGS-001|Every 2 weeks
219092874|NCT03896568|BIOLOGICAL|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
219092875|NCT03896568|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219092876|NCT04327973|BIOLOGICAL|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
219092877|NCT04327973|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
219092878|NCT03961971|DRUG|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219092879|NCT05463692|BEHAVIORAL|Camelia Cohort|Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
219218752|NCT06715033|DIAGNOSTIC_TEST|y balance and SLS|for assessment of static and dynamic balance
219218753|NCT00869232|DRUG|Velcade|1.0mg/m2 days 1, 5, 8, \& 11
219218754|NCT00869232|DRUG|Melphalan|10 mg/m2 day 3
219218755|NCT00869232|DRUG|Thalidomide|200 mg days 5-8
219218756|NCT00869232|DRUG|Dexamethasone|40 mg day 5-8
219218757|NCT00869232|DRUG|Cisplatin|10 mg/m2 day 5-8
219218758|NCT00869232|DRUG|Adriamycin|10 mg/m2 day 5-8
219218759|NCT00869232|DRUG|Cyclophosphamide|400 mg/m2 day 5-8
219218760|NCT00869232|DRUG|Etoposide|40 mg/m2 day 5-8
219218761|NCT06784180|DRUG|Morphine|200 mcg intrathecal morphine
219218762|NCT06784180|DRUG|Bupivacaine|Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)
219218763|NCT06784180|DRUG|Fentanyl|15 mcg intrathecal fentanyl
219218764|NCT06784180|DRUG|Hydromorphone|100 mcg intrathecal hydromorphone
219218765|NCT05044403|PROCEDURE|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
219218766|NCT05044403|PROCEDURE|Conventional treatment|Conventional treatment
219218767|NCT04367675|DRUG|INO-5401|INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
219092880|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
219092881|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
219092882|NCT05495737|BEHAVIORAL|Treatment As Usual/TAU|"Research team will provide:~1. feedback about level of distress at time of screening~2. local referral for psychological care"
219218768|NCT04367675|DRUG|INO-9012|INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
219092883|NCT05221931|PROCEDURE|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
219092884|NCT05827237|DIAGNOSTIC_TEST|Clinical decision rule|Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
219092885|NCT06064890|PROCEDURE|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
219092886|NCT06064890|GENETIC|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
219092887|NCT04073745|OTHER|Quality-of-Life Assessment|Ancillary studies
219092888|NCT04073745|OTHER|Questionnaire Administration|Ancillary studies
219092889|NCT04073745|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219092890|NCT01042015|COMBINATION_PRODUCT|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
219092891|NCT01042015|OTHER|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
219092892|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
219092893|NCT03004287|DRUG|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
219092894|NCT03004287|DRUG|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
219092895|NCT03004287|DRUG|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
219092896|NCT03004287|DRUG|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
219092897|NCT03004287|DRUG|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
219092898|NCT03004287|DRUG|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
219092899|NCT03004287|DRUG|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
219092900|NCT03004287|DRUG|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
219092901|NCT03004287|DRUG|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
219092902|NCT03004287|PROCEDURE|ASCT|day 0 of Transplant(s)
219682336|NCT05038449|DRUG|Standard therapy|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
219682337|NCT04476498|PROCEDURE|Pull-PEG with Gastropexy|Additionally to a conventional pull-PEG a gastropexy will be performed.
219682338|NCT05034380|BEHAVIORAL|Acute exercise|All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
219682339|NCT00421083|DRUG|tadalafil|
219682340|NCT02497404|DRUG|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
219092903|NCT03004287|DRUG|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
219092904|NCT03004287|DRUG|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
219092905|NCT06216821|DRUG|standard DAPT|standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
219092906|NCT06216821|DRUG|OPT-CAD score guided DAPT de-escalation|De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
219092907|NCT00685958|DRUG|enoxaparin (XRP4563)|14 days of treatment
219218769|NCT04367675|DEVICE|Cellectra 2000|The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
219218770|NCT06550804|BEHAVIORAL|A-TEAM|Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.
219218771|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for AUD|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode locations: FP1 for mPFC and F3 for l-dlPFC.
219218772|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for OUD|Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode location F3 for l-dlPFC.
219218773|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap with Harassment Exposure|Participants will embody a virtual avatar of their female partner in a sexual harassment scenario using full-body tracking, and identity exchange in virtual reality (VR). The goal is to assess whether experiencing harassment from a first-person perspective increases empathy and decreases tolerance toward sexual harassment.
219218774|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap without Harassment|Participants will embody a virtual avatar of their female partner in a neutral social interaction scenario using VR-based identity exchange. This condition controls for the effect of perspective-taking alone, without exposure to harassment, to evaluate its impact on empathy and gender attitudes.
219218775|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection."
219218776|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty."
219218777|NCT05665491|BEHAVIORAL|HabitWorks|Smartphone app-delivered interpretation bias intervention
219218778|NCT05665491|BEHAVIORAL|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
219218779|NCT05029284|BEHAVIORAL|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
219218780|NCT04297813|COMBINATION_PRODUCT|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
219218781|NCT04297813|PROCEDURE|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
219218782|NCT02329704|PROCEDURE|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
219218783|NCT02329704|PROCEDURE|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
219092908|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
219092909|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
219092910|NCT05763069|OTHER|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
219092911|NCT03633942|DEVICE|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
219092912|NCT04549610|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
219092913|NCT04549610|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
219092914|NCT04162093|PROCEDURE|uretero ileal anastomosis in single trough|
219092915|NCT00504426|DRUG|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
219092916|NCT03872479|DRUG|EDIT-101|Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
219092917|NCT01602406|DRUG|LJM716|LJM716
219092918|NCT01602406|DRUG|Trastuzumab|Trastuzumab
219092919|NCT02605226|PROCEDURE|Cryoablation therapy|Cryoablation therapy
219092920|NCT02605226|RADIATION|External beam radiation therapy|External beam radiation therapy
219092921|NCT02605226|DRUG|bicalutamide|bicalutamide
219092922|NCT02605226|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
219092923|NCT04050774|DEVICE|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
219092924|NCT06517667|DRUG|Icross tear substitute|Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
219092925|NCT06517667|DRUG|Hyabak tear substitute|Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
219092926|NCT00228605|DRUG|OraVescent Fentanyl|
219092927|NCT02168530|DRUG|placebo|matching placebo administered daily orally
219092928|NCT02168530|DRUG|vismodegib|vismodegib 150 mg administered daily orally
219092929|NCT02459730|PROCEDURE|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
219092930|NCT02459730|PROCEDURE|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
219092931|NCT00992680|DEVICE|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
219092932|NCT05488275|PROCEDURE|Surgery|MPFL reconstruction
219092933|NCT06007690|DRUG|Bel-sar|Bel-sar via suprachoroidal administration followed by laser application.
219092934|NCT06007690|DEVICE|Suprachoroidal Microinjector|Suprachoroidal injection device
219092935|NCT06007690|DEVICE|Infrared Laser|Laser application
219092936|NCT06007690|DEVICE|Sham Infrared Laser|Sham laser application
219092937|NCT06007690|DEVICE|Sham Microinjector|Sham injection device
219092938|NCT03059758|OTHER|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
219092939|NCT02957929|DRUG|APX001 single IV dose|
219092940|NCT02957929|DRUG|APX001 single oral dose 1|
219682341|NCT02497404|DRUG|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
219092941|NCT02957929|DRUG|APX001 single oral dose 2|
219092942|NCT02957929|DRUG|APX001 single oral dose 3|
219092943|NCT02957929|DRUG|APX001 single oral dose fasted|
219092944|NCT02957929|DRUG|APX001 single oral dose fed|
219092945|NCT02957929|DRUG|APX001 multiple oral doses 1|
219092946|NCT02957929|DRUG|APX001 multiple oral doses 2|
219092947|NCT02957929|DRUG|APX001 multiple oral doses 3|
219092948|NCT02957929|DRUG|Cytochrome P450 substrates|
219092949|NCT02957929|DRUG|Matching placebo control|
219682342|NCT02497404|DRUG|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
219682343|NCT02497404|DRUG|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
219682344|NCT02497404|RADIATION|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
219218784|NCT02329704|PROCEDURE|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
219218785|NCT02329704|PROCEDURE|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
219218786|NCT02329704|PROCEDURE|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
219218787|NCT02329704|PROCEDURE|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
219218788|NCT02329704|BIOLOGICAL|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
219218789|NCT06090240|OTHER|MI-based ACP intervention|Motivational Interviewing on Advance Care Planning Intervention: Dyads of older adults and family caregivers will receive three MI-based ACP counselling sessions: (1) a preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions in weeks 2 and 3 will last 30-45 minutes each. Before each session, the nurse interventionist will first assess the dyad's readiness to engage in ACP based on the state of change algorithm. Participants who have never thought about ACP will be in the pre-contemplation state, those who are willing to discuss EOL care and preferences to be in the contemplation state, those ready to talk about EOL planning to be in the preparation state, and those in the action state have a confirmed action plan on signing up their ADs. Readiness-based ACP goals will be established, and state-matched MI counseling will be customized for each participant.
219218790|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
219218791|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
219218792|NCT04001829|DRUG|Docetaxel|Given IV
219218793|NCT04001829|DRUG|Paclitaxel|Given IV
219218794|NCT04001829|OTHER|Quality-of-Life Assessment|Ancillary studies
219218795|NCT04001829|OTHER|Questionnaire Administration|Ancillary studies
219218796|NCT06425614|PROCEDURE|Autotransfusion|"ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center."
219218797|NCT06552351|DEVICE|Needle-Free Jet Injection of 1 % lidocaine|The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
219218798|NCT06552351|OTHER|traditional needle infiltration of 1% lidocaine|Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
219218799|NCT03592888|DRUG|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
219218800|NCT05757141|DRUG|Fosigotifator|Oral Use
219218801|NCT06481306|DRUG|BMS-986470|Specified dose on specified days
219218802|NCT06481306|DRUG|Placebo|Specified dose on specified days
219218803|NCT04688684|BEHAVIORAL|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
219218804|NCT01632956|BEHAVIORAL|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
219218805|NCT01632956|BEHAVIORAL|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
219218806|NCT00489879|DEVICE|Mobile Health Care System (DrUB)|
219218807|NCT02541305|OTHER|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
219092950|NCT06579820|COMBINATION_PRODUCT|tubular bandage|The experimental group consisted of the group in which a tubular bandage was applied over the PIC, which was routinely applied.
219092951|NCT01756911|DEVICE|MFM|Implantation of the MFM
219218808|NCT02541305|OTHER|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
219092952|NCT04876079|OTHER|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
219092953|NCT04876079|DEVICE|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
219092954|NCT04876079|OTHER|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
219092955|NCT04876079|DRUG|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
219092956|NCT03763162|DRUG|Bortezomib|Given SC
219092957|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
219092958|NCT03763162|DRUG|Dexamethasone|Given IV or PO
219092959|NCT03763162|DRUG|Ixazomib|Given PO
219092960|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
219092961|NCT04419649|DRUG|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
219092962|NCT04506775|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
219092963|NCT04506775|PROCEDURE|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
219092964|NCT04996758|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
219218809|NCT03678688|DRUG|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
219218810|NCT03678688|DRUG|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
219092969|NCT05989698|DEVICE|C-mo System|Patients will use C-mo System for a period of 24h, to assess cough characteristics.
219218811|NCT03678688|DRUG|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
219092970|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
219218812|NCT03678688|DRUG|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
219682345|NCT04686422|DEVICE|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
219092971|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
219092972|NCT06082960|DRUG|GS-9911|Tablets administered orally
219092973|NCT06082960|DRUG|Zimberelimab|Administered intravenously
219092974|NCT02175355|DRUG|Low dose of Micardis®|
219092975|NCT02175355|DRUG|Medium dose of Micardis®|
219092976|NCT02175355|DRUG|High dose of Micardis®|
219092977|NCT02175355|DRUG|Hydrochlorothiazide|
219092978|NCT02175355|DRUG|Placebo|
219092979|NCT04255628|DIAGNOSTIC_TEST|FDG PET|Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
219092980|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
219092981|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
219092982|NCT06066437|DRUG|Arm A: 177Lu rhPSMA-10.1|Participants will receive 177Lu rhPSMA-10.1 alone.
219092983|NCT06066437|DRUG|Arm B: 177Lu rhPSMA-10.1 plus Degarelix|Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
219092984|NCT04589533|OTHER|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
219092985|NCT02254226|DRUG|Salmeterol Diskus low|
219092986|NCT02254226|DRUG|Salmeterol Diskus high|
219092987|NCT02254226|DRUG|Salmeterol MDI low|
219092988|NCT02254226|DRUG|Salmeterol MDI high|
219092989|NCT03794076|DRUG|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
219092990|NCT03794076|DRUG|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
219092991|NCT00633464|DRUG|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
219682346|NCT05854485|COMBINATION_PRODUCT|REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group|Participants in this group will receive multi-muscle FES during arm robotic training
219682347|NCT05854485|COMBINATION_PRODUCT|Robot only group|Participants in this group will receive arm robotic training only
219092992|NCT00633464|DRUG|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
219092993|NCT06161311|DEVICE|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
219092994|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
219092995|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
219092996|NCT04754412|OTHER|Best Practice|Write about facts regarding their cancer diagnosis and treatment
219092997|NCT04754412|OTHER|Quality-of-Life Assessment|Ancillary studies
219092998|NCT04754412|OTHER|Questionnaire Administration|Ancillary studies
219092999|NCT04060875|DEVICE|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
219093000|NCT02612064|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
219093001|NCT02612064|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
219093002|NCT03580889|DRUG|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
219093003|NCT03580889|DRUG|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
219093004|NCT03580889|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
219093005|NCT00269802|DRUG|OROS methylphenidate HCl|
219093006|NCT00269802|DRUG|Ritalin|
219093007|NCT00269802|DRUG|Placebo|
219093008|NCT01669798|DRUG|BIBF 1120|PO 200mg BID
219093009|NCT02080975|OTHER|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
219093010|NCT03367039|PROCEDURE|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
219093011|NCT03367039|PROCEDURE|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
219093012|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219093013|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219093014|NCT05278130|OTHER|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
219093015|NCT04914611|OTHER|No intervention|No intervention
219093016|NCT01865916|DRUG|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
219093017|NCT01865916|DRUG|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
219093018|NCT06558929|BEHAVIORAL|Occupational Therapy|Participants will redesign their daily routine with support from occupational therapists and an online health management platform.
219093019|NCT06558929|OTHER|Conventional Treatment|Participants will receive conventional treatment and education on sleep hygiene.
219093020|NCT05624450|DRUG|Tozorakimab|Single IV dose of tozorakimab on Day 1.
219093021|NCT05624450|DRUG|Placebo|Single IV dose of matching placebo on Day 1.
219093022|NCT06068218|OTHER|Biopsy for the patient group|The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet. For vitiligo patients, the biopsies will be taken on a non-depigmented skin.
219093023|NCT06068218|OTHER|biopsy for the volunteer group|A publicity in the hospital will announce the study, and will be use to recruit the healthy volunteers. The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet.
219093024|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
219093025|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
219218813|NCT03678688|DRUG|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day"
219218814|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
219218815|NCT03678688|DRUG|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
219093026|NCT06576128|DEVICE|ultrasound|In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
219093027|NCT06576128|PROCEDURE|parenteral local anesthesia|As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
219093028|NCT02958852|DRUG|Letrozole|Daily orally
219093029|NCT02958852|DRUG|Letrozole and atorvastatin|Daily orally
219093030|NCT02958852|DRUG|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
219093031|NCT00554918|DRUG|docetaxel|
219093032|NCT00554918|DRUG|prednisolone|
219093033|NCT00554918|DRUG|zoledronic acid|
219093034|NCT00554918|PROCEDURE|quality-of-life assessment|
219218816|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
219218817|NCT02959411|DRUG|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
219218818|NCT02959411|DRUG|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
219218819|NCT05127057|OTHER|PRIME Parkinson Care|A novel model of care
219218820|NCT05127057|OTHER|Usual Care|Usual NHS Care
219218821|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
219218822|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
219218823|NCT05947305|PROCEDURE|Surgical Blade|Using a 15c blade to de-epithelialize the soft tissue extra-orally
219218824|NCT05947305|PROCEDURE|Mucotome|Using Megagen Mucotome to de-epithelialize the soft tissue intra-orally
219218825|NCT05947305|PROCEDURE|Diamond Bur|Using a surgical diamond bur to de-epithelialize the soft tissue intra-orally
219218826|NCT05947305|PROCEDURE|Er:YAG Laser|Using an Er:YAG Laser to de-epithelialize the soft tissue intra-orally
219218827|NCT04164446|DRUG|Placebos|The placebo that will be used contains starch and glucose.
219093035|NCT00554918|RADIATION|strontium chloride Sr 89|
219218828|NCT04164446|DIETARY_SUPPLEMENT|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
219218829|NCT04072133|BEHAVIORAL|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
219682348|NCT06289439|DIETARY_SUPPLEMENT|Green tea (Camellia sinensis) 1000 mg as extract|Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
219682349|NCT06289439|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
219682350|NCT00056303|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
219682351|NCT00056303|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
219682352|NCT05180019|DEVICE|SMD ( Self Monitoring Device)|Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
219093036|NCT00637286|DRUG|Zolmitriptan|5mg Nasal Spray
219093037|NCT06344390|DRUG|Pentoxifylline|Take pentoxifylline 0.4 g twice daily
219093038|NCT04636489|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
219093039|NCT04636489|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
219093040|NCT00653458|DRUG|Ondansetron|ODT, 8 mg, single-dose, fed conditions
219093041|NCT00653458|DRUG|Zofran|ODT, 8 mg, single-dose, under fed conditions
219093042|NCT00026143|BIOLOGICAL|recombinant interleukin-12|Given IV
219093043|NCT00026143|BIOLOGICAL|recombinant interferon alfa|Given SC
219093044|NCT00026143|OTHER|laboratory biomarker analysis|Correlative studies
219093045|NCT01678131|DRUG|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
219093046|NCT01678131|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
219093047|NCT01678131|BIOLOGICAL|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
219093048|NCT01678131|PROCEDURE|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
219093049|NCT01678131|DRUG|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
219218830|NCT03349944|BEHAVIORAL|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
219218831|NCT02162082|DEVICE|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
219218832|NCT01427517|DRUG|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
219093050|NCT01678131|PROCEDURE|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
219093051|NCT06069050|PROCEDURE|sequential adolesent left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
219093052|NCT05354232|DEVICE|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
219093053|NCT05354232|DEVICE|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
219093054|NCT05354232|DEVICE|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
219093055|NCT00941798|DRUG|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
219093056|NCT00941798|DRUG|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
219093057|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
219093058|NCT00112580|BIOLOGICAL|ipilimumab|
219093059|NCT02651935|DEVICE|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
219093060|NCT01058317|DRUG|Propranolol|Propranolol 2mg/kg divided twice daily
219093061|NCT06681857|PROCEDURE|Sinus lifting|The implant osteotomy will be initiated by pilot drill entries followed by sequential drills via the radiographic stent's sleeves to position the fixtures precisely into the pre-determined recipient sites. The Implant stability quotient (ISQ) will then be measured using an Osstell device after attaching intelligent implant pigs. Finally, the mucoperiosteal flaps will be sutured in place with 4-0 Prolene.
219093062|NCT05009082|DRUG|Carboplatin|Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
219093063|NCT05009082|DRUG|Paclitaxel|175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
219093064|NCT05009082|DRUG|Bevacizumab|7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
219093065|NCT05009082|DRUG|Niraparib|200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
219093066|NCT01969110|DIETARY_SUPPLEMENT|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
219093067|NCT01665664|OTHER|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
219218833|NCT05845970|OTHER|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
219218834|NCT05845970|COMBINATION_PRODUCT|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
219218835|NCT02677766|OTHER|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
219218836|NCT02677766|OTHER|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
219682353|NCT01408719|DIETARY_SUPPLEMENT|Control|Minimal beta-glucan
219682354|NCT01408719|DIETARY_SUPPLEMENT|3g LMW beta-glucan|3grams beta-glucan
219682355|NCT01408719|DIETARY_SUPPLEMENT|5g LMW beta-glucan|5 grams beta-glucan
219682356|NCT01408719|DIETARY_SUPPLEMENT|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
219682357|NCT01675388|OTHER|Hypothermia|Hypothermia to 33.5 deg C
219682358|NCT02797678|DEVICE|Powersleep|Participants will receive 5 nights of stimulation
219093068|NCT00652782|DRUG|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
219093069|NCT00652782|DRUG|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
219093070|NCT00983086|DRUG|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
219093071|NCT02036957|PROCEDURE|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
219682359|NCT02797678|DEVICE|Sham Powersleep|Participants will receive 5 nights of no stimulation
219682360|NCT02401035|DRUG|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
219682361|NCT05307679|DRUG|Basmisanil|Participants will receive oral basmisanil at age-appropriate dosages
219682362|NCT05307679|DRUG|Placebo|Participants will receive oral placebo
219093072|NCT02036957|PROCEDURE|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
219093073|NCT03424434|OTHER|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
219093074|NCT04781738|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
219093075|NCT04723095|OTHER|Follow-Up|Receive follow up
219093076|NCT04723095|OTHER|Medical Chart Review|Review of medical records
219093077|NCT06083415|OTHER|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system. Photographs of the teeth will also be taken to be studied by pediatric odontology researchers on the on molar and incisor hypomineralization, known as MIH.
219093078|NCT04500548|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
219218837|NCT05689606|BEHAVIORAL|Exercise|Exercise includes acute high-intensity interval training.
219218838|NCT01259570|DIETARY_SUPPLEMENT|Group 1|Skimmilk enriched with VD encapsulated in CM
219682363|NCT00168155|DRUG|perioperative chemotherapy|
219682364|NCT00281723|DRUG|Pro-Pe adhesive tablet|
219093079|NCT04500548|BIOLOGICAL|Ipilimumab|Given IV
219093080|NCT04500548|BIOLOGICAL|Nivolumab|Given IV
219093081|NCT06820593|BEHAVIORAL|Digital Asthma Intervention|The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
219093082|NCT06820593|BEHAVIORAL|Comparison Group|Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.
219093083|NCT04979312|DEVICE|LabClasp|Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
219093084|NCT05619003|DEVICE|Biatain Silicone Sacral dressing|Biatain Silicone Sacral dressing will be applied over the bony prominence of the sacral area as part of a PIP (Pressure Injury Prevention) protocol in patients at risk
219093085|NCT05366764|DRUG|SAR443765|solution for injection
219093086|NCT05366764|DRUG|Placebo|solution for injection
219093087|NCT05366764|DRUG|Salbutamol or levosalbutamol|metered dose inhaler
219093088|NCT05320731|PROCEDURE|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
219218839|NCT01259570|DIETARY_SUPPLEMENT|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
219218840|NCT01259570|DIETARY_SUPPLEMENT|group 3|3% fat milk wherein the VD will be in CM
219218841|NCT01259570|DIETARY_SUPPLEMENT|Group 4|Placebo: un-enriched skimmilk.
219218842|NCT06270953|DEVICE|Dozee Pro NX|Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements
219218843|NCT05960669|PROCEDURE|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
219218844|NCT06510140|BEHAVIORAL|Detection of the Post-operative delirium (POD)|Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
219218845|NCT05479565|DIAGNOSTIC_TEST|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
219218846|NCT02588443|DRUG|RO70097890|
219218847|NCT02588443|DRUG|nab-paclitaxel|
219218848|NCT02588443|DRUG|gemcitabine|
219218849|NCT03002194|DEVICE|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
219682365|NCT02766036|DRUG|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
219682366|NCT02766036|DRUG|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
219682367|NCT05745545|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
219093089|NCT05320731|PROCEDURE|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
219093092|NCT03901235|BIOLOGICAL|Mesenchymal Stromal Cells|Suspension of mesenchymal stromal cells for intratissular injection
219218850|NCT03002194|OTHER|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
219218851|NCT02192632|DRUG|Epiduo once daily with detailed instruction for how to apply it|
219218852|NCT02192632|DRUG|Epiduo- once daily, simple instruction for application|
219218853|NCT02192632|DRUG|BPO once daily|
219218854|NCT01905566|DRUG|Clopidogrel|75mg once a day
219218855|NCT01905566|DRUG|Ticagrelor|90mg twice a day
219218856|NCT04436549|PROCEDURE|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
219093093|NCT06865339|DRUG|Cemiplimab|Human IgG anti-PD-1 monoclonal antibody approved for treatment of advanced NSCLC with PD-L1 TPS ≥ 50% as monotherapy and in combination with chemotherapy
219093094|NCT06865339|DRUG|Fianlimab|Human IgG anti-lymphocyte activation gene 3 (LAG-3) monoclonal antibody, which is expressed by various immune cells, and regulates effector T-cell activation and responses. LAG-3 inhibition restores the effector function of exhausted T cells, enhancing their ability to attack tumor cells. Fianlimab is currently under investigation in several clinical studies involving NSCLC (NCT05800015, NCT03916627, NCT05785767).
219093095|NCT06865339|RADIATION|Radiotherapy|Thoracic radiotherapy. Conventionally fractionated 1.8-2.0 Gray (Gy) per day. Adaptive radiotherapy will not be performed unless difficulty with patient setup or changes in internal patient anatomy require repeating the CT simulation procedure
219218857|NCT04436549|DIAGNOSTIC_TEST|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
219218858|NCT04196309|DRUG|low molecular weight heparin|LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
219218859|NCT00985088|BIOLOGICAL|GSK2340274A|one or two intramuscular injections
219218860|NCT00985088|BIOLOGICAL|GSK2340273A|one or two intramuscular injections
219218861|NCT00985088|BIOLOGICAL|Saline placebo|One injection
219218862|NCT00502684|DRUG|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
219218863|NCT05346588|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
219218864|NCT05346588|OTHER|Anesthetic technique inhaled agent|must administer inhaled agent.
219218865|NCT04062578|BEHAVIORAL|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
219218866|NCT02824926|DRUG|Dapaconazole|
219218867|NCT02824926|DRUG|Ketoconazole|
219218868|NCT05795088|DEVICE|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
219218869|NCT05141968|DIETARY_SUPPLEMENT|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
219218870|NCT06445140|BEHAVIORAL|Collecting the variables and Implementation of a behavioural intervention|"The observational phase (during 15 days)~* Two measurements per day for motivational variables and physical activity and nutrition~* Two measurements per day for nutrition~* Three measurements per day for fatigue~* Continuous PA measurement by accelerometer~The interventional phase :~Part A (during 7 days)~* measuring physical activity (PA)~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue~Part B: BEHAVIORAL INTERVENTION (10 weeks),the APA teacher will call a patient once a week for follow-up.~Answer questionnaires and scales on the digital platform will be done :~* Motivational factors~* Self-evaluation of nutrition~* Self-assessment of fatigue~Part C : End of interventional phase(during 7 days)~* measuring physical activity~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue"
219218871|NCT02963571|PROCEDURE|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
219218872|NCT03607175|DRUG|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
219093096|NCT06865339|DRUG|Platinum Doublet Chemotherapy (PDC)|Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous), carboplatin/cisplatin plus etoposide (any histology), and carboplatin/cisplatin plus docetaxel or gemcitabine (squamous). Carboplatin can be used instead of cisplatin after cycle 1 in cases of cisplatin-induced neuro-/oto-/nephrotoxicity as long as the patient remains eligible for chemoradiotherapy. Weekly radiosensitizing PDC will be recommended for PD-L1 TPS \<50% patients during RT but is not required.
219218873|NCT03607175|DEVICE|Propel Stent|same information as included in the arm/group descriptions
219093097|NCT07001150|DRUG|levodopa-carbidopa|Carbidopa/levodopa is a combination of two medications: carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease. The main and most effective treatment strategy for motor symptoms in Parkinson's disease relies on replenishing dopamine levels through the use of L-dopa.
219218874|NCT05794841|DIAGNOSTIC_TEST|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
219218875|NCT06065930|DEVICE|Subcutaneous microdialysis|"Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1."
219218876|NCT03772132|BIOLOGICAL|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
219218877|NCT03211988|DRUG|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
219218878|NCT01698541|DRUG|Tacrolimus|Tested generic
219218879|NCT01698541|DRUG|Tacrolimus|Original formulation used as comparator
219218880|NCT04126577|BIOLOGICAL|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
219218881|NCT00111631|DRUG|DPP-IV Inhibitor|Escalating doses po bid
219218882|NCT00111631|DRUG|Metformin|As prescribed
219218883|NCT00111631|DRUG|Placebo|po bid
219218884|NCT02919748|OTHER|Choral Singing|Weekly sessions at 1 hour of choral singing.
219218885|NCT02919748|OTHER|Health Education Program|Weekly session at 1 hour of health education talk and group activities
219682368|NCT05745545|DRUG|Saline solution|One dose was administered by intramuscular injection, 0.5ml/vial
219682369|NCT05184387|OTHER|Blood samples|Collection of blood samples and completion of an electronic Diary (eDiary)
219218886|NCT02829398|PROCEDURE|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
219218887|NCT05320289|DEVICE|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
219218888|NCT03130894|OTHER|Plasma TMAO concentration|Plasma TMAO concentration
219682370|NCT06058273|BEHAVIORAL|Bruni® training|10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R\&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
219682371|NCT00023738|BIOLOGICAL|filgrastim|
219682372|NCT00023738|DRUG|dacarbazine|
219682373|NCT00023738|DRUG|doxorubicin hydrochloride|
219682374|NCT00023738|DRUG|ifosfamide|
219682375|NCT00023738|DRUG|semaxanib|
219682376|NCT00023738|PROCEDURE|conventional surgery|
219682377|NCT00023738|RADIATION|radiation therapy|
219682378|NCT00229749|DRUG|AVI-4065 Injection|
219682379|NCT01204086|DRUG|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
219682380|NCT01204086|DRUG|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
219682381|NCT00758381|DRUG|Sorafenib 400 mg po bid, continuously|"NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
219682382|NCT00758381|DRUG|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
219682383|NCT03938363|OTHER|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
219682384|NCT03938363|DRUG|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
219682385|NCT03938363|DIAGNOSTIC_TEST|Severity scale of the disease|JRS for BS TWSTRS for CD
219682386|NCT00048633|DRUG|Chemotherapy|
219682387|NCT01706432|RADIATION|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
219682388|NCT01706432|OTHER|laboratory biomarker analysis|Correlative studies
219682389|NCT01706432|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
219218889|NCT02958696|DRUG|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
219218890|NCT03166085|DRUG|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
219218891|NCT03166085|DRUG|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
219218892|NCT03948295|DIETARY_SUPPLEMENT|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
219218893|NCT05304624|DEVICE|laser|these lasers are routinely used in dental practice
219218894|NCT01438034|DRUG|kisspeptin 112-121|0.24 nmol/kg
219218895|NCT01438034|DRUG|GnRH|75 ng/kg
219218896|NCT04402112|DRUG|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
219218897|NCT06002867|PROCEDURE|SAPB (Serratus Anterior Plan) Block|The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
219218898|NCT01627314|BIOLOGICAL|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
219218899|NCT01627314|BIOLOGICAL|Untreated CB|Cord Blood
219218900|NCT02187536|DRUG|Telmisartan|
219218901|NCT02187536|DRUG|Simvastatin|
219218902|NCT02187536|DRUG|Telmisartan placebo|
219362094|NCT05911646|OTHER|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
219362095|NCT00695565|DRUG|Placebo Gel|TID x 12 weeks
219682390|NCT00939926|DRUG|Risperidone|
219682391|NCT04821843|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
219682392|NCT04821843|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
219682393|NCT04821843|RADIATION|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
219682394|NCT04821843|PROCEDURE|Surgery|Radical esophagectomy
219682395|NCT04821843|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
219682396|NCT04821843|DRUG|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
219682397|NCT04821843|DRUG|Nimotuzumab|200-400mg, d1,qW
219682398|NCT04900649|OTHER|chest resistance exercise|lung function.
219682399|NCT04900649|OTHER|chest expansion exercises|thoracic excursion
219682400|NCT04967105|DEVICE|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
219682401|NCT01403571|DIETARY_SUPPLEMENT|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
219682402|NCT01403571|DIETARY_SUPPLEMENT|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
219682403|NCT02951624|BEHAVIORAL|Control|Control intervention
219682404|NCT02951624|BEHAVIORAL|Breaker|Short breaks of physical activity
219682405|NCT02951624|BEHAVIORAL|Prolonger|longer breaks of physical activity
219682406|NCT02951624|BEHAVIORAL|Intermediate|Intermediate breaks of physical activity
219682407|NCT05223816|DRUG|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
219682408|NCT05223816|DRUG|Nivolumab Injection [Opdivo]|immunotherapy treatment
219682409|NCT00204061|BEHAVIORAL|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
219682410|NCT00204061|DRUG|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
219682411|NCT02344511|DRUG|Dalbavancin|Drug
219682412|NCT02344511|DRUG|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
219682413|NCT01014195|OTHER|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
219682414|NCT06043648|DEVICE|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
219682415|NCT03017196|OTHER|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
219682416|NCT02723448|DRUG|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
219093098|NCT07001150|DRUG|Silymarin|Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, is employed clinically for managing hepatic disorders. Its antioxidant effects are primarily attributed to its ability to scavenge free radicals.
219093099|NCT06998628|DRUG|Methotrexate|Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for including breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Methotrexate is also used to treat rheumatoid arthritis and other inflammatory conditions.
219093100|NCT06998628|DRUG|Pentoxifylline|Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects. In the United States, it is primarily used to treat intermittent claudication. Studies in both humans and animals have demonstrated that pentoxifylline therapy induces various physiological changes at the cellular level
219093101|NCT07001371|BEHAVIORAL|Emotional Brain Training|Emotional Brain Training (EBT) is a structured, neuroscience-based behavioral intervention that focuses on rewiring the brain's stress-related circuits to promote emotional resilience, self-regulation, and lasting behavioral change. This behavioral intervention has not been implemented in addiction treatments in the past. Unlike traditional therapies that primarily target cognitive processes or symptom management, EBT directly addresses the physiological and emotional root causes of maladaptive behaviors by engaging the brain's natural neuroplasticity mechanisms. EBT integrates rapid emotional processing tools, peer-to-peer support, clinician-facilitated sessions, and mobile app-based self-care to systematically transition brain circuits from stress-reactive to stress-resilient states.
219682417|NCT02497937|DRUG|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
219682418|NCT02497937|DRUG|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
219093102|NCT07001371|OTHER|Standard addiction counseling and medical therapy|Participants will receive standard counseling (including but not limited to cognitive behavioral therapy, motivational interviewing, etc.), which does not include EBT, in addition to medications for addiction treatment (including but not limited to buprenorphine, naltrexone, bupropion, etc.).
219093103|NCT06752668|DRUG|ORX750|ORX750 capsule.
219093104|NCT06752668|DRUG|Placebo|ORX750 matching placebo capsule.
219093105|NCT04817007|DRUG|BMS-986158|Specified dose on specified days
219093106|NCT04817007|DRUG|Ruxolitinib|Specified dose on specified days
219093107|NCT04817007|DRUG|Fedratinib|Specified dose on specified days
219093108|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
219093109|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
219362096|NCT00695565|DRUG|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
219362097|NCT00146263|BEHAVIORAL|Savyon|Computerized cognitive training
219362098|NCT00146263|BEHAVIORAL|Control|Usual activity
219682419|NCT04088539|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
219682420|NCT04088539|BEHAVIORAL|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
219218903|NCT05739370|OTHER|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
219218904|NCT06244875|OTHER|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
219218905|NCT05697835|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
219218906|NCT05697835|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
219218907|NCT05697835|OTHER|Care as usual|Care as usual, with written resources provided
219218908|NCT05352308|BEHAVIORAL|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
219218909|NCT01354444|DRUG|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
219218910|NCT01354444|DRUG|Placebo|a pill that will look like the active drug but will not contain any carvedilol
219218911|NCT06184321|BIOLOGICAL|Alteplase|Instilled into IPC
219218912|NCT06184321|DRUG|Placebo Administration|Instilled into IPC
219218913|NCT04304937|OTHER|patient reported outcome measure|2 questionnaires are tested against each other
219218914|NCT05440058|DEVICE|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
219218915|NCT00982072|DRUG|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
219218916|NCT00982072|DRUG|prednisolone|Prednisolone 1mg/kg maximum 60mg od
219218917|NCT02821936|PROCEDURE|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
219218918|NCT02103556|OTHER|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
219218919|NCT02103556|DIETARY_SUPPLEMENT|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
219218920|NCT02103556|DIETARY_SUPPLEMENT|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
219218921|NCT05783531|OTHER|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
219218922|NCT05783531|OTHER|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
219093110|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
219093111|NCT06871943|OTHER|Incremental Shuttle Walk Tests|The participants will walk on the flat around cones placed 9 meters apart inline with the procedure for the incremental shuttle walk test. They will also walk at a matched speed to the incremental shuttle walk test on a treadmill. This will be performed in a counter balanced procedure to reduce any benefit of a learning effect.
219218923|NCT00325000|BEHAVIORAL|Interpersonal Psychotherapy|
219218924|NCT00325000|DRUG|sertraline or amitriptyline|
219218925|NCT00180791|DRUG|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
219218926|NCT04162210|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219218927|NCT04162210|DRUG|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
219218928|NCT04210258|DEVICE|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
219218929|NCT04210258|DEVICE|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
219218930|NCT05121636|DEVICE|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
219218931|NCT01437410|PROCEDURE|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
219218932|NCT04828096|OTHER|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
219093112|NCT05037760|DRUG|KER-050 monotherapy|KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
219093113|NCT05037760|DRUG|KER-050 in combination with ruxolitinib|KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
219093114|NCT07006818|DEVICE|Direct current stimulation|Direct current stimulation will be applied at 2 mA for 20 minutes.
219093115|NCT07016880|BEHAVIORAL|Virtual Reality Relaxation Session|A 20 minute virtual reality session using visual and auditory stimuli for relaxation before surgery. Delivered via VR headset.
219093116|NCT07025577|DRUG|Immunoglobulin G|Participants will receive SC administrations of IgG
219218933|NCT04025255|DIETARY_SUPPLEMENT|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
219218934|NCT04025255|DIETARY_SUPPLEMENT|Placebo|Matched placebo
219218935|NCT01754051|DEVICE|PC 400 coils|
219218936|NCT03524755|OTHER|Exercise|
219218937|NCT02610608|OTHER|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
219218938|NCT00238485|DRUG|Licarbazepine|
219218939|NCT05877872|PROCEDURE|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
219218940|NCT05877872|PROCEDURE|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
219218941|NCT05877872|DRUG|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
219218942|NCT03021512|PROCEDURE|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
219218943|NCT03021512|PROCEDURE|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
219218944|NCT01480375|DEVICE|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
219218945|NCT02031185|BEHAVIORAL|FitBit only|Participants will use the FitBit device
219218946|NCT02031185|BEHAVIORAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
219218947|NCT01697683|DRUG|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
219218948|NCT01697683|DRUG|Placebo|
219218949|NCT04618250|OTHER|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
219218950|NCT06509165|PROCEDURE|Modified coronally advanced flap technique|Subepithelial connective tissue graft was applied to the relevant areas with a modified coronally placed flap technique to cover the gingival recession.
219218951|NCT06509165|PROCEDURE|Tunnel technique|Subepithelial connective tissue graft was applied to the relevant areas with the tunnel technique to cover the gingival recession.
219218952|NCT01935375|BEHAVIORAL|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
219218953|NCT01935375|BEHAVIORAL|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
219218954|NCT04589975|PROCEDURE|laparoscopic surgery|
219218955|NCT02103166|DRUG|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
219218956|NCT02103166|DRUG|Physiological serum|100 ml of physiological serum (0.9% NaCl).
219218957|NCT02903875|OTHER|Patient therapeutic education (PTE) programme|
219218958|NCT03136172|DEVICE|NIRS (near Infra-red spectroscopy)|"1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
219218959|NCT00980213|DRUG|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
219218960|NCT02138994|DEVICE|Next Science Wound Gel|
219682421|NCT00179803|PROCEDURE|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
219682422|NCT00735514|BEHAVIORAL|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
219682423|NCT00735514|OTHER|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
219093117|NCT06701435|DEVICE|Cold Compression|Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.
219093118|NCT07021963|DRUG|HRS-1893 Tablet|HRS-1893 tablet.
219093119|NCT06685861|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
219093120|NCT00199719|DRUG|Ribavirine|
219218961|NCT02138994|DRUG|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months"
219218962|NCT02897206|DRUG|Imipenem|A wide-spectre antibiotic from the carbapenem group
219218963|NCT02897206|DRUG|Placebo|An imipenem-matching placebo
219218964|NCT01458600|DRUG|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
219218965|NCT01458600|DRUG|Methimazole|T Methimazole 5 mg 3x2 for 18 months
219218966|NCT01458600|DRUG|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
219218967|NCT01458600|DRUG|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
219218968|NCT01458600|DRUG|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
219218969|NCT01329406|DRUG|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
219218970|NCT01329406|DRUG|Placebo|1 tablet by mouth twice daily for 28 days
219218971|NCT02803749|DRUG|Buspirone|
219218972|NCT02803749|DRUG|Placebo|
219218973|NCT03908606|PROCEDURE|Scaling and root planing|Supra and subgingival scaling and root planing.
219218974|NCT00369902|PROCEDURE|acupuncture|
219218975|NCT03842332|BEHAVIORAL|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
219218976|NCT00371345|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
219218977|NCT00371345|DRUG|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
219218978|NCT02180815|DEVICE|ReVENT Sleep Apnea System|
219093121|NCT07032688|DRUG|SHR-3167 Injection|SHR-3167 injection.
219093122|NCT07032688|DRUG|Insulin Degludec Injection|Insulin Degludec injection.
219093123|NCT06723158|OTHER|Virtual reality (VR) glasses with relaxation module|The relaxation module will include immersive video and audio components as a distraction from the medical procedures.
219218979|NCT06000800|OTHER|Group B|Umbilical cord clamping at 30 seconds
219218980|NCT06000800|OTHER|Group C|Umbilical cord clamping at 60 seconds
219218981|NCT06000800|OTHER|Group D|Umbilical cord clamping at 90 seconds
219218982|NCT06000800|OTHER|Group A|Umbilical cord clamping immediately after birth (5 second)
219093124|NCT06724757|OTHER|Health questionnaire|The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
219093125|NCT06724991|PROCEDURE|Lower Dose Therapy|The group receiving the lower-dose therapy consists of 5 units of Actrapid (insulin) with 25cc of Dextrose 50%. This intervention is the focus of the clinical trial and is being investigated to determine if it achieves a comparable reduction in potassium levels with fewer potential complications. The aim is to establish it as a non-inferior alternative to conventional-dose therapy in the management of mild and moderate hyperkalemia.
219093126|NCT06724991|PROCEDURE|Conventional Dose Therapy|The group receiving the conventional-dose therapy, consisting of 10 units of Actrapid (insulin) with 50cc of Dextrose 50%, which is currently in use as a standard practice in emergency departments for managing mild and moderate hyperkalemia. This dosing regimen aligns with established clinical guidelines and is widely accepted as an effective approach in controlling potassium levels.
219218983|NCT01171638|DEVICE|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
219218984|NCT04433780|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
219218985|NCT05168397|OTHER|RV4857A|RV4857A formula CD2110 is a sunscreen product
219218986|NCT01131546|DRUG|Levamlodipine besylate|Once daily, 7AM - 10AM
219218987|NCT01131546|DRUG|Amlodipine maleate|Once daily, 7AM - 10AM
219218988|NCT05991804|OTHER|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs
219218989|NCT05991804|OTHER|Inpatient rehabilitation alone|Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust
219218990|NCT00236847|DRUG|topiramate|
219093127|NCT07050758|BEHAVIORAL|Pain Reprocessing Therapy|"Each PRT session will take 45-60 minutes and includes psychoeducation about the association between pain and the brain, mindfulness, and exposure- and acceptance-based concepts. Through PRT, participants will learn about how pain can emerge from 'stuck patterns' in neural circuits in the brain. Through reflections of their own pain experiences, the patient explores evidence for whether this applies to their own pain. Patients will acquire corrective experiences in which their brain learns not to respond with pain (false alarm) in situations that are safe. One central reprocessing exercise is 'somatic tracking', in which participants explore their pain sensations in a context of safety. This includes interoceptive exposures and situational exposures to activities they fear will trigger pain. Exploring these sensations and situations through a lens of safety and curiosity allows the participants to reinterpret bodily sensations previously associated with threat or pain, as safe."
219093128|NCT06701812|DRUG|Digoxin|2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
219093129|NCT04803201|DRUG|Cyclophosphamide|Given IV
219093130|NCT04803201|DRUG|Doxorubicin|Given IV
219093131|NCT04803201|DRUG|Vincristine|Given IV
219093132|NCT04803201|DRUG|Prednisone|Given PO
219093133|NCT04803201|DRUG|Etoposide|Given IV or PO
219093134|NCT04803201|DRUG|Duvelisib|Given PO
219093135|NCT04803201|DRUG|Oral azacitidine|Given PO
219093136|NCT04081220|DRUG|IMG-7289|Single starting dose with individualized dose titrations throughout
219093137|NCT07092475|DRUG|Methadon|A long-acting synthetic opioid with a pharmacologic profile that potentially offers more stable and longer-lasting pain relief.
219093138|NCT07094022|DIETARY_SUPPLEMENT|Nutrilite Protein MetX Pro|A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
219093139|NCT07094022|DIETARY_SUPPLEMENT|Placebo Product|A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
219093140|NCT07092969|DEVICE|Treadmill Exercise|Participants in this group will perform an aerobic exercise using the Bruce Protocol on a treadmill. The test involves walking or running with gradually increasing speed and incline in predefined stages to assess cardiovascular endurance. Heart rate, blood pressure, and fatigue levels will be recorded at each stage. The session will conclude with a low-intensity cool-down phase.
219093141|NCT07092969|DEVICE|Bicycle Exercise|The Wingate Anaerobic Test will be conducted using an ergometer bike. After a standardized warm-up, participants will pedal all-out for 30 seconds against a preset resistance, aiming to evaluate their anaerobic performance. Physiological parameters including power output, heart rate, and oxygen saturation will be monitored throughout the test.
219093142|NCT07093606|DRUG|Eltrombopag|ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
219093143|NCT07094074|OTHER|Walk tests|"* 200 m walk test~* 2-minute walk test~* 6-minute walk test"
219093144|NCT07094074|OTHER|Functional testing|Timed Up and Go test (TUG), Berg Balance Test (BBT), Choice Stepping Reaction Time (CSRT), Functional Reach Test (FRT)
219093145|NCT07094074|OTHER|Balance analysis|Balance analysis
219093146|NCT07094074|OTHER|Quantified analysis of walking|On flat ground, even on slopes and stairs
219218991|NCT04905784|BEHAVIORAL|Differential learning|The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
219218992|NCT04905784|BEHAVIORAL|Usual toothbrushing|The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
219218993|NCT06465550|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
219218994|NCT03936166|DRUG|CRN01941 Oral Solution|Investigational drug
219218995|NCT03936166|DRUG|CRN01941 Oral Capsule|Investigational drug
219218996|NCT03936166|DRUG|Placebo Oral Solution|Placebo
219218997|NCT03936166|DRUG|Placebo Oral Capsule|Placebo
219218998|NCT06415994|DRUG|Buprenorphine or Methadone Treatment|Pregnant mothers must be taking Buprenorphine or Methadone
219093147|NCT07094074|OTHER|Questionnaires|Houghton, Prosthetic Profile of the Amputees-Locomotion Capabilities Index (PPA-LCI), Activities-specific Balance Confidence scale (ABC), quality of life assessed by the SF-12
219093148|NCT07094061|DEVICE|fMRI|Participants will have an MRI to scan participants brains and will wear skin conductance electrodes on the hand and fill out questionnaires. Scanning will take approximately 90 minutes. While lying in the scanner, participants will be asked to perform some tasks. The tasks will be presented to participants visually on a screen in the scanner and eye movements will also be tracked during some of these tasks. Participants will respond to stimuli with button presses that are recorded by computer.
219682424|NCT00735514|PROCEDURE|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
219093149|NCT07094061|BEHAVIORAL|Questionnaires and surveys|Participants will have multiple visits during this study and fill out various surveys at these visits.
219218999|NCT06415994|DIAGNOSTIC_TEST|Fetal and Placental MRI|"Two MRIs :~* Second Trimester~* Third Trimester"
219219000|NCT06415994|BEHAVIORAL|Child Developmental Assessment|At 1 year of life child will receive a developmental assessment
219219001|NCT06415994|BEHAVIORAL|Questionnaires|Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
219219002|NCT06415994|OTHER|Blood and Placental Samples|"At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis."
219093150|NCT07094061|BEHAVIORAL|Behavioral tasks and eye tracking|Participants will perform behavioral tasks while having eye-tracking hardware monitor participants eye movements. A video camera will be used to record eye movements during the behavioral tasks.
219093151|NCT06940336|DRUG|Tafamidis Meglumine Soft Capsules|20 mg orally once daily for 72 weeks
219093154|NCT06940154|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
219093155|NCT06940154|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
219093156|NCT07146893|DRUG|Selpercatinib|"Patients will be instructed to take selpercatinib orally (PO) twice daily (BID), approximately every 12 hours. While on study, they will undergo weight measurements and regular blood draws every 4 weeks. At the 16-week post-treatment follow-up, patients will return to the clinic for a weight assessment to evaluate potential changes in body weight.~Patients will be administered assessments including, Functional Assessment of Anorexia Cachexia Therapy (FAACT), administered at screening, at 12 weeks post-discontinuation of the study drug, and again at the 16-week follow-up."
219093157|NCT07146893|OTHER|Strength Assessment|Several strength assessment will be conducted at baseline and at 12 weeks end-of-treatment, which will include measurements such as grip strength, hallux strength, timed chair stands, leg press, and localized ultrasound of the quadriceps.
219093158|NCT07145437|DIAGNOSTIC_TEST|Radio-induced Lymphocyte Apoptosis (RILA) Assay|peripheral blood sample processed via the RILA assay to quantify apoptotic CD8+/CD4+ T cells following ex vivo irradiation.
219093159|NCT07145437|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT delivered to the prostate with image guidance, respecting dose constraints for organs at risk;
219093160|NCT07154953|DIAGNOSTIC_TEST|Serum Surfactant Protein-D|Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability
219093161|NCT02977559|DEVICE|Laryngeal Tube Suction Disposable|Device for ventilation
219093162|NCT02977559|DEVICE|Laryngeal Mask Airway AuraGain|Ventilation device
219093163|NCT07165054|OTHER|atheroma plaque|Before the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
219093164|NCT07165054|OTHER|Dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
219093165|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 1) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 1) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
219093166|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 2) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 2) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
219093167|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 3) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 3) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
219093168|NCT07165548|DIETARY_SUPPLEMENT|Placebo Bar + Hypocaloric diet (10% energy restriction)|Participants will consume three placebo bars daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
219093169|NCT06211296|DEVICE|Shortcut|Splitting bioprosthetic aortic valve leaflets
219093170|NCT01980407|DRUG|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
219093171|NCT06115330|DEVICE|Press Needle Acupuncture|Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
219093172|NCT00175344|PROCEDURE|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
219093173|NCT01837160|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
219093174|NCT01837160|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
219093175|NCT01837160|PROCEDURE|Echocardiogram|Echocardiography.
219093176|NCT01837160|RADIATION|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
219219003|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
219219004|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
219219005|NCT06835920|BEHAVIORAL|Front-of-package health warning|Participants will receive 3 different health warnings about alcohol consumption. The warnings will discuss health risks of alcohol including cancer, high blood pressure, and scarring of the liver. Labels will be placed on the front of participants' alcohol containers.
219219006|NCT06835920|BEHAVIORAL|Control label|Participants will receive a label displaying a barcode. Labels will be placed on the front of participants' alcohol containers.
219219007|NCT00686465|OTHER|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
219219008|NCT04516226|OTHER|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
219219009|NCT02432066|DRUG|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
219219010|NCT02432066|DRUG|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
219219011|NCT04178421|OTHER|Computerized training program|Eye-gaze fixation computer based training program
219219012|NCT04178421|OTHER|Placebo|Pac-Man, Zookeeper, Tetris
219219013|NCT03884842|BIOLOGICAL|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
219219014|NCT03884842|BIOLOGICAL|Placebo|Matched placebo
219093177|NCT01837160|PROCEDURE|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
219093178|NCT04215016|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
219093179|NCT00209807|DRUG|escitalopram|escitalopram 10 mg/d for 6 weeks
219093180|NCT00209807|DRUG|Reboxetine|Reboxetine 8 mg/d for 6 weeks
219093181|NCT00209807|OTHER|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
219093182|NCT03350334|DRUG|Duloxetine|Peri-operative Duloxetine administration
219219015|NCT01478594|DRUG|Tivozanib|Capsules for oral administration
219219016|NCT01478594|DRUG|Bevacizumab|Solution for intravenous infusion
219219017|NCT01478594|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
219219018|NCT02747537|DRUG|Sorafenib|
219093183|NCT03350334|DRUG|placebo|Placebo administration
219093184|NCT02384564|DEVICE|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
219093185|NCT02384564|DEVICE|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
219219019|NCT02747537|DRUG|Irinotecan|
219219020|NCT06834282|DRUG|CER-1236|an autologous chimeric engulfment receptor T-cell
219219021|NCT06834282|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219219022|NCT06834282|DRUG|Fludarabine|Lymphodepleting chemotherapy
219219023|NCT06834282|DRUG|Mesna|Chemoprotectant
219219024|NCT02530892|PROCEDURE|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
219219025|NCT00713596|DRUG|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
219219026|NCT00713596|PROCEDURE|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
219219027|NCT00713596|PROCEDURE|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
219219028|NCT00713596|PROCEDURE|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
219219029|NCT00713596|OTHER|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
219219030|NCT04275583|DRUG|TQB3602|This is a kind of proteasome inhibitor.
219219031|NCT06158672|BEHAVIORAL|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
219219032|NCT06158672|BEHAVIORAL|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
219219033|NCT05555095|BEHAVIORAL|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
219219034|NCT01642719|BEHAVIORAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
219219035|NCT01642719|BEHAVIORAL|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
219219036|NCT05340738|OTHER|LyssnCBT|LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
219219037|NCT06149299|PROCEDURE|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
219219038|NCT04545619|DEVICE|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
219219039|NCT05518214|DIETARY_SUPPLEMENT|Beetroot|Participants receive a 12-week supply of beetroot juice.
219219040|NCT05518214|DIETARY_SUPPLEMENT|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
219219041|NCT02381028|OTHER|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
219219042|NCT02381028|OTHER|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
219219043|NCT00143286|DRUG|varenicline (CP-526,555)|
219219044|NCT02011360|OTHER|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
219093186|NCT01755442|OTHER|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
219093187|NCT01755442|DRUG|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
219093188|NCT04384016|BIOLOGICAL|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
219093189|NCT06096545|PROCEDURE|Axillary sentinal lymph node biopsy|"For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively."
219219045|NCT02011360|OTHER|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
219219046|NCT04680845|BEHAVIORAL|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
219219047|NCT02639637|DRUG|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
219219048|NCT02639637|DRUG|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
219219049|NCT02639637|DRUG|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
219219050|NCT02639637|DRUG|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
219219051|NCT02639637|DRUG|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
219219052|NCT01359150|DRUG|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
219219053|NCT01359150|DRUG|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
219219054|NCT03656042|DRUG|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment"
219093190|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
219093191|NCT00768508|DRUG|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
219219055|NCT01358669|DRUG|Denosumab|60mg denosumab by injection as a single dose
219219056|NCT01358669|OTHER|Placebo|Placebo by injection as a single dose
219219057|NCT06226155|BEHAVIORAL|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
219219058|NCT06226155|OTHER|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
219093192|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
219093193|NCT00768508|OTHER|Placebo + Cognitive Behavioral Therapy|Placebo comparator
219093194|NCT04236193|DIAGNOSTIC_TEST|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
219093195|NCT02024672|OTHER|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
219093196|NCT00685945|DRUG|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
219093197|NCT00685945|DRUG|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
219093198|NCT00685945|DRUG|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
219093199|NCT00685945|DRUG|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
219093200|NCT03183388|BEHAVIORAL|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
219093201|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
219093202|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
219093203|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
219093204|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
219093205|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
219093206|NCT02820805|OTHER|Meal Skipping|No meal
219093207|NCT02820805|OTHER|French fries|50g of available carbohydrates meal
219093208|NCT02820805|OTHER|Mashed potatoes|50g of available carbohydrates meal
219093209|NCT02820805|OTHER|Hash browns|50g of available carbohydrates meal
219093210|NCT02820805|OTHER|Rice|50g of available carbohydrates meal
219093211|NCT02820805|OTHER|Beans|50g of available carbohydrates meal
219093212|NCT06788444|PROCEDURE|The colonoscopy|"Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration.~After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy."
219093213|NCT06788444|DRUG|Esketamine|The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
219093214|NCT01728792|BIOLOGICAL|TDV|TDV IM or SC injection
219219059|NCT01513616|OTHER|Pulmonary rehabilitation|8-week program, 3 supervised session per week
219219060|NCT01513616|OTHER|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
219219061|NCT02188836|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
219093215|NCT02080182|DRUG|Acetylcysteine|
219093216|NCT02080182|DRUG|placebo acetylcysteine|
219093217|NCT00071721|DRUG|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
219093218|NCT00071721|DRUG|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
219093219|NCT05417984|DEVICE|Restoris MCK|During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.
219219062|NCT02188836|DEVICE|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
219219063|NCT04105387|PROCEDURE|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
219219064|NCT04767815|DRUG|Diet A group|Fasting + DWN12088 200 mg
219219065|NCT04767815|DRUG|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
219093220|NCT04277455|DEVICE|Laser ablation of benign thyroid nodule|Ablating symptomatic benign thyroid nodules using laser
219093221|NCT00546325|DRUG|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
219093222|NCT00546325|DRUG|Placebo|Matching placebo tablets. Once daily before breakfast
219093223|NCT04834700|OTHER|online group|In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
219219066|NCT04767815|DRUG|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
219219067|NCT06120218|PROCEDURE|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
219219068|NCT03542305|DRUG|Lorlatinib|Lorlatinib single oral dose
219219069|NCT02575924|DRUG|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
219219070|NCT02575924|DRUG|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
219219071|NCT00690131|BEHAVIORAL|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
219219072|NCT02477813|DRUG|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
219219073|NCT01016457|DEVICE|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
219219074|NCT02040870|DRUG|LDK378|750 mg once daily
219219075|NCT04447898|DRUG|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
219219076|NCT04447898|DRUG|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
219219077|NCT04447898|DRUG|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
219219078|NCT04036955|OTHER|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
219219079|NCT02450708|GENETIC|KIR genotyping|
219219080|NCT02450708|GENETIC|HLA genotyping|
219219081|NCT00858650|OTHER|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
219219082|NCT02169869|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
219219083|NCT02169869|DEVICE|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
219219084|NCT02420431|BEHAVIORAL|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
219219085|NCT02420431|BEHAVIORAL|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
219219086|NCT03792932|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219219087|NCT03792932|PROCEDURE|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219219088|NCT02275611|DRUG|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
219219089|NCT02275611|DRUG|Intranasal Placebo Spray|Intranasal Placebo Spray
219219090|NCT06175520|BEHAVIORAL|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
219093224|NCT04581421|OTHER|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
219093225|NCT04581421|OTHER|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
219093226|NCT06285669|OTHER|kinesiotaping application|kinesiotaping application
219093227|NCT06155383|DRUG|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
219093228|NCT06155383|DRUG|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
219093229|NCT06155383|DRUG|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
219093230|NCT06155383|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
219093231|NCT03244722|DIETARY_SUPPLEMENT|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
219093232|NCT03244722|OTHER|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
219093233|NCT06832683|DRUG|Sevoflurane|For Group S, 8% sevoflurane was administered for induction via the procedural oxygen mask for 2 minutes through the external output of the anesthesia machine. The concentration was then reduced to 2%. If any undesired movements occurred, they were recorded, and the sevoflurane concentration was increased by 0.5%.
219093234|NCT06832683|DRUG|Propofol|In Group P, 1.0 mg/kg propofol as a bolus. In the event of undesired movements, an additional 0.5 mg/kg of propofol was administered, and all additional doses were recorded.
219093235|NCT06832683|DRUG|Ketamine|In Group P, 1 mg/kg, single dose ketamine was administered intravenously and all additional doses were recorded.
219093236|NCT03135561|BEHAVIORAL|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
219093237|NCT03135561|BEHAVIORAL|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
219093238|NCT04672096|DEVICE|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
219093239|NCT03090581|PROCEDURE|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
219093240|NCT03090581|PROCEDURE|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
219093241|NCT01950065|DEVICE|iovera|
219093242|NCT05385094|DIAGNOSTIC_TEST|S Creatinine concentration|
219093243|NCT05385094|DIAGNOSTIC_TEST|Serum Cystatin C concentration|
219093244|NCT05385094|DIAGNOSTIC_TEST|Urinary Creatinine Clearance|
219093245|NCT01799460|DRUG|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
219093246|NCT01799460|DRUG|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
219093247|NCT05677932|DEVICE|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
219093248|NCT05677932|DEVICE|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
219093249|NCT00615862|OTHER|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
219093250|NCT01934413|BEHAVIORAL|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
219093251|NCT01934413|OTHER|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
219093252|NCT03091673|DRUG|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
219093253|NCT03812211|DIETARY_SUPPLEMENT|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
219093254|NCT03812211|DIETARY_SUPPLEMENT|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
219093255|NCT01784432|DEVICE|Low-level laser therapy and training|
219093256|NCT01784432|OTHER|Training|
219093257|NCT00771303|OTHER|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
219093258|NCT06948396|BIOLOGICAL|Tezepelumab|Tezepelumab is indicated as an add-on maintenance treatment in adult and adolescent ≥12 years patients with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus long-acting β-agonists
219093259|NCT04148014|BEHAVIORAL|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
219093260|NCT02691195|DRUG|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
219219091|NCT04110301|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
219219092|NCT04110301|DRUG|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
219219093|NCT06364852|DRUG|LY007|FC and LY007 infusion
219219094|NCT02195232|DRUG|Isoquercetin|
219219095|NCT01391767|DEVICE|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
219219096|NCT04510324|OTHER|Red meat patties group|"1\. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
219219097|NCT04510324|OTHER|Plant-based patties group|Same as above
219219098|NCT05326789|DEVICE|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
219219099|NCT03329482|OTHER|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
219219100|NCT03329482|OTHER|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
219219101|NCT01354574|OTHER|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
219219102|NCT01354574|OTHER|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
219219103|NCT03865875|BEHAVIORAL|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
219219104|NCT03865875|BEHAVIORAL|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
219219105|NCT02937493|BEHAVIORAL|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
219219106|NCT04353089|OTHER|Basic life support courses|4 hours certified basic life support courses
219219107|NCT01756924|DRUG|CEM-102|
219219108|NCT01756924|DRUG|IV or Oral standard of care antibiotics|
219219109|NCT01756924|DRUG|Rifampin|
219219110|NCT01759862|DRUG|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
219093261|NCT02691195|DRUG|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
219093262|NCT01808625|OTHER|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
219093263|NCT01772784|OTHER|Phenolic acids|Phenolic acids
219093264|NCT04896333|OTHER|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
219093265|NCT05966402|OTHER|Virtual Reality|Immersion in Virtual Reality
219093266|NCT05022095|OTHER|Questionnaires|Diverse questionnaires have to be filled in.
219093267|NCT01042509|DRUG|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
219219111|NCT01759862|OTHER|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
219219112|NCT01759862|DRUG|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
219219113|NCT02254759|DRUG|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
219219114|NCT02254759|DRUG|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
219219115|NCT02254759|DRUG|RO5186582|RO5186582 120 mg film-coated release tablet.
219093268|NCT02802501|DRUG|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
219093269|NCT02802501|DRUG|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
219219116|NCT01235806|RADIATION|MRI|MRI of the scaphoid bone fracture suspicion
219219117|NCT03741621|DIETARY_SUPPLEMENT|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
219219118|NCT03741621|DIETARY_SUPPLEMENT|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
219219119|NCT03741621|DIETARY_SUPPLEMENT|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
219219120|NCT00731614|BEHAVIORAL|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
219219121|NCT00731614|BEHAVIORAL|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
219093270|NCT02802501|DRUG|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
219093271|NCT02802501|DRUG|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
219093272|NCT02802501|DRUG|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
219219122|NCT00731614|BEHAVIORAL|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
219219123|NCT00213395|DEVICE|Interface for noninvasive ventilation|
219219124|NCT05014035|BEHAVIORAL|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
219219125|NCT00821301|DRUG|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
219219126|NCT03190850|OTHER|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
219219127|NCT03190850|OTHER|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
219219128|NCT00421759|DEVICE|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
219219129|NCT03214172|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
219219130|NCT01141803|DIETARY_SUPPLEMENT|Apples|550g of apples/day
219219131|NCT01141803|DIETARY_SUPPLEMENT|Apple pomace|22g apple pomace/day
219219132|NCT02172560|DRUG|Tiotropium|
219219133|NCT05063864|OTHER|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
219219134|NCT03041233|OTHER|Observation / Data Collection|"The following data will be reviewed / collected:~Baseline Visit: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~Ablation Procedure: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6- and 12-month follow-up (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
219219135|NCT01937494|DRUG|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
219093273|NCT02802501|DRUG|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
219093274|NCT02802501|DRUG|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
219093275|NCT01670448|PROCEDURE|PECBLOCK under echoguidance|Performance of block under echography
219093276|NCT06138249|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D
219093277|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
219219136|NCT02513043|DRUG|medical abortion|medical abortion
219219137|NCT03773549|OTHER|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
219219138|NCT00131209|DIETARY_SUPPLEMENT|fortified spread (RUTF)|
219219139|NCT00131209|DIETARY_SUPPLEMENT|maize and soy flour|
219219140|NCT05782699|DEVICE|BP monitoring during tilt testing|BP measure at various times during tilt testing
219219141|NCT00005869|DRUG|gemcitabine hydrochloride|
219219142|NCT00005869|DRUG|rubitecan|
219093278|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
219093279|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
219093280|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
219093281|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
219093282|NCT01055925|DEVICE|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
219093283|NCT01055925|DEVICE|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
219093284|NCT00327002|DRUG|LY518674|
219093285|NCT06833476|OTHER|EVOQUE|This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.
219093286|NCT06043986|DEVICE|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
219093287|NCT01533363|PROCEDURE|Stapled hemorrhoidopexy|
219093288|NCT01533363|PROCEDURE|Milligan Morgan|
219093289|NCT06075563|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant
219093290|NCT05918302|DRUG|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
219093291|NCT05918302|DRUG|Everolimus|10 mg orally once daily (QD)
219093292|NCT05234307|DRUG|Adenosine A2B Receptor Antagonist PBF-1129|Given PO
219093293|NCT05234307|PROCEDURE|Biospecimen Collection|Correlative studies
219093294|NCT05234307|BIOLOGICAL|Nivolumab|Given IV
219093295|NCT03622788|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219093296|NCT03622788|DRUG|Cyclophosphamide|Given IV
219093297|NCT03622788|BIOLOGICAL|Cytokine-treated Veto Cells|Given IV
219093298|NCT03622788|DRUG|Fludarabine|Given IV
219219143|NCT00002281|DRUG|Filgrastim|
219219144|NCT00002281|DRUG|Epoetin alfa|
219093299|NCT03622788|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
219093300|NCT03622788|RADIATION|Total-Body Irradiation|Undergo TBI
219093301|NCT04669600|DRUG|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
219093302|NCT06254183|DRUG|Gabapentin|"Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG"
219093303|NCT06254183|DRUG|Placebo|A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
219093304|NCT04808505|BIOLOGICAL|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
219093305|NCT04808505|DRUG|Miglustat|65 mg oral capsules
219093306|NCT01544998|DRUG|Nesiritide|10 ug/kg
219093307|NCT01544998|DRUG|Tadalafil|5 mg
219093308|NCT01544998|DRUG|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
219093309|NCT01544998|DRUG|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
219219145|NCT00002281|DRUG|Zidovudine|
219219146|NCT01456156|RADIATION|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
219219147|NCT05615220|DRUG|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
219219148|NCT04003324|BEHAVIORAL|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
219219149|NCT01130285|GENETIC|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
219093310|NCT03379194|BEHAVIORAL|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
219093311|NCT00710606|DRUG|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
219093312|NCT00710606|DRUG|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
219093313|NCT00022230|BIOLOGICAL|aldesleukin|
219093314|NCT00022230|BIOLOGICAL|filgrastim|
219093315|NCT00022230|BIOLOGICAL|sargramostim|
219219150|NCT03229408|DRUG|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
219219151|NCT03229408|OTHER|Placebo|Appears identical to experimental drug
219219152|NCT04934943|DIAGNOSTIC_TEST|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
219219153|NCT06253546|DRUG|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
219219154|NCT06253546|DRUG|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
219219155|NCT04825743|DRUG|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
219219156|NCT04825743|DRUG|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
219219157|NCT04541589|DRUG|Iscalimab|Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).
219219158|NCT04541589|OTHER|Placebo|Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to maintain blinding until the final database lock of the core study
219219159|NCT00853606|DRUG|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
219219160|NCT01273610|DRUG|Lapatinib|250 mg tablets
219219161|NCT01273610|DRUG|Trastuzumab|Intravenous injection
219219162|NCT01273610|OTHER|laboratory biomarker analysis|
219219163|NCT01273610|OTHER|pharmacological study|
219219164|NCT06510829|DEVICE|Diode laser|Application of laser waves on the lesion
219219165|NCT05027906|DRUG|AT-1501|Investigative Arm
219219166|NCT04968587|PROCEDURE|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
219219167|NCT00687219|BIOLOGICAL|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
219219168|NCT00687219|DRUG|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
219219169|NCT01613053|DRUG|Glivec|800 mg per day
219219170|NCT06974383|OTHER|Training with Virtual Laparoscopic Hiatal Hernia Simulator (VLaHHS)|For the training phase, participants in Group 1 will perform the tasks on VLaHHS for an hour a day for a maximum of 15 sessions over 3 weeks.
219219171|NCT03383874|COMBINATION_PRODUCT|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
219219172|NCT03383874|OTHER|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
219093316|NCT00022230|BIOLOGICAL|therapeutic autologous lymphocytes|
219093317|NCT00022230|DRUG|cyclophosphamide|
219093318|NCT00022230|DRUG|doxorubicin hydrochloride|
219093319|NCT00022230|DRUG|paclitaxel|
219093320|NCT05891769|DRUG|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
219093321|NCT05316129|DRUG|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
219093322|NCT06679010|OTHER|Online group counseling|The program progresses as one weekly group session over 10 weeks, each with its own topic. The core components of the program include psychoeducation, training self-compassion and acceptance, cognitive restructuring, interpersonal skills training, systems and management of daily life activities, prevention of conflicts, and the mother-baby relation. Participants will meet online as a group together with the instructor, a consultant from the ADHD Association, who will lead and facilitate the sessions. Before each session, there is a podcast episode that covers the topic of each session. The 10 podcasts feature interviews with clinicians, researchers, and women with ADHD, focusing on the themes from the program's sessions.
219093323|NCT04292782|PROCEDURE|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
219093324|NCT04292782|PROCEDURE|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
219093325|NCT00514683|DRUG|low dose BIBF1120 once daily|low dose BIBF1120 once daily
219093326|NCT00514683|DRUG|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
219093327|NCT00514683|DRUG|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
219093328|NCT00514683|DRUG|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
219093329|NCT00514683|DRUG|placebo|placebo
219093330|NCT05868915|BIOLOGICAL|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
219219173|NCT03411941|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
219093331|NCT02736825|DEVICE|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
219093332|NCT02736825|DEVICE|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
219219174|NCT01400958|DRUG|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
219093333|NCT00790452|DRUG|Aspirin|325 mg daily by mouth
219093334|NCT00790452|DRUG|Placebo|Tablet daily by mouth
219093335|NCT00650195|DRUG|Metolazone Tablets 10 mg|10mg, single dose fasting
219093336|NCT00650195|DRUG|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
219093337|NCT05905250|BEHAVIORAL|an empirically supported protocol, further refined with evidence-based strategies|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
219093338|NCT05905250|BEHAVIORAL|Health education|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
219093339|NCT03536364|BEHAVIORAL|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
219093340|NCT03536364|BEHAVIORAL|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
219093341|NCT03536364|BEHAVIORAL|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
219219175|NCT01400958|DRUG|Placebo|Placebo x 42 days; THEN, No More Placebo
219219176|NCT06499766|OTHER|Biodiversity intervention by inactivated microbial extract|Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
219219177|NCT06499766|OTHER|Placebo intervention by colored lotion|Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
219219178|NCT02071316|DRUG|Hexacapron( Tranexamic acid)|1\. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
219219179|NCT02071316|DRUG|esomeprazole|2\. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
219219180|NCT03933137|OTHER|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
219219181|NCT00056966|DRUG|ANTI-CD45|400ug/kg Day-5 through Day-2
219219182|NCT00056966|DRUG|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
219219183|NCT00056966|DRUG|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
219219184|NCT00056966|DRUG|Fludarabine|Day-8 through Day-5 30 mg/m2
219219185|NCT00056966|RADIATION|Total Body Irradiation|Day-1 single dose 450 cGy
219219186|NCT00056966|PROCEDURE|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
219219187|NCT01780675|RADIATION|Radiation Prophylactic Cranial Irradiation|
219219188|NCT01780675|RADIATION|Radiation Hippocampal Avoidance PCI|
219219189|NCT04775667|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
219219190|NCT06267300|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
219093342|NCT01564368|PROCEDURE|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
219093343|NCT03021135|PROCEDURE|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
219093344|NCT03021135|PROCEDURE|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
219093345|NCT06347796|PROCEDURE|Conventional Surgery|Conventional surgery is surgical drainage through burr holes or craniotomy.
219093346|NCT06347796|DEVICE|Middle Meningeal Artery Embolization (MMAE)|Particle embolization of the middle meningeal artery with micron variants of the Embosphere Microspheres or CONTOUR Embolization Particles device.
219219191|NCT04518813|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
219219192|NCT01532999|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
219219193|NCT01532999|BEHAVIORAL|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
219219194|NCT04245995|DIAGNOSTIC_TEST|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
219219195|NCT01432769|DIETARY_SUPPLEMENT|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
219219196|NCT00914966|BIOLOGICAL|C1 inhibitor (human) [C1 INH]|
219219197|NCT00002095|DRUG|Ganciclovir|
219219198|NCT00311714|DRUG|CS-8958 formulated as dry powder|
219219199|NCT00311714|OTHER|Placebo|
219219200|NCT05454475|OTHER|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
219093347|NCT06176599|DRUG|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
219219201|NCT01298076|DRUG|bevacizumab|Anti-VEGF drug for intravitreal injection
219219202|NCT01298076|DRUG|dexamethasone|Slow-release steroid formulation for intravitreal injection
219219203|NCT05996393|DRUG|Ciclosporin|3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml
219219204|NCT05996393|DRUG|Avatrombopag|60 mg/d orally, 24 weeks
219219205|NCT05996393|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
219219206|NCT01800487|DRUG|silymarin|140 mg three times a day for 4 weeks
219219207|NCT01800487|DRUG|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
219219208|NCT02910973|DEVICE|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
219093348|NCT06176599|DRUG|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
219093349|NCT04794426|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
219093350|NCT04794426|DEVICE|Hall Technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
219093351|NCT04082884|BEHAVIORAL|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
219682425|NCT00735514|PROCEDURE|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
219682426|NCT00735514|PROCEDURE|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
219682427|NCT00671801|DRUG|Irinotecan|200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
219682428|NCT00671801|DRUG|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
219682429|NCT06050096|PROCEDURE|PCI|CTO patients treated by DCB
219093352|NCT01945151|OTHER|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
219093353|NCT03366922|DIETARY_SUPPLEMENT|Artemisia Annua, Moringa oleifera|As described above
219219209|NCT02910973|DEVICE|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
219682430|NCT05680077|DIAGNOSTIC_TEST|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
219682431|NCT02045186|OTHER|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
219093354|NCT00813852|BEHAVIORAL|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
219219210|NCT04409470|DIAGNOSTIC_TEST|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
219093355|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
219219211|NCT05979038|DRUG|Metformin|Patients in the intervention arm will take metformin 500mg three times a day
219219212|NCT02700269|OTHER|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
219219213|NCT03273894|DIAGNOSTIC_TEST|Coagulation testing|"* body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
219219214|NCT04910685|DRUG|Elenestinib|Elenestinib oral tablet
219219215|NCT04910685|DRUG|Placebo|Placebo oral tablet
219219216|NCT05556161|BEHAVIORAL|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check:~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
219219217|NCT06571058|OTHER|Assistance|Assist patient with walking approximately 90 feet
219219218|NCT06571058|OTHER|Educational Intervention|Receive a short instructional session
219219219|NCT06571058|DEVICE|Medical Device Usage and Evaluation|Wear the B3 Buddy device
219219220|NCT06571058|OTHER|Medical Device Usage and Evaluation|Secure the urinary drainage bag to the patient using the B3 Buddy device
219219221|NCT06571058|OTHER|Questionnaire Administration|Ancillary studies
219219222|NCT06571058|PROCEDURE|Remove|Remove the device and return urinary drainage bag to the standard position
219219223|NCT06571058|OTHER|Walking|Walk approximately 90 feet
219219224|NCT06312254|DRUG|Topical lidocaine 5%|Drug is used to pharmacologically modulate peripheral sensory afferents
219219225|NCT06312254|DRUG|Topical Phenytoin 10%|Drug is used to pharmacologically modulate peripheral sensory afferents
219219226|NCT06312254|DRUG|Topical Mepyramine 2%|Drug is used to pharmacologically modulate peripheral sensory afferents
219219227|NCT06312254|OTHER|Topical Placebo|Drug is used as control
219362099|NCT05223192|BEHAVIORAL|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
219362100|NCT06501664|DRUG|liposomal irinotecan|Liposomal irinotecan 70 mg/m²
219219228|NCT06809907|DEVICE|Kintsugi Voice Device|The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression. The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs.
219219229|NCT05557006|PROCEDURE|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
219219230|NCT00507884|PROCEDURE|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
219219231|NCT03169413|GENETIC|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
219219232|NCT03657316|BEHAVIORAL|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
219219233|NCT06652750|OTHER|Routine Management|Conducting routine in-office follow-up for CIED paitents
219362101|NCT06501664|DRUG|5-FU|5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
219362102|NCT06501664|DRUG|LV|LV 400 mg/m²
219362103|NCT06501664|DRUG|Irinotecan|Irinotecan 180 mg/m²
219093356|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
219093357|NCT01556126|DEVICE|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
219093358|NCT02014818|DEVICE|CoCr-EES|
219093359|NCT04235907|OTHER|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
219093360|NCT04235907|OTHER|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
219093361|NCT04573543|DIAGNOSTIC_TEST|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
219093362|NCT04573543|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
219093363|NCT04573543|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
219093364|NCT04573543|DIAGNOSTIC_TEST|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
219093365|NCT01887470|DRUG|Full dose preparation|
219093366|NCT01887470|DRUG|Split dose preparation|
219093367|NCT04137354|OTHER|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
219093368|NCT04137354|OTHER|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
219093369|NCT04137354|OTHER|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
219682432|NCT06047223|DIAGNOSTIC_TEST|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
219682433|NCT03790865|DRUG|Livoletide|Daily subcutaneous injection
219682434|NCT03790865|DRUG|Placebo|Daily subcutaneous injection
219682435|NCT04540328|OTHER|Non-surgical periodontal treatment|
219682436|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
219682437|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
219682438|NCT05210439|DRUG|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment for BSI-PA
219682439|NCT05210439|DRUG|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment for BSI-PA
219682440|NCT03340467|DEVICE|CGM patch|Patient receives four CGM patches.
219093370|NCT04137354|OTHER|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
219093371|NCT05674890|DIAGNOSTIC_TEST|SmartSystem VR Headset perimeter|Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
219093372|NCT04196998|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
219093373|NCT04196998|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
219093374|NCT04196998|DRUG|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
219093375|NCT01171092|DRUG|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
219093376|NCT04294992|DRUG|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
219093377|NCT06294119|PROCEDURE|Major Cardiac surgery|From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
219682441|NCT03142776|PROCEDURE|periodontal debridement|
219682442|NCT03142776|PROCEDURE|photodynamic therapy|
219682443|NCT03142776|DRUG|systemic clarithromycin|
219682444|NCT01672905|OTHER|laboratory biomarker analysis|
219682445|NCT02522793|OTHER|No intervention; this is an observational study|
219682446|NCT04993703|OTHER|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
219682447|NCT04993703|OTHER|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
219682448|NCT04993703|OTHER|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
219682449|NCT03454451|DRUG|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
219682450|NCT03454451|DRUG|CPI-006 + ciforadenant|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
219682451|NCT03454451|DRUG|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
219682452|NCT03454451|DRUG|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
219682453|NCT03454451|DRUG|CPI-006 + ciforadenant|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
219682454|NCT03454451|DRUG|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
219682455|NCT04609449|PROCEDURE|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
219682456|NCT04609449|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
219682457|NCT04965337|DRUG|ASC42|ASC42 tablet administered orally
219682458|NCT04965337|DRUG|Placebo|Matching placebo administered orally
219682459|NCT04269824|BEHAVIORAL|Behavioral intervention package|"Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~\- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~\- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior"
219682460|NCT03067259|OTHER|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
219682461|NCT02898636|OTHER|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
219219234|NCT06652750|DEVICE|5G Cloud Follow-up|This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
219219235|NCT00787709|BEHAVIORAL|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
219219236|NCT06977984|BEHAVIORAL|Integrative Breathwork Intervention|The breathwork intervention involves a sustained conscious connected breathing pattern where there is no pause between inhale and exhale. During the breathing, a participant is guided to pay attention to the strongest sensation from moment-to-moment (e.g., mindfulness of somatic sensations) and relax unnecessary effort or tension. Participants lay supine throughout the 60 minute session. The session ends with spontaneous, relaxed breathing and an opportunity to briefly share one's experience.
219219237|NCT06613048|OTHER|Breathing exercise|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
219219238|NCT06232408|DRUG|RP-1664|RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
219219239|NCT06109454|DRUG|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
219219240|NCT06109454|OTHER|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
219093378|NCT01713725|BIOLOGICAL|Omalizumab|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
219093379|NCT01713725|BIOLOGICAL|Placebo|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
219219241|NCT03643055|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
219219242|NCT02460393|DRUG|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
219219243|NCT02460393|OTHER|placebo|Subcutaneous injection of different doses for healthy people
219219244|NCT04797468|DRUG|HLX23|administered IV.
219219245|NCT06985342|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablet (ODT), administered as a single dose
219219246|NCT06985342|DRUG|Zavegepant|Zavegepant 10 mg nasal spray, administered as a single dose
219219247|NCT02544880|DRUG|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
219093380|NCT05715203|DEVICE|Pulsotonometry|Evaluation of arterial stiffness
219093381|NCT00520975|BIOLOGICAL|Bevacizumab|Given IV
219093382|NCT00520975|DRUG|Carboplatin|Given IV
219219248|NCT02544880|BIOLOGICAL|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
219219249|NCT02544880|BIOLOGICAL|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
219219250|NCT02544880|OTHER|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
219219251|NCT02544880|OTHER|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
219093383|NCT00520975|DRUG|Paclitaxel|Given IV
219093384|NCT00520975|OTHER|Placebo|Given IV
219093385|NCT00520975|BIOLOGICAL|Trastuzumab|Given IV
219093386|NCT04699955|BEHAVIORAL|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
219219252|NCT02544880|OTHER|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
219093387|NCT03384264|OTHER|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
219219253|NCT02544880|OTHER|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
219219254|NCT00062660|DRUG|Tipranavir|Tipranavir 250 mg soft elastic capsules
219093388|NCT03707288|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
219093389|NCT03707288|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
219093390|NCT04810221|OTHER|Controlled desaturation study|Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
219093391|NCT01383889|OTHER|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
219093392|NCT00264979|PROCEDURE|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
219093393|NCT00264979|PROCEDURE|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
219093394|NCT03642938|BEHAVIORAL|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
219093395|NCT03642938|BEHAVIORAL|Control|The Control group will perform 30 minutes of quiet rest.
219093396|NCT04643925|DRUG|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
219093397|NCT01042028|DRUG|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
219093398|NCT01042028|DRUG|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
219093399|NCT04570917|BEHAVIORAL|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
219093400|NCT04570917|BEHAVIORAL|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
219362104|NCT01528514|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
219362105|NCT01528514|OTHER|Placebo|Placebo in capsule form, 4 capsules 4 times/day
219362106|NCT04961788|DRUG|Gemox combimed PD1 antibody|"1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
219093401|NCT01925625|BIOLOGICAL|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
219093402|NCT01271569|DRUG|Fospropofol disodium|Fospropofol disodium： 0.5g
219093403|NCT06273111|DRUG|5% simvastatin ointment|5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
219093404|NCT06775834|DRUG|HRS-1893|HRS-1893 tablets.
219093405|NCT00105235|DRUG|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
219093406|NCT00105235|DRUG|Cyclosporine|Oral immunosuppressant
219093407|NCT00105235|DRUG|Mycophenolate mofetil|Oral immunosuppressant
219093408|NCT00105235|DRUG|Tacrolimus|Oral immunosuppressant
219093409|NCT00105235|PROCEDURE|Liver transplant|Occurs at study entry
219093410|NCT00105235|PROCEDURE|Immunosuppression withdrawal|Beginning no earlier than Year 1
219093411|NCT01956422|DEVICE|Continuous Positive Airway Pressure(CPAP)|
219219255|NCT06856421|BEHAVIORAL|Auricular point compression|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
219219256|NCT06856421|BEHAVIORAL|No pressure on the ear point|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
219219257|NCT05361733|DRUG|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
219219258|NCT05361733|DRUG|Placebo|No active ingredient drug use to blind participants and investigators
219219259|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
219219260|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
219219261|NCT04088890|DRUG|Fludarabine|Fludarabine 30 mg/m2
219093412|NCT01956422|DEVICE|Venturi Mask FiO2 40%|
219093413|NCT00361959|DRUG|Tiotropium bromide 18mcg|
219093414|NCT00361959|DRUG|Fluticasone propionate/ salmeterol combination 50/500mcg|
219093415|NCT03083938|PROCEDURE|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
219093416|NCT04340310|DIAGNOSTIC_TEST|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
219093417|NCT01995539|BEHAVIORAL|therapy regimen|Subjects will be recommend changes in therapy regimens.
219219262|NCT04088890|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2
219219263|NCT04088890|DRUG|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
219219264|NCT07012252|PROCEDURE|Optical coherence tomography|Infants underwent optical coherence tomography.
219219265|NCT07013500|PROCEDURE|Conventional Gasserian Ganglion Radiofrequency|Conventional RFA was performed at the Gasserian ganglion under fluoroscopic guidance with thermal lesioning at 70-75°C for up to 90 seconds. Sensory and motor stimulation were used to verify needle placement.
219362107|NCT00398463|DRUG|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
219093418|NCT06072222|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
219093419|NCT06072222|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
219093420|NCT06072222|DEVICE|ventilator|ventilator
219093421|NCT05886491|DRUG|GDX012|GDX012 suspension for IV infusion.
219093422|NCT05886491|DRUG|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
219093423|NCT04864002|OTHER|No intervention. only observational cross sectional study|No intervention done. only observational cross sectional study
219093424|NCT06831136|DRUG|Neoadjuvant Chemotherapy (NAC)|Participant will undergo 8 weeks of NAC (treating physician's choice). Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).
219093425|NCT06831136|DRUG|Immunotherapy (pembrolizumab)|2-12 weeks after initial chemotherapy and after the first EUS-RFA treatment, patients will receive 400 mg every 6 weeks of pembrolizumab via infusion. Participants will be administered standard of care chemotherapy and pembrolizumab every 6 weeks.
219093426|NCT06831136|DEVICE|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)|After 2-12 weeks of chemotherapy, patients will undergo EUS-RFA treatment 1 session every 6 weeks. Each RFA treatment will be for up to 5 cycles at 30W for 20 seconds or until there is an increase in measured impedance. After the 5th EUS-RFA, if there is clinical benefit, then patients will continue with EUS-RFA treatments until no active tumor is seen. During each session, the therapeutic gastroenterologist will evaluate if there is any tumor to undergo RFA. If no active tumor seen, then will abort RFA
219093427|NCT05751512|DRUG|MRG003|Administered intravenously
219093428|NCT05751512|DRUG|Cetuximab injection|Administered intravenously
219093429|NCT05751512|DRUG|Methotrexate Injection|Administered intravenously
219093430|NCT01036308|DIETARY_SUPPLEMENT|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
219219266|NCT07013500|PROCEDURE|Peripheral Pulsed Radiofrequency|PRF was applied to the peripheral branch of the trigeminal nerve at 42°C for two cycles of 120 seconds using fluoroscopic guidance. This technique was preferred in our clinic to avoid thermal complications such as hypoesthesia or motor dysfunction.
219093431|NCT01036308|DIETARY_SUPPLEMENT|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
219093432|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
219093433|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
219093434|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
219093435|NCT00642902|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
219093436|NCT03446014|DEVICE|Fitbit Sub-Study|
219093437|NCT05409989|DEVICE|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
219093438|NCT01968525|BIOLOGICAL|pre-oxygen|3 min of preoxygenation before anesthesia induction.
219093439|NCT06226766|DRUG|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
219093440|NCT04969835|DRUG|AVA6000|AVA6000 is a FAP-activated doxorubicin.
219093441|NCT00901888|DRUG|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
219093442|NCT00901888|DRUG|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
219093443|NCT05934747|DEVICE|DBS|Deep Brain Stimulation
219093444|NCT06388889|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
219093445|NCT01963338|DEVICE|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
219093446|NCT01963338|DEVICE|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
219219267|NCT07011784|OTHER|Blood flow restriction in combination with dance classes|Blood flow restriction in combination with online ballet and modern-style dance classes to test if the balance of older women can be improved. Participants will wear 5 centimetre elasticized blood flow restriction bands on their proximal thighs throughout the online ballet-modern dance classes. Tightness levels will be set at a 7/10 of the perceived tightness scale used by Wilson et al. (2013), with a total restriction time of approximately 60 minutes, twice per week.
219362108|NCT00398463|DRUG|Placebo|Saline infusion will be administered for 14-24 hours
219362109|NCT01380457|DRUG|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
219682462|NCT05329350|DEVICE|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
219682463|NCT05198856|DRUG|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
219093447|NCT01963338|DRUG|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
219093448|NCT04226222|DIAGNOSTIC_TEST|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
219093449|NCT03822572|OTHER|endurance exercise|defined exercise program
219093450|NCT03822572|OTHER|control|habitual physical activity before the diagnosis
219682464|NCT06842576|BEHAVIORAL|Health Education Videos|Participants will be prompted to explore the 7 health education videos for up to 20 minutes.
219093451|NCT05181553|OTHER|Whole-food plant based diet (WFPB diet)|28-day fully controlled dietary intervention during which participants will receive a whole food plant-based diet that reflects the recommendations of Canada's Food Guide.
219093452|NCT05181553|OTHER|Standard North American diet (SAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
219093459|NCT04575935|DRUG|Chemotherapy|Receive standard of care chemotherapy
219093460|NCT04575935|PROCEDURE|Laparotomy|Undergo laparotomy
219093461|NCT04575935|PROCEDURE|Minimally Invasive Surgery|Undergo MIS
219093462|NCT04575935|OTHER|Quality-of-Life Assessment|Ancillary studies
219093463|NCT04575935|OTHER|Questionnaire Administration|Ancillary studies
219093464|NCT05064852|DRUG|Surufatinib|The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.
219093465|NCT05073042|BEHAVIORAL|Morning exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.
219093466|NCT05073042|BEHAVIORAL|Evening exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
219219268|NCT07011784|OTHER|Dance classes alone|Online ballet and modern-dance inspired classes will be held on Zoom twice per week for 75 minutes. The sessions will span a 12 week time frame. All classes will begin with a warm-up, 1 plie exercise, 1 tendu exercise, a travelling ballet-inspired exercise, 1 travelling Graham or Limón modern dance exercise and a seated cool-down.
219093467|NCT05073042|BEHAVIORAL|Time of choice exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
219093468|NCT03649555|DRUG|[18F]-FTC-146|Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
219093469|NCT01271998|DRUG|TR-701 FA|200 mg, oral, once daily for 3 days.
219219269|NCT02520791|BIOLOGICAL|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
219219270|NCT02520791|OTHER|Laboratory Biomarker Analysis|Correlative studies
219219271|NCT02520791|OTHER|Pharmacological Study|Correlative studies
219219272|NCT07011758|DRUG|Medication for opioid use disorder|A medication treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
219219273|NCT07011758|BEHAVIORAL|psychotherapy|A behavioral treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
219219274|NCT06686667|BEHAVIORAL|Time Restricted Eating|The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
219219275|NCT06699446|OTHER|pre rehabilitation|preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
219219276|NCT07044232|COMBINATION_PRODUCT|Nicardipine|Nicardipine infusion based acute blood pressure lowering treatment
219219277|NCT07044232|COMBINATION_PRODUCT|Glyceryl trinitrate|Glyceryltrinitrate based acute blood pressure lowering treatment
219219278|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) without food|FDC without food
219219279|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) with food|FDC with food
219219280|NCT06895200|DEVICE|CVS-Notifier SaMD|The CVS-Notifier SaMD reminds surgeons to time-out to check the CVS before the division of the cystic duct.
219093470|NCT00808574|BEHAVIORAL|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
219093471|NCT00816179|PROCEDURE|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
219219281|NCT06752018|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass or sleeve gastrectomy
219219282|NCT06755944|DRUG|XY03-EA|"The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days."
219682465|NCT06842576|BEHAVIORAL|GotTransition.org Website|Participants will be prompted to explore the Gottransition.org website for up to 20 minutes
219093472|NCT05777148|DEVICE|super high-flux hemodialysis|Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)
219093473|NCT05777148|DEVICE|postdilution online hemodiafiltration|hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
219219283|NCT06769919|RADIATION|Neoadjuvant radiotherapy|The experimental group will receive neoadjuvant systemic therapy combined with neoadjuvant radiotherapy before undergoing surgery
219219284|NCT06780488|OTHER|Real Visual-Vestibuar Rehabilitation|"The Real Visual-Vestibular Rehabilitation protocol will consist of specific exercises aimed at stimulating the visuo-vestibular function within immersive virtual reality environments replicating daily life situations. Patients will perform exercises in two types of contexts. In all exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the exercises can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation.The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
219362110|NCT01380457|DRUG|Marinol|Capsules, 10 mg, single-dose, fasting conditions
219682466|NCT01888952|DRUG|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
219093474|NCT04837872|OTHER|Multimodal Physical Therapy (MPT)|Individualized physical therapy and static progressive splint (flexion with or without extension splint).
219093475|NCT01222195|DRUG|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
219093476|NCT01222195|DRUG|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
219093477|NCT00335582|DRUG|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
219093478|NCT00402571|DRUG|acetaminophen|
219093479|NCT03077984|COMBINATION_PRODUCT|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
219093480|NCT03885037|DRUG|Infliximab [infliximab biosimilar 3]|\<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
219219285|NCT06780488|OTHER|Sham Rehabilitation|"The Sham Vestibular Rehabilitation protocol will involve the use of the same immersive virtual reality contexts and will aim to achieve the same objectives as the Real Visual-Vestibular Rehabilitation protocol, but without the unexpected stimuli. In both exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the session can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation. The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
219219286|NCT04525092|DEVICE|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
219219287|NCT04525092|DEVICE|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
219093481|NCT00032890|DRUG|glucosamine|
219093482|NCT00032890|DRUG|chondroitin sulfate|
219093483|NCT00032890|DRUG|glucosamine and chondroitin sulfate combined|
219093484|NCT00032890|DRUG|celecoxib|
219093485|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 500mg per day(once a day)
219093486|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
219093487|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
219093488|NCT01499225|DRUG|INSADOL[Zea mays L. extract] 35mg Tab|"\[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day"
219093489|NCT01499225|DRUG|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
219219288|NCT04525092|DEVICE|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
219219289|NCT04021862|DRUG|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
219219290|NCT04021862|DRUG|Placebo|Placebo will be administered subcutaneously.
219219291|NCT06832358|BEHAVIORAL|Routine nursing methods|According to their condition, they receive individualized drug treatment, including the main drugs of Parkinson's disease (such as dopamine replacement drugs) and combined antidepressant drugs. Secondly, regular follow-up evaluations will be conducted to monitor disease progression and drug side effects. At the same time, patients and their families will receive health education on Parkinson's disease and depression.The patients would receive basic psychological support. Medical staff will encourage patients to express their emotions and pay attention to their psychological state, which will help alleviate anxiety and depression. Medical staff will provide patients with information about local support organizations and social groups, and encourage patients to participate in related activities to increase social interaction and emotional support.
219682467|NCT01888952|DRUG|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
219682468|NCT06612359|BEHAVIORAL|BOOST GAIT Program|In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
219682469|NCT07016100|BEHAVIORAL|Contingency management|See arm description
219682470|NCT07016100|BEHAVIORAL|Cognitive behavioral therapy/ treatment as usual|See arm description
219093490|NCT01499225|DRUG|Placebo|Placebo
219093491|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
219093492|NCT05285384|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
219093493|NCT05865613|DEVICE|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
219093494|NCT00291902|DRUG|SB-681323|
219093495|NCT02878928|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
219093496|NCT00079638|DRUG|Niacin|
219093497|NCT00079638|DRUG|Atorvastatin|
219093498|NCT00079638|DRUG|Simvastatin|
219093499|NCT00079638|DRUG|Ezetimibe|
219093500|NCT00079638|DRUG|Rosuvastatin|
219682471|NCT07016919|OTHER|early enteral nutrition|Oral nutrition started within 6hours after paediatric open appendectomy
219219292|NCT06832358|BEHAVIORAL|PERMA positive psychological intervention mode|(1) Formation of an intervention team.(2) Development and execution of interventions.The study group participated in a series of positive psychology workshop involving interviews and exercises aligned with the PERMA model as part of their routine health education. Each participant took part in individualized interviews focused on two specific topics each week until all subjects were covered, with each session lasting between 30 to 50 minutes. This interview phase continued for one month, conducted in the hospital ward.
219219293|NCT06854432|OTHER|Biometrological measurements|Measurements will be taken from the scalp: on the vertex and occiput areas.
219219294|NCT06854432|OTHER|Biological sampling|Samples will be taken from the scalp: on the vertex and occiput areas.
219219295|NCT06597201|DRUG|amino acid (15) peritoneal dialysis solution|Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
219219296|NCT06597201|DRUG|glucose peritoneal dialysis solution|Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
219219297|NCT05190172|RADIATION|Radiation therapy|Radiation therapy either with protons or photons
219219298|NCT06743581|DRUG|Cemiplimab|Cemiplimab 350 mg administered intravenously on day 1
219093501|NCT03823222|DIETARY_SUPPLEMENT|Duckweed protein|20 grams isolated protein
219093502|NCT03823222|DIETARY_SUPPLEMENT|Whey protein|20 grams isolated protein
219093503|NCT00805090|DRUG|Sporanox|200 mg
219093504|NCT00805090|DRUG|Diclofenac Sodium|37.5 mg
219093505|NCT03258424|DRUG|PTI-428|PTI-428 or placebo will be given QD for 14 days.
219093506|NCT03258424|DRUG|Placebo|PTI-428 or placebo will be given QD for 14 days.
219682472|NCT07016919|OTHER|Conventional enteral nutrition|Oral nutrition started within 24hours after paediatric open appendectomy
219219299|NCT06743581|DRUG|Dupilumab|Dupilumab 600 mg administered subcutaneously on day 1
219219300|NCT01574339|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a technical representative."
219219301|NCT05240352|DEVICE|active tDCS|Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
219682473|NCT01066871|DRUG|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
219682474|NCT01066871|DRUG|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
219682475|NCT01066871|DRUG|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
219682476|NCT01066871|OTHER|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
219682477|NCT05702099|DIAGNOSTIC_TEST|ultrasonography|By performing transvaginal or transabdominal ultrasonography on women, ovarian volume will be calculated and antral follicle will be counted.
219682478|NCT00552214|DEVICE|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
219093507|NCT01027975|PROCEDURE|laparoscopic Nissen/laparoscopic Thal|
219093508|NCT06474897|OTHER|Ozone therapy|Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
219093509|NCT06474897|OTHER|Mulligan Mobilization|Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
219093510|NCT02871960|PROCEDURE|Robotic and Laparoscopic Colectomy|
219093511|NCT00704301|DRUG|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
219093512|NCT00704301|DRUG|Placebo|Placebo, 2 times a day
219093513|NCT02893306|BIOLOGICAL|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
219093514|NCT04116697|OTHER|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
219093515|NCT04116697|OTHER|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
219093516|NCT02309112|OTHER|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
219093517|NCT02539836|DIETARY_SUPPLEMENT|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
219219302|NCT05240352|DEVICE|sham tDCS|"Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later"
219219303|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate|Intervention
219219304|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate + fluoride|Intervention
219219305|NCT06821724|DRUG|Nano hydroxyapatite paste|Intervention
219219306|NCT06821724|DRUG|Fluoride gel|Positive control
219219307|NCT05447208|DRUG|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
219219308|NCT05447208|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
219093518|NCT02539836|DIAGNOSTIC_TEST|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
219093519|NCT02873130|BEHAVIORAL|Telepractice Global Voice Prevention Model|
219219309|NCT06237673|DIAGNOSTIC_TEST|CT|CT-directed clinical management strategy
219219310|NCT06237673|DIAGNOSTIC_TEST|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
219219311|NCT06828900|BEHAVIORAL|Written Decision Aid|Participants will receive a structured booklet developed based on IPDAS guidelines to support informed decision-making regarding medication vs. no medication for ADHD treatment. The booklet provides a clear explanation of ADHD, the role of medication, and the option of not using medication, including the potential benefits, risks, and uncertainties of each choice. It presents evidence-based information in a balanced manner, helping parents understand possible outcomes such as symptom management, side effects, and long-term considerations. The booklet also includes value clarification exercises to help parents align their decision with personal preferences and concerns.
219219312|NCT06828900|BEHAVIORAL|Decision Aid + Decision Coaching|Participants will receive the written decision aid booklet, developed based on IPDAS guidelines, along with a one-on-one decision coaching session. The decision coaching will follow a structured script based on the Ottawa Personal Decision Guide (OPDG), refined through training with the principal investigator (PI). The decision coach will not give medical advice but will help parents clarify their values, address uncertainties, and weigh the benefits and risks of medication vs. no medication. Through guided value clarification exercises, parents will explore their concerns and preferences to make a well-informed decision.
219219313|NCT06828900|BEHAVIORAL|AI-Driven Support|"Participants will interact with a large language model-based AI tool (Claude) to assist in their decision-making process regarding medication vs. no medication for ADHD treatment. This AI-driven intervention is designed to provide structured, personalized decision support while maintaining an unbiased, evidence-based approach.~Participants will receive 10 structured prompts to ask the AI, covering key aspects of ADHD treatment (e.g., benefits and risks of medication, long-term outcomes, alternatives).~Following this structured phase, participants will have 15 minutes of free interaction with the AI to explore any remaining questions or concerns.~At the end of the session, they will receive a summary output of their AI interactions to review.~The AI tool is designed to translate complex medical information into user-friendly language, provide comparative treatment insights, and help parents clarify their values and concerns. However, it will not offer direct medical recommendations."
219219314|NCT06877208|OTHER|Glucagon (part C)|90 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
219219315|NCT06877208|OTHER|Glucose clamp (part C)|90 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
219219316|NCT06877208|OTHER|Saline (part C)|90 minutes intravenous infusion with isotonic NaCl.
219219317|NCT06877208|OTHER|Glucagon (part D)|210 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
219219318|NCT06877208|OTHER|Glucose clamp (part D)|210 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
219219319|NCT06877208|OTHER|Saline (part D)|210 minutes intravenous infusion with isotonic NaCl.
219219320|NCT05251363|DEVICE|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
219219321|NCT06814613|OTHER|Exercise|For the next 4 weeks, every night, 1 hour before the routine bedtime (or the time when the student planned to sleep), a video call (via the Google Meet application) was made with the student, and progressive relaxation exercises were performed. The exercise took approximately 20 minutes and followed the implementation protocol (Davis et al., 2008; Payne, 2000). Group interviews were conducted for students with similar sleep hours. They were asked to move to a ventilated room away from noise so that the exercises could be practiced comfortably and not interrupted.
219219322|NCT01093612|PROCEDURE|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
219219323|NCT01093612|RADIATION|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
219219324|NCT01093612|PROCEDURE|Biopsy|Correlative Studies
219093520|NCT02873130|BEHAVIORAL|In-person Global Voice Prevention Model|
219093521|NCT02873130|BEHAVIORAL|Telepractice, Vocal Hygiene and Vocal Education|
219093522|NCT00307749|DRUG|Placebo|once daily for 24 weeks
219093523|NCT00307749|DRUG|MCC-257|20mg, once daily for 24 weeks
219093524|NCT00307749|DRUG|MCC-257|40mg, once daily for 24 weeks
219093525|NCT00307749|DRUG|MCC-257|80mg, once daily for 24 weeks
219093526|NCT02146313|DRUG|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
219093527|NCT02767063|DRUG|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
219093528|NCT02767063|DRUG|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
219219325|NCT01093612|OTHER|Immunohistochemistry staining method|Correlative studies
219219326|NCT01093612|OTHER|laboratory biomarker analysis|Correlative studies
219219327|NCT01093612|GENETIC|mutation analysis|Correlative studies
219219328|NCT02928978|DRUG|Ruxolitinib|tablet (taken by mouth)
219219329|NCT02928978|DRUG|Placebo (for Ruxolitinib)|tablet (taken by mouth)
219219330|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
219219331|NCT03253172|DIETARY_SUPPLEMENT|Potassium Chloride|Two potassium supplements with varying anions.
219219332|NCT03253172|DIETARY_SUPPLEMENT|Potassium Citrate|Potassium Citrate
219219333|NCT03253172|DIETARY_SUPPLEMENT|Placebo|Placebo
219219334|NCT03984565|DRUG|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
219219335|NCT03984565|DRUG|Placebo|Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
219219336|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
219219337|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
219219338|NCT06489431|DRUG|Chlorhexidine|Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
219219339|NCT06489431|DRUG|Gentamicin|Aminoglycoside antibiotic irrigation
219219340|NCT06489431|DRUG|Rifampin|Antibacterial known to inhibit DNA-dependent RNA polymerase
219219341|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1\_Adults\_Placebo\_GR1 and ST1\_Adults\_Placebo\_GR2 groups in Stage 1 (Europe).
219219342|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1\_Adults\_Dose C\_GR1 and ST2\_Adults\_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2\_Children\_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1\_Adults\_Dose C\_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose C\_Safety and ST2\_Infants\_Dose C\_Dose find groups in Stage 2 (Africa).
219219343|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2\_Children\_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose B\_Safety and ST2\_Infants\_Dose B\_Dose find groups in Stage 2 (Africa).
219093529|NCT03532308|DRUG|Fermented Soy|Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
219093530|NCT03532308|OTHER|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
219093531|NCT01874457|BIOLOGICAL|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
219093532|NCT00206557|DRUG|Raloxifene|
219093533|NCT00206557|DRUG|Estradiol/dyhydroprogestrone|
219093534|NCT04299516|PROCEDURE|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
219093535|NCT04299516|PROCEDURE|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
219093536|NCT02346019|PROCEDURE|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
219093537|NCT00499863|DRUG|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
219093538|NCT00499863|DRUG|Placebo|Placebo patch
219093539|NCT00571701|DRUG|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
219093540|NCT00571701|DRUG|placebo|similar appearing capsules containing inert ingredients
219093541|NCT01112228|PROCEDURE|Bariatric surgery|Bariatric surgery: Gastric bypass, Sleeve gastrectomy, or Gastric banding
219093542|NCT01119430|DRUG|DU125530|20mg/twice a day
219093543|NCT01119430|DRUG|Placebo|Similar pill as active comparator twice a day
219093544|NCT01210521|DRUG|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
219219344|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose A\_Safety and ST2\_Infants\_Dose A\_Dose find groups in Stage 2 (Africa).
219219345|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2\_Adults\_Control C group and children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
219219346|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2\_Adults\_Control C group in Stage 2 (Africa).
219093545|NCT04580563|DRUG|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
219093546|NCT04580563|DRUG|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
219093547|NCT03180671|DEVICE|Deprogramer Sliding Guide|Use of the intraoral device.
219093548|NCT03180671|DEVICE|Deprogrammer Dawson B-Splint|Use of the intraoral device.
219093549|NCT03180671|DEVICE|Deprogrammer Kois|Use of the intraoral device.
219093550|NCT00466102|DRUG|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
219093551|NCT00466102|DRUG|Placebo|2 tablets are taken once daily during study therapy
219219347|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
219093552|NCT05449691|PROCEDURE|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
219093553|NCT06849050|BEHAVIORAL|Acute continuous exercise|Exercise, which will involve 60 minutes of brisk walking, or jogging, at 60% of peak oxygen uptake. Participants will be asked to wear a face mask, which will measure their oxygen consumption during the exercise session.
219093554|NCT00210171|PROCEDURE|Toxicity : Time to progression, 1 and 2 years survival|
219093555|NCT05952856|DRUG|Enlicitide Decanoate|Oral tablet
219093556|NCT05952856|DRUG|Placebo|Oral tablet
219093557|NCT05544708|BEHAVIORAL|Wellness Engagement Intervention|Train for, recruit participants into, and lead a 12-week lifestyle intervention delivered via weekly group meetings
219093558|NCT06796647|DIAGNOSTIC_TEST|ESAT6/CFP10 skin test|Each recruited participant would be offered standard tuberculin skin test (TST) and ESAT6/CFP10 (C-TST) skin test on the same day or setting of clinical visit. TST and C-TST would be performed by the Mantoux technique with intradermal injection of 2U purified protein derivative-RT23 on one forearm and 5U (1.0µg/0.1 ml) of recombinant fusion protein ESAT6-CFP10 on the other forearm respectively.
219093559|NCT03305523|DEVICE|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
219093560|NCT03759834|DEVICE|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
219093561|NCT05387603|DRUG|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
219093562|NCT05387603|DRUG|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
219093563|NCT05701995|DRUG|Deucravacitinib|Specified dose on specified days.
219219348|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa).
219093564|NCT05701995|OTHER|Placebo|Specified dose on specified days.
219219349|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
219219350|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
219093565|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
219093566|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
219219351|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
219219352|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
219219353|NCT06856265|PROCEDURE|radiofrequency ablation|Radiofrequency Ablation is a minimally invasive interventional technique performed via catheter guidance. It utilizes thermal energy (50-80°C) generated by high-frequency alternating current (typically 300-750 kHz) to induce coagulative necrosis or electrophysiological isolation in targeted tissues, thereby eliminating abnormal electrical activity or mechanical obstruction. In the treatment of cardiomyopathy, RFA is applied to ablate hypertrophied myocardial tissue (e.g., the ventricular septum) to alleviate left ventricular outflow tract (LVOT) obstruction.
219219354|NCT06856265|DRUG|Mavacamten|"Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily.~Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations."
219362111|NCT02549482|OTHER|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
219682479|NCT06751719|OTHER|core stabilization exercises|"The core exercises would be held for 7 to 8 seconds, repeated 10 times, and rest for 3 seconds between repetitions and 1 minute rest between each exercise. These exercises will include:~1. Abdominal hollowing~2. Supine extension bridge~3. Partial Curls"
219682480|NCT06751719|OTHER|heat therapy|The heat therapy would be applied to the lumbar region for 10 minutes.
219093567|NCT05753774|BIOLOGICAL|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
219093568|NCT05753774|DRUG|Conventional drugs|Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
219093569|NCT04858269|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
219093570|NCT04858269|DRUG|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
219093571|NCT04858269|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
219093572|NCT03056794|OTHER|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
219093573|NCT05557487|DIAGNOSTIC_TEST|Low dose computed tomography|"1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test."
219093574|NCT06721065|OTHER|Remote Simultaneous Medical Interpreting/RSMI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes."
219093575|NCT06721065|OTHER|Remote Consecutive Medical Interpreting/RCMI|"Remote Consecutive Medical Interpreting (RCMI; audio consecutive), is the most commonly utilized remote interpreting"
219093576|NCT06721065|OTHER|Remote Consecutive Video Medical Interpreting/RCVI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter"
219093577|NCT04953130|BIOLOGICAL|Gardasil® HPV vaccine|Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
219093578|NCT04545762|DRUG|Fludarabine|Given intravenously (IV)
219093579|NCT04545762|DRUG|Cyclophosphamide|Given intravenously (IV)
219093580|NCT04545762|BIOLOGICAL|anti-CD19 CAR-T cells|Single infusion
219093581|NCT03006770|BIOLOGICAL|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
219093582|NCT03006770|BIOLOGICAL|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
219093583|NCT06848231|DRUG|YA-101|"Drug: YA-101~• YA-101 taken BID"
219093584|NCT06848231|DRUG|Placebo|Placebo taken BID
219093585|NCT04987762|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
219093586|NCT01760850|OTHER|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
219093587|NCT01760850|OTHER|educational intervention|Engage in an educational information session for diabetes
219093588|NCT01760850|OTHER|questionnaire administration|Ancillary studies
219093589|NCT06170164|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
219093590|NCT05167266|BEHAVIORAL|Psychoeducation|Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
219093591|NCT01091948|DEVICE|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
219093592|NCT01091948|DEVICE|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
219093593|NCT06131580|DRUG|Intervention/Treatment|"Drug: osilodrostat~\- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."
219093594|NCT05842226|OTHER|Micro-teaching enriched with standard patient|The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
219093595|NCT04803214|DEVICE|ReActiv8|Market-approved ReActiv8 device implanted
219093596|NCT04484974|OTHER|Pecan snack|Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.
219093597|NCT04484974|OTHER|Tortilla chip snack|Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
219093598|NCT05659225|DEVICE|Electronic Stethoscope|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.
219093599|NCT05659225|OTHER|Standard treatment according to GINA(2019)|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
219093600|NCT03984370|DRUG|ZP4207|Abdominal SC administration
219219355|NCT05168384|COMBINATION_PRODUCT|Extracorporeal Photopheresis|"ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks)."
219093601|NCT03984370|OTHER|Placebo (saline)|Abdominal SC administration
219219356|NCT05168384|COMBINATION_PRODUCT|MS standard of care|Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
219219357|NCT05577910|DEVICE|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
219093602|NCT03210155|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
219219358|NCT05577910|DEVICE|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
219093603|NCT03210155|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
219093604|NCT05794633|OTHER|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
219093605|NCT05794633|OTHER|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
219219359|NCT05577910|BEHAVIORAL|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
219219360|NCT05577910|DRUG|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
219219361|NCT06749548|RADIATION|Group 1|the study is to emphasize the role of Computed Tomography Angiography (MDCTA) and Transthoracic Echocardiography (Echo) in the diagnosis of congenital cyanotic heart diseases.
219219362|NCT06777628|DRUG|Immunochemotherapy combined with antiangiogenic|Immunochemotherapy combined with antiangiogenic
219219363|NCT06778954|PROCEDURE|Arm I (Peritoneal application group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.
219219364|NCT06778954|PROCEDURE|Arm II (Subcutaneous injection group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
219219365|NCT05908227|OTHER|NHF high|Nasal high flow therapy 8L/min.
219219366|NCT05908227|OTHER|NHF low|Nasal high flow therapy 6L/min.
219219367|NCT05908227|OTHER|NCPAP|Nasal continuous positive airway pressure 6 cm H20
219219368|NCT06016257|OTHER|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
219093606|NCT04436315|DEVICE|Motor-cognitive training device|Motor-cognitive training device
219093607|NCT04436315|OTHER|Active control condition|Physical activity program
219093608|NCT01530230|DRUG|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
219093609|NCT00446069|DRUG|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
219093610|NCT01395108|DRUG|Nemonoxacin|oral once daily
219093611|NCT03988166|PROCEDURE|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
219093612|NCT03988166|DEVICE|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
219093613|NCT05960825|COMBINATION_PRODUCT|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
219093614|NCT01068808|PROCEDURE|skin prick test|skin prick test to aeroallergen
219093615|NCT06170671|DRUG|Non interventional study|CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection
219093616|NCT05125471|DRUG|Cobimetinib|Adult dosing (\>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (\<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).
219093617|NCT06566326|DRUG|Propofol and ketamine|Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
219219369|NCT05917860|DRUG|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
219219370|NCT05917860|DEVICE|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
219219371|NCT06792227|BEHAVIORAL|FBT-H|"FBT is a structured treatment lasting 6-12 months, typically in an outpatient setting, with weekly sessions that gradually decrease in frequency over time (Lock \& Le Grange, 2015). It empowers parents to manage their child's recovery from the ED. The first phase focuses on weight restoration, with parents responsible for all eating decisions and restricting physical activity to reduce ED's influence. In the second phase, eating responsibility gradually shifts back to the adolescent. The final phase supports healthy adolescent development as ED symptoms subside.~The FBT-H adapts FBT to a home setting, with treatment led by family counselors and psychologists as part of a multidisciplinary team, including therapists, psychologists, a psychiatrist and a nurse specialist."
219550261|NCT02535923|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
219682481|NCT06751719|OTHER|proprioceptive exercises|"The proprioceptive exercises will include rest for 3 seconds between repetitions and 1-minute rest between each exercise. These exercises will include:~1. One leg balance - 10 seconds hold time with 3 repetitions~2. Forward leg swings - 15 swings~3. Sideways leg swings - 15 swings"
219093618|NCT06566326|DEVICE|Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool|Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
219093619|NCT03760536|BEHAVIORAL|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
219093620|NCT03248375|RADIATION|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
219093621|NCT05059236|DRUG|Darolutamide (BAY1841788, Nubeqa)|300 mg per tablet, oral administration with food
219093622|NCT05059236|OTHER|ADT|LHRH agonist/antagonist or orchiectomy
219219372|NCT06735027|OTHER|intraarticular corticosteroid injection (IACI)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the glenohumeral joint. The injection site will then be disinfected with an alcohol wipe. A 21, 22, or 23-gauge needle (depending on provider preference) will be advanced into the glenohumeral joint under direct ultrasound visualization. After entry into the glenohumeral joint, a negative aspiration will be performed. At that time, up to 1 mL of 40mg/mL methylprednisolone acetate will be injected be injected into the joint space.
219219373|NCT06735027|OTHER|suprascapular nerve block (SSNB)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the suprascapular nerve in its path at the suprascapular notch. After disinfection of the injection site with alcohol, anatomic landmarks for SSNB as described by Dangoisse et al. \[10\] will be marked with a marking pen. Ultrasound will be utilized to guide the tip of a 21, 22, or 23 gauge (depending on provider preference) needle to the floor of the suprascapular fossa while avoiding neurovascular structures. At that time, a mixture of up to 10 mL of 0.5% bupivacaine and 20 mg triamcinolone will be slowly injected to fill the fascial contents of the suprascapular fossa under direct ultrasound guidance.
219219374|NCT03706014|BEHAVIORAL|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
219093623|NCT06275893|BIOLOGICAL|IC14|recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
219093624|NCT05759988|DEVICE|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
219219375|NCT03706014|BEHAVIORAL|Control|Contact-equivalent attention control program in which students play educational games
219219376|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with standard protein levels|Containing standard protein levels to target normal protein amount of 0.8 g of protein/kg body weight/day
219219377|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with higher protein levels|Containing higher protein levels to target elevated protein amount of 1.3 g of protein/kg body weight/day.
219219378|NCT02944500|DRUG|liraglutide|
219219379|NCT02944500|OTHER|Placebo|
219219380|NCT03880383|BEHAVIORAL|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
219219381|NCT03880383|BEHAVIORAL|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
219093625|NCT05901610|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
219093626|NCT05901610|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
219093627|NCT05901610|DEVICE|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
219093628|NCT05901610|DEVICE|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
219093629|NCT06968741|DEVICE|Artificial Urinary Sphincter (AUS)|AUS implant
219219382|NCT03880383|BEHAVIORAL|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
219219383|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
219219384|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
219219385|NCT02830204|DEVICE|Mitral Valve Replacement (MVR) with Sapien3|subjects with surgical MVR with Sapien3
219219386|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
219219387|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
219219388|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
219219389|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 infusions of 2 x 10\^7 cells/m2 administered 2 weeks apart.~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
219219390|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
219219391|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
219219392|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
219219393|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
219219394|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
219219395|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
219219396|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
219219397|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
219219398|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
219219399|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
219219400|NCT05604326|BEHAVIORAL|Pathways Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.
219219401|NCT05604326|BEHAVIORAL|Parent Education Intervention (PEI)|Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
219219402|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
219219403|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
219219404|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
219219405|NCT03894215|DRUG|AGEN2034|PD-1 antibody
219219406|NCT03894215|DRUG|AGEN1884|CTLA-4 antibody
219219407|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
219219408|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
219219409|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
219219410|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
219219411|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
219219412|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
219219413|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
219219414|NCT01341301|DRUG|Cyclophosphamide|Given IV
219219415|NCT01341301|DRUG|Tacrolimus|Given IV or PO
219219416|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
219219417|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
219093630|NCT06822400|PROCEDURE|corrective surgery within 28 days of birth|"Participants will be randomized into two groups with a 1:1 allocation:~Intervention Group: Neonates undergoing surgical correction of TOF within 28 days of birth."
219093631|NCT06822400|PROCEDURE|corrective surgery between 3-6 months of age|"Participants will be randomized into two groups with a 1:1 allocation:~Control Group: Infants undergoing surgical correction of TOF between 3-6 months of age"
219093632|NCT00079001|DRUG|zoledronic acid|Given IV
219093633|NCT00079001|OTHER|placebo|Given IV
219093634|NCT00079001|DRUG|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
219219418|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
219093635|NCT00079001|DRUG|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
219219419|NCT06888284|BEHAVIORAL|Tui Jing therapy|Tui Jing therapy (Gua Sha + Meridian pressure) was utilized, a specialized form of Gua Sha that incorporates traditional techniques with targeted pressure on specific meridians.
219219420|NCT06888284|DEVICE|sham ultrasound intervention|Participants will receive a sham ultrasound intervention on the same meridians. To enhance comfort and prevent cold sensations from the metal probe, the ultrasound device will be pre-warmed to body temperature. A gel, mimicking the texture of the lubricant used in Tui Jing therapy, will be applied. The device will mimic the motion, direction, duration, and frequency of the Tui Jing therapy, but without activating the ultrasound's therapeutic mode. The participants will be informed that they are accepting low-intensity ultrasound mode, which will not produce any sensory perception, ensuring in distinguishing ability between active and sham interventions
219219421|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
219219422|NCT02517268|PROCEDURE|Pancreaticoduodenectomy|
219219423|NCT03246802|RADIATION|HDR partial prostate brachytherapy|temporary radioactive implant
219219424|NCT06424340|BIOLOGICAL|MB-dNPM1-TCR.1|T Cell Receptor (TCR) T cell therapy
219219425|NCT06777992|OTHER|Home topographic scans|Patients randomized to the Intervention arm of the trial will additionally use Momentum SpineTM assessment from home at 2-month intervals. If a progression is detected using Momentum SpineTM the participant will be promptly invited to acquire a second set of scans for confirmation. In case of confirmation of the progression using the images from the repeated scans, the scan results will be sent to their local orthopedic surgeon.
219219426|NCT06402344|OTHER|Hormonal implant|History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
219219427|NCT06402344|OTHER|Control group|Young women who never used any hormonal implant.
219219428|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
219219429|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
219093636|NCT00079001|DIETARY_SUPPLEMENT|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
219219430|NCT05203198|BEHAVIORAL|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
219219431|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
219219433|NCT06113705|DIAGNOSTIC_TEST|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
219219434|NCT06113705|DIAGNOSTIC_TEST|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
219219435|NCT06113705|OTHER|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
219219436|NCT06113705|OTHER|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
219219437|NCT06113705|OTHER|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
219219438|NCT05854160|PROCEDURE|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
219093637|NCT00079001|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
219093638|NCT05674760|DEVICE|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
219219439|NCT06818266|DRUG|Tocilizumab (RoActemra®, 20 mg/mL).|One single intravenous infusion at 8 mg/kg (up to a maximum of 800 mg) for patients ≥ 30 kg and 12 mg/kg for patients \< 30 kg
219219440|NCT06818266|DRUG|Placebo (NaCl 0.9%)|One single intravenous infusion
219219441|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Low dose of ACI-35.030
219219442|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Medium dose of ACI-35.030
219219443|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a High dose of ACI-35.030
219219444|NCT04445831|OTHER|Placebo|Administration of Placebo
219219445|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Low dose of JACI-35.054
219219446|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Medium dose of JACI-35.054
219219447|NCT04043117|OTHER|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
219093639|NCT05674760|OTHER|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
219093640|NCT00482820|BEHAVIORAL|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
219219448|NCT04043117|OTHER|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
219219449|NCT06183619|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
219219450|NCT06183619|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation only
219219451|NCT06753461|PROCEDURE|intrahepatic blood flow occlusion|The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
219219452|NCT06753045|OTHER|Smartwatch|Sensors on the smartwatch will measure vitals such as heart rate, blood pressure, oxygen saturation, body composition, and electrocardio gram (ECG)
219219453|NCT06827756|DRUG|Norfloxacin 400 MG|Patients receiving Norfloxacin 400 Mg to prevent SBP
219219454|NCT06827756|DRUG|Nitazoxanide 500 MG|Patients receiving Nitazoxaide 500 Mg to prevent SBP
219219455|NCT06827756|DRUG|Colistin|Patients receiving Colistin 15ml three times/ day to prevent SBP
219219456|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
219219457|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
219219458|NCT06826456|PROCEDURE|sub-ablative Er,Cr:YSGG laser|The irradiations will be done with an Er,Cr:YSGG laser device Er,Cr:YSGG Laser (Waterlase iPlus 2011,Biolase,Germany). This equipment emits photons at a wavelength of 2.78 µm. The repetition rate will be fixed at 20 Hz. The pulse duration will be fixed on 140 µs. The beam diameter at the focal area for the handpiece will be 600 µm. The tip will be positioned 1.0 mm from the enamel surface (focused mode). The handpiece will be positioned perpendicularly to the enamel. Power =0.25 Watt; energy density per pulse will be 62.5 J/cm2, Time = 20 seconds; Frequency = 20 Hz; without air/water. To ensure that each spot of a fissure was irradiated, each fissure will be irradiated for 2 min with overlapping irradiation
219219459|NCT06826456|PROCEDURE|Fluoride varnish application|"The first permanent molar assigned for control group will receive fluoride varnish applications. Fluoride varnish will be applied to all teeth in the oral cavity, including the laser-treated as well as the control tooth at baseline and the 6-month recall.~Parents and children will be given age-appropriate oral hygiene instructions including proper teeth brushing with a 1100-ppm fluoride-containing dentifrice for at least 2 min twice daily especially before bedtime, as well as flossing if indicated."
219219460|NCT04912856|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
219219461|NCT06827015|BEHAVIORAL|Laughter-Based Anger Reduction Program|This intervention involves structured Laughter Yoga sessions lasting 40 minutes each, conducted twice a week. It specifically targets students with high anger levels. The program combines breathing exercises, playful laughter activities, and relaxation techniques to reduce stress and promote emotional regulation. Unlike other interventions, this program uniquely emphasizes laughter as a tool for managing anger and enhancing overall well-being.
219093641|NCT03245138|PROCEDURE|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
219093642|NCT03245138|PROCEDURE|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
219093643|NCT05632939|DRUG|ASKB589 +CAPOX+Sintilimab/Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
219219462|NCT05104515|BIOLOGICAL|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
219219463|NCT06823128|DEVICE|RIC|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure,last for 7 to 10 days.
219219464|NCT06823128|DEVICE|Sham|RIC is given twice a day with 60mmHg pressure, last for 7 to 10 days.
219219465|NCT06823128|OTHER|Guideline-based therapy|Guideline-based therapy
219219466|NCT04777084|DRUG|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
219219467|NCT05605054|BEHAVIORAL|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
219219468|NCT05605054|BEHAVIORAL|Self-study|Self-studying of programmatic information and list of service referrals
219219469|NCT05080777|BEHAVIORAL|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
219219470|NCT05080777|BEHAVIORAL|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
219219471|NCT03031483|DRUG|clarithromycin and lenalidomide|"Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
219682482|NCT06751719|OTHER|calisthenic exercises|"The calisthenic exercises will include:~1. Abductor's leg raise for 10 repetitions~2. Prone leg extension for 10 repetitions~3. Alternate toe touch for 10 repetitions"
219682483|NCT06751719|OTHER|kinesthetic exercises|"The kinesthetic exercises will have 1 minute rest in between exercises. These exercises will include:~1. Toe walking for 20 meters distance~2. Heel walking for 20 meters distance"
219682484|NCT05962827|DIAGNOSTIC_TEST|lipoprotein (a)|dosage of lipoprotein (a)
219682485|NCT04611776|DRUG|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
219682486|NCT04611776|DRUG|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
219682487|NCT04611776|DRUG|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
219682488|NCT04611776|DRUG|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
219682489|NCT04611776|DRUG|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
219093644|NCT03675152|OTHER|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
219093645|NCT03675152|OTHER|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
219093646|NCT03675152|OTHER|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
219093647|NCT03205228|DRUG|Omeprazole|A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
219682490|NCT04611776|DRUG|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
219682491|NCT04611776|DRUG|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
219093648|NCT03205228|BEHAVIORAL|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
219219472|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
219219473|NCT06809972|OTHER|Ultrasound imaging|Ultrasound, MRI and elastography to screen for and follow subclinical synovial changes in ankle, elbow and knee.
219219474|NCT06887764|DEVICE|RKO-assisted walking in children with CP|The investigators will assess walking in each of the following conditions: shod (shoes or shoes + AFO) and RKO-assisted (shoes + RKO), to achieve the following: (1) Evaluate the effect of RKO, compared to shod upon endurance in children with CP at GMFCS level II, and (2) Evaluate the effect of RKO, compared to shod, upon temporal-spatial parameters, lower limb sagittal joint kinematics, and muscle EMG in children with CP at GMFCS level II.
219219475|NCT06773390|PROCEDURE|Percutaneous liver biposy|Percutaneous liver biopsy in pediatric patient diagnostic significance and pattern of liver diseases
219093649|NCT03205228|DRUG|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
219093650|NCT06501014|OTHER|Action Observation Therapy-Experimental Group|Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
219219476|NCT06230705|OTHER|Guided management|Guided Management
219219477|NCT06230705|OTHER|Self management|Self management
219219478|NCT06137768|DRUG|HRS-5965|HRS-5965
219219479|NCT06137768|DRUG|Placebo|Placebo.
219219480|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
219219481|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
219219482|NCT06474598|DRUG|MTX228|Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
219219483|NCT06474598|DEVICE|DEXCOM G6|To monitor participants blood glucose levels continuously
219219484|NCT04721548|DRUG|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
219219485|NCT04721548|DRUG|Placebo|1 mL of solution twice a day.
219219486|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
219219487|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
219219488|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
219219489|NCT06753994|DRUG|SGLT-2 inhibitor|Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
219219490|NCT06760104|DIAGNOSTIC_TEST|Dental Plaque Detection Using AI Models|"1. AI Model Analysis:~   Description: Intraoral images of participants will be captured using standardized imaging techniques. These images will then be analyzed using various artificial intelligence models specifically designed for detecting dental plaque. The AI models will process the images to identify and quantify the presence of dental plaque.~2. Clinical Assessment:~Description: A qualified dentist will perform a traditional clinical examination of the participants to assess dental plaque using standard examination techniques. This will serve as the reference standard against which the AI models will be compared.~Study Procedures Image Acquisition: Intraoral images will be taken of each participant using \[ intraoral camera\].~AI Model Evaluation: The captured images will be analyzed using different AI algorithms, which may include."
219219491|NCT06719492|BEHAVIORAL|nutrition education|15 minutes of surgery specific nutrition education provided by a Registered Dietitian.
219219492|NCT06763263|BEHAVIORAL|Experimental|Children and their parents in this group will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. Then, the child will be allowed to choose one of the superhero clothes he/she wants in his/her room and will be allowed to wear the clothes. The superhero figure will be shown to him/her and he/she will be allowed to play with the clothes and the figure for 2 hours.
219219493|NCT06763263|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. The children will be evaluated in terms of their reactions after their hospitalization, they will not be dressed in any clothing and no superhero figures will be used. Then the questionnaire will be filled out again and scoring will be done. In order to prevent ethical bias before discharge, the child will be dressed in a superhero costume and will be allowed to spend time with the clothing and figure.
219093651|NCT06501014|OTHER|Conventional Exercises-Control Group|Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
219093652|NCT06558851|BEHAVIORAL|High intensity endurance training|12 weeks of high intensity endurance training three times a week. Two of the weekly sessions are supervised.
219093653|NCT02565563|OTHER|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
219093654|NCT02565563|DEVICE|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
219093655|NCT05271786|OTHER|Decannulation|retrospective evaluation of decannulation
219219494|NCT06820827|OTHER|Myofascial release|The participants will receive myofascial release (MFR) on erector spinae, quadratus lumborum, piriformis and gluteus medius. The duration of MFR for each muscle will be 90 to 120 seconds, three times/week for eight weeks.
219219495|NCT06820827|DEVICE|High-power pain threshold ultrasound|The participants will receive high-power pain threshold ultrasound on sacroiliac joint, 20 minutes, three times/week for eight weeks.
219219496|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
219219497|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
219219498|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
219219499|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
219219500|NCT06934616|DRUG|GB268|GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle
219219501|NCT05200572|BEHAVIORAL|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
219219502|NCT06839521|OTHER|Walk Test-T|6MWT will be conducted according to traditional protocols. During the test, parameters such as heart rate, oxygen saturation, and walking distance will be measured and compared with traditional methods.
219219503|NCT06839521|OTHER|Walk Test-A|In order to develop Android-based 6DYT, the system will be designed with a multidisciplinary team consisting of software engineer and physiotherapist. In this programme, separate algorithms will be developed for indoor and outdoor environments so that individuals can be evaluated in a hospital environment, at home or in daily life. In indoor environments, the GPS signal is lost or there is not enough signal strength. For this reason, the programme will be developed so that the gyroscope of the phone can be used for distance measurement. GPS signals will be used outdoors. In this way, the physical activity level of the individual both in the hospital and in daily life will be measured.
219219504|NCT00719888|DRUG|Cyclophosphamide|Given IV
219219505|NCT00719888|DRUG|Cyclosporine|Given IV and PO
219219506|NCT00719888|PROCEDURE|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
219093656|NCT05831696|OTHER|Powered Microprocessor-controlled Knee (PMPK)|A microprocessor-controlled Knee with standardized commercial prosthetic foot
219093657|NCT02987257|DRUG|Harmonized supportive care|Harmonized supportive care with and etanercept placebo days 1 and 4
219093658|NCT02987257|DRUG|Etanercept 50 mg sc day 1 and day 4|Harmonized supportive care with placebo
219093659|NCT06033274|DEVICE|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
219219507|NCT00719888|DRUG|Fludarabine|Given IV
219219508|NCT00719888|OTHER|Laboratory Biomarker Analysis|Correlative studies
219219509|NCT00719888|DRUG|Mycophenolate Mofetil|Given IV and PO
219219510|NCT00719888|RADIATION|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
219219511|NCT00719888|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
219219512|NCT00719888|DRUG|Thiotepa|Given IV
219219513|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
219219514|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
219219515|NCT06769789|OTHER|Drug free invitro activation Ovary|Drug free invitro activation Ovary
219219516|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
219219517|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
219219518|NCT03773107|DRUG|Dexamethasone|glucocorticoid
219093660|NCT03094624|OTHER|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
219093661|NCT03094624|OTHER|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
219219519|NCT06759493|DIAGNOSTIC_TEST|Retinol isotope dilution technique|A group of 60 school children will be recruited through a stratified sampling. To this first group of 60 school children a retinol isotope dilution (RID) test for total body store assessment will be applied. The remaining 98 school children will be recruited according to stratified sampling and divided into two groups of 49 children (females and males). To these groups of children, the modified relative dose response (MRDR) test, a qualitative measure of vitamin A status will be used to investigate the absorption of 3,4-didehydroretinyl acetate in oil.
219219520|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
219219521|NCT06944795|DEVICE|SWIR device|A Short Wave Infrared (SWIR) Otoscope will record images for both the SWIR and white light video otoscopes. These images of the middle ear will be recorded in AVI format.
219219522|NCT06944548|BIOLOGICAL|Lipidomic analyses|"3 blood samples taken from 2 x 6 mL EDTA tubes for patients~* At baseline~* Week 5 of the adapted physical activity protocol~* Follow-up visit for adapted physical activity~  1 blood sample taken from 2 x 6 mL EDTA tubes for volunteers~* At baseline"
219219523|NCT06944548|OTHER|Adapted physical activity program|8-week adapted physical activity program. This program will be adapted to each group
219219524|NCT06951022|OTHER|Sujok therapy|Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.
219219525|NCT06953492|OTHER|PSQI|PSQI
219550262|NCT05237635|OTHER|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
219093662|NCT03094624|OTHER|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
219093663|NCT03094624|OTHER|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
219093664|NCT03094624|OTHER|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
219093665|NCT04374630|DRUG|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
219093666|NCT04374630|DRUG|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
219093667|NCT06576219|BEHAVIORAL|Group Music Therapy|My Life Is Music group therapy model
219093668|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
219219526|NCT06952036|PROCEDURE|Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C|Initiated Standard DAA treatment among HCV RNA positive patients.
219219527|NCT06948045|PROCEDURE|PLLA application to the mandibular angle|The investigator will mark the application area by palpating the inferior and posterior boundaries of the face and the mandibular ramus, approximately 1 cm from these anatomical landmarks. The second PLLA injection point will be marked 1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament. The demarcated area will be anesthetized with a local infiltration of 0.3-0.5 mL of 1% lidocaine with epinephrine, using a 30G needle. PLLA will then be reconstituted in 10 mL of sterile water for injection. Administration will be performed with a 30G needle inserted perpendicularly into the marked area until the supraperiosteal plane of the mandibular angle is reached, delivering a 0.7 mL bolus of the reconstituted product. At the second site-1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament-a 0.2 mL dose of the reconstituted product will be injected.
219550263|NCT03867890|OTHER|no intervention|
219550264|NCT03173651|DEVICE|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
219550265|NCT03173651|DEVICE|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
219550266|NCT03173651|DEVICE|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
219550267|NCT05668650|DRUG|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
219550268|NCT05668650|DRUG|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
219550269|NCT01090505|DRUG|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
219550270|NCT02427919|DRUG|G-CSF|Comparison of the effect of G-CSF use
219550271|NCT02924025|BEHAVIORAL|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
219550272|NCT03578497|DRUG|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
219219528|NCT05697068|BEHAVIORAL|COVID Prevention Program (CPP)|This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
219093669|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
219093670|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
219093671|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
219093672|NCT06650761|DRUG|CDX-622|Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622
219093673|NCT06650761|DRUG|Normal Saline|Up to 4 infusions or 6 SC injections of normal saline
219093674|NCT01375829|DRUG|Ixabepilone|Given IV
219093675|NCT01375829|OTHER|Pharmacological Study|Correlative studies
219093676|NCT01375829|DRUG|Temsirolimus|Given IV
219093677|NCT00916032|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
219093678|NCT01274091|OTHER|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
219093679|NCT01274091|OTHER|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
219219529|NCT03955627|BEHAVIORAL|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
219219530|NCT06000410|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
219093680|NCT06976736|OTHER|Observational|Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products
219093681|NCT00769548|DRUG|flutamide|Drug used for TAS.
219093682|NCT00769548|DRUG|goserelin acetate|Drug used for TAS.
219093683|NCT00769548|RADIATION|low-LET photon therapy|radiation therapy
219093684|NCT00583986|DRUG|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
219093685|NCT04511754|BEHAVIORAL|Experiential Psychotherapy Skill Training|The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
219093686|NCT04511754|BEHAVIORAL|Standard Psychotherapy Skill Training|Standard didactic training with research support, examples, and opportunities to ask questions.
219093687|NCT03951454|BEHAVIORAL|Conexiones|5 Conexiones telephone sessions
219093688|NCT03951454|BEHAVIORAL|Taking Time|1 Taking Time telephone session
219093689|NCT04022967|DRUG|dolutegravir|One daily tablet (50mg) during 96 weeks
219093690|NCT04022967|DRUG|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
219093691|NCT04022967|DRUG|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
219093692|NCT04022967|DRUG|Lamivudine|One daily tablet (300mg) during 96 weeks
219093693|NCT00812279|OTHER|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
219093694|NCT00812279|OTHER|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
219219531|NCT06000410|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
219219532|NCT04192773|DRUG|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
219219533|NCT02511574|DRUG|natural progesterone|
219219534|NCT02511574|DEVICE|cervical pessary|
219219535|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
219219536|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
219219537|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
219219538|NCT04202133|BEHAVIORAL|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
219219539|NCT04202133|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
219219540|NCT04300270|DEVICE|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
219093695|NCT00812279|OTHER|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
219093696|NCT01111357|BIOLOGICAL|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
219093697|NCT03764072|DRUG|VX-150|Capsules for oral administration.
219093698|NCT03764072|DRUG|Placebo|Capsules for oral administration.
219093699|NCT00000431|DRUG|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
219093700|NCT03390387|DRUG|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
219093701|NCT03390387|DRUG|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
219093702|NCT03390387|DRUG|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
219093703|NCT03390387|DRUG|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
219093704|NCT03390387|DRUG|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
219093705|NCT03390387|DRUG|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
219093706|NCT03390387|DRUG|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
219093707|NCT03390387|DRUG|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
219093708|NCT03390387|DRUG|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
219093709|NCT03390387|DRUG|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
219093710|NCT01975155|OTHER|food questionnaire|
219093711|NCT01975155|OTHER|Urinary mycotoxin test|
219093712|NCT01592331|DRUG|Placebo|Single oral dose
219093713|NCT01592331|DRUG|RO5508887|Single oral dose
219093714|NCT01342705|PROCEDURE|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
219093715|NCT05438654|DIAGNOSTIC_TEST|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
219093716|NCT00333164|DRUG|Asprin, Cilostazol|
219093717|NCT00084370|DRUG|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
219093718|NCT00084370|PROCEDURE|oophorectomy|
219093719|NCT01965210|OTHER|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219093720|NCT01965210|OTHER|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219093721|NCT01965210|OTHER|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219093722|NCT01965210|OTHER|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219093723|NCT01965210|OTHER|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219219541|NCT04300270|DEVICE|Smartphone ECG|Smartphone connected one-lead ECG recordings.
219219542|NCT04318028|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7 Tesla MRI
219093724|NCT01965210|OTHER|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
219219543|NCT05108558|DRUG|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
219219544|NCT05108558|DRUG|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
219219545|NCT05108558|DEVICE|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
219219546|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
219219547|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
219219548|NCT05459298|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
219219549|NCT05459298|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
219219550|NCT05459298|OTHER|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
219219551|NCT05627362|DRUG|Elafibranor 80 mg|Oral Tablet
219219552|NCT05627362|DRUG|Elafibranor 120 mg|Oral Tablet
219219553|NCT05627362|DRUG|Placebo Matched to Elafibranor 80 mg|Oral Tablet
219093725|NCT04534257|DEVICE|SELUTION Sirolimus DCB|Suitable lesions will be treated with SELUTION Sirolimus DCB
219093726|NCT04725344|OTHER|ACTIV'DOS group|ACTIV'DOS group use ACTIV'DOS application (with smartphone) to do the self rehabilitation each day (15 minutes per day) during 6 weeks. There are 7 exercices.
219093727|NCT04725344|OTHER|Usual practise|Control group uses a standard sheet of paper to do the self-rehabilitation (15 minutes per day) during 6 weeks. There are 7 exercises.
219093728|NCT01637779|BEHAVIORAL|Fact sheet|fact sheet about pain management during immunization
219219554|NCT05627362|DRUG|Placebo Matched to Elafibranor 120 mg|Oral Tablet
219219555|NCT02328014|DRUG|Acalabrutinib|Oral
219219556|NCT02328014|DRUG|ACP-319|Oral
219219557|NCT01274338|BIOLOGICAL|Ipilimumab|Given IV
219219558|NCT01274338|OTHER|Quality-of-Life Assessment|Ancillary studies
219219559|NCT01274338|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
219219560|NCT06373146|DRUG|Tirzepatide|Administered SC
219219561|NCT06373146|DRUG|Mibavademab|Administered SC
219219562|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
219093729|NCT06088524|OTHER|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
219093730|NCT00606190|PROCEDURE|Retrograde brain perfusion|observational
219093731|NCT00606190|PROCEDURE|Antegrade brain perfusion|observational
219093732|NCT04794231|OTHER|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)
219093733|NCT04794231|OTHER|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
219093734|NCT04467957|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each visit
219093735|NCT04467957|DRUG|Hyperpolarized Xenon 129|Inhaled contrast for MRI occurring at each visit
219093736|NCT03323879|RADIATION|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
219093737|NCT00161239|DRUG|Doxil, Methotrexate, L-Asparaginase, Prednisone|
219219563|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
219219564|NCT03959891|DRUG|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
219219565|NCT03959891|DRUG|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
219219566|NCT03959891|DRUG|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
219219567|NCT03959891|DRUG|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
219219568|NCT06005493|DRUG|AZD5863|T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
219219569|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
219219570|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
219093738|NCT00652223|BIOLOGICAL|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
219093739|NCT05208684|OTHER|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
219093740|NCT00558064|DRUG|telmisartan+amlodipine|
219219571|NCT04651504|OTHER|Colorectal Cancer Toolkit|The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
219550273|NCT04640129|DRUG|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
219550274|NCT04640129|DRUG|Tenofovir Disoproxil Fumarate|TDF monotherapy
219093741|NCT00558064|DRUG|amlodipine|
219093742|NCT06081764|OTHER|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
219093743|NCT02801539|DEVICE|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
219093744|NCT02801539|DEVICE|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
219093745|NCT01834508|DRUG|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
219093746|NCT00765596|OTHER|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
219093747|NCT03152084|DRUG|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
219093748|NCT00982930|DRUG|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
219093749|NCT06492798|DRUG|umbilical cord mesenchymal stem cell|intravenous infusion of umbilical cord mesenchymal stem cell
219093750|NCT04484025|DRUG|Ebselen|Glutathione peroxidase mimetic
219219572|NCT05422339|DEVICE|The MapHabit system (MHS)|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
219219573|NCT05527834|DRUG|VNRX-7145|Single oral dose
219219574|NCT05527834|DRUG|Ceftibuten|Single oral dose
219219575|NCT05979272|BEHAVIORAL|Treatment as usual|Treatment as Usual at the local family court, which includes a brief, computerized motivation enhancement intervention. All CINI youth will receive TAU, regardless of condition.
219219576|NCT05979272|BEHAVIORAL|Teen Empowerment through Computerized Health (TECH) app|An adjunct smartphone app (i.e., TECH) developed to support TAU. All participants randomly assigned to TAU+TECH will receive the TECH app.
219362112|NCT04124588|DEVICE|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
219550275|NCT02233751|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
219093751|NCT04484025|DRUG|Placebo|Matching placebo containing excipients
219093752|NCT06425848|DEVICE|Observational|We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
219093753|NCT01356680|DRUG|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
219093754|NCT01356680|DRUG|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
219093755|NCT01356680|RADIATION|30Gy IF-RT (Involved-Field Radiotherapy)|
219093756|NCT01356680|RADIATION|30Gy IN-RT (Involved-Node Radiotherapy)|
219093757|NCT01489189|OTHER|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
219093758|NCT01489189|DRUG|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
219093759|NCT01489189|OTHER|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
219093760|NCT02537639|DEVICE|Transesophageal echocardiography simulator|
219093761|NCT00426725|DEVICE|EasyLabour|According to the trial protocol
219093762|NCT02822625|DRUG|QUTENZA®|
219093763|NCT02822625|OTHER|hypnotic message|
219093764|NCT02822625|OTHER|music therapy|
219093765|NCT02699879|DRUG|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
219093766|NCT01521962|DRUG|Alogliptin|Alogliptin tablets
219093767|NCT01521962|DRUG|Insulin|Insulin injection
219093768|NCT05597722|BEHAVIORAL|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
219093769|NCT05597722|DRUG|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
219093770|NCT06477640|BEHAVIORAL|Exercise|The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.
219093771|NCT06477640|BEHAVIORAL|Standard of Care|"The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
219093772|NCT03675932|OTHER|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
219093773|NCT03588793|OTHER|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
219093774|NCT01489943|DRUG|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
219093775|NCT01489943|DRUG|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
219093776|NCT01489943|DRUG|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
219093777|NCT01489943|DRUG|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
219093778|NCT01489943|DRUG|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
219219577|NCT05455814|BEHAVIORAL|Shambhavi Madamudra Kriya|The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
219219578|NCT03837483|GENETIC|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
219219579|NCT06044259|PROCEDURE|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
219219580|NCT06044259|PROCEDURE|Conventional hemiarch replacement|Coventional open hemiarch replacement
219219581|NCT03648905|DRUG|13N-Ammonia|a perfusion imaging agent
219219582|NCT03648905|DRUG|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
219219583|NCT03648905|DRUG|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
219219584|NCT03648905|DRUG|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
219219585|NCT06338917|BEHAVIORAL|Moderate-to-vigorous intensity physical activity program (+moviMENT)|The intervention comprises 16 weeks of group based High Intensity Interval Training (HIIT), with transition to individual community based Vigorous Intermittent Lifestyle Physical Activity (VILPA) over the next 12 weeks - for a total intervention period of 28 weeks.
219219586|NCT06601998|OTHER|Blood samples and Oropharyngeal swab|Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)
219219587|NCT06601998|OTHER|Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms|"* Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max"
219219588|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
219219589|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
219219590|NCT05350371|DRUG|Pirfenidone Oral Tablet|Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
219550276|NCT05471349|BEHAVIORAL|Flyer and video|Participants will view a flyer and video
219550277|NCT03097692|PROCEDURE|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
219550278|NCT03097692|DRUG|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
219550279|NCT02725619|BEHAVIORAL|CBT|
219093779|NCT02013310|DRUG|HT-0712|
219093780|NCT02013310|DRUG|Placebo|
219093781|NCT01018225|DRUG|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
219093782|NCT01018225|DRUG|Placebo|Placebo pill, once a day, for six weeks
219093783|NCT02026323|OTHER|acupuncture|acupuncture
219093784|NCT04987125|BEHAVIORAL|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
219093785|NCT04987125|BEHAVIORAL|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
219219591|NCT05350371|DRUG|Placebo|The placebo tablets will be an exact replica of the pirfenidone tablet.
219550280|NCT02725619|BEHAVIORAL|PST|
219219592|NCT04754321|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219093786|NCT04108000|BEHAVIORAL|SPIRIT-Dementia|"The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care."
219093787|NCT04108000|BEHAVIORAL|Usual Care|As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
219093788|NCT04166825|DIAGNOSTIC_TEST|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
219093789|NCT02765919|RADIATION|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
219093790|NCT02765919|RADIATION|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
219093791|NCT02536014|DRUG|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
219093792|NCT02536014|DRUG|Saline|Saline infusion during the same time period
219093793|NCT06253845|BIOLOGICAL|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline.
219093794|NCT05347758|DRUG|HRS-7535|Drug: HRS-7535
219093795|NCT05347758|DRUG|Placebo|Drug: Placebo
219093796|NCT01330810|DRUG|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
219093797|NCT00876538|DRUG|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
219093798|NCT00876538|DRUG|Placebo Control|Placebo Control 2 capsules once day with the noon meal
219093799|NCT03243162|BEHAVIORAL|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
219093800|NCT03243162|OTHER|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
219093801|NCT06624644|BIOLOGICAL|LNS8801|G protein-coupled estrogen receptor (GPER) agonist
219093802|NCT06624644|BIOLOGICAL|Pembrolizumab|Recombinant monoclonal antibody (anti-PD1)
219093803|NCT06624644|DRUG|Chemotherapy (dacarbazine or temozolomide)|chemotherapy (dacarbazine, temozolomide)
219093804|NCT06624644|BIOLOGICAL|Immunotherapy (Pembrolizumab)|pembrolizumab
219093805|NCT06624644|BIOLOGICAL|Immunotherapy (nivolumab and relatlimab)|nivolumab and relatlimab
219093806|NCT06624644|BIOLOGICAL|Immunotherapy (ipilimumab and nivolumab)|ipilimumab and nivolumab
219093807|NCT05211323|BIOLOGICAL|Atezolizumab|Given IV
219219593|NCT04754321|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
219219594|NCT04754321|BIOLOGICAL|Pembrolizumab|Given IV
219219595|NCT04754321|OTHER|Quality-of-Life Assessment|Ancillary studies
219219596|NCT04754321|PROCEDURE|Salvage Surgery|Undergo salvage surgery
219093808|NCT05211323|BIOLOGICAL|Bevacizumab|Given IV
219093809|NCT05211323|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219093810|NCT05211323|DRUG|Cisplatin|Given IV
219093811|NCT05211323|PROCEDURE|Computed Tomography|Undergo CT
219093812|NCT05211323|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo MRI
219093813|NCT05211323|DRUG|Gemcitabine Hydrochloride|Given IV
219093814|NCT05524571|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
219093815|NCT05524571|DRUG|Placebo|Matching Placebo
219093816|NCT03466918|DEVICE|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
219093817|NCT06172582|BEHAVIORAL|12-week lifestyle intervention|A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes
219093818|NCT04756726|DRUG|cemsidomide|oral cemsidomide
219219597|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
219550281|NCT02713139|DRUG|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
219219598|NCT02107989|DEVICE|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
219219599|NCT02107989|DEVICE|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
219219600|NCT02446262|BEHAVIORAL|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
219219601|NCT02446262|BEHAVIORAL|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
219219602|NCT02446262|BEHAVIORAL|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
219219603|NCT02446262|BEHAVIORAL|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
219219604|NCT06422806|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219219605|NCT06422806|PROCEDURE|Diagnostic Imaging Testing|Undergo standard imaging scans
219219606|NCT06422806|DRUG|Doxorubicin|Given IV
219219607|NCT06422806|PROCEDURE|Echocardiography Test|Undergo ECHO
219093819|NCT04756726|DRUG|Dexamethasone Oral|oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]
219093820|NCT06638398|PROCEDURE|Computed Tomography|Undergo standard of care Computed Tomography
219093821|NCT06638398|DEVICE|Diagnostic Procedure|Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
219093822|NCT06638398|OTHER|Best Practice|Receive standard of care lung nodule management
219093823|NCT06638398|OTHER|Electronic Health Record Review|Ancillary Studies
219093824|NCT06284564|DRUG|Evolocumab|Given by SC
219093825|NCT06284564|DRUG|Nivolumab|Given by IV
219093826|NCT06036238|BEHAVIORAL|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
219093827|NCT06036238|BEHAVIORAL|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
219219608|NCT06422806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219219609|NCT06422806|BIOLOGICAL|Pembrolizumab|Given IV
219219610|NCT04424303|DRUG|Tofacitinib|Observational study
219219611|NCT05712317|BEHAVIORAL|Exergame Intervention|8-week exergame-based intervention 3x per week
219219612|NCT05712317|BEHAVIORAL|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
219093828|NCT04579523|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
219093829|NCT04579523|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
219093830|NCT04579523|DRUG|Cyclophosphamide|Given IV
219093831|NCT04579523|DRUG|Fludarabine Phosphate|Given IV
219093832|NCT04579523|RADIATION|Total-Body Irradiation|Undergo TBI
219093833|NCT04579523|PROCEDURE|Biospecimen Collection|Undergo blood collection
219093834|NCT04579523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
219093835|NCT04579523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219093836|NCT04579523|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
219093837|NCT04649385|DRUG|BGB-15025|Administered orally once or twice daily (QD or BID)
219093838|NCT04649385|DRUG|Tislelizumab|Administered 200 mg intravenous (IV) infusion
219219613|NCT03547947|DEVICE|Medacta Shoulder System|Total Shoulder Arthroplasty
219219614|NCT06056310|DRUG|Xevinapant|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
219219615|NCT06056310|DRUG|Cisplatin|Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
219219616|NCT06056310|RADIATION|intensity-modulated radiation therapy (IMRT)|Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
219219617|NCT04121806|OTHER|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
219362113|NCT04124588|DEVICE|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
219093839|NCT01676337|OTHER|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
219093840|NCT06457633|BEHAVIORAL|Experiential FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) carried out experientially.
219093841|NCT06457633|BEHAVIORAL|Traditional FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.)
219093842|NCT06457633|BEHAVIORAL|Online FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) performed virtually.
219093843|NCT00486421|BIOLOGICAL|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
219093844|NCT00486421|DRUG|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
219093845|NCT04386525|DIETARY_SUPPLEMENT|Omega-3 fish oil|soft gels,1000gm, 84% of DHA and EPA
219093846|NCT06361901|DEVICE|Zenicog;language rehabilitation program|This program is an AI-based computerized cognitive and language training program.
219093847|NCT06361901|PROCEDURE|Conventional language rehabilitation|Conventional language rahabilitation therapy will apply for all participants with speech impairement
219093848|NCT05110196|DRUG|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
219093849|NCT05110196|DRUG|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
219219618|NCT04803370|OTHER|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
219219619|NCT04803370|OTHER|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
219219620|NCT06527079|OTHER|Opioid Tapering Pathway Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
219219621|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
219219622|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
219219623|NCT05370430|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
219219624|NCT04365569|BEHAVIORAL|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1\. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
219219625|NCT01176006|PROCEDURE|Reduced-intensity hematopoietic stem cell|stem cell transplant
219219626|NCT01176006|DRUG|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
219219627|NCT01176006|DRUG|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
219219628|NCT01176006|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
219219629|NCT01176006|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
219219630|NCT01176006|PROCEDURE|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
219219631|NCT01176006|PROCEDURE|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
219219632|NCT06444607|PROCEDURE|Venepuncture|Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
219093850|NCT06337370|BEHAVIORAL|Chronic Disease Self Management Program|"Experimental Intervention (Self-Management Program):~In addition to standard care from a rheumatology specialist, the intervention group will receive the Chronic Disease Self-Management Program (CDSMP). This program is a group intervention that provides education on self-managing chronic diseases. The program consists of six weekly sessions, each lasting two and a half hours (including time for breaks and refreshments), for a total of six weeks. Each group will consist of 12 to 16 participants, and the sessions will follow a standardized, scripted format. Two group leaders, who have received training from a Master Trainer certified by Stanford University in how to implement the program, will lead the activities. For this study, the principal investigator and a nurse experienced in health education will undergo training from a CDSMP Master Trainer to ensure fidelity to the intervention."
219093851|NCT06337370|BEHAVIORAL|Conventional Intervention- Standard care|"Conventional intervention (standard care):~The control group will receive standard care provided by a rheumatology specialist. This approach emphasizes clinical and clinimetric evaluations of rheumatoid arthritis. It includes applying validated disease activity indices (e.g., DAS28, CDAI, or SDAI), making therapeutic decisions, and adjusting medications according to current clinical practice guidelines. It also includes the standard clinical counseling provided during routine medical consultations. No additional self-management strategies or structured interventions beyond those already incorporated into routine healthcare practice will be included."
219093852|NCT03091257|DRUG|Dabrafenib|Administered Orally BID
219093853|NCT03091257|DRUG|Trametinib|Administered Orally once daily
219093854|NCT07128303|DRUG|GS-5319|Administered orally
219093855|NCT06655324|BIOLOGICAL|V350A|Vaccination administered via intramuscular injection
219093856|NCT06655324|BIOLOGICAL|V350B|Vaccination administered via intramuscular injection
219093857|NCT06655324|BIOLOGICAL|Placebo|Vaccination administered via intramuscular injection
219093858|NCT06979401|OTHER|Exercise|After obtaining informed consent to participate in the study, all participants will be evaluated by an experienced physiotherapist before group allocation. All participants will receive diabetic foot training. Then, the experimental group and the control group will be formed by a sequential random method. Foot sensory training will be applied to the experimental group and no intervention will be made to the control group. However, after the study is completed, sensory training will be provided to the participants in the control group who wish to do so. Foot sensory training will be performed by the researcher physiotherapist. Foot sensory training sessions will be planned for 6 weeks, 3 days a week. An initial assessment will be made before the sessions begin and a final assessment will be made after the 6-week foot sensory training program.
219093859|NCT06999694|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
219093860|NCT06999694|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
219219633|NCT06444607|PROCEDURE|Venepuncture|Volunteering for blood draw.
219219634|NCT05910528|DRUG|Afimkibart|Afimkibart will be administered during the Induction, Maintenance and OLE period.
219219635|NCT04264572|OTHER|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
219093861|NCT06999694|DRUG|Durvalumab|"Durvalumab 1500 mg will be administered as an IV infusion every 4 weeks.~Treatment Duration Guidelines:~* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years.~* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years.~* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses."
219219636|NCT04264572|BEHAVIORAL|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
219219637|NCT06056193|PROCEDURE|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
219219638|NCT05555628|OTHER|Mandibular Exercise|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
219219639|NCT05555628|OTHER|Mandibular Exercise and Postural Exercise Group|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
219093862|NCT06066333|RADIATION|Ablative Radiotherapy|All participants will first undergo ablative RT
219093863|NCT06066333|DRUG|Pembrolizumab|After completion of ablative RT, all subjects may begin pembrolizumab treatment
219093864|NCT06013748|BEHAVIORAL|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
219093865|NCT06013748|OTHER|Treatment as usual|Treatment as usual as provided by the mental health centers
219219640|NCT05555628|OTHER|Occlusal Splint Group|Patients will use occlusal splints for 6 weeks. The occlusal splints will be used only sleep time.
219219641|NCT04772378|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
219219642|NCT04984837|DRUG|Lacutamab|750 mg/IV
219093866|NCT05072548|BEHAVIORAL|The ABCs of SLEEPING|"The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on."
219093867|NCT06868108|DEVICE|Flexible Suturing System with Anchors (FSSA)|Surgically repaired full-thickness rotator cuff tendon tears with the Flexible Suturing System with Anchors (FSSA).
219093868|NCT06770738|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional cohort study. Only the information of the patients will be used.
219219643|NCT04984837|DRUG|Gemcitabine|1000 mg/m²
219219644|NCT04984837|DRUG|Oxaliplatine|100 mg/m²
219219645|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
219219646|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
219219647|NCT04891068|DRUG|Azacitidine|5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
219219648|NCT05720117|DRUG|PYX-201|IV infusion
219219649|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
219219650|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
219219651|NCT06047444|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
219219652|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections."
219219653|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections."
219219654|NCT05556512|DRUG|Tirzepatide|Administered SC
219219655|NCT05556512|DRUG|Placebo|Administered SC
219219656|NCT04563143|OTHER|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
219219657|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
219219658|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
219219659|NCT05267262|DRUG|R3R01|R3R01 administered orally for 12 weeks
219219660|NCT05390411|BEHAVIORAL|SOCIAL HF|participate in SOCIAL HF training
219219661|NCT04389437|PROCEDURE|Ophthalmological exam|OCT-A and AO
219219662|NCT04389437|PROCEDURE|Blood pressure measurement|Blood pressure measurement before the ophthalmological exam
219219663|NCT06097143|OTHER|Flowable Giomer|Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.
219362114|NCT02381119|BEHAVIORAL|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
219093869|NCT06624202|BEHAVIORAL|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) includes use of practice plans and a resource booklet aligned with the National Federation for High School guidelines for contact in practice. Coaches will also attend a pre-season coaches' clinic and be paired with a peer mentor during the season.
219093870|NCT06829667|DEVICE|Arthrex InternalBrace|Arthrex InternalBrace is composed of a polyethylene/polyester suture tape and knotless bone anchors to provide ligament repair bridging and reinforce ligament strength. There have been conflicting results surrounding the clinical efficacy of its use in lateral ligament reconstruction.
219093871|NCT06867107|DRUG|SAT-3247|AAK1 inhibitor
219093872|NCT07010575|DRUG|New TETA 4HCl Formulation|Individual patient doses will depend on the Standard of Care (SOC) therapy at study entry and guided by recommended dosing switch schedule outlined in the study protocol. The dose may subsequently be titrated based on clinical response per the investigator's judgement.
219093873|NCT07010575|DRUG|Standard of Care|Patients will be returned to their approved Wilson's Disease SOC therapy (dose and frequency) at study entry as prescribed by their treating Wilson's Disease physician.
219219664|NCT06097143|OTHER|Flowable Nano-filled composite with S-PRG barrier coat|"Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries."
219219665|NCT06097143|OTHER|Flowable Nano-filled composite|Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
219219666|NCT06474871|DEVICE|Khymeia®-Virtual Reality rehabilitation System (VRRS EVO SYSTEM or COMPACT VRRS ENGINE)|fully immersive VR software created by clinicians and experts specialized in cognitive rehabilitation. Khymeia Devices are Medical Class 1 devices according to MDR. VRRS systems consist of a central process unit, complete with a capacitive touch screen LCD monitor.
219219667|NCT06474871|BEHAVIORAL|Traditional cognitive training (TCT)|face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits
219219668|NCT05778071|COMBINATION_PRODUCT|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
219219669|NCT05778071|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
219219670|NCT03632343|OTHER|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
219219671|NCT03632343|OTHER|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
219219672|NCT05035030|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
219219673|NCT06798649|OTHER|The intervention in the GESTACOR study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs).|"This is aimed at assessing whether such feedback can encourage the adoption of healthier lifestyles and enhance adherence to preventive treatments, thereby potentially reducing the incidence of postpartum hypertension and other cardiovascular diseases.~Components of the Intervention:~Vascular Imaging:~Women in the intervention group undergo advanced vascular imaging using ultrasound technology to detect the presence of arterial plaques vs. no information about vascular images in the standard manag group.~The images are analyzed to assess the extent of vascular health, focusing on areas typically affected by cardiovascular risks such as the carotid arteries.~Feedback Delivery:~Detailed results from the vascular imaging are provided to the participants in a comprehensible format by healthcare professionals specialized in cardiovascular health.~This feedback session includes a thorough explanation of the findings, highlighting areas of concern and potential risks."
219219674|NCT06183437|OTHER|Stopping Heart Failure Medication(s)|This group will stop their heart failure medication(s) under the supervision of the study team.
219093874|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 liquid (oral) formulation
219093875|NCT07015918|DRUG|PF-07976016|PF-07976016 liquid (oral) formulation
219093876|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 intravenous (IV) formulation
219093877|NCT07014488|DRUG|HRS-5041 Tablets|HRS-5041 tablets.
219093878|NCT07014488|DRUG|Rifampicin Capsule|Rifampicin capsule.
219093879|NCT00140205|DRUG|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
219093880|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
219093881|NCT05068869|OTHER|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
219093882|NCT05068869|OTHER|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
219093883|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
219093884|NCT03920228|DRUG|PTX-022|PTX-022 QTORIN
219219675|NCT05564247|BEHAVIORAL|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
219219676|NCT04463979|OTHER|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
219219677|NCT04773275|DEVICE|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
219219678|NCT05050266|BEHAVIORAL|EBQI|"EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity)."
219219679|NCT05050266|BEHAVIORAL|REP|The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
219219680|NCT06520514|DRUG|Spesolimab|Spesolimab
219219681|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C antibody (anti-HCV) test|Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
219219682|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C RNA test and genotype test|RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
219219683|NCT06072170|DRUG|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
219219684|NCT06072170|DRUG|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
219219685|NCT04438525|DIAGNOSTIC_TEST|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
219219686|NCT04438525|OTHER|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
219093885|NCT03920228|DRUG|Placebo|Placebo topical
219093886|NCT05025020|OTHER|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
219219687|NCT03032783|RADIATION|Total-Body Irradiation|Undergo Total Body Irradiation
219219688|NCT03032783|PROCEDURE|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
219219689|NCT03032783|DRUG|Cyclophosphamide|Given IV
219219690|NCT03032783|DRUG|Tacrolimus|Given IV
219219691|NCT03032783|DRUG|Mycophenolate Mofetil|Given IV
219219692|NCT03032783|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
219093887|NCT05025020|OTHER|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
219093888|NCT05025020|OTHER|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
219093889|NCT05025020|OTHER|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
219093890|NCT07021742|DEVICE|BioHealx|Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.
219093891|NCT07021898|DRUG|ERAS-4001|ERAS-4001 Administered orally
219093892|NCT07021898|DRUG|ERAS-4001 in combination|ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
219093893|NCT00000657|DRUG|Zidovudine|
219093894|NCT00000657|DRUG|Didanosine|
219219693|NCT05317832|BEHAVIORAL|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
219093895|NCT06137157|DRUG|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
219093896|NCT04793035|DEVICE|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
219093897|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
219093898|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
219093899|NCT06872268|BEHAVIORAL|Therapeutic photography and expressive writing|Therapeutic photography, unlike phototherapy, consists of a set of photography-based activities that are initiated independently as part of an organised group or project, but in which no formal therapy is taking place within a psychotherapeutic setting. This approach, too, can be used as a routine practice in treatment pathways. The subject deepens his or her self-awareness to improve the sense of being: images become a way to express oneself, to communicate what one is unable to verbalize. Therapeutic photography can be done independently and individually, or in the presence of other professionals (nurses, sociologists, teachers, facilitators, psychologists) who accompany the individual to the understanding and production of the activity.
219093900|NCT06872268|BEHAVIORAL|Expressive writing|Expressive writing is a technique that helps to understand and manage one's experiences and emotional tensions, contributes to mental and physical well-being, decreased stress, improved relationships, and the strengthening of the immune system.
219093901|NCT07028177|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of etomidate during digestive endoscopy between insomnia group and normal sleep group.
219093902|NCT06698458|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|DaRT source will be inserted using endoscopy into the tumor. The sources release by recoil into the tumor short-lived alpha-emitting atoms
219093903|NCT06059105|DEVICE|Immediate Implant Surgery|Inverted Co-Axis 12º Southern Implants
219093904|NCT06059105|DEVICE|Immediate Implant Surgery|Internal Conical (Deep Tapered Conical) South Implants
219093905|NCT03684148|OTHER|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
219093906|NCT07028190|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
219093907|NCT07030933|DRUG|Travesol 10%|Travesol 10% (Baxter) will be administered to the post-intervention participants at a dose of 2g per kilogram of ideal body weight for up to 3 days or until the participant's discharge from the intensive care unit.
219093908|NCT06412146|BEHAVIORAL|Peer Support Group|Participation in an Online Peer Support Group
219093909|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
219093910|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
219093911|NCT07138040|BEHAVIORAL|Stage 1 Written Information|Stage 1 WI: consists of a letter from the survivorship care team with information about long-term follow-up care and relevant contacts to schedule an appointment.
219093912|NCT07138040|BEHAVIORAL|Stage 1 Low Touch Intervention|Stage 1 LTI: consists of the WI stage 1 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and one text message per week with information to schedule a follow-up care appointment.
219093913|NCT07138040|BEHAVIORAL|Stage 2 Written Information|Stage 2 WI: consists of a letter from the survivorship care team with information about what to expect at a long-term follow-up care appointment.
219093914|NCT07138040|BEHAVIORAL|Stage 2 Low Touch Intervention|Stage 2 LTI: consists of the WI stage 2 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and two to three non-tailored (generic) text messages per week related to scheduling an appointment, overcoming barriers to follow-up care, and health self-management.
219093915|NCT07138040|BEHAVIORAL|Stage 2 High Touch Intervention|Stage 2 HTI: consists of personalized mobile-friendly dashboard containing the WI letters, their treatment summary, survivorship care plan, and a growing discover section with helpful tailored resources. They will also receive four to six text messages per week with personalized messages related to their chosen health goal, personal barriers to attending cancer-related follow-up care, treatment-related risks, information about scheduling their long-term follow-up appointments, health self-management, and fun texts consisting of celebrity quotes, memes, and altruistic messages.
219093916|NCT07121712|DEVICE|Mapsd Continuous Theta Burst Stimulation|A non-invasive brain stimulation technique using a MagStim Rapid2 stimulator with a 70mm air-cooled figure-of-eight coil. The stimulation target is the left auditory association cortex (MNI: -62, -40, 10), located using a Brainsight neuronavigation system. The cTBS protocol consists of 3-pulse 50 Hz bursts repeated at a 5 Hz frequency for a total of 600 pulses, delivered at 100% of the individual's resting motor threshold (RMT).
219093917|NCT07121712|DEVICE|Sham Navigated Continuous Theta Burst Stimulation|A placebo procedure using an inert sham coil that is identical in appearance and sound to the active coil but does not deliver a significant magnetic field to the cortex. All other aspects of the procedure, including neuronavigation, coil placement, duration, and sound, are identical to the active intervention to maintain the blind.
219219694|NCT05317832|BEHAVIORAL|WI Program Reminder|Participants will be provided with reminders to use the WI program
219093918|NCT07122843|DEVICE|VR Guided Meditation|Patients will wear a VR headset for approximately 15 minutes. The headset fully covers the eyes, immersing users in a calming, 3D virtual environment. Once the headset is on, patients will engage in a guided meditation experience, set in a nature-themed scene of their choice; options include a lake, beach, mountains, desert, forest, space, and more. An AI-powered guide will lead the meditation, offering real-time, personalized support based on the patient's age and the pain-related information provided during the hospital intake process. The AI is designed to promote relaxation by helping patients focus, breathe deeply, and feel more at ease. The intervention will be standardized for all participants, with each receiving the same duration of exposure in the VR headset and access to an identical selection of nature scenes. The patients will fill our pre and post intervention pain and anxiety surveys. The pre and post surveys will take between 5-10 minutes each to complete.
219093919|NCT07038538|BEHAVIORAL|Evidence-based gastric placement|Establish an enteral nutrition management team and develop standardized procedures through a quality improvement project. Conduct a 3-month quality improvement initiative, during which regular training sessions will be provided to nurses on gastrointestinal tube placement and maintenance. These training sessions will include various formats such as lectures, group discussions, operational demonstrations, and scenario simulations, along with regular reviews of practical issues.
219093920|NCT06705270|BEHAVIORAL|Response-focused education|Once participants recover from sedation, they will receive education that is focused on their response to treatment.
219219695|NCT05317832|BEHAVIORAL|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
219219696|NCT05317832|BEHAVIORAL|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
219219697|NCT05317832|OTHER|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
219219698|NCT05317832|OTHER|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
219219699|NCT05317832|OTHER|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
219219700|NCT05317832|OTHER|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
219219701|NCT05317832|OTHER|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
219219702|NCT06088472|BIOLOGICAL|TIL injection|Autologous tumor infiltrating lymphocyte injection
219219703|NCT03852186|BEHAVIORAL|Cognitive behavioral therapy|Group based psychotherapy
219219704|NCT03852186|BEHAVIORAL|Acceptance and commitment therapy|Group based psychotherapy
219093921|NCT06705270|BEHAVIORAL|Diagnosis-focused education|Once participants recover from sedation, they will be provided education that is focused on their diagnosis of major depressive disorder.
219093922|NCT06880770|DRUG|Plozasiran|ARO-APOC3 injection
219093923|NCT06880770|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219093924|NCT06726200|DRUG|Buprenorphine + naloxone (Suboxone)|Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care
219219705|NCT00001160|DRUG|68-Gallium Dotatate|For evaluation risk/benefit evaluation
219219706|NCT05951777|BIOLOGICAL|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
219219707|NCT05951777|DRUG|Normal Saline|Sterile Saline Solution 0.9%
219219708|NCT05632887|OTHER|no intervention|no intervention
219219709|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
219219710|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
219219711|NCT06047457|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
219219712|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections."
219219713|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections."
219219714|NCT05456841|BEHAVIORAL|Empathic Communication Skills (ECS) training|"The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
219219715|NCT05456841|OTHER|Standard of Care participant interaction|Standard of Care participant interaction
219362115|NCT02381119|BEHAVIORAL|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
219093925|NCT06726200|DRUG|Buprenorphine Injection|Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
219093926|NCT07043790|OTHER|Radical cystectomy with pelvic lymphadenectomy|"Gtoup A : Radical cystectomy group Radical cystectomy included surgical removal of the bladder, adjacent organs, and regional lymph nodes. In males, it included removal of urinary bladder, prostate, and seminal vesicles whereas in females, it included removal of urinary bladder and reproductive organs (ovaries, fallopian tubes, uterus, and anterior vagina).~Standard pelvic lymph node dissection was performed to all patients in this group."
219093927|NCT07043790|RADIATION|Trimodal therapy|"Group B : trimodal therapy group~the patients underwent maximal TURBT, where as much tumor as possible was completely resected using bipolar resectoscope. The goal was to remove all visible tumor including the underlying muscle layer and tumor edges.~This was followed by radio-sensitizing chemotherapy and radiotherapy..~Chemotherapy consisted of weekly administration of iv infusion of cisplatin (40mg/m2).~Radiotherapy delivered as EBRT aimed at delivering approximately 44- 46 Gy to the urinary bladder and pelvic lymphnodes.followed by additional boost to the bladder 54 GY and a final boost to the tumor 64-65 GY"
219093928|NCT06723912|OTHER|Health Action Process Approach-Based Program|Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.
219093929|NCT06723314|PROCEDURE|Vestibular Subperiosteal Tunnel Access vista|CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
219093930|NCT06733610|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.
219093931|NCT06734611|DIETARY_SUPPLEMENT|Fortified Iodized Salt with Folic Acid (FISFA)|Addition of folic acid to iodized salt for daily consumption to assess folate levels.
219093932|NCT06465199|DRUG|Eflornithine (DFMO)|Oral DFMO capsules
219093933|NCT06465199|DRUG|AMXT 1501 Dicaprate|Capsule
219093934|NCT06897007|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
219093935|NCT05019248|BIOLOGICAL|Most recent vaccine to seasonal influenza|Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
219219716|NCT06578897|DEVICE|3D Metal Tibial and Femoral cones|"* To collect retrospective clinical outcomes and data on revision TKAs using Medacta GMK Revision with 3D metal tibial and femoral cones~* Evaluate the patient reported functionality of the operated knee~* Evaluate the clinical and radiological performance~* Evaluate safety of the cones~* Evaluate survivorship of revisions using tibial and femoral cones"
219219717|NCT06248619|BIOLOGICAL|Teprotumumab|SC injection
219219718|NCT06248619|OTHER|Placebo|SC injection
219219719|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
219219720|NCT06546189|DIETARY_SUPPLEMENT|OMNi BiOTiC® 41167|"The product OMNi BiOTiC® 41167 contains lactobacillus strains"
219219721|NCT06546189|OTHER|Placebo|Placebo
219219722|NCT02343094|DRUG|PBA 7,5g/d|Treatment for 14 days with PBA
219219723|NCT02343094|DRUG|PBA 15g/d|Treatment for 14 days with PBA
219219724|NCT06462092|DRUG|Sacituzumab Govitecan|Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
219219725|NCT06462092|DRUG|Pemetrexed|Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).
219219726|NCT04336722|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
219219727|NCT04336722|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
219219728|NCT05895344|RADIATION|Proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
219219729|NCT05895344|RADIATION|Photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
219219730|NCT00360191|DRUG|Buspirone|
219219731|NCT00360191|PROCEDURE|Motivational enhancement therapy|
219219732|NCT06049095|DRUG|LTG-001|Oral doses
219219733|NCT06049095|DRUG|Placebo|Oral doses
219219734|NCT02162394|DEVICE|Observational ambulatory ECG monitoring|
219219735|NCT00260442|BEHAVIORAL|Resistance Training|12 weeks, 3 times a week whole body resistance training
219219736|NCT00260442|BEHAVIORAL|Sedentary|Absence of physical activity
219219737|NCT03033667|DIETARY_SUPPLEMENT|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
219219738|NCT03033667|DIETARY_SUPPLEMENT|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
219219739|NCT03033667|DIETARY_SUPPLEMENT|Group C|Over night fasting with no supplementation
219219740|NCT05885620|DEVICE|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
219093936|NCT07060495|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
219093937|NCT03881696|DRUG|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
219093938|NCT03881696|DRUG|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
219093939|NCT03881696|DRUG|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
219093940|NCT03881696|DRUG|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
219093941|NCT03881696|OTHER|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~* Long-term follow-up with dietary consumption of a food; or~* Long-term follow-up with avoidance of a food; or~* Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
219093942|NCT06100822|DRUG|Metformin|500 mg capsules of Metformin Extended Release
219093943|NCT06100822|DRUG|Placebo|500 mg capsules of placebo pills
219093944|NCT06772285|OTHER|Albert Health app|Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study.
219093945|NCT07071532|DRUG|ABBV-932|Oral Capsule
219093946|NCT07071532|DRUG|Itraconazole|Oral Capsule
219093947|NCT07064330|DRUG|Cemiplimab|350 mg IV every 3 weeks as per standard of care. Patients are observed prospectively for biomarkers of response and toxicity during cemiplimab treatment.
219093948|NCT06773013|DEVICE|Acoustic Resonance (Sound) Therapy|Sonu consists of an acoustic Vibrational Headband worn circumferentially at the level of the forehead; and a Smartphone App, paired to the Headband. The App determines acoustic resonant frequencies of the subject's nasal cavity (using the facial image) and delivers treatment through bone conduction transducers in the headband
219093949|NCT04584905|DIETARY_SUPPLEMENT|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
219093950|NCT06746597|OTHER|Walking intervention on plantar skin thickness and stiffness|Walking intervention in three different air-insole pressures (80 mmHg, 160 mmHg, 240 mmHg) in two different walking durations (10 and 20 minutes).
219093951|NCT06750094|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
219093952|NCT06750094|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
219219741|NCT06492148|OTHER|Myofascial Release|The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.
219219742|NCT06492148|OTHER|Sham-Myofascial Release|The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
219219743|NCT03488459|BEHAVIORAL|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
219219744|NCT03488459|BEHAVIORAL|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
219219745|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days."
219219746|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days."
219219747|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first three days,take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the forth day to the fifth day , take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day , then 3 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
219362116|NCT03285997|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
219362117|NCT03285997|BIOLOGICAL|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
219093953|NCT06750094|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered.
219093954|NCT06750094|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
219093955|NCT06750094|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
219093956|NCT06750094|DRUG|Irinotecan|Irinotecan will be administered as chemotherapy regimen.
219219748|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first three days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the forth day to the fifth day ,take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day, then 3 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
219219749|NCT01727167|DRUG|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
219219750|NCT01727167|OTHER|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
219219751|NCT03683849|OTHER|Training|One hour of training, twice a week, for six months.
219219752|NCT01278030|PROCEDURE|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
219093957|NCT04729387|DRUG|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
219219753|NCT00885625|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
219219754|NCT05646407|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
219219755|NCT02133625|DRUG|carboplatin|
219219756|NCT02133625|DRUG|pioglitazone|
219219757|NCT00105170|DRUG|hCBE-11|
219219758|NCT02949297|DEVICE|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
219219759|NCT04093115|DRUG|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
219219760|NCT00458783|BIOLOGICAL|Prolonged RBC storage|Transfusion with oldest available matching RBCs
219219761|NCT00458783|BIOLOGICAL|Short RBC storage|Transfusion with youngest available matching RBCs
219219762|NCT01737398|DRUG|Inotersen|
219219763|NCT01737398|DRUG|Placebo|
219219764|NCT05708599|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
219219765|NCT04284839|DRUG|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
219219766|NCT04284839|DRUG|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
219219767|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
219093958|NCT04729387|DRUG|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
219093959|NCT04729387|DRUG|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
219219768|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
219219769|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
219219770|NCT06585124|DIAGNOSTIC_TEST|Flow Cytometry|Study of t cell population in flow cytometry
219219771|NCT06012240|DRUG|Upadacitinib|Oral Tablets
219219772|NCT06012240|DRUG|Placebo|Oral Tablets
219219773|NCT05815342|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
219219774|NCT05779605|DEVICE|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
219550282|NCT02713139|DRUG|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
219093960|NCT04729387|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
219219775|NCT05779605|DEVICE|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
219219776|NCT03811015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219219777|NCT03811015|DRUG|Cisplatin|Given IV
219219778|NCT03811015|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219219779|NCT03811015|PROCEDURE|Echocardiography Test|Undergo ECHO
219219780|NCT03811015|OTHER|Fludeoxyglucose F-18|Receive FDG
219219781|NCT03811015|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219219782|NCT03811015|BIOLOGICAL|Nivolumab|Given IV
219219783|NCT03811015|OTHER|Patient Observation|Undergo observation
219219784|NCT03811015|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219093961|NCT06008756|DRUG|Enlicitide Decanoate|Enlicitide Decanoate 20 mg tablet taken by mouth.
219093962|NCT06008756|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth.
219219785|NCT00061906|DRUG|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
219219786|NCT00677209|BIOLOGICAL|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
219219787|NCT02198417|DRUG|Metformin ER|Treatment with metformin ER for 12 weeks
219219788|NCT03284359|BEHAVIORAL|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
219219789|NCT01119651|DRUG|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
219093963|NCT06388421|OTHER|Prospective study assessments|Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
219219790|NCT04011930|DRUG|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
219219791|NCT04011930|DRUG|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
219219792|NCT04169776|DEVICE|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
219219793|NCT02078518|OTHER|Questionnaires|
219219794|NCT04566172|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
219219795|NCT00357994|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
219219796|NCT00357994|DRUG|Placebo gel|
219219797|NCT00357994|DRUG|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
219219798|NCT00357994|DRUG|Placebo (PBO) oral capsules|
219219799|NCT00357994|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219219800|NCT00357994|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
219219801|NCT00357994|DEVICE|J-tube|jejunal tube
219093964|NCT04852562|PROCEDURE|Modified radical endoscopic sinus surgery|Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
219093965|NCT04852562|PROCEDURE|functional endoscopic sinus surgery|Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
219093966|NCT05885659|OTHER|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
219219802|NCT05439837|PROCEDURE|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
219219803|NCT05439837|PROCEDURE|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
219219804|NCT06426953|OTHER|No intervention|No intervention
219219805|NCT03244800|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
219219806|NCT03244800|DRUG|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
219219807|NCT04718259|DRUG|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
219219808|NCT04718259|DRUG|midazolam|midazolam
219219809|NCT01581216|OTHER|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
219219810|NCT01581216|OTHER|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
219219811|NCT01581216|OTHER|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
219219812|NCT03258398|DRUG|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
219219813|NCT03258398|DRUG|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
219219814|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
219219815|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
219219816|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
219219817|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
219219818|NCT04456569|DEVICE|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
219219819|NCT06521086|DIETARY_SUPPLEMENT|Nutrition Supplements - Fresubin KCAL Drinks|Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
219219820|NCT02378376|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|
219219821|NCT02378376|DIETARY_SUPPLEMENT|Dietary fiber enriched bran|
219550283|NCT02713139|DRUG|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
219093967|NCT05885659|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
219093968|NCT05885659|BEHAVIORAL|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
219219822|NCT04518709|PROCEDURE|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
219093969|NCT03916432|DEVICE|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
219093970|NCT05787561|DRUG|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
219093971|NCT05787561|DRUG|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
219093972|NCT07081074|DRUG|Amino acid-derived lipids|Amino acid-derived lipids are applied to the treatment area, once daily during radiotherapy.
219219823|NCT04518709|PROCEDURE|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
219219824|NCT05080998|DIAGNOSTIC_TEST|CxBladder Monitor/Monitor+|CxBladder Monitor/Monitor+ is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
219219825|NCT05768282|DRUG|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
219219826|NCT04860999|PROCEDURE|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
219219827|NCT01903902|DEVICE|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
219219828|NCT04929470|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
219219829|NCT05250063|DRUG|LUM-201|Administered orally once daily
219219830|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
219219831|NCT05375071|OTHER|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
219219832|NCT05375071|OTHER|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
219219833|NCT04087889|BIOLOGICAL|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
219219834|NCT04660812|DRUG|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
219219835|NCT04660812|DRUG|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
219219836|NCT04660812|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
219219837|NCT04660812|DRUG|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
219219838|NCT04660812|DRUG|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
219219839|NCT04660812|DRUG|Regorafenib|Regorafenib is administered as part of standard chemotherapy regimen
219219840|NCT06849687|DEVICE|Whole body vibration|Participants will be asked to sit on an chair without armrests close to the platform and will be asked to perform 90° shoulder flexion, bend both elbows slightly, flex the trunk forwards and place both hands on the platform.
219219841|NCT06849687|DEVICE|Sham Whole body vibration|Participants will receive the vibration with the device turned off.
219219842|NCT06849687|OTHER|Strengthening exercises|Participants will use elastic resistance for the finger extension and flexion exercises, and ball to strength wrist flexors for two sets of 10 repetitions within a training session.
219219843|NCT04885998|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
219219844|NCT04885998|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
219550284|NCT01096329|DRUG|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
219093973|NCT07081074|BEHAVIORAL|standard of care|Standard of care
219093974|NCT06058039|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
219093975|NCT06058039|DRUG|Placebo|Placebo will be administered orally
219093976|NCT07087353|DEVICE|Edra PRO|Remote monitoring software
219093977|NCT05653882|BIOLOGICAL|etakafusp alfa (AB248)|Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug
219093978|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
219093979|NCT07092735|BEHAVIORAL|Neuro-Athletic Training|Participants receive a structured 8-week NAT program including oculomotor, vestibular, and proprioceptive drills, 3 sessions/week (35-45 minutes each).
219093980|NCT07092735|OTHER|Standard Training|Participants continue their standard in-season football training program without any NAT components.
219093981|NCT07093268|DRUG|Intrathecal Riluzole|Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.
219093982|NCT06848205|OTHER|OFF Parkinson's Medication(s)|Participants will be asked to withhold Parkinson's medications 12 hours prior to their testing visit (if extended-release Parkinson's medications are taken by the participant, they will be asked to withhold these for 24 hours prior to their testing visit).
219093983|NCT06848205|OTHER|OFF Deep Brain Stimulation|Participants will have their deep brain stimulation turned off at the beginning of their testing visit.
219093984|NCT07093333|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
219093985|NCT06393465|DRUG|Tafamidis|61 milligrams under real world conditions
219093986|NCT07102901|DRUG|SHR2554 Tablets|Oral SHR2554 tablets.
219093987|NCT07102901|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
219093988|NCT07102901|DRUG|SHR-A1904 Injection|SHR-A1904 for injection.
219093989|NCT07102901|DRUG|SHR-1701 Injection|SHR-1701 injection
219093990|NCT03868670|DEVICE|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
219219845|NCT05230433|DIETARY_SUPPLEMENT|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
219219846|NCT02927249|OTHER|Placebo|Given PO
219219847|NCT02927249|DRUG|Aspirin|Given PO
219219848|NCT05358249|DRUG|JDQ443|KRAS G12C inhibitor, oral
219219849|NCT05358249|DRUG|trametinib|MEK inhibitor, oral
219219850|NCT05358249|DRUG|Ribociclib|CDK4/6 inhibitor, oral
219219851|NCT05358249|BIOLOGICAL|cetuximab|EGFR inhibitor, intravenous
219219852|NCT03712371|DRUG|Chitosan|Increasing dose levels from 500mg twice daily to 2000mg twice daily for up to 85 days.
219093991|NCT07111039|OTHER|Airway Pressure Release Ventilation|APRV
219093992|NCT07111039|OTHER|Conventional Mechanical Ventilation|CMV
219093993|NCT06932614|PROCEDURE|Lyophilized self growth factor|Knee Intraarticular injection with Lyophilized self growth factor
219093994|NCT06932614|PROCEDURE|Platelet-Rich Plasma(PRP)|Knee Intraarticular injection with Lyophilized self growth factor
219093995|NCT06932614|PROCEDURE|Placebo|Knee Intraarticular injection with normal saline
219093996|NCT07139587|DRUG|Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel|Iparomlimab/Tuvonralimab : 5.0mg/kg, D1, Q3W Albumin-bound paclitaxel: 260mg/m², D1, Q3W
219093997|NCT07136545|DRUG|HCB101|QW
219093998|NCT07136545|DRUG|Pembrolizumab|200 mg IV on Day 1, cycled every 21 days;
219093999|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
219094000|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
219094001|NCT06747715|PROCEDURE|Serial Fat Grafting Fresh followed by Cryopreserved Fat|The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.
219094002|NCT07142850|DRUG|HRS-9190|HRS-9190
219219853|NCT02723929|DEVICE|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
219219854|NCT02723929|DEVICE|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
219219855|NCT06522568|BEHAVIORAL|MyMammogram|An online breast cancer screening decision aid
219219856|NCT06522568|OTHER|Provider communication|Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
219550285|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
219094003|NCT06945120|BEHAVIORAL|ACT Lung Health Intervention|An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.
219094004|NCT07147946|DRUG|TQC3721 Suspension for inhalation|TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor
219094005|NCT07147946|DRUG|Placebo of TQC3721 Suspension for Inhalation|Placebo without drug substance
219094006|NCT07148271|DIETARY_SUPPLEMENT|Dietary Supplement Product|Participants will receive a dietary supplement product administered orally once daily for 8 weeks. The supplement is provided in capsule form and taken with water. The intervention is designed to modulate gut microbiota composition and diversity, with the potential to influence ocular surface outcomes in patients with dry eye disease. The regimen will be self-administered at home, with adherence monitored at study visits. Stool samples will be collected at baseline and week 8 for metagenomic sequencing, and ocular surface parameters will be assessed at the same time points. Safety will be evaluated by monitoring for adverse events throughout the intervention period.
219094007|NCT07145099|OTHER|PT Group|Exercise, Manual Therapy, and education
219094008|NCT07145099|OTHER|Usual Care|Education
219094009|NCT07144956|BIOLOGICAL|Cilostazol (Pletal®) 100 mg Tablets|100 mg orally or via feeding tube twice daily for 14 days, starting within 96 hours after aneurysmal subarachnoid hemorrhage onset. Tablets may be crushed for enteral administration.
219094010|NCT07144956|DRUG|Placebo|Oral or enteral placebo, visually identical to cilostazol, twice daily for 14 days, starting within 96 hours after hemorrhage onset.
219094011|NCT07144956|DRUG|Nimodipine group|Administered orally, enterally, or intravenously for 21 days as part of standard of care. Dose, route, and duration determined by treating physician according to clinical condition and guidelines.
219094012|NCT07152847|OTHER|Psychosexual education app with artificial intelligence|"Development of the App will contain the following features:~1. A basic Mac for iphone Operating System development~2. General Data Protection Regulation compliance legal certification~3. Hosting and cloud services~4. Security Features: for encryption and secure authentication user sign in~5. Analytics Integration: for integrating app analytics tools~6. Push Notifications: incorporated into the app~7. Legal and Compliance additional General Data Protection Regulation certified~8. Custom Artificial Intelligence Models Interactive Learning Tools Artificial Intelligence will create interactive educational materials on sexual function and dysfunction~9. Artificial Intelligence cloud services~10. Natural Language Processing. Artificial Intelligence will process textual data from the feedback questions to identify emerging topics and concerns in sexual function and participants' experiences using the app."
219094013|NCT07164924|BIOLOGICAL|blood sample to analyse AMH level on the serum|Evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml)
219094014|NCT07165990|BEHAVIORAL|Food is Medicine (FIM) Intervention|"Intensive intervention phase - this phase starts at enrollment (\<=14 weeks) through 28 weeks of gestation (or at the time of GDM diagnostic test) and women i) receive a bi-weekly home delivery of a mixed box consisting of fresh produce, lean protein, and whole grains combined with culinary medicine-based nutrition education available in English and Spanish.~Maintenance phase - this phase starts at 29 weeks through 12 weeks postpartum, and women will receive biweekly deliveries of about 10-15 pounds of fresh produce (8-10 different kinds of produce) plus standard nutrition education. The box will be curated for prenatal nutrients needs and following American Diabetes Association guidelines."
219094015|NCT07165990|BEHAVIORAL|Standard of Care|Standard medical care provided at Harris Health for high-risk pregnant women, plus a voucher equal to the value of the produce and meals provided in the Food is Medicine (FIM) Intervention.
219094016|NCT07166783|DRUG|Tolvaptan|single dose oral administration of 7.5mg Tolvaptan
219094017|NCT07166744|OTHER|Biological : blood sampling|will be collected from the patient
219094018|NCT07166744|OTHER|nasopharyngeal swab|will be collected from the patient
219094019|NCT07166744|OTHER|Procedure : Lumbar puncture|will be collected from the patient
219094020|NCT07166744|OTHER|Behavioral : clinical, functional, cognitive and psychiatric evaluations|will be collected from the patient
219094021|NCT07166744|OTHER|MRI|will be done on the patient
219094022|NCT07164781|BIOLOGICAL|Bacillus clausii|The (Test group) will receive bacillus clausii (Enterogermina) 4 billion every 12h.
219094023|NCT07164781|OTHER|Sugar tablets|The (Control group) will receive placebo (sugar tablets).
219094024|NCT07164625|BEHAVIORAL|Telerehabilitation Physiotherapy|Delivered via real-time video sessions focusing on strengthening and mobility exercises.
219094025|NCT07164625|BEHAVIORAL|In person physiotherapy|face-to-face, including hands-on treatments like tactile feedback and joint mobilization.
219094026|NCT07165366|DIAGNOSTIC_TEST|Hydrogen Peroxide|
219094027|NCT07165132|DRUG|RYZ401|Ac-225
219094028|NCT07165730|BEHAVIORAL|Virtual Health Coaching with Artificial Intelligence (DIACOACH)|Participants in the intervention group will receive a 12-week virtual health coaching program using the DIACOACH application. The program includes adaptive digital education on diet, physical activity, and medication adherence, personalized reminders, daily self-monitoring, and feedback powered by artificial intelligence. The intervention is designed to improve self-care adherence and glycemic control (FBG, HbA1c, RBG) among adults with type 2 diabetes mellitus in primary care settings.
219094029|NCT07165730|BEHAVIORAL|Standard Diabetes Education|Participants in the control group will receive standard diabetes education usually provided in primary health care centers. This includes routine counseling sessions, printed educational materials, and general advice on diet, physical activity, and medication adherence, without the use of the DIACOACH application.
219094030|NCT07166796|DRUG|singe dose 15mg|succesfule screened subject, take single dose of 15mg Tolvaptan tablet with no feeding.
219094031|NCT07166796|DRUG|single dose 30mg|succesfule screened subject, take single dose of 30mg Tolvaptan tablet with no feeding.
219094032|NCT07166796|DRUG|single dose 60mg|succesfule screened subject, take single dose of 60mg Tolvaptan tablet with no feeding.
219094033|NCT07166796|DRUG|single dose 120mg|succesfule screened subject, take single dose of 120mg Tolvaptan tablet with no feeding.
219219857|NCT03636295|DRUG|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
219094034|NCT07166796|DRUG|multi dose 30mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 30mg Tolvaptan. First day, with no feeding, take single 30mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
219219858|NCT03431584|DRUG|infiltration of corticosteroids|infiltration of corticosteroids
219219859|NCT03431584|DRUG|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
219219860|NCT05140226|BEHAVIORAL|Physical Training|Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.
219219861|NCT05140226|BEHAVIORAL|Cognitive-Physical Training|Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
219219862|NCT05154214|PROCEDURE|Adenotonsillectomy|Removal of tonsils and adenoids
219219863|NCT05154214|PROCEDURE|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
219219864|NCT03039855|DEVICE|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
219219865|NCT04111978|DRUG|Letrozole 2.5mg|Aromatase inhibitor
219094035|NCT07166796|DRUG|multi dose 60mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 60mg Tolvaptan. First day, with no feeding, take single 60mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
219094036|NCT05836571|PROCEDURE|Biopsy Procedure|Undergo biopsy
219094037|NCT05836571|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine sample
219094038|NCT05836571|DRUG|Cabozantinib|Given PO
219094039|NCT05836571|PROCEDURE|Computed Tomography|Undergo CT
219094040|NCT05836571|BIOLOGICAL|Ipilimumab|Given IV
219094041|NCT05836571|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219094042|NCT05836571|BIOLOGICAL|Nivolumab|Given IV
219094043|NCT06321575|DEVICE|Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)|Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
219094044|NCT01332890|OTHER|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094045|NCT01332890|OTHER|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094046|NCT01332890|OTHER|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094047|NCT01332890|OTHER|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094048|NCT01332890|OTHER|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094049|NCT01332890|OTHER|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
219094050|NCT01582789|DEVICE|enfilcon A|enfilcon A daily wear soft contact lens
219094051|NCT01582789|DEVICE|senofilcon A|senofilcon A daily wear soft contact lens
219094052|NCT04861870|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
219094053|NCT05377359|DEVICE|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
219219866|NCT04111978|OTHER|Placebo|Placebo tablet of Femara
219362118|NCT06269445|DRUG|Icaritin Combined With Bevacizumab and FOLFIRI|Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
219094054|NCT05377359|DEVICE|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
219094055|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
219094056|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
219094057|NCT04425343|GENETIC|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
219094058|NCT06182566|PROCEDURE|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
219094059|NCT06182566|PROCEDURE|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
219094060|NCT01031901|DRUG|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
219094061|NCT01031901|DRUG|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
219094062|NCT01031901|DRUG|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
219094063|NCT05673590|DRUG|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
219219867|NCT06349317|COMBINATION_PRODUCT|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|"1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle)."
219219868|NCT06132958|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of sacituzumab tirumotecan by IV infusion
219219869|NCT06132958|DRUG|Doxorubicin|60 mg/m\^2 of doxorubicin by IV Infusion
219219870|NCT06132958|DRUG|Paclitaxel|80 mg/m\^2 of paclitaxel by IV infusion
219094064|NCT05673590|DRUG|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
219094065|NCT02012192|DRUG|Ganetespib|
219094066|NCT02012192|DRUG|Paclitaxel|
219094067|NCT00959062|DRUG|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
219094068|NCT00959062|DRUG|placebo|Preparation visually identical to clonidine.
219094069|NCT02985762|DRUG|EXPAREL|
219094070|NCT01746043|DRUG|Armodafinil|150 mg by mouth once a day for 6 weeks.
219094071|NCT01746043|OTHER|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
219094072|NCT01746043|DRUG|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
219094073|NCT01746043|BEHAVIORAL|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
219094074|NCT04761276|DEVICE|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
219094075|NCT01191840|DRUG|Vancomycin|Duration
219094076|NCT01191840|DRUG|Vancomycin|Duration
219219871|NCT06132958|DRUG|Nab-paclitaxel|100 mg/m\^2 of nab-paclitaxel by IV infusion
219219872|NCT02362035|DRUG|Acalabrutinib|Orally Administered (PO)
219219873|NCT02362035|DRUG|Pembrolizumab|Intravenous Administered (IV)
219219874|NCT04063215|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
219219875|NCT05943652|DIAGNOSTIC_TEST|Neurological examination|A neurological examination following a protocol to detect positive signs of functional neurological disorders.
219219876|NCT05943652|DIAGNOSTIC_TEST|Anamnesis|"A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?"
219219877|NCT05943652|DIAGNOSTIC_TEST|Neuropsychological testing|"Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests"
219362119|NCT05397990|BEHAVIORAL|Exercise|12 weeks of moderate intensity exercise, three times a week.
219219878|NCT05943652|DIAGNOSTIC_TEST|Questionnaires|"* Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)"
219219879|NCT05943652|DIAGNOSTIC_TEST|Tremor recording|Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
219219880|NCT06520202|DRUG|rhPRG4 (450 µg/mL)|1-2 drops of rhPRG4 450 µg/mL solution in both eyes
219094077|NCT03271476|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
219219881|NCT06520202|DRUG|Vehicle|Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
219219882|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
219219883|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
219219884|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
219219885|NCT05985681|PROCEDURE|Biospecimen Collection|Undergo blood sample and vaginal swab collection
219219886|NCT05985681|BIOLOGICAL|HPV16 RG1 VLP Vaccine|Given IM
219219887|NCT05985681|OTHER|Questionnaire Administration|Ancillary studies
219219888|NCT05985681|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
219219889|NCT04103983|DEVICE|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
219219890|NCT04497727|OTHER|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
219219891|NCT06022393|BEHAVIORAL|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
219219892|NCT06022393|BEHAVIORAL|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
219219893|NCT06641414|DRUG|Lisaftoclax (APG-2575)|QD, oral administration.
219219894|NCT06641414|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection.
219219895|NCT06641414|OTHER|Placebo|QD, oral administration.
219219896|NCT06003426|DRUG|BMS-986278|Specified dose on specified days
219219897|NCT06003426|DRUG|BMS-986278 Placebo|Specified dose on specified days
219219898|NCT04098393|DRUG|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
219219899|NCT04098393|DRUG|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
219219900|NCT04098393|DRUG|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
219219901|NCT04098393|DRUG|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
219219902|NCT04098393|DRUG|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
219219903|NCT04098393|PROCEDURE|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
219219904|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
219219905|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
219219906|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
219219907|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
219219908|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
219219909|NCT04250194|DEVICE|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
219219910|NCT04250194|DEVICE|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
219219911|NCT06462222|DRUG|Toripalimab, pemetrexed|Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
219219912|NCT05426733|DRUG|Odevixibat|Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
219219913|NCT06441786|BEHAVIORAL|A metacognitive group therapy of depression and anxiety in youth with autism|"The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions."
219219914|NCT06001788|DRUG|Ziftomenib|Oral administration
219219915|NCT06001788|DRUG|Fludarabine|Intravenous infusion
219219916|NCT06001788|DRUG|Idarubicin|Intravenous infusion
219219917|NCT06001788|DRUG|Cytarabine|Intravenous Infusion
219219918|NCT06001788|DRUG|Gilteritinib|Oral administration
219219919|NCT06001788|BIOLOGICAL|Granulocyte colony-stimulating factor|Subcutaneous injection
219219920|NCT06049017|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
219219921|NCT06049017|DRUG|Placebo|Placebo tablet will be administered orally.
219219922|NCT06049953|DRUG|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
219219923|NCT06049953|DRUG|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
219219924|NCT06049953|OTHER|No Medication|Non-psychotropic medications
219219925|NCT05460715|DEVICE|Quadra P anteverted|"* Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~* Assessment of functional recovery by gait analysis study~* Collect the rate of complications throughout the course of the study"
219094078|NCT05912140|OTHER|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
219094079|NCT01392300|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
219094080|NCT01392300|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
219094081|NCT00118781|DRUG|iseganan hydrochloride|
219094082|NCT02938169|BEHAVIORAL|exercise|"* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)"
219219926|NCT02245997|RADIATION|External beam radiotherapy|
219219927|NCT02245997|RADIATION|proton beam RT|
219219928|NCT04144335|BIOLOGICAL|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
219219929|NCT04144335|BIOLOGICAL|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
219219930|NCT00229658|DRUG|pramlintide acetate|Subcutaneous injection prior to each major meal
219219931|NCT00249769|BIOLOGICAL|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
219219932|NCT00249769|BIOLOGICAL|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
219219933|NCT06060119|DEVICE|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
219219934|NCT01630226|DRUG|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
219219935|NCT04337944|PROCEDURE|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
219219936|NCT06170619|DEVICE|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
219550286|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
219550287|NCT06628154|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
219219937|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
219094083|NCT04539457|BEHAVIORAL|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
219219938|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
219219939|NCT03389789|OTHER|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
219219940|NCT03389789|OTHER|Breastfeeding|Infants will be breastfed
219219941|NCT03389789|OTHER|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
219219942|NCT03389789|OTHER|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
219219943|NCT01862016|PROCEDURE|APRV|Pressure ventilation mode allowing early spontaneous breathing
219219944|NCT01862016|BIOLOGICAL|arterial blood gas measurement each morning|
219219945|NCT04558723|OTHER|ICD/CRT-D implantation|ICD/CRT-D implantation (if indicated)
219219946|NCT05055700|BEHAVIORAL|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
219219947|NCT05623982|DRUG|GNC-038|Administration by intravenous infusion
219219948|NCT01953224|BEHAVIORAL|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
219219949|NCT01953224|DEVICE|Smartphone|
219219950|NCT05136196|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
219219951|NCT05136196|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219219952|NCT05136196|DRUG|Cabozantinib S-malate|Given PO
219219953|NCT05136196|PROCEDURE|Computed Tomography|Undergo CT scans
219219954|NCT05136196|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
219219955|NCT05136196|BIOLOGICAL|Nivolumab|Given IV
219219956|NCT03277404|PROCEDURE|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
219219957|NCT03277404|PROCEDURE|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
219219958|NCT00210275|BEHAVIORAL|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
219219959|NCT04886349|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
219219960|NCT04104672|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
219219961|NCT04104672|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
219219962|NCT04104672|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
219094084|NCT04539457|BEHAVIORAL|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
219094085|NCT04143984|DRUG|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
219094086|NCT04143984|RADIATION|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
219094087|NCT04143984|DRUG|Camrelizumab|An anti-PD-1 antibody.
219094088|NCT02923063|BEHAVIORAL|Combined Aerobic and Resistance Exercise via videoconferencing|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
219094089|NCT06783374|PROCEDURE|Neuromodulation|A protocol of posterior tibial nerve electrostimulation will be implemented, inducing retrograde electrostimulation through the pelvic nerves, which are connected to the spinal cord via the sacral plexus at segments S2 and S3. It is recommended to conduct an average of 10 sessions to evaluate the efficacy of the treatment, within a range of 6 to 16 sessions, each lasting 30 minutes, completing a treatment period of 3 months.
219094090|NCT06783374|PROCEDURE|Exercise|Participants will engage in a 60-minute exercise session, divided into two blocks: Block 1 will comprise 10 to 12 repetitions per set, aiming to achieve a perceived exertion level of 7 to 10 on the rating of perceived exertion (RPE). Block 2 will utilize the 5P® LOGSURF Method, termed Proprioceptive Perineal Postural Reeducation, which employs unstable positions to promote postural adjustment and continuous balance. This approach facilitates the activation of the abdominopelvic muscles, enhancing control and strengthening of the pelvic-perineal region.
219094091|NCT06783374|PROCEDURE|Exercise control group|Exercise The control group engages in specific pelvic floor exercises, which are less complex in terms of neuromuscular processing, such as Kegel's exercise. The protocol for these exercises is standardized and conducted individually, comprising 8 to 12 sessions of 20-40 minutes each, performed twice weekly.
219219963|NCT04104672|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
219219964|NCT01895582|OTHER|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
219219965|NCT04817059|DEVICE|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
219219966|NCT05515146|DIAGNOSTIC_TEST|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
219219967|NCT02505750|RADIATION|3D conformal EBRT|External Beam Radiation Therapy
219219968|NCT02505750|DEVICE|Contact X-ray brachytherapy 50 kV|
219219969|NCT02505750|DRUG|Capecitabine|
219219970|NCT02586857|DRUG|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
219219971|NCT05459948|DEVICE|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
219219972|NCT06403280|DIETARY_SUPPLEMENT|Alcoholic drink|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
219219973|NCT06403280|DIETARY_SUPPLEMENT|Placebo drink|Participants will receive a non-alcoholic rum flavored orange juice.
219219974|NCT03288207|DEVICE|Step it Up mobile app|Step it Up mobile app
219219975|NCT03288207|DEVICE|Global Positioning System (GPS) Device|Global Positioning System (GPS) Device
219219976|NCT03288207|DEVICE|Bluetooth-enabled scale|Bluetooth-enabled scale
219219977|NCT03288207|DEVICE|Bluetooth-enabled glucometer|Bluetooth-enabled glucometer
219219978|NCT03288207|DEVICE|MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH)|Image Reconstruction and Analysis Software
219219979|NCT03288207|DEVICE|MRI: Research pulse sequences (Device Manufacturer: NIH)|pulse sequences
219219980|NCT03288207|DEVICE|MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.)|radiofrequency coils
219219981|NCT03288207|DEVICE|AMRA Researcher Image reconstruction software|Image reconstruction software
219362120|NCT05070377|OTHER|Physical activity|"1. structured physical activity sessions by physical education (school), twice a week, with twenty-minute each lesson;~2. self-monitoring plus goal setting by pedometer (out-of-school), progressive goals to achieve weekly;~3. healthy lifestyle guidance ( parents social support)."
219094092|NCT06783374|PROCEDURE|Sham Neuromodulation|A needle with a retractable handle will be used, commonly employed in experimental research with Streitberger and Kleinhenz placebo needles. This creates the appearance of insertion without penetrating the skin and allows the needles to remain in place for the duration of the intervention.
219094093|NCT03799068|OTHER|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
219094094|NCT03799068|OTHER|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
219094095|NCT01341002|PROCEDURE|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
219094096|NCT01341002|PROCEDURE|Transfusion|transfusion based on guidelines
219219982|NCT06121479|DRUG|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
219219983|NCT02694783|BIOLOGICAL|PyVST|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
219219984|NCT06079671|BIOLOGICAL|Volrustomig|IV Infusion
219219985|NCT06079671|OTHER|Placebo|IV Infusion
219219986|NCT06467799|DRUG|Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1|Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
219219987|NCT05477524|BIOLOGICAL|VLA15|Shot in the deltoid muscle (preferable in the nondominant arm)
219219988|NCT05477524|OTHER|Saline|Shot in the deltoid muscle (preferable in the nondominant arm)
219219989|NCT06456190|BEHAVIORAL|Skills Training in Active Recovery (STAR) Video|a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
219219990|NCT06456190|BEHAVIORAL|Text Skills Training in Active Recovery (TextSTAR) program|a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
219219991|NCT06634277|BEHAVIORAL|NavSTAR (Philly adaptation)|Patient Navigation
219094097|NCT00980317|PROCEDURE|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
219094098|NCT01802437|DRUG|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
219094099|NCT01802437|BEHAVIORAL|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
219219992|NCT06534437|DRUG|MEN1703|MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
219219993|NCT06534437|DRUG|Glofitamab|Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
219219994|NCT06223542|PROCEDURE|Biopsy Procedure|Undergo biopsy
219219995|NCT06223542|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219219996|NCT06223542|PROCEDURE|Computed Tomography|Undergo CT
219219997|NCT06223542|PROCEDURE|Echocardiography Test|Undergo ECHO
219219998|NCT06223542|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219219999|NCT06223542|DRUG|UAE Inhibitor TAK-243|Given IV
219361750|NCT05275569|PROCEDURE|Sham acupuncture + standard antiemetic treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group)."
219550288|NCT06628154|OTHER|Placebo|Single tablet encapsulated identically to losartan
219094100|NCT01802437|BEHAVIORAL|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
219094101|NCT02582346|PROCEDURE|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
219220000|NCT06962930|OTHER|8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions|The first session will lay the groundwork for the program, in which an orientation of the features of the online forum will be provided. In addition, goal setting, use of watches, and how to track progress will be discussed. During the remote sessions, the participant and coach will work through informational modules of how to overcome barriers to exercise engagement and how to manage PD symptoms. In addition, the coach will provide encouragement in relation to regular physical activity and exercise, and the participant will report on progress related to up to three realistic and individualized goals they developed. key elements: (1) participant-therapist interaction, (2) online forum featuring a physical activity guidebook and workbook, (3) an online platform with personal physical activity database, (4) a wearable smart watch for activity monitors, (5) a video exercise library, (6) online support group, and (7) incorporate adaptation to Arabic culture and available in Arabic
219220001|NCT06350903|OTHER|Fast + High-fat low-carbohydrate diet|Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
219220002|NCT06350903|COMBINATION_PRODUCT|Fast + Empagliflozin|Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
219094102|NCT06426017|OTHER|High Protein Low Calorie Dietary Intervention|High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
219094103|NCT05801731|OTHER|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
219094104|NCT05801731|OTHER|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
219220003|NCT04280289|DRUG|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
219094105|NCT04025151|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
219094106|NCT04025151|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
219094107|NCT04025151|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
219220004|NCT04026776|DRUG|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
219220005|NCT04026776|OTHER|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
219220006|NCT05902013|DEVICE|laryngoscopy|laryngoscopy for nasotracheal intubation
219220007|NCT06181435|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
219220008|NCT06181435|DRUG|Placebo|"Pharmaceutical form:~Injection solution Route of administration: SC injection"
219220009|NCT06546553|DRUG|PF-07826390|PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors
219220010|NCT06546553|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
219220011|NCT06546553|OTHER|SOC (anti-PD-1 + platinum -based chemo)|Standard of Care (anti-PD-1 + platinum -based chemo)
219220012|NCT03745313|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
219220013|NCT04567784|DRUG|Cannabidiol (CBD)|CBD 800 mg Cannabidiol - oral CBD solution
219220014|NCT04567784|DRUG|Placebo|inactive solution
219220015|NCT02748408|DEVICE|SMS femoral stem|
219220016|NCT05460676|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
219220017|NCT05460676|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
219220018|NCT05460676|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
219362121|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
219362122|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
219220019|NCT04753190|BEHAVIORAL|Baseline Sleep Satiation and Phase Stabilization|All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
219094108|NCT04025151|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
219094109|NCT04025151|BEHAVIORAL|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
219094110|NCT04025151|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
219094111|NCT02427659|BEHAVIORAL|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
219094112|NCT02427659|BEHAVIORAL|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
219220020|NCT04753190|BEHAVIORAL|Gradually Shifted Sleep|For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
219220021|NCT06852664|BEHAVIORAL|Motivational Interviewing|The participants will meet with the research staff three times a week during the eight weeks of wearing the activity monitor via video or Webex call with a duration ideally not exceeding one hour. All staff involved in these coaching sessions have been MINT trained and certified and have mastered the skills of motivational interviewing. Their goal will be to discuss with the participant about how successful they have been or not been in increasing their daily step count and movement and discussing the barriers preventing them from achieving that goal. Open-ended questions, affirmations, reflections, summaries, balancing change and sustain talk, and eliciting change behavior will all be used accordingly during the sessions. Coaching is tied to the overall results in investigating if motivational interviewing and coaching are effective in increasing movement in populations with cerebral palsy.
219220022|NCT03901755|DRUG|Alprolix|Extended half-life factor IX product
219220023|NCT05154851|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
219362123|NCT06499987|PROCEDURE|resection anastomosis|resection of stenotic part of trachea and reanastmosis
219094113|NCT02427659|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
219094114|NCT03168295|DRUG|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
219094115|NCT03168295|DRUG|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
219094116|NCT04131270|BEHAVIORAL|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
219362124|NCT02280278|PROCEDURE|Radical surgery|
219362125|NCT02280278|DRUG|Adjuvant chemotherapy|
219362126|NCT02280278|BIOLOGICAL|Cytokine-induced killer cell immunotherapy|
219362127|NCT02945631|RADIATION|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
219094117|NCT04131270|BEHAVIORAL|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
219362128|NCT02945631|RADIATION|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
219094118|NCT04709172|DRUG|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
219094119|NCT01519492|DRUG|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
219094120|NCT00002420|DRUG|Emivirine|
219094121|NCT00002420|DRUG|Hydroxyurea|
219094122|NCT00002420|DRUG|Delavirdine mesylate|
219094123|NCT00002420|DRUG|Stavudine|
219094124|NCT00002420|DRUG|Didanosine|
219094125|NCT02945332|BEHAVIORAL|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
219362129|NCT00318760|DRUG|Clonidine|0.1 or 0.2 mg oral, one dose
219094126|NCT02945332|BEHAVIORAL|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
219094127|NCT02945332|DEVICE|Fitbit Flex|
219220024|NCT04248322|BEHAVIORAL|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
219220025|NCT06557850|DRUG|Lu AG22515|Solution for infusion
219220026|NCT05988645|DEVICE|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
219220027|NCT05516992|DRUG|SB-01 For Injection|Intradiscal injection
219220028|NCT05516992|DRUG|Sham Needle|Sham needle placement
219220029|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
219220030|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
219220031|NCT04235777|RADIATION|Stereotactic body radiation therapy (SBRT)|A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC
219220032|NCT04235777|DRUG|PDS01ADC|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
219220033|NCT04235777|DRUG|M7824|1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
219220034|NCT05208567|DIAGNOSTIC_TEST|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
219220035|NCT06558643|DRUG|MMV371 LAI|Single intra-muscular dose
219220036|NCT06558643|DRUG|Placebo for MMV371|Single intramuscular dose
219220037|NCT03147885|DRUG|Selinexor|Given PO
219220038|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
219220039|NCT05825287|OTHER|Management training|Management training
219220040|NCT03415828|DEVICE|Ethanol gel|Intradiscal injection of ethanol gel
219220041|NCT03415828|DRUG|Prednisolone acetate|Intradiscal infiltration of steroids
219220042|NCT04956081|DEVICE|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
219220043|NCT06188910|OTHER|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
219220044|NCT06188910|OTHER|Health education|Health education on mobile phone addiction
219220045|NCT03516812|OTHER|Laboratory Biomarker Analysis|Correlative studies
219220046|NCT03516812|DRUG|Olaparib|Given PO
219220047|NCT03516812|OTHER|Quality-of-Life Assessment|Ancillary studies
219220048|NCT03516812|OTHER|Survey Administration|Ancillary studies
219220049|NCT03516812|DRUG|Testosterone Enanthate|Given IM
219220050|NCT03516812|DRUG|Testosterone Cypionate|Given IM
219220051|NCT04064957|BIOLOGICAL|HB-adMSCs|
219220052|NCT05100004|DEVICE|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
219220053|NCT05100004|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
219220054|NCT06042751|BEHAVIORAL|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
219220055|NCT06042751|BEHAVIORAL|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
219094128|NCT02742298|DEVICE|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
219220056|NCT04870944|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219220057|NCT04870944|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
219220058|NCT04870944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219220059|NCT04870944|PROCEDURE|Echocardiography Test|Undergo ECHO
219220060|NCT04870944|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IV
219220061|NCT04763759|DRUG|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
219094129|NCT02742298|OTHER|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
219094130|NCT06448338|BEHAVIORAL|MyDiaMate|MyDiaMate program
219094131|NCT03200106|DEVICE|Alfapump|Alfapump implant
219094132|NCT03517592|OTHER|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
219094133|NCT03517592|OTHER|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
219220062|NCT03890289|DRUG|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
219220063|NCT03890289|DRUG|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
219220064|NCT06447415|DRUG|HRS-7450|HRS-7450 Injection
219220065|NCT06447415|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection
219220066|NCT05741060|DRUG|S-equol|Experimental drug
219220067|NCT05741060|DRUG|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
219220068|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
219220069|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
219220070|NCT05963984|DRUG|Samuraciclib|Samuraciclib tablet by mouth once a day
219220071|NCT05963984|DRUG|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
219094134|NCT01927679|DRUG|Vitamin E|
219094135|NCT01927679|DRUG|Eucerin|Control
219094136|NCT03114202|OTHER|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
219094137|NCT03114202|OTHER|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
219094138|NCT02331602|DRUG|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
219094139|NCT02331602|DRUG|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
219220072|NCT06564194|BIOLOGICAL|JCXH-108|IM injection
219220073|NCT06564194|OTHER|Placebo|IM injection
219220074|NCT04239989|DRUG|Itacitinib|Given PO
219220075|NCT04239989|DRUG|Itacitinib Adipate|Given PO
219220076|NCT06413498|DRUG|Anitocabtagene Autoleucel|A single infusion of CAR+ transduced autologous T cells
219220077|NCT06413498|DRUG|Cyclophosphamide|Administered intravenously
219220078|NCT06413498|DRUG|Fludarabine|Administered intravenously
219220079|NCT06413498|DRUG|Pomalidomide|Tablet administered orally
219220080|NCT06413498|DRUG|Bortezomib|Administered intravenously or subcutaneously
219220081|NCT06413498|DRUG|Dexamethasone|Tablet administered orally
219220082|NCT06413498|DRUG|Daratumumab|Administered intravenously or subcutaneously
219220083|NCT06413498|DRUG|Carfilzomib|Administered intravenously
219220084|NCT06569082|DEVICE|CD34+ Selected Donor Cell Boost|The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
219220085|NCT06569082|PROCEDURE|Blood Stem Cell Infusion|The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
219220086|NCT06062628|DRUG|Ketamine Hydrochloride|Administration of ketamine with subsequent measurement of intracranial pressure and brain tissue oxygenation
219220087|NCT05237960|PROCEDURE|Biopsy|Undergo biopsy
219220088|NCT05237960|PROCEDURE|Biospecimen Collection|Correlative studies
219220089|NCT05237960|DRUG|Extended Release Metformin Hydrochloride|Given PO
219220090|NCT05237960|DRUG|Placebo Administration|Given PO
219220091|NCT04706429|DRUG|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
219220092|NCT04706429|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
219362130|NCT00318760|DRUG|Placebo|oral capsule 1 dose
219220093|NCT04929795|BEHAVIORAL|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
219094140|NCT03756584|DEVICE|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
219682492|NCT05080725|OTHER|TelePEPP intervention|TelePEPP sessions will be conducted twice per week by a Speech Language Pathologist and/or graduate student clinician, on the study team. This clinician will deliver the intervention from the NYU Voice Center using the web conferencing software Webex (institutional license) on a Dell desktop computer with a 3.1 GHz intel core processor and high definition camera. Each exercise set will include 40 repetitions (10 reps of effortful swallows, tongue hold swallows, effortful pitch glides and maximal posterior tongue presses). All exercises are widely-adopted by clinicians as standard of care exercises. The number of sets will be gradually increased as tolerance builds \[2 sets in week 1, 3 sets in week 2, 4 sets in weeks 3+\].
219682493|NCT03229317|OTHER|Plethysmography|Lung plethysmography
219094141|NCT04194203|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
219094142|NCT04194203|DRUG|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
219094143|NCT04194203|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219094144|NCT04194203|DRUG|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
219094145|NCT04194203|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
219094146|NCT04194203|DRUG|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
219094147|NCT01342458|OTHER|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
219220094|NCT04929795|BEHAVIORAL|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
219220095|NCT05896865|RADIATION|Whole breast / chest wall & regional lymph node irradiation|Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
219220096|NCT05896865|RADIATION|Internal mammary or supraclavicular lymph node boost|Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
219220097|NCT05878717|BIOLOGICAL|Belimumab|Belimumab will be administered.
219220098|NCT05878717|OTHER|Placebo|.Placebo will be administered.
219220099|NCT04270734|PROCEDURE|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
219220100|NCT04270734|PROCEDURE|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
219220101|NCT06370988|DEVICE|iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
219094148|NCT01177514|DRUG|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
219094149|NCT01177514|DRUG|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
219094150|NCT05138445|BEHAVIORAL|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
219220102|NCT06370988|DEVICE|Sham iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
219220103|NCT01981603|OTHER|navigator|
219220104|NCT04477707|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
219220105|NCT02075723|DIETARY_SUPPLEMENT|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
219220106|NCT02075723|BEHAVIORAL|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
219220107|NCT02227134|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
219682494|NCT02870764|DRUG|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
219094151|NCT05138445|BEHAVIORAL|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
219094152|NCT05838001|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
219220108|NCT01226316|DRUG|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
219094153|NCT05838001|PROCEDURE|marker clip localization|Positioning marker clip in the center of the breast lesion
219094154|NCT01682213|DRUG|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
219094155|NCT05570643|DRUG|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
219094156|NCT05570643|DRUG|Placebo|Injection of NaCl 0.9%.
219094157|NCT01891448|OTHER|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
219094158|NCT01891448|OTHER|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
219094159|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
219094160|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
219094161|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
219220109|NCT01226316|DRUG|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
219220110|NCT01226316|DRUG|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
219220111|NCT01226316|DRUG|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
219220112|NCT02867059|DRUG|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20\_SJ733\_Challenge Protocol\_v2.0\_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
219094162|NCT03645902|DIAGNOSTIC_TEST|Magnetic resonance imaging|
219094163|NCT02388503|DIETARY_SUPPLEMENT|no added fruit extract|
219094164|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
219094165|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
219094166|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
219094167|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
219094168|NCT05687955|OTHER|Hip Exercise Program|The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
219094169|NCT00742079|DRUG|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
219094170|NCT00742079|BEHAVIORAL|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
219094171|NCT01181726|DRUG|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
219094172|NCT01181726|DRUG|Activella®|1 mg/0.5 mg Tablets
219094173|NCT03963154|BIOLOGICAL|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
219094174|NCT03767179|DIAGNOSTIC_TEST|study|procalcitonin, sedimentation, CRP, leukocyte identification
219094175|NCT03430193|OTHER|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
219094176|NCT03430193|OTHER|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
219094177|NCT06453655|BEHAVIORAL|Nursing Process|In the first step of the nursing process, nursing diagnoses NANDA-I and nursing outcomes (NOC) appropriate to the needs of the individual were selected. Immediately afterwards, the baseline measurements of NOCs were made. In the second stage, nursing interventions were determined in line with the selected diagnoses and started to be implemented. Instructions for the implementation of the selected NICs were reminded by phone 3 days before the procedure appointment and compliance with colonoscopy preparation instructions was monitored. In the third stage, after measurement of the NOCs were performed on the day of the procedure. In addition, the BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form and the stages of the nursing process were completed.
219094178|NCT01638247|DRUG|Tamoxifen|25 mg daily.
219220113|NCT05251844|OTHER|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
219220114|NCT05273944|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
219220115|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
219220116|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
219220117|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
219220118|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
219220119|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
219220120|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
219220121|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
219220122|NCT05159453|BIOLOGICAL|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
219220123|NCT05159453|DEVICE|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
219220124|NCT02806674|DEVICE|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
219220125|NCT02806674|DEVICE|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
219094179|NCT01638247|DRUG|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
219220126|NCT00238901|DRUG|Basiliximab|
219220127|NCT00274261|DRUG|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
219220128|NCT00274261|DRUG|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
219220129|NCT02426138|OTHER|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
219220130|NCT02426138|OTHER|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
219220131|NCT03387189|OTHER|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
219220132|NCT06966778|DRUG|Oxybutynin chloride extended-release tablets 5mg/tab, 2 tab, PO, qd.|"The intervention being studied is oxybutynin chloride extended-release tablets (Oxbu), a muscarinic antagonist that is used to manage overactive bladder symptoms, including urinary incontinence. In this study, it is specifically evaluated for its potential to improve early continence recovery following robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.~This formulation is an extended-release version of oxybutynin, which allows for a slower, sustained release of the drug over time, ensuring more consistent therapeutic effects with reduced side effects compared to immediate-release formulations. The intervention involves a daily dose of 10 mg, administered as two 5 mg tablets, to assess its impact on postoperative continence recovery.~The key distinction of this intervention is its focus on improving continence recovery after prostate cancer surgery, specifically through its targeted use in early post-surgical recovery, making it different from othe"
219220133|NCT06966778|DRUG|Placebo (2 tab), PO, qd.|placebo, which is designed to look identical to the active drug but contains no therapeutic ingredient.
219220134|NCT06967597|PROCEDURE|Cholecystoscopy and gallbladder cleaning|"Upper gastrointestinal endoscopy and cholecystoscopy are performed 4 weeks after GB drainage. A standard gastroscope is used to inspect the gallbladder cavity with retrieval or lithotripsy of residual stones until complete cleaning of the GB is achieved. Several procedures may be required to achieve complete stone clearance.~Finally, the LAMS is retrieved and replaced with a double pigtail plastic stent."
219220135|NCT04071106|DRUG|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
219220136|NCT04071106|DRUG|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
219220137|NCT04071106|DRUG|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
219220138|NCT04071106|DEVICE|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
219220139|NCT04071106|DRUG|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
219220140|NCT00410254|DRUG|HCV-796|
219094180|NCT01638247|DRUG|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
219094181|NCT02267005|DIETARY_SUPPLEMENT|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
219094182|NCT02267005|DIETARY_SUPPLEMENT|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
219094183|NCT03606356|DRUG|Onabotulinum toxin A|Cranial Subcutaneous Injections
219094184|NCT05118633|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
219094185|NCT05118633|BEHAVIORAL|Reminder bracelet and journaling app control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
219094186|NCT03219385|DEVICE|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
219094187|NCT04687735|OTHER|Intervention after nerve block|Brachial plexus block + Physical therapy
219094188|NCT02000830|DRUG|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
219094189|NCT02000830|DRUG|Placebo|Matching placebo administered by IM injection
219220141|NCT00410254|DRUG|midazolam|
219220142|NCT00371670|DRUG|balicatib (AAE581)|
219220143|NCT04674813|DRUG|CC-95266|Specified dose on specified days
219220144|NCT04674813|DRUG|Fludarabine|Specified dose on specified days
219220145|NCT04674813|DRUG|Cyclophosphamide|Specified dose on specified days
219220146|NCT04674813|DRUG|Bendamustine|Specified dose on specified days
219361751|NCT01046695|DEVICE|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
219094190|NCT00509418|DIETARY_SUPPLEMENT|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
219220147|NCT05549102|BEHAVIORAL|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
219220148|NCT05549102|OTHER|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
219220149|NCT03292133|DRUG|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
219220150|NCT03292133|DRUG|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
219220151|NCT02260024|OTHER|High fat, high caloric meal|
219220152|NCT02260024|DRUG|Pramipexole IR tablets|
219220153|NCT02260024|DRUG|Pramipexole SR C|
219220154|NCT02260024|DRUG|Pramipexole SR C2|
219220155|NCT02260024|DRUG|Pramipexole SR C2A|
219220156|NCT02260024|DRUG|Pramipexole SR C2B|
219220157|NCT04707001|OTHER|Catheterization based on ultrasound|Bladder volume ultrasound
219094191|NCT00509418|OTHER|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
219220158|NCT04707001|OTHER|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
219220159|NCT00281892|BIOLOGICAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
219220160|NCT00281892|DRUG|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
219220161|NCT04381949|PROCEDURE|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
219220162|NCT06294756|OTHER|Inhalation of Sulfurous Thermal Water|Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
219220163|NCT06294756|OTHER|Inhalation of Sterile Distilled non-pyrogenic Water|Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
219094192|NCT03688152|DRUG|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
219220164|NCT01765374|DEVICE|ESAOTE MyLab60|US evaluation at different time points
219220165|NCT01765374|DRUG|Rituximab|
219094193|NCT03688152|DRUG|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
219094194|NCT06257368|DEVICE|Coloplast TFL Drive|Thulium Fiber laser
219094195|NCT01264380|DRUG|RO5185426|Single oral dose, fasted
219220166|NCT00091988|BEHAVIORAL|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
219220167|NCT00091988|BEHAVIORAL|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
219220168|NCT01672333|DRUG|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
219220169|NCT00291694|DRUG|celecoxib|Celecoxib 400 mg BID
219220170|NCT00291694|OTHER|placebo|placebo
219220171|NCT04149119|DEVICE|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
219220172|NCT02816398|DEVICE|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
219220173|NCT03658109|DRUG|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
219220174|NCT03658109|PROCEDURE|QL block|Patients will undergo a posterior QL block pre-operatively
219220175|NCT03658109|DRUG|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
219220176|NCT03658109|PROCEDURE|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
219220177|NCT02813525|OTHER|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
219220178|NCT03440996|OTHER|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
219220179|NCT03440996|OTHER|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
219220180|NCT03440996|OTHER|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
219220181|NCT06466512|BEHAVIORAL|Midwifery-embodied care|The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
219220182|NCT00401479|DRUG|Placebo|
219220183|NCT00401479|DRUG|Solabegron (GW427353)|
219220184|NCT02262299|DRUG|Pirfenidone|Receive tablets with pirfenidone
219220185|NCT02262299|DRUG|Placebo|Recieve tablets with placebo
219094196|NCT01264380|DRUG|RO5185426|Single oral dose, with high fat meal
219094197|NCT01264380|DRUG|RO5185426|Continuous administration, orally twice daily
219094198|NCT04269018|BEHAVIORAL|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
219094199|NCT04269018|BEHAVIORAL|General health messages|Daily text related with general health message
219094200|NCT01147822|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
219220186|NCT00343408|DRUG|cediranib maleate|
219220187|NCT00343408|DRUG|cisplatin|
219220188|NCT00343408|DRUG|fluorouracil|
219094201|NCT01147822|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
219094202|NCT01611584|DRUG|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
219094203|NCT04762329|OTHER|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
219094204|NCT06214078|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
219094205|NCT06214078|OTHER|placebo|The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
219094206|NCT01683760|DRUG|Fluconazole|Prophylactic fluconazole administration in VLBW infants
219094207|NCT00530803|DRUG|EMLA Cream|60 minutes x1
219094208|NCT00530803|COMBINATION_PRODUCT|Synera Patch|20 minutes x1
219094209|NCT04210414|OTHER|Embryo transfer|Transfer of only one embryo
219094210|NCT05356598|OTHER|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
219094211|NCT05356598|OTHER|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
219094212|NCT05356598|OTHER|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
219094213|NCT06235658|BEHAVIORAL|Gentle Yoga|Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
219094214|NCT00429663|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
219094215|NCT00429663|DEVICE|locking periarticular plate|Standard of care device for femur fractures
219094216|NCT03590600|DRUG|BTZ-043|Powder and solvent for oral suspension
219094217|NCT03590600|DRUG|Placebo|Matching placebo: powder and solvent for oral suspension
219220189|NCT00343408|DRUG|gemcitabine hydrochloride|
219220190|NCT00343408|DRUG|leucovorin calcium|
219220191|NCT00343408|DRUG|oxaliplatin|
219220192|NCT04217694|BEHAVIORAL|Cogstate Assessment Battery|Complete CogState testing
219220193|NCT04217694|DRUG|Memantine|Given PO
219220194|NCT04217694|DRUG|Memantine Hydrochloride|Given PO
219220195|NCT00231699|PROCEDURE|Plastic wrap (study group) and cotton (control group) wrap.|
219220196|NCT02972424|DRUG|Teriparatide Prefilled Syringe|TPTD 20 mcg
219220197|NCT02972424|DRUG|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
219094218|NCT05383417|DEVICE|EndoClip|Clip attached to mid portion of the endotracheal tube.
219220198|NCT00464893|DRUG|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
219094219|NCT06537011|DRUG|AK112|"1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery."
219094220|NCT05440513|DEVICE|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
219094221|NCT04897425|DEVICE|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
219094222|NCT01373216|DRUG|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
219094223|NCT06843512|OTHER|GLP-1 Medication Initiation|One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
219094224|NCT05130801|DIAGNOSTIC_TEST|pHLIP® ICG NIRF imaging|"Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40."
219094225|NCT03911505|BIOLOGICAL|Cipaglucosidase Alfa|Enzyme Replacement Therapy via intravenous infusion
219094226|NCT03911505|DRUG|Miglustat|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
219094227|NCT00147940|PROCEDURE|Acoustic rhinometry (procedure)|
219094228|NCT01932697|DRUG|Docetaxel|Given IV
219094229|NCT01932697|RADIATION|Hyperfractionation|Undergo hyperfractionated IMRT
219094230|NCT01932697|RADIATION|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
219094231|NCT01932697|OTHER|Laboratory Biomarker Analysis|Correlative studies
219094232|NCT01932697|OTHER|Quality-of-Life Assessment|Ancillary studies
219094233|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
219094234|NCT05557695|DRUG|Acalabrutinib|Acalabrutinib
219094235|NCT02274454|DRUG|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
219220199|NCT00464893|DRUG|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
219220200|NCT00140491|DEVICE|Vision Restoration Therapy (NOVAVISION)|
219220201|NCT06199557|DRUG|Hydroxyurea, Hydroxycarbamide|Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
219361752|NCT03072160|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
219361753|NCT01171456|DRUG|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
219361754|NCT01171456|DRUG|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
219361755|NCT01788007|DRUG|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
219220202|NCT06199557|DRUG|Valproic acid|Valproic acid (VPA) has been used clinically as an anticonvulsant and mood-stabilizing drug. During the last two decades, VPA has been described as a histone deacetylase (HDAC) inhibitor and gained increased interest for use in cancer therapy. VPA is administered orally with available routine measurements of serum levels and has a low toxicity profile.
219220203|NCT06199557|DRUG|6-Mercaptopurine (6-MP)|In 1953, 6-MP was an approved antileukemic agent resulting in remissions in children with acute lymphocytic leukemia (ALL). After adding 6-MP to methotrexate and prednisolone in the treatment regimen, the one-year mean survival of children with ALL was increased from 29% to 50%. 6-MP, even about 70 years after its discovery, remains the standard maintenance therapy once the children are in complete remission.
219220204|NCT03362190|DRUG|Avacincaptad Pegol|Avacincaptad Pegol in combination with Lucentis
219220205|NCT03362190|DRUG|Lucentis|Avacincaptad Pegol in combination with Lucentis
219094236|NCT02274454|DRUG|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
219094237|NCT01815788|DEVICE|Use of a personal sound amplifying device = TeoFirst|
219094238|NCT01079559|DEVICE|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
219094239|NCT01079559|DEVICE|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
219094240|NCT01674309|DRUG|FOLFORINOX|INTRAVENOUS administration
219094241|NCT02609217|OTHER|Questionnaires and interviews|
219094242|NCT01271348|DRUG|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
219094243|NCT01271348|DRUG|placebo|Placebo tablet, q.d.
219220206|NCT04047641|DRUG|Cladribine|Given Intravenous
219220207|NCT04047641|DRUG|Cytarabine|Given Intravenous
219220208|NCT04047641|DRUG|Idarubicin|Given Intravenous
219220209|NCT04047641|DRUG|Quizartinib|Given by mouth
219220210|NCT06971250|DRUG|Capsaicin only (7.6 ng)|Intradermal injection of 7.6 ng capsaicin (0.5 µM, 50 µL) in synthetic interstitial fluid (SIF) without Flupirtine. Used to induce experimental burning pain in the skin.
219094244|NCT01939873|BEHAVIORAL|KRISTELLER|
219220211|NCT06971250|DRUG|Capsaicin + Flupirtine 0.5 µg|Intradermal co-injection of 7.6 ng capsaicin (0.5 µM) and 0.5 µg Flupirtine in 50 µL SIF. Used to assess local analgesic effect of very low-dose Flupirtine on chemically induced pain.
219220212|NCT06971250|DRUG|Capsaicin + Flupirtine 1.2 µg|Intradermal co-injection of 7.6 ng capsaicin and 1.2 µg Flupirtine in 50 µL SIF. Part of dose-response evaluation for peripheral pain inhibition.
219220213|NCT06971250|DRUG|Capsaicin + Flupirtine 3.0 µg|Intradermal co-injection of 7.6 ng capsaicin and 3.0 µg Flupirtine in 50 µL SIF. Intermediate dose in microdose titration series.
219220214|NCT06971250|DRUG|Capsaicin + Flupirtine 7.6 µg|Intradermal co-injection of 7.6 ng capsaicin and 7.6 µg Flupirtine in 50 µL SIF. This is the highest Flupirtine microdose used in the capsaicin model.
219220215|NCT06971250|DRUG|Placebo (SIF only, no capsaicin or Flupirtine)|Intradermal injection of 50 µL synthetic interstitial fluid without capsaicin or Flupirtine. Used as negative control for capsaicin-Flupirtine co-injection conditions.
219220216|NCT06971250|DRUG|Room Temperature Injection (Control)|Intradermal slow infusion of SIF at \~23°C using a programmable pump. No capsaicin or Flupirtine included. Used as baseline control in heat model.
219220217|NCT06971250|DRUG|Heated injection without Flupirtine|Intradermal slow infusion of synthetic interstitial fluid preheated up to \~52°C. No Flupirtine included. Used to induce thermal pain in human skin.
219220218|NCT06971250|DRUG|Heated Injection with Flupirtine 124 µg|Intradermal slow infusion of synthetic interstitial fluid up to \~52°C containing 124 µg Flupirtine. Used to test local analgesic effect of high-dose Flupirtine in heat pain model.
219220219|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app|"A smartphone app has been developed and is in keeping with guideline recommendations for the treatment of e-cigarette products. This app has a user-friendly Graphic User Interface (GUI) to allow users to build their own accounts and individualized contents conveniently, based on the input the users initially provide including e-cigarette use patterns, readiness to quit e-cigarette, beliefs about e-cigarette, nicotine addiction, self-efficacy, other substance use status, and parental or peer e-cigarette use status.~The proposed AI model in this app will learn information from the input data, including progress toward e-cigarette cessation (e,g, changes of readiness of quitting, quit attempts), and additional data including emotional status, stress level, feedback to the previous learning modules, and then predict the result on the fly. Based on the predicted result, the app will send in-time motivational messages and mindfulness training modules."
219220220|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app, but with delayed access|Participants in the control group will be placed on a three-month waitlist. After this period, they will receive access to the same app-based intervention as the immediate intervention group, allowing a comparison between immediate and delayed access.
219220221|NCT06078709|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219220222|NCT06078709|PROCEDURE|Computed Tomography|Undergo CT and PET/CT scan
219220223|NCT06078709|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
219220224|NCT06078709|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
219220225|NCT06078709|DRUG|Fluorouracil|Given IV
219220226|NCT06078709|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219220227|NCT06078709|DRUG|Leucovorin Calcium|Given IV
219220228|NCT06078709|DRUG|Oxaliplatin|Given IV
219220229|NCT06078709|PROCEDURE|Positron Emission Tomography|Undergo PET and PET/CT scan
219220230|NCT06078709|OTHER|Survey Administration|Ancillary studies
219220231|NCT06078709|DRUG|Docetaxel|Given IV
219220232|NCT06078709|BIOLOGICAL|Durvalumab|Given IV
219220233|NCT02707198|DRUG|kefir|4 ounces of kefir 3 times a day, with or without food.
219220234|NCT05555485|DEVICE|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
219220235|NCT05555485|DEVICE|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
219220236|NCT05250414|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
219220237|NCT01174108|DEVICE|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
219220238|NCT01174108|OTHER|Donor derived G-CSF mobilized PBC|Cell Therapy
219220239|NCT06351579|OTHER|Control|This is an observational (registry) study for data collection only. No device or intervention will be used in this study.
219220240|NCT05536804|DRUG|Tirzepatide|Administered SC
219220241|NCT05536804|DRUG|Placebo|Administered SC
219220242|NCT05168085|DIETARY_SUPPLEMENT|Eggs|Providing 1 egg per day fo 6 months to infants
219220243|NCT04785950|DRUG|Low-dose levonorgestrel intrauterine systems (LNG-IUS)|Any low-dose intrauterine system (IUS) marketed in Spain
219220244|NCT01367236|DRUG|standard care|"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"
219220245|NCT01367236|DRUG|novel treatment|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"
219220246|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
219220247|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
219220248|NCT01596413|DRUG|Sancuso|granisetron transdermal system
219220249|NCT01596413|DRUG|IV granisetron|IV
219220250|NCT02350634|DRUG|Flortaucipir F18|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of flortaucipir.
219220251|NCT04205487|BEHAVIORAL|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
219220252|NCT04205487|BEHAVIORAL|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
219220253|NCT02610413|OTHER|Laboratory Biomarker Analysis|Correlative studies
219220254|NCT04241848|DEVICE|Keeogo|A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
219220255|NCT04241848|OTHER|Ambulation training|Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
219220256|NCT03952598|DRUG|HP 13C Pyruvate|Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)
219220257|NCT03952598|DEVICE|3T MRI scanner|Research proton MRS (1H-MRS) followed by DW-MRI
219094245|NCT06304350|DRUG|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
219094246|NCT03298230|BEHAVIORAL|REmotely SuPervised Exercise Training|As described in the Arms section.
219094247|NCT03298230|BEHAVIORAL|Supervised Exercise Training|As described in the Arms section.
219094248|NCT03065296|BEHAVIORAL|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
219094249|NCT03065296|OTHER|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
219094250|NCT00854282|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
219094251|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
219094252|NCT04156165|OTHER|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
219094253|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Control|Lighter life VLCD products
219094254|NCT04156165|OTHER|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
219094255|NCT03848702|DEVICE|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
219094256|NCT02311205|PROCEDURE|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
219094257|NCT02311205|DRUG|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
219094258|NCT05093387|DRUG|Carboplatin|Given IV
219094259|NCT05093387|BIOLOGICAL|Pembrolizumab|Given IV
219094260|NCT05093387|GENETIC|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
219220258|NCT02196623|OTHER|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
219682495|NCT02870764|DRUG|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
219094261|NCT03161457|BIOLOGICAL|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
219094262|NCT03161457|BIOLOGICAL|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
219094263|NCT01226511|DRUG|Duloxetine|Administered orally
219094264|NCT01226511|DRUG|Placebo|Administered orally
219094265|NCT04177225|PROCEDURE|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
219094266|NCT04177225|OTHER|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
219094267|NCT03424590|DEVICE|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
219094268|NCT05605210|DEVICE|Electric stimulation|Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
219094269|NCT05777967|BIOLOGICAL|human autologous synovial stem cells|A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
219094270|NCT02850822|DRUG|Demethylation drug|Demethylation drug,such as Decitabine
219094271|NCT02850822|DRUG|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
219094272|NCT01337986|DRUG|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
219094273|NCT01337986|DRUG|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
219220259|NCT02196623|OTHER|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
219220260|NCT04472767|DRUG|Nivolumab|Given IV
219220261|NCT04472767|DRUG|Ipilimumab|Given IV
219220262|NCT04472767|DRUG|Cabozantinib|Given PO
219220263|NCT04472767|PROCEDURE|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
219220264|NCT05694689|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
219220265|NCT05694689|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
219094274|NCT02835872|OTHER|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
219094275|NCT01815528|DRUG|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10"
219094276|NCT06449092|DIAGNOSTIC_TEST|Lipid profile|carotid intima media thickness
219094277|NCT02344446|OTHER|Skilled Therapy|Active physical therapy treatment
219094278|NCT03113084|BIOLOGICAL|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
219094279|NCT03113084|BIOLOGICAL|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
219094280|NCT00548132|DEVICE|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
219094281|NCT02127086|OTHER|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
219094282|NCT03830203|DRUG|BAT1806|8 mg/kg
219220266|NCT05694689|OTHER|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
219220267|NCT06499441|OTHER|Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
219220268|NCT06499441|OTHER|Preassure release|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
219220269|NCT02484599|BEHAVIORAL|Computerized attention training (CAT)|Three sessions of active computerized attention training.
219094283|NCT03830203|DRUG|Actemra(EU-licensed)|8 mg/kg
219094284|NCT00970125|BEHAVIORAL|video|outline of the goals of care
219094285|NCT03707639|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
219094286|NCT03707639|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
219094287|NCT00273702|DRUG|N-Acetyl Cysteine|
219094288|NCT04061590|DRUG|Cisplatin|Given IV
219094289|NCT04061590|BIOLOGICAL|Pembrolizumab|Given IV
219094290|NCT04061590|DRUG|Pemetrexed|Given IV
219094291|NCT04061590|DRUG|Pemetrexed Disodium|Given IV
219094292|NCT04061590|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219094293|NCT01839422|BEHAVIORAL|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
219094294|NCT01839422|OTHER|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
219094295|NCT01520402|DRUG|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
219094296|NCT06030401|DEVICE|Transthoracic Ultrasound|Sonar of The Chest
219094297|NCT00873236|BIOLOGICAL|bevacizumab|Given IV
219094298|NCT00873236|BIOLOGICAL|recombinant interferon alpha-2a|Given SC
219220270|NCT02484599|BEHAVIORAL|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
219094299|NCT04078737|DRUG|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
219094300|NCT04078737|DRUG|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
219220271|NCT06515457|DIETARY_SUPPLEMENT|Eye Empower|Participants will take three capsules of the Eye Empower supplement daily for three weeks.
219220272|NCT04091178|DIETARY_SUPPLEMENT|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
219220273|NCT04219215|DEVICE|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
219220274|NCT04219215|DEVICE|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
219220275|NCT03925649|BIOLOGICAL|HB-adMSCs|single infusion of HB-adMSCs
219220276|NCT06404723|DIAGNOSTIC_TEST|Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio|to detect their relation to disease activity to use as predective and prognostic tools
219220277|NCT04044781|DRUG|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
219220278|NCT01161953|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
219220279|NCT06197724|DEVICE|Magnetocardiography|Magnetocardiography
219220280|NCT06994559|OTHER|Preferred Music|The self-selected preferred music intervention will expose participants to music chosen based on personal tastes. Patients will be instructed to compile a playlist lasting approximately 1 hour, but preferably over 1 hour (to avoid repetition or moments without music) of their favorite music. They will be instructed to select songs that they find extremely pleasurable to listen to. Participants will be instructed to select songs that will have a higher likelihood to facilitate relaxation and introspection. This does not need to be an all-time favorite selection, but rather the music that they currently enjoy listening to the most.
219220281|NCT06994559|OTHER|Therapist-selected Music|The therapist-selected music intervention will expose participants to a curated playlist specifically designed for psychedelic treatment by expert Music Therapists, which was used in a previous study to investigate the additive hemodynamic effects of music during ketamine infusions for depression. Patients will be randomly exposed to one of 9 available playlists, all containing songs without lyrics.
219220282|NCT06994559|OTHER|Silence|The silence intervention will expose patients to the same therapeutic procedures, in the same room and context, and with the same noise-cancelling headphones. The purpose is to cancel any potentially perturbing background noise, as no music will be played.
219220283|NCT06990542|RADIATION|Image-guided tumor-focused radiation therapy|Image-guided tumor-focused radiation therapy
219220284|NCT07010107|DRUG|Anaprazole + Rabeprazole placebo|Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
219220285|NCT07010107|DRUG|Rabeprazole + Anaprazole placebo|Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
219220286|NCT06681740|DEVICE|Inspiratory muscle training|The control group will perform a standard cardiac rehabilitation program, consisting of 16 multicomponent exercise sessions, health education, and a weekly group of psychological therapy session. The intervention group will do the same program with the addition of Inspiratory Muscle Training (IMT). The following device will be used: Power Breath model: Medic Classic. The training will be performed by adjusting the device load to 70% of the Maximum Inspiratory Pressure value, performing 1 daily training session 4 days a week of 3 sets of 10 repetitions, with a rest of 3 minutes between sets, during 8 weeks. A physical therapist will teach participants how to use the device on the first day and they will be instructed to perform it at home. They will be given a diary to record their compliance. In addition, once a week the physiotherapist will supervise the execution of the IMT by the participants.
219361756|NCT01788007|DRUG|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
219220287|NCT06681740|DEVICE|Sham Inspiratory muscle training|The control group will be given the same device as experimental group, but the load for all of the participants of the control group will be 5cm de H2O. This load is so low that it´s not able to induce improvement of the inspiratory musculature.
219094301|NCT05358678|DIAGNOSTIC_TEST|cs niche group|"A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness."
219094302|NCT00925405|PROCEDURE|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
219094303|NCT00925405|PROCEDURE|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
219094304|NCT03773458|DEVICE|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
219094305|NCT05181514|OTHER|20% Intralipid|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
219094306|NCT05181514|OTHER|Normal Saline|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
219094307|NCT05404425|PROCEDURE|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
219220288|NCT07015424|DEVICE|TORe with OverStitch|Transoral Outlet Reduction with OverStitch Endoscopic Suturing System
219220289|NCT07015424|BEHAVIORAL|Intensive lifestyle modification|Intensive lifestyle modification program consists of the following: well-balanced calorie-restrictive diet, incorporation of exercise and coaching on lifestyle changes. The program should include personal discussions and goals designed and overseen by the treating physician, obesity management professional or dietician.
219220290|NCT06623240|BIOLOGICAL|allogeneic Hope Biosciences adipose-derived mesenchymal stem cells|"Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)"
219220291|NCT06623240|OTHER|Normal Saline Solution 0.9%|Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)
219220294|NCT07020234|BEHAVIORAL|Epigenetics Video|Educational video about health and epigenetics.
219220295|NCT07020234|BEHAVIORAL|Nanotechnology Video|Educational video about nanotechnology
219220296|NCT07011719|DRUG|Casdatifan|Administered as specified in the treatment arm
219220297|NCT07011719|DRUG|Cabozantinib|Administered as specified in the treatment arm
219220298|NCT07011719|DRUG|Placebo|Administered as specified in the treatment arm
219094308|NCT05404425|PROCEDURE|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
219094309|NCT04711356|DRUG|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
219094310|NCT06284863|DIETARY_SUPPLEMENT|Natritional Education Program In Hemodialysis Patients|Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
219094311|NCT01722162|DRUG|Bevacizumab|
219094312|NCT01722162|DRUG|Capecitabine|
219094313|NCT01722162|DRUG|Levocetirizine|
219094314|NCT04215263|OTHER|Questionaire|Patient was assessed using mini international neuropsychiatric interview
219094315|NCT03124199|DRUG|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
219094316|NCT06281353|DRUG|Curcumin Oral Capsule|Curcumin oral capsule in nano-sized particle.
219094317|NCT06281353|DRUG|Trichloroacetic acid|TCA 90%
219094318|NCT06281353|PROCEDURE|Blood sample collection|HIV and CD4+ 4th generation.
219094319|NCT06281353|PROCEDURE|Cotton swab|Cotton swab for collecting sample from AGW lesions.
219682496|NCT02870764|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
219094320|NCT04034394|OTHER|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
219094321|NCT04034394|OTHER|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
219220299|NCT06328777|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
219361757|NCT01788007|DRUG|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
219361758|NCT00788645|BEHAVIORAL|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
219682497|NCT03433300|DEVICE|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
219682498|NCT03433300|DEVICE|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
219682499|NCT06023862|DRUG|Dostarlimab|Intravenous (IV) infusion
219682500|NCT06023862|DRUG|Bevacizumab|Intravenous (IV) infusion
219682501|NCT06023862|DRUG|Doxorubicin|Intravenous (IV) infusion
219682502|NCT06023862|DRUG|Gemcitabine|Intravenous (IV) infusion
219682503|NCT06023862|DRUG|Paclitaxel|Intravenous (IV) infusion
219094322|NCT06569875|DEVICE|iCARE|iCARE is an internet-based cognitive behavioral therapy program designed for women experiencing symptoms of postpartum depression, including anxiety, irritability, and sadness. The program offers digital therapy through an online platform tailored to mothers with mild to moderate postpartum depression. The program consists of 7 modules, each with its own theme, incorporating cognitive behavioral therapy, a well-established therapeutic approach for depression. The content includes text, images, audio files, and short films, supplemented with small tasks to provide knowledge and tools to understand and manage one's situation. The treatment course is self-directed, allowing participants to engage with the content at their own pace and at times that are most convenient for them
219094323|NCT03086018|DEVICE|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
219682504|NCT06023862|DRUG|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
219220300|NCT06691854|OTHER|The group that applied the Intrapartum Care Model|"Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~A Personal Information form will be applied at the first clinic admission. All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations.~The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
219220301|NCT06874621|DRUG|VY7523|VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau
219094324|NCT04550663|DRUG|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
219094325|NCT02696044|DRUG|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
219094326|NCT02748694|DRUG|TAK-041|TAK-041 tablets or oral suspension.
219094327|NCT02748694|DRUG|TAK-041 Placebo|TAK-041 placebo-matching suspension or tablet.
219094328|NCT00004902|DRUG|tocladesine|
219094329|NCT03166371|DIETARY_SUPPLEMENT|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
219094330|NCT03166371|OTHER|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
219094331|NCT02922894|PROCEDURE|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
219094332|NCT02922894|PROCEDURE|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
219094333|NCT02922894|DRUG|Trazodone|100mg before bedtime
219094334|NCT02922894|DRUG|Placebo|One placebo pill before-bedtime
219220302|NCT06874621|DRUG|Placebo Comparator|Matching placebo to VY7523
219220303|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin(high dose) and Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose.
219220304|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose), Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
219094335|NCT02922894|PROCEDURE|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
219094336|NCT00361101|DRUG|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
219094337|NCT04412044|DRUG|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
219220305|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
219220306|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
219220307|NCT07026968|DRUG|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
219361759|NCT00788645|BEHAVIORAL|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
219361760|NCT02280213|DEVICE|MIL|Direct laryngoscopy 1
219682505|NCT06948617|DEVICE|digital intraoral scanner|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
219094338|NCT00586599|OTHER|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
219094339|NCT03552302|BEHAVIORAL|Yoga|"1. Yoga stretch warm-up exercise for 15 minutes.~2. Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~3. Great rest for 15 minutes"
219094340|NCT04492150|DRUG|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
219094341|NCT04492150|DRUG|Saline|250 mL/hour of normal saline intravenous drip
219094342|NCT00236171|DRUG|Protopic, Advantan|
219094343|NCT00236171|PROCEDURE|Blood and Urine Test|
219094344|NCT00236171|PROCEDURE|coherence tomography|
219220308|NCT07024420|OTHER|Sigh Breaths|Sigh breaths were added by elevating PEEP, targeting a plateau pressure of 35 cmH2O (or 40 cmH2O for patients with a Body Mass Index \> 35 kg/m2). These sigh breaths were administered once every 6 minutes at predefined stages in the perioperative period from the time of anesthesia intubation until endotracheal extubation, postoperative day 7, or death, whichever occurred first, but not during transport. Each sigh consisted of the minimum number of respiratory cycles aimed to achieve a total duration of at least 5 seconds, based on the respiratory cycle duration preset on the ventilator.
219220309|NCT07024420|OTHER|Low Tidal Volume|6-8ml/kg predicted body weight
219094345|NCT03107819|DIAGNOSTIC_TEST|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
219220310|NCT07024420|OTHER|Moderate PEEP|PEEP set according to ARDSnet low PEEP- fraction of inspired oxygen table, FiO2 was set as the lowest fraction targeted to maintain SpO2 ≥ 96%
219094346|NCT02849275|OTHER|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
219220311|NCT07028281|DRUG|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
219220312|NCT07023341|DRUG|BAY3723113|Oral tablet
219220313|NCT07034638|BEHAVIORAL|WNG|In addition to the hospital's standard care protocol, patients in this group will listen to white noise through headphones before and during the colonoscopy procedure, as directed by the researcher.
219094347|NCT02849275|OTHER|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
219094348|NCT01760421|DRUG|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
219094349|NCT02221102|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
219094350|NCT02221102|DRUG|edoxaban|orally active direct factor Xa inhibitor
219094351|NCT02221102|DRUG|placebo|
219094352|NCT02698540|OTHER|Nutritional Supplement|High calorie, high protein peptide based
219094353|NCT00077064|DRUG|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
219094354|NCT01291979|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
219220314|NCT07034638|BEHAVIORAL|PNG|In addition to the standard care protocol, patients included in this group will listen to pink noise through headphones as directed by the researcher.
219220315|NCT07032506|PROCEDURE|Intraoperative placement of an inflated intrauterine pediatric foley catheter|Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon to remain in place for 7-10 days following surgery.
219220316|NCT07032506|PROCEDURE|No Catheter placement|No Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon
219220317|NCT07032506|DRUG|Hormonal Therapy Agent|2 weeks of oral estradiol (2 mg daily) or transdermal (two 0.1 mg patches changed twice weekly) estradiol supplementation followed by 1 week of oral or transdermal estradiol (same dosing as above) with oral medroxyprogesterone acetate (10 mg daily)
219220318|NCT07032506|DRUG|Oral antibiotics|100 mg of oral doxycycline twice daily or other appropriate antibiotic in allergic patients to be given while the intrauterine stent is in place
219094355|NCT01291979|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
219094356|NCT02740322|PROCEDURE|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
219094357|NCT02740322|PROCEDURE|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
219094358|NCT02740322|DEVICE|Audiogram|A standard audiogram will be administered by an audiologist.
219094359|NCT00621543|DEVICE|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
219094360|NCT00730379|DRUG|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
219094361|NCT03607825|DEVICE|Neurapheresis System|CSF filtration system and lumbar catheter
219094362|NCT02206217|DEVICE|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
219094363|NCT04504201|OTHER|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
219094364|NCT01355458|DRUG|CD07805/47 gel|applied topically once daily
219094365|NCT01355458|DRUG|Placebo|applied topically once daily
219094366|NCT02504125|DRUG|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
219094367|NCT02504125|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
219361761|NCT02280213|DEVICE|MAC|Direct laryngoscopy 2
219361762|NCT02280213|DEVICE|WIS|Direct laryngoscopy 3
219361763|NCT02280213|DEVICE|PHIL|Direct laryngoscopy 4
219361764|NCT02287727|OTHER|Laboratory Biomarker Analysis|Correlative studies
219361765|NCT02287727|DRUG|Regorafenib|Given PO
219094368|NCT02093455|DIETARY_SUPPLEMENT|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
219094369|NCT02093455|DIETARY_SUPPLEMENT|Placebo|
219094370|NCT06303076|DRUG|Tizanidine Hcl 4Mg Tab|"Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response."
219094371|NCT06303076|DRUG|Zolpidem Tartrate 10 mg|"nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose."
219094372|NCT00828308|DRUG|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
219094373|NCT00828308|PROCEDURE|Prostatectomy|Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
219220319|NCT06384521|BEHAVIORAL|Lifestyle MIND|Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
219220320|NCT06420492|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.
219220321|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
219220322|NCT04834154|BEHAVIORAL|Control group|Wait list control
219220323|NCT06411418|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
219682506|NCT06948617|DEVICE|Alginate Impression|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
219682507|NCT06955858|DRUG|Recombinant Human Thrombopoietin（rhTPO）|"G-CSF will be administered at a dose of 10 μg/kg/day subcutaneously for 7-10 days post-chemotherapy.~rhTPO is started on the same day as G-CSF at 300 U/kg/d and injected subcutaneously until the stem cell collection was completed."
219094374|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
219094375|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
219094376|NCT04307433|BEHAVIORAL|Storytelling narrative videos on tablets|The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
219094377|NCT03720938|OTHER|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
219094378|NCT06107595|BEHAVIORAL|Placebo|Participant take 1 dose placebo (odor or pill) on post-op day 0 (POD 0) and 3 placebo dose from POD 2 to POD 17
219094379|NCT03522805|DEVICE|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
219094380|NCT03960671|DRUG|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
219094381|NCT01630720|DIETARY_SUPPLEMENT|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
219094382|NCT03839654|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
219094383|NCT00006422|PROCEDURE|current standard of care treatments|
219094384|NCT04012515|DEVICE|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
219094385|NCT04850404|PROCEDURE|abdominal nerve block|All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
219220324|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
219220325|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
219220326|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
219220327|NCT06735300|DRUG|Nirmatrelvir/Ritonavir (Paxlovid)|After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.
219220328|NCT03260387|PROCEDURE|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
219094386|NCT03949790|PROCEDURE|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
219094387|NCT03949790|PROCEDURE|Intercostal nerve block|Intercostal nerve block
219094388|NCT03715400|BEHAVIORAL|Positive Virtual Reality Training|Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
219094389|NCT02138643|PROCEDURE|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
219094390|NCT02138643|PROCEDURE|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
219094391|NCT01247428|DEVICE|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
219094392|NCT01452646|OTHER|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
219094393|NCT00021814|DRUG|Doxazosin|
219094394|NCT00021814|DRUG|Finasteride|
219094395|NCT00021814|DRUG|Doxazosin placebo|
219094396|NCT00021814|DRUG|Finasteride placebo|
219094397|NCT04072341|DRUG|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
219094398|NCT04072341|OTHER|Control Period|In the control period they will only follow standard treatment for their comorbidities.
219094399|NCT04692792|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
219094400|NCT04692792|DIETARY_SUPPLEMENT|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
219094401|NCT02475135|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
219094402|NCT02475135|DRUG|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
219094403|NCT02475135|DRUG|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
219094404|NCT02475135|DRUG|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
219094405|NCT02475135|DRUG|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
219094406|NCT02475135|OTHER|High-fat Breakfast|High-fat breakfast will be administered.
219094407|NCT02475135|OTHER|Standardized Regular Breakfast|Standardized regular breakfast will administered.
219094408|NCT03281122|DRUG|Placebo|Specified dose on specified days
219094409|NCT03281122|DRUG|BMS-986224|Specified dose on specified days
219094410|NCT02872948|GENETIC|Diagnostic|
219220329|NCT03595917|DRUG|ABL001|•ABL001 is administered daily per 28 day cycle
219220330|NCT03595917|DRUG|Dasatinib|Fixed doses oral once a day per 28 day cycle
219220331|NCT03595917|DRUG|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
219220332|NCT03595917|DRUG|Blinatumomab|By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
219220333|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
219220334|NCT02952144|DEVICE|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
219220335|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
219220336|NCT06830915|OTHER|Observation only|No intervention made
219094411|NCT04748016|OTHER|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
219220337|NCT05470114|DRUG|LEO 138559|LEO 138559 is an antibody given by subcutaneous injection.
219220338|NCT05470114|DRUG|Dupixent®|Dupixent® is an antibody given by subcutaneous injection.
219220339|NCT06936410|DRUG|Lidocaine 2% Injectable Solution|patients received Lidocaine 2%, 1 mg/kg, IV bolus over 10 mins after the induction of anaesthesia , followed by Lidocaine infusion (2 mg/kg/h) diluted in 50 ml of normal saline with a maximum dose of 200 mg/h. The tourniquet was inflated 10 minutes after the start of the Lidocaine infusion then the Lidocaine infusion stopped at the time of tourniquet deflation
219220340|NCT06936410|DRUG|Dexmedetomidine HCL Injection|patients received a loading dose of Dexmedetomidine-Pfizer (0.8 μg·kg-1 over 10 min) followed by continuous infusion of Dexmedetomidine (0.4 μg·kg-1.h-1) diluted in 50 ml of normal saline. The tourniquet was inflated 10 mins after the start of Dexmedetomidine infusion then the Dexmedetomidine infusion stopped at the time of the tourniquet deflation.
219220341|NCT06768892|OTHER|Dietary Intervention|Each study participant will offer a tailored diet regimen according to age, sex, health status, physical activity and type of work either (office work or physical demanding work) after A 24-hour Dietary recall to calculate average calories requirements for each study participant separately. The participants' meals will be based on Mediterranean Diet and The Dietary Approaches to Stopping Hypertension (DASH Diet) as they proved effectiveness in lowering the risk of cardiovascular disease, insulin resistance, hypertension, obesity and Metabolic Syndrome. Dietary intervention aimed to the extent that 5-10% reduction in body weight, following the guideline of prevention and treatment of obesity.
219361766|NCT03992625|DEVICE|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
219361767|NCT01450982|DRUG|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
219361768|NCT01091571|DRUG|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
219094412|NCT04748016|OTHER|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
219094413|NCT05797831|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
219094414|NCT05797831|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
219094415|NCT01494428|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
219094416|NCT01494428|DEVICE|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
219094417|NCT01644201|DIETARY_SUPPLEMENT|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
219682508|NCT06956118|DEVICE|Intervention (VeNS Stimulation) Device|The Modius Sleep device is a non-invasive, battery-powered headset that delivers low-level electrical stimulation (up to 1.0 mA at 0.25 Hz) to the skin behind the ears over the mastoid processes. It is worn like headphones and used for 30 minutes per session, five times per week for four weeks, under clinical supervision. Participants are assisted by a staff member to position the electrodes and adjust stimulation intensity in 0.1 mA steps, up to a maximum of 1.0 mA. The headset is turned on manually, and participants are encouraged to set it up independently after initial guidance. Sessions take place while seated, and participants remain supervised throughout to ensure correct use and safety.
219094418|NCT01644201|DIETARY_SUPPLEMENT|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
219094419|NCT00339690|OTHER|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
219094420|NCT02989272|DRUG|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
219094421|NCT02989272|OTHER|saline group|saline group (30 patients) who will receive pretreatment by saline solution
219094422|NCT01570530|PROCEDURE|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
219361769|NCT01091571|DRUG|Placebo|Placebo twice daily during seven consecutive days
219094423|NCT01570530|PROCEDURE|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
219094424|NCT04310917|OTHER|blood lipoprotein (a) test|research specific blood sample
219094425|NCT03338621|DRUG|Pretomanid|200 mg tablets
219094426|NCT03338621|DRUG|Bedaquiline|100 mg tablets
219094427|NCT03338621|DRUG|Moxifloxacin|400 mg tablets
219094428|NCT03338621|DRUG|Pyrazinamide|500 mg tablets
219094429|NCT03338621|DRUG|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
219094430|NCT03338621|DRUG|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
219682509|NCT06956118|DEVICE|Control (Sham Stimulation) Device|The sham version of the Modius Sleep device is visually and operationally identical to the active device to preserve blinding. It delivers a brief initial stimulation (30 seconds, with a 20-second taper) at 0.8 Hz to mimic the sensation of the active device without providing ongoing vestibular modulation. The appearance, placement, and user experience are the same, and participants are informed that the sensation may fade during use. Like the intervention device, the sham is used under supervision in the clinic for 30-minute sessions, ensuring identical procedures across both groups. This design maintains blinding while minimizing any physiological effects from the sham stimulation.
219094431|NCT02993887|BEHAVIORAL|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
219094432|NCT02993887|BEHAVIORAL|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
219094433|NCT02143037|BEHAVIORAL|prize contingency management for attending treatment|
219094434|NCT02143037|BEHAVIORAL|usual care|
219220342|NCT06768892|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT method will be adapted and customized to facilitate a transition towards a heightened level of physical activity and to address the emotional and practical difficulties associated with weight loss. This encompassed assisting the participants in establishing attainable weight loss goals, identifying individualized approaches to manage appetite, sustaining healthy habits, and navigating social environments and circumstances related to food. The aforementioned factors were deliberated upon within the context of both group-based and individual settings, adhering to a meticulously customized guideline. This guideline encompassed the incorporation of positive thinking tactics, accompanied by assigned tasks to be completed between each session. The Cognitive Behavioral Therapy (CBT) intervention was administered as a 20-minute component within the weekly therapy sessions. cognitive-behavioral therapy (CBT) in conjunction with lif
219361770|NCT01091571|OTHER|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
219361771|NCT02866825|BIOLOGICAL|IFX-1|
219361772|NCT02866825|BIOLOGICAL|Placebo|
219361773|NCT00005979|DRUG|FOLFIRI regimen|
219361774|NCT00005979|DRUG|fluorouracil|
219361775|NCT00005979|DRUG|irinotecan hydrochloride|
219361776|NCT00005979|DRUG|leucovorin calcium|
219682510|NCT05750563|DIETARY_SUPPLEMENT|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
219682511|NCT05750563|OTHER|Placebo|Use as comparator
219682512|NCT06134661|DEVICE|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session."
219682513|NCT05998759|BIOLOGICAL|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
219682514|NCT05998759|DRUG|Placebo|subcutaneous placebo weekly for 24 weeks.
219682515|NCT04027088|DIETARY_SUPPLEMENT|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
219682516|NCT04027088|DIETARY_SUPPLEMENT|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
219682517|NCT05133115|BEHAVIORAL|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
219682518|NCT04956211|PROCEDURE|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
219682519|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
219094435|NCT05542290|PROCEDURE|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
219094436|NCT05542290|PROCEDURE|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
219361777|NCT01827631|DRUG|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
219094437|NCT04597710|GENETIC|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
219220343|NCT06768892|OTHER|Physical exercise training|A weekly session of physical exercise training lasting 10 to 20 minutes will be incorporated at the workplace. The primary objective of the sessions was to increase muscle mass in the lower limbs for the purpose of sustaining physical capacity and boosting quiescent metabolism. The exercises comprised squats involving one or two legs, performed with or without dumbbells and core balls, as well as lunges performed while strolling forward and to each side. Additional exercises that emphasized overall strength encompassed shoulder and arm movements, as well as abdominal and back extension exercises. Participants were encouraged to execute the strength training exercises depicted in the program's takeout pamphlets twice per week. Furthermore, participants will be motivated to engage in aerobic leisure activities for a duration of two hours per week, including bicycling, walking, running, swimming, or participating in various sports.
219220344|NCT06945809|DEVICE|WeFlow-EndoPatch Aortic Endovascular Patch System|The WeFlow-EndoPatch Aortic Endovascular Patch System for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
219094438|NCT06163053|DRUG|Immunotherapy|Immune checkpoint inhibitors in approved indications
219220345|NCT06945809|OTHER|Conventional Treatment group|Doctors prescribe conventional medicines and regular imaging tests.
219220346|NCT06945341|BEHAVIORAL|Focus-Group discussion|Focus-Group discussion on factors that could lead to an increase in the adoption of neuromuscular monitoring taking into account different country-specific contexts.
219094439|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
219094440|NCT01163890|BEHAVIORAL|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
219094441|NCT01163890|BEHAVIORAL|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
219094442|NCT01291537|DRUG|Duodopa|
219094443|NCT01291537|DRUG|best médical treatment|
219220347|NCT05001139|DEVICE|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
219220348|NCT06943950|DRUG|SYHX1901|Administered orally, once daily (QD)
219220349|NCT02891967|OTHER|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
219220350|NCT02891967|OTHER|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
219220351|NCT06943846|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet-rich fibrin added to extraction socket
219220352|NCT06944951|DEVICE|Hydrophilic emulsion for the relief of haemorroidal symptoms|Administration for 2 weeks of PROCTOeze® PLUS - a soft and light hydrophilic emulsion able to provide symptomatic relief of haemorrhoids and anal irritation.
219361778|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
219361779|NCT04282031|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
219094444|NCT02661100|DRUG|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
219094445|NCT02661100|BIOLOGICAL|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
219094446|NCT02661100|BIOLOGICAL|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
219094447|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
219094448|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
219094449|NCT03815019|DRUG|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
219094450|NCT03815019|BEHAVIORAL|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
219094451|NCT05373342|DEVICE|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
219094452|NCT03133559|OTHER|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
219094453|NCT04462419|RADIATION|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
219094454|NCT04462419|OTHER|Fluciclovine F18|Given IV
219094455|NCT03775460|DRUG|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
219094456|NCT03775460|DRUG|Placebo|Participants in the control arm will receive placebo along side prednisolone
219220353|NCT06946758|OTHER|Core stabilization exercises|Patients in the core stabilisation exercise group underwent a total of 24 sessions of core stabilisation exercise programme 3 days a week (with at least 1 day of rest between each session) for a total of 8 weeks. Each exercise session was performed under the supervision of a physician in the Department of Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine. Each session was arranged as 35-minute programmes with an average of 8-10 patients, 5 minutes of which was warm-up. Before starting the exercise, patients were taught to reduce lumbar lordosis by contracting and drawing in the abdominal muscles and to find a lumbar and pelvic neutral position by moving the pelvis forwards and backwards. In each session, the neutral position was found first and attention was paid to maintain the neutral position throughout the exercise. The exercises consisted of 3 levels. The exercise level was completed gradually
219220354|NCT06946758|OTHER|Aerobic Exercises|The aerobic exercise group underwent core stabilisation exercises applied to the control group. After the core stabilisation exercises, aerobic exercise was performed with a stationary bicycle at a speed of 50 rpm for approximately 40 minutes.
219220355|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
219220356|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
219220357|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
219220358|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
219220359|NCT06950320|DEVICE|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance weighing 5 grams, designed as a disposable product for a single use. P-STIM is placed behind the patient's ear and connected to stimulation needles (usually 3 needles) on the auricle. For the study, only one stimulation needle was needed. P-STIMTM offers regular therapy over several days. The appliance transmits low frequency electric pulses to exposed nerve endings. The built-in microchip creates periods of stimulation and rest, each lasting approximately 3 hours. Stimulation was performed with a frequency of 1Hz for 40min followed by a break of 20 min.
219220360|NCT06950320|DEVICE|Placebo|The placebo device is a look-a-like, that stimulates only for 1h hour and then stops.
219220361|NCT06952192|DEVICE|Virtual reality|VR application via a head-mounted display one minute before and throughout the SPT procedure. The VR intervention utilized a Samsung Gear VR headset (Samsung, Seoul, South Korea) in conjunction with a Samsung S7 or S8 mobile device to provide an immersive and engaging experience. Children were allowed to choose from a range of age-appropriate VR content designed to enhance engagement and relaxation. Prior to the procedure, children were trained on how to use the headset by study staff to ensure a smooth experience.
219220362|NCT06950931|DIAGNOSTIC_TEST|uPTM-FeA|In this monocentric prospective cohort study, we will measure uPTM-FeA by enzyme-linked immunosorbent assay (ELISA) kit DNLite IVD 103 in cooperation with PromedeusLab. Human uPTM3-DKD ELISA is a colourimetric immunoassay for quantitatively determining human unique Fetuin-A with specific post-translational modification (PTM) in urine.
219361780|NCT04282031|DRUG|Letrozole|Letrozole 2.5 mg once daily of a 28-day cycle
219094457|NCT03775460|DRUG|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
219094458|NCT01881503|BIOLOGICAL|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
219094459|NCT05277844|RADIATION|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
219094460|NCT05277844|DRUG|TKI|TKI
219094461|NCT03654742|PROCEDURE|tonsillectomy|removal of tonsil tissue as described in the study arms
219094462|NCT06577337|BIOLOGICAL|M5542|Participants will receive single ascending dose of M5542 subcutaneously on Day 1 in Part A. Participants will receive loading dose of M5542 followed by maintenance doses in Part B.
219094463|NCT06577337|BIOLOGICAL|Placebo|Participants will receive placebo matched to M5542 in Part A and Part B.
219094464|NCT03484598|DEVICE|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
219094465|NCT06348199|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
219094466|NCT06348199|DRUG|Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
219094467|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
219094468|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
219094469|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
219094470|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
219094471|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
219220363|NCT06951516|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
219220364|NCT06950372|DRUG|Ropivacaine concentration low|Brachial plexus nerve block with ropivacaine 3.75 mg/ml
219220365|NCT06950372|DRUG|Ropivacaine concentration high|Brachial plexus nerve block with ropivacaine 7.5 mg/ml
219220366|NCT06951802|DRUG|Ketamine|Low-dose administration of ketamine during laparoscopic surgery
219220367|NCT06951802|DRUG|Propofol|Control group
219220368|NCT06950684|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants will take a daily supplement of whey protein powder (Easy Whey) providing 25 grams of protein each day for the duration of 6 months
219220369|NCT06950684|BEHAVIORAL|Resistance Training Program|Participants will engage in resistance training consisting of one guided online session each week and two additional independent resistance training sessions weekly, totaling three sessions per week, for a duration of 6 months.
219220370|NCT06952283|BEHAVIORAL|Inducing mental fatigue|"During the mental fatigue induction phase, a 30-minute Stroop task will artificially induce mental fatigue, simulating the mental fatigue state that athletes experience during competitions or training sessions. The Stroop task is a classic cognitive control task widely used for inducing mental fatigue. Research in sports science has shown that a 30-minute Stroop task significantly increases subjective fatigue and reduces physical performance. This study will use a smartphone-based version of the Stroop task (with brightness and touch sensitivity standardised), where colour words (such as red and blue) are displayed continuously, but the font colour does not match the word's meaning. Participants must ignore the word's meaning and respond only based on the font colour. The Stroop task requires sustained attention, conflict resolution, and cognitive inhibition, leading to cognitive resource depletion and mental fatigue accumulation."
219094472|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
219361781|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily of a 28-day cycle
219361782|NCT02648126|PROCEDURE|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
219361783|NCT02338687|DIETARY_SUPPLEMENT|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
219220371|NCT06952283|BEHAVIORAL|Music intervention|During the music intervention phase, participants will listen to 15 minutes of classical music to facilitate mental fatigue recovery. This study selects Mozart's Eine Kleine Nachtmusik as the intervention music, a piece that has been applied in previous mental fatigue recovery studies and has been validated as an effective intervention. The intervention duration is set at 15 minutes, as multiple studies have confirmed this duration to be sufficient to produce recovery effects without causing additional cognitive load or auditory fatigue. The music will be played through a smartphone, with the intervention volume controlled at 50-60 dBA. Considering that the maximum volume of a smartphone is approximately 105-113 dBA, the standardised intervention volume is set at 50% (52.5-56.5 dBA) of the smartphone's maximum volume to ensure consistency among all participants.
219220372|NCT06952465|DRUG|Deucravacitinib|As per product label
219220373|NCT06952465|BIOLOGICAL|Any biologic treatment for psoriasis|According to the product label
219220374|NCT06951971|DRUG|dose-modified E-Ru|Emapalumab (1-2 mg/kg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)
219094473|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
219094474|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
219094475|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
219094476|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
219094477|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
219220375|NCT06951971|OTHER|Salvage treatment and follow-up|1\) for patients who did not respond to the E-Ru regimen after 7 days or who relapsed at any point during treatment, a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP) was administered; 2) for patients diagnosed with lymphoma after enrollment, chemotherapy was initiated; 3) for patients who completed 8 weeks of treatment without recurrence and had no detected HLH-related gene mutations, follow-up was initiated; and 4) for patients who met the criteria for allo-HSCT, allo-HSCT was performed.
219220376|NCT06950996|OTHER|Risk in prostate cancer|the prediction involves the classification of the prostate cancer according to the level of prostatic antigen (PSA), the biopsy classification of the aggressiveness of the tumour, and also the localisation of the tumour
219094478|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
219220377|NCT06950996|OTHER|Life expectancy in lung cancer|Clinicians will evaluate life expectancy in lung cancer using CTs, together with some clinical information.
219220378|NCT06950996|OTHER|Histological subtype|An assessment by pathology of the subtype of breast tumour
219220379|NCT06950996|OTHER|Staging of colon cancer|classify size, lymph node involvement and possibility of metastasis in medical images (computerized tomosynthesis) of thorax and pelvis region
219220380|NCT06950996|OTHER|invasion in rectum cancer|assess whether vascular extramural o mesorectal fascia has been invaded in the tumour using magnetic resonance medical images taken at diagnosis in the pelvic region
219220381|NCT06952374|DEVICE|SmartWave Lithotripsy balloon|ntravascular lithotripsy is an approved adjunct interventional therapy in treating calcified lesions to facilitate stenotic lesion opening in peripheral vascular disease and coronary artery disease. The off-label use of current peripheral lithotripsy balloon in mitral valve as a compassionate treatment or as an adjunct treatment before mitral balloon valvuloplasty and transcatheter mitral valve replacement has been reported with success . A possible mechanism is that lithotripsy preferentially impacts hard tissue, disrupts calcium, and leaves soft tissue undisturbed, improving valve pliability, preventing leaflet damage, and making subsequent valvuloplasty safer.
219220382|NCT06950528|BEHAVIORAL|Control group|Control Group consists of six motion videos, including: crossover steps, high knees, lateral raises, punching movements, downward leg punches from a standing position, and elbow-to-chest expansions
219220383|NCT06950528|BEHAVIORAL|Kinect group|Kinect Group features the same software functionality and design as the application based on bullet-screen cameras, but the hardware is built using a Kinect sensor. The gamified platform is primarily developed and presented using Unity software. The Kinect 3D motion-sensing camera incorporates real-time dynamic capture and image recognition capabilities, offering new possibilities for interactive approaches to motion therapy
219220384|NCT06950528|BEHAVIORAL|Monocular group|The game employs a virtual avatar to replicate users' movements, thereby fostering an immersive and engaging experience. A monocular camera captures users' movements in real time, which are analyzed through pose estimation algorithms and subsequently mapped onto the virtual avatar. Users interact with the game by following on-screen visual demonstrations, presented as either static images or animations, to perform the prescribed exercises. Movement accuracy is evaluated by the system, with scores awarded based on performance. To enhance user motivation and adherence, the game incorporates a reward system, where points earned through accurate execution can be redeemed for in-game rewards, such as unlocking background music, avatar customization options, and new virtual environments.
219220385|NCT06950333|OTHER|POCUS education curriculum|The training includes a 4-hour curriculum consisting of a 1-hour didactic session covering ultrasound principles and key applications, followed by 3 hours of hands-on practice using standardized models or phantoms under instructor supervision. Core scanning topics include Focused Assessment with Sonography for Trauma (FAST), lung ultrasound for dyspnea, carotid Doppler for suspected stroke, and focused cardiac ultrasound for cardiac arrest. Post-training assessments include a written test and an Objective Structured Clinical Examination (OSCE).
219094479|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
219094480|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
219094481|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
219094482|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
219094483|NCT04494945|PROCEDURE|Biospecimen Collection|Undergo collection of saliva sample
219094484|NCT04494945|OTHER|Genetic Counseling|Receive genetic counseling if testing results are positive
219094485|NCT04494945|OTHER|Genetic Testing|Undergo genetic testing
219094486|NCT04494945|OTHER|Survey Administration|Complete a survey
219094487|NCT06515821|DIAGNOSTIC_TEST|ONCOSCREEN|Subjects samples will be tested with diagnostic tests.
219094488|NCT02886065|DRUG|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
219094489|NCT02886065|DRUG|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
219094490|NCT02886065|DRUG|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
219094491|NCT02886065|BIOLOGICAL|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
219094492|NCT05303532|DRUG|Durvalumab|Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
219094493|NCT00532155|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
219220386|NCT06951633|OTHER|Subterranean, pulmonary rehabilitation|Pulmonary rehabilitation in the underground Health Resort of the 'Wieliczka' Salt Mine
219220387|NCT05961995|BEHAVIORAL|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart. The HFN meditation will last 30 minutes. There will be a prescribed progressive relaxation technique which will last for \~ 5-10 minutes followed by the heart-based meditation.
219220388|NCT05650736|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
219220389|NCT06950294|DRUG|High dose inhaled nitric oxide|Inhaled nitric oxide starting at 250-300 ppm, 40min, every 6 hours, from day 1 to day 5
219220390|NCT06950294|OTHER|Sham treatment|Sham treatment with nitric oxide delivering and monitoring devices connected as the intervention group
219220391|NCT06950294|OTHER|standard therapy|Standard therapy pneumonia and critical illness
219361784|NCT02338687|BEHAVIORAL|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
219094494|NCT00532155|DRUG|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
219094495|NCT00532155|DRUG|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
219094496|NCT00532155|DRUG|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
219094497|NCT04987268|GENETIC|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
219094498|NCT02134925|OTHER|Laboratory Biomarker Analysis|Correlative studies
219094499|NCT02134925|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
219094500|NCT02134925|OTHER|Quality-of-Life Assessment|Ancillary studies
219094501|NCT02134925|OTHER|Saline|Given SC
219094502|NCT05823142|BEHAVIORAL|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
219094503|NCT05411029|DIAGNOSTIC_TEST|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
219220392|NCT06951867|DRUG|Tezepelumab|The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients treated with high-intensity SOC will be identified based on the presence of a trigger exposure (i.e., augmentation or change of the non-biologic high-intensity treatment that does not represent treatment de-escalation) to mirror tezepelumab start in the exposed cohort. Due to the limited knowledge of the cardiovascular profile of biologics, SOC for comparative analyses will only include non-biologic high-intensity treatment.
219220393|NCT06951724|DEVICE|Aspiration Catheter|Thrombus aspiration using Aspiration Catheter
219220394|NCT06951724|DEVICE|Export Advance Aspiration Catheter|Thrombus aspiration using Export Advance Aspiration Catheter
219220395|NCT06952296|DRUG|Dydrogesterone|"The duration of treatment with dydrogesterone is determined by the physician before inclusion in the study and will last for 6 menstrual cycles (Cycle used in the protocol refers to menstrual cycle. 1 cycle is 28 days on average)"
219220396|NCT06953258|OTHER|Home-based eccentric training at long muscle length|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm #1, four specific exercises targeting the knee extensors and plantar flexors will be performed at long muscle lengths.
219220397|NCT06953258|OTHER|Conventional home-based training|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm#2, four specific exercises targeting the knee extensors and plantar flexors will be performed in a conventional manner (i.e., at neutral or shorter muscle lengths).
219220398|NCT06951529|OTHER|Reproductive violence education|The training content, which was created by obtaining expert opinions based on literature, will cover the violence that women are exposed to or may be exposed to according to the cycles they experience during their reproductive years. Definition of Violence and Its Effects on Women's Health, Adolescence and Menstruation Period Violence, Family Planning and Infertility Violence, Pregnancy and Birth-Related Violence, Menopause-Related Violence, Legal Processes in Combating Reproductive Violence.
219220399|NCT06951360|PROCEDURE|ENERGY questionnaire|Questionnaire including NASA Task Load Index, difficulty level of operation, patient and operation factors
219094504|NCT05411029|DIAGNOSTIC_TEST|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
219094505|NCT00242372|DRUG|Tesaglitazar 0.5|
219094506|NCT00242372|DRUG|Insulin at least 30 units/day|
219094507|NCT02492854|DEVICE|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
219682520|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
219682521|NCT02944175|DRUG|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
219682522|NCT02944175|DRUG|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
219682523|NCT04808583|PROCEDURE|TLH with uterine artery ligation at its origin at the beginning of the operation|After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
219682524|NCT04808583|PROCEDURE|conventional TLH with uterine artery ligation after the cornual pedicles|"Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides."
219682525|NCT03526042|DRUG|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
219094508|NCT02492854|OTHER|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
219094509|NCT02184754|PROCEDURE|Magnetic endoscope imaging (MEI)|
219094510|NCT06067633|OTHER|Triple-Masked|Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant
219094511|NCT06067633|OTHER|Usual Procedures|Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
219220400|NCT05385588|OTHER|cognitive functional assessment|"* Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)"
219220401|NCT01563185|DRUG|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
219220402|NCT02259855|DRUG|Tipranavir|
219220403|NCT02259855|DRUG|Ritonavir|
219220404|NCT02259855|DRUG|Pegylated interferon|
219220405|NCT02259855|DRUG|Ribavirin|
219094512|NCT03483974|DIAGNOSTIC_TEST|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
219094513|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
219094514|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
219094515|NCT01326858|DRUG|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
219094516|NCT00035074|DRUG|Methotrexate|
219094517|NCT06236867|OTHER|KaleidoscopeGroup|The group consists of 34 people. Pain level was measured during 3 dialysis sessions.In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
219094518|NCT06236867|OTHER|Ice Application Group|The group consists of 34 people. Pain level was measured during 3 dialysis sessions. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point)
219094519|NCT06236867|OTHER|Control Group|The group consists of 34 people. Pain level will be measured during 3 dialysis sessions. In the control group, the vital signs of the patients before AVF cannulation will be recorded.
219094520|NCT02524041|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
219094521|NCT02524041|OTHER|blood specimen|blood specimen
219220406|NCT05994833|BEHAVIORAL|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
219220407|NCT02843191|DRUG|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
219220408|NCT06544291|DRUG|CBD 300mg|3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
219220409|NCT06544291|DRUG|CBD 600mg|6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
219220410|NCT06544291|DRUG|Placebo 0mg|6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
219361785|NCT01058096|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
219220411|NCT06264258|BEHAVIORAL|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
219220412|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
219220413|NCT06202079|DRUG|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
219220414|NCT06202079|DRUG|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
219220415|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
219220416|NCT00840047|DRUG|Methionine|Intravenous injection
219361786|NCT01058096|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
219094522|NCT00770926|BEHAVIORAL|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
219094523|NCT05205902|OTHER|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
219094524|NCT05205902|OTHER|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
219094525|NCT03349164|DIAGNOSTIC_TEST|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
219094526|NCT03872752|BEHAVIORAL|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
219094527|NCT05802368|OTHER|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
219094528|NCT05802368|OTHER|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
219094529|NCT06065566|DIETARY_SUPPLEMENT|L-alanyl-L-glutamine dipeptide|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention."
219094530|NCT06065566|OTHER|Placebo|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention."
219094531|NCT03204955|DRUG|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
219094532|NCT03204955|DRUG|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
219094533|NCT03204955|DRUG|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
219094534|NCT05059379|RADIATION|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
219220417|NCT06023043|DRUG|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
219220418|NCT06381180|DRUG|Tetrahydrocannabinol|Plant cannabis that will be smoked
219220419|NCT06381180|DRUG|Cannabidiol|Plant cannabidiol that will be smoked
219220420|NCT06381180|DRUG|Placebo|Plant will be smoked.
219220421|NCT03298243|BEHAVIORAL|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
219220422|NCT06121492|DRUG|Branched-chain amino acid|In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
219220423|NCT06121492|DRUG|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
219220424|NCT04147884|DEVICE|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
219220425|NCT04064983|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
219094535|NCT05059379|RADIATION|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
219094536|NCT04859582|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
219094537|NCT04859582|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
219094538|NCT04859582|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
219094539|NCT04859582|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
219094540|NCT04859582|DRUG|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
219094541|NCT04859582|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
219094542|NCT01552590|DRUG|Tolvaptan|
219094543|NCT01552590|DRUG|Placebo|
219094544|NCT00597948|BEHAVIORAL|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
219094545|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
219094546|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
219094547|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
219094548|NCT00654901|BIOLOGICAL|Infanrix Hexa™|0.5 mL, Intramuscular
219094549|NCT03773367|DRUG|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
219094550|NCT03773367|DRUG|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
219094551|NCT03773367|DRUG|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
219094552|NCT06461416|BEHAVIORAL|ActiveHeal|Participants will have 6 group activity sessions and six individualized sessions from home, all focused on optimizing persistence in performance of specific selected activities.
219094553|NCT05375539|DRUG|AGN-CognI.Q|Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
219094554|NCT06115252|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
219094555|NCT00724464|BIOLOGICAL|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
219094556|NCT00724464|DRUG|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
219094557|NCT04199260|DEVICE|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
219094558|NCT05873452|DEVICE|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
219094559|NCT05829083|DEVICE|Asymmetric nasal cannula - DUET|"DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions"
219094560|NCT05829083|DEVICE|Conventional nasal high flow cannula|"Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions"
219094561|NCT06451978|OTHER|Nature-based intervention|The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
219094562|NCT05983965|DRUG|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
219094563|NCT04917809|DRUG|Erdafitinib|Participants will receive erdafitinib at a dose of 6 mg orally once daily for the first 14 days (±3 days). Serum phosphate levels will be assessed on day 14 (±3 days) and the dose of erdafitinib may be lowered based on the serum phosphate level. Treatment with erdafitinib at a dose of 6 mg orally once daily, or at a lower dose level for another 14 days (±3 days) until the day of their standard-of-care TURBT/biopsy. Standard-of-care TURBT/biopsy will be performed after approximately 28 days (±5 days) from the start of treatment with erdafitinib, and biologic and pathologic tumor response will be assessed. All participants will then be followed up for recurrence or progression in accordance with the standard of care.
219094564|NCT04741997|DRUG|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
219094565|NCT04741997|DRUG|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
219094566|NCT04741997|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
219094567|NCT04425005|OTHER|Home-based exercise|Home-based exercise training, supervised by videoconference.
219094568|NCT04278625|DRUG|Acetaminophen|IV acetaminophen given as part of standard of care.
219094569|NCT04241094|BEHAVIORAL|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
219094570|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
219094571|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
219094572|NCT04423822|OTHER|stress test|endurance capacity
219094573|NCT01938651|PROCEDURE|high field strength magnetic resonance imaging|Undergo 7T MRI
219094574|NCT01938651|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo 31P MRS
219094575|NCT01938651|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
219094576|NCT01938651|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
219094577|NCT01938651|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
219094578|NCT00681304|OTHER|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
219094579|NCT01082562|DRUG|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
219094580|NCT01082562|DRUG|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
219094581|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
219094582|NCT00165425|PROCEDURE|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
219094583|NCT03843918|DRUG|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
219094584|NCT06975969|DEVICE|Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter|The Versus Pulmonary Artery Catheter is a dual-tip, infusion catheter. Two lumens access and deliver physician-specified fluids, including thrombolytics, into the pulmonary arteries of each lung via a single access site. The Secondary Catheter tip telescopes independently to facilitate infusion into the contralateral lung. The device may allow for assessment of a patient's hemodynamic condition through direct intracardiac and pulmonary artery pressure monitoring. Pressure is measured through an interface between the catheter's fluid lumen and an externally located, FDA-cleared, pressure transducer. The device may include an additional lumen that is in communication with a distal flow-directed balloon.
219094585|NCT06559956|OTHER|Daytime titration polysomnography|A titration polysomnography assesses the device settings and, if necessary, the stimulation strength will be adjusted based on observed respiratory events and/or snoring. Patients in the daytime titration PSG cohort were instructed to refrain from sleeping during the night, and in the morning, they were permitted to sleep in a soundproof room without daylight at the sleep lab.
219094586|NCT04929769|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
219094587|NCT04929769|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
219094588|NCT02332590|DRUG|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
219094589|NCT02332590|DRUG|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
219094590|NCT02332590|DRUG|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
219094591|NCT02332590|DRUG|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
219094592|NCT02591134|OTHER|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
219094593|NCT02591134|OTHER|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
219220426|NCT06822543|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
219220427|NCT06822543|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload and a cleavable linker.
219220428|NCT06822543|DRUG|Carboplatin|Carboplatin is a platinum compound chemotherapy used to treat lung cancer with a known safety profile. For more details on specific indications refer to the approved product label.
219220429|NCT06307457|DRUG|Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.
219220430|NCT06549764|BEHAVIORAL|Youth Aware of Mental Health|Help-seeking and literacy increasing intervention
219094594|NCT05152173|BIOLOGICAL|EN3835|Participant will receive a maximum dose of up to1.8mg of EN3835 injection
219094595|NCT05152173|OTHER|Placebo|Participant will receive a maximum dose of up to1.8mg of Placebo injection
219220431|NCT04794972|DRUG|GNC-039|Administration by intravenous infusion.
219220432|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
219220433|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
219220434|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
219220435|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
219094596|NCT01995487|DEVICE|BioNIR|drug-eluting stent
219094597|NCT01995487|DEVICE|Resolute|drug-eluting stent
219094598|NCT04012684|DEVICE|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
219094599|NCT04012684|DEVICE|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
219094600|NCT04035057|OTHER|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
219094601|NCT04035057|OTHER|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
219094602|NCT04285255|DRUG|Fentanyl|opioids anaesthesia
219220436|NCT05462704|DRUG|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
219220437|NCT05462704|DRUG|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
219220438|NCT05418764|OTHER|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
219220439|NCT05440851|OTHER|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
219220440|NCT05440851|OTHER|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
219220441|NCT05440851|OTHER|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
219220442|NCT05440851|OTHER|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
219220443|NCT05440851|DRUG|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
219220444|NCT05440851|DRUG|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
219094603|NCT04285255|DRUG|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
219094604|NCT04285255|DRUG|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
219094605|NCT04285255|PROCEDURE|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
219094606|NCT04285255|DRUG|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
219094607|NCT06267885|PROCEDURE|Cannulated screws vs wagner's technique|Fixation of fracture neck of femur by cannulated screws or wagner's technique
219094608|NCT06286605|PROCEDURE|A-oss and autogenous bone|Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.
219094609|NCT06286605|PROCEDURE|A-oss an LCR-A|Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
219094610|NCT04858698|DEVICE|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
219094611|NCT06380699|DRUG|QHRD106 Injection|PEG-tissue kallikrein-1
219220445|NCT05440851|DRUG|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
219094612|NCT06380699|DRUG|Human Urinary Kallidinogenase|tissue kallikrein-1
219094613|NCT06380699|DRUG|placebo|placebo
219094614|NCT04309916|DRUG|Tegoprazan|Tegoprazan 50mg tablet
219094615|NCT04309916|DRUG|Esomeprazole|Esomeprazole 40mg tablet
219094616|NCT02259504|OTHER|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
219094617|NCT02259504|OTHER|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
219094618|NCT04509895|PROCEDURE|Lateral extensile approach in calcaneal fractures fixation|The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.
219094619|NCT04509895|PROCEDURE|Minimally invasive sinus tarsi approach in calcaneal fractures fixation|An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
219094620|NCT02498834|BEHAVIORAL|Educational Video and Question Prompt List|Educational Video and Question Prompt List
219094621|NCT03438695|PROCEDURE|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
219094622|NCT01896401|DEVICE|InSeal's Vascular Closure Device|
219094623|NCT03534310|DRUG|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
219094624|NCT03534310|OTHER|lifestyle modification|
219094625|NCT03534310|OTHER|sleeve gastrectomy|
219094626|NCT00194051|PROCEDURE|gastric bypass surgery|
219094627|NCT02919722|BEHAVIORAL|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
219094628|NCT01646593|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
219094629|NCT01636999|DRUG|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
219094630|NCT06328764|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
219094631|NCT04618666|PROCEDURE|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
219094632|NCT05959343|BEHAVIORAL|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
219094633|NCT04204200|DIETARY_SUPPLEMENT|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
219094634|NCT04204200|DIETARY_SUPPLEMENT|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
219220446|NCT05440851|DRUG|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
219220447|NCT05440851|DRUG|Usual care with fludrocortisone|Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
219094635|NCT04204200|DIETARY_SUPPLEMENT|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
219094636|NCT02219984|DRUG|Anticoagulants|
219094637|NCT04604080|OTHER|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
219094638|NCT05696210|OTHER|Transfusion rate of red blood cells|Transfusion rate of red blood cells greater than 7
219220448|NCT05440851|DRUG|Usual care without fludrocortisone|Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
219220449|NCT05440851|DRUG|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
219220450|NCT05440851|DRUG|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
219220451|NCT05440851|OTHER|PEEP-20|fixed high positive end-expiratory pressure at 20 cmH2O
219220452|NCT05440851|OTHER|PEEP-AOP|positive end-expiratory pressure set according to airway opening pressure
219220453|NCT05440851|OTHER|PEEP-10|fixed lower positive end-expiratory pressure at 10 cmH2O
219220454|NCT05440851|OTHER|VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation|Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
219220455|NCT05440851|OTHER|Electrical impedance tomography (EIT)|Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
219220456|NCT06375278|DEVICE|Intra-Ear Canal Cooling Catheter|Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.
219220457|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo CARE
219220458|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo standard stretching program
219220459|NCT03284346|OTHER|Laboratory Biomarker Analysis|Correlative studies
219220460|NCT03284346|OTHER|Polar heart rate monitor|Receive Polar heart rate monitor
219220461|NCT03284346|OTHER|Quality-of-Life Assessment|Ancillary studies
219220462|NCT03284346|OTHER|Questionnaire Administration|Ancillary studies
219220463|NCT02875548|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
219220464|NCT05799274|DRUG|RAD301 ([68Ga]-RAD301)|A single dose of 68Ga-RAD301 of 150 +/- 50 MBq (\~4mCi) administered as a slow bolus injection over 2-5 minutes
219094639|NCT04284345|PROCEDURE|Saline Pd/Pa|"Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement."
219094640|NCT03915639|PROCEDURE|Peri-incisional injection|The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
219094641|NCT05788302|BEHAVIORAL|Prolonged Exposure|\- Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
219094642|NCT02764710|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
219094643|NCT02546414|OTHER|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
219094644|NCT05749848|DRUG|[¹⁴C]-LY3372689|Administered orally.
219220465|NCT04936542|BIOLOGICAL|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
219220466|NCT04936542|BIOLOGICAL|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
219094645|NCT06076720|DEVICE|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
219094646|NCT00110370|DRUG|Lispro Mixture Therapy|
219094647|NCT00110370|DRUG|Glargine Basal-Bolus Therapy|
219094648|NCT05985694|DRUG|AD17002|The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.
219094649|NCT05985694|DRUG|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
219094650|NCT06173531|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
219094651|NCT06173531|DRUG|Placebo|Placebo given TID, identical in appearance respective to carbetocin treatment
219220467|NCT06304441|DRUG|Osimertinib|Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
219220468|NCT06304441|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
219220469|NCT05108233|OTHER|Survey Administration|Complete survey
219361787|NCT04756713|PROCEDURE|Uterine curettage|Manual or electric vacuum aspiration under ultrasound guidance.
219361788|NCT04756713|DRUG|Chemotherapy|conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
219361789|NCT00309322|DRUG|Phentolamine Mesylate (NV-101)|
219361790|NCT06549387|PROCEDURE|Corneal cross linking|Applying UVA irradiation to the cornea after soaking with riboflavin
219361791|NCT03176082|OTHER|Mailed Reminders with Fecal Immunochemical Testing kits|
219220470|NCT03293264|BEHAVIORAL|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
219094652|NCT07051577|OTHER|Exercise Group|"Participants in the neuromuscular exercise group will undergo a training program supervised by the researcher, conducted twice a week for 6 weeks. This group will receive gaze stabilization training, core stabilization training, scapular stabilization training, balance training, and NeuroTracker training.~The exercises provided to the neuromuscular exercise group are structured in three phases and progressively intensified based on phase transition criteria."
219094653|NCT07051577|OTHER|control group|There are standard exercise programs consisting of scapular stabilization and balance exercises.These exercises are commonly used in clinical rehabilitation and will not include any additional neurosensory or visual components.
219094654|NCT07058311|OTHER|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Manual therapy was applied twice weekly over eight weeks, each session lasting approximately 45 minutes. Techniques included trigger point therapy, myofascial release, intraoral mobilizations to the masseter, medial and lateral pterygoid, and temporalis tendons, post-isometric relaxation for masticatory muscles, cervical traction, and suboccipital and cervical fascial release. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
219220471|NCT05873543|OTHER|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|"The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms."
219220472|NCT06393439|DIAGNOSTIC_TEST|Virtual reality motor task|After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.
219220473|NCT06353386|DRUG|Opevesostat|Oral Tablet
219220474|NCT06353386|DRUG|Olaparib|Oral Tablet
219220475|NCT06353386|DRUG|Docetaxel|IV Infusion
219220476|NCT06353386|DRUG|Cabazitaxel|IV Infusion
219220477|NCT06353386|DRUG|Fludrocortisone acetate|Oral Tablet
219220478|NCT06353386|DRUG|Dexamethasone|Oral Tablet
219220479|NCT06353386|DRUG|Prednisone|Oral Tablet
219361792|NCT03176082|OTHER|Reminder letter only|
219220480|NCT05769582|BIOLOGICAL|Anti-BK polyomavirus (AntiBKV)|"Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85."
219220481|NCT04580043|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
219094655|NCT07058311|OTHER|Home Exercise Therapy|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. The exercise program included Rocabado exercises, stretching of the platysma, masticatory and cervical muscles, resistance training (mouth opening, protrusion, and lateral mandibular movements), and postural exercises. Exercises were performed while sitting in a chair with back support in front of a mirror. Each exercise was repeated 10 times. The duration of each session was 25-30 minutes. repeat the home exercises three times a week for 8 weeks. Weekly phone calls were made to encourage compliance. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
219094656|NCT03707574|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue
219094657|NCT07054320|OTHER|Observational procedures|Patients at the Hoskinson Health and Wellness Clinic qualifying for treatment with Rapamune (Sirolimus) receive a prescription from their physician during clinic visits as part of their standard health care. This study will evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of physician-prescribed medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.
219094658|NCT07072728|DRUG|Psilocybin therapy|Following a screening period, eligible participants will undergo one cycle of psilocybin-assisted psychotherapy (PAP). Non-responders at Week 10 who continue to meet eligibility criteria will be offered a second PAP cycle at the 25 mg PEX010 dose. A maximum of two PAP cycles may be given. Long-term follow-up will include a visit at Month 3 following the final PAP cycle.
219094659|NCT06714864|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter instillation use
219094660|NCT06714864|DRUG|Standard of Care|Site specific standard of care
219094661|NCT06680037|DRUG|Azercabtagene zapreleucel (azer-cel)|IV infusion
219094662|NCT06243029|DEVICE|ECG Patch|Wearable ECG Patch designed to record and transmit physiological parameters to a mobile device or a data cloud. The device stores data locally in a memory cache designed for \>96 hours of continuous data. It continuously records a one-lead ECG and has a three-axis accelerometer. On-board algorithms use those data to compute heart rate, heart rate variability, RR-interval, respiratory rate, and an activity level indicator. The company also provides optional arrhythmia detection and reporting services, the results of which may be delivered to healthcare professionals.
219094663|NCT04008706|DRUG|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
219094664|NCT04546399|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219094665|NCT04546399|PROCEDURE|Biospecimen Collection|Undergo blood, urine and cerebrospinal fluid collection
219094666|NCT04546399|BIOLOGICAL|Blinatumomab|Given IV
219094667|NCT04546399|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219094668|NCT04546399|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219094669|NCT04546399|DRUG|Calaspargase Pegol|Given IV
219094670|NCT04546399|DRUG|Cytarabine|Given IT
219094671|NCT04546399|DRUG|Dexamethasone|Given PO or IV
219094672|NCT04546399|DRUG|Hydrocortisone Sodium Succinate|Given IT
219094673|NCT04546399|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219094674|NCT04546399|DRUG|Mercaptopurine|Given PO
219094675|NCT04546399|DRUG|Methotrexate|Given IT, PO, and IV
219094676|NCT04546399|BIOLOGICAL|Nivolumab|Given IV
219094677|NCT04546399|DRUG|Pegaspargase|Given IM or IV
219220482|NCT04580043|DEVICE|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
219220483|NCT04580043|BEHAVIORAL|Sham Training|Computer-based task practice in a non-active/inert task.
219220484|NCT04580043|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
219362131|NCT05099692|BEHAVIORAL|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
219094678|NCT04546399|DRUG|Pegcrisantaspase|Given IM or IV
219094679|NCT04546399|DRUG|Vincristine Sulfate|Given IV push or via infusion
219094680|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
219094681|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
219094682|NCT04266886|OTHER|Best Practice|Receive usual care
219094683|NCT04266886|PROCEDURE|Hypnotherapy|Receive self-hypnosis guided relaxation
219094684|NCT04266886|OTHER|Quality-of-Life Assessment|Ancillary studies
219094685|NCT04266886|OTHER|Questionnaire Administration|Ancillary studies
219094686|NCT04724330|BEHAVIORAL|Healthy for Two/Healthy for You|\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
219094687|NCT07085611|OTHER|Sample collection (blood and optional nasal swab)|Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur
219094688|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
219094689|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
219220485|NCT04842929|DEVICE|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
219220486|NCT06344377|DIETARY_SUPPLEMENT|Betaine|Betaine supplemented for 8 weeks
219094690|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
219220487|NCT06344377|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
219094691|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
219094692|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
219094693|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
219094694|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
219094695|NCT04296604|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
219094696|NCT04776278|BEHAVIORAL|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
219220488|NCT06012656|DEVICE|MiniMAX|Total or Partial Hip Arthroplasty
219220489|NCT02962284|DRUG|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
219220490|NCT05211154|DRUG|Diclofenac Potassium 50Mg/Pkt Oral Pwdr|Treatment for an acute, moderate to severe migraine attack
219220491|NCT05211154|DRUG|Rimegepant 75 MG|Treatment for an acute, moderate to severe migraine attack
219220492|NCT06049797|DRUG|Fezolinetant|Oral
219220493|NCT06049797|DRUG|Paroxetine|Oral
219220494|NCT06049797|DRUG|Citalopram|Oral
219220495|NCT06049797|DRUG|Escitalopram|Oral
219220496|NCT06049797|DRUG|Desvenlafaxine|Oral
219220497|NCT06049797|DRUG|Venlafaxine|Oral
219220498|NCT06049797|DRUG|Gabapentin|Oral
219220499|NCT06049797|DRUG|Clonidine|Oral
219220500|NCT06049797|DRUG|Pregabalin|Oral
219220501|NCT06049797|DRUG|Oxybutynin|Oral
219220502|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
219220503|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
219220504|NCT03294863|DEVICE|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
219220505|NCT03294863|OTHER|Standard of Care|Without the embrace Scar Therapy Device
219220506|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
219220507|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
219220508|NCT06307652|DRUG|balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
219220509|NCT06307652|DRUG|balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
219220510|NCT06307652|DRUG|dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
219220511|NCT06637631|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
219220512|NCT06637631|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
219220513|NCT05312879|DRUG|VX-147|Tablets for oral administration.
219220514|NCT05312879|DRUG|Placebo|Tablets for oral administration.
219220515|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastroenterologic tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
219220516|NCT06640231|OTHER|sealer activation after cleaning and shaping with XP-Endo Finisher|activation of sealer before the obturation of root canals
219220517|NCT06640231|OTHER|negative control where canals are obturated directly without sealer activation|sealer after cleaning and shaping before the obturation without using activation method
219220518|NCT06188741|DRUG|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
219220519|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
219220520|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
219220521|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
219220522|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
219220523|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
219220524|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
219220525|NCT06814171|OTHER|Low-carbohydrate breakfast|Daily low-carbohydrate breakfasts for one year.
219220526|NCT06814171|OTHER|Low-fat Control breakfast|Low-fat breakfasts for one year.
219220527|NCT05503446|OTHER|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
219220528|NCT03015896|OTHER|Laboratory Biomarker Analysis|Correlative studies
219220529|NCT03015896|DRUG|Lenalidomide|Given PO
219220530|NCT03015896|BIOLOGICAL|Nivolumab|Given IV
219220531|NCT04244942|DEVICE|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
219220532|NCT04809025|DEVICE|endoscopy|gastroscope
219220533|NCT04809025|PROCEDURE|Surgery|radical gastrectomy
219220534|NCT00259142|DRUG|Chloroquine, sulphadoxine-pyrimethamine|
219220535|NCT04756648|DRUG|CT0180 Cells|Five dose levels were tentatively determined.
219094697|NCT04776278|BEHAVIORAL|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
219094698|NCT04776278|BEHAVIORAL|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
219094699|NCT04776278|OTHER|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
219094700|NCT06910358|DRUG|Placebo|Oral dose, once a day for 24 weeks
219094701|NCT06910358|DRUG|DISC-1459|Oral dose, once a day for 24 weeks
219094702|NCT05885334|OTHER|Control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
219220536|NCT02945059|PROCEDURE|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
219220537|NCT01746576|OTHER|Use of impedance threshold device during spontaneous ventilation|
219220538|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
219220539|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
219220540|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
219220541|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
219362132|NCT03782935|DIETARY_SUPPLEMENT|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
219220542|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
219094703|NCT05885334|OTHER|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
219220543|NCT05549323|DRUG|PF-07054894|Oral
219220544|NCT05549323|DRUG|Placebo|Placebo
219220545|NCT06336382|DIAGNOSTIC_TEST|Tau PET imaging scan|Subjects will be scanned with novel tau PET tracer \[18F\] PI-2620 to determine whether neurofibrillary tangle pathology is present.
219220546|NCT04129372|BEHAVIORAL|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
219220547|NCT04926519|OTHER|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
219220548|NCT06367387|DRUG|Patient-Oriented Dosing (POD)|"Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference."
219094704|NCT05885334|OTHER|Augmented Reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
219094705|NCT06239545|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
219094706|NCT06921720|DIAGNOSTIC_TEST|intra-muscular ATP values in phosphate diabetes|intra-muscular ATP values \[ATPi\] (measured by 31P-MRS / Phosphorus-31 nuclear magnetic resonance) at rest and during standardized exercise in patients with phosphate diabetes.
219094707|NCT06921720|DIAGNOSTIC_TEST|intra-muscular phosphate values in phosphate diabetes|intra-muscular phosphate values (measured by 31P-MRS) at rest and during standardized exercise in patients with phosphate diabetes.
219094709|NCT07118072|BEHAVIORAL|Internet-Delivered Skills Training in Affective and Interpersonal Regulation|Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) is a psychological intervention that is focused on applying skills to improve emotion regulation difficulties and reduce interpersonal problems over two months (eight sessions; one session per week). i-STAIR also significantly reduces PTSD symptoms without direct discussion of the trauma and may be used alone or adjunctively to boost the effects of trauma-focused therapies.
219094710|NCT07118072|BEHAVIORAL|Online general psychoeducation|Online general psychoeducation will focus on the teaching the link between adverse childhood experiences and depression, as well as teaching healthy lifestyle changes involving diet, exercise, and sleep. The online general psychoeducation will involve engaging presentations, active discussions, and self-directed homework activities.
219094711|NCT06923592|COMBINATION_PRODUCT|PvSeroTAT|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of all eligible cluster inhabitants. In the clusters in the PvSeroTAT arm, participants with a positive P. vivax serology at baseline or month 6 will be treated with 7 days of primaquine 0.5mg/kg/day and a three-day course of either chloroquine (Ethiopia) or artesunate-amodiaquine (Madagascar).
219094712|NCT06923592|DIAGNOSTIC_TEST|Control|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of a subset of eligible cluster inhabitants. Serological status will be assessed at a later stage (months later) and will not lead to treatment of sero-positive individuals.
219094713|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
219094714|NCT07129382|DRUG|CS32582 capsule（low dose） or matched placebo|CS32582 capsule（low dose） or matched placebo，4 weeks
219094715|NCT07129382|DRUG|CS32582 capsule（high dose） or matched placebo|CS32582 capsule（high dose） or matched placebo，4 weeks
219094716|NCT07129382|DRUG|CS32582 capsule（low dose）|CS32582 capsule（low dose），12 weeks
219094717|NCT07129382|DRUG|CS32582 capsule（medium dose）|CS32582 capsule（medium dose），12 weeks
219094718|NCT07129382|DRUG|CS32582 capsule（high dose）|CS32582 capsule（high dose），12 weeks
219362133|NCT04890210|DIETARY_SUPPLEMENT|Early Diet Group|Initiation of clear fluid diet 1 hour after esophageal variceal ligation
219220549|NCT06367387|BEHAVIORAL|Pain Self-Management (PSM)|"Pain self-management (PSM) is a manualized behavioral intervention consisting of 12 sessions, comprising 6 group and 6 individual sessions. The first session will be individual, followed by a group session, and then alternating weekly for the remainder of the intervention.~Individual sessions will be led by a staff Interventionist trained in the pain self-management intervention. The interventionist will guide participants through a PSM study manual, providing education, teaching associated skills, and assisting with goal setting.~Group sessions will be led by a Peer Facilitator who has experience with chronic pain, opioid use disorder, and buprenorphine treatment. These sessions will not have specific content but will serve as supportive forums for participants to discuss their experiences with the intervention, share tips for managing chronic pain, and provide mutual support."
219220550|NCT06367387|BEHAVIORAL|Usual Care|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions."
219220551|NCT06367387|DRUG|Standard Buprenorphine Dosing Condition|Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
219220552|NCT05117541|OTHER|Interview|Participate in interviews
219220553|NCT05117541|PROCEDURE|Biospecimen Collection|Undergo collection of hair samples
219220554|NCT05117541|OTHER|Electronic Health Record Review|Medical records are reviewed
219220555|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
219220556|NCT03415412|DEVICE|IBond Universal|Adhesive systems
219220557|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
219220558|NCT06526286|OTHER|Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)|Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.
219094719|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
219094720|NCT06942936|DRUG|AZD5004|AZD50004 is administered orally as a tablet.
219094721|NCT06942936|DRUG|Itraconazole|Itraconazole is administered orally as a capsule.
219094722|NCT06942936|DRUG|EE/LNG|EE/LNG is administered orally in the form of tablet.
219094723|NCT06949631|DIETARY_SUPPLEMENT|Resistant Potato Starch|Active Ingredients: 3.5 g potato starch Inactive ingredients: 3.5 g corn starch
219094724|NCT06949631|OTHER|Placebo|Active Ingredients: N/A Inactive Ingredients: 7 g corn starch
219094725|NCT07143383|BEHAVIORAL|Social Prescribing|SP is a person-centered approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioral activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that match their preferences.
219094726|NCT07143383|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of a CAMHS clinician or researcher meeting with YP identified and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
219094727|NCT06952803|DRUG|Saruparib|Saruparib will be administered orally.
219094728|NCT06952803|DRUG|Placebo|Matching placebo to saruparib will be administered orally.
219094729|NCT06952803|DRUG|Abiraterone + Prednisolone/Prednisone|Abiraterone will be administered orally in combination with prednisone/prednisolone.
219094730|NCT06952803|DRUG|Androgen Deprivation Therapy (ADT)|Standard of care ADT will be administered.
219220559|NCT05561556|DIETARY_SUPPLEMENT|MitoQ|One 20mg capsule daily for 8 weeks
219220560|NCT02268708|PROCEDURE|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
219220561|NCT04082507|DIAGNOSTIC_TEST|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
219220562|NCT05794594|DEVICE|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
219220563|NCT03264547|DRUG|Pertuzumab|Every 3 weeks
219220564|NCT03264547|DRUG|Trastuzumab|Every 3 weeks
219220565|NCT03264547|DRUG|Docetaxel|Every 3 weeks
219220566|NCT03264547|DRUG|Paclitaxel|Every week
219220567|NCT03264547|DRUG|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
219220568|NCT01085513|DEVICE|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
219220569|NCT05588453|BIOLOGICAL|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
219220570|NCT05588453|DRUG|Temozolomide|Given PO
219220571|NCT03701308|PROCEDURE|Biospecimen Collection|Undergo blood collection
219220572|NCT03701308|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
219220573|NCT03701308|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219220574|NCT03701308|DRUG|Cytarabine|Given IV
219220575|NCT03701308|DRUG|Daunorubicin|Given IV
219220576|NCT03701308|PROCEDURE|Echocardiography Test|Undergo ECHO
219220577|NCT03701308|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219220578|NCT03701308|DRUG|Uproleselan|Given IV
219220579|NCT00903110|DRUG|Increlex®|Increlex® (mecasermin \[rDNA origin\] injection), 10 mg/ml solution for injection, 40-120mcg/kg BID or 0,04 to 0,12 mg/kg BID, as prescribed by physician
219220580|NCT03770429|DRUG|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
219220581|NCT06545916|DRUG|Sunobinop|1 tablet taken orally at bedtime
219094731|NCT06520358|OTHER|Acute Intermittent Hypoxia (AIH)|Acute intermittent hypoxia refers to brief (acute), repetitive (intermittent) episodes of breathing oxygen-deprived air (hypoxia) alternating with breathing ambient room air.
219094732|NCT06520358|BEHAVIORAL|Task specific Airway Protection Training|The vLVC maneuver involves training participants to volitionally prolong closure of the laryngeal vestibule during swallowing, beginning with swallow onset and sustaining closure for at least 2 seconds.
219220582|NCT06545916|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
219220583|NCT05303467|DEVICE|TheraSphere GBM|Single treatment of TheraSphere GBM device
219220584|NCT04187443|DRUG|MS-553|MS-553
219220585|NCT05014412|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219094733|NCT06520358|OTHER|Sham AIH|Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
219094734|NCT07153237|DEVICE|STYLAGE® HydroMax|3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)
219094735|NCT07153107|OTHER|Local Heat Therapy|"This will use a simple device provided to participants named jaw bra, which is a head wrap with straps that goes around the chin and head that holds heated gel packs over the cheeks area"
219094736|NCT07160400|DRUG|Placebo|Single dose placebo IBI3032 administered orally
219094737|NCT07160400|DRUG|IBI3032 tablets|Single dose of IBI3032 administered orally
219094738|NCT07166172|DEVICE|Fetal Treatment Arm (FETO Group)|Participants will undergo FETO surgery between 27 weeks 0 days to 29 weeks 6 days gestation. The FETO intervention involves two procedures: (1) inserting a balloon into the fetal trachea, and (2) removing the balloon before delivery. After the first FETO procedure, participants will be monitored weekly by ultrasound. Removal of the balloon will be performed at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age.
219094739|NCT07166406|BIOLOGICAL|Atezolizumab|Given IV
219094740|NCT07166406|BIOLOGICAL|Bevacizumab|Given IV
219094741|NCT07166406|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219094742|NCT07166406|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
219094743|NCT07166406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219094744|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219094745|NCT07166406|OTHER|Questionnaire Administration|Ancillary studies
219094746|NCT07166406|BIOLOGICAL|Tremelimumab|Given IV
219094747|NCT07166406|BIOLOGICAL|Durvalumab|Given IV
219094748|NCT07166406|BIOLOGICAL|Nivolumab|Given IV
219094749|NCT07166406|DRUG|Ipilimumab|Given IV
219094750|NCT07166406|RADIATION|Stereotactic Body Radiation Therapy|Undergo liver SBRT
219094751|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219094752|NCT07165457|DIETARY_SUPPLEMENT|Probiotic group|Daily consumption of one capsule containing a probiotic for 15 days
219094753|NCT07166757|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
219094754|NCT07164716|OTHER|plantar fascia recovery training group|plantar fascia recovery training group: Gliding massage,Soft tissue mobilization,Metatarsophalangeal Joint Stretching,Foam roller
219094755|NCT07164703|DRUG|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
219094756|NCT07164690|RADIATION|Low Dose Radiation Therapy|"A dose of 2 Gy/1Fx will be delivered to all currently visible lesions. Lesions in different anatomic sites may be irradiated separately, but the entire course must be completed within one week.~* Esophageal primary tumor management: If the investigator judges there is a risk of fistula or bleeding from the esophageal lesion, palliative radiotherapy at 40-50 Gy may be added.~* Immunotherapy: The original PD-1/PD-L1 inhibitor regimen will be resumed immediately after LDRT is completed and continued as maintenance therapy.~* Chemotherapy: At the investigator's discretion, standard second-line chemotherapy per the current CSCO guidelines for esophageal cancer may be administered."
219220586|NCT06680817|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
219220587|NCT04360395|BEHAVIORAL|Gait Therapy|The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
219220588|NCT05930158|OTHER|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
219220589|NCT05930158|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
219220590|NCT06016842|DRUG|Elafibranor|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
219220591|NCT06016842|OTHER|Matched 80 mg placebo|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
219220592|NCT04595266|DRUG|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
219220593|NCT04595266|BIOLOGICAL|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
219220594|NCT04595266|DRUG|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
219220595|NCT04475939|DRUG|Niraparib|Niraparib will be administered.
219220596|NCT04475939|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
219094757|NCT07164352|BEHAVIORAL|Breathing Exercises|Diaphragmatic and pursed-lip breathing exercises supervised by a physiotherapist.
219094758|NCT07164352|BEHAVIORAL|Informational Brochure|A brochure providing education about breathing exercises for cancer patients.
219094759|NCT07166536|OTHER|Provocation Test for Symptoms Using Mental Imagery|"• The mental imagery task will be guided by the examiner through continuous verbal instruction (the examiner will provide ongoing instructions throughout the entire task, not just at the beginning). During the instruction, the examiner will direct the participant's attention to visual, auditory, and proprioceptive aspects of the imagined movement or scenario. Example: Close your eyes, and without moving your head or body at all, try to imagine that you are moving your head from side to side quickly and easily, while noticing the sensation of motion, seeing the rotation through your eyes, and feeling the acceleration of your head as it moves from side to side..."
219094760|NCT07164586|DIAGNOSTIC_TEST|Respiratory Pattern Monitoring|Respiratory pattern assessment and continuous monitoring will be conducted utilizing the Respiratory Diagnostic Assistant, a device capable of providing comprehensive quantitative evaluation of respiratory variables including frequency, volume, flow rates, inspiratory/expiratory timing parameters, and respiratory entropy analysis, as well as qualitative analysis of respiratory pattern curves for volume and flow dynamics, incorporating entropy measurements for assessment of respiratory pattern complexity and variability.
219094761|NCT07164586|DIAGNOSTIC_TEST|Diaphragmatic Excursion|"Diaphragmatic mobility assessment will be conducted using diaphragmatic ultrasonography, a method capable of providing comprehensive quantitative evaluation of diaphragmatic excursion parameters including range of motion, contraction velocity, muscle thickening during inspiration and expiration, as well as qualitative analysis of diaphragm muscle morphology and echogenicity, incorporating craniocaudal displacement measurements for assessment of contractile function and early detection of diaphragmatic dysfunction."
219094762|NCT07164586|DIAGNOSTIC_TEST|Respiratory muscle electrical activity|espiratory muscle electrical activity assessment will be conducted using surface electromyography, a method capable of providing comprehensive quantitative evaluation of muscle activation parameters including electrical signal amplitude, firing frequency, muscle recruitment patterns during inspiration and expiration, as well as qualitative analysis of synchronization and coordination between respiratory muscles, incorporating Root Mean Square (RMS) measurements and spectral analysis for assessment of respiratory neuromuscular function and detection of muscle fatigue.
219094763|NCT07164586|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strength assessment will be conducted using manovacuometry, a method capable of providing comprehensive quantitative evaluation of respiratory muscle force parameters including maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), as well as qualitative analysis of contractile capacity and muscle endurance, incorporating peak pressure measurements and performance indices for assessment of global respiratory muscle function and early detection of muscle weakness
219094764|NCT07164586|DIAGNOSTIC_TEST|Pulmonary Function Assessment|"Pulmonary function assessment will be conducted using spirometry, a method capable of providing comprehensive quantitative evaluation of respiratory function parameters including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and forced expiratory flow 25-75% (FEF25-75%), as well as qualitative analysis of flow-volume and volume-time curves, incorporating lung capacity and volume measurements for assessment of respiratory mechanics and early detection of obstructive and restrictive ventilatory disorders."
219220597|NCT04475939|DRUG|Placebo|Matching placebo will be administered
219362134|NCT04890210|DIETARY_SUPPLEMENT|Late Diet Group|Initiation of clear fluid diet 6 hours after esophageal variceal ligation
219220598|NCT05980949|DRUG|KarXT|KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
219220599|NCT05980949|DRUG|KarX-EC|Specified dose on specified days
219094765|NCT07164586|OTHER|Data Acquisition System|The PowerLab C is a biomedical data acquisition system used as an auxiliary tool for physiological monitoring. In this study, it will be employed to collect respiratory signals and diaphragmatic excursion data through specific sensors, integrated with LabChart software for data visualization and analysis. The device is not considered an investigational intervention, but a supporting tool for data collection.
219094766|NCT07164586|OTHER|Nijmegen Questionnaire|The Nijmegen Questionnaire is a standardized self-report instrument designed to assess symptoms related to dysfunctional breathing and hyperventilation. In this study, it will be administered to evaluate respiratory symptoms and their impact on participants' daily life. The questionnaire is used solely for data collection and is not considered a therapeutic intervention.
219094767|NCT07164586|OTHER|System Usability Scale (SUS)|The System Usability Scale (SUS) is a standardized questionnaire used to evaluate the usability and user experience of systems and devices. In this study, it will be applied to assess participants' perceptions of the usability of an intelligent respiratory monitoring system. The SUS will be used solely as a data collection tool and does not constitute a therapeutic intervention.
219220600|NCT04956978|OTHER|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
219220601|NCT05523817|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
219220602|NCT04641247|DRUG|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
219220603|NCT03809949|DRUG|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
219220604|NCT03809949|DRUG|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
219220605|NCT06465888|OTHER|egg whites|Participants will eat four egg whites daily for the 4-week study
219220606|NCT06465888|OTHER|whole eggs|Participants will eat two eggs daily for the 4-week study
219220607|NCT06465888|OTHER|Omega-3 eggs|Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.
219220608|NCT06465888|OTHER|egg yolk|Participants will eat four egg yolks daily for the 4-week study
219220609|NCT03695601|OTHER|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
219220610|NCT04565691|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
219220611|NCT05805202|OTHER|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
219220612|NCT06387082|DRUG|HMPL-506|HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
219220613|NCT04825626|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
219220614|NCT04175938|DEVICE|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
219220615|NCT01886872|DRUG|Bendamustine Hydrochloride|Given IV
219220616|NCT01886872|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219220617|NCT01886872|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219220618|NCT01886872|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219220619|NCT01886872|PROCEDURE|Computed Tomography|Undergo CT
219220620|NCT01886872|DRUG|Ibrutinib|Given PO
219220621|NCT01886872|OTHER|Laboratory Biomarker Analysis|Correlative studies
219220622|NCT01886872|OTHER|Quality-of-Life Assessment|Ancillary studies
219220623|NCT01886872|BIOLOGICAL|Rituximab|Given IV
219220624|NCT04261894|BEHAVIORAL|OPTIMIZE|The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
219220625|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
219220626|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
219220627|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
219220628|NCT05523453|BEHAVIORAL|Processing of Positive Memories Technique (PPMT)|PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.
219220629|NCT05523453|BEHAVIORAL|Supportive Counseling (SC)|SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
219362135|NCT06144983|DRUG|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
219220630|NCT04904367|PROCEDURE|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
219220631|NCT04904367|PROCEDURE|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
219220632|NCT04941482|BEHAVIORAL|Periodic health check program for post-stroke|The stroke survivors were assessed for their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months using specific scales.
219220633|NCT04941482|BEHAVIORAL|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises were designed and guided for each patient, and they were followed up by the daily online report.
219094768|NCT07164586|OTHER|Borg Scale|The Borg Scale is a standardized self-report instrument used to assess perceived exertion and breathlessness during physical activity. In this study, it will be applied to evaluate participants' perception of respiratory effort. The scale is used solely for data collection and is not considered a therapeutic intervention.
219094769|NCT07164586|OTHER|Patient Identification Questionnaire|The Patient Identification Questionnaire is a standardized form used to collect sociodemographic and basic clinical information from participants, such as age, sex, and medical history. In this study, it will serve solely for data collection and will not constitute a therapeutic intervention.
219094770|NCT07164586|DIAGNOSTIC_TEST|Peak Expiratory Flow (PEF) Measurement|Peak Expiratory Flow (PEF) measurement is a rapid and noninvasive method to assess the maximum expiratory volume a participant can achieve after a full inhalation. In this study, participants will be seated upright and use a mouthpiece connected to a peak flow meter. After a deep inspiration, they will exhale forcefully, and three measurements will be taken with at least one minute between attempts; the highest value will be recorded. PEF values provide an objective measure of airflow limitation, correlate with asthma symptoms, and will be used solely for data collection, not as a therapeutic intervention
219220634|NCT04941482|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
219220635|NCT04941482|DEVICE|Functional near-infrared spectroscopy|The fNIRS devices served as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measurement by fNIRS could detect various mental disorders such as depression, anxiety, schizophrenia early through cognitive tasks.
219220636|NCT04132414|DIAGNOSTIC_TEST|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
219220637|NCT05740540|DEVICE|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
219220638|NCT05740540|DEVICE|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
219094771|NCT07164170|DRUG|ABSK043 in combination with Glecirasib|"Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose.~Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses.~Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity.~All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
219094772|NCT07164872|RADIATION|preoperative radiotherapy|preoperative radiotherapy
219094773|NCT07165574|OTHER|No intervention as the study is observational|As this is an observation study, participants are not assigned an intervention as part of the study
219094774|NCT07165665|OTHER|Bobath (Neurodevelopmental Treatment) approach|The control group will receive only the standard Bobath (Neurodevelopmental Treatment, NDT) approach.
219094775|NCT07165665|DEVICE|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|The intervention group will receive the standard Bobath (Neurodevelopmental Treatment, NDT) approach combined with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS).
219094776|NCT07165067|DRUG|AP601|AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months. All doses of AP601 will be admistered intraveneously. The infusion time for all doses of AP601 in each patient will be approximately 60 to 120 minutes.
219220639|NCT02509442|PROCEDURE|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
219220640|NCT05002335|DEVICE|Medacta Shoulder System|Performance of Total Shoulder Arthroplasty (anatomic/reverse) with Medacta Shoulder System
219094777|NCT07164885|RADIATION|Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）|RAPART technology is a special combination of ART and RAPRT, with a total course limit of no more than 30 exposures. The entire course of treatment can be divided into two stages: the first stage is completely the same as the conventional radiotherapy group, with a total of 23 doses of 2 Gy per session. The second stage is the combination of ART and PAPRT. ART uses a CT or PET/CT localization simulation to be performed again during the course of treatment (usually after completing the first part of 17-19 exposures) to generate a new adaptive plan, and after completing the first stage of 23 exposures, treatment is carried out according to the new adaptive plan. RAPAT uses ERCC1/2 biomarkers to predict the patient's radiation sensitivity and determine individualized radiation dose accordingly. ERCC1/2 biomarkers divided patients into 5 different radiosensitivity groups, corresponding to 5 different radiation doses (74, 66, 62, 54, and 50 Gy).
219094778|NCT07164885|RADIATION|Conventional radiotherapy|conventional radiotherapy
219094779|NCT07165080|DEVICE|smART+ REE|The two study devices will be used simultaneously: the patient's respiratory equipment will be connected directly to the smART+ REE module, and then the COSMED Q-NRG+ will be connected just downstream of that. See the diagram and key below:
219094780|NCT07166055|OTHER|Therapeutic dance|The protocol includes two sessions per week of therapeutic dance, during the months of October to May.
219094781|NCT07165184|OTHER|no intervention was applied as observation study|no intervention was applied as observation study
219094782|NCT07165834|BEHAVIORAL|"Treatment group. Take your sexuality back"|The intervention is trauma-sensitive and focus both on traumatized sexuality and positive sexuality. It incorporates regulatory skills to prevent re-traumatization when addressing sex-positive themes, thus accommodating a wide range of trauma-related symptoms, sexual shame, sexual dysfunctions, and regulation difficulties. The intervention integrates psychoeducation, exercises, reflections and sharing.
219094783|NCT07166419|BIOLOGICAL|Autologous Anti-CD19/CD20/CD22 CAR T-cells|Given IV
219094784|NCT07166419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219094785|NCT07166419|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219094786|NCT07166419|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219094787|NCT07166419|PROCEDURE|Computed Tomography|Undergo PET/CT
219094788|NCT07166419|DRUG|Cyclophosphamide|Given IV
219094789|NCT07166419|PROCEDURE|Echocardiography Test|Undergo echocardiography
219094790|NCT07166419|DRUG|Fludarabine|Given IV
219094791|NCT07166419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219094792|NCT07166419|PROCEDURE|Pheresis|Undergo apheresis
219094793|NCT07166419|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219094794|NCT07165873|PROCEDURE|Erector Spinae Plane Block|30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
219094795|NCT07165873|PROCEDURE|Serratus anterior plane block (SAP)|10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
219094796|NCT07165873|PROCEDURE|Serratus posterior superior intercostal plane block|30 mL of 0.25% bupivacaine was injected into the plane between the serratus posterior superior muscle and the rib.
219094797|NCT07164794|DRUG|Memantine Hydrochloride|"Memantine Hydrochloride is administered orally, once daily, in combination with the patient's ongoing standard of care treatment for metastatic castration-resistant prostate cancer (mCRPC).~The dosing follows a weekly titration schedule for the first three weeks to reach the maintenance dose.~Week 1: 5 mg once daily. Week 2: 10 mg once daily. Week 3: 15 mg once daily. Week 4 and onwards: 20 mg once daily. This intervention is being studied to evaluate its potential to reduce neuroendocrine differentiation and correct castration resistance in advanced prostate cancer."
219094798|NCT07165964|BEHAVIORAL|Personal interventions in Climateric|"The intervention group (IG) will participate in the climacteric care program. Each participant will receive a personal access code to a Moodle-based virtual campus, where they will find specially designed podcasts and videos, provided in addition to standard care. These digital pills have been developed by subject matter experts to support self-care during the climacteric stage and to promote positive mental health (PMH). Each resource is followed by a short quiz to assess engagement, knowledge acquisition, and adherence. A final satisfaction survey will also be included. IG participants will have two months of access to explore the content, complete the quizzes, and interact with the platform.~The intervention includes the following modules:~MODULE 1: INTRODUCTION TO THE CLIMACTERIC/MENOPAUSE MODULE 2: DIETARY HABITS AND PHYSICAL ACTIVITY MODULE 3: PSYCHOEMOTIONAL MANAGEMENT"
219094799|NCT07166146|OTHER|Surgical interventions|By leveraging a wide array of surgical interventions - including endoscopic surgery, minimally invasive surgery combined with urokinase, and craniotomy - the TORCH registry intends to provide a granular view of early hematoma evacuation surgical interventions and their impact on patient recovery and quality of life.
219094800|NCT07165821|BEHAVIORAL|Interpersonal Communication Skills Training Program|This program was developed based on DeVito's communication theory and integrated with the positive reinforcement-based interpersonal communication training developed by Thiengwiriyakul et al.(11) This program was evaluated by a panel of three experts-a psychiatrist, a psychiatric nurse, and a psychiatric nursing academic-who assessed content relevance, appropriateness, and language clarity. After revisions based on their feedback, the program achieved a Content Validity Index (CVI) of 0.93, exceeding the acceptable threshold.
219094801|NCT07165821|BEHAVIORAL|Usual care|Received routine psychiatric nursing care
219094802|NCT07164274|OTHER|Questionnaire|An online questionnaire that will be shared via online platforms for medical students and interns in the Middle East countries to fill.
219094803|NCT07165249|BEHAVIORAL|Positional release technique (PRT)|Group A (PRT): Patients lay prone for the application of the hot pack. PRT was then applied to the erector spinae muscles. The therapist identified tender points and passively positioned the patient into a position of comfort, typically involving lateral trunk flexion toward the symptomatic side. Each session involved three 90-second holds per tender point. PRT procedures followed standardized positioning principles as described in previous literature.
219362136|NCT06144983|DRUG|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
219682526|NCT03526042|DRUG|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
219094804|NCT07165249|BEHAVIORAL|Muscle energy technique|Group B (MET): Following the hot pack application, patients were assessed for segmental dysfunction via palpation of lumbar transverse processes in prone position. MET was applied using isometric contractions aimed at correcting lumbar rotational or side-bending dysfunctions. Each contraction was held for 7-10 seconds, followed by a passive stretch. The technique was repeated for 3-5 cycles per session.
219094805|NCT07164469|DRUG|Fludarabine|Given by IV
219094806|NCT07164469|DRUG|Cyclophosphamide|Given by IV
219094807|NCT07164469|DRUG|CD70.CAR NK Cells|Given by IV Infusion
219094808|NCT07164469|DRUG|Rimiducid (AP1903)|Given by IV Infusion
219094809|NCT07166497|OTHER|Cosmetic product RV4660C CY0203|The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements.
219094810|NCT07164365|BEHAVIORAL|Interdisciplinary Shared Decision-Making Consultation|One additional face-to-face consultation with a team (oncologist, palliative care, psychologist), following a six-step shared decision-making process.
219094811|NCT07165353|BEHAVIORAL|Virtual Walking|This virtual walking therapy uses a life-sized video avatar of the participant walking through a forest environment. A green screen setup combines a live video of the participant's upper body with pre-recorded walking legs, creating a full-body walking illusion. The participant is seated in a modified wheelchair that tilts 2° to each side to mimic pelvic movement during walking. This approach differs from the sham condition (Group 2), which displays only the moving forest without an avatar or wheelchair tilt, and from the standard care group (Group 3), which receives no virtual walking therapy.
219094812|NCT07165353|BEHAVIORAL|Sham Virtual Walking|Participants view a moving forest environment on a large projection screen for 10 sessions over 2 weeks (each up to 20 minutes). No avatar of the participant is displayed, and the wheelchair tilt function is disabled. This differs from the experimental intervention (Group 1), which includes a life-sized walking avatar and wheelchair tilt to mimic pelvic movement, and from the standard care group (Group 3), which receives no virtual walking therapy.
219220641|NCT03722303|OTHER|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
219220642|NCT03722303|DRUG|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
219094813|NCT07165171|PROCEDURE|Innovative periodontal monitoring (SuP innovative)|"Different types of SMS messages will be sent alternately.~* Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients.~* Type 2 SMS: Interactive SMS text messages written in the form of questions.~* Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment.~The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient:~* 1 Type 1 SMS/week (medical advice or information);~* 1 Type 2 SMS/month (interactive with suggested answers);~* 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up."
219094814|NCT07166705|OTHER|Metaverse-Based Education Group|"As part of this intervention, participants will receive palpation skills training in a metaverse-based virtual learning environment. The training consists of three modules, each of which will cover the palpation of a different anatomical region:~* Module 1: Cervical region palpation~* Module 2: Thoracic region palpation~* Module 3: Lumbo-pelvic region palpation The training will be delivered in a three-dimensional virtual classroom environment using avatars. Participants will engage in interactive exercises based on scenarios structured on the metaverse platform and, under the guidance of an instructor, will practice palpation techniques on virtual patient models.~Sessions will be conducted in a group format, allowing students to interact with each other in real-time. Voice communication, motion tracking, and virtual feedback mechanisms will be used throughout the training."
219094815|NCT07166705|OTHER|Distance/Online Education Group|"As part of this intervention, a palpation skills course will be delivered to participants online via the Microsoft Teams application. The training consists of three modules, each of which will cover the palpation of different anatomical regions.~Module 1: Cervical region palpation Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation The training will utilize theoretical information, visual materials, and live/pre-recorded practice videos. Participants will attend the course as a group and participate in structured learning sessions guided by the instructor in each module."
219094816|NCT07166705|OTHER|Traditional Face-to-Face Education Group|"As part of this intervention, participants will be taught palpation skills in a face-to-face classroom setting using traditional teaching methods. The training consists of three modules:~Module 1: Palpation of the cervical region Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation Throughout the training, the instructor will conduct structured theoretical presentations, demonstrations, and face-to-face practice sessions. Students will observe palpation techniques through live demonstrations by the instructor and then have the opportunity to practice one-on-one."
219094817|NCT07166354|DRUG|CS-002|CS-002 Topical Treatment
219094818|NCT07166354|DRUG|Placebo Topical Solution|Placebo Topical Solution
219094819|NCT07165626|DEVICE|Subtreshold micropulse laser therapy|Laser-treated group will receive additional subthreshold micropulse laser therapy (SMLT) 1 month after pars plana vitrectomy (PPV), using a 577 nm solid-state yellow diode laser applied to the macular area (thirty 5 × 5 spot sizes of 160 µm, zero-spot spacing, including the fovea; fixed power 250 mW; exposure time 200 ms; micropulse mode, 5% duty cycle). Control group (nonlaser group) will not receive additional laser treatment.
219094820|NCT07165626|PROCEDURE|Pars plana vitrectomy|Both groups will undergo pars plana vitrectomy (PPV) with epiretinal membrane (ERM) and internal limiting membrane (ILM) peeling prior to allocation to study arms.
219094821|NCT07166692|OTHER|Prof. Valmed|Prof Valmed. decision support system.
219094822|NCT07165431|DIETARY_SUPPLEMENT|Postbiotic + nutritional recommendations|Study participants will consume daily one gummy containing a postbiotic formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
219094823|NCT07165431|DIETARY_SUPPLEMENT|Placebo + nutritional recommendations|Study participants will consume daily one gummy containing a placebo formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
219220643|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
219220644|NCT05980481|DRUG|RC48-ADC（2.5mg/kg）|2.5 mg/kg intravenous infusion every 2 weeks
219220645|NCT05980481|DRUG|Trastuzumab|First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks
219220646|NCT05980481|DRUG|Toripalimab|3.0 mg/kg intravenous infusion every 2 weeks
219220647|NCT05980481|DRUG|Oxaliplatin（130mg/m2 ）|130mg/m2 intravenous infusion Q3W
219220648|NCT05980481|DRUG|Capecitabine（1000mg/m2）|1000mg/m2 per os Q3W
219220649|NCT05980481|DRUG|RC48-ADC（2.0mg/kg）|2.0 mg/kg intravenous infusion every 2 weeks
219220650|NCT05980481|DRUG|Capecitabine（750mg/m2）|750mg/m2 per os Q3W
219220651|NCT05980481|DRUG|Oxaliplatin（100mg/m2 ）|100mg/m2 intravenous infusion Q3W
219094824|NCT07165327|DEVICE|Injection Port for Insulin Administration|For two weeks, participants will use an injection port device for all prescribed insulin doses during pregnancy. The port is inserted and replaced approximately every 3 days. Insulin is delivered through the port using standard syringes or insulin pens, eliminating the need for multiple daily needle sticks.
219094825|NCT07165327|DEVICE|Single-Use Insulin Needles|For two weeks, participants will use standard single-use disposable needles for all prescribed insulin doses during pregnancy. A new sterile needle will be used for each injection, consistent with routine clinical practice.
219094826|NCT07165678|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
219094827|NCT07165223|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
219094828|NCT07165223|DRUG|Insulin Icodec group|insulin Icodec s.c., once-weekly，treat-to-target dose
219094829|NCT07165717|OTHER|No Intervention: Observational Cohort|Obsercational study
219094830|NCT07166367|DRUG|ASLAN001|400mg of Oral ASLAN001 is administered twice daily, every day of each 21-day cycle
219094831|NCT07166367|DRUG|Capecitabine|1000mg/m\^2 of Oral Capecitabine is administered twice daily, on Days 1-14 of a 21-day cycle
219094832|NCT07166809|OTHER|Pelvic Floor Muscle Training (PFMT)|A structured pelvic floor muscle training program delivered remotely for 8 weeks, including exercises designed to strengthen and improve the endurance, coordination, and control of the pelvic floor muscles.
219094833|NCT07166809|OTHER|Pelvic Floor Muscle Training combined with Dynamic Neuromuscular Stabilization (PFMT+DNS)|Participants received the same 8-week remotely monitored pelvic floor muscle training program as the PFMT group, in addition to supervised Dynamic Neuromuscular Stabilization exercises three times per week. DNS exercises aimed to enhance core stability, postural control, and coordination to support pelvic floor muscle function.
219094834|NCT07164547|DIETARY_SUPPLEMENT|Tribulus terrestris extract|625 mg oral capsule (40% saponins), single dose
219094835|NCT07164547|OTHER|Cellulose capsule (placebo)|Oral cellulose capsule, identical in appearance
219094836|NCT07164976|DRUG|Ribociclib 400mg|phase 1b cohort 1
219094837|NCT07164976|DRUG|Ribociclib 600mg|Phase 1b cohort 2
219094838|NCT07164976|DRUG|Ribociclib 600mg|phase 2
219094839|NCT07166653|BEHAVIORAL|HaH education|"The intervention consists of the online NorDigHE HaH education with tailored implementation tools em-bedded in the WHO Fast-IM. The education is delivered online and asynchronously, combining e-learning, simulations, reflection exercises, and practical task training.~The trial has adopted the evidence-based WHO Fast-track Implementation Model (WHO Fast-IM) as a framework to support the effectiveness and reporting of the implementation, and the tailored implementation tools embedded in the model will be provided as part of the intervention to support in-tegration into daily clinical routines. The tailored toolbox consists of workshops, introductory meetings, written guides, and access to a hotline staffed by project specialists to facilitate implementation."
219094840|NCT07165392|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
219094841|NCT07165392|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
219094842|NCT07165392|OTHER|Stretching|To stretch the muscles involved, 3 periods of maximum tolerable stretching without pain will be performed, lasting 20 seconds and resting for 30 seconds.
219094843|NCT07166848|DEVICE|Electrodes with Currents|Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins
219094844|NCT07166848|DEVICE|Electrodes without Currents|Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins
219094845|NCT07165470|DIETARY_SUPPLEMENT|pre-packaged low-residue diet for bowel preparation|Participants will be provided with 6 sachets of pre-packaged low-residue diet one day prior to colonoscopy
219220652|NCT05003414|DEVICE|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
219220653|NCT05688982|BEHAVIORAL|General information provision|Patients will receive information with general oral health and aSDoH resources.
219220654|NCT05688982|BEHAVIORAL|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
219094846|NCT07165769|DRUG|Induction Therapy|"All enrolled patients will receive the ZGR regimen (zanubrutinib, obinutuzumab, and lenalidomide) for induction therapy. Each cycle lasts 28 days, up to 6 cycles, followed by maintenance therapy. Patients experiencing disease progression during induction will discontinue the trial drugs but remain under survival follow-up.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Obinutuzumab: 1000 mg via intravenous infusion, administered on Days 1, 8, and 15 of Cycle 1 and subsequently on Day 1 of Cycles 2-6.~3. Lenalidomide: 25 mg once daily, taken orally on Days 1-21 of each 28-day cycle until disease progression. Doses should be taken at approximately the same time daily."
219094847|NCT07165769|DRUG|Maintenance Therapy|"Maintenance therapy consists of zanubrutinib plus lenalidomide:~Lenalidomide is continued for 1 year. Zanubrutinib is continued for 2 years. Treatment continues until disease progression, intolerability, or completion of 2 years. For patients who do not achieve complete remission (CR), therapy may continue until progression or intolerability.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Lenalidomide: 10 mg once daily, taken orally on Days 1-21, followed by a 7-day rest period, constituting a 28-day cycle."
219094848|NCT07164638|PROCEDURE|lung ultrasound (LUS)|Serial lung ultrasound will be performed to patients enrolled in this study before the beginning of the surgery, every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.lung ultrasound will be used as a tool for monitoring of EVLW to identify early the subclinical pulmonary edema and ensure timely and correct diagnosis and appropriate management.
219094849|NCT07164638|PROCEDURE|IVC collapsibility index|Serial assessment of IVC collapsibility will be used as a monitoring of volume overload in patients enrolled in this study. Basal IVC scanning using ultrasound will be performed before the start of the operation and serial IVC scanning will be done during the procedure every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.
219094850|NCT07166276|OTHER|coffee|The type of coffee consumed, the daily amount of coffee, and the frequency of consumption were measured.
219094851|NCT07164222|DIAGNOSTIC_TEST|Glycated haemoglobin and triglycerides level|Follow up with triglycerides and glucose index and ratio on diabetic type 2
219220655|NCT05688982|BEHAVIORAL|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
219220656|NCT04638478|OTHER|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
219220657|NCT04130269|OTHER|No intervention|Questionnaires, lab-run
219220658|NCT06421675|DRUG|Elranatamab injection|Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
219220659|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
219220660|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
219220661|NCT05874414|DRUG|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
219220662|NCT05191030|BEHAVIORAL|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
219220663|NCT04853251|DEVICE|PDS Implant With Ranibizumab 100 mg/ml|Ranibizumab 100 mg/mL will be delivered via PDS
219220664|NCT04853251|DRUG|LUCENTIS (Ranibizumab Injection)|Ranibizumab (0.5 mg intravitreal \[IVT\] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.
219220665|NCT06030037|BIOLOGICAL|Healthy Donor Fecal Microbiota Transplantation (hdFMT)|hdFMT (induction) via colonoscopy or oral capsule on C1D1 and C3D1. hdFMT (maintenance) via sigmoidoscopy or oral capsules will be repeated every 9 weeks.
219220666|NCT06030037|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
219220667|NCT06030037|DRUG|Lenvatinib|Lenvatinib will be administered at 20 mg daily
219220668|NCT05150015|DEVICE|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
219094852|NCT07165418|DRUG|Vorolanib Tablets+Everolimus|Subjects received oral vorinib 200 mg once daily (QD) plus everolimus 5 mg once daily (QD), administered within 30 minutes after breakfast daily. Treatment cycles lasted 28 days and continued until disease progression.
219094853|NCT07165418|DRUG|Sunitinib|Subjects received oral sunitinib 50 mg once daily (QD) in a 4-week on, 2-week off regimen or a 2-week on, 1-week off regimen until disease progression.
219094854|NCT07164560|BIOLOGICAL|Anti-TRBC1 CAR-T cells|lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR
219220669|NCT04995081|BIOLOGICAL|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
219220670|NCT04995081|OTHER|Placebo|Sterile Saline Solution 0.9%
219220671|NCT02392442|OTHER|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
219220672|NCT02392442|BIOLOGICAL|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
219220673|NCT04029896|BIOLOGICAL|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
219220674|NCT06259851|BEHAVIORAL|Dialectical behavioral therapy program|Dialectical behavioral therapy (DBT) program with all the standard DBT modules (individual therapy 1 hour per week, skills group 3 hours per week, phone coaching, and therapist consultation team 1,5 hour per week). The program takes 24 weeks in total comprising two 12-week runs of skills training. The program will be precluded with 4 individual sessions of pretreatment before the start of the main program part.
219220675|NCT06259851|DEVICE|Prefrontal rTMS treatment|rTMS will be performed by DuoMag XT with 70BF cool coil. Patients will undergo 15 daily stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds. Gradual titration of the individual resting motor threshold (RMT) will apply, meaning probands will undergo first session with 90% RMT intensity, second session with 100% RMT intensity, third session with 110% RMT intensity. All the following sessions will use the final 120% RMT intensity. In case a session is left out because of any reason, the total duration of treatment will be prolonged by one day, so that the total number of sessions underwent is the same in all patients. Patients will receive 2000 pulses during one session (total 30000 pulses during the whole procedure) with 10 Hz frequency.
219220676|NCT06259851|DEVICE|Sham rTMS sessions|Sham TMS will be performed by sham coil that looks identical to DuoMag XT in the active group. Patients will undergo 15 daily sham stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds.
219220677|NCT04909203|DEVICE|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
219220678|NCT04909203|DEVICE|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
219220679|NCT02579967|DRUG|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
219220680|NCT02579967|DRUG|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
219220681|NCT02579967|DRUG|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
219220682|NCT02579967|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
219220683|NCT02579967|PROCEDURE|Allo BMT|Allogeneic blood or marrow transplantation
219094855|NCT07166575|DIAGNOSTIC_TEST|B-mode ultrasonography|Thickness and cross-sectional area of upper trapezius muscle
219094856|NCT07165808|OTHER|Nicotine pouch: Low dose|Nicotine pouch: 3-4 mg
219094857|NCT07165808|OTHER|Nicotine pouch: High dose|Nicotine pouch: 6-8 mg
219094858|NCT07165808|OTHER|Low pH|Nicotine pouch with low pH level \[\<8.5\]
219094859|NCT07165808|OTHER|High pH|Nicotine pouch with high pH level \[\>8.5\]
219094860|NCT07164898|DEVICE|Test patches|Patches (incontinence product cut outs) either dry, 50% saturated with water or 100% saturated with water applied to the forearm and worn for 2 hours
219094861|NCT07164846|DEVICE|Therapy Sessions|You will complete up to 12 sessions using the Neuro20 suit under the direct supervision of study staff. Each session will be 1-2 hours in duration. Each session, you will change into the suit and then receive no more than 105 minutes of electrical stimulation, and then change out of the suit and have a skin check. The suit has 20 electrodes that will stimulate muscles in your upper arm (above the elbow), upper leg (above the knee), chest, abdominals, and back. Stimulation levels will be adjusted to your comfort. You will likely feel tingling and/or muscle contractions. The timing and intensity of each type of activity will depend on your individual needs and will be prescribed by the study doctor.
219094862|NCT07166445|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
219094863|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Peritoneal Fluid Level|Measurement of peritoneal fluid levels of Angiopoietin-like protein-4 (ANGPTL4) level by ELISA method.
219094864|NCT07164196|OTHER|Cancer Antigen 125 (CA-125) Serum Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
219220684|NCT02581085|DRUG|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
219220685|NCT02581085|OTHER|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
219220686|NCT05672199|DRUG|Efavaleukin alfa|Subcutaneous (SC) injection
219220687|NCT05672199|DRUG|Placebo|SC injection
219220688|NCT04907188|BIOLOGICAL|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10\^8 cells) cells approximately every 28 days.
219220689|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Semestrial administration
219094865|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Serum Level|Measurement of venous blood serum level of Angiopoietin-like protein-4 (ANGPTL4) Level level by ELISA method.
219094866|NCT07165509|DIETARY_SUPPLEMENT|T-2 Nutritional Supplement|"Nutritional supplement labeled T-2; dose 23 g twice daily, as specified in the protocol. Used only in the arm T-2 Supplement + Structured Diet."
219094867|NCT07165509|BEHAVIORAL|Structured Dietary Program|"Rigorous, structured dietary intervention applied according to the study protocol. Used in the arms T-2 Supplement + Structured Diet and Structured Diet Only."
219094868|NCT07165886|DRUG|Sirolimus for injection (albumin bound)|Sirolimus for injection (albumin bound), ivgtt., Q2W
219094869|NCT07165886|DRUG|Octreotide long-acting injection|SC, Q2W
219094870|NCT07165886|DRUG|Everolimus|Oral, once a day
219094871|NCT07164300|DRUG|Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h|Group 1: administration of tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h
219094872|NCT07164300|DRUG|Tranexamic acid at a dose of 20 mg/kg|Group 2: administration of tranexamic acid at a dose of 20 mg/kg
219220690|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Annual administration
219220691|NCT05949619|DRUG|BL-M02D1|Administration by intravenous infusion
219220692|NCT04821284|DRUG|Gemcitabine Hydrochloride|Given IV
219220693|NCT04821284|DRUG|Nab-paclitaxel|Given IV
219220694|NCT04821284|DRUG|Fluorouracil|Given IV
219220695|NCT04821284|DRUG|Irinotecan Hydrochloride|Given IV
219220696|NCT04821284|DRUG|Leucovorin Calcium|Given IV
219220697|NCT04821284|DRUG|Oxaliplatin|Given IV
219220698|NCT04821284|OTHER|Perflubutane Microbubble|Oxaliplatin
219220699|NCT04821284|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219220700|NCT04821284|OTHER|Quality-of-Life Assessment|Ancillary studies
219220701|NCT04821284|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219220702|NCT04821284|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219220703|NCT06514794|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007
219094873|NCT07164300|DRUG|Tranexamic acid at a dose of 30 mg/kg|Group 3: administration of tranexamic acid at a dose of 30 mg/kg
219094874|NCT07165899|BEHAVIORAL|EEG-Guided Binaural Beat Audio|30-minute audio session with dynamic frequency adjustments based on real-time EEG feedback
219094875|NCT07165899|BEHAVIORAL|Sham Control|30-minute audio session with identical tones presented to both ears (no binaural beat), EEG monitored but not used for frequency adjustment
219094876|NCT07166003|PROCEDURE|Pneumonectomy|Patients will receive pneumonectomy after neoadjuvant treatment
219094877|NCT07166003|PROCEDURE|lobectomy|Patients will receive lobectomy after neoadjuvant immunotherapy.
219094878|NCT07166003|RADIATION|radiotherapy|Patients will receive radiotherapy after neoadjuvant immunotherapy.
219094879|NCT07166003|DRUG|Anti-Tumor Drugs|Patients will receive anti-tumor drugs.
219094880|NCT07166315|OTHER|observational study|This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
219094881|NCT07166510|OTHER|Yoga and meditation|For 12 months, with no restrictions or imposed frequency, as often as the participant feels the need. They can take individual or group video-guided 15-minute breaks to do tailored yoga exercises targeting areas affected by repetitive movements, fatigue, and stress (hands, wrists, shoulders, and back), or mindfulness meditation sessions focused on managing fatigue, transitioning at the end of a shift, and post-shock relaxation.
219094882|NCT07165314|PROCEDURE|Free positioning|Participants are not given instructions on how to position for intubation using direct laryngoscopy.
219094883|NCT07165314|PROCEDURE|"Sitting cross-legged (Lotus position)"|Participants are requested to sit cross-legged for intubation using direct laryngoscopy.
219094884|NCT07164521|BEHAVIORAL|Music Listening (Relaxing Classical Music)|Participants listened to a standardized playlist of relaxing classical instrumental music (e.g., Mozart, Vivaldi, Debussy) for 15 minutes every hour, beginning at the 24th postpartum hour until the 48th hour. The intervention aimed to reduce postpartum anxiety and pain perception.
219094885|NCT07165262|DRUG|Fentanyl (IV)|Fentanyl, Intravenous bolus administration at a dose of 1 microgram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
219094886|NCT07165262|DRUG|Ketamine (0.5 mg/kg)|Ketamine, Intravenous bolus administration at a dose of 0.5 milligram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
219094887|NCT07165119|OTHER|Interdisciplinary group|For 12 weeks, the subjects in the interdisciplinary group participated in 45 minutes of clinical Pilates three times a week, as in the clinical Pilates group, and 45 minutes of nurse coaching once a week, as in the nurse coaching group.
219220704|NCT05318729|DEVICE|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
219220705|NCT03747458|DRUG|OPN-375|OPN-375, BID
219220706|NCT03389802|BIOLOGICAL|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
219220707|NCT03389802|BIOLOGICAL|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
219220708|NCT05174351|OTHER|beta blocker discontinuation|beta blocker discontinuation
219220709|NCT06239064|DIAGNOSTIC_TEST|Genetic testing via blood collection|blood collection
219220710|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
219220711|NCT06682429|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
219220712|NCT05469568|OTHER|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
219220713|NCT05469568|OTHER|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
219220714|NCT04594694|DRUG|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
219220715|NCT04594694|DRUG|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
219220716|NCT04594694|DRUG|OCA Placebo|One tablet daily for the remainder of the study
219220717|NCT04594694|DRUG|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
219220718|NCT04594694|DRUG|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
219220719|NCT04594694|DRUG|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
219220720|NCT04594694|DRUG|OCA|OCA one tablet will be administered.
219220721|NCT04594694|DRUG|Bezafibrate|Bezafibrate one tablet will be administered.
219220722|NCT06481774|BEHAVIORAL|CONNECT platform|CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
219220723|NCT05879887|BEHAVIORAL|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
219220724|NCT05350501|DRUG|EO2040|"EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC."
219220725|NCT05889130|OTHER|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
219220726|NCT05052099|DRUG|mFOLFOX6, Atezolizumab and Bevacizumab|"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"
219220727|NCT05787808|DIETARY_SUPPLEMENT|Calsium, Vitamin D, Jarlsberg cheese|Oral
219220728|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
219220729|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
219220730|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
219220731|NCT03192007|DEVICE|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
219220732|NCT05086432|OTHER|Sputum-guided management|As previously described.
219220733|NCT05086432|OTHER|Standard of Care|As previously described.
219220734|NCT06178952|DEVICE|Transcranial pulse stimulation Verum|Participants are slated to undergo a total of five TPS sessions over a 10-day interval. Each stimulation session will endure approximately 30 minutes and will be administered once daily.
219220735|NCT06178952|DEVICE|Transcranial pulse stimulation Sham|Placebo treatment will be performed using the same medical device, handpiece and treatment paradigm as in the verum treatment with one difference: the standoff device at the end of the handpiece. This device is designed to replicate the appearance, feel, and sound of the verum system, while omitting the transmission of any pulses.
219220736|NCT06271668|OTHER|Naloxone Co-prescribing Clinical Decision Support (CDS)|Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
219220737|NCT05857137|DEVICE|Active TMS|Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.
219220738|NCT05857137|DEVICE|Placebo TMS|Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
219220739|NCT06481982|DIAGNOSTIC_TEST|MRI|MRI sequences
219220740|NCT05956158|BEHAVIORAL|Behavioral Treatment|This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
219220741|NCT05956158|BEHAVIORAL|Sleep Education Treatment|This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
219220742|NCT05437263|DRUG|Brepocitinib|Oral Brepocitinib
219220743|NCT05437263|DRUG|Placebo|Oral Placebo
219220744|NCT05339347|DEVICE|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
219220745|NCT05703165|BEHAVIORAL|animal-assisted intervention|horse-assisted intervention
219220746|NCT05703165|BEHAVIORAL|watching the countryside|just watching the countryside
219220747|NCT06389357|BEHAVIORAL|training and counselling|It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions. Separate educational modules have been developed for parents, teachers, and peers.
219220748|NCT06389357|OTHER|Interview|As part of the needs assessment in Phase 1, individual interviews with children with cancer and their parents lasting approximately 20-30 minutes were conducted.
219220749|NCT06335875|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 19 g (=12.5 g active C8-KE) of Juvenescence Cognitive Switch™ diluted in water, twice per day
219220750|NCT06335875|BEHAVIORAL|Low Glycemic Index Diet|Participants will practice four dietary changes: 1. Not consuming sweets/candy, 2. Not consuming soda, 3. Replacing 'white' grains with complex carbohydrates such as brown rice or quinoa, and 4. Reserving any fruit consumption for the end of meals.
219094888|NCT07165119|OTHER|Clinical Pilates Group|Clinical Pilates was applied by a certified physiotherapist for 12 consecutive weeks. with 45-minute sessions 3 times a week and was delivered to small groups of participants (3-5). The Pilates program has been developed in accordance with the extant literature to cultivate strength, balance, and coordination in a range of body positions, including the supine, seated, kneeling, and standing positions. Participants were instructed to perform each movement with control and precision, focusing on proper breathing patterns (exhaling during flexion, inhaling during extension) and engaging their core muscles throughout the exercise The load level and progression were determined using the Borg CR10 scale: Borg ≤ 2 = light load; Borg \> 2 - \< 5 = moderate load; Borg ≥ 5 - \< 7 = heavy load; Borg ≥ 7 = near-maximum load. During the sessions, the effort level was generally maintained at a moderate intensity (Borg 3-4). Each time the intensity of the exercise was changed, the new loa
219094889|NCT07165119|OTHER|Nurse Coaching group|Training and follow-up was carried out with nurse coaching for 12 weeks lasting 45 minutes once a week .
219094890|NCT07164534|DIETARY_SUPPLEMENT|Sodium-copper-chlorophyllin, a semi-synthetic derivative of chlorophyll, is made up of a mixture of sodium copper salts.|Oral adjuvant sodium-copper-chlorophyllin 750mg given once daily given on an empty stomach for 3 months, starting within 2 weeks of RT completion
219094891|NCT07164378|PROCEDURE|Lens-Exchange|The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus
219220751|NCT06649045|DRUG|Orforglipron|Administered orally.
219220752|NCT06649045|DRUG|Placebo|Administered orally.
219220753|NCT06576076|BEHAVIORAL|Contingency management for cannabis abstinence|Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
219220754|NCT05536141|DRUG|casdatifan|Administered as specified in the treatment arm
219220755|NCT05536141|DRUG|Cabozantinib|Administered as specified in the treatment arm
219094892|NCT07164378|PROCEDURE|Add-on|The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.
219094893|NCT07165379|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
219094894|NCT07165379|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
219220756|NCT05536141|DRUG|Zimberelimab|Administered as specified in the treatment arm
219220757|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
219220758|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
219094895|NCT07165379|OTHER|Stretching|To stretch the muscles involved, perform three periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
219220759|NCT06350760|BEHAVIORAL|Active control condition|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021.
219094896|NCT07165587|DIAGNOSTIC_TEST|Bilateral duplex ultrasonography|Bilateral duplex ultrasound screening performed during hospitalization to detect symptomatic and asymptomatic deep vein thrombosis in patients with pelvic and acetabular fractures.
219094897|NCT07166835|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Nootropic drink containing Anthrocyanins, L-theanie and Enzogenol
219220760|NCT06350760|BEHAVIORAL|PROCARE-I+ 8-session|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021. In addition, PROCARE-I+ adds additional modules, which allow adolescents to be provided with tools to address the risk factors they present.
219220761|NCT04745676|BEHAVIORAL|Telehealth|Telehealth ACP intervention advance care planning intervention
219220762|NCT04745676|BEHAVIORAL|Control|For the control arm, no telehealth visit will be scheduled.
219094898|NCT07166835|DIETARY_SUPPLEMENT|Placebo|Taste- and appearance-matched placebo beverage without active ingredients.
219094899|NCT07165613|OTHER|Kinesiotape|Kinesiotape is applied
219094900|NCT07165613|OTHER|Dynamic tape|dynamic tape applied
219094901|NCT07165288|OTHER|Continuous midwife support care|Primiparous pregnant women are provided with continuous and individual midwife support starting from the 36th week until the postpartum period.
219094902|NCT07165288|OTHER|Pilates ball usage|Primiparous pregnant women were provided with educational support starting from the prenatal period to the postnatal period. In addition, depending on the preferences of the pregnant woman, at least one of the above-mentioned practices was chosen with the accompaniment of a midwife at the time of birth.
219094903|NCT07165288|OTHER|warm shower|It was generally applied to the majority of our pregnant women within the scope of training.
219094904|NCT07164391|BEHAVIORAL|Digital Intervention for Vietnamese-American Storytelling (VIDAS)|The intervention consists of 4 brief stories about HPV vaccine, created by Vietnamese mothers
219094905|NCT07164391|BEHAVIORAL|HPV Educational Video Intervention|The intervention consists of 4 brief informational videos about HPV and the vaccine
219094906|NCT07164391|BEHAVIORAL|Teen General Health|This intervention consists of 4 brief videos on general teen health topics, such as mental health, social media usage.
219220763|NCT04241835|DRUG|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
219094907|NCT07166679|PROCEDURE|root canal treatment with 2% taper|root canal treatment with 2%taper
219094908|NCT07166679|PROCEDURE|root canal treatment with 4% taper|root canal treatment with 4 %taper
219094909|NCT07166679|PROCEDURE|root canal treatment with 6 %taper|root canal treatment with 6 %taper
219094910|NCT06262165|OTHER|Patients with Anorexia Nervosa|Patients with Anorexia Nervosa hospitalized for malnutrition
219094911|NCT07165912|BEHAVIORAL|Health Education Program|An informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
219094912|NCT07165912|BEHAVIORAL|Individual Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
219094913|NCT07165912|BEHAVIORAL|Group training program|The group cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
219094914|NCT07166887|DRUG|Tolvaptan|One dose on the first day and one dose on days 3-9, for a total of eight doses.
219094915|NCT05650164|DRUG|avelumab|as provided in real world practice
219094916|NCT05650164|DRUG|axitinib|as provided in real world practice
219094917|NCT02044848|DRUG|Secukinumab|
219094918|NCT02044848|DRUG|Placebo|Placebo
219094919|NCT02057289|DRUG|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
219094920|NCT02935049|PROCEDURE|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
219094921|NCT05578625|OTHER|plasma circulation DNA methylation sequencing|10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
219094922|NCT01369238|DEVICE|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2\~3days/wk, for 1 month
219094923|NCT01369238|DRUG|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
219094924|NCT01500564|DEVICE|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
219094925|NCT01500564|DEVICE|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
219094926|NCT01988363|PROCEDURE|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
219094927|NCT02166450|DRUG|Nystatin|100 000 IU every 6 h as a suspension
219094928|NCT01160484|DRUG|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
219094929|NCT00803101|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
219094930|NCT00803101|BIOLOGICAL|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
219094931|NCT03578614|OTHER|Physical Activity|"3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~\- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used."
219094932|NCT05040022|DRUG|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
219094933|NCT05040022|DRUG|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
219094934|NCT03091647|BEHAVIORAL|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
219094935|NCT03091647|BEHAVIORAL|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
219094936|NCT02757924|OTHER|Infant formula supplemented with prebiotics|Sole source nutrition
219094937|NCT02623816|DRUG|Optimal Dosing of Omeprazole|Omeprazole 20 mg
219220764|NCT06730932|DRUG|JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)|"Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol"
219220765|NCT05859711|DRUG|thyme honey mouth rinse|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
219220766|NCT05859711|DRUG|saline mouth rinse|saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
219220767|NCT06300086|BEHAVIORAL|Electronically delivered nudging letters to patients with CKD|"Patients in the active arm will receive a digital nudge letter as part of the study. The nudge letter will be delivered at baseline. Letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD randomized to not receive digital nudge letters (usual care)."
219220768|NCT06300086|BEHAVIORAL|Electronically delivered nudging letter to associated GPs of patients with CKD|"The associated GPs of the patients in the active arm will receive one digital nudge letter as part of the study. The nudge letter will be delivered at baseline. The letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD whose associated GP was randomized to not receive a digital nudge letter (usual care)."
219220769|NCT05047263|DRUG|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
219220770|NCT05047263|DRUG|Placebo|Tablet, once daily, oral
219220771|NCT04863677|BEHAVIORAL|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
219220772|NCT04863677|BEHAVIORAL|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
219220773|NCT04798066|BIOLOGICAL|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
219220774|NCT05818150|DEVICE|Embosphere Microspheres|Embolic Agent: Embosphere Microspheres
219220775|NCT05818150|DRUG|Corticosteroid injection|Corticosteroid injection
219220776|NCT06465966|DEVICE|iRAI|Ionizing-radiation photo acoustic imaging (iRAI) is a method of collecting images from inside the body using acoustic (sound) waves. Researchers will collect iRAI during a participant's radiation treatments. Researchers will use this imaging to examine the delivery and dose of the radiation to the participant's prostate. Researchers will also compare the delivery and dose calculated from iRAI to the expected doses that were calculated from CT images which are done as standard of care.
219220777|NCT06810505|DRUG|Atogepant|Oral tablet
219094938|NCT01679301|DEVICE|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
219094939|NCT01679301|DEVICE|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
219094940|NCT02852122|DRUG|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
219094941|NCT06286124|PROCEDURE|Hybrid Surgery|Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
219094942|NCT04858802|DEVICE|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
219094943|NCT04858802|PROCEDURE|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
219094944|NCT00110253|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
219220778|NCT06810505|DRUG|Placebo for Atogepant|Oral tablet
219220779|NCT04870255|DEVICE|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
219220780|NCT04870255|DEVICE|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
219220781|NCT04870255|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
219220782|NCT00942981|DRUG|PET|Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
219220783|NCT07119801|DEVICE|Radial Extracorporeal Shock Wave Therapy|rESWT will be administered to the FCU and FCR muscles two days per week over a period of four weeks (8 sessions in total). The point of application will be selected as the center of the muscle belly for both the FCU and FCR. Each muscle will receive 2000 shocks using a 15 mm applicator tip at a frequency of 5 Hz. The treatment will be conducted at an intensity of 60 mJ (1 bar), with an energy flux density of 0.340 mJ/mm².
219220784|NCT07119801|OTHER|Conventional rehabilitation|Conventional rehabilitation will be administered for 1-2 hours daily, 5 days a week, for 12 weeks. It will include range of motion exercises, stretching exercises, progressive resistive exercises, positioning, postural control, weight shifting, balance, gait training, occupational therapy, and speech-language therapy according to the patient's needs.
219220785|NCT06979076|DRUG|MS-553, DS1|Oral, Dose Schedule 1
219220786|NCT06979076|DRUG|MS-553, DS2|Oral, Dose Schedule 2
219220787|NCT05775848|DRUG|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
219220788|NCT05775848|OTHER|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
219094945|NCT02827318|DIETARY_SUPPLEMENT|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
219094946|NCT02827318|DIETARY_SUPPLEMENT|Glucose|75g Glucose (high glycaemic load intervention)
219094947|NCT02827318|DIETARY_SUPPLEMENT|Sweetened water|Sweetened water will be used as a control
219094948|NCT02026232|DRUG|Hydroxychloroquine|200mg twice daily
219094949|NCT02026232|OTHER|Hydroxychloroquine Placebo|200mg placebo twice daily
219094950|NCT01529008|DRUG|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
219094951|NCT01529008|DRUG|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
219094952|NCT02556437|DRUG|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
219094953|NCT02556437|DRUG|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
219094954|NCT04402528|BEHAVIORAL|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
219094955|NCT00315913|DRUG|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
219094956|NCT00315913|OTHER|IV Placebo|IV Saline Solution
219220789|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
219094957|NCT03594903|BEHAVIORAL|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
219220790|NCT06608849|OTHER|Blood samples|Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
219220791|NCT06608849|OTHER|Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms|Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
219094958|NCT03594903|BEHAVIORAL|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
219094959|NCT04191070|DEVICE|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
219094960|NCT04191070|DEVICE|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
219220792|NCT06445023|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
219220793|NCT06445023|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
219220794|NCT04825613|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
219220795|NCT04440280|DRUG|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
219220796|NCT04440280|DRUG|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
219220797|NCT04440280|DRUG|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
219220798|NCT05023070|DRUG|Cannabidiol|Cannabidiol 200 mg
219220799|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
219220800|NCT05023070|DRUG|Cannabidiol|Epidiolex 400 mg
219220801|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
219220802|NCT06980805|DRUG|IMVT-1402|Dose 1 or Dose 2 SC QW
219220803|NCT06980805|DRUG|Placebo|Matching Placebo SC QW
219220804|NCT04226248|DRUG|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
219220805|NCT04226248|OTHER|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
219220806|NCT06782451|PROCEDURE|Surgery or biopsy|A part of the tumor sample collected during the surgery or the biopsy performed as part of routine patient care will be used for the research.
219220807|NCT06782451|PROCEDURE|Blood sample|38 mL of blood will be taken for the study.
219220810|NCT06593717|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
219220811|NCT06593717|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
219220812|NCT06593717|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
219220813|NCT06593717|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
219220814|NCT06593717|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
219094961|NCT04591535|DRUG|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
219094962|NCT00007280|DEVICE|Bioengineered skin|
219094963|NCT05279222|OTHER|Gait adaptability training|All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
219094964|NCT05553847|OTHER|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
219094965|NCT05968040|PROCEDURE|Inferior vena cava diameter measurement by ultrasonography|The diameter of the inferior vena cava will be measured at 2 cm close to the entrance of the right atrium. Ultrasound images will be taken at the end of inspiration (Dmax) and at the end expiration (Dmin) to calculate the inferior vena cava dispensability index (dIVC), and will be recorded before and after fluid challenge test of 5 ml/kg crystalloid within 15 min. The IVC distensibility index (IVC-DI) will be calculated using the formula: IVC-DI = IVCmax - IVCmin/ IVCmin. The indices will be expressed as a percentage.
219220815|NCT06593717|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
219220816|NCT06593717|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
219220817|NCT06593717|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
219220818|NCT06593717|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
219220819|NCT06602453|DRUG|GDC-8264|GDC-8264 will be administered as per pre-defined regimen.
219220820|NCT06602453|DRUG|Placebo|Placebo will be administered as per pre-defined regimen.
219220821|NCT06811454|BEHAVIORAL|MINDSET|Participants randomized to MINDSET will receive a text message at their preferred time each day for 8 weeks containing a link to the 15-minute audio content. At the end of each week (on day 7), participants will receive a second link to the weekly survey in the text. Participants will be able to play the audio content on their device by clicking the first link and access the weekly survey by clicking the second.
219220822|NCT06811454|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants will receive a 1-page brochure summarizing publicly available information on depression self-care strategies via text each week for 8 weeks on the same day they receive the text message containing a link to the weekly survey (day 7). This information will come from the Facing Forward: Life After Cancer Treatment booklet from the National Cancer Institute.38 Weekly topics will include: 1) Reducing stress; 2) Coping with stress; 3) Coping with depression; 4) Feeling angry; 5) Feeling alone; 6) Finding meaning after treatment; 7) Social relationships; and 8) Seeking support. These materials do not include any content on mindfulness or cognitive therapy.
219220823|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
219220824|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
219220825|NCT06806293|DRUG|Atogepant|Oral Tablet
219220826|NCT06806293|DRUG|Placebo for Atogepant|Oral Tablet
219220827|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
219220828|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
219220829|NCT04604288|BIOLOGICAL|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
219220830|NCT03294460|DRUG|Alcohol (Oral)|Oral Self-administration
219220831|NCT03294460|DRUG|Alcohol (IV)|IV Self-administration
219220832|NCT03294460|DRUG|Alcohol (Ethanol)|IV and Oral Self-administration
219220833|NCT06986226|BEHAVIORAL|Dose Calculations|Dose calculations either with or without performing ventilations during CPR (15:2)
219220834|NCT06986226|PROCEDURE|Ventilations|Performing ventilations during CPR in a 15:2 manner
219220835|NCT06109857|OTHER|Non-Interventional Study|Non-interventional study
219220836|NCT06098651|DRUG|DCR-STAT3|DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.
219094966|NCT05968040|PROCEDURE|difference between peak velocities of carotid artery by ultrasound|"Carotid ultrasound images will be obtained from the left CCA in both short-axis and long-axis views by experienced sonographers. The patient will be in supine position, with the head rotated slightly to the right. A broadband linear array transducer 12-4 MHz and the short-axis view will be used for orientation and identification of the CCA. Next, in the long-axis view, Peak Waveform Doppler signals will be acquired by placing a 0.5 mm calliper at the center of the vessel and parallel to the vessel walls, approximately 2 cm proximal from the carotid bifurcation. Insonation-angles between the ultrasound beam and blood flow will be maintained.~ΔVpeakCCA = (MaxCDPV-MinCDPV)+(MaxCDPV+MinCDPV)x100"
219094967|NCT05968040|PROCEDURE|cardiac output be transthoracic echocardiography|"CO will be recorded as baseline measure and after fluid administration. If CO increased more than 15%, it will be considered fluid responder. Increase in cardiac output = (cardiac output after first fluid challenge - cardiac output before)/cardiac output before) X 100.~TTE will be used to measure LTOT and VTI x HR."
219094968|NCT05942755|OTHER|Concurrent evaluation of blood and CSF ionograms to determine if there is a correlation between CSF change and the development of hyoponatremia between day 0 and day 14.|"Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral routine.~The ionic composition of CSF from patients with SAH will be compared with a control population of patients hospitalized with normal pressure hydrocephalus. A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine its ionic composition"
219094969|NCT02225379|DEVICE|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
219094970|NCT03736343|DRUG|Alcohol|Participants will complete two drinking sessions.
219094971|NCT02571322|DEVICE|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
219094972|NCT02571322|OTHER|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
219220837|NCT05867602|DRUG|Albumin|intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
219220838|NCT06660433|DEVICE|Point-of-care respiratory test platform|A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
219220839|NCT06660433|OTHER|Existing respiratory virus testing platform|Currently used respiratory virus testing platforms
219220840|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
219220841|NCT06608940|DRUG|BC3402|BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
219220842|NCT06608940|DRUG|Durvalumab|Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
219220843|NCT06608940|DRUG|Tremelimumab|Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
219220844|NCT06986200|PROCEDURE|Chest Compressions|Performing chest compressions in full firefighter's personal protcetion equipment
219220845|NCT06986200|PROCEDURE|One minute rotation intervall|Chest compressions using a one minute rotation intervall
219220846|NCT06986200|PROCEDURE|Two minute rotation intervall|Chest compressions using a two minute rotation intervall
219220847|NCT06498960|DEVICE|CereVasc eShunt System|"The eShunt System consists of the following components:~* eShunt Implant~* eShunt Delivery Catheter and Transfer Tool~* eShunt Anchor"
219094973|NCT04033172|DRUG|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
219094974|NCT00657514|DRUG|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
219094975|NCT00657514|DRUG|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
219094976|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
219094977|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
219094978|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
219094979|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
219094980|NCT03921346|DEVICE|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
219094981|NCT03921346|DEVICE|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
219094982|NCT03921346|DEVICE|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
219094983|NCT03921346|DEVICE|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
219094984|NCT00710112|GENETIC|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
219220848|NCT06498960|DEVICE|VP Shunt|Control arm - VP shunt
219220849|NCT06817889|DRUG|Remdesivir|Given IV
219220850|NCT06817889|OTHER|Survey Administration|Ancillary studies
219220851|NCT06817889|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219220852|NCT06817889|PROCEDURE|Nasal Swab|Undergo nasal swabs
219220853|NCT06586437|BEHAVIORAL|Clinical Assessments|The participant will undergo a battery of clinical assessments to identify the upper extremity motor performance, sensory acuity, and ability to complete activities of daily living. Tests 1-5 will be completed separately for each hand. All participants will be video recorded while completing these assessments. The recordings will be used for grading tasks and data analysis: Box and Blocks, 9-hold peg board, Test of Arm Selective Control, Sensory Acuity Testing, KINARM End-Point Lab Sensory Test, Section GG of the inpatient Rehabilitaion Facility-Patient Assessment Instrument, NEURO-QOL Upper Extremity Function Scale, Edinburgh Handed Inventory
219220854|NCT06586437|BEHAVIORAL|Brain-Spinal Cord fMRI|Resting state, brain-spinal cord activity, spinal cord microstructure, magnetic resonance spectroscopy
219220855|NCT06586437|BEHAVIORAL|Hoffmann Reflex Assessments|Hmax 20-50 stimulations of increasing intensity. Next, the participant will sit quietly as 10 stimulations will be delivered at the participant's Hmax with an interstimulus interval of 15 seconds. Subsequently, stimulations at the participant's Hmax will be applied as the participants produce a contraction of 10-20% of their maximum voluntary contraction (MVC). The target contraction level will be shown in real-time based on the FCR EMG activity. The participant maintains their EMG activity at the target level for 6.5 seconds as 10 stimulations are delivered at the participants Hmax.
219094985|NCT03040882|OTHER|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
219094986|NCT03040882|OTHER|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
219094987|NCT00811447|DRUG|5-fluorouracil|600 mg/m²/day intravenous
219220856|NCT06586437|BEHAVIORAL|MEG Imaging|Resting state, somatosensory, isometric force matching, entrainment
219220857|NCT06586437|BEHAVIORAL|Transcutaneous Current Stimulation|Cortical stimulation, spinal cord stimulation - sham and stim
219094988|NCT00811447|DRUG|Cisplatin|60 mg/m² or 75 mg/m² intravenous
219094989|NCT00811447|DRUG|Docetaxel|60 mg/m² intravenous
219094990|NCT04581148|DIAGNOSTIC_TEST|Blood test antibodies against SARS-CoV-2|Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
219094991|NCT04372225|OTHER|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
219094992|NCT04524078|OTHER|intensive integrated intervention care program|intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
219094993|NCT02722343|DRUG|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
219220858|NCT06593756|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
219220859|NCT06593756|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
219220860|NCT06593756|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
219220861|NCT06593756|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
219220862|NCT06593756|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
219220863|NCT06593756|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
219220864|NCT06593756|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
219220865|NCT06593756|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
219220866|NCT06593756|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning
219094994|NCT02722343|DRUG|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
219094995|NCT02582489|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
219094996|NCT02582489|PROCEDURE|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
219094997|NCT00981851|DRUG|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
219094998|NCT00981851|DRUG|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
219094999|NCT06013046|BEHAVIORAL|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
219095000|NCT06013046|BEHAVIORAL|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
219095001|NCT05975606|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied to primary motor cortex of the brain.
219095002|NCT05975606|DEVICE|functional electrical stimulation (FES) cycling|FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
219095003|NCT05957484|DEVICE|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
219095004|NCT04545996|OTHER|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
219220867|NCT06593405|COMBINATION_PRODUCT|occupational therapy interventions for low vision care|Occupational therapists utilize many different treatment strategies when caring for the client with low vision. Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Interventions include task lighting, organizational strategies, smart apps, contrast, enlarged print, typoscopes and electronic magnification devices.
219220868|NCT06246136|PROCEDURE|ELIOS|Following cataract surgery, surgeon will proceed to ELIOS treatment.
219220869|NCT06246136|PROCEDURE|Competitor Device|Following cataract surgery, surgeon will proceed to Competitor treatment.
219220870|NCT06843239|BIOLOGICAL|Tibulizumab|Anti BAFF/IL-17 antibody
219220871|NCT06843239|OTHER|Placebo|Placebo (inactive)
219220872|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
219220873|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
219220874|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
219220875|NCT05450328|DRUG|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
219220876|NCT05450328|DRUG|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
219220877|NCT06654193|DRUG|Allogeneic HB-adMSCs|Allogeneic HB-adMSCs
219220878|NCT06654193|DRUG|Normal Saline|Sterile Saline Solution
219220879|NCT02901821|GENETIC|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
219220880|NCT03942328|BIOLOGICAL|Atezolizumab|Given IV
219220881|NCT03942328|BIOLOGICAL|Bevacizumab|Given IV
219220882|NCT03942328|RADIATION|External Beam Radiation Therapy|Undergo high-dose EBRT
219220883|NCT03942328|PROCEDURE|Pheresis|Undergo apheresis
219220884|NCT03942328|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
219220885|NCT03942328|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given IT
219220886|NCT03942328|BIOLOGICAL|Tiragolumab|Given IV
219220887|NCT03942328|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
219220888|NCT03942328|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219220889|NCT03942328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219220890|NCT03942328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219220891|NCT03942328|PROCEDURE|Biopsy Procedure|Undergo biopsy
219220892|NCT03942328|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219220893|NCT02850575|DEVICE|Mpact Double Mobility cup|
219095005|NCT04545996|OTHER|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
219095006|NCT03354364|DIETARY_SUPPLEMENT|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
219095007|NCT03354364|DIETARY_SUPPLEMENT|Control|Snacks without added fiber.
219095008|NCT03725540|DEVICE|I-gel|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
219095009|NCT03725540|DEVICE|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
219095010|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
219095011|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
219095012|NCT06371599|BEHAVIORAL|Playing game|Active Distraction Methods
219095013|NCT06371599|BEHAVIORAL|Watching cartoon|Passive Distraction Methods
219095014|NCT03171480|DRUG|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
219095015|NCT03171480|DRUG|Placebo|The pharmacy has compounded an identical appearing placebo
219095016|NCT05893264|OTHER|Data collection|"Several data will be collected such as:~Age, weight, height, gender, previous spine surgery, skoliosis (Y/N), palpable spinous process (Y/N), experience in years of anesthesiologist, spine level of epidural placement~and the following sonographic parameters at the level of epidural placement: skin-spinous process distance (cm), skin-transversous process distance (cm), erector spinae plane distance (cm), superior to inferior spinous process distance (cm)"
219095017|NCT01089322|DRUG|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
219095018|NCT06339580|DEVICE|Volume-targeted non-invasive ventilation|A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
219095019|NCT03712735|DRUG|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
219095020|NCT01861574|DEVICE|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
219095021|NCT01861574|DEVICE|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
219220894|NCT06056427|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
219220895|NCT06996678|BEHAVIORAL|virtual Reality|Virtual Reality: The virtual reality system consists of a camera, television, Eye Toy Play CD and Play Station 2. It is based on the principle of capturing movements represented in a virtual environment (Gatica and Méndez, 2014). In the Eye Toy system, individuals can see themselves on the screen through the camera. In this way, the person constantly interacts with the movements and challenges brought by video games. We can simply call the Eye Toy system a webcam with a motion sensor and microphone. The individual's position in the game is determined on the screen and can perceive the person according to the movements he/she exhibits. The main skills required by the games are; target-based movement, visuomotor skills, praxis and thinking process skills.
219220896|NCT06996678|BEHAVIORAL|occupational therapy|Occupational Therapy: The basis of OT intervention consisted of activities requiring increased attention, behavioral regulation, organizational skills, multiple cognitive skills, and motor skills
219220897|NCT05598931|DEVICE|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
219220898|NCT06540521|OTHER|No intervention|No intervention
219220899|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
219220900|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
219220901|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
219220902|NCT07000279|DEVICE|Assistive exoskeleton for activities of daily living (ADLs)|Portable assistive exoskeleton to support upper limb movement during activities of daily living
219095022|NCT01861574|DEVICE|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
219095023|NCT01861574|DEVICE|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
219095024|NCT00303160|DRUG|vitamin C & E supplements|
219095025|NCT05375708|RADIATION|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
219220903|NCT07000279|DEVICE|Assistive exoskeleton for box and block|Portable assistive exoskeleton to support box and block test execution
219220904|NCT07000279|DEVICE|Assistive exoskeleton for maximum reaching height|Portable assistive exoskeleton to raise the upper limb at the maximum of its capability to reach objects at different heights
219220905|NCT06527040|OTHER|Opioid Transitions Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
219220906|NCT03334669|BEHAVIORAL|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
219220907|NCT03334669|BEHAVIORAL|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
219220908|NCT03334669|BEHAVIORAL|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
219095026|NCT05375708|DRUG|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
219095027|NCT03221088|DRUG|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
219095028|NCT03221088|DRUG|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
219095029|NCT04558190|DRUG|Intralipid, 20% Intravenous Emulsion|Lipid infusion
219095030|NCT04558190|DIETARY_SUPPLEMENT|MitoQ|Oral administration of MitoQ capsules
219095031|NCT04558190|DRUG|Salbutamol|Beta2-agonist infusion
219095032|NCT02418247|DRUG|I131|
219095033|NCT02418247|DRUG|I123|
219095034|NCT05182645|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
219095035|NCT05182645|BEHAVIORAL|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
219095036|NCT02034825|OTHER|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
219095037|NCT00145457|PROCEDURE|Blood sample|
219220909|NCT06545292|DIAGNOSTIC_TEST|Therapeutic drug monitoring with a dried blood spot and microatainer.|Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
219220910|NCT06865677|DRUG|Sacituzumab govitecan|10mg/kg administered IV infusion on days 1 and 8 of each 21-day cycle.
219095038|NCT00145457|PROCEDURE|Radiography|
219095039|NCT05548439|BIOLOGICAL|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
219095040|NCT02070900|DEVICE|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
219220911|NCT06615557|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
219220912|NCT06615557|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
219220913|NCT06010355|PROCEDURE|Discussion|Participate in focus groups
219220914|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
219220915|NCT06010355|OTHER|Interview|Undergo interview
219095041|NCT02070900|OTHER|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
219220916|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
219220917|NCT06010355|OTHER|Test|Complete test
219095042|NCT01860586|DRUG|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
219095043|NCT05986123|OTHER|Topical cream Z for PIH|The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
219095044|NCT06288061|DEVICE|Non-invasive Neuromodulation|"This intervention group will receive neuromodulation treatment two days a week for a total of six sessions.~The patient is placed in the supine position with a cushion under the knees. The physiotherapist will be positioned behind the patient's head on the side to be treated. The technique will be applied on both anterolateral sides of the neck, where the Phrenic nerve passes in front of the anterior Scalene, between the Subclavian arteries and veins. Neuromodulation will be applied with a Pointer Excel II. It will be applied with negative polarity, at a frequency of 2 Hertz (HZ) and with a current intensity varying between 0 and 45 milliamperes (mA). The intensity shall be increased progressively until the patient's diaphragmatic contraction can be observed without pain. The technique shall be applied on each side for a total of 8 minutes, divided into intervals of 10 seconds of stimulation and 20 seconds of rest."
219095045|NCT06288061|OTHER|Cervico-dorsal Massage|"This intervention group will receive manual therapy two days a week for a total of six sessions.~The patient shall be placed prone position with a cushion under his or her feet. This group will receive manual therapy on the entire posterior cervical and dorsal region, the area between the occipital bone, the shoulders and the scapulae. The massage will be carried out with a little oil or cream for about 20 minutes."
219095046|NCT04457830|DRUG|F520|3mg/kg every 3 weeks
219095047|NCT06232720|DEVICE|Q300 QART Medical|The Q300TM Imaging system includes a Quantitative Phase Microscope. Q300TM uses a low intensity coherent light source, in a uniquely configured interferometer, which measures light delay as it passes different locations across the sperm cell. The amount
219095048|NCT04526002|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%\* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
219220918|NCT05657548|RADIATION|spine and pelvis radiography|X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
219220919|NCT05959434|BEHAVIORAL|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
219220920|NCT05959434|BEHAVIORAL|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
219095049|NCT05644223|DRUG|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
219095050|NCT04207840|COMBINATION_PRODUCT|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
219220921|NCT07009379|DEVICE|Intervention A|Intervention A means Pillow Brace
219220922|NCT07009379|DEVICE|Intervention B|Intervention B means standard management
219220923|NCT06869850|DIETARY_SUPPLEMENT|MFGM-RUTF (milk fat globule membrane ready-to-use therapeutic food)|MFGM whey protein/fat concentrate powder used in place of skim milk powder in peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications. There will be 10g of MFGM-containing whey protein/fat concentrate powder per 100g of MFGM-RUTF. Other ingredients and amounts per 100g: 9.5g rice flour, 5g whey permeate, 18.5g palm oil, 31g peanut paste, 22.1g sugar, 2.9g micronutrient mix, 1g fish oil.
219220924|NCT06869850|DIETARY_SUPPLEMENT|S-RUTF (standard ready-to-use therapeutic food)|Standard peanut paste-based ready-to-use therapeutic food made with skim milk powder meeting Codex Alimentarius specifications. This RUTF is modeled on the most widely used recipe worldwide, containing per 100g: 19.5g skim milk powder, 9.3g palm oil, 7g canola oil, 31.3g peanut paste, 28g sugar, 1g soy flakes, 1g hydrogenated vegetable oil, and 2.9g micronutrient mix.
219220925|NCT06869850|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
219220926|NCT06869850|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|Malaria chemoprophylaxis, dosed by weight, to be given every month during SAM treatment
219362137|NCT00751868|DRUG|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
219362138|NCT03644238|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|75g of glucose is consumed
219095051|NCT04207840|COMBINATION_PRODUCT|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
219095052|NCT04207840|COMBINATION_PRODUCT|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
219095053|NCT00735501|DRUG|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
219095054|NCT02466646|DRUG|Klorhex® Gel, rinse and spray|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
219095055|NCT02466646|PROCEDURE|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
219095056|NCT02466646|PROCEDURE|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
219095057|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
219362139|NCT03644238|BEHAVIORAL|Inactivity|Lying or sitting down.
219362140|NCT03644238|BEHAVIORAL|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
219095058|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
219095059|NCT03261271|BEHAVIORAL|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
219095060|NCT03261271|BEHAVIORAL|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
219095061|NCT03261271|BEHAVIORAL|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
219095062|NCT00949481|OTHER|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
219095063|NCT00949481|OTHER|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
219095064|NCT05856214|BEHAVIORAL|Couple-Based Violence Prevention education(CBVPE)|Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
219095065|NCT03967769|DEVICE|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
219095066|NCT01288274|OTHER|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
219095067|NCT01114204|DRUG|Ferumoxytol|IV Ferumoxytol
219095068|NCT01114204|DRUG|Iron Sucrose|IV Iron Sucrose
219095069|NCT05786729|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
219095070|NCT05786729|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
219362141|NCT03887754|DRUG|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
219095071|NCT05771779|BIOLOGICAL|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
219095072|NCT05771779|BIOLOGICAL|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
219095073|NCT05771779|BIOLOGICAL|Measles and Rubella (MR)|Live attenuated vaccine
219095074|NCT03476629|OTHER|Physical activity|Effects of different physical activity programs
219095075|NCT03716375|DRUG|Intrapleural Medications|urokinase
219095076|NCT03420781|DRUG|Placebo|Placebo injected twice daily
219095077|NCT03420781|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily
219095078|NCT00489710|DRUG|talabostat mesylate|
219095079|NCT00489710|BIOLOGICAL|enzyme inhibitor therapy|
219095080|NCT00489710|DIAGNOSTIC_TEST|flow cytometry|
219095081|NCT00489710|DIAGNOSTIC_TEST|laboratory biomarker analysis|
219095082|NCT00489710|BIOLOGICAL|non-specific immune-modulator therapy|
219095083|NCT00915135|DRUG|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
219095084|NCT00246337|DRUG|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
219095085|NCT00246337|DRUG|MK0974|MK0974 25 mg; one orally-administered dose
219095086|NCT00246337|DRUG|MK0974|MK0974 50 mg; one orally-administered dose
219095087|NCT00246337|DRUG|MK0974|MK0974 100 mg; one orally-administered dose
219095088|NCT00246337|DRUG|MK0974|MK0974 200 mg; one orally-administered dose
219095089|NCT00246337|DRUG|MK0974|MK0974 300 mg; one orally-administered dose
219095090|NCT00246337|DRUG|MK0974|MK0974 400 mg; one orally-administered dose
219095091|NCT00246337|DRUG|MK0974|MK0974 600 mg; one orally-administered dose
219095092|NCT00246337|DRUG|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
219095093|NCT00228293|DEVICE|investigational monitor/defibrillator with CPR feedback|
219095094|NCT04382703|BEHAVIORAL|Self-Affirmation Exercise|"The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will …………………………………..~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me"
219095095|NCT04382703|BEHAVIORAL|Control|Given a questionnaire minus the self affirming exercise
219095096|NCT00338598|DRUG|Glycine|Glycine, 0.8 gr per kg given in two daily doses
219095097|NCT00338598|DRUG|placebo|
219095098|NCT05983159|DRUG|Alpelisib|Oral alpha-specific PI3-kinase inhibitor
219095099|NCT05983159|DRUG|Mirdametinib|An investigational oral MEK inhibitor
219095100|NCT00628797|RADIATION|UVA1|intraindividual half body irradiation
219095101|NCT00628797|OTHER|UVA1|60 J/cm2 at least 36 tx
219095102|NCT04302376|DIAGNOSTIC_TEST|Cather-related thrombosis ultrasonography|Doppler and compression ultrasound to detect catheter-related thrombosis
219095103|NCT06020625|GENETIC|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size \>50 genes, if \<40 ng material available."
219095104|NCT05976425|DEVICE|ModPG3 Investigational Device|"* Connex Vital Sign Monitor with ModPG3~* Laptop~* Data Collection Software~* USB cable~* Power strip~* Welch Allyn FlexiPort Disposable Blood Pressure Cuffs"
219095105|NCT05976425|DEVICE|Invasive Reference Equipment|"* Surveyor S12/S19~* Hill-Rom ICU Medical data collection cable DIR 60119852~* Hill-Rom Edwards data collection cable DIR 60119853"
219095106|NCT01837004|BEHAVIORAL|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
219095107|NCT03152955|DRUG|Ketamine|Ketamine will be applied in patient-controlled analgesia.
219095108|NCT03152955|OTHER|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
219095109|NCT03152955|DRUG|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
219095110|NCT03152955|DRUG|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
219095111|NCT03833635|OTHER|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
219095112|NCT03833635|OTHER|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
219095113|NCT05301504|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
219095114|NCT05416255|DIAGNOSTIC_TEST|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
219095115|NCT01495884|DRUG|non-pegylated liposomal doxorubicon (Myocet™)|
219095116|NCT01495884|DRUG|Lapatinib (Tyverb™)|
219095117|NCT00141739|DRUG|Etanercept|"Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
219095118|NCT05976204|PROCEDURE|ToF primary repair|ToF primary repair for patients with ToF
219095119|NCT00944723|DIETARY_SUPPLEMENT|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
219095120|NCT00944723|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement with zinc
219095121|NCT00944723|DIETARY_SUPPLEMENT|Non-fortified bread|Daily consumption of non-fortified bread
219095122|NCT00944723|DIETARY_SUPPLEMENT|Placebo supplement|Daily intake of placebo supplement
219220927|NCT06866171|OTHER|Modular child restraint|The participant will be asked to install two different child safety seats into a vehicle, presented to the participant one at a time (random order). The researcher will explain that the participant should install each seat to the best of his/her ability and may take as long as needed. When each installation is completed, the participant will be led away from the vehicle while their work is evaluated by a study-team approved researcher who is a certified Child Passenger Safety Technician (CPST). A data collection form will be used to document any installation errors. Following the installations, participants will complete a short survey with open-ended queries to describe facilitators or barriers they experienced while installing the seats, as well as what they liked or did not like about each seat. They will use a Likert scale to rate their self-efficacy in installing the seats, if they believed they were installed correctly, general ease-of-use, and which seat they preferred.
219220928|NCT04807842|DEVICE|vaginal gel|The placebo gel is a non-buffered gel. The active device is an acidic gel.
219220929|NCT04827732|RADIATION|Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy|When feasible it is strongly recommended that radiotherapy begin on a Monday
219220930|NCT04827732|DEVICE|MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine|-The device that will administer the IMPT
219220931|NCT07011030|OTHER|Measure of skeletal muscle mass|Bioimpedance analysis with integrated electrodes and osteodensitometry examination
219220932|NCT07011615|BEHAVIORAL|Brief Motivational Mobile Health (mHealth) Intervention|Participants randomized to the mHealth intervention condition will receive a five-week online program that incorporates weekly text messages. The program will begin with prompting the young adult to reflect on their journey with cannabis and to reflect on their personal goals and how cannabis is reflected in these goals. Personalized feedback about their patterns of use, motivations, emotions, and social connections will be integrated throughout the program. Text messages will be sent throughout the week to prompt reflection and support any goals the participant indicates.
219220933|NCT07011615|OTHER|Psychoeducational Attention Control (AC)|Participants randomized to the control group will receive a program to learn more about psychoeducational information about cannabis. They can opt in to receive psychoeducational material via text messages.
219220934|NCT06873581|DEVICE|Voro Urologic Scaffold|The Voro Urologic Scaffold is placed during the prostatectomy procedure after prostate removal.
219220935|NCT06873152|PROCEDURE|Control preoperative program|Patients will undergo a control preoperative program with no enhances preparation when undergoing bilateral third molar extraction
219220936|NCT06873152|PROCEDURE|Advanced preoperative program|Patients will undergo an comprehensive program including enhanced preoperative preparation and a dedicated operating room team when undergoing bilateral third molar extraction
219220937|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
219220938|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
219220939|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
219220940|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
219220941|NCT05807074|DRUG|Tranexamic Acid|Applied intraoperatively
219220942|NCT05807074|OTHER|Saline|Applied intraoperatively
219220943|NCT04476563|DIAGNOSTIC_TEST|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
219220944|NCT07020520|DEVICE|Optilume|Has pre-treatment (balloon dilation or ureterotomy) followed by paclitaxel-coated balloon (Optilume) treatment of the ureteric stricture.
219220945|NCT07014098|DEVICE|Robot-Aided Off-Axis Neuromuscular Training|A novel custom-designed elliptical trainer is developed, and its footplates are robot-controlled to be moved in four off-axis directions (sliding in/out, pivoting in/out; corresponding to knee valgus/varus, internal rotation/external rotation). Before the training, off-axis neuromechanical assessments will be conducted to determine which specific off-axis direction (valgus, varus, internal rotation, external rotation, or combination of the off-axis directions) has neuromechanical deficits. During the evaluation-based and subject-specific neuromuscular training, the different training modes will be conducted progressively from regular stepping, footplate position control, spring mode, perturbation, to slippery mode.
219220946|NCT07014098|DEVICE|Traditional elliptical regular stepping|traditional elliptical regular stepping
219220947|NCT05821426|DEVICE|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
219220948|NCT06618157|DEVICE|Cerebellothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model
219220949|NCT06618157|DEVICE|Pallidothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
219220950|NCT06618157|OTHER|No deep brain stimulation|Patients will also be tested without any deep brain stimulation
219095123|NCT01391923|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219095124|NCT00698386|DIETARY_SUPPLEMENT|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
219095125|NCT00698386|DIETARY_SUPPLEMENT|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
219095126|NCT04498325|DRUG|NT-I7|Supplied by study
219095127|NCT04498325|DRUG|Placebo|Supplied by study
219095128|NCT04498325|PROCEDURE|Blood for research purposes|Prior to injection (Day 0), Day 7, and Day 14
219095129|NCT04498325|PROCEDURE|Blood for pharmacokinetic samples|-Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
219095130|NCT04498325|PROCEDURE|Nasopharyngeal, oropharyngeal, or saliva swab|-Prior to study treatment, Day 4(optional), Day 7, and Day 14
219095131|NCT04498325|PROCEDURE|Blood for anti-drug antibody (ADA)|Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
219095132|NCT03634618|OTHER|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
219095133|NCT03634618|OTHER|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
219095134|NCT02465502|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
219095135|NCT04308902|OTHER|VLBW|Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
219220951|NCT06618157|DEVICE|Usual care deep brain stimulation|Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
219220952|NCT05435976|DEVICE|CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)|Biological membranes used in dental surgery
219220953|NCT06697197|DRUG|BMS-986482|Specified dose on specified days
219220954|NCT06697197|DRUG|Nivolumab and rHuPH20|Specified dose on specified days
219220955|NCT06697197|DRUG|Nivolumab/relatlimab/rHuPH20|Specified dose on specified days
219220956|NCT06697197|DRUG|Bevacizumab|Specified dose on specified days
219095136|NCT04308902|OTHER|Term-born Comparison|Children born \>=37 weeks gestation and weighing more than 2500g
219095137|NCT00185640|DRUG|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
219220957|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
219220958|NCT07030712|DRUG|MK-8294|30 µg via intravenous (IV) infusion
219220959|NCT07030712|DRUG|MK-8294|100 µg via intravenous (IV) infusion
219220960|NCT07030712|DRUG|MK-8294|300 µg via intravenous (IV) infusion
219220961|NCT07030712|DRUG|MK-8294|1 mg via intravenous (IV) infusion
219220962|NCT07030712|DRUG|MK-8294|3 mg via intravenous (IV) infusion
219220963|NCT07030712|DRUG|MK-8294|10 mg via intravenous (IV) infusion
219220964|NCT07030712|DRUG|MK-8294|30 mg via intravenous (IV) infusion
219095138|NCT00185640|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
219095139|NCT00185640|DRUG|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
219095140|NCT00185640|DRUG|Filgrastim|"* Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
219095141|NCT00185640|RADIATION|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
219095142|NCT00058422|BIOLOGICAL|darbepoetin alfa|
219095143|NCT00058422|BIOLOGICAL|filgrastim|
219095144|NCT00058422|BIOLOGICAL|rituximab|
219095145|NCT00058422|DRUG|cyclophosphamide|
219095146|NCT00058422|DRUG|doxorubicin hydrochloride|
219095147|NCT00058422|DRUG|prednisone|
219095148|NCT00058422|DRUG|vincristine sulfate|
219095149|NCT00058422|RADIATION|indium In 111 ibritumomab tiuxetan|
219220965|NCT07030712|DRUG|MK-8294|70 mg via intravenous (IV) infusion
219220966|NCT07030764|DEVICE|DOCT'UP|In addition to conventional physiotherapy sessions, DOCT'UP® is a mobile application which offers support programmes for patients following ACL reconstruction. This is digital therapy based on homebased physical exercises to be performed by patient.
219220967|NCT07030764|BEHAVIORAL|Physiotherapy|Physiotherapy includes sessions performed at physiotherapist office under physiotherapist overview
219220968|NCT07036159|BIOLOGICAL|RTS,S/AS01E vaccine|RTS,S/AS01E vaccine will be administered intramuscularly.
219220969|NCT06018415|BEHAVIORAL|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
219220970|NCT06018415|BEHAVIORAL|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
219095150|NCT00058422|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219095151|NCT00641914|DRUG|budesonide|
219095152|NCT00641914|DRUG|Placebo|
219095153|NCT00237939|DRUG|Aripiprazole|
219095154|NCT06449716|OTHER|12-week progressive power-oriented resistance exercise program|2x/week, 35-45 min sessions, on leg press machine
219682527|NCT03574623|DEVICE|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
219220971|NCT07035431|DEVICE|Endo-SPONGE|The intervention involves the placement of an Endo-SPONGE in the leakage cavity, and applying suction to facilitate drainage.
219220972|NCT07039916|DRUG|IMVT-1402|• Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)
219220973|NCT07039916|DRUG|IMVT-1402|"* Dose 2 SC QW for 12 weeks (Period 1)~* Dose 2 SC QW for 14 weeks (Period 2)"
219095155|NCT03248609|OTHER|Milano grapes|Milano grapes to test post-prandial glycemic response
219095156|NCT03248609|OTHER|Table grapes|Table grapes to test post-prandial glycemic response
219095157|NCT03248609|OTHER|Grape juice|Grape juice to test post-prandial glycemic response
219095158|NCT03248609|OTHER|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
219095159|NCT05007145|DRUG|PD-1 inhibitor|PD-1 Inhibitor 200mg D1 Q3W
219095160|NCT05007145|DRUG|Albumin-Bound Paclitaxel|125 mg/m\^2 D1/D8 Q3W
219095161|NCT05007145|DRUG|Cisplatin|75 mg/m\^2 D1 Q3W
219095162|NCT05007145|RADIATION|Radiation|40Gy/2.0Gy
219095163|NCT05279625|DEVICE|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
219095164|NCT00258999|DEVICE|Skin Cholesterol Testing|
219095165|NCT03651102|DRUG|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
219095166|NCT03359070|DRUG|Dapaconazole|Application of 1 gram on the lesion.
219095167|NCT03359070|DRUG|Miconazole Nitrate|Application of 1 gram on the lesion.
219095168|NCT05137379|BEHAVIORAL|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
219220974|NCT07039916|DRUG|Placebo|• Placebo SC QW for 12 weeks (Period 1)
219220975|NCT07039916|DRUG|IMVT-1402|• Dose 1 SC QW for 14 weeks (Period 2)
219220976|NCT06716931|OTHER|Exercise|"A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated.~In person exercise supervised by physical therapist and then self-directed exercise in Group A"
219220977|NCT06716931|OTHER|Exercise|Exercise virtually supervised by physical therapist and then self-directed for group B
219220978|NCT06716931|OTHER|Exercise|Self-directed and virtually supervised exercise by physical therapist for Group C
219220979|NCT06881602|PROCEDURE|Remote clinical monitoring|Patients after a distal pancreatectomy will be discharged faster from the hospital and will be remote monitored
219682528|NCT03574623|BEHAVIORAL|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
219095169|NCT00732186|BIOLOGICAL|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
219220980|NCT05888623|DEVICE|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
219220981|NCT05785832|DEVICE|t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
219220982|NCT05785832|DEVICE|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
219220983|NCT06881784|DRUG|daraxonrasib|oral tablets
219220984|NCT06881784|DRUG|docetaxel|intravenous (IV) infusion
219095170|NCT01321541|DRUG|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
219095171|NCT01321541|DRUG|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
219095172|NCT02192970|DRUG|Bevacizumab|
219095173|NCT04074590|DRUG|LYS006|capsule for oral use
219220985|NCT07041359|DRUG|Compound Danshen Dripping Pills|The experimental group used compound Danshen dripping pills as an intervention on the basis of conventional western medicine treatment.
219220986|NCT07041359|DRUG|Qishen Yiqi Drop Pills|The experimental group used Qishen Yiqi dripping pills as an intervention on the basis of conventional western medicine treatment.
219220987|NCT07041359|DRUG|Placebo|Intervention with placebo on the Basis of optimal medical treatment
219220989|NCT06888193|DRUG|Bimekizumab|Bimekizumab under the care of their treating physician.
219220990|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 52 weeks
219220991|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
219220992|NCT06727604|DRUG|Placebo|SC QW for 52 weeks
219220993|NCT06263647|BEHAVIORAL|Houston-HVIP treatment|Participants will be assigned a case manager to provide a brief assessment of , psychological and social needs and a risk assessment and create individualized discharge planning. Participants will be referred to tailored social service programs based on the needs, including assessments of social determinants of health, educational and financial needs, and subsequent referral for programs such as job training, educational support, housing assistance, or financial assistance programs for identified needs. Participants identified at risk for violence perpetration via a risk assessment screener will be referred to the violence interrupter services. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged.Participants will receive a structured curriculum that will include regular check-in with an assigned case manager over 6 months to promote successful community-based program integration and completion.
219220994|NCT06263647|BEHAVIORAL|Standard of Care|Participants will be assigned a case manager to meet with the injured patients to briefly assess (a) psychological and social needs and (b) a risk assessment and create individualized discharge planning. Resources for the patient to connect with social service programs will be provided by the case manager. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged. Follow-up contacts and services from an assigned case manager over two weeks following discharge from the hospital to ensure that the patient has contacted the community-level violence outreach organizations.
219220995|NCT07041164|DIAGNOSTIC_TEST|Bitewing radiograph|Digital radiograph, proximal caries, initial caries
219220996|NCT07041164|DIAGNOSTIC_TEST|Near-infrared light transillumination|DIAGNOcam, proximal caries, initial caries
219220997|NCT07050186|PROCEDURE|Biopsy Procedure|Undergo optional biopsy
219220998|NCT07050186|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219220999|NCT07050186|BIOLOGICAL|Cemiplimab|Given IV
219095174|NCT04074590|DRUG|Placebo|capsule for oral use
219095175|NCT01417052|DRUG|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
219095176|NCT01417052|DRUG|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
219095177|NCT01417052|DRUG|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
219095178|NCT01417052|DRUG|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
219095179|NCT01417052|DRUG|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
219095180|NCT01417052|DRUG|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
219095181|NCT01417052|DRUG|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
219221000|NCT07050186|PROCEDURE|Computed Tomography|Undergo CT
219221001|NCT07050186|OTHER|Digital Photography|Undergo digital photography
219221002|NCT07050186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219221003|NCT07050186|OTHER|Questionnaire Administration|Ancillary studies
219221004|NCT07050563|DRUG|Compound Ciwujia Granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, Compound Ciwujia Granules were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
219221005|NCT07050563|DRUG|Placebo granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, placebo granules which containing 10% of Compound Ciwujia Granules drug were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
219221006|NCT07050563|COMBINATION_PRODUCT|Standard treatment protocol for ovarian cancer combined with psychological intervention.|Standard treatment protocol for ovarian cancer: In accordance with the 2024 NCCN International Guidelines, patients opt for chemotherapy regimens containing platinum-based drugs and/or targeted therapy, anti-angiogenic therapy, hormonal therapy, etc. Psychological intervention is conducted once a week in the form of online and offline patient education sessions for psychological intervention, continuing until the end of the study period. Both the intervention group and the control group use this as the baseline treatment plan.
219221007|NCT07051148|BEHAVIORAL|UJI Online Transdiagnostic Protocol|Is a manualized treatment for emotional disorders delivered through an interactive multimedia platform. The self applied format consists of 12 self applied modules (psychoeducation, emotional processing, cognitive flexibility training, exposure, coping strategies, maladaptive behaviors, avoidance, etc)
219221008|NCT07051148|BEHAVIORAL|UJI On Line Transdiagnostic Hibrid Protocol|Hybrid format: 12 self applied modules with two synchronous sessions with a trained therapist
219221009|NCT06733675|DRUG|Ledaborbactam etzadroxil|capsules
219095182|NCT01417052|DRUG|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
219095183|NCT01417052|DRUG|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
219095184|NCT01417052|DRUG|Placebo|Matching placebo dosing in capsule form
219095185|NCT03975699|OTHER|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
219095186|NCT04923555|BEHAVIORAL|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
219095187|NCT04923555|BEHAVIORAL|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
219221010|NCT06733675|DRUG|Ceftibuten|capsules
219221011|NCT06733675|DRUG|Ceftibuten-ledaborbactam etzadroxil|Fixed Dose Combination (FDC)
219221012|NCT06733675|DRUG|Esomeprazole|40 mg capsule
219221013|NCT06733649|OTHER|substance abuse treatment education|Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
219221014|NCT07045311|DRUG|JS207 in combination with 9MW2821|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)
219221015|NCT07045311|DRUG|JS207 in combination with Albumin paclitaxel|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).
219221016|NCT06891352|BEHAVIORAL|Dietary Monitoring|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and continue their habitual eating patterns.
219221017|NCT06891352|BEHAVIORAL|Time-Restricted Eating (TRE)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window.
219221018|NCT06891352|BEHAVIORAL|Time-Restricted Eating with a Low-Glycemic Snack (TRE-LGS)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window. On nights that participants work night shifts, they will consume a low-glycemic snack provided by the research team.
219221019|NCT06734208|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective cohort.
219221020|NCT03359954|RADIATION|Radiation Therapy|Undergo radiation therapy
219221021|NCT03359954|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast surgery
219221022|NCT07127016|BEHAVIORAL|Mindfulness Sessions|8 sessions of mindfulness prior to completing their physical therapy session. Each mindfulness session will take 5-10 minutes and will be completed once weekly, immediately prior to their physical therapy sessions. Mindfulness prompts will focus on self-reflection, relaxation, body scanning and being present.
219221023|NCT07127016|BEHAVIORAL|No Mindfulness Sessions|Standard of care physical therapy without mindfulness sessions.
219095188|NCT04923555|BEHAVIORAL|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
219221024|NCT07052032|BIOLOGICAL|CND261|CND261 will be dosed according to the assigned cohort
219221025|NCT06896188|DRUG|Retifanlimab|(PD-1)-blocking monoclonal antibody
219221026|NCT06896188|DRUG|Chemotherapy|oxaliplatin - Antineoplastic - Platinum Complexes Chemotherapy agent; leucovorin - a form of Folic acid helps the body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer; irinotecan - anti-cancer medication used to treat colon cancer in combination with other chemotherapeutic agents; 5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents
219221027|NCT06896188|DRUG|9-ING-41|a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells
219362142|NCT03887754|DEVICE|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
219095189|NCT04939545|DRUG|Ropivacain|"Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
219221028|NCT04555161|DEVICE|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
219221029|NCT03414684|DRUG|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
219095190|NCT04939545|DRUG|NaCl 0.9%|"Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
219221030|NCT03414684|DRUG|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
219221031|NCT04711811|BIOLOGICAL|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
219221032|NCT06753838|BIOLOGICAL|Sampling of 3 additional BAPA tubes|the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test
219221033|NCT03570801|OTHER|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
219682529|NCT01517308|DRUG|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
219682530|NCT04090385|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
219682531|NCT00417157|DRUG|recombinant FSH (Puregon, Organon, The Netherlands)|
219682532|NCT00417157|DRUG|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
219682533|NCT00417157|DRUG|hCG (Pregnyl, Organon, The Netherlands)|
219682534|NCT02524834|PROCEDURE|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
219221034|NCT06741618|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence
219221035|NCT06741618|BEHAVIORAL|Electronic PrEP peer navigation|Electronic peer navigation to PreP services
219682535|NCT02524834|DEVICE|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
219682536|NCT03107182|DRUG|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
219682537|NCT03107182|DRUG|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
219682538|NCT03107182|DRUG|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
219682539|NCT03107182|DRUG|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
219682540|NCT03107182|DRUG|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
219682541|NCT03107182|DRUG|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
219682542|NCT03107182|DRUG|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
219682543|NCT03107182|DRUG|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
219682544|NCT03107182|DRUG|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
219682545|NCT03107182|DRUG|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
219095191|NCT01770210|DRUG|Patients on atorvastatin treatment|Statins Therapy
219095192|NCT02723058|BEHAVIORAL|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
219095193|NCT00681616|DEVICE|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
219095194|NCT00681616|DEVICE|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
219095195|NCT00681616|DEVICE|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
219095196|NCT00035035|DRUG|GEMZAR|
219095197|NCT00035035|DRUG|ALIMTA|
219221036|NCT07060365|DRUG|Saruparib|Participants will receive saruparib via oral administration.
219221037|NCT07061288|DRUG|KarXT|Specified dose on specified days
219221038|NCT04038580|DEVICE|Laminated Socket|This is the currently prescribed socket the participant normally wears.
219221039|NCT04038580|DEVICE|Quatro|The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
219221040|NCT04038580|DEVICE|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
219221041|NCT04038580|DEVICE|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
219221042|NCT01922440|OTHER|No intervention|This is a non-interventional study.
219221043|NCT07055516|DRUG|NT-0796|Orally administered capsules
219221044|NCT07055516|DRUG|Placebo|Orally administered capsules
219221045|NCT06578390|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
219221046|NCT07062094|DEVICE|Intragastric Balloon|The Orbera365™ IGB System is to be used in conjunction with a long-term supervised diet and behavior modification program designed to increase the possibility of long-term weight loss maintenance. The IGB is placed in the stomach and filled with sterile saline, causing it to expand into a spherical shape. The filled IGB is designed to occupy space and move freely within the stomach, potentially altering appetite and satiety to achieve weight loss.
219221047|NCT04907175|BIOLOGICAL|HB-adMSCs|Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.
219221048|NCT06770855|PROCEDURE|Total consolidative MPDT|After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and/or radiotherapy (SAbR or other definitive radiotherapy).
219221049|NCT07062198|DRUG|Combined metabolic activators|A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.
219095198|NCT03223532|DEVICE|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
219221050|NCT07062198|OTHER|Collagen and maltodextrin|As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.
219221051|NCT02954432|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
219221052|NCT02954432|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
219095199|NCT03223532|DEVICE|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
219095200|NCT06350929|OTHER|Cardiac output monitoring by the Starling™ SV Sebac®|"During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected."
219221053|NCT06208735|BIOLOGICAL|CLIC-2201|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.
219221054|NCT06894498|OTHER|No Intervention: Observational Cohort|No Intervention, Observational Cohort
219221055|NCT05463289|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
219095201|NCT06259643|OTHER|Power wheelchair soccer|Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
219095202|NCT06346314|OTHER|Scapular retraction exercise|Participant lies prone with hands superior to the head on a treatment plinth and lifts their elbows 10 repetitions for three sets with 30 seconds of rest between each set.
219095203|NCT05834114|OTHER|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
219095204|NCT05834114|OTHER|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
219095205|NCT03748511|OTHER|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
219095206|NCT04193501|DRUG|Melatonin 3 mg|Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
219095207|NCT04193501|OTHER|Placebo|Similar looking placebo
219095208|NCT05319106|OTHER|stem cell preparation combined with silver ion dressing|The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
219221056|NCT06161545|BIOLOGICAL|PD-L1 t-haNK cells|Irradiated PD-L1 t-haNK cells at a dose of 2 x 10\^9 administered via IV infusion over 30 minutes on Days 1, 5, 8, 12, and 15
219221057|NCT06161545|DRUG|pembrolizumab|400 mg administered as a 30 minute IV infusion on Day 1
219221058|NCT06161545|DRUG|N-803|15 ug/kg via subcutaneous injection on Day 1
219221059|NCT07057258|PROCEDURE|Endoscopic suture repair|Children receiving endoscopic suture repair of laryngeal cleft
219221060|NCT07057258|PROCEDURE|Injection laryngoplasty|Children receiving injection of the interarytenoid space for laryngeal cleft treatment
219221061|NCT06829368|OTHER|Transcranial Focused Ultrasound Stimulation|Using MRI neuronavigation, the investigators will implement theta-burst tFUS in one of the four targets.
219221062|NCT05223036|PROCEDURE|Biopsy Procedure|Undergo biopsy
219221063|NCT05223036|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219221064|NCT05223036|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
219221065|NCT05223036|BIOLOGICAL|Obeticholic Acid|Given PO
219221066|NCT05223036|DRUG|Placebo Administration|Given PO
219221067|NCT05223036|OTHER|Questionnaire Administration|Ancillary studies
219221068|NCT06854159|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR T-cell therapy
219221069|NCT06854159|BIOLOGICAL|Odronextamab|Given IV
219221070|NCT06780150|DRUG|Ocrelizumab|Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
219221071|NCT07129226|OTHER|Smart Watch|Participants will be asked to wear the smartwatch daily, for at least 12 hours per day during the 12-week study period, with breaks to recharge the watch as needed.
219221072|NCT06359041|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
219221073|NCT07076394|BEHAVIORAL|Forgiveness Education|"The curriculum will apply the textbook of Forgiveness is a Choice: A Step-by-Step Process for Resolving Anger and Restoring Hope written by Dr. Robert Enright."
219221074|NCT05340582|DRUG|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
219221075|NCT05340582|DRUG|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
219221076|NCT05340582|OTHER|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
219221077|NCT06896045|BEHAVIORAL|Assess stress levels 4 times a day before meals (morning, noon and evening and at bedtime) using a visual analogue scale|In addition to stress assessment with the stress meter, patients will be fitted with a Continious Glucose Monitoring
219221078|NCT07081243|DEVICE|Symplicity Spyral Renal Denervation System|Symplicity Renal Denervation
219221079|NCT07075237|DRUG|Paliperidone Palmitate Injection (PP1M)|"Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment).~To avoid missed doses, administration is permitted ±7 days around the scheduled monthly date."
219221080|NCT07080762|DEVICE|antimicrobial photodynamic therapy (aPDT) after non-surgical therapy|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-non-surgical site for 60 seconds to promote disinfection Other Name: antimicrobial photodynamic therapy (aPDT) after non surgical therapy
219362143|NCT03887754|DRUG|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
219095209|NCT05319106|PROCEDURE|silver ion dressing|fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
219221081|NCT06750913|PROCEDURE|Comparison between PCNL without Catheterization in the Split-leg Prone Position and Traditional PCNL|Before the start of PCNL, one group of patients was placed in the lithotomy position and then converted to the prone position, and one group of patients directly separated from the leg prone position without an external brace
219221082|NCT06077500|DRUG|BI 764532|BI 764532
219095210|NCT04975022|DRUG|N11005|oral insulin N11005, 300IU, p.o.
219095211|NCT04975022|DRUG|Novolin R|reference preparation Novolin R, 0.1 IU/Kg, i.h.
219221083|NCT06077500|DRUG|Carboplatin|Carboplatin
219221084|NCT06077500|DRUG|Etoposide|Etoposide
219095212|NCT04293263|COMBINATION_PRODUCT|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
219095213|NCT02986607|DRUG|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
219095214|NCT05313386|DRUG|BXCL501|BXCL501 is given in a film form
219095215|NCT05313386|DRUG|Placebo film|Placebo is given in a film form
219095216|NCT03260530|OTHER|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
219095217|NCT03260530|OTHER|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
219095218|NCT01865305|DRUG|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
219095219|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
219095220|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
219095221|NCT01865305|DRUG|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
219095222|NCT01865305|DRUG|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
219095223|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
219095224|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
219095225|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
219095226|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
219095227|NCT05160324|PROCEDURE|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
219095228|NCT05160324|PROCEDURE|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
219095229|NCT00691132|DRUG|phenethyl isothiocyanate|Given orally
219095230|NCT00691132|OTHER|placebo|Given orally
219095231|NCT03954743|BIOLOGICAL|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
219095232|NCT03954743|BIOLOGICAL|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
219095233|NCT01923805|DEVICE|Vitagel|Vitagel
219095234|NCT00886067|DRUG|AZD1446|Solution, oral, single dose
219095235|NCT00886067|RADIATION|2-[18F]-F-A85380|iv, single dose
219221085|NCT06077500|DRUG|Atezolizumab|Atezolizumab
219221086|NCT06077500|DRUG|Durvalumab|Durvalumab
219221087|NCT06077500|DRUG|Cisplatin|Cisplatin
219221088|NCT06744647|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously (SC).
219221089|NCT06744647|DRUG|Placebo|Placebo will be administered SC.
219682546|NCT03107182|PROCEDURE|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
219095236|NCT00329121|DRUG|PEP005|
219095237|NCT05636462|OTHER|Global postural re-education program|"Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks."
219095238|NCT05636462|OTHER|Conventional Physical Therapy|Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
219095239|NCT00829686|DRUG|Septra|(800/125) PO BID X 7 days
219095240|NCT02387996|DRUG|Nivolumab|
219095241|NCT03670225|DEVICE|Invia Motion Endure|NPWT Invia Motion Endure
219221090|NCT07084012|DRUG|hUC-MSCs treatment (high dose)|2.0×10\^8 cells per infusion, single administration on D0. Infusion of cell medium placebo on Day 7 (±2 days), and Day 14 (±2 days).
219221091|NCT07084012|DRUG|hUC-MSCs treatment (low dose)|1.0×10\^8 cells per infusion, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
219221092|NCT07084012|DRUG|Placebo|Cell medium, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
219095242|NCT02307591|DRUG|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
219221093|NCT06366750|BIOLOGICAL|barzolvolimab|subcutaneous administration
219221094|NCT06366750|OTHER|Matching Placebo|subcutaneous administration
219221095|NCT07079098|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and the first (of five) fractions. Subsequent fractions will be delivered using standard image-guided radiotherapy (IGRT) or ART; this will be decided by the treating physician and institutional guidelines.
219221096|NCT07079098|RADIATION|SBRT|Participants will receive SBRT per standard of care in up to five fractions. Fractions will be delivered once daily or once every other day over a total period of one to two weeks.
219221097|NCT06624930|OTHER|Behavioural Counselling|"The PA+BC group will receive a behavioural counselling support session with a QEP every two weeks during the intervention period (12 total). Of the 12 video-conferencing calls, one session will target reflective processes (instrumental/affective attitudes), five sessions will target behavioural regulation (action planning, coping planning, social support, goal setting), and four sessions will target reflexive processing (self-regulation, habit). The remaining two sessions are booster sessions to revisit topics discussed. The importance of sustaining PA for clinical outcomes (e.g., fatigue) and PA logs will be stressed. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up."
219221098|NCT06624930|OTHER|Exercise Counselling|The PA+EC group will receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. However, the focus will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines.
219221099|NCT06905509|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHCT
219221100|NCT06905509|DRUG|Carboplatin|Given carboplatin
219221101|NCT06905509|DRUG|Cytarabine|Given cytarabine
219221102|NCT06905509|DRUG|Dexamethasone|Given dexamethasone
219221103|NCT06905509|BIOLOGICAL|Epcoritamab|Given SC
219221104|NCT06905509|DRUG|Etoposide Phosphate|Given etoposide phosphate
219221105|NCT06905509|DRUG|Gemcitabine|Given gemcitabine
219221106|NCT06905509|DRUG|Ifosfamide|Given ifosfamide
219221107|NCT06905509|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219221108|NCT06905509|DRUG|Oxaliplatin|Given oxaliplatin
219221109|NCT06905509|BIOLOGICAL|Rituximab|Given rituximab
219221110|NCT06904274|COMBINATION_PRODUCT|BAY865028|Intrauterine delivery system
219221111|NCT06904274|DRUG|Medroxyprogesterone acetate|Oral tablet
219221112|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 1|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1
219221113|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.
219221114|NCT06527690|DRUG|Niraparib/Abirate rone acetate fixed-dose combination|Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.
219221115|NCT06527690|DRUG|Prednisone|Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.
219221116|NCT07088458|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.
219221117|NCT06902558|DRUG|ABBV-CLS-628|IntraVenous Infusion
219221118|NCT06902558|DRUG|Placebo|IntraVenous Infusion
219221119|NCT06904287|DRUG|Magnesium|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
219221120|NCT06904287|DRUG|Placebo|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)
219221121|NCT02629120|DRUG|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
219221122|NCT02629120|DRUG|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
219221123|NCT02629120|DRUG|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
219221124|NCT02629120|DRUG|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
219221125|NCT02629120|RADIATION|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
219221126|NCT02629120|BIOLOGICAL|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
219221127|NCT06766864|DRUG|DR-01|DR-01 is a monoclonal antibody
219221128|NCT06766864|OTHER|Placebo|Placebo
219221129|NCT07093398|DRUG|D3S-001|"The investigational product dose: 600 mg D3S-001 capsules.~A 600-mg oral dose of D3S-001 will be given to potential participants on Day 1 and Day 4."
219221130|NCT04625946|DRUG|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
219221131|NCT04625946|BEHAVIORAL|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
219221132|NCT04625946|DEVICE|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
219221133|NCT06731855|PROCEDURE|Abdominal Surgery for congenital gut malformation in the first 5 days of life.|Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.
219221134|NCT07098663|DRUG|MKP10241|Oral liquid suspension of unit dose strength 6.6 mg/mL
219221135|NCT07098663|DRUG|Placebo|Oral liquid suspension matched in appearance to MKP10241 at dosage strengths
219221136|NCT07099482|DEVICE|Sham ultrasound (placebo)|Participants will receive conventional wound care including debridement, cleaning, and dressing. A sham ultrasound device that emits no therapeutic waves will be applied to simulate the intervention procedure.
219221137|NCT07099482|DRUG|Propolis gel (10%)|Participants will receive topical application of 10% propolis gel on the diabetic foot ulcer followed by therapeutic ultrasound (phonophoresis) using 1 MHz frequency, 0.5-1.5 W/cm² intensity, pulsed mode (20%), for 5 minutes per session, 3 sessions/week for 4 weeks.
219221138|NCT06730386|DRUG|AK138D1|Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
219221139|NCT06770764|DRUG|ODC-IL2|ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.
219221140|NCT00310180|DRUG|Anastrozole|Given PO
219221141|NCT00310180|DRUG|Exemestane|Given PO
219221142|NCT00310180|OTHER|Laboratory Biomarker Analysis|Correlative studies
219221143|NCT00310180|DRUG|Letrozole|Given PO
219221144|NCT00310180|OTHER|Quality-of-Life Assessment|Ancillary studies
219221145|NCT00310180|RADIATION|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
219221146|NCT00310180|DRUG|Tamoxifen Citrate|Given PO
219221147|NCT06509191|DRUG|Intervention 1|Melatonin 5mg/day
219221148|NCT06509191|DRUG|Intervention 2|Melatonin 8 mg/day
219221149|NCT06509191|OTHER|Control|Placebo
219221150|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
219221151|NCT02625480|DRUG|Fludarabine|Administered intravenously
219682547|NCT03107182|RADIATION|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
219682548|NCT03107182|RADIATION|Chemoradiotherapy|"Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
219682549|NCT03187743|OTHER|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
219682550|NCT06957977|PROCEDURE|Endoscopic Cryoballoon Ablation Treatment|ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice. PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions.
219682551|NCT06957977|DRUG|PD1 Inhibitor|The first administration of the PD-1 monoclonal antibody is initiated when patients achieve a partial response (PR) following standard treatment. Subsequent administrations are given every three weeks according to the prescribing information.
219682552|NCT02675764|OTHER|Vibration|peripheral vibration at the wrist skin at an imperceptible level
219221152|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
219221153|NCT06776952|DRUG|XNW5004 ; Chidamide placebo|XNW5004 + Chidamide placebo
219221154|NCT06776952|DRUG|XNW5004 placebo; Chidamide|XNW5004 placebo + Chidamide
219682553|NCT02675764|OTHER|Placebo (for vibration)|No peripheral vibration at the wrist skin
219682554|NCT02675764|BEHAVIORAL|therapy|standardized hand therapy program
219682555|NCT01700257|RADIATION|CT scan & Early CDT Lung test|
219682556|NCT01700257|OTHER|CT scan & Early CDT Lung test|
219682557|NCT01275989|OTHER|Ear acupuncture|
219682558|NCT02806856|DEVICE|tDCS neuroConn|Cathodal on M1
219221155|NCT07098312|BEHAVIORAL|creative drama|It is aimed to develop cultural competence in nursing students through creative drama workshops.
219221156|NCT06926881|DEVICE|BiWaze Clear System|"The BiWaze Clear device includes several components as follows:~1. BiWaze Clear System.~2. BiWaze Clear Dual Lumen Breathing Circuit.~   * Dual Lumen bacterial/viral filter.~  * Dual Lumen breathing tube.~  * Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter).~3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System"
219221157|NCT06319872|DRUG|Oral disulfiram|250 mg/day
219095243|NCT02307591|DRUG|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day"
219095244|NCT02304276|RADIATION|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
219095245|NCT02304276|RADIATION|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
219221158|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
219221159|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
219221160|NCT06355310|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
219095246|NCT03160287|BEHAVIORAL|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
219095247|NCT01949103|DRUG|TD-1607|
219095248|NCT01949103|DRUG|Placebo|
219095249|NCT00345163|DRUG|bevacizumab|Intravenous repeating dose
219095250|NCT00345163|DRUG|irinotecan|Intravenous repeating dose
219095251|NCT01378910|DRUG|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
219095252|NCT04262765|DRUG|Ramipril, Amlodipine and Atorvastatin|compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
219095253|NCT02098018|BEHAVIORAL|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
219095254|NCT02098018|BEHAVIORAL|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
219221161|NCT06355310|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
219221162|NCT06618144|OTHER|Texting platform|Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
219221163|NCT03072927|DEVICE|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
219221164|NCT03072927|DEVICE|Interspinous Process Decompression|Interspinous Process Decompression
219221165|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
219221166|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.
219362144|NCT01625754|BEHAVIORAL|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
219095255|NCT02848716|PROCEDURE|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
219095256|NCT02848716|RADIATION|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
219095257|NCT02848716|RADIATION|chemoradiation|
219095258|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
219095259|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
219221167|NCT05434234|DRUG|YL201 and atezolizumab|Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle
219221168|NCT06869590|OTHER|blood sampling|When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).
219221169|NCT06869590|OTHER|blood sampling after 3-4 months|In the event of AAHIF positivity, a second sample will be taken between 12 and 16 weeks later to verify the persistence of autoantibodies: Visit 2.
219221170|NCT06515002|GENETIC|BI 3720931|BI 3720931
219221171|NCT06515002|DRUG|Placebo|Placebo
219221172|NCT06515002|DEVICE|Inhaler|Inhaler for application of BI 3720931 and placebo
219221173|NCT06564038|DRUG|AZD0486|AZD0486 will be administered as either SC injection or IV infusion.
219221174|NCT06564038|DRUG|Prednisone (or equivalent)|Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.
219221175|NCT06564038|DRUG|Rituximab|Rituximab will be administered as IV infusion as per standard of care.
219221176|NCT06564038|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as IV infusion as per standard of care.
219221177|NCT06564038|DRUG|Vincristine|Vincristine will be administered as IV infusion as per standard of care.
219095260|NCT04956328|DRUG|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
219095261|NCT04956328|DRUG|UDCA|UDCA：continue prestudy dose
219095262|NCT04956328|DRUG|Placebo|Placebo
219095263|NCT04572178|BEHAVIORAL|Cash payment and brief behavioral counseling|"The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again."
219095264|NCT00228696|OTHER|none, screening only|Screening protocol with no intervention
219095265|NCT05835557|OTHER|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
219095266|NCT05835557|OTHER|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
219221178|NCT06564038|DRUG|Doxorubicin|Doxorubicin will be administered as IV infusion as per standard of care.
219221179|NCT06564038|DRUG|Acalabrutinib|Acalabrutinib will be administered orally
219095267|NCT03352934|DRUG|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
219095268|NCT02459223|DIETARY_SUPPLEMENT|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
219095269|NCT02459223|DIETARY_SUPPLEMENT|Khichadi|Khichadi.
219221180|NCT06389136|DRUG|Upadacitinib 15mg Dose|Oral tablet
219221181|NCT06389136|DRUG|Dupilumab 300mg Dose|Subcutaneous (SC) injection
219221182|NCT06389136|DRUG|Upadacitinib 30mg Dose|Oral tablet
219221183|NCT03816345|PROCEDURE|Biospecimen Collection|Undergo collection of blood, CSF, tissue, stool and urine samples
219221184|NCT03816345|BIOLOGICAL|Nivolumab|Given IV
219095270|NCT06112730|OTHER|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
219221185|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
219221186|NCT05606341|DRUG|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
219221187|NCT05606341|DRUG|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
219221188|NCT05606341|DRUG|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
219221189|NCT05606341|DRUG|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
219221190|NCT06034353|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
219221191|NCT06910033|DEVICE|Craniomaxillofacial (CMF) porous titanium implant|All patients were treated, between 2016 and 2023, with patient-specific CMF Porous Titanium Implants for facial and/or cranial reconstruction or restoration of bone defects.
219221192|NCT07106632|DRUG|test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone|In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
219221193|NCT07106632|DRUG|In the control arm, the treatment will be as standard of care : chemo-endocrine therapy|Standard treatment: Chemotherapy followed by endocrine therapy
219221194|NCT07101926|BIOLOGICAL|blood sampling|One-time peripheral blood draw (10.8 mL total, 4 citrated tubes) collected during a routine clinical visit for thrombin generation testing on platelet-rich and platelet-poor plasma. No additional medical procedures or treatments are involved in the study.
219095271|NCT06112730|OTHER|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
219095272|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (intervention group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
219095273|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (control group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
219095274|NCT03998683|DRUG|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
219095275|NCT03998683|DRUG|Placebo|Placebo will be administered as SC injection.
219095276|NCT00002537|DRUG|topotecan hydrochloride|
219095277|NCT00002537|RADIATION|radiation therapy|
219095278|NCT05030259|PROCEDURE|fasciotomy|To perform fasciotomy
219095279|NCT00989586|BIOLOGICAL|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
219095280|NCT00989586|BIOLOGICAL|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
219095281|NCT00989586|PROCEDURE|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
219095282|NCT00989586|PROCEDURE|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
219095283|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
219095284|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
219095285|NCT00989586|PROCEDURE|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
219095286|NCT00989586|BIOLOGICAL|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
219095287|NCT02920203|GENETIC|Heart and spleen tissue|genetic sequencing
219095288|NCT03582891|DEVICE|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
219095289|NCT03582891|DIAGNOSTIC_TEST|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
219221195|NCT05809856|DEVICE|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
219221196|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
219095290|NCT03582891|DEVICE|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
219221197|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
219221198|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
219221199|NCT06921590|DRUG|AL001|Crystalized Lithium
219221200|NCT06921590|DRUG|Lithium Carbonate Capsule|Lithium Carbonate
219095291|NCT05529758|BEHAVIORAL|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
219221207|NCT07118254|DRUG|rhPRG4 450ug/ml|Treatment
219221208|NCT07118254|DRUG|Vehicle Control|PBS Based Vehicle Control
219221209|NCT06753916|PROCEDURE|Corneal Donor Tissue with Cross Linking|Participants are transplanted with corneal donor tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) with UV light treatment.
219221210|NCT06753916|PROCEDURE|Corneal Donor Tissue without Cross Linking|Participants are transplanted with corneal donor tissue that has not been treated with the UV light and the 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) without UV light treatment, this is the control group.
219221211|NCT01976260|DEVICE|Fractional Radiofrequency|
219221212|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
219221213|NCT06773897|GENETIC|Saliva sample|Saliva sample is sent via prepaid US Mail for DNA extraction
219221214|NCT06773897|OTHER|Health Surveys|Health surveys are filled out online in the study portal.
219221215|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
219221216|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
219221217|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
219221218|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
219221219|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
219095292|NCT01954368|DRUG|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
219095293|NCT01954368|DRUG|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
219095294|NCT06339060|COMBINATION_PRODUCT|Experimental: Arm 1 Organ preservation|"Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy"
219221229|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
219221230|NCT06285123|BEHAVIORAL|Facilitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
219221231|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
219221232|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
219221233|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
219221234|NCT03541902|DRUG|Cabozantinib|Given PO
219095295|NCT06339060|COMBINATION_PRODUCT|Active Comparator: Arm 2 Surgery|"Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week."
219095296|NCT02192775|DRUG|MV-NIS|one dose in conjunction with a 4 day course intravenously
219095297|NCT00145301|DRUG|Lumiracoxib|
219095298|NCT02037438|OTHER|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
219221235|NCT03541902|DRUG|Sunitinib Malate|Given PO
219221236|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
219221237|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
219221238|NCT06940427|DRUG|FAPI tracer|"radioactive substance called a tracer injected into the arm"
219221239|NCT06940427|DEVICE|PET/MRI|positron emission tomography (PET) takes pictures of inside of the body
219221240|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
219221241|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
219221242|NCT06941129|BIOLOGICAL|UCAR T-cell|universal allogeneic anti-CD19/BCMA CAR T-cells
219221243|NCT06941961|DEVICE|intermittent theta burst stimulation|The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.
219221244|NCT06941961|DEVICE|sham intermittent theta burst stimulation|Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.
219221245|NCT07144267|DRUG|Epinephrine|Normal saline bolus over 10 min followed by Epinephrine intravenous infusion of 0.05-0.1 mcg/kg/min.of epinephrine 5-10 minutes before aortic unclamping
219221246|NCT07144267|DRUG|Milrinone Injection|Milrinone initial bolus doses of 50 µg/kg, followed by 0.40 - 0.80 µg/kg/min of milrinone 5-10 minutes before aortic unclamping
219221247|NCT06945198|PROCEDURE|Anatomical reconstruction|Anatomical ligamentoplasty or anatomical reconstruction is performed under arthroscopy. The principle of this method, which lasts around 40 minutes under spinal anaesthetic or general anaesthetic, is to reconstruct the LTFA and sometimes also the LCF, if it has been damaged, using a fragment of the tendon gracilis, located in the thigh, removed through an incision under the knee
219221248|NCT06945198|PROCEDURE|Broström anatomical repair|Broström's anatomical repair is performed under arthroscopy. The principle of this method is to tighten and reattach the LTFA using very small anchors, when it is detached from the fibula but not too retracted and still of good quality. If necessary, this may also be accompanied by ligament reinforcement ('gould'), using a fragment of a fibrous structure in the ankle, the extensor retinaculum
219221249|NCT06341933|OTHER|Duration of Surgery|Total surgery time in minutes
219221250|NCT06341933|OTHER|Volume of Fluid in Surgery|Fluid volume given during surgery in ml
219221251|NCT06341933|OTHER|Blood Loss|Blood loss during surgery in ml
219221252|NCT03255746|BEHAVIORAL|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
219221253|NCT03255746|BEHAVIORAL|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
219095299|NCT02037438|OTHER|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
219095300|NCT02255032|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
219095301|NCT02255032|DRUG|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
219095302|NCT00563225|DRUG|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
219095303|NCT05168813|BIOLOGICAL|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
219095304|NCT05168813|BIOLOGICAL|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
219095305|NCT05168813|BIOLOGICAL|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
219095306|NCT04805749|OTHER|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~4. Cranial osteopathy techniques to address the vagus parasympathetic nerves."
219095307|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
219095308|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
219095309|NCT03332641|DIETARY_SUPPLEMENT|Citron peel extract|Citron peel extract for 12 weeks
219095310|NCT03332641|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219221254|NCT04801589|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
219221255|NCT04801589|DRUG|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
219221256|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219221257|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
219095311|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
219221258|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
219221259|NCT06945172|PROCEDURE|Total prostatectomy|Total prostatectomy is a surgical procedure performed to treat prostate cancer.
219095312|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
219095313|NCT06155084|DRUG|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
219095314|NCT05746481|DRUG|Tiragolumab|Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
219221260|NCT06945172|PROCEDURE|Focal HIFU|Focal HIFU treatment is an innovative technique that consists of destroying prostate tumour cells using high-intensity ultrasound focused exclusively on the affected area of the gland.
219221261|NCT06260293|BEHAVIORAL|exercise|"A total of 4 exercise interventions.~Twice In-patient exercise interventions: exercises on the ward at POD1, and POD2, and Recommended walking and stretching.~Twice home-based exercise interventions: post-discharge, Recommended 30 minutes of low to moderate-intensity walking and daily bodyweight exercises per day(150 minutes each week). and remote exercises 1 per week."
219095315|NCT05746481|DRUG|Atezolizumab|Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
219095316|NCT05746481|DRUG|Pemetrexed|Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
219095317|NCT05746481|DRUG|Carboplatin|Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
219095318|NCT04943211|DRUG|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
219095319|NCT04941664|DRUG|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
219221262|NCT06127810|DEVICE|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
219221263|NCT06127810|DRUG|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
219221264|NCT06411860|OTHER|Placebo|Participants will receive a subcutaneous (SC) injection of placebo.
219221265|NCT06411860|DRUG|Olpasiran|Participants will receive a SC injection of olpasiran at dose level 1 or 2.
219221266|NCT06411860|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
219221267|NCT07143461|BEHAVIORAL|Faith Healing|In the prayer condition, the participants will engage and vocalize in prayers they are already familiar with and commonly practice at least once, then continue silently for 10 minutes, focusing on the content. If distracted, participants should refocus on the prayer and reflect on its meaning.
219221268|NCT07143461|BEHAVIORAL|Control|In the control condition, participants will read a neutral text with no spiritual or religious content for 10 minutes. If distracted, they should refocus on the text.
219221269|NCT06950281|DRUG|Low Sodium Oxybate|Low sodium oxybate (LXB) will be administered as a twice nightly regimen. All subjects will undergo an 8 week Treatment Titration and Optimization Phase. Titration should proceed in an increment of 1.5g per night each 7 days until a 50% reduction in nocturnal headache frequency is achieved or a maximum dose (9g per night) is reached. If a subject is unable to titrate to a higher dose, they may stay at the highest tolerated dose for the duration of the study. Subjects may stop titration or have dose reduction at any time for safety and tolerability reasons.
219221270|NCT06950281|DRUG|Placebo|Placebo with equal appearance
219221271|NCT06953375|PROCEDURE|NMES|The NMES intervention protocol in this study ensures patients receive NMES intervention that is adequately dosed (dose = treatment minutes x intensity), delivered using evidence-based parameters, and feasible. The investigators will deliver NMES using a portable two-channel stimulator that the investigators have found to produce stronger muscle contractions than other portable NMES units and has been used in previous clinical studies. It also has a built-in compliance meter to monitor patient treatment minutes (adherence) to NMES application. NMES sites will perform routine collection of outcomes as part of standard practice.
219221272|NCT06953375|OTHER|Usual Care|Usual Care clinics will continue with routine collection and documentation of physical performance outcomes as standard practice. A combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Usual Care clinics including the facility, rehabilitation clinicians, and patients will not have access to NMES materials developed for this study.
219221273|NCT07148999|COMBINATION_PRODUCT|Opt-IVF|Opt-IVF provides optimized dosage profile for each patient
219221274|NCT07148999|OTHER|Control|Physicians will decide the dosage for each day for patients
219221275|NCT06948214|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
219221276|NCT06948214|OTHER|Matched Placebo (Capsules)|Administered orally once daily
219221277|NCT06951880|DRUG|AZD4916|AZD4916 will be administered as oral solution.
219221278|NCT06951880|OTHER|Placebo|Placebo will be administered as oral solution.
219362145|NCT05010356|DRUG|Insulin|Hyperinsulinemic euglycemic clamp
219095320|NCT05375955|DRUG|PF-07038124 ointment 0.01%|Atopic Dermatitis and Plaque Psoriasis
219362146|NCT00643643|DRUG|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
219362147|NCT00643643|DRUG|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
219095321|NCT05375955|DRUG|Vehicle ointment|Atopic Dermatitis and Plaque Psoriasis
219095322|NCT05375955|DRUG|PF-07038124 ointment 0.03%|Atopic Dermatitis and Plaque Psoriasis
219095323|NCT05375955|DRUG|PF-07038124 ointment 0.06%|PF-07038124 ointment 0.06% (Plaque Psoriasis only)
219095324|NCT03550391|DRUG|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
219362148|NCT00643643|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
219362149|NCT00643643|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
219095325|NCT03550391|RADIATION|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
219095326|NCT03550391|PROCEDURE|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
219095327|NCT05911451|PROCEDURE|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
219095328|NCT05911451|PROCEDURE|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
219095329|NCT05911451|PROCEDURE|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
219095330|NCT05013983|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
219095331|NCT05013983|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
219095332|NCT01351298|DRUG|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
219095333|NCT01351298|DRUG|0.05% xylometazoline hydrochloride|Decongestant
219095334|NCT01351298|DRUG|Isotonic normal saline|Placebo
219095335|NCT03383770|PROCEDURE|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
219095336|NCT03383770|PROCEDURE|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
219095337|NCT02933801|DRUG|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
219095338|NCT02933801|OTHER|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
219095339|NCT01320943|DRUG|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
219095340|NCT01320943|OTHER|Stop TDF|Participants will stop TDF therapy
219095341|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
219095342|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
219095343|NCT01856530|DRUG|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
219095344|NCT01856530|DRUG|Placebo|Matched placebo nasal spray
219095345|NCT04468269|OTHER|Task oriented balance training with sensory integration group|"Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk"
219095346|NCT04468269|OTHER|Task oriented balance training without sensory integration group|"Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk"
219095347|NCT02727686|OTHER|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
219095348|NCT05319249|BIOLOGICAL|NK cells|NK cells will be given as a single intravenous infusion.
219095349|NCT05319249|DRUG|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
219362150|NCT00643643|OTHER|Placebo|Matching placebo oral tablet twice daily for 10 days
219682559|NCT02806856|DEVICE|Sham stimulation|Sham
219682560|NCT00640939|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
219682561|NCT00640939|DRUG|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
219682562|NCT02212925|DRUG|BI 14332 CL|
219682563|NCT02212925|DRUG|Placebo|
219682564|NCT00027547|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219095350|NCT06191809|PROCEDURE|Controlled Ovarian Stimulation Protocol|"Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos."
219095351|NCT04096612|PROCEDURE|Orbital decompression combined with MPT|Orbital decompression combined with MPT
219095352|NCT01899456|DEVICE|Catheter-based renal denervation|
219095353|NCT05375123|DEVICE|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
219095354|NCT06150781|DRUG|erenumab-aooe|Dose and treatment duration will be advised by the HCP
219095355|NCT02063828|DEVICE|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
219095356|NCT02063828|DEVICE|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
219095357|NCT02063828|DEVICE|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
219095358|NCT06499623|DIAGNOSTIC_TEST|Blood test|Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
219095359|NCT06499623|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement
219095360|NCT06499623|OTHER|Nutritional Risk Assessment Questionnaire|Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
219095361|NCT06822426|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter installation use
219095362|NCT06822426|DRUG|Heparin|Heparin
219095363|NCT06205485|DRUG|Leucovorin|400 mg/m2
219095364|NCT06205485|DRUG|Oxaliplatin|85 mg/m2 or 130 mg/m2 on day 1
219095365|NCT06205485|DRUG|Fluoruracil|bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
219095366|NCT06205485|DRUG|Capecitabine|1,000 mg/m2 twice daily for 14 days
219095367|NCT06205485|RADIATION|Radiation|54 Gy (27-30 fractions)
219095368|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
219095369|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
219095370|NCT06362512|BEHAVIORAL|Dual-task training|participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
219682565|NCT00027547|DRUG|cyclosporine|
219682566|NCT00027547|DRUG|cytarabine|
219682567|NCT00027547|DRUG|fludarabine phosphate|
219682568|NCT00027547|DRUG|methotrexate|
219682569|NCT00027547|DRUG|mycophenolate mofetil|
219682570|NCT00027547|PROCEDURE|allogeneic bone marrow transplantation|
219682571|NCT00027547|PROCEDURE|peripheral blood stem cell transplantation|
219682572|NCT00027547|RADIATION|radiation therapy|
219682573|NCT00256932|DRUG|alvimopan|0.5 mg
219682574|NCT00256932|DRUG|Placebo|
219682575|NCT04362202|OTHER|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
219682576|NCT03628859|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib \[in France only\], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
219682577|NCT02586311|DRUG|CKD-330 16/5mg|Once a day, 8 weeks
219682578|NCT02586311|DRUG|Amlodipine 5mg Placebo|Once a day, 8 weeks
219095371|NCT06362512|BEHAVIORAL|Single-task training|participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.
219095372|NCT06362512|BEHAVIORAL|Upper limb strengthening exercise|participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
219095373|NCT05642429|BIOLOGICAL|AV-1959D|Three doses of AV-1959D administered as a sterile suspension via intradermal injection
219095374|NCT05642429|BIOLOGICAL|Placebo|Three doses of Placebo administered as a sterile suspension via intradermal injection
219095375|NCT03937219|DRUG|Cabozantinib|Specified dose on specified days.
219095376|NCT03937219|BIOLOGICAL|Nivolumab|Specified dose on specified days.
219095377|NCT03937219|BIOLOGICAL|Ipilimumab|Specified dose on specified days.
219095378|NCT03937219|DRUG|Cabozantinib-matched placebo|Specified dose on specified days.
219221279|NCT06950541|PROCEDURE|Myofascial therapy|The myofascial therapy in the form of Fascial Distortion Model (FDM) method is based on the idea that issues within the musculoskeletal system stem from deformations or distortions in the fascia. Once the type of deformation is identified, a specific technique is employed by the physiotherapist using their hands and pressure. FDM identifies six types of fascial distortions that can cause pain and other musculoskeletal issues. These distortions include triggerbands, continuum distortions, cylinder distortions, herniated triggerpoints, tectonic fixations, and folding distortions.
219221280|NCT06950541|PROCEDURE|Deep Tissue Massage|"A deep tissue massage is a therapeutic technique that focuses on realigning deeper layers of muscles and connective tissue. It is particularly beneficial for individuals dealing with chronic pain, muscle tension, or injury recovery.~The physiotherapist uses more intense pressure compared to other massage types, like Swedish massage. The goal is to reach deeper muscle layers to relieve tension and pain. The therapist employs various techniques, including long, slow strokes, deep finger pressure, and friction, also use elbows, knuckles, or forearms to apply pressure to specific areas."
219221283|NCT03857529|DEVICE|transcranial direct current stimulation and electrical stimulator|"Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration."
219221284|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
219221285|NCT07148232|DRUG|Nicotine Replacement Therapy (NRT)|NRT will be administered as patch (transdermal), gum, or lozenge
219221286|NCT07148232|BEHAVIORAL|Wellness Coaching|Delivered via phone call
219221287|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
219221288|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
219221289|NCT07152652|BEHAVIORAL|Groups 4 health|Groups 4 Health (G4H) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology master's students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 European Credit Transfer and Accumulation System (ECTS) credits for completing the intervention.
219221290|NCT07153250|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered program for parents that takes about 20 minutes to complete.
219221291|NCT07153250|BEHAVIORAL|Being Brave Parent Education|Being Brave Parent Education is an online, self-guided program which consists of three brief video-recorded lessons (approximately 20 minutes each) with accompanying knowledge checks and workbook on implementing parent-directed cognitive-behavioral therapy.
219221292|NCT07153250|BEHAVIORAL|Sharing Feelings|A self-guided 20-minute educational control, that teaches parents about the importance of sharing feelings and about helpful versus unhelpful expression of emotion.
219221293|NCT07152821|OTHER|Best Supportive Care|Measures designed to provide palliation of symptoms and improve quality of life as much as possible
219221294|NCT07152821|DRUG|Balstilimab|450mg IV every 3 weeks
219221295|NCT07152821|DRUG|Botensilimab|75mg IV every 6 weeks x 4 doses
219221296|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
219221297|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
219221298|NCT07157982|BEHAVIORAL|COORDINATE Program|"The COORDINATE Program is a nurse-led, multicomponent intervention designed to support older adults with multiple chronic conditions during their transition from hospital to home. The intervention is delivered over a 6-week period and includes the following components:~1. Discharge Planning Visit: Conducted in person or via video, this session includes a needs assessment and shared decision-making conversation to identify participants' values and preferences.~2. Question Prompt List: A tailored list of questions is provided to help participants engage more effectively with their care team.~3. Goal Setting: Participants work with a nurse to identify short-term goals and action steps related to their health and care needs.~4. Symptom Monitoring: Participants track symptoms weekly using a symptom checklist to support ongoing management and communication with providers."
219682579|NCT02586311|DRUG|CKD-330 16/5mg Placebo|Once a day, 8 weeks
219095379|NCT01887080|OTHER|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
219221299|NCT07157982|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive enhanced usual care, which includes standard discharge instructions, scheduled check-ins, and a resource toolkit with educational materials. The content includes guidance on symptom management, advance care planning, and available community resources. Participants will receive follow-up reminders and wellness checks but will not receive the structured, nurse-led intervention provided in the COORDINATE Program.
219221300|NCT07156084|BIOLOGICAL|HPV nonavalent vaccine (Gardasil-9)|One dose HPV nonavalent vaccine
219221301|NCT07151235|OTHER|Simulated wildfire smoke exposure|1 hour exposure to simulated wildfire smoke (300 ug/m3 PM)
219221302|NCT07151235|OTHER|Clean Air exposure|1 hour exposure to clean (HEPA-filtered) air (0 ug/m3 PM)
219221303|NCT04577651|DEVICE|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
219221304|NCT05480709|BEHAVIORAL|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
219221305|NCT07158242|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
219221306|NCT07163806|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Patients will fast for at least four hours before imaging with blood glucose level \<200 mg /dL before intravenous administration of about 3.7 MBq/kg (0.1 mCi/kg). Imaging will be performed approximately 45 to 60 min after 18F-FDG injection , an imaging field of view from the base of skull to mid thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body.~The semiquantitative analysis will be done using standardized uptake values (SUV). The SUV calculation will be done via the default method by body weight \[(SUV = mean ROI activity (MBq/g)/injected activity (MBq)/body weight (g)\]. For measurement of SUVs of lesion, multiple circular ROIs will be drawn covering the lesion over its entire length. For healthy organs, a circular ROI of 10 mm diameter will be drawn"
219221307|NCT07162948|DEVICE|The ICU-Recover Box: using smart technology for monitoring health status after ICU admission Pilot 2.0|The Corsano CardioWatch 287-2 measures blood pressure, heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature and their daily activity.This devices is used for personal management, never to directly base a diagnosis or treatment on. The patient has to download the Corsano App on his/her mobile phone.
219221308|NCT07157774|DRUG|Muvalaplin|Administered orally
219221309|NCT07157774|DRUG|Placebo|Administered orally
219221310|NCT07155057|DEVICE|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|Prospective, single-site, single-arm study enrolling 60 patients who have elected advanced IOL implantation at the time of cataract surgery and have a diagnosis of dry eye disease. The study will consist of 5 study visits, over a 3-5 month time period. Patients will receive bilateral lacrimal occlusion of crosslinked hyaluronate canalicular gel pre-operatively
219221311|NCT07164105|DEVICE|Low intensity focused ultrasound|Low intensity focused ultrasound neuromodulation of the ventral anterior cingulate cortex
219221312|NCT07164105|DEVICE|Sham modulation|Low intensity focused ultrasound with a Sorbothane membrane cover to prevent acoustic energy transmission
219095380|NCT01887080|DEVICE|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
219221313|NCT07162012|DRUG|EBV TCR-T|"After signing the informed consent form and completing screening according to the inclusion/exclusion criteria, eligible subjects will be sequentially assigned to the following dose cohorts of TCR-T cells (single administration): 1×10⁶ TCR-T cells/kg, 2.5×10⁶ TCR-T cells/kg, 5×10⁶ TCR-T cells/kg, and 10×10⁶ TCR-T cells/kg.~The first dose cohort (1×10⁶ TCR-T cells/kg) will use a rapid titration approach. If no significant safety issues occur within 28 days after infusion-defined as ≥Grade 3 non-hematologic toxicity, Grade 4 hematologic toxicity lasting more than 28 days (excluding disease- or chemotherapy-related causes), ≥Grade 2 neurotoxicity, or ≥Grade 3 cytokine release syndrome (CRS)-the next dose cohort will be initiated. If a dose-limiting toxicity (DLT) occurs, evaluation will be performed after 6 subjects have been treated.~The subsequent three dose cohorts will follow a 3+3 dose-escalation design, with 3-6 subjects per cohort receiving a single infusion. For subjects in th"
219095381|NCT01887080|OTHER|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
219095382|NCT05637203|BEHAVIORAL|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
219095383|NCT05637203|BEHAVIORAL|Discharge / Safety Planning|"* A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days"
219095384|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
219682580|NCT02586311|DRUG|Amlodipine 5mg|Once a day, 8 weeks
219682581|NCT00678015|DRUG|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
219221314|NCT07170709|DEVICE|Whole-Body Vibration|Participants will receive whole-body vibration (WBV) at 30-36 Hz under different mechanical loading conditions (e.g., standing on one foot, both feet,). Vibration-induced reflex responses will be recorded from the soleus muscle using surface electromyography. The intervention is designed to evaluate latency differences between tonic vibration reflex (TVR) and bone myoregulation reflex (BMR) under controlled biomechanical scenarios.
219095385|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
219221315|NCT07165028|DRUG|Tirzepatide|Administered SC
219095386|NCT02329548|OTHER|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
219095387|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
219095388|NCT05485792|DIAGNOSTIC_TEST|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
219095389|NCT03508739|DRUG|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
219095390|NCT03508739|DRUG|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
219095391|NCT06579105|DRUG|Placebo (placebo matching AZD5004 film-coated tablet)|Placebo film-coated tablet (matching AZD5004)
219095392|NCT06579105|DRUG|AZD5004|AZD5004 film-coated tablet, once daily during 26 weeks
219095393|NCT06579105|DRUG|Semaglutide|3-14 mg tablets of Semaglutide
219095394|NCT02934074|OTHER|No intervention|
219095395|NCT05631795|DRUG|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
219095396|NCT05631795|DRUG|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
219095397|NCT00703690|DRUG|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
219221316|NCT07165028|DRUG|Retatrutide|Administered SC
219221317|NCT07165028|DRUG|Placebo|Administered SC
219221318|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 3 cycles, IT
219221319|NCT07170592|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
219221320|NCT07170592|DRUG|Atezolizumab|1,200 mg, once q3 weeks, 2 cycles, IV
219095398|NCT00703690|DRUG|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
219095399|NCT00703690|DRUG|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
219095400|NCT01062503|DRUG|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
219095401|NCT00361439|DRUG|Mometasone|2 puffs in each nostril once daily of nasal spray
219095402|NCT00361439|DRUG|Placebo|2 puffs in each nostril once daily of nasal spray
219095403|NCT03681574|DRUG|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
219095404|NCT03681574|DRUG|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
219095405|NCT03681574|DRUG|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
219095406|NCT04104451|DRUG|Corlicyte|expanded umbilical cord lining mesenchymal stem cells
219221321|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 2 cycles, IT
219221322|NCT07170592|DRUG|OTS-412|1×10E8 pfu, once q3 weeks, 2 cycles, IT
219221323|NCT07170592|DRUG|Hydroxyurea (HU)|20 mg/kg/day, 14 days, 1 cycle, PO
219221324|NCT07170592|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
219221325|NCT07170592|DRUG|Hydroxyurea (HU)|30 mg/kg/day, 14 days, 1 cycle, PO
219221326|NCT07170592|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days q3 weeks, 2 cycles, PO
219221327|NCT07170592|DRUG|OTS-412|optimal dose, once q3 weeks, 2 cycles, IT
219221328|NCT07170592|DRUG|Hydroxyurea (HU)|optimal dose, 14 days q3 weeks, 2 cycles, PO
219221329|NCT05723107|DRUG|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
219221330|NCT05723107|DEVICE|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
219095407|NCT02158884|DEVICE|IDEO brace|All participants will receive the IDEO brace.
219221331|NCT05357144|BEHAVIORAL|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~* training on Malkia Klabu implementation;~* HIVST training (same as comparison drug shops);~* procedures for referring to youth-friendly HIV/SRH services;~* a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~* reimbursement for SRH products given to AGYW (e.g., birth control pills)."
219221332|NCT05357144|BEHAVIORAL|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
219221333|NCT03935750|PROCEDURE|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
219221334|NCT03935750|PROCEDURE|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
219221335|NCT07181408|OTHER|Wheat flour-based control snack|Consumption of a single 50-gram portion of a wheat flour-based control snack.
219221336|NCT07181408|OTHER|Snack enriched with 15% cricket flour|Consumption of a single 50-gram portion of a snack enriched with 15% cricket flour (Acheta domesticus).
219221337|NCT07181408|OTHER|Snack enriched with 15% pea flour.|Consumption of a single 50-gram portion of a snack enriched with 15% pea flour.
219221338|NCT07175506|DRUG|Placebo|Placebo injection administered IV, once.
219221339|NCT07175506|BIOLOGICAL|CM559|CM559 injection administered IV, once.
219221340|NCT07183592|PROCEDURE|7-day Infusion set replacement|7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.
219221341|NCT07183592|PROCEDURE|4-day infusion set replacement|4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.
219221342|NCT02842749|DRUG|everolimus|Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.
219221343|NCT07173491|OTHER|classical music group|classical music therapy with standard restorative treatment
219221344|NCT07173491|OTHER|turkish music group|Turkish music therapy with standard restorative treatment
219221345|NCT07173491|OTHER|control|no music therapy with standard restorative treatment
219221346|NCT05273463|BEHAVIORAL|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
219221347|NCT05273463|BEHAVIORAL|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
219221348|NCT07180680|PROCEDURE|laparoscopic assisted transanal proximal rectosigmoidectomy|using laparoscopy for such procedure in children is unique for this study
219221349|NCT07182383|DRUG|Bempedoic acid|"180 mg film coated tablet administered individually or as FDC~Component of FDC"
219221350|NCT07182383|DRUG|Ezetimibe|"10 mg tablet administered individually or as FDC~Component of FDC"
219221351|NCT07182383|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
219221352|NCT07189052|OTHER|Virtual Reality Rehabilitation|A virtual reality-based rehabilitation program including breathing, stretching, cervical range-of-motion, and posture-strengthening tasks delivered in a gamified seaside environment using a head-mounted VR display. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
219221353|NCT07189052|OTHER|Conventional Rehabilitation|Standard physiotherapy including diaphragmatic breathing, trapezius stretching, cervical range-of-motion, and posture-strengthening with proprioceptive neuromuscular facilitation. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
219221354|NCT07188506|DIAGNOSTIC_TEST|Clinical and blood parameters|Clinical data and MRI measurements
219221355|NCT07188506|GENETIC|Illumina Infinium Global Screening Array 4.0 (GSA 4.0)|Genomic analyses
219095408|NCT03970239|DRUG|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
219095409|NCT03970239|DRUG|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
219095410|NCT01659892|DRUG|Montelukast|5 mg Chewable Tablet
219095411|NCT01659892|DRUG|Singulair|5 mg Chewable Tablet
219095412|NCT05651776|OTHER|Physical Therapy, Exercise|Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
219095413|NCT00846872|DRUG|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
219095414|NCT00846872|DRUG|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
219095415|NCT00846872|DRUG|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
219095416|NCT04113954|DRUG|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
219095417|NCT04113954|DRUG|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
219095418|NCT04247659|DRUG|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
219095419|NCT00462280|DRUG|lovastatin|Given PO
219095420|NCT00462280|OTHER|placebo|Given PO
219095421|NCT00462280|PROCEDURE|biopsy|Correlative studies
219095422|NCT00462280|PROCEDURE|laboratory biomarker analysis|Correlative studies
219095423|NCT01313286|DRUG|LY2608204 Reference|Administered orally
219095424|NCT01313286|DRUG|LY2608204 Test|Administered orally.
219095425|NCT01209065|DRUG|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
219095426|NCT01209065|DRUG|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
219095427|NCT01209065|DRUG|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
219095428|NCT02335190|PROCEDURE|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
219095429|NCT02335190|PROCEDURE|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
219221356|NCT07188506|DEVICE|dTMS treatment|high-intensity deep transcranial magnetic stimulation (dTMS) device recognized for clinical application in mood disorders
219221357|NCT07190443|DRUG|Endocrine therapy + Abemaciclib|"This intervention consists of adjuvant endocrine therapy in combination with abemaciclib, a CDK4/6 inhibitor, administered to patients with HR-positive, HER2-negative breast cancer who have undergone curative-intent local treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~Abemaciclib is given orally at a dose of 150 mg twice daily for a maximum of 2 years, in accordance with the approved dosing regimen in the adjuvant setting. The choice of endocrine therapy-aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression-is determined based on menopausal status and prior treatment history."
219221358|NCT07190443|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|"This intervention consists of adjuvant endocrine therapy alone in patients with HR-positive, HER2-negative breast cancer who have undergone curative treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~The choice of endocrine therapy (aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression) is determined based on the patient's menopausal status and prior treatment history, as specified in the protocol. Treatment is continued for five years or until disease recurrence, unacceptable toxicity, or withdrawal of consent.~This intervention does not include CDK4/6 inhibitors."
219095430|NCT02335190|DRUG|Lidocaine|
219095431|NCT00755040|DRUG|cyclosporine ophthalmic emulsion|Given as eye drops
219095432|NCT00755040|OTHER|placebo|Given as eye drops
219095433|NCT06285513|DIAGNOSTIC_TEST|Cardiac ultrasound|Cardiac ultrasound : determination of impairment of cardiac function by echocardiographic analysis (at V1, V3 and V4), Glycocheck : automatic analysis of sublingual microcirculation, Indirect calorimetry : determining the increase in energy expenditure in patients with septic shock
219095434|NCT00733980|DRUG|GSK561679|GSK561679
219095435|NCT00733980|OTHER|Placebo|Placebo
219095436|NCT01258634|DRUG|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
219095437|NCT01258634|DRUG|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
219095438|NCT01258634|DRUG|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
219095439|NCT01258634|DRUG|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000"
219221359|NCT07189936|DRUG|To Measure levels of circulating monocyte/ T cell doublets at Baseline|To determine the levels of circulating monocyte/ T cell doublets on all the LCPOTS subjects
219221360|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment|Subjects will be randomized 1:1 to 2-HOBA or matching placebo. The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment
219221361|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment|The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment and compare it to the placebo arms
219221362|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA|We will Measure changes in Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and compare it with baseline during 30 Mins head up tilt . All the LCPOTS subjects will be randomized 1:1 to 2-HOBA or matching placebo
219221363|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo|We will Measure changes in splanchnic venous capacitance during 30 mins head up tilt ,after 28 days of Treatment with Placebo, we will compare it to the subjects who received 2 HOBA for 28 days
219221364|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with 2HOBA at 30 minutes of head up Tilt
219221365|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with Placebo at 30 minutes of head up Tilt and compare it with the subjects who received 28 days of 2HOBA
219221366|NCT07186647|PROCEDURE|laparoscopic-assisted Swenson-like (LASwL)|Following port placement, laparoscopic exploration was performed to evaluate the spastic colonic segment and transitional zone. An aperture was created in the sigmoid mesentery, and the sigmoid colon was mobilized. The proximal ganglionic bowel was mobilized while preserving the marginal arcades. The peritoneal reflection was sharply incised to facilitate dissection and mobilization of the aganglionic rectum. The procedure diverged between the two groups at this juncture: LASwl group: The rectum below the peritoneal reflection was dissected circumferentially up to a level 2 cm above the anal verge . LASo group: The rectum below the peritoneal reflection was minimally mobilized (within 1 cm of the peritoneal reflection). Following laparoscopic dissection, the ports were left in situ, and the position was adjusted for transanal dissection of the remaining rectum.
219221367|NCT07186647|PROCEDURE|laparoscopic-assisted Soave (LASo)|Transanal endorectal procedure was conducted according to the standard technique described by De la Torre-Mondragon and Ortega-Salgado \[12\]. A circular incision was made in the mucosa, and mucosectomy was performed. The muscle sleeve was cut, connecting the two dissection planes circularly . After keeping the muscular cuff as short as possible, a longitudinal incision was made posteriorly. Then, the bowel was extracted, and the anastomosis was performed as described above.
219221368|NCT07185555|DIETARY_SUPPLEMENT|VLEKT|Participants will follow a Very Low-Energy Ketogenic Therapy (VLEKT) providing 600-800 kcal/day for 4 weeks. The intervention consists of meal replacements (solid or liquid, ready-to-use or reconstituted) with very low carbohydrate content, high-quality proteins (milk, whey, pea, soy), and fiber (inulin, FOS). Gluten-free, lactose-free, and vegan options are available. Meal replacements are provided by Therascience or Penta at discounted prices. Participants will self-monitor capillary ketonemia daily, maintain adequate hydration, and avoid intense physical exercise. The Advanced Hybrid Closed Loop (AHCL) insulin delivery system will be used throughout the study with periodic adjustments based on device downloads. At the end of the 4-week intervention, a structured reintroduction of conventional meals will be initiated.
219221369|NCT07187648|DIETARY_SUPPLEMENT|Golden Rice Cookies With Piper crocatum|Golden Rice cookies enriched with Piper crocatum were formulated as a functional food containing β-carotene and bioactive compounds (polyphenols, flavonoids, tannins). Participants in the experimental arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are iso-caloric with control cookies but differ by inclusion of Golden Rice and Piper crocatum.
219221370|NCT07187648|OTHER|Iso-Caloric Control Cookies (Placebo)|Iso-caloric cookies made from standard flour without Golden Rice and without Piper crocatum. Participants in the control arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are designed to match the intervention cookies in calories and appearance but do not contain the active ingredients.
219221371|NCT07193264|OTHER|Caffeine (200 mg)|Participants receive a single oral dose of 200 mg caffeine under fasting conditions. Blood samples are collected before and three hours after intake to evaluate effects on hematopoietic stem and progenitor cells, including mobilization, function, gene expression, and metabolism.
219221372|NCT07190885|DRUG|YN001|YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).
219221373|NCT07196267|DEVICE|Extracorporeal Shockwave Therapy|Delivered using Shock Master (Master Plus MP200, STORZ Medical AG, Switzerland). Applied at 7 Hz frequency, 2.5-3 bar pressure, for 15 minutes per session, 3 times per week for 8 weeks. Target: supraspinatus tendon region. Applied after Cryoflow therapy in experimental group.
219221374|NCT07196267|DEVICE|Cryoflow Therapy|Delivered using Cryoflow 1000IR (Model ICE-CT, EC). Applied at 14°C for 15 minutes per session, 3 times per week for 8 weeks. Applied directly over rotator cuff tendon region before ESWT in experimental group.
219221375|NCT07196267|BEHAVIORAL|Traditional Physical Therapy Program|tretching of shoulder flexors/adductors/internal rotators Strengthening of shoulder extensors/external rotators Weight-bearing exercises (sitting \& quadruped) Neuromuscular Facilitation (PNF) for upper limb Hand dexterity training using Purdue Pegboard
219221376|NCT07196267|DEVICE|Placebo ESWT and Cryoflow|Identical device setup as active ESWT and Cryoflow, but with energy delivery disabled (no acoustic pulses, no cold air output). Applied for 15 min each, mimicking active treatment to maintain blinding where possible. Used in control group alongside traditional PT.
219221377|NCT07192874|OTHER|MyMedDiary|myMedDiary is a HIPAA-compliant, researcher-configurable mobile and web-based application designed for real-time dietary, symptom and lifestyle data collection. It was utilized to collect dietary data in an IRB-approved study at Seattle Children's Hospital evaluating the dietary cost burden of gluten-free foods in pediatric patients with celiac disease (submitted for publication). The application enables participants to log meals using barcode scanning, keyword search, and manual entry, including recipe-level data. The backend system stores encrypted data securely in Microsoft Azure, and dietary entries are automatically converted to nutrient data using a standardized reference system. Researchers access de-identified participant data and analytics through a secure online dashboard. The system supports multicenter trials.
219221378|NCT07192874|OTHER|Feedback on Gluten Exposure|The MyMedDiary Application will provide feedback on potential gluten exposure when participants input dietary record information into the application.
219221379|NCT07196449|DRUG|Methotrexate|Methotrexate Tab. 2.5 mg (Korea United Pharm)
219221380|NCT07196449|DRUG|Rifampicin|Rifampin Cap. 150 mg (Yuhan Corporation)
219221381|NCT07196449|DRUG|Cyclosporine|Cypol-N Cap. 100 mg (Chong Kun Dang)
219221382|NCT07196150|BEHAVIORAL|Exercise Program|Participants will complete an 8-week supervised exercise program, delivered twice per week. The program includes lumbopelvic stabilization, stretching, and endurance training exercises designed to reduce menstrual pain and improve physical function.
219221383|NCT07196150|BEHAVIORAL|Exercise plus Motor Imagery Training|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will practice kinesthetic motor imagery of the prescribed movements prior to performing them, aiming to enhance motor control and pain modulation.
219095440|NCT01258634|DRUG|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
219095441|NCT01258634|DRUG|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
219095442|NCT01258634|DRUG|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
219095443|NCT01258634|DRUG|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
219095444|NCT01258634|DRUG|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
219221384|NCT07196150|BEHAVIORAL|Exercise plus Pain Neuroscience Education|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will receive weekly face-to-face pain neuroscience education sessions focused on pain neurophysiology, supported with home assignments to reinforce learning.
219095445|NCT03501303|PROCEDURE|No touch technique|Veins for CABG is harvested with the no touch technique
219095446|NCT03501303|PROCEDURE|Control technique|Veins for CABG is harvested with the Control technique.
219095447|NCT04508608|DIAGNOSTIC_TEST|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
219221385|NCT07197762|BIOLOGICAL|Trumenba|"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains two lipidated factor H binding protein (fHbp) variants-A05 from subfamily A and B01 from subfamily B-delivered in a 0.5 mL prefilled syringe. Each dose includes 120 µg of protein (60 µg per variant), 0.018 mg polysorbate 80, and 0.25 mg aluminum as AlPO₄, formulated in histidine-buffered saline at pH 6.0.~A single intramuscular dose will be administered in the deltoid."
219682582|NCT02377492|DRUG|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
219682583|NCT05681364|OTHER|metabonomics|profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
219682584|NCT05017805|BIOLOGICAL|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
219682585|NCT01297543|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
219682586|NCT01297543|DRUG|G-CSF|Background therapy
219221386|NCT07197762|BIOLOGICAL|PENBRAYA|"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. It consists of two components:~* A lyophilized MenACWY portion (polysaccharides conjugated to tetanus toxoid)~* A liquid MenB portion (two recombinant fHbp variants: A05 and B01) Each 0.5 mL dose contains 20 µg of polysaccharides (5 µg per serogroup), 44 µg tetanus toxoid, 120 µg of MenB protein (60 µg per variant), plus stabilizers and aluminum phosphate.~This will be administered intramuscularly in the deltoid."
219221387|NCT00837044|DRUG|Treximet|Treximet
219221388|NCT00837044|DRUG|Migraine rescue medication of choice|Migraine rescue medication of choice
219221389|NCT04606264|DRUG|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
219095448|NCT04508608|DIAGNOSTIC_TEST|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
219221390|NCT04606264|DRUG|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
219221391|NCT04606264|DRUG|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
219221392|NCT04606264|DRUG|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
219221393|NCT04606264|DRUG|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
219221394|NCT04606264|DRUG|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
219221395|NCT04606264|DRUG|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
219221396|NCT04606264|DRUG|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
219221397|NCT06294795|PROCEDURE|congenital/pediatric cataract surgery|All procedures are performed under general anesthesia according to the standard technique of congenital/pediatric cataract surgery with an intraocular lens (IOL) implantation. Paracentesis is performed at 2.30 o\&#39;clock using a 20-gauge straight microvitreoretinal (MVR) knife; a high molecular weight ophthalmic viscosurgical devices (OVD) is injected into the anterior chamber. Then a 2.4 mm corneal tunnel incision is made at 11 o'clock with a disposable keratome knife 2.2 mm. Circular continuous capsulorhexis (≈ 5.5 mm). Сortical cleaving hydrodissection is followed by bimanual phacoaspiration in irrigation-aspiration mode. OVD is injected in the anterior chamber and an IOL is implanted in the capsular bag. Residual OVD is aspirated from the anterior chamber and behind the IOL and followed by IOL alignment. The surgery is completed with corneal hydration at the tunnel incision site.
219221398|NCT06294795|DEVICE|Non-Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF for the non-toric group (Alcon Laboratories, Inc.) ARE implanted.
219221399|NCT06294795|DEVICE|Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx for the toric group (Alcon Laboratories, Inc.) were implanted.
219221400|NCT03447509|DEVICE|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
219221401|NCT03447509|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
219221402|NCT03447509|DEVICE|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
219221403|NCT03447509|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
219221404|NCT03410589|OTHER|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
219221405|NCT05120804|BEHAVIORAL|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
219221406|NCT05120804|BEHAVIORAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
219221407|NCT03214081|DRUG|Vonoprazan|Vonoprazan tablets
219221408|NCT00981552|RADIATION|IMRT planning|
219221409|NCT00981552|RADIATION|4-Field Radiation Planning|
219221410|NCT00466037|BIOLOGICAL|Influenza vaccine|
219221411|NCT03926026|DRUG|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
219221412|NCT03926026|DRUG|Placebo|NCX 4251 Ophthalmic Suspension, 0%
219221413|NCT02577939|BEHAVIORAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
219221414|NCT03055598|DRUG|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
219221415|NCT02915315|DIETARY_SUPPLEMENT|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
219221416|NCT01343797|OTHER|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
219221417|NCT03842605|OTHER|Strength training|
219095449|NCT03626090|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
219221418|NCT00461019|PROCEDURE|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
219095450|NCT00895700|BEHAVIORAL|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
219095451|NCT02891057|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
219095452|NCT01957501|OTHER|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
219095453|NCT03347916|DRUG|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
219095454|NCT03347916|DRUG|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
219095455|NCT03515382|DRUG|GLPG1690|A single oral dose of GLPG1690.
219095456|NCT03515382|DRUG|Itraconazole|A single oral dose of itraconazole.
219095457|NCT03515382|DRUG|Voriconazole|A single oral dose of voriconazole.
219095458|NCT03682835|DIETARY_SUPPLEMENT|FDGard|capsule containing peppermint oil and caraway oil
219095459|NCT03682835|OTHER|Placebo|Placebo capsule containing cellulose
219095460|NCT05565729|DRUG|LY3471851|Administered SC.
219095461|NCT05565729|DRUG|Placebo|Administered SC.
219095462|NCT05565729|DRUG|Levocetirizine|Administered orally.
219095463|NCT03292848|DRUG|Brexpiprazole|Tablet
219095464|NCT02701010|BEHAVIORAL|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
219095465|NCT02701010|BEHAVIORAL|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
219095466|NCT02701010|BEHAVIORAL|Leaflet|"The patients who were given only educational leaflet were included in this group."
219095467|NCT02701010|BEHAVIORAL|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
219095468|NCT05476835|COMBINATION_PRODUCT|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
219095469|NCT01146314|BEHAVIORAL|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
219095470|NCT05211271|DEVICE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
219095471|NCT06510725|DEVICE|Mutitarget tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
219095472|NCT06510725|DEVICE|Single-target tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
219095473|NCT06510725|DEVICE|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
219095474|NCT03931681|DRUG|OKI-179|OKI-179 single agent
219095475|NCT03886259|OTHER|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
219095476|NCT03886259|OTHER|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
219095477|NCT02010632|DRUG|Generic clopidogrel product Apolets®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
219095478|NCT02010632|DRUG|Original clopidogrel product Plavix®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
219095479|NCT01875939|DRUG|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
219095480|NCT01875939|DRUG|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
219221419|NCT00345046|DRUG|Pred Forte|Four drops daily decreasing to once daily over four weeks.
219221420|NCT00345046|DRUG|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
219221421|NCT00345046|DRUG|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
219221422|NCT03150875|DRUG|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
219221423|NCT03150875|DRUG|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
219095481|NCT03066401|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
219221424|NCT01372085|DRUG|LY2584702 Reference Formulation|Administered orally
219221425|NCT01372085|DRUG|LY2584702 Test Formulation|Administered orally
219221426|NCT01372085|DRUG|Placebo|Administered orally
219221427|NCT00732849|DRUG|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
219221428|NCT00309036|BIOLOGICAL|Recombinant grass pollen|
219221429|NCT00263159|PROCEDURE|Pharmaceutical care for asthma patients|
219221430|NCT00790569|DRUG|nicotine|Given transdermally and orally
219095482|NCT00070135|BIOLOGICAL|filgrastim|Given SC
219221431|NCT00790569|DRUG|varenicline|Given orally
219095483|NCT00070135|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219095484|NCT00070135|DRUG|busulfan|Given IV
219095485|NCT00070135|DRUG|fludarabine phosphate|Given IV
219095486|NCT00070135|DRUG|methotrexate|Given IV
219095487|NCT00070135|DRUG|tacrolimus|Given PO or IV
219095488|NCT00070135|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
219095489|NCT01448694|OTHER|No treatment|No treatment, only collecting observational data.
219095490|NCT05669950|DRUG|Lu AG13909|Solution for infusion
219095491|NCT04869553|OTHER|Management pain with distraction methods ABC|"Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)"
219095492|NCT04869553|OTHER|Management pain with distraction methods BCA|"Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)"
219221432|NCT00790569|OTHER|placebo|Given orally
219221433|NCT04694937|DEVICE|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
219221434|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
219221435|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
219221436|NCT05310968|DRUG|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
219221437|NCT02316301|DRUG|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
219221438|NCT02316301|DRUG|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
219221439|NCT04612868|DEVICE|AEYE Software Device|"Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops."
219221440|NCT05543005|OTHER|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
219095493|NCT04869553|OTHER|Management pain with distraction methods CAB|"Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)"
219095494|NCT06341868|DEVICE|KneeStim|Participant will be randomized to either be in control or experimental group
219221441|NCT01448941|PROCEDURE|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
219221442|NCT01448941|PROCEDURE|Primary arthrodesis|Primary arthrodesis
219221443|NCT01448941|PROCEDURE|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
219221444|NCT06509607|OTHER|Concentric Lower Limb Training Program|A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
219221445|NCT06509607|OTHER|Eccentric Lower Limb Training Program|A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
219221446|NCT05099419|DEVICE|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
219221447|NCT06030960|DEVICE|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
219221448|NCT06030960|OTHER|Regular Exercises|Regular Stabilization Exercises
219221449|NCT06030960|OTHER|patient instructions and education|a unified form of patient instructions and education in regards of LBP
219095495|NCT02522936|DRUG|Biotene oral spray|Biotene oral spray will be provided to participants.
219095496|NCT01089231|DIETARY_SUPPLEMENT|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
219095497|NCT01089231|DIETARY_SUPPLEMENT|Placebo (corn oil)|corn oil (6 capsules per day)
219221450|NCT03107169|OTHER|FMT|Patients in the FMT group received FMT-FURM
219221451|NCT03107169|DRUG|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
219221452|NCT03376659|DRUG|Durvalumab|750mg IV q2 weeks
219095498|NCT03769779|DIETARY_SUPPLEMENT|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
219095499|NCT03769779|DIETARY_SUPPLEMENT|Safflower Oil|Safflower Oil
219095500|NCT04174248|OTHER|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
219095501|NCT04308564|DIAGNOSTIC_TEST|Blood test|Blood test for the identification of biomarkers
219095502|NCT05115448|OTHER|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
219221453|NCT03376659|BIOLOGICAL|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
219221454|NCT03376659|DRUG|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
219221455|NCT03376659|DRUG|Bevacizumab|5mg/kg IV q2weeks
219221456|NCT04727294|BEHAVIORAL|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
219221457|NCT03412266|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
219221458|NCT04365959|PROCEDURE|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
219221459|NCT06547125|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
219221460|NCT06547125|OTHER|Control|No-treatment control
219221461|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
219221462|NCT00077935|DRUG|Civamide|Cream 0.075%, TID for 52 weeks
219221463|NCT03676569|BIOLOGICAL|ADRC transplantation in autoimmune refractory epilepsy|
219095503|NCT00000280|DRUG|Nimodipine|
219221464|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
219221465|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
219221466|NCT00385606|DRUG|gemcitabine|
219221467|NCT00385606|DRUG|prolonged continuous infusion gemcitabine|
219221468|NCT00385606|DRUG|cisplatin|
219221469|NCT00385606|DRUG|rofecoxib|
219221470|NCT04969666|DRUG|IPED2015|Active treatment
219221471|NCT04969666|DRUG|Placebo|Placebo
219221472|NCT06100185|DEVICE|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
219095504|NCT05397535|BEHAVIORAL|Baduanjin|"Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the Fitness Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed."
219095505|NCT05397535|BEHAVIORAL|Brisk walking|Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
219095506|NCT01559233|DEVICE|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
219095507|NCT05208138|DEVICE|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
219095508|NCT06196450|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.
219095509|NCT06196450|DIETARY_SUPPLEMENT|Microcrystalline maltose|Microcrystalline maltose as placebo
219095510|NCT05897255|DEVICE|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
219095511|NCT04539314|DRUG|Bupivacain|We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
219095512|NCT04539314|DRUG|Dexmedetomidine o.5 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
219095513|NCT04539314|DRUG|Dexmedetomidine 1 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
219095514|NCT02236065|PROCEDURE|Umbilical cord blood therapy|
219095515|NCT02236065|BIOLOGICAL|Filgrastim|
219221473|NCT06100185|DEVICE|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
219221474|NCT02622698|DIETARY_SUPPLEMENT|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
219221475|NCT02622698|OTHER|Placebo|Placebo- Patients did not take any protein supplementation after surgery
219221476|NCT02861820|DEVICE|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
219095516|NCT02904876|RADIATION|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
219095517|NCT05276167|DEVICE|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
219095518|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
219095519|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
219095520|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
219095521|NCT03062462|DRUG|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
219095522|NCT03062462|DRUG|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
219221477|NCT02413138|DRUG|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
219221478|NCT01687920|DRUG|BAY94-8862 (1.25mg)|
219221479|NCT01687920|DRUG|BAY94-8862 (2.5mg)|
219221480|NCT01687920|DRUG|BAY94-8862 (5mg)|
219221481|NCT01687920|DRUG|BAY94-8862 (7.5mg)|
219221482|NCT01687920|DRUG|BAY94-8862 (10mg)|
219221483|NCT02663804|DEVICE|Total Knee Arthroplasty|
219221484|NCT03041961|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
219221485|NCT03041961|DIETARY_SUPPLEMENT|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
219221486|NCT03041961|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
219221487|NCT05485116|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
219221488|NCT03955926|DIETARY_SUPPLEMENT|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
219221489|NCT03185793|DRUG|Placebo|Placebo once daily for 5 weeks
219221490|NCT03185793|DRUG|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
219221491|NCT03185793|DRUG|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
219221492|NCT02168998|BEHAVIORAL|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
219095523|NCT05660590|OTHER|complex decongestive physiotherapy with low pressure compression bandage|both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
219095524|NCT05660590|OTHER|complex decongestive physiotherapy with high pressure compression bandage|complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
219095525|NCT06492824|BEHAVIORAL|Enjoyable Activities Condition|Participants complete an introduction video about the intervention. They will then take a pre-intervention survey, after which they will choose five enjoyable activities from a large list. Daily text message reminders will be sent to BA participants in the morning to remind them to do their enjoyable activities for the day, as well as a link to a checklist where they will report how frequently they have completed any of their five activities from the previous day (example text message in documentation). At the end of the month, they will complete a follow-up survey consisting of the same measures from the pre-intervention survey.
219095526|NCT06492824|BEHAVIORAL|Healthy Activities Condition|They will take a pre-intervention survey and choose five enjoyable activities from the same list; however, active control participants will not explicitly be asked to complete these activities for the intervention. Participants in the active control condition will be promoted to complete tasks such as drinking more water, going to bed early, brushing their teeth, showering or bathing for that day, and eating well balanced meals. Daily text reminders will be sent about these healthy living activities in the morning. In that same message, they will receive a link to a checklist where they will report about their completed healthy living activities for the previous day (example text message in documentation). At the end of the month, they will also complete a follow-up survey consisting of the same measures from the pre-intervention survey.
219095527|NCT00404495|DRUG|Irinotecan|Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
219095528|NCT00404495|DRUG|Temozolomide|Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
219095529|NCT05632835|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..
219095530|NCT05632835|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
219095531|NCT05496374|DRUG|Placebo|Placebo-matching capsules will be administered orally.
219095532|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
219095533|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
219095534|NCT02465840|PROCEDURE|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
219095535|NCT02465840|PROCEDURE|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
219095536|NCT02465840|OTHER|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
219095537|NCT05874804|DEVICE|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
219095538|NCT05874804|DRUG|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
219095539|NCT05716906|DIETARY_SUPPLEMENT|Melatonin|5mg gummy 30 min before bedtime for 2 consecutive nights
219221493|NCT03339466|DEVICE|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
219221494|NCT03473717|DEVICE|classic method|"* Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube."
219221495|NCT03473717|DEVICE|direct method|"* Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
219221496|NCT04121715|DEVICE|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
219221497|NCT04121715|DRUG|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
219095540|NCT06808984|DRUG|BMS-986368|Specified dose on specified days
219095541|NCT06808984|DRUG|Placebo|Specified dose on specified days
219095542|NCT04411849|OTHER|Best Practice|Receive usual care
219095543|NCT04411849|PROCEDURE|HPV Self-Collection|Receive HPV self-testing intervention
219095544|NCT04411849|OTHER|Informational Intervention|Receive information about cervical cancer
219221498|NCT00491296|DEVICE|SYNERGO|
219221499|NCT00491296|DEVICE|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
219221500|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
219221501|NCT00001752|DRUG|L-arginine|
219095545|NCT04411849|BEHAVIORAL|Patient Navigation Program|Receive telephone-based patient navigation
219221502|NCT00001752|DRUG|Estrogen|
219221503|NCT01100151|DRUG|RDC-1036 (ALKS 37)|Capsules for oral administration
219221504|NCT01100151|DRUG|Placebo|Capsules for oral administration
219221505|NCT01703546|PROCEDURE|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
219221506|NCT06180226|DIAGNOSTIC_TEST|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
219095546|NCT06365346|BEHAVIORAL|Dyadic video-assisted gamified group-based music breathing therapy|Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).
219095547|NCT06365346|BEHAVIORAL|Online educational modules|Six weekly educational modules on ADHD and its management via email.
219221507|NCT02941094|DEVICE|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
219095550|NCT06977100|BEHAVIORAL|Gratitude|Participants in this group will receive a gratitude journal where they will be asked to write down three things they are grateful for each day and reflect why they are grateful for these things. Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
219095551|NCT06977100|OTHER|General Wellness|Participants in this group will receive a general wellness journal where they will be asked to reflect on three things that happened, or they did during the day (daily activities). Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
219095552|NCT06512558|PROCEDURE|Additional MRI with gadolinium injection and 3D camera imaging|The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
219095553|NCT04296487|OTHER|autologous chondrocytes|autologous chondrocytes implantation (ACI)
219221508|NCT02941094|DEVICE|Ultrasound|Xario, Toshiba Tokyo Japan
219221509|NCT00705406|DRUG|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
219221510|NCT00705406|DRUG|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
219221511|NCT06509022|DIAGNOSTIC_TEST|PEPTEST test|Quantitative determination of gastric salivary amylase。
219221512|NCT02357966|BIOLOGICAL|514G3 (2 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
219095554|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
219095555|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
219095556|NCT06884176|DEVICE|Ultrasound Guided Central Venous Catheter|Patients randomized to this arm will receive an ultrasound guided central venous catheter. The catheter is 20cm in length.
219095557|NCT06884176|DEVICE|Ultrasound Guided Midline Catheter|Patients randomized to this arm will receive an ultrasound guided midline catheter. The catheter is 8-10cm in length.
219221513|NCT02357966|BIOLOGICAL|514G3 (10 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
219221514|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
219221515|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment|Sterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment
219095558|NCT04015180|DRUG|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
219095559|NCT04015180|PROCEDURE|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
219095560|NCT06491953|DRUG|SGLT-2 inhibitors|SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
219221516|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II|A single dose of 514G3 plus standard IV antibiotic therapy
219221517|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment: Phase II|A single dose of placebo plus standard IV antibiotic therapy
219221518|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
219221519|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
219221520|NCT01079806|DRUG|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
219221521|NCT01079806|DRUG|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
219221522|NCT01972906|DEVICE|moxibustion|apply moxibustion according to traditional Chinese medicine
219221523|NCT01972906|DRUG|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
219095561|NCT06807775|OTHER|Dietary Intervention (time-restricted feeding model (16:8))|Time-Restricted Feeding (16:8 model): Participants can consume food in any amount during an 8-hour window (08:00-16:00), but no food or energy-containing drinks are allowed during the remaining 16-hour fasting period.
219095562|NCT06807775|OTHER|Dietary Intervention (energy restricted dietary intervention)|Participants' daily energy needs are calculated based on their basal metabolic rate and physical activity. The energy intake is then reduced by 15-25%. The diet plan consists of 3 main meals and 2-3 snacks, with the daily intake of carbohydrates, proteins, and fats making up 50-60%, 15-20%, and 25-30% of the total daily energy, respectively.
219095563|NCT06979154|DEVICE|tACS (aperiodic)|Individualized tACS waveform based on aperiodic EEG activity will be delivered.
219095564|NCT03750006|BEHAVIORAL|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
219095565|NCT04965350|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
219095566|NCT03534973|OTHER|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
219095567|NCT03534973|OTHER|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
219095568|NCT00449280|DRUG|Sorafenib|400mg BID (200 mg twice daily)
219095569|NCT00449280|DRUG|Rapamycin|30mg once weekly
219095570|NCT00449280|DRUG|Rapamycin|3mg once daily
219095571|NCT04722445|DIAGNOSTIC_TEST|Early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation (NMES)|NMES will be applied to the quadriceps muscle to generate muscle contraction. Ultrasound measurement of the quadriceps thickness will be provided during contraction and rest, and the shortening of the quadriceps muscle will be measured. A second measurement using Shear-wave elastography measurement will also be undertaken. The measures will be undertaken at day 1 of neuromuscular blockers liberation (if any) as well as at day 3 and day 7 for the patients that will still be received mechanical ventilation at that time.
219095572|NCT06816901|DRUG|Depo Medroxyprogesterone acetate|Initiation of injectable depo medroxyprogesterone acetate (DMPA) contraception within 48 hours after birth
219095573|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
219095574|NCT06825871|DEVICE|Smart Inhaler Monitoring Platform for Asthma Management|"The intervention utilizes the aflo™ digital platform, a comprehensive system designed to improve asthma management through advanced technology. It integrates the following components:~1. Electronic Inhaler Sensor: The sensor attaches to a metered-dose inhaler (MDI) and a spacer (if applicable) to automate and provide feedback on the six critical steps of proper inhaler technique, such as shaking the inhaler, breathing out, inhaling slowly, and holding the breath. The sensor also records and stores medication usage data securely.~2. Mobile Application: The app delivers real-time notifications and feedback on inhaler technique, sends reminders for daily controller medication, tracks asthma symptoms, and provides monthly Asthma Control Test (ACT) assessments. It also offers reminders for spacer cleaning and customizable alerts for caregivers.~3. Clinician Portal: Data collected from the sensor and app is accessible via a secure clinician portal, enabling healthcare providers to monitor pa"
219095575|NCT06605612|DIAGNOSTIC_TEST|FBIndex|There will be no intervention.
219095576|NCT06596265|BEHAVIORAL|Fit2Lead Group 1-2|"Each park serves anywhere from 2 to 9 feeder schools within these neighborhoods (a target population of 34 000 youth residents aged 12-17 years), and transportation from schools to parks is provided at no cost within a 3-mile radius of a program park. Fit2Lead participants can also enroll in the MDPROS youth summer camp at no charge.~Work assignments support MDPROS operations and recreation staff. Interns in Phase II rotate every 8 weeks for exposure to different job opportunities, supervisors, and mentors.~Duke is conducting a secondary data analysis on data collected as part of the Fit2Lead study."
219095577|NCT06603077|DRUG|AVTX-009 Regimen 1|AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
219095578|NCT06603077|DRUG|AVTX-009 Regimen 2|AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
219095579|NCT06603077|DRUG|Placebo|Matching placebo will be administered as a subcutaneous injection every 2 weeks.
219095580|NCT06051890|DRUG|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
219095581|NCT06051890|DRUG|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
219095582|NCT04854304|DIAGNOSTIC_TEST|Fast Breast Abbreviated Magnetic Renounce Imaging|Fast Breast MRI Imaging
219095583|NCT04239573|PROCEDURE|Computed Tomography|Undergo CT
219221524|NCT04031365|PROCEDURE|Acupuncture|Use of sterile, disposable needles in acupuncture
219221525|NCT04031365|BEHAVIORAL|Cognitive Behavioral Therapy|psychotherapy
219095584|NCT04239573|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
219095585|NCT04239573|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219221526|NCT01332552|DRUG|GSK2485852 70 mg|single dose
219221527|NCT01332552|DRUG|GSK2485852 420 mg|single dose
219095586|NCT04239573|OTHER|Quality-of-Life Assessment|Ancillary studies
219095587|NCT04239573|OTHER|Questionnaire Administration|Ancillary studies
219095588|NCT04766944|OTHER|No intervention|No intervention
219221528|NCT01332552|DRUG|placebo|single dose
219221529|NCT01332552|DRUG|placebo|Repeat dose, once daily for 3 days
219221530|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
219221531|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
219221532|NCT01332552|DRUG|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
219221533|NCT01332552|DRUG|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
219221534|NCT01332552|DRUG|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
219095589|NCT03851133|OTHER|Blood Sample Collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
219095590|NCT03851133|OTHER|Tumor Sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
219221535|NCT01332552|DRUG|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
219221536|NCT03732807|DRUG|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
219221537|NCT03732807|DRUG|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
219221538|NCT03732807|DRUG|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
219221539|NCT03732807|DRUG|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
219221540|NCT03732807|DRUG|Placebo|Oral tablets taken QD
219095591|NCT03851133|OTHER|Data Collection|Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
219095592|NCT06610526|DRUG|Dapagliflozin|Dapagliflozin by oral administration
219221541|NCT02554006|BEHAVIORAL|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
219221542|NCT02554006|BEHAVIORAL|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
219221543|NCT01420497|DRUG|intra-articular infiltration|intra articular infiltration
219221544|NCT01420497|DRUG|epidural infiltration|epidural infiltration
219221545|NCT01779700|DRUG|Fingolimod|0.5mg each day of 8 week cycle
219221546|NCT01779700|DRUG|placebo|1 tablet each day of 8 week cycle
219221547|NCT04388137|OTHER|No intervention.|No intervention.
219221548|NCT03605732|BEHAVIORAL|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
219221549|NCT03605732|OTHER|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
219221550|NCT00019604|PROCEDURE|computed tomography|Scan to assess the effects of ablation.
219095593|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
219095594|NCT06990399|DRUG|KSI-101|Intravitreal injection
219221551|NCT00019604|PROCEDURE|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
219221552|NCT00019604|PROCEDURE|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
219095595|NCT06990399|OTHER|Sham Comparator|Sham injections
219095596|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
219095597|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
219095598|NCT04323189|DRUG|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
219095599|NCT04323189|DRUG|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
219095600|NCT06602024|BIOLOGICAL|mRNA-1010|Intramuscular (IM) injection
219095601|NCT06602024|BIOLOGICAL|Fluarix®|IM injection
219095602|NCT06602024|BIOLOGICAL|Influsplit® Tetra|IM injection
219095603|NCT06602024|BIOLOGICAL|Fluarix Tetra|IM injection
219095604|NCT06602024|BIOLOGICAL|Alpharix® Tetra|IM injection
219221553|NCT00019604|PROCEDURE|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
219221554|NCT00019604|PROCEDURE|radionuclide imaging|Imaging following injection of a radioactive material.
219221555|NCT00019604|PROCEDURE|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
219221556|NCT00019604|RADIATION|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
219221557|NCT00019604|RADIATION|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
219221558|NCT05986994|OTHER|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12
219221559|NCT05986994|DIAGNOSTIC_TEST|microRNA|Evaluation of microRNA levels
219221560|NCT05986994|OTHER|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
219221561|NCT03347409|OTHER|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
219221562|NCT03347409|OTHER|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
219221563|NCT03347409|OTHER|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
219221564|NCT04203966|DIAGNOSTIC_TEST|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
219221565|NCT04203966|DIAGNOSTIC_TEST|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
219221566|NCT02013115|DRUG|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
219221567|NCT05897905|BEHAVIORAL|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP."
219221568|NCT06509412|DEVICE|LANAP surgical protocol using ND:YAG 1064 laser|A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
219221569|NCT06509412|DEVICE|LANAP surgical protocol using diode 940 laser|Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
219221570|NCT06509412|PROCEDURE|Scaling and root planing (SRP)|Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
219221571|NCT05271994|PROCEDURE|endoscopic biliary drainage|endoscopic biliary drainage
219221572|NCT05150093|PROCEDURE|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
219221573|NCT05616494|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
219221574|NCT01115140|DRUG|metformin plus placebo|metformin 850 mg cp, 2 cps daily
219095605|NCT05596448|PROCEDURE|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
219095606|NCT02417532|DEVICE|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
219095607|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
219095608|NCT02316379|DEVICE|MRI|
219221575|NCT01115140|DRUG|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
219221576|NCT01115140|DRUG|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
219221577|NCT01115140|DRUG|placebo alone|placebo cp, 2 cps daily
219221578|NCT03441490|BEHAVIORAL|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
219221579|NCT03441490|BEHAVIORAL|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
219221580|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
219221581|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
219095609|NCT05388500|DRUG|Paclitaxel + Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
219095610|NCT05388500|DRUG|Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
219221582|NCT01697228|DIETARY_SUPPLEMENT|Vitamin D|
219221583|NCT00853255|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
219221584|NCT05081804|DIETARY_SUPPLEMENT|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
219221585|NCT04569526|DEVICE|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
219221586|NCT04514952|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
219221587|NCT04278989|DRUG|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
219221588|NCT04725916|OTHER|Showering|Patients will be instructed to shower after surgery with drains in place
219221589|NCT04725916|OTHER|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
219221590|NCT06950710|OTHER|NAFLD|This study is an observational one with no intervention
219095611|NCT06184828|BIOLOGICAL|Whole blood transfusion|The transfusion of whole blood units
219095612|NCT06184828|BIOLOGICAL|Blood components transfusion|The transfusion of blood components units rather than whole blood
219095613|NCT07135375|OTHER|Rehabilitation protocol|The modified protocol will be implementen based on available scientific evidence and guided by the consensus remaches with the traumatologist at the physiotherapy center
219095614|NCT06699758|OTHER|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
219095615|NCT05180708|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% rapamycin anhydrous gel
219095616|NCT05180708|DRUG|Vehicle|Matching vehicle (QTORIN anyhydrous gel)
219095617|NCT06716749|DRUG|Morphine|10 mg morphine in 10 mL normal saline
219095618|NCT06716749|DRUG|Vancomycin|500 mg Vancomycin in 100 mL of normal saline
219095619|NCT03387553|BIOLOGICAL|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
219221591|NCT05106361|BEHAVIORAL|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
219221592|NCT05106361|BEHAVIORAL|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
219221593|NCT05031780|DRUG|Mitapivat|Mitapivat tablets
219221594|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
219221595|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 100 mg tablets
219221596|NCT06013995|DRUG|BMS-986326|Specified dose on specified days
219221597|NCT06013995|OTHER|Placebo for BMS-986326|Specified dose on specified days
219221598|NCT00204685|DRUG|dornase alfa|
219221599|NCT02230137|BEHAVIORAL|Text message arm|Text message sent before each injection of insulin
219221600|NCT02150616|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
219221601|NCT02150616|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
219221602|NCT02150616|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
219221603|NCT02150616|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
219221604|NCT03640299|PROCEDURE|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
219095620|NCT03387553|DRUG|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
219221605|NCT01809275|DRUG|QBECO|
219221606|NCT01809275|DRUG|Placebo|
219221607|NCT02526576|BIOLOGICAL|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
219221608|NCT02526576|PROCEDURE|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
219221609|NCT05573724|DRUG|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
219221610|NCT05573724|DRUG|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
219221611|NCT01082575|DEVICE|Oxygen Monitoring|No intervention
219221612|NCT01928459|DRUG|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
219221613|NCT01928459|DRUG|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
219221614|NCT00093353|DRUG|cefixime|
219221615|NCT00093353|DRUG|irinotecan hydrochloride|
219221616|NCT00093353|DRUG|temozolomide|
219221617|NCT00586313|DEVICE|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
219221618|NCT00586313|PROCEDURE|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
219221619|NCT05610787|DEVICE|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
219221620|NCT02036112|PROCEDURE|conventional ELAPE|device
219221621|NCT02036112|PROCEDURE|Individual ELAPE|device
219221622|NCT05481346|PROCEDURE|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
219221623|NCT05316766|OTHER|Physical rehabilitation|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
219221624|NCT05316766|OTHER|Physical rehabilitation interactive table|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
219221625|NCT03653897|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
219221626|NCT03653897|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
219221627|NCT02101775|DRUG|Adavosertib|Given PO
219095621|NCT03387553|PROCEDURE|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
219095622|NCT07046572|DRUG|Methoxyflurane - Penthrox|3ml of Methoxyflurane via a Penthrox inhaler
219095623|NCT07046572|OTHER|Placebo Penthrox inhaler|3ml of normal saline via an identical placebo Penthrox inhaler
219095624|NCT07044544|DRUG|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
219095625|NCT07044544|DRUG|Decitabine|Decitabine is a hypomethylating agent.
219095626|NCT07044544|DRUG|Venetoclax|Venetoclax is a selective inhibitor of BCL-2 protein.
219095627|NCT04739761|DRUG|Trastuzumab Deruxtecan|Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
219095628|NCT06886477|OTHER|Mediterranean Diet|Mediterranean Diet foods will be provided for 4 weeks.
219095629|NCT06886477|OTHER|Usual Diet|Participants will consume their typical at home-diet.
219221628|NCT02101775|DRUG|Gemcitabine Hydrochloride|Given IV
219095630|NCT07047235|PROCEDURE|Pulmonary vein reisolation|The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.
219095631|NCT07047235|PROCEDURE|Ganglionic plexi ablation|Sites where ganglionix plexi have been found will be ablated.
219095632|NCT07047235|PROCEDURE|Substrate ablation|Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation
219095633|NCT05604716|OTHER|observational study|observational study
219095634|NCT00242281|DRUG|APC-111 MP Tablet, 775 mg|
219095635|NCT02584725|DRUG|Tranexamic Acid|Comparison of 3 different doses of the drug
219095636|NCT07050082|PROCEDURE|Bladder dissection after filling with 200 cc saline solution|Bladder filling after entering peritoneal cavity, then bladder dissection done to avoid bladder injury
219221629|NCT02101775|OTHER|Laboratory Biomarker Analysis|Correlative studies
219221630|NCT02101775|OTHER|Pharmacological Study|Correlative studies
219221631|NCT02101775|OTHER|Placebo Administration|Given PO
219221632|NCT02101775|OTHER|Questionnaire Administration|Ancillary studies
219221635|NCT03502447|DEVICE|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
219221636|NCT03502447|DEVICE|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
219221637|NCT00494949|DRUG|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
219221638|NCT00494949|DRUG|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
219095637|NCT07050082|OTHER|Bladder dissection with empty bladder|After entering peritoneal cavity, bladder dissection done with empty bladder
219095638|NCT06746285|DIETARY_SUPPLEMENT|Synbiotic Supplement|Participants will be given 1g of a synbiotic product each day, containing 4 microbial strains isolated from an infant gut (total of 1 billion cfu) and a mixture of 4 human milk oligosaccharides. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
219095639|NCT06746285|DIETARY_SUPPLEMENT|Lactose (inactive placebo)|Participants will be given 1g of lactose as a placebo. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
219095640|NCT07052214|DRUG|68Ga-PSMA-11|The radioconjugate 68Ga-PSMA-11 is composed of a human PSMA-targeting ligand peptide conjugated via the acyclic radiometal chelator, N, N'-bis \[2-hydroxy-5-(carboxyethyl)benzyl\] ethylenediamine-N, N'-diacetic acid (HBED-CC) to the radioisotope Gallium68 ( 68Ga); which binds to PSMA on the surface of cells expressing PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. 68Ga is a β+ (beta) ray emitting radionuclide that allows precise imaging via PET.
219095641|NCT05751941|DRUG|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
219095642|NCT05751941|DRUG|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
219095643|NCT05751941|DRUG|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
219095644|NCT05751941|DRUG|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
219221639|NCT03414645|BIOLOGICAL|CAM-101 10%|fibrinogen-depleted human platelet lysate
219221640|NCT03414645|BIOLOGICAL|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
219221641|NCT03414645|BIOLOGICAL|CAM-101 30%|fibrinogen-depleted human platelet lysate
219095645|NCT05259527|DRUG|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
219095646|NCT05259527|DIETARY_SUPPLEMENT|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
219095647|NCT06861933|OTHER|Physiotherapy and rehabilitation|It is reported in the literature that scapulohumeral rehabilitation applied in primary shoulder pathologies is effective. In neurological diseases, a study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with stroke and reported that it was effective. However, when the literature was examined, no study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with PD. Therefore, our aim is to compare the effectiveness of the scapulohumeral rehabilitation program to be applied for shoulder dysfunction, which is thought to be one of the early findings in PD and is reported to be related to other main findings in PD, with the upper extremity neurorehabilitation program.
219095648|NCT06764940|DRUG|Utidelone|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
219095649|NCT06764940|DRUG|Utidelone in combination with capecitabine|UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
219095650|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
219095651|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
219095652|NCT04334226|OTHER|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
219095653|NCT06772181|BEHAVIORAL|IM@Home Program|Participate in the IM@Home program delivered via Zoom
219095654|NCT06772181|OTHER|Medical Device Usage and Evaluation|Wear a FitBit activity tracker
219095655|NCT06772181|OTHER|Questionnaire Administration|Ancillary studies
219095656|NCT06772181|OTHER|Interview|Ancillary studies
219095657|NCT07073820|DRUG|PF-07868489|Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
219095658|NCT06029439|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
219095659|NCT06770387|BEHAVIORAL|mhealth|mobile application for postoperative period
219095660|NCT06779123|DEVICE|Transauricular vagus nerve stimulation.|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The electrical signals are delivered transcutaneously to the ear via two separate cables connected to two aluminium electrodes. There is no need for electrode gel application on the auricular skin, since the conductivity of the two metallic electrodes is fully sufficient for functional electrical contact. The device is powered by 4 x 1,5V AAA batteries. The electrical source is a CE-marked tens unit termed STIM-PRO X9+, AXION GmbH, Leonberg, Germany. The investigational headset with auricular electrodes is designed and manufactured by taVNS AB in Saltsjö-Duvnäs, Sweden. Stimulation will be performed for 5 min twice daily for 12 weeks.
219095661|NCT06779123|DEVICE|transauricular vagus nerve non-stimulation|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The device is placed to the ear but no stimulation will occur. The procedure is performed for 5 min twice daily for 12 weeks.
219095662|NCT07086638|DRUG|Photo-responsive nanozyme|The nanozyme scavenges ROS at the site of dermatitis and simultaneously responds to NIR light to generate mild heat, thereby promoting the healing of radiation-induced skin injury.
219095663|NCT05401110|DRUG|Osimertinib|Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
219095664|NCT05401110|DRUG|Carotuximab|Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
219221642|NCT06349538|DIAGNOSTIC_TEST|Clinical examination, blood draw, cerebral MRI, sonography, tremor analysis, OCT, olfactory mucosa swab.|see previous descriptions
219221643|NCT04362826|BIOLOGICAL|Novel probiotic|Investigational novel probiotic
219221644|NCT04362826|OTHER|Placebo|Placebo for probiotic
219221645|NCT04024943|DEVICE|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
219221646|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
219221647|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
219221648|NCT06004765|DRUG|Lenalidomide|10mg/d \*21 days, 28 days for 1 course
219221649|NCT06004765|DRUG|Azacitidine|75mg/m2/d\*5 days, 28 days for 1 course
219221650|NCT06100198|OTHER|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
219221651|NCT06541886|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
219221652|NCT05158218|BEHAVIORAL|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
219095665|NCT06859424|DRUG|Conditioning Regimen A|"Busulfan and fludarabine~Recommended schedule as below:~* Days -6 to -3: Busulfan ≥ 9 mg/kg total dose (IV or PO) with pharmacokinetic (PK) monitoring recommended as per institutional practice to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min47 or busulfan plasma exposure units (BPEU) 19.7-21.75 mg x h/L48.~* Days -6 to -2: Flu 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion (maximum cumulative dose, 150 mg/m2)."
219095666|NCT06859424|DRUG|Conditioning Regimen B|"Fludarabine and TBI The recommended fludarabine plus TBI regimen is the following:~* Days -7, -6 and -5: Flu (30 mg/m2/day, maximum cumulative dose, 90 mg/m2), IV~* Days -4 to -1: TBI (150 cGy administered twice daily, 1200 cGy total dose)~  * Radiation sources, dose rates, and shielding follow institutional practice.~ * Although not required, it is recommended that palifermin be used to mitigate the risk of mucosal toxicity with this regimen."
219095667|NCT06859424|DRUG|Conditioning Regimen C|"Fludarabine and busulfan (Flu/Bu)~The recommended Flu/Bu regimen is the following:~* Days -6 to -2: Flu (30 mg/m2/day, recommended total dose of 150 mg/m2, but not exceeding 180 mg/m2), IV Busulfan options~* Days -5 to -4: Busulfan without PK - Busulfan 3.2 mg/kg/day IV or oral equivalent; total dose of 6.4 mg/kg IV or oral equivalent respectively~* Days -5 to -4: Busulfan with PK - target doses to AUC of 4000 μMol/min or BPEU of 16.43 mg x h/L (total BPEU of 65.72 mg x h/L) or less is allowed."
219095668|NCT06859424|DRUG|Conditioning Regimen D|"Fludarabine and melphalan (Flu/Mel)~The recommended Flu/Mel regimen is the following:~* Days -7 to -3: Flu (30 mg/m2/day or 25 mg/m2/day, total dose of 125-150 mg/m2), IV~* Day -1: Mel (100-140 mg/m2 IV for recipients aged 18-59; dose of melphalan cannot exceed 100mg/m2 if age 60 or older or calculated glomerular filtration rate (GFR) is \<60 ml/min), IV"
219095669|NCT06859424|DRUG|Conditioning Regimen E|"Fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI)~The recommended Flu/Cy/TBI regimen is the following:~* Days -6 to -5: Cy (14.5 mg/kg/day IV, total dose of 29 mg/kg, or single dose 50 mg/kg on Day -6 \[Minnesota regimen\])~* Days -6 to -2: Flu (30 mg/m2/day, total dose of 150 mg/m2) IV~* Day -1: TBI 200 cGy single dose Hydration and Mesna may be administered per institutional standards. For recipients of RIC/NMA AND donors matched at \<7/8, consider the addition of TBI 200-300cGy for the Flu/Bu and Flu/Mel regimens to mitigate the risk of primary graft failure."
219095670|NCT06859424|PROCEDURE|Hematopoietic Cell Transplantation|"* On Day 0, the donor PBSC graft is infused.~* Donor PBSC will be collected per NMDP/donor registry policies with a target viable CD34+ cell dose of at least 4 × 106 /kg recipient weight (actual, ideal, or adjusted ideal per institutional practice).~* Dose of CD34+ cells/kg and CD3 cells/kg infused will be recorded.~* If the donor PBSC graft is cryopreserved prior to the start of conditioning, follow institutional practices to ensure a sufficient cell dose is available for infusion after thawing.~* The graft cannot be manipulated ex vivo to deplete T cells."
219095671|NCT06859424|DRUG|PTCy (50 mg/kg D3, D4)|"Cyclophosphamide (50mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in section 7.9.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
219095672|NCT06859424|DRUG|PTCy (25 mg/kg D3, D4)|"Cyclophosphamide (25mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in Table 4 and Table 5 in Section 7.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
219095673|NCT06859424|DRUG|Post-transplant Tacrolimus|Tacrolimus will be given per institutional practices, at a dose of 0.05 mg/kg per os (PO) or an IV dose of 0.03 mg/kg of IBW starting on Day + 5. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL. If subjects are on medications which alter the metabolism of tacrolimus (e.g., concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper is recommended to be initiated at 100 days post HCT if there is no evidence of active GVHD and ended by Day + 180 post HCT.
219095674|NCT06859424|DRUG|Post-transplant Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg 3 times daily (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day + 5 and continue until Day + 35 post-transplant, at which time it should be discontinued (no taper necessary). Study site investigators may modify dose/taper early if clinically indicated for the study subject. Dose rounding may be done per institutional practice.
219095675|NCT06859424|DRUG|Post-transplant Abatacept|Abatacept will be given at a dose of 10 mg/kg with a maximum of 1000 mg.
219095676|NCT06859424|DRUG|Post-transplant Ruxolitinib|Ruxolitinib will be given at a dose of 5 mg/kg twice daily starting at Day 30 post HCT, provided both the absolute neutrophil count (ANC) is \> 1000/μl and platelet count is \>30,000/μl.
219095677|NCT06859424|DRUG|Supportive Care: Growth Factors|Granulocyte colony-stimulating factor (G-CSF) to accelerate neutrophil recovery should be administered starting at Day +5 with dose, route of administration, formulation, and duration of administration following institutional guidelines. Filgrastim biosimilars are permissible, but granulocyte-macrophage colony-stimulating factors are not permissible.
219095678|NCT06859424|PROCEDURE|Supportive Care: Blood Products|Transfusion thresholds for blood product support will be consistent with standard institutional guidelines. All blood products must be irradiated.
219095679|NCT06859424|OTHER|Supportive Care: Infection Prophylaxis|"Subjects should receive infection prophylaxis according to institutional guidelines and in accordance with the Center for Disease Control (CDC) guidelines49. Infection prophylaxis will include, but is not limited to, agents or strategies (e.g., polymerase chain reaction \[PCR\] screening and preemptive therapy) to reduce the risk of bacterial, viral (e.g., adenovirus, CMV, EBV, herpes simplex), opportunistic (e.g. Pneumocystis jirovecii, Toxoplasma gondii) and fungal (yeast and mold) infections.~Infection risk should assess patient-, pathogen-, and immune-related factors that increase susceptibility to infection. Minimal parameters requiring prophylaxis include but are not limited to neutropenia (ANC≤500/μL), lymphopenia (ALC≤500/μL), and exposure to immunosuppression or GvHD. Use of intravenous immunoglobulin (IVIG) should be considered for total IgG\<400 mg/dL during exposure to immunosuppression and/or GvHD."
219095680|NCT06859424|OTHER|Supportive Care: Intravenous immune globulin (IVIG)|Intravenous immune globulin (IVIG) administration will be according to local institutional standard practice for hypogammaglobulinemia but is generally not recommended.
219095681|NCT06859424|DRUG|Supportive Care: Seizure prophylaxis|Subjects will receive busulfan seizure prophylaxis with levetiracetam, fosphenytoin, or lorazepam per institutional guidelines.
219095682|NCT06859424|OTHER|Supportive Care: Monitoring and management of CRS|The use of HLA-mismatched PBSC has been associated with greater risk of CRS relative to bone marrow. Following the infusion of MMUD PBSC on Day 0, subjects should be monitored daily through Day 14 for the development of CRS. High index of suspicion is urged, particularly in the few days following infusion. Many sites have successfully intervened with tocilizumab in order to avoid severe or prolonged CRS. Supportive care is encouraged for CRS Grades 1-2 and tocilizumab (or alternative) is recommended for CRS grade 3-4 where subject outcome may be impacted (Appendix G - CRS Guidance and Management).
219095683|NCT06859424|OTHER|Supportive Care: Prophylaxis against infections|"Consider monitoring for EBV reactivation during abatacept treatment and continue for six months following HCT.~Consider monitoring and prophylaxis for CMV infection/reactivation during abatacept treatment and for six months following HCT."
219095684|NCT06859424|DRUG|Supportive Care: Prophylaxis against infections|For participants receiving ruxolitinib, the recommended maximum dose of fluconazole daily is 200 mg.
219095685|NCT06859424|OTHER|Supportive Care: Lipid elevations|Assess lipid levels 8-12 weeks from start of therapy with ruxolitinib and treat as needed.
219095686|NCT06859424|OTHER|Study treatment compliance|The administration of study agents must be recorded in the subject's medical chart for verification of study treatment compliance.
219095687|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Prophylactic anti-viral cellular therapies and/or co-enrollment on studies using therapies for the prevention of GVHD is prohibited.~Subjects reported to have received prohibited therapy while on this study will be withdrawn and will not be included in the primary and secondary analyses.~No concomitant systemic immunosuppressive agents can be administered during PTCy (Day 3 and Day 4). If needed, administer at least 24 hours after completion of Day 4 PTCy.~It is crucial that no systemic immunosuppressive agents are given until at least 24 hours after completion of the Day +4 dose of PTCy. This includes corticosteroids as anti-emetics but excludes tacrolimus and MMF. Steroid use is permitted as pre-medication prior to start of conditioning but is prohibited from Day 0 through 24 hours post Day 4 PTCy administration.~If prohibited therapies are administered, these data must be reported in the study EDC on the Concomitant Medications form."
219095688|NCT06859424|OTHER|Permitted Concomitant Therapy|"Pre-medication and/or treatment for possible AEs related to PTCy are permitted. Subjects may continue all medications in compliance with local treatment center and local institutional guidelines, except those described in Section 7.9.1. If GVHD or infection occurs, enrollment on a clinical trial to treat infection or GVHD is permissible. At time of relapse, patients are permitted to enroll on a clinical trial or receive disease targeted therapy.~The following medications/therapies must be reported on the study EDC Concomitant Medications form:~* Medications taken to treat adverse events that have been reported on the study EDC Adverse Event form.~* Antimicrobial prophylaxis (viral, bacterial, fungal, parasitic).~* Antimicrobial pharmaceutical and cellular therapies used to treat grade II-III infections per BMT CTN grading criteria (Appendix D - BMT CTN Infection Grading).~* Post HCT, primary malignant disease-directed pharmaceutical and cellular therapies.~* Planned maintenance therapy"
219095689|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~No other investigational drugs for GVHD are allowed."
219095690|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible adverse events (AE)s related to abatacept are permitted.
219095691|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~Concomitant use of ruxolitinib with fluconazole doses of greater than 200 mg daily should be avoided.~No other investigational drugs for GVHD are allowed."
219095692|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible AEs related to ruxolitinib are permitted.
219095693|NCT06849791|DRUG|ABBV-932|Oral Capsule
219095694|NCT06849791|DRUG|ABBV-932|Oral tablet
219095695|NCT07096843|DRUG|budoprutug|Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183
219095696|NCT07100418|DRUG|HRS-7249 Injection|HRS-7249 injection.
219095697|NCT07100418|DRUG|Sodium Chloride Injection|Sodium chloride injection.
219221653|NCT05158218|BEHAVIORAL|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
219221654|NCT04479267|DRUG|Prednisone|Given PO
219221655|NCT04479267|DRUG|Prednisolone|Given IV
219221656|NCT04479267|DRUG|Methylprednisolone|Given IV
219221657|NCT04479267|BIOLOGICAL|Rituximab|Given IV
219221658|NCT04479267|DRUG|Polatuzumab Vedotin|Given IV
219221659|NCT04479267|DRUG|Cyclophosphamide|Given IV
219221660|NCT04479267|DRUG|Doxorubicin Hydrochloride|Given IV
219221661|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
219221662|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
219221663|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
219221664|NCT01779245|DIETARY_SUPPLEMENT|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
219221665|NCT01779245|DIETARY_SUPPLEMENT|Placebo|
219221666|NCT05886582|DRUG|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
219221667|NCT05886582|DRUG|Placebo|Placebo drug
219221668|NCT06348771|BEHAVIORAL|monounsaturated fatty acids (MUFA) peanut meal|mixed meal tolerance test and postprandial measurements
219221669|NCT06423365|OTHER|Virtual Statin Management (VSM)|"VSM is a web-based decision aid to help manage statin therapy after experiencing muscle pain perceived to be caused or worsened by their statin therapy. The introduction will feature a brief explanation of the tool and what they can expect. The modules are:~1. General education (lipids, heart disease, medications)~2. Side effects (causes, diagnosis).~3. Statin modifications. VSM will guide patients to understand their lipid-lowering options, particularly their statin options that may best match patients' stated preferences.~4. ASCVD risk \& statin benefit. Finally, the VSM experience will end by providing the patient with a summary of the results of their use of the tool, which can be used during discussions with their healthcare provider. The information gathered from the VSM will remain confidential and will not be disclosed to anyone other than the patient."
219221670|NCT06357403|DIAGNOSTIC_TEST|Anti-factor Xa activity calibrated for enoxaparin|Anti-factor Xa activity calibrated for enoxaparin
219221671|NCT04597866|BEHAVIORAL|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
219221672|NCT05071300|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
219221673|NCT03307616|BIOLOGICAL|Ipilimumab|Given IV
219221674|NCT03307616|BIOLOGICAL|Nivolumab|Given IV
219221675|NCT03307616|RADIATION|Radiation Therapy|Undergo radiation therapy
219221676|NCT00734877|DRUG|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
219095698|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
219095699|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
219095700|NCT06909500|OTHER|Text Message|Receive incentivized text messages to access vaping status
219095701|NCT06909500|OTHER|Text Message|Receive intervention text messages
219095702|NCT06909500|OTHER|Survey Administration|Ancillary studies
219095703|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
219095704|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
219095705|NCT01061333|DRUG|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
219095706|NCT01061333|DRUG|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
219095707|NCT01061333|DRUG|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
219095708|NCT01061333|DRUG|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
219095709|NCT07106437|OTHER|"Basel Model: Measure of total waste after completion of the procedure"|For each included case, the total waste generated will be measured in kilograms immediately after completion of the procedure and physically recorded by category in accordance with four predefined waste types: (i) paper and cardboard, (ii) regular waste (i.e., municipal solid waste or general trash), (iii) regulated medical waste (requiring specialized incineration including sharpsafe), and (iv) recyclable plastic
219095710|NCT07106437|OTHER|"Standard Model: Measure of total waste after completion of the procedure"|Simulation of a hypothetical but common practice in many hospitals, in which all waste generated during interventional procedures is disposed of as regulated medical waste, without separation.
219682587|NCT02761590|OTHER|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
219682588|NCT04472546|OTHER|in-vivo mesure|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
219095711|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
219095712|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
219095713|NCT06918665|DRUG|ivermectin infant formula preparation|The ivermectin infant formula preparation is produced by micronizing the standard 3mg ivermectin tablet and then blending it with Stage 1 infant formula (Blackmores brand) to produce a homogenous powder. This powder blend of ivermectin and infant formula is then filled into food grade clear capsules.
219095714|NCT06918665|DRUG|Standard ivermectin 3mg tablet|standard 3mg ivermectin tablet
219095715|NCT07123727|DRUG|Anktiva|600ug of NAI administered subcutaneously
219095716|NCT07130344|PROCEDURE|TAP CT-scan|Patient in the SOC arm will be followed by TAP CT-scan every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
219095717|NCT07130344|PROCEDURE|Bone scintigraphy|Patient in the SOC arm will be followed by bone scintigraphy every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
219095718|NCT07130344|PROCEDURE|18F-FDG PET-CT|Patient in the experimental arm will be followed by 18F-FDG PET-CT every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
219095719|NCT06933160|BEHAVIORAL|PromPT-MS|The experimental intervention is a 24-week progressive exercise intervention in which participants are supported through six physical therapy visits and are provided with educational material based on social cognitive theory. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of 2-3 moderate aerobic activity sessions and two strength-training sessions per week. There are no drugs involved in the intervention.
219095720|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
219095721|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
219095722|NCT06931210|OTHER|Sedentary behavior|Patients in the control group will maintain their sedentary lifestyle unchanged.
219221677|NCT00734877|DRUG|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
219095723|NCT06931210|BEHAVIORAL|Exercise intervention|The intervention will include a combination of aerobic and resistance exercises, performed three times per week. Each session will last 80 minutes. Aerobic and resistance training will include cycling, chest press, rowing, abdominal and back muscle exercises, as well as leg strength training.
219095724|NCT07142135|OTHER|There is no intervention, only clinical description|There is no intervention, only clinical description
219095725|NCT07146464|OTHER|Self-Assembling Peptide P11-4 Self-Assembling Peptide P11-4 is a biomimetic material applied topically to white spot lesions on the enamel. It diffuses into the lesion body and forms a three-dimension|"Intervention: Self-Assembling Peptide P11-4~Intervention Description:~Self-Assembling Peptide P11-4 (SAP P11-4) is a synthetic peptide designed to mimic natural enamel matrix proteins. It is applied to cleaned, etched enamel surfaces with white spot lesions. The peptide diffuses into the subsurface lesion and self-assembles into a 3D scaffold that promotes nucleation and growth of hydroxyapatite crystals. In this study, it is applied at baseline and re-applied after 3 months. The product used is Curodont™ Repair.~Intervention: Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)~Intervention Description:~CPP-ACP is a milk-derived peptide complex that stabilizes calcium and phosphate ions in an amorphous form. When applied to enamel surfaces, it delivers these ions to promote remineralization of white spot lesions. In this study, MI Varnish™ is used as the source of CPP-ACP. The varnish is stirred and applied as a thin, uniform layer to cleaned tooth surfaces at baseline and"
219095726|NCT06949124|DRUG|SHR7280 Tablets|SHR7280 tablets.
219095727|NCT06950905|BEHAVIORAL|Feeding your demons practice|The Feeding Your Demons (FYD) is a contemplative practice based on the Tibetan Buddhist tradition, adapted in a secular form. The intervention is online and lasts a total of 8 weeks. During this period, participants will engage in weekly home practice of the FYD method using guided audio. The intervention includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8.
219095728|NCT06950905|BEHAVIORAL|Mindfulness practice|The control group will undergo an online mindfulness meditation intervention, lasting a total of 8 weeks. It includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8. Participants will engage in weekly home practice of mindfulness meditation using guided audio.
219095729|NCT06946368|PROCEDURE|Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL|"Patients in this group will receive IPSA block and Local Infiltration Analgesia (LIA).~IPSA block is a pain numbing medication given by surgeon and injected inside the back and inner side of the knee joint. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL."
219095730|NCT06946368|PROCEDURE|Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL|ACB is a pain numbing injection given by anesthesiologist near the adductor canal, a passage in the mid-thigh that contains nerves connecting the knee region. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
219095731|NCT06946368|PROCEDURE|Local Infiltration Analgesia (LIA) of EXPAREL|Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
219095732|NCT07148726|DIETARY_SUPPLEMENT|Pyrrole Quinoline Quinone (PQQ)|Subjects will be provided with 84 capsules of the PQQ or the placebo supplement. Both supplements were in capsule form and identical in size, shape and color. The PQQ content per capsule was 10 mg. The indication was to take two capsules every evening for 6 weeks. The duration of the supplementation protocol was assessed based on a previous study (Hwang et al., 2020), while the dose was chosen according to EFSA recommendations (Turck et al., 2017).
219095733|NCT07148726|OTHER|Placebo|Subjects were provided with 84 capsules of placebo. The indication will be to take two capsules every evening for 6 weeks.
219095734|NCT07149948|BEHAVIORAL|THRIVE Integrated Care Program|The THRIVE Integrated Care Program is a psychoeducational behavioral intervention for adolescent mothers that combines reproductive health education and mental health support. It includes seven biweekly in-person or virtual sessions covering topics such as sexual health, parenting, mental health, substance use prevention, social support, and professional development. The intervention is delivered by trained medical students and staff using interactive learning modules and assessments.
219095735|NCT07151391|DRUG|Guarana|500 mg oral medication daily
219095736|NCT07151391|DRUG|Placebo|Oral medication daily
219095737|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
219095738|NCT07153003|DRUG|Oxycodone|"Patients will receive oral Oxycodone only to treat post-operative pain:~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4hr as needed~  * 2.5mg for pain rated 4-6~ * 5mg for pain rated 7-10"
219221678|NCT06062875|DRUG|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
219221679|NCT02457936|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
219221680|NCT04200664|DIAGNOSTIC_TEST|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
219221681|NCT04200664|DIAGNOSTIC_TEST|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
219221682|NCT04200664|OTHER|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
219095739|NCT07153003|DRUG|Tramadol and Oxycodone|"Patients will receive a combination of Tramadol and Oxycodone to take orally to treat post-operative pain:~Tramadol 50mg~* Patients ≤75 years old: 50 mg for pain rated 4-6; 100 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives; use 50 mg~* Dosing is every 8 hours as needed. Cumulative dose not to exceed 400mg in 24 hours~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed if still having pain after maximum tramadol administration~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4 hr as needed if still having pain after maximum tramadol administration~  * 2.5 mg for pain rated 4-6~ * 5 mg for pain rated 7-10"
219095740|NCT07152834|DIAGNOSTIC_TEST|Blood Sampling|"For AAT Level: Residual serum from routine blood samples drawn for standard clinical care will be aliquoted into polypropylene cryotubes.~For Genetic Testing: A separate capillary blood sample will be obtained via finger prick using a sterile lancet and collected on a designated filter paper."
219221683|NCT04200664|DIAGNOSTIC_TEST|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
219221684|NCT04200664|GENETIC|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
219221685|NCT06778187|DRUG|Oral arsenic trioxide|"Patients will be treated in 28-day cycles.~Each cycles will comprise:~Oral arsenic trixoide (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14~PLUS:~* Oral ascorbic acid (1000mg/day) from Days 1-14~* Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5.~* Venetoclax (100mg-400mg/day) from Days 1-14 (if used)"
219221686|NCT06433115|OTHER|Lean (≥90%) Grass-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
219221687|NCT06433115|OTHER|Lean (≥90%) Grain-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
219221688|NCT06433115|OTHER|Plant-Based Meat|Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
219221689|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Clarithromycin tablets|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
219221690|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Cyclosporine softgels|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
219221691|NCT02811510|DRUG|Placebo|Placebo pill (no active cannabinoids)
219221692|NCT02811510|DRUG|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
219221693|NCT05312671|DRUG|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
219221694|NCT05312671|DRUG|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
219221695|NCT05312671|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
219221696|NCT05312671|DRUG|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
219221697|NCT05312671|PROCEDURE|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
219221698|NCT01488968|RADIATION|Standard Radiation Treatment|39 radiation treatments
219221699|NCT01488968|RADIATION|Hypofractionated radiation treatment|25 radiation treatments
219221700|NCT04233567|DRUG|Infigratinib|Given PO
219221701|NCT03584711|COMBINATION_PRODUCT|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
219221702|NCT06192433|DEVICE|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
219221703|NCT06192433|DEVICE|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
219221704|NCT04594564|PROCEDURE|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
219221705|NCT05302115|DEVICE|S-ICD|Implantation of an S-ICD
219095741|NCT07154329|BEHAVIORAL|Internet-Based EMDR-Flash Program|"Self-guided, internet-based EMDR-Flash program (SKY-Flash) tailored to reduce test anxiety in university students. Delivered via a secure web platform with no live therapist involvement. The intervention comprises six \~40-minute modules completed independently during the study. Each module includes brief psychoeducation and step-by-step EMDR-Flash procedures (focus on a positive engaging image with brief flash cues), guided practice, and in-platform exercises. Gamification (progress tracking, badges) and automated prompts support adherence. Unlike CBT-based online programs or clinician-delivered EMDR, this is a fully automated, low-intensity Flash protocol adapted to exam-related distress. Safety messaging and referral resources are embedded; access is via individual login and usage is recorded for adherence."
219095742|NCT07157514|DRUG|131I-apamistamab|Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose.
219221706|NCT04815993|DRUG|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
219221707|NCT06787469|OTHER|Resin Cement|Bioactive self adhesive resin cement (SHOFU BeautiLink) used to cement indirect restorations to endodontically treated molars.
219221708|NCT06787469|OTHER|Resin Cement|Self adhesive resin cement
219221709|NCT05895786|DRUG|PF-06823859|anti-interferon beta therapy
219095743|NCT07157514|DRUG|Fludarabine|Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.
219095744|NCT07157514|DRUG|Cyclophosphamide|Cyclophosphamide
219095745|NCT07157514|RADIATION|Total Body Irradiation (TBI)|TBI, 200 cGy on Day -1 prior to HSCT.
219095746|NCT07157514|BIOLOGICAL|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.
219095747|NCT07155031|DEVICE|Pathogen reduced red blood cells|pathogen reduced red blood cells with biotin labeled aliquots will be transfused as part of routine care red cell exchange procedures
219095748|NCT07166627|PROCEDURE|surgical excision of cesarean section scar ectopic pregnancy|surgical excision by laparotomy.
219095749|NCT07166627|PROCEDURE|ultrasound guided evacuation of cesarean section scar ectopic pregnancy|ultrasound guided evacuation of cesarean section scar ectopic pregnancy trans-cervically.
219095750|NCT07165795|BEHAVIORAL|Transcendental Meditation|Standard TM instruction by certified TM teachers, including 4 days of initial training (60-90 min/day), then follow-up sessions (60-90 min) every 2-4 weeks.
219095751|NCT07166614|DRUG|dexmedetomidin|Dexmedetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Unlike many other sedatives, it provides sedation without significant respiratory depression, though it may cause bradycardia and hypotension
219095752|NCT07166614|DRUG|Propofol|Propofol is a short-acting intravenous anesthetic agent widely used for induction and maintenance of anesthesia as well as procedural sedation. It provides rapid onset and recovery, but is associated with respiratory depression and hypotension
219095753|NCT07165743|DIAGNOSTIC_TEST|40-Minute Real-Time First-Trimester Ultrasonography|A one-time midsagittal ultrasound performed between 11 +0 and 14 +0 weeks. Bladder emptying time and post-void longitudinal bladder diameter are recorded. No invasive procedures are performed.
219095754|NCT07165561|BEHAVIORAL|Smartphone App|This intervention is a mobile app co-created with adolescents who have experienced suicidal thoughts. It is specifically designed for youth aged 12-17 and includes a Safety Plan, tools such as a HopeBox, and psychoeducational content for young people, their loved ones, and care providers. Furthermore, there is a 'Help' button, offering direct access to crisis support. Unlike existing apps for adults, this app is tailored to the developmental needs and lived experiences of adolescents. Access is restricted to study participants to ensure controlled evaluation.
219095755|NCT07165600|OTHER|Yoga|Physical activity
219095756|NCT07165145|DIETARY_SUPPLEMENT|Organic Fruits and Vegetables|Dietary Intervention
219221710|NCT05895786|DRUG|Placebo|Placebo for PF-06823859
219221711|NCT04633148|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
219221712|NCT04633148|DRUG|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
219221713|NCT04633148|DRUG|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
219221714|NCT04633148|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
219221715|NCT00003459|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
219095757|NCT07165145|DIETARY_SUPPLEMENT|Conventional Fruits and Vegetables|Dietary Intervention
219221716|NCT03088800|DRUG|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
219221717|NCT03088800|DRUG|APAP|Oral APAP at 15mg/kg dose
219221718|NCT03582475|DRUG|Carboplatin|Given IV
219221719|NCT03582475|DRUG|Cisplatin|Given IV
219221720|NCT03582475|DRUG|Docetaxel|Given IV
219221721|NCT03582475|DRUG|Etoposide|Given IV
219221722|NCT03582475|BIOLOGICAL|Pembrolizumab|Given IV
219221723|NCT04505358|DRUG|PU-AD|active vs placebo
219221724|NCT04505358|DRUG|Placebo|active vs placebo
219221725|NCT06212297|GENETIC|LX101|Subretinal administration of LX101 to the contralateral, previously uninjected eye
219221726|NCT01121965|PROCEDURE|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
219221727|NCT04562675|BEHAVIORAL|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
219095758|NCT07164729|OTHER|PNF Stretching|Dynamic stretching of the quadriceps will be performed using walking lunges. This exercise dynamically stretches the quadriceps and hip flexors while also improving balance and coordination. During the exercise, participants stand upright, step one leg forward, and lower their body by bending the knee. They then step forward with the other leg to complete the movement. Ten steps will be performed for each leg.
219095759|NCT07164729|OTHER|Dynamic Stretching|"The Hold-Relax technique will be applied. Hold-Relax PNF stretching is based on the principle of isometric contraction of the muscle followed by passive stretching. This technique is effective for increasing muscle flexibility and reducing muscle tension. The medial and lateral parts of the quadriceps will be stretched by Flexion-Adduction-External Rotation and Flexion-Abduction-Internal Rotation patterns3. During the exercise, participants will lie prone with the knee flexed. They will be asked to attempt knee extension while the movement is resisted by the physiotherapist. The contraction will be maintained for 10 seconds, after which the participant will be instructed to relax. Following relaxation, the knee flexion angle will be increased. Ten repetitions will be performed for each leg."
219095760|NCT07165210|OTHER|No Intervention: Observational Cohort|no intervention was applied in this cohort
219095761|NCT07164508|BEHAVIORAL|Sitting Light Volleyball Intervention|16-week intervention centered around Sitting Light Volleyball, an adaptive sport developed by the Project Coordinator specifically for adults with physical disabilities.
219095762|NCT07164508|BEHAVIORAL|Group Seated Dance Intervention|16-week intervention program for adults with physical disabilities centered around para dance in a group setting of various dance styles.
219095763|NCT07166341|DEVICE|Observational|The study objectives require placement of a jugular venous bulb catheter and radial arterial line placement with ultrasound guidance. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead and two on the calf. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
219095764|NCT07164651|OTHER|Accelerated MRI scanning|"All patients underwent MRI scans of the abdominal and pelvic regions on the uMR 790 scanner at Tongji Hospital's Optical Valley Campus. The scanning protocol included multiplanar ACS T2WI sequences, TACS T2WI sequences, and conventional T2WI sequences.~ACS T2WI sequence: Used for preliminary motion artifact correction. TACS T2WI sequence: Employed for advanced motion artifact correction and provided dynamic images of organ movement.~Conventional T2WI sequence: Served as the standard reference for comparison."
219095765|NCT07166874|BEHAVIORAL|Gluten Free Diet|Patients in the experimental arm will received a gluten-free diet for 8 weeks.
219095766|NCT07166250|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided quadratus lumborum block performed preoperatively using local anesthetic injection at the thoracolumbar fascia for postoperative analgesia in lumbar disc herniation surgery.
219095767|NCT07166250|PROCEDURE|Retrolaminar Block|Ultrasound-guided retrolaminar block performed preoperatively using local anesthetic injection into the retrolaminar space for postoperative analgesia in lumbar disc herniation surgery
219095768|NCT07164417|OTHER|e-PRF membrane will be used with xenograft simultaneously with implant placement.|Peripheral blood is collected in plain tubes and centrifuged (700-2000 g, 8 min) to separate plasma from red cells. The first 2-4 mL of platelet-poor plasma (PPP) is withdrawn and heated at 75 °C for 10 minutes to form albumin gel, then cooled for 1-2 minutes. Meanwhile, the remaining blood fractions (buffy coat, liquid PRF, red cells) are kept cooled to prevent premature clotting.
219095769|NCT07164417|OTHER|PRF membrane will be used with xenograft simultaneously with implant placement|Peripheral blood is collected in 9-10 mL additive-free tubes and centrifuged horizontally at 700-2000 g for 8 minutes.
219095770|NCT07165652|DRUG|NKF-INS(L)|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
219095771|NCT07165652|DRUG|US-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
219095772|NCT07165652|DRUG|EU-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
219095773|NCT07166666|DEVICE|atomizer|use atomizer to provide the medication in procedure sedation
219095774|NCT07166666|DRUG|rescue medication|will be used as rescue if the atomizer medication not fully sedated
219095775|NCT07166666|DRUG|Midazolam|Intranasal administration for procedural sedation.
219095776|NCT07166666|DRUG|fentanyl|Intranasal administration for procedural sedation.
219095777|NCT07166666|DRUG|Dexmedetomidine|Intranasal administration for procedural sedation.
219095778|NCT07166666|DRUG|Placabo|use atomizer to provide the placebo in procedure sedation
219221728|NCT04562675|OTHER|brochure-only|brochure-only for control group (CG)
219095779|NCT07166484|OTHER|Cosmetic product RV2666C LA2984|The product is applied, according to randomization, on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.
219095780|NCT07166458|DIETARY_SUPPLEMENT|Kefir Peptide|Oral supplementation with kefir-derived bioactive peptides given daily in addition to standard care.
219221729|NCT02019459|OTHER|Very low nicotine content cigarettes|
219221730|NCT02019459|OTHER|standard nicotine content cigarettes|
219221731|NCT04008316|DRUG|Colchicine|colchicine 1mg/day
219221732|NCT01333605|DRUG|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
219221733|NCT00000127|PROCEDURE|Optic Nerve Sheath Decompression Surgery|
219221734|NCT03058757|DRUG|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery"
219095781|NCT07166458|OTHER|Standard Care (in control arm)|Standard fracture management including immobilization, pain control, and routine follow-up care.
219095782|NCT07165522|BEHAVIORAL|Transformative and Restorative Engagement Circle (TREC)|TREC will be co-developed in Phase 1, to focus on ensuring the presence of at least 3 key components: 1) a listening phase (focused on unconditionally hearing the experiences of autistic participants), 2) an acknowledgement phase (in which the experiences, including but not limited to harms and trauma, of autistic participants will be expressly addressed and acknowledged), 3) a negotiation/priority-setting phase, in which participants will collaboratively identify goals for future CER.
219095783|NCT07165522|BEHAVIORAL|Stakeholder Engagement in quEstion Development and prioritization (SEED)|The SEED Method is a PCORI-supported multilevel stakeholder engagement model, using a participatory framework to develop stakeholder priorities. The core premise of SEED is creating a level playing field for stakeholders, wherein participants learn how to collaboratively identify their own community's priorities, and then refine them together. It involves convening participatory Topic Groups of stakeholders, assembled based on their experience and knowledge of the area of focus (in this case, autism and ABA). It also involves additional consultative stakeholder participants to fill in key gaps in representation; this element may or may not be present in thi SEED iteration, based on the CAC-led adaptation. SEED participants convene over a period of time (adapted to the needs of the specific group, and will be matched to the length of TREC here) to conceptualize (i.e., learn how to build a conceptual model and conduct exercises to do so), generate questions (i.e., review the conceptual m
219095784|NCT07165691|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
219095785|NCT07165496|BEHAVIORAL|Text message-based intervention|Participants received weekly text messages to promote health and HIV testing and were followed and supported by trained healthcare counselors through two-way communication over a 12-week period. They were able to schedule a free HIV testing appointment at any time up to six months after enrollment.
219095786|NCT07165197|DEVICE|Phacoemulsification with implantation of an extended depth of focus intraocular lens|Comparison of two different Extended depth of focus intraocular lenses
219095787|NCT07165405|OTHER|Shower|Participants in this group will receive a shower administered by their partner on their back, abdomen, or entire body while standing or sitting, with the water temperature maintained between 32-37°C (the woman's preferred temperature will be applied) for at least 20 minutes upon admission to the labor room (when dilation is 4-5 cm). This will be performed under the observation of the researcher midwife. The application will be repeated when dilation reaches 7-8 cm.
219095788|NCT07165405|OTHER|Massage|Sacral Massage Application will be performed using 20x20 cm pouches filled with cherry pits. Like the shower application, massage will be performed upon admission to the delivery room (when dilation is 4-5 cm) and repeated when dilation reaches 7-8 cm. Unless the pregnant woman requests otherwise, massage will be performed while she is in the left lateral position.
219095789|NCT07165405|OTHER|Midwifery Care|Care provided by a midwife in the delivery room
219095790|NCT07166029|OTHER|russian current|russian current will be is applied in 50Hz sinusoidal bursts with a duty cycle of 50% (10ms on/10ms off). Russian Stimulation (at 2500Hz or 2.5kHz) has been shown to be effective in increasing muscle strength and torque generation through stimulation of type II muscle fiber. The stimulation will be given for duration of 10 minutes on followed by 50 sec off and again 10 sec on, three tims per week plus selsected physical therapy program.
219095791|NCT07166029|OTHER|selected physical therapy program|the patients will receive selected physical therapy program in the form of TENS for 15 min, US for 5 min and exercise for 20 min
219095792|NCT07166822|BEHAVIORAL|Experimental group using BumptUp mobile exercise app|This BumptUp app has been developed specifically for pregnancy with safety and screening feature. This intervention will be unique since the researchers will evaluate the cardiovascular health outcomes following the 8 weeks of intervention.
219221735|NCT02940249|DIETARY_SUPPLEMENT|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
219221736|NCT02940249|DIETARY_SUPPLEMENT|Placebo|
219095793|NCT07164807|DRUG|Methylene Blue (0.3%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.3% methylene blue solution (Formulation: 1.5 mL of 1% methylene blue with 3.5 mL ropivacaine hydrochloride injection).
219095794|NCT07164807|DRUG|Methylene Blue (0.1%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.1% methylene blue solution (Formulation: 0.5 mL of 1% methylene blue with 4.5 mL ropivacaine hydrochloride injection).
219221737|NCT01484743|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
219221738|NCT06191458|DRUG|Primaquine|Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
219221739|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
219221740|NCT05026970|DEVICE|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
219221741|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Kegel|Biofeedback+Kegel exercises
219221742|NCT02744066|DEVICE|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
219221743|NCT03163563|DEVICE|Easywarm|Warming blanket
219221744|NCT03163563|DEVICE|BairHugger|Patient warming mattress with continuous warm air.
219221745|NCT00623337|BEHAVIORAL|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
219221746|NCT02170337|DRUG|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
219221747|NCT02170337|DRUG|Placebo|Contains no active drug
219221748|NCT00874588|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
219221749|NCT01475110|DRUG|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
219221750|NCT02454959|DEVICE|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
219221751|NCT02454959|DEVICE|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
219221752|NCT04039776|DIAGNOSTIC_TEST|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
219095795|NCT07164482|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive allogenic HB-adMSCs through intravenous infusion only, with a treatment duration of 16 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1, infusion 2 and infusion 3, and 4 weeks between the remaining infusions.
219095796|NCT07166263|DRUG|NK510|NK510 will be administered through intravenous infusion, once a week for a total of six times.
219095797|NCT07166263|DRUG|NK510|NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles.
219095798|NCT07165925|BEHAVIORAL|Gamified music training|Instrumental musical training will progress from basic (playing simple notes) to advanced levels (playing an entire song). Key training elements will include fundamental music knowledge and skills, music improvisation, rhythm, and pitch identification exercises. In particular, the core concepts of resilience will be incorporated into the training process through various gamified music activities.
219095799|NCT07165925|BEHAVIORAL|Active placebo intervention|Participants in the active placebo control group will participate in weekly 1-hour group-based indoor community leisure activities for 6 months. These activities will include (i) drawing, (ii) drama workshops, (iii) cartoon film screenings, (iv) handcraft workshops, (v) board games, and (vi) exercise classes. Each activity will span for four sessions, that is, totally 24 sessions and will be delivered by trained staff at the study centres of the collaborating non-governmental organisations.
219095800|NCT07166328|DEVICE|BACKSCNR , measure the deviations of frontal and axial back asymmetry in AIS|BACKSCNR is a non-invasive surface topography device designed to assess spinal deformities, particularly scoliosis. It uses optical scanning technology to capture the three-dimensional shape of the back without radiation exposure.
219095801|NCT07164326|DRUG|Dexmedetomidine|Nebulization of dexmedetomidine
219095802|NCT07164326|DRUG|Saline|Nebulization of normal saline
219095803|NCT07164833|DRUG|BX-001N Experimental group 1|Each participant will receive BX-001N at a weight-based low dose via IV injection once daily for a total of three administrations.
219095804|NCT07164833|DRUG|BX-001N Experimental group 2|Each participant will receive BX-001N at a weight-based high dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
219095805|NCT07164833|DRUG|Placebo|Each participant will receive Placebo at a weight-based dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
219095806|NCT07166432|OTHER|observational diagnostic model development|observational diagnostic model development
219095807|NCT07164599|BEHAVIORAL|strength training|A 12-week strength training program designed for college dancesport athletes. Training is performed three times per week, 60 minutes per session, in addition to participants' regular dancesport training. Exercises include multi-joint resistance movements (e.g., squats, lunges, deadlifts, jumps) following NSCA guidelines with progressive overload based on 1RM. After the 12-week intervention, participants continue with an 8-week detraining phase without supplemental strength sessions and dance training.
219221753|NCT01603836|BIOLOGICAL|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
219221754|NCT01156155|RADIATION|Digital xray of jaw and teeth|one time xray of jaw and teeth
219221755|NCT01156155|PROCEDURE|Blood draw|Three to four tablespoons of blood drawn.
219221756|NCT01156155|OTHER|questionnaires|completed questionnaires regarding patient's health and functional ability.
219221757|NCT01156155|PROCEDURE|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
219221758|NCT01156155|OTHER|Bilateral digital xray of hands|One time digital xray of hands
219221759|NCT05931510|OTHER|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
219221760|NCT05931510|OTHER|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
219095808|NCT07164963|OTHER|upper cervical translatoric mobilisation|(UC-TSM) is defined as a system of manual techniques using straight-line forces delivered in a parallel or perpendicular direction to an individual vertebral joint or motion segment there is also increasing in body of evidence supporting the its clinical effectiveness and safety in the management of patients with cervical impairments.
219095809|NCT07164963|OTHER|sub occipital muscle energy technique|Muscle Energy Technique (MET) is another form of a gentle manual therapy intervention that primarily targets the soft tissues, though it also contributes significantly to joint mobilization. It has been reported that, adding MET to exercise program resulted in better improvement in CVA and FHP than exercise group only
219095810|NCT07164963|OTHER|traditional physical therapy|hot pack and kendel exercise
219095813|NCT07165847|DRUG|Iparomlimab and Tuvonralimab|q3w Iparomlimab and Tuvonralimab 5mg/kg on day 1 of each cycle
219095814|NCT07165847|DRUG|Oxaliplatin|130mg/m2 on day 1 of each cycle
219095815|NCT07165847|DRUG|Tegafur|\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid
219095816|NCT07165847|RADIATION|Radiotherapy|30 Gy/10 fractions
219095817|NCT07166068|OTHER|Manual Therapy (Mobilization with Movement)|A continuous glide to the tibia will be a combined simultaneously by whether medial, lateral, anterior, posterior, or rotational-during active knee flexion and extension repeated movement as applied by Mulligan.
219095818|NCT07166068|OTHER|Exercise|standard care (exercise program to strengthen the musculature of the knee)
219095819|NCT07166068|OTHER|sham mobilization|The therapist will simulate MWM by performing slight external rotation of the skin only. This mimics the tactile sensation of true MWM without affecting the underlying joint mechanics.
219095820|NCT07165782|BEHAVIORAL|Brief Videos Delivered by Text Message|"The intervention consists of brief videos delivered by text message, designed to deliver psychoeducation, coping strategies, and social support guidance for youth with PTSD. The focus is to reduce avoidance behaviors, increase exposure, change cognitions and enhance social support.~The text messages will follow a six-module curriculum, covering key PTSD recovery topics:~1. Psychoeducation on PTSD - Understanding symptoms, trauma responses, and brain plasticity.~2. Reducing Avoidance - Encouraging gradual engagement with feared thoughts and situations.~3. Cognitive Coping Strategies - Introducing cognitive restructuring techniques.~4. Behavioral Coping Strategies - Teaching relaxation techniques (e.g., deep breathing, grounding).~5. Social Support - Highlighting the role of social support and strategies to strengthen connections.~6. Maintenance and Relapse Prevention - Preparing for setbacks and reinforcing progress."
219095821|NCT07164456|OTHER|Education sessions|Remote and In person sessions
219095822|NCT07164456|OTHER|Questionnaire|Questionnaires given a 3,6,12 mouth follow ups
219095823|NCT01287884|OTHER|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
219221761|NCT04502472|BIOLOGICAL|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
219095824|NCT05398367|DIETARY_SUPPLEMENT|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
219095825|NCT04274959|OTHER|ceramic onlay with shoulder preparation design.|ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,
219095826|NCT04274959|OTHER|,ceramic onlay with butt joint preparation design|ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
219095827|NCT05239910|DRUG|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
219095828|NCT06336980|BEHAVIORAL|Increasing Inclusionary Practices in Faith Communities|Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
219095829|NCT02661802|OTHER|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
219095830|NCT03772899|DRUG|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
219095831|NCT06318442|DRUG|Semaglutide Oral Product|Oral semaglutide 3mg once uptitrated to twice daily
219095832|NCT06318442|DRUG|Metformin Oral Tablet|Metformin modified release tablets 500mg once daily uptitrated to twice daily).
219095833|NCT06318442|DRUG|Placebo|Placebo tablets
219095834|NCT02571465|OTHER|Passive leg raising test and fluid challenge|
219095835|NCT04187391|DEVICE|Active tDCS|Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
219095836|NCT04187391|DEVICE|Placebo tDCS|Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
219095837|NCT04187391|BEHAVIORAL|Language training|patients receive language training
219095838|NCT04187391|BEHAVIORAL|Unstructured cognitive training|patients receive unstructured cognitive training.
219095839|NCT03993236|DRUG|Experimental: Rosuvastatin/Ezetimibe 10|"* Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days"
219095840|NCT03993236|DRUG|Active Comparator: Rosuvastatin 20mg|"* Rosuvastatin 20mg~* orally administered once daily for 90 days"
219095841|NCT00190905|DRUG|duloxetine HCl|
219095842|NCT01493960|DRUG|Cobitolimod|30 mg rectal dose at week 0 and 4
219095843|NCT01493960|DRUG|Placebo|Rectal dose at week 0 and 4
219095844|NCT00249249|DRUG|Pitavastatin|
219095845|NCT00249249|DRUG|Atorvastatin|
219095846|NCT05358587|OTHER|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
219095847|NCT05358587|OTHER|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
219095848|NCT01679236|BEHAVIORAL|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
219095849|NCT01679236|BEHAVIORAL|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
219095850|NCT05418777|DRUG|Trimethoprim Sulfamethoxazole|Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
219095851|NCT05418777|DRUG|Placebo|Receipt of suspension with placebo by mouth every 12 hours for 10 days
219095852|NCT05192772|DEVICE|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
219095853|NCT00663377|DRUG|losartan|losartan 50-100mg for 16 weeks
219095854|NCT03559218|DEVICE|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
219095855|NCT03559218|OTHER|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
219095856|NCT06203652|OTHER|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
219095857|NCT00445198|DRUG|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 40 patients with SCLC"
219095858|NCT03237858|DEVICE|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
219095859|NCT03237858|DEVICE|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
219095860|NCT04302623|BEHAVIORAL|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
219095861|NCT01475695|DRUG|14C GSK2251052|1500 mg iv dose GSK2251052
219095862|NCT03812861|OTHER|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
219095863|NCT01782742|DRUG|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
219095864|NCT01782742|DRUG|Placebo|
219095865|NCT02090335|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
219095866|NCT02090335|BEHAVIORAL|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
219095867|NCT00002635|BIOLOGICAL|filgrastim|
219095868|NCT00002635|DRUG|aminocamptothecin|
219095869|NCT04435171|PROCEDURE|Renal transplantation|Open or robot assisted renal transplantation
219095870|NCT04490135|BEHAVIORAL|Group psychotherapy|As described above
219095871|NCT00238381|PROCEDURE|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
219095872|NCT00238381|PROCEDURE|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
219095873|NCT00238381|PROCEDURE|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
219095874|NCT02646215|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
219095875|NCT05384665|DRUG|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
219095876|NCT05384665|DRUG|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
219095877|NCT05384665|DRUG|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
219095878|NCT03077464|BEHAVIORAL|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
219095879|NCT00147901|DRUG|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
219095880|NCT01776021|OTHER|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
219095881|NCT01776021|OTHER|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
219095882|NCT00668135|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
219095883|NCT00668135|DRUG|Placebo|Matching placebo
219095884|NCT04757467|OTHER|Standard physiotherapy neuro-rehabilitation|Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education
219095885|NCT04757467|OTHER|Repetition-CIMT|"In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant"
219095886|NCT04757467|OTHER|Hour-CIMT|A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
219095887|NCT01382602|BIOLOGICAL|AMDC-USR|AMDC-USR Treatment
219095888|NCT01382602|BIOLOGICAL|Placebo|Placebo treatment
219095889|NCT05079815|DIAGNOSTIC_TEST|CBC and serum ferritin|take blood sample for CBC and serum ferritin
219095890|NCT00744315|PROCEDURE|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
219095891|NCT02561143|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
219095892|NCT02561143|DIETARY_SUPPLEMENT|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
219095893|NCT02561143|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
219095894|NCT02561143|OTHER|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
219095895|NCT03813342|BEHAVIORAL|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
219095896|NCT06136715|BEHAVIORAL|blood products as a part of Massive Transfusion Protocol|This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement
219095897|NCT03601455|BIOLOGICAL|Durvalumab|Given IV
219095898|NCT03601455|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219095899|NCT03601455|BIOLOGICAL|Tremelimumab|Given IV
219095900|NCT05396092|BEHAVIORAL|Integrated mindfulness-based Tai Chi Chuan|MBTCC will integrate components from both the MBI and TCC groups. The entire intervention consists of eight weekly sessions of two-and-a-half to three hours each.
219095901|NCT05396092|BEHAVIORAL|Mindfulness-based intervention|The MBI group is mainly based on the basic theory and research of the foundational mindfulness-based stress reduction program. The intervention consists of eight weekly sessions of two to two-and-a-half hours each.
219095902|NCT05396092|BEHAVIORAL|Tai Chi Chuan|TCC is mainly based on a nine-form Yang-style form of TCC, which is a brief and modified version of 64-form Yang-style TCC. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
219095903|NCT05396092|BEHAVIORAL|Sleep Hygiene Education|SHE is based on principles used in stimulus control and sleep hygiene education, which has previously been used as the control group in sleep-related research. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
219095904|NCT04395859|PROCEDURE|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
219095905|NCT04395859|OTHER|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
219095906|NCT02401373|BIOLOGICAL|Ad5-EBOV|intramuscular injection
219095907|NCT05465512|OTHER|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
219095908|NCT04496869|OTHER|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
219221762|NCT02378779|OTHER|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
219221763|NCT02378779|OTHER|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
219221764|NCT02378779|OTHER|Humour|Use the humour to approach the subject of premature ejaculation
219221765|NCT02378779|OTHER|Take the drama out|Take the drama out to approach the subject of premature ejaculation
219221766|NCT02378779|OTHER|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
219221767|NCT02378779|OTHER|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
219221768|NCT02378779|OTHER|Help to verbalize|Help for the patient to speak about premature ejaculation
219221769|NCT04444804|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
219221770|NCT04444804|DRUG|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
219221771|NCT05111951|BEHAVIORAL|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
219221772|NCT05111951|BEHAVIORAL|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
219221773|NCT05986305|BEHAVIORAL|Go Act|Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
219221774|NCT05986305|BEHAVIORAL|Peer|During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
219221775|NCT00121849|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
219221776|NCT00177177|DRUG|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
219221777|NCT02338024|BEHAVIORAL|Modified Antiretroviral Treatment Access Study intervention|
219221778|NCT00986375|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
219221779|NCT00986375|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
219221780|NCT03019835|DRUG|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
219221781|NCT03019835|OTHER|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
219221782|NCT01022125|DRUG|TMC435|
219221783|NCT02587169|DRUG|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
219221784|NCT05871658|BEHAVIORAL|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
219221785|NCT03391024|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
219221786|NCT03619642|OTHER|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
219221787|NCT00034489|DRUG|pemetrexed|
219095909|NCT05537480|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device will be worn by participants during several periods.
219095910|NCT02950857|DRUG|EPEG|(Pegylated erythropoeitin)
219095911|NCT00685321|DEVICE|H1 deep TMS coil|20 daily deep rTMS treatment
219095912|NCT00685321|DEVICE|Sham|inactive treatment
219095913|NCT02020980|BIOLOGICAL|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
219221788|NCT00034489|DRUG|gemcitabine|
219221789|NCT01044888|DRUG|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
219221790|NCT01767350|PROCEDURE|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
219095914|NCT01789996|PROCEDURE|alternative six minute walk test|"Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
219095915|NCT01789996|PROCEDURE|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
219095916|NCT00199498|DEVICE|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
219221791|NCT04693949|OTHER|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
219221792|NCT04693949|OTHER|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
219221793|NCT03293914|BEHAVIORAL|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
219221794|NCT04776096|DRUG|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
219221795|NCT04776096|DRUG|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
219221796|NCT02448524|DEVICE|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
219221797|NCT02448524|DEVICE|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
219221798|NCT00171769|DRUG|Certoparin|
219095917|NCT00199498|DEVICE|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
219095918|NCT02305381|DRUG|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
219095919|NCT02305381|DRUG|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
219095920|NCT02357290|DRUG|Open-label Treatment with N-Acetylcysteine|
219095921|NCT00006008|DRUG|arsenic trioxide|
219095922|NCT05936229|BIOLOGICAL|Interferon Beta-1A|Given IV
219095923|NCT05936229|PROCEDURE|X-Ray Imaging|Undergo x-ray
219221799|NCT00459524|BEHAVIORAL|Questionnaire|Questionnaires taking about 30 minutes to complete.
219221800|NCT00459524|BEHAVIORAL|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
219221801|NCT05309200|DRUG|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
219221802|NCT05309200|DRUG|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
219221803|NCT03693066|OTHER|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
219095924|NCT05936229|PROCEDURE|Echocardiography|Undergo ECHO
219095925|NCT05936229|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219095926|NCT05936229|PROCEDURE|Computed Tomography|Undergo CT
219095927|NCT05936229|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219095928|NCT05936229|PROCEDURE|Lumbar Puncture|Undergo LP
219095929|NCT05936229|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219095930|NCT05936229|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219095931|NCT05936229|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219095932|NCT05936229|PROCEDURE|Biopsy|Undergo tissue biopsy
219095933|NCT00469469|DRUG|Bevacizumab|
219095934|NCT04389333|DEVICE|non-contact magnetically-controlled capsule endoscopy|The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
219095935|NCT02964455|DRUG|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
219095936|NCT02964455|DRUG|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
219095937|NCT02964455|RADIATION|chest radiation|continuous chest radiation at 64 Gy/32f
219095938|NCT01240954|DRUG|OSIRIS|OSIRIS current practice
219095939|NCT01240954|DRUG|OSIRIS other concentration 1|OSIRIS new concentration 1
219095940|NCT01240954|DRUG|OSIRIS other concentration 2|OSIRIS new concentration 2
219095941|NCT06089252|DRUG|walnut extract|Four times a day over a 10-day period
219095942|NCT01388348|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
219095943|NCT02320032|DRUG|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
219095944|NCT05011825|BEHAVIORAL|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
219095945|NCT03590340|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
219095946|NCT03590340|OTHER|Normal saline|Normal saline is 0.9% sodium chloride
219095947|NCT03590340|BIOLOGICAL|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
219095948|NCT02935348|RADIATION|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
219095949|NCT01213108|BEHAVIORAL|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
219095950|NCT01213108|BEHAVIORAL|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
219095951|NCT01042743|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
219095952|NCT01042743|PROCEDURE|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
219095953|NCT06156566|DRUG|Tecovirimat Oral Capsule|600 mg, twice daily, 14 days.
219095954|NCT06156566|DRUG|Placebo|3 capsules, twice daily, 14 days.
219095955|NCT04174703|OTHER|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
219095956|NCT04851262|BEHAVIORAL|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
219095957|NCT04003779|OTHER|Room configuration|Adjust distance, handrails, degrees of turn for participant
219095958|NCT06196216|RADIATION|MSCT|Enhanced CT chest
219095959|NCT01239667|OTHER|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
219095960|NCT04863625|BEHAVIORAL|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
219095961|NCT02026180|DEVICE|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
219095962|NCT06081595|DRUG|Fluzoparib|Fluzoparib 100mg bid
219221804|NCT03693066|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
219095963|NCT06081595|DRUG|Apatinib|Apatinib 375mg qd
219095964|NCT05257330|DIAGNOSTIC_TEST|CSF Examination|Lumbar puncture for CSF Examination
219095965|NCT02487498|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
219221805|NCT03693066|OTHER|Control|
219095966|NCT02487498|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
219095967|NCT02487498|DRUG|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
219095968|NCT02487498|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
219095969|NCT04744857|COMBINATION_PRODUCT|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
219095970|NCT00676130|DRUG|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
219221806|NCT02481466|BEHAVIORAL|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
219095971|NCT00676130|DRUG|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
219095972|NCT00079508|DRUG|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
219095973|NCT04391465|OTHER|Electrophysiological Pacing|Assess the MCA CBF velocity response at different paced heart rates.
219095974|NCT05044325|DRUG|GSK3884464|GSK3884464 will be administered
219095975|NCT05044325|DRUG|Placebo|Placebo to match GSK3884464 will be administered.
219221807|NCT02481466|BEHAVIORAL|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
219221808|NCT02481466|BEHAVIORAL|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
219362151|NCT05586633|PROCEDURE|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
219095976|NCT05994391|DIETARY_SUPPLEMENT|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin"
219095977|NCT05994391|DIETARY_SUPPLEMENT|Placeo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose"
219095978|NCT05185778|BIOLOGICAL|stool examination, blood sample collected|"Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:~* Saline and iodine wet mount.~* Formalin-ethyl acetate sedimentation method.~* Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.~  * Collection of peripheral blood samples for Automated CBC and blood indices evaluation.~ * Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction)."
219095979|NCT06524063|DRUG|Survivin-loaded dendritic cell injection|The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
219095980|NCT02587026|OTHER|Blood sample collection|
219095981|NCT02587026|OTHER|Tumor tissue sample collection|
219095982|NCT00755222|BIOLOGICAL|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
219095983|NCT00755222|BIOLOGICAL|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
219095984|NCT02450721|OTHER|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
219095985|NCT04755270|DEVICE|VR Glasses|techniques of hypnofertility and VR glasses
219095986|NCT00019032|BIOLOGICAL|monoclonal antibody Mik-beta-1|
219095987|NCT01696331|BEHAVIORAL|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
219095988|NCT02492555|OTHER|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
219095989|NCT02492555|OTHER|OD|A screening of FC and DA on demand (OD)
219095990|NCT01074606|DEVICE|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
219095991|NCT02574000|OTHER|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
219095992|NCT02574000|OTHER|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
219095993|NCT02384525|PROCEDURE|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
219095994|NCT02384525|PROCEDURE|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
219095995|NCT04139980|OTHER|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
219095996|NCT05403164|PROCEDURE|Modified Widman flap|"1. Administration of anaesthesia~2. First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~3. Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~4. Second incision (sulcular incision)~5. Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~6. Root surface debridement~7. Flap adaptation, complete coverage interdentally and suturing."
219095997|NCT05403164|PROCEDURE|Gingivectomy|"1. Administration of anaesthesia~2. Marking the base of the sulcus with pocket marker tweezer.~3. First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~4. Second incision (interdental) to free the tissue which is used for analysis later.~5. Debriding the area and applying periodontal pack."
219095998|NCT03540355|DRUG|Cipros 20 association|oral, once a day
219095999|NCT03540355|DRUG|Crestor 20 mg|Oral, once a day
219096000|NCT03361995|DEVICE|Cooling Procedure using the ZOLL Thermogard XP3 IVTM System|Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
219096001|NCT03361995|DEVICE|PCI|Standard of Care for PCI
219096002|NCT02337517|OTHER|Laboratory Biomarker Analysis|Correlative studies
219096003|NCT02337517|DRUG|Vismodegib|Given PO
219096004|NCT01751230|BEHAVIORAL|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
219096005|NCT01356953|OTHER|Aerobic exercise|Intensity of aerobic exercise
219221809|NCT02481466|BEHAVIORAL|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
219362152|NCT05586633|PROCEDURE|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
219096006|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
219096007|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
219096008|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
219096009|NCT04382924|DRUG|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
219096010|NCT06834672|DRUG|IBI354|intravenous infusion of 12 mg/kg on Day 1 of each 3-week treatment cycle
219096011|NCT06834672|DRUG|paclitaxel/Gemcitabine/Liposomal doxorubicin|paclitaxel：- Usage and dosage: 80 mg/m2 administered as an intravenous infusion on Day 1 of each weekly treatment cycle。 Gemcitabine：Usage and dosage: intravenous infusion at 1000 mg/m2 on Days 1, 8 of each 3-week treatment cycle。 Liposomal doxorubicin：Usage and dosage: intravenous infusion of 40 mg/m2 on Day 1 of each 4-week treatment cycle
219096012|NCT02405260|DRUG|TTP399 400 mg|once daily
219096013|NCT02405260|DRUG|TTP399 800 mg|once daily
219096014|NCT02405260|DRUG|Sitagliptin 100 mg|once daily
219096015|NCT02405260|DRUG|Placebo|once daily
219096016|NCT05434845|OTHER|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
219096017|NCT01153139|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
219096018|NCT04000620|PROCEDURE|surgery|treatment intent surgery
219096019|NCT04000620|PROCEDURE|punture|diagnostic punture
219096020|NCT01559454|DRUG|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
219096021|NCT01559454|DRUG|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
219096022|NCT01083654|BEHAVIORAL|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
219096023|NCT01083654|BEHAVIORAL|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
219096024|NCT05582304|DEVICE|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
219096025|NCT05582304|DEVICE|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
219096026|NCT01435811|BIOLOGICAL|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
219096027|NCT00644202|BEHAVIORAL|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
219096028|NCT00644202|BEHAVIORAL|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
219096029|NCT00644202|BEHAVIORAL|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
219096030|NCT03005509|OTHER|TQIM checklist|"The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
219096031|NCT00991341|BIOLOGICAL|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
219096032|NCT00991341|BIOLOGICAL|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
219096033|NCT02862379|BEHAVIORAL|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
219221810|NCT03875066|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
219362153|NCT01088035|DRUG|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
219096034|NCT02615236|DEVICE|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
219221811|NCT03875066|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
219221812|NCT01797666|DRUG|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
219221813|NCT05609149|PROCEDURE|total mesorectal excision|patients must underwent total mesorectal excision
219221814|NCT07012096|BEHAVIORAL|counseling, leaflet and mhealth education for hypertension|Investigators will develop 6 leaflets and 24-SMSs containing messages on the burden of hypertension, consequences, and the benefits of preventing of hypertension, and the healthy practices for preventing hypertension, tobacco, physical inactivity, dietary salt intake, inadequate fruits and vegetables, overweight and obesity, and the use of trans fat. It will be written in plain and simple Bengali. Leaflets will be received by CG-1, CG-3, IG-1 and IG-3. 24-SMSs. Face-to-face counselling (approximately 20 min/session). A total of 20 sessions (1 cycle) will be provided. The session will be repeated if the cycle is over.
219362154|NCT01738971|OTHER|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
219096035|NCT02615236|PROCEDURE|Clinical diagnosis|diagnosis of OASIS clinically
219096036|NCT02098187|DRUG|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219096037|NCT02098187|DRUG|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219096038|NCT02098187|DRUG|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219096039|NCT02098187|DRUG|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219096040|NCT02098187|DEVICE|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
219096041|NCT02098187|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
219096042|NCT05152134|BEHAVIORAL|Empowered Relief On-Demand|Tailored interactive digital health treatment for chronic pain
219096043|NCT05152134|BEHAVIORAL|Health Education|The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
219096044|NCT06328582|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing."
219096045|NCT06328582|PROCEDURE|Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture|"Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral)."
219096046|NCT01494155|DRUG|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
219096047|NCT01494155|DRUG|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
219096048|NCT01494155|RADIATION|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
219096049|NCT03516643|OTHER|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
219096050|NCT00215540|DRUG|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
219096051|NCT00215540|DRUG|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
219096052|NCT00215540|DRUG|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
219096053|NCT01848379|PROCEDURE|ADT+FD|
219096054|NCT01848379|PROCEDURE|FD|
219096055|NCT02800967|DIETARY_SUPPLEMENT|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
219096056|NCT02800967|DIETARY_SUPPLEMENT|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
219221815|NCT07012096|BEHAVIORAL|Leaflets and mhealth education|"Participants will receive 6 leaflets containing messages on the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~Participants will receive 24 SMSs containing the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~And additionally receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group."
219221816|NCT07012096|OTHER|Dummy Placebo|Participants will only receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group.
219221817|NCT07012785|DRUG|Bismuth quadruple therapy|Bismuth quadruple therapy
219221818|NCT07012785|DRUG|Saccharomyces boulardii|Saccharomyces boulardii
219221819|NCT07036744|BEHAVIORAL|MIND-over-MIRROR|An eight session (plus one follow-up booster session) on Acceptance and Commitment Therapy (ACT) with compassion developed specifically for BDD, in a group setting and applied remotely or in hybrid format.
219221820|NCT07036627|OTHER|study of microbiota|"* Drug: Esomeprazole, a proton pump inhibitor commonly used in pediatric gastroenterology.~* Administration: Oral, once daily, 30 minutes before meals.~* Dosage: Personalized dosing according to body weight, with an average of approximately 0.6 mg/kg/day.~* Treatment duration: Minimum 45 days, maximum 60 days.~* Comparator: None. This is a within-subject design; each participant serves as their own control with baseline samples (t0) compared to follow-up (t1-t2).~* Monitoring: Adherence to therapy and sample collection timeline will be verified during scheduled clinical follow-up."
219221821|NCT07032051|DEVICE|Continuous Passive Motion|Continuous passive motion was applied to the left ankle joint for 30 minutes twice a day using a motorized CPM device.
219221822|NCT07036874|DIAGNOSTIC_TEST|transient elastography and oesophagogastroduodenoscopy|Liver and spleen stiffness will be measured by transient elastography. Varices will be identified by oesophagogastroduodenoscopy.
219221823|NCT07043621|PROCEDURE|Early Scalp Block Group|"Following induction of general anesthesia and prior to head pinning (Mayfield clamp placement), a scalp block was performed under aseptic conditions using 20 mL of 0.25% bupivacaine.~The block targeted six sensory nerves that innervate the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve ,Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~Each nerve was infiltrated subcutaneously at its anatomical location using a 25-gauge needle, with the total volume distributed evenly or proportionally across the injection sites."
219221824|NCT07043621|PROCEDURE|Late Scalp Block Group|"In the pre-emergence group, the scalp block was performed at the end of surgery but before emergence from general anesthesia, while the patient was still under deep anesthesia.~Under strict aseptic conditions, 20 mL of 0.25% bupivacaine was administered to block the following six sensory nerves innervating the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve, Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~The local anesthetic was injected subcutaneously at the anatomical landmarks of each nerve using a 25-gauge needle. The total volume was distributed evenly or proportionally depending on the area. No additional surgical stimulation occurred after the block, and extubation followed routine emergence from anesthesia."
219221825|NCT07043517|OTHER|RDC/TMD|TMJ functions were assessed using the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
219096057|NCT02800967|DIETARY_SUPPLEMENT|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
219096058|NCT03010462|DEVICE|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
219096059|NCT03010462|DEVICE|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
219096060|NCT00817999|DIETARY_SUPPLEMENT|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
219096061|NCT00817999|DRUG|Clopidogrel 75 mg/day|
219096062|NCT00817999|DRUG|Clopidogrel 300 mg|
219096063|NCT04911309|OTHER|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
219096064|NCT04911309|OTHER|standard therapy / treatment|12 weeks standard therapy / treatment
219096065|NCT02207725|BIOLOGICAL|Andexanet|
219096066|NCT02207725|OTHER|Placebo|
219096067|NCT02526355|BEHAVIORAL|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
219096068|NCT03766256|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
219096069|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
219096070|NCT03145766|BIOLOGICAL|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
219096071|NCT03145766|BIOLOGICAL|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
219096072|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
219096073|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
219096074|NCT03145766|BIOLOGICAL|Human Rabies Immunoglobulins (HRIG)|Commercialized formulation of HRIG
219096075|NCT03850080|DRUG|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
219096076|NCT03983122|PROCEDURE|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
219096077|NCT04242693|BEHAVIORAL|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
219096078|NCT04191629|COMBINATION_PRODUCT|EO1404|
219096079|NCT04191629|PROCEDURE|Endothelial brushing or Descemet stripping|
219096080|NCT00431184|DRUG|Pentazocine|see arms description
219096081|NCT00431184|DRUG|Lorazepam|see arms description
219096082|NCT05083143|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
219096083|NCT05210829|DIAGNOSTIC_TEST|stationary and trait anxiety scale|survey
219096084|NCT03479021|DIAGNOSTIC_TEST|Welch-Allyn Spot Vision Screener|photograph of the eye
219096085|NCT00053001|BIOLOGICAL|epoetin alfa|
219096086|NCT00053001|DRUG|thalidomide|
219096087|NCT00895882|DRUG|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
219096088|NCT00895882|DRUG|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
219096089|NCT00895882|DRUG|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
219096090|NCT00895882|DRUG|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
219096091|NCT00895882|DRUG|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
219096092|NCT01391325|DRUG|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
219096093|NCT00745706|DEVICE|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
219096094|NCT00171639|DRUG|zoledronic acid|
219096095|NCT00494533|DRUG|Remodulin (treprostinil sodium)|
219096096|NCT02547870|DRUG|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
219096097|NCT02547870|DRUG|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
219096098|NCT02547870|DRUG|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
219096099|NCT03831984|DRUG|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
219096100|NCT03831984|DRUG|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
219096101|NCT04567264|DEVICE|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
219096102|NCT02731625|OTHER|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
219096103|NCT02731625|OTHER|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
219096104|NCT02319226|OTHER|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
219096105|NCT00229957|BEHAVIORAL|Occupational therapy|
219096106|NCT00229957|BEHAVIORAL|Physiotherapy|
219096107|NCT00229957|BEHAVIORAL|Self-management|
219096108|NCT00113932|PROCEDURE|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin\* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, \& every 2 weeks until HB \>12 gm/dl\*\*\*; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount \<30,000/μl
219096109|NCT04411602|DRUG|SARS-CoV-2 plasma|To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
219096110|NCT02317055|OTHER|imaging|
219096111|NCT01253863|OTHER|exploration|exploration of wound for determining damaged tissue
219096112|NCT04642963|RADIATION|Cardiac Radiosurgery|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
219096113|NCT02799472|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
219096114|NCT02799472|DRUG|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
219096115|NCT02799472|DRUG|MTX|Capsule, tablet or liquid administered orally or as SC injection.
219096116|NCT02799472|DRUG|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
219096117|NCT01368848|DRUG|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W -\> Bevacizumab Q3W until progression"
219096118|NCT01368848|DRUG|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
219096119|NCT01368848|DRUG|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
219096120|NCT04447430|DEVICE|bright light|treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
219096121|NCT04447430|DEVICE|dim red light|treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
219096122|NCT03978910|OTHER|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
219096123|NCT01718093|DRUG|Sitagliptin|up to 50 mg twice a day
219096124|NCT01718093|DRUG|Metformin|up to 1000 mg twice a day
219096125|NCT01718093|DRUG|Sitagliptin + Metformin|up to 50/1000 mg twice a day
219096126|NCT03333798|BEHAVIORAL|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~* The Cognitive-Behavioral model~* Tackling traumatic events~* Cognitive reprocessing~* Relaxation techniques~* Prevention of revictimization~* Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
219096127|NCT03333798|BEHAVIORAL|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
219096128|NCT03611244|DEVICE|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
219096129|NCT00259064|DRUG|Gefitinib|
219096130|NCT00259064|OTHER|Placebo|
219096131|NCT03620422|OTHER|Mannitol|Mannitol-Induced Cough Challenge
219096132|NCT03620422|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
219096133|NCT03620422|OTHER|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
219096134|NCT00674570|DRUG|Hydrocortisone|25 mg/oral one hour prior to extinction task
219096135|NCT00674570|DRUG|D-Cycloserine|50 mg/oral one hour prior to extinction task
219096136|NCT00674570|DRUG|Placebo|One hour prior to extinction task
219096137|NCT02801669|DRUG|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
219096138|NCT02801669|DRUG|placebo|Placebo orally administered once daily.
219096139|NCT05982665|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 300 ml/min.
219096140|NCT05982665|OTHER|Placebo|Ambient air, flow rate 300 ml/min.
219096141|NCT01966003|DRUG|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
219096142|NCT01966003|DRUG|Paclitaxel|Administered 200 mg/m² IV Q3W
219096143|NCT01966003|DRUG|ABP 215|Administered 15 mg/kg Q3W by IV infusion
219096144|NCT01966003|DRUG|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
219096145|NCT04366063|BIOLOGICAL|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
219096146|NCT04366063|BIOLOGICAL|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
219096147|NCT02696564|DRUG|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
219096148|NCT02696564|DRUG|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
219096149|NCT04574830|OTHER|No Intervention|No Intervention
219096150|NCT01840384|DIETARY_SUPPLEMENT|Multi-micronutrients|
219096151|NCT01840384|DIETARY_SUPPLEMENT|Maltodextrin and Lactose|
219096152|NCT05147948|BEHAVIORAL|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
219096153|NCT02094014|BEHAVIORAL|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
219096154|NCT02094014|BEHAVIORAL|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
219096155|NCT02094014|BEHAVIORAL|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
219096156|NCT01995448|BIOLOGICAL|Blood test|Residue of blood further to NFS.
219096157|NCT00571961|DRUG|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
219096158|NCT00571961|DRUG|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
219096159|NCT00571961|OTHER|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
219096160|NCT04264793|BEHAVIORAL|Behavioral Lifestyle Intervention|In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
219096161|NCT04264793|BEHAVIORAL|Usual Care|Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
219096162|NCT00917163|DEVICE|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
219096163|NCT00917163|DEVICE|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
219096164|NCT03158363|OTHER|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
219096165|NCT05974995|PROCEDURE|Robot-assisted surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
219096166|NCT05974995|PROCEDURE|Laparoscopic surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
219096167|NCT03327584|PROCEDURE|Arthrocentesis|Athrocentesis
219096168|NCT01578863|OTHER|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
219096169|NCT00137943|BEHAVIORAL|Full Parent communication intervention|
219096170|NCT00137943|BEHAVIORAL|Brief Parent Communication Intervention|
219096171|NCT00137943|BEHAVIORAL|Control Parent Intervention|
219096172|NCT03304002|OTHER|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
219096173|NCT00993239|DRUG|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
219096174|NCT03633929|OTHER|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
219096175|NCT04699435|OTHER|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
219096176|NCT04699435|OTHER|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
219096177|NCT04699435|OTHER|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
219096178|NCT04119453|DRUG|Rivoceranib|Film-coated tablets
219096179|NCT00379119|OTHER|diagnostic laboratory biomarker analysis|
219096180|NCT00379119|OTHER|flow cytometry|
219096181|NCT00379119|OTHER|physiologic testing|
219096182|NCT00379119|PROCEDURE|computed tomography|
219096183|NCT03331484|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
219096184|NCT03331484|DRUG|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
219096185|NCT06052917|OTHER|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
219096186|NCT05701514|PROCEDURE|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
219096187|NCT03933111|DIAGNOSTIC_TEST|local sound velocity measurement|All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
219096188|NCT04461795|DRUG|Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]|225 MG/1.5 ML Subcutaneous Solution
219096189|NCT01180543|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
219221826|NCT07043933|BEHAVIORAL|Mobile-Compatible Web-Based Hydration Tracking Program|"Intervention Description:~The SIVI Hydration Application is a mobile-compatible, web-based behavioral intervention designed specifically for older adults. It supports self-monitoring and self-management of daily fluid intake through features such as personalized fluid goals, visual drink-logging with icons, daily reminders, progress graphics, educational videos, and motivational digital badges. The app was developed using gerotechnology and universal design principles to accommodate cognitive and sensory changes common in aging. Its unique focus on hydration behavior, combined with usability features like large fonts, high contrast, and voice-assisted guidance, distinguishes it from general health or diet tracking apps. Participants use the app for 8 weeks as part of a structured intervention with training and weekly follow-up."
219221827|NCT07043283|DRUG|Ebronucimab|Ebronucimab subcutaneous injection.
219221828|NCT07043205|BEHAVIORAL|Coastal walk|A 40-minute walk with psychophysiological monitoring in Ostend (along the beach)
219221829|NCT07043205|BEHAVIORAL|Urban walk|40' walk in Ghent (urban)
219096190|NCT01180543|DEVICE|Placebo Patch|same as active patch
219221830|NCT07042698|OTHER|Glomerular Filtration Rate measurement with iohexol clearance|After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.
219221831|NCT07042581|DRUG|Revaree Plus|Revaree Plus is a hyaluronic acid vaginal suppository
219221832|NCT07042750|OTHER|Eccentric cycling exercise|Patients perform eccentric cycling exercise instead of normal cycling exercise in addition to standard car during a cardiopulmonary rehabilitation
219221833|NCT07042750|OTHER|Standard Care Arm|Patients perform cardiopulmonary rehabilitation according to standard care
219221834|NCT07043010|DEVICE|Near-Infrared Parathyroid Tissue Sensor Imaging (PTS)|FDA-cleared imager (e.g., Fluobeam LX/PTeye) providing real-time autofluorescence to identify parathyroid tissue during surgery; no dye or radiation.
219221835|NCT07043010|PROCEDURE|Rim-Preservation Technique|Surgical excision of adenoma while leaving the NIRAF-positive rim of normal parathyroid tissue in situ; minimal defatting to ensure perfusion.
219221836|NCT07043010|PROCEDURE|En-bloc Resection Technique|Surgical excision of adenoma together with the surrounding NIRAF-positive rim; autotransplant fragment if \< 2 normal glands remain in neck.
219221837|NCT07043413|DIAGNOSTIC_TEST|thrombus analysis|Detailed expression pattern of RNA and histological characteristics will be investigated.
219221838|NCT07043075|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating in parallel on a separate screen in a blind setup, enabling clinicians to assess the analysis and recommendations provided by the software, either immediately after valve deployment or following the completion of the procedure.
219221839|NCT07043049|DRUG|Tramadol|Tramadol 1 mg/kg IV given 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering
219221840|NCT07043049|DRUG|Ketamine|Ketamine 0.5 mg/kg IV administered 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering.
219096191|NCT05703984|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
219096192|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
219096193|NCT05703984|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
219096194|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
219096195|NCT00082732|BEHAVIORAL|behavioral dietary intervention|
219096196|NCT00082732|DIETARY_SUPPLEMENT|dietary intervention|
219096197|NCT00082732|PROCEDURE|therapeutic dietary intervention|
219096198|NCT00336141|DRUG|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
219096199|NCT00529321|BIOLOGICAL|MVA-HCV (Immunotherapy)|MVA-HCV
219096200|NCT02809898|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
219096201|NCT02437825|DRUG|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
219096202|NCT02437825|OTHER|placebo|placebo ( saline) act as comperator in this study.
219096203|NCT01390714|DRUG|E3710|"Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
219096204|NCT01390714|DRUG|E3710|"Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
219096205|NCT04774133|DIAGNOSTIC_TEST|Blood sample|Pazients will undergo to blood samples at predefined times
219096206|NCT02189902|DIETARY_SUPPLEMENT|4000 IU/d D3 over 12 weeks|
219096207|NCT02189902|DIETARY_SUPPLEMENT|7000 IU/d D3 over 12 weeks|
219096208|NCT02287584|DRUG|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
219096209|NCT02287584|DRUG|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
219096210|NCT02287584|DRUG|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
219096211|NCT02287584|DRUG|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
219096212|NCT02287584|DRUG|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
219096213|NCT02269371|OTHER|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
219096214|NCT02269371|OTHER|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
219221841|NCT07042737|BEHAVIORAL|animation-based breast cancer education|The animation-based humorous application consists of four videos, each lasting 40-45 minutes, which separately explain the signs and symptoms of breast cancer, self-breast examination, clinical breast examination, and mammography through animation.
219096215|NCT01817374|DIAGNOSTIC_TEST|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
219096216|NCT00496002|DRUG|Clevudine|
219096217|NCT00496002|DRUG|Adefovir|
219096218|NCT03264885|OTHER|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
219096219|NCT01423214|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
219096220|NCT01423214|PROCEDURE|Laparoscopic surgery|Conventional laparoscopic procedures
219096221|NCT04942301|DRUG|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
219221842|NCT07042737|OTHER|Control group (placebo)|No intervention will be applied to the control group.
219362155|NCT01738971|OTHER|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
219362156|NCT00494143|DEVICE|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
219096222|NCT04942301|DEVICE|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
219096223|NCT04942301|COMBINATION_PRODUCT|combination therapy|Combination therapy with chemotherapy drugs was used
219096224|NCT03375476|DIAGNOSTIC_TEST|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
219096225|NCT03375476|DIAGNOSTIC_TEST|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
219096226|NCT03375476|DIAGNOSTIC_TEST|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
219096227|NCT03389139|DEVICE|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
219096228|NCT03389139|DEVICE|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
219096229|NCT03244462|DRUG|BAY1834845|Single oral dose (IR \[immediate release\] tablets)
219096230|NCT03244462|DRUG|BAY1834845|I.v. infusion of \[13C6\]-labeled BAY1834845
219096231|NCT03244462|DRUG|Methotrexate|Single dose of commercially available MTX
219096232|NCT00005816|BIOLOGICAL|therapeutic autologous dendritic cells|
219096233|NCT00005816|PROCEDURE|conventional surgery|
219096234|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
219096235|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
219362157|NCT00494143|DEVICE|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
219362158|NCT00494143|DEVICE|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
219096236|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
219096237|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
219096238|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
219221843|NCT07044154|OTHER|Tai Chi (Sun Style)|The Sun Tai Chi intervention will be conducted by a Sun Tai Chi instructor with 7 years of teaching experience and will take place in an exercise room at the Catholic University of Maule. The intervention will last for 12 weeks, with a frequency of twice per week, and each class will last 60 minutes. Each session will begin with 10 minutes of warm-up exercises, followed by 20 minutes of basic Sun Tai Chi exercises, including lower limb movements, overall body mobility at a slow pace, precise movements of the hands and feet, and proper body alignment. This will be followed by 20 minutes of practice of the basic movement sequence of Sun Tai Chi (Taolú), and will conclude with 5 minutes of meditation and 5 minutes of relaxation exercises.
219096239|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
219096240|NCT01487876|BIOLOGICAL|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
219096241|NCT01487876|OTHER|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
219096242|NCT00221143|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
219096243|NCT02766816|BIOLOGICAL|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
219096244|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
219096245|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
219096246|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
219096247|NCT02766816|BIOLOGICAL|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
219096248|NCT02766816|BIOLOGICAL|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
219096249|NCT03663764|DRUG|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
219096250|NCT03663764|RADIATION|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
219096251|NCT03663764|DRUG|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
219096252|NCT01454674|OTHER|2, 5 & 10 Vegetable doses|2,5 \& 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers \& tomatoes consumed for 3 week intervals
219096253|NCT02884414|DEVICE|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
219096254|NCT05537558|DRUG|Antidepressant|Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
219096255|NCT03430063|DRUG|SDREGN2810|Standard dose intravenous (IV) infusion
219221844|NCT07044154|BEHAVIORAL|Health lifestyle education|The control group will receive guidance on a healthy physical and mental lifestyle.
219362159|NCT04065529|COMBINATION_PRODUCT|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
219362160|NCT04065529|COMBINATION_PRODUCT|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
219362161|NCT02542761|DEVICE|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
219362162|NCT02542761|DEVICE|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
219096256|NCT03430063|DRUG|SDREGN2810/ipi|Combination therapy dose IV
219096257|NCT03430063|DRUG|HDREGN2810|High dose IV
219096258|NCT05857111|DEVICE|Celbrea|The test with the CELBREA® device will be added to the routine screening according to the protocols of the health facility.
219096259|NCT05058209|DRUG|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
219096260|NCT05058209|DRUG|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
219096261|NCT02798211|DRUG|Secukinumab 300 mg|150 mg x 2 s.c. injection
219096262|NCT02798211|DRUG|Secukinumab 150 mg|150 mg s.c. injection
219096263|NCT02798211|OTHER|Placebo|Placebo
219096264|NCT01982435|DRUG|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
219096265|NCT01982435|DRUG|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
219096266|NCT03844243|DRUG|NGF|Intramuscular injection
219096267|NCT03844243|DRUG|Isotonic-saline|Intramuscular injection
219096268|NCT05292534|DEVICE|hearing aid amplification|Hearing aid will be fit to prescribed participant hearing loss.
219096269|NCT05292534|DEVICE|hearing aid amplification with an added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
219096270|NCT03126864|PROCEDURE|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.
219096271|NCT03126864|DRUG|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
219096272|NCT03126864|DRUG|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
219096273|NCT03126864|BIOLOGICAL|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.
219096274|NCT00002093|DRUG|Daunorubicin (liposomal)|
219221845|NCT07043439|OTHER|Mobilization|"Participants receiving this intervention will undergo Grade 3 joint mobilization targeting the first metatarsophalangeal (1st MTP) joint. The technique will be administered by a licensed physiotherapist with the participant lying in the prone position and the foot in a neutral position.~Mobilization will be performed according to the Maitland concept, which defines Grade 3 as large-amplitude, rhythmic oscillatory movements applied within the range of motion but up to the limit of tissue resistance, without entering the paraphysiological space.~The goal of this technique will be to increase joint play and mobility, reduce stiffness, and potentially improve biomechanical alignment. The mobilization will last approximately 5 minutes, and outcome measures will be collected before and immediately after the session."
219221846|NCT07043439|OTHER|High-Velocity Low-Amplitude (HVLA) Manipulation|"This intervention will involve the application of a high-velocity, low-amplitude (HVLA) thrust manipulation to the first metatarsophalangeal (1st MTP) joint. A licensed physiotherapist will perform the procedure with the participant positioned prone and the foot placed in a neutral alignment.~The therapist will stabilize the 1st metatarsal bone with one hand and apply a quick, controlled thrust to the proximal phalanx of the hallux in a dorsal direction using the other hand. The technique will be delivered with minimal amplitude and maximal speed, aiming to restore joint motion, reduce soft tissue tension, and stimulate neuromechanical reflexes.~The manipulation procedure will take approximately 2-3 minutes, including setup and execution. Pre- and post-intervention outcome measures will be used to assess its immediate effects."
219221847|NCT07043439|OTHER|Sham Manipulation|"Participants in the control group will receive a sham (placebo) intervention designed to mimic the real treatment in setup and duration, without applying any therapeutic mechanical stimulus. The sham procedure will be conducted by the same physiotherapist with participants lying prone and their foot in a neutral position.~The physiotherapist will place their hands around the 1st MTP joint as if a manipulation were to be performed and will maintain static contact for the same duration as in the experimental group. However, no thrust, traction, or mobilization force will be applied.~The sham intervention will also last approximately 10 minutes, ensuring consistency across groups. All assessments will be conducted immediately before and after the intervention to evaluate potential placebo effects."
219221848|NCT07042373|BEHAVIORAL|Control|In the control condition, participants will purchase tobacco/nicotine products in the ETM. Cigarettes will increase in price across trials.
219221849|NCT07042373|BEHAVIORAL|Product Category Score|In the product category score condition, participants will purchase tobacco/nicotine products in the ETM where the percentage of taxes applied to each product category will be distributed between 0% and 100% proportional to their abuse liability score. Abuse liability scores will be scaled such that the product category with the highest abuse liability will be taxed at 100%.
219362163|NCT04057339|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
219096275|NCT00002093|DRUG|Bleomycin sulfate|
219096276|NCT00002093|DRUG|Vincristine sulfate|
219096277|NCT00002093|DRUG|Doxorubicin hydrochloride|
219096278|NCT06542237|DRUG|YCT-529|"In the Phase 1b portion of the study (Part 1), 4 dosing cohorts and one optional 5th cohort with 4 participants in each cohort will be evaluated (approximately 20 participants): 15, 30, 90 and 180 mg.~In the Phase 1b portion of the study (Part 2), 4 dosing cohorts with 4 participants in each cohort will be evaluated (approximately 16 participant): dose to range from 30 mg upto 180 mg.~In the Phase 2a portion of the study (Part 3), up to 3 cohorts of up to 10 participants (approximately 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion."
219096279|NCT06066281|BEHAVIORAL|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
219096280|NCT02438943|OTHER|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
219096281|NCT02438943|OTHER|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
219096282|NCT02167217|DRUG|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
219096283|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline
219096284|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
219096285|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
219096286|NCT01782872|PROCEDURE|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
219096287|NCT02775422|BIOLOGICAL|Serological Test s for the Virus Chicken Pox Virus|
219221850|NCT07042373|BEHAVIORAL|Product Category Rank|In the product category rank condition, participants will purchase tobacco/nicotine products in the ETM where the tax percentage applied to each product category will be determined by the number of categories and their position in the ranking. The product category with the highest abuse liability will be taxed at 100%; the product with the lowest abuse liability will be taxed at 0%. All other tax rates will be equally spaced across other products based on ranking.
219221851|NCT07042373|BEHAVIORAL|Product Tiers|In the product tiers condition, participants will purchase tobacco/nicotine products in the ETM where tobacco products will be placed in tax tiers to simplify the existing complex tobacco tax system. The investigators will use three tax tiers (i.e., high tax, medium tax, and no tax), as adopted by four states. Products will be placed into tiers depending on their average score (i.e. no tax: \< 0.33, medium tax: 0.33-0.66, and high tax: \>0.66). Products in the high tax tier will be taxed at 100% and products in the medium tax tier will be taxed at 50%.
219221852|NCT06890208|OTHER|No intervention|No intervention
219221853|NCT07042308|DIAGNOSTIC_TEST|Transient elastography|Liver stiffness and spleen stiffness from transient elastography
219221854|NCT06737354|GENETIC|IVB103 Injection（Low dose）|Single intravitreal injection
219221855|NCT06737354|GENETIC|IVB103 Injection（Intermediate dose）|Single intravitreal injection
219221856|NCT06737354|GENETIC|IVB103 Injection（High dose）|Single intravitreal injection
219221857|NCT06782009|OTHER|Calorie restriction|Participants will be provided with a food menu guide for fifteen days with a 30% energy restriction (kcal) according to their usual diet, with a macronutrient distribution of 20-30% protein, 50-60% carbohydrates and 20-30% fat.
219221858|NCT06782009|OTHER|Intermittent fasting 16/8|Participants will be provided with a food menu guide for fifteen days with an energy intake according to the energy expenditure determined by indirect calorimetry with normal distribution of macronutrients. Intermittent fasting will be used with a time-restricted model of 16:8. For 16 hours, they will not be able to eat or drink calories. In the other 8 hours, they need to adhere to the energy-restricted diet.
219221859|NCT06782009|OTHER|Ketogenic diet|Participants will be provided with a food menu guide for 15 days with an energy intake according to the energy expenditure determined by indirect calorimetry, with the following distribution of macronutrients: 20-25% protein, 5-10% carbohydrates, 70-80% fat.
219221860|NCT05381480|BEHAVIORAL|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
219221861|NCT05381480|BEHAVIORAL|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
219221862|NCT05320692|DRUG|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
219221863|NCT05320692|PROCEDURE|TACE|TACE Alone.
219221864|NCT06828952|DRUG|ceftriaxone|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly
219221865|NCT06828952|DRUG|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly|Conservative management
219096288|NCT05508386|OTHER|MATLAB-based interface, showing 50 EEG traces, classification of the EEG-pattern as Burst Suppression possible, yes, no.|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
219096289|NCT05731089|PROCEDURE|Phacoemulsification with IVI of aflibercept|IVI was either before or after cataract surgery
219096290|NCT01892345|DRUG|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
219096291|NCT01892345|DRUG|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
219096292|NCT00344604|BEHAVIORAL|Role of psychosocial and quality of life parameters prior to and following LASIK.|
219221866|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice A|Cranberry juices will be provided by Ocean Spray Company.
219221867|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice B|Cranberry juices will be provided from Ocean Spray Company.
219221868|NCT06066619|DIETARY_SUPPLEMENT|Placebo Juice|Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
219221869|NCT04252677|BEHAVIORAL|Obesity Prevention|This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
219221870|NCT04252677|BEHAVIORAL|Health Literacy|This intervention includes content specific to improving health literacy.
219221871|NCT04900597|OTHER|Elecare Jr|Elecare Jr is a standard pediatric elemental formula
219221872|NCT04900597|OTHER|Nourish|Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
219096293|NCT05684562|OTHER|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
219096294|NCT05684562|OTHER|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
219096295|NCT05684562|OTHER|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
219221873|NCT04900597|OTHER|Real Foods Blends|Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
219221874|NCT06823440|DEVICE|Compression using surgical gloves and compression knee socks|Compression therapy will be applied using surgical gloves and compression knee socks. The compression itself will take place on the principle of compressing the limbs, which will narrow the blood vessels and thereby limit the flow of cytostatics to the peripheral parts of the body. This is believed to reduce damage to nerve fibers. Special knee socks with compression of 20-30 mm Hg and latex/nitrile surgical gloves will be used for pressure therapy. The size of the compression aids will be determined by the nursing staff (gloves will be a tight-fitting size; they will not cause discomfort). The patients will wear the compression aids for a specific amount of time before administering paclitaxel, throughout paclitaxel infusion, and after the infusion.
219221875|NCT03713879|DEVICE|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
219221876|NCT03713879|DRUG|Indomethacin|rectally administered indomethacin before or after ERCP
219096296|NCT06009640|DEVICE|Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine|Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.
219221877|NCT06675149|DEVICE|Diacutaneus fibrolysis|Material : Stainless steel large angle and small long angle: length 22cm x height 6cm x width 2cm. Weight: 70 grams
219096297|NCT05763758|OTHER|No intervention|No intervention involved in this study
219096298|NCT03301727|OTHER|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
219221878|NCT06675149|DEVICE|Transcutaneous electrical nerve stimulation|physical therapy electrical modality
219096299|NCT05970302|DRUG|Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine|Use the above medications on a regular basis.
219096300|NCT04570995|DIETARY_SUPPLEMENT|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
219096301|NCT04570995|DIETARY_SUPPLEMENT|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
219096302|NCT02074046|BIOLOGICAL|cancer stem cell vaccine|
219096303|NCT04929093|BIOLOGICAL|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
219096304|NCT04929093|BIOLOGICAL|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
219096305|NCT04929093|BIOLOGICAL|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
219096306|NCT03759613|OTHER|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
219096307|NCT02475317|DRUG|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
219096308|NCT02475317|DRUG|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
219096309|NCT02475317|DRUG|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
219096310|NCT02607657|DRUG|Eplerenone 25 mg|
219096311|NCT02607657|DRUG|Eplerenone 50 mg|
219096312|NCT02607657|DRUG|Eplerenone 100 mg|
219221879|NCT06675149|PROCEDURE|Massage|manual therapy intervention
219221880|NCT03915106|DEVICE|Brace|Wear a rigid brace
219096313|NCT02607657|DRUG|Eplerenone 50 mg twice a day|
219096314|NCT02607657|DRUG|Eplerenone 25 mg twice a day|
219096315|NCT05357937|BEHAVIORAL|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
219221881|NCT03915106|PROCEDURE|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
219221882|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
219362164|NCT04057339|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
219221883|NCT06810466|DIETARY_SUPPLEMENT|Test Product A|Innovative formulation of a dietary supplement for mild hypercholesterolemia. Test Product A will be admistered daily for 8 weeks. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
219096316|NCT00727818|DEVICE|guided bone regeneration|
219096317|NCT01473381|DRUG|Vilazodone|Vilazodone was supplied as film-coated tablets.
219096318|NCT01473381|DRUG|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
219096319|NCT01473381|DRUG|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
219096320|NCT01473381|DRUG|Citalopram|Citalopram was supplied as encapsulated tablets.
219096321|NCT03575533|DIAGNOSTIC_TEST|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
219096322|NCT02302131|OTHER|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
219096323|NCT00214825|DRUG|eplerenone|50 mg daily for 6 weeks with placebo
219096324|NCT00214825|DRUG|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
219096325|NCT00615381|DRUG|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
219096326|NCT04397484|DRUG|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
219096327|NCT04397484|DRUG|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
219096328|NCT02442635|BEHAVIORAL|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
219096329|NCT04343586|DEVICE|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
219096330|NCT00706225|DRUG|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
219096331|NCT04268901|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
219096332|NCT04268901|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
219096333|NCT04268901|DEVICE|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
219096334|NCT01005303|DRUG|Placebo|1 Tablet Daily
219096335|NCT01005303|DRUG|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
219096336|NCT01337414|BEHAVIORAL|VMS diary booklet|
219096337|NCT01337414|BEHAVIORAL|Standard of Care|
219096338|NCT04026165|DRUG|SEL|Tablet administered orally once daily
219221884|NCT06810466|DIETARY_SUPPLEMENT|Test Product B|Classic formulation of a dietary supplement for mild hypercholesterolemia. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
219221885|NCT06810466|DIETARY_SUPPLEMENT|Placebo|"Placebo does not contain functional components and is indistinguishable from Product Test B.~After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks."
219221886|NCT06100952|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
219096339|NCT04026165|DRUG|Placebo|Tablet administered orally once daily
219096340|NCT05897801|DIAGNOSTIC_TEST|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
219096341|NCT01562535|OTHER|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
219096342|NCT01562535|OTHER|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
219096343|NCT02487810|BEHAVIORAL|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
219096344|NCT02487810|BEHAVIORAL|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
219096345|NCT06003465|DRUG|LY3437943|Administered SC
219221887|NCT06100952|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
219221888|NCT05571553|OTHER|Recommendations and reorientation towards healthcare resources|"Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
219221889|NCT06163625|DEVICE|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
219221890|NCT06163625|BEHAVIORAL|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
219221891|NCT06163625|BEHAVIORAL|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
219221892|NCT06163625|BIOLOGICAL|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
219221893|NCT06742047|BEHAVIORAL|Professional development programme|The professional development programme include dialogue groups facilitated by registered nurses (RN) who are expert and experienced supervisors that received a three day training before conducting the groups. Then including education days with joint lectures and simulations with experts in the field with experience. The programme provides NGNs with regular opportunities for reflection for learning from experiences of care to enhance personal and professional growth.
219221894|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
219221895|NCT05886530|OTHER|No intervention|Observational data collection only.
219096346|NCT06003465|DEVICE|Test|Used to administer LY3437943 SC
219096347|NCT06003465|DEVICE|Reference|Used to administer LY3437943 SC
219096348|NCT00853164|BEHAVIORAL|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
219096349|NCT00853164|BEHAVIORAL|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
219096350|NCT00853164|BEHAVIORAL|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
219096351|NCT01889186|DRUG|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
219221896|NCT06910020|OTHER|Active Cycle of Breathing Technique|"* Patients will assume the sitting position and relax their shoulders, then perform the following:~  1. Breathing control (abdominal breathing)~ 2. Chest expansion (thoracic breathing)~ 3. Huff cough (forced expiratory technique)~* After completing the above actions, patients will be asked to cough up the residual deep sputum to promote pulmonary expansion.~* The ACBT intervention will be performed for three days, each day two sessions, each session three courses, with 10 minutes of rest between them as needed."
219221897|NCT06758219|OTHER|There is no intervention in the study.|There is no intervention in the study.
219221898|NCT06779578|PROCEDURE|Bipolar pulsed radiofrequency|Bipolar pulsed radiofrequency ablation: the active comparator
219221899|NCT06779578|PROCEDURE|Mopolar pulsed radiofrequency|Monopolar pulsed radiofrequency ablation: the placebo
219221900|NCT03024866|PROCEDURE|Electronic Brachytherapy|A group receives High-dose-rate electronic brachytherapy (EBT) which provides a non-surgical treatment option and the other group receives Mohs surgery. This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs surgery in patients with NMSC.
219221901|NCT04932577|BIOLOGICAL|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
219221902|NCT04932577|BIOLOGICAL|Placebo|Placebo
219221903|NCT06347432|OTHER|Power wheelchair skills training using the IndieTrainer system|The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
219221904|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
219221905|NCT05487820|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
219221906|NCT06215144|DRUG|NRCT-101SR|NRCT-101SR is a sustained release formulation.
219221907|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
219096352|NCT01889186|DRUG|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
219096353|NCT04845724|OTHER|Standard Diet|
219096354|NCT04845724|OTHER|Modified Diet|
219096355|NCT04315532|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
219096356|NCT04315532|OTHER|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
219096357|NCT04315532|OTHER|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
219096358|NCT00441701|DRUG|Navarixin 1 mg|Navarixin 1 mg capsules
219096359|NCT00441701|DRUG|Navarixin 10 mg|Navarixin 10 mg capsules
219096360|NCT00441701|DRUG|Placebo to match navarixin|Placebo to navarixin capsules
219096361|NCT00441701|DRUG|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
219096362|NCT03112941|PROCEDURE|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
219221908|NCT05695027|DRUG|Dietary supplements - Nicotinamide and Pyruvate|Nutritional supplements
219221909|NCT05695027|DRUG|Placebo|Placebo
219221910|NCT06828276|BEHAVIORAL|Culturally adapted i-CBT|A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.
219221911|NCT04230395|BEHAVIORAL|HATHI Intervention|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
219221912|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
219221913|NCT06628674|BEHAVIORAL|core muscle exercise|Patients in experiment group will do core muscle exercise with online interactive videos
219221914|NCT06628674|BEHAVIORAL|pelvic muscle exercise|Patients in experiment group will do pelvic muscle exercise without online interactive videos
219221915|NCT06828731|DRUG|Empagliflozin 10mg daily|This intervention will assess recruitment and retention (feasibility trial).
219221916|NCT06828731|OTHER|Lifestyle education|This intervention is considered standard care for prediabetes.
219221917|NCT06784830|OTHER|Effects on Image Quality and Patient Satisfaction|Effect of nursing intervention on image quality and patient satisfaction during PET/CT imaging in Alzheimer's patients
219221918|NCT06784830|OTHER|Anxiety degree of patients after nursing|Self Rating Anxiety will be used Scale (SAS) to assess the degree of anxiety after care
219221919|NCT06381622|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
219221920|NCT06381622|DRUG|Lidocaine epinephrine|20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
219221921|NCT06381622|DRUG|Ropivacaine 0.75% Injectable Solution|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
219096363|NCT03112941|OTHER|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
219221922|NCT06098040|DEVICE|flash glucose monitoring continuous|Group 2 (FGM continuous): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion continuously for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
219221923|NCT06098040|DIAGNOSTIC_TEST|capillary blood test|Group 1 (SMBG): will be asked to test capillary blood glucose as recommended by subjects' usual provider for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
219221924|NCT06098040|DEVICE|flash glucose monitoring intermittent|Group 3 (FGM intermittent): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion 1 week off/2 weeks on for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
219221925|NCT06636773|BEHAVIORAL|Diet|A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants.
219096364|NCT01555190|DRUG|myo-inositol 1500 gr|
219096365|NCT01555190|DRUG|myo-inositol 2000 gr + folic acid 200 mcg|
219096366|NCT03987425|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
219096367|NCT04710927|DEVICE|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
219096368|NCT04710927|DEVICE|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
219096369|NCT04710927|DEVICE|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
219096370|NCT05867719|OTHER|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
219096371|NCT03328000|RADIATION|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
219096372|NCT01702441|DRUG|Subcutaneous AKB-9778|
219221926|NCT06636773|BEHAVIORAL|Aerobic Exercise|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
219221927|NCT06636773|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12 to assist in supporting recommended changes in energy intake (diet) and physical activity.
219096373|NCT05012475|BEHAVIORAL|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
219096374|NCT01578148|PROCEDURE|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~1. Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~2. Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~3. Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~4. Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
219221928|NCT06636773|BEHAVIORAL|Aerobic + Yoga Exercise|Physical activity will be recommended in the form of a combination of aerobic types of activity, such as brisk walking, and yoga. Aerobic activity will progress from 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention. When combined this will progress from a total of 100 minutes per week to 300 minutes per week across the initial 6 months of treatment. This level of physical activity will continue to be recommended between months 7-12.
219221929|NCT05140967|OTHER|High Intensity Interval Training (HIIT)|High Intensity Interval Training
219221930|NCT05140967|OTHER|Moderate Continuous Intensity Training (MICT)|Moderate Intensity Continuous Training
219221931|NCT04800367|DRUG|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
219682589|NCT04472546|OTHER|Scotch|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
219682590|NCT04472546|OTHER|Lipid index|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
219682591|NCT04472546|OTHER|Absorbant paper|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
219682592|NCT04472546|OTHER|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
219682593|NCT04472546|OTHER|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
219682594|NCT03499106|DRUG|IW-1973|Oral Tablet
219682595|NCT03499106|DRUG|Itraconazole|Oral Capsule
219682596|NCT06473116|DRUG|Isoprenaline Only Product|Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
219682597|NCT01562717|DRUG|Ibuprofen|3 times a day
219682598|NCT01562717|DRUG|Placebo|3 times a day
219682599|NCT01409915|DRUG|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
219682600|NCT01409915|DRUG|Saline -- placebo comparator|subcutaneous injection
219682601|NCT04826484|DRUG|Exparel 133 miligrams per 10 milliliter injection|Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
219682602|NCT04826484|DRUG|Bupivacaine Hydrochloride|Local wound infiltration with 0.25% bupivacaine.
219682603|NCT00511173|GENETIC|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
219682604|NCT02250300|DRUG|MLN9708 (2.3 mg)|2.3 mg
219682605|NCT02250300|DRUG|MLN9708 (4.0 mg)|4.0 mg
219682606|NCT02250300|DRUG|MLN9708 (3.0 mg)|3.0 mg
219682607|NCT03170817|DIAGNOSTIC_TEST|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes."
219682608|NCT03170817|DRUG|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
219682609|NCT03170817|DRUG|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
219682610|NCT03981146|DRUG|Nivolumab|60 Minute IV Infusion
219682611|NCT00270101|DRUG|epoetin alfa|
219096375|NCT01578148|PROCEDURE|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~1. TENS stimulation (45 minutes):~   • Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~2. Other modalities of PT per the therapist's choice:~   * Infrared treatment on the pain areas (about 15 minutes)~  * Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~  * Exercise and training:~     * Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~    * Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~  * Hot/cold pack to the pain area for about 15 minutes"
219096376|NCT03155932|DRUG|APD334|APD334 active treatment for 24 weeks.
219096377|NCT00737425|DEVICE|PainShield|
219096378|NCT00737425|DEVICE|Sham PainShield|
219096379|NCT05670483|DEVICE|Use Of APRV mode of Ventilation|"Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~1. P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~2. T high at 4-6 seconds~3. P low at 0~4. T low at 0.5 to 0.8 seconds.~5. ATC (automatic tube compensation) on.~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
219096380|NCT05670483|DEVICE|Use of conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode|"Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~1. Tidal Volume 6-8 ml/kg predicted body weight~2. Respiratory rate (RR) 14 /min~3. Positive end expiratory pressure (PEEP)= 5 cmH2o~4. Pressure Support (PS) = 10 cmH2o~5. Inspiratory time 1.4 Sec~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of mechanical ventilation will be done by switching the ventilation to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
219096381|NCT00519701|DRUG|hydroxyurea|
219096382|NCT04285632|OTHER|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
219221932|NCT04800367|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
219221933|NCT06828640|DEVICE|vaginal dilators|Evaluate the efficacy of vaginal dilators as an addition to Standard of Care in premenopausal or menopausal women, including breast cancer survivors
219221934|NCT06204250|DRUG|GS1-144|Oral tablets.
219221935|NCT06204250|DRUG|Placebo|Matching placebo tablets.
219221936|NCT04002661|DRUG|Flibanserin|Flibanserin tablet
219221937|NCT04002661|DRUG|Placebo|Oral Tablet
219221938|NCT06474728|OTHER|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
219221939|NCT06827847|PROCEDURE|Traditional polychromatic layering dental composite technique|patient received composite restoration done by layering technique
219221940|NCT06827847|PROCEDURE|Contemporary monochromatic single shade dental composite technique|patient received composite restoration done by single shade composite
219221941|NCT06047951|PROCEDURE|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc"
219362165|NCT03439150|DIAGNOSTIC_TEST|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
219682612|NCT03569098|BIOLOGICAL|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
219682613|NCT03569098|DRUG|Placebo|Investigators will inject the reconstituted solution into foot muscles.
219682614|NCT04232644|DRUG|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
219682615|NCT04232644|DRUG|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
219682616|NCT01467193|DIETARY_SUPPLEMENT|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
219682617|NCT01467193|OTHER|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
219682618|NCT00758498|DRUG|armodafinil|50 mg/day orally, once daily in the morning for 3 days
219096383|NCT04135157|PROCEDURE|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
219096384|NCT04135157|PROCEDURE|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
219096385|NCT04135157|OTHER|Control|Only general anesthesia will be performed.
219096386|NCT03649620|DIETARY_SUPPLEMENT|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
219096387|NCT03649620|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219096388|NCT02007434|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
219096389|NCT02007434|DRUG|Placebo|Phosphate buffered saline placebo for injection
219096390|NCT02007434|OTHER|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
219096391|NCT02007434|DRUG|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
219096392|NCT02007434|DRUG|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
219096393|NCT02007434|DRUG|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
219096394|NCT02007434|OTHER|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
219096395|NCT05943769|PROCEDURE|Apical microsurgery|inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.
219682619|NCT00758498|DRUG|armodafinil|150 mg/day orally, once daily in the morning for 3 days
219682620|NCT00758498|DRUG|placebo|placebo tablets, once daily in the morning for 3 days
219682621|NCT01288365|BEHAVIORAL|Exercise training|Exercise training program for 3 months (two times a week).
219682622|NCT03939923|DRUG|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
219682623|NCT03939923|DRUG|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
219682624|NCT03939923|DRUG|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
219682625|NCT03939923|DRUG|Sugammadex|Reversal with Sugammadex (2mg/kg)
219096396|NCT01287611|PROCEDURE|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
219096397|NCT01287611|PROCEDURE|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
219096398|NCT06274684|DEVICE|Use of Virtual Reality Assistance during prostate biopsies|Patient will be equipped with VR headset providing a immersive experience during prostate biopsies
219096399|NCT05492526|DEVICE|Ki Monitor without feedback|Physical activity Monitor - No feedback
219096400|NCT05492526|DEVICE|Ki monitor with contextualised data feedback|Physical activity monitor and feedback
219096401|NCT01856712|DRUG|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
219096402|NCT03076476|DEVICE|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
219096403|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
219096404|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
219096405|NCT02541032|PROCEDURE|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
219096406|NCT02541032|PROCEDURE|Standard dental treatment|Supragingival mechanical scaling and polishing.
219096407|NCT02541032|DRUG|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
219096408|NCT05578950|DRUG|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
219682626|NCT01666912|DRUG|Contraceptive implant|
219682627|NCT05720195|DIAGNOSTIC_TEST|ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC
219682628|NCT01516736|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
219682629|NCT01516736|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
219221942|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - S-LPS|In standard laparoscopy (S-LPS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent accesses were carried out in the right and left iliac fossa. In the S-LPS, these accesses are performed using a 5mm trocars. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
219221943|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - PSS|In the MiniLap® Percutaneous Surgical System (PSS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent two accesses were carried out in the right and left iliac fossa. These latter accesses are directly performed using MiniLap® with a 2.4mm incision. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
219096409|NCT05578950|DRUG|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
219221944|NCT05598398|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
219221945|NCT05598398|OTHER|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
219096410|NCT00213655|BIOLOGICAL|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
219096411|NCT03389360|DIAGNOSTIC_TEST|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
219096412|NCT03357263|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
219096413|NCT03357263|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
219096414|NCT02656576|PROCEDURE|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
219096415|NCT02656576|PROCEDURE|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
219096416|NCT04449848|OTHER|Sitting after intra tympanic injection|Sitting after intra tympanic injection
219096417|NCT06097676|DRUG|Placebo|Placebo
219096418|NCT06097676|DRUG|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
219096419|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
219096420|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
219096421|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
219096422|NCT06151990|OTHER|lipid profile|Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting
219096423|NCT03708640|OTHER|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
219096424|NCT03708640|OTHER|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
219096425|NCT03708640|OTHER|Physical Activity Counseling|Group receives baseline counseling on physical activity
219096426|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
219096427|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
219096428|NCT02525003|OTHER|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
219096429|NCT04013100|DIAGNOSTIC_TEST|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
219096430|NCT03745222|DRUG|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
219096431|NCT03745222|DRUG|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
219096432|NCT03745222|OTHER|Placebo|Placebo
219096433|NCT02480595|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
219096434|NCT03299686|DRUG|CJM112|300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
219096435|NCT03299686|OTHER|Placebo to CJM112|Placebo to match CJM112 + standard of care treatment
219221946|NCT06506422|DRUG|Empagliflozin 10 MG|10mg Empagliflozin daily for 12 weeks
219682630|NCT03450759|DRUG|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
219682631|NCT03450759|DRUG|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
219682632|NCT03450759|DRUG|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
219682633|NCT03450759|DRUG|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
219096436|NCT02709005|DRUG|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
219096437|NCT02709005|OTHER|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
219221947|NCT06506422|DRUG|Placebo|10mg Placebo daily for 12 weeks
219682634|NCT04508686|DRUG|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
219682635|NCT00526448|DRUG|ribavirin|2000 mg/day
219682636|NCT00526448|DRUG|ribavirin|1000-1200 mg/day
219096438|NCT04797091|OTHER|Retrospective data collection|Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
219096439|NCT02573025|DRUG|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
219096440|NCT02573025|DRUG|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
219096441|NCT03291886|DRUG|Entinostat|Given PO
219096442|NCT03291886|DRUG|Entinostat(Placebo)|Given PO
219096443|NCT03291886|DRUG|Exemestane|Given PO
219221948|NCT06916637|RADIATION|18F-HER2 Affibody PET scan|HER2 Affibody, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-HER2 Affibody PET scan.
219221949|NCT05819619|DRUG|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
219096444|NCT05240430|DRUG|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
219096445|NCT01291147|DRUG|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
219096446|NCT01291147|DRUG|0.9% Saline|0.9% saline continous infusion for 48 hours
219096447|NCT05549765|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
219221950|NCT05819619|DRUG|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
219221951|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
219096448|NCT05549765|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
219221952|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
219221953|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
219221954|NCT06153693|DRUG|Placebo|Placebo once daily (QD) for 12 weeks
219096449|NCT04879459|OTHER|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
219096450|NCT00259922|DRUG|Placebo|Placebo
219096451|NCT00259922|DRUG|Alvimopan|0.5 mg QD
219096452|NCT00259922|DRUG|Alviompan|0.5 mg BID
219096453|NCT00785317|DRUG|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
219096454|NCT02209012|DRUG|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
219096455|NCT02209012|DRUG|Topical Solution Vehicle|Vehicle PDT given in CP0108
219096456|NCT02209012|DEVICE|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
219096457|NCT02150200|OTHER|shorter hospitalization stay|
219096458|NCT02150200|OTHER|questionnaires|
219096459|NCT05255432|OTHER|nil intervention|Users observation using medical device on manakin, different scenarios per group
219096460|NCT02028559|DEVICE|Propulse 1|Move kidney stones with Propulse 1 device.
219221955|NCT06153693|DRUG|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
219221956|NCT06153693|DRUG|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
219221957|NCT06892769|OTHER|telehealth counseling|Patients in the intervention group will be called every week (for 4 weeks) and will be trained in line with the determined guide and scales will be filled.
219096461|NCT01974037|DIETARY_SUPPLEMENT|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin\_effect subgroups
219096462|NCT01974037|DIETARY_SUPPLEMENT|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt\_effect subgroups
219096463|NCT01064908|DEVICE|OxyMask|Novel vortex oxygen delivery mask
219096464|NCT01959347|PROCEDURE|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
219096465|NCT01959347|OTHER|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
219096466|NCT02813356|DRUG|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
219096467|NCT02813356|DRUG|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
219096468|NCT01121302|DRUG|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
219096469|NCT01121302|DRUG|Placebo|
219096470|NCT01460498|DRUG|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
219096471|NCT01460498|DRUG|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
219096472|NCT01460498|DRUG|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
219096473|NCT03321825|DEVICE|Belotero® Volume Lidocaine|Mode of application: subdermal injection
219096474|NCT05428514|OTHER|Maternity Housing|Receives a bed in the maternity home, wrap-around services, etc.
219096475|NCT05982301|DRUG|Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU|The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
219096476|NCT00860067|BIOLOGICAL|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
219096477|NCT00860067|BIOLOGICAL|FluMist/B/Yamagata|0.2 mL dose at Day 0
219096478|NCT00860067|BIOLOGICAL|FluMist/B/Victoria|0.2 mL dose at Day 0
219096479|NCT01373632|DEVICE|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
219096480|NCT01373632|DEVICE|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
219096481|NCT01455025|DRUG|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
219096482|NCT01282801|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
219096483|NCT01282801|DRUG|Effexor® XR|150 mg Extended-Release Capsule
219096484|NCT04714801|DRUG|adipose derived mesenchymal stromal cells|Intravenous infusion of cells
219096485|NCT04714801|DRUG|Saline|Intravenous infusion of saline
219096486|NCT00927056|PROCEDURE|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
219096487|NCT01988948|OTHER|Various biological sampling|
219096488|NCT00939601|BEHAVIORAL|Motivational Enhancement Therapy|
219096489|NCT00939601|BEHAVIORAL|Educational Counseling|
219096490|NCT00560612|DRUG|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
219096491|NCT00560612|DRUG|Placebo|Placebo: same as paroxetine (active comparator)
219221958|NCT06775405|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
219096492|NCT03346811|DRUG|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
219096493|NCT05590208|PROCEDURE|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
219096494|NCT01379027|BEHAVIORAL|Pure self-help Internet CBT for depression|Internet, CBT, Depression
219096495|NCT01379027|BEHAVIORAL|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
219096496|NCT01379027|BEHAVIORAL|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
219096497|NCT01060553|OTHER|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
219682637|NCT00526448|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
219096498|NCT05927025|PROCEDURE|Hand K-files|It is used for cleaning and shaping root canals.
219221959|NCT06775405|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
219221960|NCT06488274|DIETARY_SUPPLEMENT|New infant formula|The new formula will be given to infants during the 4-month study period.
219221961|NCT06813131|OTHER|Dietary counseling|This intervention uniquely focuses on the frequency of dietitian-led follow-up visits and their impact on metabolic syndrome-related parameters. The study includes three distinct groups with varying levels of follow-up intensity (control, intervention, and intensive intervention).
219221962|NCT06813131|OTHER|calling via telephone|"The intensive intervention group involves weekly diet adherence assessments via phone calls, setting it apart from other studies that typically rely on less frequent or standardized follow-up schedules. This design allows for the evaluation of how consultation frequency influences outcomes such as weight loss, blood sugar levels, lipid profile, and metabolic syndrome components."
219221963|NCT06825377|DIETARY_SUPPLEMENT|Whey protein|Whey protein powder will be provided with nutritional support in both groups if needed to meet the target protein intake.
219221964|NCT04268277|DRUG|Rituximab|100 mg concentrate for solution for infusion
219221965|NCT04268277|DRUG|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
219221966|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
219096499|NCT03263221|PROCEDURE|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
219096500|NCT03640546|BEHAVIORAL|Within My Reach/ Within Our Reach|Relationship education workshops
219096501|NCT01546259|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
219096502|NCT02385019|BIOLOGICAL|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~1. \- Negative selection of CD8 and CD19 cells~2. \- Positive selection of CD25 cells"
219096503|NCT04665011|DEVICE|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
219096504|NCT04665011|DEVICE|Caretaker|non-invasive blood pressure monitor
219096505|NCT01368445|DRUG|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM \& PM)
219096506|NCT01368445|DRUG|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
219096507|NCT01368445|DRUG|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
219096508|NCT00632281|RADIATION|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
219221967|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
219221968|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
219682638|NCT00526448|DRUG|epoetin beta|epoetin beta 450 UI/week
219682639|NCT01697800|DRUG|Tadalafil|
219221969|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
219221970|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
219221971|NCT03036462|DRUG|Iron|i.v. iron administration
219221972|NCT03036462|DRUG|Saline|i.v. NaCl administration
219682640|NCT01697800|DRUG|Placebo|
219682641|NCT03782181|DEVICE|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
219096509|NCT06089122|BIOLOGICAL|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
219096510|NCT04763811|OTHER|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
219682642|NCT04878068|DEVICE|Theram COVID-19 Rapid Antigen Test|The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
219096511|NCT04763811|OTHER|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
219096512|NCT06230614|OTHER|Colistin 1 MU in normal saline 1 ml|Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
219096513|NCT06230614|OTHER|Colistin 1 MU in normal saline 2 ml|Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
219096514|NCT04707196|DRUG|Abemaciclib|Administered orally
219096515|NCT04707196|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
219221973|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
219221974|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
219682643|NCT03289988|OTHER|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
219682644|NCT01587105|BEHAVIORAL|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
219096516|NCT04707196|DRUG|Fulvestrant|Administered intramuscularly
219096517|NCT01862796|BEHAVIORAL|Underfeeding diet|Heart healthy diet with 35% reduced calories
219096518|NCT01862796|BEHAVIORAL|Weight maintaining diet|Heart healthy weight-maintaining diet
219096519|NCT00146601|DRUG|Fulvestrant|
219096520|NCT03604757|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
219096521|NCT03604757|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
219096522|NCT04230655|DIETARY_SUPPLEMENT|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
219096523|NCT04230655|BEHAVIORAL|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
219096524|NCT04230655|DEVICE|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
219096525|NCT04037436|OTHER|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
219682645|NCT01563328|DRUG|DTG|50 mg q24h
219096526|NCT04037436|OTHER|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
219096527|NCT02382718|BIOLOGICAL|FAST fish mCyp c 1|Subcutaneous immunotherapy
219096528|NCT02382718|BIOLOGICAL|Placebo|Subcutaneous immunotherapy
219682646|NCT01563328|DRUG|BCV|800 mg q8h
219682647|NCT01563328|DRUG|TVR|750 mg q8h
219096529|NCT00302432|BEHAVIORAL|Behavior therapy, cigarette holders, Flowers Menthol|
219096530|NCT06038435|BEHAVIORAL|Cognitive Orientation Approach|Cognitive training will be given for the selected occupation
219096531|NCT06038435|BEHAVIORAL|Ayres Sensory Integration Therapy|Sensory integration therapy will be applied.
219221975|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
219221976|NCT01535430|DIAGNOSTIC_TEST|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
219221977|NCT06893523|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients areremoved surgically and concentrated growth factor isplaced in one of the extraction sockets.
219221978|NCT06893523|OTHER|Non-CGF|The other extraction socket is left empty for control purposes.
219221979|NCT06759129|BEHAVIORAL|Immediate-use of a mobile health application until completion|"Participants will use the RomSi app for approximately 14 days, completing all scheduled activities. Throughout the intervention, they will respond to ecological momentary assessments (EMA) designed to evaluate stigma, help-seeking intentions, and suicidal ideation.~The activities within the app will include interactive games aimed at fostering empathy and emotional understanding. Participants will also have continuous access to specialized help contacts to ensure their well-being during the study.~The protocol involves two groups that will receive tailored information based on their specific needs:~1. Individuals with low suicidal ideation and/or self-stigma, who will engage in activities focused on reducing personal stigma.~2. Individuals experiencing suicide bereavement, who will receive support tailored to address their loss and foster resilience.~A follow-up will be carried out one month and three months after the end of the intervention."
219221980|NCT06759129|BEHAVIORAL|Delayed use of a mobile health application until completion|"Participants assigned to the dApp group (delayed use) will not have access to the RomSi app during the first two weeks of the study. During this period, they will complete ecological momentary assessments (EMA) to evaluate stigma, help-seeking intentions, and suicidal ideation, without engaging in the intervention activities associated with the app.~After completing this initial control phase, participants in the dAPP group will begin using the RomSi app, following the same protocol as the iAPP group. This includes interactive activities, such as games designed to foster empathy and understanding, along with continuous access to specialized help contacts.~This crossover design allows for the immediate effects of the intervention to be compared between groups, while also evaluating changes in pre- and post-intervention measures across both conditions.~A follow-up will be carried out one month and three months after the end of the intervention."
219221981|NCT05810285|DEVICE|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
219221982|NCT06113536|DIAGNOSTIC_TEST|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
219221983|NCT06715514|DRUG|GLP-1 Receptor Agonist|Wegovy®
219221984|NCT06715514|DRUG|Menopausal Hormone Therapy|Estradot® and Utrogestan®\* (in women with intact uterus\*)
219221985|NCT03633604|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
219221986|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
219221987|NCT02520544|DEVICE|Accolade stem|Total hip replacement
219221988|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
219221989|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
219221990|NCT05799794|BEHAVIORAL|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
219221991|NCT06938230|BEHAVIORAL|Health Education Initiative|Participants will receive a one time 45 minute intervention session. During the session participants will receive information regarding COVID-19 disease process and behavioral effects and had the opportunity to ask questions.
219221992|NCT06344156|DRUG|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
219682648|NCT02049736|DRUG|Telbivudine|
219682649|NCT00848900|BEHAVIORAL|Outdoor activity|Adding 1 hour outdoor time into school curricula
219096532|NCT03151681|DRUG|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
219096533|NCT04130139|OTHER|oocyte pick up simulator|oocyte pick up simulation
219096534|NCT01446484|BIOLOGICAL|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
219096535|NCT01446484|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
219096536|NCT01446484|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
219096537|NCT01446484|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
219096538|NCT01446484|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
219096539|NCT01446484|DRUG|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
219096540|NCT01446484|DRUG|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
219096541|NCT01446484|PROCEDURE|Kidney transplantation|Living related kidney transplantation
219096542|NCT02816086|OTHER|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
219682650|NCT01569945|DRUG|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
219682651|NCT01569945|DRUG|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
219682652|NCT00689962|DEVICE|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
219682653|NCT00689962|DEVICE|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
219682654|NCT00005916|DRUG|rV-PSA|
219682655|NCT00005916|DRUG|rF-PSA|
219682656|NCT00005916|DRUG|rV-B7.1|
219096543|NCT02138669|DEVICE|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
219096544|NCT00232960|PROCEDURE|Radiotherapy 50 Gy|
219096545|NCT03150498|DRUG|BTD-001|BTD-001 in fed vs fasted state
219096546|NCT02377037|OTHER|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
219096547|NCT01218529|DRUG|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
219096548|NCT03911453|DRUG|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
219096549|NCT03919370|OTHER|No intervention|there will be NO intervention
219096550|NCT04829383|DRUG|Atezolizumab|1,200 mg
219096551|NCT04829383|DRUG|Bevacizumab|15 mg/kg
219096552|NCT04630496|BEHAVIORAL|Fitbit|Electronic activity tracker
219096553|NCT06066086|PROCEDURE|A hinge flap will be performed to reinforce the buccal advancement flap to close the oroantral fistula at the most posterior area of the maxilla|The hinge flap is raised via circular incision around the oral side of the oroantral fistula then sutured with purse suture to close the sinus membrane perforation and it is used as an additional layer that reinforce the buccal advancement flap
219096554|NCT06066086|PROCEDURE|An anteriorly based palatal flap will be performed to close the oroantral fistula at the most posterior area of the maxilla|Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
219096555|NCT04422093|DEVICE|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
219096556|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
219096557|NCT05852223|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200mg Q3W will be administered via IV infusion for 2 courses from the date of randomization until to the date of thyroidectomy.
219096558|NCT06250946|DRUG|HRS-7535;Placebo|HRS-7535;Placebo
219096559|NCT06250946|DRUG|Placebo|Placebo
219096560|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
219096561|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
219096562|NCT01226901|DRUG|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
219096563|NCT02034708|DRUG|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
219221993|NCT06944197|OTHER|Standard Care Guidance Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist from the primary and community care service at the Primary Care Center. During the session, participants will be provided with an informational guide focused on the management of post-stroke conditions, as well as health promotion and secondary prevention strategies relevant to stroke recovery.~The document provided is titled Guide for People Affected by Cerebrovascular Disease, Their Families, and Caregivers, published in 2022 by the Department of Health of the Generalitat de Catalunya in collaboration with the Stroke Foundation. This group serves as the control group, as the intervention closely resembles the standard care currently implemented across Primary Care Centers in Catalonia for individuals in the chronic phase of stroke recovery."
219682657|NCT02726789|DRUG|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
219096564|NCT02034708|DRUG|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
219682658|NCT02726789|DRUG|pegylated interferon|immunotherapy
219682659|NCT02726789|DRUG|entecavir|local generic entecavir
219682660|NCT01510821|OTHER|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
219682661|NCT01510821|OTHER|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
219682662|NCT01781208|DEVICE|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
219096565|NCT02716337|DIETARY_SUPPLEMENT|Addition of human milk fortifiers according to human milk analysis|
219096566|NCT01382329|BIOLOGICAL|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
219096567|NCT06293209|DEVICE|3M cold pack|3M cold pack
219096568|NCT06293209|DEVICE|Perskindol cold spray|Perskindol cold spray
219096569|NCT06293209|DEVICE|Placebo|Placebo
219096570|NCT04309084|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
219096571|NCT02708225|BEHAVIORAL|medical clown|a medical clown will assist the child during the performance of pulmonary function test
219096572|NCT03790761|BEHAVIORAL|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
219096573|NCT00683709|BEHAVIORAL|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
219096574|NCT00683709|BEHAVIORAL|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
219221994|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Document Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist at the Primary Care Center. During the session, the Home-Based Therapeutic Exercise Program document will be explained and provided. This document outlines an exercise program to be followed over a 10-week period, with a frequency of three sessions per week.~The explanatory document includes three weekly exercise charts covering a total of 30 sessions. Each session is clearly described with detailed instructions to ensure proper execution, including dosage specifications such as repetitions, sets, and load. A checklist template is also included to help participants track their progress and completed activities.~The exercise program consists of strength exercises targeting the major muscle groups of the lower extremities (LE), upper extremities (UE), and trunk; stretching exercises focused on the most relevant flexor muscles of the lower and upper extremities; and exercises aimed"
219221995|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Telerehabilitation Group|"Participants will have an individual consultation with a physiotherapist at the Primary Care Center, where an individualized therapeutic exercise program will be explained. The program spans 10 weeks with three sessions per week (totaling 30 sessions) and is delivered through the Physitrack telerehabilitation platform.~They will receive the Guide for the Use of the Physitrack Telerehabilitation Platform, which provides all necessary information for effective platform use. A brief tutorial will be given during the consultation to ensure familiarity with the tool.~The program mirrors the Therapeutic Exercise Document Group program, but with weekly progress monitoring via the platform. This allows the physiotherapist to adjust exercises or load based on progress. The platform also enables direct communication between participants and the physiotherapist, offering continuous support throughout the intervention."
219221996|NCT06951763|OTHER|stretching exrcise|The participants will receive stretching exercises program for 45 minutes, 3 days/week for 4 weeks.
219221997|NCT06951763|OTHER|myofascial release|The participants will receive the same stretching exercises program in addition to myofascial release of cesarean scar, abdominal fascia, diaphragm and psoas muscle for 30 minutes session twice a week for two weeks.
219221998|NCT06036316|BEHAVIORAL|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
219221999|NCT06036316|BEHAVIORAL|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
219222000|NCT06036316|BEHAVIORAL|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
219222001|NCT06036316|COMBINATION_PRODUCT|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
219222002|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
219682663|NCT00351585|DRUG|Vildagliptin|
219682664|NCT05118347|OTHER|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
219096575|NCT02144922|DRUG|Pitavastatin|statin
219096576|NCT02144922|OTHER|Control|Life style modification alone
219096577|NCT04419844|PROCEDURE|Tar with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
219096578|NCT00779779|BIOLOGICAL|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
219096579|NCT05699421|OTHER|screening programme|CMV screening during the first trimester of pregnancy and neonatal
219096580|NCT03350100|DIETARY_SUPPLEMENT|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
219096581|NCT04392063|DRUG|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
219096582|NCT02766621|BIOLOGICAL|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
219096583|NCT02766621|DRUG|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
219096584|NCT03091686|BEHAVIORAL|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
219096585|NCT03091686|BEHAVIORAL|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
219096586|NCT03472222|BEHAVIORAL|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
219096587|NCT04961866|DIETARY_SUPPLEMENT|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
219096588|NCT04961866|DIETARY_SUPPLEMENT|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
219096589|NCT00666432|OTHER|This is an observational study model that is family based|This is an observational study model that is family based
219222003|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
219096590|NCT04077255|DRUG|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
219096591|NCT05670925|DRUG|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
219096592|NCT02719990|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
219096593|NCT05801575|DRUG|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
219096594|NCT03169803|DEVICE|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
219096595|NCT00231907|BIOLOGICAL|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
219096596|NCT00231907|BIOLOGICAL|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
219096597|NCT02947438|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
219222004|NCT03896815|DRUG|INCB054329|
219222005|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
219222006|NCT05387564|BEHAVIORAL|SCT Documentation and Disclosure Toolkit (SCT-DD)|A toolkit of implementation strategies
219222007|NCT05941013|DEVICE|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
219222008|NCT00647387|DEVICE|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
219222009|NCT07175155|DEVICE|COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO endoscopy oropharyngeal airway with High-Flow Nasal Cannula Oxygenation in sedated gastrointestinal endoscopy for morbidly obese patients
219222010|NCT07175155|DEVICE|High-Flow Nasal Cannula Oxygenation|In this group, patients use high-flow nasal cannula oxygenation
219222011|NCT03602859|DRUG|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
219222012|NCT03602859|DRUG|Dostarlimab (TSR-042)|Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
219222013|NCT03602859|DRUG|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
219222014|NCT03602859|DRUG|Dostarlimab-Placebo|Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
219222015|NCT03602859|DRUG|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
219222016|NCT07190105|OTHER|Sonocea Sonic Augmentation Technology (SAT)|The Sonocea Sonic Augmentation Technology (SAT) is a sound-based approach delivered via headphones through a smartphone application. The approach uses music soundscapes that have been standardized in format, intensity and duration.
219222017|NCT07190105|OTHER|Truvaga Electrical Vagus Nerve Stimulator|The Truvaga Electrical Vagus Nerve Stimulator is a general wellness product that sends gentle electrical signals through the skin to stimulate the vagus nerve on the neck.
219222018|NCT07190534|DRUG|Hydroxychloroquine (HCQ)|400 mg orally once daily
219222019|NCT07190534|DRUG|Methotrexate (MTX)|15 mg weekly, orally or subcutaneously (+ concomitant medication: Folic acid 10 mg once weekly, taken 24 hours after MTX)
219222020|NCT07189572|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a medium-potency synthetic corticosteroid. This intervention is administered via a commercially available, metered-dose nasal spray that delivers 55 μg of the active drug per spray. It exerts potent local anti-inflammatory and immunomodulatory effects in the nasal mucosa and Eustachian tube orifice. In this study, it is investigated for the prevention of radiotherapy-induced otitis media with effusion in patients with nasopharyngeal carcinoma.
219222021|NCT07189572|DRUG|Placebo|The placebo nasal spray is specifically formulated to be indistinguishable from the active triamcinolone acetonide nasal spray. It is identical in all physical properties including appearance, scent, taste, packaging, and administration procedure. It contains the same inactive excipients (e.g., preservatives, suspending agents) but does not contain any triamcinolone acetonide or other active pharmaceutical ingredient.
219096598|NCT02947438|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
219096599|NCT06804122|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.
219096600|NCT06247735|DRUG|K-808 (Dose A)|Administered orally once daily
219096601|NCT06247735|DRUG|K-808 (Dose B)|Administered orally once daily
219096602|NCT06247735|DRUG|Placebo|Administered orally once daily
219096603|NCT05741385|DRUG|Caffeine|Caffeine
219096604|NCT05741385|DRUG|Warfarin sodium|Warfarin sodium
219096605|NCT05741385|DRUG|Omeprazole|Omeprazole
219096606|NCT05741385|DRUG|Metoprolol|Metoprolol
219096607|NCT05741385|DRUG|Midazolam|Midazolam
219096608|NCT05365477|BEHAVIORAL|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day
219096609|NCT05365477|DRUG|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
219096610|NCT05365477|BEHAVIORAL|Selective Therapy: Diet|"Diet:~Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements~Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d~Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium \>150mmol Reduce sodium intake to \<2000mg/d~Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
219096611|NCT05365477|DRUG|Selective Therapy: Drug|"Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
219096612|NCT03275974|BIOLOGICAL|Carbon C 11 Glutamine|Given by IV
219096613|NCT03275974|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
219096614|NCT03275974|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219096615|NCT03275974|PROCEDURE|Blood Draw|Undergo venous blood draws
219096616|NCT05098093|DIETARY_SUPPLEMENT|SBE|Hard-shell capsule
219096617|NCT05098093|DIETARY_SUPPLEMENT|DBE|Hard-shell capsule
219096618|NCT05098093|DIETARY_SUPPLEMENT|BP|Hard-shell capsule
219096619|NCT01121042|DRUG|Ondansetron|8mg per day oral capsule
219096620|NCT01121042|DRUG|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
219096621|NCT01057238|OTHER|Intensive Communication System|Regular family meetings once a week, using a standard protocol
219096622|NCT04173455|DRUG|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
219096623|NCT03464487|DIETARY_SUPPLEMENT|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
219096624|NCT01764087|DRUG|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
219096625|NCT00818961|BIOLOGICAL|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
219096626|NCT00818961|BIOLOGICAL|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
219096627|NCT00818961|BIOLOGICAL|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
219682665|NCT01289548|DEVICE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
219682666|NCT03455712|BEHAVIORAL|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
219222022|NCT07189104|BEHAVIORAL|SAGA for Toddlers|SAGA for Toddlers includes training sessions and workshops for the ECEC personnel on the mentalization-based shared reading intervention following the SAGA model. During the intervention shared reading sessions (5-10-minutes each) are held for groups of 2 to 3 children for 10 weeks (at least 3 sessions per week) at the ECEC by the personnel. Caregivers are involved in the intervention via caregiver meetings held at the ECEC by the investigators.
219096628|NCT00818961|DRUG|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
219096629|NCT00818961|DRUG|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
219096630|NCT00818961|DRUG|fludarabine phosphate|For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
219096631|NCT00818961|DRUG|methotrexate|5 mg/m2 administered on days +1, +3 and +6
219096632|NCT00818961|DRUG|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
219096633|NCT00818961|PROCEDURE|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
219096634|NCT01016301|OTHER|Pharmacist service|Medication Review, medication report
219096635|NCT03547401|DEVICE|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
219096636|NCT03547401|DEVICE|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
219096637|NCT01530672|DEVICE|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
219096638|NCT00424125|BEHAVIORAL|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
219096639|NCT00424125|BEHAVIORAL|Control|Usual care.
219096640|NCT00286793|DRUG|AT-101|Oral
219096641|NCT04151225|DRUG|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
219096642|NCT04151225|DRUG|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
219096643|NCT05861128|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
219096644|NCT03619590|OTHER|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
219096645|NCT04658641|DEVICE|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
219096646|NCT05601401|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
219096647|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
219096648|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic. Two different patches were used due to the number of allergens being tested. Each patch can only hold 10 allergens and 14 allergens were tested in patients.
219096649|NCT02650869|DIETARY_SUPPLEMENT|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
219096650|NCT02650869|DIETARY_SUPPLEMENT|Breast milk|Normal breast milk will be given as part of standard care
219096651|NCT02244255|DRUG|FLOMAX® capsules|
219096652|NCT02244255|DRUG|Ascending doses of HYTRIN® capsules|
219096653|NCT02239380|DRUG|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
219096654|NCT06317519|PROCEDURE|Physical Rehabilitation|5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
219096655|NCT06317519|DEVICE|Gait Real-time Analysis Interactive Lab|5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
219096656|NCT04662502|DIETARY_SUPPLEMENT|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month
219096657|NCT03935217|DRUG|Secnidazole|Oral Granules containing secnidazole
219096658|NCT03935217|DRUG|Placebo|Oral Granules of placebo manufactured to mimic secnidazole
219096659|NCT00874653|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
219222023|NCT07190469|DRUG|PQ203|PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.
219096660|NCT01516203|DRUG|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
219096661|NCT01516203|DRUG|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
219096662|NCT02391935|DRUG|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
219096663|NCT02391935|DRUG|Placebo|Cryomedium
219096664|NCT02391935|DEVICE|Sham injection|skin penetration of the needle without injection of liquid
219222024|NCT07191561|DIAGNOSTIC_TEST|Liver biopsy|Biopsy of the liver
219222025|NCT06389110|DRUG|Alleance®|Atropine sulfate 0.01%, ophthalmic solution.
219222026|NCT06389110|DRUG|Placebo|Ophthalmic solution.
219222027|NCT07195747|DIAGNOSTIC_TEST|Creatinine|Renal Function Follow-Up for 5 years
219222028|NCT07195708|DEVICE|Treatment group|The treatment group was the group with the placement of Orbera 365 plus lifestyle management
219222029|NCT07196384|DEVICE|Spectroscopy system|System that measures the fluorescence intensity in tissue in vivo.
219222030|NCT07196384|DRUG|Nivolumab-800CW|Fluorescent tracer
219222031|NCT07196384|DRUG|Durvalumab-680LT|Fluorescent tracer
219222032|NCT07196956|DEVICE|Low-Frequency Electromagnetic Field Therapy (0.5 Hz)|Active electromagnetic field therapy delivered via a PMT Quattro PRO device (Italy, 2002). Settings: 0.5 Hz frequency, 30 mA intensity, applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with a standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training).
219222033|NCT07196956|DEVICE|Placebo Electromagnetic Field Therapy|identical-appearing electromagnetic therapy device with no active field output (placebo/sham). Applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with the identical standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training) as the active EMT group.
219222034|NCT07196332|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
219222035|NCT07196332|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. Treatment begins with learning how to alternately tense and relax 14 major muscle groups, and then to use progressively more efficient tensing-relaxing and passive relaxation exercises, with sessions used to teach techniques and problem-solve barriers to its daily use.
219222036|NCT07196709|DEVICE|high-power laser acupuncture and the exercise program|The experimental group will receive high-power lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises
219222037|NCT07196709|DEVICE|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
219222038|NCT07196072|BEHAVIORAL|MiPAL|MiPAL participants meet with a coach to co-develop a self-directed yoga practice based on individual preferences and limitations.
219682667|NCT04474561|OTHER|Reduced sulfur diet|A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., \> 4 g/d18).
219682668|NCT02262650|DRUG|Telmisartan|
219682669|NCT02262650|DRUG|Clopidogrel|
219682670|NCT00186342|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
219682671|NCT05119127|DEVICE|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
219682672|NCT02458560|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
219682673|NCT01667445|DRUG|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
219682674|NCT01667445|DRUG|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
219682675|NCT03959007|OTHER|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
219682676|NCT03959007|OTHER|Questionnaire|Both arm at 3 times during hospitalization
219096665|NCT01882595|OTHER|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
219096666|NCT01882595|OTHER|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
219222039|NCT07197502|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
219222040|NCT07196592|BEHAVIORAL|Olfactory stimulation|"Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
219222041|NCT07196592|BIOLOGICAL|Temporal Interference,TI|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region."
219222042|NCT07196592|COMBINATION_PRODUCT|Olfactory-TI Stimulation|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region.~Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
219222043|NCT07196592|COMBINATION_PRODUCT|Sham Control|"During stimulation, the parameters were set as follows:~Δf=0Hz (2000Hz vs. 2000Hz) 2mA Stimulation duration: 20min.~Olfactory stimulation were set as follows:~Essential oil types: air. lasting 20 minutes."
219222044|NCT07196761|OTHER|Bowel care advice|"It includes: - Encourage adequate fiber intake (20 to 35 grams) each day.~* Avoid caffeine - containing foods and beverages~* Drink at least 1.5 to 2 liters of water/day~* Proper defecation position such as, sitting with knees higher than hips (use a foot stool or other flat, stable object if necessary) , lean forward and put elbows on knees, relax and bulge out the stomach and straighten the spine"
219222045|NCT07196761|DEVICE|Whole-body vibration|Crazy fit massager (made in China ) with platform surface size (65 cm X 35 cm ) base height 20 cm, heavy-duty motor wattage: 200 - 500 watts, will be used to provide whole body vibration for the participants in the experimental group, for 25 minutes, 3 times per week for 6 weeks.
219222046|NCT07197541|DRUG|Bleomycin Injection|Bleomycin injection treatment group: local injection treatment, once every 4 weeks.
219222047|NCT07197541|DRUG|Pingyangmycin Injection|Pingyangmycin injection treatment group: local injection treatment, once every 4 weeks.
219222048|NCT07196462|DEVICE|3 Minute iTBS to the L DLPFC|Five daily sessions of TMS (iTBS) to the L DLPFC target.
219222049|NCT07196462|DEVICE|One-Minute, Personalized, DMN Targeted CTBS|Personalized, DMN Targeted CTBS to the DMN for one minute, five daily sessions.
219222050|NCT07197671|DRUG|90Y-NM600|NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity
219222051|NCT07195812|DRUG|Dual Antiplatelet (DAPT) Therapy|aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days
219096667|NCT02890914|OTHER|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
219096668|NCT04188236|DEVICE|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
219096669|NCT01127217|DRUG|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
219096670|NCT01127217|DRUG|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
219096671|NCT02932839|DEVICE|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
219096672|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
219096673|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
219096674|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
219222052|NCT07195812|DRUG|Rivaroxaban|Rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily plus clopidogrel 75 mg daily for 30 days
219222053|NCT07195786|PROCEDURE|Expansion-floating Craniotomy|Following craniotomy with bone flap removal, cerebral edema is assessed. The bone flap is then elevated using 2-3 titanium connectors. The elevation height must be sufficient to at least prevent contact between the bone flap and the underlying brain tissue. If cerebral swelling proves less severe than anticipated or begins to subside, the connectors can be loosened minimally invasively after a maximum scalp expansion period of 7-10 days. The elevated bone flap gradually repositions itself. Mild compression is applied using an elastic bandage for fixation, thereby restoring cranial integrity.
219222054|NCT07195786|PROCEDURE|decompressive craniectomy|The patient is placed supine with the head rotated contralaterally. A large retroauricular question-mark incision is made in the scalp. Alternatively, a Kempe incision or preauricular incision may be used according to surgeon preference. Meticulous preservation of the superficial temporal artery (STA) is essential during the procedure to prevent ischemic complications in the flap. After elevating the myocutaneous flap to expose the operative field, a fronto-temporo-parietal craniectomy is performed. For unilateral decompressive craniectomy, the bone window should measure at least 15 × 12 cm, extending inferiorly to the floor of the temporal fossa to ensure adequate decompression.
219096675|NCT01651273|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
219096676|NCT02783222|DRUG|Nab-paclitaxel|comparison of different dosages of drug
219096677|NCT01025622|BIOLOGICAL|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
219096678|NCT02882711|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
219096679|NCT04610216|DEVICE|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
219096680|NCT01595243|BEHAVIORAL|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
219096681|NCT03861858|BEHAVIORAL|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
219096682|NCT02760056|DRUG|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
219096683|NCT02760056|DRUG|Placebo|Patient will receive a matching placebo to take twice daily for one week.
219096684|NCT02339896|BIOLOGICAL|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
219096685|NCT05720585|OTHER|Intervention of mobile health application|According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
219096686|NCT03400501|DRUG|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
219222055|NCT07195786|DRUG|drug conservative therapeutic|Pharmacotherapy for malignant cerebral edema has been implemented according to current guidelines.
219222056|NCT07196098|OTHER|Slow tempo music|Slow tempo music will be played 15 minutes before and during intravitreal injection.
219096687|NCT03400501|DRUG|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
219096688|NCT02887469|DRUG|3% hypertonic saline|The same as above
219096689|NCT02429687|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
219096690|NCT02429687|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
219096691|NCT02429687|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
219096692|NCT02429687|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
219096693|NCT02429687|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
219096694|NCT00001866|PROCEDURE|horizontal muscles of the eye will be cut and then reattached in the same position|
219096695|NCT00184483|PROCEDURE|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
219096696|NCT00184483|PROCEDURE|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
219096697|NCT00344812|DRUG|LAAM. buprenorphine and methadone|
219096698|NCT05085821|DEVICE|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
219096699|NCT05085821|DEVICE|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
219096700|NCT01012570|DRUG|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
219096701|NCT00012038|DRUG|irofulven|
219096702|NCT00133757|DRUG|Bupropion SR|
219096703|NCT03784235|OTHER|18F NaF-PET/CT and cone beam CT scans|Cross sectional measures of 18F NaF-PET/CT and cone beam CT scans
219096704|NCT01333878|BIOLOGICAL|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
219096705|NCT01933971|DRUG|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
219096706|NCT01933971|DRUG|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
219096707|NCT05971901|DIAGNOSTIC_TEST|BV|The use of the BV test, ordered at the discretion of the treating physician
219096708|NCT04705064|DIAGNOSTIC_TEST|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
219096709|NCT01437150|DEVICE|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
219222057|NCT07196202|OTHER|Laid-Back position training|This intervention is a structured training session for pregnant woman on the use of the laid-back breastfeeding position after birth. The training is designed to be delivered in a single, standardized session by the researcher during the last trimester of pregnancy to be applied within the first 24 hours post-cesarean delivery.
219096710|NCT01437150|PROCEDURE|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
219096711|NCT05502614|DEVICE|Neuromodulation|Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
219096712|NCT02126683|DRUG|Hydroxychloroquine|
219096713|NCT04703634|PROCEDURE|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
219096714|NCT06029595|DRUG|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
219096715|NCT06029595|DRUG|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
219096716|NCT04482829|DRUG|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
219096717|NCT04482829|DRUG|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
219096718|NCT04889235|PROCEDURE|Major liver resection|All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
219096719|NCT00956696|DRUG|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
219222058|NCT07196202|OTHER|Standard Postpartum Care|Postpartum mothers who receive structured training and support on the laid-back breastfeeding position
219222059|NCT07196774|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
219222060|NCT07196774|DRUG|Docetaxel injection|Docetaxel injection.
219222061|NCT07196774|DRUG|Trastuzumab Injection|Trastuzumab injection.
219222062|NCT07196774|DRUG|Carboplatin for Injection|Carboplatin for injection.
219222063|NCT07196774|DRUG|Pertuzumab Injection|Pertuzumab injection.
219222064|NCT07197112|DRUG|Gecacitinib|Administer 50 mg twice daily for a minimum of 28 days.
219222065|NCT07196553|DEVICE|Ultrasound|ultrasound examination
219222066|NCT07197710|OTHER|video-guided acupuncture imagery treatment (VGAIT)|Unlike traditional acupuncture, VGAIT can be self-administered and does not require physical needle insertion, making it a practical alternative for patients seeking non-invasive pain management.
219096720|NCT05583214|DRUG|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
219096721|NCT05583214|DRUG|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
219096722|NCT05583214|DRUG|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
219096723|NCT05164874|DEVICE|Mobile Mammography Unit|The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
219096724|NCT02098408|BEHAVIORAL|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
219096725|NCT02098408|BEHAVIORAL|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
219096726|NCT02767583|DEVICE|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
219096727|NCT01255553|RADIATION|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
219096728|NCT04933201|OTHER|Music|Perioperative musical intervention
219096729|NCT04933201|OTHER|Routine perioperative treatment|Routine perioperative treatment
219222067|NCT07197710|OTHER|Education video|Education video about postoperative precautions
219222068|NCT07196059|DIETARY_SUPPLEMENT|Delphinol|Contains maqui berry powder
219222069|NCT07196059|DIETARY_SUPPLEMENT|Placebo|Contains cellulose
219222070|NCT07196358|OTHER|Standard dressing|Intervention Description: Donor site of STSG treated with standard dressing. Wound is cleaned, paraffin gauze applied, covered with gauze pieces and bandaged. Dressing is removed on the 10th post-operative day, or earlier if excessive exudate is present. Pain and wound healing monitored per standard care protoco
219096730|NCT01909570|PROCEDURE|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
219222071|NCT07196358|OTHER|Topical Heparin Dressing|Intervention Description: Donor site of STSG treated with heparin dressing. 5 ml of 5000 IU/ml heparin is diluted in 50 ml normal saline to produce 500 IU/ml concentration. Gauze is soaked in this solution and applied to donor site immediately after graft harvest. Dressing remains in place until 10th post-operative day unless clinical indication requires earlier change. Pain, wound healing, and hypertrophic scarring assessed during follow-up.
219222072|NCT07196826|PROCEDURE|Active Aquatic Therapy|Active Aquatic Therapy involves structured, therapist-guided exercises in a heated hydrotherapy pool (32-34°C). Water buoyancy and resistance reduce spinal load, facilitate movement, and enhance muscle activation. Sessions last 45-60 minutes, 3 times per week for 4 weeks, supervised by licensed physiotherapists. Each session includes warm-up (water marching, arm swings, trunk rotations), main exercises (lumbar spine function, core strengthening, balance, hip abduction, back extensions, aqua walking, arm/leg strengthening), and cool-down (floating, deep breathing, passive stretches). Intensity is monitored using the Borg RPE scale (60-80% max HR). This intervention uniquely uses active engagement in water to reduce pain and improve strength, flexibility, and function, distinguishing it from passive aquatic therapy and land-based physiotherapy.
219222073|NCT07196826|PROCEDURE|Passive Aquatic Therapy|Passive Aquatic Therapy (Watsu) is a therapist-guided, passive aquatic technique performed in a warm hydrotherapy pool (35°C). The patient floats while the therapist gently moves their body in rhythmic, synchronized patterns, providing massage, stretching, joint mobilization, and acupressure. Sessions last 45-60 minutes, 3 times per week for 4 weeks, and include preparation/floating, cradling with passive movements, passive stretching and mobilization, acupressure, and final relaxation. Neck and knee supports are used for comfort. This intervention uniquely emphasizes passive relaxation and gentle mobilization, making it suitable for patients with severe movement limitations, distinguishing it from active aquatic therapy and conventional land-based physiotherapy.
219096731|NCT01909570|PROCEDURE|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
219096732|NCT01862991|OTHER|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
219096733|NCT01862991|DRUG|Misoprostol|400 mcg buccal misoprostol 90 pre-op
219096734|NCT01862991|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
219096735|NCT01862991|DRUG|Mifepristone|200 mcg Mifepristone orally
219096736|NCT03361891|BEHAVIORAL|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
219096737|NCT03720418|DRUG|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
219096738|NCT03720418|OTHER|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
219096739|NCT00332332|BIOLOGICAL|etanercept|etanercept subcutaneous injection
219096740|NCT01108458|DRUG|Pertuzumab|iv, 840 mg, 420 mg
219096741|NCT01108458|DRUG|Erlotinib|PO, 150 mg
219096742|NCT02328703|OTHER|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
219096743|NCT00792558|DRUG|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
219096744|NCT00001064|DRUG|Allogenic Dendritic Cells|
219096745|NCT06015555|BEHAVIORAL|TAMO|TAMO therapy
219096746|NCT06015555|BEHAVIORAL|Postural Control exercises|Postural Control exercises
219096747|NCT02842944|DEVICE|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
219096748|NCT02842944|OTHER|Routine care|Standardized routine care
219096749|NCT02366897|DEVICE|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
219096750|NCT02790073|DRUG|SNF472|SNF472 for calciphylaxis
219096751|NCT01811979|DIETARY_SUPPLEMENT|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
219096752|NCT01811979|DIETARY_SUPPLEMENT|Steril water|steril water plus topical anesthetics
219096753|NCT06445387|OTHER|Virtual Reality Glasses|"Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam."
219096754|NCT06445387|OTHER|Ice Application Group|Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.
219222074|NCT07196826|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy is a land-based intervention for chronic low back pain, delivered in an outpatient physiotherapy clinic. Sessions last 45 minutes, 3 times per week for 4 weeks, and include hot pack application (10-12 min) to reduce stiffness, electrotherapy (TENS/Interferential, 15 min) for pain modulation, and supervised therapeutic exercises (15-20 min) focusing on lumbar mobility, core stability, and spinal strengthening. Exercises include William's flexion, prone press-ups, cat-cow mobilization, hamstring stretches, pelvic tilts, and abdominal bracing. This intervention emphasizes pain reduction, postural control, and strengthening deep abdominal and paraspinal muscles, distinguishing it from passive and active aquatic therapies, and serves as the standard comparator in this crossover study.
219222075|NCT07196410|BIOLOGICAL|KAN-004|Each dose of KAN-004 contains a consortium of bacteria isolated from the stool of healthy donors formulated as a powder in a capsule intended for oral administration
219222076|NCT07197645|DRUG|153Sm-DOTMP|TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.
219222077|NCT07197840|DEVICE|Numen SILK coil embolization system|The Numen SILK coil embolization system is designed to be used in conjunction with the NumenFR detachment system. It consists of two main parts: • Introducer Sheath: The purpose of this sheath is to facilitate the introduction of the coil into the microcatheter. • Coil System: Composed of the pusher and coil implant. The coil is a permanent implant intended to occlude blood flow in vascular abnormalities. The pusher is used to deliver the coil implant to the target lesion. The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries
219222078|NCT07195669|DRUG|Suzetrigine (SUZ)|Used in the course of acute post-operative pain following oral and maxillofacial surgeries
219222079|NCT07195669|DRUG|Norco|Its standard of care
219222080|NCT07195903|DEVICE|Angioplasty or stenting|Jugular Vein Stenting
219222081|NCT07197177|PROCEDURE|regional block|We will infiltrate local anesthesia (Bupivicaine 0.25 %), in pectoral plane vs Erecter spine plane, will observe intraoperative morphine consumption, pain scores and Pacu stay.
219222082|NCT07190560|BIOLOGICAL|plasma transfusion : PC-CHIK-V|plasma transfusion , from donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection
219096755|NCT06445387|OTHER|Control Group|They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
219096756|NCT04170686|BEHAVIORAL|Zemedy App for Irritable Bowel Syndrome|The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
219096757|NCT03328143|DRUG|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
219222083|NCT07195851|OTHER|1.Bare Anatomy Expert Advanced Hair Growth Serum 2.Bare Anatomy Expert Ultra-Smoothing Shampoo 3.Bare Anatomy Expert Ultra-Smoothing Hair Serum 4.Bare Anatomy Expert Ultra-Smoothing Hair Mask|Dose: 0.1 ml of sample solution Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 48 hours.
219096758|NCT05235620|OTHER|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
219096759|NCT03393338|BEHAVIORAL|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
219096760|NCT02542540|OTHER|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
219096761|NCT05445544|OTHER|Observational studies, The diagnosis was preeclampsia|Observational studies, The diagnosis was preeclampsia
219096762|NCT02435368|DRUG|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
219222084|NCT07197203|PROCEDURE|Sacral ESP Block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
219222085|NCT07197203|PROCEDURE|Caudal epidural block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
219222086|NCT07196124|BIOLOGICAL|BCMA/GPRC5D CAR-T|A single infusion of BCMA/GPRC5D CAR-T Injection administered intravenously.
219222087|NCT07197606|DRUG|Placebo|Intravenous injection of placebo
219222088|NCT07197606|DRUG|IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)|Intravenous injection of IxCell hUC-MSC-S
219222089|NCT07196111|BIOLOGICAL|BAFFR CAR-T|A single infusion of BAFFR CAR-T Injection administered intravenously.
219222090|NCT07196475|PROCEDURE|FOCAL LASER ABLATION OF PROSTATE|All monopolar TURP procedures were performed under spinal anaesthesia, whereas all TU-FLAP procedures were conducted under local anaesthesia with intravenous sedation. A single experienced surgical team performed all operations, with each surgeon having completed over 100 similar procedures prior to the study's initiation. Prophylactic antibiotic coverage with a third-generation cephalosporin has been administered at the time of anaesthesia induction. Cases were placed in the lithotomy position, followed by diagnostic urethrocystoscopy. In the TU-FLAP group, a 980 nm diode laser fig(1) by applying end-firing fiber fig(2) was introduced via the side working channel of a 22 Fr cystoscope under local anesthesia. Laser energy was applied at 15 watts for two minutes at multiple sites within the right and left prostatic lobes, approximately 1.5 cm distal to the bladder neck, with 1 cm spacing between punctures. In cases with an enlarged median lobe, one or two additional laser punctures were
219222091|NCT07195825|GENETIC|Injecting BBM-P002 into the bilateral putamen|BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's Disease
219222092|NCT07196293|PROCEDURE|Customized Healing Abutment - bulk fill composite|instead of standard healing abutments , customization was done using bulk fill composite
219222093|NCT07196293|PROCEDURE|customized healing abutments - Bis acryl composite materials|customized healing abutments with bis acryl composite material was used instead of standard healing abutments
219222094|NCT07197437|DEVICE|Hybrid Coat desensitizer|Dental desensitization treatment
219222095|NCT07197437|DEVICE|Single Bond Universal as desensitizer|Dental desensitization treatment
219222096|NCT07196644|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219222097|NCT07197593|OTHER|Calf Raise Test|The study participants perform three single-leg CRTs (tracked by the CRT App) in a fixed sequence: concentric power, eccentric-concentric power and endurance. ATRC/LAS Individuals start with the affected leg, healthy participants with the dominant leg.
219222098|NCT07195864|DRUG|PHMB 0.08%|The study population for this study is patients diagnosed with AK treated with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program.
219222099|NCT07196046|DIETARY_SUPPLEMENT|Supplement 2|A dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
219222100|NCT07196046|DIETARY_SUPPLEMENT|Supplement 3|A third dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
219222101|NCT07196046|DIETARY_SUPPLEMENT|Supplement 1|A dietary supplement administered daily for 14 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
219222102|NCT07196436|DEVICE|Energy Recovery Ventilator|A mechanical ventilation system that exchanges stale indoor air with fresh outdoor air while transferring heat and moisture between the incoming and outgoing air streams
219222103|NCT07196436|DEVICE|Portable Air Cleaner|A standalone home device that filters indoor air to remove particulate matter, allergens, and other pollutants
219222104|NCT07196436|DEVICE|Energy Recovery Ventilator (Sham)|A home-installed ERV unit that operates in recirculation mode only, providing no fresh air exchange or heat/moisture transfer, serving as a placebo for study purposes.
219222105|NCT07196436|DEVICE|Portable Air Cleaner (Sham)|A portable air cleaner that appears to operate like an active unit but does not contain a HEPA filter and does not clean the air, serving as a placebo for study purposes
219222106|NCT07197073|OTHER|Ozonated olive oil|Ozonated olive oil mouthwash will be prepared by Smart Ozone Marvel using by company's ozone. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
219222107|NCT07197073|OTHER|Propolis|Propolis mouthwash will be prepared by using 2% raw propolis, 40 ml flavouring and 0.1 gm coloring agents, 150 ml propylene glycol, and 60 gm sorbitol. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
219222108|NCT07197073|OTHER|Chlorhexidine|The patients were given 0.12% Chlorhexidine. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
219682677|NCT02380404|PROCEDURE|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
219222109|NCT07197788|DEVICE|Endogenex System|The Endogenex System procedure utilizes a catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum.
219222110|NCT07197476|BEHAVIORAL|ASSIST Video Intervention|Video intervention for participants: adolescent trauma patient-parent dyads.
219222111|NCT07197398|OTHER|Spinal block level analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the whole study group will be assessed. Only cases with 12.5mg of hyperbaric bupivacaine will be included.
219222112|NCT07197398|OTHER|Data collection|Intervention is to retrieve and analyse anonymous perioperative data. After identification of eligible cases, statistical analysis will be performed
219222113|NCT07197398|OTHER|Sub-group analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the sub-groups of different height (\<165cm and \>165cm) will also be performed.
219222114|NCT07195656|DEVICE|Device Group|non-implanted, vaginal electrical stimulation device
219222115|NCT07195656|DRUG|Medication Group|OAB Medication
219682678|NCT06086938|DEVICE|active cTBS combined with iTBS|"Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
219096764|NCT00251095|DRUG|Taxol|
219096765|NCT00251095|DRUG|TOCOSOL Paclitaxel|100 mg/m2/week
219096766|NCT03830190|OTHER|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
219096767|NCT00936832|DRUG|FOLFIRI regimen|
219096768|NCT00936832|DRUG|fluorouracil|
219096769|NCT00936832|DRUG|irinotecan hydrochloride|
219096770|NCT00936832|DRUG|leucovorin calcium|
219096771|NCT00936832|DRUG|sunitinib malate|
219096772|NCT00936832|OTHER|laboratory biomarker analysis|
219096773|NCT00936832|OTHER|pharmacogenomic studies|
219096774|NCT00936832|OTHER|pharmacological study|
219096775|NCT05494827|OTHER|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
219096776|NCT05494827|OTHER|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
219096777|NCT05494827|OTHER|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
219096778|NCT00962143|DEVICE|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
219096779|NCT00962143|PROCEDURE|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
219096780|NCT05159323|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging|A novel diffusion-based magnetic resonance imaging method
219096781|NCT02243202|DRUG|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
219096782|NCT02243202|DRUG|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
219096783|NCT02243202|DRUG|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
219096784|NCT02243202|DRUG|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
219096785|NCT02378558|DEVICE|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
219096786|NCT00784433|DIETARY_SUPPLEMENT|alcohol|150 cc
219096787|NCT04728178|OTHER|Crystalloid solution|Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
219096788|NCT04728178|OTHER|Colloid solution|Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
219096789|NCT04773210|DEVICE|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
219222116|NCT07197879|DEVICE|Dynamic office chair (saddle chair with standard pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
219222117|NCT07197879|DEVICE|Dynamic Office Chair (office swivel chair with integrated newly developed pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
219222118|NCT07196566|PROCEDURE|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.
219222119|NCT07197515|BEHAVIORAL|Legal Navigation|• Participants will receive monthly outreach from a trained legal navigator over a 6-month period. The legal navigator is a lawyer (Juris Doctor, or JD) who will proactively address specific legal barriers the patient may encounter during treatment. Communication will include phone calls (and if requested, virtual consultations) tailored to patient needs. In between legal outreach periods, patients may call the legal navigator team themselves for legal needs that may arise.
219222120|NCT07196163|DRUG|Golidocitinib|Golidocitinib will be administered orally as capsules in a 28-day cycle.
219222121|NCT07196163|DRUG|Placebo|Placebo will be administered orally as capsules in a 28-day cycle.
219222122|NCT07195773|DEVICE|rTMS|investigate the effects of repetitive transcranial magnetic stimulation on corticomotor excitability, balance performance, and mobility in patients with Parkinson's disease, and to further explore the effects on corticomotor excitability by single low-frequency and high-frequency repetitive transcranial magnetic stimulation. Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, corticomotor excitability, balance, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
219222123|NCT07195890|OTHER|A course of teen Mental Health First Aid to be provided to participants|The teen Mental Health First Aid course consists of three sessions developed in Mental Health First Aid in Australia. It has been translated and attuned to the Chinese in Hong Kong.
219096790|NCT04773210|DEVICE|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
219096791|NCT04374396|PROCEDURE|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
219222124|NCT07197814|OTHER|Rice formula (New formula based on hydrolysed rice proteins)|Infant formula based on hydrolysed rice proteins.
219222125|NCT07197814|OTHER|Placebo formula|The placebo formula will be the formula the subject is currently successfully fed with as part of his/her diet to eliminate cow's milk proteins.
219222126|NCT02969356|BIOLOGICAL|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
219222127|NCT02969356|OTHER|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
219222128|NCT06035068|DRUG|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
219222129|NCT07196345|DRUG|TAS-102|Administered orally at 35 mg/m²/dose twice daily (morning and evening), in a bi-weekly regimen on Days 1-5.
219222130|NCT07196345|RADIATION|Radiotherapy|Total dose of 50-60 Gy, delivered in 25-28 fractions, administered Monday through Friday (daily) until the full prescribed dose is achieved.
219222131|NCT05562609|DRUG|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
219222132|NCT05562609|OTHER|Placebo|Ampoules and packaging for all arms will be identical in appearance.
219222133|NCT07196189|OTHER|Patients|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the patients eligibility criteria to be verified. If the patient is included, the self-questionnaire will be completed on site and stool collection will be carried out.
219222134|NCT07196189|OTHER|healthy volunteer|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the volunteer's eligibility criteria to be verified. If the volunteer is included, the self-questionnaire will be completed on site and stool collection will be carried out.
219222135|NCT07196800|RADIATION|High intensity laser therapy (low dose) combined with conventional physiotherapy program|840 joules delivered during each session combined with conventional physiotherapy program Participants
219222136|NCT07196800|PROCEDURE|High intensity laser therapy (High dose) combined with conventional physiotherapy program|2632 joules delivered during each session combined with conventional physiotherapy program
219222137|NCT07197827|DRUG|YL242|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.
219222138|NCT07197827|DRUG|YL242; Pembrolizumab|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. Pembrolizumab will be administered subsequent to YL242.
219222139|NCT07197827|DRUG|YL242; 5-FU; LV|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.~LV and 5-FU will be sequentially administered following YL242."
219222140|NCT07197827|DRUG|YL242; Pembrolizumab; 5-FU|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. YL242 will be administered via Intravenous (IV) Infusion.~Pembrolizumab and 5-FU will be administered in sequence after YL242."
219096792|NCT04374396|RADIATION|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
219096793|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
219222141|NCT07196514|DIETARY_SUPPLEMENT|Raw turmeric shots|This group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks.
219222142|NCT07196514|OTHER|Placebo|This group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks.
219222143|NCT07197268|DRUG|nL-ASXL3-001|Personalized antisense oligonucleotide
219222144|NCT07196579|DRUG|KXV01 TCR Lentinvivo Injection|KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.
219682679|NCT06086938|DEVICE|sham cTBS combined with iTBS|"Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
219682680|NCT02738112|DEVICE|Encore System|Hyo-mandibular suspension
219682681|NCT01089842|BEHAVIORAL|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
219682682|NCT01089842|OTHER|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
219682683|NCT03851770|OTHER|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
219096794|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
219096795|NCT02659787|DRUG|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
219096796|NCT02659787|DRUG|Placebo|Placebo
219096797|NCT04860817|BIOLOGICAL|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~1. Dose level one: 0.6×10\^7 cells/kg;~2. Dose level two: 1×10\^7 cells/kg;~3. Dose level three: 1.5×10\^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m\^2×6d, Cyclophosphamide 300 mg/m\^2×6d or Cyclophosphamide 600 mg/m\^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
219096798|NCT00582946|DEVICE|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
219096799|NCT02013388|DRUG|N91115|Given PO daily for 14 days
219096800|NCT02013388|DRUG|Placebo|Given PO daily for 14 days
219096801|NCT02013388|DRUG|N91115|Given PO only on Day 1
219096802|NCT02013388|DRUG|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
219096803|NCT03420924|DEVICE|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
219096804|NCT03420924|DEVICE|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
219096805|NCT04947163|DEVICE|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
219096806|NCT04947163|DEVICE|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
219096807|NCT00542048|DRUG|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
219096808|NCT03243422|OTHER|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
219096809|NCT03243422|OTHER|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
219096810|NCT05897632|BEHAVIORAL|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
219096811|NCT05897632|BEHAVIORAL|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
219096812|NCT02875405|PROCEDURE|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
219096813|NCT04585438|DRUG|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
219096814|NCT02173054|OTHER|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
219096815|NCT02173054|OTHER|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
219096816|NCT02173054|OTHER|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
219096817|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
219096818|NCT04671238|DEVICE|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
219096819|NCT04419402|DRUG|Lu-PSMA|"Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles."
219096820|NCT04419402|DRUG|Enzalutamide|160 mg (four 40 mg capsules) daily.
219096821|NCT00192309|BIOLOGICAL|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
219096822|NCT00192309|BIOLOGICAL|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
219222145|NCT03147287|DRUG|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
219222146|NCT03147287|DRUG|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
219222147|NCT03147287|DRUG|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
219222148|NCT07196423|DEVICE|Transcranial direct current stimulation (tDCS)|2mA anodal stimulation to be delivered for 20 minutes using a Neuroconn DC stimulator PLUS which will be repeated once after a 20-minute break.
219222149|NCT07196423|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Using a 7T Philips scanner with total scanning session lasting no more than 1 hour.
219222150|NCT07197528|BEHAVIORAL|Experimental Arm：Smart-assisted rehabilitation exercise system Control Arm：Usual care or routine physical activity|"Interventions~Behavioral: Smart-assisted rehabilitation exercise system (KNEESUP) A wearable smart-assisted rehabilitation system providing personalized, progressive lower limb resistance training for elderly residents with sarcopenia in long-term care institutions. The system includes real-time monitoring, feedback, and remote adjustment by rehabilitation specialists. Unlike traditional programs, it integrates sensor technology to track knee joint angles and exercise performance, enabling precise and adaptive training.~Other: Usual care / routine physical activity Participants follow standard daily activities and rehabilitation provided by the long-term care facility, without the smart-assisted rehabilitation system."
219222151|NCT07197034|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 50 weeks
219222152|NCT07196241|OTHER|Survey using a questionnaire.|Questionnaires regarding cancer treatment and follow-up care, fertility preservation, clinical trial participation, general information (education on health- related topics, gender, and sexual orientation, perceived needs for resources, support areas, programs and activities.), emotional health and interpersonal relationships, financial burden and mental health status.
219222153|NCT07196527|DEVICE|Puressentiel Allergy Protection Nasal Spray|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
219222154|NCT07196527|DEVICE|Saline spray (0.65%)|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
219222155|NCT07195838|BEHAVIORAL|Hybrid Mindfulness-Based Group Sessions|Eight 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. The sessions cover topics such as the eight yoga's ethical guidelines (yamas and niyamas) for positive lifestyle behaviors, breathing mechanisms, dysfunctional breathing styles, voluntary control of breathing (pranayama), relaxation and sense withdrawal (pratyahara), concentration (dharana), meditation (dhyana), and enlightenment (samadhi). Subsequent sessions will be delivered via videoconferencing using Zoom and will include guided breathing-focused practices.
219222156|NCT07195838|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Personalised mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period. The intervention protocol will cover message content library, regular message delivery and personalised chat-based support.
219222157|NCT07195838|BEHAVIORAL|Single General Education on Pulmonary Rehabilitation and Lifestyle Modification Group|The control group participants will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification based on the GOLD 2024 teaching set and HEARTS technical package for NCD prevention as recommended by the WHO.
219222158|NCT07195838|DEVICE|Activity Monitoring|All participants will wear a wristband activity tracker to monitor their physical activity in daily life.
219222159|NCT07196280|DRUG|5-Alpha Reductase Inhibitors|Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.
219222160|NCT07197138|DEVICE|Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS|iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.
219550289|NCT06687330|DEVICE|Tracking Mobility and Health Data with a Smartwatch in Discharged Oncology Patients to Predict Rehospitalization: A Prospective Study|The intervention involves daily monitoring of discharged oncology patients using a smartwatch (Huawei Watch Fit 2) to track physical activity (step count), heart rate, and sleep duration. Data is collected remotely via a smartphone app, allowing real-time tracking of health metrics post-discharge. This intervention is distinct in its focus on correlating mobility and physiological data with the risk of rehospitalization within a 30-90 day period. Patients will also receive recommendations to maintain daily walking routines as part of their post-discharge care. Additionally, quality of life and sleep quality assessments are conducted before discharge and at follow-up visits to provide a comprehensive overview of each patient's post-hospital recovery.
219096823|NCT00192309|BIOLOGICAL|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
219096824|NCT02543255|DRUG|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
219096825|NCT02543255|DRUG|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
219096826|NCT02543255|DRUG|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
219096827|NCT04050241|DEVICE|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
219096828|NCT04050241|DEVICE|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
219096829|NCT00615732|PROCEDURE|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
219096830|NCT00615732|PROCEDURE|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
219096831|NCT06524011|BIOLOGICAL|Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone|Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
219096832|NCT06118723|PROCEDURE|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
219096833|NCT06118723|PROCEDURE|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
219096834|NCT02273830|DRUG|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
219096835|NCT04228640|OTHER|NMN|Investigational Product
219096836|NCT04228640|OTHER|Placebo|Starch Powder
219096837|NCT03419416|OTHER|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
219096838|NCT00002488|DRUG|cisplatin|
219096839|NCT00002488|DRUG|cyclophosphamide|
219096840|NCT00002488|DRUG|etoposide|
219096841|NCT04943224|DRUG|Trametinib|\< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
219096842|NCT01916655|BEHAVIORAL|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
219222161|NCT07196540|COMBINATION_PRODUCT|Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab|radiotherapy + rmhTNF-NC + tislelizumab
219096843|NCT01916655|BEHAVIORAL|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
219096844|NCT01916655|BEHAVIORAL|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
219222162|NCT07196943|DEVICE|Fully guided static computer-assisted implant surgery (CAIS) for mandibular overdentures using Equator® attachments|Mandibular edentulism will be rehabilitated with implant-supported overdentures using a fully guided static computer-assisted implant surgery (CAIS) protocol. Each patient will receive four implants placed in a quadrilateral configuration (lateral incisor and first premolar regions) under a stereolithographically manufactured surgical guide. Following 3-4 months of osseointegration, definitive mandibular overdentures will be fabricated and retained exclusively with Equator® attachment systems (Rhein 83, Bologna, Italy). Patients will be followed for 3 years to assess implant survival, peri-implant soft tissue health, and marginal bone changes.
219222163|NCT07196371|BEHAVIORAL|Aerobic Training with Blood Flow Restriction|"Participants will undergo a 6-week aerobic training intervention with blood flow restriction applied to the lower limbs.~Blood flow restriction will be applied using a blood pressure cuff set between 60-80% of limb arterial occlusion pressure.~Training will consist of treadmill walking at 40-50% of heart rate reserve (HRR) for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
219222164|NCT07196371|BEHAVIORAL|Standard Aerobic Training|"Participants will follow the same aerobic training protocol as the AT+BFR group but without blood flow restriction.~Training will consist of treadmill walking at 40-50% of HRR for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
219096845|NCT05842655|PROCEDURE|The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth|A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
219096846|NCT02768610|DRUG|Dexmedetomidine|
219096847|NCT02768610|DRUG|Normal Saline|
219096848|NCT01646190|DIETARY_SUPPLEMENT|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
219096849|NCT01646190|PROCEDURE|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
219096850|NCT01646190|BEHAVIORAL|Fasting state after midnight|No preoperative glucose load
219096851|NCT01646190|BEHAVIORAL|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
219096852|NCT01646190|BEHAVIORAL|urinary catheter removal|at POD 1
219096853|NCT01646190|BEHAVIORAL|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
219096854|NCT01646190|BEHAVIORAL|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
219096855|NCT01646190|BEHAVIORAL|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), \>4h out of bed on POD1, \>6h on POD2, complete at POD3
219096856|NCT01646190|OTHER|Preanesthetic medication|Preanesthetic oral medication before surgery
219096857|NCT02401464|DRUG|TAK-536 Tablet|TAK-536 10 mg tablet
219096858|NCT02401464|DRUG|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
219096859|NCT02401464|DRUG|TAK-536 Ganule Formulation|TAK-536 granule formulation
219096860|NCT03611504|DEVICE|Hemospray®|Hemospray® application
219096861|NCT03036384|DRUG|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
219096862|NCT03036384|DRUG|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
219096863|NCT03036384|DRUG|Sufentanil|2.5µg sufentanyl
219222165|NCT07197216|BEHAVIORAL|Tap Trust|Home-based intervention includes tap water testing kits (instructions provided with videos or phone/Zoom), filtration devices if water quality concerns are identified, reusable water bottles and educational materials (handouts and videos), and phone/Zoom sessions with the research team using motivational interviewing.
219222166|NCT07196605|DRUG|Sodium Sivelestat|For enrolled patients, administer intravenous sodium sivelestat as soon as possible (recommended within 2 hours). The daily dosage is 4.8 mg/kg, delivered via continuous infusion with a microinfusion pump or intravenous drip, for a total duration of 5 days
219096864|NCT03036384|DRUG|Morphine|100 µg Morphine
219096865|NCT00864708|DEVICE|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
219096866|NCT04713267|DEVICE|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
219096867|NCT03076541|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
219096868|NCT04963374|OTHER|risk evolution scale|Padua score、Caprini score、Prime score
219096869|NCT02877030|OTHER|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
219096870|NCT02799186|PROCEDURE|blood sample for genetic analysis|
219096871|NCT05576532|DRUG|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
219096872|NCT00695630|DRUG|Flumazenil|2 mL, 0.2 mg SM
219096873|NCT00695630|DRUG|Placebo|2 mL sterile saline SM
219096874|NCT02489032|BEHAVIORAL|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
219096875|NCT02489032|OTHER|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
219096876|NCT01330316|DRUG|BI 201335|BI 201335 for 24 weeks
219096877|NCT01330316|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
219096878|NCT03291743|DEVICE|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
219096879|NCT03356730|DRUG|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
219096880|NCT03356730|OTHER|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
219096881|NCT00777907|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
219096882|NCT00777907|DEVICE|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
219096883|NCT03122054|PROCEDURE|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
219096884|NCT03818789|BEHAVIORAL|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
219096885|NCT03818789|BEHAVIORAL|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
219096886|NCT05140291|OTHER|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
219096887|NCT05140291|OTHER|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
219096888|NCT03852849|BEHAVIORAL|Personal involved intervention strategies|Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
219096889|NCT03852849|DRUG|The dosage of 400mg EFV|The dosage of 400mg EFV will be used in the antiviral therapy.
219096890|NCT02634840|PROCEDURE|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
219096891|NCT03408275|OTHER|None - observational|None - observational
219096892|NCT03381404|DRUG|[14C] MT-8554|14-C MT-8554
219096893|NCT03161366|BIOLOGICAL|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
219096894|NCT03131635|BEHAVIORAL|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
219096895|NCT02609321|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
219096896|NCT02609321|PROCEDURE|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
219096897|NCT00856674|BIOLOGICAL|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
219222167|NCT07196501|DRUG|NBI-1065845|Oral tablet
219222168|NCT07196501|DRUG|Placebo|Oral tablet
219222169|NCT07197866|DRUG|TEV-56286|administered orally
219222170|NCT05192434|BEHAVIORAL|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
219096898|NCT05673629|DRUG|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
219222171|NCT05192434|BEHAVIORAL|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
219096899|NCT05673629|DRUG|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
219096900|NCT05719948|PROCEDURE|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
219096901|NCT03645967|DEVICE|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
219096902|NCT00286208|DRUG|Mifepristone, misoprostol|
219222172|NCT07197723|GENETIC|cheek (buccal) swab|swab sample in person or at home with a mailed test kit and will fill out a survey
219222173|NCT07197723|OTHER|Assessments|about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.
219222174|NCT07197723|OTHER|optional collection of blood|for research testing
219682684|NCT01751750|OTHER|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
219682685|NCT04328909|DEVICE|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
219682686|NCT04328909|OTHER|Control Group|Usual care - No E-Care app will be provided
219682687|NCT03113669|BEHAVIORAL|CBT-GSH|
219096903|NCT03857568|DRUG|SHR0410|drug will be dosed repeatedly
219096904|NCT03857568|DRUG|Placebo|Placebo will be dosed repeatedly
219222175|NCT07197307|DRUG|Loncastuximab Tesirine and Epcoritamab|Combination therapy of loncastuximab tesirine and epcoritamab
219222176|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219682688|NCT01986803|DEVICE|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
219682689|NCT03877146|BEHAVIORAL|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
219682690|NCT04214574|DEVICE|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
219682691|NCT04214574|DEVICE|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
219682692|NCT05707416|DEVICE|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
219682693|NCT05707416|OTHER|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
219682694|NCT01553565|PROCEDURE|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
219682695|NCT00541567|DRUG|ibipinabant|oral, tablet, once daily
219222177|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219222178|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219222179|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219096905|NCT03484455|DEVICE|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
219096906|NCT03484455|DEVICE|Static cold storage|Static cold storage (standard of care)
219096907|NCT06262061|DRUG|Propranolol|20mg oral propranolol BID x 14 days
219096908|NCT06262061|DRUG|Placebo|Placebo pill orally BID x 14 days
219096909|NCT01491139|DRUG|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
219096910|NCT01491139|DRUG|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
219096911|NCT01491139|RADIATION|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
219096912|NCT00170833|DRUG|Everolimus|
219096913|NCT00632957|DIETARY_SUPPLEMENT|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
219096914|NCT00632957|DIETARY_SUPPLEMENT|Placebo|corn/soybean oil capsules 1g/three times daily
219096915|NCT01105702|DRUG|Temozolomide|
219222180|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219096916|NCT01105702|DRUG|Bevacizumab|
219096917|NCT01105702|DRUG|Lithium Carbonate|
219096918|NCT01105702|RADIATION|Radiation|
219096919|NCT03166475|PROCEDURE|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
219096920|NCT00615264|DRUG|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
219096921|NCT00615264|DRUG|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
219096922|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
219096923|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
219096924|NCT04256356|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
219096925|NCT04256356|OTHER|Breastfeeding infants|reference group
219096926|NCT04835714|DRUG|BI 1701963|BI 1701963
219096927|NCT04835714|DRUG|BI 3011441|BI 3011441
219096928|NCT01134601|PROCEDURE|Radiation Therapy|
219096929|NCT01134601|DRUG|Capecitabine|
219096930|NCT01134601|DRUG|AZD6244|
219096931|NCT00577018|DRUG|Prucalopride|4 mg o.d.
219096932|NCT00577018|DRUG|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
219096933|NCT00577018|OTHER|Placebo|o.d.
219096934|NCT00005625|DRUG|trabectedin|
219096935|NCT03725839|DEVICE|F&P Interface|F\&P Interface to be used for OSA therapy
219096936|NCT03841955|DEVICE|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
219096937|NCT03841955|DEVICE|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
219096938|NCT02986490|BIOLOGICAL|Blood sample|Blood sample
219096939|NCT03569696|BIOLOGICAL|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
219096940|NCT02105805|BEHAVIORAL|Dietetic group sessions|Group sessions to improve dietary adherence
219096941|NCT05561777|OTHER|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
219096942|NCT03015506|OTHER|Bread|
219096943|NCT02612480|DRUG|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
219096944|NCT02612480|DRUG|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
219096945|NCT02612480|DRUG|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
219096946|NCT02612480|DRUG|Placebo|7 day treatment with placebo
219096947|NCT01705535|BEHAVIORAL|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
219096948|NCT01705535|OTHER|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
219096949|NCT01705535|BEHAVIORAL|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
219096950|NCT04775238|OTHER|Silver nanoparticles|AgNPs (19±5 nm)
219096951|NCT04775238|OTHER|Copper nanoparticles|CuNPs (150-350 nm)
219096952|NCT02118480|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
219096953|NCT02118480|OTHER|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
219096954|NCT04219098|PROCEDURE|Butterfly IQ|10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
219362166|NCT05976191|BEHAVIORAL|Patients whose blood glucose is measured intravenously and from the fingertip|A satisfaction survey will be conducted after these patients have previously examined their blood glucose via intravenous route, then fingertip blood glucose will be measured and a satisfaction survey will be applied.
219096955|NCT04219098|OTHER|Standard of Care|The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
219096956|NCT03154281|DRUG|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
219222181|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
219222182|NCT07197229|BEHAVIORAL|Pulmonary Rehabilitation|A tailored pulmonary rehabilitation program combining hospital-based and home-based components over 12 weeksParticipants undergo a 12-week structured PR program including both hospital-based sessions (education, structured exercise, nutrition counseling, smoking cessation) and home-based exercises (daily walking, strength training progression
219222183|NCT07197684|DRUG|Ketamine|"Before skin incision, a bolus 0.35 mg/kg ketamine will be given followed by a continuous infusion 0.25 mg/kg/hr.~Ketamine infusion will be stopped 30 minutes before the end of the surgery"
219222184|NCT07197684|PROCEDURE|Pecs block|Pecs block will be performed before surgical incision with the help of an ultrasound (US) by experienced anesthesiologist. The drug used for the pecs block will be two syringes of 10ml and 20 ml containing bupivacaine 0.25% (total 30 ml).
219222185|NCT07197684|DRUG|Nalbuphine|Intravenous Nalbuphine 0.1 mg/kg
219222186|NCT07197684|DRUG|Paracetamol|Intravenous Paracetamol 1g or 15mg/kg (if weight is \< 50kg).
219222187|NCT07196969|DEVICE|Electric toothbrush|Two minutes; twice a day; 3-months.
219222188|NCT07196969|DEVICE|Manual toothbrush|Two minutes; twice a day; 3-months.
219222189|NCT05157581|DEVICE|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
219222190|NCT05157581|DRUG|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
219096957|NCT03154281|DRUG|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
219222191|NCT06148506|OTHER|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
219222192|NCT06148506|OTHER|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
219222193|NCT03614299|OTHER|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
219222194|NCT03614299|DIAGNOSTIC_TEST|Interferometry|Evaluation of the mebomian function using the LipiView methodology
219222195|NCT05986773|DRUG|Furosemide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
219096958|NCT04484714|BEHAVIORAL|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
219222196|NCT05986773|DRUG|Metolazone|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
219222197|NCT05986773|DRUG|Acetazolamide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
219222198|NCT04069754|BEHAVIORAL|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
219222199|NCT04908358|OTHER|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
219222200|NCT04908358|OTHER|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
219222201|NCT05507151|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
219222202|NCT06006117|DRUG|Mosunetuzumab + Lenalidomide|"* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
219222203|NCT06006117|DRUG|- Rituximab + Lenalidomide (28-days cycles|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
219362167|NCT01031446|DRUG|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
219362168|NCT01031446|DRUG|everolimus|Taken daily by mouth.
219362169|NCT01031446|DRUG|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
219222204|NCT06006117|DRUG|- Rituximab + Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
219222205|NCT06006117|DRUG|- Rituximab + CHOP (21-days cycles)|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
219222206|NCT06448624|DRUG|Ampicillin sulbactam 3 days|Ampicillin sulbactam 1.5 gram IV BID for 3 days after CIED implantation
219222207|NCT06448624|DRUG|Placebo 3 days|Placebo for 3 days after CIED implantation
219222208|NCT04986930|RADIATION|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
219222209|NCT04986930|DRUG|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
219096959|NCT03863522|PROCEDURE|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
219096960|NCT03863522|DEVICE|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
219096961|NCT04515121|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
219096962|NCT04515121|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
219096963|NCT04515121|OTHER|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
219222210|NCT04823624|DRUG|MBG453|intravenous infusion
219222211|NCT05395351|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (IV rt-PA)
219222212|NCT05696821|DIAGNOSTIC_TEST|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
219222213|NCT05295108|OTHER|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
219222214|NCT05295108|OTHER|Attention control|informational materials provided to educate on life domains that are important to social health
219222215|NCT06358755|DEVICE|Defocus Incorporated Multiple Segments lenses|Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
219222216|NCT06358755|DEVICE|single vision spectacle lenses|Single vision spectacle lenses will be given to this group of participants.
219682696|NCT00163566|DRUG|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
219682697|NCT06436079|BEHAVIORAL|Intervention group|Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.
219682698|NCT02068638|PROCEDURE|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
219682699|NCT02068638|PROCEDURE|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
219682700|NCT02068638|PROCEDURE|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
219682701|NCT02068638|PROCEDURE|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
219096964|NCT00086541|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
219096965|NCT00032045|BIOLOGICAL|gp100 antigen|
219222217|NCT06358755|DRUG|Low dose atropine|0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
219222218|NCT03945773|DRUG|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
219222219|NCT05176756|BEHAVIORAL|Gamification and Social Support|Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
219222220|NCT05176756|BEHAVIORAL|Attention control|Participants will receive a daily text message with their step count from the day prior.
219222221|NCT06242015|OTHER|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
219222222|NCT06242015|OTHER|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
219096966|NCT00032045|BIOLOGICAL|incomplete Freund's adjuvant|
219096967|NCT00032045|BIOLOGICAL|ipilimumab|
219096968|NCT04887948|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
219096969|NCT04887948|BIOLOGICAL|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
219096970|NCT04887948|OTHER|Saline|Normal saline for injection
219096971|NCT00304512|DRUG|migalastat HCl|
219096972|NCT01637701|PROCEDURE|PkEP|Plasmakinetic enucleation of the prostate
219096973|NCT01637701|PROCEDURE|B-TURP|Bipolar transurethral resection of the prostate
219550290|NCT06685900|DEVICE|digital therapeutics|Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
219096974|NCT03600896|DRUG|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
219096975|NCT06399367|DIAGNOSTIC_TEST|MSOT|The MSOT system used consists of a laser in the visible near-infrared and far-infrared wavelength range (660nm-1300nm) and an ultrasonic sensor connected to a computer. Using optical components, the area to be measured is illuminated with ultra-short light pulses of selectable wavelength. The light is absorbed to varying degrees inside the object - depending on the properties of the tissue. The absorption of light leads to local microscopic volume fluctuations and thereby emits pressure waves in the ultrasonic range (photoacoustic effect). MSOT enables non-invasive, non-ionizing 2D imaging with high spatial resolution (80 μm), which enables specific visualization of endogenous tissue pigments such as collagen fibers, fat, melanin, oxyhemoglobin and deoxyhemoglobin.
219096976|NCT02601898|DEVICE|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
219096977|NCT02601898|DRUG|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
219096978|NCT00638235|DEVICE|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
219096979|NCT00638235|DEVICE|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
219096980|NCT00638235|DEVICE|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
219096981|NCT00638235|DEVICE|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
219096982|NCT00638235|DEVICE|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
219096983|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
219096984|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
219096985|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
219096986|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
219222223|NCT04948645|DRUG|Fosigotifator|Oral
219222224|NCT04948645|DRUG|Placebo|Oral
219222225|NCT02815917|DRUG|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
219222226|NCT03432000|OTHER|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
219222227|NCT06305884|PROCEDURE|Bioelectric Impedance Analysis|Undergo BI
219222228|NCT06305884|OTHER|Exercise|Pedal an exercise bike
219550291|NCT06685900|DEVICE|digital therapeutics|Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
219550292|NCT00240032|DRUG|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
219096987|NCT02714101|OTHER|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
219096988|NCT05817578|DEVICE|Quantitative Sensory Testing / Dynamometry / Goniometry|Testing procedures that follow previously used protocols of the literature for all the Quantitative Sensory Testing, Dynamometry \& Goniometry
219096989|NCT00596596|DRUG|prucalopride|0,5 mg once daily
219096990|NCT00596596|DRUG|prucalopride|1 mg once daily
219222229|NCT06305884|PROCEDURE|Photoplethysmography|Undergo PPG
219222230|NCT06305884|BEHAVIORAL|Questionnaire Administration|Ancillary studies
219222231|NCT02562937|BEHAVIORAL|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
219222232|NCT02714777|DEVICE|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
219222233|NCT06522165|OTHER|Analysis|analysis and review of imaging and clinical data
219222234|NCT04432584|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
219222235|NCT04432584|DRUG|Eculizumab|Eculizumab will be administered at a dose of 900 mg Q2W, as per the dosing schedule described above.
219222236|NCT06840496|DRUG|Bionetide|Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
219222237|NCT06840496|DRUG|Placebo|"Placebo~• Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks"
219222238|NCT05905926|DRUG|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
219096991|NCT00596596|DRUG|2 mg prucalopride|2 mg once daily
219096992|NCT00596596|DRUG|4 mg prucalopride|4 mg once daily
219096993|NCT00596596|OTHER|Placebo|placebo once daily
219222239|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
219222240|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
219222241|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
219222242|NCT02407808|DRUG|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
219222243|NCT02407808|DRUG|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
219222244|NCT06505382|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous neuromodulation|Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
219222245|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
219222246|NCT06296940|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.
219222247|NCT06296940|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
219222248|NCT05472532|PROCEDURE|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors"
219222249|NCT05971979|OTHER|No intervention|No intervention
219222250|NCT04636138|OTHER|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
219222251|NCT05255172|OTHER|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
219362170|NCT01031446|OTHER|laboratory biomarker analysis|Blood collection
219222252|NCT05091255|PROCEDURE|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
219222253|NCT02278796|DRUG|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
219222254|NCT02278796|DRUG|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
219222255|NCT05923684|BEHAVIORAL|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
219096994|NCT04731415|DEVICE|Optical coherence tomography and optical coherence tomography angiography (Optovue®)|"Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
219096995|NCT05688735|OTHER|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
219222256|NCT06358625|OTHER|Pre-treatment biopsy|"A breast biopsy is performed just before the clip is placed in the tumour and additional blood samples are performed."
219222257|NCT05980507|DRUG|ICI201|ICI201 CAR-T cell injection
219222258|NCT02021396|PROCEDURE|Embolization|this arm of the study was interventional (splenic artery embolization)
219222259|NCT05650125|OTHER|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
219222260|NCT03983642|DEVICE|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
219222261|NCT06642584|DRUG|Semaglutide B|Semaglutide B will be administered subcutaneously.
219222262|NCT06642584|DRUG|Semaglutide J|Semaglutide J will be administered as oral tablets.
219222263|NCT06642584|DRUG|Semaglutide L|Semaglutide L will be administered as oral tablets.
219222264|NCT06642584|DRUG|Semaglutide M|Semaglutide M will be administered as oral tablets.
219222265|NCT06642584|DRUG|Semaglutide N|Semaglutide N will be administered as oral tablets.
219222266|NCT05868837|DRUG|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
219222267|NCT05868837|OTHER|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
219222268|NCT06417008|DRUG|HS-20117|Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
219222269|NCT06417008|DRUG|Aumolertinib|110 mg orally once daily.
219222270|NCT04363112|BEHAVIORAL|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
219222271|NCT01270282|DRUG|AM-101 0.81 mg/mL|
219222272|NCT01270282|DRUG|Placebo|
219222273|NCT04388865|BEHAVIORAL|Control|Subjects will engage with their providers as is standard of care.
219096996|NCT05688735|OTHER|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
219096997|NCT01336881|GENETIC|RNA analysis|
219096998|NCT01336881|GENETIC|gene expression analysis|
219222274|NCT04388865|BEHAVIORAL|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
219222275|NCT01724905|DIETARY_SUPPLEMENT|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
219222276|NCT01724905|DIETARY_SUPPLEMENT|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
219222277|NCT05964023|DEVICE|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
219222278|NCT05964023|DEVICE|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
219222279|NCT05917236|PROCEDURE|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
219222280|NCT06159959|DRUG|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
219362171|NCT00993746|DRUG|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
219362172|NCT00993746|DRUG|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
219362173|NCT06000293|OTHER|Oral health education|Anticipatory Guidance (AG) provided to the primary caregivers-infant pairs in the intervention group
219096999|NCT01336881|GENETIC|microarray analysis|
219222281|NCT04707170|DEVICE|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
219097000|NCT01336881|GENETIC|nucleic acid sequencing|
219097001|NCT01336881|OTHER|diagnostic laboratory biomarker analysis|
219097002|NCT01488708|DRUG|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
219222282|NCT05608070|DRUG|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
219222283|NCT05608070|DRUG|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
219222284|NCT00387075|PROCEDURE|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
219222285|NCT00387075|DRUG|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
219222286|NCT02824198|BIOLOGICAL|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
219097003|NCT01488708|DRUG|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
219097004|NCT03146832|BEHAVIORAL|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
219097005|NCT03146832|BEHAVIORAL|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
219097006|NCT00389181|PROCEDURE|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
219222287|NCT02824198|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
219222288|NCT02893969|BEHAVIORAL|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
219222289|NCT02893969|BEHAVIORAL|Rest|Complete physical rest until asymptomatic.
219222290|NCT01255514|DRUG|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
219222291|NCT01673399|DRUG|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
219222292|NCT01673399|DRUG|placebo|
219362174|NCT04100330|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
219362175|NCT04100330|DRUG|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
219222293|NCT04061759|OTHER|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
219222294|NCT00252005|DRUG|Apixaban|
219222295|NCT04895670|BEHAVIORAL|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
219222296|NCT04788810|OTHER|Administration of d12-Cl2BPA|Administration of d12-Cl2BPA
219222297|NCT01681823|DIETARY_SUPPLEMENT|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
219222298|NCT02108574|DEVICE|Placebo Filter|
219222299|NCT02108574|DEVICE|Rhinix Nasal Filter|
219222300|NCT00942344|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
219222301|NCT00942344|DRUG|Amlodipine|amlodipine 5mg, 10mg
219222302|NCT00942344|DRUG|Losartan|Losartan 50mg, 100mg
219222303|NCT05135234|BEHAVIORAL|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
219222304|NCT01227746|PROCEDURE|Tumor biopsies|
219097007|NCT00389181|OTHER|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
219097008|NCT04219618|DEVICE|Off-Pump|After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
219097009|NCT04219618|DEVICE|On-Pump|A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
219222305|NCT01613417|DRUG|gadoteridol|ProHance 0.1 mmol/kg
219222306|NCT01613417|DRUG|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
219222307|NCT01801800|PROCEDURE|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
219222308|NCT01223274|DEVICE|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
219222309|NCT01223274|DEVICE|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
219222310|NCT01784328|DEVICE|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
219222311|NCT06297057|OTHER|Neurophysiological Recordings|"Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound."
219097010|NCT00873665|OTHER|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
219097011|NCT00873665|OTHER|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
219097012|NCT06013501|BEHAVIORAL|puppet show|puppet show to the child before and during subcutaneous application
219097013|NCT04609124|DIAGNOSTIC_TEST|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
219097014|NCT00570024|PROCEDURE|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
219097015|NCT00570024|PROCEDURE|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
219097016|NCT03767725|BIOLOGICAL|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
219097017|NCT06019689|BEHAVIORAL|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
219222312|NCT05786872|DEVICE|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
219097018|NCT01313611|DRUG|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
219097019|NCT06025630|DRUG|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
219097020|NCT06025630|DRUG|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
219097021|NCT01945567|DEVICE|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
219222313|NCT00512252|DRUG|AMD3100|
219097022|NCT01945567|DEVICE|Empirical unblinded deep brain stimulation programming|
219097023|NCT02426723|DRUG|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
219097024|NCT02426723|DRUG|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
219097025|NCT04384822|BEHAVIORAL|Tai Chi Group|Mind-body exercise intervention
219222314|NCT00512252|DRUG|Mitoxantrone|
219222315|NCT00512252|DRUG|Etoposide|
219222316|NCT00512252|DRUG|Cytarabine|
219222317|NCT00790699|DEVICE|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
219222318|NCT00790699|OTHER|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
219097026|NCT04384822|BEHAVIORAL|CBT-I Group|First-line clinically recommended non-pharmacological treatment of insomnia
219097027|NCT01872637|BEHAVIORAL|Progressive Multi-Component Intervention|
219097028|NCT01872637|BEHAVIORAL|Usual Care|
219097029|NCT00069602|DEVICE|Continuous Glucose Monitoring System (CGMS)|
219097030|NCT00069602|DEVICE|GlucoWatch G2TM Biographer (GW2B)|
219097031|NCT03680664|DEVICE|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
219097032|NCT03680664|OTHER|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
219222319|NCT04412005|OTHER|No intervention|No intervention
219222320|NCT00729898|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219222321|NCT05884515|DIAGNOSTIC_TEST|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
219222322|NCT06092476|DEVICE|Revita® DMR Treatment|"The Revita® System is an endoscopic treatment consisting of a single catheter and console designed to lift the duodenal mucosa with saline followed by controlled circumferential hydrothermal ablation of the mucosa. For this study Revita® DMR procedure will be conducted as follows:~DMR Treatment Paradigm 1- After initial 2 Lift and Ablate step, remaining Lift: Ablate steps will be conducted in 1:1 manner."
219222323|NCT06092476|OTHER|Sham procedure|The sham control for the Revita DMR procedure.
219222324|NCT00296790|DRUG|zolpidem tartrate|
219222325|NCT03844685|DRUG|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
219097033|NCT03680664|BEHAVIORAL|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
219097034|NCT03953963|DEVICE|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
219097035|NCT01971164|DRUG|JTZ-951|Subjects will receive JTZ-951 or Placebo
219097036|NCT01971164|DRUG|Placebo|
219097037|NCT00314067|PROCEDURE|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
219097038|NCT00314067|PROCEDURE|Physician training|
219097039|NCT00314067|PROCEDURE|Practice team training|
219222326|NCT03844685|DRUG|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
219097040|NCT03802864|DRUG|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
219097041|NCT03802864|DRUG|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
219097042|NCT02569437|DRUG|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
219097043|NCT02569437|DRUG|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
219097044|NCT02569437|DRUG|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
219222327|NCT06272591|OTHER|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
219097045|NCT02569437|DRUG|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
219097046|NCT02569437|DRUG|sugar pill|placebo pill to match doxycycline
219097047|NCT05359783|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
219097048|NCT00325221|DEVICE|HM on|Home Monitoring activated after implantation
219222328|NCT06272591|OTHER|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
219222329|NCT06272591|OTHER|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
219222330|NCT06272591|OTHER|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
219222331|NCT00220532|DRUG|Folic acid with riboflavin|
219222332|NCT05416476|DRUG|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
219222333|NCT05416476|DRUG|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
219222334|NCT02708394|DRUG|olanzapine|atypical antipsychotic
219682702|NCT04088669|OTHER|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
219222335|NCT02708394|DRUG|placebo|placebo control
219362176|NCT05932550|DRUG|Maraviroc 300 mg|10 week treatment as add-on therapy to anti-depressants
219362177|NCT05033496|DIAGNOSTIC_TEST|Thyroid function test|Thyroid function test
219362178|NCT01447108|DEVICE|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
219097049|NCT00325221|DEVICE|HM Off|Home Monitoring activated 9 months after implantation
219097050|NCT06460558|OTHER|Type 1 diabetes with insulin infusion system|No intervention
219097051|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
219097052|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
219097053|NCT05028426|PROCEDURE|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
219097054|NCT02070068|DEVICE|PINPOINT System|
219097055|NCT04392778|BIOLOGICAL|MSC Treatment|"Protocol length: 1 week~Doses:~1. Application: 3 million cells/kg IV-------------------------------------------------0 day~2. Application: 3 million cells/kg IV ------------------------------------------------3rd day~3. Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
219097056|NCT04392778|BIOLOGICAL|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
219222336|NCT01046292|DRUG|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
219222337|NCT02745990|DRUG|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
219222338|NCT02745990|DRUG|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
219222339|NCT04654390|DRUG|DWP16001 Amg|Tablets, Orally, Once daily
219222340|NCT00364975|BEHAVIORAL|gourmet cooking workshop|
219097057|NCT00509834|DRUG|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
219097058|NCT00509834|DRUG|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
219222341|NCT04274790|PROCEDURE|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
219222342|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
219222343|NCT04242524|BEHAVIORAL|Circadian Clock Alignment|Use timed lights and meals to align the circadian clock
219222344|NCT04242524|BEHAVIORAL|Circadian Clock Control|No circadian clock alignment
219222345|NCT05300672|DRUG|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
219222346|NCT00599196|DRUG|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
219222347|NCT00703352|DRUG|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
219222348|NCT02683174|DEVICE|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
219222349|NCT02683174|BIOLOGICAL|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
219222350|NCT04038190|BEHAVIORAL|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
219097059|NCT00509834|DRUG|Placebo|Placebo
219097060|NCT01993459|DRUG|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
219097061|NCT01993459|DRUG|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
219222351|NCT05488405|DRUG|Mesalamine Oral Product|Mesalamine oral suspension for oral use
219097062|NCT04492319|DRUG|Control Test|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
219097063|NCT04492319|DRUG|Neostigmine|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml neostigmine 500 μg in each side .
219097064|NCT05596513|OTHER|motor learning and occupational therapy|"1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)"
219097065|NCT05596513|OTHER|Motor Learning Approaches From Working on a Vertical Surface|"1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls"
219097066|NCT02024035|RADIATION|Radiotherapy|
219097067|NCT04065100|DIAGNOSTIC_TEST|Sebum test|Measuring sebum in newborn
219097068|NCT01078480|PROCEDURE|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
219097069|NCT01078480|PROCEDURE|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
219222352|NCT03912909|DRUG|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
219362179|NCT04693962|DIAGNOSTIC_TEST|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
219550293|NCT00240032|DRUG|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
219550294|NCT05513196|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
219550295|NCT06559280|DRUG|esketamine|During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
219550296|NCT00874276|DRUG|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
219097070|NCT01448564|OTHER|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
219097071|NCT01448564|OTHER|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
219097072|NCT00804401|DRUG|Naproxen Tablets, 500 mg|
219097073|NCT03788538|DRUG|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
219097074|NCT05782049|OTHER|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
219097075|NCT05782049|OTHER|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
219097076|NCT05782049|OTHER|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
219097077|NCT01546792|BEHAVIORAL|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
219097078|NCT00897130|DRUG|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
219097079|NCT04437095|OTHER|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
219097080|NCT05619874|BEHAVIORAL|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
219097081|NCT05619874|BEHAVIORAL|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
219097082|NCT04496999|DRUG|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
219097083|NCT04496999|DRUG|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
219097084|NCT04131530|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
219097085|NCT05817266|DEVICE|Field-cycling imaging (FCI)|FCI scan
219097086|NCT02932059|BEHAVIORAL|Metamemory|Metamemory evaluation using a sentence construction strategy
219097087|NCT05254548|DRUG|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
219097088|NCT05254548|DRUG|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
219097089|NCT05254548|DRUG|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
219097090|NCT05254548|DRUG|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
219097091|NCT05276232|DRUG|Cannabis(THC) inhaled|Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
219097092|NCT02769234|PROCEDURE|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
219097093|NCT02769234|PROCEDURE|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
219097094|NCT02498353|RADIATION|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
219222353|NCT03912909|DRUG|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
219097095|NCT02498353|RADIATION|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
219097096|NCT02498353|PROCEDURE|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
219097097|NCT03738839|DEVICE|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
219097098|NCT03738839|PROCEDURE|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
219097099|NCT03738839|PROCEDURE|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
219097100|NCT02459821|OTHER|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
219097101|NCT02459821|OTHER|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
219097102|NCT03535064|OTHER|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
219097103|NCT02500329|DRUG|Gemigliptin|Gemigliptin for 4 weeks
219097104|NCT02500329|DRUG|Acarbose|Acarbose for 4 weeks
219097105|NCT05996666|DEVICE|Liver-cancer early detection test|Blood collection and liver-cancer early detection test
219097106|NCT03298282|OTHER|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
219222354|NCT01894399|DRUG|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
219222355|NCT06961305|DEVICE|Cross-linked Hyaluronic Acid Gel|This intervention involves the injection of Alexa Medium, a sterile, cross-linked hyaluronic acid gel (17.5 mg/mL). The gel is administered into the mucous membrane of the lips for aesthetic restoration of lip volume loss. The product is supplied in a pre-filled 1 mL syringe and injected by a trained medical professional. One or two injections were administered per participant, with the second injection performed at the investigator's discretion at Visit 2. The device is manufactured by Diaco Biofarmaceutici S.r.l., Italy.
219222356|NCT01204996|DRUG|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
219222357|NCT01204996|DRUG|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
219682703|NCT04088669|OTHER|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
219682704|NCT03791801|DRUG|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
219682705|NCT03791801|DRUG|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
219097107|NCT03298282|OTHER|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
219097108|NCT03298282|OTHER|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
219097109|NCT01145807|DRUG|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
219682706|NCT03791801|DRUG|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
219682707|NCT03791801|DRUG|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
219222358|NCT01204996|DRUG|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
219682708|NCT03205293|BEHAVIORAL|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
219682709|NCT02683239|DRUG|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
219682710|NCT02683239|DRUG|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
219682711|NCT03846544|DRUG|Corifollitoropin alfa (CFA)-double pick up|In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
219682712|NCT00320060|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
219682713|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 800 mg/day|FADA is given twice a day (total dose of 800 per day per patient)
219682714|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 2000 mg/day|FADA is given twice a day (total dose of 2000 per day per patient)
219222359|NCT01204996|DRUG|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
219222360|NCT03311880|BEHAVIORAL|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
219222361|NCT00849238|DRUG|mycophenolate mofetil|
219222362|NCT03819543|DEVICE|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
219222363|NCT02220452|OTHER|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
219222364|NCT02220452|OTHER|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
219222365|NCT01517503|BEHAVIORAL|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
219682715|NCT05033925|OTHER|Placebo capsule|Placebo capsule is given twice a day
219097110|NCT01145807|DRUG|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
219097111|NCT01145807|DRUG|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
219097112|NCT02796430|OTHER|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
219097113|NCT02796430|OTHER|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
219097114|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
219097115|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
219097116|NCT01677702|DIETARY_SUPPLEMENT|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
219097117|NCT00677443|DRUG|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
219097118|NCT00677443|DRUG|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
219097119|NCT04885270|DRUG|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
219097120|NCT06103084|DIETARY_SUPPLEMENT|Bahgina|Bahgina, a locally produced cereal based food, will be provided at 200g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
219097121|NCT06103084|DIETARY_SUPPLEMENT|SQLNS|Small quantity lipid based nutrient supplement (SQ-LNS) will be provided at 20g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
219097122|NCT01770301|DRUG|Paclitaxel|
219097123|NCT01770301|DRUG|Bevacizumab|
219097124|NCT04028310|OTHER|Phonological|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
219097125|NCT04028310|OTHER|Visual-attention|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
219097126|NCT05102123|DRUG|Cytisine|Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
219097127|NCT05102123|BEHAVIORAL|Video Messaging|Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
219682716|NCT05948137|DIAGNOSTIC_TEST|F-18 FDOPA PET/CT|Nuclear medicine imaging modalities
219682717|NCT04797507|DRUG|SHR-1210 plus Anlotinib|SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
219682718|NCT01610856|DRUG|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
219682719|NCT01610856|DRUG|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
219682720|NCT00629759|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
219682721|NCT01967771|DRUG|DTG|DTG will be supplied as 50 mg tablet to be administered orally
219682722|NCT01967771|DRUG|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
219097128|NCT00708435|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
219097129|NCT00708435|BIOLOGICAL|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
219097130|NCT01683162|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
219097131|NCT01683162|DRUG|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
219097132|NCT01683162|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
219097133|NCT05301062|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
219097134|NCT00978965|GENETIC|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
219097135|NCT04703296|BEHAVIORAL|MBAT course|"The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete."
219097136|NCT01433523|DRUG|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
219097137|NCT01433523|DRUG|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
219097138|NCT01433523|DRUG|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
219097139|NCT05713201|PROCEDURE|Percutaneous Coronary Intervention|Treatment of coronary stenoses with a drug-eluting stent or balloon
219097140|NCT05550363|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
219097141|NCT05550363|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
219097142|NCT02924324|DEVICE|propofol|
219097143|NCT02924324|DRUG|ropivacaine|
219097144|NCT02924324|BEHAVIORAL|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
219097145|NCT02924324|BEHAVIORAL|Post-procedural quality of life (QOL)|
219097146|NCT02672501|DRUG|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
219097147|NCT02756832|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
219097148|NCT01040390|DRUG|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
219097149|NCT02836158|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
219097150|NCT03615781|PROCEDURE|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
219097151|NCT03615781|PROCEDURE|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
219097152|NCT03615781|DRUG|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
219097153|NCT03615781|DRUG|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
219097154|NCT05157074|BEHAVIORAL|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
219097155|NCT05384925|OTHER|comparison|abdominal surgery as a risk factor for diverticulosis
219097156|NCT00294099|BIOLOGICAL|Aluminum hydroxide|Aluminum hydroxide adjuvant.
219097157|NCT00294099|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
219222366|NCT01517503|BEHAVIORAL|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
219097158|NCT01364597|DRUG|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
219097159|NCT02013596|OTHER|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
219097160|NCT02013596|OTHER|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
219222367|NCT03246750|DRUG|B-MAD chemotherapy|B-MAD chemotherapy
219097161|NCT01498822|DRUG|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
219097162|NCT01498822|DRUG|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
219097163|NCT03262558|OTHER|No intervention|Patients will undergo standard clinical routine practice in this indication
219097164|NCT04597502|DIETARY_SUPPLEMENT|Terminalia Chebula fruit extract|Oral TC fruit extract supplement taken by mouth twice per day
219097165|NCT04597502|DIETARY_SUPPLEMENT|Placebo|Oral placebo taken by mouth twice per day
219097166|NCT04597502|OTHER|Topical Terminalia Chebula|Applied to both forearms and dorsal hands
219097167|NCT04597502|OTHER|Topical Placebo|Applied to both forearms and dorsal hands
219222368|NCT05283018|DEVICE|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
219222369|NCT05283018|OTHER|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
219097168|NCT05497427|DEVICE|BrainCheck Assessment|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
219097169|NCT03884504|DEVICE|Ventricular Assist Device System|Ventricular Assist Device System
219097170|NCT04078360|BEHAVIORAL|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~1. Self awareness messages~2. Self reflection messages~3. Motivational messages~4. Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~5. Health education messages~6. Personalized feedback and information~7. Help-seeking resources~8. Goal setting messages"
219097171|NCT04078360|BEHAVIORAL|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
219097172|NCT04078360|BEHAVIORAL|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
219097173|NCT05507658|DRUG|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles."
219097174|NCT05351619|PROCEDURE|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
219097175|NCT06304662|OTHER|Yoga intervention|Over 12 weeks, students will attend 50-minute yoga sessions twice a week. Sessions start with 10 minutes of mindful breathing and gentle warm-up movements, followed by 30 minutes of tailored yoga postures for relaxation and stretching. Students progress from basic to advanced postures, with adaptations for individual needs. Each session ends with a guided meditation for inner calm. A 10-minute cool-down encourages deep relaxation. Emphasis is on stress reduction, flexibility, and mindfulness, tailored to university life challenges. Continuous assessment ensures sessions meet students' evolving needs and optimize yoga's benefits in the university setting.
219097176|NCT01566630|DRUG|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
219097177|NCT01566630|DRUG|RLX030|RLX030 1 mg/mL vials
219222370|NCT05283018|DEVICE|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
219222371|NCT05283018|DEVICE|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
219222372|NCT02798900|OTHER|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
219222373|NCT02798900|DEVICE|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
219222374|NCT00431054|DRUG|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
219222375|NCT00431054|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour every 4 weeks
219222376|NCT02301806|OTHER|dieting|
219222377|NCT02301806|DRUG|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
219222378|NCT02301806|DRUG|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
219222379|NCT01824225|DRUG|Aflibercept|
219222380|NCT01379651|OTHER|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
219222381|NCT02160119|OTHER|MRI-based techniques|fMRI, DTI
219222382|NCT02160119|OTHER|EEG|ERP
219097178|NCT03579290|BEHAVIORAL|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~* Understanding and changing patterns of drug use,~* Coping with craving,~* Substance refusal skills,~* Seemingly irrelevant decisions,~* Planning for emergencies, and~* Problem-solving skills.~* Staying Safe"
219222383|NCT05985265|PROCEDURE|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
219222384|NCT03775252|DIETARY_SUPPLEMENT|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
219222385|NCT00224835|BEHAVIORAL|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
219222386|NCT00224835|BEHAVIORAL|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
219222387|NCT00252382|DRUG|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
219222388|NCT04097509|BIOLOGICAL|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
219097179|NCT04173767|DEVICE|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated \& humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
219097180|NCT06133114|DRUG|Clonazepam|0.5 mg twice a day (1 mg a day)
219097181|NCT06133114|DRUG|Olanzapine|2.5 mg once a day of Olanzapine
219097182|NCT06133114|DRUG|Buprenorphine|2 mg once a day of Buprenorphine
219222389|NCT04097509|BIOLOGICAL|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
219222390|NCT04097509|OTHER|control|no application
219222391|NCT02522104|DRUG|Siklos|
219222392|NCT01545583|DRUG|LY3016859 intravenous|Administered intravenously
219222393|NCT01545583|DRUG|Placebo intravenous|Administered intravenously
219222394|NCT01545583|DRUG|LY3016859 subcutaneous|Administered subcutaneously
219222395|NCT01545583|DRUG|Placebo subcutaneous|Administered subcutaneously
219222396|NCT03489811|OTHER|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219222397|NCT03489811|OTHER|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
219222398|NCT03489811|OTHER|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
219222399|NCT04839809|DRUG|CC-92480|Oral
219222400|NCT04839809|OTHER|Placebo|Oral
219222401|NCT01989052|DRUG|CTO|
219222402|NCT01989052|DRUG|Lomustine|
219222403|NCT01747538|DRUG|Placebo|Solution for subcutaneous injection
219222404|NCT01747538|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
219682723|NCT06194162|DEVICE|Weighted blanket|"The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
219682724|NCT06194162|DEVICE|Non-weighted blanket|"The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
219682725|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery -\> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
219222405|NCT01747538|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
219222406|NCT03314259|DRUG|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
219222407|NCT03314259|DRUG|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
219097183|NCT01908322|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
219097184|NCT03131960|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
219097185|NCT03131960|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
219097186|NCT01361373|DRUG|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
219222408|NCT04497415|OTHER|Video-Based intervention|Three minutes video of a nurse that shares her personal story
219097187|NCT01361373|DRUG|placebo|placebo for 2 weeks
219097188|NCT05486442|BEHAVIORAL|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
219097189|NCT02768415|DRUG|Apatinib|
219097190|NCT02768415|DRUG|Oral Vinorelbine|
219097191|NCT03579914|DRUG|intravenous Placebo|Patients receive intravenous Placebo (saline) injection
219097192|NCT03579914|DRUG|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
219097193|NCT03579914|DEVICE|Romote Ischemic Conditioning (RIC)|Patients receive RIC treatment
219097194|NCT03579914|COMBINATION_PRODUCT|Metoprolol & RIC|Patients receive Metoprolol \& RIC treatment
219097195|NCT05649345|DRUG|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
219097196|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
219097197|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
219097198|NCT03139396|PROCEDURE|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
219097199|NCT02390427|DRUG|Taselisib|
219097200|NCT02390427|DRUG|Trastuzumab emtansine|
219097201|NCT02390427|DRUG|Pertuzumab|
219097202|NCT02390427|DRUG|Trastuzumab|
219097203|NCT02390427|DRUG|Paclitaxel|
219222409|NCT03813524|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
219222410|NCT03944200|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
219222411|NCT03944200|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar."
219097204|NCT01457105|DEVICE|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
219097205|NCT02232841|DEVICE|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
219097206|NCT02232841|DEVICE|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
219097207|NCT02481375|DIETARY_SUPPLEMENT|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
219097208|NCT02481375|DIETARY_SUPPLEMENT|Iron|12-wk supplementation of iron
219222412|NCT01354145|DRUG|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
219097209|NCT02481375|DIETARY_SUPPLEMENT|Placebo|12-wk supplementation of placebo
219222413|NCT01354145|DRUG|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
219097210|NCT00896428|DRUG|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
219097211|NCT00896428|DRUG|Placebo.|1 tablet morning and evening for 12 months
219097212|NCT01674621|DRUG|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Active Patch
219097213|NCT01674621|DRUG|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Active Patch
219097214|NCT01674621|DRUG|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Active Patch
219097215|NCT01674621|DRUG|Abaloparatide Injection (80 mcg)|Abaloparatide Subcutaneous Injection
219097216|NCT01674621|DRUG|Abaloparatide Placebo|Abaloparatide Transdermal Microneedle Placebo Patch
219097217|NCT02566798|DRUG|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
219097218|NCT02566798|DRUG|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
219097219|NCT01583439|DRUG|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
219097220|NCT04586413|OTHER|No intervention - quality of life measure|Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
219097221|NCT02166957|PROCEDURE|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
219097222|NCT04241692|DEVICE|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
219222414|NCT03703414|DIAGNOSTIC_TEST|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
219097223|NCT04241692|DEVICE|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
219097224|NCT02006875|DEVICE|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
219097225|NCT05565794|DRUG|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
219097226|NCT05824390|DRUG|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
219097227|NCT01148862|DEVICE|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
219097228|NCT06051487|OTHER|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
219097229|NCT02474290|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
219222415|NCT00734578|DRUG|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
219222416|NCT00734578|DRUG|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
219222417|NCT00734578|DRUG|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
219222418|NCT03735459|BEHAVIORAL|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
219222419|NCT06829199|BIOLOGICAL|Pembrolizumab|Neoadjuvant therapy - 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 24 weeks Adjuvant therapy - 200 mg IV infusion Q3W or 400 mg IV infusion every 6 weeks (Q6W) for up to approximately 30 weeks.
219222420|NCT06829199|DRUG|Paclitaxel|80 mg/m\^2 by IV infusion every week for up to 12 weeks.
219222421|NCT06829199|DRUG|Carboplatin|AUC 1.5 mg/mL/min by IV infusion every week for up to 12 weeks.
219222422|NCT06829199|DRUG|Doxorubicin (hydrochloride)|60 mg/m\^2 by IV infusion Q3W for up to 12 weeks.
219097230|NCT05300802|DRUG|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
219222423|NCT06829199|BIOLOGICAL|Boserolimab|30 mg by IV infusion every 6 weeks (Q6W) for up to 12 Weeks.
219222424|NCT06829199|DRUG|Epirubicin Hydrochloride|90 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
219222425|NCT06829199|DRUG|Cyclophosphamide|600 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
219222426|NCT06829199|DRUG|Capecitabine|1000 mg/m\^2 to 1250 mg/m\^2 by oral administration twice a day (2 weeks on and 1 week off) for up to approximately 24 weeks.
219222427|NCT06829199|DRUG|Olaparib (if approved/available locally)|300 mg by oral administration twice a day for up to approximately 52 weeks.
219222428|NCT01556594|DRUG|Nasal Glucagon 1 mg|
219222429|NCT01556594|DRUG|Nasal Glucagon 2 mg|
219222430|NCT01556594|DRUG|SC Glucagon|
219222431|NCT01556594|DRUG|Nasal Glucagon 3 mg|
219222432|NCT02085941|DEVICE|Cryoablation|Cryoablation using 17G Galil cryoprobe
219222433|NCT02085941|DEVICE|Biopsy|Biopsy using 18G Temno core biopsy needle
219222434|NCT04169828|DRUG|Methotrexate|Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
219550297|NCT00874276|GENETIC|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
219550298|NCT03967262|BEHAVIORAL|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
219097231|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
219097232|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
219097233|NCT02826369|OTHER|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
219222435|NCT04169828|DRUG|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
219222436|NCT04169828|DRUG|Folic/folinic acid|Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
219222437|NCT04163562|DRUG|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
219222438|NCT04163562|DRUG|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
219222439|NCT06950450|BEHAVIORAL|EMOTİONAL FREE TECHNIQUE|"Intervention Group Procedure Steps:~Pre-Procedure:~Nursing students in the intervention group will be informed about Emotional Freedom Techniques (EFT), and after explaining the purpose and method of the study, their consent will be obtained using the Volunteer Consent Form.~They will be asked to complete the Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI) (state-trait version) forms.~Afterwards, information about EFT will be provided, including how to perform the technique and how to carry out the tapping procedure. After a discussion that is expected to last about 20 minutes, the EFT session will begin. Before the procedure, nursing students will complete the Descriptive Information Form, the State-Trait Anxiety Inventory (STAI-I), and the VAS score forms.~1\. EFT Procedure Sequence: Nursing students who meet the inclusion criteria, including first-year nursing students with no previous clinical experience, will have an initial meeting before their first clinic"
219222440|NCT05418868|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
219682726|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
219097234|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
219097235|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
219097236|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
219097237|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
219097238|NCT02873819|DRUG|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
219097239|NCT02873819|DRUG|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
219097240|NCT02873819|DRUG|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
219682727|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
219097241|NCT02873819|DRUG|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
219097242|NCT02873819|DRUG|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
219097243|NCT03735563|DRUG|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
219097244|NCT03735563|DRUG|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
219097245|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
219097246|NCT05533528|PROCEDURE|periodontal surgery|A sulcular incision will be made in the affected teeth, followed by an incision from the buccal aspect in the mid-portion of the interproximal tissues The buccal and lingual flaps will be elevated. For periodontal granulation tissue preservation group, the soft tissues covering the alveolar crest will be prepared. A third incision will separate the pocket epithelium from the soft tissue (granulation tissue) attached to the bone. The pocket epithelium will be removed. The root surfaces will be carefully scaled and planed in both groups. Ethylenediaminetetraacetic acid (24%) will be applied to the root surfaces and removed after 2 minutes with abundant saline solution. In the experimental group, the preserved attached soft tissue and the space between it and the root surface will be irrigated with 10% polyvinylpyrrolidone-iodine. Finally, the flaps will be positioned and sutured.
219097247|NCT06145048|DRUG|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
219097248|NCT04474522|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
219097249|NCT00581373|OTHER|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
219097250|NCT04074200|PROCEDURE|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
219222441|NCT05418868|DRUG|Cabotegravir >=400 mg/mL|CAB \>=400 mg/mL will be administered by IM or SC injection.
219222442|NCT05418868|DRUG|Cabotegravir Formulation I|CAB Formulation I will be administered by IM injection.
219222443|NCT05418868|DRUG|CAB Formulation J|CAB Formulation J will be administered by IM injection.
219222444|NCT05418868|DRUG|rHuPH20|rHuPH20 will be administered.
219222445|NCT05418868|DRUG|RPV|RPV will be administered by IM injection.
219222446|NCT06107933|OTHER|Observational only|Exposure to micro and nano plastics
219097251|NCT04074200|PROCEDURE|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
219097252|NCT04074200|DEVICE|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
219097253|NCT06578715|BEHAVIORAL|Emotional Freedom Technique|EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
219222447|NCT05791162|OTHER|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
219222448|NCT05791162|OTHER|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
219222449|NCT03168750|DEVICE|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
219222450|NCT05462912|DEVICE|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
219222451|NCT06554431|BEHAVIORAL|Self-Driven Repetitive Artmaking|Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
219222452|NCT04812314|BEHAVIORAL|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
219222453|NCT04812314|BEHAVIORAL|No exercise|Participants will remain sedentary throughout the duration of the study.
219222454|NCT06478290|COMBINATION_PRODUCT|curcumin, omega-3, and vitamin D (COD)|Combination of curcumin, omega-3, and vitamin D supplements (COD). Theracurmin Double Strength/Natural Factors Canada 180 mg/day (oral, 3 tablets of 60 mg taken by mouth) Vitamin D: 2000 IU/day LipoMicel/Natural Factors Canada (oral, 1 tablet taken by mouth) Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
219222455|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
219222456|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
219222457|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
219222458|NCT04566861|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
219222459|NCT05590494|PROCEDURE|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
219362180|NCT03320122|OTHER|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
219097254|NCT06576921|DRUG|Serplulimab Combined With Chemotherapy|Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
219097255|NCT06576921|DRUG|Placebo combined with Chemotherapy|Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
219097256|NCT03485677|DRUG|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
219097257|NCT03485677|DRUG|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
219097258|NCT05306093|DIETARY_SUPPLEMENT|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
219097259|NCT05306093|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
219097260|NCT00895622|RADIATION|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
219097261|NCT00895622|RADIATION|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
219097262|NCT04842162|DRUG|indocyanine green|indocyanine green (INFRACYANINE© 25mg/10mL).
219097263|NCT05028153|DRUG|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
219097264|NCT05028153|OTHER|Placebo mixture|Placebo mixture containing no active substance
219097265|NCT04084977|DIAGNOSTIC_TEST|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
219097266|NCT02206022|DRUG|Remifentanil|Pain's evaluation for Remifentanil Group
219097267|NCT02206022|DRUG|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
219097268|NCT03331133|OTHER|No intervention|
219097269|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
219097270|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Experimental|
219097271|NCT04892784|DEVICE|Press tack needle acupuncture|Pyonex press tack needle sized 0.20x1.2mm
219097272|NCT00076960|DRUG|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
219097273|NCT03297931|DIETARY_SUPPLEMENT|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
219097274|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + hummus|Novel pulse chip + pulse spread
219097275|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
219097276|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
219097277|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
219097278|NCT03297931|DIETARY_SUPPLEMENT|Corn chips + hummus|Non-pulse chip + pulse spread
219097279|NCT03156634|OTHER|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
219097280|NCT03156634|OTHER|WebMD|WebMD is an internet based health information source.
219097281|NCT03724396|BEHAVIORAL|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
219362181|NCT03320122|OTHER|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
219097282|NCT03724396|BEHAVIORAL|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
219097283|NCT06437197|PROCEDURE|Pulpotomy|Removal of the coronal pulp chamber in an adult teeth
219097284|NCT03609346|DEVICE|PCI|The placement of 1 or more stents in the diseased coronary artery lesion(s).
219097285|NCT05525936|DIAGNOSTIC_TEST|Echocardiography and central venous pressure|To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
219097286|NCT05706545|DIAGNOSTIC_TEST|Acquisition of cardiovascular signals and microcirculation sidestream darkfield images|ECG, arterial pressure and peripheral flow velocity via a percutaneous laser doppler will be acquired together with images of the sublingual microcirculation detected with sidestream darkfield images microscope
219362182|NCT03320122|OTHER|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
219362183|NCT02447848|DRUG|sufentanil sublingual 30 mcg tablet|
219097287|NCT00823654|OTHER|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
219097288|NCT00823654|OTHER|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
219362184|NCT03302273|OTHER|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
219362185|NCT02109341|DRUG|Paclitaxel bound albumine|
219097289|NCT00387582|DRUG|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
219362186|NCT00692211|OTHER|Mailed fecal occult blood tests|Stool blood test
219682728|NCT05276206|DRUG|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
219097290|NCT00387582|PROCEDURE|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
219097291|NCT02770781|OTHER|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
219097292|NCT02386657|OTHER|Satisfaction|Satisfaction questionnaire to be filled in
219097293|NCT02386657|OTHER|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
219097294|NCT02386657|OTHER|Pain management|Validated pain scale questionnaire to be filled in
219362187|NCT00692211|OTHER|Mailed fecal immunochemical tests|Stool blood test
219362188|NCT03737773|OTHER|glasses (prismatic lenses)|
219362189|NCT03737773|OTHER|glasses (neutral)|
219362190|NCT06237894|OTHER|Multisensory Stimulation|Multisensory Stimulation
219222460|NCT05596994|DEVICE|Lighting Intervention Therapy|The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.
219222461|NCT05596994|DEVICE|Sham LIT|A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
219097295|NCT03045848|DEVICE|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
219222462|NCT00504023|DRUG|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
219222463|NCT00504023|PROCEDURE|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
219222464|NCT00504023|PROCEDURE|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
219222465|NCT01562834|DRUG|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
219222466|NCT01562834|DRUG|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
219222467|NCT04652726|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
219222468|NCT04652726|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
219222469|NCT04174339|DRUG|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
219222470|NCT04174339|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
219222471|NCT04174339|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
219222472|NCT02157116|DRUG|cisplatin|
219097296|NCT02721576|DRUG|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
219097297|NCT01490125|DRUG|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
219097298|NCT01490125|DRUG|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
219097299|NCT01490125|DRUG|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
219097300|NCT01490125|DRUG|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
219097301|NCT01490125|DRUG|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
219097302|NCT01160874|OTHER|Polysomnography|Sleep study monitoring
219097303|NCT01160874|OTHER|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
219097304|NCT01160874|BEHAVIORAL|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
219097305|NCT01160874|OTHER|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
219097306|NCT06064864|DRUG|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
219097307|NCT04616014|DRUG|ORMD-0801 QD|16 mg, QD, two capsules, 8 mg each.
219097308|NCT03060798|DRUG|Desflurane|general anesthesia using desflurane.
219097309|NCT03060798|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
219097310|NCT02889666|DRUG|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219222473|NCT02157116|DRUG|Docetaxel|
219222474|NCT02157116|DRUG|Pegfilgrastim|
219222475|NCT04739137|DIAGNOSTIC_TEST|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
219222476|NCT04739137|DIAGNOSTIC_TEST|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
219222477|NCT00370383|DRUG|Erlotinib|erlotinib 150 mg/day once daily
219097311|NCT02889666|DRUG|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219222478|NCT00370383|DRUG|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
219097312|NCT02889666|DRUG|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219097313|NCT02889666|DRUG|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219097314|NCT02889666|DRUG|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219097315|NCT02889666|DRUG|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219097316|NCT02889666|DRUG|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
219097317|NCT02889666|DRUG|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
219097318|NCT03517423|DRUG|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
219097319|NCT02507778|DEVICE|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
219097320|NCT02237508|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
219097321|NCT02237508|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
219097322|NCT02237508|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
219097323|NCT02237508|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
219097324|NCT06363825|DRUG|camrelizumab|"TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge."
219097325|NCT01320930|BEHAVIORAL|Pulmonary rehabilitation|
219097326|NCT01320930|BEHAVIORAL|conventional care|
219097327|NCT06434792|DRUG|Bronpass Tab.|Twice daily for 12 weeks
219097328|NCT06434792|OTHER|Placebo|Twice daily for 12 weeks
219097329|NCT04260477|DRUG|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
219097330|NCT04260477|DRUG|6EHRZ|"Recommended normal dose adults (WHO, 2003)~* H: 5 (4-6) mg/kg/day~* R: 10 (8-12) mg/kg/day~* Z: 25 (20-30)mg/kg/day~* E: 15 (15-18)mg/kg/day"
219097331|NCT06071026|DEVICE|Net Ultra Filtration Rate|The net ultra filtration rate is modified every 6 hours accordingly to randomisation
219222479|NCT00093496|DRUG|gemcitabine hydrochloride|Given IV
219222480|NCT00093496|DRUG|tanespimycin|Given IV
219222481|NCT04115423|DRUG|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
219222482|NCT04115423|DRUG|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
219222483|NCT01370928|DEVICE|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
219222484|NCT01370928|DEVICE|Standard colonoscope|Screening colonoscopy
219222485|NCT03936192|DRUG|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
219097332|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
219097333|NCT04967963|PROCEDURE|HAM|Transplantation of HAM
219097334|NCT06679309|OTHER|Integrated care plan|Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services
219097335|NCT06584175|BEHAVIORAL|Internet Delivered Cognitive Behavioural Therapy|The tinnitus ICBT program consists of 1) an overview of tinnitus, depression, and anxiety; 2) managing unhelpful thoughts and learning problem solving strategies association with pain, anxiety, depression, and disability; 3) management of common symptoms associated with tinnitus, anxiety, and depression; 4) developing strategies to maintain activities while minimizing fatigue; and 5) strategies to improve quality of life through effective goal setting. Supplementary lessons can be accessed at any time (e.g., sleep, communication, problem solving, assertiveness training). Materials are presented in a didactic (i.e., text-based and audio with visual images) and case-enhanced learning format (i.e., stories demonstrate the application of skills). Case vignettes that specifically reflect the experiences of those with tinnitus are included.
219097336|NCT04201106|BEHAVIORAL|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
219097337|NCT04201106|BEHAVIORAL|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
219097338|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
219097339|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
219097340|NCT05550415|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
219097341|NCT05550415|DRUG|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
219097342|NCT04954586|OTHER|Pain Informed Movement|Participants will attend a twice weekly exercise program.
219097343|NCT05590884|DRUG|Gadopiclenol|Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
219097344|NCT05840081|OTHER|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
219097345|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
219097346|NCT04997317|DRUG|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
219222486|NCT03936192|DRUG|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
219222487|NCT03936192|DRUG|Placebos|Placebo administered once daily for 12 weeks.
219222488|NCT03187678|DRUG|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
219222489|NCT03187678|DRUG|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
219362191|NCT04625127|DEVICE|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
219097347|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
219097348|NCT04000594|DRUG|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
219097349|NCT06133842|DIAGNOSTIC_TEST|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
219097350|NCT03513003|DEVICE|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
219097351|NCT03513003|BEHAVIORAL|Stop habit|Children stop the use of their pacifier and/or baby bottle
219097352|NCT05899179|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein|"Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1\. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
219097353|NCT05899179|BIOLOGICAL|Purified Protein Derivative of Tuberculin|"Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method."
219097354|NCT06120803|DRUG|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
219097355|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
219097356|NCT04754139|OTHER|WeChat mobile mini-application|Sexual health education and the role of PrEP
219097357|NCT03301012|OTHER|Recovery support as usual|same as arm
219097358|NCT03301012|OTHER|Smartphone assisted relapse prevention|same as arm
219097359|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
219097360|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
219097361|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
219097362|NCT04522180|DRUG|GHR-LRX|GHR-LRX was administered by SC injection.
219097363|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
219097364|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
219097365|NCT04705467|DEVICE|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
219097366|NCT01905046|DRUG|metformin hydrochloride|given PO
219097367|NCT01905046|OTHER|placebo|given PO
219097368|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
219682729|NCT01240499|OTHER|Health-At-Every-Size (HAES)|"1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
219097369|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
219097370|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
219097371|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
219097372|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
219097373|NCT06334042|DIAGNOSTIC_TEST|Serum Chromium Level|Measuring serum chromium levels from patients who admitted in intensive care unit.
219222490|NCT04811924|DRUG|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
219097374|NCT05885282|DEVICE|paraspinal vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
219097375|NCT05885282|DEVICE|gastrosoleus muscle complex vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
219097376|NCT05885282|OTHER|Control Exercise|Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
219097377|NCT03489057|BEHAVIORAL|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
219097378|NCT03489057|BEHAVIORAL|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
219097379|NCT03267680|DRUG|Cyclophosphamide|Given IV
219097380|NCT03267680|DRUG|Indomethacin|Given PO
219097381|NCT03267680|BIOLOGICAL|IRX-2|Given via submucosal injection or SC
219097382|NCT03267680|OTHER|Laboratory Biomarker Analysis|Correlative studies
219097383|NCT03267680|DIETARY_SUPPLEMENT|Multivitamin|Given zinc-containing multivitamin PO
219097384|NCT03267680|DRUG|Omeprazole|Given PO
219097385|NCT03267680|OTHER|Placebo|Given via submucosal injections or SC
219097386|NCT03267680|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219097387|NCT06632704|DEVICE|Colgate Toothbrush assist|toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
219097388|NCT04734548|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
219097389|NCT04734548|OTHER|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
219097390|NCT03394521|OTHER|Routine clinical practice|This is an observational study
219097391|NCT05649644|PROCEDURE|Selective Trunk Block (SeTB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
219097392|NCT05649644|PROCEDURE|Supraclavicular Brachial Plexus Block (SC BPB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
219097393|NCT02030782|OTHER|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
219097394|NCT02030782|OTHER|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
219097395|NCT03551275|BIOLOGICAL|BCD-132|Dose Escalation Study
219097396|NCT00559299|DRUG|GSK163090|
219097397|NCT00324584|DEVICE|Telemonitoring of glucose values using GlucoNet device|
219222491|NCT04811924|DRUG|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
219097398|NCT05171751|DRUG|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
219222492|NCT03932513|DRUG|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
219097399|NCT01368900|DEVICE|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
219097400|NCT01786902|DRUG|DA-3002|
219097401|NCT05478980|DIETARY_SUPPLEMENT|Night Time Tea|Night-time Tea
219222493|NCT01499316|PROCEDURE|High Flow oxygen|10 minute shigh flow oxygen
219222494|NCT01499316|PROCEDURE|Room Air|Room air breathing
219222495|NCT04105816|DEVICE|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
219222496|NCT04105816|DIAGNOSTIC_TEST|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
219222497|NCT00753493|DRUG|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
219222498|NCT05209555|DIAGNOSTIC_TEST|MoCA|MoCA test to identify Mild Cognitive Impairment
219222499|NCT05209555|DEVICE|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
219222500|NCT05209555|DIAGNOSTIC_TEST|DeltaScan|EEG to detect acute encephalopathy
219222501|NCT05209555|DIAGNOSTIC_TEST|Salivette|To collect saliva for cortisol analysis
219222502|NCT05209555|DIAGNOSTIC_TEST|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
219222503|NCT02920034|DEVICE|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
219222504|NCT02920034|DEVICE|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
219222505|NCT02920034|DEVICE|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
219222506|NCT06008236|BEHAVIORAL|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
219222507|NCT03274076|DRUG|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
219222508|NCT03274076|DRUG|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
219222509|NCT02446340|DRUG|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
219682730|NCT06314360|OTHER|No intervention.|There is no intervention in this study.
219097402|NCT05478980|DIETARY_SUPPLEMENT|Control Tea|Feel New Tea
219097403|NCT02201914|DRUG|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
219097404|NCT02201914|DRUG|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
219097405|NCT02201914|DRUG|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
219097406|NCT05753787|OTHER|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
219097407|NCT04027348|DRUG|Dexamethasone|Given IV
219097408|NCT04027348|DRUG|Metoclopramide|Given IV
219097409|NCT04027348|DRUG|Octreotide|Given IV
219222510|NCT02446340|DRUG|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
219222511|NCT00000852|PROCEDURE|Allogeneic lymphocyte transfer|
219222512|NCT00975585|DEVICE|senofilcon A|soft contact lens, 2-week replacement indicated
219222513|NCT00975585|DEVICE|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
219222514|NCT04587219|BIOLOGICAL|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
219222515|NCT03973034|DIAGNOSTIC_TEST|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
219222516|NCT05491135|BIOLOGICAL|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
219222517|NCT00310973|BEHAVIORAL|Social Network Intervention|
219222518|NCT02695264|DEVICE|HS-1000 recording|
219222519|NCT00795184|DEVICE|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
219222520|NCT00795184|DEVICE|HDWLE|
219222521|NCT00795184|DEVICE|pCLE|
219222522|NCT04379557|PROCEDURE|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
219222523|NCT04595461|OTHER|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
219222524|NCT04595461|OTHER|Control|Standard patient education with verbal and written education
219097410|NCT03943966|DIAGNOSTIC_TEST|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
219097411|NCT02701127|DRUG|Oral niacinamide, 1 gram daily|
219097412|NCT02701127|DRUG|Oral niacinamide, 3 gram daily|
219097413|NCT02701127|DRUG|Placebo|
219097414|NCT02932046|DIETARY_SUPPLEMENT|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
219097415|NCT04859634|DEVICE|Taking an ultra-widefield fundus image|The participant only needs to take an ultra-widefield fundus image as usual.
219097416|NCT04505501|DRUG|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
219097417|NCT05598242|BIOLOGICAL|Amniotic membrane extract eye drops (AMEED)|Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
219097418|NCT03817138|OTHER|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
219097419|NCT02897908|PROCEDURE|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
219097420|NCT02592538|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
219097421|NCT02592538|DRUG|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
219097422|NCT02592538|DEVICE|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
219097423|NCT01552954|BEHAVIORAL|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
219097424|NCT04843930|DEVICE|AKL-T01|AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
219097425|NCT01599923|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
219097426|NCT01581723|DEVICE|Monopolar diathermy|monopolar diathermy
219097427|NCT01581723|DEVICE|Bipolar diathermy|bipolar diathermy
219222525|NCT05031234|DRUG|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
219222526|NCT05031234|DRUG|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
219222527|NCT00651859|DRUG|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
219222528|NCT00651859|DRUG|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
219222529|NCT00651859|DRUG|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
219222530|NCT05276999|OTHER|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
219222531|NCT05276999|OTHER|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
219222532|NCT03014518|OTHER|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
219362192|NCT04625127|OTHER|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
219222533|NCT03014518|OTHER|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
219222534|NCT02220959|OTHER|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
219222535|NCT00507494|DRUG|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
219222536|NCT02553889|DRUG|ISIS 416858|subcutaneous injection
219097428|NCT00252434|BEHAVIORAL|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
219097429|NCT02573922|DRUG|oxycodone-naloxone|
219097430|NCT02573922|DRUG|Oxycodone|
219097431|NCT01547299|DRUG|Enzalutamide|
219097432|NCT01547299|DRUG|Leuprolide|
219097433|NCT01547299|DRUG|Dutasteride|
219222537|NCT02553889|DRUG|Placebo|subcutaneous injection
219097434|NCT04021186|OTHER|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
219097435|NCT02468102|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
219097436|NCT02468102|DRUG|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
219097437|NCT01576718|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
219097438|NCT01576718|OTHER|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
219222538|NCT00683800|DRUG|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
219222539|NCT00683800|DRUG|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
219222540|NCT04053270|DRUG|Afamelanotide|16mg subcutaneous implant
219222541|NCT04053270|DRUG|Placebo|Placebo subcutaneous implant
219222542|NCT00205179|DRUG|Novasoy|100mg/day soy isoflavones
219222543|NCT00205179|DRUG|Placebo|100mg/day matching placebo
219222544|NCT02763449|BEHAVIORAL|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
219097439|NCT01576718|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
219097440|NCT01576718|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
219097441|NCT02521402|BIOLOGICAL|Biovance|decellularized, dehydrated human amniotic membrane
219097442|NCT01742364|DEVICE|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
219097443|NCT01742364|DEVICE|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
219097444|NCT02836223|DEVICE|Interdental cleaning device|Water Flosser
219097445|NCT02836223|DEVICE|Manual Tooth brush|Control
219097446|NCT00992667|DRUG|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
219097447|NCT02030730|BEHAVIORAL|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
219097448|NCT00893399|DRUG|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
219097449|NCT00893399|DRUG|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
219097450|NCT01833143|DRUG|Bortezomib|
219097451|NCT01833143|DRUG|Acyclovir|
219097452|NCT01217008|BIOLOGICAL|GRNOPC1|One injection of 2 million GRNOPC1 cells.
219097453|NCT03917784|DRUG|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
219097454|NCT03917784|DRUG|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
219097455|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Single intravenous injection of CB2679d/Dalcinonacog alfa
219097456|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
219097457|NCT01737099|DIETARY_SUPPLEMENT|DHA-O|
219097458|NCT01737099|DIETARY_SUPPLEMENT|Fish oil|
219097459|NCT01737099|DIETARY_SUPPLEMENT|Placebo|
219097460|NCT05956704|DEVICE|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
219097461|NCT05956704|DEVICE|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
219097462|NCT00045708|DRUG|ixabepilone|Given IV
219097463|NCT00045708|OTHER|pharmacological study|Correlative studies
219097464|NCT00045708|DRUG|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
219097465|NCT03114371|DRUG|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
219097466|NCT03114371|DRUG|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
219097467|NCT03114371|DRUG|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
219097468|NCT00278538|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
219097469|NCT05736601|DEVICE|focus motion knee brace|knee brace that captures knee motion
219097470|NCT00765297|DEVICE|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
219097471|NCT00765297|DEVICE|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
219097472|NCT04221282|DRUG|Zebinix|ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
219097473|NCT01899066|DRUG|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
219097474|NCT01899066|DRUG|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
219097475|NCT00284141|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
219097476|NCT01266447|BIOLOGICAL|Filgrastim|Given SC
219097477|NCT01266447|OTHER|Laboratory Biomarker Analysis|Correlative studies
219097478|NCT01266447|BIOLOGICAL|Pegfilgrastim|Given SC
219097479|NCT01266447|DRUG|Topotecan Hydrochloride|Given IV
219097480|NCT01266447|DRUG|Veliparib|Given PO
219097481|NCT04318756|BEHAVIORAL|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
219097482|NCT00975221|DRUG|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
219097483|NCT00975221|DRUG|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
219097484|NCT04932005|DRUG|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
219097485|NCT04932005|DRUG|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
219097486|NCT00615394|PROCEDURE|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
219097487|NCT00201864|DRUG|Exemestane|25 mg orally per day
219097488|NCT00201864|DRUG|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
219097489|NCT02867514|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
219097490|NCT00299000|DRUG|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
219097491|NCT02412501|DEVICE|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
219097492|NCT02635165|DEVICE|Thoracic osteosyntheses with Stracos|
219097493|NCT03767270|BIOLOGICAL|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
219097494|NCT03767270|OTHER|Placebo|5% dextrose in water
219097495|NCT04396041|DEVICE|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
219097496|NCT04396041|DEVICE|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
219097497|NCT04396041|DEVICE|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
219097498|NCT04492358|DRUG|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
219222545|NCT00227175|BEHAVIORAL|Semi-structured, open ended interview|
219222546|NCT02247375|DRUG|Low dose of BIIL 284 BS tablets|
219222547|NCT02247375|DRUG|High dose of BIIL 284 BS tablets|
219222548|NCT02247375|DRUG|Placebo|
219222549|NCT00203554|GENETIC|Poly methylmetacrylate, PMMA|
219222550|NCT02079649|DRUG|AL-53817 Ophthalmic Solution, 0.1%|
219222551|NCT02079649|DRUG|AL-78843 Ophthalmic Solution, 0.03%|
219222552|NCT02079649|DRUG|Dexamethasone Ophthalmic Suspension, 0.1%|
219222553|NCT02079649|DRUG|AL-53817 Vehicle|Inactive ingredients used for masking purposes
219222554|NCT02831231|DRUG|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
219222555|NCT02831231|DRUG|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
219222556|NCT04941703|DRUG|Magnesium Citrate plus probiotic|296 ml magnesium citrate
219222557|NCT01578941|OTHER|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
219222558|NCT00344916|DRUG|Ng-monomethyl-L-arginine (drug)|
219222559|NCT02974322|DRUG|GED-0301|GED-0301
219222560|NCT02974322|DRUG|Placebo|Placebo
219222561|NCT05800236|PROCEDURE|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
219222562|NCT00229970|DRUG|montelukast sodium|7 mg or 14 mg single injection
219222563|NCT00229970|DRUG|Comparator: Placebo|Placebo single injection
219097499|NCT04492358|DRUG|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
219097500|NCT04492358|DRUG|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
219097501|NCT01489644|DRUG|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
219097502|NCT01489644|DRUG|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
219097503|NCT01489644|DRUG|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
219097504|NCT05347901|DIAGNOSTIC_TEST|Echocardiography, Genomics NGS sequencing|The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
219097505|NCT01492686|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
219097506|NCT01492686|DRUG|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
219097507|NCT01492686|DRUG|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
219097508|NCT05087914|DRUG|Carbidopa-Levodopa (100mg/25mg):|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
219097509|NCT05087914|DRUG|Naproxen|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
219097510|NCT03182140|DRUG|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
219097511|NCT00108238|DRUG|Estradiol followed by progesterone|
219097512|NCT00108238|DRUG|Raloxifene|
219097513|NCT03215901|BEHAVIORAL|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
219097514|NCT03215901|BEHAVIORAL|Active Control Video|Video on another topic.
219097515|NCT04693676|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
219097516|NCT02751918|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
219097517|NCT02751918|DRUG|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
219222564|NCT05502094|OTHER|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
219222565|NCT03387254|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
219222566|NCT03387254|DEVICE|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
219222567|NCT05926674|OTHER|Myofascial Release|Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
219222568|NCT05926674|OTHER|Light Touch Contact|The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
219097518|NCT03035305|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
219097519|NCT03035305|DRUG|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
219097520|NCT02815787|DRUG|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
219097521|NCT02815787|DRUG|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
219097522|NCT04671043|DIETARY_SUPPLEMENT|Caffeine and glucose|Caffeine and glucose powder dissolved in water
219097523|NCT04671043|DIETARY_SUPPLEMENT|Glucose alone|Glucose powder dissolved in water
219097524|NCT04671043|DIETARY_SUPPLEMENT|Placebo|Artificial sweetener dissolved in water
219097525|NCT06001502|DEVICE|Virtual Reality distraction therapy|The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
219097526|NCT02228395|DRUG|PF-04958242|Administered as specified in treatment arm
219097527|NCT02228395|DRUG|Placebo|Administered as specified in treatment arm
219097528|NCT05157659|DIAGNOSTIC_TEST|[18F]F-AraG PET-scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
219097529|NCT05298176|DRUG|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
219097530|NCT01300325|OTHER|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
219097531|NCT06497400|OTHER|Brazilian Jiu Jitsu|Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu
219097532|NCT06497400|OTHER|Hatha Yoga|Instruction of two classes each week for ten weeks of Hatha Yoga
219097533|NCT06497400|OTHER|Waitlist|Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
219097534|NCT05661721|OTHER|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
219097535|NCT05661721|OTHER|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
219097536|NCT03237273|OTHER|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
219097537|NCT00003305|DRUG|aminopterin|
219097538|NCT00003305|DRUG|leucovorin calcium|
219097539|NCT00817557|DRUG|Loteprednol|Anti-inflammatory
219097540|NCT00817557|OTHER|Rewetter|
219097541|NCT02626832|OTHER|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
219097542|NCT04227574|OTHER|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
219097543|NCT04227574|OTHER|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
219097544|NCT00985985|DRUG|Nicotine|2 mg or 4 mg nicotine lozenge
219097545|NCT00985985|DRUG|Placebo|placebo lozenge
219097546|NCT03266848|DIAGNOSTIC_TEST|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
219222569|NCT00964236|DRUG|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
219222570|NCT02398487|DEVICE|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
219222571|NCT02398487|DEVICE|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
219222572|NCT00022165|DIETARY_SUPPLEMENT|selenium|
219097547|NCT00675155|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
219097548|NCT03262857|DRUG|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
219097549|NCT05925374|BEHAVIORAL|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
219222573|NCT02980588|DEVICE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
219222574|NCT02483468|BEHAVIORAL|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
219222575|NCT02483468|DEVICE|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
219222576|NCT02483468|DEVICE|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
219222577|NCT01953692|BIOLOGICAL|Pembrolizumab|IV infusion
219222578|NCT01953692|DRUG|Lenalidomide 20 mg|oral capsule
219097550|NCT01013610|DRUG|LNK-754|Escalating dose
219097551|NCT01013610|DRUG|Placebo|Escalating dose
219097552|NCT03607357|DEVICE|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
219097553|NCT03607357|DEVICE|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
219097554|NCT02255357|DRUG|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
219222579|NCT01953692|DRUG|Lenalidomide 25 mg|oral capsule
219362193|NCT04625127|OTHER|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
219097555|NCT02255357|DRUG|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
219097556|NCT03719794|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
219222580|NCT03905278|BEHAVIORAL|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
219222581|NCT05141539|DEVICE|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
219222582|NCT05141539|DEVICE|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
219222583|NCT06369220|DIAGNOSTIC_TEST|cobas® liat CT/NG/MG nucleic acid test|The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
219222584|NCT06369220|OTHER|Standard of Care (SOC): Clinician's Standard Practice|Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
219222585|NCT04884165|DEVICE|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
219222586|NCT04884165|OTHER|Home mechanical ventilation (NIV) without remote monitoring|Usual care
219222587|NCT04033315|DEVICE|L-PLUS meter|Blood Glucose Monitoring System
219222588|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^4 pfu delivered intramuscularly
219222589|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^5 pfu delivered intramuscularly
219222590|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^6 pfu delivered intramuscularly
218984375|NCT04579575|DEVICE|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~* The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~* The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
219097557|NCT03719794|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement once daily for 12 weeks
219097558|NCT00509236|DRUG|Sitagliptin|25 mg (one 25-mg tablet) once daily
219097559|NCT00509236|DRUG|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
219097560|NCT00099099|BEHAVIORAL|Caloric Restriction (CR)|
219097561|NCT02785874|DRUG|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
219097562|NCT05900856|OTHER|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
219097563|NCT05900856|DEVICE|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
219097564|NCT04012060|PROCEDURE|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
219222591|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^7 pfu delivered intramuscularly
219222592|NCT04794218|OTHER|Placebo/Diluent|N/A delivered intramuscularly
219222593|NCT03552276|DRUG|SUNPG18_07 I (Tildrakizumab 200 mg)|injection
219222594|NCT03552276|DRUG|SUNPG18_07 II (Tildrakizumab 100 mg)|injection
219222595|NCT01644994|COMBINATION_PRODUCT|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
219362194|NCT00782366|GENETIC|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
219362195|NCT04320407|DEVICE|Osia 2 System|The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
219362196|NCT06152822|DRUG|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
218984376|NCT02548533|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
218984377|NCT02548533|DRUG|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
218984378|NCT02548533|DRUG|EMLA cream|Topical application 2 hours prior to the treatment.
219097565|NCT04012060|PROCEDURE|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
219222596|NCT01401218|OTHER|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
219222597|NCT00378300|DRUG|Oral Probiotics|
219222598|NCT05657210|GENETIC|Mutation|
219222599|NCT04623554|BEHAVIORAL|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
219222600|NCT05957510|DRUG|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
219222601|NCT05957510|DRUG|SOC|the treatment recommended by the investigator
219222602|NCT02463214|OTHER|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
219222603|NCT05999682|OTHER|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
219222604|NCT05999682|OTHER|sterilized water|Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
219222605|NCT03636854|OTHER|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
219222606|NCT03636854|OTHER|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
219222607|NCT02419300|DEVICE|ultrasoungraphy|pelvic ultrasonography and Doppler
219222608|NCT04439500|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
219362197|NCT01923688|OTHER|Informatics Alert/Nurse/physician responders|
219362198|NCT01505998|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
218984379|NCT05707767|PROCEDURE|Resection surgery|Patients undergo resection surgery in our hospital.
218984380|NCT03783364|RADIATION|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
218984381|NCT00773656|OTHER|Whole blood sample|70 ml per patient for collection of biological sample
218984382|NCT04650490|RADIATION|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
218984383|NCT04650490|DRUG|Immunotherapy|Physician's choice of immunotherapy per standard of care
218984384|NCT05205525|OTHER|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
218984385|NCT05205525|OTHER|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
218984386|NCT01034150|DEVICE|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
219097566|NCT04240184|OTHER|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
219097567|NCT06192147|DIETARY_SUPPLEMENT|protein restricted diet combined with vitamin D intervention|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
219097568|NCT00792103|DRUG|NP101|NP101 study patch 4 hour application
219222609|NCT04439500|BEHAVIORAL|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
219222610|NCT04318483|OTHER|survey|parents' telephone interview to collect medical history
219222611|NCT06210152|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
219222612|NCT06210152|DEVICE|Sham Extracorporeal Shockwave Therapy|Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
219222613|NCT06508749|DRUG|PGDM1400LS|IV Antibody Infusion based on subject's weight
219222614|NCT06508749|DRUG|VRC07-523LS|IV Antibody Infusion based on subject's weight
219222615|NCT06508749|DRUG|PGT121.414.LS|IV Antibody Infusion based on subject's weight
219222616|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1a|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
219222617|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1b|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
219222618|NCT06508749|OTHER|Analytic Treatment Interruption|(all anti-HIV agents are discontinued)
219222619|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
219222620|NCT00983294|DRUG|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
219222621|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
219222622|NCT06272188|OTHER|web-based online preconceptional counselling|web-based online preconceptional counselling
219222623|NCT00853593|DEVICE|Pacing Lead|implant and follow-up of study device
219222624|NCT03693807|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
219222625|NCT03693807|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
219222626|NCT03693807|DRUG|Gemcitabine|Please see Detailed Description.
219222627|NCT03693807|DRUG|Oxaliplatin|Please see Detailed Description.
219222628|NCT03693807|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
219222629|NCT03693807|DRUG|Fluorouracil|Please see Detailed Description.
219222630|NCT03693807|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
219222631|NCT02193932|OTHER|EEG Triggered fMRI using Micro Maglink|
219222632|NCT06195345|DIAGNOSTIC_TEST|MR Imaging|MR imaging pertaining to the patient and project (ICHOR 1)
219222633|NCT00191542|DRUG|Atomoxetine|
219222634|NCT00191542|DRUG|Placebo|
219097569|NCT03837808|DRUG|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
219097570|NCT03837808|DRUG|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
219222635|NCT03978065|DIAGNOSTIC_TEST|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
219222636|NCT05715684|OTHER|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
219222637|NCT05715684|DIETARY_SUPPLEMENT|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
219222638|NCT04251923|DEVICE|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
219097571|NCT02348684|RADIATION|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
219097572|NCT03435575|DEVICE|Boosth|Boosth activity tracker which measures steps
219097573|NCT05610891|DRUG|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
219097574|NCT00156858|DRUG|intravenous busulfan|
218984387|NCT01034150|DEVICE|Placebo stimulation|Placebo stimulation
218984388|NCT05164796|DEVICE|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~* IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~* IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~* In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
218984389|NCT05933616|DEVICE|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
218984390|NCT02040948|DEVICE|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
218984391|NCT02980783|DEVICE|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
218984392|NCT01065259|DRUG|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
218984393|NCT01065259|DRUG|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
218984394|NCT04711434|DRUG|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
218984395|NCT01095926|DRUG|doxorubicin|blood sampling before, during and after doxorubicin administration
218984396|NCT03533296|PROCEDURE|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
218984397|NCT03361163|BIOLOGICAL|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
218984398|NCT02445508|DRUG|Sevelamer|
218984399|NCT02445508|DRUG|Cholecystokinin|
218984400|NCT02445508|DRUG|Sevelamer placebo|
218984401|NCT02445508|DRUG|Isotonic saline|
218984402|NCT00763529|DRUG|Mometasone|Mometasone furoate cream 0.1% applied once daily
218984403|NCT00763529|DRUG|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
218984404|NCT00006477|DIETARY_SUPPLEMENT|mistletoe extract|
218984405|NCT00001688|DRUG|Ritonavir|
218984406|NCT00001688|DRUG|Nevirapine|
218984407|NCT00001688|DRUG|Stavudine|
218984408|NCT03026322|OTHER|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
219097575|NCT03074214|PROCEDURE|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
219097576|NCT04338854|PROCEDURE|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
219097577|NCT01572389|BEHAVIORAL|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
219097578|NCT01572389|BEHAVIORAL|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
219097579|NCT04802343|DRUG|BAY1817080|Oral, tablet.
219097580|NCT04802343|DRUG|Placebo|Oral, tablet.
219097581|NCT02307201|DRUG|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
219097582|NCT02673710|OTHER|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
219097583|NCT00977756|DRUG|Raltegravir (RAL)|400 mg twice daily (BID)
219097584|NCT00977756|DRUG|Atazanavir (ATV)|300 mg daily
219097585|NCT00977756|DRUG|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
219097586|NCT00977756|DRUG|Tenofovir (TDF)|300 mg daily
219097587|NCT00977756|DRUG|Etravirine (ETV)|200 mg BID
219097588|NCT00977756|DRUG|Darunavir (DRV)|Dosing by weight
219097589|NCT00977756|DRUG|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
219097590|NCT00977756|DRUG|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
219097591|NCT04185714|OTHER|Kinesiotaping|Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.
219097592|NCT04185714|OTHER|Placebo taping|sham taping
219097593|NCT02294188|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
219097594|NCT02294188|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
219097595|NCT02294188|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
219097596|NCT04617184|OTHER|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
219097597|NCT02648984|OTHER|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
219097598|NCT01287520|DRUG|LY2090314|Administered intravenously
219222639|NCT04171011|DEVICE|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
219222640|NCT01524497|DRUG|Trazodone|75mg tablet/150 mg tablet
219097599|NCT01287520|DRUG|pemetrexed|Administered intravenously
219097600|NCT01287520|DRUG|Carboplatin|Administered intravenously
219097601|NCT01287520|OTHER|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
219097602|NCT03319784|DRUG|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
219097603|NCT03319784|DRUG|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
219222641|NCT01524497|DRUG|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
219222642|NCT00540111|DIETARY_SUPPLEMENT|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
219222643|NCT06434584|OTHER|without AI assistance|provide insulin dosage and confidence score without AI assistance
219222644|NCT06434584|OTHER|with AI dosage assistance|provide insulin dosage and confidence score with AI dosage assistance
219097604|NCT03587142|DRUG|Buspirone|Buspirone tablet
219097605|NCT03587142|DRUG|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
219097606|NCT03874065|OTHER|Medical Chart Review|Collection of data from participant's medical chart
219097607|NCT05149092|DIETARY_SUPPLEMENT|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
219097608|NCT05149092|DIETARY_SUPPLEMENT|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
219097609|NCT02470858|DRUG|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
219222645|NCT06434584|OTHER|with explainable AI assistance|provide insulin dosage and confidence score with explainable AI assistance
219222646|NCT06434584|OTHER|with faulty explainable AI assistance|provide insulin dosage and confidence score with faulty explainable AI assistance
219222647|NCT04139304|DRUG|Cyclophosphamide|Given IV
219222648|NCT04139304|BIOLOGICAL|Daratumumab|Given IV
219222649|NCT04139304|DRUG|Doxorubicin|Given IV
219222650|NCT04139304|DRUG|Doxorubicin Hydrochloride|Given IV
219222651|NCT04139304|DRUG|Etoposide|Given IV
219222652|NCT04139304|DRUG|Prednisone|Given PO
219222653|NCT04139304|DRUG|Vincristine|Given IV
219222654|NCT04139304|DRUG|Vincristine Sulfate|Given IV
219222655|NCT03800212|DRUG|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
219222656|NCT06098482|DEVICE|Mobile Research App (MRA)|The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
219222657|NCT06098482|OTHER|SOC/validated delivery of the speech perception test material|This involves the delivery of speech perception test material in the sound booth in a clinic.
219222658|NCT03067948|BEHAVIORAL|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
219222659|NCT02138123|PROCEDURE|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
219097610|NCT02470858|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
219097611|NCT02470858|DRUG|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
219097612|NCT02768662|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
219097613|NCT03673462|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
219097614|NCT03673462|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
219097615|NCT03673462|BIOLOGICAL|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
219097616|NCT03673462|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219097617|NCT03673462|BIOLOGICAL|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
219097618|NCT03673462|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219097619|NCT03673462|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
219222660|NCT02138123|PROCEDURE|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
219550299|NCT05201339|PROCEDURE|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
219097620|NCT03673462|BIOLOGICAL|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
219097621|NCT03324659|BEHAVIORAL|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
219097622|NCT03324659|BEHAVIORAL|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
219097623|NCT01432496|DRUG|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
219097624|NCT01432496|DRUG|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
219097625|NCT04389502|DEVICE|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
219097626|NCT04389502|OTHER|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
219097627|NCT04060602|BEHAVIORAL|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
219097628|NCT04060602|BEHAVIORAL|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
219097629|NCT03749122|PROCEDURE|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
219097630|NCT03503825|DRUG|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
219097631|NCT00871884|BEHAVIORAL|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
219097632|NCT00871884|BEHAVIORAL|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
219097633|NCT00871884|BEHAVIORAL|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
219222661|NCT04468412|DIAGNOSTIC_TEST|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
219222662|NCT04230941|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
219222663|NCT03927196|BEHAVIORAL|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
219222664|NCT04197037|PROCEDURE|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
218984409|NCT03026322|OTHER|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
219222665|NCT00082836|BIOLOGICAL|rituximab|
219222666|NCT00082836|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219222667|NCT03805672|DRUG|Low Dose Enoxaparin|
219222668|NCT03805672|DRUG|High Dose Enoxaparin|
218984410|NCT01399814|BEHAVIORAL|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation
218984411|NCT01399814|BEHAVIORAL|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
218984412|NCT00202800|DRUG|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
218984413|NCT01302756|OTHER|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
218984414|NCT01302756|DIETARY_SUPPLEMENT|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
218984415|NCT06511830|DIAGNOSTIC_TEST|Dental Monitoring images|Dental Monitoring is a series of intraoral photos that will be taken and assessed to determine the subject's dental plaque levels.
218984416|NCT02072083|DRUG|Dexmedetomidine|via intranasal route 1 mcg/kg
219097634|NCT04144803|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
219097635|NCT04105530|DEVICE|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
219097636|NCT04105530|DEVICE|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
219097637|NCT04105530|DEVICE|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
219097638|NCT04105530|OTHER|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
219097639|NCT04105530|OTHER|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
219097640|NCT04105530|OTHER|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
219097641|NCT04105530|OTHER|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
219097642|NCT03542097|OTHER|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
219097643|NCT02524301|DRUG|Positron Emission Tomography using [11C]diprenorphine|PET using \[11C\]diprenorphine
218984417|NCT02072083|DRUG|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
219097644|NCT02352363|DRUG|CVT-301|
219097645|NCT02352363|OTHER|Observational cohort|
219097646|NCT00118261|BIOLOGICAL|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
219097647|NCT00118261|DRUG|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
219097648|NCT00118261|DRUG|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
219097649|NCT00118261|DRUG|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
219097650|NCT00118261|DRUG|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
219097651|NCT03193671|DIAGNOSTIC_TEST|Diagnosis|Improving diagnosis
218984418|NCT02130570|OTHER|Multi-Model Intensive Discharge Intervention|"1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information"
218984419|NCT00512005|DEVICE|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
218984420|NCT01008592|DRUG|levocetirizine or placebo|oral administration, single tablet, 5 mg.
218984421|NCT01696695|DRUG|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
218984422|NCT01696695|DRUG|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
218984423|NCT05981391|DIAGNOSTIC_TEST|resting-state functional MRI|We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.
219097652|NCT03782090|DEVICE|Endobronchial intubation|"1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
219097653|NCT05526586|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
219097654|NCT05526586|OTHER|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
219097655|NCT05526586|OTHER|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
219097656|NCT05526586|OTHER|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
219097657|NCT05526586|OTHER|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
219097658|NCT00518934|OTHER|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
219097659|NCT05061537|BIOLOGICAL|PF-07263689|Genetically engineered oncolytic vaccinia virus
219097660|NCT05061537|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
219097661|NCT02579798|DEVICE|PEEP (positive end-expiratory pressure)|
219097662|NCT03502616|DRUG|Tofacitinib|Oral administration twice per day
219097663|NCT02008591|PROCEDURE|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
219097664|NCT00727324|DRUG|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
219222669|NCT00775866|PROCEDURE|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
219097665|NCT01802814|DRUG|SR-A + Epratuzumab|
219097666|NCT01802814|DRUG|SR-B + Epratuzumab|
219097667|NCT06400966|OTHER|Training method|Jigsaw Technique
219097668|NCT03315936|DRUG|BI 894416|powder for oral solution
219097669|NCT03315936|DRUG|Placebo|Oral solution
219097670|NCT03315936|DRUG|BI 894416|Tablet
219097671|NCT00525772|DRUG|ciclesonide|low dose- 50ug and 200ug
219097672|NCT00525772|DRUG|ciclesonide|high dose- 100ug and 400ug
219097673|NCT02062866|PROCEDURE|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
219097674|NCT02062866|PROCEDURE|Second Intent|The wound will not be sutured, and allowed to heal on its own.
219097675|NCT01729884|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
219097676|NCT00628901|PROCEDURE|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
219097677|NCT00628901|DEVICE|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
219097678|NCT00628901|DEVICE|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
219097679|NCT02847299|DEVICE|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
219097680|NCT01457781|COMBINATION_PRODUCT|Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
219097681|NCT01457781|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS Device|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula
219097682|NCT01457781|COMBINATION_PRODUCT|Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
219097683|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
219097684|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
219097685|NCT01337557|DRUG|Bepotastine|1.5% bid
219097686|NCT04193839|OTHER|Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)|Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
219097687|NCT00770432|DRUG|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
219682731|NCT01965314|OTHER|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
219682732|NCT01965314|OTHER|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
219682733|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
219682734|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
219682735|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
219682736|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
219682737|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
219682738|NCT02820077|DEVICE|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
219682739|NCT00873730|DRUG|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
219682740|NCT00873730|DRUG|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
218984424|NCT05981391|DIAGNOSTIC_TEST|Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)|The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.
218984425|NCT05981391|DIAGNOSTIC_TEST|Tympanometry|Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.
218984426|NCT05981391|DIAGNOSTIC_TEST|Tinnitus Assessment|Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.
218984427|NCT05981391|DIAGNOSTIC_TEST|Otoscopy|Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear
218984428|NCT05981391|DIAGNOSTIC_TEST|Pure tone air and bone-conduction|Pure tone air- and bone-conduction threshold will be conducted to evaluate audiometry and masking levels in both ears, from 250 Hz. To 16000 Hz.
218984429|NCT05981391|DIAGNOSTIC_TEST|Speech testing|Speech testing will be conducted in both ears, which will include speech reception threshold, speech reception threshold masking level, word recognition presentation level, and word recognition masking level.
218984430|NCT05981391|DIAGNOSTIC_TEST|Loudness Discomfort|Loudness discomfort levels will be tested in both right and left ears, from 500Hz to 4000Hz and speech reception threshold.
218984431|NCT05981391|DIAGNOSTIC_TEST|Quick Speech in Noise Test|Quick Speech in Noise Test (QuickSIN) is a quick method for clinicians to quantify a patient's ability to hear in noise (1 minute).
218984432|NCT05981391|DIAGNOSTIC_TEST|Distortion-Product Otoacoustic Emissions (DPOAE)|Distortion-Product Otoacoustic Emissions (DPOAE) is an automated evaluation of cochlear function. A sensitive microphone is placed in the ear canal via a probe assembly with a disposable ear-tip attached to perform and record the measurements. DPOAEs will be elicited at multiple frequencies in both ears (10 min).
218984433|NCT05793138|BEHAVIORAL|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
219097688|NCT00770432|OTHER|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
219097689|NCT03852966|BEHAVIORAL|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
219097690|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
219097691|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
219097692|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
219097693|NCT03354650|DIAGNOSTIC_TEST|blood culture|blood culture to determine causative organisms of neonatal sepsis
219097694|NCT00818363|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
219097695|NCT00818363|DRUG|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
219097696|NCT04073264|PROCEDURE|monofilament|In the intervention group,monofilament absorbable suture,will be used.
219097697|NCT00988221|DRUG|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
219097698|NCT00988221|DRUG|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
219097699|NCT05967780|OTHER|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
219097700|NCT05967780|OTHER|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
219097701|NCT05967780|OTHER|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
219097702|NCT00977496|PROCEDURE|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
219097703|NCT00633919|BIOLOGICAL|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
219097704|NCT00633919|BIOLOGICAL|Placebo|Sublingual immunotherapy once daily for 2 years
219097705|NCT00633919|DRUG|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
219097706|NCT00633919|DRUG|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
219222670|NCT06294249|DEVICE|Laser-induced Incision|On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
219222671|NCT06294249|PROCEDURE|Punch Incision|On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
219222672|NCT06294249|PROCEDURE|Implant Placement|Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
219222673|NCT03104530|OTHER|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
219222674|NCT00139360|DRUG|Bevacizumab|Anti angiogenesis treatment
219222675|NCT05541289|BIOLOGICAL|BBV152|Single Arm; BBV152 (COVAXIN™)
219222676|NCT00600353|DRUG|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
219222677|NCT00600353|DRUG|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
219222678|NCT00600353|DRUG|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
219222679|NCT06498414|DRUG|rifampin standard arm|120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
219222680|NCT06498414|DRUG|rifampin double dose|60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
219222681|NCT06498414|DRUG|levofloxacin and rifapentine|30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
219222682|NCT03758742|BEHAVIORAL|High-Fruit Diet|In this supervised controlled feeding study, participants will consume a diet rich in whole fruit. During the Ramp-Up Phase (Weeks 1-4), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In the Main Phase (Weeks 5-12), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable throughout the intervention.
219222683|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
219222684|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
219222685|NCT02743819|DRUG|Pembrolizumab|Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
219097707|NCT00633919|DRUG|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
219222686|NCT02743819|DRUG|Ipilimumab|Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
219222687|NCT05985915|DRUG|Ianalumab (VAY736)|Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
219222688|NCT05985915|OTHER|Placebo|Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use
219222689|NCT05869734|BEHAVIORAL|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
219222690|NCT05869734|BEHAVIORAL|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
219097708|NCT00633919|DRUG|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
219097709|NCT00633919|DRUG|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
219097710|NCT00483834|DRUG|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
219097711|NCT00483834|DRUG|Irinotecan|200mg/m\^2, IV, day 1 each cycle
219097712|NCT00483834|DRUG|Capecitabine|1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
219222691|NCT05869734|BEHAVIORAL|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
219222692|NCT05948813|DRUG|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
219222693|NCT05948813|DRUG|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
219222694|NCT05886920|DRUG|D3S-002|Oral
219222695|NCT00870064|PROCEDURE|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
219682741|NCT03413163|DRUG|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
219682742|NCT03413163|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
219682743|NCT03112070|OTHER|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
219682744|NCT03633253|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
219222696|NCT00870064|PROCEDURE|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
219222697|NCT04605055|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
219222698|NCT04605055|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
219222699|NCT01553942|DRUG|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
219222700|NCT01553942|RADIATION|Radiation|Daily, Monday-Friday
219222701|NCT01553942|DRUG|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
219097713|NCT04154215|DIAGNOSTIC_TEST|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
219097714|NCT05135546|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
219097715|NCT05135546|DRUG|Placebo|6 ml of 0.9% solution of NaCl for inhalation
219097716|NCT03912623|OTHER|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
219097717|NCT03912623|OTHER|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
219097718|NCT01552122|DRUG|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
219097719|NCT01552122|DRUG|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
219097720|NCT01552122|OTHER|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
219097721|NCT01552122|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
219097722|NCT01552122|DIETARY_SUPPLEMENT|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
219097723|NCT01552122|OTHER|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
219097724|NCT03509532|DEVICE|PCI|PCI
219097725|NCT00906048|DRUG|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight \> 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
219097726|NCT01461330|OTHER|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
219097727|NCT01461330|OTHER|ADA diet|Adoption of ADA diet.
219097728|NCT03221101|DEVICE|Home ventilator|
219097729|NCT00002396|DRUG|Tenofovir disoproxil fumarate|
219097730|NCT03629860|PROCEDURE|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
219097731|NCT03028090|DEVICE|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
219097732|NCT03495804|DRUG|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
219097733|NCT03495804|DRUG|mannitol|Active comparator group was given mannitol as oral contrast agent.
219097734|NCT04005027|OTHER|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
219097735|NCT05068739|PROCEDURE|PA-EMR|Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
219097736|NCT05068739|PROCEDURE|NKF|The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
219222702|NCT01553942|DRUG|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
219222703|NCT01553942|PROCEDURE|Surgery|Surgery to remove tumor
219222704|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
219222705|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
219222706|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
219222707|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
219222708|NCT05682950|RADIATION|online adaptive radiotherapy|CTV covers pelvis.
219222709|NCT05115864|DEVICE|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
219097737|NCT02889601|OTHER|Psycho-behavioural assessment|DAPHNE Scale
219222710|NCT06344481|DEVICE|Surgical (Hyalex Cartilage Knee Implant)|Implantation of Hyalex Cartilage Knee Implant.
219097738|NCT00545350|OTHER|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
219222711|NCT06193590|DEVICE|Carevix|Cervical stabilization device that uses vacuum
219222712|NCT06193590|DEVICE|Tenaculum|standard of care cervical stabilization device
219222713|NCT00597636|BEHAVIORAL|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
219222714|NCT00597636|BEHAVIORAL|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
219222715|NCT04205903|DRUG|Nilotinib|Given PO
219222716|NCT04205903|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
219222717|NCT04205903|DRUG|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
219097739|NCT01991821|DRUG|APD421|
219097740|NCT01991821|DRUG|Placebo|
219222718|NCT04205903|OTHER|Questionnaire Administration|Ancillary studies
219222719|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
219222720|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
219222721|NCT06477653|BIOLOGICAL|dupilumab|Dupilumab is an interleukin-4 receptor alpha antagonist. Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication.
219222722|NCT06285864|BEHAVIORAL|Interoception-based intervention|Intervention will include body awareness, sensorial, and relaxation exercises, plus homework.
219222723|NCT06052332|RADIATION|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
219222724|NCT06052332|DRUG|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
219222725|NCT06052332|PROCEDURE|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
219222726|NCT06052332|COMBINATION_PRODUCT|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
219097741|NCT00187915|DRUG|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
219097742|NCT00187915|DRUG|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
219097743|NCT04203537|DRUG|CA-008|Local administration during surgery
219097744|NCT04203537|DRUG|Placebo|Local administration during surgery
219097745|NCT01537679|BEHAVIORAL|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
219222727|NCT03684993|DRUG|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
219222728|NCT03684993|DRUG|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
219222729|NCT03684993|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
219222730|NCT06067776|BIOLOGICAL|Cetuximab|Given IV
219222731|NCT06067776|DRUG|Osimertinib|Given PO
219222732|NCT06067776|DRUG|Tucatinib|Given PO
219222733|NCT06487702|DRUG|fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
219222734|NCT04346875|PROCEDURE|Regularly changing of dressing|Conventional dressing
219222735|NCT04346875|PROCEDURE|No application|No dressing change
219222736|NCT03363945|BIOLOGICAL|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
219097746|NCT01537679|BEHAVIORAL|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
219097747|NCT02569359|DIETARY_SUPPLEMENT|shea nut oil extract|
219097748|NCT02569359|OTHER|Placebo|
219222737|NCT01706159|DRUG|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
219222738|NCT01706159|DRUG|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
219222739|NCT06212479|DIAGNOSTIC_TEST|MRI Scan|Whole Body MRI Scan
219222740|NCT04816955|BEHAVIORAL|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
219097749|NCT04164654|BEHAVIORAL|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
219097750|NCT04581200|BEHAVIORAL|Lift|The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
219097751|NCT01543412|DRUG|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
219097752|NCT01423786|DIETARY_SUPPLEMENT|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
219097753|NCT01351532|BEHAVIORAL|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
219097754|NCT01351532|BEHAVIORAL|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
219222741|NCT00553332|DRUG|selumetinib|Given orally
219222742|NCT00553332|OTHER|laboratory biomarker analysis|Correlative studies
219222743|NCT06363617|OTHER|FLI|Health professionals will use the FLI test in their clinical practice
219097755|NCT01781390|OTHER|Placebo|Matching placebo solution for infusion.
219097756|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
219097757|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
219097758|NCT04754672|BEHAVIORAL|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
219097759|NCT04754672|BEHAVIORAL|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
219097760|NCT06459895|DIAGNOSTIC_TEST|Long non-coding MALAT1 gene expression assay:|RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
219097761|NCT01609816|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
219097762|NCT01625923|DRUG|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
219097763|NCT00347997|DEVICE|217z Laser|LASIK correction of myopia and myopic astigmatism
219222744|NCT04340752|DRUG|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
219097764|NCT00594191|DRUG|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
219097765|NCT00594191|DRUG|Placebo|Placebo with the same characteristics of the drug and at the same dose
219097766|NCT00159705|DRUG|pregabalin|
219097767|NCT02575898|OTHER|First Session|Creative Practice and Positive Re-enforcement
219097768|NCT02575898|OTHER|Second Session|Disease Related
219097769|NCT02575898|BEHAVIORAL|Third through Sixth Sessions|Life Review and Legacy
219097770|NCT01105013|DRUG|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
219097771|NCT00974701|DEVICE|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
219097772|NCT04404478|BEHAVIORAL|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
219097773|NCT04404478|BEHAVIORAL|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
219097774|NCT00640237|DIETARY_SUPPLEMENT|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
219097775|NCT00839345|DRUG|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
219097776|NCT05591248|DEVICE|VRR|Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
219097777|NCT04313569|PROCEDURE|Arthroscopic menisctomy|Arthroscopic medial menisctomy
219097778|NCT05864300|BEHAVIORAL|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
219097779|NCT04921384|DRUG|Placebo|0.9% normal saline, intravenously
219097780|NCT04921384|DRUG|Eptinezumab|Solution for infusion, intravenously
219097781|NCT04754256|BEHAVIORAL|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
219097782|NCT03911427|OTHER|Active oat beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
219097783|NCT03911427|OTHER|Control rice beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
219097784|NCT05174884|DRUG|22.2 mg Etonogestrel (ENG)|Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
219097785|NCT05174884|DRUG|44.4 mg Etonogestrel (ENG)|Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
219097786|NCT02523521|BEHAVIORAL|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
219097787|NCT04309929|DRUG|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
219097788|NCT06324019|OTHER|putting on an examination gown|During the gynecological examination, the patient in the experimental group will be made to wear an examination gown, while the patient in the control group will use the routine practice of the hospital. In this way, with the gynecological examination clothing to be developed, the body privacy of the patients will be protected during the examination. In addition, women will feel less anxiety during gynecological examination and important steps will be taken in maintaining women\&#39;s health by ensuring regular gynecological examination.
219097789|NCT04535323|OTHER|Quality-of-Life Assessment|Ancillary studies
219097790|NCT04535323|OTHER|Questionnaire Administration|Ancillary studies
219097791|NCT04535323|BIOLOGICAL|Therapeutic Autologous Platelet-rich Plasma|Given via injection
219097792|NCT03312608|DIAGNOSTIC_TEST|Navigated transcranial magnetic stimulation|
219097793|NCT03355430|PROCEDURE|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
219222745|NCT03775486|DRUG|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
219222746|NCT03775486|DRUG|Placebo for Olaparib|Matching tablet
219222747|NCT03775486|DRUG|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
219222748|NCT03775486|DRUG|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
219222749|NCT03775486|DRUG|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
219222750|NCT03775486|DRUG|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
219222751|NCT03775486|DRUG|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
219222752|NCT03775486|DRUG|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
219222753|NCT06648122|OTHER|laboratory results|evaluation of laboratory results (hemogram results:WBC, RBC, Hematocrit, Monocyte count, Neutrophil count, Lymphocyte count, Platelet count, PDW, MPV, MLR, NLR, NMR, PLR, PMR, PNR, PWR, SII)
219222754|NCT06623773|DRUG|Chondroitin sulfate|Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.
219222755|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD1/PD-L1 Therapy
219222756|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
219097794|NCT03355430|PROCEDURE|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
219097795|NCT02420145|BEHAVIORAL|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
219097796|NCT03154372|OTHER|Expert supervised practice with validated metrics|
219097797|NCT03154372|OTHER|self guided practice with validated metrics|
219097798|NCT04575363|OTHER|Blood sample|Blood sample
219222757|NCT04119063|DEVICE|powered orthosis|Novel powered leg brace to provide assistance during walking.
219097799|NCT00438620|BEHAVIORAL|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
219097800|NCT01438463|BIOLOGICAL|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
219222758|NCT03199404|DEVICE|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
219222759|NCT06061744|OTHER|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
219222760|NCT02055742|DEVICE|illumigene CT and NG assays, illumipro-10|
219222761|NCT01605409|PROCEDURE|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
219222762|NCT01605409|PROCEDURE|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
219097801|NCT01438463|BIOLOGICAL|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
219222763|NCT01728974|OTHER|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
219097802|NCT01438463|BIOLOGICAL|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
219097803|NCT01438463|BIOLOGICAL|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
219222764|NCT02000089|DRUG|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
219222765|NCT02000089|DIAGNOSTIC_TEST|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
219222766|NCT02000089|OTHER|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
219222767|NCT06294223|DEVICE|Exercise follow up with near-infrared spectroscopy|Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
219222768|NCT06492304|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
219097804|NCT01438463|BIOLOGICAL|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
219097805|NCT05341323|DRUG|Ketamine.|Peritonsillar infiltration of ketamine
219097806|NCT05341323|DRUG|Bupivacaine|peritonsillar infiltration of Bupivacaine
219097807|NCT01859793|DRUG|sitagliptin|100 mg pill, administered once/day orally
219097808|NCT01859793|DRUG|Placebo|Matching placebo in appearance given once/day orally
219097809|NCT04699227|PROCEDURE|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
219097810|NCT04699227|OTHER|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
219097811|NCT00351897|DEVICE|pulsed dye (585nm) laser therapy|
219097812|NCT04286126|DEVICE|Active bilateral DMPFC|Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).
219097813|NCT04286126|DEVICE|Active right-sided OFC|Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
219222769|NCT03844919|DEVICE|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
219097814|NCT03973866|DEVICE|Alfapump|Implantation of alfapump
219097815|NCT05414318|DEVICE|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
219097816|NCT01526590|DRUG|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
219097817|NCT03798600|DRUG|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
219222770|NCT03844919|BEHAVIORAL|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
219222771|NCT00002748|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
219222772|NCT00002748|BIOLOGICAL|interleukin-2 gene|
219097818|NCT06215651|DRUG|Cadonilimab lenvatinib|±TACE/HAIC
219097819|NCT01735396|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
219097820|NCT04372160|OTHER|Dietary assessment|24-hr dietary recall
219097821|NCT02002182|BIOLOGICAL|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
219222773|NCT04420767|DEVICE|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
219222774|NCT04420767|DEVICE|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
219222775|NCT04420767|BEHAVIORAL|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
219222776|NCT06101875|OTHER|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
219097822|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
219097823|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
219097824|NCT03394443|BEHAVIORAL|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~* As a first step, it will be a vertical analysis of the thematization of each interview~* Then, in a second step, a transversal analysis between the contents of the different interviews."
219097825|NCT00217880|PROCEDURE|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
219097826|NCT03988582|BIOLOGICAL|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
219097827|NCT05707611|OTHER|Running|The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
219097828|NCT05707611|OTHER|Cycling|The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
219097829|NCT05707611|OTHER|Swimming|The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
219222777|NCT06101875|OTHER|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
219222778|NCT00767741|DEVICE|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
219222779|NCT01847534|OTHER|Supplemental PN|
219222780|NCT01847534|OTHER|Standard Care|
219222781|NCT05473416|OTHER|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
219222782|NCT05473416|OTHER|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
219222783|NCT05473416|OTHER|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
219222784|NCT02235298|DRUG|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
219222785|NCT02235298|DRUG|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
219222786|NCT02235298|DRUG|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
219097830|NCT01478074|DRUG|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC \> 1000
219097831|NCT01478074|DRUG|Cytarabine|2 g/m2 daily from day -6 through -2
219222787|NCT01553487|OTHER|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
219222788|NCT00406887|DRUG|Difluprednate Ophthalmic Emulsion|
219222789|NCT03565484|DRUG|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
219222790|NCT03565484|DRUG|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
219222791|NCT03565484|DRUG|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
219222792|NCT03637296|OTHER|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
219097832|NCT01478074|DRUG|Fludarabine|30 mg/m2 daily from day -6 through -2
219222793|NCT03134300|DIAGNOSTIC_TEST|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
219222794|NCT03604146|BEHAVIORAL|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
219097833|NCT01478074|BIOLOGICAL|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg
219097834|NCT01478074|BIOLOGICAL|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
219097835|NCT05155995|DRUG|HCP2001|Take it once per period.
219097836|NCT05155995|DRUG|RLD2007|Take it once per period.
219097837|NCT05155995|DRUG|RLD2008|Take it once per period.
219097838|NCT05155995|DRUG|RLD2102|Take it once per period.
219097839|NCT03108729|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
219097840|NCT00869882|PROCEDURE|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
219222795|NCT03074656|OTHER|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
219222796|NCT03074656|OTHER|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
219222797|NCT00845364|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
219222798|NCT00845364|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
219222799|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
219222800|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
219222801|NCT02463994|DRUG|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
219222802|NCT02463994|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
219222803|NCT03784105|DRUG|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
219222804|NCT03784105|DRUG|Siripus simplex|Sugar syrup
219222805|NCT03874169|DEVICE|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
219222806|NCT04874259|PROCEDURE|Living donor liver transplantation|Living donor liver transplantation
219222807|NCT00124254|PROCEDURE|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
219222808|NCT00124254|OTHER|Usual care|Non-surgical usual care
219222809|NCT03683576|DRUG|GB001|film-coated oral tablet
219222810|NCT03683576|DRUG|Placebo|film-coated oral tablet
219222811|NCT04873206|OTHER|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
218984434|NCT05793138|BEHAVIORAL|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
218984435|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
218984436|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
218984437|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
218984438|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
218984439|NCT05345860|OTHER|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
219222812|NCT03839550|COMBINATION_PRODUCT|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
219222813|NCT03839550|PROCEDURE|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
219222814|NCT02659124|DEVICE|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
219222815|NCT02659124|PROCEDURE|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
219222816|NCT01687751|DRUG|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
219222817|NCT01687751|DRUG|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
219222818|NCT01818869|DRUG|AZD8848|Multiple doses inhaled IMP via a nebulizer
219222819|NCT01818869|DRUG|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
219222820|NCT01827839|BIOLOGICAL|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
219222821|NCT01536366|DRUG|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
219222822|NCT01536366|DRUG|Repaglinide|0.5 mg repaglinide (single-dose)
219222823|NCT03987646|PROCEDURE|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
219222824|NCT00223756|OTHER|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
219222825|NCT00873782|OTHER|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
219222826|NCT03507972|RADIATION|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
219222827|NCT03507972|RADIATION|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
219222828|NCT05359796|BIOLOGICAL|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
219222829|NCT05359796|BIOLOGICAL|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
219222830|NCT05359796|GENETIC|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
219222831|NCT05359796|DIETARY_SUPPLEMENT|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
219222832|NCT05359796|GENETIC|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
219222833|NCT05359796|BIOLOGICAL|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
219222834|NCT05359796|BIOLOGICAL|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
219222835|NCT02533232|DRUG|Minocycline|Minocycline 200mg per day
219097841|NCT00869882|PROCEDURE|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
219097842|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
219097843|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
219097844|NCT04042116|DRUG|Lucitanib|"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
219097845|NCT04042116|DRUG|Nivolumab|IV nivolumab 480 mg will be administered once every 4 weeks.
219097846|NCT05101135|DRUG|JT-001|Subjects take the investigational products once a day for 24 weeks.
219097847|NCT05101135|DRUG|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
219097848|NCT02939300|DRUG|Nivolumab|"* Melanoma:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
219097849|NCT02939300|DRUG|Ipilimumab|"* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
219097850|NCT00735111|OTHER|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
219097851|NCT00125593|DRUG|Simvastatin 20 mg|Once daily
219097852|NCT00125593|DRUG|Ezetimibe 10mg|Once daily
219097853|NCT00125593|DRUG|Placebo|Once daily
219097854|NCT06065813|DRUG|Toripalimab|200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
219097855|NCT06065813|RADIATION|Conventional segmental radiotherapy|the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
219097856|NCT06065813|OTHER|opreation|The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab
219097857|NCT01597505|DRUG|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
219097858|NCT01597505|DRUG|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
219097859|NCT01597505|DRUG|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
219097860|NCT00009581|DRUG|L-NMMA|
219097861|NCT00009581|DRUG|Acetylcholine|
219097862|NCT04225624|BEHAVIORAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
219097863|NCT04225624|BEHAVIORAL|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
219097864|NCT05437276|DEVICE|PoNS®|The PoNS device used in conjunction with rehabilitative physical therapy
219097865|NCT05960370|OTHER|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
219097866|NCT04392037|DRUG|Iberdomide plus low-dose cyclophosphamide and dexamethasone|Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
219097867|NCT00617695|DRUG|Zolmitriptan|5mg nasal spray
219097868|NCT00617695|DRUG|Placebo|
219097869|NCT05958563|DEVICE|continuous positive airway pressure treatment|CPAP treatment for one year
219097870|NCT05514951|DIAGNOSTIC_TEST|Blood sampling|Blood sampling
219097871|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 1 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
219097872|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 4 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
219097873|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 10 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
219097874|NCT05454410|DRUG|Placebo Subcutaneous Injection|0.9% sodium chloride solution administered as a single SC injection on Day 1.
219097875|NCT06070350|BIOLOGICAL|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
219222836|NCT04366193|DIAGNOSTIC_TEST|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
219222837|NCT06515210|DIETARY_SUPPLEMENT|Acacia Gum|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
218984440|NCT05345860|OTHER|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
218984441|NCT05345860|OTHER|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
218984442|NCT05667987|DRUG|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
218984443|NCT00985478|DRUG|SLV342|25 mg once daily - Maximal Tolerated Dose
218984444|NCT00985478|DRUG|placebo|matching placebo
218984445|NCT05170984|DEVICE|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
218984446|NCT00153907|DRUG|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
218984447|NCT00153907|DRUG|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
218984448|NCT03947892|DIAGNOSTIC_TEST|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
218984449|NCT03875404|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
218984450|NCT01631773|GENETIC|microRNA|Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
218984451|NCT01869439|DEVICE|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
218984452|NCT01869439|DEVICE|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
218984453|NCT01869439|DEVICE|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
218984454|NCT01869439|DEVICE|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
218984455|NCT01024075|DRUG|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
218984456|NCT01024075|DRUG|Saline|8cc of Saline mixed with Sinufoam
218984457|NCT02850354|OTHER|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
219222838|NCT06515210|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
219222839|NCT06515210|DIETARY_SUPPLEMENT|Placebo|Participants (n=23) incorporate the placebo into their usual diet daily.
219222840|NCT06051799|OTHER|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
219550300|NCT05201339|PROCEDURE|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
219550301|NCT03221530|BEHAVIORAL|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
219097876|NCT06070350|DRUG|Placebo|Placebo will be provided to the research pharmacy at each of the clinical sites
219097877|NCT06070350|DRUG|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
219097878|NCT06070350|BIOLOGICAL|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
219097879|NCT02294617|OTHER|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
219097880|NCT02294617|OTHER|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
219097881|NCT06593431|RADIATION|Consolidative Radiation|Participants will receive treatment through radiation therapy
219222841|NCT06051799|OTHER|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
219097882|NCT01220869|DRUG|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
219222842|NCT04705649|OTHER|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
219222843|NCT04350619|OTHER|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
219222844|NCT04571437|DRUG|Capecitabine|Capecitabine metronomic combined with Letrozole
219097883|NCT05261191|BIOLOGICAL|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
219097884|NCT05261191|BIOLOGICAL|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
219097885|NCT03804606|OTHER|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
219097886|NCT05004688|BIOLOGICAL|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
219097887|NCT05551702|BEHAVIORAL|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
219097888|NCT06770556|DEVICE|Sham iTBS|Participants will receive sham iTBS
219097889|NCT06770556|DEVICE|Active iTBS|Participants will receive active iTBS
219097890|NCT06770556|DEVICE|10 Hz TMS|Participant will receive 10 Hz TMS
219097891|NCT06770556|DEVICE|1 Hz TMS|Participant will receive 1 Hz TMS
219097892|NCT05256771|DEVICE|EMS|Abdominal muscle stimulation using EMS
219097893|NCT05256771|DEVICE|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
219097894|NCT05256771|DEVICE|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
219097895|NCT05800704|DIETARY_SUPPLEMENT|Nagasin|Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
219097896|NCT05800704|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin (placebo comparator)
219097897|NCT06792968|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table
219097898|NCT06792968|DRUG|Synjardy 5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets
219097899|NCT05465902|BIOLOGICAL|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
219222845|NCT04571437|DRUG|Letrozole 2.5mg|Letrozole daily alone
219222846|NCT06670651|DEVICE|total knee arthroplasty device|total knee arthroplasty device with ultracongruent bearing surface
219097900|NCT05465902|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
219097901|NCT05465902|BIOLOGICAL|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
219097902|NCT05465902|BIOLOGICAL|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
219097903|NCT03879408|DRUG|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
219097904|NCT03879408|DRUG|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
219097905|NCT03879408|DRUG|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
219097906|NCT03879408|DRUG|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
219097907|NCT03879408|DRUG|Placebo tablet|Single dose of four placebo tablets
219222847|NCT04177498|DRUG|Rigosertib Sodium|given PO or 72 hour continuous infusion
219222848|NCT04177498|OTHER|Quality-of-Life Assessment|Ancillary studies
219222849|NCT05044312|OTHER|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
219222850|NCT05014516|DRUG|129Xenon gas|Observational
219222851|NCT05175898|DEVICE|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
219222852|NCT05175898|DEVICE|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
219222853|NCT06444516|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
219222854|NCT06799351|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
219097908|NCT01081041|DRUG|Cetuximab|Administered intravenously
219222855|NCT06799351|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
219097909|NCT01081041|DRUG|Cisplatin|Administered intravenously
219097910|NCT01081041|DRUG|Carboplatin|Administered intravenously
219097911|NCT01081041|DRUG|5-Fluorouracil|Administered intravenously
219097912|NCT03918070|DEVICE|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC \& the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
219097913|NCT02601534|BEHAVIORAL|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
219097914|NCT02601534|BEHAVIORAL|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
219097915|NCT05807919|OTHER|Diet low in all FODMAP groups|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
219097916|NCT05807919|OTHER|Diet - Mediterranean|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
219097917|NCT00000881|DRUG|Cidofovir|
219097918|NCT00000881|DRUG|Probenecid|
218984458|NCT03993132|DRUG|Empagliflozin|new users (initiators) of Empagliflozin
218984459|NCT03993132|DRUG|Liraglutide|initiators of Liraglutide
218984460|NCT01578070|BIOLOGICAL|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
218984461|NCT01578070|BIOLOGICAL|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
218984462|NCT01578070|BIOLOGICAL|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
218984463|NCT01578070|BIOLOGICAL|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
218984464|NCT01578070|BIOLOGICAL|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
218984465|NCT02805972|DRUG|Naloxone|4 mg / 0.1 ml
218984466|NCT02805972|DRUG|Placebo|0.1 ml
218984467|NCT02716805|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
218984468|NCT02716805|DRUG|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing \> 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
218984469|NCT02716805|BIOLOGICAL|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
218984470|NCT02716805|DRUG|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
218984471|NCT00932126|DRUG|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
218984472|NCT05034562|PROCEDURE|Computed Tomography|Undergo PET/CT
218984473|NCT05034562|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
218984474|NCT05034562|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
218984475|NCT05034562|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
218984476|NCT01790425|PROCEDURE|to infuse water into colon to open the lumen for water infusion colonoscopy|
218984477|NCT01790425|PROCEDURE|Air colonoscopy|
218984478|NCT04419675|OTHER|Observational Cohort, usual care = physical therapy|usual care = physical therapy
218984479|NCT04177121|OTHER|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
218984480|NCT00239590|DRUG|Testosterone undecanoate|Licensed for androgen deficiency
218984481|NCT01817829|DRUG|paracetamol|500 mg oral tablet
218984482|NCT01817829|DRUG|placebo|
218984483|NCT02033187|OTHER|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
219222856|NCT03641664|BEHAVIORAL|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
219222857|NCT03641664|BEHAVIORAL|Level II or Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
219097919|NCT02622204|PROCEDURE|Corrective osteotomy|corrective osteotomy for varus alignment
219097920|NCT00283920|DRUG|[(11)C] PBR28|
219097921|NCT02076984|PROCEDURE|Laparoscopic incisional or ventral hernia repair|
219097922|NCT02487472|OTHER|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
219097923|NCT03785067|DRUG|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
219097924|NCT03785067|DRUG|Placebo oral capsule|1 capsule taken orally once daily for 36 months
219097925|NCT01622010|BEHAVIORAL|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
219097926|NCT01622010|OTHER|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
219097927|NCT01622010|DEVICE|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
219097928|NCT00220974|BEHAVIORAL|Internet-based tailored advice on cardiovascular risk|
219097929|NCT04983563|DEVICE|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
219097930|NCT00973661|BEHAVIORAL|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
219222858|NCT06619977|DEVICE|Analgesia nociception monitoring (ANI)|Analgesia nociception index (ANI; MetroDoloris Medical Systems, Lille, France) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, in particular - the parasympathetic nervous system. The ANI algorithm uses data from one lead ECG trace. Heart rate variability, or the beat-to-beat alterations in heart rate, is a well-known and recognised noninvasive indicator of autonomic nervous system activity.
219222859|NCT06883149|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency: day0 and day 3, per 3 weeks for 8 cycles;~   PIN injection dosage:~   Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion:~   PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase:~Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
219222860|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
219222861|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
219222862|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
219222863|NCT05373017|OTHER|DANE Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
219097931|NCT05782257|DIETARY_SUPPLEMENT|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
219097932|NCT05782257|OTHER|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
219097933|NCT03455322|DRUG|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
219097934|NCT00153959|BEHAVIORAL|acute psychiatric day care|
219097935|NCT01265901|DRUG|Sunitinib|As per label.
219097936|NCT01265901|BIOLOGICAL|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
219097937|NCT01265901|DRUG|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
219222864|NCT05373017|OTHER|Questionnaires|Physical, cognitive, and psychological assessments
219222865|NCT06061107|BEHAVIORAL|"The cartoon version of the ACP for Seniors brochure"|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
219097938|NCT01265901|DRUG|IMA901|Intradermal vaccinations with IMA901 vaccine.
219097939|NCT00516464|DRUG|Lucentis (ranibizumab)|
219097940|NCT03119727|DEVICE|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
219222866|NCT06463366|DEVICE|3D-MRE,MRI-PDFF|3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
219222867|NCT06492083|OTHER|traditional Chinese medicine hot bag|traditional Chinese medicine hot bag
219222868|NCT06826898|DEVICE|DEFEHERE Absorbable Adhesion Barrier|DEFEHERE Absorbable Adhesion Barrier, 1.0 mL/syringe
219222869|NCT06826898|DEVICE|Sham (No Treatment)|conventional therapy without using any antiadhesion product
219222870|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
219222871|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
219222872|NCT02492074|DRUG|Placebo|oral administration of placebo
219550302|NCT03221530|BEHAVIORAL|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
219550303|NCT00840840|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
219550304|NCT00840840|DRUG|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
218984484|NCT02033187|OTHER|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
218984485|NCT03638622|COMBINATION_PRODUCT|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
218984486|NCT04020588|DRUG|Celecoxib 200mg|Will be administered for 6 weeks
218984487|NCT04020588|DRUG|Placebo oral capsule|Will be administered for 6 weeks
218984488|NCT04020588|DRUG|Minocycline 100mg|Will be administered for 6 weeks
218984489|NCT03311529|BEHAVIORAL|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
218984490|NCT02362269|DIETARY_SUPPLEMENT|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
218984491|NCT06201442|OTHER|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
218984492|NCT06201442|OTHER|Blood sampling|blood sample taken and analysis - not standard of care
218984493|NCT06201442|OTHER|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
218984494|NCT06201442|OTHER|Activity monitoring|Actigraph measurement- not standard of care
218984495|NCT06201442|OTHER|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
218984496|NCT06201442|BEHAVIORAL|Questionnaires|Patient reported outcomes (PROMS)
218984497|NCT04043273|BEHAVIORAL|Noninterventional characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
218984498|NCT00122096|DRUG|valdecoxib|
218984499|NCT01515878|DEVICE|Hemocontrol|Blood Volume Tracking system using biofeedback
218984500|NCT01903031|DEVICE|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
218984501|NCT01903031|DRUG|EFV|Participants received EFV 600 mg daily with two or more NRTIs
218984502|NCT01903031|DRUG|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
218984503|NCT01903031|DRUG|TDF|Participants received 300 mg of tenofovir in Arm C
218984504|NCT01903031|DRUG|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
218984505|NCT06069323|DEVICE|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
218984506|NCT02560909|BIOLOGICAL|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
218984507|NCT02560909|BIOLOGICAL|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
218984508|NCT05255211|DRUG|Remimazolam tosilate|IV before procedure
218984509|NCT05255211|DRUG|Propofol|IV before procedure
218984510|NCT05255211|OTHER|saline solution|IV before procedure
219097941|NCT01970605|PROCEDURE|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
219097942|NCT03042598|DEVICE|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
219097943|NCT04391946|BEHAVIORAL|Data registry|Collection of clinical data, treatment regimens and survival data
218984511|NCT01332084|OTHER|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
218984512|NCT01168141|DRUG|ZD4054|10mg ZD4054 daily in tablet form
218984513|NCT05096728|DRUG|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"
218984514|NCT00033605|DRUG|octreotide acetate|
218984515|NCT00033605|OTHER|placebo|
218984516|NCT00033605|RADIATION|radiation|
219097944|NCT03655925|DIAGNOSTIC_TEST|plasmatic HLA-G|plasmatic HLA-G by blood sample
219097945|NCT01355601|OTHER|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
219097946|NCT01355601|OTHER|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
219097947|NCT00223626|DRUG|Topiramate|the maximum topiramate test dose is 200 mg/d.
219097948|NCT00545961|DRUG|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
219097949|NCT00545961|DRUG|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
219097950|NCT01931735|PROCEDURE|Randomized Meniscectomy|Arthroscopic meniscectomy
219097951|NCT01931735|PROCEDURE|Randomized Lavage|Arthroscopic Lavage
219097952|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
219097953|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
219097954|NCT04786379|PROCEDURE|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
219097955|NCT04786379|PROCEDURE|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
219097956|NCT05732792|OTHER|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
219097957|NCT05957926|PROCEDURE|hyaluronic acid added to hydroxyapetite|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
219097958|NCT05957926|PROCEDURE|Hydroxyapatite alone|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
219097959|NCT00947661|DRUG|SPARC0912|Eye drops, once daily, 12 weeks
219097960|NCT00947661|DRUG|Reference0912|Eye drops, once daily, 12 weeks
219097961|NCT05272332|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound upon fasting, after 4 hours, and after nasogastric aspiration, to estimate gastric volume
219097962|NCT04309825|PROCEDURE|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
219097963|NCT01886001|DRUG|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
219097964|NCT01886001|DRUG|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
219097965|NCT01886001|DRUG|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
219097966|NCT01886001|OTHER|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
218984517|NCT02863744|PROCEDURE|coronally advanced flap with subepithelial connective tissue graft|"* Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
218984518|NCT05702918|DEVICE|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
218984519|NCT05702918|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
218984520|NCT02620722|DEVICE|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
218984521|NCT02620722|DEVICE|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
218984522|NCT04436159|PROCEDURE|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
218984523|NCT04436159|PROCEDURE|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
218984524|NCT01216670|BEHAVIORAL|remote patient's management|scheduled remote CareLink data transmission
218984525|NCT03373292|PROCEDURE|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
218984526|NCT03373292|PROCEDURE|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
218984527|NCT02489578|OTHER|other|retrospective cohort study
218984528|NCT01126086|DRUG|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
218984529|NCT00366574|DEVICE|Amadeus Microkeratome|
218984530|NCT00366574|DEVICE|IntraLase|
218984531|NCT02551861|DRUG|Daclatasvir|
218984532|NCT02551861|DRUG|Sofosbuvir|
218984533|NCT02551861|DRUG|Ribavirin|
218984534|NCT03540030|DRUG|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984535|NCT03540030|DRUG|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984536|NCT03540030|DRUG|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984537|NCT03540030|DRUG|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984538|NCT03540030|DRUG|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984539|NCT03540030|DRUG|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984540|NCT03540030|DRUG|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984541|NCT03540030|DRUG|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984542|NCT03540030|DRUG|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984543|NCT03540030|DRUG|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
218984544|NCT03540030|DRUG|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
219097967|NCT00524199|DRUG|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
219097968|NCT00524199|OTHER|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
219097969|NCT00865943|DRUG|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
219097970|NCT00865943|DRUG|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
218984545|NCT03225599|OTHER|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
218984546|NCT00027716|DRUG|bortezomib|
219097971|NCT04949958|OTHER|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
219097972|NCT04949958|OTHER|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
219097973|NCT04949958|OTHER|Control|General advice to be active
219097974|NCT03538483|DRUG|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
219097975|NCT03538483|DRUG|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
219097976|NCT02552238|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
219097977|NCT03285048|BEHAVIORAL|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
219097978|NCT01677143|DRUG|Bupivacaine 5mg/ml|5 ml in trocar area
219097979|NCT00774384|BIOLOGICAL|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
219097980|NCT01870362|DRUG|Probiotic (Inersan)|
219097981|NCT01870362|DRUG|Placebo|
218984547|NCT00227006|BEHAVIORAL|Behavioral lifestyle/weight-loss intervention|
218984548|NCT01469234|DRUG|loratadine|loratadine, one 10 mg tablet, orally
218984549|NCT01469234|DRUG|fexofenadine|fexofenadine, one 180 mg tablet, orally
218984550|NCT01469234|DRUG|placebo to loratadine|one tablet, orally
218984551|NCT01469234|DRUG|placebo to fexofenadine|one tablet, orally
218984552|NCT04823182|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
218984553|NCT02747290|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
218984554|NCT05744011|OTHER|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
218984555|NCT05744011|OTHER|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
218984556|NCT05820607|BIOLOGICAL|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
218984557|NCT02552589|OTHER|Amine fluoride|toothpaste
218984558|NCT02552589|OTHER|Placebo|toothpaste
218984559|NCT01681940|DRUG|Lamazym|ERT, i.v. infusions weekly
218984560|NCT02858960|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
218984561|NCT02858960|DEVICE|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
218984562|NCT05182190|DIETARY_SUPPLEMENT|White bread|Toasted white bread
218984563|NCT05182190|DIETARY_SUPPLEMENT|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
218984564|NCT05182190|DIETARY_SUPPLEMENT|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
218984565|NCT05182190|DIETARY_SUPPLEMENT|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
218984566|NCT05182190|DIETARY_SUPPLEMENT|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
218984567|NCT05578170|DRUG|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
218984568|NCT02515396|DRUG|MMI-0100|
218984569|NCT02515396|DRUG|Placebo|
218984570|NCT01227317|OTHER|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
218984571|NCT00237172|DRUG|Imatinib Mesylate|once daily
218984572|NCT04239053|DRUG|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
218984573|NCT00334321|RADIATION|IMRT|
218984574|NCT00334321|RADIATION|Intracavitary vaginal brachytherapy|
218984575|NCT00334321|DRUG|Paclitaxel|
218984576|NCT00334321|DRUG|Carboplatin|
218984577|NCT02481583|DRUG|Levosulpiride|different formulations of levosulpiride
218984578|NCT03842514|DIETARY_SUPPLEMENT|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
218984579|NCT01307982|PROCEDURE|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
218984580|NCT01307982|PROCEDURE|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
218984581|NCT03974243|DRUG|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
219097982|NCT00586170|DEVICE|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
219222873|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
219222874|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
219682745|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
219682746|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
219682747|NCT00664118|PROCEDURE|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
219682748|NCT00664118|PROCEDURE|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
219682749|NCT00006029|DRUG|gemcitabine hydrochloride|
219682750|NCT00006029|DRUG|pegylated liposomal doxorubicin hydrochloride|
219682751|NCT00006029|DRUG|vinorelbine tartrate|
219682752|NCT04612985|DEVICE|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
219682753|NCT03826537|OTHER|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
219682754|NCT00884260|DRUG|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
219682755|NCT02535650|DRUG|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
219682756|NCT01749046|DRUG|Remegal|Remegal 1500 mg for 12 weeks
219682757|NCT04263246|DIETARY_SUPPLEMENT|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
219682758|NCT04263246|DIETARY_SUPPLEMENT|Inulin|Inulin (6 capsules per day)
219682759|NCT01942876|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
219682760|NCT01942876|BEHAVIORAL|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
219682761|NCT00010751|PROCEDURE|Reiki|
219682762|NCT00503347|DRUG|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
219682763|NCT00528749|OTHER|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
219682764|NCT02809950|OTHER|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
219682765|NCT02809950|OTHER|control group|NPO from midnight of the day before surgery
218984582|NCT03974243|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
218984583|NCT00515411|DRUG|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
219682766|NCT00943397|DRUG|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
219222875|NCT06516887|DRUG|bemcentinib|Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
219222876|NCT06516887|DRUG|pacritinib|For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
219222877|NCT06939491|DEVICE|Ultrasound guided electrolysis therapy|"Ultrasound-guided galvanic electrolysis (USGET) is a technique most commonly used on chronically affected tissue. A galvanic current flows through an acupuncture needle producing an inflammatory reaction in the tissue. The inflammatory reaction will trigger a host of biological processes in the body. These will ultimately start the generation of new immature collagen fibres. The fibres become mature by means of training stimulus.~The technique shows good results on tendons in the chronic phase, and may be used for injuries, such as long-standing muscle injury and treatment of myofascial pain syndrome and trigger points."
218984584|NCT00515411|DRUG|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
219222878|NCT06939491|DEVICE|Sham Electrolysis|The same intervention as the electrolysis group with the device turned on but the current intensity turned to 0 mA (e.g., no galvanic current).
219222879|NCT06951282|DIETARY_SUPPLEMENT|Selenium|200 microgram selenium was given daily for 3 months
219222880|NCT06951282|DRUG|Methotrexate|0.4 mg/kg/week sub cutaneous methotrexate for 3 months
219222881|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
219550305|NCT02341547|DRUG|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
219550306|NCT06582264|BIOLOGICAL|MB310|Live bacterial therapeutic for oral administration
219550307|NCT06582264|OTHER|Placebo|MB310-matching placebo for oral administration
218984585|NCT00515411|DRUG|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
218984586|NCT02270008|OTHER|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
218984587|NCT01599195|DEVICE|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
218984588|NCT03808129|DRUG|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
218984589|NCT00252746|DRUG|ZD6474 (vandetanib) 100mg|once daily oral dose
218984590|NCT00252746|DRUG|ZD6474 (vandetanib) 200mg|once daily oral dose
218984591|NCT00252746|DRUG|ZD6474 (vandetanib) 300mg|once daily oral dose
218984592|NCT02564497|BIOLOGICAL|Process E Belatacept|
218984593|NCT02564497|BIOLOGICAL|Process C Belatacept|
218984594|NCT03259217|DRUG|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
218984595|NCT00921401|BEHAVIORAL|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
218984596|NCT01593085|BEHAVIORAL|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~\--------------------------------------------------------------------------------"
218984597|NCT02904993|OTHER|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
218984598|NCT02904993|OTHER|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
218984599|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
218984600|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
218984601|NCT01462487|DRUG|Treatment with zanamivir|Subjects treated with zanamivir
218984602|NCT00347360|DRUG|lisinopril|
218984603|NCT00347360|DRUG|carvedilol controlled release formulation|
218984604|NCT02850107|DEVICE|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
218984605|NCT02850107|DEVICE|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
219097983|NCT00586170|DEVICE|Placebo Device|10 hours of treatment per day for up to 24 weeks
219097984|NCT00586170|PROCEDURE|Surgery|Open Reduction and Internal Fixation of the nonunion site
219222882|NCT06950567|OTHER|psycho-educational intervention and therapeutic activity|"The objective is to provide knowledge and skills to tolerate/reduce discomfort so that they can begin to reduce or discontinue medication (BZD).~The focus is on the effect of combined care, but the implementation of this approach is also evaluated, which will provide valuable knowledge for further health developments in Primary Care."
219097985|NCT05158296|DRUG|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
219097986|NCT05158296|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
219097987|NCT02725125|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
219097988|NCT03034018|DRUG|suvorexant|10-20 mg taken at bedtime for four weeks
219097989|NCT03034018|DRUG|placebo|placebo taken at bedtime for four weeks
219097990|NCT02542644|DEVICE|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
219222883|NCT06950567|OTHER|Control|"Sending a Benzocarta to each person's postal address-a personalized letter signed by their Family Doctor, an explanatory sheet on how to gradually reduce medication, and infographics on sleep hygiene, stress, or anxiety."
219097991|NCT05771701|DEVICE|Pain pressure threshold measurement|"Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis)."
219097992|NCT00898040|GENETIC|polymorphism analysis|
219097993|NCT04285658|PROCEDURE|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
219097994|NCT04285658|PROCEDURE|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
219097995|NCT04285658|PROCEDURE|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
219097996|NCT02036645|BIOLOGICAL|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
219222884|NCT06951061|PROCEDURE|IVF/ICSI|In vitro fertilization with or without ICSI with ejaculated and surgically retrieved sperm.
219222885|NCT00491894|DRUG|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
219222886|NCT06952205|OTHER|Experimental group|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments were applied.To experimental group, functional taping were applied in addition of these treatments.
219222887|NCT06952205|OTHER|only exercises|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments
219097997|NCT02036645|BIOLOGICAL|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
219097998|NCT02036645|BIOLOGICAL|IV Placebo|Placebo for IV injection
219222888|NCT06950918|OTHER|Experimental|"This study is a quasi-experimental parallel group design comparing Flipped Classroom (FC) and Flip-Jigsaw models in a theoretically-oriented public health course. Both groups used the same pre-prepared video lectures to standardize content, but differentiated in-class strategies: The FC group used instructor-led discussions, while the Flip-Jigsaw group used Jigsaw technique and peer teaching (students learning subtopics in expert groups and teaching them in master groups). Unlike traditional FC, this hybrid model includes systematic peer collaboration and role-based accountability mechanisms. Theoretical knowledge acquisition, motivation and engagement outcomes were assessed through quantitative tests (pre-post-retention tests) and qualitative interviews, and objectivity was ensured in practical exams with single-blinded assessors. The study brings innovation to the literature as it is the first study to demonstrate the unique effect of Flip-Jigsaw in theoretical courses in the fie"
219222889|NCT05434598|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
219222890|NCT03496766|DRUG|Tipifarnib|Tipifarnib 600 mg will be administered until progression
219222891|NCT05825885|DRUG|E2|micronized E2 at a daily dose of 4-6mg,
219222892|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
219097999|NCT02036645|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
219098000|NCT03781921|OTHER|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
219222893|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
219222894|NCT05231018|OTHER|Psychotherapy|8-sessions psychotherapy
219222895|NCT03427463|DRUG|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
219222896|NCT03427463|DRUG|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
219222897|NCT06341023|BEHAVIORAL|Functional Balance Intervention|Participants in the intervention group will undergo a multi-component FBI exercise program, both in a lab setting (Study 1) and at home (Study 2), for 2 days/week over 4 months. This evidence-based protocol, previously piloted with chronic stroke patients, older adults with mild cognitive impairment, and pre-frail older adults, focuses on improving physical (endurance, strength, balance, and gait) and cognitive function (processing speed, attention, and memory). The program consists of functional agility, functional strength, dual-task, and vestibular exercises, with each 1-hour session including 10 minutes dedicated to each component. The exercise order will be randomized for each session, preceded by a warm-up with gentle self-stretching exercises.
219222898|NCT06341023|BEHAVIORAL|Stretching|Participants in the control group will undergo a 4-month lab-based stretching program, with the same frequency and session length as the intervention group (1 hour/session for 2 days/week). The stretching regimen will include progressive stretches targeting upper and lower-limb muscles, core, and back muscles, followed by a 10-minute cool-down comprising relaxation and breathing exercises. These stretches are designed to improve performance in daily living activities. In Study 2, stretching participants will receive a detailed printed exercise manual for home-based training, ensuring consistency with the lab-based program. No additional equipment, such as computers or tablets, is required for the home stretching program.
219222899|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
219682767|NCT00943397|DRUG|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
219098001|NCT01986101|DRUG|Placebo|Placebo comparator
219098002|NCT01986101|DRUG|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
219098003|NCT01986101|DRUG|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
219098004|NCT02817035|DEVICE|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
219098005|NCT05541302|DEVICE|TMS|Transcranial Magnetic Stimulation
219098006|NCT03842839|DRUG|Tiotropium Inhalation Powder [Spiriva] 0.018mg|Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
219098007|NCT03842839|DRUG|Salbutamol sulphate aerosol (Ventolin) 0.01mg|As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
219098008|NCT02571790|BEHAVIORAL|Relaxation optimized virtual reality|
219098009|NCT02571790|BEHAVIORAL|Classical relaxation (without Virtual Reality)|
219098010|NCT02595216|DEVICE|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
219098011|NCT05290844|OTHER|cricoid pressure|cricoid force in pediatric patients
219222900|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
218984606|NCT02850107|DEVICE|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
218984607|NCT02850107|DEVICE|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
218984608|NCT02850107|DEVICE|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
218984609|NCT03598543|OTHER|no intervention|no intervention, this is an obervational study.
218984610|NCT03398044|DRUG|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
218984611|NCT03398044|DRUG|Placebo|Placebo will be administered to patients randomised into the control group arm.
218984612|NCT02009306|DRUG|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
218984613|NCT02009306|DRUG|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide"
219222901|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
219098012|NCT06520943|OTHER|blood gas analysis|"1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)"
219098013|NCT06023875|DRUG|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
219098014|NCT06023875|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
219098015|NCT06023875|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
219098016|NCT02583438|DRUG|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
219098017|NCT03295513|OTHER|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
218984614|NCT02009306|DRUG|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
218984615|NCT05004077|DRUG|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
219098018|NCT03295513|OTHER|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
219098019|NCT05373797|BEHAVIORAL|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
219098020|NCT01455935|DRUG|Anti-platelets and statin|
219222902|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219222903|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
218984616|NCT03763175|DRUG|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
218984617|NCT03763175|DRUG|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
218984618|NCT03763175|DRUG|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
218984619|NCT04271527|PROCEDURE|cognitive fusion targeted biopsy|A cognitive fusion targeted biopsy
218984620|NCT02819739|DRUG|medical oxygen|
218984621|NCT05157438|BEHAVIORAL|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
218984622|NCT05157438|BEHAVIORAL|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
218984623|NCT02187744|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
218984624|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
218984625|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
218984626|NCT02187744|BIOLOGICAL|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
218984627|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
219098021|NCT01455935|DRUG|alteplase|"Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours"
219098022|NCT01455935|PROCEDURE|intra arterial intervention|"1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)"
219098023|NCT02404389|DRUG|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
219098024|NCT02404389|DRUG|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
219098025|NCT02104492|OTHER|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
219098026|NCT02104492|OTHER|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
219098027|NCT03221725|PROCEDURE|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
219098028|NCT04990869|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
219682768|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia (TEA) group|Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
219098029|NCT04990869|DIETARY_SUPPLEMENT|Placebo|Placebo
219098030|NCT03265106|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
219098031|NCT05239325|BEHAVIORAL|World Cancer Day Walk|Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
219098032|NCT05509725|DRUG|Probiotic formulation|Participants will be asked to take 2 doses daily
219098033|NCT05509725|DRUG|Placebo|Participants will be asked to take 2 doses daily
219098034|NCT00652938|BIOLOGICAL|HPV Vaccine (GSK580299) Cervarix TM|IM administration
219098035|NCT00652938|BIOLOGICAL|Engerix B|IM administration
219098036|NCT03324880|BIOLOGICAL|rhPTH (1-84)|rhPTH (1-84) SC injection.
219098037|NCT03324880|BIOLOGICAL|Placebo|Placebo QD SC injection.
219098038|NCT01412801|BIOLOGICAL|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
219682769|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
219682770|NCT06262971|DEVICE|Percutaneous coronary intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
219098039|NCT02013492|DRUG|propranolol hydrochloride|Given PO
219098040|NCT02013492|OTHER|Correlative Studies|"Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
219098041|NCT04837859|DRUG|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
219098042|NCT00116272|DRUG|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
219098043|NCT04859660|DRUG|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
219098044|NCT04859660|DRUG|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
219098045|NCT04795310|DEVICE|Pulsed dye laser|"PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment."
219098046|NCT04376554|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days
219098047|NCT04376554|DRUG|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
219098048|NCT06225102|BEHAVIORAL|Kegel Exercise|"* Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
219098049|NCT05647525|DIAGNOSTIC_TEST|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
219098050|NCT00824980|DRUG|IP10.C8|IP10.C8 Gel 1%
219098051|NCT03711630|BEHAVIORAL|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
219098052|NCT00871650|OTHER|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
219098053|NCT00871650|OTHER|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
219098054|NCT00871650|OTHER|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
219098055|NCT00081302|BIOLOGICAL|cetuximab|
219098056|NCT00081302|DRUG|carboplatin|
219098057|NCT00081302|DRUG|paclitaxel|
219098058|NCT00081302|RADIATION|radiation therapy|
219098059|NCT00829335|PROCEDURE|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
219098060|NCT03217435|PROCEDURE|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
219098061|NCT03217435|PROCEDURE|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
219098062|NCT03217435|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
219098063|NCT03217435|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
219098064|NCT03253484|RADIATION|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
219098065|NCT04588935|DRUG|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
219098066|NCT06260735|DEVICE|Trans-spinal electrical stimulation|Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).
219098067|NCT06260735|DEVICE|Electrical muscle activation|Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.
219098068|NCT06260735|OTHER|Treadmill walking|Stepping on a treadmill with individually preferred speed.
219098069|NCT04490564|DIAGNOSTIC_TEST|PD-L1 Kit|Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples
219098070|NCT01092481|DRUG|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
219098071|NCT00421434|DRUG|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
219098072|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
219098073|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
219098074|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
219098075|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
219682771|NCT01608464|DRUG|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
219682772|NCT01608464|DRUG|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
219682773|NCT01499693|DRUG|Magnesium Pantoprazole 20 mg|oral dose, twice a day
219682774|NCT01499693|DRUG|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
219682775|NCT01499693|DRUG|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
219682776|NCT01966887|GENETIC|MYDICAR-single intracoronary infusion|AAV1/Serca2a
219682777|NCT01966887|GENETIC|Placebo; single intracoronary infusion|single intracoronary infusion
219098076|NCT01339286|DRUG|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
219098077|NCT02931201|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
219098078|NCT02012062|DRUG|TPF neoadjuvant chemotherapy|
219098079|NCT02012062|DRUG|Concurrent chemotherapy with cisplatin during radiotherapy|
219098080|NCT02012062|DRUG|Concurrent nimotuzumab during radiotherapy|
219098081|NCT02012062|RADIATION|Radical radiotherapy|
219098082|NCT01023243|OTHER|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
219098083|NCT01023243|OTHER|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
219098084|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
219098085|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
219098086|NCT00800280|DRUG|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
219098087|NCT02936050|PROCEDURE|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
219098088|NCT05490264|BIOLOGICAL|[68Ga]Ga-NOTA-SNA002|\[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
219098089|NCT03551314|OTHER|Nasal Intermittent Positive Pressure|"\- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
219098090|NCT03551314|OTHER|Continuous Positive Airway Pressure|"\- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
219098091|NCT04706533|DIAGNOSTIC_TEST|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
219098092|NCT00853502|DRUG|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
219098093|NCT00070811|PROCEDURE|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
219098094|NCT00782496|DEVICE|Education + new meter|Diabetes education and a new meter with basic features
219098095|NCT00782496|DEVICE|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
219098096|NCT01481545|RADIATION|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
219098097|NCT01481545|DRUG|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
219098098|NCT01481545|DRUG|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
219098099|NCT01481545|DRUG|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
219098100|NCT01481545|DRUG|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
219098101|NCT01481545|DRUG|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
219098102|NCT02503683|DRUG|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
219098103|NCT02503683|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
219098104|NCT01208740|DRUG|Metformin|500 mg three times daily
219098105|NCT01208740|DRUG|Placebo|1 pill three times daily
219098106|NCT03831321|DRUG|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
219098107|NCT03831321|DEVICE|Cystoscopy|Diagnostic cystoscopy
219098108|NCT03831321|DRUG|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
219098109|NCT00844909|DRUG|CNTO 136|
219682778|NCT04878055|DRUG|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
219098110|NCT01038115|PROCEDURE|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
219098111|NCT03642860|DRUG|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
219098112|NCT03642860|DRUG|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
219098113|NCT03562065|BIOLOGICAL|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
219098114|NCT03392207|BIOLOGICAL|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
219098115|NCT03371641|BEHAVIORAL|ASQ parental questionnaire|ASQ parental questionnaire
219098116|NCT03371641|BEHAVIORAL|Development scales|WPPSI - IV and NEPSY development scales
219098117|NCT03371641|BEHAVIORAL|Scale of Conners|Scale of Conners
219098118|NCT03371641|BEHAVIORAL|SCQ Questionnaire|SCQ questionnaire
219098119|NCT03371641|PROCEDURE|Blood sample (mother)|Blood sample (mother) before delivery
219098120|NCT03371641|PROCEDURE|Cord blood sample|Cord blood sample after delivery
219682779|NCT04878055|OTHER|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
219682780|NCT04178408|OTHER|No intervention|No intervention
219682781|NCT01827735|DRUG|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
219682782|NCT02407873|OTHER|Non|
219682783|NCT01865721|DRUG|Entonox|Entonox will be used according to the allocated method
219682784|NCT01968811|DEVICE|Avance Foam dressing kit|
219222904|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
219222905|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219222906|NCT06532136|DRUG|Deucravacitinib|Deucravacitinib 6 mg orally once daily.
219222907|NCT06532136|DRUG|Placebo|Matching placebo orally once daily.
219222908|NCT05393024|DRUG|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
219222909|NCT05876338|OTHER|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
219222910|NCT06117124|RADIATION|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
219098121|NCT03371641|PROCEDURE|Placenta sample|Placenta sample
219098122|NCT00584402|DRUG|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
219098123|NCT02283489|DRUG|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
219098124|NCT02283489|DRUG|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
219098125|NCT02283489|DRUG|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
219098126|NCT00462137|PROCEDURE|Sleep Studies|
219098127|NCT00990340|DEVICE|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
219098128|NCT00990340|PROCEDURE|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
219098129|NCT01987817|BIOLOGICAL|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
219098130|NCT01987817|BIOLOGICAL|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
219098131|NCT02821624|DRUG|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
219098132|NCT02821624|DRUG|Placebo|Placebo
219098133|NCT02094521|DRUG|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
219098134|NCT06291662|DEVICE|3D printer applications|Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
219098135|NCT04438863|DIAGNOSTIC_TEST|home spirometry|portable hand-held spirometer to collect and store daily spirometric data (including FVC, FEV1, forced expiratory flow after 25 to 75% of vital capacity has been expelled, and peak flow).
219098136|NCT04244851|OTHER|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
219098137|NCT00210327|DRUG|Bortezomib (drug)|
219222911|NCT06117124|DIAGNOSTIC_TEST|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
219222912|NCT07189390|DRUG|Probiotic|Probiotic capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. Probiotic Infloran® Hard capsules (Bifidobacterium bifidum \& Lactobacillus acidophilus) are a listed medicine on the Australian Register of Therapeutic Goods (ARTG). Infloran® has been previously used in infants including pre-term infants for other indications including supporting healthy digestion or improving digestive system flora. Infloran® is manufactured by Laboratorio Farmaceutico SIT S.r.l., Via Cavour 70 - 27035 Mede (PV) Italy.
219222913|NCT07189390|DRUG|Matching placebo|Placebo contains the same excipients as Infloran, it is also made from the same capsule, but it does not contain any bacterial strains. Placebo capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. The placebo is manufactured by Syntro Health, 558-562 Swan St, Richmond, VIC 3121.
218984628|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
218984629|NCT04259320|DEVICE|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
218984630|NCT04259320|BIOLOGICAL|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
218984631|NCT06005480|DRUG|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
219098138|NCT03285841|DEVICE|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
219098139|NCT02459158|DRUG|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
219098140|NCT02459158|DRUG|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
219550308|NCT06582264|DRUG|Vancomycin|Antibiotic
218984632|NCT05106517|DRUG|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
218984633|NCT05106517|DRUG|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
219222914|NCT07197463|OTHER|drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）|The experimental group received Phase I cardiac rehabilitation intervention + medication treatment + general treatment, while the control group only received medication treatment + general treatment.
219222915|NCT07196657|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
219222916|NCT07196657|DRUG|Crisugabalin|For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.
219222917|NCT07197658|PROCEDURE|endodontic microsurgery / rotary bur osteotomy|Endodontic microsurgery will be executed by use of a rotary bur
219222918|NCT07197658|PROCEDURE|Endodontic microsurgery / piezo osteotomy|Endodontic microsurgery will be performed by use of a piezosurgery unit
219222919|NCT07197658|PROCEDURE|Endodontic microsurgery / bone window|'Bone window' technique will be performed by use of piezoelectric surgery
219222920|NCT07196878|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|An ultrasound-guided puncture is performed to place one needle near the sciatic nerve and another near the peroneal nerve. Then, an electrical stimulus at 10 Hz is applied for 10 seconds, repeated 10 times.
219222921|NCT07196397|PROCEDURE|cardioneuroablation|Cardioneuroablation and related autonomic interventions aim to modulate parasympathetic and/or sympathetic inputs to the heart in order to treat functional bradycardia, inappropriate sinus tachycardia, vasovagal syncope, and other reflex arrhythmias. Techniques include catheter-based ablation of ganglionated plexi, thoracoscopic sinus node-sparing ablation, cardiac sympathetic denervation, and percutaneous stellate ganglion blockade. These procedures are tailored to each patient's autonomic profile and diagnosis.
219222922|NCT07196397|PROCEDURE|SN sparing hybrid ablation|Sinus node-sparing hybrid ablation is a minimally invasive surgical procedure that modulates autonomic inputs to the sinoatrial node while preserving its intrinsic function. The intervention is performed via video-assisted thoracoscopic surgery (VATS) and targets the epicardial autonomic ganglia and neural connections responsible for inappropriate sinus tachycardia or autonomic dysfunction. Unlike traditional sinus node modification, this approach avoids direct ablation of the sinus node and focuses on surrounding autonomic structures. The goal is to reduce pathologic chronotropic activity and improve symptom control without inducing iatrogenic bradycardia.
219222923|NCT07196397|PROCEDURE|Cardiac sympathetic denervation|Cardiac sympathetic denervation is an interventional procedure aimed at reducing excessive sympathetic drive to the heart by ablating or removing components of the sympathetic nervous system. It is typically performed via a thoracoscopic approach and involves bilateral or left-sided denervation of the stellate ganglion and thoracic sympathetic chain (usually T2-T4). CSD is used in patients with arrhythmias associated with sympathetic overactivity, such as long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), or autonomic dysfunction-related tachyarrhythmias. The procedure helps reduce arrhythmic burden, modulate autonomic tone, and improve symptom control.
219222924|NCT07196397|BEHAVIORAL|Hybrid Cardiac Rehabilitation Program|A two-phase program combining supervised inpatient exercise, respiratory training, psychological support, and education with a home-based telerehabilitation phase (Nordic walking, remote ECG and vital sign monitoring). The aim is to restore functional capacity, reduce symptoms, and improve autonomic balance.
219098141|NCT03590756|OTHER|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
219098142|NCT01100554|DEVICE|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
219098143|NCT02070484|BIOLOGICAL|NuCel|
219098144|NCT02070484|BIOLOGICAL|Demineralized Bone Matrix|
219098145|NCT04059757|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
219098146|NCT00682643|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray
219098147|NCT00682643|DRUG|vehicle placebo nasal spray|placebo
219098148|NCT01054261|DRUG|avanafil|200 mg avanafil tablet QD
219550309|NCT01253564|DRUG|RO5185426|960 mg b.i.d. orally
219550310|NCT06765668|DRUG|CREXONT ER|CREXONT ER capsule.
218984634|NCT00270439|PROCEDURE|removal of omentum|patients with type 2 diabetes had their omentum removed
218984635|NCT01821196|PROCEDURE|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
218984636|NCT04691271|PROCEDURE|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
218984637|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
218984638|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
218984639|NCT04548583|OTHER|Placebo|Normal saline
218984640|NCT00853775|OTHER|No intervention, observational study|
218984641|NCT05596344|OTHER|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
218984642|NCT05072704|DRUG|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
219098149|NCT02243241|DRUG|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.
219098150|NCT02243241|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
219098151|NCT02243241|DRUG|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
219098152|NCT02243241|DRUG|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
219098153|NCT02293772|OTHER|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
219098154|NCT02293772|OTHER|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
219098155|NCT02293772|OTHER|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
219098156|NCT02529150|BEHAVIORAL|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
219098157|NCT00190502|DRUG|Polyclonal anti-T-cell antibodies|
219098158|NCT05848479|OTHER|Abdominal bracing|they will perform 3 times/week of static abdominal contraction for six weeks.
219222925|NCT07196397|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique in which the vagus nerve is stimulated via surface electrodes placed on the skin, most commonly in the auricular region (e.g., tragus or cymba conchae). The intervention is performed using a certified external stimulation device that delivers mild electrical impulses to activate afferent vagal fibers. tVNS is used in the treatment of various conditions, including depression, epilepsy, migraine, chronic pain, and disorders of the autonomic nervous system such as postural orthostatic tachycardia syndrome (POTS) and inappropriate sinus tachycardia (IST). In this study, tVNS is applied as a supportive neuromodulatory therapy with individualized stimulation parameters and session duration based on clinical response and patient tolerance.
219222926|NCT07195968|DIAGNOSTIC_TEST|NTG-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Intracoronary NTG dosage will follow the protocol based on blood pressure.
219222927|NCT07195968|DIAGNOSTIC_TEST|Saline-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Ten millilitres of intracoronary saline will be given over five seconds.
219222928|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
219682785|NCT04658264|DIETARY_SUPPLEMENT|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
219682786|NCT06358833|PROCEDURE|endodontic needle (EN)|the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.
219682787|NCT06358833|PROCEDURE|Endodontic activation (EA)|the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
219682788|NCT02591641|DEVICE|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
219098159|NCT05848479|OTHER|clamshell exercise|Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
219098160|NCT04681118|BIOLOGICAL|NurOwn (MSC-NTF cells)|Intrathecal administration
219098161|NCT04045730|DRUG|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
219098162|NCT03118284|OTHER|urine collection|
219098163|NCT03118284|OTHER|Blood collection|
219098164|NCT03118284|BEHAVIORAL|NRS|
219098165|NCT01949688|BIOLOGICAL|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
219098166|NCT06349148|DIETARY_SUPPLEMENT|enteral immunonutrition|Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).
219098167|NCT06349148|DIETARY_SUPPLEMENT|standard oral enteral nutrition|Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).
219098168|NCT03187990|DRUG|[68Ga]PSMA-11|PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.
219222929|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
219222930|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
219222931|NCT07196488|OTHER|Dyadic Co-learning Intervention|Participants in the experimental group will receive routine care plus an 8-week Dyadic Co-learning Intervention, which will consist of three components: (1) a co-learning handbook, (2) a co-learning mobile app, and (3) professional support.
219222932|NCT07196228|DEVICE|Intervention Name (Arm 1): Narrow tie-base abutment Intervention Name (Arm 2): Regular tie-base abutment|"Arm 1 - Narrow tie-base abutment~Intervention Name: Narrow tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a narrow-diameter tie-base abutment.~Arm 2 - Regular tie-base abutment~Intervention Name: Regular tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a regular-diameter tie-base abutment."
219682789|NCT02591641|OTHER|Standard of Care|Standard ambulance stretcher mattress
219098169|NCT03187990|DRUG|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
219222933|NCT07197697|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy|The dosage of Iparomlimab and Tuvonralimab Injection is 5mg/kg, administered intravenously, with each treatment cycle lasting every 3 weeks. The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles. A total of 8 cycles of neoadjuvant chemotherapy combined with immunotherapy were performed before the surgery. It is recommended that the surgery be conducted within 4 weeks after the completion of neoadjuvant treatment. The postoperative adjuvant treatment can be continued with postoperative adjuvant chemotherapy and the treatment of the etolo combination antibody according to the decision of the researcher and/or the willingness of the subject.
219222934|NCT07196215|PROCEDURE|passive ultrasonic activation|passive ultrasonic irrigant activation will be performed by using a stainless steel ultrasonic Irrisafe file of size 20 (IRRI S 21/25; VDW, Germany) mounted on ultrasonic unit (Woodpecker Ultrasonic Scaler UDS-J). The file will be kept 2 mm short of working length loosely without binding to the canal. 2.5% NaOCl will be activated for 30 seconds by using a power setting of five
219222935|NCT07196215|PROCEDURE|sonic activation|root canals will be filled with 2.5% sodium hypochlorite and medium size tip (red, 25/04) of EndoAcivator (YAHOPE A3, China) will be used keeping it 2 mm short of working length. The activation of irrigant will be done in 2-3 mm vertical strokes for 30 seconds in between each instrumentation
219222936|NCT07197008|DRUG|Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab|Eligible patients will receive Sacituzumab tirumotecan at a dose of 4 mg/kg in combination with bevacizumab 5mg/kg by intravenous infusion on day 1 and day 15 of each 28-day cycle.
219222937|NCT07195682|DRUG|BMS-986506|Specified dose on specified days
219222938|NCT07197411|DIAGNOSTIC_TEST|Evaluating the Consistency and Accuracy of Two Devices in Monitoring Hemodynamic Parameters|This portable patch-type carotid ultrasound has not yet been used in clinical settings.
219222939|NCT07197411|DEVICE|Hemodynamic monitoring|Whether the parameters monitored by portable patch-based ultrasound devices agree with the gold standard has not yet been thoroughly validated
219222940|NCT07196631|DRUG|Liposomal Bupivicaine|patients randomized to the intervention arm received 133mg of liposomal bupivacaine
219222941|NCT07196631|DRUG|ropivacaine|those in the control group received 80mg of ropivacaine
219222942|NCT07196865|PROCEDURE|Open Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after external stripping and internal ligation, the surgical wound is left entirely open without sutures to heal by secondary intention. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
219222943|NCT07196865|PROCEDURE|Closed Hemorrhoidectomy (Ferguson Technique)|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the entire surgical wound is closed primarily using interrupted non-absorbable sutures. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
219098170|NCT05780294|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
219098171|NCT05780294|DRUG|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
219098172|NCT05780294|DRUG|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
219098173|NCT05780294|DRUG|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
219098174|NCT00566176|DEVICE|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
219098175|NCT05180292|DRUG|Carvedilol 12.5 MG|Carvedilol 12.5 mg
219098176|NCT04211922|DRUG|Alkotinib Capsules|Alkotinib 400mg QD
219098177|NCT05529160|DEVICE|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
219098178|NCT03549884|PROCEDURE|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
219098179|NCT03549884|PROCEDURE|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
219098180|NCT03390868|BEHAVIORAL|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
219222944|NCT07196865|PROCEDURE|Semi-Closed Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the distal half of the incision (away from the anal canal) is closed with interrupted sutures, while the proximal half remains open. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
219222945|NCT07197450|DRUG|intravenous administration of PTH1-84 mRNA|intravenous administration of PTH1-84 mRNA
219222946|NCT07197164|DRUG|Remdesivir (RDV)|Participants will receive their first dose of remdesivir also within the 24 (+/-12) hours prior to going to the operating room. Remdesivir doses will be 200 mg on day 1, followed by 100 mg daily from days 2 to 10, for a total of 10 days.
219222947|NCT07196852|DIETARY_SUPPLEMENT|N Acetyl L Cysteine|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ).
219098181|NCT01177423|PROCEDURE|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
219098182|NCT04065503|BIOLOGICAL|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
219098183|NCT01870388|DRUG|Baricitinib|Administered orally
219098184|NCT01852058|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
219098185|NCT02930473|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
219682790|NCT05258734|OTHER|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
219222948|NCT07196852|DIETARY_SUPPLEMENT|Placebo|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day.
219222949|NCT07196891|OTHER|frontal-QRST angle|The frontal QRS/T angle represents the angle between the ventricular depolarization (QRS) and repolarization (T) vectors on the ECG and serves as a parameter for assessing cardiac electrical heterogeneity. In this study, the frontal QRS/T angle was calculated using data obtained from standard 12-lead surface ECGs. The QRS and T axes in the frontal plane were derived from the automated ECG device reports.
219222950|NCT07196891|OTHER|Hunt-Hess scale|The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5: - Grade 1: Asymptomatic or minimal headache, slight neck stiffness. - Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy. - Grade 3: Drowsiness, confusion, or a mild focal deficit. - Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance. - Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance.
219682791|NCT05258734|OTHER|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
219098186|NCT02930473|DRUG|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
219098187|NCT00957606|PROCEDURE|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
219098188|NCT05316584|BEHAVIORAL|Remote monitoring|See prior description of the intervention.
219098189|NCT04770363|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
219098190|NCT00622180|DEVICE|NBUVB|NBUVB hand foot box
219098191|NCT00622180|DEVICE|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
219098192|NCT06300255|BEHAVIORAL|H.O.O.V.E.S. Healing Intensives|"H.O.O.V.E.S. is a private, donor-supported charity dedicated to providing fully-funded, \[4\]-day, non-clinical healing intensives for veterans, their families and caregivers, and first responders across the nation who are seeking recovery from service-connected stress. 1~References~1\. Home. HOOVES for Vets. Accessed January 24, 2024. https://www.hooves.us/."
219098193|NCT02280239|DRUG|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
219682792|NCT00463918|DRUG|varenicline|
219682793|NCT00055445|DRUG|IdB 1016|
219682794|NCT01014247|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
219682795|NCT01014247|DRUG|Placebo|Single dose of matching tablet
219682796|NCT00137345|DRUG|sirolimus|
219682797|NCT02285075|DRUG|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).
219098194|NCT02280239|DRUG|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
219098195|NCT06292351|DRUG|DMB-I (Dimebon)|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
219098196|NCT06292351|OTHER|Placebo|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
219098197|NCT02439749|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
219098198|NCT02439749|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
219098199|NCT05505877|DRUG|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
219098200|NCT02616887|RADIATION|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
219098201|NCT06332079|PROCEDURE|166Holmium TARE|166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.
219098202|NCT06332079|DRUG|Cetuximab|Target agent
219098203|NCT06332079|DRUG|Panitumumab|Target agent
219098204|NCT06332079|DRUG|5-Fluorouracil|Chemotherapy
219098205|NCT06332079|DRUG|Bevacizumab|Target agent
219098206|NCT06332079|DRUG|Capecitabine|Chemotherapy
219098207|NCT00217646|DRUG|Sorafenib Tosylate|Given orally
219098208|NCT04978155|DIAGNOSTIC_TEST|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
219098209|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
219098210|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
219098211|NCT06447350|BEHAVIORAL|Induced hypocrisy|Induced hypocrisy task
219098212|NCT06447350|BEHAVIORAL|social identity mapping|Social identity mapping task
219098213|NCT06447350|BEHAVIORAL|Motivational modeling|Motivational modeling task
219098214|NCT06447350|BEHAVIORAL|motivational interviewing|motivational interviewing
219098215|NCT02385994|DEVICE|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
219098216|NCT05203120|RADIATION|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
219098217|NCT01353222|BIOLOGICAL|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
219098218|NCT01353222|OTHER|Standard of Care|Observation only until documentation of disease recurrence.
219550311|NCT04085861|BEHAVIORAL|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
219550312|NCT04085861|BEHAVIORAL|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
219098219|NCT06320301|DRUG|Adebrelimab + GEMOX + TKI|"Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated."
219550313|NCT01723202|DRUG|dabrafenib|150 mg orally twice daily given orally
219550314|NCT01723202|DRUG|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
219550315|NCT07070856|DIETARY_SUPPLEMENT|WHO-recommended standard therapeutic milk used for stabilization phase in SAM)|F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
219098220|NCT02636270|DRUG|Increlex|Treat PAPP-A2 deficient patients with Increlex
219098221|NCT05597657|OTHER|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
219098222|NCT01119898|DRUG|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
219098223|NCT01119898|DRUG|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
219098224|NCT04762693|DEVICE|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
219098225|NCT02572557|DEVICE|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
219098226|NCT02572557|DRUG|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
219098227|NCT03407690|OTHER|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
219098228|NCT02432469|BEHAVIORAL|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
219098229|NCT01806584|BIOLOGICAL|SRM003|One time implant (3 SRM003 pieces) on surgery day.
219098230|NCT01806584|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
219098231|NCT01574768|PROCEDURE|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
219098232|NCT03945864|DEVICE|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
219098233|NCT03945864|DEVICE|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
219098234|NCT01455207|BEHAVIORAL|Neuropsychological testing|assessment of memory, executive functions and ataxia
219098235|NCT01455207|BIOLOGICAL|blood draw|hepatic markers, red blood markers and vitamin markers
219098236|NCT01455207|GENETIC|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
219098237|NCT01455207|OTHER|Brain imaging examination|MRI, DTI and PET examinations
219098238|NCT03207139|DRUG|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
219098239|NCT05716984|DRUG|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
219098240|NCT05716984|DRUG|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
219682798|NCT01678118|BEHAVIORAL|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
219222951|NCT07196891|OTHER|modified Fisher scale|The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed: - Grade 0: No hemorrhage apparent in CT. - Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH). - Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH. - Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH. - Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH.
219222952|NCT07196254|PROCEDURE|sandwich mesh technique|the hernia repair include using double mesh onlay and sublay
219222953|NCT07197385|PROCEDURE|Laparoscopic Ureterolithotomy|Keyhole laparoscopic approach to remove proximal ureteral stones by direct ureteral incision and closure.
219222954|NCT07197385|PROCEDURE|Ureteroscopic Lithotripsy|Semirigid ureteroscopic fragmentation of upper ureteral stones using pneumatic lithotripsy.
219222955|NCT07196696|DEVICE|GMA-Tulip|Under general anesthesia, GMA-Tulip laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
219682799|NCT04993079|DEVICE|Clotild®|Use of Clotild® as neurovascular guidewire
219682800|NCT03235466|BEHAVIORAL|Voice Therapy|See Arm 1 \& 2
219682801|NCT03235466|BEHAVIORAL|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 \& 3
219682802|NCT03235466|BEHAVIORAL|Heart Rate Variability Biofeedback|See Arm 2 \& 3
219682803|NCT00116948|DEVICE|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
218984643|NCT05072704|DRUG|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
219682804|NCT03038529|PROCEDURE|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
219682805|NCT03038529|PROCEDURE|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
219682806|NCT01433419|DRUG|TAK-875|
219682807|NCT01433419|DRUG|TAK-875|
219682808|NCT02300623|DRUG|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
219682809|NCT02300623|DRUG|Antiretroviral therapy alone|Standard antiretroviral therapy
219682810|NCT05807971|DRUG|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
219682811|NCT05807971|DRUG|Placebo|Identical capsule to the drug without the active ingredient.
219682812|NCT02372344|DRUG|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
219682813|NCT01018758|DRUG|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
219682814|NCT02309970|DRUG|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
219682815|NCT02309970|DRUG|alteplase|subject in this group will receive intravenous tPA
219682816|NCT02309970|PROCEDURE|endovascular|
219682817|NCT02923583|BIOLOGICAL|M834|
219682818|NCT02923583|BIOLOGICAL|US-Sourced Orencia®|
219682819|NCT02923583|BIOLOGICAL|EU-Sourced Orencia®|
219682820|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
218984644|NCT01406743|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
218984645|NCT03812107|OTHER|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
218984646|NCT03812107|OTHER|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
218984647|NCT06499649|DIETARY_SUPPLEMENT|IBSA Probiotics|Dietary supplement base on probiotic strains.
218984648|NCT06499649|DIETARY_SUPPLEMENT|Placebo|The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
218984649|NCT03318510|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
218984650|NCT00209534|DRUG|fospropofol disodium|
218984651|NCT00159120|OTHER|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
219682821|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
219682822|NCT05225558|DRUG|Delpazolid|BID, PO
219682823|NCT05225558|DRUG|Vancomycin|IV infusion per 2020 IDSA guideline
219682824|NCT05225558|DRUG|Placebo of Delpazolid|BID, PO
219682825|NCT05453110|BEHAVIORAL|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
219682826|NCT03006562|DRUG|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
219682827|NCT05793749|BEHAVIORAL|Prophylactic lymphedema treatment|1\. perform manual lymphatic drainage twice a week after the start of radiotherapy for a total of 10 times, and wear lymphedema compression stockings after each manual lymphatic drainage, 2. teach patients how to care for their skin. 3. perform functional exercises for lymphedema of the lower extremities twice a day for 15 \~ 20 minutes each time. 4. follow up observation: before the start of radiotherapy, every Friday during radiotherapy, and every 3 months after the end of radiotherapy, the occurrence of lymphedema and related symptoms and quality of life were evaluated.
219222956|NCT07196696|DEVICE|I-gel|Under general anesthesia, I-gel laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
219222957|NCT07196696|DEVICE|LMA-Supreme insertion|Under general anesthesia, LMA Supreme laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
219222958|NCT07197801|BEHAVIORAL|Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment|The intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and aﬃliational support to participants.
219222959|NCT07196007|BEHAVIORAL|Community-Clinical Intervention|The intervention involves enhancing usual care for screening patients with diabetes for unmet social needs and referring those who screen positive to a Community Health Worker. Patients who screen positive for unmet social needs will work with CHWs to be connected to community organizations.
219222960|NCT04152408|DEVICE|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
219222961|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
219222962|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
218984652|NCT01187433|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
219222963|NCT04302233|OTHER|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
219222964|NCT07197151|OTHER|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
219222965|NCT07197554|DRUG|ST-01156|ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer
218984653|NCT01187433|BIOLOGICAL|NaCl 0.9%|0.5 mL, Subcutaneous
218984654|NCT01187433|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
218984655|NCT01187433|BIOLOGICAL|Meningococcal A+C vaccine|0.5 mL, Intramuscular
218984656|NCT01349179|DEVICE|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
218984657|NCT00526942|BEHAVIORAL|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
218984658|NCT02236442|OTHER|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
218984659|NCT03748108|DRUG|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
218984660|NCT03748108|DRUG|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
218984661|NCT01773252|DEVICE|Flow Detection System|
218984662|NCT00547547|DIETARY_SUPPLEMENT|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
218984663|NCT00547547|DRUG|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
218984664|NCT00547547|DRUG|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
218984665|NCT00074269|BIOLOGICAL|anti-thymocyte globulin|
218984666|NCT00074269|BIOLOGICAL|filgrastim|
218984667|NCT00074269|BIOLOGICAL|graft-versus-tumor induction therapy|
218984668|NCT00074269|BIOLOGICAL|therapeutic allogeneic lymphocytes|
218984669|NCT00074269|DRUG|cyclosporine|
218984670|NCT00074269|DRUG|fludarabine phosphate|
218984671|NCT00074269|DRUG|melphalan|
218984672|NCT00074269|DRUG|methotrexate|
218984673|NCT00074269|PROCEDURE|peripheral blood stem cell transplantation|
218984674|NCT04495270|DIAGNOSTIC_TEST|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
218984675|NCT00144391|DRUG|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
219098241|NCT06185010|OTHER|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
219098242|NCT06185010|OTHER|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
219098243|NCT06185010|OTHER|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
219098244|NCT06185010|OTHER|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
219098245|NCT06185010|OTHER|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
219098246|NCT01665703|PROCEDURE|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
219222966|NCT07196618|DRUG|dimethyl sulfoxide|dentin pretreated using dimethyl sulfoxide and follow up of patients at 2 weeks, 3 months and 6 months
219222967|NCT07196618|DRUG|Cholorhexidine|dentin pretreated using chlorhexidine and follow up of patients at 2 weeks, 3months and 6 months
219222968|NCT07197567|DRUG|Sevoflurane + Remifentanil|Combination of an inhalational anesthetic (sevoflurane) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
219222969|NCT07197567|DRUG|Propofol + Remifentanil|Combination of an intravenous anesthetic (propofol) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for induction and maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
219222970|NCT07197567|DRUG|Sevoflurane + Propofol + Remifentanil|Combination of an inhalational anesthetic (sevoflurane), an intravenous anesthetic (propofol), and an intravenous opioid analgesic (remifentanil). These agents are routinely used together in clinical practice for combined intravenous-inhalational anesthesia (CIVIA). All drugs are administered according to standard of care, not as experimental interventions.
219098247|NCT05378243|DEVICE|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
219098248|NCT05378243|BEHAVIORAL|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
219222971|NCT07196306|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution|At the time of enrollment, the intervention arm subjects are administered single or double dose of study drug while the placebo arm subjects are administered the placebo drug (normal saline). Subjects will be assigned to the intervention or placebo arm in random order.
219222972|NCT07196306|DRUG|Placebo|Normal saline 0.9% 1.14 mL Subcutaneous x 1 or 2 dose(s)
219222973|NCT07195981|DEVICE|virtual reality|The virtual reality (VR) technology is defined as a system that allows users to interact with images and sounds in a virtual environment, which can stimulate responses and provide real-time feedback concerning their performance.
219222974|NCT07195981|OTHER|selected physical therapy|selected physical therapy program only included: (Therapeutic Ultrasound device, Transcutaneous Electrical Nerve Stimulation (TENS) and Hot packs)
219222975|NCT07197580|RADIATION|177Lu-TLX250|3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals
219222976|NCT07197424|DIAGNOSTIC_TEST|Robot assisted magnetically controlled capsule endoscopy|Examination of the upper GI tract (oesophagus and stomach) with robot assisted magnetically controlled capsule endoscopy. Examination of the small bowel will be completed using the same capsule, however it will not be robot assisted.
219222977|NCT07197294|DRUG|nL-MAPK8-001|Personalized antisense oligonucleotide
219098249|NCT01593202|BEHAVIORAL|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
219098250|NCT01593202|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
219098251|NCT05063214|DIAGNOSTIC_TEST|Muscle ultrasound evaluation|Muscle ultrasound evaluation will be performed in patients admitted with COVID-19 requiring invasive mechanical ventilation. The measurements of thickness and thickening fraction will occur for diaphragm, abdominal - rectus abdominis, internal oblique, external oblique and transverse abdomen - and parasternal intercostal muscles. Serial measurements of the thickness and echogenicity of the quadriceps femoris muscle will also be performed.
219222978|NCT07196670|DRUG|intralesional vitamin D3 versus intralesional acyclovir|injecting intralesional vitamin D in group A versus injecting intralesional acyclovir in group B in treatment of plantar warts
219098252|NCT02907814|DEVICE|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
219098253|NCT02907814|OTHER|Eye Exam|This is a brief, non-contact ocular exam.
219098254|NCT00834808|DRUG|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
219222979|NCT07195877|DEVICE|Insertion/placement of tension threads|"* Standard preoperative anti-staphylococcal antibiotic prophylaxis by intramuscular injection.~* Disinfection of the surgical area.~* Marking of the paths of the threads to be implanted according to the physician's choice.~* Placement of sterile surgical drapes.~* Local anesthesia of the paths.~* Implantation of a needle (manufactured by Thread \& Lift) and pulling of the threads into the subcutaneous tissue. Adjustment of the tension of all the implanted threads. Cutting of the ends of the threads."
219098255|NCT05788835|PROCEDURE|DEB-TACE and HAIC|Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
219098256|NCT05788835|PROCEDURE|DEB-TACE|Drug-eluting bead transarterial chemoembolization
219098257|NCT02716389|OTHER|Zebris CMS 70|
219098258|NCT02716389|OTHER|3-D Bulls Eye Spirit Meter|
219098259|NCT03716284|PROCEDURE|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
219098260|NCT00583622|DRUG|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
219098261|NCT00583622|DRUG|Carboplatin|333 mg/m\^2 by vein over 2 hours for 3 Days
219098262|NCT00583622|DRUG|Docetaxel|300 mg/m\^2 by vein over 2 hours for 1 Day
219098263|NCT00583622|DRUG|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
219098264|NCT00583622|DRUG|Melphalan|50 mg/m\^2 by vein over 15 minutes for 3 Days
219098265|NCT00583622|PROCEDURE|Stem Cell Transplant|"* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
219098266|NCT04023071|DRUG|FT516|Experimental Interventional Therapy
219098267|NCT04023071|DRUG|Rituximab|Monoclonal Antibody
219098268|NCT04023071|DRUG|Obinutuzumab|Monoclonal Antibody
219098269|NCT04023071|DRUG|Cyclophosphamide|Conditioning agent
219098270|NCT04023071|DRUG|Fludarabine|Conditioning agent
219098271|NCT04023071|DRUG|IL-2|Biologic response modifier
219098272|NCT04023071|DRUG|Bendamustine|Conditioning agent
219098273|NCT05403190|DEVICE|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
219098274|NCT03266614|BEHAVIORAL|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
219098275|NCT00163995|DRUG|urotensin II|
219098276|NCT04398537|DEVICE|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
219222980|NCT07197632|PROCEDURE|Surgery with intraoperative MRI|In this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically
219098277|NCT04398537|DEVICE|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
219098278|NCT03994783|DRUG|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
219098279|NCT03994783|DRUG|Methylprednisolone|Intravenous infusion of methylprednisolone
219098280|NCT03994783|DRUG|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
219098281|NCT03994783|PROCEDURE|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
219682828|NCT00553488|DRUG|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
219098282|NCT03333850|DEVICE|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
219098283|NCT03333850|DEVICE|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
219098284|NCT03333850|DEVICE|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
219098285|NCT02717169|DEVICE|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
219222981|NCT07197853|DRUG|Huaier Granule|Patients in this arm will undergo CT-guided percutaneous microwave ablation using a standard protocol (2450 MHz, 30-50 W, 5-10 minutes per lesion, multi-probe as needed based on tumor size). Seven days post-ablation, patients will start oral administration of Huaier granules at a dose of 10g, three times daily (TID), for 72 consecutive weeks. The combined therapy aims to improve local tumor control and modulate anti-tumor immunity.
219098286|NCT05919693|DRUG|EYE103|EYE103 is a humanized antibody formulated for IVT administration
219098287|NCT06918379|DEVICE|Cogmed Working Memory Training (CWMT)|"This is an intensive, eye-tracking working memory (WM) training in school-aged children and young adults with severe cerebral palsy. The Cogmed Working Memory Training (CWMT) software was used as intervention software. The CWMT is adaptive, meaning, it becomes either progressively more difficult or less difficult depending on participants' performance. When a participant completes a trial correctly, the level will increase for the next trial. When a participant makes an error, the next trial will either remain on the same level or decrease in level depending on the type of error made. The CWMT program thus adapts on an individualized basis to participant's performance, allowing for training to occur at or close to an individual's highest capacity.~Participants with severe cerebral palsy, users of eye-tracking technology, trained for \~30 minutes, 5 days a week for 5 weeks, i.e. 25 training sessions in total."
219098288|NCT01194284|DRUG|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
219098289|NCT04203927|DRUG|Empagliflozin 25 MG|SGLT-2 inhibitor
219098294|NCT01486615|DRUG|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
219098295|NCT01486615|DRUG|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
219098296|NCT01486615|DRUG|(alprax) alprazolam|0.5 mg alprazolam
219098297|NCT01486615|DRUG|placebo|similar looking placebo tablet
219098298|NCT04182230|OTHER|No intervention. This study was an evalution with no intervention.|Not an interventional study
219098299|NCT03298620|OTHER|Electric toothbrush|
219098300|NCT03298620|OTHER|Control|Manual toothbrush
219098301|NCT04186676|OTHER|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
219098302|NCT04186676|DIAGNOSTIC_TEST|CCTA Phenotypes|"1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges"
219098303|NCT03610737|DEVICE|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
219222982|NCT07195916|DRUG|INCA036873|Intravenously (IV)
219222983|NCT07196787|OTHER|Exercise|"The 18-Week Program Structure This program is divided into three 6-week phases. Each week consists of 5 sessions, mixing different focuses to ensure balanced development.~Day 1: Foundational Strength \& Stability~Day 2: Low-Impact Cardio \& Active Recovery~Day 3: Core Focus \& Hip Stability~Day 4: Low-Impact Cardio \& Mobility~Day 5: Full Body Integration \& Strength"
219222984|NCT07197021|DEVICE|TEER|TEER
219222985|NCT07197021|DRUG|GDMT|GDMT
219682829|NCT00553488|DRUG|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
219682830|NCT02702089|PROCEDURE|Rectal cancer surgery|Rectal cancer resection
219098304|NCT03610737|OTHER|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
219222986|NCT07197346|DEVICE|rTMS - cTBS (Continuous Theta-Burst Stimulation)|Continuous theta-burst stimulation (cTBS) is a patterned form of rTMS consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz), administered continuously without breaks. In this study, cTBS is delivered over the target cortical area according to established safety guidelines (e.g., a continuous 40s train for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure is used to induce a transient reduction in cortical excitability as a priming intervention prior to motor practice.
219098305|NCT05220007|DIAGNOSTIC_TEST|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
219098306|NCT03303677|DRUG|Saline Nasal|topical nasal saline rinses
219098307|NCT03303677|DRUG|Budesonide Nasal|saline + budesonide nasal saline irrigation
219098308|NCT03303677|DRUG|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
219098309|NCT00575497|PROCEDURE|More frequent hemodialysis|Six Day per week short daily hemodialysis
219098310|NCT00575497|PROCEDURE|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
219098311|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other day short daily hemodialysis
219098312|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other night hemodialysis
219098313|NCT00575497|PROCEDURE|More frequent hemodialysis|5 days per week short daily hemodialysis
219098314|NCT00575497|PROCEDURE|More frequent hemodialysis|5 nights per week hemodialysis
219098315|NCT00575497|PROCEDURE|Conventional Hemodialysis|3 days per week short daily hemodialysis
219098316|NCT01788345|OTHER|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
219098317|NCT03221010|BEHAVIORAL|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
219098318|NCT03221010|BEHAVIORAL|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
219098319|NCT01616875|DRUG|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
219098320|NCT04319601|DRUG|Rituximab|a new chemotherapy regimen
219222987|NCT07197346|BEHAVIORAL|Self-controlled (autonomy)|Self-controlled practice is a motor learning intervention in which participants are granted autonomy to make choices about key aspects of their practice sessions (e.g., when to receive feedback, the sequence/timing of trials, or selection of specific practice parameters). This design allows participants to actively control elements of the training experience according to their preference, thereby fostering intrinsic motivation and engagement. The intervention is grounded in the OPTIMAL theory of motor learning, which highlights the role of autonomy support in enhancing learning outcomes and motivation. In this study, participants in the self-controlled practice group make their own decisions regarding practice conditions, in contrast to yoked controls who follow externally assigned parameters.
219222988|NCT07197346|DEVICE|Sham|Sham TBS involves the application of a sham theta-burst stimulation protocol designed to mimic the sensory experience of active TBS without delivering effective magnetic pulses to the brain. This is typically achieved by angling the coil to prevent cortical stimulation. The procedure controls for placebo effects and participant expectations while ensuring blinding. The sham stimulation session matches the timing and setup of active TBS interventions but does not induce cortical excitability changes.
219098321|NCT03841123|OTHER|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
219098322|NCT02674932|BEHAVIORAL|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
219098323|NCT02674932|BEHAVIORAL|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
219098324|NCT02674932|BEHAVIORAL|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
219098325|NCT02931890|DRUG|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
219098326|NCT02931890|DRUG|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
219098327|NCT02931890|DRUG|Capecitabine|oral capecitabine in arm 1 and 2
219098328|NCT02931890|PROCEDURE|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
219098329|NCT02931890|RADIATION|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
219098330|NCT02931890|DRUG|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
219098331|NCT02931890|DRUG|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
219098332|NCT00002443|DRUG|Indinavir sulfate|
219098333|NCT00002443|DRUG|Zidovudine|
219098334|NCT04380129|OTHER|Music therapy-conversation sessions|"The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. The musical hearing will include Helen Bonny's program Caring, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio~* Dvorak - Serenade in E-Dur, Larghetto~* Warlock - Capriol Suite, Pieds en I'air"
219098335|NCT04380129|OTHER|Music Listening|Music Listening to Helen Bonny's programme.
219098336|NCT04438902|DRUG|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
219098337|NCT02057601|DRUG|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
219098338|NCT01833312|DEVICE|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
219098339|NCT01833312|DRUG|Buspirone|anti-shivering treatment
219098340|NCT01833312|DRUG|Pethidine|anti-shivering treatment
219098341|NCT03634501|BIOLOGICAL|Activated NK|Cell suspension
219098342|NCT01047644|OTHER|Reduced port-flush schedule|3-month port-flushing
219098343|NCT00357045|DRUG|Paroxetine|
219098344|NCT05514262|OTHER|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
219098345|NCT05514262|DEVICE|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
219098346|NCT06286553|BEHAVIORAL|Trunk exercise|Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.
219098347|NCT06286553|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Inspiratory muscle strengthening exercises using inspiratory resistance (IMT devices)
219098348|NCT06286553|BEHAVIORAL|Control Group|Participants in the Control Group will receive general management information for DRA, written instructions and a single educational exercise session for contracting the deeper abdominals and pelvic floor muscles.
219098349|NCT05514119|DRUG|Fenofibrate|160mg once daily orally for 12 weeks
219098350|NCT06066710|DRUG|Propranolol|Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
219098351|NCT06066710|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
219098352|NCT06066710|DRUG|Placebo|Placebo will be given on the same schedule as the propranolol regime.
219098353|NCT02991482|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
219098354|NCT02991482|DRUG|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
219098355|NCT02991482|DRUG|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
219098356|NCT03450655|OTHER|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
219098357|NCT05391932|BEHAVIORAL|MINDGAPS|Utilize wearable sensor technology to provide simple, precise measures of gaze and postural stability, as well as remote monitoring of patient adherence to vestibular exercises during a 6-week training period. Additionally, NIH Toolbox data will be used to display patient status compared to normative values and to indicate progress over time relative to measurement error.
219098358|NCT05873725|DRUG|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
219098359|NCT06191263|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
219098360|NCT06191263|DRUG|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
219098361|NCT06847126|DRUG|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks and standard care
219098362|NCT06847126|DRUG|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks
219098363|NCT06847126|OTHER|Standard medical care|Percutaneous drainage or aspiration of the abscess along resuscitative and symptomatic medications
219098364|NCT02320422|BEHAVIORAL|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
219098365|NCT01421095|DRUG|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
219098366|NCT01724645|DIETARY_SUPPLEMENT|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
219098367|NCT01724645|DIETARY_SUPPLEMENT|Control group|"Told to  eat as usal diets."
219098368|NCT05426564|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219098369|NCT04293588|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
219098370|NCT05900622|OTHER|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
219098371|NCT05900622|OTHER|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
219098372|NCT05624840|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir (Paxlovid)
219098373|NCT04398446|DRUG|Hemp-based CBD|3x Daily dosing for 12 weeks
219098374|NCT04398446|OTHER|Placebo oral tablet|3x Daily dosing for 12 weeks
219098375|NCT02105441|DEVICE|Cochlear implant|Implantable hearing device
219098376|NCT00756522|OTHER|There is no intervention. Study is observational.|There is no intervention. Study is observational.
219098377|NCT00518128|PROCEDURE|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
219098378|NCT00518128|PROCEDURE|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
219098379|NCT05721508|OTHER|Combined physical and cognitive program|All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
219098380|NCT05899660|DIETARY_SUPPLEMENT|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
219098381|NCT05899660|DIETARY_SUPPLEMENT|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
219098382|NCT00400543|DEVICE|Continuous positive airway pressure (CPAP)|
219098383|NCT02396537|DRUG|Lidocaine|Administered intranasally prior to Midazolam administration.
219098384|NCT02396537|DRUG|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
219098385|NCT02396537|DRUG|0.9% Saline|Administered intranasally prior to Midazolam administration.
219222989|NCT07197346|BEHAVIORAL|Yoked Practice|Yoked practice refers to a motor learning protocol in which participants perform tasks under externally controlled practice conditions, matched to the parameters (e.g., feedback) of a paired participant from a self-controlled practice group. This design removes participant autonomy over practice choices, allowing comparison between self-controlled and externally controlled practice to evaluate the effects of autonomy on motor learning and motivation.
219550316|NCT07070856|DIETARY_SUPPLEMENT|HO-recommended Rice based therapeutic milk used for stabilization phase in SAM)|Rice based F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
219550317|NCT03694197|DRUG|Praluent|Subcutaneous (SC) administration
219550318|NCT03806257|OTHER|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
219098386|NCT03774602|BEHAVIORAL|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
219098387|NCT05447624|PROCEDURE|Radiofrequency ablation of genicular nerves|The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
219098388|NCT00871403|DRUG|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
219098389|NCT00871403|DRUG|pemetrexed and cisplatin|pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
219098390|NCT02599103|OTHER|Fat-free milkshake|participants drinks a fat-free milk shakes
219222990|NCT07197346|DEVICE|rTMS- iTBS (Intermittent Theta-Burst Stimulation)|Intermittent theta-burst stimulation (iTBS) is a patterned form of repetitive transcranial magnetic stimulation (rTMS) consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz). In this study, iTBS is delivered over the target cortical area using standard protocols (e.g., 2s trains of TBS repeated every 10s for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure aims to facilitate cortical excitability as a priming intervention prior to motor practice.
219222991|NCT07196982|OTHER|No intervention (observational study)|This is an observational retrospective case-control study. No experimental intervention is administered. All participants received standard surgical management for intertrochanteric femoral fractures according to clinical practice, including proximal femoral nail antirotation (PFNA) with or without additional lateral wall plate fixation. The study only compares clinical and radiological data between patients with isolated intertrochanteric fractures and those with concomitant lateral wall involvement.
219098391|NCT02599103|OTHER|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
219098392|NCT02599103|OTHER|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
219098393|NCT02599103|OTHER|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
219098394|NCT02599103|OTHER|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
219098395|NCT02599103|OTHER|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
219098396|NCT02599103|OTHER|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
219098397|NCT02599103|OTHER|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
219098398|NCT02599103|OTHER|Tallow|participants drinks the milk shakes prepared from 60g of tallow
219098399|NCT02599103|OTHER|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
219098400|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
219098401|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
219098402|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
219098403|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
219098404|NCT01562912|DEVICE|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
219098405|NCT01562912|DEVICE|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
219098406|NCT05420441|DEVICE|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
219098407|NCT05420441|DEVICE|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
219098408|NCT05420441|PROCEDURE|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
219098409|NCT05989373|DIAGNOSTIC_TEST|Scratch collapse test|Scratch test performed by the surgeon but with a dynamometer
219098410|NCT00748124|DEVICE|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
219098411|NCT00748124|PROCEDURE|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
219098412|NCT03405272|BIOLOGICAL|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
219098413|NCT00787319|OTHER|no intervention|Outpatients with age-related macular degeneration (AMD)
219098414|NCT01729117|OTHER|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
219550319|NCT07139067|BIOLOGICAL|YK1101 cells|Drug: Fludarabine + Cyclophosphamide
219550320|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
219098415|NCT01729117|OTHER|Standard Care|Standard Care only
219098416|NCT00371527|DRUG|ipratropium|
219098417|NCT02342665|DRUG|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
219098418|NCT02312856|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
219098419|NCT05461014|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
219098420|NCT03861520|DEVICE|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
219098421|NCT03861520|GENETIC|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
219222992|NCT06413979|BEHAVIORAL|Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)|(1) Family Engagement of caregivers and primary supports in treatment planning and services; (2) Relational Reframing of family constraints, resiliencies, and social capital connected to the youth's ID symptoms; (3) Functional Analysis of the youth's ID symptoms and related behaviors; (4) Cognitive-behavioral therapy (CBT) core techniques to address the youth's ID symptoms and functional needs, featuring three transdiagnostic interventions (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation underlying both depression and anxiety; and (5) Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of youth self-harm. All interventions featured in each module have strong empirical support.
219222993|NCT06414577|DRUG|Irinotecan Liposomal combined With Nituzumab|Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
219098422|NCT00602680|DRUG|SSR180711C|duration of treatment: 4 weeks
219098423|NCT00602680|DRUG|donepezil|duration of treatment: 4 weeks
219098424|NCT00602680|DRUG|placebo|duration of treatment: 4 weeks
219098425|NCT01170195|DIETARY_SUPPLEMENT|Calmera-Licorice Root Extract (Licogen)|100 mg per day
219098426|NCT00063102|DRUG|ABT-751|
219098427|NCT04415151|DRUG|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
219098428|NCT04415151|DRUG|Placebo|Matching placebo tablets will be administered.
219098429|NCT02732626|PROCEDURE|radiofrequency ablation|
219098430|NCT05414097|OTHER|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
219098431|NCT05414097|OTHER|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
219098432|NCT05414097|OTHER|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
219098433|NCT05414097|OTHER|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
219098434|NCT05414097|OTHER|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
219098435|NCT01778946|DRUG|Low Dose Nicotine (7mg)|
219098436|NCT01778946|DRUG|Moderate Dose Nicotine (14mg)|
219098437|NCT03237520|OTHER|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
219098438|NCT03237520|OTHER|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
219098439|NCT03046511|DRUG|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
219098440|NCT01310309|DEVICE|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
219098441|NCT03360877|OTHER|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
219098442|NCT02150837|OTHER|5 & 2 & 2 Plan|Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, \>72g protein, \>100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
219222994|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
219222995|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
219098443|NCT02150837|OTHER|4 & 2 & 1 Plan|Medifast has developed the 4 \& 2 \& 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 \& 2 \& 1 Plan consists of 4 Medifast meal replacements, 2 Lean \& Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, \>72g protein, \>100g carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
219098444|NCT00460720|OTHER|Observational treatment compliance survey|Observational treatment compliance survey
219098445|NCT01581697|DIETARY_SUPPLEMENT|Oat bran|
219098446|NCT02922790|BEHAVIORAL|standard health information|Subjects will review standard health information
219098447|NCT02922790|BEHAVIORAL|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
219098448|NCT02922790|BEHAVIORAL|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
219222996|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
219098449|NCT02478021|OTHER|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
219098450|NCT03365986|DIAGNOSTIC_TEST|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
219098451|NCT02459249|OTHER|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
219098452|NCT02459249|OTHER|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
219222997|NCT04994301|DIAGNOSTIC_TEST|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
219222998|NCT04692532|OTHER|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
219222999|NCT04692532|OTHER|Calorie restriction|25% energy restriction every day
219223000|NCT05475015|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
219098453|NCT02080195|DRUG|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
219098454|NCT02080195|DRUG|Fludarabine|30 mg/m\^2/day on Days -6 through -2.
219098455|NCT02080195|DRUG|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
219098456|NCT02080195|DRUG|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
219098457|NCT02080195|DRUG|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
219098458|NCT02080195|RADIATION|Total body irradiation|200 centigray on Day -1.
219098459|NCT02080195|BIOLOGICAL|Allogeneic bone marrow transplant|Infusion on Day 0.
219098460|NCT00335686|DRUG|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
219098461|NCT00335686|DRUG|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
219098462|NCT02211534|DEVICE|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
219098463|NCT02211534|DEVICE|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
219098464|NCT02608905|DRUG|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
219223001|NCT05475015|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
219098465|NCT02608905|DRUG|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
219098466|NCT02329301|DRUG|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
219098467|NCT02329301|DRUG|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
219098468|NCT04261660|OTHER|NO intervention|NO INTERVENTION
219098469|NCT04446715|DRUG|sufentanil|Patients will receive sufentanil in spinal anesthesia
219098470|NCT04446715|DRUG|meperidine|Patients will receive meperidine in spinal anesthesia
219223002|NCT06256393|OTHER|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
219223003|NCT06075966|OTHER|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
219098471|NCT04446715|DRUG|Bupivacaine|Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
219098472|NCT03717662|DRUG|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
219098473|NCT03784092|OTHER|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
219682831|NCT05861830|DRUG|The combination of Dalpiciclib with physician-selected endocrine therapy|"* Dalpiciclib: 150 mg, orally, once daily, on days 1-21, every 28 days (3 weeks on, 1 week off)~* Letrozole: 2.5 mg, orally, once daily (continuous), every 28 days OR Anastrozole: 1.0 mg, orally, once daily (continuous), every 28 days OR Exemestane: 25 mg, orally, once daily (continuous), every 28 days OR Fulvestrant: 500 mg, intramuscular injection on day 1/15 of the first cycle, then on day 1 of each subsequent cycle, every 28 days OR Tamoxifen: 10-20 mg, orally, twice daily (continuous), every 28 days~* Pre/perimenopausal women also require ovarian function suppression (OFS), which can be achieved through bilateral oophorectomy or the use of gonadotropin-releasing hormone (GnRH) analog drugs"
218984676|NCT04647864|DEVICE|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
218984677|NCT00672646|DRUG|AZD1386|95mg, oral solution, single dose
218984678|NCT00672646|DRUG|Naproxen|500mg, capsule, single dose
218984679|NCT00672646|DRUG|Placebo|AZD1386 Placebo oral solution
218984680|NCT00066352|DRUG|bortezomib|
218984681|NCT05223933|BEHAVIORAL|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
218984682|NCT05499000|BEHAVIORAL|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
218984683|NCT02269306|DRUG|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
218984684|NCT03883711|OTHER|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
218984685|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
218984686|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
218984687|NCT04993820|BEHAVIORAL|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
219098474|NCT03353259|COMBINATION_PRODUCT|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
219098475|NCT04501289|DRUG|Low dose magnesium sulphate|Participants in this arm will receive 4g of 20% intravenous (I.V.) MgSO4 (Magphate®) given over 10 minutes, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 administered intramuscularly 4 hourly for 24 hours, for participants with severe preeclampsia and for 24 hours post delivery or post last seizure episode, whichever occurs last, for cohorts with eclampsia.
219098476|NCT04501289|DRUG|Pritchard regimen|Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
219098477|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg \[3.7 MBq/kg\] (minimum dose 1mCi \[37MBq\] but not to exceed 5 mCi \[185 MBq\]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
219098478|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed \> 23 Gy to the kidneys, \> 30 Gy to the liver, or \> 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
219098479|NCT03894150|DRUG|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
219098480|NCT03862287|DRUG|Lidocaine|See arm description.
219223004|NCT06075966|OTHER|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
219223005|NCT04858412|DIETARY_SUPPLEMENT|β-hydroxy β-methyl butyrate (HMB) enriched amino acid|β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
219223006|NCT04858412|DIETARY_SUPPLEMENT|Balanced amino acid|Balanced amino acid is the balanced mixture of the various essential amino acids.
219682832|NCT05861830|DRUG|Chemotherapy selected by the physician|The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
219098481|NCT03862287|DRUG|Bupivacaine Hcl 0.5% Inj_#2|See arm description.
219223007|NCT04148742|DRUG|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
219223008|NCT05396638|BEHAVIORAL|Contingency Management|Participants will be paid for abstinence at each study visit.
219223009|NCT06217588|OTHER|Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.|The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.
219550321|NCT03749720|OTHER|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
219550322|NCT05419934|BEHAVIORAL|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization."
219550323|NCT05419934|BEHAVIORAL|CBT Control therapy|Children in the control group receive Cognitive Behavioral Therapy (CBT) administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P).Cognitive and behavioral therapies are a standard treatment in the care service. Children in the control group will receive CBT specific to the treatment of PTSD in children under 6 years of age. CBT treatments dedicated to early childhood trauma have already been tested in the United States, and have shown evidence of effectiveness in randomized controlled trials (Mc Guire et al., 2021; Scheeringa et al., 2011).
219550324|NCT05638633|DRUG|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
219550325|NCT05638633|DRUG|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
219550326|NCT05638633|DRUG|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
219682833|NCT01429467|DEVICE|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
219682834|NCT02137941|BEHAVIORAL|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
219223010|NCT06282913|BEHAVIORAL|Mindfulness Meditation|Mindfulness Meditation application will be implemented online by the researcher in 20-minute group sessions once a week for 8 weeks. Participants will be asked to provide a quiet, ventilated, dimly lit environment for the practice. The researcher will start the application when the participants take their places as they feel comfortable. In the first stage, the researcher will teach physicians and nurses to take deep diaphragmatic breaths through the nose and out through the mouth.
219223011|NCT02808468|BEHAVIORAL|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
219223012|NCT05405140|OTHER|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
219223013|NCT05405140|OTHER|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
219223014|NCT05887531|OTHER|Prehabilitation|Patients will be included in a prehabilitation program
219223015|NCT01434251|OTHER|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
219223016|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
219223017|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
219223018|NCT02632994|DRUG|LY2503029|Administered orally.
219223019|NCT02632994|DRUG|LY3023414|Administered orally.
219223020|NCT02632994|DRUG|LY3838915|Administered orally.
219223021|NCT02632994|DRUG|LY3847429|Administered orally.
219223022|NCT04266236|PROCEDURE|L3 LPB|ultrasound-guided L3 lumbar plexus block
219098482|NCT01208298|DEVICE|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
219098483|NCT01694602|BIOLOGICAL|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
219223023|NCT04266236|PROCEDURE|L4 LPB|ultrasound-guided L4 lumbar plexus block
219223024|NCT04266236|PROCEDURE|T12 block|ultrasound-guided thoracic 12th segment nerve block
219223025|NCT04266236|PROCEDURE|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
219223026|NCT04266236|DRUG|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
219098484|NCT05485610|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
219098485|NCT05485610|OTHER|Placebo|NMN-free placebo capsules for 3 months
219098486|NCT05379257|COMBINATION_PRODUCT|Random dosage and time of furosemide|Random dosage and time of furosemide, using a designated app
219098487|NCT05067569|BEHAVIORAL|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
219223027|NCT04266236|DRUG|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
219223028|NCT04266236|PROCEDURE|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
219223029|NCT03469791|PROCEDURE|Surgical treatment of Degenerative Spondylolisthesis|
219223030|NCT06247904|DEVICE|Active rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
219223031|NCT06247904|DEVICE|sham rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
219223032|NCT06429449|DRUG|Venetoclax|Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
219223033|NCT06429449|DRUG|Azacitidine|An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
219223034|NCT06429449|DRUG|Mitoxantrone|Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
219223035|NCT05006482|OTHER|Best Practice|Receive usual follow-up survivorship care
219223036|NCT05006482|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
219223037|NCT05006482|OTHER|Educational Intervention|Participate in survivorship health education sessions
219223038|NCT05006482|OTHER|Exercise Intervention|Participate in EXCAP program
219223039|NCT05006482|OTHER|Questionnaire Administration|Ancillary studies
219223040|NCT05006482|PROCEDURE|Tailored Intervention|Participate in GEM consultation
219223041|NCT04172675|DRUG|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
219098488|NCT05067569|BEHAVIORAL|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
219098489|NCT00955786|DRUG|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
219098490|NCT01347385|PROCEDURE|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
219098491|NCT01347385|PROCEDURE|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
219098492|NCT05675852|OTHER|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
219223042|NCT04172675|DRUG|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
219223043|NCT04172675|DRUG|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
219223044|NCT05641766|DRUG|THC|Participants will receive THC into a rapidly flowing IV infusion.
219682835|NCT02137941|BEHAVIORAL|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
219223045|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
219682836|NCT01963702|DRUG|Docetaxol|
219682837|NCT01963702|DRUG|Oxaliplatin|
219682838|NCT01963702|DRUG|Capecitabine|
219682839|NCT03826017|DIETARY_SUPPLEMENT|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
219682840|NCT03826017|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
219682841|NCT05947604|DRUG|Acoziborole|Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
219098493|NCT05936606|DRUG|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
219098494|NCT05936606|DRUG|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
219098495|NCT05631184|BEHAVIORAL|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
219098496|NCT05631184|BEHAVIORAL|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
219098497|NCT00429689|PROCEDURE|Saliva sample|
219098498|NCT00927355|DRUG|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
219098499|NCT00927355|DRUG|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
219098500|NCT03842410|DEVICE|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
219098501|NCT05313750|DRUG|anti-infective therapy sitafloxacin|anti-infective therapy
219098502|NCT05313750|DRUG|anti-infective therapy levofloxacin|anti-infective therapy
219098503|NCT03975764|DIAGNOSTIC_TEST|Collection of fecal sample|Analysis of fecal microbiome
219098504|NCT01800201|BEHAVIORAL|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
219098505|NCT03704532|PROCEDURE|Operative treatment|Open surgical repair of tendon rupture
219098506|NCT03704532|PROCEDURE|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
219098507|NCT03654339|PROCEDURE|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
219098508|NCT02895022|DRUG|Lidocaine 2% adrénalinée|
219098509|NCT02895022|DEVICE|Epidural catheter|
219098510|NCT02895022|PROCEDURE|Caesarean section|
219098511|NCT00030420|DRUG|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
219098512|NCT00030420|DRUG|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
219098513|NCT05916976|DIAGNOSTIC_TEST|cardiac MRI|Multiparametric MRI of the heart
219098514|NCT01896284|DRUG|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
219098515|NCT04995237|BEHAVIORAL|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
219098516|NCT05553639|BIOLOGICAL|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
219223046|NCT03013218|DRUG|Evorpacept (ALX148)|Evorpacept (ALX148)
219223047|NCT03013218|DRUG|Pembrolizumab|Keytruda
219682842|NCT05947604|DRUG|Midazolam|• Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
219223048|NCT03013218|DRUG|Trastuzumab|Herceptin
219223049|NCT03013218|DRUG|Rituximab|Rituxan
219223050|NCT03013218|DRUG|Ramucirumab + Paclitaxel|Standard of care chemotherapy
219223051|NCT03013218|DRUG|5-FU + Cisplatin|Standard of care chemotherapy
219223052|NCT04400188|DRUG|Fluzoparib|Given PO
219223053|NCT04400188|DRUG|temozolomide|Given PO
219223054|NCT04400188|BIOLOGICAL|SHR-1316|Given injection
219223055|NCT06830681|DIETARY_SUPPLEMENT|New generation eHF|New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.
219223056|NCT06830681|DIETARY_SUPPLEMENT|Commercial eHF|Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.
219682843|NCT05947604|DRUG|Dextromethorphan|• Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
219682844|NCT01971814|DRUG|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
219223057|NCT06786351|PROCEDURE|Right atrial balloon occlusion|Thoracic endovascular aortic repair with right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
219682845|NCT00710255|PROCEDURE|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
219682846|NCT00572260|DRUG|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
219682847|NCT02975401|PROCEDURE|rTAPP technique|robot-assisted rTAPP technique
219682848|NCT01178905|PROCEDURE|ultrashort heat inactivation|
219682849|NCT02643641|BIOLOGICAL|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
219682850|NCT02643641|BIOLOGICAL|Placebo|Placebo contains aluminum hydroxide only
219682851|NCT02816294|BEHAVIORAL|Housing Prescription|
219682852|NCT00147706|PROCEDURE|Tailored Healthmedia programs on EHR Patient Portal|
219682853|NCT01551966|DEVICE|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
219682854|NCT02427841|DRUG|Fluorouracil|Given IV
219682855|NCT02427841|DRUG|Gemcitabine|Given IV
219682856|NCT02427841|RADIATION|Image Guided Radiation Therapy|Undergo IG-IMRT
219682857|NCT02427841|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
219682858|NCT02427841|OTHER|Laboratory Biomarker Analysis|Correlative studies
219098517|NCT05025501|BEHAVIORAL|Family based Executive Function Training|Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
219098518|NCT05801458|PROCEDURE|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
219098519|NCT05801458|PROCEDURE|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
219098520|NCT01737684|DRUG|Vibegron|50 mg tablet, oral
219098521|NCT05741099|BIOLOGICAL|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
219682859|NCT02427841|DRUG|Nab-paclitaxel|Given IV
219682860|NCT02427841|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219682861|NCT02945826|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
219682862|NCT02945826|DEVICE|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
219682863|NCT06249581|DRUG|AUX-001 40mg once-daily|AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
219098522|NCT05741099|OTHER|Comparator|Patients in comparator group will receive placebo treatment
219098523|NCT04167995|DRUG|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
219098524|NCT00472771|DRUG|INNO-206|
219098525|NCT03990584|PROCEDURE|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
219098526|NCT03990584|PROCEDURE|conventional needle irrigation|conventional needle irrigation
219098527|NCT00877981|PROCEDURE|Minimal invasive Parathyroid surgery|
219098528|NCT01386996|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
219098529|NCT01386996|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
219098530|NCT01822938|OTHER|incentive program for physical activity|
219098531|NCT03819725|DEVICE|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
219098532|NCT02462850|DRUG|CL-108|
219098533|NCT02990416|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
219098534|NCT02990416|BIOLOGICAL|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
219098535|NCT02990416|RADIATION|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
219098536|NCT02266602|RADIATION|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
219098537|NCT02224963|BEHAVIORAL|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
219098538|NCT02224963|BEHAVIORAL|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
219223058|NCT06786351|PROCEDURE|Non right atrial balloon occlusion|Thoracic endovascular aortic repair not using right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
219223059|NCT04786262|BIOLOGICAL|VX-880|Infused into the hepatic portal vein.
219223060|NCT05317689|DRUG|Psilocin|17.5mg oral psilocin with psychological support and physiological monitoring
219223061|NCT05317689|DRUG|Psilocybin|25mg oral psilocybin with psychological support and physiological monitoring
219098539|NCT01106053|DRUG|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
219098540|NCT01276561|PROCEDURE|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
219098541|NCT01276561|PROCEDURE|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
219223062|NCT05317689|DRUG|Sublingual Psilocin|2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
219098542|NCT01117701|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
219098543|NCT02572947|DRUG|Dolutegravir|
219223063|NCT04228991|RADIATION|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
219223064|NCT04228991|RADIATION|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
219223065|NCT06963437|OTHER|Diet|A four-stage dietary program will be implemented in accordance with ASMBS guidelines. To the best of our knowledge, there is currently no study comparing the dietary approach following revisional bariatric surgery with ketogenic and intermittent fasting diets
219550327|NCT05638633|DRUG|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
219682864|NCT01339871|DRUG|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
219682865|NCT01339871|DRUG|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
219682866|NCT05881655|DEVICE|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
219682867|NCT05881655|DEVICE|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
219682868|NCT00827710|BEHAVIORAL|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
219682869|NCT00827710|BEHAVIORAL|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
219682870|NCT02266446|BEHAVIORAL|Attention & Interpretation Modification|
219682871|NCT03236597|OTHER|Treadmill desk|A standing height desk with a treadmill attached.
219682872|NCT05438277|DRUG|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
219682873|NCT05438277|DRUG|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
219682874|NCT01217996|BEHAVIORAL|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
219682875|NCT01217996|BEHAVIORAL|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
219682876|NCT02068937|DRUG|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
219682877|NCT02068937|DRUG|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
219098544|NCT03645135|OTHER|Goal elicitation|Patients will be asked to list 2 goals for their visit
219223066|NCT06963437|OTHER|Ketogenic diet|A high-protein Very Low-Calorie Ketogenic Diet (VLCKD) will be implemented as the nutritional intervention. In line with previous studies, the daily energy intake of the ketogenic diet will be planned as 600-800 kcal, with approximately 10% of energy from carbohydrates (\<30 g/day), 40-45% from protein, and 40-50% from fat. Total carbohydrate intake will be restricted to less than 30 g per day, primarily from vegetables, while fat intake will derive from natural protein sources and 10 g of olive oil per day.
218984688|NCT04993820|BEHAVIORAL|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
219098545|NCT01598402|DRUG|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
219098546|NCT00591201|DRUG|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
219098547|NCT00591201|DRUG|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
219223067|NCT06963437|OTHER|Fasting|Patients in this group will follow a time-restricted eating pattern (16/8) for a duration of 6 weeks, with food intake limited to an 8-hour window each day. Intermittent fasting will preferably be observed between 6:00 PM and 10:00 AM; however, patients may choose alternative 16-hour fasting periods such as 7:00 PM-11:00 AM or 8:00 PM-12:00 PM, depending on their individual routines. During the 8-hour feeding window, patients will adhere to the stage 4 post-bariatric dietary guidelines in accordance with ASMBS recommendations
219223068|NCT06963437|OTHER|Control|No individualized diet will be planned
219223069|NCT04182646|DEVICE|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
218984689|NCT04482257|DRUG|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
218984690|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
218984691|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
218984692|NCT05711784|OTHER|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
218984693|NCT04960514|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
218984694|NCT04760821|DRUG|Trimetazidine|Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
218984695|NCT05678777|DEVICE|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
218984696|NCT01769807|DEVICE|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
218984697|NCT04721171|DEVICE|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
218984698|NCT05747430|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
218984699|NCT05747430|DRUG|Providone-Iodine|5% Providone-Iodine
218984700|NCT06505564|BEHAVIORAL|AVATAR therapy|In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
219223070|NCT06432881|DEVICE|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
219098548|NCT06056921|BIOLOGICAL|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
219223071|NCT05635643|DRUG|CHS-114|CHS-114
219223072|NCT05635643|DRUG|toripalimab|toripalimab-tpzi
219223073|NCT00570999|DRUG|Palifermin|60 mg/kg/day
219223074|NCT00570999|OTHER|Placebo|1,2 mL once daily
219223075|NCT06465017|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG and 68Ga-FAPI PET/CT), 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG and 68Ga-FAPI) and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
219223076|NCT05349721|DRUG|PTC857|PTC8657 will be administered as an oral solution twice a day.
219223077|NCT05349721|DRUG|Placebo|Matching placebo will be administered as an oral solution twice a day.
219098549|NCT01691521|DRUG|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
219098550|NCT01691521|DRUG|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
219098551|NCT01691521|DRUG|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
219098552|NCT01691521|DRUG|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
219098553|NCT01581840|DRUG|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
219098554|NCT01581840|DRUG|Panitumumab|3 or 6 mg/kg (according to dose level)
219223078|NCT03070392|BIOLOGICAL|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
219223079|NCT03070392|DRUG|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
219223080|NCT03070392|BIOLOGICAL|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
219223081|NCT03070392|BIOLOGICAL|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
219223082|NCT02276443|DRUG|Chemotherapy|Receive standard chemotherapy
219223083|NCT02276443|OTHER|Immunotherapy|Receive standard immunotherapy
219223084|NCT02276443|OTHER|Laboratory Biomarker Analysis|Correlative studies
219223085|NCT02276443|PROCEDURE|Lymph Node Biopsy|Undergo baseline lymph node evaluation
219223086|NCT02276443|PROCEDURE|Ultrasonography|Undergo standard ultrasound
219223087|NCT05718245|DEVICE|HEPA filter|HEPA filters with the capacity to reduce PM2.5 levels
219223088|NCT05718245|DEVICE|Sham filter|sham filters without the capacity to reduce PM2.5 levels
219223089|NCT04762758|DRUG|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
219223090|NCT04762758|DRUG|Placebo|liquid oral solution
219223091|NCT04675294|DRUG|evorpacept|IV Q3W
219223092|NCT04675294|DRUG|pembrolizumab|IV Q3W
219223093|NCT05994014|DIAGNOSTIC_TEST|PET/CT|Experimental test for detecting atherosclerosis
219223094|NCT06267729|BIOLOGICAL|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
219223095|NCT02976961|OTHER|Supportive care|Information, guidance, supportive care, and psychological intervention
219223096|NCT02972034|DRUG|MK-8353|PO capsule
219223097|NCT02972034|BIOLOGICAL|Pembrolizumab|IV infusion
219223098|NCT05812976|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
219223099|NCT05812976|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
219223100|NCT05327608|OTHER|Time Restricted Eating|Undergo intermittent fasting
219223101|NCT00466869|DRUG|Betahistine|
219223102|NCT05424666|PROCEDURE|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
219223103|NCT03861052|DRUG|Tirzepatide|Administered SC
219223104|NCT03861052|DRUG|Dulaglutide|Administered SC
219223105|NCT04378205|PROCEDURE|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
219223106|NCT04378205|PROCEDURE|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
219223107|NCT04180943|DRUG|interscalene nerve block|intra and post-operative analgesia
219098555|NCT05811039|DEVICE|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
219098556|NCT01033214|DEVICE|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
219098557|NCT01153269|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
219098558|NCT01864863|DRUG|HGP1206|One Bosentan 125 mg tablet
219098559|NCT01864863|DRUG|Traclear|Two Bosentan 62.5 mg tablets
219223108|NCT03823703|DRUG|Miricorilant|Tablets taken orally
219682878|NCT02592447|OTHER|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
219682879|NCT02592447|OTHER|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
219682880|NCT01841970|DEVICE|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
219223109|NCT03823703|DRUG|Placebo|Placebo tablets
219223110|NCT03265756|DEVICE|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
219682881|NCT01425736|DRUG|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
219682882|NCT01425736|DRUG|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
219682883|NCT00750113|DRUG|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
219682884|NCT00750113|DRUG|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
219098560|NCT03541044|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
219098561|NCT03541044|DRUG|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
219682885|NCT00750113|DRUG|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
219682886|NCT03692429|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
219682887|NCT03692429|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
219682888|NCT03692429|DRUG|FOLFIRI|5-FU, leucovorin and irinotecan
219682889|NCT02652169|DRUG|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
219682890|NCT02652169|DRUG|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
219682891|NCT02652169|DRUG|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
219682892|NCT02652169|OTHER|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
219682893|NCT03861780|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219682894|NCT03861780|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219682895|NCT03861780|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
219098562|NCT02635724|DRUG|Peramivir|
219098563|NCT02190825|DEVICE|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
219098564|NCT04665622|OTHER|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
219098565|NCT02111837|OTHER|Standard infant formula|
219682896|NCT00902655|DRUG|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
219682897|NCT05410678|DRUG|Renal stent|renal stent implantation in ectatic/aneurysmatic coronary arteries
219682898|NCT05926648|DEVICE|INVSENSOR00061|Noninvasive pulse oximetry and pulse rate device
219098566|NCT02111837|OTHER|Standard infant formula with PL1|
219098567|NCT02111837|OTHER|Standard infant formula with PL2|
219098568|NCT05794516|DRUG|ZB004|ZB004 single doses administered subcutaneously as solution
219098569|NCT05794516|DRUG|Placebo|Placebo single doses administered subcutaneously as solution
219098570|NCT04596137|BEHAVIORAL|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
219098571|NCT05517200|DIAGNOSTIC_TEST|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
219098572|NCT00212901|DRUG|High dose ACE-I vs ARB|
219682899|NCT05855434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
219682900|NCT01983215|DEVICE|Prevena vac|
219682901|NCT01290510|DEVICE|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
219682902|NCT01048541|DEVICE|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
219682903|NCT01048541|DEVICE|SpeediCath|Catheter for intermittent catheterisation
219682904|NCT00236691|DRUG|topiramate|
219223111|NCT03072810|BEHAVIORAL|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
219098573|NCT02558270|DRUG|Dapagliflozin|
219098574|NCT02558270|DRUG|Placebo|
219098575|NCT01262326|OTHER|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
219098576|NCT01930630|DEVICE|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
219223112|NCT03617575|DIETARY_SUPPLEMENT|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)
219223113|NCT03617575|DIETARY_SUPPLEMENT|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
219223114|NCT03617575|DIETARY_SUPPLEMENT|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
219223115|NCT03617575|DIETARY_SUPPLEMENT|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
219682905|NCT03578627|BEHAVIORAL|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
219682906|NCT02770911|PROCEDURE|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
219682907|NCT02770911|PROCEDURE|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
219223116|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
219682908|NCT01848171|DRUG|L-thyroxine|
219682909|NCT03647306|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
219682910|NCT03647306|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
219682911|NCT03647306|BEHAVIORAL|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
219098577|NCT05966935|COMBINATION_PRODUCT|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
219098578|NCT01566175|DEVICE|Neovac coronary sinus reducer|reducer
219098579|NCT02252614|DRUG|naproxen sodium codein|Pain intensity, contramal consumption
219682912|NCT03743766|DRUG|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
219682913|NCT03743766|DRUG|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
219223117|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
219223118|NCT01451359|DEVICE|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
219223119|NCT00151866|PROCEDURE|platelet transfusion|
219223120|NCT01491815|DRUG|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
219223121|NCT01491815|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
219682914|NCT03743766|DRUG|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
219682915|NCT04195724|OTHER|mNGS for pathogen detection|mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
219223122|NCT01491815|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
219223123|NCT01491815|BIOLOGICAL|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
219223124|NCT00664599|DRUG|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
219223125|NCT00664599|DRUG|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
219223126|NCT05944094|DEVICE|Clorhexidine|Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
219223127|NCT01970878|DRUG|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
219223128|NCT01970878|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
219223129|NCT01970878|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
219223130|NCT01970878|DRUG|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
219223131|NCT06317610|OTHER|growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI|biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
219682916|NCT02410408|DEVICE|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
219223132|NCT01840085|DRUG|0.03% DSC127 topical gel|
219223133|NCT02412540|BEHAVIORAL|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
219223134|NCT03050931|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
219223135|NCT01858649|PROCEDURE|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
219223136|NCT01858649|DRUG|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
219223137|NCT01858649|DRUG|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
219223138|NCT01858649|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
219223139|NCT01858649|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
219223140|NCT05512819|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
219223141|NCT05512819|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
219682917|NCT02410408|OTHER|information package|Information on PSC and RCA
219682918|NCT05268341|BEHAVIORAL|My Sentence Builder|computer-assisted treatment program for expressive grammar
219682919|NCT06843486|OTHER|Multicomponent Exercise|Training sessions will include aerobic, resistance, balance and flexibility exercises, following the American College of Sports Medicine (ACSM) guidelines for osteoporosis prevention.
219682920|NCT03153241|OTHER|No intervention|No intervention
219098580|NCT02252614|DRUG|paracetamol codein|Pain intensity, contramal consumption
219098581|NCT02252614|DRUG|Placebo|Pain intensity, contramal consumption
219098582|NCT02424591|DRUG|Ketamine|Infusion at a rate of 10 mcg/kg/min
219098583|NCT02424591|OTHER|Placebo|Placebo IV
219098584|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
219098585|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
219098586|NCT00312702|BIOLOGICAL|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
219098587|NCT00003315|BIOLOGICAL|sargramostim|
219098588|NCT00003315|DRUG|liposomal amphotericin B|
219098589|NCT02038686|DEVICE|PFN-A|
219098590|NCT01405755|BEHAVIORAL|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
219098591|NCT04678921|DRUG|TJ210001|human anti-C5aR monoclonal antibody
219098592|NCT03511417|DEVICE|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
219098593|NCT03584503|OTHER|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
219098594|NCT05829291|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|"Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device."
219098595|NCT04559282|DEVICE|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
219098596|NCT04806646|DRUG|Sonidegib|TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
219098597|NCT02653573|BEHAVIORAL|Coaching|Self-management education
219098598|NCT02929550|OTHER|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
219098599|NCT00021034|DRUG|chemotherapy|
219098600|NCT00021034|DRUG|taurolidine|
219098601|NCT03243643|DRUG|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
219098602|NCT03243643|DRUG|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
219098603|NCT06344234|DIAGNOSTIC_TEST|End-inspiratory Maneuvers|Airway pressure, flow, and esophageal pressure will be continuously recorded in all patients using a dedicated pneumotachograph and pressure transducer: all signals will be acquired and stored. Once a stable ventilation pattern is observed NIV will be administered by setting ventilator in invasive-pressure support ventilation. PEEP and PS-level will by kept constant while expiratory trigger will be adjusted to optimize patient-ventilatory synchrony. Immediately after, sudden end-inspiratory and end-expiratory occlusion maneuvers will be performed to measure plateau pressure and end-expiratory airway occlusion pressure (ΔPocc), respectively. Invasive PSV will be used only to perform the occlusion maneuvers, subsequently, PSV will be delivered in non-invasive PSV mode. Patient's blood-gas parameters and vital signs will be collected, including discomfort assessment. During the occlusion maneuvers, diaphragm ultrasound will be performed, and images will be recorded.
219098604|NCT04114747|OTHER|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
219223142|NCT06292689|DRUG|Cardunolizumab|"1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment."
219223143|NCT04589624|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219098605|NCT02568943|DRUG|Panobinostat|Panobinostat (PAN \[LBH589\]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
219223144|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219098606|NCT04097405|DRUG|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
219098607|NCT04097405|DRUG|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
219098608|NCT05506865|DRUG|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
219098609|NCT05506865|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
219098610|NCT00353613|BEHAVIORAL|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
219098611|NCT01605760|DRUG|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
219098612|NCT04479280|DEVICE|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
219098613|NCT02635074|DRUG|Cytarabine|Given IV
219098614|NCT02635074|DRUG|Ibrutinib|Given PO
219098615|NCT02635074|DRUG|Idarubicin|Given IV
219098616|NCT04190147|OTHER|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
219098617|NCT01535742|DEVICE|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
219098618|NCT01535742|DEVICE|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
219098619|NCT01535742|DEVICE|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
219098620|NCT01535742|DEVICE|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
219098621|NCT05091866|OTHER|Quality-of-Life Assessment|Ancillary studies
219098622|NCT05091866|OTHER|Questionnaire Administration|Ancillary studies
219098623|NCT05091866|BIOLOGICAL|Therapeutic Progesterone|Given SC
219223145|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo hpMRI
219098624|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
219098625|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
219098626|NCT01650493|DEVICE|Clinpro 5000|Dentrifice containing 950ppm fluoride
219098627|NCT01650493|DEVICE|MI Paste Plus|Dentrifice containing 950ppm fluoride
219098628|NCT01650493|DEVICE|Tom's of Maine|Dentrifice that is fluoride free
219682921|NCT00913211|DEVICE|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
219682922|NCT00913211|PROCEDURE|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
219682923|NCT00913211|PROCEDURE|rTMS and Tracking|Combination of rTMS and finger tracking
219682924|NCT00913211|DEVICE|Sham rTMS|Sham treatment of rTMS
219682925|NCT01340729|DRUG|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
219682926|NCT01015716|BEHAVIORAL|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
219682927|NCT01015716|BEHAVIORAL|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
219682928|NCT00622102|BEHAVIORAL|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
219682929|NCT00622102|BEHAVIORAL|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
219682930|NCT00062348|DRUG|boronophenylalanine-fructose complex|
219682931|NCT00062348|DRUG|sodium borocaptate|
219682932|NCT00062348|PROCEDURE|conventional surgery|
219682933|NCT03521869|DEVICE|Compression bandage|Compression bandage placed after total knee replacement
219682934|NCT03521869|DEVICE|Gauze dressing|standard of care gauze dressing placed after total knee replacement
219682935|NCT00327717|DRUG|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
219682936|NCT00327717|DRUG|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
219098629|NCT04787510|DRUG|low molecular weight Heparin as standard of care treatment|STANDARD OF CARE
219223148|NCT06578949|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
219223149|NCT04456413|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
219223150|NCT04456413|OTHER|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
219682937|NCT02734134|PROCEDURE|One-stage exchange joint replacement surgery|
219682938|NCT02734134|PROCEDURE|Two-stage exchange joint replacement surgery|
219682939|NCT03647566|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
219682940|NCT03647566|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
219682941|NCT03647566|DIAGNOSTIC_TEST|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
219682942|NCT00239473|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
219682943|NCT00239473|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
219682944|NCT04997876|OTHER|Biomarker analysis|Biomarkers from presurgical OCTs are assessed
219223151|NCT00418652|DEVICE|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
219223152|NCT00418652|DEVICE|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
219682945|NCT05065294|DRUG|Psilocybin therapy|\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
219682946|NCT01635374|PROCEDURE|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
219098630|NCT04737902|PROCEDURE|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
219098631|NCT03209141|DIAGNOSTIC_TEST|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
219098632|NCT01686880|DEVICE|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
219223153|NCT00418652|DEVICE|TMS over the vertex|10Hz TMS for over vertex.
219223154|NCT03115099|DRUG|LY3325656|Administered orally
219223155|NCT03115099|DRUG|Placebo|Administered orally
219223156|NCT03115099|DRUG|Liraglutide|Administered subcutaneously
219682947|NCT01737879|DRUG|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
219682948|NCT01737879|DRUG|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
219682949|NCT06324643|PROCEDURE|sensory motor integration training|one group treated by strengthening exercises , stretching ,and occupational therapy and other group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training
219682950|NCT00202098|PROCEDURE|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
219682951|NCT02574364|RADIATION|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
219682952|NCT02574364|OTHER|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
219682953|NCT06067997|DIAGNOSTIC_TEST|pulmonary embolism diagnosis|"The diagnosis of pulmonary embolism will be made using the diagnostic algorithm suggested by the 2019 European guidelines . The pre-test clinical probability of pulmonary embolism will be defined based on the simplified Wells score. In patients with a low pre-test clinical probability and a D-dimer level below the threshold value the diagnosis of pulmonary embolism will be excluded. The D-dimer level will be measured using the quantitative assay routinely used in each participating center; the threshold value for a positive result compared to a negative result is 500 μg per milliliter for patients under 50 years of age. For each additional decade of age, the exclusion cutoff will increase by 100 μg per milliliter.~The criterion for the presence of pulmonary embolism is the detection of an intraluminal filling defect on CT."
219682954|NCT00063804|DRUG|Ritonavir|
219682955|NCT00063804|DRUG|AMD070|
219682956|NCT05264909|DEVICE|Multi-channel Transcranial direct current stimulation|A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
219682957|NCT02084017|DEVICE|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
219682958|NCT02084017|DEVICE|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
219682959|NCT05980897|BEHAVIORAL|Naming treatment|"In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing."
219682960|NCT05816668|DRUG|Tranexamic acid|Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
219682961|NCT05816668|OTHER|Placebo|Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
219223157|NCT03115099|DRUG|Sitagliptin|Administered orally
219223158|NCT02372799|DRUG|Vilazodone|
219223159|NCT02372799|DRUG|Placebo|
219223160|NCT02372799|DRUG|Fluoxetine|
219223161|NCT00000388|BEHAVIORAL|Psychosocial treatment|
219682962|NCT03875196|DEVICE|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
219682963|NCT03875196|DEVICE|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
219682964|NCT02742363|OTHER|Collecting data|Collecting data from patient records
219682965|NCT00064415|DRUG|arformoterol|Arformoterol inhalation solution, 50 mcg QD
219682966|NCT00064415|DRUG|Salmeterol|Salmeterol MDI, 42 mcg BID
219098633|NCT03075059|BEHAVIORAL|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
219098634|NCT04747730|OTHER|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
219098635|NCT05962710|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
219098636|NCT02277743|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
219098637|NCT02277743|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
219098638|NCT01093144|DEVICE|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
219098639|NCT04654988|DRUG|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
219098640|NCT04654988|DRUG|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
219098641|NCT04654988|DRUG|Placebo Prednisone|Placebo Prednisone
219098642|NCT04654988|DRUG|Placebo Azathioprine|Placebo Azathioprine
219098643|NCT01224158|DEVICE|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
219098644|NCT01224158|DEVICE|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
219098645|NCT01674374|OTHER|placebo|Given PO
219223162|NCT00000388|DRUG|Anti-ADHD medication|
219223163|NCT00000388|BEHAVIORAL|Assessment-and-Referral|
219223164|NCT00089609|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
219223165|NCT00089609|DRUG|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
219223166|NCT00089609|DRUG|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
219682967|NCT05285787|DRUG|EPN-701 (Oral)|MK-7
219682968|NCT01509612|DRUG|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
219682969|NCT01509612|DRUG|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
219682970|NCT04827758|PROCEDURE|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
219682971|NCT03278366|BEHAVIORAL|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
219682972|NCT02195973|DRUG|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
219682973|NCT02360280|DRUG|ketamine|sedative
219682974|NCT02360280|DRUG|midazolam|sedative
219223167|NCT00089609|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
219682975|NCT02472886|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219682976|NCT02472886|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219682977|NCT04058197|DRUG|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
219682978|NCT04058197|OTHER|Placebo|Placebo Patch
219682979|NCT00921583|DEVICE|Long-term examination|Follow-up dental implants 20 year in function
219682980|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
219682981|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
219682982|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
219682983|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
219682984|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
219682985|NCT06101147|DRUG|Vitamin D3|These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
219682986|NCT06101147|DRUG|Placebo Oral Tablet|These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
219682987|NCT03343743|OTHER|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
219682988|NCT03662035|DRUG|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
219098646|NCT01674374|PROCEDURE|quality-of-life assessment|Ancillary studies
219098647|NCT01674374|OTHER|questionnaire administration|Ancillary studies
219098648|NCT01674374|DRUG|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
219098649|NCT02055157|DRUG|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
219098650|NCT03976466|DEVICE|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
219098651|NCT03976466|PROCEDURE|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
219098652|NCT01557322|BIOLOGICAL|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
219098653|NCT01557322|DRUG|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
219098654|NCT02247336|BEHAVIORAL|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
219098655|NCT00733499|DEVICE|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
219098656|NCT00733499|DEVICE|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
219098657|NCT06405399|OTHER|Educational intervention. observation guide|An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).
219098658|NCT03809364|BEHAVIORAL|START Together|Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
219098659|NCT03177122|DRUG|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
219098660|NCT02739347|DEVICE|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
219098661|NCT02739347|DEVICE|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
219098662|NCT05995626|DRUG|Hyaluronidase|Hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.
219098663|NCT05995626|DEVICE|CO2 laser|CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue, which will then be cleanly incised. The CO2 lasers have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
219098664|NCT06501898|DIETARY_SUPPLEMENT|CoreBiome|300 mg, once daily of tributyrin for 4 weeks
219098665|NCT06501898|DIETARY_SUPPLEMENT|Placebo|300 mg, once daily of placebo for 4 weeks
219098666|NCT00967382|DRUG|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
219223168|NCT00089609|GENETIC|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
219223169|NCT00089609|OTHER|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
219223170|NCT00089609|OTHER|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
219223171|NCT00089609|OTHER|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
219223172|NCT03706261|DRUG|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
219223173|NCT03706261|DRUG|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
219223174|NCT03799588|DEVICE|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
219223175|NCT00004807|DRUG|dextromethorphan|
219223176|NCT00004807|DRUG|topiramate|
219223177|NCT00004807|DRUG|Donepezil|
219223178|NCT05284643|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
219223179|NCT05284643|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
219550328|NCT03506633|DIETARY_SUPPLEMENT|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each participant in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
219098667|NCT00177203|BEHAVIORAL|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
219098668|NCT02218879|DRUG|Tecfidera|Oral Tecfidera 240 mg bid
219098669|NCT03929562|BEHAVIORAL|Brief advice|One 10-minute brief advice session
219098670|NCT03929562|BEHAVIORAL|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
219682989|NCT03662035|DRUG|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
219682990|NCT01539746|PROCEDURE|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
219682991|NCT01539746|PROCEDURE|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
219682992|NCT05857800|OTHER|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
219682993|NCT00704951|DRUG|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
219682994|NCT00098007|DRUG|Everolimus (Certican)|
219682995|NCT00627926|BIOLOGICAL|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
219682996|NCT00627926|DRUG|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
219682997|NCT00627926|DRUG|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
219682998|NCT00627926|OTHER|Placebo|Telaprevir matching placebo
219682999|NCT02017093|DEVICE|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
219683000|NCT02017093|DEVICE|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
219683001|NCT03037346|OTHER|Questionnaire Administration|Complete questionnaires about MPOAD
219683002|NCT03037346|OTHER|Questionnaire Administration|Ancillary studies
219683003|NCT03037346|OTHER|Video|Watch educational video
219683004|NCT02981914|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
219683005|NCT03913871|BEHAVIORAL|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
219683006|NCT03913871|BEHAVIORAL|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
219683007|NCT04322669|DRUG|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
219683008|NCT04322669|DRUG|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
219683009|NCT02169843|DRUG|Sevoflurane|inhale Sevoflurane
219683010|NCT02169843|DRUG|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
219098671|NCT00378443|DRUG|prednisone + Inhibace/Cozaar|
219098672|NCT00378443|DRUG|Inhibace/Cozaar|
219683011|NCT02169843|DRUG|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
219683012|NCT00164632|BEHAVIORAL|counselling, exercise, referrals (behavior)|
219683013|NCT00666159|DRUG|tacrolimus ointment|topical
219683014|NCT00666159|DRUG|pimecrolimus cream|topical
219683015|NCT01463800|BEHAVIORAL|Structured exercise training|12 weeks low level ambulatory structured exercise training
219683016|NCT01681238|PROCEDURE|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb\> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
219223180|NCT03028389|PROCEDURE|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
219223181|NCT00353691|DRUG|glimepiride|
219223182|NCT00353691|DRUG|metformin|
219223183|NCT00747006|DRUG|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
219223184|NCT00747006|DRUG|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
219223185|NCT01053650|DRUG|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
219223186|NCT03106259|DRUG|FURESTEM-RA Inj.|Non-interventional observational study
219223187|NCT03689946|DRUG|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
219098673|NCT01190046|BEHAVIORAL|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
219098674|NCT02461810|DEVICE|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
219098675|NCT02461810|PROCEDURE|Balloon Kyphoplasty|
219223188|NCT03689946|DIAGNOSTIC_TEST|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
219223189|NCT03689946|DIAGNOSTIC_TEST|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
219223190|NCT03689946|DRUG|Omnipaque|contrast agent for CCTA
219683017|NCT01681238|PROCEDURE|Protocol group 1|The goal of this protocol is to ensure MAP\> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
219683018|NCT03360019|DEVICE|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
219683019|NCT03360019|OTHER|Activlink Phone Application|Smartphone tool used for monitoring location
219683020|NCT00200577|DRUG|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
219683021|NCT00736294|DRUG|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
219098676|NCT00465933|DRUG|AIDA|
219098677|NCT05225688|BEHAVIORAL|Bike exertion test|maximal exercise test
219098678|NCT00103961|BEHAVIORAL|Questionnaire|A behavioral questionnaire will occur at Week 8
219683022|NCT00736294|DRUG|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
219683023|NCT03253536|OTHER|observational|none (observational study)
219683024|NCT02132143|RADIATION|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
219683025|NCT02132143|RADIATION|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
219683026|NCT02496364|OTHER|Observational|
219683027|NCT05207527|OTHER|cardiovascular exercise|Exercise that mainly stimulates the cardiovascular and respiratory systems.
219098679|NCT05648162|DEVICE|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
219098680|NCT05648162|DEVICE|Acupuncture|Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
219098681|NCT05648162|DEVICE|tDCS|tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
219098682|NCT05648162|DEVICE|sham tDCS|tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
219223191|NCT03689946|DRUG|Metoprolol|beta blocker to optimize heart rate during CCTA
219223192|NCT03689946|DRUG|Nitroglycerin|premedication for CCTA
219098683|NCT05648162|OTHER|NDT-Bobath Rehabilitation|NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
219098684|NCT00953537|DRUG|capecitabine|
219098685|NCT00953537|OTHER|laboratory biomarker analysis|
219098686|NCT00953537|OTHER|pharmacological study|
219098687|NCT00779974|OTHER|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
219223193|NCT00943969|PROCEDURE|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
219223194|NCT03110809|DIETARY_SUPPLEMENT|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
219223195|NCT03110809|DIETARY_SUPPLEMENT|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
219223196|NCT04716517|OTHER|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
219223197|NCT04716517|OTHER|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
219223198|NCT02761499|DEVICE|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
219683028|NCT05207527|OTHER|Muscle strength|Exercise that primarily stimulates the musculoskeletal system.
219683029|NCT05207527|OTHER|Mixed|Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
219683030|NCT04337021|BEHAVIORAL|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
219683031|NCT01462110|DEVICE|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
219683032|NCT01462110|DEVICE|W002194-0221P|5% hydroalcohol mouthrinse
219683033|NCT03009227|PROCEDURE|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
219683034|NCT03009227|PROCEDURE|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
219683035|NCT02454751|DRUG|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
219683036|NCT00203697|DRUG|minocycline|
219683037|NCT00594230|DRUG|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
219683038|NCT01789788|DRUG|Placebo|Matching placebo, multiple doses
219683039|NCT01789788|DRUG|RO6811135|multiple ascending doses
219683040|NCT04847583|DRUG|Telacebec|Telacebec 100 mg tablet
219683041|NCT04847583|DRUG|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
219098688|NCT06253949|PROCEDURE|ligation of inferior mesenteric artery in colorectal cancer|This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
219098689|NCT00285493|DRUG|Antibiotics|
219098690|NCT00742638|DRUG|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
219098691|NCT00742638|DRUG|Sodium valproate|Sodium valproate tablet 200 mg
219098692|NCT01727063|PROCEDURE|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
219098693|NCT04520802|DIAGNOSTIC_TEST|18F-DPA-714 PET/CT neuroimaging|"* Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response"
219223199|NCT05051826|OTHER|Resistance training that combines water and land|"Device: Swimmers in the experimental group received resistance training in water for 12 weeks, and the resistance training in the experimental group was divided into 3 categories:Resistance palm and resistance umbrella, resistance suit.~Device: The swimmers in the experimental group underwent core strength training on land for 12 weeks, and the resistance training in the experimental group was divided into 4 types of resistance zones: Swiss ball, medicine ball and drive zone.The combination of two resistance training methods can improve teenagers' swimming performance."
219223200|NCT06640842|DIAGNOSTIC_TEST|A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.|Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
219223201|NCT05678725|DEVICE|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
219223202|NCT05678725|DEVICE|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
219223203|NCT05678725|DEVICE|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
219223204|NCT02625025|PROCEDURE|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
219223205|NCT02625025|PROCEDURE|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
219683042|NCT05501392|BEHAVIORAL|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
219683043|NCT02017275|DEVICE|BuMA|This group will contain 1175 subjects.
219683044|NCT02017275|DEVICE|EXCEL|This group will contain 1175 subjects.
219683045|NCT03320174|DRUG|Tafenoquine|Tafenoquine 200mg
219683046|NCT03320174|OTHER|Placebo|Placebo
219683047|NCT01091870|DRUG|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
219683048|NCT01091870|DRUG|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
219683049|NCT01091870|DRUG|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
219683050|NCT06198998|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
219683051|NCT02805946|DRUG|posaconazole|iv versus oral
219683052|NCT03135509|DRUG|CC-220|CC-220 gelatin capsules
219683053|NCT00333710|BEHAVIORAL|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
219683054|NCT00333710|BEHAVIORAL|Telehealth Intervention|Individual telephone contact with educational and goal setting components
219683055|NCT01096381|OTHER|laboratory biomarker analysis|Blood collection
219683056|NCT01096381|OTHER|questionnaire administration|Survey regarding baseline health and activity level.
219683057|NCT06392464|DEVICE|Clinical decision support system (software)|"Use of a clinical decision support system. Naevia Medical is clinical decision support software (CDSS) that, based on clinical input data (patient history, symptoms, complementary test data, etc.) from adult patients with heart disease, provides healthcare professionals with prioritized, justified, and referenced recommendations and knowledge-related suggestions related to diagnosis, prognosis, and/or treatment (recommended tests, medications, alerts, etc.)"
219683058|NCT00866112|OTHER|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
219683059|NCT00866112|OTHER|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
219683060|NCT02928523|DRUG|Autologous Fecal Microbiota Transplantation|
219683061|NCT06467747|OTHER|Music|Music group: wear earphones to listen to music and receive standardized anesthesia protocol
219683062|NCT06467747|OTHER|Mute|Mute group: wear earphones without music and receive standardized anesthesia protocol
219683063|NCT01100632|DIETARY_SUPPLEMENT|Ginseng, vitamins, minerals|2 capsules per day
219683064|NCT01100632|OTHER|Placebo - Gelatin capsule|2 capsules per day
219683065|NCT04525040|DIETARY_SUPPLEMENT|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
219683066|NCT04525040|OTHER|Pragmatic comparator|Standard of care as usual without a preventive intervention
219683067|NCT03902470|PROCEDURE|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
219683068|NCT03156257|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
219683069|NCT02729480|DEVICE|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
219683070|NCT02149264|DRUG|Testosterone gel (FE 999303)|
219683071|NCT06071117|DEVICE|Virtual Reality Glasses (VR)|Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
219683072|NCT06071117|OTHER|White noise|"Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter"
219683073|NCT06071117|BEHAVIORAL|Basic behavior management techniques|Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
219683074|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
219683075|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
219683076|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
219683077|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
219683078|NCT01236040|OTHER|Placebo|Intramuscular injection, two doses
219683079|NCT03283930|BEHAVIORAL|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
219683080|NCT03283930|BEHAVIORAL|Placebo Attention Bias Modification Training|
219683081|NCT00697853|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
219683082|NCT00697853|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
219683083|NCT04329845|PROCEDURE|open splenectomy|open splenectomy for treatment of splenic injury
219683084|NCT04329845|PROCEDURE|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
219683085|NCT01610869|DRUG|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
219683086|NCT00805129|DRUG|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
219683087|NCT00753129|PROCEDURE|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
219223206|NCT02625025|PROCEDURE|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
219683088|NCT01243515|DEVICE|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
219683089|NCT01243515|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
219223207|NCT04468737|BEHAVIORAL|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
219683090|NCT02590237|DEVICE|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
219098694|NCT05114525|BEHAVIORAL|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
219098695|NCT01741116|DRUG|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
219098696|NCT01778556|BIOLOGICAL|Metreleptin|Recombinant analog of the human hormone, leptin
219098697|NCT03020225|DIETARY_SUPPLEMENT|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
219098698|NCT03020225|DIETARY_SUPPLEMENT|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
219098699|NCT03020225|DIETARY_SUPPLEMENT|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
219098700|NCT03299790|OTHER|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
219223208|NCT05357820|DRUG|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
219683091|NCT02590237|DEVICE|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
219683092|NCT03293017|DRUG|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
219683093|NCT03293017|DRUG|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
219683094|NCT03293017|DRUG|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
219683095|NCT04258124|OTHER|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
219683096|NCT03973541|BEHAVIORAL|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
219683097|NCT03973541|BEHAVIORAL|Relaxation Therapy|Relaxation Therapy
219683098|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-anodal group|2mA/20mins/session; 2sessions/day,5days
219683099|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-sham group|0mA/20mins/session; 2sessions/day,5days
219683100|NCT02499120|DRUG|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
219683101|NCT02499120|DRUG|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
219683102|NCT02499120|DRUG|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
219683103|NCT03821077|BIOLOGICAL|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
219683104|NCT06111898|OTHER|No Intervention|No intervention
219683105|NCT01833585|BIOLOGICAL|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
219683106|NCT04036591|DIAGNOSTIC_TEST|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
219683107|NCT02810275|DRUG|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
219683108|NCT02810275|DRUG|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
219683109|NCT04639362|DRUG|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
219223209|NCT05357820|DRUG|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
219098701|NCT03299790|OTHER|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
219223210|NCT03499964|DEVICE|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
219223211|NCT03499964|DEVICE|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
219223212|NCT06462963|RADIATION|single-fraction SBRT|Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
219223213|NCT06462963|RADIATION|multiple-fraction SBRT|Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
219223214|NCT00622856|BEHAVIORAL|psychological intervention|Psychological intervention
219223215|NCT00622856|BEHAVIORAL|Diabetes education|5 sessions with diabetes nurse
219223216|NCT05346094|OTHER|No intervention|No intervention
219223217|NCT03305445|DRUG|Ipilimumab|Ipilimumab (1mg/kg)
219223218|NCT03305445|DRUG|Nivolumab|Nivolumab (3mg/kg)
219223219|NCT02596919|OTHER|photography|photography of meibomian glands
219223220|NCT03071354|DIETARY_SUPPLEMENT|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
219223221|NCT03071354|DIETARY_SUPPLEMENT|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
219223222|NCT06016400|DRUG|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
219223223|NCT06016400|DRUG|Placebo|Placebo
219223224|NCT02909959|DRUG|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
219223225|NCT02909959|DRUG|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
219683110|NCT04639362|DRUG|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
219098702|NCT05540314|PROCEDURE|robotic bariatric surgery|robotic bariatric surgery
219098703|NCT00593125|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
219098704|NCT03682705|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
219098705|NCT03682705|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
219223226|NCT04160741|OTHER|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
219223227|NCT04160741|OTHER|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
219223228|NCT04160741|RADIATION|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
219223229|NCT04160741|OTHER|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
219223230|NCT00806767|BIOLOGICAL|therapeutic immune globulin|
219223231|NCT00806767|DRUG|busulfan|
219223232|NCT00806767|DRUG|fludarabine phosphate|
219223233|NCT00806767|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219223234|NCT03615612|OTHER|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
219223235|NCT05390905|DRUG|HSK21542 Injection|1μg/kg/dose
219223236|NCT05390905|DRUG|Tramadol hydrochloride|50mg/dose
219223237|NCT05390905|DRUG|placebo|placebo
219223238|NCT01798667|DRUG|DA-8031|
219223239|NCT01798667|DRUG|Placebo|Placebo of DA-8031, undistinguishable
219683111|NCT01948921|DRUG|placebo|
219683112|NCT01948921|DRUG|Meperidine|
219683113|NCT00100347|DRUG|PPI-2458|
219683114|NCT03883763|DRUG|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 20 mg
219683115|NCT03883763|DRUG|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 20 mg
219223240|NCT06038695|DEVICE|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"* Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
219223241|NCT03213145|DRUG|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
219098706|NCT03682705|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
219098707|NCT03682705|DRUG|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
219223242|NCT03213145|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
219223243|NCT03213145|DRUG|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
219223244|NCT00853580|DRUG|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
219223245|NCT00853580|DEVICE|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
219223246|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit # 1
219223247|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit #1
219223248|NCT01700205|OTHER|Type of Formula|infant formula
219223249|NCT02394106|DRUG|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
219098708|NCT00584935|DRUG|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
219098709|NCT04409067|DIAGNOSTIC_TEST|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
219098710|NCT04410289|PROCEDURE|Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
219098711|NCT04410289|PROCEDURE|Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
219098712|NCT02768454|DRUG|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
219098713|NCT04002804|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
219098714|NCT01919970|OTHER|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
219223250|NCT02394106|OTHER|Placebo|Normal saline, 1000 ml, administered once
219223251|NCT05202366|DRUG|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
219223252|NCT06511284|OTHER|High protein dose|High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition
219223253|NCT06511284|OTHER|Usual protein dose|Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
219223254|NCT01728324|DRUG|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
219098715|NCT01919970|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
219223255|NCT01728324|DRUG|Ribavirin: 24-week treatment|24 weeks of active treatment
219223256|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
219223257|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
219223258|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
219223259|NCT01728324|DRUG|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
219223260|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
219223261|NCT01728324|DRUG|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
219223262|NCT01728324|DRUG|Faldaprevir: 16-week treatment|16 weeks of active treatment
219223263|NCT01728324|DRUG|Ribavirin: 16-week treatment|16 weeks of active treatment
219223264|NCT01728324|DRUG|RBV: 24-week treatment|24 weeks of active treatment
219223265|NCT01728324|DRUG|BI 207127: 16-week treatment|16 weeks of active treatment
219223266|NCT02884245|DRUG|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
219223267|NCT02732990|BEHAVIORAL|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
219223268|NCT02604251|DEVICE|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
219223269|NCT02604251|DEVICE|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
219223270|NCT03712150|DEVICE|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
219098716|NCT04043962|BEHAVIORAL|Web-based CBT (Web-MAP)|see arm description
219223271|NCT05642806|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
219223272|NCT05642806|OTHER|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
219223273|NCT04288167|DIAGNOSTIC_TEST|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
219223274|NCT02438007|DRUG|Galeterone|2550 mg galeterone tablets once daily PO
219223275|NCT02438007|DRUG|Enzalutamide|160 mg enzalutamide capsules once daily PO
219223276|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
219223277|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
219223278|NCT03642366|OTHER|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
219223279|NCT00000215|DRUG|Pergolide|
219223280|NCT04352400|DRUG|Nafamostat Mesilate|administered intravenously as a continuous infusion
219223281|NCT04352400|DRUG|Placebo|administered intravenously as a continuous infusion
219223282|NCT00144235|DRUG|Pharmaton PHL 00749|
219223283|NCT00144235|DRUG|Placebo|
219223284|NCT02535221|DRUG|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
219223285|NCT02535221|DRUG|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
219223286|NCT01170208|DEVICE|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
219223287|NCT01351376|DEVICE|Low Level Laser Therapy|Placebo LLL combined with CDT
219098717|NCT02162303|DRUG|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
219098718|NCT02162303|DRUG|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
219098719|NCT01667367|DRUG|RG1662|Single oral dose
219098720|NCT01667367|DRUG|placebo|Single oral dose
219098721|NCT02541825|DEVICE|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
219098722|NCT02541825|DEVICE|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
219098723|NCT03575338|PROCEDURE|Open Scarf Osteotomy|Open Scarf Osteotomy
219098724|NCT03575338|PROCEDURE|Minimally invasive scarf Osteotomy|Minimally invasive scarf Osteotomy
219223288|NCT01351376|DEVICE|Low Level Laser|Active LLL combined with CDT
219223289|NCT02322372|DRUG|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
219223290|NCT02322372|DRUG|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
219223291|NCT00766909|DRUG|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
219098725|NCT05248321|DRUG|Tranexamic Acid Powder|2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
219098726|NCT04615182|DEVICE|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
219098727|NCT05233943|DEVICE|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
219098728|NCT02629211|DEVICE|NaviAid™ AB|NaviAid™ AB Procedure
219098729|NCT00206193|DRUG|mifepristone|
219098730|NCT00206193|DRUG|misoprostol|
219098731|NCT00206193|DRUG|sulprostone|
219098732|NCT02084537|PROCEDURE|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
219098733|NCT02084537|PROCEDURE|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
219098734|NCT04952584|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
219098735|NCT00188955|DRUG|sirolimus|
219683116|NCT02377232|BEHAVIORAL|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
219683117|NCT02377232|BEHAVIORAL|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
219683118|NCT00065702|DRUG|Active liquid remedy|
219683119|NCT03653845|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
219683120|NCT03653845|DRUG|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
219683121|NCT02629744|DRUG|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
219683122|NCT02629744|DEVICE|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
219098736|NCT04247997|PROCEDURE|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
219683123|NCT06024707|DRUG|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
219683124|NCT02985112|DEVICE|FFR and IVUS-NIRS|
219683125|NCT06305975|PROCEDURE|Blunt fascial abdominal entry|Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
219683126|NCT06305975|PROCEDURE|Veress needle abdominal entry|Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
219683127|NCT03571724|OTHER|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
219683128|NCT03571724|OTHER|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
219683129|NCT03571724|OTHER|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
219683130|NCT03571724|OTHER|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
219683131|NCT03729791|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
219683132|NCT00964028|BIOLOGICAL|Infanrix™-IPV/Hib|Intramuscular, three doses
219683133|NCT03666949|DRUG|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
219683134|NCT03666949|DRUG|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
219683135|NCT01421992|DRUG|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
219683136|NCT01421992|DRUG|Placebo|one tablet placebo per day during 3 weeks
219683137|NCT03577314|OTHER|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
219683138|NCT00183508|BEHAVIORAL|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
219683139|NCT00183508|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
219098737|NCT06181032|DRUG|Adebrelimab|Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;
219098738|NCT06181032|DRUG|Apatinib|Apatinib: 250 mg, po, QD, Q3W;
219098739|NCT06181032|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;
219098740|NCT06181032|DRUG|Cisplatin|Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
219098741|NCT05338918|OTHER|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
219098742|NCT05338918|OTHER|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
219098743|NCT01335516|OTHER|Glypressin (terlipressin)|Study drug (without placebo)
219098744|NCT02995850|DRUG|CRS+HIPEC|"1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
219098745|NCT02384655|DRUG|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
219098746|NCT03054038|DRUG|Afatinib|Given by mouth
219098747|NCT03054038|BIOLOGICAL|Necitumumab|Given IV
219098748|NCT03054038|OTHER|Laboratory Biomarker Analysis|Correlative studies
219098749|NCT03803891|PROCEDURE|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
219098750|NCT06333210|BIOLOGICAL|anti-TRBV9 monoclonal antibody infusions|infusions
219683140|NCT02385110|DRUG|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
219683141|NCT02385110|DRUG|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
219683142|NCT02385110|DRUG|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
219683143|NCT02385110|DRUG|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
219098751|NCT06333210|OTHER|Placebo infusions|infusions
219098752|NCT06333210|DRUG|Adalimumab subcutaneous injection|subcutaneous injection
219223292|NCT00766909|DRUG|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
219098753|NCT06333210|OTHER|Placebo subcutaneous injection|subcutaneous injection
219098754|NCT04886427|OTHER|No intervention|Measure the experiences of the current care
219098755|NCT05408143|OTHER|CC|To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).
219223293|NCT00766909|OTHER|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
219223294|NCT01116206|DRUG|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
219223295|NCT01116206|DRUG|Placebo|1 tablet, orally once dailyfor 12 weeks
219223296|NCT04877756|DRUG|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
219223297|NCT04181099|OTHER|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
219223298|NCT06635759|OTHER|Upper trapezius low-load endurance exercise|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
219098756|NCT05408143|DEVICE|enhanced telemedicine (ETM)|"An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, \& ears, auscultate the heart \& lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations."
219098757|NCT03516864|DEVICE|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
219223299|NCT06635759|OTHER|Upper trapezius stretching exercise|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
219223300|NCT02432898|DEVICE|3D OCT-1|Spectral Domain OCT Device
219223301|NCT02432898|DEVICE|3D OCT-2000|Spectral Domain OCT Device
219223302|NCT02432898|DEVICE|DRI OCT-1|Swept Source OCT Device
219098758|NCT03516864|DEVICE|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
219098759|NCT00637819|DRUG|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
219223303|NCT02432898|DEVICE|NW-300|Fundus Camera
219223304|NCT02432898|DEVICE|CT-1P|Tonometry
219223305|NCT02432898|DEVICE|TRK-2P|Tonometry, Corneal Topography
219223306|NCT02432898|DEVICE|SP-1P|Specular Microscopy
219223307|NCT02432898|DEVICE|SL-D701|Slit Lamp Imaging
219098760|NCT03204058|DRUG|Placebos|Oral prophylaxis followed by placement of placebo gel
219098761|NCT03204058|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
219098762|NCT03204058|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
219098763|NCT00477477|OTHER|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
219098764|NCT00477477|OTHER|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
219223308|NCT02432898|DEVICE|MC-4S|Visual Acuity Testing
219223309|NCT02168309|DRUG|Labetalol|Titrate up for blood pressure control
219223310|NCT02168309|DRUG|Nifedipine|Titrate up to achieve blood pressure control
219223311|NCT02233556|DRUG|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50"
219223312|NCT05230966|DEVICE|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
219223313|NCT04422392|DRUG|Carboplatin|(IV, Q3W)
219223314|NCT04422392|DRUG|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
219223315|NCT04422392|DRUG|PD-1 antibody|(IV, Q3W)
219223316|NCT04934033|OTHER|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
219223317|NCT05230264|OTHER|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
219223318|NCT03773471|BEHAVIORAL|Mobile Health App|ArthritisPower App
219223319|NCT00691691|RADIATION|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
219223320|NCT03989310|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
219223321|NCT03989310|DRUG|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
219223322|NCT03989310|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
219098765|NCT05214313|BEHAVIORAL|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~* 10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~* Active phase: (25 min)~* 5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~* 20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~* 10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
219098766|NCT03281824|BIOLOGICAL|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
219223323|NCT03989310|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
219223324|NCT04318691|BIOLOGICAL|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
219223325|NCT04318691|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
219223326|NCT03726593|DRUG|Artesunate and Pyronaridine|Standard weight based dosing
219223327|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
219223328|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
219223329|NCT05925335|DEVICE|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
219223330|NCT06630325|DRUG|Abemaciclib|Given PO
219223331|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
219223332|NCT06630325|PROCEDURE|Bone Scan|Undergo bone scan
219223333|NCT06630325|DRUG|Carboplatin|Given IV
219223334|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
219223335|NCT06630325|DRUG|Exemestane|Given PO
219223336|NCT06630325|DRUG|Fulvestrant|Given IM
219223337|NCT06630325|DRUG|Gefitinib|Given PO
219223338|NCT06630325|DRUG|Gemcitabine|Given IV
219223339|NCT06630325|DRUG|Letrozole|Given PO
219223340|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219223341|NCT06630325|DRUG|Olaparib|Given PO
219223342|NCT06630325|DRUG|Osimertinib|Given PO
219223343|NCT06630325|DRUG|Paclitaxel|Given IV
219223344|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219223345|NCT06630325|DRUG|Pemetrexed|Given IV
219223346|NCT06630325|OTHER|Survey Administration|Ancillary studies
219223347|NCT06630325|DRUG|Tamoxifen|Given PO
219223348|NCT06630325|DRUG|Temozolomide|Given PO
219223349|NCT06630325|PROCEDURE|Biospecimen Collection|Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
219223350|NCT01722409|DRUG|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
219223351|NCT01722409|DRUG|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
219223352|NCT03677037|OTHER|Short-term MBT|Short-term mentalization-based therapy
219223353|NCT03677037|OTHER|Long-term MBT|Long-term mentalization-based therapy
219223354|NCT06495970|DEVICE|Gradient Denervation System|The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
219223355|NCT03335488|DRUG|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
219223356|NCT03335488|DRUG|NaPBA|"* NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose"
219223357|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
219223358|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
219098767|NCT02140710|PROCEDURE|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
219098768|NCT03129048|BEHAVIORAL|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
219223359|NCT03696056|BEHAVIORAL|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
219223360|NCT03696056|BEHAVIORAL|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
219223361|NCT00388726|DRUG|E7389|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
219223362|NCT00388726|DRUG|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
219223363|NCT06174948|DEVICE|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
219223364|NCT06174948|DEVICE|CUE1+ device active vs sham CUE1+ device|30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks
219683144|NCT02385110|BEHAVIORAL|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
219683145|NCT02385110|DRUG|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
219683146|NCT03472521|DRUG|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
219683147|NCT03472521|DRUG|Placebo|Placebo to match gabapentin
219223365|NCT04346914|BIOLOGICAL|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
219223366|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
219683148|NCT04054726|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
219683149|NCT04054726|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
219683150|NCT00343629|DRUG|sulindac|
219683151|NCT00343629|OTHER|pharmacological study|
219098769|NCT05674591|BEHAVIORAL|Cognitive Processing Therapy (CPT)|The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
219098770|NCT02826525|DRUG|AZD4076|Investigational product
219098771|NCT02826525|DRUG|Placebo|Control
219098772|NCT01336621|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
219098773|NCT03715712|OTHER|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure \> 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion
219098774|NCT03715712|OTHER|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
219098775|NCT03571737|DRUG|Ibuprofen|Ibuprofen tablet
219098776|NCT03571737|DRUG|Lidocaine Patch 4%|Lidocaine patch
219098777|NCT00056225|DRUG|Folate|
219098778|NCT00056225|DRUG|Vitamin B6|
219098779|NCT00056225|DRUG|Vitamin B12|
219098780|NCT05453747|OTHER|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
219098781|NCT05453747|OTHER|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
219098782|NCT05128643|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
219098783|NCT01771822|DRUG|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
219098784|NCT01771822|DRUG|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
219098785|NCT01771822|DRUG|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
219098786|NCT01771822|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
219098787|NCT00001565|DRUG|phenylbutyrate|
219098788|NCT01126060|DRUG|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
219098789|NCT01126060|PROCEDURE|Thyroidectomy|surgical removal of bilateral thyroid glands
219098790|NCT00628836|DEVICE|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
219098791|NCT00002928|DRUG|paclitaxel|
219098792|NCT01874145|DRUG|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
219098793|NCT01874145|DRUG|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
219098794|NCT03299764|DEVICE|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
219098795|NCT03299764|DEVICE|Standard non-invasive ventilation|Standard non-invasive ventilation
219098796|NCT01659398|DEVICE|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
219098797|NCT05772429|DRUG|Epidiolex|Administered as an oral solution
219098798|NCT04453215|DEVICE|GaAlAs semiconductor diode laser device|low-level laser therapy
219098799|NCT01273428|DRUG|HP011-101|
219223367|NCT05038839|DRUG|Cabozantinib|Given PO
219223368|NCT05038839|DRUG|Pamiparib|Given PO
219223369|NCT06336590|BEHAVIORAL|Morning Exercise|Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
219098800|NCT01273428|DEVICE|HP-828-101|
219098801|NCT01273428|OTHER|Standard Care|
219223370|NCT02662205|OTHER|Psychotherapy Group|Traditional process group
219223371|NCT02662205|OTHER|Yoga class|Yin yoga class
219683152|NCT03934840|DRUG|Cabazitaxel|20 mg/m2 Q 21 days
219683153|NCT03934840|DRUG|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
219683154|NCT03934840|DRUG|Abiraterone|1000 mg PO daily
219683155|NCT03934840|DRUG|Prednisone|5 mg PO daily on chemotherapy completion
219683156|NCT02371876|DEVICE|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
219098802|NCT04929808|OTHER|Hydrating emollient for acute radiodermatitis|"The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist."
219223372|NCT02662205|OTHER|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
219223373|NCT00324948|DRUG|Topical alprostadil (PGE-1)|
219223374|NCT05841342|OTHER|No intervention|No intervention
219223375|NCT03336892|BEHAVIORAL|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
219098803|NCT04929808|OTHER|Standard institutional skin care|The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
219098804|NCT05715359|PROCEDURE|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
219098805|NCT00595972|DRUG|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219098806|NCT01861834|DRUG|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
219098807|NCT06419244|DIAGNOSTIC_TEST|Myosteatosis|Determination of myosteatosis by imaging
219098808|NCT04575727|DRUG|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)
219098809|NCT00730314|PROCEDURE|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
219098810|NCT01635075|BEHAVIORAL|Exercise|1-mile treadmill walk
219098811|NCT01635075|BEHAVIORAL|passive control|20 min inactivity
219098812|NCT04898712|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets
219098813|NCT04898712|DRUG|Placebo|The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
219223376|NCT06013124|OTHER|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
219223377|NCT04316494|DRUG|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
219223378|NCT04316494|DRUG|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
219223379|NCT01347294|DRUG|Bleomycin|Intralesional
219223380|NCT01347294|DRUG|Fibrovein|Intralesional
219223381|NCT01347294|DRUG|Bleomycin + Fibrovein|Intralesional
219683157|NCT02284386|DRUG|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
219683158|NCT02284386|DRUG|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
219683159|NCT03634202|COMBINATION_PRODUCT|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
219683160|NCT04956939|DRUG|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
219683161|NCT04956939|DRUG|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
219683162|NCT03051347|OTHER|Itch Questionnaire and Interview|
219683163|NCT03051347|OTHER|Stigma Questionnaire and Interview|
219683164|NCT03051347|OTHER|Cognitive Interview and PROMIS Itch Questionnaire|
219683165|NCT05085470|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
219683166|NCT05085470|BIOLOGICAL|Placebo mock infection|Placebo mock infection with water
219683167|NCT01122459|OTHER|fluid administration|1.5mls/kg/hr fasting
219683168|NCT01002248|DRUG|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
219683169|NCT01002248|DRUG|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
219098814|NCT00416260|OTHER|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
219223382|NCT04409392|OTHER|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
219223383|NCT03208465|DRUG|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
219223384|NCT03208465|DRUG|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
219223385|NCT05749120|PROCEDURE|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
219223386|NCT04374981|DRUG|Celecoxib 100mg|Tablets
219223387|NCT04374981|DRUG|Montelukast 10mg|Tablets
219223388|NCT04964037|OTHER|No intervention|No intervention
219223389|NCT05912218|BIOLOGICAL|MEI6570|Saline Control
219223390|NCT04638816|DEVICE|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
219223391|NCT04638816|DEVICE|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
219223392|NCT04309552|DRUG|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
219223393|NCT04309552|DRUG|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
219223394|NCT06315985|OTHER|Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia|The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
219223395|NCT02400931|PROCEDURE|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
219223396|NCT02400931|PROCEDURE|no mask ventilation|
219223397|NCT02400931|DRUG|Rocuronium|
219223398|NCT02251652|DRUG|Ingenol Mebutate|Ingenol mebutate 0.05% gel
219223399|NCT02251652|PROCEDURE|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
219223400|NCT04207424|PROCEDURE|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
219223401|NCT04543812|DRUG|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
219098815|NCT04485130|DRUG|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
219223402|NCT04543812|DRUG|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
219223403|NCT03885245|DRUG|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
219223404|NCT03885245|DRUG|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
219223407|NCT03852082|PROCEDURE|percutaneous coronary intervention|Patients with coronary heart disease co-morbid depression post percutaneous coronary intervention.
219098816|NCT04485130|DRUG|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
219098817|NCT05238064|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
219098818|NCT05238064|DRUG|CHOP|Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
219098819|NCT00402337|DRUG|linaclotide acetate|oral, once daily.
219098820|NCT00402337|DRUG|Matching placebo|oral, once daily
219098821|NCT05909839|OTHER|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
219098822|NCT05784805|DEVICE|PLIFU|Participants will be treated with up to 2 sessions of PLIFU (on the same day), while monitored with surface EEG and will be observed for the remainder of the hospital stay as deemed by the primary care team. The system non-invasively delivers ultrasound sonications intracranially that selectively target specific areas of the brain.
219098823|NCT02178566|DRUG|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
219098824|NCT04634461|DEVICE|Cardiac Monitor|RHYTHMSTAR Mobile Cardiac Monitoring System
219098825|NCT03731754|PROCEDURE|Traditional Closure|Primary closure discontinuously the perineal wound of APR
219098826|NCT03731754|PROCEDURE|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
219223408|NCT06230731|OTHER|Oxygen saturation|Measure oxygen levels in 5 proximal colon mucosa locations.
219223409|NCT00984048|OTHER|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
219098827|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
219098828|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
219098829|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
219098830|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
219223410|NCT00176202|DRUG|Divalproex Sodium|Divalproex sodium is a mood stabilizer
219223411|NCT00176202|DRUG|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
219223412|NCT01964781|DRUG|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
219223413|NCT01964781|DRUG|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
219223414|NCT01964781|DRUG|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
219223415|NCT01964781|DRUG|tranexamic acid plus saline|
219223416|NCT01964781|DRUG|saline|
219223417|NCT03496883|BIOLOGICAL|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
219098831|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
219223418|NCT03496883|BIOLOGICAL|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
219223419|NCT02873559|DRUG|testosterone|Testosterone supplemented in 5 months
219223420|NCT02873559|OTHER|Progressive muscle training|Progressive muscle training during 4 months
219223421|NCT04366024|OTHER|other|clinical diagnosis
219223422|NCT04989296|DIAGNOSTIC_TEST|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
219223423|NCT00826995|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
219223424|NCT04514718|DEVICE|Holmium laser|low energy holmium laser
219223425|NCT01160354|DRUG|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
219223426|NCT01160354|DRUG|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
219223427|NCT01822756|DRUG|ruxolitinib|
219223428|NCT01822756|DRUG|gemcitabine|Other names: Gemzar®
219223429|NCT01822756|DRUG|nab-paclitaxel|Other names: Abraxane®
219098832|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
219098833|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
219098834|NCT01237795|OTHER|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
219098835|NCT03705819|DRUG|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
219098836|NCT03705819|RADIATION|PET/CT scan|After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
219098837|NCT04341961|OTHER|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
219098838|NCT02658630|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
219098839|NCT03013088|DEVICE|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
219098840|NCT02124343|OTHER|Interval Exercise|
219098841|NCT02915094|DRUG|Anakinra|
219098842|NCT03249506|DRUG|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
219098843|NCT03249506|DRUG|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
219223430|NCT01822756|DRUG|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
219223431|NCT04738656|DIETARY_SUPPLEMENT|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
219223432|NCT04876495|DIETARY_SUPPLEMENT|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
219223433|NCT04876495|DIETARY_SUPPLEMENT|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
219223434|NCT04876495|DIETARY_SUPPLEMENT|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~* Tropicana Trop50 Orange Juice 183mL~* Water 67mL~* Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
219223435|NCT05483088|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
219223436|NCT01328496|DRUG|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
219223437|NCT03440086|DEVICE|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
219223438|NCT01918176|DRUG|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
219223439|NCT01918176|DRUG|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
219223440|NCT05783843|BEHAVIORAL|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
219223441|NCT05783843|BEHAVIORAL|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
219683170|NCT01002248|DRUG|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
219683171|NCT01002248|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
219098844|NCT03249506|DRUG|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
219098845|NCT03249506|DRUG|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
219098846|NCT03249506|DRUG|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
219098847|NCT03249506|DRUG|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
219098848|NCT03249506|DRUG|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
219098849|NCT03249506|DRUG|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
219098850|NCT00187330|DRUG|Intravenous N-acetylcysteine|
219223442|NCT05783843|BEHAVIORAL|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
219683172|NCT02076815|DRUG|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
219683173|NCT02076815|DRUG|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
219683174|NCT04918472|PROCEDURE|MCCE|Mangetically controlled capsule endoscopy will be performed
219098851|NCT02125448|DEVICE|MRI and PET-CT|
219098852|NCT00066430|PROCEDURE|infrared photocoagulation therapy|
219098853|NCT00066430|DEVICE|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
219098854|NCT04846023|DEVICE|aEEG via vEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
219223443|NCT05035329|OTHER|Outcome measurements|Outcome measurements were applied.
219223444|NCT01025128|DRUG|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
219683175|NCT01768923|PROCEDURE|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)
219683176|NCT01768923|PROCEDURE|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
219683177|NCT03705286|DEVICE|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
219683178|NCT03705286|DEVICE|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
219683179|NCT00534638|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
219683180|NCT00534638|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
219683181|NCT02741232|DRUG|Lidocaine 1% with epinephrine 1/400000|
219683182|NCT02741232|OTHER|sham block|
219683183|NCT05382013|DRUG|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
219098855|NCT05767775|OTHER|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
219098856|NCT04462315|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
219098857|NCT04462315|DEVICE|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
219098858|NCT03482505|DEVICE|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
219098859|NCT01737346|DRUG|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
219098860|NCT00793156|DRUG|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
219098861|NCT00793156|DRUG|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
219098862|NCT00793156|OTHER|Placebo|Placebo daily dose
219098863|NCT05124093|PROCEDURE|Apnoeic oxygenation|"After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%."
219098864|NCT02048748|DEVICE|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
219098865|NCT02048748|DEVICE|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
219098866|NCT04601441|DRUG|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
219098867|NCT06203184|OTHER|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
219098868|NCT00910455|DRUG|SRX246|single oral dose of SRX246 capsule
219098869|NCT00910455|DRUG|Placebo|Single oral dose of placebo capsule
219098870|NCT06459830|OTHER|Mime Therapy with Neural Mobilization|"Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
219550329|NCT01348958|DEVICE|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
219550330|NCT00368082|BIOLOGICAL|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2"
219550331|NCT02783326|OTHER|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
219550332|NCT03391622|DEVICE|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
219550333|NCT06533072|OTHER|The group receiving infrared LED therapy|Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
219550334|NCT00159419|DRUG|Alendronate|
219550335|NCT00159419|DRUG|Pamidronate|
219550336|NCT03004508|DIETARY_SUPPLEMENT|Gingko Biloba Extract|120mg/day, twice a day, 6 month
219550337|NCT03004508|DIETARY_SUPPLEMENT|Placebo|120mg/day, twice a day, 6 month
219550338|NCT03516487|DRUG|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
219550339|NCT03516487|DRUG|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
219550340|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
219550341|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
219550342|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
219550343|NCT06678295|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly sessions of individual cognitive behavioral therapy
219550344|NCT00002224|DRUG|Nelfinavir mesylate|
219223445|NCT03849066|OTHER|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
219098871|NCT06459830|OTHER|Mime Therapy with Placebo Mobilization|"Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
219098872|NCT02821819|OTHER|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
219683184|NCT05382013|OTHER|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
219683185|NCT05382013|OTHER|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
219683186|NCT03193229|BEHAVIORAL|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
219098873|NCT02821819|DRUG|Gonadotrophins|Urinary FSH 150-225 IU/d
219098874|NCT02821819|DRUG|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
219098875|NCT02821819|DRUG|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
219098876|NCT03565068|DRUG|MK-8189|MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
219098877|NCT03565068|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
219098878|NCT03565068|DRUG|Background AAP Therapy|Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
219098879|NCT06205797|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA"
219098880|NCT06205797|DRUG|Xeomin®|"Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA"
219098881|NCT02911350|DRUG|Hormone Suppressors|
219683187|NCT03193229|DEVICE|Fitbit|Fitbit
219683188|NCT03694223|OTHER|Health education delivery methods|
219683189|NCT02338401|DIETARY_SUPPLEMENT|Omega-3 Complete|Fish Oil Capsules
219683190|NCT02338401|DIETARY_SUPPLEMENT|Placebo Pill|Olive Oil Capsules
219098882|NCT02911350|DRUG|Paclitaxel|
219098883|NCT02911350|RADIATION|Radiation Therapy|
219683191|NCT05297461|OTHER|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
219683192|NCT00001013|DRUG|Trimetrexate glucuronate|
219683193|NCT00001013|DRUG|Pentamidine isethionate|
219683194|NCT00001013|DRUG|Sulfamethoxazole-Trimethoprim|
219683195|NCT00001013|DRUG|Leucovorin calcium|
219683196|NCT02709837|OTHER|Nutritional|
219683197|NCT05627050|DEVICE|An Online Augmented Reality (AR) Training Platform|The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
219683198|NCT00003925|DRUG|gemcitabine hydrochloride|
219683199|NCT00003925|DRUG|leucovorin calcium|
219683200|NCT00003925|DRUG|tegafur-uracil|
219098884|NCT01978080|DEVICE|Kinesia HomeView|
219098885|NCT01199159|DRUG|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
219098886|NCT01199159|DRUG|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
219098887|NCT00085202|BIOLOGICAL|filgrastim|Given subcutaneously
219098888|NCT00085202|DRUG|cisplatin|Given IV
219098889|NCT00085202|DRUG|cyclophosphamide|Given IV
219098890|NCT00085202|DRUG|vincristine|Given IV
219098891|NCT00085202|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
219223446|NCT00297349|DRUG|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
219223447|NCT00367874|DRUG|Buprenorphine|
219223448|NCT00367874|DRUG|Valproate|
219098892|NCT00085202|RADIATION|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
219098893|NCT05635292|BEHAVIORAL|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
219223449|NCT03243006|DRUG|Paracetamol|2 tablets of 500mg of paracetamol
219223450|NCT03243006|DRUG|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
219683201|NCT03155555|OTHER|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
219683202|NCT02106351|BIOLOGICAL|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
219683203|NCT00992641|OTHER|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
219683204|NCT00992641|OTHER|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
219683205|NCT02188524|OTHER|Exercise|Tai Chi and Compensatory Stepping
219683206|NCT03924388|DEVICE|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
219683207|NCT03924388|DEVICE|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
219683208|NCT00524706|DRUG|S-1, oral Leucovorin, Oxaliplatin|
219683209|NCT02214030|DEVICE|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
219683210|NCT02405767|OTHER|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
219683211|NCT00094523|DRUG|Fosamprenavir|Fosamprenavir
219683212|NCT05405764|DIETARY_SUPPLEMENT|Porcine protein supplement|Porcine protein supplementation
219683213|NCT05405764|DIETARY_SUPPLEMENT|Control product maltodextrin supplement|Maltodextrin supplementation
219098894|NCT02654210|OTHER|No Intervention|No Intervention
219098895|NCT01985828|RADIATION|CyberKnife|
219098896|NCT01985828|OTHER|Androgen Deprivation Therapy (ADT)|
219098897|NCT01985828|RADIATION|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
219098898|NCT05978505|DRUG|Reboxetine 4 MG Oral Tablet|7 nightly doses (4mg) to commence after surgery.
219223451|NCT03243006|DRUG|Placebo Oral Tablet|2 tablets of placebo
219223452|NCT01543893|BEHAVIORAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
219223453|NCT01543893|BEHAVIORAL|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
219683214|NCT00000256|DRUG|20% N2O|
219683215|NCT00000256|DRUG|40% N2O|
219683216|NCT00000256|DRUG|60% N2O|
219683217|NCT00000256|DRUG|80% N2O|
219683218|NCT00287209|DRUG|Amiodarone|
219683219|NCT06477705|OTHER|FAM|Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
219683220|NCT04506723|PROCEDURE|Percutaneous Nephrolithotomy|PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
219098899|NCT05978505|DRUG|Placebo|7 nightly doses to commence after surgery.
219098900|NCT05558514|OTHER|Place-based cochlear implant mapping|Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
219550345|NCT00002224|DRUG|Stavudine|
219550346|NCT00002224|DRUG|Didanosine|
219550347|NCT04096651|OTHER|gait recordings|gait recordings
219550348|NCT04096651|OTHER|brain magnetic resonance imaging|brain magnetic resonance imaging
219550349|NCT04096651|OTHER|oculomotor movement recordings|oculomotor movement recordings
219550350|NCT01404962|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
219550351|NCT01985464|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
219550352|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
219683221|NCT04506723|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
219683222|NCT04506723|PROCEDURE|Radical nephrectomy|Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
219098901|NCT05558514|OTHER|Default cochlear implant mapping|At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
219098902|NCT05423691|DRUG|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
219098903|NCT00658138|DEVICE|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
219098904|NCT00658138|DEVICE|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
219098905|NCT06444360|BEHAVIORAL|IMPACT|The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
219098906|NCT06444360|BEHAVIORAL|eSOC|The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
219098907|NCT04016948|DEVICE|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
219098908|NCT04016948|DEVICE|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
219098909|NCT06682078|OTHER|Not applicable . Non-interventional retrospective study, only on datas.|Not applicable . Non-interventional retrospective study, only on datas.
219223454|NCT01708278|DRUG|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
219223455|NCT01708278|OTHER|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
219223456|NCT01122914|DRUG|Anakinra|
219223457|NCT03829436|DRUG|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
219223458|NCT03829436|DRUG|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
219223459|NCT03829436|DRUG|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
219550353|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
219550354|NCT01847924|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
219550355|NCT01847924|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
219550356|NCT03816436|OTHER|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
219550357|NCT05692882|DEVICE|Drug-Eluting Stents|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
219550358|NCT00301886|DRUG|ibandronate|
219550359|NCT00301886|DRUG|zoledronate|
219550360|NCT00301886|PROCEDURE|quality-of-life assessment|
219550361|NCT06627556|DRUG|H021|H021 oral tablet.
219550362|NCT06627556|DRUG|H021 Placebo|H021 placebo oral tablet.
219550363|NCT02041013|OTHER|Taking Card|Recordable greeting card-style discharge instruction card
219550364|NCT02973906|OTHER|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
219550365|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
219550366|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
219550367|NCT00258687|BIOLOGICAL|GVAX|4 vaccines every two weeks
219550368|NCT03196557|DRUG|Prenisolone|Specified dose on specified days
219550369|NCT03196557|DRUG|Placebo|Specified dose on dose on specified days
219550370|NCT03736460|BEHAVIORAL|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
219550371|NCT03736460|BEHAVIORAL|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
219550372|NCT00504062|DRUG|budesonide|
219550373|NCT00504062|DRUG|fluticasone|
219550374|NCT00162929|BIOLOGICAL|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
219550375|NCT02435433|DRUG|Ramucirumab|Administered IV
219550376|NCT02435433|DRUG|Placebo|Administered IV
219098910|NCT05851937|BEHAVIORAL|Written language intervention|Young adults with Intellectual and Developmental Disabilities (IDD) are taught reading comprehension strategies in three phases (before, during, after) using a graphic organizer as visual support. At the beginning of each phase, the interventionist: (a) defines the strategies, (b) describes and models how to use the strategies, and (c) answers questions about the strategies. Then the participant practices the strategies during 45-min sessions, two times per week, over 3 months. Each session follows the teach-model-coach-review format, the interventionist: (a) reviews the strategies (5 min), (b) models the strategies using a think-aloud (10 min), (c) prompts the participant to practice the strategies with support (15 min), (d) prompts the participant to use a think-aloud to practice the strategies independently using a functional literacy text (10 min), and (e) reviews and summarizes the session (review; 5 min).
219098911|NCT06077773|DRUG|Oral EP262|Once daily
219098912|NCT06077773|DRUG|Placebo|Once daily
219098913|NCT02803268|DRUG|MT-8554 low dose|
219098914|NCT02803268|DRUG|MT-8554 middle dose|
219098915|NCT02803268|DRUG|MT-8554 high dose|
219098916|NCT02803268|DRUG|Placebo|
219098917|NCT05256095|BEHAVIORAL|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
219098918|NCT02081950|BIOLOGICAL|Enoxaparin sodium|comparison of 2 different administration of drug
219098919|NCT04844580|DRUG|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
219098920|NCT04844580|DRUG|Placebo|Aviptadil Placebo will be used for this arm.
219098921|NCT01741519|DRUG|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
219098922|NCT01741519|DRUG|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
219098923|NCT05558865|BEHAVIORAL|somnovia|Participants receive access to the digital health application somnovia
219098924|NCT03017326|DRUG|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
219098925|NCT03017326|DRUG|Doxorubicin|Arms C, D and E used in combination
219098926|NCT03017326|DRUG|Carboplatin|Arms C and D used in combination
219098927|NCT03017326|DRUG|5Fluorouracil|Arm C used alone
219098928|NCT03017326|DRUG|Vincristine|Arms C and D used in combination
219098929|NCT03017326|DRUG|Etoposide|Arm D used in combination
219098930|NCT03017326|DRUG|Irinotecan|Arm D used in combination
219683223|NCT00520039|PROCEDURE|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
219098931|NCT03017326|DRUG|Gemcitabine|Arm F used in combination
219098932|NCT03017326|DRUG|Oxaliplatin|Arm F used in combination
219098933|NCT03017326|DRUG|Sorafenib|Arm used in combination
219223460|NCT03829436|DRUG|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
219223461|NCT03102034|BIOLOGICAL|D46/NS2/N/ΔM2-2-HindIII|10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
219098934|NCT02020239|OTHER|Exercise|
219098935|NCT01436201|DRUG|Digoxin|Administered orally
219098936|NCT01436201|BIOLOGICAL|Dulaglutide|Administered as subcutaneous injection
219098937|NCT00524225|DRUG|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
219098938|NCT00110890|DRUG|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
219098939|NCT00110890|OTHER|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
219098940|NCT05234359|DIAGNOSTIC_TEST|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
219098941|NCT05234359|DIAGNOSTIC_TEST|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
219098942|NCT00263328|DRUG|Tacrolimus|Standard of care
219098943|NCT00263328|DRUG|CP-690,550|CP-690,550 5 mg BID
219098944|NCT00263328|DRUG|CP-690,550|CP-690,550 10 mg BID
219098945|NCT01602081|DEVICE|reinforce soft tissue|reinforce soft tissue
219098946|NCT06194409|DIAGNOSTIC_TEST|Echocardiography, Urine analysis , blood culture|All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography
219098947|NCT03056625|OTHER|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
219098948|NCT03056625|OTHER|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
219098949|NCT02092558|DRUG|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
219098950|NCT02092558|DRUG|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
219098951|NCT01199926|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
219098952|NCT01199926|DRUG|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
219223462|NCT03102034|BIOLOGICAL|Placebo|Isotonic diluent; administered as nose drops
219683224|NCT02329327|BIOLOGICAL|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
219683225|NCT03905941|DRUG|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
219683226|NCT03905941|DRUG|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
219683227|NCT03562858|PROCEDURE|Immediate dentin sealing protocol|Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
219683228|NCT03562858|PROCEDURE|Delayed dentin sealing protocol|Sealing the dentin just prior to cementation
219683229|NCT01801111|DRUG|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
219683230|NCT01801111|DRUG|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
219683231|NCT01184612|BEHAVIORAL|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
219683232|NCT05533489|OTHER|No intervention|No intervention This study is a retrospective descriptive study.
219683233|NCT01137097|PROCEDURE|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
219683234|NCT00244153|DRUG|intraarticular morphine|
219683235|NCT00244153|DRUG|intraarticular dexamethasone|
219683236|NCT04710069|BEHAVIORAL|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
219683237|NCT04870957|BEHAVIORAL|PainGuide|A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
219683238|NCT04870957|BEHAVIORAL|MBSR|"In this group (mindfulness-based stress reduction) participants will take part in 9 group sessions.~The groups sessions will be divided into 8 weekly 2-hour groups sessions and one 6-hour retreat. During the sessions participants will practice mindfulness exercises directed by the a MBSR therapist. Additionally, participants will also be asked to practice daily formal mindfulness at home using audio recordings of 30-45 minute guided meditation exercises. These audio recordings can be accessed online. The sessions may take place in-person or virtually."
219098953|NCT00717821|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
219098954|NCT00717821|DRUG|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
219098955|NCT00717821|DRUG|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
219098956|NCT01960530|DRUG|Hydrocortisone granules|Multi-particulate granules
219098957|NCT01960530|DRUG|Hydrocortisone Tablet|Standard hydrocortisone tablets
219098958|NCT01960530|DRUG|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
219098959|NCT01960530|OTHER|Dexamethasone|Challenge agent
219223463|NCT01203293|BEHAVIORAL|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
219223464|NCT01203293|BEHAVIORAL|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
219098960|NCT03899168|OTHER|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
219098961|NCT03899168|OTHER|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
219098962|NCT03899168|OTHER|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
219098963|NCT02676596|DRUG|K-312 10 mg QD|
219098964|NCT02676596|DRUG|K-312 25 mg QD|
219098965|NCT02676596|DRUG|K-312 50 mg QD|
219098966|NCT02676596|DRUG|K-312 100 mg QD|
219098967|NCT02676596|DRUG|K-312 200 mg QD|
219098968|NCT02676596|DRUG|K-312 400 mg QD|
219098969|NCT02676596|OTHER|Placebo|
219098970|NCT01301274|DRUG|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
219098971|NCT01301274|DRUG|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
219098972|NCT02890537|DRUG|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
219098973|NCT02890537|DRUG|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
219098974|NCT01925027|DEVICE|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
219683239|NCT04870957|BEHAVIORAL|PT and exercise|"Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability."
219683240|NCT04870957|DEVICE|Self -administered acupressure|"A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions."
219683241|NCT04870957|DRUG|Duloxetine|For days 1-7, patients will take 30mg of duloxetine once a day, in the morning. Starting day 8, participants tolerating the medication will be escalated to 60mg once a day. They will also have the option of staying at 30mg, once a day or stopping the medication. At the end of the 8-week intervention period, participants will have the option to continue the medication commercially (non-study medication) under the care of their physician or taper off the medication. During the entire 8-week intervention, patients will be asked to keep a daily log of medication dosage, any missed doses, and any side-effects they may have experienced.
219683242|NCT04870957|DEVICE|Pro-Diary monitor|"Participants will wear during 5 separate 7-day home monitoring periods to assess physical activity (objectively measured via accelerometry), and ecological momentary assessment (EMA) of mental and physical symptoms. EMA will be collected during Weeks 1, 6, 15, 24 and 36."
219098975|NCT04365517|DRUG|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
219223465|NCT00785200|OTHER|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
219683243|NCT05492513|BEHAVIORAL|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 1.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
219683244|NCT06822387|BEHAVIORAL|Mindfulness-Based Intervention|Learning to BREATHE (L2B) is an evidence-based mindfulness curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
219683245|NCT06822387|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition education and 3) physical activity education. Parents set weekly goals to implement what they learned in each session at home with their family.
219683246|NCT06822387|BEHAVIORAL|Physical Activity|Focuses on using cardio and resistance training to improve cardiorespiratory health in youth.
219683247|NCT06822387|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education is based on the Learning to BREATHE curriculum.
219683248|NCT06822387|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
219683249|NCT06822387|BEHAVIORAL|Nutrition and Cooking Education|Nutrition education and hands-on cooking lessons for the whole family.
219683250|NCT04140214|DRUG|Hypertonic saline|Nebulized hypertonic saline solution (6%)
219683251|NCT04140214|DRUG|Carbocysteine 750 MG|Carbocisteine tablet
219683252|NCT06241885|BEHAVIORAL|Intervention group I|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
219683253|NCT01223937|DRUG|Desmopressin|
219683254|NCT01223937|DRUG|Placebo|
219683255|NCT00223665|DRUG|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
219683256|NCT00223665|DRUG|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
219683257|NCT03871985|PROCEDURE|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
219683258|NCT03871985|PROCEDURE|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
219683259|NCT05176717|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
219683260|NCT05176717|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
219683261|NCT05263518|PROCEDURE|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
219683262|NCT05263518|PROCEDURE|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
219683263|NCT03208608|DIAGNOSTIC_TEST|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
219683264|NCT00534417|DRUG|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
219683265|NCT00534417|DRUG|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
219683266|NCT00765817|DRUG|placebo|subcutaneous injection, twice a day
219683267|NCT00765817|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
219683268|NCT04239352|DIAGNOSTIC_TEST|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
219683269|NCT04239352|DIAGNOSTIC_TEST|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
219683270|NCT04753333|BEHAVIORAL|Electromyography biofeedback (EMG-BF)|Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
219683271|NCT04753333|BEHAVIORAL|Sham electromyography biofeedback (EMG-BF)|Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
219683272|NCT02308228|BEHAVIORAL|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
219683273|NCT02308228|DRUG|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
219683274|NCT04360369|DEVICE|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (\>23 mmHg).
219683275|NCT04360369|DEVICE|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
219683276|NCT04360369|DEVICE|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
219683277|NCT01043133|BEHAVIORAL|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
219683278|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
219683279|NCT03772834|DRUG|Methylphenidate|Given PO
219683280|NCT03772834|OTHER|Placebo|Given PO
219683281|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
219683282|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
219683283|NCT03772834|OTHER|Stretching|Undergo stretching
219683284|NCT06607796|DRUG|Toluenesulfonamide (PTS) Intratumoral Injection|intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
219683285|NCT06608017|DRUG|Chinese Herbal Medicine granules|Treatment group
219683286|NCT06608017|OTHER|Placebo|Placebo-controlled group
219683287|NCT05732558|PROCEDURE|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
219683288|NCT06480786|DEVICE|Spinal cord stimulation|active spinal cord stimulation
219683289|NCT06480786|DEVICE|Sham stimulation|Sham stimulation
219683290|NCT04460248|DRUG|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
219683291|NCT00298883|DRUG|Myfortic|Myfortic 360mg PO BID for six weeks
219683292|NCT06730152|BEHAVIORAL|WeChat Intervention Based on the IMB Model|The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
219683293|NCT03999749|DRUG|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
219683294|NCT03999749|DRUG|Nivolumab|Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years
219683295|NCT03999749|DRUG|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
219683296|NCT03852823|DRUG|SG001|Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
219683297|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
219683298|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
219683299|NCT00255164|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
219683300|NCT02017626|BIOLOGICAL|mCyp c 1|2 patient groups with different doses of allergen.
219683301|NCT03369873|OTHER|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
219683302|NCT03378245|BEHAVIORAL|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
219683303|NCT06671977|DRUG|DMT-Medium Dose|14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
219098976|NCT04836117|OTHER|SomaSignal Test Results|SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
219098977|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219683304|NCT06671977|DRUG|DMT-Low Dose|10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
219683305|NCT06671977|DRUG|THC-Medium Dose|0.5 mg over 5 minutes and then 2 mg over and 55 minutes
219683306|NCT06671977|DRUG|THC-Low Dose|0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
219683307|NCT05219968|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
219683308|NCT05219968|DRUG|Sham procedure control|Sham procedure control
219098978|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
219098979|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
219098980|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
219098981|NCT03489096|DEVICE|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
219098982|NCT03288090|OTHER|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
219683309|NCT05219968|OTHER|Background Therapy|Daily Saline Irrigation
219683310|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
219683311|NCT04157205|DIAGNOSTIC_TEST|Non-invasive ECG imaging - CardioInsight test|"1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics"
219683312|NCT06445582|DIAGNOSTIC_TEST|[18F]SDM-8|synaptic vesicle glycoprotein 2 A（SV2A）PET tracer \[18F\]SDM-8
219098983|NCT03288090|OTHER|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
219683313|NCT03888326|DEVICE|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
219683314|NCT03888326|DEVICE|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
219683315|NCT03888326|BEHAVIORAL|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
219683316|NCT03782805|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
219683317|NCT03782805|DIETARY_SUPPLEMENT|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
219683318|NCT04911491|DEVICE|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
219098984|NCT03288090|OTHER|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
219098985|NCT05765279|DRUG|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
219098986|NCT05765279|DRUG|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
219098987|NCT05765279|DRUG|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
219098988|NCT05765279|DRUG|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
219098989|NCT02970253|PROCEDURE|Capsular resection|Capsular resection
219098990|NCT02970253|PROCEDURE|Capsular retention|Capsular retention
219098991|NCT03324399|DIETARY_SUPPLEMENT|probiotic|a proprietary probiotic formulation
219098992|NCT04154865|OTHER|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
219098993|NCT04154865|DEVICE|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
219098994|NCT04154865|DEVICE|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
219098995|NCT04154865|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
219223466|NCT00785200|OTHER|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
219223467|NCT00843934|DRUG|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
219223468|NCT00843934|DRUG|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
219223469|NCT00347204|DRUG|ketorolac (Acular LS)|
219223470|NCT00347204|DRUG|Nepafenac (Nevanac)|
219223471|NCT05927220|DIAGNOSTIC_TEST|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
219683319|NCT04911491|DEVICE|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
219683320|NCT02066597|DEVICE|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
219098996|NCT03020875|DRUG|Ofirmev|Intravenously administered acetaminophen.
219098997|NCT03020875|DRUG|Per Os Acetaminophen|Orally administered acetaminophen.
219098998|NCT06203886|DEVICE|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
219683321|NCT04587336|BEHAVIORAL|Cognitive Interview|Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
219683322|NCT04587336|BEHAVIORAL|Baseline Survey|Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
219683323|NCT04587336|BEHAVIORAL|Qualitative Interviews|Describe self-management challenges and preferred learning strategies to inform intervention components and delivery approach for Veterans with T2D.
219683324|NCT06950047|PROCEDURE|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System
219098999|NCT06410495|BEHAVIORAL|NiteCAPP SINCC|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
219099000|NCT06581809|OTHER|Algosteril|hemostatic dressing
219099001|NCT06581809|OTHER|Other Dressings: interface, hydrocellular, hydrofiber|Non-haemostatic dressing
219099002|NCT05726058|DEVICE|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
219683325|NCT06950047|PROCEDURE|distal femoral osteotomies using the 90°LCP-PCP|distal femoral osteotomies using the 90°LCP-PCP
219683326|NCT06949007|BEHAVIORAL|Yoga|Duration: 12 weeks; Class length: Three ∼75-minute classes per week. Two in-person/virtual (hybrid), one virtual only (MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
219099003|NCT04332042|DRUG|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
219099004|NCT02635269|OTHER|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
219099005|NCT00609427|BEHAVIORAL|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
219099006|NCT00609427|BEHAVIORAL|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
219099007|NCT04512066|DRUG|RO6889450|Participants will receive oral RO6889450 QD.
219099008|NCT04512066|DRUG|Placebo|Participants will receive oral placebo QD.
219099009|NCT04512066|DRUG|Risperidone|Participants will receive oral risperidone QD.
219099010|NCT00871052|DRUG|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
219099011|NCT04989127|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
219099012|NCT04989127|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
219223472|NCT03382470|OTHER|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
219223473|NCT01894217|GENETIC|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
219223474|NCT00405158|PROCEDURE|Acupuncture treatment|
219223475|NCT00405158|PROCEDURE|Administration of oxytocin nasal spray|
219223476|NCT00405158|PROCEDURE|Improved breast milk removal|
219223477|NCT00405158|PROCEDURE|Warmth applied to breasts|
219223478|NCT00405158|PROCEDURE|Breast massage|
219683327|NCT06949007|BEHAVIORAL|Chronic Pain Health Education|Duration: 12 weeks (short videos and PowerPoint presentations); Class length: Interactive 15-30 minute education sessions delivered via video conference (i.e., MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
219683328|NCT06955156|DRUG|Trilaciclib|trilaciclib 240mg/m2 ivgtt d1 Q3w; anti-PD-1 antibody 200mg ivgtt d1 Q3w; Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w; carboplatin AUC=5 ivgtt d1 Q3w; Review every 2 cycles until the best efficacy or intolerable toxicity, usually 6-8 cycles;
219683329|NCT06432478|DEVICE|3D-printed custom applicator|3D-printed custom applicator
219099013|NCT04989127|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
219683330|NCT04722107|DRUG|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
219683331|NCT04776928|BEHAVIORAL|Push reports|"Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc."
219683332|NCT05521048|DRUG|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
219683333|NCT06777329|BEHAVIORAL|10 days of dry immersion|The volunteers in this arm will be immersed up to the neck for 10 days in a specially designed bath filled with tap water.
219683334|NCT06777329|BEHAVIORAL|10 days of Head Down Bed Rest|The volunteers in this arm will spend 10 days in -6° head down bed rest.
219683335|NCT00103285|RADIATION|3-Dimensional Conformal Radiation Therapy|Some patients undergo cranial radiotherapy
219683336|NCT00103285|DRUG|Cyclophosphamide|Given IV
219683337|NCT00103285|DRUG|Cytarabine|Given IV or SC
219683338|NCT00103285|DRUG|Dexamethasone|Given IV or PO
219683339|NCT00103285|DRUG|Doxorubicin Hydrochloride|Given IV or IT
219683340|NCT00103285|DRUG|Leucovorin Calcium|Given PO
219099014|NCT04989127|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
219099015|NCT04989127|DRUG|Analgesic|Analgesics are prescribed for the patients.
219099016|NCT04989127|DRUG|Antibiotic|Patients with penicillin allergy
219099017|NCT03520400|BEHAVIORAL|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
219099018|NCT00859651|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
219099019|NCT00859651|DRUG|Placebo capsule|Matching placebo capsules
219099020|NCT00445679|DRUG|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
219099021|NCT00445679|DRUG|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
219099022|NCT06509451|DRUG|Giomer pit and fissure sealant without etching|S-PRG filler containig pit and fissure sealant without etching step
219099023|NCT06509451|DRUG|Giomer pit and fissure sealant with etching|S-PRG filler containig pit and fissure sealant with etching step
219099024|NCT05199623|DRUG|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
219099025|NCT05199623|BEHAVIORAL|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
219223479|NCT00405158|DRUG|Anti-pyretic medication, paracetamol|
219223480|NCT00405158|DRUG|cefadroxil|
219223481|NCT00405158|DRUG|penicillin|
219223482|NCT00405158|DRUG|flucloxacillin|
219683341|NCT00103285|DRUG|Mercaptopurine|Given PO
219683342|NCT00103285|DRUG|Methotrexate|Given IM or IT
219683343|NCT00103285|DRUG|Pegaspargase|Given IM
219683344|NCT00103285|DRUG|Thioguanine|Given PO
219683345|NCT00103285|DRUG|Vincristine Sulfate|Given IV
219683346|NCT02150941|DEVICE|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
219683347|NCT02150941|DEVICE|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
219683348|NCT00913081|DIETARY_SUPPLEMENT|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
219683349|NCT00913081|DIETARY_SUPPLEMENT|Placebo|Placebo PO one time
219683350|NCT00103558|DRUG|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
219683351|NCT00452439|DRUG|Actonel (Risedronate)|35 mg (pill) by mouth weekly
219683352|NCT00452439|DIETARY_SUPPLEMENT|Calcium|500 mg by mouth twice a day for a total of 24 months.
219683353|NCT00452439|DIETARY_SUPPLEMENT|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
219099026|NCT06341621|DRUG|3-year abemaciclib without chemo|aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
219683354|NCT02847325|DRUG|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
219683355|NCT02847325|DRUG|Placebo capsules|Placebo capsules
219099027|NCT06341621|DRUG|treatment of physician's choice|treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
219099028|NCT02837354|OTHER|No intervention|
219099029|NCT03857230|DRUG|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
219099030|NCT03857230|DRUG|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
219099031|NCT04366726|COMBINATION_PRODUCT|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
219099032|NCT01654601|DRUG|DWCZP|Multiple dose
219099033|NCT01654601|DRUG|Clozaril|multiple-dose
219099034|NCT04834817|DEVICE|Celluma POD|A blue and near infrared handheld LED device
219099035|NCT04451408|DRUG|LY3372993|Administered IV or SC.
219099036|NCT04451408|DRUG|Placebo|Administered IV or SC.
219099037|NCT04248647|BEHAVIORAL|Multimodal prehabilitation|"This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist."
219099038|NCT06104280|OTHER|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
219099039|NCT06104280|OTHER|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
219099040|NCT06104280|OTHER|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
219099041|NCT06104280|BEHAVIORAL|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
219099042|NCT06104280|DEVICE|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
219223483|NCT05606484|OTHER|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
219223484|NCT05606484|OTHER|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
219683356|NCT01407016|DRUG|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
219683357|NCT03052205|DRUG|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
219683358|NCT06337734|BEHAVIORAL|AI-Driven Lifestyle Coaching Program|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
219683359|NCT03974802|DEVICE|somofilcon A contact lens|Contact Lens
219683360|NCT03974802|DEVICE|fanfilcon A contact lens|Contact Lens
219683361|NCT05707390|DRUG|Mezigdomide|Specified dose on specified days
219683362|NCT00437996|DRUG|Clonidine|
219683363|NCT00437996|DRUG|Levobupivacaine|
219099043|NCT06104280|OTHER|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
219223485|NCT01724996|OTHER|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
219683364|NCT00437996|DRUG|Sufentanil|
219683365|NCT04232020|DIAGNOSTIC_TEST|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
219683366|NCT00378885|BEHAVIORAL|Cognitive-behavioral tailored intervention|
219683367|NCT03515863|GENETIC|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
219683368|NCT03515863|DEVICE|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
219683369|NCT03515863|OTHER|Collection of life style data|Collection of life style data using quality of life questionnaire
219683370|NCT00898430|GENETIC|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
219683371|NCT00898430|GENETIC|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
219683372|NCT00898430|GENETIC|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
219683373|NCT02259205|OTHER|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
219683374|NCT02259205|OTHER|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
219683375|NCT02809924|OTHER|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
219683376|NCT02809924|OTHER|Video training|Video describing endotracheal intubation
219683377|NCT02202798|DEVICE|Syringe device|
219683378|NCT03763201|DIAGNOSTIC_TEST|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
219683379|NCT00535431|DRUG|AER 001|60 mg (in nebuliser), twice daily for 28 days
219683380|NCT00535431|DRUG|placebo|Sterile saline nebulised, twice daily for 28 days
219683381|NCT05556460|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
219683382|NCT05556460|DRUG|Medical therapy|Subjects will continue to be managed on medical therapy, per physician discretion
219683383|NCT00186407|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
219683384|NCT03512353|DRUG|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
219099044|NCT06104280|OTHER|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
219099045|NCT06384339|DIAGNOSTIC_TEST|CSIV, Social motive|The CSIV is a self-report measure and assesses interpersonal values using eight octant scales, which are aggregated into overall communion and agency scores, ranging from -4 to +4 .
219099046|NCT06384339|DIAGNOSTIC_TEST|Interpersonal messages and behavior|"The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report transactional inventory designed to measure a target person's interpersonal behavior on four octant scales dominance, hostility, submissiveness, and friendliness by assessing the covert responses or impact messages of another person. Each subscale consists of 7 items, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very much so). The minimum score per scale is 7 and the maximum score is 28."
219099047|NCT06384339|DIAGNOSTIC_TEST|CCS, Social motive|The CCS is a elf-report inventory, that measures tendencies towards competitiveness versus caring in social interactions. The minimum score for the two subscales competitiveness and caring are 9 and the maximum score is 90.
219099048|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
219099049|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
219099050|NCT01511822|DRUG|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
219099051|NCT01511822|DRUG|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
219683385|NCT03512353|DRUG|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
219099052|NCT01511822|DRUG|placebo|
219683386|NCT00630799|DRUG|leuprolide acetate|17 mg i.m.
219683387|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by children preference
219683388|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to randomization|The parent who will accompany the child during the perioperative period will be determined by randomization.
219683389|NCT03782987|DRUG|BI 730357|0 mg BI 730357 tablet orally on Day 1
219683390|NCT03782987|DRUG|Itraconazole|20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
219683391|NCT01229215|DRUG|FCFD4514S|Repeating intravitreal injection
219683392|NCT01229215|DRUG|sham|Repeating sham injection
219683393|NCT04214496|DEVICE|Sedline|Intraoperative EEG monitorization
219099053|NCT02427711|DEVICE|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
219099054|NCT06614049|BEHAVIORAL|Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications|Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
219099055|NCT05153395|OTHER|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
219099056|NCT05153395|OTHER|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
219683394|NCT01877668|DRUG|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
219683395|NCT01877668|DRUG|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
219683396|NCT01877668|DRUG|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
219683397|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
219683398|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
219099057|NCT05153395|DRUG|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
219099058|NCT04754607|OTHER|Low Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
219099059|NCT04754607|OTHER|Sham|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
219099060|NCT05968976|PROCEDURE|Awake DBS|55 patients receive awake DBS (current standard procedure)
219099061|NCT05968976|PROCEDURE|Asleep DBS|55 patients receive asleep DBS
219099062|NCT06626373|OTHER|Elderberry Juice|Participants will consume elderberry juice 1-week.
219099063|NCT06626373|OTHER|Placebo Beverage|Participants will consume placebo beverage twice/day for 1-week.
219099064|NCT06624774|OTHER|Prehabilitation|The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
219099065|NCT02272725|DRUG|Ibuprofen|Ibuprofen
219099066|NCT02272725|DRUG|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
219099067|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
219099068|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
219099069|NCT01817192|DRUG|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
219223486|NCT01125124|DRUG|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
219223487|NCT01259557|DRUG|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
219223488|NCT06064669|DRUG|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
219683399|NCT03251157|OTHER|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
219683400|NCT01810562|OTHER|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
219683401|NCT03424798|DEVICE|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
219683402|NCT00319709|DRUG|SR58611A|
219683403|NCT03157674|OTHER|Non-Interventional|Non-Interventional
219683404|NCT01808274|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
219683405|NCT03685097|DIAGNOSTIC_TEST|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
219683406|NCT02508376|OTHER|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
219683407|NCT02508376|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
219683408|NCT02508376|BIOLOGICAL|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
219683409|NCT05121610|PROCEDURE|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
219683410|NCT01828970|DRUG|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
219683411|NCT04572776|DRUG|Resiniferatoxin|Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
219099070|NCT01817192|OTHER|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
219099071|NCT01817192|OTHER|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
219099072|NCT06913127|OTHER|High intensity exercise post stroke|The patients are all admitted with an acute/ subacute stroke in an inpatient rehabilitation ward. They are randomized into a high intensity exercise or a low intensity exercise group that will last for 20 consecutive sessions. At the end of the experimental period, outcomes including functional outcomes, questionnaires, physical activity and fNIRS (functional near infrared spectroscopy) measurements will be compared between the two groups.
219099073|NCT06925594|OTHER|Human TH-SC01 cell injection|Human TH-SC01 cell injection is a cell suspension in aseptic buffered solution containing human expanded umbilical cord-derived stem cells of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
219099074|NCT06925594|OTHER|Saline solution|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
219099075|NCT06925035|DEVICE|1927nm fractional thulium fiber laser(TFL)|Prior to each session, Compound Lidocaine Cream (Beijing Ziguang Medication Manufacture Corporation Ltd.) was administered topically to the participants' faces for a duration of 30-40 minutes. Following sterilization with alcohol, the entire facial area was treated with a 1927 nm fractional thulium fiber laser (TFL) (WONTECH, Lavieen, South Korea). TFL parameters included a pulse energy of 8-10 mJ, an output power of 10 W, and a pulse spacing of 0.8 mm, ensuring comprehensive coverage of photodamaged regions.
219099076|NCT06925035|DRUG|supramolecular salicylic acid(SSA)|30% SSA (SSA and placebo are provided by Broda ,Shanghai Rui Zhi Medicine Technology, Shanghai, China.) or placebo(the base material of 30% SSA) were randomly assigned to be applied on one side of the face immediately after completion of the 1927nm TFL treatment. The 30% SSA was maintained on facial skin until reaching the clinical endpoint, manifested as mild erythema and/or a characteristic frost-like epidermal whitening. Additionally, the combination therapy side of the subjects was treated with one session of 30% SSA biweekly and 2% SSA daily over a period of 16 weeks.
219099077|NCT06925971|DEVICE|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
219099078|NCT06925971|DEVICE|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
219223489|NCT06064669|DRUG|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
219223490|NCT06064669|DRUG|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
219683412|NCT04572776|OTHER|Standard of Care|Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
219683413|NCT04708158|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
219683414|NCT04708158|BIOLOGICAL|Placebo|Saline
219683415|NCT04113291|OTHER|DASH Diet|12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
219683416|NCT04113291|OTHER|Usual diet|12 weeks usual diet \<2300 mg Na/day
219683417|NCT04179877|BEHAVIORAL|IPS|Occupational rehabilitation and support Integrated with clinical treatment
219683418|NCT01507116|OTHER|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
219683419|NCT01914237|DEVICE|Castor Stent Graft|Endovascular Repair of Aortic Dissection
219683420|NCT03319433|DEVICE|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
219683421|NCT03045653|DRUG|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
219683422|NCT04487808|DRUG|Pecan|Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
219683423|NCT04487808|OTHER|Average American Diet devoid of nuts|Diet mimicking usual American intake
219683424|NCT04147247|DRUG|BI 905681|Infusion
219683425|NCT00388648|DRUG|mixture of amino and keto acids|
219683426|NCT03788161|OTHER|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
219683427|NCT03788161|OTHER|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
219683428|NCT01255072|PROCEDURE|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
219683429|NCT01255072|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
219683430|NCT06234540|PROCEDURE|PRP|a-PRP intrauterine instillation before frozen-thawed embryo transfer cycle
219683431|NCT06234540|OTHER|Standard treatment|Standard treatment
219683432|NCT01328639|OTHER|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
219683433|NCT01328639|OTHER|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
219683434|NCT04954521|DRUG|Anlotinib|This is an observational study
219683435|NCT03239678|DRUG|100% Oxygen|Conventional preoxygenation with 100% oxygen
219683436|NCT03239678|DRUG|30% Oxygen|preoxygenation with 30% oxygen
219683437|NCT03239678|DRUG|21% Oxygen|preoxygenation with 21% oxygen
219683438|NCT03239678|DRUG|40% Oxygen|preoxygenation with 40% oxygen
219683439|NCT03239678|DRUG|60% Oxygen|preoxygenation with 60% oxygen
219683440|NCT03239678|DRUG|80% Oxygen|preoxygenation with 80% oxygen
219683441|NCT00994110|DRUG|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
219683442|NCT00994110|OTHER|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
219683443|NCT03457389|DRUG|Cabergoline|Cabergoline tablet
219683444|NCT04363060|COMBINATION_PRODUCT|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
219683445|NCT04363060|DRUG|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
219683446|NCT03983538|OTHER|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
219683447|NCT06100796|COMBINATION_PRODUCT|Pembrolizumab|Immune check inhibitor with OHA
219683448|NCT01193946|DIETARY_SUPPLEMENT|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
219099079|NCT06925971|DEVICE|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China)
219099080|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
219099081|NCT06351111|DEVICE|Active VNS|Subjects will receive active VNS paired with either of the three rehabilitation trainings
219099082|NCT02136433|DEVICE|Tablet - self exercise|
219099083|NCT02136433|OTHER|GRASP self exercise|
219099084|NCT00095914|DRUG|paclitaxel|
219099085|NCT00095914|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219683449|NCT03049423|DEVICE|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
219099086|NCT00764374|DRUG|YM443|oral
219099087|NCT05398380|OTHER|Liver transplantation|Liver transplantation
219099088|NCT00823420|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
219099089|NCT00128011|BIOLOGICAL|killed oral cholera vaccine|
219099090|NCT00369681|DRUG|Bleomycin|
219099091|NCT00369681|BIOLOGICAL|Rituximab|
219099092|NCT00369681|DRUG|Dacarbazine|
219099093|NCT00369681|DRUG|Doxorubicin|
219683450|NCT03049423|DIAGNOSTIC_TEST|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
219683451|NCT01111565|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
219683452|NCT01111565|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
219099094|NCT00369681|DRUG|Vinblastine|
219099095|NCT04717973|DIAGNOSTIC_TEST|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
219099096|NCT01022086|PROCEDURE|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
219099097|NCT01022086|BIOLOGICAL|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
219099098|NCT03436134|OTHER|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
219223491|NCT06064669|DRUG|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
219223492|NCT05048758|OTHER|No intervention|No intervention
219223493|NCT00160498|DRUG|Lercanidipine|
219223494|NCT00167921|DRUG|Premarin® Vaginal Cream|
219683453|NCT05026944|OTHER|Percussive massage and static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
219683454|NCT05026944|OTHER|static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
219683455|NCT02581683|DRUG|Magnesium Sulfate|Given via adductor canal block
219683456|NCT02581683|DRUG|Ropivacaine|Given via adductor canal block
219683457|NCT02581683|OTHER|Sham|Sham adductor canal block
219099099|NCT03436134|OTHER|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
219099100|NCT05772234|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
219099101|NCT05772234|DRUG|normal saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
219099102|NCT00694382|DRUG|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219099103|NCT00694382|DRUG|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
219683458|NCT06959316|DEVICE|Hybrid closed loop insulin delivery system|Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.
219683459|NCT00368108|DRUG|2 mg perampanel|2 mg perampanel
219683460|NCT00368108|DRUG|4 mg perampanel|4 mg perampanel
219683461|NCT00368108|DRUG|placebo comparator|placebo comparator
219683462|NCT00635921|DRUG|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
219683463|NCT00635921|DRUG|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
219683464|NCT06958952|DIETARY_SUPPLEMENT|Digestive Aid|one tablet daily for one month
219683465|NCT06958952|DIETARY_SUPPLEMENT|Placebo|Placebo
219683466|NCT04131712|OTHER|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
219683467|NCT02858635|OTHER|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
219683468|NCT00809536|DRUG|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
219683469|NCT00809536|DRUG|Metformin|Single, oral, 500 mg of metformin immediate release
219683470|NCT00809536|DRUG|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
219683471|NCT00809536|DRUG|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
219683472|NCT00534027|DRUG|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
219683473|NCT00534027|OTHER|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
219683474|NCT05208333|DRUG|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
219223495|NCT00167921|DRUG|Premarin® oral tablets|
219683475|NCT03679559|OTHER|Best Practice|Continue usual physical activity
219683476|NCT03679559|BEHAVIORAL|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
219683477|NCT03679559|BEHAVIORAL|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
219683478|NCT03679559|BEHAVIORAL|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
219683479|NCT03679559|OTHER|Informational Intervention|Watch video
219683480|NCT03679559|OTHER|Laboratory Biomarker Analysis|Correlative studies
219683481|NCT03679559|DEVICE|Monitoring Device|Wear Fitbit
219683482|NCT03679559|OTHER|Quality-of-Life Assessment|Ancillary studies
219683483|NCT03679559|OTHER|Questionnaire Administration|Ancillary studies
219683484|NCT03221998|DRUG|IV paracetamol|100 gram paracetamol infusion for moderate pain management
219683485|NCT03221998|DRUG|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
219683486|NCT03131115|PROCEDURE|Lateral Crural Strut Graft|surgical technique as described
219683487|NCT03131115|PROCEDURE|Bone Anchored Suspension|Surgical technique as described
219683488|NCT05662748|DEVICE|Transfemoral aortic valve replacement|aortic valve replacement
219683489|NCT04591756|OTHER|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
219683490|NCT04533113|PROCEDURE|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
219099104|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
219099105|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
219099106|NCT01921881|OTHER|St John's wort|
219683491|NCT01901042|DIETARY_SUPPLEMENT|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
219099107|NCT01396577|DRUG|perampanel|3 x 2 mg perampanel once per day
219683492|NCT01901042|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will receive sachets containing maltodextrin
219099108|NCT01396577|DRUG|perampanel|6 mg perampanel once per day
219099109|NCT03134014|DIETARY_SUPPLEMENT|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
219099110|NCT00276107|BIOLOGICAL|Prevenar|
219099111|NCT01619332|DRUG|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
219099112|NCT01619332|DRUG|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
219099113|NCT01619332|DRUG|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
219099114|NCT03083535|PROCEDURE|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
219099115|NCT03083535|PROCEDURE|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
219099116|NCT03083535|PROCEDURE|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
219223496|NCT03853538|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
219099117|NCT00409695|DRUG|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
219099118|NCT00409695|DRUG|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
219099119|NCT02596763|DRUG|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
219099120|NCT02710786|PROCEDURE|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
219099121|NCT00998907|DEVICE|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
219099122|NCT00998907|DEVICE|PDS II|polyglactin 910 suture material for abdominal wall closure
219099123|NCT00084214|DRUG|STA-4783|
219099124|NCT00084214|DRUG|Paclitaxel|
219099125|NCT02183935|DEVICE|Duodena-jejunal liner|
219099126|NCT02347514|BEHAVIORAL|Diabetes group visit|
219223497|NCT03853538|OTHER|Semisolid vaseline|Product is applied to one hemiface.
219223498|NCT03132298|OTHER|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
219683493|NCT00130689|DRUG|Cetuximab|
219099127|NCT05867641|BEHAVIORAL|Immersive VR Therapy in Head-Mounted Display (HMD) (Solo)|"Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for two weeks. The caregiver will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
219099128|NCT05867641|BEHAVIORAL|Immersive VR Therapy in a Head-Mounted Display (HMD) (Social)|"Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, 2 to 3 times per week, for 2 weeks. A research assistant who is trained in dementia care will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
219099129|NCT06000319|BIOLOGICAL|Natural Matrix Protein (NMP) Fibers|human bone allograft
219099130|NCT06000319|PROCEDURE|Lumbar interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
219099131|NCT06000319|PROCEDURE|Cervical interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
219099132|NCT01802684|BIOLOGICAL|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
219099133|NCT02710305|DRUG|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
219099134|NCT02710305|DRUG|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
219683494|NCT03602716|DEVICE|HD-tDCS|HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
219683495|NCT03602716|DEVICE|Sham HD-tDCS|HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
219683496|NCT04574453|DEVICE|Iracross|Administration of max 2ml of Iracross at first visit
219683497|NCT04574453|DEVICE|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
219683498|NCT05765357|DRUG|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
219683499|NCT05765357|DRUG|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
219683500|NCT06418113|RADIATION|hypofractionated stereotactic radiotherapy|conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
219683501|NCT06418113|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy
219683502|NCT06418113|PROCEDURE|resection|supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
219683503|NCT06418113|DRUG|Chemotherapy|4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
219683504|NCT06418113|RADIATION|radiotherapy Stupp protocol|radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
219683505|NCT06418113|DRUG|Chemotherapy Stupp Protocol|temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
219683506|NCT01659840|RADIATION|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
219683507|NCT01659840|RADIATION|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
219683508|NCT03158961|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
219683509|NCT04279080|OTHER|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
219683510|NCT00973583|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 400 IU daily
219683511|NCT00973583|DIETARY_SUPPLEMENT|placebo|placebo
219683512|NCT06169306|PROCEDURE|throat pack|Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
219099135|NCT02692690|DEVICE|Stimulette r4x|
219099136|NCT00327184|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
219099137|NCT00327184|BIOLOGICAL|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
219099138|NCT00327184|BIOLOGICAL|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
219683513|NCT04328025|OTHER|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
219099139|NCT00327184|BIOLOGICAL|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
219223499|NCT03132298|OTHER|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
219683514|NCT02258217|DRUG|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
219683515|NCT01252771|OTHER|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
219683516|NCT02770638|DEVICE|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
219683517|NCT02770638|DEVICE|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
219683518|NCT01142934|DEVICE|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
219683519|NCT02415153|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219683520|NCT02415153|OTHER|Pharmacological Study|Correlative studies
219683521|NCT02415153|DRUG|Pomalidomide|Given PO
219683522|NCT03561896|RADIATION|IGRT|Image-Guided Radiation Therapy
219683523|NCT03561896|RADIATION|SRS|stereotactic radiation therapy
219683524|NCT04102293|PROCEDURE|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
219099140|NCT00401635|DRUG|liposomal doxorubicin|
219099141|NCT00401635|DRUG|carboplatin|
219099142|NCT03396484|DRUG|Methyldopa|Tablet for oral dosing
219683525|NCT04102293|PROCEDURE|manual K-files|manual instrumentation used in pulp therapy
219683526|NCT01726075|DRUG|COLIRIOBCN070660|One drop per eye twice a day during 24 months
219683527|NCT01726075|DRUG|Placebo|One drop per eye twice a day during 24 months
219683528|NCT01726075|DRUG|Brimonidine|One drop per eye twice a day during 24 months
219683529|NCT04007965|PROCEDURE|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
219099143|NCT03396484|DRUG|Placebo|Tablet for oral dosing
219099144|NCT00532324|OTHER|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
219099145|NCT04121481|DIETARY_SUPPLEMENT|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
219099146|NCT04121481|DIETARY_SUPPLEMENT|Broad Spectrum Safety|Benefits in Sports Nutrition
219099147|NCT02560935|DRUG|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
219099148|NCT02560935|DRUG|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
219099149|NCT00328640|DRUG|Optimal treatment|
219099150|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
219099151|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
219099152|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
219099153|NCT01427192|DRUG|acetazolamide|250 mg bid
219099154|NCT01427192|OTHER|Supplemental oxygen|Oxygen deliverded by nasal cannula
219099155|NCT01427192|PROCEDURE|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
219099156|NCT01427192|OTHER|Room air|Room air applied via sham oxygen concentrator
219099157|NCT01427192|DRUG|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
219099158|NCT01295567|DRUG|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
219099159|NCT01295567|DRUG|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
219099160|NCT03533634|PROCEDURE|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
219099161|NCT03533634|PROCEDURE|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
219099162|NCT05019274|OTHER|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
219099163|NCT05019274|OTHER|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
219099164|NCT03075904|DRUG|ALXN1830|Administered via IV infusion.
219099165|NCT00099593|BIOLOGICAL|Autologous Dendritic Cell Vaccine|
219099166|NCT03155230|OTHER|no intervention|no intervention
219099167|NCT05107479|BEHAVIORAL|COVID-19 Vaccine IVR Training|The intervention consists of 5 interactive voice response (IVR) modules conveying information about COVID-19 vaccines and vaccine administration best practices. Module topics include the following: 1) the importance of COVID-19 vaccines and recipient eligibility, 2) overview of and differences between approved COVID-19 vaccines , 3) surveillance of adverse vaccine events, 4) organizing a vaccination site, and safe storage and handling COVID-19 vaccines, and 5) micro planning and communication strategies for COVID-19 vaccination efforts. The training will be offered in five local languages: French, Lingala, Swahili, Kikongo, and Tshiluba.
219683530|NCT04870021|BIOLOGICAL|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
219683531|NCT04870021|BEHAVIORAL|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
219683532|NCT04043429|BEHAVIORAL|Vision Restoration Training (VRT)|
219683533|NCT04043429|BEHAVIORAL|Vision Exploration Training (VET)|
219683534|NCT02254772|BIOLOGICAL|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
219683535|NCT02254772|DRUG|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
219683536|NCT02254772|RADIATION|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
219683537|NCT04288947|OTHER|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
219683538|NCT00584584|DRUG|QAX576|
219683539|NCT00584584|DRUG|Placebo|
219683540|NCT03904420|OTHER|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
219683541|NCT03904420|OTHER|Traditional Model|Standard clinical practice and education
219683542|NCT01001910|DRUG|Carboplatin|Given IV
219683543|NCT01001910|OTHER|Laboratory Biomarker Analysis|Correlative studies
219683544|NCT01001910|DRUG|Pemetrexed Disodium|Given IV
219099168|NCT05107479|BEHAVIORAL|Control Condition|The control arm will receive the COVID-19 Vaccine IVR Training after an estimated month-long delay. The control arm will be told upon completion of the baseline survey that the training will commence at a later estimated date and will not receive any additional information until the treatment group completes training.
219099169|NCT00175968|PROCEDURE|bed rest, hypocaloric nutrition|
219223500|NCT03298789|OTHER|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
219223501|NCT03298789|OTHER|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
219223502|NCT05508607|OTHER|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
219683545|NCT00078013|DRUG|MCC-135|
219683546|NCT03583658|DRUG|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
219683547|NCT03583658|DRUG|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
219683548|NCT01089127|DRUG|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219683549|NCT01089127|DRUG|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
219683550|NCT01089127|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219683551|NCT01089127|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
219099170|NCT03837392|DIAGNOSTIC_TEST|Baseline Assessment (18-26 weeks pregnant)|At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
219683552|NCT01042834|OTHER|Air pollution study on healthy volunteers.|"The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air."
219099171|NCT03837392|BEHAVIORAL|Online Intervention and Phone Coaching Interventions|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
219099172|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
219099173|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 8 weeks postpartum|The follow-up assessment at 8-weeks postpartum will be completed via phone.
219099174|NCT00625235|DIETARY_SUPPLEMENT|VLED followed by a high protein or high carbohydrate diet|
219099175|NCT04215185|DEVICE|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
219099176|NCT03427554|DRUG|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
219099177|NCT03427554|DRUG|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
219099178|NCT03427554|DRUG|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
219099179|NCT00539643|DEVICE|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
219099180|NCT00539643|OTHER|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
219099181|NCT03697525|DEVICE|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
219099182|NCT06510530|DIETARY_SUPPLEMENT|Astragalus|Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
219099183|NCT06510530|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
219099184|NCT02648971|PROCEDURE|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
219099185|NCT02648971|PROCEDURE|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
219099186|NCT03620838|DRUG|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
219099187|NCT04935814|DRUG|Vasopressin, Arginine|Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
219099188|NCT02530814|OTHER|Blood Collection|Onetime blood collection.
219099189|NCT02220296|DRUG|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
219099190|NCT02220296|DRUG|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
219683553|NCT02025192|DRUG|Tucatinib|Administered twice per day, orally.
219683554|NCT02025192|DRUG|Capecitabine|1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
219683555|NCT02025192|DRUG|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
219683556|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
219099191|NCT02220296|DRUG|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
219099192|NCT02220296|DRUG|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
219099193|NCT04725656|PROCEDURE|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
219099194|NCT04725656|OTHER|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
219099195|NCT05072925|OTHER|Tobacco products|Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
219099196|NCT05639790|COMBINATION_PRODUCT|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
219099197|NCT05639790|OTHER|Health Counselling|Health Counselling from a licensed mental health counselor
219099198|NCT01759069|PROCEDURE|Surgical treatment with microscope|
219683557|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
219099199|NCT01933451|OTHER|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
219099200|NCT02675790|DRUG|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
219099201|NCT02675790|DRUG|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
219099202|NCT01664520|DRUG|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
219099203|NCT02452086|DEVICE|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
219099204|NCT02452086|PROCEDURE|Placebo|LLLT with zero intensity
219099205|NCT00174603|DRUG|quetiapine|
219099206|NCT05716620|DIAGNOSTIC_TEST|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
219099207|NCT06120673|DRUG|Obinutuzumab|"Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion."
219099208|NCT06120673|DRUG|Oral prednisolone and cyclophosphamide|"Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight"
219099209|NCT05747339|BIOLOGICAL|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
219099210|NCT01167283|DEVICE|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
219099211|NCT01167283|DEVICE|Sham stimulation|Sham stimulation: 1 h; 5 times/week
219099212|NCT05389111|OTHER|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
219099213|NCT05389111|OTHER|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
219099214|NCT03733561|DRUG|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
219099215|NCT03733561|DRUG|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
219099216|NCT03921190|PROCEDURE|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
219099217|NCT00825097|PROCEDURE|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
219683558|NCT01734447|DRUG|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
219683559|NCT03576339|PROCEDURE|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
219683560|NCT03576339|DEVICE|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
219683561|NCT03576339|DEVICE|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
219683562|NCT03280485|OTHER|no intervention|no intervention validation of guidelines via database
219683563|NCT02622152|PROCEDURE|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
219683564|NCT02622152|PROCEDURE|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
219683565|NCT02622152|PROCEDURE|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
219683566|NCT02622152|PROCEDURE|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
219683567|NCT02622152|PROCEDURE|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
219683568|NCT04110431|PROCEDURE|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
219683569|NCT04110431|PROCEDURE|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
219683570|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
219683571|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
219683572|NCT00958854|DRUG|cyclophosphamide|
219683573|NCT00958854|DRUG|fludarabine phosphate|
219683574|NCT00958854|DRUG|thalidomide|
219683575|NCT00958854|OTHER|laboratory biomarker analysis|
219683576|NCT06238024|DRUG|Tocilizumab|Single dose intravenous application
219099218|NCT00825097|DRUG|Botulinum toxin injection|Botulinum toxin type A
219099219|NCT01480596|BIOLOGICAL|Belimumab|10mg/kg IV infusion
219099220|NCT01480596|OTHER|Placebo|placebo IV infusion
219099221|NCT04503096|DEVICE|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
219099222|NCT00058201|DRUG|fluorouracil|Given IV
219099223|NCT00058201|DRUG|gemcitabine hydrochloride|Given IV
219099224|NCT00058201|DRUG|leucovorin calcium|Given IV
219099225|NCT00058201|OTHER|clinical observation|No intervention
219099226|NCT02343003|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
219683577|NCT06238024|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
219683578|NCT03200548|BEHAVIORAL|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
219683579|NCT03200548|BEHAVIORAL|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
219683580|NCT03200548|BEHAVIORAL|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
219683581|NCT03200548|BEHAVIORAL|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
219683582|NCT03035565|BEHAVIORAL|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
219683583|NCT03035565|BEHAVIORAL|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
219683584|NCT05704868|BEHAVIORAL|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
219099227|NCT02343003|DRUG|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
219099228|NCT03072225|DRUG|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
219099229|NCT03072225|DRUG|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
219099230|NCT05797064|PROCEDURE|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
219099231|NCT01299090|DEVICE|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
219099232|NCT02281760|DRUG|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
219683585|NCT03555487|DRUG|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
219683586|NCT00447772|BIOLOGICAL|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
219683587|NCT02177929|OTHER|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
219683588|NCT03098680|DRUG|Albuterol Sulfate|see arm/group descriptions
219683589|NCT03098680|DRUG|Nicardipine Hydrochloride|see arm/group descriptions
219099233|NCT02281760|DRUG|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
219099234|NCT02544828|DRUG|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
219099235|NCT02544828|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
219683590|NCT03098680|DRUG|Dobutamine Hydrochloride|see arm/group descriptions
219683591|NCT03098680|DRUG|Phenylephrine Hydrochloride|see arm/group descriptions
219683592|NCT03098680|DRUG|Verapamil Hydrochloride|see arm/group descriptions
219683593|NCT03098680|DRUG|Phentolamine Mesylate|see arm/group descriptions
219683594|NCT03098680|DRUG|Placebo|see arm/group descriptions
219683595|NCT04577989|OTHER|data collection|data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.
219683596|NCT00716456|DRUG|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
219683597|NCT04651998|DIAGNOSTIC_TEST|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
219683598|NCT04046068|PROCEDURE|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
219683599|NCT04010409|OTHER|no intervention|no intervention
219683600|NCT02862080|DEVICE|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
219099236|NCT03183583|PROCEDURE|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
219683601|NCT02862080|DEVICE|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
219683602|NCT02862080|DEVICE|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
219683603|NCT00875563|DEVICE|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
219683604|NCT03404986|PROCEDURE|ureteroscopy|The patients will be subjected to rigid ureteroscopy
219683605|NCT03404986|RADIATION|Ultrasonography|The patients will be subjected to Ultrasonography
219683606|NCT00920153|BIOLOGICAL|bleomycin sulfate|Given IV
219683607|NCT00920153|DRUG|ABVD regimen|Given IV
219683608|NCT00920153|DRUG|carmustine|Given IV
219683609|NCT00920153|DRUG|cisplatin|Given IV
219683610|NCT00920153|DRUG|cytarabine|Given IV
219683611|NCT00920153|DRUG|dacarbazine|Given IV
219683612|NCT00920153|DRUG|dexamethasone|Given orally
219683613|NCT00920153|DRUG|doxorubicin hydrochloride|Given IV
219683614|NCT00920153|DRUG|etoposide|Given IV
219683615|NCT00920153|DRUG|gemcitabine hydrochloride|Given IV
219683616|NCT00920153|DRUG|ifosfamide|Given IV
219683617|NCT00920153|DRUG|melphalan|Given IV
218984701|NCT06004362|BEHAVIORAL|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~* Basic principles of a plant-based whole-food nutrition~* Procedures of hydrotherapy according to Kneipp~* Self-help strategies (e.g. teas, wraps, compresses etc.)~* Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~* Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
219099237|NCT04334421|DEVICE|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
219099238|NCT04048863|DEVICE|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
219683618|NCT00920153|DRUG|methylprednisolone|Given IV
219683619|NCT00920153|DRUG|mitoguazone|Given IV
219683620|NCT00920153|DRUG|vincristine sulfate|Given IV
219683621|NCT00920153|DRUG|vindesine|Given IV
219683622|NCT00920153|DRUG|vinorelbine tartrate|Given IV
219683623|NCT00920153|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
219683624|NCT00920153|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
219683625|NCT06405178|DRUG|Metformin|Insulin Sensitizer
219099239|NCT04048863|DEVICE|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
219683626|NCT06405178|DRUG|Dapagliflozin|Sodium-Glucose Co-transporter-2
219683627|NCT06405178|DRUG|Dapagliflozin/Metformin|Anti diabetic drug
219683628|NCT06405178|DRUG|Letrozole|Aromataze inhibitor
219683629|NCT00059228|DRUG|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
219683630|NCT00059228|DRUG|Placebos|Placebo skin patch for 6 weeks
219683631|NCT00060970|PROCEDURE|Physical Therapy|
219683632|NCT01730807|DEVICE|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
219683633|NCT03151382|DRUG|Tandospirone Citrate|Tandospirone, 30-60 mg/d
219683634|NCT03151382|DRUG|Donepezil Hydrochloride|Donepezil, 10 mg/d
219683635|NCT02896569|OTHER|Topical combination therapy|
219683636|NCT06273761|BEHAVIORAL|Medication Management Service (MMS)|Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
219683637|NCT02938364|OTHER|Earplugs|Plastic earplugs on both ears
219683638|NCT02938364|OTHER|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
219683639|NCT02938364|OTHER|Placebo|Non pressure bands put on the wrists of the participant
219683640|NCT01033500|DRUG|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
219683641|NCT05554029|DIAGNOSTIC_TEST|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
219683642|NCT06363643|DEVICE|ELECTROSTIMULATION (ES)|ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.
219683643|NCT06363643|OTHER|EXERCISE (C)|C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
219683644|NCT00130507|DRUG|Vinorelbine|
219683645|NCT00130507|DRUG|Capecitabine|
219683646|NCT00130507|DRUG|Trastuzumab|
219683647|NCT03745053|DEVICE|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
219683648|NCT03745053|DEVICE|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
219683649|NCT01464190|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
219683650|NCT01464190|DRUG|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
219683651|NCT03787823|PROCEDURE|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
219683652|NCT04985045|OTHER|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
219683653|NCT00970489|DRUG|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
219099240|NCT05733962|DEVICE|Use of the device DBL-4pen|"During the treatment period, the patient will use~* the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~* the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~* the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
219099241|NCT02378532|DRUG|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
219099242|NCT02378532|RADIATION|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
219099243|NCT02378532|DRUG|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
219099244|NCT03582605|DRUG|Amoxicillin|see previous descriptions
219099245|NCT03582605|DRUG|Placebo oral capsule|see previous descriptions
219099246|NCT04785664|OTHER|Community-based pro-Active Monitoring Program|The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
219099247|NCT01576367|BIOLOGICAL|ACZ885|
219099248|NCT04944355|OTHER|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
219099249|NCT04146246|DIAGNOSTIC_TEST|G6PD assay|A test for G6PD deficiency.
219099250|NCT03059875|BEHAVIORAL|Medical consultation for a Standardized Geriatric Evaluation|
219099251|NCT02948881|DRUG|ibandronate|
219099252|NCT01453348|BIOLOGICAL|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
219099253|NCT01453348|BIOLOGICAL|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
219099254|NCT01453348|BIOLOGICAL|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
219099255|NCT01453348|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
219099256|NCT02085681|OTHER|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
219099257|NCT02085681|OTHER|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
219099258|NCT06163352|DRUG|Norepinephrine|The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
219099259|NCT00595270|BIOLOGICAL|IC51|
219099260|NCT00602914|DEVICE|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
219099261|NCT00602914|DEVICE|MicronJet|MicronJet, Intradermal Injection
219099262|NCT01673893|DEVICE|ClearWay™ Rx catheter|
219223503|NCT05162716|DEVICE|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
219223504|NCT03711084|DIETARY_SUPPLEMENT|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
219099263|NCT04919902|PROCEDURE|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
219099264|NCT02999425|OTHER|Education|Educational intervention
219099265|NCT04821128|OTHER|Radiologic and pathological review.|"We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis."
219099266|NCT03432884|DRUG|BGB-3111|Subjects will receive BGB-3111
219099267|NCT03432884|DRUG|Placebo|Subjects will receive Placebo
219223505|NCT03711084|DIETARY_SUPPLEMENT|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
219550377|NCT02599662|RADIATION|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
219099268|NCT03432884|DRUG|Moxifloxacin|Subjects will receive Moxifloxicin
219683654|NCT00970489|DRUG|Placebo|Olive Oil capsules
219683655|NCT01268852|DEVICE|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
219683656|NCT01268852|DEVICE|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
219683657|NCT00394186|DRUG|GW427353|
219683658|NCT00394186|DRUG|Placebo|
219683659|NCT02277327|BEHAVIORAL|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
219683660|NCT02277327|BEHAVIORAL|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
219683661|NCT00002610|BIOLOGICAL|dactinomycin|
219683662|NCT00002610|BIOLOGICAL|filgrastim|
219683663|NCT00002610|DRUG|carboplatin|
219683664|NCT00002610|DRUG|cyclophosphamide|
219683665|NCT00002610|DRUG|doxorubicin hydrochloride|
219683666|NCT00002610|DRUG|etoposide|
219683667|NCT00002610|DRUG|vincristine sulfate|IV
219683668|NCT00002610|PROCEDURE|conventional surgery|
219099269|NCT03763916|PROCEDURE|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
219099270|NCT03763916|PROCEDURE|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter
219099271|NCT03763916|PROCEDURE|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
219099272|NCT01059032|OTHER|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
219099273|NCT00003137|DRUG|irinotecan hydrochloride|
219099274|NCT01412190|DEVICE|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
219099275|NCT01412190|OTHER|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
219099276|NCT04359771|DEVICE|Yellow micro-pulse laser|applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
219099277|NCT04359771|DEVICE|Diode micro-pulse laser|applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
219099278|NCT00002763|BIOLOGICAL|recombinant interferon alfa|
219099279|NCT05680961|DEVICE|Monitoring Device|Monitoring Device
219099280|NCT04122391|OTHER|sound level volume|Noise level during cardiac arrest
219099281|NCT00257959|DRUG|amiodarone beta blocker sotalol|
219099282|NCT05330416|DEVICE|Group Reference Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.
219099283|NCT05330416|OTHER|Group Test Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
219550378|NCT02599662|RADIATION|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
219099284|NCT05296291|DEVICE|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
219099285|NCT05296291|DEVICE|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
219550379|NCT02599662|RADIATION|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
219099286|NCT05296291|DEVICE|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
219099287|NCT01398423|DRUG|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
219099288|NCT01398423|DRUG|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
219099289|NCT03427190|OTHER|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
219099290|NCT00390195|DRUG|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
219099291|NCT00390195|DRUG|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
219099292|NCT01445223|DRUG|Lopinavir ritonavir|400mg BD 100mg BD
219099293|NCT01445223|DRUG|Atazanavir ritonavir|300mg QD 100mg QD
219099294|NCT01445223|DRUG|Efavirenz|600mg QD
219099295|NCT00480896|DRUG|tacrolimus ointment|Topical application
219099296|NCT00480896|DRUG|Placebo ointment|Topical application
219099297|NCT00326638|RADIATION|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16"
219099298|NCT00326638|OTHER|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
219099299|NCT05172895|OTHER|Presence, prevalence, severity, and morphological characteristics of anemia|Evaluation of the presence, prevalence, severity, and morphological characteristics of anemia, trying to define, when possible, the underlying pathogenetic mechanisms, paying particular attention to the characteristics of menstrual cycles, the iron, folate and vitamin B12 metabolism, any chronic inflammatory state, and thyroid hormones.
219550380|NCT01581892|PROCEDURE|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
219683669|NCT00002610|RADIATION|radiation therapy|
219683670|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
219683671|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
219683672|NCT06304571|DRUG|HC006|Specified dose on specified days
219683673|NCT05417412|BEHAVIORAL|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
219683674|NCT02704312|RADIATION|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
219683675|NCT02227277|DRUG|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
219683676|NCT03415516|DEVICE|Gluma Universal|Adhesive systems
219099300|NCT05172895|OTHER|Effect of gluten-free diet on anemia|Evaluation of the therapeutic responses (i.e., improvement/regression) of anemia after at least one year of GFD.
219099301|NCT00363610|DRUG|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
219099302|NCT00890175|DRUG|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
219683677|NCT03415516|DEVICE|All Bond Universal|Adhesive systems
219683678|NCT03415516|DRUG|Single Bond2|Adhesive systems
219683679|NCT01305811|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
219683680|NCT06376487|DEVICE|Flow rate evaluation|Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
219683681|NCT02339103|OTHER|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
219683682|NCT02339103|OTHER|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
219683683|NCT03107910|BEHAVIORAL|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
219099303|NCT00890175|DRUG|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
219099304|NCT00954733|OTHER|Arterial blood draw|One arterial blood draw
219099305|NCT03592277|DRUG|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
219099306|NCT03592277|DRUG|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
219099307|NCT04996290|PROCEDURE|PENG + LFCN block|Regional anesthesia technique
219099308|NCT04996290|DRUG|Ropivacaine injection|Local anesthetic used for peripheral nerve block.
219099309|NCT01852331|DRUG|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
219099310|NCT01852331|DRUG|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
219099311|NCT04325087|DEVICE|iTBS|Administration of an iTBS protocol over the dlPFC
219683684|NCT03107910|BEHAVIORAL|Health Information Seeking|Seeking and evaluating online health information will be assessed.
219683685|NCT03301662|DIAGNOSTIC_TEST|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
219683686|NCT03478371|DEVICE|tampon D|regular absorbency tampon
219683687|NCT03478371|DEVICE|tampon M|regular absorbency tampon
219099312|NCT04325087|DEVICE|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
219099313|NCT00622713|DRUG|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm\^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\^2.
219099314|NCT02112760|OTHER|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
219099315|NCT01108757|DRUG|Bactrim|Bactrim DS BID for 3 days
219099316|NCT01108757|OTHER|Placebo|Corn starch capsules
219099317|NCT02918500|DRUG|Nicoderm Patch|Nicotine replacement therapy patch
219099318|NCT04866121|PROCEDURE|Acupuncture|A standardized acupuncture protocol will be administered
219099319|NCT03051022|DRUG|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
219099320|NCT03051022|DRUG|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
219099321|NCT01373996|DEVICE|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
219099322|NCT01462162|DRUG|Tocilizumab|
219099323|NCT01503840|DRUG|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
219099324|NCT01503840|DRUG|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
219099325|NCT03853460|PROCEDURE|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
219099326|NCT03853460|PROCEDURE|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
219099327|NCT01255943|BEHAVIORAL|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
219099328|NCT03485911|DRUG|BCX7353 capsules|BCX7353 oral capsules administered once daily
219099329|NCT03485911|DRUG|Placebo oral capsule|Matching oral capsules administered once daily
219099330|NCT04175353|DIETARY_SUPPLEMENT|Dairy snack|The effects of dairy snack are compared with orange juice.
219099331|NCT04175353|DIETARY_SUPPLEMENT|Berry snack|The effects of two berry snacks are compared with berry soup.
219099332|NCT00002757|BIOLOGICAL|filgrastim|
219099333|NCT00002757|DRUG|cyclophosphamide|
219099334|NCT00002757|DRUG|cytarabine|
219099335|NCT00002757|DRUG|doxorubicin hydrochloride|
219099336|NCT00002757|DRUG|etoposide|
219099337|NCT00002757|DRUG|methotrexate|
219099338|NCT00002757|DRUG|prednisolone|
219099339|NCT00002757|DRUG|prednisone|
219099340|NCT00002757|DRUG|therapeutic hydrocortisone|
219099341|NCT00002757|DRUG|vincristine sulfate|
219099342|NCT02394041|DEVICE|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
219099343|NCT02394041|DEVICE|Sham acupuncture|Sham acupuncture with sham needles
219099344|NCT04757818|OTHER|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
219099345|NCT04757818|OTHER|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
219099346|NCT00282724|DRUG|Liarozole|
219099347|NCT04912674|DEVICE|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
219550381|NCT00757705|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
219550382|NCT02336633|DIETARY_SUPPLEMENT|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
219550383|NCT02336633|OTHER|Placebo|
219550384|NCT04483349|OTHER|Survey Administration|Complete survey
219550385|NCT04346680|PROCEDURE|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
219550386|NCT03242980|BEHAVIORAL|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
219550387|NCT04537520|DEVICE|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
219550388|NCT03400774|OTHER|Stair-climbing|Short bouts of moderate intensity stair-climbing
219099348|NCT05383664|OTHER|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
219099349|NCT03775226|DEVICE|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
219099350|NCT00000157|DRUG|Aspirin|
219099351|NCT01346514|BEHAVIORAL|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
219099352|NCT01346514|BEHAVIORAL|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
219099353|NCT00909480|DRUG|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
219099354|NCT00909480|DRUG|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
219099355|NCT00861601|DRUG|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
219099356|NCT00861601|DRUG|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
219099357|NCT01215357|DRUG|Ecopipam|50mg tablets
219099358|NCT02561169|DRUG|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
219099359|NCT02561169|OTHER|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
219099360|NCT04454086|OTHER|Aerobic Exercise|Undergo aerobic exercise
219099361|NCT04454086|OTHER|Exercise Counseling|Receive behavioral activity counseling
219099362|NCT04454086|OTHER|Nutritional Assessment|Receive nutritional counseling
219099363|NCT04454086|OTHER|Quality-of-Life Assessment|Ancillary studies
219099364|NCT04454086|OTHER|Questionnaire Administration|Ancillary studies
219550389|NCT05039541|DEVICE|Alio Device|Subjects will wear the Alio device over their vasculature.
219550390|NCT05493358|PROCEDURE|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
219550391|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
219099365|NCT04454086|OTHER|Resistance Training|Undergo resistance exercises
219099366|NCT00355017|PROCEDURE|BNP-guided care in addition to multidisciplinary management|
219099367|NCT04978259|DRUG|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
219099368|NCT05782205|PROCEDURE|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
219099369|NCT00977405|DEVICE|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
219099370|NCT00098163|BIOLOGICAL|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
219099371|NCT00098163|BIOLOGICAL|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
219099372|NCT04599738|OTHER|Wheat muffin|Participants consumed a control muffin made of wheat flour.
219099373|NCT04599738|OTHER|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
219099374|NCT03571984|BEHAVIORAL|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
219099375|NCT02881008|DRUG|Entecavir|
219099376|NCT02881008|DRUG|Myrcludex B|
219099377|NCT00002159|DRUG|Itraconazole|
219550392|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
219550393|NCT01389713|DRUG|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
219550394|NCT01389713|DRUG|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
219099378|NCT00002159|DRUG|Amphotericin B|
219099379|NCT04783064|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is performed at ipsilateral side of the affected shoulder.
219099380|NCT04191109|OTHER|Observational study|This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
219099381|NCT01492491|DEVICE|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
219683688|NCT03478371|DEVICE|tampon T|regular absorbency tampon
219683689|NCT03478371|DEVICE|tampon V|regular absorbency tampon
219683690|NCT00132080|DRUG|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
219683691|NCT03943498|DRUG|Fingolimod|Given PO daily for 4 weeks
219683692|NCT03943498|DRUG|Fingolimod Hydrochloride|Given PO
219683693|NCT03943498|OTHER|Questionnaire Administration|Ancillary studies
219683694|NCT03308240|BEHAVIORAL|Magic Therapy|As described in the arm description
219683695|NCT03994978|PROCEDURE|elective sigmoidectomy|elective sigmoidectomy
219099382|NCT04990206|BEHAVIORAL|TranS-C|"TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change."
219099383|NCT05647863|OTHER|Functional Cognitive and Sensory Treatment (F-CaST)|F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
219099384|NCT02410993|PROCEDURE|CABG surgery|
219550395|NCT02783287|BEHAVIORAL|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
219550396|NCT02783287|BEHAVIORAL|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
219099385|NCT02374632|OTHER|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
219099386|NCT02374632|OTHER|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
219099387|NCT02374632|OTHER|Sham feeding|
219099388|NCT05458167|DEVICE|Hedia Diabetes Assistant bolus calculator with a physical activity module|Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
219550397|NCT06086314|DEVICE|reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
219550398|NCT06086314|DEVICE|reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
219550399|NCT06086314|OTHER|neurorehabilitation program with functional reaching training without device.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
219550400|NCT00002923|DRUG|KRN5500|
219550401|NCT01013818|DRUG|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
219550402|NCT00735696|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
219550403|NCT00735696|DRUG|Paclitaxel|200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
219550404|NCT00735696|DRUG|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
219550405|NCT02297230|RADIATION|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
219550406|NCT02297230|DRUG|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
219550407|NCT02297230|DRUG|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
219099389|NCT03002038|DRUG|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
219099390|NCT03002038|DRUG|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
219099391|NCT03982043|BEHAVIORAL|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
219099392|NCT03690830|OTHER|metabolomics analysis|collect blood samples and endometrial cells
219099393|NCT05436912|DRUG|Selpercatinib|Administered orally.
219099394|NCT00003086|BIOLOGICAL|filgrastim|
219099395|NCT00003086|DRUG|CAF regimen|
219099396|NCT00003086|DRUG|carboplatin|
219099397|NCT00003086|DRUG|cisplatin|
219099398|NCT00003086|DRUG|cyclophosphamide|
219099399|NCT00003086|DRUG|doxorubicin hydrochloride|
219223506|NCT03711084|DIETARY_SUPPLEMENT|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
219099400|NCT00003086|DRUG|fluorouracil|
219099401|NCT00003086|DRUG|ifosfamide|
219099402|NCT00003086|DRUG|melphalan|
219099403|NCT00003086|DRUG|paclitaxel|
219099404|NCT00003086|DRUG|thiotepa|
219099405|NCT00003086|PROCEDURE|peripheral blood stem cell transplantation|
219099406|NCT00003086|RADIATION|samarium Sm 153 lexidronam pentasodium|
219099407|NCT01959191|DRUG|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
219099408|NCT01295723|RADIATION|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
219099409|NCT01295723|RADIATION|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
219099410|NCT01616576|DEVICE|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
219099411|NCT01616576|DEVICE|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
219099412|NCT04278378|DIETARY_SUPPLEMENT|Riboflavin|1.6 mg riboflavin / day for 24 weeks
219099413|NCT04278378|DIETARY_SUPPLEMENT|Folic acid|0.4 mg folic acid / day for 24 weeks
219099414|NCT04278378|DIETARY_SUPPLEMENT|Placebo|
219099415|NCT02904902|DRUG|adalimumab|Subcutaneous Injection
219099416|NCT04396080|PROCEDURE|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
219099417|NCT02904616|DEVICE|mobile spectrofluorimeter|
219099418|NCT04453514|BEHAVIORAL|Trauma-informed yoga video recording|Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
219099419|NCT04780698|DIAGNOSTIC_TEST|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
219099420|NCT04047511|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
219099421|NCT04047511|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
219099422|NCT04047511|BEHAVIORAL|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
219099423|NCT00699140|BIOLOGICAL|IGIV3I Grifols|Immune Globulin Intravenous (Human)
219099424|NCT03266822|OTHER|No intervention|Observational study
219099425|NCT02335151|DRUG|Desflurane|Apply desflurane as anesthetic
219099426|NCT02576158|PROCEDURE|TCT，HPV，colposcopic inspection|
219099427|NCT02283359|DRUG|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
219099428|NCT02283359|DRUG|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
219099429|NCT05423327|PROCEDURE|No Intervention|Single blood draw
219223507|NCT03711084|DIETARY_SUPPLEMENT|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
219683696|NCT00261755|PROCEDURE|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
219099430|NCT00634816|RADIATION|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
219099431|NCT03018002|OTHER|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
219099432|NCT04750655|DRUG|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
219099433|NCT01216163|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
219099434|NCT01216163|DRUG|Acetaminophen|Single-dose of acetaminophen (1000mg)
219099435|NCT01216163|DRUG|Placebo|Single-dose of placebo
219099436|NCT02914314|DRUG|perampanel|oral suspension.
219099437|NCT03564782|BIOLOGICAL|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
219099438|NCT05680974|OTHER|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
219099439|NCT02786264|DRUG|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
219099440|NCT02786264|DRUG|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
219099441|NCT02080104|DRUG|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
219099442|NCT01583023|DRUG|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
219099443|NCT01583023|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
219099444|NCT01583023|OTHER|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
219099445|NCT01583023|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
219099446|NCT00210262|BEHAVIORAL|Feedback and Education|
219099447|NCT04111523|DRUG|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
219099448|NCT01047722|DRUG|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
219683697|NCT00261755|OTHER|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
219683698|NCT00261755|OTHER|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
219683699|NCT02667925|DRUG|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
219683700|NCT02849743|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
219683701|NCT02849743|DRUG|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
219683702|NCT00594776|DEVICE|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
219683703|NCT03064113|DRUG|Placebo|
219683704|NCT03064113|DRUG|TD-4208 700 μg|
219683705|NCT03064113|DRUG|TD-4208 350 μg|
219683706|NCT03064113|DRUG|Ipratropium 500 μg|
218984702|NCT06004362|BEHAVIORAL|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
218984703|NCT01457144|DRUG|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
218984704|NCT05121896|DEVICE|MRI Scan|7.0 tesla functional MRI scan
218984705|NCT00142298|DRUG|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
218984706|NCT02996513|OTHER|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
218984707|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
218984708|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
218984709|NCT01269632|BIOLOGICAL|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires"
218984710|NCT05497583|OTHER|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
218984711|NCT05497583|OTHER|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
218984712|NCT00300274|DRUG|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
218984713|NCT00300274|DRUG|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
218984714|NCT00300274|DRUG|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
218984715|NCT00300274|DRUG|corticosteroids|Corticosteroids standard dose.
218984716|NCT00916097|DRUG|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
218984717|NCT03498144|DEVICE|Anterior segment OCT|lower punctum examination by AS-OCT
218984718|NCT00242216|DRUG|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
218984719|NCT00242216|DRUG|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
219099449|NCT01047722|PROCEDURE|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
219683707|NCT05682417|DEVICE|Body Map Assessment Tool: MOVE Tool|"In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area."
219683708|NCT05682417|OTHER|PAQ questionnaire|This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
219683709|NCT05682417|OTHER|F-DFlex questionnaire|This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
219683710|NCT05682417|OTHER|BSQ questionnaire|"The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological."
219683711|NCT05682417|OTHER|Silhouette testing|Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
219683712|NCT05682417|OTHER|Eating Disorder Inventory - 2|"Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)"
219683713|NCT05682417|OTHER|EDEQ questionnaire|"Or Eating Disorders Examination - Questionnaire (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days."
219683714|NCT05682417|OTHER|STAI questionnaire|The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
219099450|NCT01947660|DRUG|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
219099451|NCT01947660|DRUG|Systemic analgesia|Systemic analgesia as usual
219099452|NCT03614338|BEHAVIORAL|Small changes weight loss program|"This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions."
219099453|NCT00993824|DRUG|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
219099454|NCT00993824|DRUG|placebo|
219099455|NCT01720823|DEVICE|home polysomnography (GETEMED)|
219099456|NCT01720823|DEVICE|standard polysomnography (BRAINNET II)|
219099457|NCT02413463|PROCEDURE|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
219099458|NCT02413463|PROCEDURE|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
219099459|NCT06495541|DRUG|Pyrotinib|Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
219099460|NCT05250401|DIAGNOSTIC_TEST|liver functions and thyroid functions|laboratory tests
219099461|NCT03788460|OTHER|no intervention|no intervention
219099462|NCT00557609|DRUG|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
219099463|NCT01302561|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose twice daily for 24 weeks
219099464|NCT01302561|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
219099465|NCT03472703|OTHER|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
219099466|NCT02702700|DRUG|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
219099467|NCT02702700|DRUG|Verteporfin|Visudyne® IV 3 mg/m2
219099468|NCT02702700|DEVICE|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
219099469|NCT05288023|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
219099470|NCT04459559|DEVICE|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
219099471|NCT04146896|DRUG|NYX-2925 50 mg|NYX-2925 administered orally
219099472|NCT04146896|DRUG|Placebo|Placebo administered orally
219099473|NCT02118337|BIOLOGICAL|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
219099474|NCT02118337|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
219099475|NCT02118337|BIOLOGICAL|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
219099476|NCT00004924|DRUG|irinotecan hydrochloride|
219683715|NCT05682417|OTHER|BECK questionnaire|Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
219683716|NCT00002293|DRUG|Nystatin|
219099477|NCT00004924|DRUG|paclitaxel|
219099478|NCT03628963|DEVICE|Concerto+|a user-centered, multifunctional and personalized eHealth platform
219099479|NCT00720174|BIOLOGICAL|Cixutumumab|Given IV
219099480|NCT00720174|DRUG|Doxorubicin Hydrochloride|Given IV
219099481|NCT00720174|OTHER|Laboratory Biomarker Analysis|Correlative studies
219099482|NCT02707419|DEVICE|Experimental group|Video of the exercises
219683717|NCT03407417|OTHER|virtual technology|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
219099483|NCT02707419|DEVICE|Control group|video of nature scenes
219099484|NCT02707419|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
219099485|NCT00073437|DRUG|Infliximab|
219683718|NCT05865223|OTHER|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
219683719|NCT05865223|OTHER|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
219683720|NCT02167438|DEVICE|Hem-Avert Perianal Stabilizer|
219099486|NCT02053025|DIETARY_SUPPLEMENT|mycoprotein|
219099487|NCT02053025|DIETARY_SUPPLEMENT|control protein|
219099488|NCT03215940|DRUG|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
219099489|NCT03215940|DRUG|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
219099490|NCT03215940|DRUG|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
219099491|NCT01261143|DRUG|BK-C-0701|tablet, 8 weeks
219099492|NCT02555462|DEVICE|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
219099493|NCT04296890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
219099494|NCT06018909|BEHAVIORAL|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
219099495|NCT00798226|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
219099496|NCT00798226|DIETARY_SUPPLEMENT|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
219099497|NCT04506190|PROCEDURE|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
219099498|NCT02962570|DEVICE|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
219099499|NCT02962570|DEVICE|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
219099500|NCT02962570|DEVICE|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
219099501|NCT05400746|BIOLOGICAL|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
219099502|NCT02628392|DRUG|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
219099503|NCT02628392|DRUG|Sitagliptin|capsules
219099504|NCT02628392|DRUG|placebo|matching DS-8500a tablets and sitagliptin capsules
219099505|NCT03184896|PROCEDURE|Hip Fracture Surgery|Hip Fracture Surgery
219099506|NCT02227316|DRUG|IV Ibuprofen|Uterine fibroid embolization
219099507|NCT02227316|DRUG|IV Acetaminophen|Uterine fibroid embolization
219099508|NCT02227316|DRUG|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
219099509|NCT05971914|PROCEDURE|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
219099510|NCT04491812|OTHER|Kinesio Tape|Elastic Kinesiology Tape
219099511|NCT04491812|OTHER|Physical therapy program|designed physical therapy program
219683721|NCT02026765|DEVICE|traditional lens|A random eyes with traditional lens
219683722|NCT02026765|DEVICE|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
219683723|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
219683724|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
219683725|NCT05831124|BIOLOGICAL|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
219683726|NCT05831124|BIOLOGICAL|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
219683727|NCT05438979|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to CFB
219683728|NCT05438979|DIETARY_SUPPLEMENT|Calcium Fructoborate|216mg CFB
219683729|NCT03874013|DRUG|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
219683730|NCT03874013|DRUG|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
219683731|NCT04331691|DRUG|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
219683732|NCT04331691|DRUG|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
219099512|NCT01970787|DEVICE|Radiofrequency Ablation (RFA) using the HALO Ablation System|
219099513|NCT01633125|OTHER|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
219683733|NCT02605759|DEVICE|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
219099514|NCT00061763|DRUG|Deferasirox|
219099515|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
219099516|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
219099517|NCT00166725|DRUG|Octreotide LAR|
219683734|NCT05814315|BEHAVIORAL|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
219683735|NCT05747859|OTHER|teletherapy|speech therapy remotely delivered
219683736|NCT00943657|BIOLOGICAL|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
219683737|NCT06333730|PROCEDURE|inferior alveolar nerve block|After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.
218984720|NCT01786941|OTHER|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
218984721|NCT01786941|OTHER|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
218984722|NCT00214760|DEVICE|PGET|resolbable liner
218984723|NCT00214760|DEVICE|PMMA|cement liner
218984724|NCT03950011|PROCEDURE|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
218984725|NCT00981240|DRUG|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
219683738|NCT06333730|PROCEDURE|mental nerve block|After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
219683739|NCT05469126|DRUG|LY3502970|Administered orally.
219683740|NCT05469126|DRUG|Clarithromycin|Administered orally.
219683741|NCT06040814|BEHAVIORAL|Rehabilitation Training|12 week Rehabilitation Training course
219683742|NCT02902835|BEHAVIORAL|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
219683743|NCT02902835|BEHAVIORAL|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
219683744|NCT06324877|DRUG|Nicotinamide riboside|Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
218984726|NCT02597231|DIETARY_SUPPLEMENT|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
218984727|NCT02597231|OTHER|Placebo|Patients in this group will receive a matching placebo pill.
218984728|NCT05212571|DRUG|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
218984729|NCT05212571|DRUG|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
219683745|NCT02909010|DEVICE|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
219683746|NCT02909010|OTHER|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
219683747|NCT03507855|OTHER|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
219683748|NCT03507855|OTHER|Normal|No change in the normal operating room environment.
219683749|NCT06312865|DEVICE|Ophthalmic exam|include best corrected visual acuity and cycloplegic refraction data
219683750|NCT00325910|DRUG|Metformin|
219683751|NCT00922116|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
219683752|NCT00741312|BEHAVIORAL|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
219683753|NCT00741312|BEHAVIORAL|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
219683754|NCT05015036|PROCEDURE|ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
219683755|NCT05015036|PROCEDURE|Minimally invasive surgery|Classic Minimally invasive surgery of the lumbar spine
219683756|NCT05179824|OTHER|Observation|No Intervention
219683757|NCT04607135|DEVICE|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
219683758|NCT04607135|DEVICE|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
219683759|NCT05288114|DEVICE|Signal Relief Patch|Eligible subjects will be provided a Signal Relief patch, the instructions for use, and patch placement materials (adhesive, athletic tape, or wrap as applicable for the location of the pain). Subjects will be instructed to use the patch daily for seven days. The patch must be worn constantly except when showing or swimming.
219683760|NCT05490355|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
219683761|NCT05490355|PROCEDURE|Perineural Steroid Injection|Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
219683762|NCT06060496|DEVICE|Active cTBS|Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
218984730|NCT06183177|OTHER|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
219683763|NCT06060496|DEVICE|Sham cTBS|Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
219683764|NCT05465369|OTHER|giomer|injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
219223508|NCT03711084|DIETARY_SUPPLEMENT|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
219223509|NCT00196521|DEVICE|Tension-free vaginal tape obturator system|
219223510|NCT03611075|OTHER|No Intervention|No interventions are administered in this study
219683765|NCT05465369|OTHER|high viscosity glass ionomer|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
219683766|NCT06958549|PROCEDURE|Nerve block with Lidocain|Injection of Lidocaine (7mg/kg) with Epinephrine 1:100000 under Ultrasonographical guidance
219683767|NCT06958549|DRUG|pharmacological analgesics|Oral Paracetamol (500mg/6hr), IV Ketolac (15mg/6hr) and IV perfelgan (1gm/6hr)
219683768|NCT06958445|DRUG|Alginos Oral Suspension|containing: Sodium alginate 50mg/mL Sodium bicarbonate 26.7mg/mL Calcium carbonate 16mg/mL
218984731|NCT06183177|OTHER|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
218984732|NCT00069056|PROCEDURE|Laser Treatment|
218984733|NCT06016725|OTHER|Exercise Intervention|Participate in online resistance training sessions
218984734|NCT06016725|OTHER|Informational Intervention|Given educational materials
218984735|NCT06016725|OTHER|Nutritional Assessment|Participate in online nutritional counseling
218984736|NCT06016725|OTHER|Physical Performance Testing|Ancillary studies
218984737|NCT06016725|OTHER|Quality-of-Life Assessment|Ancillary studies
218984738|NCT06016725|OTHER|Questionnaire Administration|Ancillary studies
218984739|NCT02872493|PROCEDURE|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
218984740|NCT05472779|DRUG|Periurethral application of estradiol cream|The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
218984741|NCT05472779|DRUG|Intravaginal application of estradiol cream|The control group will apply 1 gram estradiol cream intravaginally using an applicator.
218984742|NCT06973746|OTHER|sitting out of bed in an arm-chair position|"Once the patient has been awake with a RASS score between -1 and +1 for more than 12 hours, he or she must be placed in a chair (by any means) every day for a minimum of 30 minutes until discharge from intensive care (or until D28, depending on which comes first), unless there are transient contraindications. If the patient is unable to signal his or her wish to stop the chair session, the criteria for intolerance will be sought and the patient placed in the chair, but in all cases the chair session will not exceed 4 hours."
218984743|NCT06109649|DRUG|Afamelanotide and NB-UVB Light|Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
218984744|NCT06109649|PROCEDURE|NB-UVB Light|Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.
218984745|NCT06150924|DRUG|Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD|Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks
218984746|NCT06150924|DRUG|Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD|Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks
218984747|NCT04651296|BEHAVIORAL|compassion meditation|manualized compassion meditation training
218984748|NCT04651296|BEHAVIORAL|health education|manualized health education group
218984749|NCT04439201|DRUG|Palbociclib|Given PO
218984750|NCT05394675|DRUG|DS-9606a|Intravenous infusion
218984751|NCT06975072|DRUG|Magnesium sulfate administration|A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min).
218984752|NCT06576466|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
218984753|NCT06576466|OTHER|Placebo|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
218984754|NCT06640530|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
218984755|NCT06640530|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
218984756|NCT05733390|DRUG|JZP541|Oral suspension
218984757|NCT05733390|OTHER|Placebo|Oral suspension
219099518|NCT01257711|PROCEDURE|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
219099519|NCT03300570|DRUG|Dolcanatide|Given PO
219099520|NCT03300570|OTHER|Laboratory Biomarker Analysis|Correlative studies
219683769|NCT05722821|OTHER|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
219683770|NCT03990051|DRUG|Pro-ocular™ topical gel|Topical gel for forehead dermal application
219683771|NCT03990051|DRUG|Placebo topical gel|Topical gel for forehead dermal application
219683772|NCT06444503|OTHER|Biological samples|Blood and urine will be taken in larger quantity
219683773|NCT06444503|OTHER|Biological|Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
219099521|NCT03300570|OTHER|Placebo Administration|Given PO
219099522|NCT03300570|OTHER|Questionnaire Administration|Ancillary studies
219099523|NCT03154502|DIAGNOSTIC_TEST|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
219099524|NCT04318158|DRUG|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
219099525|NCT04318158|DRUG|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
219099526|NCT04318158|DRUG|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
219099527|NCT05845775|PROCEDURE|Percutaneous dilatational tracheostomy|The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy
219099528|NCT05845775|DEVICE|Bronchoscopy|Fiberoptic bronchoscopy
219099529|NCT05845775|DEVICE|ultrasonography|ultrasonography
219099530|NCT05845775|DIAGNOSTIC_TEST|Bronchoscopy application|Fiberoptic bronchoscopy application
219099531|NCT05845775|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination
219099532|NCT03527355|BIOLOGICAL|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
219683774|NCT00618826|DRUG|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
219683775|NCT00618826|DRUG|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
219683776|NCT00618826|DRUG|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
219683777|NCT04167189|DRUG|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
219683778|NCT01161810|OTHER|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
219099533|NCT03527355|BIOLOGICAL|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
219683779|NCT04006470|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
219683780|NCT04006470|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
219683781|NCT04006470|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
219099534|NCT03527355|OTHER|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
219099535|NCT01417611|PROCEDURE|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
219099536|NCT04045444|OTHER|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
219099537|NCT04045444|OTHER|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
219683782|NCT01509664|BEHAVIORAL|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
219683783|NCT02855567|DEVICE|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
219683784|NCT05519956|RADIATION|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
218984758|NCT06141031|DRUG|TTI-101|TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
218984759|NCT06252636|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein.
218984760|NCT06252636|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein.
218984761|NCT02989025|DRUG|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
218984762|NCT03651206|DRUG|Niraparib|PARP Inhibitor
218984763|NCT03651206|COMBINATION_PRODUCT|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
218984764|NCT03651206|DRUG|Chemotherapy Drugs|Chemotherapies given in standard of care
218984765|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
218984766|NCT04107766|DEVICE|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
218984767|NCT06656494|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
218984768|NCT06656494|DRUG|Azacitidine|Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.
218984769|NCT04039633|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
218984770|NCT04039633|PROCEDURE|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
219099538|NCT03188120|DRUG|Spiriva Respimat|Drug
219683785|NCT05519956|RADIATION|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
219683786|NCT01025102|DRUG|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
219683787|NCT02372994|OTHER|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
219683788|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
219683789|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
219683790|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
219683791|NCT02431104|DEVICE|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
219683792|NCT01960465|DEVICE|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
219550408|NCT02297230|DRUG|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
219683793|NCT05306847|DRUG|Sintilimab|Sintilimab will be given intravenously at a dose of 200mg every 21 days.
219683794|NCT05306847|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
219683795|NCT00374348|DRUG|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
219683796|NCT02213315|DRUG|100mg Mavrilimumab|100mg Mavrilimumab
219683797|NCT02213315|DRUG|150mg mavrilimumab|150mg mavrilmumab
219683798|NCT02213315|OTHER|Placebo|Placebo
219683799|NCT05582629|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
219683800|NCT05582629|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
219683801|NCT02144038|DRUG|LGH447|pan-PIM inhibitor
219683802|NCT02144038|DRUG|BYL719|PI3K-alpha inhibitor
219683803|NCT04832256|DEVICE|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
219683804|NCT03626701|DEVICE|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
219683805|NCT03626701|COMBINATION_PRODUCT|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
219683806|NCT03626701|PROCEDURE|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
219683807|NCT03289767|OTHER|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
219683808|NCT05061147|DRUG|MAX-40279-01|"Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA"
219683809|NCT03701880|DRUG|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
219683810|NCT03701880|DRUG|Bisoprolol|Bisoprolol is beta-blocker
218984771|NCT04786977|OTHER|No Intervention, Observational Study|No Intervention
218984772|NCT03451266|DRUG|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
218984773|NCT03451266|DRUG|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
218984774|NCT04845477|DEVICE|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
218984775|NCT04845477|DEVICE|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
218984776|NCT04144972|DEVICE|Medtronic Summit RC+S or Percept RC|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
218984777|NCT06662942|DRUG|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
218984778|NCT06662942|DRUG|Placebo|The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
218984779|NCT06666127|OTHER|LONG and SHORT Resistance Training|One side of the body will be randomly assigned to perform exercises in position 3 (LONG) with the other randomly assigned to position 2 (SHORT) of Prime Fitness horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Each exercise will include 1 warm up set at 50% 1RM followed by 4-5 sets of 8-12 repetitions per limb. 2 minutes of rest between sets on the same side of body will be administered as the participant will alternate between the right and left limb. The left and right side limbs will alternate each session in which one starts each exercise, resulting in 10 training sessions each where the left and right limbs starts first on each exercise. All sets will be performed to momentary failure. A Dynamic Double Progression will be employed to ensure intensity is maintained.
218984780|NCT06666127|OTHER|Maximal Isotonic Strength Testing (1RM)|Each limb will perform a 1RM strength test with each Prime Fitness machine training horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension respectively. Each machine will be set to position 1 (maximal load in mid-range). Testing will occur in weeks 1 and 12 of the study with the non-dominant arm and leg tested before the dominant arm and leg in each exercise. Participants self-selects first warm up set with a weight that is performed between 6-10 repetitions on both limbs. Rest for 1 minute between limbs and subsequent set. A weight is then selected by research staff to perform 3 repetitions with based on previous set. Load is now increased until 1RM is achieved. Rest periods should remain at least 1 minute alternating between limbs, with 1RM being complete within 3-5 attempts. Participant will rest 2-5 minutes before starting testing on the next exercise. Repeat for all exercises. Use pre testing data to inform 1RM attempts for post testing.
219683811|NCT00807885|DRUG|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
219683812|NCT06355661|DIETARY_SUPPLEMENT|ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
219683813|NCT06355661|DIETARY_SUPPLEMENT|MCC: 400 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
219683814|NCT00503893|BEHAVIORAL|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
219683815|NCT00503893|OTHER|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
219683816|NCT04909515|DRUG|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
219683817|NCT04909515|DRUG|GM-CSF|250 - 500 microgram/m2/day
219683818|NCT04909515|DRUG|Isotretinoin|160 mg/m2/day
219683819|NCT01095627|OTHER|Metacholine challenge|Exhaled breath analysis following metacholine challenge
219683820|NCT04797988|DEVICE|eon® FR 1064 nm device|The subject will be treatment area - flanks, will be treated with the eon device.
219683821|NCT05625724|DRUG|Aspirin|Experimental drug administrated orally
219683822|NCT05625724|DRUG|Placebo|Treatment for the control group
219683823|NCT00524251|DRUG|esomeprazole|
219683824|NCT01366313|DRUG|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
219683825|NCT01366313|DRUG|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
219683826|NCT01366313|DRUG|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
219683827|NCT02364388|DEVICE|Imagio IUS|Imagio diagnostic gray-scale ultrasound
219683828|NCT02364388|DEVICE|Imagio OA/US|Diagnostic opto-acoustic +gray-scale ultrasound
219683829|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
219683830|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
219683831|NCT02356952|BEHAVIORAL|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
219683832|NCT02356952|BEHAVIORAL|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
219683833|NCT02356952|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
219683834|NCT04884347|DIETARY_SUPPLEMENT|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
219683835|NCT04884347|DIETARY_SUPPLEMENT|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
219683836|NCT05682833|PROCEDURE|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
219683837|NCT04710875|DRUG|Na-lactate|intravenous
219683838|NCT04710875|DRUG|Sodium chloride|Intravenous
219683839|NCT04919148|BEHAVIORAL|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
219683840|NCT04773821|OTHER|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
219683841|NCT04714645|DEVICE|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
219683842|NCT04714645|DEVICE|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
219683843|NCT00889655|DRUG|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
219683844|NCT00889655|DRUG|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
219683845|NCT03126786|DRUG|IVT aflibercept|IVT aflibercept \[2 mg/0.05 mL\]
219683846|NCT03126786|DRUG|Sham SC|sham SC
219683847|NCT03126786|DRUG|SC CLS-TA|CLS-TA \[4 mg/100 μL\] SC injection
219683848|NCT04428840|DEVICE|Self-measurement kiosk|Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
219683849|NCT05030532|BEHAVIORAL|EVERYbody Project|Brief behavioral group intervention (4 hours across two meetings)
219683850|NCT05030532|OTHER|Video + Expressive Writing|Brief video-based group intervention (4 hours across two meetings)
219683851|NCT03234803|OTHER|poly-amide|new denture base material
219683852|NCT03234803|OTHER|poly-methyl methacrylate|gold standard for denture base materials
219683853|NCT02602314|DRUG|Imatinib|
219683854|NCT02602314|DRUG|Nilotinib|
219683855|NCT00905424|DRUG|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
219683856|NCT00905424|DRUG|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
219683857|NCT00037063|DRUG|Thiamine hydrochloride|
218984781|NCT06666127|OTHER|Isokinetic Strength Testing|Participants will engage in isokinetic strength testing on the isokinetic dynamometer (Biodex) in weeks 1 and 12 for each of the four movements: Horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Participants will perform each movement unilaterally. Participants will start with the non-dominant arm and leg for each movement. Each movement will be tested through A maximal active range of motion. Participants will complete 10 sub-maximal repetitions to allow familiarization each movement. After a 2-minute rest, participants will complete 3 maximal concentric and eccentric repetitions with 30 seconds rest at 30 degrees per second before the Biodex is reset for the next movement.
219099539|NCT00920023|DRUG|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
219099540|NCT02807428|DRUG|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
219099541|NCT02807428|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
219099542|NCT01235403|DRUG|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
219099543|NCT03591367|DIAGNOSTIC_TEST|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
219099544|NCT03591367|DIAGNOSTIC_TEST|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
219683858|NCT00037063|DRUG|Riboflavin|
218984782|NCT06666127|OTHER|Muscle Oxygenation|During the first and last LONG and SHORT training session (visit 5 and visit 24), A near infrared spectroscopy sensor (NIRS device) (Trainred) will be affixed to the muscle belly of the deltoid during the lateral raise exercise to measure muscle oxygenation.
218984783|NCT06605456|OTHER|Proprioceptive neuromuscular facilitation with postural education|"Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles. Then, resisted scapular posterior depression PNF exercise also employed.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
218984784|NCT06605456|OTHER|Active neck muscle stretching and strengthening exercises|"Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
218984785|NCT06987370|RADIATION|Conventional Radiotherapy (CRT)|The conventional radiotherapy group, that is, the control group, administering conventional external beam radiotherapy with a dose of 30 Gy in 10 fractions to the bone metastasis lesions.
219099545|NCT00538928|OTHER|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
219099546|NCT02296190|DRUG|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
219099547|NCT02296190|DRUG|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
219099548|NCT02978443|DRUG|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
219683859|NCT00037063|DRUG|Ascorbic acid|
219683860|NCT00037063|DRUG|Vitamin E|
219683861|NCT00991289|DRUG|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
219683862|NCT00991289|DRUG|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
219683863|NCT00991289|DRUG|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
219683864|NCT00426764|DRUG|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
219683865|NCT02412176|PROCEDURE|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
219683866|NCT02412176|PROCEDURE|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
219683867|NCT00379899|DRUG|cinacalcet|Low dose vitamin D with cinacalcet
219683868|NCT02404610|PROCEDURE|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
219683869|NCT02404610|PROCEDURE|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
219683870|NCT02404610|DRUG|propofol|
219683871|NCT06149572|PROCEDURE|lateral position procedure|Lateral positioning will be used as an intervention for spinal hypotension.
219683872|NCT06149572|PROCEDURE|sitting position porocedure|parturients will get spinal punctures in the sitting position
219683873|NCT05360407|OTHER|Using mobile information application about before and after surgery|"The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password."
219683874|NCT06523049|DRUG|Vorolanib Tablets|Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
219683875|NCT06523049|DRUG|Sintilimab Injection|Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
219683876|NCT01701804|DRUG|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
219683877|NCT01701804|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
218984786|NCT06987370|RADIATION|SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）|"Stereotactic Central Ablative Radiotherapy (SCART): When using SCART to treat bone metastases with associated soft tissue components, the gross tumor volume (GTV) of the bone metastases must be accurately delineated according to the guidelines. The GTV are contracted to derive the SCART-Treatment Volume (STV). An initial dose of 8-12 Gy in a single fraction is delivered to the STV, followed by a dose of 25-40 Gy in 5 fractions to the clinical target volume (CTV). Spatially Fractionated Radiation Therapy (SFRT): The GTV are reduced to form a LATTICE target area. Several vertices are uniformly contoured along the edges of the LATTICE. A dose of 8-12 Gy in a single fraction is delivered to the vertices, followed by a dose of 25-40 Gy in 5 fractions to the CTV."
218984787|NCT06987071|PROCEDURE|Acupuncture|Insertion of sterile, single-use needles at specific acupuncture points (LI4, PC6, ST36, SP6) for 20 minutes with manual stimulation, administered 30 minutes before the biopsy by a licensed acupuncturist.
218984788|NCT06987071|PROCEDURE|sham acupuncture|Superficial needle insertion at non-acupuncture points without stimulation, administered 30 minutes before the biopsy, mimicking the acupuncture procedure without therapeutic intent.
219099549|NCT02978443|DRUG|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
219683878|NCT01701804|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.
219683879|NCT01701804|PROCEDURE|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
219683880|NCT00013871|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
219683881|NCT00013871|BIOLOGICAL|Measles-Mumps-Rubella Vaccine (Live)|
219683882|NCT00013871|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
219683883|NCT00013871|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
219099550|NCT04860947|DIAGNOSTIC_TEST|Brain MRI|"* Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection."
219099551|NCT04860947|DIAGNOSTIC_TEST|Spinal Cord MRI|Sagittal T2 Sagittal T1 with Gadolinium injection
219099552|NCT04860947|DIAGNOSTIC_TEST|Retinal imaging|spectral-domain high definition optical coherence tomography
219683884|NCT00013871|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
219683885|NCT05225389|DRUG|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
219683886|NCT02235025|OTHER|Cardio-pulmonary exercise testing|
219683887|NCT04069676|OTHER|EEG|EEG, ECG and EDR record during a behavioral task
219683888|NCT03695263|BEHAVIORAL|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
219683889|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
219683890|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
219683891|NCT02074293|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
219683892|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683893|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
219683894|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
219683895|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683896|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219099553|NCT06184243|BEHAVIORAL|Parent Training|Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
219099554|NCT06184243|BEHAVIORAL|Video Modeling|The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
219683897|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683898|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219099555|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
219683899|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683900|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683901|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
219683902|NCT02074293|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219683903|NCT02074293|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219683904|NCT00532532|DRUG|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
219683905|NCT00532532|DRUG|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
219683906|NCT00532532|DRUG|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
219683907|NCT01340755|PROCEDURE|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
219683908|NCT05923918|DRUG|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
219683909|NCT05923918|DRUG|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
219683910|NCT05923918|DRUG|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
219683911|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
219683912|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
219683913|NCT05329857|DRUG|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
219683914|NCT03804268|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
219683915|NCT03804268|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
219550409|NCT04172324|DEVICE|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
219550410|NCT04172324|OTHER|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
219550411|NCT05308823|PROCEDURE|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
219550412|NCT03546049|PROCEDURE|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
219550413|NCT03546049|PROCEDURE|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
219550414|NCT03063372|DIETARY_SUPPLEMENT|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
219550415|NCT03063372|OTHER|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
219550416|NCT04943107|OTHER|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
219550417|NCT00425009|DRUG|Berberine|
219550418|NCT00425009|DRUG|Metformin|
219550419|NCT03155893|DRUG|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
219550420|NCT03155893|DRUG|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.
219550421|NCT03155893|DRUG|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.
219550422|NCT03155893|DRUG|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.
219550423|NCT03155893|DRUG|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
219550424|NCT03155893|DRUG|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
219550425|NCT03155893|DRUG|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
219550426|NCT03155893|DRUG|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
219550427|NCT03155893|DRUG|ODV 200 mg|Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
219550428|NCT03155893|DRUG|ODV 125 mg|Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
219550429|NCT03155893|DRUG|ODV 100 mg|Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
219550430|NCT03155893|DRUG|SMV 150 mg|Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
219550431|NCT03155893|DRUG|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
218984789|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
219099556|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
219099557|NCT04305002|DRUG|Exenatide|Injections, 2 mg once weekly for 18 months
219099558|NCT04305002|DRUG|Placebo|Injections, once weekly for 18 months
219099559|NCT03278535|DIAGNOSTIC_TEST|CAREN-based gait analysis|subjects only walk at CAREN at different speed
219099560|NCT02607371|OTHER|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
218984790|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
218984791|NCT06992440|DRUG|Empagliflozin 10 MG|10 mg tablet once daily
218984792|NCT06992440|DRUG|Placebo|matching tablet once daily
219099561|NCT02607371|OTHER|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219099562|NCT02607371|OTHER|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219099563|NCT02607371|OTHER|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219550432|NCT00640393|DRUG|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
219550433|NCT00640393|DEVICE|nbUVB|
219550434|NCT03929328|PROCEDURE|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
219550435|NCT03132311|BIOLOGICAL|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
219550436|NCT00030511|DRUG|fluorouracil|
219550437|NCT00030511|PROCEDURE|conventional surgery|
219550438|NCT00030511|RADIATION|radiation therapy|
219550439|NCT00697918|DRUG|RWJ-333369|100 mg to 400 mg twice daily
219683916|NCT03037515|DRUG|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
219683917|NCT04915560|DEVICE|Connected T-shirt|Ware of a connected T-shirt
219683918|NCT03585972|BEHAVIORAL|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
219683919|NCT06156605|PROCEDURE|Sidelying lumbar manipulation|R sided lumbar manipulation
219683920|NCT03158610|DRUG|Capecitabine|Oral fluorouracil
219683921|NCT02362893|OTHER|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
219683922|NCT05315648|PROCEDURE|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
218984793|NCT01052376|DEVICE|Confocal endomicroscopy|
218984794|NCT06862635|OTHER|Hydrotherapy|Patients will receive hydrotherapy sessions including stretching, resistance, and balance exercises in water
218984795|NCT06862635|OTHER|traditional land-based balance exercises|Patients will receive traditional land-based balance exercises in the form of stretching, strengthening and balance exercises.
219099564|NCT02607371|OTHER|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219099565|NCT02564783|OTHER|No intervention|No intervention
219099566|NCT00717314|DRUG|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
219099567|NCT00717314|DRUG|CNI (50%)|50% reduction from BL
219099568|NCT00717314|DRUG|CNI (≥75%)|≥75% reduction from BL
219099569|NCT06249763|DIETARY_SUPPLEMENT|High gluten diet|Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
219099570|NCT06249763|DIETARY_SUPPLEMENT|Gluten free diet|Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
219099571|NCT00117156|DRUG|Fludarabine|
219099572|NCT00117156|DRUG|Rituximab|
219099573|NCT03402516|DEVICE|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
219099574|NCT03402516|DEVICE|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
219099575|NCT02992587|OTHER|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
219099576|NCT01474213|DRUG|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
219099577|NCT01474213|DRUG|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
219550440|NCT06058806|OTHER|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
219550441|NCT04981457|DRUG|Misoprostol and iso sorbide mononitrates|drug
218984796|NCT06857357|OTHER|Questionnaires|"The Tampa Kinesiophobia Questionnaire is a 17-question questionnaire that assesses avoidance of injury and fear of movement. The scale is scored using a Likert scale (1 = Strongly disagree, 4 = Strongly agree). Items 4, 8, 12 and 16 are reversed to calculate the total score of the scale. The total score is between 17 and 68. As the score of the person increases, it is understood that their kinesiophobia is high. A total score higher than 37 is considered as high kinesiophobia. However, since not every item of the questionnaire addresses patients with headache in this study, some questions were removed, some questions were edited and some questions were added to create a kinesiophobia questionnaire for headache. The newly created questionnaire consists of 23 items. Again, it is scored using a Likert scale with 1 = Strongly disagree, 4 = Strongly agree. As the score increases, it is understood that the level of kinesiophobia is high."
218984797|NCT06615739|DEVICE|Regenerex Tissue Attachment Augments|Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
219099578|NCT01450202|OTHER|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
219099579|NCT01450202|OTHER|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
219099580|NCT02206490|DRUG|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
219099581|NCT02206490|DRUG|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
219099582|NCT00511979|DRUG|Technosphere Insulin|
219099583|NCT00511979|DRUG|Technosphere insulin|
219099584|NCT00511979|DRUG|Technosphere insulin|
219099585|NCT00511979|DRUG|Regular human insulin|
219099586|NCT01521884|OTHER|SC anti-TNF|SC anti-TNF
219099587|NCT02540395|DRUG|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
219099588|NCT02540395|DRUG|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
219550442|NCT03092388|DIAGNOSTIC_TEST|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
219550443|NCT03092388|DIAGNOSTIC_TEST|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
219550444|NCT03092388|DIAGNOSTIC_TEST|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
219550445|NCT03092388|DIAGNOSTIC_TEST|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
219550446|NCT03624777|BEHAVIORAL|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
219550447|NCT03624777|BEHAVIORAL|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
219099589|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
219099590|NCT02540395|DRUG|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
219099591|NCT02540395|DRUG|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
219099592|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
219099593|NCT04183907|BEHAVIORAL|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
219099594|NCT05368181|DRUG|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
219099595|NCT04013217|COMBINATION_PRODUCT|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
219099596|NCT04668300|BIOLOGICAL|Durvalumab|Given IV
219099597|NCT04668300|BIOLOGICAL|Oleclumab|Given IV
219099598|NCT06134856|PROCEDURE|Ankle mobilization|Ankle joint mobilization as described in treatment arm description
219099599|NCT06134856|PROCEDURE|Sham treatment|Light passive movement of the foot and ankle, avoiding the end-ranges which may actually elicit a mechanical change
219099600|NCT00006018|DRUG|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
219099601|NCT00006018|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
219099602|NCT03238300|DRUG|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
219099603|NCT03238300|DRUG|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
219099604|NCT01394874|BEHAVIORAL|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
219099605|NCT06327464|DIETARY_SUPPLEMENT|Exogenous ketones|Consumption of a single exogenous ketone supplement with breakfast
219099606|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus Placebo|15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
219099607|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus iron Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
219099608|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus zinc Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
219099609|NCT04073810|DIAGNOSTIC_TEST|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
219550448|NCT01956162|DEVICE|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
219550449|NCT01956162|DEVICE|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
219550450|NCT04406194|DRUG|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
219550451|NCT04406194|DRUG|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
219550452|NCT05196789|DIAGNOSTIC_TEST|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
219550453|NCT01941069|BEHAVIORAL|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
219099610|NCT04073810|DIAGNOSTIC_TEST|Coronary CT angiography|CTCA at baseline and 2 years
219099611|NCT04073810|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
219683923|NCT02716779|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
219683924|NCT02716779|DRUG|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
219683925|NCT02716779|DRUG|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
218985071|NCT06259721|DRUG|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
219683926|NCT00658892|BIOLOGICAL|B7-DC cross-linking antibody rHIgM12B7|
219683927|NCT00658892|OTHER|flow cytometry|
219683928|NCT00658892|OTHER|immunologic technique|
219683929|NCT00658892|OTHER|laboratory biomarker analysis|
219683930|NCT05524454|DEVICE|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
219683931|NCT01156805|OTHER|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
219683932|NCT02666001|DRUG|BMS-663068|BMS-663068
219683933|NCT02666001|DRUG|Methadone|Methadone
219683934|NCT02666001|DRUG|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
219683935|NCT02931786|DRUG|propofol|propofol, midazolam and atropine administration via intravenous cannula.
219099612|NCT06578936|OTHER|abdominal massage andwarm application|Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
219099613|NCT03011723|BEHAVIORAL|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
219099614|NCT03620630|DEVICE|myCOPD|myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
219683936|NCT02931786|DRUG|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
219683937|NCT00601315|DRUG|Clarithromycin|
219683938|NCT01843803|OTHER|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
219683939|NCT01843803|OTHER|attention control|Patients will view a brief healthy living video on an iPad
219683940|NCT03311841|DRUG|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
219683941|NCT03311841|DRUG|Dabigatran and pitavastatin oral solution|375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
219683942|NCT03311841|DRUG|Atorvastatin and rosuvastatin oral solution|100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
219683943|NCT03311841|DRUG|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
219683944|NCT04917614|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
219683945|NCT05205304|DRUG|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
219683946|NCT00107757|DRUG|GW685698X|
219683947|NCT03790852|DRUG|KSI-301|Intravitreal injection
219683948|NCT00985972|BEHAVIORAL|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
219683949|NCT05332314|DRUG|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
219683950|NCT01972412|BEHAVIORAL|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
219683951|NCT04734808|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
219683952|NCT04734808|DIAGNOSTIC_TEST|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
219683953|NCT03048669|OTHER|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
219683954|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
219683955|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
219099615|NCT01286441|DRUG|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
219099616|NCT01286441|DRUG|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
219099617|NCT01286441|DRUG|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
219099618|NCT01286441|DRUG|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
219099619|NCT01203670|DIETARY_SUPPLEMENT|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
219099620|NCT02101086|OTHER|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
219099621|NCT01435655|DRUG|tafamidis|tafamidis meglumine 20 mg QD
219099622|NCT03852043|BEHAVIORAL|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
219099623|NCT03852043|BEHAVIORAL|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
219099624|NCT05968014|PROCEDURE|PENG vs FICB|pericapsular nerve group block versus fascia iliaca compartment block
219099625|NCT04987632|DRUG|Letrozole|Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.
219099626|NCT04987632|DEVICE|acupuncture|Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.
219099627|NCT04987632|OTHER|Governor vessel moxibustion|It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation
219099628|NCT06022835|OTHER|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
219099629|NCT05446610|OTHER|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
218985072|NCT05697315|PROCEDURE|Control|No block was performed
219099630|NCT00887276|DRUG|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
218985073|NCT05697315|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
218985074|NCT01546207|PROCEDURE|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
218985075|NCT04475991|DRUG|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
219683956|NCT05719298|DEVICE|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
219683957|NCT06253533|BIOLOGICAL|ICVAX|ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
219683958|NCT06253533|OTHER|Placebo|Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
219550454|NCT01941069|BEHAVIORAL|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
218984798|NCT06673446|PROCEDURE|vestibular socket therapy|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra"
219550455|NCT02505035|BEHAVIORAL|Default ordering of palliative consult|
219550456|NCT01878435|OTHER|SMS reminder|
219550457|NCT01878435|OTHER|Travel subsidy|
219550458|NCT01878435|OTHER|Travel subsidy 2|
219550459|NCT04945096|DRUG|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
219550460|NCT04945096|DRUG|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
219550461|NCT04945096|DRUG|Semustine|Semustine: 250 mg/m2/day on day -9.
219550462|NCT04945096|DRUG|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
219550463|NCT04945096|DRUG|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
219550464|NCT04945096|DRUG|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
219550465|NCT04945096|DRUG|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
219550466|NCT04945096|DRUG|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
219550467|NCT04945096|DRUG|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
219550468|NCT00214864|DRUG|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
219550469|NCT03484234|DEVICE|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
219550470|NCT03484234|DEVICE|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
219550471|NCT02443285|DRUG|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
219550472|NCT02443285|DRUG|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
219683959|NCT04387461|BIOLOGICAL|CG0070|Engineered Oncolytic Adenovirus
219683960|NCT04387461|BIOLOGICAL|Pembrolizumab Injection|Immune checkpoint inhibitor, Monoclonal antibody
219683961|NCT04387461|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
219683962|NCT01324635|DRUG|Panobinostat|Given PO
219683963|NCT01324635|RADIATION|Stereotactic body radiation therapy|Undergo SBRT
219683964|NCT01324635|PROCEDURE|Quality-of-life assessment|Ancillary studies
219683965|NCT01324635|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
219683966|NCT05598749|DIETARY_SUPPLEMENT|Placebo|Arabic gum, sucrose and silicon dioxide mix
219683967|NCT05598749|DIETARY_SUPPLEMENT|Verum|Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
219683968|NCT04713930|DRUG|JNJ-61393215|JNJ-61393215 will be administered orally.
219683969|NCT04713930|DRUG|Placebo|Placebo will be administered orally.
219683970|NCT03339414|OTHER|collect blood|collect blood at different time point
219683971|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
219683972|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
219683973|NCT04028063|DRUG|Balstilimab|Balstilimab (AGEN2034) is a human monoclonal antibody that targets programmed cell death 1 (PD-1). Engagement of PD-1 by its ligands, programmed death ligand (PD-L1) and PD-L2, leads to signal transduction that inhibits important aspects of T cell function including proliferation, cytokine production and cytolytic activity. Balstilimab (AGEN2034) potently inhibits PD-1 binding to PD- L1 and PD- L2 and is intended to reverse the immunosuppressive effects of this signaling pathway in the context of tumor immuno-surveillance by T cells. Balstilimab (AGEN2034) is intended for development as a treatment for advanced malignancies as a single agent or in combinations.
219683974|NCT04028063|DRUG|Zalifrelimab|Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies.
219683975|NCT04028063|DRUG|Doxorubicin|Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
219683976|NCT04028063|DRUG|Botensilimab|Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
218984799|NCT07001605|DRUG|ketamine|after induction of anesthesia, patients will receive ketamine bolus of 0.5 mL/kg followed by continuous infusion of 0.12 mL/k/hr until the end of surgical procedure.
219683977|NCT04677530|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
219683978|NCT04677530|DRUG|Matching Placebo|Matching placebo will be administered orally.
219683979|NCT01693770|PROCEDURE|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
219683980|NCT06188325|DRUG|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
218984800|NCT07001605|OTHER|Erector Spinae Plane Block|after induction of anesthesia, patients will receive ultrasound guided ESPB. A total of 40 mL of 0.25% bupivacaine will be injected bilaterally at the level of transverse process opposing to the mid-point of the planned incision.
218984801|NCT07001605|OTHER|Wound infiltration|wound infiltration at the end of the surgery before the closure of fascia and subcutaneous tissues using a total of 20 ml of 0.25% bupivacaine
218984802|NCT05701033|OTHER|Access to heritage|Unmediated access to heritage sites for wellbeing
218984803|NCT06679413|DRUG|midazolam|Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
218984804|NCT06679413|DRUG|metformin|Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
219683981|NCT04631237|OTHER|Observational, no intervention|No intervention involved
219683982|NCT06387446|PROCEDURE|Valve transplant|Heart valves from an organ donor will be transplanted into recipient
219683983|NCT04110899|OTHER|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
219683984|NCT01674465|BIOLOGICAL|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
219683985|NCT03955159|DIETARY_SUPPLEMENT|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
219683986|NCT03138577|DIAGNOSTIC_TEST|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
219683987|NCT03138577|DRUG|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
219683988|NCT03138577|OTHER|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
219683989|NCT03140163|RADIATION|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
219683990|NCT03140163|RADIATION|CXR|Conventional chest radiograph
219683991|NCT01051817|DRUG|AIN457|infusion 10 mg/Kg
219683992|NCT01051817|DRUG|Placebo|infusion
219683993|NCT05728333|DRUG|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
219683994|NCT05728333|DRUG|Alteplase|Intravenous alteplase before endovascular thrombectomy.
219683995|NCT00826059|DEVICE|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
219683996|NCT00826059|DEVICE|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
219683997|NCT01026948|DRUG|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
219683998|NCT01026948|DEVICE|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
219683999|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
219684000|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
219684001|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
219099631|NCT00887276|DRUG|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
219684002|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
219684003|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
219099632|NCT06040996|BEHAVIORAL|Improving Parenting Skills adult ADHD (IPSA)|Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.
219684004|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
219684005|NCT05205200|DRUG|SHR-1316|PD-L1 antibody
219684006|NCT05205200|DRUG|SHR6390|CDK4/6 inhibitor
219684007|NCT05205200|DRUG|Nab paclitaxel|Albumin bound paclitaxel
219684008|NCT05205200|DRUG|SERD|Fulvestrant
219684009|NCT05205200|DRUG|AI|aromatase inhibitor
219684010|NCT00701792|PROCEDURE|liver transplantation|liver transplantation
219684011|NCT00701792|OTHER|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
219684012|NCT03155347|DRUG|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
219684013|NCT03155347|DRUG|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
219684014|NCT03155347|DRUG|Placebo Matched to MTX|Placebo matched to MTX.
219684015|NCT03155347|DRUG|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
218984805|NCT06679413|DRUG|bupropion|Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
218984806|NCT06679413|DRUG|fenfluramine HCl|Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
218984807|NCT04055948|BEHAVIORAL|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)
218984808|NCT04055948|BEHAVIORAL|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
219684016|NCT01951118|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
219684017|NCT04657263|OTHER|Vaccine coverage assessment|Vaccine coverage assessment
218985076|NCT04475991|PROCEDURE|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
218985077|NCT04475991|DRUG|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
219684018|NCT05324553|PROCEDURE|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
219684019|NCT05324553|DIAGNOSTIC_TEST|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
219684020|NCT05324553|DIAGNOSTIC_TEST|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
219684021|NCT06336057|BEHAVIORAL|Mentalization|complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
219684022|NCT05604404|OTHER|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
219684023|NCT05604404|OTHER|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
219684024|NCT05604404|OTHER|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
219684025|NCT06378203|OTHER|tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)|"A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system."
219684026|NCT05798156|DRUG|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
219684027|NCT05798156|DRUG|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
219684028|NCT05798156|DRUG|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
218984809|NCT06681883|BEHAVIORAL|Action group|"A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program."
218984810|NCT06139861|BEHAVIORAL|TranS-C|Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
219099633|NCT06040996|OTHER|Continued Routine Services|Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
219099634|NCT05325255|OTHER|Myofascial release of subscapularis|It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
219099635|NCT05325255|OTHER|Maitland mobilization|It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
219099636|NCT05325255|OTHER|Stretching exercises|It is the technique use to increase flexibility and range of motion of short and hypomobile structures
219099637|NCT05325255|OTHER|Cold pack|It is the application of cold to provide analgesic effects
219099638|NCT03926793|DRUG|GB002|GB002 low dose or high dose for inhalation
219099639|NCT03926793|DRUG|Placebo|Placebo for inhalation
219099640|NCT03926793|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 or Placebo delivery
219099641|NCT05020262|OTHER|CT Image reconstruction|Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
219099642|NCT01975220|DRUG|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
219099643|NCT01975220|DRUG|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
219223511|NCT05395234|BEHAVIORAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
219099644|NCT01975220|DRUG|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
219099645|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
219099646|NCT01975220|DRUG|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
219099647|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
219223512|NCT00676091|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
219099648|NCT02980926|DRUG|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
219223513|NCT00676091|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
219223514|NCT03358433|OTHER|Exercise|
219684029|NCT05798156|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
219684030|NCT01678664|DRUG|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
219684031|NCT01678664|DEVICE|embolization|2 sessions embolization with spheric particles
219684032|NCT01678664|DRUG|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
219684033|NCT05312970|DRUG|Varithena®|Varithena® (polidocanol injectable foam) 1%
219684034|NCT05312970|DEVICE|FDA-approved Endothermal Ablation (ETA) systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
219684035|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
219684036|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
219684037|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
219099649|NCT02980926|DRUG|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
219099650|NCT00003884|DRUG|zoledronic acid|
219099651|NCT00003884|PROCEDURE|quality-of-life assessment|
219099652|NCT00710632|OTHER|laboratory biomarker analysis|
219099653|NCT00710632|OTHER|physiologic testing|
219099654|NCT00710632|OTHER|questionnaire administration|
219684038|NCT01852513|DRUG|QNASL|
219684039|NCT01852513|DRUG|Placebo nasal spray|
219684040|NCT05886088|DRUG|LID104|Experimental
219684041|NCT05886088|DRUG|Dapagliflozin|Active comparator
219684042|NCT05886088|DRUG|Linagliptin|Active comparator
219684043|NCT00884078|OTHER|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
219684044|NCT00753675|DRUG|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219684045|NCT00753675|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219684046|NCT00753675|DRUG|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219684047|NCT00753675|DRUG|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
219684048|NCT06415019|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
219684049|NCT06415019|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
219684050|NCT06415019|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch.
219684051|NCT04478162|OTHER|Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.|At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
219684052|NCT01441128|DRUG|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
219684053|NCT01441128|DRUG|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
219684054|NCT03914274|DEVICE|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
219684055|NCT02529254|BEHAVIORAL|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
219684056|NCT03162185|DRUG|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
219684057|NCT03162185|DRUG|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
219684058|NCT02686164|DRUG|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
219684059|NCT02686164|DRUG|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
219684060|NCT02487797|DRUG|Oxytocin|
219684061|NCT02487797|OTHER|Sodium Chloride 0.9%|
219684062|NCT04819139|OTHER|Active Excersises|Active thumb exercises
219684063|NCT04819139|OTHER|Reeducation ADL|Reeducation in the activities daily life
219684064|NCT04819139|OTHER|Joint protection|Used of a thumb orthosis
219684065|NCT04819139|OTHER|Proprioception exercises|Specific proprioception exercises
219684066|NCT02824627|DRUG|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
219684067|NCT02824627|DRUG|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
219684068|NCT00672633|DRUG|Lovaza|Lovaza , 4 grams/day orally for 6 months
219684069|NCT00672633|DRUG|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
219684070|NCT05661695|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
219684071|NCT02797977|DRUG|SRA737, gemcitabine, cisplatin|
219684072|NCT02797977|DRUG|SRA737, gemcitabine|
218984811|NCT06139861|BEHAVIORAL|Psychoeducation|The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
218984812|NCT01072383|DRUG|BT061|administration of BT061 either intravenous or subcutaneous
218984813|NCT01072383|DRUG|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
218984814|NCT06681155|DIAGNOSTIC_TEST|Assessment of plaque morphology, structure, and stability in non-culprit lesions|Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
218984815|NCT06680960|OTHER|Trunk stabilisation exercises|This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.
218984816|NCT06680960|OTHER|Respiratory exercises|This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
218984817|NCT06706271|DRUG|Vitamin D|2000 IU of Vitamin D
218984818|NCT06708104|DEVICE|Outdoor horse-assisted perturbation training|This is balance training in which a special carriage, i.e. a dynamic standing platform, is pulled by a horse on the outside surface, providing the trainee with multi-directional 3D balance perturbations that depend on the topography of the training area (various slopes and surface types), the horse walking speed, and its ability to stop, accelerate, and turns.
218985078|NCT04475991|DRUG|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
218985079|NCT00020904|DRUG|ixabepilone|
219099655|NCT00710632|PROCEDURE|management of therapy complications|
219099656|NCT02839343|RADIATION|radiation therapy|
219099657|NCT02839343|PROCEDURE|surgery|
219684073|NCT05716685|OTHER|Health coaching|The intervention consisted of transferring the knowledge acquired on health coaching by the nurses of the cardiology unit to their care activity with CHF patients. To this end, all the nurses in the cardiology unit received two training packages: 1) five theoretical and practical sessions on health coaching competencies, emotional intelligence, communication and support for CHF patients in the hospital setting; and 2) training sessions 7 months after the first training package to reinforce the theoretical and practical knowledge acquired in health coaching. During this period, debriefing was carried out to provide feedback on the health coaching process with patients.
219684074|NCT00778791|DRUG|metformin HC1 750 mg extended-release tablets|
219684075|NCT02235129|OTHER|breath-holding|
219684076|NCT02775097|DEVICE|OCT|OCT for all Arms
218985080|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
219684077|NCT00929344|DRUG|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
219684078|NCT00929344|DRUG|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
219684079|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
219684080|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
218985081|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
218985082|NCT00724022|DRUG|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
218985083|NCT01394432|PROCEDURE|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
218985084|NCT05081154|OTHER|Product A|P1012915, a nicotine pouch with 8 mg nicotine
218985085|NCT05081154|OTHER|Product B|P1013018, a nicotine pouch with 10 mg nicotine
218985086|NCT05081154|OTHER|Product C|P1013015, a nicotine pouch with 8 mg nicotine
218985087|NCT05081154|OTHER|Product D|P1012815, a nicotine pouch with 8 mg nicotine
218985088|NCT05081154|OTHER|Product E|P1013315, a nicotine pouch with 8 mg nicotine
218985089|NCT05081154|OTHER|Product F|P1013115, a nicotine pouch with 8 mg nicotine
218985090|NCT05081154|OTHER|Product G|P1013215, a nicotine pouch with 8 mg nicotine
218985091|NCT01694472|BIOLOGICAL|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
218985092|NCT04194398|DEVICE|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
218985093|NCT00057317|DRUG|Ro 205-2349|
218985094|NCT05292443|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
218985095|NCT02555683|DRUG|QAW039|QAW039 150 mg once daily
218985096|NCT02555683|DRUG|QAW039|QAW039 450 mg once daily
218985097|NCT02555683|DRUG|Placebo|Placebo once daily
218985098|NCT02072018|DRUG|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
218985099|NCT02072018|DRUG|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
218985100|NCT00402415|DRUG|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
218985101|NCT00402415|DRUG|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
218985102|NCT05074667|DEVICE|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
218985103|NCT05074667|OTHER|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
218985104|NCT06136832|BEHAVIORAL|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
218985105|NCT06158373|OTHER|infant massage practice|infant massage practice
218985106|NCT06158373|OTHER|Safe Swaddling|Safe Swaddling
218985107|NCT06158373|OTHER|Control|Control
218985108|NCT03513328|DRUG|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
218985109|NCT03513328|DRUG|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
218985110|NCT01245660|DRUG|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
218985111|NCT02949037|OTHER|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
218985112|NCT00883805|BIOLOGICAL|Blood draw|Subjects will give blood for analysis of metal ion concentrations
218985113|NCT00883805|RADIATION|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
218985114|NCT03142087|OTHER|exercises|exercise
218985115|NCT04195087|DEVICE|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
218985116|NCT04942444|OTHER|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
219684081|NCT00929344|DRUG|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
218984819|NCT07049523|DEVICE|Robotic-assisted gait training|"The intervention group will receive robotic-assisted gait training using the RoboCT Pediatric Lower Limb Rehabilitation Robot (RoboCT Limited Co., Hangzhou, China), a pediatric exoskeleton system designed for overground locomotor training. This device integrates real-time motion sensing, adaptive control algorithms, and customizable joint actuation to deliver precise and individualized gait training for children with minimal voluntary motor control. The system allows for the modulation of key gait parameters including joint angles, step length, and walking speed, and incorporates both postural correction and dynamic support harnessing to maintain safety and alignment throughout the session.~Robotic sessions will be conducted three times per week over a period of 24 weeks, with each session lasting approximately 45 minutes. All sessions will be conducted at a designat"
218984820|NCT07053605|PROCEDURE|laparoscopic resection of splenic artery aneurysm with preservation of spleen|The laparoscopic resection of splenic artery aneurysm with preservation of spleen is performed by the same surgical team.
218984821|NCT00219739|DRUG|Imatinib mesylate 400 mg|
218984822|NCT00219739|DRUG|Imatinib mesylate 600 mg|
219684082|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
219684083|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
219684084|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
219684085|NCT00696735|PROCEDURE|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
219684086|NCT00696735|PROCEDURE|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
219684087|NCT03452956|OTHER|None-Observation Only|No intervention-this is an observational study
219684088|NCT04213092|PROCEDURE|ERCP+LC|Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
219684089|NCT04213092|PROCEDURE|OC+CBD|Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
218984823|NCT00219739|DRUG|Imatinib 400 mg + Peg-Interferon|
218984824|NCT00219739|DRUG|Imatinib mesylate 400 mg + Cytarabine|
218984825|NCT06680193|BEHAVIORAL|Processing of Positive Memories Technique|"PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination."
218984826|NCT06951191|DRUG|Benzocaine 20%|Benzocaine 20% topical spray
218984827|NCT06951191|DRUG|Lidocaine 2%|Lidocaine 2% injectable solution
218984828|NCT06951191|OTHER|Sham injection|Sham injection to mimic Lidocaine paracervical block. Will use an injection needle and sham inject (no actual injection of fluid)
218984829|NCT06951191|DRUG|Saline 0.9%|Saline spray to mimic use of benzocaine spray
218984830|NCT04833465|OTHER|No Intervention|No Intervention
218984831|NCT05123131|DRUG|Isatuximab|Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.
218984832|NCT05123131|DRUG|Bortezomib|Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.
218984833|NCT05123131|DRUG|Lenalidomide|Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 to \<60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.
219099658|NCT02839343|DRUG|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
219099659|NCT02839343|DRUG|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
219099660|NCT05878392|OTHER|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
219099661|NCT01774864|DRUG|DA-8159 (Udenafil)|
219099662|NCT01774864|DRUG|Placebo|
219099663|NCT01915576|DRUG|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
219099664|NCT01915576|DRUG|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
219099665|NCT01915576|DRUG|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
219099666|NCT05813067|DIETARY_SUPPLEMENT|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
219223515|NCT05063045|BEHAVIORAL|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
219223516|NCT03160521|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
219223517|NCT03160521|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
219223518|NCT03160521|DRUG|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
219223519|NCT02071043|DRUG|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
219684090|NCT04293497|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~1. conventional cytology staining method~2. new cytology staining method using antibody of methionyl-tRNA synthetase 1"
219684091|NCT02714010|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
219684092|NCT02714010|RADIATION|whole brain radiotherapy|30Gy/10F
219684093|NCT03967041|DIAGNOSTIC_TEST|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
219684094|NCT06442722|PROCEDURE|DDH with capsulorrhaphy|group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,
219684095|NCT06442722|PROCEDURE|DDH without capsulorrhaphy|group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
219684096|NCT01115777|OTHER|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
218984834|NCT05123131|DRUG|Dexamethasone (IV)|Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
218984835|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
218984836|NCT05222308|OTHER|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
218984837|NCT04189770|DEVICE|Accelerometer|Wear accelerometer
218984838|NCT04189770|OTHER|Ecological Momentary Assessment|Complete EMA questionnaire
218984839|NCT04189770|OTHER|Questionnaire Administration|Complete questionnaire
218984840|NCT04189770|OTHER|Survey Administration|Complete survey
218984841|NCT06812793|OTHER|Measurement of Core Muscle Endurance|Endurance of the flexor, extensor and lateral trunk muscles will be assessed using the McGill Trunk Endurance Tests.
218984842|NCT06812793|OTHER|Respiratory Muscle Strength|Inspiratory and expiratory muscle strength will be made with a portable, electronic intra-oral pressure measuring device.
218984843|NCT06812793|OTHER|Respiratory Muscle Endurance|Respiratory muscle endurance testing will be measured using an inspiratory muscle training device at increasing threshold load.
218984844|NCT06812793|OTHER|Peripheral Muscle Endurance|Peripheral muscle endurance will be assessed by performing 30 and 60 second sit-to-stand tests.
218984845|NCT06208865|PROCEDURE|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
218984846|NCT04680052|DRUG|tafasitamab|tafasitamab will be administered IV for 12 cycles
218984847|NCT04680052|DRUG|rituximab|Rituximab will be administered IV on cycles 1 - 5
218984848|NCT04680052|DRUG|lenalidomide|Lenalidomide will be administered PO for 12 cycles
218984849|NCT04680052|DRUG|placebo|placebo will be administered IV for 12 cycles
218984850|NCT06083038|DRUG|Alpelisib|Patients will receive standard of care alpelisib
218984851|NCT06083038|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
218984852|NCT05898971|OTHER|Robotic|Patients receive robotic training (grasp and grip)
218984853|NCT05898971|OTHER|Mirror|Patients receive mirror therapy
218984854|NCT01818921|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
218984855|NCT01818921|DRUG|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
218984856|NCT01818921|DRUG|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
218984857|NCT06292286|PROCEDURE|Carboplatin or cisplatin|Carboplatin of cisplatin for 3-6 cycles
218984858|NCT06292286|DRUG|Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar|Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
218984859|NCT06292286|DRUG|Bevacizumab or biosimilar|Optional
218984860|NCT06292286|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery after chemotherapy
218984861|NCT02204397|DRUG|INGAP Peptide, Ustekinumab|
219684097|NCT02477358|PROCEDURE|Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
219099667|NCT05813067|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
219099668|NCT04182711|DEVICE|Device|Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
219099669|NCT02009202|DRUG|polyethylene glycol|
219099670|NCT02009202|DRUG|picosulphate|
219099671|NCT04885933|DIAGNOSTIC_TEST|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
219099672|NCT00114361|DRUG|Ribavirin|1200 mg a day, 48 weeks
219099673|NCT00114361|DRUG|Peginterferon alpha 2a|180 µg per week, 48 weeks
219099674|NCT01576822|OTHER|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
219099675|NCT02434289|DIETARY_SUPPLEMENT|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
219099676|NCT02434289|OTHER|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
219099677|NCT04729894|OTHER|Medication Lockbox|Participants will receive a medication lockbox to store medications in their home.
219099678|NCT04729894|BEHAVIORAL|Education|Participants will receive information on safe medication storage practices.
219099679|NCT04104750|OTHER|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
219099680|NCT02000414|DRUG|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
219099681|NCT02249455|DEVICE|Acapella|Treatment time for 20 min twice daily
219099682|NCT02249455|OTHER|ELTGOL|ELTGOL technique 20 min twice daily
219099683|NCT02249455|OTHER|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
219684098|NCT02477358|PROCEDURE|Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
219684099|NCT01689441|DRUG|Calcitriol|
219684100|NCT01689441|DRUG|Placebo|
219684101|NCT02741375|DEVICE|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
219684102|NCT00571662|DRUG|Pentostatin|4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
219099684|NCT00180128|DRUG|all-trans retinoid acid|
219099685|NCT00180128|DRUG|idarubicin|
219099686|NCT00180128|DRUG|mitoxantrone|
219099687|NCT00180128|DRUG|daunorubicin|
219099688|NCT00180128|DRUG|cytarabine|
219099689|NCT01814059|DRUG|sirolimus|
219099690|NCT03490214|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
219099691|NCT03778034|OTHER|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
219099692|NCT03778034|OTHER|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
219684103|NCT00571662|RADIATION|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
219684104|NCT00571662|DRUG|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
219684105|NCT00571662|DRUG|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
219099693|NCT00755014|OTHER|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
219099694|NCT04465825|BEHAVIORAL|HITT: intermittent high intensity exercise|Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
219099695|NCT02296632|BEHAVIORAL|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
219099696|NCT01099514|DRUG|Nilotinib|D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
219099697|NCT03241602|DRUG|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
219223520|NCT02071043|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
219223521|NCT05481905|DRUG|ENX-101|Adjunctive treatment to current antiseizure medication
219223522|NCT02213146|DRUG|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
218984862|NCT04785521|RADIATION|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
219684106|NCT00571662|DRUG|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
219684107|NCT03134729|DRUG|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
219684108|NCT00970645|PROCEDURE|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
219684109|NCT00970645|PROCEDURE|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
219684110|NCT01839916|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
219684111|NCT01839916|OTHER|laboratory biomarker analysis|Correlative studies
219684112|NCT03471832|DEVICE|stenfilcon A lens|contact lens
219684113|NCT03471832|DEVICE|narafilcon A lens|contact lens
219684114|NCT01815502|DIAGNOSTIC_TEST|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
219684115|NCT01476800|DRUG|YM178 OCAS|oral
219684116|NCT01476800|DRUG|Ketoconazole|oral
218984863|NCT04785521|DIAGNOSTIC_TEST|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
218984864|NCT00730145|DRUG|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
218984865|NCT03813849|DIAGNOSTIC_TEST|Sonographic examination of uterus after surgical evacuation|
218984866|NCT06956170|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
218984867|NCT06956170|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
218984868|NCT06956170|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
218984869|NCT06956170|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
218984870|NCT01006096|DRUG|erlotinib|100mg tablet, once daily for 16 weeks
218984871|NCT01006096|OTHER|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
218984872|NCT05770856|DIAGNOSTIC_TEST|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
218984873|NCT00902915|DRUG|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
218984874|NCT05503615|OTHER|Observational|No application will be made to the control group.
218984875|NCT05503615|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
218984876|NCT05296512|DRUG|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
218984877|NCT05296512|DRUG|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
218984878|NCT01643356|BEHAVIORAL|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
218984879|NCT04432285|DEVICE|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
218984880|NCT04432285|DRUG|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
218984881|NCT02675283|DEVICE|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
218984882|NCT03400878|BIOLOGICAL|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
218984883|NCT03400878|BIOLOGICAL|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
218984884|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
218984885|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
218984886|NCT03064984|OTHER|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
218984887|NCT03064984|OTHER|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
218984888|NCT01968759|DRUG|Sevelamer|
218984889|NCT01968759|DRUG|Ramipril and Irbesartan|
218984890|NCT02990689|DEVICE|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
218984891|NCT02990689|DEVICE|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
218984892|NCT02990689|DEVICE|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
218984893|NCT00432419|PROCEDURE|autologous peripheral blood cell transplantation|
219099698|NCT03241602|PROCEDURE|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
219099699|NCT03241602|COMBINATION_PRODUCT|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
219099700|NCT02261584|DEVICE|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
219099701|NCT02261584|DEVICE|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
219099702|NCT01003925|BEHAVIORAL|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
219099703|NCT01003925|BEHAVIORAL|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
219099704|NCT01909414|BIOLOGICAL|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
219099705|NCT01909414|BIOLOGICAL|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.
219099706|NCT01909414|BIOLOGICAL|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
219099707|NCT01909414|BIOLOGICAL|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
219099708|NCT05461261|DRUG|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
219099709|NCT05461261|DRUG|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
219099710|NCT05461261|DRUG|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
219099711|NCT06451822|DEVICE|mIntense L+AS|The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
219099712|NCT01121198|DRUG|ASP1941|oral
219099713|NCT01121198|DRUG|placebo|oral
219099714|NCT00661661|DRUG|CP-690,550|5 mg BID up to 10 mg BID until launch
219223523|NCT02213146|DRUG|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
219684117|NCT05395156|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
219684118|NCT00843011|DRUG|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
219684119|NCT01060917|DEVICE|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
219684120|NCT01060917|PROCEDURE|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
219684121|NCT01060917|DEVICE|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
219684122|NCT00999622|OTHER|laboratory biomarker analysis|
219684123|NCT00999622|OTHER|questionnaire administration|
219099715|NCT00656318|OTHER|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
219099716|NCT01893827|DRUG|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
219099717|NCT01893827|DRUG|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
219099718|NCT01897701|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
219099719|NCT01897701|BIOLOGICAL|Adjuvant 1|
219099720|NCT01897701|BIOLOGICAL|Placebo|
219099721|NCT02740855|DEVICE|Alcomed 3011®|Endtidal ethanol measurement
219099722|NCT04064242|DRUG|CMK389|single i.v. dose every 4 weeks
219099723|NCT04064242|DRUG|Placebo|single i.v. dose every 4 weeks
219099724|NCT04211415|DRUG|DS-2741a|Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
219099725|NCT04211415|DRUG|Placebo|Single, subcutaneous injection administered weekly for 4 weeks
219099726|NCT02005315|DRUG|Vantictumab|Administered intravenous (IV) infusion.
219099727|NCT02005315|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
219099728|NCT02005315|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
219099729|NCT04182880|DRUG|CPL-01|CPL-01 will be administered
219099730|NCT04182880|DRUG|Placebo|Placebo will be administered
219223524|NCT02213146|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
219099731|NCT03389477|DRUG|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
219099732|NCT03389477|DRUG|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
219099733|NCT03389477|DRUG|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
219099734|NCT03389477|RADIATION|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
219684124|NCT00613392|DIETARY_SUPPLEMENT|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
219684125|NCT00613392|DIETARY_SUPPLEMENT|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
219099735|NCT03389477|PROCEDURE|Tumor biopsy|"* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
219099736|NCT03389477|PROCEDURE|Peripheral blood draw|Baseline and post-treatment
219099737|NCT06100510|DRUG|Aspirin 325mg|Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
219684126|NCT01330550|DIETARY_SUPPLEMENT|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
219684127|NCT02494895|DRUG|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
219684128|NCT02494895|DRUG|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
219684129|NCT04544059|DRUG|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
219684130|NCT02587195|DRUG|Teriflunomide|
219684131|NCT04235504|OTHER|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
219684132|NCT04235504|DEVICE|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
219684133|NCT06180161|BEHAVIORAL|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
219684134|NCT03168451|BEHAVIORAL|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
219684135|NCT04715282|PROCEDURE|Epley maneuver|Epley maneuver
219684136|NCT06503978|COMBINATION_PRODUCT|MTP-101P|MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.
219684137|NCT06503978|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 14 Days"
219684138|NCT06503978|COMBINATION_PRODUCT|Miralax|Miralax is a common over-the-counter laxative and bowel cleanse
219684139|NCT06503978|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12 weeks"
219684140|NCT06503978|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12 weeks"
219684141|NCT06503978|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 14 days"
219684142|NCT05454020|DRUG|XG004|XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
219684143|NCT05454020|DRUG|Placebo|Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
219684144|NCT05365815|BEHAVIORAL|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
219684145|NCT03460626|DRUG|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
219684146|NCT03460626|OTHER|Placebo|an odorless oil without any therapeutic effect
219223525|NCT00533494|BEHAVIORAL|physician feedback (A)|Feedback information to physicians
219223526|NCT03608293|DIAGNOSTIC_TEST|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
219684147|NCT00870467|BIOLOGICAL|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
219684148|NCT00870467|DRUG|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
219684149|NCT00870467|BIOLOGICAL|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
219684150|NCT00870467|BIOLOGICAL|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
219684151|NCT00167518|DRUG|Triamcinolone acetate|
219684152|NCT02340143|OTHER|Control|Marketed partially hydrolyzed cow's milk protein infant formula
219684153|NCT02340143|OTHER|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
219684154|NCT00181883|DRUG|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
219684155|NCT00101868|DEVICE|Discharge communication software|Computerized physician order entry software used by discharging physician
219684156|NCT00101868|OTHER|Usual care discharge process|Handwritten
219684157|NCT06376617|DEVICE|fibroptic bronchoscopy|take bal through fibrooptic bronchoscopy and send for stain and culcure
219684158|NCT02005237|BEHAVIORAL|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
219684159|NCT02986347|PROCEDURE|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
219684160|NCT02986347|PROCEDURE|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
218984894|NCT02095977|PROCEDURE|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
219223527|NCT06264583|OTHER|HDV screening|1\. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
219684161|NCT03876483|BEHAVIORAL|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
219684162|NCT01394341|DRUG|Liraglutide|Daily sc. injection, individual dosage
219684163|NCT02708797|OTHER|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
219684164|NCT02708797|OTHER|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
219684165|NCT04261647|OTHER|kinesio-taping techniques.|
219684166|NCT04261647|OTHER|Pelvic floor exercise|
219684167|NCT04261647|OTHER|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
219684168|NCT05495529|PROCEDURE|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
219684169|NCT01941199|DRUG|DA-1229|
219684170|NCT01941199|DRUG|metformin|
219684171|NCT01941199|DRUG|DA-1229 + metformin|
219684172|NCT00069823|DRUG|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
218985117|NCT01947582|DEVICE|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
218985118|NCT04070430|OTHER|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
218985119|NCT04070430|OTHER|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
218985120|NCT02949869|OTHER|Spinal Sonography|As described previously
219684173|NCT00069823|DRUG|Placebo proton pump inhibitor|Placebo proton pump inhibitor
219684174|NCT01034228|OTHER|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
218985121|NCT03098953|DRUG|Loteprednol Etabonate|one drop per eye for each eye
218985122|NCT01826604|DEVICE|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
218985123|NCT01826604|OTHER|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
219684175|NCT01034228|OTHER|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
219684176|NCT00683761|DRUG|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
219099738|NCT03536546|BEHAVIORAL|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
219099739|NCT03536546|BEHAVIORAL|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
219099740|NCT04044729|DRUG|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
219099741|NCT04044729|DRUG|Placebo|Placebo
219099742|NCT00142727|DRUG|Methadone|
219099743|NCT00142727|DRUG|Full opioid agonist|
219099744|NCT00142727|DRUG|Partial opioid agonist|
219099745|NCT00142727|DRUG|Opioid antagonist|
219099746|NCT04143841|DEVICE|Viveye OMNS treatment|The Viveye OMNS treatment ( \~30 min) will be applied once, during the treatment visit only
219099747|NCT04143841|DEVICE|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( \~30 min) will be applied once, during the treatment visit only
219099748|NCT03202381|DRUG|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
219099749|NCT03403426|DEVICE|Wingman Crossing Catheter|Endovascular CTO crossing
219099750|NCT04834310|DRUG|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
219099751|NCT04834310|DRUG|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
219099752|NCT04834310|OTHER|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
219099753|NCT05217238|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the rocuronium injection
219099754|NCT04482543|DRUG|Methotrexate|Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
219223528|NCT02736851|OTHER|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
219223529|NCT01701401|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
219684177|NCT04296578|DRUG|Abiraterone Acetate|Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
219684178|NCT04296578|DRUG|Sodium Selenite|11 mg tablets
219684179|NCT04296578|DRUG|Prednisone|SOC prednisone 5 mg PO twice daily
219684180|NCT01544647|OTHER|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
219684181|NCT01544647|OTHER|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
219684182|NCT05679245|DIAGNOSTIC_TEST|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
219684183|NCT06483906|DRUG|Venetoclax, Azacitidine and Homoharringtonine|Patients will receive the VAH regimen for the treatment of AML
219684184|NCT03560869|OTHER|Normal hydration|see description in 'arms'
219099755|NCT00909428|DRUG|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
219099756|NCT03021668|DEVICE|Prevena Peel & Place Dressing|Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
219099757|NCT03021668|OTHER|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
219684185|NCT03560869|OTHER|Dehydration|see description in 'arms'
219684186|NCT04072250|PROCEDURE|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
219684187|NCT01210482|DRUG|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
219684188|NCT06180148|DEVICE|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
219099758|NCT03904030|OTHER|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
219099759|NCT01920048|PROCEDURE|Percutaneous Coronary Intervention|
219099760|NCT01920048|DRUG|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
219223530|NCT01701401|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219684189|NCT04482088|BEHAVIORAL|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
219684190|NCT04482088|BEHAVIORAL|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
219099761|NCT01920048|DEVICE|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
219099762|NCT03791580|BEHAVIORAL|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
219223531|NCT00933270|DEVICE|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
219223532|NCT00989196|BIOLOGICAL|Human-cl rhFVIII|50 IU/kg for PK dose
219684191|NCT03284853|DRUG|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
219684192|NCT03284853|DRUG|GANFORT®|Topical sterile ophthalmic solution
219684193|NCT06283407|OTHER|ICF-based cross-country comparative analysis|ICF-based cross-country comparative analysis
219684194|NCT03905304|BIOLOGICAL|Medytoxin|Intramuscular injection up to 300U.
219684195|NCT03905304|BIOLOGICAL|Botox|Intramuscular injection up to 300U.
219684196|NCT02429570|DRUG|Meclofenamate|
219684197|NCT06611566|BEHAVIORAL|VR-guided aerobic exercise|The intervention was 5 minutes of VR-guided aerobic exercise
219223533|NCT00989196|BIOLOGICAL|Kogenate FS|50 IU/kg for PK dose
219223534|NCT01000805|DRUG|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
219223535|NCT01000805|DRUG|Placebo|Participants received placebo QD, po for 8 weeks.
219223536|NCT06106100|PROCEDURE|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
219684198|NCT06611566|BEHAVIORAL|VR-guided mindfulness exercise|The intervention was 5 minutes of VR-guided mindfulness exercise
219684199|NCT06611566|BEHAVIORAL|TV-guided aerobic exercises|The intervention was 5 minutes of TV-guided aerobic exercises
219684200|NCT06611566|BEHAVIORAL|TV-guided mindfulness exercises|The intervention was 5 minutes of VR-guided mindfulness exercises
219684201|NCT06147258|BEHAVIORAL|expressive writing|A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
219684202|NCT05076877|DRUG|Lazertinib|Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
219684203|NCT05076877|DRUG|Midazolam|Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
219684204|NCT05076877|DRUG|Rosuvastatin|Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
219684205|NCT05076877|DRUG|Metformin|Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
219684206|NCT03263715|DRUG|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
219684207|NCT03263715|DRUG|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
219684208|NCT03263715|DRUG|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
219223537|NCT06106100|PROCEDURE|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
219099763|NCT03791580|BEHAVIORAL|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
219099764|NCT01122381|DRUG|ethosuximide|ethosuximide (ESX)
219099765|NCT01122381|OTHER|placebo comparator|placebo
219099766|NCT00651053|DEVICE|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
219223538|NCT00755144|DEVICE|LCS Knee|Cementless total knee arthroplasty with LCS Knee
219099767|NCT02461095|OTHER|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
219099768|NCT02461095|OTHER|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
219099769|NCT02447289|DRUG|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
219099770|NCT02447289|DRUG|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
219684209|NCT05869071|DEVICE|Sensor analyzing software (own development)|A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
219684210|NCT05869071|DEVICE|Body plethysmograph|Body plethysmograph measures specific airway resistance
219099771|NCT02447289|DRUG|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
219099772|NCT02447289|DRUG|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
219099773|NCT02217280|DRUG|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
219099774|NCT00554008|PROCEDURE|laparoscopic appendectomy|appendix removal via scope
219099775|NCT00554008|PROCEDURE|open appendectomy|open operation for removal of appendix
219099776|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
219684211|NCT05570552|BEHAVIORAL|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
219684212|NCT05801861|DEVICE|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
219099777|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
219099778|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
219099779|NCT02515565|DRUG|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
219099780|NCT02515565|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
219099781|NCT04781361|DRUG|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
219223539|NCT00755144|DEVICE|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
219223540|NCT00005974|DRUG|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
219099782|NCT04781361|DRUG|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L"
219099783|NCT02380222|OTHER|Interview|Single interview lasting approximately one hour
219223541|NCT06666543|OTHER|Questionary|"The questionnaire will address the following topics for each child who is not infected with HIV and was born to an infected mother at the time of birth:~* Pregnancy progression~* Immediate postpartum course~* Medical development of the child from 0 to 3 years~* Medical development of the child from 3 to a maximum of 15 years"
219223542|NCT02223923|DRUG|AZD6738|
219223543|NCT02223923|RADIATION|Palliative radiotherapy|
219223544|NCT00266448|DRUG|Chlorhexidine solution 4%|
219684213|NCT05801861|DEVICE|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
219684214|NCT05801861|DEVICE|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219684215|NCT05801861|DEVICE|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
218984895|NCT02095977|PROCEDURE|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
218984896|NCT02095977|PROCEDURE|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
219684216|NCT02915172|DRUG|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
219684217|NCT02915172|DRUG|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
218984897|NCT05112471|DEVICE|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
219684218|NCT02855775|OTHER|additional blood sample|blood sample every 3 weeks
219684219|NCT01845597|PROCEDURE|MAKOplasty® medial UKA|A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
219684220|NCT05927077|PROCEDURE|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
219684221|NCT04403113|OTHER|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
219684222|NCT04403113|OTHER|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
218984898|NCT05112471|DEVICE|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
218984899|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
219099784|NCT02582138|OTHER|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~* a daily total energy intake of 25-30 kcal/kg body weight;~* an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
219099785|NCT02582138|OTHER|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
219684223|NCT04403113|OTHER|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
219684224|NCT02581488|BIOLOGICAL|Santyl|
219684225|NCT02581488|OTHER|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
219684226|NCT01302418|DEVICE|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
219684227|NCT06212986|DEVICE|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
219684228|NCT05681013|BEHAVIORAL|Laughter Therapy|The effect of the Laughter Therapy on nursing students
219684229|NCT00230334|DRUG|Gleevec|
219684230|NCT04754646|DEVICE|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
219684231|NCT04754646|DEVICE|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
219684232|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
219684233|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
219684234|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
219684235|NCT01214889|BIOLOGICAL|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
219684236|NCT01214889|BIOLOGICAL|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
218984900|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
218984901|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
218984902|NCT02400333|DRUG|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
218984903|NCT03646318|DRUG|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
218984904|NCT03646318|OTHER|Placebo|Glucose 5% solution
219684237|NCT06046677|OTHER|No intervention|No intervention
219684238|NCT00657800|BEHAVIORAL|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
219684239|NCT01842269|DRUG|Mycophenolate Mofetil 500mg|
219684240|NCT01842269|DRUG|Mycophenolate Mofetil 250mg|
218984905|NCT06385639|DIETARY_SUPPLEMENT|Probiotic|This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
219223545|NCT03685071|OTHER|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~* patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~* correlation between the outcome and CBC will be done."
219223546|NCT04840433|DEVICE|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
219684241|NCT00377637|DRUG|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
219684242|NCT00377637|DRUG|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3."
219684243|NCT00377637|DRUG|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
219684244|NCT00377637|DRUG|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
219684245|NCT00377637|DRUG|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
219684246|NCT00377637|DRUG|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
219684247|NCT06435975|OTHER|Physical Activity|Participants will perform a baseline +4000 steps/day for the duration of the study. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
219684248|NCT06435975|OTHER|Survey|Participants will complete a series of survey at multiple points throughout this study to assess quality of life issues. Questionnaires may be completed via paper forms with prepaid postage envelopes or using a REDCap online survey.
219684249|NCT06435975|BEHAVIORAL|Telehealth Lifestyle Coaching|Participants will meet with a health coach, the Principal Investigator, to review baseline bowel habits and symptoms as well as discuss physical activity and potential strategies to achieve this goal, on a weekly basis for 12 weeks.
219684250|NCT00735345|DRUG|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
219684251|NCT00735345|DRUG|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
219684252|NCT00735345|DRUG|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
219684253|NCT00735345|BIOLOGICAL|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
219684254|NCT00735345|RADIATION|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
219684255|NCT01759953|OTHER|Game|InsuOnline game, on the web, in the player´s own time and rhythm
219684256|NCT01759953|OTHER|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
219684257|NCT02029131|BEHAVIORAL|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
219684258|NCT06465472|DRUG|Stiripentol Oral Capsule|The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
219684259|NCT06465472|DRUG|Placebo Oral Capsule|Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
219684260|NCT06465472|BIOLOGICAL|Urine samples collect|Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
219099786|NCT04798443|PROCEDURE|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
219099787|NCT04798443|PROCEDURE|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
219099788|NCT04567511|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
219099789|NCT01057784|PROCEDURE|Bariatric surgery.|Bariatric Surgery
219099790|NCT03829163|DEVICE|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
219099791|NCT03829163|DEVICE|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
219099792|NCT01705743|DRUG|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
219684261|NCT06465472|BIOLOGICAL|Blood samples collect|Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
219684262|NCT06465472|OTHER|Kidney imaging|Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
218984906|NCT02145780|DIETARY_SUPPLEMENT|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
218984907|NCT02145780|DIETARY_SUPPLEMENT|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
218984908|NCT00956020|BIOLOGICAL|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
218984909|NCT04460638|BIOLOGICAL|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
218984910|NCT04460638|OTHER|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
218984911|NCT00962910|OTHER|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
218984912|NCT03924453|DIAGNOSTIC_TEST|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
218984913|NCT05036824|DRUG|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
218984914|NCT01332500|DRUG|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
218984915|NCT01332500|DRUG|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
218984916|NCT05343598|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
218984917|NCT05343598|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
218984918|NCT01866696|DEVICE|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up"
218984919|NCT05572320|DIAGNOSTIC_TEST|Platelet Aggregometry Testing|1.6 ml of blood collected in hirudin-coated tubes before the surgery
219099793|NCT01705743|DRUG|Sevoflurane|100% oxygen+ Sevoflurane
219099794|NCT02833688|DRUG|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
219099795|NCT02833688|DRUG|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
219099796|NCT05514080|OTHER|Insulin closed-loop|41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
219099797|NCT01905644|PROCEDURE|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
219223547|NCT05753176|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
219223548|NCT04491292|OTHER|Questionnaire Administration|Complete questionnaires
219684263|NCT06465472|OTHER|Quality of Life questionnaires|"Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available."
219684264|NCT02799563|OTHER|Coach, Preselected number of cases|
219684265|NCT02799563|OTHER|Coach, Self-selected number of cases|
219684266|NCT02799563|OTHER|No coach, Preselected number of cases|
219684267|NCT02799563|OTHER|No coach, Self-selected number of cases|
219684268|NCT03243825|RADIATION|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
219684269|NCT03243825|DRUG|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
219684270|NCT03141190|BEHAVIORAL|Mindfulness Based Stress Reduction - modified|already described
219684271|NCT03141190|BEHAVIORAL|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
219684272|NCT03414333|PROCEDURE|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
219684273|NCT03414333|DRUG|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
219684274|NCT01601769|DEVICE|Vitom|Patients treated and diagnosed by vitom
219684275|NCT01601769|DEVICE|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
219684276|NCT04571047|OTHER|Time to treatment|Treatment before or after 4 weeks after diagnosis
219684277|NCT00017641|DRUG|anti-thymocyte globulin|
219684278|NCT00017641|DRUG|cyclophosphamide|
219684279|NCT00017641|DRUG|filgrastim|
219684280|NCT00017641|PROCEDURE|CD34+ Peripheral Blood Stem Cell Reinfusion|
219684281|NCT02070510|DRUG|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
219684282|NCT02070510|DRUG|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
219099798|NCT03661502|DEVICE|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
219099799|NCT03661502|DEVICE|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
219684283|NCT02070510|DRUG|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
219684284|NCT02070510|DRUG|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
219684285|NCT02589080|BEHAVIORAL|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
219684286|NCT00036088|DRUG|Olanzapine|
219684287|NCT04632277|OTHER|Water|Participants will receive a tab water
219099800|NCT01771393|DEVICE|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
219099801|NCT01771393|DEVICE|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
219099802|NCT03474549|DEVICE|Tigertriever revascularization device|Mechanical Thrombectomy
219099803|NCT03988075|OTHER|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
219099804|NCT03988075|OTHER|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
219099805|NCT01988272|DEVICE|SPECT/CT imaging|Patients will undergo scanning on the above system.
219099806|NCT06139068|OTHER|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.
219099807|NCT06139068|OTHER|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
219223549|NCT06977828|DRUG|tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy|After receiving 4 cycles of tislelizumab combined with anlotinib and platinum-based doublet chemotherapy, the subjects will be evaluated by a multidisciplinary team (MDT) to determine whether to proceed with radical surgical resection. The surgery will be performed within 3 to 7 weeks after the last neoadjuvant treatment. Postoperatively, patients will be divided into two subgroups based on the pathological results: For patients with postoperative pathological pCR, tislelizumab monotherapy will be used for maintenance treatment; For patients with postoperative pathological non-pCR, tislelizumab combined with anlotinib will be used for maintenance treatment. Both groups will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor therapy, death, or other situations specified in the protocol that require treatment cessation, whichever occurs first. The maximum treatment duration is 12 months
219223550|NCT05250206|OTHER|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
219223551|NCT04986475|OTHER|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
219099808|NCT02262546|DRUG|Pramipexole extended-release (ER) tablets|
219099809|NCT02262546|DRUG|Pramipexole immediate-release (IR) tablets|
219099810|NCT02262546|DRUG|Moxifloxacin|
219099811|NCT02262546|DRUG|Pramipexole Placebo|
219684288|NCT04632277|DIETARY_SUPPLEMENT|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
219223552|NCT05519852|BEHAVIORAL|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
219223553|NCT06587919|DEVICE|Neurofeedback|EEG-based neurofeedback, administered with the Neuroguide software.
219223554|NCT06605053|BEHAVIORAL|Co-produced intervention to optimize PMTCT care engagement|While the specific interventions package will developed earlier in the project, it may include evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. Overall, the interventions should be brief and easy to integrate into standard care, aiming to 'nudge' or motivate participants (towards improved engagement, retention, and outcomes) as well as health care providers or community stakeholders to better understand and support girls/young women\&#39;s specific needs. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
219684289|NCT04632277|DIETARY_SUPPLEMENT|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
219684290|NCT05763810|OTHER|Erector Spinae Plane Block|Erector Spinae Plane Block
219684291|NCT05763810|OTHER|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
219684292|NCT03560011|DRUG|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
219684293|NCT02487537|DIETARY_SUPPLEMENT|custom-made soft drink|
219099812|NCT02262546|DRUG|Moxifloxacin Placebo|
219099813|NCT02442843|DEVICE|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
219099814|NCT02442843|DEVICE|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
219099815|NCT03680625|DEVICE|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
219223555|NCT06586398|DEVICE|rTMS|Participants will be randomized to 15 sessions of double-blind multi-target rTMS treatment (active vs sham) and then will receive only open-label active stimulation for another 15 sessions. Each session will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).
219223556|NCT03476798|DRUG|Rucaparib|Rucaparib 600mg PO BID daily
219684294|NCT02403011|OTHER|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
219684295|NCT02403011|OTHER|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
219684296|NCT06010797|DEVICE|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
219684297|NCT01254656|DRUG|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
219684298|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
219684299|NCT01254656|DRUG|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
219684300|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
219684301|NCT01254656|DRUG|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
219684302|NCT01254656|DRUG|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
219684303|NCT05352932|DIAGNOSTIC_TEST|pancreatic duct biopsy|"Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination."
219684304|NCT05502952|DRUG|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
219684305|NCT03795337|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
219684306|NCT00814138|DRUG|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
219684307|NCT00814138|OTHER|Placebo|Weekly
218984920|NCT02280304|BEHAVIORAL|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
218984921|NCT02280304|BEHAVIORAL|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
218984922|NCT05846074|DIAGNOSTIC_TEST|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
218984923|NCT04967144|DIAGNOSTIC_TEST|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
218984924|NCT04967144|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
218984925|NCT00488462|DEVICE|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
218984926|NCT04966624|PROCEDURE|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
218984927|NCT04966624|PROCEDURE|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
218984928|NCT03200405|DEVICE|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
218984929|NCT03200405|DEVICE|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
218984930|NCT01354340|DIETARY_SUPPLEMENT|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
218984931|NCT01354340|DIETARY_SUPPLEMENT|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
218984932|NCT01354340|OTHER|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
218984933|NCT00185939|DRUG|Augmentin|
219684308|NCT05364476|BEHAVIORAL|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
219684309|NCT02381678|DEVICE|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
219684310|NCT01407991|OTHER|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
219684311|NCT01407991|OTHER|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
219223557|NCT03476798|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
219223558|NCT06855706|BEHAVIORAL|Behavioral Intervention|Receive personalized PA goals and positive feedback
218984934|NCT01148472|DRUG|Escitalopram|20mg once daily; orally
218984935|NCT01148472|DRUG|Duloxetine|60mg once daily; orally
218984936|NCT03967652|DIAGNOSTIC_TEST|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
218984937|NCT00874107|BIOLOGICAL|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
218984938|NCT00874107|BIOLOGICAL|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
218984939|NCT00874107|DRUG|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
218984940|NCT00874107|DRUG|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
218984941|NCT05420597|DRUG|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
218984942|NCT06240871|OTHER|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
218984943|NCT00539656|BIOLOGICAL|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
218984944|NCT06350396|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
218984945|NCT06350396|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
218984946|NCT00313261|DRUG|Clevudine|
218984947|NCT01431170|DRUG|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
218984948|NCT01431170|DRUG|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
218984949|NCT04987775|DRUG|N-Acetyl Cysteine|900mg 2x daily
218984950|NCT04987775|DRUG|Placebo|Matching placebo bid
218984951|NCT00353665|DRUG|Memantine (Ebixa)|10 mg bid
218984952|NCT00353665|DRUG|riluzole|riluzole 50 mg bid
218984953|NCT00353665|DRUG|Placebo|
218984954|NCT06139965|OTHER|Validity and Reliability|Assessment study
218984955|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
218984956|NCT00934089|DRUG|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
218984957|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
218984958|NCT00934089|DRUG|latanoprost|Topical ocular solution, once-daily for 14 days
218984959|NCT00003473|DRUG|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
218984960|NCT00003473|DRUG|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
218984961|NCT03352297|BIOLOGICAL|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
219099816|NCT03680625|DEVICE|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
219099817|NCT04369001|BEHAVIORAL|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
219099818|NCT04369001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
219099819|NCT02355613|RADIATION|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
219099820|NCT02355613|RADIATION|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
219223559|NCT06855706|OTHER|Best Practice|Receive general PA counseling
219223560|NCT06855706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219684312|NCT02196857|DRUG|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
219684313|NCT02196857|DRUG|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
219684314|NCT00712257|DEVICE|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
219684315|NCT05636813|OTHER|Training|Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
219684316|NCT02336867|DEVICE|Closure clip (OTSC® Proctology)|
219684317|NCT01749410|BIOLOGICAL|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
219684318|NCT00346957|DRUG|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
219684319|NCT00346957|DRUG|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
219684320|NCT00346957|DRUG|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
219684321|NCT00346957|OTHER|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
219684322|NCT02534597|BEHAVIORAL|Promotores Training|
219684323|NCT02534597|BEHAVIORAL|Delayed Promotores training|
219684324|NCT02534597|BEHAVIORAL|Caregiver training|
219684325|NCT02534597|BEHAVIORAL|Delayed caregiver training|
219684326|NCT02534597|BEHAVIORAL|Materials support|
219684327|NCT02534597|BEHAVIORAL|Delayed materials support|
219684328|NCT02534597|BEHAVIORAL|Technical assistance|
219684329|NCT02534597|BEHAVIORAL|Delayed technical assistance|
219684330|NCT00583908|DEVICE|senofilcon A|toric contact lens
219684331|NCT00583908|DEVICE|balafilcon A toric|toric contact lens
219684332|NCT00583908|DEVICE|lotrafilcon B toric|toric contact lens
219684333|NCT00583908|DEVICE|omafilcon A|toric contact lens
219684334|NCT05591157|DEVICE|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
219684335|NCT00027885|BIOLOGICAL|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
219684336|NCT00027885|DRUG|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
219684337|NCT00027885|DRUG|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
219684338|NCT00027885|DRUG|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
219099821|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
219684339|NCT00027885|PROCEDURE|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
219684340|NCT00027885|PROCEDURE|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
219684341|NCT00027885|PROCEDURE|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
219684342|NCT00027885|RADIATION|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
219684343|NCT02037815|DRUG|20% mannitol solution, 125 ml, IV infusion in 15 min|
219684344|NCT02037815|DRUG|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
219684345|NCT04678843|BEHAVIORAL|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
219684346|NCT01253096|DRUG|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
219684347|NCT02664012|OTHER|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
219684348|NCT02664012|OTHER|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
219684349|NCT02664012|OTHER|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
219684350|NCT02664012|OTHER|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
219684351|NCT02664012|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
219684352|NCT05713357|PROCEDURE|Catheter ablation|Endocardial catheter ablation
219684353|NCT06049446|DEVICE|Pintuition|Magnetic seed localization
219684354|NCT05270980|OTHER|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
218984962|NCT01842321|DRUG|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
218984963|NCT02982668|OTHER|Initial enteral feeding|
218984964|NCT02982668|DRUG|metoclopramide or mosapride|gastrointestinal (GI) motility improving
218984965|NCT03416725|DEVICE|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
218984966|NCT03717818|BEHAVIORAL|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
218984967|NCT03717818|BEHAVIORAL|treatment as usual|non-specific intervention
218984968|NCT00666172|BEHAVIORAL|Exercise|
218984969|NCT00666172|BEHAVIORAL|Weight Loss|
218984970|NCT01171430|DEVICE|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
218984971|NCT05607615|DRUG|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
218984972|NCT05607615|DRUG|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
218984973|NCT02846584|BIOLOGICAL|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
218984974|NCT03625622|DRUG|AR1001|AR1001 Active Oral Tablet
218984975|NCT03625622|DRUG|Placebo|Placebo Oral Tablet
218984976|NCT03190590|PROCEDURE|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
218984977|NCT03190590|PROCEDURE|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
218984978|NCT03190590|PROCEDURE|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
219099822|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
219684355|NCT03131284|BEHAVIORAL|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
219684356|NCT05946200|PROCEDURE|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
219684357|NCT03072667|DRUG|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
219684358|NCT05897866|PROCEDURE|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
219684359|NCT02879955|OTHER|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
219684360|NCT02879955|OTHER|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
219684361|NCT02879955|OTHER|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
219684362|NCT02879955|OTHER|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
219684363|NCT05722717|GENETIC|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
219684364|NCT04354415|PROCEDURE|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
219684365|NCT02248064|DEVICE|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
219684366|NCT02942069|BEHAVIORAL|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
219684367|NCT01116037|DEVICE|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
219684368|NCT03452462|DEVICE|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
219684369|NCT00890448|OTHER|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
219099823|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
219099824|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
219099825|NCT00020553|PROCEDURE|psychosocial assessment and care|
219099826|NCT00270361|DRUG|nesiritide|
219684370|NCT05952921|OTHER|Mouthwash|Concentration rinse with 0.05% HOCl
219684371|NCT05952921|OTHER|Chlorhexidine|A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
219684372|NCT02351401|BEHAVIORAL|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
219684373|NCT03297229|BEHAVIORAL|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
219684374|NCT03297229|BEHAVIORAL|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
219099827|NCT00270361|DRUG|usual long term cardiac medications|
219099828|NCT00270361|DRUG|nesiritide|
219099829|NCT03584620|OTHER|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
219223561|NCT06855706|OTHER|Electronic Health Record Review|Ancillary studies
219223562|NCT06855706|OTHER|Exercise Intervention|Participate in MVPA
219223563|NCT06855706|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit Sense 2 and CGM device
219223564|NCT06855706|OTHER|Questionnaire Administration|Ancillary studies
219223565|NCT06855706|OTHER|Supportive Care|Receive ongoing support
219684375|NCT05194345|BEHAVIORAL|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
219099830|NCT03584620|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
219099831|NCT06113848|DRUG|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
219099832|NCT06113848|DRUG|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
219099833|NCT06113848|DRUG|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
219099834|NCT06113848|OTHER|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
219099835|NCT01620567|OTHER|avocado|1 avocado/day for 6 months
219099836|NCT01620567|OTHER|potato or chickpea|1 cup potatoes or chickpeas/day for 6 months
219099837|NCT03445065|DEVICE|Eversense XL CGM System|The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
219099838|NCT03445065|DEVICE|Usual SMBG or FGM device used by participants|Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
219099839|NCT03315130|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
219099840|NCT03315130|DRUG|Placebo|Daily subcutaneous (SC) injection
219684376|NCT05194345|BEHAVIORAL|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
219684377|NCT02266823|BEHAVIORAL|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
219684378|NCT04987463|DRUG|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
219684379|NCT04987463|DRUG|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
219684380|NCT04987463|DRUG|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
219684381|NCT04987463|DRUG|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
219684382|NCT03870334|DRUG|BT-11 880 mg|Oral once daily tablet
219684383|NCT03870334|DRUG|Placebo|Oral once daily tablet
219099841|NCT00036998|PROCEDURE|conventional surgery|
219099842|NCT00036998|PROCEDURE|neoadjuvant therapy|
219099843|NCT00036998|PROCEDURE|thermal ablation therapy|
219099844|NCT03007654|DEVICE|Mediclore|apply medical device fully around intrauterine surgery area
219099845|NCT03007654|DEVICE|Adept|apply medical device fully around intrauterine surgery area
219099846|NCT00212498|PROCEDURE|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
219099847|NCT03540914|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219099848|NCT03540914|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219223566|NCT05950672|BEHAVIORAL|CAT Intervention Group|The experimental group will take part in the CAT intervention after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
219684384|NCT04388410|BIOLOGICAL|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
219684385|NCT00887614|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
219684386|NCT03967288|DRUG|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
219684387|NCT03967288|DRUG|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
219099849|NCT06361472|OTHER|Standard Care|Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).
219684388|NCT00848757|BEHAVIORAL|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
219099850|NCT06361472|BEHAVIORAL|Contextual Factors|Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
219223567|NCT04927494|BEHAVIORAL|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
219099851|NCT06858566|OTHER|Kaligo + score|The Kaligo + Score will be taken twice a week during baseline and intervention and once a week during follow-up.
219223568|NCT06016088|DRUG|RSP-1502|RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
219223569|NCT06016088|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
219223570|NCT06151782|DIETARY_SUPPLEMENT|Wheat gluten 1000 mg|Nothing to add here
219223571|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 1000 mg|Nothing to add here
219223572|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 50 mg|Nothing to add here
219223573|NCT06151782|DIETARY_SUPPLEMENT|Barley hydrolyzed gluten 50 mg|Nothing to add here
219223574|NCT06151782|DIETARY_SUPPLEMENT|Placebo slurry|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
219223575|NCT05882695|DRUG|SPG302|synthetic small molecule
219223576|NCT05882695|DRUG|Placebo|Placebo
219223577|NCT06981078|DRUG|Verekitug|Verekitug (UPB-101) formulated solution
219223578|NCT06981078|OTHER|Placebo|Matching Placebo to Verekitug (UPB-101)
219223579|NCT06602999|OTHER|Nutritional Intervention|Receive a booklet on nutrition and physical activity for cancer survivors
219223580|NCT06602999|OTHER|Instacart Voucher|Receive Instacart grocery delivery voucher
219223581|NCT06602999|BEHAVIORAL|Telephone-Based Intervention|Receive nutrition navigation phone calls
219223582|NCT06841289|COMBINATION_PRODUCT|Pediatric Invasive Pictorial Shield (PIPS)|It is a device used to distract children during clinical procedures (blood sampling, invasive procedures, etc.) by making them feel less pain, stress and fear. It is an 18x15 cm 3D printed device designed to be worn around the upper arm, above the elbow, and used to hide the procedure from view and attract the child's attention with stickers printed on one side. The device is fixed on the child's arm by means of a tourniquet that can be interchangeably attached. The child asked questions about the pictures related to the stickers to distract his/her attention from the procedure. While answering these questions, the child will not see the procedures and will pay attention to the pictures, while the procedural procedure (such as blood sampling, intravenous intervention) will be performed. For the children in this group, the pain, fear will be scored 1 minute before, during and 1 minute after the blood collection procedure.
219223583|NCT06841289|BEHAVIORAL|Distraction cards|Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns can only seen by the child if he/she looks carefully. During the procedure, the child is expected to focus on the cards and answerabout the pictures and shapes on the cards. In this study, 5X8 cm cards with various pictures and shapes will be used.
219223584|NCT06841172|RADIATION|radiotherapy|Radiotherapy (Biologically Equivalent Dose \[BED\]≥60Gy)
219684389|NCT05775601|DRUG|18F-LY3950321|3 millicuries (±1 mCi)
219684390|NCT05775601|PROCEDURE|PET Scan|positron emission tomography (PET) scan
219684391|NCT00488423|PROCEDURE|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
219223585|NCT06841172|DRUG|Systemic therapy (Continuation of current first-line systemic therapy)|Continuation of current first-line systemic therapy, which may include, but is not limited to, combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at the discretion of the treating physician.
219223586|NCT06841172|DRUG|Systemic therapy (Early switch to second-line systemic therapy)|For patients who received sorafenib as FLST, regorafenib will be the preferred second-line option. For patients who received other FLST regimens, the SLST selection will be determined through an MDT discussion led by the treating physician based on the patient's overall condition, prior therapies, drug indications, and potential adverse effects, ensuring an individualized treatment approach. The specific dosing regimen, administration frequency, and dose adjustments will strictly follow the same prescribing information for each drug.
219099852|NCT05335382|BEHAVIORAL|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
219099853|NCT05335382|BEHAVIORAL|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
219099854|NCT00278070|DRUG|vinorelbine oral formulation|Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
219099855|NCT02089230|DRUG|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
219099856|NCT01921816|DEVICE|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
219223587|NCT06842121|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 hours (h)
219684392|NCT02447445|PROCEDURE|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men \< 27 kg and women \<16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
219099857|NCT00686140|DRUG|celecoxib|400mg/day, twice a day, 12 weeks
219099858|NCT00686140|DRUG|Placebo|twice a day, 12 weeks
219684393|NCT01361750|PROCEDURE|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
219684394|NCT02479659|OTHER|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
219684395|NCT02479659|OTHER|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
219099859|NCT06619691|OTHER|Fine motor skills|Only intervention
219099860|NCT05465161|DEVICE|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
219223588|NCT06842121|DRUG|Sodium Phosphates Injection|Inorganic phosphate (NaP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 h
219223589|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
219223590|NCT06515301|BEHAVIORAL|Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.|Information already available
219684396|NCT02479659|OTHER|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
219223591|NCT05460741|OTHER|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
219684397|NCT02479659|OTHER|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
219684398|NCT02479659|OTHER|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
219684399|NCT03718390|DRUG|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
219684400|NCT03718390|DRUG|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
219223592|NCT05460741|OTHER|educational program|educational program related to menstrual cycle will be given to females.
219223593|NCT05678231|DEVICE|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
219223594|NCT06609187|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
219223595|NCT06857968|BEHAVIORAL|Mobile Mindfulness Training|Participants will be instructed to complete a mobile application-based mindfulness training daily for 30 days.
219684401|NCT03718390|DRUG|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
219684402|NCT03718390|DRUG|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
219684403|NCT03718390|DRUG|Formulation E|Placebo Capsule containing microcrystalline cellulose
219684404|NCT03718390|PROCEDURE|Endoscopy|Endoscopy at 2 hours post dosing
219684405|NCT03718390|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
219684406|NCT03534661|DRUG|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
219684407|NCT03534661|DRUG|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
219684408|NCT03534661|DRUG|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
219684409|NCT03472638|DEVICE|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
219684410|NCT01769677|DRUG|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
219684411|NCT05022277|BEHAVIORAL|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
219684412|NCT05022277|BEHAVIORAL|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
219684413|NCT04064112|PROCEDURE|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
219684414|NCT04064112|PROCEDURE|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
219684415|NCT04986241|DRUG|Statin|Chronic use of statin prescribed previously by the assistant physician.
219684416|NCT04986241|OTHER|Physical activity|Physically active participants
219684417|NCT04986241|OTHER|Sedentary|Physically inactive or sedentary participants.
219684418|NCT05837273|DEVICE|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
219684419|NCT05837273|BEHAVIORAL|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
219684420|NCT04521556|PROCEDURE|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
219684421|NCT04521556|PROCEDURE|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
219684422|NCT04521556|PROCEDURE|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
219684423|NCT04521556|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
219684424|NCT04616716|DRUG|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
219684425|NCT04406922|PROCEDURE|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
219684426|NCT03865030|DEVICE|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~\- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
219684427|NCT01518803|DIETARY_SUPPLEMENT|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
219684428|NCT01518803|DIETARY_SUPPLEMENT|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
219684429|NCT01129401|BEHAVIORAL|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
219684430|NCT02727738|DIETARY_SUPPLEMENT|Selenium|Selenium 80 mg bid for 90 days
219684431|NCT02727738|DRUG|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
219684432|NCT05688865|OTHER|urinary markers|urinary marker testing
219684433|NCT00533819|OTHER|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
219099861|NCT02561286|BEHAVIORAL|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
219684434|NCT01517633|DEVICE|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
219684435|NCT04988204|BEHAVIORAL|Diabetes Prevention Program|The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
219684436|NCT03164447|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion
219684437|NCT03164447|DRUG|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
219684438|NCT03155711|PROCEDURE|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
219684439|NCT03155711|PROCEDURE|Standard group|Supplemental oxygen through venturi mask
219684440|NCT02068911|DEVICE|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
219223596|NCT04827810|DRUG|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
219223597|NCT06670313|OTHER|postop Erector spinae plane block|Postoperative ESP block was performed as the control group
219223598|NCT06612840|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
219223599|NCT05282706|DRUG|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
219223600|NCT05282706|DRUG|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
219223601|NCT05282706|DRUG|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
219223602|NCT05282706|OTHER|Placebo|A placebo patch containing no aromatherapy oil
219223603|NCT03737409|OTHER|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
219223604|NCT03737409|OTHER|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
219223605|NCT06587789|DRUG|Ribociclib|Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
219223606|NCT06592859|DIETARY_SUPPLEMENT|NMN|NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
219223607|NCT06592859|DIETARY_SUPPLEMENT|placebo|Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
219684441|NCT02532374|OTHER|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
219684442|NCT02532374|OTHER|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
219684443|NCT03286218|DRUG|Lasmiditan|Administered orally
219684444|NCT03286218|DRUG|Alprazolam|Administered orally
219684445|NCT03286218|DRUG|Placebo|Administered orally
219684446|NCT04553666|DRUG|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
219684447|NCT01979874|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
219684448|NCT01979874|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
219684449|NCT02044757|BEHAVIORAL|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
219684450|NCT06102720|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).
219684451|NCT06102720|DRUG|Clopidogrel|Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
219684452|NCT02931760|DEVICE|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
219684453|NCT02931760|DEVICE|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
219684454|NCT01493050|DRUG|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
219684455|NCT01493050|DRUG|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
219684456|NCT02896764|DEVICE|Cone-beam CT|
219684457|NCT02990013|DEVICE|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
219684458|NCT02990013|DRUG|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
219684459|NCT02990013|DRUG|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
219684460|NCT02990013|DRUG|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
219684461|NCT04184557|BEHAVIORAL|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
219684462|NCT02862145|DRUG|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
219684463|NCT02862145|DRUG|Dexamethasone|Premedication during the week of treatment
219684464|NCT04008225|PROCEDURE|Bronchoalveolar lavage|
219684465|NCT02762084|DRUG|Patidegib|
219684466|NCT02762084|DRUG|Vehicle gel|
219684467|NCT01015326|OTHER|Questionnaire|Administered questionnaire
219684468|NCT01015326|OTHER|Questionnaire|Administered questionnaire
219684469|NCT03141112|PROCEDURE|renal replacement therapy|
219684470|NCT01348139|DRUG|AZD3199|Inhaled via single inhaler device (SID)
219684471|NCT01348139|DRUG|AZD3199|Inhaled via Turbuhaler inhaler
219684472|NCT01348139|OTHER|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
219684473|NCT01961414|DRUG|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
219684474|NCT03190824|DRUG|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
219684475|NCT02869763|DIETARY_SUPPLEMENT|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
219684476|NCT02869763|DIETARY_SUPPLEMENT|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
219684477|NCT02869763|DIETARY_SUPPLEMENT|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
218984979|NCT04021771|OTHER|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
219684478|NCT03262077|DRUG|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
219684479|NCT03262077|DRUG|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
219684480|NCT00037050|DRUG|Linezolid|
219684481|NCT00037050|DRUG|Vancomycin|
219684482|NCT00037050|DRUG|Oxacillin|
219684483|NCT00037050|DRUG|Dicloxacillin|
219684484|NCT01428843|DRUG|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
219684485|NCT01428843|DRUG|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
219684486|NCT04702152|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
219684487|NCT00090727|DRUG|AQ4N|
219684488|NCT01164202|DRUG|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
219684489|NCT01164202|DRUG|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
219684490|NCT01164202|PROCEDURE|transarterial chemoembolization|Chimioembolisation
219684491|NCT00857662|DEVICE|Onyx|Embolization
219684492|NCT00857662|DEVICE|TRUFILL|Embolization
219684493|NCT03980262|BEHAVIORAL|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
219684494|NCT03980262|BEHAVIORAL|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
219684495|NCT02576262|PROCEDURE|TCT，HPV，colposcopic inspection|
219684496|NCT03248869|OTHER|Current Daily Survey|need description
219684497|NCT03248869|OTHER|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
219684498|NCT03416270|DRUG|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
219684499|NCT03416270|DRUG|Placebo|Placebo once daily for 12 weeks
219684500|NCT03984344|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
219684501|NCT03984344|DEVICE|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
219684502|NCT03984344|DEVICE|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
219684503|NCT05380245|DRUG|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
219684504|NCT05380245|DRUG|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
219684505|NCT01781962|OTHER|No Treatment|No Treatment was given in this study.
219684506|NCT03398694|PROCEDURE|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
219684507|NCT02525016|BIOLOGICAL|Blood sampling|
219684508|NCT02525016|DRUG|Lidocaine|
219684509|NCT03257436|DEVICE|CRT-D|Left Ventricular MultiSite Pacing
219684510|NCT01619852|DRUG|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
218984980|NCT00763620|DEVICE|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
218984981|NCT01492985|BIOLOGICAL|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
218984982|NCT01492985|BIOLOGICAL|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
219684511|NCT01619852|DRUG|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
219684512|NCT03428100|DRUG|Baricitinib|Administered orally.
219684513|NCT03428100|DRUG|Placebo|Administered orally.
219684514|NCT03428100|DRUG|Topical corticosteroid|Administered as standard-of-care.
219684515|NCT03854721|DRUG|VAX014|Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
219684516|NCT04556760|DRUG|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
219684517|NCT04556760|DRUG|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
219684518|NCT04556760|OTHER|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
218984983|NCT01090271|DEVICE|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
219684519|NCT03286920|DIETARY_SUPPLEMENT|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
219684520|NCT03286920|DIETARY_SUPPLEMENT|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
219684521|NCT05116436|PROCEDURE|Blood sample|It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
219684522|NCT05116436|PROCEDURE|Spine X-ray|To determine the scoliosis
219684523|NCT05673356|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
219684524|NCT05399199|PROCEDURE|virtual reality distraction|study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
219684525|NCT02873767|DRUG|PR1|"* Active substance: UCB4019~* Route of Administration: subcutaneously"
219684526|NCT02873767|OTHER|PL1|"* Active substance: Placebo~* Concentration: 0.9 % saline~* Route of Administration: subcutaneously"
219684527|NCT03278496|BEHAVIORAL|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
219684528|NCT03278496|BEHAVIORAL|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
218984984|NCT06467968|OTHER|Cardiac ECG-gated PET imaging will added|Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
218984985|NCT02821169|DRUG|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
218984986|NCT02821169|DRUG|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
219684529|NCT03278496|BEHAVIORAL|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
219684530|NCT03089463|DIAGNOSTIC_TEST|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
219684531|NCT04564911|COMBINATION_PRODUCT|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
219684532|NCT04564911|COMBINATION_PRODUCT|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
219684533|NCT06136468|BEHAVIORAL|Virtual coach|The virtual coch will be displayed to the participants using an optical see-through head-mounted display
219684534|NCT06213987|DRUG|0.025% Tretinoin|Total duration of 8 weeks.
219684535|NCT05340335|DRUG|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
219684536|NCT02979821|DRUG|Poziotinib|A cycle of study treatment is defined as 28 days.
219684537|NCT00400075|DRUG|azathioprine|
219684538|NCT00400075|DRUG|cyclophosphamide|
219684539|NCT04604834|OTHER|PFAT first|Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
219684540|NCT04604834|OTHER|APRP first|Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
218984987|NCT04702061|OTHER|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
219684541|NCT04633746|DIAGNOSTIC_TEST|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
219684542|NCT01047280|DIETARY_SUPPLEMENT|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
219684543|NCT01047280|DIETARY_SUPPLEMENT|Safflower oil|3.5 g/d of safflower oil
219684544|NCT01047280|DIETARY_SUPPLEMENT|G-c9, t11|3.5 g/day of c9, t11 CLA
219684545|NCT06391424|DIAGNOSTIC_TEST|Spontaneous Breathing Trial|Patients will undergo an SBT to determine whether they are ready for extubation.
219684546|NCT01954589|DRUG|ACT-462206 5 mg|
219684547|NCT01954589|DRUG|ACT-462206 25 mg|
219684548|NCT01954589|DRUG|ACT-462206 100mg|
219684549|NCT01954589|DRUG|ACT-462206 200mg|
219684550|NCT01954589|DRUG|ACT-462206 400mg|
219684551|NCT01954589|DRUG|ACT-462206 1000 mg|
219684552|NCT01954589|DRUG|ACT-462206 1500mg|
219684553|NCT01954589|DRUG|Almorexant 400mg|
219684554|NCT01954589|DRUG|Placebo|
219684555|NCT01877200|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
219684556|NCT01759706|BEHAVIORAL|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
219684557|NCT01759706|PROCEDURE|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
219684558|NCT01759706|DRUG|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
219684559|NCT01759706|OTHER|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
219684560|NCT01759706|DRUG|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
219684561|NCT01759706|DRUG|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
219684562|NCT01759706|BEHAVIORAL|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
219684563|NCT01759706|DRUG|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
219684564|NCT05528172|DRUG|Ripasudil|K-321 ophthalmic solution
219684565|NCT05528172|DRUG|Placebo|Placebo ophthalmic solution
219684566|NCT04307862|DRUG|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
219684567|NCT04307862|DRUG|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
219684568|NCT04307862|DRUG|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
218984988|NCT04702061|OTHER|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
219684569|NCT02168491|DRUG|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
218984989|NCT04144660|DEVICE|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
218984990|NCT02408627|DEVICE|EEG|
219684570|NCT02168491|DRUG|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
219684571|NCT02303639|PROCEDURE|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
219684572|NCT02303639|DRUG|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
219684573|NCT05530772|DEVICE|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
219684574|NCT03624491|OTHER|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
219684575|NCT05772676|DRUG|Aprepitant|80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
219684576|NCT05772676|OTHER|Placebo|Placebo + standard antiemetic regimen, once two hours before surgery
219684577|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
219684578|NCT05728736|DRUG|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
218984991|NCT03539471|DIAGNOSTIC_TEST|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
218984992|NCT06557083|BEHAVIORAL|Polyvagal Breathing Exercises|Breathing exercises provided include, square breathing, modified Qigong breathing, and three step breathing
219684579|NCT05728736|DRUG|Placebo|Placebo will be taken nightly for two consecutive nights
219684580|NCT04592016|DRUG|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
219684581|NCT04592016|DRUG|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
219684582|NCT04592016|DRUG|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
219684583|NCT04592016|DEVICE|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
219684584|NCT04592016|DEVICE|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
219684585|NCT04592016|PROCEDURE|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
219684586|NCT04592016|PROCEDURE|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
219684587|NCT03335800|DEVICE|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
219684588|NCT05143684|PROCEDURE|Left Lateral Uterine Displacement|a wooden wedge wrapped with cotton, to make it comfortable, and medical sheets with a measured angle of 15° under the right flank of the laying down patient
219684589|NCT00844090|DRUG|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
218984993|NCT06557083|OTHER|No Intervention|The control group will not perform any intervention.
219684590|NCT04753294|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
219684591|NCT04753294|DEVICE|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
219684592|NCT03628651|OTHER|Blood Sample Collection|HCC subjects will have one blood sample collected.
219684593|NCT03628651|OTHER|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
219684594|NCT00180089|DRUG|Budesonide|
219684595|NCT04976439|OTHER|co-occuring mutation|APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
219684596|NCT05594147|DRUG|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
219684597|NCT05594147|DRUG|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
219684598|NCT05594147|DRUG|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
219684599|NCT05594147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
219684600|NCT00380536|BEHAVIORAL|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
219684601|NCT02691546|OTHER|blood sample collection|
219684602|NCT02481076|DEVICE|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
219684603|NCT02481076|OTHER|Braun frame|The leg is elevated on a Braun frame
219684604|NCT02481076|DEVICE|compression bandage|application of flowtron hydroven boot and compression bandage
219684605|NCT04705012|OTHER|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
219684606|NCT01204203|DRUG|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
219684607|NCT01096160|DRUG|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
219684608|NCT01096160|DRUG|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
218984994|NCT04194580|BEHAVIORAL|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
218984995|NCT02154776|DRUG|LEE011|3 weeks on and 1 week off
218984996|NCT02154776|DRUG|Buparlisib|daily
218984997|NCT02154776|DRUG|Letrozole|2.5 mg daily;
219684609|NCT01096160|DRUG|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
219684610|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
219684611|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
219684612|NCT01096160|DRUG|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
219684613|NCT01096160|DRUG|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
219684614|NCT01096160|DRUG|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
219684615|NCT01096160|DRUG|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
219684616|NCT01096160|DRUG|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
219684617|NCT06164457|OTHER|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,\[4\] the EuroQol EQ5D-5L,\[5\] the Medical Outcomes Study Social Support Scale (8 item version),\[6\] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools\[7\], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).\[8\]
219684618|NCT01536210|DRUG|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
219684619|NCT01536210|DRUG|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
219684620|NCT05931536|OTHER|Dietary fibre|Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
219684621|NCT05660382|DRUG|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
219684622|NCT05660382|OTHER|Placebo|Twice daily application, for 14 days
219684623|NCT01610037|DRUG|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
219684624|NCT01610037|DRUG|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
219684625|NCT01610037|DRUG|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
219684626|NCT00715234|OTHER|Reminder/recall notices for vaccines|"1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter."
219684627|NCT01460732|DEVICE|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
219684628|NCT01837251|DRUG|Carboplatin|
219684629|NCT01837251|DRUG|PLD|
219684630|NCT01837251|BIOLOGICAL|Bevacizumab|
219684631|NCT05375500|DEVICE|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
219684632|NCT03796312|BEHAVIORAL|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
219684633|NCT03796312|BEHAVIORAL|Sponge Bathing|Sponge bathing is routine care of the clinic
219684634|NCT02824835|PROCEDURE|biopsy during colonoscopy|sampling the lesion with forcept biopter
219684635|NCT03573596|DRUG|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
219684636|NCT00705757|DRUG|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
219684637|NCT00705757|DRUG|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
219684638|NCT00705757|DRUG|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
219684639|NCT01644721|BIOLOGICAL|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
219684640|NCT03217292|PROCEDURE|Serratus Anterior Plane Block|
219684641|NCT03217292|DRUG|IV patient-controlled analgesia (PCA) tramadol|
219684642|NCT04113941|DRUG|Neuronox|intradetrusor injection
219684643|NCT04113941|DRUG|Placebo|intradetrusor injection
219684644|NCT06336421|OTHER|Virtual Reality|"VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes."
219684645|NCT05321420|DRUG|Placebo|placebo
219684646|NCT05321420|DRUG|Pirfenidone|pirfenidone 801 mg TID
219684647|NCT05321420|DRUG|Deupirfenidone|Deupirfenidone
219684648|NCT02202304|DRUG|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
219684649|NCT00971477|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
219684650|NCT00971477|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
219684651|NCT01484080|DRUG|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
219684652|NCT01484080|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
219684653|NCT00413543|OTHER|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
219684654|NCT05532423|DRUG|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
219684655|NCT05532423|DRUG|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
219684656|NCT03817944|OTHER|Warm Water|300 mL Warm Water per day for 8 weeks
219684657|NCT03817944|OTHER|Caffeinated Coffee|300 mL Caffeinated Coffee per day for 8 weeks
218984998|NCT00217061|DEVICE|Decision Aid Statin Choice|
219684658|NCT03817944|OTHER|Decaffeinated Coffee|300 mL Decaffeinated Coffee per day for 8 weeks
219684659|NCT04758351|OTHER|Usual clinical practice|Based on European Respiratory Society guidelines on management for chronic cough.
219684660|NCT05377372|BEHAVIORAL|Breastfeeding support group|community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women
219684661|NCT05377372|OTHER|Observation|Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease
219684662|NCT01411852|DRUG|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
219684663|NCT01411852|DRUG|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
219684664|NCT06010602|PROCEDURE|Quadratus lumborum block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
219684665|NCT06010602|PROCEDURE|İlioinguinal-İliohipogastric nerve block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
219684666|NCT06047756|OTHER|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
219684667|NCT06047756|OTHER|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
219684668|NCT00921661|DRUG|AVE0005 (aflibercept)|IV infusion
219684669|NCT01698970|OTHER|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
219684670|NCT01698970|OTHER|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
219684671|NCT03193047|DRUG|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
219684672|NCT03193047|OTHER|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
219684673|NCT03193047|DRUG|evolocumab|Monthly PCSK9i (evolocumab) background therapy
218984999|NCT03109249|DRUG|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
218985000|NCT03109249|DRUG|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
219684674|NCT03861091|DRUG|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
219684675|NCT03861091|DRUG|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
219684676|NCT03887182|DIAGNOSTIC_TEST|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
219684677|NCT03887182|DIAGNOSTIC_TEST|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
219684678|NCT03887182|GENETIC|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
219684679|NCT03887182|DIAGNOSTIC_TEST|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
219684680|NCT03887182|DIAGNOSTIC_TEST|multidisciplinary consultation|"multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation"
219684681|NCT00467428|DRUG|NS2359|
219684682|NCT00467428|DRUG|Placebo|
219684683|NCT05042752|PROCEDURE|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
219684684|NCT05643391|RADIATION|Radioembolization using Holmium-166|This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
218985001|NCT01501175|OTHER|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
219684685|NCT01328938|BIOLOGICAL|GCPGC 3.6mg|Stage I:Single blinded
219684686|NCT01328938|BIOLOGICAL|GCPGC 6mg|Stage I: Single blinded;
219684687|NCT01328938|BIOLOGICAL|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
219684688|NCT01328938|BIOLOGICAL|GCPGC 6mg|Experimental: Stage II
219684689|NCT01942811|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
219684690|NCT06438887|DIETARY_SUPPLEMENT|Placebo|Corn-Starch Maltodextrin
219684691|NCT06438887|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine
219684692|NCT04642482|DIETARY_SUPPLEMENT|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
219684693|NCT04642482|DRUG|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
219684694|NCT05489107|OTHER|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
219684695|NCT04724785|OTHER|only monitoring|monitoring the viraemia only
219684696|NCT04724785|OTHER|monitoring and regimen change if necessary|if those patients agree, the regimen will be changed.
219684697|NCT04724785|DRUG|regimen change|Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
219099862|NCT02561286|BEHAVIORAL|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
219099863|NCT06624891|OTHER|perioperative fluid responsiveness with the Pleth variability index|Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.
219099864|NCT06624891|OTHER|perioperative fluid responsiveness with delta PP|fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
219684698|NCT03743025|DRUG|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
219684699|NCT03743025|OTHER|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
219684700|NCT05262335|DRUG|Anlotinib + Oxaliplatin + Capecitabine|"1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
219684701|NCT05262335|DRUG|Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|"1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
219684702|NCT05262335|DRUG|Anlotinib + Standard first-line chemotherapy|"1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
219684703|NCT04753502|PROCEDURE|Laparoscopy|laparoscopic removal of pathologic appendix
219684704|NCT05876884|DEVICE|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
219684705|NCT02413957|OTHER|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
219684706|NCT02413957|OTHER|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
219684707|NCT02420119|OTHER|non interventional|
219684708|NCT00149396|DRUG|NV1020|NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
219684709|NCT02690012|OTHER|Magnesium Oxide|Magnesium Oxide
219684710|NCT02690012|OTHER|Magnesium Citrate|Magnesium Citrate
219684711|NCT03093441|OTHER|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
219684712|NCT04001192|BEHAVIORAL|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
219684713|NCT02236312|DRUG|Botulinum Toxin Type A|
219684714|NCT02236312|DRUG|Placebo|
219684715|NCT05756881|OTHER|Cosmetic product|Apply on the face twice a day
219684716|NCT03069534|DRUG|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
219684717|NCT00306046|DRUG|Bisphosphonate treatment|
219684718|NCT05437809|OTHER|Intake of nutritionally diverse ultra-processed foods|All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
219684719|NCT01158937|DRUG|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
219684720|NCT01308892|DIETARY_SUPPLEMENT|High flavanol chocolate|chocolate high in flavanols
219684721|NCT01308892|DIETARY_SUPPLEMENT|Low flavanol chocolate|chocolate low in flavanols
219684722|NCT01308892|DIETARY_SUPPLEMENT|High fat challenge|Milkshake with 95g fat
219684723|NCT02681458|OTHER|Direct Examination|It was an observational study and subjects received their routine treatment.
219684724|NCT00287521|DRUG|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
219684725|NCT00287521|DRUG|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
219684726|NCT00287521|OTHER|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
219684727|NCT00287521|DRUG|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
219684728|NCT00186485|DEVICE|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
219684729|NCT00228839|DRUG|Infliximab|
219684730|NCT01954238|DRUG|GCC-4401C|"* Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
219684731|NCT01954238|DRUG|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
219684732|NCT01954238|DRUG|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
219684733|NCT00227539|DRUG|cisplatin|
219684734|NCT00227539|DRUG|pemetrexed disodium|
218985002|NCT02530060|DRUG|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
218985003|NCT04177667|DIETARY_SUPPLEMENT|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
218985004|NCT04177667|OTHER|Placebo|Treatment with placebo for Placebo Arm
219684735|NCT00227539|PROCEDURE|adjuvant therapy|
219684736|NCT00227539|PROCEDURE|therapeutic conventional surgery|
219684737|NCT00227539|RADIATION|fludeoxyglucose F 18|
219684738|NCT02250339|OTHER|LAKU family program|Multi-systemic and multicomponent family-based intervention program
219684739|NCT02250339|OTHER|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
219684740|NCT02250339|OTHER|Family therapy|Treatment as usual (TAU)
219684741|NCT04780672|DRUG|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
219684742|NCT04780672|DRUG|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
219684743|NCT03307941|DRUG|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
219684744|NCT03307941|DRUG|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
219684745|NCT03307941|DRUG|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
219684746|NCT03307941|RADIATION|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
218985005|NCT00989560|PROCEDURE|endoscopy|patients receive best treatment and care with an additional endoscopy
218985006|NCT01991769|BEHAVIORAL|47 min moderate intensity training|
218985007|NCT01991769|BEHAVIORAL|exercise healthy volunteers|
218985008|NCT01991769|BEHAVIORAL|control; no exercise training|
218985009|NCT02208479|OTHER|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
218985010|NCT01747044|DRUG|Milnacipran|100mg/day
218985011|NCT01747044|DRUG|Placebo|
218985012|NCT00955071|OTHER|Exercise: LVLI|low volume, low intensity
218985013|NCT00955071|OTHER|Exercise: HVLI|high volume, low intensity
219684747|NCT03307941|OTHER|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
219684748|NCT03307941|PROCEDURE|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
219684749|NCT04693780|OTHER|Structured guide|Structured guide
219684750|NCT04693780|OTHER|List|List
219684751|NCT03215537|BEHAVIORAL|comprehensive intervention|preoperative and postoperative exercise program
219684752|NCT02900248|OTHER|Provider determined|Provider will treat patient as he/she feels best
219684753|NCT06367946|PROCEDURE|mechanical ventilation|Mechanical ventilation is machine-delivered flow of gases to both oxygenate and ventilate a patient who is unable to maintain physiological gas exchange.
219684754|NCT00673257|OTHER|pharmacological study|pharmacological studies
219684755|NCT00673257|PROCEDURE|dual x-ray absorptimetry|
219684756|NCT05855837|OTHER|Ready to Eat Cereal|Cereal products available in retail stores
219684757|NCT04956510|OTHER|Evaluation|health status and quality of life were evaluated
219684758|NCT02183012|DRUG|Ibuprofen extrudate|
219684759|NCT02183012|DRUG|Ibuprofen lysinate|
219684760|NCT02183012|DRUG|Ibuprofen|
219684761|NCT02638779|BIOLOGICAL|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
219684762|NCT04979091|DIAGNOSTIC_TEST|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
219684763|NCT04846192|OTHER|Nutritional evaluation|Collecting existing data on pre operative nutritional status and outcomes after surgery
219684764|NCT02996916|DRUG|Olmesartan|10-40mg daily
218985014|NCT00955071|OTHER|Exercise: LVHI|low volume, high intensity
219684765|NCT02996916|DRUG|Amlodipine|2.5-10mg daily
219684766|NCT03365661|BIOLOGICAL|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains \> 2 x 105 α/β T cells/kg recipient weight.
219223608|NCT06665022|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
219223609|NCT06665022|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
219223610|NCT06668142|DEVICE|Beacon Platform|The Beacon Platform is a robotically assisted surgical (RAS) device. It enables the urologist, through software, to control and move surgical instruments for a variety of transurethral, endoscopic procedures
219223611|NCT04025164|RADIATION|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
219223612|NCT04025164|RADIATION|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
219223613|NCT06994377|BEHAVIORAL|ED and quality of life assessment|Patients will undergo ED and quality of life assessments through specific questionnaires completion
219684767|NCT06121440|OTHER|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
219684768|NCT06121440|OTHER|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
219684769|NCT03540732|OTHER|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
219684770|NCT03540732|PROCEDURE|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
219684771|NCT02256839|DEVICE|CST_001|
219684772|NCT01918917|DRUG|Levobupivacaine|intraarticular
219684773|NCT01918917|DRUG|Dexmedetomidine|intraarticular 1 ml (100 mcg)
219684774|NCT01918917|DRUG|Morphine|intravenously, patient-controlled analgesia
219684775|NCT04928144|DRUG|SHJ - Low concentration|Topical ophthalmic
219684776|NCT04928144|DRUG|SHJ - Mid concentration|Topical ophthalmic
219684777|NCT04928144|DRUG|SHJ - High concentration|Topical ophthalmic
218985015|NCT05120778|BEHAVIORAL|exercise training|as appear in arm description.
218985016|NCT05120778|OTHER|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
218985017|NCT01325961|RADIATION|Intensity-Modulated Radiation Therapy|
218985018|NCT02304679|OTHER|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled"
218985019|NCT02304679|DRUG|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
219684778|NCT04928144|DRUG|SHJ - Maximum tolerated|SHJ - Maximum tolerated
219684779|NCT01834456|OTHER|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
219684780|NCT00121719|DRUG|Lenvatinib|Lenvatinib tablets taken orally, once daily.
219684781|NCT01748019|DRUG|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
219684782|NCT06420817|BEHAVIORAL|Indian version of a 'Portfolio' diet|The participants will be required to follow the prescribed diet plan for 4 weeks
219684783|NCT06420817|BEHAVIORAL|Physical Activity|"The participants will be required to join for an hour of group online exercise program 3 days a week for 4 weeks~• (Exercise Duration = 180 minutes per week including cardio, strength training and flexibility)"
219684784|NCT06420817|BEHAVIORAL|Intermittent fasting|The participants will be required to do intermittent fasting for 12 hours daily for 4 weeks
219684785|NCT06420817|BEHAVIORAL|Monitoring of sleep and stress levels|The participants will be required to monitor their sleep and stress levels
219684786|NCT02664077|DRUG|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
219684787|NCT02664077|DRUG|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
219684788|NCT01816178|BEHAVIORAL|communication training|Participants were instructed in the use of a voices output communication aid.
219684789|NCT02925858|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
219684790|NCT02925858|DRUG|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
219684791|NCT03764514|DEVICE|Spinal Cord Stimulator|Permanent Implantation
219684792|NCT03999502|DEVICE|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
219684793|NCT03708263|DEVICE|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
219684794|NCT03708263|DEVICE|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
219684795|NCT01972737|BIOLOGICAL|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
219684796|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
219684797|NCT02837302|DRUG|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
219684798|NCT02571556|DRUG|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
219684799|NCT02732288|DIETARY_SUPPLEMENT|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
219684800|NCT01829698|DRUG|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
219684801|NCT01829698|DRUG|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
219684802|NCT01822210|DRUG|Botox|injection by gastroscopy (100 Allergen units)
219684803|NCT00443222|DRUG|Infliximab|
219684804|NCT06521190|DRUG|ACOU085 (bimokalner)|Transtympanic injection
219684805|NCT06521190|DRUG|Placebo|Transtympanic injection
219684806|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
219684807|NCT01938846|DRUG|exemestane|exemestane once daily
219684808|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
219684809|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
219684810|NCT01938846|DRUG|paclitaxel|paclitaxel once weekly
219684811|NCT04568798|DEVICE|Sana Sham Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
219684812|NCT00473447|BEHAVIORAL|Modified Constraint-induced movement therapy|
219684813|NCT02465164|DEVICE|Cook catheter|
219684814|NCT02465164|DRUG|Oxytocin|
218985020|NCT02304679|OTHER|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled"
219684815|NCT02171117|PROCEDURE|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
219684816|NCT02171117|BIOLOGICAL|HLA-mismatched donor peripheral stem cell infusion|
219684817|NCT04551664|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
219684818|NCT04551664|PROCEDURE|Endovascular therapy|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
219684819|NCT01853293|DRUG|Kudzu extract|
219684820|NCT01853293|DRUG|Placebo|
219684821|NCT01853293|BEHAVIORAL|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
219684822|NCT00178516|OTHER|behavior, procedure|
219684823|NCT02324361|OTHER|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
219684824|NCT02324361|BEHAVIORAL|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
219684825|NCT04575441|OTHER|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
219099865|NCT06625424|OTHER|Short Sprint Interval Training with passive recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc. Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
219223614|NCT05346224|DRUG|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
219684826|NCT01481558|DEVICE|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
219099866|NCT06625424|OTHER|Short Sprint Interval Training with Active Recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which the Subjects will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
219099867|NCT06624761|DEVICE|ShotBlocker|A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
219684827|NCT00353223|BEHAVIORAL|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
219684828|NCT00353223|BEHAVIORAL|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
219099868|NCT00186498|DRUG|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
219099869|NCT00186498|DRUG|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
219099870|NCT06901128|BEHAVIORAL|cognitive therapy|The CT-SAD-A manual developed by Clark and Leigh
219684829|NCT02568462|DEVICE|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
219684830|NCT01655095|DRUG|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
219099871|NCT01147289|DRUG|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
219099872|NCT01147289|DRUG|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
219223615|NCT05346224|DRUG|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
219684831|NCT01655095|DRUG|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
219684832|NCT01655095|DRUG|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
219099873|NCT02790021|PROCEDURE|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
219099874|NCT01009879|DRUG|Etanercept|Etanercept 50 mg SQ qweek
219684833|NCT01655095|DRUG|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
219684834|NCT01655095|PROCEDURE|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
219684835|NCT01655095|PROCEDURE|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
219684836|NCT03097432|DRUG|ORALVAC COMPACT BÄUME|
219684837|NCT00291564|DEVICE|Cardiac Resynchronization Therapy Device|
219684838|NCT03030625|RADIATION|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
219684839|NCT02592941|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
219684840|NCT04988334|OTHER|Wait Control|usual activities
219684841|NCT03669601|DRUG|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
219684842|NCT03669601|DRUG|Gemcitabine|Nucleoside metabolic inhibitor.
219684843|NCT00246584|DRUG|SPP100|
219684844|NCT06469450|DRUG|Atorvastatin|one 40 mg atorvastatin tablet once daily for 28 days
219684845|NCT03819413|DIAGNOSTIC_TEST|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
219684846|NCT03819413|DIAGNOSTIC_TEST|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
219684847|NCT03819413|DIAGNOSTIC_TEST|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
219684848|NCT05031377|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
219684849|NCT05031377|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
219684850|NCT00559143|OTHER|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
219684851|NCT04102384|OTHER|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
219684852|NCT00043277|DRUG|Angiomax (bivalirudin)|
219684853|NCT00309023|DRUG|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
219684854|NCT05291923|OTHER|no intervention|no intervention
219684855|NCT04969588|DIAGNOSTIC_TEST|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
219684856|NCT04969588|DIAGNOSTIC_TEST|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
219684857|NCT04969588|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
219684858|NCT03259256|PROCEDURE|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
219684859|NCT02320448|DRUG|PIPAC|
219684860|NCT05905432|DRUG|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM\_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
219099875|NCT06916689|DRUG|1L PEG-Asc|PEG 3350 plus sodium sulfate plus sodium chloride plus potassium chloride plus ascorbic acid plus sodium ascorbate
219099876|NCT06926270|DEVICE|TMS|Magstim ,Rapid 2
219099877|NCT03469284|OTHER|Best Practice|Given standard of care therapy
219684861|NCT03833232|DEVICE|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
219684862|NCT04499833|PROCEDURE|liver transplant|liver transplant
219684863|NCT01901016|BEHAVIORAL|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
219099878|NCT03469284|DRUG|Methylene Blue|Given lower dose PO
219099879|NCT03469284|DRUG|Methylene Blue|Given medium dose PO
219684864|NCT01901016|BEHAVIORAL|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
219684865|NCT03492879|DEVICE|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
219684866|NCT05681832|BEHAVIORAL|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
219684867|NCT02357056|OTHER|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
219684868|NCT02357056|OTHER|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
219684869|NCT02357056|OTHER|Virtual Reality|daVinci Surgical Skills simulation
219684870|NCT05929989|DIAGNOSTIC_TEST|ELISA TEST|ELISA TEST for cystatin D and fibrinogen like protein
219684871|NCT02666833|DEVICE|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
219684872|NCT03228940|DRUG|RVX000222|oral, BID
219684873|NCT03389880|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
219684874|NCT03389880|PROCEDURE|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
219684875|NCT04929977|DEVICE|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
219684876|NCT04825756|BEHAVIORAL|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
219684877|NCT05314777|PROCEDURE|Low dose ESWT application|Patients trained for low dose ESWT application.
219684878|NCT05314777|PROCEDURE|High dose ESWT application|Patients trained for high dose ESWT application.
219684879|NCT05314777|PROCEDURE|Sham ESWT|Patients trained for sham ESWT.
219684880|NCT05314777|PROCEDURE|Exercise Training|Patients trained for exercise training.
219684881|NCT04028791|OTHER|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
219684882|NCT00928850|PROCEDURE|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
219099880|NCT03469284|DRUG|Methylene Blue|Given higher dose PO
219099881|NCT00211978|DRUG|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
219099882|NCT00211978|DRUG|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
219099883|NCT05059912|BIOLOGICAL|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
219099884|NCT04000659|DEVICE|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
219099885|NCT04000659|PROCEDURE|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
219099886|NCT04716413|DRUG|Dsuvia|Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
219099887|NCT06106815|OTHER|Rehabilitation exercises|The Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve upper extremity function in individuals with stroke. The GRASP program includes exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
219099888|NCT06106815|OTHER|Usual Care|Usual Care
219099889|NCT03895437|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
219099890|NCT03895437|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
219099891|NCT05474729|DRUG|minocycline|minocycline capsule 100mg per day orally
219099892|NCT02843802|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
219684883|NCT00928850|PROCEDURE|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
219684884|NCT00928850|PROCEDURE|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
219099893|NCT02843802|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
219684885|NCT00928850|PROCEDURE|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
219099894|NCT03950180|OTHER|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
219099895|NCT02202434|DEVICE|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
219099896|NCT02202434|DEVICE|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
219099897|NCT02202434|DEVICE|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
219099898|NCT06244121|DRUG|Pyridoxine|pyridoxine (Vitamin B6) will be given as an anti oxidant.
219099899|NCT06244121|DRUG|Placebo|Placebo will be given in control group
219099900|NCT04013958|DRUG|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
219099901|NCT04013958|DRUG|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
219099902|NCT02323347|OTHER|Progesterone|Progesterone level
219684886|NCT03798548|BEHAVIORAL|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
219684887|NCT04069143|DIAGNOSTIC_TEST|18F-BMS-986327|Imaging Agent
219684888|NCT03701412|RADIATION|MRI|MRI brain
218985021|NCT02304679|OTHER|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
218985022|NCT02304679|DEVICE|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
219684889|NCT02423083|DRUG|Guanabenz|
219684890|NCT05680428|OTHER|early feeding|oral feeding within 12hours after stoma reversal
219684891|NCT05680428|PROCEDURE|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
219684892|NCT06092528|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
218985023|NCT02304679|DEVICE|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
219223616|NCT02823028|DRUG|NRT|8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
219223617|NCT02823028|BEHAVIORAL|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
219223618|NCT02823028|BEHAVIORAL|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
219223619|NCT03765567|DRUG|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
219684893|NCT06092528|OTHER|Upper extremity aerobic exercise training|Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
219684894|NCT06092528|OTHER|Lower extremity aerobic exercise training|Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
219684895|NCT06092528|OTHER|Resistant exercise training|Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
219684896|NCT06092528|OTHER|Thoracic expansion exercises|The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
219684897|NCT00069849|DRUG|ABT-089|
219684898|NCT01074177|DRUG|BIBW 2992|Taken orally once a day
219684899|NCT05429671|PROCEDURE|total knee arthroplasty|Participants will have total knee arthroplasty
219684900|NCT05429671|DRUG|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
219684901|NCT05429671|DRUG|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
219684902|NCT05429671|DEVICE|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
219684903|NCT00691288|DRUG|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
219684904|NCT00691288|DRUG|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
219684905|NCT05455151|PROCEDURE|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
219684906|NCT05455151|BIOLOGICAL|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
219684907|NCT05455151|BIOLOGICAL|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
219684908|NCT05455151|BIOLOGICAL|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
219684909|NCT01514383|DEVICE|Cyanoacrylate (Octylseal )|surgical adhesive
219684910|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
219684911|NCT02584478|DRUG|Paclitaxel|"Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week"
219684912|NCT02584478|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard"
219684913|NCT02584478|DRUG|Topotecan|Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
219684914|NCT02584478|DRUG|Topotecan|Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard
219684915|NCT02584478|DRUG|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
219684916|NCT02584478|DRUG|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
219684917|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
219684918|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
219684919|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
219684920|NCT02581033|DRUG|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
219684921|NCT01401543|DRUG|LY2452473|Administered orally
219684922|NCT01401543|DRUG|Tadalafil|Administered orally
219684923|NCT01401543|DRUG|LY900010|Administered orally
219099903|NCT01105806|BEHAVIORAL|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
219684924|NCT05643729|DRUG|Zofin|Intravenous Infusion (IV) of Zofin
219684925|NCT05643729|OTHER|Placebo|Intravenous Infusion of sterile saline
219684926|NCT00086606|DRUG|Xolair (omalizumab)|
219099904|NCT01105806|BEHAVIORAL|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
219099905|NCT01886963|DEVICE|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
219684927|NCT01739504|PROCEDURE|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
219684928|NCT01739504|BIOLOGICAL|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
219684929|NCT00160264|DRUG|Lactulose, Vitamin D, Calcium|
219684930|NCT02541409|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
219684931|NCT02541409|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
219684932|NCT02541409|DRUG|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
219684933|NCT01494012|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219684934|NCT01494012|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
219099906|NCT01886963|DEVICE|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
219684935|NCT01494012|PROCEDURE|computed tomography|Undergo FDG-PET/CT
219684936|NCT01494012|OTHER|questionnaire administration|Ancillary studies
219684937|NCT01494012|DRUG|fludeoxyglucose F 18|Undergo FDG-PET/CT
219684938|NCT02150252|DRUG|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
219099907|NCT03659253|DIAGNOSTIC_TEST|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
219684939|NCT02574936|PROCEDURE|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
219684940|NCT04633993|BEHAVIORAL|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
219684941|NCT01727830|OTHER|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
219684942|NCT00684164|DRUG|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
219684943|NCT00684164|OTHER|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
219684944|NCT04468724|BEHAVIORAL|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
219684945|NCT03448523|BEHAVIORAL|Right To Play's Positive Child and Youth Development program|"1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
219684946|NCT05003869|PROCEDURE|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
219684947|NCT03192124|DEVICE|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
219684948|NCT04560959|DEVICE|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
219099908|NCT03659253|PROCEDURE|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
219684949|NCT05947162|BEHAVIORAL|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
219684950|NCT05947162|BEHAVIORAL|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
219684951|NCT05947162|BEHAVIORAL|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
219684952|NCT05947162|BEHAVIORAL|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
219684953|NCT05947162|BEHAVIORAL|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
219684954|NCT00292253|DEVICE|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
219684955|NCT00292253|DEVICE|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
219684956|NCT04284826|PROCEDURE|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
219684957|NCT04804176|DEVICE|Ultra-low frequency repetitive transcranial magnetic stimulation|Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
219684958|NCT02950038|DRUG|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
219684959|NCT02950038|DRUG|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
219684960|NCT02595112|OTHER|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
219684961|NCT05276102|OTHER|Emollient cream|Commercially available emollient cream
219684962|NCT05204914|DEVICE|Supra glottic airway devices|Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
219684963|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
219684964|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
219684965|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
219684966|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
219684967|NCT01290419|BIOLOGICAL|Placebo|Placebo; Day 0 and Day 30
219684968|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
219099909|NCT03659253|PROCEDURE|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
219099910|NCT03659253|BEHAVIORAL|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
219099911|NCT03659253|PROCEDURE|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
219099912|NCT01686165|DRUG|belinostat|Given IV
219099913|NCT01686165|BIOLOGICAL|rituximab|Given IV
219099914|NCT01686165|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219099915|NCT04290065|OTHER|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
219099916|NCT00345319|BIOLOGICAL|rabies vaccine|Administration of PCECV according to ESSEN regimen
219684969|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
219684970|NCT02152215|PROCEDURE|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
219684971|NCT02152215|PROCEDURE|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
219684972|NCT00831402|DIETARY_SUPPLEMENT|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
219684973|NCT00831402|DIETARY_SUPPLEMENT|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
219684974|NCT02731170|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
219684975|NCT05308849|OTHER|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
219684976|NCT03500926|DEVICE|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
219684977|NCT03500926|DEVICE|total hip replacement - short femoral stem|total hip replacement with short femoral stem
219684978|NCT00142272|DRUG|Ciprofloxacin|
219684979|NCT05130645|DIAGNOSTIC_TEST|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
219684980|NCT00765947|DRUG|Aliskiren|Aliskiren 150 or 300 mg
219684981|NCT00765947|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
219684982|NCT00765947|DRUG|Amlodipine|Amlodipine 5 or 10 mg
219684983|NCT03104608|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
219684984|NCT03104608|OTHER|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
219684985|NCT02058589|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219684986|NCT02058589|DRUG|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219684987|NCT04516239|DEVICE|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
219684988|NCT04516239|DEVICE|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
219684989|NCT00420719|DEVICE|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
219684990|NCT02638987|PROCEDURE|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
219684991|NCT02143024|BEHAVIORAL|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
219684992|NCT02143024|BEHAVIORAL|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
219223620|NCT02409680|DRUG|Low dose aspirin|Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
219223621|NCT02409680|DRUG|Placebo|Placebo
219223622|NCT06536504|OTHER|Steinway Spirio M recording/player piano|Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.
219223623|NCT06863051|PROCEDURE|Immediate Implant Placement and Alb-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and Albumin PRF Gel
219223624|NCT06863051|PROCEDURE|Immediate Implant Placement and L-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and L-PRF
219684993|NCT01792102|DRUG|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
219223625|NCT06857981|OTHER|Clinical data collection|Patient's data will be collected, including: date of birth, age, gender/sex, pathology for admission, comorbidities, treatment received, and proposed interventions based on initial assessment.
219223626|NCT05355428|OTHER|offering of breast milk feed 3 hours prior to planned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
219223627|NCT06020274|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
219223628|NCT02761616|OTHER|eBC treated participants|No intervention administered in this retrospective observational study.
219223629|NCT06211530|DEVICE|SpO2 Sensor Testing|Participants participating in this study will be connected sensors.The participants are exposed to a desaturation protocol. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
219684994|NCT02894814|BEHAVIORAL|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
219684995|NCT02894814|BEHAVIORAL|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
219684996|NCT01945944|DRUG|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
219684997|NCT01945944|DRUG|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
219684998|NCT01167400|BEHAVIORAL|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
219684999|NCT01167400|BEHAVIORAL|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
219685000|NCT06813339|DRUG|UDP-003|The UDP-003 finished product is clear, colourless to yellow liquid that is intended to be a sterile solution for IV bolus push administration in sterile water at a concentration of 300 mg/mL.
219685001|NCT06813339|OTHER|Placebo|Placebo will be provided as a sterile clear, colourless solution formulated to match viscosity of the UDP-003 solution.
219685002|NCT03973398|PROCEDURE|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
219685003|NCT06600919|OTHER|Preoperative Music Therapy Session|"Upon admission to the operating room:~Patients in the music therapy group will undergo a 20-minute music therapy session while lying on a stretcher in a designated room. This session will be conducted using the Music Care® application (https://www.music.care).~The sessions are standardized and divided into several phases, following a U-shaped sequence. The effect of this U-sequence is first achieved by a phase of reduced tempo, instrumental density, frequency, and sound volume , followed by a phase of reactivation .~Patients will be allowed to choose the musical style based on their preferences (influenced by their musical tastes and ethnicity). Given the ethnically diverse population of Réunion Island, a wide range of musical preferences is expected."
219223630|NCT07006532|DRUG|Tocilizumab|The trial is an open-labeled randomized clinical trial that evaluates the safety and efficacy of Tocilizumab as an add-on therapy to standard of care treatment of Plasmapheresis, IVIG, and Rituximab in treatment of CAMR in kidney transplant recipients.
219685004|NCT01908309|DRUG|Iobitridol 350|
219685005|NCT01908309|DRUG|Iodixanol 320|
219685006|NCT05754541|DEVICE|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
219685007|NCT02711358|DRUG|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
219685008|NCT02711358|DRUG|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
219685009|NCT04442477|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
219685010|NCT04442477|DIETARY_SUPPLEMENT|Protein Fraction|Protein fractions
219685011|NCT04794517|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
219685012|NCT04794517|OTHER|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
219685013|NCT02213588|DIETARY_SUPPLEMENT|AOX blend|Antioxidant supplement
219685014|NCT02213588|DIETARY_SUPPLEMENT|Placebo|
219685015|NCT02385565|OTHER|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
219685016|NCT02385565|OTHER|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
219685017|NCT04501055|BEHAVIORAL|perineal nerve block|An anesthesia method to block perineal nerve
219685018|NCT04501055|BEHAVIORAL|periprostatic block|An anesthesia method to block periprostate
219685019|NCT04041921|PROCEDURE|Percutaneous coronary intervention|
219685020|NCT04041921|PROCEDURE|Coronary Artery Bypass Grafting|
219685021|NCT04041921|DRUG|Medical treatment|
219685022|NCT03932461|PROCEDURE|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
219685023|NCT03932461|PROCEDURE|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
219685024|NCT04435938|RADIATION|Stereotactic Body Radiotherapy (SBRT)|45 Gy in 5 fractions delivered once every 3-4 days
219685025|NCT04917705|OTHER|Collection of biological samples|Skin, muscle fiber and blood sampling
219685026|NCT03809234|DRUG|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
219685027|NCT03809234|DRUG|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
218985024|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
219685028|NCT06342856|DRUG|co enzyme Q10 , L- Carnitine|Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
219685029|NCT05011578|RADIATION|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
219685030|NCT02049983|DEVICE|Use of Levita Magnetics Grasper|
219685031|NCT01575756|BIOLOGICAL|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
219685032|NCT01575756|BIOLOGICAL|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
219685033|NCT00959283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219685034|NCT00959283|OTHER|Pharmacological Study|Correlative studies
219685035|NCT06587633|DEVICE|Endoscopic procedure|tSVFem injection + 3D scaffold placement
219685036|NCT03927859|OTHER|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
219685037|NCT04177433|DRUG|Depo-Medrol Injectable Product|Corticosteroid
219685038|NCT04177433|DRUG|Saline|Placebo
219685039|NCT06609291|BEHAVIORAL|Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology|The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
218985025|NCT02304679|OTHER|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
218985026|NCT02304679|DEVICE|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
218985027|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
218985028|NCT02304679|OTHER|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
218985029|NCT02304679|OTHER|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
218985030|NCT03479970|OTHER|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
218985031|NCT03479970|OTHER|GNPT|It's a computeritzed program of cognitive telerehabilitation
218985032|NCT05305820|BEHAVIORAL|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
218985033|NCT05305820|BEHAVIORAL|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
219685040|NCT06859983|BEHAVIORAL|progressive relaxation exercise|he researcher will provide approximately 45 minutes of information about relaxation exercises to the nurses. During the application of progressive relaxation exercises, the necessary precautions to be taken during and after the exercise will be explained to the nurses. In the study, a sound recording that includes the PRE will be uploaded to each nurse's phone. The relaxation exercises CD created by the Turkish Psychologists Association will be used for the sound recording. The first section of the CD, which is 10 minutes long, defines deep relaxation, its purpose, and the precautions to be taken during the exercise. The second 30-minute section explains the relaxation exercises with the sound of a stream and verbal instructions. The third 30-minute section contains only relaxation music without any verbal instructions. After the training, nurses will be given the sound recording in CD form. Nurses will be asked to perform the PRE according to the instructions. They will be instructed
219685041|NCT06404359|OTHER|Exercise|"There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets."
219685042|NCT06404359|OTHER|Physical activity recommendations|They will be provided with a physical activity plan to be followed on a weekly basis.
219685043|NCT00610779|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
219685044|NCT00610779|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
219685045|NCT06613295|RADIATION|SABR|SABR
219685046|NCT06613295|PROCEDURE|Separation surgery|Separation surgery
219685047|NCT03552601|OTHER|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
219685048|NCT03552601|OTHER|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
219685049|NCT06612138|OTHER|pilates exercises|the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises
219685050|NCT06612138|OTHER|yoga exercises|"the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing."
219685051|NCT06612138|OTHER|tai chi exercises|the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.
219099917|NCT03942679|OTHER|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
219099918|NCT03942679|OTHER|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
219099919|NCT02825134|DEVICE|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
219099920|NCT02825134|DEVICE|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
219099921|NCT05168917|DIAGNOSTIC_TEST|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
219099922|NCT05182073|DRUG|FT576 (Allogenic CAR NK cells with BCMA expression)|Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
219099923|NCT05182073|DRUG|Cyclophosphamide|Conditioning Agent
219099924|NCT05182073|DRUG|Fludarabine|Conditioning Agent
219685052|NCT06612138|OTHER|tradional physical therapy|Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
219685053|NCT06613373|DRUG|Dalpiciclib|Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
219685054|NCT06613191|DRUG|Aspirin|Participant will be on aspirin alone or P2Y12 inhibitor alone
219685055|NCT06613191|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|Participant will be taking either P2Y12 inhibitor at time of colonoscopy
219685056|NCT06612450|DEVICE|turbinate surgery|Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
219685057|NCT06612398|BEHAVIORAL|Preoperative preparation video|An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
219685058|NCT06612411|DRUG|B. subtilis|2 capsules, 3 times a day, orally taken for one month
219099925|NCT05182073|DRUG|Daratumumab|Anti-CD38 Monoclonal Antibody
219099926|NCT05182073|DRUG|Bendamustine|Conditioning Agent
219099927|NCT00649363|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
219099928|NCT00649363|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
219099929|NCT01313546|OTHER|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
219099930|NCT03615521|OTHER|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
219099931|NCT03615521|OTHER|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
219099932|NCT03615521|OTHER|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
218985034|NCT04524897|DRUG|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
218985035|NCT01582165|DRUG|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
218985036|NCT01582165|DRUG|Placebo.|Placebo once daily vs rosuvastatin for 6 months
218985037|NCT00569881|DRUG|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
218985038|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
218985039|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
218985040|NCT06505421|BEHAVIORAL|Resistance training|Eccentric resistance training and tradional resistance training
218985041|NCT02671305|PROCEDURE|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
219685059|NCT06612411|DRUG|Dead B. subtilis|2 capsules, 3 times a day, orally taken for one month
219685060|NCT04495751|DIETARY_SUPPLEMENT|Muscadine grape extract|Four pills twice daily
218985042|NCT02671305|PROCEDURE|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
218985043|NCT00814970|DEVICE|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
219685061|NCT04495751|DRUG|Placebo|Four pills twice daily.
219685062|NCT04495751|OTHER|Quality of Life Assessment|Ancillary studies
219685063|NCT04495751|OTHER|Questionnaires|Ancillary studies
219685064|NCT04495751|OTHER|Participant Feedback|Ancillary studies
219685065|NCT05430685|DIETARY_SUPPLEMENT|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
219685066|NCT05430685|OTHER|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
219685067|NCT02643433|BIOLOGICAL|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
219685068|NCT02643433|BIOLOGICAL|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
219685069|NCT04862260|DRUG|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
219685070|NCT03082469|DEVICE|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
219685071|NCT01470703|DEVICE|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O
219685072|NCT01470703|OTHER|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for \>6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
219685073|NCT00049725|DRUG|Daclizumab|
219685074|NCT00379405|DRUG|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
219685075|NCT05094375|DRUG|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219685076|NCT05094375|DRUG|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219685077|NCT00092924|DRUG|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
219685078|NCT04056949|DRUG|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
219685079|NCT04056949|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
219099933|NCT03615521|OTHER|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
219685080|NCT04042584|PROCEDURE|Visio conference device evaluation (DVCM)|Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
219685081|NCT00889629|DRUG|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
219685082|NCT00889629|DRUG|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
219099934|NCT03615521|OTHER|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
219685083|NCT00889629|DRUG|25-OH Vitamin D3|All groups received cholecalciferol
219685084|NCT02772666|DEVICE|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
219099935|NCT04297787|DEVICE|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
219099936|NCT05885113|BEHAVIORAL|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
219099937|NCT02176044|DRUG|Sodium Nitroprusside infusion|
219099938|NCT02176044|OTHER|Placebo|
219099939|NCT05404230|DIETARY_SUPPLEMENT|Fish oil|Fish oil containing poly unsaturated fatty acids.
219099940|NCT05404230|DIETARY_SUPPLEMENT|Corn oil|Corn oil
219099941|NCT01713699|PROCEDURE|lumbar puncture|
219099942|NCT05538182|DEVICE|Spectacles|Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
219099943|NCT03045029|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
219099944|NCT02679521|DEVICE|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
219099945|NCT02679521|DEVICE|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
219099946|NCT05449886|PROCEDURE|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
219685085|NCT02772666|OTHER|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
219685086|NCT01046864|DRUG|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
219685087|NCT01046864|DRUG|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
219685088|NCT01046864|DRUG|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
219685089|NCT01046864|DRUG|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
219685090|NCT01046864|DRUG|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
219685091|NCT01046864|DRUG|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
219685092|NCT01046864|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
219685093|NCT03618901|OTHER|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
219685094|NCT03618901|OTHER|PD SAFEx|Progressive proprioception training.
219685095|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
219685096|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
219685097|NCT05006378|DIETARY_SUPPLEMENT|Placebo Capsule|"Placebo capsules consumed by subjects as described in Placebo Comparator study arms section."
219685098|NCT03541291|DEVICE|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
219685099|NCT00687986|RADIATION|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
219685100|NCT00687986|PROCEDURE|primary surgery|an anatomical surgical resection with lymph node dissection
219685101|NCT00675987|DRUG|losartan|losartan 100 mg tablets 1 tab po QD
219685102|NCT00675987|DRUG|Placebo control|Placebo 1 po QD
219685103|NCT03885414|BEHAVIORAL|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
219685104|NCT03885414|BEHAVIORAL|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
219685105|NCT03714763|DRUG|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
219685106|NCT03714763|OTHER|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
219685107|NCT02359110|DRUG|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
219685108|NCT02359110|OTHER|Placebo|Patient will receive placebo tab less than 1 hour before surgery
219685109|NCT01429662|BEHAVIORAL|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
219685110|NCT01429662|BEHAVIORAL|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
219685111|NCT02174107|RADIATION|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1\*8 Gy; 5\*4 Gy and 10\*3 Gy
219685112|NCT02174107|PROCEDURE|Percutaneous vertebroplasty|
219685113|NCT04771013|BIOLOGICAL|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
219685114|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
219685115|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
219685116|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
219685117|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
219685118|NCT02762448|DRUG|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
219685119|NCT00823134|DEVICE|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
219685120|NCT03941340|DRUG|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1
219685121|NCT05909020|OTHER|No intervention.|No intervention.
219685122|NCT06520527|DIETARY_SUPPLEMENT|Andrographis paniculata|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
219685123|NCT06520527|BEHAVIORAL|Brisk Walking Exercise|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
219685124|NCT06520527|OTHER|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
219685125|NCT01019161|DRUG|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
218985044|NCT03986398|OTHER|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
218985045|NCT05754931|OTHER|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
218985046|NCT05754931|OTHER|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
218985047|NCT00222443|DRUG|Irinotecan|
218985048|NCT02826902|DRUG|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
219099947|NCT02317224|PROCEDURE|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
219099948|NCT02317224|PROCEDURE|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
219099949|NCT02317224|PROCEDURE|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
219099950|NCT00204269|DRUG|Testosterone Gel Wolff|
219099951|NCT06020664|DRUG|NOX-1416+SOC|NOX1416+SOC as provided in Arm/group description
219099952|NCT06020664|OTHER|Placebo+SOC|Placebo+SOC as provided in Arm/group description
219685126|NCT01019161|DRUG|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
219685127|NCT06129383|PROCEDURE|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
219685128|NCT01403558|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
219685129|NCT05897749|OTHER|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
219685130|NCT05897749|OTHER|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
219685131|NCT02976610|DEVICE|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
219685132|NCT06491355|DRUG|mfolfox6 and hlx04 regimen and Serplulimab|mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
219685133|NCT06491355|DRUG|mfolfox6 and hlx04 regimen|In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
219685134|NCT05235932|PROCEDURE|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
218985049|NCT02826902|DRUG|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
218985050|NCT02671175|DRUG|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
218985051|NCT02671175|DRUG|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
218985052|NCT04893044|BEHAVIORAL|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
218985053|NCT04694742|OTHER|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
218985054|NCT02998944|OTHER||not any intervention for this study
218985055|NCT00793091|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
218985056|NCT00793091|DRUG|Placebo|4 drops applied daily for 120 days
218985057|NCT02515825|DEVICE|CADence|
219685135|NCT05235932|PROCEDURE|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
219685136|NCT03983408|DIETARY_SUPPLEMENT|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
219099953|NCT01547520|DRUG|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
219099954|NCT01547520|DRUG|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
219685137|NCT03983408|DIETARY_SUPPLEMENT|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
219685138|NCT01906242|OTHER|water|
219685139|NCT01906242|OTHER|sodium hypochlorite|
219685140|NCT01906242|OTHER|sodium bicarbonate|
219685141|NCT01906242|OTHER|chlorhexidine|
219099955|NCT00888758|DEVICE|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
219099956|NCT00888758|DEVICE|everolimus|200 patients with STEMI will be treated with PROMUS DES.
219099957|NCT03815084|DRUG|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
219099958|NCT04740203|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
219099959|NCT00997724|PROCEDURE|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
219099960|NCT00487734|RADIATION|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
219099961|NCT00487734|DRUG|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
219099962|NCT05289284|OTHER|No intervention|No intervention
219685142|NCT01061697|DRUG|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
219685143|NCT00193414|DRUG|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
219685144|NCT00193414|DRUG|Gemcitabine|1500mg/m2, 30min IV
219685145|NCT00493012|DIETARY_SUPPLEMENT|vitamin D|6 drops of a vitamin D containing oil
219685146|NCT05435469|OTHER|Questionnaires|Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
219685147|NCT00563121|PROCEDURE|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
219685148|NCT04561648|DRUG|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
219685149|NCT01519817|BIOLOGICAL|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
219685150|NCT04228484|OTHER|Placebo|Placebo infusion
219685151|NCT04228484|OTHER|GIP receptor antagonization|GIP(3-30)NH2 infusion
219685152|NCT04545450|DRUG|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
219685153|NCT04545450|DRUG|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
219685154|NCT02585453|DEVICE|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
219685155|NCT02585453|DEVICE|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
219685156|NCT02585453|DEVICE|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
219685157|NCT02962427|DRUG|Sphenopalatine ganglion Block|
219685158|NCT02962427|PROCEDURE|Epidural blood patch|
219685159|NCT00742794|OTHER|Observation|Observation of sting frequency
219685160|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 60 mg iron sulfate|control agent
219685161|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (60 mg iron)|contains 60 mg of iron
219685162|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (10 mg iron)|contains 10 mg iron
219685163|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 10 mg iron sulfate|control agent
219685164|NCT03407313|DEVICE|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
219685165|NCT02667340|DIETARY_SUPPLEMENT|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game \& at halftime)
219685166|NCT02667340|OTHER|Placebo|0.7 g glucose per kg body mass in two ingestions (before game \& at halftime)
219685167|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
219685168|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
219685169|NCT02881658|DIETARY_SUPPLEMENT|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
219685170|NCT02881658|DIETARY_SUPPLEMENT|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
219685171|NCT03234036|DRUG|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
219685172|NCT03234036|DRUG|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
219685173|NCT03234036|DRUG|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
219099963|NCT01420432|BIOLOGICAL|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
219099964|NCT05957302|DRUG|Ketamine|100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
219099965|NCT05957302|DRUG|Fentanyl|100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
219685174|NCT03234036|DRUG|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
219685175|NCT05857722|BEHAVIORAL|Jóvenes Capibara|Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
219685176|NCT01913301|DRUG|Alagebrium|
219685177|NCT02999789|DEVICE|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
219685178|NCT02999789|DEVICE|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
219685179|NCT00975377|PROCEDURE|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
219685180|NCT06077539|DRUG|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
219099966|NCT05174923|BEHAVIORAL|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
219099967|NCT05174923|BEHAVIORAL|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
219099968|NCT05174923|BEHAVIORAL|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
219099969|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) according to Expiratory Flow Limitation|Positive End expiratory pressure will be set according to the positive end-expiratory pressure able to revert the expiratory flow limitation.
219685181|NCT06077539|DRUG|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
219685182|NCT06077539|DRUG|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
219685183|NCT06077539|OTHER|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
219685184|NCT03221114|BEHAVIORAL|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
219685185|NCT06959082|DRUG|VS-101|VS-101
219685186|NCT06959082|DRUG|Cisplatin|Cisplatin
219685187|NCT06959082|RADIATION|Radiation|Radiation
219685188|NCT06225973|DRUG|TL-925|TL-925 is an eye drop.
219685189|NCT06225973|OTHER|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
219685190|NCT00552695|DEVICE|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
219685191|NCT00552695|DEVICE|Placebo|Placebo patch identical in appearance to Synera
219685192|NCT06959069|OTHER|Intermittent Fasting - Late feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The first window will allow a feeding period from12 p.m. to 8 p.m. (late feeding window).
219685193|NCT06959069|OTHER|Intermittent Fasting - Early feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The second window will allow a feeding period from 8 a.m. to 4 p.m (early feeding window).
219685194|NCT00191243|DRUG|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
219685195|NCT00191243|DRUG|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
219099970|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) not according to Expiratory Flow Limitation|Positive End expiratory pressure will be set not according to the positive end-expiratory pressure able to revert the expiratory flow limitation but to a standard level of 4 cmH2O.
219099971|NCT00351637|DRUG|Sublingual Methadone|
219223631|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
219099972|NCT04328402|DIAGNOSTIC_TEST|Polysomnography|Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
219099973|NCT02670252|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
219099974|NCT02670252|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
219099975|NCT02670252|RADIATION|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
219099976|NCT02336919|BEHAVIORAL|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
219685196|NCT06958692|DRUG|Dextromethorphan and Bupropion Sustained-Release Tablets|Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
219099977|NCT01407588|PROCEDURE|Magnetic navigation|Ablation with use of the magnetic navigation system
219685197|NCT06958692|DRUG|Placebo|Oral placebo tablets, taken daily for 6 weeks.
219685198|NCT00408551|DRUG|floxuridine|Given IV
219685199|NCT00408551|DRUG|fluorouracil|Given IV
219099978|NCT01407588|PROCEDURE|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
219099979|NCT03913208|PROCEDURE|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
219099980|NCT03913208|PROCEDURE|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
219099981|NCT04094337|BEHAVIORAL|Internet-assisted treatment|Internet-assisted treatment
219685200|NCT00408551|DRUG|irinotecan hydrochloride|Given IV
219685201|NCT00408551|DRUG|leucovorin calcium|Given IV
219685202|NCT00408551|DRUG|oxaliplatin|Given IV
219685203|NCT06959134|BEHAVIORAL|The intervention will be mainly focused on the lifestyle modification and medication adherence, and self monitoring at home|In the intervention arm, study participants will received health education mainly based on lifemodification changes which will include; eating healthy diet, adopting healthy physical exercise, smoking cessation , moderate alcohol consumption and stress amanagement), and will be taugh on medication adherence, but also on self monitoring of blood pressure for detecting the variation and react accordingly.
219685204|NCT04831034|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
219685205|NCT01569282|PROCEDURE|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
219685206|NCT01569282|PROCEDURE|Stent strategy|Biliary and/or enteral stents on demand
219099982|NCT02489266|BIOLOGICAL|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
219099983|NCT02489266|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
219099984|NCT02489266|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
219099985|NCT02489266|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219099986|NCT04988425|DRUG|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
219685207|NCT00600093|DRUG|Amantadine|IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
219685208|NCT04214587|DIAGNOSTIC_TEST|tissue and blood sampling|only diagnostics will be peformed
219685209|NCT01417468|BEHAVIORAL|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
219685210|NCT01417468|BEHAVIORAL|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
219685211|NCT00917826|DRUG|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
219685212|NCT00917826|DRUG|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
219685213|NCT00917826|DRUG|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
219685214|NCT02408848|OTHER|Observational|This is an observational study. There is no intervention.
219685215|NCT00994942|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
219685216|NCT03600831|DRUG|Docetaxel plus cisplatin|cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
219685217|NCT03600831|RADIATION|radiotherapy|radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
219685218|NCT00197093|DRUG|SB773812|
219099987|NCT04988425|DRUG|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
219685219|NCT04102618|BIOLOGICAL|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
219685220|NCT04102618|DRUG|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
219685221|NCT04102618|DRUG|Atezolizumab|1200 mg administered intravenously on Day 3
219685222|NCT04102618|DRUG|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
219685223|NCT06034093|DEVICE|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
219685224|NCT05827276|OTHER|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
219685225|NCT05621447|DRUG|TAS-303, [14C]TAS-303|oral administration on day 1
219685226|NCT00018317|BEHAVIORAL|low protein diet|
219685227|NCT00018317|BEHAVIORAL|resistance training|
219685228|NCT00018317|BEHAVIORAL|combination of diet control and exercise|
219685229|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
219685230|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
219685231|NCT06958497|DEVICE|Sphinkeeper™|The procedure was performed under spinal anesthesia, with the patients in lithotomy position. Ten 2-mm perianal skin incisions were made 1-2 cm from the anal margin (i.e., 0.5-1 cm from the intersphinteral sulcus), equidistant one each other, around the entire anal circumference, to allow implantation of 10 prostheses using a specifically designed delivery system (THD Sphinkeeeper Delivery System, THD Sp, Correggio, Italy). The introducer was placed through each skin incision in the intersphincteric space where the prostheses were delivered at a level below the puborectalis muscle. All of the steps were verified by palpation and direct vision using the Eisenhammer anal speculum. Patients were discharged on the same day and recommended to avoid any trauma or sexual practice during the first 48 hours after implantation. A 5-day course of antibiotics was also prescribed.
219685232|NCT04547140|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
219685233|NCT04547140|DRUG|Placebo|Intravenous infusion
219685234|NCT04547140|DRUG|Standard Medical Treatment|SMT
219685235|NCT01819714|OTHER|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
219685236|NCT05369143|OTHER|Chiropractic care|The mechanical properties of chiropractic adjustment have been investigated; and although the actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent68 and the duration of the thrust is always less than 200 milliseconds.
219685237|NCT05369143|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
219685238|NCT05083663|DRUG|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
219685239|NCT01344239|PROCEDURE|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
219685240|NCT06300502|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
219685241|NCT06300502|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
219685242|NCT06300502|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion.
219685243|NCT06300502|DEVICE|1064nm Nd:YAG Laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
219685244|NCT05116553|BEHAVIORAL|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
219685245|NCT05116553|DEVICE|APP + CA|An APP with a CA (Conversational Agent).
219685246|NCT02196298|DEVICE|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
219685247|NCT02196298|OTHER|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
219685248|NCT04613739|BEHAVIORAL|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
219685249|NCT05382546|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
219685250|NCT00517608|DEVICE|Laparoscopic colectomy|
219685251|NCT03458377|OTHER|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
219099988|NCT04988425|DRUG|Saline|Injection of the same volume of saline immediately after admission before surgery
219685252|NCT05853029|COMBINATION_PRODUCT|Combined shockwave therapy & conventional therapy , focused shockwave therapy& conventional therapy , conventional therapy|"The device used for management is from Storz-Medical company; Duolith-SD1 with focused and radial module.~\- Conventional therapy in the form of eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007)."
219685253|NCT00003537|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
219685254|NCT03209193|DRUG|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
219685255|NCT03209193|DRUG|Desflurane|Desflurane use as main anesthetic drug during the surgery
219099989|NCT02540785|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
219099990|NCT02540785|PROCEDURE|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
219099991|NCT03880084|OTHER|Observation|To systematically assess the onset of delirium, quantify the level of agitation/sedation, estimate the grade of pain and survey the level of dyspnea in patients undergoing non invasive mechanical ventilation
219099992|NCT04372823|BEHAVIORAL|Policy/program|Policy/program to improve nutrition and increase physical activity
219099993|NCT05094193|PROCEDURE|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
219099994|NCT05094193|PROCEDURE|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
219685256|NCT04221360|DRUG|CKD-375|Test drug, QD, PO
219685257|NCT04221360|DRUG|D390|Reference drug, QD, PO
219685258|NCT02953496|DRUG|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
219685259|NCT05532384|BEHAVIORAL|Early resumption of oral intake|as above
219685260|NCT05532384|BEHAVIORAL|Late resumption of oral intake|as above
219685261|NCT02958787|RADIATION|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
219685262|NCT00093483|BIOLOGICAL|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
219685263|NCT00093483|DRUG|arsenic trioxide|IV over 1 hour on day 1
219685264|NCT00093483|DRUG|cytarabine|IV over 1 hour every 12 hours on days 1-6
219685265|NCT00093483|DRUG|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
219685266|NCT01033630|DRUG|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
219685267|NCT01033630|DRUG|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
219685268|NCT01033630|DRUG|Placebo|Image-matched placebo, made with starch.
219685269|NCT04658979|OTHER|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
219099995|NCT05094193|PROCEDURE|Trocar site infiltration placebo|20 mL of normal saline
219685270|NCT00099164|DRUG|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
219685271|NCT03019991|DRUG|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
219685272|NCT03019991|DRUG|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
219685273|NCT03019991|DRUG|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
219685274|NCT00061841|BEHAVIORAL|exercise|
219099996|NCT05094193|PROCEDURE|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
219685275|NCT00944346|DRUG|Metformin HCl|
219685276|NCT00945412|DEVICE|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
219099997|NCT04108481|DRUG|Durvalumab|Immunotherapy
219099998|NCT04108481|RADIATION|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
219099999|NCT01285193|BEHAVIORAL|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
219100000|NCT05770830|DEVICE|Esophageal temperature|Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
219100001|NCT05770830|DEVICE|Skin core temperature|Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
219685277|NCT00945412|DEVICE|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
219685278|NCT03175926|DEVICE|placebo Diskus®|device will be given daily for one week, two puffs per day
219685279|NCT03175926|DEVICE|placebo Ellipta®|device will be given daily for one week, one puff per day
219685280|NCT03175926|DEVICE|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
219685281|NCT01050946|BIOLOGICAL|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
219685282|NCT04024605|DIETARY_SUPPLEMENT|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
219685283|NCT04024605|DIETARY_SUPPLEMENT|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
219685284|NCT04024605|DIETARY_SUPPLEMENT|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
219685285|NCT04024605|DIETARY_SUPPLEMENT|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
219685286|NCT04978324|BIOLOGICAL|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
219685287|NCT04978324|PROCEDURE|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
219685288|NCT02757729|DRUG|PAC-14028 cream 0.1%|Topical application
219685289|NCT02757729|DRUG|PAC-14028 cream 0.3%|Topical application
219685290|NCT02757729|DRUG|PAC-14028 cream 1.0%|Topical application
219685291|NCT02757729|DRUG|PAC-14028 cream vehicle|Topical application
219685292|NCT03409536|DEVICE|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
219685293|NCT02972983|DRUG|Daptomycin|Adjuvant therapy for up to five days
219685294|NCT02972983|OTHER|Placebo|Placebo
219685295|NCT04559646|PROCEDURE|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
219685296|NCT04559646|DRUG|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
219685297|NCT04559646|DRUG|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
219685298|NCT04559646|DIAGNOSTIC_TEST|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
219685299|NCT04559646|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
219685300|NCT04559646|DIAGNOSTIC_TEST|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
219685301|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and dairy fat|12-weeks, 3x per day
219685302|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and plant fat|12-weeks, 3x per day
219685303|NCT05235360|BEHAVIORAL|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
219685304|NCT05235360|BEHAVIORAL|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
219685305|NCT05235360|BEHAVIORAL|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
219685306|NCT05235360|BEHAVIORAL|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
219685307|NCT05235360|BEHAVIORAL|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
219685308|NCT05235360|BEHAVIORAL|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
219685309|NCT05235360|BEHAVIORAL|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
219100002|NCT06329193|OTHER|Mid-Season Camp Period Loading|The daily gym included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), crunches, sit-ups, reverse sit-ups, prone bridge, side bridge, bench press, mini squat (with body weight and/or ancillary equipment), lunge (with body weight and/or ancillary equipment), leg extension, leg curl, leg press, calf raises (with body weight and/or ancillary equipment), and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities). The field-based exercises included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), dynamic balance (with different balance trainer such as Both Sides Utilized \[BOSU\], trampoline), tactical training, passing, dribbling, and shooting practice, agility and speed practice, and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities)
219100003|NCT01494870|PROCEDURE|PCI|urgent PCI on admission
219100004|NCT00242801|DRUG|Gefitinib|
219685310|NCT00270296|DRUG|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
219685311|NCT00270296|DRUG|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
219685312|NCT00270296|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
219685313|NCT00270296|DRUG|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
219685314|NCT05337176|OTHER|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
219685315|NCT05983796|DIAGNOSTIC_TEST|18F-HER2 PET|18F-HER2 PET
219100005|NCT04588818|DRUG|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
219100006|NCT06047236|OTHER|Sampling|Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
219685316|NCT06470490|BEHAVIORAL|psychoeducational|educational program
219685317|NCT05448378|DIETARY_SUPPLEMENT|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
219685318|NCT04685252|OTHER|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
219685319|NCT04685252|OTHER|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
219685320|NCT02090504|DRUG|Sodium Oxybate (SMO)|
219685321|NCT02090504|DRUG|Oxazepam|
219100007|NCT04092179|DRUG|Enasidenib|Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.
219100008|NCT04092179|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
219685322|NCT02432885|DRUG|Enalapril|up to 20mg bid
219685323|NCT00737100|DRUG|Placebo Respimat|patient to receive placebo matching active drug once daily
219685324|NCT00737100|DRUG|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
219685325|NCT00737100|DRUG|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
219685326|NCT02571140|DRUG|Teriparatide|subcutaneous standard injection
219685327|NCT02571140|DRUG|Oral PTH (1-34)|Different optimization of API
219685328|NCT04240223|DRUG|Brilacidin|Brilacidin
219685329|NCT04240223|DRUG|Placebo|Placebo
219685330|NCT04240223|RADIATION|4Mq 99mTc-DTPA|4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
219685331|NCT00580957|DRUG|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
219685332|NCT00580957|DRUG|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
219685333|NCT00631059|OTHER|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
219685334|NCT00427141|DRUG|GSK580416|
219685335|NCT03249428|DEVICE|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
219100009|NCT00294216|DRUG|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
219100010|NCT00380120|DRUG|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
219100011|NCT00380120|DRUG|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
219100012|NCT04034459|DRUG|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1
219100013|NCT04034459|DRUG|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
219100014|NCT04034459|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
219100015|NCT04034459|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² day 1
219100016|NCT04034459|DRUG|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
219685336|NCT04245592|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
219685337|NCT04245592|DIETARY_SUPPLEMENT|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
219685338|NCT00735943|OTHER|No intervention|No intervention
219685339|NCT00434772|DRUG|glucagon|
219685340|NCT01265394|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
219685341|NCT05423457|BEHAVIORAL|Vegan diet|The participants were advised to eat foods in their original type.
219685342|NCT02464124|DRUG|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
219685343|NCT02464124|DRUG|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
219685344|NCT01629550|PROCEDURE|skin disinfection prior catheter insertion|
219685345|NCT00746226|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
219685346|NCT00746226|BIOLOGICAL|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
219685347|NCT04033146|DEVICE|Ankle Exoskeleton Assistance|The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.
219685348|NCT00275171|DRUG|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
219685349|NCT00275171|DRUG|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
219685350|NCT00275171|OTHER|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
219685351|NCT02739217|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
219685352|NCT00500578|DRUG|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
219685353|NCT00500578|DRUG|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
219685354|NCT01908712|DRUG|Lamazym|ERT, i.v. infusions weekly
219685355|NCT02548624|DEVICE|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
219685356|NCT01719380|DRUG|LGX818|
219685357|NCT01719380|DRUG|Cetuximab|
219685358|NCT01719380|DRUG|BYL719|
219685359|NCT05991011|OTHER|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
219100017|NCT04034459|DRUG|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
219100018|NCT02831179|DRUG|Capecitabine|Given PO
219100019|NCT02831179|DRUG|Temozolomide|Given PI
219100020|NCT02831179|DRUG|Veliparib|given PO
219100021|NCT02831179|OTHER|Pharmacological Study|Correlative studies
219100022|NCT02831179|OTHER|Laboratory Biomarker Analysis|Correlative studies
219100023|NCT03514862|BEHAVIORAL|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
219100024|NCT03514862|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
219100025|NCT03514862|BEHAVIORAL|Self-Practice|4 weeks of self-practice after the MBI training.
219100026|NCT00406471|DRUG|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
219100027|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
219685360|NCT05991011|OTHER|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
219685361|NCT05991011|OTHER|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
219685362|NCT05991011|OTHER|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
219685363|NCT05991011|OTHER|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
219100028|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
219685364|NCT05991011|OTHER|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
219685365|NCT02962310|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
219100029|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
219100030|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
219100031|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
219100032|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
219100033|NCT02536001|DEVICE|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
219100034|NCT02536001|DEVICE|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
219100035|NCT01435434|DEVICE|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
219100036|NCT02415777|DRUG|Ursodeoxycholic acid, thiamine, riboflavin|
219100037|NCT01610154|DRUG|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
219100038|NCT05332977|DEVICE|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
219100039|NCT05332977|DEVICE|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
219100040|NCT00426322|DEVICE|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
219100041|NCT01678443|BIOLOGICAL|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
219100042|NCT01678443|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
219100043|NCT01678443|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
219100044|NCT03322826|PROCEDURE|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
219685366|NCT02962310|DRUG|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
219685367|NCT00777868|DRUG|Low Strength IDP-108|Topical application once a day for 9 months
219685368|NCT00777868|DRUG|High Strength IDP-108|Topical application once a day for 9 months
219100045|NCT03322826|PROCEDURE|lymphadenectomy|Routine lymph nodes dissection in lung cancer
219685369|NCT00777868|DRUG|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
219100046|NCT03623932|DRUG|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
219100047|NCT03623932|BEHAVIORAL|Hypnosis|8 hypnosis group sessions during 2 months
219100048|NCT03413254|OTHER|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
219685370|NCT00777868|DRUG|Vehicle|Topical application once a day for 9 months
219685371|NCT02842047|BEHAVIORAL|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
219685372|NCT02842047|BEHAVIORAL|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
219685373|NCT02842047|BEHAVIORAL|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
219685374|NCT00455169|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
219685375|NCT02311829|OTHER|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
219685376|NCT02479555|DRUG|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
219685377|NCT04601727|DIAGNOSTIC_TEST|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
219685378|NCT02874612|OTHER|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
219685379|NCT01064414|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
219685380|NCT01064414|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
219685381|NCT02603198|DRUG|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
219685382|NCT02603198|DRUG|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
219685383|NCT00107562|BEHAVIORAL|Adolescent Safer Sex Social Network Intervention|
219685384|NCT03065491|DIETARY_SUPPLEMENT|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
219685385|NCT03065491|OTHER|Placebo|Oral administration: 1 tablet per day
219685386|NCT02708550|BEHAVIORAL|Participatory Organizational Intervention|
219685387|NCT00995839|DRUG|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
219685388|NCT00995839|DRUG|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
219685389|NCT00995839|DRUG|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
219685390|NCT00354965|DRUG|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
219685391|NCT04795063|PROCEDURE|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
219685392|NCT04795063|PROCEDURE|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
219685393|NCT04381780|DIETARY_SUPPLEMENT|Recovery Factors|A unique porcine serum based polypeptide nutritional support
219685394|NCT01582113|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
219685395|NCT01582113|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
219685396|NCT00249873|DRUG|clopidogrel (SR25990C)|oral administration (tablets)
219100049|NCT03413254|PROCEDURE|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
219100050|NCT03413254|PROCEDURE|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
219100051|NCT03780127|DRUG|Fenfluramine Hydrochloride|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
219685397|NCT00249873|DRUG|placebo|oral administration (tablets)
219685398|NCT03315845|OTHER|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
219685399|NCT03860740|OTHER|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
219685400|NCT03860740|OTHER|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
219685401|NCT04348708|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
219100052|NCT01860443|OTHER|Telepsychiatry collaborative program|"The intervention includes:~* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~* Online supervision in a web platform by specialists~* Telephone monitoring"
219100053|NCT01860443|OTHER|Usual care|"* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
219100054|NCT01024790|BEHAVIORAL|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
219100055|NCT02715817|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
219685402|NCT03131167|DRUG|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
219685403|NCT03131167|DRUG|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
219685404|NCT01699048|PROCEDURE|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
219685405|NCT01699048|PROCEDURE|PCI|Multi-vessel PCI with DES
219685406|NCT01699048|PROCEDURE|CABG|Coronary artery bypass graft (CABG) treatment
219685407|NCT00165503|DRUG|Cisplatin|
219685408|NCT00165503|DRUG|Sodium Thiosulfate|
219685409|NCT00165503|DRUG|ALIMTA|
219685410|NCT00643201|DRUG|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
219685411|NCT00643201|DRUG|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
219685412|NCT00643201|DRUG|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
219685413|NCT00643201|DRUG|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
219685414|NCT00643201|DRUG|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
219685415|NCT00643201|DRUG|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
219100056|NCT02715817|OTHER|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
219685416|NCT02976519|DRUG|BI 443651|twice daily
219100057|NCT02715817|OTHER|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
219100058|NCT02435771|DRUG|Ergocalciferols|Treatment 1- 400,000 IU
219100059|NCT02435771|DRUG|Ergocalciferols|Treatment 2- 800,000 IU
219100060|NCT02304250|DRUG|Dexamethasone|dexamethasone 1ml (5mg)
219100061|NCT02304250|DRUG|saline|saline 1ml
219100062|NCT00073879|BIOLOGICAL|alemtuzumab|
219100063|NCT00073879|BIOLOGICAL|graft-versus-tumor induction therapy|
219100064|NCT00073879|DRUG|cyclophosphamide|
219100065|NCT00073879|DRUG|fludarabine phosphate|
219100066|NCT00073879|PROCEDURE|allogeneic bone marrow transplantation|
219100067|NCT00073879|PROCEDURE|peripheral blood stem cell transplantation|
219100068|NCT02117232|DEVICE|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
219100069|NCT02117232|DEVICE|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
219100070|NCT05236621|DRUG|Pomalidomide|4 mg pomalidomide capsules administered orally
219100071|NCT05236621|DRUG|Dexamethasone|40 mg dexamethasone tablets administered orally
219100072|NCT01091623|OTHER|training|
219100073|NCT01091623|OTHER|training|
219100074|NCT01091623|OTHER|training|
219100075|NCT02757482|OTHER|training|
219685417|NCT02976519|DRUG|Placebo|twice daily
219685418|NCT04716972|OTHER|survey|Online survey
219685419|NCT04716972|OTHER|Interview|Interview
219685420|NCT02346708|DEVICE|Real TMS|real treatment
219685421|NCT02346708|DEVICE|Sham TMS|placebo treatment
219685422|NCT02085200|OTHER|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
219685423|NCT02085200|OTHER|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
219685424|NCT04215562|COMBINATION_PRODUCT|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
219685425|NCT01908868|OTHER|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
219685426|NCT01908868|OTHER|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
219685427|NCT01908868|OTHER|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
219685428|NCT05419297|DRUG|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
219685429|NCT05419297|OTHER|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
219100076|NCT06158763|BEHAVIORAL|Web-based CBT guided self-help Interventions|An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
219100077|NCT04508179|DRUG|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
219685430|NCT05419297|DEVICE|actigraph|Subjects will wear this device to monitor sleep and activity
219685431|NCT05419297|BEHAVIORAL|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
219685432|NCT05419297|OTHER|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
219685433|NCT05419297|OTHER|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
219685434|NCT05419297|BEHAVIORAL|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
219685435|NCT05419297|BEHAVIORAL|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
219685436|NCT03728439|DEVICE|LED before|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
219685437|NCT03728439|DEVICE|LED interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
219685438|NCT03728439|DEVICE|LED after|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
219685439|NCT03069872|DIAGNOSTIC_TEST|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
219685440|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
219685441|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
219685442|NCT00928434|DRUG|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
219685443|NCT03928054|OTHER|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
219685444|NCT06410664|OTHER|72-hour HME exchange interval group|All patients in the experimental arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 72 hours. At the exchange point, both outlets of the HME filter will be swabbed.
219685445|NCT06410664|OTHER|24-hour HME exchange interval group|All patients in the control arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 24 hours. At the exchange point, both outlets of the HME filter will be swabbed.
219685446|NCT04758013|PROCEDURE|Epidural injection through thoracic epidural catheter|The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.
219100078|NCT04508179|DRUG|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
219100079|NCT04508179|DRUG|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
219100080|NCT04508179|DRUG|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
219100081|NCT04508179|DRUG|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
219685447|NCT04758013|PROCEDURE|Without epidural injection|The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
219685448|NCT02607501|DEVICE|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
219685449|NCT05767853|OTHER|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
219685450|NCT03263455|OTHER|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
219685451|NCT03263455|OTHER|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
219685452|NCT04702464|DRUG|Fedratinib|Fedratinib
219100082|NCT04100122|PROCEDURE|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
219685453|NCT04702464|DRUG|Fluconazole|Fluconazole
219685454|NCT04549662|DIETARY_SUPPLEMENT|Active A|Powdered formula containing whey protein and arginine
219685455|NCT04549662|DIETARY_SUPPLEMENT|Active B|Powdered formula containing whey protein
219685456|NCT04549662|DIETARY_SUPPLEMENT|Lipid bolus|Omega-3 fatty acids
219685457|NCT04549662|DIETARY_SUPPLEMENT|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
219685458|NCT06331507|DEVICE|CMR patch|The Cardiac Magnetic Resonance (MR) patch is a sequence modification for enhancing the images in patients with devices (CIED) for assessing heart muscle scar. The Philips tested patch supports multiple cardiac MR imaging enhancements compiled from several individual patches generated by multiple Philips MR research collaborators for use on 1.5 Tesla Philips scanners.
219100083|NCT01662531|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
219100084|NCT01207323|DRUG|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
219100085|NCT06468072|OTHER|Expressivity protocol for children with autism|The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
219685459|NCT01687114|OTHER|cranberry juice|27% cranberry juice
219685460|NCT05224700|BEHAVIORAL|JAPI|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. All the activities are games with the following structure: an introduction with instructions and protagonist selection, followed by a practice exercise to ensure that the children understand what they have to do (the exercise is repeated until the child performs it correctly), and, finally, the activity itself (4 different activities with 5 tries each). The first 10 sessions jointly stimulate working memory and emotion knowledge (4 activities focused on each skill per session), while the 10 remaining sessions stimulate inhibitory control and the selection of prosocial behaviours. In the inhibitory control activities, they must suppress automatic stimuli and processes; in the emotion recognition activities, they must identify basic emotions; and in the selection of prosocial behaviours, they must choose an option to deal with a social problem.
218985124|NCT05633823|OTHER|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
219685461|NCT05224700|BEHAVIORAL|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
219685462|NCT02281617|BEHAVIORAL|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
219685463|NCT06410716|DEVICE|Valve-regulated pleural drainage system|Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
219685464|NCT03276598|DRUG|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
219685465|NCT03276598|DRUG|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
219685466|NCT03276598|DRUG|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
219685467|NCT03276598|DRUG|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
219685468|NCT03276598|DRUG|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
218985125|NCT00491075|DRUG|Pemetrexed|500 mg/m\^2 IV Over 10 Minutes on Day 1.
218985126|NCT00491075|DRUG|Gemcitabine|1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
218985127|NCT03660540|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
219685469|NCT02138565|PROCEDURE|Gastric by-pass surgery|
219685470|NCT01278342|DRUG|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
219685471|NCT01278342|DRUG|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
219685472|NCT01278342|DRUG|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
219685473|NCT05862493|DIAGNOSTIC_TEST|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
219685474|NCT02016768|PROCEDURE|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
219685475|NCT03210493|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
219685476|NCT05946226|BIOLOGICAL|IMC002 injection|"three different IMC002 Doses will be escalated in 3+3 design"
218985128|NCT04316065|DRUG|YHP1906|YHP1906 Tab. 5 mg
218985129|NCT04316065|DRUG|YHR1902|Comparator. YHR1902 Tab. 5 mg
218985130|NCT01603355|DRUG|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
218985131|NCT03177694|DEVICE|Wireless bed sensor|Remote data collection
218985132|NCT05746312|BEHAVIORAL|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
218985133|NCT04798924|DEVICE|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
218985134|NCT04798924|DEVICE|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
219100086|NCT06468072|OTHER|Expressivity protocol for non-autistic children|The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
219685477|NCT04869592|BIOLOGICAL|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
219685478|NCT04869592|BIOLOGICAL|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
219685479|NCT04869592|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
219685480|NCT00171990|DRUG|Famciclovir|
219685481|NCT00224302|DRUG|Duloxetine|
219685482|NCT04968678|DIAGNOSTIC_TEST|P-wave duration measurement on 12 lead ECG with standard parameters|Hospital records will be used in order to obtain baseline characteristics and the most recent 12-lead ECG in sinus rhythm prior to ablation will be used to calculate PWD. Measurement of the PWD will be obtained at standard surface ECG recording settings of 25mm/s and 10mm/mV and measured accordingly to our previous protocol. In brief, all ECGs obtained will subsequently be anonymised and randomised by an Independent Clinical Investigator (ICI) before measured by the main clinical investigators blinded to initial results. If a dispute of the measurements arouse, consensus will be used to resolve it after consulting the Chief Investigator (CI) blinded to the results. Bland-Altman plots to minimise bias will be used
219685483|NCT05439421|BEHAVIORAL|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
219685484|NCT05439421|BEHAVIORAL|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
219685485|NCT06195436|BEHAVIORAL|Acceptance and Commitment Therapy for people with and without depression|Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
219100087|NCT05147168|OTHER|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
219685486|NCT01848574|OTHER|standardized multifaceted information procedure to improve patients' comprehension|
219685487|NCT06223230|OTHER|Nutritional psychological interventions and vomit-free management|Nutritional psychological interventions and vomit-free management
219685488|NCT04253340|DIAGNOSTIC_TEST|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
219685489|NCT02654639|DRUG|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
219685490|NCT02654639|DRUG|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
219685491|NCT03606811|PROCEDURE|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
219685492|NCT03606811|PROCEDURE|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
219685493|NCT03154580|DRUG|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
219685494|NCT02348229|PROCEDURE|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
219685495|NCT02348229|PROCEDURE|ERAS protocols|No bowel preparation
219685496|NCT02348229|PROCEDURE|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
219685497|NCT02348229|PROCEDURE|ERAS protocols|Vasoactive drugs used if need be
219685498|NCT02348229|PROCEDURE|ERAS protocols|Temperature management
219685499|NCT02348229|PROCEDURE|ERAS protocols|Intra-abdominal drains not to be used
219685500|NCT02348229|PROCEDURE|ERAS protocols|Intraperitoneal Ropivicaine infusion
219685501|NCT02348229|PROCEDURE|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
219685502|NCT02348229|PROCEDURE|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
219685503|NCT02348229|PROCEDURE|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
219685504|NCT02348229|PROCEDURE|ERAS protocols|On the5-6th postoperative day Check discharge criteria
219685505|NCT02348229|PROCEDURE|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
219685506|NCT02348229|PROCEDURE|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
219685507|NCT02348229|PROCEDURE|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
219685508|NCT02348229|PROCEDURE|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
219100088|NCT05923580|BEHAVIORAL|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
219100089|NCT02941393|DEVICE|Intrauterine pressure catheter|
219100090|NCT02941393|DEVICE|External tocodynamometry|
219100091|NCT06371131|PROCEDURE|Right -stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
219685509|NCT02348229|PROCEDURE|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
219685510|NCT02348229|PROCEDURE|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
219685511|NCT03011866|DRUG|Wound topically irrigated with 500mg TXA|
219685512|NCT03011866|DRUG|1mg/kg/hr TXA intravenous infusion till the last suture|
219685513|NCT02996071|PROCEDURE|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
219685514|NCT05481801|BIOLOGICAL|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
219685515|NCT05481801|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
219685516|NCT05481801|BIOLOGICAL|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
219685517|NCT05481801|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
219685518|NCT04214522|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
219685519|NCT00987168|DRUG|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
219685520|NCT03760224|OTHER|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
219685521|NCT03760224|OTHER|SMS group|SMS group for 8 weeks
219685522|NCT05459909|DIETARY_SUPPLEMENT|Synbiotic supplementation|Daily supplementation of synbiotic
219685523|NCT05459909|BEHAVIORAL|Dietary intervention|Increased fruits and vegetables consumption
219685524|NCT02256098|DEVICE|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
219685525|NCT02256098|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
219685526|NCT00021723|BIOLOGICAL|AN-1792 also known as AIP-001|
219685527|NCT02988011|PROCEDURE|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
219685528|NCT02988011|DIETARY_SUPPLEMENT|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
219685529|NCT04806022|OTHER|Fatigability assessment|Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
219685530|NCT02773498|PROCEDURE|conventional TESE|usual procedure for sperm extraction
219685531|NCT02773498|PROCEDURE|Micro TESE|procedure of extraction is performed under the operating microscope
219685532|NCT00313846|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
219685533|NCT00313846|DRUG|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
219100092|NCT02640443|DRUG|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
219685534|NCT02276963|DRUG|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
219685535|NCT03049826|OTHER|Nutritional status|Body composition and nutrient status
219685536|NCT01462630|DRUG|pazopanib hydrochloride|Given PO
219685537|NCT01462630|OTHER|laboratory biomarker analysis|Correlative studies
219685538|NCT01462630|PROCEDURE|positron emission tomography|Correlative studies
219685539|NCT01462630|PROCEDURE|computed tomography|Correlative studies
219685540|NCT01462630|RADIATION|fludeoxyglucose F 18|Correlative studies
219685541|NCT03943628|BEHAVIORAL|Familias Unidas|
219685542|NCT01809756|OTHER|Caphosol|Caphosol 4 times a day
219685543|NCT03565354|DRUG|iron isomaltoside(Monofer®)|intravenous iron isomaltoside
219685544|NCT01102712|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
219685545|NCT01302405|DRUG|PRI-724|Dose escalation
219685546|NCT01765296|DRUG|CG100649|2 mg capsule
219685547|NCT01765296|DRUG|Celecoxib|200 mg capsule
219685548|NCT01765296|DRUG|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
219685549|NCT03936088|DEVICE|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
219685550|NCT03936088|DEVICE|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
219685551|NCT06314386|OTHER|Systems Analysis and Improvement Approach for TB (SAIA-TB)|The Systems Analysis and Improvement Approach for TB (SAIA-TB) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by clinic staff with support from study personnel in intervention clinics. Components of the intervention include TB cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally optimize TB screening, evaluation, diagnosis, TB preventive therapy and TB disease treatment initiation, successful treatment, and TB-free survival among the population at the intervention clinics.
219685552|NCT00707044|PROCEDURE|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
219685553|NCT00707044|PROCEDURE|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
219685554|NCT06446934|DEVICE|CPAP|Initial CPAP titration and subsequent CPAP therapy for 12 weeks
219685555|NCT05934006|BIOLOGICAL|spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples
219685556|NCT02541344|DEVICE|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
219685557|NCT02541344|DEVICE|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
219685558|NCT02541344|DEVICE|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
219685559|NCT04358016|DRUG|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
219685560|NCT04358016|DRUG|Somatostatin|Somatostatin
219685561|NCT05370898|DRUG|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
219685562|NCT05370898|DRUG|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
219685563|NCT05370898|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
219685564|NCT05122689|DIETARY_SUPPLEMENT|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
219685565|NCT05122689|DIETARY_SUPPLEMENT|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
219685566|NCT03933449|BIOLOGICAL|pembrolizumab|IV infusion
219685567|NCT03933449|DRUG|paclitaxel|IV infusion
219685568|NCT03933449|DRUG|docetaxel|IV infusion
219685569|NCT03933449|DRUG|irinotecan|IV infusion
219685570|NCT02376686|OTHER|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
219100093|NCT02446795|DRUG|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
219100094|NCT02446795|DRUG|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
219685571|NCT06519916|BEHAVIORAL|Assessment of mental performance|There was no intervention, the mental performance was assessed
219685572|NCT02659943|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
219685573|NCT02659943|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
219685574|NCT02659943|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
219685575|NCT00345124|BEHAVIORAL|high sodium diet|250-350 mmol
219685576|NCT00345124|BEHAVIORAL|Low Sodium Diet|25-35 mmol
219685577|NCT03705702|OTHER|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
219685578|NCT03705702|BEHAVIORAL|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
219685579|NCT02463669|DEVICE|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
219685580|NCT01359930|OTHER|placebo|matching placebo
219685581|NCT01359930|DRUG|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
219685582|NCT02198196|BEHAVIORAL|Weight Talk-Mindfulness|
219685583|NCT01474850|PROCEDURE|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
219685584|NCT01576575|DRUG|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
219685585|NCT01576575|DRUG|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
219685586|NCT01576575|DRUG|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
219685587|NCT01576575|DRUG|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
219100095|NCT02446795|DRUG|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
219100096|NCT04564950|OTHER|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
219100097|NCT02428244|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
219100098|NCT02428244|BEHAVIORAL|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
219100099|NCT05915962|PROCEDURE|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
219100100|NCT01115985|DRUG|ASP1585|oral
219100101|NCT01115985|DRUG|atorvastatin|oral
219100102|NCT05118230|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
219100103|NCT01511796|OTHER|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
219100104|NCT03372837|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
219100105|NCT02689934|DIETARY_SUPPLEMENT|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
219100106|NCT02689934|DIETARY_SUPPLEMENT|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
219100107|NCT00247819|PROCEDURE|Blood draw|
219100108|NCT01110343|BEHAVIORAL|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
219100109|NCT01110343|BEHAVIORAL|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
219100110|NCT06342427|DIAGNOSTIC_TEST|DESTINEX|A panel of microRNA, whose expression level is tested in serum samples.
219100111|NCT02131038|OTHER|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
219100112|NCT03528174|DEVICE|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
219100113|NCT03528174|DEVICE|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
219100114|NCT06363058|OTHER|ES Cycling Training|Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks
219100115|NCT05878119|DRUG|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
219100116|NCT05878119|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
219100117|NCT05878119|OTHER|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
219100118|NCT05878119|OTHER|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
219223632|NCT06871228|DEVICE|PPG/ECG dual mode based smartwatch|The intervention initiates anticoagulation when AF is detected as either a single episode ≥1 hour or cumulative ≥2 hours/24h (adjusted for monitoring compliance), triggering a 30-day NOAC therapy cycle that restarts if AF recurs during treatment. Participants are required to wear the device ≥12 hours daily, supported by automated reminders (vibration/SMS/phone alerts) and a reward system to reinforce adherence.
219223633|NCT06871228|DRUG|Continuous DOAC therapy|Continuous standard-dose DOAC therapy with dose adjustments per the drug labels.
219223634|NCT06683105|OTHER|MyIBDDiet app|Participants in the Standard of Care arm will be administered the intervention (using the app) for 30 days, and participants in the MYIBDDiet arm will use the app for 60 days.
219685588|NCT01321034|DRUG|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
219685589|NCT03971331|DEVICE|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
219685590|NCT05649670|OTHER|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
219685591|NCT03400527|OTHER|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
219685592|NCT05562245|OTHER|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
219685593|NCT01670864|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
219685594|NCT01670864|BEHAVIORAL|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
219685595|NCT04270812|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
219685596|NCT05122611|OTHER|no intervention, imaging study only|Imaging study only
219685597|NCT03531866|BEHAVIORAL|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
219685598|NCT06551896|DRUG|Pemigatinib|Pemigatinib and immune checkpoint inhibitors
219685599|NCT01723072|BIOLOGICAL|Omalizumab|Humanized monoclonal antibody against human IgE
219685600|NCT01723072|DRUG|Placebo|Placebo to omalizumab
219685601|NCT03511703|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
219685602|NCT03511703|DRUG|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
219685603|NCT01418469|DIETARY_SUPPLEMENT|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
219685604|NCT01418469|DIETARY_SUPPLEMENT|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
219685605|NCT01418469|DIETARY_SUPPLEMENT|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
219685606|NCT01418469|DIETARY_SUPPLEMENT|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
219685607|NCT02785211|BEHAVIORAL|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
219685608|NCT03362762|OTHER|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
219685609|NCT04001088|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
219685610|NCT04001088|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
219685611|NCT02671253|PROCEDURE|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
219685612|NCT04664257|BEHAVIORAL|e-CBT|e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
219685613|NCT01753882|DRUG|Lexapro|Agent + training vs Placebo + training
219685614|NCT01753882|DRUG|Placebo|Agent + training vs Placebo + training
219685615|NCT00954681|DRUG|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
219685616|NCT00222703|BEHAVIORAL|Smoking relapse prevention|
219685617|NCT04564001|DRUG|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
219685618|NCT04564001|DRUG|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
219685619|NCT03172728|BEHAVIORAL|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
219685620|NCT05401994|PROCEDURE|screw retained arch bar|maxillomandibular fixation with bone screwed arch bar
219685621|NCT05401994|PROCEDURE|conventional Erich's Arch Bar|maxillomandibular fixation with conventional arch bar fixed to the teeth
219685622|NCT02307227|DRUG|Trastuzumab|
219685623|NCT02307227|DRUG|Paclitaxel|
219685624|NCT02307227|DRUG|Epirubicin|
219685625|NCT02307227|DRUG|Docetaxel|
219685626|NCT03490617|DRUG|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
219685627|NCT03786107|DIAGNOSTIC_TEST|Almac HER-Seq Assay|whole blood sample analysis
219685628|NCT01666483|PROCEDURE|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
219685629|NCT01666483|PROCEDURE|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
219685630|NCT04283812|DEVICE|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
219685631|NCT04572828|PROCEDURE|Paracervical Block|Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
219685632|NCT04572828|DRUG|550 mg Naproxen Sodium 60 minutes before the procedure|550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
219685633|NCT04572828|PROCEDURE|The capped needle|The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
219685634|NCT03949595|OTHER|Data collection|
219100119|NCT01356316|BIOLOGICAL|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
219100120|NCT02263001|OTHER|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
219100121|NCT02263001|OTHER|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
219100122|NCT04976114|PROCEDURE|Story book with information about surgery techniques|Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
219100123|NCT04976114|PROCEDURE|Video with information about surgery techniques|Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
219100124|NCT04976114|PROCEDURE|Story book and Video with information about surgery techniques|Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
219100125|NCT00380016|PROCEDURE|Percutaneous Transluminal Angioplasty|
219100126|NCT00006002|DRUG|dexamethasone|
219100127|NCT00006002|DRUG|semaxanib|
219685635|NCT02590666|PROCEDURE|Bipolar Polypectomy|Polyps resection with bipolar electrode
219685636|NCT02590666|PROCEDURE|Mechanical Polypectomy|Polyps resection with microscissors or graspers
219685637|NCT02590666|DEVICE|Bipolar electrode|Bipolar electrode used to performs polypectomy
219685638|NCT02590666|DEVICE|Microscissors or graspers|Mechanical instruments used to performs polypectomy
219685639|NCT02895269|BEHAVIORAL|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
219685640|NCT06057168|DRUG|Elucirem|Intravenous administration
219685641|NCT06057168|DRUG|Dotarem|Intravenous administration
219685642|NCT06169735|DRUG|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
219685643|NCT06169735|DEVICE|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
219685644|NCT02990130|OTHER|Observational|
219685645|NCT06957951|OTHER|Conventional Physiotherapy|Application of hot packs, TENS (transcutaneous electrical nerve stimulation), therapeutic ultrasound, and posture/activity education for low back pain management.
219685646|NCT06957951|BEHAVIORAL|Core Stabilization Exercises|Supervised core stabilization exercises including planks, bird-dog, and pelvic bridging, targeting trunk muscle strength and stability.
219685647|NCT06957951|BEHAVIORAL|WBV-Supported Core Exercises|Core stabilization exercises performed on a whole-body vibration platform (30 Hz frequency, low amplitude \~2 mm) during exercise execution to enhance neuromuscular stimulation.
219685648|NCT06474039|DRUG|Trelegy or Anoro|Both drugs delivered via Ellipta device and blinded package appearance
219685649|NCT06483932|OTHER|Dried barberry|Subjects will ingest 10 grams of powdered seedless barberry on a daily basis, in conjunction with the low-calorie diet.
219685650|NCT06483932|OTHER|Low-calorie diet|Diet with 500 kcal subtracted from the daily energy requirement
219685651|NCT02633969|DRUG|Indomethacin Capsules low dose|
219685652|NCT02633969|DRUG|Indomethacin Capsules high dose|
219685653|NCT04715464|OTHER|review of surveillance cultures within the past year|"ASC results are reported as positive or negative based on the culture source. Antimicrobial susceptibility testing is performed but not reported; however, physicians may obtain susceptibility information for MDR GNB only if clinically indicated through the microbiology department.~1. Nasal swab for MRSA~2. Respiratory specimens~i. Sputum for MRSA, VRE, and Multi Drug Resistant gram-negative Bacteria (MDR GNB) (if not intubated but with productive cough) ii. Endotracheal aspirate for MRSA, VRE, and MDR GNB (if intubated) c. Drainage from any wounds for MRSA, VRE, and MDR GNB d. Rectal/ perianal swab for VRE, and MDR GNB e. Urine for MRSA, VRE, and MDR GNB (from patients catheterized prior to admission only)"
219685654|NCT05237726|DRUG|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
219685655|NCT05237726|DRUG|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
219685656|NCT05237726|DRUG|Unfractionated heparin 5000 U q8 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
219685657|NCT02038179|DRUG|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
219685658|NCT02038179|DRUG|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
219685659|NCT02899975|OTHER|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
219685660|NCT02927054|OTHER|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
219685661|NCT02426008|OTHER|Growth Factors and Cytokine adding to embryo culture media|
219685662|NCT02426008|OTHER|No Intervention|Nothing to Add
219685663|NCT00181675|DRUG|galantamine HBr|
219685664|NCT02221648|DRUG|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
219100128|NCT00997737|DEVICE|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
219100129|NCT01379976|DRUG|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
219223635|NCT07007247|OTHER|Mind-WIN self-help only|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication
219223636|NCT07007247|OTHER|Mind-WIN blended care|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication. In addition to the content provided by the Mind-WIN aftercare module participants get six digital contacts with a psychotherapist.
219223637|NCT06873204|DIETARY_SUPPLEMENT|Soluble Arabinoxylan|10 grams of soluble arabinoxylan diluted in 200 mL of water, twice daily for 3 consecutive weeks.
219100130|NCT01379976|DRUG|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
219223638|NCT06873204|DIETARY_SUPPLEMENT|Rice Bran|10 grams of rice bran fiber diluted in 200 mL of water, twice daily for 3 consecutive weeks.
219223639|NCT06873204|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10 grams of maltodextrin diluted in 200 mL of water, twice daily for 3 consecutive weeks.
219223640|NCT06867705|DEVICE|Resilience PRO|The patient will use Resilience PRO remote symptoms monitoring.
219223641|NCT07014280|DRUG|Bevacizumab|anti-VEGF
219223642|NCT07014280|DRUG|Triamcinolone Acetonide|corticosteroid
219685665|NCT02221648|DRUG|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
219685666|NCT01820247|DRUG|enteral nutrition|
219685667|NCT01820247|DRUG|Tripterygium glycosides|
219685668|NCT00184938|DRUG|morphine|
219685669|NCT00184938|DRUG|naloxone|
219685670|NCT00184938|DRUG|Technetium-TC99m-labeled Annexin A5|
219685671|NCT00184938|PROCEDURE|forearm ischemic exercise|
219685672|NCT00184938|PROCEDURE|ten minute forearm ischemia|
219685673|NCT00953888|DRUG|AZD5069|Single dose of oral solution.
219685674|NCT00953888|DRUG|Placebo|Single dose of oral solution.
219685675|NCT06397430|DIETARY_SUPPLEMENT|parenteral nutrition supplements|parenteral nutrition
219685676|NCT06397430|DIETARY_SUPPLEMENT|enteral nutrition supplements|enteral nutrition
219685677|NCT06397430|DIETARY_SUPPLEMENT|mixed nutrition supplements|mixed nutrition
219223643|NCT07012330|DRUG|Capecitabine (Xeloda)|Capecitabine (1650 mg/m2/day) was administered for two weeks from the start of each PRRT cycle.
219685678|NCT03975257|DEVICE|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
219685679|NCT03639246|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
219685680|NCT03639246|DRUG|Paclitaxel (Pac)|Paclitaxel is active comparator
219685681|NCT03639246|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
219223644|NCT07012330|DRUG|177Lu-DOTATATE|Patients with advanced somatostatin receptor positive GEP NET or bronchopulmonary NET were included to receive four cycles of 7.4 GBq 177Lu-Dotatate.
219223645|NCT07014150|DRUG|Lenvatinib|daily,8mg/ day for less than 60kg, 12mg/ day for more than 60kg, for 9 weeks
219685682|NCT03639246|OTHER|Placebo|Placebo comparator
219685683|NCT05430802|DRUG|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
219685684|NCT01168921|DRUG|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
219685685|NCT05074641|OTHER|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
219685686|NCT05074641|OTHER|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
219685687|NCT02438189|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
219685688|NCT02937623|DEVICE|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
219685689|NCT06522815|DEVICE|CART-I plus|"CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method."
219685690|NCT06522815|DEVICE|Polysomnography|"In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring"
219685691|NCT00324974|DRUG|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
219685692|NCT00324974|DRUG|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
219685693|NCT05060575|OTHER|Education and Telephone Counceling|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
219685694|NCT03207191|DRUG|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
219685695|NCT03207191|DRUG|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
219685696|NCT04687904|BEHAVIORAL|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
219685697|NCT04687904|BEHAVIORAL|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
219685698|NCT02533934|DRUG|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
219685699|NCT03198858|PROCEDURE|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
219685700|NCT03198858|PROCEDURE|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
219685701|NCT01922258|DRUG|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
219685702|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
219685703|NCT00299819|BIOLOGICAL|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
219685704|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
219685705|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
219685706|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
219685707|NCT04397874|DIAGNOSTIC_TEST|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
219685708|NCT04552132|DEVICE|Multisonic vs Sonic activation of irrigants|Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
219100131|NCT04813601|DEVICE|ATLAS 2030|The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
219100132|NCT00979602|BIOLOGICAL|GSK2340274A|One intramuscular injection
219100133|NCT00979602|BIOLOGICAL|GSK2340273A|One intramuscular injection
219100134|NCT04658823|DRUG|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
219100135|NCT04658823|DRUG|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
219100136|NCT00235924|DRUG|soy isoflavone|
219100137|NCT04244435|PROCEDURE|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
219100138|NCT04244435|DRUG|thoracic epidural analgesia|thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
219100139|NCT04244435|DRUG|analgesia of opioids|Opioids will be used for perioperative analgesia
219100140|NCT03040921|PROCEDURE|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
219100141|NCT04803617|OTHER|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
219100142|NCT05531032|OTHER|Phone Interview|Phone interview questionnaire
219223646|NCT07014150|DRUG|Iparomlimab and Tuvonralimab|7.5mg/kg, every 3 weeks, for 3cycles.
219685709|NCT03722706|OTHER|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
219685710|NCT00920959|DRUG|FP 100mcg|Once-daily dosing
219685711|NCT00920959|DRUG|FSC 100/50mcg|Once-daily dosing
219685712|NCT00920959|DRUG|Placebo|Once-daily dosing
219685713|NCT05679453|DRUG|Lornoxicam 8 Mg Oral Tablet|Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
219685714|NCT05023538|OTHER|Cycling|Exercise on bicycle ergometer
219685715|NCT06478329|OTHER|Progressive Core Stabilization Exercise Training|The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
219685716|NCT00595543|DRUG|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
219685717|NCT00595543|DRUG|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
219685718|NCT00595543|DRUG|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
219685719|NCT00512499|BEHAVIORAL|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
219685720|NCT00512499|BEHAVIORAL|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
219685721|NCT00512499|BEHAVIORAL|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
219685722|NCT03930095|BEHAVIORAL|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
219100143|NCT06636838|BEHAVIORAL|Spanish-Speaking Provider|Spanish speaking patients will be seen by our Spanish-speaking provider
219100144|NCT06315803|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
219223647|NCT07012317|OTHER|High Fiber Bar with Inulin|Bar with Inulin - high fiber
219223648|NCT07012317|OTHER|High Fiber bar with Fiber Blend|Bar with a fiber blend of psyllium husk and bran fibers - high fiber
219100145|NCT02872298|DEVICE|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
219100146|NCT06431438|DRUG|TQA3810|TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
219100147|NCT02926235|DRUG|Amino Acid|Treatment arm
219100148|NCT02926235|OTHER|Placebo|
219100149|NCT01719237|DRUG|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
219100150|NCT01719237|DRUG|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
219685723|NCT03930095|BEHAVIORAL|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
219100151|NCT02712398|DEVICE|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
219685724|NCT03119948|DRUG|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
219100152|NCT04402164|DEVICE|Herbst appliance|telescopic appliance for mandibular advancement
219100153|NCT01516411|BEHAVIORAL|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
219100154|NCT02238717|DRUG|PF-06372865 (65mg)|single oral dose (65 mg)
219100155|NCT02238717|DRUG|PF-06372865 (15mg)|single oral dose (15mg)
219100156|NCT02238717|DRUG|Pregabalin|single oral dose (300mg)
219100157|NCT02238717|DRUG|Placebo|matching oral placebo
219100158|NCT05302505|OTHER|simulation-based training|Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
219685725|NCT03119948|DRUG|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
219685726|NCT03119948|DRUG|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
219685727|NCT04964661|OTHER|Medical Imaging|MRI imaging
219100159|NCT06107764|DEVICE|intermittant theta burst stimulation (iTBS)|iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.
219685728|NCT01951417|DRUG|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
219685729|NCT01951417|OTHER|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
219685730|NCT01951417|OTHER|Foam Wash|Foam Wash (twice daily)
219685731|NCT04577417|DRUG|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
219685732|NCT01472445|DRUG|Vitamin D|
219685733|NCT00382785|BEHAVIORAL|moderated support|one 12-week online support group led by a professional healthcare provider
219685734|NCT00382785|BEHAVIORAL|peer-led|12-week online support in a peer-led format
219100160|NCT06107764|DEVICE|continuous theta burst stimulation (cTBS)|cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses
219685735|NCT01649115|OTHER|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
219685736|NCT00649077|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fasting
219685737|NCT00649077|DRUG|Mobic® Tablets 15 mg|15mg, single dose fasting
219685738|NCT01598610|DEVICE|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
219685739|NCT00653367|PROCEDURE|Nerve section|Intercostal nerve is divided during surgery
219685740|NCT00228228|BIOLOGICAL|T cell vaccination|
219685741|NCT02921945|BIOLOGICAL|SCT800|recombinant human coagulation factor VIII
219100161|NCT06107764|DEVICE|sham rTMS|sham rTMS does not deliver a significant change in magnetic field strength
219685742|NCT01043978|BEHAVIORAL|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
219685743|NCT05397197|OTHER|Electroencephalography|experimental task, neuropsychological evaluation, clinical exam
219100162|NCT03517618|DRUG|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
219100163|NCT04670237|DEVICE|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
219100164|NCT03551808|DRUG|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
219100165|NCT05345379|OTHER|Single intervention|Single intervention at the day of fixed orthodontic appliance bonding
219100166|NCT00006232|DRUG|dexamethasone|
219100167|NCT00006232|DRUG|doxorubicin hydrochloride|
219685744|NCT01705977|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
219685745|NCT01705977|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
219685746|NCT01705977|OTHER|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
219685747|NCT04009265|COMBINATION_PRODUCT|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
219685748|NCT01162616|DIETARY_SUPPLEMENT|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
219685749|NCT03573635|DEVICE|Supratube|Aspiration of orotracheal secretions with supratube device
219685750|NCT03573635|OTHER|Reference|Usual aspiration with any other device
219685751|NCT02156440|DIETARY_SUPPLEMENT|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
219685752|NCT02156440|DIETARY_SUPPLEMENT|Placebo|
219100168|NCT00006232|DRUG|idarubicin|
219100169|NCT00006232|DRUG|vincristine sulfate|
219223649|NCT07012317|OTHER|High Fiber Bar with Resistant Starch type 4|Bar with Resistant Starch type 4 - High Fiber
219223650|NCT07012317|OTHER|Low Fiber Bar|Snack Bar - Low Fiber
219223651|NCT07014163|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|0.1 mL or 0.15 mL of a 10 mg/mL deoxycholic acid solution will be injected into every 1\*1 cm2 of the lipoma using an insulin syringe with a 1cm needle attached (the max volume of injection is 2 cc in each treatment session).
219223652|NCT07013565|DRUG|Vinblastine (Velban)|Low risk cohort patients will receive 2 cycles of Induction therapy with single-drug vinBLAStine (VBL), then undergo disease assessment. If complete remission (CR) and MRD -, LR patients will continue single-drug VBL for a total of 24 months (if absent disease progression or unacceptable toxicity).
219223653|NCT07013565|DRUG|Brentuximab vedotin (Adcetris)|HR cohort patients with no previous exposure to BV will receive 2 cycles of Induction therapy with BV and NIVO \[BV + NIVO\] one every 21 days, then undergo disease assessment. Patients in CR will proceed with consolidation with RTC allogeneic SCT (SCT)\*. If patient has any response other than CR and MRD-, they will receive 2 cycles of BV, VBL, and NIVO \[BV + VBL + NIVO\] once every 21 days
219685753|NCT03066830|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219685754|NCT03066830|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219685755|NCT03066830|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219685756|NCT03066830|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
219685757|NCT03310632|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
219685758|NCT06201039|DRUG|0.5% Lidocaine Hydrochloride|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
219100170|NCT05434117|BEHAVIORAL|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
219100171|NCT05434117|BEHAVIORAL|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
219100172|NCT00710372|BIOLOGICAL|CYT006-AngQb|s.c. injection
219685759|NCT06201039|DRUG|0.9% Normal Saline|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
219685760|NCT03714464|OTHER|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
219685761|NCT03714464|OTHER|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
219685762|NCT03714464|OTHER|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
219685763|NCT02288819|DEVICE|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
219685764|NCT02288819|DRUG|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved."
219100173|NCT04627519|DIETARY_SUPPLEMENT|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
219100174|NCT05388058|DRUG|Cannabidiol|Applied topically
219223654|NCT07013565|DRUG|Nivolumab (Opdivo)|High risk cohort patients with previous exposure to Brentuximab vedotin (BV) will receive 2 cycles of Induction therapy with VBL and NIVO \[VBL + NIVO\] on day 1 and 15, then undergo disease assessment. If response is not CR, or patient has PR/SD/PD, patient will receive \[BV+VBL+NIVO\] and subsequent therapy as defined for the HR2 cohort.
219685765|NCT02039778|RADIATION|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
219100175|NCT05388058|DRUG|Placebo Administration|Applied topically
219685766|NCT06265337|DIETARY_SUPPLEMENT|Lactate|Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
219685767|NCT06265337|OTHER|Placebo|Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
219685768|NCT04736095|DIAGNOSTIC_TEST|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
219685769|NCT04736095|DIAGNOSTIC_TEST|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
219685770|NCT06553404|DEVICE|Myoslow|The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
219100176|NCT05388058|OTHER|Quality-of-Life Assessment|Ancillary studies
219100177|NCT05388058|OTHER|Questionnaire Administration|Ancillary studies
219100178|NCT05720013|DIETARY_SUPPLEMENT|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
219223655|NCT07012746|DRUG|TJ0113 capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
219223656|NCT07012746|DRUG|Placebo capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
219685771|NCT06553404|DEVICE|Single Vision|Single vision glasses
219100179|NCT05720013|DIETARY_SUPPLEMENT|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
219100180|NCT02812472|OTHER|Treadmill training with functional electrical stimulation|
219100181|NCT02812472|OTHER|Treadmill training without functional electrical stimulation|
219100182|NCT00102479|DRUG|Aripiprazole|
219685772|NCT01537848|PROCEDURE|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
219100183|NCT02484001|DRUG|ESL 800 mg|one (1) tablet of 800 mg (QD).
219685773|NCT05222165|DRUG|Infigratinib|Hard gelatin capsules for oral use
219685774|NCT01131390|DEVICE|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
219685775|NCT01185470|DEVICE|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
219685776|NCT00096538|DRUG|valganciclovir|
219685777|NCT04522557|DRUG|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
219685778|NCT00598065|OTHER|PET/CT|Synchronized PET/CT Imaging
219685779|NCT03603119|DRUG|Normal saline, Midazolam|2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
219100184|NCT02484001|DRUG|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
219100185|NCT02484001|DRUG|ESL 1600 mg|two (2) tablets of 800 mg (QD).
219685780|NCT03603119|DRUG|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
219685781|NCT00563615|DRUG|Tegaserod|
219100186|NCT02484001|DRUG|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
219100187|NCT04618263|DRUG|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
219100188|NCT00227864|BEHAVIORAL|Behavior Therapy|
219100189|NCT00227864|OTHER|Treatment as Usual|
219685782|NCT00073450|DRUG|Farnesyl Protein Transferase Inhibitor|
219685783|NCT02260206|DRUG|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
219685784|NCT00823238|DRUG|ceftazidime and tobramycin|
219685785|NCT00823238|DRUG|inhaled tobramycin|
219685786|NCT03145103|DEVICE|CT ASPHINA 409|intraocular lens
219685787|NCT00384202|DRUG|Tacrolimus|Immunosuppression
219685788|NCT05150457|DRUG|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
219685789|NCT02390089|DRUG|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
219685790|NCT02390089|OTHER|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
219100190|NCT02139657|BIOLOGICAL|RIG-C|
219100191|NCT04257708|DIAGNOSTIC_TEST|ultrasound|Transvaginal us to assess the cavity
219100192|NCT03282279|PROCEDURE|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
219685791|NCT02390089|RADIATION|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
219685792|NCT02390089|DEVICE|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
219100193|NCT01222429|OTHER|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
219685793|NCT02958371|PROCEDURE|fMRI|
219685794|NCT02958371|BEHAVIORAL|fruit-flavored drink ingestion|
219685795|NCT00039624|RADIATION|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
219685796|NCT01377636|DRUG|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
219685797|NCT01388933|DRUG|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
219685798|NCT01388933|DRUG|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
219685799|NCT00808067|DRUG|dabigatran dose 1|dabigatran high dose twice daily
219685800|NCT00808067|DRUG|dabigatran dose 2|dabigatran low dose twice daily
219685801|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
219685802|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
219685803|NCT01494805|OTHER|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
219685804|NCT01878318|DRUG|methotrexate|stable dose
219685805|NCT01878318|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
219685806|NCT04350645|DRUG|Tranexamic acid injection|1g slow bolus of tranexamic acid over 2 minutes
219685807|NCT04350645|DRUG|Normal Saline 0.9%|10mls normal saline 0.9% over 2 minutes
219685808|NCT02841384|OTHER|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
219100194|NCT01222429|OTHER|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
219685809|NCT02841384|OTHER|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
219685810|NCT00812942|PROCEDURE|colonoscopy|colonoscopy screening
219685811|NCT00812942|PROCEDURE|faecal test|faecal occult blood test for screening
219685812|NCT01383408|OTHER|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
219685813|NCT06272149|DRUG|VGN-R08b|VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
219685814|NCT02532283|DRUG|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
219685815|NCT02532283|DRUG|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
219685816|NCT02532283|DRUG|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
219685817|NCT01150253|DIETARY_SUPPLEMENT|L. paracasei fermented milk|
219685818|NCT06542900|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (SCC, VC/VS, ALIC, ITP, NAc, LHb, MFB, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
219685819|NCT00418028|DRUG|Capecitabine|
219685820|NCT03205475|BEHAVIORAL|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
219685821|NCT03205475|BEHAVIORAL|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
219685822|NCT03205475|BEHAVIORAL|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
219685823|NCT03205475|BEHAVIORAL|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
219685824|NCT03205475|BEHAVIORAL|Video Feedback Only Phase 2|Receive video feedback and calls only
219685825|NCT00526318|BIOLOGICAL|filgrastim|
219685826|NCT00526318|DRUG|carboplatin|
219685827|NCT00526318|DRUG|cisplatin|
219100195|NCT01949597|PROCEDURE|laparoscopic surgery for deep endometriosis|
219100196|NCT05834036|DRUG|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
219100197|NCT01749072|DRUG|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
219100198|NCT01749072|DRUG|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
219100199|NCT02013336|DRUG|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|chemotherapy
219100200|NCT03148236|DRUG|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
219685828|NCT00526318|DRUG|cyclophosphamide|
219685829|NCT00526318|DRUG|dacarbazine|
219685830|NCT00526318|DRUG|doxorubicin hydrochloride|
219100201|NCT03148236|OTHER|Placebo|50mL infused over 30 minutes
219100202|NCT02207517|PROCEDURE|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
219685831|NCT00526318|DRUG|etoposide phosphate|
219685832|NCT00526318|DRUG|ifosfamide|
219685833|NCT00526318|DRUG|isotretinoin|
219685834|NCT00526318|DRUG|melphalan|
219685835|NCT00526318|DRUG|topotecan hydrochloride|
219685836|NCT00526318|DRUG|vincristine sulfate|
219685837|NCT00526318|DRUG|vindesine|
219685838|NCT00526318|PROCEDURE|autologous hematopoietic stem cell transplantation|
219685839|NCT00526318|RADIATION|iobenguane I 131|
219685840|NCT00526318|RADIATION|radiation therapy|
219685841|NCT06373120|DEVICE|Microaxial flow pump|The microaxial flow pump (The CorVad percutaneous ventricular assist system device) is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.
219685842|NCT06373120|DEVICE|VA-ECMO|Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
219685843|NCT02850549|OTHER|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
219685844|NCT02578849|DRUG|L-DOPA|Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
219685845|NCT04608331|DRUG|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
219685846|NCT04608331|DRUG|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
219685847|NCT02837393|PROCEDURE|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
219685848|NCT01545141|DRUG|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
219685849|NCT01545141|DRUG|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
219685850|NCT01545141|DRUG|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
218985135|NCT04798924|DEVICE|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
218985136|NCT05751928|BIOLOGICAL|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
218985137|NCT05751928|BIOLOGICAL|anti-PD1|anti-PD1 agent in the adjuvant setting
218985138|NCT05751928|PROCEDURE|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
218985139|NCT05751928|PROCEDURE|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
218985140|NCT05396612|OTHER|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
218985141|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
218985142|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
219685851|NCT04972799|OTHER|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
219685852|NCT04972799|OTHER|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
219685853|NCT00042055|DRUG|CP-461|
219685854|NCT04262193|DRUG|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
219685855|NCT04262193|DRUG|Suvorexant Placebo|Suvorexant Placebo
219685856|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
219685857|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer only|classical arthrocentesis with lactate ringer only (control group).
219685858|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)|classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
219685859|NCT02768688|OTHER|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
219685860|NCT02768688|DRUG|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
219685861|NCT03271593|OTHER|No intervention|No intervention
219223657|NCT07013604|DEVICE|Neuromuscular Electrical Stimulation (NMES) Group,Resistance + BFR Group|"NMES Group: Receives neuromuscular electrical stimulation to the thigh muscles for 30 minutes, three times per week, over 8 weeks.~Resistance + BFR Group: Performs low-load resistance exercises with blood flow restriction applied to the thighs, also for 30 minutes per session, three times per week, over 8 weeks.~Control Group: Receives placebo treatment using a turned-off stimulation device with no active intervention during the 8-week period."
219223658|NCT07013526|PROCEDURE|Ropivacaine|Administration of ropivacaine in a Suprazygomatic maxillary nerve block
219685862|NCT05298683|DRUG|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
219685863|NCT05298683|DRUG|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
219685864|NCT05298683|DRUG|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
219685865|NCT05298683|DRUG|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
219685866|NCT05298683|DRUG|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
219685867|NCT05298683|DRUG|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
219685868|NCT00263471|DRUG|7-methylxanthine|
219223659|NCT07012512|DRUG|Use of phentolamine eye drops to reverse cycloplegia|Use of phentolamine 0.75% eye drops to reverse cycloplegia
219223660|NCT07012512|DRUG|Pilocarpine 0.1%|Use of pilocarpine 0.1% to reverse cycloplegia
219685869|NCT05701254|PROCEDURE|Transilial bone biopsy|The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
219685870|NCT06598137|PROCEDURE|Ex vivo confocal laser microscopy|Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
219685871|NCT06591793|BIOLOGICAL|AAVB-081|Single subretinal administration
219685872|NCT06609200|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
219685873|NCT00490971|DRUG|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
219685874|NCT00490971|DRUG|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
219685875|NCT00490971|DRUG|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
218985143|NCT06372964|DRUG|Lumateperone|Lumateperone administered orally, once daily.
218985144|NCT06372964|DRUG|Placebo|Matching placebo administered orally, once daily.
219223661|NCT07012512|DRUG|Combination of pilocarpine 0.1% and phentolamine 0.75%|Combination of pilocarpine 0.1% and phentolamine 0.75%
219223662|NCT07014319|DRUG|Maribavir|Participants will receive maribavir 400 mg twice daily starting from Week 1 and continuing until clearance of CMV. CMV clearance is defined as either an unquantifiable plasma CMV DNA titer (i.e., below the lower limit of quantification \[LLOQ\]) as assessed by the local laboratory, or a CMV DNA level below 500 IU/mL in plasma without evidence of CMV disease.
219685876|NCT05908253|BEHAVIORAL|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
219685877|NCT05908253|BEHAVIORAL|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
219685878|NCT05908253|BEHAVIORAL|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
219685879|NCT06613282|DEVICE|Low Intensity Transcranial Magnetic Stimulation|"* Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters."
219685880|NCT06613282|DEVICE|Auditory and visual stimulation|"* Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx."
219685881|NCT02253888|DRUG|TPV - Room condition|
219685882|NCT02253888|DRUG|TPV - Refrigerated conditions|
219685883|NCT02253888|DRUG|Ritonavir (RTV)|
219685884|NCT00691652|BIOLOGICAL|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
219685885|NCT00691652|DRUG|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
219685886|NCT00691652|GENETIC|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
219685887|NCT00691652|GENETIC|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
219685888|NCT00691652|GENETIC|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
219685889|NCT00691652|GENETIC|polymerase chain reaction|
219685890|NCT00691652|OTHER|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
219685891|NCT00691652|OTHER|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
219100203|NCT04521517|BEHAVIORAL|pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning|a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
219223663|NCT07011823|RADIATION|Partial breast-irradiation|"First, 8Gy partial breast irradiation will be delivered in immune-cold triple-negative breast cancer (TNBC) confirmed by PD-L1 and TILs.~Sequentially, standard neoadjuvant chemotherapy for triple-negative breast cancer including pembrolizumab, paclitaxel, carboplatin, doxorubicin, and cyclophosphamide (KeyNote-522 regimen) will be administered, followed by surgical treatment."
219685892|NCT00003832|DRUG|bromodeoxyuridine|Given IV
219685893|NCT00003832|PROCEDURE|conventional surgery|Undergo surgery
219685894|NCT00003832|OTHER|laboratory biomarker analysis|Correlative studies
219223664|NCT07013838|DRUG|Deucravacitinib|Deucravacitinib is a new, oral, selective, allosteric inhibitor of TYK2. It was first approved in the United States on 09-Sep-2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
219685895|NCT03328442|PROCEDURE|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
219685896|NCT03328442|PROCEDURE|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
219685897|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
219685898|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
219685899|NCT06611826|DRUG|GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy|The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
219685900|NCT04303416|DRUG|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
219685901|NCT06392035|OTHER|health education, web-based education|Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
219685902|NCT00395993|DRUG|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
219685903|NCT00395993|DRUG|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
219685904|NCT00971217|OTHER|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
219685905|NCT00971217|BEHAVIORAL|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
219685906|NCT00293553|PROCEDURE|Electronic Barostat|
219685907|NCT06525519|DRUG|ATLG|5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
219685908|NCT06525519|DRUG|ATLG|7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
219685909|NCT01984710|DEVICE|Medtronic Activa PC+S System|
219685910|NCT06473558|DEVICE|Biometrics (or AI Biomaker)|Patients will be asked to read a story and their facial expressions and audio cues will be recorded.
219685911|NCT01212094|DRUG|Rituximab|
219685912|NCT01212094|OTHER|normal saline|normal saline
219223665|NCT07013838|DRUG|Adalimumab|TNFα inhibitors have already been used in TAK treatment. Several retrospective studies have demonstrated the treatment effects of these agents in patients with TAK, including disease remission, GC tapering and vascular inflammation control. According to the ACR and EULAR guidelines, TNFis are recommended to be considered in cases of relapsing or refractory TAK. These agents (including adalimumab) are the most frequently analyzed therapeutic modalities in recent studies of TAK.
219685913|NCT01490892|DRUG|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
219685914|NCT00913601|DEVICE|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
219685915|NCT05985863|DRUG|standard medical treatment|standard medical treatment for ACLF
219685916|NCT05985863|DRUG|Placebo|5% human serum albumin in 0.9% saline (at week0, week1 and week2)
219685917|NCT05985863|DRUG|hUC-MSC|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
219685918|NCT05985863|DRUG|hUC-MSC_Prolonged|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
219223666|NCT07012993|DRUG|18F-Florbetapir or 18F-Flutemetamol|Participants will be injected with 18F-Florbetapir or 18F-Flutemetamol and imaged for up to 3 hours on a PET scanner
219223667|NCT07012811|DRUG|Topical tretinoin 0.05%|Topical tretinoin cream 0.05% applied once daily at night
219685919|NCT02112695|OTHER|[11C]diprenorphine|3 micrograms \[11C\]diprenorphine - intravenous use - 1 time
219685920|NCT00863915|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
219685921|NCT00863915|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
219685922|NCT03650153|PROCEDURE|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
219685923|NCT03650153|PROCEDURE|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
219685924|NCT01042340|OTHER|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
219685925|NCT03180203|DEVICE|INTELLiVENT-ASV|"After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if \>10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate \>35b/min or increases \>100% since start of SBT, FiO2 \>50%, PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
219685926|NCT03180203|DEVICE|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if \>10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate \>35b/min or increases \>100% since the start of SBT, saturation \<92% or the PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
219685927|NCT02065401|DRUG|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
219685928|NCT02065401|DRUG|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
219685929|NCT02065401|DRUG|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
219685930|NCT01301300|DEVICE|Disinfecting Cap|Replace standard practice with using the disinfecting cap
219685931|NCT02467361|DRUG|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
219685932|NCT02467361|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
219685933|NCT02467361|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
219685934|NCT02467361|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
219685935|NCT02019550|DEVICE|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
219685936|NCT02019550|DEVICE|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
219685937|NCT04161235|DEVICE|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
219685938|NCT04264780|OTHER|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
219685939|NCT02133391|OTHER|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
219685940|NCT02133391|OTHER|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
218985145|NCT03821649|BEHAVIORAL|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
219685941|NCT01450319|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
219685942|NCT01561937|DRUG|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
219685943|NCT01561937|DRUG|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
219685944|NCT01561937|DRUG|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
219100204|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
219100205|NCT02243774|BEHAVIORAL|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
219100206|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
219223668|NCT07012811|DRUG|Topical tretinoin 0.05% + oral isotretinoin (0.5 mg/kg/day)|Topical tretinoin cream 0.05% once daily at night + oral isotretinoin capsule in the dose of 0.5 mg/kg/day
219685945|NCT03463629|OTHER|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
219685946|NCT03463629|OTHER|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
219685947|NCT04787367|PROCEDURE|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
219685948|NCT00078403|DRUG|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
219685949|NCT00078403|DRUG|Ribavirin|One tablet or capsule containing ribavirin 200 mg
219685950|NCT02291029|DRUG|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
219685951|NCT02291029|DRUG|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
219685952|NCT02291029|DRUG|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
219685953|NCT02291029|DRUG|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
219685954|NCT02291029|DRUG|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
219685955|NCT02291029|DRUG|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
219685956|NCT05002166|OTHER|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
219100207|NCT02243774|BEHAVIORAL|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
219100208|NCT05453175|OTHER|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
219100209|NCT03813628|OTHER|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
219100210|NCT03813628|OTHER|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
219100211|NCT03813628|OTHER|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
219100212|NCT00440089|BEHAVIORAL|Hands-on-Healing|
219100213|NCT04091360|DRUG|Part A: RPL554|Single dose RPL554 via metered dose inhaler.
219100214|NCT04091360|DRUG|Placebos|Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
219100215|NCT04091360|DRUG|Part B: RPL554|Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
219100216|NCT06494969|DEVICE|Intraocular pressure measurement|Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
219100217|NCT01998490|OTHER|Animal-assisted activity|
219100218|NCT01998490|OTHER|Robot-assisted activity|
219100219|NCT02230436|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
219100220|NCT02230436|OTHER|Late drain removal|Removing drain(s) on postoperative day 4 or later
219100221|NCT01617317|DRUG|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
219100222|NCT01617317|DRUG|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
219100223|NCT05799664|DEVICE|TLD|Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
219100224|NCT05799664|OTHER|Sham TLD procedure|Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
219100225|NCT05799664|OTHER|Standard of care|Patients will also receive standard of care that meet the recommendations of GOLD guideline.
219100226|NCT04266288|DRUG|Ketamine|Active drug
219100227|NCT04266288|DRUG|Sodium Chloride 0.9%|Placebo
219100228|NCT01426282|OTHER|no intervention|no intervention
219100229|NCT01426282|OTHER|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
219100230|NCT05108064|DIAGNOSTIC_TEST|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
219100231|NCT00363194|DRUG|Pazopanib (GW786034)|Pazopanib (GW786034)
219100232|NCT00653549|DRUG|Torsemide|Tablets, 20 mg, single-dose
219100233|NCT00653549|DRUG|Demadex|tablets, 20 mg, single-dose
219100234|NCT01973036|DEVICE|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
219100235|NCT01973036|DRUG|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
219100236|NCT01455792|PROCEDURE|Biopsies using image fusion|MRI and soft image fusion guided biopsy
219100237|NCT01455792|PROCEDURE|Gold standard biopsy|Gold standard TRUS biopsy
219100238|NCT06547372|OTHER|Dietary Intervention on Atopy|The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
219100239|NCT00803621|OTHER|Toxoplasma PCR assay|Toxoplasma PCR assay
219100240|NCT04235634|DRUG|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
219685957|NCT02558842|OTHER|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
219685958|NCT06344715|BIOLOGICAL|SL-T10|A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants
219685959|NCT06344715|BIOLOGICAL|GX-I7|A T-cell growth factor
219685960|NCT06344715|BIOLOGICAL|Pembrolizumab|An immune check point inhibitor
219685961|NCT02410863|DRUG|Dabrafenib|150 mg twice daily
219685962|NCT02410863|DRUG|Trametinib|2 mg daily
219685963|NCT04265222|DEVICE|Hipcheck Software|Software
219685964|NCT04265222|OTHER|Conventional Fluoroscopy|Conventional Fluoroscopy
219685965|NCT04750018|OTHER|surgery|Patients were divided into surgery and no disease.
219685966|NCT01116947|OTHER|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
219685967|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + resveravine|
219685968|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
219685969|NCT00303238|DRUG|Rose hips extract + resveravine + Aframomum melegueta extract|
219100241|NCT01821417|DEVICE|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
219685970|NCT05934916|DEVICE|CPAP ( Continuous positive airway pressure)|The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
219685971|NCT05934916|DEVICE|oxygen therapy|both groups will receive oxygen
219685972|NCT03423212|BEHAVIORAL|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
219685973|NCT03423212|BEHAVIORAL|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
219685974|NCT03043742|DRUG|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
219685975|NCT00732927|DRUG|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
219685976|NCT00732927|DRUG|aspirin|tablets, 100 mg for 3 months
219685977|NCT00368303|DRUG|Paroxetine CR|
219685978|NCT00368303|DRUG|Paroxetine IR|
219685979|NCT02194972|DRUG|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
219685980|NCT02922153|DEVICE|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
219685981|NCT02922153|DRUG|Standard of Care|Institutional SOC for pain management will be followed.
219685982|NCT03429348|OTHER|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
219685983|NCT05439746|DEVICE|Microlyte® Matrix|Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
219100242|NCT01821417|DEVICE|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
219100243|NCT05988164|OTHER|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
219685984|NCT01461642|OTHER|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
219685985|NCT05179304|PROCEDURE|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
219100244|NCT03561337|DIETARY_SUPPLEMENT|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
219685986|NCT05945238|OTHER|Thrower's Ten Exercise Program|T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
219100245|NCT03561337|DIETARY_SUPPLEMENT|CARBOHDYRATE|CHO before and after training
219100246|NCT04772053|PROCEDURE|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
219100247|NCT06323811|DIAGNOSTIC_TEST|CMR|Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
219100248|NCT04599101|DEVICE|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
219685987|NCT01086670|OTHER|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
219685988|NCT06080516|OTHER|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
219685989|NCT01693679|DRUG|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
219685990|NCT02692586|DEVICE|FlowTriever System|
219685991|NCT03709251|BEHAVIORAL|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
219685992|NCT03709251|BEHAVIORAL|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
219685993|NCT06244732|PROCEDURE|Postoperative pain control|Postoperative analgesia after OR-AAA
219685994|NCT02752815|DRUG|Rituximab|
219685995|NCT02752815|DRUG|Cyclophosphamide|
219685996|NCT02752815|DRUG|Epirubicin|
218985146|NCT03821649|BEHAVIORAL|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
218985147|NCT00144690|DRUG|E2007 (perampanel)|
218985148|NCT00144690|DRUG|Placebo|
218985149|NCT00716703|OTHER|CT Scan using IV contrast alone|CT scan using IV contrast alone
218985150|NCT04766060|OTHER|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
218985151|NCT02911857|BIOLOGICAL|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
218985152|NCT03191422|BEHAVIORAL|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
218985153|NCT02061774|DRUG|Acetaminophen|1 gram of intravenous Acetaminophen
218985154|NCT02061774|DRUG|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
218985155|NCT00380822|DRUG|miglitol|
218985156|NCT03670888|BIOLOGICAL|JHL1101|100 mg/10 mL solution in a single-use vial
219685997|NCT02752815|DRUG|Vincristine|
219685998|NCT02752815|DRUG|Prednisone|
219685999|NCT03539107|PROCEDURE|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
219686000|NCT03539107|OTHER|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
219686001|NCT04421040|DEVICE|Biotronik Biomonitor 3 implant of device|The Biotronik Biomonitor 3 device will be implanted by the research team physician.
219686002|NCT04421040|DEVICE|Biotronik Biomonitor 3 explant of device|The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
219686003|NCT02318888|PROCEDURE|Surgery|
219686004|NCT02318888|DRUG|Icodextrin|
219686005|NCT01051557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219686006|NCT01051557|DRUG|Perifosine|Given PO
219686007|NCT01051557|DRUG|Temsirolimus|Given IV
219686008|NCT01051557|PROCEDURE|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
219686009|NCT00293852|PROCEDURE|Outpatient clinic follow-up|
219686010|NCT04724551|PROCEDURE|pancreatoduodenectomy (PD)|A pancreaticogastrostomy or -jejunostomy duct-to-mucosa was achieved according to the surgeon's preference and pancreatic texture.
219686011|NCT04858308|DRUG|YYC506|YYC506
219686012|NCT04858308|DRUG|Control|Active control
219686013|NCT04858308|DRUG|YYC506 Placebo|Placebo
219686014|NCT04858308|DRUG|Control Placebo|Placebo
219686015|NCT03202420|OTHER|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
219686016|NCT03808233|OTHER|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
218985157|NCT03670888|BIOLOGICAL|Rituximab|100 mg/10 mL solution in a single-use vial
219686017|NCT04124770|OTHER|Movement|Re-positioning of neck
219686018|NCT03723863|BEHAVIORAL|Occupational Therapy|Receive in-person occupational therapist-led work consultation
219686019|NCT04020029|OTHER|Mindset|Mindset Intervention will include watching three brief \~10-25 minute films
218985158|NCT06190990|OTHER|Otago Exercise + Exer gaming|In this group the participant will receive otago exercises and exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 week
218985159|NCT06190990|OTHER|exer gaming based programme|In this group the participant will receive exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 weeks and then after 4 weeks.
218985160|NCT02614586|DRUG|TAK-058|TAK-058 oral solution.
219686020|NCT04020029|OTHER|Reflection activities|Reflection activity include exercises to internalize the message
219686021|NCT03476421|PROCEDURE|Hepatic resection|Surgery of the liver; removal of a part of the liver
219686022|NCT04742504|BIOLOGICAL|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
218985161|NCT02614586|DRUG|Ondansetron|Ondansetron capsule.
218985162|NCT02614586|DRUG|TAK-058 Placebo|TAK-058 placebo-matching, solution.
218985163|NCT02614586|DRUG|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
218985164|NCT06177938|DIETARY_SUPPLEMENT|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
218985165|NCT05971160|BEHAVIORAL|Financial education videos|Brief videos providing structured information on managing one's money
218985166|NCT05971160|OTHER|Microgrant|$150 stipend
218985167|NCT05971160|BEHAVIORAL|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
218985168|NCT03016806|RADIATION|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
218985169|NCT03016806|RADIATION|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
219686023|NCT05865470|DRUG|Cannabis|smoked cannabis
219686024|NCT05865470|DRUG|Dronabinol|Oral delta-9-THC
219686025|NCT05865470|DRUG|Smoked Placebo|Placebo Cannabis
219686026|NCT05865470|DRUG|Oral Placebo|Oral Placebo
219686027|NCT03878823|DRUG|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
219686028|NCT00609544|DRUG|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
219686029|NCT02760719|DRUG|nebulized 3% hypertonic solution|already described
219686030|NCT00360425|DRUG|ferumoxytol|
219686031|NCT00360425|DRUG|moxifloxacin|
219686032|NCT00360425|DRUG|placebo|
219686033|NCT04754815|DRUG|Pembrolizumab|PD-L1 inhibitor administered as an intravenous (IV) infusion.
219686034|NCT04754815|DRUG|Pemetrexed|Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
219686035|NCT04754815|DRUG|Paclitaxel|A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
219686036|NCT04754815|DRUG|Nab-paclitaxel|Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
219686037|NCT04754815|OTHER|Laboratory Biomarker Analysis|Correlative studies
219686038|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
219686039|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
219686040|NCT04110314|BEHAVIORAL|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
219686041|NCT03052881|DEVICE|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of \<10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
219686042|NCT01099358|DRUG|Cetuximab|Administered Intravenously
218985170|NCT03016806|DRUG|Cyclophosphamide|50 mg/kg or 60 mg/kg
218985171|NCT03016806|DRUG|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
218985172|NCT03016806|PROCEDURE|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
218985173|NCT03016806|DRUG|Busulfan|0.8 mg/kg x 16 doses
219686043|NCT01099358|DRUG|Cisplatin|Administered Intravenously
219686044|NCT01099358|DRUG|5 - Fluorouracil|Administered Intravenously
219686045|NCT03072290|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
219686046|NCT03072290|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
219686047|NCT03746834|DEVICE|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
219686048|NCT04241770|OTHER|no intervention|no intervention
219686049|NCT05018702|DRUG|ARX788|1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
219686050|NCT03459716|OTHER|No intervention|No intervention
219686051|NCT04658797|DEVICE|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
219686052|NCT04658797|DEVICE|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
219686053|NCT04658797|OTHER|Personal Facemask|Personal Facemask
219686054|NCT02946892|DRUG|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
219686055|NCT02946892|DRUG|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
219686056|NCT00122291|DRUG|Capecitabine|
219686057|NCT00122291|PROCEDURE|Pelvic radiation|
219686058|NCT01178125|DRUG|DR-102|
219686059|NCT02948829|BIOLOGICAL|TDV|TDV SC injection.
219686060|NCT05088499|GENETIC|DNA analysis|GWAS
219686061|NCT05441228|DEVICE|Oculus Quest 2|Oculus Quest 2 is virtual reality headset with 2 hand control remotes. Beat Saber application will be used on Oculus Quest 2.
219686062|NCT05441228|DEVICE|Mirror therapy box|Mirror therapy is provided by mirror therapy box by placing it in sagittal plane of patient.
219686063|NCT04126044|DRUG|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
219686064|NCT04126044|DRUG|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
219686065|NCT01004978|DRUG|Cisplatin|Undergo TACE
219686066|NCT01004978|PROCEDURE|Computed Tomography|Undergo CT scan
219686067|NCT01004978|DRUG|Doxorubicin Hydrochloride|Undergo TACE
219686068|NCT01004978|DRUG|Doxorubicin-Eluting Beads|Undergo TACE
219686069|NCT01004978|OTHER|Laboratory Biomarker Analysis|Correlative studies
219686070|NCT01004978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219100249|NCT04599101|DEVICE|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
219686071|NCT01004978|DRUG|Mitomycin|Undergo TACE
219686072|NCT01004978|OTHER|Pharmacological Study|Correlative studies
219686073|NCT01004978|OTHER|Placebo Administration|Given PO
219686074|NCT01004978|DRUG|Sorafenib Tosylate|Given PO
219686075|NCT00369915|DRUG|Scopolamine|
219686076|NCT00369915|DRUG|Scopolamine|
219686077|NCT02575417|BEHAVIORAL|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
219686078|NCT01711983|DEVICE|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
219686079|NCT04473872|OTHER|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
219686080|NCT04350268|DEVICE|Wearable sensor|Wireless sensor
219686081|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
219686082|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
219686083|NCT02907567|DRUG|CT1812|Active study drug
219686084|NCT02907567|DRUG|Placebo|non-active study drug
219686085|NCT01276912|DRUG|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
219686086|NCT01276912|BEHAVIORAL|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
219686087|NCT01497548|DRUG|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
219686088|NCT01497548|DRUG|Placebo|Placebo given on morning (0800) and noon (1200)daily
219161406|NCT02939573|DRUG|Colchicine|Randomized to colchicine 0.6 mg x 2/day
219100252|NCT04804774|BEHAVIORAL|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
219100253|NCT02909036|DEVICE|Melphalan|
219100254|NCT02909036|DRUG|Pegfilgrastim|
219100255|NCT02909036|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|
219100256|NCT01916941|DRUG|Prazosin|
219100257|NCT01916941|DRUG|Placebo|
219100258|NCT00098254|DRUG|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
219100259|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
219100260|NCT03017131|DRUG|Cyclophosphamide|Given IV
219100261|NCT03017131|DRUG|Decitabine|Given IV
219100262|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
219100263|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
219100264|NCT00006115|DRUG|FOLFIRI regimen|
219100265|NCT00006115|DRUG|FOLFOX regimen|
219100266|NCT00006115|DRUG|fluorouracil|
219100267|NCT00006115|DRUG|irinotecan hydrochloride|
219100268|NCT00006115|DRUG|leucovorin calcium|
219686676|NCT06955650|DRUG|Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor|"13N-Oxytocin is a newly developed radiotracer designed to bind selectively to oxytocin receptors. It is labelled with nitrogen-13, a short-lived positron-emitting isotope, and is administered intranasally to facilitate direct access to the central nervous system via the nasal and trigeminal pathways. This radiotracer is investigational and is not intended to exert pharmacological effects. It is used solely for imaging purposes to assess the distribution and potential receptor binding sites of oxytocin in the human brain and the trigeminal nerve.~Following administration, PET imaging is conducted using a hybrid PET/MRI scanner. The imaging procedure enables visualisation of the biodistribution of 13N-Oxytocin in vivo. The PET scan protocol includes dynamic image acquisition to track tracer uptake over time and is used in conjunction with MRI for precise anatomical localisation."
219686677|NCT06950255|DEVICE|Cane|"Individuals will receive a single-point cane, individually adjusted to maintain each individual's elbow at approximately 30 degrees of flexion. Participants will be instructed to use the device on dominant side or the side with less impairment. The training with the cane will be carried out by a trained physiotherapist. The training protocol will include gait training with the cane on different surfaces and speeds. At the beginning of each training session, individuals will have the opportunity to address any questions they may have about using a cane in their daily life context.~Individuals will be re-evaluated after the end of the training sessions. After revaluation, the canes will be left with participants who will be instructed as follows: Feel free to use the cane at any time as needed. Another diary will be provided for the participant to record the use of the device after the end of the intervention"
219686678|NCT06950255|OTHER|static stretching and health education|"The intervention for the control group will consist of 20 minutes of global static stretching and 20 minutes of guidance on general health care. The stretches will be performed in three sets of 30 seconds each, targeting different muscle groups. If a participant is unable to perform the self-stretches, the researchers responsible for implementing the intervention will provide assistance. The health education component will cover information on Parkinson's disease (PD) and fall prevention.~The intervention will be offered by the same physiotherapist responsible for training the experimental group. Individuals will be re-evaluated after the end of the training sessions. After revaluation, the participants will be instructed as follows: Feel free to continue stretching exercises and use the health information discussed as needed. Another diary will be provided for the participant to record the stretching exercises performed after the end of the intervention."
219686679|NCT06954896|DRUG|Bupivacain|The superior hypogastric plexus block (SHPB) was performed following uterine removal and closure of the vaginal cuff, but prior to trocar removal from the abdominal cavity. The promontory was identified under laparoscopic visualization. The posterior peritoneum overlying the promontory was gently grasped and elevated with an instrument to create a peritoneal tent. A needle was then inserted at the apex of the tent and advanced approximately 1 cm. At this point, a subperitoneal space was further expanded using a surgical instrument, and 30 ml of 0.25% bupivacaine was injected into the area
219686680|NCT06954896|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|In cases where the VAS score exceeded 3 in the postoperative period, it was deemed that the patient's analgesia was insufficient, prompting the intravenous administration of 50 mg of dexketoprofen sodium.
219686681|NCT06954896|DRUG|Intraperitoneal Bupivacaine spray|The peritoneal cavity and abdominal wall were treated with 30 milliliters of 0.25% bupivacaine, with a focus on areas involving the peritoneum in the lower abdominal region.
219686682|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，25mg|Usage and dosage: 25mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
219686683|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，50mg|Usage and dosage: 50mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
219686684|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，75mg|Usage and dosage: 75mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
219686685|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，100mg|Usage and dosage: 100mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
219686686|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，125mg|Usage and dosage: 125mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
219686687|NCT06955793|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
219686688|NCT06955793|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
219686689|NCT06955611|OTHER|Community based optometry with Virtual Review|Community based OCT imaging with optometrist and virtual review by ophthalmologist
219686690|NCT06955611|OTHER|Usual Care|Hospital eye services review conducted by an ophthalmologist
219686691|NCT06955182|OTHER|Dynamic hot spring hydrotherapy intervention|Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training
219686692|NCT06955182|OTHER|Conventional rehabilitation intervention|Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training
219686693|NCT06955260|DRUG|Empagliflozin 10 mg|Participants will take 10 mg of empagliflozin once daily
219686694|NCT06955260|OTHER|Placebo|Participants will take 10 mg of placebo once daily
219100269|NCT00006115|DRUG|oxaliplatin|
219100270|NCT02835846|DRUG|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
219100271|NCT02115997|DRUG|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
219161407|NCT02939573|DRUG|Dapsone|Randomized to dapsone 150 mg/day
219100272|NCT02115997|DRUG|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
219100273|NCT02115997|DRUG|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
219686695|NCT06402461|BEHAVIORAL|Mindfulness of the breath|A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy
219686696|NCT06402461|BEHAVIORAL|Mindfulness of sounds|A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy
219686697|NCT06402461|BEHAVIORAL|Audiobook control|Listening to a 10 minute extract from an audiobook
219100274|NCT04404608|DIAGNOSTIC_TEST|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
219100275|NCT04855305|DRUG|Hyperpolarized 129Xe|Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
219161408|NCT02939573|DRUG|Azathioprine|Randomized to azathioprine 2 mg/kg/day
219550473|NCT04170452|PROCEDURE|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
219550474|NCT06254560|DRUG|Rituximab|Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
219550475|NCT01664039|DRUG|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
219550476|NCT01664039|DRUG|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
219550477|NCT05734716|DRUG|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
219550478|NCT05734716|DRUG|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
219550479|NCT05734716|DRUG|Sterile Sodium Chloride|sham treatment with sterile saline
219550480|NCT01310855|DRUG|cediranib maleate|
219550481|NCT01310855|DRUG|gefitinib|
219550482|NCT01310855|DRUG|Placebo|
219550483|NCT00622362|BIOLOGICAL|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
219550484|NCT00622362|BIOLOGICAL|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
219550485|NCT00622362|BIOLOGICAL|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
219550486|NCT03480230|DRUG|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
219550487|NCT02818530|DEVICE|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
219686698|NCT04570709|OTHER|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
219100276|NCT02974881|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
219100277|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 21 of a 28 day cycle
219100278|NCT02555839|DRUG|Dexamethasone|40 mg (≤75 years) or 20mg (\>75 years) oral on d1, 8, 15, 22 of a 28 day cycle
219100279|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 14 of a 21 day cycle
219686699|NCT02202369|OTHER|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
219686700|NCT02202369|OTHER|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
219686701|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
219686702|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
219686703|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
219686704|NCT05449444|DRUG|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
219686705|NCT05449444|DRUG|Placebo|Matching placebo
219686706|NCT05449444|OTHER|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
219686707|NCT05449444|DRUG|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
219686708|NCT03740204|DRUG|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
219686709|NCT03740204|DRUG|Placebo patch and pill|Placebo patch and pill
219686710|NCT02728232|PROCEDURE|internal iliac artery ligation|
219686711|NCT02728232|PROCEDURE|Cesarean Hysterectomy|
219686712|NCT05004090|DIAGNOSTIC_TEST|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
219686713|NCT05004090|DIAGNOSTIC_TEST|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
219686714|NCT05004090|DIAGNOSTIC_TEST|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
219686715|NCT05190874|DEVICE|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
219686716|NCT03003910|BEHAVIORAL|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
219686717|NCT03003910|BEHAVIORAL|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
219686718|NCT06253377|DEVICE|Adsorption membrane filter Oxiris™|Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
219686719|NCT04789382|DEVICE|LID018869+RepleniSH|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
219686720|NCT04789382|DEVICE|LID018869+Biotrue|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
219686721|NCT04789382|DEVICE|Biofinity+RepleniSH|Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
219686722|NCT04789382|DEVICE|PV+Biotrue|Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
219100280|NCT02555839|DRUG|Dexamethasone|cycle 1-8: 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 8, 9 of a 21 day cycle
219161409|NCT04592523|OTHER|No Intervention|This is a non-interventional study.
219100281|NCT02555839|DRUG|Bortezomib|cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,
219100282|NCT04046003|BEHAVIORAL|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
219100283|NCT04893590|BEHAVIORAL|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
219100284|NCT02475603|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
219100285|NCT00674466|DRUG|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
219100286|NCT00674466|DRUG|Placebo|twice-a-week
219100287|NCT05847179|DRUG|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
219100288|NCT05460923|OTHER|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
219100289|NCT05460923|OTHER|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
219100290|NCT03381222|DIAGNOSTIC_TEST|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
219161410|NCT05923463|BEHAVIORAL|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
219161411|NCT05923463|BEHAVIORAL|standard feedback email messages|Providers receive metrics in a common format.
219550488|NCT02818530|DEVICE|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
219550489|NCT03577535|DIETARY_SUPPLEMENT|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
219550490|NCT01186458|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
219686723|NCT02126280|OTHER|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
219686724|NCT01851993|DRUG|Ondansetron|
219686725|NCT01851993|DRUG|Placebo|0.9% saline
219686726|NCT02991963|OTHER|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
219686727|NCT02991963|OTHER|Blood collection (Dried Blood Spot)|Dried Blood Spot
219686728|NCT02991963|OTHER|Blood Collection (Venous Blood collection)|Venous Blood collection
219686729|NCT02991963|OTHER|Blood Smear|Slide blood smear
219686730|NCT02277275|DIETARY_SUPPLEMENT|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
219686731|NCT02277275|DIETARY_SUPPLEMENT|Placebo|Placebo will be provided to the other two arms for six months
219686732|NCT02677415|OTHER|Intravenous anesthetics|
219550491|NCT01186458|DRUG|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
219550492|NCT01186458|DRUG|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
219550493|NCT03090022|PROCEDURE|Strattice|Intra-abdominally Fixation
219550494|NCT03090022|PROCEDURE|Single running suture of abdominal fascia|Intra-abdominal suture
219550495|NCT03487939|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
219550496|NCT04419935|PROCEDURE|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
219550497|NCT00272441|DRUG|inhaled corticosteroids|
219686733|NCT02677415|OTHER|local anesthesia|
219686734|NCT02677415|OTHER|Controlled ventilation|
219686735|NCT02677415|OTHER|Spontaneous breathing|
219686736|NCT03834311|DEVICE|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
219686737|NCT03834311|OTHER|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
219686738|NCT04394598|DRUG|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
219686739|NCT04394598|RADIATION|Pelvic Radiation|50Gy/25Fx
219686740|NCT04394598|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
219686741|NCT04394598|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
219686742|NCT04394598|OTHER|Placebo|3g tid per day for 5weeks
219686743|NCT05299684|OTHER|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
219686744|NCT02192671|PROCEDURE|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
219100291|NCT03146039|RADIATION|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
219100292|NCT01996358|DRUG|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
219100293|NCT01996358|DRUG|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
219100294|NCT01996358|DRUG|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
219100295|NCT04603976|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
219100296|NCT02729935|DRUG|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
219100297|NCT02729935|DRUG|Placebo|An equal volume of saline
219686745|NCT02192671|PROCEDURE|Radiofrequency Ablation|
219100298|NCT05529745|OTHER|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
219100299|NCT00781066|PROCEDURE|Controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure."
219100300|NCT00781066|PROCEDURE|No controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
219100301|NCT04727073|DRUG|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
219100302|NCT04727073|DRUG|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
219686746|NCT05734820|DIAGNOSTIC_TEST|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
219686747|NCT05734820|DIAGNOSTIC_TEST|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
219100303|NCT01186614|DEVICE|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
219686748|NCT03036371|BEHAVIORAL|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
219686749|NCT04575220|OTHER|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
219686750|NCT00419757|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
219686751|NCT00419757|DRUG|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
219686752|NCT03112694|OTHER|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
219100304|NCT01186614|DEVICE|ECMO|Insertion of peripheral VA ECMO
219100305|NCT01186614|PROCEDURE|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
219100306|NCT01186614|PROCEDURE|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
219686753|NCT04536714|BEHAVIORAL|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
219686754|NCT05932758|PROCEDURE|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
219686755|NCT05932758|PROCEDURE|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
219686756|NCT05240235|OTHER|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
219686757|NCT05240235|OTHER|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
219686758|NCT00480090|DRUG|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
219686759|NCT00877318|DEVICE|SCAD information system|Cardiac rehabilitation at home by telemedicine
219686760|NCT05988567|DIETARY_SUPPLEMENT|Placebo candy|consume 2 tablets per day
219686761|NCT05988567|DIETARY_SUPPLEMENT|melon and oil olive pressed candy|consume 2 tablets per day
219686762|NCT04222920|OTHER|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
219100307|NCT02294539|DRUG|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
219100308|NCT02294539|DRUG|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
219100309|NCT02294539|DRUG|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
219100310|NCT02294539|DRUG|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
219100311|NCT04430413|BIOLOGICAL|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
219100312|NCT05013866|PROCEDURE|Repair resin composite proximal|Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
219100313|NCT03889613|OTHER|prospective follow-up with videocapsule|prospective follow-up with videocapsule
219161412|NCT06783595|OTHER|intraoral scan|Device that scans the mouth with by taking numerous pictures of the mouth and stitches them together to form a three-dimensional copy of the patient teeth.
219686763|NCT04222920|OTHER|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
219686764|NCT04222920|DRUG|Adalimumab|Adalimumab
219100314|NCT02139358|DRUG|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
219100315|NCT02139358|DRUG|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
219100316|NCT02139358|DRUG|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
219100317|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 10 or 20 mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
219161413|NCT05319431|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
219161414|NCT05319431|DRUG|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
219686765|NCT00327340|DRUG|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
219734600|NCT03325803|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
219734601|NCT00005596|DRUG|cyclophosphamide|
219734602|NCT00005596|DRUG|cytarabine|
219734603|NCT00005596|DRUG|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
219734604|NCT00005596|DRUG|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
219734605|NCT00005596|DRUG|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
219161415|NCT05319431|PROCEDURE|TACE|On demand TACE
219734606|NCT00005596|DRUG|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
219734607|NCT00005596|DRUG|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
219734608|NCT00005596|DRUG|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX
219734609|NCT00005596|DRUG|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
219734610|NCT00005596|DRUG|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
219734611|NCT04065854|BEHAVIORAL|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
219734612|NCT03958487|BEHAVIORAL|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
219734613|NCT06539377|PROCEDURE|Living donor liver transplantation|"Liver transplantation from living donor donation (SII/III as left-lateral donation during a two stage-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma."
219734614|NCT03206385|RADIATION|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
219734615|NCT03206385|RADIATION|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
219734616|NCT02222181|OTHER|Pharmacotherapy Management|"* assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
219734617|NCT02100033|DEVICE|acupuncture|
219686766|NCT00327340|DRUG|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
219100318|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|"For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
219686767|NCT02935556|OTHER|no intervention|database and epigenetic study
219686768|NCT01116921|DEVICE|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
219686769|NCT01116921|DEVICE|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
219686770|NCT01116921|DRUG|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
219686771|NCT04669431|OTHER|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
219686772|NCT04669431|OTHER|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
219686773|NCT03144648|OTHER|lifestyle|Observational study
219686774|NCT01460303|DEVICE|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
219686775|NCT01460303|DEVICE|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
219686776|NCT00778596|DRUG|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
219686777|NCT00778596|DRUG|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
219686778|NCT03894839|OTHER|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686779|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686780|NCT03894839|OTHER|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686781|NCT03894839|OTHER|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686782|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686783|NCT03894839|OTHER|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
219686784|NCT06141785|OTHER|Nutritional intervention|An individually targeted nutritional intervention, and a simple home-based physical exercise program. The Nutritional intervention will be delivered by a clinical dietitian, from treatment initiation and throughout the treatment trajectory
219686785|NCT05525351|DEVICE|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
219686786|NCT05525351|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
219100319|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 5 or 10mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
219686787|NCT05525351|DRUG|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
219686788|NCT05525351|DRUG|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
219686789|NCT00270452|DRUG|WT1 and PR1 Peptide Vaccine|
219686790|NCT03316586|DRUG|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
219686791|NCT03316586|DRUG|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
219686792|NCT04232930|OTHER|Music|Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
219686793|NCT03070795|PROCEDURE|early feeding|start oral sips four hours after cesarean section
219686794|NCT03070795|PROCEDURE|delayed feeding|start oral feeding on post operation day 1 (\>12hours) after surgery
219686795|NCT01065753|BEHAVIORAL|Lifestyle Counseling|Diet control with exercise
219686796|NCT00032448|PROCEDURE|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
219686797|NCT06506201|DEVICE|Velys hip navigation|Computer assisted surgery
219686798|NCT06506201|PROCEDURE|Standard of care|surgery without navigation
219686799|NCT01095497|BIOLOGICAL|CINRYZE|C1 esterase inhibitor (human)
219686800|NCT02092753|OTHER|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
219686801|NCT02092753|OTHER|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
219686802|NCT02092753|OTHER|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
219100320|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
219100321|NCT00347581|PROCEDURE|Base-in prism glasses for reading|
219686803|NCT01712828|DRUG|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
219686804|NCT01712828|DRUG|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
219686805|NCT01712828|DRUG|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
219686806|NCT01712828|DRUG|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
219100322|NCT00347581|PROCEDURE|Placebo reading glasses|
219686807|NCT06251271|DEVICE|Point-of-Care Ultrasound|Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
219686808|NCT03645642|DRUG|Midodrine|Midodrine 5 mg thrice daily
219686809|NCT03645642|BIOLOGICAL|Albumin|Albumin 20g/l
219686810|NCT03645642|DRUG|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
219686811|NCT01396083|DRUG|Ranibizumab|
219686812|NCT01396083|DRUG|Dexamethasone implant and sham injections|
219100323|NCT04557826|DEVICE|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
219100324|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|Participants will used the serum twice daily for 8 weeks
219686813|NCT03159936|BIOLOGICAL|Tofacitinib citrate|10 mg daily by mouth
219686814|NCT04993573|OTHER|Questionnaire|Questions about the impact of COVID-19 in their works
219100325|NCT04631705|BIOLOGICAL|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
219686815|NCT04993573|OTHER|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
219686816|NCT02806713|DRUG|Phenazopyridine|
219686817|NCT02806713|OTHER|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
219686818|NCT00735709|DRUG|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
219686819|NCT00735709|DRUG|Placebo|Vortioxetine placebo-matching capsules
219686820|NCT03485443|DRUG|%0.9 NaCl 10ml/kg|Fluid administration
219100326|NCT04631705|BIOLOGICAL|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
219100327|NCT04631705|DRUG|Placebo|Inhalation of DZIF-10c diluent as placebo
219100328|NCT04631705|DRUG|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
219100329|NCT04551092|DEVICE|NEVR|a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
219100330|NCT02130284|DEVICE|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
219100331|NCT00377780|DRUG|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
219100332|NCT01802255|DRUG|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
219100333|NCT01802255|DRUG|Midazolam|Intravenous sedation.
219100334|NCT01875185|DRUG|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
219100335|NCT03280771|COMBINATION_PRODUCT|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
219100336|NCT03280771|COMBINATION_PRODUCT|Control group soap|A colourful, translucent bar or soap with the toy alongside it
219100337|NCT04838613|DRUG|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
219100338|NCT04838613|DRUG|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
219100339|NCT03651050|BEHAVIORAL|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
219100340|NCT03651050|BEHAVIORAL|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
219100341|NCT03319082|COMBINATION_PRODUCT|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
219100342|NCT00600379|DEVICE|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
219100343|NCT00008021|BIOLOGICAL|filgrastim|
219100344|NCT00008021|BIOLOGICAL|monoclonal antibody Lym-1|
219100345|NCT00008021|DRUG|cyclosporine|
219100346|NCT00008021|DRUG|paclitaxel|
219100347|NCT00008021|PROCEDURE|peripheral blood stem cell transplantation|
219100348|NCT00008021|RADIATION|indium In 111 monoclonal antibody Lym-1|
219550498|NCT04436419|DIETARY_SUPPLEMENT|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
219100349|NCT00008021|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
219686821|NCT03485443|DRUG|%0.9 NaCl 20ml/kg|Fluid administration
219686822|NCT00524927|DRUG|Methoxyflurane|
219686823|NCT00524927|DRUG|Normal Saline|
219686824|NCT03056521|OTHER|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
219686825|NCT05428956|PROCEDURE|Single Inhalation technique|Single maximal inhalation with breath hold technique
219100350|NCT01686581|DRUG|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
219100351|NCT02287116|DEVICE|Easy Flow system and INCA® nasal cannulae set|
219161416|NCT06784492|BEHAVIORAL|Healthy Living Intervention-1|Participants will receive a text or email each day with instructions about a healthy intervention.
219686826|NCT05428956|PROCEDURE|Tidal inhalation technique|5 tidal breaths technique
219686827|NCT06431464|OTHER|picosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
219686828|NCT06431464|OTHER|nanosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
219686829|NCT03569501|DIETARY_SUPPLEMENT|DHA|500 mg DHA tablets
219686830|NCT03569501|DIETARY_SUPPLEMENT|oat grains|90 mg oat, containing 4.05 mg β-glucan
219100352|NCT04802096|OTHER|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
219100353|NCT04802096|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
219100354|NCT02378740|DRUG|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
219100355|NCT02378740|DRUG|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
219100356|NCT01618084|DEVICE|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
219100357|NCT02597465|DRUG|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
219100358|NCT02597465|DRUG|Reference1507|Investigators choice including chemotherapy or supportive therapy
219686831|NCT05175781|DRUG|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
219100359|NCT00913185|DRUG|Acne Free, Proactiv|
219100360|NCT05042089|OTHER|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
219100361|NCT00775814|DRUG|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
219100362|NCT00775814|DRUG|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
219100363|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
219100364|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
219686832|NCT05175781|DRUG|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
219686833|NCT05175781|DRUG|Placebo|Normal saline
219686834|NCT02492802|DRUG|posaconazole|collection plasma samples for measuring posaconazole drug concentration
219686835|NCT01165307|DRUG|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
219686836|NCT01165307|DRUG|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
219686837|NCT01165307|DEVICE|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
219686838|NCT01126099|DRUG|Prazosin|4 mg capsules twice daily for 12 weeks
219686839|NCT01126099|DRUG|Placebo|Placebo capsules twice daily for 12 weeks
219686840|NCT02920190|DRUG|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
219686841|NCT00311493|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
219686842|NCT00015704|DRUG|Aldesleukin|
219686843|NCT00356447|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
219686844|NCT00356447|DRUG|Placebo|Same administration.
219686845|NCT02355717|OTHER|Observational Study|
219686846|NCT03535961|DRUG|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
219686847|NCT00692380|RADIATION|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
219100365|NCT01807650|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
219100366|NCT01807650|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
219100367|NCT03076944|DRUG|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
219686848|NCT05667662|DRUG|Itraconazole Powder|Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
219686849|NCT05667662|DRUG|Placebo|Capsules with 11.8 mg total powder (excipients only)
219686850|NCT01055015|DRUG|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
219686851|NCT01055015|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
219100368|NCT03076944|DRUG|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
219100369|NCT02486679|DRUG|Prostin (PGE2) tablets|
219100370|NCT02486679|DEVICE|Foley catheter|
219100371|NCT02976142|PROCEDURE|neoadjuvant chemoimmunotherapy|
219100372|NCT06318325|DIAGNOSTIC_TEST|examination|examination of tendon, muscle joints and injuries
219100373|NCT01086865|DRUG|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
219100374|NCT02621957|DRUG|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
219100375|NCT02621957|DRUG|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
219686852|NCT02955875|BEHAVIORAL|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
219686853|NCT04531423|DRUG|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
219686854|NCT04531423|OTHER|SSRI + placebo|placebo
219686855|NCT05625685|OTHER|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
219686856|NCT05625685|OTHER|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
219686857|NCT05625685|OTHER|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
219686858|NCT05625685|OTHER|SDoH Control|No SDoH intervention
219686859|NCT04531124|OTHER|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
219686860|NCT03328481|PROCEDURE|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
219686861|NCT03328481|PROCEDURE|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
219100376|NCT01507636|OTHER|Occupational Therapy|Occupational therapy using a special arm function training.
219100377|NCT01507636|OTHER|Physical therapy|Physical therapy for arm force training.
219686862|NCT03328481|PROCEDURE|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
219686863|NCT02396225|DRUG|Voriconazole|
219686864|NCT01116336|DRUG|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
219686865|NCT01116336|DIETARY_SUPPLEMENT|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
219686866|NCT06958757|OTHER|Standard Exercise Therapy + Ankle Dorsiflexion Training|"The experimental group receives:~Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Ankle Dorsiflexion Training (15 min/session, 3x/week for 8 weeks): Mobilization techniques (posterior glides of the talus), Resistance band exercises (dorsiflexion against elastic bands), Progressive Achilles tendon stretching (weight-bearing calf stretches).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
219686867|NCT06958757|OTHER|Standard Exercise Therapy Only|"Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
219686868|NCT06958029|PROCEDURE|Cardiac surgery|Patients receiving general anesthesia for cardiac surgery
219686869|NCT02537951|DEVICE|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
219686870|NCT02537951|DEVICE|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
219686871|NCT02537951|DEVICE|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
219686872|NCT06958601|OTHER|surgical procedure|Effectiveness of different surgical modalities in the treatment of thyroid cancer
219686873|NCT02666989|DRUG|placebo|2 placebo pills twice a day
219686874|NCT02148393|PROCEDURE|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
219686875|NCT02148393|PROCEDURE|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
219100378|NCT01563848|PROCEDURE|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
219686876|NCT02148393|DRUG|Pregnyl®|1500 IU
219686877|NCT02148393|DRUG|Utrogestan®|200 mg tid
219686878|NCT02148393|DRUG|Progynova®|2 mg bid
219686879|NCT02148393|DEVICE|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
219686880|NCT06959212|OTHER|Physiological recordings, Semi-structured interviews, Psychological scales|(Neuro)-physiological paradigms based on EEG, ECG, electrodermal activity, and respiratory activity recordings, and auditory and olfactive stimuli, to assess memory processes without the need to communicate ('no report' approach) in patients suffering from a Disorder of Consciousness and conscious controls. Semi-structured interviews and neuropsychological assessments (scales) in patients who have recovered from a Disorder of Consciousness and conscious controls to explore memories and subjective experience of the ICU
219686881|NCT00521365|DRUG|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
219686882|NCT00006193|BEHAVIORAL|diet|
219686883|NCT04839744|DRUG|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
219686884|NCT04839744|DRUG|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
219686885|NCT03627832|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
219686886|NCT03627832|BEHAVIORAL|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
219686887|NCT04391257|DEVICE|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
219686888|NCT00624793|OTHER|Acupuncture|Standard Acup point protocol for treating nausea
219686889|NCT00624793|OTHER|Individualized Acup based on TCM diagnosis|Acup
219686890|NCT00624793|OTHER|Sham Acup|Sham Acup - Non-Active
219161417|NCT06784492|BEHAVIORAL|Healthy Living Intervention-2|Participants will receive a text or email each day with instructions about a healthy intervention.
219686891|NCT00169676|OTHER|observation|registry and database for surgery outcomes
219686892|NCT02390154|DRUG|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution
219686893|NCT02390154|DRUG|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
219686894|NCT05888298|PROCEDURE|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
219686895|NCT03477578|OTHER|freezers|neuropsychological evaluation
219686896|NCT03477578|OTHER|non freezers|neuropsychological evaluation
219686897|NCT02729337|BEHAVIORAL|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
219686898|NCT03150082|DRUG|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
219686899|NCT03150082|DRUG|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
219686900|NCT06959459|DEVICE|Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.|Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.
219686901|NCT06959459|DEVICE|Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.|Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.
219686902|NCT00275522|DRUG|Sirolimus|
219686903|NCT03049501|BEHAVIORAL|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
219686904|NCT03049501|BEHAVIORAL|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
219686905|NCT02631005|OTHER|"Walk With Ease"|Six-week walking program
219100379|NCT01563848|PROCEDURE|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
219100380|NCT01563848|PROCEDURE|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
219686906|NCT06959615|DRUG|JAB-23E73|Administered orally
219686907|NCT06959615|DRUG|JAB-23E73|Administered orally
219686908|NCT06959576|OTHER|nanoparticles|Nanoparticles improve the dimensional stability of 3D printed denture base resin, so preventing instability of the denture over time
219686909|NCT02731378|DRUG|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
219686910|NCT02731378|DRUG|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
219686911|NCT02731378|DRUG|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
219161418|NCT06230198|PROCEDURE|retrograde autologous priming (RAP)|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
219161419|NCT06230198|PROCEDURE|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
219161420|NCT04185532|OTHER|Rebound ACL brace and physioterapy|Usage of rebound ACL brace and physioterapy supervised by physioterapist
219161421|NCT04185532|OTHER|Physioterapy|Physioterapy supervised by physioterapist
219161422|NCT06787638|DRUG|full dose of Neostigmine|"• Group A: received 10ml (a full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
219161423|NCT06787638|DRUG|half dose of Neostigmine|"• Group B: received 10ml (a half dose of Neostigmine (0.04 mg/kg) plus Atropine (20 mic/kg+8ml normal saline).~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
219161424|NCT06789068|OTHER|lactose free regimen|lactose free formula and solid foods that lack lactose for infants above 6 months, ensuring adequate macro and micronutrients intake according to recommended daily allowances (RDA) for age and sex.
219686912|NCT02731378|DRUG|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
219686913|NCT06959498|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty
219100381|NCT02522858|DRUG|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
219100382|NCT02522858|DRUG|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
219100383|NCT02522858|DRUG|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
219100384|NCT05435755|BIOLOGICAL|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
219100385|NCT05435755|BIOLOGICAL|placebo (saline)|2 times placebo (normal saline) injections as control group
219100386|NCT03078088|DRUG|Tham|alkalinizer
219100387|NCT03078088|DRUG|Saline|Placebo
219686914|NCT04880668|DEVICE|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
219686915|NCT04408664|DRUG|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
219686916|NCT04408664|DRUG|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
219686917|NCT03290430|BEHAVIORAL|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
219686918|NCT03290430|BEHAVIORAL|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
219686919|NCT03290430|BEHAVIORAL|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
219686920|NCT03290430|BEHAVIORAL|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
219686921|NCT03290430|BEHAVIORAL|Texting support|Texts with smoking cessation support throughout the program
219686922|NCT03290430|DRUG|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
219686923|NCT03893760|DIAGNOSTIC_TEST|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
219686924|NCT02777905|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
219686925|NCT01554124|DRUG|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
219100388|NCT02329184|DRUG|MYK-461|
219100389|NCT01015976|PROCEDURE|bariatric surgery|Roux en Y bariatric surgery
219100390|NCT01015976|OTHER|control|No surgery
219100391|NCT00667472|DRUG|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
219100392|NCT00667472|DEVICE|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
219100393|NCT00736489|DRUG|AZD3199|Dry powder for inhalation, single dose
219686926|NCT02824146|OTHER|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
219100394|NCT00736489|DRUG|Formoterol|Dry powder for inhalation, single dose
219100395|NCT00736489|DRUG|Placebo|Dry powder for inhalation, single dose
219686927|NCT02174224|BEHAVIORAL|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
219686928|NCT02174224|BEHAVIORAL|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
219686929|NCT02174224|BEHAVIORAL|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
219686930|NCT04126304|DRUG|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
219686931|NCT04126304|DRUG|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
219686932|NCT04126304|DIAGNOSTIC_TEST|Mycoplasma detection|"1. common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~2. community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
219686933|NCT04126304|OTHER|Data collection|"1. Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~2. Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~3. Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
219686934|NCT04126304|OTHER|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
219686935|NCT04784234|DIETARY_SUPPLEMENT|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
219686936|NCT04784234|OTHER|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
219686937|NCT01676493|DRUG|Codeine|
219100396|NCT02174887|DRUG|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
219100397|NCT02131870|DIETARY_SUPPLEMENT|L plantarum DSM 9843 or placebo|
219100398|NCT00016692|DRUG|Z-100|
219100399|NCT00116844|DRUG|Valaciclovir|Valtrex 1g once daily
219100400|NCT00116844|DRUG|Placebo|placebo
219100401|NCT04760522|GENETIC|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
219100402|NCT02640248|DEVICE|Cuff ETT|
219100403|NCT00762632|DRUG|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
219100404|NCT00762632|DRUG|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
219100405|NCT01899313|BEHAVIORAL|CBT- based SMS text messaging intervention|
219100406|NCT01899313|BEHAVIORAL|CBT group therapy|
219100407|NCT01933880|DRUG|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
219100408|NCT01933880|OTHER|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
219100409|NCT02513108|PROCEDURE|same day discharge|same day discharge after PCI for stable CAD
219100410|NCT00709462|BIOLOGICAL|CDX1307|
219100411|NCT04418635|DIETARY_SUPPLEMENT|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
219100412|NCT03135665|DEVICE|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
219100413|NCT04810117|DIAGNOSTIC_TEST|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
219686938|NCT05656170|PROCEDURE|Stellate ganglion block|"Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total)."
219100414|NCT02645084|OTHER|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
219100415|NCT05396989|OTHER|No intervention|No intervention
219100416|NCT02244164|DRUG|Incretinomimetics|
219100417|NCT02244164|DRUG|DPP-4 inhibitors|
219100418|NCT04751422|OTHER|Electronic Health Record Review|Medical data is collected
219100419|NCT05278689|OTHER|No intervention|No intervention
219686939|NCT05656170|DRUG|Bupivacain|The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
219686940|NCT05656170|DRUG|Saline|The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
219100420|NCT04618601|DRUG|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
219686941|NCT03572673|DEVICE|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
219100421|NCT04453423|DRUG|Anlotinib + Pemetrexed+Carboplatin|"Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle"
219100422|NCT04453423|DRUG|Pemetrexed|500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
219100423|NCT04453423|DRUG|Anlotinib + Pemetrexed|"Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)"
219100424|NCT04453423|DRUG|Anlotinib|12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
219686942|NCT03572673|DEVICE|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
219100425|NCT01385358|PROCEDURE|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
219100426|NCT01385358|PROCEDURE|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
219100427|NCT05535543|PROCEDURE|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
219100428|NCT02395133|DRUG|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
219100429|NCT02395133|DRUG|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
219100430|NCT03784040|DRUG|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
219100431|NCT03784040|DRUG|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
219161425|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
219161426|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
219686943|NCT03564990|OTHER|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
219686944|NCT03564990|OTHER|conventional approach|conventional follow-up
219686945|NCT03660748|BIOLOGICAL|MET-2|Ingestion of a novel human microbiome preparation
219686946|NCT05366595|DRUG|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
219686947|NCT05093556|BEHAVIORAL|iCHART - Interactive CBT for Headache And Relaxation Training|IVR based cognitive behavioral therapy for headache
219686948|NCT00524524|DRUG|ARQ 501|Weekly IV Infusion; 450 mg/m2
219686949|NCT00412841|DRUG|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
219686950|NCT00412841|PROCEDURE|MRI, Venipuncture|MRIs done baseline, four and nine months
219686951|NCT00412841|DRUG|Placebo|Tablets identical to atorvastatin 40mg
219686952|NCT02541331|BIOLOGICAL|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
219686953|NCT02541331|BIOLOGICAL|PLACEBO|Matched tablets without any active substance.
219686954|NCT00144677|DRUG|sirolimus|
219686955|NCT00144677|DRUG|tacrolimus|
219686956|NCT01639612|BIOLOGICAL|ALD-451|ALD-451 iv
219686957|NCT02016443|DRUG|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
219686958|NCT02016443|DRUG|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
219686959|NCT02885038|OTHER|Platelet concentrate transfusion|
219686960|NCT00458003|DRUG|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
219686961|NCT00458003|DRUG|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
219686962|NCT00003740|BIOLOGICAL|trastuzumab|
219686963|NCT03136718|OTHER|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
219686964|NCT03920475|DRUG|Sertraline or venlafaxine|Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
219686965|NCT03920475|DIAGNOSTIC_TEST|Immune parameters|Serum was taken before, during an after treatment for measurement of different immune parameters.
219686966|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
219100432|NCT03784040|DRUG|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
219100433|NCT02789475|DRUG|Amlodipine|Amlodipine administration
219100434|NCT02789475|DRUG|Rosuvastatin|Rosuvastatin administration
219161427|NCT06791772|DRUG|Placebo|Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
219161706|NCT02109601|OTHER|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
219161707|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
219550499|NCT04436419|DIETARY_SUPPLEMENT|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
219550500|NCT01207479|DEVICE|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
219550501|NCT02033902|DRUG|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
219550502|NCT04129177|OTHER|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
219550503|NCT01987128|PROCEDURE|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
219550504|NCT01987128|PROCEDURE|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
219686967|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
219686968|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
219686969|NCT01951144|DRUG|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
219686970|NCT04426942|OTHER|survey|survey on sexuality during pregnancy
219686971|NCT01040949|BEHAVIORAL|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
219686972|NCT01040949|BEHAVIORAL|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
219686973|NCT03353324|DRUG|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
219686974|NCT03353324|RADIATION|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
219686975|NCT05934474|BIOLOGICAL|Peripheral venipuncture blood sampling, as part of standard care procedures|Collection of 36 mL of blood
219686976|NCT05934474|OTHER|Interview with a psychiatrist|Research project data collection
219686977|NCT04238936|DIAGNOSTIC_TEST|Serum amyloid A values|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
219686978|NCT04238936|DIAGNOSTIC_TEST|Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
219686979|NCT01758497|PROCEDURE|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
219550505|NCT01987128|DRUG|Ropivacaine|
219550506|NCT01987128|DEVICE|PAJUNK SonoPlex 22G needle.|
219550507|NCT01959828|DRUG|IK-3001|
219550508|NCT01501786|DRUG|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
219550509|NCT01501786|DRUG|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
219550510|NCT01501786|DRUG|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
219686980|NCT01758497|PROCEDURE|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
219686981|NCT03540862|DEVICE|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
219686982|NCT00809445|BEHAVIORAL|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
219686983|NCT00809445|BEHAVIORAL|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
219686984|NCT00809445|BEHAVIORAL|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
219686985|NCT04822714|BEHAVIORAL|Mobile Career Competencies Intervention|Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
219686986|NCT02048722|DRUG|regorafenib|Given PO
219686987|NCT01339039|DRUG|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
219686988|NCT01339039|DRUG|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
219686989|NCT01339039|DRUG|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
219550511|NCT05435196|OTHER|Therapeutic exercise|"The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc."
219550512|NCT01371435|DRUG|Paroxetine|
219550513|NCT00473954|GENETIC|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
219550514|NCT02442687|DRUG|JKB-121: 5 mg twice daily|
219550515|NCT02442687|DRUG|JKB-121: 10 mg twice daily|
219550516|NCT02442687|DRUG|Placebo|
219550517|NCT05231603|DRUG|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
219550518|NCT05231603|OTHER|Placebo|Similar to drug in term of tablets
219550519|NCT05711901|DEVICE|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
219550520|NCT01459380|BIOLOGICAL|Bevacizumab|Given IV
219550521|NCT01459380|DRUG|Carboplatin|Given IV
219550522|NCT01459380|OTHER|Laboratory Biomarker Analysis|Correlative studies
219550523|NCT01459380|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219550524|NCT01459380|DRUG|Veliparib|Given PO
219686990|NCT01339039|DRUG|Plerixafor|Daily administration for 5-9 days prior to surgery
219686991|NCT01339039|PROCEDURE|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
219686992|NCT04760301|DRUG|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
219686993|NCT04760301|OTHER|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
219686994|NCT02570386|PROCEDURE|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
219100435|NCT04916964|OTHER|Test and exercise home-based program|"Eight home-based physiotherapy sessions will occur in two months, once a week, to activate the preserved implicit memory (PIM). The recommendations are to train three weeks with the same exercise program, three times a week (one time coached by the attributed physiotherapist and two times coached by a natural or family caregiver). After three weeks, the participants can choose if they want to keep the same exercises or change all or some of these, in testing other tasks. Every training session will be planned to last 45 minutes. During each training session, the participant will note on his/her own Training booklet each task performed. The Training booklet will be used to plane, organize, and remember details for the next training session."
219100436|NCT03537079|OTHER|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
219100437|NCT02079064|DRUG|Desflurane|Inhalational anesthetic
219100438|NCT02079064|DRUG|Propofol|Intravenous anesthetic that can be given by continuous infusion
219100439|NCT02609646|DRUG|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
219100440|NCT02609646|DRUG|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
219100441|NCT02609646|DRUG|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
219100442|NCT02609646|DRUG|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
219100443|NCT03968757|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
219100444|NCT05084417|OTHER|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
219100445|NCT02824302|OTHER|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
219100446|NCT01768208|DRUG|Saxagliptin|
219686995|NCT02570386|PROCEDURE|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
219686996|NCT01870986|BIOLOGICAL|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
219686997|NCT01870986|BIOLOGICAL|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
219686998|NCT01870986|BIOLOGICAL|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
219686999|NCT02406456|OTHER|Neurofeedback|
219687000|NCT00405405|DRUG|Cisplatin|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
219687001|NCT00405405|DRUG|Docetaxel|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
219687002|NCT00405405|DRUG|Bevacizumab|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
219100447|NCT02491190|BEHAVIORAL|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
219100448|NCT03737084|BEHAVIORAL|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
219100449|NCT03245385|DRUG|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
219687003|NCT00405405|DRUG|Erlotinib|"* Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
219687004|NCT00405405|RADIATION|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
219687005|NCT03983200|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
219687006|NCT03983200|DRUG|Mecobalamin|mecobalamine 0.5mg,tid
219687007|NCT01021397|DRUG|rHPIV3cp45|10\^5 TCID50 nasal drops
219687008|NCT01021397|DRUG|rHPIV3cp45 placebo|1X-L15 nasal drops
219100450|NCT06341725|OTHER|malignant lymph nodes|observational study
219100451|NCT03444233|OTHER|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
219100452|NCT00722501|DRUG|ERB-257|
219687009|NCT05870306|PROCEDURE|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
219687010|NCT05870306|PROCEDURE|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
219687011|NCT05766579|DEVICE|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
219687012|NCT05564598|BIOLOGICAL|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
219687013|NCT05564598|DRUG|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months"
219687014|NCT03588130|DRUG|EscharEx (5% EX-02 formulation)|Active arm
219687015|NCT03588130|DRUG|Gel Vehicle|Control arm
219687016|NCT03588130|DRUG|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
219687017|NCT06581783|DRUG|Simethicone plus NAC|Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
219687018|NCT01487083|DRUG|Pomaglumetad methionil|Administered orally
219100453|NCT00722501|OTHER|placebo|
219100454|NCT04896632|DRUG|INE 963|Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
219100455|NCT04896632|OTHER|Placebo|Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
219100456|NCT05841238|DRUG|LY3502970|Administered orally.
219100457|NCT00962247|DEVICE|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
219100458|NCT03062202|BEHAVIORAL|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
219100459|NCT05360030|DRUG|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
219687019|NCT06958562|DIAGNOSTIC_TEST|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.
219687020|NCT00507936|DRUG|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
219100460|NCT05360030|DRUG|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
219100461|NCT05360030|DRUG|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
219100462|NCT05360030|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
219100463|NCT05360030|DEVICE|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
219687021|NCT00507936|DRUG|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
219687022|NCT00507936|DRUG|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
219687023|NCT00507936|DRUG|placebo|placebo capsule BID throughout the treatment period
219687024|NCT00507936|DRUG|Duloxetine|Duloxetine 60 mg QD throughout treatment period
219687025|NCT06545903|DEVICE|LMA Supreme|The device is inserted and the manikin ventilated
219687026|NCT06545903|DEVICE|SLIPA|The device is inserted and the manikin ventilated
219687027|NCT06545903|DEVICE|I-gel|The device is inserted and the manikin ventilated
219687028|NCT06545903|DEVICE|AuraGain|The device is inserted and the manikin ventilated
219687029|NCT06038942|BEHAVIORAL|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
219687030|NCT06038942|BEHAVIORAL|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
219687031|NCT03107208|DRUG|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
219687032|NCT03107208|DEVICE|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
219687033|NCT04078711|DRUG|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
219687034|NCT04078711|DRUG|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
219687035|NCT04078711|DRUG|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
219687036|NCT04804761|OTHER|Electroacupuncture|Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
219687037|NCT02511925|OTHER|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
219687038|NCT02511925|OTHER|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
219687039|NCT02511925|OTHER|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
219687040|NCT01747356|DEVICE|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
219687041|NCT04835727|OTHER|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
219687042|NCT01272908|DRUG|rituximab|1000 mg intravenously on Days 1 and 15
219687043|NCT00183118|BEHAVIORAL|Adapted Enhanced-RESPECT (HIV prevention intervention)|
219687044|NCT03602703|DIAGNOSTIC_TEST|Flow cytometry and Western Blot analysis|Diagnostic tests
219687045|NCT02482142|DIETARY_SUPPLEMENT|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
219687046|NCT05803694|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
219687047|NCT05739604|DIAGNOSTIC_TEST|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
219687048|NCT05534568|OTHER|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
219687049|NCT03899857|DRUG|Pembrolizumab|Pembrolizumab will be added to standard of care
219687050|NCT01360346|PROCEDURE|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
219687051|NCT01360346|PROCEDURE|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
219687052|NCT03162406|DIETARY_SUPPLEMENT|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
219687053|NCT03162406|DIETARY_SUPPLEMENT|Placebo|Oral supplementation once per week for 6 months
219687054|NCT06047639|DEVICE|Bone-anchored hearing implants|surgically placed hearing device
219687055|NCT03489343|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
219687056|NCT01388855|DRUG|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
219687057|NCT01388855|DRUG|Placebo|Pills made to look like vitamin D but have no medication in them
219687058|NCT02862964|OTHER|identify L4/L5|"* For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
219687059|NCT04414852|DRUG|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
219687060|NCT01158261|BIOLOGICAL|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
219687061|NCT03143101|BIOLOGICAL|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
219687062|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
219687063|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
219687064|NCT05052853|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
219687065|NCT05052853|DRUG|Placebo Cap|Use of placebo as a comparator
219687066|NCT01493245|DRUG|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
219687067|NCT01912950|DEVICE|Prowave LX IPL|
219687068|NCT02373150|DRUG|Imeglimin|
219687069|NCT02373150|DRUG|Placebo|
219687070|NCT05357534|OTHER|Physical activity|Physical activity: 10 km run on a treadmill
219687071|NCT05028764|DIAGNOSTIC_TEST|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
219687072|NCT04708080|PROCEDURE|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
219687073|NCT00201344|DRUG|Cisplatin,5-FU,Leucovorin|
219687074|NCT01285869|OTHER|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
219687075|NCT02908152|DIETARY_SUPPLEMENT|curcumin|"1500 mg~1 capsule / day for 12 weeks"
219687076|NCT02908152|DIETARY_SUPPLEMENT|placebo|"1500 mg~1 capsule / day for 12 weeks"
219687077|NCT01518647|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
219687078|NCT04687410|DEVICE|ProControl, MediGlobe|standard 22G FNA needle
219687079|NCT04687410|DEVICE|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
219687080|NCT01630135|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
219687081|NCT01630135|DRUG|Placebo|Placebo, intranasal, 2 weeks
219687082|NCT05535608|DIETARY_SUPPLEMENT|SRW Cel System|Dietary supplement
219687083|NCT02554760|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
219687084|NCT02631317|BEHAVIORAL|Advance hospital notification by EMS|Advance hospital notification by EMS
219687085|NCT02631317|BEHAVIORAL|stroke team notification|stroke team notification
219687086|NCT02631317|BEHAVIORAL|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
219687087|NCT02631317|BEHAVIORAL|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
219100464|NCT05360030|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
219100465|NCT03156322|DRUG|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
219687088|NCT02631317|BEHAVIORAL|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
219687089|NCT06223295|PROCEDURE|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
219687090|NCT06223295|PROCEDURE|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
219687091|NCT06303206|DEVICE|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values."
219687092|NCT06009679|DRUG|Misoprostol 200mcg Tab|Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
219687093|NCT02260219|PROCEDURE|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
219687094|NCT06129097|OTHER|Thyme honey mouthwash|"* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."
219687095|NCT03099577|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219687096|NCT03099577|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219687097|NCT03099577|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219100466|NCT03156322|DRUG|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
219100467|NCT03156322|DRUG|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
219100468|NCT01487044|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
219100469|NCT02653638|OTHER|Control|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
219100470|NCT02653638|DRUG|Indomethacin|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
219100471|NCT00346801|DRUG|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
219687098|NCT03099577|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219687099|NCT03099577|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219687100|NCT03099577|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219100472|NCT00346801|DRUG|Cisplatin|25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8
219687101|NCT03099577|RADIATION|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
219100473|NCT00346801|DRUG|CPT-11|30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
219100474|NCT00346801|RADIATION|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
219100475|NCT02462954|DEVICE|ContraGel|
219100476|NCT02462954|DEVICE|HEC Universal Placebo gel|
219100477|NCT02233933|OTHER|Hemospray|hemospray is used after argon coagulation to stop bleeding
219687102|NCT05259319|DRUG|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
219687103|NCT05259319|DRUG|Tiragolumab|Treatment given every 21 days during 24 months or until progression
219687104|NCT05259319|RADIATION|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
219687105|NCT05227118|DRUG|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
219100478|NCT06383780|DRUG|GP combined with Tislelizumab|Gemcitabine combined with cisplatin regimen combined with Tislelizumab
219687106|NCT05227118|DRUG|Placebo|MK-8189 matching placebo administered orally QD
219687107|NCT05921656|OTHER|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"1. Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~2. Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
219100479|NCT06383780|DRUG|TPC combined with Tislelizumab|cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
219100480|NCT00509548|DRUG|TG100801|Eye drop, twice a day, 30 days.
219100481|NCT04040257|BEHAVIORAL|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
219100482|NCT00740558|PROCEDURE|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
219100483|NCT00740558|PROCEDURE|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
219100484|NCT01161368|DRUG|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle."
219100485|NCT04612946|BEHAVIORAL|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
219100486|NCT04612946|BEHAVIORAL|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
219687108|NCT00394888|DEVICE|MRI|MRI of the spine.
219161708|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
219161709|NCT04602975|BIOLOGICAL|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
219161710|NCT04602975|BIOLOGICAL|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
219687109|NCT00394888|DEVICE|MRI of head and neck|MRI of head and C-spine
219687110|NCT00394888|OTHER|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
219687111|NCT00394888|OTHER|Cardiac examination|Complete cardiac examination
219687112|NCT00394888|DEVICE|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
219100487|NCT01373762|BEHAVIORAL|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
219100488|NCT01580839|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
219100489|NCT01580839|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
219100490|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Holmium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser
219100491|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Thulium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
219100492|NCT02223039|BIOLOGICAL|AbGn-168H|AbGn-168H monoclonal antibody
219223724|NCT07031271|BEHAVIORAL|Tangram game|Tangram game; It is a very old intelligence and attention game of Chinese origin. This game stands out with its both entertaining and educational aspects. Tangram consists of seven geometric pieces formed from a square shape. These 7 pieces; 2 large right triangles, 1 medium right triangle, 2 small right triangles, 1 square and 1 parallelogram. The aim is to create various shapes (animals, people, objects, letters, etc.) with these pieces. The aim of the Tangram game is to recreate the same appearance with a given shape (silhouette) using the pieces. All 7 pieces must be used in the game, the pieces must not be overlapped, the pieces must not be cut or divided, the pieces can be rotated or turned according to the selected shape. For example, the person is asked to create a cat figure with these 7 pieces in accordance with the rules. This game is one of the non-pharmacological pain management techniques by diverting the attention of the patients. It is easy to apply and cheap.
219223725|NCT07038135|DIETARY_SUPPLEMENT|Novel Natural Supplement (NNS)|Multi-ingredient formula including whey protein, pea protein, oats, sweet potato, flaxseed, chia seeds, spinach powder, cardamom, green tea extract, beetroot powder, and stevia. Administered daily for 8 weeks.
219223726|NCT07038135|DIETARY_SUPPLEMENT|Placebo|A placebo containing maltodextrin, microcrystalline cellulose, and beetroot powder, matched in appearance, flavor, and texture to the NNS. Administered daily for 8 weeks.
219223727|NCT06718127|BIOLOGICAL|blood samples collection|blood samples collected at D0 ,W1, W5, M3 and M6
219223728|NCT03562741|PROCEDURE|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
219687113|NCT02541864|DRUG|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
219687114|NCT02541864|DRUG|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
219687115|NCT03389100|DRUG|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
219687116|NCT01526564|DRUG|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks
219687117|NCT01526564|DRUG|Placebo|3 t.i.d, two plates per time
219687118|NCT00561938|PROCEDURE|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
219100493|NCT02223039|BIOLOGICAL|Placebo|Placebo of AbGn-168H
219100494|NCT04209413|PROCEDURE|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
219100495|NCT01106443|PROCEDURE|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
219235342|NCT01535261|DRUG|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
219687119|NCT00561938|PROCEDURE|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
219687120|NCT03727841|DRUG|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
219687121|NCT01601496|DEVICE|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
219687122|NCT02653911|OTHER|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
219687123|NCT02653911|OTHER|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
219687124|NCT02342392|DRUG|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
219687125|NCT04771078|BIOLOGICAL|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
219687126|NCT04607902|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
219687127|NCT04607902|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
219687128|NCT04607902|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
219687129|NCT01679392|DRUG|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
219687130|NCT03243305|DRUG|AMPHORA|non-hormonal contraceptive vaginal gel
219687131|NCT01155622|PROCEDURE|Endovascular Cooling|Infusion of \<8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
219687132|NCT01406119|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
219687133|NCT04781296|DEVICE|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
219687134|NCT01523145|BEHAVIORAL|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
219235343|NCT02404298|DRUG|IVIg|
219687135|NCT01523145|OTHER|Control Group|usual follow-up Standard follow-up at the participating heart center
219687136|NCT03130374|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
219687137|NCT04718480|DRUG|Placebo|po placebo tablets
219687138|NCT04718480|DRUG|Fluvoxamine|po fluvoxamine tablets
219687139|NCT05251116|DEVICE|FreeStyle Libre|FreeStyle Libre 2 continuous Glucose Monitoring System
219687140|NCT02689804|DRUG|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
219687141|NCT02689804|DRUG|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
219687142|NCT01519011|DRUG|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
219687143|NCT01519011|DRUG|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
219687144|NCT01655719|DRUG|Pioglitazone|
219687145|NCT03964077|DIAGNOSTIC_TEST|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
219687146|NCT00757393|DIETARY_SUPPLEMENT|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
219687147|NCT00757393|DRUG|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
219687148|NCT03425318|DEVICE|CNAP|Application of CNAP in patients with ARDS
219687149|NCT01820897|DRUG|Fosfomycin-Trometamol|
219687150|NCT01820897|DRUG|Sulfamethoxazole trimethoprim|
219687151|NCT02565316|DRUG|Nepeta menthoides Boiss & Bohse freeze dried extract|
219687152|NCT02565316|DRUG|Sertraline|
219687153|NCT00116961|DRUG|Velcade|
219687154|NCT00116961|DRUG|Doxil|
219687155|NCT00116961|DRUG|Dexamethasone|
219235344|NCT04812977|DRUG|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
219235345|NCT05881213|DRUG|CKD-378 (low-dose)|Quaque day (QD), PO
219235346|NCT02040038|BEHAVIORAL|LIVE|3-D Virtual Environment for DSMT/S
219235347|NCT02040038|BEHAVIORAL|Website|2-D Website participation for DSMT/S
219235348|NCT05798598|OTHER|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
219687156|NCT03351543|BIOLOGICAL|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
219687157|NCT00861666|BEHAVIORAL|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
219100496|NCT01106443|PROCEDURE|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
219100497|NCT01106443|PROCEDURE|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
219100498|NCT01106443|PROCEDURE|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
219100499|NCT00910403|PROCEDURE|LASIK|Excimer Laser Ablation using LASIK
219223729|NCT07040605|OTHER|Deep cervical flexors muscle training and sensorimotor training|"deep cervical flexor muscle training will be performed according to the protocol of Jull and Falla using a pressure biofeedback unit. Participants will be positioned in a supine crook-lying posture with the neck in a neutral position, and the air bag of the pressure biofeedback unit will be placed beneath the cervical lordosis and inflated to a baseline of 20 mmHg. Patients will be instructed to perform a gentle nodding action, increasing the pressure by 2 mmHg increments up to 30 mmHg. Each increment will be held for ten seconds, repeated in three sets of ten repetitions, with a two-minute rest between sets. To enhance activation of the deep flexors, patients will be instructed to keep their mouth open during the exercise.~Proprioception training will include head relocation practice, oculomotor exercises, and eye-head coordination exercises."
219223730|NCT07040605|OTHER|conventional physical therapy exercise|"will include stretching exercises targeting the sternocleidomastoid, upper trapezius, levator scapulae, scalene, Rhomboids and pectoralis muscles, performed in three repetitions, holding each stretch for thirty seconds, strengthening exercises will be provided Isometrically for the cervical flexors, extensors and at sides using a prescription of three sets of ten repetitions with a ten-second hold and two minutes of rest between sets.~TENS and Hot back."
219687158|NCT05337865|OTHER|Aerobic exercise test.|Aerobic exercise test at a treadmill.
219687159|NCT01569126|DRUG|LY110140|Administered orally as capsules
219687160|NCT01569126|DRUG|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
219687161|NCT04010292|BEHAVIORAL|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
219687162|NCT01921803|RADIATION|hypofractionation|
219687163|NCT03390595|COMBINATION_PRODUCT|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~* Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~  * Intravenously every 2 weeks for two cycles.~ * During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~ * Intravenously every 2 weeks until progressive disease or intolerance.~* Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~  * Carboplatin 5AUC day +1.~ * Gemcitabine 1000mg/m2 day +1 and +8."
219687164|NCT03390595|COMBINATION_PRODUCT|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~* Carboplatin 5AUC day +1.~* Gemcitabine 1000mg/m2 day +1 and +8."
219687165|NCT01124318|DRUG|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
219687166|NCT01124318|DRUG|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
219687167|NCT01166750|BEHAVIORAL|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
219100500|NCT04741516|DRUG|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
219100501|NCT00493077|DRUG|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
219100502|NCT00921063|DRUG|PD 0332334|250 mg capsule, BID for 4 weeks
219550525|NCT04573569|BEHAVIORAL|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
219550526|NCT03785262|DEVICE|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
219100503|NCT00921063|DRUG|PD 0332334|100 mg capsule, BID for 4 weeks
219100504|NCT00921063|DRUG|placebo|0 mg capsule, BID for 4 weeks
219100505|NCT00921063|DRUG|Alprazolam extended release|1 mg capsule, BID for 4 weeks
219100506|NCT00045435|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
219100507|NCT00045435|DRUG|fludarabine phosphate|Given IV
219100508|NCT00045435|RADIATION|total-body irradiation|Undergo TBI
219100509|NCT00045435|DRUG|cyclosporine|Given PO
219100510|NCT00045435|DRUG|mycophenolate mofetil|Given PO
219100511|NCT00045435|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
219100512|NCT00674622|DRUG|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
219100513|NCT00674622|PROCEDURE|Placebo|Saline/lidocaine
219550527|NCT03785262|DEVICE|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
219550528|NCT00270634|DRUG|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
219550529|NCT00270634|DRUG|tacrolimus|tacrolimus 0.05 mg/kg po BID
219550530|NCT04789434|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
219550531|NCT00354835|DRUG|Cyclophosphamide|Given IV
219550532|NCT00354835|BIOLOGICAL|Dactinomycin|Given IV
219550533|NCT00354835|DRUG|Irinotecan Hydrochloride|Given IV
219550534|NCT00354835|OTHER|Laboratory Biomarker Analysis|Correlative studies
219550535|NCT00354835|OTHER|Questionnaire Administration|Ancillary studies
219550536|NCT00354835|RADIATION|Radiation Therapy|Undergo radiotherapy
219550537|NCT00354835|DRUG|Vincristine Sulfate|Given IV
219550538|NCT06289296|OTHER|Fatty acid intake in lean and obese males|Acute and chronic intake of MCT and LCT
219550539|NCT01968551|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
219550540|NCT01968551|DRUG|DRV|800 mg tablet administered orally once daily
219550541|NCT01968551|DRUG|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
219550542|NCT05709496|RADIATION|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
219550543|NCT05077449|DRUG|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
219550544|NCT05077449|DRUG|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
219550545|NCT00167453|PROCEDURE|Exercise, Education|
219550546|NCT01181635|BEHAVIORAL|Psychotherapy|Standard psychotherapy for psychiatric disorders.
219550547|NCT03896594|DRUG|HL237|Experimental
219550548|NCT03896594|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
219550549|NCT04260373|DRUG|[14C]SHR4640|Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
219550550|NCT03045458|DEVICE|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
219550551|NCT03045458|DEVICE|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
219550552|NCT00431041|DRUG|solifenacin|Oral
219550553|NCT00431041|DRUG|oxybutynin immediate release|Oral
219550554|NCT02112123|DRUG|Icariin|
219550555|NCT02112123|DIETARY_SUPPLEMENT|Matching placebo|
219550556|NCT00573313|DRUG|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
219550557|NCT00573313|DRUG|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
219550558|NCT02607826|PROCEDURE|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
219550559|NCT02318420|OTHER|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
219550560|NCT05722080|OTHER|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
219550561|NCT05722080|OTHER|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
219550562|NCT03640741|PROCEDURE|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
219550563|NCT03300011|DEVICE|stent|PTCA or PCI
219550564|NCT05509023|DRUG|ADX-914|Subcutaneous administration of ADX-914
219100514|NCT03621202|DEVICE|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
219100515|NCT00738101|DRUG|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
219550565|NCT05509023|DRUG|Placebo|Subcutaneous administration of Placebo
219550566|NCT00102349|BEHAVIORAL|Behavior Therapy|
219100516|NCT02484170|DRUG|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
219161711|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
219550567|NCT00978536|OTHER|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
219550568|NCT06626802|PROCEDURE|Balloon Dilation + Topical Mitomycin|Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
219550569|NCT06626802|PROCEDURE|Balloon Dilation + Injection Triamcinolone|Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
219550570|NCT02226250|DIETARY_SUPPLEMENT|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
219550571|NCT05150223|OTHER|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
219550572|NCT05150223|OTHER|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
219550573|NCT03805633|DIAGNOSTIC_TEST|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
219550574|NCT03805633|DIAGNOSTIC_TEST|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
219550575|NCT00841022|OTHER|Information with comics|Information of children with comic leaflet
219550576|NCT02740257|OTHER|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
219550577|NCT05232539|DEVICE|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
219550578|NCT01839539|BIOLOGICAL|dendritic and cytokine-induced killer cells|
219550579|NCT01326663|DRUG|Medication Trial|
219550580|NCT01373515|BIOLOGICAL|DCP-001|4 bi-weekly vaccinations
219550581|NCT00310115|BEHAVIORAL|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
219550582|NCT00310115|BEHAVIORAL|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
219550583|NCT00310115|BEHAVIORAL|Counseling Intervention|2 in-person counseling sessions
219550584|NCT03879187|DIETARY_SUPPLEMENT|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
219550585|NCT00891787|DIETARY_SUPPLEMENT|Probiotic Supplement|
219550586|NCT03431558|COMBINATION_PRODUCT|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
219550587|NCT03431558|DRUG|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
219550588|NCT05535868|OTHER|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
219550589|NCT03562182|OTHER|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
219550590|NCT05346172|DEVICE|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
219550591|NCT06466317|BEHAVIORAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
219100517|NCT02484170|DRUG|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
219100518|NCT01948635|DEVICE|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
219100519|NCT01948635|DEVICE|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
219550592|NCT06466317|BEHAVIORAL|Walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
219100520|NCT00402194|DRUG|Losartan|Tablet, 100mg, once per day for 3 months
219100521|NCT03288896|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
219550593|NCT00748696|DIETARY_SUPPLEMENT|Fortimel Extra®|260kcal and 20g protein per day
219550594|NCT00748696|OTHER|resistance training|3 sessions of resistance training per week
219550595|NCT00748696|OTHER|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
219550596|NCT01640743|DRUG|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
219550597|NCT01640743|DRUG|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
219550598|NCT02959619|DRUG|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
219550599|NCT00796913|OTHER|Stop medication|Stop medication Stop medication + se supplement
219550600|NCT01398085|RADIATION|I131 1.1 GBq|Radio-iodine
219550601|NCT05532631|PROCEDURE|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
219550602|NCT05532631|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
219550603|NCT06627660|PROCEDURE|Valsalva maneuver|Closure of the nose and mouth during expiration for 20 sec
219550604|NCT02873182|DEVICE|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
219550605|NCT03732144|BEHAVIORAL|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
219550606|NCT03732144|OTHER|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
219550607|NCT01807026|DRUG|LY2886721|
219550608|NCT01807026|DRUG|Placebo|
219550609|NCT00396929|DRUG|local intracoronary dosis of Paclitaxel|
219550610|NCT05822726|DIAGNOSTIC_TEST|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
219550611|NCT01597791|DEVICE|Foley catheter|Foley catheter placement after CSE.
219687168|NCT01166750|BEHAVIORAL|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
219687169|NCT01358292|PROCEDURE|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
219687170|NCT01358292|PROCEDURE|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
219687171|NCT04332068|DRUG|Oral ivermectin|Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
219687172|NCT04332068|DRUG|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
219687173|NCT04332068|OTHER|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
219687174|NCT04332068|OTHER|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
219687175|NCT03812939|DRUG|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
219687176|NCT04576728|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days.
219687177|NCT04576728|OTHER|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days.
219100522|NCT04895514|PROCEDURE|Gamma-irradiated corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
219687178|NCT06010212|DRUG|Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin|"Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled."
219687179|NCT05499884|PROCEDURE|Endovaginal ultrasound|"Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion"
219100523|NCT04997707|DRUG|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
219100524|NCT04997707|DRUG|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
219100525|NCT04997707|DIAGNOSTIC_TEST|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
219100526|NCT01406522|DRUG|Oral tacrine|Tacrine, 160 mg per day, four times daily
219100527|NCT01406522|DRUG|Oral placebo|Microcrystalline cellulose
219100528|NCT05839223|OTHER|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
219687180|NCT02503241|PROCEDURE|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
219687181|NCT02503241|PROCEDURE|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
219687182|NCT04266899|DEVICE|Foot Drop Stimulator - Neuro Orthosis|The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
219687183|NCT04266899|DEVICE|Treadmill|Gait training on a treadmill
219687184|NCT01585246|DRUG|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
219687185|NCT01585246|DRUG|soybean oil soft gel|placebo (soybean oil soft gel)
219687186|NCT05897515|DIAGNOSTIC_TEST|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
219100529|NCT04416698|BEHAVIORAL|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
219100530|NCT04416698|BEHAVIORAL|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
219100531|NCT01958840|BEHAVIORAL|Behavioral Activation for Depression Treatment|
219100532|NCT01958840|BEHAVIORAL|Supportive Counseling|
219100533|NCT04953364|BEHAVIORAL|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
219687187|NCT01704807|DEVICE|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
219687188|NCT01704807|DEVICE|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
219100534|NCT04953364|BEHAVIORAL|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
219100535|NCT03520465|DEVICE|DynaMesh®-CICAT longitudinal measure 10x35 cm|
219100536|NCT01397994|DRUG|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
219100537|NCT01397994|DRUG|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
219100538|NCT03448159|DRUG|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
219100539|NCT03448159|OTHER|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
219100540|NCT03448159|BEHAVIORAL|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
219100541|NCT05119075|OTHER|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
219100542|NCT05119075|OTHER|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
219100543|NCT03311932|DRUG|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
219100544|NCT03311932|DRUG|Cortef®|Immediate release hydrocortisone tablets
219100545|NCT00203060|DRUG|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
219100546|NCT00203060|DRUG|placebo|tablet, once daily, 58 weeks
219550612|NCT01597791|OTHER|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
219100547|NCT02168764|DEVICE|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
219100548|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
219100549|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+CaCO3|
219100550|NCT00051168|DRUG|Travatan|Travoprost (0.004%) 1 drop each eye once daily
219100551|NCT04236258|DRUG|NIFEdipine ER|Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
219100552|NCT04236258|DRUG|Enalapril|Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
219100553|NCT00709059|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
219100554|NCT00709059|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks
219100555|NCT06053034|DEVICE|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
219100556|NCT05048849|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
219223731|NCT06724471|DEVICE|Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials|Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).
219223732|NCT07042620|DEVICE|SonoClear(R) System|The SonoClear(R) System is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
219550613|NCT05718180|OTHER|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
219550614|NCT01232660|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
219550615|NCT03069976|DRUG|Metronidazole|Flagyl x 14 days.
219550616|NCT05963464|DEVICE|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
219550617|NCT03909633|BEHAVIORAL|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
219550618|NCT05757830|DEVICE|UANGO suite exoskeleton|"Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3."
219550619|NCT00458822|DRUG|bortezomib|Given IV
219550620|NCT00458822|DRUG|dexamethasone|Given orally
219550621|NCT01476501|DRUG|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
219100557|NCT05823246|DRUG|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
219100558|NCT04531566|DIETARY_SUPPLEMENT|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
219687189|NCT01688323|OTHER|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
219687190|NCT00145769|DRUG|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
219687191|NCT00145769|DRUG|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
219687192|NCT00145769|RADIATION|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
219687193|NCT00145769|RADIATION|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
219687194|NCT00145769|DRUG|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
219687195|NCT00145769|PROCEDURE|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
219687196|NCT00219947|OTHER|blood draw|"* T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing"
219687197|NCT05171010|OTHER|no study-based therapeutic interventions|no study-based therapeutic interventions
219687198|NCT04739033|BEHAVIORAL|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
219687199|NCT02417753|DRUG|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
219687200|NCT03638960|DRUG|Bupivacaine liposome|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
219687201|NCT03638960|DRUG|Bupivacaine Hydrochloride|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
219687202|NCT03113968|PROCEDURE|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
219687203|NCT03113968|DRUG|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
219100559|NCT04531566|DIETARY_SUPPLEMENT|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
219687204|NCT01660009|OTHER|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
219687205|NCT03217552|DIAGNOSTIC_TEST|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
219687206|NCT01387178|DRUG|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
219687207|NCT01387178|DRUG|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
219687208|NCT04805671|DRUG|ADG20|Single dose of ADG20
219100560|NCT06053554|PROCEDURE|Phakoemulsification|Femtolaser is used to perform a standard 5.0mm CCC centred on the pupil or limbus and to fragment the lens nucleus toguarantee reproducible results in every eye.After the CCC and nucleus fragmentation the anterior segment is filled with viscoelastics, the rhexis lenticule is removed and hydrodisection of the nucleus is performed. Subsequently phacoemulsification for nucleus and irrigation/aspiration of the lens cortex is performed. The capsular bag and AC is then filled with a cohesive viscoelastic and the IOL is implanted with the haptics in the back or with the haptics in the sulcus. At the end of surgery, the viscoelastic is removed using the irrigation aspiration probe, intracameral antibiotic is instilled, the CCI and paracenteses are hydrated and sealed.
219100561|NCT06053554|DEVICE|Ziemer Z8 Femtolaser|The femto second laser used for certain steps (capsulorhexis, nucleus fragmentation) of the cataract surgery.
219100562|NCT06053554|DEVICE|Kowa Avansee Preset|The used 3 piece intra ocular lens
219687209|NCT04805671|DRUG|Normal saline|Single dose of normal saline
219687210|NCT00140062|DRUG|latanoprost 0.005% (Xalatan)|
219687211|NCT02550743|DRUG|BYL719|
219687212|NCT02550743|DRUG|Capecitabine|
219687213|NCT02550743|RADIATION|Radiation|
219100563|NCT01786330|DEVICE|Procare abdominal binder|
219100564|NCT01786330|OTHER|Standard of Care|
219100565|NCT01154569|DRUG|Azithromycin|500 mg single dose
219100566|NCT00855010|DRUG|pioglitazone|pioglitazone 45 mg daily
219100567|NCT00855010|DRUG|placebo|one daily
219100568|NCT01933022|DRUG|Eligard|Subcutaneous Injection
219100569|NCT00671203|PROCEDURE|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
219550622|NCT04090658|BIOLOGICAL|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV\_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
219550623|NCT04090658|DRUG|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
219550624|NCT03019016|PROCEDURE|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
219550625|NCT05956717|DEVICE|Orthokeratology|The experimental group wore orthokeratology lenses
219100570|NCT05382754|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
219100571|NCT05382754|DIAGNOSTIC_TEST|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
219100572|NCT06487598|DRUG|inj insulin to one group|One group- only inj insulin for 3 months.
219550626|NCT02545179|OTHER|web-based daily care training|12 week interactive web based caring training education
219550627|NCT05789121|DEVICE|walking 25 m in 4 different conditions|"The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation"
219550628|NCT01102907|OTHER|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
219550629|NCT01102907|OTHER|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
219550630|NCT00467597|DRUG|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
219550631|NCT00109057|DRUG|Avastin (bevacizumab)|
219550632|NCT03756233|DRUG|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
219550633|NCT00634205|DRUG|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
219550634|NCT02722798|DRUG|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
219550635|NCT02096705|DRUG|Dapagliflozin|Tablet
219550636|NCT02096705|DRUG|Dapagliflozin Placebo|Tablet
219550637|NCT00417677|DRUG|Combination of Temsirolimus and Sunitinib|
219550638|NCT03710629|OTHER|Patients with driver genes|Patients with driver genes
219550639|NCT06122805|DEVICE|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
219550640|NCT04563260|DRUG|Normal saline injection|Normal saline 2 mL, intravenous injection
219550641|NCT04563260|DRUG|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
219550642|NCT04163094|DRUG|W_ova1 Vaccine|Patients will be treated with a W\_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
219550643|NCT03669731|OTHER|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
219550644|NCT03277248|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
219550645|NCT03277248|DRUG|Teriflunomide|Film coated tablets administered orally.
219550646|NCT03277248|DRUG|Oral Placebo|Administered orally.
219550647|NCT03277248|DRUG|IV Placebo|Administered as an IV Infusion.
219550648|NCT02472834|DIETARY_SUPPLEMENT|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
219550649|NCT00476034|DRUG|lumiracoxib|
219550650|NCT01963455|BIOLOGICAL|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
219550651|NCT03404921|PROCEDURE|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
219550652|NCT03404921|PROCEDURE|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
219550653|NCT02238587|OTHER|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
219550654|NCT02238587|DIETARY_SUPPLEMENT|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
219550655|NCT02235870|DEVICE|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
219550656|NCT02235870|DEVICE|Sham Device|Sham Intragastric Balloon
219687214|NCT02111174|DEVICE|Scrambler Therapy|
219687215|NCT02111174|DEVICE|Sham Therapy|
219687216|NCT02361034|DRUG|GRC 27864|
219687217|NCT02361034|DRUG|Placebo|
219687218|NCT03551847|DRUG|Antibiotic|The intervention involves giving an infected patient antibiotics.
219687219|NCT03551847|DRUG|No antibiotics|The intervention involves not giving an infected patient antibiotics.
219687220|NCT00251134|DRUG|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
219100573|NCT06487598|DRUG|Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day|second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
219100574|NCT02007005|DRUG|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
219100575|NCT00356954|DRUG|N-acetylcystein|
219687221|NCT00251134|DRUG|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
219687222|NCT01657162|DRUG|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
219100576|NCT00356954|DRUG|ascorbic acid|
219100577|NCT00411593|DRUG|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
219100578|NCT00411593|DRUG|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
219100579|NCT05924399|BEHAVIORAL|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
219100580|NCT00256503|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
219100581|NCT01568346|OTHER|MRI|Breast MRI
219100582|NCT03340948|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
219100583|NCT03977558|BEHAVIORAL|Intervention group|Isocaloric diet including \~50g canola oil
219687223|NCT00657423|DRUG|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
219687224|NCT00657423|DRUG|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
219687225|NCT00901342|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
219687226|NCT02970955|PROCEDURE|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
219687227|NCT02993861|OTHER|Anti-epileptics|
219100584|NCT03977558|BEHAVIORAL|Control group|ESC/EAS Guidelines for the management of dyslipidemias
219100585|NCT02969525|OTHER|Placebo|
219100586|NCT02969525|DRUG|Bimekizumab|Bimekizumab in different dosage regimens.
219100587|NCT00241527|DRUG|Esomeprazole|
219100588|NCT00414739|DRUG|Benzalkonium chloride|
219100589|NCT02172625|DIETARY_SUPPLEMENT|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
219161712|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
219161713|NCT00727909|DEVICE|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
219161714|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
219161715|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
219161716|NCT04587505|PROCEDURE|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
219161717|NCT04587505|DRUG|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
219161718|NCT04587505|PROCEDURE|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
219687228|NCT06314334|DRUG|Sintilimab+Pegaspargase|"1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;"
219687229|NCT06314334|DRUG|P-GemOx|"1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip"
219687230|NCT06314334|DRUG|GELAD|"1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip."
219687231|NCT06314334|RADIATION|IMRT|Intensity modulated radiotherapy (50-56Gy)
219687232|NCT00729716|BIOLOGICAL|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
219100590|NCT02172625|OTHER|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
219100591|NCT05962983|BEHAVIORAL|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
219100592|NCT00524030|DRUG|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
219100593|NCT00524030|DRUG|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
219100594|NCT01218945|PROCEDURE|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
219100595|NCT02707692|BIOLOGICAL|Fluarix|Intramuscular injection with Fluarix® .
219100596|NCT02707692|BIOLOGICAL|Pneumovax|Intramuscular injection with Pneumovax.
219223733|NCT07042360|DIAGNOSTIC_TEST|ReDs Pro|"The basic principle invovles emitting low-power electromagnetic sgnals into the lungs and measuring the dielectric properties of lung tissue~The varing dielectric constants of these components result in differences in the impedance values for electromagnetic waves. Therefore, using the impedance method allows the estimation of the dielectric properties of lung tissue, which can be further converted into lung fluid content data through calculations."
219223734|NCT07042360|DIAGNOSTIC_TEST|Fibroscan|Using external ultrasound scanner to check fo rliver stiffness using acoustic energy
219223735|NCT07043231|OTHER|Creative materials|This intervention provides professionals with co-created creative materials specifically designed to facilitate structured, safe conversations about suicidality with children and adolescents. Unlike standard tools, it offers three flexible pathways-Conversation, Drawing, and Walking-allowing a personalized approach tailored to the young person's preferences and context. The materials guide professionals through the assessment of suicidal intent, risk and protective factors, and help formulate a risk assessment and Safety Plan. The content is aligned with national clinical guidelines but uniquely integrates experiential insights from youth with lived experience, ensuring both theoretical grounding and practical applicability.
219687233|NCT00729716|PROCEDURE|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
219687234|NCT05621044|BEHAVIORAL|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
219687235|NCT05621044|BEHAVIORAL|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
219687236|NCT01246895|DEVICE|Microfracture with BST-CarGel|
219687237|NCT01246895|DEVICE|Microfracture without BST-CarGel|
219687238|NCT03603522|DIETARY_SUPPLEMENT|BioGaia-DSM17938|2mL per day (1x10\^9 CFU) per day taken orally for 28 days
219100597|NCT02707692|OTHER|Placebo|Intramuscular injection with sterile saline (placebo).
219100598|NCT00849004|OTHER|silicone gel|silicone gel
219100599|NCT00849004|OTHER|silicone sheet|silicone sheet
219100600|NCT00849004|OTHER|paper tape|paper tape
219100601|NCT06565104|BEHAVIORAL|Multidimensional Sleep Health Sessions|The two sleep health educational sessions will include didactic content on defining sleep health, reviewing sleep recommendations, outlining the role of sleep in preserving cardiometabolic health, and correcting unhelpful sleep-related beliefs and debunking myths. Participants will learn to maximize the benefits of self-monitoring using a Fitbit and will receive a sleep mask, ear plugs, a blue light blocker, and an indoor air purifier to improve their sleep environment.
219100602|NCT06565104|BEHAVIORAL|Healthy Diet Sessions|The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods such as fruits, vegetables, and whole grains, promote choosing more lean proteins such as fish, and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages.
219100603|NCT06565104|BEHAVIORAL|Physical Activity Sessions|The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise and a healthy living community resource mapping exercise. These sessions also address achieving and maintaining a healthy body weight.
219100604|NCT05128149|OTHER|no intervention|no intervention
219100605|NCT05055856|DIAGNOSTIC_TEST|urine sample|Each participant will give a urine sample for diagnose of asymptomatic bacteriuria
219100606|NCT05055856|DIAGNOSTIC_TEST|Blood and urine sample|Each participant will give a urine and blood sample for diagnose of SIADH
219100607|NCT01060202|DRUG|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
219100608|NCT05806749|COMBINATION_PRODUCT|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
219100609|NCT06979414|BEHAVIORAL|Nurse-led Transfer Programme with Family Involvement|This behavioral intervention was structured in three phases: (1) Pre-transfer preparation, where the patient's primary caregiver visited the ICU for emotional support following verbal instruction and infection control measures; (2) Accompanied transfer to the general ward, led by an ICU nurse, with the caregiver present to provide emotional reassurance; (3) Post-transfer monitoring, where the patient's vital signs and anxiety levels were reassessed within 30-60 minutes of arrival. The goal of the intervention was to reduce ICU transfer-related anxiety through nurse-led, family-involved emotional support.
219100610|NCT00649558|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
219687239|NCT03603522|OTHER|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
219100611|NCT00649558|DRUG|Actos® Tablets 45 mg|45mg, single dose fasting
219687240|NCT04838002|DEVICE|Extracorporeal shock wave|Focus and Radial types Extracorporeal shock wave therapy
219687241|NCT03502499|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
219687242|NCT03502499|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
219687243|NCT03200353|DEVICE|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
219687244|NCT01148264|DRUG|olanzapine|1x10mg per day for three days
219687245|NCT01148264|DRUG|metoclopramide|3x10mg per day for three days
219687246|NCT03560453|BEHAVIORAL|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
219687247|NCT03153046|DIETARY_SUPPLEMENT|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
219687248|NCT03153046|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
219687249|NCT00614172|RADIATION|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
219687250|NCT04038112|OTHER|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
219687251|NCT01941784|OTHER|educational intervention|Undergo health education program
219687252|NCT01941784|OTHER|counseling intervention|Undergo health education program
219687253|NCT01941784|BEHAVIORAL|telephone-based intervention|Receive follow-up phone calls
219687254|NCT01941784|OTHER|questionnaire administration|Ancillary studies
219100612|NCT05323461|BIOLOGICAL|SCTV01C|intramuscular injection
219100613|NCT05323461|BIOLOGICAL|SCTV01E|intramuscular injection
219100614|NCT05323461|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
219100615|NCT05323461|BIOLOGICAL|Comirnaty|intramuscular injection
219100616|NCT05448300|DEVICE|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
219100617|NCT01888211|DIETARY_SUPPLEMENT|Omega 3 fatty acid supplementation|2 grams Omacor daily
219100618|NCT01888211|DIETARY_SUPPLEMENT|Olive Oil|2 grams olive oil daily
219100619|NCT04180644|OTHER|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
219100620|NCT05129267|OTHER|Group B|Scaling and Root debridement + iPRF
219100621|NCT05129267|OTHER|Group C|Scaling and Root debridement + iPRF together with vitamin C
219223736|NCT07042282|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
219687255|NCT01941784|PROCEDURE|quality-of-life assessment|Ancillary studies
219687256|NCT01648062|BEHAVIORAL|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
219687257|NCT04374370|BIOLOGICAL|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
219687258|NCT04824898|DRUG|Simvastatin|Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
219687259|NCT04824898|OTHER|injectable plasma rich fibrin|I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
219687260|NCT01051479|DRUG|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
219687261|NCT06137248|DIETARY_SUPPLEMENT|Energy drink|Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
219687262|NCT00120705|DRUG|darbepoetin alfa|
219687263|NCT04968093|BEHAVIORAL|Mindfulness-based therapy.|"Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts."
219687264|NCT06240481|DRUG|Test Regimen|toothpaste \& mouthwash
219687265|NCT06240481|DRUG|Control Regimen|toothpaste
219687266|NCT04871152|DRUG|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
219687267|NCT01383434|PROCEDURE|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
219687268|NCT05221970|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219687269|NCT05221970|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219100622|NCT05944055|BIOLOGICAL|Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?|Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
219100623|NCT03790670|DRUG|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
219100624|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: low-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
219100625|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: medium-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
219100626|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: control|Supplement containing placebo
219687270|NCT05221970|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
219687271|NCT05380154|DRUG|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
219687272|NCT05380154|DRUG|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
219687273|NCT03505372|DEVICE|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
219687274|NCT03065647|DEVICE|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
219687275|NCT05601817|BEHAVIORAL|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
219687276|NCT05601817|BEHAVIORAL|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
219687277|NCT05601817|BEHAVIORAL|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
219687278|NCT06171750|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
219100627|NCT04131569|DIAGNOSTIC_TEST|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
219100628|NCT03664505|DEVICE|Compression garment (manual)|Garment based on manual measurement
219100629|NCT03664505|DEVICE|Compression garment (scan)|Garment based on scan measurement
219100630|NCT06711744|DIAGNOSTIC_TEST|Implant stability quotient|Screw a smart peg into the implant and record the values from a dedicated device
219100631|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
219161719|NCT04587505|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
219687279|NCT06171750|DRUG|Cemiplimab|Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.
219687280|NCT06009159|DEVICE|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
219687281|NCT05694806|OTHER|analysis of thoracic scans|analysis of thoracic scans realised in standard care
219687282|NCT05995002|OTHER|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
219687283|NCT01821274|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
219687284|NCT01821274|DRUG|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
219687285|NCT01821274|DRUG|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
219100632|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
219100633|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
219100634|NCT06624748|BEHAVIORAL|emotional and physical support to the pregnant woman provided by attendant|The companion will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, taking a warm shower, etc.), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
219100635|NCT05871710|OTHER|Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale|The Tele-Pulmonary Rehabilitation Acceptance Scale is a measuring tool that assesses the level of acceptance towards telerehabilitation programs among healthcare providers and patients in the field of pulmonary rehabilitation. It is used to evaluate the attitudes, beliefs, and perceptions of potential users towards telerehabilitation, which is a form of healthcare delivery that utilizes telecommunication technology to provide remote rehabilitation services to patients. The scale is intended to provide a standardized data collection tool that can be used to measure the level of acceptance of telerehabilitation programs among different groups of potential users. This scale will be translated into Turkish by a researcher who has an advanced level of knowledge in English and whose native language is Turkish.
219100636|NCT05871710|OTHER|Scale Evaluation Form|The healthcare providers and the patients will be asked about their opinions on the scale's construction, usefulness, and scope using a 100 mm visual analog scale.
219100637|NCT06626152|DRUG|Apo-levocarb|As above.
219100638|NCT00091247|DRUG|tetracycline hydrochloride|
219100639|NCT00091247|OTHER|placebo|
219161720|NCT00537212|OTHER|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
219161721|NCT00537212|OTHER|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
219161722|NCT00537212|OTHER|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
219550657|NCT02235870|BEHAVIORAL|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
219100640|NCT04959890|GENETIC|Strimvelis|This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
219687286|NCT01821274|DRUG|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
219687287|NCT02373423|OTHER|Advocacy|See above for description
219687288|NCT02799017|OTHER|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
219687289|NCT02799017|OTHER|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
219100641|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
219100642|NCT06634069|DRUG|Sodium Lactate|0.5M HSL (containing 504mM of sodium and lactate)
219223737|NCT07042282|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
219550658|NCT03058107|DIETARY_SUPPLEMENT|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
219687290|NCT01553448|GENETIC|gene expression analysis|
219687291|NCT01553448|GENETIC|protein expression analysis|
219687292|NCT01553448|OTHER|enzyme-linked immunosorbent assay|
219687293|NCT01553448|OTHER|immunohistochemistry staining method|
219687294|NCT01553448|OTHER|laboratory biomarker analysis|
219687295|NCT01553448|OTHER|medical chart review|
219687296|NCT04872387|DRUG|BAY2586116|Nasal administration
219687297|NCT04872387|DRUG|Placebo|Matching placebo
219100643|NCT06634069|DRUG|3% NaCl|active compartor 3% NaCl
219100644|NCT05047874|BEHAVIORAL|systemic methylprednisolone|short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
219100645|NCT01949233|DRUG|Irbesartan 150-300mg capsules daily for 6 months|
219100646|NCT01949233|DRUG|Doxycycline 100-200mg capsules daily for 6 months|
219100647|NCT01949233|DRUG|Doxycycline placebo capsules daily for 6 months|
219100648|NCT01949233|DRUG|Irbesartan placebo capsules daily for 6 months|
219100649|NCT00459238|OTHER|counseling intervention|subjects will receive telephone based counseling
219100650|NCT00459238|OTHER|educational intervention|subjects will received telephone based education
219223738|NCT07042282|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
219687298|NCT05452915|DIAGNOSTIC_TEST|Neuropsychological (NPA)|"The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session"
219687299|NCT05452915|OTHER|Imaging|"Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR)."
219687300|NCT05452915|DIAGNOSTIC_TEST|Inflammatory biomarkers|Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
219687301|NCT01916460|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
219687302|NCT03300440|DIETARY_SUPPLEMENT|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
219687303|NCT03300440|DIETARY_SUPPLEMENT|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
219687304|NCT01963884|PROCEDURE|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
219687305|NCT01963884|RADIATION|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
219687306|NCT01963884|OTHER|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
219687307|NCT01871077|DRUG|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
219687308|NCT04090346|DRUG|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
219687309|NCT03183115|PROCEDURE|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
219687310|NCT03183115|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
219687311|NCT03183115|DRUG|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
219687312|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
219687313|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
219687314|NCT01119521|BIOLOGICAL|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
219687315|NCT01119521|DRUG|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
219223739|NCT07043894|DRUG|Romiplostim N01|Participants receive weekly subcutaneous injections of romiplostim N01 (250 μg/vial; Qilu Pharmaceutical) starting at 2 μg/kg. Doses are adjusted weekly based on platelet counts: increased by 2 μg/kg if platelets are \<50 × 10⁹/L, by 1 μg/kg if 50-99 × 10⁹/L, up to a maximum of 10 μg/kg. Treatment continues for up to 2 weeks but stops early if platelets reach ≥100 × 10⁹/L or increase by ≥30 × 10⁹/L from baseline.
219687316|NCT03822260|DIAGNOSTIC_TEST|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
219687317|NCT02105194|DRUG|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
219687318|NCT01326247|OTHER|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
219687319|NCT02141191|DRUG|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
219687320|NCT04878120|DEVICE|Standard HCL System|Standard HCL system (USS Virginia)
219687321|NCT04878120|DEVICE|HCL System with Smart Bolus Calculator|HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
219687322|NCT03513679|PROCEDURE|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
219687323|NCT02882126|DRUG|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
219687324|NCT06360965|DRUG|Improved warm meridians and relieve pain plaster|Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
219687325|NCT06360965|DRUG|Traditional warm meridians and relieve pain plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
219687326|NCT06360965|DRUG|Placebo plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
219687327|NCT05959967|BEHAVIORAL|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
219687328|NCT05959967|BEHAVIORAL|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
219687329|NCT02298426|BEHAVIORAL|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
219687330|NCT02298426|BEHAVIORAL|General Management|We provide general information about health. Information is provided through telephones and materials.
219687331|NCT02298426|OTHER|Placebo|We use placebo to replace the health product.
219100651|NCT06899893|DEVICE|iTBS|Sixty patients experiencing post-stroke negative emotions were recruited and categorized into groups based on their conditions. The group with post-stroke balance dysfunction underwent intermittent theta burst stimulation (iTBS) of the cerebellum, while the group with post-stroke cognitive dysfunction received iTBS stimulation of the left dorsolateral prefrontal cortex (DLPFC), and the group with post-stroke motor dysfunction underwent iTBS stimulation of the primary motor cortex (M1).The TMS stimulation protocol consisted of 20-minute sessions, five times a week, for a total of ten sessions, utilizing a figure-of-eight coil (model B9076, coil diameter 92 mm, manufactured by Yiruide Company in Wuhan, China, transcranial magnetic therapy device model NS5000). The stimulation intensity was set at 80% of the active motor threshold, with the coil positioned tangentially to the scalp and the handle oriented upwards.
219100652|NCT06899477|DRUG|mFOLFOXIRI|Up to 6 cycles, every 2 weeks, mFOLFOXIRI: Oxaliplatin 85 mg/m2 2 h day 1, Irinotecan 150 mg/m2 60-90 min day 1, Folinic acid 400 mg/m2 \~1 h day 1, followed by 5-FU 2400 mg/m2 46 h
219100653|NCT06899477|DRUG|mFOLFOX-6|Up to 6 cycles, every 2 weeks, mFOLFOX-6: Oxaliplatin 85 mg/m2 2 h day 1, Folinic acid 400 mg/m2 \~1 h day 1, (optional: 5-FU 400 mg/m2 bolus), followed by 5-FU 2400 mg/m2 46 h.
219687332|NCT02298426|DIETARY_SUPPLEMENT|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
219687333|NCT04633681|DIETARY_SUPPLEMENT|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
219100654|NCT06899477|DRUG|CAPOX|Up to 4 cycles, every 3 weeks, CAPOX: Oxaliplatin 130 mg/m2 3 h day 1, Capecitabine 1000 mg/m2 ORALLY taken twice daily d1-d14
219550659|NCT03058107|DIETARY_SUPPLEMENT|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
219550660|NCT03234309|DRUG|Ferumoxytol|Given IV
219550661|NCT03234309|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219550662|NCT02638428|PROCEDURE|CancerSCAN™|Targeted deep sequencing
219550663|NCT02638428|DRUG|Ifosfamide|
219550664|NCT02638428|DRUG|Carboplatin|
219550665|NCT02638428|DRUG|Etoposide|
219550666|NCT02638428|DRUG|Fludarabine|
219550667|NCT02638428|DRUG|Cytarabine|
219550668|NCT02638428|DRUG|Pazopanib|
219550669|NCT02638428|DRUG|Sorafenib|
219550670|NCT02638428|DRUG|Axitinib|
219550671|NCT02638428|DRUG|Crizotinib|
219550672|NCT02638428|DRUG|Dasatinib|
219550673|NCT02638428|DRUG|Erlotinib|
219550674|NCT02638428|DRUG|Everolimus|
219550675|NCT02638428|DRUG|Imatinib|
219550676|NCT02638428|DRUG|Ruxolitinib|
219550677|NCT02638428|DRUG|Vandetanib|
219550678|NCT02638428|DRUG|Vemurafenib|
219550679|NCT02638428|DRUG|Trastuzumab|
219550680|NCT02763345|OTHER|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
219550681|NCT02763345|OTHER|Standard care|
219550682|NCT00842127|DRUG|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
219550683|NCT06348576|DRUG|AD-209|PO, Once daily(QD), 8weeks
219550684|NCT06348576|DRUG|AD-2091|PO, Once daily(QD), 8weeks
219550685|NCT06348576|DRUG|AD-209 Placebo|PO, Once daily(QD), 8weeks
219550686|NCT06348576|DRUG|AD-2091 Placebo|PO, Once daily(QD), 8weeks
219550687|NCT04668820|DIAGNOSTIC_TEST|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
219100655|NCT06898983|DRUG|Romiplostim N01|Romiplostim N01 will be administered via subcutaneous injection once weekly when patients develop Grade 3 thrombocytopenia (platelet count \< 50×10⁹/L) following leukemia treatment. The recommended initial dose is 5 µg/kg, with a maximum single dose not exceeding 250 µg. Treatment may continue for up to 8 doses.
219100656|NCT06462716|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
219100657|NCT06846554|DRUG|APL-9796|3 Cohorts are planned in Part A.
219100658|NCT06846554|DRUG|APL-9796|The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
219100659|NCT05145413|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
219100660|NCT05145413|DRUG|Placebo|Placebo Capsules
219100661|NCT05159401|PROCEDURE|prevention of respiratory failure|Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
219687334|NCT01211756|DRUG|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
219100662|NCT06924983|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
219100663|NCT06924983|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate. Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days.
219235349|NCT05991518|COMBINATION_PRODUCT|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
219100664|NCT06921304|BEHAVIORAL|Intensive Lifestyle Intervention|ILI combines a low-calorie dietary approach with improved lifestyle and physical activity, in addition to usual medical care. Behavioral support for lifestyle intervention will also be provided.
219100665|NCT00421213|DRUG|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
219100666|NCT06925191|DIAGNOSTIC_TEST|Group A (Experimental): 29 affected ankles of both genders diagnosed with Chronic ankle instability (CAI) who met the inclusion criteria. Group B (Control): 29 matched non-affected with CAI|"1-90-90Active knee extension test 2.Core muscles endurance tests(a. The static endurance tests b. The dynamic endurance tests)~Time Frame: 1 session"
219687335|NCT01211756|DRUG|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
219687336|NCT01691378|OTHER|Window to Hope|Psychotherapy - Group
219687337|NCT01691378|OTHER|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
219687338|NCT01634503|GENETIC|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
219100667|NCT06925009|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
219100668|NCT06926556|DEVICE|Defocus microlenses|Different microlenses array (H.M.E.C，High Precision Micro Encircle and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
219100669|NCT05208554|BEHAVIORAL|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
219100670|NCT00193713|DRUG|bifeprunox|
219100671|NCT02640378|OTHER|NO intervention|This study was a cross-sectional study. It had no intervention.
219100672|NCT00818103|DRUG|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
219100673|NCT00818103|DRUG|β-interferon|β-interferon 50ug i.m. qod for 2 years
219100674|NCT00818103|DRUG|EPO|EPO 10000U i.h. bid for 5 days
219100675|NCT03279055|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
219100676|NCT02392611|DRUG|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
219100677|NCT02392611|DRUG|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
219100678|NCT02392611|DRUG|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
219100679|NCT01468779|DIETARY_SUPPLEMENT|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
219100680|NCT01468779|DIETARY_SUPPLEMENT|Sugar pill|
219100681|NCT03325205|OTHER|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
219100682|NCT03325205|OTHER|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
219100683|NCT05434143|BEHAVIORAL|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises."
219100684|NCT06331429|BEHAVIORAL|EmoTiCare|"The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication"
219100685|NCT04243460|PROCEDURE|Xenogeneic collagen matrix (XCM) graft augmentation|"12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:"
219235350|NCT05991518|COMBINATION_PRODUCT|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
219687339|NCT04338477|DRUG|Nephrosolid tablets|Adminstration of drug
219687340|NCT01827592|DRUG|Elobixibat 10 mg|Elobixibat 10 mg/day
219687341|NCT01827592|DRUG|Elobixibat 5 mg|Elobixibat 5 mg/day
219687342|NCT01827592|DRUG|Placebo|Placebo
219687343|NCT00331565|PROCEDURE|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
219687344|NCT05651386|OTHER|Diet|No blinded, no controlled intervention.
219687345|NCT02057263|DRUG|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
219687346|NCT02057263|DRUG|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
219687347|NCT02057263|DRUG|Placebo|Participants will receive 4 doses of placebo during the course of the study.
219687348|NCT01676246|DRUG|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
219687349|NCT01676246|DRUG|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
219687350|NCT01676246|DRUG|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
219687351|NCT01676246|PROCEDURE|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
219100686|NCT04243460|PROCEDURE|Connective tissue graft augmentation (CTG)|12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
219100687|NCT01129531|DRUG|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
219687352|NCT01676246|PROCEDURE|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
219687353|NCT03472911|OTHER|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
219687354|NCT02340377|DEVICE|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
219100688|NCT01129531|DRUG|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
219100689|NCT02030912|DRUG|3 doses of amoxicillin daily for 7 days|
219100690|NCT02030912|DRUG|2 doses of minocycline daily for five days|
219100691|NCT02030912|OTHER|2 doses of placebo daily for five days|
219100692|NCT00172120|DRUG|ALX1-11|
219100693|NCT00965003|PROCEDURE|MRI scan|Standard of Care
219100694|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
219100695|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
219100696|NCT02185885|PROCEDURE|Increased bloodpressure during CPB.|
219100697|NCT04409548|OTHER|All of the spatial and Temporal Gait parameters|
219100698|NCT02760758|DRUG|CDI-31244|NNI
219100699|NCT02760758|DRUG|Placebo|no active ingredients
219100700|NCT05813626|DRUG|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
219687355|NCT01836068|DRUG|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
219687356|NCT01542138|DRUG|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
219100701|NCT05995080|OTHER|clorhexidine gluconate bathing|daily skin cleansing with chlorhexidine gluconate
219100702|NCT03690934|PROCEDURE|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
219687357|NCT01542138|DRUG|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
219687358|NCT01542138|DRUG|Placebo|Humectant placebo cream
219687359|NCT00387322|DRUG|erlotinib hydrochloride|Given orally
219687360|NCT00387322|DRUG|pemetrexed disodium|Given IV
219687361|NCT04030741|DRUG|Meronem and flagyl|meronem and flagy
219687362|NCT04030741|PROCEDURE|Appendectomy|Appendectomy as treatment for acute appendicitis
219687363|NCT01189877|PROCEDURE|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
219100703|NCT03690934|PROCEDURE|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
219100704|NCT04636801|DRUG|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
219100705|NCT04636801|DRUG|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
219100706|NCT04636801|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid.
219100707|NCT02691689|OTHER|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
219687364|NCT01602796|BEHAVIORAL|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
219687365|NCT00751140|PROCEDURE|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
219687366|NCT05005936|PROCEDURE|Ultrasonography|Undergo ABUS
219687367|NCT05005936|PROCEDURE|Ultrasonography|Undergo WBUS
219687368|NCT02413632|OTHER|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
219687369|NCT02413632|OTHER|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
219687370|NCT02665247|BEHAVIORAL|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
219687371|NCT02665247|OTHER|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
219687372|NCT02001701|PROCEDURE|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
219687373|NCT00374023|DRUG|Zinc, or Vitamin A or both|
219687374|NCT03880552|OTHER|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
219687375|NCT05278741|PROCEDURE|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months, six months and 12 months: 2 questionnaires + two tests will be perfomed"
219100708|NCT04404621|BEHAVIORAL|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
219100709|NCT04923477|OTHER|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
219100710|NCT00433615|DRUG|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
219100711|NCT00433615|DRUG|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
219100712|NCT02354716|DEVICE|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
219100713|NCT00056940|BEHAVIORAL|Stages of Change|
219100714|NCT00056940|BEHAVIORAL|Safety Check approach|
219100715|NCT00482638|DRUG|MK0493|
219100716|NCT04930107|DRUG|Fluconazole 150 mg|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
219100717|NCT04930107|DRUG|Boric Acid Supp,Vag|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
219687376|NCT01893697|OTHER|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
219687377|NCT02564276|PROCEDURE|Sentinel lymph node biopsy|
219687378|NCT03629769|DRUG|Proxelan|Administration of one suppository of proxelan once a day for 30 days
219100718|NCT01213043|BIOLOGICAL|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
219100719|NCT01213043|BIOLOGICAL|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
219100720|NCT05484583|DRUG|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
219100721|NCT05484583|RADIATION|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
219100722|NCT05484583|DRUG|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
219100723|NCT00791115|PROCEDURE|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
219161428|NCT05678400|BEHAVIORAL|Hypopressive abdominal techniques|Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.
219687379|NCT04001803|DRUG|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
219161429|NCT05678400|BEHAVIORAL|Stretching of proprioceptive neuromuscular facilitation|Stretching of proprioceptive neuromuscular facilitation
219687380|NCT00908271|DRUG|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
219687381|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under Lidocaine alone|In this conventional procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.
219687382|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under a combination of Lidocaine and Ropivacaine|In this experimental procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 18 mL + ropivacaine 7.5 mg/mL 2 mL or 15 mg. For a total of 20 mL: lidocaine 9mg/mL, ropivacaine 0.75 mg/mL, adrenaline 0.005 mg/mL
219687383|NCT01750645|DRUG|Intradetrusor Injection of Type-A Botulinum Toxin|
219687384|NCT01750645|OTHER|Other interventions analyzed according to protocol|"* Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs"
219687385|NCT05799430|BEHAVIORAL|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~5. FP and PCN communicate to PCP final agreement with patient and/or carer~6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
219687386|NCT05799430|BEHAVIORAL|Control group|Usual care by FP an PCN
219687387|NCT02447770|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
219687388|NCT04743089|DEVICE|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
219687389|NCT04743089|OTHER|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
219687390|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
219687391|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
219687392|NCT02493517|DRUG|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
219687393|NCT02493517|DRUG|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
219687394|NCT00914225|OTHER|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
219100724|NCT06696040|DEVICE|Passive mobilization using a device|"The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again."
219100725|NCT02998814|OTHER|acid-etch|acid-etch
219100726|NCT02998814|OTHER|self-etch adhesive|Self etch (7th generation ) bonding agent
219100727|NCT02998814|OTHER|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
219100728|NCT02998814|OTHER|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
219100729|NCT05621083|DIETARY_SUPPLEMENT|Omega- 3|In the fish oil supplement period, the participants will receive concentrated fish oil which is equal to in total 2.3 g EPA+DHA per day during 6 weeks.
219100730|NCT05621083|DIETARY_SUPPLEMENT|HOSO|In the HOSO period, the participants will receive similar amount of HOSO per day during 6 weeks.
219687395|NCT03189355|PROCEDURE|Blood sampling|"* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin"
219687396|NCT03189355|PROCEDURE|Bioelectrical impedance vector analysis|"* D1~* D4"
219687397|NCT03189355|PROCEDURE|Muscular echography|"* D1~* D4"
219687398|NCT02249104|DRUG|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
219687399|NCT02249104|OTHER|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
219100731|NCT04143334|DIAGNOSTIC_TEST|Conventional survey|
219100732|NCT03609125|OTHER|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
219100733|NCT04953338|OTHER|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
219100734|NCT05043701|DRUG|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
219100735|NCT01380886|OTHER|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
219100736|NCT01380886|OTHER|Infant formula powder|powdered infant formula to be fed ad libitum
219100737|NCT02221856|PROCEDURE|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
219687400|NCT00507260|BEHAVIORAL|Food Record|A record of the amount and kind of food and drink you intake will be completed.
219687401|NCT00507260|OTHER|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
219687402|NCT03718429|DRUG|Rivaroxaban 2.5 mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
219687403|NCT05254340|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
219687404|NCT04305028|DRUG|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
219687405|NCT04305028|DRUG|Aspirin|Aspirin 75-100 mg once daily, tablet
219687406|NCT00887705|BEHAVIORAL|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
219687407|NCT00325819|DRUG|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
219687408|NCT00325819|OTHER|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
219687409|NCT03625739|DRUG|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
219687410|NCT02983890|DRUG|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
219687411|NCT02983890|DRUG|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
219687412|NCT02047279|PROCEDURE|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
219100738|NCT02221856|PROCEDURE|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
219100739|NCT05138159|DRUG|Donafenib|Donafenib: 200mg po bid.
219687413|NCT02047279|PROCEDURE|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
219687414|NCT02047279|PROCEDURE|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
219687415|NCT05545137|DRUG|Pivmecillinam hydrochloride tablets|400mg tablet
219687416|NCT05545137|DRUG|Fosfomycin Tromethamine Granules|3g/pack
219687417|NCT00498953|DRUG|carboplatin|
219687418|NCT00498953|DRUG|cisplatin|
219687419|NCT00498953|DRUG|docetaxel|
219687420|NCT00498953|DRUG|fluorouracil|
219687421|NCT00498953|DRUG|lapatinib ditosylate|
219687422|NCT00498953|GENETIC|cytogenetic analysis|
219687423|NCT00498953|GENETIC|fluorescence in situ hybridization|
219687424|NCT00498953|GENETIC|in situ hybridization|
219687425|NCT00498953|GENETIC|polymerase chain reaction|
219687426|NCT00498953|GENETIC|reverse transcriptase-polymerase chain reaction|
219687427|NCT00498953|OTHER|immunohistochemistry staining method|
219687428|NCT00498953|OTHER|laboratory biomarker analysis|
219687429|NCT00498953|PROCEDURE|conventional surgery|
219687430|NCT00498953|PROCEDURE|neoadjuvant therapy|
219687431|NCT00498953|RADIATION|fludeoxyglucose F 18|
219687432|NCT00498953|RADIATION|radiation therapy|
219687433|NCT04811807|DEVICE|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
219687434|NCT02346877|BEHAVIORAL|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
219687435|NCT03054181|BIOLOGICAL|HyQvia|
219687436|NCT03185286|DEVICE|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
219687437|NCT06236321|OTHER|Fast Field Cycling MRI scan|Three scans to be done over the period of cancer treatment
219687438|NCT06236321|OTHER|Provision of saliva and faecal samples|Three times over the period of cancer treatment
219687439|NCT02154438|DRUG|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
219687440|NCT06173479|BEHAVIORAL|HeBSaPU|HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
219687441|NCT03827694|DIAGNOSTIC_TEST|Non-Invasive Testing for PIFI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
219687442|NCT06593834|DRUG|bacillus coagulans combined with the best treatment options for preventing aGVHD|BAT means the best treatment options for preventing aGVHD
219687443|NCT06593834|DRUG|BAT|BAT
219687444|NCT06597292|DEVICE|Vision improvement|Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
219687445|NCT05773625|DEVICE|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
219687446|NCT04839718|BEHAVIORAL|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
219687447|NCT00508911|DRUG|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
219687448|NCT00508911|DRUG|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
219687449|NCT06612567|DIAGNOSTIC_TEST|PET/CT|is an imaging test that can help reveal the metabolic or biochemical function of your tissues and organs. The PET scan uses a radioactive drug called a tracer to show both typical and atypical metabolic activity. A PET scan can often detect the atypical metabolism of the tracer in diseases before the disease shows up on other imaging tests, such as computerized tomography (CT) and magnetic resonance imaging (MRI).
219687450|NCT05130034|BEHAVIORAL|Home-based pulmonary rehabilitation|Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
219687451|NCT06865872|OTHER|Direct Sexual Communication|Participants assigned to receive direct communication about their sexual preferences from their partner.
219687452|NCT06865872|OTHER|Indirect Sexual Communication|Participants assigned to receive indirect communication about their sexual preferences from their partner.
219687453|NCT06865872|DRUG|Alcohol (Ethanol)|Participants assigned to moderate alcohol dose condition (target BrAC .10%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.
219687454|NCT06865872|OTHER|No-Alcohol Control|Participants assigned to a no-alcohol control beverage.
219687455|NCT05442697|DEVICE|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
219687456|NCT05442697|DEVICE|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
219687457|NCT06589648|OTHER|mandala painting|Mandala coloring creates a relaxing effect on individuals because it starts with a pattern that develops like a flower around a point; it allows the individual to stay in the moment, to get away from stress, anxiety and worries, and it relaxes the mind.
219687458|NCT03811821|BEHAVIORAL|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
219687459|NCT03811821|DEVICE|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
219687460|NCT06453733|DEVICE|Crainio|Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
219687461|NCT02794298|DEVICE|Transcranial direct current stimulation (tDCS)|
219687462|NCT02794298|DEVICE|sham-tDCS|
219687463|NCT00087100|DRUG|pemetrexed disodium|
219687464|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
219687465|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
219687466|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
219687467|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
219687468|NCT07035340|OTHER|inspiratory muscle training|inspiratory muscle traning MIP%40-60
219687469|NCT07035340|OTHER|standart care|standart care
219100740|NCT05138159|DRUG|S1|S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
219100741|NCT02949921|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
219687470|NCT05275933|OTHER|TCM intervention|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
219687471|NCT05275933|OTHER|Placebo intervention|Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
219687472|NCT06524154|BEHAVIORAL|positive reinforcement|normal treatment with with praising the child with encouraging words and pleasing smiles.
219687473|NCT06524154|BEHAVIORAL|rewarding|normal treatment with giving simple gifts like stickers at the end of the procedure.
219687474|NCT06524154|BEHAVIORAL|contingent escape|normal treatment with giving some rest of the procedure while the child on the chair.
219687475|NCT04888494|DEVICE|Transcranial Magnetic Stimulation|For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (\~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups
219687476|NCT04888494|DEVICE|Sham rTMS|Sham rTMS
219687477|NCT03945071|DEVICE|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
219687478|NCT06404255|BEHAVIORAL|Stress management training|Stress management training
219100742|NCT01007890|OTHER|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
219687479|NCT00304460|BIOLOGICAL|aldesleukin|
219687480|NCT02506062|DEVICE|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
219687481|NCT02155452|PROCEDURE|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
219687482|NCT04940156|DEVICE|Confirm Rx (Implantable Cardiac Monitor)|Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
219687483|NCT04940156|DEVICE|Reveal LINQ (Implantable Cardiac Monitor)|Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
219687484|NCT03574038|DEVICE|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
219100743|NCT03075241|DRUG|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
219100744|NCT03075241|DRUG|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
219100745|NCT03075241|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
219687485|NCT03574038|OTHER|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
219687486|NCT01438138|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219687487|NCT00933504|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks.
219687488|NCT07068230|DRUG|Ondansetron 8mg|Ondansetron 8 mg IV Administered 5 minutes before spinal anesthesia
219687489|NCT07068230|DRUG|Dexamethasone|Dexamethasone 8 mg IV Administered 5 minutes before spinal anesthesia
219687490|NCT07068230|DRUG|Saline|5ml normal saline Administered 5 minutes before spinal anesthesia
219687491|NCT07073508|OTHER|Renal Artery Duplex|Renal artery duplex will be performed to all patients in terms of renal resistivity index (RRI).
219687492|NCT07072559|OTHER|dental simulation game|At the first visit children will play on any procedure in dental simulation game, after that the child will be shown two animals, after which they virtually do a root canal procedure. Tasks include performing a dental X-ray, anesthetizing the tooth using a syringe, drilling decayed cavity and start pulp treatment, rinsing, pulp treatment and filling the tooth, applying light cure and finally polishing the teeth. The second visit for pulpotomy procedure will be scheduled two days after first visit. Children will be managed using the TSD (Tell-Show-Do) technique.
219687493|NCT07072559|OTHER|tell show do|"For the control group (group 1) TSD (Tell-Show-Do) technique group, children will be managed with a verbal explanation and a friendly, non-threatening demonstration of the upcoming dental treatment. The do phase involved carrying out the dental procedure as per the prior explanation and demonstration"
219687494|NCT07072078|BEHAVIORAL|Video-based Communication|Participants received structured video-based communication sessions with their family members using the WhatsApp platform. The intervention was delivered once daily for three consecutive days, with each session lasting between 5 and 20 minutes. Communication was guided to include emotional support, positive conversations, and future-oriented discussion. The sessions were facilitated by nurses who ensured clinical stability, technical setup, and emotional readiness of the patient. This intervention aimed to reduce emotional and social loneliness among ICU patients and was integrated into standard intensive care routines without disrupting medical care.
219687495|NCT04019886|OTHER|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
219687496|NCT04551235|OTHER|there are not any interventions in this study|there are not any interventions in this study
219687497|NCT02278705|OTHER|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
219687498|NCT02278705|OTHER|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
219100746|NCT06267443|PROCEDURE|Comparison of erector spina plane block, parasternal block plus local infiltration to the tube sides for postoperative analgesia|"Group 1: erector spina plane block: With USG guidance at the thoracal level of 4-5, with 20ml 2.5% bupivacaine ESPB will be performed. after surgery in the ICU pain score and atelectasia will be evaluated.~Group 2: With USG guidance parasternal block will be performed after intubation bilaterally with 10 ml 0.25% bupivacaine each side. at the end of the surgery infiltration of chest tube sides will be performed with 10 ml 2.5% bupivacain."
219100747|NCT00720408|DRUG|Prograf-XL|oral
219100748|NCT00720408|DRUG|Prograf|oral
219100749|NCT00720408|DRUG|MMF|oral
219687499|NCT02278705|OTHER|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
219687500|NCT00447902|DRUG|tipranavir|
219687501|NCT00447902|DRUG|ritonavir|
219687502|NCT06948032|DRUG|BLU-808|BLU-808 will be administered per schedule specified in the arm description.
219687503|NCT06948032|DRUG|Placebo|BLU-808 matching placebo will be administered per schedule specified in the arm description.
219100750|NCT01175148|DRUG|Atorvastatin calcium (Lipitor)|40 mg PO daily
219687504|NCT06948032|DRUG|Midazolam|Midazolam will be administered per schedule specified in the arm description.
219687505|NCT06955533|DRUG|Double dose tamsulosin and solifenacin|Odd number
219687506|NCT06955533|DRUG|Single dose tamsulosin and solifenacin|Even number
219687507|NCT01466361|DRUG|Nicotine lower dose|lower dose nicotine lozenge
219687508|NCT01466361|DRUG|Nicotine higher dose|higher dose nicotine lozenge
219687509|NCT01466361|DRUG|Placebo|placebo
219687510|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
219687511|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
219687512|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
219687513|NCT02302274|DRUG|flecainide iv|infusion over 10 min
219687514|NCT01271647|DRUG|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
219687515|NCT01271647|DRUG|placebo|granules,18g per time,two times per day,six months
219687516|NCT01805661|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
219100751|NCT01010477|DRUG|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
219100752|NCT01010477|BEHAVIORAL|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
219100753|NCT04108546|DEVICE|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
219687517|NCT01805661|PROCEDURE|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
219687518|NCT04584814|DEVICE|No intervention|Basal analysis
219687519|NCT04584814|DEVICE|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
219687520|NCT04584814|DEVICE|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
219687521|NCT06489561|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
219100754|NCT04108546|DRUG|Epidural analgesia|Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg
219100755|NCT03570983|DRUG|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
219100756|NCT03570983|DRUG|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
219100757|NCT03570983|DRUG|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
219100758|NCT03570983|DRUG|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
219687522|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
219687523|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
219687524|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
219687525|NCT00664352|DRUG|Mannose-6-Phophate (Juvidex)|"* 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
219687526|NCT00664352|DRUG|Placebo|"* 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
219687527|NCT02317991|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV
219687528|NCT02317991|BIOLOGICAL|ramucirumab|Ramucirumab 8 mg/kg IV
219687529|NCT01814410|DRUG|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
219687530|NCT01814410|DRUG|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
219687531|NCT01814410|DRUG|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
219687532|NCT03643718|PROCEDURE|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
219687533|NCT00775762|DRUG|aspirin|Aspirin (75-100 mg)die for three months
219687534|NCT00775762|DRUG|clopidogrel|Clopidogrel (75mg) die for three months
219687535|NCT00775762|DRUG|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
219687536|NCT03275207|DRUG|saline|an equal volume of saline
219687537|NCT03275207|DRUG|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
219687538|NCT03361462|BEHAVIORAL|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
219687539|NCT06109389|DRUG|Lidocaine IV|LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
219687540|NCT02630862|DRUG|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
219687541|NCT02630862|DRUG|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
219687542|NCT04211350|DEVICE|NightBalance Sleep Position Trainer (SPT)|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
219687543|NCT04211350|DEVICE|Automatic Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
219687544|NCT00001057|DRUG|Zidovudine|
219687545|NCT00001057|DRUG|Didanosine|
219687546|NCT02178904|PROCEDURE|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
219687547|NCT02981030|DRUG|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
219687548|NCT02981030|DRUG|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
219687549|NCT01437618|DRUG|FOLFOXIRI plus bevacizumab|"* BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
219687550|NCT04066933|COMBINATION_PRODUCT|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
219687551|NCT05988762|OTHER|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
219687552|NCT05988762|OTHER|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
219687553|NCT04810988|BEHAVIORAL|Unified Protocol|The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.
219687554|NCT04810988|BEHAVIORAL|Therapist Support|4 video calls with study therapists
219687555|NCT01325350|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219687556|NCT01325350|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219687557|NCT01325350|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219687558|NCT01325350|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
219687559|NCT01325350|DRUG|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
219100759|NCT03570983|DRUG|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
219100760|NCT03585296|DRUG|ATI-502|Topical Solution
219100761|NCT03841656|PROCEDURE|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
219100762|NCT05613101|PROCEDURE|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
219100763|NCT05613101|PROCEDURE|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
219100764|NCT05124106|DIAGNOSTIC_TEST|Raman Spectrometry|Bladder tumor is examined with Raman spectrometry during endoscopy
219687560|NCT00505050|OTHER|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
219687561|NCT00006877|DRUG|temozolomide|
219100765|NCT01633801|DEVICE|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
219100766|NCT01633801|DEVICE|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
219687562|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
219687563|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
219100767|NCT05046522|DRUG|Palmitoylethanolamide sold as Levagen +|Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
219687564|NCT03337815|DRUG|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
219687565|NCT03337815|DRUG|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
219687566|NCT02477592|PROCEDURE|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
219100768|NCT05046522|DRUG|Placebo comparator - maltodextrin and microcrystalline cellulose mix|Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
219687567|NCT02477592|PROCEDURE|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
219687568|NCT05517629|OTHER|It is an observational cross-sectional study|It is an observational cross-sectional study
219687569|NCT00962312|DRUG|capecitabine|
219687570|NCT00962312|DRUG|lapatinib ditosylate|
219100769|NCT04436458|DRUG|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
219100770|NCT04436458|DRUG|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
219687571|NCT00241202|BEHAVIORAL|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
219100771|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
219100772|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
219687572|NCT02614989|PROCEDURE|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
219687573|NCT03852589|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
219687574|NCT03852589|DEVICE|Blind|PLMA will inserted by anesthesiologist with digital finger.
219687575|NCT05355467|DRUG|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
219687576|NCT05355467|OTHER|Historical Data|Historical Data
219687577|NCT01980433|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
219687578|NCT01980433|OTHER|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
219687579|NCT01980433|OTHER|WCRS|Writer's cramp rating scale
219687580|NCT01980433|OTHER|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
219687581|NCT01980433|OTHER|visual analog scale of discomfort writing and parameters collected on touchpad|
219100773|NCT00462670|DRUG|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
219100774|NCT00026858|BEHAVIORAL|collaboration|
219100775|NCT04421742|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
219100776|NCT02205216|DEVICE|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
219687582|NCT02601079|DEVICE|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
219687583|NCT02601079|DEVICE|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
219687584|NCT00734292|DRUG|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
219687585|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
219687586|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
219687587|NCT03278821|BEHAVIORAL|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
219687588|NCT03278821|BEHAVIORAL|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
219687589|NCT04958070|OTHER|MPS I|MPS I, symptoms of disease onset , ERT
219687590|NCT05677711|DEVICE|ultimaster|Subjects who received Ultimaster stent will be included.
219100777|NCT02205216|DEVICE|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
219235351|NCT01075854|DRUG|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
219687591|NCT01893112|BEHAVIORAL|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).
219687592|NCT01893112|BEHAVIORAL|Breast Cancer Screening|
219687593|NCT05660278|OTHER|Milk containing A1 and A2 beta-casein|Single dose of milk
219687594|NCT05660278|OTHER|Milk containing only A2 beta-casein|Single dose of milk
219687595|NCT01716806|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
219687596|NCT01716806|DRUG|bendamustine|70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
219687597|NCT01716806|DRUG|dacarbazine|375 mg/m\^2 every 3 weeks by IV infusion
219100778|NCT02205216|BEHAVIORAL|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
219100779|NCT02245763|DEVICE|Leaflet Clip|
219100780|NCT06546098|DRUG|Molgramostim nebulizer solution|Solution for inhalation
219687598|NCT01716806|DRUG|nivolumab|3 mg/kg every 3 weeks by IV infusion
219687599|NCT03662126|DRUG|KRT-232|KRT-232, administered by mouth
219687600|NCT03662126|DRUG|Best Available Therapy (BAT)|"Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed)."
219687601|NCT00956839|DRUG|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
219687602|NCT00347750|DRUG|Lopinavir pharmacokinetic/pharmacodynamic analysis|
219687603|NCT03403907|OTHER|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
219687604|NCT02597777|OTHER|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
219687605|NCT02597777|OTHER|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
219687606|NCT00508950|PROCEDURE|Large volume blood draw|Large volume blood draw
219687607|NCT04230369|BEHAVIORAL|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
219687608|NCT04230369|OTHER|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
219100781|NCT02110732|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|
219687609|NCT00831116|DEVICE|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
219100782|NCT02144948|DRUG|e.-coli-nissle|1 ml qd for 24 weeks
219687610|NCT01150630|DRUG|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
219687611|NCT01150630|DRUG|cisplatin|30 mg/mq every 14 days for 6 months
219687612|NCT01150630|DRUG|epirubicin|30 mg/mq every 14 days for 6 months
219687613|NCT01150630|DRUG|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
219687614|NCT03506438|BEHAVIORAL|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
219100783|NCT03606122|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
219100784|NCT02160171|DEVICE|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
219100785|NCT02425748|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
219100786|NCT02425748|BIOLOGICAL|γδ T Cell|γδ T cells will be used against non small lung tumor.
219687615|NCT03506438|OTHER|Usual care|Usual ICU care as per the standards of the ICU attending
219687616|NCT03527277|OTHER|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
219687617|NCT03527277|OTHER|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
219100787|NCT02425748|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
219100788|NCT04940013|DRUG|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
219100789|NCT00039325|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
219100790|NCT03082716|DRUG|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
219235352|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
219235353|NCT01757288|DRUG|PACLITAXEL|
219235354|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
219100791|NCT03082716|DRUG|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
219687618|NCT02277483|DRUG|LAIS®|10 X 1,000 / twice a week
219687619|NCT01128296|DRUG|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
219100792|NCT00799695|BEHAVIORAL|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
219687620|NCT01128296|DRUG|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
219687621|NCT02527629|OTHER|Decellularized human heart valves|Decellularized human aortic heart valves
219687622|NCT04155463|OTHER|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
219687623|NCT04155463|OTHER|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
219687624|NCT05975814|DEVICE|dental implant|dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
219687625|NCT05868317|DRUG|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
219687626|NCT05868317|RADIATION|Radiotherapy|Short Course Radiotherapy
219687627|NCT01491022|DRUG|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
219687628|NCT01491022|DRUG|placebo first, then Ampyra|placebo
219687629|NCT05633433|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
219687630|NCT05633433|DRUG|Placebo|Placebo
219687631|NCT03729050|BEHAVIORAL|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
219687632|NCT03790410|OTHER|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
219687633|NCT03790410|OTHER|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
219100793|NCT04981691|BIOLOGICAL|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
219687634|NCT02597517|DEVICE|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
219687635|NCT01914393|DRUG|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
219687636|NCT00228163|DRUG|teriflunomide (HMR1726)|tablet, oral administration once daily.
219687637|NCT01317147|PROCEDURE|Roux-en-Y gastric bypass (RYGBP)|
219687638|NCT04135404|OTHER|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
219100794|NCT00840008|OTHER|Educational intervention|As per detailed protocol.
219161723|NCT01432106|DRUG|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
219161724|NCT05990738|DRUG|BI 764532|BI 764532
219687639|NCT01071174|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
219100795|NCT03798002|OTHER|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
219100796|NCT03798002|OTHER|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
219100797|NCT03497507|DEVICE|Sham bracelet|Patients will wear bracelets on both hands
219100798|NCT03497507|DEVICE|Acupressure bracelet|Patients will wear bracelets on both hands.
219687640|NCT01071174|OTHER|Placebo|Vaginal Ring containing no drug substance
219687641|NCT02553824|DRUG|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
219687642|NCT02553824|DRUG|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
219687643|NCT02513004|DRUG|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
219687644|NCT02513004|DRUG|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
219687645|NCT00383201|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
219687646|NCT00345917|DEVICE|Retinal transplantation instrument|
219687647|NCT00345917|DEVICE|Fetal tissue.|
219687648|NCT04488445|BEHAVIORAL|Strength training|3 sets of 3 to 5 repetitions with 4 minutes of rest between sets. 90% load of 1 maximum repetition of a resistance exercise
219687649|NCT04488445|BEHAVIORAL|Stretch and balance training|3 sets of 3 exercises of stretching and balance of one minute each. One minute of resting time between sets.
219687650|NCT03060304|DRUG|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
219687651|NCT03060304|DRUG|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
219687652|NCT05466721|DEVICE|Hydrustoma C3|The participant will use the device for 14 days.
219687653|NCT05466721|DEVICE|Coloplast Alterna|The participant will use the device for 14 days.
219100799|NCT03313102|BIOLOGICAL|blood samples|sample of 16 blood tubes
219100800|NCT01469455|DRUG|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
219100801|NCT00633932|DRUG|Esomeprazole|20mg once daily
219100802|NCT00633932|DRUG|Esomeprazole|40 mg once daily
219100803|NCT00633932|DRUG|Omeprazole|20mg once daily
219100804|NCT04719663|BEHAVIORAL|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
219100805|NCT04719663|BEHAVIORAL|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
219100806|NCT04719663|DRUG|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
219100807|NCT04719663|BEHAVIORAL|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
219161725|NCT05990738|DRUG|Topotecan|Topotecan
219687654|NCT05726435|DIETARY_SUPPLEMENT|Soluble dietary fiber with prebiotic properties|14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
219687655|NCT05726435|DIETARY_SUPPLEMENT|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
219687656|NCT04935203|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take \~2 min.
219687657|NCT01541709|DRUG|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
219687658|NCT02697643|BEHAVIORAL|BHCDS-based recommendations|
219687659|NCT02697643|BEHAVIORAL|Non-tailored recommendations|
219687660|NCT06958224|GENETIC|Large and early multigene sequencing|"Part 1 sequential multi-gene sequencing (Simple NGS),~* Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations)~* And if no contributive:~Part 2: randomized study between two sequential approaches~\- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel)~1. MMR status in molecular biology~2. \- Tumour Mutational Burden~   * Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary"
219687661|NCT00999505|DRUG|Amantadine|Amantadine 200mg twice a day over 12 weeks
219100808|NCT03221062|DEVICE|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
219100809|NCT02529475|DRUG|Gadoteric acid|Comparison with patients with Meniere's disease
219100810|NCT00482274|DRUG|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
219100811|NCT03794258|DRUG|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
219100812|NCT03794258|DRUG|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
219100813|NCT06463821|OTHER|observational questionnaires|Patient data were collected from questionnaires.
219100814|NCT01262443|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
219100815|NCT04836858|BIOLOGICAL|CMK389|Active
219100816|NCT04836858|BIOLOGICAL|Placebo|Placebo Comparator
219100817|NCT05781139|DIAGNOSTIC_TEST|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
219100818|NCT04184323|DRUG|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
219100819|NCT04184323|DRUG|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
219687662|NCT00999505|DRUG|Placebo|Placebo capsules twice a day over 12 weeks
219100820|NCT02695602|PROCEDURE|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
219687663|NCT01718483|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
219687664|NCT01718483|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
219687665|NCT05402956|BEHAVIORAL|Aerobic exercise|Moderate aerobic exercise training
219687666|NCT04275258|OTHER|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
219687667|NCT06958809|DIAGNOSTIC_TEST|Echography|An exhaustive echography will be performed to determine fluid responsiveness (using a passive leg raising test and cardiac output measurement by left ventricular outflow tract velocity time integral)
219100821|NCT02695602|PROCEDURE|Submucous Resection with non powered instrument|
219687668|NCT03462810|DRUG|cabotegravir, CAB|open label investigational product
219687669|NCT06958588|DEVICE|Experimental: Hyperslim|The PEMF will be carried out using the Hyperslim® device. The Hyperslim® device is produced by Medical San (Lageado, RS, Brazil).
219100822|NCT04394507|DIAGNOSTIC_TEST|Near-Infrared Fluorescence imaging|.Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.
219161726|NCT05990738|DRUG|Single agent chemotherapy|single agent chemotherapy
219687670|NCT06958588|DEVICE|Active Comparator #1|The intermittent pneumatic compression group will use the devices Covidien Kendall SCD 700® (Cardinal Health) or Doctor Life 2600® (Venosan).
219734618|NCT05507164|DRUG|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
219100823|NCT04394507|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
219100824|NCT00004011|DRUG|carboplatin|
219100825|NCT00004011|DRUG|paclitaxel|
219100826|NCT00004011|PROCEDURE|conventional surgery|
219100827|NCT00001015|DRUG|Ribavirin|
219100828|NCT00621907|DRUG|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
219100829|NCT00621907|DRUG|sodium chloride|sodium chloride : 0,9% 30 ml
219100830|NCT00642798|DRUG|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
219100831|NCT03361787|BEHAVIORAL|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
219100832|NCT04599686|DRUG|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
219100833|NCT04599686|RADIATION|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
219100834|NCT03060564|PROCEDURE|tendon graft|JRF Orthopedics Tendon Graft
219100835|NCT03060564|OTHER|No intervention|No intervention
219100836|NCT03056664|PROCEDURE|Routine drainage surgery|
219100837|NCT03056664|BIOLOGICAL|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
219100838|NCT03056664|BIOLOGICAL|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
219100839|NCT03056664|OTHER|placebo|NS injection instead of MSC
219687671|NCT06959056|DEVICE|cryo nerve block at T3-T8 intercostal nerves bilaterally|In order to obtain better analgesia at the level of the chest wall, where the chest is bilaterally opened for lung extraction and donor lung implantation, intraoperative cryo-ablation will be applied to the intercostal nerves at the bilateral intercostal spaces 3-8, 3cm lateral to the sympathetic chain, under direct visualization during surgery, as such covering 2 intercostal levels above as well as below the normal access of ICR 4 or 5. By providing analgesia to level 8, we will also cover the area of chest drains, which also tend to cause pain in the postoperative course, especially when patients start mobilizing at the ward. Each nerve bundle will be cooled to a temperature between -65 and -72 °C during 120 seconds by means of the CyroSphere v2 probe (AtriCure Inc; Mason, OH, USA) connected to the provided instrument tower (AtriCure CryoICE box) including a processor device measuring and regulating the N2O flow through the probe.
219687672|NCT04137809|DEVICE|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
219100840|NCT05735457|OTHER|A short, animated storytelling video on dietary sodium|Participants in the Intervention Arm will view a short, animated storytelling video on dietary sodium and the risks of cardiovascular disease due to increased intake of sodium.
219734619|NCT06238700|DIETARY_SUPPLEMENT|pregnenolone|Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
219100841|NCT05735457|OTHER|A short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
219100842|NCT06001983|OTHER|imaginary resisted exercises|"1. Imagination of squeezing a Sponge ball 15 reps~2. Imagination of Finger Exerciser 15 reps~3. Imagination of Theraband 15 reps~4. Imagination of pressing Rubber ball 15 reps~5. Imagination of pressing Hard object 15 reps"
219100843|NCT06001983|OTHER|physical resisted exercises|"1. Resisted exercise of Squeezing a Sponge ball 15 reps~2. Resisted exercise of Finger Exerciser 15 reps~3. Resisted exercise of pulling theraband 15 reps~4. Resisted exercise of pressing Rubber ball 15 reps~5. Resisted exercise of pressing Hard object 15 reps"
219100844|NCT02948959|DRUG|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219734620|NCT06238700|OTHER|placebo|Placebo pills are identical-appearing capsules containing cellulose
219734621|NCT03931512|DEVICE|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
219100845|NCT02948959|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219100846|NCT02948959|DRUG|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
219100847|NCT02948959|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
219100848|NCT05258123|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract with 360mg was administered
219100849|NCT05258123|DRUG|Placebo oral tablet|Placebo with nine tables was administered
219100850|NCT02199821|DIETARY_SUPPLEMENT|Formula with soybean oil, medium-chain triglycerides|
219100851|NCT02199821|DIETARY_SUPPLEMENT|Soybean oil formula commonly used in the hospital|
219100852|NCT06159374|OTHER|exercise and environmental conditions|Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
219734622|NCT03768674|OTHER|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
219734623|NCT01742052|DRUG|MT-1303-Low|
219235355|NCT03883984|DRUG|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
219734624|NCT01742052|DRUG|MT-1303-Middle|
219734625|NCT01742052|DRUG|MT-1303-High|
219734626|NCT01742052|DRUG|Placebo|
219734627|NCT05592730|GENETIC|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
219734628|NCT05592730|GENETIC|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
219734629|NCT01248468|DRUG|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
219734630|NCT01248468|DRUG|Sumatriptan|100 mg Sumatriptan
219734631|NCT01248468|DRUG|Placebo|placebo
219734632|NCT06359535|DRUG|HSK21542|This study is an economic study and does not interfere with patients' medical treatment.
219734633|NCT06359535|DRUG|Placebo|Placebo
219734634|NCT03124602|DEVICE|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
219734635|NCT02608346|PROCEDURE|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
219734636|NCT03801109|OTHER|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
219734637|NCT03801109|OTHER|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
219734638|NCT03801109|OTHER|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
219734639|NCT03801109|OTHER|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
219734640|NCT06249477|DEVICE|Wrist activity tracker and scale|Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
219734641|NCT06249477|BEHAVIORAL|Nutritional Coaching group sessions|Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
219734642|NCT00917020|DRUG|Nasal CO2|As-Needed during the 14 day Treatment Period
219734643|NCT00917020|DRUG|Inactive Placebo Gas|Placebo
219100853|NCT03062059|DRUG|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
219100854|NCT03062059|OTHER|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
219100855|NCT06091462|OTHER|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
219100856|NCT05936632|OTHER|Discrete Choice Experiment (DCE)|DCE survey experiment
219687673|NCT01851941|DRUG|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
219687674|NCT02941315|DRUG|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
219687675|NCT02941315|DRUG|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
219687676|NCT02941315|DRUG|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
219687677|NCT02941315|DRUG|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
219687678|NCT04567940|BEHAVIORAL|ENRED@TE: Behavioural multicomponent intervention|Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
219687679|NCT06954324|PROCEDURE|Erector spinae plane block|This study aims to compare the effects of erector spinae plane block (ESPB) and systemic tramadol use as postoperative analgesia methods on the systemic immune-inflammatory index (SII) in patients undergoing breast cancer surgery.
219687680|NCT06958172|OTHER|Exercise|Study Group received core stabilization, thoracic mobility and hip mobility exercises
219687681|NCT06958614|DRUG|Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor|The experimental group received prophylactic PEG-rhG-CSF 48 hours after chemotherapy
219687682|NCT05731115|BIOLOGICAL|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
219687683|NCT06958250|DEVICE|Novel Bite Block|Patients to utilize novel bite block during routine endoscopic procedures
219687684|NCT03884010|OTHER|No intervention|Cross-sectional
219687685|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
219687686|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
219687687|NCT00927199|DIETARY_SUPPLEMENT|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
219100857|NCT01835600|OTHER|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
219100858|NCT00560664|PROCEDURE|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
219100859|NCT00560664|PROCEDURE|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
219100860|NCT02596022|DRUG|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
219100861|NCT02596022|DRUG|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
219100862|NCT00103337|DRUG|cilengitide|Given IV
219100863|NCT00103337|OTHER|laboratory biomarker analysis|Correlative studies
219100864|NCT03038984|BEHAVIORAL|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
219100865|NCT03038984|BEHAVIORAL|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
219235356|NCT03883984|DRUG|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
219687688|NCT06958887|OTHER|Betwixt app intervention|Narrative gaming smartphone app
219687689|NCT05203653|BEHAVIORAL|Resistance exercise only|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
219687690|NCT05203653|BEHAVIORAL|Resistance exercise plus cool down|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
219734644|NCT02176525|DRUG|BI 207127 NA|
219734645|NCT02176525|DRUG|Placebo|
219734646|NCT00544726|BEHAVIORAL|Physical training|
219734647|NCT00544726|BEHAVIORAL|No training|
219734648|NCT00468546|DRUG|MabThera/Rituxan|1
219687691|NCT06957925|BEHAVIORAL|educational|Teachers were provided with a manual that could be implemented in a flexible way adapted to the local context of the school consisting of six sessions. The manual assisted teachers to prepare students for success in understanding what is a good mental health (session 1), how to optimize and maintain good mental health, with a particular focus on being mentally, spiritually, socially and physically active including coping with stressors via breathing exercises and progressive muscle relaxation techniques (session 2), physical activity participation (session 3) and sleep hygiene measures (session 4), the importance of belongingness and commitment (session 5), and how to seek support including peer support, community engagement and existing local services (session 6). The first 6 sessions were facilitated by the teacher, and the next 6 by peers.
219687692|NCT00477763|DRUG|Restasis, Refresh Endura|"1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
219687693|NCT03996668|OTHER|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
219687694|NCT03608605|DEVICE|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
219687695|NCT03535363|DRUG|Osimertinib|Drug: Osimertinib 80mg or 40mg
219687696|NCT06151808|DRUG|XTR006|All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
219687697|NCT01884883|DEVICE|PROTEOR Internal unicompartmental knee brace|
219734649|NCT00468546|DRUG|Methotrexate|2
219734650|NCT00468546|OTHER|Placebo|3
219161430|NCT06789094|OTHER|Ain Shams University Cognitive Assessment (ASCA) tool|The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.
219734651|NCT05158803|RADIATION|ultrasound and C.T|lung ultrasound in comparison to C.T
219734652|NCT05206435|DRUG|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
219734653|NCT05206435|DRUG|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
219734654|NCT02451735|BEHAVIORAL|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
219734655|NCT02451735|BEHAVIORAL|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
219734656|NCT06964074|DEVICE|Nebulization with OPEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
219734657|NCT06964074|DEVICE|Nebulization with PEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
219734658|NCT06964074|DEVICE|Nebulization with Pari LC Sprint|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
219734659|NCT05128448|OTHER|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
219734660|NCT05128448|OTHER|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
219734661|NCT00787488|DEVICE|Hyperthermia|Every 3 weeks
219734662|NCT04619888|DIAGNOSTIC_TEST|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
219734663|NCT03346317|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
219734664|NCT03346317|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
219734665|NCT03346317|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
219161431|NCT05791071|DEVICE|Floreo VR Building Social Connections|Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
219161432|NCT05791071|DEVICE|Sham|This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.
219161433|NCT06459739|PROCEDURE|sacral ESPB|sacral ESPB
219100866|NCT05910086|OTHER|collection of data from the medical record|"collection of data from the medical record:~1. During epidural space puncture = cerebrospinal fluid (CSF) reflux, presence of glucose / strip, saline injection, intrathecal catheter insertion, intrathecal levobupivacaine and sufentanil injection, catheter insertion time, number of punctures, function of the person performing the procedure.~2. Analgesia and hemodynamics during labor, blood pressure, pulse rate, amount of local anesthetic used, whether emergency cesarean section was performed~3. Demographic data (age, weight, height, body mass index (BMI))~4. Post-partum monitoring of decubitus or orthostatic headaches, intensity, any other associated clinical signs~5. Analgesics used and their efficacy~6. The use of one or more blood patches, with the volume injected and their efficacy~7. Identification of the breach during epidural analgesia or after delivery~8. Call the patient at 1 week to reassess the episode and its consequences."
219100867|NCT00793221|DEVICE|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
219100868|NCT00793221|DEVICE|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
219100869|NCT03459703|BEHAVIORAL|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
219687698|NCT03587233|BEHAVIORAL|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
219687699|NCT03587233|DEVICE|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
219687700|NCT03587233|BEHAVIORAL|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
219687701|NCT03943355|OTHER|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
219687702|NCT03943355|OTHER|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
219687703|NCT03646942|RADIATION|low level laser therapy|low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.
219687704|NCT03646942|DEVICE|Lingual Orthodontics|Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
219687705|NCT06828991|DRUG|Mosunetuzumab|Mosunetuzumab consolidation therapy will consist of 6 cycles of IV mosunetuzumab at the standard ramp-up dosing (Day 1 1mg, Day 8 2mg, D15 60mg, C2D1 60mg, and 30mg on day 1 of the subsequent 21-day cycles)
219687706|NCT04105608|DIETARY_SUPPLEMENT|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
219687707|NCT04105608|DIETARY_SUPPLEMENT|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
219687708|NCT02347709|PROCEDURE|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
219687709|NCT02347709|OTHER|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
219100870|NCT03459703|BEHAVIORAL|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
219100871|NCT03459703|BEHAVIORAL|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
219100872|NCT03644355|BEHAVIORAL|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
219100873|NCT02309177|DRUG|nab-Paclitaxel|
219100874|NCT02309177|DRUG|Nivolumab|
219100875|NCT02309177|DRUG|Gemcitabine|
219100876|NCT02309177|DRUG|Carboplatin|
219100877|NCT01098149|OTHER|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
219100878|NCT01698086|OTHER|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
219687710|NCT02347709|OTHER|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
219687711|NCT02347709|OTHER|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
219687712|NCT04993872|DRUG|Biktarvy Tab|Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
219100879|NCT00157274|DRUG|alemtuzumab|
219100880|NCT04180839|BEHAVIORAL|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
219100881|NCT04180839|BEHAVIORAL|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
219100882|NCT00597714|DRUG|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
219687713|NCT01818089|DEVICE|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
219687714|NCT00738634|BEHAVIORAL|Self-motivated physical activity|"Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
219687715|NCT00738634|BEHAVIORAL|Nutrition|"Components:~1. Nutrition education booklet (Double-sided A4 page)~2. Nutrition motivation tips (single-sided A4 page)~3. Nutrition monitoring chart~4. Online presentation of common obstacles and ways to overcome these obstacles"
219687716|NCT00738634|BEHAVIORAL|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
219687717|NCT02976246|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
219687718|NCT02976246|OTHER|Placebo|One tablet of placebo given once daily.
219687719|NCT02787499|PROCEDURE|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
219687720|NCT05433610|DEVICE|Non-invasive Ventilation|Exercise capacity testing using the device
219687721|NCT04553081|DRUG|Dual versus triple therapy in treatment of HIV-1 infection.|cfr arm description
219687722|NCT01831427|DRUG|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
219687723|NCT01831427|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
219687724|NCT02403804|DIETARY_SUPPLEMENT|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
219687725|NCT02403804|DIETARY_SUPPLEMENT|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
219100883|NCT01350141|OTHER|Placebo|An infusion lasting approximately 60 minutes
219100884|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
219100885|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
219100886|NCT00802555|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
219100887|NCT06121960|DIAGNOSTIC_TEST|spirometry|"Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance"
219100888|NCT05198193|BEHAVIORAL|No Message Given|Participants in this arm are not given any intervention.
219100889|NCT05198193|BEHAVIORAL|Positive Message Given - Older Adults|Participants in this arm are given a positively framed message from an older adult's point of view.
219687726|NCT02403804|DIETARY_SUPPLEMENT|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
219687727|NCT06122350|BEHAVIORAL|Earthquake preparedness training|Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
219687728|NCT05686655|OTHER|questionnaire about sleep quality in diabetic children|Pittsburgh sleep quality index
219687729|NCT00536510|DRUG|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
219687730|NCT00536510|DRUG|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
219687731|NCT05869669|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
219687732|NCT05869669|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
219100890|NCT05198193|BEHAVIORAL|Negative Message Given - Older Adults|Participants in this arm are given a negatively framed message from an older adult's point of view.
219100891|NCT05198193|BEHAVIORAL|Positive Message Given - Younger Adults|Participants in this arm are given a positively framed message from an adult child's point of view.
219100892|NCT05198193|BEHAVIORAL|Negative Message Given - Younger Adults|Participants in this arm are given a negatively framed message from an adult child's point of view.
219687733|NCT02169505|DRUG|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
219687734|NCT06122389|DRUG|SHR2554; Chidamide analog tablets|SHR2554 + Chidamide analog tablets
219100893|NCT04736017|DEVICE|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
219100894|NCT02461875|DRUG|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
219100895|NCT02461875|DRUG|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
219687735|NCT06122389|DRUG|SHR2554 analog tablets; Chidamide|SHR2554 analog tablets + Chidamide
219100896|NCT03192540|OTHER|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
219687736|NCT00048035|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
219687737|NCT02077998|RADIATION|carbon C 14 oxaliplatin|Given IV
219687738|NCT02077998|DRUG|oxaliplatin|Given IV
219687739|NCT02077998|OTHER|laboratory biomarker analysis|Correlative studies
219100897|NCT00519896|DRUG|sunitinib malate|Given PO
219100898|NCT00810082|DEVICE|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
219100899|NCT00810082|OTHER|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
219100900|NCT01286220|OTHER|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
219100901|NCT01286220|OTHER|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
219687740|NCT01825304|DEVICE|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
219687741|NCT00510341|BEHAVIORAL|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
219687742|NCT02246738|OTHER|Blood Collection|
219687743|NCT03072095|BEHAVIORAL|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
219734666|NCT05236465|BEHAVIORAL|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
219734667|NCT05236465|BEHAVIORAL|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
219734668|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
219734669|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
219734670|NCT06081465|DRUG|VG290131|The study drug and matching placebo will be administered orally.
219734671|NCT03531502|PROCEDURE|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
219734672|NCT03531502|OTHER|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
219734673|NCT03531502|PROCEDURE|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
219734674|NCT02551107|DEVICE|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
219734675|NCT01151631|DEVICE|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
219734676|NCT03997734|DRUG|AB001|single and repeated dosing
219734677|NCT03997734|DRUG|oral capsule|single dose
219734678|NCT03997734|DRUG|positive comparative patch|single and repeated dosing
219734679|NCT03997734|DRUG|Placebos|single and repeated dosing
219734680|NCT01216085|DRUG|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
219734681|NCT00641212|DRUG|Budesonide|
219734682|NCT00641212|DRUG|Placebo|
219734683|NCT04044248|DEVICE|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
219734684|NCT05549882|OTHER|no intervention|no intervention
219734685|NCT03375164|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
219734686|NCT00484328|DRUG|Ribavirin|different dosing regimes of Ribavirin
219100902|NCT01588990|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
219100903|NCT01588990|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
219100904|NCT01588990|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
219100905|NCT01588990|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
219687744|NCT03072095|BEHAVIORAL|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
219687745|NCT02043288|DRUG|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
219687746|NCT02043288|DRUG|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
219687747|NCT02035553|DRUG|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
219687748|NCT02035553|DRUG|Placebo|Placebo, two tablets, once daily by mouth
219687749|NCT02895685|OTHER|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
219687750|NCT05137717|DRUG|Maribavir|Maribavir tablets
219687751|NCT02735980|DRUG|Prexasertib|Administered IV
219687752|NCT00509899|DRUG|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
219100906|NCT01588990|DRUG|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
219100907|NCT01588990|DRUG|Irinotecan|Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
219100908|NCT05635318|DEVICE|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
219100909|NCT05635318|DRUG|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
219100910|NCT02892487|OTHER|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
219100911|NCT02784470|DEVICE|gastroduodenal stent placement|
219100912|NCT02784470|PROCEDURE|gastrojejunostomy|
219100913|NCT00750282|DRUG|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
219687753|NCT05192317|DEVICE|Sollievo Fisiolax|Class IIb Medical Device
219687754|NCT05192317|OTHER|Sollievo Fisiolax Placebo|Placebo
219687755|NCT02749162|DRUG|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
219687756|NCT02749162|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
219687757|NCT02749162|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
219100914|NCT02367716|DEVICE|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
219100915|NCT00494260|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
219100916|NCT00494260|BEHAVIORAL|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
219100917|NCT02900612|OTHER|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
219100918|NCT02900612|OTHER|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
219100919|NCT02900612|OTHER|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
219550688|NCT00990574|DEVICE|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
219687758|NCT02749162|DRUG|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
219687759|NCT02749162|DRUG|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
219687760|NCT02501746|OTHER|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
219734687|NCT01440751|DEVICE|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
219734688|NCT01440751|DRUG|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
219734689|NCT05249348|DRUG|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
219550689|NCT00990574|DEVICE|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
219550690|NCT04898504|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
219734690|NCT05306145|PROCEDURE|High freqnence Irreversible electroporation|High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia
219734691|NCT05306145|PROCEDURE|Trans Urethral Resection Prostate|Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
219734692|NCT02393469|OTHER|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
219734693|NCT02393469|OTHER|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
219734694|NCT02970812|DEVICE|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
219734695|NCT02970812|DEVICE|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
219734696|NCT00827307|DRUG|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
219734697|NCT00827307|DRUG|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
219687761|NCT02501746|OTHER|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
219687762|NCT02501746|OTHER|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
219687763|NCT00002192|DRUG|Rifapentine|
219687764|NCT00002192|DRUG|Ethambutol hydrochloride|
219687765|NCT00002192|DRUG|Clarithromycin|
219100920|NCT05151497|OTHER|Experimental group:Halliwick + Método Watsu|Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
219100921|NCT05151497|OTHER|Control group:Halliwick|Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
219100922|NCT05438186|DRUG|Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
219100923|NCT02508532|DRUG|Avapritinib|avapritinib tablets
219100924|NCT00500240|DRUG|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
219687766|NCT00002192|DRUG|Azithromycin|
219687767|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(montly)|once a month
219100925|NCT00500240|DRUG|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
219100926|NCT02334566|BEHAVIORAL|NET TX|Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
219100927|NCT01756521|DRUG|Moxifloxacin|
219100928|NCT05529784|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
219100929|NCT03097861|DRUG|Lubiprostone|24 mcg administered orally BID
219100930|NCT03097861|DRUG|Placebo|24 mcg administered orally BID
219100931|NCT01021774|PROCEDURE|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
219100932|NCT02430701|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
219100933|NCT02430701|DEVICE|NanoKnife|
219100934|NCT04458116|DIETARY_SUPPLEMENT|Curcumin|Participants will receive 1.5 grams of turmeric 95% curcumin for 1 month (3 capsules / day containing 500mg each for 4 weeks).
219100935|NCT01898702|BEHAVIORAL|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
219100936|NCT03577158|DEVICE|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
219100937|NCT03577158|DEVICE|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
219100938|NCT03577158|DEVICE|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
219100939|NCT06450717|DEVICE|Khymeia VRRS|VRRS is an electronic device for remote rehabilitation of cognitive (e.g., memory, attention, spatial perception, logical-mathematical skills, language, executive functions...) and motor (gross and fine motor skills) functions. It can be used in on-line and off-line mode at home, and the exercises are chosen by the therapist according to the patient's specific difficulties and needs from a cognitive and motor library.
219687768|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(weekly)|once a week
219687769|NCT02781987|OTHER|chronic pancreatitis|patients with chronic pancreatitis
219687770|NCT00713843|OTHER|Manual Therapy Utrecht|Manual Therapy (6 weeks).
219687771|NCT00713843|OTHER|Physical Therapy|Physical Therapy (six weeks).
219687772|NCT05078203|BEHAVIORAL|Exercise|36 minutes of Exercise
219687773|NCT03273920|PROCEDURE|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
219687774|NCT03273920|PROCEDURE|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
219100940|NCT03138174|DEVICE|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
219100941|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection once a week, 0.1/cm2
219100942|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection twice a week, 0.1/cm2
219100943|NCT01896635|BIOLOGICAL|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
219100944|NCT01896635|OTHER|Placebo infusion|Placebo infusion not containing any donor microbial material
219100945|NCT04477421|PROCEDURE|FS-SMILE|Femtosecond small incision lenticule extraction
219100946|NCT04477421|PROCEDURE|S-LASIK|Femtosecond laser Insitu keratomileusis
219100947|NCT00154310|DRUG|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
219100948|NCT00154310|DRUG|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
219100949|NCT00154310|DRUG|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
219100950|NCT00154310|DRUG|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
219100951|NCT04399356|DRUG|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
219100952|NCT04399356|DRUG|Placebo|The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
219100953|NCT04399356|OTHER|Telehealth monitoring|In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
219550691|NCT04898504|PROCEDURE|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
219687775|NCT00976326|DRUG|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
219687776|NCT03426410|OTHER|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
219687777|NCT03677115|DRUG|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
219100954|NCT04125524|DIAGNOSTIC_TEST|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
219100955|NCT00790153|DRUG|Insulin|Insulin infusion given during 3 hours at one occasion.
219100956|NCT00790153|DRUG|AZD1656|Single dose oral suspension given at one occasion.
219100957|NCT00961025|DRUG|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
219100958|NCT00961025|DRUG|Placebo|placebo
219550692|NCT01458886|DRUG|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
219550693|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
219550694|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
219550695|NCT01458886|DRUG|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
219550696|NCT02956681|BEHAVIORAL|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
219550697|NCT02956681|BEHAVIORAL|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
219687778|NCT02326272|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
219550698|NCT06529146|DRUG|BHV-4157|BHV-4157 (troriluzole) 200 mg QD
219687779|NCT02326272|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
219687780|NCT04777981|DIETARY_SUPPLEMENT|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
219687781|NCT04777981|DIETARY_SUPPLEMENT|Placebo|Placebo
219100959|NCT04458623|DIAGNOSTIC_TEST|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
219100960|NCT02478346|DRUG|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
219100961|NCT06160622|DRUG|Leritrelvir|Oral
219100962|NCT02321280|DRUG|Denosumab|Single dose subcutaneous administration
219100963|NCT03735160|DEVICE|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
219100964|NCT02235363|PROCEDURE|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
219100965|NCT04508296|DIAGNOSTIC_TEST|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
219100966|NCT00965796|DRUG|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
219100967|NCT04566302|DEVICE|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
219687782|NCT01162889|DRUG|Placebo SC Injection|Single injection
219687783|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
219687784|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
219687785|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
219687786|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
219687787|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
219687788|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
219687789|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
219687790|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
219687791|NCT01162889|DRUG|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
219687792|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
219687793|NCT00114985|DEVICE|Prostate Immobilization Device|Device placed during radiation treatment
219687794|NCT05343663|BEHAVIORAL|Education|Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
219687795|NCT01407809|DEVICE|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
219687796|NCT05543538|OTHER|multimedia audio-visual program|Participants in the control group will receive teaching method with multimedia audio-visual material.
219687797|NCT05543538|OTHER|experiential learning programmes|Participants in the experimental group will receive teaching method with experiential learning.
219687798|NCT05543538|OTHER|teachers' personal demonstration|Participants in the experience group will receive teachers' personal demonstration.
219687799|NCT02104661|DRUG|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
219687800|NCT02104661|DRUG|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
219687801|NCT03099460|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
219687802|NCT03099460|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
219687803|NCT03099460|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
219687804|NCT03273959|OTHER|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
219687805|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
219734698|NCT02464358|BEHAVIORAL|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
219100968|NCT05822336|OTHER|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
219687806|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
219687807|NCT05534139|DIAGNOSTIC_TEST|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
219687808|NCT05534139|DIAGNOSTIC_TEST|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
219687809|NCT05534139|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
219687810|NCT05534139|DIAGNOSTIC_TEST|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
219687811|NCT01943487|DRUG|EC905|Oral
219687812|NCT01943487|DRUG|verapamil|Oral
219100969|NCT05437354|OTHER|survey|Oncology medical staff should respond to a survey
219687813|NCT03713684|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219687814|NCT03713684|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219100970|NCT06444022|BIOLOGICAL|Human amniotic epithelial stem cells（hAESCs）|Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)
219100971|NCT06444022|BIOLOGICAL|placebo (cell preservation solution)|Same dose placebo (cell preservation solution) injections as control group
219100972|NCT01850368|RADIATION|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
219100973|NCT01028261|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
219687815|NCT03713684|DRUG|Background therapy|Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
219100974|NCT06249490|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
219550699|NCT00532012|DRUG|RhuDex®|
219550700|NCT02166606|DEVICE|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
219550701|NCT04980170|DRUG|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
219550702|NCT04980170|DRUG|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
219550703|NCT04862806|DIAGNOSTIC_TEST|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
219550704|NCT02083809|DRUG|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
219550705|NCT02083809|DRUG|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
219100975|NCT06249490|DEVICE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219100976|NCT06249490|DRUG|Lidocaine Hydrochloride Injection|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219100977|NCT05016544|DRUG|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
219100978|NCT05016544|DRUG|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
219687816|NCT04637243|OTHER|Treatment of Benign or Malignant Liver and Bile Duct Diseases|Available treatment of Benign or Malignant Liver and Bile Duct Diseases
219687817|NCT04542980|DIAGNOSTIC_TEST|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
219687818|NCT01803087|DRUG|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
219687819|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
219687820|NCT01803087|DRUG|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
219687821|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) (CTR)|
219687822|NCT01611623|DRUG|SNX-5422|Tablets dose every other day; dose escalation based on safety
219687823|NCT05150431|DRUG|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
219687824|NCT05150431|DRUG|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
219687825|NCT00003713|DRUG|intoplicine|
219687826|NCT02975180|DEVICE|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
219687827|NCT02975180|BEHAVIORAL|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
219687828|NCT01513993|PROCEDURE|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
219687829|NCT04767113|DRUG|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
219687830|NCT04767113|DRUG|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
219687831|NCT04653831|DRUG|Pirfenidone|Treatment with Pirfenidone as mentioned in the experimental arm description.
219687832|NCT04653831|OTHER|Standard of care|Treatment with SoC as mentioned in the control arm description.
219687833|NCT02185417|DRUG|Hydrochlorothiazide (HCTZ)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
219687834|NCT02185417|DRUG|Chlorthalidone (CTD)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
219687835|NCT04096846|DIAGNOSTIC_TEST|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
219687836|NCT02361112|DRUG|pyrotinib combined with capecitabine|
219687837|NCT01819675|DEVICE|Low frequency rTMS|
219687838|NCT01819675|DEVICE|High frequency rTMS|
219687839|NCT01819675|DEVICE|Sham rTMS|
219734699|NCT02464358|BEHAVIORAL|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
219734700|NCT05562921|BEHAVIORAL|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
219734701|NCT05562921|BEHAVIORAL|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
219734702|NCT01993758|PROCEDURE|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
219100979|NCT02749851|DEVICE|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
219100980|NCT02749851|DEVICE|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
219100981|NCT05815732|OTHER|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
219100982|NCT01536041|DRUG|ONO-6950|200 mg QD, single dose
219687840|NCT03533231|COMBINATION_PRODUCT|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
219687841|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Propolis Paste|
219687842|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Metronidazole Paste|
219687843|NCT03533231|COMBINATION_PRODUCT|Propolis + Metronidazole paste|
219687844|NCT03721224|DIAGNOSTIC_TEST|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
219687845|NCT05508373|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
219687846|NCT02437760|OTHER|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~* at time of diagnosis~* every 3 month during treatment~* stop at the progression or after 12 months"
219687847|NCT00000399|DRUG|Hormone replacement therapy|
219687848|NCT00000399|PROCEDURE|Strength training|
219687849|NCT00974311|DRUG|Enzalutamide|MDV3100, 160 mg orally per day
219100983|NCT01536041|DRUG|ONO-6950|20 mg QD, single dose
219100984|NCT01536041|DRUG|Montelukast|10 mg Montelukast, QD single dose
219100985|NCT01536041|DRUG|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
219100986|NCT02019134|BEHAVIORAL|relaxation exercise|relaxation exercise
219100987|NCT02019134|OTHER|ususal care|
219100988|NCT03278301|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
219687850|NCT00974311|DRUG|Placebo|Placebo comparator
219687851|NCT00763997|DRUG|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
219687852|NCT00763997|DRUG|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
219687853|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
219687854|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
219687855|NCT00763997|DRUG|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
219687856|NCT00763997|OTHER|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
219687857|NCT02595502|DEVICE|JJVC Marketed Contact Lens (Test)|
219687858|NCT02595502|DEVICE|Competitor Marketed Contact Lens (Control)|
219687859|NCT01158560|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
219687860|NCT01158560|BEHAVIORAL|Gargling|gargling with tap water, twice daily
219687861|NCT01158560|DIETARY_SUPPLEMENT|Placebo|matched placebo for active vitamin D
219687862|NCT04152681|DRUG|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
219100989|NCT03395249|DRUG|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
219687863|NCT03193632|DIAGNOSTIC_TEST|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
219100990|NCT03395249|DRUG|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
219100991|NCT03395249|DRUG|Orapenem®|Tebipenem pivoxil granules
219687864|NCT03193632|DIAGNOSTIC_TEST|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
219687865|NCT01853787|DRUG|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
219687866|NCT01853787|DRUG|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
219734703|NCT01993758|PROCEDURE|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
219734704|NCT03116269|DRUG|Cilostazol 100mg|
219734705|NCT03116269|DRUG|Aspirin|
219734706|NCT00291226|DRUG|Glycine|Glycine 0.4 g/kg bid
219734707|NCT00291226|DRUG|Placebo|Placebo
219734708|NCT06293144|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
219734709|NCT00557102|BIOLOGICAL|cetuximab|
219734710|NCT00557102|BIOLOGICAL|filgrastim|
219734711|NCT00557102|DRUG|fluorouracil|
219734712|NCT00557102|DRUG|irinotecan hydrochloride|
219734713|NCT00557102|DRUG|leucovorin calcium|
219734714|NCT06285903|PROCEDURE|internal sinus lift surgery|surgery approach
219734715|NCT06460909|OTHER|Psychological support|An interview with the psychologist before surgery.
219734716|NCT03377127|BEHAVIORAL|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
219734717|NCT03377127|OTHER|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
219734718|NCT01236807|PROCEDURE|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
219734719|NCT01236807|PROCEDURE|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
219734720|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
219734721|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|
219734722|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
219734723|NCT05605080|DEVICE|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
219734724|NCT05605080|OTHER|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
219734725|NCT02734914|DEVICE|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
219734726|NCT02734914|DEVICE|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
219734727|NCT03397758|DEVICE|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
219734728|NCT00483392|DRUG|metformin, rosiglitazone|
219734729|NCT05231941|DRUG|Lidocaine IV|Bolus and infusion of lidocaine will be administered
219734730|NCT05231941|DRUG|Ropivacaine|Bilateral TAP block will be given to these patients
219734731|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
219734732|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
219100992|NCT03900377|DRUG|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
219100993|NCT04530539|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C, at bedtime
219100994|NCT04530539|DIETARY_SUPPLEMENT|melatonin|10mg melatonin, at bedtime
219100995|NCT04530539|DIETARY_SUPPLEMENT|Placebo|Placebo at bedtime
219100996|NCT04530539|OTHER|Symptom Survey|Daily symptom survey to be completed by patient electronically
219100997|NCT00175461|PROCEDURE|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
219100998|NCT01247519|OTHER|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
219100999|NCT00668499|DRUG|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
219687867|NCT04121338|PROCEDURE|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
219687868|NCT04121338|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
219687869|NCT00549796|OTHER|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
219687870|NCT06150300|BEHAVIORAL|Pulmonary rehab program|Exercise videos, breathing exercises, and educational messages delivered virtually
219687871|NCT06150300|BEHAVIORAL|Placebo|Breathing exercises and educational messages
219687872|NCT05074875|OTHER|Questionnaires and Patient Reported Outcomes (PROs)|"* EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~* St. George's Respiratory Questionnaire (SGRQ)~* Impact of Events Scale Revised (IES-R)~* Generalized Anxiety Disorder 7-Item (GAD-7)~* Patient Health Questionnaire (PHQ-9)"
219101000|NCT04219722|DEVICE|Injection of DESIRIAL®|"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
219101001|NCT04219722|OTHER|Injection of placebo|"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
219101002|NCT05712161|DEVICE|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
219101003|NCT04232046|OTHER|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
219101004|NCT00507741|DRUG|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
219101005|NCT00507741|DRUG|Ertafolide|
219161434|NCT04765865|OTHER|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
219161435|NCT06411574|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
219161436|NCT05307978|DRUG|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
219161437|NCT05307978|DRUG|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
219161438|NCT05454774|GENETIC|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
219161439|NCT06834737|OTHER|ecological sampling method|6-item diary, twice a day, over the course of 2 months.
219161440|NCT05607407|DRUG|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
219161441|NCT05607407|PROCEDURE|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
219161442|NCT05607407|DIAGNOSTIC_TEST|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
219161443|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
219101006|NCT01187329|OTHER|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is \<110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose \> 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
219101007|NCT01187329|OTHER|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose \>150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose \< 180 mg/dL.
219101008|NCT02952664|BEHAVIORAL|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
219101009|NCT01287637|PROCEDURE|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
219101010|NCT01287637|PROCEDURE|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
219101011|NCT00885573|DEVICE|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
219101012|NCT04481828|PROCEDURE|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
219101013|NCT03187015|DRUG|Entinostat|HDAC (histone deacetylase inhibitor)
219550706|NCT03610607|BEHAVIORAL|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
219687873|NCT05074875|DIAGNOSTIC_TEST|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
219687874|NCT05074875|GENETIC|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
219687875|NCT05074875|DIAGNOSTIC_TEST|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
219687876|NCT05074875|DIAGNOSTIC_TEST|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
219687877|NCT05074875|DIAGNOSTIC_TEST|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
219687878|NCT05074875|DIAGNOSTIC_TEST|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
219550707|NCT01940159|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
219550708|NCT01940159|DRUG|Placebo|single oral dose placebo
219550709|NCT02520193|PROCEDURE|Protocolized early mobilization in ICU|
219550710|NCT02824510|OTHER|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
219550711|NCT02824510|OTHER|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
219550712|NCT02824510|DRUG|Insulin aspart, glargine and detemir|
219550713|NCT03214237|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
219550714|NCT05569109|DEVICE|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
219687879|NCT05074875|DIAGNOSTIC_TEST|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
219687880|NCT05074875|DIAGNOSTIC_TEST|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
219687881|NCT05074875|DIAGNOSTIC_TEST|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
219687882|NCT05074875|DIAGNOSTIC_TEST|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
219687883|NCT05556148|DRUG|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
219687884|NCT03566095|BEHAVIORAL|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
219101014|NCT03187015|DRUG|Midazolam|benzodiazepine central nervous system (CNS) depressant
219101015|NCT05275491|DIAGNOSTIC_TEST|Calcium|Free calcium serum levels
219101016|NCT05275491|DIAGNOSTIC_TEST|Fibroblast growth factor 23|Serum level
219687885|NCT03566095|BEHAVIORAL|Voices for Food Kit|Voices for Food Kit
219687886|NCT00433550|DRUG|capecitabine|given orally
219687887|NCT00433550|DRUG|irinotecan hydrochloride|given IV
219687888|NCT00433550|DRUG|oxaliplatin|given IV
219687889|NCT02818855|PROCEDURE|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
219687890|NCT02818855|DRUG|Collagen Matrix|A new collagen membrane
219687891|NCT02818855|PROCEDURE|Subepithelial connective tissue graft|Connective tissue graft
219687892|NCT03158207|DEVICE|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
219687893|NCT03158207|OTHER|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
219687894|NCT01081782|DRUG|ONO-4641|0.15 mg once per day for 26 weeks
219687895|NCT01081782|DRUG|ONO-4641|0.1 mg once per day for 26 weeks
219687896|NCT01081782|DRUG|ONO-4641|0.05 mg once per day for 26 weeks
219101017|NCT05275491|DIAGNOSTIC_TEST|Sclerostin|Serum level
219687897|NCT01081782|DRUG|ONO-4641 placebo|Placebo once per day for 26 weeks
219687898|NCT06344975|BIOLOGICAL|STR-V003/Placebo|IM
219101018|NCT05275491|DIAGNOSTIC_TEST|parathyroid hormone|serum level
219687899|NCT00189163|DRUG|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
219687900|NCT00189163|DRUG|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
219687901|NCT02718872|BEHAVIORAL|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
219101019|NCT02299258|DEVICE|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
219101020|NCT02299258|DEVICE|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
219101021|NCT02841293|PROCEDURE|Biological mesh|The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
219687902|NCT06165432|DRUG|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
219687903|NCT06165432|OTHER|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
219687904|NCT03266900|PROCEDURE|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
219687905|NCT03266900|DRUG|6 weeks BCG instillation|standard 6 weeks of BCG induction
219687906|NCT03006536|DEVICE|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
219101022|NCT02841293|PROCEDURE|Primary perineal wound closure|The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
219101023|NCT04180241|PROCEDURE|POEM|Peroral endoscopic myotomy
219101024|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
219101025|NCT03078153|BEHAVIORAL|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
219101026|NCT03078153|BEHAVIORAL|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
219101027|NCT04359030|DIAGNOSTIC_TEST|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
219101028|NCT04359030|DIAGNOSTIC_TEST|Transthoracic stress echocardiography|Transthoracic stress echocardiography
219101029|NCT06339554|DRUG|Alectinib 150 MG [Alecensa]|First line treatment for cohorts A and B
219101030|NCT00274001|DRUG|Nevirapine|
219101031|NCT01544959|DRUG|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
219101032|NCT01544959|DRUG|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
219101033|NCT04080310|DRUG|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
219687907|NCT05181150|OTHER|Meal test|Ingestion of an oral liquid meal (nutridrink), 200 mL.
219687908|NCT05181150|OTHER|GIP|Subcutaneous GIP injection.
219687909|NCT05181150|OTHER|GLP-2|Subcutaneous GLP-2 injection.
219687910|NCT05181150|OTHER|GIP + GLP-2|Subcutaneous GIP + GLP-2 injection.
219687911|NCT05181150|OTHER|Placebo|Subcutaneous saline injection.
219687912|NCT05235152|OTHER|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~* Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~* Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~* Individual proprioceptive training."
219734733|NCT02922660|DRUG|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
219734734|NCT02922660|PROCEDURE|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
219734735|NCT02922660|PROCEDURE|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
219734736|NCT02922660|DRUG|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
219734737|NCT02922660|DRUG|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
219734738|NCT03298100|OTHER|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
219734739|NCT06375720|BEHAVIORAL|Lower frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
219734740|NCT06375720|BEHAVIORAL|Higher frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
219734741|NCT06375720|BEHAVIORAL|Lower frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
219734742|NCT06375720|BEHAVIORAL|Higher frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
219734743|NCT06375720|BEHAVIORAL|Standard Health Education|Participants would take standard health education 0.5 hour/ session, 2 sessions/month for 6 months.
219101034|NCT02375282|PROCEDURE|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
219101035|NCT04303312|OTHER|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
219101036|NCT04303312|COMBINATION_PRODUCT|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
219101037|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
219101038|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-7
219101039|NCT00868699|DRUG|Placebo|Placebo Comparator
219101040|NCT01834222|BIOLOGICAL|Non-intervention|Non-intervention
219235357|NCT02081976|BEHAVIORAL|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
219687913|NCT05235152|OTHER|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
219687914|NCT05262816|OTHER|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
219687915|NCT05695742|OTHER|Active Smoking|Being active smoker
219687916|NCT05695742|OTHER|Passive smoker|Being exposed to secondhand smoke
219687917|NCT05695742|OTHER|Non-smoker|Not being an active or passive smoker.
219687918|NCT01167569|DRUG|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
219687919|NCT01167569|OTHER|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
219687920|NCT04100928|OTHER|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
219687921|NCT01139996|DRUG|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
219687922|NCT01139996|DRUG|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
219687923|NCT02766348|DRUG|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
219687924|NCT02766348|BIOLOGICAL|DC-CTL|8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
219687925|NCT02766348|DRUG|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
219687926|NCT03212716|DRUG|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
219687927|NCT03212716|DRUG|Diltiazem|60 mgx3 per day during 10 days.
219687928|NCT03212716|DRUG|Placebos|Placebo of diltiazem
219687929|NCT04746469|BEHAVIORAL|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
219687930|NCT03143361|PROCEDURE|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
219687931|NCT03772808|DIETARY_SUPPLEMENT|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
219687932|NCT06265090|OTHER|therapeutic exercises|Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.
219687933|NCT06265090|OTHER|exercises|"The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
219101041|NCT04172805|DRUG|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
219101042|NCT02398968|DIETARY_SUPPLEMENT|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
219101043|NCT01208155|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
219101044|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
219101045|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
219101046|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
219101047|NCT04251065|DRUG|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade \> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
219101048|NCT03892629|BEHAVIORAL|Baduanjin exercise|Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
219101049|NCT03892629|DEVICE|Instrument rehabilitation|Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
219101050|NCT01054573|DRUG|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
219235358|NCT02081976|OTHER|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
219235359|NCT01029639|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
219235360|NCT01516710|PROCEDURE|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
219235361|NCT01516710|PROCEDURE|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
219235362|NCT00195988|DRUG|tacrolimus, steroids, mycophenolate mofetil|
219687934|NCT00821275|PROCEDURE|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
219101051|NCT01054573|DRUG|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
219101052|NCT01054573|DRUG|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
219101053|NCT03213990|OTHER|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
219101054|NCT03213990|OTHER|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
219687935|NCT00676403|DRUG|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
219687936|NCT00676403|DRUG|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
219687937|NCT00676403|DRUG|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
219687938|NCT00676403|DRUG|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
219687939|NCT00676403|DRUG|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
219687940|NCT00676403|DRUG|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
219101055|NCT02694003|BEHAVIORAL|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
219101056|NCT01069575|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
219235363|NCT02493556|DEVICE|LLLT before muscle damage|
219101057|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
219101058|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
219235364|NCT02493556|DEVICE|Placebo LLLT before muscle damage|
219687941|NCT03747848|BEHAVIORAL|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
219687942|NCT01831869|DRUG|L-thyroxine|
219687943|NCT03648788|OTHER|NA (Observation study)|NA (Observation study)
219687944|NCT04987112|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
219687945|NCT04823780|DIETARY_SUPPLEMENT|nutrient solution|For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
219687946|NCT04844216|DEVICE|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
219687947|NCT04844216|DEVICE|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
219235365|NCT02493556|DEVICE|LLLT after muscle damage|
219235366|NCT02493556|DEVICE|Placebo LLLT after muscle damage|
219687948|NCT01746862|DRUG|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
219161727|NCT06122688|BEHAVIORAL|Navigator Plus App Intervention|Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
219161728|NCT06050317|DRUG|Sintilimab Plus mFFN or NALIRIFOX and Radiation|Sintilimab Plus mFFN or NALIRIFOX and Radiation
219161729|NCT00411151|DRUG|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
219161730|NCT04192422|OTHER|no intervention|This is a cohort study no intervention
219161731|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (40 -80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
219687949|NCT01746862|DRUG|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
219161732|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
219161733|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
219687950|NCT03087864|DRUG|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
219687951|NCT03087864|DRUG|Carboplatin|Chemotherapy
219687952|NCT03087864|DRUG|Paclitaxel|Chemotherapy
219687953|NCT03087864|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy
219101059|NCT05299021|PROCEDURE|Double-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
219101060|NCT05299021|PROCEDURE|Single-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
219101061|NCT03885011|DRUG|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
219101062|NCT03885011|DRUG|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
219235367|NCT01962376|DRUG|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
219235368|NCT01962376|DRUG|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
219235369|NCT04584736|DRUG|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
219687954|NCT06076785|DEVICE|OdySight|At home measurements of visual acuity through a mobile app.
219687955|NCT02136537|DEVICE|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
219687956|NCT02136537|OTHER|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
219687957|NCT04742673|DRUG|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
219687958|NCT04742673|DRUG|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
219687959|NCT02327234|DRUG|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
219687960|NCT02327234|DRUG|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
219687961|NCT03668106|PROCEDURE|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
219687962|NCT05799846|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention
219687963|NCT05799846|BEHAVIORAL|PREVENT Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
219687964|NCT05799846|BEHAVIORAL|PROMOTE Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
219687965|NCT03286764|OTHER|Peppermint Oil|
219687966|NCT03286764|OTHER|Distilled water|Distilled water spray as a placebo during Colonoscopy
219101063|NCT03885011|DRUG|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
219687967|NCT04335435|DIETARY_SUPPLEMENT|Oat Bran Consumption|Oat bran (120 g), single dose.
219687968|NCT02233530|BEHAVIORAL|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
219687969|NCT03744442|PROCEDURE|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
219101064|NCT05266963|DRUG|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
219101065|NCT05266963|DRUG|Placebo|Placebo
219101066|NCT05075187|DIAGNOSTIC_TEST|Genetic Screening|Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
219101067|NCT02826590|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
219101068|NCT02826590|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
219687970|NCT03744442|PROCEDURE|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
219687971|NCT03744442|PROCEDURE|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
219687972|NCT00006077|DRUG|NS2330|
219687973|NCT00006077|DRUG|Levodopa and Domperidone|
219101069|NCT03813212|DEVICE|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
219687974|NCT05714462|OTHER|meals consisting of primarily animal protein sources|an omnivorous diet
219101070|NCT01141023|DRUG|DaTscan|
219687975|NCT05714462|OTHER|meals consisting of plant protein sources|an herbivorous diet
219687976|NCT01558934|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
219687977|NCT00905996|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
219687978|NCT00905996|DRUG|Beta-blocker (propranolol)|
219687979|NCT01207947|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
219687980|NCT05862935|OTHER|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
219235370|NCT02301078|PROCEDURE|Percutaneous Needle Aponeurotomy|single procedure (day 0)
219687981|NCT05862935|OTHER|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
219101071|NCT05863286|DRUG|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
219101072|NCT01304121|DEVICE|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
219101073|NCT02704897|OTHER|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
219101074|NCT00517985|DRUG|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
219101075|NCT04342624|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon supplement
219101076|NCT04342624|OTHER|Placebo|Placebo
219687982|NCT06058390|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219101077|NCT01441817|PROCEDURE|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
219101078|NCT01235572|PROCEDURE|standard follow-up care|Undergo early discharge and standard outpatient care
219687983|NCT02065180|DIETARY_SUPPLEMENT|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
219687984|NCT02065180|DIETARY_SUPPLEMENT|placebo|
219687985|NCT04818073|DEVICE|New FINGER|New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
219687986|NCT02788721|DRUG|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
219687987|NCT02788721|DRUG|Placebo|Placebo, oral suspension, daily
219687988|NCT04569175|OTHER|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
219687989|NCT04577508|BEHAVIORAL|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
219687990|NCT04577508|OTHER|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
219687991|NCT06556173|DRUG|VTX3232|Dose A
219687992|NCT03836027|OTHER|No intervention|No intervention
219687993|NCT04334759|DRUG|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
219687994|NCT04334759|DRUG|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
219687995|NCT04334759|DRUG|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
219687996|NCT05714501|DEVICE|Millipede System|Mechanical thrombectomy
219687997|NCT05293860|OTHER|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
219687998|NCT05293860|OTHER|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
219687999|NCT05257551|OTHER|Observation|No intervention
219688000|NCT06958289|DEVICE|Cryoneurolysis|Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal. Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact. Therefore, the axon can regenerate, following the same path as prior to treatment.
219101079|NCT01235572|OTHER|medical chart review|Undergo early discharge and standard outpatient care
219101080|NCT01235572|PROCEDURE|quality-of-life assessment|Ancillary studies
219688001|NCT06958471|BEHAVIORAL|Individualized Developmental Care Education Group|"An educational program will be implemented for the mothers in the intervention group throughout the hospitalization period of their premature infants, in line with the objectives of the study.~P1:Pretests for the mothers will be completed within the first three days of the infant's admission to the neonatal intensive care unit (NICU). Mothers will be given a brochure titled Your Premature Baby, prepared by the researcher, which includes information about the NICU and its staff, visiting hours/conditions, and breast milk expression times.~P2:Education will be provided on the characteristics, feeding, and care of premature infants.~P3:Mothers will receive training on environmental regulations (temperature, light, sound), kangaroo care,non-nutritive sucking, and parent-infant interaction. Each training session will be delivered each lasting no longer than 30-45 minutes.~P4:A final training session will be provided on home care for the premature infant."
219688002|NCT04399369|DEVICE|SDF|38% silver diamine fluoride solution
219101081|NCT01725386|DRUG|Capecitabine|Oral tablet(s) administered according to prescribing information
219101082|NCT01596218|DRUG|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
219688003|NCT04399369|DEVICE|NaF|5% sodium fluoride varnish
219101083|NCT01140334|BEHAVIORAL|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
219101084|NCT01140334|BEHAVIORAL|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
219101085|NCT02204137|OTHER|Falls Risk Questionnaire|
219688004|NCT03456817|DRUG|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
219688005|NCT03456817|DRUG|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
219101086|NCT02204137|OTHER|Cancer and Aging Research Group Geriatric Assessment|
219101087|NCT02204137|OTHER|Falls Efficacy Scale-International (FES-1)|
219101088|NCT02204137|OTHER|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
219101089|NCT03690219|OTHER|no intervention|no intervention
219101090|NCT02822560|DEVICE|pEVAR|percutaneous femoral access using a suture-mediated closure device
219101091|NCT02822560|PROCEDURE|open femoral access|cutdown to femoral artery and surgical closure
219223740|NCT07043985|DIAGNOSTIC_TEST|biopsy|Diagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany).
219223741|NCT07043127|OTHER|Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
219688006|NCT03361306|DRUG|Elotuzumab|Experimental
219688007|NCT06962007|DRUG|Sugammadex 1 mg/kg Group|Participants receive 1 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
219688008|NCT06962007|DRUG|Sugammadex 2 mg/kg Group|Participants receive 2 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
219223742|NCT07043127|OTHER|BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
219688009|NCT06962007|DRUG|Sugammadex 4 mg/kg Group|Participants receive 4 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
219688010|NCT06962007|DRUG|Pyridostigmine/Glycopyrrolate Group|Participants receive pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg intravenously for reversal of rocuronium-induced neuromuscular blockade.
219688011|NCT04073303|BIOLOGICAL|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
219688012|NCT04073303|OTHER|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
219688013|NCT05417568|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
219688014|NCT05417568|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
219688015|NCT01096953|BEHAVIORAL|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
219688016|NCT01096953|BEHAVIORAL|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
219688017|NCT00001328|DRUG|Cytovene (Ganciclovir Sodium)|
219688018|NCT00001328|DEVICE|G1TKSVNa.53 Producer Cell Line|
219688019|NCT01898403|DRUG|Indocyanine green solution|Administered peri-tumoral and intradermally
219688020|NCT01898403|DRUG|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
219688021|NCT01898403|DIAGNOSTIC_TEST|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
219688022|NCT00437164|DRUG|Insulin|
219688023|NCT00437164|DRUG|Oral GW677954 Capsules (15 mg)|
219688024|NCT04189432|BIOLOGICAL|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
219688025|NCT04189432|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
219688026|NCT02377609|DRUG|Tacrolimus|oral
219688027|NCT01475903|PROCEDURE|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
219688028|NCT02131064|DRUG|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w
219688029|NCT02131064|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infusion q3w
219688030|NCT02131064|DRUG|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
219688031|NCT02131064|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
219688032|NCT02131064|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
219688033|NCT01062893|OTHER|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
219235371|NCT02301078|DRUG|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
219688034|NCT01062893|OTHER|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
219688035|NCT05664308|OTHER|Clinical follow-up (ECG)|Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
219688036|NCT05664308|OTHER|Ongoing monitoring|"Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center."
219688037|NCT05292261|OTHER|Recreational team handball|Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
219688038|NCT04086810|DRUG|DCCR|Once daily oral administration
219688039|NCT03287076|DRUG|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
219688040|NCT06431529|BIOLOGICAL|tumor neoantigen specific T cell|Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
219688041|NCT04464291|OTHER|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
219688042|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
219235372|NCT00795392|OTHER|ASA scale|ASA scale evaluation before operation
219235373|NCT00795392|OTHER|Full-scale psychological assessment|Full-scale psychological evaluation before operation
219101092|NCT05289258|BEHAVIORAL|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
219101093|NCT05289258|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
219223743|NCT07042477|BEHAVIORAL|Integrated Telemedicine Program|The integrated telemedicine program is short-term bridge support provided by a virtually accessible team, including a behavioral health provider (Health Psychologist or Licensed Clinical Social Worker \[LCSW\]) and Community Health Worker (CHW). Once stabilized, members transition from bridge support to ongoing care with a Geisinger Health System Primary Care Provider and Behavioral Health Provider.
219101094|NCT05289258|BEHAVIORAL|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
219101095|NCT03812536|OTHER|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
219101096|NCT00152009|DRUG|SPD503 (Guanfacine hydrochloride) (2 mg)|
219101097|NCT00152009|DRUG|SPD503 (3 mg)|
219101098|NCT00152009|DRUG|SPD503 (4 mg)|
219223744|NCT07042919|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219223745|NCT07042919|PROCEDURE|Computed Tomography|Undergo CT
219223746|NCT07042919|PROCEDURE|Echocardiography Test|Undergo ECHO
219688043|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
219688044|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
219101099|NCT00152009|DRUG|Placebo|
219101100|NCT05773014|PROCEDURE|Speculum Exams|Same as arm
219101101|NCT05773014|PROCEDURE|Digital Exams|Same as arm
219223747|NCT07042919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219223748|NCT07042919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219223749|NCT07042919|DRUG|Zanzalintinib|Given PO
219223750|NCT07042438|BIOLOGICAL|Axicabtagene Ciloleucel|Given CAR-T cells
219223751|NCT07042438|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219223752|NCT07042438|DRUG|Chemotherapy|Receive chemotherapy
219223753|NCT07042438|PROCEDURE|Fecal Microbiota Transplantation|Given PO
219223754|NCT07042438|PROCEDURE|Leukapheresis|Undergo leukapheresis
219223755|NCT07042438|DRUG|Placebo Administration|Given PO
219688045|NCT00672568|DRUG|Placebo|Solution, single dose, injection
219688046|NCT03086629|OTHER|Patient Concerns Inventory|
219688047|NCT03086629|OTHER|No Patient Concerns Inventory|
219101102|NCT03597035|DRUG|Spironolactone|The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
219688048|NCT02269839|DEVICE|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
219688049|NCT05354518|BEHAVIORAL|gestational diabetes management of midwifery students|Gestational diabetes management of midwifery students with a simulator
219688050|NCT06175208|BEHAVIORAL|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
219101103|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
219101104|NCT04702568|DRUG|Eculizumab|Administered at stable dose at the time of study entry
219101105|NCT04702568|DRUG|Ravulizumab|Administered at stable dose at the time of study entry
219101106|NCT00363337|DRUG|aripiprazole|open label treatment with aripiprazole
219223756|NCT07042269|BEHAVIORAL|Aerobic Exercise|Performed daily 10,000-step walking (5 days/week)
219235374|NCT02875444|OTHER|Angio-CT|
219235375|NCT00604396|DRUG|insulin detemir|
219235376|NCT00604396|DRUG|insulin NPH|
219101107|NCT04598906|BEHAVIORAL|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
219101108|NCT04598906|BEHAVIORAL|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
219101109|NCT02650232|DEVICE|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
219101110|NCT02650232|PROCEDURE|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position"
219101111|NCT02650232|DEVICE|Finapres Nova device (FMS system)|
219101112|NCT00393523|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
219101113|NCT00393523|BIOLOGICAL|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
219101114|NCT01696318|BEHAVIORAL|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
219223757|NCT07042269|BEHAVIORAL|Respiratory Muscle Training|Performed 12-week progressive resistance training using the Lung Fitness® breathing trainer (initial/moderate/high resistance levels)
219223758|NCT07044024|COMBINATION_PRODUCT|CeraVe|"Patients with GEA classification 1 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Blemish Control Gel.~Patients in GEA Class 2 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with GEA classification 3 will be assigned to use CeraVe Foaming Facial Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with a GEA classification of 4 and above will be assigned to use CeraVe Hydrating Facial Cleanser in combination with CeraVe Moisturising Cream in conjunction with a commonly used sunscreen product in combination with an oral medication."
219688051|NCT06175208|BEHAVIORAL|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
219688052|NCT00810069|DRUG|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
219688053|NCT00810069|DRUG|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
219688054|NCT04893551|BIOLOGICAL|Tilvestamab|Tilvestamab will be administered as IV infusion.
219688055|NCT04998890|OTHER|adventure-based cognitive behavioral intervention|"The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues."
219688056|NCT03675360|BEHAVIORAL|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
219688057|NCT00785161|DEVICE|Penumbra System|Mechanical Thrombectomy in acute stroke
219101115|NCT05859633|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio in acute pancreatitis|role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
219688058|NCT03242941|PROCEDURE|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
219688059|NCT02915146|RADIATION|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
219688060|NCT03031717|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
219101116|NCT04339517|PROCEDURE|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
219101117|NCT06320665|OTHER|Radiographic measurement|Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)
219101118|NCT02544802|DRUG|Adipose-Derived Mesenchymal Stem Cells|
219101119|NCT06100055|DEVICE|Rectal Irrigation|"Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation."
219101120|NCT05021003|OTHER|pressure biofeedback|: Core stabilization training with pressure biofeedback unit
219101121|NCT05021003|OTHER|core stabilization exercises|: Core stabilization training without pressure biofeedback unit
219101122|NCT00423852|BIOLOGICAL|filgrastim|
219101123|NCT00423852|DRUG|carboplatin|
219101124|NCT00423852|DRUG|ifosfamide|
219101125|NCT00423852|DRUG|paclitaxel|
219101126|NCT00423852|PROCEDURE|autologous hematopoietic stem cell transplantation|
219101127|NCT00423852|PROCEDURE|peripheral blood stem cell transplantation|
219101128|NCT06189404|DRUG|Tigulixostat|300 mg oral dose
219101129|NCT06189404|DRUG|Theophylline|400 mg oral dose
219101130|NCT03934632|OTHER|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
219223759|NCT07043062|PROCEDURE|Open surgical Interference|to compare the outcomes of Laparoscopic repair versus Open surgical repair of Genitovesical fistula in females.
219223760|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks
219688061|NCT02899065|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
219688062|NCT02899065|OTHER|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
219688063|NCT06524986|BEHAVIORAL|Self-efficacy promoting program using computer game|The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment
219688064|NCT06524986|BEHAVIORAL|Standard nursing care|The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
219688065|NCT00971867|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
219688066|NCT04799925|DRUG|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
219688067|NCT05532215|DRUG|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
219688068|NCT05532215|DRUG|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
219688069|NCT04619784|OTHER|Pilates Exercises|Patients will receive 12 sessions of pilates.
219688070|NCT04619784|OTHER|control|Their routine medical treatments were continued
219688071|NCT01244074|BEHAVIORAL|biofeedback training|
219688072|NCT00217035|DIETARY_SUPPLEMENT|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
219688073|NCT05774561|DIAGNOSTIC_TEST|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
219688074|NCT05774561|DIAGNOSTIC_TEST|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
219688075|NCT04767373|BIOLOGICAL|Clesrovimab|Clesrovimab solution
219688076|NCT04767373|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCL\]) solution
219688077|NCT04959448|DRUG|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
219688078|NCT00367003|DEVICE|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
219688079|NCT02983045|DRUG|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
219101131|NCT03934632|OTHER|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
219223761|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks
219223762|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
219101132|NCT03934632|PROCEDURE|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
219223763|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
219223764|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
219101133|NCT00419653|DRUG|Amisulpride|
219101134|NCT00419653|DRUG|Olanzapine|
219101135|NCT00419653|DRUG|Haloperidol|
219101136|NCT00273559|DRUG|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
219101137|NCT02273297|OTHER|Maternal factors|
219101138|NCT01589952|DRUG|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
219223765|NCT02136654|BEHAVIORAL|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
219223766|NCT02773225|DRUG|Eltrombopag|"* CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
219235377|NCT03118609|OTHER|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
219223767|NCT02773225|DRUG|Placebo (for Eltrombopag)|"* CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --\> dose escalation~* 12 month after start of eltrombopag --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
219223768|NCT06469554|BEHAVIORAL|MEP-only group|Participants in this group will receive a Multicomponent Exercise Program (MEP) consisting of: Supervised aerobic training on a stationary bike Progressive resistance/strength training using weight machines Balance training exercises The MEP sessions will be 30-40 minutes long and conducted over 4 consecutive days.
219223769|NCT06469554|BEHAVIORAL|MEP-VR group|"Participants in this group will receive the same MEP intervention as the MEP-only group.~Additionally, they will use an immersive virtual reality (IVR) system during the exercise program"
219101139|NCT03350243|OTHER|CCENT Intervention|"1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
219101140|NCT05345288|DEVICE|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
219223770|NCT06749119|PROCEDURE|Free gingival graft operation|Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .
219101141|NCT05345288|DEVICE|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
219101142|NCT05433155|DEVICE|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
219688080|NCT02983045|DRUG|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
219688081|NCT02983045|DRUG|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
219688082|NCT02983045|DRUG|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
219688083|NCT02186977|DEVICE|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
219688084|NCT02186977|DRUG|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
219688085|NCT02186977|DRUG|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
219688086|NCT02658669|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
219688087|NCT02658669|BEHAVIORAL|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
219101143|NCT05230979|OTHER|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
219223771|NCT06768411|DRUG|PEG-rhGH|1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH
219223772|NCT06768411|DRUG|GnRHa|"1. pubertal children of short stature without GnRHa treatment~2. pubertal children of short stature with GnRHa treatment"
219223773|NCT06751186|BEHAVIORAL|Teté Dance Guided Support|A culturally tailored behavioral intervention combining physical activity and community engagement to support breastfeeding practices.
219688088|NCT02732392|PROCEDURE|standard lymphadenectomy|
219688089|NCT02732392|PROCEDURE|lymphadenectomy radio-isotope method|
219688090|NCT02932800|PROCEDURE|"Fixation with ballerina technique and flip"|
219688091|NCT02932800|PROCEDURE|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
219101144|NCT05230979|OTHER|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
219101145|NCT05230979|OTHER|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
219101146|NCT05230979|OTHER|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
219101147|NCT05230979|OTHER|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
219223774|NCT06759441|BEHAVIORAL|Reframe-It+|Reframe-IT+ is an individual intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, which is carried out at the Educational Establishment with a trained psychologist. It consists of 13 weekly sessions of 25 minutes each, of which 5 sessions have a face-to-face component and 8 sessions have a face-to-face-digital component where students use a computer always in the company of a psychologist facilitating the program.
219223775|NCT06647979|BIOLOGICAL|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein
219223776|NCT06647979|DEVICE|Sequencing Assay for Variant rs114518452|Device used to carry out the diagnostic testing for exclusion criteria number 12
219688092|NCT02932800|OTHER|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
219688093|NCT01396889|DRUG|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
219688094|NCT01396889|DRUG|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
219688095|NCT03132090|DIAGNOSTIC_TEST|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
219688096|NCT00419042|DRUG|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
219688097|NCT00419042|DRUG|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
219688098|NCT03752879|PROCEDURE|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
219688099|NCT05391997|OTHER|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
219688100|NCT05391997|OTHER|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
219688101|NCT04211012|DRUG|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
219688102|NCT06117696|OTHER|Animated video|delivery of written and oral information, supported by animated videos.
219688103|NCT02240017|DRUG|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
219688104|NCT02240017|DRUG|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
219101148|NCT05230979|OTHER|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
219101149|NCT06354335|OTHER|Employees exposed to a major hospital reorganisation|Occupational exposure
219101150|NCT05320016|DRUG|Remimazolam|Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
219101151|NCT04294394|OTHER|rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
219101152|NCT04294394|OTHER|erector spinae block|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area
219101153|NCT04294394|OTHER|control|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
219223777|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 1|Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
219688105|NCT02240017|DRUG|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
219688106|NCT06218615|OTHER|Educational Intervention (Video)|Watch video
219688107|NCT06218615|OTHER|Survey Administration|Answer survey questions
219101154|NCT06464471|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
219101155|NCT04636606|PROCEDURE|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
219688108|NCT02078193|DRUG|Belatacept|Patients will be converted from their MMF to Belatacept
219688109|NCT03764280|OTHER|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
219688110|NCT03773289|OTHER|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
219688111|NCT02589470|OTHER|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
219688112|NCT02830412|OTHER|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
219688113|NCT01028729|DRUG|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
219688114|NCT01028729|DRUG|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
219688115|NCT02205372|DRUG|MT-3995|
219688116|NCT02205372|DRUG|Placebo|
219688117|NCT04175275|OTHER|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
219688118|NCT04238377|PROCEDURE|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
219688119|NCT04238377|DRUG|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
219688120|NCT02245165|BIOLOGICAL|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
219688121|NCT02245165|BIOLOGICAL|saline|
219688122|NCT03740269|OTHER|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
219688123|NCT05399797|OTHER|Educational training|Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
219688124|NCT05507892|DRUG|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
219688125|NCT05507892|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
219688126|NCT02208544|PROCEDURE|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
219688127|NCT02208544|DEVICE|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
219688128|NCT02208544|RADIATION|FDG-PET/CT|Head and Neck FDG-PET/CT
219688129|NCT01575171|BEHAVIORAL|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
219688130|NCT00300222|DRUG|NGX-4010|
219223778|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 2|Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
219223779|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 3|Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
219223780|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 4|Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
219223781|NCT06821373|BEHAVIORAL|Chatbot|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
219223782|NCT06821373|BEHAVIORAL|Control|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
219688131|NCT01442662|DRUG|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
219688132|NCT03421379|DRUG|Glucagon Nasal Powder|Administered intranasally
219688133|NCT03421379|DRUG|Glucagon Hydrochloride Solution|Administered IM
219223783|NCT02864550|DRUG|Doxycycline|doxycycline 100mg orally daily
219223784|NCT02864550|OTHER|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
219223785|NCT06683989|OTHER|Pilates training|One hour of Pilates training was conducted for eight weeks, two days a week. Every training session was carried out by a certified and experienced physiotherapist from the Australian Institute of Pilates and Physiotherapy. The one-hour session was structured as a warm-up, a cool-down, and Pilates exercises.
219688134|NCT05113680|BEHAVIORAL|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
219688135|NCT05113680|BEHAVIORAL|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
219688136|NCT02782741|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
219688137|NCT02782741|DRUG|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
219688138|NCT06145503|DEVICE|Dance Intervention Group|The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
219688139|NCT04157088|DRUG|Darolutamide (Nubeqa, BAY1841788)|600mg, twice daily
219688140|NCT04157088|DRUG|Enzalutamide|160mg, once daily
219223786|NCT06683989|OTHER|Prenatal care|Regular prenatal care for participants in the CG included standard nursing and medical treatments.
219688141|NCT04292210|DEVICE|Perisafe|A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
219223787|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
219223788|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
219223789|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
219223790|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
219688142|NCT03663296|OTHER|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
219688143|NCT00035178|DRUG|Argatroban|
219688144|NCT00201019|BEHAVIORAL|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
219688145|NCT06074783|BIOLOGICAL|Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)|50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
219688146|NCT02105233|BIOLOGICAL|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
219688147|NCT01136252|DRUG|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
219688148|NCT00908414|DRUG|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
219688149|NCT00908414|DRUG|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
219688150|NCT00908414|DRUG|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
219688151|NCT00908414|DRUG|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
219688152|NCT00908414|DRUG|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
219688153|NCT00908414|DRUG|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
219688154|NCT00908414|DRUG|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
219688155|NCT00908414|DRUG|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
219688156|NCT00908414|DRUG|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
219688157|NCT00908414|DRUG|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
219688158|NCT00908414|DRUG|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
219688159|NCT00908414|DRUG|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
219101156|NCT04636606|PROCEDURE|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
219101157|NCT04636606|PROCEDURE|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
219101158|NCT02914379|DRUG|[¹⁴C]-LY3337641|Administered orally
219101159|NCT02746042|DRUG|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
219101160|NCT02746042|DRUG|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
219101161|NCT01515189|BIOLOGICAL|Ipilimumab|
219101162|NCT03787680|DRUG|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
219101163|NCT03787680|DRUG|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
219101164|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
219688160|NCT00908414|DRUG|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
219688161|NCT00908414|DRUG|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
219688162|NCT00908414|DRUG|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
219688163|NCT00908414|DRUG|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
219688164|NCT00908414|DRUG|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
219101165|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
219101166|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
219101167|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
219101168|NCT00702416|PROCEDURE|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
219688165|NCT00992017|BIOLOGICAL|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
219688166|NCT02992119|BIOLOGICAL|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
219101169|NCT00702416|PROCEDURE|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current \<0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
219688167|NCT02992119|BIOLOGICAL|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
219688168|NCT02992119|BIOLOGICAL|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
219101170|NCT00702416|DRUG|Ropivacaine|"Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min"
219101171|NCT00702416|DRUG|Paracetamol|1 g iv q8h
219101172|NCT00702416|DRUG|Morphine|5 mg im prn q1h (in the postoperative period)
219101173|NCT00702416|DRUG|Fentanyl|50 µg iv prn (in the intraoperative period)
219688169|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
219688170|NCT02992119|BIOLOGICAL|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
219101174|NCT00702416|PROCEDURE|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
219235378|NCT02054442|DRUG|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
219235379|NCT02054442|DRUG|Methotrexate|
219688171|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
219688172|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
219688173|NCT02701725|DEVICE|CRI status|Measurement of CRI
219688174|NCT03620188|OTHER|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
219101175|NCT06082414|OTHER|no interventions|no interventions because of an observational study
219688175|NCT02721615|PROCEDURE|Insertion of intra spinal sub dural pressure monitor|
219688176|NCT02721615|PROCEDURE|Insertion of sub dural microdialysis probe|
219688177|NCT01720316|DRUG|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
219688178|NCT01720316|DRUG|placebo|
219688179|NCT01735149|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
219688180|NCT01735149|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
219688181|NCT03923153|DEVICE|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
219688182|NCT03923153|DEVICE|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
219688183|NCT03438201|DIETARY_SUPPLEMENT|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
219688184|NCT03438201|DIETARY_SUPPLEMENT|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
219688185|NCT04793984|DEVICE|Carragelose|inhalation 3 times a day
219688186|NCT04793984|DEVICE|NaCl|inhalation 3 times a day
219688187|NCT05292885|DIAGNOSTIC_TEST|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
219688188|NCT01264809|BEHAVIORAL|Specific consultation for physical activity counseling|Specific consultation
219688189|NCT01264809|BEHAVIORAL|Consultation for physical activity counseling|Specific consultation
219688190|NCT05200585|BEHAVIORAL|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
219688191|NCT05200585|BEHAVIORAL|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
219688192|NCT02267915|DRUG|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
219688193|NCT06128421|DIETARY_SUPPLEMENT|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
219688194|NCT01104883|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
219688195|NCT01104883|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
219688196|NCT00446017|DRUG|adrenaline|
219688197|NCT00446017|DRUG|milrinone|
219688198|NCT03356600|COMBINATION_PRODUCT|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
219688199|NCT02155985|DRUG|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
219688200|NCT02155985|DRUG|Placebo|Placebo for aspirin
219688201|NCT03110133|DRUG|Full Spectrum Microbiota|Orally administered donor derived microbiota
219688202|NCT03110133|DRUG|Placebo|Placebo for CP101
219688203|NCT02998151|DRUG|Acamprosate|two 666mg pills
219688204|NCT02998151|DRUG|Lovastatin|two 20mg pills
219688205|NCT02998151|DRUG|Minocycline|two 135mg pills
219688206|NCT02998151|DRUG|Placebo|placebo pill
219688207|NCT02998151|DRUG|Baclofen|one 30mg pill
219688208|NCT02573259|DRUG|PF-06801591|IV every 21 days (Part 1)
219688209|NCT02573259|DRUG|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
219688210|NCT05347810|OTHER|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
219688211|NCT02864732|OTHER|Rehabilitation exercises|
219688212|NCT02864732|DEVICE|Electrical Stimulation|
219688213|NCT02316639|OTHER|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
219688214|NCT04143191|DRUG|Sorafenib|Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
219688215|NCT04143191|PROCEDURE|Transarterial chemoembolization|TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
219688216|NCT04273516|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
219688217|NCT04273516|DRUG|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
219688218|NCT03588858|OTHER|structured interview questionnaires|"* Module (1): Socio-demographic characteristics~* Module (2) :Occupational history~* Module (3): Presence of work related injuries and diseases by history and observation.~* Module (4): Food frequency questionnaires (FFQ) during the past week.~* Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
219688219|NCT04776577|DEVICE|Wirecath@ and Abbott PressureWire® (20 patients)|Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
219688220|NCT04776577|DEVICE|Wirecath® (20 patients)|FFR measurement with Wirecath® only
219688221|NCT04776577|DEVICE|Coronary flow reserve|Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
219688222|NCT02665819|OTHER|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
219688223|NCT05254899|DRUG|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
219688224|NCT05254899|DRUG|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
219688225|NCT05254899|DRUG|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
219688226|NCT05254899|DRUG|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
219688227|NCT05254899|RADIATION|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
219688228|NCT04621058|DRUG|Vitamin D|In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
219688229|NCT04621058|DRUG|PLACEBO|Placebo capsules exactly the same as the above, but without the active component.
219688230|NCT02472262|DIETARY_SUPPLEMENT|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
219688231|NCT02472262|DIETARY_SUPPLEMENT|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
219688232|NCT02472262|DIETARY_SUPPLEMENT|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
219688233|NCT05936814|PROCEDURE|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
219688234|NCT02571764|OTHER|Nutritional Oats Cookie|
219688235|NCT05940415|BEHAVIORAL|active surveillance|active surveillance without prostate biopsy
219688236|NCT01146847|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
219688237|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
219688238|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
219688239|NCT05547256|DRUG|Placebo|Saline solution
219688240|NCT03279809|DRUG|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
219688241|NCT03279809|DRUG|Placebo|Case with placebo medication for 6 months after stenting
219688242|NCT02852421|PROCEDURE|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
219688243|NCT02852421|PROCEDURE|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
219688244|NCT03516565|OTHER|Saliva collection|
219688245|NCT03516565|OTHER|GCF collection|
219101176|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
219223791|NCT03909347|BEHAVIORAL|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
219688246|NCT01305707|DEVICE|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
219688247|NCT01305707|DRUG|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
219688248|NCT00090909|DRUG|cisplatin|
219688249|NCT00090909|DRUG|dexamethasone|
219688250|NCT00090909|DRUG|gemcitabine hydrochloride|
219235380|NCT05500261|DRUG|Dexmedetomidine|intranasal administration of dexmedetomidine
219688251|NCT04264845|OTHER|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
219101177|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
219688252|NCT04264845|OTHER|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
219688253|NCT04264845|OTHER|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
219688254|NCT02021214|DRUG|Methylphenidate|
219688255|NCT02021214|DRUG|Placebo|
219688256|NCT05914350|PROCEDURE|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
219688257|NCT05914350|DRUG|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
219688258|NCT05914350|DRUG|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
219688259|NCT05914350|DRUG|medical ozone|10 ml of medical ozone
219688260|NCT01153607|DRUG|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
219688261|NCT01153607|DRUG|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
219688262|NCT01153607|DRUG|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
219688263|NCT01803659|DIETARY_SUPPLEMENT|b-carotene|
219688264|NCT01803659|DIETARY_SUPPLEMENT|retinyl palmitate|
219688265|NCT01803659|DIETARY_SUPPLEMENT|placebo|
219688266|NCT01817075|PROCEDURE|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
219688267|NCT01817075|OTHER|Laboratory Biomarker Analysis|Correlative studies
219688268|NCT01817075|PROCEDURE|Mild Soap Skin Cleanser|Given control cleansing
219688269|NCT01817075|OTHER|Questionnaire Administration|Ancillary studies
219688270|NCT03889249|DRUG|Tenecteplase|Stroke Thrombolytic
219688271|NCT03889249|DRUG|Alteplase|Stroke Thrombolytic
219688272|NCT03758599|PROCEDURE|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
219688273|NCT03758599|PROCEDURE|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
219688274|NCT03758599|PROCEDURE|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
219688275|NCT06611670|DEVICE|Cataract surgery with Active Sentry|Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.
219688276|NCT06611670|PROCEDURE|Traditional cataract surgery|Cataract surgery performed with high intraocular pressures
219688277|NCT06611449|OTHER|The minimal flow anesthesia with sevoflurane group|"In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
219101178|NCT05120648|BEHAVIORAL|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
219101179|NCT04706130|DRUG|Primaquine|After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
219101180|NCT04706130|DRUG|Artesunate|All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
219101181|NCT05654168|DIAGNOSTIC_TEST|Imaging|The thickness of the musculature to be studied will be measured with ultrasonography
219235381|NCT00399828|DEVICE|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
219235382|NCT00836537|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
219688278|NCT06611449|OTHER|The high flow anesthesia with sevoflurane group|"Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
219101182|NCT05229653|DRUG|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
219101183|NCT05229653|DRUG|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
219101184|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
219101185|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
219688279|NCT05212168|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
219688280|NCT05212168|OTHER|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
219688281|NCT05212168|BIOLOGICAL|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
219101186|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
219101187|NCT06023901|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
219101188|NCT05997290|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|BNT162b2 monovalent (Omicron XBB.1.5)
219688282|NCT03574974|DEVICE|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
219688283|NCT03574974|DEVICE|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
219101189|NCT05997290|BIOLOGICAL|BNT162b2 (Omi JN.1)|BNT162b2 monovalent (Omicron JN.1)
219688284|NCT06082726|DIETARY_SUPPLEMENT|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
219688285|NCT06729528|DIAGNOSTIC_TEST|The PePCI and ManTIS scores|The PePCI and ManTIS scores have been developed to predict the indication for whole-body CT in pediatric cases presenting to the emergency department with trauma. These scores help reduce unnecessary radiation exposure in pediatric trauma cases.
219101190|NCT05997290|BIOLOGICAL|BNT162b2 (Omi KP.2)|BNT162b2 monovalent (Omicron KP.2)
219101191|NCT00594217|DRUG|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
219223792|NCT03909347|BEHAVIORAL|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
219223793|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
219223794|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
219688286|NCT00564941|DRUG|deferasirox|
219688287|NCT02194894|DRUG|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
219688288|NCT03206827|OTHER|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
219101192|NCT00594217|OTHER|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
219101193|NCT00856947|DIETARY_SUPPLEMENT|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
219101194|NCT00856947|OTHER|Placebo tablet|2 tablets containing no active substance
219101195|NCT04949711|BEHAVIORAL|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
219223795|NCT03343704|DRUG|Idarucizumab|Intravenous
219223796|NCT06754059|DRUG|Pyrotinib|In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
219223797|NCT06757686|DEVICE|Mousetrap appliance|two mini-implant will be inserted in the palate. then, the mousetrap appliance will be inserted on the mini-implant and activated with power chain.
219235383|NCT00836537|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
219101196|NCT04949711|BEHAVIORAL|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
219688289|NCT03206827|OTHER|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
219688290|NCT03206827|OTHER|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
219688291|NCT01502488|PROCEDURE|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
219688292|NCT03013192|OTHER|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
219688293|NCT03921476|OTHER|Online survey|Online survey completion through Northwestern's REDCap
219688294|NCT01039779|BEHAVIORAL|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
219688295|NCT04385979|OTHER|Gel|containing herbal Curcumin or NanoCurcumin
219688296|NCT00433433|DRUG|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
219688297|NCT00433433|DRUG|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l
219688298|NCT00433433|RADIATION|IN-RT 30 Gy (+ boost 6 Gy residual)|
219688299|NCT00433433|PROCEDURE|FDG-PET scan|
219688300|NCT04367662|PROCEDURE|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
219688301|NCT00616746|DRUG|Nicotine|1.0 microg/kg/min IV x 10 minutes
219688302|NCT00616746|DRUG|Ethanol|IV
219688303|NCT07073300|DEVICE|Endoscopy|Upper Endoscopy and colonoscopy will be used
219688304|NCT06732180|DRUG|GT-02287|Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
219688305|NCT05732831|DRUG|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
219688306|NCT05732831|DRUG|Pembrolizumab|An anti PD-1 antibody, will be administered intravenously
219688307|NCT00496704|DRUG|capecitabine|
219688308|NCT00496704|DRUG|gemcitabine hydrochloride|
219688309|NCT00496704|DRUG|oxaliplatin|
219688310|NCT03066037|PROCEDURE|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
219688311|NCT06949683|BEHAVIORAL|Meal-Exercise|Breakfast intake before 22 minutes of brisk walking, followed by a lunch intake for another 75 minutes of observation period. The entire experiment lasted a total of 150 minutes.
219688312|NCT06949683|BEHAVIORAL|Exercise-Meal|22 minutes of brisk walking before breakfast intake, followed by 75 minutes of observational period. The entire experiment lasted a total of 150 minutes
219688313|NCT06956027|DIAGNOSTIC_TEST|Ultrasound assesment|Ultrasound image taken using MV-flow technique for measuring the distance skin-lesion and echogenicity measurement
219688314|NCT06956027|PROCEDURE|ROM measurement|Range Of Motion measurement of affected finger(s) where the ultrasound image will be taken from.
219101197|NCT05672680|DRUG|0.25% Bupivacaine|received during TAP block
219101198|NCT05672680|DRUG|Placebo|placebo equivalent
219101199|NCT05672680|PROCEDURE|TAP block|The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
219101200|NCT04974398|DRUG|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) +cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per cycle; followed by penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment.
219101201|NCT04974398|DRUG|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per cycle; followed by placebo(200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment. Subjects in Arm B will have the opportunity to crossover to openlabel treatment with penpulimab monotherapy after radiographic disease progression.
219223798|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
219223799|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
219223800|NCT06508437|BIOLOGICAL|Influenza Vaccination|Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe
219223801|NCT06756386|DEVICE|extra corporeal shock wave therapy (ESWT )|Using wound area measurements and histological/immunohistochemical analysis of wound biopsies, we show ESWT enhanced healing of chronic ulcers associated with improved wound angiogenesis ), significantly decreased-positive macrophages per biopsy area and generally increased macrophage activity ,this activity prevent bacterial infection which delay healing
219223802|NCT06756386|DEVICE|Low Level Laser Therapy|"Low-level laser therapy (LLLT) has been used as an adjuvant to conventional therapy with promising results,improve healing by delivering nutrient substances , especially in patients with acute and bloody ulcers.~Positive effects include acceleration of tissue repair, increased formation of granulation tissue, wound contraction, inflammation modulation, and pain reduction The biochemical effects of LLLT are associated with the release of preformed substances (histamine, serotonin, and bradykinin), which stimulate the production of ATP and inhibit the production of prostaglandins."
219223803|NCT06756386|OTHER|conservative treatments|( compression pandaging, lifestyle changes, physical activities)
219688315|NCT06955390|DRUG|SHR-A2102+HRS-4642|A fixed dose was used for SHR-A2102,HRS-4642 can be dose adjusted.
219688316|NCT06955559|DRUG|Magnesium sulfate|inhaled magnesium sulfate (MgSO4)
219688317|NCT06954883|BEHAVIORAL|Augmented Reality Distraction|Participants in this group wore augmented reality (AR) goggles during local anesthesia administration and dental extraction. The AR system displayed interactive 3D animated videos (celestial bodies) to divert attention and reduce procedural pain and anxiety.
219688318|NCT06955507|BEHAVIORAL|reflexology|Foot reflexology will be applied by the researcher Neziha BAYAZIT, who will receive training on this subject, in the quietest and most comfortable position possible. Foot reflexology will be applied by the researcher to the women in the experimental group. The researcher will receive training on foot reflexology before the study. In the clinic where the study will be conducted, the hours of foot reflexology application will be determined considering the analgesic treatment protocol applied. Accordingly, analgesic treatment is routinely applied to the women who will receive foot reflexology at the 4th hour according to hospital procedure. Foot reflexology will be applied by the researcher at least 1 hour before the analgesic treatment (3rd hour - 15th hour after birth). The same foot reflexology will be repeated 12 hours later at the 15th hour after the first foot reflexology is performed at the 3rd hour after birth. Each woman will be given an explanation before the application. Foot r
219688319|NCT06955767|OTHER|Blood will be drawn from 2 additional tubes of 5 ml each|Blood will be drawn from 2 additional tubes of 5 ml each
219688320|NCT06955949|OTHER|Control Group|The control classes applied the drugs by doing home training with eccentric strengthening exercises with dumbbells (3 sets of 10 repetitions). They were asked to flex the wrist while the wrist was fully extended. Weights were given to strengthen the wrist extensor muscles with 0.5 kg in the first week, 1 kg in the second week and 1.5 kg in the third week. In addition, stretching exercises for the wrist extensor muscles (3 sets of 20 seconds) were performed and 20 seconds of rest were given between sets. After the exercises, we applied cold therapy for 15 minutes. All treatment types were treated by the same physiotherapist in accordance with the treatment protocols and treatment sessions were performed twice a week for 3 weeks. One session lasted between 35-45 minutes.
219688321|NCT06955949|OTHER|ESWT Group|Extracorporeal Shock Wave Therapy (ESWT) is palpated at the starting areas of the extensor carpi radialis brevis and longus muscles, at tender points, and placed at the bone-tendon junctions. This budget was set at 90 Hz, and the pulse rate was determined as 10 pulses:1500.
219688322|NCT06955949|OTHER|Mobilization movement group|Mobilization Technique (lateral glide) was recorded from the Mulligan method. Patients were placed in supine positions, height was recorded together and the application was done with a belt method. During this glide movement, the patient was asked to actively perform 3 sets of 10 repetitions of wrist extension. 15-20 seconds of rest was given between sets.
219688323|NCT06955949|OTHER|Combined MWM-ESWT|In addition to mobilization with movement and ESWT treatment, this group applied home training by doing eccentric exercises with dumbbells (3 sets of 10 repetitions). 15-20 seconds of rest was given between sets. In addition, stretching exercises (3 sets of 20 seconds) were performed to strengthen the wrist extensor muscles and 20 seconds of rest was given between sets. During the exercises, a position was given such that the elbow was in extension, the forearm was in pronation and the wrist was in ulnar deviation. We apply cold therapy for 15 minutes after the exercises.
219688324|NCT06955000|DEVICE|traidmail|Patients in this group were instructed to sit on a stationary bicycle ergometer. The patients will be given explained the aerobic interval exercise training program and the intensity will be assessed using a modified Borg scale
219688325|NCT06955000|DEVICE|laser puncture therapy|This group's patients were all exposed to LLLT utilising Phyaction CL Phyaction, Bilzen, Belgium, which had the following specs: frequency 500 Hz, output 5-20 MW, wavelength 905 nm. For five minutes, a laser probe was applied to acupuncture sites
219688326|NCT01023607|DRUG|Atorvastatin|Atorvastatin 20mg/day
219688327|NCT01023607|DRUG|Atorvastatin|Atorvastatin, 60mg/day
219688328|NCT01023607|DRUG|Rosuvastatin|Rosuvastatin,10mg/day
219688329|NCT02898857|OTHER|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
219688330|NCT04378712|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
219688331|NCT04378712|OTHER|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
219688332|NCT00334789|DRUG|Belinostat|Given IV
219688333|NCT00334789|DRUG|Isotretinoin|Given orally
219688334|NCT00334789|OTHER|Pharmacological Study|Correlative studies
219688335|NCT02861508|OTHER|Point-of-care ultrasound|
219688336|NCT02861508|OTHER|Usual care|
219688337|NCT00105612|DEVICE|Memory and Organizational Aid|
219688338|NCT00105612|BEHAVIORAL|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
219688339|NCT01621386|DRUG|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
219688340|NCT01621386|DRUG|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
219688341|NCT05874232|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
219688342|NCT05468255|OTHER|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
219688343|NCT03904823|DRUG|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
219101202|NCT06562842|OTHER|Regular exercise|Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.
219101203|NCT06562842|OTHER|Control comparator|Participants will remain sedentary throughout the 16-weeks intervention period.
219101204|NCT03635489|DRUG|Paclitaxel|175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
219688344|NCT03904823|DRUG|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
219101205|NCT03635489|DRUG|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
219101206|NCT03635489|DRUG|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
219101207|NCT03635489|DRUG|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
219101208|NCT01454453|DRUG|Patients- dose titration|dose titration (patients) - 4-10 weeks
219101209|NCT05078060|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
219101210|NCT05078060|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
219101211|NCT03167684|DEVICE|Oral appliance therapy|Fitted oral appliance
219688345|NCT03979066|DRUG|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
219688346|NCT03979066|DRUG|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
219101212|NCT04822844|OTHER|Lavender Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
219101213|NCT04822844|OTHER|Ginger Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
219688347|NCT03308422|BEHAVIORAL|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
219688348|NCT00913549|DRUG|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
219688349|NCT00913549|DRUG|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
219688350|NCT06106230|COMBINATION_PRODUCT|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
219688351|NCT03934216|DRUG|BMS-986165|Specified Dose on Specified Days
219688352|NCT03934216|OTHER|Placebo|Specified Dose on Specified Days
219688353|NCT04131920|DEVICE|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
219688354|NCT00243009|DRUG|cyclosporine|
219688355|NCT00243009|DRUG|fludarabine phosphate|
219688356|NCT00243009|DRUG|mycophenolate mofetil|
219223804|NCT06929286|DRUG|Nadofaragene Firadenovec|For patients randomized to receive nadofaragene firadenovec, the patient will receive nadofaragene firadenovec as of normal saline instilled intravesically every 3 months for up to 12 months.
219223805|NCT06929286|DRUG|Gemcitabine|gemcitabine instilled intravesically for 1 h, then drained completely out of the bladder
219688357|NCT00243009|PROCEDURE|allogeneic bone marrow transplantation|
219688358|NCT00243009|PROCEDURE|peripheral blood stem cell transplantation|
219688359|NCT00243009|RADIATION|radiation therapy|
219688360|NCT04021966|PROCEDURE|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
219688361|NCT02696824|BEHAVIORAL|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
219688362|NCT00619827|DRUG|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
219688363|NCT00619827|DRUG|Placebo tablet|Placebo tablet once daily during four months
219688364|NCT01063855|DRUG|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
219101214|NCT04957862|PROCEDURE|Robotic Assisted Evacuation|On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
219101215|NCT06374940|PROCEDURE|Manipulator-assisted Abdominal Hysterectomy|Manipulator-assisted Abdominal Hysterectomy
219101216|NCT00943306|DRUG|lomitapide|5-60 mg po every day
219101217|NCT04531163|DRUG|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
219101218|NCT05765864|DIAGNOSTIC_TEST|Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3|The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
219101219|NCT05765864|DIAGNOSTIC_TEST|Columbia Suicide Severity Rating Scale (CSSRS)|"The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77."
219101220|NCT05765864|DIAGNOSTIC_TEST|The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)|"used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46."
219688365|NCT01063855|DRUG|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
219688366|NCT01063855|DRUG|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
219688367|NCT00434031|DRUG|docetaxel|
219688368|NCT00434031|DRUG|cyclophosphamide|
219688369|NCT00434031|DRUG|trastuzumab|
219688370|NCT00434031|DRUG|liposomal doxorubicin|
219688371|NCT00004246|DRUG|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
219688372|NCT00004246|RADIATION|Radiation Therapy (RT)|Days 1-5 for 7 weeks
219688373|NCT03632564|DEVICE|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
219688374|NCT03087305|DIAGNOSTIC_TEST|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
219101221|NCT05765864|DIAGNOSTIC_TEST|Experiences in Close Relationships-Relationship Structures (ECR-RS)|"Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65."
219101222|NCT05765864|DIAGNOSTIC_TEST|Trauma Symptom Checklist for Children (TSCC)|"The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx"
219101223|NCT05765864|DIAGNOSTIC_TEST|Personality Assessment Inventory-Adolescent (PAI-A)|"An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx"
219101224|NCT05765864|DIAGNOSTIC_TEST|Inventory Of Statements About Self-Injury; ISAS|"A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669."
219101225|NCT05765864|DIAGNOSTIC_TEST|The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0|"A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14."
219101226|NCT05765864|DIAGNOSTIC_TEST|Borderline Personality Features Scale, BPFSC-11|"The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78."
219223806|NCT06929286|DRUG|Docetaxel|followed by docetaxel instilled intravesically for 1 h. This is given once weekly for 6 weeks for induction. Those who have a complete response typically proceed with once-monthly instillations of GemDoce for up to 24 months as maintenance therapy
219223807|NCT07087145|DIAGNOSTIC_TEST|Mail-based Saliva Sample Kit|Sent via United States Postal Service and returned via FedEx
219223808|NCT07087145|OTHER|Study-related Surveys|Online surveys will be administered
219223809|NCT06743568|DEVICE|Transcatheter aortic valve replacement|Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.
219223810|NCT06890117|DEVICE|Ultrasonic Scalers with EMS PI tip and Saline Irrigation|Control Group: Non-surgical peri-implantitis treatment using ultrasonic scalers and EMS PI tips designed for implants, combined with saline irrigation to remove plaque and biofilm from implant surfaces.
219223811|NCT06890117|DEVICE|Er:YAG (2940nm) and Diode (808nm) Laser|Experimental Group: Non-surgical peri-implantitis treatment using Er:YAG laser (2940nm) and Diode laser (808nm) for decontamination of the implant surface and surrounding tissues. The Er:YAG laser is used for mechanical debridement and biofilm removal, while the Diode laser has biostimulatory effects.
219223812|NCT04564547|DRUG|Islatravir|ISL capsule taken by mouth.
219101227|NCT05765864|OTHER|Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)|"It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404."
219101228|NCT05765864|OTHER|Adolescent Self-Harm Risk Scale; ASHRS|It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).
219101229|NCT05765864|DIAGNOSTIC_TEST|Lifetime Incidence of Traumatic Events questionnaire (LITE)|"Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315"
219101230|NCT05765864|GENETIC|Genetic methods|DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
219101231|NCT04987190|PROCEDURE|alveolar bone graft|alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
219101232|NCT00372801|DRUG|Ibuprofen|
219101233|NCT01847170|BIOLOGICAL|Fecal Microbial Transplantation|
219101234|NCT02323087|DEVICE|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
219223813|NCT04564547|DRUG|Ulonivirine|Ulonivirine tablet taken by mouth.
219223814|NCT04564547|DRUG|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
219223815|NCT04564547|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
219223816|NCT04564547|DRUG|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
219223817|NCT04564547|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
219223818|NCT03728335|DRUG|Enasidenib Mesylate|Given PO
219688375|NCT02472730|DEVICE|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
219223819|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
219223820|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
219223821|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
219223822|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
219688376|NCT02484144|OTHER|modern information|information by video for coronarography
219688377|NCT02484144|OTHER|usual information|usual information for coronarography
219688378|NCT02163395|DEVICE|FullCeram implant|FullCeram implantation
219688379|NCT02976311|PROCEDURE|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
219688380|NCT02976311|PROCEDURE|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
219688381|NCT04348526|PROCEDURE|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
219688382|NCT04348526|PROCEDURE|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
219688383|NCT04078620|DIAGNOSTIC_TEST|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
219688384|NCT01241474|DIETARY_SUPPLEMENT|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
219688385|NCT01241474|DIETARY_SUPPLEMENT|Maize (corn) oil|6 x 1g capsules per day for 9 months
219688386|NCT01195649|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
219223823|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
219688387|NCT05020041|BEHAVIORAL|Physical activity|"The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance."
219688388|NCT02536872|OTHER|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
219688389|NCT06321822|DIAGNOSTIC_TEST|Whole exome sequencing (WES)|Patient selected for genetic study will undergo blood sample collection for DNA estraction, biobank storage and WES study
219688390|NCT03080740|DRUG|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
219688391|NCT03080740|DRUG|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
219688392|NCT05324319|DRUG|Ad26COVS1|Heterologous vaccination
219688393|NCT05324319|DRUG|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
219688394|NCT05324319|DRUG|BNT162B2|Homologous vaccination
219688395|NCT05324319|DRUG|mRNA-1273|Homologous vaccination
219688396|NCT06253936|OTHER|Magnetic Resonance Venography|Detect the anatomical variants of dural sinuses by Magnetic Resonance Venography
219688397|NCT01401595|DRUG|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
219688398|NCT02084524|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
219688399|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
219688400|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
219688401|NCT01950299|DRUG|Placebo|Placebo 0.67 ml injections twice daily
219688402|NCT01389739|OTHER|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
219688403|NCT00005868|DRUG|cisplatin|
219688404|NCT00005868|DRUG|docetaxel|
219688405|NCT06550843|PROCEDURE|mesentery-guided division|In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
219688406|NCT06958770|DIAGNOSTIC_TEST|Electrical impedance tomography|"* Electrical impedance tomography (EIT)：Assessing pulmonary function in chronic lung diseases.~* Lung ultrasound：Assessing diaphragm atrophy in mechanically ventilated patients.~* Esophageal pressure：The work of breathing, or the energy required by respiratory muscles to meet ventilatory demands, can be directly evaluated by esophageal pressure~* Oxygen consumption：Indirectly evaluated by measuring oxygen consumption (V̇O2) during mechanical ventilation The oxygen cost of breathing, reflected the increase in V̇O2 when transitioning from mechanical ventilation to spontaneous breathing, has been shown to predict weaning outcomes."
219688407|NCT01960101|OTHER|LactoXeros|
219688408|NCT01960101|DEVICE|Aequasyal|
219688409|NCT06958575|PROCEDURE|Septal extension graft|Septal extension graft will be used. The triangle-shaped cartilage graft prepared from the septal cartilage is placed into one or bothsides of the caudal septum reciprocally according to its structure and curvature and sutured with horizontal mattress sutures. After graft stabilization, two insulin needles are passed through the medial crura and the graft to determine its level of placement. After the rotation and nasal projection are adjusted, the medial crura are sutured to the septal graft.
219688410|NCT06958575|PROCEDURE|Columellar strut|Columellar strut graft will be used. A strut graft 1012 mm long is placed into a web created between the two medial crura and stabilized by sutures placed between the graft and medial crura.
219688411|NCT03041441|DEVICE|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
219223824|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
219223825|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
219223826|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
219223827|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
219223828|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
219688412|NCT03041441|PROCEDURE|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
219688413|NCT03041441|PROCEDURE|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
219688414|NCT06957964|OTHER|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is an intervention in which a suction is applied at applied thus creating a negative pressure which not only removes any exudate but also aids in formation of granulation tissue. NPWT is provided along with empirical prophylactic antibiotics
219688415|NCT06957964|DRUG|Standard Antibiotic Treatment|According to hospital antibiogram, empirical antibiotics are given prophylactically
219688416|NCT06958146|DRUG|oral azithromycin|we will be administering single-dose oral azithromycin to ladies who go into labor and have no risk factors for sepsis, as there is increased risk of postpartum sepsis in both mother and neonate after normal vaginal delivery in low-income and middle-income countries
219688417|NCT06958146|OTHER|no azithromycin|participants in this arm will be given only standard labor care and no oral azithromycin
219688418|NCT00807066|DRUG|Gefitinib|Gefitinib 250 mg/day
219688419|NCT00807066|DRUG|Platinum|Platinum based chemotherapy with cycles every 21 days
219688420|NCT03675646|DRUG|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
219688421|NCT05588531|DRUG|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
219223829|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
219223830|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
219688422|NCT05588531|DRUG|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
219688423|NCT05588531|DRUG|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
219688424|NCT05588531|DRUG|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
219688425|NCT05588531|DRUG|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
219688426|NCT05588531|DRUG|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
219688427|NCT05043740|DRUG|Repatha or Praluent|Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
219688428|NCT02505958|OTHER|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.
219688429|NCT02505958|OTHER|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
219688430|NCT01959113|BIOLOGICAL|Autologous Microbiome Transplant|
219688431|NCT01959113|OTHER|Placebo Arm|
219688432|NCT00710931|DEVICE|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
219101235|NCT02323087|DEVICE|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
219223831|NCT06892600|DRUG|Combined Spinal anesthesia (heavy bupivacaine 0.5%) and General anesthesia|Combined spinal and general anesthesia Spinal anesthesia with Bupivacaine heavy 0.5% 10 mg General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg
219223832|NCT06892600|DRUG|General Anesthesia (control group)|Lidocaine 1.5mg/kg, fentanyl 2 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg
219688433|NCT03566277|BEHAVIORAL|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
219688434|NCT03566277|BEHAVIORAL|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
219688435|NCT03566277|BEHAVIORAL|Feedback|Participants will receive text message feedback each day about progress towards their goal
219688436|NCT01608165|PROCEDURE|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
219688437|NCT01608165|PROCEDURE|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
219688438|NCT01608165|PROCEDURE|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
219688439|NCT03166020|OTHER|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
219688440|NCT00000795|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
219688441|NCT05906147|OTHER|Regular follow-up|Follow-up of the population was conducted to track the incidence of fractures
219101236|NCT04617132|BEHAVIORAL|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
219101237|NCT02168543|DRUG|Alendronate|
219688442|NCT00000687|DRUG|Interferon alfa-2a|
219688443|NCT00000687|DRUG|Zidovudine|
219688444|NCT05597995|DRUG|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
219688445|NCT04601168|DEVICE|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
219688446|NCT01045005|OTHER|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
219688447|NCT01045005|OTHER|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
219101238|NCT02168543|DRUG|Placebo|
219223833|NCT06191302|PROCEDURE|blood sample|Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.
219223834|NCT06191302|OTHER|Online questionaire|The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.
219688448|NCT02930057|DRUG|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
219688449|NCT02930057|PROCEDURE|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
219688450|NCT02930057|DRUG|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
219688451|NCT05687097|DEVICE|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
219688452|NCT05687097|DEVICE|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
219688453|NCT05687097|DEVICE|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
219688454|NCT04685993|DRUG|LPCN 1144|Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
219688455|NCT01480388|DRUG|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
219688456|NCT01480388|DRUG|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
219688457|NCT01480388|DRUG|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
219688458|NCT01480388|DRUG|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
219688459|NCT01480388|DRUG|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
219688460|NCT04776408|DEVICE|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
219688461|NCT04776408|DEVICE|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
219688462|NCT05492149|OTHER|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
219688463|NCT06018805|OTHER|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
219688464|NCT06018805|OTHER|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
219688465|NCT01854697|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219688466|NCT01854697|DRUG|Ribavirin|Tablet
219688467|NCT01854697|DRUG|Telaprevir|Film-coated tablet
219688468|NCT01854697|DRUG|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
219688469|NCT02335255|DRUG|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
219688470|NCT02335255|DRUG|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
219688471|NCT02335255|DRUG|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
219688472|NCT00179595|BEHAVIORAL|relaxation response- meditation|
219688473|NCT03186144|GENETIC|Blodd punction for genetic analysis|
219688474|NCT00166868|DRUG|Lactobacillus casei rhamnosus (Lcr35)|
219223835|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
219688475|NCT00166868|DRUG|Neomycin|
219101239|NCT01648621|BEHAVIORAL|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
219101240|NCT01648621|BEHAVIORAL|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
219101241|NCT01648621|BEHAVIORAL|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
219688476|NCT03175796|BEHAVIORAL|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
219101242|NCT01648621|BEHAVIORAL|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
219223836|NCT06909799|DRUG|N-Acetyl Cysteine (NAC)|NAC will be provided as 600 mg capsules from NOW Healthgroup. Standard TB treatment will be provided as fixed dose combination tablets.
219688477|NCT04839172|DIAGNOSTIC_TEST|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
219688478|NCT03900208|DIAGNOSTIC_TEST|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
219688479|NCT02539992|DEVICE|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
219688480|NCT02539992|DEVICE|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
219688481|NCT02539992|DEVICE|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
219688482|NCT04387123|PROCEDURE|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
219688483|NCT01240096|DRUG|Mirtazapine|Mirtazapine 15 mg daily
219688484|NCT04861142|DRUG|Anti-osteoporotic medication( alendronate or denosumab)|Initiation of anti-osteoporotic medication (alendronate or denosumab)
219688485|NCT00115778|DRUG|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
219688486|NCT00115778|OTHER|Placebo|0.1% Albumin in an equal volume to the investigational product
219688487|NCT04428385|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
219688488|NCT04428385|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
219688489|NCT00528424|BIOLOGICAL|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
219688490|NCT06086990|DEVICE|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
219688491|NCT00483652|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
219688492|NCT00483652|DRUG|Placebo|placebo (sugar pill)
219688493|NCT02548936|DRUG|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
219688494|NCT03255369|OTHER|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
219688495|NCT03326440|OTHER|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
219688496|NCT05673447|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10\^8, 1×10\^9, 1.5×10\^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
219688497|NCT02089477|OTHER|Support group|"The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
219688498|NCT03387605|DRUG|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
219688499|NCT03387605|DRUG|Placebo|matching placebo given 2 times daily for 72 hours
219688500|NCT00663650|PROCEDURE|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
219223837|NCT06909799|DRUG|Standard TB treatment|Standard TB treatment will be provided as fixed dose combination tablets.
219223838|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
219688501|NCT00663650|PROCEDURE|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
219688502|NCT00120692|DRUG|Darbepoetin Alfa|
219101243|NCT01648621|BEHAVIORAL|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness \[MRC\] Class 4 \& 5 or modified MRC \[mMRC\] 3 \& 4) f. frequent ED visits (\> 2) in last 12 months~5\. 12 weeks of clinical stability with no ED visits."
219101244|NCT01648621|BEHAVIORAL|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
219101245|NCT01648621|BEHAVIORAL|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
219101246|NCT01648621|BEHAVIORAL|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
219101247|NCT01648621|BEHAVIORAL|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate."
219101248|NCT01648621|BEHAVIORAL|Smoking cessation|Referral to a smoking cessation program (as applicable)
219101249|NCT01648621|BEHAVIORAL|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
219688503|NCT00120692|DRUG|Recombinant Human Erythropoietin|
219688504|NCT04282174|DEVICE|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
219688505|NCT04282174|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
219688506|NCT04282174|DRUG|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
219688507|NCT04282174|DRUG|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
219688508|NCT04282174|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
219688509|NCT04282174|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
219688510|NCT04282174|DRUG|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
219688511|NCT04282174|DRUG|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
219688512|NCT04366245|BIOLOGICAL|Hyperimmune plasma|PLASMA OF CONVALESCENT COVID-19
219688513|NCT04366245|DRUG|Standard of care for SARS-CoV-2 infection|Standard of care for SARS-CoV-2 infection
219688514|NCT02501824|OTHER|anthroposophic therapeutic speech|anthroposophic therapeutic speech
219688515|NCT02071459|DRUG|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
219688516|NCT02071459|DRUG|placebo|initial period (4 weeks) followed by 8 weeks
219688517|NCT02376504|BEHAVIORAL|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
219688518|NCT00468585|DRUG|Capecitabine|
219688519|NCT00468585|DRUG|Bevacizumab|
219688520|NCT04802499|PROCEDURE|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
219688521|NCT04101292|OTHER|Characterization of tumor tissue by fluorescence|"* HSI Imaging of the resected specimen, from the serum and the mucous side~* FF-OCT imaging of the tumor and the healthy tissue biopsies~* Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~* Standard anti-VEGF Immunohistochemistry and pathology"
219688522|NCT02154139|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
219688523|NCT03644771|DRUG|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
219688524|NCT04872088|BEHAVIORAL|Strengthened SBCC|Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
219688525|NCT04872088|DIETARY_SUPPLEMENT|Preventive nutritional supplement|"Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~\- \[6-17\]months old children diagnosed as non-wasted (MUAC\>=125mm)"
219688526|NCT04872088|BEHAVIORAL|Family MUAC|"MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family."
219688527|NCT04872088|BEHAVIORAL|Active screening by NASGs|"Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled."
219101250|NCT01648621|BEHAVIORAL|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
219101251|NCT01759654|BIOLOGICAL|AdimFlu-V|
219101252|NCT06245122|DRUG|CS23546|Tablets administered orally.
219101253|NCT00925821|PROCEDURE|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
219101254|NCT00925821|DRUG|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
219223839|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
219688528|NCT04872088|BEHAVIORAL|Intensified followup of children with wasting referred to and enrolled in CMAM treatment|NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
219688529|NCT04872088|BEHAVIORAL|Relapse prevention|NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
219688530|NCT04872088|BEHAVIORAL|Cooking demonstrations|NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
219688531|NCT02087774|BEHAVIORAL|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
219688532|NCT04581434|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
219688533|NCT04581434|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
219688534|NCT04581434|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation"
219688535|NCT00255619|DEVICE|Baxter's UltraBag® and FMC Andy·Disc®|
219688536|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
219688537|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
219688538|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
219688539|NCT05444790|DIAGNOSTIC_TEST|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
219688540|NCT03677635|BEHAVIORAL|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
219688541|NCT03478709|OTHER|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
219688542|NCT03478709|OTHER|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
219688543|NCT04036604|OTHER|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
219688544|NCT00496340|DRUG|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3."
219688545|NCT00496340|DRUG|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
219688546|NCT00496340|DRUG|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines."
219688547|NCT00496340|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
219688548|NCT00597818|DRUG|Cobiprostone|18 mcg cobiprostone capsules for oral administration
219688549|NCT00597818|DRUG|Placebo|Matching placebo capsules for oral administration
219688550|NCT00597818|DRUG|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
219688551|NCT02157519|OTHER|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
219688552|NCT01656395|DRUG|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
219223840|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
219223841|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
219223842|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
219101255|NCT03114917|OTHER|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
219101256|NCT00432081|DRUG|indomethacin|
219235384|NCT01883609|BIOLOGICAL|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
219688553|NCT01656395|DRUG|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
219688554|NCT01656395|DRUG|Placebo|Parts I-II: Participants will receive Placebo tablets QD
219688555|NCT03075267|DRUG|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
219688556|NCT03075267|DRUG|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
219688557|NCT03075267|DRUG|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
219688558|NCT02314858|BEHAVIORAL|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
219688559|NCT02314858|BEHAVIORAL|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
219688560|NCT02314858|BEHAVIORAL|Treatment as Usual (TAU)|The TAU group will not watch a video.
219688561|NCT00850369|OTHER|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
219688562|NCT02490826|OTHER|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
219688563|NCT02490826|OTHER|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
219688564|NCT06241911|DEVICE|transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
219688565|NCT03235037|DRUG|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
219688566|NCT00844402|DRUG|Atorvastatin|oral, 10 mg, daily, 48 weeks
219688567|NCT03506048|DRUG|Lenvatinib|Given orally once daily continuously
219688568|NCT02911649|OTHER|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
219688569|NCT02911649|OTHER|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
219688570|NCT02911649|OTHER|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
219688571|NCT02911649|OTHER|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
219688572|NCT06100536|BEHAVIORAL|Music-with-movement|The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
219688573|NCT04319393|BEHAVIORAL|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
219101257|NCT01036022|DRUG|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
219101258|NCT06391684|BEHAVIORAL|Social/non social; predictable vs unpredictable|Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
219101259|NCT04904822|PROCEDURE|Vaginal bisection|Uterine bisection vaginally by scalpel 24
219101260|NCT04904822|PROCEDURE|Abdominal bisection|Uterine bisection by endokinfe
219101261|NCT02447835|DRUG|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
219101262|NCT04362163|DEVICE|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
219101263|NCT04686162|OTHER|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
219101264|NCT03070717|PROCEDURE|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
219101265|NCT04238312|DEVICE|RESPeRATE™|Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
219101266|NCT04238312|BEHAVIORAL|Tell, Show and Do technique|Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
219101267|NCT00576732|DRUG|Placebo|Oral solution qd or bid for 6 weeks
219101268|NCT00576732|DRUG|Risperidone high dose|Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
219101269|NCT00576732|DRUG|Risperidone low dose|Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
219688574|NCT06160089|OTHER|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
219101270|NCT01491074|DRUG|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
219101271|NCT01491074|DRUG|NaCl 0.9% 100 ml|Placebo
219101272|NCT01769170|DRUG|Brincidofovir|
219101273|NCT01769170|OTHER|Placebo|
219101274|NCT02536638|OTHER|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
219101275|NCT04902222|DRUG|Morphine|Administration of 0.1 mg/kg (IBW) intravenous morphine
219101276|NCT00693576|DRUG|simvastatin|20 mg simvastatin daily
219688575|NCT06160089|OTHER|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
219101277|NCT00524914|DRUG|apomorphine|Acute apomorphine subcutaneous 3 mg
219101278|NCT00524914|DRUG|placebo|placebo subcutaneous
219101279|NCT04797182|DRUG|avatrombopag|avatrombopag,60 mg/d,po
219101280|NCT03145571|PROCEDURE|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
219101281|NCT05076149|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
219101282|NCT05076149|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
219101283|NCT05076149|DRUG|IVA|Tablet for oral administration.
219101284|NCT05076149|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
219101285|NCT05076149|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
219101286|NCT05076149|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
219101287|NCT02914925|DEVICE|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
219101288|NCT05096208|BIOLOGICAL|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
219101289|NCT05096208|BIOLOGICAL|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
219101290|NCT05096208|BIOLOGICAL|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
219101291|NCT05096208|BIOLOGICAL|Placebo|Placebo
219101292|NCT05219266|DRUG|midostaurin|Patients receive midostaurin
219688576|NCT03625726|BIOLOGICAL|Thrombin generation assay (in vitro)|One blood sample.
219688577|NCT02052986|OTHER|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
219688578|NCT04623866|DRUG|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
219688579|NCT04623866|DRUG|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
219101293|NCT00844116|DEVICE|spirometry|Conventional and telematic spirometry
219101294|NCT03907163|DRUG|Dronabinol|Capsules containing 5 mg Dronabinol
219101295|NCT03907163|OTHER|Placebo|capsules identical in appearance to dronabinol
219101296|NCT05842785|DRUG|Phase I dose escalation|The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
219101297|NCT05842785|DRUG|Phase II-HNSCC|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
219101298|NCT05842785|DRUG|Phase II-Advanced melanoma|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
219101299|NCT05842785|DRUG|Phase II-solid tumors or lymphomas|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
219101300|NCT02087501|DEVICE|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
219101301|NCT04498195|BEHAVIORAL|increased exercise and physical activity|Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
219101302|NCT00094328|DRUG|Bicalutamide|oral
219101303|NCT00094328|DRUG|Anastrozole|oral
219101304|NCT02978001|OTHER|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
219101305|NCT04338425|BEHAVIORAL|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
219101306|NCT04338425|BEHAVIORAL|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
219235385|NCT01883609|BIOLOGICAL|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
219235386|NCT01883609|BIOLOGICAL|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
219235387|NCT06037044|OTHER|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
219101307|NCT04330365|BEHAVIORAL|Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm|Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
219101308|NCT04158180|DIAGNOSTIC_TEST|Questionnaire|A battery of questionnaires will be propose to the participants
219223843|NCT06909942|DIAGNOSTIC_TEST|Psoas Muscle Index|The PMI is typically calculated using cross-sectional imaging (CT or MRI) at the level of the third lumbar vertebra (L3).The total psoas area is normalized to patient height: PMI = Total psoas muscle area (cm²) / height² (m²).The PMI is particularly valuable in hospital settings where patients may have difficulty performing functional tests like handgrip strength measurements, offering an objective assessment of muscle status from readily available imaging data.
219223844|NCT06909942|DEVICE|Handgrip Dynamometer|Handgrip strength (HGS) is one of the key diagnostic criteria for sarcopenia according to several international consensus guidelines, including those from the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS).Men: \<27 kg and women: \<16 kg values indicates sarcopenia for each patient.Handgrip strength measurement with a dynamometer provides a standardized, reliable, and clinically relevant assessment that helps identify individuals with sarcopenia who may benefit from early intervention strategies.
219235388|NCT06037044|OTHER|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
219688580|NCT02360514|DRUG|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
219688581|NCT05191966|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|"S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
219688582|NCT05191966|PROCEDURE|Thoracic Paravertebral Block|"TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
219688583|NCT05719194|OTHER|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
219688584|NCT05719194|OTHER|SBT with T-piece or PSV|"\- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~\- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful."
219688585|NCT05563337|PROCEDURE|Arteriography and renal denervation|Diagnostic renal Arteriography - Randomization - Renal denervation
219688586|NCT05563337|PROCEDURE|Arteriography without renal denervation|Diagnostic renal Arteriography - Randomization
219688587|NCT05696964|BEHAVIORAL|Motivational interviewing training enhanced with artificial intelligence|The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
219688588|NCT00967304|OTHER|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
219688589|NCT02895035|DRUG|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
219688590|NCT02895035|DRUG|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
219688591|NCT01039467|DEVICE|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
219101309|NCT06010901|DRUG|TQB2618 injection|TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
219688592|NCT03520452|OTHER|Green coffee extract|Reconstituted in water and given to subjects
219688593|NCT03520452|OTHER|Placebo|Placebo
219688594|NCT00908765|BEHAVIORAL|Exercise|"1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
219688595|NCT00661089|DRUG|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
219101310|NCT06010901|DRUG|Penpulimab injection|Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
219101311|NCT06010901|DRUG|Anlotinib hydrochloride capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219101312|NCT06287996|OTHER|footbath and actigraphy|Receive warm water foot bath for 4 weeks, 1 hour before going to bed every night (7-9PM), temperature 42℃ for 20 minutes, water depth 10cm above the ankle joint and wearing an actigraphy for 4 weeks
219101313|NCT06287996|DEVICE|actigraphy|Wearing an actigraphy for 4 weeks
219688596|NCT00661089|DRUG|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
219688597|NCT02977793|DEVICE|Tomey EM-4000 Specular Microscope|
219688598|NCT02977793|DEVICE|Konan CellChek XL Specular Microscope|
219688599|NCT00570375|DRUG|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
219688600|NCT01500798|DRUG|20 mg bardoxolone methyl|20 mg, oral, once daily
219688601|NCT01500798|DRUG|Placebo|Oral, once daily
219688602|NCT01187732|DEVICE|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
219688603|NCT02979964|BEHAVIORAL|Audit and Feedback|
219688604|NCT04228224|DEVICE|Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)|The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
219688605|NCT04228224|BEHAVIORAL|Conventional gait rehabilitation|Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
219688606|NCT00621790|DRUG|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
219688607|NCT00621790|DRUG|placebo|placebo
219688608|NCT00274742|BIOLOGICAL|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
219688609|NCT05296707|OTHER|Inspiratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
219688610|NCT05296707|OTHER|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
219688611|NCT05296707|OTHER|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
219688612|NCT04712292|PROCEDURE|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~* any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~* surgery for radicalization of cancer polyps previously removed endoscopically~* surgery for excision of large polyps which are not removable endoscopically~* staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~* palliative surgery (defined as any surgery with no curative intent)"
219688613|NCT02786992|DRUG|Misoprostol|
219688614|NCT02786992|DRUG|Oxytocin|
219688615|NCT02786992|DRUG|Carbetocin|
219688616|NCT02786992|DRUG|Placebo|
219101314|NCT01905254|DEVICE|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
219101315|NCT01905254|OTHER|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
219101316|NCT02213328|DRUG|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
219101317|NCT03207906|DRUG|VBP-926|Topical VBP-926 solution
219101318|NCT05617001|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
219101319|NCT02457416|OTHER|Peanut|Treatment with peanut in increasing doses until a maintenance dose
219101320|NCT04459286|DRUG|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
219688617|NCT03064711|DIAGNOSTIC_TEST|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
219688618|NCT01575080|DEVICE|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
219101321|NCT04459286|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
219688619|NCT00617552|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
219688620|NCT00617552|DRUG|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
219101322|NCT03861806|BEHAVIORAL|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
219101323|NCT03861806|BEHAVIORAL|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
219688621|NCT00617552|DRUG|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
219101324|NCT00226512|DRUG|Campath-1H /ATG|
219101325|NCT00737880|OTHER|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
219688622|NCT00617552|DRUG|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
219688623|NCT00617552|DRUG|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
219688624|NCT00617552|DRUG|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
219688625|NCT00617552|DRUG|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
219101326|NCT00722579|DEVICE|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
219101327|NCT02402296|DRUG|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
219101328|NCT02402296|OTHER|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
219688626|NCT00617552|DRUG|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
219688627|NCT02697071|DRUG|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
219688628|NCT02697071|DRUG|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
219688629|NCT02163161|DRUG|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
219688630|NCT02163161|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
219688631|NCT02163161|DRUG|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
219688632|NCT04503317|DEVICE|active acupuncture low level laser in addition to nasal laser irradiation|laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
219688633|NCT04503317|OTHER|treadmill exercise|aerobic exercise once per day, 3 times per week for three months
219688634|NCT03927092|OTHER|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
219688635|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
219688636|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
219688637|NCT00157339|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
219688638|NCT00157339|DRUG|injected insulin|patient specific dose, injected, before meals, 12 months.
219688639|NCT01720641|BEHAVIORAL|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
219688640|NCT01720641|BEHAVIORAL|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
219688641|NCT01720641|BEHAVIORAL|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
219688642|NCT01529606|OTHER|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
219688643|NCT01529606|PROCEDURE|Plasma treatment|plasma treatment after preparation and for caries prevention
219688644|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - ULTRASOUND|At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
219688645|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - SURGERY|Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
219688646|NCT02572453|DRUG|Onalespib|Given IV
219688647|NCT03511677|DEVICE|Insole|Customized insole
219688648|NCT03511677|DEVICE|Placebo Insole|Placebo flat insole
219688649|NCT05074966|DRUG|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
219688650|NCT05074966|DRUG|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
219688651|NCT01341496|BIOLOGICAL|Epigenetically Modified Autologous Tumor|5x 10\^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
219688652|NCT01341496|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
219688653|NCT01341496|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
219688654|NCT02844166|OTHER|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
219688655|NCT02844166|OTHER|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
219688656|NCT01210794|PROCEDURE||The influence of different food components on zinc absorption in young adults consuming zinc fortified porridges prepared from maize, beans and sorghum
219688657|NCT05943366|DEVICE|Keep-on-Keep-Up Nutrition (KOKU-Nut)|Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
219688658|NCT05075278|BEHAVIORAL|Survey|A survey will be completed by the participants at the conclusion of each day.
219688659|NCT01285843|PROCEDURE|Anterior Minimally Invasive Approach (AMIS)|
219688660|NCT03713099|DEVICE|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
219688661|NCT04621721|BEHAVIORAL|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
219688662|NCT04693793|OTHER|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
219688663|NCT03352076|DRUG|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
219688664|NCT03352076|DRUG|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
219688665|NCT05313724|OTHER|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
219688666|NCT05485311|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
219688667|NCT00766766|BEHAVIORAL|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
219688668|NCT00766766|BEHAVIORAL|Telephone Coaching Sessions|Telephone Coaching Sessions
219688669|NCT00766766|BEHAVIORAL|Physician Feedback Letter|Physician Feedback Letter
219688670|NCT02114021|DRUG|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
219688671|NCT02114021|DRUG|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
219688672|NCT02114021|DRUG|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
219688673|NCT04552197|DRUG|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
219688674|NCT04552197|DRUG|Tofacitinib|Tofacitinib tablets will be administered orally.
219688675|NCT02151721|DRUG|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
219688676|NCT01613924|DEVICE|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
219688677|NCT01613924|DEVICE|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
219688678|NCT04222816|DRUG|Lithium Carbonate|Lithium carbonate 800-900 mg orally daily for 12 weeks
219688679|NCT04222816|DRUG|Sodium chloride|Sodium chloride 1gm daily per orally for 12 weeks
219688680|NCT01879293|DRUG|Metformin|
219688681|NCT01879293|DRUG|placebo|
219688682|NCT01900444|BIOLOGICAL|IMOJEV|0.5 mL, Subcutaneous
219688683|NCT05033626|PROCEDURE|Simultaneous thyroidectomy and hyoid suspension|Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.
219688684|NCT05033626|PROCEDURE|Thyroidectomy|The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
219688685|NCT00096213|PROCEDURE|conventional surgery|surgery
219688686|NCT01726166|PROCEDURE|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
219688687|NCT01726166|PROCEDURE|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
219101329|NCT02993939|PROCEDURE|Interscalene block|Ultrasound guided single shot block above the clavicle
219688688|NCT03434639|DIAGNOSTIC_TEST|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
219688689|NCT03423043|RADIATION|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
219688690|NCT05606601|BEHAVIORAL|Minder|"There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support."
219688691|NCT05509361|BIOLOGICAL|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
219688692|NCT04074265|DRUG|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
219101330|NCT02993939|PROCEDURE|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
219688693|NCT04074265|DRUG|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
219688694|NCT02991365|OTHER|nasal insulin|
219688695|NCT02991365|OTHER|placebo spray|
219688696|NCT03694379|OTHER|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
219688697|NCT00072384|DRUG|liposomal vincristine sulfate|Given IV
219688698|NCT00072384|PROCEDURE|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
219688699|NCT00072384|PROCEDURE|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
219688700|NCT00072384|DRUG|carboplatin|Given IV
219688701|NCT00072384|DRUG|etoposide|Given IV
219688702|NCT00072384|BIOLOGICAL|filgrastim|Given subcutaneously
219688703|NCT01825200|BIOLOGICAL|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
219688704|NCT01825200|BIOLOGICAL|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
219688705|NCT04507152|OTHER|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
219688706|NCT04507152|OTHER|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
219688707|NCT03222908|BEHAVIORAL|Intervention1: Contract Agreement|Smoking Cessation Contract
219688708|NCT03222908|BEHAVIORAL|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
219688709|NCT00065299|BEHAVIORAL|Restricted phenylalanine diet|
219688710|NCT06402019|DRUG|Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)|Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
219688711|NCT06402019|DRUG|normal saline|Group went under multiple sessions of normal saline injection.
219688712|NCT02810782|DRUG|Phenobarbital|Phenobarbital per os
219688713|NCT02810782|DRUG|Chlorpromazine|Chlorpromazine per os
219688714|NCT02810782|DRUG|Morphine|Morphine per os
219688715|NCT03460041|DRUG|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
219688716|NCT03460041|DRUG|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
219688717|NCT03460041|DRUG|Bupivacaine|Caudal bupivacaine for pain management
219688718|NCT00490035|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
219688719|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
219688720|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
219688721|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
219688722|NCT04076241|OTHER|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
219688723|NCT04076241|OTHER|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
219688724|NCT06295432|DRUG|DZD9008+AZD4205|Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
219101331|NCT02541214|DEVICE|Trial Nasal Mask|
219101332|NCT01025934|DRUG|Bevacizumab|
219101333|NCT01025934|OTHER|sham|
219101334|NCT00960674|PROCEDURE|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
219101335|NCT00960674|BEHAVIORAL|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
219101336|NCT05726682|DRUG|SAR445419|Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
219101337|NCT03718962|DEVICE|Surrounding needling+ phototherapy|Surrounding needling+ phototherapy
219101338|NCT03718962|DEVICE|phototherapy|phototherapy
219101339|NCT00001060|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
219101340|NCT00280826|DRUG|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
219101341|NCT04902820|OTHER|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
219101342|NCT04902820|OTHER|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
219101343|NCT03612427|DIETARY_SUPPLEMENT|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
219101344|NCT04931394|OTHER|Adjuvant chemotherapy guided by organoid drug sensitivity test|Adjuvant chemotherapy guided by organoid will be given to pancreatic cancer patients.
219688725|NCT03519009|BEHAVIORAL|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
219688726|NCT05686577|OTHER|no intervention|no intervention
219688727|NCT03877744|BEHAVIORAL|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
219101345|NCT05072184|PROCEDURE|ESP block|ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
219101346|NCT02487095|DRUG|Topotecan|Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
219101347|NCT02487095|DRUG|VX-970 (M6620)|VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
219101348|NCT00347243|PROCEDURE|phacoemulsification (cataract surgery)|
219688728|NCT03877744|BEHAVIORAL|live technician|parents will install car seat through guidance from a live certified technician who is present
219101349|NCT05809661|BEHAVIORAL|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
219101350|NCT02041689|BEHAVIORAL|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
219235389|NCT04464499|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
219101351|NCT02041689|BEHAVIORAL|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
219688729|NCT03672864|BEHAVIORAL|Intensive exercise|Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
219688730|NCT02509377|PROCEDURE|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
219688731|NCT00669188|OTHER|Information absent|Information
219688732|NCT00669188|OTHER|Information|Information
219688733|NCT05720559|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
219688734|NCT05720559|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
219688735|NCT05720559|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
219688736|NCT05720559|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
219688737|NCT05720559|DRUG|Vitamin A|Vitamin A 25,000 units/time, qd
219688738|NCT05720559|DRUG|Folic acid|Folic acid 0.4 mg/time, qd
219235390|NCT02770274|DRUG|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
219235391|NCT02770274|DRUG|Aspirin|Monotherapy with aspirin 100 mg once daily
219688739|NCT05720559|DRUG|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
219688740|NCT01439113|PROCEDURE|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
219688741|NCT04302402|DRUG|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
219688742|NCT04302402|DRUG|Placebo|Similar looking placebo
219688743|NCT05209880|BEHAVIORAL|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
219688744|NCT00432900|RADIATION|[(11)C]PBR28|PET Ligand
219688745|NCT03301402|DEVICE|Air purifier|Air purifier with filter at automatic mode on all time
219688746|NCT06044818|DEVICE|Accexible|Speech Analysis
219688747|NCT03413514|DRUG|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)
219688748|NCT03413514|PROCEDURE|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
219688749|NCT03413514|PROCEDURE|Surgery|Radical surgery with D2 lymph node dissection
219688750|NCT03413514|DRUG|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)
219688751|NCT03413514|OTHER|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
219235392|NCT02379975|PROCEDURE|Non-surgical Periodontal Therapy|
219688752|NCT04261140|OTHER|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
219688753|NCT04261140|OTHER|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
219688754|NCT04261140|OTHER|NexComp Flow|Apply in 2-mm increment light cure for 20 s
219688755|NCT04261140|OTHER|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
219688756|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
219688757|NCT06958627|DRUG|pyrotinib|Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.
219235393|NCT03031782|DRUG|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
219235394|NCT03031782|OTHER|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
219688758|NCT06958939|DRUG|Dose level 1 group|1.0 × 10e6/kg S103 CAR-T cells
219688759|NCT06958939|DRUG|Dose level 2 group|2.0 × 10e6/kg S103 CAR-T cells
219688760|NCT06958939|DRUG|Dose level 3 group|4.0 × 10e6/kg S103 CAR-T cells
219688761|NCT06958939|DRUG|Dose level 4 group|8.0 × 10e6/kg S103 CAR-T cells
219688762|NCT06958055|RADIATION|videofluroscopy evaluation of swallowing function|Videofluoroscopy swallowing evaluation was done using solid food bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
219688763|NCT06958640|BEHAVIORAL|Lifestyle interventions|"Dietary intervention: 30kcal energy intake per kilogram of body weight per day, increase vegetable intake, control sugar and alcohol intake, encourage overweight and obese people to lose weight, lose 0.5-1kg per month until the weight reaches the target.~Exercise intervention: Appropriate physical activity in spare time, 30-40 minutes per day, 5 times a week."
219688764|NCT06959628|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
219688765|NCT06849466|DRUG|Dexmedetomidine|Dexmedetomidine Hydrochloride Nasal Spray Dexmedetomidine is a selective alpha-2 adrenergic agonist primarily used for its sedative, anxiolytic, and analgesic effects. It works by inhibiting the release of norepinephrine in the central nervous system, leading to sedation, decreased anxiety, and reduced pain sensitivity. When used intranasally, it can offer an effective, non-invasive method for sedating patients and improving sleep quality, particularly in perioperative settings.
219101352|NCT02041689|BEHAVIORAL|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
219101353|NCT04092465|PROCEDURE|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
219101354|NCT01965379|OTHER|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
219101355|NCT01965379|OTHER|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
219101356|NCT05398146|BEHAVIORAL|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
219101357|NCT05398146|BEHAVIORAL|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
219101358|NCT05398146|BEHAVIORAL|listening to music|Children were allowed to listen to music with headphones during dressing changes.
219101359|NCT05398146|OTHER|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
219101360|NCT05041816|DEVICE|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
219101361|NCT01639105|PROCEDURE|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
219101362|NCT02705781|DEVICE|smARTrack Feeding Tube System|
219101363|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
219101364|NCT05889923|DEVICE|With EDU|using the EDU to perform the procedure
219101365|NCT06163664|BEHAVIORAL|Use of chatGPT for 1 week|Use of chatGPT for 1 week
219101366|NCT05965843|OTHER|underling disease|"Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19."
219101367|NCT00732602|OTHER|GIP-infusion|
219101368|NCT00732602|OTHER|Sodium-chloride|
219101369|NCT00732602|OTHER|GLP-2 infusion|
219101370|NCT06547034|DEVICE|Ultrasound|Breast Ultrasound
219101371|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
219101372|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
219235395|NCT02109913|DRUG|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
219688766|NCT06849466|DRUG|Saline solution|The saline solution will be used as a placebo, and the same device will be employed for intranasal administration.
219688767|NCT06090357|OTHER|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
219688768|NCT05498428|DRUG|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
219101373|NCT06818201|DEVICE|NIBS|A total of 16 sessions will be scheduled, distributed over 8 weeks (2 sessions/week). The continuous current intensity will be set at 2 mA, for 20 minutes. Two electrodes, anode (red) and cathode (black), will be used along with two sponge pads with conductive gel, all combined into a helmet for each patient. The electrodes will be placed according to the international 10-20 system in tDCS. The stimulated area will be the primary motor cortex (M1), so the anode will be placed at the C3 or C4 points and the cathode will be placed at the contralateral supraorbital area Fp1 or Fp2.
219101374|NCT06818201|PROCEDURE|Rehabilitation|This protocol will consist of 72 sessions, distributed as 3 sessions per week over a period of 24 weeks. Strength will be the prioritized method of work and will be present in all phases. Additionally, periodic measurements will be included to ensure that the patient is making adequate progress and meets the necessary progression criteria to advance to the next phase
219101375|NCT06818201|BEHAVIORAL|Sham Comparator|The device will be configured to produce an ascending ramp lasting 30 seconds, identical to the one used in the experimental group, followed by a descending ramp of another 30 seconds. Thus, the control group will experience a sensation of tingling on the scalp, similar to that felt by the experimental group. This stimulation will have a total duration of 1 minute, which will not be sufficient to induce changes in cortical excitability
219101376|NCT00156806|PROCEDURE|Aloe barbadensis topical application in a moisturizing cream vehicle.|
219101377|NCT04504643|OTHER|Technology-assisted circuit training|Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
219101378|NCT04504643|OTHER|Conventional circuit training|Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
219101379|NCT04504643|OTHER|Nordic walking|Classic nordic walking 3 times a week for one hour during 8 weeks
219101380|NCT01454635|DRUG|Sertraline|dosage,frequency and duration
219101381|NCT00978484|BEHAVIORAL|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
219101382|NCT00978484|BEHAVIORAL|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
219101383|NCT01758484|OTHER|palliative care|Undergo supportive care intervention
219101384|NCT01758484|OTHER|questionnaire administration|Ancillary studies
219688769|NCT05498428|DRUG|Lazertinib|Lazertinib will be administered as an oral tablet.
219688770|NCT05498428|DRUG|Carboplatin|Carboplatin will be administrated by IV infusion.
219688771|NCT05498428|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion.
219688772|NCT05498428|DRUG|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
219688773|NCT05498428|DRUG|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
219688774|NCT05573451|DIAGNOSTIC_TEST|ultrasound - transvaginal/transrectal + transabdominal|Each patient undergoes at least ultrasound examination and PET-CT.
219688775|NCT05240014|DEVICE|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
219688776|NCT06438744|PROCEDURE|Thread embedding acupuncture (TEA) + standard therapy|"* TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA"
219688777|NCT05542199|OTHER|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
219688778|NCT05542199|BEHAVIORAL|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
219688779|NCT04758806|BIOLOGICAL|Fecal microbial transplantation|Procured faeces procured from unrelated donor
219688780|NCT04179279|DEVICE|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
219101385|NCT01758484|PROCEDURE|quality-of-life assessment|Ancillary studies
219101386|NCT01279343|DEVICE|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
219101387|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
219101388|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
219101389|NCT04444284|OTHER|Placebo|Single dose administered intranasally on Day 1
219101390|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
219101391|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
219101392|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
219101393|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, \<= 4 mg, Once daily, 7 days
219101394|NCT00836602|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
219688781|NCT03437694|OTHER|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
219688782|NCT04144322|DEVICE|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
219688783|NCT04144322|DEVICE|Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
219101395|NCT02110745|DRUG|Sevofluorane|Comparison of different induction drugs and techniques
219101396|NCT02110745|DRUG|Propofol|Comparison of different induction drugs and techniques
219101397|NCT00161070|DRUG|anticoagulation|
219235396|NCT00620139|BIOLOGICAL|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
219688784|NCT05692401|BEHAVIORAL|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
219688785|NCT06187337|DEVICE|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
219688786|NCT03327818|PROCEDURE|hysterectomy|
219688787|NCT03327818|PROCEDURE|uterine conservative study|
219688788|NCT02871609|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
219688789|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219688790|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
219688791|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
219688792|NCT05688215|DRUG|Fluorouracil|Given IV
219688793|NCT05688215|DRUG|Irinotecan|Given IV
219688794|NCT05688215|DRUG|Leucovorin|Given IV
219688795|NCT05688215|DRUG|Leucovorin Calcium|Given IV
219101398|NCT00161070|DRUG|aspirin and dipyridamole|
219101399|NCT00161070|DRUG|aspirin alone|
219101400|NCT01226914|DRUG|EVICEL|EVICEL
219101401|NCT03454464|PROCEDURE|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
219101402|NCT03454464|PROCEDURE|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
219101403|NCT03163576|DRUG|Niacin|tablets
219101404|NCT03163576|DRUG|Phosphate Binder|tablets
219101405|NCT03245255|DRUG|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
219101406|NCT01800695|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
219101407|NCT01800695|DRUG|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
219101408|NCT01800695|RADIATION|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
219235397|NCT03576118|DRUG|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
219688796|NCT05688215|DRUG|Oxaliplatin|Given IV
219688797|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
219688798|NCT05688215|DRUG|Zimberelimab|Given IV
219688799|NCT04817332|DRUG|Brensocatib|Selective, competitive, and reversible inhibitor of DPP1
219688800|NCT04817332|DRUG|Placebo|Matched placebo
219688801|NCT00333489|DRUG|valsartan|
219688802|NCT05200273|DRUG|AK114|AK114 administered by subcutaneous injection
219688803|NCT04390646|DRUG|GnRH, gonadorelin acetate|Drug administered by a subcutaneous pump
219688804|NCT04390646|DRUG|0.9% NaCl|Drug administered by a subcutaneous pump
219688805|NCT00203515|DEVICE|Standard Latex Foley Catheter|
219688806|NCT00203515|DEVICE|Silver Coated Latex Foley Catheter|
219688807|NCT03307928|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
219688808|NCT03307928|DIAGNOSTIC_TEST|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
219688809|NCT01368263|DRUG|goserelin acetate|Given SC
219688810|NCT01368263|DRUG|letrozole|Given PO
219688811|NCT01368263|DRUG|anastrozole|Given PO
219688812|NCT01368263|DRUG|chemotherapy|Standard chemotherapy
219688813|NCT01368263|PROCEDURE|Surgery|
219688814|NCT04987866|DEVICE|vibration device , Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China|The vibration device is a reusable, handheld device with a battery-powered motor and a vibration frequency of approximately 6000 times per minute (Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China)
219101409|NCT05640622|OTHER|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
219688815|NCT05793281|OTHER|No Drug|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
219688816|NCT03095807|DRUG|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
219688817|NCT03095807|DRUG|Placebo|Administered subcutaneously (s.c., under the skin)
219688818|NCT06215742|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
219688819|NCT06215742|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219688820|NCT01724827|DEVICE|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
219688821|NCT01724827|DEVICE|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
219688822|NCT01982695|DRUG|Losartan|
219688823|NCT01982695|DRUG|Lisinopril|
219688824|NCT03460678|DRUG|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
219688825|NCT03460678|DRUG|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
219688826|NCT06148870|DEVICE|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
219688827|NCT06148870|DEVICE|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
219688828|NCT04754997|OTHER|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
219688829|NCT04754997|OTHER|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
219688830|NCT03781466|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
219688831|NCT03781466|DRUG|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
219688832|NCT05656300|DIAGNOSTIC_TEST|MRI scan using USPIO particles|Diagnostic imaging
219688833|NCT02614638|OTHER|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
219688834|NCT02614638|OTHER|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
219688835|NCT02686853|DRUG|Liposomal amphotericin B|
219101410|NCT01919359|DIETARY_SUPPLEMENT|Multizyme Cellular Vitality Cyruta Plus SHEP|
219101411|NCT04765735|DEVICE|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
219101412|NCT01196208|DRUG|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
219101413|NCT02623114|DRUG|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
219101414|NCT02623114|DRUG|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
219235398|NCT03576118|DRUG|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
219101415|NCT00968435|OTHER|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
219688836|NCT05180045|BEHAVIORAL|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
219688837|NCT04795466|BIOLOGICAL|Canakinumab|Biological subcutaneous injection
219688838|NCT04795466|OTHER|Placebo|Matching placebo subcutaneous injection
219688839|NCT05635045|DRUG|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
219688840|NCT04692493|DRUG|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
219688841|NCT04692493|DRUG|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
219688842|NCT05776303|BEHAVIORAL|Good Bowls|Healthy, frozen subsidized meals are made conveniently available on worksites.
219688843|NCT05776303|BEHAVIORAL|Good Bowls + App Nudges|"Healthy, frozen subsidized meals are made conveniently available on worksites.~Additionally, Bluetooth enabled beacons will be set up at each worksite that will send location specific messages to an individual's Smartphone via an App. These messages will include nutritional information, tips, and behavioral nudges."
219688844|NCT06314503|DEVICE|WEAKID|"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"
219688845|NCT05316142|PROCEDURE|AGV with intraoperation MMC and postoperative BSS|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
219688846|NCT05316142|PROCEDURE|AGV with intraoperation MMC and post operation 5FU|This method will use Ahmad FP7 model valve shunt (New World Medical, LA). First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed.
219688847|NCT05608018|OTHER|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
219688848|NCT05608018|OTHER|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
219688849|NCT05608018|OTHER|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
219688850|NCT05608018|OTHER|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
219688851|NCT03832361|DRUG|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
219101416|NCT02458001|BEHAVIORAL|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
219101417|NCT02613221|DRUG|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
219688852|NCT03796936|BEHAVIORAL|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
219688853|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
219688854|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
219688855|NCT06001697|BEHAVIORAL|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.
219688856|NCT06001697|BEHAVIORAL|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
219235399|NCT03855514|OTHER|NuShield|NuShield® is a dehydrated placental allograft.
219235400|NCT02170207|DRUG|Lansoprazole|Lansoprazole 30 mg injection
219235401|NCT04263688|OTHER|Non-Intervention|Non-Intervention
219101418|NCT02411838|OTHER|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI\>28 will follow a regimen of fasting for three days per week."
219223845|NCT06909942|OTHER|SARC-F Score|"The SARC-F is a simple screening tool used to identify individuals at risk for sarcopenia, which is the progressive loss of muscle mass and strength typically associated with aging.~The SARC-F questionnaire consists of 5 components that assess key aspects related to muscle function:~Strength: Difficulty lifting and carrying 10 pounds Assistance with walking: Difficulty walking across a room Rising from a chair: Difficulty transferring from a chair or bed Climbing stairs: Difficulty climbing a flight of 10 stairs Falls: Frequency of falls in the past year~Each component is scored from 0-2 points:~0 = No difficulty~1. = Some difficulty~2. = A lot of difficulty or unable to do~The total score ranges from 0-10, with higher scores indicating higher risk:~A score of 4 or greater suggests risk of sarcopenia A score of less than 4 suggests low risk"
219688857|NCT00764569|DEVICE|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
219688858|NCT03270033|DRUG|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
219688859|NCT03270033|DRUG|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
219688860|NCT00242047|BIOLOGICAL|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
219688861|NCT02778152|DEVICE|Laser depilation|Laser depilation of natal cleft (pilonidal region)
219688862|NCT04351165|DRUG|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
219688863|NCT01451918|DRUG|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
219688864|NCT04986774|PROCEDURE|Rescue intracranial stenting|Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
219688865|NCT03565757|BEHAVIORAL|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
219688866|NCT06278948|OTHER|Group TP|Application full face, twice daily, in the morning and at bedtime for 4 months
219688867|NCT06278948|DRUG|Group CYS|Application short contact, of thin layer once daily at bedtime for 4 months
219688868|NCT01218542|RADIATION|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
219688869|NCT01493895|DEVICE|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
219688870|NCT01493895|DEVICE|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
219688871|NCT05044429|DRUG|Intravenous Lidocaine|Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
219688872|NCT05044429|DRUG|Transversus abdominis plane (TAP) block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
219688873|NCT05044429|DRUG|Quadratus Lumborum (QL) Block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
219688874|NCT05046015|OTHER|10% Urea foot lotion|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
219688875|NCT05046015|OTHER|10% Urea foot ointment|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves."
219688876|NCT05157880|BEHAVIORAL|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
219101419|NCT04307459|OTHER|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
219101420|NCT03758014|DRUG|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
219101421|NCT03758014|DRUG|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
219101422|NCT01322789|BIOLOGICAL|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
219223846|NCT06909942|DEVICE|Train-of-Four(TOF)|"A Train of Four (TOF) device is a specialized neuromuscular monitoring tool used primarily in anesthesiology and critical care to assess the degree of neuromuscular blockade in patients who have received neuromuscular blocking agents (NMBAs).The device delivers four sequential electrical stimuli (hence train of four) at 0.5-second intervals to a peripheral nerve, typically the ulnar nerve at the wrist. It then measures the resulting muscle contractions, usually of the adductor pollicis muscle (thumb).Modern TOF devices provide a numerical value called the TOF ratio or count, which compares the strength of the fourth twitch to the first twitch.~Ratio of fourth twitch to first twitch amplitude \<0.7: Significant residual blockade 0.7-0.9: Moderate recovery 0.9: Adequate recovery for extubation"
219688877|NCT05157880|BEHAVIORAL|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
219688878|NCT02263053|PROCEDURE|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
219688879|NCT02263053|PROCEDURE|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
219688880|NCT03580161|OTHER|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688881|NCT03580161|OTHER|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688882|NCT03580161|OTHER|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688883|NCT03580161|OTHER|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688884|NCT03580161|OTHER|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688885|NCT03580161|OTHER|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219688886|NCT03580161|OTHER|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
219101423|NCT05030896|OTHER|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
219101424|NCT02978053|BEHAVIORAL|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
219101425|NCT02978053|BEHAVIORAL|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
219101426|NCT00449098|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
219101427|NCT00449098|DRUG|Trabeculectomy with MMC|Trabeculectomy with MMC
219101428|NCT05958160|OTHER|Modified Atkins diet|The modified Atkins diet is a less restrictive version of the ketogenic diet
219101429|NCT05958160|DRUG|Topiramate|Topiramate is an anti-seizure medication
219101430|NCT00632008|DRUG|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
219101431|NCT00632008|DRUG|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
219101432|NCT00399763|DRUG|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
219101433|NCT00399763|DRUG|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
219101434|NCT03475121|COMBINATION_PRODUCT|Combination Chemotherapy plus Intrathecal Topotecan|Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin
219101435|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan
219101436|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm
219101437|NCT03475121|OTHER|No Adjuvant Therapy|Patients will not receive any adjuvant therapy after enucleation of the affected eye.
219101438|NCT03746184|OTHER|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
219688887|NCT02212119|DRUG|Botulinum Toxin|
219688888|NCT02212119|DRUG|Saline|
219688889|NCT02652637|DRUG|neomycin, metronidazole, polyethylene glycol (PEG)|
219688890|NCT02104024|OTHER|Contrast Enhanced Ultrasound Scanning|
219688891|NCT02389660|BEHAVIORAL|Blended Cognitive Behavioural Therapy (CBT)|
219688892|NCT02389660|BEHAVIORAL|Treatment as usual|
219688893|NCT01056393|DRUG|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
219688894|NCT01056393|DRUG|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
219101439|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
219101440|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
219101441|NCT06806020|OTHER|SEAS approach|"The SEAS approach provides a thorough evaluation of the patient before the treatment starts. In addition to the usual measurements for the specific assessment of the scoliosis (Cobb degrees, Bunnel, trunk decompensation, sagittal postural structure and aesthetic parameters), the patient performs a series of tests. The objectives are: assessment of physical conditions (strength and elasticity of certain muscle areas that are more likely 6 influence the structure of the pelvis and the spine), assessment of neuromotor ability related to the alignment of the spine and the pelvis (balance, management of body movements with closed eyes, optical/manual skills) (Romano et al, 2015).~The main aim of SEAS is to reverse the Stokes vicious cycle, so, the abnormal loading created by the scoliosis with an asymmetric growth leading to worsening of curves that will lead to further asymmetric growth due to increased asymmetrical loading (ettany et al 2014).~The goal of SEAS exercises is to develop an a"
219101442|NCT06806020|OTHER|BSPTS school|"Barcelona scoliosis physical therapy school (BSPTS): Based on the theory that scoliosis posture promotes curve progression, according to the vicious cycle model, Barcelona Scoliosis Physical Therapy School (BSPTS) is a physiotherapeutic method that can be defined as a therapy plan of cognitive, sensory-motor, and kinesthetic training to teach the patient to improve their scoliosis 3D posture and shape. The BSTPS method aims to: 1) improve aesthetics and correct scoliotic posture; 2) stabilize the spine and stop the progression of the curve; 3) inform patients and their families about the condition and available treatments; 4) enhance breathing; 5) increase activity, including daily living activities and functional mobility; 6) enhance general self-image and self-esteem; and 7) reduce pain. The initial ideas serve as the foundation for BSPTS correctional Principles (Berdishevsky et al 2016)."
219688895|NCT02732808|DRUG|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
219688896|NCT05083910|DRUG|I.V Oxytocin administration|Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
219688897|NCT00543114|DRUG|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
219101443|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
219101444|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
219101445|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
219223847|NCT06909942|DEVICE|Bispectral Index(BIS)|"A Bispectral Index (BIS) device is a specialized monitoring system used primarily in anesthesiology and critical care to assess a patient's level of consciousness during sedation and general anesthesia.Uses a sensor placed on the patient's forehead to capture electroencephalogram (EEG) signals from the brain.Employs advanced algorithms to analyze the raw EEG data, examining frequency, power, and phase relationships.Processes the EEG information into a dimensionless number (the BIS value) ranging from 0 to 100.~BIS Scale:~100-80: Awake, normal consciousness 80-60: Light to moderate sedation 60-40: General anesthesia (surgical level of hypnosis) 40-20: Deep hypnotic state 20-0: Burst suppression to flatline EEG (very deep anesthesia)"
219688898|NCT00543114|DRUG|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
219101446|NCT03706118|OTHER|Magnetic resonance imaging|At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
219101447|NCT00626366|RADIATION|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
219101448|NCT00626366|DRUG|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
219101449|NCT00626366|DRUG|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
219101450|NCT00001599|DRUG|Thalidomide|
219688899|NCT00543114|DRUG|Rituximab|Given intravenously on Day 1 of each 28 day cycle
219101451|NCT01657266|DRUG|PRO-155|Pre-medication (before surgery) and maintenance treatment.
219101452|NCT01657266|DRUG|Nevanac|Pre-medication (before surgery) and maintenance treatment.
219101453|NCT05312437|OTHER|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (\>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~1. Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~2. Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~3. Disagree with alert and provide a rationale for disagreement (CDS complete)~4. Indicate suicide risk face-to-face screening has already occurred (CDS complete)~5. Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
219223848|NCT06758076|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
219223849|NCT06758076|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
219688900|NCT05430425|OTHER|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
219688901|NCT04453761|DRUG|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
219688902|NCT04453761|DRUG|Placebo|Intravenous NaCl0.9%
219688903|NCT03984084|OTHER|no intervention|no intervention
219688904|NCT02047370|OTHER|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
219688905|NCT02047370|OTHER|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
219688906|NCT06518733|OTHER|appliance type|different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews
219101454|NCT05312437|OTHER|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (\>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
219101455|NCT05880589|DIETARY_SUPPLEMENT|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
219101456|NCT05880589|DIETARY_SUPPLEMENT|Placebo group|Take 2 tablet 2 times per day for 14 days
219101457|NCT01457040|DRUG|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
219101458|NCT01457040|DRUG|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
219101459|NCT03972774|DIAGNOSTIC_TEST|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
219101460|NCT03972774|OTHER|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
219101461|NCT01816763|BEHAVIORAL|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
219101462|NCT01816763|BEHAVIORAL|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
219101463|NCT01816763|BEHAVIORAL|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
219101464|NCT03651063|OTHER|social robot|Reach To Grasp games with a social robot
219101465|NCT03651063|OTHER|computer group|reach to grasp games with a computer screen
219688907|NCT06268834|DIAGNOSTIC_TEST|Blood for zonulin level was drawn from the group.|Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
219688908|NCT01598805|BEHAVIORAL|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
219688909|NCT03429790|COMBINATION_PRODUCT|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
219688910|NCT03429790|COMBINATION_PRODUCT|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
219688911|NCT03003247|DRUG|IDP-120 Gel|IDP-120 Gel is a combination product
219688912|NCT03003247|DRUG|IDP 120 Component A Gel|Monad of Component A
219688913|NCT03003247|DRUG|IDP 120 Component B Gel|Monad of Component B
219688914|NCT03003247|DRUG|IDP 120 Vehicle Gel|Vehicle
219688915|NCT00802646|DRUG|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
219688916|NCT00802646|DRUG|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
219688917|NCT02421419|DRUG|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
219688918|NCT02421419|DRUG|Xylocaine|a local anesthetic agent
219101466|NCT02271750|PROCEDURE|lumbar puncture|for spinal fluid
219101467|NCT04768933|DIETARY_SUPPLEMENT|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
219101468|NCT01170975|DRUG|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
219101469|NCT01170975|DRUG|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
219101470|NCT04934137|BEHAVIORAL|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
219101471|NCT04934137|BEHAVIORAL|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
219101472|NCT02241720|DRUG|regorafenib|
219688919|NCT02421419|DRUG|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
219101473|NCT01633086|DRUG|nitric oxide gel|"1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days"
219101474|NCT01633086|DRUG|placebo gel|placebo gel,BID local use X 28 days
219101475|NCT02327624|DRUG|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
219101476|NCT02327624|DRUG|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
219101477|NCT02327624|DRUG|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
219101478|NCT01342185|DEVICE|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
219101479|NCT01342185|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
219688920|NCT00726180|DRUG|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
219688921|NCT02674139|DEVICE|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
219688922|NCT04997603|OTHER|Accelerometer|Fitbit brand
219688923|NCT06401824|DRUG|Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab|Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
219688924|NCT00097214|DRUG|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
219688925|NCT00097214|BIOLOGICAL|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
219688926|NCT04549181|BEHAVIORAL|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
219688927|NCT03224793|DRUG|BIIB059|Administered as specified in the treatment arm
219688928|NCT03224793|DRUG|Placebo|Administered as specified in the treatment arm
219688929|NCT06360523|DIAGNOSTIC_TEST|AI modal|The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
219688930|NCT06360523|DIAGNOSTIC_TEST|Standard review|The MRI image will be reviewed by radiologist.
219688931|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
219688932|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
219688933|NCT01829958|DRUG|rituximab|
219688934|NCT01829958|DRUG|prednisone|
219101480|NCT01342185|DRUG|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
219101481|NCT02215330|DRUG|Eplerenone|
219101482|NCT02215330|DRUG|Maltodextrin|
219101483|NCT03125590|OTHER|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
219101484|NCT03423875|DIAGNOSTIC_TEST|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
219101485|NCT00429494|DRUG|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
219101486|NCT00429494|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
219688935|NCT01829958|BEHAVIORAL|Geriatric Assessment|
219688936|NCT03439267|COMBINATION_PRODUCT|Coronary Artery Calcium Screening and Statin Treatment|Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.
219688937|NCT03439267|OTHER|Standard Treatment|Patients will be managed following the AHA/ACC guidelines for statin initiation and follow-up.
219688938|NCT02040753|BEHAVIORAL|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
219101487|NCT00429494|PROCEDURE|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
219101488|NCT00345813|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
219688939|NCT04195061|PROCEDURE|Cardiopulmonary exercise test (CPET)|CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
219688940|NCT04460872|DRUG|Testosterone Enanthate|Subjects receive testosterone (100 mg/week) by intramuscular injection
219688941|NCT04460872|BEHAVIORAL|Locomotor Training|Subjects receive locomotor training (4 sessions/week for 2-3 months)
219688942|NCT04739969|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
219688943|NCT04739969|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219688944|NCT05566301|DRUG|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
219688945|NCT05566301|DRUG|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
219688946|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
219688947|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
219688948|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
219688949|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
219688950|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
219688951|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
219688952|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
219688953|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
219688954|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
219688955|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
219688956|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
219101489|NCT00345813|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
219101490|NCT00345813|OTHER|placebo|Given orally
219101491|NCT00675324|DRUG|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
219101492|NCT00675324|DIETARY_SUPPLEMENT|Fresubin Energy drink|30 kcal/kg\*day five days before colonoscopy
219101493|NCT04684641|DRUG|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
219688957|NCT03377270|BEHAVIORAL|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
219688958|NCT05067790|DRUG|Nusinersen|Administered as specified in the treatment arm
219688959|NCT05132504|DRUG|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
219101494|NCT04684641|OTHER|Placebo|Participants will be randomized to receive the placebo.
219101495|NCT01163903|DRUG|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
219101496|NCT01163903|DRUG|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
219101497|NCT05595421|DEVICE|Transcranial direct current stimulation (tDCS)|See detail in arm/group descriptions regarding the intervention.
219101498|NCT05267314|DEVICE|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
219101499|NCT00976703|OTHER|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
219688960|NCT05132504|DRUG|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
219101500|NCT00976703|OTHER|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
219101501|NCT02041247|BIOLOGICAL|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
219101502|NCT00347100|DRUG|Insulin Glargine|Throughout study period
219101503|NCT00347100|DRUG|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
219101504|NCT00347100|DRUG|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
219688961|NCT00196105|DEVICE|6 mm Nitinol Zilver Stent|
219688962|NCT00196105|DEVICE|10 mm Nitinol Zilver Stent|
219688963|NCT00196105|DEVICE|10 mm Stainless Steel Wallstent|
219688964|NCT01328470|DRUG|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
219688965|NCT04863872|OTHER|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
219688966|NCT04863872|BEHAVIORAL|MyHC-T2D education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
219688967|NCT05866393|BEHAVIORAL|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
219688968|NCT04808934|DRUG|Apixaban|Adults receiving apixaban
219688969|NCT04808934|DRUG|dabigatran|Adults receiving dabigatran
219688970|NCT04808934|DRUG|rivaroxaban|Adults receiving rivaroxaban
219688971|NCT04808934|DRUG|VKAs|Adults receiving VKA
219101505|NCT00347100|DRUG|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
219101506|NCT00347100|DRUG|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
219101507|NCT00347100|DRUG|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
219101508|NCT03289481|DIETARY_SUPPLEMENT|Active lozenge|nitric oxide generating lozenge
219101509|NCT03289481|DRUG|Placebo|placebo tablet
219101510|NCT05627401|PROCEDURE|Modified multiple orbital wall decompression|Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
219101511|NCT03128437|BEHAVIORAL|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
219101512|NCT02365974|DEVICE|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
219101513|NCT02365974|DEVICE|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
219101514|NCT02129816|DRUG|Bryophyllum|
219101515|NCT03075501|BEHAVIORAL|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
219688972|NCT00002295|DRUG|Inosine pranobex|
219688973|NCT04058028|DRUG|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
219688974|NCT04058028|DRUG|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
219688975|NCT04680533|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
219101516|NCT03075501|DRUG|Stimulant or sedative|CS+ for paired, CS0 for unpaired
219101517|NCT03075501|DRUG|Placebo|CS- for paired, CS0 for unpaired
219101518|NCT01114750|DRUG|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
219101519|NCT06217887|DRUG|loxenatide Group|Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219101520|NCT06217887|DRUG|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
219223850|NCT06830460|OTHER|Training|"The training will consist of a four-hour session, including a 30-minute lecture on ocular anatomy and ultrasound techniques, a real-time demonstration, and supervised hands-on practice with at least 20 measurements.~Participants must achieve a score of at least 70% on a multiple-choice test to proceed to practical verification, where they will measure the ONSD in five healthy volunteers. These measurements will be compared to those taken by an expert tutor."
219223851|NCT05829629|BIOLOGICAL|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
219223852|NCT05829629|DRUG|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
219223853|NCT05835219|DRUG|REBYOTA™|REBYOTA™ is administered in the rectum
219223854|NCT04578938|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
219223855|NCT04578938|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
219223856|NCT04578938|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
219688976|NCT03666416|BEHAVIORAL|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
219688977|NCT00980824|BEHAVIORAL|Cognitive behavioural therapy|Six sessions brief CBT.
219688978|NCT00980824|OTHER|Standard treatment|Referral to NHS services appropriate to patient's needs
219688979|NCT04848636|DIAGNOSTIC_TEST|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
219688980|NCT05447845|DIAGNOSTIC_TEST|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
219688981|NCT03771963|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
219688982|NCT05201612|DRUG|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
219688983|NCT05201612|DRUG|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
219688984|NCT02696395|DEVICE|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
219688985|NCT02696395|DEVICE|DePuy Corail® femoral stem + Deltamotion® acetabular component|
219688986|NCT00485069|DRUG|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
219101521|NCT02261090|DRUG|Formulation B: Pramipexole Slow release (SR) tablet|
219101522|NCT02261090|DRUG|Formulation C: Pramipexole Slow release tablet|
219101523|NCT02261090|DRUG|Formulation D: Pramipexole Slow release tablet|
219101524|NCT02261090|DRUG|Formulation E: Pramipexole Slow release tablet|
219101525|NCT02261090|DRUG|Formulation F: Pramipexole Slow release tablet|
219101526|NCT02261090|DRUG|Formulation G: Pramipexole Slow release tablet|
219101527|NCT02261090|DRUG|Formulation H: Pramipexole Slow release tablet|
219101528|NCT02261090|DRUG|Pramipexole immediate release (IR) tablets|
219101529|NCT05142670|PROCEDURE|experimental group: task-oriented training individualized by the gravity perception|All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
219101530|NCT05142670|PROCEDURE|control group: visual feedback treatment|Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
219101531|NCT02349568|PROCEDURE|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
219101532|NCT02349568|PROCEDURE|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
219688987|NCT00485069|DRUG|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
219688988|NCT01057836|BEHAVIORAL|Neck endurance training|
219688989|NCT01057836|BEHAVIORAL|Stretching|
219688990|NCT03747705|OTHER|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
219688991|NCT05555238|DRUG|single arm, single group(No interventional)|(Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
219688992|NCT01944436|DRUG|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
219688993|NCT02081378|DRUG|Asciminib (ABL001)|Asciminib was be administered orally in a dose escalation schedule.
219688994|NCT02081378|DRUG|Nilotinib|Asciminib and Nilotinib was administered orally in CML patients
219688995|NCT02081378|DRUG|Imatinib|Asciminib and imatinib was administered orally in CML patients
219688996|NCT02081378|DRUG|Dasatinib|Asciminib and dasatinib was administered orally in CML patients
219688997|NCT00000237|DRUG|Buprenorphine|
219688998|NCT02988700|DRUG|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
219688999|NCT02988700|DRUG|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
219689000|NCT03552991|DRUG|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
219101533|NCT02184663|OTHER|without APA program|Control Arm : chemotherapy alone
219101534|NCT02184663|OTHER|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
219101535|NCT02813967|RADIATION|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
219101536|NCT02813967|RADIATION|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
219101537|NCT02813967|DRUG|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
219689001|NCT06556719|BEHAVIORAL|Hoosier Sport Re-Social|Hoosier Sport Re-Social is a 6-week school-based intervention designed to reduce cardiovascular disease risk in rural children. It includes twice-weekly physical activity sessions during PE classes and weekly social media literacy training in health classes, promoting healthier physical and digital behaviors.
219689002|NCT04751383|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219689003|NCT04751383|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219689004|NCT04751383|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219689005|NCT04751383|PROCEDURE|Computed Tomography|Undergo CT
219689006|NCT04751383|BIOLOGICAL|Dinutuximab|Given IV
219689007|NCT04751383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219101538|NCT05520385|DIAGNOSTIC_TEST|blood group and Rh|check of blood group , Rh for patient and control
219223857|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
219223858|NCT04287647|DEVICE|Transpyloric stent|See arm/group descriptions
219223859|NCT04287647|OTHER|Sham|Sham
219689008|NCT04751383|BIOLOGICAL|Magrolimab|Given IV
219689009|NCT04751383|PROCEDURE|Resection|Undergo surgical resection
219223860|NCT04069247|BEHAVIORAL|e-CBT-I|The e-CBT-I will be delivered through a mobile application (eSleep) with a personal password.
219101539|NCT02994602|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
219101540|NCT02177539|DRUG|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
219101541|NCT02177539|DRUG|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
219101542|NCT05918562|DIETARY_SUPPLEMENT|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
219689010|NCT03751475|OTHER|Nutritional Strategy - OptiMA|"All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
219689011|NCT03751475|OTHER|Effective nutritional standard strategy|"Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
219689012|NCT05468463|BEHAVIORAL|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
219689013|NCT05234177|OTHER|Observation|No intervention
219689014|NCT06466161|DEVICE|Upper Arm Cylindrical Blood Pressure Cuff|In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.
219689015|NCT06466161|DEVICE|Forearm Conical Blood Pressure Cuff|In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
219689016|NCT05750264|DRUG|Ibuprofen|800 mg of IV ibuprofen
219689017|NCT06411821|DRUG|Ulixertinib|300 mg twice daily, for every 28-day cycle.
219689018|NCT06574568|DRUG|YKST02|BCMA-CD3 bispecific antibody
219689019|NCT03171597|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
219101543|NCT05918562|DIETARY_SUPPLEMENT|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
219101544|NCT02753205|DRUG|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
219101545|NCT02753205|DRUG|normal saline|infusion of normal saline
219101546|NCT01062763|DRUG|spironolactone|25 to 50 mg once daily
219101547|NCT01062763|DRUG|placebo|addition of placebo 1 to 2 tablets daily
219689020|NCT03171597|DRUG|Lipid Regulating Drugs|Mainly including statins
219689021|NCT03171597|DRUG|Coronary Vasodilator|Mainly including nitrates
219689022|NCT03171597|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
219689023|NCT03171597|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
219689024|NCT03171597|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
219101548|NCT06190262|BEHAVIORAL|The intervention is community based group psychoeducation|The intervention is community based group psychoeducation
219101549|NCT05510726|DEVICE|shearwave elastography|shearwave elastography on upper or lower limb
219101550|NCT02494921|DRUG|Docetaxel-PNP|Given IV
219101551|NCT02494921|DRUG|Ribociclib|Given Orally
219101552|NCT02494921|DRUG|Prednisone|Given Orally
219689025|NCT02943798|DRUG|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
219689026|NCT02943798|DRUG|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
219689027|NCT04443647|DRUG|Oxytocin|Syntocinon nasal spray
219689028|NCT04443647|DRUG|Placebo|Placebo nasal spray
219689029|NCT05456724|DRUG|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
219101553|NCT02494921|DRUG|Filgrastim|Given IV
219101554|NCT01913158|DRUG|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
219101555|NCT01913158|DRUG|Placebo suppository|Hydrogenated palm kernel oil suppositories
219101556|NCT03534765|DIAGNOSTIC_TEST|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
219101557|NCT03534765|DIAGNOSTIC_TEST|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
219101558|NCT03534765|PROCEDURE|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
219101559|NCT02152228|DRUG|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
219101560|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
219223861|NCT04069247|BEHAVIORAL|e-HE|The e-HE will be delivered in control though a mobile application (eSleep) with a personal password.
219223862|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
219689030|NCT05456724|OTHER|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
219689031|NCT04262011|PROCEDURE|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
219101561|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
219101562|NCT01247714|DIETARY_SUPPLEMENT|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
219101563|NCT01247714|DIETARY_SUPPLEMENT|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
219101564|NCT04618822|BEHAVIORAL|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
219689032|NCT04262011|PROCEDURE|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
219689033|NCT04333212|DEVICE|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
219689034|NCT02529930|BIOLOGICAL|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
219689035|NCT05857410|DRUG|Dexmetomidine|Dexmetomidine (H20183219) 0.4μg / (kg·min)；
219101565|NCT04618822|BEHAVIORAL|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
219101566|NCT04618822|BEHAVIORAL|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
219101567|NCT00660335|DRUG|RG1068 (synthetic human secretin)|Single-dose, IV infusion
219223863|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
219223864|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
219223865|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
219223866|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
219223867|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
219689036|NCT05857410|DEVICE|Lower limb heating blanket|Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
219101568|NCT05762614|OTHER|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
219101569|NCT00847795|DRUG|Avotermin|Intradermal administration
219101570|NCT00847795|DRUG|Placebo|Placebo
219101571|NCT02795208|PROCEDURE|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
219101572|NCT01556698|DRUG|NVN1000|
219689037|NCT05970380|OTHER|Erector spinae plane block|Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.
219689038|NCT05970380|OTHER|Local anesthesia|Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
219689039|NCT03314883|DIAGNOSTIC_TEST|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
219689040|NCT02300870|DRUG|Optison|Echocardiogram with IV contrast
219689041|NCT00397605|DRUG|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
219101573|NCT01556698|DRUG|Vehicle|Placebo
219689042|NCT00061178|DRUG|rhuMAb VEGF (Bevacizumab)|
219689043|NCT04381078|OTHER|ACE - AudioVisual Guide|Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
219689044|NCT00888888|PROCEDURE|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
219689045|NCT01121939|DRUG|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
219689046|NCT01121939|DRUG|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
219101574|NCT02254083|DRUG|BIBT 986 BS - low|
219101575|NCT02254083|DRUG|BIBT 986 BS - high|
219101576|NCT02254083|DRUG|Placebo|
219101577|NCT04845464|OTHER|Cognitive Assessment (not diagnostic)|Sleep quality and cognition will be assessed in young adults
219101578|NCT03260127|BEHAVIORAL|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
219101579|NCT03260127|BEHAVIORAL|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
219101580|NCT05624866|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
219101581|NCT05624866|DRUG|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
219101582|NCT04822740|DEVICE|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
219101583|NCT05430048|DRUG|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
219101584|NCT02714868|BEHAVIORAL|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
219101585|NCT02714868|BEHAVIORAL|Matched Comparison|Participants set goal to try a new activity in the community
219689047|NCT01121939|DRUG|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
219689048|NCT00477802|BIOLOGICAL|Botulinum Toxin Type A|Injected once during the course of the study.
219689049|NCT00477802|BIOLOGICAL|Placebo|Injected once during the course of the study.
219689050|NCT05438238|DEVICE|Oncomfort|Virtual Reality
219689051|NCT03256019|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
219101586|NCT00981474|DRUG|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
219689052|NCT02864407|DRUG|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
219689053|NCT03625596|DIETARY_SUPPLEMENT|L-Arginine|Acute intervention (3 hours)
219689054|NCT03625596|DIETARY_SUPPLEMENT|Nitrate / Nitrite|Acute intervention (3 hours)
219689055|NCT03625596|DIETARY_SUPPLEMENT|Placebo|Acute intervention (3 hours)
219689056|NCT05780138|BEHAVIORAL|Parents Taking Action|Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
219101587|NCT00981474|DEVICE|Control group|Institutional standard of care.
219101588|NCT04639778|OTHER|Control Group|Clinical visits conducted by a multidisciplinary team every year
219101589|NCT04639778|OTHER|Intervention Group|Clinical visits are triggered by weight evolution measured by connected balance
219689057|NCT02811315|OTHER|Observational. Non interventional study|Observational. Non interventional study
219689058|NCT04226781|DIAGNOSTIC_TEST|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
219689059|NCT04226781|DIAGNOSTIC_TEST|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
219689060|NCT02788643|BIOLOGICAL|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
219689061|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal brushing|Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.
219689062|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal biopsy|Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
219689063|NCT03002636|PROCEDURE|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
219689064|NCT04577794|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
219101590|NCT05439239|OTHER|Repeated sprint training|"Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7."
219101591|NCT03800979|DRUG|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
219689065|NCT04577794|DRUG|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
219689066|NCT05460299|COMBINATION_PRODUCT|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
219689067|NCT06484283|OTHER|Meditation|Guided meditation will be applied within the scope of the study. A guided meditation video prepared by a Yoga Alliance-certified researcher will be used for this intervention. Guided meditation aims to ensure being in the moment (here and now) with the help of breathing. Meditation practice will take participants 10 minutes.
219689068|NCT04659148|PROCEDURE|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
219689069|NCT01858038|DEVICE|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
219689070|NCT00002029|DRUG|Fat Emulsion 2%|
219689071|NCT00002029|DRUG|Fat Emulsion 20%|
219689072|NCT00109746|DIETARY_SUPPLEMENT|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
219689073|NCT05217602|BEHAVIORAL|AC+ARwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
219689074|NCT05217602|BEHAVIORAL|AC+RwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
219689075|NCT05217602|BEHAVIORAL|Usual Calm Control (UC)|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
219689076|NCT00263198|DRUG|PTK787/ZK222584|
219689077|NCT00263198|DRUG|Letrozole|
219689078|NCT02849080|DRUG|semaglutide|Oral administration once-daily.
219689079|NCT02849080|DRUG|sitagliptin|Oral administration once-daily.
219689080|NCT04288934|BIOLOGICAL|Collection and expansion of BM-MSC|MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
219689081|NCT04288934|DIAGNOSTIC_TEST|VI-SCI evaluation and patients' follow up|"* At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection."
219101592|NCT04463121|DEVICE|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
219101593|NCT04463121|DEVICE|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
219689082|NCT00713271|DRUG|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
219689083|NCT00713271|DRUG|Placebo|
219689084|NCT00713271|DRUG|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
219689085|NCT00713271|DRUG|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
219101594|NCT05340257|DRUG|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
219689086|NCT01819727|DRUG|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
219101595|NCT05516225|DRUG|PBCLN-003|Human Milk Oligosaccharide Concentrate
219101596|NCT03542526|DEVICE|electrogradiogram|12 lead ecg ambulatory blood prussre
219101597|NCT03542526|DEVICE|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
219101598|NCT03270514|DRUG|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
219101599|NCT03270514|DRUG|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
219101600|NCT03395808|DRUG|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
219101601|NCT03781830|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
219101602|NCT05304715|DRUG|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
219101603|NCT05304715|DRUG|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
219101604|NCT02398058|DRUG|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
219689087|NCT06197308|DRUG|oral vancomycin and oral amoxicillin|In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.
219689088|NCT03050827|DRUG|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
219689089|NCT03050827|DRUG|Placebo|Non-active placebo for 3% oxybutynin
219689090|NCT04449289|DRUG|Intravenous lidocaine|Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
219689091|NCT04449289|DRUG|Epidural ropivacaine|Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
219689092|NCT04224025|OTHER|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
219689093|NCT00952315|DEVICE|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
219101605|NCT02398058|DRUG|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
219101606|NCT06476626|OTHER|Maternal Reflective Function Workshop|4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
219101607|NCT05165953|OTHER|no intervention|there was no intervention in the study
219101608|NCT00498563|PROCEDURE|altitude exposure in hypobaric chamber|
219689094|NCT00952315|DEVICE|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
219689095|NCT00952315|DEVICE|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
219689096|NCT03163407|DRUG|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
219689097|NCT03163407|DRUG|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
219689098|NCT05251272|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
219689099|NCT00018642|DRUG|quetiapine|
219689100|NCT00018642|DRUG|haloperidol decanoate|
219101609|NCT02991443|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
219101610|NCT00302783|BEHAVIORAL|Multi-Source Feedback: including self-assessment & coaching|
219101611|NCT05730790|OTHER|Cognitive-motor dual task training (DTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
219101612|NCT05730790|OTHER|Cognitive single task training (CSTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
219101613|NCT05730790|OTHER|Motor single task training (MSTT)|For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
219101614|NCT02875275|OTHER|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
219101615|NCT02875275|OTHER|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
219101616|NCT02875275|OTHER|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
219101617|NCT02875275|OTHER|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
219101618|NCT02833441|BEHAVIORAL|Peer Support|
219689101|NCT04148547|DEVICE|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
219101619|NCT01250964|PROCEDURE|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
219689102|NCT04148547|DEVICE|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
219689103|NCT05930314|DRUG|CNCT19 cell injection|"Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells"
219689104|NCT05062746|OTHER|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
219689105|NCT05062746|OTHER|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
219689106|NCT00404209|PROCEDURE|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
219689107|NCT03248648|DRUG|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
219689108|NCT03248648|DRUG|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
219101620|NCT03247374|DEVICE|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
219689109|NCT03839394|BEHAVIORAL|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
219689110|NCT03839394|OTHER|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
219689111|NCT00338403|PROCEDURE|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
219689112|NCT01976481|DEVICE|sunbed exposure|exposure to sunbed ultraviolet radiation
219689113|NCT04039724|DRUG|HCP0605 + HGP0816|
219689114|NCT04039724|DRUG|HCP1305|
219689115|NCT04201236|OTHER|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
219689116|NCT04201236|OTHER|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
219101621|NCT03247374|OTHER|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
219689117|NCT02258594|OTHER|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
219101622|NCT05363657|PROCEDURE|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
219101623|NCT05363657|PROCEDURE|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
219689118|NCT02258594|BEHAVIORAL|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
219689119|NCT02426034|DRUG|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
219689120|NCT03176719|OTHER|Venipuncture|"1. Full blood count and leukocyte differentiation.~2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~3. Detection of anemia, thallasemia and sickle cell anemia (XN-20)~4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~5. Circulating cytokines and inflammatory markers (ELIZA)~6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~7. pan-Salmonella PCR~8. Gametocyte PCR"
219689121|NCT01367249|DRUG|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
219689122|NCT01367249|DRUG|Placebo|Sterile ophthalmic solution
219689123|NCT03588897|DIETARY_SUPPLEMENT|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
219689124|NCT01624285|DRUG|sorafenib tosylate|Given PO
219689125|NCT01624285|OTHER|placebo|Given PO
219689126|NCT01624285|OTHER|laboratory biomarker analysis|Correlative studies
219689127|NCT00060606|PROCEDURE|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
219689128|NCT00060606|PROCEDURE|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
219689129|NCT06612801|BEHAVIORAL|The REThink Game|REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
219689130|NCT06612775|DRUG|Test drug CB03-154 5mg group|CB03-154 tablet (5mg/tablet) once daily.
219689131|NCT06612775|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
219689132|NCT06612775|DRUG|Test drug CB03-154 20mg group|Four CB03-154 tablets (5mg/tablet) once daily.
219689133|NCT06612775|DRUG|Placebo group|Four Placebo tablets once daily.
219689134|NCT04853043|DRUG|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
219689135|NCT00593450|DRUG|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
219101624|NCT05363657|PROCEDURE|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
219101625|NCT05363657|DIAGNOSTIC_TEST|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
219101626|NCT00612157|DRUG|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
219101627|NCT00612157|DRUG|Placebo control|Matching placebo
219101628|NCT00305500|DRUG|escitalopram|
219101629|NCT02853461|OTHER|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
219689136|NCT00593450|DRUG|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
219689137|NCT01475344|DRUG|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
219101630|NCT02853461|OTHER|Microbiological analysis|Plating the sonicates on agar plates.
219101631|NCT02111226|OTHER|SMS text messaging|short message service
219101632|NCT05885919|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
219101633|NCT05885919|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
219101634|NCT01335503|DIETARY_SUPPLEMENT|AN-PEP|Endoprotease enzyme (AN-PEP)
219101635|NCT00133939|PROCEDURE|Mechanical ventilation|
219101636|NCT04524728|DRUG|Palbociclib|tablets
219101637|NCT04524728|DRUG|Letrozole 2.5mg|tablets
219101638|NCT04524728|DRUG|Fulvestrant|intramuscolar injections
219101639|NCT00829205|BIOLOGICAL|filgrastim|
219101640|NCT00829205|BIOLOGICAL|rituximab|
219101641|NCT00829205|DIETARY_SUPPLEMENT|Se-methyl-seleno-L-cysteine|
219101642|NCT00829205|DRUG|carboplatin|
219101643|NCT00829205|DRUG|etoposide|
219101644|NCT00829205|DRUG|ifosfamide|
219101645|NCT00829205|OTHER|laboratory biomarker analysis|
219101646|NCT00829205|OTHER|pharmacological study|
219689138|NCT01475344|DRUG|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
219101647|NCT06062940|BEHAVIORAL|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
219101648|NCT03447730|DRUG|SYNB1020|SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
219101649|NCT03447730|OTHER|Placebo|Subjects received placebo orally in a chilled buffered solution (100 mL).
219101650|NCT04001179|OTHER|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
219101651|NCT03115749|OTHER|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
219101652|NCT03115749|OTHER|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
219689139|NCT06553482|OTHER|FatMAx training intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them
219689140|NCT06553482|OTHER|FatMax and physical endurance exercise intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise
219101653|NCT02501213|DRUG|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
219101654|NCT00034840|DRUG|telmisartan, valsartan|
219101655|NCT05737433|DRUG|[14C]-rencofilstat 225mg|radio-labelled 225mg oral dose of rencofilstat
219101656|NCT01031875|DRUG|pazopanib hydrochloride|
219101657|NCT01031875|RADIATION|fludeoxyglucose F 18|
219101658|NCT00572624|BEHAVIORAL|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
219101659|NCT00572624|PROCEDURE|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
219101660|NCT02951559|DEVICE|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
219101661|NCT06382285|DRUG|Continues peripheral block|ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
219101662|NCT04191681|DRUG|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
219101663|NCT04191681|DRUG|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
219101664|NCT04669223|DEVICE|Seldinger chest drain insertion|Different sizes of chest drain will be inserted with seldinger technique
219223868|NCT01086241|PROCEDURE|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
219223869|NCT01086241|PROCEDURE|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
219689141|NCT06553482|OTHER|Control|No intervention pf physical activity
219689142|NCT00273598|PROCEDURE|Moss Miami Spine Instrumentation System|
219689143|NCT00273598|PROCEDURE|Universal Spine Instrumentation System|
219689144|NCT01599169|DIETARY_SUPPLEMENT|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
219689145|NCT01599169|DIETARY_SUPPLEMENT|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
219689146|NCT03981016|OTHER|Biological collection|"* blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
219689147|NCT07069348|OTHER|No intervention|There is no treatment or intervention administered to the patients
219689148|NCT07072208|DRUG|Induction therapy-Pro regimen|"Pro regimen induction(21days per cycle\*1 cycle)~* Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle~* Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle~* Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle"
219689149|NCT07072208|DRUG|Consolidation therapy-Pro-pola regimen|Pro-pola regimen consolidation(21days per cycle\*6 cycle) -Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle -Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle -Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle -Polatuzumab vedotin 30mg per vial 1.8 mg/kg, intravenous drip, Day 1 of each cycle
219689150|NCT07073027|OTHER|2D video on smartphone|2D video with audio viewed on smartphone
219689151|NCT07073027|OTHER|360 video on smartphone|360 video with audio viewed on smartphone (not in virtual reality)
219689152|NCT07073027|OTHER|360 video on smartphone inserted into VR cardboard headset|360 video with audio in virtual reality
219689153|NCT07072507|BEHAVIORAL|Chilbirth Education|Participants divided into training groups will receive training on pregnancy, birth, breastfeeding, preparation for parenthood, and baby care in groups of 6-8 people, 2 hours a week for five weeks.
219689154|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
219689155|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
219689156|NCT03466632|DRUG|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
219689157|NCT03466632|DRUG|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
219689158|NCT02430558|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
219689159|NCT02110251|BEHAVIORAL|Supervised Exercise Therapy|
219689160|NCT06214884|BEHAVIORAL|Mindfulness for All|"Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
219689161|NCT06253702|DRUG|Indomethacin|to inhibit cyclooxygenase (COX)
219689162|NCT06253702|DRUG|Placebo|Placebo
219689163|NCT06253702|DRUG|Orilissa|to suppress hormones 200mg dose 2x per day (all participants)
219689164|NCT06253702|DRUG|Testosterone gel|50 mg each morning for add back phase (male participants)
219689165|NCT06253702|DRUG|Anastrozole|1mg/day in men to prevent conversion of testosterone to estradiol
219689166|NCT06253702|DRUG|Estradiol|Women will receive oral estradiol 2mg/daily
219223870|NCT01054287|OTHER|Multifactorial falls prevention program|
219689167|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
219689168|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
219689169|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
219689170|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
219689171|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
219689172|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
219223871|NCT01054287|OTHER|No falls prevention intervention|
219223872|NCT06214052|DRUG|VH4524184|VH4524184 was administered as tablets orally at Day 1.
219223873|NCT06214052|DRUG|Matching Placebo|VH4524184 Matching Placebo was administered as tablets orally at Day 1.
219689173|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
219689174|NCT05962398|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
219689175|NCT06050642|OTHER|enhanced care model provided by Timkl, a home support provider|A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
219689176|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
219689177|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
219689178|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
219689179|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
219689180|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
219689181|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
219101665|NCT06250439|OTHER|ECMO-Flow variations|"The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow."
219689182|NCT06539988|BEHAVIORAL|Clinician Coaching Sessions|PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.
219689183|NCT06539988|OTHER|Personalized text messages to patients|Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
219689184|NCT06243068|BEHAVIORAL|Educate and Engage|Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.
219689185|NCT06243068|BEHAVIORAL|Educate and Engage Plus Kidney Supportive Care Program|"In addition to bundle described under Educate and Engage, nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist."
219689186|NCT06955754|DRUG|BI 764198, formulation 1|BI 764198, formulation 1
219101666|NCT05590546|OTHER|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
219101667|NCT06058923|PROCEDURE|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
219101668|NCT06058923|PROCEDURE|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
219101669|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
219101670|NCT02583763|OTHER|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
219223874|NCT06214052|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
219689187|NCT06955754|DRUG|BI 764198, formulation 2|BI 764198, formulation 2
219689188|NCT06955754|DRUG|BI 764198, formulation 3|BI 764198, formulation 3
219689189|NCT05074329|DEVICE|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
219689190|NCT02114138|PROCEDURE|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
219689191|NCT02114138|DIAGNOSTIC_TEST|urine collection|urine collection will be performed on both the control group and hospitalized participants
219689192|NCT05664581|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
219689193|NCT06189755|DEVICE|Positive Airway Pressure|Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
219689194|NCT00116181|DRUG|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
219101671|NCT02583763|PROCEDURE|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 9 years of age.
219689195|NCT05943951|PROCEDURE|Right hemicolectomy|It begins with a thorough laparoscopic inspection of the abdomen for evidence of metastatic disease and to confirm the location of the tumor. Usually is performed dissection using a medial-to-lateral approach. A lateral or inferior approach can also be used depending on the anatomy. The vascular dissection may begin at the ileocolic pedicle or over the superiore mesenteric vein. After completing the medial-to-lateral dissection, the sourgeons return to the ileocolic pedicle to begin vascular dissection. Whether a D2 (until encountering the right branch of the middle colic) or D3 dissection (until the root of ileocolic artery and vein) is performed depends upon the tumor stage. For an intracorporeal anastomosis, the bowel is transected proximally and distally using a linear stapler. The terminal ileum is positioned along the transverse colon in an isoperistaltic fashion. After that a colotomy and an enterotomy are made on the antimesenteric edge of the colon and small bowel respectively
219689196|NCT05541939|DRUG|Mizagliflozin|Encapsulated or Liquid Formulation
219689197|NCT03101150|DRUG|400 IU Vitamin D3|Antenatal multivitamin
219689198|NCT03101150|DRUG|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
219689199|NCT00059553|BEHAVIORAL|Locomotor treadmill training with body weight support|
219689200|NCT04355364|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
219689201|NCT04355364|PROCEDURE|standard procedure|Patients will receive the usual care in accordance with good practice.
219689202|NCT03627325|OTHER|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
219689203|NCT03167203|BIOLOGICAL|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
219689204|NCT03323593|DRUG|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
219689205|NCT02564367|DRUG|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks"
219689206|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
219689207|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
219689208|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
219689209|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
219689210|NCT03556995|OTHER|bariatric surgery patients|
219689211|NCT00004558|BEHAVIORAL|dietary n-3 polyunsaturated fatty acids|
219689212|NCT04588974|DEVICE|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
219689213|NCT01095172|DRUG|Rituximab|375mg/m\^2, single dose given 2-4 weeks prior to transplantation
219101672|NCT04804371|DRUG|F18-FDG|Evaluate FDG uptake
219101673|NCT06599619|DRUG|Single agent, adjuvant anti-PD1 therapy|"One of the following Single-agent, adjuvant anti-PD1 therapies:~Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.~Dose = 240 mg IV every 2 weeks/480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.~Dose = 200 mg IV every 3 weeks/ 400 mg every 6 weeks"
219223875|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
219689214|NCT01095172|DRUG|Tacrolimus|dose calculated to give levels of 3-7ng/ml
219689215|NCT01095172|DRUG|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
219689216|NCT01095172|DRUG|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
219689217|NCT01095172|DRUG|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
219689218|NCT01095172|DRUG|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
219689219|NCT01738945|DRUG|Amlodipine|10 mg/day for 12 weeks
219689220|NCT03594929|DEVICE|Active RIC|
219223876|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
219689221|NCT03594929|DEVICE|Sham Control|
219689222|NCT06469957|OTHER|Questionnaires and data collection sheet|Questionnaires
219689223|NCT05900375|BEHAVIORAL|Parent Decision Aid|A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
219689224|NCT03163446|BIOLOGICAL|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
219689225|NCT03163446|DRUG|Placebo|Placebo, given as a single 2 hour iv infusion
219689226|NCT02365662|DRUG|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
219689227|NCT00350441|DRUG|Sildenafil Citrate|
219689228|NCT01317641|DRUG|ODM-201|ODM-201 administered orally daily
219689229|NCT00611806|DIETARY_SUPPLEMENT|Folic Acid|Folic acid 2mg po daily
219689230|NCT00611806|DIETARY_SUPPLEMENT|B12|B12 400 micrograms po daily
219689231|NCT00611806|OTHER|Placebo|1 capsule po daily
219689232|NCT05108766|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
219689233|NCT05108766|DRUG|Placebo|Matching placebo to tildrakizumab administered SC
219689234|NCT01228591|DEVICE|Acuvue Advance Plus|Silicone hydrogel contact lens.
219689235|NCT01228591|DEVICE|Acuvue Advance|Silicone hydrogel contact lens
219689236|NCT03159403|DRUG|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
219689237|NCT01121471|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
219689238|NCT01121471|DIETARY_SUPPLEMENT|Safflower OIl|8.0g/day safflower oil
219689239|NCT00944918|DRUG|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
219689240|NCT00944918|DRUG|anastrozole|Tablet, oral, once daily until disease progression.
219689241|NCT00944918|DRUG|exemestane|Tablet, oral, once daily until disease progression.
219689242|NCT00199953|DRUG|Rabeprazole 20 mg twice a day for 90-day period treatment|
219689243|NCT00010140|DRUG|docetaxel|
219689244|NCT00010140|DRUG|epirubicin hydrochloride|
219689245|NCT00010140|DRUG|tamoxifen citrate|
219689246|NCT00010140|PROCEDURE|adjuvant therapy|
219689247|NCT04333004|DRUG|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
219689248|NCT01505920|PROCEDURE|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
219689249|NCT01505920|PROCEDURE|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
219689250|NCT06365905|OTHER|Non-Interventional Study|Non-Interventional Study
219689251|NCT01356095|OTHER|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
219689252|NCT01356095|OTHER|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
219689253|NCT04603352|OTHER|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
219689254|NCT06241118|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219689255|NCT06241118|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219689256|NCT06241118|DRUG|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
219689257|NCT06241118|DRUG|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
219689258|NCT03629288|OTHER|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
219689259|NCT03629288|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
219689260|NCT05509400|DRUG|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
219689261|NCT05509400|DRUG|Placebo|DB Phase: matching placebo
219689262|NCT05509400|DRUG|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
219689263|NCT00431093|DRUG|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
219689264|NCT00431093|DRUG|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
219689265|NCT05042817|DRUG|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
219689266|NCT05042817|DRUG|0.9% NaCl|NaCl 0.9%
219689267|NCT05042817|DRUG|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
219689268|NCT05042817|PROCEDURE|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
219689269|NCT02490774|DRUG|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
219689270|NCT02490774|DRUG|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
219689271|NCT02490774|DRUG|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
219689272|NCT00090896|BIOLOGICAL|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
219689273|NCT04884100|OTHER|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
219689274|NCT02676557|DEVICE|Exposed to the high pressure during the surgery|
219689275|NCT04792320|DIETARY_SUPPLEMENT|Active bamboo charcoal|4g particle
219689276|NCT04792320|DIETARY_SUPPLEMENT|probiotics|0.8g powder
219689277|NCT01921517|DEVICE|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
219689278|NCT01921517|DEVICE|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
219689279|NCT00305669|BIOLOGICAL|sargramostim|
219689280|NCT00305669|OTHER|immunohistochemistry staining method|
219689281|NCT00305669|OTHER|immunological diagnostic method|
219689282|NCT00305669|OTHER|laboratory biomarker analysis|
219689283|NCT00305669|PROCEDURE|conventional surgery|
219689284|NCT00305669|PROCEDURE|neoadjuvant therapy|
219689285|NCT02402946|BEHAVIORAL|Biofeedback|
219689286|NCT02402946|DRUG|Placebo|
219689287|NCT01505777|DRUG|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
219689288|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
219689289|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
219689290|NCT01505777|DRUG|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
219689291|NCT01505777|DRUG|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
219689292|NCT05702437|OTHER|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
219689293|NCT05852314|BEHAVIORAL|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
219101674|NCT05815316|DRUG|18F-PSMA-1007|(3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
219101675|NCT03390777|PROCEDURE|surgery|surgery without the use of prgf
219223877|NCT06940960|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
219223878|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
219223879|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
219689294|NCT00616551|DRUG|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
219689295|NCT00616551|DRUG|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
219689296|NCT02751112|BIOLOGICAL|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
219689297|NCT00269945|DRUG|epoetin alfa|
219689298|NCT03903263|DIAGNOSTIC_TEST|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
219689299|NCT04727957|OTHER|Diagnostic and prognostic models for VA-LRTIs|Diagnostic and prognostic models for VA-LRTIs
219689300|NCT05748132|PROCEDURE|combined conventional and pulsed RF|"1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
219101676|NCT03390777|DEVICE|PRGF after surgery|surgery and application of PRGF
219101677|NCT00885989|DRUG|SLV338|5 - 1000 mg IV
219101678|NCT00885989|DRUG|Placebo|Placebo
219223880|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
219223881|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
219223882|NCT05529472|DEVICE|Peripheral Orbital Atherectomy System (OAS)|Treatment with Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA), pre-dilation and Drug Coated Balloon (DCB) - Medtronic IN.PACT™ Admiral™
219223883|NCT06947876|OTHER|Enrolment 3T MRI research scan|Enrolment research scan performed with 3T magnetic resonance imaging scanner.
219101679|NCT06160752|DRUG|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
219101680|NCT06160752|DRUG|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
219101681|NCT01108393|DRUG|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
219101682|NCT01108393|DRUG|Placebo|Placebo
219101683|NCT02753348|OTHER|Echocardiography|
219101684|NCT02753348|OTHER|Blood analysis from umbilical cord blood|
219101685|NCT02753348|OTHER|ECG|
219101686|NCT02753348|OTHER|Measurement of oxygen saturation|
219689301|NCT01823471|OTHER|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
219689302|NCT01973686|BEHAVIORAL|Physical activity|
219689303|NCT02787304|DRUG|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
219689304|NCT02787304|DRUG|Placebo|Matching placebo
219689305|NCT04818944|DRUG|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
219689306|NCT04818944|DRUG|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
219101687|NCT04378660|DIAGNOSTIC_TEST|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
219689307|NCT05447273|DIAGNOSTIC_TEST|Multi-parametric, functional magnetic resonance imaging (MRI)|Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
219689308|NCT03561454|DEVICE|IORT|Intra-Operative Radiation Therapy
219101688|NCT02995902|DEVICE|FLT-PET|
219101689|NCT02995902|DEVICE|MRI|
219101690|NCT01988896|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
219101691|NCT01988896|DRUG|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
219101692|NCT05341778|OTHER|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
219101693|NCT05341778|OTHER|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
219101694|NCT05341778|OTHER|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
219101695|NCT05341778|OTHER|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
219101696|NCT05341778|OTHER|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
219223884|NCT06947876|OTHER|Enrolment Field-cycling Imaging research scan|Enrolment research scan performed with Field-Cycling Imaging scanner.
219223885|NCT06947876|OTHER|Enrolment ultra-low field MRI research scan|Enrolment research scan performed with ultra-low field MRI scanner
219223886|NCT06947876|OTHER|Follow up 3T MRI research scan|Follow up research scan performed with 3T magnetic resonance imaging scanner, 18-months after baseline scans.
219223887|NCT06947876|OTHER|Follow up Field-cycling Imaging research scan|Follow up research scan performed with Field-Cycling Imaging scanner, 18-months after baseline scans.
219223888|NCT06947876|OTHER|Follow up ultra-low field MRI research scan|Follow up research scan performed with Ultra-low field MRI scanner, 18-months after baseline scans.
219689309|NCT01997034|BEHAVIORAL|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
219689310|NCT04579809|PROCEDURE|4 strand technique|4 strand technique reapir of tendin flexor injury
219689311|NCT01810224|PROCEDURE|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
219223889|NCT06947876|OTHER|Enrolment cognitive assessment interview|Enrolment interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test.
219223890|NCT06947876|OTHER|Follow up cognitive assessment interview|Follow up interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test. Performed 18-months after baseline interview.
219223891|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 8mA|Phrenic nerve stimulation (PNS) at 8mA is applied.
219223892|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA is applied.
219223893|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA combined with phrenic-abdominal stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA combined with phrenic-abdominal stimulation at 15mA is applied.
219223894|NCT06951243|DRUG|MHB088C for Injection (B7-H3 ADC)|MHB088C for Injection, an antibody drug-conjugated molecule (ADC), is conjugated from a humanized monoclonal antibody targeting the B7-H3 molecule and a DNA topoisomerase I inhibitor (TOP1i) via protease-hydrolyzable linkers.The intervention will be administered intravenously at a dose of 2.0 mg/kg every 2 weeks (Q2W) until disease progression, withdrawal from the study, or death.
219223895|NCT06952088|OTHER|Training on Neonatal Resuscitation|Improve training of health care personnel (physicians, nurses and midwives) on neonatal resuscitation through manikin simulation using two different devices: a face mask and a laryngeal mask. Before the simulations begin, each participant will receive a brief introduction on the technical characteristics of the manikin and how to use the two masks. A stopwatch will be used to record the time required to achieve effective ventilation, defined by the expansion of one-third of the newborn manikin's rib cage. Consideration will also be given to whether corrective maneuvers will need to be performed during the use of each mask and the timing with which these maneuvers will be applied. Finally, a pseudonymous questionnaire will be administered to participants to assess their perceptions of the ease of use of each mask.
219689312|NCT02745652|DEVICE|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
219689313|NCT02745652|DEVICE|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
219689314|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
219689315|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
219689316|NCT00991081|BEHAVIORAL|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD"
219689317|NCT00991081|BEHAVIORAL|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
219689318|NCT00991081|DRUG|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion"
219689319|NCT00991081|BEHAVIORAL|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
219689320|NCT00991081|BEHAVIORAL|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
219689321|NCT04938076|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
219689322|NCT04938076|DEVICE|sham control|sham control
219689323|NCT01638715|DRUG|Remicade|\- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
219689324|NCT01638715|DRUG|Orencia|\- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
219689325|NCT01638715|DRUG|Ro-Actemra|\- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
219689326|NCT01638715|DRUG|Mabthera|"\- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
219689327|NCT02100280|DRUG|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
219689328|NCT01796028|DRUG|METFORMIN|
219689329|NCT01796028|DRUG|Placebo|
219689330|NCT01796028|DRUG|TAXOTERE®|
219689331|NCT02507791|OTHER|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
219689332|NCT06455657|OTHER|breast cancer education|Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
219689333|NCT03937115|DEVICE|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
219101697|NCT05341778|OTHER|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
219101698|NCT05341778|OTHER|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
219101699|NCT05341778|OTHER|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
219101700|NCT05341778|DEVICE|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
219689334|NCT03937115|DEVICE|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
219689335|NCT03937115|DEVICE|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
219689336|NCT03937115|DEVICE|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
219689337|NCT04454008|BEHAVIORAL|executive function family training|Intervention programs include executive function training for children with ADHD and parenting guidance for parents
219689338|NCT04454008|BEHAVIORAL|treat as usual|Outpatient routine health education, behavioral guidance and family support
219689339|NCT04265521|DEVICE|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
219689340|NCT02843009|BEHAVIORAL|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
219689341|NCT02843009|DIETARY_SUPPLEMENT|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
219689342|NCT03110354|DRUG|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
219689343|NCT06338306|DRUG|Tacrolimus（FK506）|Prograf
219689344|NCT04101383|DRUG|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
219689345|NCT04101383|DRUG|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
219689346|NCT05761353|DEVICE|Endermologie|"Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
219689347|NCT05761353|DEVICE|Negative pressure therapy|"Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
219689348|NCT00379834|DRUG|Cosopt|Cosopt twice daily in both eyes
219689349|NCT03984396|OTHER|Educational Materials - Patient & Clinician|deprescribing information for patient \& clinician
219689350|NCT05415189|OTHER|Not relevant|This is a non-intervention cohort study
219689351|NCT05700734|DRUG|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
219689352|NCT02233218|DRUG|Telmisartan|
219689353|NCT02233218|DRUG|Amlodipine|
219689354|NCT02233218|DRUG|Rosuvastatin|
219689355|NCT02907242|OTHER|Revealment|Cerebroplacental ratio revealment
219689356|NCT03856372|RADIATION|Hypofractionated|daily fractions, five fractions per week.
219689357|NCT03856372|RADIATION|Conventional|daily fractions, five fractions per week.
219689358|NCT03041389|BEHAVIORAL|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
219689359|NCT03041389|BEHAVIORAL|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
219689360|NCT01595373|DRUG|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
219689361|NCT01595373|DRUG|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
219689362|NCT03533218|DEVICE|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
219689363|NCT03504215|OTHER|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
219689364|NCT04577638|COMBINATION_PRODUCT|Nivolumab and Intensity Modulated Radiotherapy (IMRT)|"Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption."
219689365|NCT00115310|DRUG|NGX-4010|
219689366|NCT03909048|BEHAVIORAL|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
219689367|NCT03909048|BEHAVIORAL|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
219689368|NCT00811694|OTHER|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
219689369|NCT02027233|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
219689370|NCT04192149|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
219689371|NCT03328234|RADIATION|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
219689372|NCT03328234|DRUG|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
219689373|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
219101701|NCT06437665|BEHAVIORAL|The intervention name in this study is ADAS-integrated driver simulation training.|The intervention involves providing older drivers (≥65 years of age) with training sessions utilizing a high-fidelity driving simulator. This training focuses on the integration and use of Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies, collectively referred to as ADAS. The training is designed to familiarize participants with these advanced driver assistance systems, enabling them to effectively utilize these features while driving.
219223896|NCT06951854|DRUG|Drug: NV01-A02|NV01-A02 will be administered orally at a different dose once daily for 8 weeks. The formulation is a white, film-coated tablet, designed for use in patients with mild to moderate cognitive impairment.
219101702|NCT04848194|PROCEDURE|skin biopsy and blood sampling|"* 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample"
219101703|NCT03881176|DEVICE|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
219101704|NCT05458024|DRUG|Vitamin D 2|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
219101705|NCT05458024|DRUG|Vitamin D2 Placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
219689374|NCT03328234|DRUG|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
219689375|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
219689376|NCT03328234|OTHER|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
219689377|NCT01256528|PROCEDURE|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
219689378|NCT01298700|DRUG|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
219689379|NCT01298700|DRUG|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
219689380|NCT00129441|DRUG|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
219689381|NCT00129441|DRUG|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
219689382|NCT05555498|DEVICE|Virtual Reality glasses|The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
219689383|NCT03425669|DEVICE|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
219223897|NCT06951854|DRUG|Drug: Placebo (ZP8396)|ZP8396 is a matching placebo tablet administered orally once daily for 8 weeks. The placebo is identical in appearance to NV01-A02 but contains no active ingredient.
219223898|NCT02370797|RADIATION|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
219223899|NCT05587764|DIAGNOSTIC_TEST|Standard of Care|Standard of care for emergency events per local guidelines.
219689384|NCT03425669|DEVICE|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
219689385|NCT03425669|DRUG|Active medication|Patients will be examined with and without medication.
219689386|NCT00667329|DRUG|2CdA|1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
219689387|NCT00667329|DRUG|Cyclophosphamide|40 mg/m\^2 PO twice daily x 7 days.
219689388|NCT00667329|DRUG|Rituximab|375 mg/m\^2 IV once weekly x 4 weeks.
219689389|NCT01001429|DRUG|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
219689390|NCT01001429|DRUG|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
219689391|NCT04643132|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
219689392|NCT04643132|DRUG|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
219689393|NCT04643132|DRUG|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
219689394|NCT02880254|DEVICE|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
219689395|NCT02880254|DEVICE|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
219689396|NCT01348126|DRUG|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
219689397|NCT01348126|DRUG|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
219223900|NCT02921711|DEVICE|LVIS®|Low-profile Visualized Intraluminal Support device
219223901|NCT06518486|OTHER|Foot-ankle exercise|Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
219223902|NCT06518486|OTHER|Walking exercise|Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
219223903|NCT06518486|OTHER|Usual care and health education|Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
219223904|NCT05253781|DRUG|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
219689398|NCT02627079|OTHER|Daily SMS text messaging|
219689399|NCT01725633|BEHAVIORAL|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
219689400|NCT01725633|BEHAVIORAL|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
219689401|NCT01725633|OTHER|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
219689402|NCT01725633|OTHER|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
219689403|NCT01690507|DRUG|Decitabine|20 mg/m²/day for 5 days
219689404|NCT01690507|DRUG|Cytarabine|
219689405|NCT01690507|DRUG|aclacinomycin|
219689406|NCT01690507|DRUG|Granulocyte colony-stimulating factor|
219689407|NCT01690507|OTHER|HLA haploidentical mononuclear cells infusion|
219689408|NCT04321928|BEHAVIORAL|Personalized health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
219689409|NCT04321928|BEHAVIORAL|General health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
219689410|NCT01092013|BEHAVIORAL|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
219689411|NCT01092013|BEHAVIORAL|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
219689412|NCT01092013|BEHAVIORAL|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
219689413|NCT01838239|DIETARY_SUPPLEMENT|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
219689414|NCT03008811|PROCEDURE|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
219689415|NCT03008811|PROCEDURE|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
219689416|NCT03756948|OTHER|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
219689417|NCT03756948|OTHER|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
219689418|NCT04882696|OTHER|Non-slip socks|Patients will wear non-slip socks during their hospitalization
219689419|NCT00104936|PROCEDURE|adjuvant therapy|
219689420|NCT00104936|RADIATION|radiation therapy|
219689421|NCT00104936|RADIATION|stereotactic radiosurgery|
219689422|NCT02189668|DRUG|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
219689423|NCT03732027|PROCEDURE|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
219101706|NCT05851248|PROCEDURE|Buccal muco-gingival tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site."
219689424|NCT03732027|PROCEDURE|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
219689425|NCT01549145|DEVICE|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
219689426|NCT05471011|OTHER|Blood and nasal swab sampling|Blood and nasal swab sampling
219689427|NCT02179125|DEVICE|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
219689428|NCT03984708|OTHER|Samples|Blood sample, skin biopsy
219689429|NCT03984708|OTHER|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
219689430|NCT03984708|OTHER|Electrical bioimpedance|Measurement of electrical bioimpedance
219689431|NCT04657939|DRUG|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
219689432|NCT04657939|DRUG|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
219689433|NCT00643760|DRUG|Placebo|placebo
219689434|NCT00643760|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
219689435|NCT00643760|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
219689436|NCT00643760|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
219689437|NCT00643760|DRUG|Pregabalin|pregabalin 300mg/day
219689438|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
219689439|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
219689440|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
219689441|NCT04790695|DRUG|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
219689442|NCT02063672|DEVICE|Lutonix DCB|
219689443|NCT02063672|DEVICE|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
219689444|NCT01053741|BIOLOGICAL|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
219689445|NCT01053741|BIOLOGICAL|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
219689446|NCT04881643|BEHAVIORAL|Trauma-focused cognitive behavioural therapy via a digital support|A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
219689447|NCT03143257|DEVICE|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
219689448|NCT02536937|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
219689449|NCT00236002|DRUG|Alendronate|Alendronate 70mgm once a week for one year
219689450|NCT00933725|OTHER|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
219689451|NCT00933725|OTHER|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
219689452|NCT02244983|OTHER|Patients History|History taking and drawing of a blood sample
219689453|NCT03916666|PROCEDURE|Epiduroscopy|Endoscopic intervention
219689454|NCT00843141|BEHAVIORAL|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
219223905|NCT05253781|OTHER|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
219223906|NCT06017505|DIAGNOSTIC_TEST|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
219223907|NCT00237016|DRUG|doxycycline treatment|
219223908|NCT06470503|BEHAVIORAL|Exercise Program|8-week program and four-week short maintenance period.
219689455|NCT00843141|BEHAVIORAL|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
219689456|NCT03301389|OTHER|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
219689457|NCT03795480|BEHAVIORAL|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
219689458|NCT05971771|OTHER|Placebo|Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
219689459|NCT05971771|DIETARY_SUPPLEMENT|Treatment|14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
219689460|NCT03844659|OTHER|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
219689461|NCT03844659|OTHER|No Song|No song will be played during subjects labor epidural placement.
219689462|NCT05619666|PROCEDURE|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
219689463|NCT00104052|BIOLOGICAL|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
219689464|NCT00104052|DRUG|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
219689465|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
219689466|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
219689467|NCT01195779|BIOLOGICAL|Fluarix™|Intramuscular injections
219689468|NCT04500574|DRUG|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
219689469|NCT04500574|DRUG|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
219689470|NCT03850717|DEVICE|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
219689471|NCT02850094|BEHAVIORAL|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
219689472|NCT04135547|DEVICE|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
219689473|NCT03819517|DRUG|Resveratrol|Over the counter supplementation
219689474|NCT03819517|OTHER|Placebo|Empty white colored soft vegetarian capsule
219689475|NCT05985746|OTHER|Augmented reality group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
219689476|NCT05985746|OTHER|Traditional learning group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
219689477|NCT01932489|PROCEDURE|Biopsy of a metastatic lesion.|
219689478|NCT04995913|OTHER|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
219101707|NCT05851248|PROCEDURE|Palatal connective tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone."
219689479|NCT02507570|DRUG|Enzalutamide|used concomitantly
219689480|NCT02507570|RADIATION|Radium ra 223 dichloride|
219689481|NCT03159585|DRUG|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
219689482|NCT06958913|DRUG|Propofol group|In group P, 0.125 cc/kg saline infusion was administered in 10 minutes. Fentanyl was administered at a dose of 3 mcg/kg at 5 minutes of this application. Then propofol was administered until the eyelash reflex disappeared and the BIS value was 40. 0.6 mg/kg rocuronium was administered to facilitate intubation. All patients received 8 mg dexamethasone and lidocaine at a dose of 1 mg/kg.
219689483|NCT06958913|DRUG|Dexmedetomidine|In group DP, dexmedetomidine at a dose of 0.5 mck/kg was administered over 10 minutes. At the 5th minute of this infusion, fentanyl was administered at a dose of 3 mcg/kg. Propofol was added until the BIS value was 40. The patients received 0.6 mg/kg rocuronium, 8 mg dexamethasone, and 1 mg/kg lidocaine.
219689484|NCT03208816|BEHAVIORAL|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
219689485|NCT03551795|BIOLOGICAL|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) in one course of treatment.
219689486|NCT03577249|DRUG|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
219689487|NCT01503554|BEHAVIORAL|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
219689488|NCT01503554|BEHAVIORAL|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
219689489|NCT01166256|DEVICE|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 \>92% or PaO2 \>65 mmHg.
219689490|NCT01166256|DEVICE|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 \>92% or PaO2 \>65 mmHg.
219689491|NCT03259958|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
219689492|NCT03259958|DRUG|Aricept|Aricept Tablet
219689493|NCT06472947|DEVICE|ULM and MSOT|transplanted kidney will be examined non-invasively with ULM and MSOT
219689494|NCT01591798|PROCEDURE|Robotic surgery|Robotic assisted rectal resection
219689495|NCT01591798|PROCEDURE|Laparoscopic surgery|Laparoscopic assisted rectal resection
219689496|NCT03915834|DEVICE|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
219689497|NCT02600117|DRUG|Tenofovir disoproxil fumarate|300 mg, oral, once a day
219689498|NCT03041662|DIAGNOSTIC_TEST|MR/MRCP|MR/MRCP
219689499|NCT02948712|BEHAVIORAL|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
219689500|NCT02948712|BEHAVIORAL|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
219689501|NCT02737267|BEHAVIORAL|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
219689502|NCT02737267|BEHAVIORAL|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
219689503|NCT03194009|DRUG|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
219689504|NCT03194009|BEHAVIORAL|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
219101708|NCT05701176|DIAGNOSTIC_TEST|[18F]F-AraG PET scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
219689505|NCT03117504|OTHER|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
219689506|NCT03021811|DEVICE|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
219689507|NCT02292459|DRUG|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
219689508|NCT02292459|DRUG|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
219223909|NCT06464016|DEVICE|Ventricular Assist Device with Berlin Heart EXCOR|"The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body."
219223910|NCT04153682|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
219689509|NCT04797208|DEVICE|Real-Time CGM|Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
219689510|NCT04797208|DEVICE|Capillary blood glucose testing with masked CGM|Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
219689511|NCT04052646|OTHER|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
219689512|NCT02619617|DRUG|SOM230|The study evaluated SOM230 vs Placebo
219689513|NCT02619617|DRUG|Placebo|The study evaluated SOM230 vs Placebo
219689514|NCT03414853|DIAGNOSTIC_TEST|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
219689515|NCT02416232|DRUG|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
219689516|NCT02416232|DRUG|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
219689517|NCT00527280|PROCEDURE|Feasibility ot face transplantation|Feasibility ot face transplantation
219689518|NCT02584283|PROCEDURE|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
219689519|NCT02584283|DEVICE|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
219689520|NCT02584283|PROCEDURE|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
219689521|NCT02584283|DRUG|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
219689522|NCT01768780|DEVICE|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
219689523|NCT03007303|DRUG|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
219689524|NCT03007303|OTHER|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
219689525|NCT02515630|DRUG|MMB|Momelotinib (MMB) tablet administered orally once daily
219689526|NCT05648799|DRUG|GP30341 capsules 200 mg|orall take of capsules twice a day
219689527|NCT05648799|DRUG|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
219689528|NCT04073719|DIETARY_SUPPLEMENT|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
219689529|NCT04073719|DIETARY_SUPPLEMENT|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
219101709|NCT06453096|OTHER|prevalence of personality disorders|the prevalence of personality disorders will be investigated with a retrospective study
219101710|NCT03653832|DRUG|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
219101711|NCT03653832|DRUG|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
219689530|NCT00905242|DRUG|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
219689531|NCT05558319|DRUG|Bortezomib|Bortezomib
219689532|NCT05558319|DRUG|Isatuximab|Isatuximab
219689533|NCT05558319|DRUG|Iberdomide|Iberdomide
219689534|NCT05558319|DRUG|Lenalidomide|Lenalidomide
219689535|NCT05558319|DRUG|Dexamethasone|Dexamethasone
219689536|NCT00926250|DIETARY_SUPPLEMENT|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
219689537|NCT00926250|DIETARY_SUPPLEMENT|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
219689538|NCT02904746|BEHAVIORAL|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
219689539|NCT05380765|BEHAVIORAL|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
219689540|NCT05959265|BEHAVIORAL|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
219689541|NCT02306889|DRUG|Fenofibrate|130mg Capsules
219689542|NCT02306889|DRUG|ANTARA® (fenofibrate)|130mg Capsules
219689543|NCT01477762|DRUG|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
219689544|NCT01477762|DRUG|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
219689545|NCT02151357|DRUG|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
219689546|NCT02130999|DRUG|tasimelteon 20 mg capsule|
219689547|NCT02130999|DRUG|tasimelteon 2 mg I.V.|
219689548|NCT00697320|DRUG|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
219689549|NCT04979481|BEHAVIORAL|BRAVE|The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.
219689550|NCT04979481|BEHAVIORAL|STEM|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
219689551|NCT03391752|COMBINATION_PRODUCT|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
219689552|NCT00789503|DIETARY_SUPPLEMENT|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
219689553|NCT02809365|DEVICE|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
219689554|NCT02809365|DEVICE|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
219689555|NCT01848106|DRUG|pegnivacogin/anivamersen|
219689556|NCT01848106|DRUG|Bivalirudin|
219689557|NCT04723459|OTHER|ivermectin impregnated mask|mask with ivermectin nano solution
219689558|NCT05848960|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral supplement|2 supplements per day
219689559|NCT05848960|OTHER|Mediterranean diet|Mediterranean diet
219689560|NCT02353026|DRUG|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
219689561|NCT00230048|BEHAVIORAL|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
219689562|NCT03199352|OTHER|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
219223911|NCT04153682|DIAGNOSTIC_TEST|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
219689563|NCT03199352|OTHER|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
219689564|NCT06053385|OTHER|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
219689565|NCT06053385|OTHER|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
219689566|NCT01566604|DRUG|NVA237|Delivered via a single dose dry powder inhaler
219689567|NCT01566604|DRUG|Placebo|Delivered via a single dose dry powder inhaler
219689568|NCT00339417|DRUG|Albendazole|
219689569|NCT00339417|DRUG|Ivermectin|
219689570|NCT05067855|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
219689571|NCT02421692|OTHER|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
219689572|NCT02903342|OTHER|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
219101712|NCT03653832|DRUG|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
219101713|NCT05257057|DIAGNOSTIC_TEST|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
219101714|NCT05777174|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
219223912|NCT05432986|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
219689573|NCT03225170|BEHAVIORAL|Self Affirmation (SA)|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
219689574|NCT03225170|BEHAVIORAL|Control|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
219689575|NCT01204034|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
219689576|NCT01668836|DRUG|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
219689577|NCT01668836|BEHAVIORAL|Caloric restriction|Diet of 1000kcal per day for 30 days
219689578|NCT04936516|DEVICE|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
219689579|NCT05916222|BEHAVIORAL|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
219689580|NCT01631448|BIOLOGICAL|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
219689581|NCT02955303|OTHER|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
219689582|NCT06232096|DRUG|MBS314 Injection|"Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ."
219689583|NCT00405301|DRUG|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
219689584|NCT04310722|OTHER|None intervention. This is an observational study.|None intervention. This is an observational study.
219689585|NCT00731822|DRUG|GW685698/GW642444|GW685698/GW642444
219689586|NCT04585919|BEHAVIORAL|Paired Screening Intervention|The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
219689587|NCT06354491|DEVICE|Magnetic Resonance Imaging (MRI)|MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.
219689588|NCT06354491|DEVICE|Ultrasound (US)|In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
219689589|NCT02432599|RADIATION|F18-choline PET examination|F18-choline PET examination will be performed before surgery
219689590|NCT02779985|DIETARY_SUPPLEMENT|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
219689591|NCT02779985|DIETARY_SUPPLEMENT|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
219689592|NCT01987856|PROCEDURE|Blastocyst morphology|microscopic examination only
219689593|NCT05294952|GENETIC|real time PCR|diagnostic test
219689594|NCT05218187|DEVICE|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
219223913|NCT05791227|DIAGNOSTIC_TEST|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
219689595|NCT05218187|OTHER|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
219689596|NCT06475365|OTHER|Sodium chloride gargle|15mL salt water gargle
219689597|NCT05263934|BIOLOGICAL|Depemokimab|Depemokimab will be administered
219689598|NCT05263934|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered
219689599|NCT05263934|DRUG|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
219689600|NCT05263934|DRUG|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
219689601|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
219689602|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
219689603|NCT05549622|OTHER|Low-soluble fiber diet|12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
219689604|NCT05549622|OTHER|High-soluble fiber diet|12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
219689605|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
219689606|NCT05335811|DRUG|4-[18F]Fluoro-1-Naphthol|By vein (IV)
219689607|NCT02511327|DRUG|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
219689608|NCT02889224|OTHER|Obese|
219689609|NCT02889224|PROCEDURE|Hypercortisolism|
219689610|NCT02889224|OTHER|Hydrocortisone|
219223914|NCT05791227|DIAGNOSTIC_TEST|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
219689611|NCT02889224|OTHER|Control|
219689612|NCT02539069|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
219689613|NCT00194935|DRUG|Topotecan|
219689614|NCT06200935|DIETARY_SUPPLEMENT|Probiotic blend|Administration of one stick of combined probiotics per day for 5 months
219689615|NCT02558049|OTHER|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
219689616|NCT06810882|DRUG|Perineural ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes.
219689617|NCT06810882|DRUG|Intravenous ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.
219689618|NCT06962098|DRUG|Isuzinaxib|Oral dosing regimen once daily
219689619|NCT06962098|DRUG|Placebo|Oral dosing regimen once daily
219101715|NCT05777174|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System was initiated to collect background fluorescence. When this was completed, participants received a single dose of MB-102. Fluorescent measurements were collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body.
219101716|NCT05310279|OTHER|GAIMplank|The GAIMplank video game controller will be used to play active video games.
219101717|NCT02667886|DRUG|X4P-001|Continuous, oral dosing
219101718|NCT02667886|DRUG|axitinib|Continuous, oral dosing
219101719|NCT06028958|OTHER|Neck Isometrics Exercises|Isometric exercises are tightening (contractions) of a specific muscle or group of muscles. During isometric exercises, the muscle doesn't noticeably change length. The affected joint also doesn't move. Isometric exercises help maintain strength.
219101720|NCT06028958|OTHER|Global Posture Re-Education|Global postural rehabilitation (GPR) is an approach that considers the body in its overall aspect. This technique aims to relax the envelope of the muscles (fascia) while relaxing the muscle chains to reduce the strain on the joints. The end result is a more suitable posture and less pain.
219689620|NCT05538871|DIAGNOSTIC_TEST|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
219689621|NCT02532335|DRUG|Obeticholic acid|active drug
219101721|NCT05487794|DRUG|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
219223915|NCT06027996|DEVICE|Absorbable Antibacterial Matrix|Soft tissue support coated with antibiotics
219689622|NCT02532335|DRUG|Obeticholic acid placebo|matching placebo
219689623|NCT05854420|PROCEDURE|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
219689624|NCT05800756|DRUG|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
219689625|NCT03589807|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
219689626|NCT03589807|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
219689627|NCT03589807|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
219689628|NCT03589807|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
219689629|NCT00719160|DRUG|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
219689630|NCT00719160|DRUG|Placebo|Placebo 20 mg twice a day for 9 days
219689631|NCT03746925|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
219689632|NCT03746925|PROCEDURE|SuperPATH|SuperPATH approach surgery to replace the hip.
219689633|NCT02357225|DRUG|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
219689634|NCT05493293|DRUG|NBI-921352|Tablets for oral administration
219689635|NCT03383991|PROCEDURE|Reverse Total Shoulder Arthroplasty|
219689636|NCT03383991|PROCEDURE|Hemiarthroplasty|
219689637|NCT02435303|DRUG|Sildenafil|
219689638|NCT02435303|DRUG|Placebo|
219689639|NCT06028737|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
219689640|NCT06028737|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
219101722|NCT03997578|PROCEDURE|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
219101723|NCT03997578|PROCEDURE|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
219689641|NCT06028737|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
219689642|NCT06028737|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
219689643|NCT05920499|OTHER|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
219689644|NCT02638974|OTHER|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
219101724|NCT03442673|DRUG|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
219101725|NCT03442673|DRUG|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
219101726|NCT03442673|DRUG|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
219101727|NCT05809531|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219101728|NCT00617721|OTHER|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
219689645|NCT02558764|DEVICE|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
219101729|NCT05581615|OTHER|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
219101730|NCT03764098|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
219101731|NCT03764098|OTHER|Placebo|Placebo
219689646|NCT04346576|DIETARY_SUPPLEMENT|Probiotics prevent health problems in children|A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
219101732|NCT06413784|OTHER|Morning chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of morning chronotype individuals were examined.
219101733|NCT06413784|OTHER|Intermediate chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of intermediate chronotype individuals were examined.
219689647|NCT01579513|DRUG|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
219689648|NCT01579513|DRUG|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
219689649|NCT02390271|OTHER|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
219689650|NCT05694858|COMBINATION_PRODUCT|Lignocaine-loaded maltose microneedle array patch|A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to venepuncture.
219689651|NCT05694858|DRUG|EMLA 5% patch|EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to venepuncture
219689652|NCT04547777|DRUG|D2C7-IT|D2C7-IT intratumoral infusion
219689653|NCT04547777|DRUG|2141-V11|2141-11 intratumoral infusion
219689654|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks
219689655|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
219689656|NCT05936151|DRUG|Retatrutide|Administered SC
219689657|NCT05936151|DRUG|Placebo|Administered SC
219689658|NCT04741009|DEVICE|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
219689659|NCT06247696|OTHER|Herbal Pillows|Pillows containing herbs
219689660|NCT02691390|DEVICE|Active dTMS|dTMS to ACC
219689661|NCT02691390|DEVICE|Sham dTMS|SHAM - no stimulation
219689662|NCT03488797|BEHAVIORAL|Supervised web- and home-based exercise intervention|"* The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
219689663|NCT00472745|BEHAVIORAL|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
219689664|NCT00472745|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 months
219689665|NCT04535999|DRUG|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
219689666|NCT05657366|PROCEDURE|Peritoneal lavage|Continuous abdominal flushing with normal saline
219689667|NCT03003442|DIETARY_SUPPLEMENT|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
219689668|NCT03003442|DIETARY_SUPPLEMENT|Placebo|Placebo
219689669|NCT01431339|DRUG|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
219689670|NCT01431339|DRUG|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
219689671|NCT00260546|PROCEDURE|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
219689672|NCT03166787|OTHER|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
219101734|NCT06413784|OTHER|Evening chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of evening chronotype individuals were examined.
219101735|NCT02650843|OTHER|DAT SPECT imaging|
219101736|NCT05250011|DRUG|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
219689673|NCT03166787|OTHER|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
219689674|NCT03166787|OTHER|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
219689675|NCT03166787|DRUG|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
219689676|NCT03166787|OTHER|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
219689677|NCT03166787|DRUG|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
219689678|NCT03166787|DRUG|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
219223916|NCT06082518|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device).|"40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada."
219223917|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
219223918|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
219223919|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
219223920|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
219689679|NCT03462784|OTHER|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
219689680|NCT04907214|DRUG|Empagliflozin 25 MG|Oral empagliflozin daily
219689681|NCT01205347|DRUG|Simvastatin 80mg|Simvastatin 80mg once a day
219689682|NCT01205347|DRUG|Simvastatin 10mg|Simvastatin 10mg once a day
219689683|NCT00385918|DEVICE|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
219689684|NCT00385918|OTHER|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
219689685|NCT06421389|DRUG|Tranexamic Acid Powder|2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
219689686|NCT03988153|COMBINATION_PRODUCT|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
219689687|NCT02727049|OTHER|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
219689688|NCT00000962|DRUG|Nevirapine|
219689689|NCT04710719|DRUG|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
219689690|NCT04710719|DRUG|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
219689691|NCT03030677|PROCEDURE|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
219223921|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
219223922|NCT05567016|OTHER|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
219223923|NCT05567016|OTHER|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
219101737|NCT06278246|RADIATION|PET Scan|PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state
219101738|NCT06823843|DRUG|Glycerin trinitrate (GTN)|2 sublingual puffs for a total dose of 800 µg
219101739|NCT06823843|DRUG|Saline (NaCl 0,9 %) (placebo)|2 puffs of sublingual saline
219101740|NCT04959929|DEVICE|Focal vibration therapy|Myovolt is a wearable rehabilitative device that delivers vibration to the region of the body where the motors are worn. Participants are asked to apply the vibration to specific leg locations twice a day, for about 30 minutes at a time, and to record their response using a provided log. They may be asked to try applying the device at different location or using different vibration parameters (pulse frequency or intensity).
219689692|NCT03030677|PROCEDURE|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
219689693|NCT03030677|OTHER|catheter insertion|catheter insertion after Lidocaine dissection
219689694|NCT04609657|OTHER|Flavored carbonated soft drink (CSD)|Beverage
219223924|NCT05567016|OTHER|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
219689695|NCT03940196|DEVICE|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
219689696|NCT03940196|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
219689697|NCT06328257|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219689698|NCT01900041|DRUG|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
219689699|NCT01900041|DRUG|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
219689700|NCT01023594|PROCEDURE|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
219689701|NCT01935024|OTHER|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
219689702|NCT04912843|DRUG|NR082 injection|Intravitreal injection（IVT）
219689703|NCT04912843|DEVICE|Sham Injection|Sham Intravitreal Injection
219689704|NCT03902769|PROCEDURE|Prescribing conventional chemotherapy while with holding allo-SCT|Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
219689705|NCT01171157|OTHER|Routine sample collection|Collection of routine nasal/throat swab samples
219689706|NCT01997008|BEHAVIORAL|Intervention|Positive Affect Skills Training
219689707|NCT05545176|OTHER|termination of resuscitation rules|Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
219689708|NCT02100046|DRUG|Zarontin® (ethosuximide) and Stodal®|
219689709|NCT03857698|OTHER|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~* Ice application for pain, edema control~* Patellar mobilization~* Three-way straight leg lifting exercises~* Isometric exercises around the hips and knees~* Active assisted, active, resistant knee range of motion exercises~* Heel shift exercises in supine and sitting~* Hip abduction on the side lying~* Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~* Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
219689710|NCT03857698|OTHER|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension"
219689711|NCT03615313|BIOLOGICAL|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
219689712|NCT01655225|DRUG|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
219689713|NCT01655225|DRUG|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
219689714|NCT01655225|DRUG|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
219689715|NCT01655225|DRUG|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
219689716|NCT01655225|DRUG|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
219689717|NCT01655225|DRUG|Abemaciclib|Administered orally
219689718|NCT01655225|DRUG|Letrozole|Administered orally
219689719|NCT01634646|DIETARY_SUPPLEMENT|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
219689720|NCT01878903|OTHER|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
219101741|NCT03614962|DEVICE|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
219101742|NCT03614962|DEVICE|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
219101743|NCT03614962|DEVICE|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
219689721|NCT06634147|BEHAVIORAL|Exercise|"Multicomponent individualized exercise intervention As mentioned earlier, patients in the control group (G0) will receive the usual care currently provided to other patients, which includes a referral to physical therapy if needed.~The intervention for the multicomponent physical exercise intervention group (G1) will consist of a multicomponent physical training program that includes progressive and supervised aerobic endurance, strength, and balance training lasting 4-7 days during their hospitalization. This will be supervised by the research team from the Geriatrics Unit. Additionally, after hospital discharge, they will receive individualized guidelines to engage in multicomponent physical exercise for 3 months, along with individualized recommendations from the Nutrition and Dietetics Service of HUN.~The multicomponent physical training program will consist of chair squat exercises. The main part of the training will utilize machines for strength training for the lower extremit"
219689722|NCT01676701|DRUG|Tabalumab Auto-Injector|Administered SC by auto-injector
219689723|NCT01676701|DRUG|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
219689724|NCT02197390|BEHAVIORAL|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
219689725|NCT02197390|BEHAVIORAL|Obesity chronic care model|
219689726|NCT02197390|BEHAVIORAL|Physical activity, healthy eating, water drinking, healthy sleep promotion|
219689727|NCT02197390|BEHAVIORAL|Environment, policy, systems changes in clinic setting only|
219689728|NCT02197390|BEHAVIORAL|No intervention|No intervention.
219689729|NCT02197390|BEHAVIORAL|Environment, policy, and systems changes in schools, early child care education & recreation|
219689730|NCT01342354|RADIATION|Stereotactic Radiation 10 Gy|10 Gy three times over 10 days
219689731|NCT01342354|RADIATION|Stereotactic Radiation 12.5 Gy|12.5 Gy three times over 10 days
219689732|NCT01342354|RADIATION|Stereotactic Radiation 15 Gy|15 Gy three times over 10 days
219689733|NCT06521047|OTHER|NA - Observational study|Observational study, data collection only.
219689735|NCT06554288|DRUG|Trihexyphenidyl|6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
219689736|NCT03635697|BEHAVIORAL|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
219689737|NCT05388981|BIOLOGICAL|SBT115301|Immunomodulatory dimeric fusion protein
219689738|NCT05388981|BIOLOGICAL|Placebo|Matched placebo
219689739|NCT03913819|DRUG|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
219689740|NCT03913819|DRUG|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
219689741|NCT03913819|DRUG|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
219689742|NCT03913819|PROCEDURE|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
219689743|NCT04536701|BEHAVIORAL|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
219689744|NCT04167358|DRUG|Linerixibat|All participants will receive linerixibat.
219689745|NCT06318026|BEHAVIORAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use
219689746|NCT06318026|OTHER|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
219689747|NCT00965133|OTHER|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
219689748|NCT01307059|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
219689749|NCT04884646|OTHER|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
219689750|NCT04884646|OTHER|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
219101744|NCT03614962|DEVICE|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
219689751|NCT04884646|OTHER|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
219689752|NCT05029687|BEHAVIORAL|Youth-Led Hypertension Education Digital Intervention|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
219689753|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
219689754|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
219689755|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
219689756|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
219689757|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
219689758|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
219101745|NCT03614962|DEVICE|control|No warmth pad and TENS electrodes presented in the cap.
219689759|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
219689760|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689761|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689762|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689763|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
219689764|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689765|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
219689766|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
219689767|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
219689768|NCT04999761|DRUG|Ramucirumab|Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
219689769|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
219689770|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
219101746|NCT00747123|BIOLOGICAL|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
219101747|NCT00747123|BIOLOGICAL|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
219101748|NCT04910984|BEHAVIORAL|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
219689771|NCT04999761|DRUG|Bevacizumab|Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
219689772|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
219689773|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689774|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689775|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
219689776|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
219689777|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689778|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689779|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
219689780|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689781|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689782|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
219689783|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
219689784|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
219689785|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689786|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689787|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
219101749|NCT04910984|BEHAVIORAL|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
219689788|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689789|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689790|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
219689791|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
219689792|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
219689793|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689794|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
219689795|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
219689796|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
219689797|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
219689798|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
219689799|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
219689800|NCT02787577|BEHAVIORAL|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
219689801|NCT06152185|BEHAVIORAL|Mindfulness Training|The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.
219689802|NCT06152185|BEHAVIORAL|Enhanced Usual Care|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
219689803|NCT00816114|OTHER|Chart Review|Investigator review of MDACC CML patient charts.
219689804|NCT03298997|PROCEDURE|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
219689805|NCT03298997|PROCEDURE|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
219689806|NCT01275443|DRUG|300mg TMC278LA|300mg TMC278LA intramuscular injection
219689807|NCT01275443|DRUG|150mg TMC278LA|150mg TMC278LA intramuscular injection
219689808|NCT01275443|DRUG|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
219689809|NCT01275443|DRUG|600mg TMC278LA|600mg TMC278LA intramuscular injection
219689810|NCT03174015|BEHAVIORAL|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
219689811|NCT01309412|DRUG|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
219689812|NCT03414944|RADIATION|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
219689813|NCT05199922|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
219689814|NCT04519983|DRUG|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
219689815|NCT01001312|OTHER|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
219689816|NCT01001312|OTHER|Clinical volume status assessment|Volume assessment based on history and physical examination
219689817|NCT02899247|PROCEDURE|Surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
219689818|NCT02899247|PROCEDURE|No surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
219689819|NCT00791219|DRUG|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
219689820|NCT00791219|DRUG|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
219689821|NCT00791219|DRUG|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
219689822|NCT03328247|OTHER|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
219689823|NCT01628848|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
219689824|NCT01628848|DRUG|Placebo|Placebo transdermal patch
219689825|NCT03513263|PROCEDURE|Scaling and polishing|An electronic scaler will be used to clean the gums
219689826|NCT03513263|OTHER|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
219689827|NCT02819570|DRUG|I.V cefuroxime 750 mg*3/d for 2 days|
219689828|NCT02819570|DRUG|I.V ampicillin 2 gram x4/d for 2 days|
219689829|NCT02819570|DRUG|P.O cefuroxime 500 mgx2/d for 5 days|
219689830|NCT02819570|DRUG|P.O roxithromycin 150 mg*2/d for 7 days|
219689831|NCT02819570|DRUG|P.O moxypen 500 mgx3/d for 5 days|
219689832|NCT00003471|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219689833|NCT04611100|DEVICE|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
219689834|NCT01681758|OTHER|IV fluid according to PPV|intravenous fluids
219689835|NCT01681758|OTHER|fluids according to standard care|
219689836|NCT04253158|BEHAVIORAL|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
219689837|NCT04253158|BEHAVIORAL|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
219689838|NCT04253158|BEHAVIORAL|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
219689839|NCT04253158|BEHAVIORAL|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
219689840|NCT04253158|BEHAVIORAL|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
219689841|NCT04253158|BEHAVIORAL|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
219689842|NCT04253158|BEHAVIORAL|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
219689843|NCT04253158|BEHAVIORAL|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
219689844|NCT00463736|DRUG|Magnesium sulfate|
219689845|NCT02104895|RADIATION|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
219689846|NCT02104895|RADIATION|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
219689847|NCT01241422|DRUG|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
219689848|NCT01241422|DRUG|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
219689849|NCT01241422|DRUG|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
219689850|NCT06519838|OTHER|Local anesthesia solution at room temperature|The local anesthesia cartridge is used at room temperature (average of 21 °C)
219689851|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 37°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 37°C at 120 seconds."
219235402|NCT02341222|DEVICE|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
219101750|NCT06452511|DRUG|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
219689852|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 40°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 40°C at 130 seconds."
219689853|NCT06519838|OTHER|Maxillary infiltration technique|A 30 gauge short needle is oriented so that the bevel is facing the bone. The syringe is held parallel to the long axis of the tooth and the needle is inserted into the height of the mucobuccal fold over the offending tooth. The needle is advanced to a depth of 1 millimeter into the tissues. Aspiration is done, and once it is negative then 0.6 ml (nearly one third of the cartridge) of the anesthetic solution is injected slowly without permitting the tissues to balloon.
219689854|NCT06519838|OTHER|Inferior alveolar nerve block technique|While the mouth is opened as wide as possible, the index finger palpates the external oblique ridge reaching the Coronoid notch. A 27-gauge long dental needle will be used for injection. The needle will be directed between the two primary molars on the opposing side of the arch, penetrating the tissues at the point halfway between coronoid notch and the pterygomandibular raphe at the occlusal plane level or slightly lower.The needle is withdrawn 2mm to aspirate. Once negative aspiration is checked, the remainder of the solution is deposited slowly. Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. The average depth of insertion is about 15mm, which is nearly two-thirds the needle length.
219689855|NCT03825822|BEHAVIORAL|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
219689856|NCT03825822|OTHER|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
219689857|NCT02404051|DRUG|Everolimus|10 mg daily tablets
219689858|NCT02404051|DRUG|Exemestane|25 mg daily tablets
219689859|NCT02404051|DRUG|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
219689860|NCT02755506|DEVICE|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
219689861|NCT01863615|DRUG|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
219223925|NCT06449521|BEHAVIORAL|BECOME intervention|The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
219223926|NCT05707013|DEVICE|HP Arize 3D-Printed Orthotics|Custom 3D-printed orthotics manufactured by HP.
219223927|NCT05707013|DEVICE|Traditional Orthotics|Traditionally fabricated custom orthotics manufactured by a local supplier.
219689862|NCT01863615|DRUG|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
219689863|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|One basal rate
219689864|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|Multiple basal rates
219101751|NCT06452511|DRUG|pep2dia|In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
219101752|NCT06188065|DIAGNOSTIC_TEST|Blood eosinophil count|To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
219101753|NCT02401074|BIOLOGICAL|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
219689865|NCT03311945|DRUG|Raltegravir|Raltegravir (1200 mg QD)
219689866|NCT03311945|DRUG|Lamivudine|Lamivudine (300 mg QD)
219689867|NCT00260260|DRUG|Oxycodone|
219689868|NCT01107925|DRUG|prasugrel|Administered orally, daily for 12 days
219689869|NCT01107925|DRUG|clopidogrel|Administered orally, daily for 12 days
219689870|NCT01960166|BEHAVIORAL|Active Distraction|iPad will be used as active distraction
219689871|NCT01960166|BEHAVIORAL|Passive Distraction|child will watch TV as passive distraction
219689872|NCT02916134|PROCEDURE|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
219223928|NCT06118086|DRUG|REM-422|"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"
219689873|NCT02916134|DRUG|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
219689874|NCT01078142|DRUG|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
219689875|NCT04877990|DRUG|Deucravacitinib|Specified dose on specified days
219689876|NCT01007604|DEVICE|Peristaltic pulse PCD|Daily use for two hours
219689877|NCT01007604|OTHER|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
219689878|NCT02693457|PROCEDURE|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
219689879|NCT02693457|PROCEDURE|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
219689880|NCT00894088|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
219689881|NCT05291130|DEVICE|Plasmafit® Vitelene® Vitamin E|Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
219689882|NCT01361828|PROCEDURE|Electrophysiology|Visual Evoked Potential and Elctroretinogram
219689883|NCT03649893|DEVICE|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
219689884|NCT05816382|DRUG|TAK-861|TAK-861 tablets
219689885|NCT05987826|DRUG|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
219689886|NCT01619878|DRUG|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
219689887|NCT04970121|DRUG|Duloxetine|"Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition."
219689888|NCT01137513|DEVICE|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
219689889|NCT01137513|DEVICE|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
219689890|NCT00667485|DRUG|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
219689891|NCT00667485|DRUG|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
219689892|NCT00667485|DRUG|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
219689893|NCT03113565|BEHAVIORAL|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
219689894|NCT02264808|OTHER|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
219689895|NCT06439108|PROCEDURE|single symphyseal plating in management of vertically unsable open book pelvic ring injuries|open book pelvic ring injuries can be managed via the two techniques.
219689896|NCT01219712|PROCEDURE|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
219689897|NCT04241549|DRUG|Cusatuzumab|Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
219689898|NCT04241549|DRUG|Azacitidine|Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
219689899|NCT01733745|OTHER|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
219689900|NCT01733745|OTHER|SYSTANE® BALANCE|Lubricant Eye Drops
219689901|NCT01733745|DIETARY_SUPPLEMENT|SYSTANE® Vitamins|
219689902|NCT01733745|OTHER|Microfiber towels (as warm compresses, with or without saline eye drops)|
219689903|NCT05016375|OTHER|Interview|Interview with individuals with T2DM
219689904|NCT03635827|COMBINATION_PRODUCT|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
219689905|NCT03635827|COMBINATION_PRODUCT|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
219689906|NCT05348044|OTHER|Res-ET intervention|Remote IMST delivery on Resilience
219223929|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
219101754|NCT03461848|OTHER|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
219101755|NCT03461848|OTHER|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
219223930|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
219223931|NCT05465941|PROCEDURE|Biopsy|Undergo biopsy
219223932|NCT05465941|DRUG|Pegylated SN-38 Conjugate PLX038|Given IV
219689907|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
219689908|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
219689909|NCT03916445|OTHER|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
219689910|NCT02895295|BEHAVIORAL|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
219689911|NCT02895295|BEHAVIORAL|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
219689912|NCT02895295|BEHAVIORAL|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
219689913|NCT04147143|OTHER|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
219689914|NCT03739424|OTHER|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
219689915|NCT03739424|OTHER|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
219223933|NCT05465941|PROCEDURE|Computed Tomography|Undergo CT
219223934|NCT05465941|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219689916|NCT03739424|OTHER|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
219689917|NCT02103660|DRUG|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
219689918|NCT02103660|DRUG|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
219689919|NCT06610643|DRUG|combination therapy|A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
219101756|NCT00973570|BEHAVIORAL|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
219101757|NCT06143696|DRUG|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
219101758|NCT06143696|DRUG|Femoston|Oral administration, 1 pill each time, once a day
219101759|NCT05094167|OTHER|V9|one times a day during the whole treatment
219101760|NCT05094167|OTHER|placebo|placebo
219689920|NCT06610643|DRUG|SOC|Standard of care
219689921|NCT06824415|DEVICE|TMS|Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.
219689922|NCT04821830|DRUG|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
219689923|NCT06611904|DRUG|Dulaglutide|Combined treatment with dulaglutide and dapagliflozin
219689924|NCT06611904|DRUG|DPP-4 Inhibitors|DPP-4i treatment as an add-on to metformin
219689925|NCT06611865|PROCEDURE|Intraligamentary anaesthesia|Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
219689926|NCT06611865|PROCEDURE|Inferior alveolar nerve block|Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
219689927|NCT06612476|DRUG|Interleukin 6-guided antibiotic therapy|In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
219689928|NCT06612476|DRUG|GOLD-guided antibiotic therapy|In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
219689929|NCT06612489|DEVICE|biofeedback based dynamic-difficulty game|A biofeedback based dynamic-difficulty serious game rooted in distraction therapy.
219689930|NCT06612489|DEVICE|fixed difficulty game|A fixed difficulty serious game rooted in distraction therapy.
219101761|NCT06342180|DIAGNOSTIC_TEST|Serum uric acid level|An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
219101762|NCT02702310|OTHER|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
219101763|NCT02702310|OTHER|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
219101764|NCT01359267|DRUG|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
219101765|NCT06560957|BEHAVIORAL|Time restricted eating|Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
219101766|NCT06560957|BEHAVIORAL|Eating ad libitum with nutritional counselling|Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
219101767|NCT01615354|DRUG|Aleglitazar|Multiple oral doses
219101768|NCT01615354|DRUG|Microgynon®|Multiple oral doses
219101769|NCT01615354|DRUG|Placebo|Multiple oral doses
219101770|NCT01447849|DRUG|lubiprostone|24mcg twice a day (BID) 1 week
219101771|NCT01447849|DRUG|placebo|Placebo pills twice a day for one week.
219101772|NCT02774603|OTHER|Aquatic Locomotor Training|
219101773|NCT02774603|OTHER|Land Locomotor Training|
219223935|NCT05763953|DRUG|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
219101774|NCT03123289|DRUG|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
219223936|NCT03295227|BIOLOGICAL|Pembrolizumab|Given IV
219223937|NCT05018624|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
219689931|NCT06611462|BEHAVIORAL|Prehabilitation (the STRONG programme)|Participants screened positive for one or more SNAP factors and randomised to the intervention group will receive an individualised plan for prehabilitation of their specific SNAP factors.
219689932|NCT06612528|DEVICE|tDCS|"The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle."
219689933|NCT06612528|DEVICE|Flexible tube in water|"The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy."
219689934|NCT06612385|DEVICE|platelet indices|Significance of platelet indices and ratios in different degrees of burn
219101775|NCT03123289|DRUG|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
219101776|NCT05448898|DRUG|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
219101777|NCT05448898|OTHER|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
219101778|NCT02201056|DRUG|TAK-935|TAK-935 oral solution
219101779|NCT02201056|DRUG|Placebo|TAK-935 placebo-matching oral solution
219101780|NCT04732208|DIAGNOSTIC_TEST|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
219101781|NCT01395823|DIETARY_SUPPLEMENT|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
219101782|NCT01395823|OTHER|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
219101783|NCT00898014|GENETIC|fluorescence in situ hybridization|
219101784|NCT00898014|OTHER|immunologic technique|
219101785|NCT00898014|OTHER|laboratory biomarker analysis|
219101786|NCT02081222|PROCEDURE|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
219101787|NCT03919812|DIETARY_SUPPLEMENT|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
219101788|NCT01789697|OTHER|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
219101789|NCT02780830|DRUG|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
219689935|NCT06999980|DRUG|Ipilimumab 3mg/kg and nivolumab 1mg/kg|Neoadjuvant for 2 doses on days 1 and 22
219689936|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg and ipilimumab 1mg/kg|Neoadjuvant for 2 doses at days 1 and 29
219101790|NCT02780830|DRUG|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
219689937|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg|Neoadjuvant for 2 doses on days 1 and 29
219689938|NCT07003984|BIOLOGICAL|CHIKV VLP vaccine|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
219689939|NCT07003984|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
219689940|NCT07006896|DEVICE|Foley balloon|Foley balloon for induction of labor
219101791|NCT04485715|OTHER|AI system|The real-time assistance of AI system
219101792|NCT05305014|DIAGNOSTIC_TEST|blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)|Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
219101793|NCT00160420|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 months
219101794|NCT02628132|DRUG|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
219689941|NCT07006896|DRUG|Oxytocin|Pitocin for induction of labor
219689942|NCT00994747|OTHER|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
219689943|NCT00994747|OTHER|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
219101795|NCT02628132|DRUG|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
219101796|NCT03219008|DRUG|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
219101797|NCT03219008|COMBINATION_PRODUCT|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
219101798|NCT03219008|DRUG|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
219101799|NCT03219008|COMBINATION_PRODUCT|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
219101800|NCT03219008|DRUG|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
219101801|NCT03219008|DRUG|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
219101802|NCT03219008|COMBINATION_PRODUCT|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
219101803|NCT03219008|COMBINATION_PRODUCT|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
219101804|NCT03219008|DRUG|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
219101805|NCT03219008|COMBINATION_PRODUCT|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
219101806|NCT03219008|DRUG|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
219101807|NCT03219008|COMBINATION_PRODUCT|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
219223938|NCT05018624|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
219223939|NCT05018624|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
219689944|NCT06695507|DRUG|Ruxolitinib|Participants will receive ruxolitinib for 6 months.
219101808|NCT03219008|OTHER|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
219101809|NCT01472874|DRUG|Once a day Trientine|Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
219101810|NCT04961008|OTHER|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
219101811|NCT04961008|OTHER|Routine physiotherapy|Routine pulmonary physiotherapy
219101812|NCT00671008|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219101813|NCT00671008|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219101814|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
219223940|NCT05018624|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
219223941|NCT05018624|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
219101815|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
219101816|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
219101817|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
219101818|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
219101819|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
219101820|NCT01592162|DRUG|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
219101821|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
219689945|NCT05443451|DEVICE|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
219689946|NCT06882031|DRUG|Treatment A: Arsenic Trioxide (ATO) Intravenous|0.15 mg/kg 2-hour IV infusion of ATO administered under fasted state in single dose
219689947|NCT06882031|DRUG|Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state|0.15 mg/kg SDK001 administered orally under fasted state in single dose
219689948|NCT06882031|DRUG|Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state|0.15 mg/kg SDK001 administered orally under fed state (high fat breakfast) in single dose
219689949|NCT06882031|DRUG|Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate|0.15 mg/kg SDK001 administered orally with calcium carbonate in tablet form (1g) under fasted state in single dose
219689950|NCT06706232|DRUG|Psilocybin|Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
219101822|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
219101823|NCT05375435|DRUG|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
219101824|NCT05375435|DRUG|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
219101825|NCT02810093|OTHER|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
219101826|NCT01765595|OTHER|DDI+|
219101827|NCT03771196|OTHER|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
219101828|NCT03771196|OTHER|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
219101829|NCT02465996|DEVICE|pCLE examination|All FD patients received pCLE examination.
219101830|NCT02465996|DRUG|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
219101831|NCT05916092|DEVICE|TransLoc 3D|TransLoc 3D SI Joint Fusion System
219689951|NCT06706232|BEHAVIORAL|Therapeutic Support|"Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before.~Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life.~If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not."
219689952|NCT03563898|OTHER|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
219689953|NCT00960804|BIOLOGICAL|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
219101832|NCT03458767|BEHAVIORAL|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
219101833|NCT01483937|DEVICE|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
219101834|NCT01483937|OTHER|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
219101835|NCT03877965|DRUG|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
219101836|NCT02920775|OTHER|Non-interventional study - retrospective database review|
219101837|NCT01876641|DRUG|Vemurafenib + Cobimetinib, Decitabine|
219101838|NCT04534634|COMBINATION_PRODUCT|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m\^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10\^7/kg, intravenously infusion."
219101839|NCT01268202|DRUG|Pravastatin|Pravastatin 40mg/day during 12 months
219101840|NCT02138266|DEVICE|Topcon Specular Microscope SP-1P|
219101841|NCT02138266|DEVICE|Konan Specular Microscope CELLCHEK XL|
219101842|NCT00501878|DRUG|2.5% or 10% phenylephrine|
219101843|NCT01508013|BEHAVIORAL|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
219101844|NCT01508013|BEHAVIORAL|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
219101845|NCT01202487|DRUG|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
219689954|NCT00960804|BIOLOGICAL|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
219689955|NCT00960804|OTHER|Placebo|IV, q 8 weeks, for up to 80 weeks
219101846|NCT03555357|OTHER|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
219101847|NCT03555357|OTHER|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
219689956|NCT04235166|OTHER|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
219689957|NCT04235166|OTHER|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
219689958|NCT00651300|DRUG|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
219689959|NCT00651300|DRUG|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
219689960|NCT02248168|DRUG|Pramipexole|
219689961|NCT00490919|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
219689962|NCT00490919|DRUG|Placebo|transdermal system (placebo) worn for 7 days
219689963|NCT01296139|DRUG|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
219101848|NCT04566588|PROCEDURE|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
219101849|NCT04566588|PROCEDURE|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
219101850|NCT00015821|DRUG|thalidomide|Given PO
219101851|NCT00015821|OTHER|laboratory biomarker analysis|Correlative studies
219101852|NCT02117934|BIOLOGICAL|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
219101853|NCT02117934|BIOLOGICAL|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
219223942|NCT06230783|OTHER|TalkTracker|Participants will be asked to complete the speech collection procedures remotely/at home once per week for 8 weeks. The 8-week period of weekly remote speech collection will take place yearly for a total of 3 years. At the end of each 8-week study period for years 1-3, participants will complete a survey that asks questions about how easy/difficult the application was to use, how frustrated they felt using the application, and other usability questions.
219689964|NCT02176369|DRUG|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
219689965|NCT01014598|DRUG|Cisplatin|Given intra-arterially via isolated lung suffusion
219689966|NCT01014598|OTHER|Pharmacological Study|Correlative studies
219689967|NCT02193204|BEHAVIORAL|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
219689968|NCT02193204|BEHAVIORAL|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
219101854|NCT04888247|DEVICE|CLARITY|Trans-septal mitral valve replacement
219101855|NCT05778526|BEHAVIORAL|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
219101856|NCT05778526|BEHAVIORAL|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
219101857|NCT05433324|OTHER|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
219689969|NCT03896750|DRUG|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
219689970|NCT07065643|OTHER|Phase 1 - Maintenance Diet|3d maintenance diet (MT, fixed macronutrient composition of 15% protein, 30% fat and 55% CHO), fed to energy requirements (1.3 X RMR)
219689971|NCT07065643|OTHER|Phase 2 - Weight loss diet|6 week calorie restricted high protein diet (CR, fixed macronutrient composition as 30% protein, 35% fat and 35% CHO) fed to energy requirements \[0.8 X Resting Metabolic Rate (RMR)\], with stepwise reduction of 100kcal/d at week 3 and 5
219689972|NCT07064902|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Ivonescimab (AK112) is a novel PD-1/VEGF bispecific antibody designed to simultaneously block PD-1-mediated immune evasion and inhibit VEGF-driven angiogenesis. In this study, ivonescimab is administered intravenously at a dose of 10 mg/kg every 3 weeks, starting on Day 1 of induction chemotherapy (3 cycles), followed by concurrent chemoradiotherapy (no ivonescimab), and then continued as adjuvant monotherapy for 9 additional cycles.
219689973|NCT07066566|DEVICE|Asymmetric nasal cannula - DUET|DUET asymmetric nasal high flow interface that fits best to patients' nostrils (size: one nostril of the patient should be fully occluded) Patients will be crossed - over between the 2 interventions
219689974|NCT07066566|DEVICE|Conventional nasal high flow cannula|Well - established conventional nasal high flow cannula (size: medium) Patients will be cross - over between the 2 interventions
219689975|NCT07072572|DRUG|Lower albumin dosage|A fixed dose of 35 grams of albumin on they one and day two.
219689976|NCT07073612|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing (CPET)|CPET will be performed on a cycle ergometer using a ramp protocol designed to achieve an exercise time of 8-12 min. The entire procedure duration is approximately 60 min. CPET will be completed 6 months to 1 day before the cardiac catheterization and will be repeated 3-6 months following cardiac catheterization.
219689977|NCT07073612|DIAGNOSTIC_TEST|Shear Wave Elastography Scan|The study lasts approximately 20 minutes. Shear Wave Elastography will be completed 6 months to 1 day before the cardiac catheterization. The Scan will be repeated 2-4 weeks following cardiac catheterization, and 3-6 months following cardiac catheterization.
219689978|NCT07073768|DRUG|Trelagliptin 100 mg|Trelagliptin will be administered as oral tablets at a dose of 100 mg once weekly for 3 months. Participants will continue background metformin therapy as prescribed. Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and differs from daily DPP-4 inhibitors due to its longer duration of action, allowing weekly dosing.
219689979|NCT07073768|DRUG|Sitagliptin 100mg OD|Sitagliptin will be administered as oral tablets at a dose of 100 mg once daily for 3 months. Participants will continue background metformin therapy as prescribed. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and requires daily dosing.
219689980|NCT07072637|DIAGNOSTIC_TEST|Neurological function assessment|Neurological evaluations including neurological examination (NE), nerve conduction study (NCS), quantitative sensory testing (QST), autonomic function testing (AFT), and the Toronto Clinical Neuropathy Score (TCNS) questionnaire. Assessments will be conducted at baseline and every three months until six months after completion of EV treatment.
219689981|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 50 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
219689982|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 100 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
219689983|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 200 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
219689984|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
219689985|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly) and carboplatin/paclitaxel (3-weekly)
219689986|NCT07073014|DRUG|Vosoritide|Open-label administration of vosoritide using weight-band dosing
219101858|NCT05336409|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
219101859|NCT05336409|BIOLOGICAL|IL-2|IL-2 subcutaneous (SQ) injection
219101860|NCT05336409|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
219689987|NCT07072676|DEVICE|Assistive gait devices combined with physiotherapy|During the intervenation week, the patient undergoes 12 hours/week of gait training, fall prevention, balance group and physiotherapy as part of their inpatient rehabilitation programme. The individual sessions last 30 minutes each.
219101861|NCT04856501|BEHAVIORAL|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
219689988|NCT06882096|DRUG|Nicotinamide Mononucleotide (NMN)|Nicotinamide Mononucleotide (NMN)
219689989|NCT06882096|DRUG|Nicotinamide (NAM)|Nicotinamide (NAM)
219689990|NCT05960240|DRUG|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
219689991|NCT05960240|DRUG|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
219689992|NCT05960240|DRUG|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
219689993|NCT00978952|DEVICE|Large Diameter Advanta™ V12 Covered Stent|Stent placement
219223943|NCT06484751|DEVICE|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
219101862|NCT04856501|BEHAVIORAL|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
219101863|NCT05425251|DIAGNOSTIC_TEST|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
219101864|NCT03557086|BEHAVIORAL|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
219101865|NCT03557086|OTHER|Verbal Narrative|Verbal description of end of life care options
219101866|NCT06362902|PROCEDURE|Laparoscopic right hemicolectomy with transrectal specimen extraction|Laparoscopic right hemicolectomy with transrectal specimen extraction
219101867|NCT00555022|DRUG|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
219101868|NCT00555022|DRUG|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
219101869|NCT00555022|DRUG|Placebo|Subjects will receive placebo.
219223944|NCT04907617|OTHER|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
219689994|NCT06959277|DEVICE|Walkasins|Walkasins® is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
219689995|NCT06959277|OTHER|Fall Prevention Training|"Participants will watch 6 Steps to Prevent a Fall, a short (2 minute) educational video from the National Council on Aging, which describes simple steps to reduce fall risk. To improve their access to the education provided, participants will also receive three handouts, produced by the Center for Disease Control and Prevention (CDC) STEADI initiative (Stopping Elderly Accidents, Deaths, and Injuries), to review after the study visit. The STEADI Initiative is a coordinated approach for healthcare providers to implement the American and British Geriatrics Societies' Clinical Practice Guideline for fall prevention (https://www.cdc.gov/steadi/index.html)."
219689996|NCT00598728|BEHAVIORAL|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
219689997|NCT04802434|BEHAVIORAL|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
219689998|NCT04802434|BEHAVIORAL|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
219689999|NCT00715559|DRUG|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
219101870|NCT05740410|DEVICE|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
219101871|NCT05520840|DIAGNOSTIC_TEST|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
219101872|NCT02390934|RADIATION|Radium 223|
219101873|NCT05706090|DRUG|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
219101874|NCT05706090|PROCEDURE|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
219101875|NCT06259383|DRUG|Ivermectin|3-day 1 daily dose of 400 μg/kg oral ivermectin
219101876|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
219101877|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
219101878|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
219101879|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
219223945|NCT04907617|OTHER|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
219101880|NCT01129635|PROCEDURE|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate"
219690000|NCT03373214|BIOLOGICAL|Na-GST-1|Na-GST-1/Alhydrogel®
219101881|NCT03204084|DEVICE|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
219101882|NCT03040284|DEVICE|Echodia® hand-held equipment (ELIOS)|
219101883|NCT04534114|DRUG|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
219101884|NCT04534114|DRUG|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
219101885|NCT05288725|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
219101886|NCT05288725|DRUG|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
219101887|NCT05288725|DEVICE|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
219101888|NCT03287414|DRUG|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
219101889|NCT03287414|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
219101890|NCT03287414|DRUG|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
219101891|NCT01529281|DIETARY_SUPPLEMENT|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.
219101892|NCT01529281|DIETARY_SUPPLEMENT|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
219101893|NCT00367965|DRUG|Eszopiclone|eszopiclone 3 mg
219101894|NCT00367965|DRUG|placebo|placebo tablet
219101895|NCT03340584|OTHER|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
219101896|NCT03340584|OTHER|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
219101897|NCT02759185|DRUG|High THC cannabis|Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
219101898|NCT02759185|DRUG|High CBD cannabis|Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
219690001|NCT03373214|BIOLOGICAL|CPG 10104|CPG 10104
219101899|NCT02759185|DRUG|THC/CBD cannabis|Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
219101900|NCT02759185|DRUG|Placebo cannabis|Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
219101901|NCT06540001|DEVICE|Automated visual acuity|The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
219101902|NCT03839732|DIAGNOSTIC_TEST|Score of abdominal aorta calcifications|Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
219101903|NCT01970852|OTHER|Standard tablet computer|No special enhancements or links to personal health information.
219101904|NCT01970852|OTHER|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
219101905|NCT01465607|BEHAVIORAL|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
219101906|NCT01465607|BEHAVIORAL|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
219690002|NCT00965107|DRUG|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
219690003|NCT00965107|DRUG|Propofol|Propofol given as a bolus dose of 1 mg/kg.
219690004|NCT00500448|DEVICE|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
219690005|NCT01051921|DRUG|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
219690006|NCT01051921|DRUG|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
219690007|NCT01051921|DRUG|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
219690008|NCT03103191|DIAGNOSTIC_TEST|KL-6 levels|Measure of KL-6 in serum
219690009|NCT02408042|DRUG|Pembrolizumab|
219690010|NCT02408042|DRUG|Etoposide|
219690011|NCT02408042|DRUG|Ifosfamide|
219690012|NCT02408042|DRUG|Mesna|
219690013|NCT02408042|DRUG|Carboplatin|
219101907|NCT03626532|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
219101908|NCT03626532|BEHAVIORAL|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
219101909|NCT01704911|PROCEDURE|Transradial Coronary Intervention|
219101910|NCT01704911|PROCEDURE|Transfemoral Coronary Intervention|
219101911|NCT01704911|DEVICE|Coronary Stent System|Any kind of coronary stent system
219101912|NCT01838408|OTHER|Ez2go Complete|EZ2Go Complete
219101913|NCT01838408|OTHER|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
219101914|NCT01913106|DRUG|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
219101915|NCT02668016|DRUG|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
219101916|NCT02668016|OTHER|Placebo|Placebo tablets taken orally once daily for one month
219101917|NCT00019539|DRUG|bevacizumab|
219690014|NCT02408042|DRUG|Brentuximab vedotin|
219101918|NCT00019539|DRUG|thalidomide|
219690015|NCT02408042|DRUG|Rituximab|
219690016|NCT04545801|DRUG|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
219690017|NCT04545801|DRUG|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
219690018|NCT02938572|DRUG|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
219690019|NCT02938572|DRUG|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
219690020|NCT04318704|DRUG|Ifenprodil|Ifenprodil 20 mg TID
219690021|NCT00036764|DRUG|ixabepilone|Given IV
219690022|NCT00036764|OTHER|pharmacogenomic studies|Correlative studies
219101919|NCT02848482|DEVICE|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
219690023|NCT00036764|OTHER|laboratory biomarker analysis|Correlative studies
219690024|NCT02501408|DEVICE|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
219690025|NCT03040167|PROCEDURE|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
219690026|NCT03040167|DRUG|Bupivacaine with epinephrine|Treatment group
219690027|NCT03040167|DRUG|Normal saline|Placebo group
219690028|NCT04268407|DRUG|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
219690029|NCT00116688|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
219690030|NCT02864069|BEHAVIORAL|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
219690031|NCT02864069|BEHAVIORAL|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
219690032|NCT02864069|BEHAVIORAL|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
219690033|NCT01775670|DEVICE|Off-the-shelf splint|Subjects will use an off-the-shelf splint
219690034|NCT01775670|DEVICE|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
219690035|NCT03593200|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219690036|NCT04383301|PROCEDURE|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
219101920|NCT02848482|PROCEDURE|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
219101921|NCT02848482|DRUG|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
219101922|NCT00248196|DEVICE|Reprieve Endovascular Temperature Therapy System|
219101923|NCT06201221|PROCEDURE|single-port laparoscopy surgery|The two groups underwent different surgical procedures.
219101924|NCT06201221|PROCEDURE|multiport laparoscopy surgery|The two groups underwent different surgical procedures.
219101925|NCT04636346|BEHAVIORAL|Acceptance and Commitment Therapy|Seven group sessions
219101926|NCT04636346|OTHER|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
219101927|NCT04065217|PROCEDURE|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
219101928|NCT03652753|DRUG|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
219690037|NCT04383301|PROCEDURE|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
219690038|NCT02794129|OTHER|Functional Magnetic Resonance Imaging|
219101929|NCT03652753|DRUG|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
219101930|NCT03002064|DRUG|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
219101931|NCT03002064|DRUG|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
219101932|NCT03002064|DRUG|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
219101933|NCT04444648|COMBINATION_PRODUCT|No intervention|No intervention
219690039|NCT05257317|OTHER|Osteopathic Medicine|"Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones."
219101934|NCT04463368|PROCEDURE|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
219101935|NCT04463368|DRUG|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
219101936|NCT04463368|DRUG|Nivolumab|4 courses of nivolumab 1mg/kg every third week
219101937|NCT02844699|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
219101938|NCT02844699|DRUG|Placebo|5% infusion solution of dextrose (glucose)
219101939|NCT02636257|PROCEDURE|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
219690040|NCT05257317|OTHER|Placebo therapy|Circular movements will be induced in a frontal and parietal bones
219690041|NCT01455870|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
219690042|NCT01455870|DRUG|sitagliptin|oral sitagliptin 100 mg/day
219690043|NCT06109012|PROCEDURE|duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
219690044|NCT00449839|DRUG|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
219690045|NCT01897337|DRUG|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
219690046|NCT01897337|DRUG|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
219690047|NCT04006145|DRUG|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
219690048|NCT04006145|DRUG|Placebo oral tablet|Placebo identical in appearance to active drug
219690049|NCT04622917|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
219690050|NCT04622917|DRUG|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
219101940|NCT02636257|PROCEDURE|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
219101941|NCT00000605|DRUG|hormone replacement therapy|
219101942|NCT00000605|DRUG|estrogens|
219101943|NCT00000605|DRUG|medroxyprogesterone|
219101944|NCT05093049|DEVICE|Renuvion APR System|The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
219101945|NCT05093049|PROCEDURE|Gynecomastia Correction Surgery|Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
219101946|NCT05850468|DRUG|fentanyl infusion after general anesthesia and erector spinea block|intraoperative opioid infusion in active comparative group
219101947|NCT05850468|DRUG|lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block|intraoperative non opioid infusion in experimental group
219101948|NCT02805426|DRUG|Tranexamic Acid|
219101949|NCT02805426|DRUG|Placebo|
219101950|NCT02805426|DRUG|Misoprostol|
219101951|NCT04768842|DRUG|LY3209590|Administered SC.
219101952|NCT02623010|DRUG|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
219101953|NCT01191203|DRUG|Copper IUD|Copper IUD (CuT360)
219101954|NCT01191203|DRUG|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
219101955|NCT02719379|BIOLOGICAL|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
219101956|NCT01316770|DRUG|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
219101957|NCT01316770|DRUG|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
219101958|NCT04138836|DRUG|BBT-877|BBT-877 oral capsule.
219101959|NCT04138836|DRUG|Midazolam|Midazolam oral syrup.
219101960|NCT04138836|DRUG|Itraconazole|Itraconazole oral capsule.
219101961|NCT04138836|DRUG|Esomeprazole|Esomeprazole oral capsule.
219101962|NCT02106585|DRUG|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
219101963|NCT03595930|DRUG|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
219101964|NCT00246987|DRUG|Muraglitazar|
219101965|NCT04958330|PROCEDURE|lateral prostate capsule sparing|When resect the bladder and prostate, the lateral prostate capsule will be preserved.
219101966|NCT01618474|DRUG|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
219101967|NCT01618474|DRUG|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
219101968|NCT06068231|DEVICE|Temporary Crown|Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.
219690051|NCT01053156|DRUG|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
219690052|NCT01053156|DRUG|Placebo|Placebo will be given daily for 3 months.
219690053|NCT00010257|DRUG|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
219690054|NCT00010257|DRUG|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
219690055|NCT03799614|DEVICE|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
219101969|NCT06068231|DEVICE|Permanent Crown|Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.
219101970|NCT03322098|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
219101971|NCT03322098|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
219101972|NCT02571374|DIETARY_SUPPLEMENT|symbiotic group|this group received sachets of symbiotic
219101973|NCT02571374|DIETARY_SUPPLEMENT|placebo group|this group received placebo
219101974|NCT06148220|RADIATION|[18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
219101975|NCT02102880|GENETIC|the polymerase chain reaction (PCR)|
219101976|NCT03294889|RADIATION|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~* 19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~* 17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
219101977|NCT05837208|OTHER|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
219690056|NCT03799614|DEVICE|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
219690057|NCT01996371|DEVICE|Pedicle Screw|
219690058|NCT06379243|PROCEDURE|PVP/PKP|PVP or PKP surgery in patients with osteoporotic vertebral compression fractures
219101978|NCT04227743|DEVICE|cryobiopsy|. The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
219101979|NCT04882774|DRUG|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
219101980|NCT03269240|BEHAVIORAL|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
219101981|NCT03269240|OTHER|Onsite training|Participants are training at their health facilities
219690059|NCT02112942|DRUG|IDX21459|
219690060|NCT02112942|DRUG|Matching Placebo|
219690061|NCT04065490|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System
219101982|NCT03269240|OTHER|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
219101983|NCT03684122|BIOLOGICAL|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
219101984|NCT05145725|BEHAVIORAL|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
219101985|NCT03186482|DRUG|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
219101986|NCT03186482|DRUG|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
219101987|NCT03186482|DRUG|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
219101988|NCT01622244|OTHER|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
219101989|NCT01622244|OTHER|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
219101990|NCT01622244|BEHAVIORAL|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
219223946|NCT04907617|OTHER|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
219690062|NCT04065490|DEVICE|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
219690063|NCT02498678|PROCEDURE|Tetanus|tetanic electric stimulation
219690064|NCT03610893|DRUG|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
219690065|NCT03610893|DRUG|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
219690066|NCT03186313|DRUG|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
219690067|NCT03186313|DRUG|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.
219690068|NCT03186313|DRUG|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
219101991|NCT01680393|DEVICE|Sequential compression device|a sequential compression device will be applied to the legs
219101992|NCT01680393|OTHER|TED stockings|TED stockings will be applied to the patients legs during surgery
219101993|NCT04999644|DRUG|Full Nicotine Cigarettes|A full nicotine tobacco cigarette that will be smoked by participants
219101994|NCT04999644|DRUG|Reduced Nicotine Cigarettes|A reduced nicotine tobacco cigarette that will be smoked by participants
219101995|NCT04999644|BEHAVIORAL|Average Nicotine Expectancy|"Participant instructed the cigarette is the same level of nicotine as your usual brand."
219101996|NCT04999644|BEHAVIORAL|Very Low Nicotine Expectancy|"Participant instructed the cigarette is a very low level of nicotine compared to your usual brand."
219101997|NCT04146649|PROCEDURE|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
219101998|NCT02260401|OTHER|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
219690069|NCT03186313|DRUG|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
219690070|NCT00785083|DRUG|FTY720|
219690071|NCT00785083|DRUG|Placebo|
219690072|NCT00122434|DRUG|BEA 2180 BR|
219690073|NCT00122434|DRUG|tiotropium|
219690074|NCT02754232|OTHER|Telemedical training|Intervention will involve resistance training and anaerobic training
219690075|NCT04854239|PROCEDURE|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
219690076|NCT02750631|OTHER|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
219690077|NCT04789304|DRUG|BI 1595043|BI 1595043
219690078|NCT04789304|DRUG|Placebo|Placebo
219101999|NCT05272670|BEHAVIORAL|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
219102000|NCT06243185|DRUG|Dalpiciclib plus letrozole|Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
219102001|NCT01674348|DRUG|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
219102002|NCT01674348|DRUG|Placebo|Placebo
219102003|NCT05222464|OTHER|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
219102004|NCT00771225|PROCEDURE|fascial repair|surgery to treat genital prolapse with fascia repair
219102005|NCT00771225|PROCEDURE|mesh repair|surgery to genital prolapse with mesh
219102006|NCT03252080|BEHAVIORAL|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
219102007|NCT03252080|BEHAVIORAL|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
219102008|NCT02730182|OTHER|altitude exposure|altitude exposure
219102009|NCT01677364|DRUG|Oxytocin|Arm - Induction of labour
219102010|NCT00114608|DEVICE|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
219102011|NCT03547492|BEHAVIORAL|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
219102012|NCT03547492|BEHAVIORAL|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
219102013|NCT03547492|BEHAVIORAL|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
219102014|NCT03547492|BEHAVIORAL|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
219102015|NCT03547492|BEHAVIORAL|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
219102016|NCT03547492|BEHAVIORAL|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
219102017|NCT03468959|BEHAVIORAL|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
219102018|NCT01691625|OTHER|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
219690079|NCT04789304|DRUG|Midazolam|Midazolam
219690080|NCT03913234|DRUG|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
219690081|NCT00927875|DRUG|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
219690082|NCT00927875|DRUG|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
219102019|NCT01691625|OTHER|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
219690083|NCT00927875|DRUG|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
219690084|NCT00239720|DRUG|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
219690085|NCT00239720|DRUG|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
219690086|NCT04353726|OTHER|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
219690087|NCT06159504|DRUG|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
219690088|NCT06159504|DIAGNOSTIC_TEST|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
219690089|NCT00215917|DRUG|D-serine 2100 mg daily|
219690090|NCT00464022|DEVICE|Carbon dioxide|
219690091|NCT04339049|DRUG|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
219102020|NCT01583101|OTHER|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
219102021|NCT01583101|OTHER|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
219690092|NCT04339049|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
219690093|NCT04339049|DRUG|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
219690094|NCT01484951|DRUG|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
219102022|NCT04444635|PROCEDURE|Serratus Anterior Plan Block+ Fentanyl infusion|"After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion"
219102023|NCT04444635|DRUG|Fentanyl|Continuous fentanyl infusion throughout the surgical procedure.
219102024|NCT02633930|DRUG|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
219102025|NCT02633930|DRUG|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
219102026|NCT02633930|DRUG|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
219102027|NCT02633930|DRUG|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
219102028|NCT02633930|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
219690095|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
219690096|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
219690097|NCT00453375|DRUG|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
219690098|NCT00453375|DRUG|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
219690099|NCT02092454|DRUG|Benzocaine|topical otic solution
219690100|NCT02092454|DRUG|Placebo|topical otic solution
219690101|NCT06309823|DRUG|MAS825|MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
219690102|NCT03976908|DEVICE|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
219690103|NCT01249417|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
219690104|NCT01249417|DRUG|Placebo|I.M. injection on day 1 of a single treatment cycle.
219690105|NCT02507492|DRUG|RM-493|
219690106|NCT00917124|DEVICE|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
219690107|NCT05055726|DRUG|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
219690108|NCT05634655|OTHER|no interventions between two groups|no interventions between two groups
219690109|NCT02412124|PROCEDURE|Supportive Care|Complete W2W mentoring program
219690110|NCT02412124|OTHER|Quality-of-Life Assessment|Complete the FACT-G
219690111|NCT02412124|OTHER|Questionnaire Administration|Complete the W2W Patient Survey
219102029|NCT05401643|OTHER|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
219102030|NCT01021592|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
219690112|NCT00723827|DRUG|Temozolomide|Administration of temozolomide based on the product labeling.
219690113|NCT00723827|RADIATION|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
219690114|NCT03690713|DIAGNOSTIC_TEST|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
219690115|NCT05882500|OTHER|No intervention, observation|
219690116|NCT02168959|DRUG|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
219690117|NCT02938468|DRUG|Dexamethasone|
219690118|NCT02938468|PROCEDURE|Any surgical intervention aim at treating chronic subdural hematoma|
219102031|NCT04450186|OTHER|EEG/fMRI neurofeedback|EEG/fMRI neurofeedback
219102032|NCT01422525|PROCEDURE|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
219102033|NCT06197906|DEVICE|Device implant|subcutaneous device implanting
219102034|NCT02345525|BEHAVIORAL|mCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
219102035|NCT02345525|BEHAVIORAL|hCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
219102036|NCT04511416|DRUG|Metformin XR, 500-2000mg nocte|Metformin XR, 500-2000mg nocte
219102037|NCT04059692|OTHER|Cervical manipulation intervention|Cervical manipulative technique
219102038|NCT04059692|OTHER|Placebo intervention|Sham intervention
219102039|NCT04242433|DRUG|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
219690119|NCT00126594|DRUG|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
219690120|NCT00126594|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10\^6 international units twice daily
219690121|NCT00126594|OTHER|Laboratory Biomarker Analysis|Correlative studies
219690122|NCT01703494|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
219690123|NCT01703494|BIOLOGICAL|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
219690124|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
219690125|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
219690126|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
219690127|NCT04207905|OTHER|Healthy Michigan Plan (HMP) coverage with work requirements|For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
219690128|NCT01041222|DRUG|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
219690129|NCT03769649|DEVICE|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
219690130|NCT01421498|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
219690131|NCT01421498|DRUG|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
219690132|NCT01622556|DRUG|Fludarabine|35 mg/m2 IV/day x 5 days
219690133|NCT01622556|DRUG|Busulfan|.8 mg/kg IV Q6h x 8 doses
219690134|NCT01622556|DRUG|Thymoglobulin|1.5 mg/kg/day x 3 days
219690135|NCT01622556|RADIATION|Total Body Irradiation|150 cGy for 2 days
219690136|NCT01622556|BIOLOGICAL|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
219690137|NCT05793021|DIAGNOSTIC_TEST|Blood sample|Blood sample pre and post surgery to determine the level of FKBP51s protein
219690138|NCT01290718|DRUG|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
219690139|NCT01290718|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
219690140|NCT00473655|DRUG|rosuvastatin|10mg or 20mg
219690141|NCT00371735|DRUG|chlorproguanil-dapsone-artesunate|
219690142|NCT00371735|DRUG|chlorproguanil-dapsone|
219102040|NCT04151784|OTHER|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
219223947|NCT04907617|OTHER|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
219223948|NCT02873897|DIETARY_SUPPLEMENT|Session A: Experimental products (selected enriched products)|
219223949|NCT02873897|DIETARY_SUPPLEMENT|Experimental session: to select enriched products|
219690143|NCT01895985|DRUG|Latanoprostene bunod|
219690144|NCT04035616|DIETARY_SUPPLEMENT|microbial cell preparation [MCP]|active microbial cell preparation
219690145|NCT04035616|OTHER|placebo|inactive ingredient
219690146|NCT02617615|DRUG|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
219690147|NCT02617615|DRUG|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
219690148|NCT01635660|DEVICE|Intubation|Tracheal Intubation with the assigned video laryngoscope
219690149|NCT05619328|DRUG|Vitamin B combination tablet|Once daily, with some liquid with or after a meal
219690150|NCT05619328|DRUG|Placebo Tablet|Once daily, with some liquid with or after a meal
219690151|NCT04546633|DRUG|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
219690152|NCT04546633|DRUG|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
219690153|NCT04546633|DRUG|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
219690154|NCT04536363|DRUG|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
219223950|NCT02873897|DIETARY_SUPPLEMENT|Session B: Control (standard products without enrichment)|
219223951|NCT02873897|DIETARY_SUPPLEMENT|Control session|
219102041|NCT04151784|OTHER|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
219102042|NCT03945318|DRUG|BION-1301 Single Dose|A solution for IV infusion administered as a single dose.
219102043|NCT03945318|DRUG|Placebo Single Dose|A solution by IV infusion administered as a single dose.
219102044|NCT03945318|DRUG|BION-1301 Multiple Doses|A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
219102045|NCT03945318|DRUG|Placebo Multiple Doses|A solution by IV infusion administered as multiple doses.
219102046|NCT03945318|DRUG|BION-1301 Single Dose|SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
219102047|NCT04235790|DEVICE|Eye Tracking Device|Eye tracking glasses
219102048|NCT05282290|DRUG|Antihypertensive drugs (no restriction on the type of drugs)|"The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening."
219102049|NCT02093325|DRUG|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
219102050|NCT02093325|DRUG|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
219102051|NCT01443221|DRUG|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
219102052|NCT01443221|DRUG|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
219102053|NCT02165332|DRUG|Part 1: SAD RO7033877|Single dose
219102054|NCT02165332|DRUG|Part 1: SAD placebo|Single dose
219102055|NCT02165332|DRUG|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
219102056|NCT02165332|DRUG|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
219102057|NCT02165332|DRUG|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
219102058|NCT02165332|DRUG|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
219102059|NCT03080116|DRUG|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
219102060|NCT03080116|DRUG|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
219102061|NCT03080116|OTHER|Placebo|4 tablets, per OS
219102062|NCT05420922|DRUG|Lenvatinib Oral Product|Lenvatinib or Sorafenib
219102063|NCT05420922|DRUG|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
219102064|NCT05420922|PROCEDURE|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
219102065|NCT05882201|PROCEDURE|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
219102066|NCT05882201|PROCEDURE|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
219102067|NCT05882201|PROCEDURE|General care|using ordinary technique
219102068|NCT03944044|OTHER|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
219102069|NCT02073825|BEHAVIORAL|Web Brief Intervention (WBI)|4-session WBI
219102070|NCT02310022|DRUG|Drug Omega 3|4 g (4 capsules) once a day, administered with food
219102071|NCT02310022|DRUG|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
219102072|NCT01437163|DEVICE|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
219102073|NCT01437163|DEVICE|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
219102074|NCT04595721|BEHAVIORAL|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
219102075|NCT04595721|BEHAVIORAL|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
219102076|NCT00002947|RADIATION|indium In 111 pentetreotide|
219102077|NCT01217424|OTHER|questionnaire administration|
219690155|NCT04536363|DRUG|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
219690156|NCT05937880|DRUG|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
219690157|NCT03467074|BIOLOGICAL|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
219690158|NCT00243919|BEHAVIORAL|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
219690159|NCT00243919|BEHAVIORAL|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
219690160|NCT00243919|BEHAVIORAL|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
219102078|NCT01217424|PROCEDURE|aromatherapy and essential oils|
219102079|NCT01217424|PROCEDURE|management of therapy complications|
219102080|NCT01217424|PROCEDURE|massage therapy|
219102081|NCT01217424|PROCEDURE|psychosocial assessment and care|
219102082|NCT01217424|PROCEDURE|reflexology procedure|
219102083|NCT01665339|OTHER|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
219102084|NCT01665339|OTHER|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
219102085|NCT04076410|DEVICE|Z1 lens|CE marked device
219102086|NCT04076410|DEVICE|Experimental Lens 1|CE marked device
219102087|NCT04076410|DEVICE|Experimental Lens 2|CE marked device
219102088|NCT04076410|DEVICE|Experimental Lens 3|CE marked device
219102089|NCT04076410|DEVICE|Experimental Lens 4|CE marked device
219102090|NCT04099043|DEVICE|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
219102091|NCT05421338|DRUG|BI 456906 (C-14)|BI 456906 (C-14)
219102092|NCT02981901|OTHER|Patient with ovarian epithelial cancer|
219102093|NCT02234063|OTHER|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
219102094|NCT03009682|DRUG|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
219102095|NCT01974700|DRUG|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
219102096|NCT01793025|BIOLOGICAL|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
219102097|NCT04142502|DRUG|Propofol|Propofol as a sedation drug
219102098|NCT04142502|DRUG|Dexmedetomidin|Dexmedetomidine as a sedation drug
219102099|NCT02228954|PROCEDURE|Molecular imaging|
219102100|NCT04106232|OTHER|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
219102101|NCT02946918|DRUG|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
219102102|NCT00830622|OTHER|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
219690161|NCT06437925|DIETARY_SUPPLEMENT|probiotic ayran drink|The test group has received probiotic ayran drink for 6 weeks
219690162|NCT06437925|DIETARY_SUPPLEMENT|Placebo ayran drink|The control group has received placebo ayran drink for 6 weeks
219690163|NCT00612820|DRUG|GSK256066|200mcg bd,
219102103|NCT00496405|DRUG|bevacizumab|
219102104|NCT04061226|DEVICE|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
219102105|NCT02467517|DRUG|Ketamine|
219102106|NCT02467517|DRUG|Magnesium Sulfate|
219102107|NCT02467517|DRUG|placebo : sodium chloride|
219102108|NCT03732625|DRUG|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
219102109|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
219102110|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
219102111|NCT05613114|DRUG|Dalfampridine 10 MG|The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
219102112|NCT05613114|DRUG|Placebo|Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
219690164|NCT00612820|DRUG|fluticasone propionate|200mcg od,100mcg bd
219102113|NCT05613114|BEHAVIORAL|Physiotherapy|Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
219102114|NCT04606537|DRUG|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
219102115|NCT04606537|DRUG|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
219102116|NCT04606537|DRUG|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
219223952|NCT03008785|OTHER|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
219223953|NCT03008785|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
219690165|NCT00109863|BIOLOGICAL|hu14.18-IL2 fusion protein|
219102124|NCT05884463|DRUG|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
219102125|NCT05884463|DRUG|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
219102126|NCT02473458|DRUG|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules"
219102127|NCT02473458|DRUG|Placebo|
219102128|NCT04182854|DRUG|Furosemid hydrochlorothiazide|furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
219223954|NCT03008785|OTHER|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
219102129|NCT04192084|PROCEDURE|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
219102130|NCT00069784|DRUG|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
219102131|NCT00069784|DRUG|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
219102132|NCT00069784|DRUG|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
219102133|NCT00069784|DEVICE|reusable pen device for insulin injection|
219102134|NCT02843256|DEVICE|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
219223955|NCT06369714|DRUG|Concerta|Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
219690166|NCT05273762|DEVICE|FlowTriever|Mechanical thrombectomy for pulmonary embolism
219690167|NCT01805895|DRUG|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
219690168|NCT00254436|DRUG|Procrit (epoetin alfa)|Weekly dose
219690169|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
219690170|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
219690171|NCT02762032|DRUG|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
219690172|NCT06515756|OTHER|Post operative pain assessment after root canal treatment|the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
219690173|NCT04942262|DRUG|denture adhesive (Polident®, GlaxoSmithKline, Ireland)|cream-type denture adhesive available as an over-the-counter product in Thailand
219690174|NCT00000867|DRUG|Memantine|
219690175|NCT00247468|PROCEDURE|Strict Glucose Control|
219690176|NCT02048800|DRUG|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)
219690177|NCT01268267|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
219690178|NCT03846401|DEVICE|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate \& BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~1. Direct smear by Gram stain and ZeihlNelseen stain~2. Samples culturedinBact/alert bottle(BioMérieux, France).~3. Isolation of causative organism from positive cases by:~   Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~4. Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~5. Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
219690179|NCT04541563|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
219690180|NCT00703300|DRUG|bortezomib|Given IV
219102135|NCT03800732|OTHER|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
219102136|NCT03800732|OTHER|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
219102137|NCT03800732|OTHER|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
219102138|NCT00106132|DRUG|Triamcinolone Acetonide|
219102139|NCT03339284|DRUG|Dexamethasone sodium phosphate|Dexamethasone injection
219690181|NCT00703300|DRUG|decitabine|Given IV
219102140|NCT03339284|DRUG|Ropivacaine Hydrocloride|Ropivacaine injection
219102141|NCT03339284|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
219102142|NCT05683717|DRUG|TT-01488 Tablets|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
219102143|NCT02654990|DRUG|Panobinostat Capsules|20 mg, 10 mg or 15 mg (for dose reductions only)
219102144|NCT02654990|DRUG|Bortezomib Injection|1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.
219690182|NCT00703300|OTHER|pharmacological study|Correlative studies
219690183|NCT00703300|OTHER|laboratory biomarker analysis|Optional correlative studies
219690184|NCT04176939|BIOLOGICAL|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) revaccination doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
219690185|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)
219102145|NCT02654990|DRUG|Dexamethasone tablets|Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
219102146|NCT03757143|DRUG|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
219102147|NCT03757143|DRUG|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
219102148|NCT03757143|DEVICE|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
219102149|NCT03757143|DEVICE|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
219102150|NCT01147484|DRUG|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
219102151|NCT02519101|DEVICE|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
219102152|NCT05722470|BEHAVIORAL|eating disorders|Assessment of eating disorders among adolescents
219102153|NCT00003640|BIOLOGICAL|filgrastim|
219102154|NCT00003640|DRUG|cisplatin|
219102155|NCT00003640|DRUG|doxorubicin hydrochloride|
219102156|NCT00003640|DRUG|methotrexate|
219102157|NCT00003640|DRUG|vinblastine sulfate|
219102158|NCT00003640|PROCEDURE|surgical procedure|
219102159|NCT00003640|RADIATION|radiation therapy|
219102160|NCT00097643|BEHAVIORAL|exercise|
219102161|NCT00097643|BEHAVIORAL|health promotion|
219102162|NCT03465020|OTHER|Observation|Safety and efficacy outcomes of patients on different treatments
219102163|NCT03267823|DIAGNOSTIC_TEST|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
219102164|NCT01710163|DRUG|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
219690186|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
219690187|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)
219102165|NCT01710163|DRUG|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
219102166|NCT05556317|BEHAVIORAL|Resistive exercise|advices and resistive exercise
219102167|NCT02294474|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
219102168|NCT02294474|DRUG|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
219102169|NCT02294474|DRUG|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
219102170|NCT01456234|DRUG|Oseltamivir|Oseltamivir 75 mg BID
219102171|NCT06340074|BEHAVIORAL|HELM|HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.
219102172|NCT06340074|BEHAVIORAL|Implementation Attention Control (IAC)|Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
219102173|NCT04015115|BEHAVIORAL|Youth Opioid Recovery Support service model|see arm 1 description
219102174|NCT00203151|DRUG|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
219102175|NCT04815317|OTHER|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
219102176|NCT04815317|OTHER|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
219102177|NCT04815317|OTHER|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
219102178|NCT04815317|OTHER|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
219102179|NCT05200936|DRUG|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
219102180|NCT05200936|OTHER|Placebo|A treatment which is designed to have no therapeutic value.
219102181|NCT05664932|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
219102182|NCT05664932|BIOLOGICAL|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
219102183|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
219102184|NCT04553263|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
219102185|NCT04553263|DRUG|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
219102186|NCT03115554|PROCEDURE|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
219102187|NCT03115554|PROCEDURE|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
219102188|NCT01756261|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
219102189|NCT04036461|DRUG|CC-99712|CC-99712
219690188|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)
219690189|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
219690190|NCT03250689|DRUG|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
219102190|NCT04036461|DRUG|BMS-986405|BMS-986405
219102191|NCT04255342|DEVICE|Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery|At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
219102192|NCT05277675|DRUG|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
219102193|NCT05277675|PROCEDURE|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
219223956|NCT06369714|DEVICE|Digital therapeutics|30 sessions of digital therapeutics, each lasting 30 minutes, will be conducted with a frequency of once every 1-2 days over an 8-week period.
219223957|NCT06364280|DEVICE|BVM|Bag-Valve-Mask Ventilation
219223958|NCT06364280|DEVICE|SGA|Supraglottic Airway
219223959|NCT06364280|DEVICE|ETI|Endotracheal Intubation
219102194|NCT01672853|BIOLOGICAL|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
219102195|NCT01672853|BIOLOGICAL|Placebo|Subcutaneous injections weekly for a total of 96 injections
219102196|NCT05098106|DIAGNOSTIC_TEST|Bronchoscopy, blood sampling; testing.|BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
219223960|NCT06794138|PROCEDURE|dental implant placement|The fit of the surgical guide was checked and a flapless procedure was performed under local anesthesia. However, in cases where the width of keratinized mucosa was insufficient a limited full-thickness flap was elevated. The surgical template was fixed on the remaining dentition and mucosa using template fixation pins. Fully guided implant bed preparation was performed. Osteotomies were carried out with external cooling at a drill rotation speed of 800 rpm. Implant placement was performed using a manual torque wrench Dental implants were placed non-submerged. In cases of flap elevation, wound margins were stabilized with single interrupted sutures. Sutures were removed at 7 days postop.
219223961|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
219223962|NCT04329598|OTHER|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
219223963|NCT04329598|OTHER|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
219690191|NCT03250689|DRUG|Placebo|Placebo will be available as oval shaped, white film coated tablets.
219690192|NCT03250689|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
219102197|NCT05878275|BEHAVIORAL|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
219102198|NCT06480110|DRUG|Docetaxel + Ebastine|Ebastine is administered once daily.
219102199|NCT06480110|DRUG|Docetaxel|docetaxel every three weeks
219102200|NCT04765319|BEHAVIORAL|CPT for PTSD|Evidence based psychotherapy for PTSD
219102201|NCT04875364|DRUG|Eszopiclone|2mg of Eszopiclone just before going to sleep.
219102202|NCT04875364|OTHER|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
219102203|NCT04875364|DEVICE|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
219102204|NCT04893655|DRUG|Dobutamine Hydrochloride|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
219102205|NCT01620905|PROCEDURE|Manipulation|Single level cervical spine joint manipulation
219102206|NCT01858467|DEVICE|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
219102207|NCT01858467|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
219102208|NCT06016530|BEHAVIORAL|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
219102209|NCT06016530|DRUG|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
219223964|NCT03009344|DRUG|Tazemetostat|Tazemetostat tablets.
219223965|NCT00378898|DEVICE|BRAVO capsule|
219223966|NCT00378898|PROCEDURE|Fluoroscopy|"one time xray to determine evacuation of bravo"
219223967|NCT00378898|OTHER|sham BRAVO capsule placement|
219223968|NCT02794428|DRUG|Eflornithine|Eflornithine\*, 2 tablets, Oral, Daily for 18 months
219223969|NCT02794428|OTHER|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
219690193|NCT03250689|DRUG|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
219690194|NCT03847740|DEVICE|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
219690195|NCT04361084|OTHER|traditional simulated training|traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
219690196|NCT04361084|OTHER|mixed reality simulation|using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
219102210|NCT01690884|DRUG|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
219102211|NCT01126138|DRUG|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
219102212|NCT01126138|DRUG|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
219102213|NCT01897831|DRUG|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
219102214|NCT04131790|BEHAVIORAL|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
219102215|NCT04131790|BEHAVIORAL|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
219102216|NCT02649062|BIOLOGICAL|NGM282|
219102217|NCT02649062|OTHER|Placebo|
219102218|NCT06491199|OTHER|Home blood pressure telemonitoring program and clinician monitoring|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Clinician monitoring includes OBIM physicians reviewing transmitted BP data and contacting patients to adjust antihypertensive medication regimens."
219102219|NCT05035368|DRUG|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
219102220|NCT05035368|OTHER|Placebo|Placebo is administered with the same schedule of Ladarixin.
219102221|NCT03185559|DEVICE|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
219102222|NCT03185559|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
219223970|NCT02534233|DEVICE|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
219102223|NCT03079310|DEVICE|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
219102224|NCT00295438|DEVICE|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
219223971|NCT05867381|DEVICE|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
219223972|NCT05867381|DEVICE|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
219102225|NCT00295438|DEVICE|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
219102226|NCT02914132|DEVICE|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
219102227|NCT05302557|OTHER|Ileostomy stimulation|Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
219102228|NCT02944656|DRUG|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
219102229|NCT02944656|DRUG|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
219102230|NCT00017056|DRUG|ixabepilone|
219102231|NCT01583244|DRUG|No Intervention (subjects were previously treated with Orencia®)|No Intervention
219102232|NCT04839198|BEHAVIORAL|Android Wear smartwatch|All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).
219223973|NCT03393559|PROCEDURE|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
219223974|NCT00369460|OTHER|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
219223975|NCT05905549|PROCEDURE|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
219690197|NCT06514079|PROCEDURE|Esophageal dilatation with steroids injection|Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
219102233|NCT04839198|BEHAVIORAL|Adaptive Treatment|"Participants will have access to a Dashboard button in the InsightTM app that displays personalized statistics based on their progress and patterns in the study.The dashboard will update as more data is collected about the participant's smoking habits, starting in the pre-quit period and continuing through the post-quit period. Second, in the post-quit period, participants will receive treatment messages when the machine learning algorithm determines that they are at high risk for lapse.At the follow-up visit, participants will complete a survey to evaluate what they liked and disliked about the intervention, how accurate they thought the app was in predicting their risk, and how useful they found the dashboard."
219102234|NCT04839198|DRUG|Nicotine Patch|At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)
219102235|NCT04839198|BEHAVIORAL|interviewing-based counseling|At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.
219102236|NCT04916418|DRUG|Placebo|TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
219102237|NCT04916418|DRUG|Ropivacaine|TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
219102238|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
219102239|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
219102240|NCT05091853|DEVICE|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
219102241|NCT02232308|DRUG|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
219102242|NCT02232308|DRUG|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
219102243|NCT02232308|DRUG|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
219102244|NCT04394364|DEVICE|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
219102245|NCT04537468|OTHER|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
219102246|NCT04537468|OTHER|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
219102247|NCT04537468|OTHER|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
219102248|NCT01330602|BEHAVIORAL|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy"
219690198|NCT03871153|DEVICE|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
219690199|NCT03871153|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
219690200|NCT03871153|DRUG|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
219690201|NCT03871153|RADIATION|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
219102249|NCT00385892|DEVICE|Abdominal binder|
219102250|NCT05721001|DEVICE|Surgical Repair|In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first.
219102251|NCT06606366|PROCEDURE|Blood sample taken for the liquid biopsy|36 mL will be taken for the study.
219223976|NCT03136159|DEVICE|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
219690202|NCT03871153|PROCEDURE|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
219690203|NCT02318849|BEHAVIORAL|Web intervention|interactive website using social media and gamification
219690204|NCT03175081|DRUG|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
219102252|NCT03387202|PROCEDURE|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
219102253|NCT03387202|DIAGNOSTIC_TEST|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
219102254|NCT00118898|DRUG|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
219102255|NCT00118898|DRUG|Atazanavir|300 mg tablet taken orally daily
219102256|NCT00118898|DRUG|Efavirenz|600 mg tablet taken orally daily
219102257|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
219102258|NCT00118898|DRUG|Ritonavir|100 mg tablet taken orally daily
219102259|NCT00118898|DRUG|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
219102260|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
219102261|NCT05473000|BEHAVIORAL|Exercise|Submaximal and maximal exercise
219102262|NCT05473000|OTHER|Ozone|Delivery of ozone air pollution at 170ppb
219102263|NCT05473000|OTHER|Room air|Delivery of room air
219102264|NCT06667505|BEHAVIORAL|Choice-ICD|The eHealth intervention theoretically driven, interactive and provides personalised information to patients and family members when and where they wish to access it. Five short (2-3 minutes) videos, involving patients, caregivers and professionals, are uploaded onto the APP, alongside animation clips and useful links to online resources. A discussion forum will be accessible for participants using the APP, which will be closely moderated by the researcher, who will ensure any concerning posts or dialogue are promptly removed, and the necessary action is taken. The diary function will allow patients to record and be reminded of future appointments. Patients and family members will engage with the intervention for 3 months.
219102265|NCT06613529|OTHER|online mindfulness training|"Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning."
219102266|NCT06163560|DEVICE|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
219102267|NCT06163560|DEVICE|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
219102268|NCT06625008|OTHER|3D-printed model|The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
219102269|NCT06626113|DRUG|ascorbic acid|ascorbic acid
219102270|NCT06624553|DEVICE|FreeStyle Libre 2, flash glucose monitoring|"Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit."
219102271|NCT05304598|DRUG|Dexmedetomidine|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
219102272|NCT05304598|OTHER|Usual Care|routine awake intubation as per current unit standard of care,
219102273|NCT06687265|DRUG|Metformin|one pill of 500 mg per os twice a day for 28 days.
219102274|NCT06687265|DRUG|Placebo|one pill per os twice a day for 28 days.
219102275|NCT04454398|BIOLOGICAL|COVI-GUARD|COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein
219690205|NCT03175081|DRUG|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
219690206|NCT02228005|DRUG|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
219690207|NCT06389981|OTHER|Veterans peer connect Program|To assess outcomes of the Peer-led program, the study team will collect information from Veteran pilot test participants via surveys and data abstraction on healthcare utilization (Lung cancer screening completion, tobacco treatment) from the Veterans Affairs Corporate Data Warehouse. Survey data will be collected at 3 timepoints: baseline, post-Peer-led orientation, and 3-months post-enrollment. Healthcare utilization data will be abstracted from the corporate data warehouse to reflect the 3-month post-enrollment timepoint. Finally, interviews will be conducted with a subset of participants.
219690208|NCT03184311|OTHER|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
219690209|NCT03184311|OTHER|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
219102276|NCT04454398|OTHER|Standard of Care|Standard of Care as determined by the Investigator
219102277|NCT04454398|DRUG|Placebo|Diluent
219102278|NCT06926517|OTHER|life and death courses|Life and death issues in the post-epidemic era - Curriculum planning that integrates life and death care, reflective learning and teaching practice on the new coronavirus pneumonia issue, introducing 18-week theme courses, each course is 100 minutes
219102279|NCT03874845|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
219102280|NCT03874845|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
219102281|NCT06900868|OTHER|Assigned Interventions|SDR Smart dentine replacement material nonbioactive
219102282|NCT05984680|OTHER|Observational Phase 1|Noninterventional study
219102283|NCT05984680|OTHER|Observational Phase 2, Group I|Noninterventional study
219102284|NCT05984680|OTHER|Observational Phase 2, Group II|Noninterventional study
219102285|NCT05984680|OTHER|Observational Phase 3|Noninterventional study
219102286|NCT06900673|BEHAVIORAL|Collaborative Life Skills|Student, parents, and teachers in the intervention condition will receive the digitally adapted Collaborative Life Skills program.
219102287|NCT06900101|OTHER|Study the evolution and correlation between cerebral autoregulation index|"Objective n°1: Study the correlation between autoregulation index:~The investigators will look for a correlation between several auroregulation index such as the PRx, ORx and Cox.~Objective n°2: Evaluation and detection of EEG prognostic patterns: The investigators will look for quantitaive EEG changes during the early phase of acute brain injuries."
219102288|NCT06899386|OTHER|Group CI and CII - BeautiBond Xtreme (total-etch technique) + Beautifil LS|the enamel was etched for 30 seconds and the dentin for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray. To protect the dentin during air blasting, an absorbent paper was held over it using clinical tweezers, ensuring a whitish appearance for the enamel and slightly moist dentin. Excess water on the cotton roll was dried as well. The BeautiBond Xtreme adhesive system was applied without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. Finally, the adhesive was light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
219102289|NCT06899386|OTHER|Group TI and TII - BeautiBond Xtreme (self-etch technique) + Beautifil LS:|no acid etching was performed on either the enamel or dentin. The BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
219102290|NCT06899386|OTHER|Group TIII and TIV - BeautiBond Xtreme (selective acid-etch technique) + Beautifil LS|the enamel was etched for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray, leaving the enamel with a whitish appearance. Excess water on the cotton roll was also dried. Next, the BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
219690210|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
219102291|NCT06901102|DRUG|Bee Venom Injection|This intervention involves the administration of purified bee venom from Apis mellifera species (Abevac) via subcutaneous injections. The dosage starts at 0.05 mL three times a week and gradually escalates to 0.5 mL three times a week by week 5. The total duration of the treatment is 6 months. Bee venom is being evaluated for its potential immunomodulatory effects, including enhancing regulatory T cell function and improving mineral bone disorder (MBD) in patients undergoing hemodialysis.
219223977|NCT00916110|DRUG|ATN-103|1.5 mg solution, single subcutaneous injection
219223978|NCT00916110|DRUG|ATN-103|4 mg solution, single subcutaneous injection
219102292|NCT06901102|DRUG|Standard Care for CKD-MBD|This intervention represents the standard care for patients with chronic kidney disease-mineral bone disorder (CKD-MBD) undergoing hemodialysis. The treatment typically includes phosphate binders to control phosphorus levels, vitamin D receptor activators to regulate calcium and phosphorus metabolism, and calcimimetics to control parathyroid hormone (PTH) levels. The specific regimen may vary according to individual patient needs, but the control group will not receive bee venom injections as part of their therapy.
219102293|NCT06899685|OTHER|tradional physical therapy treatment|Instructions, hot backs, Deep transverse friction massage, passive \&self stretch, Neck isometric and Scapular retraction exercises
219102294|NCT06899685|OTHER|KT|Kinesiotaping
219102295|NCT06899685|DEVICE|IASTM|Instrument Assisted Soft Tissue Mobolization
219102296|NCT06900790|PROCEDURE|ERCP|There are two intervention methods for pediatric pancreatic duct stones. One is to remove the pancreatic duct stones through Endoscopic Retrograde Cholangiopancreatography(ERCP), while simultaneously dilating the pancreatic duct and placing a stent to assist in the normal drainage of pancreatic juice. The other is local resection of the pancreatic head combined with longitudinal pancreaticojejunostomy (Frey surgery).
219102297|NCT06899906|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, and medical management (antibiotic therapy)
219102298|NCT06900387|DIETARY_SUPPLEMENT|Tablet Calcinum-Calcium Carbonate (500mg) daily and Vitamin D3 (Cholecalciferol) tablet (60,000 IU) once a month.|Oral Calcium Carbonate supplement 500 mg from La Renon Healthcare Pvt Ltd to be administered daily for the period of 6 months. Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
219102299|NCT06900387|DIETARY_SUPPLEMENT|Tablet Tayo- Vitamin D3 (Cholecalciferol) (60,000 IU) once a month.|Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
219102300|NCT06900387|OTHER|Control Group|No additional intervention was given to control group.
219102301|NCT06899698|OTHER|Inspiratory muscle training|Only participants in the Study group 'Thirty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive inspiratory muscle training using Respiratory muscle strength: Threshold Inspiratory muscle trainer (TIMT): Philips Respironics model (Tayland- B00J417PHM), for 30 minutes per day for at least 3 days a week for 8 weeks.
219102302|NCT06899698|OTHER|Traditional Training|Both the study and control group 'Sixty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive a. bobath technique 'passive mobilization associated with tactile and proprioceptive stimuli aims to inhibits spasticity'; b. Proprioceptive neuromuscular facilitation 'based on spiral and diagonal patterns of movements in line to achieve normal movements' c. Rood technique 'focuses on the developmental sequence of recovery (from basic to complex) and the use of sensory stimulation to facilitate movement and postural responses' d. Johnstone method 'includes positioning and splinting to inhibit abnormal patterns and controlling tone to restore central control' e. Functional electrical stimulation; f. Balance training, j. Pelvic, and gait training, h. Activities of daily living, and finally, g. Sensrimotor training 'Active and active-assistive range-of motion exercises, Graded activities Start with easy activities'.
219102303|NCT06899958|DEVICE|Fractional Laser|Three fractional laser treatments to the abdomen and thighs at 4 week intervals.
219102304|NCT06901076|DIETARY_SUPPLEMENT|Nisatol|Nisatol® (developed by PharmExtracta) containing Nigella sativa seeds oil and Vitamin E, 1 capsule soft gel after breakfast and 1 capsule soft gel after dinner for 6 months
219102305|NCT06901076|OTHER|Placebo|Placebo
219102306|NCT01165073|DIETARY_SUPPLEMENT|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
219102307|NCT01165073|DIETARY_SUPPLEMENT|Normal oral intake & supplementation if necessary|Enteral nutrition
219102308|NCT03909802|BEHAVIORAL|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
219102309|NCT03909802|OTHER|Usual care|Usual care
219102310|NCT04410679|BIOLOGICAL|injectable PRF|blood sample and centrifuged to obtain i-PRF
219102311|NCT00311155|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
219102312|NCT02243631|DRUG|Probenecid|Treatment
219102313|NCT03117517|DRUG|Metformin|Metformin (1000 mg)
219223979|NCT00916110|DRUG|ATN-103|10 mg solution, single subcutaneous injection
219223980|NCT00916110|DRUG|ATN-103|25 mg solution, single subcutaneous injection
219223981|NCT00916110|DRUG|ATN-103|25 mg solution, single intravenous injection
219102314|NCT03117517|DRUG|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
219223982|NCT00916110|DRUG|ATN-103|50 mg solution, single subcutaneous injection
219223983|NCT00916110|DRUG|ATN-103|100 mg solution, single subcutaneous injection
219223984|NCT00916110|DRUG|ATN-103|200 mg solution, single subcutaneous injection
219223985|NCT00916110|DRUG|ATN-103|200 mg solution, single intravenous injection
219690211|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
219690212|NCT02979782|PROCEDURE|Endo-CABG|minimal invasive cardiac intervention
219102315|NCT04878419|OTHER|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
219102316|NCT02765555|DRUG|RBP-7000|Single dose
219223986|NCT03137459|BEHAVIORAL|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
219690213|NCT02979782|PROCEDURE|PCI|stenting procedure
219690214|NCT00818584|DRUG|Micafungin|IV Administration
219690215|NCT04851106|DIAGNOSTIC_TEST|Endoscopic ultrasound|Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
219690216|NCT00388791|DRUG|Systane Free|
219690217|NCT00370500|DRUG|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
219690218|NCT01136018|PROCEDURE|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
219690219|NCT04644406|OTHER|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
219690220|NCT03444844|DRUG|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
219690221|NCT04919317|DRUG|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
219102317|NCT03717675|DEVICE|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
219102318|NCT04670926|DIAGNOSTIC_TEST|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of \> 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of \> 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
219102319|NCT04670926|OTHER|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
219223987|NCT03137459|OTHER|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
219223988|NCT04557566|BEHAVIORAL|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
219690222|NCT04919317|DRUG|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
219690223|NCT04856111|DRUG|Pirfenidone|Same as arm description
219690224|NCT04856111|DRUG|Nintedanib|Same as arm description
219690225|NCT01975558|BIOLOGICAL|Sampling at baseline, one week after baseline, two weeks after baseline|
219690226|NCT01975558|BIOLOGICAL|Sampling at baseline, during radiotherapy and after|
219690227|NCT00299065|DRUG|Zileuton injection|
219690228|NCT02869789|DRUG|Nivolumab in combination with Ipilimumab|Specified dose on specified days
219690229|NCT02389959|DRUG|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
219690230|NCT02389959|DRUG|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
219690231|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
219690232|NCT05259488|DIETARY_SUPPLEMENT|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
219690233|NCT03710330|DRUG|normal saline|110 ml normal saline IV just before skin incision
219690234|NCT03710330|DRUG|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
219690235|NCT03710330|DRUG|0.5 gm tranexamic acid|0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
219690236|NCT06087770|DRUG|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
219690237|NCT01243060|DRUG|Almorexant|100mg
219690238|NCT01243060|DRUG|Almorexant|200mg
219690239|NCT01243060|DRUG|Zolpidem 10mg|10mg
219102320|NCT02948348|DRUG|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
219102321|NCT02948348|DRUG|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
219690240|NCT01243060|DRUG|Placebo|One-time dose of Placebo
219102322|NCT05655104|OTHER|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
219690241|NCT04060953|OTHER|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
219690242|NCT02634073|DRUG|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
219690243|NCT02634073|DRUG|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
219102323|NCT06421909|BEHAVIORAL|mindfulness-based educational intervention|Mindfulness-based educational intervention is a structured program that incorporates principles of mindfulness to help individuals develop greater awareness and acceptance of their thoughts, feelings, and bodily sensations. The intervention typically includes mindfulness meditation practices, cognitive-behavioral techniques, and educational components about stress management and emotional regulation. By fostering a non-judgmental and present-focused attitude, participants learn to manage their symptoms more effectively and improve their overall quality of life.
219102324|NCT01705275|DRUG|ONO-8539|ONO-8539
219102325|NCT01705275|OTHER|Placebo|Identical to ONO-8539 tablet but without active ingedient
219102326|NCT04166929|BIOLOGICAL|Haplo SCT with NK cells|Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
219102327|NCT04166929|BIOLOGICAL|Haplo SCT|Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
219102328|NCT01785628|DIETARY_SUPPLEMENT|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
219102329|NCT01785628|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo is dextrin composition.
219690244|NCT00132535|DRUG|sulfadoxine-pyrimethamine intermittent preventive treatment|
219102330|NCT00840996|DRUG|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
219102331|NCT00840996|DRUG|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
219102332|NCT00321334|PROCEDURE|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
219102333|NCT01364402|DRUG|Epoetin beta|50,000U intravenously
219690245|NCT00132535|DRUG|chloroquine|
219102334|NCT01364402|DRUG|Saline 0.9%|normal saline intravenously
219102335|NCT01934699|DEVICE|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
219690246|NCT03043456|DEVICE|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
219690247|NCT03043456|DEVICE|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
219690248|NCT02256696|DRUG|PA-824|200 mg QD
219690249|NCT02256696|DRUG|Rifampin|600 mg QD
219690250|NCT02256696|DRUG|Rifabutin|300 mg QD
219690251|NCT02256696|DRUG|Pyrazinamide|25mg/kg QD
219690252|NCT02256696|DRUG|Ethambutol|15mg/kg QD
219690253|NCT02256696|DRUG|Isoniazid|300 mg QD
219690254|NCT04263259|BEHAVIORAL|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
219690255|NCT05797025|OTHER|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
219690256|NCT04216147|OTHER|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
219690257|NCT04216147|PROCEDURE|Surgery for CTS|Median nerve release
219690258|NCT06561633|DRUG|Sugammadex administration|After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
219690259|NCT02577640|DIETARY_SUPPLEMENT|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
219690260|NCT05316558|BEHAVIORAL|Body Confident Coaching|The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
219690261|NCT05562063|DRUG|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
219690262|NCT05562063|DRUG|Placebo|Matching placebo for 6 months.
219690263|NCT06290089|OTHER|Enterotoxigenic E. coli (ETEC) strain|Challenge strain
219690264|NCT04089046|BEHAVIORAL|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
219690265|NCT04089046|BEHAVIORAL|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
219690266|NCT05186129|DRUG|Clopid® 75 mg Tablet|Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
219690267|NCT05186129|DRUG|Plavix® 75mg Tablet|Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
219690268|NCT04741438|DRUG|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~* Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~* Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
219690269|NCT04741438|DRUG|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
219690270|NCT02824107|BIOLOGICAL|blood sample|
219690271|NCT02824107|BEHAVIORAL|questionnaires for psychosocial factors|
219690272|NCT06582875|DRUG|Tirzepatide|Titrated to dose of 5 mg once weekly subcutaneous
219690273|NCT06582875|OTHER|Placebo|Titrated to dose of 5 mg once weekly subcutaneous
219690274|NCT04261439|DRUG|NIZ985|NIZ985 injection
219690275|NCT04261439|DRUG|Spartalizumab|Spartalizumab infusion
219102336|NCT01934699|DEVICE|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
219690276|NCT04261439|DRUG|Tislelizumab|Tislelizumab infusion
219690277|NCT01443858|DRUG|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
219690278|NCT01443858|DRUG|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
219690279|NCT01443858|DRUG|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
219690280|NCT02296658|RADIATION|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
219102337|NCT02424409|BEHAVIORAL|2: Intervention|"1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
219690281|NCT02296658|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
219690282|NCT01417975|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
219690283|NCT01417975|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
219690284|NCT00398944|DEVICE|Evaluation of the impact of a guideline based computerized decision support system.|
219690285|NCT04663685|OTHER|Exercise program|Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.
219690286|NCT04663685|OTHER|Nutrition education|Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
219690287|NCT05661019|OTHER|Obtain Myotrace measurements|Myotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
219690288|NCT01793753|DRUG|Propofol|
219690289|NCT04368507|DRUG|YYB101|"1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity"
219690290|NCT03081247|DRUG|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
219102338|NCT02424409|BEHAVIORAL|1: Control|patients without discharge protocol
219102339|NCT02479516|BEHAVIORAL|Community Health Assessment Program Philippines (CHAP-P)|
219102340|NCT00517465|DRUG|Placebo|po bid
219102341|NCT00517465|DRUG|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
219102342|NCT03804515|DRUG|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
219690291|NCT03081247|DRUG|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
219690292|NCT02849587|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
219690293|NCT05619731|OTHER|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
219102343|NCT02047565|DRUG|60mg edoxaban|
219102344|NCT02047565|DRUG|180mg edoxaban|
219102345|NCT02047565|DRUG|50 IU/kg Beriplex P/N|
219102346|NCT02047565|DRUG|25 IU/kg Beriplex P/N|
219102347|NCT02047565|DRUG|10 IU/kg Beriplex P/N|
219102348|NCT02128165|DEVICE|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
219102349|NCT02128165|DEVICE|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
219102350|NCT01568632|DRUG|Imetelstat|
219102351|NCT02942680|DRUG|acetylsalicylic acid started for 24 hours before surgery|
219102352|NCT02942680|DRUG|acetylsalicylic acid stayed for 5 days before surgery|
219102353|NCT02382237|DEVICE|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
219102354|NCT02746575|DRUG|metoprolol|
219102355|NCT02839122|DRUG|Tadalafil|
219102356|NCT02839122|DRUG|Dutasteride|
219102357|NCT05606315|DRUG|Remimazolam Besylate|NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
219102358|NCT05606315|DRUG|Propofol|Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
219102359|NCT05606315|DRUG|Midazolam|Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
219102360|NCT03221504|OTHER|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
219102361|NCT03221504|OTHER|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
219690294|NCT03976752|DRUG|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
219102362|NCT00674635|DRUG|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
219102363|NCT00674635|DRUG|Placebo|matching placebo
219102364|NCT04691713|DRUG|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
219102365|NCT00753883|DRUG|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
219102366|NCT00753883|DRUG|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
219102367|NCT04910815|DEVICE|Atmo Gas Capsule|The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
219102368|NCT04910815|DIAGNOSTIC_TEST|Glucose Breath Test|Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
219102369|NCT04910815|DIAGNOSTIC_TEST|Fructoolifosaccharides (FOS) Breath Test|FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
219102370|NCT04910815|PROCEDURE|Jejunal Aspiration and culture|Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
219102371|NCT04910815|DRUG|Rifaximin|Rifaximin (550g) 1 capsule twice a day for 14 days.
219102372|NCT04910815|DRUG|Placebo|randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
219102373|NCT01950442|DEVICE|Balloon dilation|
219102374|NCT03375125|DIETARY_SUPPLEMENT|Probiotic|L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
219102375|NCT03375125|OTHER|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
219102376|NCT02970032|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
219102377|NCT02970032|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
219102378|NCT02471885|PROCEDURE|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
219102379|NCT02471885|OTHER|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
219102380|NCT06155578|DRUG|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
219102381|NCT06155578|DRUG|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
219102382|NCT01938105|OTHER|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~\--------------------------------------------------------------------------------"
219102383|NCT00561444|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
219102384|NCT03966079|DRUG|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
219102385|NCT05551481|PROCEDURE|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
219102386|NCT04655079|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
219102387|NCT04655079|DEVICE|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
219102388|NCT00004585|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
219690295|NCT06448949|OTHER|Flow Diverter Implantation|Patients must undergo flow diverter implantation and have DSA examinations of the parent artery and TCCD examinations of Flow Diverter Implantation performed preoperatively, three days postoperatively, and six months postoperatively.
219102389|NCT00004585|DRUG|Lamivudine/Zidovudine|
219690296|NCT04014231|PROCEDURE|Diagnostic Imaging|Undergo placement of single wave application
219690297|NCT04014231|OTHER|Laboratory Biomarker Analysis|Correlative studies
219690298|NCT06328738|DRUG|ELVN-002|capsule
219690299|NCT06328738|DRUG|Trastuzumab|intravenous
219690300|NCT06328738|DRUG|5-Fluorouracil|intravenous
219690301|NCT06328738|DRUG|Oxaliplatin|intravenous
219690302|NCT06328738|DRUG|Capecitabine|capsule
219690303|NCT06328738|DRUG|Eribulin|intravenous
219102390|NCT00004585|DRUG|Abacavir sulfate|
219102391|NCT00004585|DRUG|Efavirenz|
219102392|NCT00957931|PROCEDURE|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
219102393|NCT00957931|BIOLOGICAL|Mesenchymal Stromal Cells|
219102394|NCT02682212|OTHER|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
219102395|NCT04178538|PROCEDURE|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
219102396|NCT04178538|PROCEDURE|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
219690304|NCT06328738|DRUG|paclitaxel|intravenous
219690305|NCT06328738|DRUG|Leucovorin|intravenous
219690306|NCT04938960|DIAGNOSTIC_TEST|blood draw|blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
219690307|NCT03576638|DRUG|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
219690308|NCT03576638|DRUG|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
219690309|NCT01372631|DEVICE|miniature spectral imaging system|Use of miniature spectral imaging system
219690310|NCT01372631|DEVICE|Bench-top optical spectrometer|Use of bench-top optical spectrometer
219690311|NCT01372631|DEVICE|High resolution microendoscope|Use of high resolution microendoscope
219690312|NCT00781053|DRUG|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
219102397|NCT05488938|OTHER|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
219102398|NCT02409550|OTHER|CARATKids Questionnaire|
219102399|NCT00857805|PROCEDURE|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
219102400|NCT00857805|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
219102401|NCT02372123|OTHER|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
219102402|NCT02372123|OTHER|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
219102403|NCT01712555|PROCEDURE|autologous fat grafting with PRP to anophthalmic orbits|
219102404|NCT00659594|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
219102405|NCT00659594|DRUG|Placebo|placebo
219102406|NCT06319768|DRUG|Pentoxifylline|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
219102407|NCT06319768|DRUG|platelet rich plasma|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
219102408|NCT06319768|DRUG|combined pentoxifylline and platelet rich plasma|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
219102409|NCT04867785|DRUG|LY3437943|Administered SC
219690313|NCT01234597|DRUG|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219690314|NCT01234597|DRUG|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
219690315|NCT06387758|BEHAVIORAL|Low systemic strength training|Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.
219102410|NCT04867785|DRUG|Dulaglutide|Administered SC
219102411|NCT04867785|DRUG|Placebo|Administered SC
219102412|NCT01289041|DRUG|BKM120|
219102413|NCT00208585|DRUG|sertraline|
219102414|NCT04162990|BEHAVIORAL|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
219102415|NCT04162990|BEHAVIORAL|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
219690316|NCT06387758|BEHAVIORAL|Moderate systemic exercise|Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
219690317|NCT03923881|DEVICE|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
219102416|NCT01751815|PROCEDURE|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
219102417|NCT01751815|PROCEDURE|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
219690318|NCT03094585|OTHER|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
219223989|NCT04918719|DRUG|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
219102418|NCT01110083|DRUG|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
219102419|NCT01403441|DEVICE|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
219102420|NCT03926065|OTHER|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
219102421|NCT03926065|OTHER|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
219102422|NCT03926065|OTHER|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
219102423|NCT03926065|OTHER|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
219102424|NCT04661475|DRUG|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
219223990|NCT04918719|DRUG|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
219690319|NCT03094585|OTHER|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
219690320|NCT03782714|DEVICE|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
219690321|NCT00916552|DRUG|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
219102425|NCT04661475|DRUG|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
219102426|NCT03833128|DRUG|Low Dose REN001|Oral
219102427|NCT03833128|DRUG|High Dose REN001|Oral
219102428|NCT01914809|OTHER|samples blood|
219102429|NCT01914809|OTHER|biopsy placentaire|
219102430|NCT03833180|DRUG|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
219102431|NCT02300337|DEVICE|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
219102432|NCT02393521|DEVICE|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
219102433|NCT03394456|OTHER|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
219223991|NCT03770715|DEVICE|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
219223992|NCT03888807|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
219690322|NCT06119230|BEHAVIORAL|Activity Counselling|Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
219102434|NCT03394456|OTHER|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
219102435|NCT02678767|DRUG|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
219102436|NCT00082537|DRUG|caspofungin acetate|Duration of Treatment: 28-90 days
219102437|NCT00082537|DRUG|Comparator: AmBisome|Duration of Treatment: 28-90 days
219102438|NCT01293019|PROCEDURE|Osteopathic treatment|Real treatment of osteopathy
219102439|NCT01293019|PROCEDURE|Sham Placebo|Sham treatment of osteopathy
219102440|NCT01293019|PROCEDURE|Usual care|Classical treatment of pain in cystic fibrosis patients
219102441|NCT03239873|BIOLOGICAL|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
219102442|NCT03239873|BIOLOGICAL|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
219102443|NCT03239873|BIOLOGICAL|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
219102444|NCT02446925|DEVICE|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
219102445|NCT02446925|DEVICE|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
219102446|NCT03996408|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
219690323|NCT05282628|BEHAVIORAL|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
219102447|NCT03996408|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219102448|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (low dose).
219223993|NCT03888807|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
219223994|NCT06301048|PROCEDURE|Stent Placement in Pancreatic and Bile Ducts|Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
219223995|NCT01732757|DRUG|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
219223996|NCT01732757|DRUG|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
219102449|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (high dose).
219102450|NCT02040987|DRUG|Placebo|Placebo oral solution - one single dose
219102451|NCT02040987|DRUG|Moxifloxacin|Moxifloxacin tablet - one single dose
219102452|NCT06297499|DRUG|Ondansetron 8mg|administration of an IV solution of 8mg ondansetron (4ml)
219223997|NCT01732757|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
219102453|NCT02169895|DRUG|BIA 9-1067|
219102454|NCT02169895|DRUG|Placebo|
219102455|NCT02169895|DRUG|Prolopa®|levodopa/benserazide 100/25 mg
219102456|NCT00605319|DRUG|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
219102457|NCT02505139|OTHER|the number of circulating tumor cells|
219102458|NCT05491668|DIAGNOSTIC_TEST|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
219102459|NCT00239018|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219102460|NCT01239693|DIETARY_SUPPLEMENT|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
219102461|NCT01239693|DIETARY_SUPPLEMENT|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
219102462|NCT01239693|DIETARY_SUPPLEMENT|LNS|Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
219102463|NCT01926522|DEVICE|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
219102464|NCT01926522|OTHER|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
219102465|NCT02670538|DRUG|Cariprazine|Cariprazine capsule one per day orally.
219102466|NCT02670538|DRUG|Placebo|Matching placebo capsule one per day orally.
219690324|NCT05871840|OTHER|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
219690325|NCT02709148|DEVICE|Activa PC+S|DBS
219102467|NCT05340218|OTHER|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
219102468|NCT01886638|DRUG|Abacavir|
219102469|NCT02819856|DRUG|Placebo|0 mg SPI-1005 bid po x 21d
219102470|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
219102471|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
219690326|NCT01775007|DEVICE|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
219690327|NCT04957524|DEVICE|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
219102472|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
219102473|NCT00002163|DRUG|Abacavir sulfate|
219102474|NCT01250119|DRUG|erlotinib [Tarceva]|150 mg daily, orally
219102475|NCT01383057|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
219102476|NCT02887989|DEVICE|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
219102477|NCT02887989|DEVICE|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
219102478|NCT03508999|DRUG|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
219102479|NCT03508999|OTHER|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
219690328|NCT05898841|DRUG|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
219690329|NCT05898841|DRUG|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day|TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
219690330|NCT05898841|DRUG|Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
219102480|NCT03508999|OTHER|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
219102481|NCT01486602|DRUG|carboplatin|IV
219102482|NCT01486602|DRUG|paclitaxel|IV
219102483|NCT01486602|RADIATION|radiation therapy|Defined per the protocol
219102484|NCT03820531|DIAGNOSTIC_TEST|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
219102485|NCT03820531|DIAGNOSTIC_TEST|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst"
219102486|NCT03820531|DIAGNOSTIC_TEST|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
219102487|NCT03820531|DIAGNOSTIC_TEST|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
219102488|NCT06359600|DRUG|HS-10501 tablet|Administered orally
219102489|NCT06359600|DRUG|Placebo|Administered orally
219102490|NCT01132638|DRUG|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
219102491|NCT01132638|DRUG|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
219102492|NCT00436579|DRUG|sorafenib tosylate|Given orally
219102493|NCT00436579|OTHER|pharmacological study|
219102494|NCT00436579|PROCEDURE|assessment of therapy complications|Ancillary studies
219102495|NCT00436579|OTHER|laboratory biomarker analysis|Correlative studies
219102496|NCT00076791|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
219102497|NCT00076791|DRUG|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
219102498|NCT04762225|BIOLOGICAL|RPTR-168|Escalating doses of RPTR-168 as a monotherapy
219690331|NCT05716009|DRUG|Dose Escalation -tagraxofusp-erzs|Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
219690332|NCT05716009|DRUG|Dose Expansion at RP2D -tagraxofusp-erzs|Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
219102499|NCT01342822|DEVICE|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
219102500|NCT05648357|BIOLOGICAL|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
219102501|NCT00255346|DRUG|Dasatinib (BMS-354825)|70 mg orally twice daily
219102502|NCT03620721|BEHAVIORAL|mindfulness|8-week mindfulness based group intervention
219102503|NCT03813550|DIAGNOSTIC_TEST|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
219102504|NCT05309538|OTHER|Modified eply & Semont maneuver|repositioning maneauvers
219102505|NCT05309538|OTHER|betahistine & Modified eply & Semont maneuver|antihistamine plus repositioning maneuvers
219690333|NCT05455710|DEVICE|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
219102506|NCT03644069|BIOLOGICAL|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
219102507|NCT03644069|BIOLOGICAL|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
219102508|NCT05855902|BEHAVIORAL|group art therapy|Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
219102509|NCT00674323|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
219102510|NCT00674323|DRUG|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
219102511|NCT03595501|DEVICE|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
219102512|NCT03595501|DEVICE|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
219102513|NCT05765084|BIOLOGICAL|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
219102514|NCT05765084|DRUG|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
219102515|NCT05765084|DRUG|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
219102516|NCT04806230|DRUG|sertraline, mirtazapine, venlafaxine, citalopram, escitalopram|Naturalistic treatment
219102517|NCT00894634|DRUG|Brompheniramine maleate|
219102518|NCT00171132|DRUG|valsartan|
219102519|NCT00171132|DRUG|atenolol|
219102520|NCT00171132|DRUG|hydrochlorothiazide|
219102521|NCT00675194|DRUG|Cisplatin, Irinotecan, Capecitabine|
219102522|NCT06428461|PROCEDURE|Supraclavicular brachial plexus block|A supraclavicular brachial plexus block will be performed under ultrasound guidance. The patient will be taken to the preoperative block room, positioned supine with the bed elevated at a 30° angle, and the head turned away from the arm being blocked. To avoid intraneural injection, the block will use both ultrasound and a nerve stimulator (Plexygon, Vygon-Italy) with a 22G 50 mm 20° stimulating needle (Echoplex, Braun-France). A low-frequency ultrasound probe will be placed above the clavicle to visualize the subclavian artery and vein. Using an in-plane approach, the needle will be inserted laterally to medially from the mid-clavicular point through the skin and subcutaneous tissue. Under ultrasound guidance, the needle will be advanced towards the anatomical corner where the brachial plexus and subclavian artery are adjacent (corner pocket), and a local anesthetic agent will be injected to perform the block.
219690334|NCT04406714|BEHAVIORAL|Trial Mailed FIT Intervention - Age Group 50-75|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
219102523|NCT06428461|DEVICE|Measurement of Optic Nerve Sheath Diameter (ONSD) Using B-Mode Ultrasound|Before the block, both eyes will be measured for optic nerve sheath diameter (ONSD) using B-mode ultrasound (USG) with a GE LOGIQ E device. The patient will be supine with the bed elevated at a 30° angle, eyes closed, and a protective barrier applied. Both globes will be filled with water-soluble ultrasound gel, and imaging will be done with a 7.5 MHz linear probe at a 7 cm depth. For transverse ONSD measurement, the probe will be placed transversely in the coronal plane, with the marker notch pointing right. When the optic nerve entry into the globe is clear, transverse ONSD will be measured 3 mm below. For sagittal measurement, the probe will be placed sagittally in the coronal plane, with the marker notch pointing towards the body. Sagittal ONSD will be measured 3 mm below the entry point. Both internal and external diameters of the optic nerve sheath will be measured in transverse and sagittal planes, and the transverse diameter of the globe will also be measured.
219102524|NCT06428461|DEVICE|Assessment of Peripheral Nerve Block Success Using Perfusion Index Measurement|Investigator plan to measure the Perfusion Index (PI) as an objective method for determining the success of peripheral nerve blocks, different from traditional tests. PI is an indicator of peripheral perfusion that can be continuously measured non-invasively with a pulse oximeter. PI represents the ratio of pulsatile blood flow to non-pulsatile blood flow in peripheral tissue. The Mindray uMEC 12 device will be used for this measurement.
219102525|NCT06428461|DEVICE|End-Tidal Carbon Dioxide (EtCO2) Measurement|End-tidal carbon dioxide (EtCO2) measurement: The Medtronic Capnostream 35 device will be used for EtCO2 measurements. All patients will receive oxygen support at a rate of 1-2 L/min. If peripheral oxygen saturation falls below 95%, oxygen support will be increased to 3-6 L/min via nasal cannula.
219102526|NCT02437474|BEHAVIORAL|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
219102527|NCT02437474|BEHAVIORAL|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
219102528|NCT02437474|BEHAVIORAL|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
219102529|NCT01989286|OTHER|Assessment|The posture, motor development and balance are going to be assessed.
219102530|NCT00708526|OTHER|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
219102531|NCT00708526|DEVICE|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
219102532|NCT01408758|OTHER|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
219102533|NCT01408758|OTHER|No VCRT, only physician counseling at visits|No intervention
219102534|NCT01828190|OTHER|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
219102535|NCT00750100|DRUG|human chorionic gonadotropin|hCG 200IU in the late follicular phase
219102536|NCT00750100|DRUG|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
219223998|NCT00925548|BIOLOGICAL|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)"
219102537|NCT05683106|DEVICE|Custom silicone digital orthosis (CSDO)|Custom silicone digital orthosis (CSDO) will be made under mold to provide realignment of toes, protection or replacement of a segment that was amputated.They will be indicated for corrections of rigid/fixed or flexible toes deformities.CSDO will be constructed using different types of silicone and different hardness considering whether the deformities are rigid or flexible and,when necessary,these components of the orthoses will be merged.Intervention participants will be asked to clean the CSDO and interdigital spaces with soap and water;adequate drying of the fingers and interdigital region;always wear the CSDO with appropriate footwear and socks;keep monitoring the integrity of the CSDO and always communicate any identification of changes in the feet or CSDO.Adverse effects will be evaluated, such as:possible skin irritation; discomfort or pain;contractures;trauma due to friction.Adherence will be verified every 3 months and via telephone contact,monthly.
219102538|NCT01042899|BEHAVIORAL|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
219102539|NCT01042899|BEHAVIORAL|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
219102540|NCT01042899|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
219102541|NCT00714532|BEHAVIORAL|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
219102542|NCT00714532|BEHAVIORAL|Enhanced Expert System|"The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
219102543|NCT00805493|DRUG|Riluzole|
219102544|NCT00367913|DRUG|Addition of clarithromycin to rifampicin and ethambutol|
219102545|NCT00367913|DRUG|Addition of Ciprofloxacin to rifampicin and ethambutol|
219102546|NCT00367913|BIOLOGICAL|Vaccination with M.vaccae|
219102547|NCT03446105|BEHAVIORAL|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
219102548|NCT03446105|BEHAVIORAL|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
219102549|NCT01676532|OTHER|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
219102550|NCT00248300|OTHER|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
219102551|NCT02208570|OTHER|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
219102552|NCT02208570|DRUG|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
219223999|NCT00925548|BIOLOGICAL|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
219224000|NCT00925548|DRUG|cyclophosphamide|300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
219224001|NCT00925548|DRUG|sodium chloride (NaCl)|NaCl 9 g/L infusion
219224002|NCT06086548|OTHER|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
219224003|NCT01619007|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
219102553|NCT02208570|OTHER|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
219102554|NCT04470219|OTHER|Cognitive support by RemindMe|
219102555|NCT05065385|DIAGNOSTIC_TEST|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
219102556|NCT01917305|DEVICE|platform-shifted implant|
219102557|NCT01520389|DRUG|MM-151|MM-151
219102558|NCT01520389|DRUG|MM-151 + irinotecan|MM-151 + irinotecan
219102559|NCT05639907|DEVICE|K21 Cavity cleanser|K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
219102560|NCT05639907|DEVICE|Ethanol control|Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
219102561|NCT05130255|DRUG|GD2-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
219102562|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
219102563|NCT03654781|DRUG|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
219102564|NCT03654781|PROCEDURE|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
219102565|NCT02799303|DEVICE|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
219102566|NCT02799303|OTHER|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
219102567|NCT01942902|DEVICE|Continuous Glucose Monitoring System|
219102568|NCT00813696|DRUG|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
219102569|NCT00813696|DRUG|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
219102570|NCT01614639|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
219102571|NCT01654991|BEHAVIORAL|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
219102572|NCT01654991|BEHAVIORAL|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
219690335|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|"Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call."
219102573|NCT03434002|OTHER|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
219102574|NCT03434002|OTHER|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
219102575|NCT05099913|DRUG|Deanxit|Central neuromodulators was applied in refractory FD patients for different time
219102576|NCT02372760|DEVICE|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
219102577|NCT02372760|OTHER|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
219102578|NCT02372760|DRUG|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
219102579|NCT03697382|BEHAVIORAL|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219102580|NCT03697382|BEHAVIORAL|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219102581|NCT03697382|BEHAVIORAL|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
219102582|NCT00409786|BEHAVIORAL|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
219102583|NCT01884714|OTHER|High fat/high calorie meal|All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
219102584|NCT05672303|BEHAVIORAL|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
219102585|NCT05913375|RADIATION|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
219102586|NCT06437730|OTHER|Integrated Neuromuscular Inhibition Technique:|MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint. Compression will be increased gradually until first resistance will feel and maintained until it resolves, further increases then until no tissue resistance will be felt under thumb. This process is maintained for 30sec and repeated 3-5 times per session. Positional release technique: after applying pressure on trigger point, patient will acquire position of ease that is maintained for 20 sec whether its extension or flexion of knee. This process is repeated 3-5 times per session. Muscle Energy Technique will be applied on the muscle in which isometric contraction is maintained for 7-10sec against 20-25% strength. After completion of muscular contraction, the limb is moved away for muscular stretch and then position is maintained for 30 seconds
219102587|NCT06437730|OTHER|Dry needling:|"Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.~For vastus laterals patient is supine line with knee extended performing an isometric quadriceps contraction, maintaining a clean technique by using gloves and performing an alcohol wipe down bracket the tissue to be treated and inserting needle with direct approach towards the femur, performing pistoning. For vastus medialis patient is supine line with 30 degrees of knee flexion. A headless 0.25x25mm needle fixed between the fingers of non-dominant hand and inserted perpendicularly to the MTrPs with metacarpophalangeal flexion extension of 1st and 2nd fingers of dominant hand. For Gastrocnemius patient is prone lying and bolstered supported slight knee bend, for the upper part anterior medial approach is used and center of muscle belly slight medial anterior approach is used."
219690336|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
219690337|NCT06452771|DRUG|ALN-ANG3|Administered subcutaneous (SC) injection
219690338|NCT06452771|DRUG|Placebo (PB)|Administered SC injection
219102588|NCT05268575|OTHER|performing endoscopy|Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
219102589|NCT06139991|DRUG|Treatment A (BDA MDI HFO)|Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
219102590|NCT06139991|DRUG|Treatment B (BDA MDI HFA)|Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
219102591|NCT01749501|DRUG|Rocuronium|0.6 mg/Kg once
219102592|NCT01749501|OTHER|Placebo|Normal saline same amt as 0.6mg/kg of study drug
219102593|NCT00976469|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
219102594|NCT00976469|BIOLOGICAL|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
219102595|NCT01357590|DEVICE|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
219690339|NCT06432933|OTHER|No preventive oxygen therapy (2L)|Participants will not receive preventive oxygen 2L during the first postoperative night after bariatric surgery.
219690340|NCT06432933|OTHER|Preventive oxygen therapy (2L) standard care|Participants will receive preventive oxygen 2L during the first postoperative night after bariatric surgery, standard care.
219690341|NCT05918406|COMBINATION_PRODUCT|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
219690342|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
219690343|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
219690344|NCT00549549|DRUG|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
219690345|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
219690346|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
219690347|NCT00549549|DRUG|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
219690348|NCT02155699|BEHAVIORAL|Exercise 1|65% of VO2max and 2 sessions per week
219690349|NCT02155699|BEHAVIORAL|Exercise 2|85% intensity and 3 sessions per peek
219690350|NCT02227784|DRUG|Evacetrapib|Administered orally
219690351|NCT02227784|DRUG|Atorvastatin|Administered orally
219690352|NCT02227784|DRUG|Ezetimibe|Administered orally
219690353|NCT02227784|DRUG|Placebo|Administered orally
219102596|NCT06297681|DRUG|Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin|The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
219102597|NCT05642546|DRUG|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
219102598|NCT05642546|DRUG|Placebo|Saline Placebo
219102599|NCT03388112|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
219102600|NCT02999711|DRUG|REGN3500|REGN3500 dose
219102601|NCT02999711|DRUG|Placebo|Matching placebo
219102602|NCT03988010|DRUG|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
219102603|NCT03988010|DRUG|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
219102604|NCT01760746|OTHER|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
219102605|NCT03229616|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
219102606|NCT03229616|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
219102607|NCT03229616|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
219102608|NCT04048759|BEHAVIORAL|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
219102609|NCT04048759|BEHAVIORAL|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
219102610|NCT04048759|BEHAVIORAL|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
219102611|NCT03668730|RADIATION|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
219690354|NCT00550797|BIOLOGICAL|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
219690355|NCT00550797|BIOLOGICAL|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
219690356|NCT02992028|DRUG|Intravenous Nutrition (Vitamins) injection|
219690357|NCT02992028|DRUG|Intravenous Saline injection|
219690358|NCT04554602|DIAGNOSTIC_TEST|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
219102612|NCT03668730|DRUG|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
219102613|NCT03668730|DRUG|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
219102614|NCT03668730|DRUG|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
219102615|NCT01077362|DRUG|placebo|SC injections
219102616|NCT01077362|DRUG|ustekinumab 45 mg|SC injections
219102617|NCT01077362|DRUG|ustekinumab 90 mg|SC injections
219102618|NCT02100150|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
219102619|NCT02100150|DRUG|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
219102620|NCT05344261|PROCEDURE|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
219102621|NCT05344261|PROCEDURE|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
219102622|NCT05344261|PROCEDURE|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
219690359|NCT00424281|DRUG|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
219690360|NCT05580484|PROCEDURE|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
219690361|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
219690362|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
219690363|NCT00653393|DRUG|Tranylcypromine|Tablets, 10 mg, single-dose
219690364|NCT00653393|DRUG|Parnate|Tablets, 10 mg, single-dose
219690365|NCT02890316|OTHER|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
219690366|NCT02890316|RADIATION|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
219690367|NCT05775419|COMBINATION_PRODUCT|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
219690368|NCT05775419|COMBINATION_PRODUCT|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
219690369|NCT06557135|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
219102623|NCT01971606|DRUG|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
219102624|NCT02691104|DEVICE|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
219102625|NCT02691104|DEVICE|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
219224004|NCT01619007|DRUG|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
219224005|NCT00374998|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
219224006|NCT00374998|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
219690370|NCT04974528|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
219690371|NCT04974528|BIOLOGICAL|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
219690372|NCT04974528|BIOLOGICAL|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219690373|NCT06320951|DRUG|Vericiguat 10 MG|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
219690374|NCT06320951|OTHER|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
219690375|NCT06320951|OTHER|Insulin Sensitivity Test|An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
219690376|NCT06320951|OTHER|Resting Energy and Exercise Energy Expenditure Assessment|Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
219690377|NCT06320951|OTHER|White Adipose Tissue Biopsy|Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
219690378|NCT06320951|OTHER|MRI-PET Scan for Brown Adipose Tissue Volume Assessment|Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
219690379|NCT03851848|OTHER|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
219224007|NCT04407247|BIOLOGICAL|Infliximab|Given IV
219224008|NCT04407247|BIOLOGICAL|Vedolizumab|Given IV
219224009|NCT02781519|DRUG|THC|Active THC (0.015mg/kg) administered over 10 minutes
219224010|NCT02781519|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
219690380|NCT03851848|OTHER|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
219690381|NCT00292552|OTHER|Novel endpoint determination|Novel endpoint determination
219690382|NCT03461458|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
219690383|NCT01794962|OTHER|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
219690384|NCT01794962|OTHER|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
219102626|NCT06179264|BEHAVIORAL|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
219102627|NCT05603988|DEVICE|Intracanal Diode laser irradiation|After endodontic retreatment, root canals will be irradiated with a 980 nm diode laser coupled with optical fibre 200 μm (Litemedics, Italy) with setting 1.2-watt power, in pulsed mode. The irradiation protocol will be of 5-sec irradiation followed by a 10-sec pause, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth. The tip will be positioned 1 mm short of the apex. Followed by activation during which it will be slowly dragged at a speed of approximately 2 mm/ sec in a way that the root canals will be irradiated from the apical to the coronal portion, in a helicoidal movement touching the canal walls.
219102628|NCT05603988|OTHER|Placebo|"After endodontic retreatment, mock laser application (Placebo group) will be applied:~The fiberoptic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated"
219224011|NCT04921358|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
219224012|NCT04921358|DRUG|Docetaxel|75 mg/m\^2 intravenously once every 3 weeks
219102629|NCT03584893|PROCEDURE|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
219102630|NCT01349413|DRUG|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
219102631|NCT01349413|OTHER|Placebo|Identical looking placebo
219102632|NCT03619941|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
219224013|NCT04921358|DRUG|Sitravatinib|100 mg orally once daily
219224014|NCT04632290|DEVICE|STIMO-BSI system implantation|Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
219224015|NCT04632290|DEVICE|ARC-BSI Lumbar System|ARC-BSI Lumbar System for participants entering the optional extension with system upgrade: replacement of the neurostimulator, and upgrade of the WIMAGINE system and STIMO system wearable devices.
219102633|NCT03619941|DIETARY_SUPPLEMENT|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
219102634|NCT00460317|DRUG|AMG 706|125 mg QD orally every day
219102635|NCT00460317|DRUG|placebo|125 mg QD orally every day
219102636|NCT00460317|DRUG|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
219102637|NCT00460317|DRUG|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
219102638|NCT03068013|BEHAVIORAL|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
219224016|NCT03546829|DRUG|Vancomycin|125 mg, 4x daily for 5 weeks
219224017|NCT03546829|RADIATION|Precision hypofractionated radiation|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
219224018|NCT04926857|OTHER|Non-Interventional|Non-Interventional
219224019|NCT06130046|BIOLOGICAL|MR-proADM dosage|Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
219224020|NCT04350502|PROCEDURE|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).
219224021|NCT04350502|BIOLOGICAL|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
219224022|NCT04350502|DRUG|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
219224023|NCT04920253|DEVICE|Study Device Debridement|debritom+ water jet debridement
219224024|NCT04920253|DEVICE|SOC Debridement|Sharp Scalpel
219224025|NCT05646719|DRUG|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
219690385|NCT01787006|DRUG|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
219102639|NCT03068013|BEHAVIORAL|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
219102640|NCT03149016|PROCEDURE|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
219102641|NCT05772975|BIOLOGICAL|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
219102642|NCT05772975|BIOLOGICAL|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
219102643|NCT04903457|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
219102644|NCT04903457|BEHAVIORAL|Motor learning|Sequential finger tapping task training is applied to stroke patients.
219102645|NCT06340165|DRUG|Anlotinib|Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
219102646|NCT02585596|DRUG|YH23537 1000mg/day|YH23537 500mg 2 tab
219102647|NCT02585596|DRUG|YH23537 2000mg/day|YH23537 500mg 4 tab
219102648|NCT02585596|DRUG|YH23537 3000mg/day|YH23537 500mg 6 tab
219102649|NCT02585596|DRUG|placebo|YH23537 500mg tab placebo
219102650|NCT00301080|DRUG|D-cycloserine|
219102651|NCT00301080|OTHER|Placebo|
219690386|NCT01787006|DRUG|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
219690387|NCT01787006|RADIATION|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
219690388|NCT00000863|DRUG|Sitamaquine|
219690389|NCT00248651|DRUG|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
219690390|NCT00248651|DRUG|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
219690391|NCT00248651|DRUG|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
219102652|NCT01595412|PROCEDURE|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
219102653|NCT01595412|PROCEDURE|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
219102654|NCT00358137|BEHAVIORAL|Aerobic Conditioning Program|
219102655|NCT00358137|BEHAVIORAL|Strength Training Program|
219102656|NCT05914402|PROCEDURE|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
219102657|NCT06164925|DIAGNOSTIC_TEST|Nutrition screening and assessment|"The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength."
219102658|NCT06139874|BEHAVIORAL|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
219224026|NCT05646719|OTHER|Placebo|Vehicle for Phentolamine Ophthalmic Solution
219690392|NCT04904679|DEVICE|Pars plana Vitrectomy with internal limiting membrane peeling|"The pars plana 23-gauge (23G) vitrectomy technique will be performed with removal of the internal limiting membrane (ILM) (when adhered to the macula) and placement of either an amniotic membrane plug or an ILM flap in the macular hole. This will be followed by a fluid-air exchange and buffering gas infusion (12.5% C3F8).~The amniotic membrane plug will be prepared using a dermatological punch with a diameter of 1 to 2 mm, depending on the size of the macular hole as measured by OCT. It will be positioned inside the macular hole using 23G forceps, with its chorionic side facing the retinal pigmented epithelium (RPE).~The ILM flap will be created at the time of peeling-with an inverted flap in primary cases and a free flap in refractory cases. It will be positioned over the hole (inverted flap) or inside the macular hole (free flap) using 23G ILM forceps.~These techniques will be assisted by the use of an extra lighting sclerotomy."
219690393|NCT02108977|OTHER|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
219102659|NCT06139874|BEHAVIORAL|Parenting Wisely|Online asynchronous parenting program.
219224027|NCT05646719|DRUG|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
219224028|NCT05646719|OTHER|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
219224029|NCT05554159|BEHAVIORAL|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
219102660|NCT04508556|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
219102661|NCT04508556|DIAGNOSTIC_TEST|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
219102662|NCT04508556|DIAGNOSTIC_TEST|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
219102663|NCT00219440|OTHER|Actos plus standard diet|Actos plus standard diet
219102664|NCT00219440|OTHER|Actos plus structured diet|Actos plus structured diet
219102665|NCT00219440|OTHER|Metformin plus standard diet|Metformin plus standard diet
219102666|NCT03207217|OTHER|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
219102667|NCT02761655|BEHAVIORAL|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
219102668|NCT03719053|DRUG|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
219102669|NCT01641926|BIOLOGICAL|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
219102670|NCT01641926|BIOLOGICAL|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
219102671|NCT03485014|DRUG|Exparel|EXPAREL 4 mg/kg
219102672|NCT02899364|DRUG|Sodium thiosulfate|see description under experimental arm
219102673|NCT02899364|DRUG|Sodium chloride 0.9%|see description under placebo comparator arm
219102674|NCT02899364|PROCEDURE|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
219102675|NCT02899364|OTHER|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
219224030|NCT05554159|BEHAVIORAL|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
219690394|NCT02108977|OTHER|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
219690395|NCT02688933|DRUG|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
219690396|NCT02688933|DRUG|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
219690397|NCT02688933|DRUG|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
219102676|NCT06158425|RADIATION|long-leg radiograph|A flat-panel digital radiography(DR) equipment (Siemens DR AXIOM Aristos AX/VX) was used to capture full-length bipedal lower extremities in a standing position. The technician moved the detector from top to bottom, capturing four parts: the bilateral hip joints, femur, tibia and fibula and ankle joint. The exposure parameters for each part were as follows: 1st exposure - 85kV, 75mAs; 2nd exposure - 80kV, 50mAs; 3rd exposure - 75kV, 40mAs; 4th exposure - 68kV, 20mAs. The distance from the source (kv-kg) was 300cm, and the field of view was 43.18cm x 43.18cm. All 4 X-rays were stitched using the Siemens DR Station.
219102677|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with uncoated balloon|
219102678|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with Paclitaxel balloon|
219102679|NCT03062774|BIOLOGICAL|PB-119 injection|
219102680|NCT00885963|DRUG|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
219102681|NCT02916797|OTHER|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
219102682|NCT00084643|BIOLOGICAL|GTI-2040|Given IV
219102683|NCT00084643|DRUG|oxaliplatin|Given IV
219102684|NCT00084643|DRUG|capecitabine|Given orally
219102685|NCT00084643|OTHER|pharmacological study|Correlative studies
219102686|NCT00084643|OTHER|laboratory biomarker analysis|Correlative studies
219102687|NCT00288301|BEHAVIORAL|Weight loss intervention|weight loss intervention
219102688|NCT00415792|DRUG|Arvekap, Pregnyl|
219102689|NCT02294630|DRUG|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
219102690|NCT04040881|BEHAVIORAL|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
219102691|NCT00749125|DRUG|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
219102692|NCT02567825|DEVICE|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
219102693|NCT02567825|DRUG|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
219102694|NCT02567825|DRUG|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
219102695|NCT05512429|OTHER|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
219102696|NCT03202095|DRUG|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
219102697|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
219102698|NCT03749577|DIETARY_SUPPLEMENT|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
219102699|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
219102700|NCT03749577|DIETARY_SUPPLEMENT|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
219102701|NCT01548937|DRUG|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
219102702|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
219690398|NCT04664101|BEHAVIORAL|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
219690399|NCT04664101|OTHER|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
219690400|NCT05053269|OTHER|good body weight growth|body weight growth after birth is consistent with the growth curve
219690401|NCT05053269|OTHER|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
219690402|NCT01275144|DRUG|LY2216684|Administered orally
219690403|NCT01275144|DRUG|Placebo|Administered orally
219690404|NCT01275144|DRUG|Lorazepam|Administered orally
219690405|NCT00828113|DRUG|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
219690406|NCT00828113|DRUG|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
219690407|NCT00828113|BEHAVIORAL|Individual smoking cessation counseling|Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
219102703|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
219102704|NCT01626222|DRUG|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
219102705|NCT01626222|DRUG|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
219102706|NCT04863989|PROCEDURE|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
219690408|NCT03767842|DEVICE|Visor System|Subjects are monitored one time with the Visor System.
219690409|NCT01365130|DRUG|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
219690410|NCT03683836|DIAGNOSTIC_TEST|No intervention|No intervention
219690411|NCT06165211|OTHER|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
219690412|NCT06165211|OTHER|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
219690413|NCT04621799|DRUG|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
219690414|NCT00101244|DRUG|ispinesib|Given IV
219690415|NCT00101244|OTHER|laboratory biomarker analysis|Correlative studies
219690416|NCT00101244|OTHER|pharmacological study|Correlative studies
219102707|NCT03195465|DIETARY_SUPPLEMENT|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
219102708|NCT02943889|BIOLOGICAL|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
219102709|NCT05250622|OTHER|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
219102710|NCT05250622|OTHER|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
219102711|NCT00167895|PROCEDURE|Adding platelet concentrate to the wound|
219102712|NCT02913976|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
219102713|NCT02913976|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
219102714|NCT04865211|DRUG|Liposomal bupivacaine|Use of liposomal bupivicaine as intraoperative local anesthesia
219102715|NCT04865211|DRUG|Bupivacaine Injection|Use of bupivicaine as intraoperative local anesthesia
219102716|NCT04865211|DRUG|Placebo|Use of saline as placebo for local anesthesia
219102717|NCT00458614|DRUG|Lansoprazole|
219102718|NCT00904891|BEHAVIORAL|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
219690417|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
219690418|NCT04819165|OTHER|COVID-19|Impact of covid-19 on infections associated with health care devices.
219690419|NCT00909064|DRUG|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
219102719|NCT00904891|BEHAVIORAL|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
219102720|NCT04266639|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
219102721|NCT04266639|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
219102722|NCT01540565|OTHER|Laboratory Biomarker Analysis|Correlative studies
219102723|NCT01540565|DRUG|Veliparib|Given PO
219102724|NCT05489939|DRUG|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
219102725|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
219102726|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
219102727|NCT01101360|DEVICE|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
219690420|NCT05931874|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
219102728|NCT01101360|DEVICE|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
219102729|NCT01101360|DEVICE|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
219102730|NCT01222468|DRUG|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
219690421|NCT05931874|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
219690422|NCT05931874|BEHAVIORAL|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
219102731|NCT01222468|DRUG|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
219102732|NCT05872529|BEHAVIORAL|Education|The education which consists processed EEG monitoring and SBI approach
219690423|NCT05931874|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
219690424|NCT05931874|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
219690425|NCT04108195|DRUG|Daratumumab|Participants will receive daratumumab.
219690426|NCT04108195|DRUG|Talquetamab|Participants will receive talquetamab.
219690427|NCT04108195|DRUG|Teclistamab|Participants will receive teclistamab.
219690428|NCT04108195|DRUG|Pomalidomide|Participants will receive pomalidomide.
219690429|NCT05708898|DEVICE|Pharyngeal exerciser|
219690430|NCT05708898|DEVICE|sham pharyngeal exerciser|
219690431|NCT05254886|OTHER|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~* Report the presence of pre-existing comorbidities/EIMs~* Detect the presence of risk factors~* Implement recommendations for the detection and/or management of comorbidities/EIMs."
219690432|NCT05607576|OTHER|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
219690433|NCT06441604|DRUG|Extended-release Buprenorphine|"First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion."
219690434|NCT05646030|DIAGNOSTIC_TEST|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
219690435|NCT05646030|DIAGNOSTIC_TEST|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
219102733|NCT00242203|DRUG|Zometa|
219102734|NCT00242203|DRUG|Epirubicin|
219102735|NCT00242203|DRUG|Docetaxel|
219102736|NCT00242203|DRUG|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
219102737|NCT00242203|RADIATION|External beam radiation|
219102738|NCT00242203|PROCEDURE|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
219102739|NCT00975052|DRUG|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
219102740|NCT00975052|DRUG|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
219102741|NCT00975052|DRUG|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
219102742|NCT00975052|DRUG|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
219102743|NCT02590692|BIOLOGICAL|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
219102744|NCT04194996|PROCEDURE|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
219102745|NCT06383325|COMBINATION_PRODUCT|Chemotherapy|Detection of hepatotoxicity in acute leukemia patients during chemotherapy
219102746|NCT01678820|DRUG|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
219102747|NCT01678820|DRUG|Sitagliptin|Sitagliptin 100 mg tablet
219102748|NCT01678820|DRUG|Simvastatin|Simvastatin 40 mg tablet
219690436|NCT05646030|DIAGNOSTIC_TEST|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
219102749|NCT01678820|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
219690437|NCT06355440|BEHAVIORAL|Financial Navigation|"One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting"
219690438|NCT06355440|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
219690439|NCT05321368|BEHAVIORAL|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
219690440|NCT04203641|BIOLOGICAL|L-DOS47|A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.
219690441|NCT04203641|DRUG|Doxorubicin|A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23
219102750|NCT01678820|DRUG|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
219102751|NCT01678820|DRUG|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
219690442|NCT04503967|DRUG|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
219690443|NCT04764188|DRUG|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
219690444|NCT06139354|BEHAVIORAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
219690445|NCT06327490|PROCEDURE|ICG-guided manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.
219690446|NCT06327490|PROCEDURE|Traditional manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.
219102752|NCT01678820|DRUG|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study
219102753|NCT01678820|DRUG|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
219102754|NCT04476420|DIETARY_SUPPLEMENT|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
219102755|NCT04476420|DRUG|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
219690447|NCT06327490|DRUG|Indocyanine green|All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
219690448|NCT05582343|BEHAVIORAL|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!"
219102756|NCT02306265|DEVICE|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
219102757|NCT02306265|DEVICE|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
219102758|NCT03191357|OTHER|n/a observational|Observational study
219690449|NCT05276778|DIAGNOSTIC_TEST|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
219690450|NCT05589753|OTHER|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
219102759|NCT04071119|DRUG|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
219102760|NCT04071119|DRUG|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
219102761|NCT04488003|DRUG|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
219102762|NCT04488003|DRUG|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
219102763|NCT03349268|DEVICE|Pulsed xenon ultraviolet (PX-UV) Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
219102764|NCT03349268|DEVICE|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
219102765|NCT01706419|DIETARY_SUPPLEMENT|Fortified rice cold extruded kernel|
219102766|NCT01706419|DIETARY_SUPPLEMENT|fortified rice warm extruded kernel|
219102767|NCT01706419|DIETARY_SUPPLEMENT|fortiified rice hot extruded kernel|
219102768|NCT02419729|DEVICE|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
219102769|NCT02419729|DRUG|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
219102770|NCT02419729|DRUG|Placebo of Estrogen|Placebo of topical estrogen cream.
219102771|NCT02419729|DEVICE|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
219102772|NCT01994356|BEHAVIORAL|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
219102773|NCT01994356|BEHAVIORAL|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
219102774|NCT03436966|DEVICE|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
219102775|NCT05808530|BEHAVIORAL|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
219102776|NCT03869515|OTHER|No intervention|It's an observational study, so no intervention will be carried out.
219690451|NCT05589753|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
219102777|NCT02168790|DEVICE|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
219102778|NCT04213313|DRUG|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
219102779|NCT04213313|DRUG|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
219102780|NCT04213313|DRUG|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
219102781|NCT04213313|DIAGNOSTIC_TEST|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
219102782|NCT04213313|OTHER|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
219102783|NCT06111690|PROCEDURE|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
219102784|NCT02611544|BEHAVIORAL|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
219224031|NCT06362200|DEVICE|40 Hz tACS intervention|The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 21 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
219690452|NCT05930678|PROCEDURE|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
219690453|NCT05930678|PROCEDURE|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
219690454|NCT06576323|BEHAVIORAL|An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU|We will use implementation mapping to develop a suite of implementation strategies to deliver evidence-based MOUD prescription to mothers attending the bedside of their infants hospitalized in the NICU. The intervention itself is buprenorphine induction and treatment, however the model for delivery is not yet developed, consistent with the need for results from Aim 1 to inform the approach used to develop the implementation model in Aim 2.
219102785|NCT02611544|BEHAVIORAL|Survivorship Education|6-week survivorship education group (SE; n=32)
219690455|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
219224032|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
219224033|NCT05893966|RADIATION|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
219102786|NCT02611544|BEHAVIORAL|Enhanced Usual Care|enhanced usual care (EUC; n=26)
219102787|NCT01350505|BEHAVIORAL|White light exposure|\~200 lux of broad spectrum white light
219102788|NCT01350505|BEHAVIORAL|Dim white light exposure|\~28 lux of broad spectrum white light
219102789|NCT01350505|BEHAVIORAL|Very dim white light exposure|\<0.5 lux of broad spectrum white light
219102790|NCT01350505|BEHAVIORAL|Dim orange light exposure|\~28 lux of orange light
219102791|NCT04406350|PROCEDURE|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
219102792|NCT00245401|DEVICE|CYPHERTM Sirolimus-Eluting Coronary Stent|
219102793|NCT02733705|OTHER|Control|normal saline IV
219102794|NCT02733705|DRUG|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
219102795|NCT02733705|DRUG|propofol|propofol infusion
219102796|NCT00572338|OTHER|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
219102797|NCT00779558|DRUG|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
219224034|NCT01205633|PROCEDURE|venous angioplasty|catheter venous angioplasty via femoral vein approach
219102798|NCT00779558|DRUG|Placebo infusion|Infusion of normal saline
219224035|NCT01742494|PROCEDURE|Water-jet POEM|Water-jet assisted POEM procedure was performed
219224036|NCT01742494|PROCEDURE|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
219224037|NCT05773235|DIAGNOSTIC_TEST|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
219224038|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
219224039|NCT02637063|BEHAVIORAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
219102799|NCT01774318|OTHER|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
219224040|NCT02637063|BEHAVIORAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
219224041|NCT02637063|OTHER|Usual care|No intervention beyond participants' own medical care.
219102800|NCT01992705|OTHER|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
219102801|NCT01992705|DRUG|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
219102802|NCT01992705|DRUG|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
219224042|NCT05989542|DRUG|PLB1001|200mg BID Oral
219224043|NCT03116464|BEHAVIORAL|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
219224044|NCT00447837|DRUG|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
219224045|NCT03324724|BEHAVIORAL|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
219690456|NCT02983578|DRUG|Danvatirsen|Given IV
219690457|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
219690458|NCT05230797|DRUG|Zinc oxide Propolis|antibacterial and anti-inflammatory
219102803|NCT01992705|DRUG|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
219102804|NCT00640796|PROCEDURE|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
219102805|NCT00640796|DRUG|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
219102806|NCT00640796|DEVICE|CliniMACS|Cell selection system based on magnetic-activated cell sorting
219102807|NCT00003379|DRUG|cisplatin|
219102808|NCT00003379|DRUG|paclitaxel|
219102809|NCT00003379|RADIATION|brachytherapy|
219102810|NCT00003379|RADIATION|radiation therapy|
219102811|NCT00544960|DRUG|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
219102812|NCT00544960|DRUG|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
219224046|NCT03464955|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
219224047|NCT00491400|DRUG|Fenofibrate|140 mg/day for 8 weeks
219690459|NCT05230797|DRUG|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
219690460|NCT04531332|DRUG|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
219102813|NCT04145037|DRUG|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
219102814|NCT04602897|OTHER|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
219102815|NCT03324711|DIAGNOSTIC_TEST|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
219102816|NCT00812513|DRUG|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
219102817|NCT01756560|DRUG|dexamethsone|
219102818|NCT01756560|DRUG|Bupivacaine|
219102819|NCT01907139|BEHAVIORAL|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
219224048|NCT00491400|DRUG|Atorvastatin|20 mg/day for 8 weeks
219224049|NCT01084525|DRUG|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
219224050|NCT01084525|DRUG|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
219690461|NCT04531332|DRUG|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
219690462|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
219224051|NCT01084525|DRUG|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
219690463|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
219690464|NCT04881214|OTHER|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
219690465|NCT00810199|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
219690466|NCT00810199|DRUG|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
219690467|NCT00810199|DRUG|placebo|Placebo matching methotrexate capsule taken orally once a week.
219690468|NCT01448252|BIOLOGICAL|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
219690469|NCT01448252|BIOLOGICAL|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
219690470|NCT05867134|BEHAVIORAL|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
219690471|NCT04312243|DRUG|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
219102820|NCT01907139|BEHAVIORAL|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
219224052|NCT05912374|BEHAVIORAL|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
219690472|NCT00000887|DRUG|Nelfinavir mesylate|
219224053|NCT05912374|BEHAVIORAL|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
219224054|NCT06341959|PROCEDURE|Oral screening|The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
219224055|NCT03929471|OTHER|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
219224056|NCT06543797|DEVICE|wearable rTMS|Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
219224057|NCT00597376|OTHER|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
219690473|NCT00000887|DRUG|Lamivudine|
219690474|NCT00000887|DRUG|Zidovudine|
219690475|NCT06486285|BEHAVIORAL|Auditory-cognitive dual-task training (ACDT)|The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
219690476|NCT01091246|BIOLOGICAL|Q/LAIV (MEDI3250)|10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
219690477|NCT01091246|BIOLOGICAL|FluMist/B/Yamagata|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
219690478|NCT01091246|BIOLOGICAL|FluMist/B/Victoria|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
219690479|NCT03821987|DRUG|Fludarabine|Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
219690480|NCT00417664|DRUG|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
219224058|NCT00597376|OTHER|Cerefolin NAC placebo|Placebo tablet once a day
219224059|NCT03261466|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
219224060|NCT03261466|DRUG|Placebos|
219690481|NCT00417664|DRUG|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
219690482|NCT00417664|DRUG|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
219690483|NCT02287038|DRUG|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
219102821|NCT01907139|BEHAVIORAL|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
219102822|NCT02307513|DRUG|Apremilast|Tablets for oral administration
219102823|NCT02307513|DRUG|Placebo|Tablets for oral administration
219102824|NCT02055937|PROCEDURE|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
219102825|NCT03179943|DRUG|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
219102826|NCT03179943|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
219102827|NCT00754975|DEVICE|JACTAX LD DES|Drug Eluting Stent
219102828|NCT00754975|DEVICE|TAXUS™ Libertè™ DES|Drug Eluting Stent
219102829|NCT05242016|OTHER|structured individual reminiscence|reminiscence therapy
219102830|NCT05242016|OTHER|unstructured social interview|placebo
219102831|NCT00057187|BEHAVIORAL|Contracting, Prompting and Reinforcing|
219102832|NCT01837290|DRUG|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
219102833|NCT01837290|DRUG|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
219102834|NCT01837290|DRUG|saline infusion|Saline infusion to facilitate blinding
219102835|NCT01837290|DRUG|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
219102836|NCT02223117|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
219102837|NCT02223117|BIOLOGICAL|Placebo|
219224061|NCT04726657|DRUG|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
219102838|NCT02777996|DEVICE|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
219102839|NCT03622203|DEVICE|Biofreedom|Use of Biofreedom in real life patients
219224062|NCT04726657|DRUG|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
219690484|NCT06517433|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
219690485|NCT03481452|BEHAVIORAL|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
219690486|NCT02874313|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
219102840|NCT03375632|DRUG|FYU-981|Oral daily dosing for 14 weeks
219690487|NCT02874313|DRUG|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
219224063|NCT01030237|OTHER|FID 114657|1 drop both eyes four times a day for 6 weeks
219224064|NCT01030237|OTHER|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
219102841|NCT02936713|OTHER|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
219102842|NCT00548067|DRUG|Valsartan/hydrochlorothiazide (HCTZ)|
219102843|NCT00548067|DRUG|Valsartan/amlodipine|
219102844|NCT00548067|DRUG|Amlodipine/hydrochlorothiazide(HCTZ)|
219102845|NCT00548067|DRUG|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
219102846|NCT03868241|DEVICE|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
219102847|NCT03868241|DEVICE|Control|Devices without coating available at each participating intensive care unit
219102848|NCT05285254|OTHER|Certified Child Life Specialist Support|Provides psychosocial care to children and families confronting stressful and painful situations
219102849|NCT01053754|BIOLOGICAL|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
219102850|NCT00181090|BEHAVIORAL|Modified Atkins diet|
219224065|NCT01681563|DRUG|Pentostatin|Lyophilized powder for intravenous administration.
219224066|NCT01681563|DRUG|Cyclophosphamide|IV
219224067|NCT01681563|DRUG|Ofatumumab|Liquid concentrate for solution for infusion.
219224068|NCT03353285|PROCEDURE|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
219690488|NCT02874313|OTHER|Conventional anti-diabetic diet recommendations|
219690489|NCT02713178|DRUG|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
219690490|NCT02713178|DRUG|Placebo|Normal saline.
219690491|NCT04652557|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
219690492|NCT04652557|DRUG|Placebo|no active component
219102851|NCT05059054|OTHER|Strengthening exercise|"Strengthening exercise program Participants performed this protocol at home for 3 times per day. The participants progress their exercise based on the achievement of the previous level of each exercise protocol. The physical therapist recorded the level of each exercise for each participant during eight times of treatment. Total time for this section is approximately 30 minutes. Detail of the strengthening exercise is in the following.~1. Toe curl exercise (toe flexors strengthening)~2. Ankle evertor exercise (peroneal strengthening)~3. Ankle invertor exercise (tibialis posterior strengthening)~4. Heel raise exercise (high-load strength training)"
219102852|NCT05059054|OTHER|Insole (CFO) group|"The CFO insole group The participants will receive the foot assessment before making the CFO for each participant. The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC) and one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort.~The participants will be asked to use the CFO in daily life during weight-bearing activities."
219102853|NCT00709748|DEVICE|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
219102854|NCT00709748|DEVICE|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
219102855|NCT05006677|DRUG|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
219102856|NCT05006677|DRUG|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
219102857|NCT05006677|DRUG|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
219102858|NCT05006677|OTHER|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
219102859|NCT01083940|OTHER|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
219102860|NCT06383702|DRUG|pregabalin sustained-release tablets|Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
219102861|NCT06383702|DRUG|Placebo|Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
219102862|NCT00744263|BIOLOGICAL|VACCINE: placebo|0.5 mL, single intra-muscular injection
219102863|NCT00744263|BIOLOGICAL|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
219690493|NCT01298167|DEVICE|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
219690494|NCT00924846|PROCEDURE|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
219690495|NCT00174200|DRUG|Risperidone 2 mg|
219102864|NCT03084497|PROCEDURE|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
219224069|NCT01035372|DIETARY_SUPPLEMENT|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
219102865|NCT06539975|DRUG|Evening Primrose Oil 1000 MG|Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
219102866|NCT04361032|DRUG|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
219102867|NCT04361032|DRUG|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
219102868|NCT03491423|OTHER|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
219102869|NCT03491423|BIOLOGICAL|glucose meter|glucose meter to measure lactatemia
219102870|NCT03491423|OTHER|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
219102871|NCT03491423|OTHER|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
219224070|NCT03667833|OTHER|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
219224071|NCT03559205|OTHER|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring."
219224072|NCT00562094|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
219224073|NCT03944694|DIAGNOSTIC_TEST|Delirium assessment.|Full blood count analysis.
219690496|NCT00280592|DRUG|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
219690497|NCT00280592|DRUG|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
219690498|NCT00183651|BEHAVIORAL|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
219102872|NCT03491423|OTHER|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
219102873|NCT04261179|DRUG|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
219102874|NCT04261179|DRUG|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
219102875|NCT02872727|OTHER|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
219102876|NCT03769805|DRUG|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
219102877|NCT03577574|PROCEDURE|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
219102878|NCT03577574|PROCEDURE|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
219102879|NCT03577574|PROCEDURE|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
219102880|NCT01351428|DRUG|Nifedipine|30-60 mg, twice daily
219102881|NCT03748017|DIETARY_SUPPLEMENT|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
219224074|NCT01144559|PROCEDURE|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
219102882|NCT03748017|DIETARY_SUPPLEMENT|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
219102883|NCT02771730|BIOLOGICAL|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
219102884|NCT02771730|BIOLOGICAL|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
219102885|NCT02771730|OTHER|Placebo Comparator|Oral sucrose capsules
219102886|NCT02771730|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
219102887|NCT02977884|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
219102888|NCT05232513|OTHER|Hand massage|Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
219102889|NCT00910520|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
219224075|NCT01144559|PROCEDURE|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
219224076|NCT01600482|DEVICE|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
219224077|NCT01555138|DRUG|Indacaterol|Indacaterol is delivered via a SDDPI.
219102890|NCT00910520|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
219102891|NCT05240274|DRUG|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
219102892|NCT05240274|DRUG|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
219102893|NCT03214289|BIOLOGICAL|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
219224078|NCT01555138|DRUG|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
219224079|NCT05381519|BIOLOGICAL|DXP604|1800mg，IVgtt
219224080|NCT01065532|DEVICE|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
219224081|NCT01065532|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
219224082|NCT04620252|DRUG|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
219690499|NCT00183651|BEHAVIORAL|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
219690500|NCT00183651|BEHAVIORAL|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
219102894|NCT03467438|DRUG|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
219102895|NCT03467438|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
219102896|NCT00279656|BEHAVIORAL|Pharmaceutical care|
219102897|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
219102898|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
219102899|NCT06012864|PROCEDURE|PNL|percutaneous extraction of the stones in the kidney
219102900|NCT04175418|OTHER|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
219102901|NCT04175418|OTHER|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
219102902|NCT02351323|DRUG|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
219102903|NCT02351323|BEHAVIORAL|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
219102904|NCT00624715|DRUG|THC|"* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
219102905|NCT00624715|DRUG|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
219102906|NCT05016011|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
219102907|NCT05016011|PROCEDURE|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
219102908|NCT06053060|OTHER|Randomisation Standard Dynacup or Dynacup One C|Randomisation
219102909|NCT06134323|DEVICE|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
219102910|NCT06134323|DEVICE|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
219102911|NCT05389891|OTHER|Hemoglobinopathy Nursing Program|"Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2"
219224083|NCT04620252|DRUG|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
219224084|NCT04620252|DRUG|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
219690501|NCT03338764|DRUG|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
219690502|NCT03338764|DRUG|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
219690503|NCT04866966|BEHAVIORAL|Shared medical appointments for weight loss|Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
219690504|NCT01754064|DEVICE|Cardiac Rhythm Management device|
219690505|NCT01533116|DRUG|BIA 9-1067|
219690506|NCT01533116|DRUG|Placebo|
219102912|NCT00453102|DRUG|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
219102913|NCT00453102|DRUG|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
219102914|NCT00875732|DEVICE|Bi Ventricular Pacing|
219224085|NCT04620252|DRUG|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
219224086|NCT04620252|DRUG|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
219102915|NCT00875732|DEVICE|Right Ventricular Pacing|
219690507|NCT01533116|DRUG|levodopa/carbidopa|
219690508|NCT01533116|DRUG|levodopa/benserazide|
219690509|NCT03361241|OTHER|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
219690510|NCT03361241|OTHER|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
219690511|NCT03568578|DRUG|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
219690512|NCT03568578|DRUG|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
219690513|NCT06145126|OTHER|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
219690514|NCT06145126|OTHER|Placebo|Placebo to predinisolon
219102916|NCT03733743|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
219102917|NCT00159978|PROCEDURE|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
219102918|NCT03758118|DIETARY_SUPPLEMENT|Citicoline|Citicoline administered in oral solution
219102919|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
219102920|NCT00001495|DRUG|irinotecan (CPT-11)|
219224087|NCT04620252|DRUG|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
219224088|NCT04620252|DRUG|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
219224089|NCT04926259|DRUG|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
219224090|NCT01703598|DEVICE|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
219690515|NCT03158168|DRUG|Candida Antigen|Candida Albicans Antigen injection
219690516|NCT03158168|DRUG|Zinc Sulfate|Zinc Sulfate injection
219690517|NCT03898193|DRUG|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
219690518|NCT03898193|DRUG|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
219690519|NCT02740959|DRUG|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
219690520|NCT02740959|DRUG|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
219102921|NCT03154944|DEVICE|Ostomy device 1|This device consists of a known adhesive and a new top film
219102922|NCT03154944|DEVICE|Ostomy device 2|This device consists of a new adhesive and a known top film
219102923|NCT03154944|DEVICE|Ostomy device 3|This device consists of a known adhesive and a new top film
219102924|NCT01782963|DRUG|Lenalidomide|
219102925|NCT01782963|DRUG|Bortezomib|
219102926|NCT01782963|DRUG|Dexamethasone|
219102927|NCT06215690|DIAGNOSTIC_TEST|Ultrasound measurements|"Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth"
219102928|NCT04973111|DRUG|CT-868 as SC Injection|CT-868
219102929|NCT04973111|DRUG|Placebo as SC Injection|Placebo
219102930|NCT04973111|DRUG|Active Comparator as SC Injection|Active Comparator
219102931|NCT02980003|DRUG|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
219102932|NCT02980003|DRUG|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
219102933|NCT02980003|DRUG|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
219102934|NCT03705455|BEHAVIORAL|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
219102935|NCT05509543|DRUG|IY-NT-T|Ilaprazole 20mg
219102936|NCT05509543|DRUG|IY-NT-R|Ilaprazole 10mg
219102937|NCT04249219|OTHER|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
219102938|NCT05236413|BEHAVIORAL|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
219102939|NCT05236413|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
219102940|NCT05236413|BEHAVIORAL|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
219102941|NCT02479997|DRUG|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
219102942|NCT02479997|DRUG|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
219102943|NCT05758545|DEVICE|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.
219102944|NCT05758545|DEVICE|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
219102945|NCT05790239|DRUG|3,4-methylenedioxymethamphetamine|Initial doses per Experimental Session include 68 mg or 100 mg MDMA (equivalent to 80 mg or 120 mg MDMA HCl), followed 1.5 to 2 hours later by a supplemental dose of 34 mg or 50 mg MDMA (equivalent to 40 mg or 60 mg MDMA HCl).
219224091|NCT01703598|PROCEDURE|DBS surgery|Placement of DBS electrodes
219102946|NCT05790239|DRUG|d-amphetamine|Initial dose per experimental session will be 5 mg or 10 mg d-amphetamine, followed 1.5 to 2 hours later by supplemental dose of 2.5 mg or 5 mg d-amphetamine.
219102947|NCT05790239|BEHAVIORAL|Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
219102948|NCT06473701|DRUG|Dronabinol 2.5mg Capsule|Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.
219102949|NCT06473701|DRUG|Placebo|Dronabinol-matched placebo capsule containing no active substance.
219102950|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
219102951|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy + app|In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
219102952|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy|In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
219102953|NCT03351218|BEHAVIORAL|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
219102954|NCT02541383|DRUG|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
219690521|NCT02667301|DEVICE|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
219102955|NCT02541383|DRUG|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
219102956|NCT02541383|DRUG|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
219102957|NCT03946800|BIOLOGICAL|MEDI1191|Subjects will receive MEDI1191 (at least twice)
219102958|NCT03946800|BIOLOGICAL|Durvalumab|Subject will receive durvalumab every 4 weeks
219102959|NCT05500703|DRUG|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
219102960|NCT05500703|DRUG|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
219102961|NCT06077110|OTHER|Precision Care Clinic services|The Service Intervention is the Precision Care Clinic being delivered at the Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
219102962|NCT06647524|DRUG|THC|Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
219102963|NCT06647524|DRUG|Placebo|Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
219102964|NCT05706532|DIAGNOSTIC_TEST|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
219224092|NCT01231178|DIETARY_SUPPLEMENT|Alginate beverage|The dosage is 3x500ml daily
219224093|NCT01231178|DIETARY_SUPPLEMENT|Control beverage|The dosage is 3x500ml daily
219224094|NCT04186377|OTHER|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
219224095|NCT04186377|DRUG|S26E|Daily application of S26E extract on wound site
219224096|NCT05771857|DEVICE|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
219102965|NCT01533571|PROCEDURE|Immediate implant placement with simultaneous bone grafting|"* Flapless surgery is used for surgical implant installation.~* Implant is placed in the cingulum position of adjacent teeth incisal edge.~* After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~* Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
219102966|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
219690522|NCT02667301|DEVICE|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
219102967|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
219102968|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
219102969|NCT06412328|OTHER|Psychoeducation|The psychoeducation program based on psychosocial support is a total of 8 sessions. Families participating in the study received the psychoeducation program over 4 weeks, with two sessions per week, each session lasting 60 minutes. Parents were included in group work during the psychoeducation program.
219102970|NCT03754205|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
219102971|NCT06465277|DIAGNOSTIC_TEST|Dobutamine stress CMR|"Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team."
219102972|NCT06465277|DIAGNOSTIC_TEST|Cardiac biomarker sample|blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
219102973|NCT04250753|OTHER|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
219102974|NCT03264963|OTHER|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
219102975|NCT03264963|OTHER|Control|Recording of sleep environment 2 nights per week for 12 weeks
219102976|NCT04808375|OTHER||
219102977|NCT00259415|BEHAVIORAL|Caregiver support via telephone|
219102978|NCT02286167|OTHER|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
219690523|NCT02667301|DEVICE|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
219102979|NCT04859894|DIAGNOSTIC_TEST|Physiological testing|Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
219102980|NCT03589742|DEVICE|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
219102981|NCT02760329|PROCEDURE|Blood draw|Biomarkers analyses
219102982|NCT02760329|PROCEDURE|Urine|Biomarker analyses
219102983|NCT02760329|PROCEDURE|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
219690524|NCT04753957|DRUG|micronized Progesterone|200mg micronized progesterone placed vaginally
219690525|NCT00053209|DRUG|gemcitabine hydrochloride|
219690526|NCT00053209|DRUG|pemetrexed disodium|
219690527|NCT03199950|DRUG|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
219690528|NCT03199950|DRUG|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
219102984|NCT02760329|PROCEDURE|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
219102985|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
219102986|NCT02690077|PROCEDURE|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
219102987|NCT02690077|PROCEDURE|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
219690529|NCT00849563|OTHER|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
219690530|NCT02611947|RADIATION|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
219690531|NCT01858870|DRUG|lacosamide|routine clinical practice
219690532|NCT02937480|OTHER|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
219102988|NCT05472584|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
219102989|NCT05472584|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
219102990|NCT05472584|OTHER|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
219102991|NCT05472584|OTHER|Activity-based training|Motor task
219102992|NCT05472584|OTHER|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
219102993|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
219102994|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
219690533|NCT02937480|OTHER|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
219102995|NCT03694132|DEVICE|functional MRI|conditioning brain activity with peripheral stimulations
219102996|NCT03694132|DEVICE|structural MRI|diffusion MRI and tractography for evaluating the brain structures
219690534|NCT00239070|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219102997|NCT03694132|DEVICE|EEG/MEG|conditioning brain activity with peripheral stimulations
219102998|NCT01845974|DEVICE|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
219102999|NCT01845974|DEVICE|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
219103000|NCT04399460|OTHER|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
219103001|NCT04399460|OTHER|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
219103002|NCT04913129|OTHER|Exercise Training|8 week home-based exercise therapy 4-5 times/week
219103003|NCT06844539|DEVICE|Fully automated insulin delivery with CamAPS HX|Fully automated insulin delivery with CamAPS HX app, Libre 3 glucose sensor and Ypsopump insulin pump.
219103004|NCT06844539|DEVICE|Standard diabetes therapy with a glucose sensor|Standard diabetes therapy with a Freestyle Libre 3 glucose sensor
219103005|NCT04918225|RADIATION|Magnetic Resonance Imaging|"Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities"
219103006|NCT04918225|DIAGNOSTIC_TEST|Neurological examination|Global disability will be scored using the Expanded Disability Status Scale score
219103007|NCT04918225|DIAGNOSTIC_TEST|Multiple Sclerosis Functional Composite|"* Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test"
219103008|NCT04918225|DIAGNOSTIC_TEST|Physiotherapist examination|"* American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale"
219103009|NCT04967391|PROCEDURE|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
219224097|NCT00355745|DEVICE|Ultrasound breast scanning|breast scanning
219224098|NCT00540956|DRUG|cytarabine|
219224099|NCT00540956|OTHER|laboratory biomarker analysis|
219224100|NCT00239967|DRUG|Rimonabant (SR141716)|
219224101|NCT00239967|DRUG|Placebo|
219103010|NCT04879199|DIAGNOSTIC_TEST|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
219103011|NCT04879199|DIAGNOSTIC_TEST|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
219103012|NCT01618890|PROCEDURE|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
219103013|NCT06439940|DIAGNOSTIC_TEST|Blood sample extraction|We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
219103014|NCT05189054|RADIATION|stereotacitic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
219103015|NCT00426426|BEHAVIORAL|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
219103016|NCT00426426|BEHAVIORAL|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
219103017|NCT00426426|BEHAVIORAL|Waiting list|
219103018|NCT00578721|DRUG|Aspirin|325 mg taken daily with an arginine-restricted diet
219103019|NCT02440347|DEVICE|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
219103020|NCT02440347|DEVICE|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
219103021|NCT00405639|DRUG|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
219103022|NCT00405639|DRUG|Placebo|Normal saline will be used for placebo.
219103023|NCT03992534|COMBINATION_PRODUCT|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
219103024|NCT00265330|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
219103025|NCT00142922|BEHAVIORAL|Breaking Down Barriers|completed
219103026|NCT03108157|PROCEDURE|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
219103027|NCT01087996|BIOLOGICAL|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
219103028|NCT01087996|BIOLOGICAL|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
219103029|NCT01984801|DRUG|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
219103030|NCT01984801|DRUG|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
219103031|NCT01984801|DRUG|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
219103032|NCT01984801|OTHER|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
219103033|NCT01984801|OTHER|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
219103034|NCT01984801|OTHER|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
219103035|NCT01984801|OTHER|Patch only|Only patch will be applied
219103036|NCT04236921|DRUG|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
219103037|NCT04236921|DRUG|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
219103038|NCT06255015|DEVICE|Breastfeeding toolkit card|The card is delivered at 24 weeks and is also referred to in the 32 and 36 week antenatal meetings. It will also be referred to in the first 24 hours post-partum and in home visits.
219224102|NCT04241640|DRUG|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
219103039|NCT00594971|OTHER|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
219690535|NCT00005067|DRUG|motexafin lutetium|Given IV
219103040|NCT00594971|OTHER|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
219103041|NCT01298921|DRUG|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
219103042|NCT01298921|DRUG|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
219103043|NCT00812188|OTHER|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
219103044|NCT00812188|OTHER|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
219103045|NCT04846764|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure"
219103046|NCT02681705|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
219103047|NCT02681705|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
219103048|NCT04075617|DEVICE|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
219103049|NCT04075617|OTHER|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
219103050|NCT05791890|DRUG|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
219103051|NCT05764291|BEHAVIORAL|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
219103052|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
219103053|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with DracoBelleTM Nu.|Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
219103054|NCT00058227|DRUG|alvocidib|Given IV
219103055|NCT00058227|DRUG|fludarabine phosphate|Given IV
219103056|NCT00058227|BIOLOGICAL|rituximab|Given IV
219103057|NCT00058227|OTHER|pharmacological study|Correlative studies
219103058|NCT00615134|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
219103059|NCT00615134|DRUG|Optimized background ARV therapy|As prescribed
219103060|NCT04197011|DEVICE|prosthetic device|Individuals with TFA will use a combination of prosthetic devices.
219103061|NCT02172703|DEVICE|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
219690536|NCT00005067|DRUG|photodynamic therapy|Undergo photodynamic therapy
219690537|NCT02421354|OTHER|Laboratory Biomarker Analysis|Correlative studies
219690538|NCT02421354|BIOLOGICAL|Nivolumab|Given IV
219690539|NCT02421354|OTHER|Quality-of-Life Assessment|Ancillary studies
219690540|NCT05003544|PROCEDURE|Group A|PENG BLOCK
219690541|NCT05003544|PROCEDURE|Group B|Intra-articular
219103062|NCT04379037|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
219103063|NCT03908073|DEVICE|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
219103064|NCT03879603|BIOLOGICAL|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
219103065|NCT03879603|OTHER|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
219103066|NCT02237339|DRUG|Allopurinol|Uric acid lowering medication.
219103067|NCT02237339|DRUG|Placebo|
219690542|NCT05003544|PROCEDURE|Group C|Quadratus lumborum block
219690543|NCT04852731|PROCEDURE|Cardiac MRI|Injected cardiac MRI
219690544|NCT04852731|OTHER|Blood collection|Blood collection (including genetics at the inclusion visit)
219690545|NCT04852731|PROCEDURE|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
219690546|NCT05962112|OTHER|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
219690547|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
219690548|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
219690549|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
219690550|NCT00846586|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219690551|NCT00846586|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
219690552|NCT00846586|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219690553|NCT04118647|DRUG|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
219690554|NCT03113110|DRUG|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
219690555|NCT02915224|DRUG|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
219690556|NCT02915224|DRUG|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
219690557|NCT00144430|DRUG|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
219690558|NCT00655252|DRUG|Everolimus|
219690559|NCT00105742|PROCEDURE|Diagnosis|
219690560|NCT05098080|BIOLOGICAL|Hutrukin|Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
219690561|NCT05098080|BIOLOGICAL|Placebo|Placebo control for Hutrukin IV push.
219690562|NCT00766324|DRUG|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
219690563|NCT00766324|DRUG|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
219690564|NCT00120471|DRUG|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
219103068|NCT02066896|DEVICE|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
219103069|NCT02066896|DEVICE|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
219103070|NCT00513786|DRUG|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
219224103|NCT04241640|DRUG|Placebo|Placebo
219690565|NCT00120471|DRUG|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
219690566|NCT00120471|DRUG|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
219690567|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
219690568|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
219690569|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
219690570|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
219690571|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
219690572|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
219690573|NCT01061606|DRUG|temsirolimus|Given IV
219690574|NCT00735007|DRUG|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
219690575|NCT03664115|DRUG|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
219690576|NCT03664115|DRUG|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
219690577|NCT00715403|DRUG|BIBF 1120|
219690578|NCT00012025|DRUG|fulvestrant|
219690579|NCT03644017|DEVICE|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
219690580|NCT06385171|DRUG|Botulinum toxin type A|The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
219103071|NCT00513786|DRUG|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
219103072|NCT00513786|DRUG|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
219103073|NCT03764540|DRUG|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
219103074|NCT03764540|DRUG|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
219103075|NCT03794375|OTHER|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
219103076|NCT03794375|OTHER|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
219103077|NCT06489223|DEVICE|Orofacial Myofunctional Rehabilitation Pacifier|The pacifier will be offered to the child
219103078|NCT05067933|DRUG|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
219103079|NCT05067933|OTHER|Placebo Tablets|Placebo tablets matching the active vaccine tablets
219690581|NCT02700048|DRUG|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
219690582|NCT02700048|DRUG|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
219103080|NCT04553692|DRUG|Aplitabart (IGM-8444)|DR5 Agonist Investigational Drug
219103081|NCT04553692|DRUG|FOLFIRI|Chemotherapy Regimen
219103082|NCT04553692|DRUG|Bevacizumab (and approved biosimilars)|Targeted Therapy
219690583|NCT00325741|DRUG|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
219690584|NCT06489912|DIAGNOSTIC_TEST|WAIS IV|Psychological assessement
219103083|NCT04553692|DRUG|Birinapant|SMAC-mimetic Investigational Drug
219103084|NCT04553692|DRUG|Venetoclax|Targeted Therapy
219103085|NCT04553692|DRUG|Gemcitabine|Chemotherapy
219103086|NCT04553692|DRUG|Docetaxel|Chemotherapy
219103087|NCT04553692|DRUG|Azacitidine|Chemotherapy
219103088|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
219103089|NCT03522077|DEVICE|RadAR EasyCLik plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
219103090|NCT03522077|DEVICE|TR BAND® Compression device plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
219103091|NCT03522077|DEVICE|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
219103092|NCT03522077|DEVICE|VascBand™ Hemostat|The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
219103093|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
219103094|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
219224104|NCT02489357|PROCEDURE|Cryosurgery|Undergo whole gland cryoablation
219224105|NCT02489357|DRUG|Degarelix|Given SC
219103095|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
219103096|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
219103097|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
219103098|NCT04570774|PROCEDURE|Repetitive transcranial magnetic stimulation|rTMS over cerebral motor cortex and cerebellar hemisphere
219103099|NCT06118996|DEVICE|3D Ultrasound Image Acquisition|A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
219103100|NCT04127552|PROCEDURE|Adrenalectomy|Adrenalectomy according to 2016 ESE guidelines
219103101|NCT06285968|BEHAVIORAL|Multidimensional Sleep Health Promotion Intervention|Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
219103102|NCT01065350|DRUG|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
219103103|NCT01065350|DRUG|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
219103104|NCT00246233|DRUG|methylphenidate|
219103105|NCT05601934|OTHER|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
219103106|NCT03566303|DRUG|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
219103107|NCT03566303|DRUG|Warfarin|Warfarin
219103108|NCT01053377|DRUG|Tamiflu (verum)|
219103109|NCT01053377|DRUG|Tamiflu placebo|
219103110|NCT01468441|DRUG|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
219103111|NCT01468441|DRUG|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
219103112|NCT02891343|OTHER|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
219103113|NCT03443713|DEVICE|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
219103114|NCT04686279|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
219103115|NCT05694182|OTHER|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
219103116|NCT05034848|PROCEDURE|Assessment of BMD by DXA and HRpQCT|"* DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples"
219103117|NCT01905709|BIOLOGICAL|Human fecal matter|
219103118|NCT05879198|BEHAVIORAL|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
219103119|NCT04567394|BEHAVIORAL|Peer Network Counseling-txt|4-week text counseling program
219103120|NCT06624319|DRUG|Dexmedetomidine as adjuvent to bupvacaine in tap block|The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block
219103121|NCT06875947|DIETARY_SUPPLEMENT|Moringa Oleifera Leaf Micronized Powders in Capsule|"Moringa Oleifera Leaf Micronized Powders (MOLMP)~Source: Derived from finely ground Moringa Oleifera leaves using micronization technology to enhance bioavailability.~Dosage: 650 mg per capsule, taken three times daily (1,950 mg/day). Administration Duration: 60 days. Monitoring: Self-administration under weekly compliance checks."
219224106|NCT02489357|OTHER|Laboratory Biomarker Analysis|Correlative studies
219224107|NCT02489357|BIOLOGICAL|Pembrolizumab|Given IV
219103122|NCT06875947|DIETARY_SUPPLEMENT|Standard Iron Tablets (Fe + Folic Acid)|Dosage: One tablet containing 60 mg iron and 400 mcg folic acid per day. Administration Duration: 60 days.
219103123|NCT06829901|PROCEDURE|Fetoscopic Laser Photocoagulation|Patients who choose to undergo fetoscopic selective laser photocoagulation for complicated monochorionic-diamniotic twin pregnancies with twin-to-twin transfusion syndrome will be offered participation in the study. All participants will undergo selective laser photocoagulation and entry into the uterus will be achieved using one of two accepted methods, either direct entry or the Seldinger technique.
219103124|NCT06370689|OTHER|Preoxygenation|Preoxygenation of volunteers over 3 minutes
219103125|NCT06900400|DIAGNOSTIC_TEST|"Sustained-Paced Finger Tapping (Petilli et al., 2018)"|"Sustained-Paced Finger Tapping (Petilli et al., 2018) a computerized test that lasts approximately 10 minutes. It involves maintaining and reproducing the rhythm of a sound (auditory version)."
219690585|NCT01143285|OTHER|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
219103126|NCT06925828|OTHER|No intervention|No intervention
219103127|NCT06901375|DRUG|Vonoprazan|20 mg tablet twice daily
219103128|NCT06901375|DRUG|Amoxicillin|1 g tablet three times daily
219103129|NCT06901375|DRUG|Zuojin Wan|3 g tablet twice daily
219103130|NCT05963386|DRUG|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
219690586|NCT06091566|DEVICE|UCon-Bar|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for either 4 weeks or 12 weeks using UCon with the Bar electrode
219690587|NCT02740816|OTHER|Comparative blood analysis|Collection of menstrual blood and systemic blood
219103131|NCT06384456|DRUG|Topical TRanexamic Acid|10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
219690588|NCT05944575|DEVICE|active taVNS|The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.
219690589|NCT05944575|DEVICE|sham-taVNS|The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
219103132|NCT06384456|DRUG|Placebo|10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
219103133|NCT06925867|OTHER|Frequency Filtered Music|The frequency filtered music intervention is 2.5 hours of classical music that has been filtered by applying an algorithm to alternate narrowing and expanding the range of acoustic frequencies over time, with the alternations intensifying in frequency range over the course of administration. The filtering is optimized for the frequency response of adult human hearing and intended to mimic the expression of the human voice around a central set of frequencies of 800-1200 Hz, the approximate resonant frequency of the human ear. The filtering method is similar to adjusting the treble and bass settings on a stereo system while music is playing; the melody and instruments can still be heard, but the highest and lowest pitches are modulated over time.
219103134|NCT06925867|OTHER|Unfiltered Music|The unfiltered music intervention is 2.5 hours of classical music with. The playlist of pieces is identical to the filtered music condition.
219103135|NCT06925867|BEHAVIORAL|Cognitive Processing Therapy for PTSD|Cognitive processing therapy (CPT) is a cognitive therapy that focuses on why patients believe the traumatic event occurred, how that event affected their beliefs about self and others, and how to evaluate their beliefs. Patients then learn to label events, thoughts, and subsequent emotions while the therapist helps them examine the facts and context of the trauma through Socratic questioning. Using progressive worksheets, patients are taught to examine their own thoughts and emotions and develop new, more balanced thinking about traumatic events.
219103136|NCT06924905|DIAGNOSTIC_TEST|the pelvic floor disability index|20 questions divided into three sections: Pelvic Organ prolapse Distress Inventory 6 (POPDI-6), Colorectal-Anal distress Inventory 8 (CRAD-8) and Urinary distress Inventory 6 (UDI-6).
219103137|NCT06925698|DRUG|Placebo plus immunosuppression|"Participants in this arm will receive placebo plus standard immunosuppressive therapy consisting of:~Azathioprine (2.5 mg/kg/day, maximum 200 mg/day, oral) Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol) This intervention represents the standard treatment for venous thrombosis associated with Behçet's Disease and serves as the control arm of the study."
219224108|NCT05703659|DIETARY_SUPPLEMENT|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
219690590|NCT02175225|DRUG|Deferoxamine Mesylate|
219690591|NCT02175225|DRUG|Placebo (for Deferoxamine Mesylate)|
219690592|NCT00078286|DRUG|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
219690593|NCT00078286|DRUG|Placebo|Dosage ranging from 50 mg to 200 mg once a day
219690594|NCT05108701|BEHAVIORAL|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
219103138|NCT06925698|DRUG|Rivaroxaban plus immunosupression|"Participants in this arm will receive standard immunosuppressive therapy as described above, plus Rivaroxaban (20 mg/day, oral, for 12 months).~This intervention aims to evaluate whether the addition of oral anticoagulation (Rivaroxaban) to immunosuppressive therapy reduces the risk of thrombotic relapse and post-thrombotic syndrome compared to immunosuppressive therapy alone."
219103139|NCT06916780|OTHER|Laser and ultrasound|Laser and ultrasound will be applied in group A as traditional method. On the other hand they will applied axillary in experimental groups
219103140|NCT06922903|DRUG|INR101|INR101
219103141|NCT00663117|DRUG|Naltrexone-HCl|naltrexone 4.5 mg
219103142|NCT00663117|DRUG|Placebo|Placebo
219690595|NCT04028362|DRUG|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
219690596|NCT02946359|DRUG|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
219690597|NCT02340000|DRUG|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
219103143|NCT05569824|DIAGNOSTIC_TEST|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
219690598|NCT02340000|DRUG|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
219690599|NCT04191889|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
219103144|NCT00395915|DRUG|aripiprazole|
219103145|NCT00268619|DRUG|Ramipril|
219103146|NCT05544058|OTHER|Retrospective study|Retrospective study
219103147|NCT00933842|DRUG|LACTIC ACID(ND)|Treatment duration: 5 weeks
219103148|NCT04722861|OTHER|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
219690600|NCT01284894|DEVICE|Conventional manometry|Conventional esophageal manometry
219690601|NCT01284894|DEVICE|High resolution manometry|High resolution esophageal manometry
219690602|NCT04549493|BEHAVIORAL|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
219690603|NCT01753609|DEVICE|Tulip capsule|swallowing Tulip capsule for up to 29 days
219103149|NCT01484795|DEVICE|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
219103150|NCT01484795|DEVICE|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
219103151|NCT04142814|PROCEDURE|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
219103152|NCT04142814|PROCEDURE|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
219103153|NCT01178437|DEVICE|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
219103154|NCT05176782|DRUG|HTK cardioplegia|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
219103155|NCT05176782|DRUG|Cold Cadioplegia|as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
219103156|NCT02818660|DRUG|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
219103157|NCT01959945|BIOLOGICAL|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
219103158|NCT01959945|BIOLOGICAL|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
219103159|NCT01992549|BIOLOGICAL|Human-cl rhFVIII|
219103160|NCT03396731|DEVICE|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
219103161|NCT05834582|DRUG|Fluzoparib+Paclitaxel|Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
219103162|NCT05834582|DRUG|Epirubicin+Cyclophosphamide|Epirubicin+Cyclophosphamide
219103163|NCT04198740|DIAGNOSTIC_TEST|Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry|During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
219103164|NCT00000990|DRUG|Zidovudine|
219103165|NCT01495221|DRUG|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
219103166|NCT02689856|DRUG|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
219103167|NCT02689856|DRUG|Placebo control|Vehicle cream alone
219103168|NCT02689856|DRUG|Hydrocortisone acetate|hydrocortisone alone
219103169|NCT02689856|DRUG|Lidocaine hydrochloride|lidocaine alone
219103170|NCT01556074|BEHAVIORAL|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
219103171|NCT00896129|OTHER|HRQOL Survey Packet|Questionnaires
219103172|NCT02019563|PROCEDURE|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
219103173|NCT02019563|PROCEDURE|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
219103174|NCT06529549|OTHER|Organoid-Based Drug Sensitivity Screening|Residual tissue of bone metastatic sites from biopsies for genetic testing will be collected to culture organoid and perform drug sensitivity screening
219103175|NCT02323035|DEVICE|Headgear|Investigative Headgear with CPAP Mask.
219103176|NCT04866511|OTHER|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
219103177|NCT03765463|BEHAVIORAL|Habit Reversal Training|4 sessions of habit reversal training
219103178|NCT00991159|BIOLOGICAL|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
219103179|NCT00485576|DRUG|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
219103180|NCT02209636|DRUG|Lanthanum carbonate|Non-calcium containing phosphorus binder
219103181|NCT02209636|DRUG|placebo|Table identical to lanthanum carbonate but with no active ingredient
219103182|NCT02209636|DRUG|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
219103183|NCT02209636|DRUG|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
219103184|NCT02209636|PROCEDURE|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
219103185|NCT02209636|PROCEDURE|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
219690604|NCT05414851|OTHER|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
219103186|NCT02209636|PROCEDURE|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
219103187|NCT00767104|OTHER|Silk like Pillowcase|sleep on silk-like pillowcase each night
219103188|NCT00767104|OTHER|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
219103189|NCT02705040|OTHER|Normal|bone mineral density T\>=-1.0
219103190|NCT02705040|OTHER|Osteopenia|bone mineral density -1.0\>T\>=-2.5
219103191|NCT02705040|OTHER|Osteoporosis|bone mineral density T\<-2.5
219103192|NCT05601713|OTHER|No cooling (control)|Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
219103193|NCT05601713|OTHER|Lower limb immersion|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.
219103194|NCT05601713|OTHER|Lower limb immersion + neck cooling|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
219103195|NCT04048499|DEVICE|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
219103196|NCT05860725|BEHAVIORAL|PSA Development|Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
219103197|NCT05860725|BEHAVIORAL|HPV vaccination focused social marketing campaign|Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
219103198|NCT01315275|DRUG|Ranibizumab|
219103199|NCT03657381|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
219103200|NCT06039228|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.
219103201|NCT05601921|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.
219103202|NCT05601921|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
219103203|NCT05027737|PROCEDURE|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
219103204|NCT03648125|DEVICE|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
219103205|NCT03648125|DEVICE|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
219103206|NCT01108835|OTHER|Comprehensive care programme|"Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
219103207|NCT01858480|DRUG|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
219103208|NCT01858480|OTHER|Placebo|Placebo dosage form designed to mock active.
219224109|NCT05703659|DIETARY_SUPPLEMENT|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
219690605|NCT04522648|OTHER|Prospective surveillance|A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
219690606|NCT00298064|GENETIC|Tissue Repository|
219690607|NCT01707641|DIETARY_SUPPLEMENT|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
219690608|NCT01707641|OTHER|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
219690609|NCT03832647|COMBINATION_PRODUCT|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
219690610|NCT03832647|DRUG|Salicylic Acid|Salicylic Acid
219690611|NCT03832647|OTHER|Hydréane légère|moisturizer
219690612|NCT05155748|OTHER|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
219690613|NCT05829499|DEVICE|HPMC-HA eyedrops|Ocular drops based upon HPMC and HA
219690614|NCT02582333|OTHER|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
219690615|NCT05656196|OTHER|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
219690616|NCT01883895|DEVICE|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
219690617|NCT01883895|OTHER|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
219690618|NCT01883895|OTHER|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
219690619|NCT03532737|DRUG|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
219224110|NCT02166632|PROCEDURE|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
219103209|NCT00638196|DRUG|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
219103210|NCT03285295|DEVICE|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103211|NCT03285295|DEVICE|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103212|NCT03285295|DEVICE|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103213|NCT03285295|DEVICE|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103214|NCT03285295|DEVICE|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103215|NCT03285295|DEVICE|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
219103216|NCT03264768|DEVICE|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
219103217|NCT03264768|BEHAVIORAL|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
219103218|NCT03264768|PROCEDURE|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
219103219|NCT01015807|DRUG|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
219103220|NCT01015807|DRUG|Clonidine Placebo|2 x 1mL 0.9% NaCl
219103221|NCT01015807|DRUG|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
219103222|NCT01015807|DRUG|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
219103223|NCT02732093|PROCEDURE|stellate block|
219103224|NCT02732093|DRUG|Na.Cl 0.9% (placebo)|
219103225|NCT02732093|DRUG|lidocaine 2%|
219103226|NCT04748419|RADIATION|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
219103227|NCT04748419|DRUG|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
219103228|NCT02629068|BEHAVIORAL|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
219103229|NCT05721443|DRUG|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
219224111|NCT02166632|PROCEDURE|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
219224112|NCT04514653|BIOLOGICAL|Ranibizumab|Ranibizumab (anti-VEGF agent)
219690620|NCT03969615|DEVICE|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
219690621|NCT03969615|DEVICE|Supplemental oxygen|5lpm of supplemental oxygen
219690622|NCT02010112|OTHER|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
219690623|NCT02164955|DRUG|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
219690624|NCT00073918|DRUG|cyclophosphamide|Given IV
219690625|NCT00073918|DRUG|etoposide|Given IV
219690626|NCT00073918|RADIATION|iodine I 131 tositumomab|Given IV
219690627|NCT00073918|PROCEDURE|quality-of-life assessment|Ancillary study
219690628|NCT00073918|PROCEDURE|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
219690629|NCT01409239|DRUG|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
219690630|NCT01409239|DRUG|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
219690631|NCT05440981|DEVICE|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
219690632|NCT05593484|OTHER|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
219690633|NCT05593484|OTHER|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
219690634|NCT06063200|DRUG|Methylphenidate Pill|Single encapsulated pill
219690635|NCT05456893|PROCEDURE|Procedure: endoscopic biopsy|Per-endoscopic biopsies
219690636|NCT05456893|PROCEDURE|Blood sampling|Blood sampling
219690637|NCT05456893|PROCEDURE|stool sampling|stool sampling
219690638|NCT05816915|BEHAVIORAL|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
219690639|NCT04826393|DRUG|ASP8374|every 3 weeks by intravenous infusion
219690640|NCT04826393|DRUG|cemiplimab|intravenous infusion
219690641|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site
219103230|NCT01381627|DRUG|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
219103231|NCT01381627|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
219690642|NCT02539017|DRUG|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
219690643|NCT02539017|BIOLOGICAL|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
219690644|NCT06221371|DRUG|rhTNK-tPA|rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.
219690645|NCT06221371|DEVICE|direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
219690646|NCT01325545|OTHER|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
219690647|NCT02938117|OTHER|cycling exercises|
219690648|NCT03159832|DRUG|SHR3824|All subjects were given SHR3824 20mg only one time.
219690649|NCT01537770|PROCEDURE|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
219690650|NCT01537770|PROCEDURE|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
219690651|NCT05973955|BEHAVIORAL|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
219690652|NCT05973955|BEHAVIORAL|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
219690653|NCT06111222|DEVICE|AT ELANA|The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
219103232|NCT01061437|DRUG|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
219103233|NCT01061437|DRUG|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
219103234|NCT01061437|DRUG|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
219103235|NCT04777929|OTHER|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
219103236|NCT05017324|DEVICE|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
219103237|NCT02610218|OTHER|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
219103238|NCT05468515|DIAGNOSTIC_TEST|pulse oxygen saturation|preductal oxygen saturation
219103239|NCT02045433|RADIATION|SABR Boost Therapy|"1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
219103240|NCT02880007|RADIATION|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
219103241|NCT02880007|RADIATION|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
219103242|NCT02880007|DRUG|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
219103243|NCT00891306|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
219103244|NCT00891306|DRUG|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
219103245|NCT00891306|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
219103246|NCT00891306|DRUG|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
219103247|NCT03295903|DIETARY_SUPPLEMENT|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
219103248|NCT01406704|DRUG|Rosiglitazone|Rosiglitazone (8 mg/day)
219103249|NCT01406704|DRUG|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
219103250|NCT01406704|DRUG|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
219103251|NCT03279848|OTHER||Stroke rehabilitation
219103252|NCT02986061|DEVICE|Urinary catheter|
219103253|NCT01656837|BEHAVIORAL|Comprehensive Community Treatment|
219103254|NCT01656837|BEHAVIORAL|MST-BSF|
219103255|NCT02176421|DEVICE|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
219103256|NCT02406885|DRUG|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
219103257|NCT03389841|OTHER|Education|Education of the caregiver about early symptoms and signs of heart failure
219103258|NCT01496534|DRUG|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
219103259|NCT01496534|DRUG|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
219103260|NCT04676126|DIETARY_SUPPLEMENT|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
219103261|NCT04676126|DRUG|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
219103262|NCT04676126|OTHER|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
219103263|NCT05594849|DRUG|Budesonide Orodispersible Tablets (Jorveza)|Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
219103264|NCT01486134|PROCEDURE|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
219103265|NCT04885114|GENETIC|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
219690654|NCT06987682|OTHER|Balance training|Participants will don a safety harness that is secured to an overhead track. Each balance training session will involve 45 minutes of visual feedback balance training (VFBT) (Figure 1) followed by 45 minutes of reactive balance training (RBT), totaling 90 minutes. This combination will ensure all systems of postural control are targeted by the training, and that both standing and stepping are practiced. For both groups, FES and tSCS will be set up, including placing electrodes and setting stimulation amplitudes.
219103266|NCT00642629|DRUG|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
219103267|NCT00642629|DRUG|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
219103268|NCT02145078|DRUG|docetaxel|Given IV
219103269|NCT02145078|DRUG|pemetrexed disodium|Given IV
219103270|NCT02145078|DRUG|gemcitabine hydrochloride|Given IV
219103271|NCT02145078|OTHER|laboratory biomarker analysis|Correlative studies
219103272|NCT03298503|OTHER|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
219103273|NCT00170404|DRUG|Folic Acid|
219103274|NCT00170404|DRUG|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
219103275|NCT00170404|DRUG|Selenium|
219103276|NCT00170404|DRUG|Vitamin A|
219103277|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
219103278|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
219103279|NCT02440594|BEHAVIORAL|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
219103280|NCT02440594|BEHAVIORAL|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
219103281|NCT03775408|DEVICE|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
219103282|NCT06205732|OTHER|Immunotherapy, targeted therapy.|Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
219103283|NCT02999620|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
219103284|NCT02999620|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
219103285|NCT01657630|DEVICE|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
219103286|NCT05902130|OTHER|symptoms of a myocardial infarction|Analysis of the differences in symptoms of a myocardial infarction between a man and a woman
219103287|NCT00613288|DRUG|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment."
219103288|NCT01839357|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
219103289|NCT00213564|DRUG|response to infliximab associated with methotrexate|
219103290|NCT04017429|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.
219103291|NCT04017429|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
219103292|NCT03232320|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
219224113|NCT04514653|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
219103293|NCT03232320|DRUG|Placebo|Placebo (Normal saline)
219103294|NCT00739895|PROCEDURE|Cardiac magnetic Resonance study|follow-up studies
219103295|NCT00739895|PROCEDURE|Blood testing|Blood sample tested for myocardial biomarkers
219103296|NCT02341456|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
219103297|NCT02341456|DRUG|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
219103298|NCT02341456|DRUG|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
219103299|NCT05819905|DIAGNOSTIC_TEST|PET/CT|Pre treatment staging 18F-FDG PET/CT
219103300|NCT00888901|DRUG|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
219103301|NCT00888901|DRUG|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
219103302|NCT01503138|BEHAVIORAL|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
219690655|NCT06295458|DEVICE|David Delight Plus Device|Flicker exposure via a light and sound device-based stimulation-provided sensory stimulation device. The DAVID Delight Plus device consists of light-emitting goggles and sound-emitting headphones that are turned on and off with a repetition rate of 40 Hz connected to a controller operated by the participant or study partner (if the participant elects to have an optional study partner). At the baseline visit, light and sound intensity levels (auditory: 0-80 dBA, visual: 0-1400 lux) will be programmed into each participant's controller based on their unique response to tolerance and EEG entrainment testing which occurred at screening. The participant may not detect gamma-flicker frequency.
219103303|NCT00125099|BIOLOGICAL|VRC-HIVDNA009-00-VP|
219103304|NCT03975426|PROCEDURE|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
219103305|NCT01812382|DRUG|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
219103306|NCT00509002|DRUG|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
219103307|NCT01532817|DEVICE|AlphaCore|A single 90 second stimulation to the vagus nerve on the right side of the neck
219103308|NCT00618696|BIOLOGICAL|anti-CD45 monoclonal antibody AHN-12|150 mg/m\^2 cold antibody at Day 0
219103309|NCT00618696|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m\^2
219103310|NCT03380793|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
219103311|NCT01111838|DRUG|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
219103312|NCT03347175|PROCEDURE|Volume controlled ventilation|Volume controlled ventilation mode
219103313|NCT03347175|PROCEDURE|Pressure controlled ventilation|Pressure controlled ventilation
219103314|NCT03347175|PROCEDURE|CPAP mode|CPAP mode only
219103315|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
219103316|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
219103317|NCT02707458|DRUG|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
219103318|NCT03303469|DRUG|FMISO|FMISO PET/CT imaging at baseline
219103319|NCT03303469|DRUG|FMISO|FMISO PET/CT post TACE
219103320|NCT03303469|DRUG|FMISO|FMISO PET/CT post SBRT
219103321|NCT01920425|DEVICE|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
219103322|NCT01920425|OTHER|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
219103323|NCT02487550|BIOLOGICAL|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
219103324|NCT02487550|BIOLOGICAL|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
219103325|NCT03170245|DIAGNOSTIC_TEST|Interleukin-6|serum samples used for doing the test by ELISA
219103326|NCT03170245|DIAGNOSTIC_TEST|HsC-RP|serum samples used for doing the test by ELISA
219103327|NCT03170245|DIAGNOSTIC_TEST|Adiponectin level|serum samples used for doing the test by ELISA
219103328|NCT03170245|DIAGNOSTIC_TEST|Carotid intima media thickness|Done by carotid doppler
219103329|NCT02444663|RADIATION|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
219103330|NCT02444663|RADIATION|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
219224114|NCT04514653|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
219224115|NCT04514653|GENETIC|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
219224116|NCT04514653|DRUG|Local Steroid|Local steroid
219224117|NCT04514653|DRUG|Topical Steroid|Topical steroid
219103331|NCT02444663|RADIATION|Device Valgus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103332|NCT02444663|RADIATION|Device Valgus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
219103333|NCT02444663|RADIATION|Device Valgus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103334|NCT02444663|RADIATION|Device Valgus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103335|NCT02444663|RADIATION|Device Varus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103336|NCT02444663|RADIATION|Device Varus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103337|NCT02444663|RADIATION|Device Varus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103338|NCT02444663|RADIATION|Device Varus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
219103339|NCT00766454|GENETIC|DNA analysis|
219103340|NCT00766454|GENETIC|mutation analysis|
219103341|NCT00766454|GENETIC|polymorphism analysis|
219103342|NCT00766454|OTHER|laboratory biomarker analysis|
219103343|NCT00766454|OTHER|medical chart review|
219103344|NCT00766454|OTHER|questionnaire administration|
219103345|NCT00766454|PROCEDURE|evaluation of cancer risk factors|
219103346|NCT02923102|DIETARY_SUPPLEMENT|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
219103347|NCT02923102|DIETARY_SUPPLEMENT|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
219690656|NCT06295458|OTHER|Sham Therapy|Sham therapy will be provided in the same manner as the flicker light. The difference is that it will be a constant light and sound from the same device instead of the 40hz light treatment and sound.
219690657|NCT04721197|OTHER|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
219690658|NCT04721197|OTHER|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
219103348|NCT04741802|BEHAVIORAL|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
219103349|NCT01212536|DEVICE|Airtraq laryngoscopy|laryngoscopy and intubation
219103350|NCT00553098|BIOLOGICAL|Alemtuzumab|Given IV
219103351|NCT00553098|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo HCT
219103352|NCT00553098|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
219103353|NCT00553098|DRUG|Cyclosporine|Given PO or IV
219103354|NCT00553098|DRUG|Fludarabine Phosphate|Given IV
219103355|NCT00553098|OTHER|Laboratory Biomarker Analysis|Correlative study
219103356|NCT00553098|DRUG|Mycophenolate Mofetil|Given PO or IV
219103357|NCT00553098|RADIATION|Total-Body Irradiation|Undergo low dose TBI
219103358|NCT01785563|DEVICE|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
219103359|NCT02766179|DEVICE|CPAP|CPAP is used for 6 weeks
219103360|NCT02766179|DEVICE|Somnoguard|Somnoguard is used for 6 weeks
219103361|NCT01872910|DRUG|Placebo|Administered orally
219103362|NCT01872910|DRUG|LY3023703|Administered orally
219103363|NCT01872910|DRUG|Celecoxib|Administered orally
219103364|NCT02093676|BEHAVIORAL|"experimental protocol treatment The New Authority"|
219103365|NCT01767935|PROCEDURE|cryosurgery|Undergo cryosurgery
219103366|NCT01767935|RADIATION|radiation therapy|Undergo radiation therapy
219690659|NCT06610175|DEVICE|Quantitative MRI and anatomical MRI|The total scanning time will be approximately 40 minutes. Additionally, 10 healthy participants and 10 patients with symptomatic CDDD will undergo a second MRI with additional sequences for assessment of reproducibility on another day/time. Also: included participants will undergo neurologic examination and fill out questionnaires for NDI, VAS-arm, VAS-neck, WA-SI, EQ-5D-5L, CSI, mJOA and Nurick.
219103367|NCT01767935|PROCEDURE|quality-of-life assessment|Ancillary studies
219103368|NCT05224635|PROCEDURE|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
219103369|NCT01238224|DRUG|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
219103370|NCT00310323|DRUG|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
219103371|NCT00310323|DRUG|Caffeine|Administered as 4 ounces of Coca-Cola
219103372|NCT03017157|OTHER|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
219103373|NCT03017157|OTHER|Blood test|Blood test to determine thyroid function
219103374|NCT02861144|OTHER|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
219103375|NCT02861144|OTHER|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
219103376|NCT03548116|DEVICE|Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
219103377|NCT03548116|DEVICE|Sham Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
219103378|NCT06160739|DRUG|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug
219103379|NCT03101241|DRUG|CX-8998|T-type calcium channel blocker
219103380|NCT03101241|DRUG|Placebo|Placebo comparator
219103381|NCT02746913|DEVICE|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
219103382|NCT02746913|DEVICE|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
219103383|NCT01998594|PROCEDURE|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
219103384|NCT01904214|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
219103385|NCT00975988|DRUG|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
219103386|NCT02925260|OTHER|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
219103387|NCT00191360|DRUG|Somatropin|
219103388|NCT03469349|DRUG|Actovegin|Actovegin intravenous infusion and tablets.
219103389|NCT03469349|DRUG|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
219690660|NCT06673303|BEHAVIORAL|Dynamic perceptual discrimination task|The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
219690661|NCT06673303|DIAGNOSTIC_TEST|fMRI|Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
219690662|NCT07016074|DRUG|Sodium Nitrate|The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.
219690663|NCT07016074|DRUG|Placebo|The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule
219690664|NCT00919633|DRUG|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
219690665|NCT00919633|DRUG|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
219690666|NCT00919633|DRUG|ribavirin, USP|All patients will receive oral ribavirin
219103390|NCT04049903|DRUG|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
219103391|NCT01422369|DRUG|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
219690667|NCT00919633|DEVICE|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
219103392|NCT01422369|DRUG|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
219224118|NCT04693637|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
219224119|NCT04237792|DRUG|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
219224120|NCT04237792|DRUG|propofol|propofol IV administration will be given if needed to maintain sedation
219690668|NCT00288119|DEVICE|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
219690669|NCT00288119|PROCEDURE|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
219690670|NCT06466434|OTHER|Prebiotic Food-Enriched Diet|Given by PO
219690671|NCT07034248|OTHER|Electrochemical biosensor|considering benefits of the nitrogen, sulfur-doped graphene quantum dot (NSGQDs) and 3-dimensional gold nanoparticle (AuNP), we used these materials for the construction of a novel electrochemical biosensor to apply the synergy contributions on the enhancement of the potential in clinical and cancer diagnostic applications. The synthesis of a novel nanocomposite through the integration of NSGQDs with AuNP yields a hybrid material (NSGQDs/AuNP) that combines the advantages of both its organic and inorganic properties, potentially revealing unique characteristics to enhance the electrochemical behaviors, which establishes a robust foundation for constructing a label-free electrochemical biosensor. This pioneering biosensor was then conjugated with PhaL (NSGQDs/AuNP/PhaL) through the amide bond between the COOH group of NSGQDs and the NH2 group of PhaL, which has the potential for the ultra-sensitive detection of cancer markers, featuring heightened electrochemical and sensing capabilitie
219690672|NCT06709781|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the heat while being exposed to no cooling modality.
219690673|NCT06709781|OTHER|Water Spray|Subjects will exercise for 60 minutes in the heat while being exposed to skin wetting. Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
219690674|NCT06882733|DEVICE|Transcutaneous Electrical Nerve Stimulation，TENS|low frequency (4Hz) and sympathetic ganglion(T12.L1.L2) low frequency (4Hz) and gastrocnemius high frequency (80Hz) and sympathetic ganglion(T12.L1.L2) high frequency (80Hz) and gastrocnemius
219690675|NCT06884579|OTHER|Strength training, nutrition, and behavioral training|"This arm of the study consists of a supervised strength training program, conducted over 12 weeks with three weekly sessions. The sessions follow a wave-like periodization, with intensities ranging from 70% to 85% of 1-RM. Exercises focus on enhancing neuromuscular strength in the lower limbs, such as leg presses and hip extensions, under the supervision of a multidisciplinary team.~Participants will also receive nutritional guidance based on the Mediterranean diet, as well as cognitive-behavioral therapy strategies aimed at optimizing fatigue management and boosting energy levels."
219690676|NCT06884579|OTHER|Self-Guided and Unsupervised Program with General Recommendations|This arm of the study consists of a self-guided and unsupervised program based on physical exercise (3 times per week), nutrition, and cognitive-behavioral habits. Participants will access online modules that provide guidelines for performing resistance exercises with bands, dietary recommendations following the principles of the Mediterranean diet, and cognitive-behavioral techniques for fatigue management.
219690677|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
219690678|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
219103393|NCT04299334|PROCEDURE|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
219103394|NCT05082896|PROCEDURE|Type of anesthesia choice|Use of conscious sedation vs. general anesthesia
219103395|NCT06186557|OTHER|No intervention|No intervention
219103396|NCT01393080|DRUG|Nimotuzumab and TP regimen|"1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
219103397|NCT01393080|DRUG|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
219103398|NCT05829980|PROCEDURE|Laser assisted in-situ keratomileusis|Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
219103399|NCT05829980|PROCEDURE|Photorefractive keratectomy|Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
219103400|NCT03984032|DEVICE|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
219103401|NCT03984032|DEVICE|LMA Supreme|Assessing the clinical performance of LMA Supreme
219103402|NCT00079911|DRUG|valacyclovir hydrochloride|valacyclovir hydrochloride
219103403|NCT05244811|DRUG|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
219103404|NCT05244811|DRUG|Progestin|effect of progestin in treatment of ovarian cystn
219103405|NCT00166686|DRUG|Clonidine|
219103406|NCT01961596|OTHER|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
219103407|NCT01961596|OTHER|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
219103408|NCT01572246|OTHER|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
219103409|NCT06481254|OTHER|Hawthorn Vinegar Group|To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
219690679|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
219690680|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
219103410|NCT06481254|OTHER|Black Mulberry Syrup Group|To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
219103411|NCT06481254|OTHER|Green Tea Group|To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
219690681|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
219103412|NCT05256693|DRUG|Vancomycin|Oral vancomycin (powder) 125mg twice a day
219103413|NCT05256693|DRUG|Placebo|Vancomycine placebo (powder) twice a day
219103414|NCT04572529|PROCEDURE|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
219103415|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
219103416|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
219103417|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
219103418|NCT00517075|DEVICE|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
219103419|NCT05512728|DEVICE|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
219103420|NCT05512728|DRUG|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
219103421|NCT02970513|OTHER|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
219103422|NCT04678622|DEVICE|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
219103423|NCT01927692|OTHER|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
219103424|NCT01927692|OTHER|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
219224121|NCT02322489|DEVICE|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
219690682|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
219690683|NCT06686355|DRUG|Yiqilishui formula|Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
219690684|NCT06686355|OTHER|Placebo|5% Yiqilishui Granules + 95% Dextrin;
219690685|NCT06726473|DIAGNOSTIC_TEST|Wet Blood Gas Analyzer (ABL90)|This group involves the use of the ABL90 wet blood gas analyzer for measuring arterial whole blood samples. The results obtained from the ABL90 analyzer will be compared with those obtained from the EG-i30 dry blood gas analyzer
219690686|NCT06726473|DIAGNOSTIC_TEST|Dry Blood Gas Analyzer (EG-i30)|This group involves the use of the EG-i30 dry blood gas analyzer for measuring arterial whole blood samples. The results obtained from the EG-i30 analyzer will be compared with those obtained from the ABL90 wet blood gas analyzer.
219690689|NCT06737601|DEVICE|shock waves|three sessions, weekly frequency
219690690|NCT06735885|DEVICE|Matter Neuroscience App|An iPhone smartphone application
219690691|NCT06735885|DEVICE|Stock Photos|Stock Photos
219690692|NCT06735885|OTHER|No Home Training|No Home Training
219690693|NCT06634316|OTHER|Mediterranean diet|Mediterranean diet recommendations and daily physical exercise
219690694|NCT06634316|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral nutritional supplement|Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
219690695|NCT06634316|DIETARY_SUPPLEMENT|Protein module|Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
219103425|NCT04586777|DEVICE|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
219690696|NCT06634316|COMBINATION_PRODUCT|Vitamin D supplementation|Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
219690697|NCT06634316|COMBINATION_PRODUCT|Physical exercise|Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
219690698|NCT07047677|OTHER|Early assessment of tissue uptake of experimental ligands|Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue using autohistoradiography
219690699|NCT05072210|OTHER|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
219690700|NCT04183725|DRUG|Reduning injection|"Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5."
219690701|NCT04183725|DRUG|Oseltamivir phosphate granules|"Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5."
219690702|NCT02789969|DRUG|Hydromorphone|Hydromorphone 15mcg/kg IV
219690703|NCT02789969|DRUG|Fentanyl|Fentanyl 1.5mcg/kg IV
219690704|NCT01939730|DRUG|Rituximab|375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
219690705|NCT01939730|DRUG|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
219690706|NCT03291821|DRUG|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
219690707|NCT03291821|DRUG|GnRH antagonist|GnRH antagonist subcutaneously
219690708|NCT03291821|DRUG|GnRH analog|GnRH analog subcutaneously
219103426|NCT02487940|DRUG|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
219103427|NCT02487940|DRUG|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
219690709|NCT03291821|PROCEDURE|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
219103428|NCT00985543|DRUG|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
219103429|NCT00611117|OTHER|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
219103430|NCT02326350|DRUG|Aspirin 75mg|Active treatment
219690710|NCT03291821|DIAGNOSTIC_TEST|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
219690711|NCT03291821|PROCEDURE|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
219690712|NCT03291821|PROCEDURE|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
219690713|NCT03291821|DIAGNOSTIC_TEST|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
219690714|NCT03291821|PROCEDURE|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
219690715|NCT03291821|DIAGNOSTIC_TEST|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
219690716|NCT03291821|PROCEDURE|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
219690717|NCT03291821|PROCEDURE|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
219690718|NCT06749210|BEHAVIORAL|Tango|The intervention being studied is a 16 session intervention (2x4-week modules), delivered over an 8-week period by community-based individuals with expertise in dance and patient care and certified in Adapted Tango or AdapTango dance instruction. Steps available to teach, including order and cues to teach them, are detailed in Hackney's AdapTango manual. All steps are based on the Argentine Tango steps that emerged within working class community centers in Buenos Aires, Argentina (milongas) in the late 1800s and have been adapted by the investigators for use as medical exercise among people with mobility deficits. Of note, Argentine Tango is distinct from, and the precursor for, the American Tango style of competitive ballroom dance: where American Tango highlights showmanship and complicated footwork, Argentine Tango prioritizes connection between partners and musicality within a basic walk motion.
219690719|NCT01635621|DRUG|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
219690720|NCT01635621|DRUG|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
219690721|NCT03429621|DRUG|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
219690722|NCT04491461|DIETARY_SUPPLEMENT|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
219690723|NCT04491461|DIETARY_SUPPLEMENT|Warm water|1 cup of warm water
219690724|NCT00847418|DRUG|esketamine hydrochloride|
219690725|NCT01775423|DRUG|BBI608|
219690726|NCT03810456|BEHAVIORAL|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
219690727|NCT03810456|BEHAVIORAL|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
219103431|NCT02326350|DRUG|Lactose powder|Placebo
219103432|NCT05677737|OTHER|Education|"Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months."
219690728|NCT02007720|DRUG|Serelaxin|Intravenous infusion
219690729|NCT02007720|DRUG|Placebo|Intravenous infusion
219690730|NCT02007720|OTHER|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
219690731|NCT06333886|DEVICE|Sacral electromyography|Assessment of neuro-sacral function using point-of-care sacral surface electromyography
219690732|NCT00082212|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
219690733|NCT06404619|BEHAVIORAL|Education program|The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
219690734|NCT03127319|DRUG|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
219690735|NCT03127319|DRUG|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
219103433|NCT00407784|DRUG|eplerenone|
219103434|NCT05177575|PROCEDURE|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
219103435|NCT04860414|BIOLOGICAL|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
219103436|NCT04860414|OTHER|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
219690736|NCT04825951|OTHER|CS 2000|treating growing Skeletal growing Class III patients
219690737|NCT02717728|PROCEDURE|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
219690738|NCT02717728|PROCEDURE|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
219690739|NCT00428480|BEHAVIORAL|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
219690740|NCT00428480|BEHAVIORAL|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
219103437|NCT04860414|OTHER|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
219103438|NCT04860414|OTHER|Objective taste tests|Recording of gustatory evoked potentials
219690741|NCT00005743|BEHAVIORAL|exercise|
219690742|NCT00005743|BEHAVIORAL|weight loss|
219103439|NCT00642135|DRUG|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
219690743|NCT06467695|DEVICE|BIOPAC Stimsola|Transcranial Electrical Stimulator
219103440|NCT00642135|DRUG|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
219103441|NCT02357810|DRUG|Pazopanib Hydrochloride|Given PO
219103442|NCT02357810|DRUG|Oral Topotecan Hydrochloride|Given PO
219103443|NCT02357810|OTHER|Laboratory Biomarker Analysis|Correlative studies
219690744|NCT06467695|DEVICE|BIOPAC Stimsola Sham (zero amps)|Transcranial Electrical Stimulator set to 0 amps
219690745|NCT04743622|DRUG|Monoprost|preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
219103444|NCT03621293|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
219103445|NCT02734680|RADIATION|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
219103446|NCT02734680|RADIATION|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
219103447|NCT02734680|DRUG|S-1|Taking S-1 orally after radiation
219103448|NCT02218840|OTHER|Smoking topography|Evaluation of cigar smoking topography
219103449|NCT01406002|DRUG|darexaban|oral
219103450|NCT01406002|DRUG|Rifampicin|oral
219103451|NCT00726349|OTHER|No intervention|Observational study.
219103452|NCT00714623|DEVICE|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
219103453|NCT00278590|BIOLOGICAL|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
219690746|NCT04743622|DRUG|Xalatan|preserved latanoprost 1 drop once a day for 12 weeks to target eyes
219690747|NCT01725685|DRUG|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
219690748|NCT01725685|DRUG|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
219690749|NCT01725685|DRUG|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
219103454|NCT01015313|OTHER|intensive sodium management|"1. dietary sodium restriction~2. avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
219103455|NCT00980005|BIOLOGICAL|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
219103456|NCT00980005|BIOLOGICAL|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
219103457|NCT02378519|BEHAVIORAL|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
219103458|NCT02378519|BEHAVIORAL|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
219103459|NCT01026714|DRUG|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
219103460|NCT01026714|DRUG|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
219103461|NCT01026714|DRUG|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
219103462|NCT04106843|DRUG|Lutetium Lu 177 Dotatate|Given IV
219103463|NCT02893683|OTHER|Paris Visual Learning Test|
219103464|NCT01474460|DIETARY_SUPPLEMENT|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
219103465|NCT00825032|PROCEDURE|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
219103466|NCT00825032|PROCEDURE|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
219103467|NCT00692406|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
219103468|NCT02082626|DRUG|Eribulin mesylate|
219103469|NCT06288711|BEHAVIORAL|Prolonged exposure therapy|Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.
219103470|NCT06288711|BEHAVIORAL|Financial incentives|Financial incentives contingent upon completion of prolonged exposure therapy sessions
219103471|NCT06288711|BEHAVIORAL|Treatment as usual|Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
219103472|NCT05461690|DRUG|Niraparib|200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
219103473|NCT05971134|BEHAVIORAL|Acupreesure applied|Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
219103474|NCT03102658|DRUG|Micafungin|Administration of study drug
219103475|NCT02869919|OTHER|AKI|Vitamin D levels
219103476|NCT04151875|DEVICE|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
219103477|NCT04151875|DEVICE|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
219103478|NCT04323982|PROCEDURE|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
219103479|NCT04323982|PROCEDURE|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
219103480|NCT01762423|DEVICE|Active Device (IVIVI SofPulse)|
219103481|NCT01762423|DEVICE|Sham Device|
219103482|NCT05713682|PROCEDURE|alveolar ridge preservation|bone grafting at extracted sites
219103483|NCT02418975|OTHER|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
219103484|NCT02418975|OTHER|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
219103485|NCT00433953|DRUG|Mycophenolate Mofetil (CellCept)|
219103486|NCT00433953|BEHAVIORAL|Dietary Monitoring|
219103487|NCT00433953|BEHAVIORAL|Drug Diary|
219103488|NCT00433953|PROCEDURE|Blood Sampling|
219103489|NCT05122572|BIOLOGICAL|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
219103490|NCT04363385|BIOLOGICAL|Biological test|Blood sample
219103491|NCT00179699|DRUG|CC-5013|
219103492|NCT00179699|DRUG|pemetrexed|
219103493|NCT01560260|OTHER|Laboratory Biomarker Analysis|Correlative studies
219103494|NCT01560260|DRUG|Linsitinib|Given PO
219103495|NCT01560260|OTHER|Pharmacological Study|Correlative studies
219690750|NCT06765356|DEVICE|Farapulse Catheter System|"The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed (basket-shaped) configuration to a fully deployed (flower-shaped) configuration with five petals."
219690751|NCT06765356|DRUG|Low-dose Colchicine|For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.
219690752|NCT07062835|BEHAVIORAL|Perioperative Paediatric Application|"Children in the experimental group will start receiving interactive perioperative preparation training with the PeroPap application 1 day before surgery and play the PeroPap game. Children will learn about the operation process by watching and playing the PeroPap character's cartoon story about the operation process. They will also listen to the song PeroPap is having surgery and play the PeroPap Game in the application, which they can play before and after surgery. At the same time, in the parent module, information will be provided for parents with the cartoon story PeroPap is Having Surgery."
219690753|NCT07062835|OTHER|Control|"In order to meet the perioperative health care needs of the children and their parents in the control group, when they applied to the outpatient clinic for anaesthesia consultation on the working day before the operation, standard individualised care interventions will be provided according to their needs preoperatively and until their discharge, and children and parents will be given surgery preparation training with the education booklet PeroPap is Having Surgery."
219690754|NCT07066358|PROCEDURE|Simultaneous Bilateral RF Thalamotomy|This intervention involves simultaneous bilateral radiofrequency (RF) lesioning of the ventral intermediate nucleus (Vim) of the thalamus using a stereotactic frame under local anesthesia. The procedure begins with RF ablation on the side contralateral to the dominant hand. Intraoperative MRI is then performed to confirm the absence of hemorrhagic complications. If no bleeding or other adverse events are detected, the procedure proceeds to the contralateral Vim. If hemorrhage is identified, the surgery is terminated after unilateral treatment. This technique allows for immediate bilateral tremor reduction in patients with medication-refractory essential tremor, while prioritizing patient safety through intraoperative imaging-based decision-making.
219690755|NCT07063706|OTHER|Pharmaceutical Care|Participants in the intervention group received pharmaceutical care
219690756|NCT07066501|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
219690757|NCT07072884|DRUG|GC012F injection|Subjects who meet the CAR-T cell infusion criteria will receive GC012F Injection infusion within 48-72 hours after completion of lymphodepleting preconditioning.
219690758|NCT07072364|BEHAVIORAL|Video on uterine fibroids|Patients will be sent a link to a 5 minute video on uterine fibroids including their diagnosis, symptoms and treatment options prior to their scheduled appointment.
219690759|NCT07072312|BEHAVIORAL|Adjuvant Patient Navigation for Tobacco Treatment|Patients in the study meet with the Patient Navigator two weeks after their first tobacco treatment visit and again after their second visit with the Tobacco Treatment Provider. The Patient Navigator will discuss psychosocial and other cessation barriers. The Patient Navigator will connect the patients with appropriate resources to help overcome these barriers.
219103496|NCT02534532|OTHER|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
219103497|NCT04654247|BEHAVIORAL|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
219103498|NCT04654247|BEHAVIORAL|Control|None feedback.
219103499|NCT04060225|OTHER|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
219103500|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
219103501|NCT00282997|DRUG|pregabalin|
219103502|NCT06044363|OTHER|Satir group|Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
219103503|NCT02235701|DRUG|170 mg/m2 aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
219103504|NCT02235701|DRUG|250 mg/m2 aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
219103505|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
219103506|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
219103507|NCT00525265|DRUG|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
219103508|NCT00525265|DRUG|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
219103509|NCT02104635|BEHAVIORAL|Delivery of a Post-Partum Package|
219103510|NCT00073827|DRUG|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
219103511|NCT00073827|DRUG|racemic albuterol MDI|racemic albuterol 180 mcg QID
219103512|NCT00073827|DRUG|Placebo|Placebo MDI QID
219690760|NCT07073846|DRUG|Intravenous Lidocaine infusion + Standard Anesthesia|Continuous IV infusion of lidocaine 1 % (10 mg mL-¹) at 0.3 mL kg-¹ h-¹ (≈ 1.5 mg kg-¹ h-¹) from induction of anaesthesia to skin closure. No loading bolus, no post-operative infusion.
219690761|NCT07073846|DRUG|Intravenous Dexmedetomidine infusion + Standard Anesthesia|Continuous IV infusion of dexmedetomidine 1 µg mL-¹ at 0.3 mL kg-¹ h-¹ (≈ 0.3 µg kg-¹ h-¹) without loading dose, started after induction and stopped at skin closure. No post-operative infusion.
219690762|NCT07073846|DRUG|Lidocaine + Dexmedetomidine Combination (LIDEX) + Standard Anesthesia|Single syringe containing lidocaine 1 % (10 mg mL-¹) + dexmedetomidine 1 µg mL-¹, infused IV at 0.3 mL kg-¹ h-¹ (delivering ≈ 1.5 mg kg-¹ h-¹ lidocaine + 0.3 µg kg-¹ h-¹ dexmedetomidine) from induction to skin closure.
219103513|NCT05415033|OTHER|BREAST-Q|arabic version of breast questionnaire
219103514|NCT06061432|PROCEDURE|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
219103515|NCT03107377|DRUG|EVO100|5 g dose applied up to 1 hour prior to coitus
219690763|NCT07073846|DRUG|0.9 % Saline Placebo + Standard Anesthesia|Volume-matched IV infusion of 0.9 % normal saline at 0.3 mL kg-¹ h-¹ for the same duration and through the same delivery line as active arms; identical syringe appearance.
219690764|NCT07072338|BEHAVIORAL|Stress management training|The stress management training is the WHO SH+ (Self-Help Plus) program, a low-intensity, group-based intervention developed by the World Health Organization to improve stress management and psychological flexibility. It combines pre-recorded audio sessions with an illustrated self-help guide and is based on Acceptance and Commitment Therapy (ACT). The program is delivered over five sessions and supported by a digital platform for at-home practice.
219690765|NCT07072338|BEHAVIORAL|Multidomain cognitive training|The multidomain cognitive training is a low-intensity, group-based intervention aimed at sustainably improving a healthy lifestyle, which in turn supports brain health and cognitive functioning. It combines pre-recorded audio sessions with an illustrated self-help guide and provides knowledge about aging and how to enhance three key lifestyle factors-social engagement, physical activity, and cognitive stimulation. The training uses metacognitive strategies and monitoring tools to help participants sustainably integrate these behaviors into their daily lives. The program is delivered over five sessions and supported by a digital platform for at-home practice.
219690766|NCT07072338|BEHAVIORAL|Social activities|The social activity intervention consists of a podcast discussion group in which participants listen to short podcasts on aging-related topics during each group session. Topics include driving (Session 1), intergenerational relationships (Session 2), technology (Session 3), the transition to retirement (Session 4), and travel (Session 5). These themes are deliberately chosen to be neutral and are not directly related to the techniques or content used to enhance well-being or cognitive functioning in the SH+ or COG interventions. The program is delivered over five sessions.
219690767|NCT07073872|OTHER|IDEAL Discharge Education Program|Participants in the intervention group received the nurse-led IDEAL Discharge Education Program (IDEP) and the control group received a standard 15-minute face-to-face discharge education the day of discharge day. The IDEP is a nurse-led, structured discharge education program in accordance with IDEAL Discharge Planning that uses the teach-back method. IDEP is an individualized discharge educational program for surgical patients that utilizes the teach-back method and a printed booklet.
219103516|NCT03107377|DRUG|Placebo|5 g dose applied up to 1 hour prior to coitus
219103517|NCT03826511|OTHER|Tiszasüly hot mud-pack therapy|Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
219103518|NCT03826511|OTHER|Kolop mud-pack|Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
219103519|NCT05353959|OTHER|No intervention|No intervention
219103520|NCT01729234|DIETARY_SUPPLEMENT|Nitrate|Dietary Supplement
219103521|NCT01729234|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement
219103522|NCT05436964|OTHER|saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
219103523|NCT05436964|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
219103524|NCT03648203|BEHAVIORAL|Technology Enabled Asthma Management System|See description of arm
219103525|NCT03596437|DEVICE|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
219103526|NCT01448954|DRUG|ADC3680B oral|Once daily for 28 days
219103527|NCT01448954|DRUG|Placebo oral|Once daily for 28 days
219103528|NCT02482636|BIOLOGICAL|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
219103529|NCT02482636|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
219103530|NCT02482636|BIOLOGICAL|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
219103531|NCT02482636|BIOLOGICAL|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
219103532|NCT02482636|BIOLOGICAL|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
219103533|NCT02482636|BIOLOGICAL|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
219690768|NCT07073872|OTHER|control group|This group receives routine hospital discharge instructions for 15 minutes on the day of discharge.
219690769|NCT07072065|DRUG|protein purified derivative|tuberculin purified protein derivative with dose 5 tuberculin unit
219103534|NCT04169711|DRUG|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
219103535|NCT02415374|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
219103536|NCT00211237|DEVICE|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
219103537|NCT00211237|OTHER|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
219103538|NCT00227500|DRUG|Pravastatin|
219103539|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
219103540|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
219103541|NCT05921071|DRUG|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
219103542|NCT05921071|DRUG|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
219103543|NCT02100722|PROCEDURE|FFR guided PCI|
219103544|NCT02100722|PROCEDURE|CABG|Coronary Artery Bypass Graft Surgery (CABG)
219103545|NCT02100722|DEVICE|Resolute Integrity Stent|Durable polymer zotarolimus-eluting stent
219103546|NCT02100722|DEVICE|Resolute Onyx Stent|Durable polymer zotarolimus-eluting stent
219103547|NCT01261715|PROCEDURE|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
219103548|NCT00185510|DRUG|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
219103549|NCT00185510|DRUG|Placebo|2 days a week Vehicle (Advabase)
219103550|NCT02300285|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
219103551|NCT00827593|BEHAVIORAL|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
219103552|NCT00827593|BEHAVIORAL|Weight Watchers|Participants will receive 12 months of Weight Watchers
219103553|NCT00827593|BEHAVIORAL|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
219103554|NCT06335108|PROCEDURE|General Anaesthesia|Breast surgery is carried out under general anesthesia.
219103555|NCT06335108|PROCEDURE|Local tumescent anaesthesia|Breast surgery is carried out under local tumescent anesthesia.
219103556|NCT03961009|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
219103557|NCT04394585|BEHAVIORAL|smart phone app based human coaching program|"1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
219103558|NCT03875079|DRUG|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
219103559|NCT03875079|DRUG|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
219103560|NCT05647551|DRUG|BOTOX®/VISTABEL®|Facial Injection
219690770|NCT07070219|DRUG|CTD402 CAR T Cell Injection|CAR T cells
219690771|NCT07073690|DRUG|Luspatercept|According to the product label
219690772|NCT07073430|DEVICE|AI models with NBI|AI models for detecting intestinal adenoma in magnifying endoscopy with NBI.
219690773|NCT07073534|DRUG|SHR-1501, Adebrelimab|the combination of SHR-1501 and Adebrelimab
219690774|NCT07072286|PROCEDURE|Regional Anesthesia|"* Supra-inguinal fascia iliaca block (SIFI)~* Lumbar erector spinae plane block (ESP)~* Transmuscular quadratus lumborum block (QLB) All blocks will be performed by experienced anesthesiologists under ultrasound guidance, using long-acting anesthetics (ropivacaine) at fixed concentrations and doses within weight-based safety limits."
219690775|NCT07072286|DRUG|Multimodal analgesia|All enrolled subjects will be treated according to the standard analgesic protocol for pelvic fractures, in accordance with available literature and institutional guidelines. Specifically, the protocols include the use of multimodal analgesia techniques in line with current clinical practice, including paracetamol, non-steroidal anti-inflammatory drugs, opioids.
219690776|NCT07072117|DRUG|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety & Respiratory Complications|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
219690777|NCT07072117|DRUG|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
219690778|NCT07072117|DRUG|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
219690779|NCT07072520|BEHAVIORAL|Questionnaire|Questionnaire including sociodemographic characteristics and dietary assessment
219690780|NCT07072520|OTHER|Body composition assessment|Body Composition Assessment via bioelectrical impedance analysis (BIA)
219690781|NCT07072351|RADIATION|hypofractionated radiotherapy|In Phase Ib, HFRT will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
219690782|NCT07072351|DRUG|SOX Chemotherapy|SOX chemotherapy regimen: Oxaliplatin 130 mg/m² administered by intravenous infusion on Day 1; S-1 administered orally for 14 consecutive days followed by a 7-day rest period. The dosage of S-1 is based on body surface area (BSA): 40 mg twice daily for BSA ≤1.5 m², 50 mg twice daily for BSA between 1.5-1.6 m², and 60 mg twice daily for BSA ≥1.6 m². Each cycle is repeated every 3 weeks.
219690783|NCT07072351|DRUG|PD-1 inhibitor|Sintilimab 200 mg administered by intravenous infusion on Day 1 of each 3-week cycle.
219690784|NCT07073833|DRUG|IBR900 cell injection|NK cells
219690785|NCT07073833|DRUG|rituximab|CD20 antibody
219690786|NCT06602414|PROCEDURE|Conservative treatment|Conservative treatment instead of surgical repair
219690787|NCT01386606|DRUG|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
219690788|NCT01386606|DRUG|Testosterone|"topical gel~1X a day 6 weeks"
219690789|NCT04361656|DRUG|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
219690790|NCT04361656|DRUG|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
219690791|NCT04016974|DRUG|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
219690792|NCT04016974|DRUG|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
219103561|NCT05647551|DEVICE|Juvéderm® VOLBELLA® with Lidocaine|Facial Injection
219690793|NCT05556252|OTHER|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
219690794|NCT05556252|OTHER|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
219690795|NCT05714553|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
219690796|NCT05714553|DRUG|Leucovorin|Intravenous infusion
219103562|NCT05647551|DEVICE|Juvéderm® VOLIFT® with Lidocaine|Facial Injection
219690797|NCT05714553|DRUG|Pembrolizumab|Intravenous infusion
219690798|NCT05714553|DRUG|Docetaxel|Intravenous infusion
219690799|NCT06141967|DEVICE|WITHINGS Sleep Analyzer|"Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography."
219103563|NCT05647551|DEVICE|Juvéderm® VOLUMA® with Lidocaine|Facial Injection
219103564|NCT05425303|DIAGNOSTIC_TEST|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
219103565|NCT04658186|DRUG|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
219103566|NCT04658186|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
219103567|NCT05652036|BIOLOGICAL|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
219103568|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
219103569|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
219103570|NCT05335109|DRUG|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
219103571|NCT05335109|DRUG|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
219103572|NCT05786274|DIAGNOSTIC_TEST|Cerebral autoregulation monitoring|Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
219224122|NCT02322489|DEVICE|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
219224123|NCT00807079|DRUG|carboplatin|
219224124|NCT00807079|DRUG|topotecan hydrochloride|
219103573|NCT00785525|DRUG|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
219103574|NCT04978545|OTHER|calciumhydroxide, intracanal medicament|In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
219690800|NCT03621956|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
219690801|NCT03621956|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
219103575|NCT04978545|OTHER|chlorhexidine, intracanal medicament|, chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
219103576|NCT03705845|DRUG|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
219103577|NCT03705845|DRUG|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
219103578|NCT05796518|OTHER|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
219103579|NCT05796518|OTHER|Survey|A brief survey before and after use of the tool will also be completed by participants.
219690802|NCT02242617|DEVICE|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
219690803|NCT02242617|DEVICE|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
219690804|NCT06446622|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
219690805|NCT01022203|BEHAVIORAL|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
219103580|NCT05796518|OTHER|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
219103581|NCT05437822|DRUG|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
219103582|NCT03500640|BEHAVIORAL|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
219103583|NCT03500640|BEHAVIORAL|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
219224125|NCT04272385|OTHER|Observational|Observational
219224126|NCT00003167|BIOLOGICAL|Ad5CMV-p53 gene|Given intravesically
219103584|NCT06139718|BEHAVIORAL|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
219103585|NCT03546348|OTHER|no intervention|only measurement of the carrying angle
219103586|NCT01650519|DRUG|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
219103587|NCT01650519|DRUG|IV ketorolac|30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds
219224127|NCT03177707|OTHER|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
219224128|NCT05155046|DRUG|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
219224129|NCT03181100|DRUG|Atezolizumab|Given IV
219224130|NCT03181100|BIOLOGICAL|Bevacizumab|Given IV
219690806|NCT01022203|OTHER|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
219690807|NCT00563290|DRUG|dasatinib|Given PO
219690808|NCT00563290|OTHER|laboratory biomarker analysis|Correlative studies
219690809|NCT01094288|DRUG|Alisertib|Alisertib ECT
219690810|NCT01094288|DRUG|Docetaxel|Docetaxel IV infusion
219690811|NCT01317940|DIETARY_SUPPLEMENT|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
219690812|NCT02981511|DEVICE|optiflow|Optiflow device used for preoxygenation
219690813|NCT04939467|DRUG|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
219690814|NCT04939467|DRUG|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
219690815|NCT04939467|DRUG|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
219690816|NCT06516640|BEHAVIORAL|Continuous Glucose Monitoring Academy|Educational materials as well as online sessions with diabetes educators.
219690817|NCT06516640|BEHAVIORAL|Standard Education|Standard of care receives general education about diabetes.
219103588|NCT04031521|DIAGNOSTIC_TEST|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
219103589|NCT02320747|OTHER|Tai Chi|
219103590|NCT01737281|BEHAVIORAL|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
219103591|NCT01737281|BEHAVIORAL|Usual care|Usual smoking cessation care from VA clinical staff.
219690818|NCT04152200|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
219690819|NCT06039189|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219690820|NCT06039189|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
219103592|NCT03486587|DRUG|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
219103593|NCT05408468|BEHAVIORAL|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
219690821|NCT02637596|PROCEDURE|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
219690822|NCT02687672|BIOLOGICAL|Stem Cell Transplantation|Transplantation of autologous stem cells
219690823|NCT05703542|DRUG|BXCL701|Tablet, taken Orally
219690824|NCT04980014|DRUG|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
219690825|NCT00593814|DEVICE|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
219690826|NCT04912076|DRUG|BM41|Subcutaneous injection of increasing doses of BM41
219690827|NCT04912076|OTHER|Placebo|Subcutaneous injections of placebo containing aluminium hydroxide.
219690828|NCT04912076|DRUG|ALK Alutard SQ Betula verrucosa|Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
219690829|NCT05187221|BEHAVIORAL|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
219103594|NCT04186403|DRUG|Brexpiprazole|Administered as tablets.
219103595|NCT06851104|DRUG|Cadonilimab (AK104)|Patients with hepatocellular carcinoma after curative hepatectomy would receive cadonilimab 10 mg/kg intravenous infusion (dissolved in 0.9% NaCl 250 mL, within 60 minutes) Q3W, until disease progression, death, intolerance to toxicity, withdrawal of informed consent, initiation of new anti-tumor treatment, or termination of treatment for other reasons specified in the protocol. The maximum treatment duration for cadonilimab is 6 months.
219103596|NCT00930943|DRUG|Oxymorphone ER|40 mg qd twice
219103597|NCT05762848|DEVICE|Mobile Phone Head Circumference App|Measurement of Head circumference of Babies/Infants with a mobile phone application.
219103598|NCT00025584|DRUG|bortezomib|Given IV
219103599|NCT00025584|OTHER|laboratory biomarker analysis|Correlative studies
219103600|NCT02688465|DRUG|Apomorphine|
219224131|NCT03181100|DRUG|Cobimetinib|Given PO
219224132|NCT03181100|DRUG|Nab-paclitaxel|Given IV
219224133|NCT03181100|DRUG|Paclitaxel|Given IV
219224134|NCT03181100|DRUG|Vemurafenib|Given PO
219690830|NCT00829556|DEVICE|Integuseal|
219690831|NCT02593500|DRUG|Budesonida Pulmictan® 200 µg|
219690832|NCT02593500|DRUG|Budesonide 200 µg|
219690833|NCT02022553|PROCEDURE|usual rectal cancer surgery|
219690834|NCT02022553|PROCEDURE|RACHEL|
219690835|NCT00093522|BIOLOGICAL|autologous tumor cell vaccine|
219690836|NCT00093522|BIOLOGICAL|keyhole limpet hemocyanin|
219690837|NCT00093522|BIOLOGICAL|therapeutic autologous dendritic cells|
219690838|NCT00093522|DRUG|fludarabine phosphate|
219690839|NCT00093522|PROCEDURE|conventional surgery|
219690840|NCT06422169|DEVICE|ArToFILL|ArToFILL is an injectable medical device (class III) intended for use as a temporary filler in joints. It is a sterile, non-pyrogenic, colorless and transparent hyaluronic acid gel of non-animal origin. ArToFILL is a hydrogel consisting of a mixture of two different molecular weights of hyaluronic acid, for a total HA concentration of 2.7 %.
219690841|NCT00903643|OTHER|Physical examination|Physical examination and multiple questionnaires will be administered
219690842|NCT02699996|OTHER|Questionnaire Administration|Complete interview
219690843|NCT02699996|BEHAVIORAL|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
219690844|NCT00151333|DRUG|SRA-333|
219690845|NCT01288599|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
219690846|NCT04009603|DRUG|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
219690847|NCT04009603|DRUG|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
219690848|NCT02296489|DEVICE|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
219690849|NCT04069715|DIETARY_SUPPLEMENT|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
219690850|NCT04069715|OTHER|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
219690851|NCT02594319|BEHAVIORAL|Monetary incentives|
219690852|NCT02594319|BEHAVIORAL|Self monitoring|
219103601|NCT03482856|BEHAVIORAL|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
219690853|NCT05471388|DIAGNOSTIC_TEST|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
219690854|NCT05721664|OTHER|Trianing program for nurse in how to provide evidence based practices for mechanically Ventilated Patients|"Short Name: (EBNPTP) for Caring of Mechanically Ventilated Patients in terms of standardized care.~Duration: Two weeks A number of Contact Hours: 30 hrs. associated arm (interventional arm): for study group of ICU Nurses working at National Hepatology and Tropical Medicine Research Institute (NHTMRI)"
219690855|NCT05876325|OTHER|FINassist Patient|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
219690856|NCT05876325|OTHER|FINassist Caregiver|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
219690857|NCT01026025|DEVICE|Duet TRS|This is a single arm study.
219690858|NCT05116917|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
219690859|NCT05116917|DRUG|Ipilimumab|1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
219690860|NCT05116917|BIOLOGICAL|Influenza vaccine|Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
219690861|NCT05116917|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
219103602|NCT03482856|BEHAVIORAL|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
219690862|NCT05538013|OTHER|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
219690863|NCT03687983|DEVICE|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
219690864|NCT02723188|DEVICE|Sham stimulation (1.5 milliampere,30 seconds)|
219690865|NCT02723188|DEVICE|DC stimulation (1.5 milliampere, 20 minutes)|
219690866|NCT02723188|DEVICE|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
219103603|NCT02553811|DIAGNOSTIC_TEST|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
219103604|NCT01431040|OTHER|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
219103605|NCT01431040|OTHER|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
219690867|NCT02182310|DRUG|BI 201335 low dose|
219690868|NCT02182310|DRUG|BI 201335 placebo|
219690869|NCT02182310|DRUG|Moxifloxacin|
219690870|NCT02182310|DRUG|BI 201335 high dose|
219690871|NCT01145365|PROCEDURE|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
219103606|NCT01008475|DRUG|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
219103607|NCT01008475|DRUG|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
219690872|NCT00817622|DIETARY_SUPPLEMENT|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
219690873|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
219690874|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
219690875|NCT01095835|DRUG|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
219690876|NCT05719896|DRUG|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
219690877|NCT05719896|DRUG|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
219690878|NCT05719896|DRUG|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
219690879|NCT01797393|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
219690880|NCT01797393|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
219690881|NCT01797393|OTHER|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
219690882|NCT01912976|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
219103608|NCT01008475|DRUG|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
219103609|NCT01008475|DRUG|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
219224135|NCT03542747|DEVICE|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
219224136|NCT03542747|DEVICE|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
219690883|NCT01912976|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
219690884|NCT04331288|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
219690885|NCT04331288|OTHER|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
219690886|NCT05362708|DEVICE|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
219690887|NCT03884881|DIAGNOSTIC_TEST|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
219690888|NCT03884881|DIAGNOSTIC_TEST|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
219690889|NCT03884881|DRUG|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
219690890|NCT05743530|DEVICE|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
219690891|NCT05743530|OTHER|Placebo|Pre-operative day 1 till postoperative day 14.
219690892|NCT01198002|DRUG|LY2127399|Administered Subcutaneously (SC)
219690893|NCT01198002|DRUG|Placebo Q2W|Administered SC
219690894|NCT01198002|DRUG|Placebo Q4W|Administered SC
219690895|NCT01198002|DRUG|Methotrexate|Methotrexate is a background therapy.
219103610|NCT01008475|DRUG|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
219103611|NCT01008475|DRUG|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
219690896|NCT05702008|OTHER|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
219690897|NCT00001322|DRUG|Leuprolide Acetate 3.75|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
219690898|NCT00001322|DRUG|Estradiol|Transdermal Estradiol, 100mcg/day by skin patch
219690899|NCT00001322|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
219690900|NCT00001322|DRUG|Placebo suppository|Placebo suppository twice daily
219690901|NCT00001322|DRUG|Placebo patch|Placebo by skin patch
219690902|NCT02668965|PROCEDURE|Intrauterine hCG (pregnyl)|
219690903|NCT02074202|DRUG|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
219690904|NCT02074202|DRUG|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
219690905|NCT00057291|BEHAVIORAL|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
219690906|NCT01719549|DRUG|Dovitinib|"* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks"
219690907|NCT05141006|DRUG|BOTOX|Injection into the bladder
219690908|NCT05141006|DRUG|Placebo for BOTOX|Injection into the bladder
219690909|NCT00238407|DRUG|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
219690910|NCT00238407|RADIATION|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
219690911|NCT02601755|BEHAVIORAL|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
219690912|NCT02601755|BEHAVIORAL|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
219690913|NCT01328015|DRUG|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
219690914|NCT05426746|DRUG|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
219690915|NCT05426746|OTHER|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
219690916|NCT02660255|DRUG|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
219690917|NCT02334163|DRUG|Nitazoxanide|500 mg nitazoxanide tablets twice daily
219690918|NCT02334163|DRUG|Oral lactulose|Oral lactulose (65%)
219690919|NCT02334163|DRUG|Metronidazole|250 mg metronidazole tablets every 8 hours
219690920|NCT02334163|DRUG|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
219690921|NCT00729521|OTHER|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
219103612|NCT02500459|DRUG|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
219690922|NCT00729521|OTHER|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
219690923|NCT04260620|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
219690924|NCT00933595|OTHER|Smoking Cessation|"A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
219690925|NCT00092196|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
219690926|NCT03628443|DIAGNOSTIC_TEST|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
219690927|NCT01837836|BEHAVIORAL|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
219690928|NCT02546648|DRUG|Tranexamic Acid|
219690929|NCT02546648|DRUG|Tranexamic Acid Placebo|
219690930|NCT02546648|DRUG|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
219690931|NCT04735705|DEVICE|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
219690932|NCT00226252|PROCEDURE|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
219690933|NCT00226252|PROCEDURE|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
219690934|NCT04718597|PROCEDURE|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
219690935|NCT04718597|PROCEDURE|Open inguinal hernia repair|Classical approach (open repair)
219690936|NCT01645436|OTHER|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
219690937|NCT01935999|DEVICE|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
219690938|NCT00846144|DIETARY_SUPPLEMENT|copper sulfate|copper sulfate 3mg/d for a period of 6 months
219103613|NCT02500459|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
219103614|NCT01463280|DRUG|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
219103615|NCT04472377|DEVICE|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
219103616|NCT00737412|OTHER|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
219690939|NCT04630977|DIETARY_SUPPLEMENT|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
219690940|NCT04630977|OTHER|Progressive Resistance Training|The information about it has been detailed in advance.
219690941|NCT04630977|BEHAVIORAL|Nutritional Patterns Guideline|This intervention has also been described in advance.
219690942|NCT02130869|BIOLOGICAL|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
219690943|NCT02130869|BIOLOGICAL|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
219690944|NCT02130869|BIOLOGICAL|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
219690945|NCT02130869|DRUG|Busulfan|Given IV - Group A only.
219690946|NCT02130869|DRUG|Melphalan|Given IV - All groups.
219690947|NCT02130869|BIOLOGICAL|GM-CSF|Given SQ - All groups.
219103617|NCT00737412|OTHER|Placebo|Matching capsules devoid of microorganisms
219103618|NCT02917941|DRUG|Ixazomib|Ixazomib capsules
219103619|NCT02917941|DRUG|Lenalidomide|Lenalidomide capsules
219103620|NCT02917941|DRUG|Dexamethasone|Dexamethasone Tablets
219103621|NCT04923308|OTHER|Triage results disclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will be communicated to the specialist using a standardized clinical note, prior to the patient's consultation and without further discussion.
219103622|NCT04923308|OTHER|Triage results undisclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will not be communicated to the specialist.
219103623|NCT05205317|DRUG|Metformin Hydrochloride Sustained-release Tablets|drug
219224137|NCT00330499|DRUG|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
219690948|NCT02130869|DRUG|Bendamustine|Given IV - Group B only.
219690949|NCT02130869|DRUG|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
219690950|NCT02130869|DRUG|Cytarabine|Given IV - Group B only.
219690951|NCT02130869|DRUG|Carboplatin|Given IV - Group C only.
219690952|NCT02130869|DEVICE|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
219690953|NCT02130869|BIOLOGICAL|G-CSF|Given SQ - All Groups.
219103624|NCT05205317|PROCEDURE|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
219103625|NCT03629652|OTHER|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
219103626|NCT03629652|OTHER|Conventional Rehabilitation|The body is in the supine position without lowered head
219103627|NCT02210793|PROCEDURE|transepithelial PRK|
219690954|NCT02130869|DRUG|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
219103628|NCT02210793|PROCEDURE|LASIK|
219103629|NCT03425448|DRUG|Heparin|Heparin hemodialysis catheter lock solution
219103630|NCT03425448|DEVICE|Neutrolin|Neutrolin hemodialysis catheter lock
219103631|NCT02205801|PROCEDURE|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
219103632|NCT02205801|PROCEDURE|Local Wound Infiltration|0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
219103633|NCT02205801|DRUG|0.9% saline|
219103634|NCT02205801|DRUG|Marcaine|
219103635|NCT06356194|DRUG|Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
219103636|NCT06356194|DRUG|Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
219103637|NCT00674089|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A 50,000 IU
219690955|NCT02130869|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219103638|NCT00674089|DIETARY_SUPPLEMENT|Placebo|Vitamin A Placebo
219103639|NCT00840255|BEHAVIORAL|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
219103640|NCT00840255|OTHER|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
219103641|NCT05356390|OTHER|Stabilization exercises|"Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
219103642|NCT05356390|OTHER|Muscle energy techniques|"Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
219103643|NCT06214858|DRUG|SHEN211 tablets|SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
219103644|NCT06214858|DRUG|SHEN211 placebo tablets|placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
219103645|NCT01547988|OTHER|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
219690956|NCT05190796|OTHER|platelet indices|One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
219690957|NCT03271138|DIETARY_SUPPLEMENT|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10\^9 CFU Bifidobacterium infantis NLS super strain
219690958|NCT03271138|OTHER|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
219690959|NCT03652818|DRUG|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
219690960|NCT03652818|DRUG|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
219690961|NCT03652818|DRUG|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
219690962|NCT03652818|DRUG|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
219690963|NCT03652818|DRUG|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
219690964|NCT03652818|DRUG|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
219690965|NCT05724303|OTHER|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
219690966|NCT03034369|OTHER|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
219690967|NCT03034369|OTHER|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
219690968|NCT03034369|OTHER|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
219690969|NCT03034369|OTHER|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
219103646|NCT01373450|DRUG|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
219103647|NCT01373450|DRUG|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
219690970|NCT03034369|OTHER|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
219690971|NCT03034369|OTHER|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
219103648|NCT01373450|DRUG|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
219224138|NCT00330499|RADIATION|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
219224139|NCT05243056|OTHER|Best Practice|Receive enhanced usual care
219690972|NCT03034369|OTHER|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
219690973|NCT03034369|OTHER|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
219690974|NCT03034369|OTHER|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
219690975|NCT03034369|OTHER|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
219103649|NCT01373450|DRUG|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
219103650|NCT01373450|DRUG|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
219103651|NCT05541562|DIAGNOSTIC_TEST|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
219103652|NCT00158340|BEHAVIORAL|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
219103653|NCT00158340|BEHAVIORAL|Usual clinical care|Control group participants receive treatment as usual.
219224140|NCT05243056|OTHER|Educational Intervention|Receive Y-AMBIENT
219224141|NCT05243056|OTHER|Quality-of-Life Assessment|Ancillary studies
219690976|NCT03034369|OTHER|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
219690977|NCT03034369|OTHER|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
219224142|NCT05243056|OTHER|Questionnaire Administration|Ancillary studies
219224143|NCT00456339|DRUG|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
219690978|NCT03034369|OTHER|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
219690979|NCT06032728|DRUG|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
219690980|NCT04449965|DRUG|Povidone-iodine|This will be performed twice daily for two weeks.
219690981|NCT04449965|DRUG|Placebo|This will be performed twice daily for two weeks.
219690982|NCT03964207|DRUG|Tiotropium Respimat® (T1)|inhalation solution
219690983|NCT03964207|DRUG|Tiotropium Handihaler® (T2)|Inhalation Powder
219690984|NCT02908139|DEVICE|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
219690985|NCT02908139|DEVICE|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
219690986|NCT05190614|DIAGNOSTIC_TEST|The biotype of gingiva|The biotype of gingival was determined by periodontal probe.
219690987|NCT03735290|BIOLOGICAL|ilixadencel|Intra-tumoral injection
219690988|NCT03735290|DRUG|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
219690989|NCT05606861|OTHER|Mindfulness Based Interventions in Pediatric Nurses|This intervention are structured mindfulness program including meditation and breathing techniques .
219690990|NCT04938791|OTHER|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
219690991|NCT04535427|DRUG|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219690992|NCT04535427|DRUG|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
219690993|NCT01737606|DEVICE|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
219690994|NCT03597802|OTHER|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
219690995|NCT03597802|OTHER|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
219690996|NCT01930539|DEVICE|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
219690997|NCT04405258|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
219690998|NCT04405258|PROCEDURE|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
219690999|NCT00624091|PROCEDURE|Cardiac surgery|Cardiac surgery within 48 hours of randomization
219691000|NCT00624091|PROCEDURE|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
219691001|NCT02960412|DRUG|furosemide|10mg lasix given intraoperatively
219691002|NCT02960412|DRUG|Normal Saline|Normal saline given intraoperatively as placebo
219691003|NCT02292576|OTHER|Cocoa Pure|Cocoa Pure.
219691004|NCT02292576|OTHER|Placebo|Placebo.
219691005|NCT02217748|OTHER|Survey questionnaire|
219691006|NCT00966576|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
219691007|NCT05843409|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
219691008|NCT02090296|DRUG|Hydroxyurea|
219691009|NCT02090296|OTHER|Placebo|
219691010|NCT05609669|OTHER|CADENCE program|The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
219691011|NCT05869799|DIETARY_SUPPLEMENT|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
219691012|NCT05869799|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
219691013|NCT01591148|DRUG|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
219691014|NCT04933318|OTHER|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
219691015|NCT04933318|OTHER|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
219691016|NCT04933318|OTHER|IFC|Interferential current therapy (IFC)- analgesic current therapy
219691017|NCT04933318|OTHER|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
219691018|NCT02982707|DRUG|BMS-986177|Single oral dose
219691019|NCT03468088|BEHAVIORAL|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
219691020|NCT03468088|BEHAVIORAL|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
219691021|NCT06958484|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab|The patients with high-risk recurrence will be treated with Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment .
219691022|NCT03256617|OTHER|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
219103654|NCT01536184|BEHAVIORAL|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
219103655|NCT04659395|OTHER|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
219691023|NCT01241279|DEVICE|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
219691024|NCT01241279|DEVICE|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
219691025|NCT03091153|OTHER|Medication Review|In depth medication review with a focus on deprescribing
219691026|NCT03445026|DIAGNOSTIC_TEST|dental panorama|radiographic examination
219691027|NCT04864743|DRUG|ADVATE|a single dose.
219691028|NCT04864743|DRUG|FRSW117|a single dose.
219691029|NCT02354326|RADIATION|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
219691030|NCT02354326|RADIATION|computed tomography|Undergo CT without VNC
219691031|NCT05252858|DEVICE|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
219691032|NCT05252858|OTHER|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
219691033|NCT00301834|BIOLOGICAL|alemtuzumab|
219691034|NCT00301834|DRUG|busulfan|
219691035|NCT00301834|DRUG|cyclosporine|
219691036|NCT00301834|DRUG|fludarabine phosphate|
219103656|NCT03192644|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
219103657|NCT03192644|PROCEDURE|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
219103658|NCT03192644|DRUG|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
219103659|NCT03192644|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
219103660|NCT02813746|DIETARY_SUPPLEMENT|Fitness program|
219103661|NCT02813746|BEHAVIORAL|Stop smoking|
219103662|NCT02813746|PROCEDURE|Endometrial fluid collection|
219103663|NCT05164302|PROCEDURE|Auricular acupuncture|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
219103664|NCT02034253|DRUG|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
219691037|NCT00301834|DRUG|methotrexate|
219691038|NCT00301834|DRUG|methylprednisolone|
219691039|NCT00301834|PROCEDURE|allogeneic bone marrow transplantation|
219691040|NCT00301834|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219691041|NCT00301834|PROCEDURE|peripheral blood stem cell transplantation|
219691042|NCT00301834|PROCEDURE|umbilical cord blood transplantation|
219691043|NCT03294642|DIETARY_SUPPLEMENT|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
219691044|NCT03294642|DIETARY_SUPPLEMENT|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
219691045|NCT03294642|DIETARY_SUPPLEMENT|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
219691046|NCT02786303|DEVICE|Whole-body diffusion- weighted MRI|
219691047|NCT06473350|OTHER|The application of right lateral, supine, and prone positions to preterm infants after feeding|Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
219103665|NCT05296499|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
219691048|NCT06458114|OTHER|Assessment of caregiver feeling|The study group includes any caregiver who supported an extremely preterm newborn in a palliative care approach in the delivery room with as intervention type a questionnaire and individual semi-structured interview.
219691049|NCT05053906|DEVICE|Endoscope|effect of FESS on eustachian tube function
219691050|NCT03599570|BEHAVIORAL|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
219691051|NCT01811732|DRUG|Delafloxacin|Delafloxacin
219691052|NCT01811732|DRUG|Vancomycin|Vancomycin
219691053|NCT01811732|DRUG|Aztreonam|Aztreonam
219691054|NCT01811732|DRUG|Placebo|Placebo
219691055|NCT01962675|DEVICE|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
219691056|NCT01962675|BEHAVIORAL|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
219103666|NCT05296499|DIAGNOSTIC_TEST|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
219103667|NCT05296499|OTHER|6 minute walk test|6MWT
219103668|NCT05296499|DIAGNOSTIC_TEST|Blood tests|FBC, U\&E, LFTS
219103669|NCT05296499|OTHER|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
219103670|NCT05296499|OTHER|Repeat baseline assessments|repeat baseline
219103671|NCT05296499|DIAGNOSTIC_TEST|MR venogram|MRI scan of venous system
219103672|NCT02503267|OTHER|none intervention|
219224144|NCT04091347|BEHAVIORAL|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
219224145|NCT05371483|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
219224146|NCT05371483|DIAGNOSTIC_TEST|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
219691057|NCT04173091|DIAGNOSTIC_TEST|No Intervention|No Intervention planed
219691058|NCT02519725|OTHER|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
219691059|NCT04514900|BEHAVIORAL|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
219691060|NCT04514900|BEHAVIORAL|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
219691061|NCT04514900|BEHAVIORAL|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
219691062|NCT04514900|BEHAVIORAL|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
219103673|NCT00087542|DRUG|ACP-103|
219103674|NCT03120689|OTHER|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
219103675|NCT03120689|OTHER|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
219103676|NCT03120689|OTHER|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
219691063|NCT03496389|DRUG|Gabapentin|Gabapentin 300mg daily
219691064|NCT03496389|DRUG|Tramadol|Tramadol 50mg QID
219691065|NCT03496389|DRUG|Panadol|Panadol 500mg QID
219691066|NCT01078038|DEVICE|Cypher|Sirolimus-eluting stent implantation
219691067|NCT01078038|DEVICE|Xience V|Everolimus-eluting Stent implantation
219691068|NCT05573230|DRUG|Midazolam|Administered orally.
219691069|NCT05573230|DRUG|LY3502970|Administered orally.
219691070|NCT05573230|DRUG|Cyclosporine|Administered orally.
219691071|NCT05859217|DRUG|Cabozantinib|Oral once per day, Days 1 - 21 every 21 days
219691072|NCT05859217|DRUG|Atezolizumab|Intravenous (IV) once every 21 days
219103677|NCT03120689|OTHER|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
219103678|NCT04842214|BEHAVIORAL|Oncological Rehabilitation|Multidimensional rehabilitation
219103679|NCT04665024|PROCEDURE|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
219103680|NCT04665024|PROCEDURE|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
219103681|NCT04645784|OTHER|Supporting Student-Athletes Mental Wellness|The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
219103682|NCT01416233|PROCEDURE|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
219103683|NCT01575743|BEHAVIORAL|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
219103684|NCT03373864|PROCEDURE|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
219103685|NCT03373864|PROCEDURE|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
219103686|NCT01715610|DRUG|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
219103687|NCT01715610|DRUG|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
219103688|NCT01715610|DRUG|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
219103689|NCT05826015|DRUG|Paclitaxel|IV over 3 hours
219103690|NCT05826015|DRUG|Batiraxcept|IV over 60 minutes
219103691|NCT04909580|BEHAVIORAL|Decision coaching with a patient decision aid|Decision coaching guided by the Ottawa Decision Support Framework
219691073|NCT01405560|DRUG|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
219691074|NCT01405560|BIOLOGICAL|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
219691075|NCT01405560|DRUG|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
219691076|NCT04887363|BEHAVIORAL|Core exercise|Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
219691077|NCT04887363|BEHAVIORAL|Tai Chi exercise|Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
219691078|NCT03658291|DRUG|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
219691079|NCT03658291|DRUG|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
219691080|NCT03658291|DRUG|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
219691081|NCT00664586|DRUG|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
219691082|NCT02518334|OTHER|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
219691083|NCT03622762|DRUG|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
219691084|NCT03622762|DRUG|Placebo|Placebo capsules, 400 mg twice daily fasting
219691085|NCT05251584|DRUG|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
219691086|NCT05251584|DRUG|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
219691087|NCT02043977|DRUG|propofol injectable emulsion|
219691088|NCT04533178|DEVICE|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
219691089|NCT04533178|OTHER|Resting from all sports activities|Resting from all sports activities
219691090|NCT01607164|BEHAVIORAL|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
219103692|NCT01395654|DRUG|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
219691091|NCT01988207|BEHAVIORAL|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
219691092|NCT01988207|BEHAVIORAL|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
219691093|NCT02452047|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
219691094|NCT02452047|DRUG|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
219691095|NCT02452047|DRUG|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
219691096|NCT02452047|DRUG|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
219691097|NCT02856958|PROCEDURE|Nerve decompression|
219691098|NCT02856958|OTHER|Non-operative|Physical therapy
219691099|NCT04820907|DRUG|HCP1904-1|Take it once daily for 8 weeks orally.
219691100|NCT04820907|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
219691101|NCT03830021|BEHAVIORAL|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
219691102|NCT03830021|BEHAVIORAL|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
219691103|NCT00308867|PROCEDURE|Photodynamic Therapy|
219103693|NCT01407211|DIETARY_SUPPLEMENT|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
219103694|NCT02716038|DRUG|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
219103695|NCT02716038|DRUG|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
219103696|NCT02716038|DRUG|Nab-paclitaxel|Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
219103697|NCT05254639|DRUG|DONEPEZIL|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
219691104|NCT00308867|PROCEDURE|Cryosurgery|
219691105|NCT02908334|DRUG|Sertraline|400 mg/day sertraline
219691106|NCT00288912|BEHAVIORAL|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
219691107|NCT00288912|BEHAVIORAL|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
219691108|NCT02410759|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
219691109|NCT02410759|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
219691110|NCT04751617|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
219103698|NCT05254639|DRUG|PLACEBO|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
219103699|NCT03760263|DRUG|Tacrolimus|Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
219103700|NCT03573908|DRUG|Linaclotide|Oral capsule
219691111|NCT06120725|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219691112|NCT06120725|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219691113|NCT05672563|DRUG|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
219691114|NCT01740232|PROCEDURE|trephination|Artroscopic meniskal repair with trephination.
219691115|NCT01740232|PROCEDURE|Normal meniscal repair|Artroscopic meniskal repair without trephination.
219691116|NCT03657069|DEVICE|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
219691117|NCT03657069|OTHER|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
219691118|NCT00000732|DRUG|Sulfamethoxazole-Trimethoprim|
219691119|NCT00000732|DRUG|Zidovudine|
219691120|NCT05300386|DRUG|Escitalopram|We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
219691121|NCT04900454|BIOLOGICAL|DVX201|Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
219103701|NCT03573908|DRUG|Placebo|Matching placebo oral capsule
219691122|NCT05319548|OTHER|Purple-Red Carrot Juice|Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins
219103702|NCT02630095|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
219103703|NCT02630095|DEVICE|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
219103704|NCT01222143|DRUG|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
219103705|NCT01222143|DRUG|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10."
219103706|NCT04596033|BIOLOGICAL|GEN-011|Personalized neoantigen adoptive cell therapy (ACT)
219103707|NCT04596033|DRUG|IL-2|Cytokine
219103708|NCT04596033|DRUG|Fludarabine|Lymphodepletion drug
219103709|NCT04596033|DRUG|Cyclophosphamide|Lymphodepletion drug
219691123|NCT05319548|OTHER|Red Carrot Juice|Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..
219691124|NCT05319548|OTHER|Purple Carrot Juice|Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
219103710|NCT04006925|DRUG|Sodium Oxybate|"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
219691125|NCT01112319|DEVICE|Elf care|elfcare device
219691126|NCT01112319|OTHER|control group|regular physiotherapy treatment
219691127|NCT01105520|PROCEDURE|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
219691128|NCT02789501|DEVICE|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
219691129|NCT02789501|DEVICE|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
219691130|NCT00217282|DRUG|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
219103711|NCT04006925|OTHER|Placebo|Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
219103712|NCT04816019|BIOLOGICAL|ChAdOx1 nCov-19|A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
219103713|NCT06480214|PROCEDURE|endoscopic spine surgery|we would administer the endoscopic spine surgery to patients with Lumbar spinal stenosis and Lumbar disc herniation.
219103714|NCT05586464|DRUG|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
219103715|NCT05586464|DRUG|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
219103716|NCT01551004|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
219103717|NCT01551004|OTHER|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
219103718|NCT01874314|DRUG|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
219103719|NCT01874314|OTHER|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
219103720|NCT01874314|DRUG|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
219103721|NCT01525134|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
219103722|NCT01525134|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
219103723|NCT04549311|DRUG|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
219103724|NCT04549311|DRUG|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
219103725|NCT05249062|DEVICE|SHAPES app|Participants will be asked to use the app and connected devices daily for 3 months.
219103726|NCT01755143|OTHER|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
219103727|NCT01755143|DEVICE|Pacemaker System|
219103728|NCT05796180|BEHAVIORAL|Behavioral: sexual health counseling based on the BETTER model|"The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
219103729|NCT04963361|OTHER|patients were exposed to fear of movement|Patients completed the questionnaires independently
219103730|NCT04963361|OTHER|patients were not exposed to fear of movement|Patients completed the questionnaires independently
219103731|NCT01706302|OTHER|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
219103732|NCT04655885|BEHAVIORAL|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
219103733|NCT04655885|BEHAVIORAL|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
219103734|NCT04466215|DRUG|Miricorilant|900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
219103735|NCT04466215|DRUG|Placebo oral tablet|Six placebo tablets taken orally once daily for two weeks
219691131|NCT03388424|DIAGNOSTIC_TEST|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
219691132|NCT01607593|DRUG|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
219691133|NCT04126434|DEVICE|mask|facemask
219691134|NCT00003146|DRUG|busulfan|
219691135|NCT00003146|DRUG|melphalan|
219691136|NCT00003146|DRUG|thiotepa|
219691137|NCT00003146|PROCEDURE|bone marrow transplantation|
219691138|NCT00003146|PROCEDURE|peripheral blood stem cell transplantation|
219691139|NCT03899727|DEVICE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
219691140|NCT03495063|DIETARY_SUPPLEMENT|Natural Caffeine|Consumption of 400mg of natural caffeine
219103736|NCT00134602|BEHAVIORAL|Needs assessment followed by tailored intervention|
219691141|NCT03495063|DIETARY_SUPPLEMENT|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
219691142|NCT00145886|DRUG|rhPTH|Subjects will be treated with rhPTH for 12 months.
219691143|NCT03540693|PROCEDURE|RYGB|RYGB-weight loss surgery
219103737|NCT05154123|DRUG|Drug: AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered."
219103738|NCT05154123|DRUG|AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)"
219103739|NCT02669095|DEVICE|Investigational Contact Lenses (Test)|
219691144|NCT03540693|PROCEDURE|SG|SG- weight loss surgery
219691145|NCT03540693|PROCEDURE|LAGB|LAGB- weight loss surgery
219103740|NCT02669095|DEVICE|Marketed Contact Lenses (Control)|
219103741|NCT00832195|DEVICE|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
219103742|NCT00832195|DEVICE|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
219103743|NCT02949401|BEHAVIORAL|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
219103744|NCT04994496|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
219103745|NCT04994496|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
219103746|NCT01623648|OTHER|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
219691146|NCT04630678|OTHER|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
219691147|NCT04630678|OTHER|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
219691148|NCT04630678|OTHER|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
219691149|NCT02799927|PROCEDURE|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
219691150|NCT02799927|PROCEDURE|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
219103747|NCT01623648|OTHER|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
219103748|NCT01623648|OTHER|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
219103749|NCT04263103|OTHER|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
219103750|NCT04212364|BEHAVIORAL|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
219103751|NCT04212364|DRUG|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
219103752|NCT04345458|DRUG|prefilled liquid etanercept(Yisaipu)|
219103753|NCT04345458|DRUG|lyophilized etanercept powder(Yisaipu)|
219103754|NCT01292070|BIOLOGICAL|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm."
219103755|NCT01292070|BIOLOGICAL|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
219103756|NCT01292070|BIOLOGICAL|Positive Control - Histamine Prick|1.0 mg/mL
219103757|NCT01292070|BIOLOGICAL|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
219103758|NCT04804995|OTHER|There is no intervention.|No intervention.
219103759|NCT03399162|BEHAVIORAL|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
219691151|NCT03168373|PROCEDURE|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
219691152|NCT00249704|DRUG|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
219691153|NCT00249704|PROCEDURE|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
219691154|NCT00249704|PROCEDURE|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
219691155|NCT00249704|DRUG|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
219691156|NCT05064254|OTHER|Treatment as usual (TAU)|TAU may include self-help methods, physician visit, provision of resources etc.
219691157|NCT05064254|OTHER|Mindful Adaptive Practice in Pregnancy Therapy|MAP teaches: a) recognition of personal maladaptive/ distressing patterns driving anxiety; b) how to relate differently; and c) cultivation of more adaptive ways of dealing with anxiety and learning how to effectively control it rapidly which allows re-engagement with life in more flexible ways.
219103760|NCT03399162|BEHAVIORAL|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
219103761|NCT06437093|OTHER|TEACHING RELACTATION TECHNIQUES|"In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally."
219103762|NCT02778126|DRUG|[¹⁴C]Prexasertib|Administered IV Infusion
219103763|NCT02778126|DRUG|Prexasertib|Administered IV Infusion
219103764|NCT03430141|OTHER|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
219103765|NCT02871830|BEHAVIORAL|Physical Activity|15 mins physical activity per day within the school setting.
219103766|NCT01555164|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
219103767|NCT01555164|DRUG|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
219103768|NCT01555164|DRUG|Metformin|Metformin tablet(s) administered orally once daily
219103769|NCT01555164|DRUG|Placebo to match metformin|Placebo to match metformin for the duration of the study
219103770|NCT01555164|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
219103771|NCT01555164|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
219103772|NCT03290612|DIETARY_SUPPLEMENT|Vitamin C|1.5g Ascorbic Acid
219103773|NCT03290612|OTHER|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
219691158|NCT01350635|BIOLOGICAL|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
219691159|NCT05105074|DRUG|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
219691160|NCT05105074|DRUG|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
219691161|NCT03472131|PROCEDURE|Unilateral Posterolateral Approach and Debridement|
219103774|NCT04547270|OTHER|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
219691162|NCT03472131|OTHER|Titanium cage insertion supplemented by screw fixation|
219103775|NCT00352898|BIOLOGICAL|MeMuRu-OKA (study vac)|
219103776|NCT00352898|BIOLOGICAL|MMR, Varicella vacc (control)|
219103777|NCT01424475|GENETIC|Healthy|Healthy Volunteers
219103778|NCT01424475|GENETIC|PKD Patients|PKS Patients
219103779|NCT01655602|PROCEDURE|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
219103780|NCT01655602|PROCEDURE|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
219103781|NCT01655602|PROCEDURE|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
219691163|NCT01861067|PROCEDURE|LESS-TLH|
219691164|NCT01861067|PROCEDURE|LESS-LAVH|
219103782|NCT01204268|PROCEDURE|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
219691165|NCT03588273|DRUG|Amoxil 500 MG Oral Capsule|
219691166|NCT04835545|OTHER|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
219691167|NCT06422728|OTHER|Unified Protocol for Anxiety Disorders|"The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later."
219103783|NCT01204268|PROCEDURE|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
219103784|NCT05787158|OTHER|Muscle energy techniques|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
219103785|NCT00926003|BEHAVIORAL|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
219103786|NCT00926003|BEHAVIORAL|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
219103787|NCT01589562|DRUG|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
219103788|NCT01589562|DRUG|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
219103789|NCT01986361|DRUG|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
219103790|NCT01986361|DRUG|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
219103791|NCT02801188|DRUG|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
219103792|NCT02801188|DRUG|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
219691168|NCT06422728|OTHER|Client-centered Supportive Therapy|Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
219103793|NCT00002760|DRUG|ketoconazole|400 mg PO tid for as long as treatment is effective
219103794|NCT00002760|DRUG|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
219103795|NCT00002760|OTHER|Withdrawal of antiandrogen therapy|no drugs given
219103796|NCT02109198|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
219103797|NCT02109198|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
219103798|NCT06014138|DRUG|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
219103799|NCT06014138|DRUG|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
219103800|NCT06017830|DEVICE|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
219103801|NCT00202774|DRUG|(capecitabine, oxaliplatin, 5-fluorouracil)|
219103802|NCT02260076|DRUG|PEG 400|
219103803|NCT02260076|DRUG|Placebo|
219103804|NCT03791502|OTHER|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
219103805|NCT02408237|DEVICE|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
219691169|NCT04414007|BEHAVIORAL|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
219691170|NCT04414007|BEHAVIORAL|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
219691171|NCT02815306|DEVICE|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
219691172|NCT01682824|OTHER|Nutritional Assessment|Complete dietary intake assessment
219691173|NCT01682824|OTHER|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
219691174|NCT01682824|OTHER|Questionnaire Administration|Complete EQ-EMA questionnaire
219691175|NCT02091232|BIOLOGICAL|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
219691176|NCT03468842|BIOLOGICAL|Probiotic|Already described
219691177|NCT03468842|BIOLOGICAL|Placebo|Placebo
219691178|NCT04654013|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
219691179|NCT06521177|OTHER|Hand Serum and Glove|Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
219691180|NCT06360861|BIOLOGICAL|Allogenic placenta derived mesenchymal stem cells|Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
219691181|NCT00003012|DRUG|CMF regimen|
219103806|NCT02408237|DEVICE|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
219691182|NCT00003012|DRUG|cyclophosphamide|
219691183|NCT00003012|DRUG|epirubicin hydrochloride|
219103807|NCT02408237|DEVICE|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
219691184|NCT00003012|DRUG|fluorouracil|
219691185|NCT00003012|DRUG|methotrexate|
219691186|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 125 mg|One capsule before breakfast for 84 days
219691187|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 250 mg|One capsule before breakfast for 84 days
219691188|NCT04733924|OTHER|Microcrystalline Cellulose|One capsule before breakfast for 84 days
219691189|NCT00076388|DRUG|Gefitinib|
219691190|NCT00076388|DRUG|Docetaxel|
219691191|NCT02935569|DEVICE|Compression HeadBand|"* commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
219691192|NCT01991353|PROCEDURE|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
219691193|NCT01991353|PROCEDURE|Without PRP|Standard of care meniscal repair without augmentation.
219691194|NCT05081388|DRUG|REGN14256|Sub-cutaneous (SC) single dose
219691195|NCT05081388|DRUG|imdevimab|SC single dose
219691196|NCT05081388|DRUG|casirivimab + imdevimab|SC single dose
219691197|NCT05081388|DRUG|Placebo|SC single dose
219691198|NCT03928457|OTHER|Parental questionnaire|Parental questionnaire on pregnancy history and environmental exposure
219691199|NCT03928457|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
219691200|NCT03928457|OTHER|Follow-up of daily infants environmental and clinical parameters|Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures…)
219691201|NCT03928457|OTHER|Nocturnal polysomnography|Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
219691202|NCT03928457|DIAGNOSTIC_TEST|cerebral hemodynamics|cerebral hemodynamics (near infrared spectroscopy)
219691203|NCT03928457|DIAGNOSTIC_TEST|activity of the autonomic nervous system|activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
219103808|NCT02408237|DEVICE|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
219103809|NCT05720234|DRUG|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
219103810|NCT02430363|DRUG|MK - 3475|Administered Intravenously
219103811|NCT02430363|BIOLOGICAL|Suppressor of the PI3K/Akt pathways|Capsules orally with food
219103812|NCT05166525|OTHER|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
219103813|NCT06129201|OTHER|Tongue image|Using intelligent imaging devices to collect subject tongue images
219103814|NCT03340558|BIOLOGICAL|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
219103815|NCT03340558|DRUG|Cobimetinib|MEK inhibitor
219103816|NCT00406224|DRUG|breathing 100% oxygen|
219103817|NCT00374660|DRUG|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
219103818|NCT00374660|DRUG|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
219103819|NCT04576364|DRUG|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
219103820|NCT04576364|DRUG|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
219103821|NCT03253016|DIAGNOSTIC_TEST|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
219103822|NCT02477280|DRUG|Methylphenidate|Cross-over
219103823|NCT02477280|DRUG|Placebo|Medikinet
219103824|NCT06183814|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
219103825|NCT06250647|OTHER|vitamin K diet|500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
219103826|NCT04840277|DEVICE|Remote hearing aid adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
219691204|NCT03348605|DEVICE|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
219691205|NCT05989555|OTHER|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
219103827|NCT01709305|DRUG|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
219103828|NCT01709305|DRUG|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
219103829|NCT01709305|DRUG|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
219103830|NCT01709305|DRUG|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
219103831|NCT01709305|DRUG|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
219103832|NCT01709305|DRUG|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
219103833|NCT02281526|DRUG|BIA 2-093|
219103834|NCT02255396|OTHER|ESTRADIOL|
219691206|NCT04817306|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
219691207|NCT02182401|DRUG|BI 207127 NA|Days 3-8 and days 25-30
219691208|NCT02182401|DRUG|BI 201335 NA|Days 15-30
219691209|NCT02182401|DRUG|Midazolam|Days 1, 7, 23 and 29
219103835|NCT01396317|DRUG|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
219103836|NCT01736501|OTHER|Genetics education at baseline|
219103837|NCT01736501|OTHER|Hypothetical genomic scenarios at follow-up|
219103838|NCT05171413|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
219103839|NCT03909178|PROCEDURE|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
219103840|NCT03909178|PROCEDURE|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
219103841|NCT00813137|DRUG|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
219103842|NCT05958498|COMBINATION_PRODUCT|injectable platelet rich fibrin and microosteoperforation|i-PRF which second product of blood versus mops which is surgical procedure
219103843|NCT02294136|BEHAVIORAL|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
219691210|NCT02182401|DRUG|Tolbutamide|Days 1, 7, 23 and 29
219103844|NCT02294136|BEHAVIORAL|Educational Control|Attention Control
219103845|NCT05904223|DIAGNOSTIC_TEST|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
219103846|NCT00077311|BIOLOGICAL|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL
219103847|NCT00077311|BIOLOGICAL|pegfilgrastim|6 mg sub Q day 2 of each cycle
219103848|NCT00077311|DRUG|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
219103849|NCT00077311|DRUG|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
219103850|NCT00077311|DRUG|BNP7787|40 g IV over 30 min Day 1 of each cycle
219103851|NCT00267696|DRUG|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
219103852|NCT00267696|DRUG|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
219103853|NCT00267696|DRUG|Carboplatin|
219103854|NCT03178955|DRUG|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
219103855|NCT04296474|DRUG|ALK Alutard 5-grasses and birch|Intralymphatic injections
219103856|NCT04296474|DRUG|ALK Diluent|intralymphatic injections
219103857|NCT02333760|GENETIC|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
219103858|NCT01001949|DIETARY_SUPPLEMENT|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
219103859|NCT01001949|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
219103860|NCT01362556|DRUG|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1"
219103861|NCT01362556|DRUG|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1"
219103862|NCT06014736|DRUG|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
219103863|NCT06014736|DRUG|Placebo|Placebo contains only excipients.
219103864|NCT00171873|DRUG|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
219103865|NCT00171873|DRUG|Placebo|Sodium chloride intramuscularly every 28 days
219103866|NCT03697980|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
219103867|NCT00305383|DRUG|Viramidine|
219103868|NCT00305383|DRUG|Peginterferon alfa-2b|
219103869|NCT02440984|PROCEDURE|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
219103870|NCT04496141|DIAGNOSTIC_TEST|SARS-CoV-2 antibody immunoassays|Different commercial SARS-CoV-2 antibody immunoassays
219103871|NCT06351644|DRUG|ON 123300|"dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study."
219103872|NCT06351644|DRUG|Dexamethasone|Weekly oral dexamethasone 20mg
219103873|NCT05104502|BEHAVIORAL|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
219691211|NCT03384589|BIOLOGICAL|PCV13|Vaccine against pneumococcal disease
219691212|NCT05138146|DRUG|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
219691213|NCT05138146|DRUG|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
219103874|NCT05821413|BEHAVIORAL|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
219103875|NCT05821413|BEHAVIORAL|Standard of Care|Participants can use standard case management and other services offered by the clinic.
219103876|NCT00946335|DRUG|veliparib|Given PO
219103877|NCT00946335|DRUG|temozolomide|Given PO
219103878|NCT00946335|OTHER|pharmacological study|Correlative studies
219103879|NCT00946335|OTHER|laboratory biomarker analysis|Correlative studies
219103880|NCT03696030|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
219103881|NCT04352478|DIAGNOSTIC_TEST|Histopathological result|Incidental gallbladder cancer and other pathology
219103882|NCT06423378|DEVICE|OSSIOfiber® Trimmable Fixation Nails|"Subjects will be treated with cannulated nails before or after arthroscopic management of their concomitant pathology at the discretion of the investigator. Technique described below. Following nail placement, tissue layers will be closed in standard fashion.~1. Preop MRI views used to estimate the proper depth \& location of nail placement on the femur and/or tibia~2. Exposure is gained to medial tibia~3. 1.4 mm K-Wire is placed through medial tibia parallel to the articular joint surface \~ 1 cm distal to the articular joint line~4. A depth gauge is placed over K-Wire to determine required length of cannulated nail~5. A 4.0 mm cannulated drill bit used over K-Wire to prepare the pilot hole~6. Tamp is used to insert pre-trimmed 4.0 mm cannulated nail into the pilot hole and K-Wire is subsequently removed~7. Intraop fluoroscopy can confirm adequate nail placement prior to removing K-wire~8. Repeat steps for additional nails"
219103883|NCT05485415|BEHAVIORAL|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
219103884|NCT05485415|BEHAVIORAL|Control|General sleep advice
219103885|NCT02178644|DRUG|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
219103886|NCT01381419|DRUG|GSK1144814|Single dose.
219103887|NCT01381419|DRUG|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
219103888|NCT01381419|DRUG|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
219103889|NCT03408743|BEHAVIORAL|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
219103890|NCT03408743|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103891|NCT03408743|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219103892|NCT03408743|BEHAVIORAL|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103893|NCT03408743|BEHAVIORAL|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219103894|NCT03408743|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219691214|NCT02059239|DRUG|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
219691215|NCT02059239|DRUG|Carmustine|300 mg/m2 on Day -6
219691216|NCT02059239|DRUG|Etoposide|100 mg/m2 on days -5 to -2
219691217|NCT02059239|DRUG|Melphalan|140mg/m2 on Day -1
219691218|NCT02059239|DRUG|Cytarabine|200 mg/m2 on days -5 to -2
219691219|NCT02059239|DRUG|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
219691220|NCT02059239|BIOLOGICAL|Autologous Stem Cell Transplantation|
219103895|NCT03408743|BEHAVIORAL|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103896|NCT03408743|BEHAVIORAL|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103897|NCT03408743|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
219103898|NCT03408743|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219691221|NCT02059239|BIOLOGICAL|Allogeneic Stem Cell Transplantation|
219691222|NCT02059239|DRUG|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
219691223|NCT05998681|OTHER|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages|"Participants in the experimental group were provided with education on Breastfeeding and Basic Maternal-Neonatal Care at the hospital and mobile messages were sent with the same content as education program for 6 weeks after discharge."
219103899|NCT03408743|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219103900|NCT03408743|BEHAVIORAL|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103901|NCT03408743|BEHAVIORAL|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219103902|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103903|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219691224|NCT05567081|DRUG|Triamcinolone Acetonide 40mg/mL|Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
219103904|NCT03408743|BEHAVIORAL|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103905|NCT03408743|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
219103906|NCT03408743|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103907|NCT03408743|BEHAVIORAL|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219103908|NCT03408743|BEHAVIORAL|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219691225|NCT05567081|DRUG|PRP|Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
219691226|NCT01319565|DRUG|Aldesleukin|Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
219691227|NCT01319565|DRUG|Cyclophosphamide|Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
219103909|NCT03408743|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219103910|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103911|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219691228|NCT01319565|DRUG|Fludarabine|Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
219691229|NCT01319565|BIOLOGICAL|Young TIL|Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
219691230|NCT01319565|RADIATION|Total Body Irradiation (TBI)|Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
219691231|NCT01969526|OTHER|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
219691232|NCT02447419|DRUG|Gefitinib|Gefitinib 250mg will be administered orally daily
219103912|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219691233|NCT05793411|OTHER|Questionnaire risk behaviors in adolescents with chronic diseases|Questionnaire risk behaviors in adolescents with chronic diseases
219691234|NCT02359461|DEVICE|Combination pulsatile Stendo3|
219691235|NCT06306976|PROCEDURE|Elective Midline Laparotomy|"Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio."
219691236|NCT06306976|PROCEDURE|Imaging: Ultrasound|"Ultrasound procedure will involve the following steps:~1\. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest."
219691237|NCT06306976|OTHER|Tensiometry|"For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed."
219691238|NCT04092738|BEHAVIORAL|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
219691239|NCT00125918|DRUG|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
219691240|NCT00125918|DRUG|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
219691241|NCT00125918|DRUG|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
219103913|NCT03408743|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
219103914|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103915|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219103916|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219691242|NCT00125918|DRUG|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
219691243|NCT00125918|DRUG|placebo|placebo tablet taken by mouth once a day for 16 weeks
219691244|NCT02528474|DEVICE|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
219691245|NCT02528474|DEVICE|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
219691246|NCT03514550|DRUG|Propofol|Propofol will be used for anesthesia during surgery
219691247|NCT03514550|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
219691248|NCT03514550|PROCEDURE|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
219103917|NCT03408743|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
219103918|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103919|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
219691249|NCT00802711|RADIATION|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
219691250|NCT00802711|RADIATION|brachytherapy|Given twice a day for 10 fractions
219103920|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
219103921|NCT02490891|DEVICE|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
219224147|NCT06951295|PROCEDURE|Thyroidectomy operation is a surgical removal of thyroid, injury of recurrent laryngeal nerve one of common complications of thyroidectomy Which can affect Vocal cords mobility|Assessment of vocal cords mobility at thyroidectomy operation is very important and life saving for patient, during thyroidectomy one of common complications, injury of recurrent laryngeal nerve unilateral or bilateral, unilateral injury may complicate to dysphonia, bilateral injury may complicate to dyspnea
219103922|NCT00234156|PROCEDURE|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
219103923|NCT03221660|DEVICE|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
219103924|NCT03104647|OTHER|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
219103925|NCT06527547|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Treatment using the Huatuo electronic acupuncture device (model SDZ-IIB) with electrodes placed on the auricular points related to the heart and kidney. Pulsed wave type is sparse-dense wave, with a frequency of 20Hz and intensity set to the highest level tolerable without pain. Patients will perform self-treatment at home for 30 minutes, twice daily, for 5 days a week over 4 weeks.
219103926|NCT06527547|DEVICE|Sham Stimulation|Treatment using the same Huatuo electronic acupuncture device with electrodes placed on different ear points (over the ear helix). The device settings (pulse type, frequency, intensity) are the same as the experimental group but do not correspond to traditional acupuncture points. Patients will also perform self-treatment at home as per the same schedule as the experimental group.
219103927|NCT05371509|DEVICE|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
219103928|NCT05371509|OTHER|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
219103929|NCT05840861|DRUG|Vortioxetine|All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
219224148|NCT02304809|DRUG|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
219224149|NCT05716100|DRUG|XEN1101|XEN1101 Capsules
219224150|NCT05716100|DRUG|Placebo|Placebo Capsules
219224151|NCT03760913|DRUG|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
219224152|NCT03760913|DRUG|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
219691251|NCT00523913|DRUG|rosiglitazone|
219691252|NCT02219685|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219224153|NCT03760913|OTHER|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
219224154|NCT03760913|OTHER|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
219224155|NCT06079242|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
219224156|NCT03813472|DEVICE|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
219224157|NCT06075017|PROCEDURE|dental implant placement|Comparing the amount and type of biofilm on zirconia vs. titanium implants
219691253|NCT02219685|DRUG|Placebo|Tablet administered orally once daily
219691254|NCT00001989|DRUG|Trichosanthin|
219691255|NCT00001989|DRUG|Zidovudine|
219691256|NCT01909700|DEVICE|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
219691257|NCT02551458|OTHER|Systematic surgery|
219691258|NCT02551458|OTHER|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
219691259|NCT06211400|OTHER|Whole body vibration exercise|6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
219691260|NCT00137553|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
219691261|NCT03602105|BEHAVIORAL|Exercise|Exercises in group and/or individually
219691262|NCT04276441|DEVICE|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
219691263|NCT04276441|DEVICE|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
219691264|NCT06641102|OTHER|Self-Guided Program (Tier 1)|"The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions)."
219691265|NCT06641102|OTHER|Coach Assisted Program (Tier 3)|"The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session."
219103930|NCT05840861|DRUG|Quetiapine|All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
219103931|NCT01091402|PROCEDURE|autologous serum skin test, serum IL-18|
219103932|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
219103933|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
219103934|NCT06926582|DRUG|HS-10374 6mg tablets|Administered orally QD for 12 weeks
219103935|NCT06926582|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
219103936|NCT06924931|BEHAVIORAL|LCME training programme|A LCME training program was conducted from March 2017 to October 2017 in the CDR, inspired by the National English Laparoscopic Colorectal Surgery Course. All certified colorectal surgeons from three public hospitals in the CDR were invited. The training programme was conducted over 2-3 days, occurring twice within an 8-month period.
219103937|NCT06926465|OTHER|Conventional treatment|conventional treatment including (hot pack, Stretching of the pectoralis minor, Resisted shoulder external rotation , Prone Extension ,Prone Horizontal Abduction with External Rotation ,Side-lying Forward Flexion ,Posterior capsule stretch (sleeper stretch)
219103938|NCT06926465|OTHER|Trunk integrated kinetic chain exercises|"This group will receive conventional treatment plus four trunk integrated kinetic chain exercises:~1. Quadruped shoulder flexion~2. Shoulder flexion with trunk rotation~3. Shoulder external rotation from shoulder at 45° internal rotation and the elbow at 90° flexion with trunk rotation~4. Shoulder external rotation from shoulder at 90° abduction and the elbow at 90° flexion while with trunk rotation"
219103939|NCT06926101|DEVICE|dental implants|dental implant placement by full or partial thickness flap
219103940|NCT06925763|DRUG|Nitroglycerin|cardiac disease treatment drug
219103941|NCT06926504|BEHAVIORAL|The care process S-TeamBirth|The intervention consists of the entire care team conducting huddles together with the birthing woman and her partner to plan the care, using the S-TeamBirth whiteboard to communicate and visualize decisions
219103942|NCT06926504|BEHAVIORAL|S-TeamBirth|Involving the entire care team including the woman and her partner in planning the care using team huddles and the S-TeamBirth whiteboard
219103943|NCT06926127|GENETIC|Whole Exome Sequencing (WES)|Blood samples, buccal swabs, and pathological tissue samples (skin/muscle) will be collected, and subsequently, DNA extracted from those tissues will be used for genomic analysis using Whole Exome Sequencing. The sample will follow the diagnostic pipeline already established inside the hospital. Moreover, the remaning aliquots of DNA extracted from the tissue (peripheral blood or tissue specimen) will be sent by the Genomics core facility to the Biobank for storage upon analysis completion.
219691266|NCT06641102|OTHER|Standard of Care (SOC)|SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
219691267|NCT05669118|PROCEDURE|Tooth Autotransplantation|Place another tooth in the place of the newly extracted tooth in the same patient.
219691268|NCT05669118|PROCEDURE|Immediate implant|Place a dental implant immediately after tooth extraction.
219691269|NCT02127658|OTHER|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
219103944|NCT06925841|OTHER|Experimental|Two pre-selected mother-baby themed images to be used in the study will be printed separately on A4-sized papers (21.0 cm × 29.7 cm). Each participant will receive a new image every day.At the beginning of the study, each participant will be provided with a set of 12 colored pencils (orange, red, pink, purple, light blue, dark blue, light green, dark green, light brown, dark brown, black, and white). Colored pencils have been preferred over soft-tipped pencils due to their requirement for greater physical effort and their ability to facilitate a clearer expression of emotions. Participants in the intervention group will receive routine care and will engage in a 30-minute daily coloring activity.
219103945|NCT06925841|OTHER|routine care|The control group will receive routine care provided by the nurse.
219103946|NCT02073097|DRUG|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
219103947|NCT02073097|BIOLOGICAL|Rituximab|Given IV (375mg/m\^2)
219103948|NCT02073097|DRUG|Cyclophosphamide|Given IV (750mg/m\^2)
219103949|NCT02073097|DRUG|Doxorubicin hydrochloride|Given IV (50mg/m\^2)
219691270|NCT02127658|OTHER|Sodium Hypochlorite|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
219691271|NCT02127658|DRUG|Mupirocin ointment|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
219691272|NCT03471052|PROCEDURE|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
219691273|NCT02585869|DRUG|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
219691274|NCT02585869|DRUG|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
219691275|NCT02585869|DRUG|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
219691276|NCT02585869|DRUG|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
219691277|NCT02585869|DRUG|Placebo|Blinded capsule and tablets, once daily, 84 days
219103950|NCT02073097|DRUG|Vincristine sulfate|Given IV (1.4mg/m\^2)
219103951|NCT02073097|DRUG|Prednisone|Given PO (100mg)
219103952|NCT02073097|DRUG|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
219103953|NCT02073097|DRUG|Acyclovir|PO (400mg)
219103954|NCT05172206|OTHER|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
219103955|NCT05172206|OTHER|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
219224158|NCT01515241|DRUG|CER-001|Weekly injection
219224159|NCT03363984|DRUG|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
219103956|NCT06899672|OTHER|Alginate mixed with distilled water|Alginate will be mixed with distilled water only, without any disinfectant additive, to serve as the control for comparison
219103957|NCT06899672|OTHER|0.2% Chlorhexidine + Alginate|Alginate will be mixed with 0.2% Chlorhexidine solution to evaluate its effect on the linear dimensional stability of alginate impressions
219103958|NCT06899672|OTHER|1% Chitosan + Alginate|Alginate will be mixed with 1% Chitosan solution to assess its influence on the linear dimensional stability of alginate impressions
219103959|NCT06899672|OTHER|0.2% Silver Nitrate + Alginate|Alginate will be mixed with 0.2% Silver Nitrate solution to determine its effect on the dimensional stability of alginate impressions
219103960|NCT06899672|OTHER|Green-synthesized Silver Nanoparticles + Alginate|Alginate will be mixed with a solution of green-synthesized Silver Nanoparticles to investigate its effect on the dimensional stability of alginate impressions
219103961|NCT06899672|OTHER|15% Povidone-Iodine + Alginate|Alginate will be mixed with 15% Povidone-Iodine solution to analyze its influence on the dimensional stability of alginate impressions
219103962|NCT06900517|DIETARY_SUPPLEMENT|Salvia officinalis Gel|From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).
219103963|NCT06899581|DIETARY_SUPPLEMENT|Enteral nutrition Food Derived Ingredient|"For this case-control analysis, children with AML will be matched to cancer-free controls for age, sex and race. No antibiotics for 6 months. In collaboration with Professor Konstantinos Gerasimidis Professor of Clinical Nutrition School of Medicine. University of Glasgow. Healthy children have been recruited from the community via poster and social media advertisement. The whole bowel movement was collected in a disposable stool collection kit and stored in a benchtop freezer provided to study participants. Researcher defrosted the sample, homogenised it with mechanical kneading and aliquots were stored in -80.~Cases: children with AML: Stool specimens will be obtained at three predefined time points for microbiome analysis: baseline start of AML treatment (within 2 weeks of admission); after induction chemotherapy initiation (6-8weeks); recovery phase 6-8 months."
219103964|NCT06899659|DEVICE|JuggerStitch™ Meniscal Repair Device|Participants assigned to investigational group undergoing arthroscopy meniscal repair with JuggerStitch™ Meniscal Repair Device.
219224160|NCT03363984|DRUG|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
219691278|NCT03738930|BEHAVIORAL|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
219224161|NCT01979276|DRUG|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
219224162|NCT01979276|DRUG|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
219224163|NCT01979276|DRUG|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
219224164|NCT02546531|BIOLOGICAL|Defactinib|
219691279|NCT03540264|DEVICE|Clearfil Majesty TM|Tooth wear - composite resin
219103965|NCT06899659|DEVICE|Fast-Fix 360 Meniscal Repair System|Participants assigned to control group undergoing arthroscopy meniscal repair with the Fast-Fix 360 Meniscal Repair System.
219103966|NCT06900829|BEHAVIORAL|HIV team implementation|"A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on:~* audit and feedback (reminding health care professionals to test for hiv)~* stigma reduction (raising awareness on existing hiv stigma towards hiv)~* education (increasing knowledge on hiv among health care professionals)~* linkage to prevention and care (improving pathways for hiv care and prevention)"
219103967|NCT06763107|PROCEDURE|Athletic Shoulder (ASH) and Inverse Athletic Shoulder (IASH) Tests|Participants perform the Athletic Shoulder (ASH) test and Inverse Athletic Shoulder (IASH) test to measure maximal isometric shoulder strength in three positions (180º, 135º, 90º) during two separate sessions. Data is used to assess test reliability and validity for high-performance swimmers.
219103968|NCT06925256|DIAGNOSTIC_TEST|nerve conduction study|median ulnar and radial motor- sensory nerve conduction studies will be performed.
219103969|NCT01438788|OTHER|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
219103970|NCT06736977|BEHAVIORAL|The Onsite Nurse-Led Education Programme on IPC|"The programme was designed to enhance CCWs' IPC knowledge and attitudes through lectures, interactive discussions, information sharing, and Q\&A sessions. It also aims to improve their IPC practices and self-efficacy through demonstrations, role-playing exercises, and a work assignment focused on IPC self-monitoring.~The programme includes five educational sessions totalling 12 hours, along with one session for work assignment on daily self-monitoring of IPC practices over five days. The educational sessions cover the following topics:~1. General concepts of infectious diseases~2. Vaccination~3. Standard precautions: The use of personal protective equipment, environmental cleaning and disinfection, handling food and feeding, and waste management~4. Standard precautions: Hand hygiene~5. Common infectious diseases in DCCs and management."
219103971|NCT06736977|BEHAVIORAL|The Online Nurse-Led Education Programme on IPC|The online version of the nurse-led education programme was conducted using an online meeting platform. It includes the same content, learning activities, and materials as the onsite delivery programme, except for the practice stations, which cannot be provided to participants in the online delivery. Additionally, all documents will be available for download via the online platform.
219103972|NCT06907550|DIAGNOSTIC_TEST|The Mitomic Endometriosis Test (MET) blood test for early detection of endometriosis|Patients will complete a questionnaire about their endometriosis symptoms and a sample of blood will be taken prior to their laparoscopy and sent to the laboratory for testing.
219103973|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
219691280|NCT03540264|DEVICE|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
219691281|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
219691282|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
219691283|NCT00445471|BEHAVIORAL|Mifne Approach to PDD|
219103974|NCT05118815|OTHER|Standard abutment|Use a standard abutment
219103975|NCT03491098|DRUG|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
219103976|NCT03491098|DRUG|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
219103977|NCT03491098|DRUG|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
219103978|NCT03073460|OTHER|Ultrasound examination|This exam is performed at 40 weeks gestation
219103979|NCT01628211|PROCEDURE|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
219103980|NCT01628211|PROCEDURE|peritonectomy|for patients with PCI \< 20
219103981|NCT01628211|DRUG|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI \< 20
219224165|NCT02546531|BIOLOGICAL|Pembrolizumab|
219224166|NCT02546531|DRUG|Gemcitabine|
219691284|NCT00445471|BEHAVIORAL|Treatment as usual|
219691285|NCT05670743|DRUG|38% silver diamine fluoride|Topical application of 38% silver diamine fluoride to dental caries lesions
219691286|NCT01867008|DEVICE|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
219103982|NCT01628211|DRUG|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI \< 20
219103983|NCT01628211|DRUG|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI \< 20
219103984|NCT01628211|DRUG|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI \> 20
219103985|NCT02981784|DRUG|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
219691287|NCT01711112|DRUG|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
219691288|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
219691289|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
219103986|NCT02981784|PROCEDURE|allogeneic stem cell transplantation|
219103987|NCT03770013|DRUG|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
219103988|NCT03770013|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
219691290|NCT02517957|DRUG|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
219691291|NCT02517957|DRUG|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
219691292|NCT02517957|DRUG|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
219691293|NCT02517957|DRUG|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
219691294|NCT01534273|DRUG|LY2886721|Administered orally.
219691295|NCT01534273|DRUG|Placebo|Administered orally.
219691296|NCT00745303|PROCEDURE|Tai Chi Cuan|Tai Chi Cuan training for 3 months
219691297|NCT00891280|DRUG|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
219691298|NCT03586050|DEVICE|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
219691299|NCT04912492|BEHAVIORAL|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
219691300|NCT04912492|BEHAVIORAL|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
219103989|NCT03770013|DRUG|clonidine|1ug/kg clonidine
219103990|NCT03770013|DRUG|placebo|add placebo 9normal saline)
219103991|NCT02947464|PROCEDURE|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
219103992|NCT02947464|DEVICE|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
219103993|NCT02769065|DRUG|TAK-071|TAK-071 capsules
219691301|NCT04912492|BEHAVIORAL|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
219691302|NCT04912492|BEHAVIORAL|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
219691303|NCT04912492|BEHAVIORAL|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
219691304|NCT03665662|OTHER|Music|Intra-procedure music through headphones
219691305|NCT04598217|OTHER|anesthesiologist|non-interventional observational
219691306|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
219691307|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
219691308|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
219103994|NCT02769065|DRUG|Donepezil|Donepezil over-encapsulated tablet
219103995|NCT02769065|DRUG|TAK-071 Placebo|TAK-071 placebo-matching capsules
219103996|NCT02769065|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
219103997|NCT06228664|OTHER|foam rolling|Foam Rolling Technique on trapezius and suboccipital muscles.conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range). Patients will be treated 3 times per week for 6 consecutive weeks
219103998|NCT06228664|OTHER|bowen therapy|Bowen Therapy. conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range) will be given to both groups. Patients will be treated 3 times per week for 6 consecutive weeks
219103999|NCT04285437|BEHAVIORAL|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
219691309|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
219691310|NCT01435759|DRUG|Antidepressant + Placebo|oral, once daily for 8 weeks
219691311|NCT03713671|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
219691312|NCT01211145|DRUG|Placebo|Placebo nasal spray
219691313|NCT01211145|DRUG|Zolmitriptan|0.5 mg nasal spray
219691314|NCT01211145|DRUG|Zolmitriptan|2.5 mg nasal spray
219691315|NCT01211145|DRUG|Zolmitriptan|5.0 mg nasal spray
219691316|NCT06237933|BEHAVIORAL|Enhanced intervention via social networking site (SNS)|We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
219691317|NCT06237933|BEHAVIORAL|Standard intervention|In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
219691318|NCT05596071|DRUG|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
219691319|NCT05596071|DRUG|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
219691320|NCT05596071|PROCEDURE|Epidural catheter|Intraoperative and postoperative analgesia
219691321|NCT01643330|GENETIC|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
219691322|NCT01643330|GENETIC|Placebo|Single intracoronary infusion
219691323|NCT00570401|DRUG|dasatinib|
219691324|NCT04650074|DRUG|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
219691325|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
219104000|NCT00519246|DRUG|Saline|Saline 5 ml administrated intravenously
219104001|NCT00519246|DRUG|Opioid|Butorphanol tartrate 1 mg i.v.
219104002|NCT00519246|DRUG|Opioid|Butorphanol Tartrate 2 mg i.v.
219104003|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 50 mg i.v.
219104004|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 100 mg i.v.
219104005|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 10 mg i.v.
219104006|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 20 mg i.v.
219691326|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
219691327|NCT05460546|DRUG|Jincaopian Tablets high dose|Jincaopian Tablets 0.2g tid p.o.
219691328|NCT05460546|DRUG|Jincaopian Tablets low dose|Jincaopian Tablets 0.1g tid p.o.
219691329|NCT05460546|OTHER|Placebo|Placebo tid p.o.
219691330|NCT00023868|DRUG|FOLFIRI regimen|
219691331|NCT00023868|DRUG|cisplatin|
219104007|NCT02831829|OTHER|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
219691332|NCT00023868|DRUG|doxorubicin hydrochloride|
219691333|NCT00023868|DRUG|fluorouracil|
219691334|NCT00023868|DRUG|irinotecan hydrochloride|
219691335|NCT00023868|DRUG|leucovorin calcium|
219691336|NCT00023868|DRUG|mitomycin C|
219691337|NCT03312816|OTHER|cookies enriched with POP|Cookies
219691338|NCT05944185|DRUG|αPD1-MSLN-CAR T Cells|αPD1-MSLN-CAR T Cells
219104008|NCT02831829|OTHER|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
219104009|NCT00552786|DRUG|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
219104010|NCT00552786|DRUG|glucose|1 gm glucose capsule
219104011|NCT00003241|DRUG|phenylacetate|
219104012|NCT02764775|DEVICE|Headpod|Adaptive equipment to assist with active head movements
219104013|NCT02910518|DRUG|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219104014|NCT02910518|DRUG|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219104015|NCT02910518|DRUG|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
219104016|NCT02910518|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219104017|NCT02910518|DRUG|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
219104018|NCT02910518|DRUG|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
219104019|NCT02910518|DRUG|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
219104020|NCT03549234|DRUG|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
219104021|NCT03549234|DRUG|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
219104022|NCT04708301|DIAGNOSTIC_TEST|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
219104023|NCT02055703|DRUG|E2609|
219104024|NCT02055703|DRUG|itraconazole|
219104025|NCT02055703|DRUG|rifampin|
219104026|NCT02055703|DRUG|digoxin|
219104027|NCT02055703|DRUG|donepezil|
219104028|NCT05878223|DEVICE|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
219104029|NCT05056064|OTHER|Oral exercise|exercise remain tongue
219104030|NCT04472780|DEVICE|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
219104031|NCT01265030|DRUG|Sirolimus|"* Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
219691339|NCT03503110|OTHER|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
219691340|NCT03503110|OTHER|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
219691341|NCT05628246|OTHER|Telemedicine|Telemedicine
219691342|NCT05628246|OTHER|In-person|In-person
219691343|NCT04202497|DRUG|TAK-418|TAK-418 orally.
219691344|NCT04202497|DRUG|[18F]MNI-1054 (radiotracer)|\[18F\]MNI-1054 injection.
219691345|NCT05290948|DRUG|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
219691346|NCT05290948|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
219691347|NCT03026946|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
219224167|NCT04389385|BIOLOGICAL|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
219224168|NCT02238041|DEVICE|GlucoClear System|
219691348|NCT03026946|DRUG|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
219691349|NCT06280898|PROCEDURE|Remote ischemic conditioning|Remote ischemic condition
219691350|NCT05007119|PROCEDURE|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
219104032|NCT05176704|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219104033|NCT05611697|PROCEDURE|Single anastomosis sleeve ileal bypass|The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
219224169|NCT06180070|DRUG|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
219224170|NCT06180070|DRUG|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
219691351|NCT05007119|PROCEDURE|Cupping|Cupping with blood letting
219691352|NCT06467214|BEHAVIORAL|CONNECTED|CONNECTED is a manualized, peer-led, group-based social isolation intervention for diverse veteran populations in VA primary care settings. It is delivered via videoconference through individual and group sessions over 8 weeks.
219691353|NCT06467214|BEHAVIORAL|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA) over videoconference or phone.
219691354|NCT05010278|PROCEDURE|Latarjet|Patients followed up 6 months after a Latarjet procedure
219691355|NCT01777841|OTHER|Electronic Care plan delivery|
219691356|NCT01777841|OTHER|Standard care|
219691357|NCT05934851|PROCEDURE|Frozen-Section Directed Excision|Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
219224171|NCT03739866|DRUG|Lenacapavir|Administered subcutaneously in the abdomen
219224172|NCT03739866|DRUG|Placebo|Administered subcutaneously in the abdomen
219224173|NCT03739866|DRUG|B/F/TAF|50/200/25 mg tablets administered orally once daily
219224174|NCT03739866|DRUG|TAF|Tablets administered orally
219691358|NCT05934851|PROCEDURE|Wide Local Excision|Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
219691359|NCT06483061|DRUG|Ferumoxytol|Ferumoxytol will be injected to enhance MRI images
219691360|NCT02201342|DRUG|Udenafil|Drug
219691361|NCT06018337|DRUG|DB-1303/BNT323|IV
219691362|NCT06018337|DRUG|Capecitabine|Oral
219691363|NCT06018337|DRUG|Paclitaxel|IV
219691364|NCT06018337|DRUG|Nab-paclitaxel|IV
219691365|NCT06334133|DRUG|Cadisegliatin 800 mg QD|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
219691366|NCT06334133|DRUG|Cadisegliatin 800 mg BID|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
219691367|NCT06334133|DRUG|Placebo|Placebo (insulin alone)
219691368|NCT02115607|DRUG|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
219104034|NCT05611697|PROCEDURE|Sleeve gastrectomy|In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
219104035|NCT02110446|DRUG|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
219104036|NCT02110446|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
219104037|NCT05696418|PROCEDURE|Total knee arthroplasty with a Mobile Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.
219104038|NCT05696418|PROCEDURE|Total knee arthroplasty with a Fixed Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
219104039|NCT06285942|DRUG|Edoxaban|To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
219104040|NCT06285942|DRUG|No Edoxaban|Other DOACs through PEG or subcutaneous heparin or LMWH
219104041|NCT00288197|DRUG|voriconazole|
219104042|NCT06386081|DIETARY_SUPPLEMENT|Citrus pectin with low DE|Dietary intervention with citrus pectin with low DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
219104043|NCT06386081|DIETARY_SUPPLEMENT|Apple pectin with high DE|Dietary intervention with apple pectin with high DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
219104044|NCT06386081|DIETARY_SUPPLEMENT|Placebo|Participants will orally take the placebo (maltodextrin) twice a day, after dissolving it in 100ml of water, for 2 months. Maltodextrin is highly digestible and in small amounts will have limited impact on gut microbiome.
219104045|NCT00814515|DRUG|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
219104046|NCT00814515|DRUG|NOVA22007|Vehicle
219104047|NCT04855110|DRUG|Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
219104048|NCT04855110|DRUG|Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
219104049|NCT01590771|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
219104050|NCT01590771|DRUG|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
219104051|NCT01590771|DRUG|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
219104052|NCT01590771|DRUG|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
219104053|NCT01590771|DRUG|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
219104054|NCT02729636|DEVICE|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
219104055|NCT02729636|OTHER|Conventional therapy|2\. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
219104056|NCT04489589|DRUG|Midodrine|10mg PO/NG q8h
219104057|NCT04489589|DRUG|Placebo|10mg PO/NG q8h
219104058|NCT02253524|DRUG|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
219104059|NCT02253524|DRUG|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
219104060|NCT03289390|DRUG|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
219104061|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
219224175|NCT05860504|DIAGNOSTIC_TEST|Echocardiography|All patients in the study will be examined with echocardiography
219691369|NCT01622933|BIOLOGICAL|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
219691370|NCT01622933|BIOLOGICAL|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
219104062|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
219104063|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
219104064|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
219104065|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; coronary artery status|
219104066|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
219104067|NCT00726336|DRUG|GSK1349572 and tenofovir|
219104068|NCT05468775|BEHAVIORAL|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
219104069|NCT02585037|OTHER|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
219104070|NCT02585037|OTHER|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
219104071|NCT02585037|OTHER|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
219104072|NCT04358341|DRUG|Irinotecan|150 mg/m2 ivdrip every 14 days
219104073|NCT04358341|DRUG|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
219104074|NCT04358341|DRUG|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
219104075|NCT04853901|DRUG|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
219104076|NCT04853901|DRUG|Standard of care_1|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
219691371|NCT03954093|DEVICE|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
219691372|NCT03844048|DRUG|Venetoclax|oral; film-coated tablets or tablets for oral suspension
219104077|NCT04853901|DRUG|Standard of care_2|Methylprednisolone 1-2mg/kg for 5-7 days
219104078|NCT03220945|OTHER|Yoga|Receive yoga instruction
219104079|NCT00162643|DRUG|zidovudine+lamivudine+lopinavir/ritonavir|
219104080|NCT00162643|DRUG|zidovudine + lamivudine + efavirenz|
219104081|NCT06285760|DRUG|Standarized diuretic therapy|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.
219104082|NCT03880318|PROCEDURE|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
219104083|NCT01997320|OTHER|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
219104084|NCT01997320|OTHER|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
219104085|NCT04255082|OTHER|assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.|"Effectiveness of the mindfulness-based intervention which will be assessed by:~Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.~Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study."
219691373|NCT05078983|DIAGNOSTIC_TEST|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
219691374|NCT04616560|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219691375|NCT04616560|PROCEDURE|Echocardiography Test|Undergo echocardiography
219224176|NCT05860504|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
219224177|NCT05860504|DIAGNOSTIC_TEST|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
219691376|NCT04616560|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219691377|NCT04616560|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219104086|NCT04022889|DEVICE|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
219104087|NCT00003320|PROCEDURE|surgical procedure|
219691378|NCT06958003|OTHER|Air Therapy|3-5 minutes of air therapy in addition to routine diaper care
219104088|NCT00003320|RADIATION|radiation therapy|
219104089|NCT00003320|RADIATION|stereotactic radiosurgery|
219104090|NCT02783820|DRUG|MMV390048 40 mg|
219691379|NCT04921345|DRUG|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
219691380|NCT04921345|DRUG|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
219691381|NCT05533060|OTHER|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
219104091|NCT02783820|DRUG|Placebo to match MMV390048 40 mg|
219104092|NCT02783820|DRUG|MMV390048 80 mg|
219104093|NCT02783820|DRUG|Placebo to match MMV390048 80 mg|
219691382|NCT06516042|DRUG|Dihydroartemisinin-piperaquine|Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
219691383|NCT06843148|DRUG|Niacin (250mg)|"Niacin will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
219691384|NCT06843148|DRUG|Placebo Oral Tablet|"Placebo will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
219691385|NCT03064048|DIETARY_SUPPLEMENT|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
219104094|NCT02783820|DRUG|MMV390048 120 mg|
219104095|NCT02783820|DRUG|Placebo to match MMV390048 120 mg|
219104096|NCT04151693|BEHAVIORAL|Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)|Adaptation (support own agency), rehabilitation and improvement of functional capacity.
219104097|NCT04674774|DRUG|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
219104098|NCT04674774|DRUG|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
219104099|NCT00856934|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
219691386|NCT03064048|DIETARY_SUPPLEMENT|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
219691387|NCT05117112|DIETARY_SUPPLEMENT|XS Muscle Multiplier|Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
219691388|NCT01320241|DEVICE|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
219691389|NCT01320241|DEVICE|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
219691390|NCT05982106|DRUG|TQ05105 Tablets|TQ05105 tablet is a novel JAK2 inhibitor.
219691391|NCT04998864|DEVICE|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
219691392|NCT05911477|DRUG|RhBMP-2|1mg RhBMP-2 for one fusion-level
219104100|NCT00856934|BIOLOGICAL|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
219104101|NCT00856934|OTHER|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
219104102|NCT02668406|OTHER|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
219104103|NCT02668406|OTHER|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
219104104|NCT02668406|OTHER|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
219104105|NCT02668406|OTHER|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
219104106|NCT06230302|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
219691393|NCT01136577|DEVICE|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
219691394|NCT01157611|BEHAVIORAL|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
219691395|NCT01031303|BIOLOGICAL|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
219691396|NCT00102596|DRUG|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
219104107|NCT06230302|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
219691397|NCT03344835|OTHER|No intervention|
219691398|NCT03366857|DRUG|Oxygen 30 %|The oxygen concentration will be set at 30%.
219691399|NCT03366857|DRUG|Oxygen 80 %|The oxygen concentration will be set at 80%.
219691400|NCT05385198|BEHAVIORAL|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
219691401|NCT03358550|DIAGNOSTIC_TEST|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
219104108|NCT01900054|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
219104109|NCT05936203|OTHER|Insulin therapy adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
219104110|NCT05936203|OTHER|Nutritional adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
219104111|NCT05936203|OTHER|Combination of strategies|Strategies used to manage glucose control during a prolonged aerobic exercise
219104112|NCT01186328|DRUG|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
219104113|NCT01186328|DRUG|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~1. \- 1.99 years: 16 mg~2. \- 2.99 years: 20 mg~3. \- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
219104114|NCT01186328|DRUG|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
219104115|NCT01186328|DRUG|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
219104116|NCT01186328|DRUG|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
219104117|NCT01186328|DRUG|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
219104118|NCT01186328|DRUG|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
219104119|NCT01186328|DRUG|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
219104120|NCT03047174|OTHER|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
219104121|NCT03047174|OTHER|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
219104122|NCT06007079|DEVICE|CPM Device|Wearable monitor
219691402|NCT05286853|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.
219104123|NCT01265641|DRUG|AZD1981, 2000mg|Single oral dose, tablets
219104124|NCT01265641|DRUG|AZD1981, 200mg|Single oral dose, tablets
219104125|NCT01265641|DRUG|Moxifloxacin, 400mg|Single oral dose, capsule
219104126|NCT01265641|DRUG|Placebo|Single oral dose, tablets
219691403|NCT05286853|PROCEDURE|Sham Comparator|Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
219691404|NCT01660867|DRUG|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
219104127|NCT05114694|PROCEDURE|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
219104128|NCT05114694|PROCEDURE|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
219104129|NCT04278677|DIETARY_SUPPLEMENT|melatonin|Melatonin capsules to be taken for 6 weeks
219104130|NCT02890238|DRUG|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
219104131|NCT02890238|DRUG|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
219691405|NCT01660867|DRUG|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
219691406|NCT00555074|DRUG|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
219104132|NCT02890238|DRUG|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
219104133|NCT02473861|OTHER|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
219104134|NCT04172493|PROCEDURE|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
219104135|NCT04172493|DEVICE|White Light Endoscopy (WLE)|Undergo white light endoscopy
219104136|NCT00665990|DRUG|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
219104137|NCT00665990|DRUG|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
219104138|NCT00665990|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
219104139|NCT03015116|OTHER|Stretching|Daily foot and ankle stretching protocol
219104140|NCT03015116|OTHER|Cryotherapy|Daily cryotherapy in conjunction with stretching
219104141|NCT03015116|DEVICE|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
219104142|NCT03015116|DEVICE|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
219691407|NCT00555074|DRUG|Placebo|Placebo, BID, oral route during 6 weeks
219691408|NCT05246891|OTHER|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
219691409|NCT00303030|PROCEDURE|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
219691410|NCT00303030|PROCEDURE|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
219691411|NCT03087734|DEVICE|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
219691412|NCT03087734|DEVICE|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
219104143|NCT02075021|DRUG|Lenalidomide|
219104144|NCT02075021|DRUG|nab-paclitaxel|
219104145|NCT02200939|DEVICE|Bioinductive implant|
219104146|NCT02200939|DEVICE|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
219104147|NCT02778191|DRUG|cisplatin|100 mg/m2 day 1, 22 and 43
219104148|NCT02778191|DRUG|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
219104149|NCT02778191|DRUG|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
219104150|NCT00783471|DRUG|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
219104151|NCT00783471|DRUG|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
219104152|NCT00361361|DEVICE|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
219104153|NCT03053921|PROCEDURE|recession coverage|recession coverage done using Zuchellis technique
219104154|NCT03053921|PROCEDURE|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
219104155|NCT03924713|BEHAVIORAL|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
219104156|NCT02951910|DEVICE|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
219104157|NCT01352143|DRUG|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
219104158|NCT01352143|DRUG|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
219104159|NCT04066985|BEHAVIORAL|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
219104160|NCT04066985|BEHAVIORAL|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
219104161|NCT04066985|BEHAVIORAL|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
219104162|NCT00634985|DRUG|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
219104163|NCT02762981|DRUG|Relacorilant with nab-paclitaxel|Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
219104164|NCT02384967|DRUG|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
219104165|NCT02134210|DRUG|Etanercept|Head-to-head comparison
219104166|NCT02134210|DRUG|CHS-0214|
219104167|NCT04944030|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
219104168|NCT01296490|OTHER|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
219104169|NCT04242420|DIAGNOSTIC_TEST|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
219104170|NCT04242420|DIAGNOSTIC_TEST|Lung function|Spirometry,
219104171|NCT04242420|DIAGNOSTIC_TEST|Microbiology|Bacterial culture from Sputum or swab
219104172|NCT04242420|DIAGNOSTIC_TEST|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
219104173|NCT04242420|DIAGNOSTIC_TEST|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
219104174|NCT01492179|DRUG|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
219104175|NCT01492179|DRUG|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
219104176|NCT01492179|DRUG|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
219104177|NCT00808301|OTHER|Gluten-free products|Gluten-free bakery products containing oatmeal.
219104178|NCT03383796|PROCEDURE|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
219104179|NCT03383796|PROCEDURE|Open resection for pCCA|Open resection for pCCA
219104180|NCT04978610|BEHAVIORAL|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
219104181|NCT02308332|DRUG|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
219104182|NCT00720902|PROCEDURE|Blood draws|Subjects will have serum cardiovascular markers assessed
219104183|NCT00720902|DRUG|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
219224178|NCT01503372|DRUG|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
219104184|NCT00720902|PROCEDURE|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
219104185|NCT00720902|PROCEDURE|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
219104186|NCT00720902|PROCEDURE|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
219104187|NCT00782977|OTHER|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
219104188|NCT04968262|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
219224179|NCT01503372|DRUG|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
219224180|NCT02629224|DRUG|ASP8825|Oral
219691413|NCT03564470|DRUG|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
219104189|NCT04968262|OTHER|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
219104190|NCT04835896|DRUG|M7824+paclitaxel|M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
219104191|NCT05480332|DEVICE|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
219104192|NCT00871819|DEVICE|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
219104193|NCT05260372|DIAGNOSTIC_TEST|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
219104194|NCT03505450|OTHER|Population Sample|full sample of recruited participants
219104195|NCT03505450|OTHER|Purposive sample|purposive sample of recruited participants
219104196|NCT01752595|BEHAVIORAL|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
219104197|NCT01752595|OTHER|Preference Based Music Intervention|
219104198|NCT00003759|BIOLOGICAL|BCG vaccine|
219104199|NCT00003759|DRUG|valrubicin|
219104200|NCT00003759|PROCEDURE|conventional surgery|
219104201|NCT01496716|PROCEDURE|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
219104202|NCT02859467|OTHER|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia."
219104203|NCT02859467|OTHER|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
219104204|NCT03847038|PROCEDURE|Preventive strategies advice and dementia risk estimate disclosure|The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
219104205|NCT01334944|DRUG|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
219104206|NCT02254408|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
219104207|NCT02254408|DRUG|Placebo|Tablets administered orally or via nasogastric tube
219104208|NCT01526811|DEVICE|Endurant Stent graft|Endurant Stent graft implantation
219104209|NCT04199533|BEHAVIORAL|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
219104210|NCT04199533|BEHAVIORAL|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
219104211|NCT02519647|DEVICE|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
219104212|NCT02519647|DEVICE|Tracheal intubation with S-guide|Tracheal intubation with S-guide
219104213|NCT01365533|DRUG|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
219104214|NCT01365533|DRUG|Placebo|Placebo, one tablet once daily, orally
219104215|NCT02914184|BIOLOGICAL|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
219104216|NCT02914184|BIOLOGICAL|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
219104217|NCT03712540|DRUG|BMS-986278|Oral administration 30 mg
219691414|NCT03564470|DRUG|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
219104218|NCT03712540|DRUG|Rifampin|Oral administration 600 mg
219104219|NCT03841825|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions and motivation
219104220|NCT04861662|PROCEDURE|Free gingival graft procedure|Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
219104221|NCT00798174|DEVICE|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
219104222|NCT03410290|OTHER|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
219104223|NCT00011024|PROCEDURE|Self Hypnosis|
219104224|NCT00011024|PROCEDURE|Acupuncture|
219104225|NCT00011024|PROCEDURE|Osteopathic Manipulation|
219104226|NCT00580996|OTHER|water high dose|water 16 oz PO x 1
219104227|NCT00580996|OTHER|water tiny dose|water 1 oz PO x 1
219104228|NCT03755635|COMBINATION_PRODUCT|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
219104229|NCT01516775|OTHER|clear fluid ingestion|drinking of clear fluid in preoperative period
219104230|NCT00602186|DRUG|tamsolusin|0.4 mg /day
219104231|NCT00602186|DRUG|prazosin|1 mg/day
219104232|NCT06241690|OTHER|the cold applications in post-suture pain reduces the child's pain|The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
219104233|NCT02790216|PROCEDURE|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
219104234|NCT03316417|OTHER|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
219104235|NCT01083147|DEVICE|FORESEE HOME|Home Monitoring
219104236|NCT00005788|BIOLOGICAL|aldesleukin|
219104237|NCT01478113|DRUG|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
219104238|NCT01478113|DRUG|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
219104239|NCT01478113|BEHAVIORAL|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
219104240|NCT06243107|BEHAVIORAL|Tai-chi|Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
219104241|NCT02991235|DIETARY_SUPPLEMENT|PRJ212|6 capsules of study product will be taken daily and orally.
219104242|NCT02991235|DIETARY_SUPPLEMENT|Placebo|6 capsules of study product will be taken daily and orally.
219104243|NCT00674115|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
219104244|NCT00674115|DRUG|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
219104245|NCT00674115|DRUG|sodium bicarbonate|Sodium bicarbonate. Single dose.
219104246|NCT00721656|DRUG|Placebo|
219104247|NCT00721656|DRUG|KLS-0611|
219104248|NCT05099016|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
219104249|NCT05099016|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
219104250|NCT06305689|PROCEDURE|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
219104251|NCT06305689|PROCEDURE|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
219104252|NCT03837613|PROCEDURE|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
219104253|NCT03355755|DEVICE|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
219104254|NCT03971838|BEHAVIORAL|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2\. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
219691415|NCT04536662|DRUG|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
219691416|NCT04536662|DRUG|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
219691417|NCT04536662|DRUG|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
219691418|NCT02900742|DRUG|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
219691419|NCT02900742|DRUG|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
219691420|NCT02900742|DRUG|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
219691421|NCT02900742|DRUG|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
219691422|NCT02900742|DRUG|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
219691423|NCT02900742|DRUG|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
219104255|NCT05217043|OTHER|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
219104256|NCT05072288|OTHER|Remote activity program|Participant will have to do exercise at home everyday (15min/day)
219104257|NCT04707404|PROCEDURE|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
219104258|NCT05600725|OTHER|novel atrial pacing approach|See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
219104259|NCT05600725|OTHER|sham pacing approach|A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
219104260|NCT02811016|DRUG|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
219104261|NCT02811016|DRUG|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
219104262|NCT02811016|DRUG|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
219691424|NCT02900742|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
219691425|NCT02667652|PROCEDURE|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
219104263|NCT02825901|DIETARY_SUPPLEMENT|Placebo|Ingest placebo drink 100ml/day for 8 weeks
219104264|NCT02825901|DIETARY_SUPPLEMENT|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
219104265|NCT02825901|DIETARY_SUPPLEMENT|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
219104266|NCT04369638|DEVICE|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
219104267|NCT04369638|DEVICE|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
219104268|NCT03491345|DRUG|Avelumab|avelumab 10mg/kg, IV, q 2 weeks
219104269|NCT02304965|BEHAVIORAL|Daily physical activity|A combination of walking (\> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
219104270|NCT01392716|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
219691426|NCT02667652|PROCEDURE|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
219691427|NCT03768713|DRUG|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
219691428|NCT03768713|DRUG|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
219691429|NCT05473299|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
219691430|NCT03871530|OTHER|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
219691431|NCT03871530|OTHER|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
219104271|NCT01112514|DRUG|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
219104272|NCT02282410|DRUG|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
219104273|NCT05201911|DRUG|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
219104274|NCT05859802|DRUG|Dalfampridine Pill|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
219104275|NCT05859802|DRUG|Placebo|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
219104276|NCT02611050|BEHAVIORAL|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
219104277|NCT02611050|BEHAVIORAL|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
219104278|NCT04157998|DRUG|normal saline|intrvenous administration of 10ml normal saline preoperative
219104279|NCT04157998|DRUG|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
219104280|NCT01118455|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
219104281|NCT01118455|DRUG|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
219104282|NCT02768948|DRUG|telmisartan during 6 months|telmisartan during 6 months
219104283|NCT02768948|DRUG|Losartan during 6 months|Losartan during 6 months
219104284|NCT02768948|PROCEDURE|blood sample|blood sample
219104285|NCT04235101|DRUG|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
219104286|NCT02852018|GENETIC|Identification of genetic polymorphisms|
219691432|NCT03871530|OTHER|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
219691433|NCT03871530|OTHER|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
219691434|NCT03871530|OTHER|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
219691435|NCT03871530|OTHER|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
219104287|NCT01538108|DEVICE|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
219691436|NCT03871530|OTHER|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
219691437|NCT03871530|OTHER|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
219104288|NCT01538108|PROCEDURE|Plain Balloon angioplasty (PBA)|PBA
219104289|NCT01995019|DRUG|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
219104290|NCT01995019|DRUG|Physiologic saline|1 ml intra-articular placebo
219104291|NCT04239729|BEHAVIORAL|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
219691438|NCT03871530|OTHER|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
219691439|NCT03871530|OTHER|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
219691440|NCT03871530|OTHER|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
219104292|NCT06010290|DRUG|18F-SMBT-1|Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
219104293|NCT00150995|DRUG|Tetrathiomolybdate|
219104294|NCT02275247|DRUG|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
219104295|NCT02492113|PROCEDURE|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
219104296|NCT02492113|PROCEDURE|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
219104297|NCT04563390|BEHAVIORAL|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
219691441|NCT03871530|OTHER|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
219691442|NCT03871530|OTHER|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
219691443|NCT03871530|OTHER|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
219691444|NCT00152113|PROCEDURE|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
219691445|NCT00152113|DEVICE|CliniMACS|
219691446|NCT00152113|DRUG|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
219104298|NCT04563390|BEHAVIORAL|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
219104299|NCT02070120|DRUG|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
219104300|NCT02070120|PROCEDURE|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
219104301|NCT04734535|DEVICE|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
219104302|NCT04734535|DEVICE|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
219104303|NCT04937426|DIAGNOSTIC_TEST|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|Diagnostic laboratory test for detection of helicobacter pylori
219104304|NCT00477906|BIOLOGICAL|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
219104305|NCT06342895|DEVICE|Nutritional support prescription and delivery monitoring feedback|Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device
219104306|NCT06342895|DEVICE|Usual care|Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
219104307|NCT00237484|DRUG|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
219104308|NCT00237484|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
219104309|NCT04759742|DRUG|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
219104310|NCT03375580|DIETARY_SUPPLEMENT|TLC|transform life custom (TLC)
219104311|NCT03375580|DRUG|metformin|0.5g metformin group，PO tid
219104312|NCT03375580|DRUG|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
219104313|NCT03375580|DRUG|Simvastatin|20mg simvastatin, PO qn
219104314|NCT06475469|BIOLOGICAL|Blood sampling & Chest CT without injection|Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
219104315|NCT01758861|DRUG|EPO group|
219691447|NCT01832337|PROCEDURE|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
219691448|NCT02952690|DEVICE|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
219691449|NCT02952690|DEVICE|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
219691450|NCT05446961|DIETARY_SUPPLEMENT|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
219691451|NCT05446961|DRUG|Placebo|orally capsules
219691452|NCT03391102|OTHER|Observational study|
219104316|NCT01758861|DRUG|Placebo|
219104317|NCT05362682|OTHER|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
219104318|NCT01974505|DEVICE|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
219104319|NCT02139475|PROCEDURE|Colonoscopy|
219104320|NCT00158210|DRUG|Rivastigmine|
219104321|NCT03327402|DRUG|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
219104322|NCT01231841|DRUG|cyclosporine|Given orally
219691453|NCT00535652|DRUG|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
219104323|NCT01231841|BIOLOGICAL|anti-thymocyte globulin|Given IV
219104324|NCT03165162|BEHAVIORAL|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
219104325|NCT02674490|DEVICE|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
219104326|NCT02674490|BEHAVIORAL|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
219104327|NCT02674490|DEVICE|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
219104328|NCT04170868|OTHER|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
219104329|NCT01673074|DRUG|(PDT) Photodynamic therapy|photosensitizer
219104330|NCT03836508|DEVICE|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
219104331|NCT03836508|DEVICE|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
219691454|NCT05032014|OTHER|M9|one times a day during the whole treatment
219691455|NCT05032014|OTHER|placebo|placebo
219691456|NCT01516723|DEVICE|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
219691457|NCT02523430|PROCEDURE|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
219691458|NCT02825914|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|
219691459|NCT02825914|DIETARY_SUPPLEMENT|Placebo|
219691460|NCT00069264|DRUG|E7389|E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
219691461|NCT05547386|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219691462|NCT05547386|DRUG|Gallium Ga 68 Gozetotide|Given IV
219691463|NCT05547386|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219691464|NCT03909646|DRUG|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
219691465|NCT03909646|DRUG|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
219691466|NCT03909646|OTHER|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
219691467|NCT04622969|BEHAVIORAL|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
219104332|NCT04940182|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
219104333|NCT04940182|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 full days
219104334|NCT00910637|DRUG|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
219691468|NCT05969730|DRUG|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
219691469|NCT05969730|DRUG|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
219691470|NCT02094794|DRUG|etoposide|Given IV
219691471|NCT02094794|DRUG|cyclophosphamide|Given IV
219691472|NCT02094794|RADIATION|total marrow irradiation|Undergo TMLI
219691473|NCT02094794|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
219691474|NCT02094794|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
219104335|NCT06257719|OTHER|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
219691475|NCT04467515|DRUG|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
219691476|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
219691477|NCT06969014|DEVICE|Microwave ablation|Microwave ablation of lung tumors
219691478|NCT06514430|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken prior to the Botox® injection procedure as an analgesic.
219104336|NCT04563806|DEVICE|Magnetic Resonance Imaging|Undergo MRI-guided surgery
219691479|NCT06514430|DRUG|1% lidocaine with sodium bicarbonate|50cc of 1% lidocaine with 50cc sodium bicarbonate injected into the bladder lumen prior to the Botox® injection procedure.
219691480|NCT04252625|DRUG|Q-Urol|Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
219691481|NCT04252625|DRUG|Placebo|placebo capsule
219691482|NCT05616013|BIOLOGICAL|Bimagrumab|Human monoclonal antibody to the activin receptor type II
219691483|NCT05616013|DRUG|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
219691484|NCT05616013|OTHER|Placebo|Placebo
219691485|NCT06409663|BIOLOGICAL|NVX-CoV2705 Vaccine|All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.
219691486|NCT06420089|DRUG|Senza5 CART5|The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
219691487|NCT05454592|BEHAVIORAL|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
219691488|NCT06970769|OTHER|Vagus nerve stimulation|In our study, the auricular branch in the pinna was superficially stimulated with a TENS-based vagustim device for non-invasive vagus nerve stimulation. The application was performed in regular sessions with a physiotherapist according to the recorded protocol. This deactivation aimed at modulation of the autonomic nervous system via the vagus nerve.
219691489|NCT06970769|OTHER|Deep Breathing Exercises|In the study, the participants who were given deep breathing exercises were taught the correct technique in a semi-sitting position. During the exercises, deep breathing and relaxation periods were applied for certain periods. The respiratory rhythm was arranged as controlled inspiration and expiration. The participants were given an application practice so that they could continue the exercise at home.
219691490|NCT06970223|DRUG|Cabotegravir long-acting|A single CAB LA injection administered intramuscularly.
219691491|NCT06970223|DRUG|Lenacapavir long-acting|Two LEN LA injections administered subcutaneously.
219104337|NCT04563806|PROCEDURE|Therapeutic Conventional Surgery|Undergo spinal surgery
219104338|NCT00226564|DRUG|Alfentanil|
219691492|NCT04832607|OTHER|Multivirus (CMV, EBV, AdV)-specific T cells|Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
219104339|NCT01898143|OTHER|Whole body vibration|
219104340|NCT01377415|DRUG|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
219691493|NCT05010577|DRUG|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
219691494|NCT05010577|DRUG|Placebo|Nebulized placebo
219691495|NCT06456788|BIOLOGICAL|MMR vaccination|MMR vaccination status
219104341|NCT03810313|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
219104342|NCT03810313|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
219104343|NCT03810313|OTHER|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
219104344|NCT03136796|DRUG|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
219104345|NCT00595829|DRUG|XL019|XL019 capsules administered orally
219691496|NCT04788277|PROCEDURE|Biospecimen Collection|Undergo collection of urine samples
219691497|NCT05492006|BEHAVIORAL|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
219691498|NCT05492006|BEHAVIORAL|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
219691499|NCT05116202|DRUG|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
219691500|NCT05116202|DRUG|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
219691501|NCT05116202|DRUG|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
219691502|NCT05116202|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
219691503|NCT05116202|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
219691504|NCT05116202|DRUG|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
219691505|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
219691506|NCT03834506|DRUG|Docetaxel|IV infusion
219691507|NCT03834506|DRUG|Prednisone|Oral tablets
219691508|NCT03834506|DRUG|Placebo|IV infusion
219691509|NCT03834506|DRUG|Dexamethasone|Oral tablets
219691510|NCT05658393|BEHAVIORAL|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
219691511|NCT06801379|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
219104346|NCT03580213|OTHER|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
219104347|NCT03580213|OTHER|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
219104348|NCT05164731|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
219104349|NCT01678014|PROCEDURE|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
219104350|NCT01678014|PROCEDURE|Capsulotomy|
219104351|NCT05027399|BEHAVIORAL|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
219104352|NCT00018005|BEHAVIORAL|Self-Management|18 in-person group sessions providing self-management training.
219104353|NCT00018005|OTHER|attention control|18 educational mailings follow by a a telephone call.
219104354|NCT05125523|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
219104355|NCT00439166|DRUG|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
219104356|NCT00439166|DRUG|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
219104357|NCT00439166|DRUG|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
219691512|NCT06801379|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
219104358|NCT00439166|DRUG|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
219104359|NCT04953013|DRUG|sodium bicarbonate|Drug exposure
219104360|NCT00816387|PROCEDURE|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
219104361|NCT00816387|PROCEDURE|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
219104362|NCT00144872|DRUG|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
219104363|NCT00512551|PROCEDURE|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
219104364|NCT02738671|BEHAVIORAL|Cognitive assessment|
219104365|NCT02738671|OTHER|functional magnetic resonance imaging|
219104366|NCT02738671|OTHER|olfactory function measurement|
219104367|NCT02738671|PROCEDURE|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
219104368|NCT01079689|OTHER|needle stimulation|stimulation with acupuncture needles
219104369|NCT04439006|OTHER|Best Practice|Receive usual care
219104370|NCT04439006|DRUG|Ibrutinib|Given PO
219104371|NCT01625195|DIETARY_SUPPLEMENT|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
219104372|NCT01625195|DIETARY_SUPPLEMENT|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
219104373|NCT01738022|OTHER|Administration of gas mixtures|
219104374|NCT05002374|OTHER|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
219104375|NCT05002374|OTHER|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
219104376|NCT00584805|BIOLOGICAL|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is \< 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
219104377|NCT01993823|DRUG|G238|Five drops into the ear canal twice daily for 14 days
219104378|NCT01993823|DRUG|Clotrimazole|Five drops into the ear canal twice daily for 14 days
219104379|NCT03915080|DRUG|Oktokog alpha|adjusting dose and dose interval according to MyPKFIT
219104380|NCT03133663|OTHER|Electrocardiogram group|Experimental
219104381|NCT03133663|OTHER|Pulse oximeter and auscultation group|Control
219691513|NCT05040087|OTHER|Intensification of diabetes medication based largely on HbA1c levels|Use of diabetes Rx in controls will be guided largely by HbA1c levels.
219691514|NCT05040087|OTHER|Intensification of diabetes medication based on glucose levels|Use of diabetes Rx in the intensive Rx groups will be guided by participants' self-monitored blood glucose levels (SMBG), with management aimed to keep glucose levels within the normal range.
219691515|NCT03859050|OTHER|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
219691516|NCT06298357|BEHAVIORAL|Immediate Start - Virtual Reality|Participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness. They will start using the headsets in the hospital and then will continue to do so for 8 weeks after hospital discharge.
219691517|NCT06298357|BEHAVIORAL|Delayed Start - Virtual Reality|Participants will receive usual care in the hospital and outside of the hospital for 8 weeks. After the 8 week post-discharge period, participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness for an 8 week period.
219691518|NCT06384027|OTHER|Non-invasive ventilation|Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
219691519|NCT05067972|DRUG|PF-07260437|B7-H4 x CD3 bi-specific mAb
219691520|NCT05067972|DIAGNOSTIC_TEST|B7-H4 IHC|B7-H4 expression
219691521|NCT05608304|BEHAVIORAL|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
219691522|NCT05608304|BEHAVIORAL|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
219691523|NCT05608304|BEHAVIORAL|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
219691524|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
219104382|NCT03043222|DEVICE|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
219691525|NCT05217108|DEVICE|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
219691526|NCT00000411|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
219691527|NCT00000411|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
219691528|NCT06380062|OTHER|Plasma concentration of choline|The exposure in this observational study is plasma concentrations of choline
219691529|NCT03666247|BEHAVIORAL|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
219104383|NCT03043222|DEVICE|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
219104384|NCT01740102|PROCEDURE|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
219104385|NCT06241261|DRUG|Silver diamine fluoride gel|Application of 38% SDF gel every 6 months
219104386|NCT06241261|DRUG|Silver diamine fluoride solution|Application of 38% SDF solution every 6 months
219104387|NCT03179800|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
219104388|NCT03179800|OTHER|Sham Implantation|Sham Implantation
219691530|NCT03666247|BEHAVIORAL|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
219691531|NCT05448742|DEVICE|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
219691532|NCT04391842|COMBINATION_PRODUCT|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device"
219104389|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
219104390|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
219104391|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
219104392|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
219104393|NCT01829893|DRUG|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
219104394|NCT01829893|DRUG|GL2701 capsule|oral medication with 240 mL water
219104395|NCT01217489|PROCEDURE|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
219224181|NCT05011955|BEHAVIORAL|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
219691533|NCT05135936|BEHAVIORAL|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
219691534|NCT05135936|BEHAVIORAL|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
219691535|NCT00223002|DRUG|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
219691536|NCT04296708|OTHER|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
219691537|NCT00006146|BIOLOGICAL|Approved influenza virus vaccine.|
219104396|NCT04672512|DRUG|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
219104397|NCT04672512|DRUG|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
219104398|NCT04672512|DRUG|Prednisone|Prednisone tablet for oral administration
219104399|NCT03923361|DRUG|Diprivan|Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
219691538|NCT00637026|DRUG|Gefitinib|Iressa
219691539|NCT03337620|DEVICE|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
219691540|NCT00010504|PROCEDURE|Acupuncture|
219691541|NCT02731300|DEVICE|tDCS|brain stimulation by cathodal electrode at motor cortex
219691542|NCT01067534|DRUG|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
219691543|NCT04916717|OTHER|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
219691544|NCT05717712|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
219104400|NCT05334121|DIETARY_SUPPLEMENT|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
219104401|NCT05334121|OTHER|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
219104402|NCT05749601|OTHER|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
219104403|NCT05749601|OTHER|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
219104404|NCT05749601|OTHER|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
219104405|NCT02379559|BEHAVIORAL|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
219104406|NCT02379559|BEHAVIORAL|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
219691545|NCT00002314|DRUG|Ro 24-7429|
219691546|NCT04485728|BEHAVIORAL|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
219691547|NCT02606240|DEVICE|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
219104407|NCT03029780|BIOLOGICAL|Opdivo|Specified dose on specified days
219104408|NCT03029780|BIOLOGICAL|Yervoy|Specified dose on specified days
219104409|NCT04323228|DIETARY_SUPPLEMENT|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
219224182|NCT05011955|BEHAVIORAL|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
219691548|NCT05537311|BEHAVIORAL|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
219691549|NCT00768690|DRUG|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
219691550|NCT00768690|DRUG|ketoconazole|Tablet, see arms for intervention description
219691551|NCT00768690|DRUG|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
219691552|NCT01834339|BIOLOGICAL|AlloDerm|
219691553|NCT01834339|BIOLOGICAL|EVPOME|
219691554|NCT03651817|DEVICE|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
219104410|NCT04323228|DIETARY_SUPPLEMENT|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
219104411|NCT03066622|DRUG|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
219104412|NCT03066622|DRUG|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
219104413|NCT03311425|DRUG|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
219104414|NCT03311425|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
219104415|NCT00002901|DRUG|docetaxel|
219104416|NCT00958022|DRUG|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
219104417|NCT06355635|OTHER|Choice and Monitoring|current practive of vasoactive and inotrope drugs
219104418|NCT06310902|DIAGNOSTIC_TEST|Single-cell Sequencing Analysis|Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
219104419|NCT01460160|DRUG|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
219104420|NCT05806502|DIAGNOSTIC_TEST|Nω-hydroxy-nor-arginine|Arginase inhibitor
219104421|NCT01616771|DEVICE|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
219104422|NCT01616771|DEVICE|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
219104423|NCT01616771|DEVICE|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
219104424|NCT00100932|DRUG|E7389 28 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
219224183|NCT05011955|OTHER|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
219224184|NCT05866575|OTHER|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
219224185|NCT05866575|OTHER|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
219691555|NCT04007328|DRUG|Methylprednisolone Sodium Succinate|methylprednisolone vial
219691556|NCT04007328|DRUG|Placebo|Normal saline manufactured to mimic methylprednisolone vial
219691557|NCT01217827|BEHAVIORAL|Clinical Reminder|
219104425|NCT00100932|DRUG|E7389 21 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
219104426|NCT00744328|DRUG|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
219104427|NCT00744328|DRUG|Sertraline|Sertraline dose will range from 50 - 200 mg/day
219104428|NCT00744328|OTHER|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
219104429|NCT00000508|BEHAVIORAL|smoking cessation|
219104430|NCT00000508|BEHAVIORAL|diet, reducing|
219104431|NCT00000508|BEHAVIORAL|exercise|
219104432|NCT00000508|BEHAVIORAL|diet, fat-restricted|
219104433|NCT02720822|DRUG|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
219104434|NCT02720822|DRUG|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
219104435|NCT02720822|DRUG|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
219104436|NCT02720822|DRUG|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
219104437|NCT02720822|DEVICE|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
219104438|NCT04066140|OTHER|No intervention|No Intervention. Observational Study.
219104439|NCT04229030|DRUG|RZL-012|small synthetic molecule for the treatment of Dercum's Disease lipomas
219104440|NCT04229030|DRUG|Vehicle|Vehicle of RZL-012 drug product
219104441|NCT00815035|DRUG|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
219104442|NCT00815035|DRUG|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
219104443|NCT01784692|DIETARY_SUPPLEMENT|Immulina|
219104444|NCT02387216|DRUG|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
219104445|NCT02387216|DRUG|Docetaxel|approved chemotherapy treatment for NSCLC
219104446|NCT02724722|BEHAVIORAL|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
219104447|NCT02724722|BEHAVIORAL|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
219104448|NCT04381936|DRUG|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
219691558|NCT06354218|DRUG|Serplulimab|Serplulimab （4.5mg/Kg every 3 weeks）
219691559|NCT02408198|BEHAVIORAL|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
219691560|NCT06005363|DRUG|Dexmedetomidine|dexmedetomidine infusion
219691561|NCT06005363|DEVICE|anesthesia depth monitoring|intraoperative anesthesia depth monitoring to keep BIS 40-60
219691562|NCT01016145|DRUG|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
219691563|NCT01016145|DRUG|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
219691564|NCT03345381|OTHER|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
219691565|NCT03345381|OTHER|Usual care|Treatment as usual
219691566|NCT00596271|BIOLOGICAL|IC51|
219691567|NCT00596271|BIOLOGICAL|HAVRIX|
219691568|NCT00596271|OTHER|Placebo|
219691569|NCT00953290|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
219104449|NCT04381936|DRUG|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
219691570|NCT01105312|DRUG|letrozole|
219691571|NCT01105312|DRUG|panobinostat|
219104450|NCT04381936|DRUG|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
219691572|NCT01105312|GENETIC|RNA analysis|
219691573|NCT01105312|GENETIC|microarray analysis|
219691574|NCT01105312|GENETIC|reverse transcriptase-polymerase chain reaction|
219691575|NCT01105312|OTHER|enzyme-linked immunosorbent assay|
219691576|NCT01105312|OTHER|immunohistochemistry staining method|
219691577|NCT01105312|OTHER|laboratory biomarker analysis|
219691578|NCT05358548|DRUG|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
219691579|NCT05358548|DRUG|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
219691580|NCT05358548|DRUG|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
219104451|NCT04381936|DRUG|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
219104452|NCT04381936|BIOLOGICAL|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
219104453|NCT04381936|DRUG|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
219104454|NCT04381936|BIOLOGICAL|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
219691581|NCT05358548|DRUG|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
219691582|NCT05358548|DRUG|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
219691583|NCT00441285|DRUG|Praziquantel|\- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
219691584|NCT00441285|DRUG|Albendazole|"* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
219691585|NCT00441285|DRUG|ABZ Placebo|\- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
219691586|NCT00441285|DRUG|PZQ Placebo|\- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
219691587|NCT00152607|PROCEDURE|donor right hepatic lobectomy|
219691588|NCT03890458|DRUG|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
219691589|NCT03024983|OTHER|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
219691590|NCT03024983|OTHER|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
219691591|NCT03024983|OTHER|Bread|Bread (122 g) eaten with 500 mL of water
219691592|NCT03024983|OTHER|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
219691593|NCT03024983|OTHER|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
219691594|NCT03024983|OTHER|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
219691595|NCT05225545|DRUG|Sucrosomial Iron|Experimental Arm
219691596|NCT05225545|DRUG|Oral Iron|Active Comparator
219691597|NCT05252741|OTHER|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
219691598|NCT01351818|DRUG|Growth Hormone|
219691599|NCT04826627|OTHER|glycemia|capillary glycemia
219691600|NCT06331663|DRUG|Remifentanil|first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
219691601|NCT03587064|DEVICE|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
219691602|NCT03587064|DEVICE|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
219691603|NCT06310811|DRUG|RD06-04 Cells injection|Patient will be treated with RD06-04 cells when enrolled in the study
219691604|NCT00314158|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
219691605|NCT00314158|DRUG|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
219691606|NCT00314158|DRUG|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
219691607|NCT03856697|DRUG|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
219691608|NCT03856697|DRUG|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
219691609|NCT03856697|DRUG|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
219691610|NCT03856697|DRUG|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
219691611|NCT06406335|OTHER|Health education program|Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
219691612|NCT02089048|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
219691613|NCT00190424|DRUG|CpG-ODN|
219691614|NCT05775627|BEHAVIORAL|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
219691615|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
219104455|NCT04381936|DRUG|Synthetic neutralising antibodies|Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
219104456|NCT04381936|DRUG|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
219691616|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
219691617|NCT01388153|DRUG|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
219691618|NCT02256813|DRUG|BIRT 2584 XX|
219691619|NCT02256813|DRUG|Warfarin sodium|
219691620|NCT02256813|DRUG|Omeprazole|
219691621|NCT02256813|DRUG|Dextromethorphan hydrobromide|
219691622|NCT02256813|DRUG|Caffeine|
219691623|NCT02256813|DRUG|Midazolam hydrochloride|
219104457|NCT04381936|DRUG|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
219104458|NCT04381936|DRUG|Baricitinib|UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
219104459|NCT04381936|DRUG|Anakinra|For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
219104460|NCT04381936|DRUG|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
219691624|NCT02256813|DRUG|Vitamin K1|
219691625|NCT04784078|PROCEDURE|Coronary Angiography and Intervention|Transradial access puncture site
219691626|NCT03442647|DIAGNOSTIC_TEST|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
219691627|NCT04328428|OTHER|acupuncture|Use one acupuncture needle insert in a acupoint.
219691628|NCT02283658|DRUG|Everolimus|Given PO
219691629|NCT02283658|OTHER|Laboratory Biomarker Analysis|Correlative studies
219691630|NCT02283658|DRUG|Letrozole|Given PO
219691631|NCT01283100|DRUG|GSK1349572|50mg once every 24 hours for 7 days
219691632|NCT01283100|DRUG|GSK2248761|200 mg once every 24 hours for 7 days
219691633|NCT05282368|BEHAVIORAL|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
219691634|NCT04229043|DIETARY_SUPPLEMENT|Sports drink|Drink that will be ingested
219691635|NCT04229043|DIETARY_SUPPLEMENT|Water|Drink that will be ingested
219104461|NCT04381936|DRUG|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
219104462|NCT04381936|DRUG|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
219104463|NCT04381936|DRUG|Sotrovimab|UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
219104464|NCT04381936|DRUG|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
219104465|NCT04381936|DRUG|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
219104466|NCT04381936|DRUG|Baloxavir Marboxil|"Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4."
219104467|NCT04381936|DRUG|Oseltamivir|"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)"
219224186|NCT03090711|DEVICE|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
219691636|NCT05996939|OTHER|To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.|Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
219691637|NCT02076620|DRUG|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
219104468|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
219104469|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
219691638|NCT02076620|DRUG|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
219691639|NCT00847600|DIETARY_SUPPLEMENT|Pregnenolone|50 mg, caps.
219104470|NCT04891796|OTHER|No intervention|No intervention
219691640|NCT00847600|DIETARY_SUPPLEMENT|Placebo|caps
219104471|NCT06626100|BEHAVIORAL|Exercise-themed game|The intervention includes three parts: quiz questions on knowledge on and benefits of exercise; monitored step count using smartphone tracker; whatsapp reminders on the benefits of exercise.
219104472|NCT06626100|BEHAVIORAL|Diet-themed game|The intervention includes two parts: quiz questions on knowledge on and benefits of healthy diet; whatsapp reminders on the benefits of healthy diet.
219104473|NCT03389607|DIAGNOSTIC_TEST|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
219104474|NCT04498247|BIOLOGICAL|V591|1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
219104475|NCT04498247|OTHER|Placebo|Placebo (0.9% sodium chloride) administered via IM injection.
219104476|NCT00852826|PROCEDURE|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
219104477|NCT00852826|PROCEDURE|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
219104478|NCT01090908|DRUG|Antibiotic|
219104479|NCT05642273|DEVICE|oXiris membrane|oXiris membrane for 24h
219104480|NCT05642273|DIAGNOSTIC_TEST|Blood tests|Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
219104481|NCT01077726|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
219104482|NCT04919174|DRUG|Remimazolam|Sedation with remimazolam
219104483|NCT04919174|DRUG|Dexmedetomidine|Sedation with dexmedetomidine
219104484|NCT06108089|DIAGNOSTIC_TEST|[18F]MISO-PET/CT|18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
219104485|NCT06321978|DEVICE|Mepilex Border Flex|Usage of Mepilex Border Flex according to intended use and standard of care.
219104486|NCT03492736|DIETARY_SUPPLEMENT|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
219104487|NCT03492736|OTHER|Placebo|30 days placebo taken nightly 1 hour before bed
219104488|NCT04069260|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
219104489|NCT04041440|BEHAVIORAL|clEAR auditory training|Children play auditory brain training computer games
219104490|NCT01624649|DRUG|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
219104491|NCT01624649|DRUG|Atomoxetine|Form = tablet, route = oral;
219104492|NCT02784223|DEVICE|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
219104493|NCT02773680|DEVICE|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
219104494|NCT00008463|DRUG|Ribavirin|
219104495|NCT00008463|DRUG|Interferon alfa-2a|
219104496|NCT00008463|DRUG|Peginterferon alfa-2a|
219104497|NCT05852028|DRUG|Selinexor|this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
219104498|NCT00003048|DRUG|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
219224187|NCT03090711|DEVICE|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
219104499|NCT06265883|PROCEDURE|Len+DEB-TACE+HAIC|Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
219104500|NCT06265883|PROCEDURE|Len+DEB-TACE|Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
219104501|NCT01381874|DRUG|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
219104502|NCT01381874|DRUG|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
219104503|NCT01381874|DRUG|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
219104504|NCT03257423|DRUG|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
219104505|NCT03257423|DRUG|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
219104506|NCT03257423|PROCEDURE|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
219104507|NCT03257423|OTHER|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
219104508|NCT01113619|DRUG|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
219104509|NCT01113619|DRUG|RP-G28 or placebo|Daily dosing
219104510|NCT01731587|OTHER|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
219104511|NCT01731587|DRUG|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
219104512|NCT04142060|DRUG|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
219104513|NCT00664820|DIETARY_SUPPLEMENT|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
219104514|NCT02247804|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
219104515|NCT02247804|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
219104516|NCT02247804|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
219104517|NCT02247804|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
219691641|NCT04181671|OTHER|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
219104518|NCT01646684|DRUG|SOM230|
219104519|NCT00509158|BIOLOGICAL|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
219104520|NCT00509158|BIOLOGICAL|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
219104521|NCT03456167|OTHER|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
219104522|NCT05716789|PROCEDURE|CPR|CPR in cardiac arrest patients
219104523|NCT02917265|DEVICE|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
219104524|NCT02917265|DEVICE|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
219104525|NCT05377970|OTHER|Thinkific Prehabilitation Exercise Program|Prehabilitation exercise program through the Thinkific platform
219104526|NCT00128622|BIOLOGICAL|denileukin diftitox|
219104527|NCT00128622|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
219104528|NCT00128622|BIOLOGICAL|therapeutic autologous dendritic cells|
219104529|NCT01419860|PROCEDURE|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
219104530|NCT00452179|DRUG|APD125|
219104531|NCT04346550|OTHER|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS \> 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS\<3, no fever and tolerating oral intake
219104532|NCT04752891|OTHER|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
219104533|NCT04752891|OTHER|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
219104534|NCT02467322|DRUG|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
219104535|NCT02467322|DRUG|ascitic fluid|
219691642|NCT04181671|OTHER|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
219691643|NCT03964389|OTHER|"Pain Neuroscience Education (PNE)"|A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
219691644|NCT03283735|BEHAVIORAL|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
219691645|NCT06311058|DIETARY_SUPPLEMENT|Whey protein isolate|25g of whey protein isolate
219691646|NCT06311058|DIETARY_SUPPLEMENT|Protein + BAA|"* Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)"
219691647|NCT06311058|DIETARY_SUPPLEMENT|Placebo|• isocaloric-matched (25g) maltodextrin supplement
219691648|NCT00689338|DRUG|Anidulafungin|Anidulafungin Intravenous Administration
219104536|NCT00452413|DRUG|enzastaurin|Administered orally
219104537|NCT00452413|DRUG|erlotinib|Administered orally
219104538|NCT05083260|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
219691649|NCT00689338|DRUG|Fluconazole|Oral Administration of Fluconazole
219691650|NCT00689338|DRUG|Voriconazole|Oral Administration of Voriconazole
219104539|NCT05083260|DRUG|placebo|Hard gelatin capsule containing only common excipients for oral formulations
219104540|NCT01248962|DRUG|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
219104541|NCT01248962|DRUG|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
219104542|NCT02854358|DRUG|mixed powder of A. digitata and M. sylvestris|
219104543|NCT02854358|DRUG|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
219691651|NCT02464137|RADIATION|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
219691652|NCT01414998|BEHAVIORAL|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
219691653|NCT01414998|BEHAVIORAL|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
219691654|NCT00170209|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
219691655|NCT00170209|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
219691656|NCT01789047|DRUG|Topiramate|Topiramate as adjunct to amantadine
219691657|NCT01789047|DRUG|Placebo|Placebo control
219691658|NCT01789047|DRUG|Amantadine|Existing treatment for all participants
219691659|NCT05447065|DIETARY_SUPPLEMENT|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
219691660|NCT02078271|OTHER|FBDG group|The group received food based dietary guidelines for complementary feeding
219691661|NCT02078271|OTHER|Stimulation|The group received psychosocial stimulation
219691662|NCT02078271|OTHER|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
219691663|NCT02078271|OTHER|Control group|
219691664|NCT00002535|BIOLOGICAL|aldesleukin|
219691665|NCT00002535|BIOLOGICAL|lymphokine-activated killer cells|
219691666|NCT00002535|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219691667|NCT00002535|DRUG|cyclophosphamide|
219691668|NCT00002535|DRUG|indomethacin|
219691669|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
219691670|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
219691671|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
219691672|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
219691673|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
219691674|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
219691675|NCT02951312|DRUG|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
219691676|NCT04928781|BEHAVIORAL|Smoking Cessation Counseling|Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
219691677|NCT00284921|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219691678|NCT03074877|BEHAVIORAL|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
219691679|NCT00463645|PROCEDURE|microdialysis|
219691680|NCT00463645|PROCEDURE|microperfusion|
219691681|NCT03511768|DRUG|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
219691682|NCT03511768|DEVICE|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
219691683|NCT02668640|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
219691684|NCT04819217|DIETARY_SUPPLEMENT|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR \> 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
219691685|NCT04819217|DIETARY_SUPPLEMENT|Probiotics|Probiotics
219691686|NCT01278758|DRUG|ASA404, DMXAA or DXAA|
219691687|NCT05333497|DEVICE|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
219104544|NCT02476955|DRUG|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
219104545|NCT02476955|DRUG|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
219104546|NCT02476955|DRUG|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
219691688|NCT05333497|DEVICE|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
219691689|NCT06337500|DEVICE|Neurophysiological measure (EEG)|Cerebral electric activity recorded with EEG
219104547|NCT03283696|DRUG|Olaratumab|Administered IV
219104548|NCT03283696|DRUG|Doxorubicin|Administered IV
219104549|NCT03283696|DRUG|Ifosfamide|Administered IV
219104550|NCT03283696|DRUG|Mesna|Administered per standard of care
219104551|NCT00692640|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
219104552|NCT00692640|DRUG|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
219104553|NCT02104830|BIOLOGICAL|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
219104554|NCT02104830|BIOLOGICAL|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
219104555|NCT02104830|BIOLOGICAL|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
219104556|NCT02104830|BIOLOGICAL|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
219104557|NCT02104830|BIOLOGICAL|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
219104558|NCT04530357|BIOLOGICAL|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
219104559|NCT04530357|OTHER|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
219104560|NCT05790226|DEVICE|Sentry System|any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
219104561|NCT03290573|DEVICE|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
219104562|NCT02583568|DRUG|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
219104563|NCT01539863|OTHER|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
219104564|NCT01539863|OTHER|Treatment as needed|Participants may never receive treatment, there is no upper limit
219104565|NCT04962438|DRUG|Anti-VEGF|Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
219691690|NCT06337500|OTHER|Survey|Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
219691691|NCT02605200|BEHAVIORAL|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
219104566|NCT01962025|PROCEDURE|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
219104567|NCT02765490|DRUG|AL-335|AL-335 800 mg (2\*400) tablet will be administered once daily.
219104568|NCT02765490|DRUG|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
219104569|NCT02765490|DRUG|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
219104570|NCT02381002|OTHER|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
219104571|NCT02551744|DRUG|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
219104572|NCT02551744|DRUG|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
219104573|NCT03147066|DRUG|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
219104574|NCT03147066|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
219104575|NCT01425164|DRUG|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
219104576|NCT01425164|DRUG|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
219104577|NCT05096676|DRUG|Oxytocin: Including placebo|Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
219104578|NCT00007475|PROCEDURE|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
219104579|NCT00007475|DRUG|Cyclophosphamide|For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
219104580|NCT00247364|DRUG|Levetiracetam (Keppra)|
219104581|NCT03591757|DRUG|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
219104582|NCT05399095|BEHAVIORAL|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
219104583|NCT05399095|BEHAVIORAL|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
219104584|NCT02172300|DRUG|Tiotropium inhalation capsules|
219104585|NCT02172300|DRUG|Placebo inhalation capsules|
219104586|NCT01472562|DRUG|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
219104587|NCT01472562|BIOLOGICAL|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
219104588|NCT00260819|DRUG|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
219104589|NCT00260819|DRUG|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
219104590|NCT03788902|DRUG|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
219104591|NCT03311022|DRUG|Nefopam Hydrochloride 30mg Tablets|
219104592|NCT03311022|DRUG|Acupan® 30mg Tablets|
219104593|NCT01512745|DRUG|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
219104594|NCT01512745|DRUG|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
219104595|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
219691692|NCT02605200|BEHAVIORAL|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
219691693|NCT02481050|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
219691694|NCT03220841|DRUG|Adalimumab Injection|Standard dose adalimumab induction and maintenance
219691695|NCT03220841|DRUG|Thiopurine|Dose optimized thiopurine
219691696|NCT03220841|PROCEDURE|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
219691697|NCT04159714|DEVICE|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
219691698|NCT03353376|BEHAVIORAL|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
219691699|NCT06073288|OTHER|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
219104596|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
219104597|NCT01557621|BEHAVIORAL|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
219104598|NCT06116201|OTHER|Estradiol|Estradiol
219104599|NCT06116201|OTHER|Estradiol and Anti-Androgen|Estradiol and Anti-Androgen
219691700|NCT03933488|DRUG|TAK-994|TAK-994 tablets.
219691701|NCT03933488|DRUG|TAK-994 Placebo|TAK-994 placebo-matching tablets.
219104600|NCT06116201|OTHER|No intervention|No intervention
219104601|NCT01274065|GENETIC|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
219104602|NCT00243828|DEVICE|Total Face Mask|
219104603|NCT03062098|DEVICE|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
219104604|NCT03866642|DEVICE|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
219691702|NCT04420988|BIOLOGICAL|COVID-19 Convalescent Plasma|COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
219691703|NCT02676804|OTHER|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own."
219691704|NCT03105011|BEHAVIORAL|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
219691705|NCT05139342|DEVICE|expiratory muscle strentgh training (EMST)|"All patients undergo EMST training, and results will be compared between groups.~After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days."
219691706|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
219691707|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
219691708|NCT03246347|DRUG|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
219691709|NCT06400212|OTHER|Cardiopulmonary exercise test|Participants undergo a cardiopulmonary exercise test following a standardised protocol used in national guidelines
219691710|NCT04923529|DRUG|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
219691711|NCT04893161|DRUG|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
219691712|NCT05675163|DIETARY_SUPPLEMENT|Vitamin K2|(K2VITAL® 1% MCT Oil)
219691713|NCT05675163|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
219691714|NCT04113694|DEVICE|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
219691715|NCT00464685|DRUG|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
219104605|NCT00813410|PROCEDURE|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
219691716|NCT00464685|DRUG|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
219691717|NCT00464685|PROCEDURE|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
219691718|NCT06432348|OTHER|Reformer pilates|Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Reformer Pilates sessions and three team training days.
219691719|NCT06432348|OTHER|Mat Pilates|Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Mat Pilates sessions and three team training days.
219691720|NCT04100213|BEHAVIORAL|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
219691721|NCT01208272|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219691722|NCT01208272|BEHAVIORAL|Interpersonal Therapy (IPT)|
219691723|NCT01092468|PROCEDURE|Diathermy|flap dissection with conventional diathermy
219691724|NCT01092468|PROCEDURE|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
219691725|NCT06447714|BEHAVIORAL|smoke|cotinine detection
219104606|NCT04935723|OTHER|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
219104607|NCT01416701|DIETARY_SUPPLEMENT|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
219104608|NCT01416701|DIETARY_SUPPLEMENT|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
219224188|NCT03090711|DEVICE|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
219224189|NCT03090711|DEVICE|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
219104609|NCT02761460|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
219104610|NCT03541772|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
219104611|NCT03541772|DIETARY_SUPPLEMENT|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
219224190|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
219104612|NCT05296096|OTHER|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
219691726|NCT02064244|OTHER|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
219691727|NCT04015362|PROCEDURE|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
219691728|NCT04015362|PROCEDURE|Sham|Application of sham magnetic stimulation to spinal cord
219691729|NCT02414282|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219691730|NCT05510817|OTHER|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
219691731|NCT02674503|BEHAVIORAL|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
219691732|NCT02674503|BEHAVIORAL|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
219691733|NCT03663270|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
219104613|NCT00668824|DRUG|Vasovist|
219691734|NCT04576013|DEVICE|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
219691735|NCT04576013|BEHAVIORAL|Intensive upper extremity motor training|
219691736|NCT04472221|PROCEDURE|Arterioarterial synthetic graft|Synthetic poly tetraflouroethylene graft
219691737|NCT03874793|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
219691738|NCT03874793|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
219691739|NCT06211023|DRUG|SHR-1921|SHR-1921
219104614|NCT01466296|DEVICE|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
219224191|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
219224192|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
219691740|NCT06211023|DRUG|carboplatin|carboplatin AUC 4
219691741|NCT06211023|DRUG|carboplatin|carboplatin AUC 5
219691742|NCT06211023|DRUG|platinum-based doublet chemotherapy|platinum-based doublet chemotherapy
219691743|NCT02053103|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
219691744|NCT02053103|DRUG|Placebo|Tablet, 0 mg, twice daily, 6 weeks
219691745|NCT02737761|BEHAVIORAL|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
219691746|NCT00587067|DRUG|FLOXURIDINE|"\[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is \>25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
219691747|NCT00329108|DRUG|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
219691748|NCT00329108|DRUG|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
219691749|NCT00903201|DRUG|SB656933|20 mg
219691750|NCT00903201|DRUG|SB656933|50mg
219691751|NCT00903201|DRUG|Placebo|placebo
219691752|NCT03604003|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
219691753|NCT03615963|DIAGNOSTIC_TEST|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
219691754|NCT02611882|DRUG|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
219104615|NCT01466296|DEVICE|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
219691755|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
219691756|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
219691757|NCT03994380|DRUG|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
219691758|NCT00560729|DIETARY_SUPPLEMENT|Renutryl 500|
219691759|NCT00560729|DIETARY_SUPPLEMENT|Generique|
219691760|NCT00560729|DIETARY_SUPPLEMENT|Generique + Renutryl 500|
219691761|NCT04269616|BEHAVIORAL|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
219691762|NCT04269616|BEHAVIORAL|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
219691763|NCT01389232|DEVICE|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
219691764|NCT00002551|DRUG|fluorouracil|See arm assignments.
219691765|NCT00002551|DRUG|leucovorin calcium|See arm assignments.
219691766|NCT00002551|DRUG|levamisole hydrochloride|See arm assignments.
219691767|NCT00002551|RADIATION|radiation therapy|See arm assignments.
219104616|NCT01466296|DEVICE|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
219691768|NCT04678284|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
219691769|NCT05695703|OTHER|Core Strength Training Group|"The participants of experimental group will perform core strength training regime for 6 weeks (3 days per week). Each exercise session will last for a period of 45 mins, the exercises would be performed in 3 sets of 5 repetitions with 5 seconds hold time and 10 seconds rest between each repetition and a minutes rest in between each set.~Following exercises would be performed :~Bridge, Crunch, Plank, Side Plank, Mountain Climb."
219691770|NCT05695703|OTHER|Conventional Training Group|"The participants of conventional group will perform following exercises :~Running (10 repetitions X 3 sets), Jogging (10 repetitions X 3 sets), Stretching (10 repetitions X 3 sets)~Rest between Exercises : 10-15 Seconds Rest between Set of Exercises : 30-60 Seconds Cricketers will receive exercises for 8 weeks. There will be 3 sessions per week."
219691771|NCT04802200|OTHER|Data collect|Data collect following a vascular closure by MANTA
219691772|NCT03906864|OTHER|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
219691773|NCT01865357|OTHER|Brain MRI - Clinical and cognitive evaluation|"* Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
219691774|NCT01865357|OTHER|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
219691775|NCT01334086|DRUG|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
219691776|NCT05623410|BIOLOGICAL|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
219691777|NCT05623410|BIOLOGICAL|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
219691778|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
219691779|NCT06258434|DIAGNOSTIC_TEST|multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)|Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
219691780|NCT03205150|DRUG|LIK066|Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
219691781|NCT03205150|DRUG|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
219691782|NCT03040271|OTHER|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
219691783|NCT00955500|DIETARY_SUPPLEMENT|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
219691784|NCT00955500|DIETARY_SUPPLEMENT|Maltodextrin|30 grams of oral maltodextrin daily
219691785|NCT04578704|OTHER|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
219691786|NCT04243629|DRUG|Rapid-Acting Insulin|Novorapid or Humalog insulin delivered in a basal-bolus manner.
219691787|NCT04243629|DRUG|Placebo|Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
219691788|NCT04243629|DRUG|Pramlintide Acetate|Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
219691789|NCT04243629|DEVICE|Artificial Pancreas|Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
219691790|NCT05563545|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.
219691791|NCT06571162|OTHER|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
219691792|NCT06571162|OTHER|Usual Care|Patient will receive usual care for their LDL-C management.
219691793|NCT00871624|DRUG|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
219691794|NCT00871624|DRUG|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
219691795|NCT04779424|OTHER|POCT|Capillary blood sample antibody point of care test
219691796|NCT00738712|PROCEDURE|MRI Magnetic Resonance Imaging|MRI
219691797|NCT04967053|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy gives long-standing improvement or resolution of obesity-related conditions and also survival benefit. It is highly cost-effective. Surgical procedures for the treatment of obesity.
219104617|NCT00936221|DRUG|AZD6244|oral capsules, 75mg twice daily
219104618|NCT00936221|DRUG|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
219104619|NCT00936221|DRUG|Placebo|Placebo
219104620|NCT01376960|PROCEDURE|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
219104621|NCT03151395|OTHER|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
219104622|NCT03093857|DIAGNOSTIC_TEST|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
219104623|NCT05247827|OTHER|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
219104624|NCT05981963|DRUG|[14C]-BMS-986196|Specified dose on specified days
219104625|NCT00728117|OTHER|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
219104626|NCT00728117|OTHER|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
219104627|NCT01878123|BIOLOGICAL|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
219104628|NCT01878123|OTHER|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
219104629|NCT01141270|DRUG|AFOLIA|single sc injection, 225 IU
219104630|NCT01141270|DRUG|Gonal-f|single sc injection, 225IU
219104631|NCT00879996|DRUG|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
219104632|NCT00879996|DRUG|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
219691798|NCT04539418|DRUG|Vitamin K 2|Patients will be monitored during the whole protocol.
219691799|NCT03246464|DEVICE|Orthokeratology lenses|Rigid gas permeable contact lenses
219691800|NCT03246464|DEVICE|Single-vision spectacles|Regular single vision spectacles
219104633|NCT02078505|BEHAVIORAL|diet|Carbohydrate poor diet
219104634|NCT01229982|DRUG|Latanoprost-PPDS|Punctal Plug
219104635|NCT05538260|PROCEDURE|Repair of ocular trauma in children below 16 years old|Diagnosis and repair of pediatric ocular trauma
219104636|NCT01566929|DIETARY_SUPPLEMENT|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
219104637|NCT01339598|DEVICE|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
219104638|NCT02340702|OTHER|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
219104639|NCT02641249|DEVICE|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
219104640|NCT05157516|PROCEDURE|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
219104641|NCT05157516|PROCEDURE|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
219104642|NCT03942380|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
219104643|NCT01285284|OTHER|Music|A previously defined list of songs will be administered by headphones to these patients.
219104644|NCT01285284|OTHER|No music|No music will be administered by the headphones connected to the MP3 device.
219104645|NCT03811106|DEVICE|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
219104646|NCT03811106|OTHER|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
219104647|NCT00204308|DRUG|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
219104648|NCT04426084|OTHER|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
219104649|NCT04426084|OTHER|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
219104650|NCT04426084|OTHER|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
219691801|NCT01127100|DRUG|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
219691802|NCT04970212|DEVICE|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
219691803|NCT02184819|DRUG|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
219691804|NCT02184819|DRUG|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
219691805|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
219691806|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
219691807|NCT06135181|DRUG|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
219691808|NCT03082508|DEVICE|Algisyl|Algisyl device (implants) administered during a surgical procedure
219691809|NCT03082508|DRUG|Standard Medical Therapy|as per protocol
219691810|NCT00857506|DRUG|florbetapir F 18|370 Mega Becquerel (10 mCi)
219691811|NCT02887703|BEHAVIORAL|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
219691812|NCT00313729|DRUG|temozolomide|Chemotherapy
219691813|NCT05871307|RADIATION|Preoperative Radiotherapy|Resection of brain mestases following
219691814|NCT05871307|RADIATION|Intraoperative Radiation|While Resection
219691815|NCT05871307|RADIATION|Postoperative Radiotherapy|After resection
219691816|NCT03566225|DRUG|Pioglitazone|Insulin sensitizing agents
219691817|NCT03566225|DRUG|Metformin|Insulin sensitizing agent
219691818|NCT03566225|DRUG|Clomiphene Citrate|Induction drug
219691819|NCT06379373|OTHER|Spine manipulation; westren medicine|"First Cervical traction,than spine release method,Massage the neck for about 10 minutes to realease muscles.Doctor use his two hands work together to pull the neck forward and upward,meanwhile, the patient's head is passively rotated to the right to the maximum, being rotated slightly with appropriate force, Doctor's left thumb pushes the crooked spinous process to the right, and the reduction sound can be heard at this time.~If patient has upper thoracic spine misalignment, the dislocated segment needs to be adjusted.~If patient has scoliosis, the affected spine segment should also be adjusted. If patient's lumbar facet joints are misaligned, or one of the lumbar muscles is spasmal, also the disorder joints need to be adjusted."
219691820|NCT02402517|OTHER|Control|Non pulse extruded snack
219691821|NCT02402517|OTHER|Small particle size pea flour|Pulse extruded snack
219691822|NCT02402517|OTHER|Large particle size pea flour|Pulse extruded snack
219691823|NCT02402517|OTHER|Lentil flour|Pulse extruded snack
219691824|NCT02402517|OTHER|Navy bean flour|Pulse extruded snack
219691825|NCT02402517|OTHER|Pinto bean flour|Pulse extruded snack
219691826|NCT05260814|DEVICE|Electric toothbrush with smart phone app|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
219691827|NCT01530269|DRUG|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
219691828|NCT01668420|OTHER|thermal stimulation|hot and cold/warm and cool pads applying.
219691829|NCT01009593|DRUG|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
219691830|NCT01009593|DRUG|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
219691831|NCT01537224|OTHER|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
219691832|NCT04744298|OTHER|TheraPPP|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
219691833|NCT00789321|DRUG|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
219691834|NCT00789321|DRUG|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
219691835|NCT05570448|PROCEDURE|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
219104651|NCT04426084|DRUG|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
219104652|NCT04426084|DRUG|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
219691836|NCT05570448|PROCEDURE|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
219691837|NCT00454961|DRUG|artemether-lumefantrine|
219691838|NCT02048423|DRUG|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
219691839|NCT03980548|PROCEDURE|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
219104653|NCT04426084|OTHER|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
219104654|NCT00242749|DRUG|Gefitinib, Cisplatin and Radiotherapy|
219104655|NCT02597933|DRUG|Nintedanib|
219104656|NCT02597933|DRUG|Placebo|
219104657|NCT05424445|DRUG|Misoprostol|Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
219691840|NCT02355678|DRUG|dexamethasone|IV 0.5 mg/kg
219691841|NCT02355678|DRUG|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
219691842|NCT02355678|DRUG|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
219691843|NCT02355678|PROCEDURE|Tonsillectomy|Mono-polar electrocautery or cold dissection
219691844|NCT02355678|PROCEDURE|gastric content suction|By orogastric tube
219691845|NCT02355678|DRUG|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
219691846|NCT02355678|DRUG|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
219691847|NCT02355678|DRUG|Paracetamol Suppository|If Visual Analogue Scale was less than 4
219691848|NCT03583957|DEVICE|Observational only|Device is only observational and used to record EEG.
219691849|NCT03583957|BEHAVIORAL|Psychological and Behavioral interaction with a seizure forecasting mobile app|Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
219691850|NCT03583957|COMBINATION_PRODUCT|Seizure Alerting and Prediction System|The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
219691851|NCT02899520|OTHER|Reference method|Electrostimulation associated to perineal training
219691852|NCT02899520|OTHER|CMP ® method|Method based on Knowledge and Control of Perineum
219104658|NCT01627080|OTHER|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
219104659|NCT04205929|DRUG|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
219691853|NCT02959801|PROCEDURE|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
219691854|NCT05697913|OTHER|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
219691855|NCT01078493|DEVICE|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
219104660|NCT04205929|DRUG|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
219104661|NCT01806519|BEHAVIORAL|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
219104662|NCT05666414|PROCEDURE|sandwich interpositional bone grafting computer guided|performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
219104663|NCT05666414|PROCEDURE|conventional interpositional bone grafting|performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
219104664|NCT04116944|BEHAVIORAL|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
219691856|NCT02516072|OTHER|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
219691857|NCT04686916|DRUG|IP2018|Test drug
219691858|NCT04686916|DRUG|Placebo|Placebo
219691859|NCT00830219|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
219691860|NCT00830219|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
219104665|NCT04116944|OTHER|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
219104666|NCT04489420|BIOLOGICAL|CYNK001-IV|Planned Starting dose dor IV 1.2x10\^9 cells/dose
219104667|NCT04489420|BIOLOGICAL|CYNK001-IT|Planned starting dose for IT 200 x10\^6 +/- 50 x10\^6 cells dose
219104668|NCT01617005|DRUG|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
219104669|NCT04232189|OTHER|no intervention|no intervention, just specimen collection
219104670|NCT02476214|BEHAVIORAL|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
219104671|NCT05284292|DEVICE|GUARDIAN platform|The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
219691861|NCT02695069|PROCEDURE|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
219691862|NCT02901223|PROCEDURE|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
219691863|NCT02901223|PROCEDURE|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
219691864|NCT06388772|DRUG|QHRD106 Injection|250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
219104672|NCT02720289|OTHER|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
219104673|NCT02720289|OTHER|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
219691865|NCT06388772|DRUG|placebo|placebo
219691866|NCT01064011|PROCEDURE|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
219691867|NCT01064011|PROCEDURE|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
219691868|NCT02352857|OTHER|Sugar|100g of sponge cakes made with 24g of dextrose.
219691869|NCT02352857|OTHER|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
219691870|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
219691871|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
219691872|NCT01294423|DRUG|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
219691873|NCT01953029|PROCEDURE|cardiac imajing|Cardiac MRI
219691874|NCT00717145|DRUG|risedronate|one risedronate 20 mg DR tablet
219104674|NCT00547690|OTHER|Acupuncture and Strengthening|Acupuncture and strengthening
219104675|NCT00547690|OTHER|Strengthening Alone|Strengthening training program
219104676|NCT05977920|OTHER|Caffeine|s. description
219104677|NCT03331029|DEVICE|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
219104678|NCT01698658|OTHER|ultrasound tomography|Undergo ultrasound tomography using SoftVue
219104679|NCT01698658|PROCEDURE|magnetic resonance imaging|Undergo MRI of the breast
219104680|NCT01159223|DRUG|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
219104681|NCT06031597|RADIATION|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
219104682|NCT06031597|DRUG|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
219104683|NCT06031597|DRUG|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
219104684|NCT06031597|DRUG|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
219104685|NCT01946581|PROCEDURE|Cataract Surgery|
219104686|NCT04443387|DRUG|Vitamin D|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
219104687|NCT04443387|OTHER|Placebo|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
219104688|NCT05242575|BEHAVIORAL|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
219104689|NCT04548271|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
219104690|NCT04548271|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
219104691|NCT03757806|OTHER|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
219104692|NCT04078035|BEHAVIORAL|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
219104693|NCT04078035|BEHAVIORAL|Control, Quiet Rest|5-minute quiet rest period.
219104694|NCT05250258|OTHER|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
219104695|NCT00288028|DRUG|bortezomib|Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
219104696|NCT05889884|DEVICE|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
219104697|NCT00612534|DRUG|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
219104698|NCT00612534|DRUG|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
219224193|NCT02714075|OTHER|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
219224194|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
219224195|NCT02714075|OTHER|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
219104699|NCT00612534|DRUG|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
219104700|NCT00612534|DRUG|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
219104701|NCT05915390|DIETARY_SUPPLEMENT|walnuts|walnuts will provide 15% of the total energy
219104702|NCT05915390|DIETARY_SUPPLEMENT|Habitual diet|continue with habitual diet and abstain from walnuts
219104703|NCT02223754|DEVICE|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
219104704|NCT02223754|DEVICE|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
219104705|NCT00722384|DRUG|bevasiranib|
219104706|NCT00722384|DRUG|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
219104707|NCT01194895|OTHER|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
219104708|NCT01194895|OTHER|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
219104709|NCT06560411|DEVICE|Non-Invasive Ventilation|Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
219104710|NCT00664638|DEVICE|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
219104711|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
219104712|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
219104713|NCT02381990|PROCEDURE|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
219104714|NCT05188755|OTHER|Indirect calorimetric test during submaximal exercise|"* metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity"
219104715|NCT04363099|OTHER|observational|observational management of outpatients COVID 19
219104716|NCT04942808|RADIATION|Periapical radiographs|Periapical radiographs on reevaluation
219104717|NCT05684913|PROCEDURE|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
219104718|NCT05684913|PROCEDURE|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
219104719|NCT00816933|PROCEDURE|appendectomy|appendectomy according to the number of trocar
219104720|NCT06127576|DEVICE|paraboloid geometry double and triple dental abutment-implant|"The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made."
219104721|NCT00189592|DEVICE|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
219104722|NCT00189592|PROCEDURE|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
219104723|NCT02985983|DRUG|Brodalumab|Administered Brodalumab by subcutaneous (SC) injection until week 66.
219104724|NCT02985983|DRUG|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
219104725|NCT03893201|OTHER|Questionnaires|Questionnaires to assess quality of life
219104726|NCT00627900|DEVICE|bare metal stent|implantation of a bare metal stent
219104727|NCT00627900|DEVICE|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
219104728|NCT06483425|GENETIC|Sequencing of DNA, RNA, and Proteins|Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
219104729|NCT02865070|DEVICE|Skin Sensor|Wireless vitals monitor
219104730|NCT01906671|DRUG|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
219104731|NCT01906671|DRUG|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
219104732|NCT01928316|DRUG|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
219104733|NCT01928316|DRUG|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
219104734|NCT05794802|DIETARY_SUPPLEMENT|BHB supplement|Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)
219104735|NCT05794802|OTHER|Placebo solution|80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
219104736|NCT06382714|OTHER|For the intervention group, a museum visit with virtual reality glasses will be applied.|Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
219104737|NCT04653441|BEHAVIORAL|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
219104738|NCT00235599|PROCEDURE|IGFBP-3 Stimulation Test|
219691875|NCT00717145|DRUG|risedronate|One risedronate 20 mg DR tablet
219691876|NCT00717145|DRUG|risedronate|One risedronate 35 mg DR tablet
219691877|NCT00717145|DRUG|risedronate|One risedronate 35 mg IR tablet
219691878|NCT06307353|OTHER|trends of contraception methods|family planning practice will include number of women current use of family planning methods and its type planning fot ffuture pregnancy suggested duration before next pregnancy.women'ssatisfaction with family planning services atElBalyana urban Medical Center accessibility of the site suitability of waiting time
219691879|NCT03521310|PROCEDURE|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
219691880|NCT03521310|PROCEDURE|Conventional care|Neonates will get Conventional care the first 72 hours after birth
219691881|NCT04605900|DEVICE|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
219691882|NCT04605900|DEVICE|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
219691883|NCT04605900|DEVICE|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
219104739|NCT00510458|DEVICE|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
219104740|NCT05573503|OTHER|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
219224196|NCT00255372|DRUG|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
219224197|NCT00255372|DRUG|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
219224198|NCT01335867|DRUG|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
219691884|NCT04605900|BEHAVIORAL|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
219691885|NCT01825824|RADIATION|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
219691886|NCT03570216|OTHER|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
219691887|NCT03570216|OTHER|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
219691888|NCT03570216|OTHER|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
219691889|NCT05573152|PROCEDURE|Control|All previously selected patients will be under passive warming by means of blankets
219691890|NCT05573152|PROCEDURE|Nursing|All previously selected patients will be under active air flow warming device at 43 Celsius
219691891|NCT01270035|DRUG|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
219691892|NCT01145482|DRUG|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
219691893|NCT01145482|OTHER|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
219691894|NCT06959693|DRUG|Cetuxima-β|500 mg/m², initial intravenous infusion (IV)\>120 min, subsequent IV \>60 min , D1，every 2 weeks
219691895|NCT06959693|DRUG|Envafolimab|a single fixed dose of 200 mg, subcutaneous injection(SC), every 2 weeks (Day 1 of each cycle \[D1\])
219691896|NCT06959693|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m² , IV, over 120 min, Day 1; Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1; 5-FU 400 mg/m² , bolus injection, followed by 1200 mg/(m²·d) continuous IV for 2 days (total dose 2400 mg/m² over 46 - 48 hours)
219691897|NCT04773223|PROCEDURE|Open surgery and complex EVAR due to AAA|"There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)"
219691898|NCT02190188|DEVICE|Wedge Insole 5mm|
219104741|NCT02929225|DRUG|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
219104742|NCT02929225|OTHER|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
219104743|NCT02043028|DEVICE|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
219104744|NCT02043028|DEVICE|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
219104745|NCT05585138|OTHER|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
219104746|NCT05585138|OTHER|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
219104747|NCT00425425|BIOLOGICAL|cetuximab|
219104748|NCT00425425|DRUG|fluorouracil|
219104749|NCT00425425|DRUG|oxaliplatin|
219104750|NCT00425425|PROCEDURE|conventional surgery|
219691899|NCT02190188|DEVICE|Knee Brace|
219691900|NCT03556033|DRUG|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
219691901|NCT03556033|DRUG|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
219691902|NCT02067858|RADIATION|Stereotactic Radiosurgery|
219691903|NCT01944657|DEVICE|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
219104751|NCT00425425|PROCEDURE|neoadjuvant therapy|
219691904|NCT01944657|DRUG|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
219691905|NCT00512525|DRUG|Ghrelin and saline (as placebo)|Intravenous infusion
219691906|NCT01699750|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
219691907|NCT01699750|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
219691908|NCT01699750|DEVICE|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
219691909|NCT01699750|DEVICE|BIOTRUE®|Contact lens care system, Phase 2
219104752|NCT00425425|RADIATION|radiation therapy|
219104753|NCT00539279|BEHAVIORAL|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
219104754|NCT00539279|BEHAVIORAL|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
219104755|NCT06810622|OTHER|Navigate-Kidney CHW|A CHW will provide support during visits every 2 weeks for 3 months (i.e., 6 visits during first 3 months) followed by monthly visits until end of study or until 3 months following KRT start. As well as receiving educational materials that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
219691910|NCT01699750|DEVICE|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
219691911|NCT01699750|DEVICE|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
219691912|NCT02119299|DEVICE|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
219691913|NCT01284868|DRUG|mirabegron|oral
219691914|NCT01284868|DRUG|Bisoprolol|oral
219691915|NCT01284868|DRUG|propranolol|oral
219691916|NCT01284868|DRUG|placebo|oral
219691917|NCT02004223|RADIATION|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
219691918|NCT05271565|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral formula
219691919|NCT05271565|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
219691920|NCT02026141|DRUG|Dexmedetomidine|
219691921|NCT02026141|DRUG|Normal Saline Placebo|
219691922|NCT02557724|PROCEDURE|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
219691923|NCT02557724|PROCEDURE|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
219691924|NCT04945785|OTHER|No intervention|no intervention
219691925|NCT01288690|BEHAVIORAL|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
219691926|NCT06524661|DEVICE|AS-OCT after vitrectomy|AS-OCT is a light based imaging technique of the anterior segment of the eye in this study it is used to measure the anterior chamber angle changes after pars plana vitrectomy.
219691927|NCT00751127|DRUG|PhXA41|One drop in the affected eye once daily for six months.
219691928|NCT00751127|DRUG|timolol|One drop in the affected eye twice daily for six months.
219691929|NCT05037162|DIAGNOSTIC_TEST|Biochemistry blood test|preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
219691930|NCT05037162|DIAGNOSTIC_TEST|Hematology blood test|preformed on days 1-14 and day 28. complete CBC.
219691931|NCT05037162|DIAGNOSTIC_TEST|D-Dimer test (coagulation)|performed on days 1,2,7,14 and 28.
219691932|NCT05037162|DIAGNOSTIC_TEST|Inflammatory markers|performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
219691933|NCT05037162|DIAGNOSTIC_TEST|Vital signs|performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
219691934|NCT05037162|DIAGNOSTIC_TEST|VAS scale|performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
219691935|NCT05037162|DIAGNOSTIC_TEST|WHO Ordinal Score|performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
219691936|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Related Symptoms assessment|performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
219691937|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Impact on Quality-of-Life Questionnaire|performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
219691938|NCT05037162|DIAGNOSTIC_TEST|POST- COVID-19 Functional Status Scale:|performed on day 28. score: 0-3 ; a higher score indicates better recovery.
219691939|NCT05037162|DIAGNOSTIC_TEST|Pregnancy test|performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
219691940|NCT05037162|DIAGNOSTIC_TEST|Physical examination|performed on days 1-14 and day 28. a full examination by a doctor.
219691941|NCT05037162|DIAGNOSTIC_TEST|PK parameters|"performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)"
219691942|NCT05037162|DIAGNOSTIC_TEST|SARS-CoV-2 test (PCR)|performed on days 1,14 and 28.
219691943|NCT05037162|DIAGNOSTIC_TEST|ECG|performed on days 1 and 28.
219691944|NCT05037162|DRUG|Treatment administration (twice a day)|performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
219691945|NCT01107145|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
219691946|NCT01107145|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
219691947|NCT01107145|DRUG|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
219691948|NCT01702467|DRUG|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
219691949|NCT01702467|DRUG|Placebo|Matching placebo capsules.
219691950|NCT03907696|OTHER|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
219691951|NCT04065243|OTHER|Overfeeding diet|Two weeks of overfeeding
219104756|NCT06810622|OTHER|Standard Care|Participants will receive standard medical care as well as educational materials developed that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
219104757|NCT06243289|OTHER|Tolerance induction|Exposure of peripheral blood mononuclear cells extracted from donated patient blood to a combination of vitamin D3 and interleukin 10 to test whether tolerogenic dendritic cells can be generated and have the same functional capacity between donors with and without kidney disease (exposure of PBMC to the uremic environment)
219224199|NCT01335867|DRUG|Placebo|Placebo pills
219691952|NCT04065243|OTHER|Isocaloric diet|Two weeks of isocaloric weight maintenance
219691953|NCT01327794|GENETIC|polymorphism analysis|
219691954|NCT01327794|OTHER|immunologic technique|
219691955|NCT01327794|OTHER|laboratory biomarker analysis|
219691956|NCT01327794|OTHER|medical chart review|
219691957|NCT00327223|DRUG|imexon|
219691958|NCT04301050|OTHER|Yoga Intervention|Weekly 75-minute yoga classes.
219691959|NCT00565461|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
219691960|NCT04752371|DRUG|Camoteskimab (CERC-007, AVTX-007, AEVI-007)|Intravenous (IV) Infusion
219691961|NCT00596219|DRUG|celecoxib|celecoxib
219691962|NCT03139734|DEVICE|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
219691963|NCT04794907|OTHER|Observation|Patient data will be collected from eye exams, surveys and medical record review.
219691964|NCT00119574|PROCEDURE|Collaborative Chronic Illness Model|
219691965|NCT02672241|DRUG|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
219691966|NCT02672241|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
219691967|NCT05218876|OTHER|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
219104758|NCT06660212|DEVICE|Photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. Doses will increase from 40%-100% power over the course of the intervention
219104759|NCT06660212|DEVICE|Sham photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants tolerance. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. . Doses will always be set to 1% power over the course of the intervention
219104760|NCT06660212|PROCEDURE|Multimodal physiotherapy|A total of 10 sessions of multimodal physiotherapy interventions will be provided to each of the participants in the multimodal physiotherapy (mPT) and multimodal physiotherapy combined with photobiomodulation treatment (mPT+PBM) groups. In general, each session will take place in the following order:1) Subjective assessment of the condition and screening for adverse effects or deterioration of the condition, 2)Education, 3) Relaxation Techniques, 4) Pelvic Floor Muscle Exercises, 5) Manual techniques, 6) exercises with accommodators, 7) Global exercises, 8) Assessment of the post-treatment condition and 9) adjustment of the weekly exercise program to be done at home. Each of these 9 treatments will be adjusted and tailored to each participant and progressed based on individual preference and response to treatment under the discretion of the study physiotherapist.
219104761|NCT06181721|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
219104762|NCT04396821|DRUG|TST001|TST001 is a humanized IgG1 monoclonal antibody.
219104763|NCT04396821|DRUG|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
219104764|NCT04396821|DRUG|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
219104765|NCT04396821|DRUG|Gemcitabine|Chemotherapy medication
219104766|NCT04396821|DRUG|Albumin-Bound Paclitaxel|Chemotherapy medication
219104767|NCT06624579|PROCEDURE|confocal endomicroscopy|The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
219104768|NCT06925048|DRUG|PD-1 inhbitor+SHR0302|PD-1 inhbitor+SHR0302 in the maintenance treatment
219104769|NCT06925048|DRUG|PD-L1 inhibitor+SHR0302|PD-L1 inhibitor+SHR0302 in second line
219104770|NCT06925568|OTHER|No Intervention: Observational Cohort|"This is an observational study, so there is no direct intervention. However, the study involves documenting and analyzing the existing management strategies, including~* use of diagnostic tools ECG, troponin tests, etc~* Administration of medications such as antiplates and anticoagulants.~* Reperfusion therapies -thrombolysis, PCI"
219104771|NCT06926413|DRUG|Aumolertinib；midazolam|"Midazolam :~The enrolled subjects will receive a single oral dose of Midazolam 2 mg (2 mg/mL, 1 mL) on D1 of the run-in period and on C2D1.~Aumolertinib :~Starting from C1D1, the enrolled subjects will receive oral dose of aumolertinib 110 mg (55 mg/tablet, 2 tablets) once daily until the criteria for terminating treatment are met."
219104772|NCT06891937|BEHAVIORAL|Positive psychology|5-week positive psychology intervention
219104773|NCT06895317|BEHAVIORAL|Remote rehabilitation|To develop and validate a quantitative assessment system based on wearable sensors
219104774|NCT06895317|BEHAVIORAL|Rehabilitation face to face|Compare the validity of face-to-face physiotherapy with remote physiotherapy
219104775|NCT02332343|OTHER|No intervention - Natural history study|
219104776|NCT03681418|PROCEDURE|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
219104777|NCT06810518|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
219104778|NCT06897670|OTHER|Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.|"Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex.~Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns.~* Resting-State Measurement: 5-10 min resting-state scans.~* Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min).~* During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG).~* Each participant will complete 3 sets of resting-state and task-based measurements.~Total estimated time for fNIRS assessment: 45-60 min."
219104779|NCT06899568|PROCEDURE|z mini plate with lingual extension|parasympheseal fracture model fixed with z mini plate with lingual extension
219104780|NCT06899568|PROCEDURE|two mini plates|parasympheseal fracture model fixed with conventional 2 mini plates
219104781|NCT06899841|DRUG|Dexmedetomidine|different doses of dexmedetomidine added to bupivacaine in erector spinae plane block
219691968|NCT05218876|OTHER|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
219691969|NCT01783743|OTHER|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
219691970|NCT02995993|DRUG|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
219691971|NCT00358696|DRUG|tenofovir|See Detailed Description.
219104782|NCT06900582|PROCEDURE|Sentinel Lymph Node Mapping|The SLN mapping protocol will follow the EU guidelines and the consensus in competency assessment tool. Prior to SLN mapping, a full inspection of the pelvic areas with white light is performed to exclude the presence of extrauterine disease. The next surgical steps will be 1- identification of external iliac vessels, 2- identification of internal iliac artery, 3- dissection of the ureter, 4- development of paravesical space and 5- identification of obliterated umbilical ligament. The dissection technique must avoid disrupting lymphatic channels and isolate nodal tissue from the local anatomy. Indocyanine green (1.25mg/mL) will be injected in the cervix at the 3 and 9 o'clock positions, with 1mL superficial and 1mL deep, for a total of 4mL. All mapped SLNs must be completely excised, and any visually suspicious nodes should also be removed, regardless of the mapping results. If the SLN mapping appears to be unfeasible, a side-specific pelvic lymphadenectomy will be performed.
219104783|NCT06900582|PROCEDURE|Comprehensive pelvic and para-aortic lymphadenectomy|"The resection of at least one lymph node in each of the 12 retroperitoneal regions is necessary:~A: upper para-aortic region B: lower para-aortic region C: interaorto-caval region D: paracaval region E: right and left iliaca communis region F: right and left iliaca externa region G: right and left fossa obturatoria region: defined by external and internal arteria iliaca, pelvic sidewall H: right and left iliaca interna region: lymph nodes adjacent to or medial of the internal iliacal artery"
219104784|NCT06899867|OTHER|Measure of cardiac index with thermodilution and transesophageal echocardiography|At 4 times of surgery, end-expiratory occlusion (EEO) test and measure of cardiac index before and after test with ETO and thermodilution
219104785|NCT06899867|OTHER|Surgical anastomosis echography|Visualisation of surgical anastomosis through transesophageal echocardiography : stenosis, doppler velocity, collar diameter
219104786|NCT06899464|DRUG|14-day Cerebrolysin treatment|14-day cerebrolysin treatment initiated within 6 hours of onset of stroke
219104787|NCT06899464|OTHER|Standard of Care (SOC)|Standard of care treatment
219104788|NCT06900179|OTHER|MFWs with AR|MFWs with AR This study utilized MyWeb AR as the primary development platform to create an AR-enhanced teaching curriculum for malignant fungating wound (MFW) care. Based on the 2022 Clinical Care Guidelines for Malignant Fungating Wounds and expert input from oncology specialists, the content covers key aspects of MFW care, including wound assessment, symptom identification, and care principles such as odor control, exudate management, and infection prevention. The program uses 3D object elements and animations to create interactive AR scenarios, allowing participants to engage in simulated clinical decision-making and care management, thereby enhancing their skills in a safe and controlled environment.
219104789|NCT06900179|OTHER|Classroom Teaching|Classroom Teaching and Case Sharing Introduction to Updated MFWs Care Guidelines and Clinical Applications MFWs Wound Care Management of Common MFWs-Related Complications Case Sharing on MFWs Complication Management: Researchers
219104790|NCT06899997|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting period
219104791|NCT06899997|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period
219104792|NCT05859165|DIETARY_SUPPLEMENT|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
219104793|NCT05859165|DIETARY_SUPPLEMENT|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
219104794|NCT06900959|COMBINATION_PRODUCT|transcranial static field stimulation (tSMS) and transcranial (tDCS)|"* tSMS is a non-invasive brain stimulation (NIBS) technique that involves the application of a neodymium magnet to the scalp. Since the initial study introducing this method, numerous subsequent studies have confirmed that tSMS can lead to a reduction in corticospinal excitability.~* Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) technique that applies low-voltage electrical currents through surface electrodes on the scalp. Depending on the stimulation type (anodal or cathodal) tDCS can induce long-lasting increases or decreases in neuronal excitability and vascular-neuronal activity coupling. Cathodal stimulation leads to hyperpolarization and a reduction in excitability, whereas anodal stimulation induces depolarization and enhances excitability."
219104795|NCT06899412|OTHER|self adhesive flowable composite|FIT SA is a self-adhesive, light-cured, flowable restorative with two discrete viscosities, F03 (low flow) and F10 (high flow) UDMA,HEMA,Phosphonic acid monomer, S-PRG filler based on fluoroboroaluminosilicate glass, Polymerizationinitiator,Pigments and others, Shofu's exclusive GIOMER technology gives FIT SA the ability to release and recharge fluoride and other beneficial ions for the life of the restoration.
219224200|NCT02520674|OTHER|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
219224201|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
219691972|NCT04281082|DRUG|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
219691973|NCT04016376|DRUG|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
219224202|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
219691974|NCT04016376|DRUG|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
219691975|NCT04016376|DRUG|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
219224203|NCT00831506|DRUG|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
219691976|NCT04530045|OTHER|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
219224204|NCT03057600|DRUG|Paclitaxel|standard weekly paclitaxel in 28-day cycles
219224205|NCT03057600|DRUG|CB-839|CB-839 administered as oral tablets twice daily (BID)
219104796|NCT06899412|OTHER|Conventional flowable composite|Conventional flowable composite (bulk fil)
219104797|NCT06887621|DRUG|Encapsulated amisulpride 50 mg (matched for color, weight, smell and size)|Amisulpride will be delivered orally 1 hour before anesthesia induction.
219104798|NCT06887621|DRUG|Encapsulated placebo (matched for color, weight, smell and size)|Placebo will be delivered orally 1 hour before anesthesia induction.
219104799|NCT06907095|DIAGNOSTIC_TEST|biological samples|biological samples (blood, urine, saliva, stools in option)
219104800|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
219104801|NCT01693692|DRUG|TD-9855 Group 1|
219104802|NCT01693692|DRUG|TD-9855 Group 2|
219104803|NCT01693692|DRUG|Placebo|
219104804|NCT06917235|PROCEDURE|Wrist and carpal arthrodesis|All patients that fit the inclusion criteria and accept the arthrodesis surgery will be followed up over the course of 1 year. The wrist and carpal arthrodesis procedures will include radioscapholunate, scaphoid-trapezium-trapezoid (STT), and four-corner arthrodeses.
219104805|NCT06925152|DRUG|Bupivicaine intervention arm|TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine
219104806|NCT06925152|DRUG|Placebo arm|Placebo group TAP block syringe will include 30mL normal saline
219104807|NCT06925334|DRUG|Degludec insulin|The pre-mixed human insulin or insulin analogues were stopped, and the treatment was switched to Delgol insulin liraglutide injection. The initial dose was subcutaneous injection of 80% (not more than 16 units) of the full daily dose of medium-acting insulin in the original insulin, once a day, and the dose of Delgol insulin liraglutide injection was adjusted according to the fasting blood glucose level. Example 1: If the patient is currently using Novorin 30 20iu bid, the conversion calculation is 40\*70%\*80%=22.4 units, which should be 16 units; In example 2, the patient applied eubrine 50 20 IU bid, and the conversion calculation was 40\*50%\*80%=16 units.
219104808|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
219104809|NCT01382940|DRUG|rituximab|1000 mg in 250 mL intravenous infusion
219104810|NCT01382940|DRUG|methotrexate|10 to 25 mg/week (oral or parenteral)
219104811|NCT01382940|DRUG|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
219104812|NCT01382940|DRUG|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
219104813|NCT01382940|DRUG|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
219104814|NCT02350920|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
219104815|NCT00937170|DEVICE|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
219104816|NCT00937170|DEVICE|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
219104817|NCT00937170|DEVICE|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
219104818|NCT01982877|BEHAVIORAL|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
219691977|NCT02771275|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
219104819|NCT01982877|BEHAVIORAL|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
219104820|NCT03804996|DRUG|TG-1801|Intravenous infusion over 1 hour every 4 weeks
219104821|NCT03804996|BIOLOGICAL|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
219104822|NCT04360122|DRUG|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
219104823|NCT04360122|DRUG|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
219104824|NCT04360122|DRUG|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
219104825|NCT03622385|OTHER|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
219104826|NCT00221949|DEVICE|Ultrasound|
219104827|NCT01596283|PROCEDURE|Standard fluid management|The patient will receive standard fluid management
219224206|NCT00748982|DRUG|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
219691978|NCT02512887|DRUG|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
219691979|NCT02512887|DRUG|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
219691980|NCT06499194|OTHER|DASH diet|The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
219691981|NCT05225948|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
219691982|NCT05225948|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
219691983|NCT02647138|OTHER|white noise|exposure to white noise
219691984|NCT06090838|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
219691985|NCT02354287|PROCEDURE|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
219104828|NCT01596283|DEVICE|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
219691986|NCT04478058|BEHAVIORAL|Live CBT|Weekly in-person Cognitive Behavioural Therapy
219691987|NCT04478058|BEHAVIORAL|e-CBT|Weekly online Cognitive Behavioural Therapy
219691988|NCT04204005|DIETARY_SUPPLEMENT|Probiotics|"Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively."
219104829|NCT05535140|OTHER|G8 Screening Tool|Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients \>65y/o who are scheduled with the medical oncology department.
219104830|NCT01486758|DRUG|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
219104831|NCT01486758|DRUG|Placebo|
219104832|NCT02906085|DRUG|Endothelin-1|
219104833|NCT02906085|DRUG|Placebo|Isotonic saline
219104834|NCT02655471|DRUG|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
219224207|NCT00748982|DRUG|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
219224208|NCT01793779|PROCEDURE|cold water immersion|
219224209|NCT01793779|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
219224210|NCT01793779|DIETARY_SUPPLEMENT|Placebo|
219691989|NCT01262144|RADIATION|Radiotherapy|Radiotherapy for cervical cancer
219691990|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
219691991|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
219691992|NCT04821063|DRUG|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
219691993|NCT04821063|DRUG|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
219691994|NCT04821063|DRUG|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
219691995|NCT06435013|DRUG|Lenvatinib|Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
219691996|NCT05201092|DRUG|[14C]-Lu AG06466|\[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
219691997|NCT03054142|OTHER|no intervention|
219691998|NCT04149444|DRUG|Trifluridine/Tipiracil|Oral medication
219691999|NCT01380236|DRUG|ASM8|
219692000|NCT03228641|DEVICE|micro-excisional skin removal with coring needle|
219692001|NCT03345641|OTHER|describe precocious maternal impressions when confronting the premature birth of her infant|
219104835|NCT03366220|DRUG|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
219104836|NCT03366220|DRUG|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
219104837|NCT02608489|DRUG|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
219104838|NCT02608489|DRUG|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
219104839|NCT03758820|BEHAVIORAL|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
219104840|NCT03605160|PROCEDURE|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
219104841|NCT03605160|PROCEDURE|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
219104842|NCT01411501|OTHER|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
219104843|NCT01411501|DRUG|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
219104844|NCT05250713|DEVICE|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
219104845|NCT00289237|BEHAVIORAL|Lifestyle intervention|
219104846|NCT05134714|DEVICE|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
219104847|NCT05134714|DEVICE|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
219104848|NCT01712243|OTHER|Light|
219104849|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a prefilled syringe presentation|efgartigimod PH20 SC as a prefilled syringe presentation
219104850|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a vial + syringe presentation|efgartigimod PH20 SC as a vial + syringe presentation
219104851|NCT04316728|DEVICE|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
219104852|NCT04130334|PROCEDURE|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
219104853|NCT04130334|PROCEDURE|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
219104854|NCT05697549|BEHAVIORAL|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
219224211|NCT04305197|DRUG|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
219692002|NCT04608071|PROCEDURE|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
219692003|NCT00000638|DRUG|Isoniazid|
219692004|NCT00000638|DRUG|Pyrazinamide|
219692005|NCT00000638|DRUG|Pyridoxine hydrochloride|
219692006|NCT00000638|DRUG|Rifampin|
219692007|NCT03289338|DRUG|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
219692008|NCT03289338|DRUG|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
219692009|NCT03289338|DRUG|Placebos|Normal saline intravenous once a month for 3 months
219104855|NCT03550430|BEHAVIORAL|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
219104856|NCT03550430|BEHAVIORAL|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
219104857|NCT03550430|OTHER|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
219104858|NCT03607201|OTHER|No intervention|Routine care
219104859|NCT06019013|DRUG|QLF3108|QLF3108 will be administered independent of body weight.
219104860|NCT01057030|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
219104861|NCT01057030|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
219692010|NCT04140773|DIETARY_SUPPLEMENT|D-serine|Capsule D-serine
219692011|NCT04140773|OTHER|Placebo|Capsule D-serine
219104862|NCT05417334|DEVICE|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
219104863|NCT05126979|BIOLOGICAL|Inactivated Split Influenza Vaccine|
219692012|NCT06059040|PROCEDURE|eliminating gastric residual volume monitoring|eliminating gastric residual volume monitoring from routine care
219692013|NCT00728494|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
219692014|NCT00728494|DRUG|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
219104864|NCT05126979|BIOLOGICAL|Placebo|
219104865|NCT06255821|BEHAVIORAL|Exposure|One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
219104866|NCT02482272|DRUG|Lamivudine|Lamivudine 100mg/day orally
219104867|NCT02482272|DRUG|Adefovir|Adefovir 10mg/day orally
219104868|NCT02482272|DRUG|Entecavir|Entecavir 1mg/day orally
219224212|NCT04305197|DRUG|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
219104869|NCT02313818|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
219104870|NCT00298142|PROCEDURE|Usual Care provided by a medical doctor (GP or Neurologist)|
219104871|NCT00298142|PROCEDURE|Usual care plus Physio-/ Manual Therapy|
219104872|NCT01671839|DEVICE|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
219104873|NCT01918696|BEHAVIORAL|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
219104874|NCT01918696|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
219692015|NCT00728494|BEHAVIORAL|Patient Assistance Program|"The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects."
219692016|NCT00914147|PROCEDURE|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
219692017|NCT05192265|DRUG|Antimalarials, pyronaridine-artesunate|The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.
219692018|NCT05192265|DRUG|Antimalarials, Artemether + Lumefantrine|Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
219692019|NCT04772066|OTHER|Measure of medication adherence|Measure of medication adherence
219692020|NCT05638282|DRUG|Cendakimab|Specified dose on specified days
219692021|NCT05638282|DRUG|Placebo|Specified dose on specified days
219692022|NCT05925439|DEVICE|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
219692023|NCT05925439|DEVICE|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
219692024|NCT00324922|DRUG|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
219692025|NCT00324922|DRUG|vancomycin|1g iv bid
219692026|NCT02294279|DRUG|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
219692027|NCT02706288|OTHER|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose \~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
219692028|NCT02308800|DEVICE|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
219692029|NCT02308800|DEVICE|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
219104875|NCT01918696|BEHAVIORAL|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
219104876|NCT01077479|DRUG|Metformin|Metformin 1500mg nocte for 6 months
219104877|NCT04534413|DEVICE|composite optical fiberscope (COF)|Fiber Technology
219104878|NCT02163655|DRUG|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
219104879|NCT02163655|DRUG|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
219104880|NCT00905502|DRUG|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
219692030|NCT00000798|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
219692031|NCT06047405|DEVICE|Average Volume-Assured Pressure Support (AVAPS)|A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
219692032|NCT06047405|DEVICE|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
219104881|NCT00905502|DRUG|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
219104882|NCT03297008|OTHER|No internvetion|No intervention, this is an observational study
219692033|NCT02460510|DRUG|Mannitol|
219104883|NCT03873194|OTHER|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
219104884|NCT03873194|OTHER|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
219692034|NCT02460510|DRUG|3% hypertonic saline|
219692035|NCT00364065|DEVICE|Ferris PainWrap|
219692036|NCT00572091|DEVICE|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
219692037|NCT04067869|PROCEDURE|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
219692038|NCT00520143|BIOLOGICAL|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
219692039|NCT03674268|DIAGNOSTIC_TEST|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
219692040|NCT00782197|DEVICE|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
219104885|NCT01703702|DRUG|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
219104886|NCT03093428|DRUG|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
219104887|NCT03093428|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
219104888|NCT04570553|PROCEDURE|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
219104889|NCT06152016|OTHER|BE-FAST|This intervention includes those randomized to the education with the BE-FAST mnemonic.
219692041|NCT00782197|DEVICE|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
219104890|NCT06152016|OTHER|FAST|This intervention includes those randomized to the education with the FAST mnemonic.
219104891|NCT05907460|DEVICE|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
219104892|NCT06305039|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant or acoustic hearing function|Because the cochlear implant participants in the study will use cochlear implant devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of cochlear implant or acoustic hearing function. This will include perceptual tests of sound localization, speech understanding in noise, binaural fusion, and loudness comparisons.
219104893|NCT06305039|BEHAVIORAL|Targeted aural rehabilitation of the poorer performing ear|Subjects will undergo listening practice on a tablet computer over headphones at home. For the test group, the aural rehabilitation will be targeted at the poorer ear. For the comparison control group, a sham aural rehabilitation will present speech to both ears.
219104894|NCT00978354|DRUG|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
219104895|NCT00978354|DRUG|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
219104896|NCT03020563|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine
219104897|NCT03020563|DRUG|Bupivacaine|Bupivacaine
219104898|NCT04334239|OTHER|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
219104899|NCT00954954|DEVICE|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
219104900|NCT00954954|DEVICE|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
219104901|NCT01179360|OTHER|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
219104902|NCT03980184|DRUG|Guanfacine|Guanfacine 3mg/day Versus Placebo
219104903|NCT03980184|OTHER|Behavioral Counseling|placebo
219104904|NCT01653808|DEVICE|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
219104905|NCT01653808|PROCEDURE|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
219104906|NCT01653808|PROCEDURE|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
219692042|NCT03439137|DRUG|MT-6548|Oral tablet
219692043|NCT03439137|DRUG|Darbepoetin alfa|Intravenous administration
219692044|NCT03439137|DRUG|MT-6548-matching placebo|Oral tablet
219104907|NCT00525135|DRUG|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
219104908|NCT01642602|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
219104909|NCT02504437|BIOLOGICAL|BMMSCs|
219104910|NCT03804190|OTHER|questionaire|dutch musculoskeletal questionaire
219104911|NCT00421525|BIOLOGICAL|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
219104912|NCT05304923|PROCEDURE|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
219104913|NCT05304923|PROCEDURE|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
219104914|NCT02291432|BIOLOGICAL|autologous muscle-derived cells (AMDC)|Cell treatment
219692045|NCT03439137|DRUG|Darbepoetin alfa-matching placebo|Intravenous administration
219692046|NCT02517281|PROCEDURE|Biopsy|
219104915|NCT04977518|OTHER|no intervention|no intervention
219104916|NCT00790920|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
219104917|NCT00790920|DRUG|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
219104918|NCT04619953|OTHER|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
219224213|NCT04305197|DRUG|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
219224214|NCT04305197|DRUG|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
219692047|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)|"Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
219104919|NCT04619953|OTHER|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
219104920|NCT04619953|OTHER|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
219104921|NCT04107623|DIAGNOSTIC_TEST|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
219104922|NCT04315103|COMBINATION_PRODUCT|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
219104923|NCT05985603|OTHER|CIMT Group|In this group of patients CIMT technique will be used for treatment
219104924|NCT05985603|OTHER|Mirror Therapy group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
219104925|NCT04684082|DEVICE|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
219104926|NCT06099951|DRUG|Serplulimab + FOLFOXIRI|Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
219104927|NCT06099951|RADIATION|Radiation therapy|Radiation therapy
219104928|NCT03009890|PROCEDURE|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
219104929|NCT03009890|PROCEDURE|Cast treatment|Hospitals may use their preferred protocol
219104930|NCT01200030|BEHAVIORAL|electrical stimulation with exercises|electrical stimulation with exercises
219104931|NCT01200030|BEHAVIORAL|placebo stimulation with exercises|placebo stimulation with exercises
219104932|NCT02770508|DRUG|darunavir/ritonavir|
219104933|NCT02770508|DRUG|Lamivudine|
219104934|NCT02770508|DRUG|emtricitabine-tenofovir(FTC/TDF)|
219104935|NCT02127827|DEVICE|Automated Ambulatory Glycemic Controller (AAGC)|
219104936|NCT02013973|OTHER|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
219104937|NCT00136812|BEHAVIORAL|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
219104938|NCT04283344|OTHER|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
219104939|NCT03072381|BIOLOGICAL|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
219104940|NCT03072381|DRUG|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
219104941|NCT03019120|DRUG|Vitamin D|"1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
219104942|NCT04736589|DRUG|Inetetamab|Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
219104943|NCT04736589|DRUG|Rapamycin|Oral 2mg, once a day.
219104944|NCT04736589|DRUG|Pyrotinib|Oral 400mg, once a day.
219104945|NCT04736589|DRUG|Chemotherapy|Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
219104946|NCT00499850|DRUG|ZD6474 (vandetanib)|once daily oral dose
219104947|NCT00499850|DRUG|5-Fluorouracil|intravenous infusion
219104948|NCT00499850|DRUG|Leucovorin|intravenous infusion
219104949|NCT00499850|DRUG|Oxaliplatin|intravenous infusion
219104950|NCT01914367|BIOLOGICAL|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
219104951|NCT01914367|BIOLOGICAL|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
219104952|NCT00422799|DRUG|Bortezomib|Once weekly for 3 weeks
219104953|NCT00422799|DRUG|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
219104954|NCT00102050|DRUG|NM-702 (phosphodiesterase inhibitor)|
219104955|NCT04733911|OTHER|75 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
219224215|NCT01968967|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
219104956|NCT04733911|OTHER|150 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
219104957|NCT04733911|OTHER|300 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
219104958|NCT03266471|DIAGNOSTIC_TEST|Baseline blood sample|Blood sample for cytokine measurements and genetics.
219104959|NCT03266471|DIAGNOSTIC_TEST|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
219104960|NCT03266471|OTHER|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
219104961|NCT03266471|DIAGNOSTIC_TEST|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
219104962|NCT03266471|DIAGNOSTIC_TEST|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
219104963|NCT03266471|DIAGNOSTIC_TEST|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
219104964|NCT03266471|DIAGNOSTIC_TEST|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
219104965|NCT06110845|DEVICE|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
219104966|NCT02025920|OTHER|Salmon Group|
219104967|NCT02025920|OTHER|Cod Group|
219104968|NCT02025920|OTHER|Meat Group|
219104969|NCT05297721|OTHER|Knowledge|Measuring the level of knowledge about skin tears
219104970|NCT04542226|DRUG|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
219104971|NCT01305746|DRUG|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
219104972|NCT01305746|DRUG|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
219104973|NCT01305746|DRUG|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
219104974|NCT04695340|DIETARY_SUPPLEMENT|Psyllium|Psyllium is given to patients
219104975|NCT03874780|DEVICE|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
219104976|NCT05601635|DIETARY_SUPPLEMENT|ButyraGen™|ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
219104977|NCT03848091|OTHER|Antibiotic pretreatment|a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
219104978|NCT02456974|PROCEDURE|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
219104979|NCT02456974|PROCEDURE|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
219104980|NCT02456974|PROCEDURE|blood sampling in patients receiving vancomycin as part of routine clinical care.|
219104981|NCT02456974|PROCEDURE|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
219104982|NCT02456974|PROCEDURE|blood sampling in patients receiving meropenem as part of routine clinical care.|
219104983|NCT02456974|PROCEDURE|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
219104984|NCT02456974|PROCEDURE|blood sampling in patients receiving amikacin as part of routine clinical care.|
219104985|NCT01503541|GENETIC|DNA analysis|
219104986|NCT01503541|GENETIC|RNA analysis|
219104987|NCT01503541|GENETIC|gene expression analysis|
219104988|NCT01503541|GENETIC|mutation analysis|
219104989|NCT01503541|GENETIC|polymerase chain reaction|
219104990|NCT01503541|OTHER|laboratory biomarker analysis|
219104991|NCT05835193|OTHER|Diagnostic Test: Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
219224216|NCT01968967|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
219224217|NCT04715815|OTHER|No intervention (only interview)|Interview
219104992|NCT06170957|OTHER|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
219104993|NCT04746547|DRUG|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
219104994|NCT04746547|DRUG|Dolutegravir 10 MG|Twice daily dolutegravir with rifampicin containing TB treatment
219104995|NCT02546154|DRUG|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
219104996|NCT02802683|DRUG|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
219104997|NCT02802683|DRUG|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
219104998|NCT02802683|DRUG|Phenylephrine|continous infusion of phenylephrine
219104999|NCT02802683|DRUG|normal saline|continous infusion of normal saline
219105000|NCT04463784|DRUG|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
219105001|NCT04463784|DRUG|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
219105002|NCT02792985|BEHAVIORAL|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
219105003|NCT02792985|BEHAVIORAL|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
219105004|NCT00547287|DRUG|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
219105005|NCT00547287|DRUG|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
219105006|NCT02810314|BEHAVIORAL|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
219105007|NCT02810314|OTHER|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
219105008|NCT00635765|DRUG|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
219105009|NCT00284869|DRUG|LPS|
219105010|NCT03539367|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219105011|NCT03539367|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219105012|NCT00810758|DRUG|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
219105013|NCT00810758|DRUG|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
219105014|NCT00810758|DRUG|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
219105015|NCT03748602|PROCEDURE|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
219105016|NCT00001202|DRUG|Spironolactone|
219105017|NCT00001202|DRUG|Testolactone|
219105018|NCT00001202|DRUG|Deslorelin|
219105019|NCT04202744|OTHER|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
219105020|NCT01474616|OTHER|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
219105021|NCT02091739|DRUG|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219105022|NCT02091739|DRUG|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219105023|NCT02091739|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219105024|NCT06624943|DRUG|biosimilar insulin glargine|Once daily injection of biosimilar insulin glargine via reusable pen
219105025|NCT01948180|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T-cells
219105026|NCT00713674|OTHER|Theraworx|Theraworx swab intranasal BID for 5 days
219692048|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Live (ORCA-L)|"A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
219692049|NCT04866576|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
219692050|NCT04866576|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
219692051|NCT01297686|OTHER|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
219692052|NCT01297686|OTHER|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
219692053|NCT01297686|OTHER|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
219105027|NCT00713674|DRUG|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
219105028|NCT00022217|DRUG|carboplatin|
219105029|NCT00022217|DRUG|cisplatin-e therapeutic implant|
219105030|NCT00022217|DRUG|paclitaxel|
219105031|NCT02979626|PROCEDURE|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
219105032|NCT03213496|BEHAVIORAL|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
219105033|NCT03213496|OTHER|Conventional care|Patient do not walk before surgery
219105034|NCT01336959|DRUG|BCT197 Part A|open label single dose administration of 10mg BCT197, 2 hours prior to surgery
219105035|NCT01336959|DRUG|Placebo|Single dose matching placebo administered 2 prior to surgery
219692054|NCT01297686|OTHER|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
219105036|NCT01336959|DRUG|BCT197 Part B|BCT197 50mg single dose administered 2 hours prior to surgery
219105037|NCT03771157|DRUG|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
219692055|NCT01297686|OTHER|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
219692056|NCT01297686|OTHER|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
219692057|NCT01297686|OTHER|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
219692058|NCT01297686|DRUG|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
219692059|NCT01207843|BEHAVIORAL|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
219692060|NCT06580015|PROCEDURE|Computed Tomography|Undergo PET-CT
219105038|NCT02796781|BIOLOGICAL|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
219105039|NCT00722995|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
219105040|NCT00722995|PROCEDURE|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
219105041|NCT01737996|DRUG|BI 207127 + faldaprevir|fixed dose combination
219692061|NCT06580015|OTHER|Flotufolastat F-18 Gallium|Given IV
219692062|NCT06580015|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
219692063|NCT06580015|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219692064|NCT01959100|DRUG|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
219692065|NCT01959100|DRUG|Placebo|250 mg x 3/week during a meal for a period of 2 years
219692066|NCT05512663|DEVICE|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
219692067|NCT04327778|PROCEDURE|Music Therapy|Automate music therapy every two weeks
219692068|NCT04804137|OTHER|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
219692069|NCT04804137|OTHER|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
219692070|NCT04804137|OTHER|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
219692071|NCT04804137|OTHER|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
219105042|NCT05268484|DEVICE|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
219105043|NCT02746822|OTHER||
219105044|NCT06123572|OTHER|Placebo|Placebo Comparator
219105045|NCT06123572|OTHER|Anti-Ageing and Skin Brightening Gel|Anti-Ageing and Skin Brightening Gel.
219105046|NCT03438240|DRUG|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
219105047|NCT03438240|DRUG|Fentanyl|Plus 50 µg fentanyl
219105048|NCT03438240|DRUG|Dexmedetomidine|Plus 50 µg dexmedetomidine
219692072|NCT05131763|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
219692073|NCT01727921|DEVICE|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
219692074|NCT01727921|DEVICE|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
219692075|NCT05087589|DRUG|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
219692076|NCT01531634|BEHAVIORAL|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
219692077|NCT04671199|OTHER|MP 3000 monitor|Additional monitoring
219692078|NCT00748241|DEVICE|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
219692079|NCT05746806|RADIATION|Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy|Ultrahypofractioned radiotherapy for patients with isolated local recurrence after radical prostatectomy in 5 fractions
219692080|NCT05746806|DRUG|Androgen deprivation therapy|"In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The preferred drug concept used is:~\- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection~Alternatively the following oral drug concept can be used, if the patient rejects injections:~\- GnRH (gonadotropin-releasing hormone)-antagonist with tablet intake for 6 months (e.g. Orgovyx® Tablets 120mg; first day 360mg, after second day 120mg per day)"
219692081|NCT01240382|DRUG|3% DE-089 ophthalmic solution|
219692082|NCT01240382|DRUG|0.1% sodium hyaluronate ophthalmic solution|
219692083|NCT02076100|DRUG|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
219692084|NCT06029972|DRUG|Tilpisertib Fosmecarbil|Tablets administered orally
219692085|NCT06029972|DRUG|Placebo|Tablets administered orally
219692086|NCT04654741|DRUG|Medroxyprogesterone Acetate|1 pill per day
219692087|NCT04654741|DRUG|Ganirelix Acetate|1 injection per day
219692088|NCT02456727|PROCEDURE|Group/Community Acupuncture|Acupuncture treatment in a group setting.
219692089|NCT02456727|PROCEDURE|Individual Acupuncture|Acupuncture treatment in an individual setting.
219692090|NCT04236037|PROCEDURE|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
219692091|NCT04236037|PROCEDURE|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
219692092|NCT01616043|PROCEDURE|Glyaderm|acellular dermis
219692093|NCT01616043|PROCEDURE|STSG|autologous split skin only
219692094|NCT02643693|OTHER|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
219692095|NCT02643693|OTHER|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
219105049|NCT03119610|DRUG|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
219105050|NCT03119610|DRUG|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
219692096|NCT02643693|OTHER|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
219692097|NCT00016536|DRUG|Naphthalene 2-sulfonate polymer|
219692098|NCT00016536|DRUG|Carbopol polymer|
219692099|NCT00005998|DRUG|carmustine|
219692100|NCT00005998|DRUG|cyclophosphamide|
219692101|NCT00005998|DRUG|cytarabine|
219692102|NCT00005998|DRUG|dexamethasone|
219105051|NCT04929366|PROCEDURE|Hypothermic dialysis followed with routine dialysis|Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)
219105052|NCT04929366|PROCEDURE|Routine dialysis followed with hypothermic dialysis|Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
219692103|NCT00005998|DRUG|etoposide|
219692104|NCT00005998|DRUG|filgrastim|
219692105|NCT00005998|DRUG|mitoxantrone hydrochloride|
219692106|NCT00005998|DRUG|retrovirus vector LN|
219692107|NCT00005998|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219105053|NCT01711957|PROCEDURE|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
219105054|NCT04960553|DEVICE|Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
219105055|NCT00114634|DIETARY_SUPPLEMENT|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
219105056|NCT00114634|DIETARY_SUPPLEMENT|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
219105057|NCT05763082|DRUG|roflumilast cream 0.3%|test product
219105058|NCT05763082|DRUG|Zoryve|Reference Listed Drug product
219105059|NCT05763082|DRUG|Placebo|placebo
219105060|NCT05606263|DRUG|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
219105061|NCT04924764|OTHER|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
219105062|NCT03524456|OTHER|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
219692108|NCT00005998|PROCEDURE|peripheral blood stem cell transplantation|
219692109|NCT00005998|PROCEDURE|radiation therapy|
219692110|NCT03541837|DRUG|Ropivacaine|ESP catheter
219692111|NCT04343352|OTHER|implementation of mobile epilepsy training program|"Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied."
219692112|NCT02758782|BIOLOGICAL|Golimumab|
219692113|NCT02758782|DRUG|Celecoxib|
219105063|NCT04538924|OTHER|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
219105064|NCT05924282|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
219105065|NCT01054690|DEVICE|Bactiguard Infection Protection (BIP) Cathter.|
219692114|NCT02666976|DRUG|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
219105066|NCT01054690|DEVICE|Silicone Urinary Catheter|
219105067|NCT03376503|DRUG|Pegfilgrastim|PK,PD and safety assessment
219105068|NCT03601104|OTHER|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
219105069|NCT03601104|OTHER|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
219105070|NCT03601104|OTHER|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
219105071|NCT03601104|OTHER|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
219105072|NCT01003184|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once a week
219105073|NCT01003184|DRUG|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
219105074|NCT00557622|DRUG|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
219105075|NCT00557622|OTHER|placebo|placebo
219692115|NCT05804812|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
219692116|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
219692117|NCT00685815|DRUG|Placebo|250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
219692118|NCT03241095|PROCEDURE|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
219105076|NCT06281262|DIAGNOSTIC_TEST|Peripheral blood collection|"The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations."
219105077|NCT06281262|DIAGNOSTIC_TEST|Swab sample collection|Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
219105078|NCT05434221|OTHER|COPE|"The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months."
219105079|NCT01097486|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
219105080|NCT01097486|PROCEDURE|Allograft|Single Dose Allograft Surgical Implantation
219105081|NCT03450681|PROCEDURE|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
219105082|NCT03450681|PROCEDURE|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
219105083|NCT04780724|OTHER|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
219105084|NCT04780724|OTHER|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
219105085|NCT04780724|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
219105086|NCT04412590|OTHER|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
219105087|NCT04412590|OTHER|Treatment as Usual|Pediatric care as usual.
219692119|NCT03241095|PROCEDURE|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
219692120|NCT04758728|PROCEDURE|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
219692121|NCT04758728|DRUG|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
219692122|NCT04758728|DRUG|normal saline|Use of normal saline solution NaCl 0,9% topically
219105088|NCT01468922|DRUG|Pazopanib|Vascular endothelial growth factor (VEGFR) inhibitor
219105089|NCT01468922|DRUG|ARQ 197|Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
219692123|NCT03957785|DEVICE|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
219692124|NCT04577599|OTHER|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
219692125|NCT02377856|DRUG|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
219692126|NCT00676117|DRUG|Esomeprazole (D961H)|20mg
219105090|NCT04315714|OTHER|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
219692127|NCT00676117|DRUG|Loxoprofen|60mg tablet
219105091|NCT04079283|DIAGNOSTIC_TEST|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
219692128|NCT05068843|PROCEDURE|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
219105092|NCT04079283|DIAGNOSTIC_TEST|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
219105093|NCT04079283|DIAGNOSTIC_TEST|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
219692129|NCT05068843|OTHER|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
219692130|NCT02974868|DRUG|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
219692131|NCT02974868|DRUG|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
219692132|NCT02974868|DRUG|Placebo|Placebo
219692133|NCT02193750|DIETARY_SUPPLEMENT|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
219692134|NCT02193750|DIETARY_SUPPLEMENT|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
219105094|NCT02991144|GENETIC|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
219105095|NCT02991144|DRUG|Reactive Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
219105096|NCT02991144|DRUG|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
219105097|NCT01719224|PROCEDURE|elevated body position|45 degrees elevated upper body position
219105098|NCT01719224|PROCEDURE|supine body position|non-elevated upper body position
219105099|NCT06320873|OTHER|archery respiratory parameters|Evaluation of respiratory functions, respiratory muscle strength and shooting performance in archers
219105100|NCT02665702|DRUG|NVB|25mg/m2 ，D1，8
219105101|NCT02665702|DRUG|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
219105102|NCT02665702|DRUG|Endostar|15mg/d，d1-d7 civ
219105103|NCT02548858|PROCEDURE|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
219105104|NCT02548858|PROCEDURE|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
219105105|NCT03354130|OTHER|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
219692135|NCT02193750|DIETARY_SUPPLEMENT|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
219692136|NCT01755507|DRUG|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
219692137|NCT01755507|DRUG|Placebo|
219692138|NCT04197271|PROCEDURE|Emergency Hernia Repair|Emergency repair of hernia using method selected by treating surgeon.
219692139|NCT04197271|OTHER|Conservative management|Treatment of hernia without resort to surgery
219692140|NCT03817606|DEVICE|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
219692141|NCT03817606|DEVICE|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
219692142|NCT06074185|DRUG|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
219692143|NCT03089476|OTHER|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
219692144|NCT03089476|OTHER|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
219692145|NCT00575354|DRUG|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
219692146|NCT00575354|DRUG|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
219692147|NCT03313739|OTHER|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
219692148|NCT06529341|OTHER|High-definition transcranial direct current stimulation|HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
219692149|NCT06529341|OTHER|High-definition transcranial direct current stimulation pseudo-stimulation control group|The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
219692150|NCT04619017|BIOLOGICAL|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
219692151|NCT02410447|DEVICE|Defocused shock wave therapy (DUOLITH® SD1)|
219692152|NCT00659087|PROCEDURE|Femoral Block|Those receiving femoral block postoperatively
219692153|NCT00659087|OTHER|Usual Care|Those receiving only usual pain management postoperatively
219692154|NCT05238636|PROCEDURE|Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication|This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
219692155|NCT03641261|OTHER|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
219105106|NCT02563522|GENETIC|Engensis (VM202)|gene therapy
219105107|NCT02563522|DRUG|Placebo|Standard of care plus placebo
219105108|NCT02007408|DRUG|Paracervical block|
219105109|NCT02007408|DRUG|Lidocaine spray|
219105110|NCT02007408|DRUG|Paracervical block + lidocaine spray|
219105111|NCT04651400|DRUG|Antithrombin III|Antithrombin III
219105112|NCT03767634|OTHER|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
219105113|NCT01458184|BEHAVIORAL|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
219105114|NCT02762838|BIOLOGICAL|BCD-055|BCD-055 is infliximab biosimilar
219105115|NCT02762838|BIOLOGICAL|Remicade®|
219692156|NCT03212040|DIAGNOSTIC_TEST|needle biopsy|breast biopsy using different needle gauges
219692157|NCT00025389|BIOLOGICAL|bevacizumab|
219692158|NCT00025389|DRUG|carboplatin|
219692159|NCT00025389|DRUG|paclitaxel|
219692160|NCT00025389|PROCEDURE|conventional surgery|
219692161|NCT00025389|PROCEDURE|neoadjuvant therapy|
219692162|NCT05705999|DEVICE|transcranial magnetic stimulation|The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session
219692163|NCT02515435|DRUG|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
219105116|NCT02762838|DRUG|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
219105117|NCT02762838|DRUG|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
219105118|NCT00675506|DRUG|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
219105119|NCT00675506|DRUG|Placebo|2-mg sub-cutaneous injections once daily for 12 months
219105120|NCT03820323|DIAGNOSTIC_TEST|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL\>1000 copies/mL) is detected.
219105121|NCT03820323|DIAGNOSTIC_TEST|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
219105122|NCT00796432|DRUG|OROS paliperidone|
219105123|NCT01100060|DRUG|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
219105124|NCT01100060|DRUG|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
219105125|NCT01100060|DRUG|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
219105126|NCT01100060|DRUG|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
219105127|NCT01312987|DIETARY_SUPPLEMENT|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
219105128|NCT04797325|DRUG|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
219105129|NCT04797325|DRUG|Prednisolone|tablet prednisolone plus infliximab in severe cases.
219105130|NCT03928145|DRUG|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
219105131|NCT03928145|DRUG|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
219105132|NCT03928145|DRUG|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
219105133|NCT03928145|DRUG|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
219105134|NCT00476619|DRUG|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
219105135|NCT03462134|OTHER|Survey|Survey amongst orthopaedic surgeons
219105136|NCT03485274|DRUG|Vortioxetine|oral medication taken once daily
219692164|NCT01876524|DEVICE|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
219105137|NCT03485274|OTHER|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
219105138|NCT05739032|OTHER|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
219105139|NCT06469411|BIOLOGICAL|Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)|Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
219105140|NCT06469411|OTHER|4 cc distilled water dissolved in albumin 20%|Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
219105141|NCT00001626|DRUG|antithymocyte globulin|antithymocyte globulin
219105142|NCT00001626|DRUG|cyclophosphamide|cyclophosphamide
219105143|NCT00001626|DRUG|cyclosporine|cyclosporine
219105144|NCT04035655|BEHAVIORAL|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
219105145|NCT04035655|DIAGNOSTIC_TEST|Electrophysiological recordings|"The electrophysiological assessment consisted of:~* a 5 minutes resting state high-density EEG recording~* a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
219105146|NCT00543660|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
219692165|NCT03575702|DRUG|Uritos®|film-coated tablets 0.1 mg
219692166|NCT03575702|DRUG|Urotol®|film coated tablets, 2 mg
219692167|NCT01106131|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
219692168|NCT01106131|DRUG|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
219692169|NCT00368628|PROCEDURE|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
219692170|NCT03903172|DEVICE|Abdominal binder|Abdominal binder
219692171|NCT01545388|DRUG|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
219692172|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
219692173|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
219692174|NCT01545388|DRUG|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
219692175|NCT01711697|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219692176|NCT01711697|DRUG|carboplatin|
219692177|NCT01711697|DRUG|paclitaxel|
219692178|NCT01711697|RADIATION|radiation therapy|Undergo radiation therapy
219692179|NCT05295381|DEVICE|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
219692180|NCT05295381|DEVICE|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
219692181|NCT03780582|BEHAVIORAL|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
219692182|NCT02633722|BEHAVIORAL|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
219692183|NCT02633722|BEHAVIORAL|Lifestyle Intervention D|Time limiting feeding (12-9pm)
219692184|NCT00358358|DRUG|Fluticasone Propionate/Salmeterol 500/50mcg combination|
219692185|NCT00358358|DRUG|Fluticasone Propionate 500mcg|
219692186|NCT00358358|DRUG|Salmeterol 50mcg|
219692187|NCT02541617|PROCEDURE|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
219692188|NCT02541617|PROCEDURE|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
219105147|NCT03357367|DEVICE|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
219105148|NCT00695747|PROCEDURE|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
219692189|NCT01255163|DRUG|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
219692190|NCT01255163|DRUG|Placebo SC|Placebo SC twice daily
219692191|NCT02423226|PROCEDURE|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
219692192|NCT02423226|DRUG|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
219692193|NCT04078464|OTHER|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
219692194|NCT04078464|OTHER|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
219692195|NCT04078464|OTHER|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
219105149|NCT03747770|BIOLOGICAL|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
219692196|NCT04477135|OTHER|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
219692197|NCT04477135|PROCEDURE|ultrasonography|ultrasonography
219692198|NCT02338817|DEVICE|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
219692199|NCT04952259|DRUG|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
219692200|NCT04952259|PROCEDURE|routine treatment|percutaneous coronary intervention
219692201|NCT02495389|DRUG|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
219692202|NCT05233735|OTHER|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
219692203|NCT05233735|OTHER|Topical treatment|betamethasone ointment treatment once per day
219692204|NCT04351620|DRUG|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
219692205|NCT04474925|PROCEDURE|Brain Surgery|Surgery to remove brain metastases
219692206|NCT04474925|RADIATION|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
219692207|NCT01297283|OTHER|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
219692208|NCT01297283|OTHER|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
219692209|NCT05396287|DEVICE|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
219692210|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
219692211|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
219692212|NCT02265965|DRUG|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
219692213|NCT06552117|OTHER|an elastoMRI sequence|Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
219692214|NCT02142816|DEVICE|Doppler|Fluid therapy guided by doppler
219692215|NCT02142816|OTHER|PVI'|Fluid therapy guided by PVI
219692216|NCT02276469|BEHAVIORAL|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
219692217|NCT03642028|DRUG|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
219105150|NCT03459313|OTHER|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
219105151|NCT02142582|DIETARY_SUPPLEMENT|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
219692218|NCT03642028|OTHER|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
219692219|NCT01802385|DRUG|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
219692220|NCT06780267|DRUG|HRS-2129|HRS-2129; low dose
219692221|NCT06780267|DRUG|HRS-2129|HRS-2129; high dose
219105152|NCT02142582|DIETARY_SUPPLEMENT|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
219692222|NCT06780267|DRUG|HRS-2129 placebo|HRS-2129 placebo
219692223|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
219692224|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
219692225|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
219692226|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
219105153|NCT03070509|DRUG|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
219105154|NCT05561348|DEVICE|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
219105155|NCT02712697|DRUG|WM (Shentong Granules)|Shentong Granules with Prednisone
219105156|NCT02712697|DRUG|Hormone (prednisone)|Oral prednisone
219105157|NCT05342103|PROCEDURE|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
219224218|NCT04624139|BEHAVIORAL|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
219692227|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
219692228|NCT00371956|DRUG|raloxifene|60mg/day
219692229|NCT00371956|DRUG|placebo|tab 1 daily
219692230|NCT05252715|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
219692231|NCT05252715|BIOLOGICAL|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
219692232|NCT05668897|DRUG|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
219105158|NCT06081335|DEVICE|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
219105159|NCT06081335|DEVICE|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
219105160|NCT04746651|OTHER|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
219105161|NCT01920503|DRUG|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
219105162|NCT03555630|DIAGNOSTIC_TEST|Thromboelastogram|Blood sample processing for thromboelastogram
219692233|NCT05668897|DRUG|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
219105163|NCT01863927|OTHER|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
219105164|NCT02081235|PROCEDURE|surgery for congenital heart disease|surgery for congenital heart disease
219105165|NCT00221286|DRUG|pegylated interferon alfa-2a|
219105166|NCT00221286|DRUG|tenofovir DF / emtricitabine combination therapy|
219105167|NCT00221286|DRUG|pegIFN / TDF / FTC combination therapy|
219105168|NCT00642837|DRUG|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
219105169|NCT00642837|DRUG|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
219105170|NCT00642837|DRUG|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
219105171|NCT00642837|DRUG|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
219105172|NCT00642837|DRUG|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
219105173|NCT00642837|DRUG|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
219105174|NCT00642837|DRUG|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
219105175|NCT00642837|DRUG|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
219105176|NCT00642837|DRUG|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
219105177|NCT00642837|DRUG|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
219105178|NCT04227496|DEVICE|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
219105179|NCT01107743|DRUG|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
219105180|NCT00308737|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
219105181|NCT00308737|DRUG|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
219105182|NCT04975828|DIAGNOSTIC_TEST|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
219105183|NCT05431634|DRUG|Experimental drug: ESK-001|Multiple doses of ESK-001
219105184|NCT05431634|OTHER|Placebo|Placebo
219105185|NCT05394233|DRUG|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
219105186|NCT02224482|BEHAVIORAL|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
219105187|NCT01915433|OTHER|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
219105188|NCT01915433|OTHER|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
219105189|NCT02218528|DIETARY_SUPPLEMENT|Plant-based ingredient|
219105190|NCT02218528|DIETARY_SUPPLEMENT|No Plant-based ingredient|
219105191|NCT01880372|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Same as Arm description
219105192|NCT00880321|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
219105193|NCT00880321|DRUG|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
219105194|NCT00880321|DRUG|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
219105195|NCT05145946|BEHAVIORAL|Video Game Training Group 1|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week.
219105196|NCT05145946|BEHAVIORAL|Video Game Training Group 2|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week.
219105197|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
219692234|NCT03414190|BEHAVIORAL|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
219692235|NCT01651364|DRUG|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
219692236|NCT01651364|DRUG|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
219692237|NCT03512522|BEHAVIORAL|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
219105198|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
219105199|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream|Patients using Hirudoid® alone
219105200|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
219105201|NCT00373932|BEHAVIORAL|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
219105202|NCT00373932|BEHAVIORAL|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
219105203|NCT01805882|DRUG|Sofosbuvir|
219105204|NCT01805882|DRUG|Ledipasvir|
219105205|NCT01805882|DRUG|GS-9669|
219224219|NCT04624139|BEHAVIORAL|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
219224220|NCT03489369|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
219224221|NCT00002437|DRUG|Cidofovir|
219692238|NCT03512522|BEHAVIORAL|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
219692239|NCT03669588|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
219105206|NCT01805882|DRUG|GS-9451|
219224222|NCT00002437|DRUG|Probenecid|
219692240|NCT03669588|BIOLOGICAL|Placebo|Intravenous administration of placebo
219692241|NCT01705041|DEVICE|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
219692242|NCT05150665|PROCEDURE|En-masse retraction|"Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew"
219692243|NCT05150665|PROCEDURE|Two step Retraction|"Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw."
219105207|NCT01225822|DRUG|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
219105208|NCT01225822|DRUG|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
219105209|NCT01225822|DRUG|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
219105210|NCT01225822|DRUG|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
219105211|NCT01225822|DRUG|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
219105212|NCT00002658|BIOLOGICAL|filgrastim|
219105213|NCT00002658|DRUG|amsacrine|
219105214|NCT00002658|DRUG|cyclophosphamide|
219105215|NCT00002658|DRUG|cytarabine|
219105216|NCT00002658|DRUG|daunorubicin hydrochloride|
219105217|NCT00002658|DRUG|etoposide|
219105218|NCT00002658|DRUG|idarubicin|
219105219|NCT00002658|DRUG|mitoxantrone hydrochloride|
219105220|NCT00002658|DRUG|thioguanine|
219105221|NCT00002658|DRUG|tretinoin|
219105222|NCT00002658|PROCEDURE|allogeneic bone marrow transplantation|
219105223|NCT00002658|PROCEDURE|autologous bone marrow transplantation|
219105224|NCT00002658|PROCEDURE|peripheral blood stem cell transplantation|
219105225|NCT00002658|RADIATION|radiation therapy|
219105226|NCT03987256|OTHER|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
219224223|NCT03044457|PROCEDURE|TKA|"femoral and tibial positioning using the reversed gap technique"
219224224|NCT05558072|GENETIC|Toll-like receptor 4|Toll-like receptor 4
219105227|NCT03987256|PROCEDURE|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
219105228|NCT03987256|PROCEDURE|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
219105229|NCT01360567|DIETARY_SUPPLEMENT|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
219105230|NCT01360567|DIETARY_SUPPLEMENT|Placebo|500 mg . one capsule of placebo, 3 times per day
219105231|NCT00818064|DRUG|anti-IL-20|Single s.c. injection (per dose cohort)
219105232|NCT00818064|DRUG|placebo|Single s.c. injection (per dose cohort)
219105233|NCT02221245|PROCEDURE|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
219105234|NCT04336423|DIAGNOSTIC_TEST|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
219105235|NCT02390063|BIOLOGICAL|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
219105236|NCT02390063|BIOLOGICAL|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
219105237|NCT02390063|DRUG|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
219105238|NCT02225977|DRUG|Gilenya|
219105239|NCT05769751|OTHER|Electronic medical record and hospital information system or other available resources|This is a non-interventional study. No study medication will be provided to the participants.
219105240|NCT06489691|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
219105241|NCT06568744|OTHER|Intervention resuscitation|"In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: \>14, or an increase \>4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk \>14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk \> 15 mmHg or \>5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed."
219105242|NCT06568744|OTHER|Standard of Care resuscitation|In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
219105243|NCT00741715|DRUG|AVE5530|oral administration once daily in the evening with dinner
219105244|NCT00741715|DRUG|atorvastatin|oral administration once daily in the evening with dinner
219692244|NCT06167941|BIOLOGICAL|Lung cancer types|Cancer tissue matched to normal tissue, all from the same patient
219692245|NCT05988372|DRUG|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
219692246|NCT05988372|DRUG|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
219692247|NCT01206023|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
219692248|NCT01721447|DRUG|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
219105245|NCT00741715|DRUG|placebo|oral administration once daily in the evening with dinner
219105246|NCT02735837|DRUG|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
219692249|NCT00369343|DRUG|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
219692250|NCT00369343|DRUG|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
219692251|NCT05796700|PROCEDURE|Microwave Ablation|"Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation"
219105247|NCT02735837|DRUG|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
219105248|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
219105249|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
219105250|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
219105251|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
219105252|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension BID
219105253|NCT04642586|DIAGNOSTIC_TEST|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
219105254|NCT04642586|DIAGNOSTIC_TEST|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
219105255|NCT04642586|DIAGNOSTIC_TEST|neuropsychological assessment|neuropsychological assessment
219105256|NCT05867264|OTHER|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is ≥ 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
219105257|NCT05867264|COMBINATION_PRODUCT|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
219105258|NCT05867264|OTHER|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
219105259|NCT02164097|DRUG|ODSH|
219105260|NCT05825664|PROCEDURE|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
219105261|NCT01349894|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
219105262|NCT00099723|DRUG|VSL#3|
219105263|NCT05482737|OTHER|no intervention|This is an observational retrospective study (meta-analysis)
219105264|NCT03622879|BEHAVIORAL|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
219105265|NCT03622879|DEVICE|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
219105266|NCT03622879|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
219105267|NCT05330741|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
219105268|NCT05330741|OTHER|Whole-Body Vibration|"The designed physical therapy program (mentioned before)~\+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively."
219105269|NCT05330741|OTHER|Gravity Force Stimulation|"The designed physical therapy program (mentioned before)~\+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)"
219692252|NCT04208672|DEVICE|UMindSleep|CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
219692253|NCT01124747|DRUG|ASP1585|Oral
219692254|NCT01124747|DRUG|14C-Labeled ASP1585|Oral
219692255|NCT04405323|DRUG|Lu AG06466|hard capsules, orally, single doses
219692256|NCT04405323|DRUG|Itraconazole|200 and 300 mg, capsules, orally
219692257|NCT01623921|DRUG|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
219692258|NCT01623921|DRUG|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
219224225|NCT02408913|BIOLOGICAL|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
219224226|NCT02408913|BIOLOGICAL|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
219224227|NCT00076115|DRUG|Risperidone|
219224228|NCT04255225|BEHAVIORAL|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
219224229|NCT04255225|BEHAVIORAL|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
219105270|NCT05324345|BEHAVIORAL|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
219105271|NCT02888067|DRUG|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
219105272|NCT02888067|DRUG|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
219105273|NCT02888067|DRUG|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
219105274|NCT02888067|DRUG|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
219105275|NCT03361696|OTHER|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
219105276|NCT04778514|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
219105277|NCT04778514|DRUG|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
219105278|NCT00960921|DRUG|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
219105279|NCT00960921|DRUG|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
219224230|NCT04255225|BEHAVIORAL|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
219224231|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
219692259|NCT01623921|DRUG|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
219105280|NCT03679767|DRUG|Retifanlimab|Retifanlimab administered intravenously at 500 mg every 4 weeks
219105281|NCT02310698|DEVICE|contrast enhanced digital mammography (CEDM)|
219105282|NCT02310698|DEVICE|whole breast screening ultrasound (WBUS)|
219105283|NCT02954458|DRUG|TED|0.05 mg/kg SC injection once daily.
219105284|NCT02954458|OTHER|SOC|Standard safety assessments and adjustments in nutritional support.
219105285|NCT02954458|DEVICE|Syringe|Teduglutide will be administered using syringe.
219105286|NCT02954458|DEVICE|Needle|Teduglutide will be administered using needle.
219105287|NCT03173092|DRUG|Ixazomib|Ixazomib capsules.
219105288|NCT03173092|DRUG|Lenalidomide|Lenalidomide capsules.
219105289|NCT03173092|DRUG|Dexamethasone|Dexamethasone.
219105290|NCT04161040|BEHAVIORAL|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
219105291|NCT05998837|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
219105292|NCT05998837|DRUG|Placebo|"Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
219105293|NCT04772885|DRUG|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
219105294|NCT04772885|DRUG|KT-474|KT-474 oral tablet(s)
219105295|NCT02820363|DEVICE|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids."
219105296|NCT02820363|PROCEDURE|SOC treatment|surgical repair of tibial fracture
219105297|NCT05487430|BEHAVIORAL|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
219105298|NCT01407354|DEVICE|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
219105299|NCT01407354|OTHER|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
219224232|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
219692260|NCT01623921|DRUG|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
219692261|NCT03189212|BEHAVIORAL|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
219692262|NCT03189212|BEHAVIORAL|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
219692263|NCT03035513|OTHER|Continuous spikes and waves during slow sleep (CSWS)|
219692264|NCT03132545|DIAGNOSTIC_TEST|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
219105300|NCT02118662|OTHER|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
219105301|NCT02118662|OTHER|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
219105302|NCT02118662|OTHER|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
219105303|NCT02118662|OTHER|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
219105304|NCT04849221|OTHER|Tympanometry measurement in both ears|Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE
219105305|NCT04849221|OTHER|Collection of clinical and paraclinical data|"Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria..."
219105306|NCT04849221|OTHER|Intracranial pressure reading (ICP)|a single measure
219105307|NCT02556151|PROCEDURE|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
219105308|NCT00762840|DEVICE|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
219105309|NCT00762840|PROCEDURE|Conventional endodontic procedure|Standard root canal treatment
219105310|NCT02204579|DRUG|NPSP795|
219105311|NCT00723437|DRUG|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
219105312|NCT02081456|OTHER|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
219105313|NCT02081456|DEVICE|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
219105314|NCT03027063|BEHAVIORAL|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
219105315|NCT03027063|BEHAVIORAL|Usual Care|Participants will receive the ACC/AHA exercise guidelines
219105316|NCT05528718|DRUG|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
219105317|NCT05528718|DRUG|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
219224233|NCT03411382|OTHER|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
219692265|NCT03132545|DIAGNOSTIC_TEST|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
219105318|NCT04542408|DRUG|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
219224234|NCT03411382|OTHER|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
219224235|NCT03411382|OTHER|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
219224236|NCT03411382|OTHER|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
219692266|NCT00924924|BEHAVIORAL|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
219692267|NCT00924924|BEHAVIORAL|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
219692268|NCT06316635|PROCEDURE|ventilation tube insertion|a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
219692269|NCT02171000|DRUG|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
219692270|NCT05995938|BEHAVIORAL|Mindfullnes-Based Cognitive Therapy|Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
219105319|NCT04542408|DRUG|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
219105320|NCT00621816|DRUG|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
219105321|NCT00621816|DRUG|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
219105322|NCT03581123|BEHAVIORAL|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
219105323|NCT03581123|OTHER|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
219105324|NCT03581123|COMBINATION_PRODUCT|SMT + SSM|Combination Treatment
219224237|NCT00023400|DRUG|Nelfinavir|
219224238|NCT00023400|DRUG|Rifabutin|
219224239|NCT05340452|DRUG|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
219224240|NCT05340452|DRUG|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
219105325|NCT03581123|DRUG|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
219105326|NCT06172608|OTHER|psychoeducational intervention|". Intervention group (I) will receive psychosocial education which will be consist of two parts. 1) Face to Face 2) Community based intervention.~1. Face to face: This face to face session will be consisting of 30-minute session soon after inclusion into the study. A leaflet consisting of all information will be provided to all the patents taking part in the study.~2. Community Based Intervention: In community based interventions prerecorded videos about all the topics covered in face to face session will be made available to parents via a secure online platform. Parents can easily browse it easily when they need it. These videos will be recorded in local language (Urdu), which is easy to understand for almost all the people."
219105327|NCT04483934|BIOLOGICAL|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
219105328|NCT04483934|DEVICE|LED phototherapy|LED phototherapy
219105329|NCT00049400|DRUG|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
219105330|NCT02572843|DRUG|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
219105331|NCT02039661|DRUG|Lidocaine Spray|These patients received 2 puff lidocaine spray
219105332|NCT02039661|DRUG|Placebo|
219105333|NCT02952911|DEVICE|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
219105334|NCT00853281|OTHER|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
219105335|NCT00853281|OTHER|Standard vector control measures|Insectice-treated net
219224241|NCT06510569|DEVICE|U lab aligners|Aligner group change the aligner every 10 days
219224242|NCT06510569|DEVICE|oramco bracket|changing orthodontic wire every one month
219224243|NCT06104618|DRUG|Enfortumab Vedotin|Given IV
219224244|NCT06104618|PROCEDURE|Computed Tomography|Undergo CT
219224245|NCT06104618|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219224246|NCT04154007|DIAGNOSTIC_TEST|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
219224247|NCT03937765|PROCEDURE|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
219224248|NCT05538572|DRUG|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
219224249|NCT00592891|DRUG|Hyperbaric oxygen therapy|Total body pressurized oxygen
219224250|NCT05146635|DRUG|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
219224251|NCT05146635|DRUG|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
219105336|NCT06350292|BEHAVIORAL|SLEEP: COPE|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
219105337|NCT03207646|OTHER|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
219105338|NCT00914290|DRUG|IPX056|IPX056 ER capsule containing 10 mg baclofen
219105339|NCT00914290|DRUG|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
219105340|NCT00914290|DRUG|Placebo IPX056|Placebo capsule for IPX056
219105341|NCT00914290|DRUG|Placebo IR|Placebo encapsulated baclofen placebo tablet
219105342|NCT00003216|DRUG|fluorouracil|
219105343|NCT00003216|DRUG|gemcitabine hydrochloride|
219105344|NCT00003216|RADIATION|radiation therapy|
219224252|NCT04419207|DIAGNOSTIC_TEST|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
219105345|NCT06476184|DRUG|Carboplatin|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
219105346|NCT06476184|DRUG|Paclitaxel|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
219105347|NCT04140253|BEHAVIORAL|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
219105348|NCT01336985|DRUG|Irinotecan|
219105349|NCT01336985|PROCEDURE|Chemoembolization|
219105350|NCT01336985|DEVICE|Drug-Eluting Beads|
219105351|NCT01336985|PROCEDURE|Biopsy|
219105352|NCT00953303|DRUG|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
219105353|NCT00953303|DRUG|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
219105354|NCT02120664|DRUG|Florbetapir (18F)|
219105355|NCT02120664|DRUG|11C-PiB|
219105356|NCT05480670|DIETARY_SUPPLEMENT|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
219105357|NCT03916744|DRUG|Giredestrant|Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
219105358|NCT03916744|PROCEDURE|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
219224253|NCT02423642|PROCEDURE|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
219224254|NCT02423642|PROCEDURE|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
219224255|NCT05328466|DEVICE|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
219224256|NCT03771066|BEHAVIORAL|bisphenol A|Vanilla wafer cookie with bisphenol A administered
219224257|NCT03771066|BEHAVIORAL|Placebo|Vanilla wafer cookie with no bisphenol A
219224258|NCT03183804|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
219224259|NCT03183804|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
219224260|NCT00856362|DRUG|Moxidectin|
219224261|NCT00856362|DRUG|Midazolam|
219224262|NCT04482413|DRUG|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
219224263|NCT04482413|DRUG|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
219224264|NCT02604693|OTHER|Nothing|No interventions will be administered.
219224265|NCT02022670|DRUG|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
219224266|NCT02022670|DRUG|Sodium Nitrite|80 mg/d or 160 mg/d
219105359|NCT00884754|DEVICE|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
219105360|NCT06062459|OTHER|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
219105361|NCT06062459|OTHER|Balance Training|Balance training exercises on to enhance proprioception and stability
219105362|NCT06062459|OTHER|Control Group|Participants received hot pack and stretching exercise
219105363|NCT00477061|DRUG|Morphine|
219105364|NCT01231139|DRUG|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
219105365|NCT01231139|DRUG|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
219105366|NCT06345001|DRUG|BAY3630942|IV, Single administration
219105367|NCT06345001|DRUG|BAY3547922|IV, Single infusion
219105368|NCT00004062|DRUG|azacitidine|
219105369|NCT00004062|DRUG|liothyronine sodium|
219105370|NCT00004062|RADIATION|iodine I 131|
219105371|NCT06028035|DIETARY_SUPPLEMENT|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
219105372|NCT05922839|DRUG|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
219105373|NCT02480816|DIETARY_SUPPLEMENT|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
219105374|NCT04524598|DEVICE|Limbix Spark|The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
219105375|NCT04524598|OTHER|Psychoeducation|The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
219105376|NCT04930237|DRUG|Relistor Injectable Product|12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
219224267|NCT02113449|DRUG|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
219224268|NCT02792738|BEHAVIORAL|hypnosis|
219224269|NCT00868894|DRUG|DE-104 medium concentration|Topical ocular application
219224270|NCT00868894|DRUG|DE-104 high concentration|Topical ocular application
219224271|NCT00868894|DRUG|Placebo|Topical ocular application
219224272|NCT00868894|DRUG|0.005% latanoprost|Topical ocular application
219224273|NCT04931966|PROCEDURE|block|Adductor canal block
219692271|NCT06069804|DRUG|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
219692272|NCT06069804|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
219692273|NCT05763927|DRUG|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
219692274|NCT05763927|DRUG|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
219692275|NCT05763927|RADIATION|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
219692276|NCT05763927|PROCEDURE|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
219692277|NCT01406535|DRUG|Vardenafil|5 mg vardenafil per os twice daily
219692278|NCT01406535|OTHER|Placebo|5 mg placebo per os twice daily
219692279|NCT02358122|OTHER|Wholegrain rye|A variety of cereal foods providing \>100g/day wholegrain from rye
219105377|NCT04930237|DRUG|Docusate Calcium|Standard of care
219105378|NCT04930237|DRUG|Bisacodyl|Standard of Care
219105379|NCT04930237|DRUG|Milk of magnesia|Standard of Care
219105380|NCT04930237|DRUG|Magnesium citrate|Standard of Care
219105381|NCT04930237|DRUG|Senna|Standard of Care
219105382|NCT04930237|DRUG|Enema|Standard of Care
219105383|NCT02558361|DRUG|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. \[30mg po BID after initial titration\]
219105384|NCT04395183|DRUG|5-Hydroxytryptophan 100 MG|5-HTP 100mg PO BID
219105385|NCT04395183|DRUG|Creatine monohydrate|Creatine monohydrate 5g PO qday
219105386|NCT04395183|DRUG|placebo matched to 5-HTP|placebo matched to 5-HTP
219692280|NCT02358122|OTHER|Wholegrain wheat|A variety of cereal foods providing \>100g/day wholegrain from wheat
219692281|NCT02358122|OTHER|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
219692282|NCT01100502|DRUG|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
219105387|NCT04395183|DRUG|Placebo|Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
219105388|NCT00017940|GENETIC|Human Nerve Growth Factor|
219105389|NCT06050902|DEVICE|Subclavian venipuncture for catheter placement using the needle-steering device|"1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture."
219105390|NCT05651360|DIAGNOSTIC_TEST|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
219105391|NCT03556358|BIOLOGICAL|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
219105392|NCT03556358|BIOLOGICAL|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
219105393|NCT03556358|DRUG|Paclitaxel|175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
219692283|NCT01100502|DRUG|placebo|Every 21 days by IV infusion
219692284|NCT01531400|OTHER|self-selected music|Investigators played self-selected background music in the music group
219692285|NCT02546011|OTHER|Fetal Heart Rate Monitor|Standard of care, not part of research
219692286|NCT05571410|BEHAVIORAL|HTN Chat bot|Remote monitoring via automated messaging program
219105394|NCT03556358|DRUG|Epirubicin|75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
219105395|NCT03556358|DRUG|Cyclophosphamide|600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
219105396|NCT00315588|DRUG|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
219105397|NCT02491021|OTHER|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
219105398|NCT04195880|OTHER|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
219105399|NCT04121039|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
219105400|NCT04121039|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
219224274|NCT04931966|PROCEDURE|adductor canal block|adductor canal block bupivacain
219224275|NCT04931966|PROCEDURE|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
219692287|NCT02841358|BIOLOGICAL|Blood sampling|
219692288|NCT02841358|BIOLOGICAL|Biopsy|
219692289|NCT06327412|OTHER|Aerobic exercise on the treadmill|According to the cardiopulmonary exercise (CPET) test, 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level recorded individually in patients, 5 days a week for 4 weeks.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily
219105401|NCT01351025|DRUG|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
219105402|NCT01351025|DRUG|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
219105403|NCT01351025|DRUG|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
219105404|NCT01252121|OTHER|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
219105405|NCT01252121|OTHER|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
219105406|NCT01252121|OTHER|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
219105407|NCT00515437|BIOLOGICAL|Botulinum Toxin Type B (Myobloc)|
219105408|NCT00515437|BIOLOGICAL|Matched placebo to Myobloc|
219692290|NCT06327412|OTHER|Walking between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg Scale|He/she will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE according to the Modified Borg scale.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily.Treatment compliance will be increased by making weekly phone calls to patients in order to increase treatment compliance and evaluate compliance.
219692291|NCT04014218|DRUG|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
219692292|NCT04014218|DRUG|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
219105409|NCT02733783|DEVICE|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
219692293|NCT05005624|OTHER|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
219692294|NCT04298580|PROCEDURE|PVB block|PVB block before surgery versus after surgery
219692295|NCT00461825|DRUG|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
219692296|NCT00461825|DRUG|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
219692297|NCT00461825|DRUG|Group B: CsA + CellCept(500 mg x 2/day)|
219692298|NCT00461825|DRUG|Group C: CsAm|
219692299|NCT01604889|DRUG|Epacadostat|
219692300|NCT01604889|DRUG|Placebo|Placebo
219692301|NCT01604889|DRUG|ipilimumab|ipilimumab 3 mg/kg IV
219692302|NCT01604889|DRUG|ipilimumab|Doses to be determined following the completion of Phase I of the study
219692303|NCT02322749|DRUG|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
219692304|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
219692305|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
219692306|NCT06291857|BIOLOGICAL|CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant|CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain
219692307|NCT06291857|BIOLOGICAL|Novavax COVID-19 Vaccine|Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant
219692308|NCT06291857|BIOLOGICAL|tNIV Vaccine|2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)
219105410|NCT06445790|BEHAVIORAL|Cognitive Behavior Therapy for Chronic Pelvic Pain-CBT-cp|CBT-cp will be administered weekly sessions for 12 weeks.
219105411|NCT03915184|BIOLOGICAL|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
219105412|NCT06210906|OTHER|Assessment of gastric volume|Gastric volume is assessed using ultrasound.
219105413|NCT03393702|DRUG|Gabapentin|"1. Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~2. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
219105414|NCT03393702|DRUG|Placebo|"1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day."
219224276|NCT04931966|PROCEDURE|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
219105415|NCT06248840|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
219105416|NCT06248840|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
219105417|NCT04761614|BIOLOGICAL|Bevacizumab|Given IVPB
219105418|NCT04761614|DRUG|Fluorouracil|Given IV
219105419|NCT04761614|DRUG|Leucovorin Calcium|Given IVPB
219105420|NCT04761614|DRUG|Oxaliplatin|Given IVPB
219105421|NCT04761614|DRUG|Riluzole|Given PO
219105422|NCT01139463|DRUG|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
219105423|NCT02206308|BIOLOGICAL|Chimeric anti-CD20 monoclonal antibody|
219105424|NCT03260582|OTHER|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
219105425|NCT04623320|DIAGNOSTIC_TEST|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
219105426|NCT04623320|DIAGNOSTIC_TEST|13C glucose breath test|13C glucose breath test to compare with the golden standard
219105427|NCT05555992|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
219105428|NCT02516722|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
219105429|NCT03607188|DRUG|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
219105430|NCT01175889|DEVICE|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
219105431|NCT02569710|DRUG|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
219105432|NCT02569710|DRUG|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
219105433|NCT02569710|DRUG|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
219105434|NCT05102422|DRUG|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
219692309|NCT06291857|BIOLOGICAL|Fluzone High Dose|Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
219105435|NCT05102422|DRUG|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
219692310|NCT03482271|OTHER|No intervention - data collection only|No intervention - data collection only
219692311|NCT03675568|PROCEDURE|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
219692312|NCT03675568|PROCEDURE|Split skin Graft|A traditional method for treatment of burn wounds
219692313|NCT05895357|OTHER|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
219105436|NCT04433962|OTHER|Exercise training|
219105437|NCT03352843|DRUG|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
219105438|NCT00116402|DRUG|fluticasone and salmeterol|"1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
219105439|NCT02269514|OTHER|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
219105440|NCT02269514|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
219224277|NCT02590198|OTHER|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
219224278|NCT02590198|OTHER|PCT algorithm|care based on PCT algorithm
219224279|NCT04008953|DEVICE|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
219224280|NCT02042092|DEVICE|Ultrasound|
219224281|NCT02042092|DEVICE|MRA|
219692314|NCT05749016|DRUG|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
219692315|NCT02121860|DRUG|IDN-6556|
219692316|NCT03007355|OTHER|peripheral perfusion index measurement|
219692317|NCT05265117|PROCEDURE|HIPEC|HIPEC is given after primary or interval debulking surgery.
219692318|NCT01374022|OTHER|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
219105441|NCT02269514|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
219105442|NCT02269514|OTHER|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
219105443|NCT02269514|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
219105444|NCT02149784|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
219692319|NCT01374022|OTHER|ARDSNet Strategy|Conventional mechanical ventilation strategy.
219692320|NCT01190813|DRUG|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
219692321|NCT01190813|DRUG|Placebo|Oral placebo tid
219105445|NCT02603822|DIETARY_SUPPLEMENT|12C mannitol|12C mannitol 100 mg
219105446|NCT02603822|DRUG|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
219105447|NCT02603822|DIETARY_SUPPLEMENT|13C mannitol|13C mannitol 100 mg
219105448|NCT02603822|DIETARY_SUPPLEMENT|Lactulose|lactulose 1 g
219105449|NCT01861522|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
219105450|NCT01861522|DRUG|Placebo|Two Placebo tablets will be taken orally twice a day
219224282|NCT03917186|DRUG|Sevoflurane|administration of sevoflurane
219105451|NCT05341102|DRUG|LY3556050|Administered orally.
219105452|NCT05341102|DRUG|Placebo|Administered orally.
219105453|NCT00893347|BEHAVIORAL|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
219105454|NCT00893347|BEHAVIORAL|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
219105455|NCT03158389|DRUG|APG101|weekly i.v.
219105456|NCT03158389|DRUG|Alectinib|twice daily (oral)
219105457|NCT03158389|DRUG|Idasanutlin|orally on 5 days of a 28 days cycle
219105458|NCT03158389|DRUG|Atezolizumab|i.v. every 3 weeks
219105459|NCT03158389|DRUG|Vismodegib|daily orally
219105460|NCT03158389|DRUG|Temsirolimus|weekly i.v.
219105461|NCT03158389|DRUG|Palbociclib|orally on 21 days of a 28 days cycle
219105462|NCT05806944|DEVICE|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
219224283|NCT03917186|DRUG|Desflurane|administration of Desflurane
219224284|NCT03441009|OTHER|Physio-/occupational therapy|Physio-/occupational therapy, ADL
219692322|NCT01190813|OTHER|Patching|Two hours of daily patching
219692323|NCT06075472|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
219692324|NCT06075472|OTHER|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
219692325|NCT05837455|DEVICE|VENTANA MIB-1 Ki67 assay|Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
219692326|NCT05837455|DEVICE|Oncotype DX® Recurrence Score|Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
219692327|NCT05837455|DEVICE|PAM50-based Prosigna breast cancer gene signature assay|This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
219692328|NCT05837455|DRUG|Anastrozole|Standard of care
219105463|NCT05806944|DEVICE|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
219105464|NCT00550550|DRUG|Placebo|Placebo sublingual tablet, once daily
219105465|NCT00550550|BIOLOGICAL|SCH 697243|Grass sublingual tablet, once daily
219105466|NCT00550550|DRUG|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
219105467|NCT00550550|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
219105468|NCT00550550|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
219692329|NCT05837455|DRUG|Combination anthracycline and/or taxane based treatment|Standard of care
219692330|NCT05748730|BEHAVIORAL|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
219692331|NCT05748730|BEHAVIORAL|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
219692332|NCT04344028|BEHAVIORAL|True Cognitive Training Program|The training program is a personal device-based adaptive version of a visual N-back task.
219692333|NCT04344028|BEHAVIORAL|Control Cognitive Training Program|The training program is a personal device-based adaptive version of a knowledge task (control).
219105469|NCT00550550|DRUG|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
219105470|NCT00550550|DRUG|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
219692334|NCT04344028|BEHAVIORAL|Positive Expectation Induction|The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
219692335|NCT04344028|BEHAVIORAL|Negative Expectation Induction|The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
219692336|NCT01542008|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
219692337|NCT01542008|BEHAVIORAL|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
219692338|NCT04037371|OTHER|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
219692339|NCT05158140|BIOLOGICAL|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
219105471|NCT00550550|DRUG|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
219105472|NCT00550550|DRUG|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
219105473|NCT03952221|DEVICE|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
219105474|NCT03952221|DEVICE|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
219692340|NCT05158140|BIOLOGICAL|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
219692341|NCT05158140|BIOLOGICAL|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
219692342|NCT05158140|BIOLOGICAL|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
219692343|NCT05158140|BIOLOGICAL|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
219692344|NCT04000438|DRUG|DF01|DF01: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
219692345|NCT04000438|DRUG|PL1|DF01: The subject receives sc injections of placebo solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
219692346|NCT04279067|DEVICE|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
219692347|NCT04279067|BEHAVIORAL|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
219692348|NCT04279067|BEHAVIORAL|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
219692349|NCT06810713|BEHAVIORAL|Gatekeeper training (e-learning)|"This training supplements existing modules for healthcare providers working with individuals experiencing suicidal thoughts (https://sp-reflex.zelfmoord1813.be/e-learning).~Specific information on working with men will be added:~* Information on suicidality among men and the importance of gender-sensitive care.~* Guidance on recognizing signs of suicidality in men and understanding gender differences in suicide-related communication.~* Insights into the impact of gender norms and socialization on suicidality and help-seeking behavior in men experiencing suicidal thoughts.~* Awareness of providers' own gender biases and the influence of societal gender norms in treating men with suicidal ideation.~* Recommendations for engaging men in treatment, with specific guidance on language and approaches for interacting with men who have suicidal thoughts.~Additionally, the e-learning will a model psychoeducation about the role of norms for men experiencing suicidal ideation."
219692350|NCT04414787|BEHAVIORAL|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
219692351|NCT02214342|OTHER|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
219692352|NCT05870540|DRUG|BPL-003|A single dose administered intranasally
219692353|NCT05870540|DRUG|BPL-003|A single dose administered intranasally (administered as 2 nasal sprays minutes apart)
219692354|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
219692355|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
219692356|NCT00807365|DRUG|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
219692357|NCT00185042|DRUG|Pactimibe, CS-505|
219692358|NCT06612164|OTHER|kefir|Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
219105475|NCT03952221|DEVICE|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
219105476|NCT03952221|DEVICE|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
219105477|NCT06076356|OTHER|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
219224285|NCT06303869|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
219224286|NCT06454721|DRUG|[89Zr]Zr-DFO-BIIB080|Administered as specified in the treatment arm.
219692359|NCT06871865|OTHER|Oculomotor Exercises|Oculomotor exercises are designed to improve eye movement control, coordination, and visual tracking.
219692360|NCT06871865|OTHER|Posture Exercises|Postural exercises help strengthen core muscles, improve alignment, and enhance stability. They are essential for maintaining proper posture, preventing pain, and reducing the risk of musculoskeletal imbalances.
219692361|NCT06871865|OTHER|Neck Stretching and Strengthing Exercises|Neck stretching and strengthening exercises help improve flexibility, reduce stiffness, and enhance muscle support for the cervical spine. They are beneficial for relieving neck pain, improving posture, and preventing injuries.
219692362|NCT01526785|DRUG|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
219692363|NCT07048366|BEHAVIORAL|Integrated Rehabilitation Program at the University Museum|This intervention consists of an 8-week integrated rehabilitation program, with weekly 60-minute sessions, conducted at the University Museum (Museo Universitario UD'A). The program includes mindfulness techniques, conscious breathing exercises, body scan meditation, mindfulness walking within the museum's exhibition spaces, specific stretching and mobilization techniques, and gratitude and recognition exercises, all framed by the artistic and cultural context of the museum. The museum environment is utilized as a therapeutic setting to amplify the benefits of the behavioral techniques.
219692364|NCT07048366|OTHER|Waitlist for Conventional Treatments|This arm of the study serves as the control group. Participants in this group will be placed on a waitlist for conventional treatments and will not receive the museum-based integrated rehabilitation program during the study period. They will not undergo any active intervention specifically tested within the scope of this study.
219692365|NCT05163392|DEVICE|Silverlon|SIlver-plated biopatch
219105478|NCT06076356|OTHER|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
219105479|NCT05156502|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
219105480|NCT05156502|DEVICE|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
219105481|NCT04740619|PROCEDURE|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
219105482|NCT01612325|DEVICE|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
219105483|NCT00987064|DEVICE|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
219224287|NCT06454721|DRUG|BIIB080|Administered as specified in the treatment arm.
219224288|NCT00087022|BIOLOGICAL|girentuximab|Given IV
219224289|NCT00087022|OTHER|placebo|Given IV
219692366|NCT05163392|DEVICE|Control|Tegaderm without biopatch
219692367|NCT00738426|DEVICE|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
219692368|NCT00738426|DEVICE|Sham device|non-therapeutic light energy output
219692369|NCT01505413|DRUG|Erlotinib|Erlotinib 100 mg po qd daily
219692370|NCT01505413|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
219692371|NCT01505413|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
219692372|NCT07061860|DEVICE|digital complete denture|different method of denture construction
219692373|NCT07061860|DEVICE|metal reinforced complete denture|different method of denture construction
219105484|NCT00987064|DEVICE|Placebo TLA|TLA treatment with disabled filtration function
219105485|NCT06335732|DIAGNOSTIC_TEST|Cross section study; single group related measurement design.|Two hundred pediatric physiotherapists from both genders were participated in the current study. They were selected randomly from the Outpatient Clinic of pediatric physiotherapists of Hospitals of Ministry of Health in Cairo-Egypt, the duration of this study was six months started from December 2022 to June 2023
219105486|NCT02640391|OTHER|colonoscopy|
219105487|NCT02826967|PROCEDURE|Colonic Irrigation|
219105488|NCT05186337|BEHAVIORAL|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
219105489|NCT04803578|OTHER|Conventional physiotherapy|The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
219105490|NCT00370721|DRUG|bevacizumab|
219105491|NCT00377286|DIETARY_SUPPLEMENT|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
219105492|NCT00377286|OTHER|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
219224290|NCT05212272|PROCEDURE|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
219224291|NCT05212272|DIAGNOSTIC_TEST|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
219224292|NCT05212272|BEHAVIORAL|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
219224293|NCT05212272|PROCEDURE|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
219224294|NCT01280513|DIETARY_SUPPLEMENT|High protein intake|30% of energy intake coming from proteins
219224295|NCT01280513|DIETARY_SUPPLEMENT|Low Protein intake|9% of energy intake coming from proteins
219692374|NCT07066761|DEVICE|Laparoscopic lateral suspension with surgical mesh (LatGYNious)|Laparoscopic lateral suspension with LatGYNious (with uterus preservation or after hysterectomy)
219105493|NCT04446897|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
219105494|NCT04446897|OTHER|standard treatment|standard treatment according to clinical protocols
219105495|NCT05474521|DEVICE|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
219105496|NCT04089098|DIAGNOSTIC_TEST|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
219105497|NCT02565121|DRUG|corticosteroids|
219105498|NCT02565121|BEHAVIORAL|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
219105499|NCT04129814|PROCEDURE|Non surgical periodontal therapy|single session full-mouth scaling and root planing
219105500|NCT02456805|OTHER|Infant Formula 1|Feed ab libitum
219105501|NCT02456805|OTHER|Infant Formula 2|Feed ab libitum
219105502|NCT03626441|DIETARY_SUPPLEMENT|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
219105503|NCT03626441|DIETARY_SUPPLEMENT|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
219105504|NCT03573661|DEVICE|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
219105505|NCT05674630|DEVICE|Magic Touch drug eluting balloon based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
219692375|NCT07068672|BEHAVIORAL|Kaleidoscope|A handheld kaleidoscope was used as a passive distraction tool during venipuncture. The device was introduced to the child 2 minutes before the procedure and remained in view during blood collection. It provided dynamic, colorful visual stimuli to help reduce pain and anxiety.
219692376|NCT07068672|BEHAVIORAL|Helicone|A helicone toy was used as an active distraction tool. Children held and rotated the device beginning 2 minutes before and during venipuncture. The interactive movement and shape-shifting design engaged the child's attention to reduce procedural pain and anxiety.
219692377|NCT07073703|PROCEDURE|APA|2 adapted physical activity (APA) sessions per week for 4 weeks before and after surgery
219692378|NCT07073703|BEHAVIORAL|Therapeutic education workshops|Therapeutic education workshops tailored to individual needs, covering topics as physical activity, nutrition, treatments, fatigue, and relaxation.
219692379|NCT07073703|PROCEDURE|DAPAP|"Referral to the department's DAPAP for a 12-week bridge program, consisting of one session per week."
219105506|NCT05674630|DEVICE|Drug-eluting stent-based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
219105507|NCT05886322|DIAGNOSTIC_TEST|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
219105508|NCT05886322|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
219105509|NCT05886322|DIAGNOSTIC_TEST|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
219105510|NCT03757234|DRUG|Omadacycline|po tablets
219105511|NCT03757234|DRUG|Levofloxacin|iv solution/po tablets
219105512|NCT03757234|DRUG|Omadacycline|iv solution
219105513|NCT02456701|BIOLOGICAL|KTN3379|IV every 2 weeks
219105514|NCT02456701|DRUG|vemurafenib|960 mg po bid
219105515|NCT04269915|BIOLOGICAL|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
219105516|NCT00697190|DEVICE|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
219105517|NCT00697190|DEVICE|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
219105518|NCT03583645|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
219105519|NCT03583645|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
219105520|NCT01654081|DRUG|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
219105521|NCT02837562|OTHER|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
219105522|NCT04555902|BEHAVIORAL|Postcard|The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
219105523|NCT04555902|BEHAVIORAL|Small Gift|Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
219105524|NCT04555902|BEHAVIORAL|Loss Frame and Fear Appeals|The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
219692380|NCT07072702|BEHAVIORAL|Managing Post-Injury Challenges (MPIC)|A brief evidence-informed intervention was developed to reduce post-injury perceptions of injustice. The intervention is referred to as 'Mastering Post-Injury Challenges' (MPIC). MPIC consists of 4 weekly 30-minute virtual meetings with a psychologist trained in the delivery of the intervention. MPIC is delivered concurrently with the physiotherapy treatment to which the injured worker has been referred. MPIC combines elements of validation, motivational interviewing, acceptance and problem-solving .
219692381|NCT07073144|BEHAVIORAL|Virtual walking|Participants in the intervention group will wear a head-mounted display and hold a controller to swing their arm and control the virtual avatar walking in the virtual world. The intervention will include 10 scenarios of virtual walking intervention (1 scenario daily, each lasting for 15-20 minutes).
219105525|NCT05603832|DRUG|F14|625 mg intra-articular sustained-release celecoxib
219105526|NCT05603832|DRUG|0.25 % Bupivacaine HCl|Local anesthetic
219105527|NCT05603832|DRUG|Acetaminophen|Analgesic
219105528|NCT05603832|DRUG|Methocarbamol|Muscle relaxant
219692382|NCT07073144|BEHAVIORAL|Passive observing walking|Participants in the control group will be given 10 different walking videos in total, one for each day, each approximately 15 minutes in length.
219692383|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 2|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
219692384|NCT07072104|DIAGNOSTIC_TEST|MRI - Grade 2|■ Diagnostic Imaging: structural and resting-state functional MRI (T1-weighted and rs-fMRI)
219692385|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 3|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
219105529|NCT02377960|BEHAVIORAL|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
219105530|NCT02377960|BEHAVIORAL|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
219105531|NCT02377960|BEHAVIORAL|Usual care|Usual care
219105532|NCT05917301|RADIATION|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
219105533|NCT03034499|PROCEDURE|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
219105534|NCT03034499|PROCEDURE|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
219105535|NCT00911313|DRUG|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
219105536|NCT00911313|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
219105537|NCT00911313|DRUG|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
219105538|NCT05232474|DEVICE|KomPas+|KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
219105539|NCT05232474|DEVICE|KomPas|KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
219105540|NCT02708433|DRUG|Lidocaine|Lidocaine
219105541|NCT00799643|DRUG|Salsalate|Salsalate 3.5 g/d orally, divided dosing
219105542|NCT00799643|DRUG|Salsalate Placebo|
219105543|NCT04699916|OTHER|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
219105544|NCT06670781|DEVICE|Experimental: Intervention arm: Goal-Directed Valsalva maneuver|For the Goal directed Valsalva maneuver, the same method patients are instructed to blow into a plastic pipe connected to the manometer device, in order to reach a pressure of 40 mmHg for at least 5 seconds. Then patients are instructed to exhale quickly.
219105545|NCT06670781|DEVICE|Control - standard of care: Self-Directed Valsalva maneuver|The Valsalva maneuver is performed by the patient taking a normal (or deep) inspiration, followed by forceful expiration against a closed airway for up to 15 to 20 sec and then release of the expiratory effort on entry of saline into the right atrium.
219105546|NCT01338012|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
219105547|NCT06611683|PROCEDURE|Inspiratory muscle training|A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.
219692386|NCT07072130|OTHER|Control group (wet cotton)|The diaper area of the newborns in the control group was cleaned using only cottons moistened with boiled and warmed water. In the preparation stage, the cottons were placed in disposable containers and boiled and warmed water was poured over them to moisten the entire surface of the cottons. Excess water was removed by gently squeezing the cottons. After cleaning, the application was completed by drying the gland area with dry cotton.
219692387|NCT07072130|OTHER|Experimental group (baby oil-impregnated cotton)|Diaper area cleaning of newborns in the experimental group was performed only with cottons impregnated with baby oil. In the preparation of these cottons, a sufficient amount of baby oil was added to the cottons placed in disposable containers and the entire surface of the cottons was allowed to absorb the oil. Excess oil was removed by gently squeezing the cottons. After the cleaning process was completed, the diaper area was dried with dry cotton wool and the process was terminated.
219105548|NCT06611683|PROCEDURE|Routine care|Subjects received routine care without intervention.
219105549|NCT02714205|DRUG|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
219105550|NCT02714205|DRUG|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
219105551|NCT00381641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219105552|NCT00381641|OTHER|Pharmacogenomic Study|Optional correlative studies
219105553|NCT00381641|DRUG|Sunitinib|Given PO
219105554|NCT00381641|DRUG|Sunitinib Malate|Given PO
219105555|NCT06679114|BEHAVIORAL|Acceptance and Commitment Therapy|The single-session ACT group intervention will involve a mixture of didactic instruction, discussion, metaphors, and experiential activities. ACT activities will help women notice and accept that negative thoughts, emotions, and experiences while being displaced by war are part of migratory and post-migratory life. ACT activities will also help them identify, reorient towards, and commit to values-consistent behaviors through effective goal-setting. The single-session will be approximately 3 hours long.
219105556|NCT06679114|BEHAVIORAL|Attention control|Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
219692388|NCT07073625|OTHER|Stress Ball|Children arriving at the hospital's emergency department and meeting the study criteria will be randomly assigned to the stress ball group. Before inhalation therapy, the child will begin squeezing the chosen stress ball. This will distract their attention, transforming the frightening hospital environment into a fun one. The questionnaires will be completed by the nurse and family five minutes before, during, and after the inhalation therapy.
219692389|NCT07073625|OTHER|Reading Storybook|The storybook for the children will be selected by child psychologists. The book will be read to the children by their parents. The storybook reading will begin 15 minutes before the inhalation therapy and will be completed before the treatment begins. The storybook will be read to the children only once.
219692390|NCT07072156|OTHER|Stress ball|"First Interview: Consent is obtained; group allocation is done.~Pre-test: Patient information form, DT, STAI, and vital signs are assessed.~Intervention: Stress ball use for 15-20 minutes during chemotherapy.~Post-test: Same measurements are repeated."
219692391|NCT07073651|OTHER|Moderate Intensity Aerobic Exercise|moderate intensity aerobic exercises (using treadmill training) 5 times per week for 12 weeks. Each participating child started the session with 5 minutes of warming-up exercises. Then the main exercise phase is performed at 50-60% of age-predicted peak heart rate using a treadmill for 30 minutes. Finally, a 5 min cool-down period is allowed, the total session took 40 minutes.
219692392|NCT07073651|OTHER|Dietary Advices|The Obese adolescent children participated in the study received diet advices based on a balanced low calorie diet (1500 Kcal)
219692393|NCT07073651|OTHER|Virtual reality games exercise|Virtual reality games exercises 5 times per week for 12 weeks. Each participating child started the session with 5 minutes warming up exercises then followed by the main part which was consisted of 30 min of exercise where the child played the game using virtual reality X-Box and did different physical activities that included both the upper and lower extremities according to the game's requirements, and after that a 5 min cool-down part that involved some static flexibility exercises to allow the heart rate to lower, the total session that would be applied about 40 min (including 30 mins of Virtual reality exercises)
219692394|NCT07073131|OTHER|Vicryl Rapide suturing|Post episiotomy vicryl rapide suturing material is used for stitching episiotomy laceration.
219692395|NCT07073131|OTHER|Chromic catgut suturing|Post episiotomy chromic catgut suturing material is used for stitching episiotomy laceration
219692396|NCT07072260|OTHER|Sham Stroking|Participants in this group receive a sham intervention consisting of light soft tissue stroking around the talocrural joint without joint manipulation. The application mimics the duration and setup of the experimental group but does not include any mechanical stimulus.
219692397|NCT07072260|OTHER|Activator Manipulation|Participants in this group receive a single session of activator-assisted manipulation using the Activator Adjustment Instrument (AAI) to the talocrural (ankle) joint. Six impulses (three anterior and three posterior) are applied with the ankle in a neutral position.
219692398|NCT07072754|OTHER|Mind-body therapy|The yoga program, led by a physiotherapist who is also a certified yoga instructor , with two sessions per week lasting one hour each. Foam yoga blocks, belts, and armless chairs were also available in the classes, where the participants were to support compliance with the program. The yoga program was planned as 10 minutes of centering and breathing practice, 10 minutes of warm-up practice, 30 minutes of supine, standing, sitting, prone, and supine yoga postures, and 10 minutes of relaxation. New postures were introduced every two weeks as the program progressed. After the eight-week session, the participants were encouraged to continue the program at home twice a week
219692399|NCT07072754|OTHER|Exercise|Patients in the exercise group were given a program that included warm-up, low-impact aerobic, strengthening, and cooling phases, totaling 60 minutes, repeated twice a week for eight weeks. Aerobic exercise was performed by standing still for 25 minutes at moderate intensity based on perceived effort. Strengthening exercises included one set of 10 repetitions for each movement. Exercises were progressed according to the modified Borg's scale. Strengthening exercises included core muscles such as the deltoid, abdominals, quadriceps femoris, and hamstrings and were performed using body weight or elastic resistance bands
219692400|NCT07073729|PROCEDURE|Corneal Neurotization|Surgical technique involving the transfer of healthy donor sensory nerves to the anesthetic cornea to restore corneal innervation and sensation in patients with neurotrophic keratitis.
219692401|NCT07073729|DRUG|Cenergermin|Topical recombinant human nerve growth factor (rhNGF) approved for the treatment of neurotrophic keratitis. Administered as eye drops, it promotes epithelial healing and nerve regeneration.
219692402|NCT07072780|DEVICE|Low-Level Laser Therapy (904 nm)|Low-level laser therapy using the LTU-904 device (RianCorp, Australia) at a wavelength of 904 nm, applied to the fibrotic area of the upper limb after CDPT.
219692403|NCT07072780|DEVICE|Low-Level Laser Therapy (650 nm)|Low-level laser therapy using the Salus Talent device (Remed, USA) at a wavelength of 650 nm, applied to the fibrotic area of the upper limb after CDPT.
219692404|NCT07072780|DEVICE|Sham Laser Therapy|Placebo laser therapy with no active laser emission, administered after CDPT.
219692405|NCT07073053|DRUG|Semaglutide 1.0 mg|add-on current standard treatment which includes SGLT2 inhibitor
219692406|NCT07073053|DRUG|Semaglutide 0.5 mg|add-on current standard treatment which includes SGLT2 inhibitor
219105557|NCT06624605|OTHER|Large Language Model-generated Plain Language Summary of Ophthalmology notes|Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
219224296|NCT05951036|PROCEDURE|Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 70% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
219692407|NCT07072897|OTHER|Fluid bolus administration|fluid boluses 250 ml were given when required
219692408|NCT07072897|OTHER|Frusemide was given when required|fluid is given in a fixed regimen
219692409|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound ( expert radiologist)|tracheal ultrasound, performed by expert radiologist, for preterm neonates for confirmation of ETT site
219692410|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound by trainee neonatologist|tracheal ultrasound, performed by trainee neonatologist ( after receiving training for the procedure) , for preterm neonates for confirmation of ETT site
219692411|NCT07073105|DIAGNOSTIC_TEST|Chest x-ray|chest xray done for confirmation of ETT site
219692412|NCT07073898|OTHER|Repeated Text Messages (TM+)|The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).
219692413|NCT07073898|OTHER|Conversational Agent (CA)|The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.
219692414|NCT07073898|OTHER|Educational Video|The educational video provides patients with information and answers commonly asked questions about LCS.
219692415|NCT07073898|OTHER|Proactive Patient Navigation (PPN)|Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.
219692416|NCT07073898|OTHER|Reactive Patient Navigation (RPN)|Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.
219105558|NCT06689618|DEVICE|Exercise|The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
219105559|NCT01598298|DRUG|duloxetine hydrochloride|Given PO
219105560|NCT01598298|OTHER|placebo|Given PO
219692417|NCT07073677|DRUG|IN-115314 Ointment 1%|Twice daily(BID), for 56 day
219105561|NCT06701994|BEHAVIORAL|Innovative Kinesiotaping Bandage Group|This group will receive an innovative kinesiotaping bandage developed specifically for this study. The kinesiotape will be applied directly to the skin on the ankle, combining water resistance with restrictive properties to stabilise the joint while maintaining flexibility. Unlike traditional tape, the kinesiotape is designed to perform well in aquatic conditions, making it suitable for triathlon demands. It provides joint support while allowing a greater range of motion, aiming to enhance performance across all phases of the sport. To maintain blinding, the bandage will also be covered with an opaque stocking.
219105562|NCT06701994|BEHAVIORAL|Traditional Tape Bandage Group|Participants in this group will receive a traditional ankle bandage using functional tape. The bandage is applied directly to the skin and is designed to restrict ankle inversion and plantar flexion, providing stability to prevent recurrent injuries. Traditional tape bandages are widely used in sports due to their effective joint stabilisation. However, they have significant limitations in aquatic environments as they lack water resistance, which makes them less effective during the swimming phase of triathlons. The bandage will be covered with an opaque stocking to ensure blinding, preventing participants or evaluators from identifying the type of intervention.
219692418|NCT07073677|DRUG|IN-115314 Ointment 3%|Twice daily(BID), for 56 day
219692419|NCT07073677|DRUG|IN-115314 Ointment placebo|Twice daily(BID), IN-115314 Ointment Placebo for 28 days+ IN-115314 Ointment 3% for 28 days
219105563|NCT06701994|BEHAVIORAL|Placebo Bandage Group|Participants in this group will receive a placebo bandage consisting of a simple gauze wrap applied directly to the ankle. The gauze lacks stabilising or therapeutic properties and is used as a control to account for potential placebo effects. Although it mimics the application process of the other bandages, it does not provide functional or structural support to the ankle joint. An opaque stocking will cover the gauze to ensure that neither participants nor evaluators can distinguish the placebo bandage from the others, maintaining the integrity of the blinding process.
219105564|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
219692420|NCT07072247|GENETIC|CD19 and BCMA-targeted allogeneic CAR-T cells|Lymphodepletion chemotherapy followed by CD19 and BCMA-targeted allogeneic CAR-T cells infusion
219692421|NCT07071961|DRUG|Regorafenib (CT)|Given by po
219692422|NCT07071961|DRUG|Lorigerlimab|Given by IV
219692423|NCT06899776|DEVICE|Abbott i-STAT point of care (POC) device|During the study period all ED patients with chest pain will have an extra lithium heparin blood sample obtained for each troponin test ordered and collected in the ED (typically 2, but this may range from 1-3 troponin measures), which will be used for immediate hs-cTnI measurement by research personnel using an Abbott i-STAT POC device.
219692424|NCT01778413|DRUG|ATRIPLA|
219692425|NCT07073742|PROCEDURE|CLaCS|CLaCS is hybrid outpatient procedure combining Nd:YAG 1064 nm laser treatment with injection of a sclerosant (either 70% glucose or 0.2% polidocanol foam).
219692426|NCT07073859|OTHER|Fluid expansion|Data will be collected retrospectively, after fluid expansion administration, by the prescribing physician through. These data will be collected from standard monitoring and/or from the patient's medical record. Data will therefore only be collected at a single point in time.
219692427|NCT07073599|OTHER|Creative Drama Education|"This study is a pre-test/post-test controlled experimental design aimed at evaluating the effectiveness of creative drama education on awareness of breast and gynecological cancers.~Students in the intervention group will receive creative drama-based training structured and implemented by the researcher. This training is designed to increase awareness of breast and gynecological cancers.~The effectiveness of the training will be assessed by comparing participants' awareness levels before and after the intervention. For this purpose, the following data collection tools will be used:~Personal Information Form Breast Cancer Awareness Scale Gynecological Cancers Awareness Scale The impact of the creative drama education on the awareness levels of students in the intervention group regarding breast and gynecological cancers will be evaluated through statistical analysis."
219692428|NCT07072442|DRUG|Western Medicine|Western medicine treatment only
219692429|NCT07072442|PROCEDURE|herbal medicine and acupuncture|Western medicine combined acupuncture and herbal medicine treatemnt
219105565|NCT05252819|DIAGNOSTIC_TEST|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
219105566|NCT06707818|OTHER|Preoperative Interventions|During the initial surgical consultation, participants will provide informed consent. Demographic data and several validated assessment scales will be collected, including the Perceived Socioeconomic Status Scale (8), Ten-Item Personality Inventory (9), Pain Catastrophizing Scale (10), Hospital Anxiety and Depression Scale (11), Rosenberg Self-Esteem Scale (12), Quality of Recovery-15 (QoR-15) questionnaire (13), and the Visual Analog Scale (VAS) for pain (14).
219105567|NCT06707818|OTHER|Intraoperative Interventions|All surgical procedures will follow the standard general anesthesia protocol of the hospital. General anesthesia induction will involve propofol (1-2 mg/kg), fentanyl (1 mcg/kg), and rocuronium (0.6 mg/kg) for endotracheal intubation. Anesthesia maintenance will be performed with desflurane (4-6%) and remifentanil (0.1 mcg/kg/min), with adjustments as needed based on blood pressure and heart rate. Post-induction, dexamethasone (4 mg) will be administered for anti-inflammatory effects. To support postoperative pain management, tramadol (1 mg/kg), ibuprofen (400 mg), and paracetamol (1 g) will be administered before the end of the procedure. Ondansetron (4 mg) will be used for nausea prophylaxis. All intraoperative medications and dosages will be recorded without intervention.
219692430|NCT07072442|DRUG|herbal medicine|Western medicine combined herbal medicine
219692431|NCT07072442|PROCEDURE|acupuncture|western medicine combined acupuncture
219105568|NCT06707818|OTHER|Postoperative Interventions|"In the recovery room, analgesic interventions will follow the hospital's standard protocol: patients with VAS scores between 3 and 7 will receive 25 mcg of fentanyl, while those with scores above 7 will receive 50 mcg.~All patients will receive standard multimodal analgesia during the ward stay, including paracetamol (1 g, three times daily) and ibuprofen (400 mg, twice daily). Patient-controlled analgesia (PCA) devices will administer tramadol (10 mg IV per patient request, without continuous infusion)."
219105569|NCT06716359|OTHER|Observational study without intervention|Observational study without intervention
219105570|NCT06925880|DIETARY_SUPPLEMENT|Creatine Monohydrate|The intervention will consist of daily supplementation with micronized creatine monohydrate (FullGas Sport Creatine 200 mesh) for 12 weeks. The intervention will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast). Creatine should be consumed with food to improve its absorption.
219692432|NCT07072949|OTHER|Metformin Monotherapy|Participants in this group (n = 30) received metformin alone, administered in a daily dose of 1000 to 2000 mg divided into two doses, over a period of four weeks.
219692433|NCT07072949|OTHER|Metformin combined with probiotic (Normia® Jadran Galenski Laboratory) supplementation|Participants (n = 30) received metformin (1000-2000 mg/day, divided in two doses) combined with a probiotic supplement (1 capsule three times daily) over a four-week period.
219692434|NCT07072949|OTHER|Triple therapy - metformin, probiotic and ursodeoxycholic acid (Bilexin®, Bosnalijek)|Participants in this group (n = 30) were treated with a combination of metformin (1000 - 2000 mg/day), a probiotic (1 capsule three times daily) and ursodeoxycholic acid (UDCA, 1 capsule (250mg) three times daily) for four weeks.
219692435|NCT07064629|BEHAVIORAL|Relaxation in virtual reality with biofeedback.|In this intervention, biofeedback is provided based on the respiratory rate measured by a Vernier Go respiration belt. This belt sends signals (respiratory effort) to the application that calculates the level of synchronisation and gives the visual biofeedback in two forms: 1) a deer simultanously breathing with the participant (realtime biofeedback, present in the initial phase only), 2) a growing tree - if breathing is regulated following a given rhytm, a growing tree is giving the targeted biofeedback.
219692436|NCT07064629|BEHAVIORAL|Relaxation in virtual reality without biofeedback|In this control intervention, participants' respiratory rate is still being measured by the respiratory belt VernierGo; however, they are not receiving any visual biofeedback inside the virtual relaxation application (no deer is present, the tree is constantly growing regardless of the breathing pattern of the participant).
219692437|NCT07073326|OTHER|HYPOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between 15 and 16 FiO2%
219692438|NCT07073326|OTHER|NORMOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between at normal (around 21) FiO2%
219692439|NCT07073716|OTHER|aerobic exercise|"the exercise protocol was applied following these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training."
219692440|NCT07073716|DIETARY_SUPPLEMENT|phoenix seed|consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day
219692441|NCT07073716|COMBINATION_PRODUCT|aerobic exercise+ phoenix seed|"a specialized programme of aerobic exercise.the exercise protocol follow these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training.~the specialized program of phoenix seed consumption (consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day)"
219692442|NCT07072182|DEVICE|Palatal wound will be covered with Ora-aid patch|Palatal wound will be covered with Ora-aid patch
219105571|NCT06925880|OTHER|Placebo|The control group will follow the same rehabilitation regimen as the intervention group and will receive a placebo with FullGas Sport microcrystalline cellulose. Its physical and organoleptic characteristics are the same as micronized creatine monohydrate. The dosage will be the same as that indicated for the study intervention: it will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast).
219105572|NCT06926257|OTHER|Experimental group (B) - breathing training using VR|"The Flowborne VR - Biofeedback Breathing Meditation game is an interactive training environment that guides the participant through a series of breathing exercises. The app adjusts the difficulty level and pace of the workout in real time based on the participant's physiological parameters, such as breathing rhythm.~Types of exercises in the game:~1. diaphragmatic breathing - the participant takes slow, controlled breaths, inhaling into the diaphragm and exhaling at a set pace. The game visualizes breathing through animations of water waves and background color changes.~2. rhythmic breathing - the participant sts his breathing rhythm to the changing visual and audio stimuli, allowing for synchronous breathing control.~3. Controlled exhalation lengthening - the participant learns the technique of slow exhalation of air to improve relaxation and reduce tension."
219692443|NCT07072182|DEVICE|Palatal wound will be covered with Composite stent|Palatal wound will be covered with Composite stent
219105573|NCT06926257|OTHER|Experimental group (C) - breathing training using relaxation music|"* Diaphragmatic breathing - the conscious engagement of the diaphragm in the inhalation process.~* Controlled exhalation lengthening - a technique to lengthen the exhalation phase.~* Rhythmic breathing - synchronizing breathing with a set pace to improve breath control.~Structure of each session:~1. introductory phase (3 minutes)~   * Participants assume a comfortable sitting or lying position.~  * Brief instruction on proper breathing.~2. training phase (15 minutes).~   * Participants listen to relaxation music while focusing on the breathing techniques they learned before the session.~  * Breathing techniques used include those learned during the training: diaphragmatic breathing, controlled expiration lengthening, rhythmic breathing.~     3 Relaxation phase (2 minutes)~  * Gradual exit from the training session, focusing attention on the sensations of the body and mind."
219105574|NCT06925919|DRUG|IDB-011 dose level 1|IDB-774 + IDB-898
219105575|NCT06925919|DRUG|IDB-011 dose level 2|IDB-774 + IDB-898
219692444|NCT07072182|COMBINATION_PRODUCT|Palatal wound will be covered with PRF|Palatal wound will be covered with PRF
219692445|NCT07072858|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Cine CMR imaging was performed with steady-state free precession covering short axis continuously from the mitral annulus to the apical level in the 2-, 3- and 4- chamber views using the following parameters: repetition time (TR) = 3.73 ms, echo time (TE) = 1.87 ms, flip angle = 60°, slice thickness 8.0 mm. Cine images of all included patients were acquired prior to contrast administrations. Late gadolinium enhancement images (LGE) images were obtained 10-15 minutes after intravenous injection of gadolinium (0.1 mmol/kg at 3ml/s) at end-diastolic phase on the short axis (TR=6.09 ms; TE= 3.0 ms; flip angle 60°; thickness 8.0 mm) with breath-hold phase-sensitive segmented inversion recovery (PSIR) fast field echo sequence. T2-weighted sequence was performed using turbo spin-echo (TSE)-sequence (TR=1714-2000 ms; TE=8.04 ms; slice thickness 8.0 mm) to estimate myocardial edema. Images were analyzed on freely available validated cardiovascular image analysis software CVI42 (Circle Cardiovas
219692446|NCT06821477|OTHER|Superficial EMG|Superfiscial EMG during ASLR without knee brace follow by EMG during ASLR with knee brace under certain commands
219692447|NCT05619289|DRUG|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
219692448|NCT05619289|DRUG|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
219692449|NCT07072052|OTHER|No intervention planned|No interventions planned
219692450|NCT07072936|BEHAVIORAL|mediterranean diet|All questions of the intervention group, in which behavioural change was expected, were answered by the dietitian throughout the study and compliance with the diet was monitored with food consumption records.
219692451|NCT07072715|BEHAVIORAL|PAPE Training|A neuromuscular activation protocol involving heavy banded squats (\~85% 1RM) to induce post-activation performance enhancement. Applied three times weekly over 8 weeks following the warm-up. Participants then continued with regular football training.
219692452|NCT07072715|BEHAVIORAL|Plyometric Training|A program of depth jumps designed to enhance explosive power, speed, and agility. Applied 3 times weekly over 8 weeks following the warm-up. Participants then continued with their regular football training.
219692453|NCT07072299|PROCEDURE|DEB-BACE|Drug-Eluting Bead microspheres used for embolization: Drug-Eluting Bead microspheres 1tube was loaded and adsorbed chemotherapy. End point of embolization: stagnation of blood flow in tumor feeding artery
219692454|NCT07072494|DRUG|CD19 CAR-T cells injection|Lymphodepleting pre-treatment will begin one week before the CAR-T cell infusion to reduce the burden of abnormal immune cells in the body, creating a favorable environment for the infused CAR-T cells. The suggested pre-treatment regimen is based on the FC regimen (Fludarabine + Cyclophosphamide).After the pre-treatment, patients will undergo CAR-T cell infusion, where the genetically modified T-cells are infused back into the patient's body.
219692455|NCT07072169|DRUG|ABO2203 Injection|SC or IV
219692456|NCT07073196|PROCEDURE|Dental implant treatment (narrow implants)|Replacement of a missing molar tooth with a narrow dental implant
219692457|NCT07073196|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing molar tooth with a standard dental implant
219692458|NCT07072923|DRUG|Antibiotic loaded calcium sulfate beads|Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin, daptomycin, cefazolin, cefepime, tobramycin, amphotericin B, micafungin, and voriconazole).
219692459|NCT07072923|DEVICE|Calcium sulfate beads (sham beads)|Calcium sulfate beads will be prepared without added antibiotics and placed during the second surgery.
219105576|NCT06925919|DRUG|IDB-011 dose level 3|IDB-774 + IDB-898
219692460|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access and human guide|Receives (1) donor search materials, (2) electronic resource access messages, (3) practical assistance to use the intervention and empower taking the outreach action and (4) telephonic human guide
219692461|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access only (unguided)|Receives (1) donor search materials, (2) electronic resource access messages, and (3) practical assistance to use the intervention and empower taking the outreach action.
219692462|NCT05280093|DEVICE|AtriCure ISOLATOR Synergy Surgical Ablation System|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
219692463|NCT07072533|OTHER|blood flow restriction training|individual will do aerobic training .
219692464|NCT07073222|OTHER|Escape room game|Escape room games are live action team-based games where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal within a limited time.
219105577|NCT06925919|DRUG|IDB-011 dose level 4|IDB-774 + IDB-898
219105578|NCT06925919|DRUG|IDB-011 dose level 5|IDB-774 + IDB-898
219105579|NCT06925919|OTHER|Placebo|Normal saline
219105580|NCT06926218|DRUG|HSK47388|cohort 1 to cohort 5
219105581|NCT06926218|DRUG|Placebo|cohort 1 to cohort 5
219105582|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
219105583|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.
219692465|NCT07072039|PROCEDURE|Paramedic Evaluation for acute COPD Exacerbation|The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) program is a mobile integrated health initiative that aims to evaluate and treat COPD exacerbation in the home. The goal of the intervention is to expedite the recognition and treatment of COPD exacerbation as well as For this intervention, ambulatory teams can refer patients for PEACE visits when a patient has been identified as suffering from symptoms consistent with COPD exacerbation. Once a visit is requested via electronic health record order, a community paramedic presents to the patient's home within 2 hours, evaluates the patient using mobile diagnostic testing, and initiates pharmacological therapies protocolized by the pulmonary team. A standardized clinical approach and documentation strategy is used including a focused history and physical exam, venous blood gas, trending pulse-oximetry, and mobile x-ray. The community paramedic is supervised in real-time by an emergency physician to establish a care plan and di
219692466|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
219692467|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
219692468|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
219692469|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
219105584|NCT06925412|PROCEDURE|MMC sponge application|Three micro swabs soaked in 0.03% MMC were subconjunctivally applied, followed by the creation of a fornix-based conjunctival flap. Subsequently, the standard trabeculectomy procedure was initiated without additional irrigation of the MMC application site
219105585|NCT06925412|PROCEDURE|Sub-tenon MMC injection|MMC was administered via a sub-tenon injection. A 30-gauge needle was inserted into the conjunctiva and carefully advanced laterally along Tenon's capsule. A cannula was employed to minimize the excessive spread of MMC over the anticipated conjunctival incision site. After MMC delivery, a fornix-based conjunctival peritomy was performed, and both groups proceeded to undergo standard trabeculectomy
219105586|NCT06924996|PROCEDURE|Endovascular Thrombectomy (EVT)|A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed
219105587|NCT06365411|DIAGNOSTIC_TEST|Biomarker discovery and validation - with focus on genomic biomarkers|Biomarker discovery and validation - with focus on genomic biomarkers
219105588|NCT05174793|OTHER|dehydration and rehydration|dehydration and rehydration
219105589|NCT06574854|OTHER|DSW|Descending Stair Walking
219105590|NCT06574854|OTHER|ASW|Ascending Stair Walking
219105591|NCT06780566|DIAGNOSTIC_TEST|Point-of-care PCR testing for respiratory viruses|A nasal swab will be collected by trained research staff in full personal protective equipment (PPE) and placed into 3 mL of viral transport medium. The sample will be immediately processed and analysed in the ED using the Xpert® Xpress SARS-CoV-2/Flu/RSV test according to the manufacturer's instructions. The results of the test will be documented in the patient's paper or electronic case notes, and the clinical team will be directly informed of all results. The participant or legal guardian who signs the consent form will also be informed of the results when appropriate.
219105592|NCT06780566|DIAGNOSTIC_TEST|Laboratory PCR testing for respiratory viruses|The ordering of test for respiratory pathogens will be decided by the treating clinical team. All tests will be performed using the standard methods of the hospital laboratory.
219105593|NCT06900010|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration
219105594|NCT06899724|DRUG|Anesthetics, Inhalation|Inhaled analgesia
219105595|NCT06899724|DRUG|Intravenous Sedatives with or Without Analgesia|IV Fentanyl and midazolam
219105596|NCT06900166|DRUG|PegIFN alfa-2b|180 μg/ 0.5 ml ,hypodermic injection once a week
219105597|NCT06900166|DRUG|PegIFN alfa-2b and NUC|180 μg/ 0.5 ml ,hypodermic injection once a week, NUC drugs should be used according to the instructions of each drug
219105598|NCT06735261|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
219105599|NCT06925997|DRUG|Colesevelam|Colesevelam is an approved drug with well known adverse events. Gastrointestinal side effects (Obstipation, flatulence, abdominal pain, diarrhea, nausea, meteorism, vomiting, chanced faeces) are very common (\>10%) or common (1-10%), but are mild and tolerable in most cases. All participants will be monitored closely, and colesevelam will be discontinued if the subject experience unreserved adverse events. All effects of colesevelam are transient (17-19) as the compound is not absorbed to the systemic circulation, i.e. treatment effects cease when the drug is excreted from the intestine. Specifically, no permanent metabolic effects of colesevelam has been observed in crossover experiments (27). Therefore, 8 weeks of colesevelam treatment as planned in the current study will have no long lasting positive or negative effects on the participants.
219105600|NCT06926088|DRUG|Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety|Patients aged ≥18 years with advanced HR-positive breast cancer who received CDK4/6 inhibitors at six hospitals in China were included in this study.
219105601|NCT06925126|OTHER|Not applicable- observational study|This is an observational cohort study with no planned interventions. Participants will be followed over multiple time points to evaluate treatment outcomes based on the standard care process.
219105602|NCT06925425|OTHER|Task specific electrical stimulation ( TASES )|"Each child in group B receive the designed program plus the task specific electrical stimulation (TASES) for 20 minutes during the weight bearing exercises as push up , prone on hands on wedge and quadruped with weight shifting.~The electrical stimulation is applied with the following parameters. Pulse frequency 25-50 HZ, pulse duration 300 micro second, intensity to display a visible muscle contraction, for 20 minutes.~First channel, one electrode will be placed at the middle of triceps muscle, the second electrode will be placed more distal towards the elbow joint itself (about 3 cm above the olecranon process).~Second channel, one electrode will be placed over finger and wrist extensors motor point to allow activation of fingers and wrist extensors. The other electrode will be placed over the tendonous portion of the forearm between motor points of extensor carpi radialis and extensor carpi ulnaris muscles."
219105603|NCT06925425|OTHER|Designed Physical therapy program|The program used a combination of open-and closed-chain exercises. Exercises for facilitating transitions as supine to sit with hand weight bearing , side lying to side sit , side sitting to quadruped, weight bearing exercises as prone on hands on wedge , quadruped with weight shifting and push up exercise for one hour.
219105604|NCT06926166|OTHER|No intervention|No intervention
219105605|NCT06926439|DRUG|Long chain lipid emulsion|For patients presenting with fat soluble drug overdose, administer a weight-based infusion of long-chain lipid emulsion at 0.05 ml/kg/min for 1 hour, not to exceed a total of 250 mL.
219105606|NCT06925711|DEVICE|Near-Infrared Spectroscopy (NIRS)|Controlled hypotensive anesthesia during orthognathic surgery with cerebral oxygen saturation monitoring using Near-Infrared Spectroscopy (NIRS). NIRS was used to continuously monitor regional cerebral oxygen saturation (rSO2) throughout the procedure to observe the effects of controlled hypotension on cerebral perfusion
219105607|NCT06926478|DRUG|Adalimumab Injection|10% (4.0mg/0.04ml) dissolved in sterile saline to be injected once during the time of the Boston Keratoprosthesis (Kpro) Surgery.
219692470|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
219692471|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
219692472|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
219692473|NCT07072013|OTHER|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib was based solely on clinical judgement.
219692474|NCT06500741|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
219692475|NCT06776705|DEVICE|Low-intensity transcranial ultrasound stimulation|Low-intensity TUS, as an advanced modality of transcranial brain stimulation, enables to stimulate the deep brain structures with optimized focality and specific frequency.
219692476|NCT01408212|PROCEDURE|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
219692477|NCT02216279|DRUG|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
219692478|NCT06916091|DRUG|Eloralintide|Administered subcutaneously (SC)
219692479|NCT06916091|DRUG|Placebo|Administered SC
219692480|NCT04884139|DRUG|Dolutegravir/Lamivudine as a single pill|\- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
219105608|NCT06900465|BEHAVIORAL|Caregiver Psychoeducation Group for Children and Adolescents with Emotional and Behavioral Disorders (CPG-CA)|The CPG-CA intervention is a group psychoeducational internvention for family caregivers of children and adolescents with E/BDs in China. It will consist of 10 to 15 family caregivers of children and adolescents with E/BDs, meeting once a week for 1.5 to 2 hours per session, for a total of 12 sessions over a 3-month period. The sessions will cover the following themes: (1) knowledge about child and adolescent emotional and behavioral disorders; (2) coping skills for common emotional and behavioral problems in children and adolescents; (3) problem-solving skills; (4) communication skills with children and adolescents; (5) positive parenting techniques; and (6) self-care techniques. A variety of facilitation techniques will be used in the intervention, including didactic teaching, group discussion, role-playing, and homework assignment.
219105609|NCT06901180|PROCEDURE|short scar periareolar inferior pedicle reduction mammoplasty|reduction mammoplasty that minimizes scar with better cosmetic outcomes
219105610|NCT06900192|BIOLOGICAL|Orca-Q|Allogeneic (donor) stem cell graft
219105611|NCT06900192|DRUG|myeloablative regimen|Myeloablative regimen of busulfan, fludarabine, and thiotepa.
219105612|NCT06900036|PROCEDURE|Platelet-Rich Fibrin (PRF) Application for Alveolar Preservation|This intervention involves the application of platelet-rich fibrin (PRF) in the extraction socket following premolar extraction to assess its effectiveness in alveolar bone preservation. PRF is a biological autologous material derived from the patient's own blood, promoting bone regeneration, wound healing, and tissue repair.
219105613|NCT06900322|OTHER|Experimental Group (stimuli and handling; physical therapy [PediaSuit])|"Participants underwent a one-hour daily protocol (5 times a week) of stimuli and handling based on the neuroevolutionary concept, and motor physical therapy with therapeutic garments (PediaSuit).~During therapy based in PediaSuit protocol therapy suits were used to stimulate proprioception, muscle contraction, and postural stability.Traction bands were placed on the trunk to stimulate muscle control by stabilizing this area and the antigravity muscles.The ability exercise unit was also used to stimulate postural stability and muscle resistance, according to the functional ability of each child.~Neuroevolutionary concept is a problem-solving approach focused on the treatment of functional impairments, postural alignment and movement.~Therefore, Neuroevolutionary concept is an individualised approach aimed at improving functionality and, consequently, the quality of life of individuals with neurological deficits."
219105614|NCT06900322|OTHER|control group (conventional physical therapy)|Participants kept the therapeutic routine (conventional physical therapy).
219105615|NCT06900686|DRUG|PD1 Inhibitor|PD1 Inhibitor
219105616|NCT06212908|OTHER|Basic Periodontal Therapy|All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
219105617|NCT06900738|DEVICE|Inflammometer|Patients wear an inflammometer for Photoplethysmography measurements.
219224297|NCT05951036|PROCEDURE|Sham Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 10% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
219692481|NCT04884139|DRUG|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"* Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks."
219692482|NCT06919653|BEHAVIORAL|The Workplace program to Improve the Safe Handling of hazardous drugs (WISH)|The WISH intervention is targeted to promote the adherence to chemotherapy handling guidelines among oncology nurses. The WISH intervention will include two components 1) an individualized online educational component on chemotherapy exposure and the safe handling guidelines with incorporating novel instructional technology tools and 2) debriefing sessions on the incidents of chemotherapy exposure.
219692483|NCT06934018|PROCEDURE|Surgery and procedure|"According to the Chinese Guidelines for the Diagnosis and Comprehensive Treatment of Liver metastases of Colorectal Cancer (2023 edition), R0 resection of metastatic tumors is satisfied, and the objective is to preserve sufficient functional liver tissue, and the surgical margin width is less than 7mm"
219692484|NCT06934018|PROCEDURE|Surgery and procedure|Combined with intraoperative B-ultrasound guidance, 3D reconstruction and intraoperative navigation, the surgical margin width of metastatic tumor was greater than or equal to 7mm
219692485|NCT06933940|BEHAVIORAL|Nutrition Matters|The intervention will consist of two components: educational sessions and a structured PA component. The primary purpose of the educational sessions is to increase experimental group participants' scientific knowledge and skills in healthy cooking and eating. NUTRITION-MATTERS includes weekly 1.5-hour education sessions for a total of 12 weeks. The sessions will be sequenced carefully to blend brief lectures by experts, experience sharing by participants, and an interactive cooking demonstration. All participants will be provided with $20 of food that corresponds to the cooking demonstration and recipes in the participant handbook.The curriculum will include evidence based information on managing chronic diseases with nutrition and will be culturally tailored to include foods, music, and/or same race/ethnicity role models.
219105618|NCT06900478|DRUG|Icariin Soft Capsules+TACE|"TACE: perform preoperative infusion chemotherapy, then selectively inject 2 to 5 mL of iodized oil and embolize.~Icariin Soft Capsules：take 6 tablets each time, orally, twice a day."
219105619|NCT06900075|DRUG|Efsubaglutide Alfa 3mg Q2W and 1mg QW|Efsubaglutide Alfa 3 mg administered once every two weeks for 8 weeks, followed by a switch to Efsubaglutide Alfa 1 mg administered once weekly for an additional 8 weeks of treatment.
219224298|NCT05951036|PROCEDURE|High-load Eccentric training|Physical therapist will ask participants to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 70% of repetition maximum.
219224299|NCT06394947|OTHER|Fluid administration (any type)|The fluid challenge (FC) (bolus) is defined as the administration of any bolus of fluid (crystalloid or colloid) which is expected to affect pressure/flow/perfusion variables. The FC is expected to be completed within 30 min.
219224300|NCT00824642|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
219692486|NCT06938828|OTHER|Observational cohort group|As this is an observational cohort study, there will be no intervention. In this study, only retrospective data will be collected for subsequent analysis. Similarly, the aim is to assess the relationship between the time on sick leave and the type of physiotherapy treatment received by patients. As this is an observational and retrospective cohort study, there is no risk derived from the development of the study for the subjects whose data form part of the study.
219692487|NCT06942104|DRUG|18F-TRX|Given Intravenously (IV)
219692488|NCT06942104|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging procedure
219692489|NCT06942104|PROCEDURE|Tumor Biopsy|May undergo tumor biopsy
219692490|NCT06942104|PROCEDURE|Blood Specimen Collection|Undergo blood sample collection
219692491|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 250 mg|Participants will receive a dietary supplement containing 250 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
219692492|NCT06954038|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo capsule identical in appearance to the active supplement, administered twice daily for 30 consecutive days.
219692493|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 500 mg|Participants will receive a dietary supplement containing 500 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
219692494|NCT05379205|BEHAVIORAL|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
219692495|NCT05379205|BEHAVIORAL|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
219692496|NCT05379205|OTHER|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
219105620|NCT06900075|DRUG|Efsubaglutide Alfa 1mg QW and 3mg Q2W|Efsubaglutide Alfa 1 mg administered once weekly for 8 weeks, followed by a switch to Efsubaglutide Alfa 3 mg administered once every two weeks for an additional 8 weeks of treatment.
219105621|NCT06926400|DEVICE|Coronary artery sawtooth cutting balloon dilation catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a coronary artery sawtooth cutting balloon dilation catheter.
219105622|NCT06926400|DEVICE|Cutting balloon catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a cutting balloon catheter.
219105623|NCT06925087|OTHER|Myofascial Release Technique|During the application of Myofascial Release Technique (MRT), the fingers or hand will be first placed on the treatment area. Pressure will be applied to the soft tissue until the restricted layer was felt, and then the fascia was moved along the surface of the underlying layers while maintaining contact with the deeper layers. Tension will be applied for approximately 60-90 seconds, and if a release will not felt, the duration will extended until the release occurred. MRT will be performed with dry hands, without the use of any intermediary substances, and will be applied in both supine and prone positions. In the treatment program, anterolateral release techniques (targeting fascia superficialis, fascia transversalis, and fascia extraperitonealis) will be applied in the supine position, while posterior release techniques (targeting fascia thoracolumbalis and erector spinae) will be applied in the prone position.
219692497|NCT02503163|DRUG|KCT-0809 ophthalmic solution|
219692498|NCT04194814|DRUG|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
219692499|NCT04194814|DRUG|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
219692500|NCT02188160|DRUG|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
219692501|NCT02188160|DRUG|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
219692502|NCT01802047|PROCEDURE|milk expression with electric pump|
219692503|NCT03088059|DRUG|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
219692504|NCT03088059|DRUG|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
219692505|NCT03088059|DRUG|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
219692506|NCT03088059|DRUG|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
219692507|NCT03088059|DRUG|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
219692508|NCT03088059|DRUG|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
219692509|NCT03088059|DRUG|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
219692510|NCT02628977|BEHAVIORAL|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
219692511|NCT02628977|BEHAVIORAL|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
219692512|NCT05280990|DIAGNOSTIC_TEST|mHBS|Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
219692513|NCT05280990|DIAGNOSTIC_TEST|CT/MRI volumetry|Preoperative FLRF assessment using CT/MRI volumetry
219692514|NCT02225418|DRUG|Ropivacaine|
219105624|NCT06925087|OTHER|Kinesio Taping Technique|"Two different techniques will be used in the Kinesio Taping application. First, four I-shaped Kinesio tapes (Kinesio Tex® Gold), each 5 cm wide and 0.5 mm thick, will be applied in a star-shaped pattern using the space correction technique with 25-50% tension at the S2-S4 level (sacral region) while the participant will in a seated position. Additionally, to direct the uterus into retroversion during menstruation, a 15 cm long I-shaped tape will be applied to the suprapubic region using the ligament correction technique with 100% tension."
219692515|NCT02225418|DRUG|saline|
219692516|NCT05458778|DEVICE|Daily test with urine by the product|Women perform the hCG test and share the test results
219692517|NCT00002557|DRUG|CHOP regimen|
219105625|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
219105626|NCT03616067|DRUG|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
219105627|NCT03616067|DRUG|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
219105628|NCT04000737|DRUG|Sorafenib+YIV-906|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
219105629|NCT04000737|DRUG|Sorafenib+placebo|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
219105630|NCT03813147|DRUG|Azacitidine|Given IV
219105631|NCT03813147|DRUG|Cytarabine|Given intrathecally and IV
219105632|NCT03813147|DRUG|Fludarabine Phosphate|Given IV
219105633|NCT03813147|DRUG|Methotrexate|Given intrathecally
219105634|NCT03813147|DRUG|Pevonedistat|Given IV
219105635|NCT03813147|DRUG|Therapeutic Hydrocortisone|Given intrathecally
219105636|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
219224301|NCT00824642|DEVICE|placebo|placebo TENS applied prior to exercise
219692518|NCT00002557|DRUG|doxorubicin hydrochloride|
219692519|NCT00002557|DRUG|etoposide|
219692520|NCT00002557|DRUG|leucovorin calcium|
219692521|NCT00002557|DRUG|methotrexate|
219692522|NCT06011863|PROCEDURE|Thoracic Epidural Analgesia|Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
219692523|NCT06011863|PROCEDURE|Erector spinae plane block|Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
219692524|NCT04350593|DRUG|Dapagliflozin 10 milligram (mg)|Active Comparator: Dapagliflozin 10 mg
219692525|NCT04350593|DRUG|Placebo|Placebo Comparator
219692526|NCT03106116|DEVICE|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
219692527|NCT03106116|DRUG|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
219692528|NCT03222726|OTHER|exercise group|less than 6000 steps/day or 40,000 steps/week
219692529|NCT03638128|DRUG|Denosumab|Solution for injection
219692530|NCT03638128|DRUG|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
219692531|NCT03484169|OTHER|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
219692532|NCT00489463|DEVICE|intra-uterine device (TCu 380A)|
219692533|NCT02976883|OTHER|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of \[18F\]HX4 and PET/CT scan
219105637|NCT06925516|DRUG|Apatinib and Adebrelimab in Combination With chemotherapy|Patients would receive Adebrelimab (IV 1200mg q3w) and apatinib (PO 250mg qd) plus GEMOX (up to 6 cycles) in 21day cycles. Apatinib and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
219105638|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Intervention (I2P) and coaching sessions|Online learning sessions for parents of preterm children
219105639|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions|Online microlearning sessions for parents of preterm children
219105640|NCT06767293|OTHER|Internet Resources|control condition
219105641|NCT06912061|PROCEDURE|Needle tendon lengthening technique|"Percutaneous Achilles tendon lengthening with the needle technique is performed by applying a series of microtenotomies to the tendon using needle pricks while the tendon is stretched. A withdrawal needle with a diameter of 1.1-1.2 mm is used. The needle pricks gradually weaken the tendon and stretch it to the desired length without opening the skin or tendon sheath. As a rule, it is desirable to achieve approximately 10-15 degrees of dorsiflexion before concluding the lengthening.~Local infiltration anesthesia is applied, followed by a simple bandage. The surgical procedure typically takes 3-4 minutes. Finally, a boot cast in soft plaster with the foot and ankle in neutral position is applied, and it can be fully weight-bearing immediately.~The cast is removed at the clinic after 4 weeks. After cast removal, the child/adolescent should be allowed gentle activity - not sports - for another 4 weeks, thereafter unrestricted activity.~Physical therapy may be utilized as needed, locally."
219692534|NCT02371616|DEVICE|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
219692535|NCT02371616|OTHER|Sodium fluoride|1426 ppm fluoride as sodium fluoride
219692536|NCT02371616|OTHER|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
219692537|NCT04187313|OTHER|INSTEP2 intervention package|"The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients."
219692538|NCT04832737|BEHAVIORAL|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
219692539|NCT00754741|BEHAVIORAL|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
219105642|NCT06920667|DIETARY_SUPPLEMENT|Protein-Creatine-Omega-3-Vitamin D Supplement|Participants will receive a daily powdered supplement containing 30 g of whey protein isolate, 5 g of creatine monohydrate, 1 g of omega-3 fatty acids (EPA/DHA), and 1,000 IU of vitamin D3. The supplement will be taken once daily for 12 weeks, dissolved in water. It is designed to reduce glycemic variability and improve metabolic parameters in individuals with recently diagnosed type 2 diabetes.
219105643|NCT06920667|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Participants will receive a daily powdered placebo formulated with maltodextrin, without any active ingredients (no whey protein, creatine, omega-3, or vitamin D). It is identical in appearance, taste, and packaging to the active supplement. It will be taken once daily for 12 weeks and administered in the same conditions as the intervention group.
219224302|NCT06218745|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
219692540|NCT00754741|BEHAVIORAL|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
219692541|NCT00152347|DRUG|Botox|See Detailed Description
219692542|NCT05066529|PROCEDURE|dry-needling|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.
219692543|NCT04706377|DIETARY_SUPPLEMENT|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
219692544|NCT04706377|OTHER|Placebo|Placebo tablet
219692545|NCT00511719|DRUG|Technosphere Insulin|48U
219692546|NCT00511719|DRUG|Actrapid|24IU
219692547|NCT04331626|DRUG|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
219692548|NCT02212067|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
219692549|NCT02212067|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
219105644|NCT06918223|BEHAVIORAL|Thyroid Informed Surgical Consent Augmenting Video (TISCAV)|Participants randomized to the intervention group will receive a surgeon-created Thyroid Informed Surgical Consent Augmenting Video (TISCAV). This 8-minute video includes animated visuals and a surgeon voiceover explaining thyroid anatomy, surgical options (lobectomy vs. total thyroidectomy), risks, benefits, and expectations. The TISCAV was designed and reviewed by an endocrine surgery team to improve patient comprehension, confidence, satisfaction, and reduce decision regret compared to standard verbal consent alone.
219692550|NCT03988361|DIAGNOSTIC_TEST|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
219692551|NCT05771870|OTHER|Peer mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program."
219692552|NCT05771870|OTHER|Nurse mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study."
219692553|NCT05796713|OTHER|Hydrocephalus|Interview
219692554|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
219692555|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
219692556|NCT01321671|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
219692557|NCT00683228|BEHAVIORAL|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
219692558|NCT00405171|DRUG|Nevirapine|
219105645|NCT06918223|BEHAVIORAL|Standard Consent|Participants receiving the Standard Consent intervention will undergo the routine informed consent process for thyroid surgery provided by their surgeon. This process includes a verbal discussion covering thyroidectomy procedure details, potential risks and complications, benefits, alternatives such as active surveillance, and an opportunity to ask questions.
219105646|NCT06473012|BEHAVIORAL|Cognitive Behavioral Therapy for Caregivers of Older Adults|Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
219105647|NCT06473012|BEHAVIORAL|Control intervention for Caregivers of Older Adults|The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
219105648|NCT06919445|OTHER|'Text Connect' text messages|The Text Connect message includes 1) a link to a FindHelp (an online social resource database available in over 100 languages) search tailored to the recipient's home ZIP code 2) information regarding applying for the Supplemental Nutrition Assistance Program (SNAP), and information regarding applying for the Special Supplemental Program for Women, Infants, and Children (WIC). All text message content was initially developed in consultation with caregivers of children with FI identified during an admission through a Community Engagement studio and was approved by the institution's Effective Health Communication Core. The investigators have adapted the content based on feedback from participants in the pilot study.
219105649|NCT06921616|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
219692559|NCT03756415|DEVICE|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
219692560|NCT03756415|DEVICE|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
219360861|NCT04460755|OTHER|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219692561|NCT00350883|BEHAVIORAL|Cognitive Therapy|Goal-oriented talk therapy
219692562|NCT00350883|OTHER|Treatment as Usual|Keep getting usual care
219692563|NCT03160391|BEHAVIORAL|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
219692564|NCT03160391|BEHAVIORAL|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
219692565|NCT03586310|DEVICE|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
219692566|NCT04437758|DIETARY_SUPPLEMENT|Collagen and Vitamin C powder mix nutritional intervention|20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
219692567|NCT04437758|OTHER|Maltodextrin placebo powder|20 g maltodextrin placebo daily, 60 min prior to exercise
219692568|NCT04437758|OTHER|Maximum power training exercise|Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
219692569|NCT02007317|DRUG|Oshadi D & Oshadi R|Anti tumor agents
219692570|NCT02063113|OTHER|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
219692571|NCT01056692|DRUG|OC000459|Capsules twice daily for 15 days
219105650|NCT06921616|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|"For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate.~Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days."
219105651|NCT00297193|PROCEDURE|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
219105652|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
219105653|NCT06925958|DIAGNOSTIC_TEST|Flow cytometry|CD38 Flow cytometry testing
219105654|NCT06926452|PROCEDURE|Pontic site augmentation with sub-epithelial connective tissue graft.|Pontic site augmentation with sub-epithelial connective tissue graft.
219105655|NCT06926452|PROCEDURE|Pontic site augmenation using multi-layered platelet rich fibrin|Pontic site augmenation using multi-layered platelet rich fibrin
219692572|NCT01056692|DRUG|Placebo|Capsules twice daily for 15 days
219692573|NCT03332186|DRUG|BMS-986231|Intravenous infusion administration
219692574|NCT03028142|DRUG|1.5 mg RPL554 plus tiotropium|
219105656|NCT06925139|DEVICE|Non-ablative monopolar radiofrequency treatment|"Protocol for the experimental group:~Tissue preparation phase: 5 minutes with the circular resistive monopolar electrode, applying slow circular or semicircular movements in the perineal area. The temperature will be gradually increased based on the patient's temperature perception, ensuring it remains comfortable (approximately 5 out of 10).~Main phase: 10 minutes using the intracavitary capacitive electrode connected to the PLUMA handle, lightly resting it on the tissues and continuously moving the electrode. The temperature should reach 40-42°C in the tissue and be maintained for at least 10 minutes.~Final phase: 5 minutes with the circular resistive monopolar electrode, applying it similarly to the preparatory phase, with a subthermal effect, reaching a self-reported thermal sensation of 3 to 4 out of 10.~Protocol for the sham group: this group will receive the same treatment protocol that treatment group, but without the application of heat."
219105657|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
219692575|NCT03028142|DRUG|6 mg RPL554 plus tiotropium|
219692576|NCT03028142|DRUG|Placebo plus tiotropium|
219692577|NCT02644044|DRUG|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
219692578|NCT00125450|PROCEDURE|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
219692579|NCT00125450|PROCEDURE|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
219692580|NCT02810418|DRUG|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
219692581|NCT02810418|DRUG|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
219692582|NCT02810418|DEVICE|Mesothelin Expression|Research blood test for Arm B1 eligibility
219692583|NCT02810418|DRUG|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
219692584|NCT01336725|BEHAVIORAL|Teaching life style changes|Single group: Teaching, group sessions, physical activity
219692585|NCT01336725|OTHER|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
219692586|NCT01336725|OTHER|Teaching|Morbid obesity group attend 40 hours of group sessions
219692587|NCT06286917|OTHER|NIV initiation in patients with ALS|NIV initiation according to standard care
219692588|NCT01799759|BEHAVIORAL|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
219692589|NCT01799759|OTHER|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
219692590|NCT04125069|PROCEDURE|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
219692591|NCT02766647|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
219692592|NCT02766647|BIOLOGICAL|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
219692593|NCT00956436|DRUG|BIIB022|IV Q3W
219692594|NCT00956436|DRUG|Sorafenib|Standard dosing of Sorafenib
219692595|NCT03273478|DEVICE|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~* The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~* The patients will only be enrolled in the study if they give their written consent.~* If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
219692596|NCT04415801|DIAGNOSTIC_TEST|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
219692597|NCT01347463|PROCEDURE|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
219692598|NCT01547715|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
219692599|NCT00511381|GENETIC|No intervention|No intervention
219692600|NCT05550636|DRUG|BI 1015550|BI 1015550
219692601|NCT05550636|DRUG|midazolam|midazolam
219692602|NCT06443294|BEHAVIORAL|Smoking cessation video series.|The intervention in this study is a series of six videos totally approximately 40 minutes. These videos are led by a doctoral psychology student with experience in working with tobacco smokers. Videos utilize empirically-supported strategies for smoking cessation.
219692603|NCT04510272|OTHER|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
219105658|NCT04009187|BEHAVIORAL|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
219692604|NCT05063253|DRUG|TG103|TG103 injection, SC, once weekly
219692605|NCT05063253|DRUG|Placebo|Placebo, SC, once weekly
219692606|NCT04273815|DRUG|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
219692607|NCT04273815|DRUG|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
219692608|NCT03011203|OTHER|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
219692609|NCT01965327|DRUG|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
219692610|NCT00005793|DRUG|Cytarabine|
219692611|NCT00005793|DRUG|Daunorubicin|
219692612|NCT00005793|DRUG|Etoposide|
219692613|NCT00005793|DRUG|Topotecan|
219692614|NCT05788263|OTHER|neuroscience based aproach|exercise for pain
219692615|NCT06419491|OTHER|Partner notification by a trained counsellor|"One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them.~During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient"
219692616|NCT05145985|DIAGNOSTIC_TEST|Senior Fitness Test|"Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)"
219692617|NCT01474395|DRUG|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
219692618|NCT01474395|DRUG|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
219692619|NCT01474395|BEHAVIORAL|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
219692620|NCT06249516|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
219105659|NCT04009187|BEHAVIORAL|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
219105660|NCT01768546|BEHAVIORAL|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
219105661|NCT01768546|BEHAVIORAL|Interactive tracking and problem solving web portal|
219105662|NCT05899582|PROCEDURE|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
219105663|NCT05899582|OTHER|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
219105664|NCT05672212|DEVICE|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
219105665|NCT05672212|DEVICE|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
219105666|NCT05672212|DRUG|Sufentanil|Sufentanil
219105667|NCT01829984|OTHER|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
219105668|NCT01829984|OTHER|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
219105669|NCT06230991|DIETARY_SUPPLEMENT|SIM05|SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
219105670|NCT03657927|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
219105671|NCT03657927|DEVICE|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
219105672|NCT04532242|BEHAVIORAL|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
219105673|NCT01532180|DEVICE|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
219692621|NCT06249516|BIOLOGICAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219692622|NCT02626416|DEVICE|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
219692623|NCT05441800|OTHER|Observational Study|observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases
219692624|NCT04273321|DRUG|Methylprednisolone|Methylprednisolone 1mg/kg/day ivgtt for 7 days.
219692625|NCT00257790|DRUG|Tobramycin once a day|
219692626|NCT02221752|DIETARY_SUPPLEMENT|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
219692627|NCT02221752|DIETARY_SUPPLEMENT|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
219692628|NCT02785393|DRUG|Sugar Pill|The administration of a sugar pill
219692629|NCT02785393|DRUG|Doxazosin|The administration of the Doxazosin medication
219105674|NCT03739294|DRUG|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
219105675|NCT02936037|DRUG|MD1003 100mg capsule|
219105676|NCT02936037|DRUG|PLACEBO|an inactive substance
219105677|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
219105678|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
219105679|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
219105680|NCT00944281|DIETARY_SUPPLEMENT|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
219105681|NCT04057911|DEVICE|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
219105682|NCT04057911|DEVICE|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
219105683|NCT04986735|DRUG|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
219105684|NCT03672513|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
219105685|NCT03672513|DIETARY_SUPPLEMENT|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
219105686|NCT03672513|DIETARY_SUPPLEMENT|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
219360862|NCT04460755|OTHER|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219692630|NCT01980953|DRUG|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
219692631|NCT01980953|DRUG|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
219692632|NCT01980953|DRUG|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
219692633|NCT01603680|PROCEDURE|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
219692634|NCT01603680|PROCEDURE|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
219692635|NCT03370952|PROCEDURE|laproscopy|laparoscopic ovarian cystectomy
219692636|NCT03370952|PROCEDURE|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
219692637|NCT01929889|DRUG|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
219692638|NCT04493606|OTHER|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
219692639|NCT04493606|BEHAVIORAL|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
219692640|NCT04531865|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
219692641|NCT04531865|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
219692642|NCT04531865|DRUG|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
219692643|NCT03316846|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|
219692644|NCT02657330|DRUG|SBP-101|Subcutaneous drug, escalating dose cohorts
219692645|NCT03814564|DEVICE|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
219692646|NCT03713463|OTHER|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
219692647|NCT01669434|DRUG|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
219692648|NCT01669434|DRUG|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
219692649|NCT01003106|DRUG|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
219692650|NCT01003106|DRUG|Ranibizumab 2.0mg (monthly)|
219692651|NCT01003106|DRUG|Pro re nata (prn) ranibizumab|
219692652|NCT01003106|PROCEDURE|Pro re nata (prn) Laser photocoagulation|
219692653|NCT06200012|BEHAVIORAL|Multi-level stigma reduction intervention: educational training plus controlled substance agreement policy change|Pairing a professional training targeting known attitudinal and knowledge drivers of substance use stigma with a policy altering potentially stigmatizing features of controlled substance agreements.
219235403|NCT02341222|DEVICE|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
219692654|NCT06200012|BEHAVIORAL|Single-level stigma reduction intervention: educational training|A professional training targeting known attitudinal and knowledge drivers of substance use stigma
219692655|NCT00947206|BEHAVIORAL|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
219692656|NCT00947206|BEHAVIORAL|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
219692657|NCT05199246|DEVICE|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
219692658|NCT00809796|DRUG|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
219235404|NCT04619108|BIOLOGICAL|Thrombosomes®|
219692659|NCT02420639|DEVICE|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
219692660|NCT02860988|BEHAVIORAL|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
219692661|NCT06037317|DRUG|SY-3505|LTK tyrosine kinase inhibitor
219692662|NCT01968421|DRUG|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
219692663|NCT04795635|DEVICE|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
219692664|NCT05158621|PROCEDURE|blood collection for research (next generation sequencing [NGS])|participants will have whole blood collected for NGS
219692665|NCT05158621|PROCEDURE|blood collection for research (HLA typing)|participants will have whole blood collected for HLA typing
219692666|NCT05158621|PROCEDURE|blood collection for research (circulating tumor DNA [ctDNA])|participants will have whole blood collected for ctDNA detection
219692667|NCT05831800|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
219692668|NCT01082029|DRUG|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
219692669|NCT01082029|DRUG|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
219692670|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
219692671|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
219692672|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
219692673|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
219692674|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
219692675|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
219692676|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
219692677|NCT05469646|DRUG|BI 1819479|BI 1819479
219224303|NCT04180683|OTHER|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
219692678|NCT05469646|DRUG|Matching placebo|Matching placebo
219692679|NCT04891172|BIOLOGICAL|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
219692680|NCT00569985|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
219692681|NCT00569985|DRUG|carmustine|Given IV
219692682|NCT00569985|DRUG|cyclophosphamide|Given IV
219692683|NCT00569985|DRUG|etoposide|Given IV
219692684|NCT00569985|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
219692685|NCT06371391|OTHER|No intervention|No intervention
219692686|NCT01735604|BIOLOGICAL|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
219692687|NCT01735604|OTHER|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
219692688|NCT05345184|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
219692689|NCT05345184|BEHAVIORAL|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
219692690|NCT00573664|DRUG|Gabapentin|single oral dose of 600mg gabapentin
219692691|NCT00573664|OTHER|lactose|Single dose
219692692|NCT03952819|DIAGNOSTIC_TEST|serum sclerostin|blood samples obtained
219692693|NCT00461058|DRUG|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
219692694|NCT00461058|DRUG|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
219692695|NCT01102023|OTHER|ordinary salt based- diet|
219692696|NCT02687854|DRUG|Apixaban|As prescribed by treating physicians
219692697|NCT02687854|DRUG|Vitamin K antagonist|As prescribed by treating physicians
219692698|NCT03562078|BEHAVIORAL|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
219692699|NCT05418829|DRUG|AT-007|AT-007 20 mg/kg once daily
219692700|NCT02830568|PROCEDURE|open donor nephrectomy|open donor nephrectomy
219692701|NCT02830568|PROCEDURE|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
219692702|NCT02830568|PROCEDURE|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
219692703|NCT04578366|DEVICE|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
219692704|NCT04578366|OTHER|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
219692705|NCT06001671|DRUG|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
219692706|NCT06472752|RADIATION|Neoadjuvant radiotherapy|Patients with a clear pathological diagnosis of high-risk UTUC were treated with a short course of 5 days of naSBRT: radiotherapy irradiation was directed to the primary lesion on the affected side and to the lymphatic drainage area, with a dose of 25 Gy (5 Gy\*5 days).The safety of the neoadjuvant radiotherapy dose and regimen can be evaluated by metrological ramping in the initial 5 patients, with subsequent patients following the optimal dose from ramping.
219692707|NCT06472752|COMBINATION_PRODUCT|Neoadjuvant drug therapy|Patients will concurrently complete at least 2-4 cycles of preoperative neoadjuvant chemotherapy/immunotherapy/ADCs as well.
219692708|NCT01041170|DRUG|THC|
219692709|NCT01041170|DRUG|Rimonobant|
219692710|NCT01041170|DRUG|Rimonabant|
219692711|NCT03469544|OTHER|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
219692712|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
219224304|NCT04180683|OTHER|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
219692713|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
219224305|NCT00951132|DRUG|rosuvastatin|10mg tablets, once daily in three months
219224306|NCT00951132|DRUG|Placebo|tablet, once daily, three months
219224307|NCT02035046|PROCEDURE|Samplings of blood|
219224308|NCT02035046|PROCEDURE|Sampling of urine|
219224309|NCT02035046|PROCEDURE|Measure of the blood pressure|
219224310|NCT02035046|PROCEDURE|glycemia test|
219224311|NCT03700554|DEVICE|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
219224312|NCT03700554|PROCEDURE|Chest tube|Chest tube insertion
219224313|NCT02520219|DRUG|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
219224314|NCT02520219|BIOLOGICAL|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
219224315|NCT02161354|DRUG|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
219692714|NCT04635839|DRUG|Standard Dose of Unfractionated Heparin|5,000 units subcutaneous unfractionated heparin every 12 hours
219692715|NCT04635839|DRUG|Gestational Age-Based Dose of Unfractionated Heparin|"* First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours"
219692716|NCT02737358|DRUG|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
219692717|NCT02737358|OTHER|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
219692718|NCT02870868|BEHAVIORAL|Slow breathing|Slow breathing techniques from yoga
219692719|NCT04306523|OTHER|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
219692720|NCT01217593|PROCEDURE|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
219692721|NCT01217593|PROCEDURE|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
219692722|NCT00744939|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
219105687|NCT06102031|DEVICE|ReDS-Guided|"ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization."
219105688|NCT06102031|OTHER|Usual care|ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
219105689|NCT05371119|OTHER|Exercise Intervention|Training with light load with blood flow restriction (BFR)
219105690|NCT04567693|OTHER|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
219105691|NCT01821430|DRUG|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
219105692|NCT01821430|DRUG|Placebo|Placebo group will follow the same titration as the pregabalin group
219105693|NCT00749385|DRUG|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
219105694|NCT00749385|DRUG|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
219105695|NCT00749385|DRUG|EC naproxen|Enteric-coated naproxen tablet (500mg)
219105696|NCT00749385|DRUG|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
219105697|NCT01230606|OTHER|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
219105698|NCT03855163|BEHAVIORAL|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
219105699|NCT03855163|BEHAVIORAL|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
219105700|NCT03855163|BEHAVIORAL|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
219105701|NCT06131996|OTHER|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
219224316|NCT02161354|DRUG|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
219692723|NCT04211584|DEVICE|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
219692724|NCT05827848|DEVICE|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
219692725|NCT06019871|PROCEDURE|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
219105702|NCT06131996|OTHER|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
219105703|NCT03462706|PROCEDURE|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
219105704|NCT03462706|PROCEDURE|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
219105705|NCT03462706|PROCEDURE|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
219692726|NCT03019848|DIETARY_SUPPLEMENT|Curcumin|
219105706|NCT03462706|PROCEDURE|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
219105707|NCT04805463|OTHER|Control group|The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
219105708|NCT04805463|OTHER|PRF group|The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
219105709|NCT04805463|OTHER|CGF group|The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
219105710|NCT04805463|OTHER|AFG group|The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
219105711|NCT05568836|DIETARY_SUPPLEMENT|vitamin D supplementation|Intervention group will receive a single IM injection of 300000 IU vitamin D
219105712|NCT05568836|OTHER|control|control group will receive nothing
219105713|NCT05310201|BEHAVIORAL|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
219105714|NCT00749216|DRUG|Solanezumab|
219105715|NCT02468609|RADIATION|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
219105716|NCT03729102|BIOLOGICAL|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
219105717|NCT05121623|OTHER|Questionnaire|Online auto-administered Questionnaire
219105718|NCT02231229|OTHER|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
219105719|NCT02231229|DRUG|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
219105720|NCT05081505|BEHAVIORAL|Structural exercise course|12-week structured exercise class, team competition, social support, and incentive strategy
219105721|NCT05081505|BEHAVIORAL|Autonomous group class|12-week autonomous group class, team competition, social support, and incentive strategy
219105722|NCT05520502|OTHER|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
219105723|NCT03816241|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
219105724|NCT03816241|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
219105725|NCT03842462|OTHER|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
219105726|NCT03842462|OTHER|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
219105727|NCT03842462|OTHER|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
219105728|NCT00708721|DRUG|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
219105729|NCT05730738|DRUG|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
219105730|NCT05730738|DRUG|Placebo|placebo similar to Dalfampridine capsule
219105731|NCT01033292|DRUG|BSI-201|IV infusion, 5.6 mg/kg
219224317|NCT02161354|DRUG|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
219692727|NCT03019848|OTHER|Placebo|
219692728|NCT03151369|DRUG|Morphine|patients with the visual analog scale over 3 will receive morphine
219692729|NCT02532400|DRUG|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
219692730|NCT02532400|DRUG|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
219692731|NCT00180908|DRUG|Etoposide, Ifosfamide, Methotrexate|
219692732|NCT00180908|DRUG|Doxorubicin, Methotrexate|
219105732|NCT03729921|PROCEDURE|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
219105733|NCT03729921|PROCEDURE|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
219105734|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
219105735|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
219105736|NCT06183086|DEVICE|Linovera®|Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
219105737|NCT04105972|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
219105738|NCT04105972|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219105739|NCT04105972|DRUG|IVA|Mono tablet for oral administration.
219105740|NCT03792321|DRUG|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
219105741|NCT03792321|DRUG|Placebo|
219105742|NCT03711864|BIOLOGICAL|IM21 CAR-T cells|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
219105743|NCT00553202|BIOLOGICAL|anti-thymocyte globulin|Given IV
219105744|NCT00553202|DRUG|busulfan|Given IV
219692733|NCT04341935|DRUG|Linagliptin|5 mg Linagliptin administered by mouth once daily
219105745|NCT00553202|DRUG|cyclophosphamide|Given IV
219105746|NCT00553202|DRUG|cyclosporine|Given IV or orally
219105747|NCT00553202|DRUG|methotrexate|Given IV
219105748|NCT00553202|DRUG|methylprednisolone|Given IV
219105749|NCT00553202|DRUG|tacrolimus|Given IV
219105750|NCT00553202|OTHER|laboratory biomarker analysis|Correlative studies
219105751|NCT00553202|OTHER|pharmacological study|Correlative studies
219105752|NCT00553202|PROCEDURE|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
219105753|NCT00553202|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
219105754|NCT03963323|DIETARY_SUPPLEMENT|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
219105755|NCT03963323|OTHER|Placebo|Given PO
219105756|NCT05208853|BIOLOGICAL|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
219105757|NCT05486429|COMBINATION_PRODUCT|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~* Complete history taking with stress on:~  * Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~ * History of intake of lipid lowering drugs.~* Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~* Laboratory Investigation:~  1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~  .2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~* Radiological Investigation:~  1.Abdominal ultrasound.~* FIB - 4 it combines platelets count, ALI, AST and age.~* AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10\^9/L) ×100."
219105758|NCT00764192|PROCEDURE|blood sample|blood sample before and after a single HD
219105759|NCT00764192|PROCEDURE|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
219105760|NCT02593305|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
219105761|NCT02593305|DIETARY_SUPPLEMENT|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
219105762|NCT04561882|DEVICE|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
219105763|NCT02621736|OTHER|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
219224318|NCT04352517|OTHER|Online Survey|Online survey completion through google app.
219692734|NCT04341935|DRUG|Insulin regimen|Standard of care insulin regimen as per hospital protocol
219692735|NCT03013400|DRUG|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
219692736|NCT03013400|DRUG|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
219692737|NCT01249911|DIETARY_SUPPLEMENT|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
219692738|NCT01249911|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
219105764|NCT05402540|OTHER|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
219105765|NCT05402540|OTHER|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
219105766|NCT00365560|DRUG|tiotropium|
219105767|NCT00365560|DRUG|placebo|
219105768|NCT01161472|DRUG|4mg fesoterodine|4mg tablet once daily for 6 days
219105769|NCT01161472|DRUG|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
219105770|NCT01161472|DRUG|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
219105771|NCT01161472|DRUG|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
219692739|NCT04882371|DRUG|Chemotherapy|Neoadjuvant Chemotherapy for Breast Cancer
219692740|NCT04882371|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
219105772|NCT03659643|DIAGNOSTIC_TEST|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
219105773|NCT03963947|BIOLOGICAL|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
219105774|NCT05039762|PROCEDURE|Extracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
219224319|NCT06090513|COMBINATION_PRODUCT|Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation|TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
219224320|NCT06090513|DIAGNOSTIC_TEST|limited genetic testing or no testing|Minimal genetic testing for eligible patients or treatment without testing
219692741|NCT04882371|DIAGNOSTIC_TEST|Positron emission tomography - Copmputer Tomography (PET-CT)|Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
219692742|NCT00927407|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
219692743|NCT00927407|DRUG|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
219692744|NCT03881683|DIAGNOSTIC_TEST|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
219692745|NCT04768140|PROCEDURE|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
219692746|NCT04768140|PROCEDURE|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
219692747|NCT05461066|BEHAVIORAL|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
219692748|NCT03991871|DEVICE|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
219692749|NCT06228976|BEHAVIORAL|Mindfulness-based, smoking cessation focused text messages.|Participants will receive mindfulness-based, smoking cessation focused text messages everyday for 12 weeks.
219692750|NCT06228976|BEHAVIORAL|Educational messages|Text messages focus on the health risks of smoking and secondhand smoking, once everyday for 12 weeks.
219105775|NCT05039762|PROCEDURE|Intracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
219105776|NCT01449240|OTHER|No treatment|
219105777|NCT01996072|DRUG|EC17|
219105778|NCT01715337|OTHER|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
219105779|NCT06004284|OTHER|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
219105780|NCT06004284|OTHER|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
219105781|NCT00612222|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
219105782|NCT00612222|BIOLOGICAL|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
219692751|NCT06228976|BEHAVIORAL|Control messages|Text messages focus on the general healthy lifestyle, once everyday for 12 weeks.
219692752|NCT03532763|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
219692753|NCT03532763|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
219692754|NCT04710212|OTHER|No intervention.|Observational study with no intervention.
219692755|NCT05332223|DIAGNOSTIC_TEST|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
219692756|NCT02691715|PROCEDURE|Endometrial saline plus curettage|
219105783|NCT00612222|BIOLOGICAL|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
219105784|NCT00612222|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
219105785|NCT00612222|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
219105786|NCT02726776|OTHER|Suspension in a harness|
219105787|NCT02726776|OTHER|Climbing|
219224321|NCT00035100|DRUG|epothilone b|
219692757|NCT02691715|PROCEDURE|Endometrial curettage|
219692758|NCT01868646|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
219692759|NCT01868646|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
219105788|NCT00554983|BIOLOGICAL|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
219105789|NCT00554983|BIOLOGICAL|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
219105790|NCT03117465|OTHER|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
219692760|NCT03792334|DEVICE|depth of anesthesia|monitoring of depth of anesthesia
219692761|NCT01878799|DRUG|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
219692762|NCT03613831|DEVICE|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
219692763|NCT00291369|DRUG|Interleukin-2|
219692764|NCT00291369|DRUG|Interferon alfa|
219105791|NCT03117465|OTHER|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
219105792|NCT03326089|PROCEDURE|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
219105793|NCT02342314|DRUG|LY3143753 (Part A)|Administered via SC injection
219105794|NCT02342314|DRUG|LY3185643 (Part B)|Administered via SC injection
219692765|NCT00291369|DRUG|medroxyprogesterone acetate|
219692766|NCT04212767|PROCEDURE|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
219692767|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
219692768|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
219692769|NCT01198405|DEVICE|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
219692770|NCT01198405|DRUG|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
219692771|NCT00932256|DRUG|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
219692772|NCT01748370|DRUG|Vitamin D supplementation in hypogonadal men|
219692773|NCT01748370|DRUG|Vitamin D supplementation in eugonadal men|
219692774|NCT01748370|DRUG|Placebo hypogonadal|
219692775|NCT01748370|DRUG|Placebo eugonadal|
219692776|NCT02966704|DIETARY_SUPPLEMENT|intrinsically labeled milk protein|
219105795|NCT02342314|DRUG|Placebo (Part A and Part B)|Administered via SC injection
219105796|NCT02342314|DRUG|rGlucagon (Part B)|Administered via SC injection
219105797|NCT05640739|BEHAVIORAL|Demonstration method for the use of the Metered Dose Inhaler|The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
219105798|NCT05640739|BEHAVIORAL|Video watching method for the use of the Metered Dose Inhaler|The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
219105799|NCT03756454|BIOLOGICAL|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
219692777|NCT00619788|DEVICE|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
219692778|NCT06320210|BEHAVIORAL|Multicomponent program|The intervention is a multi-component program that includes in-depth training for current school teachers/staff who are critical in asthma care, restructured processes to identify students with asthma, technological adaptations to support integrated systems for asthma care and absenteeism, strategies to enhance communication about asthma within school and between school and home, protocols for routine care (e.g., participation in gym/recess) and emergencies, and education for all students about asthma.
219692779|NCT00941850|PROCEDURE|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
219692780|NCT01911832|PROCEDURE|esophagojejunostomy after total gastrectomy|
219692781|NCT01911832|PROCEDURE|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
219692782|NCT01911832|PROCEDURE|wide tube reconstruction after subtotal gastrectomy|
219692783|NCT01911832|PROCEDURE|narrow tube reconstruction after subtotal gastrectomy|
219692784|NCT03191799|DRUG|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
219692785|NCT06258850|DRUG|Calcifediol Oral Capsule|One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
219105800|NCT03756454|OTHER|Normal Saline|Placebo
219105801|NCT05920525|DEVICE|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
219105802|NCT05920525|PROCEDURE|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
219105803|NCT05635136|OTHER|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
219105804|NCT01567943|BEHAVIORAL|Contingency Management|Behavioral reinforcement for alcohol abstinence
219105805|NCT02020499|DRUG|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
219105806|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 alone for 21 days
219105807|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
219105808|NCT04275180|DRUG|Argatroban|Argatroban plus standard medical treatment
219105809|NCT04829435|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
219105810|NCT04829435|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
219105811|NCT01481155|PROCEDURE|ablative CO2 laser therapy|CO2 laser therapy
219692786|NCT06258850|DRUG|Placebo|One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
219692787|NCT05709665|OTHER|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
219105812|NCT01481155|PROCEDURE|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
219105813|NCT06210451|OTHER|Sterile water-based gel|Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
219105814|NCT02436083|DRUG|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
219105815|NCT04291235|PROCEDURE|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
219105816|NCT04291235|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
219105817|NCT03418870|BEHAVIORAL|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
219105818|NCT00768430|DRUG|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
219105819|NCT00768430|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
219105820|NCT02415920|DRUG|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
219105821|NCT02415920|DRUG|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
219105822|NCT05327335|DEVICE|Intelligent robotics for elderly assistance - sarcopenia|Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype. The system, connected to mobile apps and the Internet, will serve as a platform to measure and record data on how the participants engage in pre-specified activities. The experiment will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the design specifications for functionalities and reliability, user experiences, system security and privacy.
219692788|NCT01192165|DRUG|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
219692789|NCT01192165|DRUG|Docetaxel|Chemotherapy
219692790|NCT01192165|DRUG|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
219105823|NCT04033679|OTHER|Active TDCS|Participants will receive active TDCS stimulation.
219105824|NCT04033679|OTHER|Sham TDCS|Participants will receive sham TDCS stimulation.
219105825|NCT03054688|DEVICE|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
219105826|NCT01842737|PROCEDURE|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
219692791|NCT01192165|DRUG|Pemetrexed|Chemotherapy
219692792|NCT01192165|DRUG|Carboplatin|Chemotherapy
219692793|NCT01192165|DRUG|nab-Paclitaxel|Chemotherapy
219692794|NCT01192165|DRUG|Cisplatin|Chemotherapy
219692795|NCT04158765|OTHER|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
219692796|NCT01565863|BEHAVIORAL|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
219692797|NCT02064036|RADIATION|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
219692798|NCT02064036|DRUG|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
219105827|NCT01842737|PROCEDURE|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
219692799|NCT02064036|DRUG|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
219105828|NCT02459184|OTHER|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
219105829|NCT03118375|DEVICE|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
219105830|NCT05428904|OTHER|Virtual Reality Simulation|Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
219105831|NCT05751538|OTHER|No intervention|No intervention
219105832|NCT01983137|DRUG|Targinact® (oxycodone/naloxone)|
219105833|NCT03181126|DRUG|Navitoclax|tablet
219105834|NCT03181126|DRUG|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
219105835|NCT03181126|DRUG|Venetoclax|tablet
219105836|NCT02734108|DEVICE|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
219105837|NCT04315025|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
219105838|NCT04315025|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
219105839|NCT04712201|PROCEDURE|En bloc transurethral resection of bladder tumor (TURBT)|En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
219105840|NCT04712201|PROCEDURE|Conventional TURBT|Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
219692800|NCT05811481|PROCEDURE|TACE|Transcatheter Arterial Chemoembolization
219692801|NCT05811481|DRUG|Regorafenib|Regorafenib alone
219692802|NCT03893578|DEVICE|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
219692803|NCT05925192|OTHER|Observational study|N/A - observational study
219105841|NCT01400230|PROCEDURE|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
219105842|NCT04042285|DEVICE|Extracorporeal shockwave therapy in addition to standard care|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period. Standard care as per the NICE and IWGDF guidelines.
219105843|NCT04506008|RADIATION|Ultra-Hypo-fractionation Radiotherapy|Five fractions of pre-operative radiation
219692804|NCT06235671|PROCEDURE|Chiropractic care|6 weeks of chiropractic care
219692805|NCT02271321|OTHER|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
219692806|NCT03059914|DEVICE|InterOss|Anorganic bovine bone mineral - Xenograft
219105844|NCT04506008|PROCEDURE|Resection|Surgery
219105845|NCT04506008|OTHER|Questionnaire Administration|Ancillary studies
219105846|NCT04506008|RADIATION|Moderately-Hypo-fractionation Radiotherapy|15 fractions of pre-operative radiation
219105847|NCT05084222|DRUG|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
219105848|NCT05084222|DRUG|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
219105849|NCT05084222|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
219692807|NCT03059914|DEVICE|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
219692808|NCT00956085|DRUG|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
219692809|NCT02099513|DEVICE|The Mobile Health Platform|
219692810|NCT03108482|DRUG|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
219692811|NCT03108482|DRUG|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
219692812|NCT03108482|DRUG|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
219692813|NCT03108482|DRUG|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
219105850|NCT02629055|OTHER|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
219105851|NCT02696122|PROCEDURE|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
219105852|NCT02696122|PROCEDURE|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
219105853|NCT00041756|DRUG|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
219105854|NCT00041756|DRUG|Placebo|One placebo tablet, twice daily for for one year
219105855|NCT00041756|DRUG|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
219105856|NCT00041756|DRUG|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
219105857|NCT00041756|DRUG|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
219105858|NCT01030978|BEHAVIORAL|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
219105859|NCT01030978|BEHAVIORAL|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
219105860|NCT00603265|DRUG|ADL5859|
219105861|NCT00603265|DRUG|Duloxetine|
219105862|NCT00603265|DRUG|Placebo|
219105863|NCT02128256|DEVICE|Cerament G|
219105864|NCT05192850|DRUG|Metformin use|As an observational study, this is past exposure to metformin that occurred during the study period
219105865|NCT04859439|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
219692814|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
219105866|NCT05798039|BEHAVIORAL|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
219105867|NCT05975502|OTHER|Epidemiological study|Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
219105868|NCT02002884|DRUG|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
219105869|NCT02002884|DRUG|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
219105870|NCT02002884|DRUG|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
219105871|NCT02966002|DRUG|Aspirin|
219105872|NCT06261047|RADIATION|radiotherapy|radiotherapy
219105873|NCT06261684|DRUG|Intralesional Acyclovir|Intralesional Acyclovir in plantar warts
219105874|NCT06261684|DEVICE|Cryotherapy|Cryotherapy of plantar warts
219105875|NCT01052402|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
219105876|NCT03498222|DRUG|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
219105877|NCT03498222|DRUG|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
219105878|NCT03498222|DRUG|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
219105879|NCT03498222|DRUG|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
219105880|NCT04095143|DIAGNOSTIC_TEST|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
219105881|NCT04095143|DIAGNOSTIC_TEST|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
219105882|NCT04095143|DIAGNOSTIC_TEST|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
219105883|NCT04095143|DIAGNOSTIC_TEST|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
219105884|NCT04095143|DIAGNOSTIC_TEST|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
219105885|NCT04095143|DIAGNOSTIC_TEST|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
219105886|NCT04095143|DIAGNOSTIC_TEST|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
219105887|NCT00544063|DRUG|irinotecan hydrochloride|
219105888|NCT00544063|DRUG|oxaliplatin|
219105889|NCT01226563|DEVICE|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
219105890|NCT01226563|DEVICE|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
219105891|NCT02618720|DRUG|ornidazole|
219692815|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
219692816|NCT02675166|OTHER|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
219692817|NCT04212117|OTHER|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
219692818|NCT04212117|OTHER|WebMD|Randomization into WebMD arm.
219692819|NCT01893606|DRUG|N-acetyl-D-glucosamine|
219692820|NCT01893606|DRUG|placebo|
219692821|NCT03986099|DIAGNOSTIC_TEST|Monitoring virus load|Near point of care
219692822|NCT00021788|PROCEDURE|islet cell transplantation|
219692823|NCT02735031|DRUG|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
219692824|NCT02735031|DRUG|Placebo|6 weeks treatment with placebo on top of insulin treatment
219692825|NCT05387616|DRUG|Copanlisib|"Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle."
219692826|NCT05387616|DRUG|Obinutuzumab|"Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks."
219692827|NCT00915590|DRUG|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
219692828|NCT00915590|DRUG|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
219692829|NCT00873158|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
219105892|NCT02618720|DRUG|Placebo|
219692830|NCT06445933|COMBINATION_PRODUCT|Vitamin B6|The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
219692831|NCT06445933|COMBINATION_PRODUCT|Placebo|Placebo
219692832|NCT06227650|DEVICE|hybrid closed loop insulin delivery system|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
219692833|NCT00848016|DRUG|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
219692834|NCT05577416|PROCEDURE|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
219692835|NCT05577416|DRUG|Part A: Safusidenib Erbumine|Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
219105893|NCT03377790|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
219105894|NCT03377790|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
219692836|NCT05577416|PROCEDURE|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
219692837|NCT05577416|DRUG|Part B: Safusidenib Erbumine|Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
219692838|NCT04816916|DRUG|AXA1665|AXA1665 administered TID with food
219692839|NCT04816916|DRUG|Placebo|Matching placebo administered TID with food
219692840|NCT01054963|BEHAVIORAL|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
219105895|NCT02632786|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
219105896|NCT02632786|DRUG|Placebo|Saline Bag
219105897|NCT05539196|DEVICE|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
219105898|NCT02096614|DRUG|TBI-1201|TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
219105899|NCT02096614|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
219105900|NCT02096614|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
219105901|NCT03457285|OTHER|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
219105902|NCT04799860|BEHAVIORAL|health promotive work-way|"Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations"
219105903|NCT04767360|DEVICE|Bioness-300|Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
219105904|NCT05950854|DIAGNOSTIC_TEST|Weight-bearing MRI|Four MRI scans with 0.25T scanner: weight-bearing and non-weight-bearing with flexed and extended knee
219105905|NCT04922996|DRUG|Calcium Dobesilate|Dosage of calcium dobesilate in different tissues
219105906|NCT01760018|DRUG|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
219692841|NCT02280330|DIETARY_SUPPLEMENT|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
219692842|NCT02280330|OTHER|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
219692843|NCT02426801|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
219692844|NCT02426801|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
219105907|NCT01760018|DRUG|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
219105908|NCT01232309|DIETARY_SUPPLEMENT|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
219692845|NCT01958905|DRUG|Artemether-lumefantrine fixed combination|
219692846|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692847|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219105909|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
219105910|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
219105911|NCT01232309|DIETARY_SUPPLEMENT|Placebo|3 x 500 mg capsules (tid)
219105912|NCT03709290|RADIATION|mri|mri brain \& spinal cord
219105913|NCT06450574|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
219692848|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692849|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692850|NCT03634423|BEHAVIORAL|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692851|NCT03634423|BEHAVIORAL|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219105914|NCT06450574|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
219105915|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|10 weeks after Chemoradiotherapy
219105916|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery|Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
219105917|NCT03051126|OTHER|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
219105918|NCT00982150|DRUG|Talampanel|50mg capsules tid
219105919|NCT06345222|PROCEDURE|Prolotherapy|"The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament."
219105920|NCT02524132|BEHAVIORAL|Physical Activity|
219105921|NCT00780936|PROCEDURE|femoral nerve block|
219692852|NCT03634423|BEHAVIORAL|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692853|NCT03634423|BEHAVIORAL|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692854|NCT03634423|BEHAVIORAL|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692855|NCT03634423|BEHAVIORAL|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219105922|NCT02663414|DEVICE|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
219105923|NCT03941314|DEVICE|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
219105924|NCT03941314|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
219105925|NCT00152763|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
219105926|NCT00152763|OTHER|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
219105927|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
219105928|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
219105929|NCT05693493|DEVICE|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
219105930|NCT05799300|PROCEDURE|Intrathecal anaesthesia|Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
219105931|NCT05843474|BEHAVIORAL|Take it Personal!|Take it Personal! is a six-week indicated prevention program for youth with a mild intellectual disability or borderline intellectual functioning. The program aims to teach youngsters skills to reduce their substance use (alcohol, cannabis, and other drugs). The prevention program differentiates four personality profiles associated with a higher risk for problematic substance use: sensation seeking, impulsivity, anxiety sensitivity and negative thinking. For each of the four personality profiles, different program outlines were developed that are similar in structure but have their own personality-specific materials, games and (psychomotor) exercises. There are weekly individual- and group sessions with three to four participants, led by a clinical psychologist and a psychomotor therapist. Motivational interviewing and cognitive behavioral therapeutic principles are applied, both of which have proven effectiveness in decreasing substance use the target group.
219105932|NCT01824563|OTHER|Observational study|
219105933|NCT03930914|DEVICE|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
219105934|NCT02294110|OTHER|spinal anesthesia|non diabetes mellitus
219105935|NCT00569803|DRUG|belatacept|single dose, 116 days
219105936|NCT00569803|DRUG|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
219105937|NCT04343781|OTHER|observation|observation of clinical symptoms related to COVID-19 disease
219105938|NCT01324479|DRUG|INC280|
219692856|NCT03634423|BEHAVIORAL|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692857|NCT03634423|BEHAVIORAL|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
219692858|NCT04615936|OTHER|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
219692859|NCT00889239|OTHER|lithia-disilicate-based crown|all-ceramic crown
219105939|NCT00994474|PROCEDURE|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
219105940|NCT00994474|PROCEDURE|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
219692860|NCT04644172|BEHAVIORAL|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
219105941|NCT00695682|DRUG|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
219105942|NCT05643417|DRUG|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
219105943|NCT03338205|DRUG|Ketamine|1 mg/kg ketamine bolus IV
219105944|NCT01235975|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
219105945|NCT01235975|BIOLOGICAL|MencevaxACWY TM|Subcutaneous injection
219105946|NCT02580773|DRUG|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
219105947|NCT02580773|DRUG|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
219105948|NCT04989985|DRUG|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
219105949|NCT04989985|DRUG|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
219692861|NCT04644172|BEHAVIORAL|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
219105950|NCT01282671|OTHER|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
219105951|NCT01933503|DRUG|OCA 5 mg|
219105952|NCT01933503|DRUG|OCA 10 mg|
219105953|NCT01933503|DRUG|OCA 25 mg|
219105954|NCT05261932|PROCEDURE|AI-assisted guided biopsy|The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
219105955|NCT00791921|DRUG|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
219105956|NCT00791921|DRUG|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
219105957|NCT04825821|PROCEDURE|Clinical and ultrasonographic assessment|Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
219105958|NCT01175538|DRUG|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
219105959|NCT01175538|DRUG|Lactulose|lactulose will be used in 30-60ml/day
219105960|NCT01197079|OTHER|Survey|Self administered anonymous survey
219105961|NCT03188900|BIOLOGICAL|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
219105962|NCT01134133|OTHER|Anti-gurgling intervention|1\. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
219105963|NCT00988546|OTHER|Computer based template for exam documentation|exam documentation performed using computer based template
219105964|NCT00988546|OTHER|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
219105965|NCT00474175|DRUG|Placebo gel|single dose (less than 1g) of a matching placebo gel
219105966|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
219105967|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
219692862|NCT04644172|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
219692863|NCT04644172|OTHER|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
219692864|NCT00346866|DRUG|anecortave acetate|
219692865|NCT00492297|DRUG|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
219692866|NCT00193453|DRUG|Gemcitabine|1000mg/m2 30min IV, Day 1 \& 8
219692867|NCT00193453|DRUG|Docetaxel|30mg/m2, 30min IV, day 1 \& 8
219692868|NCT00193453|DRUG|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
219692869|NCT02774317|BIOLOGICAL|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
219692870|NCT01408706|DEVICE|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
219692871|NCT01408706|DEVICE|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
219692872|NCT06138210|DRUG|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
219692873|NCT06138210|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
219692874|NCT00919880|DRUG|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
219692875|NCT00919880|DRUG|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
219692876|NCT05414214|PROCEDURE|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
219692877|NCT05414214|PROCEDURE|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
219692878|NCT05414214|PROCEDURE|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
219692879|NCT03693196|OTHER|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
219105968|NCT01620359|DEVICE|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
219105969|NCT01047475|DRUG|MB-6|6# TID with meal
219105970|NCT01047475|DRUG|Placebo|6# TID with meal
219105971|NCT05255484|DRUG|LM-108|Administered intravenously
219105972|NCT05255484|DRUG|An Anti-PD-1 Antibody|Administered intravenously
219105973|NCT04204213|BEHAVIORAL|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
219105974|NCT01818934|PROCEDURE|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
219105975|NCT01152541|DRUG|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
219105976|NCT01152541|DRUG|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
219105977|NCT00504465|DRUG|dinoprostone|
219105978|NCT02728921|DRUG|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
219105979|NCT02728921|DRUG|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
219105980|NCT06381440|DEVICE|Lokomat device (Hocoma AG, Volketswil, Switzerland).|Robot Assisted Gait Training device
219105981|NCT06381440|OTHER|Conventional walking training|Self-paced supervised walking training
219105982|NCT01430312|DRUG|azelaic acid pre-foam formulation|
219105983|NCT01430312|DRUG|Vehicle pre-foam formulation|
219105984|NCT01430312|DRUG|Water|
219105985|NCT01430312|DRUG|Sodium lauryl sulfate|
219105986|NCT01950117|PROCEDURE|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
219105987|NCT01950117|PROCEDURE|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
219105988|NCT04037384|BEHAVIORAL|Eye yoga|Eye yoga exercises at home given by a trained instructor
219105989|NCT04037384|BEHAVIORAL|Passive Reading|Passive reading at home
219105990|NCT00157742|PROCEDURE|Spinal Cord Stimulation (SCS)|
219105991|NCT00157742|PROCEDURE|Percutaneous Myocardial Laser Revascularisation (PMR)|
219105992|NCT03169179|BEHAVIORAL|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
219105993|NCT02196493|DRUG|Azithromycin|250mg azithromycin three times per week for 12 weeks
219692880|NCT03693196|OTHER|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
219105994|NCT06530901|DIAGNOSTIC_TEST|Multidimensional ultrasound of the inferior vena cava|Cross-sectional parameters of the inferior vena cava include two-dimensional longitudinal diameter, cross-sectional length and short diameter, circumference, and cross-sectional area, as well as cross-sectional length and short diameter, circumference, and cross-sectional area in three-dimensional imaging
219692881|NCT03693196|OTHER|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
219105995|NCT00684086|BEHAVIORAL|Diabetes Self Management Program|
219105996|NCT04316767|BEHAVIORAL|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
219105997|NCT02183870|DRUG|Crizotinib|250mg crizotinib bid until end of treatment
219105998|NCT06275425|DRUG|Total intravenous anesthesia with Byfavo|General anesthesia is maintained with intravenous continuous administration of Byfavo.
219105999|NCT06275425|DRUG|Inhalation anesthesia with Sevoflurane|General anesthesia is maintained with Sevoflurane.
219106000|NCT05297643|DEVICE|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
219106001|NCT05297643|OTHER|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
219106002|NCT00831363|PROCEDURE|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
219692882|NCT03693196|OTHER|Demographic|Age, gender and state of smoking were compared between groups.
219692883|NCT06063889|DIAGNOSTIC_TEST|Maximal Rate of Force Development Test for Ankle Muscles|This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.
219692884|NCT06027840|DRUG|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
219692885|NCT06027840|BEHAVIORAL|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
219692886|NCT06027840|BEHAVIORAL|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
219692887|NCT00888654|DRUG|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
219692888|NCT00888654|PROCEDURE|Radical Prosatectomy|
219692889|NCT04737525|DEVICE|Dental implant placement, bone and soft tissue augmentation on buccal site|"1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray"
219692890|NCT06203938|DEVICE|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
219106003|NCT00831363|PROCEDURE|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
219692891|NCT06203938|DEVICE|Sham|Identical to TILS, but with lights off
219692892|NCT04151069|OTHER|Procedure A|Up-dosing nut drink at home
219692893|NCT04151069|OTHER|Procedure B|Up-dosing nut drink at the hospital
219692894|NCT04151069|OTHER|Control group|Strict avoidance of tree nut consumption
219106004|NCT00616564|DRUG|GM-CSF|Concomitant Priming with GM-CSF
219106005|NCT03096171|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
219106006|NCT05016414|OTHER|Lower body negative pressure|lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
219106007|NCT02095795|DEVICE|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
219106008|NCT02095795|OTHER|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
219106009|NCT00310895|DRUG|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
219106010|NCT03008525|BIOLOGICAL|subcutaneous and visceral adipose tissue biopsies|Subcutaneous and visceral adipose tissue biopsies during operation
219692895|NCT05494528|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
219106011|NCT03008525|BIOLOGICAL|blood samples analysis|"Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin."
219106012|NCT03484338|BEHAVIORAL|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
219106013|NCT02304016|BEHAVIORAL|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
219692896|NCT05494528|DRUG|Entecavir|Entecavir 0.5 mg once per day
219692897|NCT04080726|DRUG|HIP1601|Oral esomeprazole
219692898|NCT04080726|DRUG|HGP1705|Oral Nexium Tab
219692899|NCT04080726|DRUG|HIP1601 Placebo|Oral Placebo
219692900|NCT04080726|DRUG|HGP1705 Placebo|Oral Placebo
219692901|NCT03071211|DEVICE|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
219692902|NCT03071211|DEVICE|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
219106014|NCT04985006|BEHAVIORAL|running at moderate intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.
219692903|NCT03669549|DRUG|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
219692904|NCT02238730|DEVICE|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
219692905|NCT02238730|DEVICE|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
219692906|NCT04614298|DRUG|KHK4827-Active|Single SC administration
219106015|NCT04985006|BEHAVIORAL|running at high intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
219106016|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
219106017|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
219692907|NCT04614298|DRUG|KHK4827-Placebo|Single SC administration
219106018|NCT03560258|BIOLOGICAL|Full-length p55^gag pDNA vaccine|4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
219106019|NCT03560258|BIOLOGICAL|Placebo|1 mL placebo administered by one injection/electroporation
219106020|NCT00010686|DRUG|Dietary Phytoestrogens|
219692908|NCT04845997|BIOLOGICAL|COVID-19 Vaccine|Patients with rheumatic diseases who have been vaccinated for COVID-19
219692909|NCT00055341|DRUG|Peginterferon alfa-2a|
219692910|NCT00055341|DRUG|Ribavirin|
219692911|NCT05262920|BEHAVIORAL|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
219106021|NCT00946179|BIOLOGICAL|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
219106022|NCT01798186|DRUG|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
219106023|NCT03354325|BEHAVIORAL|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
219106024|NCT03354325|BEHAVIORAL|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
219106025|NCT02357043|DEVICE|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
219106026|NCT02357043|DEVICE|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
219692912|NCT05262920|BEHAVIORAL|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
219692913|NCT06282991|DRUG|Lorlatinib|ALK/ROS1 tyrosine kinase inhibitor
219692914|NCT00750763|DRUG|Colonlytely|Bowel preparation
219692915|NCT00750763|DRUG|Picolax/Picoprep|Bowel preparation
219692916|NCT00750763|DRUG|Fleet|Bowel preparation
219692917|NCT03492229|OTHER|tDCS|1 mA of tDCS
219692918|NCT03492229|OTHER|AMT|Ankle motor training
219692919|NCT03492229|BEHAVIORAL|Treadmill training|High intensity treadmill training
219692920|NCT05537857|OTHER|High dietary salt|Controlled feeding study that varies in salt content.
219692921|NCT01947348|PROCEDURE|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
219692922|NCT00004658|DRUG|ribose|
219692923|NCT00004658|DRUG|thymidine|
219692924|NCT00004658|DRUG|uridine|
219106027|NCT01291238|BEHAVIORAL|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
219106028|NCT05208385|PROCEDURE|video-assisted umbilical closure|video-assisted umbilical closure
219106029|NCT00101660|DRUG|Dasatinib|Tablets; oral; 70 mg BID, depending on response
219106030|NCT01321398|OTHER|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
219106031|NCT06089174|OTHER|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
219106032|NCT01113658|DEVICE|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
219106033|NCT05666544|OTHER|Web-based patient decision aid|After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
219106034|NCT05666544|OTHER|Written health education leaflets|After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
219106035|NCT00192023|DRUG|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
219106036|NCT00192023|DRUG|placebo|
219106037|NCT00192023|DRUG|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
219106038|NCT00192023|DRUG|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
219692925|NCT02605330|PROCEDURE|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
219692926|NCT05701813|DIETARY_SUPPLEMENT|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
219692927|NCT05701813|DIETARY_SUPPLEMENT|CELLULOSE|4.3 grams of cellulose once a day for 90 days.
219692928|NCT00698815|OTHER|Laboratory Biomarker Analysis|Correlative studies
219692929|NCT00698815|DRUG|Pemetrexed Disodium|Given IV
219692930|NCT00698815|DRUG|Sunitinib Malate|Given PO
219692931|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
219692932|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
219106039|NCT01083420|DRUG|Minocycline|Minocycline 0.2% mouthwash
219106040|NCT01083420|DRUG|Dexamethasone|Dexamethasone 0.01% mouthwash
219692933|NCT01362764|DRUG|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
219692934|NCT02121171|DEVICE|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
219692935|NCT02121171|PROCEDURE|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
219692936|NCT05385146|OTHER|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
219106041|NCT06489574|PROCEDURE|thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour)."
219106042|NCT06489574|PROCEDURE|thoracic epidural with fentanyl in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour)."
219106043|NCT06319235|DRUG|IMP|DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
219106044|NCT06319235|DRUG|Placebo|0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
219106045|NCT01797341|DRUG|Tacrolimus|
219106046|NCT01797341|DRUG|Tacrolimus|
219692937|NCT00229671|OTHER|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
219106047|NCT02676323|DRUG|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
219106048|NCT02676323|DRUG|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).
219106049|NCT02676323|DRUG|Cytarabine|Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).
219106050|NCT02676323|DRUG|Intrathecal Triples|Given intrathecally (IT).
219106051|NCT02676323|DRUG|Leucovorin|Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
219106052|NCT04769713|PROCEDURE|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
219106053|NCT04769713|DRUG|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
219106054|NCT04769713|DRUG|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
219106055|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
219106056|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
219106057|NCT02086162|BEHAVIORAL|Web-based motivational decision support system|
219106058|NCT02086162|BEHAVIORAL|NCI Education|
219106059|NCT02934360|DEVICE|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
219106060|NCT00398775|PROCEDURE|antibiotic discontinuation|
219106061|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham|"With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
219106062|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine|"With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
219106063|NCT04337060|OTHER|Pain follow-up and monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
219692938|NCT00229671|OTHER|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
219692939|NCT02436824|DRUG|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
219692940|NCT02436824|OTHER|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
219692941|NCT05938218|DEVICE|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
219692942|NCT04479839|DIAGNOSTIC_TEST|Ultrasound of the airway|Placing ultrasound on the neck after intubation
219692943|NCT03901846|DEVICE|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
219692944|NCT00994305|DRUG|N-acetylcysteine|600 mg bid po 0-7 PO
219692945|NCT00994305|DRUG|control|No treatment: standard care provided. No N-acetylcysteine administration.
219692946|NCT02130947|BEHAVIORAL|Exercise|
219692947|NCT00297648|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
219692948|NCT04566068|BEHAVIORAL|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.
219692949|NCT04566068|BEHAVIORAL|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
219692950|NCT02882334|DEVICE|Finger Force Manipulandum|
219692951|NCT02882334|OTHER|Conventional physiotherapy|
219692952|NCT00480571|DRUG|BL-1020|BL-1020 Low Dose
219692953|NCT00480571|DRUG|BL 1020 High Dose|BL 1020 High Dose
219692954|NCT06125093|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
219692955|NCT00750802|DRUG|AZD6280|10mg Capsule, oral, single-dose
219692956|NCT00750802|DRUG|AZD6280|40mg Capsule, oral, single-dose
219692957|NCT00750802|DRUG|Lorazepam|2mg tablet, oral single-dose
219692958|NCT00750802|DRUG|Placebo|
219692959|NCT06028789|DIAGNOSTIC_TEST|Blood sample test|"The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)"
219692960|NCT06028789|PROCEDURE|Thoracic Aortic Surgery|Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
219692961|NCT03522116|OTHER|No intervention|No intervention
219224322|NCT00817154|BEHAVIORAL|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
219692962|NCT01663402|DRUG|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
219692963|NCT01663402|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
219692964|NCT01663402|DRUG|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
219692965|NCT04710004|DEVICE|Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device|Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
219692966|NCT01088971|DIETARY_SUPPLEMENT|Duolac7S|1 capsule two times everyday for 6 weeks
219106064|NCT03326947|DRUG|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
219106065|NCT01027364|DRUG|Factor IX (rFIXFc)|
219106066|NCT01027364|DRUG|rFIX|
219106067|NCT00303563|DRUG|P38 Inhibitor (4)|50mg po qd
219106068|NCT00303563|DRUG|P38 Inhibitor (4)|150mg po qd
219692967|NCT01088971|DIETARY_SUPPLEMENT|starch|1capsule two times everyday for 6 weeks
219692968|NCT02262780|DRUG|Low dose of telmisartan|
219692969|NCT02262780|DRUG|High dose of telmisartan|
219692970|NCT02262780|DRUG|HCTZ|
219106069|NCT00303563|DRUG|P38 Inhibitor (4)|300mg po qd
219106070|NCT00303563|DRUG|Placebo|po qd
219106071|NCT03620682|BEHAVIORAL|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
219106072|NCT03620682|BEHAVIORAL|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
219692971|NCT00388245|PROCEDURE|Percutaneous Coronary Intervention|
219106073|NCT03895736|BIOLOGICAL|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
219106074|NCT00863889|DRUG|Depomedrol injection|1 cc of Depomedrol 80
219106075|NCT00863889|DRUG|Lidocaine, Marcaine|4 cc of each local anesthetic
219106076|NCT01605734|PROCEDURE|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
219106077|NCT01605734|DRUG|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
219106078|NCT01381835|DRUG|TMC435|150 mg capsule once daily for 7 days
219106079|NCT04654546|OTHER|Ultrasound abdominal scan|"A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system."
219224323|NCT05422846|OTHER|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
219224324|NCT05422846|OTHER|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
219692972|NCT00388245|PROCEDURE|Coronary Artery Bypass Grafting|
219692973|NCT05796791|DRUG|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
219692974|NCT05796791|BEHAVIORAL|Motivational enhancement therapy|Brief motivational based therapy
219692975|NCT06889129|OTHER|Experimental- Heat application|"Heat application + standard protocol=Hot Application Protocol~Hot application will start daily and continue until the completion of 4 weeks. The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be 40°C. The application will last for 30 minutes.~Patients will be advised to avoid contact with cold water, as well as the consumption of cold food and beverages."
219692976|NCT06889129|OTHER|Experimental-Cold application|"Cold application + standard protocol=Cold application will start daily and continue until the completion of 4 weeks.~The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be between 23-26°C. The application will be performed by the researcher on the day the patient comes for weekly chemotherapy treatment.~Patients will be advised to avoid contact with hot water, as well as the consumption of hot food and beverages."
219692977|NCT05701111|BEHAVIORAL|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
219692978|NCT05701111|BEHAVIORAL|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
219692979|NCT05701111|BEHAVIORAL|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
219692980|NCT05701111|BEHAVIORAL|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
219106080|NCT04402658|DRUG|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately \~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
219106081|NCT01149213|DEVICE|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
219106082|NCT00822003|DRUG|Oral GLP-1|GLP-1 tablet (2mg)
219106083|NCT00822003|DRUG|Placebo|Control tablet
219106084|NCT05091944|DEVICE|web-based birth decision aid|Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
219106085|NCT00240838|DRUG|acetaminophen extended release caplets|
219106086|NCT05706792|DEVICE|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
219106087|NCT01001780|DRUG|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
219692981|NCT05701111|GENETIC|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
219106088|NCT00332605|DRUG|Naltrexone plus N-Acetyl Cysteine|daily
219106089|NCT00332605|DRUG|Placebo|daily
219106090|NCT03266185|OTHER|Shorter PICT|Shorter post-infusion cooling time
219106091|NCT00485056|DRUG|Pioglitazone|45mgs daily
219106092|NCT00245856|DRUG|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
219692982|NCT06551688|DIAGNOSTIC_TEST|Serum 25(OH)D level|The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
219692983|NCT06441318|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
219692984|NCT06441318|DRUG|Placebo|Placebo will be administered at protocol defined dose.
219692985|NCT06441318|DRUG|Moxifloxacin|Moxifloxacin will be administered at protocol defined dose.
219692986|NCT03288038|DRUG|Rosuvastatin|
219692987|NCT03288038|DRUG|Ezetimibe|
219692988|NCT00209001|PROCEDURE|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
219692989|NCT00209001|PROCEDURE|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
219692990|NCT02277028|BEHAVIORAL|priming and task specific training|This task specific training protocol has been used in several clinical trials.
219692991|NCT05193513|DEVICE|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
219692992|NCT04295577|OTHER|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
219692993|NCT05510258|OTHER|Physiotherapy|TWO GROUPS CONTROL ND EXPERIMENTAL
219692994|NCT05259826|OTHER|biopsy sampling|"1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression."
219692995|NCT00993551|PROCEDURE|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
219106093|NCT00245856|DRUG|Warfarin|Titrated to INR 2-3 through study month 3
219692996|NCT02398110|PROCEDURE|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
219692997|NCT02398110|PROCEDURE|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
219106094|NCT04229680|OTHER|High Salt|Consumption of pills containing table salt for 10 days.
219692998|NCT04739228|BEHAVIORAL|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
219692999|NCT04739228|BEHAVIORAL|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
219693000|NCT05002972|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
219693001|NCT06101498|DIAGNOSTIC_TEST|Akut kidnet injury(AKI)|postoperative 24 hours
219693002|NCT06270108|DRUG|Riluzole|50mg twice daily (100mg total daily) for 56 days.
219693003|NCT05564572|OTHER|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
219693004|NCT04195594|OTHER|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
219106095|NCT04229680|OTHER|Recommended Salt|Consumption of pills containing dextrose for 10 days.
219693005|NCT01268163|DRUG|European Taxotere®|60-100 mg/m\^2 IV
219693006|NCT01268163|DRUG|American Taxotere®|60-100 mg/m\^2 IV
219106096|NCT04361513|DRUG|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
219106097|NCT04361513|DRUG|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
219106098|NCT01165840|DRUG|Dapsone|100 mg PO x 1 dose
219106099|NCT01764373|OTHER|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
219106100|NCT04393740|DIAGNOSTIC_TEST|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
219106101|NCT01280240|DRUG|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
219106102|NCT04535336|OTHER|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
219106103|NCT04535336|OTHER|Control|Participants maintained their daily activities.
219106104|NCT04114240|DRUG|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
219693007|NCT01268163|DRUG|Hospira Docetaxel Injection|60-100 mg/m\^2 IV
219106105|NCT01754883|DRUG|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
219106106|NCT03662997|DEVICE|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
219106107|NCT03662997|DEVICE|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
219693008|NCT02240667|DRUG|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
219693009|NCT02240667|DRUG|Vitamin K antagonists|International Normalized Ratio (INR) 2-3
219693010|NCT05518539|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
219693011|NCT03077893|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
219693012|NCT03077893|DEVICE|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
219106108|NCT03662997|DEVICE|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
219106109|NCT04479722|DEVICE|Left atrial appendage closure procedure|Implant LAAC system in LAA through percutaneous intervention
219106110|NCT01777594|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
219106111|NCT03000673|DRUG|Enoxaparin|Specified dose of Enoxaparin on specified days
219106112|NCT03000673|DRUG|unfractionated heparin (UFH)|Specified dose of UFH on specified days
219106113|NCT03000673|DRUG|BMS-986177|Specified dose of BMS-986177 on specified day
219106114|NCT01121484|DRUG|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
219106115|NCT01121484|DRUG|placebo|Placebo tablets taken orally once daily.
219106116|NCT04775121|OTHER|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
219106117|NCT04299477|PROCEDURE|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
219106118|NCT00562978|BIOLOGICAL|filgrastim|
219106119|NCT00562978|DRUG|cyclophosphamide|
219106120|NCT00562978|DRUG|etoposide|
219693013|NCT02690272|BEHAVIORAL|Psychic processes|Quantitative and qualitative aprroche of the psychic process
219693014|NCT04860479|DEVICE|ultrasound|ultrasonography to inguinal region
219693015|NCT02053493|DRUG|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
219693016|NCT02053493|DRUG|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
219693017|NCT02084901|DEVICE|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
219693018|NCT02084901|DEVICE|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
219693019|NCT01429844|DRUG|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
219693020|NCT01429844|DRUG|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
219106121|NCT00562978|PROCEDURE|AHSCT|
219106122|NCT00562978|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219106123|NCT03949660|DEVICE|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
219106124|NCT03949660|DEVICE|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
219106125|NCT03949660|DEVICE|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
219106126|NCT03949660|DEVICE|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
219106127|NCT01780129|DRUG|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
219106128|NCT06272305|PROCEDURE|This research does not require any specific investigation and does not imply any modification of treatment.|Collection of data from the medical record for patients with a non specific carotid endarterectomy
219106129|NCT04002219|DIETARY_SUPPLEMENT|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
219106130|NCT00258180|BIOLOGICAL|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
219106131|NCT00258180|DRUG|cyclophosphamide|Administered IV over 1 hour on days 1-4
219106132|NCT05602207|DRUG|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
219106133|NCT05425849|OTHER|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
219106134|NCT00028860|BIOLOGICAL|filgrastim|
219106135|NCT00028860|DRUG|carboplatin|
219106136|NCT00028860|DRUG|gemcitabine hydrochloride|
219106137|NCT00028860|DRUG|ifosfamide|
219106138|NCT00028860|DRUG|paclitaxel|
219106139|NCT00028860|PROCEDURE|adjuvant therapy|
219106140|NCT02921373|BIOLOGICAL|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
219693021|NCT02965404|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
219693022|NCT02965404|BIOLOGICAL|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
219693023|NCT02965404|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
219106141|NCT02921373|DEVICE|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
219106142|NCT03954457|BEHAVIORAL|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
219106143|NCT03954457|BEHAVIORAL|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
219106144|NCT00687336|OTHER|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
219106145|NCT00687336|OTHER|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
219106146|NCT00252213|DRUG|Human BNP|
219106147|NCT04848181|DRUG|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
219106148|NCT04848181|DRUG|finasteride|two weeks finasteride administration before TURP
219106149|NCT04848181|DRUG|no treatment received|no treatment received before TURP
219106150|NCT05156463|COMBINATION_PRODUCT|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
219106151|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
219106152|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
219106153|NCT02207439|DRUG|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
219106154|NCT02207439|OTHER|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
219106155|NCT06381011|OTHER|Local Vibration|The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
219106156|NCT04825444|DEVICE|Photoacoustic inspection|Use photoacoustic imaging system to image breast blood vessels
219106157|NCT00482222|BIOLOGICAL|cetuximab|
219106158|NCT00482222|DRUG|capecitabine|
219106159|NCT00482222|DRUG|fluorouracil|
219106160|NCT00482222|DRUG|leucovorin calcium|
219224325|NCT05422846|OTHER|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
219106161|NCT00482222|DRUG|oxaliplatin|
219106162|NCT00482222|OTHER|study of socioeconomic and demographic variables|
219106163|NCT00482222|PROCEDURE|adjuvant therapy|
219106164|NCT00482222|PROCEDURE|neoadjuvant therapy|
219106165|NCT00482222|PROCEDURE|quality-of-life assessment|
219224326|NCT01291212|DRUG|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
219224327|NCT01291212|DRUG|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
219224328|NCT03232398|DRUG|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
219106166|NCT04785326|DRUG|DMB-3115|45mg or 90mg dose subcutaneous administration
219106167|NCT04785326|DRUG|Stelara|45mg or 90mg dose subcutaneous administration
219106168|NCT04878016|BIOLOGICAL|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
219106169|NCT04878016|DRUG|Placebo|Patients will receive placebo administered by IV infusion every 21days.
219106170|NCT04878016|DRUG|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
219106171|NCT04878016|DRUG|Etoposide|"Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
219106172|NCT02781896|DEVICE|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
219106173|NCT02781896|DEVICE|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
219106174|NCT02912468|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219106175|NCT02912468|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219106176|NCT02912468|DRUG|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
219106177|NCT05800782|BEHAVIORAL|Face Memory Training|Computer-based training using faces targeting face memory
219106178|NCT05800782|BEHAVIORAL|Face Perception Training|Computer-based training using faces targeting improving face perception
219106179|NCT05800782|BEHAVIORAL|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
219106180|NCT04723043|DEVICE|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
219106181|NCT02183116|DRUG|Meloxicam|
219106182|NCT00967213|DRUG|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
219106183|NCT01440127|DRUG|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
219106184|NCT06205641|DRUG|Xuanfei Baidu Granule Placebo|Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
219224329|NCT03232398|DRUG|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
219693024|NCT04881344|PROCEDURE|laser hemorrhoidoplasty|"* Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able."
219693025|NCT04881344|PROCEDURE|mucopexy|"* Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention)."
219106185|NCT06205641|DRUG|Xuanfei Baidu Granule|Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
219106186|NCT06205641|DRUG|Baloxavir Marboxil Tablet|Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
219106187|NCT01413230|DRUG|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
219224330|NCT03141918|DIETARY_SUPPLEMENT|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
219224331|NCT03141918|OTHER|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
219224332|NCT00109031|DRUG|palifermin|Administered as one daily intravenous bolus.
219224333|NCT00109031|RADIATION|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
219224334|NCT00109031|DRUG|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
219693026|NCT03569397|OTHER|Music Therapy|Patients will be administered music therapy during the operation.
219106188|NCT04230460|DRUG|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
219106189|NCT04230460|DRUG|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
219106190|NCT04230460|DRUG|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
219106191|NCT04230460|DRUG|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
219106192|NCT02779023|BEHAVIORAL|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
219106193|NCT04062435|DRUG|Drop application in the inferior fornix|See Arms
219106194|NCT04062435|DRUG|Drop application on the cornea|See Arms
219106195|NCT01876563|DIETARY_SUPPLEMENT|vitamin D|one tab 4000 IU/day vitamin D
219106196|NCT01876563|DIETARY_SUPPLEMENT|placebo|one tab per day placebo
219106197|NCT03452176|DEVICE|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
219106198|NCT03452176|DEVICE|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
219106199|NCT05146960|OTHER|Temporal summation|Temporal summation will be evoked in each predetermined area
219106200|NCT05146960|OTHER|Placebo|PPTs will be assessed once in each predetermined area
219106201|NCT00811421|DRUG|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
219106202|NCT00811421|DRUG|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
219106203|NCT00811421|DRUG|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
219106204|NCT00811421|DRUG|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
219106205|NCT00811421|DRUG|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
219106206|NCT01570595|BEHAVIORAL|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
219106207|NCT01570595|BEHAVIORAL|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
219106208|NCT02674360|BEHAVIORAL|SDM Training|
219106209|NCT02826980|OTHER|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
219106210|NCT02920151|OTHER|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
219106211|NCT03222258|BEHAVIORAL|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
219106212|NCT03222258|BEHAVIORAL|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
219693027|NCT04613518|DRUG|BMS-986165|Specified Dose on Specified Days
219106213|NCT02811094|OTHER|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
219106214|NCT02108145|PROCEDURE|bilateral metal stent insertion|
219106215|NCT02108145|PROCEDURE|unilateral metal stent insertion|
219106216|NCT03853317|BIOLOGICAL|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
219106217|NCT03853317|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219106218|NCT03853317|BIOLOGICAL|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
219224335|NCT00109031|DRUG|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
219693028|NCT04613518|OTHER|Placebo Comparator|Specified Dose on Specified Days
219693029|NCT04002791|DEVICE|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
219693030|NCT02764502|DEVICE|Pressure Gauge Manometer|Identification of epidural space
219106219|NCT04868643|DEVICE|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
219224336|NCT00109031|DRUG|Placebo|Administered as one daily intravenous bolus.
219693031|NCT02216383|DRUG|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
219693032|NCT02216383|DRUG|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
219106220|NCT00900081|OTHER|immunohistochemistry staining method|
219693033|NCT02216383|DRUG|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
219106221|NCT00900081|OTHER|laboratory biomarker analysis|
219106222|NCT00900081|OTHER|medical chart review|
219224337|NCT05966012|DRUG|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
219106223|NCT05666687|DRUG|MIJ821|MIJ821 will be administered as an i.v. infusion
219106224|NCT00344006|DRUG|chlorproguanil-dapsone-artesunate|
219106225|NCT00344006|DRUG|artemether-lumefantrine|
219106226|NCT01874106|OTHER|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
219106227|NCT01874106|OTHER|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
219106228|NCT00817804|DEVICE|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
219224338|NCT00881296|DRUG|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
219224339|NCT00881296|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
219224340|NCT03413085|DEVICE|soft contact lens|"Group A~Group B"
219224341|NCT02309294|DEVICE|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
219224342|NCT02309294|DEVICE|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
219224343|NCT02309294|DEVICE|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
219224344|NCT02309294|DEVICE|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
219224345|NCT02309294|DEVICE|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
219224346|NCT04068272|DRUG|Bosentan|Eyedrop
219224347|NCT04068272|DRUG|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
219224348|NCT06682143|BEHAVIORAL|Virtual Reality (VR)|Participants will engage in a virtual reality greenspace activity for a period of 5 minutes
219224349|NCT06682143|BEHAVIORAL|Control|Participants will sit quietly for a period of 5 minutes
219106229|NCT02276391|DRUG|Telmisartan/HCTZ combination|
219106230|NCT02276391|DRUG|Telmisartan|
219106231|NCT04842864|BEHAVIORAL|Fasting|23 hours fasting
219106232|NCT01803230|DIETARY_SUPPLEMENT|creatine supplementation|creatine supplementation
219106233|NCT01803230|DIETARY_SUPPLEMENT|Placebo|
219106234|NCT04760730|BIOLOGICAL|AZD1222|"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
219106235|NCT04760730|BIOLOGICAL|rAd26-S|"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
219106236|NCT05386251|BEHAVIORAL|BPT/OST|See Arm description.
219106237|NCT05386251|BEHAVIORAL|Peer Support|See Arm description
219106238|NCT02772575|PROCEDURE|Hepatic trans-arterial embolization (TAE)|
219106239|NCT02772575|DEVICE|MRI/CT scan|
219106240|NCT02772575|PROCEDURE|biopsy|
219224350|NCT03520036|DRUG|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
219224351|NCT03520036|DRUG|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
219224352|NCT03520036|DRUG|Placebo|Placebo QD, oral, 16 weeks
219224353|NCT01878305|DEVICE|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
219693034|NCT00026091|DRUG|fenretinide|Given orally
219693035|NCT00026091|OTHER|laboratory biomarker analysis|Correlative studies
219693036|NCT00026091|OTHER|pharmacological study|Correlative studies
219106241|NCT02772575|OTHER|blood draw|
219106242|NCT02289989|DRUG|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
219106243|NCT02289989|DRUG|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
219106244|NCT04353193|DRUG|Terlipressin|Terlipressin 1mg IV bolus
219106245|NCT04353193|DRUG|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
219106246|NCT04353193|DRUG|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
219224354|NCT00012259|DRUG|troxacitabine|
219224355|NCT03981588|OTHER|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
219224356|NCT04448652|DRUG|NSAID|no other intervention than described in the groups.
219693037|NCT04528316|BEHAVIORAL|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:"
219693038|NCT04528316|BEHAVIORAL|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
219693039|NCT04528316|BEHAVIORAL|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
219693040|NCT04852250|OTHER|Virtual centralized multidisciplinary tumour board|Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
219693041|NCT02828488|OTHER|No intervention|It is a descriptive study. No intervention
219693042|NCT04770506|OTHER|Data extraction from medical files|Data extraction from medical files
219693043|NCT05098873|OTHER|psychodynamic|intervention with adolescents through the presentation of questions to be completed
219693044|NCT00160108|BEHAVIORAL|dietary intervention|
219693045|NCT04805138|OTHER|Spectrophotometer|To objectively measure the discoloration of the peri-implant mucosa, spectrophotometric measurements of the buccal mucosa will be performed at study implant and at control tooth.
219106247|NCT04885387|DEVICE|chest CT|chest CT pectus deformities diagnostic
219106248|NCT04885387|DEVICE|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
219106249|NCT01333085|DRUG|carboplatin|
219106250|NCT01333085|DRUG|RAD001|
219106251|NCT01333085|DRUG|paclitaxel|
219106252|NCT01377558|OTHER|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
219106253|NCT01377558|OTHER|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
219224357|NCT02424474|DEVICE|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
219693046|NCT02756702|DEVICE|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
219693047|NCT01619865|DRUG|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
219693048|NCT01494818|DEVICE|Hydrogen peroxide-based contact lens care system|
219693049|NCT01494818|DEVICE|PHMB-containing contact lens solution|
219693050|NCT01494818|DEVICE|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
219693051|NCT04737850|DRUG|Hetrombopag|Thrombopoietin receptor agonist
219693052|NCT04737850|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
219693053|NCT04843982|DRUG|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
219693054|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
219693055|NCT04790578|DEVICE|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
219106254|NCT01377558|OTHER|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
219224358|NCT02424474|BIOLOGICAL|Regular serum screening|
219693056|NCT04790578|BEHAVIORAL|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
219106255|NCT01458990|DRUG|Omeprazole|20mg PO BID for 20 days
219106256|NCT03603392|OTHER|Physical activity program|
219106257|NCT01743690|BIOLOGICAL|Probiotic lactobacilli reuteri|
219106258|NCT01743690|DRUG|Nystatin|
219106259|NCT01743690|DRUG|fluocinolone|
219106260|NCT00873301|PROCEDURE|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
219106261|NCT00986115|DRUG|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
219106262|NCT00986115|DRUG|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
219106263|NCT01442272|DRUG|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
219106264|NCT01442272|DRUG|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
219106265|NCT01442272|DRUG|Habitual medication|Habitual medication
219106266|NCT03290560|DRUG|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
219106267|NCT03290560|OTHER|Placebo|Placebo Comparator: Phosphate buffered saline
219106268|NCT06488391|BEHAVIORAL|Using a Portable Visualized Device for Self-Directed Breathing Training|Using a Portable Visualized Device for Self-Directed Breathing Training
219106269|NCT01953770|DRUG|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
219106270|NCT01953770|DRUG|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
219224359|NCT00758550|DEVICE|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
219106271|NCT01953770|DRUG|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
219106272|NCT01953770|DRUG|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
219106273|NCT01953770|DRUG|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
219106274|NCT01953770|DRUG|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
219106275|NCT01953770|RADIATION|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients \>3 years of age
219106276|NCT01953770|DRUG|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
219106277|NCT00406419|DRUG|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
219106278|NCT00406419|DRUG|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
219106279|NCT00406419|DRUG|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
219106280|NCT04362657|DIAGNOSTIC_TEST|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
219106281|NCT01937637|BEHAVIORAL|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
219106282|NCT02690636|RADIATION|radiotherapy|daily fractions, five fractions per week.
219224360|NCT00758550|DEVICE|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
219224361|NCT01588093|DRUG|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
219224362|NCT01588093|DRUG|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
219693057|NCT00294814|DEVICE|Proximal anastomosis using Heartstring anastomotic device|
219693058|NCT00205114|BEHAVIORAL|Individualized multifactorial intervention for community-living high-risk older adults|
219693059|NCT00205114|BEHAVIORAL|Health professional education program about fall prevention|
219693060|NCT02898233|OTHER|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
219693061|NCT02898233|DEVICE|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
219693062|NCT02898233|DEVICE|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
219693063|NCT00791999|DRUG|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
219693064|NCT00791999|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
219693065|NCT00791999|DRUG|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
219693066|NCT00791999|DRUG|Placebo of CDP870|given every 2 weeks until Week22 (SC)
219693067|NCT03200210|DRUG|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
219693068|NCT03200210|DRUG|Placebo|Pills manufactured to mimic Febuxostat tablets
219693069|NCT00430846|DRUG|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
219693070|NCT04694001|DEVICE|Use of the Atalante exoskeleton|A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
219106283|NCT03246243|DEVICE|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
219106284|NCT05179941|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
219106285|NCT05564741|DRUG|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
219106286|NCT01913639|DRUG|Regorafenib|
219106287|NCT01913639|DRUG|5-Fluorouracil|
219693071|NCT01876108|DRUG|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
219693072|NCT02993848|OTHER|No intervention|
219693073|NCT05450913|DRUG|Priformis intramuscular injection with %2 lidocain|Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
219693074|NCT01077323|DRUG|exenatide|subcutaneous injection, dosing according to normal clinical practice
219693075|NCT01077323|DRUG|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
219693076|NCT01077323|OTHER|No diabetes therapy|Subjects not diagnosed with diabetes
219693077|NCT01654770|DEVICE|video capsule endoscopy|
219693078|NCT01654770|DEVICE|double balloon enteroscopy|
219693079|NCT05628701|PROCEDURE|Ileorectal anastomosis (IRA)|After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
219693080|NCT05628701|PROCEDURE|Ileal pouch anal anastomosis (IPAA)|The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
219693081|NCT05628701|PROCEDURE|ileostomy|no reconstruction is performed and the patient is left with his/her ileostomy
219693082|NCT00120237|DRUG|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
219693083|NCT06404892|PROCEDURE|Single-lung ventilation|Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
219106288|NCT01913639|DRUG|Leucovorin|
219106289|NCT01913639|DRUG|Oxaliplatin|
219106290|NCT02109796|DEVICE|transcranial Direct current stimulation|
219106291|NCT04985734|DIAGNOSTIC_TEST|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
219106292|NCT03706911|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
219693084|NCT00509717|OTHER|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
219693085|NCT00509717|OTHER|control|educational manual
219106293|NCT05269537|RADIATION|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
219106294|NCT05269537|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
219106295|NCT05269537|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
219106296|NCT05269537|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
219106297|NCT05269537|DRUG|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
219106298|NCT05269537|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
219106299|NCT05269537|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
219693086|NCT03906812|OTHER|Telemetry|Bed type assignment
219693087|NCT03906812|OTHER|Unmonitored|Bed type assignment
219693088|NCT04873089|OTHER|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product"
219693089|NCT03898622|DRUG|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
219693090|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
219693091|NCT01768663|DRUG|Lumacaftor|tablet, 200mg taken every 12 hours
219106300|NCT05269537|DRUG|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
219106301|NCT00493337|BEHAVIORAL|advanced adherence counseling+reminder|
219106302|NCT00493337|DEVICE|Compliance Card|
219106303|NCT01903343|DEVICE|shear wave elastography|ultrasound
219106304|NCT03862196|BEHAVIORAL|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
219106305|NCT01290822|DEVICE|BiVP|Biventricular pacing
219106306|NCT01290822|DEVICE|AAI Pacing|Atrial pacing
219106307|NCT00101309|BIOLOGICAL|aldesleukin|
219106308|NCT00101309|BIOLOGICAL|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
219106309|NCT00101309|BIOLOGICAL|therapeutic autologous lymphocytes|
219106310|NCT06387589|PROCEDURE|Core stability exercises|"Core stability Exercises will include:~PLANK SIDE PLANK BIRD DOG MS GILL CURLUP PLANK + LEG RAISES SIDE PLANK + LEG RAISES PLANK + WALKS SIDE TO SIDE SIDE PLANK + TWIST BIRD DOG"
219693092|NCT01768663|DRUG|Ivacaftor|tablet, 250mg taken every 12 hours
219693093|NCT01768663|DRUG|Ciprofloxacin|750 mg taken every 12 hours
219693094|NCT01768663|DRUG|Itraconazole|200mg taken once daily
219693095|NCT01768663|DRUG|Rifampin|600mg taken once daily
219106311|NCT06387589|PROCEDURE|Static Stretching of Iliopsoas|Static Stretching of Iliopsoas (Hold for 7-8s x 10 reps) Week 1 Lifting the leg while lying in a prone position with the knee bent Week 2 Lifting the leg in a prone position with a straight knee Week 3 Stretch in the modified Thomas test position Week 4 Modified launch stretch
219693096|NCT01811537|DEVICE|Artificial Chordae|
219693097|NCT00427908|BIOLOGICAL|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
219106312|NCT06387589|PROCEDURE|Post Facilitation Stretch of Iliopsoas|"Post Facilitation Stretch of Iliopsoas (5-10s x 10 reps) Patient's position supine at the edge of the table, non-effected hip and knee in flexion, experimental thigh and leg hang on the edge of table. Extend the hip of the opposite thigh up to the barrier. After that, the patient flexes the hip against maximal resistance (isometric) and breathes in for 5-10 seconds. Tell the patient Relax, whereas the therapist applies a rapid stretch to a new barrier and is held for 10 seconds."
219106313|NCT03501693|DEVICE|DBT plus S-View|DBT plus S-View images
219106314|NCT03501693|DEVICE|FFDM Alone|FFDM alone images
219106315|NCT00321204|PROCEDURE|TZD reducing the incidence of atrial arrhythmias|
219106316|NCT00089895|DRUG|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
219106317|NCT00089895|DRUG|Placebo|intravenous; delivery to match eptifibatide to maintain blind
219106318|NCT00000942|DRUG|Nevirapine|
219106319|NCT00829361|OTHER|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
219106320|NCT04996199|DRUG|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
219106321|NCT04996199|DRUG|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
219693098|NCT00427908|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
219693099|NCT00427908|BIOLOGICAL|Meningitec™|One intramuscular dose.
219693100|NCT05868590|OTHER|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
219693101|NCT01710020|DRUG|CP-690,550|CP-690,550 10 mg oral powder for constitution
219693102|NCT02984982|DRUG|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219693103|NCT02984982|DRUG|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
219693104|NCT02984982|DRUG|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
219693105|NCT02984982|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
219693106|NCT02984982|DRUG|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
219693107|NCT02984982|DRUG|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
219693108|NCT02984982|DRUG|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
219693109|NCT02984982|DRUG|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
219106322|NCT03767985|OTHER|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
219106323|NCT03767985|OTHER|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
219693110|NCT06328972|BEHAVIORAL|systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.
219106324|NCT00023790|DRUG|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
219106325|NCT00189111|PROCEDURE|Cardiac Imaging + Treatment|
219106326|NCT01644396|BIOLOGICAL|Adalimumab|
219106327|NCT06495437|BIOLOGICAL|Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.|The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
219106328|NCT04192474|DEVICE|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
219106329|NCT06241196|DEVICE|implant|Implant will be placed through the surgical guide in the extraction socket
219106330|NCT06241196|PROCEDURE|Vestibular Socket Therapy|tunnel incision will be made in labial vestibule
219106331|NCT06241196|DRUG|Alloderm|allogenic soft tissue substitute
219106332|NCT06241196|DRUG|Xenogenic bone membrane shield|xenogenic bone membrane
219106333|NCT06241196|PROCEDURE|Connective tissue graft|soft tissue harvesting from palate
219106334|NCT06475287|DRUG|HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450|The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
219106335|NCT00927043|OTHER|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
219106336|NCT04394845|DIAGNOSTIC_TEST|[18F]GTP1|\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
219106337|NCT04683523|OTHER|Exercise|Resistance training using dumbbells and therabands
219106338|NCT06153940|DEVICE|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
219106339|NCT05453981|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
219106340|NCT05696314|DIAGNOSTIC_TEST|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
219106341|NCT05696314|DIAGNOSTIC_TEST|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
219106342|NCT05644353|DRUG|Mirikizumab|Administered SC.
219106343|NCT05657444|DRUG|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
219106344|NCT03535831|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
219106345|NCT04937036|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
219106346|NCT00740103|DRUG|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
219693111|NCT06328972|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
219693112|NCT06328972|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
219693113|NCT02153918|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
219106347|NCT04637165|OTHER|This is a non-interventional study|This is a non-interventional study
219106348|NCT06159413|DEVICE|VIRTUAL REALITY|LUMBAR MULTIFIDUS MUSCLES FUNCTION AMONG PATIENTS WITH LOW BACK PAIN: VIRTUAL REALITY VERSUS STABILIZATION EXERCISES.
219106349|NCT04783298|OTHER|App|An application to deliver a series of behavioral questionnaires and decision-making game
219106350|NCT01181505|DRUG|Tolterodine|
219693114|NCT02153918|BIOLOGICAL|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
219106351|NCT03065114|OTHER|PGS|chromosome abnormality test from PGS and relationship between embryo development
219693115|NCT05344846|OTHER|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
219693116|NCT03970525|DEVICE|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
219693117|NCT03970525|DEVICE|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
219693118|NCT02162160|DEVICE|probiotic creme|Probiotic creme applied
219693119|NCT02162160|DRUG|Placebo|Creme without probiotics applied in same manner
219693120|NCT00447668|BEHAVIORAL|Yoga|Yoga for back pain
219106352|NCT03116490|PROCEDURE|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
219106353|NCT00049998|DRUG|topotecan|
219106354|NCT01535274|OTHER|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
219106355|NCT05943314|BIOLOGICAL|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
219106356|NCT03548805|PROCEDURE|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
219106357|NCT03548805|PROCEDURE|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
219106358|NCT05210556|OTHER|Diagnosed with Surgical Site Infection|As an observational study, this notates patients who were diagnosed with a deep organ/space surgical site infection within 30 days of surgery
219106359|NCT04730843|DRUG|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
219106360|NCT02130453|DRUG|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
219106361|NCT06850831|DRUG|Antipac|The first group is the NAC group, which will get intracoronary NAC 480 mg immediately after the lesion is opened during primary PCI. And the second group will have placebo immediately after the lesion is opened during primary PCI.
219106362|NCT05763784|DEVICE|Tightrope|Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
219106363|NCT05851599|OTHER|SKF7® Labisia pumila standardized extract|Botanical extract of Labisia pumila (Kacip Fatimah)
219106364|NCT03033459|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
219106365|NCT03033459|BEHAVIORAL|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
219693121|NCT00447668|BEHAVIORAL|Exercise|exercises for back pain
219693122|NCT00447668|BEHAVIORAL|Self-care book recommendations|Self-care book for back pain
219106366|NCT05779306|DEVICE|IOL Master 700|Biometry using the IOL Master 700
219106367|NCT05779306|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
219106368|NCT05779306|DEVICE|MS-39|Corneal Topography using the MS-39
219106369|NCT05779306|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
219106370|NCT05779306|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
219106371|NCT05779306|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
219106372|NCT03999268|BEHAVIORAL|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
219224363|NCT06406426|DRUG|Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin|Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
219693123|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
219224364|NCT01989416|DRUG|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
219224365|NCT01989416|DRUG|Soap|The ICU patients will be bathing with Soap
219224366|NCT03936023|DRUG|Saxagliptin|Saxagliptin dispensing claim is the exposure
219224367|NCT03936023|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
219224368|NCT00869934|OTHER|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
219224369|NCT00869934|OTHER|Behavior Therapy|Sleep restriction and stimulus control
219224370|NCT00869934|OTHER|Cognitive Therapy|Cognitive restructuring therapy
219693124|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
219693125|NCT03832283|OTHER|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.
219693126|NCT03832283|OTHER|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
219693127|NCT02616783|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
219693128|NCT02616783|DRUG|TDF|300 mg tablet administered orally once daily
219693129|NCT02616783|DRUG|FTC|200 mg capsule administered orally once daily
219693130|NCT02616783|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
219106373|NCT03999268|BEHAVIORAL|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
219224371|NCT02278666|PROCEDURE|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
219224372|NCT02278666|DEVICE|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
219224373|NCT02278666|DEVICE|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
219224374|NCT04565977|OTHER|Observational|Retrospective chart review
219224375|NCT02617693|BEHAVIORAL|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
219224376|NCT02617693|OTHER|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
219693131|NCT02616783|DRUG|3TC|Tablet administered orally
219693132|NCT02616783|DRUG|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
219693133|NCT00203801|DRUG|Sulfadoxine-pyrimethamine|
219693134|NCT00203801|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
219693135|NCT00203801|DRUG|Artemether-lumefantrine|
219693136|NCT01367015|OTHER|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
219693137|NCT01367015|OTHER|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
219693138|NCT04344301|OTHER|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
219106374|NCT01621204|DRUG|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
219106375|NCT01621204|DRUG|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
219106376|NCT03347747|OTHER|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
219106377|NCT02778399|DRUG|Placebo|Placebo tablets for oral administration once daily
219106378|NCT02778399|DRUG|OBE2109|OBE2109 tablets for oral administration once daily
219106379|NCT03501043|DRUG|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
219106380|NCT02475525|DIETARY_SUPPLEMENT|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
219106381|NCT04268992|OTHER|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
219224377|NCT02574806|PROCEDURE|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
219693139|NCT00955799|DRUG|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
219106382|NCT04189263|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
219106383|NCT04189263|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
219106384|NCT00852670|DRUG|ACT-128800|ACT-128800 administered orally once daily
219106385|NCT00852670|DRUG|Placebo|Matching placebo capsules administered orally once daily
219106386|NCT05650944|DIAGNOSTIC_TEST|Hemogram|Sysmex XN-1000 hematological analyzer
219106387|NCT02538770|OTHER|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
219106388|NCT02538770|OTHER|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
219106389|NCT02088632|BIOLOGICAL|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
219106390|NCT02088632|OTHER|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
219693140|NCT00955799|DRUG|Placebo|Double-blind treatment period of 29 weeks placebo
219693141|NCT03973580|BEHAVIORAL|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
219693142|NCT03973580|BEHAVIORAL|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
219693143|NCT01747499|DRUG|Azacitidine|
219693144|NCT00571623|OTHER|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
219693145|NCT04036487|DRUG|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
219693146|NCT04036487|DRUG|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
219106391|NCT06199661|BEHAVIORAL|APEX|Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
219106392|NCT01280734|DRUG|Circadin (R) 2 mg|One 2 mg tablet at 23:00
219106393|NCT01280734|DRUG|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
219106394|NCT01280734|DRUG|Placebo|One tablet or encapsulated tablet at 23:00
219106395|NCT03179813|PROCEDURE|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
219106396|NCT03179813|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group
219693147|NCT03111524|OTHER|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
219693148|NCT03111524|OTHER|No intervention|No intervention is administered in this group as these are control groups
219693149|NCT00165126|PROCEDURE|Radiation therapy|Given as standard therapy
219693150|NCT02903446|DRUG|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
219693151|NCT05506423|DEVICE|CycloPen Cyclodialysis System|The CycloPen Micro-Interventional Cyclodialysis System is used to create and cyclodialysis cleft and deliver allograft scleral tissue and/or viscous material to reinforce and maintain the cleft postoperatively.
219106397|NCT02009696|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
219106398|NCT02009696|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
219106399|NCT03428126|DRUG|Durvalumab|Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
219106400|NCT03428126|DRUG|Trametinib|"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."
219106401|NCT00773058|DRUG|hydrocortisone|hydrocortisone 100mg q8h
219106402|NCT00773058|DRUG|placebo|normal saline 100ml q8h
219106403|NCT05903716|DIAGNOSTIC_TEST|Hormone|At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients
219106404|NCT05903716|DRUG|Isotretinoin|İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
219106405|NCT03671733|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
219693152|NCT06120205|DEVICE|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
219693153|NCT05794295|OTHER|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored.
219693154|NCT05794295|OTHER|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored.
219106406|NCT03671733|DRUG|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
219106407|NCT03671733|DRUG|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
219106408|NCT02703207|DEVICE|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
219106409|NCT02703207|DEVICE|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
219106410|NCT04407351|DEVICE|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
219106411|NCT04407351|DEVICE|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
219106412|NCT00447954|COMBINATION_PRODUCT|High Dose NT-501 implant|High Dose NT-501
219106413|NCT00447954|COMBINATION_PRODUCT|Low Dose NT-501 implant|Low Dose NT-501
219106414|NCT00447954|OTHER|Sham|Sham Procedure
219106415|NCT06084559|OTHER|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
219106416|NCT06084559|OTHER|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
219693155|NCT06469463|DEVICE|MRI|The healthy subjects in the control group will perform an MRI head scan, which will be used to construct 3D head models and headcasts.
219693156|NCT06469463|DEVICE|MEG|The healthy subjects will undergo hpMEG data while wearing 3D-printed headcasts created from high resolution MRI
219693157|NCT06469463|DEVICE|EEG|"The healthy participants will undergo a similar session using EEG recording, using a Polhemus Fastrak system for localization of EEG electrodes and precise co-registration with anatomy and hpMEG data.~The patients group will take part in the same EEG recording session."
219693158|NCT05511922|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
219693159|NCT05511922|DRUG|Drug: KVD900 300 mg|KVD900 Tablet 300 mg
219693160|NCT05214118|BEHAVIORAL|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
219106417|NCT05536102|DRUG|PLD|20mg/m2, day 1, q3w
219106418|NCT05536102|DRUG|Oxaliplatin|130 mg/m2, day 1, q3w
219106419|NCT05536102|DRUG|Capecitabine|1000 mg/m2, days 1-14, q3w
219106420|NCT05536102|DRUG|Tislelizumab|200 mg, day 1, q3w
219106421|NCT01834443|DEVICE|Direct current galvanic vestibular stimulation|
219106422|NCT00856661|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
219106423|NCT00856661|DRUG|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
219106424|NCT05043402|DRUG|navicixizumab|navicixizumab IV
219106425|NCT05043402|DEVICE|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
219106426|NCT01233583|DRUG|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
219693161|NCT05885451|DRUG|AMG 592|Administered as SC injection
219693162|NCT05885451|OTHER|Placebo|Administered as SC injection
219693163|NCT06020703|BEHAVIORAL|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
219693164|NCT00727935|DRUG|Lidocaïne|
219693165|NCT00727935|DRUG|Ropivacaïne|
219693166|NCT00727935|DRUG|Placebo|
219693167|NCT02619097|DRUG|Pegol-sihematide injection|single dose
219693168|NCT04010461|DEVICE|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
219693169|NCT04010461|BEHAVIORAL|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
219693170|NCT03797898|OTHER|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
219693171|NCT04733586|PROCEDURE|Sonar guided fascia iliaca|Sonar guided fascia iliaca
219693172|NCT04733586|PROCEDURE|Sonar guided quadratus lumborum block|Sonar guided quadratus lumborum block
219106427|NCT02630524|BEHAVIORAL|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
219106428|NCT00903734|DRUG|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
219106429|NCT00061113|DRUG|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
219106430|NCT00061113|DRUG|fluoxetine|20mg, QD x 16 weeks
219106431|NCT00061113|DRUG|placebo + CBT|single fixed morning dose X 16 weeks
219106432|NCT03545347|DRUG|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.
219106433|NCT03545347|DIETARY_SUPPLEMENT|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
219106434|NCT03545347|OTHER|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
219106435|NCT03545347|DRUG|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
219224378|NCT05364697|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
219224379|NCT06476015|OTHER|Therapeutic exercise|Duration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
219224380|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
219224381|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
219693173|NCT04543175|OTHER|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
219693174|NCT00254865|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
219693175|NCT05901337|COMBINATION_PRODUCT|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin c~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
219693176|NCT05901337|DRUG|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
219693177|NCT05304845|DRUG|DWP14012|Potassium-competitive acid blocker
219693178|NCT05304845|DRUG|Aspirin|acetylsalicylic acid
219693179|NCT06558331|OTHER|Preoperative Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, preoperative
219693180|NCT06558331|OTHER|Postoperative 24th hour Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
219693181|NCT05074953|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
219693182|NCT05572645|DRUG|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
219693183|NCT05572645|DRUG|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
219693184|NCT06054386|OTHER|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
219693185|NCT06054386|OTHER|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
219693186|NCT01717222|DRUG|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
219106436|NCT04402437|PROCEDURE|LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
219693187|NCT01717222|DRUG|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
219693188|NCT01081613|OTHER|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
219693189|NCT00086190|DRUG|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
219693190|NCT00086190|DRUG|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
219693191|NCT00086190|OTHER|placebo|an inactive substance
219693192|NCT03115034|DRUG|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
219693193|NCT03115034|DRUG|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
219693194|NCT03115034|OTHER|blank|Patients under CEA without taking melatonin or placebo
219693195|NCT06457139|DIAGNOSTIC_TEST|Glucose tolerance test (2 hour)|Early testing with the 2 hour glucose tolerance test will occur during their inpatient postpartum hospitalization.
219693196|NCT06457139|OTHER|Active Comparator|Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of administration of educational materials adapted from the American Diabetes Association that discusses healthy lifestyle behaviors and the increased risks of developing T2DM after a pregnancy complicated by GDM.
219106437|NCT04402437|PROCEDURE|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
219693197|NCT02574169|OTHER|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
219106438|NCT04152343|DEVICE|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions \>2cm
219106439|NCT03519243|BIOLOGICAL|BCD-131|subcutaneously monthly
219106440|NCT03519243|BIOLOGICAL|Mircera|subcutaneously monthly
219106441|NCT05354063|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
219106442|NCT05354063|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
219106443|NCT05354063|DRUG|Placebo|Placebo IM on day 0 and day 21.
219106444|NCT03585101|DRUG|Elbasvir/grazoprevir|Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
219106445|NCT01164228|DRUG|Gemcitabine|Given IV
219106446|NCT01164228|DRUG|Sunitinib|Given PO
219106447|NCT01965938|DEVICE|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
219106448|NCT01965938|DEVICE|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
219106449|NCT00005837|DRUG|oxaliplatin|
219224382|NCT03018067|DRUG|RDX227675|
219224383|NCT03018067|DRUG|Placebo|
219106450|NCT03804775|DIAGNOSTIC_TEST|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
219693198|NCT02574169|OTHER|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
219693199|NCT03012932|BEHAVIORAL|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
219693200|NCT05588986|OTHER|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
219693201|NCT04232345|DRUG|AZD4831|Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
219693202|NCT04232345|DRUG|Placebo|Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
219693203|NCT00004547|PROCEDURE|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
219693204|NCT00004547|PROCEDURE|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
219693205|NCT00004547|DRUG|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M\^2) and 1 L of normal saline containing paclitaxel (125 mg/M\^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
219693206|NCT03902613|DRUG|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
219693207|NCT02262910|BIOLOGICAL|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
219106451|NCT02568579|PROCEDURE|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
219693208|NCT00852813|DIETARY_SUPPLEMENT|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
219106452|NCT03716674|DEVICE|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
219693209|NCT02027025|DRUG|SPARC1103 low dose|once daily
219693210|NCT02027025|DRUG|SPARC1103 high dose|once daily
219693211|NCT02027025|DRUG|SPARC Placebo|
219693212|NCT04044105|OTHER|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
219106453|NCT04570241|BEHAVIORAL|Malaria toolkit|Knowledge, attitude, and practice on malaria
219693213|NCT04044105|OTHER|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
219693214|NCT06272981|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
219693215|NCT04087239|OTHER|HIV|
219693216|NCT05750030|COMBINATION_PRODUCT|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
219693217|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
219693218|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
219693219|NCT03494127|DEVICE|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
219693220|NCT03494127|DEVICE|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
219693221|NCT05977608|BEHAVIORAL|Telephone Reminiscence Intervention|Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.
219693222|NCT05141513|RADIATION|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
219106454|NCT06550349|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
219106455|NCT02961114|PROCEDURE|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
219106456|NCT02961114|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
219693223|NCT04795999|BEHAVIORAL|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
219693224|NCT05714033|PROCEDURE|Ventilatory Strategy To Prevent Atelectasis|Given
219693225|NCT05714033|PROCEDURE|Lateral Decubitus Strategy (LADS)|Given
219693226|NCT03828227|DRUG|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus"
219693227|NCT03828227|DRUG|Capecitabine plus bevacizumab|"* Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
219693228|NCT00918593|DRUG|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
219693229|NCT00918593|RADIATION|Radiotherapy|Radiotherapy according to hospital procedures.
219693230|NCT00918593|DRUG|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
219693231|NCT03775083|DRUG|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
219693232|NCT05617807|PROCEDURE|Nanoscopic partial meniscectomy|Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
219693233|NCT05617807|PROCEDURE|Standard Partial Meniscectomy|Patients will have partial meniscectomy performed using standard arthroscopic equipment
219106457|NCT02961114|BIOLOGICAL|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
219106458|NCT02617225|BEHAVIORAL|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
219106459|NCT02617225|BEHAVIORAL|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
219106460|NCT01661556|DRUG|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
219106461|NCT01661556|DRUG|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
219106462|NCT01747590|DRUG|Zolpidem|
219106463|NCT01747590|DRUG|Alprazolam|
219106464|NCT01747590|DRUG|Caffeine|
219106465|NCT01747590|OTHER|Placebo|
219106466|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
219693234|NCT01897051|DRUG|Rifaximin + propranolol|"1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
219693235|NCT01897051|DRUG|Propranolol + Placebo|"1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
219693236|NCT06553690|OTHER|Brain Gym Therapy|Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
219106467|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
219106468|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
219693237|NCT04796766|DIAGNOSTIC_TEST|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
219106469|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
219106470|NCT05357560|BIOLOGICAL|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
219106471|NCT00249743|DEVICE|FallSaver (formerly called NOCwatch)|
219106472|NCT05496322|DEVICE|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
219106473|NCT05496322|DEVICE|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
219106474|NCT06624384|DRUG|Group 1 drug|Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
219106475|NCT06624384|DRUG|Group 2: Drug and placebo|Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
219106476|NCT06624384|DRUG|Group 3: Drug and palcebo|Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
219106477|NCT04287868|BIOLOGICAL|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
219106478|NCT04287868|BIOLOGICAL|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
219106479|NCT04287868|BIOLOGICAL|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
219106480|NCT06710990|DRUG|SHR-A1811|SHR-A1811
219224384|NCT05793996|DRUG|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
219224385|NCT05793996|OTHER|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
219224386|NCT02577926|DRUG|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
219224387|NCT02577926|DRUG|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
219224388|NCT03988283|BIOLOGICAL|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
219224389|NCT03988283|DEVICE|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
219224390|NCT03988283|PROCEDURE|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
219693238|NCT04796766|DIAGNOSTIC_TEST|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
219693239|NCT01124669|GENETIC|DNA analysis|
219693240|NCT01124669|GENETIC|mutation analysis|
219693241|NCT01124669|OTHER|laboratory biomarker analysis|
219693242|NCT02360488|DEVICE|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
219693243|NCT02360488|BEHAVIORAL|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
219693244|NCT00426881|BEHAVIORAL|Exercise Training|Twice weekly resistance training for 52 weeks.
219106481|NCT06710990|DRUG|Ritonavir|Ritonavir
219106482|NCT06710990|DRUG|Itraconazole|Itraconazole
219106483|NCT06882447|DRUG|Trial drug: QL1706, HPV 9-valent vaccine|QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on day 1 of each cycle and once every 3 weeks (21 days).
219106484|NCT06925230|PROCEDURE|arthroscopic assisted volar scapholunate capsulodesis|arthroscopic assisted volar scapholunate capsulodesis using PDS 2.00 sutures
219106485|NCT06925230|PROCEDURE|arthroscopic assisted dorsal scapholunate capsulodesis|arthroscopic assisted dorsal scapholunate capsulodesis using PDS 2.00 sutures
219106486|NCT06925230|PROCEDURE|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis using PDS 2.00 sutures
219106487|NCT06924944|PROCEDURE|cataract surgery|cataract surgery treated with bilateral Clareon Vivity toric and non-toric IOL
219224391|NCT06266611|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
219224392|NCT06266611|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
219693245|NCT00426881|BEHAVIORAL|Exercise training|Once weekly resistance training for 52 weeks.
219693246|NCT00426881|BEHAVIORAL|Exercise training|Twice weekly resistance training for 52 weeks.
219693247|NCT00633607|OTHER|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
219693248|NCT02930694|DRUG|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
219693249|NCT02930694|DRUG|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
219693250|NCT01107548|OTHER|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
219693251|NCT02530437|DRUG|Carboplatin|Given IV
219693252|NCT02530437|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219693253|NCT02530437|OTHER|Laboratory Biomarker Analysis|Correlative studies
219693254|NCT02530437|DRUG|Paclitaxel|Given IV
219693255|NCT02530437|DRUG|Taladegib|Given PO
219693256|NCT01163552|PROCEDURE|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
219693257|NCT04153279|BIOLOGICAL|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
219693258|NCT05211440|DIETARY_SUPPLEMENT|Placebo + Meal|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a placebo capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
219693259|NCT05211440|DIETARY_SUPPLEMENT|BC-006 + Meal|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a BC-006 capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
219693260|NCT03503279|DEVICE|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
219693261|NCT02851602|BIOLOGICAL|Blood sample|
219693262|NCT03666442|DRUG|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
219693263|NCT06154837|DRUG|GSK3862995B|GSK3862995B will be administered.
219693264|NCT06154837|DRUG|Placebo|Placebo will be administered.
219693265|NCT04953507|PROCEDURE|Thermal Radiofrequency|Radiofrequency lesioning at level of T2 and T3 using 80°c for 120 seconds
219693266|NCT04953507|PROCEDURE|Chemical Neurolysis|injection of 1.5 ml of the chemical neurolytic agent (phenol in saline 8%) at each level
219693267|NCT05138978|DRUG|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
219693268|NCT05138978|DRUG|Colgate Cavity Protection|Toothpaste
219693269|NCT06979531|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection
219693270|NCT06979531|DRUG|Placebo|Administered once weekly by subcutaneous injection
219693271|NCT06374459|DRUG|Zumsemetinib|Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
219693272|NCT06374459|DRUG|Capecitabine|Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
219106488|NCT06025877|OTHER|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
219106489|NCT06899529|PROCEDURE|Bevacizumab|Bevacizumab will be given immediately after surgery in the Treatment Group
219693273|NCT06374459|DRUG|Zoledronic acid|Standard of care. Will receive zoledronic acid or denosumab.
219693274|NCT06374459|DRUG|Denosumab|Standard of care. Will receive zoledronic acid or denosumab.
219693275|NCT06657560|DRUG|HRS-9231|HRS-9231
219693276|NCT01190085|DRUG|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
219693277|NCT01190085|DRUG|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
219693278|NCT01190085|DRUG|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
219693279|NCT03304080|DRUG|Anastrozole|1 mg orally daily, day 1 to day 28
219693280|NCT03304080|DRUG|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
219693281|NCT03304080|DRUG|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
219693282|NCT03304080|DRUG|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
219693283|NCT06611943|BEHAVIORAL|DietCoach|Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
219693284|NCT06993220|DIAGNOSTIC_TEST|Evaluation of residual congestion at discharge|"Evaluation of residual congestion at discharge will be made using:~* Clinical variables: composite congestion score calculated by summing the individual scores for orthopnoea, jugular venous distension and pedal oedema;~* Imaging variables: non-invasive left ventricular filling pressure, number of LUS B lines and the presence of pleural effusion, Venous Excess UltraSound (VExUS) score;~* Laboratory variables: hemoglobin and hematocrit, NT-proBNP, CA-125, ST2, troponin T, creatinine, AST, ALT, Na, K, urea, bilirubin, C-reactive protein."
219693285|NCT06177171|DRUG|Olaparib|Given orally
219693286|NCT06177171|DRUG|ASTX727|Given Orally
219693287|NCT06687538|OTHER|Mobile application|The content of the mobile application training to be developed for patients who will undergo transurethral prostate resection will consist of 3 modules including preoperative, postoperative and discharge training process.
219693288|NCT02522416|DEVICE|Central corneal thickness measurement|
219693289|NCT01461733|DRUG|amiodarone|standard dose amiodarone
219693290|NCT01461733|DRUG|Placebo|placebo delivered blinded
219693291|NCT03416192|DEVICE|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
219693292|NCT03416192|DEVICE|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
219693293|NCT04406467|DEVICE|Xen Gel Stent|Ab-interno or Ab-Externa Xen with closed or open conjunctiva.
219693294|NCT02391051|RADIATION|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
219693295|NCT04350827|DEVICE|Platelet Rich Plasma|Platelet rich plasma injection into patellar tendon
219693296|NCT04350827|DEVICE|Platelet Rich Plasma plus IGF|Platelet rich plasma plus IGF injection into patellar tendon
219693297|NCT06420388|DRUG|2% Lidocaine Gel|"The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications."
219693298|NCT06420388|DRUG|Water-based Lubricant Gel (K-Y Gel)|The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
219106490|NCT02405117|BEHAVIORAL|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
219106491|NCT03518528|DRUG|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
219106492|NCT03518528|DRUG|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
219106493|NCT04867876|BEHAVIORAL|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
219693299|NCT06420388|DRUG|Standard Postoperative Analgesics|"Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous"
219693300|NCT07063147|DIAGNOSTIC_TEST|TTE|All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
219693301|NCT07066644|PROCEDURE|central node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
219693302|NCT07072390|OTHER|Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP)|A culturally adapted Turkish version of the Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP), used to evaluate clinical skills in final-year physiotherapy students.
219693303|NCT07073638|DRUG|RESP30TB|Nitric Oxide agent
219693304|NCT07073638|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
219693305|NCT07072273|OTHER|Probiotic Ointment|Ointment containing Lactobacillus reuteri BGR46
219693306|NCT07072377|BEHAVIORAL|Intensity of Nutritional Intervention|Participants will either receive High or Low intensity nutritional support.
219693307|NCT07072377|BEHAVIORAL|Remote or In-Person|Patients will either receive their support in-person or remotely.
219693308|NCT06148792|DRUG|Tafenoquine|oral treatment
219693309|NCT06148792|DRUG|Primaquine|oral treatment
219693310|NCT07073352|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Participants will consume 1,000 mg of nicotinamide riboside (NR) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. NR is a naturally occurring vitamin B3 derivative readily taken up by cells as a direct NAD+ precursor. Similar NR supplementation protocols are well-tolerated, boost NAD+ concentrations by \~100-140% achieving a steady state within 1-2 weeks, and increase SIRT activity in humans.
219106494|NCT00241137|DRUG|valsartan|
219106495|NCT03045393|DRUG|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
219106496|NCT01562847|DRUG|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
219693311|NCT07073352|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1,000 mg of placebo (microcrystalline cellulose) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring.
219106497|NCT04666922|DRUG|BI 765080|BI 765080
219106498|NCT04666922|DRUG|Placebo|Placebo; 0.9% saline for injection
219106499|NCT05241561|DRUG|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
219106500|NCT05241561|BIOLOGICAL|Blood sample|biomonitoring and pharmacokinetics
219106501|NCT05241561|OTHER|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
219693312|NCT07073040|DEVICE|Cold atmospheric plasma (CAP)|"CAP therapy will be administered once daily for the first five days and then every other day thereafter, for a total of 13 sessions. Each session will last approximately 25 minutes, as recommended by the manufacturer. During treatment, the affected limb will be enclosed in a sterile treatment bag, sealed with medical adhesive tape. The CAP device will operate in two sequential modes: a disinfection mode delivering ozone-rich (O₃) plasma-activated gas for 20 minutes, followed by a healing mode delivering nitric oxide (NO)-rich plasma-activated gas for 5 minutes. All procedures will be performed in accordance with the manufacturer's instructions and the device's standard operating protocol."
219693313|NCT07073040|DEVICE|Sham Procedure|Participants in the placebo group will undergo a sham procedure, in which the electric field required for plasma generation will be disabled, so that no plasma will be produced. Only the operating sounds of the device will be simulated, ensuring blinding for both participants and clinical staff.
219693314|NCT07073040|OTHER|Successful infrapopliteal angioplasty|All patients will undergo successful infrapopliteal angioplasty, with less than 30% residual stenosis confirmed by digital subtraction angiography.
219693315|NCT07073391|DEVICE|Recording with laminar arrays|Part of the intervention is reliant on FDA approved laminar recording electrodes already available in the US. The other part will be an investigational device that is currently being considered by the FDA for an Investigational Device Exclusion.
219693316|NCT06259695|DEVICE|Adjustable Aquatic Therapy Prosthesis|We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
219693317|NCT06780930|DRUG|Vorasidenib|For oral administration once daily
219693318|NCT06780930|DRUG|Placebo|For oral administration once daily
219106502|NCT06429358|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|The probiotic supplement was delivered in the form of easy-to-swallow capsules.
219106503|NCT06429358|OTHER|Control Group|Participants in the control group were given a placebo that looked, tasted, and felt just like the probiotic pill.
219106504|NCT01228344|OTHER|Artemether-lumefantrine|
219106505|NCT00794001|BEHAVIORAL|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
219106506|NCT05878782|OTHER|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
219106507|NCT05878782|OTHER|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
219106508|NCT00000343|BEHAVIORAL|counseling|
219224393|NCT06266611|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
219106509|NCT03465449|BEHAVIORAL|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
219224394|NCT04537403|DRUG|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
219693319|NCT07073118|DEVICE|Endovascular treatment with placement of a flow-diverting stent|Flow diverter stents (FDS) are braided stents with specific porosity that promotes the flow redirection within the parent vessel and outside the aneurysm sac, and the endothelialization. The FDS placed in the parent artery and covering the aneurysm sac will promote the intra-aneurysmal blood stagnation and parent vessel wall healing. All of these promoting, the aneurysm's thrombosis and ist regression
219693320|NCT07072741|OTHER|Shamiri Queen of Katwe Intervention|The intervention involves screening the film Queen of Katwe to high school students in a school setting.
219106510|NCT03465449|OTHER|usual care|Nephrologist based usual care
219224395|NCT04537403|DRUG|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
219224396|NCT02147717|DEVICE|Laser stimulation|"Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
219693321|NCT07072806|DRUG|Letibotulinum toxin A|Letibotulinum toxin A (Botulax) is a botulinum toxin type A formulation developed for aesthetic indications. In this trial, it was administered as the test intervention. Each participant received 2 units injected at four forehead sites (total 8 units), diluted to 20 U/mL, on one side of the forehead. The diffusion characteristics and efficacy were compared with those of onabotulinum and prabotulinum toxin A in a double-blind, randomized, split-face design.
219693322|NCT07072806|DRUG|Prabotulinum toxin A|Prabotulinum toxin A (Nabota) is a botulinum toxin type A product approved for aesthetic use in South Korea and other countries. It was used as a comparator agent in this trial. Participants received subcutaneous injections at four forehead sites (2 units per site, 8 units total), diluted to 20 U/mL, on one side of the forehead in a randomized, split-face design.
219106511|NCT00244374|BIOLOGICAL|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects\>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
219693323|NCT07072806|DRUG|Onabotulinum toxin A|Onabotulinum toxin A (Botox) is an FDA-approved botulinum neurotoxin type A formulation used for cosmetic treatment of glabellar lines and other facial wrinkles. In this study, it was injected subcutaneously into the forehead at four standardized sites at a dose of 2 units per site (8 units total), diluted to 20 U/mL, and used as a comparator in the split-face design.
219693324|NCT06290622|DRUG|Retifanlimab, INCAGN02385, INCAGN02390|"Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles."
219693325|NCT01009853|DRUG|Codeine Sulfate|15 mg tablet
219106512|NCT00244374|BEHAVIORAL|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
219106513|NCT00244374|BEHAVIORAL|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
219106514|NCT00244374|BEHAVIORAL|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
219106515|NCT00000342|DRUG|Risperidone|
219106516|NCT04343443|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
219106517|NCT04343443|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
219106518|NCT04343443|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
219106519|NCT04343443|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
219106520|NCT04343443|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
219106521|NCT02608762|RADIATION|standard adjuvant local radiation therapy or cranial radiation therapy|
219106522|NCT03722264|DEVICE|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
219106523|NCT03722264|DEVICE|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
219224397|NCT02147717|DEVICE|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
219224398|NCT06215391|DEVICE|3d printed mask|"* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted."
219693326|NCT02507076|DRUG|isolated limb perfusion|Undergo ILP with melphalan
219693327|NCT02507076|DRUG|melphalan|Undergo ILP with melphalan
219693328|NCT02507076|PROCEDURE|quality-of-life assessment|Ancillary studies
219693329|NCT03071601|DRUG|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
219693330|NCT03071601|DRUG|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
219693331|NCT01528371|DRUG|Midazolam|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
219693332|NCT01528371|DRUG|Normal Saline Solution (NSS)|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
219693333|NCT05005598|OTHER|catheter dysfunction|prevalence of catheter dysfunction
219693334|NCT00884442|DRUG|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
219693335|NCT00884442|DRUG|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
219693336|NCT01152671|DRUG|Placebo|single oral dose
219106524|NCT05193084|DEVICE|Heartfelt Device|"The Heartfelt Device is a CE marked device that measures the volume of the foot/lower leg. By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Feet identification software, complemented by manual checks, ensures that photographs are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. For this study, no personal identifiable data will be stored on the device or on the servers used by the device.~The volume readings collected can be presented to the clinical team on a web interface. This is not presented against identifiable data, but only participant ID. However, in the current pilot, volume readings will not be reviewed by the clinical team until the point of data analysis, after the study period."
219106525|NCT05193084|DEVICE|Connected weighing scales|"The connected weighing scales are Xiaomi Smart Scales (CE marked, manufactured by Anhui Huami Informeyshn Technologies).~The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional(s) (the fact that a participant has not used scales regularly in the past is not an exclusion criteria). The weighing scales display weight so that the participants can record the weight in their own heart failure records (paper weight diary).~The study team will check the patient's paper weight diary in case they choose to use another set of scales.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will record patient weight as well as the date and time of the measurements."
219106526|NCT04178512|DRUG|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
219106527|NCT06414564|DEVICE|Medtronic 780G insulin pump|Subjects on insulin infusion by 780G AHCL system
219106528|NCT02959671|DEVICE|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
219224400|NCT04354389|DRUG|DAS181|4.5 mg b.i.d
219106529|NCT00054964|DRUG|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
219106530|NCT00054964|DRUG|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
219224401|NCT04354389|DRUG|Placebo|q.d. or b.i.d.
219224402|NCT04354389|DRUG|DAS181|4.5 mg q.d.
219224403|NCT02933294|PROCEDURE|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
219224404|NCT02933294|PROCEDURE|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
219224405|NCT04810390|DRUG|Bilastine|Ophthalmic solution 0.6%
219224406|NCT04810390|DRUG|Placebo|Ophthalmic solution
219224407|NCT01584752|PROCEDURE|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
219224408|NCT03665792|DEVICE|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
219693337|NCT01152671|DRUG|RO5024048|single oral dose
219693338|NCT01493622|DRUG|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
219693339|NCT01493622|DRUG|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
219693340|NCT06134063|DRUG|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
219693341|NCT06134063|DRUG|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
219693342|NCT01571843|OTHER|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
219693343|NCT01571843|OTHER|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
219224409|NCT00476905|DEVICE|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
219224410|NCT01548703|DRUG|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
219693344|NCT02859298|DEVICE|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
219693345|NCT00916578|RADIATION|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
219693346|NCT00916578|DRUG|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
219693347|NCT00001038|DRUG|Valacyclovir hydrochloride|
219693348|NCT00001038|DRUG|Acyclovir|
219693349|NCT03272204|BEHAVIORAL|No pubic hair|Natural pubic hair to fully removed pubic hair
219693350|NCT03272204|BEHAVIORAL|Pubic Hair|Removed pubic hair to natural pubic hair
219693351|NCT03847571|DRUG|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
219693352|NCT00025779|DRUG|methylphenidate|
219693353|NCT00025779|DRUG|guanfacine|
219693354|NCT02117518|OTHER|blood drawing|
219693355|NCT00641563|DRUG|Dexmedetomidine|Infusion of dexmedetomidine
219693356|NCT00641563|DRUG|Midazolam|Midazolam infusion
219693357|NCT00641563|DRUG|Remifentanil|Infusion of remifentanil
219693358|NCT01655901|BEHAVIORAL|Active video gaming|
219693359|NCT01655901|BEHAVIORAL|Passive video gaming|
219693360|NCT01655901|BEHAVIORAL|Resting|
219693361|NCT01220570|DRUG|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
219693362|NCT01220570|DRUG|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
219693363|NCT01220570|DRUG|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
219693364|NCT00934375|DRUG|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
219693365|NCT00934375|DRUG|placebo|
219693366|NCT04243278|DRUG|Low-dose aspirin|81 mg of low dose aspirin PO for 6 months
219693367|NCT04243278|DRUG|Placebo oral tablet|placebo PO for 6 months
219693368|NCT00729742|DRUG|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
219693369|NCT00729742|DRUG|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
219693370|NCT01757015|DRUG|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
219693371|NCT01757015|DRUG|Placebo to NVA237|Placebo to NVA237
219693372|NCT00265434|DRUG|Pulmozyme|
219224411|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
219224412|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
219224413|NCT06179875|DRUG|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
219693373|NCT01782339|DRUG|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
219693374|NCT00860639|DRUG|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
219693375|NCT02019355|DRUG|5-fluorouracil 5% cream|
219693376|NCT02019355|DRUG|Calcipotriol 0.005% ointment|
219693377|NCT02019355|DRUG|Vaseline|
219693378|NCT02262897|DRUG|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
219693379|NCT05601349|BEHAVIORAL|Telehealth-based strategy|Teleducation course, based on the CPG recommendations
219693380|NCT00945243|DEVICE|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
219693381|NCT04292236|DIETARY_SUPPLEMENT|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
219106531|NCT03020329|DRUG|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
219106532|NCT03020329|DRUG|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
219106533|NCT03020329|DRUG|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
219106534|NCT03020329|RADIATION|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
219693382|NCT03256578|DEVICE|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
219693383|NCT04670601|DRUG|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
219106535|NCT02617264|PROCEDURE|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
219106536|NCT05808335|DRUG|Standard of care|"The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)"
219693384|NCT04670601|DRUG|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
219693385|NCT06349876|PROCEDURE|laparoscopic cholecystectomy|slandered laparoscopic cholecystectomy
219693386|NCT02316925|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning
219106537|NCT03499015|PROCEDURE|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
219106538|NCT05904743|BIOLOGICAL|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
219106539|NCT05904743|BIOLOGICAL|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219106540|NCT05904743|BIOLOGICAL|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
219106541|NCT05904743|BIOLOGICAL|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
219106542|NCT02896816|OTHER|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
219693387|NCT02316925|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning
219693388|NCT02576899|BEHAVIORAL|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
219693389|NCT02576899|BEHAVIORAL|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
219106543|NCT02896816|OTHER|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
219693390|NCT04694092|DRUG|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
219106544|NCT01464008|DRUG|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
219693391|NCT04694092|DRUG|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
219693392|NCT03571035|DIAGNOSTIC_TEST|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
219106545|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219693393|NCT05974761|OTHER|massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.
219693394|NCT05974761|OTHER|Traditional Chinese massage|Through the point, massage, bone-setting treatment
219693395|NCT00922636|DRUG|LY2216684|Taken in tablet form QD po.
219693396|NCT00922636|DRUG|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
219693397|NCT00922636|DRUG|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
219693398|NCT00922636|DRUG|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
219693399|NCT01861392|PROCEDURE|sensorio-motor training|
219106546|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219106547|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219106548|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219693400|NCT04969289|BEHAVIORAL|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
219224414|NCT03975400|BEHAVIORAL|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
219224415|NCT03454256|DEVICE|Virtual Reality|Virtual Reality Rehabilitation System
219224416|NCT02401503|DRUG|Bendamustine|Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.
219693401|NCT02266017|BEHAVIORAL|Pain Coping Skills Training|
219693402|NCT00824668|DRUG|biphasic insulin aspart 30|
219693403|NCT00824668|DRUG|insulin glargine|
219693404|NCT00824668|DRUG|insulin glulisine|
219106549|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219224417|NCT02401503|DRUG|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
219693405|NCT05953727|OTHER|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
219106550|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219106551|NCT00847821|DRUG|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219106552|NCT00847821|DRUG|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
219106553|NCT03463915|DRUG|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
219106554|NCT03463915|DRUG|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
219106555|NCT01123460|OTHER|enzyme-linked immunosorbent assay|
219106556|NCT01123460|OTHER|laboratory biomarker analysis|
219106557|NCT04354766|OTHER|Blood sample|This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
219106558|NCT04068363|OTHER|non interventional|non interventional study
219106559|NCT01732146|DRUG|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
219106560|NCT01732146|DRUG|Placebo|
219106561|NCT03218332|DIAGNOSTIC_TEST|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
219106562|NCT02803060|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
219106563|NCT06120517|COMBINATION_PRODUCT|emg- biofeedback|EMG activity shows the electrical activity measured during striated muscle contraction. The electrical activity of the muscle is in microvolts (1 volt = 1,000,000μV). Biofeedback units usually produce audio or visual feedback depending on the amount of electrical activity. Recording the bio-electrical activity of the muscle is a practical indicator of its contractility.
219106564|NCT04380298|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
219106565|NCT04380298|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
219106566|NCT04380298|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
219693406|NCT05953727|OTHER|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
219106567|NCT02341287|DEVICE|Warming hydrogel glove|Subjects wore the warming hydrogel glove in either the first or second two-week period.
219106568|NCT02341287|DEVICE|Non-thermal glove|Subjects wore the non-thermal glove in either the first or second two-week period.
219106569|NCT02687412|PROCEDURE|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
219106570|NCT02687412|PROCEDURE|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
219106571|NCT02687412|PROCEDURE|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
219693407|NCT04377867|DRUG|Abatacept Injection [Orencia]|Patients on abatacept to control disease symptoms
219693408|NCT00557466|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
219106572|NCT02687412|PROCEDURE|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
219106573|NCT02687412|PROCEDURE|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
219106574|NCT02687412|PROCEDURE|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
219106575|NCT02687412|PROCEDURE|Postoperative glycaemic control|Postoperative glycaemic control;
219106576|NCT02687412|PROCEDURE|postoperative nausea and vomiting (PONV) control;|
219106577|NCT02687412|PROCEDURE|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
219106578|NCT02687412|PROCEDURE|pre-operative fasting at least 8h|
219106579|NCT02687412|PROCEDURE|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
219106580|NCT02687412|PROCEDURE|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
219106581|NCT04651114|BEHAVIORAL|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
219693409|NCT00557466|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
219106582|NCT01923896|BEHAVIORAL|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
219106583|NCT01923896|DRUG|d-cycloserine (DCS)|
219106584|NCT01923896|DRUG|Placebo|lactose powder
219106585|NCT01097395|DRUG|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
219106586|NCT00647634|DRUG|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
219106587|NCT00647634|DRUG|Xanax XR® Tablets (3 mg|3mg, single dose fasting
219106588|NCT03707444|DEVICE|Scrambler Therapy Device|Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
219106589|NCT02040272|PROCEDURE|(Extended) pleurectomy decortication|
219106590|NCT05284305|OTHER|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
219106591|NCT02410967|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
219106592|NCT02410967|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
219106593|NCT01643941|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
219106594|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219106595|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
219106596|NCT01643941|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
219693410|NCT00557466|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
219693411|NCT00557466|DRUG|placebo to formoterol|Placebo AEROLIZER® device
219693412|NCT00557466|DRUG|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
219106597|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219106598|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
219106599|NCT01643941|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
219106600|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219106601|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
219106602|NCT01643941|BIOLOGICAL|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
219693413|NCT00435344|BEHAVIORAL|Pediatric Practice-Based Smoking Intervention|
219693414|NCT04492423|DIAGNOSTIC_TEST|VerifyNow PRUTest|VerifyNow PRUTest for platelet aggregation
219693415|NCT03268343|DRUG|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
219693416|NCT02626598|DEVICE|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
219693417|NCT00764101|BEHAVIORAL|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
219106603|NCT01643941|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
219106604|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
219106605|NCT01643941|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
219106606|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
219106607|NCT01643941|PROCEDURE|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
219224418|NCT02401503|DRUG|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
219224419|NCT05131685|PROCEDURE|Reduction|closed reduction under conscious sedation followed by casting
219693418|NCT02365350|PROCEDURE|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
219693419|NCT02365350|PROCEDURE|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
219693420|NCT03925142|OTHER|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
219693421|NCT03925142|OTHER|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
219693422|NCT01799447|BEHAVIORAL|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
219224420|NCT05131685|PROCEDURE|Immobilization|immobilization in cast without reduction
219693423|NCT00236054|DRUG|Gabitril|
219693424|NCT01251952|DRUG|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
219693425|NCT05251350|PROCEDURE|surgery|our study is observational and we use secondary data
219693426|NCT02797834|PROCEDURE|Endometrial fluid collection|
219693427|NCT00680329|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
219693428|NCT00680329|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
219693429|NCT05598060|RADIATION|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
219693430|NCT01726296|OTHER|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
219693431|NCT01726296|OTHER|medical chart review|Complete patient medical chart audit
219693432|NCT01571960|BIOLOGICAL|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
219693433|NCT01571960|BIOLOGICAL|MVA/HIV62B (MVA62B) vaccine|1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
219693434|NCT01571960|BIOLOGICAL|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
219693435|NCT01571960|BIOLOGICAL|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
219693436|NCT05173077|PROCEDURE|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
219693437|NCT05173077|OTHER|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (\>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
219693438|NCT05173077|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
219106608|NCT03906305|OTHER|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
219106609|NCT03906305|OTHER|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
219106610|NCT01401413|DRUG|ramelteon|8 mg nightly for 30 nights
219224421|NCT02542943|DEVICE|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
219693439|NCT05173077|OTHER|Blood sample collection|Serum, plasma sampling for group description and stratification.
219693440|NCT05173077|DIAGNOSTIC_TEST|Microbiota testing|Faecal samples for microbiota testing.
219693441|NCT05173077|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
219693442|NCT02486692|OTHER|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
219693443|NCT00699777|DRUG|Risedronate|1 risedronate 150 mg tablet administered orally
219693444|NCT00699777|DRUG|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
219693445|NCT02344329|DEVICE|Topical wound dressing|Topical Wound Dressing
219693446|NCT02344329|BIOLOGICAL|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
219693447|NCT02344329|OTHER|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
219693448|NCT02477176|OTHER|Discectomy|Lumbar discectomy
219693449|NCT03278574|PROCEDURE|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
219693450|NCT03278574|DEVICE|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
219693451|NCT03278574|DEVICE|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
219693452|NCT00653874|DEVICE|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
219693453|NCT00653874|PROCEDURE|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
219106611|NCT01401413|DRUG|placebo|placebo control i pill nightly for 30 nights
219106612|NCT04394520|OTHER|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
219106613|NCT04394520|OTHER|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
219106614|NCT04394520|OTHER|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
219106615|NCT04394520|OTHER|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
219106616|NCT05145842|PROCEDURE|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
219106617|NCT05145842|PROCEDURE|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
219106618|NCT00474929|DRUG|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
219106619|NCT00474929|DRUG|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
219106620|NCT00819403|DRUG|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
219106621|NCT00819403|DRUG|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
219224422|NCT02542943|DEVICE|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
219224423|NCT02542943|OTHER|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
219693454|NCT00653874|OTHER|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
219693455|NCT06102317|OTHER|nursing consultancy with smartphone support|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
219693456|NCT05229328|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
219693457|NCT00648180|DRUG|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
219693458|NCT00648180|DRUG|Adoxa Tablets 100 mg|100mg, single dose fed
219693459|NCT00004862|BIOLOGICAL|filgrastim|
219693460|NCT00004862|BIOLOGICAL|oblimersen sodium|
219693461|NCT00004862|DRUG|cytarabine|
219693462|NCT00004862|DRUG|fludarabine phosphate|
219693463|NCT01183364|DRUG|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
219693464|NCT01477801|DRUG|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
219693465|NCT01477801|DRUG|PLACEBO|Standard guideline based therapy plus placebo
219693466|NCT00607243|BIOLOGICAL|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
219693467|NCT02224625|DRUG|2% CHG Cloth solution|Investigational CHG
219693468|NCT02224625|DEVICE|Vehicle Cloth|Excipients from CHG cloth only
219693469|NCT02224625|DRUG|Active Comparator|Active comparator
219693470|NCT02224625|OTHER|Saline|Negative control
219106622|NCT03661996|DRUG|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
219106623|NCT03661996|DRUG|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
219224424|NCT02542943|DRUG|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
219224425|NCT03126604|DIAGNOSTIC_TEST|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
219106624|NCT03661996|DEVICE|ElastoGel|Cooling Device
219106625|NCT03661996|DEVICE|Breg Ice Water Pump|Cooling Device
219106626|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
219224426|NCT05527808|DRUG|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
219224427|NCT05527808|DRUG|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
219106627|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
219106628|NCT00421226|DRUG|ACZ885|
219106629|NCT03785457|OTHER|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
219106630|NCT03785457|OTHER|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
219106631|NCT01176604|RADIATION|Yttrium Y 90 Glass Microspheres|Given via catheter
219106632|NCT04906109|DRUG|Vemlidy Tab|1T
219106633|NCT04906109|DRUG|DA-2803 Tab|1T
219106634|NCT04914052|OTHER|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
219106635|NCT04981132|BEHAVIORAL|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
219106636|NCT04981132|BEHAVIORAL|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
219106637|NCT03678259|DRUG|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
219106638|NCT01735357|DIETARY_SUPPLEMENT|EPA-rich triacylglycerol oil|
219106639|NCT01735357|DIETARY_SUPPLEMENT|Placebo - olive oil (BP specification)|
219106640|NCT01735357|DIETARY_SUPPLEMENT|DHA-rich triacylglycerol oil|
219106641|NCT02807740|OTHER|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
219106642|NCT02807740|OTHER|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
219106643|NCT06124742|DEVICE|clear aligners|taste perception will be evaluated before and after using clear aligners.
219106644|NCT00068380|DRUG|imatinib mesylate|Given orally
219224428|NCT05527808|DRUG|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
219224429|NCT05527808|DRUG|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
219224430|NCT03315299|DRUG|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
219224431|NCT05097105|DEVICE|MRI|MRI sequences: TI. T2 and diffusion weighted
219224432|NCT06153745|DEVICE|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, California USA)|pediatric cataract surgery
219224433|NCT04814108|DRUG|ZN-c3|ZN-c3 is an investigational drug.
219224434|NCT05731440|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
219224435|NCT03848143|DRUG|onabotulinum toxin A|Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
219106645|NCT00068380|OTHER|laboratory biomarker analysis|Correlative studies
219224436|NCT06242535|BIOLOGICAL|GLY-LOW|This supplement is available for over-the-counter purchase. Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg). The supplement, GLY-LOW, is FDA approved for use as a dietary supplement (IND 162006)
219224437|NCT06227130|BEHAVIORAL|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
219224438|NCT04190550|DRUG|Cytarabine|Given IV
219693471|NCT02224625|OTHER|SLS|Provides a slight irritation for a positive control
219693472|NCT02118103|PROCEDURE|Spinal Manipulation|Lumbar spinal manipulation
219693473|NCT01276158|PROCEDURE|Ultrasound|Ultrasound used to place arterial line
219693474|NCT01276158|PROCEDURE|Doppler|Doppler used to place arterial line
219693475|NCT04271124|OTHER|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
219106646|NCT01190215|BIOLOGICAL|FluarixTM|One Intramuscular injection
219106647|NCT01190215|BIOLOGICAL|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
219106648|NCT05883917|PROCEDURE|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
219693476|NCT00697099|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219693477|NCT00697099|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219693478|NCT00697099|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
219693479|NCT01988467|OTHER|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
219693480|NCT02586376|DEVICE|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
219693481|NCT02586376|DEVICE|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
219693482|NCT02586376|DEVICE|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
219693483|NCT02586376|DEVICE|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
219106649|NCT01556815|PROCEDURE|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
219106650|NCT01556815|OTHER|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
219106651|NCT05800808|PROCEDURE|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
219106652|NCT05800808|PROCEDURE|Moderate Exercise|81 minutes of cycling at 50% VO2peak
219106653|NCT00584701|DRUG|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
219106654|NCT01001481|OTHER|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
219106655|NCT04502056|BEHAVIORAL|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
219106656|NCT04502056|BEHAVIORAL|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
219106657|NCT04502056|BEHAVIORAL|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
219106658|NCT04502056|BEHAVIORAL|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
219693484|NCT01307787|OTHER|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
219106659|NCT04502056|BEHAVIORAL|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
219106660|NCT04502056|BEHAVIORAL|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
219106661|NCT04502056|BEHAVIORAL|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
219106662|NCT04502056|BEHAVIORAL|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
219106663|NCT04502056|BEHAVIORAL|Placebo videos|Videos not related to covid-19 will be shown
219224439|NCT04190550|DRUG|Idarubicin Hydrochloride|Given IV
219224440|NCT04190550|DRUG|Navtemadlin|Given PO
219693485|NCT01307787|OTHER|no intervention|waiting list control group with no intervention
219693486|NCT00945841|BIOLOGICAL|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
219693487|NCT02309086|BIOLOGICAL|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
219693488|NCT05402709|OTHER|Posterior mobilisation technique|Posterior mobilisation technique were applied
219693489|NCT05402709|OTHER|Posterior capsule stretching|Posterior capsule stretching were applied
219693490|NCT02991391|OTHER|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
219693491|NCT06416631|PROCEDURE|artificial intelligence based screw planning|artificial intelligence technology helps to plan screws in robot assisted spinal surgery
219693492|NCT06416631|PROCEDURE|manually screw planning|the screw trajcetories are manually planned
219106664|NCT03311763|BEHAVIORAL|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
219693493|NCT01739881|DEVICE|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
219106665|NCT03311763|BEHAVIORAL|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
219693494|NCT06221709|PROCEDURE|Conventional Radiofrequency (CRF group)|Radiofrequency will be performed with a 22-gauge CRF cannula, 10/15 cm long, 10mm curved active tip, at 90º for 90 seconds, introduced in the anteroposterior and lateromedial directions, to reach the teardrop landmark. Denervation of the articular branches of the Obturator Nerve will be performed in 2 cycles, starting lateral to the lateral edge of the obturator foramen, followed by a point approximately 1cm lateral to the first point. Next, the cannula will be repositioned in a more cranial location, parallel to the superolateral edge of the acetabular dome, to reach the sensory branches of the Femoral Nerve, performing 3 cycles at the 01, 12, and 11 o'clock positions. All lesions will be preceded by motor stimulation at 2,5V and cycles will be followed by the infusion of 2ml of 1% ropivacaine. After concluding the procedure, hip intraarticular infiltration will be performed as described for the control group.
219106666|NCT00010439|DRUG|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
219693495|NCT06221709|PROCEDURE|Intraarticular Infiltration ( Control group)|For the control group (IA), an epidural anesthesia needle (22G spinal needle) will be used, positioned anteroposteriorly towards the central portion of the femoral neck, which will be introduced until transfixion of the anterior hip capsule through tactile sensitivity. After checking the correct positioning with the use of fluoroscopy and infusion of 3 ml of 50% diluted iodinated contrast, an infusion of 4 ml of 1% Ropivacaine and 80mg of methylprednisolone 40mg/ml will be done.
219693496|NCT06151379|OTHER|Neoadjuvant therapy|To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
219693497|NCT04758455|DIAGNOSTIC_TEST|P53, Ki67 and Cyclin A IHC.|P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.
219693498|NCT01364155|DRUG|LIM-0705|
219693499|NCT01364155|DRUG|Placebo capsules|
219693500|NCT02510937|DRUG|CC-90001|
219693501|NCT05088772|DEVICE|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
219693502|NCT04072874|DRUG|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
219106667|NCT01819025|BEHAVIORAL|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
219106668|NCT01819025|BEHAVIORAL|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
219106669|NCT03880695|DRUG|Anlotinib+ Liposomal Doxorubicin|Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
219106670|NCT01073800|DRUG|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
219106671|NCT01073800|DRUG|placebo|placebo
219106672|NCT01342692|DRUG|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
219106673|NCT01342692|DRUG|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~\- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~\- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
219106674|NCT01342692|DRUG|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
219106675|NCT01342692|DRUG|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
219106676|NCT00742820|DRUG|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
219106677|NCT00742820|DRUG|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
219106678|NCT00742820|DIETARY_SUPPLEMENT|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
219693503|NCT01125098|OTHER|PRO-CT values|"* continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
219693504|NCT00482937|DRUG|CD-NP|
219693505|NCT03342001|DRUG|Calcitonin|calcitonin nasal spray
219693506|NCT00452374|DRUG|Cytarabine|1 g/m\^2 given IV for two days (Days 2 and 3).
219693507|NCT00452374|DRUG|Fludarabine|30 mg/m\^2 given IV for two days (Days 2 and 3).
219106679|NCT02122341|DEVICE|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
219106680|NCT00975572|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
219693508|NCT00452374|DRUG|Oxaliplatin|Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).
219693509|NCT00452374|DRUG|Rituximab|375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
219693510|NCT02144766|DRUG|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
219693511|NCT02144766|DRUG|saline|caudal block with 1 ml/kg of saline
219106681|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
219106682|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
219106683|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
219106684|NCT00975572|BIOLOGICAL|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
219106685|NCT00975572|BIOLOGICAL|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
219224441|NCT05728840|OTHER|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
219693512|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
219693513|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
219693514|NCT03477162|DRUG|Metformin|Metformin will be given to patients prior to surgery.
219693515|NCT01507181|DRUG|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
219693516|NCT01507181|DRUG|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
219693517|NCT04161391|DRUG|TPX-0046|Oral TPX-0046 capsules
219693518|NCT03136393|BEHAVIORAL|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
219693519|NCT03136393|BEHAVIORAL|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
219693520|NCT05684848|DEVICE|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
219106686|NCT00951262|BEHAVIORAL|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
219106687|NCT00067990|DRUG|Losartan 100mg|To be started within three months of transplant and continued for five years.
219106688|NCT00067990|DRUG|Placebo|No treatment with continued follow-up for five years.
219106689|NCT04935138|GENETIC|cfDNA analysis|sequencing data from cfDNA analysis
219106690|NCT00002456|DRUG|cyclosporine|
219106691|NCT00002456|DRUG|methotrexate|
219106692|NCT00002456|PROCEDURE|allogeneic bone marrow transplantation|
219106693|NCT05905991|OTHER|Enhanced Stress Resilience Training|"The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week."
219106694|NCT00724139|DEVICE|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
219106695|NCT00004650|DRUG|conjugated estrogens|
219106696|NCT00004650|DRUG|Medroxyprogesterone|
219693521|NCT05684848|DEVICE|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
219106697|NCT03558958|DRUG|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
219106698|NCT03971708|DRUG|Lidocaine|Local anesthetic
219106699|NCT03971708|DRUG|Ropivacaine|Local anesthetic
219106700|NCT01973491|DRUG|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
219693522|NCT05037630|BEHAVIORAL|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
219693523|NCT04744818|DIETARY_SUPPLEMENT|Iron syrup|Daily supplementation with iron
219693524|NCT04744818|DIETARY_SUPPLEMENT|Multivitamin syrup|Daily supplementation with multivitamins
219106701|NCT04595539|BEHAVIORAL|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
219106702|NCT00981396|BEHAVIORAL|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
219106703|NCT00981396|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
219106704|NCT00529919|DIETARY_SUPPLEMENT|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
219106705|NCT02576782|DRUG|Perineural Dexamethasone and bupivacaine|
219106706|NCT02576782|DRUG|Systemic Dexamethasone plus perineural bupivacaine|
219106707|NCT02576782|DRUG|intravenous saline plus perineural bupivacaine|
219106708|NCT06341426|DRUG|Single Psychedelic Dose Psilocybin|One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
219106709|NCT06341426|DRUG|Two Psychedelic Doses Psilocybin|Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
219106710|NCT03848364|BEHAVIORAL|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
219106711|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 4000IU/100µg.|Vitamin D3 supplementation
219693525|NCT00419185|PROCEDURE|Delamination of the Internal limiting membrane|
219693526|NCT03794492|DRUG|Mycophenolate mofetil 500mg Tab. or 250mg Cap.|\- Orally, up to 1g BID(total 2g daily)
219693527|NCT03794492|DRUG|Tacrolimus|\- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
219693528|NCT03794492|DRUG|Methylprednisolone/prednisolone|\- Methyprednisolone 500mg / Prednisolone 5mg
219693529|NCT03794492|DRUG|Basiliximab|\- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
219693530|NCT06332222|DIETARY_SUPPLEMENT|Tart Cherry|7 day supplementation
219693531|NCT06332222|OTHER|Placebo|7 day supplementation
219693532|NCT01857752|DRUG|Temozolomide|
219693533|NCT05423418|BIOLOGICAL|A244|Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
219693534|NCT05423418|BIOLOGICAL|B.63521|Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
219693535|NCT05423418|BIOLOGICAL|50μg ALFQ|Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
219693536|NCT05423418|BIOLOGICAL|100μg ALFQ|Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
219693537|NCT05423418|BIOLOGICAL|200μg ALFQ|Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
219693538|NCT02579629|DRUG|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
219693539|NCT02579629|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
219693540|NCT02579629|DRUG|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
219693541|NCT02579629|DEVICE|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
219693542|NCT02047578|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
219693543|NCT02351934|DRUG|Furosemide|
219693544|NCT02351934|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
219693545|NCT02351934|DRUG|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
219106712|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 600IU/15µg.|Vitamin D3 supplementation
219106713|NCT01432535|DRUG|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
219693546|NCT06325163|DIAGNOSTIC_TEST|CBCT|Mandibular molar indicated for retreatment will be scanned using limited field of view CBCT to examine the number of canals
219693547|NCT06325163|DIAGNOSTIC_TEST|clinical examination under dental operating microscope|the number of canals will be examined by an a randomly assigned operator following gutta percha removal under dental operating microscope
219693548|NCT06325163|DIAGNOSTIC_TEST|canal detection AI software (diagnocat)|software used to analyze CBCT images and report the number of canals
219106714|NCT00543400|DRUG|M118|intravenous (IV) infusion
219106715|NCT00543400|DRUG|Unfractionated Heparin|IV infusion
219106716|NCT06028581|OTHER|breastfeeding support system|Using the breastfeeding support system
219693549|NCT03320356|OTHER|the French version of the Oxford Shoulder Score|
219693550|NCT00896493|DRUG|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
219693551|NCT00896493|DRUG|cyclosporine|5 mg/kg PO or IV
219693552|NCT00896493|RADIATION|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
219693553|NCT03185000|DRUG|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
219693554|NCT01115452|DRUG|5% Potassium nitrate|5% potassium nitrate solution
219693555|NCT01115452|DRUG|2.5% Potassium nitrate|2.5% potassium nitrate solution
219693556|NCT01115452|OTHER|Sterile water|Sterile water
219693557|NCT06290986|PROCEDURE|Pyrocardan® implant|Biconcave-shaped CMC-1 interposition implant
219693558|NCT06290986|PROCEDURE|Ligament reconstruction and tendon interposition (LRTI)|Weilby slightly modified as described by Burton and Pellegrini
219693559|NCT04315441|DIAGNOSTIC_TEST|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
219106717|NCT01584492|DRUG|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
219106718|NCT01584492|DRUG|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
219106719|NCT01584492|DRUG|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
219106720|NCT01584492|DRUG|Formoterol + Beclomethasone dipropionate|"* Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation"
219693560|NCT02744716|DRUG|Aspirin|low dose of Aspirin after operation
219106721|NCT01584492|DRUG|Placebo (6 inhalations)|Matched placebo via pMDI
219106722|NCT04464616|PROCEDURE|spinal anaesthesia|spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
219693561|NCT02744716|DEVICE|intrauterine balloon|insert intrauterine balloon after operation
219693562|NCT01739335|DRUG|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
219106723|NCT06167629|DIAGNOSTIC_TEST|PET 18F-PSMA|Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.
219106724|NCT04693936|COMBINATION_PRODUCT|Nutraceutical Combination Plan|"Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment."
219106725|NCT05565274|DRUG|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
219106726|NCT00385853|DRUG|PTK787/ZK 222584|Twice daily for each 28-day cycle
219106727|NCT00385853|DRUG|Temozolomide|Daily for each 28-day cycle
219106728|NCT00385853|PROCEDURE|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
219106729|NCT01216891|BEHAVIORAL|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
219106730|NCT03200301|PROCEDURE|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
219106731|NCT04879758|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
219693563|NCT01739335|DRUG|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
219693564|NCT04718922|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
219693565|NCT00619840|DRUG|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
219693566|NCT00619840|DRUG|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
219693567|NCT04333693|PROCEDURE|Vascular surgery|Open vascular, endovascular or hybrid procedures
219693568|NCT05310877|BEHAVIORAL|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
219106732|NCT04879758|OTHER|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
219106733|NCT01928225|BIOLOGICAL|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
219106734|NCT06381817|BIOLOGICAL|Haplo-cord HCT|Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit
219106735|NCT06381817|BIOLOGICAL|Haplo-HCT|Hematopoietic cell transplantation will be performed with a haploidentical donor
219106736|NCT01768754|BEHAVIORAL|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
219224442|NCT05728840|OTHER|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
219693569|NCT05885217|OTHER|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
219693570|NCT02105324|DEVICE|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
219693571|NCT02105324|OTHER|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
219106737|NCT05276843|COMBINATION_PRODUCT|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
219106738|NCT03197103|DRUG|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
219106739|NCT02302950|DRUG|raltegravir|HIV therapy component
219106740|NCT01451736|DRUG|paliperidone palmitate|long-acting injectable
219106741|NCT01451736|DRUG|risperidone|oral
219106742|NCT05279430|BEHAVIORAL|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
219224443|NCT05510310|PROCEDURE|Breast stimulation|By breast pump
219106743|NCT02265224|DRUG|N-acetylcysteine|The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
219106744|NCT05389020|OTHER|Newly developed real-size infant's arm and leg manikin|The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
219693572|NCT03057574|DRUG|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
219693573|NCT04609137|PROCEDURE|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
219693574|NCT04609137|PROCEDURE|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
219693575|NCT04325880|DRUG|Mirabegron 50 MG|Patients in this arm will receive Mirabegrone 50 MG once daily
219106745|NCT03681795|DIAGNOSTIC_TEST|Experimental MRI exam and PET scan exam with radiotracer|MRI exam and PET scan exam with radiotracer
219106746|NCT01754454|BIOLOGICAL|Human Umbilical Cord Derived MSC|1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
219106747|NCT02724813|BEHAVIORAL|Cognitive Orientation to Occupational Preformance (COOP)|
219106748|NCT04572919|PROCEDURE|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
219106749|NCT04572919|PROCEDURE|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
219106750|NCT03942913|OTHER|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
219224444|NCT05510310|BIOLOGICAL|Oxytocin|Oxytocin will be administered intravenously and titrated
219224445|NCT00644514|BIOLOGICAL|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
219693576|NCT04325880|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin o.4 MG once daily
219106751|NCT01127906|DRUG|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
219106752|NCT01127906|DRUG|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
219106753|NCT01127906|DRUG|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
219106754|NCT01127906|DRUG|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
219106755|NCT01127906|DRUG|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
219224446|NCT06236802|DEVICE|ProVee device|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
219224447|NCT06521619|PROCEDURE|Femoral and sciatic nerve blocks|Patients receiving Adductor canal block and infiltration of posterior capsule of knee
219224448|NCT02335554|BEHAVIORAL|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
219224449|NCT02335554|BEHAVIORAL|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
219224450|NCT00893555|DRUG|voriconazole|TDM (through level of 2-5mg/L).
219224451|NCT00893555|DRUG|voriconazole (dosing according to the SPC)|No serum concentrations are determined
219106756|NCT02134119|DIETARY_SUPPLEMENT|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
219106757|NCT02134119|DRUG|Placebo|Sugar pill manufactured to mimic dietary supplement
219106758|NCT03693716|PROCEDURE|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
219106759|NCT04679103|BIOLOGICAL|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
219106760|NCT02710760|OTHER|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
219106761|NCT02710760|OTHER|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
219106762|NCT01454830|BEHAVIORAL|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
219106763|NCT01454830|OTHER|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
219106764|NCT03929419|DRUG|intranasal insulin|application of 160 units human insulin
219693577|NCT04325880|DRUG|Solifenacin Succinate 10 MG|Patients in this arm will receive Solifenacin Succinate 10 MG once daily
219106765|NCT03929419|DRUG|Placebo spray|nasal spray containing placebo solution
219106766|NCT03006627|DRUG|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
219106767|NCT04932382|DRUG|Misoprostol|will be used 3 h before IUD insertion
219106768|NCT04932382|DEVICE|IUD|a copper T380A IUD
219106769|NCT00393744|DRUG|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
219106770|NCT00393744|DRUG|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
219106771|NCT04683289|PROCEDURE|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
219106772|NCT02006420|DEVICE|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
219106773|NCT03304860|OTHER|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
219106774|NCT04883593|DRUG|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
219106775|NCT04883593|DRUG|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
219106776|NCT01907074|DRUG|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
219106777|NCT06056986|DIAGNOSTIC_TEST|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
219106778|NCT05294874|OTHER|gait training|walking forward, sideway and backward walking on balance board
219106779|NCT00003220|DRUG|bryostatin 1|
219106780|NCT00389974|DRUG|sunitinib malate|Given PO
219106781|NCT05496621|OTHER|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
219106782|NCT01965158|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
219106783|NCT01965158|DRUG|Placebo|Placebo tablet taken orally once a day
219224452|NCT06979323|BIOLOGICAL|Depemokimab|Depemokimab will be administered.
219224453|NCT04267588|OTHER|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
219693578|NCT04325880|DRUG|Placebo oral tablet|Patients in this arm will receive placebo oral tablet once daily
219693579|NCT01679743|DRUG|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
219693580|NCT01679743|DRUG|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
219693581|NCT06429904|DRUG|Nimotuzumab+ NALIRIFOX|"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"
219693582|NCT02659501|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
219693583|NCT02659501|DRUG|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
219693584|NCT02659501|DRUG|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
219693585|NCT02659501|DRUG|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
219693586|NCT02659501|DRUG|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
219693587|NCT02555592|PROCEDURE|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2\~4 weeks after adjuvant chemotherapy.
219693588|NCT00691275|DRUG|Ondansetron|
219693589|NCT00691275|DRUG|Saline|
219693590|NCT03280407|DRUG|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
219693591|NCT03280407|DRUG|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
219693592|NCT03280407|DRUG|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
219693593|NCT02982759|BEHAVIORAL|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
219224454|NCT06854640|DRUG|BAY3389934|Solution for IV infusion
219224455|NCT04644575|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:Solution for Injection Route of administration: Intravenous
219693594|NCT02982759|BEHAVIORAL|Genetic Newsletters|The comparison will receive generic newsletters
219693595|NCT03485534|DRUG|Tenofovir Disoproxil Fumarate|Viread 300mg
219693596|NCT03485534|DRUG|Tenofovir Disoproxil|Virehepa 245mg
219693597|NCT05495178|PROCEDURE|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
219693598|NCT06313645|OTHER|Several biomarkers|Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
219693599|NCT00937963|DIETARY_SUPPLEMENT|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
219693600|NCT05282147|DEVICE|Neocam|Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
219106784|NCT04217993|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
219106785|NCT00967174|DRUG|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
219106786|NCT00967174|DRUG|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
219106787|NCT00967174|DRUG|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
219106788|NCT01365520|DRUG|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
219106789|NCT04571762|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
219106790|NCT03022838|DRUG|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
219106791|NCT02572336|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
219106792|NCT02572336|DRUG|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
219106793|NCT02572336|DRUG|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
219106794|NCT00005881|OTHER|Quality of Life Forms|Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
219106795|NCT00247624|DRUG|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
219106796|NCT00247624|DRUG|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
219106797|NCT00247624|DRUG|Placebo|Placebo every night for 8 weeks
219106798|NCT03074812|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
219106799|NCT00000811|DRUG|Azithromycin|
219106800|NCT00000811|DRUG|Atovaquone|
219106801|NCT00000811|DRUG|Sulfamethoxazole-Trimethoprim|
219106802|NCT03716544|DEVICE|Amplification with hearing aid|Use of hearing aids
219106803|NCT03716544|DEVICE|Customized music|Customized music delivered via an iPod
219224456|NCT06585865|BEHAVIORAL|Resistance training|After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
219224457|NCT06585865|DIETARY_SUPPLEMENT|Resveratrol 500 mg oral once daily.|Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
219106804|NCT03486925|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
219224458|NCT06585865|DIETARY_SUPPLEMENT|Placebo|Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
219224459|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
219224460|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
219224461|NCT02581137|OTHER|Laboratory Biomarker Analysis|Correlative studies
219106805|NCT03486925|DRUG|placebo treatment|intranasal administration of placebo
219106806|NCT04131478|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
219106807|NCT01502995|DEVICE|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
219106808|NCT03296709|DEVICE|PPC z|Installation of a preformed pediatric zircona crown
219106809|NCT03296709|DEVICE|PPC m|Installation of a preformed pediatric metal crown
219106810|NCT04499716|PROCEDURE|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
219106811|NCT04499716|PROCEDURE|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
219106812|NCT04499716|PROCEDURE|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
219106813|NCT04499716|PROCEDURE|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
219106814|NCT04499716|PROCEDURE|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
219106815|NCT04499716|PROCEDURE|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
219693601|NCT04715490|OTHER|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
219693602|NCT04715490|OTHER|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
219693603|NCT04596969|OTHER|Soluble Fiber Dextrin|Ingredient based on resistant starch
219693604|NCT03529500|DIAGNOSTIC_TEST|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
219693605|NCT03529500|DIAGNOSTIC_TEST|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: \< 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and \> 2.0 ml/min = high flow.
219693606|NCT03529500|DIAGNOSTIC_TEST|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
219106816|NCT01382485|OTHER|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
219106817|NCT01382485|OTHER|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
219106818|NCT01190332|PROCEDURE|endoscopic sphincterotomy by conventional method|
219224462|NCT02581137|DRUG|Metformin Hydrochloride|Given PO
219224463|NCT04463446|BEHAVIORAL|Use of the CHD app|Use of the CHD app
219224464|NCT04463446|BEHAVIORAL|Nurse-led intervention|Teaching session with clinic nurse
219224465|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive clinically-optimized open loop stimulation to the pallidum/subthalmaic nucleus.
219224466|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive increased adaptive stimulation to the pallidum/subthalmaic nucleus.
219106819|NCT01190332|PROCEDURE|endoscopic sphincterotomy by rendezvous method|
219106820|NCT05942352|DRUG|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
219106821|NCT05942352|DRUG|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
219106822|NCT05942352|DRUG|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
219106823|NCT05942352|DRUG|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
219106824|NCT02006121|DRUG|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
219106825|NCT02006121|DRUG|Placebo|Sodium chloride 9 mg/ml
219106826|NCT03337191|DRUG|Levobupivacaine|% 0,125 levobupivacaine
219106827|NCT03337191|DRUG|Morphine Sulfate|10 mq/kg morphine sulfate
219106828|NCT03337191|DEVICE|Ultrasound|Ultrasound guided caudal block
219106829|NCT02420756|DEVICE|PET Scan|
219224467|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive decreased adaptive stimulation to the pallidum/subthalmaic nucleus.
219224468|NCT06816927|DRUG|Nivolumab|For Neoadjuvant treatment, on both Arms 1 and 2, all 92 patients will receive single dose of 480 mg by IV infusion on Day 1 followed by surgery. Post-resection, in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Nivolumab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
219106830|NCT04307498|BEHAVIORAL|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, \& Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
219106831|NCT03290157|DEVICE|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
219224469|NCT06816927|DRUG|Relatlimab|For Neoadjuvant treatment, only on Arm 2, 69 patients will receive a single dose of 480 mg of nivolumab and 480 mg of relatimab by IV infusions on Day 1 followed by surgery. Post resection in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab and relatlimab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Relatimab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
219224470|NCT06816927|DRUG|TMZ|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment setting will receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. In Part 2 Adjuvant Treatment of TMZ dosing with TMZ will continue for up to 6 cycles with 150 mg/m2 for cycle 3 and escalating to 200 mg/m2 for cycles 4 to 8 day 1 to 5 for these 6 cycles.
219224471|NCT06816927|RADIATION|Radiation Therapy|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment will receive External Beam Radiation 2 Gy/day (60 Gy in total) Once daily, 5 days per week, for 6 weeks Starting on Day 1
219106832|NCT00068874|BEHAVIORAL|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
219106833|NCT00068874|BEHAVIORAL|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
219106834|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
219224472|NCT06061978|PROCEDURE|left bundle branch of His pacing|left bundle branch of His pacing
219224473|NCT06061978|PROCEDURE|right ventricular pacing|right ventricular pacing
219106835|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
219106836|NCT06321250|DRUG|JMKX003948|Subjects will receive JMKX003948 tablets until disease progression
219106837|NCT04696718|DIETARY_SUPPLEMENT|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
219224474|NCT03532477|DRUG|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
219224475|NCT00592345|RADIATION|Proton Beam Radiation|Administered over a period of 12 weeks.
219224476|NCT00592345|RADIATION|Photon Beam Radiation|Administered over a period of 12 weeks.
219224477|NCT00592345|RADIATION|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
219224478|NCT06855745|DRUG|zabalafin|Active IP
219224479|NCT06594445|DRUG|GTB-360|"GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day"
219693607|NCT01674725|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219693608|NCT01674725|DRUG|Ribavirin|Tablet
219693609|NCT03567408|PROCEDURE|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
219224480|NCT06386744|DRUG|Dusquetide|1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
219224481|NCT06988059|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion
219224482|NCT05824559|DRUG|ME-344|ME-344 will be administered intravenously (IV)
219224483|NCT05824559|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV)
219224484|NCT06196840|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
219224485|NCT06196840|BIOLOGICAL|Aflibercept intravitreal injection|Commercially available Active Comparator
219224486|NCT06993415|OTHER|data collection|"The ORACLE program is a prospective, deep phenotyping, study based on multimodal information and artificial intelligence computation. We will prospectively collect in-hospital and out-of-hospital data of a large cohort of patients presenting with MI, including data from wearable devices recording continuous ECG, interstitial-fluids, non-invasive blood pressure and mobility, behavioural patterns from a dedicated mobile application, blood and urine biomarkers and non-invasive imaging. We will leverage on AI, using statistical learning methods and neural networks, to explore patterns and higher order interactions within the data to provide novel computational biomarkers of ischemic and bleeding risk."
219224487|NCT06994975|DRUG|0.25mg/kg TNK|Patients in the tenecteplase group were administered a 0.25mg/kg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.
219224488|NCT06994975|DRUG|Standard medical treatment|Patients in the standard medical treatment group will receive the standard treatment selected by local doctors, including antithrombotic agents, lipid-lowering agents, antihypertensive drugs, and hypoglycemic agents. Patients would be ineligible if bridging endovascular treatment is planned at the time of randomization.
219693610|NCT03567408|DRUG|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
219106838|NCT02254837|DEVICE|Zilver PTX Drug-Eluting Stent|
219693611|NCT02870647|OTHER|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
219693612|NCT05775380|DRUG|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
219106839|NCT03961113|OTHER|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
219106840|NCT02493218|BEHAVIORAL|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
219693613|NCT01304797|DRUG|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
219693614|NCT01304797|DRUG|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
219693615|NCT01304797|DRUG|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
219693616|NCT01304797|DRUG|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
219106841|NCT02493218|BEHAVIORAL|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
219106842|NCT03788005|PROCEDURE|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
219106843|NCT06442813|BEHAVIORAL|EFT GROUP|One times one pregnancy
219106844|NCT02190760|DRUG|Dexamethasone|
219106845|NCT02190760|DRUG|Bupivacaine|
219106846|NCT01088308|PROCEDURE|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
219224489|NCT04411199|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
219224490|NCT04411199|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
219693617|NCT03758469|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
219693618|NCT03758469|DRUG|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
219693619|NCT02672072|OTHER|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
219106847|NCT01088308|PROCEDURE|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
219106848|NCT02693834|DEVICE|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
219106849|NCT02693834|DEVICE|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
219106850|NCT04707131|DRUG|LEM-S401|siRNA encapsulated in DegradaBALL®
219106851|NCT04707131|DRUG|Placebo|Placebo
219106852|NCT04848662|DRUG|BDA MDI (PT027) 160/180 μg|Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
219106853|NCT04848662|DRUG|Pulmicort Respules 0.5 MG/ML Inhalation Suspension|Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
219106854|NCT03072082|DRUG|Danlou Tablet|Conventional western medicine \& Danlou Tablet
219106855|NCT03072082|DRUG|DanLou Tablet placebo|Conventional western medicine \& placebo (for Danlou Tablet)
219106856|NCT03072082|DRUG|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
219106857|NCT03072082|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
219106858|NCT03072082|DRUG|Atorvastatin calcium|10 mg tablet, two tablets each night.
219106859|NCT03072082|DRUG|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
219106860|NCT03072082|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
219106861|NCT03072082|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
219693620|NCT02672072|OTHER|questionnaire to define the presence of job strain at 6 months|
219693621|NCT02672072|OTHER|questionnaire to define the presence of job strain at 12 months|
219693622|NCT02900352|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
219693623|NCT02900352|DRUG|Placebo|Placebo
219693624|NCT03074695|PROCEDURE|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
219693625|NCT03074695|PROCEDURE|Standard Epidural (EPL)|Standard epidural placement
219693626|NCT03074695|DRUG|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
219693627|NCT03074695|DRUG|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
219693628|NCT02945436|BEHAVIORAL|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
219693629|NCT02945436|BEHAVIORAL|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
219106862|NCT00894582|PROCEDURE|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
219106863|NCT00152971|DRUG|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
219106864|NCT00152971|DRUG|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
219106865|NCT00152971|DRUG|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
219106866|NCT00152971|DRUG|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
219106867|NCT00152971|DRUG|Enoxaparin|30 mg subcutaneously twice daily
219106868|NCT02707523|DRUG|Azithromycin 10 mg|
219106869|NCT02707523|DRUG|Azithromycin 20mg|
219106870|NCT02707523|DRUG|Placebo|
219224491|NCT06156410|DRUG|Cabozantinib|Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
219693630|NCT00053885|DRUG|PTK787/ZK 222584|oral
219693631|NCT03017807|BIOLOGICAL|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
219106871|NCT00955734|OTHER|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
219106872|NCT00955734|OTHER|Immobilization|This set of patients will be casted for 6 weeks after surgery.
219106873|NCT01615575|PROCEDURE|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
219106874|NCT01615575|PROCEDURE|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
219693632|NCT00061789|DRUG|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
219693633|NCT00407225|DRUG|Difluprednate Ophthalmic Emulsion|
219693634|NCT01227369|OTHER|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
219106875|NCT04619342|DEVICE|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
219106876|NCT04619342|PROCEDURE|Surgical Resection|Surgical Resection of PVTT
219106877|NCT05164497|OTHER|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
219693635|NCT02360046|DRUG|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
219693636|NCT02360046|DRUG|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
219693637|NCT00468117|PROCEDURE|Islet transplantation|
219693638|NCT00468117|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
219693639|NCT00468117|BIOLOGICAL|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
219106878|NCT05164497|OTHER|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
219106879|NCT03343405|BEHAVIORAL|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
219106880|NCT04070053|OTHER|TheraPPP Pathway|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
219106881|NCT03143335|PROCEDURE|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
219224492|NCT06995625|DRUG|SNE-101|Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6)
219224493|NCT03615352|PROCEDURE|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
219224494|NCT03615352|PROCEDURE|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
219224495|NCT06677203|DRUG|ASN51|Oral capsules
219224496|NCT06677203|DRUG|Placebo|Oral capsules
219693640|NCT00468117|BIOLOGICAL|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
219693641|NCT00468117|BIOLOGICAL|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
219106882|NCT03143335|PROCEDURE|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
219106883|NCT02926508|DIETARY_SUPPLEMENT|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
219106884|NCT02926508|OTHER|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
219106885|NCT04475848|DRUG|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
219106886|NCT04475848|DRUG|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
219106887|NCT04475848|DRUG|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
219106888|NCT03312686|DIAGNOSTIC_TEST|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
219106889|NCT00583232|DRUG|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
219106890|NCT06227962|DIAGNOSTIC_TEST|Neuropsychological assesment|Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test
219106891|NCT06227962|DIAGNOSTIC_TEST|Psychosocial functioning and quality of life (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)
219106892|NCT06227962|DIAGNOSTIC_TEST|Parental psychosocial functioning (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
219106893|NCT00526383|DRUG|Tricyclic antidepressants|antidepressant version medical dispositive
219106894|NCT04488367|DRUG|Tranexamic acid|10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
219106895|NCT04488367|DRUG|Normal Saline|100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
219106896|NCT01291316|DRUG|Clonazepam|clonazepam, 1 mg, single oral dose
219106897|NCT01291316|DRUG|Tolterodine|Tolterodine 1,37mg, single oral dose
219106898|NCT01291316|DRUG|clobazam|clobazam 20 mg, single oral dose
219106899|NCT03047772|DRUG|Atorvastatin|Routine dose of Atorvastatin therapy
219106900|NCT03047772|DRUG|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
219106901|NCT03047772|DRUG|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
219106902|NCT03047772|DRUG|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
219106903|NCT03047772|DRUG|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
219106904|NCT03047772|DRUG|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
219106905|NCT04911062|DRUG|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
219106906|NCT04911062|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
219106907|NCT04911062|DEVICE|Luer Lock Applicator|Applicator for instillation.
219224497|NCT07002593|OTHER|Myofascial release (MFR)|A 10-minute manual myofascial release (MFR) technique targeting active upper trapezius trigger points (MTrPs), applying sustained pressure until tissue release was achieved.
219693642|NCT03006237|DRUG|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
219106908|NCT05014321|DEVICE|EC16 medical device (CE marked)|Application on brown spots located on the face (1 treatment during the study).
219106909|NCT05014321|DEVICE|device prototype (810A-v1)|Application on brown spots located on the face (4 treatments during the study).
219106910|NCT05014321|DEVICE|device prototype (810B-v1)|Application on brown spots located on the face (4 treatments during the study).
219106911|NCT05014321|DEVICE|device prototype (810C-v1)|Application on brown spots located on the face (4 treatments during the study).
219106912|NCT04023149|DRUG|recombinant human interleukin-2 (rhIL-2)|Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
219224498|NCT07002593|OTHER|Muscle Stretching|Three 30-second static muscle stretches were performed for the upper trapezius by placing neck side flexion with contralateral rotation.
219224499|NCT07002593|OTHER|High-powered pulsed therapeutic ultrasound (HPPT-US)|A 5-minute high-powered pulsed therapeutic ultrasound (HPPT) was delivered subcutaneously with specific parameters of 1.5 W/cm², 1 MHz, and pulsed mode.
219224500|NCT03559413|BIOLOGICAL|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
219224501|NCT01836445|BEHAVIORAL|Keep It Up!|
219693643|NCT03006237|DEVICE|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
219106913|NCT04023149|DRUG|placebo|Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
219106914|NCT03646903|BEHAVIORAL|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
219106915|NCT03646903|BEHAVIORAL|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
219106916|NCT05571384|BEHAVIORAL|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
219106917|NCT01960075|DRUG|Fosphenytoin|
219106918|NCT01960075|DRUG|Levetiracetam|
219106919|NCT01960075|DRUG|Valproic acid|
219106920|NCT00449241|DEVICE|Acupuncture|
219106921|NCT03501329|COMBINATION_PRODUCT|Biological,Psychological and Social support|
219106922|NCT00161395|BEHAVIORAL|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
219106923|NCT00161395|BEHAVIORAL|Preconception advice|Preconception advice for diet and frequency of intercourse.
219106924|NCT04113681|PROCEDURE|Geniculate Artery Embolization|"1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)"
219106925|NCT00061516|DRUG|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
219106926|NCT00061516|DRUG|AZOPT (brinzolamide)|brinzolamide suspension, 1%
219106927|NCT01396395|DRUG|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
219106928|NCT01396395|DRUG|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
219106929|NCT05779553|DIAGNOSTIC_TEST|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
219106930|NCT02400437|DRUG|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
219106931|NCT02400437|DRUG|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
219106932|NCT02400437|DRUG|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
219106933|NCT05646199|DRUG|Metformin|Participants will receive metformin
219106934|NCT05646199|DRUG|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
219106935|NCT00004202|DRUG|carboplatin|
219106936|NCT00004202|DRUG|chemotherapy|
219106937|NCT00004202|DRUG|efaproxiral|
219224502|NCT01836445|BEHAVIORAL|HIV Knowledge Control|
219693644|NCT05482802|BEHAVIORAL|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
219106938|NCT00004202|DRUG|paclitaxel|
219106939|NCT00004202|RADIATION|radiation therapy|
219106940|NCT00882921|BIOLOGICAL|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
219106941|NCT00817375|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
219106942|NCT00817375|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
219106943|NCT04845035|DRUG|Dasatinib|By mouth
219106944|NCT04845035|DRUG|Ponatinib|By mouth
219106945|NCT04845035|DRUG|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
219106946|NCT04845035|DRUG|Methotrexate and Cytarabine|Intrathecal
219106947|NCT05907577|OTHER|Observational|No interventions.
219693645|NCT05482802|BEHAVIORAL|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
219693646|NCT02337062|DRUG|APD421|
219693647|NCT02337062|DRUG|Placebo|
219693648|NCT01210638|DRUG|Oxymorphone|10 mg tablet
219693649|NCT02871674|BEHAVIORAL|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
219693650|NCT03758729|DRUG|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
219693651|NCT03758729|RADIATION|Radiation Therapy|Radiation Therapy
219693652|NCT01232790|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
219693653|NCT01232790|DRUG|Placebo|Placebo
219693654|NCT00002441|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
219693655|NCT02788487|DEVICE|Tongue retaining device|Tongue retaining device is used for 3 weeks
219106948|NCT01154894|OTHER|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
219106949|NCT01364974|DRUG|ASP015K|oral
219106950|NCT01364974|DRUG|Placebo|oral
219106951|NCT00641758|DRUG|Pycnogenol|Pycnogenol 100mg twice daily
219693656|NCT02788487|DEVICE|CPAP|CPAP is used for 3 weeks
219693657|NCT05306990|DRUG|Atorvastatin 40 Mg Oral Tablet|patients followed up for 3 months
219693658|NCT05306990|DRUG|Rosuvastatin 20 Mg Oral Tablet|patients followed up for 3 months
219693659|NCT01978457|DRUG|cocaine hydrochloride|
219693660|NCT01978457|DRUG|propranolol|
219693661|NCT01978457|DRUG|placebo|
219693662|NCT06043466|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219693663|NCT01239797|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
219693664|NCT01239797|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
219693665|NCT01239797|DRUG|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
219693666|NCT01239797|DRUG|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
219693667|NCT01239797|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219693668|NCT01276977|DRUG|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
219693669|NCT01276977|DRUG|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
219693670|NCT05567536|DRUG|Antiplatelet Agents|Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
219693671|NCT01854814|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
219693672|NCT01854814|DRUG|Losartan|Maximum tolerated labeled dose of Losartan
219106952|NCT00641758|DRUG|Placebo|Placebo 100mg twice daily
219106953|NCT01790360|BEHAVIORAL|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
219106954|NCT01790360|BEHAVIORAL|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
219106955|NCT01317290|DIETARY_SUPPLEMENT|n-3 PUFA free olive oil|negative control
219106956|NCT01317290|DIETARY_SUPPLEMENT|linseed oil|
219224503|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
219224504|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
219106957|NCT02568332|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
219106958|NCT02568332|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
219106959|NCT04301440|DEVICE|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
219106960|NCT04301440|DEVICE|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
219106961|NCT05527730|DEVICE|Comparison of PRO-FIT or SELF-FIT fitting|add
219106962|NCT04248842|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
219106963|NCT03910348|DEVICE|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
219106964|NCT03910348|OTHER|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
219106965|NCT05570682|PROCEDURE|TCI|General anesthesia will be induced with a TCI pump
219106966|NCT05570682|PROCEDURE|Manual induction|General anestehsia will be induced and maintained using a pro kilo regimen.
219106967|NCT06480799|DIETARY_SUPPLEMENT|Fibre intervention|Inulin fibre (5g) and Pectin fibre (15g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
219106968|NCT06480799|DIETARY_SUPPLEMENT|Placebo intervention|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with inulin and pectin.
219106969|NCT06534970|DEVICE|Three-dimensional stereophotogrammetry|Three stereoscopic photographs
219106970|NCT06534970|OTHER|Questionnaires|"* SF-36 quality of life scale for general health inquiry~* Rosenberg Self-Esteem Scale~* Self-perception scale"
219106971|NCT04844437|DIAGNOSTIC_TEST|Transperineal ultrasound|The fetal head station is evaluated by transperineal ultrasonography in valsalva.
219224505|NCT07003906|DEVICE|Negative pressure wound therapy|"Avance Solo Negative Pressure Wound Therapy (NPWT) System is a portable battery powered single use negative pressure system, suitable for use in closed incision and chronic wound indications.~The system consists of Avance Solo Pump, Avance Solo Canister 50 mL, Avance Solo Border Dressing and Avance Solo Foam."
219224506|NCT07003906|DEVICE|Standard postoperative dressing|Mepilex Border Post-Op is a self-adhesive absorbent surgical dressing designed for exuding wounds. It is intended for acute wounds, such as surgical wounds, cuts and abrasions.
219224507|NCT07004634|PROCEDURE|Chest mediastinal tube|Transthoracic mediastinal drainage was performed for postoperative management of the patient.
219106972|NCT05545241|BEHAVIORAL|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
219106973|NCT05545241|BEHAVIORAL|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
219106974|NCT05115409|DRUG|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
219106975|NCT03317223|DRUG|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
219106976|NCT01569035|DRUG|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
219106977|NCT06055192|OTHER|Survey|Survey
219106978|NCT05490329|BEHAVIORAL|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
219106979|NCT05523440|DRUG|Bevacizumab|Bevacizumab infusion.
219106980|NCT05523440|DRUG|Niraparib|Niraparib oral capsule.
219106981|NCT03492892|DEVICE|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
219106982|NCT03492892|DEVICE|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
219106983|NCT04707339|PROCEDURE|Appendicectomy|Laparoscopic or Open Appendicectomy
219106984|NCT05363969|DEVICE|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
219106985|NCT00385554|DRUG|UC-781 carbomer gel, 0.1% and 0.25%|
219106986|NCT04417387|OTHER|Observational|
219106987|NCT06112223|DRUG|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
219106988|NCT06112223|DRUG|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
219106989|NCT02420743|PROCEDURE|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
219693673|NCT03614000|OTHER|Screening Questionnaires|"Measurement tools:~* Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~* The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~* The VG\&O The VG\&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
219693674|NCT00458237|DRUG|Everolimus|Everolimus is being administered orally 7 days per week.
219106990|NCT02420743|PROCEDURE|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
219106991|NCT04013412|DIETARY_SUPPLEMENT|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
219224508|NCT07004634|PROCEDURE|Abdominal mediastinal tube|Transperitoneal mediastinal drainage was performed for postoperative management of the patient.
219106992|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 1|
219224509|NCT07004634|PROCEDURE|Chest tube + chest mediastinal tube|Chest tube insertion combined with transthoracic mediastinal drainage was performed for postoperative management of the patient.
219106993|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 2|
219106994|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 3|
219106995|NCT01980615|DRUG|Inhaled GFF (PT003)|
219224510|NCT06674889|OTHER|Rehabilitation-based intervention|Assessment of the subject by a specialty consultation and exercise program development.
219224511|NCT07002502|DRUG|PRaG-1(cordycepin tablet)|"The PRaG-1 cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201."
219693675|NCT00458237|DRUG|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
219106996|NCT01980615|DRUG|Inhaled Symbicort Dose 1|
219106997|NCT01980615|DRUG|Inhaled Symbicort Dose 2|
219106998|NCT04966143|BIOLOGICAL|LY011|Targeting CLDN 18.2 Car-T injection
219106999|NCT02460263|DEVICE|Tablo Hemodialysis System|
219107000|NCT04662463|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
219224512|NCT07000851|DIAGNOSTIC_TEST|C-11 ER176 Radiotracer|PET scan looking for inflammation
219224513|NCT07000851|DIAGNOSTIC_TEST|C-11 PiB|PET scan looking for amyloid protein
219107001|NCT04662463|BEHAVIORAL|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
219107002|NCT01170416|OTHER|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
219107003|NCT03176238|DRUG|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
219107004|NCT03176238|DRUG|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
219107005|NCT00497640|PROCEDURE|Artificial Neural Network|Use of a predicted optimal CPAP
219107006|NCT05029024|OTHER|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
219693676|NCT02899611|DRUG|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
219107007|NCT05029024|OTHER|control group|standard care alone
219224514|NCT07000851|DIAGNOSTIC_TEST|AV1451 Tau|Pet scan looking for Tau protein
219224515|NCT06092970|DRUG|RBT-1|Intravenous administration
219693677|NCT02873234|DRUG|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
219693678|NCT02873234|DRUG|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
219107008|NCT04771338|BEHAVIORAL|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
219107009|NCT02301156|DRUG|Ublituximab|Administered as an IV infusion
219107010|NCT02301156|DRUG|Ibrutinib|Administered orally
219107011|NCT00486135|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
219107012|NCT00486135|DRUG|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
219107013|NCT03679195|DIETARY_SUPPLEMENT|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
219693679|NCT03528148|BEHAVIORAL|cycling|Active cycling
219693680|NCT03528148|BEHAVIORAL|Physical therapy|Conventional physical therapy
219693681|NCT00560365|OTHER|laboratory biomarker analysis|
219693682|NCT00560365|PROCEDURE|computed tomography|
219693683|NCT00560365|PROCEDURE|magnetic resonance imaging|
219693684|NCT00560365|PROCEDURE|quality-of-life assessment|
219107014|NCT03679195|DIETARY_SUPPLEMENT|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
219107015|NCT01473472|DRUG|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
219107016|NCT01473472|DRUG|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
219107017|NCT02811757|PROCEDURE|tenotomy|
219107018|NCT02811757|PROCEDURE|tenodesis|
219107019|NCT05334927|BEHAVIORAL|Medicine Overuse Headache/New Daily Persistent Headache|At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
219107020|NCT05334927|BEHAVIORAL|Chronic Migraine|long-term follow-up
219107021|NCT05334927|BEHAVIORAL|Patients with other types of primary headache|No collection Brain imaging、Cognitive function test、Biological sample
219107022|NCT03324503|DRUG|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
219107023|NCT03211715|OTHER|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
219107024|NCT02676908|OTHER|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
219224516|NCT06092970|DRUG|Placebo|Intravenous administration
219693685|NCT02479750|DEVICE|ColdZyme® mouth spray|
219693686|NCT02479750|DEVICE|Placebo|
219107025|NCT03368079|DEVICE|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
219107026|NCT00194480|DRUG|Pegylated Interferon|Weekly injections of pegIntereferon
219107027|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
219693687|NCT04664218|DEVICE|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
219693688|NCT04009616|DRUG|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
219693689|NCT04009616|DRUG|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
219693690|NCT04009616|DRUG|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
219693691|NCT02051296|DRUG|Minocycline|RCT blinded placebo trial
219693692|NCT02051296|DRUG|placebo|RCT blinded placebo trial
219107028|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
219107029|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
219107030|NCT05730530|BEHAVIORAL|Nutrition education curriculum|This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
219224517|NCT02037126|DRUG|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
219224518|NCT02037126|DRUG|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
219224519|NCT05865392|BEHAVIORAL|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
219224520|NCT07003061|PROCEDURE|Standard Anesthesia Management|All patients will receive standard anesthesia care as per institutional protocols. No experimental intervention will be applied.
219224521|NCT07007052|DRUG|Venetoclax|Single interventional arm
219693693|NCT03794895|DEVICE|Doppler|Doing doppler for women having IUCD associated menorrhagia
219107031|NCT03515057|DIAGNOSTIC_TEST|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
219224522|NCT07007052|DRUG|Tagraxofusp|Single interventional arm
219693694|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
219693695|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
219693696|NCT02631941|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
219693697|NCT02631941|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
219693698|NCT02631941|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
219693699|NCT02631941|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
219693700|NCT04603755|DEVICE|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
219693701|NCT01225549|DRUG|AZD5423|Suspension for nebulisation once daily 7 days
219224523|NCT06069297|OTHER|Multimodal Prehabilitation|Preoperative multimodal intervention including exercise training, nutritional therapy and psychosocial counseling, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a 2 to 3-day per week exercise program for 4-6 weeks including endurance, resistance, and inspiratory muscle training, tailored to individual preferences and clinical conditions. Based on dietary habits and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Patients will meet with a psychologist to explore their emotional and psychosocial needs related to their current situation.
219224524|NCT07011966|DEVICE|ASV therapy|Adaptive servo ventilation (ASV) therapy using ResMed AirCurve 11 device will be used to target potential upper airway resistance and respiratory related arousals in patients with insomnia. The ASV device is approved for the treatment of obstructive sleep apnea, and this will be designated as the investigational device for this study with appropriate labelling.
219693702|NCT01225549|DRUG|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
219693703|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
219693704|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
219224525|NCT07012850|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|To reduce radiation exposure while simultaneously allowing for the visualization of soft tissues, newer imaging methods, including magnetic resonance imaging (MRI), as well as Black Bone and CT-like MRI protocols (ZTE, UTE), are being explored. These MRI techniques offer high-resolution, non-ionizing alternatives, showing promise for diagnosing soft tissue injuries and fractures without radiation risks.
219693705|NCT00578903|DRUG|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
219693706|NCT00578903|DRUG|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
219693707|NCT00578903|RADIATION|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
219693708|NCT00578903|DRUG|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
219693709|NCT00578903|DRUG|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
219693710|NCT00578903|PROCEDURE|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
219693711|NCT02858401|DRUG|Vesatolimod|Tablet(s) administered orally once every 2 weeks
219693712|NCT02858401|DRUG|Placebo|Tablet(s) administered orally once every 2 weeks
219693713|NCT02858401|DRUG|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
219693714|NCT00380900|DRUG|AGG-523|
219693715|NCT03046849|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation.
219107032|NCT00854516|PROCEDURE|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
219107033|NCT02260505|DRUG|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
219693716|NCT05803460|BEHAVIORAL|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
219693717|NCT05803460|BEHAVIORAL|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
219693718|NCT05803460|BEHAVIORAL|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
219693719|NCT05803460|BEHAVIORAL|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
219693720|NCT05803460|BEHAVIORAL|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
219693721|NCT05803460|BEHAVIORAL|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
219107034|NCT04011579|OTHER|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
219107035|NCT02932592|DEVICE|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
219693722|NCT05278897|DEVICE|Soft Tissue Adapted Biocompatible Hyaluronic Acid|1% sodium hyaluronate
219693723|NCT00299858|DRUG|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
219107036|NCT00280657|DRUG|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
219107037|NCT00280657|DRUG|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
219107038|NCT00280657|DRUG|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
219107039|NCT02454829|OTHER|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
219224526|NCT07013058|DIETARY_SUPPLEMENT|Nigella sativa extract (Nisatol®)|Participants will take 2 softgel capsules daily of Nigella sativa oil standardized to 10% thymoquinone (Nisatol®), one capsule with lunch and one with dinner, for 4 months.
219693724|NCT03371914|BEHAVIORAL|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
219693725|NCT02513550|DRUG|Ixekizumab|Administered SQ
219693726|NCT02513550|DRUG|Placebo|Administered SQ
219224527|NCT07013058|BEHAVIORAL|Mediterranean Diet|Participants will follow a Mediterranean diet for 4 months under dietary guidance, without receiving any Nigella sativa supplementation.
219693727|NCT00074893|DEVICE|piezoelectric wrist brace|
219693728|NCT00685516|DIETARY_SUPPLEMENT|green tea|6 cups of green tea daily for 2-8 weeks
219693729|NCT00685516|DIETARY_SUPPLEMENT|placebo|6 cups of water daily for 2-8 weeks
219693730|NCT00685516|DIETARY_SUPPLEMENT|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
219693731|NCT03804658|DEVICE|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
219693732|NCT04122261|DEVICE|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
219693733|NCT04122261|DEVICE|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
219693734|NCT01792739|DRUG|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
219693735|NCT01792739|DRUG|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
219693736|NCT04487990|DRUG|unfractionated Heparin|Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
219107040|NCT02975635|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
219107041|NCT04280822|DRUG|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"
219107042|NCT03848598|DIAGNOSTIC_TEST|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
219107043|NCT03810222|OTHER|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
219693737|NCT00290563|DRUG|MK0594|
219107044|NCT03323580|OTHER|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
219107045|NCT03323580|OTHER|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
219107046|NCT02402088|BEHAVIORAL|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
219107047|NCT02402088|BEHAVIORAL|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
219107048|NCT02402088|BEHAVIORAL|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
219107049|NCT03322371|DEVICE|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
219107050|NCT01370681|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001|
219107051|NCT01370681|DRUG|Period I : CJ30001, Period II : HKB0701 and SLM0807|
219107052|NCT02090634|BEHAVIORAL|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
219107053|NCT02090634|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
219107054|NCT04946929|DRUG|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
219107055|NCT04946929|DRUG|Low molecular weight heparin|half amount low molecular weight heparin
219107056|NCT03036059|DRUG|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
219107057|NCT05995301|DRUG|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
219107058|NCT05995301|DRUG|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
219107059|NCT01164462|BIOLOGICAL|blood test: rapid finger-stick blood specimen test|
219107060|NCT01164462|BIOLOGICAL|blood test: conventional test|
219107061|NCT06056622|OTHER|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
219693738|NCT06466343|PROCEDURE|hysteroscopic resection of lower edge of cesarean scar niche|"Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.~The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)"
219107062|NCT06056622|OTHER|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
219107063|NCT05643820|DRUG|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
219107064|NCT05643820|DRUG|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
219107065|NCT01457235|OTHER|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
219107066|NCT00167830|BEHAVIORAL|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
219107067|NCT00167830|BEHAVIORAL|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
219107068|NCT00167830|BEHAVIORAL|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
219107069|NCT02440802|GENETIC|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
219107070|NCT02390856|DEVICE|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
219107071|NCT02390856|DEVICE|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
219107072|NCT00838799|DRUG|RGH-896|45 mg TID, capsules, 14 weeks.
219107073|NCT00838799|DRUG|RGH-896|30 mg TID, capsules, 14 weeks.
219107074|NCT00838799|DRUG|RGH-896|15 mg TID, capsules, 14 weeks.
219107075|NCT00838799|DRUG|pregabalin|100 mg, TID, capsules, 14 weeks.
219107076|NCT00838799|DRUG|placebo|TID, capsules, 14 weeks.
219224528|NCT07012369|OTHER|Experimental group: sanitary pads with messages about family planning on them|"Sanitary pads with messages about family planning on them.~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Giving 2 packages of sanitary pads (14 in each package, 28 in total) with messages about family planning methods, Notifying that contact will be made three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participating in the study and saying goodbye."
219107077|NCT05710705|DEVICE|portable prototype of bioimpedance measurement|"The device will be installed during the patient's operation. It will be attached to the healthy skin of the flap (without wound or scar) by sterile glue. It will then be covered with a self-adhesive tegaderm type dressing. The wound will be isolated from the device with a hermetic silicone dressing of the Mepilex type, for example. There will therefore be no communication between the measuring device and the surgical wound."
219107078|NCT01257659|PROCEDURE|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
219107079|NCT01257659|PROCEDURE|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
219693739|NCT04046900|BIOLOGICAL|Vaginal microbiome transplant|Vaginal fluid from healthy donors
219693740|NCT04046900|DRUG|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
219693741|NCT04046900|OTHER|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
219693742|NCT01307956|DRUG|Fluorouracil|Given IV
219693743|NCT01307956|OTHER|Laboratory Biomarker Analysis|Correlative studies
219693744|NCT01307956|DRUG|Leucovorin Calcium|Given IV
219107080|NCT05023135|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
219107081|NCT02468635|OTHER|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
219107082|NCT02468635|OTHER|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
219107083|NCT03846414|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
219107084|NCT04152265|PROCEDURE|colonoscopy|colonoscopy
219107085|NCT04152265|OTHER|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
219107086|NCT04152265|OTHER|demographic data collections|completing the demographic questionnaire
219107087|NCT04152265|OTHER|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
219107088|NCT04152265|PROCEDURE|Collecte the biological samples|blood and faeces collections
219693745|NCT01307956|DRUG|Oxaliplatin|Given IV
219693746|NCT01307956|BIOLOGICAL|Panitumumab|Given IV
219693747|NCT01307956|OTHER|Pharmacological Study|Correlative studies
219693748|NCT01307956|RADIATION|Radiation Therapy|Undergo radiation therapy
219693749|NCT01307956|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219107089|NCT03604822|PROCEDURE|Music therapy|ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
219107090|NCT00671905|PROCEDURE|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
219107091|NCT00671905|PROCEDURE|PV isolation|Circumferential PV isolation
219107092|NCT05412810|OTHER|oxygen|oxygen exposure of more than 50% for 1.5 hours
219107093|NCT01320423|PROCEDURE|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
219107094|NCT05494229|OTHER|Pars-plana vitrectomy|Pars-plana vitrectomy
219107095|NCT04890795|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
219107096|NCT00886639|OTHER|6MWT with oxygen|2 liter per minute as continuous-flow
219107097|NCT00886639|OTHER|6MWT with medical air|2 liters as continuous-flow
219107098|NCT00308932|DRUG|HFA FP MDI|
219550715|NCT04997551|DRUG|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
219107099|NCT05694403|OTHER|Survey|Questionnaire
219107100|NCT02974816|DEVICE|Glooko's mobile application|Standard of care and Remote monitoring
219107101|NCT01338922|DEVICE|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
219107102|NCT01338922|DEVICE|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
219107103|NCT03203694|BEHAVIORAL|Walking: Intervention arm in diabetics|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
219107104|NCT03203694|OTHER|Walking: No intervention in diabetics|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
219107105|NCT03203694|OTHER|Walking: Healthy cohort as reference controls|Subjects will be studied at one time only.
219107106|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in healthy subjects|This intervention consists of 60 minutes of lower body heating (40-42 degree C).
219550716|NCT00000698|DRUG|Ganciclovir|
219550717|NCT02036398|DEVICE|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
219550718|NCT02036398|DEVICE|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
219107107|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in diabetics|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
219107108|NCT03203694|OTHER|Lower body heating: Healthy cohort as reference controls|Subjects will be studied at one time only.
219107109|NCT05999708|DRUG|GSK4381406|GSK4381406 will be administered.
219107110|NCT05999708|DRUG|Placebo|Placebo will be administered.
219107111|NCT05999708|DRUG|Indomethacin|Indomethacin will be administered.
219107112|NCT05024422|DRUG|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
219107113|NCT05024422|DRUG|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
219107114|NCT05982704|DRUG|tixagevimab/cilgavimab 150+150 mg|Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.
219107115|NCT05982704|DRUG|tixagevimab/cilgavimab 300+300 mg|Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.
219107116|NCT05982704|DRUG|regdanvimab|Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
219107117|NCT00984360|DRUG|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
219107118|NCT02122653|OTHER|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
219107119|NCT02122653|DEVICE|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
219107120|NCT02040558|DRUG|MNK-010|
219107121|NCT00977769|DRUG|carbetocin 100 µg|Hemodynamic effect of
219107122|NCT00977769|DRUG|oxytocin 5 u|Hemodynamic effect of
219107123|NCT00977769|DRUG|placebo (NaCl)|Hemodynamic effect of
219107124|NCT04195529|GENETIC|presence of genetic variants|identification of the presence of genetic variants
219107125|NCT00628914|DRUG|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
219107126|NCT00628914|DRUG|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
219107127|NCT00628914|DRUG|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
219107128|NCT05932056|BEHAVIORAL|Miles de Manos (Thousands of Hands)|Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
219693750|NCT04566107|BEHAVIORAL|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
219693751|NCT04566107|BEHAVIORAL|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
219693752|NCT02204917|DRUG|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
219693753|NCT04907292|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
219693754|NCT05896436|BEHAVIORAL|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
219693755|NCT00984932|DRUG|Rosuvastatin|40 mg of rosuvastatin daily
219693756|NCT04624113|DRUG|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
219693757|NCT04624113|DRUG|Pembrolizumab|Pembrolizumab is commercially available
219693758|NCT04071041|DRUG|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
219693759|NCT04256343|OTHER|Deuterium Oxide (D2O) Dose|1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
219693760|NCT01885013|DRUG|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
219693761|NCT01885013|DRUG|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
219693762|NCT04726735|BIOLOGICAL|Samples of bladder tissue|Samples of bladder tissue collected between 2007 and 2011.
219693763|NCT04188054|BEHAVIORAL|Change in sleeping position|The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.
219693764|NCT04188054|BEHAVIORAL|No change in sleeping position|No change to your normal sleeping position
219693765|NCT00937339|DEVICE|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
219693766|NCT00937339|DEVICE|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
219693767|NCT06115018|PROCEDURE|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
219693768|NCT06115018|BEHAVIORAL|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
219693769|NCT06115018|COMBINATION_PRODUCT|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
219693770|NCT00485355|PROCEDURE|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
219107129|NCT05854030|DIAGNOSTIC_TEST|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
219107130|NCT02578914|DRUG|NS2 Ophthalmic Drops (0.5%)|
219107131|NCT02578914|DRUG|NS2 Ophthalmic Drops Vehicle (0.0%)|
219107132|NCT01103960|DRUG|Telmisartan80mg+Amlodipine5mg|combination therapy
219107133|NCT01103960|DRUG|amlodipine 5mg|monotherapy
219107134|NCT01103960|DRUG|Telmisartan80mg+Amlodipine 5mg|combination therapy
219107135|NCT01215214|DRUG|midazolam|midazolam: 3mg iv
219693771|NCT00485355|PROCEDURE|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
219693772|NCT02499055|BEHAVIORAL|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
219107136|NCT03454425|DEVICE|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
219107137|NCT03454425|DEVICE|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
219107138|NCT04612816|OTHER|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
219107139|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
219107140|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
219107141|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
219107142|NCT02875834|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
219107143|NCT04732429|DRUG|HST5040|Liquid solution
219107144|NCT04732429|DRUG|Placebo|Liquid solution
219107145|NCT03396432|DEVICE|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
219107146|NCT03396432|DEVICE|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
219107147|NCT05893680|OTHER|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
219107148|NCT05893680|OTHER|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
219224529|NCT07012369|OTHER|Control group: not be given any materials|"Not be given any materials~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Notifying that contact will be established three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participation in the study and saying goodbye,"
219550719|NCT01196598|OTHER|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
219550720|NCT04431973|DEVICE|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
219550721|NCT05125276|DRUG|No aspirin|No aspirin
219550722|NCT05125276|DRUG|Aspirin|75-100 mg once daily
219550723|NCT01724762|OTHER|Nursing Orientation|"* Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
219550724|NCT03113227|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
219550725|NCT03113227|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
219550726|NCT00144222|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
219550727|NCT00144222|DRUG|Telmisartan 40 mg|
219550728|NCT00273130|PROCEDURE|transnasal endoscopy|
219550729|NCT00273130|PROCEDURE|transoral thin endoscopy|
219550730|NCT05465096|PROCEDURE|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
219550731|NCT00884390|DRUG|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
219550732|NCT00884390|PROCEDURE|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
219550733|NCT01152112|DEVICE|Myomectomy|Removal of fibroids and / or polyps
219550734|NCT05086913|OTHER|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
219550735|NCT05086913|OTHER|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
219550736|NCT05086913|OTHER|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
219550737|NCT05646238|OTHER|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
219693773|NCT04942886|DRUG|Baracle Tab.®|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
219107149|NCT05893680|DRUG|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
219107150|NCT05893680|OTHER|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
219693774|NCT00317915|DRUG|Irbesartan treatment|
219107151|NCT01032044|DEVICE|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
219107152|NCT01032044|DEVICE|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
219693775|NCT00379145|DRUG|trabectedin|
219107153|NCT03311230|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
219107154|NCT03311230|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
219107155|NCT03311230|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
219107156|NCT02973555|OTHER|PRP injection|autologous intrauterine infusion of PRP
219107157|NCT03342053|DRUG|RO7234292 (RG6042)|Intrathecal injection
219107158|NCT01302938|DRUG|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
219107159|NCT01302938|DRUG|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
219107160|NCT00957164|BEHAVIORAL|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
219107161|NCT00957164|BEHAVIORAL|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
219107162|NCT00957164|BEHAVIORAL|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
219107163|NCT05884229|OTHER|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
219107164|NCT01233609|DRUG|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
219107165|NCT01233609|DRUG|Placebo|Dosage per subject weight- same schedule as the active comparator
219107166|NCT02319733|DEVICE|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
219107167|NCT05505253|DRUG|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
219693776|NCT02765152|OTHER|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
219693777|NCT02765152|OTHER|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
219107168|NCT05505253|DRUG|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
219693778|NCT02765152|OTHER|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
219693779|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
219693780|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
219693781|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
219693782|NCT00514618|DRUG|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
219693783|NCT00514618|DIETARY_SUPPLEMENT|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
219693784|NCT00678418|DRUG|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
219693785|NCT00678418|DRUG|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
219693786|NCT03924323|DRUG|Escitalopram|8-weeks of treatment followed by 1-week taper down period
219693787|NCT03924323|OTHER|Placebo|Matching oral administration of inactive substance once daily
219693788|NCT00706680|DRUG|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
219693789|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
219693790|NCT03351712|BEHAVIORAL|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
219693791|NCT03351712|BEHAVIORAL|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
219693792|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
219693793|NCT03405727|DIETARY_SUPPLEMENT|Oral dietary supplements|Protein enriched diet
219107169|NCT01115543|DRUG|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
219693794|NCT06050213|DEVICE|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
219693795|NCT00529711|DRUG|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
219693796|NCT00529711|DRUG|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
219693797|NCT06550479|PROCEDURE|AVF|Distal forearm AVF for hemodialysis.
219693798|NCT03619473|BEHAVIORAL|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~* proper helmet wearing~* how to differentiate non-standard and standard helmets~* how to keep motorcycle safe using ABCD concept~* importance of wearing bright clothes~* police summon for not wearing helmets~* live demo on poor performance of non-standard helmet~* giving away standard motorcycle child safety helmets~* oath taking by parents and children~* distribution and placement of VEM on parents' motorcycles"
219107170|NCT05031676|OTHER|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
219224530|NCT07012941|DEVICE|Superpulse Thulium Fiber laser (SPTFL) ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Superpulsed Thulium Laser
219693799|NCT01584713|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
219693800|NCT04976127|DRUG|Talineuren|Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
219693801|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
219693802|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
219693803|NCT02805738|DRUG|CKD-390|CKD-390 1 Tablet (48 weeks)
219693804|NCT02805738|DRUG|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
219693805|NCT01597986|DRUG|isavuconazole|oral
219693806|NCT01597986|DRUG|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
219693807|NCT00662077|DRUG|Ibandronate|Ibandronate endovenous 3 mg every 3 months
219693808|NCT00662077|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
219107171|NCT03881930|OTHER|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
219107172|NCT03881930|OTHER|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
219107173|NCT00230139|DEVICE|SPECT/CT|
219107174|NCT04453241|BIOLOGICAL|NBP615|Intramuscular injection, 0.5ml
219107175|NCT04453241|BIOLOGICAL|Gardasil|Intramuscular injection, 0.5ml
219693809|NCT04362124|BIOLOGICAL|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
219693810|NCT04362124|OTHER|Placebo|A single dose intradermal application of normal saline solution.
219693811|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
219107176|NCT00204126|DEVICE|Treadmill with partial body weight support|
219107177|NCT00204126|DEVICE|Surface Functional Electrical Stimulation|
219107178|NCT02961374|DRUG|Erlotinib|Given PO
219107179|NCT02961374|DRUG|Erlotinib Hydrochloride|Given PO
219107180|NCT03178513|OTHER|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team"
219693812|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
219693813|NCT00666302|DRUG|tacrolimus ointment|topical
219693814|NCT00666302|DRUG|pimecrolimus cream|topical
219693815|NCT04182919|DRUG|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
219693816|NCT04182919|DRUG|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
219107181|NCT02291484|DEVICE|Cardiac CT scan|CT-guided management
219107182|NCT03386955|DRUG|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
219107183|NCT04670003|OTHER|users|Data of users of the web-application
219107184|NCT03664219|OTHER|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
219107185|NCT03835936|OTHER|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
219107186|NCT03835936|OTHER|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
219107187|NCT02069574|PROCEDURE|non-surgical periodontal therapy|
219107188|NCT03265990|PROCEDURE|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
219107189|NCT03265990|PROCEDURE|Conventional haemorrhoidectomy|"According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
219107190|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
219107191|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
219107192|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
219107193|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
219107194|NCT00735644|BIOLOGICAL|Hepatitis A vaccine|0.5 mL, Intramuscular
219107195|NCT05727943|DRUG|Clioquinol|add on clioquinol to concomitant ASM
219107196|NCT00003344|DRUG|irinotecan hydrochloride|
219107197|NCT00003344|RADIATION|radiation therapy|
219107198|NCT00002536|DRUG|cisplatin|
219107199|NCT00002536|DRUG|vincristine sulfate|
219107200|NCT00002536|PROCEDURE|surgical procedure|
219107201|NCT00002536|RADIATION|radiation therapy|
219107202|NCT01639794|DRUG|Vesitirim™ (Solifenacin)|Oral
219107203|NCT01586312|OTHER|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
219107204|NCT01586312|DRUG|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
219107205|NCT03966612|OTHER|Questionnaires|"Questionnaires about:~* Socio-professional situation~* Lifestyle~* Health~* NME 1~* specific breast cancer survey~* Imaging"
219107206|NCT04032379|OTHER|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
219107207|NCT00296387|DRUG|Rosuvastatin|
219107208|NCT00296387|DRUG|Atorvastatin|
219107209|NCT05126043|DIAGNOSTIC_TEST|Triglycerides/high density lipoprotein ratio|Lipid profile
219107210|NCT01325649|PROCEDURE|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
219224531|NCT07012941|DEVICE|Holmium: YAG laser ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Holmium: YAG Laser
219693817|NCT03356652|PROCEDURE|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
219693818|NCT05176639|DRUG|VRDN-001 Phase 3 Cohort (THRIVE)|5 IV Infusions of veligrotug (VRDN-001) 10mg/kg
219107211|NCT01325649|RADIATION|long course 5-FU bases radiochemotherapy|
219107212|NCT02587559|PROCEDURE|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
219107213|NCT00119990|DRUG|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
219107214|NCT00119990|DRUG|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
219107215|NCT05096468|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
219107216|NCT05096468|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
219107217|NCT01068301|DRUG|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
219107218|NCT03661034|DEVICE|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
219107219|NCT01327118|DRUG|Prostaglandin F2alpha|intravenous injection
219107220|NCT01327118|DRUG|Isoton sodium chloride|intravenous injection
219107221|NCT03029260|OTHER|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
219107222|NCT03029260|OTHER|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
219107223|NCT03274219|BIOLOGICAL|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
219107224|NCT05914025|BEHAVIORAL|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
219107225|NCT00654134|BIOLOGICAL|Clinical Center Reference Endotoxin|20,000 EU inhaled
219107226|NCT02780622|DRUG|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
219107227|NCT02780622|DRUG|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
219224532|NCT07012200|OTHER|Immersive Interactive Nursing Instruction|360-degree introduction to the environment of the cardiac catheterization laboratory, cardiac catheterization procedures (including preoperative, intraoperative, and postoperative), wound care, and precautions for home care (including diet, medication, and exercise)
219224533|NCT07012200|OTHER|Routine Nursing Instructions|Health education by talking and leaflets and key explanations, and providing talks and consultations
219693819|NCT05176639|DRUG|VRDN-001 Placebo|5 IV Infusions of veligrotug (VRDN-001) placebo
219693820|NCT03834493|BIOLOGICAL|Pembrolizumab|IV infusion
219693821|NCT03834493|DRUG|Enzalutamide|Capsules/Tablets
219107228|NCT02956434|BEHAVIORAL|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
219107229|NCT01100047|DRUG|AZD5069|Oral suspension
219107230|NCT01100047|DRUG|Placebo|Oral suspension
219107231|NCT01173640|DRUG|Midazolam|2 mg oral dose
219107232|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (single dose)|1 g oral dose
219107233|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (multiple dose)|1 g oral dose for 8 days
219107234|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
219693822|NCT03834493|DRUG|Placebo|IV infusion
219107235|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
219107236|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
219107237|NCT05147727|DRUG|Fluconazole、Famitinib|Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
219107238|NCT03346213|DRUG|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
219107239|NCT03039439|PROCEDURE|Biospecimen Collection|Previously collected tumor tissue and blood samples
219107240|NCT03039439|OTHER|Laboratory Biomarker Analysis|Correlative studies
219107241|NCT04826328|DRUG|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
219107242|NCT04826328|DRUG|Normal Saline|Single peripheral nerve injection
219107243|NCT06411990|DEVICE|Fenestrated Endovascular Aneurysm Repair using the LIFE Device System|Fenestrated Endovascular Aneurysm Repair
219107244|NCT04007445|BEHAVIORAL|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
219107245|NCT04007445|OTHER|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
219107246|NCT06291935|DRUG|VG901|"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"
219107247|NCT03280134|PROCEDURE|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
219107248|NCT03884114|OTHER|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
219107249|NCT03884114|OTHER|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
219107250|NCT03884114|OTHER|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
219107251|NCT01809041|DRUG|Sevoflurane|
219107252|NCT01809041|DRUG|propofol|
219107253|NCT01809041|DRUG|remifentanil|
219693823|NCT05078775|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
219107254|NCT05014581|DRUG|Noradrenaline|Pre-emptive continuous infusion of noradrenaline during the peri-intubation period
219107255|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine 0.25% and magnesium sulfate|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus 3.75 ml NS and 125 mg MgSO4 (1.25ml)."
219224534|NCT07012382|PROCEDURE|Inferior Alveolar Nerve Block|Administration of standard IANB with 2% lidocaine containing 1:80,000 epinephrine
219107256|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine and dememdetomidine|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg."
219107257|NCT04196218|OTHER|Driving simulator|Computer simulated driving assessment
219107258|NCT06384612|BEHAVIORAL|use of pocket cards|Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes
219107259|NCT01518946|DRUG|Midodrine HCl|dose at the subject's current dose level
219107260|NCT01518946|DRUG|Placebo|single dose of matching placebo
219107261|NCT01147692|BIOLOGICAL|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
219224535|NCT07012382|PROCEDURE|Inferior-Alveolar-Nerve-Block|Administration of IANB with 2% lidocaine containing 1:80,000 epinephrine
219107262|NCT04821739|DEVICE|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
219107263|NCT06645054|BEHAVIORAL|Standard rehabilitation|The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).
219550738|NCT05646238|OTHER|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
219550739|NCT02733211|DEVICE|MD- Logic Closed Loop System|Closed Loop System
219550740|NCT02733211|DEVICE|sensor augmented pump therapy|Sensor augmented pump therapy
219550741|NCT02473237|DRUG|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
219550742|NCT02473237|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
219550743|NCT04630795|DEVICE|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
219550744|NCT04630795|DEVICE|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
219550745|NCT00292760|DRUG|Alemtuzumab|
219550746|NCT00292760|DRUG|Methyprednisolone|
219550747|NCT06067789|PROCEDURE|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
219550748|NCT05348616|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
219550749|NCT05348616|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
219550750|NCT00415935|DRUG|methotrexate|
219550751|NCT00614276|BEHAVIORAL|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
219550752|NCT00614276|BEHAVIORAL|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
219550753|NCT00614276|BEHAVIORAL|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
219550754|NCT00614276|BEHAVIORAL|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
219550755|NCT01300273|DIETARY_SUPPLEMENT|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
219550756|NCT03981731|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~\- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
219550757|NCT05815394|DRUG|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
219550758|NCT03008616|BIOLOGICAL|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
219550759|NCT03008616|OTHER|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
219550760|NCT00951535|OTHER|questionnaire administration|
219550761|NCT00951535|PROCEDURE|quality-of-life assessment|
219550762|NCT00951535|RADIATION|image-guided radiation therapy|
219550763|NCT00951535|RADIATION|intensity-modulated radiation therapy|
219550764|NCT00951535|RADIATION|radiation therapy treatment planning/simulation|
219550765|NCT05753904|PROCEDURE|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
219550766|NCT01873391|PROCEDURE|Diagnostic hysteroscopy|
219693824|NCT05929027|BEHAVIORAL|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
219107264|NCT06645054|DEVICE|Lower-limb prosthesis|The patients from the LLL group will be fitted with an appropriate lower-limb prosthesis.
219107265|NCT06645054|DEVICE|Lower-limb orthosis|The patients from the LLO group will be fitted with an appropriate lower-limb orthosis.
219107266|NCT00384059|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
219107267|NCT00384059|BIOLOGICAL|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
219107268|NCT00384059|BIOLOGICAL|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
219107269|NCT00384059|BIOLOGICAL|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
219107270|NCT00384059|BIOLOGICAL|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
219107271|NCT05917223|DIETARY_SUPPLEMENT|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
219107272|NCT05917223|DIETARY_SUPPLEMENT|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
219107273|NCT05917223|DIETARY_SUPPLEMENT|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
219107274|NCT05917223|DIETARY_SUPPLEMENT|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
219107275|NCT00914277|DRUG|SAR407899|Oral administration
219107276|NCT00914277|DRUG|Placebo|Oral administration
219693825|NCT05929027|BEHAVIORAL|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, \<15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
219693826|NCT06283212|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
219693827|NCT06958978|DEVICE|Quantum RF|Patented handpiece device designed for skin rejuvenation and tightening through intraoperative subdermal Radiofrequency treatment.
219693828|NCT02756910|DEVICE|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
219107277|NCT00914277|DRUG|Sildenafil|Oral administration
219107278|NCT04601363|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
219107279|NCT01774071|DRUG|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan."
219107280|NCT01774071|DRUG|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
219107281|NCT04852588|PROCEDURE|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
219107282|NCT04852588|PROCEDURE|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
219107283|NCT06519825|OTHER|Exercise|Inspiratory muscle strength training program will be applied to the FHP-C group for 7 days/6 weeks.
219107284|NCT02493049|DRUG|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
219107285|NCT04632628|BEHAVIORAL|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
219107286|NCT06919172|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
219107287|NCT06619730|DEVICE|Sedline Brain Function Monitor|The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
219107288|NCT06619782|OTHER|Practice Facilitation|Practice facilitation (PF) is a supplemental support to increase competence and and adoption of the National Institute of Mental Health (NIMH) youth suicide prevention. pathway in primary care. Practices will receive 6 months of PF which involves clinic- and provider- level data review and adoption data for the 5 components of the prevention pathway, clinical coaching around implementing the different components , logistical coaching in identifying multilevel contextual barriers to implementation and strategies to overcome them
219693829|NCT06834126|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219693830|NCT06834126|PROCEDURE|Computed Tomography|Undergo CT
219693831|NCT06834126|DRUG|Consolidation Therapy|Receive CC with mFOLFOX6 or CAPOX
219693832|NCT06834126|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
219693833|NCT06834126|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
219107289|NCT06619782|OTHER|Training in National Institute of Mental Health Youth Suicide Prevention Pathway|Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
219107290|NCT06621966|OTHER|Olive Oil Topical Oil|The IVG will receive standard PI prevention care along with a topical application of olive oil for 7 consecutive days. PI point prevalence and baseline risk assessments will be performed prior to the intervention. Post-intervention assessments will be conducted from days 3 to 8. Descriptive statistics and paired sample t-tests will be utilized for data analysis.
219235405|NCT00362284|BEHAVIORAL|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
219693834|NCT06834126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219693835|NCT06834126|DRUG|Papaverine|Given IV
219693836|NCT06834126|RADIATION|Radiation Therapy|Undergo RT
219693837|NCT06834126|PROCEDURE|Total Mesorectal Excision|Undergo ToME
219693838|NCT03555851|DRUG|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
219693839|NCT03555851|OTHER|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
219693840|NCT04683640|DIETARY_SUPPLEMENT|GABA|Daily oral GABA for 4 weeks
219693841|NCT04683640|DRUG|Placebo|Daily oral Placebo for 4 weeks
219693842|NCT06523621|DRUG|Nivolumab|2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
219693843|NCT05674240|DEVICE|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
219693844|NCT05674240|COMBINATION_PRODUCT|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
219693845|NCT06408207|BEHAVIORAL|CGM Academy|Educational materials as well as online sessions with diabetes educators.
219693846|NCT03899779|OTHER|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
219693847|NCT03899779|OTHER|Online hypnotherapy|12 weeks treatment with online hypnotherapy
219693848|NCT03899779|OTHER|Online psychoeducation|12 weeks treatment with online psychoeducation
219693849|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
219693850|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
219693851|NCT05621863|OTHER|Aim 1 Meal Challenge 1|A meal challenge will be provided that contains 1 serving of peaches and 2 servings of strawberries as a smoothie and 2 servings of tomatoes and 1 serving of carrot as a vegetable dish.
219693852|NCT05621863|OTHER|Aim 1 Meal Challenge 2|A meal challenge will be provided that contains 1 serving of banana and 2 servings of peaches as a smoothie and 1 serving of tomatoes and 2 servings of green beans as a vegetable dish.
219693853|NCT05621863|OTHER|Aim 1 Meal Challenge 3|A meal challenge will be provided that contains 2 serving of bananas and 1 serving of strawberries as a smoothie and 1 serving of green beans and 2 servings of carrots as a vegetable dish.
219107291|NCT03768765|PROCEDURE|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
219693854|NCT05621863|OTHER|Aim 2 Typical American Diet|The diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. No bananas, strawberries, peaches, green beans, carrots, or tomatoes will be provided.
219693855|NCT05621863|OTHER|Aim 2 Typical American Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts less than or equal to 1 serving per day each.
219693856|NCT05621863|OTHER|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain whole grains and high amounts of fruits and vegetables, representative of the Dietary Guidelines for Americans. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts greater than or equal to 1 serving per day each.
219693857|NCT03041636|DRUG|Ruxolitinib|Given PO
219693858|NCT03041636|DRUG|Ruxolitinib Phosphate|Given PO
219693859|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
219693860|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
219693861|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
219693862|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
219693863|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
219693864|NCT01704365|BIOLOGICAL|Placebo|0.5mL IM Injection
219693865|NCT00076037|BIOLOGICAL|HIV CTL MEP administered with RC529-SE adjuvant|
219693866|NCT00076037|DRUG|GM-CSF|
219693867|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
219693868|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
219693869|NCT04192240|OTHER|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
219693870|NCT04192240|OTHER|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
219693871|NCT06332196|OTHER|Analysis of biological sample and clinical data|Analysis of biological sample and clinical data
219107292|NCT06623968|PROCEDURE|Dental implants|Long-term follow-up study on singel-tooth implants
219107293|NCT06875687|OTHER|Prostaglandin Analog-Based Eyelash Serum|This intervention consists of a prostaglandin analog-based eyelash serum applied once daily to the upper eyelid margin for six weeks. The serum contains dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE), a prostaglandin analog known to promote eyelash growth. The formulation also includes panax ginseng root extract, urtica dioica extract, panthenol, niacinamide, and biotinoyl tripeptide-1, which contribute to hair follicle nourishment. The study evaluates its effects on ocular surface integrity, tear film stability, and eyelash growth.
219107294|NCT06691893|DEVICE|RELiZORB|RELiZORB (immobilized lipase) is a therapeutic device designed to enhance fat absorption in patients receiving enteral tube feedings. It works by hydrolyzing fats found in enteral formulas. RELiZORB is a single-use cartridge that connects in-line with enteral feeding sets. It contains lipase covalently bound to small polymer beads, forming a complex called iLipase, which remains within the cartridge. As the enteral formula passes through the cartridge, its fat content is hydrolyzed upon contact with iLipase. This process is especially beneficial for the absorption of long-chain polyunsaturated fatty acids, which require hydrolysis by pancreatic lipase for proper intestinal absorption. RELiZORB is compatible with a wide variety of commercially available enteral formulas.
219107295|NCT04540302|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
219693872|NCT02718911|DRUG|LY3022855|Administered IV
219693873|NCT02718911|DRUG|Durvalumab|Administered IV
219693874|NCT02718911|DRUG|Tremelimumab|Administered IV
219107296|NCT04540302|DEVICE|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
219107297|NCT05786781|DEVICE|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
219107298|NCT06713460|BEHAVIORAL|BEAM|Multicomponent intervention
219107299|NCT01315730|DEVICE|Tactile Stimulation|See Arms
219107300|NCT06925360|DRUG|intravenous immunoglobulin|1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable 1\~2 times if necessary (5 days after the last infusion).
219107301|NCT05691361|DRUG|ADX-324|siRNA duplex oligonucleotide
219107302|NCT05691361|DRUG|Placebo|saline
219107303|NCT04259671|DEVICE|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
219693875|NCT01132183|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
219693876|NCT02728063|DIETARY_SUPPLEMENT|Lactibiane Tolerance|probiotics
219693877|NCT04198831|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
219693878|NCT04198831|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
219693879|NCT01447888|DRUG|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
219693880|NCT01447888|OTHER|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
219693881|NCT03812419|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
219693882|NCT03812419|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
219107304|NCT06796699|DRUG|GH56 Capsule|GH56 capsule for oral administration at specified doses on scheduled days.
219107305|NCT06899880|OTHER|Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.|Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.
219107306|NCT06899373|DEVICE|Continuous glucometer|The continuous glucometer is a wearable device that measures interstitial glucose levels 24 hours per day and transmits readings every one minute.
219107307|NCT06900309|OTHER|Specific exercise program|An 8-weeks specific exercise program based on lower limb plyomteric exercises
219107308|NCT06900309|OTHER|General exercise program|An 8-weeks of general exercise program focused on whole-body exercises
219107309|NCT06926309|OTHER|Peer mentoring|The peer mentor selected by the researchers will be given postpartum perineal care education and peer mentoring education. The peer mentor will prepare perineal care education materials under the supervision of the researchers. Then, the experimental group will be divided into small groups and given 4 hours of perineal care education to their peers.
219107321|NCT01830088|BEHAVIORAL|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
219107322|NCT01830088|BEHAVIORAL|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
219107323|NCT06901206|PROCEDURE|Neonatologist performed lung ultrasound|Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
219107324|NCT06900504|OTHER|Sleep hygiene education|A structured training booklet will be prepared to ensure sleep hygiene for individuals. In addition, sleep hygiene training will be provided to individuals.
219107325|NCT06831149|PROCEDURE|Removal of pharyngeal mucosa with decreased perfusion will be performed|Surgical removal of underperfused tissue versus nonremoval of tissue
219107326|NCT06831149|DEVICE|SPY-PHI|SPY Portable Handheld Imaging (SPY-PHI)
219107327|NCT06831149|DRUG|ICG (Indocyanine Green)|ICG will be used in conjunction with the SPY-PHI system for tissue imaging.
219107328|NCT06899425|OTHER|Hot pack|The participants will be treated by hot packs on neck for 15 minutes, 3 times per weeks for 12 weeks.
219107329|NCT06899425|OTHER|Kinesio tape|The participants will be treated by hot packs and kinesio tape. The tape will be placed for several days (3-5 days of application) then it will be removed and repeated for 12 weeks.
219107330|NCT04591977|DEVICE|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
219107331|NCT05164432|DIAGNOSTIC_TEST|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
219107332|NCT06925607|DRUG|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
219107333|NCT02556905|DRUG|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
219107334|NCT02556905|DRUG|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
219107335|NCT06927180|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
219107336|NCT06927180|DRUG|Pertuzumab|Pertuzumab
219107337|NCT06927180|DRUG|Albumin-Paclitaxel|Nab paclitaxel
219107338|NCT06927180|DRUG|Docetaxel|Docetaxel
219107339|NCT06927180|DRUG|Carboplatin|Carboplatin
219107340|NCT06927180|DRUG|Trastuzumab|Trastuzumab
219107341|NCT04961320|BEHAVIORAL|Occupational Therapy|Participate in OT session
219107342|NCT04961320|OTHER|Questionnaire Administration|Complete questionnaires
219107343|NCT04474015|DEVICE|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
219107344|NCT03177889|COMBINATION_PRODUCT|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics \[ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid\];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
219107345|NCT02762344|DRUG|heparin|routinary heparin administration during coronary angiography/PCI
219107346|NCT03350113|DEVICE|Blood sampling for analysis|Blood Sampling for Analysis
219107347|NCT00892190|DRUG|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
219107348|NCT00892190|DRUG|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
219107349|NCT03935464|BEHAVIORAL|PUMA|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
219107350|NCT00650390|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
219107351|NCT05046535|BEHAVIORAL|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
219107352|NCT05046535|GENETIC|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
219107353|NCT05046535|DIAGNOSTIC_TEST|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
219107354|NCT05046535|BEHAVIORAL|Smoking|Surveys that measure nicotine dependence and smoking behavior
219107355|NCT05764226|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
219107356|NCT05793710|BEHAVIORAL|The principle of laughter plus Qigong|"The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes."
219107357|NCT02281175|BEHAVIORAL|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
219107358|NCT02281175|BEHAVIORAL|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
219107359|NCT03481790|DRUG|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
219107360|NCT03481790|DRUG|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
219107361|NCT03743896|DRUG|Transdermal Glucosamine Cream|
219107362|NCT02712671|RADIATION|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
219107363|NCT02712671|PROCEDURE|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
219107364|NCT02712671|PROCEDURE|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
219107365|NCT02712671|PROCEDURE|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
219107366|NCT02712671|OTHER|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
219107367|NCT02712671|PROCEDURE|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
219107368|NCT00375141|DEVICE|Pulsed dye laser, Intense pulsed light|
219107369|NCT03164941|PROCEDURE|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
219107370|NCT00505726|PROCEDURE|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
219693883|NCT03184740|DEVICE|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
219693884|NCT03184740|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
219693885|NCT01172873|DRUG|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
219107371|NCT00235443|DRUG|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
219107372|NCT00376051|DRUG|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
219107373|NCT00296842|BEHAVIORAL|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
219107374|NCT04719403|OTHER|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
219107375|NCT03488290|BEHAVIORAL|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
219107376|NCT03488290|OTHER|Treatment as Usual|The Treatment as Usual group will receive routine care
219107377|NCT03313219|DRUG|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
219107378|NCT03029247|DRUG|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
219107379|NCT03029247|DRUG|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
219107380|NCT00206154|DRUG|Budesonide/formoterol pMDI|
219107381|NCT00206154|DRUG|Budesonide pMDI|
219107382|NCT00206154|DRUG|Formoterol Turbuhaler|
219107383|NCT01045122|DRUG|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
219107384|NCT01045122|DRUG|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
219107385|NCT00807521|DRUG|Dexamethasone|Single high dose bolus of dexamethasone before surgery
219107386|NCT00807521|DRUG|Placebo|Placebo for dexamethasone
219693886|NCT01172873|BEHAVIORAL|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
219693887|NCT05870852|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
219693888|NCT05870852|OTHER|PNF|PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
219693889|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
219693890|NCT00983372|DRUG|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
219107387|NCT01048645|DRUG|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
219107388|NCT01048645|OTHER|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
219107389|NCT02606955|DEVICE|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
219107390|NCT01976364|DRUG|Tofacitinib|Tofacitinib 5 mg tablet twice daily
219107391|NCT01976364|DRUG|Tofacitinib|Tofactinib 10 mg tablet twice daily
219107392|NCT01976364|DRUG|Methotrexate|Methotrexate 7.5-20 mg weekly
219107393|NCT01976364|DRUG|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
219107394|NCT02757521|DRUG|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
219107395|NCT02757521|DRUG|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
219107396|NCT02851966|PROCEDURE|mTESE|mTESE time may be postponed or advanced.
219107397|NCT00586079|PROCEDURE|Deep brain stimulation surgery.|Deep brain stimulation surgery.
219693891|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
219693892|NCT04175171|DRUG|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
219693893|NCT04175171|DRUG|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
219693894|NCT06281561|DRUG|Normal Saline|Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
219693895|NCT06281561|DRUG|Dexmedetomidine|Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
219693896|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
219693897|NCT04690348|PROCEDURE|Craniotomy|Craniotomy
219693898|NCT04690348|RADIATION|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
219693899|NCT00359203|DEVICE|Dual chamber pacemeker|
219107398|NCT03369184|DRUG|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
219107399|NCT03369184|OTHER|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
219693900|NCT00190788|DRUG|Drotrecogin Alfa (Activated)|
219693901|NCT00190788|DRUG|placebo|
219693902|NCT00889941|PROCEDURE|LASIK|laser-assisted in situ keratomileusis
219107400|NCT01279330|OTHER|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
219107401|NCT01279330|OTHER|Control|No intervention (Patients receive by mail the materials needed for stool samples).
219107402|NCT05264610|OTHER|Data collection (Laboratory tests, Radiologic diagnostics, Patient data taken from existing medical charts)|Data collection: Bone turnover laboratory parameters: alkaline phosphatase (AP), calcium (corrected for albumin), PTH, Calcidiol (25-OH-D3), N-terminales Kollagen Typ 1 -. Propeptid (P1NP), glomerular filtration rate (GFR), calcium/creatinine (in urine); Radiologic diagnostics: Bone densitometry (DEXA), X-rays, computer tomograms, MRI for analysis of time of the bone healing (or a non-union); Patient data taken from existing medical charts: side effects, tolerability of PTH, patient compliance, presence of previous illnesses as risk factors for the formation of pseudoarthrosis, indication for therapy, time at which therapy started and length of therapy with PTH, precise characterization of the operation (type and whether it is a revision or first operation).
219107403|NCT04811963|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
219107404|NCT00003511|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219107405|NCT00462722|DRUG|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
219107406|NCT00462722|DRUG|Placebo|with each exercise session (up to 5 days per week) for 9 months
219107407|NCT00462722|BEHAVIORAL|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
219107408|NCT01306721|DRUG|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
219107409|NCT01306721|DRUG|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
219107410|NCT01306721|DRUG|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
219107411|NCT01306721|DRUG|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
219107412|NCT01395043|PROCEDURE|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
219107413|NCT01395043|DRUG|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
219107414|NCT05990920|BIOLOGICAL|SNK02|SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
219107415|NCT02949674|DRUG|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
219107416|NCT02949674|DRUG|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
219107417|NCT02333929|DEVICE|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
219107418|NCT04853147|DRUG|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
219107419|NCT04853147|DRUG|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
219107420|NCT02569450|BEHAVIORAL|Surgical outcomes monitoring using Shewhart control chart|"* Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization"
219107421|NCT03355963|OTHER|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
219224536|NCT07013331|OTHER|[18F]MPPF PET-MRI|"Patients will be seen during an first inclusion visit during which a review of eligibility criteria, medical history and a clinical examination will be done. Participants will be scheduled for a PET-MRI scan within 2 to 8 weeks. For all women of childbearing age a urine pregnancy test will be performed before the PET-MRI.~Anatomical MR imaging will be first acquired for anatomical co-registration and morphometry analyses (Neuromelanin sensitive images and 3D anatomical T1-weighted covering the whole brain volume with 1mm3 cubic voxels) After i.v. injection of a bolus of 180 MBq ± 10%, with a maximum of 198 MBq MBq, of \[18F\]-MPPF, a dynamic emission scan consisting of 35 frames of increasing duration (20s to 5min) will be acquired over 90-min post-injection"
219224537|NCT07012902|DRUG|Etomidate|Group A was induced with etomidate, the initial dose was 0.120mg/kg, and the ratio of adjacent doses was 1:0.6
219224538|NCT07012902|DRUG|Remimazolam|Group B was induced with remimazolam, the initial dose was 0.20mg/kg, and the ratio of adjacent doses was 1:0.8
219224539|NCT07012902|DRUG|Remimazolam-etomidate|In group C, 0.25ED50 remimazolam +0.75ED50 etomidate was used as the initial measurement In group D, 0.5ED50 remimazolam +0.5ED50 etomidate was used as the initial measurement In group E, 0.75ED50 of remimazolam +0.25ED50 of etomidate was used as the initial measurement
219224540|NCT07013084|BEHAVIORAL|3D VR smoking cessation program|Participants in the experimental group engaged with the VR system using a head-mounted display, allowing for full immersion in the virtual environment.
219224541|NCT07014553|BEHAVIORAL|web based nursing navigator programme|health education guidance surveillance case management
219224542|NCT07017192|PROCEDURE|SIFI Block|Infiltration of local anesthetics in the suprainguinal iliac fascia (Ropivacaine 0.375 40 mls)
219693903|NCT05469529|DRUG|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
219693904|NCT03147872|OTHER|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
219693905|NCT01956890|DRUG|PET|18F-FLT PET and MRI of the breast
219693906|NCT04091464|BEHAVIORAL|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
219693907|NCT04091464|BEHAVIORAL|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
219693908|NCT05499975|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
219693909|NCT01898247|OTHER|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
219107422|NCT03355963|BIOLOGICAL|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
219107423|NCT03355963|BIOLOGICAL|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
219224543|NCT07017192|PROCEDURE|ESP block|Infiltration of local anesthetics in the fascial plane underneath the erector spoinae mulscle at lumbar level (Ropivacaine 0.375 40 mls)
219693910|NCT05863819|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
219693911|NCT01463787|PROCEDURE|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
219693912|NCT01463787|PROCEDURE|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
219693913|NCT05801003|DEVICE|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
219693914|NCT05801003|DEVICE|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
219693915|NCT04458675|DEVICE|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
219693916|NCT04458675|DRUG|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
219693917|NCT00904007|OTHER|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
219693918|NCT00902070|DRUG|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
219107424|NCT06457100|DRUG|Esmolol Injection|Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.
219107425|NCT06457100|DRUG|Lidocaine IV|Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
219107426|NCT00404534|DRUG|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
219107427|NCT01708889|BIOLOGICAL|BMS-914143 (Peginterferon Lambda-1a)|
219107428|NCT06529900|BEHAVIORAL|oral mastication training|Through specific exercises and techniques aimed at enhancing masticatory function and overall oral health.
219107429|NCT06529900|BEHAVIORAL|texture and diet education|Teach the knowledge and techniques of softening food textures.
219107430|NCT06017687|DEVICE|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
219107431|NCT00823550|DRUG|Entecavir|entecavir 0.5 mg QD
219107432|NCT00823550|DRUG|Lamivudine|lamivudine 100 mg QD
219224544|NCT07017829|BIOLOGICAL|Anti-CFH Monoclonal Antibody GT103|Given IV
219224545|NCT07017829|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219224546|NCT07017829|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219224547|NCT07017829|PROCEDURE|Computed Tomography|Undergo CT
219224548|NCT07017829|PROCEDURE|Echocardiography Test|Undergo ECHO
219224549|NCT07017829|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219224550|NCT07017829|BIOLOGICAL|Pembrolizumab|Given IV
219224551|NCT07011836|BEHAVIORAL|mNav Interactive Video + Navigator|A personalized, video-based tool paired with navigator support to address individual screening barriers.
219107433|NCT03376841|DRUG|Cenicriviroc|1 tablet; single-dose oral administration
219693919|NCT05626309|DRUG|Qizhu Yuling Prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
219693920|NCT05626309|DRUG|Placebo|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
219693921|NCT04521595|BEHAVIORAL|Weigh Smart Telehealth intervention|Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
219693922|NCT02793765|DRUG|Docetaxel|
219693923|NCT02793765|BIOLOGICAL|Sipuleucel-T|
219693924|NCT01032447|BEHAVIORAL|Navigator Support|Standard of Care
219693925|NCT03838939|OTHER|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
219693926|NCT03490955|OTHER|salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning
219693927|NCT03490955|OTHER|salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
219693928|NCT03490955|OTHER|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
219693929|NCT03490955|OTHER|salad|Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning
219693930|NCT03490955|OTHER|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning
219693931|NCT03490955|OTHER|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning
219693932|NCT03490955|OTHER|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning
219693933|NCT03490955|OTHER|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
219107434|NCT05980429|OTHER|Music Therapy, prescribed|"All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group."
219107435|NCT05980429|OTHER|Music Therapy, self-selected|All music pieces were self-selected by the participant
219107436|NCT01668433|DRUG|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
219107437|NCT02318719|DRUG|Placebo|Placebo
219107438|NCT02318719|DRUG|DS-5565|
219107439|NCT02767635|DRUG|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
219107440|NCT02767635|DRUG|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
219107441|NCT02767635|DRUG|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
219107442|NCT01868035|DRUG|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
219224552|NCT07011836|BEHAVIORAL|Educational Video|A culturally tailored cervical cancer education video without additional support or tailoring.
219235406|NCT00886834|DRUG|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
219235407|NCT00886834|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
219693934|NCT03151850|OTHER|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
219693935|NCT03151850|OTHER|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
219693936|NCT01826942|DEVICE|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
219693937|NCT01826942|DEVICE|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
219107443|NCT02492646|PROCEDURE|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
219107444|NCT02492646|PROCEDURE|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
219107445|NCT03656484|DRUG|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
219107446|NCT03656484|DRUG|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
219107447|NCT03103022|DRUG|Acetaminophen|Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
219107448|NCT03103022|DRUG|ibuprofen|Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
219107449|NCT00432835|DEVICE|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
219107450|NCT05707650|PROCEDURE|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
219107451|NCT00802659|RADIATION|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
219107452|NCT06037174|PROCEDURE|minimally invasive procedure|different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)
219107453|NCT06037174|PROCEDURE|Conventional Open Surgery|Conventional Open Surgery
219693938|NCT05560620|BEHAVIORAL|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
219107454|NCT04853862|OTHER|questionnaire|Questionnaire for health-related quality of life evaluation
219107455|NCT00164853|PROCEDURE|endoscopic balloon dilatation|Refer to description under arms
219693939|NCT05560620|OTHER|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
219693940|NCT05560620|OTHER|No Caffeine|De-caffeinated coffee
219693941|NCT01559805|BEHAVIORAL|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
219693942|NCT01559805|BEHAVIORAL|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
219693943|NCT04666545|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
219693944|NCT02415543|PROCEDURE|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
219693945|NCT02415543|PROCEDURE|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
219107456|NCT00164853|PROCEDURE|Standard sphincterotomy|Refer to under arms
219107457|NCT03393299|PROCEDURE|STOPP/START criteria|software which helps to do the drug reconciliation
219107458|NCT03959774|DEVICE|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
219107459|NCT01704885|BEHAVIORAL|Play Intervention|
219107460|NCT01704885|OTHER|Questionnaires|
219107461|NCT03685032|DRUG|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
219107462|NCT03685032|DRUG|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
219107463|NCT03685032|DRUG|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
219693946|NCT02631395|OTHER|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
219693947|NCT02631395|OTHER|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
219107464|NCT04130711|OTHER|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
219693948|NCT00617357|DEVICE|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
219693949|NCT03806543|DRUG|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
219693950|NCT00373503|DRUG|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
219693951|NCT00373503|DRUG|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
219693952|NCT00373503|DRUG|Marijuana|marijuana intoxication, withdrawal and relapse assessed
219693953|NCT01917279|DRUG|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
219107465|NCT04130711|OTHER|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
219107466|NCT04130711|OTHER|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
219107467|NCT02916082|PROCEDURE|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
219107468|NCT00423293|DRUG|fluorouracil|1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
219693954|NCT01917279|DRUG|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
219693955|NCT01917279|DRUG|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
219693956|NCT03792646|DIETARY_SUPPLEMENT|Whey protein|Exercise training + 20g whey protein
219693957|NCT03792646|OTHER|Exercise training|Strength exercise
219693958|NCT02524639|DRUG|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
219693959|NCT01764841|DRUG|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
219693960|NCT01764841|DRUG|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
219693961|NCT03311191|DEVICE|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
219107469|NCT00423293|DRUG|mitomycin C|10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.
219224553|NCT07012070|BEHAVIORAL|supervised exercise therapy (SET)|Supervised exercise therapy (SET) is a structured program of exercise designed for individuals with peripheral artery disease (PAD) and intermittent claudication (IC). It consists of 12 weeks of intermittent treadmill walking to moderate to severe claudication pain at a speed of ≈2 mph and at a grade equal to 40% of the highest workload achieved during the baseline maximal treadmill test, with intermittent period of rest, for at least 3 times per week with a minimum of 30-45 minutes per session
219693962|NCT05639517|OTHER|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
219693963|NCT05639517|OTHER|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
219693964|NCT05289700|DEVICE|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
219693965|NCT05289700|DEVICE|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
219693966|NCT02865863|DIETARY_SUPPLEMENT|Eurycomalongifoliawater extract (Physta®)|
219693967|NCT02865863|DIETARY_SUPPLEMENT|Placebo|
219693968|NCT02865863|DIETARY_SUPPLEMENT|Multivitamin|
219693969|NCT00006015|BIOLOGICAL|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)
219693970|NCT00006015|DRUG|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
219693971|NCT00006015|DRUG|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
219693972|NCT00006015|DRUG|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
219693973|NCT00866905|DRUG|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
219693974|NCT00866905|DRUG|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
219693975|NCT00040599|DRUG|hMN14 (labetuzumab)|
219693976|NCT05030844|BEHAVIORAL|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
219693977|NCT05767489|COMBINATION_PRODUCT|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
219693978|NCT01103323|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
219693979|NCT01103323|DRUG|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
219693980|NCT01103323|OTHER|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
219693981|NCT00248209|DRUG|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
219693982|NCT06852170|OTHER|Co-Design Sessions (CDS)|CDS uses principles and activities from Liberating Structures (LS) and Group Model Building (GMB). Each method uses semi-structured processes for engaging partners to collaborate with one another and address complex problems. Example activities and discussions include: identifying a shared vision for how data can inform decisions related to substance use service delivery and overdose prevention; identifying relevant data that should be disseminated; identifying decisions to be supported with data. Methods from human-centered design - an approach for developing products that are useful and easy to use - will be used to refine data products developed by the study team so that the data products are acceptable and useful to end users. Together, these three methods (Liberating Structures, group model building, human-centered design) will be used to engage partners to iteratively co-design products for disseminating data back to partners to inform their daily substance use service delivery.
219693983|NCT06852170|OTHER|Data products|Data products disseminate localized data from local, state, or regional-level data sources to local (i.e., county) decision makers to inform their daily decision-making. Data products in counties assigned to CDS will receive fully tailored data products, while no-CDS counties will receive standardized data products. A suite of data products will be made available to inform diverse decisions by a variety of end users. Data products will be identified and prioritized during CDS, but may include reports, policy briefs, journey maps, and technical assistance for data interpretation.
219107470|NCT00423293|RADIATION|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes \> 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
219693984|NCT06232967|PROCEDURE|Primary tumor resection or not|For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
219107471|NCT02676752|PROCEDURE|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
219107472|NCT02676752|OTHER|Questionnaire Administration|Completion of questionnaires
219107473|NCT02676752|PROCEDURE|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
219107474|NCT02430818|DRUG|ketamine|
219107475|NCT02430818|DRUG|morphine|
219107476|NCT02486549|PROCEDURE|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
219107477|NCT02486549|PROCEDURE|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
219107478|NCT02486549|DRUG|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
219107479|NCT02486549|DEVICE|Ultrasound|The Ultrasound will be used for brachial plexus visualization
219693985|NCT00732069|DRUG|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
219693986|NCT00732069|DRUG|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
219693987|NCT00732069|DRUG|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
219693988|NCT03640169|OTHER|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
219693989|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
219693990|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
219693991|NCT00577317|OTHER|Quality-of-Life Assessment|Ancillary studies
219693992|NCT04460326|DRUG|Insulin glargine|Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%
219693993|NCT04460326|DRUG|NovoLog|Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
219693994|NCT04460326|DRUG|Insulin Fiasp|Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
219693995|NCT04460326|OTHER|Standard carbohydrate diet|Standard carbohydrate diet as per usual hospital care (75g with each meal)
219693996|NCT06209073|OTHER|Virtual Reality exercise|after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
219693997|NCT06209073|OTHER|conventional treatment|the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
219693998|NCT00631254|PROCEDURE|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
219107480|NCT02342925|OTHER|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
219107481|NCT02342925|DRUG|RG1662|Oral administration twice daily
219107482|NCT02342925|DRUG|metformin|Single 850 mg dose of metformin
219107483|NCT01912222|DRUG|IXAZOMIB|
219693999|NCT00631254|PROCEDURE|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
219694000|NCT02209363|DEVICE|auto-adjusting positive airway pressure|nightly use for 6 months
219694001|NCT02209363|OTHER|Nasal dilator strips|nightly use for 6 months
219694002|NCT01331369|BEHAVIORAL|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
219694003|NCT01331369|OTHER|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
219694004|NCT01345812|DRUG|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
219694005|NCT01345812|DRUG|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
219107484|NCT01862458|BIOLOGICAL|tPA alone|
219107485|NCT01862458|BIOLOGICAL|tPA plus dornase|
219107486|NCT03902938|BIOLOGICAL|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
219107487|NCT03902938|OTHER|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
219107488|NCT01727492|DRUG|Antioxidantia|
219107489|NCT03904537|BIOLOGICAL|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
219107490|NCT03051490|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
219107491|NCT03051490|DRUG|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
219107492|NCT05112341|RADIATION|radiation therapy|the patient first is simulated then delineation is done
219107493|NCT04821999|DEVICE|a 940-nm diode laser|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
219694006|NCT03686072|PROCEDURE|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
219694007|NCT00004293|DRUG|glucocerebrosidase|
219694008|NCT02151617|DRUG|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
219694009|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
219694010|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
219694011|NCT02151617|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219694012|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
219694013|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
219694014|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
219107494|NCT03529448|DRUG|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
219107495|NCT03529448|DRUG|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
219107496|NCT03529448|RADIATION|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
219107497|NCT01138930|DRUG|Berberine|1.5g daily for 3 month
219107498|NCT01138930|DRUG|Placebo|placebo daily
219107499|NCT03535402|DRUG|Sarilumab|SC administration of 200 mg twice a week
219107500|NCT06365307|COMBINATION_PRODUCT|"Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)"|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
219107501|NCT06365307|OTHER|Synthetic osteoplastic material based on β-TCP or bone autograft|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
219107502|NCT05815927|DRUG|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
219107503|NCT05815927|RADIATION|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
219107504|NCT02328092|DEVICE|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
219694015|NCT02151617|DRUG|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
219694016|NCT02151617|DRUG|PF-06743649|Tablet, to be decided dose, once daily, 14 days
219694017|NCT02151617|DRUG|Placebo|Tablet, once daily, 14 days
219694018|NCT06255080|OTHER|Training intervention|"The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared."
219694019|NCT00583310|BEHAVIORAL|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
219694020|NCT03160716|DEVICE|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
219694021|NCT01831895|DEVICE|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
219694022|NCT01443169|DRUG|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694023|NCT01443169|DRUG|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694024|NCT01443169|DRUG|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694025|NCT01443169|DRUG|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
219694026|NCT01443169|DRUG|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
219694027|NCT01443169|DRUG|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694028|NCT01443169|DRUG|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
219694029|NCT01443169|DRUG|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694030|NCT01443169|DRUG|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694031|NCT01443169|DRUG|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
219694032|NCT01443169|DRUG|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694033|NCT01443169|DRUG|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694034|NCT01443169|DRUG|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
219107505|NCT02421900|OTHER|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
219107506|NCT05340751|DIAGNOSTIC_TEST|Blood drawn|Hemoglobin and Hematocrit Levels
219107507|NCT00118625|BIOLOGICAL|Tree MATA MPL|
219107508|NCT04399551|DRUG|CAB OLI|CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
219107509|NCT04399551|DRUG|CAB LA|CAB LA 600 mg will be administered as intramuscular (IM) injection.
219235408|NCT00900302|GENETIC|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
219694035|NCT01443169|DRUG|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694036|NCT01443169|DRUG|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
219694037|NCT01443169|DRUG|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
219694038|NCT01443169|DRUG|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694039|NCT01443169|DRUG|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694040|NCT01443169|DRUG|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
219694041|NCT01443169|DRUG|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
219107510|NCT04399551|DRUG|RPV OLI|RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
219107511|NCT04399551|DRUG|RPV LA|RPV LA 900 mg will be administered as IM injection.
219107512|NCT04399551|OTHER|Continuous Quality Improvement (CQI) calls|CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
219107513|NCT05469542|DEVICE|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
219107514|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
219107515|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
219107516|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
219107517|NCT00420134|PROCEDURE|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
219694042|NCT04794751|DEVICE|JJVC Investigational Multifocal Contact Lens|senofilcon A C3
219694043|NCT04794751|DEVICE|Dailies Total 1® Multifocal Contact Lens|delefilcon A
219694044|NCT05662020|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.
219694045|NCT05662020|BIOLOGICAL|GARDASIL® 9|20-26 years possitive control group will be vaccinated at months 0, 2 and 6
219694046|NCT02928796|BEHAVIORAL|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
219694047|NCT04036721|DRUG|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
219694048|NCT04036721|DRUG|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
219694049|NCT00914407|DRUG|Oxygen|100% Oxygen inhalation for 30 minutes
219694050|NCT04892732|DRUG|Budesonide|Budesonide dispensing claim is used as the reference group.
219694051|NCT04892732|DRUG|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
219107518|NCT02961881|DRUG|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
219107519|NCT06428149|PROCEDURE|Midline interproximal soft-tissue incision|Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
219694052|NCT04426097|PROCEDURE|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
219694053|NCT04426097|PROCEDURE|Without Blockade|Without Blockade
219694054|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
219694055|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
219694056|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
219107520|NCT06428149|PROCEDURE|Marginal approach by palatal incision|First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
219107521|NCT06428149|PROCEDURE|Minimally invasive surgical technique|The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
219107522|NCT02803567|BEHAVIORAL|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
219107523|NCT05429658|DEVICE|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
219107524|NCT02268617|OTHER|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
219107525|NCT03579797|BEHAVIORAL|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
219107526|NCT05246072|DRUG|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
219107527|NCT05246072|DRUG|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
219107528|NCT03720782|DEVICE|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
219107529|NCT01912781|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
219107530|NCT01912781|DEVICE|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
219694057|NCT05525546|OTHER|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
219694058|NCT02395068|DRUG|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
219107531|NCT01912781|DEVICE|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
219107532|NCT01982214|DEVICE|sedentary|No intervention
219107533|NCT01982214|DEVICE|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
219694059|NCT02395068|DRUG|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
219107534|NCT04183634|DRUG|Rotigotine TTS (Test)|Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
219107535|NCT04183634|DRUG|Neupro (Reference)|Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
219107536|NCT01971580|DRUG|Ambrisentan|
219694060|NCT04321902|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
219107537|NCT00701337|DRUG|oestradiol|oestradiol 2 mg oral route 30 days
219694061|NCT04297202|DRUG|Apatinib Combined With SHR-1210 Injection|"3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;"
219694062|NCT02383524|PROCEDURE|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
219694063|NCT05476393|OTHER|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
219694064|NCT02491138|BEHAVIORAL|Appearance-based intervention|
219694065|NCT02491138|OTHER|Pamphlets|
219694066|NCT02038556|BEHAVIORAL|cognitive behaviorial therapy -Insomnia|
219107538|NCT00701337|DRUG|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
219107539|NCT05691348|PROCEDURE|Ambulatory appendectomy|Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
219107540|NCT05691348|PROCEDURE|Conventional appendectomy|Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
219107541|NCT00854295|DEVICE|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
219107542|NCT01014221|OTHER|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
219107543|NCT01014221|DRUG|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
219107544|NCT06384378|DRUG|11C-ER176|ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
219107545|NCT04923295|DRUG|Dapagliflozin 10Mg Tab|Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
219107546|NCT00953914|DRUG|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
219107547|NCT00953914|DRUG|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
219107548|NCT04856943|PROCEDURE|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
219107549|NCT04856943|OTHER|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
219107550|NCT03154359|DRUG|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
219107551|NCT04250337|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
219107552|NCT04250337|OTHER|Placebo|Subcutaneous injection
219107553|NCT04250337|OTHER|Topical Corticosteroid|Topical Corticosteroid
219107554|NCT04127084|DRUG|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
219107555|NCT02301637|DEVICE|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
219107556|NCT00003284|BIOLOGICAL|filgrastim|
219107557|NCT00003284|DRUG|carboplatin|
219107558|NCT00003284|DRUG|etoposide|
219107559|NCT00003284|DRUG|ifosfamide|
219107560|NCT00003284|DRUG|paclitaxel|
219107561|NCT00003284|PROCEDURE|peripheral blood stem cell transplantation|
219107562|NCT00003284|RADIATION|radiation therapy|
219107563|NCT00026897|PROCEDURE|Gamma-camera imaging|
219107564|NCT00026897|PROCEDURE|Low-risk biopsy|
219694067|NCT00974363|PROCEDURE|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
219107565|NCT04208360|DEVICE|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
219694068|NCT04221919|DRUG|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
219107566|NCT06391814|BIOLOGICAL|EBV-specific T cells|Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells
219107567|NCT02611310|OTHER|No intervention|No intervention administered in this study.
219107568|NCT03497494|PROCEDURE|2 cm away from the pylorus edge|2 cm away from the pylorus edge
219107569|NCT03497494|PROCEDURE|4 cm away from the pylorus edge|4 cm away from the pylorus edge
219107570|NCT03497494|PROCEDURE|6 cm away from the pylorus edge|6 cm away from the pylorus edge
219107571|NCT03497494|PROCEDURE|LRYGB|laparoscopic Roux-en-Y gastric bypass
219107572|NCT01582880|DRUG|Riboflavin|Used to treat donor cornea before implantation
219107573|NCT02874664|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
219107574|NCT02027363|DRUG|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
219107575|NCT02027363|OTHER|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
219224554|NCT07012070|DEVICE|Wearable activities monitor (WAM)|The WAM use in this study is the FitBit Inspire 3 Advanced Activity Tracker (FitBit Inc. San Francisco, CA, USA), which is a commercially available tri-axis accelerometer and heart rate monitor capable of continuous monitoring of heart rate using LED sensor, and activities including daily steps count and derived daily activity level, detection of arrythmia and measuring peripheral capillary oxygen saturation. Fitbit devices connect with HOBBIT-PAD platform which was developed specifically for patients with PAD based on user-centred design. It contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. Important and thorough customizations will be made to tailor this mobile health platform for this study, which includes the addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise.
219224555|NCT07012070|BEHAVIORAL|enhanced HBET|Instructions for HBET are programmed according to the AHA recommendation on the exercise programs for patients with PAD and are automatically generated by the mobile apps. Patients will be prompted to use the exercise function on the mobile apps at least 3 times per week. Once the exercise function is activated, it will extract the steps counts and the walking pace from the WAM during exercise. Patients will be instructed to walk to maximal claudication symptom before stopping, at which point they will press pause on the WAM which will mark the claudication onset time. After the claudication subside, they can resume walking and resume recording on their WAM. Each exercise session will last for 45 minutes excluding rest periods, but the subject can terminate the exercise before the session ends.
219694069|NCT04145856|DIETARY_SUPPLEMENT|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
219694070|NCT04145856|COMBINATION_PRODUCT|I31 probiotic combined to Alverine/Simethicone|"* I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
219694071|NCT04145856|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
219694072|NCT05705830|DEVICE|Pulse magnetic therapy|Pulse magnetic therapy SM-II (2019102133903)
219694073|NCT05705830|DRUG|Selective serotonin reuptake inhibitors （SSRI）|Anti-anxiety Drugs
219694074|NCT05705830|DEVICE|Shame magnetic therapy|Shame magnetic therapy
219694075|NCT01981668|DRUG|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
219694076|NCT03280459|PROCEDURE|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
219694077|NCT02145455|DEVICE|Unity Total Knee Replacement System|
219694078|NCT02145455|DEVICE|Unity Total Knee Replacement System|
219694079|NCT04103190|DEVICE|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
219694080|NCT00780975|DRUG|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
219107576|NCT03219203|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
219107577|NCT03984019|DIAGNOSTIC_TEST|Cardiac condition measurements|Cardiac MRI, ECG, echocardiography, cardiac blood markers
219107578|NCT03077373|BEHAVIORAL|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
219107579|NCT01418612|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
219107580|NCT00969345|OTHER|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
219107581|NCT00969345|OTHER|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
219107582|NCT02566070|OTHER|Continuous Gastric Feeding|
219694081|NCT03459625|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
219694082|NCT03459625|BEHAVIORAL|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
219694083|NCT04525430|OTHER|childbirth education|"The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking."
219694084|NCT04525430|OTHER|childbirth education and was subjected to a birth plan|In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
219694085|NCT04471701|BEHAVIORAL|Environmental exposure and clinical features|Environmental exposures and clinical features are measured by means of a self-administered 38-item on-line questionnaire containing mainly mandatory and closed questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the lockdown.
219694086|NCT01939314|DRUG|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
219694087|NCT01939314|DRUG|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
219107583|NCT02566070|OTHER|Bolus Gastric Feeding|
219694088|NCT02993198|DRUG|Carvedilol|
219694089|NCT04879017|DRUG|FHD-286|FHD-286 as a single agent
219694090|NCT04054544|DIETARY_SUPPLEMENT|Gluten powder 4g|Gluten powder 4g oral BID
219694091|NCT00100399|BIOLOGICAL|Fluarix|
219694092|NCT03179735|DRUG|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
219694093|NCT03179735|DRUG|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
219694094|NCT03179735|DRUG|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
219694095|NCT02743364|OTHER|Laboratory Biomarker Analysis|Correlative studies
219694096|NCT02743364|OTHER|Placebo Administration|Given PO
219694097|NCT02743364|OTHER|Quality-of-Life Assessment|Ancillary studies
219694098|NCT02743364|OTHER|Questionnaire Administration|Ancillary studies
219694099|NCT02743364|DRUG|Simvastatin|Given PO
219694100|NCT01338324|DRUG|Simvastatin|Simvastatin 20 mg single dose on day 1
219694101|NCT00969228|BIOLOGICAL|Rotarix ™|Two oral doses
219107584|NCT00872430|OTHER|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
219694102|NCT00969228|BIOLOGICAL|Placebo|Two oral doses
219107585|NCT00872430|OTHER|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
219694103|NCT04751695|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
219107586|NCT00462436|BEHAVIORAL|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
219107587|NCT02951351|DRUG|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
219107588|NCT02951351|PROCEDURE|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
219107589|NCT04765293|OTHER|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
219694104|NCT02563899|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
219694105|NCT02563899|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
219694106|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
219694107|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
219107590|NCT05969938|DIAGNOSTIC_TEST|MRD detection|Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.
219107591|NCT05033743|DRUG|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
219107592|NCT01479686|PROCEDURE|iMRI|3.0TiMRI guided resection in adults with glioma
219224556|NCT07012070|BEHAVIORAL|Mobile application|The mobile apps and mobile platform are adopted from the HOBBIT-PAD platform prototype that was developed specifically for patients with PAD based on user-centred design. This platform contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. The source code for this platform is publicly available. Important customization will be made to tailor this mobile health platform for this study, which includes addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise. These materials are adopted from the patient education materials available on the Hospital Authority and the AHA website. This information will be periodically sent to the subject's mobile device as a push notification to help them better understand their disease and to promote independent self-care and healthy lifestyle.
219224557|NCT07013279|BIOLOGICAL|DWP712 inj.|Clostridium botulinum Toxin
219107593|NCT01479686|PROCEDURE|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
219107594|NCT04720963|DRUG|Remimazolam|intranasal remimazolam
219694108|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
219694109|NCT00410358|DRUG|Gimatecan|
219694110|NCT06157229|OTHER|MAT|"The protocol consists of four phases: 1) immobilization phase, 2) early protective phase, 3) intermediate phase and 4) late phase. The detailed guideline can be found in the following article:~Gaunt, B. W., Shaffer, M. A., Sauers, E. L., Michener, L. A., McCluskey, G. M., \& Thigpen, C. A. (2010). The American Society of Shoulder and Elbow Therapists' Consensus Rehabilitation Guideline for Arthroscopic Anterior Capsulolabral Repair of the Shoulder. Journal of Orthopaedic \& Sports Physical Therapy, 40(3), 155-168. https://doi.org/10.2519/jospt.2010.3186"
219694111|NCT06157229|OTHER|CABRR|"The protocol consists of four phases: 1) immobilization phase, 2) early phase, 3) intermediate phase and 4) advanced phase.~The protocol comprises education, modified cognitive behavioral therapy, neuromuscular control exercises, kinetic chain exercises, range of motion enhancing exercises, strength and conditioning exercises, and sport-specific exercises. The protocol is currently unpublished."
219107595|NCT04720963|OTHER|Distilled water for injection|intranasal distilled water for injection
219107596|NCT04720963|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
219224558|NCT07013279|BIOLOGICAL|Botox® 100 Units|Clostridium botulinum Toxin
219107597|NCT04084782|DEVICE|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
219107598|NCT00356486|DRUG|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
219107599|NCT00356486|DRUG|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
219107600|NCT02591420|BIOLOGICAL|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
219107601|NCT02591420|BIOLOGICAL|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
219107602|NCT02591420|DRUG|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
219694112|NCT02245711|BIOLOGICAL|Stem Cell|
219107603|NCT05073744|DRUG|Nalbuphine|Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
219694113|NCT00661635|DRUG|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
219107604|NCT05073744|DRUG|Morphine|Morphine hydrochloride injection is used for perioperative tumor ablation
219107605|NCT03305302|PROCEDURE|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
219107606|NCT05637411|OTHER|Predictive model|We will define and validate predictive models of risk of exacerbations in asthmatic patients
219107607|NCT03308058|BEHAVIORAL|Breastfeeding computer education|Breastfeeding computer education
219107608|NCT03321006|DEVICE|Phonak Audeo B-R 90 hearing aid device (Active)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
219107609|NCT03321006|DRUG|Duloxetine or escitalopram|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
219107610|NCT03321006|DEVICE|Audeo B-R 90 hearing aid device (Sham)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
219107611|NCT01109823|DRUG|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
219107612|NCT02672384|PROCEDURE|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
219107613|NCT01622543|DRUG|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
219107614|NCT01622543|DRUG|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
219107615|NCT00885352|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
219224559|NCT07013721|PROCEDURE|Transversus Abdominis Plane Block, TAPB|The procedure was performed by anesthesiologists with extensive expertise in nerve blockade techniques. For upper abdominal surgical incisions, a subcostal approach transversus abdominis plane block (TAPB) was implemented under ultrasound guidance to identify the transversus abdominis plane. A total of 20 mL of 0.33% ropivacaine hydrochloride injection (Naropin®) was incrementally administered, followed by contralateral application using identical techniques, with ultrasonographic confirmation of fusiform drug distribution within the transversus abdominis plane to achieve upper abdominal incision analgesia. For lower abdominal incisions, a lateral approach was employed, with the same dosage of local anesthetic injected at the target site and bilateral blocks performed after confirming fluid dispersion patterns under real-time ultrasound visualization.
219224560|NCT07015437|DEVICE|INTERCEPT Blood System for RBCs|RBCs treated with the INTERCEPT Blood System for RBCs
219107616|NCT00885352|DRUG|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
219107617|NCT00885352|DRUG|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
219694114|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
219107618|NCT00885352|DRUG|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
219107619|NCT00885352|DRUG|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
219694115|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
219107620|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
219107621|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
219107622|NCT03337932|DRUG|Controls without a history of lyme disease.|No intervention.
219224561|NCT07015437|OTHER|Infusion of autologous radiolabeled RBCs|Subject will receive a single intravenous infusion of approximately 10 to 30 mL of autologous Day 35 51Cr radiolabeled RBCs and fresh 99mTc RBCs.
219224562|NCT07012629|DRUG|acetylsalicyclic acid (ASA)|Daily dose 75 mg to 100 mg p.o.
219694116|NCT01173315|DIETARY_SUPPLEMENT|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
219694117|NCT00794664|DRUG|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
219694118|NCT00794664|DRUG|Placebo|1 mL weekly subcutaneous injections for 26 weeks
219694119|NCT03708445|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases"
219694120|NCT02434874|DEVICE|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
219694121|NCT02923999|DRUG|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
219694122|NCT02923999|DRUG|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
219694123|NCT02923999|DRUG|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
219694124|NCT01062308|PROCEDURE|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique"
219107623|NCT03719365|DEVICE|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
219107624|NCT00365378|BIOLOGICAL|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
219107625|NCT00365378|BIOLOGICAL|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
219224563|NCT07012629|DRUG|Clopidogrel|Daily dose 75 mg p.o.
219224564|NCT07012629|DRUG|Rosuvastatin|"Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated).~If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed."
219107626|NCT00992537|DRUG|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
219107627|NCT00992537|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
219107628|NCT00992537|DRUG|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
219107629|NCT06456099|DRUG|Ultrasound-guided corticosteroid injection|Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
219224565|NCT07012629|DRUG|Atorvastatin|Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.
219224566|NCT07012798|DRUG|Durvalumab|1120mg, iv, q3w
219224567|NCT07012798|DRUG|Bevacizumab|15mg/kg, iv, q3w
219224568|NCT07012798|DRUG|HAIC of FOLFOX|"HAIC (FOLFOX): oxaliplatin 100mg/m2, 4h, day 1 + leucovorin 300mg/m2, 2h, day~1 + fluorouracil 500mg/m2, 20min, day 1 + fluorouracil 1500mg/m2, 20h, q3w"
219224569|NCT07020390|PROCEDURE|Anesthesia method|Patients will be divided into subgroups according to different anesthesia methods (general, spinal, and combined spinal-epidural anesthesia) and compared in terms of recovery quality (QoR-40) and other parameters.
219224570|NCT07016399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219224571|NCT07016399|PROCEDURE|Breast Biopsy Procedure|Undergo breast biopsies
219224572|NCT07016399|DRUG|Carboplatin|Given IV
219224573|NCT07016399|DRUG|Cyclophosphamide|Given IV
219224574|NCT07016399|DRUG|Darolutamide|Given PO
219107630|NCT06456099|BEHAVIORAL|Home exercise program|"Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog)."
219107631|NCT06456099|BEHAVIORAL|Patient information leaflet|"In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice."
219107632|NCT02093039|DEVICE|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
219107633|NCT04452448|DEVICE|LASIK|All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
219107634|NCT02508922|DIETARY_SUPPLEMENT|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
219107635|NCT02508922|DIETARY_SUPPLEMENT|Placebo|Matching placebo drops will be taken daily for 20 weeks
219107636|NCT02733302|BEHAVIORAL|Hope theory|Adapted Physical Activity
219107637|NCT02019784|DRUG|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
219107638|NCT02019784|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219107639|NCT03278886|DRUG|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
219107640|NCT03278886|DRUG|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
219107641|NCT05960383|DIAGNOSTIC_TEST|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
219107642|NCT05839353|OTHER|SBAR training by serious game|SBAR training by serious game
219107643|NCT04082091|BEHAVIORAL|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium - receive fasting glucose test and BP measurement; and low risk. All subjects in each category will be enrolled in an e\_Prescription intervention for lifestyle change tailored to their individual risk profile."
219107644|NCT01316341|DRUG|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
219107645|NCT01316341|DRUG|Placebo|patient to receive two placebos
219107646|NCT01316341|DRUG|Placebo|patient to receive two placebos
219107647|NCT01316341|DRUG|Placebo|patient to receive two placebos
219107648|NCT01316341|DRUG|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
219107649|NCT00717678|DRUG|Prograf-XL|oral
219107650|NCT00717678|DRUG|Prograf|oral
219107651|NCT00717678|DRUG|MMF|oral
219107652|NCT04161807|DEVICE|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
219107653|NCT02390843|DRUG|Simvastatin|The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
219107654|NCT02390843|DRUG|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
219107655|NCT02390843|DRUG|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
219107656|NCT02390843|DRUG|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
219107657|NCT04791202|DRUG|Dextrose|See arm descriptions
219107658|NCT04791202|DRUG|Methylprednisolone Acetate 40 MG/ML|See arm descriptions
219694125|NCT01062308|PROCEDURE|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
219694126|NCT04890808|DIETARY_SUPPLEMENT|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
219694127|NCT04890808|DIETARY_SUPPLEMENT|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
219694128|NCT05867056|DRUG|IMC-I109V Single Ascending Dose|Single dose administration of IMC-I109V
219694129|NCT05867056|DRUG|IMC-I109V Multiple Ascending Doses|Multidose administration of IMC-I109V
219694130|NCT05867056|DRUG|HBV HCC Module MAD|Multidose administration of IMC-I109V
219694131|NCT01305564|DEVICE|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
219694132|NCT00457730|DRUG|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
219694133|NCT00457730|DRUG|Placebo|Subjects are randomized to either Duloxetine or Placebo
219694134|NCT02195635|DRUG|Telotristat etiprate|500 mg telotristat etiprate
219107659|NCT02312180|BIOLOGICAL|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
219107660|NCT02875301|BEHAVIORAL|150 Minutes Week|This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
219107661|NCT02875301|BEHAVIORAL|225 Minutes Week|This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
219224575|NCT07016399|DRUG|Doxorubicin|Given IV
219694135|NCT02195635|DRUG|Octreotide acetate|200 µg octreotide acetate three times daily
219694136|NCT04692987|OTHER|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
219694137|NCT01289886|DRUG|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
219694138|NCT02150928|DRUG|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"* Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
219694139|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
219694140|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
219224576|NCT07016399|DRUG|Epirubicin|Given IV
219224577|NCT07016399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219224578|NCT07016399|DRUG|Paclitaxel|Given IV
219224579|NCT07016399|BIOLOGICAL|Pembrolizumab|Given IV
219224580|NCT07016399|PROCEDURE|Surgical Procedure|Undergo breast surgery
219224581|NCT07016399|PROCEDURE|Ultrasound Imaging|Undergo US
219694141|NCT00081887|DRUG|Clofarabine|Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
219694142|NCT03883243|DEVICE|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
219694143|NCT06983366|DIAGNOSTIC_TEST|Lung Ultrasound|All enrolled patient will be subjected to Lung Ultrasound examination LUS
219107662|NCT02875301|BEHAVIORAL|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
219107663|NCT04649827|OTHER|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
219107664|NCT00864526|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
219107665|NCT00864526|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
219224582|NCT00504322|GENETIC|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
219224583|NCT00504322|GENETIC|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
219694144|NCT02706262|OTHER|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
219694145|NCT02706262|OTHER|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
219224584|NCT07011953|DRUG|Antipsychotics plus Levothyroxine Sodium|Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water).
219224585|NCT07011953|DRUG|Antipsychotics plus Placebo|"All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet.~Placebo characteristics \& Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging.~Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions."
219224586|NCT05366751|DRUG|SAGE-324|SAGE-324 oral tablets
219224587|NCT00179933|BEHAVIORAL|Newborn Individualized Assessment Program|
219224588|NCT07013357|BEHAVIORAL|Virtual Community Intervention|Modules of community building, civic participation, and achieving personal goals
219224589|NCT07013357|BEHAVIORAL|Control|Civic participation websites and educational information on civic and social connection provided to participants
219224590|NCT07014072|PROCEDURE|intensive toe pressure evaluation|This measurement is non-invasive, painless and is also carried out as part of the care in the follow-up of critical limb ischemia. It takes place like a blood pressure measurement except that it is carried out at the level of a toe.
219107666|NCT04822480|BEHAVIORAL|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
219107667|NCT03383562|PROCEDURE|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
219694146|NCT02706262|OTHER|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
219694147|NCT02706262|BEHAVIORAL|Annual Follow-up Visits|Metabolic health will be assessed 1 and 2-years after competing the diet intervention study. No intervention will be performed during the time.
219107668|NCT04745494|OTHER|OT administration|OT nasal administration
219107669|NCT04745494|OTHER|Placebo administration|Placebo nasal administration
219107670|NCT04318730|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
219107671|NCT04738721|BEHAVIORAL|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
219107672|NCT04699357|DRUG|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
219107673|NCT01899274|DEVICE|bant iPhone application|
219107674|NCT00439829|DRUG|Gonal F|"* 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
219107675|NCT00439829|DRUG|Luveris|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
219224591|NCT07014072|OTHER|data collection|retrospective data
219224592|NCT06691113|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219224593|NCT06691113|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
219224594|NCT06691113|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
219224595|NCT04894591|DRUG|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
219224596|NCT06699784|BEHAVIORAL|Progressive lenses intervention|Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
219694148|NCT06981533|OTHER|Auricular acupressure therapy|Auricular acupressure will be performed using Cowherb seeds (Wangbuliuxing seeds) applied to specific acupoints, including Shenmen (TF4), Sympathetic (AH6a), Endocrine (CO18), Liver (CO12), Kidney (CO10), Subcortex (AT4), and Zero Point on one ear, with treatment administered once a week, alternating between the left and right ears. In total, auricular acupressure was applied 8 times over a period of 8 weeks. The first treatment session occurred 5-7 days prior to the onset of menstruation. Participants were instructed to perform acupressure at the acupoint sites three times daily-morning, noon, and evening-pressing each point for 1 minute per session.
219694149|NCT06981533|OTHER|Sham auricular acupressure therapy|Sham auricular acupressure therapy will be performed using similarly sized adhesive patches without seeds, applied to the same acupoint locations as in the intervention group. The procedure steps and the duration of the trial were the same as in the auricular acupressure group.
219107676|NCT00439829|DRUG|Cetrotide|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
219107677|NCT00439829|DRUG|hCG|"\- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter"
219107678|NCT01705808|DRUG|Protein C concentrate|
219107679|NCT04386226|DIETARY_SUPPLEMENT|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
219107680|NCT04386226|DIETARY_SUPPLEMENT|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
219694150|NCT06981533|OTHER|Lifestyle modifications|"Lifestyle modifications will be followed according to the Guidelines for the Management of Premenstrual Syndrome by the Royal College of Obstetricians and Gynaecologists (RCOG), which will include: Regular moderate exercise (such as walking, yoga, or swimming), stress reduction, and ensuring quality sleep (7-8 hours per night); Reducing intake of salt, sugar, and foods containing saturated fats; Increasing intake of high-fiber foods such as fruits and vegetables; Avoiding smoking, and limiting alcohol, and other stimulants."
219694151|NCT03933306|DRUG|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
219694152|NCT03933306|DRUG|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
219694153|NCT03933306|OTHER|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
219107681|NCT04386226|OTHER|Placebo|Maltodextrin
219107682|NCT02848261|BEHAVIORAL|Developmental Demands|Education and training related to use of CGM in this age group
219107683|NCT02848261|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
219107684|NCT02848261|BEHAVIORAL|Remote Monitoring|Education and training on the use of remote monitoring
219107685|NCT02848261|BEHAVIORAL|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
219107686|NCT02848261|BEHAVIORAL|No intervention|No intervention - serves as the control group
219107687|NCT03740880|OTHER|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
219107688|NCT03254160|DRUG|DNS-3379|DNS-3379
219107689|NCT03254160|DRUG|Placebo|Placebo
219107690|NCT04931459|DRUG|ACU193|Intravenous ACU193
219107691|NCT04931459|DRUG|Placebo|Intravenous Placebo
219107692|NCT04139148|DEVICE|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
219107693|NCT04139148|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
219107694|NCT05992714|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
219107695|NCT05992714|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
219694154|NCT03933306|OTHER|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
219694155|NCT06611995|OTHER|observational study|Observational study without intervention
219694156|NCT06612216|OTHER|No intervention was carried out|This study observed differences in microbiota among different groups and therefore did not involve intervention.
219694157|NCT06612905|OTHER|Detection of the time spent on social media|The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).
219694158|NCT06612905|OTHER|Evaluation of body composition and basal metabolic rate|They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)
219107696|NCT02252458|DRUG|Fentanyl|
219107697|NCT03562546|OTHER|Strength From Within|A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
219107698|NCT03491748|DRUG|ETX0282|Oral Gelatin capsules
219107699|NCT03491748|DRUG|Cefpodoxime proxetil|Oral tablets
219107700|NCT03491748|DRUG|Placebo|Oral Gelatin capsules
219107701|NCT06153823|OTHER|virtual reality glasses|child behavior management will be done by using VR glasses distraction
219107702|NCT06153823|OTHER|Tell Show and Do|child behavior management will be done by using tell show and do technique
219107703|NCT05445856|DRUG|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
219107704|NCT05445856|DRUG|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
219107705|NCT06184490|PROCEDURE|Prone position with thoraco-abdominal cushion|Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
219107706|NCT04316390|DIETARY_SUPPLEMENT|Control|study drink (two weeks)
219107707|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
219107708|NCT04316390|DIETARY_SUPPLEMENT|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
219107709|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
219107710|NCT03523182|DIETARY_SUPPLEMENT|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
219107711|NCT03523182|DIETARY_SUPPLEMENT|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
219107712|NCT00151918|DRUG|Lanthanum carbonate|
219107713|NCT02490618|OTHER|Probiotic tablet- Biogaia|
219107714|NCT02490618|OTHER|Placebo tablet|
219107715|NCT00082602|DRUG|galantamine ER|
219694159|NCT06612905|OTHER|Evaluation of eating behavior among social media users|Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
219694160|NCT07001956|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
219694161|NCT03893929|DIAGNOSTIC_TEST|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
219694162|NCT07016646|COMBINATION_PRODUCT|Self-Help Plus (SH+) and cash transfer|"SH+: Self-Help Plus (SH+) is a five-session stress management program developed by the World Health Organization (WHO) for groups of up to 30 participants. It is facilitated by non-specialists who undergo brief training and use pre-recorded audio along with an illustrated guide, Doing What Matters in Times of Stress, to teach stress management techniques. Designed for adults experiencing stress, SH+ is adaptable to diverse living situations and circumstances. Research has demonstrated its effectiveness in alleviating psychological distress and preventing the onset of mental health disorders. Its flexible format makes it an excellent complement to other mental health interventions, whether as an initial step in a stepped care approach or as a community-based program integrated with broader community initiatives.~Cash Assistance: A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira after each session)"
219694163|NCT07016646|OTHER|Cash transfer|A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira each week for 5 weeks)
219694164|NCT07021222|PROCEDURE|Full Analysis|Population 1 receives all three groups of analyses:Clinical-metabolical analyses, Biological-biochemical analyses, and Biomechanical-functional analyses.
219694165|NCT07021222|PROCEDURE|Partial Analysis|Population 2 receives two groups of analyses:Clinical-metabolical analyses and Biological-biochemical analyses.
219694166|NCT06185686|OTHER|Cognitive testing|NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)
219224597|NCT06699784|BEHAVIORAL|Single-vision lenses intervention|Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
219224598|NCT07030842|PROCEDURE|liver resection|"This is a retrospective observational study analyzing existing clinical data; no experimental interventions were administered. The study evaluates the predictive performance of two deep learning models (preoperative and postoperative) using standard-of-care medical data collected during routine clinical practice, including:~Preoperative contrast-enhanced MRI scans Postoperative hematoxylin and eosin (H\&E)-stained whole slide images Clinical variables (laboratory results, pathology reports, and demographic data)~All data were collected as part of standard diagnostic and treatment protocols for hepatocellular carcinoma (HCC) patients undergoing liver resection. No additional interventions or modifications to clinical care were implemented for study purposes. The artificial intelligence models were applied to previously acquired, de-identified data to predict aggressive recurrence patterns"
219224599|NCT05502523|PROCEDURE|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
219224600|NCT05502523|PROCEDURE|Biospecimen Collection|Correlative studies
219224601|NCT07032584|OTHER|Telerehabilitation Intervention|TheTelerehabilitation Intervention (TR) group utilizes a touchscreen tablet equipped with a computer-guided rehabilitation program that provides ongoing support and feedback for home-based rehabilitation.
219224602|NCT07035470|OTHER|PhenoAge-Based Biological Age Assessment|Biological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records.
219224603|NCT07039214|OTHER|Observation of low-back pain symptoms|No intervention was applied.
219224604|NCT07039214|OTHER|Observation of healthy comparators|No intervention was applied.
219107716|NCT04015791|OTHER|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
219107717|NCT00282815|DEVICE|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
219107718|NCT00282815|DEVICE|sham CPAP|sham CPAP
219107719|NCT00624325|DRUG|interferon alfa-2b|12 MU daily continuously subcutaneous
219107720|NCT00624325|DRUG|interferon alfa-2b|9 MU daily continuously subcutaneous
219107721|NCT00624325|DRUG|interferon alfa-2b|6 MU daily continuously subcutaneous
219224605|NCT07035171|OTHER|Multimodal prehabilitation intervention|"Multimodal prehabilitation interventions (CABGpreHAB):~* Home-based exercise intervention delivered by a skilled physiotherapist via a web-based application.~* Nutritional intervention~* Psycho-educative intervention~* Smoking cessation~* Alcohol cessation"
219694167|NCT06185686|DEVICE|Resting State MRI/Precision functional mapping|At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
219694168|NCT07024550|DEVICE|Treatment with BTL-699-2 device|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The therapy parameters will be adjusted according to patient feedback, but should never exceed 70% of the individual's MT in the active group.
219694169|NCT07024550|DEVICE|Treatment with BTL-699-2 device with intensity below therapeutic threshold|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The intensity of the energy will be set below the therapeutic threshold.
219694170|NCT07028723|OTHER|proprioceptive profile measurement|"Proprioceptive profile is measured by assessing static bipodal balance on a force platform. The patient is asked to stand motionless in bipodal support on a stable and then unstable floor, with vision masked by an eye mask. The investigators randomly apply a tendon vibration (80Hz) to the subjects' Achilles tendons or paravertebral muscles.~This vibration alters proprioceptive information in the vibrated zone, leading to a disturbance in postural balance and an increased displacement of the center of pressure, whose position is continuously calculated from the force platform's sensors.~Thus, depending on the amount of displacement of the center of pressure, the investigator calculates a proprioceptive weighting ratio (PWR) to deduce the weight assigned by the Central Nervous System to the various proprioceptive inputs during the postural task.~An PWR of 1 indicates 100% use of information from the ankle, while an PWR of 0 means 100% use of information from the hip."
219694171|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
219694172|NCT02440061|DRUG|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
219694173|NCT02440061|DRUG|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
219224606|NCT07035171|OTHER|Control (Standard treatment)|This includes standard information about CABG surgery, pre- and postoperative care, and postoperative physical activity advice. Patients are either admitted days before or on the day before surgery. They receive written materials and links to animated videos about preparing for surgery. This preparation includes counseling with a multidisciplinary team, including a department nurse, a physiotherapist, a cardiac anesthesiologist, and a surgeon.
219694174|NCT02440061|DRUG|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
219694175|NCT03940833|BIOLOGICAL|BCMA CAR-NK 92 cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
219694176|NCT01265186|DEVICE|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
219694177|NCT01265186|DEVICE|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
219694178|NCT04178304|DRUG|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
219694179|NCT00545623|PROCEDURE|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
219694180|NCT00545623|BEHAVIORAL|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
219694181|NCT00545623|OTHER|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
219694182|NCT07072000|RADIATION|standard CTV delineation|The anterior border of CTV2 is delineated at the posterior 1/3 of the nasal cavity.
219694183|NCT07072000|RADIATION|reduced CTV delineation|The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.
219694184|NCT07072793|DRUG|nirmatrelvir-ritonavir|Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at high-risk for progressing to severe disease
219694185|NCT07073092|DRUG|propolis|propolis medicated jelly candy.
219694186|NCT07073092|DRUG|chlorohexidine mouthwash and topical antifungal|chlorohexidine mouthwash and topical antifungal
219694187|NCT07073443|BEHAVIORAL|Experimental: Memory Therapy Group|Evaluation of the Effect of Memory-Based Recall Therapy on the Cognitive Status, Psychological Flexibility, and Cognitive Flexibility of Elderly Individuals Diagnosed with Dementia
219694188|NCT07072663|OTHER|Baseline and 3-month follow-up|"At baseline and day 90 (±14) post-enrollment:~1. Collect clinical data;~2. Administer multiple scales to assess clinical symptom severity and neuropsychological status;~3. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~4. Collect peripheral blood and cerebrospinal fluid (CSF) samples for biomarker level analysis."
219694189|NCT07072663|OTHER|Baseline|"At baseline:~1. Collect clinical data;~2. Assess intracranial and extracranial arterial and venous systems;~3. Administer multiple scales to assess neuropsychological status;~4. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~5. Collect peripheral blood samples for biomarker level analysis."
219694190|NCT07071987|PROCEDURE|Thread Embedding Acupuncture+Electroacupuncture|Thread embedding acupuncture will be administered at bilateral ST36, ST37, and PC6 acupoints at 2h after surgery and electroacupuncture at same acupoints at 2h 24h, 48h, and 72h after surgery. Absorbable polydioxanone sutures will be embedded into subcutaneous tissue using sterile embedding needles. All procedures will be conducted by licensed acupuncturists following standardized operating protocols.
219694191|NCT07071987|PROCEDURE|Electroacupuncture|Electroacupuncture will be performed at the same bilateral acupoints (ST36, ST37, and PC6)
219694192|NCT06754046|DEVICE|RP-MUS|a standard urethral sling placement for treatment of stress urinary incontinence
219694193|NCT06754046|PROCEDURE|PAHG|A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.
219107722|NCT01129505|BEHAVIORAL|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
219107723|NCT01471158|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
219107724|NCT01471158|DRUG|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
219107725|NCT04955704|DEVICE|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
219107726|NCT03312179|DEVICE|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
219107727|NCT03312179|DRUG|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
219107728|NCT00669903|DRUG|AZD0328|
219107729|NCT00669903|DRUG|Placebo|
219107730|NCT00504296|DRUG|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
219107731|NCT00504296|OTHER|immunoenzyme technique|
219107732|NCT00504296|OTHER|immunohistochemistry staining method|
219107733|NCT00504296|OTHER|immunologic technique|
219694194|NCT06903208|DEVICE|STARMed VIVA Combo RF System|RFA is a kind of treatment that uses a long thin needle, called a probe, to melt the lipoma. After numbing the skin with a local anesthetic, using an ultrasound machine as a guide, the study surgeon will insert the probe into the center of the lipoma. The probe will then deliver heat to the lipoma, melting it. The ultrasound is a machine which bounces sound waves to create an image that the study doctor sees on a screen. These ultrasound images will help the study surgeon to accurately guide the probe to the correct location of the lipoma. Once the lipoma is melted, the study surgeon will aspirate any residual liquid out.
219694195|NCT06809725|DIAGNOSTIC_TEST|SPARK Cognitive Status Indicator (software support data collected via EEG)|"The SPARK Cognitive Status Indicator software (collected via EEG) is being validated to aid in the diagnosis of Alzheimer's disease in persons aged 65-90 with suspected cognitive impairment. The device, once validated, shall provide a clinician with a positive or negative output to indicate whether the subject's electroencephalogram (EEG) is consistent with EEGs of subjects diagnosed with Alzheimer's disease."
219694196|NCT06751576|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
219694197|NCT06055244|DRUG|Amantadine|Subjects will be give amantadine 100 mg twice daily.
219694198|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
219694199|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
219694200|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
219694201|NCT06497504|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219694202|NCT06497504|DRUG|Placebo|Placebo will be administered.
219694203|NCT07073287|DEVICE|Cerebello-spinal direct current stimulation|csDCS influences both ascending and descending spinal pathways and reflex excitability, promoting prolonged functional neuroplastic changes.
219694204|NCT07073287|DEVICE|Sham Comparator|Masking for cerebello-spinal direct current stimulation involves the electric current stopping after 30 seconds, providing a sensation without producing neuromodulation.
219107734|NCT00504296|OTHER|laboratory biomarker analysis|
219107735|NCT00504296|OTHER|liquid chromatography|
219107736|NCT00504296|OTHER|mass spectrometry|
219107737|NCT00504296|OTHER|pharmacological study|
219224607|NCT07036224|DEVICE|Exergaming Training using Kinect sensor device|A 6-week standardized training program was carried out with the use of the game rehabilitation platform with Kinect sensor device. The subjects exercised under the supervision of an instructor for at least 30 minutes twice a week.
219107738|NCT06031909|DIAGNOSTIC_TEST|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~* Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~* Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~* Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~* Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~* Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
219107739|NCT00458679|BIOLOGICAL|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
219107740|NCT01915199|OTHER|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
219224608|NCT07043829|DIETARY_SUPPLEMENT|SAEP (Solution of Cimarrón Bean Extrudate in Water)|A single oral dose of 10 grams of Cimarrón bean (Phaseolus vulgaris, variety Cimarrón) extrudate dissolved in 500 mL of water, consumed once under fasting conditions. Used to evaluate acute effects on platelet function and postprandial glycemia.
219224609|NCT07044284|DEVICE|Fractal mindfulness recombination|Immersive virtual reality using fractal mindfulness software
219224610|NCT07044076|OTHER|Quality of life|The four questionnaires (MQOL, EQ-5D, Karnofsky, and FACT-Br) will be sent to patients online using the secure online platform Redcap.
219694205|NCT06935188|DRUG|Dalpicilib combined with cetuximab|The participants receive cetuximab in combination with Dalpiciclib until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2. Dalpiciclib is administered orally at a dose of 150 mg once daily for 21 consecutive days, followed by a 7-day break. Each 28 days were deemed as a treatment cycle. If the patient vomits or misses a dose, it should not be made up on the same day. The next dose should be taken as usual.
219694206|NCT06935188|DRUG|cetuximab|The participants receive cetuximab alone until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2.
219694207|NCT00054288|DRUG|gemcitabine hydrochloride|
219694208|NCT00054288|DRUG|irinotecan hydrochloride|
219694209|NCT06524388|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
219694210|NCT06524388|DEVICE|placebo cognitive training|Participants received cognitive training tasks of fixed difficulty.
219694211|NCT00496769|DRUG|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
219694212|NCT00496769|DRUG|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
219694213|NCT05511857|BEHAVIORAL|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
219694214|NCT05511857|BEHAVIORAL|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
219694215|NCT05511857|BEHAVIORAL|Distraction|The participants will engage in a distraction task.
219694216|NCT03482050|BIOLOGICAL|AstroRx|Astrocytes derived from human embryonic stem cells
219694217|NCT06238180|DEVICE|VIOSync-SPI|The intervention in this study involves an AI-driven clinical decision-support system, VIOSync Sepsis Prediction Index (SPI), designed for the early prediction of sepsis in patients undergoing abdominal surgery. VIOSync integrates data from PPG-based wearable wireless devices that monitor vital signs, electronic health records, and laboratory tests. The AI model analyzes this multimodal data to proactively identify signs of sepsis providing an early warning score, the SPI, to clinicians. The distinguishing feature of this intervention is its use of real-time data and advanced AI analytics to enhance early sepsis detection, aiming to improve patient outcomes in postoperative care.
219694218|NCT00230035|PROCEDURE|Leukapheresis|
219694219|NCT00230035|PROCEDURE|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
219694220|NCT00230035|PROCEDURE|Autologous CD34+HPC transplantation (HSCT)|
219694221|NCT00230035|PROCEDURE|Plasmapheresis|
219694222|NCT00230035|DRUG|Rabbit anti-thymocyte globulin|
219224611|NCT07043179|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
219694223|NCT00230035|DRUG|Methylprednisolone|
219694224|NCT00230035|DRUG|Growth colony stimulating factor (G-CSF)|
219694225|NCT00230035|DRUG|Corticosteroids|
219694226|NCT00230035|DRUG|Mycophenolate mofetil|
219694227|NCT00230035|DRUG|Azathioprine|
219694228|NCT00230035|DRUG|Intravenous immunoglobulin|
219694229|NCT00230035|DRUG|Methotrexate|
219694230|NCT00230035|DRUG|Rituximab|
219694231|NCT00230035|DRUG|Leflunomide|
219694232|NCT00048152|DRUG|Corticosteroids|As prescribed
219694233|NCT00048152|DRUG|Neoral|Low dose (target trough level 50-100ng/mL)
219694234|NCT00048152|DRUG|Neoral|Standard dose (target trough level 150-300ng/mL)
219694235|NCT00048152|DRUG|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
219694236|NCT00048152|DRUG|mycophenolate mofetil [CellCept]|1g po bid
219694237|NCT02812186|PROCEDURE|Deep to Moderate NMB|"Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
219107741|NCT01082172|DEVICE|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
219107742|NCT06082622|COMBINATION_PRODUCT|laxatives|triple therapy of drugs, behaviour and mental axis
219107743|NCT03203668|RADIATION|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
219107744|NCT02419430|BEHAVIORAL|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
219694238|NCT02812186|PROCEDURE|Moderate to Deep NMB|"Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
219694239|NCT02812186|DRUG|Rocuronium|
219694240|NCT02169440|DRUG|BIA 9-1067|BIA 9-1067 25 mg
219694241|NCT02169440|DRUG|Warfarin|Warfarin 25 mg
219694242|NCT04897386|DRUG|Duvalizumab|Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
219694243|NCT04702360|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
219694244|NCT04702360|DRUG|IVA|IVA monotablet for oral administration.
219694245|NCT00327483|BEHAVIORAL|Internet based education software|
219694246|NCT01299558|DRUG|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
219107745|NCT02419430|BEHAVIORAL|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --\> Happier~  \+ Exercising --\> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation"
219224612|NCT07043179|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
219224613|NCT07043179|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Corticosteroid injections will be administered at least 24 weeks apart, and the second injection dosage may be adjusted based on the patient's condition, with a maximum dose of 80mg. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
219694247|NCT01299558|DRUG|fluticasone furoate|Single IV dose of FF (250mcg)
219694248|NCT01299558|DRUG|GW642444|Single IV dose of GW642444 (55mcg)
219694249|NCT03894995|OTHER|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
219107746|NCT02419430|BEHAVIORAL|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
219107747|NCT05597800|DRUG|Nivolumab and Ipilimumab|"Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles)."
219694250|NCT02746835|OTHER|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
219694251|NCT02303665|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
219694252|NCT02303665|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
219694253|NCT00455286|DRUG|Methotrexate|
219694254|NCT00455286|DRUG|Methylprednisolone|
219694255|NCT00455286|DRUG|Temozolomide|
219694256|NCT01614301|DRUG|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
219694257|NCT05252403|GENETIC|PTG-CARCIK-CD19|PTG-CARCIK-CD19 cells is a gene therapy medicinal product (GTMP) composed of genetically modified allogeneic T lymphocytes formulated as cell suspension in normal saline solution and freezing media
219694258|NCT02425137|DRUG|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
219107748|NCT05402800|OTHER|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
219107749|NCT01356641|DRUG|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
219107750|NCT01356641|PROCEDURE|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
219694259|NCT01573000|BIOLOGICAL|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
219694260|NCT02324686|DRUG|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
219694261|NCT06481787|DRUG|Vonorasan Fumarate|Vonorasan fumarate is taken 30min before breakfast and dinner.
219694262|NCT06481787|DRUG|Zuojin Pills|Zuojin Pills should be taken 30min after breakfast and dinner.
219694263|NCT03353792|DEVICE|CL/AP system|CL/AP system enabled insulin pump/CGM combination
219694264|NCT03353792|DEVICE|usual diabetic care|usual diabetic care (insulin pump therapy) along with CGM recording
219694265|NCT02598453|DRUG|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
219694266|NCT03614403|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
219694267|NCT02814071|OTHER|Early enteral feeding|Early enteral feeding as per description
219694268|NCT01477281|DRUG|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
219694269|NCT01477281|DRUG|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
219694270|NCT00372138|PROCEDURE|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
219694271|NCT00194129|DRUG|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
219694272|NCT00194129|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
219694273|NCT00194129|DRUG|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
219694274|NCT02198534|DEVICE|Methodology of visual acuity assessment|
219107751|NCT00837525|PROCEDURE|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
219107752|NCT05842460|BEHAVIORAL|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
219107753|NCT05842460|BEHAVIORAL|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
219694275|NCT01266616|BIOLOGICAL|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
219694276|NCT01266616|BIOLOGICAL|IL-12|Administered at Weeks 0, 4, and 12
219694277|NCT01266616|OTHER|Placebo|Saline injections at Weeks 0, 4, and 12
219694278|NCT00801944|DRUG|Solifenacin succinate|oral
219694279|NCT00801944|DRUG|Placebo|oral
219694280|NCT04212429|DRUG|Levofloxacin Ophthalmic Product|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
219694281|NCT04212429|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
219694282|NCT04907123|OTHER|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
219694283|NCT04907123|OTHER|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
219694284|NCT02158689|DRUG|Letrozole|
219694285|NCT02158689|DRUG|human menopausal gonadotropin (hMG)|
219694286|NCT02332603|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
219694287|NCT02332603|DRUG|Isotonic Sodium Chloride|Placebo
219694288|NCT05209659|OTHER|Pragmatic Mobilization|"The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)"
219107754|NCT03316612|DIETARY_SUPPLEMENT|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219107755|NCT03316612|DIETARY_SUPPLEMENT|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219107756|NCT00773955|DRUG|R-(-)-gossypol acetic acid|Given orally
219107757|NCT00773955|OTHER|pharmacological study|Correlative studies
219107758|NCT00773955|OTHER|laboratory biomarker analysis|Correlative studies
219694289|NCT01433159|DRUG|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
219694290|NCT01433159|DRUG|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
219694291|NCT00084240|DRUG|Azithromycin/Chloroquine|
219694292|NCT00084240|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
219694293|NCT01100853|DRUG|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
219694294|NCT03277937|PROCEDURE|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
219694295|NCT02624999|BIOLOGICAL|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
219694296|NCT02624999|DRUG|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
219694297|NCT03991390|OTHER|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
219694298|NCT03991390|OTHER|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
219107759|NCT00058019|DRUG|ixabepilone|Given IV
219694299|NCT02858466|RADIATION|MRI scan|
219107760|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
219107761|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
219224614|NCT07044219|PROCEDURE|Third molar surgery|During the operation, after local anaesthetics (LIDOCAIN-ADRENALIN 20 mg/0,01 mg/ml) the same mucoperiosteal (sulcular flap without vertical incision) is raised. Bone removal happens with physio-dispenser driven surgical handpiece (60ml/min irrigation; 8.000-16.000 rpm) and tungsten carbide round drills. Tooth section is made where indicated. After tooth removal wound is rinsed with 10-20ml physiologic salt, the wound is closed with 4.0 monofil non-resorbable suture material and then gel test or placebo is injected with syringe and applicator tip into the wound and on the surface of the wound. Patient bites a gauze for 20 minutes.
219107762|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
219107763|NCT04789577|BIOLOGICAL|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
219107764|NCT04789577|BIOLOGICAL|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
219107765|NCT04789577|DRUG|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
219107766|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
219107767|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
219107768|NCT02443662|OTHER|Catheterization|Routine catheterization during follow up.
219107769|NCT01827254|OTHER|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
219224615|NCT07043218|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|chimeric antigen receptor T cells
219107770|NCT03967990|OTHER|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
219107771|NCT03967990|OTHER|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
219107772|NCT03967990|OTHER|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
219107773|NCT04905732|DEVICE|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
219107774|NCT04905732|DEVICE|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
219107775|NCT00387257|DRUG|Rilapladib (SB-659032)|
219107776|NCT01561092|DRUG|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
219107777|NCT01561092|DRUG|Placebo|Tablets
219107778|NCT02096133|DRUG|Cholecalciferol|Vitamin D3 solution
219107779|NCT02096133|OTHER|Placebo comparator|Placebo comparator
219107780|NCT00840372|PROCEDURE|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
219694300|NCT00532051|DEVICE|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
219694301|NCT01423825|BIOLOGICAL|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
219694302|NCT01423825|BIOLOGICAL|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
219694303|NCT01423825|OTHER|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
219107781|NCT04724356|OTHER|Virtual Reality|Intervention was led once per day, five days a week, over 8 weeks.
219107782|NCT04724356|OTHER|Resistance Exercise|Intervention was led once per day, five days a week, over 8 weeks.
219107783|NCT06392672|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
219694304|NCT01682096|RADIATION|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
219694305|NCT01682096|PROCEDURE|Exercise stress echocardiography|Limited by symptoms
219694306|NCT02442609|OTHER|questionaire|questionaire before surgery
219694307|NCT03788694|DRUG|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
219694308|NCT03109483|OTHER|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
219694309|NCT05299866|DRUG|S-ketamine|After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
219694310|NCT05299866|DRUG|Placebo|After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
219694311|NCT00670059|GENETIC|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
219694312|NCT00670059|GENETIC|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
219694313|NCT00825123|DRUG|Ivabradine|Ivabradine 10 mg once
219694314|NCT00825123|DRUG|Metoprolol|Metoprolol 50 mg once
219107784|NCT02223065|DRUG|Saxagliptin|
219107785|NCT02223065|DRUG|Dapagliflozin|
219107786|NCT05656443|DRUG|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
219107787|NCT05656443|DRUG|Placebo|Placebo
219694315|NCT00825123|DRUG|Placebo|Lactose powder
219107788|NCT06286540|DEVICE|Lymphoblock|1 time per surgery with the exposition for 20 minutes.
219107789|NCT06286540|DEVICE|Placebo|1 time per surgery with the exposition for 20 minutes.
219694316|NCT01190891|PROCEDURE|Manual Physical Therapy|Same as arm description
219694317|NCT01190891|PROCEDURE|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
219694318|NCT00044291|DRUG|atamestane|
219694319|NCT00044291|DRUG|toremifene|
219694320|NCT00044291|DRUG|letrozole|
219694321|NCT00044291|DRUG|aromatase inhibition|
219694322|NCT00044291|PROCEDURE|hormone therapy|
219694323|NCT00044291|PROCEDURE|endocrine therapy|
219694324|NCT00044291|PROCEDURE|antiestrogen therapy|
219694325|NCT00266708|DRUG|Risedronate|risedronate 35 mg weekly
219694326|NCT00266708|DRUG|Placebo|Risedronate Placebo 35 mg weekly
219107790|NCT02783118|OTHER|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts"
219107791|NCT05170308|DEVICE|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
219107792|NCT06174935|DRUG|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
219107793|NCT00078104|PROCEDURE|Extraction of wisdom teeth|
219694327|NCT00348400|DRUG|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
219694328|NCT01926028|BIOLOGICAL|NDV-3A|0.5mL injection IM
219694329|NCT01926028|BIOLOGICAL|NDV-3|0.5mL injection IM
219107794|NCT06222008|OTHER|no Intervention|Observational study, no intervention
219107795|NCT01634958|BIOLOGICAL|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
219107796|NCT05150587|DRUG|Rifaximin|Rifaximin tablets
219694330|NCT01926028|BIOLOGICAL|Placebo|aluminum hydroxide and buffered saline
219224616|NCT07042659|DEVICE|Photobiomodulation|Accelerated photobiomodulation therapy using EmoLED™, a portable blue LED device (415 nm, 120 mW/cm², 7.2 J/cm²). The device delivers continuous blue light at 4 cm from the wound surface, 60 seconds per 25 cm² sub-area (120 seconds for diabetic wounds), administered twice weekly for 4 consecutive weeks. The protocol is combined with standard wound care (cleansing, dressings, compression as indicated). The intervention is designed to promote wound healing in hard-to-heal wounds by modulating inflammation, enhancing angiogenesis, fibroblast activation, and re-epithelialization. This accelerated protocol (twice weekly vs. standard weekly regimens) aims to optimize clinical outcomes in a nurse-led outpatient setting and distinguishes this intervention from lower-frequency or red/infrared-based photobiomodulation approaches.
219694331|NCT03012269|BEHAVIORAL|Working memory training|
219694332|NCT04892069|DRUG|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
219694333|NCT02932436|DRUG|Empagliflozin|10 mg per os daily for 12 weeks
219107797|NCT05150587|DRUG|Placebo|Placebo tablets
219107798|NCT02364232|BEHAVIORAL|bilateral training with and without mirror feedback|
219107799|NCT01674933|DRUG|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
219107800|NCT01674933|BEHAVIORAL|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
219107801|NCT05231564|OTHER|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
219107802|NCT03900143|DEVICE|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
219107803|NCT01614847|DRUG|Artificial tears|At random, subjects will receive isotonic artificial tear or a control (normal saline).
219107804|NCT02810730|PROCEDURE|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
219107805|NCT05947773|OTHER|Learning to walk with a robot|The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)
219694334|NCT02932436|DRUG|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
219107806|NCT05947773|OTHER|Walking group|The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.
219107807|NCT05947773|OTHER|Control group|The control group performed the physiotherapy treatment for 3 weeks.
219107808|NCT01643746|DEVICE|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
219107809|NCT01643746|DEVICE|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
219107810|NCT00249496|BEHAVIORAL|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
219107811|NCT00249496|BEHAVIORAL|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
219694335|NCT04577872|OTHER|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
219694336|NCT01130272|DRUG|Eluxadoline|Tablets, orally, twice daily.
219694337|NCT01130272|DRUG|Placebo|Matching placebo oral tablets twice daily.
219694338|NCT01548404|DRUG|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
219694339|NCT01548404|DRUG|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
219694340|NCT03559634|DIAGNOSTIC_TEST|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
219694341|NCT03559634|OTHER|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
219694342|NCT00641056|DRUG|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
219694343|NCT00641056|DRUG|Insulin Glargine|subcutaneous injection, variable dose, QD
219694344|NCT00737048|DRUG|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
219694345|NCT00737048|DRUG|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
219694346|NCT00737048|DRUG|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
219694347|NCT00737048|DRUG|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
219694348|NCT04175717|OTHER|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
219694349|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
219694350|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
219694351|NCT05591521|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
219224617|NCT07044206|DEVICE|Use of bone substitute during intervertebral fusion surgery|Participants randomized will receive bone substitute during intervertebral fusion surgery. Routine postoperative follow-up procedure (identical for both groups) with two postoperative visits at 3 months and 12 months.
219694352|NCT01530542|DRUG|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
219694353|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
219694354|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
219694355|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
219694356|NCT01530542|DRUG|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
219694357|NCT03210740|DRUG|AM001 Cream, 7.5%|Active Cream
219107812|NCT01247493|DRUG|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
219107813|NCT04561011|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
219107814|NCT02066350|PROCEDURE|Single pancreas transplantation|
219107815|NCT04639089|DRUG|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
219107816|NCT04874376|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
219107817|NCT05531019|DIETARY_SUPPLEMENT|Echinochrome A|Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.
219107818|NCT05531019|OTHER|Control|Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
219107819|NCT01738893|DRUG|Gabapentin 300 mg|Test product
219107820|NCT01738893|DRUG|Gabapentin 300 mg|Reference product
219107821|NCT04806412|DIAGNOSTIC_TEST|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
219107822|NCT00000143|DEVICE|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
219107823|NCT00000143|DRUG|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
219224618|NCT07042906|DEVICE|anesthesia depth monitorizing, awareness|Investigation of BIS and PSI Monitoring Methods for Anesthetic Depth and the Factors Affecting These Methods in Open-Heart Surgery
219694358|NCT03210740|DRUG|Vehicle Cream|Placeo
219694359|NCT03821961|PROCEDURE|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
219694360|NCT05645198|DRUG|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
219107824|NCT05923593|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
219107825|NCT00044460|DRUG|rosiglitazone|
219107826|NCT02456337|DEVICE|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
219107827|NCT02456337|DEVICE|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
219107828|NCT02456337|PROCEDURE|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
219694361|NCT05645198|DRUG|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
219694362|NCT05941806|DRUG|pr Sandoz Tamsulosin|Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
219107829|NCT02885727|DRUG|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
219107830|NCT02885727|RADIATION|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
219107831|NCT01923389|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
219107832|NCT01923389|DRUG|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
219107833|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
219107834|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
219694363|NCT05941806|DRUG|Glucose|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
219694364|NCT00004817|DRUG|phenytoin|
219694365|NCT00004817|DRUG|valproate sodium|
219107835|NCT03802162|DRUG|CKD-355A (D797/Memantine HCl 20mg)|once a day
219107836|NCT03802162|DRUG|CKD-355B (D797/Memantine HCl 20mg)|once a day
219107837|NCT03802162|DRUG|D797|once a day
219694366|NCT01086488|DRUG|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
219107838|NCT03802162|DRUG|D324 (Memantine HCl 10mg)|twice a day
219107839|NCT05575674|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
219107840|NCT01887314|DIETARY_SUPPLEMENT|Standardized Ginger extract|
219107841|NCT00649740|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
219107842|NCT00649740|DRUG|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
219107843|NCT02827786|DEVICE|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
219107844|NCT03903679|DEVICE|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
219107845|NCT03903679|DEVICE|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
219107846|NCT03758027|BEHAVIORAL|CARESS|"The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing."
219694367|NCT01657617|RADIATION|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
219694368|NCT03498677|BEHAVIORAL|presentation order|section presentation one
219694369|NCT03498677|BEHAVIORAL|alternative presentation order|section presentation two
219694370|NCT04020367|PROCEDURE|biopsy of mucosa's olfactory|intervention under general or local anesthesia
219694371|NCT06257732|OTHER|Exercise|The exercise interventions in this study include High-Intensity Interval Training (HIIT), involving brief bursts of intense exercise; Resistance Exercise, focusing on strength and muscle endurance; and Fatmax Exercise, tailored to optimize fat oxidation during aerobic activity.
219694372|NCT06257732|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will be employed as a counseling technique to elicit behavior change by fostering collaborative and empathetic conversations, enhancing motivation for positive lifestyle modifications in individuals with liver fat accumulation.
219694373|NCT04602286|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
219107847|NCT03758027|BEHAVIORAL|Isometric Exercise|5-minute protocol for cravings management and affect regulation
219107848|NCT05983926|PROCEDURE|Subtotal colectomy was performed|"Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements."
219107849|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 M probe|Measurement of liver stiffness
219107850|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 S probe|Measurement of liver stiffness
219694374|NCT03774108|DRUG|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
219694375|NCT03774108|OTHER|Placebo|8 weeks tratment with oral placebo
219694376|NCT03228082|DEVICE|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
219694377|NCT04040439|DRUG|Dexmedetomidine Hydrochloride|"\[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
219694378|NCT01309386|DRUG|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
219694379|NCT01309386|DRUG|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
219694380|NCT04785729|DRUG|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
219694381|NCT00778050|DRUG|Amoxicillin 600mg|
219694382|NCT01414478|OTHER|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
219694383|NCT00224263|DRUG|Lingzhi (Ganoderma)|
219694384|NCT05676229|DIETARY_SUPPLEMENT|Probiotic blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
219694385|NCT05676229|DIETARY_SUPPLEMENT|Placebo|Maltodextrin only (vehicle)
219694386|NCT04811157|DIETARY_SUPPLEMENT|Test product|200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
219107851|NCT03068806|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
219107852|NCT02378402|OTHER|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
219694387|NCT04811157|DIETARY_SUPPLEMENT|Control product|200 g/day of unsweetened yogurt
219694388|NCT05626569|DRUG|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
219107853|NCT03292146|DRUG|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
219107854|NCT03292146|DRUG|Placebo Injection|Placebo Injection at baseline and 6 months
219107855|NCT03292146|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
219107856|NCT01058434|DRUG|TKI258|
219107857|NCT05983744|OTHER|0 Hz Control|Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
219107858|NCT05983744|OTHER|0.1 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
219107859|NCT05983744|OTHER|0.05 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
219107860|NCT01070823|DRUG|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
219107861|NCT00545363|DRUG|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
219107862|NCT05799937|PROCEDURE|Non Surgical Root Canal Treatment|After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
219107863|NCT02231437|DRUG|Berodual®|
219107864|NCT04017390|DRUG|Theraworx Foam|Apply Theraworx Foam alone
219107865|NCT04017390|DRUG|Placebo Foam|Apply placebo foam alone
219694389|NCT04249479|OTHER|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
219694390|NCT04249479|OTHER|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
219694391|NCT04249479|OTHER|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
219694392|NCT00243763|DRUG|TKI258|
219694393|NCT05449899|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
219694394|NCT05449899|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
219694395|NCT05449899|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
219694396|NCT05449899|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
219694397|NCT05449899|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
219694398|NCT00146562|DRUG|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
219694399|NCT00146562|DRUG|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
219694400|NCT00146562|DRUG|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
219107866|NCT04017390|OTHER|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
219107867|NCT04017390|OTHER|Placebo Foam and night time splint|Apply placebo foam and night time splint
219107868|NCT01197820|DEVICE|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
219107869|NCT00366301|DRUG|Insulin glargine injection|Once daily for 14 weeks
219107870|NCT00366301|DRUG|metformin|Up to 4 pils per day (2g per day) maximum
219107871|NCT00366301|DRUG|Placebo pill|Up to 4 pills per day
219107872|NCT05351645|BEHAVIORAL|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
219107873|NCT00299195|DRUG|sulindac|Sulindac 150 mg po bid x 24 weeks
219107874|NCT00299195|DRUG|Placebo|Placebo bid x 24 weeks
219694401|NCT00146562|DRUG|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
219694402|NCT00146562|DRUG|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
219694403|NCT01403662|DRUG|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
219224619|NCT07042646|BEHAVIORAL|Sexual and Reproductive Health Training program|'The Sexual and Reproductive Health education program was prepared by researchers who are experts in the field of public health and public health nursing. The program was implemented once a week for 3 weeks (why 3 weeks) in 50-60 minute sessions (Table 1). The content and duration of the application were prepared in accordance with the Ministry of Health Sexual and Reproductive Health: National Strategic Action Plan for the Health Sector (2005-2015) and the Turkey Reproductive Health Program Sexual and Reproductive Health Service Standards (2007). Each program session was two education sessions, and all the questions of the disabled woman were answered .
219694404|NCT06195423|BEHAVIORAL|Stop OsteoARthritis (SOAR) program|"The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of;~1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day.~2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals."
219107875|NCT03792217|OTHER|1.3% NaOCl|Endodontic irrigant
219107876|NCT03792217|OTHER|5.25% NaOCl|Endodontic irrigant
219107877|NCT02354963|PROCEDURE|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
219107878|NCT04737317|DIAGNOSTIC_TEST|ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy|ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
219107879|NCT00179712|DRUG|CC-5013|
219107880|NCT00179712|DRUG|topotecan|
219107881|NCT01348776|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
219107882|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
219107883|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
219107884|NCT01463293|DIETARY_SUPPLEMENT|Placebo|Capsule containing no probiotic once a day
219107885|NCT01305278|OTHER|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
219107886|NCT03655990|DEVICE|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
219694405|NCT06195423|BEHAVIORAL|Living Well after ACLR program|Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
219694406|NCT00756626|BEHAVIORAL|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
219694407|NCT04184401|DRUG|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution"
219694408|NCT04184401|DRUG|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~\- 70% of ascites: replacement with Hartmann's solution"
219694409|NCT03568201|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
219694410|NCT00103454|DRUG|GW685698X|
219694411|NCT00644761|DRUG|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
219694412|NCT05343325|DRUG|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
219694413|NCT05343325|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
219694414|NCT02419872|DRUG|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
219694415|NCT02552485|OTHER|No intervention was applied, because it is an observational study|
219694416|NCT01774981|DRUG|Placebo|Administered IV
219694417|NCT01774981|DRUG|LY3016859|Administered IV
219694418|NCT04345003|DEVICE|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
219694419|NCT05022498|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
219694420|NCT02625701|PROCEDURE|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
219694421|NCT02625701|PROCEDURE|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
219694422|NCT00960193|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
219694423|NCT00960193|OTHER|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
219107887|NCT01099930|OTHER|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
219107888|NCT01099930|OTHER|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
219107889|NCT05243381|BIOLOGICAL|20 ml blood test|20 ml blood test
219107890|NCT03452605|DIETARY_SUPPLEMENT|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
219107891|NCT03976895|PROCEDURE|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
219107892|NCT03976895|PROCEDURE|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
219107893|NCT01361620|DRUG|aspirin|aspirin 81mg, 7-10 days
219107894|NCT00706784|DRUG|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
219694424|NCT05719181|BIOLOGICAL|rhBMP-2|Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
219694425|NCT01324102|BEHAVIORAL|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
219694426|NCT03362944|BEHAVIORAL|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
219694427|NCT03362944|BEHAVIORAL|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
219694428|NCT01235065|DEVICE|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
219694429|NCT00386334|DRUG|Eszopiclone|2 mg tablet once per day in the evening
219694430|NCT00386334|DRUG|Placebo|Tablet one per day in the evening.
219694431|NCT01091922|DIETARY_SUPPLEMENT|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
219694432|NCT01091922|DIETARY_SUPPLEMENT|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
219107895|NCT04896125|DRUG|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
219694433|NCT03843372|DEVICE|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
219107896|NCT03125941|DRUG|Dexamethasone|pre-operative intravenous administration
219107897|NCT01619046|BIOLOGICAL|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min
219224620|NCT07043114|OTHER|BFR-Walking|The training consists of the patients walking on a treadmill twice a week for a total of six weeks until their pain becomes too severe and they have to take a break. After a one-minute break, this is increased again until the pain reaches its maximum. This is done a total of three times per appointment. Additionally, patients will receive a individual BFR intervention bilaterally with a exercise pressure corresponding to 60% of their LOP.
219224621|NCT07042568|BEHAVIORAL|Nursing education aimed at preventing oral mucositis|The intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.
219694434|NCT00902577|DRUG|FMISO|FMISO PET scans
219694435|NCT00902577|OTHER|MRI|Undergo MRI
219694436|NCT00902577|OTHER|PET|Undergo FMISO PET scan
219694437|NCT00902577|OTHER|MRS|
219694438|NCT05781867|OTHER|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
219694439|NCT03537066|DEVICE|CPAP|All patients included will be treated by CPAP
219694440|NCT03702660|OTHER|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
219694441|NCT03702660|OTHER|Peripheral venous cannulation|Intravenous access for infusions
219107898|NCT01619046|BIOLOGICAL|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
219694442|NCT03702660|OTHER|GLP-1|Peptide infusion
219694443|NCT01236924|OTHER|Global postural reeducation|
219694444|NCT06078215|COMBINATION_PRODUCT|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
219694445|NCT05342896|BEHAVIORAL|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
219107899|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
219107900|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
219107901|NCT03176446|DEVICE|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
219107902|NCT03176446|DEVICE|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
219224622|NCT07043660|BEHAVIORAL|AdoptMindful2Care|AdoptMindful2Care is a mindful parenting post-adoption intervention with eight weekly group sessions (approximately 90 minutes each), delivered in person by trained psychologists, plus one follow-up session held two months after completion. The intervention integrates psychoeducation, mindfulness-based exercises, mindful parenting and self-compassion practices, as well as strategies informed by Cognitive Behavioral Therapy (CBT). The program is designed to help adoptive parents reduce parenting stress and promote positive parenting practices.
219694446|NCT05342896|BEHAVIORAL|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
219694447|NCT06213558|DEVICE|Rectangular and square striaght archwire technique|The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
219694448|NCT06082479|PROCEDURE|intraoral cryotherapy,ice gel|A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
219694449|NCT04343183|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
219694450|NCT02560168|DEVICE|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
219694451|NCT02560168|DEVICE|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
219694452|NCT02560168|DEVICE|Transthoracic Echocardiography|
219694453|NCT00785356|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
219694454|NCT00785356|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
219694455|NCT00785356|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
219694456|NCT02888834|OTHER|Adverse drug reaction|
219224623|NCT07043465|DIAGNOSTIC_TEST|14 days ambulatory rhythm monitoring|14 days ambulatory rhythm monitoring using Byteflies
219224624|NCT07043530|BEHAVIORAL|In-person sleep hygiene-based intervention|The in-person sleep hygiene-based intervention will be delivered in 8 sessions by an sleep expert using digital resources, previously designed and expert validated. During the intervention, the following topics will be covered: (1) sleep hygiene generalities, (2) sleep and environment, (3) sleep and technology, (4) sleep and diet, (5) sleep and excercise, (6) sleep and stimulus control, (7) breathing techniques, (8) mindfulness. The sessions will be delivered twice a week with an approximated duration of 45 minutes each, until completed.
219694457|NCT02280252|DRUG|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
219694458|NCT02280252|RADIATION|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
219694459|NCT01559662|DIETARY_SUPPLEMENT|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
219694460|NCT04267978|DRUG|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
219694461|NCT05452265|PROCEDURE|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was \>2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
219107903|NCT03176446|DEVICE|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
219224625|NCT07043530|BEHAVIORAL|Online sleep hygiene-based intervention|The online sleep hygiene-based intervention will be delivered in 8 sessions through a self-paced educational platform; the content will be the same as in the in-person intervention, but tailored for use in digital learning platforms. The suggest completion time for each session will be 45 minutes. Although its self-paced nature, participants are required to complete it within one month, following the same timeline as the face-to-face arm.
219694462|NCT02815085|OTHER|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
219694463|NCT03238417|OTHER|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
219694464|NCT03102502|DEVICE|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
219107904|NCT03176446|DRUG|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
219107905|NCT03176446|DRUG|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
219107906|NCT01989559|BIOLOGICAL|gp100:209-217(210M) Peptide Vaccine|Given SC
219107907|NCT01989559|BIOLOGICAL|HPV 16 E7:12-20 Peptide Vaccine|Given SC
219107908|NCT01989559|OTHER|Laboratory Biomarker Analysis|Correlative studies
219107909|NCT00131859|PROCEDURE|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
219107910|NCT01122004|DRUG|Pregabalin|
219107911|NCT01122004|DRUG|Pregabalin|
219107912|NCT05185518|DEVICE|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
219107913|NCT02918240|PROCEDURE|Appointment intervals|
219107914|NCT02918240|DEVICE|fixed orthodontic braces|
219107915|NCT01710917|DRUG|Targinact® (oxycodon/naloxon)|
219107916|NCT05904860|OTHER|Backward Gait Training|Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
219107917|NCT05904860|OTHER|Forward Gait Training|Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
219107918|NCT04583683|BEHAVIORAL|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
219694465|NCT03102502|DRUG|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
219694466|NCT04163848|OTHER|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
219694467|NCT00821535|DRUG|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
219694468|NCT02310074|DRUG|Pulsatile Gonadotropin Releasing Hormone|
219107919|NCT04583683|PROCEDURE|Metabolic Surgery|Patients will undergo metabolic surgery
219694469|NCT02310074|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
219107920|NCT00195390|BIOLOGICAL|Prevenar|Prevenar 0.5ml/ Vial and PFS
219107921|NCT03965819|DIETARY_SUPPLEMENT|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
219107922|NCT03965819|OTHER|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
219107923|NCT03965819|OTHER|Placebo|No active ingredients
219107924|NCT00111124|DRUG|Enbrel®|
219107925|NCT00779584|DRUG|MK-8776|IV infusion
219107926|NCT00779584|DRUG|Gemcitabine|IV infusion
219360863|NCT04460755|OTHER|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219694470|NCT02310074|DRUG|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
219694471|NCT05455827|OTHER|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
219694472|NCT05455827|OTHER|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
219694473|NCT00716612|DRUG|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
219694474|NCT00716612|DRUG|Placebo control|po Placebo QD
219107927|NCT00084734|DRUG|capecitabine|Oral
219107928|NCT00084734|DRUG|cisplatin|IV
219107929|NCT00084734|DRUG|docetaxel|IV
219107930|NCT05032118|DRUG|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
219107931|NCT05032118|DRUG|Propofol|Standard of care titratable propofol infusion.
219107932|NCT05425030|DIETARY_SUPPLEMENT|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
219107933|NCT05425030|BEHAVIORAL|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
219107934|NCT01896115|DEVICE|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
219107935|NCT04833101|BIOLOGICAL|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
219107936|NCT04833101|BIOLOGICAL|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
219107937|NCT04833101|BIOLOGICAL|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
219107938|NCT02796287|PROCEDURE|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
219107939|NCT02796287|PROCEDURE|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
219107940|NCT02796287|RADIATION|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
219107941|NCT01253122|DRUG|TRx0037|
219107942|NCT01086566|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
219107943|NCT02467413|DRUG|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
219107944|NCT02467413|OTHER|BAC Matched Vehicle|BAC Matched Vehicle
219694475|NCT03918265|DRUG|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
219694476|NCT05540145|DRUG|SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
219694477|NCT00083915|DRUG|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
219694478|NCT00083915|DRUG|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
219694479|NCT00083915|DRUG|Adriamycin|20mg/m2 continuous infusion -3 and -2.
219694480|NCT00083915|DRUG|Etoposide|80mg/m2 continuous infusion -3 and -2.
219694481|NCT00083915|DRUG|Melphalan|200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
219694482|NCT00083915|DRUG|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).
219694483|NCT00083915|DRUG|Dexamethasone|40 mg po days 1 - 4 (4 days)
219694484|NCT04555603|DRUG|Inlyta|axitinib
219107945|NCT03603015|DIAGNOSTIC_TEST|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
219694485|NCT04555603|DRUG|Bavencio|avelumab
219694486|NCT04555603|DRUG|Keytruda|Pembrolizumab
219694487|NCT00122057|DRUG|antibiotic treatment|
219694488|NCT05117853|DRUG|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized"
219694489|NCT05117853|PROCEDURE|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
219694490|NCT05670444|DRUG|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
219694491|NCT02135952|PROCEDURE|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
219694492|NCT02135952|OTHER|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
219107946|NCT01280318|PROCEDURE|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
219107947|NCT00536068|DRUG|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"1. Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~2. Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~3. Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~4. Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
219107948|NCT03122262|DRUG|Dolutegravir|DTG 50mg Oral Tablet once daily
219107949|NCT03122262|DRUG|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
219360864|NCT02988102|OTHER|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
219694493|NCT02135952|DRUG|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
219107950|NCT03122262|DRUG|Truvada|
219107951|NCT03122262|DRUG|Atripla|
219107952|NCT02878213|DEVICE|D700 System|Atrial Fibrillation Ablation Procedure
219107953|NCT04887181|OTHER|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
219694494|NCT00434824|DRUG|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
219694495|NCT00434824|DRUG|Placebo|treatment for 12 months with placebo in divided doses
219694496|NCT01126216|DRUG|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,
219694497|NCT01126216|RADIATION|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
219694498|NCT01126216|DRUG|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33
219694499|NCT01126216|RADIATION|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
219107954|NCT04887181|OTHER|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
219107955|NCT04887181|OTHER|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
219694500|NCT00253136|DRUG|risperidone|
219694501|NCT02787980|BIOLOGICAL|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
219694502|NCT00001567|DRUG|Roferon-A|
219107956|NCT04786522|DIAGNOSTIC_TEST|Bioimpedenziometry, Handgrip strenght evaluation|The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.
219107957|NCT04786522|DIAGNOSTIC_TEST|Evaluation on blood specimens|Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)
219107958|NCT00264472|DRUG|ADH300004|5 mg
219107959|NCT05542732|DEVICE|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
219694503|NCT00853762|DRUG|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
219107960|NCT00974519|DRUG|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
219107961|NCT00974519|DRUG|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
219107962|NCT00974519|DRUG|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
219694504|NCT00853762|DRUG|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
219694505|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
219107963|NCT05083624|BEHAVIORAL|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
219107964|NCT00886262|DRUG|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
219107965|NCT00886262|DRUG|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
219360865|NCT00578123|BEHAVIORAL|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
219360866|NCT00445887|OTHER|Laboratory Biomarker Analysis|Correlative studies
219360867|NCT00445887|DRUG|Levonorgestrel|Given orally
219694506|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
219694507|NCT05866913|PROCEDURE|Sciatic nerve slippage.|Sciatic nerve slippage.
219694508|NCT05866913|PROCEDURE|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
219694509|NCT05866913|PROCEDURE|passive shoulder mobilization.|passive shoulder mobilization.
219694510|NCT02321852|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
219360868|NCT00445887|OTHER|Placebo|Given orally
219360869|NCT01860560|DEVICE|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
219107966|NCT03713372|DRUG|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
219107967|NCT05477706|OTHER|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
219694511|NCT02321852|DRUG|Placebo|Once daily oral administration of placebo mannitol for 7 days
219694512|NCT01800045|DRUG|Pitolisant|1 capsule in the morning before breakfast
219694513|NCT01800045|DRUG|Placebo|1 capsule in the morning before breakfast
219694514|NCT05584995|PROCEDURE|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
219694515|NCT05584995|PROCEDURE|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
219694516|NCT02461693|DRUG|Caffeine|200mg delivered as pill; one-time dose
219694517|NCT02461693|DRUG|Placebo|Lactose-based pill; one-time dose
219694518|NCT04761003|DEVICE|Thoracoscopy forceps|take pleural biopsy
219694519|NCT00945646|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
219694520|NCT00945646|DRUG|Vehicle|Instill four times two times a day
219694521|NCT04998708|OTHER|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
219694522|NCT02653846|PROCEDURE|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
219694523|NCT02653846|PROCEDURE|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
219694524|NCT02000921|OTHER|VLNC cigarettes|Modified risk tobacco product
219694525|NCT02000921|OTHER|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
219694526|NCT02000921|OTHER|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
219694527|NCT02000921|OTHER|CN cigarettes|Experimental cigarettes with conventional nicotine content.
219694528|NCT01517217|PROCEDURE|No girdle|No girdle is used for the first five postoperative days
219694529|NCT01517217|PROCEDURE|Girdle|Girdle the first five postoperative days
219694530|NCT00583648|OTHER|Urinanlysis|sending a Urine sample to the laboratory for processing
219694531|NCT04237948|DEVICE|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
219694532|NCT04237948|BEHAVIORAL|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
219694533|NCT00746369|BEHAVIORAL|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
219694534|NCT04905043|DRUG|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
219694535|NCT04905043|DRUG|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
219694536|NCT00106002|DRUG|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
219694537|NCT05374096|OTHER|Patient-Chosen Music|Music played into headphones.
219694538|NCT05374096|OTHER|Placebo|Silence into headphones.
219107968|NCT05477706|OTHER|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
219107969|NCT01610232|DEVICE|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
219694539|NCT05899361|DEVICE|Electromagnetic Guided Laparoscopy|Standard Care
219694540|NCT05899361|DEVICE|Ultrasound|Standard Care
219694541|NCT04215835|DRUG|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
219694542|NCT04215835|DRUG|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
219694543|NCT04895501|OTHER|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
219694544|NCT03485586|DEVICE|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
219694545|NCT03485586|DEVICE|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
219694546|NCT04246463|DEVICE|Thoracic|Implant of a Relay stent graft system
219694547|NCT04246463|DEVICE|Abdominal|Implant with an Anaconda or Treo Stent graft system
219107970|NCT01610232|OTHER|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
219694548|NCT04246463|DEVICE|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
219107971|NCT06475716|BEHAVIORAL|Internet-based guided programme Spring|Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
219360870|NCT01860560|DEVICE|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
219694549|NCT04246463|DEVICE|Illiac Artery|Implant with an Anaconda Iliac leg only
219694550|NCT02765737|OTHER|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
219694551|NCT02765737|DEVICE|Mepilex Ag|
219694552|NCT01790399|PROCEDURE|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
219694553|NCT02173782|DRUG|Berodual® Respimat ® high dose|
219694554|NCT02173782|DRUG|Berodual® Respimat ® low dose|
219694555|NCT02173782|DRUG|Berodual® MDI|
219694556|NCT02173782|DRUG|Placebo|
219694557|NCT00501631|DRUG|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
219694558|NCT00501631|DRUG|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
219694559|NCT03336125|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
219694560|NCT03336125|DIETARY_SUPPLEMENT|Placebo|120 mg olive oil
219694561|NCT02837588|DEVICE|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
219694562|NCT04717635|BIOLOGICAL|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
219694563|NCT00179140|DRUG|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
219694564|NCT00179140|BEHAVIORAL|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
219107972|NCT03716622|DRUG|Furazolidone|bismuth-furazolidone-containing quadruple regimens
219694565|NCT04236843|DIETARY_SUPPLEMENT|Feces|Feces from healthy donor
219694566|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
219694567|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
219694568|NCT05025930|DEVICE|endoscopic surgical instrument control system (SP1000: single-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
219694569|NCT05025930|DEVICE|endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
219694570|NCT01005238|DRUG|Lamivudine|
219694571|NCT01005238|DRUG|Telbivudine|
219694572|NCT01014234|DRUG|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
219694573|NCT01014234|DRUG|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
219694574|NCT05009355|DRUG|Vitamin C|antioxidant
219694575|NCT04215367|DIETARY_SUPPLEMENT|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
219694576|NCT04215367|DIETARY_SUPPLEMENT|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
219694577|NCT03836586|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
219694578|NCT03836586|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
219694579|NCT04456686|DRUG|LY3016859|LY3016859 given IV.
219694580|NCT04456686|DRUG|Placebo|Placebo given IV.
219694581|NCT00902863|BEHAVIORAL|YOGA|Patients with chronic pain will undergo a six week course of YOGA
219694582|NCT03670992|PROCEDURE|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
219694583|NCT00494663|DRUG|DIO-902|150mg tablet once per day for 16 weeks
219694584|NCT00494663|DRUG|DIO-902|300mg tablet once per day for 16 weeks
219694585|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
219694586|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
219694587|NCT00494663|DRUG|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
219694588|NCT00494663|DRUG|DIO-902|300mg DIO-902 tablet daily for 16 weeks
219694589|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet for 16 weeks
219694590|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
219694591|NCT01252368|BIOLOGICAL|hypertension|patients taking daily ACE inhibitors or sartanes
219694592|NCT02007902|OTHER|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"* Patient inclusion at birth~* Total plasma protein values measurement on cord blood sample at birth~* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth."
219694593|NCT00639119|DRUG|Ropinirole|8 + 8 weeks cross-over placebo controlled
219694594|NCT00891813|DRUG|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
219694595|NCT00743210|DRUG|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
219694596|NCT00743210|DRUG|Placebo|Placebo, 3 grams once per day for 3 weeks.
219107973|NCT03716622|DRUG|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
219107974|NCT05771584|DRUG|AST-301|100 μg
219107975|NCT05771584|DRUG|rhuGM-CSF|100 μg
219107976|NCT06023355|PROCEDURE|HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
219107977|NCT04263090|DRUG|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
219107978|NCT04263090|DRUG|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
219694597|NCT06195085|RADIATION|CT-guided radioactive iodine-125 seed implantation|The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
219694598|NCT06458348|BEHAVIORAL|Local opera appreciating and Medical gymnastics training|To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
219694599|NCT02532036|BIOLOGICAL|Aerosol inhaled MVA85A|
219694600|NCT02532036|BIOLOGICAL|Intramuscular MVA85A|
219694601|NCT02532036|BIOLOGICAL|Intramuscular Saline placebo|
219694602|NCT02532036|BIOLOGICAL|Aerosol inhaled Saline placebo|
219694603|NCT04974073|DRUG|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
219694604|NCT04823234|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound signs in Covid 19 positive pregnant patients
219694605|NCT01329198|DEVICE|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
219694606|NCT02349555|DIETARY_SUPPLEMENT|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
219694607|NCT02581592|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
219694608|NCT01189448|DRUG|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
219694609|NCT01189448|DRUG|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
219694610|NCT03242785|OTHER|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
219694611|NCT01976000|PROCEDURE|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
219694612|NCT04833374|DRUG|Methylprednisolone|Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
219694613|NCT00473083|DRUG|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
219694614|NCT00473083|DRUG|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
219694615|NCT00473083|DRUG|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
219694616|NCT00473083|DRUG|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
219694617|NCT03377465|DIAGNOSTIC_TEST|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
219694618|NCT02340455|DRUG|Pregabalin_male|Pregabalin 150mg bid 1day Men
219694619|NCT02340455|DRUG|Pregabalin_female|Pregabalin 150mg bid 1day Women
219694620|NCT02340455|DRUG|Placebo_Men|Placebo durg
219360573|NCT05713643|PROCEDURE|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
219694621|NCT02340455|DRUG|Placebo_Women|Placebo\_Women
219694622|NCT00003360|RADIATION|iodine I 131 monoclonal antibody A33|
219107979|NCT01790321|DEVICE|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
219107980|NCT02498730|BEHAVIORAL|Interval Training|High Intensity Interval Training at 100% VO2Max
219694623|NCT02415530|BEHAVIORAL|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months
219107981|NCT02498730|BEHAVIORAL|Continuous Training|Continuous Stimulous at 60% VO2Max
219107982|NCT02498730|BEHAVIORAL|Control|Only Dependent Variables Measures
219107983|NCT02660762|DRUG|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
219694624|NCT02415530|OTHER|No intervention|No intervention
219694625|NCT00402935|OTHER|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
219694626|NCT00402935|PROCEDURE|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
219694627|NCT00402935|PROCEDURE|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
219694628|NCT00402935|PROCEDURE|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
219694629|NCT00880841|DRUG|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
219694630|NCT02915835|DRUG|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
219107984|NCT02660762|DRUG|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
219107985|NCT02660762|DRUG|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
219107986|NCT02660762|DRUG|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
219107987|NCT02660762|DRUG|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
219107988|NCT02660762|DRUG|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
219107989|NCT02660762|DRUG|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
219107990|NCT02660762|DRUG|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
219107991|NCT02660762|DRUG|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
219107992|NCT02660762|DRUG|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
219107993|NCT02660762|DRUG|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
219107994|NCT02660762|DRUG|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
219107995|NCT02660762|DRUG|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
219107996|NCT01245868|DRUG|Lidocaine|
219107997|NCT01245868|DRUG|bupivacaine|
219107998|NCT03411889|DIAGNOSTIC_TEST|MRI scanning|MRI scanning during tear drainage
219107999|NCT01534455|DRUG|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
219108000|NCT01534455|DRUG|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
219108001|NCT06441058|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
219108002|NCT00516750|DRUG|cisplatin|
219694631|NCT02915835|DRUG|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
219694632|NCT00967122|PROCEDURE|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
219694633|NCT03722576|DRUG|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
219108003|NCT00516750|DRUG|doxorubicin hydrochloride|
219694634|NCT06375382|OTHER|acupuncture|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
219694635|NCT06375382|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
219108004|NCT00516750|DRUG|methotrexate|
219108005|NCT00516750|DRUG|vinblastine|
219108006|NCT00516750|GENETIC|gene expression profiling|
219108007|NCT00516750|PROCEDURE|neoadjuvant therapy|
219108008|NCT00508339|BEHAVIORAL|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
219694636|NCT00299520|DRUG|intravenous iclaprim or intravenous linezolid|
219694637|NCT03118180|BIOLOGICAL|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
219694638|NCT00072553|DRUG|celecoxib|
219694639|NCT00072553|DRUG|fluorouracil|
219694640|NCT00072553|DRUG|leucovorin calcium|
219360574|NCT02838407|OTHER|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
219108009|NCT06115902|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
219108010|NCT02562963|BIOLOGICAL|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
219108011|NCT02496403|BEHAVIORAL|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
219360575|NCT02838407|OTHER|Nasopharyngeal swab sampling|1 swab, Day 0
219694641|NCT00072553|DRUG|oxaliplatin|
219694642|NCT00072553|PROCEDURE|adjuvant therapy|
219694643|NCT00072553|PROCEDURE|conventional surgery|
219694644|NCT00072553|PROCEDURE|neoadjuvant therapy|
219108012|NCT02494206|DRUG|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
219108013|NCT04440644|BEHAVIORAL|BBI|administration of psychometric test
219108014|NCT02626702|OTHER|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
219108015|NCT06007482|DRUG|ES009|ES009 is administered via intravenous infusion, once every 21 days.
219108016|NCT04986982|DRUG|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
219694645|NCT05551416|OTHER|Identification of risk factors|Demographics, life habits and risk factors studies
219694646|NCT05551416|OTHER|Characterization of premalignant gastric lesions|Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
219694647|NCT05551416|OTHER|Identification of biomarkers|Multiomic studies
219694648|NCT05551416|OTHER|Identification of gastric cancer hereditary predisposition|Genomic studies for the identification of individuals with hereditary GC predisposition
219694649|NCT03059667|DRUG|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
219694650|NCT03059667|DRUG|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
219694651|NCT03059667|DRUG|Carboplatin|In accordance with the summary of product characteristics.
219694652|NCT03059667|DRUG|Etoposide|In accordance with the summary of product characteristics.
219694653|NCT02530775|PROCEDURE|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
219694654|NCT02530775|PROCEDURE|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
219694655|NCT04474483|DRUG|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
219694656|NCT04474483|OTHER|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
219694657|NCT04499079|OTHER|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
219694658|NCT00192114|DRUG|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
219694659|NCT06270641|OTHER|ExerciseRx intervention|ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
219694660|NCT06523127|OTHER|Recording data from the ICU stay and the post-ICU follow-up.|Record analysis of the post-ICU follow-up with the Interpretative Phenomenological Analysis
219694661|NCT05475509|OTHER|Virtually reality|Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
219694662|NCT00113607|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
219108017|NCT04986982|OTHER|Placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
219108018|NCT05298098|DRUG|Hypertonic Saline Solution|Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.
219694663|NCT00113607|DRUG|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
219694664|NCT00113607|DRUG|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
219694665|NCT01418339|DRUG|Aripiprazole|Aripiprazole tablet administered orally once a week.
219694666|NCT01418339|DRUG|Placebo|Aripiprazole-matching placebo tablet administered orally once a week.
219108019|NCT05298098|DRUG|Placebo|Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
219108020|NCT01155661|DRUG|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
219694667|NCT03885908|OTHER|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
219694668|NCT03885908|OTHER|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
219694669|NCT00909844|DRUG|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
219108021|NCT01155661|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
219108022|NCT01860014|DRUG|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
219108023|NCT01860014|DRUG|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
219108024|NCT04513678|BEHAVIORAL|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
219694670|NCT01766362|PROCEDURE|PRPC using Pascal laser|
219694671|NCT03003234|PROCEDURE|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
219694672|NCT03003234|DEVICE|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
219694673|NCT03003234|DIETARY_SUPPLEMENT|Nutri drink|Liquid meal of 200 ml.
219694674|NCT06343116|DRUG|Nimotuzumab injection|Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
219694675|NCT06343116|DRUG|Placebo|Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
219694676|NCT06343116|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
219694677|NCT00706004|DRUG|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
219694678|NCT01064479|DRUG|Carboplatin|Given IV
219694679|NCT01064479|DRUG|Cisplatin|Given IV
219694680|NCT01064479|DRUG|Docetaxel|Given IV
219694681|NCT01064479|DRUG|Erlotinib Hydrochloride|Given PO
219694682|NCT01064479|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219694683|NCT01064479|OTHER|Pharmacological Study|Optional correlative studies
219694684|NCT01064479|OTHER|Placebo|Given PO
219108025|NCT02101918|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
219108026|NCT02101918|OTHER|Laboratory Biomarker Analysis|Correlative studies
219108027|NCT02101918|BIOLOGICAL|Ziv-Aflibercept|Given IV
219108028|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
219108029|NCT01370005|DRUG|BI 10773|BI 10773 high dose once daily
219360576|NCT01478854|RADIATION|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
219360577|NCT01478854|DRUG|Chemotherapy|Temozolomide
219694685|NCT01064479|OTHER|Quality-of-Life Assessment|Ancillary studies
219694686|NCT00216255|DRUG|Pagoclone|
219694687|NCT00216255|DRUG|Placebo|
219694688|NCT04423471|DIAGNOSTIC_TEST|Sociodemographic variables|"* Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~* General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~* Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~* Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~* Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~* Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~* Result variables: Changes in PASI or MADRS scores"
219108030|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
219108031|NCT01370005|DRUG|BI 10773|BI 10773 low dose once daily
219108032|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
219108033|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
219108034|NCT02302066|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
219108035|NCT02302066|BIOLOGICAL|TDV Placebo|Placebo-matching vaccine
219108036|NCT02069769|BEHAVIORAL|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
219108037|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 1|1 x 10\^7 Inf.U MVA-BN-WEV vaccine
219108038|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 2|1 x 10\^8 Inf.U MVA-BN-WEV vaccine
219108039|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 3|2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
219108040|NCT00274690|DRUG|GW679769|
219108041|NCT02974530|OTHER|Neurological evaluation|
219108042|NCT02974530|OTHER|Laryngological evaluation|
219108043|NCT02974530|OTHER|MRI evaluation|
219108044|NCT02974530|OTHER|Breathing investigation|
219108045|NCT02974530|OTHER|MRI and articulatory investigation|
219108046|NCT02974530|OTHER|Postural investigation|
219694689|NCT06202846|GENETIC|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
219694690|NCT00749398|BIOLOGICAL|Infliximab|According to local country regulations.
219694691|NCT03940872|DIAGNOSTIC_TEST|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~\- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
219694692|NCT04915235|BEHAVIORAL|Algorithm|Algorithm
219694693|NCT03226444|DRUG|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
219694694|NCT03226444|DRUG|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
219694695|NCT03226444|DRUG|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
219694696|NCT00466817|OTHER|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
219694697|NCT00466817|DRUG|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
219694698|NCT05918536|DIAGNOSTIC_TEST|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
219694699|NCT01639352|BIOLOGICAL|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
219694700|NCT05294861|OTHER|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
219694701|NCT05294861|OTHER|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
219694702|NCT04517292|DRUG|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
219694703|NCT04517292|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
219694704|NCT03093181|OTHER|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
219694705|NCT03093181|OTHER|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
219694706|NCT03093181|OTHER|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
219694707|NCT03093181|OTHER|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
219108047|NCT02974530|OTHER|Voice and soundscape investigation|
219694708|NCT00038766|DRUG|semapimod|semapipmod 60 mg IV x 5 days
219694709|NCT00038766|DRUG|semapimod|IV 30 mg x 5 days
219694710|NCT00038766|DRUG|placebo|placebo IV
219694711|NCT05983263|DRUG|Capsaicin|Capsaicin 8% patch (QUTENZA) apposed in coccygeal area
219694712|NCT03851263|BIOLOGICAL|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
219694713|NCT04283786|OTHER|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
219694714|NCT01564004|OTHER|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
219108048|NCT04380532|BIOLOGICAL|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
219694715|NCT00349141|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
219108049|NCT03236922|PROCEDURE|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
219108050|NCT03236922|PROCEDURE|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
219108051|NCT02592200|DIETARY_SUPPLEMENT|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
219108052|NCT02592200|DIETARY_SUPPLEMENT|Placebo|Two doses per day for 28 days
219108053|NCT01326273|PROCEDURE|Lymphopheresis|Lymphopheresis
219108054|NCT01326273|PROCEDURE|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
219108055|NCT01326273|PROCEDURE|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
219108056|NCT01326273|PROCEDURE|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
219108057|NCT00001266|DRUG|Suramin|
219108058|NCT04848883|BEHAVIORAL|Advanced AMS program|"1. \- Telephone acces to infectious disease experts to discuss patients' therpies during working days.~2. \- Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
219108059|NCT04848883|BEHAVIORAL|Standard AMS program|"1. \- Educational materials.~2. \- Updated local antibiotic guidelines.~3. \- Promotion of delayed antibiotic prescription.~4. \- Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. \- Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. \- Quarterly reports to prescribers of AMS outcomes at the centre-level."
219108060|NCT05373134|DRUG|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
219694716|NCT01219582|DRUG|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
219694717|NCT06506123|DEVICE|Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies|Machine learning algorithm to detect and classify patient-ventilator dyssynchronies, which is integrated in the mechanical ventilator (Fleximag Max, Magnamed, Brazil).
219694718|NCT04620577|OTHER|antibiotic|normal saline
219694719|NCT04210986|DIETARY_SUPPLEMENT|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
219694720|NCT04210986|DRUG|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
219694721|NCT02740842|BEHAVIORAL|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
219694722|NCT02740842|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
219694723|NCT06422039|DRUG|HRS-7535（D）Tablets|One HRS-7535（D）Tablet is administered to healthy subjects.
219694724|NCT06422039|DRUG|HRS-7535（C）Tablets|Two HRS-7535（C）Tablets is administered to healthy subjects.
219694725|NCT04971603|OTHER|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) \*, Sanyinjia (SP 6) \*, Weizhong (BL 40) \*, Baihui (GV 20), Shuigou (GV 26) \*, Zusanli (ST 36) \*, Quchi (LI 11) \*, Waiguan (TE 5) \*, Hegu (LI 4) \*, Huantiao (GB 30) \*, Yanglingquan (GB 34)\* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
219694726|NCT00542893|DRUG|Genasense® (G3139, oblimersen sodium)|
219694727|NCT00542893|DRUG|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
219694728|NCT00542893|DRUG|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
219694729|NCT00487903|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
219694730|NCT04322032|DRUG|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
219694731|NCT04322032|DRUG|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
219694732|NCT02378662|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
219694733|NCT01701245|DEVICE|GammaCore|vagal stimulation
219694734|NCT02400801|DRUG|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
219694735|NCT02400801|DRUG|ethinylestradiol + dienogest|oral oestroprogestogen
219694736|NCT01159574|DRUG|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
219694737|NCT01159574|DRUG|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
219694738|NCT01159574|DRUG|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
219694739|NCT05276791|OTHER|EMR|Endoscopic mucosal resection, according to standard care
219694740|NCT05276791|OTHER|ESD|Endoscopic submucosal dissection, according to standard care
219694741|NCT03369574|DRUG|Reslizumab|reslizumab administration
219694742|NCT01081197|OTHER|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
219694743|NCT01940822|OTHER|Energy Drink|
219108061|NCT05373134|OTHER|Placebo|Placebo
219108062|NCT01394484|OTHER|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
219108063|NCT01394484|DIETARY_SUPPLEMENT|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
219108064|NCT00525603|DRUG|Cyclophosphamide|200 mg/m\^2/day 3-5 IV 5-30 minutes
219108065|NCT00525603|DRUG|Fludarabine|20 mg/m\^2/day 3-5 IV 5-30 minutes
219108066|NCT00525603|DRUG|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
219108067|NCT00525603|DRUG|Rituximab|375 mg/m\^2/day 2 IV 4-6 hours
219108068|NCT02638623|DRUG|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
219108069|NCT02638623|DRUG|Placebo|No additional fluids will be administered
219108070|NCT02918929|DRUG|EDP 305|
219108071|NCT02918929|DRUG|Placebo|placebo to match EDP 305
219694744|NCT01940822|OTHER|Placebo Drink|
219694745|NCT02897557|DEVICE|Insulet Artificial Pancreas (AP) System|
219694746|NCT04189016|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
219108072|NCT03493763|DIAGNOSTIC_TEST|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
219108073|NCT03510624|DRUG|Rebaudioside A|Rebaudioside A 3g
219108074|NCT03510624|DRUG|Placebo|Empty capsules
219108075|NCT04535622|BEHAVIORAL|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
219108076|NCT02520648|OTHER|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
219108077|NCT02520648|OTHER|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
219108078|NCT02520648|OTHER|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
219108079|NCT02010801|PROCEDURE|irreversible electroporation|
219694747|NCT01627548|BEHAVIORAL|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
219694748|NCT02965924|DRUG|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
219694749|NCT03343548|DRUG|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
219694750|NCT03343548|DRUG|normal saline|2cc of normal saline will be administered epidurally
219108080|NCT02010801|DEVICE|nanoknife AngioDynamics US Ltd|
219108081|NCT02743923|DRUG|carboplatin|AUC 6
219108082|NCT02743923|DRUG|paclitaxel|200mg/m2
219108083|NCT02743923|DRUG|Bevacizumab|15 mg/kg
219108084|NCT02743923|DRUG|Pemetrexed|500 mg/m2
219108085|NCT02743923|DRUG|cisplatin|75 mg/m2
219108086|NCT02514421|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
219108087|NCT02514421|DRUG|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
219108088|NCT02514421|DRUG|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
219108089|NCT05134402|DIAGNOSTIC_TEST|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
219694751|NCT02282462|OTHER|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
219108090|NCT03646630|PROCEDURE|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
219108091|NCT03646630|PROCEDURE|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
219108092|NCT01279733|GENETIC|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
219108093|NCT01465828|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
219108094|NCT01465828|DRUG|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
219108095|NCT01534884|BIOLOGICAL|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
219694752|NCT02282462|OTHER|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
219694753|NCT02282462|OTHER|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
219694754|NCT02282462|OTHER|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
219694755|NCT02282462|OTHER|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
219694756|NCT02282462|OTHER|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
219694757|NCT02666222|DEVICE|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
219694758|NCT03149536|DIAGNOSTIC_TEST|Pharmacogenetic test|To develop a pharmacogenetic prediction test
219694759|NCT04781712|BEHAVIORAL|Modular mHealth for Tailored Rehabilitation|an individually tailored self-management through the mHealth app with a smart band worn on the wrist
219694760|NCT00562406|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
219694761|NCT00562406|PROCEDURE|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
219694762|NCT02443623|BIOLOGICAL|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
219694763|NCT05919628|OTHER|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
219694764|NCT00942136|DRUG|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
219694765|NCT00942136|DRUG|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
219694766|NCT00942136|DRUG|Placebo|Placebo Suspension as a single dose.
219694767|NCT00942136|DRUG|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
219694768|NCT02841124|OTHER|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
219694769|NCT04032132|DRUG|curcumin paste|curcumin is a herb used for medical purpose
219694770|NCT04032132|PROCEDURE|curettage|open flab debridement surgery
219694771|NCT00853294|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
219694772|NCT00853294|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
219694773|NCT01533532|DRUG|KLH-2109|
219108096|NCT02955121|OTHER|Prescriber Access to Genetic Information|
219108097|NCT02390739|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
219108098|NCT02390739|DRUG|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
219108099|NCT02390739|DRUG|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
219108100|NCT02390739|BIOLOGICAL|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
219108101|NCT00650143|DRUG|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
219108102|NCT00650143|DRUG|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
219108103|NCT00650143|DRUG|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
219694774|NCT01533532|DRUG|KLH-2109|
219694775|NCT01533532|DRUG|KLH-2109|
219694776|NCT01533532|DRUG|placebo|
219694777|NCT00169299|DRUG|Black cohosh|
219694778|NCT00169299|DRUG|Multibotanical preparation|
219694779|NCT00169299|DRUG|Multibotanical preparation + dietary soy counseling|
219694780|NCT00169299|DRUG|Conjugated equine estrogen +/- medroxyprogesterone acetate|
219108104|NCT00650143|DRUG|Gelatin|One capsule p.o. per day for 28 days
219108105|NCT01606696|BEHAVIORAL|HIIT|Higher intensity interval training.
219108106|NCT01606696|BEHAVIORAL|Standard intensity non-interval training|Standard intensity non-interval training.
219108107|NCT05893199|DEVICE|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
219108108|NCT05893199|OTHER|Usual care|usual follow-up in primary care both arms
219108109|NCT00347516|PROCEDURE|IOL calculation formula|
219694781|NCT01474486|DRUG|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
219694782|NCT04753866|DEVICE|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
219694783|NCT03839134|DEVICE|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
219694784|NCT03839134|DRUG|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
219694785|NCT03797859|PROCEDURE|Apneic ventilation|Ventilation by THRIVE
219694786|NCT04534309|BEHAVIORAL|Written Weight Loss Material|Participants will receive written weight loss material by email.
219694787|NCT04534309|BEHAVIORAL|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
219694788|NCT04534309|BEHAVIORAL|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
219694789|NCT05817123|OTHER|Questionnaires|"Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)"
219694790|NCT03504917|DRUG|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
219694791|NCT03504917|DRUG|Placebo|Participants will receive matching placebo.
219694792|NCT04219189|OTHER|Vaping condition|Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
219694793|NCT04219189|OTHER|Control condition|Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
219108110|NCT05053243|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
219108111|NCT03331185|BIOLOGICAL|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
219108112|NCT03331185|BIOLOGICAL|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
219108113|NCT01632943|DEVICE|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
219108114|NCT01871558|DRUG|Vildagliptin|50 mg b.i.d
219108115|NCT01871558|DRUG|Metformin|metformin is to be kept unchanged
219108116|NCT01871558|DRUG|sulfonylurea (SU)|
219108117|NCT01871558|DRUG|Basal Insulin|
219108118|NCT06040034|DRUG|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
219108119|NCT02139423|OTHER|CMV PCR|
219108120|NCT02698449|PROCEDURE|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
219108121|NCT02698449|PROCEDURE|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
219694794|NCT04870996|DEVICE|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
219108122|NCT02698449|PROCEDURE|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
219694795|NCT04870996|BEHAVIORAL|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
219694796|NCT01381497|DRUG|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
219694797|NCT01381497|DRUG|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
219694798|NCT02381236|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
219108123|NCT02698449|PROCEDURE|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
219108124|NCT02698449|RADIATION|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
219108125|NCT03317028|DRUG|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
219108126|NCT01695733|BIOLOGICAL|trivalent influenza vaccine|
219108127|NCT02057003|DRUG|DAA against HCV|
219108128|NCT04904081|DRUG|Indocyanine green|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
219108129|NCT03696719|DEVICE|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
219108130|NCT03696719|BIOLOGICAL|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
219108131|NCT04398615|DEVICE|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
219108132|NCT01067027|DIETARY_SUPPLEMENT|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
219108133|NCT03545373|DRUG|Azithromycin|Azithromycin tablet taken orally
219108134|NCT03545373|DRUG|Amoxicillin|Amoxicillin tablets taken orally
219108135|NCT05815901|DRUG|Epaminurad 6 mg|Epaminurad 6 mg tablet
219108136|NCT05815901|DRUG|Epaminurad 9 mg|Epaminurad 9 mg tablet
219108137|NCT05815901|DRUG|Febuxostat 40 mg|Febuxostat 40 mg tablet
219108138|NCT05815901|DRUG|Febuxostat 80 mg|Febuxostat 80 mg tablet
219108139|NCT05815901|DRUG|Epaminurad 6 mg placebo|Placebo tablet
219108140|NCT05815901|DRUG|Epaminurad 9 mg placebo|Placebo tablet
219108141|NCT05815901|DRUG|Febuxostat 40 mg placebo|Placebo tablet
219108142|NCT05815901|DRUG|Febuxostat 80 mg placebo|Placebo tablet
219108143|NCT03798704|DIAGNOSTIC_TEST|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
219108144|NCT02529878|DRUG|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
219694799|NCT05654038|BIOLOGICAL|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
219694800|NCT05322096|DRUG|RGH-706|"Capsules~Oral administration"
219108145|NCT02041923|BEHAVIORAL|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
219108146|NCT02041923|OTHER|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
219108147|NCT02687490|DRUG|Abraxane|125 mg/m2, D1, D8, D15
219108148|NCT02693301|OTHER|Exercise program|
219108149|NCT00371852|DRUG|lactoserum|
219108150|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
219108151|NCT02021539|BIOLOGICAL|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
219108152|NCT02021539|DRUG|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
219108153|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
219694801|NCT05322096|DRUG|Placebo|"Capsules~Oral administration"
219694802|NCT03473405|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
219694803|NCT03473405|OTHER|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
219694804|NCT03101020|OTHER|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
219694805|NCT03101020|OTHER|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
219694806|NCT03101020|OTHER|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
219694807|NCT02228252|OTHER|Whey protein|
219694808|NCT02228252|OTHER|Casein|
219694809|NCT02228252|OTHER|Gluten protein|
219694810|NCT04233879|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
219108154|NCT06000982|DRUG|PTCY|PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
219108155|NCT02415998|PROCEDURE|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
219108156|NCT04902417|OTHER|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
219108157|NCT00874432|DRUG|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
219108158|NCT00874432|DRUG|lisinopril|1 x 40 mg per day
219694811|NCT04233879|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
219694812|NCT04233879|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
219694813|NCT04233879|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
219694814|NCT02040714|PROCEDURE|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
219694815|NCT02040714|PROCEDURE|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
219694816|NCT02040714|PROCEDURE|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
219694817|NCT02040714|PROCEDURE|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
219694818|NCT00003837|DRUG|nelarabine|
219694819|NCT00826839|DRUG|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
219694820|NCT00826839|DRUG|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
219694821|NCT00381212|BIOLOGICAL|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
219694822|NCT00869869|DRUG|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
219108159|NCT04235582|BEHAVIORAL|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
219108160|NCT04235582|BEHAVIORAL|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
219108161|NCT02763683|RADIATION|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
219108162|NCT06624397|OTHER|CAREFREE Carer's Programme|This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
219108163|NCT06886737|OTHER|Virtual-reality convergence training game|The participant plays a custom virtual-reality game that is designed to train convergence.
219108164|NCT03150927|DIETARY_SUPPLEMENT|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
219108165|NCT03150927|DIETARY_SUPPLEMENT|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
219108166|NCT06899399|PROCEDURE|Endovascular treatment|"Participants will receive carotid artery stenting as the primary intervention. The procedure will be performed via femoral artery access (radial access allowed for anatomically challenging cases) with mandatory use of an embolic protection device (EPD). Stent selection and EPD type will be determined by the operator based on lesion characteristics.~Pre-procedural dual antiplatelet therapy (DAPT: aspirin 100 mg/day + clopidogrel 75 mg/day) will be administered for ≥3-5 days. Post-procedural DAPT will continue for 3 months, transitioning to aspirin monotherapy (100 mg/day) thereafter. Statins and risk factor management (blood pressure、LDL-C, glycemic control) will align with standardized protocols."
219108167|NCT06899399|DRUG|Best medical treatment|Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance. Statin therapy and risk factor control targets (blood pressure, lipids, glucose, lifestyle) will mirror the experimental group. Both groups will undergo regular follow-up for adherence monitoring.
219108168|NCT00877903|DRUG|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
219108169|NCT00877903|DRUG|Placebo|Intravenous infusion of excipients of Prochymal®
219161444|NCT06831578|PROCEDURE|seratuse anterior plane block|after patient consenting, induction of anathesia Under sterile conditions, and while the patients will be still on the lateral position with the diseased side up after induction of anesthesia, a linear ultrasound transducer (10-12 MHz) will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage. Then counting down ribs till the seventh rib will be identified in the mid-axillar\]y line. The following muscles will be identified overlying the sixth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle . Under continuous ultrasound guidance, 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter.
219161445|NCT06831578|PROCEDURE|paravertebral plane block|after concenting patient, induction of anathesia Paravertebral plan block will be performed while the patient is still in lateral position and a linear ultrasound transducer (10-12 MHz) will be used for ultrasound guidance. A sagittal or transverse image can be obtained at the appropriate vertebral level. After image optimization, the Tuohy needle is advanced in plane until the tip rests in the thoracic paravertebral space. Injection of small amounts of fluid (hydrodissection) will aid in needle tip location. Saline or local anesthetic is injected through the Tuohy needle. The endpoint for a successful block is anterior displacement of the pleura. 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter. The catheter is threaded through the Tuohy needle and its position is confirmed by injecting local anesthetic or small air bubbles. Pleural depression should agai
219224626|NCT07044128|DEVICE|Digital stethoscope using MEMS sensor and mobile application for cardiac auscultation|The intervention is a digital stethoscope system comprising a handheld device with a micro-electromechanical system (MEMS) sensor and a Bluetooth Low Energy (BLE) connection to a mobile application (Keikku Mobile App) installed on an iOS or Android smartphone. The device captures auscultation sounds from standard precordial locations (mitral, tricuspid, aortic, and pulmonary), transmits them in real time to the mobile application, and stores the recordings on a secure, GDPR-compliant cloud server. The device does not interpret sounds. Each auscultation lasts 15 seconds per site. Physicians use Bluetooth headphones to listen during recording. The application allows for annotation and review of sound data. The intervention is administered once per participant during a single study visit, immediately followed by a comparator auscultation using a conventional analog stethoscope by a second blinded physician.
219694823|NCT00869869|DRUG|placebo|placebo
219694824|NCT01868659|BEHAVIORAL|Diagnostic checklist|Diagnostic checklist used before patient discharged
219694825|NCT01868659|BEHAVIORAL|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
219694826|NCT03303495|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
219694827|NCT03303495|DRUG|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
219694828|NCT03303495|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
219108170|NCT01828307|BEHAVIORAL|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
219108171|NCT01828307|BEHAVIORAL|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
219108172|NCT01828307|BEHAVIORAL|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
219108173|NCT03649269|DIETARY_SUPPLEMENT|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
219108174|NCT03649269|DRUG|Bezafibrate|Patients were prescribed 200 mg/day at night.
219108175|NCT02370290|OTHER|Medical Chart Review|Clinical and imaging information collected
219108176|NCT02370290|OTHER|Informational Intervention|Clinical and imaging data collected
219108177|NCT00747383|DRUG|Glimepiride|3mg oral tablet.
219108178|NCT00747383|DRUG|Sitagliptin|100mg oral tablet.
219108179|NCT00743990|OTHER|Ointment containing camphor, eucalyptus oil, and menthol|One time use
219108180|NCT00743990|OTHER|Petroleum jelly|One time use
219108181|NCT02709642|BEHAVIORAL|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
219108182|NCT04361474|DRUG|Budesonide Nasal|Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
219108183|NCT04361474|OTHER|Physiological serum|Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
219694829|NCT03303495|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
219694830|NCT03303495|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
219694831|NCT02948647|OTHER|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
219108184|NCT04910087|DIAGNOSTIC_TEST|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
219108185|NCT06494319|BEHAVIORAL|Stress NAVIGATOR (Mobile Health Application)|Participants will be prompted to complete their assessments each week (or upon completion of each session) via the Stress NAVIGATOR mobile health app
219108186|NCT06494319|BEHAVIORAL|SIT NAVIGATOR|Participants will complete 11 self-paced virtual SIT sessions in the SIT-NAVIGATOR classroom. Participants will be asked to complete at least one session per week, in a minimum of 12 weeks and a maximum of 14 weeks.
219108187|NCT00451841|DEVICE|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
219108188|NCT01167179|BEHAVIORAL|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
219108189|NCT04161599|DRUG|Cefuroxime (750mg) I.V|Extra dosage
219108190|NCT04161599|PROCEDURE|Colonic Surgery|Colonic Surgery
219108191|NCT04161599|DRUG|Cefuroxime 750mg oral|Oral prophylaxis
219108192|NCT04161599|DRUG|Metronidazole 250 MG Oral Tablet [Flagyl]|Oral prophylaxis
219694832|NCT04851132|RADIATION|Radiotherapy|IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.
219694833|NCT04851132|DRUG|Durvalumab|Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
219108193|NCT04161599|DRUG|Metronidazole 1 g Intravenous|IV prophylaxis
219108194|NCT04161599|DRUG|Cefuroxime 1,5 g Intravenous|IV prophylaxis
219108195|NCT04161599|DRUG|Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral|Laxative for bowel cleansing
219108196|NCT05456815|OTHER|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
219108197|NCT01352234|DRUG|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
219108198|NCT01352234|DRUG|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
219108199|NCT01976611|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
219108200|NCT02781506|DRUG|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
219108201|NCT02781506|RADIATION|SAbR|SAbR (1-3 lesions)
219108202|NCT01158378|DEVICE|Adherus Dural Sealant|In situ polymerizing sealant
219108203|NCT06275932|OTHER|Interventional group|Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.
219108204|NCT06275932|OTHER|Standard of care group|Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
219108205|NCT02597205|BEHAVIORAL|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
219108206|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
219108207|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
219108208|NCT02885519|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
219108209|NCT02885519|BEHAVIORAL|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
219108210|NCT02043730|DRUG|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
219108211|NCT02043730|DRUG|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
219108212|NCT03990077|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
219108213|NCT03990077|DRUG|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
219108214|NCT05189509|DRUG|TNK-Tissue Plasminogen Activator|0.25 mg TNK thrombolysis
219108215|NCT03335930|BEHAVIORAL|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
219694834|NCT03918811|PROCEDURE|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
219694835|NCT03918811|PROCEDURE|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
219108216|NCT02892942|DRUG|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
219108217|NCT02892942|DRUG|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
219108218|NCT02892942|DRUG|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
219694836|NCT03585270|DRUG|Clazosentan|Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
219694837|NCT03585270|DRUG|Placebo|Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
219108219|NCT05683236|OTHER|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
219108220|NCT05683236|OTHER|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
219224627|NCT07044271|DRUG|Olomorasib|Single dose
219108221|NCT05683236|OTHER|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
219108222|NCT05683236|OTHER|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
219694838|NCT05733663|DIAGNOSTIC_TEST|Endoscopic procedure with duodenal biopsy|"* In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
219694839|NCT05654571|DIAGNOSTIC_TEST|mammography|All patients are checked for mammography every year after surgery.
219694840|NCT02117258|DRUG|Z-360|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
219694841|NCT02117258|DRUG|Placebo|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
219694842|NCT00603031|OTHER|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
219694843|NCT00603031|OTHER|NaCl|infusion with NaCl for 120 minutes as placebo-arm
219694844|NCT00603031|OTHER|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
219694845|NCT03292016|DRUG|APL-130277|APL-130277 sublingual thin film
219694846|NCT03292016|DRUG|APO-go|Subcutaneous APO-go
219694847|NCT03292016|DRUG|Apokyn|Subcutaneous APOKYN
219694848|NCT01042626|OTHER|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
219694849|NCT05630872|DRUG|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
219108223|NCT05683236|OTHER|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
219108224|NCT05683236|OTHER|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
219108225|NCT04602494|DRUG|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
219108226|NCT04602494|DRUG|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
219694850|NCT05630872|DRUG|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
219694851|NCT05630872|DRUG|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
219694852|NCT05630872|DRUG|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
219694853|NCT04623710|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
219694854|NCT03195439|DEVICE|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
219694855|NCT02506387|DEVICE|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
219108227|NCT03731130|OTHER|EORTC QLQ C30|standardized questionaire
219694856|NCT05339958|DIETARY_SUPPLEMENT|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
219694857|NCT05339958|OTHER|Placebo Supplement|The placebo capsules contain no active ingredients.
219694858|NCT04690465|BEHAVIORAL|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
219694859|NCT04690465|BEHAVIORAL|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
219694860|NCT04477369|DRUG|DWJ1439|300mg single dose
219694861|NCT04477369|DRUG|DWJ1464|300mg single dose
219694862|NCT04477369|DRUG|DWC202003|300mg single dose
219694863|NCT04477369|DRUG|DWC202004|300mg single dose
219694864|NCT03539978|OTHER|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
219694865|NCT02115984|DRUG|Panagen|
219694866|NCT02115984|DRUG|Placebo|
219694867|NCT02115984|PROCEDURE|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
219694868|NCT04771910|OTHER|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
219694869|NCT04771910|OTHER|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
219694870|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
219694871|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
219694872|NCT02414698|PROCEDURE|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
219694873|NCT02414698|DRUG|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
219694874|NCT00225745|PROCEDURE|Blood draw|One blood draw prior to first treatment
219694875|NCT06326736|PROCEDURE|Surgery|Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.
219108228|NCT03731130|OTHER|EORTC QLQ CR29|standardized questionaire
219108229|NCT00062621|PROCEDURE|Combined bone marrow and kidney transplant|
219108230|NCT00338767|BEHAVIORAL|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
219108231|NCT00338767|DRUG|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
219694876|NCT06326736|DRUG|Camrelizumab|Camrelizumab will be administered 6 weeks post-tumor resection.
219694877|NCT06326736|BIOLOGICAL|SJ-Neo006|SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).
219694878|NCT06326736|DRUG|Gemcitabine+Abraxane|Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
219694879|NCT02133157|DRUG|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
219694880|NCT01804088|DEVICE|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
219694881|NCT06373341|BEHAVIORAL|VR training for arm and hand rehabilitation|The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
219694882|NCT02567383|RADIATION|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
219694883|NCT02567383|DEVICE|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
219694884|NCT02567383|DRUG|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
219694885|NCT02567383|DRUG|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
219694886|NCT04771845|DEVICE|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
219694887|NCT00001781|DRUG|CGP 77116|
219694888|NCT01076543|OTHER|Laboratory Biomarker Analysis|Correlative studies
219694889|NCT01076543|DRUG|Lenalidomide|Given PO
219694890|NCT01076543|DRUG|Temsirolimus|Given IV
219694891|NCT02016989|DEVICE|RGTA OTR4120 (CACICOL20)|
219694892|NCT02016989|DEVICE|physiological salt solution|
219108232|NCT03084419|DRUG|Abatacept|"The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg \>100kg=1g~This equates to approximately 10mg/kg."
219694893|NCT02199769|OTHER|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
219694894|NCT01905618|BEHAVIORAL|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
219694895|NCT01905618|BEHAVIORAL|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
219694896|NCT01905618|BEHAVIORAL|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
219694897|NCT01905618|BEHAVIORAL|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
219694898|NCT02345005|DEVICE|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
219694899|NCT03502538|DEVICE|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
219694900|NCT03502538|DEVICE|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
219694901|NCT02143219|DRUG|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
219694902|NCT02143219|DRUG|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
219694903|NCT02143219|DRUG|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
219694904|NCT02143219|DRUG|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
219694905|NCT01393145|DRUG|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
219694906|NCT01393145|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
219694907|NCT03416439|OTHER|lifestyle intervention|lifestyle intervention program carried out by trained professionals
219694908|NCT04256980|DRUG|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
219694909|NCT03994913|BIOLOGICAL|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
219108233|NCT04675112|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
219108234|NCT01919463|BEHAVIORAL|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
219108235|NCT01919463|DEVICE|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
219108236|NCT00794625|DRUG|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
219108237|NCT00794625|DRUG|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
219108238|NCT00794625|DRUG|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
219694910|NCT05867758|OTHER|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer \& Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
219694911|NCT03113370|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil capsules
219694912|NCT03113370|DIETARY_SUPPLEMENT|Placebo|Olive Oil
219694913|NCT00003677|DRUG|Dolastatin 10|IV bolus once every 21 days.
219694914|NCT01563523|DRUG|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
219694915|NCT01563523|DRUG|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
219694916|NCT00068276|DIETARY_SUPPLEMENT|cholecalciferol|
219694917|NCT03667768|PROCEDURE|Glass ionomer sealant|
219694918|NCT03667768|BEHAVIORAL|Non-sealant (toothbrushing)|
219694919|NCT01492504|DRUG|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
219694920|NCT05824013|DIAGNOSTIC_TEST|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
219694921|NCT04630223|DIAGNOSTIC_TEST|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
219108239|NCT00794625|DRUG|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
219108240|NCT00794625|BEHAVIORAL|Behavioral family counseling|Weekly behavioral counseling with a therapist
219108241|NCT02593539|DRUG|Nemiralisib|Participants will be administered nemiralisib
219108242|NCT06208722|BEHAVIORAL|Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism|Information provided in arm descriptions.
219108243|NCT04091906|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
219108244|NCT00259376|DRUG|Dronedarone (SR33589)|oral administration
219108245|NCT00259376|DRUG|placebo|oral administration
219108246|NCT02701322|BEHAVIORAL|Medical clown|
219108247|NCT00766896|DRUG|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
219108248|NCT06043596|BEHAVIORAL|SafeSpace Sexual Health|The overall goal of the program is to prevent adolescent pregnancy and STIs by increasing sexual agency, increasing the use of condoms and contraception, and promoting healthy relationships and healthy life skills among adolescents.
219108249|NCT06043596|BEHAVIORAL|SafeSpace General Health|This arm represents the comparison group. SafeSpace General Health will act as the active comparator, while providing youth with lessons, facts, and resources about general health topics.
219108250|NCT01971320|DEVICE|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
219108251|NCT02671721|OTHER|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
219108252|NCT02671721|OTHER|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
219108253|NCT00226473|DRUG|Cisplatin, Vindesine, Dacarbazine (drugs)|
219108254|NCT00000611|DRUG|hormone replacement therapy|
219108255|NCT00000611|DRUG|estrogens|
219108256|NCT00000611|DRUG|progestins|
219108257|NCT00000611|DRUG|estrogen replacement therapy|
219108258|NCT00000611|BEHAVIORAL|diet, fat-restricted|
219108259|NCT00000611|DRUG|calcium|
219694922|NCT05970250|OTHER|Whole body vibration group|Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
219108260|NCT00000611|DRUG|vitamin D|
219108261|NCT00000611|BEHAVIORAL|dietary supplements|
219108262|NCT00649389|DRUG|Olmesartan medoxomil|40mg olmesartan medoxomil
219108263|NCT00649389|DRUG|Amlodipine|Amlodipine 10mg
219224628|NCT07042932|OTHER|Exercise|26 weeks online high intensity functional training, performed 1-2 times per week + access to a LIFESTYLE PHYSICAL ACTIVITY WEBSITE including 8 modules; 1) Welcome, information about the intervention and the aims of the study, 2) Living a physically active lifestyle, 3) Sedentary behavior, 4) General exercise recommendations, 5) How to stay motivated, 6) Strength training, 7) flexibility, balance, and coordination, and 8) Healthy eating + weekly motivational counseling
219694923|NCT05970250|OTHER|Weight bearing exercises|Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
219694924|NCT05970250|DRUG|vitamin D supplements and calcium|vitamin D supplements and calcium
219694925|NCT05355285|PROCEDURE|Glucose Clamp|Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
219694926|NCT02488226|OTHER|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
219694927|NCT00992862|DRUG|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
219694928|NCT00992862|DRUG|Univasc® 15mg Tablets|
219694929|NCT03055884|DEVICE|tDCS|active tDCS versus sham tDCS
219694930|NCT03055884|BEHAVIORAL|Verbal paired-associate learning task|with or without repeated retrieval practice
219694931|NCT04632004|OTHER|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
219108264|NCT00649389|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
219108265|NCT05664139|DRUG|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
219108266|NCT05386186|DRUG|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
219108267|NCT05386186|DRUG|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
219108268|NCT01806740|DRUG|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
219108269|NCT05115019|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
219108270|NCT05115019|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
219108271|NCT04059393|OTHER|Internet-Based Intervention|Complete web-based legacy intervention
219108272|NCT04059393|OTHER|Best Practice|Receive standard of care
219108273|NCT04059393|OTHER|Quality-of-Life Assessment|Ancillary studies
219108274|NCT04059393|OTHER|Questionnaire Administration|Ancillary studies
219108275|NCT03176095|DIETARY_SUPPLEMENT|Probiotic|
219108276|NCT03176095|DIETARY_SUPPLEMENT|Placebo|
219108277|NCT02049060|DRUG|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
219108278|NCT03941613|PROCEDURE|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
219108279|NCT03941613|PROCEDURE|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
219224629|NCT06745362|OTHER|self-monitoring of breath acetone|Participants perform self-monitoring of braeth acetone in order to get information about their ketosis state.
219224630|NCT06745362|OTHER|lifestyle-intervention via LIM-App|Participants are offered a lifestyle intervention via LIM-App.
219108280|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
219694932|NCT01483638|DRUG|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
219694933|NCT01483638|DRUG|placebo|will be administered orally with the same schedule of axitinib
219694934|NCT00484770|DEVICE|Brain Natriuretic Peptide Levels -- Diagnostic testing|
219108281|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
219108282|NCT04152785|BEHAVIORAL|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
219108283|NCT05392140|BEHAVIORAL|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
219108284|NCT05392140|BEHAVIORAL|Standart care|Standart care
219108285|NCT02571205|DRUG|Sustanon (testosterone)|Standard incremental regimen of Sustanon
219694935|NCT00484770|OTHER|clinical assessment|
219694936|NCT01348724|DRUG|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
219108286|NCT02391870|BEHAVIORAL|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
219108287|NCT00153946|DRUG|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
219108288|NCT02444988|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
219108289|NCT02444988|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
219108290|NCT02448836|DEVICE|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
219108291|NCT02448836|DEVICE|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
219108292|NCT04551196|DRUG|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
219694937|NCT01791985|DRUG|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
219694938|NCT03440476|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
219694939|NCT03440476|BEHAVIORAL|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
219694940|NCT03440476|BEHAVIORAL|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
219108293|NCT04551196|DRUG|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
219108294|NCT05140811|DRUG|IMM01|IMM01 is intravenously once a week, every 28 days for a treatment cycle;
219108295|NCT05140811|DRUG|Azacitidine|Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
219108296|NCT02801474|PROCEDURE|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
219108297|NCT02801474|PROCEDURE|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
219108298|NCT04126096|DIAGNOSTIC_TEST|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
219108299|NCT06081374|DEVICE|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
219108300|NCT00563589|DRUG|mycophenolate mofetil, methotrexate, cyclosporin|
219108301|NCT00563589|DRUG|Methotrexate and cyclosporin|
219108302|NCT04373915|BEHAVIORAL|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
219694941|NCT03656627|DRUG|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
219694942|NCT05733897|DRUG|hydroxychloroquine|Using hydroxychloroquine to treat nonalcoholic steatohepatitis
219694943|NCT00863382|DEVICE|Standard Event Monitor|Standard Event Monitor
219694944|NCT00863382|DEVICE|Sleuth Monitor|Implantable Sleuth Recorder
219694945|NCT02552108|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|
219694946|NCT04204161|BIOLOGICAL|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
219694947|NCT01309321|BEHAVIORAL|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
219694948|NCT01309321|BEHAVIORAL|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
219694949|NCT05734261|PROCEDURE|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
219694950|NCT03598400|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
219694951|NCT03598400|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
219694952|NCT02484014|OTHER|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
219694953|NCT02484014|OTHER|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
219694954|NCT04809441|OTHER|Diet change|A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
219694955|NCT01155817|DRUG|Nilotinib|200, 400, 800, oral
219694956|NCT04014530|DRUG|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
219694957|NCT03754920|BEHAVIORAL|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
219694958|NCT05418465|DRUG|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
219694959|NCT05418465|DRUG|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
219694960|NCT01937897|OTHER|Bi-lateral massage|Unilateral massage on the left side of the body.
219694961|NCT00848523|DRUG|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
219694962|NCT03142945|OTHER|Traditional Physical Therapy|Physical therapy-based interventions
219694963|NCT03142945|OTHER|MDT based physical therapy|MDT based physical therapy
219108303|NCT01301768|OTHER|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
219108304|NCT01040767|OTHER|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
219108305|NCT00196989|DRUG|Pioglitazone|
219108306|NCT00196989|DRUG|GW677954|
219108307|NCT01517243|DRUG|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
219108308|NCT01517243|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
219108309|NCT00983489|BEHAVIORAL|video demonstration|video will be shown to mothers
219108310|NCT00983489|BEHAVIORAL|counselling|breast feeding counselling
219108311|NCT03083392|PROCEDURE|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
219108312|NCT03083392|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
219108313|NCT01728038|BEHAVIORAL|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
219108314|NCT01493661|OTHER|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
219108315|NCT02105636|DRUG|Nivolumab|
219108316|NCT02105636|DRUG|Cetuximab|
219694964|NCT00372424|DRUG|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
219694965|NCT00372424|DRUG|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
219694966|NCT00372424|DRUG|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
219694967|NCT00072410|BIOLOGICAL|90Y-hu3S193|Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
219694968|NCT00072410|BIOLOGICAL|111In-hu3S193|Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
219694969|NCT02358057|DRUG|Dexmedetomidine|
219694970|NCT02358057|DRUG|Alfentanil|
219694971|NCT01458067|DRUG|GSK2636771|Oral capsules
219694972|NCT04511325|OTHER|Potato Regimen|100 grams cooked white russet potato with the skin
219694973|NCT04511325|OTHER|Refined Grain Regimen|75 grams of cooked long-grain white rice
219694974|NCT00480844|DRUG|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
219108317|NCT02105636|DRUG|Methotrexate|
219694975|NCT00480844|DRUG|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
219694976|NCT04157361|DIAGNOSTIC_TEST|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
219694977|NCT06428435|DIAGNOSTIC_TEST|Vision Test|Remote vision testing via digital screen
219694978|NCT06352814|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
219694979|NCT03977012|DRUG|Buprenorphine|5\~20 mcg
219694980|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
219694981|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
219694982|NCT06014060|PROCEDURE|24 Months DAPT|All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization. The DAPT will last for 24 months after PCI.
219694983|NCT06014060|PROCEDURE|12 Months DAPT|All the subjects will receive aspirin (100 mg/day) + a placebo that is exactly the same in size, color, smell, taste and appearance as clopidogrel for 12 months after randomization. The DAPT will last for 12 months after PCI.
219108318|NCT02105636|DRUG|Docetaxel|
219108319|NCT03413410|DRUG|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
219108320|NCT05689086|OTHER|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
219108321|NCT05197257|DRUG|Ga-PSMA-11|The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
219694984|NCT04586049|DEVICE|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
219108322|NCT02381743|BEHAVIORAL|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
219108323|NCT02381743|BEHAVIORAL|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
219108324|NCT04071977|DRUG|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
219108325|NCT04071977|OTHER|Placebo|It consists in a capsule with 100 mg of magnesium oxide
219108326|NCT00592319|DRUG|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
219694985|NCT04586049|DEVICE|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
219694986|NCT04586049|OTHER|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
219694987|NCT05315440|OTHER|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
219108327|NCT00592319|DEVICE|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
219108328|NCT00592319|PROCEDURE|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
219108329|NCT04944394|OTHER|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~\- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
219108330|NCT04944394|OTHER|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
219108331|NCT02483013|OTHER|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
219108332|NCT02483013|OTHER|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
219108333|NCT05217836|DIAGNOSTIC_TEST|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
219108334|NCT02010697|BEHAVIORAL|Messages targeting nonsmokers|
219108335|NCT02010697|BEHAVIORAL|Messages targeting smokers|
219108336|NCT03431051|OTHER|Healthy Beverage Initiative|A Healthy Beverage Initiative will be instituted at two hospital campuses.
219108337|NCT03746743|DIAGNOSTIC_TEST|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
219108338|NCT00023842|BIOLOGICAL|BCG vaccine|
219108339|NCT00023842|DRUG|mitomycin C|
219108340|NCT00023842|PROCEDURE|adjuvant therapy|
219694988|NCT05315440|OTHER|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
219108341|NCT00023842|PROCEDURE|conventional surgery|
219108342|NCT03321513|DRUG|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
219108343|NCT03321513|DRUG|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
219108344|NCT02814474|OTHER|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
219108345|NCT02814474|OTHER|Saline|Infusion of 0.9 % saline
219108346|NCT01935921|BIOLOGICAL|Cetuximab|Given IV
219108347|NCT01935921|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219108348|NCT01935921|BIOLOGICAL|Ipilimumab|Given IV
219108349|NCT01935921|OTHER|Laboratory Biomarker Analysis|Correlative studies
219108350|NCT02250521|DEVICE|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
219108351|NCT00312858|BIOLOGICAL|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
219108352|NCT00312858|BIOLOGICAL|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
219108353|NCT00312858|BIOLOGICAL|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
219108354|NCT00204659|DRUG|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
219108355|NCT02604836|DRUG|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
219108356|NCT05051332|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
219108357|NCT05051332|PROCEDURE|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
219108358|NCT01200537|DRUG|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
219108359|NCT01200537|DRUG|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
219108360|NCT01073839|DRUG|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
219694989|NCT03988140|DEVICE|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
219694990|NCT05556980|PROCEDURE|totally laparoscopic distal gastrectomy|all the surgical procedure would be finished under laparoscopy
219108361|NCT02360839|DEVICE|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
219108362|NCT04161417|OTHER|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
219108363|NCT04134858|OTHER|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
219108364|NCT03406793|DIETARY_SUPPLEMENT|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
219108365|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
219108366|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
219694991|NCT00758446|DRUG|BLX-028914|50 mg capsules, p.o, daily, 14 days
219108367|NCT03406793|DIETARY_SUPPLEMENT|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
219694992|NCT00758446|DRUG|BLX-028914|15 mg capsules, p.o, daily, 14 days
219694993|NCT00758446|DRUG|placebo|capsules, p.o, daily, 14 days
219694994|NCT00767572|DRUG|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
219694995|NCT00767572|DRUG|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
219108368|NCT03406793|DIETARY_SUPPLEMENT|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
219108369|NCT03406793|DIETARY_SUPPLEMENT|Placebo powder|Daily provision of a placebo powder for 24 weeks.
219108370|NCT01336634|DRUG|Dabrafenib|Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
219694996|NCT04554589|DRUG|Glycopyrrolate 0.2 MG|injections
219694997|NCT04554589|DRUG|normal saline|normal saline
219694998|NCT01368419|DRUG|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
219694999|NCT01368419|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
219695000|NCT03363971|DRUG|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
219695001|NCT03363971|DRUG|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
219108371|NCT01336634|DRUG|Trametinib|Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
219108372|NCT05012449|PROCEDURE|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
219108373|NCT01446263|PROCEDURE|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
219108374|NCT05518292|OTHER|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
219695002|NCT06108908|BEHAVIORAL|Reminder|1\. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
219108375|NCT05518292|OTHER|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
219108376|NCT00947037|DRUG|AP-CD/LD|
219108377|NCT04289701|OTHER|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
219108378|NCT04532021|DIAGNOSTIC_TEST|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
219108379|NCT01863043|PROCEDURE|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
219108380|NCT01863043|PROCEDURE|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
219108381|NCT03301688|BIOLOGICAL|Toripalimab|To compare the different drug batch number with different process
219695003|NCT04830566|OTHER|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
219695004|NCT04830566|OTHER|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
219695005|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2321138A|One intramuscular injection
219695006|NCT01204671|BIOLOGICAL|FluarixTM|One intramuscular injection
219695007|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2604409A|One intramuscular injection
219695008|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
219695009|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
219695010|NCT01035749|BIOLOGICAL|Placebo (saline)|One dose intramuscularly
219695011|NCT06521970|DIAGNOSTIC_TEST|The kyphosis angle|The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.
219695012|NCT06521970|DIAGNOSTIC_TEST|dynamic postural performance|The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
219695013|NCT06521970|DIAGNOSTIC_TEST|forward head position|The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (\>8 cm)
219695014|NCT03049878|DRUG|Paracetamol Codeine|preoperative administration
219695015|NCT03049878|DRUG|Placebo Oral Tablet|preoperative administration
219695016|NCT04078971|OTHER|Western diet|Subjects in this intervention will follow a normal western diet
219108382|NCT01068314|OTHER|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
219108383|NCT03376802|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219695017|NCT04078971|OTHER|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
219108384|NCT03376802|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
219108385|NCT04232098|OTHER|Heat to ankle|Heat administered via hot water to ankle level
219108386|NCT04232098|OTHER|Heat to calf|Heat administered via hot water to calf level
219695018|NCT06297070|BEHAVIORAL|Whole Health Lifestyle Care for Reproductive Well-being pilot program|The program consists of an individual Integrative Health and Medicine (IHM) consultation with a CWH IHM provider, 4 Shared Medical Appointments (SMA), and 4 individual Health and Wellness Coaching (HWC) sessions. The SMA sessions occur at the UH CWH Beachwood office conference and movement rooms. The HWC sessions are virtual. The consultations are either virtual or in person at UH CWH Beachwood.
219695019|NCT01064271|DRUG|Risperidone|Risperidone Tablets 1 mg
219695020|NCT06655987|OTHER|Unrestrained Femoral Internal Rotation (UFIR) manipulation|This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.
219695021|NCT06655987|OTHER|Sham manipulation|This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
219695022|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
219695023|NCT07048236|DIAGNOSTIC_TEST|Specimen and clinical data collection|Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, pulmonary function test,Questionnaire
219695024|NCT00054496|DRUG|erlotinib hydrochloride|
219108387|NCT01515904|BEHAVIORAL|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
219108388|NCT01973894|PROCEDURE|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
219108389|NCT04808128|OTHER|Drink A + SC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
219695025|NCT01702909|DRUG|Interleukin-2|Interleukin-2
219695026|NCT02260960|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
219695027|NCT05231889|DEVICE|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
219695028|NCT05231889|DEVICE|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
219695029|NCT01814007|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219695030|NCT02374320|DRUG|liposomal bupivacaine|injected as an axillary block
219695031|NCT02670369|BEHAVIORAL|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
219695032|NCT07073482|OTHER|Using stress ball|The participant will be told that the stress balls will be used for 15 minutes during the surgery, and the researcher will inform the participant when the 15 minutes are up and the patient will be asked to release the balls.
219695033|NCT06835556|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals will be assessed for which psychological factors are maintaining paranoia in their daily lives. They will collaboratively identify one maintenance factor to focus on (e.g. worry, anomalous experience, self-confidence, PTSD) for 8 weeks of individual therapy. Then, all participants will transition to 8 weeks of individual therapy focused on dropping safety behaviors and re-engaging in everyday life.
219695034|NCT06835556|BEHAVIORAL|TAU|Individuals will continue treatment as usual (TAU). In addition they will have contact with a study therapist weekly via phone to provide information on what treatment they received. Phone check-ins will last approximately 5-10 minutes.
219108390|NCT04808128|OTHER|Drink B + SC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
219108391|NCT04808128|OTHER|Drink C + SC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
219108392|NCT04808128|OTHER|Drink A + CC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
219108393|NCT04808128|OTHER|Drink B + CC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
219695035|NCT06767072|BEHAVIORAL|Tailored Multichannel interventions|"To ensure the feasibility of the intervention, the intervention will be designed by an interdisciplinary team including academic researchers from different specialties (experts in the fields of community health, psychiatry health, and nutrition), as well as 3 research assistants.~The designing process for each individual in the intervention group involved the following 4 subsequent steps: (1) intervention nurses assess HBM constructs, which are used to collect data on each unique perception regarding overweight(Saghafi-Asl et al., 2020). (2) data are reviewed, identified, and summarized by the interdisciplinary team; (3) the interdisciplinary team then creates an intervention plan based on the summarized needs and (4) the intervention plan will be shared with the participant to ensure collaboration.~The intervention will adopt the strategies of the Diabetes Prevention Program (DDP) (The Diabetes Prevention Program (DPP), 1996)."
219695036|NCT03991533|OTHER|multiparametric MRI|preoperative multiparametric MRI
219695037|NCT02357459|DRUG|FX006|Single 5 mL IA injection
219108394|NCT04808128|OTHER|Drink C + CC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
219108395|NCT04743375|OTHER|wound dressing application|Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
219695038|NCT02357459|DRUG|Placebo|Single 5 mL IA injection
219695039|NCT02357459|DRUG|TCA IR 40|Single 1 mL IA injection
219695040|NCT04025216|BIOLOGICAL|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
219108396|NCT01478815|BEHAVIORAL|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
219108397|NCT01478815|OTHER|Standard Care|Standard Care
219108398|NCT00641849|BEHAVIORAL|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
219108399|NCT00641849|BEHAVIORAL|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
219108400|NCT00692055|DRUG|PN400|naproxen 375 mg / esomeprazole 20 mg
219108401|NCT00692055|DRUG|Naproxen|naproxen 375 mg
219108402|NCT04537897|DRUG|BI 474121|BI474121
219108403|NCT04537897|DRUG|Midazolam|Midazolam
219108404|NCT04537897|DRUG|Placebo|Placebo
219108405|NCT02662803|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
219695041|NCT04025216|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
219695042|NCT04025216|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
219695043|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
219695044|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
219695045|NCT05112978|DIAGNOSTIC_TEST|MRI|MRI genu non contrast
219695046|NCT03136575|BEHAVIORAL|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
219695047|NCT03136575|BEHAVIORAL|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
219108406|NCT02662803|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
219108407|NCT02936154|DRUG|PF-06650833|
219108408|NCT02936154|DRUG|placebo|
219108409|NCT04966780|PROCEDURE|acute abdominal surgery|Acute surgery for acute abdominal disease
219108410|NCT00642928|DRUG|Placebo|1 capsule per day during 4 weeks
219108411|NCT00642928|DRUG|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
219108412|NCT00642928|DRUG|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
219108413|NCT00642928|DRUG|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
219108414|NCT00642928|DRUG|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
219108415|NCT03136250|OTHER|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
219108416|NCT03136250|OTHER|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
219108417|NCT03136250|OTHER|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
219108418|NCT05816148|OTHER|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
219108419|NCT01580098|OTHER|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
219108420|NCT01580098|OTHER|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
219108421|NCT04384458|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
219108422|NCT04384458|DRUG|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
219695048|NCT01548599|OTHER|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
219695049|NCT03310567|DRUG|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
219695050|NCT04394325|BEHAVIORAL|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
219695051|NCT01474343|GENETIC|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
219108423|NCT00197028|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
219108424|NCT00197028|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
219108425|NCT00197028|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
219695052|NCT03218501|DRUG|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
219108426|NCT03531255|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219108427|NCT00345384|DRUG|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
219108428|NCT00345384|OTHER|Placebo (Normal Saline)|
219108429|NCT03036501|DRUG|[^14C]-Risdiplam|\[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.
219108430|NCT04607824|BEHAVIORAL|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
219108431|NCT04607824|BEHAVIORAL|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
219108432|NCT01602757|DRUG|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
219108433|NCT02355522|DRUG|Intrauterine lidocaine|
219108434|NCT02355522|DRUG|Lidocaine gel|
219108435|NCT02355522|DRUG|KY jelly|
219108436|NCT02355522|DRUG|Intrauterine normal saline|
219108437|NCT01852656|BEHAVIORAL|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
219108438|NCT01852656|BEHAVIORAL|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
219108439|NCT01852656|BEHAVIORAL|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
219108440|NCT04997044|OTHER|Concomitant physical rehabilitation|Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.
219108441|NCT04997044|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.
219108442|NCT04997044|OTHER|selective dorsal rhizotomy|The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
219108443|NCT03263234|OTHER|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
219695053|NCT03218501|DRUG|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
219695054|NCT03218501|DRUG|Placebo|Placebo is to be administered orally once daily for 2 weeks
219695055|NCT00453908|DRUG|Alfuzosin|
219695056|NCT01626170|OTHER|laboratory biomarker analysis|Correlative studies
219695057|NCT05630196|DRUG|LY3857210|Administered orally
219695058|NCT05630196|DRUG|Placebo|Administered orally
219108444|NCT04946955|OTHER|Application and website with or without promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
219695059|NCT05258552|PROCEDURE|enema|preoperative enema
219695060|NCT00976365|DIETARY_SUPPLEMENT|THL-P|20ml/bottle, TID, 24weeks
219695061|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
219695062|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
219108445|NCT02696330|DRUG|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
219695063|NCT00878865|DRUG|Alprazolam|1 mg tablet one oral dose
219108446|NCT02696330|DRUG|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
219108447|NCT02696330|DRUG|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
219108448|NCT01170884|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
219108449|NCT01170884|DRUG|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
219108450|NCT00683280|BEHAVIORAL|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
219108451|NCT00683280|OTHER|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
219108452|NCT00683280|OTHER|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
219695064|NCT00878865|DRUG|Alprazolam|1 mg tablet
219695065|NCT00352118|BIOLOGICAL|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
219695066|NCT00352118|BIOLOGICAL|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
219695067|NCT00352118|DRUG|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
219695068|NCT00352118|DRUG|docetaxel|Intravenous over 1 hour on day 1.
219695069|NCT00352118|DRUG|fluorouracil|Intravenous continuously on days 1-4.
219695070|NCT00352118|PROCEDURE|conventional surgery|As appropriate, neck dissection.
219695071|NCT00352118|RADIATION|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
219695072|NCT05320471|OTHER|This is an observational study|This is an observational study
219695073|NCT00276302|DRUG|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
219108453|NCT04102436|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
219108454|NCT04102436|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
219108455|NCT04102436|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
219108456|NCT04102436|BIOLOGICAL|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
219695074|NCT00613795|DIETARY_SUPPLEMENT|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
219695075|NCT00613795|DIETARY_SUPPLEMENT|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
219695076|NCT02990000|BEHAVIORAL|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
219108457|NCT01199458|DRUG|alfentanil|20 mikrogr/kg
219108458|NCT01199458|DRUG|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
219108459|NCT06098495|GENETIC|search for epigenetic profile of infertility|examine the epigenetic profile of DNA extracted from MGCs and blood sample
219108460|NCT05391360|DRUG|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
219108461|NCT05391360|DRUG|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
219108462|NCT05391360|DRUG|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
219108463|NCT05391360|DRUG|entecavir tablets|once daily for consecutive 28 days
219108464|NCT01372605|OTHER|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
219108465|NCT01372605|OTHER|Enhanced Usual Care|
219108466|NCT05434299|DRUG|TFX05-01|TFX05-01 for intravenous
219108467|NCT01108510|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
219108468|NCT01108510|DRUG|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
219108469|NCT01108510|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
219108470|NCT01108510|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
219108471|NCT01108510|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
219108472|NCT01108510|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
219108473|NCT04924972|PROCEDURE|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
219108474|NCT03650660|OTHER|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
219108475|NCT02796963|BEHAVIORAL|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
219108476|NCT02796963|BEHAVIORAL|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
219695077|NCT06391411|DIETARY_SUPPLEMENT|a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg)|In this three-arm randomized, controlled trial, with one arm represented by healthy subjects, eligible participants were randomly divided into two groups. Fifteen patients were randomly allocated to the intervention group and received, for 6 months, intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg). The other fifteen patients was assigned to the control group and only received the intravitreal anti-VEGF treatment at a fixed regimen for 6 months
219695078|NCT06391411|DRUG|anti-VEGF treatment|Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
219695079|NCT00108446|DRUG|dextromethorphan|
219695080|NCT00108446|DRUG|naloxone|
219695081|NCT00108446|DRUG|fentanyl|
219695082|NCT00108446|DRUG|lidocaine|
219695083|NCT01966783|DRUG|Budesonide 2 mg suppository|per day
219695084|NCT01966783|DRUG|Budesonide 4 mg suppository|per day
219695085|NCT01966783|DRUG|Mesalazine 1 g suppository|per day
219695086|NCT01966783|DRUG|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
219695087|NCT02308046|DRUG|Terconazole|
219695088|NCT02308046|DRUG|Placebo|
219695089|NCT05497752|OTHER|cervical rehabilitation program|"(Positional release technique on trapezius muscle): The subject was supine The therapist applied Pressure by pinching the trapezius muscle between the thumb and fingers.~Suboccipital muscle release):~The patient will be in a Supine lying position therapist places both his palms at suboccipital region with upward pressure causing a stretch and distraction for 30 seconds. This technique was performed 3 times in one session with a rest interval of 1 minute after each time.~(Stretching of pectoralis muscle):. once daily Stretching with repetition of five, three times a day for 1week"
219108477|NCT03741244|DRUG|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
219108478|NCT03741244|DRUG|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
219695090|NCT05497752|OTHER|control group|Relax shoulders and neck sufficiently look down turn face to the right turn face to the left incline head to the right incline head to the left turn shoulders round and round slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening).
219695091|NCT04577066|OTHER|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
219695092|NCT04577066|OTHER|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
219695093|NCT04577066|OTHER|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
219695094|NCT05658939|OTHER|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
219108479|NCT04246515|DEVICE|Blood Flow Restriction Training|Vascular occlusion of the injured limb.
219108480|NCT04246515|DEVICE|Sham Blood Flow Restriction Training|Blood Flow Restriction material will be attached to the limb without vascular occlusion.
219108481|NCT04246515|OTHER|Classic rehabilitation|Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
219108482|NCT00003415|DRUG|amifostine trihydrate|
219108483|NCT00003415|DRUG|topotecan hydrochloride|
219108484|NCT03917641|BIOLOGICAL|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
219695095|NCT02392780|DRUG|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
219695096|NCT02392780|DRUG|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
219695097|NCT02392780|DRUG|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
219695098|NCT05889975|DEVICE|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
219695099|NCT05889975|DEVICE|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
219695100|NCT05889975|DEVICE|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
219695101|NCT04830735|DRUG|Dasatinib Anhydrous|Given PO
219695102|NCT04830735|DRUG|Placebo Administration|Given PO
219695103|NCT00419705|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
219695104|NCT05553327|BEHAVIORAL|Multimodal prehabilitation|"* Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~* Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~* Mental health: mindfulness group sessions led by psychologists will be held."
219695105|NCT03768193|PROCEDURE|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
219695106|NCT03768193|PROCEDURE|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
219695107|NCT03318185|PROCEDURE|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
219695108|NCT03318185|PROCEDURE|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
219695109|NCT04309513|BEHAVIORAL|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
219695110|NCT04309513|BEHAVIORAL|Step Counter to motivate physical activity|Step Counter to motivate physical activity
219695111|NCT06262984|OTHER|Therapeutic Play|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
219695112|NCT06069388|PROCEDURE|diaphragm technique|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
219695113|NCT06069388|PROCEDURE|conventional therapy|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
219695114|NCT02617537|DRUG|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
219695115|NCT02617537|DRUG|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
219695116|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
219695117|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
219695118|NCT02267941|OTHER|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
219695119|NCT03740464|DRUG|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
219695120|NCT03740464|DRUG|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
219695121|NCT02313402|DEVICE|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
219695122|NCT01549574|DRUG|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
219695123|NCT01549574|DRUG|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
219695124|NCT05076227|DRUG|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
219695125|NCT05076227|DRUG|IM injection of vaccination (vector based vaccination)|vector based vaccination
219695126|NCT01244867|BIOLOGICAL|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
219695127|NCT01244867|BIOLOGICAL|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
219695128|NCT01244867|BIOLOGICAL|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
219695129|NCT01244867|BIOLOGICAL|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
219108485|NCT06072820|DEVICE|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
219695130|NCT01244867|BIOLOGICAL|Placebo|2 doses given 21 days apart of the placebo
219695131|NCT00356018|BEHAVIORAL|Compliance|
219108486|NCT03096301|DEVICE|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
219695132|NCT06514287|BEHAVIORAL|Individualized intervention|It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
219695133|NCT00526474|DRUG|Vorapaxar|2.5-mg tablet daily for at least 1 year
219108487|NCT03096301|DEVICE|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
219108488|NCT03096301|DEVICE|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
219695134|NCT00526474|DRUG|Placebo|matching tablet daily for at least 1 year
219695135|NCT01587885|DRUG|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
219695136|NCT01587885|DRUG|Omeprazole 20 mg|Tablets, orally
219695137|NCT02517619|DRUG|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
219695138|NCT02517619|DRUG|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
219695139|NCT02975596|OTHER|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
219108489|NCT00592046|DRUG|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
219695140|NCT02975596|OTHER|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
219695141|NCT02975596|OTHER|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
219108490|NCT00951509|OTHER|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
219108491|NCT04453501|DRUG|favorable outcome|Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
219108492|NCT04930328|DRUG|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
219695142|NCT02975596|OTHER|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
219695143|NCT03243149|DEVICE|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
219108493|NCT02454036|BEHAVIORAL|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
219108494|NCT02753725|DRUG|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
219108495|NCT02753725|DRUG|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
219108496|NCT05768724|BEHAVIORAL|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
219108497|NCT05768724|BEHAVIORAL|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~\- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
219108498|NCT00582491|DRUG|Modafinil|Modafinil 400mg orally every day for 16 days
219108499|NCT00582491|DRUG|Placebo|Placebo orally everyday for 16 days
219108500|NCT06266702|OTHER|Experimental Oil with Phospholipids|Consumed on white bread
219108501|NCT06266702|OTHER|Control Polyunsaturated Oil Blend|Consumed on white bread
219108502|NCT03692221|DRUG|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
219108503|NCT03692221|DRUG|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
219108504|NCT03692221|OTHER|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
219108505|NCT04876651|OTHER|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
219108506|NCT04876651|DRUG|Standard of Care|enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
219108507|NCT00781534|DRUG|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
219108508|NCT00781534|DRUG|Ginseng|
219108509|NCT00781534|DRUG|ginsenoside RE|active metabolite of ginseng
219108510|NCT00781534|DIETARY_SUPPLEMENT|Placebo (sugar pill)|placebo group
219108511|NCT00040092|DRUG|Virulizin®|
219108512|NCT04817917|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
219108513|NCT04817917|OTHER|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
219108514|NCT00089713|DRUG|alagebrium chloride (ALT-711)|
219108515|NCT02829333|OTHER|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
219695144|NCT01346865|DRUG|Cilostazol|Cilostazol 100mg bid
219695145|NCT01346865|DRUG|Placebo|Placebo 1tablet bid
219108516|NCT02829333|OTHER|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
219108517|NCT03698760|DIAGNOSTIC_TEST|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
219108518|NCT02327273|DRUG|BMS-963272|
219108519|NCT02327273|DRUG|Placebo|
219108520|NCT01933386|DEVICE|SoundBite|Non-surgical removable bone conduction device via the teeth.
219108521|NCT03791203|BEHAVIORAL|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
219108522|NCT03820791|DEVICE|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
219108523|NCT04192630|DEVICE|CVisc50 OVD|Bausch + Lomb CVisc50 Cohesive OVD
219108524|NCT04192630|DEVICE|ProVisc OVD|ProVisc OVD
219108525|NCT04192630|PROCEDURE|Cataract Surgery|Cataract Surgery
219108526|NCT01683240|DEVICE|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
219108527|NCT01812538|DRUG|DIC075V|"Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments."
219108528|NCT01425632|DRUG|TAU-284|TAU-284 Low
219108529|NCT01425632|DRUG|TAU-284|TAU-284 High
219108530|NCT01425632|DRUG|Placebo|Placebo
219108531|NCT03145467|DRUG|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
219108532|NCT03145467|DRUG|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
219108533|NCT04894461|DEVICE|Moxibustion|The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
219108534|NCT05199805|BEHAVIORAL|Mindfulness-based pain management|The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
219108535|NCT05911490|BEHAVIORAL|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
219108536|NCT05911490|BEHAVIORAL|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
219108537|NCT03664037|DRUG|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
219108538|NCT03664037|DRUG|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
219695146|NCT03020485|OTHER|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
219695147|NCT03020485|OTHER|Sucrose|Sucrose is normal table sugar
219695148|NCT05130424|DRUG|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
219695149|NCT06235112|DEVICE|Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment|The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
219108539|NCT02958618|PROCEDURE|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
219695150|NCT00989885|OTHER|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
219695151|NCT01228006|DIETARY_SUPPLEMENT|NatusGerin|1 capsule, 2 times a day.
219695152|NCT01228006|OTHER|Placebo capsules|1 capsule, 2 times a day
219108540|NCT02958618|PROCEDURE|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
219224631|NCT06812507|PROCEDURE|intact umbilical milking|"Umbilical cord milking will be performed by holding the newborn at or~∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team."
219695153|NCT02779491|BEHAVIORAL|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
219695154|NCT06144255|DRUG|Intranasal insulin|"Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken."
219695155|NCT03309553|OTHER|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
219108541|NCT02958618|PROCEDURE|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
219108542|NCT04797819|DIAGNOSTIC_TEST|Coronary plaque components|Coronary plaque components were detected by CCTA method
219108543|NCT00450320|DRUG|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
219108544|NCT02450864|OTHER|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
219108545|NCT01885273|PROCEDURE|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
219108546|NCT01885273|PROCEDURE|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
219108547|NCT02843958|DEVICE|HEMOPTIC|
219108548|NCT01339364|OTHER|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
219108549|NCT01339364|OTHER|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
219108550|NCT01339364|OTHER|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
219108551|NCT04831008|OTHER|Figure-of-eight suture|Using the figure-of-eight closure technique when closing access for structural heart therapies.
219108552|NCT04831008|OTHER|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
219695156|NCT03309553|OTHER|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
219108553|NCT04021992|DRUG|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
219108554|NCT06110741|OTHER|Blood and saliva sampling|Collecting blood and saliva sample
219108555|NCT06110741|OTHER|Survey|Collecting data on infectious diseases during the study period
219108556|NCT02969980|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
219108557|NCT02654093|DRUG|Cholecalciferol|
219108558|NCT02654093|DRUG|Raloxifene|
219695157|NCT00752089|DRUG|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
219108559|NCT02654093|DRUG|Cholecalciferol and Raloxifene co-administration|
219108560|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
219108561|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding self-harm
219108562|NCT03783481|DEVICE|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
219108563|NCT03783481|OTHER|No Mobile community|No Mobile community
219108564|NCT01115023|OTHER|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
219108565|NCT03487718|BIOLOGICAL|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
219108566|NCT03487718|DEVICE|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
219108567|NCT04141072|DIAGNOSTIC_TEST|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
219108568|NCT04047381|OTHER|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
219108569|NCT01208415|DEVICE|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
219108570|NCT06291532|DEVICE|Rehabilitation with VRRS|"The patients underwent an experimental intervention lasting two months (9 sessions lasting about 40 minutes) integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.~The proposed exercises were 2D and the patient interacted with the scenarios through the touch screen. For all participants, the tasks were the same, but difficulty and duration varied according to the needs and goals to be achieved."
219108571|NCT04645524|DRUG|AD182|Oral capsule administered before bed
219108572|NCT04645524|DRUG|AD504|Oral capsule administered before bed
219108573|NCT04645524|DRUG|Placebo|Oral capsule administered before bed
219108574|NCT04645524|DIAGNOSTIC_TEST|Polysomnography|for all arms
219108575|NCT06360003|PROCEDURE|Right Ventricular Outflow Tract Posterior Septum Pacing|The Right Ventricular Outflow Tract (RVOT) posterior septum pacing is routinely performed to observe the QRS complex characteristics of the 12 lead ECG (with a focus on comparing their differences with the R-wave amplitude of spontaneous ventricular arrhythmias in the right chest (V1\~V3) leads). When the pacing-induced R-wave amplitudes are all lower than spontaneous VAs in V1\~V3, we predict the origin of Left Ventricular Outflow Tract (LVOT), mapping and ablation in LVOT; otherwise we predict the origin of RVOT, mapping and ablation in RVOT.If fails, go to the opposite site to do mapping and ablation. If still fails, go to distal great cardiac vein (DGCV) to do mapping and ablation.
219108576|NCT06360003|PROCEDURE|systemic mapping and ablation|The TC or ST ablation catheter is delivered to ventricular outflow tract (VOT) to perform systemic mapping and ablation.
219108577|NCT01115491|DRUG|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
219108578|NCT01115491|DRUG|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
219108579|NCT00322608|DRUG|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
219108580|NCT02930642|BEHAVIORAL|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
219108581|NCT02930642|OTHER|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
219695158|NCT00752089|DRUG|NaF/KNO3 Dentifrice|Experimental toothpaste
219108582|NCT05914831|RADIATION|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
219695159|NCT00752089|DRUG|NaF Dentifrice|Active comparator
219695160|NCT00752089|OTHER|Placebo Dentifrice|Placebo comparator
219695161|NCT04117022|DIETARY_SUPPLEMENT|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
219695162|NCT00028717|BIOLOGICAL|filgrastim|
219695163|NCT00028717|BIOLOGICAL|rituximab|
219108583|NCT05914831|RADIATION|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
219108584|NCT02708589|DIETARY_SUPPLEMENT|probiotic|
219108585|NCT02708589|OTHER|Placebo|
219108586|NCT01830192|OTHER|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
219695164|NCT00028717|DRUG|cyclophosphamide|
219695165|NCT00028717|DRUG|doxorubicin hydrochloride|
219695166|NCT00028717|DRUG|prednisone|
219695167|NCT00028717|DRUG|vincristine sulfate|
219695168|NCT05635903|PROCEDURE|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
219695169|NCT05635903|PROCEDURE|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
219695170|NCT05635903|PROCEDURE|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
219695171|NCT01248897|OTHER|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
219108587|NCT01830192|OTHER|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
219108588|NCT01607385|DRUG|GSK2330672|BID, repeat doses
219108589|NCT01607385|DRUG|Placebo|BID, repeat doses
219108590|NCT01607385|DRUG|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
219108591|NCT03436160|DRUG|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
219108592|NCT03436160|DRUG|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
219108593|NCT03436160|DRUG|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
219108594|NCT00828906|DRUG|DuoTrav|DuoTrav Eye Drops
219108595|NCT04297241|DRUG|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
219108596|NCT05947123|BEHAVIORAL|Patient health care observational follow up after 2 prophylactic tratments|Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
219108597|NCT03959592|DRUG|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
219108598|NCT03959592|OTHER|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
219108599|NCT04075799|OTHER|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
219108600|NCT04694729|OTHER|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
219108601|NCT04694729|OTHER|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
219108602|NCT02827942|DRUG|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
219108603|NCT02827942|DRUG|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
219108604|NCT02827942|DRUG|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
219108605|NCT02827942|DRUG|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
219108606|NCT02827942|DRUG|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
219108607|NCT03349372|PROCEDURE|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
219108608|NCT06158308|PROCEDURE|Laproscopic Appendicectomy|A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
219108609|NCT06158308|PROCEDURE|Open Appendicectomy|A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
219695172|NCT04458896|BEHAVIORAL|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~* Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, \& the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~* Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~* An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
219695173|NCT02227641|BIOLOGICAL|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
219695174|NCT05671081|DRUG|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
219695175|NCT05671081|DRUG|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
219695176|NCT05671081|DRUG|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
219695177|NCT02930785|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)"
219695178|NCT00000755|BIOLOGICAL|rgp120/HIV-1MN|
219695179|NCT00000755|DRUG|Zidovudine|
219695180|NCT05945095|OTHER|Gum chewing group|The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
219695181|NCT00052104|BEHAVIORAL|Cognitive-Behavioral Family Systems Intervention|
219695182|NCT02731196|BEHAVIORAL|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
219108610|NCT01003639|DRUG|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
219108611|NCT01003639|DRUG|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
219108612|NCT01003639|BEHAVIORAL|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
219108613|NCT04503382|OTHER|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
219108614|NCT02092038|DRUG|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
219108615|NCT02092038|RADIATION|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
219108616|NCT02092038|PROCEDURE|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
219108617|NCT02092038|PROCEDURE|craniotomy and tumor resection|maximal safe resection
219108618|NCT01903408|RADIATION|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
219695183|NCT00231790|DRUG|MK-0634 50 mg|one capsule orally, once daily in morning
219695184|NCT00231790|DRUG|MK-0634 125 mg|one or three capsules orally, once daily in morning
219695185|NCT00231790|DRUG|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
219695186|NCT05232227|DRUG|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
219695187|NCT05232227|DRUG|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
219695188|NCT06238414|OTHER|Early psychotherapeutic intervention|The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
219695189|NCT03027947|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
219695190|NCT01658280|DEVICE|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
219695191|NCT02191826|DRUG|SOM0226|Oral
219695192|NCT05493826|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical record
219695193|NCT06323759|OTHER|educational intervention|In antenatal breastfeeding education: Theoretical contributions on BF (physiology of lactation, frequency complications), hands-on workshop, Provision of educational tools to promote the learning environment: breastfeeding booklet, educational video on breastfeeding, link to a BF specific platform, access to a telephone platform. In short-term postnatal breastfeeding education: Three systematic fallow-up at home or at midwives' office are planned. During these visits, a time of systematic discussion is planned with the nursing mothers. Their knowledge and ability to manage their breastfeeding are checked. The physiology of lactation, the gestures of breastfeeding and the occurrence of common complications are systematically recalled by the liberal midwife. In long-term postnatal breastfeeding education: Invitation of nursing mothers to breastfeeding information meetings at 2nd and 4th month after birth. These meetings will be facilitated either by the liberal midwives.
219695194|NCT03211065|DRUG|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
219108619|NCT06106074|DRUG|Tolebrutinib|Tablet, oral
219108620|NCT06106074|DRUG|Placebo|Tablet, oral
219108621|NCT05171140|PROCEDURE|Triangular Nail Placement of Femoral Neck|Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
219108622|NCT05811429|OTHER|Aerobic exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
219108623|NCT05811429|OTHER|Pilates exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
219108624|NCT06255093|BEHAVIORAL|Community-based recreation program referral|Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
219695195|NCT00001566|BIOLOGICAL|therapeutic autologous dendritic cells|3 syringes containing 1 x 10\^6peptide pulsed dendritic cells
219695196|NCT00001566|DRUG|indinavir sulfate|Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
219108625|NCT06255093|BEHAVIORAL|Pre-surveys only|Receive online wellness education and anxiety treatment options information
219695197|NCT00001566|PROCEDURE|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
219695198|NCT05263362|OTHER|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
219695199|NCT01088087|DIETARY_SUPPLEMENT|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
219108626|NCT04071470|BEHAVIORAL|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
219108627|NCT04071470|DRUG|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
219108628|NCT02811900|PROCEDURE|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
219108629|NCT02811900|PROCEDURE|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
219108630|NCT02811900|PROCEDURE|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
219695200|NCT02745288|PROCEDURE|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
219695201|NCT00383799|DRUG|iv Amiodarone|
219695202|NCT00383799|DRUG|iv Procainamide|
219695203|NCT02903979|OTHER|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
219695204|NCT02903979|OTHER|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
219695205|NCT02917746|DRUG|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
219108631|NCT02811900|PROCEDURE|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
219108632|NCT05448586|DRUG|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
219108633|NCT05937009|OTHER|Orienteering exercise program|Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
219108634|NCT04362137|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets
219108635|NCT04362137|DRUG|Placebo|Matching-image placebo
219108636|NCT03676920|BEHAVIORAL|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
219695206|NCT02917746|PROCEDURE|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
219695207|NCT05398107|BEHAVIORAL|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
219695208|NCT05398107|BEHAVIORAL|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
219108637|NCT00114309|DRUG|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
219108638|NCT00114309|DRUG|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
219108639|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
219108640|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
219108641|NCT02383511|DRUG|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
219108642|NCT00253786|OTHER|Intensive multifactorial therapy|Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
219108643|NCT00253786|OTHER|Standard therapy|Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
219108644|NCT06100601|BEHAVIORAL|ANS regulation therapy|innovative intervention for functional dysphonia
219108645|NCT06100601|BEHAVIORAL|conventional voice therapy (CVT)|conventional voice therapy traditionally provided for functional dysphonia
219695209|NCT06317012|PROCEDURE|Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate|"Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software."
219695210|NCT01153919|BIOLOGICAL|romiplostim|Given subcutaneously
219695211|NCT01153919|DRUG|ribavirin|Given orally
219695212|NCT01153919|OTHER|placebo|Given subcutaneously
219108646|NCT06100601|BEHAVIORAL|ANS regulation therapy + CVT|combination of ANS regulation therapy and CVT
219108647|NCT00771875|DRUG|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
219108648|NCT00771875|DRUG|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
219695213|NCT01153919|BIOLOGICAL|PEG-interferon alfa-2a|Given subcutaneously
219695214|NCT01153919|OTHER|laboratory biomarker analysis|Correlative studies
219695215|NCT02914834|OTHER|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
219695216|NCT02914834|OTHER|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
219695217|NCT03361046|DEVICE|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
219695218|NCT05748899|BEHAVIORAL|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
219695219|NCT03060473|DRUG|Azithromycin|Azithromycin 1 gm PO once
219695220|NCT03060473|DRUG|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
219695221|NCT03060473|DRUG|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
219695222|NCT03060473|DRUG|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
219695223|NCT02172976|DRUG|Gemcitabine|
219695224|NCT02172976|DRUG|Oxaliplatin|
219695225|NCT02172976|DRUG|5-Fluorouracil|
219695226|NCT02172976|DRUG|Irinotecan|
219695227|NCT02172976|DRUG|Natriumfolinate|
219695228|NCT04443335|BEHAVIORAL|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
219695229|NCT04443335|BEHAVIORAL|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
219695230|NCT00345085|DEVICE|Wavefront and Contrast Sensitivity|
219695231|NCT03962400|PROCEDURE|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
219695232|NCT03962400|PROCEDURE|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
219695233|NCT00109096|DRUG|Pemetrexed|
219695234|NCT00975416|BEHAVIORAL|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
219695235|NCT00975416|DRUG|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
219108649|NCT00771875|DRUG|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
219108650|NCT00771875|DRUG|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
219108651|NCT00771875|DRUG|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
219108652|NCT00771875|DRUG|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
219108653|NCT00941538|DIAGNOSTIC_TEST|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
219108654|NCT02032667|BEHAVIORAL|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
219108655|NCT03306043|DRUG|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
219695236|NCT00975416|DRUG|Placebo|Placebo given in the context of cognitive behavioral therapy
219695237|NCT03017092|BEHAVIORAL|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
219695238|NCT06227169|BEHAVIORAL|JJ-COPES Training|• The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
219695239|NCT00374010|BEHAVIORAL|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~1. Representational assessment (10 - 15 minutes);~2. Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~3. Creating conditions for conceptual change (5 minutes);~4. Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~5. Summary (3 - 5 minutes)"
219695240|NCT04753034|DRUG|TER-101|Active Comparator
219695241|NCT04753034|DRUG|Vehicle|Placebo Comparator
219695242|NCT04896216|BEHAVIORAL|Stigma Reduction Intervention|Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
219695243|NCT04372368|BIOLOGICAL|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
219695244|NCT06313463|DRUG|Carrellizumab + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
219695245|NCT06313463|DRUG|Placebo + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
219695246|NCT04382534|COMBINATION_PRODUCT|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
219695247|NCT00672802|DRUG|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
219695248|NCT02097498|OTHER|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
219108656|NCT04089774|BEHAVIORAL|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
219108657|NCT02685371|BEHAVIORAL|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
219108658|NCT05245799|BEHAVIORAL|Speech Language Therapy|Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.
219108659|NCT05245799|BEHAVIORAL|Digital Software Application|The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
219695249|NCT02097498|OTHER|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
219695250|NCT01653275|OTHER|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
219695251|NCT01249131|DRUG|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
219695252|NCT00137709|DRUG|Sodium valproate|Week 1 \& 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
219695253|NCT00137709|DRUG|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
219108660|NCT03497884|DEVICE|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
219695254|NCT04301973|OTHER|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
219695255|NCT05058963|BEHAVIORAL|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
219695256|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
219695257|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
219695258|NCT01219608|DIETARY_SUPPLEMENT|Enteral Nutrition|Ordinary Enteral Nutrition
219108661|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108662|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108663|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108664|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108665|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108666|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
219108667|NCT05565235|DRUG|patients will receive intraoperative serratus block with bupivacaine|no additives
219108668|NCT05565235|DRUG|serratus block with bupivacaine /magnesium|magnesium added
219695259|NCT06342232|BEHAVIORAL|Neurofeedback mindfulness|The participants used a portable EEG headband to complete 10 minutes of neurofeedback mindfulness practice for 8 weeks. While being seated comfortably, they could modify their brains rates based on the audio neurofeedback they received.
219108669|NCT05565235|DRUG|serratus block with bupivacaine with nalbuphine|nalbuphine added
219108670|NCT02529397|BEHAVIORAL|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
219108671|NCT02529397|BEHAVIORAL|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
219695260|NCT06342232|BEHAVIORAL|Simple attention controlled task|The controlled group of this project also received an intervention which included an audiobook. While wearing the headband, the controlled participants muted their neurofeedback sounds and only focused on an audiobook while remaining relaxed. A summary of their brain states was given to them when completing their practice every day.
219695261|NCT04069117|DRUG|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
219695262|NCT06473441|BEHAVIORAL|Tele-Rehabilitation Therapy|Twice-weekly sessions with remote supervision and guidance from therapists.
219695263|NCT06473441|BEHAVIORAL|Health Education|Health education based on individual assessments.
219695264|NCT06473441|BEHAVIORAL|Exercise Prescription|Exercise prescription tailored to individual needs.
219695265|NCT06473441|BEHAVIORAL|Home Exercise Equipment Use|Use of a home exercise bike, resistance bands, respiratory muscle training device, and a portable heart rate monitor.
219695266|NCT06473441|BEHAVIORAL|Exercise Log|Logging daily exercise intensity and duration in a rehabilitation diary
219695267|NCT06473441|BEHAVIORAL|Follow-Up Calls|Regular follow-up calls to monitor progress and address any issues.
219695268|NCT02227095|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
219695269|NCT02227095|BEHAVIORAL|After-school program|Supervised recreational program with token economy
219695270|NCT02824445|DEVICE|individualized Transcranial Magnetic Stimulation|
219695271|NCT01774591|DRUG|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
219695272|NCT01774591|DRUG|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
219695273|NCT06106750|DEVICE|Endoscopic nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.
219695274|NCT06106750|DEVICE|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
219695275|NCT05812248|DIAGNOSTIC_TEST|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
219695276|NCT01690663|DRUG|Bupivacaine 0.25%|
219695277|NCT01690663|DRUG|Dexamethasone|
219695278|NCT01690663|DRUG|normal saline|placebo
219695279|NCT03555149|DRUG|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
219695280|NCT03555149|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
219695281|NCT03555149|DRUG|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
219695282|NCT03555149|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
219695283|NCT03555149|DRUG|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
219108672|NCT04276090|DEVICE|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
219108673|NCT04276090|DRUG|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
219108674|NCT04276090|DRUG|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
219108675|NCT04276090|DRUG|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
219108676|NCT01799720|DIETARY_SUPPLEMENT|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
219108677|NCT01799720|DIETARY_SUPPLEMENT|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
219695284|NCT03555149|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
219108678|NCT01799720|DRUG|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
219108679|NCT04465058|OTHER|COVID19|viral infection
219108680|NCT00002499|DRUG|asparaginase|
219108681|NCT00002499|DRUG|cytarabine|
219108682|NCT00002499|DRUG|daunorubicin hydrochloride|
219695285|NCT03555149|DRUG|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
219695286|NCT03555149|DRUG|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
219108683|NCT00002499|DRUG|dexamethasone|
219695287|NCT03555149|GENETIC|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
219695288|NCT04244136|DEVICE|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
219108684|NCT00002499|DRUG|methotrexate|
219108685|NCT00002499|DRUG|prednisone|
219108686|NCT00002499|DRUG|vincristine sulfate|
219108687|NCT00002499|RADIATION|radiation therapy|
219108688|NCT01234649|DRUG|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
219695289|NCT00706316|BIOLOGICAL|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
219695290|NCT05480059|OTHER|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
219695291|NCT03876925|DRUG|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
219695292|NCT03352284|DEVICE|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
219695293|NCT00898937|GENETIC|microarray analysis|tumor specimen will be assessed by microarray analysis
219695294|NCT00898937|PROCEDURE|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
219695295|NCT05791617|DIAGNOSTIC_TEST|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
219695296|NCT05791617|DIAGNOSTIC_TEST|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
219108689|NCT01234649|DRUG|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
219108690|NCT00566943|DEVICE|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
219108691|NCT00566943|PROCEDURE|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
219108692|NCT00515398|OTHER|Observation|Ex vivo administration of AT2220
219108693|NCT04454762|DRUG|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
219108694|NCT00318149|BIOLOGICAL|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
219108695|NCT00318149|BIOLOGICAL|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
219108696|NCT00318149|BIOLOGICAL|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
219695297|NCT05791617|DIAGNOSTIC_TEST|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
219695298|NCT05939687|PROCEDURE|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
219108697|NCT00318149|BIOLOGICAL|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
219108698|NCT00318149|BIOLOGICAL|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
219108699|NCT03948425|RADIATION|spectral CT|Head spectral CT
219108700|NCT02916004|DEVICE|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
219108701|NCT04663568|DEVICE|Levonorgestrel-releasing intrauterine system|Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
219108702|NCT05713760|DRUG|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
219108703|NCT01304082|DRUG|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
219108704|NCT01304082|DRUG|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
219108705|NCT01304082|DRUG|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
219108706|NCT05148832|DRUG|Administration of Systemic Corticosteroid|10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
219108707|NCT01015222|DRUG|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
219108708|NCT01015222|DRUG|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
219108709|NCT01015222|DRUG|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
219108710|NCT01779479|DRUG|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
219695299|NCT05939687|PROCEDURE|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
219695300|NCT00352183|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
219695301|NCT00352183|DRUG|Simvastatin|Simvastatin 40mg
219695302|NCT02935920|BEHAVIORAL|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
219695303|NCT05810701|OTHER|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
219695304|NCT00328705|DEVICE|Implantable Cardioverter Defibrillator|
219695305|NCT05817669|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
219695306|NCT05817669|BIOLOGICAL|Placebo|Patients receiving placebo infusions
219695307|NCT04583982|OTHER|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
219108711|NCT01779479|DRUG|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
219108712|NCT06428838|BIOLOGICAL|Eptinezumab|The study treatment consists of a single infusion of eptinezumab (100mg/mL).
219108713|NCT06428838|OTHER|Standard of Care|SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.
219108714|NCT06547398|RADIATION|Adaptive radiotherapy +/- Margin Reduction|Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
219695308|NCT01330082|OTHER|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
219695309|NCT01330082|OTHER|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
219108715|NCT06547398|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for prostate cancer
219108716|NCT01269008|DEVICE|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
219108717|NCT03267290|DIAGNOSTIC_TEST|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
219108718|NCT06220383|PROCEDURE|Hall technique|Prepless crown technique
219108719|NCT06220383|PROCEDURE|Conventional technique|1 or 1,5 mm preparation on mesial, distal and occlusal of the tooth
219108720|NCT02591680|OTHER|Neuromuscular training|
219108721|NCT02591680|OTHER|Muscle strengthening|
219695310|NCT01330082|OTHER|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
219108722|NCT02591680|DEVICE|Sensorimotor|
219108723|NCT06312293|DEVICE|Transcutaneous Vagus Nerve Stimulation|All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
219108724|NCT04324255|PROCEDURE|LT|Liver transplantation
219108725|NCT04524572|BEHAVIORAL|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
219108726|NCT02901145|DRUG|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
219108727|NCT00054925|BEHAVIORAL|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
219695311|NCT04268355|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
219695312|NCT05283746|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
219695313|NCT02750995|BIOLOGICAL|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
219695314|NCT02750995|DRUG|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
219695315|NCT03220022|DRUG|Cyclophosphamide|Given IV
219695316|NCT03220022|DRUG|Doxorubicin Hydrochloride|Given IV
219695317|NCT03220022|DRUG|Etoposide|Given IV
219695318|NCT03220022|BIOLOGICAL|Filgrastim|Given SC
219108728|NCT00054925|BEHAVIORAL|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
219108729|NCT03093740|DRUG|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
219108730|NCT03093740|DRUG|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
219108731|NCT05291221|DRUG|intratracheal saline|At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
219695319|NCT03220022|DRUG|Ibrutinib|Given PO
219695320|NCT03220022|OTHER|Laboratory Biomarker Analysis|Correlative studies
219695321|NCT03220022|BIOLOGICAL|Pegfilgrastim|Given SC
219695322|NCT03220022|OTHER|Pharmacological Study|Correlative studies
219695323|NCT03220022|DRUG|Prednisone|Given PO
219695324|NCT03220022|BIOLOGICAL|Rituximab|Given IV
219695325|NCT03220022|DRUG|Vincristine Sulfate|Given IV
219695326|NCT05220488|OTHER|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
219695327|NCT03786380|DRUG|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
219695328|NCT02973828|PROCEDURE|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
219695329|NCT01664091|RADIATION|post-mastectomy radiation therapy (PMRT)|
219695330|NCT01664091|DEVICE|tissue expander (TE)|
219695331|NCT01664091|DEVICE|acellular dermal matrix (ADM)|
219695332|NCT02143232|DEVICE|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
219108732|NCT05291221|DRUG|intratracheal Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
219108733|NCT05291221|DRUG|intratracheal Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
219695333|NCT05861375|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
219108734|NCT01805817|DRUG|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
219108735|NCT01805817|DEVICE|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
219108736|NCT01805817|DEVICE|levonorgestrel-releasing system|intrauterine device
219108737|NCT03572855|COMBINATION_PRODUCT|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
219108738|NCT01633216|BIOLOGICAL|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
219108739|NCT01633216|BIOLOGICAL|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
219108740|NCT01633216|BIOLOGICAL|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
219108741|NCT01633216|BIOLOGICAL|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
219108742|NCT01633216|BIOLOGICAL|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
219695334|NCT06261723|PROCEDURE|non-chirurgical periodontal treatment|The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
219695335|NCT03057886|DEVICE|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
219695336|NCT00761228|DRUG|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
219695337|NCT00761228|DRUG|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
219695338|NCT05448638|PROCEDURE|the combination of transversus thoracic muscle plane and pectoral nerves blocks|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
219695339|NCT05448638|PROCEDURE|the pectoral nerves block only|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
219108743|NCT05518422|DRUG|Hyperinsulinemic, euglycemic infusion|60 minute infusion
219108744|NCT00412035|DRUG|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
219108745|NCT00412035|DRUG|saline injection|10 units per kilo to maximum of 400 units
219108746|NCT05341375|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
219108747|NCT05341375|DRUG|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
219108748|NCT05341375|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
219108749|NCT05341375|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
219108750|NCT06481852|DRUG|MTT with antibiotic preconditioning + fiber supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
219108751|NCT06481852|DRUG|MTT with antibiotic preconditioning + placebo supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
219108752|NCT06481852|OTHER|MTT with placebo + placebo supplementation.|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
219108753|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique|The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
219695340|NCT06602544|DEVICE|Robotic Apparel|A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
219695341|NCT03160040|DRUG|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
219695342|NCT06301789|DRUG|Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries|Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
219695343|NCT01038687|DRUG|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
219108754|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
219108755|NCT01358838|DEVICE|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
219108756|NCT02586337|DRUG|Anlotinib|Anlotinib p.o. qd
219108757|NCT02586337|DRUG|Placebo|Placebo p.o. qd
219108758|NCT01898637|OTHER|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
219108759|NCT01898637|DEVICE|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
219108760|NCT05724056|DEVICE|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
219695344|NCT01038687|DRUG|placebo|placebo
219695345|NCT06065644|DEVICE|CTMA|Induced displacement of the Sacroiliac joint
219695346|NCT05030649|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
219695347|NCT05030649|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
219108761|NCT05724056|DEVICE|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
219108762|NCT01266694|DRUG|Colchicines|oral form, 1 mg, once a day during 14 days
219108763|NCT01266694|DRUG|Placebo|oral form, placebo
219108764|NCT02008968|DRUG|allopurinol 300 mg./day|
219108765|NCT02008968|OTHER|No intervention|
219108766|NCT02008968|DRUG|Normouricemic|
219108767|NCT03581877|DRUG|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
219108768|NCT03581877|DEVICE|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
219108769|NCT02215733|DRUG|ARB|other than telmisartan
219108770|NCT02215733|DRUG|ACEI|
219695348|NCT00000694|DRUG|Interferon alfa-2b|
219695349|NCT00000694|DRUG|Zidovudine|
219695350|NCT00000694|DRUG|Sargramostim|
219695351|NCT02480738|BEHAVIORAL|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
219108771|NCT02215733|DRUG|Beta-blockers|
219108772|NCT02215733|DRUG|Diuretics|
219108773|NCT02215733|DRUG|Telmisartan|
219108774|NCT00538174|DRUG|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
219108775|NCT00538174|DRUG|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
219108776|NCT01028079|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
219108777|NCT01028079|DRUG|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
219108778|NCT01028079|DRUG|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
219108779|NCT05518760|OTHER|no intervention|no intervention
219108780|NCT01177839|OTHER|Screening sheets|Reviewing screening sheets
219695352|NCT02039258|DRUG|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
219695353|NCT05057221|DRUG|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
219695354|NCT04849793|OTHER|Acupressure|Before starting the application, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. . The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes
219108781|NCT04321967|DRUG|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
219108782|NCT04321967|DRUG|Dermabond|Topical skin adhesive
219108783|NCT05738460|DRUG|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
219108784|NCT04527848|DRUG|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
219108785|NCT05598177|DRUG|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
219108786|NCT05598177|DRUG|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
219108787|NCT03001232|BEHAVIORAL|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
219108788|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
219108789|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
219108790|NCT01143623|OTHER|Placebo|Placebo
219108791|NCT00105586|DRUG|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
219695355|NCT04072029|PROCEDURE|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
219108792|NCT02306122|BEHAVIORAL|Pharmacist calls patient unless physician cancels call|
219108793|NCT02306122|BEHAVIORAL|Patient nonadherence information sent to physician|
219108794|NCT02306122|BEHAVIORAL|Pharmacist calls patient if physician requests call|
219108795|NCT02306122|BEHAVIORAL|Doctor receives information and may be allowed certain actions|
219108796|NCT01805193|OTHER|Computed tomography myocardial perfusion imaging|
219695356|NCT04144192|DRUG|Lidocaine patch 1.8%|
219695357|NCT04144192|DRUG|Lidocaine 5% patch|
219695358|NCT04144192|DRUG|Lidocaine 2% Injectable Solution|
219695359|NCT03368313|DEVICE|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
219695360|NCT05434455|DEVICE|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
219695361|NCT02067520|DRUG|intrathecal hydromorphone (IT hydromorphone)|
219695362|NCT03119597|DIETARY_SUPPLEMENT|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
219695363|NCT03119597|DIETARY_SUPPLEMENT|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
219695364|NCT04880434|DRUG|Fludarabine|Administered intravenously
219695365|NCT04880434|DRUG|Cyclophosphamide|Administered intravenously
219108797|NCT01805193|OTHER|Oxygen 15 labelled water positron emission tomography|
219108798|NCT05097768|DRUG|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
219108799|NCT05097768|DRUG|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
219108800|NCT05097768|DRUG|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
219108801|NCT05097768|DRUG|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
219108802|NCT05097768|DRUG|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
219108803|NCT02262260|DRUG|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
219108804|NCT02262260|DRUG|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
219108805|NCT00675415|DIAGNOSTIC_TEST|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
219108806|NCT00780182|DRUG|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
219108807|NCT00198601|DRUG|Gentamicin in Uniject Pre-filled syringe|
219108808|NCT01354834|DRUG|hMG|Patients with a condition
219108809|NCT01642082|BIOLOGICAL|Dalantercept|Given SC
219108810|NCT01642082|OTHER|Laboratory Biomarker Analysis|Correlative studies
219108811|NCT01761539|OTHER|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
219108812|NCT01761539|OTHER|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
219108813|NCT02312674|DIETARY_SUPPLEMENT|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
219108814|NCT00128245|DRUG|Pimecrolimus|
219695366|NCT04880434|BIOLOGICAL|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
219695367|NCT00667641|DRUG|bortezomib|Starting dose level 0.70mg/m2
219695368|NCT00667641|DRUG|paclitaxel|Starting dose level 40mg/m2
219695369|NCT03601169|DIETARY_SUPPLEMENT|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
219695370|NCT03601169|DIETARY_SUPPLEMENT|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
219695371|NCT03601169|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
219695372|NCT03040232|OTHER|biomechanical assessment|biomechanical and strength assessment of both groups
219695373|NCT05944835|OTHER|Analyzed on the post-operative scanner|Analyzed on the post-operative scanner
219695374|NCT05222880|DEVICE|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
219695375|NCT06139848|OTHER|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
219108815|NCT00128245|DRUG|Vehicle|Placebo
219108816|NCT01794117|DRUG|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
219108817|NCT04022005|DRUG|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
219224632|NCT06812507|PROCEDURE|cut umbilical milking|Another technique, used more often in Asia, involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM
219108818|NCT03904511|OTHER|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
219108819|NCT03904511|OTHER|Placebo|Placebo
219108820|NCT03132623|DRUG|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
219108821|NCT03132623|DRUG|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
219108822|NCT03734991|DRUG|Ibrexafungerp|Ibrexafungerp 300 mg BID for 1 day
219108823|NCT03734991|DRUG|Placebo|Matching placebo
219108824|NCT05825898|PROCEDURE|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
219108825|NCT05958329|BEHAVIORAL|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
219108826|NCT00735449|DRUG|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
219108827|NCT00735449|DRUG|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
219108828|NCT00735449|DRUG|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
219108829|NCT04287049|DRUG|Azithromycin|Azithromycin 250 mg PO daily
219108830|NCT00240292|DRUG|Rosuvastatin|
219108831|NCT05127798|OTHER|Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.|Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
219108832|NCT01849900|OTHER|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
219108833|NCT01849900|BEHAVIORAL|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
219108834|NCT03513601|DRUG|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
219108835|NCT03513601|DRUG|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
219108836|NCT02322814|DRUG|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
219108837|NCT02322814|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
219108838|NCT02322814|DRUG|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
219108839|NCT02322814|DRUG|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
219108840|NCT02322814|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
219108841|NCT06493136|DRUG|lidocaine gel|questionnaire
219224633|NCT06812507|PROCEDURE|Delayed cord clamping|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60-second before clamping the cord.
219224634|NCT06876194|OTHER|Music intervention|A previously defined list of songs will be administered to these patients during the procedure.
219224635|NCT05206513|DRUG|Placebo|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
219224636|NCT05206513|DRUG|Valbenazine|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
219108842|NCT04875832|BEHAVIORAL|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
219108843|NCT03587298|PROCEDURE|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
219108844|NCT02462525|DRUG|ABBV-838|Varying doses of ABBV-838
219108845|NCT02462525|DRUG|Pomalidomide|Administered orally per the label.
219108846|NCT02462525|DRUG|Dexamethasone|Administered orally per the label.
219108847|NCT05907486|DRUG|N-acetyl-cysteine|8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45
219108848|NCT05907486|DRUG|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
219695376|NCT06139848|OTHER|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
219695377|NCT01741415|BEHAVIORAL|SIDI|
219108849|NCT05907486|DRUG|Cytarabine|2g/m2, day -8, intravenously
219224637|NCT04033224|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
219695378|NCT01741415|BEHAVIORAL|SC|
219695379|NCT05245383|OTHER|ten products (S01~S10) and two blank (BK1, BK2)|"S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back."
219695380|NCT03727490|OTHER|Repair|The subscapularis will be repaired.
219695381|NCT03727490|OTHER|Standard Treatment|No repair will be performed
219695382|NCT05518123|DRUG|Rimegepant|Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
219695383|NCT05518123|DRUG|Placebo|Matching placebo with every other day dosing during DBT phase
219695384|NCT04726826|DIAGNOSTIC_TEST|Diagnostic and prognostic biomarkers|Observational study of biomarkers predictive of morbidity and mortality in febrile children
219695385|NCT05802017|OTHER|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
219695386|NCT05650203|DRUG|JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006|"1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w)."
219695387|NCT06508255|BEHAVIORAL|Early Time-Restricted Eating|Eat between 8:00 and 16:00 for 2 weeks
219108850|NCT05907486|DRUG|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
219108851|NCT02290002|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
219108852|NCT02290002|OTHER|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
219108853|NCT02310451|BIOLOGICAL|blood test|blood test to J0-M3-M6-M12
219108854|NCT03668262|DRUG|Cis-atracurium|Different concentration of cis-atracurium
219108855|NCT02874651|DRUG|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
219695388|NCT06508255|BEHAVIORAL|Late Time-Restricted Eating|Eat between 13:00 and 21:00 for 2 weeks
219695389|NCT06284499|OTHER|measuring tooth stability after orthodontic treatment using a Periotest® device.|The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
219695390|NCT04754893|DEVICE|Healthdot application|Healthdot device is applied on subject's chest after surgery
219695391|NCT01996111|PROCEDURE|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
219695392|NCT01996111|PROCEDURE|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
219695393|NCT01996111|PROCEDURE|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
219695394|NCT01996111|PROCEDURE|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
219695395|NCT05430165|OTHER|Standard mHealth screening (triage) tool|"Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey."
219695396|NCT05928923|DEVICE|CPAP|CPAP usage 3 months
219695397|NCT04151511|PROCEDURE|Continuous Erector Spinae Plane Block|"1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block"
219695398|NCT01552486|OTHER|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
219695399|NCT01552486|OTHER|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
219695400|NCT01565577|BIOLOGICAL|MenbVac|Blood test
219695401|NCT02578017|BEHAVIORAL|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
219695402|NCT05403645|DIAGNOSTIC_TEST|Movement With Mobilization|with the help of Movement With Mobilization technique
219695403|NCT05403645|DIAGNOSTIC_TEST|Exercise Therapy|with the help of Exercise Therapy technique
219695404|NCT01404910|DEVICE|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
219695405|NCT00417196|DRUG|QAX576|
219695406|NCT03447548|BEHAVIORAL|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
219695407|NCT03447548|BEHAVIORAL|Active control|Commercially available games on tablet
219695408|NCT06367075|DRUG|Cadonilimab|injectable solution
219695409|NCT06367075|DRUG|Adriamycin|injectable solution
219695410|NCT02956382|DRUG|Ibrutinib|Ibrutinib is dispensed as a capsule.
219695411|NCT02956382|DRUG|Venetoclax|Venetoclax is dispensed as a tablet.
219695412|NCT04213014|BEHAVIORAL|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
219695413|NCT06490055|DRUG|Paclitaxel|Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)
219695414|NCT04094311|BIOLOGICAL|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
219695415|NCT06460233|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Laparoscopic sleeve gastrectomy performed according to the current surgical standards
219695416|NCT06404970|OTHER|Screening intervention|Intervention to improve identification and management of functional impairment among older Veterans in VA primary care settings. Intervention includes 5 components: (1) routine, standardized functional status measurement; (2) nursing screening followed by follow-up primary care provider assessment; (3) electronic tools and templates to facilitate screening, assessment, and documentation; (4) interprofessional educational session; (5) tailored reports on functional status
219695417|NCT06404970|OTHER|Standard bundle of implementation strategies|Standard strategies include champions plus system-level audit and feedback
219695418|NCT06404970|OTHER|Enhanced bundle of implementation strategies|Enhanced strategies include technical assistance plus clinician-level audit and feedback
219695419|NCT04840472|DRUG|111I-n panitumumab|Imaging Agent
219695420|NCT04840472|PROCEDURE|Single photon emission computed tomography/computed tomography (SPECT/CT) scans|Day 1 to 5 (Day of Surgery inclusive)
219695421|NCT06363266|BEHAVIORAL|TEMPO|"Stage 1 interventions (weeks 1-12): TEMPO.~After 12 weeks, the benefit of the initial assignment will be assessed. Benefit is defined as a score \< 3 on the ESAS-r anxiety item (range 0-10) or a decrease \>= 2 points from eligibility screening. If both dyad members had anxiety symptoms at recruitment, both must meet the benefit criterion. If one member no longer meets the criterion, the dyad is considered did not benefit.~Stage 2 interventions (weeks 13-25): TEMPO or lay guidance.~1. TEMPO responders will continue with TEMPO. Dyads who did not benefit will be re-randomized to:~   1. Stepping up to lay guidance (8 x 20-minute calls via phone or Teams). Guides will receive TEMPO training and conduct semi-structured exit interviews.~  2. More time with TEMPO for dyads who benefited from it.~2. Non-responders to usual care in Stage 1 will be stepped up to TEMPO."
219108856|NCT02874651|DRUG|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
219108857|NCT04137614|PROCEDURE|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
219108858|NCT04137614|PROCEDURE|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
219108859|NCT00238732|DRUG|Bazedoxifene/Conjugated Estrogen|
219108860|NCT04506749|DIETARY_SUPPLEMENT|Dietary supplement consumption|The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
219108861|NCT00591864|DEVICE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
219108862|NCT00118092|DRUG|tanespimycin|Given IV
219108863|NCT00118092|OTHER|laboratory biomarker analysis|Correlative studies
219108864|NCT02459093|DEVICE|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
219108865|NCT02459093|DEVICE|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
219108866|NCT05095363|BEHAVIORAL|PCplanner|A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
219108867|NCT04247399|OTHER|Simulation-based learning|Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
219108868|NCT01741454|DRUG|Tamsulosin|0.4 mg by mouth once per day.
219108869|NCT01741454|DRUG|Tolterodine ER|4 mg by mouth once a day.
219108870|NCT04714437|BEHAVIORAL|F|The participant will be asked to chew the latex bag naturally.
219108871|NCT04714437|BEHAVIORAL|R|The participant will be asked to chew the latex bag unilaterally on the right-side.
219695422|NCT06363266|OTHER|Active Monitoring dyads' anxiety|"Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 13-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures."
219695423|NCT06312800|DRUG|Acamprosate|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
219695424|NCT06312800|DRUG|Placebo|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
219108872|NCT04714437|BEHAVIORAL|L|The participant will be asked to chew the latex bag unilaterally on the left-side.
219108873|NCT04714437|BEHAVIORAL|A1|The participant will be asked to chew the latex bag changing the side once.
219108874|NCT04714437|BEHAVIORAL|A3|The participant will be asked to chew the latex bag changing the side three times.
219108875|NCT04714437|BEHAVIORAL|A5|The participant will be asked to chew the latex bag changing the side five times.
219108876|NCT03555825|DEVICE|Hocoma ArmeoSpring|A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
219108877|NCT04337086|DEVICE|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
219108878|NCT04337086|DEVICE|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
219108879|NCT05089435|DEVICE|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
219224638|NCT06898073|BEHAVIORAL|cognitive dual-task group|Cognitive tasks as the second task in addition to walking
219108880|NCT02601716|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
219108881|NCT02601716|BIOLOGICAL|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
219224639|NCT06898073|BEHAVIORAL|Single-task group|walking without performing a second task during the walking training
219224640|NCT06803615|DEVICE|Electrocardiographic imaging|Electrocardiographic imaging is an electrophysiological mapping technique which is used to noninvasively map cardiac arrhythmias.
219224641|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
219224642|NCT04278833|DRUG|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
219224643|NCT04278833|DRUG|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
219108882|NCT02601716|BIOLOGICAL|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
219108883|NCT03579264|BEHAVIORAL|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
219108884|NCT02820584|BIOLOGICAL|GSC-loaded autologous dendritic cells|
219108885|NCT01222923|DRUG|Risperidone|1 mg orally disintegrating tablets
219108886|NCT04598893|BIOLOGICAL|Teplizumab|Received teplizumab in PROTECT Study
219108887|NCT04598893|OTHER|Placebo|Received placebo in PROTECT study
219108888|NCT03412968|PROCEDURE|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
219108889|NCT03412968|PROCEDURE|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
219108890|NCT03885466|BEHAVIORAL|Nordic Walking exercise|Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
219108891|NCT02873026|DRUG|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
219108892|NCT05997121|DEVICE|Transforaminal lumbar interbody fusion|Transforaminal Lumbar Interbody Fusion indicates a surgical approach in the lumbar spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height. Screws and rods are also added to maintain the level secure while the bones fuse together.
219108893|NCT02028832|PROCEDURE|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
219108894|NCT02028832|PROCEDURE|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
219108895|NCT03729024|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
219108896|NCT01978366|DRUG|HT-100|May be administered in either fed or fasted state
219108897|NCT00070993|DRUG|creatine monohydrate|
219108898|NCT05265455|DIETARY_SUPPLEMENT|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
219108899|NCT05265455|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
219108900|NCT05984316|OTHER|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
219108901|NCT05876611|DEVICE|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
219108902|NCT02698683|OTHER|lymphocyte count|lymphocyte count
219108903|NCT01676948|DRUG|ACZ885|
219224644|NCT05292989|OTHER|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
219224645|NCT05292989|OTHER|Standard Care|Standard care practice
219108904|NCT01676948|DRUG|Canakinumab|
219108905|NCT01676948|DRUG|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
219108906|NCT01676948|DRUG|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
219108907|NCT03233178|OTHER|Non-interventional|
219224646|NCT04185363|DRUG|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
219224647|NCT06750653|OTHER|CeraVe Moisturizing Cream|CeraVe is a formulation of Purified Water, Glycerin, Cetareth-20 and Cetearyl Alcohol, Caprylic/Capric Triglyceride, Behentrimonium Methosulfate and Cetearyl Alcohol, Cetyl Alcohol, Petrolatum, Dimethicone, Hyaluronic Acid, Ceramide 1, Ceramide 3, Ceramide 6-II, Cholesterol, Phytosphingosine, Potassium Phosphate, Dipotassium phosphate, Phenoxyethanol, Methylparaben, Propylparaben, Disodium EDTA, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum, manufactured by L'Oréal, for topical skin use.
219224648|NCT06750653|DRUG|Vaseline|Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.
219108908|NCT00502034|DRUG|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
219108909|NCT00502034|DRUG|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
219108910|NCT02067234|OTHER|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
219108911|NCT02067234|BEHAVIORAL|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
219108912|NCT02641457|DRUG|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
219108913|NCT02641457|DRUG|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
219108914|NCT01744925|DRUG|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
219108915|NCT01744925|DRUG|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
219108916|NCT02736968|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
219108917|NCT02736968|OTHER|Placebo|Placebo
219108918|NCT00147225|DRUG|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
219108919|NCT00147225|DRUG|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
219108920|NCT00147225|DRUG|Adriamycin|75-90 mg/m\^2 IV
219108921|NCT00147225|DRUG|Ifosfamide|10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
219108922|NCT01225913|DRUG|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
219108923|NCT01225913|DRUG|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
219108924|NCT05036928|DIAGNOSTIC_TEST|Monocyte distribution width (MDW）|All enrolled patients will receive test with MDW.
219108925|NCT06038890|PROCEDURE|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
219695425|NCT06312800|DRUG|Methazolamide|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
219695426|NCT06683911|DRUG|non Opioids|It is planned to avoid opioid side effects by applying opioid-free anesthesia during the perioperative period.
219224649|NCT06771661|OTHER|Workshops|The investigators will conduct workshops with parents to get closer to the main topic.
219108926|NCT02324764|DEVICE|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
219108927|NCT02324764|DEVICE|standard 6- French radial sheath|
219695427|NCT06683911|DRUG|Opioid|Routine general anesthesia in cardiac surgery
219108928|NCT01861457|OTHER|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
219108929|NCT01861457|OTHER|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
219108930|NCT03798834|DRUG|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
219108931|NCT03798834|OTHER|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
219108932|NCT05287516|OTHER|Breakfast meal|A meal consisting of breakfast biscuits and water.
219108933|NCT05510635|OTHER|interactive bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
219108934|NCT05510635|OTHER|reading bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
219108935|NCT03780270|DEVICE|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
219108936|NCT03780270|DEVICE|Curodont Repair|P11-4 (monomeric peptide) - for professional use
219108937|NCT03780270|DEVICE|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
219224650|NCT06771661|OTHER|Focus group interviews|The investigators will conduct focus group interviews with parents on their needs before and during child loss.
219224651|NCT06771661|OTHER|Narrative interviews|The investigators will conduct narrative interviews with parents to gain an in-depth understanding of their lived experience before and during the intrauterine or perinatal child loss.
219695428|NCT03058354|DRUG|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
219695429|NCT03058354|PROCEDURE|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
219695430|NCT01190917|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
219695431|NCT01190917|BEHAVIORAL|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
219695432|NCT04630028|DRUG|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
219695433|NCT04630028|DRUG|Matching Placebo|Placebo will be administered subcutaneously.
219695434|NCT05549180|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
219695435|NCT05549180|DRUG|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
219695436|NCT00361452|DRUG|nebulized epinephrine and nebulized albuterol|
219695437|NCT02368132|BEHAVIORAL|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
219695438|NCT02368132|BEHAVIORAL|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
219695439|NCT02543047|DEVICE|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
219695440|NCT05554497|BEHAVIORAL|Mindfulness-based stress reduction curriculum|Standard 8-week mindfulness-based stress reduction curriculum
219224652|NCT06771661|OTHER|Delphi approach|The investigators will carry out a Delphi approach with parents to translate and confirm or revise the findings into treatment recommendations for healthcare professionals.
219695441|NCT04156126|OTHER|Blood Collection|Blood Collection
219695442|NCT00608400|DIETARY_SUPPLEMENT|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
219695443|NCT02133430|DEVICE|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
219695444|NCT02134093|DRUG|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
219695445|NCT02134093|DRUG|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
219695446|NCT02134093|DRUG|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
219695447|NCT02134093|DRUG|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
219108938|NCT06380634|BEHAVIORAL|Experimental group- Motivational Interview|Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
219108939|NCT02049710|BEHAVIORAL|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
219108940|NCT02049710|BEHAVIORAL|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
219108941|NCT01283321|DRUG|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
219695448|NCT02314728|DRUG|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
219695449|NCT02314728|DRUG|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
219695450|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695451|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695452|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695453|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695454|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695455|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695456|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
219695457|NCT05002595|DRUG|H. pylori eradication|Antimicrobial agents for H. pylori eradication
219695458|NCT03597737|DEVICE|Pain APP|pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
219108942|NCT01283321|OTHER|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
219108943|NCT05492812|OTHER|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
219108944|NCT05492812|DRUG|Chloral Hydrate|Chloral Hydrate
219108945|NCT05492812|DRUG|Hydroxyzine|Hydroxyzine
219108946|NCT05492812|DRUG|Melatonin|Melatonin
219108947|NCT00721643|DIETARY_SUPPLEMENT|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
219108948|NCT00721643|DIETARY_SUPPLEMENT|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
219695459|NCT02599532|DRUG|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
219695460|NCT02306876|DRUG|PF-06412562 3mg BID|PF-06412562
219108949|NCT03762629|BEHAVIORAL|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
219108950|NCT03713021|DEVICE|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
219108951|NCT05390398|BEHAVIORAL|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
219108952|NCT05555160|DEVICE|PICC|Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
219108953|NCT01076283|DRUG|Baclofen|Baclofen 10mg t.i.d.
219695461|NCT02306876|DRUG|PF-06412562 15mg BID|PF-06412562
219108954|NCT01076283|DRUG|Cyproheptadine|'active' placebo
219108955|NCT06819319|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 is administered intravenously, Adebrelimab is administered intravenously
219108956|NCT02671383|DRUG|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
219108957|NCT02671383|DRUG|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
219108958|NCT06594679|DRUG|Niraparib Tosylate Monohydrate|Combination of niraparib and abemaciclib
219108959|NCT04991506|DRUG|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
219108960|NCT04991506|DRUG|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
219108961|NCT06613126|BEHAVIORAL|Symptom Management APP group|Based on symptom management theory and the relevant literature, the researcher designed a symptom management APP. The APP includes a symptom recording system, symptom management skills, and Tourette Syndrome knowledge information to facilitate parents' and children's joint learning.
219224653|NCT06410001|DEVICE|Epidural Spinal Cord Stimulation (eSCS)|"The spinal cord stimulator system (Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead) will be used for this study which is manufactured by Abbott Laboratories. The The stimulators will be surgically inserted above the dura in the spinal canal and administer an electrical signal from the neurostimulator to specific sections of the spinal cord underlying the electrodes. The duration of implantation will be 10 years (the longevity of the device battery). The device will not be removed unless it causes complications such as malfunction, illness, or other harm.~The device can also be removed electively for any reason."
219224654|NCT06901648|DRUG|HS-20094|Administrated by subcutaneous injection once a week
219695462|NCT02306876|OTHER|Placebo|Placebo
219695463|NCT03118934|DEVICE|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
219108962|NCT06613126|OTHER|health education instructions group|To receive outpatient verbal and paper health education guidance from healthcare providers.
219108963|NCT06617104|OTHER|no intervention|no intervention
219108964|NCT06624683|DEVICE|Intelligent footbath basin|before night sleep, takes 30 mins, starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
219108965|NCT03478462|DRUG|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
219108966|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
219108967|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
219695464|NCT03118934|DEVICE|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
219695465|NCT03118934|DEVICE|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
219695466|NCT04458519|OTHER|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
219108968|NCT02867657|BEHAVIORAL|Mindfulness|Five days MBSR curriculum with meditation and yoga
219108969|NCT06715007|DRUG|Clopidogrel|Patients will take Clopidogrel
219108970|NCT06715007|DRUG|Aspirin|Patients will take Rivaroxaban
219108971|NCT06715007|DRUG|Cilostazol + Isosorbide Mononitrate|Patients will take Cilostazol plus Isosorbide Mononitrate
219108972|NCT06889207|BEHAVIORAL|Physical exercise prehabilitation|Patients in the intervention group will have two supervised training sessions per week for eight weeks in group sessions supervised by a physiotherapist.
219108973|NCT06925308|BEHAVIORAL|Conversation|The design consists of two parts. In the first part, the researcher will have a conversation (with a formal and informal phase, where the subject will be given the idea that only the formal part is part of the study) with an adult with ASD during which covert recordings of the subject's eye behavior will be made, and in addition skin conductance and duration/frequency of eye contact of the subject will be recorded, without the subject knowing that this is intended for the purpose of studying eye contact. In the second part, the researcher and subject will watch the covert recording of the subject's eye behavior, during which the subject's skin conductance will be recorded and details of the subject's behavior as seen by the researcher.
219108974|NCT06925347|OTHER|medical adhesive tape|After the patients were assigned to the control and experimental groups, the tube of the patient in the control group was fixed with acrylic medical adhesive tape, and the tube of the patient in the experimental group was fixed with silicone medical adhesive tape.
219108975|NCT01919996|DRUG|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
219108976|NCT06130813|OTHER|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
219108977|NCT06900972|DRUG|Gelafundin|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution.
219108978|NCT06900972|DRUG|Saline (NaCl 0,9 %) (placebo)|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution
219108979|NCT06900491|OTHER|self-questionnaires|Patients will fill in these self-questionnaires on a tablet or on paper, depending on the availability of tablets in the centres, before and after consulting the doctor. These questionnaires assess the severity of the disease and quality of life.
219108980|NCT06900491|OTHER|unique collection of saddles|Stool samples will be taken at each visit, i.e. approximately every 6 months for patients
219695467|NCT04458519|OTHER|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
219695468|NCT00842634|BIOLOGICAL|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
219695469|NCT00842634|OTHER|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
219695470|NCT03174444|BEHAVIORAL|Small Media|Bilingual brochures and access to bilingual website
219695471|NCT05646368|DIETARY_SUPPLEMENT|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
219108981|NCT06900660|DIETARY_SUPPLEMENT|Collagen Drinks|Dosage: 50 mL/day; duration: 8 weeks
219108982|NCT04086953|DIAGNOSTIC_TEST|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
219108983|NCT04086953|DIAGNOSTIC_TEST|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
219695472|NCT05646368|DIETARY_SUPPLEMENT|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
219108984|NCT04086953|DIAGNOSTIC_TEST|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
219695473|NCT03804281|PROCEDURE|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
219695474|NCT03804281|PROCEDURE|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
219695475|NCT01614470|DRUG|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
219695476|NCT01614470|DRUG|Placebo|oral use, administered twice a day (q12h)
219695477|NCT02354612|DRUG|TRC105|
219695478|NCT02354612|DRUG|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
219695479|NCT02354612|DRUG|Axitinib|companion therapy selection depends on companion therapy used in the parent study
219695480|NCT02354612|DRUG|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
219108985|NCT04086953|DIAGNOSTIC_TEST|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
219695481|NCT02354612|DRUG|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
219695482|NCT01219543|DRUG|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
219695483|NCT01219543|DRUG|AZD1480 BID|Oral Dose, Capsule, BID Dosing
219108986|NCT04086953|DIAGNOSTIC_TEST|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
219108987|NCT03271034|DIETARY_SUPPLEMENT|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.
219108988|NCT03148977|PROCEDURE|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
219108989|NCT00405353|DRUG|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
219108990|NCT03606941|DEVICE|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
219108991|NCT03606941|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
219108992|NCT04683809|OTHER|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
219108993|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
219108994|NCT00141882|DRUG|memantine|
219108995|NCT03598218|RADIATION|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
219108996|NCT03598218|RADIATION|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
219108997|NCT00386308|DRUG|Tranexamic acid tablets|3900 mg/Day
219108998|NCT00386308|DRUG|Placebo tablets|
219108999|NCT02906683|DRUG|TAS-303|Oral administration for 8 weeks, once daily.
219109000|NCT02906683|DRUG|Placebo|Oral administration for 8 weeks, once daily.
219109001|NCT04377022|OTHER|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~1. Combined therapy~2. Conventional Therapy"
219109002|NCT02546687|OTHER|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
219109003|NCT01340482|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
219109004|NCT04917549|OTHER|detection of oral lesions|oral lesions in patient diagnosed with COVID-19
219224655|NCT06901648|DRUG|Dulaglutide|Administrated by subcutaneous injection once a week
219224656|NCT06901648|DRUG|Palcebo|Administrated by subcutaneous injection once a week
219695484|NCT06108999|DEVICE|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
219695485|NCT03733808|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
219695486|NCT01255215|DRUG|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
219224657|NCT03505905|DRUG|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
219695487|NCT03217591|DRUG|IW-1973|Oral Tablet
219695488|NCT03217591|DRUG|IW-1973|Oral Tablet
219695489|NCT03217591|DRUG|Placebo|Oral Tablet
219109005|NCT02351440|DRUG|duloxetine|patients will be randomized to receive either duloxetine or placebo
219109006|NCT02351440|DRUG|placebo|placebo
219224658|NCT03505905|DRUG|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
219695490|NCT02200146|DRUG|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
219224659|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
219224660|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
219224661|NCT05847257|DRUG|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
219224662|NCT05847257|DIETARY_SUPPLEMENT|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
219695491|NCT02200146|DRUG|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
219695492|NCT04232839|DRUG|BI 894416 Reference Formulation|R1 - 60 milligram (6 x 10 milligram tablets) BI 894416 Reference Formulation, immediate release (IR) tablets taken orally with 240 mL of water after an overnight fast of at least 10 hours.
219695493|NCT04232839|DRUG|BI 894416 Formulation A2|T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
219695494|NCT04232839|DRUG|BI 894416 Formulation C2|"T2 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T5 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
219695495|NCT04232839|DRUG|BI 894416 Formulation D2|T3 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation D2, extended release (ER) capsule (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
219695496|NCT04232839|DRUG|BI 894416 Formulation F2|"T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
219695497|NCT00249834|DRUG|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
219695498|NCT00249834|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
219695499|NCT00972270|DEVICE|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
219695500|NCT00972270|DEVICE|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
219695501|NCT05324306|DEVICE|combat application tourniquets (CAT)|"CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities."
219695502|NCT00244049|BEHAVIORAL|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
219695503|NCT00244049|OTHER|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
219109007|NCT04346641|DIAGNOSTIC_TEST|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
219109008|NCT01662622|DRUG|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
219109009|NCT01396928|PROCEDURE|Colonic reservoir|Type of reservoir to be performed
219109010|NCT02074540|OTHER|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
219109011|NCT05741970|PROCEDURE|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
219224663|NCT06906887|DRUG|Induction Chemotherapy (modified FLOT or modified FOLFOX-6)|Subjects are expected to receive 2-4 months of induction chemotherapy; the interval and dosages will be determined and can be modified at the discretion of their medical oncologist. The preferred induction chemotherapies are modified FLOT or FOLFOX-6. Subjects can enroll if they receive less than 2 months of induction chemotherapy as long as they are deemed to be a candidate for concurrent chemoradiation therapy.
219224664|NCT06906887|DRUG|Chemotherapy|The preferred concurrent chemoradiation is carboplatin/paclitaxel weekly.
219224665|NCT06906887|RADIATION|Conventional Radiation|For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.
219224666|NCT06906887|RADIATION|Pulsed Low-Dose-Rate (PLDR) Radiation|"For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.~For PLDR radiation therapy, each fraction will be delivered as a series of 20 cGy (or 0.2 Gy) pulses that are separated by 3-minute time intervals."
219695504|NCT02313051|DRUG|Everolimus|mTOR inhibitor
219695505|NCT02313051|DRUG|Goserelin|
219695506|NCT02313051|DRUG|Letrozole|
219695507|NCT04332263|OTHER|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
219695508|NCT04813523|DRUG|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
219695509|NCT05444816|DEVICE|Personalised Neurofeedback training at home|"The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed."
219695510|NCT03962621|RADIATION|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
219695511|NCT03962621|RADIATION|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
219695512|NCT00159315|PROCEDURE|Inhalation Challenge with ATP|
219695513|NCT00159315|PROCEDURE|Inhalation Challenge with AMP|
219695514|NCT01705938|DRUG|SP-333|
219695515|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
219695516|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
219224667|NCT06906887|PROCEDURE|Surgery|Esophagectomy is not required for trial and will be administered per medical judgement of the treating physicians. Surgery will take place at the time directed by the surgeon. This typically will take place approximately 6-13 weeks after chemoradiation therapy.
219695517|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
219695518|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
219224668|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
219224669|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
219224670|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
219695519|NCT03830268|DIETARY_SUPPLEMENT|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
219695520|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
219695521|NCT02806440|DRUG|Low dose naltrexone|Active comparator
219695522|NCT02806440|DRUG|Placebo|Placebo comparator
219695523|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
219109012|NCT06439290|PROCEDURE|Phonosurgery|Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
219109013|NCT06439290|PROCEDURE|Mastectomy/breast augmentation|Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
219109014|NCT05723848|DEVICE|Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
219109015|NCT02044237|BEHAVIORAL|Decoupling|
219109016|NCT02044237|BEHAVIORAL|Progressive relaxation|
219109017|NCT03629873|DRUG|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2
219109018|NCT01282476|DRUG|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
219109019|NCT04822935|PROCEDURE|Vertebral Body Tethering|VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
219109020|NCT04324463|DRUG|Colchicine|oral medication
219109021|NCT04324463|DRUG|Interferon-Beta|subcutaneous injection
219109022|NCT04324463|DRUG|Aspirin|oral medication
219224671|NCT07098962|OTHER|Kinesiotaping|In this group, KinesioTaping will be applied around the thoracic drain sites alongside standard analgesic therapy. This physical therapy technique uses elastic tapes placed on the skin to support healing, reduce pain, and improve patient comfort. The tapes will remain in place for 2-3 days and will be removed together with the drains.
219224672|NCT07098962|DRUG|Dexketoprofen, tramadol|Patients in this group will be treated with painkillers consisting of tramadol and dexketoprofen.
219224673|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:2. Mechanical power was calculated geometrically (MPgeo) using ventilator screenshots, and results were compared with dynamic mechanical power (MPdyn) values.
219695524|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
219695525|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
219695526|NCT03707834|BEHAVIORAL|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
219695527|NCT00914134|DRUG|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
219695528|NCT00714974|DEVICE|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
219109023|NCT04324463|DRUG|Rivaroxaban|oral medication
219109024|NCT02328157|DEVICE|Vitrectomy with cataract surgery and toric IOL|
219109025|NCT02328157|DEVICE|Vitrectomy with cataract surgery and common IOL|
219109026|NCT00366860|BEHAVIORAL|Soy bread|
219109027|NCT00743587|DRUG|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
219109028|NCT00743587|DRUG|Oxycodone|Oral, 1 x 20mg controlled-release tablets
219109029|NCT00743587|DRUG|Tramadol|Oral, 2 x 50mg immediate release capsules
219109030|NCT00743587|DRUG|Naproxen|Oral, 1 x 500mg enteric-coated
219109031|NCT04118985|BEHAVIORAL|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
219109032|NCT04118985|BEHAVIORAL|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
219109033|NCT03124680|COMBINATION_PRODUCT|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
219109034|NCT03124680|COMBINATION_PRODUCT|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
219109035|NCT02377830|DEVICE|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
219109036|NCT02377830|OTHER|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
219109037|NCT01336062|DRUG|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
219224674|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:1. MPgeo was computed from ventilator screenshots and compared to MPdyn values to assess agreement.
219224675|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:2. Mechanical power was measured using both geometric (MPgeo) and dynamic (MPdyn) methods for validation purposes.
219224676|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:1. Geometric mechanical power calculations from ventilator screenshots were compared with MPdyn values for accuracy assessment.
219109038|NCT02320786|BEHAVIORAL|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
219109039|NCT03552718|BIOLOGICAL|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
219109040|NCT03687268|DRUG|Naloxone HCl PR tablets|oral administration
219109041|NCT03687268|DRUG|Placebo Oral Tablet|Placebo
219695529|NCT03718715|DRUG|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
219695530|NCT02895347|BEHAVIORAL|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
219695531|NCT04609683|DEVICE|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
219695532|NCT05916898|DEVICE|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
219695533|NCT02610517|BEHAVIORAL|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
219109042|NCT03847779|OTHER|"Rest"|Cutaneous perfusion and vasomotion assessment at rest in supoine position
219109043|NCT03847779|OTHER|"Exercise"|Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
219224677|NCT05909995|DRUG|INCB 99280 with Ipilimumab|Dose Escalation and expansion of INCB 99280 with Ipilimumab
219224678|NCT06486051|DRUG|Fludarabine|30 mg/m\^2/day IV for three consecutive days
219224679|NCT06486051|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for three consecutive days
219224680|NCT06486051|BIOLOGICAL|WZTL-002 CAR T-cells|"WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy."
219224681|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
219695534|NCT02610517|BEHAVIORAL|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
219695535|NCT03421938|OTHER|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
219109044|NCT03847779|OTHER|"Foot lowering"|Cutaneous perfusion and vasomotion assessment after foot lowering
219109045|NCT03847779|OTHER|"Hyperthermia"|Cutaneous perfusion and vasomotion assessment during hyperthermia
219109046|NCT00437125|DRUG|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
219109047|NCT01542541|DRUG|Rifaximin|550mg BID for 2 days
219109048|NCT00355407|DRUG|Darbepoetin alfa|
219109049|NCT02248961|DRUG|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
219109050|NCT02248961|DRUG|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
219109051|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
219109052|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
219109053|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
219109054|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
219695536|NCT03621033|PROCEDURE|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
219695537|NCT05739487|PROCEDURE|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
219695538|NCT00142649|BEHAVIORAL|diet|
219695539|NCT00142649|BEHAVIORAL|physical activity|
219695540|NCT02589145|DRUG|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
219695541|NCT02589145|DRUG|Vorinostat|1000 mg by mouth on Days -9 to -2.
219695542|NCT02589145|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
219695543|NCT02589145|DRUG|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
219695544|NCT02589145|DRUG|Melphalan|60 mg/m2 by vein on days -3 and -2.
219695545|NCT02589145|DRUG|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
219695546|NCT02589145|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
219695547|NCT02589145|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
219695548|NCT02589145|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
219695549|NCT02589145|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
219695550|NCT02589145|DRUG|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
219695551|NCT02589145|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
219695552|NCT02589145|DRUG|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
219695553|NCT01542450|DRUG|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
219695554|NCT01542450|DRUG|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
219695555|NCT04028726|OTHER|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
219695556|NCT01707888|PROCEDURE|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
219695557|NCT04385433|DRUG|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
219695558|NCT04385433|OTHER|CONTROL GROUP|"Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
219109055|NCT06066489|OTHER|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
219695559|NCT04385433|RADIATION|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
219695560|NCT01673178|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
219695561|NCT01673178|DRUG|25 mg PF-05231023|25 mg IV once a week for 4 weeks
219695562|NCT01673178|DRUG|50 mg PF-05231023|50 mg IV once a week for 4 weeks
219695563|NCT01673178|DRUG|100 mg PF-05231023|100 mg IV once a week for 4 weeks
219109056|NCT03257592|DRUG|[11C]DPA-713|\[11C\]DPA-713 PET imaging
219109057|NCT05012215|PROCEDURE|Paravertebral|Ultrasound-guided paravertebral block
219109058|NCT05012215|PROCEDURE|Caudal block|Caudal block
219109059|NCT01628302|BEHAVIORAL|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
219109060|NCT06354621|DIETARY_SUPPLEMENT|Vitamin-D supplementation|Participants receiving a daily dose of vitamin D supplementation
219109061|NCT00165295|DRUG|Sildenafil citrate (Viagra)|
219109062|NCT00206960|DRUG|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
219109063|NCT00206960|DRUG|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
219109064|NCT00763399|DIETARY_SUPPLEMENT|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
219109065|NCT02033460|OTHER|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
219109066|NCT02033460|OTHER|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
219695564|NCT01673178|DRUG|150 mg PF-05231023|150 mg IV once a week for 4 weeks
219695565|NCT05199792|DIAGNOSTIC_TEST|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
219695566|NCT04990193|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
219695567|NCT04990193|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
219695568|NCT02361775|DEVICE|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
219695569|NCT02361775|DEVICE|opioid iv pca|opioid pca consisting of hydromorphone
219695570|NCT02361775|DRUG|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
219695571|NCT02361775|DEVICE|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
219695572|NCT04474886|DIETARY_SUPPLEMENT|Fresubin® powder fibre|2 servings per day
219695573|NCT03177148|BEHAVIORAL|Intervention by Clinicians|"•Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone."
219695574|NCT03177148|BEHAVIORAL|Usual Care|Pediatric clinicians provide care as normal
219695575|NCT03724357|DRUG|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
219109067|NCT02033460|OTHER|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
219224682|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
219224683|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
219224684|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
219224685|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
219695576|NCT04522219|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
219695577|NCT05923047|DRUG|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
219695578|NCT05923047|PROCEDURE|Polypeptomy|This group will undergone in-office nasal polypectomy.
219695579|NCT02843126|DRUG|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
219695580|NCT02843126|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
219695581|NCT06410651|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
219695582|NCT00331838|DRUG|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
219695583|NCT00331838|DRUG|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
219695584|NCT00331838|DRUG|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
219695585|NCT00331838|DRUG|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
219109068|NCT01602952|DRUG|Radotinib|50mg, 100mg or 200mg Capsule BID
219109069|NCT05755230|OTHER|No intervention|No intervention
219109070|NCT05297916|OTHER|enteral feeding|to intake oral feeding or delay it
219109071|NCT04842994|DEVICE|IONM tube|The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
219695586|NCT00254553|DRUG|Testim 1% (testosterone gel)|Testim\_ 100 mg: two tubes of 50 mg of Testim\_per day
219695587|NCT00254553|DRUG|Placebo|two tubes of placebo per day
219695588|NCT03237897|BEHAVIORAL|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
219695589|NCT03237897|BEHAVIORAL|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
219695590|NCT05582278|DRUG|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
219695591|NCT05582278|DRUG|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
219695592|NCT05582278|DRUG|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg
219695593|NCT05582278|DRUG|tislelizumab|tislelizumab 200 mg, every 3 weeks.
219695594|NCT02456194|DEVICE|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
219695595|NCT02123719|OTHER|Surgery|
219695596|NCT00742911|DRUG|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
219695597|NCT00742911|DRUG|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
219695598|NCT01419314|DEVICE|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
219695599|NCT01419314|DEVICE|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
219695600|NCT01439035|DEVICE|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
219695601|NCT05185466|BEHAVIORAL|Nurse-Supported Self Management Programme|Training and incentives to improve nutrition habits and sleep health.
219695602|NCT00965237|DEVICE|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
219695603|NCT00965237|DEVICE|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
219695604|NCT00965237|OTHER|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
219695605|NCT01945983|DRUG|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
219695606|NCT01945983|DRUG|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
219695607|NCT06080009|GENETIC|exome sequencing (retrospective) and exome and methylome sequencing (prospective)|"Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed."
219695608|NCT05798715|DRUG|Gleptomet 50/1000(Metformin HCl & Sitagliptin)|Test drug
219695609|NCT05798715|DRUG|Janumet 50/1000(Metformin HCl & Sitagliptin)|Reference drug
219695610|NCT06085521|DRUG|LNK01001 Dose A|Capsules taken orally
219695611|NCT06085521|DRUG|LNK01001 Dose B|Capsules taken orally
219695612|NCT06085521|DRUG|placebo|Capsules taken orally
219695613|NCT02926963|OTHER|samples collection : hair and skin biopsy|
219695614|NCT05947669|DRUG|Infliximab|Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
219695615|NCT05947669|DRUG|Methylprednisolone|Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
219695616|NCT05947669|DRUG|Prednisolone|Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
219224686|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
219109072|NCT01316146|DRUG|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
219695617|NCT04550078|DIETARY_SUPPLEMENT|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
219695618|NCT04550078|DIETARY_SUPPLEMENT|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
219695619|NCT04550078|DIETARY_SUPPLEMENT|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
219695620|NCT03620799|PROCEDURE|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
219695621|NCT00510614|DRUG|tinidazole|1 gram twice weekly for 12 weeks
219695622|NCT00510614|DRUG|Placebo|one pill twice weekly for 12 weeks
219695623|NCT04020211|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
219695624|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
219695625|NCT05032144|DRUG|Placebo|Intravenous injection
219695626|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
219695627|NCT05032144|DRUG|Placebo|Intravenous injection
219109073|NCT06071520|DRUG|Fostamatinib|Patient treated with fostamatinib in the period described
219109074|NCT00670462|BEHAVIORAL|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
219109075|NCT00670462|BEHAVIORAL|Maintenance-Tailored Treatment (MTT)|
219109076|NCT05155592|BIOLOGICAL|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
219109077|NCT00864838|DRUG|Acetazolamide|250 mg 1 hour before intravitreal injection
219109078|NCT00864838|DRUG|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
219109079|NCT00864838|PROCEDURE|Anterior chamber paracentesis|Immediately after bevacizumab injection
219695628|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
219695629|NCT05032144|DRUG|Placebo|Intravenous injection
219695630|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
219695631|NCT05032144|DRUG|Placebo|Intravenous injection
219695632|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
219695633|NCT05032144|DRUG|Placebo|Intravenous injection
219695634|NCT03479112|BEHAVIORAL|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
219695635|NCT03479112|BEHAVIORAL|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
219695636|NCT03479112|BEHAVIORAL|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
219695637|NCT03479112|BEHAVIORAL|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
219695638|NCT04083560|DRUG|Vit B12|Vitamin B12 250mcg
219695639|NCT02141906|OTHER|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
219695640|NCT00002935|DRUG|porfimer sodium|
219695641|NCT03698292|DRUG|Itopride|Prokinetic Drug
219695642|NCT03698292|DRUG|Metoclopramide 10mg|Prokinetic Drug
219695643|NCT00302978|BEHAVIORAL|Behavior therapy|
219695644|NCT05862051|PROCEDURE|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation \[radiofrequency ablation (RFA) or microwave ablation (MWA)\]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
219695645|NCT05862051|PROCEDURE|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
219695646|NCT06323785|DEVICE|Active whole-body hyperthermia|Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
219695647|NCT06323785|DEVICE|Sham whole-body hyperthermia|Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
219695648|NCT03606564|OTHER|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
219109080|NCT01339988|DRUG|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
219109081|NCT04662671|DEVICE|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
219109082|NCT05245604|DRUG|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
219109083|NCT05245604|DRUG|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
219109084|NCT01549522|BEHAVIORAL|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
219695649|NCT02084511|DRUG|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
219695650|NCT02084511|DRUG|BI 1026706|BI 1026706
219695651|NCT02084511|DRUG|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
219695652|NCT02084511|DRUG|Celecoxib|Celecoxib capsule
219695653|NCT00295165|DRUG|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
219695654|NCT00295165|DRUG|Placebo|Placebo subcutaneously once daily
219695655|NCT01555658|DRUG|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
219695656|NCT01555658|DRUG|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
219695657|NCT02749344|OTHER|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
219695658|NCT04454424|DRUG|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
219695659|NCT04454424|DRUG|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
219695660|NCT01954849|DIETARY_SUPPLEMENT|Probiotic formulation|
219695661|NCT01328964|DRUG|Fluticasone propionate|fluticasone propionate 44 mcg
219695662|NCT01328964|DRUG|Budesonide|budesonide
219695663|NCT01328964|DRUG|Montelukast|montelukast
219695664|NCT01859182|DRUG|selumetinib|Given PO
219695665|NCT01859182|DRUG|Akt inhibitor MK2206|Given PO
219695666|NCT01859182|OTHER|laboratory biomarker analysis|Correlative studies
219695667|NCT01859182|OTHER|pharmacogenomic studies|Correlative studies
219695668|NCT01859182|PROCEDURE|quality-of-life assessment|Ancillary studies
219109085|NCT01549522|BEHAVIORAL|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
219109086|NCT01742637|DRUG|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
219109087|NCT01742637|DRUG|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
219109088|NCT01742637|DRUG|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
219109089|NCT05451381|DRUG|Propofol|sedation after cardiac surgery
219109090|NCT05451381|DRUG|Dexmedetomidine|sedation after cardiac surgery
219695669|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
219695670|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
219695671|NCT00763789|OTHER|local anaesthesia and remifentanil sedation|
219695672|NCT00763789|OTHER|total intravenous anaesthesia|
219695673|NCT01733277|OTHER|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
219695674|NCT01562977|DRUG|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
219695675|NCT04313517|OTHER|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
219695676|NCT01032564|OTHER|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
219695677|NCT01754519|PROCEDURE|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
219695678|NCT01754519|RADIATION|Radiation Therapy|Undergo SFRT
219695679|NCT01754519|OTHER|Laboratory Biomarker Analysis|Correlative studies
219695680|NCT01754519|OTHER|Quality-of-Life Assessment|Ancillary studies
219695681|NCT01548807|DRUG|Everolimus (RAD001)|
219695682|NCT02964130|OTHER|No name|
219695683|NCT06160336|OTHER|Transcutaneous Electrical Nerve Stimulation|"Phase 1: Participants undergo a comprehensive assessment in a single experimental session (mapping session) aimed at mapping the regions and sensations that can be electrically stimulated. This mapping protocol is conducted on both the intact and amputated limbs.~Phase 2: This phase comprises a 4-week experimental protocol, including:~1. four mapping sessions conducted at the onset of each week, where the protocol is randomly applied to the participant's intact and amputated limb.~2. three stimulation sessions held over three consecutive days in the initial week to assess the participant's ability to discern stimuli of varying intensities.~3. ten sessions utilizing an end-effector gait rehabilitation robot, aiming to train the participant in walking using the proposed sensory feedback restoration system based on TENS under controlled and repeatable experimental conditions."
219695684|NCT03427710|DRUG|CiVi007|cholesterol lowering drug
219695685|NCT03427710|OTHER|Placebo|matching placebo to CiVi007
219109091|NCT05451381|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
219109092|NCT03378843|OTHER|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
219109093|NCT01784315|DRUG|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
219109094|NCT01784315|DRUG|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
219109095|NCT02746757|OTHER|Remote conditioning|
219695686|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve preservation|In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
219695687|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve is not preserved|In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
219695688|NCT04247516|BEHAVIORAL|Online-intervention group I (IGI)|Narrative-based online intervention program to promote self-regulatory competences.
219695689|NCT04247516|BEHAVIORAL|Online-intervention group II (IGII)|Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
219695690|NCT05943353|OTHER|Pentoxifylline|Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
219695691|NCT04845334|BEHAVIORAL|RR intervention|"The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain"
219695692|NCT00288652|DRUG|[S,S]-Reboxetine|
219695693|NCT00887484|DRUG|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
219695694|NCT00887484|DRUG|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
219109096|NCT02746757|DRUG|Exendin 9-39|
219109097|NCT00453310|DRUG|sunitinib malate|
219109098|NCT01267825|DRUG|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
219109099|NCT01267825|DRUG|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
219109100|NCT00259818|DRUG|EM-1421|
219109101|NCT02790593|DEVICE|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
219109102|NCT02790593|DEVICE|Standard Compression|Compression bandaging
219109103|NCT02790593|DEVICE|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
219109104|NCT02790593|DEVICE|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
219695695|NCT03687632|BIOLOGICAL|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
219695696|NCT05813756|OTHER|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+\~2.5 months), at the end of the intervention (T2 : T0+\~5 months) and 3 months after the intervention (T3 : T0+\~8 months). At the same time psychological questionnaires and scales will be completed
219695697|NCT03728062|BEHAVIORAL|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
219695698|NCT03728062|BEHAVIORAL|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
219695699|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
219695700|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
219695701|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
219695702|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
219695703|NCT02943772|OTHER|Local hypothermia|Cooled brick
219695704|NCT02943772|OTHER|Control|Control brick
219695705|NCT03044314|DRUG|Iloprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
219695706|NCT04226417|DEVICE|Transcranial direct current stimulation|Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
219695707|NCT01298947|DEVICE|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
219695708|NCT04213664|OTHER|prognosis|cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
219695709|NCT04523012|OTHER|Seroprevalence of SARS-CoV-2 infection in patients with HIV infection|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
219109105|NCT04651270|DEVICE|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
219109106|NCT03922802|DEVICE|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
219109107|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
219109108|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
219109109|NCT06286579|DEVICE|Immediately implant placement|After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
219224687|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice combined with caffeine (COM)|"* 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session~* 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session"
219695710|NCT05267210|OTHER|Questionnaire|"1. Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~2. Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
219695711|NCT03508778|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
219695712|NCT03508778|DEVICE|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
219695713|NCT03508778|PROCEDURE|Cataract surgery|Cataract surgery per investigator's standard practice
219695714|NCT03880747|PROCEDURE|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
219695715|NCT04801251|DIAGNOSTIC_TEST|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
219695716|NCT03854942|DRUG|Placebo|Placebo oral tablet daily
219695717|NCT03854942|DRUG|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
219695718|NCT03106077|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
219695719|NCT00541242|DRUG|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
219695720|NCT00541242|DRUG|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
219695721|NCT04547855|DRUG|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
219695722|NCT03548077|BEHAVIORAL|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
219224688|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice placebo with caffeine (CAF)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session
219695723|NCT04309032|PROCEDURE|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
219695724|NCT06378424|OTHER|Cold Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
219224689|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice with caffeine placebo (BRJ)|\- 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
219224690|NCT06758323|OTHER|Beetroot placebo with caffeine placebo (PLA)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
219695725|NCT06378424|OTHER|Heat Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
219109110|NCT06286579|DEVICE|Delayed|"After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered"
219109111|NCT04453670|PROCEDURE|autopsy|autopsy
219109112|NCT03815279|DRUG|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
219109113|NCT03815279|DRUG|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
219109114|NCT03815279|DRUG|Dexamethasone|Dexamethasone will be administered weekly
219109115|NCT05706987|DRUG|Lidocaine|continuous lidocaine infusion perioperatively
219109116|NCT05706987|DRUG|Normal saline|normal saline
219109117|NCT00871351|DRUG|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
219109118|NCT00871351|DRUG|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
219109119|NCT00871351|DRUG|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
219109120|NCT00871351|DRUG|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
219109121|NCT00744237|DRUG|Nebivolol|"* Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
219109122|NCT00744237|DRUG|Metoprolol ER|"* Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
219109123|NCT00744237|DRUG|HCTZ|"* HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
219109124|NCT02640599|OTHER|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
219109125|NCT02640599|OTHER|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
219109126|NCT01743300|DRUG|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
219109127|NCT01743300|DRUG|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
219109128|NCT01743300|OTHER|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
219109129|NCT01743300|OTHER|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
219109130|NCT03992885|DRUG|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
219224691|NCT06942806|OTHER|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V
219695726|NCT06378424|OTHER|Vibration Application|With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
219695727|NCT04881812|DEVICE|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
219695728|NCT04881812|DEVICE|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
219109131|NCT00291655|DRUG|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
219109132|NCT03169192|DRUG|Zoledronic Acid|intravenous injections once every 3 months
219695729|NCT00606307|DRUG|ITF2357|50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
219109133|NCT02791490|DRUG|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
219109134|NCT02791490|DRUG|Placebo|Oral tablet, once daily at approximately the same time each day
219109135|NCT02791490|DRUG|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
219109136|NCT03693274|BEHAVIORAL|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
219161446|NCT06788730|BEHAVIORAL|Transtheoretical Model Based Healthy Internet Use Programme Intervention Supported by Mindfulness Exercise Applied to Adolescents|Transtheoretical Model Based Healthy Internet Use Programme Supported by Mindfulness Exercise will be carried out as one session per week for 8 weeks. The training programme will be carried out by dividing the students into 2 groups (the first group is 18 and the second group is 19 people). The training programme will be applied to the groups two days in the same week at the times determined by the guidance teacher. Interventions will be applied to the intervention group with trainings, homework applications and interventions to increase healthy internet use.
219109137|NCT03240536|OTHER|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
219109138|NCT01175772|DRUG|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
219109139|NCT00771693|DRUG|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
219109140|NCT00836173|DRUG|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
219109141|NCT00836173|DRUG|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
219695730|NCT05681117|OTHER|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
219695731|NCT04119934|BEHAVIORAL|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
219695732|NCT00900939|BEHAVIORAL|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
219695733|NCT00900939|BEHAVIORAL|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
219695734|NCT01274533|DRUG|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
219695735|NCT00597272|BIOLOGICAL|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
219695736|NCT03781726|DRUG|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
219695737|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
219695738|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
219224692|NCT06942806|OTHER|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V
219224693|NCT06951373|PROCEDURE|Multiple Percutaneous Needle Aspiration (MPNA)|A minimally invasive technique involving repeated needle aspiration of breast abscess fluid without making an incision.
219695739|NCT05247762|DEVICE|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
219695740|NCT01892332|DRUG|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
219224694|NCT06951373|PROCEDURE|Incision and Drainage (ID)|A surgical procedure involving an incision in the abscess to allow drainage of pus, followed by wound care.
219109142|NCT01984424|DRUG|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
219109143|NCT01984424|DRUG|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
219109144|NCT01984424|OTHER|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
219109145|NCT01984424|DRUG|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
219109146|NCT01984424|OTHER|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
219695741|NCT05261165|PROCEDURE|hysterectomy|Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
219695742|NCT01118052|OTHER|Laboratory Biomarker Analysis|Correlative studies
219695743|NCT01118052|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
219695744|NCT02757157|BEHAVIORAL|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
219695745|NCT02757157|BEHAVIORAL|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
219695746|NCT04991714|DRUG|Lactisole|sweet taste inhibitor (decreases sweetness)
219695747|NCT04991714|DRUG|Rebaudioside M|Sweetener (increases sweetness)
219695748|NCT04991714|OTHER|Sucrose|10% Sucrose corresponding to a regular soft drink
219695749|NCT01171378|DRUG|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
219695750|NCT04188600|DIETARY_SUPPLEMENT|Libicare|"The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)"
219695751|NCT04188600|DIETARY_SUPPLEMENT|active control|Selenium and vitamins B complex
219695752|NCT05423834|DRUG|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
219695753|NCT05423834|DRUG|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
219695754|NCT05696951|OTHER|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
219695755|NCT02949947|DRUG|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
219695756|NCT02949947|DIETARY_SUPPLEMENT|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
219695757|NCT02949947|BEHAVIORAL|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
219695758|NCT02232204|BEHAVIORAL|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
219109147|NCT01984424|DRUG|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
219109148|NCT01551316|DRUG|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
219109149|NCT01551316|DRUG|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
219109150|NCT05516368|BEHAVIORAL|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
219109151|NCT02643719|BEHAVIORAL|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
219109152|NCT02643719|DRUG|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
219109153|NCT02643719|DRUG|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
219109154|NCT02643719|DRUG|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
219109155|NCT02802319|DEVICE|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
219695759|NCT03993483|BEHAVIORAL|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
219695760|NCT00020657|DRUG|dolasetron mesylate|
219695761|NCT00020657|DRUG|granisetron hydrochloride|
219695762|NCT00020657|DRUG|ondansetron|
219695763|NCT00020657|DRUG|prochlorperazine|
219695764|NCT00020657|PROCEDURE|quality-of-life assessment|
219695765|NCT00380263|DRUG|PACAP38|10 pmol/kg/min given one time
219695766|NCT01187316|DEVICE|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
219695767|NCT01187316|OTHER|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
219695768|NCT02349035|DEVICE|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
219695769|NCT02349035|PROCEDURE|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
219695770|NCT00193375|DRUG|Irinotecan|50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
219695771|NCT00193375|DRUG|Carboplatin|AUC 5
219109156|NCT02802319|DEVICE|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
219109157|NCT02532959|DEVICE|Diagnostic Breath Analysis|Conduct exhaled breath samples
219109158|NCT03780595|DRUG|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
219109159|NCT03780595|DRUG|Control|Control pills administration up to 6 pills per day
219109160|NCT00077636|DRUG|Copegus|400mg po bid for 16 weeks
219109161|NCT00077636|DRUG|Copegus|400mg po bid for 24 weeks
219109162|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
219109163|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
219695772|NCT00193375|DRUG|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
219695773|NCT00193375|RADIATION|Radiation|
219695774|NCT00492726|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
219695775|NCT00492726|DRUG|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
219695776|NCT00254514|DRUG|somatropin|
219109164|NCT00027521|BIOLOGICAL|bleomycin sulfate|
219109165|NCT00027521|DRUG|electroporation therapy|
219109166|NCT06313996|DRUG|Cyclophosphamide|Specified dose on specified days
219109167|NCT06313996|DRUG|Doxorubicin|Specified dose on specified days
219109168|NCT06313996|DRUG|Vincristine|Specified dose on specified days
219109169|NCT06313996|DRUG|Rituximab|Specified dose on specified days
219109170|NCT06313996|DRUG|Prednisone|Specified dose on specified days
219109171|NCT06313996|DRUG|Bendamustine|Specified dose on specified days
219109172|NCT06313996|DRUG|Lenalidomide|Specified dose on specified days
219109173|NCT06313996|DRUG|Fludarabine|Specified dose on specified days
219109174|NCT06313996|DRUG|Liso-cel|Specified dose on specified days
219224695|NCT06950827|PROCEDURE|laparoscopic right hemihepatectomy|Laparoscopic surgery has many advantages, such as small surgical incision and fast postoperative recovery. In recent years, more and more centers have gradually transitioned to performing right hemihepatectomy through laparoscopy as much as possible.
219109175|NCT02686541|DEVICE|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
219109176|NCT01422681|DEVICE|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
219109177|NCT02133482|DRUG|Placebo|placebo solution
219109178|NCT02133482|DRUG|BI 639667|oral solution BI 639667, single rising doses
219109179|NCT03545113|PROCEDURE|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
219109180|NCT03545113|PROCEDURE|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
219695777|NCT04386902|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
219695778|NCT02343861|BEHAVIORAL|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
219695779|NCT02343861|BEHAVIORAL|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
219109181|NCT02032173|DRUG|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
219224696|NCT06953206|PROCEDURE|Transcatheter aortic valve (S3UR) replacement (TAVR)|Elective transfemoral TAVi procedure with S3UR valve.
219695780|NCT00828711|DRUG|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219695781|NCT00828711|DRUG|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219695782|NCT00828711|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219695783|NCT05213299|PROCEDURE|AURICULAR ACUPUNCTURE|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.
219695784|NCT05213299|OTHER|PLACEBO|For this intervention, instead of needles, the investigators use four pieces of tape.
219695785|NCT03778008|DRUG|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
219695786|NCT03778008|COMBINATION_PRODUCT|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
219695787|NCT01494636|DRUG|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
219695788|NCT01494636|DRUG|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
219109182|NCT05082142|DRUG|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
219109183|NCT05149781|PROCEDURE|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
219109184|NCT01163110|DIETARY_SUPPLEMENT|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
219109185|NCT00061230|BEHAVIORAL|biofeedback-monitored relaxation training|
219109186|NCT03938064|DRUG|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
219109187|NCT04639921|DIAGNOSTIC_TEST|positive test followed by gluten-free diet|DBPCFC with gluten
219109188|NCT04639921|DIETARY_SUPPLEMENT|Placebo|Placebo
219109189|NCT03669653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
219695789|NCT01494636|DRUG|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
219109190|NCT03669653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
219109191|NCT05414838|DIETARY_SUPPLEMENT|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
219109192|NCT01694810|DRUG|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
219109193|NCT01694810|DRUG|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
219109194|NCT01694810|DRUG|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
219109195|NCT01694810|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
219109196|NCT06307119|BEHAVIORAL|Occupational Therapy and Relaxation Group|"MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds."
219109197|NCT06307119|BEHAVIORAL|Relaxation Group|Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
219695790|NCT01494636|DRUG|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
219695791|NCT06254989|OTHER|Aerobic Exercise|"Participants will engage in aerobic exercise at HNH fitness at a minimum of 2 days a week for 12 weeks. Participants will have their daily step count collected via the Fitbit during this period. VO2 measurements will also be collected during active intervention using the UNCCRI protocol.~The structured aerobic exercise program (Weeks 3-14) will entail 30 minutes of aerobic activity, 3 days a week, on the treadmill, at a goal of between 50 to 70% of predicted VO2 maximum heart rate. All structured aerobic program sessions will take place at Holy Name Health (HNH) Fitness and will be overseen by our collaborator and Director of Human Performance (Reg Grant). Exercise data will be recorded in the Technogym MyWellness cloud. Participants who drop out or discontinue attendance (defined as 4 consecutive sessions missed without notification of absence) before completion of the 12-week study intervention period will be replaced."
219695792|NCT01896063|PROCEDURE|Electroacupuncture|
219695793|NCT04012528|OTHER|ERAS program|ERAS program
219695794|NCT04308863|DRUG|Chitosan scaffold/ MTA pulp dressing material|Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
219695795|NCT04308863|DRUG|MTA pulp dressing material|MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
219695796|NCT01608880|DRUG|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
219695797|NCT01608880|DRUG|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
219695798|NCT02646683|DRUG|vedolizumab|
219695799|NCT05311826|PROCEDURE|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
219695800|NCT05311826|PROCEDURE|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
219695801|NCT03521557|BEHAVIORAL|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
219695802|NCT03521557|BEHAVIORAL|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
219695803|NCT00483535|DRUG|GW273225|GW273225 will be available as 25 milligram tablets.
219695804|NCT00483535|DRUG|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
219695805|NCT02230891|DRUG|Carvedilol|Carvedilol is a non selective beta blocker
219695806|NCT02230891|DRUG|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
219695807|NCT02230891|OTHER|Usual care|standard care as per primary care provider
219695808|NCT04767464|OTHER|Compass Course|The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer. Enrollment in this arm will involve participation in the Compass Course virtually.
219695809|NCT02404545|DEVICE|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
219695810|NCT01661738|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
219695811|NCT04782817|OTHER|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
219695812|NCT04782817|OTHER|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
219695813|NCT02370511|DEVICE|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
219695814|NCT06855576|DRUG|Paracetamol ODT|Experimental Paracetamol 500 mg ODT
219109198|NCT01993017|OTHER|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
219695815|NCT06855576|DRUG|Alvedon film-coated tablet|Marketed Paracetamol 500 mg film-coated tablet
219695816|NCT06855576|DRUG|Panadol film-coated Tablet|Marketed Paracetamol 500 mg film-coated tablet
219695817|NCT05320835|BEHAVIORAL|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
219695818|NCT03882918|DRUG|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
219109199|NCT01993017|DRUG|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
219695819|NCT06615102|DRUG|Angiotensin II|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
219695820|NCT06615102|DRUG|Noradrenalin|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
219695821|NCT06388967|DIAGNOSTIC_TEST|PANcreatic cancer Exosome Early detectiON (PANXEON)|This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
219695822|NCT06699615|OTHER|Once time de-identified Qualtrics survey|Once time de-identified Qualtrics survey
219109200|NCT01993017|OTHER|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
219109201|NCT01993017|OTHER|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
219109202|NCT01993017|OTHER|No intervention|
219695823|NCT04720989|PROCEDURE|Bathing With Baby Cleanser and water|Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
219109203|NCT05412459|DRUG|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
219109204|NCT02280057|DRUG|Metformin|Metformin 1500 mg (=2 pills) per day in six months
219695824|NCT04720989|PROCEDURE|Bathing With only Water|Preterm infants will have their first baths only with water.
219695825|NCT03828955|DIETARY_SUPPLEMENT|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
219695826|NCT03828955|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
219695827|NCT01369459|BEHAVIORAL|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
219695828|NCT00975728|DIETARY_SUPPLEMENT|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
219695829|NCT07060638|DRUG|IL-22|F-652 (IL-22) is a fusion protein of human IL-22 with IgG2 fragment, and has anti-inflammatory effects
219695830|NCT07060638|DRUG|Prednisone|Prednisone is an adrenal glucocorticoid with anti-inflammatory effects
219695831|NCT07060638|DRUG|Acamprosate|Acamprosate is a propane-1 sulfonic acid with anti-ethanol dependency effects
219695832|NCT07060638|DRUG|Prednisone placebo|Matching placebo
219695833|NCT07060638|DRUG|IL-22 (F-652) Placebo|Matching Placebo
219695834|NCT07060638|BEHAVIORAL|Motivational Interviewing (MI)|MI is an evidence-based counseling style to overcome ambivalence to treatment in AUD patients
219695835|NCT07060638|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is an MI-based approach that includes 2-4 behavioral treatment sessions based on the Platform Treatment Manual
219695836|NCT07060638|BEHAVIORAL|Usual Care|defined as a brief intervention with advice not to drink alcohol-containing beverages and referral to a 12-step program
219695837|NCT00901043|DIETARY_SUPPLEMENT|Walnut supplementation|Eight weeks of walnut supplementation
219695838|NCT00901043|DIETARY_SUPPLEMENT|Ad lib diet|Eight weeks without walnut supplementation
219695839|NCT03863847|PROCEDURE|Neurofeedback|The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
219109205|NCT02280057|DRUG|Placebo|2 pills per day in six months; pills look like metformin pills
219109206|NCT06030453|COMBINATION_PRODUCT|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
219109207|NCT06030453|COMBINATION_PRODUCT|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
219109208|NCT02800824|DRUG|Budesonide|
219109209|NCT02800824|DRUG|Uceris|
219109210|NCT01508299|PROCEDURE|skin test|skin test with the Suspected raw food
219109211|NCT01683994|DRUG|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
219109212|NCT01683994|DRUG|Docetaxel|75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
219695840|NCT03863847|PROCEDURE|Sham|The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
219695841|NCT04235400|DIAGNOSTIC_TEST|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
219695842|NCT04022317|BIOLOGICAL|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
219695843|NCT04022317|BIOLOGICAL|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
219695844|NCT02100124|BEHAVIORAL|Reproductive Life Planning (RLP)|
219695845|NCT02100124|BEHAVIORAL|Contraceptive Action Planning|
219695846|NCT02100124|BEHAVIORAL|Contraception information|
219695847|NCT07056686|DIAGNOSTIC_TEST|Mammogram|Each patient will undergo a mammogram and echo of the breast used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear.
219695848|NCT04360265|OTHER|No Investigational Product|No investigational product will be administered in this follow-up trial.
219695849|NCT04360265|DRUG|Adjuvant Immunomodulatory (IM) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
219109213|NCT01683994|DRUG|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
219109214|NCT02419547|DRUG|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
219109215|NCT02419547|DRUG|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
219109216|NCT02419547|DRUG|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
219109217|NCT02419547|DRUG|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
219109218|NCT01026376|DRUG|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
219695850|NCT06761339|DIETARY_SUPPLEMENT|Azka Nasal and Throat for Children|Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.
219695851|NCT06761339|DRUG|Prospan cough Syrup|The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
219695852|NCT07061548|OTHER|No Intervention: Observational Cohort|No intervention
219695853|NCT06758583|DRUG|Dapiglutide 7.5 mg|Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.
219109219|NCT01026376|DRUG|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
219695854|NCT07072221|DRUG|BCL regimen|"Induction therapy period (28 days\*6)~Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.; for age≤70 years; 70mg/m2 d1-2, ivgtt.; for age\>70 years;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks, po.; for age≤70 years; 15mg biw for 2 weeks, po.; for age\>70 years;~Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.; for age≤70 years; 10mg qd d1-d14, po.; for age\>70 years;"
219109220|NCT03979261|DIAGNOSTIC_TEST|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
219109221|NCT04868474|BEHAVIORAL|Training program and decision aid|1\) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.
219109222|NCT04868474|BEHAVIORAL|Refresher course|A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
219109223|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
219109224|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
219109225|NCT00027638|DRUG|thalidomide|
219109226|NCT03507543|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
219109227|NCT02858765|OTHER|Application of white polychromatic light for 2h30 at different times of day|
219109228|NCT03157024|DEVICE|Ring Sham (RS)|
219109229|NCT03157024|DEVICE|Real Needle (RN)|
219109230|NCT03157024|DEVICE|Kim Sham (KS)|
219109231|NCT02213419|DRUG|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
219109232|NCT03859375|OTHER|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
219695855|NCT07072221|PROCEDURE|Cohort 1 (ASCT-eligible)|"Autologous hematopoietic stem cell transplantation~SEAM conditioning~Simustine 250mg/m2 orally, d1;~Etoposide 200mg/m2 intravenous infusion, d2-d5;~Cytarabine 400mg/m2 intravenous infusion, d2-d5;~Metformin 140mg/m2 intravenous infusion, d6;"
219695856|NCT07072221|DRUG|Cohort 2 (ASCT--ineligible)|"Maintenance therapy period (2 years)~Chidamide; Specification: 5mg per tablet; 15mg biw for 2 weeks per 3 weeks, po.;"
219695857|NCT06826313|BIOLOGICAL|VRT106|Intravenous drip administration
219695858|NCT04417062|DRUG|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
219695859|NCT04417062|DRUG|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
219695860|NCT06769594|DEVICE|Investigational CT Scan|All pre-contrast testing and administration of supporting medications shall be done according to the hospital's SOC. Images will then be compared with the previously acquired imaging conducted as standard of care. The investigational scan takes between 10-30 minutes.
219109233|NCT00268931|BEHAVIORAL|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
219695861|NCT06828679|OTHER|Acupuncture|Patients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) \[66\]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) \[67\]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) \[68\]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation \[69\] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation \[70\]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1).
219695862|NCT06828679|OTHER|control group|Subjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1).
219109234|NCT00268931|BEHAVIORAL|Social Training|This group underwent special social interactions with their parents two times each day.
219109235|NCT06171906|BIOLOGICAL|mesenchymal stromal cells|On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10\^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
219109236|NCT01863602|DRUG|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
219109237|NCT03063970|DEVICE|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
219109238|NCT03063970|OTHER|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
219109239|NCT00243555|PROCEDURE|allergy skin testing|
219109240|NCT00243555|PROCEDURE|venepuncture|
219109241|NCT00719602|DRUG|Lamivudine|Taken orally twice daily
219109242|NCT00719602|DRUG|Lopinavir/Ritonavir|Taken orally twice daily
219109243|NCT00719602|DRUG|Nevirapine|Taken orally twice daily
219109244|NCT00719602|DRUG|Zidovudine|Taken orally twice daily
219109245|NCT04037111|DEVICE|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
219109246|NCT04037111|DEVICE|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
219109247|NCT04037111|DRUG|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
219695863|NCT06828679|DEVICE|Robotic Training|For this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support \[60\]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window.
219695864|NCT06828679|DEVICE|Neuromuscular Electrical Stimulation Group|For this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts \[63\]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot.
219695865|NCT06833333|PROCEDURE|Central venous catheter|Central venous catheter will be introduced to measure central venous pressure
219695866|NCT06833333|DIAGNOSTIC_TEST|IVC collapsibility index|In supine position, IVC will be assessed in the anteroposterior plane in the subxiphoid view using two-dimensional mode till an optimal view of IVC entering the right atrium will be obtained. Then, measurement of its collapsibility will be done.
219695867|NCT06378177|BIOLOGICAL|LVGN6051 Monoclonal Antibody Injection|LVGN6051 Monoclonal Antibody Injection:1 mg/kg or 2 mg/kg, every 3 weeks(Q3W) , on the first day of the treatment cycle for up to 2 years.
219695868|NCT06378177|BIOLOGICAL|toripalimab Injection|toripalimab Injection: 240mg fixed dose,Q3W, on the first day of the treatment cycle for up to 2 years.
219695869|NCT06378177|DRUG|Paclitaxel injection|paclitaxel Injection:5ml:100 mg/m2(80 mg/m2 or 60 mg/m2 can be used if necessary),Q3W,on the first and eighth day of the treatment cycle for up to 2 years
219695870|NCT05571813|DRUG|CKD-341|A single dose of 1tablets under fasting condition
219109248|NCT02606669|DIETARY_SUPPLEMENT|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
219109249|NCT02960763|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
219109250|NCT02960763|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
219109251|NCT02960763|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
219109252|NCT02960763|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
219109253|NCT02960763|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
219109254|NCT02348398|DRUG|Pazopanib|600 mg by mouth daily in a 28 day cycle.
219109255|NCT02348398|DRUG|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
219109256|NCT02348398|BEHAVIORAL|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
219109257|NCT05985057|OTHER|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
219109258|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
219109259|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
219109260|NCT00656461|DRUG|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
219109261|NCT04343482|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
219695871|NCT04818775|DEVICE|HemaClear|HemaClear Model A
219695872|NCT04818775|DEVICE|Pneumatic Tourniquet|Pneumatic Tourniquet
219695873|NCT03710954|DIAGNOSTIC_TEST|Experimental Group|All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
219109262|NCT02774408|DEVICE|Saturation sensitive backup ventilation|
219109263|NCT00548041|OTHER|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
219109264|NCT03638635|DRUG|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
219109265|NCT03638635|DRUG|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
219109266|NCT01603420|DRUG|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
219109267|NCT01603420|DRUG|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
219695874|NCT04685954|DEVICE|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
219109268|NCT01603420|OTHER|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
219109269|NCT02100540|DRUG|I placebo capsule|I placebo capsule
219109270|NCT02100540|DRUG|II RDC 0.3mg capsule|II RDC 0.3mg capsule
219109271|NCT02100540|DRUG|III RDC 0.6mg capsule|III RDC 0.6mg capsule
219109272|NCT05140187|BIOLOGICAL|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10\^3/kg, 1×10\^5/kg, and 5×10\^5/kg CMV-TCR-T cells per dose.
219109273|NCT01905579|PROCEDURE|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
219109274|NCT01617083|DRUG|Azithromycin|Antibiotic used to treat infections
219109275|NCT01617083|DRUG|Placebo|Thickening compound with sugar and flavoring
219109276|NCT00157651|DRUG|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
219109277|NCT00157651|DRUG|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
219109278|NCT06108115|BEHAVIORAL|CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
219109279|NCT06781281|DRUG|Serplulimab|Serplulimab
219109280|NCT06781281|DRUG|NabPE|Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
219109281|NCT06523738|DIAGNOSTIC_TEST|1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation|1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
219109282|NCT00861926|DRUG|Ventolin|Ventolin : salbutamol sulfate 100µg
219109283|NCT00861926|DRUG|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
219109284|NCT03379064|BEHAVIORAL|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
219109285|NCT05625581|DRUG|tofacitinib|All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
219109286|NCT00125580|BEHAVIORAL|Infant sleep instruction|
219109287|NCT02721641|DRUG|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
219109288|NCT00313911|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
219109289|NCT00313911|BIOLOGICAL|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
219109290|NCT03350659|DRUG|Midodrine|Midodrine single 5mg/day
219109291|NCT03350659|DRUG|Atomoxetine|Atomoxetine single 18mg/day
219109292|NCT04192513|DRUG|J. lividum|Investigational Product
219109293|NCT02193802|DEVICE|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
219109294|NCT03901560|OTHER|Music Therapy|
219109295|NCT06441825|OTHER|Increased multimodal observation including digital monitoring|Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
219109296|NCT04041752|BEHAVIORAL|SOLID|condition with a classical meal served using solid food items
219109297|NCT04041752|BEHAVIORAL|LIQUID_P|condition with a liquid meal served using a powder solution
219109298|NCT04041752|BEHAVIORAL|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
219109299|NCT04396223|DRUG|Avelumab Injection|Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
219695875|NCT04685954|DEVICE|Filtek Ultimate Universal|Incremental restorative composite
219695876|NCT01965873|DIETARY_SUPPLEMENT|Enteral nutrition|Same as arm description
219109300|NCT04396223|DRUG|Methotrexate 1 GM Injection|methotrexate administration at 1mg/kg/day during 4 months ½ (median)
219109301|NCT04974814|DRUG|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
219109302|NCT04974814|DRUG|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
219109303|NCT04974814|DRUG|Control Test|patients in control arm will not preloaded with statin in ER before PCI
219109304|NCT01855581|DRUG|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
219109305|NCT00884858|DRUG|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
219109306|NCT00899587|DRUG|enalapril|enalapril 5 mg every night
219109307|NCT00899587|OTHER|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
219109308|NCT00899587|DRUG|placebo|
219109309|NCT06122532|PROCEDURE|Stem cell preparation combined with Reticular skin|The dose of transplanted stem cells per wound (100cm2) is 1×10\^6, then cover the wound with autologous regular skin.
219109310|NCT06122532|PROCEDURE|Stem cell preparation combined with MEEK skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous MEEK skin.
219109311|NCT06122532|PROCEDURE|Stem cell preparation combined with split-thickness skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous split-thickness skin.
219109312|NCT06122532|PROCEDURE|autologous skin grafting|After cleaning the wound, use autologous skin (Reticular skin/MEEK skin/split-thickness skin) grafting and cover the wound surface。
219109313|NCT06001281|OTHER|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
219109314|NCT00818415|DRUG|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
219109315|NCT00818415|DRUG|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
219109316|NCT00087789|GENETIC|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg
219109317|NCT01219803|DRUG|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
219109318|NCT01219803|DRUG|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
219695877|NCT04270773|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
219695878|NCT04947891|PROCEDURE|Intensive recovery management|Intensive recovery management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
219695879|NCT01712516|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
219695880|NCT01712516|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219695881|NCT01712516|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219695882|NCT01712516|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
219695883|NCT00968487|BIOLOGICAL|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
219695884|NCT00968487|OTHER|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
219695885|NCT00869414|DRUG|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
219695886|NCT00869414|DRUG|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
219695887|NCT00869414|DRUG|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
219695888|NCT01181167|DRUG|edoxaban|
219695889|NCT01181167|DRUG|enoxaparin sodium|
219695890|NCT00161213|DRUG|gemcitabine hydrochloride|
219695891|NCT00161213|DRUG|imatinib mesylate|
219695892|NCT05027854|OTHER|TMS or tES|Transcranial magnetic or electric stimulation
219695893|NCT05027854|OTHER|sham TMS or tES|Sham transcranial magnetic or electric stimulation
219695894|NCT00327158|PROCEDURE|Transesophageal transducer|One time use of reamer during surgery
219695895|NCT00327158|PROCEDURE|echocardiography|takes photos of right atrium during the reaming processes
219695896|NCT04755010|DEVICE|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
219695897|NCT03042845|DEVICE|Tiger cardiac catheter|Tiger cardiac catheter
219695898|NCT03042845|DEVICE|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
219695899|NCT04600869|OTHER|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
219695900|NCT04149340|DRUG|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
219695901|NCT03928366|DRUG|Propofol|sedation
219695902|NCT03928366|DRUG|Remifentanil|remifentanil
219695903|NCT02433769|DEVICE|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
219695904|NCT02433769|DEVICE|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
219695905|NCT06285500|OTHER|Patient-specific treatments|Treatment will be decided specifically for the patient based on biomarker test results.
219695906|NCT01384877|DRUG|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
219695907|NCT01384877|DRUG|Placebo (D5W)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
219695908|NCT05412277|OTHER|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
219695909|NCT03938571|PROCEDURE|Duodenal Switch|
219695910|NCT02388451|DEVICE|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
219695911|NCT03630393|OTHER|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
219695912|NCT03630393|OTHER|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
219695913|NCT00618293|DRUG|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
219695914|NCT00618293|OTHER|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
219695915|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
219695916|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
219695917|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
219695918|NCT00408499|DRUG|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
219695919|NCT00408499|DRUG|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
219695920|NCT00435071|PROCEDURE|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
219695921|NCT00435071|PROCEDURE|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
219695922|NCT00039403|DRUG|7-hydroxystaurosporine|Given IV
219695923|NCT00039403|DRUG|gemcitabine hydrochloride|Given IV
219695924|NCT00039403|OTHER|pharmacological study|Correlative studies
219695925|NCT00039403|OTHER|laboratory biomarker analysis|Correlative studies
219695926|NCT01042795|DRUG|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
219695927|NCT00524433|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
219695928|NCT00524433|DRUG|placebo|
219695929|NCT01077492|OTHER|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
219109319|NCT01219803|DRUG|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
219109320|NCT01219803|DRUG|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
219109321|NCT04633083|OTHER|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
219109322|NCT01936129|DRUG|Copaxone|
219695930|NCT00702780|DRUG|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
219695931|NCT00702780|DRUG|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
219695932|NCT00997334|DRUG|Erlotinib|
219695933|NCT02273401|DRUG|BI 11054 CL|
219695934|NCT02273401|DRUG|Placebo|
219695935|NCT02828865|DEVICE|Irreversible Electroporation (IRE) System|
219695936|NCT01586195|DRUG|Vemurafenib|Vemurafenib 960 mg BID
219695937|NCT01694693|DRUG|Orencia|No Intervention
219695938|NCT05883865|DRUG|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
219695939|NCT04785417|OTHER|touch screen tablet|traditional occupational therapy in addition to games on tablet
219695940|NCT05588258|OTHER|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
219109323|NCT01936129|DRUG|Placebo (buffered normal saline w/v)|
219109324|NCT03636360|DEVICE|Light|15 hours of light exposure
219109325|NCT01533714|BIOLOGICAL|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
219695941|NCT01376869|DIETARY_SUPPLEMENT|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
219695942|NCT01376869|OTHER|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
219695943|NCT02402400|DRUG|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
219695944|NCT03107429|DRUG|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
219695945|NCT03107429|DRUG|Placebo|Placebo was a sugar based placebo placed in a capsule.
219695946|NCT03107429|OTHER|Trendelenburg Position|Placed in Trendelenburg Position
219695947|NCT02078544|OTHER|Integrated Molecular Analysis|
219695948|NCT03946059|DEVICE|iTBS then cTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
219695949|NCT03946059|DEVICE|cTBS then iTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
219695950|NCT00114556|DRUG|zoledronic acid|
219695951|NCT00495053|DRUG|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
219695952|NCT00495053|OTHER|Placebo|Matching placebo (PBS-20% sucrose)
219695953|NCT02654678|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
219695954|NCT00730184|DIETARY_SUPPLEMENT|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
219695955|NCT00730184|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
219695956|NCT05182944|DRUG|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
219109326|NCT02500212|DRUG|ENVARSUS®|
219109327|NCT02500212|DRUG|ADVAGRAF®|
219109328|NCT03664739|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
219109329|NCT03664739|DRUG|IDp-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
219109330|NCT03634137|DRUG|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
219109331|NCT03634137|DRUG|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
219109332|NCT04381767|DEVICE|EYE-SYNC|Evaluation of oculomotor performance using visual presentation and eye tracking analysis
219695957|NCT05182944|DRUG|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
219695958|NCT05182944|DRUG|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
219695959|NCT05182944|DRUG|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
219695960|NCT03456661|DRUG|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
219695961|NCT03456661|DRUG|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
219695962|NCT05184855|DIETARY_SUPPLEMENT|Blueberry|Blueberry powder intake
219695963|NCT05184855|DIETARY_SUPPLEMENT|Placebo|Placebo powder intake
219695964|NCT04322136|PROCEDURE|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
219695965|NCT04322136|DEVICE|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
219695966|NCT03053739|DRUG|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
219695967|NCT03053739|DRUG|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
219695968|NCT05440032|DIAGNOSTIC_TEST|Semi-quantitative electrochemical leukocyte esterse test strip|Electrochemical assay to detect level of leukocyte esterase in sample
219695969|NCT05440032|DIAGNOSTIC_TEST|Roche Chemstrip|Urinalysis chemstrip
219695970|NCT02678117|DRUG|Pregabalin & Placebo|
219695971|NCT02678117|DRUG|Magnesium sulphate & Placebo|
219695972|NCT02678117|DRUG|Pregabalin & Magnesium sulphate|
219695973|NCT02678117|DRUG|Placebo|
219695974|NCT00374634|DRUG|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
219695975|NCT00374634|DRUG|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
219695976|NCT04946812|OTHER|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
219695977|NCT02683109|DRUG|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
219109333|NCT03475719|DRUG|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
219109334|NCT03475719|DRUG|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
219109335|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
219109336|NCT02917044|DEVICE|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
219109337|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
219695978|NCT02683109|DRUG|Placebo|
219695979|NCT02683109|DRUG|Tiotropium|
219695980|NCT02683109|DRUG|Olodaterol|
219695981|NCT02417025|BEHAVIORAL|PE|Prolonged Exposure
219695982|NCT01099644|BIOLOGICAL|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
219695983|NCT00798005|DRUG|XRP0038 (NV1FGF)|
219695984|NCT00539396|DRUG|Technosphere Insulin|
219109338|NCT02917044|DEVICE|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
219109339|NCT00599989|PROCEDURE|adjuvant therapy|
219109340|NCT00599989|PROCEDURE|conventional surgery|
219695985|NCT01762488|PROCEDURE|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
219695986|NCT01762488|PROCEDURE|Renal angiography|Renal angiography by femoral access
219109341|NCT00599989|RADIATION|3-dimensional conformal radiation therapy|
219109342|NCT00599989|RADIATION|brachytherapy|
219109343|NCT00599989|RADIATION|intracavitary balloon brachytherapy|
219109344|NCT00599989|RADIATION|proton beam radiation therapy|
219695987|NCT04137198|DRUG|Sufentanil|intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
219695988|NCT00553774|DIETARY_SUPPLEMENT|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
219695989|NCT00553774|OTHER|Placebo|Placebo (BD 21 - 28 Days)
219695990|NCT00546403|DRUG|Modafinil|Adjunctive treatment with titrated dose of modafinil
219695991|NCT00546403|DRUG|Placebo|Adjunctive treatment with placebo
219109345|NCT05385328|DEVICE|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
219109346|NCT05385328|DEVICE|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
219109347|NCT03173781|DRUG|droxidopa|medication
219109348|NCT03173781|DRUG|Placebo|medication
219109349|NCT03748836|DRUG|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
219109350|NCT03748836|DRUG|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
219109351|NCT04408547|DEVICE|embryo transfer catheter|undergoing embryo transfer
219109352|NCT01421589|DRUG|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
219109353|NCT02293525|DEVICE|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
219109354|NCT02293525|DRUG|Ropivacaine|
219109355|NCT02293525|DRUG|Saline|
219109356|NCT02293525|DRUG|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
219109357|NCT02293525|DRUG|Oxycodone|10mg every 4-6 hours
219109358|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
219109359|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
219695992|NCT04626323|PROCEDURE|Roux-en-Y gastric bypass|"1. Pneumoperitoneum closed with Veress needle~2. Identification of Treitz angle~3. Measurement of biliary loop (50 cm)~4. Bowel transection with linear stapler (white load)~5. Measurement of the alimentary limb (100 cm)~6. Laterolateral Entero-anastomoses (white load)~7. Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~8. Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~9. Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
219695993|NCT04626323|DRUG|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
219695994|NCT05314309|DIAGNOSTIC_TEST|Comparison of two tests (FIT and mtFIT) in the same bowel movement|Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
219695995|NCT00183430|DRUG|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
219695996|NCT00183430|DRUG|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
219695997|NCT00183430|BEHAVIORAL|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
219695998|NCT05088265|DEVICE|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
219109360|NCT01311362|DRUG|St. Johns wort|"* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
219109361|NCT00251927|DRUG|esomeprazole|40 mg oral tablet administered daily
219109362|NCT00251927|PROCEDURE|Laparoscopic fundoplication (surgery)|Surgery
219695999|NCT04625036|DIAGNOSTIC_TEST|Single passive leg movement|"The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds."
219109363|NCT03790514|OTHER|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
219109364|NCT05303597|DIAGNOSTIC_TEST|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
219109365|NCT03048032|PROCEDURE|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
219696000|NCT02124824|DRUG|BQ-123|Endothelin subtype A antagonist
219696001|NCT06134635|DRUG|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
219696002|NCT06134635|DRUG|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
219696003|NCT05981924|OTHER|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
219696004|NCT03485625|DRUG|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
219696005|NCT03485625|DRUG|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
219696006|NCT03485625|DRUG|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
219696007|NCT05388799|OTHER|Educational intervention|In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
219696008|NCT04642989|OTHER|Sham Treatment|All movements of facial effleurage except applying pressure
219109366|NCT03048032|PROCEDURE|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
219109367|NCT04204772|BIOLOGICAL|Activated charcoal and Tap Water|12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
219109368|NCT04204772|BIOLOGICAL|Activated Charcoal and Apple Juice|12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
219109369|NCT01576055|DEVICE|TIGRIS Vascular Stent|Implant
219109370|NCT01576055|DEVICE|BARD LifeStent|Implant
219109371|NCT06526377|DRUG|Natrunix|Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.
219109372|NCT06526377|DRUG|Placebo|Placebo
219109373|NCT02153021|RADIATION|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
219109374|NCT01039350|DRUG|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
219109375|NCT02909023|BIOLOGICAL|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
219109376|NCT00047983|DIETARY_SUPPLEMENT|Canola oil|
219696009|NCT04642989|OTHER|Facial Effleurage|Facial massage to remove any lymphatic blockages
219109377|NCT00047983|DIETARY_SUPPLEMENT|Arginine|
219109378|NCT00047983|DIETARY_SUPPLEMENT|Fish oil emulsion|
219109379|NCT02632019|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
219696010|NCT04642989|DRUG|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
219696011|NCT03845894|DRUG|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
219696012|NCT03845894|DRUG|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
219696013|NCT05232552|DRUG|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
219109380|NCT02632019|BIOLOGICAL|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
219109381|NCT04506996|BEHAVIORAL|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
219109382|NCT04506996|BEHAVIORAL|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
219109383|NCT04506996|BEHAVIORAL|Educational Materials|After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
219109384|NCT00936520|DRUG|SAR 1118 0.1%|Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
219109385|NCT00936520|DRUG|SAR 1118 1.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
219696014|NCT05232552|DRUG|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
219696015|NCT05232552|RADIATION|concurrent chemoradiation|definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
219109386|NCT00936520|DRUG|SAR 1118 5.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
219109387|NCT00857376|DIETARY_SUPPLEMENT|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
219109388|NCT01224808|BIOLOGICAL|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
219109389|NCT03652194|OTHER|in vitro evaluation of epithelial immune response during C. glabrata infection|"1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method"
219109390|NCT03652194|OTHER|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model."
219109391|NCT00990301|DRUG|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
219109392|NCT00990301|DRUG|Uniretic® 15mg/25mg Tablets|reference drug
219109393|NCT02694640|BEHAVIORAL|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
219696016|NCT04942704|OTHER|Non interventional Imaging - MRI|MRI Scanning using short protocols
219696017|NCT02987881|BEHAVIORAL|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
219696018|NCT02171351|DEVICE|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).
219696019|NCT02171351|DEVICE|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)
219696020|NCT02171351|OTHER|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)
219696021|NCT00426270|DRUG|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
219696022|NCT02880423|PROCEDURE|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
219696023|NCT02880423|PROCEDURE|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
219696024|NCT04135534|DRUG|group A|mutonpain 0.05 mg/kg
219696025|NCT04135534|DRUG|group B|mutonpain 0.1 mg/kg
219696026|NCT04135534|DRUG|group C|mutonpain 0.2 mg/kg
219696027|NCT02057770|DRUG|busulfan|
219696028|NCT02057770|DRUG|fludarabine phosphate|
219696029|NCT02057770|RADIATION|total-body irradiation (TBI)|
219696030|NCT02057770|PROCEDURE|Stem cell transplant|
219696031|NCT02057770|DRUG|cyclophosphamide|
219696032|NCT02057770|DRUG|tocilizumab|
219696033|NCT05415306|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
219696034|NCT05415306|BEHAVIORAL|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
219696035|NCT05415306|BEHAVIORAL|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
219696036|NCT00450957|DIETARY_SUPPLEMENT|lycopene|Given orally
219696037|NCT00450957|OTHER|pharmacological study|Correlative studies
219696038|NCT02783612|OTHER|glucose buddy application|
219696039|NCT01058447|DRUG|AZD1981|Oral tablet, 250 mg, single dose
219696040|NCT03102762|DRUG|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
219696041|NCT03102762|DRUG|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
219696042|NCT00958074|DRUG|vorinostat|Given PO
219696043|NCT00958074|OTHER|flow cytometry|correlative study
219696044|NCT00958074|OTHER|laboratory biomarker analysis|correlative study
219696045|NCT02709746|DRUG|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
219696046|NCT02709746|DRUG|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
219161447|NCT06214351|OTHER|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
219696047|NCT02709746|DRUG|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
219696048|NCT02709746|OTHER|Placebo|Encapsulated tablet
219696049|NCT06029764|PROCEDURE|extended one-level interbody fusion|For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
219696050|NCT02433847|DRUG|Mosapride|
219696051|NCT01596569|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
219696052|NCT01596569|BEHAVIORAL|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
219696053|NCT03962608|DEVICE|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
219109394|NCT02694640|BEHAVIORAL|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
219109395|NCT02694640|BEHAVIORAL|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
219696054|NCT03962608|DEVICE|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
219696055|NCT02018133|DRUG|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
219109396|NCT06442072|BEHAVIORAL|guided online self-help program|16 weeks of training and application of psychotherapeutic methods
219696056|NCT02018133|DRUG|Placebo|placebo 2 capsule daily
219109397|NCT00071240|DRUG|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
219109398|NCT01832415|DRUG|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
219109399|NCT01044342|DRUG|AZD1446|capsule; single oral dose
219696057|NCT04927910|OTHER|Ture self-acupressure|8-week intervention of self-acupressure on acupoints
219696058|NCT04927910|OTHER|Sham self-acupressure|8-week intervention of self-acupressure on non-acupoints
219696059|NCT04927910|OTHER|Usual care|routine care by hospitals
219696060|NCT00158353|BEHAVIORAL|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
219696061|NCT00158353|BEHAVIORAL|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
219696062|NCT00190268|DRUG|3,4-diaminopyridine|3,4-diaminopyridine
219696063|NCT03572712|OTHER|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
219109400|NCT01044342|DRUG|AZD1446|capsule, single oral dose
219109401|NCT01044342|DRUG|donepezil|capsule, single oral dose
219696064|NCT03961867|DRUG|Docetaxel|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
219696065|NCT03961867|DRUG|Oxaliplatin|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
219696066|NCT03318263|DIAGNOSTIC_TEST|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
219696067|NCT04716244|OTHER|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
219696068|NCT03123081|PROCEDURE|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
219696069|NCT03114293|BEHAVIORAL|Smartphone App|The app includes an EBPI and physical activity feedback
219696070|NCT00695227|DIAGNOSTIC_TEST|Screening for Barrett's Esophagus|
219696071|NCT06450769|OTHER|Aronia juice|100% aronia juice, 100 mL/day, twelve-week follow-up
219696072|NCT06450769|OTHER|Mediterranean diet|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet
219696073|NCT06450769|OTHER|Low-fat diet|An individually planned nutrition program suitable for the energy-restricted low-fat diet
219696074|NCT02755753|DRUG|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
219696075|NCT02755753|DRUG|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
219696076|NCT02755753|DRUG|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
219696077|NCT05353088|OTHER|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
219696078|NCT05353088|OTHER|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
219696079|NCT04232007|DEVICE|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
219696080|NCT01816321|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
219696081|NCT01816321|DRUG|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
219696082|NCT01816321|DRUG|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
219696083|NCT01816321|DRUG|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
219109402|NCT01044342|DRUG|Placebo|capsule, single oral dose
219109403|NCT04004572|DRUG|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
219109404|NCT06106841|DRUG|400mg of TQB3909 tablets|TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
219109405|NCT06106841|DRUG|600mg of TQB3909 tablets|TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
219109406|NCT04227860|OTHER|Balance exercise program|"Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
219109407|NCT04227860|OTHER|Strengthening exercise program|"Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
219109408|NCT00077350|DRUG|triapine|Given IV
219109409|NCT00077350|DRUG|gemcitabine hydrochloride|Given IV
219109410|NCT00077350|OTHER|laboratory biomarker analysis|Correlative studies
219109411|NCT03729895|DEVICE|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
219109412|NCT02222896|DRUG|Chlorhexidine Gluconate|2% CHG solution on cloth
219109413|NCT02222896|OTHER|Vehicle|Excipients of CHG product only
219109414|NCT02222896|DRUG|DynaHex-2|2% CHG solution
219109415|NCT03103932|OTHER|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
219109416|NCT00406120|PROCEDURE|Fine needle aspiration biopsy|
219109417|NCT02677363|OTHER|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
219109418|NCT05435235|DRUG|Dapagliflozin 10mg Tab|One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.
219109419|NCT05540093|OTHER|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
219109420|NCT05540093|OTHER|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
219109421|NCT05298462|DIAGNOSTIC_TEST|Livzon Rapid Antibody Test for COVID-19|Point-of-care Rapid Antibody Test for COVID-19
219109422|NCT00179348|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219109423|NCT00179348|PROCEDURE|Yoga|Undergo a yoga-based rehabilitation program
219696084|NCT03474224|DEVICE|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
219109424|NCT02220335|PROCEDURE|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
219109425|NCT02220335|DRUG|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
219696085|NCT02035566|OTHER|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
219696086|NCT04517682|DIAGNOSTIC_TEST|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
219696087|NCT04825665|OTHER|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
219696088|NCT04825665|OTHER|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
219696089|NCT02184104|DIETARY_SUPPLEMENT|Caffeine|
219696090|NCT06464627|BEHAVIORAL|Physical activity|16 weeks
219696091|NCT02017002|PROCEDURE|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
219696092|NCT02017002|PROCEDURE|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
219696093|NCT00551369|RADIATION|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
219109426|NCT04815486|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS in 10 daily sessions in two weeks of sequential application of: 90% RMT at 1Hz, 1000 pulses/day, 25s inter train on M1 of lesioned hemisphere and 90% RMT at 10Hz, 1000 pulses/day, 50s inter train on M1 of healthy hemisphere.
219109427|NCT04815486|DEVICE|Motor Imagery (MI) through a Brain-Computer Interface (BCI) training platform in Virtual Reality (VR) with NeuRow|It will consist of a combination of the bilateral rTMS protocol and the MI-neurofeedback training. During this therapy, the patient received 10 consecutive daily sessions of bilateral rTMS (Monday to Friday, two weeks), with the same stimulation parameters as another therapy, and 12 non-consecutive sessions of MI-neurofeedback (three times a week for four weeks). The first 6 MI-neurofeedback sessions were carried out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks.
219109428|NCT00002802|DRUG|carboplatin|
219109429|NCT00002802|DRUG|cisplatin|
219109430|NCT00002802|DRUG|cyclophosphamide|
219109431|NCT00002802|DRUG|dacarbazine|
219696094|NCT05885932|PROCEDURE|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
219696095|NCT05885932|DRUG|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
219696096|NCT05885932|PROCEDURE|mono anti-platelet therapy|mono anti-platelet therapy
219696097|NCT04768088|OTHER|Falling Training|For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
219696098|NCT00787826|BIOLOGICAL|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
219696099|NCT01213381|DRUG|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
219696100|NCT01213381|DRUG|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
219696101|NCT01213381|DRUG|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
219696102|NCT00117390|PROCEDURE|Measurement of inulin clearance|
219696103|NCT05115799|OTHER|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
219696104|NCT05115799|OTHER|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
219696105|NCT00254371|PROCEDURE|Androgen Replacement|
219696106|NCT00597259|DRUG|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
219696107|NCT00597259|DRUG|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
219696108|NCT03927443|DRUG|SDP-133|one drop
219696109|NCT03927443|DRUG|Lumigan|one drop
219696110|NCT04041817|OTHER|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
219696111|NCT02704767|DRUG|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
219696112|NCT02704767|DRUG|Tarceva|
219696113|NCT02704767|DRUG|Placebo|
219696114|NCT02143817|DIETARY_SUPPLEMENT|L-citrulline supplementation|
219696115|NCT02143817|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
219696116|NCT04259333|DRUG|Celecoxib 200mg|Celecoxib tablet
219696117|NCT04259333|DRUG|Acetaminophen, Codeine Drug Combination|acetaminophen-codeine-caffeine tablet
219696118|NCT00560716|DRUG|CYC116|Dose escalation of CYC116
219696119|NCT03037840|DEVICE|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
219109432|NCT00002802|DRUG|doxorubicin hydrochloride|
219109433|NCT00002802|DRUG|etoposide|
219109434|NCT00002802|DRUG|ifosfamide|
219109435|NCT00002802|DRUG|melphalan|
219109436|NCT00002802|DRUG|mesna|
219109437|NCT00002802|DRUG|vincristine sulfate|
219109438|NCT00002802|DRUG|vindesine|
219109439|NCT00002802|PROCEDURE|autologous bone marrow transplantation|
219696120|NCT03656341|BEHAVIORAL|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
219696121|NCT03073772|BEHAVIORAL|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
219696122|NCT03073772|BEHAVIORAL|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
219696123|NCT00719901|DRUG|obatoclax mesylate|Given IV
219696124|NCT00719901|DRUG|bortezomib|Given IV
219696125|NCT00719901|OTHER|laboratory biomarker analysis|Correlative studies
219696126|NCT00926523|OTHER|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
219696127|NCT00926523|OTHER|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
219696128|NCT00926523|OTHER|Spirometry|To assess subjects lung function
219696129|NCT00926523|OTHER|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
219696130|NCT05465395|PROCEDURE|Upper Cervical Adjustemnt|Upper cervical adjustement
219696131|NCT05465395|PROCEDURE|Thoracic Adjustemnt|Thoracic adjustment
219696132|NCT01548963|PROCEDURE|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
219696133|NCT04905992|OTHER|Hypertonic saline at 6%|Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
219696134|NCT04905992|OTHER|Airway clearance techniques (oscillating positive expiratory pressure therapy)|Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
219696135|NCT00516971|DRUG|Esomeprazole 20mg once daily|
219696136|NCT02902926|BEHAVIORAL|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
219696137|NCT02902926|BEHAVIORAL|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
219109440|NCT00002802|PROCEDURE|conventional surgery|
219109441|NCT00002802|RADIATION|low-LET cobalt-60 gamma ray therapy|
219109442|NCT00002802|RADIATION|low-LET electron therapy|
219109443|NCT00002802|RADIATION|low-LET photon therapy|
219109444|NCT00002802|RADIATION|radioisotope therapy|
219109445|NCT02058420|DRUG|Low tocotrienols group|300 mg tocotrienols daily
219109446|NCT02058420|DRUG|High tocotrienols group|600 mg tocotrienols daily
219696138|NCT04393727|BIOLOGICAL|CONVALESCENT PLASMA|Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
219696139|NCT03101306|OTHER|MR scans|Additional imaging using MR scans.
219696140|NCT01256307|OTHER|training and educational program|8 weeks
219696141|NCT01256307|OTHER|educational program|8 weeks
219696142|NCT01122173|DEVICE|Ablation|Atrial fibrillation ablation procedure
219696143|NCT02598674|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
219696144|NCT02598674|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
219696145|NCT02598674|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
219696146|NCT02598674|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
219696147|NCT02598674|DRUG|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
219696148|NCT05111717|DRUG|Desflurane|Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
219109447|NCT04503538|OTHER|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
219109448|NCT00759772|DRUG|Placebo|sc daily for 6 months
219109449|NCT00759772|DRUG|Teriparatide|20 mcg sc daily for 6 months
219109450|NCT06229184|DIAGNOSTIC_TEST|Fecal Calprotectin Test|Fecal samples are taken fom obese and healthy adolescents for study
219696149|NCT02923869|DRUG|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
219696150|NCT02923869|DRUG|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
219696151|NCT03225430|BEHAVIORAL|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
219696152|NCT03225430|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
219696153|NCT01184872|DRUG|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
219696154|NCT01184872|DRUG|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
219696155|NCT05815966|BEHAVIORAL|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
219696156|NCT00651209|DRUG|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
219696157|NCT03794596|DRUG|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
219696158|NCT03794596|DRUG|Aspirin|300mg tablets
219696159|NCT03794596|DRUG|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
219696160|NCT02576470|BEHAVIORAL|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
219696161|NCT02576470|DEVICE|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
219696162|NCT02576470|BEHAVIORAL|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
219696163|NCT02576470|BEHAVIORAL|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
219696164|NCT02576470|RADIATION|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
219696165|NCT02576470|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
219696166|NCT02576470|DEVICE|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
219696167|NCT03920956|OTHER|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
219696168|NCT00965614|OTHER|MCG|Cardiac Arrhythmia,Heart Disease
219696169|NCT02123641|OTHER|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
219109451|NCT01568827|DIETARY_SUPPLEMENT|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
219696170|NCT02123641|OTHER|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
219696171|NCT02123641|OTHER|Control|No training
219161448|NCT06787170|DIAGNOSTIC_TEST|MRI habitat imaging|Habitat imaging, a data-driven image processing technique that divides the entire lesion into multiple sub-regions without assuming anything prior, has capacity to noninvasively evaluate the intratumoral heterogeneity.
219161449|NCT06791785|OTHER|Before Application|All groups will be asked to fill out forms before the application (Westside test anxiety scale, burdon attention test, descriptive information form)
219109452|NCT05351138|DEVICE|TENS|In the study, CE certified tens device with Biolito brand, which is used specifically for incontinence treatment, will be used. The electrodes used during the intervention will be placed to the parasacral region (S2-S4). While the current is given, the power of the device will be gradually increased in 1 mA intervals. The lower value of the stimulation will be 10 mA and the upper value will be 25 mA, and the treatment will be continued with any value that the child can tolerate in this range.
219109453|NCT05351138|OTHER|Massage|The massage will be applied to the abdominal area between the subcostal lower border and the anterior superior of the spina iliaca. Massage techniques are as follows: Abdominal patting, colon patting, colon kneading, colon patting again, abdominal patting again. It will be advanced with deep abdominal strokes, then the starting point will be returned with transverse superficial strokes for the transversus abdominis muscle and oblique superficial strokes for the rectus abdominis muscle, and these strokes will be repeated 3 times each, a total of 6 times. Afterwards, 3 times column brushing, 3 times column kneading and 3 times column plastering will be done, respectively. At the end, a total of 6 abdominal strokes will be performed for both the transversus abdominis and oblique abdominal muscles as in the beginning.
219109454|NCT02265029|OTHER|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
219109455|NCT02265029|OTHER|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
219109456|NCT00213330|PROCEDURE|rectal distension|
219696172|NCT01988324|OTHER|FDHT-PET scan|
219696173|NCT01988324|OTHER|FES-PET scan|
219696174|NCT01988324|OTHER|CT-scan|
219696175|NCT01988324|OTHER|Bone scintigraphy|
219696176|NCT01988324|OTHER|Tumor biopsy|
219696177|NCT00689065|DRUG|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
219696178|NCT03426345|DRUG|Placebo|Placebo injected subcutaneously twice daily.
219696179|NCT03426345|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
219696180|NCT03594006|BEHAVIORAL|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
219696181|NCT05581563|PROCEDURE|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
219696182|NCT03534024|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
219696183|NCT03534024|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
219696184|NCT02463383|DRUG|Ibuprofen Tab 400 MG|400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
219696185|NCT02463383|DRUG|Placebo tab|A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
219696186|NCT01448733|DRUG|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
219696187|NCT03139539|DEVICE|Ioban|
219696188|NCT02497469|DRUG|Vedolizumab|Vedolizumab infusion
219696189|NCT02497469|DRUG|Adalimumab placebo|Adalimumab placebo-matching injection
219696190|NCT02497469|DRUG|Adalimumab|Adalimumab injection
219696191|NCT02497469|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching infusion
219696192|NCT06228404|DRUG|Enhanced autologous PSMA-CAR T|"3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T:~cohort A： CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort B： CART-PSMA cells 0.75×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort C： CART-PSMA cells 2×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;"
219696193|NCT04906798|DRUG|CKD-385|Test Drug
219696194|NCT04906798|DRUG|D744|Reference Drug
219696195|NCT03916588|BEHAVIORAL|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
219109457|NCT03354520|BEHAVIORAL|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
219109458|NCT03354520|BEHAVIORAL|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
219109459|NCT03354520|BEHAVIORAL|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
219109460|NCT02978313|DRUG|Cetuximab|anti-EGFR monoclonal antibody
219109461|NCT02978313|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
219109462|NCT02978313|DRUG|FOLFIRI|Irinotecan+LV5FU2
219109463|NCT02226172|DRUG|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
219109464|NCT02226172|DRUG|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
219109465|NCT00002474|DRUG|carboplatin|
219109466|NCT00002474|DRUG|cyclophosphamide|
219696196|NCT03479554|OTHER|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
219109467|NCT00002474|DRUG|mitoxantrone hydrochloride|
219109468|NCT00002474|PROCEDURE|autologous bone marrow transplantation|
219109469|NCT00002474|PROCEDURE|bone marrow ablation with stem cell support|
219109470|NCT01865617|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
219109471|NCT03782896|OTHER|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
219109472|NCT03306407|OTHER|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
219109473|NCT01989598|OTHER|Laboratory Biomarker Analysis|Correlative studies
219109474|NCT01989598|OTHER|Pharmacological Study|Correlative studies
219109475|NCT01989598|DRUG|Trametinib|Given PO
219109476|NCT01989598|DRUG|Uprosertib|Given PO
219109477|NCT04724720|DRUG|Famotidine|Standard or care treatment plus prescribed famotidine
219109478|NCT04724720|DRUG|Placebo|Standard of care treatment plus placebo
219109479|NCT02161601|PROCEDURE|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
219109480|NCT04132570|DRUG|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.
219109481|NCT04132570|OTHER|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.
219109482|NCT03979950|BEHAVIORAL|Survey|Solid Organ Transplant patients will be recruited via social media. Co-investigators will reach out to the administrators of various social media networks to share information regarding the study with their networks on our behalf. Potential participants who are interested in participating, can then follow the link to the online survey tool, which includes the participant demographic information (age, ethnicity and highest level of education) and questionnaire. The questionnaire is 30 questions long and takes approximately 15 minutes to complete. This questionnaire will be a single, cross-sectional survey. No personal information will be documented on the questionnaire. All responses will be anonymous. Participants will be recruited for 6 months.
219109483|NCT03851874|PROCEDURE|Bariatric surgery|Bariatric surgery
219109484|NCT03646227|OTHER|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
219109485|NCT00000700|DRUG|Zidovudine|
219109486|NCT05445024|PROCEDURE|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
219109487|NCT05445024|PROCEDURE|sufentanil group|sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
219696197|NCT03479554|OTHER|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
219109488|NCT01466764|DRUG|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
219109489|NCT01466764|OTHER|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
219109490|NCT05693467|DRUG|Dexamethasone palmitate emulsion(DXP) plus ropivacaine|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
219109491|NCT05693467|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 7.5mL of ropivacaine added to 22.5mL of saline for Group B . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
219109492|NCT05366049|OTHER|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
219109493|NCT05445596|BEHAVIORAL|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
219696198|NCT01005667|DEVICE|BirthTrack|Measurement of cervical dilation and head station
219696199|NCT01338896|DRUG|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
219696200|NCT02889068|OTHER|Blood sample|
219696201|NCT01472055|DRUG|Fludarabine|"1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
219109494|NCT05036889|DIAGNOSTIC_TEST|Mind.Px Report|Use of Mind.Px report as a reference for potential better matching of biologics to patients.
219109495|NCT03225521|BEHAVIORAL|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
219109496|NCT06362343|DRUG|Rivaroxaban|Rivaroxaban
219109497|NCT04879498|DRUG|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
219109498|NCT04879498|OTHER|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
219696202|NCT05341024|OTHER|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
219696203|NCT02711462|DRUG|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
219109499|NCT04879498|OTHER|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
219696204|NCT02711462|DRUG|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
219696205|NCT02991274|PROCEDURE|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
219696206|NCT00572689|DRUG|Exenatide|10 microgram injected sub-cutaneously once
219696207|NCT00572689|GENETIC|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
219696208|NCT05982327|PROCEDURE|ORIF|fixation of scapular fractures by plate and screws
219696209|NCT00289211|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
219696210|NCT00289211|DRUG|Placebo (saline)|
219696211|NCT05912868|DEVICE|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
219696212|NCT01279746|DEVICE|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
219696213|NCT00630916|DEVICE|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
219696214|NCT00243243|DRUG|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
219109500|NCT01621958|BEHAVIORAL|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
219109501|NCT01621958|BEHAVIORAL|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
219109502|NCT04065282|DRUG|Sintilimab|3 cycles before radical surgery
219109503|NCT04065282|DRUG|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
219696215|NCT00243243|DRUG|Placebo|intravenous infusion of placebo (sterile water)
219696216|NCT00003686|DRUG|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
219696217|NCT00003686|DRUG|Placebo|Placebo 5 mg po qid x 4 weeks
219696218|NCT01685879|OTHER|Rice|Rice portion containing 50 g total carbohydrate
219696219|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
219696220|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
219696221|NCT01685879|OTHER|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
219696222|NCT05338463|DRUG|Fespixon Cream|"1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks"
219109504|NCT04065282|DRUG|Capecitabine|1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
219696223|NCT00000575|DRUG|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
219696224|NCT00000575|DRUG|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
219696225|NCT00000575|DRUG|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
219696226|NCT03002896|BEHAVIORAL|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
219696227|NCT03002896|OTHER|Treatment as Usual|
219696228|NCT04451018|OTHER|evaluation of arterial anomalies in upper limbs|evaluation of arterial anomalies in upper limbs with doppler ultrasound
219696229|NCT05284175|DRUG|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
219696230|NCT06330714|OTHER|Symptoms of chronic illness.|"The patient is advised to monitor BP and body weight daily in a standardized fashion as described below:~* Body weight should be measured in the morning without clothes or shoes after emptying the urinary bladder but before breakfast.~* BP should be measured in the morning preferably using the right arm, sitting comfortably in a chair after 5 minutes of rest in the seated position."
219696231|NCT06222801|DRUG|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
219696232|NCT06222801|DRUG|Interferon gamma|Immunostimulating agent.
219696233|NCT01367197|BEHAVIORAL|exercise training|group based exercise training
219696234|NCT03386526|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
219696235|NCT03863353|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
219696236|NCT05715619|BIOLOGICAL|VRELysin™|A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
219696237|NCT05715619|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
219696238|NCT06580223|DRUG|Aspirin 100mg|Aspirin, enteric coating of tablets, oral administration
219696239|NCT06580223|DRUG|Rivaroxaban 10mg|Rivaroxaban, tablets, oral administration.
219696240|NCT05647187|DIAGNOSTIC_TEST|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
219696241|NCT05647187|RADIATION|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
219696242|NCT01299584|DRUG|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219696243|NCT01166919|DEVICE|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
219696244|NCT01389778|DRUG|Metformin ER|Metformin ER 1500 mg for 12 weeks
219696245|NCT01389778|DRUG|Metformin|
219696246|NCT02121977|DEVICE|Elevate Anterior and Apical|
219696247|NCT02121977|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
219696248|NCT02005796|OTHER|Dietary intervention|
219696249|NCT00448656|PROCEDURE|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
219696250|NCT03972033|BEHAVIORAL|EMDR|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
219696251|NCT03972033|BEHAVIORAL|CBT|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
219696252|NCT02806167|OTHER|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
219696253|NCT03273062|DRUG|Tolcapone 200 MG|Tolcapone 200 MG TID
219696254|NCT03273062|OTHER|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
219696255|NCT05012267|OTHER|16-hour PP|PP according to previous study
219109505|NCT00099489|DRUG|Interferon Beta-1a|
219109506|NCT00258440|DRUG|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
219109507|NCT00258440|DRUG|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
219696256|NCT02618746|OTHER|Telerehabilitation|
219696257|NCT02618746|OTHER|Hospital based Rehabilitation|
219696258|NCT03240419|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
219696259|NCT03240419|DIETARY_SUPPLEMENT|Placebo|capsule manufactured to mimic probiotic capsules.
219696260|NCT03884335|PROCEDURE|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
219696261|NCT00411320|DRUG|oral steroid-dexamethasone|2 week steroid trial
219696262|NCT05572203|DIETARY_SUPPLEMENT|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
219696263|NCT01434446|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
219696264|NCT00773617|BEHAVIORAL|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
219109508|NCT00737061|DEVICE|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
219109509|NCT03917810|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
219109510|NCT02169947|BEHAVIORAL|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
219109511|NCT02169947|BEHAVIORAL|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
219109512|NCT02869269|DEVICE|Early stage|patients who classed as clinical stage 1 and 2
219109513|NCT02869269|DEVICE|Late stage|patients who classed as clinical stage 3 and 4
219109514|NCT01406561|DRUG|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
219109515|NCT01406561|DRUG|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
219109516|NCT01347853|DRUG|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
219109517|NCT01347853|DRUG|Placebo|Intranasal post-surgery for up to 5 days total
219109518|NCT00115219|DRUG|Etanercept|
219109519|NCT04112940|OTHER|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
219109520|NCT04112940|OTHER|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
219109521|NCT06196580|DRUG|repaglinide; midazolam; SHR4640|repaglinide; midazolam; SHR4640
219109522|NCT06196580|DRUG|repaglinide; midazolam; SHR4640; SHR4640 placebo|repaglinide; midazolam; SHR4640; SHR4640 placebo
219109523|NCT06196580|DRUG|repaglinide; midazolam; SHR4640 placebo|repaglinide; midazolam; SHR4640 placebo
219109524|NCT03748238|PROCEDURE|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
219696265|NCT00773617|BEHAVIORAL|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
219109525|NCT00075569|BIOLOGICAL|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
219109526|NCT05908890|DEVICE|Experimental Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
219109527|NCT05908890|DEVICE|Fixodent True Feel Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
219109528|NCT03148847|OTHER|Baseline care|
219109529|NCT03148847|OTHER|Referential's dissemination|
219109530|NCT03855410|BEHAVIORAL|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
219109531|NCT03855410|BEHAVIORAL|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
219109532|NCT01035333|DRUG|Orlistat|60mg capsule three times a day for up to 6 months
219109533|NCT04310943|DRUG|Tislelizumab|Tislelizumab, 200mg, Q3W ,use until disease progression
219109534|NCT00994786|DRUG|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
219109535|NCT00994786|DRUG|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
219109536|NCT01072123|OTHER|Quest for the Code|interactive asthma-based computer program
219109537|NCT01844115|DRUG|Placebo|
219109538|NCT01844115|DRUG|Vilazodone|Viibryd
219109539|NCT01873547|BIOLOGICAL|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
219109540|NCT01873547|OTHER|rehabilitation|Patients only receive rehabilitation of limb function.
219696266|NCT01891214|OTHER|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
219696267|NCT03955172|DRUG|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
219696268|NCT06405893|BEHAVIORAL|Mindful breathing exercise|Participants do a 10 minute guided mindful breathing exercise or participants do listen to a 10 minute control recording
219109541|NCT00758160|DRUG|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
219109542|NCT05686915|DIAGNOSTIC_TEST|MARS MRI|metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities
219109543|NCT05686915|DIAGNOSTIC_TEST|Titanium Labs|Labs to look at titanium levels in blood
219109544|NCT05686915|DIAGNOSTIC_TEST|Cobalt Labs|Labs to look at cobalt levels in blood
219109545|NCT05686915|DIAGNOSTIC_TEST|Chromium Labs|Labs to look at chromium levels in blood
219109546|NCT00038441|DRUG|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
219109547|NCT02084719|DEVICE|Oraquick HCV Rapid Antibody Test|
219109548|NCT02084719|DEVICE|Standard algorithm|
219109549|NCT05912114|DRUG|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
219696269|NCT02679976|DEVICE|etafilcon A|Marketed Multifocal Contact Lens
219109550|NCT05912114|DRUG|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
219109551|NCT02220504|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
219109552|NCT02220504|OTHER|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
219109553|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
219109554|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
219109555|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
219109556|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
219109557|NCT00707213|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
219109558|NCT02265081|PROCEDURE|ultrasound|pelvic floor ultrasound
219109559|NCT02265081|PROCEDURE|uroflow-meter|uroflow meter: measurement of passed urine volume
219109560|NCT02710695|BEHAVIORAL|Control|This group will receive a standardized 10 minute discussion.
219109561|NCT02710695|BEHAVIORAL|Intervention|This group will receive a standardized 10 minute discussion
219696270|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
219696271|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
219696272|NCT01951716|DRUG|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
219696273|NCT01951716|DRUG|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
219109562|NCT00747526|DRUG|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
219109563|NCT00747526|DRUG|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
219109564|NCT02691351|OTHER|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
219109565|NCT05075343|DEVICE|Custom foot orthoses|"3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could."
219109566|NCT00002215|DRUG|Emivirine|
219109567|NCT00002215|DRUG|Nelfinavir mesylate|
219109568|NCT00624663|DRUG|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
219109569|NCT02153359|DEVICE|High Efficiency Particulate Air Cleaner|
219109570|NCT02153359|DEVICE|Sham air cleaner|
219109571|NCT02238197|DRUG|Atrovent® Inhalation Solution|
219109572|NCT00056758|BIOLOGICAL|Autologous Dendritic Cell HIV Vaccination|
219109573|NCT04422639|RADIATION|SRS/SRT|Comparing pre-operative SRS/SRT to post-operative SRS/SRT
219109574|NCT01964521|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
219109575|NCT06289634|BEHAVIORAL|Man-made sounds|Participants will be asked to listen to the assigned sounds (relaxing music) for 30 minutes a day for 15 days.
219109576|NCT06289634|BEHAVIORAL|Natural sounds|Participants will be asked to listen to the assigned sounds (birds, ocean, wind) for 30 minutes a day for 15 days.
219109577|NCT03377868|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
219109578|NCT03377868|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
219109579|NCT01832103|DRUG|MK-7145|
219109580|NCT06038903|OTHER|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
219109581|NCT01290536|DEVICE|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
219696274|NCT01951716|DRUG|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
219109582|NCT01167686|DIETARY_SUPPLEMENT|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
219109583|NCT06236360|BEHAVIORAL|Mediterranean Diet Intervention|The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
219696275|NCT01951716|DRUG|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
219109584|NCT05987501|DIAGNOSTIC_TEST|Multimodal ultrasound|Contrast enhanced ultrasound and shear wave elastography on target intestinal loop are perfomed before and at different timepoints after treatment induction
219109585|NCT04358796|DEVICE|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
219109586|NCT04358796|DEVICE|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
219696276|NCT01951716|DRUG|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
219696277|NCT01951716|DRUG|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
219696278|NCT02333253|DRUG|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach \>12 mm
219696279|NCT04061785|OTHER|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
219696280|NCT04735042|DRUG|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
219109587|NCT01900574|DRUG|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
219109588|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
219109589|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
219161450|NCT06791785|OTHER|Before the 1st Written Exam|Fill out forms before the 1st written exam (Westside test anxiety scale, burdon attention test, descriptive information form)
219161451|NCT06791785|OTHER|End of Term|Fill out forms at the end of the term (Westside test anxiety scale, burdon attention test, descriptive information form)
219161452|NCT06792097|DIAGNOSTIC_TEST|Ga-68 Dolacga PET scan|"Contrast Name: Nuclear Medicine Dolacga (Lyophilized product for the preparation of gallium Ga68 Dolacga injection).~Active Ingredient, Dosage, Route: NOTA-Hexa lactoside (INER038), 40 micrograms, IV injection.~PET Imaging Schedule: Before radiofrequency ablation therapy, one month after ablation therapy, and follow-up every three months thereafter."
219109590|NCT01356992|DRUG|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
219109591|NCT02867969|OTHER|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
219109592|NCT03103230|DEVICE|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
219109593|NCT04825860|DRUG|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
219109594|NCT04825860|DRUG|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
219109595|NCT04825860|DRUG|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
219109596|NCT03941743|DRUG|Fingolimod|Given PO
219109597|NCT03941743|DRUG|Fingolimod Hydrochloride|Given PO
219109598|NCT03941743|OTHER|Questionnaire Administration|Ancillary studies
219109599|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to \< 212 days of age"
219109600|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to \< 12 months of age"
219109601|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to \< 24 months of age"
219109602|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to \< 72 months of age"
219109603|NCT02328976|OTHER|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
219109604|NCT03154840|DRUG|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
219696281|NCT04735042|DRUG|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
219109605|NCT02110524|DEVICE|Percutaneous Transluminal Angioplasty|
219109606|NCT05196048|OTHER|No Intervention|No Intervention
219109607|NCT02952573|DRUG|JNJ-42756493|Once daily dosing
219109608|NCT02952573|DRUG|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
219109609|NCT04330014|BEHAVIORAL|vaccine|affect vaccination on children
219109610|NCT02963688|GENETIC|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
219109611|NCT05403060|BEHAVIORAL|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
219109612|NCT01294501|OTHER|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
219109613|NCT02401308|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
219109614|NCT01720784|DIETARY_SUPPLEMENT|Alginate dietary fiber|
219109615|NCT01720784|DIETARY_SUPPLEMENT|Placebo|
219109616|NCT04100512|DEVICE|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
219109617|NCT04100512|DEVICE|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
219109618|NCT00412633|BEHAVIORAL|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
219109619|NCT00412633|BEHAVIORAL|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
219109620|NCT05309460|DRUG|Labetalol Oral Tablet|See Labetalol arm.
219109621|NCT05309460|DRUG|NIFEdipine ER|See Nifedipine arm.
219109622|NCT02998021|DEVICE|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
219109623|NCT02998021|DEVICE|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
219109624|NCT06180941|DRUG|magnesium sulfate.|magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
219109625|NCT06180941|DRUG|clonidine.|clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
219109626|NCT01335295|DRUG|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
219109627|NCT00319059|DRUG|systemic administration of 99mTc-HYNIC-Annexin A5|
219109628|NCT00319059|BEHAVIORAL|10 minutes of ischemic handgripping|
219109629|NCT04737213|DRUG|SGM-101|Fluorescence guided surgery
219109630|NCT00932334|BEHAVIORAL|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
219109631|NCT00932334|BEHAVIORAL|TALK Standard|Participants receive and educational video and booklet about living kidney donation
219696282|NCT05658068|BEHAVIORAL|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
219696283|NCT02819713|OTHER|ultrasound gel|
219696284|NCT02819713|OTHER|Instillagel|
219696285|NCT06501521|DIAGNOSTIC_TEST|Diagnostic test|No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
219696286|NCT03810183|DRUG|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
219696287|NCT03810183|DRUG|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
219696288|NCT00072449|BIOLOGICAL|rituximab|
219109632|NCT00932334|BEHAVIORAL|Usual Care|Participants receive their usual care
219109633|NCT00216450|DRUG|rabeprazole sodium|
219109634|NCT05185596|DEVICE|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
219109635|NCT02372864|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
219109636|NCT00517309|BIOLOGICAL|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
219109637|NCT00517309|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
219109638|NCT04275843|DIETARY_SUPPLEMENT|Traditional Diet|Consuming an traditional whole foods based diet for 4 weeks.
219109639|NCT04275843|DIETARY_SUPPLEMENT|Modern Diet|Consuming an processed formulation of the traditional diet for 4 weeks.
219109640|NCT00460148|DRUG|Ropinirole|
219109641|NCT05690542|OTHER|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
219109642|NCT00179530|BEHAVIORAL|Relaxation Response|Relaxation training
219109643|NCT03135704|DEVICE|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
219696289|NCT06550778|BEHAVIORAL|Mindfulness-based emotional regulation intervention|"The intervention was conducted once a week for 6 weeks, with each session lasting 90-120 minutes, including a 30-minute parenting course each week. The intervention program was divided into 6 themes, including Entering mindfulness, feeling the connection between emotions and the body, Dealing with negative emotions, Moderate emotional expression, Mindfulness to relieve anxiety, Learning to be grateful and Embrace future life. The intervention content integrates mindfulness training, parental mindful parenting exercises and emotion regulation skills. For details, refer to Greenland's Mindfulness Games, Bögels' Mindful Parenting Manual, mindful breathing and meditation in MBSR and MBCT, as well as emotion regulation skills. The intervention location was the activity room of the child and adolescent psychology unit of the hospital."
219696290|NCT02064556|DRUG|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
219109644|NCT03135704|OTHER|Physiotherapy|Usual protocol for treatment of low back pain
219109645|NCT03152045|BEHAVIORAL|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
219109646|NCT00278382|DRUG|sorafenib tosylate|Given orally
219109647|NCT00278382|OTHER|laboratory biomarker analysis|Correlative studies
219109648|NCT00599547|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
219696291|NCT02064556|DRUG|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
219696292|NCT06960993|BEHAVIORAL|Intervention website|Website that includes experiential information, stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
219696293|NCT06960993|BEHAVIORAL|Enhanced Usual Care (Control) Website|Website that includes stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
219696294|NCT06960928|DRUG|Low-dose sirolimus|"Participants will take sirolimus, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (1mg)~* 2 pills once a week for 2 weeks (2mg)~* 4 pills once a week for 8 weeks (4mg)"
219696295|NCT06960928|DRUG|Placebo|"Participants will take a matching placebo, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (0mg)~* 2 pills once a week for 2 weeks (0mg)~* 4 pills once a week for 8 weeks (0mg)"
219696296|NCT01656044|PROCEDURE|wound care management|Receive SSD
219696297|NCT01656044|PROCEDURE|wound care management|Receive NPT
219696298|NCT05963399|DEVICE|CAREUP platform|The Experimental Group will test the CAREUP platform at home for 12 months.
219696299|NCT00323063|DRUG|gemcitabine hydrochloride|Given IV
219696300|NCT00323063|DRUG|imatinib mesylate|Given orally
219696301|NCT02009943|DRUG|Ferric carboxymaltose|One time dosing
219696302|NCT02009943|DRUG|Iron sucrose|Goal-directed dosing
219696303|NCT02499562|DRUG|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
219696304|NCT02499562|DRUG|Placebo|
219696305|NCT02499562|DRUG|Entecavir|
219696306|NCT03228901|DRUG|Oxytocin|Administration of the hormone oxytocin
219696307|NCT03228901|DRUG|Placebos|
219109649|NCT04536571|DEVICE|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
219109650|NCT04536571|DEVICE|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
219696308|NCT02305264|DRUG|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
219696309|NCT04500951|OTHER|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
219696310|NCT04500951|OTHER|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
219696311|NCT03881436|DIAGNOSTIC_TEST|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence"
219696312|NCT03167242|DRUG|KAF156|KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
219696313|NCT03167242|DRUG|Coartem|Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
219696314|NCT03167242|DRUG|Lumefantrine Solid Dispersion Formulation|LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
219109651|NCT04340908|DRUG|Dapagliflozin 10 MG|10 mg tablet, oral, once daily, 1-year treatment, postoperation
219109652|NCT04340908|DRUG|Placebos|matching placebo tablet, oral, once daily, 1-year treatment, postoperation
219109653|NCT02141958|DRUG|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
219696315|NCT03971760|OTHER|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
219696316|NCT00764218|DEVICE|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
219696317|NCT00764218|OTHER|No positive airway pressure treatment|No treatment
219696318|NCT03211507|OTHER|Computer-assisted telephone interview|Occupational history
219696319|NCT03211507|GENETIC|Genetic analysis|To include analysis of known susceptibility markers
219696320|NCT04490408|PROCEDURE|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
219696321|NCT04490408|PROCEDURE|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
219696322|NCT06550323|DEVICE|Group using virtual reality glasses|Group using virtual reality glasses: During the procedure, individuals will wear glasses.
219696323|NCT02253264|DRUG|Rituximab|
219109654|NCT02141958|DRUG|Placebo|A matching placebo will be used to keep the study double-blind.
219109655|NCT01567865|BIOLOGICAL|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
219109656|NCT01567865|BIOLOGICAL|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
219109657|NCT02061696|DEVICE|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
219696324|NCT00566488|BIOLOGICAL|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
219696325|NCT06433167|OTHER|Pedobarographic analysis|During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
219696326|NCT04102826|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
219696327|NCT02536911|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
219696328|NCT05931263|DRUG|C-BEAM Regimen|Chidemide，carmustine, etoposide, cytarabine, and melphalan
219696329|NCT05931263|DRUG|BEAM Regimen|carmustine, etoposide, cytarabine, and melphalan
219696330|NCT05577728|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
219696331|NCT05577728|DRUG|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
219696332|NCT02783898|DEVICE|AliveCor Heart Monitor|Smart phone based ECG event recorder
219696333|NCT01938196|DRUG|KWA-0711|
219696334|NCT01938196|DRUG|Placebo|
219696335|NCT04713072|BIOLOGICAL|ABY-035|ABY-035 solution for injection
219696336|NCT04713072|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
219696337|NCT04056208|DRUG|Pistachio|Unsalted pistachios
219696338|NCT04056208|OTHER|Usual care|Advice and resources will be provided
219696339|NCT04625335|OTHER|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
219696340|NCT04625335|OTHER|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
219696341|NCT02831582|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO.
219109658|NCT02061696|PROCEDURE|Standard Manual Compression|Closure procedure by Manual Compression
219109659|NCT03987230|DRUG|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
219109660|NCT03987230|OTHER|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
219109661|NCT03987230|OTHER|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
219109662|NCT03987230|OTHER|Blephadex Lid Wipes|Blephadex Lid Wipes
219109663|NCT03987230|OTHER|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
219109664|NCT03987230|OTHER|Blephademodex|Blephademodex
219109665|NCT00381355|PROCEDURE|Written Action Plan for Acute Asthma|
219109666|NCT00119925|BEHAVIORAL|patient education|patient leaflets about national guideline contents
219696342|NCT02831582|OTHER|Placebo|Given PO.
219696343|NCT04470973|DRUG|Cefuroxime|Patients receive cefuroxime as part of standard care.
219696344|NCT04470973|DRUG|Amikacin|Patients receive amikacin as part of standard care.
219696345|NCT03464760|DIETARY_SUPPLEMENT|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
219696346|NCT03464760|DIETARY_SUPPLEMENT|placebo|5 tablets per day of potato-based placebo
219696347|NCT02244671|PROCEDURE|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
219696348|NCT02244671|DRUG|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
219696349|NCT02244671|DEVICE|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
219696350|NCT01331811|OTHER|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~* interview on anamnesis~* clinical examination~* evaluation of HIV infection stage~* hematology and biochemistry tests~* CD4 count~* HIV viral load~* IGRA~* chest radiograph~* Abdominal ultrasonograph to detect abdominal lymphadenopathy~* Tuberculin skin test~* gastric aspirates, sputum and string tests according to the age of children~* nasopharyngeal aspirate~* stool sample~* lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
219696351|NCT06044103|DRUG|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
219696352|NCT00549393|DRUG|2% Chlorhexidine gluconate cloth|Daily bathing
219696353|NCT05944939|PROCEDURE|Surgical extraction of impacted third molar|After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
219696354|NCT00623675|DIETARY_SUPPLEMENT|Mineralox C|Mineralox C 2 capsules three times a day.
219696355|NCT04600349|BEHAVIORAL|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
219696356|NCT04600349|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
219696357|NCT03568435|OTHER|Non-Interventional|Non-Interventional
219696358|NCT02980315|OTHER|CAR-T cells|the patients treat with CAR-T cells
219696359|NCT01612195|PROCEDURE|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
219696360|NCT01048424|DEVICE|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
219696361|NCT01048424|OTHER|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
219696362|NCT02144701|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given PO
219696363|NCT02144701|OTHER|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
219696364|NCT01307813|DEVICE|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
219696365|NCT00683423|DRUG|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
219109667|NCT00119925|BEHAVIORAL|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
219109668|NCT00119925|BEHAVIORAL|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
219109669|NCT00119925|OTHER|information tools|tools and checklists to improve information provision
219109670|NCT02750176|OTHER|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
219109671|NCT02762734|OTHER|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
219109672|NCT01476488|DRUG|tacrolimus|
219109673|NCT05596357|OTHER|questionnaires|The patient must answer questionnaires before and after reconstructive surgery
219109674|NCT00309608|DRUG|Linagliptin|Linagliptin medium dose tablet once daily
219109675|NCT00309608|DRUG|Linagliptin|Linagliptin high dose tablet once daily
219109676|NCT00309608|DRUG|Linagliptin|Linagliptin low dose tablet once daily
219109677|NCT00309608|DRUG|Placebo|Placebo tablets once daily
219109678|NCT00309608|DRUG|Glimepiride|Glimepiride tablets once daily
219109679|NCT04613882|DEVICE|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
219109680|NCT04613882|DEVICE|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
219109681|NCT04613882|DEVICE|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
219109682|NCT00004438|DRUG|leuprolide|
219109683|NCT00621296|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
219109684|NCT04426344|DEVICE|ensoETM device|Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\[41\] If patient temperature increases above this range and reaches 39.8°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).
219109685|NCT06017674|PROCEDURE|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
219109686|NCT06017674|DRUG|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
219109687|NCT02810067|PROCEDURE|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
219109688|NCT02810067|PROCEDURE|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
219109689|NCT04723849|DIETARY_SUPPLEMENT|Auxilie® Immuplus, Envicon Medical, Verona, Italy|"Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT)."
219109690|NCT01440582|DRUG|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
219109691|NCT01440582|DRUG|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
219109692|NCT01440582|DRUG|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
219109693|NCT01440582|DRUG|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
219109694|NCT01440582|BEHAVIORAL|Symptom Questionnaire|Completed on day 1 of each cycle.
219109695|NCT03918954|DEVICE|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
219109696|NCT03918954|OTHER|Sensory room|A room with calming elements that patients can use to feel calm.
219109697|NCT00101335|DRUG|celecoxib|
219109698|NCT03643146|BEHAVIORAL|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
219109699|NCT03643146|BEHAVIORAL|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
219109700|NCT03150524|DIAGNOSTIC_TEST|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
219696366|NCT00683423|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
219696367|NCT01491425|DEVICE|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
219696368|NCT01491425|DEVICE|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
219696369|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
219696370|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (The Upjohn Company)|
219109701|NCT03150524|BEHAVIORAL|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
219109702|NCT03150524|OTHER|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
219696371|NCT01145664|DRUG|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
219109703|NCT03150524|DIAGNOSTIC_TEST|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
219109704|NCT03150524|DRUG|Nimodipine|Participants will be administered nimodipine every 4 hours.
219109705|NCT03150524|DRUG|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
219109706|NCT02671318|DRUG|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
219109707|NCT02671318|DRUG|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
219109708|NCT04922190|BEHAVIORAL|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
219109709|NCT02844491|OTHER|additional biological samples|blood and tissue samples
219109710|NCT02765022|DEVICE|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
219696372|NCT01145664|DRUG|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
219696373|NCT01145664|DRUG|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
219696374|NCT00485862|DRUG|Atomoxetine Hydrochloride|
219696375|NCT00485862|DRUG|Sertraline|
219696376|NCT00485862|DRUG|Placebo|
219696377|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
219696378|NCT05604898|OTHER|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
219696379|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
219696380|NCT05604898|OTHER|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
219696381|NCT02979704|DRUG|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
219696382|NCT02979704|DRUG|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
219696383|NCT01218802|DRUG|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
219109711|NCT02765022|PROCEDURE|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
219109712|NCT05996952|DRUG|RC48-ADC|Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
219109713|NCT03402373|DIETARY_SUPPLEMENT|Lycoderm|soft gel contains nutritional supplement
219109714|NCT03402373|DIETARY_SUPPLEMENT|Placebo|soft gel without active ingredients
219109715|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109716|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109717|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109718|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109719|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109720|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109721|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
219109722|NCT03230383|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
219109723|NCT03244293|OTHER|no intervention|
219109724|NCT05778721|OTHER|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
219696384|NCT01218802|DRUG|Placebo|participants will take a sugar pill daily for 96 weeks
219109725|NCT03453827|OTHER|no intervention|no intervention
219696385|NCT01350219|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
219109726|NCT02327819|DIETARY_SUPPLEMENT|Branched-chain amoni acids (BCAA)|
219109727|NCT02327819|DIETARY_SUPPLEMENT|non-BCAA protein supplement|
219109728|NCT05501171|BEHAVIORAL|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
219109729|NCT05501171|BEHAVIORAL|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~1. Education about general wellness.~2. Nutrition.~3. Exercise.~4. Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
219109730|NCT03399149|OTHER|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
219109731|NCT06204562|BEHAVIORAL|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
219109732|NCT04140825|DEVICE|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
219109733|NCT04052191|BIOLOGICAL|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
219109734|NCT04850287|BEHAVIORAL|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
219696386|NCT03327324|BEHAVIORAL|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
219696387|NCT00160511|DRUG|Levetiracetam|
219109735|NCT04727476|DRUG|Lisdexamfetamine|Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
219696388|NCT00133198|DRUG|Pramipexole|
219109736|NCT04644640|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
219109737|NCT04644640|OTHER|In-person Rehabilitation Therapy|Range of motion exercises for the knee, proprioception and balance training
219109738|NCT01759615|OTHER|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
219109739|NCT01759615|OTHER|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
219109740|NCT06396754|OTHER|AI-analysis on diagnostic and surgical specimens|The analysis will report a list of AI-based biomarkers to assess the tumour-immune spatial microenvironment as well as final spatial immune-ecology prognostic (SIPA) reports for every patient.
219696389|NCT01927094|DIETARY_SUPPLEMENT|Probiotic|Comparison of probiotics vs. ORS
219696390|NCT01927094|DIETARY_SUPPLEMENT|ORS|ORS ad libitum
219696391|NCT06177288|COMBINATION_PRODUCT|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
219696392|NCT02125890|DRUG|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
219696393|NCT00771368|DRUG|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
219696394|NCT05966233|DRUG|R-DHAP|"* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
219696395|NCT05966233|DRUG|Pola-R-DHAP|"* Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
219696396|NCT06123702|BEHAVIORAL|Fear extinction|Extinction of conditioned fear response
219696397|NCT06123702|DRUG|Cannabidiol Cap/Tab|12 50-mg capsules
219696398|NCT06123702|DRUG|Placebo|12 placebo capsules
219696399|NCT03874442|OTHER|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
219696400|NCT05202834|DEVICE|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
219696401|NCT04168034|BEHAVIORAL|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
219224697|NCT06950216|OTHER|IONM|The probe needle electrodes were inserted into the corpus cavernosum penis, ischiocavernosus muscle, bulbocavernosus muscle, anal sphincter, etc., and each monitoring electrode was connected to the nerve monitor. The changes of electromyography of each effector during the operation were monitored in real time. The stimulation electrode was placed in the abdominal cavity during the operation. During the resection of the prostate, electrical stimulation was performed on the possible running area of the NVB, and the stimulation site where the signal was monitored was protected from resection and burning under the premise of safe surgery.
219696402|NCT04168034|BEHAVIORAL|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
219696403|NCT02060357|DEVICE|Optical coherence tomography|
219696404|NCT05731310|DRUG|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
219696405|NCT00032773|DRUG|pentostatin for injection|
219696406|NCT05589974|DRUG|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
219696407|NCT04500444|OTHER|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
219696408|NCT02778217|PROCEDURE|Culture media renwal|
219696409|NCT03019484|BEHAVIORAL|Breastfeeding support|Self-efficacy
219696410|NCT03795506|DEVICE|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
219696411|NCT03795506|DEVICE|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
219109741|NCT04999371|BEHAVIORAL|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
219109742|NCT04999371|BEHAVIORAL|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
219109743|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
219360871|NCT05756725|OTHER|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
219696412|NCT01065012|DRUG|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219696413|NCT01065012|DRUG|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219696414|NCT01065012|DRUG|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219360872|NCT04861337|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
219696415|NCT01065012|DRUG|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219696416|NCT01065012|DRUG|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219109744|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
219109745|NCT03692715|DRUG|Ciprofloxacin|Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
219109746|NCT03692715|DRUG|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
219109747|NCT01369134|DEVICE|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
219696417|NCT01065012|DRUG|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
219696418|NCT03708471|PROCEDURE|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
219696419|NCT03708471|PROCEDURE|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
219696420|NCT06415461|BIOLOGICAL|PremierMaxCB®-Platinum (CFL001);|Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
219696421|NCT03458520|DIAGNOSTIC_TEST|PET/MR imaging|undergo PET/MR imaging
219696422|NCT03458520|DIAGNOSTIC_TEST|MR imaging|Undergo MR imaging
219696423|NCT03458520|DIAGNOSTIC_TEST|PET/CT imaging|Undergo PET/CT imaging
219696424|NCT06357624|OTHER|Mulligan mobilization|The SNAGS technique was applied to 3 sets of 10 repetitions with 15-30 seconds rest between sets while the participants were in a sitting position. A physiotherapist applied passive motion to facet joints at each spinal level. The participant was questioned in which direction he/she felt pain during cervical ROM and the application was carried out in the painful/limited directions.
219696425|NCT06357624|OTHER|Self-Mobilization|For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.
219696426|NCT03821038|BIOLOGICAL|CYT107|IV twice a week at 10µg/kg for 3 weeks
219696427|NCT03821038|DRUG|Placebos|IV twice a week at the same volume for 3 weeks
219696428|NCT03167554|OTHER|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
219696429|NCT03167554|OTHER|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
219696430|NCT03167554|OTHER|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
219109748|NCT06291155|DRUG|SGLT2 inhibitor|All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
219109749|NCT03861507|DEVICE|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
219696431|NCT02144870|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
219696432|NCT02144870|BEHAVIORAL|Resources activation|
219696433|NCT05458986|OTHER|Media Intervention|Watch an educational video
219696434|NCT05458986|OTHER|Best Practice|Receive usual care
219696435|NCT05458986|OTHER|Questionnaire Administration|Ancillary studies
219696436|NCT04673773|BEHAVIORAL|A Massive Open Online Course|Same as intervention
219109750|NCT02269761|DEVICE|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
219109751|NCT06860529|DRUG|Serplulimab|Serplulimab is administered intravenously
219109752|NCT06860529|DRUG|Epirubicin|Epirubicin ivgtt
219109753|NCT06860529|DRUG|Albumin Paclitaxel|Albumin Paclitaxel ivgtt
219109754|NCT03367936|BEHAVIORAL|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
219109755|NCT03367936|BEHAVIORAL|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
219109756|NCT03367936|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
219109757|NCT06623214|DEVICE|nebulyft|Micro Radiofrequency Skin Treatment Device(nebulyft)
219109758|NCT06625840|DRUG|MK-1167|Oral Administration
219696437|NCT06284421|DEVICE|Shore durometer|The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
219696438|NCT02072642|DEVICE|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
219696439|NCT02072642|DEVICE|Placebo light therapy|4 weeks with Placebo light therapy
219696440|NCT00269152|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
219696441|NCT00269152|DRUG|cisplatin|75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
219696442|NCT00269152|DRUG|carboplatin|area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
219696443|NCT04249427|DRUG|Erenumab Prefilled Syringe|140mg Erenumab, pre-filled syringe given by subcutaneous injection
219696444|NCT04249427|OTHER|Placebo|Placebo, pre-filled syringe given by subcutaneous injection
219696445|NCT05179408|BEHAVIORAL|Targeted-telerehabilitation|Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
219696446|NCT05179408|BEHAVIORAL|Waitlist|8-week waiting period prior to targeted telerehabilitation
219696447|NCT03779347|DRUG|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
219109759|NCT06625840|DRUG|Placebo|Oral Administration
219109760|NCT00079456|DRUG|temsirolimus|Given IV
219109761|NCT00079456|OTHER|pharmacological study|Correlative studies
219109762|NCT00079456|OTHER|laboratory biomarker analysis|Correlative studies
219109763|NCT06625814|DRUG|Levothyroxine|single oral dose
219109764|NCT06625814|DRUG|Enlicitide Decanoate|single oral dose
219109765|NCT03190681|DRUG|Ritalin 10Mg Tablet|oral ingestion of 3 tablets in a single-dose
219109766|NCT03190681|DRUG|Placebo Oral Tablet|oral ingestion of 3 tablets in a single-dose
219109767|NCT06700226|DEVICE|AblaView® Unipolar PFA System|Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.
219109768|NCT05597956|PROCEDURE|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
219109769|NCT05597956|PROCEDURE|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
219109770|NCT05597956|PROCEDURE|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
219109771|NCT03391960|DEVICE|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
219696448|NCT03779347|DIAGNOSTIC_TEST|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
219109772|NCT06925386|DRUG|Standard therapy|The standard therapy for participants included a structured skincare regimen. A face wash was used once daily before bedtime to cleanse the skin. In the morning, a non-comedogenic sunscreen and a moisturizer were applied to protect and hydrate the skin. Additionally, a night cream containing clindamycin and tretinoin was applied once daily at night, specifically on acne-affected areas, to target inflammation and promote skin renewal.
219109773|NCT06925386|DIETARY_SUPPLEMENT|HEXBIO|The oral probiotics given are Hexbio®, an oral probiotic containing multiple beneficial bacterial strains, including Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium longum BCMC® 02120, and Bifidobacterium infantis BCMC®02129. This probiotic was administered in granule form and swallowed directly. Participants consumed the probiotic twice daily, after breakfast and dinner, for eight weeks to support gut microbiome balance and potential skin health benefits.
219109774|NCT06925386|BIOLOGICAL|Secretome|The topical secretome used is a hydrogel-based serum containing secretome components, including cytokines, growth factors, exosomes, microvesicles, and cell differentiation factors. The serum is formulated with a hydrogel base consisting of xanthan gum, sclerotium gum, 1% alginate, 2% glycerin, 1% caprylyl glycol, and 96% aqua. It is applied after cleansing the face with a facial cleanser, twice daily, in the morning and evening, for eight weeks
219696449|NCT03779347|DIAGNOSTIC_TEST|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
219696450|NCT05325996|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
219109775|NCT06926569|DRUG|Amphotericin B|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy
219696451|NCT05325996|DIAGNOSTIC_TEST|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
219696452|NCT05325996|DIAGNOSTIC_TEST|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
219161453|NCT05073302|PROCEDURE|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
219696453|NCT05325996|DIAGNOSTIC_TEST|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
219109776|NCT06926569|DRUG|AmBisome|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy.
219109777|NCT06734351|DEVICE|NOA VOLUME|Subcutaneous and/or Supraperiosteal Plane Injection
219109778|NCT06734351|DEVICE|VOLUMA XC|Subcutaneous and/or Supraperiosteal Plane Injection
219696454|NCT01886508|PROCEDURE|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
219696455|NCT01886508|PROCEDURE|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
219696456|NCT05908396|DRUG|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
219696457|NCT05148637|DRUG|Maintenance of general anesthesia by Sevoflurane|Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
219696458|NCT05148637|DRUG|Maintenance of general anesthesia by Desflurane|Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
219696459|NCT05148637|DRUG|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
219696460|NCT03053882|OTHER|mouthwash|mouthwash containing herbal peppermint or green tea
219696461|NCT02576392|BEHAVIORAL|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
219696462|NCT02557399|DRUG|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
219696463|NCT02557399|DRUG|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
219696464|NCT02557399|DRUG|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
219696465|NCT01170325|DRUG|Divalproex Sodium|
219696466|NCT01170325|DRUG|Placebo Comparator|
219696467|NCT06308471|OTHER|Baby massage was applied to the intervention group (n=20) of the study|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
219696468|NCT06308471|OTHER|Oral stimulation|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
219109779|NCT01413672|DEVICE|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
219109780|NCT02358798|OTHER|3 years-assessment of respiratory function|
219109781|NCT06900608|BEHAVIORAL|Acceptance and Commitment Therapy|A 6-session ACT intervention was implemented targeting Cognitive Defusion (CD) and Values-Based Activity Scheduling (VBAS). During the first 3 sessions, the therapist taught participants how to defuse from negative self-thoughts using didactic and experiential techniques and emphasized the relationship between negative thoughts and the self and learning to observe negative thoughts for what they are - thoughts, words, ideas, and evaluations. During sessions 4-6, the therapist used similar techniques to focus on behaving in meaningful ways without letting negative thoughts dictate behavior. During these VBAS sessions, the participant identified their values and worked with the therapist to decide on goals that were values-consistent, and focused on those foals without letting negative thoughts and emotions get in the way of living toward them.
219161454|NCT05650554|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
219696469|NCT02712957|DRUG|NEO6860|TRPV1 antagonist
219696470|NCT02712957|DRUG|NEO6860 placebo|Inactive substance
219696471|NCT02712957|DRUG|Naproxen|NSAID
219696472|NCT02712957|DRUG|Naproxen placebo|inactive substance
219696473|NCT03260608|BEHAVIORAL|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
219696474|NCT02848664|DEVICE|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
219696475|NCT05208996|DRUG|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
219696476|NCT05504096|DEVICE|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
219696477|NCT05504096|DEVICE|SVT In-Ear Prototype (IEP)|In-Ear wearable
219696478|NCT00402727|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
219696479|NCT00402727|DRUG|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
219109782|NCT06900608|BEHAVIORAL|Treatment as usual|"The 6-session supportive therapy (ST) condition emphasized the exploration of feelings; helping the client to become aware of and talk about emotional experiences with no attempt to change thoughts, behaviors, or the client's experiences directly (Greenberg et al., 1998). Psychoeducation emphasized the untoward effects of not acknowledging or exploring feelings and benefits of identification and talking about feelings. The therapist used open-ended questions, reflective listening, empathy, and clarification questions. Therapists did not give advice, offer solutions, make interpretations, or disagree with/confront the client. For homework, the participants were asked to complete awareness homework, involving monitoring of presence, intensity, and duration of emotions with no prescription to change them or do anything differently."
219109783|NCT06900907|DEVICE|Diode laser|A single session was applied to three points of the tooth extraction site.
219109784|NCT06900907|COMBINATION_PRODUCT|Hyaluronic acid|1 cc of hyaluronic acid gel was placed into the extraction socket, followed by suturing.
219696480|NCT01784874|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
219696481|NCT01784874|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
219696482|NCT03546712|OTHER|Tactile Localization|tactile localization is help to assess touch sensation
219696483|NCT03580070|BIOLOGICAL|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
219696484|NCT03474796|BEHAVIORAL|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
219696485|NCT04996420|DEVICE|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
219696486|NCT03529253|DRUG|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
219696487|NCT03529253|DRUG|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
219696488|NCT00004002|DRUG|bortezomib|
219696489|NCT04951089|DEVICE|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
219696490|NCT04951089|DEVICE|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
219696491|NCT04022330|OTHER|Blood sampling|The blood sampling will be done just before surgery
219109785|NCT06900907|COMBINATION_PRODUCT|Ozone|Topical ozone was applied to the extraction socket, followed by suturing.
219109786|NCT06900907|DRUG|Methylprednisolone|In addition to the standard prescribed medication, 4 mg of oral methylprednisolone was prescribed postoperatively.
219109787|NCT06900907|PROCEDURE|Control|Only the standard prescribed medication was provided.
219360873|NCT04861337|DRUG|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
219360874|NCT03793400|DRUG|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
219696492|NCT03188055|OTHER|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
219696493|NCT01148394|OTHER|Multimodal rehabilitation|
219696494|NCT01405898|DIETARY_SUPPLEMENT|beetroot juice|Beetroot juice 4 weeks 250ml daily
219696495|NCT01405898|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
219696496|NCT03800316|DEVICE|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
219696497|NCT02894333|BEHAVIORAL|behavioral observation|
219696498|NCT02630810|OTHER|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
219696499|NCT02630810|OTHER|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
219696500|NCT02701621|OTHER|MIRT-AT|Aquatic therapy
219696501|NCT02701621|OTHER|MIRT|Land-based Therapy
219696502|NCT00944710|DRUG|Atropine|Weekend atropine 1%
219696503|NCT00944710|DEVICE|Plano lens|plano lens over the sound eye
219696504|NCT00944710|DRUG|Atropine|Weekend atropine 1%
219696505|NCT00898066|GENETIC|cytogenetic analysis|marrow and peripheral blood
219696506|NCT00898066|GENETIC|fluorescence in situ hybridization|marrow and peripheral blood
219109788|NCT06818032|OTHER|Negative control|Participants will be given a breakfast meal with 76 grams of bread and 60 grams of jam per 2000 daily calories.
219109789|NCT06818032|OTHER|Avocado|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 84 grams of avocado per 2000 daily calories.
219109790|NCT06818032|OTHER|Fat and fiber addition|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 13 grams of fat (mix of high-oleic safflower oil, safflower oil, palm oil, and macadamia nut oil) and 5.5 grams of fiber (mix of cellulose and pectin) per 2000 daily calories.
219109791|NCT06899984|BEHAVIORAL|Patient Navigator|Patient Navigator will provide additional support to participants using their standard of care CGM device.
219109792|NCT06901219|BEHAVIORAL|Running Fatigue Protocol|The experimental group went through a fatigue protocol, in which speed and incline increase one unit each minute passing, and stopped when rate of perceived exertion level reached ≥ 18, and the plasma lactate level differed from the baseline by ≥ 4mmol/L.
219109793|NCT06901271|DRUG|EMLA Cream|EMLA cream (2.5 grams) was applied to the treatment area 60 minutes before the procedure and covered with a transparent and impermeable dressing.
219109794|NCT06901271|DEVICE|Buzzy|The buzzy device was placed on the procedure area 60 seconds before the procedure and turned on. The cold and vibration application continued during the procedure.
219109795|NCT06901271|DRUG|Cold spray|Cold spray was applied to the procedure area for 5 seconds from a distance of 15 cm immediately before the procedure.
219109796|NCT06900088|DRUG|Selinexor|maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation
219109797|NCT06848894|DRUG|Human urinary kallidinogenase (HUK)|HUK (0.15 PNA) and sodium chloride injection (100ml), once per day
219109798|NCT06848894|DRUG|Placebo|placebo (0 PNA) and sodium chloride injection (100ml), once per day
219109799|NCT06901232|BEHAVIORAL|Mindfulness Training|"All participants will complete a single 45-minute mindfulness training at Visit 2, with a refresher prior to the second mbNF session at Visit 3. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
219109800|NCT06901232|BEHAVIORAL|Active mindfulness-based neurofeedback (Active mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During active mbNF (6 runs, 2.5 minutes each), participants will use mental noting with the aim of controlling visual feedback. Specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
219109801|NCT06901232|BEHAVIORAL|Sham mindfulness-based neurofeedback|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During sham mbNF, participants will view a visual display (white dot, red and blue circles) extracted from a previously acquired mbNF session. The display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures participants across groups are viewing equivalent stimuli for the same amount of overall time.
219109802|NCT06901050|OTHER|FAST HUGS WITH ICU approach|"FAST HUGS WITH ICU; It is an abbreviation of Feeding, Analgesia, Sedation, Thromboembolic prophylaxis, Head of bed elevation, Stress Ulcer prophylaxis and Glucose control Spontaneous breathing trial, Water Balance and constipation, Investigation and results, Therapy, Hypo-hyper delirium, Invasive devices, Check the daily infection parameters, Use a checlist. With this approach, patients will be followed up."
219696507|NCT05909540|PROCEDURE|Posterior facet distraction and fusion|With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.
219161455|NCT05650554|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
219161456|NCT05650554|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
219161457|NCT05650554|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
219360875|NCT01344967|DRUG|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
219360876|NCT00003632|BIOLOGICAL|filgrastim|
219360877|NCT00003632|DRUG|carmustine|
219360878|NCT00003632|DRUG|cytarabine|
219360879|NCT00003632|DRUG|etoposide|
219360880|NCT00003632|DRUG|melphalan|
219696508|NCT00691522|DRUG|Xerecept|
219696509|NCT05256823|DRUG|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
219360881|NCT00003632|DRUG|methotrexate|
219360882|NCT00003632|PROCEDURE|peripheral blood stem cell transplantation|
219696510|NCT05256823|DRUG|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
219696511|NCT00264147|DRUG|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
219696512|NCT00264147|DRUG|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
219696513|NCT00264147|DRUG|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
219696514|NCT00264147|DRUG|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
219696515|NCT00264147|DRUG|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
219696516|NCT00264147|DRUG|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
219696517|NCT00264147|DRUG|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
219696518|NCT04827277|PROCEDURE|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
219696519|NCT04827277|PROCEDURE|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
219696520|NCT03234465|BIOLOGICAL|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
219696521|NCT03234465|OTHER|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
219696522|NCT03464435|DRUG|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
219696523|NCT00986414|DRUG|AFQ056|
219696524|NCT00986414|DRUG|AFQ056|
219696525|NCT00986414|DRUG|AFQ056|
219696526|NCT00986414|DRUG|AFQ056|
219696527|NCT00986414|DRUG|AFQ056|
219696528|NCT00986414|DRUG|Placebo|
219161458|NCT04661501|DEVICE|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
219696529|NCT04040517|DIAGNOSTIC_TEST|Evoked potential audiometer|The ASSR \[ steady state response\] test stimuli are modulated pure tones with insert earphone..
219696530|NCT02493972|PROCEDURE|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
219696531|NCT02493972|PROCEDURE|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
219696532|NCT03854331|BEHAVIORAL|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
219696533|NCT00449163|BIOLOGICAL|Bevacizumab|
219696534|NCT00449163|DRUG|Floxuridine|
219696535|NCT00449163|DRUG|Irinotecan|
219696536|NCT00449163|DRUG|Leucovorin|
219696537|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
219696538|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
219696539|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
219161459|NCT04661501|DEVICE|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
219161460|NCT04661501|DEVICE|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
219696540|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
219696541|NCT05859607|PROCEDURE|laparoscopic cholecystectomy|conventional laparoscopic cholecystectomy with calculation of difficulty scorings
219696542|NCT05994547|DRUG|Byfavo|For induction and maintenance of sedation
219696543|NCT05994547|DRUG|Midazolam|For induction and maintenance of sedation
219696544|NCT04321772|OTHER|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
219696545|NCT04321772|OTHER|Traditional Resistance Training|Subjects trained the other leg with HIIRT
219696546|NCT02473185|DRUG|Methylphenidate|Cross-over
219696547|NCT05637983|PROCEDURE|US-guided femoral puncture vs Fluoroscopy-guided puncture|US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
219696548|NCT04577105|DIAGNOSTIC_TEST|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
219109803|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
219109804|NCT05905497|DRUG|Bemnifosbuvir (BEM)|BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
219109805|NCT06828549|BEHAVIORAL|MOSAIC|All MOSAIC PWD participants receive monthly phone coaching following a semi-structured protocol plus daily automated text message support. MOSAIC uses the mobile phone-delivered structure and functionality developed for FAMS (NCT04347291). Tailoring rules novel to MOSAIC determine phone coaching protocol content, text message content, and the involvement of a SP. Semi-structured protocols used in prior studies (and in the case of NCT04334109 adapted for mobile phone-delivery) are employed. Per tailoring rules, enrolled SPs may be invited to participate in monthly coaching calls with the PWD and/or receive text messages about supporting the PWD. The study will not assess outcomes or effects among SPs.
219224698|NCT05436665|PROCEDURE|UT-DSAEK|"The main incision (3.5-5mm) is created at the corneal limbus or via a cornea-scleral tunnel with 2-3 smaller (approx. 1mm) paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber, according to the surgeon's preference. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed. Once the anterior chamber is prepared, OVD or air has been removed, then the eye is ready for the new corneal graft.~The pre-cut corneal tissue delivered by the bank is then gently rinsed and may be stained with 0.06% trypan blue if required. The tissue is loaded into a glide or injector, and pulled into the anterior chamber using a smooth-tipped micro-forceps (e.g., Busin forceps). Once the graft enters the eye, it is lifted to the posterior cornea. The graft is further centred using air (or SF6 Gas) in the anterior chamber."
219360883|NCT03720899|DRUG|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
219696549|NCT00952666|DEVICE|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
219696550|NCT02911454|OTHER|Infant formula|
219696551|NCT06294288|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (Dose 1) was administered intravenously.
219696552|NCT06294288|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (Dose 2) was administered intravenously.
219696553|NCT06294288|BIOLOGICAL|LP-003 Dose 3 (Single)|A single dose of LP-003 (Dose 3) was administered intravenously.
219696554|NCT06294288|BIOLOGICAL|LP-003 Dose 4 (Single)|A single dose of LP-003 (Dose 4) was administered intravenously.
219109806|NCT06828549|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters
219696555|NCT06294288|BIOLOGICAL|LP-003 Dose 5 (Single)|A single dose of LP-003 (Dose 5) was administered intravenously.
219696556|NCT06294288|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
219696557|NCT06294288|BIOLOGICAL|LP-003 Dose 6 (Multiple)|LP-003 (Dose 6) was administered multiple times subcutaneously.
219696558|NCT06294288|BIOLOGICAL|LP-003 Dose 7 (Multiple)|LP-003 (Dose 7) was administered multiple times subcutaneously.
219696559|NCT06294288|BIOLOGICAL|LP-003 Dose 8 (Multiple)|LP-003 (Dose 8) was administered multiple times subcutaneously.
219696560|NCT06294288|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
219696561|NCT06055413|OTHER|Remote patient monitoring (RPM) bundle|"Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment."
219696562|NCT06025292|OTHER|Lean Pork vs Plant-Based Protein|Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
219696563|NCT02033759|DEVICE|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
219696564|NCT02033759|OTHER|Anxiety Questionnaire|21 item questionnaire
219696565|NCT02033759|OTHER|Traditional Circumferential Measurements|
219696566|NCT04347408|DIAGNOSTIC_TEST|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
219696567|NCT04347408|OTHER|Blood Storage|Storage of blood for multi-omics analysis
219696568|NCT04687852|OTHER|Conservative and Non-conservative treatments|This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
219696569|NCT05691101|OTHER|CISB with IV PCA group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine 4 ml/hour was injected through the continuous brachial plexus block catheter. IV-PCA with fentanyl (basal flow 0 ml with patient selected bolus 14 mcg, lockout 10 minutes) was started."
219696570|NCT05691101|OTHER|CISB group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine (4 ml/hour with patient selected bolus 5 ml, lockout 60 minutes) was injected through the continuous brachial plexus block catheter."
219696571|NCT05569798|DIAGNOSTIC_TEST|Whole body point of care ultrasound scan|"The INSIGHT Scan is a whole-body PoCUS scan which comprises imaging the following windows:~1. subcostal~2. inferior vena cava cardiac view~3. left hemidiaphragm~4. bladder~5. right hemidiaphragm~6. six major central veins (left/right internal jugular/ subclavian/ femoral veins)~The scan should take no more than 10 minutes to perform. Simple yes/no questions are asked for each window to identify any significant abnormalities. For example, is the left ventricle bigger than the right ventricle; is there a pleural effusion; is the bladder distended etc.~The scan is reported in the intensive care online medical notes and reviewed by the clinical team as soon as possible."
219109807|NCT02468921|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
219109808|NCT01935960|OTHER|Laboratory Biomarker Analysis|Correlative studies
219109809|NCT01935960|OTHER|Pharmacological Study|Correlative studies
219109810|NCT01935960|OTHER|Placebo|Given PO
219109811|NCT01935960|DRUG|Retinoid 9cUAB30|Given PO
219109812|NCT02142920|DRUG|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
219109813|NCT04048070|DRUG|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
219109814|NCT04048070|DRUG|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
219109815|NCT04048070|BEHAVIORAL|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
219109816|NCT04048070|BEHAVIORAL|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
219696572|NCT04327921|BEHAVIORAL|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
219696573|NCT04327921|BEHAVIORAL|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
219696574|NCT03175887|DEVICE|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
219696575|NCT01162733|DRUG|Vancomycin|15mg/kg
219696576|NCT01162733|DRUG|Vancomycin|30mg/kg
219696577|NCT04966286|OTHER|multimedia education|The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
219696578|NCT00308945|DRUG|travoprost 0.004% (drug)|local drop application
219696579|NCT00308945|DRUG|latanoprost 0.005% (drug)|local drop application
219109817|NCT04048070|BEHAVIORAL|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
219109818|NCT04048070|BEHAVIORAL|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
219109819|NCT01288781|DRUG|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
219109820|NCT01288781|DRUG|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
219109821|NCT02164162|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
219109822|NCT02164162|OTHER|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
219109823|NCT03518658|OTHER|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
219109824|NCT03518658|OTHER|Control Group (Historical)|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
219109825|NCT01419145|OTHER|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
219109826|NCT01419145|OTHER|Standard care|Standard cancer care
219109827|NCT04014478|DEVICE|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
219109828|NCT02762383|DRUG|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
219109829|NCT01619657|DRUG|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
219109830|NCT01619657|DRUG|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
219109831|NCT04917380|OTHER||Retrospective clinical study，no intervention
219109832|NCT03420235|OTHER|Home monitoring program|The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
219109833|NCT01463774|DRUG|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
219109834|NCT01463774|DRUG|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
219109835|NCT01463774|DRUG|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
219109836|NCT04762173|DEVICE|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
219109837|NCT04647019|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
219109838|NCT04647019|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
219109839|NCT03472287|DRUG|Diacerein 1% Ointment|Diacerein 1% Ointment administered topically
219109840|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release oral tablet
219109841|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release tablet
219109842|NCT03106961|DEVICE|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
219360884|NCT03720899|DRUG|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
219360885|NCT02723825|PROCEDURE|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
219360886|NCT02723825|PROCEDURE|Open reduction|Open reduction and internal fixation
219360887|NCT02088385|DEVICE|Hemospray|
219360888|NCT02088385|DEVICE|Combined Conventional Technique|
219109843|NCT01656603|BIOLOGICAL|unlicensed CBU|infusion of unlicensed cord blood units
219109844|NCT06219343|DEVICE|Non-invasive vagus nerve stimulation|Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
219109845|NCT05760729|DIAGNOSTIC_TEST|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
219109846|NCT04520958|BEHAVIORAL|Mindfulness of Breath|Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
219109847|NCT04520958|BEHAVIORAL|Mindfulness of Pain|Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.
219109848|NCT04520958|BEHAVIORAL|Cognitive-Behaviorally Based Pain Psychoeducation|Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
219109849|NCT03945110|DEVICE|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
219109850|NCT05687617|DRUG|Indocyanine green|0,25mg/kg IV at the start of the surgery,
219109851|NCT03347864|DRUG|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
219109852|NCT02723279|BEHAVIORAL|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
219696580|NCT03912740|DRUG|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
219696581|NCT03912740|DRUG|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
219696582|NCT03912740|DRUG|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
219696583|NCT04301856|DRUG|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
219109853|NCT02723279|DRUG|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
219109854|NCT03342781|DEVICE|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
219109855|NCT03342781|DEVICE|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
219109856|NCT01890902|DRUG|Ketoprofen 10% Cream|
219109857|NCT01890902|DRUG|Placebo|
219109858|NCT03135132|BEHAVIORAL|Control group|Recommend to consume usual diet during 12-week study period
219109859|NCT03135132|BEHAVIORAL|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
219109860|NCT00280423|DRUG|GW679769|
219109861|NCT01750593|PROCEDURE|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
219109862|NCT00003534|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219109863|NCT03140917|DIAGNOSTIC_TEST|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
219109864|NCT05010694|DRUG|GH35 Tablet|GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
219161461|NCT04661501|DEVICE|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
219109865|NCT01084928|BEHAVIORAL|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
219109866|NCT06349785|DEVICE|rehabilitation of mechanically ventilated patients|"1. mechanical ventilation~2. silicon resuscitation bag (500ml) connected to pressure manometer with an oxygen flow of 10 l.min-1~3. Endotracheal closed suction with pressure control ventilation (PCV)"
219109867|NCT06349785|PROCEDURE|supportive care|\- Children in study group B will receive standard Physical therapy program including suction, percussion and vibration with total duration of session in group a will be 15 minutes, daily for successive two weeks
219109868|NCT06500182|OTHER|hippotherapy sessions|Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
219109869|NCT03442023|DRUG|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
219109870|NCT03442023|DRUG|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
219109871|NCT00164177|DRUG|HalfLytely|
219109872|NCT05707832|DRUG|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
219696589|NCT06802913|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
219696590|NCT06802913|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
219696591|NCT00232700|DRUG|Escitalopram|
219696593|NCT00733278|DEVICE|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
219696594|NCT05994963|DRUG|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
219696595|NCT02479074|DRUG|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
219696596|NCT02479074|DRUG|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
219696597|NCT02479074|DRUG|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
219109873|NCT06548685|PROCEDURE|Bone Grafting|Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites
219696598|NCT00988702|BEHAVIORAL|Dan Tian Breathing|Dan Tian Breathing for one month
219696599|NCT00988702|BEHAVIORAL|Progressive muscle training|Progressive muscle training for one month
219696600|NCT02764801|DRUG|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
219696601|NCT02764801|DEVICE|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
219696602|NCT01088633|OTHER|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
219696603|NCT04964115|OTHER|Cohort study|This cohort study does not involve an intervention
219696604|NCT01288300|BEHAVIORAL|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
219696605|NCT01288300|BEHAVIORAL|Diabetes lecture|Diabetes self-management lecture
219696606|NCT06231641|DRUG|Lemborexant 5 MG [Dayvigo]|Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
219696607|NCT06231641|OTHER|Matching Placebo|Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
219109874|NCT06548685|OTHER|Vegetable Derived|Tooth extraction followed by socket preservation with vegetable ivory
219109875|NCT05583747|DEVICE|iTBS|rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
219109876|NCT02621567|DEVICE|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
219109877|NCT02621567|DEVICE|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
219109878|NCT02891590|DRUG|DTRMWXHS-12|
219109879|NCT05591625|BEHAVIORAL|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
219696608|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
219696609|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
219696610|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
219696611|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
219696612|NCT06596291|DRUG|EG110A|Participants treated with EG110A
219696613|NCT06821035|BEHAVIORAL|Garnering Resilience in Traumatized youth and families (GRIT)|Dyads randomly assigned to Garnering Resilience in Traumatized youth and families (GRIT) will receive a community health worker delivered psychoeducational intervention that includes 6 weekly sessions focused on: 1) supportive health coaching to garner resilience via psychoeducation and the promotion of buffering protective factors in both youth and caregivers and 2) facilitating self-regulation using heart rate variability (HRV) biofeedback.
219696614|NCT06821035|BEHAVIORAL|Digital Citizenship Curriculum (DCC)|Dyads randomly assigned to DCC will receive a community health worker-delivered, school grade-specific intervention that includes 6 weekly sessions focused on helping youth navigate the complexities of living in a digital world.
219696615|NCT00103948|DRUG|Aricept|
219696616|NCT00058253|DRUG|tanespimycin|Given IV
219696617|NCT00058253|DRUG|docetaxel|Given IV
219696618|NCT06458985|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
219696619|NCT06612892|DEVICE|Virtual reality games in immersive VR modality|virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.
219696620|NCT06612892|DEVICE|Virtual reality show in passive VR modality:|In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.
219696621|NCT06612892|OTHER|traditional physiotherapy|Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
219696622|NCT06612814|DRUG|Fluzoparib|Parp inhibitor
219696623|NCT06612814|DRUG|Dalpiciclib|CDK4/6 inhibitor
219696624|NCT06612814|DRUG|Fulvestrant/AI|Endocrine therapy
219696625|NCT06612021|PROCEDURE|Beautibond universal adhesive|HEMA free universal adhesive
219696626|NCT06612021|PROCEDURE|Tetric N universal bond|HEMA containing universal bond
219696627|NCT00003039|DRUG|alvocidib|
219109880|NCT02835456|DEVICE|Sharklet Catheter insertion|
219696628|NCT01471977|OTHER|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
219696629|NCT06992882|DRUG|Capecitabine|capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)
219109881|NCT02835456|DEVICE|Silicone Foley Catheter insertion|
219696630|NCT06992882|DRUG|Paclitaxel|paclitaxel (80mg/m2, qw, D1, 8, 15, intravenous, q3w) trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6mg/kg, q3w, subcutaneous or intravenous for 1 year)
219109882|NCT00917267|DRUG|exenatide once weekly|2.0mg subcutaneous injection, once a week
219109883|NCT00917267|DRUG|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
219696631|NCT00481884|OTHER|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
219696632|NCT00481884|OTHER|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
219696633|NCT01645150|BEHAVIORAL|Progressive strength training|12 weeks of supervised progressive strength training
219696634|NCT06996184|DRUG|Vamifeport (PR formulation)|Vamifeport will be administered orally
219696635|NCT07002554|DEVICE|Bright light therapy|the Verilux® HappyLight® Lumi Plus light therapy box, which delivers UV-free, full-spectrum LED light at an intensity of 10,000 lux
219696636|NCT07002554|DEVICE|dim red light|The control group will use the same light box device, configured to emit dim red light. This will be achieved by setting the box to its lowest brightness setting and overlaying a translucent red filter over the light display. This setup is intended to maintain the appearance and experience of light exposure while minimizing any therapeutic effect.
219696637|NCT06613022|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
219696638|NCT06613022|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
219696639|NCT07011472|OTHER|Decision-Aid with 2-options|This decision aid offers 2 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen) or an opioid (hydrocodone).
219696640|NCT07011472|OTHER|Decision aid with 3 options|"This decision aid offers 3 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen), an opioid (hydrocodone), or a non-opioid combination with a just-in-case opioid prescription."
219696641|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
219696642|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
219109884|NCT03652480|DRUG|MethylPREDNISolone Acetate 40 MG/ML|
219109885|NCT00936338|BEHAVIORAL|splint and joint mobilization self exercise|
219109886|NCT02977065|DRUG|Atorvastatin 20mg|PO daily for 4weeks
219696643|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
219696644|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
219696645|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
219696646|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
219696647|NCT01450020|OTHER|educational intervention|Receive ACS material
219696648|NCT01450020|OTHER|questionnaire administration|Ancillary studies
219696649|NCT01450020|OTHER|counseling intervention|Undergo PN session
219696650|NCT01450020|OTHER|survey administration|Ancillary studies
219696651|NCT01450020|PROCEDURE|quality-of-life assessment|Ancillary studies
219696652|NCT06338943|DIAGNOSTIC_TEST|Echocardiography|Echocardiography to diagnose HFpEF
219109887|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
219109888|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
219109889|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
219109890|NCT02977065|DRUG|Rosuvastatin 10 mg|PO daily for 4weeks
219109891|NCT02977065|DRUG|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
219109892|NCT04402593|BEHAVIORAL|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
219109893|NCT00061620|DRUG|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
219109894|NCT03728153|DRUG|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
219224699|NCT05436665|PROCEDURE|DMEK|"The main incision (2.8-3mm) is created superior or temporally at the corneal limbus and is accompanied by 2-3 smaller paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed.~The DMEK roll is poured into a basin and rinsed. The graft is then stained with 0.06% trypan blue to aid in graft visualization. The graft is loaded into an injector and introduced into the anterior chamber. The graft is unrolled using external manoeuvres and once unrolled, it is lifted to the back of the cornea. The eye is then pressurised with a full air fill from 10 to 120 minutes. The pressure is then reduced and the case is completed by suturing any incisions required."
219224700|NCT00604890|DRUG|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
219696653|NCT06338943|OTHER|Questionnaire|Questionnaire to determine the presence of adverse pregnancy outcomes history
219109899|NCT06530524|DRUG|OnabotulinumtoxinA|Injection of onabotulinumtoxinA into the at-risk major salivary glands
219109900|NCT06530524|DRUG|Placebo|Injection of normal saline into the at-risk major salivary glands
219696654|NCT05455333|OTHER|Questionnaires|Sends and returns questionnaires to families.
219696655|NCT03122392|DEVICE|AMS 800|AMS 800 Artificial Urinary Sphincter
219696656|NCT01124812|OTHER|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~1. Cohorts 1, 2 \& 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 \& 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 \& 3. Treatment cycles will be repeated every 28 days.~2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~   * Total treatment duration is 8-16 weeks"
219696657|NCT01419535|DRUG|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
219696658|NCT01419535|DRUG|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
219696659|NCT04788095|BEHAVIORAL|Behavioral Intervention|Participate in an app-based mindfulness program
219696660|NCT04788095|OTHER|Quality-of-Life Assessment|Ancillary studies
219109901|NCT05612776|OTHER|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
219109902|NCT05612776|OTHER|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
219109903|NCT01017120|DRUG|Tazarotene Foam|Tazarotene foam once a day application to the face
219109904|NCT01017120|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
219109905|NCT04764929|DEVICE|Helmet CPAP|Vyatil nonpowered oxygen tent system
219109906|NCT05620030|OTHER|Univentricular Heart|Prevention of complications when discovered
219109907|NCT01095705|PROCEDURE|Conventional procedure|Local anaesthesia (Lidocaïne)
219109908|NCT01095705|PROCEDURE|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
219109909|NCT00252590|BEHAVIORAL|Health Motivational Feedback|Personalized feedback on health status
219109910|NCT00252590|BEHAVIORAL|Health Education|Generalized health education related to alcohol use
219109911|NCT00252590|BEHAVIORAL|Control - treatment as usual|Control group with no additional intervention
219109912|NCT05332574|BIOLOGICAL|GB263T|Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
219224701|NCT00604890|DRUG|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
219224702|NCT00604890|OTHER|Placebo|Topical treatment placebo applied to the lesion
219224703|NCT06132737|DRUG|[90Y]Y-PentixaTher|\[90Y\]Y-PTT i.v. injection
219696661|NCT04788095|OTHER|Questionnaire Administration|Ancillary studies
219696662|NCT04020419|DRUG|PediaBerry|PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
219696663|NCT00929838|BEHAVIORAL|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
219696664|NCT00929838|BEHAVIORAL|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
219696665|NCT00929838|BEHAVIORAL|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
219109913|NCT04873622|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
219109914|NCT03188614|DRUG|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
219696666|NCT00929838|BEHAVIORAL|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
219696667|NCT02344316|DRUG|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
219696668|NCT02344316|OTHER|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
219696669|NCT05619471|DEVICE|VIO Imaging|Skin conditions that are candidates for skin biopsies
219696670|NCT06924502|OTHER|Protective Balm|The test product will be applied in addition to an additional washing product in the test area.
219696671|NCT06502847|OTHER|Exosome profile study|Neonatal serum and maternal exosome profiles will be studied in all groups.
219696672|NCT06173284|DRUG|611|subcutaneous injection
219696673|NCT06173284|DRUG|Matching placebo|subcutaneous injection
219109915|NCT00289770|BIOLOGICAL|Twinrix™|Intramuscular injection, 3 doses
219109916|NCT02916992|RADIATION|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
219109917|NCT02916992|GENETIC|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
219109918|NCT00498836|DRUG|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
219109919|NCT00498836|DRUG|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
219109920|NCT01158430|BEHAVIORAL|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
219109921|NCT01702428|BIOLOGICAL|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
219109922|NCT01702428|BIOLOGICAL|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
219696674|NCT00196599|DRUG|emtricitabine, FTC (drug)|
219696675|NCT00196599|DRUG|didanosine, ddI (drug)|
219696676|NCT00196599|DRUG|efavirenz (drug)|
219696677|NCT00788333|DRUG|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
219696678|NCT00788333|DRUG|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
219696679|NCT00154388|DRUG|Imatinib mesylate|
219696680|NCT00564980|PROCEDURE|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
219696681|NCT00564980|PROCEDURE|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
219696682|NCT00964704|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
219696683|NCT00964704|DRUG|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
219696684|NCT00964704|DRUG|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
219696685|NCT00964704|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
219696686|NCT04364490|DEVICE|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
219696687|NCT04364490|DEVICE|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
219696688|NCT04364490|OTHER|Control group|Usual care
219696689|NCT04375124|BIOLOGICAL|Biological/Vaccine: Angiotensin peptide (1-7) derived plasma|angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
219696690|NCT04832217|OTHER|Pyrenees´ Beef diet|24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
219696691|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
219696692|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
219696693|NCT00480116|BIOLOGICAL|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
219696694|NCT00190034|DRUG|N-Acetylcysteine 600mg/tab|
219696695|NCT03344471|OTHER|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
219109923|NCT01702428|BIOLOGICAL|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
219109924|NCT01702428|BIOLOGICAL|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
219109925|NCT01702428|BIOLOGICAL|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
219224704|NCT03715946|DRUG|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
219696696|NCT03813108|BIOLOGICAL|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
219696697|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
219696698|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
219696699|NCT03813108|BIOLOGICAL|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
219696700|NCT03813108|DRUG|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
219696701|NCT00870727|DRUG|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
219109926|NCT05491343|DRUG|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
219109927|NCT05491343|DEVICE|Other|Follow up using US
219109928|NCT04995497|DRUG|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
219109929|NCT04995497|DRUG|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
219109930|NCT04958928|PROCEDURE|Catheter ablation|All patients received radiofrequncy ablation.
219109931|NCT00154063|DRUG|E2007|
219109932|NCT00154063|OTHER|Placebo|
219224705|NCT03715946|RADIATION|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
219224706|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
219224707|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
219696702|NCT00870727|DRUG|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
219696703|NCT04038827|DIAGNOSTIC_TEST|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
219696704|NCT00879853|BEHAVIORAL|Interpersonal Therapy|
219109933|NCT04155437|BEHAVIORAL|Health Facility Level Interventions|"* Intensified counseling on maternal dietary diversity and quality using job aids~* Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~* Distribution/prescription of IFA tablets at each ANC visit~* Use of pill card/reminders for pregnant women and their spouses~* Monthly IFA tablet stock monitoring to assure sufficient supplies~* Measurement of weight gain during each ANC visit and advise on healthy weight gain~* Checks for functioning scales and use of monitoring sheets~* Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~* Reminder on importance of early ANC attendance and 4+ visits"
219224708|NCT00302211|DRUG|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
219109934|NCT04155437|BEHAVIORAL|Community Level Interventions|"* Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~* Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~* Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~* Early identification of pregnant women~* Support women's group discussions~* 2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
219109935|NCT04155437|BEHAVIORAL|Health System Level Interventions|"* Training on nutrition interventions during ANC for all ANC providers and community health workers~* Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~* Quarterly supportive supervision of health facility staff by the health district management team~* Monthly supportive supervision of ASBCs~* Monthly review between health facilities and ASBCs~* Training and use of data registers~* Training and use of mother's cards to record up to 8 ANC visits and nutrition services~* Training on data utilization to improve coverage and quality"
219224709|NCT00302211|DRUG|Inhaled Placebo|inhaled placebo
219696705|NCT03337412|OTHER|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
219696706|NCT06167057|DRUG|Mitomycin/Gemcitabine|UTUC treatment
219696707|NCT06167057|DRUG|Saline|UTUC treatment
219696708|NCT04089722|DRUG|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
219696709|NCT00720278|DRUG|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
219696710|NCT00720278|DRUG|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
219696711|NCT00720278|DRUG|Placebo|0 mcg Placebo daily
219696712|NCT01020422|PROCEDURE|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
219696713|NCT02729857|DIETARY_SUPPLEMENT|SFA muffin|Muffin rich in saturated fat.
219696714|NCT02729857|DIETARY_SUPPLEMENT|PUFA muffin|Muffin rich in polyunsaturated fat.
219696715|NCT04656613|BIOLOGICAL|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
219224710|NCT00302211|DRUG|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
219224711|NCT00302211|DRUG|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
219224712|NCT04716101|OTHER|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
219224713|NCT04716101|OTHER|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
219696716|NCT04656613|OTHER|placebo|Placebo Comparator
219696717|NCT04630548|DEVICE|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
219696718|NCT05333211|DRUG|Ortho-R/PRP|Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
219696719|NCT02281708|DRUG|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
219696720|NCT00313690|DRUG|Bortezomib, Docetaxel and Cisplatin|
219696721|NCT03350386|DRUG|FYU-981|Single administration
219696722|NCT03350386|DRUG|Oxaprozin|Repeated administration
219696723|NCT00872547|DEVICE|DePuy ASR™ Hip System|Resurfacing system
219696724|NCT00872547|DEVICE|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
219696725|NCT05426590|DEVICE|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
219696726|NCT05888519|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
219696727|NCT05888519|OTHER|FID123301 ocular lubricant|Investigational ocular lubricant
219696728|NCT05888519|OTHER|FID122505 ocular lubricant|Comparator ocular lubricant
219696729|NCT03885973|DRUG|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
219696730|NCT03885973|DRUG|Placebo|Fermented milk containing placebo for three weeks
219696731|NCT03405311|DEVICE|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
219696732|NCT03405311|OTHER|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
219696733|NCT00283179|DRUG|Aripiprazole|
219696734|NCT00283179|DRUG|Risperidone|
219696735|NCT02208908|OTHER|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
219696736|NCT03964948|DIAGNOSTIC_TEST|Kidney MRI|An MRI examination will be completed per research MRI protocol.
219696737|NCT03408899|DRUG|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
219696738|NCT00606008|DRUG|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
219696739|NCT05325359|BEHAVIORAL|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
219696740|NCT00596492|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
219696741|NCT00596492|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
219696742|NCT03963440|OTHER|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
219696743|NCT04937790|BEHAVIORAL|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
219696744|NCT04937790|BEHAVIORAL|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
219696745|NCT04805268|DIAGNOSTIC_TEST|18F FDG PET/CT|18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
219696746|NCT00571675|DRUG|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
219109936|NCT00807690|DRUG|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
219109937|NCT00072852|DRUG|Irinotecan|
219109938|NCT00839774|OTHER|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
219109939|NCT00839774|OTHER|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
219109940|NCT00839774|OTHER|White wheat flour|White wheat flour will be administered at 50 g/day
219109941|NCT05756452|DIAGNOSTIC_TEST|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
219696747|NCT00571675|DRUG|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
219696748|NCT06098989|PROCEDURE|Radio frequency ablation|Radio frequency ablation
219696749|NCT06132971|BEHAVIORAL|New Beginnings Program|
219696750|NCT02106481|DRUG|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
219696751|NCT02106481|DRUG|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
219696752|NCT06432387|OTHER|Patients undergoing complex thoraco-abdominal aortic aneurysm repair|Patients undergoing complex thoraco-abdominal aortic aneurysm repair
219109942|NCT02091869|OTHER|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
219109943|NCT02091869|DEVICE|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
219109944|NCT05293288|DEVICE|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
219109945|NCT01804673|DRUG|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
219109946|NCT01403389|DRUG|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
219109947|NCT01403389|DRUG|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
219696753|NCT02328508|DEVICE|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
219696754|NCT03809390|PROCEDURE|Vaginal seeding|The same as that stated in arm descriptions.
219696755|NCT00879190|DRUG|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
219696756|NCT00879190|DRUG|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
219109948|NCT04563442|OTHER|complication|complication co morbidities
219109949|NCT02161900|OTHER|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
219109950|NCT02451501|DEVICE|AKITA|
219109951|NCT01677780|DRUG|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
219109952|NCT00172081|DRUG|placebo|Daily subcutaneous injection with placebo
219109953|NCT00172081|DRUG|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
219109954|NCT04706741|DRUG|Izokibep|Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously
219109955|NCT04706741|DRUG|Prednisone/Prednisolone|Background Corticosteroid
219109956|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Group Treatment|group treatment
219109957|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Individual Treatment|individual treatment
219109958|NCT01574430|PROCEDURE|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
219109959|NCT00462046|DRUG|Berberine|
219696757|NCT01248455|DRUG|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
219696758|NCT03169569|PROCEDURE|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
219109960|NCT06364241|OTHER|Focus group|During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.
219109961|NCT00004203|DRUG|oxaliplatin|
219109962|NCT00002708|PROCEDURE|surgical procedure|
219109963|NCT00002708|RADIATION|radiation therapy|
219109964|NCT00002708|RADIATION|stereotactic radiosurgery|
219109965|NCT04367402|OTHER|BioMedomics COVID-19 IgM-IgG Rapid Test|Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
219109966|NCT02328196|BEHAVIORAL|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
219696759|NCT03169569|PROCEDURE|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
219696760|NCT04116333|DEVICE|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
219696761|NCT04116333|DEVICE|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
219696762|NCT06064240|OTHER|We do not have any intervention type|We do not have any intervention type
219696763|NCT04956809|DRUG|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
219696764|NCT04956809|DRUG|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
219109967|NCT00000517|DRUG|warfarin|
219109968|NCT04534335|DEVICE|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
219109969|NCT03223272|DRUG|Reserpine|Open label reserpine 0.1 mg pill orally
219109970|NCT00451217|DRUG|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
219109971|NCT00451217|DRUG|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
219109972|NCT00245375|DRUG|Tylenol #3|
219109973|NCT00245375|DRUG|Combination Tylenol and Ibuprofen|
219109974|NCT01982344|DEVICE|mini-exchange-room|
219109975|NCT05622890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
219224714|NCT06272110|OTHER|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
219696765|NCT02209064|DEVICE|Pericardial access|Access to the pericardium to enable further treatments.
219696766|NCT01117870|OTHER|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
219696767|NCT01117870|OTHER|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
219109976|NCT04147182|DRUG|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
219109977|NCT02997839|BEHAVIORAL|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
219109978|NCT04924686|OTHER|Observational studies, no intervention|Observational studies, no intervention
219109979|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
219109980|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
219109981|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
219109982|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
219109983|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
219109984|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
219109985|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
219109986|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
219109987|NCT02654223|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
219224715|NCT06397235|DRUG|DEB-TACE+HAIC|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."
219224716|NCT06397235|DRUG|DEB-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
219696768|NCT05623800|OTHER|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
219696769|NCT00272402|BEHAVIORAL|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
219696770|NCT00272402|BEHAVIORAL|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
219696771|NCT01669239|DRUG|Liposomal Doxorubicin|"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
219224717|NCT01961063|DRUG|busulfan|Given IV
219224718|NCT01961063|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
219224719|NCT01961063|OTHER|pharmacological study|Correlative studies
219696772|NCT05944796|OTHER|Diathermy|The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
219696773|NCT05944796|OTHER|Placebo|The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
219696774|NCT05409391|DEVICE|Insulin Titration System|A noval insulin titration system, which is based on deep learning
219696775|NCT02841696|DEVICE|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
219109988|NCT02654223|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
219224720|NCT01961063|OTHER|laboratory biomarker analysis|Correlative studies
219109989|NCT05158439|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219109990|NCT05809349|DEVICE|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
219109991|NCT01448720|DRUG|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
219109992|NCT06356727|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
219696776|NCT04942067|DRUG|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
219696777|NCT04942067|DRUG|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
219696778|NCT01260909|DEVICE|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
219696779|NCT05170113|DIETARY_SUPPLEMENT|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
219696780|NCT05170113|DIETARY_SUPPLEMENT|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
219109993|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
219696781|NCT05170113|DIETARY_SUPPLEMENT|Caffeine formulation|Caffeine formulation capsule- I capsule daily
219696782|NCT05170113|DIETARY_SUPPLEMENT|Placebo|Placebo capsule- 1 capsule daily
219696783|NCT00618501|DRUG|cytarabine|
219696784|NCT00618501|DRUG|daunorubicin hydrochloride|
219696785|NCT00618501|DRUG|etoposide|
219696786|NCT00618501|DRUG|imatinib mesylate|
219696787|NCT00618501|DRUG|leucovorin calcium|
219696788|NCT00618501|DRUG|methotrexate|
219109994|NCT02406261|DRUG|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
219696789|NCT00618501|DRUG|prednisolone|
219696790|NCT00618501|DRUG|therapeutic hydrocortisone|
219109995|NCT02406261|DRUG|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
219696791|NCT00618501|DRUG|vincristine sulfate|
219696792|NCT00618501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219109996|NCT02406261|DRUG|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
219109997|NCT02406261|DRUG|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
219109998|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
219109999|NCT04432402|DRUG|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
219110000|NCT02125032|DEVICE|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
219110001|NCT02125032|DEVICE|Placebo Transcranial low voltage electromagnetic fields|
219110002|NCT03165006|PROCEDURE|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
219110003|NCT03165006|PROCEDURE|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
219110004|NCT03753711|PROCEDURE|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
219696793|NCT00489242|PROCEDURE|Procedure / Percutaneous angioplasty|
219696794|NCT06297512|DRUG|Radiotherapy, Temozolomide, Doxorubicin|"Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);"
219696795|NCT01429090|PROCEDURE|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
219696796|NCT01429090|DRUG|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
219696797|NCT01429090|DRUG|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
219696798|NCT01429090|PROCEDURE|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
219110005|NCT04443439|DEVICE|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
219110006|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
219110007|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
219110008|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
219110009|NCT00227760|DRUG|Cediranib Maleate|Given PO
219110010|NCT00227760|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
219110011|NCT00227760|OTHER|Laboratory Biomarker Analysis|Correlative studies
219696799|NCT01429090|PROCEDURE|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
219696800|NCT01429090|PROCEDURE|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
219696801|NCT05190627|DRUG|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
219696802|NCT05190627|DRUG|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
219696803|NCT03933163|DRUG|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
219696804|NCT01224379|DEVICE|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
219110012|NCT00227760|OTHER|Pharmacological Study|Correlative studies
219110013|NCT03154203|OTHER|No intervention in this study|No intervention in this study
219110014|NCT04215393|DRUG|Conbercept eye drop|In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
219110015|NCT04215393|DRUG|Placebo|In the second stage, subjects will be receive Conbercept eys drop or a placebo.
219110016|NCT05462652|DEVICE|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
219110017|NCT05092048|OTHER|questionnaire|PHQ-9 and GAD-7 questionnaire
219110018|NCT02605382|DRUG|Chlorhexidine gluconate|
219110019|NCT02605382|DRUG|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
219110020|NCT04005937|DIAGNOSTIC_TEST|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
219161462|NCT05075408|DRUG|Nemolizumab|Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
219161463|NCT05075408|DRUG|Nemolizumab|Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
219161464|NCT05075408|DRUG|Placebo|Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
219161465|NCT06822179|OTHER|Education for self-management|Education program performed online including information, recommendations and guidance for promoting self-management
219161466|NCT06822179|OTHER|Personalised exercise program|Individualized exercise that includes progressive load adapted to each patient. It includes making flexible adjustments to their exercise (up or down as needed) to help them gradually improve their physical abilities while staying within their energy limits
219161467|NCT06822179|OTHER|Usual Care|Usual care these patients may receive out from the clinical trial.
219110021|NCT03575689|DEVICE|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
219224721|NCT05621174|DRUG|Dexamfetamine|Magisterial Dexamfetamine
219224722|NCT05621174|DRUG|Dexamfetamine|Tentin
219696805|NCT01224379|DEVICE|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
219696806|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
219696807|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
219696808|NCT04345276|DRUG|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
219696809|NCT01206465|DRUG|pralatrexate|Given IV
219224723|NCT03445689|OTHER|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
219224724|NCT03445689|OTHER|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
219224725|NCT03445689|OTHER|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
219224726|NCT03445689|OTHER|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
219696810|NCT01206465|DRUG|fluorouracil|Given IV
219696811|NCT01206465|OTHER|laboratory biomarker analysis|Correlative studies
219696812|NCT01206465|GENETIC|DNA analysis|Correlative studies
219696813|NCT01206465|OTHER|high performance liquid chromatography|Correlative studies
219696814|NCT01206465|GENETIC|polymerase chain reaction|Correlative studies
219696815|NCT01206465|GENETIC|nucleic acid sequencing|Correlative studies
219696816|NCT01206465|OTHER|pharmacological study|Correlative studies
219110022|NCT05428462|OTHER|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
219110023|NCT00152490|DRUG|Certolizumab Pegol (CDP870)|
219110024|NCT03324542|DRUG|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
219224727|NCT03445689|OTHER|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
219696817|NCT01206465|OTHER|pharmacogenomic studies|Correlative studies
219696818|NCT01206465|GENETIC|polymorphism analysis|Correlative studies
219696819|NCT03322293|DRUG|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
219696820|NCT03322293|DEVICE|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
219696821|NCT05580016|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activation Receptor measurement|In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
219696822|NCT01178294|BIOLOGICAL|OBI-1|Intravenous infusion
219696823|NCT02953730|DRUG|PEG-rhG-CSF|
219696824|NCT02089347|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
219696825|NCT02089347|BIOLOGICAL|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
219696826|NCT02948816|BEHAVIORAL|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
219110025|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
219696827|NCT02948816|BEHAVIORAL|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
219696828|NCT02948816|BEHAVIORAL|Colouring|Participants will spend 30 minutes colouring quietly.
219696829|NCT02783066|DEVICE|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
219696830|NCT05052580|OTHER|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
219696831|NCT05251597|OTHER|green exercise with aerobic exercise|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
219696832|NCT01300403|OTHER|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
219696833|NCT01300403|OTHER|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
219696834|NCT01300403|OTHER|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
219696835|NCT04894058|PROCEDURE|Ureteroscopic lithotripsy|"After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz."
219696836|NCT06147934|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Liver biopsy will be conducted by experienced interventionists and reported by pathologists. There should be a maximum interval of no more than 1 month between the liver biopsy and ultrasound examination, and the length of specimen should be more than 1.0cm."
219696837|NCT00566085|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
219110026|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
219110027|NCT01488864|BEHAVIORAL|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
219696838|NCT05269329|DRUG|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
219696839|NCT05269329|DRUG|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
219696840|NCT05269329|DRUG|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
219696841|NCT05269329|DRUG|Placebo|1, 2, or 4 tablets twice a day
219696842|NCT02415972|OTHER|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
219696843|NCT00259935|DRUG|topotecan|topotecan
219110028|NCT04241575|DIAGNOSTIC_TEST|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
219110029|NCT00652262|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
219110030|NCT06349122|DIAGNOSTIC_TEST|Vaginal flora abnormalities screening and quantification using molecular biology technique|Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.
219110031|NCT06349122|DRUG|Azithromycine|In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
219110032|NCT06349122|DRUG|Ceftriaxone|In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
219110033|NCT06349122|DRUG|Metronidazole|Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
219110034|NCT06349122|DRUG|Clotrimazole, Vaginal|In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
219110035|NCT06349122|OTHER|Usual Care|Patients will not be screened using molecular biology techniques in this group. The management of these patients is a matter of routine for health professionals. They will be free to prescribe a standard vaginal swab if symptoms are present and to treat their patients according to their usual protocols. No routine sampling is recommended in the absence of a history
219110036|NCT02530138|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
219110037|NCT02530138|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules per day for 28 weeks
219110038|NCT05468125|PROCEDURE|guidance|either follow the care bundle or the best evidence practice
219110039|NCT00380341|PROCEDURE|Instrument-applied spinal manipulative therapy|
219110040|NCT04548531|BEHAVIORAL|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
219110041|NCT04746274|BEHAVIORAL|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
219110042|NCT04746274|BEHAVIORAL|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
219110043|NCT06339294|DRUG|Clotrimazole Cream|Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
219110044|NCT06339294|DRUG|Povidone-Iodine|Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
219110045|NCT06012565|DRUG|KAND567|2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
219110046|NCT06012565|DRUG|Microcrystalline cellulose|Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
219110047|NCT00432575|DRUG|surinabant (SR147778)|oral administration
219110048|NCT00432575|DRUG|placebo|oral administration
219110049|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion low level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.
219110050|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion high level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.
219110051|NCT04099381|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
219110052|NCT03562169|DRUG|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
219110053|NCT03562169|DRUG|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
219110054|NCT03562169|DRUG|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
219110055|NCT03562169|DRUG|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
219110056|NCT01713790|DEVICE|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
219110057|NCT01713790|DEVICE|Exergame|training program over 10 weeks, three times a week.
219110058|NCT01713790|DEVICE|Leg press|training program over 10 weeks, three times a week.
219110059|NCT04676711|DRUG|GFH312|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
219110060|NCT04676711|DRUG|Placebo|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
219110061|NCT04205175|DRUG|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
219110062|NCT01804543|DRUG|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
219696844|NCT04752930|DIAGNOSTIC_TEST|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
219696845|NCT04752930|DIAGNOSTIC_TEST|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
219696846|NCT01880606|PROCEDURE|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
219696847|NCT03846869|DIAGNOSTIC_TEST|major cations|blood sample
219696848|NCT03176771|DRUG|MT-5199|MT-5199 40 mg capsules
219696849|NCT03176771|DRUG|Placebo|MT-5199 placebo capsules
219696850|NCT02445469|OTHER|MRI exam of the brain|MRI exam of the brain
219696851|NCT06440928|BEHAVIORAL|mobilization|mobilization and exercise to be applied to patients with chronic lateral epicondylitis
219696852|NCT06440928|OTHER|standard treatment|standard treatment
219696853|NCT06440928|OTHER|deep friction|deep friction
219696854|NCT02879292|OTHER|Spinal anesthesia|Spinal Anesthesia
219696855|NCT03030521|DIAGNOSTIC_TEST|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
219110063|NCT02397486|DRUG|Pentoxifylline|
219696856|NCT00000948|DRUG|Aldesleukin|Il-2
219696857|NCT00000948|DRUG|ART|antiretroviral therapy for the treatment of HIV
219696858|NCT00626288|DRUG|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
219696859|NCT00626288|DRUG|Placebo|Placebo cpr, t.i.d. 12 weeks
219110064|NCT02397486|DRUG|Vitamin E|
219110065|NCT02397486|DRUG|Cisplatin|
219110066|NCT02397486|RADIATION|Radiation therapy|
219110067|NCT06529354|BEHAVIORAL|Moderate-intensity Group|In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
219110068|NCT06529354|BEHAVIORAL|High-intensity Group|In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
219110069|NCT04039178|DEVICE|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
219110070|NCT04039178|DEVICE|Sham|Sham BQ device
219110071|NCT06400680|DEVICE|Spine Kinematic Assessment with Optoelectronic system|"All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators."
219110072|NCT00636584|DRUG|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
219110073|NCT00636584|DRUG|placebo|placebo
219110074|NCT01474447|BEHAVIORAL|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
219110075|NCT05929365|PROCEDURE|colonoscopy|determine the mutation profile of resected colorectal neoplasia
219110076|NCT00439179|DRUG|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
219110077|NCT00439179|DRUG|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
219110078|NCT00439179|DRUG|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
219110079|NCT00439179|DRUG|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
219110080|NCT00088179|DRUG|pexelizumab in conjunction with CABG|
219110081|NCT04957732|DEVICE|Standard of Care (SoC)|SoC consisted of irrigation with normal saline, using the same proprietary abscess irrigation tip as the Irrisept arm. SoC was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
219110082|NCT04957732|DEVICE|Irrisept Delivery System|Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
219696860|NCT04925102|OTHER|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
219696861|NCT00687934|DRUG|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
219696862|NCT01997125|DEVICE|Neural Bridge System|Implanted device
219696863|NCT04550117|PROCEDURE|Insertion of Intraspinal pressure monitor|A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
219110083|NCT03034213|DEVICE|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
219110084|NCT03034213|DEVICE|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
219110085|NCT04570345|DRUG|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
219110086|NCT04570345|DRUG|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
219110087|NCT03999905|BEHAVIORAL|Counseling training|Online training using Moodle.
219110088|NCT05761145|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
219110089|NCT03395834|DEVICE|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
219161468|NCT06389201|DRUG|HCQ|HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
219161469|NCT06389201|OTHER|Placebo|Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.
219110090|NCT03191929|OTHER|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
219110091|NCT03191929|OTHER|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
219110092|NCT00715663|DRUG|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
219110093|NCT01982396|DRUG|ABC Twice Daily|
219110094|NCT01982396|DRUG|ABC Once Daily|
219110095|NCT01982396|DRUG|3TC Once Daily|
219110096|NCT01982396|DRUG|3TC Twice Daily|
219224728|NCT03445689|OTHER|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
219224729|NCT05655949|DRUG|Gemcitabine|Intravenous infusion
219696864|NCT03276208|OTHER|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
219696865|NCT03276208|OTHER|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
219696866|NCT02059707|DEVICE|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
219696867|NCT01514916|DEVICE|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
219696868|NCT05805449|PROCEDURE|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
219696869|NCT05805449|OTHER|Platelet-rich plasma (PRP)|Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
219696870|NCT05805449|DEVICE|Matrix|"Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition."
219696871|NCT03805334|OTHER|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
219696872|NCT02016846|DRUG|Liraglutide|
219696873|NCT02016846|DRUG|Placebo|
219696874|NCT02732639|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
219696875|NCT02499588|DEVICE|Esteem Plus with ConvaTec Moldable Technology|
219696876|NCT02499588|DEVICE|Natura with ConvaTec Moldable Technology|
219110097|NCT02348853|BEHAVIORAL|Healthy Weight for Living (HWL)|
219110098|NCT02348853|BEHAVIORAL|Current Best Practice (CBP)|
219110099|NCT01613027|BIOLOGICAL|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
219110100|NCT05100719|DRUG|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
219110101|NCT05100719|DRUG|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
219110102|NCT03305224|DRUG|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
219224730|NCT05655949|DRUG|Cisplatin|Intravenous infusion
219696877|NCT02499588|DEVICE|Natura Accordion with ConvaTec Moldable Technology|
219696878|NCT02499588|DEVICE|Esteem synergy Plus with ConvaTec Moldable Technology|
219110103|NCT00993317|DRUG|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
219110104|NCT00993317|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
219110105|NCT00993317|DRUG|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
219110106|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 100|
219110107|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 300|
219110108|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 1000|
219110109|NCT02712593|OTHER|Placebo|
219110110|NCT05774405|DRUG|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
219110111|NCT05774405|OTHER|Hydrogel patch|Adhesive Hydrogel patch
219224731|NCT05655949|DRUG|Durvalumab|Intravenous infusion
219224732|NCT05655949|RADIATION|Yttrium-90|Injection of radiation microsphere beads
219110112|NCT06495255|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMOs)|HMOs will be applied as a neutral-flavoured powder
219110113|NCT06495255|DIETARY_SUPPLEMENT|Control|will be applied as powder
219110114|NCT02579018|BEHAVIORAL|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
219110115|NCT05024149|OTHER|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
219110116|NCT05892523|PROCEDURE|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
219110117|NCT00765427|DRUG|QLT091001|7-day repeated dose
219110118|NCT00350701|DRUG|androgel|androgel 5g
219110119|NCT00350701|DRUG|androgel 10g|androgel 10g
219110120|NCT00350701|DRUG|placebo|placebo
219110121|NCT03364439|DRUG|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
219110122|NCT05089058|BEHAVIORAL|Brief, digitally delivered imagery-competing task intervention package, comprised of:|"Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) task procedure: a memory cue followed by playing imagery-competing computer game task with mental rotation instructions. Monitoring of intrusive memories to select hotspot cue, and which intrusion to target.~(ii) accompanying information, including rationale for the brief cognitive task.~(iii) option to use the brief cognitive task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
219110123|NCT05089058|BEHAVIORAL|Brief, digitally delivered relaxation task intervention, comprised of:|"Brief, digitally delivered relaxation task intervention, comprised of:~Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) relaxation exercise task using instruction components from progressive muscle relaxation~(ii) accompanying information, including rationale for the brief relaxation exercise task.~(iii) option to use the brief relaxation exercise task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
219696879|NCT02987010|DRUG|IDH305|Isocitrate Dehydrogenase 1 inhibitor
219696880|NCT03387293|OTHER|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
219696881|NCT03387293|OTHER|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
219696882|NCT00116142|DRUG|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
219696883|NCT00116142|DRUG|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
219696884|NCT00116142|DRUG|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
219696885|NCT00644059|BIOLOGICAL|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
219696886|NCT00644059|BIOLOGICAL|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
219696887|NCT00644059|BIOLOGICAL|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections"
219696888|NCT02054780|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
219110124|NCT02424552|DRUG|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
219110125|NCT02424552|DRUG|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
219110126|NCT01168063|DRUG|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
219110127|NCT01168063|DRUG|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1\) PPI + Amoxicillin + Clarithromycin for 7 days~1\) PPI + Amoxicillin + Metronidazole for 14 days"
219110128|NCT04466423|BEHAVIORAL|Small group meetings (COMPASS: COlleagues Meeting to Promote And Sustain Satisfaction)|The first 15 minutes of each session will be semi-structured discussion involving i) check in and ii) dialogue about the assigned question. Group leaders will be provided 3-4 discussion questions for each session. The group (or the leader) can choose the one they are most interested in and will then spend 10-15 minutes discussing the question together. Questions will touch on key themes for discussion (see the attached topics list) and are derived from our previous intervention studies. The remainder of the time can be used for socializing and building relationships with colleagues.
219110129|NCT04003662|DEVICE|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
219110130|NCT02512510|DRUG|TD-4208|
219110131|NCT02512510|DRUG|Placebo|
219696889|NCT02054780|BEHAVIORAL|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
219696890|NCT01499485|DRUG|Acetazolamide|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
219696891|NCT01499485|DRUG|Placebo|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
219696892|NCT02431598|DRUG|gadoxetate disodium|
219696893|NCT02431598|DRUG|gadoterate dimeglumine|
219696894|NCT02431598|DRUG|Saline|
219696895|NCT05475639|OTHER|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
219696896|NCT05475639|OTHER|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
219696897|NCT05475639|OTHER|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
219696898|NCT02818504|OTHER|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
219696899|NCT00051701|DRUG|alemtuzumab|
219696900|NCT04081688|DRUG|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
219696901|NCT04081688|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
219110132|NCT01598974|PROCEDURE|Traditional Acupuncture|
219110133|NCT01598974|PROCEDURE|Laser Acupuncture|
219110134|NCT02569320|DRUG|Dexamethasone|Given PO
219110135|NCT02569320|DRUG|HDAC Inhibitor AR-42|Given PO
219110136|NCT02569320|OTHER|Laboratory Biomarker Analysis|Correlative studies
219696902|NCT04081688|DRUG|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
219696903|NCT02986776|BEHAVIORAL|Inpatient Care|21 days of inpatient substance misuse treatment
219696904|NCT02986776|BEHAVIORAL|Outpatient Care|21 days of outpatient substance misuse treatment
219696905|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
219110137|NCT02569320|DRUG|Pomalidomide|Given PO
219696906|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
219696907|NCT04023578|DEVICE|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
219696908|NCT02116868|DEVICE|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
219696909|NCT02116868|DRUG|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
219110138|NCT03587792|PROCEDURE|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
219110139|NCT00724425|DRUG|IPI-493|Capsules, Multiple Schedules
219110140|NCT02861391|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
219110141|NCT02861391|DEVICE|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
219110142|NCT00762684|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
219110143|NCT00762684|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
219110144|NCT05136911|BEHAVIORAL|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
219110145|NCT06240858|PROCEDURE|Laparoscopic transabdominal preperitoneal hernia repair.|The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.
219110146|NCT06240858|PROCEDURE|Lichtenstein hernia repair.|The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
219110147|NCT03856996|BIOLOGICAL|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
219110148|NCT03856996|BIOLOGICAL|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
219110149|NCT03856996|BIOLOGICAL|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
219110150|NCT04408027|BEHAVIORAL|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
219110151|NCT03411824|OTHER|no intervention|Non applicable
219110152|NCT02324023|DEVICE|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
219110153|NCT02646306|OTHER|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
219110154|NCT02582164|DEVICE|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
219110155|NCT04149041|DIAGNOSTIC_TEST|ultrasound|POCUS is applied to adult patients in an emergency department.
219110156|NCT02085837|OTHER|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
219110157|NCT02085837|OTHER|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
219110158|NCT02085837|OTHER|Universal Dietary education|To improve diet and health
219696910|NCT02116868|DRUG|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
219696911|NCT01023204|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
219696912|NCT06216418|DEVICE|BRFS-18G-S100WH|A facial tissue fixation material made of polydioxanone (PDO).
219696913|NCT06216418|DEVICE|MINT Lift FINE+|A facial tissue fixation material made of polydioxanone (PDO).
219696914|NCT06115655|DIAGNOSTIC_TEST|cfDNA methylation detection|Extract cfDNA from bile and plasma, and perform methylation detection.
219696915|NCT05024279|DEVICE|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
219696916|NCT05024279|DEVICE|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
219696917|NCT06429865|DIAGNOSTIC_TEST|cytosponge|Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
219696918|NCT00138528|DRUG|Fluvastatin|
219696919|NCT02455128|OTHER|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
219696920|NCT02662569|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219110159|NCT02085837|OTHER|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
219110160|NCT02085837|OTHER|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
219696921|NCT02662569|DRUG|Atorvastatin|Administered orally once a day
219696922|NCT02662569|OTHER|Placebo|Placebo to evolocumab administered by subcutaneous injection
219696923|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
219696924|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
219696925|NCT04324749|OTHER|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
219696926|NCT04324749|OTHER|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
219110161|NCT02085837|OTHER|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
219110162|NCT02340520|DRUG|Theophylline|Oral
219110163|NCT02340520|DRUG|Roflumilast|Oral
219110164|NCT03259282|BIOLOGICAL|Analysis of gamma globulin|Electrophoresis of proteins
219110165|NCT01464255|DEVICE|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
219696927|NCT04324749|OTHER|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
219696928|NCT03846934|DEVICE|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
219696929|NCT03129932|DIETARY_SUPPLEMENT|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
219696930|NCT03129932|DIETARY_SUPPLEMENT|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
219696931|NCT00984412|PROCEDURE|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
219696932|NCT02347046|DRUG|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
219696933|NCT00305162|DRUG|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
219110166|NCT01464255|DEVICE|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
219110167|NCT01918319|BEHAVIORAL|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
219110168|NCT05174104|PROCEDURE|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
219696934|NCT00305162|DRUG|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
219696935|NCT00305162|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
219110169|NCT01231503|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=\<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =\< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
219110170|NCT01231503|BIOLOGICAL|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
219110171|NCT01231503|BIOLOGICAL|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
219696936|NCT00305162|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
219696937|NCT00305162|DRUG|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
219696938|NCT02679664|DRUG|Rosuvastatin|20 mg tablet of rosuvastatin
219696939|NCT05719168|DEVICE|Body Surface Gastric Mapping|64-channel electrode array placed on the outer abdomen
219696940|NCT05265702|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
219696941|NCT01787552|DRUG|LDE225|
219110172|NCT01231503|BIOLOGICAL|BCG|1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)
219110173|NCT01231503|BIOLOGICAL|OPV|4 doses, orally, at birth (=\< 7 days of age) and at 6, 10 and 14 weeks of age
219696942|NCT01787552|DRUG|INC424|
219110174|NCT01231503|BIOLOGICAL|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
219110175|NCT02552433|DIETARY_SUPPLEMENT|protein intake assessment and optimisation|
219110176|NCT03126032|OTHER|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
219110177|NCT05276323|DRUG|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
219110178|NCT05276323|DRUG|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
219110179|NCT01586338|DRUG|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
219110180|NCT03803020|OTHER|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
219110181|NCT00284089|DRUG|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
219110182|NCT01146574|BIOLOGICAL|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
219110183|NCT01146574|BIOLOGICAL|Placebo|Placebo
219110184|NCT04237974|DEVICE|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
219110185|NCT03942874|BEHAVIORAL|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
219696943|NCT04053582|BEHAVIORAL|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
219696944|NCT04053582|BEHAVIORAL|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
219696945|NCT04703413|DEVICE|LoFric® OrigoTM and LoFric® SenseTM|The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
219696946|NCT01556217|DRUG|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
219696947|NCT01556217|DRUG|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
219696948|NCT04174066|OTHER|blood sample|blood sample during planned in the follow-up of patients.
219696949|NCT04174066|OTHER|tissue sample|tissue sample during planned in the follow-up of patients.
219696950|NCT04174066|OTHER|excreta|urine sample during planned in the follow-up of patients.
219696951|NCT00400244|PROCEDURE|Wheelchair skills traing program|
219696952|NCT06095908|DRUG|Bupivacain|Bupivacain administered with two different ways to the patients, postoperative pain recorded
219110186|NCT05926128|DRUG|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
219110187|NCT03051659|DRUG|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
219110188|NCT03051659|DRUG|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
219110189|NCT01604811|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
219110190|NCT01604811|DRUG|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
219110191|NCT01604811|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
219110192|NCT01604811|DRUG|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
219110193|NCT02055573|OTHER|Ready To Learn (RTL)|See arm description
219110194|NCT02055573|OTHER|All Babies Cry (ABC)|See arm description
219110195|NCT03535051|DEVICE|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
219110196|NCT03535051|DRUG|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
219110197|NCT06141304|DRUG|Plerixafor|Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
219110198|NCT01076088|DRUG|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
219696953|NCT03423069|DIETARY_SUPPLEMENT|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
219696954|NCT03423069|DIETARY_SUPPLEMENT|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
219696955|NCT05198141|DRUG|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
219696956|NCT05198141|PROCEDURE|laparoscopic salpingectomy|laparoscopic salpingectomy
219696957|NCT02005107|DRUG|Venlafaxine IR and Venlafaxine XR|
219696958|NCT00282217|DRUG|Sirolimus|
219696959|NCT01932385|DRUG|Sorafenib|
219696960|NCT01932385|OTHER|Best Supportive Care|
219110199|NCT01076088|DRUG|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
219110200|NCT01076088|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
219110201|NCT01076088|DRUG|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
219110202|NCT01076088|DRUG|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
219696961|NCT02425306|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219696962|NCT02425306|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
219110203|NCT05818059|DIAGNOSTIC_TEST|Diagnosis of Tuberculosis with computer-aided detection (CAD) software|"After enrolment, each subject will be assessed according to ARM 1 (assessment by clinician #1 without CAD) or ARM 2 (assessment by clinician #1 with CAD). Allocation to sequence ARM 1 or ARM 2 will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."
219110204|NCT03053492|DEVICE|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
219110205|NCT03053492|BEHAVIORAL|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
219110206|NCT00786474|DRUG|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
219110207|NCT00786474|DRUG|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
219696963|NCT02425306|DRUG|polyICLC|polyICLC, local adjuvant
219696964|NCT02425306|DRUG|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
219696965|NCT06170710|DRUG|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
219696966|NCT06170710|OTHER|Postoperative CCRT|Postoperative chemoradiotherapy
219696967|NCT02978469|OTHER|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
219696968|NCT04023201|OTHER|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
219696969|NCT00838071|DRUG|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
219696970|NCT02295644|DEVICE|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
219696971|NCT01380366|DRUG|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
219696972|NCT01380366|PROCEDURE|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
219696973|NCT01380366|PROCEDURE|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
219696974|NCT01380366|OTHER|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
219696975|NCT01380366|OTHER|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
219696976|NCT01380366|OTHER|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
219696977|NCT01108939|DRUG|Antimalarial treatment|
219696978|NCT01108939|OTHER|Observation|
219696979|NCT00121004|BEHAVIORAL|Advance Directive Selection|
219696980|NCT00003819|BIOLOGICAL|QS21|
219696981|NCT00003819|BIOLOGICAL|TF(c)-KLH conjugate vaccine|
219696982|NCT00003819|BIOLOGICAL|Thomsen-Friedenreich antigen|
219696983|NCT00003819|BIOLOGICAL|keyhole limpet hemocyanin|
219696984|NCT03945513|DRUG|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
219696985|NCT02108301|DRUG|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
219696986|NCT01075776|DRUG|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
219696987|NCT01075776|DRUG|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
219696988|NCT01075776|DRUG|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
219696989|NCT00650962|OTHER|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
219110208|NCT04851860|DRUG|sublingual immunotherapy|sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
219110209|NCT00004399|DRUG|magnesium sulfate|
219110210|NCT00004399|DRUG|nimodipine|
219110211|NCT01868074|DEVICE|Insole|Custom-molded arch-supporting insole
219696990|NCT00650962|OTHER|Rhythm analysis|Rhythm analysis as soon as AED is ready
219696991|NCT04079790|DRUG|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
219110212|NCT02663375|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
219110213|NCT00029575|DEVICE|Surgi-Vision Guidewire Coil|
219224733|NCT05908773|DRUG|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
219110214|NCT02378064|DRUG|6-month treatment|
219110215|NCT06425978|DRUG|Cellular Matrix / A-CP-HA Kit|"For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina."
219696992|NCT04079790|DRUG|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
219696993|NCT02204189|DRUG|TongFuSan|TongFuSan 1g
219696994|NCT00324155|DRUG|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
219696995|NCT00324155|DRUG|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
219696996|NCT00324155|DRUG|Dacarbazine|Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
219696997|NCT05964062|DEVICE|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219696998|NCT05964062|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219696999|NCT02531685|OTHER|Placebo|Placebo: 0.9% Sodium Chloride injection.
219697000|NCT02531685|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
219697001|NCT00390689|DRUG|Pramipexole 0.125 mg tablet|
219697002|NCT00390689|DRUG|Pramipexole 0.5 mg tablet|
219697003|NCT04817878|COMBINATION_PRODUCT|Developmental assessment|Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
219697004|NCT04397978|RADIATION|Stereotactic radiotherapy|Local ablative therapy with SRT
219697005|NCT01253161|DRUG|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
219697006|NCT00113477|DRUG|Q10|
219697007|NCT00113477|DRUG|Selen|
219697008|NCT02768987|BEHAVIORAL|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
219697009|NCT03871556|DIAGNOSTIC_TEST|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
219224734|NCT04380805|BIOLOGICAL|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
219224735|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
219224736|NCT02294461|DRUG|Enzalutamide|Oral
219224737|NCT02294461|DRUG|Placebo|Oral
219697010|NCT05976789|DEVICE|Sound therapy using low-level background sound|"This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief."
219697011|NCT05976789|BEHAVIORAL|Remote counseling using HAT-Online|This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
219697012|NCT05976789|OTHER|Sound therapy using successive approximations|This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
219697013|NCT01924533|DRUG|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
219697014|NCT01924533|DRUG|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
219697015|NCT01924533|DRUG|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
219697016|NCT01310283|OTHER|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
219697017|NCT00417066|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
219697018|NCT00417066|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
219697019|NCT02747927|DRUG|Placebo|TDV placebo-matching SC injection.
219697020|NCT02747927|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
219697021|NCT00017251|BIOLOGICAL|oblimersen sodium|Given IV
219697022|NCT00017251|DRUG|carboplatin|Given IV
219697023|NCT00017251|DRUG|etoposide|Given IV
219697024|NCT00017251|OTHER|pharmacological study|Correlative studies
219697025|NCT00017251|OTHER|laboratory biomarker analysis|Correlative studies
219110216|NCT06425978|DRUG|Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)|Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
219110217|NCT03835637|DRUG|ORIC-101|Capsule or oral suspension
219110218|NCT04574154|PROCEDURE|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
219110219|NCT04574154|PROCEDURE|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
219110220|NCT04574154|PROCEDURE|spinal anesthesia|bupivacaine 0,5% 2.2 ml
219110221|NCT00334425|DRUG|MENOPUR; GONAL-F|
219110222|NCT00492804|PROCEDURE|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
219110223|NCT00492804|PROCEDURE|Neurectomy|Neurectomy
219110224|NCT01544491|DRUG|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
219110225|NCT01544491|DRUG|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
219110226|NCT03982888|PROCEDURE|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
219110227|NCT03982888|DEVICE|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
219110228|NCT02521324|DEVICE|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
219110229|NCT01763528|OTHER|nutrition intervention|high protein diet
219110230|NCT01501422|DRUG|Estrogen patch|50 microgram estrogen patch weekly
219110231|NCT01501422|DRUG|Placebo|Placebo patch for 8 weeks
219110232|NCT05592535|PROCEDURE|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
219110233|NCT05344989|DRUG|APNmAb005|Administered by IV infusion
219110234|NCT05344989|DRUG|Placebo|Administered by IV infusion
219110235|NCT02290717|DEVICE|Fractional CO2 laser|
219110236|NCT02290717|OTHER|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
219110237|NCT02290717|DRUG|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
219110238|NCT06083103|DIAGNOSTIC_TEST|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
219110239|NCT00160160|DRUG|eprosartan/HCTZ|
219110240|NCT05130788|BEHAVIORAL|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (\<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
219110241|NCT05130788|BEHAVIORAL|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
219110242|NCT05130788|DRUG|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
219110243|NCT01428804|DEVICE|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
219110244|NCT05754138|DEVICE|Sport SICD|Follow up
219110245|NCT00967018|DRUG|Degarelix|
219110246|NCT03897205|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
219110247|NCT03897205|OTHER|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
219110248|NCT00857441|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
219110249|NCT00857441|DEVICE|Liberté|Bare metal stent
219110250|NCT00857441|DEVICE|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
219110251|NCT00857441|DEVICE|Taxus|Paclitaxel eluting stent
219110252|NCT05364918|DRUG|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
219110253|NCT05515718|OTHER|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
219110254|NCT05515718|OTHER|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
219110255|NCT03268460|DIAGNOSTIC_TEST|Arterial blood gases|blood PH, HCO3
219110256|NCT03268460|DIAGNOSTIC_TEST|Blood anion gap|(Na+) - (Cl- + HCO3-)
219110257|NCT03268460|DIAGNOSTIC_TEST|serum electrolytes|Na+ , K+ , Cl- and calcium
219697026|NCT05363228|BEHAVIORAL|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
219697027|NCT05363228|BEHAVIORAL|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
219697028|NCT05246254|DIAGNOSTIC_TEST|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
219697029|NCT05677399|OTHER|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
219697030|NCT06369636|PROCEDURE|Thyroid Surgery|EGRI scores and airway ultrasonographic values will be recorded in patients who undergo thyroid surgery.
219697031|NCT05412134|DEVICE|Pro2 - 75% of participant's MIP|"Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
219697032|NCT05412134|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
219697033|NCT05720403|OTHER|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
219697034|NCT02928484|DIETARY_SUPPLEMENT|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
219697035|NCT02928484|DIETARY_SUPPLEMENT|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
219697036|NCT03120611|OTHER|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
219110258|NCT03268460|DIAGNOSTIC_TEST|renal function test|blood urea and serum creatinine
219110259|NCT03268460|DIAGNOSTIC_TEST|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
219110260|NCT01272882|DEVICE|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
219110261|NCT01454180|DRUG|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
219697037|NCT03120611|OTHER|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
219697038|NCT03072186|DEVICE|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
219697039|NCT01482559|DRUG|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
219697040|NCT01482559|DRUG|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
219697041|NCT00915174|DRUG|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
219697042|NCT06312982|DRUG|Tislelizumab|Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
219110262|NCT01454180|DRUG|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
219110263|NCT02646111|DRUG|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
219110264|NCT02646111|DRUG|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
219697043|NCT06523179|OTHER|quantify the impact of genetic risk factors|the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
219697044|NCT04643886|DRUG|GEM103|Biological
219697045|NCT01339065|DRUG|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
219697046|NCT01441986|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
219697047|NCT01441986|DRUG|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
219697048|NCT01441986|DRUG|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
219697049|NCT01441986|DRUG|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
219697050|NCT01549158|DRUG|torasemide-PR|Single oral dose of torasemide PR 10 mg
219697051|NCT01549158|DRUG|Furosemide-IR|Single oral dose of furosemide IR 40 mg
219697052|NCT01549158|DRUG|torasemide-IR|Single oral dose of torasemide IR 10 mg
219697053|NCT02332265|OTHER|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
219697054|NCT02390232|BIOLOGICAL|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
219697055|NCT02390232|BIOLOGICAL|collection of stools|collection of stools
219697056|NCT02390232|BIOLOGICAL|blood sample|collection of blood sample
219697057|NCT05512117|DEVICE|Midline insertion|Midline catheter insertion
219697058|NCT00971113|DIETARY_SUPPLEMENT|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
219110265|NCT02646111|DRUG|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
219697059|NCT03691636|DEVICE|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
219697060|NCT03691636|DEVICE|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
219110266|NCT03739320|DRUG|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
219110267|NCT00820820|BIOLOGICAL|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (\>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
219110268|NCT00820820|BIOLOGICAL|placebo|Vehicle (water for injection), 0.5 ml, once
219110269|NCT03414697|OTHER|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
219110270|NCT03414697|PROCEDURE|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
219697061|NCT04275336|DRUG|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
219697062|NCT04275336|BEHAVIORAL|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
219697063|NCT04275336|OTHER|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
219697064|NCT05017844|DRUG|KSR-001-04|One drop to both eyes four times a day for 12 weeks
219697065|NCT05017844|DRUG|KSR-001-02|One drop to both eyes four times a day for 12 weeks
219697066|NCT05017844|DRUG|KSR-001-03|One drop to both eyes four times a day for 12 weeks
219110271|NCT05214014|BIOLOGICAL|Autologous Regulatory Т-cells|Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
219110272|NCT05214014|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Systemic Sclerosis according to the clinical protocols
219110273|NCT00002720|DRUG|tamoxifen citrate|
219110274|NCT00002720|PROCEDURE|conventional surgery|
219110275|NCT02904109|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
219110276|NCT02904109|DRUG|Placebo|Once daily oral administration of placebo mannitol for 8 days.
219110277|NCT02112058|BEHAVIORAL|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
219110278|NCT00580229|DRUG|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
219110279|NCT02394899|BEHAVIORAL|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
219110280|NCT02394899|OTHER|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
219110281|NCT01839968|OTHER|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
219110282|NCT00301002|DRUG|Alefacept|
219110283|NCT06237374|BEHAVIORAL|Digital Vaccine Education Training & Patient-facing Chatbot Tool|The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
219110284|NCT06237374|BEHAVIORAL|Standard Training|All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
219110285|NCT04642469|DRUG|Durvalumab|Intravenous administration of Durvalumab
219110286|NCT04642469|OTHER|Placebo|Placebo Comparator
219110287|NCT01429506|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
219110288|NCT01429506|DRUG|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
219110289|NCT02359591|OTHER|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
219110290|NCT04131959|DEVICE|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
219110291|NCT04924140|DRUG|Aducanumab|Administered as specified in the treatment arm
219110292|NCT02767700|GENETIC|NGS|Next generation sequencing
219110293|NCT02773706|OTHER|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
219110294|NCT02773706|OTHER|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
219110295|NCT04658732|DRUG|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
219110296|NCT05592080|RADIATION|MRI|MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
219110297|NCT01355874|DRUG|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
219110298|NCT01355874|DRUG|Placebo|Placebo ointment BID for 14 days during double blind.
219110299|NCT01355874|DRUG|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
219110300|NCT00719303|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary intervention
219110301|NCT00719303|BEHAVIORAL|Compliance Monitoring|Complete daily fat gram and step diaries
219110302|NCT00719303|OTHER|Counseling|Undergo face-to-face and telephone counseling
219110303|NCT00719303|OTHER|Educational Intervention|Receive educational materials
219697067|NCT05484830|PROCEDURE|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
219110304|NCT00719303|BEHAVIORAL|Exercise Intervention|Undergo physical activity intervention
219110305|NCT00719303|OTHER|Laboratory Biomarker Analysis|Correlative studies
219110306|NCT00719303|OTHER|Quality-of-Life Assessment|Ancillary studies
219110307|NCT00719303|OTHER|Questionnaire Administration|Ancillary studies
219110308|NCT02228525|DRUG|selinexor (KPT-330)|
219110309|NCT00680056|DRUG|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
219224738|NCT05326646|DIETARY_SUPPLEMENT|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
219697068|NCT05484830|PROCEDURE|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.)."
219697069|NCT06014177|BEHAVIORAL|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
219697070|NCT06014177|OTHER|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
219697071|NCT03055936|DRUG|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
219697072|NCT03055936|DRUG|Carbidopa|Carbidopa 12.5 mg or 25 mg or 65 mg
219697073|NCT03055936|DRUG|ODM-104|ODM-104 50 mg or 100 mg
219697074|NCT04664205|OTHER|High Intensity Interval Exercise|One session of high intensity interval exercise
219697075|NCT04664205|OTHER|Moderate Intensity Continuous Exercise|One session of calorically matched moderate intensity exercise
219697076|NCT04664205|OTHER|Control|No exercise, resting measures
219697077|NCT00128128|DRUG|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
219697078|NCT04059718|BEHAVIORAL|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
219697079|NCT01464567|PROCEDURE|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
219697080|NCT01464567|PROCEDURE|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
219224739|NCT03508232|DRUG|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
219224740|NCT03508232|DRUG|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
219697081|NCT02125240|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
219697082|NCT02125240|DRUG|Placebo|1 tablet three times daily by mouth
219697083|NCT01203696|DRUG|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
219697084|NCT01203696|DRUG|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
219697085|NCT02552927|DEVICE|Chest shield with aluminum foil (CALF)|
219697086|NCT02552927|DEVICE|SHIELD|
219697087|NCT04547400|OTHER|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
219110310|NCT00680056|DRUG|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
219110311|NCT03333174|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
219110312|NCT05522920|OTHER|Therapy with and without spinal cord stimulation|Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
219110313|NCT02733042|DRUG|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
219110314|NCT02733042|DRUG|Lenalidomide|Administered orally
219110315|NCT02733042|DRUG|Rituximab|Administered by intravenous infusion
219110316|NCT02733042|DRUG|Ibrutinib|Administered orally
219110317|NCT02733042|DRUG|Bendamustine|Administered as a 30-minute intravenous infusion
219110318|NCT00403975|DRUG|diquafosol tetrasodium ophthalmic solution, 2%|
219110319|NCT03489005|DRUG|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"
219110320|NCT03489005|DRUG|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~\- placebo, as 12 × 0-mg tablets"
219697088|NCT03886909|BEHAVIORAL|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
219697089|NCT03886909|BEHAVIORAL|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
219697090|NCT02542969|DRUG|Simvastatin|
219697091|NCT02542969|DRUG|Rosuvastatin|
219697092|NCT02542969|DRUG|MGL-3196|
219697093|NCT05143424|DRUG|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
219110321|NCT03489005|DRUG|Moxifloxacin 400 mg|"Administered as follows:~\- 400 mg moxifloxacin, as 1 × 400-mg tablet"
219110322|NCT00823732|OTHER|educational intervention|Undergo individualized interdisciplinary palliative care intervention
219110323|NCT00823732|OTHER|medical chart review|Ancillary studies
219110324|NCT00823732|OTHER|questionnaire administration|Ancillary studies
219110325|NCT00823732|PROCEDURE|end-of-life treatment/management|Undergo end-of-life treatment/management
219110326|NCT00823732|PROCEDURE|psychosocial assessment and care|Undergo psychosocial assessment and care
219110327|NCT00823732|PROCEDURE|quality-of-life assessment|Ancillary studies
219110328|NCT00823732|PROCEDURE|management of therapy complications|Undergo management of therapy complications
219110329|NCT00823732|PROCEDURE|assessment of therapy complications|Undergo assessment of therapy complications
219697094|NCT01494207|BEHAVIORAL|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
219697095|NCT05024383|OTHER|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
219697096|NCT05024383|OTHER|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
219697097|NCT05233813|BEHAVIORAL|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
219697098|NCT00748202|DRUG|C1-Esterase Inhibitor|1000 I.E.
219697099|NCT03639168|DRUG|Chidamide combined with cisplatin|Chidamide combined with cisplatin
219697100|NCT03113045|OTHER|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
219697101|NCT00049816|BEHAVIORAL|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
219697102|NCT00049816|BEHAVIORAL|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
219110330|NCT05047796|OTHER|Intervention Protocol|The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
219697103|NCT05516303|GENETIC|Genetic polymorphism|One blood tube will be taken for genetic testing
219110331|NCT05047796|OTHER|Sham Protocol|The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
219697104|NCT05516303|DIAGNOSTIC_TEST|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
219697105|NCT01836237|DEVICE|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
219697106|NCT00709189|DRUG|Norgestimate/Ehinyl Estradiol; Folic acid.|
219110332|NCT04763135|DRUG|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
219110333|NCT04763135|DRUG|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
219110334|NCT06058871|BEHAVIORAL|Regular messages|The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
219697107|NCT02073786|DEVICE|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
219110335|NCT06058871|BEHAVIORAL|Nurse-led real-time support messages (chat type)|The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
219697108|NCT02073786|DEVICE|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
219697109|NCT04119648|BEHAVIORAL|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
219697110|NCT01105052|BEHAVIORAL|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
219697111|NCT02709317|BEHAVIORAL|Prevention Intervention|
219697112|NCT02709317|BEHAVIORAL|Brief Intervention|
219697113|NCT02716740|DIETARY_SUPPLEMENT|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
219110336|NCT03522987|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
219110337|NCT01673360|DEVICE|Elevate PC|List of AMS prolapse products
219110338|NCT01673360|DEVICE|Mini Arc Pro|List of AMS Urinary Incontinence devices
219697114|NCT00637013|PROCEDURE|Acromioplasty|Arthroscopic or open acromioplasty
219697115|NCT00637013|PROCEDURE|Physiotherapy|Physiotherapy according to a standardized protocol
219697116|NCT02629978|PROCEDURE|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
219110339|NCT01673360|DEVICE|RetroArc|List of AMS Urinary Incontinence devices
219110340|NCT03957135|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
219110341|NCT03957135|PROCEDURE|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
219697117|NCT04550299|OTHER|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
219110342|NCT02595177|PROCEDURE|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
219110343|NCT06233123|BEHAVIORAL|the Medisafe android application (https://www.medisafe.com).|software for Android mobile phones that can remind the patient of his treatment on time
219110344|NCT05372887|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
219110345|NCT05372887|DRUG|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
219110346|NCT01264029|BEHAVIORAL|Mindful Tai Chi Intervention|
219110347|NCT01264029|BEHAVIORAL|Mindfulness Meditation|
219110348|NCT01264029|BEHAVIORAL|Mall Walking|
219110349|NCT01264029|BEHAVIORAL|Weekly Discussion|
219110350|NCT06231290|OTHER|Adult full pulpotomy procedure|The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
219697118|NCT06050681|BEHAVIORAL|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 \& 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
219697119|NCT02910232|DEVICE|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
219697120|NCT03153670|OTHER|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
219697121|NCT05720819|DEVICE|Combined biofeedback-virtual reality device|The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
219697122|NCT01498302|OTHER|diagnostic laboratory biomarker analysis|
219697123|NCT01498302|OTHER|flow cytometry|
219697124|NCT00599560|GENETIC|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
219697125|NCT01963468|BEHAVIORAL|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
219697126|NCT01578772|DRUG|Telmisartan|80mg tablets po daily for 6 weeks
219697127|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
219697128|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
219697129|NCT00705419|DRUG|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
219697130|NCT00705419|DRUG|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
219697131|NCT02457975|DEVICE|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
219110351|NCT05244590|OTHER|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
219110352|NCT00802828|DRUG|Famotidine Tablets, 40 mg|
219110353|NCT05273086|BEHAVIORAL|Sleep Intervention Group|"The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system."
219110354|NCT03432949|DRUG|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
219110355|NCT04412252|DRUG|Tofacitinib|10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
219110356|NCT04412252|OTHER|Placebo|Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
219110357|NCT05975437|OTHER|personalized surveillance plans (PSP) and personalized aftercare plans (PAP)|The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
219110358|NCT01821898|DRUG|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
219110359|NCT01821898|OTHER|Elimination diet|This group will receive an elimination diet
219110360|NCT05067946|BIOLOGICAL|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
219110361|NCT05067946|OTHER|Placebo|GX-19N formulation buffer
219110362|NCT01967264|DRUG|Udenafil|Udenafil tablets
219110363|NCT01967264|DRUG|Placebo|Placebo tablets
219697132|NCT02457975|DRUG|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
219697133|NCT00423046|BIOLOGICAL|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
219697134|NCT00423046|BIOLOGICAL|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
219697135|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
219697136|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
219697137|NCT01909804|DRUG|SOF|400 mg tablet administered orally once daily
219697138|NCT01909804|DRUG|VEL|Tablet administered orally once daily
219697139|NCT01909804|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219697140|NCT04182958|DRUG|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
219697141|NCT03432481|PROCEDURE|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
219697142|NCT03432481|DEVICE|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
219697143|NCT03292510|OTHER|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
219697144|NCT03292510|OTHER|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
219110364|NCT04976595|DRUG|Natesto|Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
219110365|NCT03016117|PROCEDURE|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
219110366|NCT04587531|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
219697145|NCT03487770|DRUG|Aripiprazole Oral Solution|Aripiprazole 2\~15 mg/day (2\~15 mL/day)
219697146|NCT03487770|DRUG|Placebo Oral Solution|Placebo 2\~15 mg/day (2\~15 mL/day)
219697147|NCT03776448|DIETARY_SUPPLEMENT|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
219697148|NCT03776448|DIETARY_SUPPLEMENT|Activated Charcoal Softgels|This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
219697149|NCT00830128|DRUG|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
219697150|NCT05401565|DRUG|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
219697151|NCT05401565|DRUG|Placebo|Matching placebo
219697152|NCT04463134|DRUG|NTM drug treatment|NTM drug treatment according to guideline and sensitivity test results
219110367|NCT03772106|DRUG|Propofol Fresenius|Propolipid 1% : IV
219110368|NCT03772106|DRUG|sevorane|sevorane Quick fill (sevoflurane) : inhalation
219110369|NCT04133428|DRUG|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
219697153|NCT01572402|OTHER|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
219110370|NCT05451511|OTHER|Door-In-The-Face Technique|Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.
219110371|NCT05451511|OTHER|Foot-In-The-Door Technique|Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
219110372|NCT04540484|OTHER|Screening|Blood test screening for covid
219110373|NCT05753423|DIAGNOSTIC_TEST|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
219110374|NCT02817620|DIETARY_SUPPLEMENT|Spirulysat®|
219110375|NCT02817620|DIETARY_SUPPLEMENT|Placebo|
219110376|NCT05177731|DRUG|Venetoclax|Orally by mouth
219110377|NCT05177731|DRUG|Decitabine for Injection|Intravenous infusion
219110378|NCT05177731|DRUG|Cytarabine|Intravenous infusion
219110379|NCT05177731|DRUG|Idarubicin|Intravenous infusion
219110380|NCT05177731|DRUG|Gilteritinib|Orally by mouth
219110381|NCT02917577|BIOLOGICAL|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
219697154|NCT01572402|OTHER|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
219697155|NCT01572402|OTHER|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
219697156|NCT05690880|DEVICE|Foresee Home|The ForeseeHome Monitoring System, a non-significant risk device, is prescribed by eye care providers to patients as part of their clinical care. Notal Vision Monitoring Center (NVMC) is an independent diagnostic testing facility responsible for clinical monitoring of FSH data. The NVMC communicates with the patients (for training on the use of the device, troubleshooting of device issues, adherence monitoring, etc.) and with the patients' eyecare providers (for reporting FSH alerts, monitoring of clinical outcomes to assess device functionality and ongoing need for the device, etc.).
219110382|NCT02917577|BIOLOGICAL|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
219110383|NCT04938115|BIOLOGICAL|CD7 CART|Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
219697157|NCT02886923|DEVICE|Hioxifilcon A Test|contact lens made with hioxifilcon A material
219697158|NCT02886923|DEVICE|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
219697159|NCT01201642|DRUG|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
219697160|NCT01201642|DEVICE|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
219697161|NCT01201642|OTHER|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
219697162|NCT00260988|DRUG|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
219110384|NCT05171868|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Each participant in the intervention group will receive 8 individual, weekly EMDR sessions over 8 weeks. Each session will take approximately 60-90 minutes. The sessions will be delivered at a place convenient to the participant. Trained EMDR therapists will deliver the intervention.
219110385|NCT02222519|DRUG|Rocuronium|Rocuronium 0.6mg/kg iv single dose
219110386|NCT03696875|OTHER|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
219110387|NCT03696875|OTHER|Standard of care|Standard of care
219110388|NCT01424059|OTHER|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
219110389|NCT04882761|DEVICE|Dental implant|Comparative
219110390|NCT04980768|PROCEDURE|Root canal treatment|Patients with apical periodontitis will undergo root canal treatment.
219110391|NCT05410236|OTHER|3D bronchial tree model|A detachable 3D printed bronchial tree model
219110392|NCT03511872|OTHER|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
219110393|NCT00662493|BEHAVIORAL|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
219697163|NCT00260988|DRUG|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
219697164|NCT02461537|DRUG|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
219110394|NCT00662493|BEHAVIORAL|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
219110395|NCT03656731|OTHER|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session."
219110396|NCT05321706|DRUG|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
219110397|NCT05321706|DRUG|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
219110398|NCT02631421|PROCEDURE|Blood Sampling|
219110399|NCT02631421|OTHER|Cardiac MRI|
219110400|NCT00002502|DRUG|busulfan|
219110401|NCT00002502|DRUG|cyclophosphamide|
219110402|NCT00002502|DRUG|cytarabine|
219110403|NCT00002502|PROCEDURE|allogeneic bone marrow transplantation|
219697165|NCT02461537|DRUG|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
219110404|NCT03383003|DRUG|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
219110405|NCT03383003|DRUG|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
219110406|NCT03383003|DRUG|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
219110407|NCT03383003|DRUG|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
219110408|NCT02481843|OTHER|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
219110409|NCT02011425|DEVICE|mandibular advancement appliance|mandibular advancement appliance
219110410|NCT04011332|OTHER|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
219110411|NCT00337662|DRUG|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
219110412|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, for 10 weeks.
219110413|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, 10 weeks
219110414|NCT00073385|DRUG|Pivanex|
219110415|NCT00073385|DRUG|Docetaxel|
219110416|NCT03949088|OTHER|UF and Na profiling|Modulation of UF and dialysate sodium
219110417|NCT00132379|DRUG|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
219110418|NCT00132379|DRUG|docetaxel|75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
219110419|NCT06329674|DRUG|AJU-A51|Subjects take the investigational products once a day for 24 weeks.
219110420|NCT06329674|DRUG|A51R2|Subjects take the investigational products once a day for 24 weeks.
219110421|NCT06329674|DRUG|A51R3|Subjects take the investigational products once a day for 24 weeks.
219110422|NCT06329674|DRUG|AJU-A51 Placebo|Subjects take the investigational products once a day for 24 weeks.
219110423|NCT06329674|DRUG|A51R2 Placebo|Subjects take the investigational products once a day for 24 weeks.
219110424|NCT00410787|DRUG|OROS hydromorphone HCI (slow release)|
219110425|NCT00994773|DRUG|Simvastatin|daily doses for 14 days
219110426|NCT00994773|DRUG|Tenofovir|
219110427|NCT00994773|DRUG|Entecavir|Entecavir
219110428|NCT03402880|BIOLOGICAL|Pembrolizumab|Given IV
219110429|NCT03402880|DRUG|Epacadostat|Given PO
219110430|NCT03402880|OTHER|Laboratory Biomarker Analysis|Correlative studies
219110431|NCT02173730|DRUG|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
219110432|NCT02173730|DRUG|Pantoprazole|Pantoprazole tablet 40 mg
219697166|NCT01560247|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
219697167|NCT04829071|BEHAVIORAL|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
219697168|NCT04829071|BEHAVIORAL|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
219697169|NCT02862301|BIOLOGICAL|blood sample|
219697170|NCT00726609|DRUG|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
219110433|NCT03691948|OTHER|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
219697171|NCT03444558|DIETARY_SUPPLEMENT|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
219697172|NCT03444558|OTHER|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
219697173|NCT02405819|OTHER|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
219697174|NCT02405819|OTHER|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
219697175|NCT04415346|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
219697176|NCT06180057|DRUG|Chenodeoxycholic acid|Two capsules were administered orally
219697177|NCT06180057|DRUG|Chenodeoxycholic acid leadiant|Two capsules were administered orally
219697178|NCT05143463|DRUG|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
219697179|NCT02183363|DRUG|BI 1356 - Tablet TFII|
219697180|NCT02183363|DRUG|BI 1356 - Tablet iFF|
219697181|NCT02183363|DRUG|BI 1356 - Tablet TFIIb|
219697182|NCT06454786|OTHER|Simulation Method|Management of cardiogenic shock scenario on an advanced simulation mannequin
219697183|NCT00808340|DEVICE|balafilcon A|multifocal contact lens
219697184|NCT00808340|DEVICE|senofilcon A production|multifocal contact lens
219697185|NCT00808340|DEVICE|senofilcon A test|multifocal contact lens
219110434|NCT03691948|OTHER|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
219110435|NCT01381952|RADIATION|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
219697186|NCT05939908|OTHER|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
219697187|NCT02402374|DEVICE|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
219697188|NCT02402374|DEVICE|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
219110436|NCT01381952|RADIATION|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
219697189|NCT06516120|BEHAVIORAL|RGS-app|Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
219697190|NCT03617887|OTHER|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
219697191|NCT03617887|OTHER|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
219697192|NCT02622243|DRUG|Tiotropium|long acting muscarinic antagonist
219697193|NCT02622243|DRUG|glycopyrronium|long acting muscarinic antagonist
219697194|NCT02622243|DEVICE|Respimat|inhaler device used to deliver active tiotropium or placebo
219697195|NCT02622243|DEVICE|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
219697196|NCT01516138|DRUG|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
219697197|NCT01516138|DRUG|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
219110437|NCT04795817|DEVICE|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
219110438|NCT04325464|DEVICE|PEAR-003A|PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
219110439|NCT02478125|DRUG|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
219110440|NCT02478125|DRUG|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
219110441|NCT02478125|DRUG|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
219110442|NCT02344537|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
219110443|NCT01031472|DRUG|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
219110444|NCT01031472|DRUG|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
219110445|NCT01031472|DRUG|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
219110446|NCT01031472|DRUG|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
219110447|NCT05877300|COMBINATION_PRODUCT|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
219110448|NCT01494714|DRUG|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
219110449|NCT01494714|DRUG|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
219697198|NCT00909168|DRUG|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
219697199|NCT01394289|BIOLOGICAL|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
219697200|NCT01007799|DIETARY_SUPPLEMENT|vitamin D placebo|12 weeks of placebo
219697201|NCT01007799|DIETARY_SUPPLEMENT|Vitamin D|12 weeks supplementation based on serum vitamin D levels
219110450|NCT01494714|DRUG|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
219110451|NCT01494714|DRUG|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
219110452|NCT01494714|DRUG|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
219110453|NCT00798486|DEVICE|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
219110454|NCT03274154|DIETARY_SUPPLEMENT|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
219110455|NCT04446780|PROCEDURE|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
219110456|NCT04517422|DIETARY_SUPPLEMENT|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
219110457|NCT04517422|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
219697202|NCT03257748|RADIATION|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
219697203|NCT03257748|RADIATION|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
219697204|NCT02855489|BEHAVIORAL|Attitudes Only|
219697205|NCT02855489|BEHAVIORAL|Norms Only|
219697206|NCT02855489|BEHAVIORAL|Perceived Behavioral Control Only|
219110458|NCT01863641|DRUG|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
219697207|NCT02855489|BEHAVIORAL|Intentions Only|
219697208|NCT02855489|BEHAVIORAL|Three Constructs|
219110459|NCT01863641|DRUG|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
219110460|NCT03016793|DRUG|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
219110461|NCT03016793|DRUG|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
219110462|NCT03016793|DRUG|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
219110463|NCT00467922|DRUG|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
219110464|NCT00467922|DRUG|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
219697209|NCT02855489|BEHAVIORAL|Four Constructs|
219697210|NCT00499811|DRUG|vorinostat|Given orally
219697211|NCT00499811|OTHER|pharmacological study|Correlative studies
219697212|NCT04264208|DRUG|68-Ga RM2.|PET radiopharmaceutical
219697213|NCT04264208|DRUG|68-Ga PSMA11|PET radiopharmaceutical
219697214|NCT04264208|DEVICE|PET/MRI|PET/MR scanner by GE healthcare
219697215|NCT03080935|DRUG|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
219697216|NCT04157010|DRUG|Tocilizumab|
219697217|NCT04157010|DRUG|Methotrexate|
219697218|NCT02175121|DRUG|Placebo|Tablet, once daily for 28 days
219697219|NCT02175121|DRUG|PF-06291874|Tablet, 15 mg, once daily for 28 days
219697220|NCT02175121|DRUG|PF-06291874|Tablet, 35 mg, once daily for 28 days
219697221|NCT02175121|DRUG|PF-06291874|Tablet, 75 mg, once daily for 28 days
219697222|NCT02175121|DRUG|PF-06291874|Tablet, 150 mg, once daily for 28 days
219697223|NCT04010279|PROCEDURE|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
219110465|NCT00960752|DRUG|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
219110466|NCT00960752|DRUG|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
219110467|NCT00960752|DRUG|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
219697224|NCT04726553|DRUG|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
219697225|NCT04726553|DRUG|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
219697226|NCT01776086|BEHAVIORAL|Neurological testing|
219697227|NCT05802888|DRUG|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
219697228|NCT05802888|DRUG|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
219697229|NCT03665337|BEHAVIORAL|mTranS-C|MOBILE HEALTH
219697230|NCT03665337|BEHAVIORAL|Control|MOBILE HEALTH
219697231|NCT02758418|OTHER|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
219697232|NCT03329885|DRUG|BMS-986251|Escalating oral dose
219697233|NCT03329885|OTHER|Placebo|Escalating oral dose
219697234|NCT03622450|DRUG|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
219697235|NCT03622450|DRUG|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
219697236|NCT00521183|DRUG|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
219697237|NCT00521183|DRUG|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
219697238|NCT00521183|RADIATION|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
219110468|NCT04020159|OTHER|Patient Registry|No intervention/treatment
219110469|NCT05259774|DEVICE|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
219697239|NCT02037893|DRUG|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
219697240|NCT02037893|DRUG|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
219110470|NCT01719601|DRUG|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
219110471|NCT00461292|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection \> Week 12; injections into detrusor
219110472|NCT00461292|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
219110473|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection \> 12 weeks; injections into detrusor
219110474|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
219110475|NCT02180438|DRUG|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
219697241|NCT02037893|DRUG|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
219697242|NCT02037893|DRUG|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
219697243|NCT02039934|OTHER|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
219697244|NCT04627636|OTHER|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
219697245|NCT04627636|OTHER|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
219697246|NCT04627636|OTHER|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
219697247|NCT06404437|DIAGNOSTIC_TEST|Auscultation|Auscultation at five auscultation points using a digital stethoscope and a smartphone
219697248|NCT01566110|DIETARY_SUPPLEMENT|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
219697249|NCT04775030|DRUG|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
219697250|NCT04775030|DEVICE|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
219697251|NCT05593588|DRUG|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
219697252|NCT05593588|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
219697253|NCT00537888|DRUG|fluconazole|Intravenous or oral 400 md/d
219697254|NCT02936375|DRUG|Iguratimod|25mg twice a day, orally administrated
219697255|NCT02936375|DRUG|Cyclophosphamide|1g/m², every 4 weeks, intravenous
219697256|NCT02936375|DRUG|Azathioprine|2mg/kg·d, once a day, orally administrated
219697257|NCT02936375|DRUG|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
219110476|NCT02926664|OTHER|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
219110477|NCT05232435|OTHER|pilate mat exercise will be performed|pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)
219697258|NCT01251042|DEVICE|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
219697259|NCT03886272|DRUG|BI 730357 (Test)|tablet
219697260|NCT03886272|DRUG|BI 730357 (Reference)|tablet
219697261|NCT06415435|DEVICE|Radiofrequency Microneedling|Sylfirm X radiofrequency microneedling device
219110478|NCT05232435|OTHER|MET|Will receive MET for hamstring and erectorspinae plus standard treatment
219110479|NCT05232435|OTHER|control group receive standard treatment|electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
219697262|NCT04001556|DIAGNOSTIC_TEST|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
219697263|NCT04001556|DIAGNOSTIC_TEST|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
219697264|NCT04001556|DIAGNOSTIC_TEST|MSG US|Ultrasonography of Major Salivary Glands
219697265|NCT02926105|BEHAVIORAL|T&E Home-based exercise programme|"T\&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
219697266|NCT02926105|BEHAVIORAL|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
219110480|NCT03176589|DEVICE|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
219697267|NCT02926105|BEHAVIORAL|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
219697268|NCT03025633|OTHER|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
219697269|NCT00098241|DRUG|Certican|
219697270|NCT01119690|DIETARY_SUPPLEMENT|Cold-pressed turnip rapeseed oil (CTPRO)|"1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
219697271|NCT01119690|DIETARY_SUPPLEMENT|milk fat|"1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.~2. In the 5-hour oral glucose and fat tolerance test: glucose and cream"
219697272|NCT03950453|BEHAVIORAL|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
219697273|NCT03950453|BEHAVIORAL|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.
219697274|NCT03950453|OTHER|Non-randomized historical control (WLC) assessment only|Non-randomized, historical control group with only assessments during intervention and follow-up period.
219697275|NCT00250822|DRUG|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16"
219697276|NCT00689689|DEVICE|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
219697277|NCT00689689|DEVICE|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
219697278|NCT01350817|DRUG|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
219697279|NCT01350817|DRUG|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
219697280|NCT06436989|OTHER|hot purified water|Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
219697281|NCT01844037|DEVICE|OneShot Ablation System|Renal denervation
219697282|NCT00931632|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
219697283|NCT00931632|DRUG|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
219697284|NCT05778474|OTHER|Healthy subjects|"Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~1. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~3. Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section."
219697285|NCT05778474|OTHER|Pathologic group|"Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4\. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5\. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning."
219697286|NCT02569892|DEVICE|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
219697287|NCT01121510|DEVICE|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
219697288|NCT05868538|DIAGNOSTIC_TEST|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
219110481|NCT03176589|DEVICE|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
219110482|NCT03176589|OTHER|Deep breathing maneuvers|deep breathing maneuvers 3 times 10 breahs without any device at expiration
219110483|NCT03387241|DRUG|Fluticasone/ Formoterol|See above
219110484|NCT03387241|DRUG|fluticasone/ salmeterol|See above
219110485|NCT01811940|DRUG|Adderall-ER|MAS-ER 60mg/day
219110486|NCT01811940|DRUG|Topiramate|Topiramate 100 mg bid.
219110487|NCT01811940|OTHER|Placebo|Placebo
219110488|NCT03547284|DRUG|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
219110489|NCT02581176|DRUG|Apixaban|
219110490|NCT03115008|BEHAVIORAL|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
219110491|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg BID
219110492|NCT01057108|OTHER|FOSTRAP Chewing Gum|40 mg BID
219110493|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
219110494|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
219110495|NCT01057108|OTHER|Placebo chewing gum|
219110496|NCT02737020|DRUG|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
219110497|NCT02737020|DRUG|Placebo|up to four times a day
219110498|NCT01267981|DRUG|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
219110499|NCT01267981|DRUG|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
219697289|NCT02923700|BIOLOGICAL|Leukocyte-rich PRP intra-articular injections|
219697290|NCT02923700|BIOLOGICAL|Leukocyte-poor PRP intra-articular injections|
219697291|NCT01904890|BEHAVIORAL|CRC Prevention and Screening Education|Refer to Arm Description
219697292|NCT01904890|BEHAVIORAL|Nutrition Education|Refer to Arm Description
219697293|NCT00099112|GENETIC|microarray analysis|
219697294|NCT00099112|PROCEDURE|biopsy|
219697295|NCT00099112|PROCEDURE|evaluation of cancer risk factors|
219697296|NCT03045939|DEVICE|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
219697297|NCT00526422|PROCEDURE|Dental Preventive|
219697298|NCT04037124|PROCEDURE|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
219697299|NCT01655316|DRUG|Verapamil|
219697300|NCT05562869|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
219697301|NCT04645563|OTHER|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
219697302|NCT02764437|BIOLOGICAL|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
219697303|NCT00015002|DRUG|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
219697304|NCT04806269|DEVICE|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
219697305|NCT01687218|DRUG|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
219697306|NCT01687218|DRUG|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
219697307|NCT01687218|DRUG|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
219697308|NCT01835912|OTHER|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
219697309|NCT03301636|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
219697310|NCT03301636|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
219697311|NCT03301636|DRUG|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
219110500|NCT01267981|DRUG|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
219110501|NCT00042796|DRUG|decitabine|Given IV
219110502|NCT00042796|OTHER|pharmacological study|Correlative studies
219110503|NCT00042796|OTHER|laboratory biomarker analysis|Correlative studies
219697312|NCT00623532|BEHAVIORAL|Mind-body exercises|
219697313|NCT00623532|BEHAVIORAL|Adapted Tai-chi|
219110504|NCT06391216|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052 and Bifidobacterium longum R0175|8-week supplementation (56 days); 3 × 10\^9 CFU/day
219697314|NCT03139552|OTHER|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
219697315|NCT03139552|OTHER|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
219110505|NCT06391216|DIETARY_SUPPLEMENT|Placebo|8-week supplementation (56 days)
219110506|NCT04779905|DIAGNOSTIC_TEST|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
219224741|NCT06075121|OTHER|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
219224742|NCT05581953|OTHER|Omnivorous|Pork-added plant-forward diet
219110507|NCT04484766|OTHER|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~* Physical examination: height, weight, BMI, blood pressure~* Cardiac examination: cardiac output~* Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~* Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
219110508|NCT03784534|OTHER|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
219110509|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
219110510|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
219161470|NCT06829992|DEVICE|Kinesio Taping|"KT will be applied by a physiotherapist with experience in the Kinesio Taping method by Kenzo Kase. Three I-shaped Kinesio tapes will be used, 5 cm wide, covering the T-11 and T-12 dermatomes. The first tape will be applied vertically between the navel and pubis, with the participant in an orthostatic position with slight trunk extension.~The second tape, with the same length as the first, will be applied with its central region over the middle zone of the first, perpendicularly. The third tape will be applied horizontally to the lower back, covering the spines posterosuperior iliac muscles, with the participant in an orthostatic position, performing light trunk flexion."
219697316|NCT03139552|OTHER|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
219697317|NCT04321577|PROCEDURE|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
219697318|NCT04512807|DIAGNOSTIC_TEST|AMH|AMH \& PREGNANCY
219697319|NCT01257347|BEHAVIORAL|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.
219697320|NCT01257347|DEVICE|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
219224743|NCT05581953|OTHER|No meat|Plant-forward no meat
219224744|NCT03753555|DRUG|Atorvastatin Calcium|20mg Qd for 12 months
219224745|NCT03753555|DRUG|Atorvastatin Calcium|40-80mg Qd for 6 months
219224746|NCT03753555|DRUG|Probucol|0.5g Bid for 6 months
219697321|NCT03204643|BEHAVIORAL|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
219697322|NCT05316064|BIOLOGICAL|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
219697323|NCT05316064|OTHER|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
219697324|NCT01768325|DEVICE|EUS-TCB needle (QuickCore) standard of care|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
219224747|NCT03753555|DRUG|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
219224748|NCT03357562|DEVICE|lung MRI|lung MRI without contrast injection
219224749|NCT02200276|BIOLOGICAL|Influenza|
219110511|NCT05365113|PROCEDURE|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
219110512|NCT02664779|OTHER|Arrhythmia diagnosis with the 10 steps method|
219110513|NCT02664779|OTHER|Arrhythmia diagnosis with the 6 steps method|
219697325|NCT01768325|DEVICE|EUS-Guided biopsy needle (ProCore)|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
219697326|NCT00380172|DEVICE|Rheopheresis blood filtration|
219697327|NCT02351947|OTHER|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
219697328|NCT04260516|DRUG|N-acetyl cysteine|Mucolytic and antioxidant drug
219697329|NCT06019572|PROCEDURE|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
219697330|NCT00221013|PROCEDURE|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
219697331|NCT03604939|DIAGNOSTIC_TEST|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
219697332|NCT03604939|DIAGNOSTIC_TEST|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
219110514|NCT02664779|OTHER|Arrhythmia diagnosis with the 4 steps method|
219110515|NCT00180713|DRUG|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
219110516|NCT00180713|DRUG|Placebo|Placebo tablet once daily.
219110517|NCT03343860|PROCEDURE|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
219697333|NCT01820663|OTHER|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
219697334|NCT01820663|OTHER|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
219110518|NCT03343860|PROCEDURE|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
219110519|NCT03343860|PROCEDURE|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
219110520|NCT03343860|PROCEDURE|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
219110521|NCT03343860|PROCEDURE|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
219110522|NCT03343860|PROCEDURE|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
219110523|NCT03343860|PROCEDURE|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
219110524|NCT03343860|PROCEDURE|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
219110525|NCT03343860|PROCEDURE|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
219110526|NCT03343860|PROCEDURE|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
219110527|NCT04103554|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
219110528|NCT04103554|DRUG|Standard of care|standard of care used for treating BP
219110529|NCT04124874|OTHER|There will be no intervention|There will be no intervention
219110530|NCT05711888|BEHAVIORAL|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
219110531|NCT06576115|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
219110532|NCT06576115|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
219110533|NCT06576115|DEVICE|TheraBionic P1|This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
219110534|NCT06574828|DRUG|BIIB091|Administered as specified in the treatment arm.
219110535|NCT06574828|DRUG|Moxifloxacin|Administered as specified in the treatment arm.
219110536|NCT06574828|DRUG|BIIB091-matched Placebo|Administered as specified in the treatment arm.
219697335|NCT03717103|DRUG|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
219697336|NCT02485665|DEVICE|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
219697337|NCT03017222|DRUG|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
219697338|NCT03017222|DRUG|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
219697339|NCT01505283|DRUG|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
219697340|NCT01505283|DRUG|Sufentanil|epidural administration of sufentanil 10 µg
219697341|NCT01505283|DRUG|lidocaine|epidural administration of lidocaine 50 mg
219697342|NCT00261105|DRUG|telithromycin|
219697343|NCT03368807|DEVICE|Continuous Glucose Monitoring|Commercially available
219697344|NCT03368807|DRUG|Insulin Lispro|As prescribed.
219110537|NCT06574828|DRUG|Moxifloxacin-matched Placebo|Administered as specified in the treatment arm.
219110538|NCT06206616|BEHAVIORAL|Gluten-free diet|"Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.~Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis."
219110539|NCT03761082|OTHER|NA(observation study)|NA(observation study)
219110540|NCT05536778|OTHER|Realization of the 3 tests|The participants will have to perform the isokinetic evaluation during one session and the two functional tests during another session. Those sessions will be separated by 14 days.
219110541|NCT05254444|BEHAVIORAL|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
219110542|NCT05254444|BEHAVIORAL|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
219697345|NCT01102309|DEVICE|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
219697346|NCT01102309|OTHER|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
219697347|NCT03912389|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
219697348|NCT03912389|DRUG|Pemetrexed|IV infusion
219697349|NCT03912389|DRUG|Cisplatin (or carboplatin)|IV infusion
219697350|NCT03912389|OTHER|Placebo|IV infusion
219697351|NCT00264212|DRUG|irbesartan and irbesartan-hydrochlorothiazide|
219110543|NCT04963894|OTHER|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
219110544|NCT04963894|OTHER|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
219110545|NCT05315661|DRUG|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
219110546|NCT00964457|DRUG|cetuximab|cetuximab 500mg per meter square every second week
219697352|NCT05217030|OTHER|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
219110547|NCT03030937|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
219110548|NCT03030937|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC.
219110549|NCT04871035|DEVICE|Immunoadsorption|1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
219697353|NCT03035448|BEHAVIORAL|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
219110550|NCT04871035|DEVICE|Plasma Exchange|1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
219110551|NCT03301090|OTHER|Placebo|Placebo
219110552|NCT03301090|BIOLOGICAL|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
219110553|NCT03301090|BIOLOGICAL|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
219110554|NCT00610701|DEVICE|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
219110555|NCT00610701|DEVICE|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
219110556|NCT01152294|BEHAVIORAL|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
219224750|NCT06269263|BEHAVIORAL|Home-based cardiac rehabilitation|Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
219697354|NCT03035448|OTHER|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
219697355|NCT00045266|BIOLOGICAL|ziv-aflibercept|
219697356|NCT03220308|OTHER|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
219697357|NCT03220308|OTHER|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
219697358|NCT05107661|BEHAVIORAL|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
219697359|NCT06003361|DEVICE|Digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for depression.
219697360|NCT06003361|OTHER|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
219697361|NCT01198912|DRUG|placebo|during 56 days
219697362|NCT01198912|DRUG|doxycycline 100 mg|during 56 days
219697363|NCT02833896|GENETIC|surgery|
219110557|NCT03329521|OTHER|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
219110558|NCT06461819|RADIATION|Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.|this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
219110559|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by Nurea System|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea
219110560|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by hospital practitioner|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
219110561|NCT05760976|DRUG|Cisatracurium|Advanced intravenous injection of cisatracurium before the succinylcholine injection
219110562|NCT01628627|DEVICE|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
219110563|NCT01628627|DEVICE|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
219110564|NCT05639621|PROCEDURE|Accompaniment|presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
219110565|NCT02500563|OTHER|Amino acid based infant formula|
219697364|NCT01973218|BIOLOGICAL|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
219697365|NCT01973218|BIOLOGICAL|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
219110566|NCT02500563|OTHER|Extensively hydrolyzed casein infant formula|
219110567|NCT02500563|OTHER|Mother's own breast milk|
219110568|NCT05315284|PROCEDURE|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
219110569|NCT00641173|DRUG|paroxetine|treatment with SSRI paroxetine
219697366|NCT01973218|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
219697367|NCT02247466|DRUG|Rocuronium and Sugammadex|
219697368|NCT02001571|DRUG|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
219110570|NCT00641173|DRUG|placebo|treatment with placebo
219110571|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
219697369|NCT00221819|DEVICE|heated humidifier (device)|
219697370|NCT00221819|DEVICE|Heat and moisture exchanger (device)|
219697371|NCT03242317|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
219697372|NCT03242317|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
219697373|NCT06188117|OTHER|'Digital Game Addiction Awareness Training'|"Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'."
219697374|NCT01618968|DRUG|MTX|"* Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
219110572|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
219110573|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
219110574|NCT01800708|DRUG|Triamcinolone acetonide|
219110575|NCT01800708|DRUG|Prednisolone syrup|
219161471|NCT06829992|DEVICE|Placebo Group|The quantity of tapes, type, size and region of application will be the same as the group KT, however, in this group the tapes will be applied without tension and with procedure different from that recommended, first starting to adhere a side anchor into the skin, followed by the center and then the other side anchor.
219697375|NCT05794815|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
219110576|NCT01411722|DEVICE|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
219110577|NCT05626972|DRUG|Tenecteplase|Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
219697376|NCT05794815|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
219697377|NCT00456872|DRUG|lidocaine|
219697378|NCT01039766|DRUG|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
219697379|NCT01039766|DRUG|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
219697380|NCT04347772|DIETARY_SUPPLEMENT|Oral Nutrition Support|Intensive Nutrition Intervention
219697381|NCT01259947|DRUG|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
219697382|NCT05637034|DIAGNOSTIC_TEST|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
219697383|NCT02821494|BIOLOGICAL|Hespecta|A dose escalation of Amplivant® conjugated peptide
219697384|NCT05652127|OTHER|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
219697385|NCT02952651|PROCEDURE|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
219110578|NCT00265707|DEVICE|Blood pressure measurement|
219110579|NCT03218696|DEVICE|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
219110580|NCT03218696|DEVICE|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
219110581|NCT00847990|OTHER|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
219110582|NCT00941564|OTHER|Infant Formula milk based|Consume ad lib
219697386|NCT04778852|DEVICE|Experimental: EksoGT|EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
219697387|NCT04778852|OTHER|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
219697388|NCT05359471|DEVICE|Bone densitometry|It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
219697389|NCT05359471|OTHER|Questionnaires|Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
219697390|NCT05359471|DEVICE|Review of medical chart|History of previous liver diseases including hepatitis B, C, and HIV
219697391|NCT04533256|PROCEDURE|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
219697392|NCT04865588|PROCEDURE|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
219697393|NCT04865588|DEVICE|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
219110583|NCT00941564|OTHER|Infant formula milk based|consume ad lib
219110584|NCT00549887|DRUG|Analog or Human Insulin|prescribed in accordance with usual clinical practice
219110585|NCT05591560|DRUG|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
219110586|NCT05591560|DRUG|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
219697394|NCT04865588|DEVICE|plain old balloon|current standard treatment of stent placement
219697395|NCT03573037|DRUG|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
219110587|NCT05023967|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219697396|NCT02559037|DEVICE|Acupuncture and moxibustion|"Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
219697397|NCT02559037|DEVICE|Sham acupuncture and moxibustion|"The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
219697398|NCT04356937|DRUG|Tocilizumab|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
219697399|NCT04356937|DRUG|Placebos|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
219697400|NCT02091700|OTHER|Indocyanine Green ICG|
219697401|NCT01835106|PROCEDURE|Epidural catheter is used postoperatively|
219697402|NCT01835106|PROCEDURE|Fascia iliaca compartment catheter is used postoperatively|
219697403|NCT03533751|BIOLOGICAL|Etokimab|Humanized monoclonal antibody, administered by subcutaneous injection
219697404|NCT03533751|DRUG|Placebo|Administered by subcutaneous injection
219697405|NCT05252637|PROCEDURE|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
219697406|NCT03311308|DRUG|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
219697407|NCT03311308|DRUG|Metformin|500 mg, by mouth, twice a day for nine weeks.
219697408|NCT06985199|BEHAVIORAL|Enhanced Usual Care Group|A culturally-adapted mobile health platform will be used in the intervention to enable participants to record blood pressure and heart rate readings at home and store data in the mobile platform. Providers will have access to the store data using a provider-facing app.
219110588|NCT05023967|DRUG|Extended Release Metformin Hydrochloride|Given PO
219110589|NCT05023967|OTHER|Monitoring|Use continuous glucose monitoring system
219110590|NCT05023967|OTHER|Nutritional Assessment|Receive nutritional counseling
219110591|NCT05023967|OTHER|Short-Term Fasting|Perform intermittent fasting
219110592|NCT01051063|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
219110593|NCT02274649|BEHAVIORAL|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
219697409|NCT06607406|RADIATION|Accelerated radiotherapy|6 fractions per week, BID fractions one day per week
219697410|NCT06607406|RADIATION|Conventional radiotherapy|5 fractions per week, daily M-F
219697411|NCT00419536|DRUG|LBH589|
219697412|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
219697413|NCT04398719|RADIATION|[11C]PBR28|The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
219697414|NCT04398719|DRUG|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
219697415|NCT04398719|DRUG|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
219697416|NCT06612996|DRUG|Tramadol|Intravenous tramadol
219697417|NCT06612996|DRUG|Magnesium sulphate|Intravenous magnesium sulphate
219697418|NCT06612996|OTHER|Saline|Normal saline
219110594|NCT02274649|BEHAVIORAL|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
219110595|NCT01420263|PROCEDURE|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
219110596|NCT01420263|PROCEDURE|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
219110597|NCT01393041|DEVICE|Angio-Seal VIP|Vascular Closure Device
219110598|NCT01928680|DRUG|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
219110599|NCT00231660|DRUG|topiramate|
219697419|NCT06314152|PROCEDURE|Lightweight mesh fixation in 3 points or 1 point|Lightweight mesh fixation in 3 points
219697420|NCT07006987|DEVICE|A non-invasive blood-based (HerResolve)|A non-invasive blood-based test can detect endometriosis as compared to diagnostic laparoscopy
219697421|NCT03025373|OTHER|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
219697422|NCT05117060|DRUG|LEO 152020 tablet|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
219110600|NCT00192140|BIOLOGICAL|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
219110601|NCT00836654|BIOLOGICAL|Catumaxomab (Removab)|Puncture free survival
219110602|NCT00836654|PROCEDURE|paracentesis|
219110603|NCT04049292|OTHER|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
219110604|NCT04049292|OTHER|Usual care|Usual care is determined by the treating health care professional
219110605|NCT01474837|BEHAVIORAL|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
219110606|NCT02675140|DRUG|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
219110607|NCT02675140|DRUG|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
219110608|NCT01815814|OTHER|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
219697423|NCT05117060|DRUG|LEO 152020 placebo tablet|LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
219110609|NCT01007240|DEVICE|polyethylenimine (PEI) nanoparticles.|
219110610|NCT06272019|OTHER|Iodine gargle|Iodine gargle 0.2 %
219110611|NCT00790114|DRUG|AZD7325|Oral, day 1-12
219110612|NCT00790114|DRUG|Midazolam|single dose, twice during treatment
219110613|NCT00790114|DRUG|Caffeine|single dose, twice during treatment
219110614|NCT06114563|OTHER|Spirulina yogurt|High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
219110615|NCT06114563|OTHER|Conventional yogurt|High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
219110616|NCT03075956|DRUG|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
219110617|NCT03075956|DRUG|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
219697424|NCT07026890|OTHER|Evaluation visits|"3 assessment visits (initial (V1), intermediate (V2) and final (V3).~A series of motor assessments carried out by the physiotherapist:~* Timed Up and Go Test (TUG)~* 10 m walk test (TM10)~* Functional Reach Test (FRT)~* Minimum Motor Test (TMM)~* 10 m walk test combined with a verbal task such as naming different animals"
219697425|NCT07026890|OTHER|Rehabilitation sessions|Usual treatment: 4 to 5 rehabilitation sessions per week, each lasting 45 minutes.
219110618|NCT03075956|DRUG|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
219110619|NCT03075956|DRUG|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
219110620|NCT01783353|DIETARY_SUPPLEMENT|Zinc gluconate|
219110621|NCT01783353|DIETARY_SUPPLEMENT|Corn starch pill|
219110622|NCT02678325|OTHER|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
219110623|NCT02678325|OTHER|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
219110624|NCT05324930|DEVICE|Piscean collagen dressing|Piscean collagen dressing
219110625|NCT05324930|DEVICE|Saline infused dressing|Saline infused dressing
219110626|NCT02320643|DEVICE|Seratom® PA mesh|Partially absorbable mesh
219110627|NCT03857841|BIOLOGICAL|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
219110628|NCT03857841|BIOLOGICAL|Phosphate-buffered saline|Phosphate-buffered saline
219110629|NCT02149602|RADIATION|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
219110630|NCT03055611|DRUG|ELOCTA|Extended half-life factor VIII product
219110631|NCT03055611|DRUG|ALPROLIX|Extended half-life factor IX product
219110632|NCT01052909|DRUG|Glimepiride|Glimepiride tablets 1 mg
219697426|NCT07026890|OTHER|Virtual reality sessions|3 virtual reality sessions per week, each lasting 30 minutes.
219697427|NCT07026890|OTHER|Additional rehabilitation sessions|3 additional rehabilitation sessions per week. These sessions correspond to standard rehabilitation sessions.
219697428|NCT03141359|RADIATION|SBRT|Primary tumor SBRT
219697429|NCT03141359|DRUG|Carboplatin|concurrent chemotherapy
219697430|NCT03141359|DRUG|Paclitaxel|concurrent chemotherapy
219697431|NCT03141359|DRUG|cis Platinum|concurrent chemotherapy
219110633|NCT06617234|OTHER|Nurse-led Intervention Program|"Nurse-led Intervention Program: This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.~LINEbot Automated Robot System: This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management."
219110634|NCT06617234|OTHER|LINEbot Automated Robot System|Participants in this group will use the \&amp;#34;LINEbot\&amp;#34; automated robot system, which sends push notifications through the LINE app. The system delivers education messages, exercise guidance, and health tracking prompts. It provides daily reminders for cardiac rehabilitation participation, as well as customized messages on health management, such as diet, medication, and self-care. The system also allows users to log health data like blood pressure and heart rate.
219110635|NCT06622785|BEHAVIORAL|Physical activity|Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
219110636|NCT06622785|BEHAVIORAL|Exercise Benefits|Data were collected using a Exercise Benefits/Barriers Scale .
219110637|NCT04921969|DRUG|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
219110638|NCT04921969|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
219110639|NCT06897020|OTHER|(Group A: Bioflx crowns)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2.The tooth will be prepared similarly to stainless steel crowns (SSCs): • Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done. 3.All sharp line angles and corners will be smoothed to ensure proper crown fit. 4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin. 5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked."
219110640|NCT06897020|OTHER|(Group B: Preformed Zirconia crown|"1. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.~2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.~3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.~4. Interproximal Reduction: 1mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330tapered carbide bur.~5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.~6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.~7. Glass ionomer cement will be used for cementation."
219110641|NCT02751736|DIETARY_SUPPLEMENT|CJLP243|Perioperative administration till postoperative weeks 3
219697432|NCT03141359|DRUG|Etoposide|concurrent chemotherapy
219697433|NCT03141359|RADIATION|IMRT|mediastinal radiation
219697434|NCT03141359|DRUG|Durvalumab|adjuvant immunotherapy
219697435|NCT04227717|DIAGNOSTIC_TEST|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
219697436|NCT02440893|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
219697437|NCT01466738|BIOLOGICAL|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
219697438|NCT01466738|BIOLOGICAL|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
219697439|NCT01081626|DRUG|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
219697440|NCT04703985|DIETARY_SUPPLEMENT|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
219697441|NCT01503983|DRUG|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
219697442|NCT01503983|DRUG|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
219697443|NCT01503983|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
219110642|NCT02751736|DIETARY_SUPPLEMENT|Placebo|Perioperative administration till postoperative weeks 3
219110643|NCT03661229|DEVICE|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
219110644|NCT05718648|DRUG|BI 1015550|BI 1015550
219110645|NCT02446093|BIOLOGICAL|Aglatimagene besadenovec|Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
219110646|NCT02446093|RADIATION|Chemoradiation|CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
219110647|NCT02446093|RADIATION|Stereotactic body radiation therapy|SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
219697444|NCT04158219|BEHAVIORAL|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
219110648|NCT02446093|PROCEDURE|Surgery|Surgical resection should be performed within 8 weeks after completing CR or SBRT.
219110649|NCT00000692|DRUG|Butyldeoxynojirimycin|
219697445|NCT01911416|DRUG|LDE225|
219110650|NCT02326844|DRUG|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
219110651|NCT00004928|DIETARY_SUPPLEMENT|calcitriol|
219110652|NCT00004928|DRUG|zoledronic acid|
219697446|NCT03213847|DEVICE|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
219697447|NCT03048045|PROCEDURE|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD \>/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
219697448|NCT02074514|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
219110653|NCT06280963|BEHAVIORAL|muscle energy technique|in muscle energy technique, the target is gluteus maximus muscle ( hip extension ) and repeat the method from three to five times .
219110654|NCT06280963|BEHAVIORAL|posterior innominate mobilization|in posterior innominate mobilization ( grade 3 mobilization ) , frequency of mobilizations is 30 oscillations , 3 sets per session ( every set has 30 oscillations )
219110655|NCT06280963|BEHAVIORAL|conventional treatment|"conventional treatment include~* TENS ( 45 minutes of conventional TENS )~* Ultrasound (pulsed mode 1:1 ,5 min .1.5W/cm2 )~* Stretching exercises ( hamstrings ,hip flexors and hip adductors)~* Strengthening exercises (lower abdomen and glutes muscles )~* Lumpopelvic stabilization exercise"
219110656|NCT02339649|PROCEDURE|Blood Sample|Blood Sample
219110657|NCT02339649|BEHAVIORAL|Neurocognitive Assessment|Neurocognitive Assessment
219110658|NCT02339649|OTHER|Resting State EEG|10-20 Minutes of Resting State EEG
219110659|NCT02339649|PROCEDURE|Lumbar Puncture|Lumbar Puncture
219110660|NCT02339649|OTHER|MRI|60 Minutes MRI
219110661|NCT05685771|DEVICE|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
219110662|NCT03630562|PROCEDURE|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
219110663|NCT04348682|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
219110664|NCT01091428|DRUG|Alisertib|Alisertib tablets
219110665|NCT01091428|DRUG|Paclitaxel|Paclitaxel intravenous infusion
219110666|NCT03863743|OTHER|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
219110667|NCT03863743|OTHER|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
219110668|NCT03386695|OTHER|Education by Pamphlets|Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
219110669|NCT03386695|OTHER|Health education programme|Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
219110670|NCT06115850|PROCEDURE|Music|In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
219697449|NCT02074514|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219697450|NCT03842904|DRUG|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
219697451|NCT03842904|DRUG|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
219697452|NCT02354768|DRUG|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
219697453|NCT02354768|DRUG|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
219697454|NCT03546673|BEHAVIORAL|Self-Regulation Condition|
219697455|NCT03546673|BEHAVIORAL|Emotional Disclosure Condition|
219697456|NCT04281329|PROCEDURE|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
219697457|NCT06778486|OTHER|Artificial Intelligence Chatbot|The intervention is a generative artificial intelligence large language model chatbot that has a structured prompt with fill-in-the-blank style questions that the participant will complete.
219697458|NCT06942897|DIETARY_SUPPLEMENT|Melissa officinalis supplement|This intervention consists of a standardized oral dietary supplement containing 400 mg of Melissa officinalis extract formulated in phospholipids. The supplement is administered once daily for 3 weeks to evaluate its potential effects on mood, stress perception, and cortisol levels in healthy adults.
219697459|NCT06940648|DEVICE|The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.|This study is to evaluate the use of the Virtuoso Endoscopy System (VES), which is a robotic enhanced system, to perform safe and effective bladder lesion excisions.
219110671|NCT04468243|OTHER|Nurse-led diabetes care|Nurse-led brief diabetes education, instructions on glucometer and Metformin use, patients receive prescriptions for Metformin and blood glucose testing kit
219697460|NCT06955169|DRUG|[177Lu]Lu-DOTATATE|The treatment regimen consists of 4 (+2 optional) administrations of \[177Lu\]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
219697461|NCT06955169|OTHER|Standard of Care treatments|Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Local SOC therapy with one of the following agents: bevacizumab, everolimus, hydroxyurea, or sunitinib.
219697462|NCT02528032|OTHER|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
219697463|NCT03470467|OTHER|No intervention|No intervention planed
219697464|NCT03772223|DRUG|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
219697465|NCT03772223|DRUG|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
219697466|NCT03772223|DRUG|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
219697467|NCT05907265|BEHAVIORAL|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
219697468|NCT05907265|BEHAVIORAL|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
219697469|NCT00413023|DRUG|GW679769|
219697470|NCT04127370|PROCEDURE|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
219697471|NCT01697241|OTHER|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
219697472|NCT01697241|OTHER|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
219697473|NCT02757196|DRUG|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
219697474|NCT02757196|DRUG|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
219697475|NCT01402856|OTHER|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long \& utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, \& interactive games simulating distracted driving.
219697476|NCT04085640|OTHER|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
219697477|NCT04085640|OTHER|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
219697478|NCT01493817|OTHER|laboratory biomarker analysis|Correlative studies
219697479|NCT03473990|OTHER|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
219697480|NCT06053229|DEVICE|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
219697481|NCT06053229|COMBINATION_PRODUCT|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
219697482|NCT03356717|BEHAVIORAL|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
219697483|NCT03356717|BEHAVIORAL|educational intervention|without observer tool
219110672|NCT05507489|DRUG|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
219110673|NCT06134245|DEVICE|Entia Liberty|Home monitoring
219110674|NCT02531295|DRUG|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
219697484|NCT06017271|DIAGNOSTIC_TEST|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
219697485|NCT04447859|DRUG|Semaglutide|Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
219697486|NCT04447859|OTHER|label recommended titration|label recommended titration
219697487|NCT04364516|DRUG|Anticoagulation|Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
219697488|NCT03103958|DIETARY_SUPPLEMENT|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
219697489|NCT03103958|DIETARY_SUPPLEMENT|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
219697490|NCT01324297|OTHER|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
219697491|NCT00368251|OTHER|Placebo|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use"
219697492|NCT00368251|DRUG|BRV 2.5 mg|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
219697493|NCT00368251|DRUG|BRV 25 mg|"* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
219697494|NCT00368251|DRUG|BRV 50 mg|"* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
219110675|NCT02338258|DEVICE|Anti-rotational plate|
219697495|NCT03699592|BEHAVIORAL|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
219697496|NCT03294915|DIETARY_SUPPLEMENT|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
219697497|NCT03294915|DIETARY_SUPPLEMENT|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
219697498|NCT03759925|OTHER|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
219697499|NCT04457856|BIOLOGICAL|TJ003234 injection|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
219697500|NCT01627132|DRUG|Dasatinib|100mg QD
219697501|NCT01156519|OTHER|Salivary Cortisol|"* Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am \> 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy"
219697502|NCT04031495|DEVICE|central vein cannulation|central vein cannulation
219697503|NCT03159143|DRUG|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
219697504|NCT03159143|DRUG|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
219697505|NCT03312738|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
219110676|NCT02338258|DEVICE|Exchanged Intramedullary nailing|
219110677|NCT03435458|COMBINATION_PRODUCT|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
219697506|NCT03312738|DRUG|Exemestane|Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
219697507|NCT03312738|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
219697508|NCT02613130|DRUG|Stannous fluoride toothpaste|
219697509|NCT02613130|DRUG|Potassium nitrate toothpaste|
219697510|NCT01130844|DRUG|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
219110678|NCT03435458|DRUG|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
219110679|NCT01154023|BEHAVIORAL|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
219110680|NCT02382510|DRUG|TRN-157|
219110681|NCT02382510|OTHER|Placebo|
219110682|NCT02382510|DRUG|Tiotropium|
219697511|NCT01130844|DRUG|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
219110683|NCT01167270|BEHAVIORAL|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
219697512|NCT01130844|DRUG|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
219697513|NCT01450735|DEVICE|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
219697514|NCT06183138|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
219697515|NCT04597567|PROCEDURE|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
219697516|NCT00003062|DRUG|temozolomide|
219697517|NCT03895801|DRUG|IFX-1|intravenously administered
219697518|NCT03895801|DRUG|Placebo-IFX-1|intravenously administered
219697519|NCT03895801|DRUG|Glucocorticoid (GC)|orally administered
219110684|NCT01167270|BEHAVIORAL|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
219697520|NCT03895801|DRUG|Placebo-Glucocorticoid (Placebo-GC)|orally administered
219697521|NCT03175211|DRUG|BI 456906|single dose
219110685|NCT01315743|BEHAVIORAL|Team COOL|1\) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
219110686|NCT01060020|DRUG|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
219697522|NCT03175211|DRUG|Placebo|single dose
219697523|NCT05029661|DIAGNOSTIC_TEST|Carotid ultrasound|"* Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~* Intima-media thickness~* Pulse wave velocity"
219697524|NCT02466399|DRUG|POLAT-001|Subconjunctival injection
219697525|NCT02466399|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
219697526|NCT04670211|DEVICE|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
219697527|NCT00064311|DRUG|ravuconazole|
219697528|NCT06329167|DRUG|Daphnetin|150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
219697529|NCT06329167|DRUG|Aescuven|150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
219697530|NCT00279084|DRUG|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
219697531|NCT00279084|DRUG|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
219697532|NCT01123330|BEHAVIORAL|Motivational Interviewing|
219697533|NCT03885557|OTHER|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
219697534|NCT03885557|OTHER|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
219697535|NCT02686996|DIETARY_SUPPLEMENT|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
219697536|NCT02686996|OTHER|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
219697537|NCT05276739|BEHAVIORAL|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
219697538|NCT05276739|BEHAVIORAL|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
219697539|NCT05276739|BEHAVIORAL|Dim light|dim light (\<3 lux) throughout the 16-hour wake episode
219697540|NCT05276739|BEHAVIORAL|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
219110687|NCT04424290|DRUG|BI 764524|BI 764524
219110688|NCT04424290|DRUG|Sham control of BI 764524|Sham control of BI 764524
219697541|NCT03984929|BEHAVIORAL|Conexion Localized|The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.
219110689|NCT03298607|DIETARY_SUPPLEMENT|Placebo|2 months treatment
219697542|NCT03984929|BEHAVIORAL|Conexion Generic|The generic version of Conexion is an online health information resource on diabetes and depression.
219697543|NCT02889913|OTHER|No intervention only description|No intervention only description
219697544|NCT06102551|BEHAVIORAL|Recurrence after surgery|Recurrence after repair was the main outcome
219697545|NCT00607893|DEVICE|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
219697546|NCT00607893|DEVICE|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
219697547|NCT04096690|DRUG|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
219697548|NCT04096690|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
219110690|NCT03298607|DIETARY_SUPPLEMENT|Serelys PMS|2 months treatment
219110691|NCT04671290|OTHER|Any intervention|No intervention
219110692|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
219110693|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
219697549|NCT03220503|PROCEDURE|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
219697550|NCT03097601|DIAGNOSTIC_TEST|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
219697551|NCT03170713|DRUG|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
219110694|NCT02477891|DRUG|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
219110695|NCT02011256|DEVICE|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
219110696|NCT04854538|DRUG|Ekmasonid|1 extended release tablet contains 9 mg Budesonide
219110697|NCT04854538|DRUG|Uceris (first dose)|1 extended release tablet contains 9 mg Budesonide
219110698|NCT04854538|DRUG|Uceris (second dose)|1 extended release tablet contains 9 mg Budesonide
219110699|NCT06109506|PROCEDURE|Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess|Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.
219110700|NCT03393403|DRUG|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
219110701|NCT03393403|DRUG|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine\_adj group and control group
219110702|NCT03408834|OTHER|pulse variability index|fluid management with pulse variability index or conventional
219697552|NCT03170713|DRUG|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
219697553|NCT03170713|OTHER|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
219697554|NCT02669849|DRUG|VX-210|
219697555|NCT02669849|DRUG|Placebo|
219697556|NCT00581217|OTHER|Aquacel Ag|Aquacel Ag will be applied to one donor site.
219697557|NCT00581217|OTHER|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
219697558|NCT02543840|OTHER|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
219697559|NCT02543840|OTHER|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
219110703|NCT04544228|PROCEDURE|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
219110704|NCT04544228|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
219110705|NCT04544228|DRUG|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
219697560|NCT05385406|DIAGNOSTIC_TEST|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
219697561|NCT05385406|DIAGNOSTIC_TEST|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter \> 5mm of acetowhite lesion)."
219697562|NCT00980876|DRUG|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
219697563|NCT00980876|DRUG|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
219697564|NCT01592214|OTHER|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
219697565|NCT01592214|DRUG|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
219697566|NCT01592214|DRUG|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
219697567|NCT04689542|OTHER|Sit-To-Stand test|The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
219697568|NCT03953742|DRUG|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
219697569|NCT01955811|DRUG|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
219110706|NCT04544228|DRUG|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
219110707|NCT04544228|DRUG|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
219110708|NCT06306560|DRUG|adebrelimab|adebrelimab IV
219110709|NCT06306560|DRUG|famitinib|famitinib PO
219110710|NCT06306560|DRUG|chemotherapy|chemotherapy IV
219110711|NCT01899118|RADIATION|Preoperative irradiation|50.4Gy/28F/5.5w
219110712|NCT01899118|DRUG|Nimotuzumab|400mg/w，0-5w
219110713|NCT01899118|DRUG|Oxaliplatin|130mg/m2 d1
219110714|NCT01899118|DRUG|Capecitabine|825mg/m2 bid d1-5/w,1-5w
219110715|NCT03434236|DIETARY_SUPPLEMENT|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
219110716|NCT03434236|DIETARY_SUPPLEMENT|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
219110717|NCT03434236|DIETARY_SUPPLEMENT|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
219110718|NCT05078684|PROCEDURE|Left ganglion stellate block|Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
219110719|NCT05078684|PROCEDURE|Sham left ganglion stellate block|Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
219110720|NCT04448236|DEVICE|Blood flow restriction resistance exercise|"Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension"
219110721|NCT04249336|DRUG|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
219110722|NCT04249336|DRUG|8% Arginine based dentifrices|Tubular occluding formulation
219110723|NCT04249336|DRUG|8% Strontium Acetate|Tubular occluding formulation
219110724|NCT04249336|DRUG|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
219110725|NCT01242176|DRUG|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
219110726|NCT01242176|DRUG|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
219110727|NCT03452020|DEVICE|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
219110728|NCT03636945|OTHER|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
219110729|NCT03013699|BEHAVIORAL|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
219110730|NCT03013699|BEHAVIORAL|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
219110731|NCT02527837|DRUG|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
219110732|NCT02527837|DRUG|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
219110733|NCT05444400|OTHER|Strengthening|Strengthening
219110734|NCT05444400|OTHER|Conventional protocol|Conventional protocol
219697570|NCT02915939|BEHAVIORAL|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
219110735|NCT00612703|DRUG|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
219697571|NCT01525953|DRUG|Chemotherapy|Chemotherapy according to standard
219110736|NCT02127320|DRUG|Rosuvastatin 20mg|
219110737|NCT02127320|DRUG|Ezetimibe 10mg|
219110738|NCT02127320|DRUG|Rosuvastatin 20mg + Ezetimibe 10mg|
219110739|NCT05769699|PROCEDURE|blood sample|blood sample
219110740|NCT02612896|DRUG|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
219110741|NCT02612896|BEHAVIORAL|Health education|in all study arms, using village meetings, posters, pamphlets.
219697572|NCT01525953|RADIATION|Radiotherapy|Radiotherapy according to local standard
219697573|NCT00348257|DEVICE|Hair removal by laser/IPL device|
219697574|NCT05572580|OTHER|questionnaire|the patients are asked to fill in a questionnaire
219110742|NCT04103320|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
219110743|NCT01074632|DRUG|Lurasidone HCl|
219110744|NCT01183702|PROCEDURE|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
219110745|NCT01183702|OTHER|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
219110746|NCT03390036|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
219697575|NCT06399601|OTHER|Drug allergy training program|Two identical didactic courses on drug allergy were designed. Each course will last 12 hours and conducted over 2 consecutive days (6 hours each day). All candidates will attend physically and on-site. Various aspects of drug allergy with pre-set learning objectives will be taught in-person by instructors (physicians or nurses specializing in drug allergy nominated by the University of Hong Kong). Course materials and instructors will be identical for each course.
219697576|NCT05828342|PROCEDURE|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
219697577|NCT01055990|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
219697578|NCT01055990|OTHER|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
219697579|NCT06452342|DRUG|Tranexamic acid|Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
219697580|NCT06452342|OTHER|No Tranexamic acid|Routine clinical care without Tranexamic acid
219697581|NCT01248416|DRUG|Aromatase Inhibitor|
219697582|NCT01248416|DRUG|Growth Hormone|
219697583|NCT01248416|DRUG|Aromatase Inhibitor and Growth Hormone|
219110747|NCT03390036|DEVICE|Monovisc|Hyaluronic Acid
219110748|NCT03390036|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
219110749|NCT03010579|DRUG|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
219110750|NCT03010579|DRUG|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
219110751|NCT06018597|DRUG|Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL|No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
219110752|NCT01614977|DRUG|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
219110753|NCT02329106|DEVICE|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
219110754|NCT02171364|PROCEDURE|Virtual ablation in based 3D CT of patient who diagnosed AF|
219110755|NCT02171364|PROCEDURE|conventional ablation based on physician's personal experience|
219697584|NCT04745351|DRUG|Remdesivir|Administered as Intravenous (IV) infusion once daily
219697585|NCT04745351|DRUG|RDV Placebo|Administered as IV saline once daily
219697586|NCT04745351|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
219110756|NCT02443922|DRUG|Glimepiride|Glimepiride 2mg qam
219110757|NCT02443922|DRUG|Sitagliptin|Sitagliptin 100mg qam
219110758|NCT02443922|DRUG|Metformin|Metformin as prescribed
219110759|NCT00358215|DRUG|Darbepoetin alfa|Administered by subcutaneous injection
219110760|NCT00358215|DRUG|Placebo|Placebo subcutaneous injection
219110761|NCT00410631|BIOLOGICAL|filgrastim|
219110762|NCT00410631|DRUG|carboplatin|
219110763|NCT00410631|DRUG|cisplatin|
219110764|NCT00410631|DRUG|cyclophosphamide|
219110765|NCT00410631|DRUG|dacarbazine|
219110766|NCT00410631|DRUG|doxorubicin hydrochloride|
219110767|NCT00410631|DRUG|etoposide phosphate|
219110768|NCT00410631|DRUG|ifosfamide|
219110769|NCT00410631|DRUG|isotretinoin|
219110770|NCT00410631|DRUG|melphalan|
219110771|NCT00410631|DRUG|topotecan hydrochloride|
219110772|NCT00410631|DRUG|vincristine sulfate|
219110773|NCT00410631|DRUG|vindesine|
219110774|NCT00410631|PROCEDURE|autologous hematopoietic stem cell transplantation|
219110775|NCT00410631|PROCEDURE|conventional surgery|
219110776|NCT00410631|PROCEDURE|peripheral blood stem cell transplantation|
219110777|NCT00410631|RADIATION|iobenguane I 131|
219110778|NCT00410631|RADIATION|radiation therapy|
219110779|NCT04261738|DEVICE|Hyperbaric Oxygen|Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
219697587|NCT05802433|DIETARY_SUPPLEMENT|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
219697588|NCT06293742|DRUG|ECC5004|ECC5004 tablet will be administered orally.
219697589|NCT06293742|DRUG|Midazolam|Midazolam will be administered orally.
219697590|NCT06293742|DRUG|Rosuvastatin|Rosuvastatin will be administered orally.
219697591|NCT06293742|DRUG|Digoxin|Digoxin will be administered orally.
219697592|NCT06293742|DRUG|Atorvastatin|Atorvastatin will be administered orally.
219697593|NCT01244477|BEHAVIORAL|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
219697594|NCT00300196|BIOLOGICAL|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
219697595|NCT00300196|DRUG|Placebo|0.6 mL/kg/hr
219697596|NCT01863771|DRUG|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
219697597|NCT01863771|OTHER|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
219697598|NCT04867759|PROCEDURE|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
219697599|NCT06071416|PROCEDURE|Lateral sinus floor augmentation|maxillary sinus floor augmentation by lateral approach
219697600|NCT06071416|DRUG|Biphasic Calcium Phosphate|appliaction of BCP bone substitute
219697601|NCT06071416|PROCEDURE|Injectable platlets rich fibrin|centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
219697602|NCT02014272|DRUG|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
219697603|NCT02014272|DRUG|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
219697604|NCT05090644|GENETIC|DNA analysis|GWAS
219697605|NCT01715246|OTHER|Infant Formula|
219697606|NCT04621331|DRUG|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
219697607|NCT00480714|BIOLOGICAL|BCG (SSI Strain)|
219697608|NCT03499795|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid \[DNA\] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
219697609|NCT03499795|DEVICE|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
219697610|NCT02719977|DRUG|CX5461|
219697611|NCT03281044|DRUG|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
219697612|NCT03281044|DRUG|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
219697613|NCT02014623|OTHER|Grass pollen sublingual immunotherapy tablet|
219697614|NCT02014623|DRUG|Control|
219697615|NCT03627676|PROCEDURE|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
219697616|NCT03636256|DRUG|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
219697617|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
219697618|NCT03636256|OTHER|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
219697619|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
219697620|NCT05181072|BEHAVIORAL|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
219697621|NCT05181072|BEHAVIORAL|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
219110780|NCT02240589|DRUG|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
219110781|NCT02240589|DRUG|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
219697622|NCT02741284|DRUG|Room air|
219110782|NCT03743363|OTHER|Exergame 2/week|virtual training 2 times a week(8 week-long)
219110783|NCT03743363|OTHER|Exergaming 3/week|virtual training 3 times a week(8 week-long)
219110784|NCT03743363|OTHER|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
219110785|NCT00030368|DRUG|bortezomib|Given IV
219697623|NCT02741284|DRUG|10L Oxygen by nonrebreather mask|
219697624|NCT05807282|OTHER|Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho|The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
219697625|NCT04615000|DIAGNOSTIC_TEST|SARS-CoV-2 serological assessment (IgG)|Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
219697626|NCT00488397|OTHER|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
219697627|NCT00132886|DRUG|tolvaptan|
219697628|NCT05540431|DRUG|Activated Charcoal|RCT
219697629|NCT05540431|DIETARY_SUPPLEMENT|Probiotic|RCT
219110786|NCT00030368|DRUG|paclitaxel|Given IV
219110787|NCT00030368|OTHER|laboratory biomarker analysis|Correlative studies
219110788|NCT06031168|OTHER|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
219110789|NCT06031168|OTHER|uncoated hydrophilic dental implants|Patients treated by uncoated implants
219110790|NCT04235868|BIOLOGICAL|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
219110791|NCT04235868|BIOLOGICAL|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
219110792|NCT04328363|BEHAVIORAL|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
219110793|NCT04529720|BIOLOGICAL|Biological/Vaccine: Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
219110794|NCT04529720|BIOLOGICAL|Biological/Vaccine: Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
219110795|NCT04529720|BIOLOGICAL|Biological/Vaccine: Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
219697630|NCT05540431|OTHER|No intervention|RCT
219697631|NCT01218308|BIOLOGICAL|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
219697632|NCT01218308|BIOLOGICAL|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
219697633|NCT00930020|DRUG|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
219697634|NCT00930020|DRUG|Matched placebo|matched placebo (cornstarch) once a day for 5 days
219697635|NCT02937376|DRUG|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
219110796|NCT00285181|DRUG|Simvastatin|
219110797|NCT02471859|DRUG|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
219110798|NCT02471859|DRUG|Placebo|Placebo at various doses, depending on the cohort and treatment period
219110799|NCT02352662|OTHER|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
219110800|NCT00631384|BEHAVIORAL|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
219697636|NCT02937376|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
219697637|NCT04931615|DRUG|ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|Wound sealant
219697638|NCT04931615|OTHER|no ARTISS|Wound closed without sealant
219697639|NCT02424825|BEHAVIORAL|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
219697640|NCT00183339|DRUG|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
219697641|NCT00183339|DRUG|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
219697642|NCT05761847|OTHER|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
219697643|NCT02548871|BEHAVIORAL|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
219697644|NCT02961842|DRUG|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
219697645|NCT02961842|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
219697646|NCT02961842|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
219697647|NCT02961842|DRUG|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
219697648|NCT02961842|DRUG|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
219697649|NCT02961842|DRUG|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
219697650|NCT02961842|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
219697651|NCT02961842|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
219697652|NCT02961842|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
219697653|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
219697654|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
219697655|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
219697656|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
219110801|NCT00631384|BEHAVIORAL|Individual VCT|Women to receive individual VCT
219110802|NCT01936610|OTHER|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
219110803|NCT01936610|OTHER|lecture|Describe advantages and disadvantages in one 90-min session
219110804|NCT04692844|DRUG|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
219697657|NCT04639882|BEHAVIORAL|Personalized normative feedback|Information presenting perceived and actual drinking norms.
219697658|NCT03843996|DEVICE|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
219697659|NCT03163628|BIOLOGICAL|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~* A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~* A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
219697660|NCT02849028|BEHAVIORAL|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
219697661|NCT05139355|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
219697662|NCT01516216|DRUG|FOLFOX + bevacizumab|
219697663|NCT01516216|DIETARY_SUPPLEMENT|Vitamin D|
219697664|NCT05396690|DRUG|Remimazolam Injection [Byfavo]|Induction dose: 6 mg/kg/h with sufentanil Maintenance dose: 1\~2 mg/kg/h with sufentanil If arousal occurs during surgery, rapidly increase the infusion rate of remimazolam to 12 mg/kg/h and infuse for 1 minute. If the patient's arousal persists after these measures, stop remimazolam infusion and replace with another drug.
219697665|NCT05396690|DRUG|Sevoflurane|Induction dose: 2\~3 mg midazolam with sufentanil Maintenance: Adjust the concentration to be BIS 35-65 based on 0.5 mac If arousal occurs during surgery, raise the concentration of sevoflurane to 1.5 MAC (increase the total gas flow rate to 8 l/min) and if arousal persists after 1 minute, administer midazolam 2-3 mg.
219697666|NCT04784130|BEHAVIORAL|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
219110805|NCT04692844|DRUG|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
219110806|NCT05097118|DRUG|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
219697667|NCT04784130|BEHAVIORAL|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
219110807|NCT01801553|OTHER|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
219697668|NCT04784130|BEHAVIORAL|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
219697669|NCT03299985|OTHER|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
219697670|NCT03299985|OTHER|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
219697671|NCT03197636|DRUG|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
219697672|NCT01712282|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
219110808|NCT01801553|OTHER|sham spinal manipulation|
219110809|NCT01801553|OTHER|Usual medical care|
219110810|NCT02387437|BEHAVIORAL|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
219110811|NCT02387437|BEHAVIORAL|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
219110812|NCT02387437|BEHAVIORAL|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
219110813|NCT05461105|DRUG|rencofilstat, 75 mg|1 softgel capsule
219697673|NCT03759080|PROCEDURE|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
219110814|NCT05461105|DRUG|rencofilstat, 150mg|2 softgel capsules
219110815|NCT05461105|DRUG|rencofilstat, 225 mg|3 softgel capsules
219110816|NCT05713812|PROCEDURE|Kinesiotaping|Kinesiotape will be applied
219110817|NCT05713812|PROCEDURE|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
219110818|NCT04216979|PROCEDURE|laparoscopy entry policy|"Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site."
219110819|NCT06531135|BEHAVIORAL|T-CBSM|A 10-week remotely-delivered group, lasting about 120 minutes each session.
219110820|NCT06531135|BEHAVIORAL|Support group|Participants will receive weekly supportive-expressive group intervention for two hours per week for five weeks total.
219110821|NCT00167986|DRUG|vancomycin-resistant enterococci and ESBL|
219110822|NCT03273140|DEVICE|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
219110823|NCT05641142|OTHER|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~* hemoglobin and ferritin levels~* transfusion or intravenous iron~* hospitalization for bleeding or thrombose~* digestive bleeding and/or another haemorrhagic accident~* severity of epistaxis~* quality of life"
219110824|NCT02523313|DRUG|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
219697674|NCT03759080|PROCEDURE|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
219697675|NCT03092427|DIETARY_SUPPLEMENT|VSL#3|Dietary Supplement
219697676|NCT03092427|OTHER|Placebo|Placebo
219697677|NCT05529537|OTHER|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
219697678|NCT05529537|OTHER|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
219110825|NCT02523313|DRUG|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
219110826|NCT02523313|DRUG|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
219110827|NCT04658160|BEHAVIORAL|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
219110828|NCT05731882|DEVICE|E-SeaLA, CardioPulse PFA system|First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
219697679|NCT01490411|DRUG|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
219697680|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
219697681|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
219697682|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
219697683|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
219697684|NCT00187408|DRUG|Low Molecular Weight Heparin (dalteparin)|
219697685|NCT02674724|OTHER|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
219697686|NCT02674724|OTHER|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
219697687|NCT02674724|OTHER|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
219110829|NCT02423590|DRUG|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
219110830|NCT02423590|DRUG|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
219110831|NCT02423590|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
219110832|NCT04169919|DRUG|Povidone-Iodine|Povidone-Iodine 5% eye wash
219110833|NCT04169919|DRUG|Normal Saline Flush|Normal Saline eye wash
219110834|NCT03621722|OTHER|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
219110835|NCT05826522|OTHER|observationnal|cohort of blood collection and severals exams
219110836|NCT02354924|DEVICE|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
219110837|NCT02354924|DEVICE|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
219110838|NCT03953404|DIAGNOSTIC_TEST|SPLA2-IIA|bedside blood test
219110839|NCT05141981|DEVICE|inbody device|measure muscle mass
219110840|NCT01849120|DEVICE|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
219110841|NCT05744050|BEHAVIORAL|Low energy density lunch|Particpants will be provided with a lunch low in energy density (\~1.1kcal/g)
219110842|NCT05744050|BEHAVIORAL|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(\~1.7kcal/g)
219110843|NCT05744050|BEHAVIORAL|High energy density lunch|Participants will be provided with a lunch high in energy density (\~3kcal/g)
219110844|NCT01432015|DRUG|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
219110845|NCT01432015|DRUG|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
219110846|NCT01432015|OTHER|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
219110847|NCT01432015|OTHER|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
219110848|NCT00263120|BEHAVIORAL|Pain Questionnaire|
219697688|NCT05213091|OTHER|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
219110849|NCT05634122|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
219110850|NCT05634122|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment for patients with chronic pain
219110851|NCT00262288|DRUG|i.v. recombinant human C1 inhibitor|
219110852|NCT06268639|PROCEDURE|Osseodensification|The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
219110853|NCT05889819|DIETARY_SUPPLEMENT|Almond orange potato cookies for stunted under-five children|"Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study."
219110854|NCT04262492|DRUG|Rivaroxaban|Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID
219110855|NCT04645238|OTHER|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
219110856|NCT04645238|OTHER|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
219110857|NCT04765592|DEVICE|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
219110858|NCT05351060|OTHER|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
219110859|NCT01562002|PROCEDURE|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
219697689|NCT02471443|PROCEDURE|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
219110860|NCT06104072|DEVICE|REHACOM Software|"It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning \& executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~* For each Cognitive training domain there is one hundred levels of difficulty.~* Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~* The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level."
219110861|NCT06104072|OTHER|A Designed Physical Therapy Program|A designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, postural correction, gait training, balance training on different base of supports using static and dynamic balance training with reciprocal and weight shifting exercises.
219110862|NCT04329104|BIOLOGICAL|VRC-MALMAB0100-00-AB (CIS43LS)|Administered via one-time intravenous infusion
219110863|NCT04329104|OTHER|Normal saline|Administered via one-time intravenous infusion
219110864|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 100mg|Take it with 240ml water in fasted condition.
219110865|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 300mg|Take it with water in fasted condition or after taking infant formula.
219110866|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 25mg|Take it with 240ml water on an empty stomach.
219110867|NCT05932459|DRUG|Deuremidevir Hydrobromide tablets 100mg|Take it with 240ml water in fasted condition.
219697690|NCT03777501|BEHAVIORAL|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
219697691|NCT03777501|BEHAVIORAL|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
219697692|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
219697693|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
219697694|NCT01030146|DRUG|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
219697695|NCT04606303|DRUG|Toripalimab combination with platinum-containing dual-drug chemotherapy.|"cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician."
219697696|NCT05424341|OTHER|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
219697697|NCT05424341|OTHER|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
219697698|NCT01603602|BIOLOGICAL|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
219697699|NCT01603602|DRUG|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
219697700|NCT01176929|OTHER|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians."
219697701|NCT01176929|OTHER|Usual Treatment|Usual Treatment
219697702|NCT00304629|DRUG|galantamine|
219697703|NCT02641054|DRUG|CVXL-0107|
219110868|NCT06768957|OTHER|Single leg hop for distance|"Patients will have to perform a Single leg hop for distance.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1\. Patient balanced on 1 foot, hands crossed over shoulders. 2. Jump as far as possible.~3\. Stabilise 1 time, keeping hands on shoulders."
219161472|NCT05247242|BEHAVIORAL|Lakeshore Online Fitness (Online)|Online physical activity program delivered to residents of Tarrant, AL via teleconferencing technology to a local community center. Instructors from Lakeshore will lead the physical activity program. This intervention will last six weeks.
219161473|NCT05247242|BEHAVIORAL|Get Active with Virtual Reality (VR)|Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
219697704|NCT02641054|DRUG|Placebo|
219697705|NCT02641054|DRUG|Levodopa|
219697706|NCT00910598|DRUG|glatiramer acetate|20 mg daily s.c. for 1 year
219697707|NCT00666250|DIETARY_SUPPLEMENT|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
219697708|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and calcium sulfate|
219697709|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and xenograft|
219697710|NCT01040819|DRUG|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin \>162 mg/d, steroids and prostaglandin analogs will be prohibited.
219110869|NCT06768957|OTHER|Single leg hop for distance plus cognitive task|"Patients were asked to perform a single leg hop for distance in addition to a cognitive task.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1. Patient balanced on 1 foot, hands crossed over shoulders.~2. Observe a sequence of 5 digits, appearing every 4 seconds, on the computer in front of you.~3. As soon as the 5th digit appears, jump as far as you can.~4. Stabilise 1 time, keeping your hands on your shoulders.~5. Replay the sequence of 5 numbers that appear on the screen, in reverse order."
219110870|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
219110871|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
219110872|NCT05285917|DRUG|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
219110873|NCT03884231|DEVICE|Infinity DBS System with MR Conditional labelling|Patients implanted with the Infinity DBS system with MR Conditional labeling
219110874|NCT06076473|DIAGNOSTIC_TEST|Untargeted metabolomics|Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
219110875|NCT03849872|DRUG|ONO-5788|Investigational Drug
219110876|NCT03849872|DRUG|[14C]-ONO-5788|Investigational Drug
219110877|NCT00559910|DRUG|PH-797804|PH-797804 at four dose levels
219110878|NCT00559910|DRUG|Placebo|Placebo
219697711|NCT04748718|OTHER|Exercise-based injury prevention program|\~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
219697712|NCT03073707|BEHAVIORAL|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
219697713|NCT04738383|PROCEDURE|Version 1: Paramedic|Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.
219697714|NCT04738383|PROCEDURE|Version 2: Physician-on-call|This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.
219697715|NCT04738383|PROCEDURE|Version 3: Trained instructor|The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
219697716|NCT03056053|DRUG|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
219697717|NCT01951300|OTHER|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
219697718|NCT01592955|DEVICE|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
219110879|NCT06345209|DEVICE|Sirolimus-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
219110880|NCT06345209|DEVICE|Drug-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Drug-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
219110881|NCT01349010|DRUG|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
219697719|NCT01065818|DRUG|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
219697720|NCT02186041|DEVICE|Sacral Nerve Modulation|
219110882|NCT01349010|DRUG|Placebo|1 tablet bid. p.o for 8 weeks
219110883|NCT00911924|DEVICE|iStent|Glaukos iStent, medication
219110884|NCT06475560|DIAGNOSTIC_TEST|CCE arm|Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.
219110885|NCT06475560|DIAGNOSTIC_TEST|OC arm|Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.
219110886|NCT01548014|DIETARY_SUPPLEMENT|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
219110887|NCT00145717|DRUG|Plant sterol enriched milk tea|
219110888|NCT01853254|DRUG|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
219110889|NCT01853254|DRUG|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
219110890|NCT02359149|PROCEDURE|intravitreal injections given by a nurse|
219110891|NCT02359149|PROCEDURE|intravitreal injections given by a physician|
219110892|NCT02359149|PROCEDURE|Intravitreal injections|
219110893|NCT02359149|DRUG|Anti-VEGF agents|
219110894|NCT02653014|DRUG|KBP-5074|
219224751|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219224752|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219697721|NCT01450813|DRUG|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
219697722|NCT01450813|DRUG|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
219697723|NCT01450813|DRUG|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
219697724|NCT01450813|DRUG|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
219110895|NCT02679768|BEHAVIORAL|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
219110896|NCT02679768|BEHAVIORAL|Standard treatment|Standard treatment plus electronical monitoring
219110897|NCT04055506|DRUG|BMS-986165|Dose 1
219110898|NCT04055506|DRUG|Ritonavir|100 mg
219110899|NCT06469073|PROCEDURE|Transversus thoracic muscle plane block or Erector spinal plane block|Transversus thoracic muscle plane block or Erector spinal plane block
219110900|NCT02755454|DEVICE|Perfusion CT Imaging|
219110901|NCT01854294|DRUG|GM604|GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
219110902|NCT01854294|DRUG|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
219110903|NCT03620903|DRUG|Ibrutinib / Bortezomib / Rituximab|Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
219110904|NCT02903628|BEHAVIORAL|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
219110905|NCT03753282|OTHER|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication"
219110906|NCT03753282|OTHER|questionnaire for course of the disease|"questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions"
219110907|NCT00398398|DRUG|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
219110908|NCT03823976|OTHER|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
219110909|NCT05471869|DIAGNOSTIC_TEST|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
219224753|NCT05649137|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
219224754|NCT03997786|DRUG|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
219224755|NCT03997786|DRUG|Placebo|(Weeks 0 to 16)
219224756|NCT03997786|DRUG|Tildrakizumab|(Weeks 16 to 52)
219697725|NCT01935089|DRUG|Pegylated Interferon alpha 2b|1µg/kg/week
219697726|NCT01994213|DRUG|Famitinib|Famitinib 25 mg p.o. qd
219697727|NCT02052362|DRUG|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
219697728|NCT05301439|PROCEDURE|Restoration with Resin|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months."
219697729|NCT05301439|PROCEDURE|Hall Technique|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
219697730|NCT05301439|PROCEDURE|Conventional Steel Crown|"* Prophylaxis;~* Relative isolation;~* The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~* Cleaning the cavity with water;~* Slight drying;~* Trial of steel crown;~* Relative isolation;~* Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~* Clinical and radiographic control at 1, 3, 6 and 12 months."
219110910|NCT03428061|OTHER|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
219110911|NCT03279705|DEVICE|Water jet channel|The separate water jet channel was used for infusing water.
219110912|NCT03279705|DEVICE|Accessory channel|The accessory channel was used for infusing and/or suctioning water
219110913|NCT03674606|DRUG|Low dose aspirin|One 75 mg aspirin dose taken daily
219110914|NCT02262611|DRUG|Micardis®|
219110915|NCT02262611|DRUG|MicardisPlus®|
219697731|NCT01400048|DIETARY_SUPPLEMENT|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
219697732|NCT01400048|DIETARY_SUPPLEMENT|Placebo control|60mg Ascorbic acid
219697733|NCT00208364|DEVICE|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
219697734|NCT04236284|DEVICE|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 \_ 7 cm saline-soaked surface sponge electrodes.
219697735|NCT04236284|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
219697736|NCT00218907|PROCEDURE|Educational video|
219697737|NCT04483414|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
219697738|NCT04483414|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
219697739|NCT02271451|DEVICE|Q collar|collar worn around neck
219697740|NCT02147171|DIETARY_SUPPLEMENT|VisionAce|
219697741|NCT02147171|DIETARY_SUPPLEMENT|Placebo|
219697742|NCT06021327|PROCEDURE|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
219110916|NCT01339611|BEHAVIORAL|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
219110917|NCT03932448|OTHER|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
219110918|NCT04176133|DRUG|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
219110919|NCT04176133|DRUG|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
219110920|NCT04176133|DRUG|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
219110921|NCT01314781|DRUG|solifenacin|solifenacin 5mg tablet once daily
219697743|NCT06021327|PROCEDURE|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
219697744|NCT00723229|DRUG|acyclovir|Acyclovir 400 mg PO BID for 28 days
219697745|NCT02337491|DRUG|Pembrolizumab|
219697746|NCT02337491|DRUG|Bevacizumab|
219697747|NCT03455517|DRUG|Venetoclax|Venetoclax and rituximab association
219697748|NCT03455517|DRUG|Rituximab|Venetoclax and rituximab association
219697749|NCT00703235|DRUG|Bevacizumab|
219697750|NCT04320498|BIOLOGICAL|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
219110922|NCT01314781|PROCEDURE|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
219110923|NCT04327908|OTHER|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
219110924|NCT06480643|OTHER|High load exercise type|Heavier load, fewer reps
219110925|NCT06480643|BEHAVIORAL|Low load exercise type|Lighter load, more reps
219110926|NCT01645332|DRUG|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
219110927|NCT01645332|DRUG|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
219110928|NCT01645332|OTHER|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
219110929|NCT01755286|DRUG|OTO-201|Single intra-operative injection
219110930|NCT01755286|DRUG|Placebo|Single intratympanic injection
219110931|NCT01755286|DRUG|Sham|Simulated single intratympanic injection
219110932|NCT01730781|RADIATION|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
219110933|NCT00210665|DRUG|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
219110934|NCT00380887|DRUG|Premarin|
219697751|NCT04320498|DRUG|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
219697752|NCT04320498|BEHAVIORAL|sitz bath|participants were told to take a hot water sitz bath once a day
219697753|NCT04320498|DIETARY_SUPPLEMENT|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
219697754|NCT03261076|BEHAVIORAL|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
219697755|NCT00354315|BEHAVIORAL|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
219697756|NCT01368510|BEHAVIORAL|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
219697757|NCT01368510|BEHAVIORAL|Waitlist|Minimal contact waitlist weekly for 4 weeks
219697758|NCT04213443|OTHER|Analysis of a patient registry|Analysis of a patient registry.
219697759|NCT03106688|DIAGNOSTIC_TEST|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
219697760|NCT03106688|DIAGNOSTIC_TEST|[11C]carfentanil PET scan|\[11C\]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
219697761|NCT03106688|DIAGNOSTIC_TEST|[18F]FMPEP-d2 PET scan|\[18F\]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
219697762|NCT03106688|DIAGNOSTIC_TEST|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand \[18F\]-FDG.
219697763|NCT03106688|DIAGNOSTIC_TEST|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
219697764|NCT03106688|DIAGNOSTIC_TEST|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
219697765|NCT03106688|DIAGNOSTIC_TEST|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
219697766|NCT03106688|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
219697767|NCT05846750|DRUG|Obinutuzumab|"Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression"
219697768|NCT05846750|DRUG|lenalidomide|"Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression"
219697769|NCT03848559|DEVICE|Airway management with a submerged model|Airway management with a submerged manikin using different airway devices in randomized order
219697770|NCT03885947|BIOLOGICAL|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
219110935|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
219110936|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
219697771|NCT03885947|DRUG|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
219697772|NCT03885947|DRUG|Fludarabine|Fludarabine 150 mg/m2
219697773|NCT03885947|DRUG|cytoxan|Cytoxan 50 mg/m2
219697774|NCT03885947|DRUG|Thiotepa|Thiotepa 10 mg/m2
219697775|NCT03885947|BIOLOGICAL|TBI|TBI 400cGy
219697776|NCT01057355|PROCEDURE|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
219110937|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
219110938|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
219110939|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
219224757|NCT03997786|DRUG|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
219110940|NCT06458829|BEHAVIORAL|SEARCH-AF|SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
219110941|NCT05200390|DEVICE|Continuous glucose monitor|FreeStyle Libre 2 system
219110942|NCT00555204|DRUG|ABT-089|10 mg - capsules once daily for 12 weeks
219110943|NCT00555204|DRUG|ABT-089|5 mg - capsules once daily for 12 weeks
219110944|NCT00555204|DRUG|ABT-089|15 mg - capsules once daily for 12 weeks
219110945|NCT00555204|DRUG|ABT-089|20 mg - capsules once daily for 12 weeks
219110946|NCT00555204|DRUG|ABT-089|30 mg - capsules once daily for 12 weeks
219110947|NCT00555204|DRUG|ABT-089|35 mg - capsules once daily for 12 weeks
219110948|NCT00555204|DRUG|placebo|placebo - capsules once daily for 12 weeks
219110949|NCT05054127|OTHER|foiiow up patients|observational study
219110950|NCT00284375|PROCEDURE|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
219110951|NCT01087723|DRUG|Bivalirudin|
219110952|NCT01087723|DRUG|Heparin|
219110953|NCT04539119|DRUG|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.
219110954|NCT04539119|DRUG|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
219110955|NCT02717013|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
219110956|NCT02717013|DIETARY_SUPPLEMENT|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
219110957|NCT00079794|DRUG|Iscar|
219110958|NCT00079794|DRUG|mistletoe|
219110959|NCT04782310|DRUG|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
219110960|NCT04782310|DRUG|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
219110961|NCT03976310|DRUG|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
219110962|NCT03976310|OTHER|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
219110963|NCT02338713|DRUG|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
219110964|NCT02338713|DRUG|Noncarbonated Water|Noncarbonated water 200 mL
219110965|NCT05232149|DRUG|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
219110966|NCT05232149|DRUG|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
219110967|NCT02444585|DRUG|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
219110968|NCT03836898|DEVICE|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
219110969|NCT02054312|BEHAVIORAL|Family Based Interpersonal Psychotherapy (FB-IPT)|
219110970|NCT02054312|BEHAVIORAL|Client Centered Therapy (CCT)|
219110971|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
219110972|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
219110973|NCT00806624|DRUG|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
219110974|NCT00893568|OTHER|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
219110975|NCT05993195|DEVICE|Conduit Titanium Interbody Graft|The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
219110976|NCT05993195|DEVICE|Concorde Bullet Device|This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
219110977|NCT01918293|DEVICE|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
219110978|NCT04746430|DRUG|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
219110979|NCT01508143|DRUG|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
219110980|NCT01508143|DRUG|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
219110981|NCT01565018|DRUG|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
219110982|NCT01565018|DRUG|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
219110983|NCT02550132|PROCEDURE|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
219110984|NCT02550132|DEVICE|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
219110985|NCT03134378|DRUG|Rabeprazole Sodium 20mg|Twice daily
219110986|NCT03134378|DRUG|Clarithromycin 500mg|Twice daily
219110987|NCT03134378|DRUG|Amoxicillin 500 Mg|Twice daily
219110988|NCT01615588|DIETARY_SUPPLEMENT|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
219110989|NCT01177202|BIOLOGICAL|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
219110990|NCT00239629|DRUG|Teriparatide|
219110991|NCT00239629|DRUG|Strontium ranelate|
219110992|NCT00239629|PROCEDURE|Transiliac bone biopsy|
219110993|NCT03483077|DRUG|BI 730460|tablets
219697777|NCT04474340|DRUG|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
219110994|NCT03483077|DRUG|Placebo|tablets
219110995|NCT05258747|DRUG|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
219110996|NCT05258747|DRUG|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
219697778|NCT04383197|BEHAVIORAL|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
219697779|NCT04383197|DRUG|Semaglutide|3 months of therapeutic treatment with semaglutide
219697780|NCT04951141|BIOLOGICAL|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
219697781|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
219697782|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
219697783|NCT04082052|BEHAVIORAL|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
219697784|NCT02896166|OTHER|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
219697785|NCT02025075|DRUG|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
219697786|NCT01064544|PROCEDURE|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
219697787|NCT03073486|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
219110997|NCT06060834|DIETARY_SUPPLEMENT|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
219110998|NCT04392232|DRUG|Convalescent Plasma|"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."
219110999|NCT04295746|OTHER|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
219111000|NCT03747289|OTHER|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
219111001|NCT03747289|OTHER|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
219111002|NCT02364453|DRUG|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
219111003|NCT06249620|DIETARY_SUPPLEMENT|Inmunoferon|The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
219224758|NCT03997786|DRUG|Tildrakizumab|(Weeks 0 to 16)
219224759|NCT03997786|DRUG|Etanercept|(Weeks 0 to 16)
219224760|NCT03997786|DRUG|Placebo|(Weeks 16 to 52)
219697788|NCT03073486|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
219111004|NCT06249620|DIETARY_SUPPLEMENT|Placebo|The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
219111005|NCT01929330|DRUG|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
219111006|NCT01929330|DRUG|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
219111007|NCT04386590|OTHER|Manual Therapy Plus Pulmonary Rehabilitation|Manual therapy combined with Pulmonary Rehabilitation
219111008|NCT04386590|OTHER|Sham Intervention|Detuned US plus Pulmonary Rehabilitation
219111009|NCT04882020|DIAGNOSTIC_TEST|cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha|compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
219111010|NCT06054620|DIETARY_SUPPLEMENT|Collagen and Vitamin C|Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
219111011|NCT06054620|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Iso-caloric Placebo (30g maltodextrin).
219111012|NCT00007293|DEVICE|UV-B Lightsource and Fiber Optic Comb|
219697789|NCT03766035|DEVICE|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
219697790|NCT02391831|OTHER|Strength, function and activity measurements|
219697791|NCT02391831|OTHER|Muscle MRI|
219697792|NCT02391831|OTHER|Electrophysiology measurements|
219697793|NCT02391831|OTHER|Blood sampling for biomarker analysis|
219697794|NCT03236454|DEVICE|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
219697795|NCT04960215|DRUG|Coenzyme Q10|Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
219697796|NCT04960215|DRUG|Placebo|A soft gelatin capsule containing soy oil, 5 capsules a day.
219111013|NCT00255658|DRUG|sorafenib tosylate|Given orally
219111014|NCT00255658|DRUG|temsirolimus|Given IV
219111015|NCT00255658|OTHER|laboratory biomarker analysis|Correlative studies
219111016|NCT00956540|PROCEDURE|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
219111017|NCT00956540|PROCEDURE|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
219111018|NCT01805765|DRUG|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
219697797|NCT01120262|GENETIC|gene expression analysis|
219111019|NCT01805765|DRUG|Placebo|Containing 2% of Qing'E pills
219111020|NCT00698321|BEHAVIORAL|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
219111021|NCT00698321|BEHAVIORAL|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
219111022|NCT01629654|BEHAVIORAL|Health promotion program|"A 13 weeks organized program:~* One group session about poststroke fatigue involving both patient and relatives~* Two personal meetings, involving both patient and relatives~* Three telephone meetings, involving only patient"
219111023|NCT02584764|BEHAVIORAL|Cognitive behavior therapy|
219111024|NCT02584764|BEHAVIORAL|Internet support|
219111025|NCT01554943|OTHER|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
219111026|NCT04241874|OTHER|Mechanical Ventilation|Respiratory support through mechanical ventilator
219111027|NCT00432861|DRUG|PANCRECARB® (pancrelipase)|Capsules
219111028|NCT00432861|DRUG|Placebo|Capsules
219111029|NCT00563992|DRUG|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
219697798|NCT01120262|GENETIC|polymorphism analysis|
219697799|NCT01120262|OTHER|laboratory biomarker analysis|
219697800|NCT03469115|DIAGNOSTIC_TEST|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
219697801|NCT00239148|DRUG|E1 and G1|
219697802|NCT02763774|OTHER|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
219697803|NCT02763774|OTHER|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
219697804|NCT02763774|OTHER|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
219697805|NCT06525116|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
219111030|NCT00563992|DRUG|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
219697806|NCT03671070|DRUG|Epinephrine|IV Low dose Boluses
219697807|NCT03671070|DRUG|Traditional management of shock|"1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
219697808|NCT03173417|BIOLOGICAL|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
219697809|NCT03173417|DRUG|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
219697810|NCT01483118|DRUG|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
219697811|NCT01483118|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing ground cereal.
219697812|NCT03098316|DIAGNOSTIC_TEST|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
219697813|NCT02791256|DRUG|Ribavirin|
219697814|NCT02791256|DRUG|peginterferon alfa-2a|
219111031|NCT02766673|DRUG|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
219111032|NCT02766673|DRUG|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
219111033|NCT00467142|BIOLOGICAL|bevacizumab|
219111034|NCT00467142|DRUG|fluorouracil|
219111035|NCT00467142|DRUG|irinotecan hydrochloride|
219111036|NCT00467142|DRUG|leucovorin calcium|
219111037|NCT00467142|GENETIC|polymorphism analysis|
219111038|NCT00279994|PROCEDURE|Exercise therapy|
219111039|NCT00279994|DEVICE|Accelerometer (PAM; Personal Activity Monitor)|
219111040|NCT00279994|PROCEDURE|Oral Exercise Therapy advise|
219111041|NCT01034579|OTHER|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
219111042|NCT01034579|OTHER|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
219111043|NCT03498079|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
219697815|NCT02932657|OTHER|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
219697816|NCT03785028|BEHAVIORAL|working memory and attention|working memory and attention tasks
219697817|NCT03518359|BEHAVIORAL|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
219697818|NCT03518359|BEHAVIORAL|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
219697819|NCT03757416|OTHER|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
219111044|NCT04873778|DEVICE|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
219697820|NCT01746719|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
219111045|NCT04873778|DEVICE|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
219111046|NCT01803295|DEVICE|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
219111047|NCT01803295|OTHER|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
219111048|NCT01803295|DEVICE|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
219111049|NCT03893825|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm description.
219111050|NCT03893825|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
219111051|NCT04942860|DRUG|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
219697821|NCT01746719|DRUG|Etodolac|500 mg tablet once a day
219697822|NCT02870491|BEHAVIORAL|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
219111052|NCT04942860|DRUG|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
219111053|NCT05765097|DEVICE|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
219111054|NCT03022240|DRUG|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
219111055|NCT03022240|DRUG|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
219111056|NCT03022240|DRUG|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
219111057|NCT03022240|DRUG|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
219697823|NCT02870491|BEHAVIORAL|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
219697824|NCT05704816|OTHER|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
219697825|NCT02104440|BIOLOGICAL|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
219697826|NCT03844841|DRUG|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
219111058|NCT05206864|OTHER|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
219111059|NCT05206864|OTHER|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
219111060|NCT04017702|DEVICE|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
219111061|NCT04350476|DIAGNOSTIC_TEST|VitalConnect Vital Sign Patch|"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."
219111062|NCT00535743|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
219111063|NCT00535743|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
219111064|NCT00535743|DRUG|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
219111065|NCT02864043|DEVICE|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
219111066|NCT02864043|PROCEDURE|esophagogastroduodenoscopy (EGD)|Standard of care EGD
219111067|NCT05689814|DEVICE|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
219111068|NCT04657549|PROCEDURE|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
219111069|NCT04657549|PROCEDURE|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
219111070|NCT00239785|DRUG|FTY720|
219111071|NCT03781232|DEVICE|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
219111072|NCT00497965|PROCEDURE|Chiropractic Manipulation|
219224761|NCT05355792|DEVICE|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
219697827|NCT03844841|DRUG|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
219697828|NCT01126892|DRUG|Nilotinib|
219697829|NCT01079780|BIOLOGICAL|cetuximab|Given IV
219697830|NCT01079780|BIOLOGICAL|ramucirumab|Given IV
219697831|NCT01079780|DRUG|irinotecan hydrochloride|Given IV
219697832|NCT05496023|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES"
219697833|NCT02696889|PROCEDURE|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
219697834|NCT02081989|PROCEDURE|Renal denervation|Renal denervation
219224762|NCT05098171|BIOLOGICAL|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
219111073|NCT00497965|BEHAVIORAL|Balance Exercises|
219111074|NCT02332330|DEVICE|VEST|
219111075|NCT00874289|OTHER|NGAL kit|Kit to test NGAL levels in heart failure patients
219111076|NCT05690061|DIETARY_SUPPLEMENT|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
219111077|NCT05690061|DIETARY_SUPPLEMENT|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
219111078|NCT05690061|DIETARY_SUPPLEMENT|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
219697835|NCT01392599|PROCEDURE|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
219697836|NCT02158897|OTHER|Prolon diet|3 cycles of a 5-day Prolon diet very month
219697837|NCT01093768|DRUG|Oxytocin|
219697838|NCT01093768|DRUG|Vasopressin|
219697839|NCT01937988|OTHER|Doula Arm|
219161474|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
219111079|NCT03190863|BEHAVIORAL|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
219111080|NCT03190863|BEHAVIORAL|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
219111081|NCT03190863|BEHAVIORAL|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
219111082|NCT00922844|DRUG|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
219111083|NCT06316219|DRUG|Nomegestrol Acetate/Estradiol 2.5mg/1.5mg|hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
219111084|NCT02240719|DRUG|everolimus|Given PO
219111085|NCT02240719|DRUG|bendamustine hydrochloride|Given IV
219224763|NCT05405101|PROCEDURE|Thermal ablation of aldosterone producing adenoma.|"On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance."
219224764|NCT05405101|PROCEDURE|Unilateral adrenalectomy|Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
219111086|NCT04610762|DIAGNOSTIC_TEST|GeneXpert HCV VL Fingerstick test|The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
219111087|NCT00957788|DRUG|NST-001|Comparison of different dosages of drug.
219111088|NCT00734214|DRUG|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
219111089|NCT00734214|DRUG|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
219111090|NCT00431639|BEHAVIORAL|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
219111091|NCT05046977|PROCEDURE|Single osteotomy|Single tibial osteotomy
219111092|NCT05046977|PROCEDURE|Double Osteotomy|Double Tibial Osteotomy
219111093|NCT04516421|DIETARY_SUPPLEMENT|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
219111094|NCT04516421|DIETARY_SUPPLEMENT|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
219111095|NCT03209401|DRUG|Niraparib|an oral PARP inhibitor
219111096|NCT03209401|DRUG|Carboplatin|a platinum-based injection
219111097|NCT00953095|BEHAVIORAL|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
219111098|NCT04055168|DRUG|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
219111099|NCT04055168|DRUG|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
219697840|NCT03435055|DRUG|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
219697841|NCT04630743|BEHAVIORAL|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
219224765|NCT06453681|OTHER|bilateral PECS|ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
219111100|NCT03562351|OTHER|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
219111101|NCT03562351|OTHER|Video Educational Intervention|Caregivers will undergo training with an educational video
219111102|NCT03562351|OTHER|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
219111103|NCT02459080|DRUG|TD-4208|
219111104|NCT02459080|DRUG|Placebo|
219697842|NCT03908346|OTHER|Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest|a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
219697843|NCT02431689|PROCEDURE|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
219697844|NCT04325997|DEVICE|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
219697845|NCT04325997|DEVICE|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
219697846|NCT05463965|BIOLOGICAL|QM1114-DP|Intramuscular injection
219697847|NCT05463965|BIOLOGICAL|OnabotulinumtoxinA|Intramuscular injection
219697848|NCT05463965|BIOLOGICAL|Placebo|Intramuscular injection
219697849|NCT01876095|PROCEDURE|Multidisciplinary medication review|"Consists of the following steps:~* 1\. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~* 2\. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~* 3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~* 5\. Execution of pharmaceutical care plan according to agreed schedule."
219697850|NCT04999241|COMBINATION_PRODUCT|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
219697851|NCT04999241|COMBINATION_PRODUCT|regular food|Administration of regular food in the induction phase and the later time.
219697852|NCT02121197|DRUG|Ozurdex|
219697853|NCT03913962|OTHER|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
219697854|NCT00586560|DRUG|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
219697855|NCT01235988|DRUG|Eltrombopag|Eltrombopag 50mg \& standard of care
219697856|NCT01235988|DRUG|Placebo|Placebo + standard of care
219697857|NCT03712280|DRUG|MNK6106|1 gram tablet of MNK6106 for oral administration
219111105|NCT01448421|DEVICE|Keystone Heart Embolic Deflection Device|The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
219697858|NCT03712280|DRUG|Rifaximin|550 mg tablet of rifaximin for oral administration
219697859|NCT04818099|DRUG|Vortioxetine 10 mg|Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
219697860|NCT04818099|OTHER|Placebo|Placebo will be used with a dosage of one tablet once a day for 2 months.
219697861|NCT03797352|OTHER|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
219697862|NCT04268693|OTHER|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
219697863|NCT00236743|DRUG|topiramate|
219697864|NCT05334667|OTHER|Routine management|Routine management
219111106|NCT04800523|DEVICE|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
219111107|NCT00240526|BIOLOGICAL|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
219697865|NCT05334667|DEVICE|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
219697866|NCT05334667|DEVICE|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
219111108|NCT00240526|BIOLOGICAL|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
219697867|NCT03736252|DEVICE|Orthosis provision|Hely and Weber CMC controller
219697868|NCT03176485|OTHER|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
219697869|NCT03802552|DRUG|Cefadroxil|oral one-time dose of cefadroxil
219111109|NCT02976597|DRUG|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
219697870|NCT03802552|DRUG|Cephalexin|oral one-time dose of cephalexin
219697871|NCT01939912|DRUG|Adenosine|Antiarrhythmic agent.
219697872|NCT05751551|OTHER|Personalized, home-based motor-cognitive training|"The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration."
219111110|NCT02976597|DRUG|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
219111111|NCT02976597|DRUG|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
219111112|NCT03550586|OTHER|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
219111113|NCT05575115|BEHAVIORAL|Peer Comparison|"Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers."
219111114|NCT02307110|OTHER|cross-sectional observation|cross-sectional opthalmic examination
219111115|NCT01716208|DRUG|Ofatumumab + Fresh Frozen Plasma|
219697873|NCT01066234|RADIATION|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
219697874|NCT01066234|DRUG|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
219697875|NCT05847608|DIETARY_SUPPLEMENT|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
219697876|NCT05847608|DIETARY_SUPPLEMENT|Placebo|Oleic Acid, Linoleic Acid
219697877|NCT01873014|DRUG|chinese herbs-I|two agent per day, twice a day
219111116|NCT03905590|PROCEDURE|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
219111117|NCT03905590|PROCEDURE|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
219111118|NCT01061918|DEVICE|Tecnis MF|20 patients in the Tecnis MF group.
219111119|NCT01061918|DEVICE|ReSTOR|20 patients in the ReSTOR group.
219111120|NCT00517426|DRUG|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
219111121|NCT02179372|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
219111122|NCT02179372|DIETARY_SUPPLEMENT|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
219111123|NCT06042868|OTHER|Nursing protocol|Emergency nursing protocol
219111124|NCT05348408|DRUG|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
219111125|NCT05658835|OTHER|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
219111126|NCT00664703|DRUG|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
219111127|NCT00664703|DRUG|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
219697878|NCT01873014|DRUG|chinese herbs-II|two agent per day, twice a day
219697879|NCT01607658|DRUG|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
219697880|NCT01607658|DRUG|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
219697881|NCT01607658|DRUG|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
219697882|NCT01607658|DRUG|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
219697883|NCT03248297|DRUG|Azithromycin|Azithromycin tablet
219697884|NCT03248297|DRUG|Azithromycin and amoxicillin|azithromycin and amoxicillin
219111128|NCT00664703|DRUG|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
219111129|NCT04901364|BEHAVIORAL|Sensitivity and specificity of risk factors for degeneration of IPMNs|Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen
219111130|NCT02590068|DRUG|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
219111131|NCT03632434|DEVICE|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
219111132|NCT02826148|OTHER|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
219697885|NCT03248297|DRUG|Placebo|Placebo tablet
219697886|NCT00733967|DRUG|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
219697887|NCT00733967|DRUG|Placebo|Matching oral placebo capsules as control.
219697888|NCT05789966|GENETIC|Genetic Risk Estimate+Health Coaching|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
219111133|NCT01751113|DRUG|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
219111134|NCT01751113|DRUG|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
219111135|NCT01751113|DRUG|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
219111136|NCT00325936|DRUG|Cilnidipine|10\~20mg, qd, po for 3 months or 12 months.
219111137|NCT02965118|DRUG|PAC-14028 cream 1.0%|topical application
219111138|NCT02965118|DRUG|PAC-14028 cream Vehicle|topical application
219111139|NCT03162757|PROCEDURE|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
219111140|NCT04855292|DRUG|TG103 injection|TG103 injection, SC, once weekly
219111141|NCT04855292|DRUG|Placebo|Placebo control, SC, once weekly
219111142|NCT01775930|DRUG|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
219111143|NCT06022718|OTHER|Taping|Kinesio taping and Rigid taping was applied.
219111144|NCT06461013|BEHAVIORAL|Blood flow restriction|A common clinical tourniquet (7cm \* 50cm in size) is placed in the middle section of the patient's thigh on the affected side, connected to a pressure gauge, observed and gradually pressurized to 160-170mmHg for about 10 minutes, then depressurized for 1 minute, and then re pressurized to 160-170mmHg. Each training session lasts for 20 minutes, once a day, five times a week, for a total of 8 weeks.
219111145|NCT03403777|DRUG|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
219111146|NCT01182727|DRUG|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
219111147|NCT01606956|PROCEDURE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
219111148|NCT01606956|PROCEDURE|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
219111149|NCT02218385|DEVICE|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
219697889|NCT05789966|DEVICE|Genetic Risk Estimate + Fitbit Functions+Health Coaching|"Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well"
219697890|NCT02479841|OTHER|Self management program|
219697891|NCT04206865|DRUG|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
219697892|NCT04206865|DRUG|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
219697893|NCT02700399|DEVICE|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
219697894|NCT02700399|DEVICE|Traditional tilt table from Rehab-Care|Traditional tilt table
219697895|NCT04554472|DIAGNOSTIC_TEST|Intraoperative ultrasound|During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
219111150|NCT00846833|BIOLOGICAL|Haploidentical NK cell|"1. Collection of PBMCs by leukapheresis~2. CD3+ depletion of apheresis product using CliniMACS®"
219111151|NCT01551303|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
219111152|NCT01551303|DRUG|Placebo|Matched nasal spray placebo
219111153|NCT02701751|OTHER|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
219111154|NCT03648593|BEHAVIORAL|work recovery intervention|Recover! app: one hour weekly for two months
219111155|NCT03648593|BEHAVIORAL|waiting list control|no treatment during 6 months,then Recover! app
219111156|NCT00786201|DRUG|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
219111157|NCT00786201|DRUG|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
219111158|NCT00786201|DRUG|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
219697896|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
219697897|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
219697898|NCT03894358|DIETARY_SUPPLEMENT|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
219697899|NCT05379920|BEHAVIORAL|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
219111159|NCT00786201|DRUG|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
219111160|NCT00363896|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
219111161|NCT00363896|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
219111162|NCT05142410|DIAGNOSTIC_TEST|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
219224766|NCT06453681|DRUG|Dexmedetomidine|Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
219697900|NCT05379920|BEHAVIORAL|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
219697901|NCT05608057|OTHER|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
219697902|NCT05608057|RADIATION|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
219697903|NCT03528421|BIOLOGICAL|IM19|CAR-T cells
219697904|NCT03528421|DRUG|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
219697905|NCT03528421|DRUG|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
219697906|NCT01267279|DRUG|Zoledronic acid|Zoledronic acid per protocol
219697907|NCT01267279|OTHER|Placebo|Placebo
219697908|NCT01559441|DIETARY_SUPPLEMENT|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
219697909|NCT01559441|DIETARY_SUPPLEMENT|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
219697910|NCT04786769|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
219697911|NCT00906126|DRUG|Misoprostol|Oral misoprostol
219697912|NCT03530293|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
219697913|NCT03530293|DRUG|Placebo oral capsule|non-active dosage form
219697914|NCT04614506|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
219697915|NCT04614506|DEVICE|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
219697916|NCT02069795|OTHER|Voice recording|
219697917|NCT04326257|DRUG|Nivolumab+Relatlimab|IV administration of both Nivolumab and Relatlimab
219697918|NCT04326257|DRUG|Nivolumab+Ipilimumab|IV administration of both Nivolumab and Ipilimumab
219697919|NCT02980016|DRUG|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
219697920|NCT02980016|DRUG|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
219111163|NCT01572324|DRUG|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
219224767|NCT04680481|DEVICE|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
219697921|NCT02365883|DEVICE|Photoacoustic Imaging System|manufactured by Endra
219697922|NCT04741048|DEVICE|CI624 Slim 20 Electrode|Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
219697923|NCT02024061|BEHAVIORAL|Peer support|
219697924|NCT02024061|BEHAVIORAL|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
219697925|NCT03385733|OTHER|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
219697926|NCT03541993|DIETARY_SUPPLEMENT|Resveratrol|
219697927|NCT03541993|OTHER|Placebo|
219697928|NCT01753349|BIOLOGICAL|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
219697929|NCT00914121|DRUG|SKI-606|
219697930|NCT00914121|DRUG|Placebo|
219697931|NCT00914121|DRUG|Moxifloxacin|
219697932|NCT00306254|DRUG|PD 0348292|
219697933|NCT00306254|DRUG|Enoxaparin|
219697934|NCT05728476|PROCEDURE|Vitrectomy combined with ILM peeling|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
219697935|NCT05728476|DRUG|Conbercept intravitreal injection|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
219697936|NCT06157450|DRUG|ZSP1273|Participants receive ZSP1273 orally.
219697937|NCT00231023|DRUG|Peribulbar Triamcinolone Acetonide|
219697938|NCT00609817|DRUG|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
219697939|NCT00609817|DRUG|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
219697940|NCT04676204|DRUG|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
219697941|NCT04676204|DRUG|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
219697942|NCT04676204|DRUG|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
219697943|NCT04676204|DRUG|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
219697944|NCT04676204|DRUG|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
219697945|NCT04676204|DRUG|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
219697946|NCT04229823|DIAGNOSTIC_TEST|Video-oculography|Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
219697947|NCT04229823|DIAGNOSTIC_TEST|Clinical Scales|All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
219697948|NCT04229823|DIAGNOSTIC_TEST|Genotyping|Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
219697949|NCT03022409|DRUG|Ceralasertib|"Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members."
219697950|NCT03022409|DRUG|Olaparib|"Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents."
219697951|NCT02944292|PROCEDURE|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
219697952|NCT02944292|DRUG|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
219697953|NCT01812187|BEHAVIORAL|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
219697954|NCT06436716|RADIATION|MRI|Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
219224768|NCT05683457|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
219224769|NCT05683457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219111164|NCT02351882|DRUG|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
219697955|NCT03588117|BEHAVIORAL|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
219697956|NCT06013566|DEVICE|SSVEP|Non-invasive, non-interventional SSVEP EEG device
219697957|NCT05762575|OTHER|knotting methods|The volunteers in experimental group study new knotting technology.
219697958|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
219697959|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
219697960|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
219697961|NCT05555680|OTHER|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
219697962|NCT02730962|DRUG|Vancomycin|Vancomycin 3 times a day for 7 days
219697963|NCT02730962|OTHER|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
219697964|NCT02730962|DRUG|Neomycin|Neomycin 3 times a day for 1 day
219697965|NCT02730962|DRUG|Clindamycin|Clindamycin 3 times a day for 5 days
219697966|NCT02730962|PROCEDURE|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
219697967|NCT02142842|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
219697968|NCT03980119|OTHER|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
219697969|NCT02860936|DRUG|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
219697970|NCT05376501|DIETARY_SUPPLEMENT|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
219697971|NCT05376501|OTHER|Placebo|Modified food starch
219697972|NCT01668797|DRUG|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
219697973|NCT01668797|DRUG|Placebo|Placebo comparator for 52 weeks
219111165|NCT02351882|DRUG|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
219111166|NCT03657264|DRUG|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
219697974|NCT03706846|PROCEDURE|fasting|fasting before gastrointestinal endoscopy
219697975|NCT00677638|DEVICE|Ventor Embracer|Implantation of Ventor Embracer
219697976|NCT04075448|OTHER|Control|100 grams breakfast cereal
219697977|NCT04075448|OTHER|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
219697978|NCT02530385|OTHER|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
219697979|NCT02530385|BIOLOGICAL|FMT Capsules|Capsules will be generated as per FDA-approved procedures
219697980|NCT03044418|OTHER|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
219111167|NCT03657264|DRUG|Moxifloxacin 400mg|One tablet per os
219111168|NCT03657264|DRUG|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
219111169|NCT03657264|DRUG|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
219111170|NCT03422458|DEVICE|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
219111171|NCT04814927|DRUG|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
219111172|NCT04814927|DRUG|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
219111173|NCT04814927|DRUG|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
219111174|NCT04814927|DRUG|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
219111175|NCT02385578|OTHER|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
219111176|NCT03555604|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
219111177|NCT02619227|OTHER|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
219111178|NCT06420674|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|"The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments."
219111179|NCT02443025|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
219111180|NCT02715895|DIETARY_SUPPLEMENT|Friso|Friso formula feeding on demand for 3 months
219111181|NCT02715895|DIETARY_SUPPLEMENT|Wyeth|Wyeth formula feeding on demand for 3 months
219111182|NCT02715895|DIETARY_SUPPLEMENT|Breast milk|Breast milk feeding on demand
219111183|NCT04519541|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
219111184|NCT04950556|OTHER|Exercise|Pelvic floor muscle exercise will be given to the exercise group
219111185|NCT04950556|OTHER|Control|No intervention
219111186|NCT05938725|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
219111187|NCT05938725|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219697981|NCT01569022|DEVICE|CPAP|CPAP Treatment for 12 weeks
219697982|NCT01569022|DEVICE|MAD|MAD Treatment for 12 weeks
219697983|NCT05238662|PROCEDURE|pedicle screw fixation on one side and intervertebral cage on the other sided|pedicle screw fixation on one side and intervertebral cage on the other sided
219697984|NCT05238662|PROCEDURE|pedicle screw fixation and interbody cage on the same side|pedicle screw fixation and interbody cage on the same side
219697985|NCT03613493|DIAGNOSTIC_TEST|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
219697986|NCT03613493|BEHAVIORAL|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
219697987|NCT03613493|BEHAVIORAL|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
219697988|NCT03613493|BEHAVIORAL|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
219697989|NCT01149941|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
219111188|NCT00924469|DRUG|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
219697990|NCT06266013|OTHER|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
219697991|NCT01135342|BEHAVIORAL|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
219697992|NCT01135342|BEHAVIORAL|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
219111189|NCT00924469|DRUG|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
219111190|NCT00924469|DRUG|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
219111191|NCT02433548|PROCEDURE|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
219111192|NCT02433548|PROCEDURE|Sham injection|subcutaneous of 5 cc of normal saline
219111193|NCT04573413|DEVICE|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
219111194|NCT04573413|DEVICE|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
219224770|NCT05830825|PROCEDURE|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
219697993|NCT01135342|BEHAVIORAL|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
219697994|NCT00253942|PROCEDURE|Injecting bee venom as a treatment for OA|
219697995|NCT02111083|BIOLOGICAL|Insulin Lispro|LY275585 administered SC.
219697996|NCT02818543|DRUG|LYC-30937|
219697997|NCT05151913|OTHER|Exploratory|Fecal microbiome
219697998|NCT00433836|DRUG|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
219697999|NCT00433836|DRUG|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
219698000|NCT05355155|DRUG|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
219111195|NCT04913818|BEHAVIORAL|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.
219111196|NCT04913818|OTHER|Control arm (Usual care)|Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
219111197|NCT02473887|DRUG|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
219111198|NCT03623880|BEHAVIORAL|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
219111199|NCT03623880|BEHAVIORAL|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
219111200|NCT04526405|DIAGNOSTIC_TEST|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
219111201|NCT01350622|DRUG|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
219111202|NCT01350622|DRUG|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
219111203|NCT06488560|DIETARY_SUPPLEMENT|commercial blenderized tube feed (CBTF)|Based on assessment by a dietician the participant will be fed the commercial blenderized formula to meet their caloric needs
219111204|NCT06488560|DIETARY_SUPPLEMENT|commercial formulas (CF)|Participant will be fed the commercial formula to meet their caloric needs per standard of care
219111205|NCT01013532|DRUG|Cilostazol|Cilostazol 100mg bid
219111206|NCT01013532|DRUG|Probucol|Probucol 250mg bid
219698001|NCT01163799|DRUG|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
219111207|NCT01013532|DRUG|Aspirin|Aspirin 100mg qd
219111208|NCT01013532|DRUG|placebo of cilostazol|same shape and size of active cilostazol
219111209|NCT01013532|DRUG|placebo of aspirin|same size and shape of active aspirin 100mg
219111210|NCT01013532|DEVICE|ankle-brachial index (ABI)|measurement of ABI every years during follow up
219111211|NCT01013532|DEVICE|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
219111212|NCT01013532|DEVICE|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
219111213|NCT01013532|DEVICE|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
219111214|NCT04171830|OTHER|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as \>0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~1. Edmonton Symptom Assessment System Revised: scores \>6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~2. 4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
219224771|NCT05741229|DRUG|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
219698002|NCT05601336|DRUG|Dapagliflozin 5 MG|SGLT2 inhibitor
219698003|NCT05601336|DRUG|Metformin Hydrochloride 1000 MG|metformin
219224772|NCT05741229|DRUG|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
219698004|NCT05601336|DRUG|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
219698005|NCT03368417|OTHER|Usual Care|"Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours."
219111215|NCT02638610|DEVICE|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
219111216|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 7 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
219111217|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 14 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
219111218|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 6 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
219111219|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 12 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
219111220|NCT01993537|DRUG|Vitamin D|
219111221|NCT02848612|DRUG|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
219111222|NCT03504735|BEHAVIORAL|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
219111223|NCT03504735|DRUG|Caduet Pill|Take once daily.
219111224|NCT03504735|DRUG|Placebo|Take once daily.
219111225|NCT00361075|DRUG|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
219111226|NCT00630058|DRUG|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
219111227|NCT00630058|DRUG|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
219698006|NCT03368417|OTHER|Wireless HBPM System|"BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control."
219111228|NCT01651936|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
219111229|NCT01651936|DRUG|Methotrexate|MTX dosed at the stable dose received upon study entry
219111230|NCT01651936|DRUG|Dose-match placebo|Dose-matched placebo dosed orally BID
219111231|NCT02465021|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
219111232|NCT04276662|DRUG|DS-3201b|1 dose of 50 mg DS-3201b
219111233|NCT03044353|DRUG|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
219111234|NCT03044353|BIOLOGICAL|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
219111235|NCT04788069|DIETARY_SUPPLEMENT|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
219111236|NCT04788069|DIETARY_SUPPLEMENT|Sourdough bread|180g sourdough bread/day + fixed portion at test day
219111237|NCT04788069|DIETARY_SUPPLEMENT|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
219111238|NCT01079143|DRUG|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
219111239|NCT01079143|DRUG|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
219224773|NCT06006455|DEVICE|Erchonia LunulaLaser|405nm violet and 635nm red laser light therapy.
219224774|NCT02357654|DRUG|GnRH|single shot of GnRH agonist
219224775|NCT02357654|DRUG|placebo|placebo
219224776|NCT02400060|BEHAVIORAL|Telephone-Based Intervention|Receive text messaging
219224777|NCT02400060|OTHER|Survey Administration|Ancillary studies
219224778|NCT02400060|OTHER|Laboratory Biomarker Analysis|Correlative studies
219224779|NCT03543059|DRUG|GnRH analogue|gonadotrophin releasing hormone analogue
219224780|NCT02395497|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
219224781|NCT02395497|DRUG|Tacrolimus|
219111240|NCT01079143|DRUG|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
219111241|NCT01079143|DRUG|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
219111242|NCT01079143|DRUG|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
219111243|NCT02162992|OTHER|No intervention|Observational
219111244|NCT06528561|PROCEDURE|Sef-care program with exercise|Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
219111245|NCT06442020|PROCEDURE|Tadalafil (PDE5i)|Tadalafil at a dose of 5mg/day
219111246|NCT02821832|PROCEDURE|Saliva collection|For biomarker assessments
219111247|NCT02821832|PROCEDURE|Urine collection|For biomarker assessments
219111248|NCT02821832|PROCEDURE|Sputum collection|For primary endpoint assessments and other biomarker assessments
219111249|NCT02821832|PROCEDURE|Blood Collection|For biomarker and eligibility assessments
219111250|NCT02821832|RADIATION|PET/CT Scan|Imaging of the lungs to establish disease extent and severity
219111251|NCT02821832|DRUG|Isoniazid, Rifampicin, Pyrazinamide and Ethambutol|Treatment-standard of care
219111252|NCT02141659|DRUG|TAK-385|TAK-385 Tablets.
219111253|NCT04001764|PROCEDURE|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
219111254|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
219111255|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
219111256|NCT04173312|COMBINATION_PRODUCT|Bupivacaine infusion|Local systemic Infusion of anesthetic
219111257|NCT04173312|COMBINATION_PRODUCT|Saline|Local systemic infusion of saline
219111258|NCT02825953|DRUG|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
219111259|NCT02825953|DEVICE|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
219111260|NCT02825953|DEVICE|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
219111261|NCT02825953|DEVICE|Neopuff|Fisher and Paykel, Auckland, New Zealand
219111262|NCT02825953|DEVICE|neonatal ventilator|GE Healthcare, Madison, USA
219111263|NCT02053428|PROCEDURE|percutaneous image-guided gastrostomy|
219111264|NCT03893864|DIETARY_SUPPLEMENT|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, \> 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
219111265|NCT03893864|PROCEDURE|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
219111266|NCT03893864|DIAGNOSTIC_TEST|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
219111267|NCT03893864|DIAGNOSTIC_TEST|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
219111268|NCT04708288|DEVICE|ARCHIMEDES Biodegradable Biliary and Pancreatic Stent|Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
219111269|NCT02857803|PROCEDURE|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
219111270|NCT02857803|PROCEDURE|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
219111271|NCT02857803|PROCEDURE|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
219224782|NCT02395497|PROCEDURE|Penile Allotransplantation|
219224783|NCT04376788|BIOLOGICAL|exchange blood transfusion from normal donor|IV method
219224784|NCT04376788|BIOLOGICAL|plasma from convalescent patients with COVID-19|IV method
219224785|NCT04376788|DRUG|Methylene Blue 5 MG/ML|IV method
219111272|NCT03877705|DRUG|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
219111273|NCT00676975|DRUG|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
219111274|NCT00676975|DRUG|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
219111275|NCT04329858|PROCEDURE|silver modified glass ionomer|occlusal cavity filled with silver modified
219111276|NCT04329858|PROCEDURE|zinc modified|occlusal cavity filled with zinc modified
219111277|NCT04329858|PROCEDURE|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
219111278|NCT02954900|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
219111279|NCT02954900|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
219111280|NCT01062412|DEVICE|LensAR Laser System|Laser treatment of the crystalline lens
219111281|NCT03745794|OTHER|Best Practice|Given standard of care
219111282|NCT03745794|DRUG|Quadratus Lumborum Block|Undergo QL block
219111283|NCT03745794|OTHER|Quality-of-Life Assessment|Ancillary studies
219111284|NCT03745794|OTHER|Questionnaire Administration|Ancillary studies
219698007|NCT03368417|BEHAVIORAL|BP Monitoring Incentives|"Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~* Participants receive SGD 3 for each day they measure their BP, up to three times per week.~* Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~* Participants receive an initial health capital of SGD 72~* Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading."
219111285|NCT03558464|DIETARY_SUPPLEMENT|Intervention (integrated package)|"During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
219111286|NCT03558464|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
219111287|NCT02886546|PROCEDURE|pneumoperitoneum|
219111288|NCT02886546|DEVICE|oesophageal Doppler monitor|
219111289|NCT01315405|BEHAVIORAL|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~\+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
219111290|NCT04110366|BIOLOGICAL|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
219111291|NCT04110366|OTHER|Vehicle control|Vehicle control nasal challenge
219111292|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111293|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111294|NCT05939817|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111295|NCT01247441|OTHER|Clinical data|
219111296|NCT05139641|BEHAVIORAL|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
219698008|NCT01877798|PROCEDURE|volume resuscitation, vasoactive drug|
219698009|NCT01780623|DEVICE|Bright white light|
219698010|NCT01780623|DEVICE|Dim red light|
219698011|NCT05722691|DRUG|Double-Stranded RNA sodium salt|Once intramuscular injection 5 mg (1 vial)
219698012|NCT05722691|DRUG|Placebo|Once intramuscular injection (1 vial)
219111297|NCT02406989|DRUG|MS-553|Study Drug
219111298|NCT02406989|DRUG|Placebo|Matching placebo to MS-553
219111299|NCT04448431|DRUG|Vortioxetine|10 or 20 mg/day, capsules, orally
219111300|NCT04448431|DRUG|Desvenlafaxine|50 mg/day capsules, orally
219111301|NCT02520180|DEVICE|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
219111302|NCT02520180|DEVICE|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
219111303|NCT02125123|OTHER|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
219111304|NCT02125123|OTHER|Counseling|Dietary counseling
219111305|NCT00326768|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
219111306|NCT00326768|DRUG|Telmisartan 40 mg|
219111307|NCT00326768|DRUG|Telmisartan 80 mg/HCTZ 12.5 mg|
219111308|NCT06278116|OTHER|Aligners cleansing with water|The product is masked in a spraying bottle without any labels. Once a day, for 14 days, the patient sprays the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
219698013|NCT02446691|BIOLOGICAL|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
219698014|NCT03650647|PROCEDURE|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
219698015|NCT00472420|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
219698016|NCT00472420|DRUG|First line chemotherapy|As prescribed
219698017|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
219698018|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
219698019|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
219111309|NCT06278116|OTHER|Aligners cleansing with dish soap Svelto|the product is masked in a transparent bottle without any labels. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
219111310|NCT06278116|OTHER|Aligners cleansing with Polident Antibacterial Denture Cleaner|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the tablet in a glass full of warm water (30-35 °C), then the aligner is placed inside it for 5 minutes. Afterward the aligner is rinsed under fresh running water.
219111311|NCT06278116|OTHER|Aligners cleansing with Invisalign Cleaning Crystals|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the crystals in a glass full of warm water (30-35 °C) mixing with a spoon for 20 seconds; then, the aligner is placed inside the glass for 15 minutes. Afterward, the aligner is rinsed under fresh running water.
219111312|NCT06278116|OTHER|Aligners cleansing with Geldis|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
219698020|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
219698021|NCT03144232|DEVICE|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
219111313|NCT01356173|DRUG|GDC-0349|Oral escalating dose
219111314|NCT02543021|DEVICE|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
219111315|NCT02543021|PROCEDURE|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
219111316|NCT01498913|DRUG|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
219111317|NCT01002664|DRUG|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
219111318|NCT01002664|DRUG|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
219111319|NCT05104918|DRUG|Vortioxetine|10 mg tablets
219111320|NCT05104918|DRUG|Venlafaxine|75 mg tablets
219111321|NCT00981825|DRUG|Fluoride|Whole mouth brushing for 7 days
219111322|NCT00981825|DRUG|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
219111323|NCT00976079|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
219111324|NCT00976079|DEVICE|Placebo TENS|Placebo TENS use
219111325|NCT02743793|PROCEDURE|Blood Draw|
219111326|NCT03543722|BEHAVIORAL|National Career Coach Program|Intensive employment services as described above.
219111327|NCT03543722|BEHAVIORAL|Local Community Resources Program|Usual employment services as described above.
219698022|NCT03144232|DEVICE|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
219698023|NCT04489368|RADIATION|Neo-Adjuvant Radiotherapy|Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
219698024|NCT04489368|DRUG|Neo-Adjuvant Chemotherapy|Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
219698025|NCT04489368|PROCEDURE|Esophagectomy|Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
219698026|NCT04549194|BIOLOGICAL|Blood collection|A blood sample will be collected before during and after the treatment.
219698027|NCT04549194|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
219698028|NCT04549194|BEHAVIORAL|Psychological questionnaires|"The participants will fill in several psychological questionnaires before, during and after treatment administration:~* Life Event Checklist~* Moral injury~* Posttraumatic Checklist~* Burnout Assessment Tool~* State-Trait Anger Expression Inventory-2~* Ruminative Response Scale - Reconsidered~* Deployment Risk and Resilience Inventory-2~* Questionnaire about tobacco use"
219111328|NCT02697006|DEVICE|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
219111329|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111330|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111331|NCT05887804|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
219111332|NCT03119571|PROCEDURE|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
219111333|NCT03119571|DIAGNOSTIC_TEST|Initial ICU admission|Evaluate for additional testing and/or procedures
219111334|NCT03969082|BEHAVIORAL|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
219698029|NCT04549194|DEVICE|Photoplethysmography|Photoplethysmography recording will be performed before during and after the treatment.
219698030|NCT04549194|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
219698031|NCT00840125|DRUG|erlotinib|150mg tablet daily
219698032|NCT00840125|DRUG|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
219698033|NCT03022006|DRUG|elbasvir, grazoprevir|
219111335|NCT01880060|BEHAVIORAL|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; \>20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
219111336|NCT01880060|BEHAVIORAL|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
219111337|NCT05310032|DRUG|HSG4112|Once-daily oral adminstration
219111338|NCT05310032|DRUG|Placebo|Once-daily oral adminstration
219111339|NCT06160713|DRUG|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
219698034|NCT05397652|DRUG|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
219698035|NCT05397652|DRUG|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
219698036|NCT02963480|PROCEDURE|Cardiac Surgery|
219698037|NCT03798236|DRUG|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
219698038|NCT03798236|DRUG|Placebo oral capsule|solid microcrystalline cellulose
219698039|NCT06379126|DIAGNOSTIC_TEST|Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）|Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
219698040|NCT05946733|PROCEDURE|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
219698041|NCT05946733|PROCEDURE|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
219698042|NCT05946733|OTHER|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
219698043|NCT03877822|BEHAVIORAL|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
219698044|NCT03877822|BEHAVIORAL|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
219698045|NCT00000442|DRUG|naltrexone (Revia)|
219698046|NCT02104687|PROCEDURE|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
219698047|NCT02104687|PROCEDURE|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
219698048|NCT05150574|BEHAVIORAL|Core Health Program|8-week structured stress management and health behaviour change program
219698049|NCT05150574|BEHAVIORAL|Daily resting HRV|Take regular HRV readings in the morning
219698050|NCT05150574|BEHAVIORAL|Momentary HRV feedback|Take regular HRV readings throughout the day when stressed and perform mindfulness activity
219698051|NCT05150574|BEHAVIORAL|Behavioural initiation coaching|15-minute health coaching session in first week of program to help participant set goals and create an action plan
219698052|NCT05150574|BEHAVIORAL|Practice with feedback coaching|15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
219111340|NCT06160713|OTHER|Standard care|Standard care for bronchiectasis
219111341|NCT02438150|BEHAVIORAL|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
219698053|NCT03467451|PROCEDURE|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
219698054|NCT01755299|OTHER|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
219698055|NCT01755299|OTHER|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
219698056|NCT01755299|OTHER|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
219698057|NCT01755299|OTHER|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
219698058|NCT00313235|BIOLOGICAL|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
219698059|NCT03217409|DRUG|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
219698060|NCT03217409|DRUG|Rosuvastatin|Rosuvastatin 5Mg Tablet
219698061|NCT03457857|OTHER|Cleanser|Cosmetic Baby Cleanser/Shampoo
219111342|NCT02438150|BEHAVIORAL|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
219698062|NCT03457857|OTHER|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
219698063|NCT01026493|DRUG|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
219698064|NCT01026493|DRUG|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
219698065|NCT01026493|DRUG|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
219698066|NCT01026493|DRUG|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
219111343|NCT00282230|DRUG|FK778|
219111344|NCT04267575|DEVICE|Canady Helios Cold Plasma Scalpel|Device used to distribute cold plasma energy at the resected tumor margins.
219698067|NCT01026493|DRUG|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
219698068|NCT01026493|DRUG|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
219698069|NCT02674516|DEVICE|Transcranial direct current stimulation|
219111345|NCT01387503|PROCEDURE|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
219111346|NCT02342587|DRUG|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
219111347|NCT01254175|BIOLOGICAL|rHPIV3cp45 Vaccine|10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops
219111348|NCT01254175|BIOLOGICAL|Placebo Vaccine|Placebo vaccine, delivered as nose drops
219111349|NCT05390138|BEHAVIORAL|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
219224786|NCT06549725|DEVICE|software Lipidica|"The investigational in vitro diagnostic medical device-software (IVDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device."
219224787|NCT06549725|PROCEDURE|endoscopic ultrasonography|Endoscopic ultrasonography - maximum frequency: 3 times during the participation
219111350|NCT05390138|BEHAVIORAL|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
219111351|NCT03108963|DRUG|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
219111352|NCT03108963|DRUG|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
219111353|NCT02622633|DEVICE|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
219111354|NCT01461993|BIOLOGICAL|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
219111355|NCT01461993|BIOLOGICAL|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
219111356|NCT01461993|BIOLOGICAL|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
219111357|NCT03309163|DRUG|Tramadol|Patient-controlled intravenous analgesia with Tramadol
219111358|NCT03309163|DRUG|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
219111359|NCT03309163|DRUG|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
219111360|NCT00787722|PROCEDURE|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
219111361|NCT00787722|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
219111362|NCT00787722|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
219111363|NCT00787722|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
219111364|NCT00787722|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
219111365|NCT00787722|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
219111366|NCT00787722|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
219111367|NCT00219141|DRUG|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
219111368|NCT00219141|DRUG|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
219698070|NCT02674516|DEVICE|Sham transcranial direct current stimulation|
219698071|NCT03430739|OTHER|No intervention|No intervention
219698072|NCT04653311|DEVICE|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
219698073|NCT02879214|RADIATION|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
219698074|NCT06520956|BEHAVIORAL|Video based exercise group|In each session, 2 videos will be applied and each will be repeated 2-3 times, with a 3-minute rest break between each video. The total session will last an average of 20-30 minutes and 16 sessions of physical activity will be performed twice a week for a total of 8 weeks.
219698075|NCT02838745|DRUG|Pemetrexed|
219698076|NCT02838745|DRUG|Cisplatin|
219698077|NCT00439972|DRUG|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
219698078|NCT00439972|DRUG|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
219698079|NCT00439972|DRUG|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
219698080|NCT00270673|PROCEDURE|Early lactate-directed therapy|
219698081|NCT03348449|OTHER|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
219698082|NCT00601055|BEHAVIORAL|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
219698083|NCT00601055|BEHAVIORAL|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
219698084|NCT04989673|OTHER|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
219111369|NCT00219141|DRUG|Aliskiren placebo|Aliskiren 150 mg placebo tablet
219111370|NCT00219141|DRUG|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
219224788|NCT06549725|PROCEDURE|magnetic resonance|Magnetic resonance - maximum frequency: 3 times during the participation
219698085|NCT04989673|OTHER|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
219698086|NCT04989673|OTHER|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
219224789|NCT06549725|DIAGNOSTIC_TEST|laboratory examination|Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
219224790|NCT06549725|PROCEDURE|computed tomography|computed tomography - maximum frequency: 3 times during the participation
219111371|NCT03368924|OTHER|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
219111372|NCT01088529|DRUG|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
219111373|NCT01088529|DRUG|Prednisone|5 mg orally daily.
219111374|NCT01088529|DRUG|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
219111375|NCT03056859|DEVICE|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
219111376|NCT06116214|OTHER|Vachellia Nelotica|As a root canal irrigant (herbal)
219111377|NCT06116214|OTHER|sodium hypochlorite|As a root canal irrigant
219111378|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
219111379|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
219698087|NCT04989673|OTHER|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
219698088|NCT03319771|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
219698089|NCT03319771|BEHAVIORAL|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
219698090|NCT03636399|BEHAVIORAL|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
219698091|NCT03636399|BEHAVIORAL|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
219698092|NCT00125008|BIOLOGICAL|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
219698093|NCT00125008|BIOLOGICAL|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
219698094|NCT02597413|PROCEDURE|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
219698095|NCT01795443|OTHER|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
219698096|NCT01795443|OTHER|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
219111380|NCT05045911|PROCEDURE|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
219111381|NCT02547571|DRUG|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
219111382|NCT02547571|DRUG|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
219111383|NCT02547571|DRUG|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
219111384|NCT02547571|DRUG|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
219111385|NCT02547571|OTHER|Clear liquid diet|
219111386|NCT02547571|OTHER|Low residue diet|
219111387|NCT02547571|OTHER|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
219111388|NCT02547571|OTHER|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
219111389|NCT05490693|OTHER|Experimental group|Experimental group: 26 control group group: 26
219698097|NCT01795443|OTHER|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
219698098|NCT01795443|OTHER|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
219698099|NCT01795443|OTHER|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
219698100|NCT05089214|DEVICE|Intra oral cameras|Diagnostic comparison of two intra oral cameras
219698101|NCT06163118|DIAGNOSTIC_TEST|Deglut'G test|"Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal."
219698102|NCT06163118|DIAGNOSTIC_TEST|SLP swallowing test|"At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient."
219698103|NCT06163118|DIAGNOSTIC_TEST|ENT doctor swallowing test|"At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient."
219698104|NCT03056924|BIOLOGICAL|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
219111390|NCT04000932|DRUG|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
219111391|NCT04000932|DRUG|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
219111392|NCT02228473|DRUG|Glycopyrrolate|Glycopyrrolate will be administered.
219111393|NCT02228473|DRUG|Atropine|Atropine will be administered.
219111394|NCT03660033|DIAGNOSTIC_TEST|ECG in delivery room|See arm/group discussions
219111395|NCT01780493|PROCEDURE|The Direct Nipple Ureteroneocystostomy Technique|
219111396|NCT02323893|DRUG|[18F]F-AraG|
219111397|NCT05447793|DEVICE|Fitostimoline plus|Formulation in gauzes and cream
219111398|NCT05447793|DEVICE|Connettivina bio plus|Formulation in gauzes and cream
219111399|NCT02689791|DIETARY_SUPPLEMENT|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
219111400|NCT02518724|PROCEDURE|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
219111401|NCT02518724|PROCEDURE|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
219111402|NCT02341144|PROCEDURE|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
219111403|NCT02341144|PROCEDURE|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
219698105|NCT03056924|BIOLOGICAL|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
219698106|NCT03056924|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
219698107|NCT02820662|OTHER|RETCAM|
219111404|NCT02341144|DRUG|Ropivacaine|
219111405|NCT02349464|OTHER|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
219111406|NCT05342116|OTHER|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
219111407|NCT05342116|OTHER|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
219111408|NCT05882084|DIETARY_SUPPLEMENT|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
219111409|NCT05882084|DIETARY_SUPPLEMENT|Placebo|Placebo
219111410|NCT02579356|DRUG|Telmisartan|
219111411|NCT02579356|DRUG|Atorvastatin|
219111412|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
219111413|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
219111414|NCT01885260|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
219111415|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
219111416|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
219111417|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
219111418|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
219111419|NCT02066532|DRUG|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219111420|NCT02066532|DRUG|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab \> 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
219111421|NCT03499379|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
219111422|NCT03499379|DEVICE|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
219111423|NCT00181038|DEVICE|Peri-Neuronal Catheter|
219698108|NCT02820662|BIOLOGICAL|Blood samples|
219698109|NCT06369480|PROCEDURE|Resection/Ablation of tumor|Curative treatment
219698110|NCT06369480|PROCEDURE|Palliative chemotherapy|Chemotherapeutic medications
219698111|NCT06369480|PROCEDURE|Neoadjuvant chemotherapy|Chemotherapeutic medications after surgery
219698112|NCT06369480|PROCEDURE|Stereotatic radiotherapy|Radiotherapy
219698113|NCT06369480|PROCEDURE|Best supportive care|Symptomatic treatment, non-curative treatment
219698114|NCT04365335|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
219698115|NCT04365335|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
219698116|NCT04365335|OTHER|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
219698117|NCT04365335|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
219698118|NCT01995916|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
219698119|NCT01995916|BEHAVIORAL|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
219111424|NCT04834778|DRUG|HC-5404-FU|HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
219698120|NCT03915743|OTHER|palliative care|complex and multi-faceted individualized palliative care
219698121|NCT00580320|DRUG|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
219698122|NCT03377439|OTHER|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
219698123|NCT05821049|OTHER|UPI65 (Low Dose)|Red colored Capsules
219698124|NCT05821049|OTHER|UP165 (High Dose)|Red colored Capsules
219698125|NCT05821049|OTHER|Placebo|Red colored Capsules
219111425|NCT03009721|DRUG|Other: Not applicable-observational study|
219111426|NCT01265823|BIOLOGICAL|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
219111427|NCT04707690|DEVICE|Intraurethral laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
219111428|NCT04707690|DEVICE|Intraurethral SHAM laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
219111429|NCT05281003|DRUG|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
219111430|NCT05281003|DRUG|Paclitaxel|Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
219111431|NCT05281003|DRUG|Cisplatin|Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
219111432|NCT03915119|OTHER|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
219111433|NCT01007968|DRUG|LBH589|
219111434|NCT04181840|DIAGNOSTIC_TEST|Blood and faeces tests|During V1 - Laboratory tests, particularly for calprotectin concentration assessment
219111435|NCT04181840|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of anal sphincter muscles will be measured
219111436|NCT04181840|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
219698126|NCT03021915|OTHER|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
219698127|NCT00075075|DRUG|Infliximab|
219698128|NCT06144372|DEVICE|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
219698129|NCT04800497|PROCEDURE|Hepatic resection|Hepatic resection for HCC
219698130|NCT03546465|DRUG|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
219698131|NCT02173613|OTHER|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~* It is highly recommended to stop antibiotics if PCT \<0.1ng/ml, and the recommended stop if 0.1ng/ml \<PCT \<0.25 ng / ml.~* It is recommended to continue treatment if 0.25 ng / ml \<PCT ng / ml.~* Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
219698132|NCT03307174|DRUG|Bupivacaine|
219698133|NCT03307174|DRUG|Fentanyl|
219698134|NCT01923519|PROCEDURE|bronchofiberscopy|
219698135|NCT03179358|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
219698136|NCT05948085|DRUG|Zavegepant 10 mg IN|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
219698137|NCT04519424|BIOLOGICAL|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
219698138|NCT04519424|DRUG|Placebo|Normal saline (0.9% sodium chloride)
219698139|NCT01760902|BEHAVIORAL|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
219698140|NCT00158808|BIOLOGICAL|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
219111437|NCT04181840|DIAGNOSTIC_TEST|Transanal ultrasonography|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
219111438|NCT04181840|DIAGNOSTIC_TEST|Anorectal manometry|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
219111439|NCT04181840|OTHER|Determining the degree of sphincter injury|During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
219111440|NCT02401958|OTHER|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
219111441|NCT01018563|DRUG|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
219111442|NCT01356667|BEHAVIORAL|DARTNA|3-hour protocol provided 2x/week over 12 weeks
219111443|NCT01356667|BEHAVIORAL|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
219111444|NCT04107896|DRUG|Silodosin|Cap silodosin
219111445|NCT04107896|DRUG|Tamsulosin|Cap tamsulosin
219111446|NCT00447044|BEHAVIORAL|Resistance Exercise|Subjects will lift weights with their legs.
219111447|NCT00447044|DIETARY_SUPPLEMENT|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
219111448|NCT00447044|DIETARY_SUPPLEMENT|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
219111449|NCT03781765|DRUG|Methylphenidate|stimulant medication
219111450|NCT03781765|DRUG|Atomoxetine|non-stimulant medication
219698141|NCT01334294|DEVICE|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
219111451|NCT05504382|DEVICE|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
219698142|NCT05621161|DRUG|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
219698143|NCT03962361|OTHER|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
219111452|NCT03857412|PROCEDURE|Capsular polishing|Capsular polishing taking place during cataract surgery
219111453|NCT03857412|OTHER|Non capsular polishing|No capsular polishing taking place during cataract surgery
219111454|NCT02161861|OTHER|cFFE increase the fusiogenic capacities of a gamete|
219111455|NCT04264234|DIAGNOSTIC_TEST|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
219111456|NCT04264234|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
219111457|NCT05923086|DRUG|ORE001|Administration before major meal
219111458|NCT05923086|DRUG|Placebo|Administration before major meal
219111459|NCT04943263|OTHER|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
219111460|NCT01979731|OTHER|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
219111461|NCT01979731|OTHER|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
219111462|NCT06442540|PROCEDURE|Physical Agents|Hot pack
219111463|NCT06442540|PROCEDURE|Manipulation|HVLA manipulation of SI joint
219111464|NCT06442540|PROCEDURE|Core Stability Exercises|Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.
219111465|NCT06442540|PROCEDURE|Intramusular electrotherapy|Intramuscular electrotherapy/ 3 sessions per week
219111466|NCT06442540|PROCEDURE|Soft tissue mobility|Stretching and Myofacial Release of piriformis and erector spinae
219111467|NCT04688593|DEVICE|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
219111468|NCT01022801|DRUG|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
219111469|NCT00507221|DRUG|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
219111470|NCT00507221|DRUG|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
219111471|NCT00507221|DRUG|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
219698144|NCT00496561|BIOLOGICAL|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
219698145|NCT00496561|OTHER|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
219698146|NCT06088641|DIAGNOSTIC_TEST|preoperative BNP value|preoperative BNP value
219698147|NCT00244439|DRUG|MALG|30 minute application
219698148|NCT00244439|DRUG|Ovide (malathion) lotion 0.05%|8-12 hour application
219698149|NCT00244439|DRUG|Permethrin 1%|10 minute application
219698150|NCT01036802|DRUG|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
219698151|NCT01036802|DRUG|Placebo|
219698152|NCT03826251|PROCEDURE|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
219698153|NCT03435588|PROCEDURE|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
219698154|NCT03435588|PROCEDURE|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
219698155|NCT03435588|PROCEDURE|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
219698156|NCT04190355|OTHER|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
219698157|NCT04190355|DRUG|5.25% NaOCl|5.25% NaOCl solution
219698158|NCT04190355|DRUG|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
219698159|NCT00333567|DRUG|Lumiracoxib|
219698160|NCT00094991|DRUG|Muraglitazar|
219698161|NCT01085643|DRUG|Lubiprostone|24mcg PO taken once
219698162|NCT01085643|DRUG|Placebo|24mcg placebo capsule taken once
219698163|NCT01612663|DEVICE|Pain relief by Acupuncture needle at non-specific site|
219698164|NCT01612663|DEVICE|Acupuncture needle|
219698165|NCT01612663|DEVICE|Acupuncture needle|
219698166|NCT01612663|DEVICE|Acupuncture needle|
219698167|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) System|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors."
219698168|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch"
219111472|NCT03251560|DRUG|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
219111473|NCT03251560|DRUG|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
219111474|NCT05191641|OTHER|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
219111475|NCT03620643|DRUG|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
219698169|NCT05023122|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3 (cholecalciferol) 800 IU QD
219698170|NCT05023122|DIETARY_SUPPLEMENT|calcium|calcium citrate 600 mg QD
219698171|NCT02909062|DEVICE|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
219698172|NCT02909062|BEHAVIORAL|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
219698173|NCT01164761|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
219698174|NCT01164761|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
219111476|NCT03620643|DRUG|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
219111477|NCT04022460|DIAGNOSTIC_TEST|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
219111478|NCT04022460|DIAGNOSTIC_TEST|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
219224791|NCT03845699|DEVICE|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
219698175|NCT03307421|OTHER|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
219698176|NCT03307421|OTHER|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
219698177|NCT01510405|OTHER|Tissue Collection|Tissue sample collection
219698178|NCT01984957|PROCEDURE|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
219698179|NCT03618875|OTHER|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
219698180|NCT03618875|OTHER|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
219698181|NCT03748134|BIOLOGICAL|Sintilimab|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
219111479|NCT04022460|OTHER|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
219111480|NCT00514046|DRUG|Vandetanib|once daily continuously (28 day cycles)
219111481|NCT05989165|DRUG|Minoxidil 5% Topical Solution|Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
219111482|NCT05989165|DEVICE|microneedling|Patient will be given microneedling treatment every 4 weeks
219111483|NCT00591123|DRUG|FOLFOX|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
219111484|NCT00591123|DRUG|5-FU|5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
219698182|NCT03748134|DRUG|Cisplatin|75mg/m\^2 IV Q3W day 1
219698183|NCT03748134|DRUG|Paclitaxel|87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
219111485|NCT00591123|DRUG|Erlotinib|All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
219224792|NCT02640703|BIOLOGICAL|Infanrix + Prevenar 13|Different time of application
219698184|NCT03748134|DRUG|Fluorouracil|800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
219698185|NCT03748134|DRUG|Placebo|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
219698186|NCT05371561|DEVICE|reusable respirators|Dentist wearing reusable respirator will examin the patient
219698187|NCT03380286|DEVICE|Firehawk|Firehawk stent
219698188|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
219698189|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
219111486|NCT00383240|DRUG|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
219111487|NCT00383240|DRUG|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
219111488|NCT00383240|DRUG|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
219111489|NCT00383240|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
219111490|NCT02397265|DEVICE|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
219111491|NCT02397265|DEVICE|Standard opened loop pump|Using a standard opened loop pump
219111492|NCT02397265|DEVICE|Insulin closed loop|Using a closed loop
219111493|NCT02023879|DRUG|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
219224793|NCT00846222|PROCEDURE|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
219698190|NCT03172598|DRUG|MT-8554 low dose|Capsule
219698191|NCT03172598|DRUG|MT-8554 middle dose|Capsule
219698192|NCT03172598|DRUG|MT-8554 high dose|Capsule
219698193|NCT03172598|DRUG|Placebo|Capsule
219698194|NCT06183034|OTHER|Very Low Calorie Diet|Participants will receive a very low calorie diet as described in the arm/group
219111494|NCT02023879|DRUG|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
219111495|NCT02023879|DRUG|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
219111496|NCT02023879|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
219111497|NCT03233061|DIAGNOSTIC_TEST|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
219111498|NCT02924389|DRUG|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
219111499|NCT02924389|DRUG|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
219698195|NCT05718349|OTHER|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
219698196|NCT05062096|OTHER|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
219698197|NCT05062096|OTHER|Skin biopsy|Biopsy of the skin lesion (optional)
219698198|NCT01414244|DRUG|Glutamine|Drug
219698199|NCT03273855|OTHER|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
219698200|NCT03273855|OTHER|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
219698201|NCT05034549|DEVICE|Noninvasive ventilation|The non-invasive ventilator at home (≥5h/ night)
219698202|NCT02193841|PROCEDURE|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
219111500|NCT02924389|DRUG|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
219224794|NCT05033327|BEHAVIORAL|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
219224795|NCT02304614|OTHER|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
219698203|NCT02193841|DEVICE|Curette|A small surgical instrument with a rounded edge designed for scraping
219698204|NCT02193841|DEVICE|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
219698205|NCT04040686|DRUG|Injection of 99mTc-NM-02|Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
219698206|NCT00721799|DRUG|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
219698207|NCT03342729|BEHAVIORAL|Intervention|Participants receive the AMP 10-week program immediately
219698208|NCT03342729|BEHAVIORAL|Control|Participants will not received the AMP 10-week program immediately, rather will wait 3-months
219698209|NCT05383742|DRUG|Rifampicin (RIF)|Rifampicin 35 mg/kg
219698210|NCT05383742|DRUG|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
219698211|NCT05383742|DRUG|Linezolid (LZD)|1200 mg
219698212|NCT05383742|DRUG|Pyrazinamide (PZA)|25 mg/kg
219698213|NCT05383742|DRUG|ethambutol (EMB)|20 mg/kg
219698214|NCT05383742|DRUG|Rifampicin|10 mg/kg
219698215|NCT05383742|DRUG|Isoniazid|5 mg/kg
219698216|NCT01845779|DRUG|DCF regimen|
219698217|NCT03985683|OTHER|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
219111501|NCT00582530|OTHER|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
219111502|NCT00896623|GENETIC|mutation analysis|
219111503|NCT00896623|GENETIC|polymorphism analysis|
219111504|NCT00896623|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
219111505|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
219111506|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
219111507|NCT02743715|DEVICE|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
219111508|NCT02743715|DEVICE|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
219111509|NCT04944225|OTHER|Opioid Reduction Strategy|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
219111510|NCT04378634|BEHAVIORAL|Exercise|Sub-maximal exercise test
219111511|NCT04378634|OTHER|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
219111512|NCT01345643|OTHER|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
219698218|NCT03985683|DIETARY_SUPPLEMENT|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
219698219|NCT01776970|DRUG|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
219698220|NCT02958579|OTHER|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
219698221|NCT02785198|DEVICE|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
219698222|NCT03497871|DEVICE|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
219698223|NCT04391478|DRUG|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
219698224|NCT04391478|DRUG|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
219698225|NCT01331317|DRUG|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
219111513|NCT01345643|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
219111514|NCT00341640|PROCEDURE|Blood testing|
219111515|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
219111516|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
219698226|NCT06555445|OTHER|BREATHING EXERCISE|Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
219111517|NCT00911963|BIOLOGICAL|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
219111518|NCT00911963|DRUG|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
219111519|NCT05486208|DRUG|LY3844583|Administered SC and/or IV.
219111520|NCT05486208|DRUG|Placebo|Administered SC and/or IV.
219111521|NCT05416775|DRUG|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
219111522|NCT05416775|DRUG|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
219111523|NCT05416775|DRUG|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
219698227|NCT06555445|OTHER|BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE|The resistance on the BREATHER device will be adjusted to match each participant's abilities and progression. The resistance level will be challenging yet manageable, ensuring participant comfort. Each daily session will consist of 15-30 minutes with the BREATHER device and can be split into two shorter sessions if necessary. The total duration of this treatment protocol will span 2 months. The BREATHER device will be employed for both inspiratory and expiratory muscle training. Alongside the device usage, specific breathing exercises, such as diaphragmatic and pursed lip breathing, will be performed
219111524|NCT06251726|DIAGNOSTIC_TEST|Immunoscore Colon Test|"Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor."
219111525|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
219111526|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
219111527|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
219111528|NCT00632710|OTHER|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
219698228|NCT03980067|OTHER|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
219698229|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 2 mA|
219698230|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 3 mA|
219698231|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 2 mA|
219111529|NCT00632710|OTHER|phototherapy placebo|disconnected laser (same device - experimental group)
219111530|NCT02873286|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
219111531|NCT02873286|OTHER|Placebo|Tris Buffered Saline, sterile
219111532|NCT04857190|DEVICE|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
219111533|NCT04857190|DEVICE|Conventional Malleable Stylet|Conventional Malleable Stylet
219111534|NCT00030433|DRUG|gemcitabine hydrochloride|
219111535|NCT00030433|DRUG|irinotecan hydrochloride|
219111536|NCT03918239|DRUG|SHP643|Participants will receive injection of SHP643.
219111537|NCT05672082|DRUG|[18F]DPA-714|Participant received one injection of 200 MBq of \[18F\]DPA-714
219111538|NCT02840396|DEVICE|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
219698232|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 3 mA|
219698233|NCT02112253|DEVICE|Deep brain stimulator empirical programming|
219698234|NCT04833894|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of Efgartigimod
219698235|NCT06380920|DEVICE|"AI Mindful Eating App"|"The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI."
219698236|NCT06380920|BEHAVIORAL|Outpatient regular follow-up|Outpatient regular follow-up
219111539|NCT02840396|DEVICE|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
219111540|NCT04890522|DRUG|Triprilimab(JS001)|Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
219111541|NCT04890522|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
219698237|NCT05812950|BEHAVIORAL|GST|Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
219698238|NCT05812950|BEHAVIORAL|CBT-E|Outpatient eating disorder treatment (20-40 weekly individual sessions)
219698239|NCT03255356|OTHER|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
219698240|NCT07025629|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..
219111542|NCT04890522|DRUG|5-Fluorouracil|Maximum 6 cycles for combined therapy.
219111543|NCT04890522|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
219111544|NCT02292810|DEVICE|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
219111545|NCT02292810|DEVICE|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
219111546|NCT06077916|DRUG|Azithromycin|azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
219698241|NCT07025629|DRUG|One tablet of placebo of dapagliflozin 10 mg|One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.
219698242|NCT06725147|BEHAVIORAL|AI enabled wellness chatbot|Elomia uses generative AI to respond to user input about psychological stress and distress. It was trained on the responses of real therapists with expertise in cognitive-behavioral therapy. It provides an array of wellness interventions including exercises for calming; • exercises for falling asleep; • grounding techniques; • exercises to reduce anxiety; • breathing exercises; • exercises to improve self-esteem.
219698243|NCT06725147|BEHAVIORAL|Penn Digital Wellness Resources|This active control intervention consists of a variety of digital wellness and stress management resources that are freely available to all Penn students.
219698244|NCT05965752|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
219698245|NCT05965752|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
219698246|NCT05965752|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
219698247|NCT05965752|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
219698248|NCT05965752|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
219698249|NCT03934671|DEVICE|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
219698250|NCT03934671|DEVICE|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
219698251|NCT04039620|OTHER|Observational study, no interventions expected|No interventions are planned
219698252|NCT05098327|DRUG|Pioglitazone 30 mg|pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
219698253|NCT05098327|DRUG|Placebo|placebo pills containing cellulose 1 pill daily will be given for 12 weeks
219698254|NCT00198991|DRUG|Cyclophosphamide|Cytostatic drug
219698255|NCT00198991|DRUG|Dexamethasone|Antileukemic drug
219698256|NCT00198991|DRUG|Vincristine|Cytostatic drug
219698257|NCT00198991|DRUG|Daunorubicin|Cytostatic drug
219111547|NCT06077916|DRUG|Saline solution|placebo consisting of saline solution 250 mL is administered
219111548|NCT00963989|DEVICE|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
219111549|NCT03069820|DRUG|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
219111550|NCT01941550|DRUG|Cabazitaxel chemotherapy|given in 6 cycles
219111551|NCT00231998|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
219111552|NCT01402167|PROCEDURE|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
219111553|NCT01402167|PROCEDURE|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
219111554|NCT04228549|DEVICE|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
219698258|NCT00198991|DRUG|Asparaginase|Cytostatic drug
219698259|NCT00198991|DRUG|Methotrexate|Cytostatic drug
219698260|NCT00198991|DRUG|Cytarabine|Cytostatic drug
219698261|NCT00198991|DRUG|Mercaptopurine|Cytostatic drug
219698262|NCT00198991|DRUG|G-CSF|Growth factor
219698263|NCT00198991|DRUG|Vindesine|Cytostatic drug
219698264|NCT00198991|DRUG|Etoposide|Cytostatic drug
219698265|NCT00198991|DRUG|Prednisolone|Antileukemic drug
219698266|NCT00198991|DRUG|Adriamycin|Cytostatic drug
219698267|NCT00198991|DRUG|Thioguanine|Cytostatic drug
219698268|NCT00198991|DRUG|Teniposide|Cytostatic drug
219698269|NCT00198991|PROCEDURE|CNS irradiation|Cytostatic drug
219698270|NCT00198991|PROCEDURE|Mediastinal Irradiation|Irradiation
219698271|NCT00198991|PROCEDURE|Stem cell transplantation (SCT)|Stem cell transplantation
219698272|NCT00198991|DRUG|Idarubicin|Cytostatic drug
219698273|NCT00198991|DRUG|Fludarabine|Cytostatic drug
219698274|NCT00198991|DRUG|Cladribine|Cytostatic drug
219698275|NCT04401332|OTHER|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
219698276|NCT02675205|DRUG|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
219698277|NCT02675205|DRUG|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
219698278|NCT02675205|DRUG|aspirin|
219698279|NCT03620513|DRUG|Decongestant (oxymetazoline 0.05%)|As described in arm/group
219698280|NCT03620513|DRUG|Anesthesia (Lidocaine 15%)|As described in arm/group
219111555|NCT04228549|DEVICE|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
219111556|NCT05009706|OTHER|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
219111557|NCT01666054|OTHER|PSV|Pressure Support Ventilation will be used until patient is extubated
219111558|NCT01666054|OTHER|PAV|Proportional Assist Ventilation will be used until patient is extubated.
219698281|NCT03620513|DRUG|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
219698282|NCT03620513|DRUG|Normal saline|Spray of normal saline as premedication
219698283|NCT03228030|DIETARY_SUPPLEMENT|Thiamine|Capsules
219698284|NCT03228030|DIETARY_SUPPLEMENT|Placebo|Identical capsules
219698285|NCT06204497|PROCEDURE|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
219698286|NCT02078258|BEHAVIORAL|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
219698287|NCT01822444|OTHER|Biomarker analysis|
219698288|NCT06748157|DEVICE|CardiaCare RR2|CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.
219698289|NCT06748157|DEVICE|Sham Device|Sham device will be dispensed, which will create a sensation but not provide therapy
219698290|NCT06955325|DRUG|Icotinib|Oral icotinib tablets (125 mg) administered three times daily (TID) for up to 1 year or until disease recurrence or unacceptable toxicity. Icotinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
219698291|NCT06955325|DRUG|Rezivertinib|Oral rezivertinib capsules (100 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Rezivertinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
219111559|NCT00000174|DRUG|Rivastigmine|
219111560|NCT05964881|PROCEDURE|sacrospinous hysteropexy|sacrospinous hysteropexy
219111561|NCT01086605|DRUG|pixantrone dimaleate|Given IV
219111562|NCT01958177|BIOLOGICAL|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
219111563|NCT03126305|OTHER|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
219698292|NCT06955325|DRUG|Ensartinib|Oral ensartinib capsules (225 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Ensartinib is an ALK/ROS1 tyrosine kinase inhibitor designed to inhibit ALK/ROS1 fusion-driven NSCLC.
219698293|NCT06955325|DRUG|Benmelstobart|Intravenous infusion of bemosumab 1200 mg every 3 weeks (Q3W). Treatment continues for up to 4 cycles initially, and may be extended (maintenance) for up to 3 years or until disease recurrence or unacceptable toxicity. Bemosumab is a monoclonal antibody under investigation for immunotherapy in NSCLC.
219698294|NCT03210532|DRUG|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
219698295|NCT03210532|DRUG|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
219698296|NCT03210532|DRUG|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
219698297|NCT02273947|DRUG|BMS-955176|Single dose by mouth for each treatment specified
219698298|NCT03912636|BEHAVIORAL|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
219698299|NCT03912636|BEHAVIORAL|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
219698300|NCT03912636|BEHAVIORAL|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
219111564|NCT04020003|DRUG|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
219111565|NCT06082531|DRUG|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
219111566|NCT05406037|BIOLOGICAL|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
219111567|NCT03906513|DEVICE|OMK2|OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
219111568|NCT00824174|BEHAVIORAL|Questionnaire|1 questionnaire, about 15-20 minutes.
219111569|NCT03172117|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
219111570|NCT03172117|OTHER|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
219111571|NCT01718236|DRUG|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
219111572|NCT01718236|DRUG|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
219111573|NCT03554161|BIOLOGICAL|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
219111574|NCT00593554|RADIATION|Total Body Irradiation|8 Gy on Day -9
219111575|NCT00593554|DRUG|Thiotepa|5 mg/kg/d on Day -8 to -7
219111576|NCT00593554|DRUG|Fludarabine|40 mg/m2/d on Day -6 to -3
219224796|NCT02304614|OTHER|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
219698301|NCT04278352|BEHAVIORAL|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
219698302|NCT05739916|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
219698303|NCT05739916|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
219698304|NCT00718601|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
219698305|NCT01351636|DRUG|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
219698306|NCT01351636|DRUG|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
219111577|NCT00593554|BIOLOGICAL|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
219698307|NCT01987115|PROCEDURE|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
219698308|NCT01987115|PROCEDURE|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
219698309|NCT05627115|DRUG|Tislelizumab, AVD, Radiotherapy|"GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy."
219698310|NCT02873689|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule
219698311|NCT02873689|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
219111578|NCT00593554|DRUG|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
219698312|NCT00350545|DRUG|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
219698313|NCT00350545|DRUG|Prednisone|1 mg/kg; po per day with taper
219111579|NCT00422370|DEVICE|lipid based additives based on vegetable oil & lecithin|
219111580|NCT00001010|DRUG|Zidovudine|
219111581|NCT00001010|DRUG|Acyclovir|
219224797|NCT02304614|OTHER|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
219224798|NCT02304614|OTHER|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
219224799|NCT05033522|BIOLOGICAL|AlloStim® immunotherapy|3 cycles of intradermal and intravenous administrations
219224800|NCT05033522|DRUG|FOLFOX regimen|Comparative arm: Physician Choice of FOLFOX4 chemotherapy
219111582|NCT01024959|OTHER|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
219111583|NCT00636792|DRUG|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
219111584|NCT00636792|DRUG|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
219111585|NCT00636792|DRUG|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
219111586|NCT01414413|OTHER|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
219111587|NCT01414413|OTHER|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
219698314|NCT00350545|DRUG|Cyclosporine A|trough 200-300 or lower; po
219698315|NCT00350545|DRUG|tacrolimus|trough 5-10 or lower; po
219111588|NCT01987596|BIOLOGICAL|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
219111589|NCT04813757|OTHER|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
219111590|NCT04813757|OTHER|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
219111591|NCT00709592|BIOLOGICAL|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
219111592|NCT00709592|RADIATION|Total-Body Irradiation|Undergo TBI
219111593|NCT00709592|PROCEDURE|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
219111594|NCT00709592|DRUG|Tacrolimus|Given PO
219111595|NCT00709592|DRUG|Mycophenolate Mofetil|Given PO
219224801|NCT05033522|DRUG|Sorafenib|Comparative arm: Physician Choice of Sorafenib
219698316|NCT03925155|DRUG|EZ scrub vaginal chlorhexidine 4% solution|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
219698317|NCT03925155|DRUG|10% provodine-iodine vaginal preparation|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
219698318|NCT05992441|OTHER|SCALE DEVELOPMENT STUDY|"The study to be carried out is a scale development study. The steps to be followed for the scale development study are as follows;~1. Creating an item pool by making use of the literature review on the subject,~2. Questioning the relevance of the prepared question pool to the subject to be measured with the Expert Evaluation Form by experts in the field,~3. Pilot application,~4. Switching to the main study after the pilot application,~5. After the factor and item analyzes, the final arrangements regarding the item and form of the scale will be completed.~As a result of this study, an awareness scale related to physiotherapy will be created for individuals with breast cancer."
219698319|NCT03143023|DRUG|arginine toothpaste|acid neutralizer toothpaste
219698320|NCT03143023|DRUG|fluoride toothpaste|bactericidal toothpaste
219111596|NCT01129336|DRUG|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
219111597|NCT01129336|DRUG|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
219224802|NCT05033522|DRUG|Lenvatinib|Comparative Arm: Physician's Choice of Levantinib
219224803|NCT02344680|DRUG|Anti-HIV Agents|
219224804|NCT01655563|DRUG|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
219698321|NCT01794702|DRUG|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
219698322|NCT01794702|DRUG|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
219698323|NCT01794702|DRUG|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
219111598|NCT02351596|OTHER|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
219111599|NCT02351596|OTHER|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
219111600|NCT05778331|PROCEDURE|Antagonist protocol for induction of ovulation|Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
219698324|NCT01794702|DRUG|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
219698325|NCT00775879|DRUG|Induction with Sevoflurane|
219698326|NCT01729195|PROCEDURE|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
219111601|NCT00821132|OTHER|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
219698327|NCT00948545|OTHER|Observational study - there is no intervention|Observational study - there is no intervention
219698328|NCT04908618|OTHER|digital impression for normal abutment|Accuracy of scan body impression
219698329|NCT04908618|OTHER|open tray impression|Accuracy of open tray impression
219698330|NCT04908618|OTHER|closed tray impression|Accuracy of closed tray impression
219698331|NCT04059250|DEVICE|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
219698332|NCT04059250|DEVICE|traditional composite|traditional composite which has no bactericidal activities
219111602|NCT03978754|DIAGNOSTIC_TEST|ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report|All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
219698333|NCT01341704|BIOLOGICAL|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
219698334|NCT01341704|BIOLOGICAL|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
219698335|NCT01341704|OTHER|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
219698336|NCT02265523|OTHER|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
219698337|NCT03999047|DIAGNOSTIC_TEST|PRISMA score|Screening for frailty using PRISMA-7
219698338|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
219698339|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
219698340|NCT02097732|DRUG|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
219698341|NCT02097732|PROCEDURE|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
219698342|NCT03351270|OTHER|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
219111603|NCT03978754|DIAGNOSTIC_TEST|Bioelectrical impedance technology、CM|These two methods are routine evaluation methods for breast cancer patients before surgery
219111604|NCT03989635|DRUG|QAW039|QAW039 450mg
219111605|NCT00436176|BEHAVIORAL|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
219111606|NCT06315764|PROCEDURE|Reflexology|"Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology .~Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated as well as reflexology three times each week for eight weeks"
219698343|NCT04765787|DRUG|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
219698344|NCT02327455|PROCEDURE|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
219698345|NCT02130219|DEVICE|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
219698346|NCT02130219|DEVICE|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
219698347|NCT02130219|PROCEDURE|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
219698348|NCT03150043|DEVICE|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
219698349|NCT05104593|OTHER|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system. CAREPATH consists of an integrated, patient-centred, flexible and modular system that will provide a viable solution for the improvement of the management of multimorbid elderly patients with Mild Cognitive Impairment or mild dementia, with the help of clinicians. CAREPATH will act on patients and their informal caregivers, and its main objective is to empower multimorbid patients with MCI or mild dementia to manage their health condition together with their informal caregiver by providing assistance and reinforcement to follow their individual care plans, so independence and quality of life will increase for both of them. The intervention will provide a personalized care plan and activities proposal (treatment, activities proposal, lifestyle changes, referrals etc.) to patients and caregivers, considering the various sources of patient data available through the CAREPATH platform, and with the help of clinicians.
219698350|NCT02855255|BEHAVIORAL|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
219111607|NCT00505167|DRUG|Memantine|Patients randomized to receive either memantine or donepezil
219111608|NCT00505167|DRUG|Donepezil|Patients randomized to receive either memantine or donepezil
219111609|NCT00358150|DRUG|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
219111610|NCT04403958|PROCEDURE|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
219698351|NCT02855255|BEHAVIORAL|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
219698352|NCT04938050|DIAGNOSTIC_TEST|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
219698353|NCT01029756|DEVICE|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
219111611|NCT04403958|PROCEDURE|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
219224805|NCT05125224|DRUG|Dihydropyridine calcium channel blocker|Dihydropyridine calcium channel blocker claim is used as the exposure group.
219224806|NCT05125224|DRUG|Hydrochlorothiazide|Hydrochlorothiazide claim is used as the reference group.
219224807|NCT00156507|BEHAVIORAL|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
219111612|NCT04668989|DEVICE|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
219111613|NCT04668989|DEVICE|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
219698354|NCT01029756|DEVICE|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
219698355|NCT00566826|BEHAVIORAL|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
219698356|NCT00566826|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
219698357|NCT05029492|OTHER|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
219698358|NCT05029492|OTHER|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
219698359|NCT04166214|OTHER|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
219698360|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
219698361|NCT01100788|OTHER|Placebo|Treatment without scFOS fiber
219698362|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
219698363|NCT00906321|BEHAVIORAL|Web-Based Decision Support|
219698364|NCT00300157|DEVICE|Percutaneous coronary intervention with Taxus stent|
219698365|NCT02431013|DRUG|Simvastatin|Simvastatin 40 mg on Day 1 \& Day 8.
219698366|NCT02431013|DRUG|Pravastatin|Pravastatin 20 mg on Day 1 \& Day 8.
219111614|NCT00991614|DEVICE|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
219224808|NCT01898585|DRUG|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
219224809|NCT04909333|DRUG|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
219698367|NCT02431013|DRUG|Cilostazol|Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
219698368|NCT02997163|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
219698369|NCT01059331|DRUG|Pregabalin|150 mg x 2 daily for 2 days
219698370|NCT01059331|DRUG|Sugar pill|1 tablet x 2 daily, for 2 days
219698371|NCT04518696|PROCEDURE|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
219698372|NCT00434629|DRUG|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
219698373|NCT05786859|DRUG|Rifaximin 200 mg|Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
219698374|NCT05786859|OTHER|Standard Treatment without Rifaximin|The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
219698375|NCT02337764|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
219698376|NCT06238739|OTHER|Control - Standard Strategies for hypothermia prevention|Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
219698377|NCT06238739|OTHER|Fluid warming before infusion and infiltration|Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
219111615|NCT01980901|DEVICE|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
219111616|NCT04550273|BEHAVIORAL|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
219111617|NCT01714973|BIOLOGICAL|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
219111618|NCT01812343|OTHER|Exercise test|
219111619|NCT00179010|DRUG|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
219111620|NCT00179010|DRUG|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
219111621|NCT01622348|DRUG|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
219111622|NCT01622348|DRUG|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
219111623|NCT01622348|DRUG|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
219111624|NCT01942655|OTHER|Blood sample and recto-colic biopsies|
219111625|NCT03765762|DRUG|GRF6019|GRF6019 for IV infusion
219224810|NCT04909333|DRUG|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
219224811|NCT04415775|OTHER|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
219224812|NCT04415775|OTHER|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
219224813|NCT05136794|OTHER|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
219698378|NCT06238739|DEVICE|Thermal convection blanket by water flow (Blanketrol)|Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
219698379|NCT06238739|DEVICE|Conductive fabric electric warming device (HotDog)|HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
219698380|NCT00745888|OTHER|Chemiluminescence Analyzer|measure reactive oxygen species
219698381|NCT06522321|BIOLOGICAL|i-PRF and FDBA|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with FDBA and I-PRF (experimental group) will be placed according to the standard protocol.~An immediate implant with FDBA( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with sutures"
219698382|NCT05053490|OTHER|Static Stretching|Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.
219698383|NCT05053490|OTHER|dynamic stretching|Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
219698384|NCT00000220|DRUG|Buprenorphine|
219698385|NCT02470741|DRUG|Letrozole|
219224814|NCT01096472|DRUG|LAS41003|Once daily
219224815|NCT01096472|DRUG|LAS189961|Once daily
219698386|NCT02470741|OTHER|Placebo|
219698387|NCT05259631|DRUG|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
219698388|NCT05259631|DRUG|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
219698389|NCT05478109|DRUG|[14C]XZP-3287|360 mg suspension containing 50µCi of \[14C\] XZP-3287
219698390|NCT01446705|OTHER|Active Health Information Exchange|Patients selected to share data between the VA \& external healthcare agencies.
219698391|NCT01446705|OTHER|Non-Active Health Information exchange|Patients not selecting to share data
219111626|NCT03765762|OTHER|Placebo|Placebo for IV infusion
219111627|NCT04466332|DEVICE|LifeCath-CT PICC easy™ (Vygon)|"ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position."
219224816|NCT01096472|DRUG|LAS189962|Once daily
219224817|NCT00745875|DRUG|ZD4054|10mg oral tablet, once daily
219698392|NCT04238741|OTHER|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
219698393|NCT01680263|DEVICE|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
219698394|NCT01680263|PROCEDURE|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
219698395|NCT04814797|OTHER|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
219698396|NCT03653741|DRUG|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
219698397|NCT05798312|OTHER|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
219698398|NCT05798312|OTHER|Non-customizable support material|Non-customizable support material will include general breast cancer information.
219698399|NCT03631641|BIOLOGICAL|Nivolumab|Given IV
219698400|NCT00532623|DRUG|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
219698401|NCT00532623|DRUG|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
219698402|NCT04149418|OTHER|Yogurt|Low-fat flavored yogurt
219698403|NCT04149418|OTHER|Control food|Low-fat flavored soy pudding
219698404|NCT01677286|DRUG|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
219698405|NCT04208893|BEHAVIORAL|Exercise training|See description of Arms
219698406|NCT03367000|DIETARY_SUPPLEMENT|Ceprolac|The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
219698407|NCT03367000|OTHER|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
219698408|NCT05152121|OTHER|Carb and fat counting|In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
219698409|NCT04996030|DRUG|SY-2101|SY-2101 will be administered per dose and schedule specified in arm description.
219698410|NCT04996030|DRUG|Arsenic Trioxide|IV ATO will be administered per dose and schedule specified in arm description.
219698411|NCT02633774|DRUG|Propafenone|AAD(antiarrhythmic drug)
219698412|NCT02633774|DRUG|Apixaban|anti-coagulation
219698413|NCT04955756|DIAGNOSTIC_TEST|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
219698414|NCT04955756|DIAGNOSTIC_TEST|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
219224818|NCT00745875|DRUG|Pemetrexed|500mg2/m IV infusion
219698415|NCT00038662|DRUG|Atrasentan|
219698416|NCT00881166|DRUG|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
219698417|NCT00881166|DRUG|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
219698418|NCT00881166|DRUG|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
219698419|NCT00881166|DRUG|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
219698420|NCT00881166|DRUG|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
219698421|NCT03031925|OTHER|ANXA2|serum and urinary concentration
219698422|NCT01967199|DEVICE|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
219698423|NCT01967199|DEVICE|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
219698424|NCT03309618|DRUG|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
219698425|NCT03309618|DRUG|placebo|
219698426|NCT02638792|BEHAVIORAL|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
219224819|NCT00745875|DRUG|Placebo|10mg oral tablet, once daily
219224820|NCT01487460|DRUG|TAP311|
219224821|NCT01602913|DRUG|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
219111628|NCT04466332|DEVICE|PowerPICC-SOLO® (C.R. Bard)|"ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position."
219111629|NCT02484560|DRUG|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
219111630|NCT05162807|BEHAVIORAL|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
219111631|NCT05162807|BEHAVIORAL|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
219111632|NCT02392767|DIETARY_SUPPLEMENT|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
219111633|NCT02392767|DIETARY_SUPPLEMENT|Placebo|corn starch
219698427|NCT02638792|BEHAVIORAL|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
219698428|NCT05285839|DRUG|Dupixent|dupilumab 300mg
219698429|NCT00299039|DRUG|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
219698430|NCT00299039|DRUG|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
219698431|NCT00001132|DRUG|Abacavir sulfate|
219698432|NCT00903968|DRUG|Plerixafor|
219698433|NCT00903968|DRUG|bortezomib|
219698434|NCT00903968|DRUG|Dexamethasone|
219698435|NCT00189930|BIOLOGICAL|MVA-nef|3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm
219698436|NCT00189930|BIOLOGICAL|IMVAMUNE|3 immunizations: 1E8\_TCID50 IMVAMUNE
219698437|NCT00339053|DRUG|Immunonutrition ( Impact)|
219698438|NCT04539275|DRUG|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
219698439|NCT04539275|OTHER|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
219698440|NCT00105430|PROCEDURE|Deep Brain Stimulation|
219698441|NCT02318199|PROCEDURE|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
219111634|NCT05125042|PROCEDURE|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
219111635|NCT05125042|DRUG|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
219111636|NCT01762163|DRUG|Qizhitongluo Capsule|
219111637|NCT01762163|DRUG|Naoxintong Capsule|
219698442|NCT03598296|OTHER|Large size tube|Patients in Group A are inserted the large size tube (28F).
219698443|NCT03598296|OTHER|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
219698444|NCT03736967|DRUG|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
219698445|NCT03736967|DRUG|Dupilumab|Administered SC q2w
219698446|NCT03736967|DRUG|REGN3500 + Dupilumab Combo|Administered SC q2w
219698447|NCT03736967|DRUG|Placebo|Administered SC q2w
219698448|NCT03810443|DIAGNOSTIC_TEST|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
219698449|NCT05877989|DRUG|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
219698450|NCT05877989|PROCEDURE|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
219111638|NCT01762163|DRUG|Aspirin Enteric-coated Tablets|
219111639|NCT01762163|BEHAVIORAL|the routine recovery training|
219698451|NCT02271178|OTHER|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
219111640|NCT01762163|DRUG|placebo|
219111641|NCT04877704|OTHER|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
219111642|NCT04877704|OTHER|Placebo|Matched placebo to Symprove probiotic
219698452|NCT02271178|OTHER|Conventional therapy|Usual therapy
219698453|NCT02419807|DRUG|Indocyanine Green Solution|Given subdermally
219698454|NCT02419807|RADIATION|Technetium Tc-99m Sulfur Colloid|Given via injection
219111643|NCT02167152|OTHER|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
219111644|NCT05401422|OTHER|treatment|types
219698455|NCT02419807|PROCEDURE|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
219698456|NCT02419807|PROCEDURE|Axillary Lymph Node Biopsy|Undergo biopsy
219698457|NCT02623192|OTHER|Patients who have performed the ARDS pulmonary function test|
219698458|NCT05849857|DRUG|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
219698459|NCT00883727|DRUG|Stem cell|IV infusion of stem cells
219698460|NCT00883727|DRUG|Plasmalyte A|IV infusion
219698461|NCT01353534|BIOLOGICAL|A/H5N1 Antigen|A/H5N1 Antigen
219698462|NCT01353534|DRUG|Vaccine Enhancement Patch|Vaccine Enhancement Patch
219698463|NCT01458587|DRUG|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
219698464|NCT01458587|DRUG|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
219698465|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219698466|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219698467|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219698468|NCT06064448|DRUG|Sildenafil|Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
219698469|NCT06064448|DRUG|Ningmitai capsule|The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
219698470|NCT06064448|DRUG|Ningbitai capsule + sildenafil|The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
219698471|NCT02090881|OTHER|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
219698472|NCT02932943|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
219111645|NCT01592695|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
219111646|NCT01592695|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
219698473|NCT02932943|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
219698474|NCT01506076|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
219698475|NCT04015739|DRUG|Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination|"Patients will receive a combination of these 3 drugs :~Bevacizumab 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w"
219698476|NCT01477307|OTHER|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
219698477|NCT00692575|BEHAVIORAL|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
219698478|NCT00692575|OTHER|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
219698479|NCT04058496|OTHER|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
219698480|NCT02017301|OTHER|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
219111647|NCT01592695|BEHAVIORAL|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
219111648|NCT01592695|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219111649|NCT01592695|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219698481|NCT00421278|DRUG|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
219698482|NCT01995383|OTHER|LS followed by NS diet condition|LS diet period followed by NS diet period
219698483|NCT01995383|OTHER|NS followed by LS diet condition|NS diet period followed by LS diet period
219698484|NCT01995383|DRUG|Placebo|Single oral administrations
219698485|NCT01995383|DRUG|Placebo|2 single oral administrations
219698486|NCT01995383|DRUG|RO6836191|Orally administered, single ascending doses
219698487|NCT01995383|DRUG|RO6836191|2 single oral doses
219698488|NCT01995383|DRUG|RO6836191|Intravenous administration
219698489|NCT03824431|DIAGNOSTIC_TEST|Endoscopic esophageal biopsies|
219698490|NCT00270023|DRUG|epoetin alfa|
219698491|NCT03175497|DRUG|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
219698492|NCT03337516|BIOLOGICAL|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
219698493|NCT03337516|GENETIC|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
219698494|NCT04221334|DEVICE|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
219698495|NCT04221334|OTHER|oral health care application|phone application that shows the user brushing efficiency real time
219698496|NCT00591799|DEVICE|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
219698497|NCT00022477|DRUG|BMS-247550|
219698498|NCT04722562|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
219698499|NCT05620524|DRUG|Extra blood samples for determining exposure to 5-FU|Extra blood samples for determining exposure to 5-FU
219698500|NCT02779569|DRUG|decitabine|
219698501|NCT02627560|DRUG|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
219698502|NCT02627560|DRUG|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
219698503|NCT03181308|DRUG|Carotuximab (TRC105)|Anti Endoglin Antibody
219698504|NCT03181308|DRUG|OPDIVO|Programmed Death Receptor-1
219698505|NCT02607631|DRUG|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
219698506|NCT02606812|DIETARY_SUPPLEMENT|Traditional-food|Intake of ethnic local food
219698507|NCT04836741|DEVICE|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
219698508|NCT04836741|DEVICE|Laparoscope|The surgeries are performed with the laparoscope
219111650|NCT01592695|DRUG|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219111651|NCT01592695|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219111652|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219698509|NCT05278468|OTHER|PCR test for covid-19|real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
219698510|NCT02924935|DIETARY_SUPPLEMENT|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
219698511|NCT01663623|BIOLOGICAL|Placebo|Placebo
219698512|NCT01663623|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
219698513|NCT01663623|DRUG|Azathioprine|Azathioprine
219698514|NCT03096535|PROCEDURE|Cooling|Individualized cooling protocol.
219698515|NCT03096535|PROCEDURE|Thermoneutral|Thermoneutral control day.
219698516|NCT01272206|DRUG|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
219698517|NCT01272206|DRUG|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
219698518|NCT00667511|DEVICE|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
219111653|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219111654|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
219111655|NCT01592695|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
219111656|NCT01592695|BEHAVIORAL|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
219111657|NCT01592695|BEHAVIORAL|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
219111658|NCT02381860|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
219111659|NCT02381860|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
219698519|NCT03447834|OTHER|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
219698520|NCT03447834|OTHER|Standard PPCI|PPCI per routine
219698521|NCT00311051|DRUG|ramatroban|
219698522|NCT00311051|DRUG|montelukast|
219698523|NCT01100385|DIETARY_SUPPLEMENT|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
219698524|NCT01100385|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule, taken once daily for 56 days
219698525|NCT02222662|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
219698526|NCT02222662|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
219111660|NCT04758221|OTHER|Treatment by composite coronal build-up|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
219111661|NCT05663983|BEHAVIORAL|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
219111662|NCT04515160|DIAGNOSTIC_TEST|Clinical Frailty Scale|Clinical fragility scale will be recorded in the first 24 hours of intensive care admissions.
219111663|NCT04515160|DIAGNOSTIC_TEST|Modified Frailty Index|Modified Frailty Index will be recorded in the first 24 hours of intensive care admissions.
219111664|NCT01085929|PROCEDURE|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
219698527|NCT00004700|DRUG|insulin-like growth factor I|
219698528|NCT01543165|DRUG|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
219111665|NCT01085929|PROCEDURE|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
219111666|NCT06527651|DRUG|Genicular blocks (dexamethazone and lidocaine)|Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
219111667|NCT01096199|DRUG|TS-ONE, Cisplatin, RAD001|
219111668|NCT03254693|COMBINATION_PRODUCT|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
219111669|NCT03254693|COMBINATION_PRODUCT|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
219111670|NCT03254693|OTHER|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
219111671|NCT03254693|OTHER|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
219111672|NCT05674084|DIAGNOSTIC_TEST|Capillary refill time|CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and \> 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
219111673|NCT02120846|OTHER|Flywheel leg-press resistance exercise|
219111674|NCT03912480|BIOLOGICAL|Stem cells from human exfoliated teeth|Intravenous infusion of pulp mesenchymal stem cells
219111675|NCT03179631|DRUG|Ataluren|10, 20 mg/kg
219111676|NCT03179631|DRUG|PLACEBO|10, 20 mg/kg
219111677|NCT00919893|DRUG|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
219111678|NCT00919893|DRUG|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
219111679|NCT05050474|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219111680|NCT05773131|DEVICE|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
219111681|NCT00453479|DRUG|GSK233705B|
219111682|NCT01375959|DIETARY_SUPPLEMENT|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
219111683|NCT01375959|DRUG|Placebo|3 placebo capsules orally twice a day for 6 weeks
219111684|NCT00242463|DRUG|Nandrolone (anabolic steroid)|
219111685|NCT00242463|DRUG|Placebo|
219111686|NCT03866772|DRUG|Misoprostol Oral Tablet|50 mcg oral consumption
219111687|NCT03866772|DEVICE|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
219111688|NCT03774992|DEVICE|Orthokeratology lenses|Custom fit, form stable contact lenses
219111689|NCT00178256|DRUG|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
219111690|NCT00178256|PROCEDURE|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
219111691|NCT06115278|OTHER|survey|survey
219111692|NCT01763788|DRUG|Necitumumab|Administered IV
219698529|NCT01543165|DRUG|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
219698530|NCT01543165|DRUG|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
219698531|NCT03147326|DIAGNOSTIC_TEST|FDG-PET-CT|scanning method
219698532|NCT03147326|DIAGNOSTIC_TEST|NaF-PET-CT|scanning method
219698533|NCT03147326|DIAGNOSTIC_TEST|Whole-body MRI|scanning method
219698534|NCT02817139|DEVICE|TDCS|
219698535|NCT03738735|DRUG|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
219698536|NCT01381120|DRUG|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
219698537|NCT01381120|DRUG|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
219698538|NCT04898881|OTHER|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
219698539|NCT04898881|OTHER|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
219698540|NCT06519058|OTHER|self-myofascial stretching|self-myofascial stretching exercise
219111693|NCT01763788|DRUG|Gemcitabine|Administered IV
219111694|NCT01763788|DRUG|Cisplatin|Administered IV
219698541|NCT06519058|OTHER|conventional physical therapy|conventional physical therapy treatment, including exercises
219698542|NCT04896463|RADIATION|Abdominal ultrasound (US)|abdominal examination with US device
219698543|NCT02891473|OTHER|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
219698544|NCT02891473|OTHER|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
219698545|NCT04337632|DRUG|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
219698546|NCT04337632|DRUG|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
219698547|NCT04151394|PROCEDURE|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
219698548|NCT04172740|DEVICE|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
219698549|NCT00856180|DRUG|Bevacizumab|
219111695|NCT03567954|DIAGNOSTIC_TEST|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
219111696|NCT01241253|OTHER|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
219111697|NCT05540743|DRUG|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
219111698|NCT01006317|BEHAVIORAL|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
219111699|NCT01006317|BEHAVIORAL|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
219111700|NCT01006317|OTHER|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
219111701|NCT02123537|DEVICE|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
219698550|NCT00856180|DRUG|Cyclophosphamide|
219698551|NCT02265510|DRUG|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
219698552|NCT02265510|DRUG|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
219698553|NCT02265510|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
219111702|NCT00960102|DEVICE|cochlear implant|Multichannel Nucleus cochlear implant
219111703|NCT00960102|DEVICE|hearing aid|Phonak hearing aid
219111704|NCT00332683|PROCEDURE|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
219111705|NCT00332683|PROCEDURE|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
219111706|NCT02354859|DRUG|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
219111707|NCT02354859|DRUG|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
219111708|NCT03008421|DIETARY_SUPPLEMENT|Astarte® (HSO Health Care GmbH, Vienna, Austria)|oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described
219111709|NCT03008421|OTHER|Placebo|Identical-looking oral potato-maltodextrin-based placebo
219111710|NCT05406960|DIETARY_SUPPLEMENT|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
219111711|NCT02086552|OTHER|Laboratory Biomarker Analysis|Correlative studies
219111712|NCT02086552|DRUG|Lenalidomide|Given PO
219111713|NCT02086552|DRUG|Sonidegib|Given PO
219111714|NCT06371365|PROCEDURE|Free Flap surgery|No intervention, this is an observational study
219111715|NCT06152523|DRUG|Monalizumab/MEDI5257|Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
219111716|NCT02735733|DEVICE|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
219698554|NCT02265510|DRUG|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
219698555|NCT02265510|DRUG|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
219698556|NCT02265510|DRUG|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
219698557|NCT02265510|DRUG|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
219698558|NCT02265510|DRUG|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
219698559|NCT02265510|DRUG|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
219698560|NCT02265510|DRUG|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
219111717|NCT06436963|BEHAVIORAL|narrative medicine training combined with CBL training|The experimental group received narrative medicine training combined with CBL training.
219698561|NCT02265510|DRUG|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
219698562|NCT02265510|DRUG|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
219698563|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
219698564|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
219698565|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
219698566|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
219698567|NCT05430906|DRUG|AK104 - Chemotherapy|AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
219698568|NCT01979432|OTHER|Cardiovascular evaluation|
219698569|NCT01985178|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|
219698570|NCT02130440|DRUG|Resveratrol nasal spray|
219698571|NCT02415946|PROCEDURE|Sinus floor augmentation (lateral)|
219698572|NCT02415946|PROCEDURE|Sinus floor augmentation (transcrestal)|
219111718|NCT06436963|BEHAVIORAL|CBL training|The control group received normal CBL training.
219111719|NCT01380301|DRUG|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
219111720|NCT01380301|DRUG|Miltefosine alone|short course (half)
219111721|NCT04139915|DRUG|Dactolisib|TORC1 inhibitor
219111722|NCT04139915|DRUG|Placebo|Placebo capsule
219111723|NCT03088358|DRUG|TeaRx|
219111724|NCT03088358|DRUG|Enoxaparin|
219111725|NCT00708305|DRUG|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
219224822|NCT01602913|DRUG|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
219224823|NCT01602913|DRUG|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
219698573|NCT02859883|DEVICE|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
219698574|NCT06420739|DIAGNOSTIC_TEST|Gastric Ultrasound|Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.
219111726|NCT00708305|DRUG|Placebo|Fluoride free toothpaste (0ppmF)
219111727|NCT04711460|BEHAVIORAL|Younger participants|Younger Participants 19-29 years received TAU + Tx over 5 weeks
219111728|NCT04711460|BEHAVIORAL|Older participants|older participants 30-54 years received TAU + Tx over 5 weeks
219111729|NCT04711460|BEHAVIORAL|TAU|Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
219111730|NCT04711460|BEHAVIORAL|TAU + MIndfulness practice|Participants received TAU + mindfulness training
219111731|NCT02761174|DRUG|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
219111732|NCT02761174|OTHER|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
219111733|NCT02544269|PROCEDURE|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
219111734|NCT02544269|PROCEDURE|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
219111735|NCT04422366|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
219111736|NCT04422366|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
219111737|NCT02406313|OTHER|CTS|Standardized Thermal Cure
219698575|NCT04506736|OTHER|ARM|"The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step."
219698576|NCT04506736|OTHER|spontanous ventilation|volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
219698577|NCT05540119|PROCEDURE|Surgery|Patients who undergo surgery are separately assessed
219698578|NCT00614835|DRUG|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
219698579|NCT01562899|DRUG|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
219698580|NCT01562899|DRUG|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
219111738|NCT02406313|OTHER|ETP|Patient Therapeutic Education
219111739|NCT02851160|OTHER|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
219698581|NCT06201091|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
219698582|NCT04695561|OTHER|Self Myofascial Relaxation|Total of 12 times for 6 weeks
219698583|NCT04695561|OTHER|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
219698584|NCT04695561|OTHER|Only Exercise (Control)|Every day for 6 weeks
219698585|NCT04595058|DEVICE|Double pigtail plastic stent through lumen-apposing metal stent|Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent
219698586|NCT04595058|DEVICE|Lumen-apposing metal stent without double pigtail plastic stent|Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
219698587|NCT04260633|DEVICE|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
219698588|NCT01352039|BIOLOGICAL|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
219698589|NCT01352039|BIOLOGICAL|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
219698590|NCT00282932|DRUG|Detrol LA|
219698591|NCT05321537|OTHER|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
219698592|NCT05230901|OTHER|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
219111740|NCT02851160|OTHER|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
219111741|NCT03180879|DRUG|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
219111742|NCT03180879|DRUG|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
219111743|NCT03180879|DRUG|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
219698593|NCT05230901|DRUG|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
219698594|NCT05230901|DRUG|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
219698595|NCT04361058|DRUG|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
219698596|NCT02667899|DEVICE|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
219698597|NCT02667899|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
219698598|NCT02667899|OTHER|Routine treatment|Means without above additional treatment.
219698599|NCT00002419|DRUG|Abacavir sulfate|
219698600|NCT00002419|DRUG|Amprenavir|
219698601|NCT00002419|DRUG|Efavirenz|
219698602|NCT00002419|DRUG|Adefovir dipivoxil|
219698603|NCT03236792|DRUG|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
219111744|NCT01808976|OTHER|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
219111745|NCT01808976|BEHAVIORAL|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
219111746|NCT01808976|BEHAVIORAL|Basic health push app|This is an app that send daily tips for improving your mood.
219111747|NCT00323713|BEHAVIORAL|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
219111748|NCT00323713|BEHAVIORAL|Low protein diet|0.6 g of protein per kilo of body weight per day
219111749|NCT00385450|DRUG|Nelfinavir/placebo|1250mg/twice each day/four days.
219111750|NCT02771210|BIOLOGICAL|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
219111751|NCT02771210|DRUG|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
219111752|NCT00139022|DEVICE|Continuous Positive Airway Pressure|
219111753|NCT05388994|OTHER|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
219111754|NCT00002793|DRUG|fluorouracil|
219111755|NCT00002793|DRUG|leucovorin calcium|
219111756|NCT03132493|DRUG|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
219698604|NCT03236792|DRUG|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
219698605|NCT03236792|DRUG|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
219111757|NCT00402545|DRUG|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
219698606|NCT02602951|OTHER|Pilot MRI program|Pilot MRI program
219698607|NCT02602951|OTHER|MRI with 4D Flow sequence|MRI with 4D Flow sequence
219698608|NCT00368550|DRUG|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
219111758|NCT00402545|DRUG|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
219111759|NCT00402545|DRUG|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
219111760|NCT00402545|DRUG|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
219111761|NCT00723424|DRUG|AZD5672|50 mg, for 13 days
219111762|NCT00723424|DRUG|Digoxin|0.5mg dose
219111763|NCT02826018|DRUG|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
219111764|NCT02826018|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219111765|NCT05056090|PROCEDURE|Patients will receive MV in PP|Putting the patient in a prone position
219111766|NCT01930435|DEVICE|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
219111767|NCT01495182|OTHER|Dietary fiber|A proprietary fiber will be given to subjects
219111768|NCT03017989|DEVICE|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
219111769|NCT00464919|DRUG|Sorafenib|
219111770|NCT00464919|DRUG|tegafur/uracil (UFUR®)|
219111771|NCT01269814|PROCEDURE|Gastroscopy|Gastroscopy
219111772|NCT03650595|DEVICE|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy"
219111773|NCT00004003|DRUG|cisplatin|
219111774|NCT00004003|DRUG|fluorouracil|
219111775|NCT00004003|DRUG|gemcitabine hydrochloride|
219111776|NCT05819060|DRUG|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
219111777|NCT03324737|DEVICE|Interactive Smartphone App|"There are six main components to the APP.~* Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~* Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~* Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~* Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~* Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
219111778|NCT00326690|DEVICE|Blue Egg Device|
219698609|NCT00368550|DRUG|Placebo|Placebo for 14-week treatment period
219698610|NCT04376281|DRUG|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
219698611|NCT05518721|PROCEDURE|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
219698612|NCT00486044|DRUG|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
219698613|NCT00486044|DRUG|Placebo|Matching tablet each night for 9 months
219698614|NCT03072550|DEVICE|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
219698615|NCT03306199|DEVICE|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
219698616|NCT01670292|OTHER|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
219698617|NCT00379106|PROCEDURE|Arm exercises.|Basic active exercise program at home.
219698618|NCT00379106|PROCEDURE|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
219111779|NCT01560377|DEVICE|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
219224824|NCT05691842|OTHER|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
219698619|NCT03108612|DIAGNOSTIC_TEST|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
219698620|NCT00781846|DRUG|ridaforolimus|oral tablets, daily for 5 days/week
219698621|NCT00781846|DRUG|bevacizumab|IV infusion
219698622|NCT01751282|GENETIC|Stem Cell|
219698623|NCT06550492|DEVICE|smoke filtering electrocautery device|A smoke-filtering electrocautery device was used during surgery.
219698624|NCT06550492|OTHER|double mask|A double-layer mask was used during the operation.
219698625|NCT04420091|DIETARY_SUPPLEMENT|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
219698626|NCT00792181|DRUG|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
219698627|NCT00792181|OTHER|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
219698628|NCT03675217|OTHER|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
219698629|NCT03675217|OTHER|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
219698630|NCT04976816|PROCEDURE|peri-levator betamethasone injection|The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
219698631|NCT04976816|PROCEDURE|peri-levator triamcinolone injection|The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
219698632|NCT04976816|PROCEDURE|peri-levator and retrobulbar betamethasone injection|In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
219111780|NCT02325232|DEVICE|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
219111781|NCT00003143|DRUG|Amifostine|
219111782|NCT00003143|DRUG|DHAP|
219111783|NCT02796547|DRUG|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
219111784|NCT02796547|OTHER|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
219111785|NCT00872469|DRUG|Tranexamic acid|1-2 grams by intravenous injection
219698633|NCT04976816|PROCEDURE|peri-levator and retrobulbar triamcinolone injection|In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
219698634|NCT05185063|DIAGNOSTIC_TEST|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
219111786|NCT00872469|DRUG|Placebo [Saline]|Matched to active comparator
219111787|NCT04012814|DEVICE|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
219111788|NCT02089581|DRUG|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
219111789|NCT02089581|DRUG|MRXXX|MRXXX
219698635|NCT04142333|GENETIC|GIA|Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
219111790|NCT02089581|DRUG|MR1XXX|
219111791|NCT02089581|DRUG|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
219111792|NCT04397523|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
219111793|NCT02932969|DRUG|BMS-986231|
219111794|NCT02932969|DRUG|BMS-986231 Placebo|
219111795|NCT00849082|DRUG|cyproterone acetate|
219111796|NCT00849082|DRUG|goserelin acetate|
219111797|NCT00849082|RADIATION|radiation therapy|
219224825|NCT05691842|OTHER|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
219698636|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
219698637|NCT00607217|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
219698638|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
219698639|NCT01603277|BIOLOGICAL|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
219698640|NCT01603277|OTHER|Placebo|Normal Saline
219698641|NCT00089219|BIOLOGICAL|IFA|vaccine adjuvant
219698642|NCT00089219|BIOLOGICAL|6MHP|melanoma helper peptides
219698643|NCT00089219|BIOLOGICAL|GM-CSF|vaccine adjuvant
219698644|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
219698645|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
219111798|NCT02810691|DIETARY_SUPPLEMENT|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
219111799|NCT02810691|DIETARY_SUPPLEMENT|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
219111800|NCT02183428|DRUG|BI 1356|
219111801|NCT02183428|DRUG|Glyburide|
219224826|NCT03486574|DIAGNOSTIC_TEST|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
219111802|NCT02183428|DRUG|BI 1356 + Glyburide|
219111803|NCT04555915|OTHER|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
219111804|NCT01275196|DRUG|Nilotinib|
219111805|NCT01275196|DRUG|Imatinib|
219111806|NCT00562068|BIOLOGICAL|alemtuzumab|
219111807|NCT00562068|DRUG|cyclophosphamide|
219111808|NCT00562068|DRUG|doxorubicin hydrochloride|
219111809|NCT00562068|DRUG|prednisolone|
219111810|NCT00562068|DRUG|vincristine sulfate|
219111811|NCT00562068|GENETIC|polymerase chain reaction|
219111812|NCT00562068|OTHER|flow cytometry|
219111813|NCT00562068|OTHER|laboratory biomarker analysis|
219111814|NCT00562068|OTHER|pharmacological study|
219111815|NCT02636894|DEVICE|Restylane Silk|
219111816|NCT04496414|DEVICE|Bactiseal Catheter|Bactiseal Catheter manufactured by Codman \& Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.
219111817|NCT00684762|DRUG|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
219111818|NCT00684762|DRUG|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
219111819|NCT03257293|BEHAVIORAL|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
219111820|NCT03257293|BEHAVIORAL|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
219111821|NCT00362102|DRUG|Cetuximab|
219111822|NCT03923218|OTHER|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
219111823|NCT03923218|OTHER|Serum Vitamin D3 levels|Collected serum
219111824|NCT03923218|OTHER|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
219111825|NCT02572817|BIOLOGICAL|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
219111826|NCT02572817|BIOLOGICAL|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
219111827|NCT03937323|OTHER|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
219111828|NCT00368862|DRUG|Ebixa (memantine hydrochloride)|
219111829|NCT00368862|DRUG|Cipralex (escitalopram)|
219111830|NCT03379714|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
219111831|NCT04562103|DRUG|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
219698646|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
219698647|NCT01925443|OTHER|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
219698648|NCT04880109|DRUG|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
219698649|NCT04880109|DRUG|Placebo|Oral administration of placebo capsule once daily for 14 days
219698650|NCT03225963|RADIATION|Chemoradiation with temozolomide|
219698651|NCT04112576|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
219111832|NCT04562103|DRUG|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
219111833|NCT02546063|OTHER|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
219111834|NCT01510613|DRUG|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
219111835|NCT03034317|DEVICE|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
219698652|NCT01192321|DEVICE|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
219698653|NCT01192321|DEVICE|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
219698654|NCT04525521|OTHER|Hand sanitizer and hand washing|All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
219698655|NCT02950701|DEVICE|Observational data collection.|
219698656|NCT01515839|DIETARY_SUPPLEMENT|Multivitamin Supplement intervention|"We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss"
219698657|NCT05211934|OTHER|No intervention|No intervention
219698658|NCT02472899|OTHER|Blood sample|Non-interventional study based on blood samples taken at a single study visit
219111836|NCT03862651|DRUG|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
219111837|NCT00199030|DRUG|Alemtuzumab (MabCampath)|
219111838|NCT00199030|DRUG|Cladribine|
219111839|NCT04022837|DRUG|Pantoprazole 40mg|effect of this drug on renal function
219111840|NCT00230321|DRUG|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
219111841|NCT00832338|DRUG|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
219111842|NCT00832338|DRUG|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
219111843|NCT01193543|DIETARY_SUPPLEMENT|calanus oil|1 gram twice daily
219111844|NCT01193543|DIETARY_SUPPLEMENT|olive oil|1 gram twice daily
219111845|NCT00742105|DRUG|BGT226|
219698659|NCT00550199|DRUG|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
219698660|NCT04486664|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
219698661|NCT04435496|DEVICE|GYN-CS|placement of the GYN-CS device
219698662|NCT01183923|OTHER|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
219698663|NCT01183923|OTHER|Alfalfa Sprouts|Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
219698664|NCT05759572|DRUG|Apatinib|TKI
219111846|NCT03410914|DEVICE|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
219111847|NCT05776082|OTHER|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
219111848|NCT04112472|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
219111849|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
219111850|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
219111851|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
219111852|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
219111853|NCT02293174|DEVICE|Topcon TRC-NW400|Retinal Fundus Camera
219111854|NCT02293174|DEVICE|TRC-NW8|Retinal Fundus Camera
219111855|NCT02293174|DEVICE|TRC-NW400|Retinal Fundus Camera
219111856|NCT02293174|DEVICE|Canon-CR2|Retinal Fundus Camera
219111857|NCT02293174|DEVICE|Zeiss Visucam PRO|Retinal Fundus Camera
219224827|NCT02955199|BEHAVIORAL|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
219224828|NCT02955199|BEHAVIORAL|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
219224829|NCT02929420|DRUG|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
219698665|NCT05759572|DRUG|Dalpiciclib|CDK4/6 inhibitor
219698666|NCT05759572|DRUG|Fulvestrant/AI|Endocrine therapy
219698667|NCT04494646|DRUG|Bardoxolone Methyl|Once-daily administration of bardoxolone methyl (20mg)
219698668|NCT04494646|DRUG|Placebo|Once-daily administration of matching placebo
219698669|NCT02506920|DIETARY_SUPPLEMENT|Six different types of fat in a meal in random order|Oral fat tolerance test
219698670|NCT00286182|DRUG|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
219698671|NCT00286182|DRUG|Placebo|Placebo
219698672|NCT03818152|OTHER|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
219698673|NCT02785939|DRUG|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
219111858|NCT04579120|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
219111859|NCT04579120|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
219111860|NCT02693886|OTHER|doctor experience|
219111861|NCT05086822|DRUG|Irinotecan liposome|Irinotecan liposome
219111862|NCT05015660|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
219111863|NCT05015660|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
219111864|NCT02214823|DEVICE|FES-Cycling|
219111865|NCT02214823|OTHER|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
219111866|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 3)|
219111867|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 5)|
219111868|NCT04961736|OTHER|no intervention|This is an observation study, with no intervention
219111869|NCT01991249|OTHER|blood draw|
219111870|NCT03013686|PROCEDURE|Interval appendectomy|Laparoscopic appendectomy
219111871|NCT03013686|PROCEDURE|Follow-up with MRI|Abdominal MRI
219111872|NCT01948271|DRUG|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
219111873|NCT05251441|DIETARY_SUPPLEMENT|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
219698674|NCT02785939|OTHER|Laboratory Biomarker Analysis|Correlative studies
219698675|NCT02785939|DRUG|Palbociclib|Given PO
219698676|NCT05033132|DRUG|Balstilimab|Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
219698677|NCT05033132|DRUG|Balstilimab + Zalifrelimab|An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
219698678|NCT05543304|DIAGNOSTIC_TEST|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
219698679|NCT05461040|PROCEDURE|optic capture|optic capture of Intraocular lens without anterior vitrectomy
219698680|NCT05461040|PROCEDURE|In-the-bag implantation of Intraocular lens|in-the-bag implantation of Intraocular lens with anterior vitrectomy
219698681|NCT00966433|PROCEDURE|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
219698682|NCT00966433|DEVICE|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
219698683|NCT00966433|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
219111874|NCT02803320|DRUG|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
219698684|NCT05052840|OTHER|Muscle endurance training (MET)|Experimental group will be given MET Program, stretching \& strengthening exercises and Hot packs (for 15 minutes). MET program will include warm up, endurance and cool down exercises. The warm up and cool down period will be consisted of 5-minute walking, and 10 repetitions of stretching exercises. Endurance exercises will consist of 4 levels.
219698685|NCT05052840|OTHER|Conventional Treatment|"Conventional treatment group will be given hot packs (for 15 minutes) and Strengthening \& stretching exercise program including:~STRETCHING EXERCISES (lumbar extensor muscles, iliopsoas muscles, hamstring muscles, gastrocnemius muscles and pectoral muscles).~STRENGTHENING EXERCISES (rectus abdominus crunch, oblique crunch, pelvic elevation, single leg pelvic elevation, lumbal spine extension, on hands and knees position with the raise of one leg, on hands and knees position with the raise of opposite arm and leg). Each exercise will be repeated 10 times."
219698686|NCT03735615|BEHAVIORAL|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
219698687|NCT00006022|BIOLOGICAL|aldesleukin|
219111875|NCT03319186|PROCEDURE|EDIT Management|"EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
219111876|NCT03319186|PROCEDURE|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
219698688|NCT00006022|DRUG|bryostatin 1|
219698689|NCT00522665|DRUG|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
219698690|NCT00522665|BIOLOGICAL|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
219698691|NCT00522665|BIOLOGICAL|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
219698692|NCT04845230|BEHAVIORAL|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
219698693|NCT01012050|DEVICE|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
219698694|NCT01012050|OTHER|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
219698695|NCT01096940|DRUG|AZD1656|Oral tablet, BID dose
219698696|NCT01096940|DRUG|simvastatin|Oral tablet, single dose
219698697|NCT02137798|DEVICE|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
219698698|NCT05861908|OTHER|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
219698699|NCT05861908|OTHER|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
219698700|NCT05861908|OTHER|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
219698701|NCT05861908|OTHER|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
219698702|NCT02391337|DRUG|Bisoprolol|Drug intervention
219698703|NCT02391337|DRUG|Digoxin|Drug intervention
219698704|NCT02596048|OTHER|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
219111877|NCT03918538|BEHAVIORAL|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
219111878|NCT02441946|DRUG|Abemaciclib|Administered orally
219111879|NCT02441946|DRUG|Loperamide|Administered orally
219111880|NCT02441946|DRUG|Anastrozole|Administered orally
219698705|NCT00773357|DRUG|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
219698706|NCT00773357|DRUG|placebo|placebo
219698707|NCT00846053|DIAGNOSTIC_TEST|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
219698708|NCT06017245|DEVICE|whole-body vibration to Control|Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
219698709|NCT00111761|DRUG|Irinotecan|Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
219698710|NCT00111761|BIOLOGICAL|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
219698711|NCT00111761|DRUG|5-Fluorouracil|Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
219698712|NCT00111761|DRUG|Leucovorin|Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
219698713|NCT02361866|BIOLOGICAL|GC1107|0.5 ml, Intramuscular, single dose(day0)
219698714|NCT02361866|BIOLOGICAL|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
219698715|NCT01824017|OTHER|Blood Draw|
219698716|NCT06508086|PROCEDURE|laser ablation technique in the treatment of pilonidal sinus|group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser
219698717|NCT06508086|PROCEDURE|Karydakis technique in the treatment of pilonidal sinus|group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
219698718|NCT02386852|DRUG|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
219698719|NCT02386852|DRUG|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
219698720|NCT02386852|DRUG|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
219111881|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
219224830|NCT02929420|DRUG|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
219698721|NCT04918862|DRUG|Granisetron|210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
219698722|NCT00563771|DRUG|Rasburicase|
219698723|NCT00153426|BEHAVIORAL|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
219698724|NCT06478641|DRUG|Tafenoquine|Tafenoquine will be self-administered orally as 2 x 100 mg dark pink coated tablets once daily (total daily dose 200 mg) with food on Days 1, 2, 3 \& 4 then weekly thereafter (starting on day 11) until the patient has two consecutive negative PCR tests for Babesia parasites and symptoms of babesiosis have resolved.
219698725|NCT06517992|OTHER|Health education for cadre (communicated project)|The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.
219111882|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
219111883|NCT03237962|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
219224831|NCT05603182|DRUG|PRA052|PRA052
219698726|NCT01763541|DRUG|leuprolide acetate|Given to both arms to induce hypogonadism
219698727|NCT01763541|DRUG|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
219111884|NCT03237962|DEVICE|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
219111885|NCT04392440|BEHAVIORAL|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
219111886|NCT04392440|OTHER|usual care|regular nephrology care
219111887|NCT02111213|BEHAVIORAL|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
219111888|NCT02111213|BEHAVIORAL|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
219111889|NCT06477367|OTHER|Video-Based Breathing Exercises|Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day. The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
219111890|NCT05706181|OTHER|Home-based leg heat therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
219111891|NCT05706181|OTHER|Home-based sham therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
219111892|NCT03443596|BIOLOGICAL|Early intensive BP control|Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
219698728|NCT04127617|OTHER|Osteopathic Manipulative Treatment|"Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment"
219698729|NCT04127617|OTHER|Nursing Educational Care|"Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs."
219698730|NCT00746551|DRUG|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
219698731|NCT00746551|DRUG|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
219698732|NCT05216484|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
219698733|NCT04265677|OTHER|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
219111893|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 1|\~125 g fresh weight (1 cup equivalent)
219111894|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 2|\~250 g fresh weight (2 cup equivalent)
219224832|NCT05603182|OTHER|Placebo|Placebo
219111895|NCT02479035|DIETARY_SUPPLEMENT|Control meal|0 g red raspberry
219111896|NCT00095030|DRUG|muraglitazar|
219224833|NCT01532648|DRUG|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
219224834|NCT01532648|DRUG|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
219224835|NCT01532648|DRUG|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
219111897|NCT02314741|PROCEDURE|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
219111898|NCT01629680|DRUG|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
219111899|NCT01629680|DRUG|Placebo|coated tablets identical in number and appearance as the study drug
219111900|NCT06435949|DRUG|Fentanyl (as Citrate)|intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
219111901|NCT01570179|DRUG|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
219111902|NCT01570179|DRUG|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
219111903|NCT01570179|DRUG|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
219111904|NCT01570179|DRUG|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
219111905|NCT02761629|DRUG|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
219111906|NCT02761629|DRUG|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.
219111907|NCT01694992|OTHER|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
219111908|NCT03300089|PROCEDURE|General anaesthesia|General anaesthesia
219111909|NCT03300089|PROCEDURE|Regional anaesthesia|Regional anaesthesia
219111910|NCT02001974|DRUG|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
219698734|NCT04265677|OTHER|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
219111911|NCT05374759|DIAGNOSTIC_TEST|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
219111912|NCT05374759|DIAGNOSTIC_TEST|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
219111913|NCT00210119|DRUG|Glivec|
219111914|NCT02554630|OTHER|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
219111915|NCT02554630|OTHER|Blood Collection|Blood collection will be performed on all groups.
219111916|NCT01330693|DRUG|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
219111917|NCT01330693|DRUG|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
219111918|NCT03971812|BIOLOGICAL|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
219111919|NCT01714102|DIETARY_SUPPLEMENT|Placebo|Placebo manufactured to mimic resveratrol tablet
219111920|NCT01714102|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol PO BID for 30 days
219111921|NCT01830881|DRUG|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
219111922|NCT01830881|DRUG|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
219111923|NCT01830881|OTHER|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
219111924|NCT01830881|DRUG|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
219111925|NCT01476436|OTHER|Low carbohydrate dietary advice|Dietary advice
219111926|NCT01476436|OTHER|Continue usual diet|Dietary advice
219111927|NCT01475916|BEHAVIORAL|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
219111928|NCT00119262|DRUG|doxorubicin hydrochloride|Given IV
219111929|NCT00119262|DRUG|cyclophosphamide|Given IV
219698735|NCT01220791|OTHER|In vitro fertilization treatment for infertility|IVF treatment
219698736|NCT02246933|OTHER|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
219698737|NCT02246933|OTHER|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
219111930|NCT00119262|BIOLOGICAL|bevacizumab|Given IV
219111931|NCT00119262|DRUG|paclitaxel|Given IV
219111932|NCT00119262|BIOLOGICAL|filgrastim|Given SC
219111933|NCT00119262|BIOLOGICAL|pegfilgrastim|Given SC
219111934|NCT00119262|RADIATION|radiation therapy|Undergo radiation therapy
219111935|NCT00119262|DRUG|tamoxifen citrate|Given orally
219111936|NCT00119262|DRUG|aromatase inhibition therapy|Receive aromatase inhibition therapy
219111937|NCT02038764|DRUG|Placebo|Placebo
219111938|NCT02038764|BIOLOGICAL|PF-06342674 Dose A|Multiple SC Doses
219111939|NCT02038764|BIOLOGICAL|PF-06342674 Dose B|Multiple SC Doses
219111940|NCT02038764|BIOLOGICAL|PF-06342674 Dose C|Multiple SC Doses
219111941|NCT02038764|BIOLOGICAL|PF-06342674 Dose D|Multiple SC Doses
219111942|NCT02136498|DRUG|Varenicline|Standard 12 week course of varenicline, provided in both arms
219111943|NCT02136498|BEHAVIORAL|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
219111944|NCT02136498|BEHAVIORAL|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
219111945|NCT04844918|DRUG|Tirzepatide|Administered SC
219111946|NCT04844918|OTHER|Placebo|Administered SC
219111947|NCT03477786|COMBINATION_PRODUCT|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
219111948|NCT03653663|DRUG|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
219111949|NCT03653663|DRUG|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
219111950|NCT01684995|BEHAVIORAL|Brief physician advice|Brief physician advice to quit smoking
219111951|NCT01684995|DRUG|nicotine patch|nicotine patch
219111952|NCT01684995|BEHAVIORAL|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
219111953|NCT01971190|DRUG|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
219698738|NCT01092767|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
219111954|NCT01971190|DRUG|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
219224836|NCT03637036|OTHER|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
219111955|NCT01971190|PROCEDURE|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
219111956|NCT02029040|DRUG|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
219111957|NCT02029040|DRUG|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
219111958|NCT00679484|DRUG|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
219111959|NCT00679484|DRUG|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
219111960|NCT02035813|DRUG|Ribociclib|Ribociclib/Everolimus in combination with endocrine therapy
219111961|NCT02035813|DRUG|Eribulin|
219698739|NCT03398473|DRUG|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
219698740|NCT03398473|DRUG|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
219698741|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
219111962|NCT03590665|OTHER|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
219111963|NCT03593993|PROCEDURE|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
219111964|NCT01910727|BEHAVIORAL|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
219111965|NCT01472913|DRUG|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
219111966|NCT01472913|DRUG|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
219111967|NCT01518660|BEHAVIORAL|Training|Bi-weekly progressive resistance training
219111968|NCT01017653|DRUG|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
219111969|NCT01017653|DRUG|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
219111970|NCT00211341|DIETARY_SUPPLEMENT|Vitamin A|Weekly single oral dose 7000 micrograms
219111971|NCT03005093|OTHER|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
219698742|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
219698743|NCT00652444|DRUG|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
219111972|NCT03005093|OTHER|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
219224837|NCT00479375|PROCEDURE|Adding Human Papillomavirus testing to organised cervical screening|
219224838|NCT03983759|DRUG|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
219224839|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
219698744|NCT00652444|DRUG|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
219698745|NCT00652444|DRUG|Placebo (Unspecified)|Matching ezetimibe placebo
219698746|NCT05125445|PROCEDURE|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
219698747|NCT05125445|PROCEDURE|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
219224840|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
219224841|NCT02753998|PROCEDURE|Conventional angioplasty|
219224842|NCT00031720|DIETARY_SUPPLEMENT|soy protein|Given orally
219224843|NCT00031720|DIETARY_SUPPLEMENT|isoflavones|Given orally
219698748|NCT02707497|DRUG|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
219698749|NCT02707497|DRUG|Placebo|The control group will not use any platelet-increased drugs.
219111973|NCT05392075|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
219111974|NCT05392075|BIOLOGICAL|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
219111975|NCT04193293|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
219111976|NCT04193293|BIOLOGICAL|Pembrolizumab|Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
219111977|NCT02874066|DRUG|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
219111978|NCT05975866|DIETARY_SUPPLEMENT|curcumin|Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
219111979|NCT05975866|BEHAVIORAL|Anti-inflammatory diet|The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
219698750|NCT02436863|PROCEDURE|Surgical performance|Two different surgical performances
219111980|NCT02030275|DRUG|RXI-109|surgery.
219111981|NCT02030275|DRUG|Placebo|surgery.
219111982|NCT06480669|OTHER|Time Restricted Feeding|8 participants who practiced a 12/12 TRF (12 hours of fasting, from approximately 20:30 to 8:30 the following day).
219111983|NCT06480669|OTHER|Mediterranean Diet|A control group consisting of 9 participants who followed a standard Mediterranean diet.
219111984|NCT02923219|BIOLOGICAL|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
219111985|NCT03728192|OTHER|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
219111986|NCT00320879|DRUG|irbesartan|
219111987|NCT03862989|PROCEDURE|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
219111988|NCT04676828|DIAGNOSTIC_TEST|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
219111989|NCT00714350|BEHAVIORAL|New ICU Display Visualization|
219111990|NCT05033080|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
219111991|NCT05033080|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
219111992|NCT05033080|DRUG|IVA|Tablet for oral administration.
219111993|NCT05033080|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
219111994|NCT05033080|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
219111995|NCT05033080|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
219111996|NCT04801745|OTHER|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
219111997|NCT04801745|OTHER|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
219111998|NCT04801745|OTHER|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
219224844|NCT00031720|DRUG|Tamoxifen|
219224845|NCT00031720|OTHER|Placebo|Oral
219224846|NCT01990508|BEHAVIORAL|Targeted beverage education and financial incentives|
219111999|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
219112000|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk with added egg yolk|Buttermilk with added egg yolk
219112001|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
219112002|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
219112003|NCT03270813|BEHAVIORAL|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
219112004|NCT03270813|BEHAVIORAL|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
219112005|NCT02543190|BEHAVIORAL|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
219112006|NCT03135457|PROCEDURE|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
219112007|NCT03135457|PROCEDURE|Saline transfusion|Saline transfusion 300ml 10ml/min
219112008|NCT04096573|DRUG|LC51-0255|LC51-0255
219112009|NCT04096573|DRUG|Placebo|Placebo
219112010|NCT01263106|DRUG|LY2216684|18-mg LY2216684 oral dose
219112011|NCT01263106|DRUG|Theophylline|200-mg theophylline oral dose
219112012|NCT03939247|OTHER|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
219112013|NCT03939247|OTHER|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
219112014|NCT03939247|OTHER|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
219112015|NCT03996044|OTHER|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
219224847|NCT01990508|BEHAVIORAL|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
219224848|NCT01160588|DRUG|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
219224849|NCT00352131|DRUG|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
219224850|NCT00794807|DRUG|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
219698751|NCT03366662|DEVICE|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
219698752|NCT05123573|BEHAVIORAL|Clinical Skills|evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
219112016|NCT03996044|OTHER|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
219112017|NCT03996044|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
219112018|NCT03996044|BIOLOGICAL|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
219112019|NCT01985477|DRUG|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
219112020|NCT01985477|DRUG|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
219112021|NCT01985477|DRUG|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
219112022|NCT04324294|DRUG|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
219112023|NCT01680458|DRUG|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
219112024|NCT01756820|PROCEDURE|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
219698753|NCT01317563|DIETARY_SUPPLEMENT|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
219698754|NCT01317563|DIETARY_SUPPLEMENT|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
219698755|NCT04217291|DRUG|SY-004|Take orally once a day
219112025|NCT01756820|PROCEDURE|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
219112026|NCT00715741|OTHER|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
219112027|NCT00715741|OTHER|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
219112028|NCT00715741|OTHER|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 \>0.9 with 3-5 cm water PEEP
219698756|NCT04217291|OTHER|SY-004 matching placebo|Take orally once a day
219698757|NCT05545475|DRUG|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
219698758|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
219698759|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
219698760|NCT06202859|DEVICE|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
219112029|NCT00715741|OTHER|FiO2 >0.9 without PEEP|FiO2 \>0.9 without PEEP
219112030|NCT02191384|DRUG|Orcinoside|oral, twice per day
219698761|NCT01344135|DIETARY_SUPPLEMENT|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
219112031|NCT04992936|DIETARY_SUPPLEMENT|Extract from the wine industry|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219112032|NCT04992936|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219112033|NCT03665883|PROCEDURE|Monopolar energy|Monopolar energy in TEP for inguinal hernia
219112034|NCT03665883|PROCEDURE|Blunt dissection|Blunt dissection in TEP for inguinal hernia
219112035|NCT05902221|DRUG|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
219112036|NCT05902221|DRUG|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
219698762|NCT01344135|DIETARY_SUPPLEMENT|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
219698763|NCT01344135|BEHAVIORAL|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~1. Optimising dietary intake to physical activity pattern and energy expenditure.~2. Minimize deterioration of dietary intake during acute exacerbations.~3. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~4. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
219698764|NCT01344135|BEHAVIORAL|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
219698765|NCT03786835|OTHER|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
219698766|NCT02025608|DRUG|Pramipexole|
219698767|NCT02025608|DRUG|Placebo|
219698768|NCT06545305|PROCEDURE|Lensectomy and vitrectomy|Corrections
219698769|NCT01202500|PROCEDURE|reducing treatment to 3 months|The treatment will be stopped after 3 months
219698770|NCT01202500|PROCEDURE|registered length of treatment|The treatment procedure will follow the actual recommandation
219698771|NCT02797028|DIETARY_SUPPLEMENT|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
219112037|NCT05295914|DIAGNOSTIC_TEST|TREAT-B score|TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis
219112038|NCT05956548|PROCEDURE|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
219698772|NCT02797028|DIETARY_SUPPLEMENT|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
219698773|NCT02797028|DRUG|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
219112039|NCT03295266|DRUG|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
219698774|NCT02204670|OTHER|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
219698775|NCT04014010|OTHER|Blood pressure|"Systolic Blood Pressure (SBP)~1. Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative SBP~3. Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~4. Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~1. Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative MAP~3. Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~4. Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
219698776|NCT04014010|OTHER|Heart rate|"1. Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~2. Relative change (%) from preoperative heart rate (positive and negative)~3. Maximum pulse variation (maximum heart rate minus minimum heart rate)~4. Longest single episode (minutes) a) below 60, and b) above 100BPM~5. Cumulative duration (minutes) a) below 60, and b) above 100BPM"
219112040|NCT05667779|DRUG|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
219112041|NCT05667779|OTHER|Placebo|A placebo comparator will be administered at all dose levels.
219112042|NCT02578511|DRUG|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
219112043|NCT02626858|DEVICE|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
219112044|NCT05605717|RADIATION|Fibroscan|Liver fibroscan and ultrasonography
219224851|NCT00808834|DEVICE|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
219698777|NCT04014010|OTHER|Use of hemodynamic medications (i.e. special medications for blood pressure)|"1. Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~2. Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~3. Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~4. Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~5. Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
219112045|NCT00210522|DRUG|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
219112046|NCT06480682|RADIATION|Dual x-ray scan|Annual whole body scan monitoring bone mineral density for whole body, radius, L1-4 and femur and body composition
219112047|NCT06480682|DIAGNOSTIC_TEST|Blood screen|Three times a year blood samples will be taken to measure: full blood count, ferritin, B12, folate, erythrocyte sedimentation rate (ESR), renal function, liver function, thyroid stimulating hormone (TSH), Free thyroxine (T4), luteinizing hormone (LH), oestradiol, testosterone, follicle-stimulating hormone (FSH), coeliac screen, vitamin D (25(OH)D), Leptin and Ghrelin
219112048|NCT06480682|OTHER|Questionnaires|Informed consent; Low energy availability questionnaires for males and females; General health including menstrual status (females)
219112049|NCT06480682|OTHER|Anthropometric measurements|Three times a year participant's measurements will be taken: stature, body mass and body composition (bio-impedence)
219112050|NCT06480682|PROCEDURE|Resting Metabolic rate|Resting metabolic rate will be measured by resting gas analysis. Each participant will lie down for a period of 15 minutes, in the final 5 minutes their expired gases are analysed using a breath-by-breath gas analyser (Cortex).
219112051|NCT06480682|OTHER|Energy expenditure|Energy expenditure was estimated using accelerometery (Genieactive) and activity logs in the participants' normal environment, assessed during 3 weekdays of scheduled dance training and 2 weekend days without scheduled dance training. Focus is on daily energy expenditure
219112052|NCT06280287|DIAGNOSTIC_TEST|FAPI PET|68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
219112053|NCT00335205|DRUG|ropinirole|
219112054|NCT04180735|PROCEDURE|Liver transplantation|Liver transplantation
219112055|NCT03612518|BEHAVIORAL|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
219112056|NCT03612518|BEHAVIORAL|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
219224852|NCT00808834|DEVICE|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
219698778|NCT04014010|OTHER|Oxygen saturation by pulse oximetry (SpO2)|"1. Longest single episode (minutes) below a) 88, and b) 90%~2. Cumulative duration (minutes) below a) 88, and b) 90%"
219698779|NCT04014010|OTHER|End-tidal Carbon dioxide (EtCO2)|"1. Longest single episode (minutes) a) below 30, and b) above 45mmHg~2. Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
219698780|NCT05965596|OTHER|a psycho educational intervention program|The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.
219698781|NCT05965596|OTHER|the routine care|the routine care provided for all gynecological cancer patients in the study setting
219698782|NCT00727129|DRUG|Divigel|
219698783|NCT00004102|DRUG|FOLFOX regimen|
219698784|NCT00004102|DRUG|fluorouracil|
219698785|NCT00004102|DRUG|leucovorin calcium|
219698786|NCT00004102|DRUG|oxaliplatin|
219698787|NCT00000363|DRUG|Antihistamine|
219698788|NCT00000363|DRUG|Corticosteroid|
219112057|NCT02857660|OTHER|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
219112058|NCT02857660|DIETARY_SUPPLEMENT|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
219112059|NCT04263298|DRUG|Fulvestrant|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
219112060|NCT04263298|DRUG|Capecitabine Oral Product|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
219112061|NCT05295303|DEVICE|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
219112062|NCT03933332|OTHER|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
219112063|NCT03933332|OTHER|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2
219112064|NCT03933332|OTHER|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm\^2
219112065|NCT03933332|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
219112066|NCT04109742|DRUG|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
219112067|NCT04109742|DRUG|Placebo curcumin capsule|matching placebo to active curcumin capsules
219112068|NCT03250351|OTHER|Neural mobilization group|See arm/group descriptions
219112069|NCT03250351|OTHER|Control group|See arm/group descriptions
219112070|NCT02693340|BIOLOGICAL|sampling|"• Sampling period(s):~* Blood: W0, W6, W14, W30 and W52 and relapse.~* Biopsies and fecal: W0, W14 and M52 and relapse."
219112071|NCT04725630|BEHAVIORAL|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
219112072|NCT04725630|BEHAVIORAL|Healthy food prescription|A one-time healthy food prescription pamphlet
219112073|NCT03784352|DEVICE|Virtual Reality|A calming virtual reality game will be played
219698789|NCT06265831|OTHER|Hand-fan application to the face|Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
219698790|NCT03372798|PROCEDURE|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
219698791|NCT04149717|DIETARY_SUPPLEMENT|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4\. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5\. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
219698792|NCT02526485|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
219698793|NCT04823312|DEVICE|Experimental prospective single arm evaluating the Medtronic Duo Extended Set|Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
219698794|NCT02779140|BIOLOGICAL|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
219698795|NCT02779140|OTHER|Placebo|Placebo
219698796|NCT02037672|DRUG|metformin|
219698797|NCT02037672|DRUG|metformin and roflumilast|
219698798|NCT03209479|DRUG|Glatiramer acetate|Copaxone subcutaneous injection syringe
219698799|NCT00502567|DRUG|AZD2171|oral tablet once daily
219698800|NCT00502567|DRUG|FOLFOX|intravenous infusion
219112074|NCT00479089|DRUG|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
219112075|NCT00479089|DRUG|ZD1839|250 mg by mouth daily, without break.
219698801|NCT00502567|DRUG|Pemetrexed|intravenous infusion
219698802|NCT00502567|DRUG|Irinotecan (administered with & without Cetuximab)|intravenous injection
219698803|NCT00502567|DRUG|Docetaxel|intravenous infusion
219698804|NCT03936569|DRUG|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
219698805|NCT03936569|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
219112076|NCT00479089|DRUG|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
219112077|NCT00405704|DRUG|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
219112078|NCT00405704|DRUG|Placebo|Cherry flavored liquid suspension matched to active comparator.
219112079|NCT03751163|DRUG|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
219698806|NCT00072111|BIOLOGICAL|anakinra|
219698807|NCT04824807|OTHER|Yoga|"The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana."
219112080|NCT03751163|DRUG|Hydroquinone 4% Cream|Hydroquinone 4% Cream
219112081|NCT03751163|OTHER|Sunscreen|Sunscreen SPF 30
219112082|NCT03751163|DEVICE|Placebo|Encapsulated placebo
219112083|NCT02323503|DEVICE|CRT-D device replacement|
219112084|NCT03133949|OTHER|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
219112085|NCT05728567|OTHER|whether the participants had T2DM|whether the participants had T2DM
219112086|NCT04281433|OTHER|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
219112087|NCT04959760|DIAGNOSTIC_TEST|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
219112088|NCT03666884|DRUG|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
219112089|NCT03666884|BIOLOGICAL|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
219112090|NCT03012061|DRUG|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
219112091|NCT03012061|DRUG|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
219112092|NCT03012061|DRUG|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
219112093|NCT03012061|DRUG|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
219112094|NCT05493384|OTHER|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
219698808|NCT04824807|OTHER|Clinical Pilates|"before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge."
219698809|NCT04824807|OTHER|An educational booklet|Only educational booklets will be given to the control group
219698810|NCT02171546|DRUG|Dabigatran etexilate capsules|
219698811|NCT02171546|DRUG|Quinidine sulfate tablets|
219698812|NCT02171546|DRUG|Fexofenadine tablets|
219698813|NCT02694133|PROCEDURE|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
219698814|NCT02694133|PROCEDURE|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
219698815|NCT04422938|OTHER|Manuel chest compressions handled by clinicians|Compressions will be handled by human efforts
219112095|NCT03859401|DEVICE|EnMPC (Ensemble Model Predictive Control) AP Controller|This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
219112096|NCT03859401|DEVICE|rMPC (Naïve Model Predictive Control) AP Controller|This AP controller does not have the ability to anticipate exercise activity.
219698816|NCT04422938|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
219698817|NCT00461734|OTHER|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
219698818|NCT02236000|DRUG|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
219698819|NCT02236000|DRUG|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
219698820|NCT03723434|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
219698821|NCT03723434|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
219698822|NCT03723434|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
219698823|NCT03538080|DEVICE|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
219698824|NCT03538080|DEVICE|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
219112097|NCT06358911|OTHER|Poly amido amine dendrimer (PAMAM)|"Desensitizing agents was applied once after the bleaching procedure,as follows:~1-Bleaching/PAMAM group, patients received bleaching followed by the application of PAMAM for 30 minutes according to previous studies."
219112098|NCT06358911|OTHER|Manufacturer's desensitizing agent, Ultra EZ|"Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes."
219112099|NCT06358911|OTHER|MI paste plus, desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes."
219112100|NCT06358911|OTHER|Hydroxyapatite and F (ReminPro), desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes"
219112101|NCT02574676|OTHER|non-interventional|
219112102|NCT02696902|DRUG|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
219112103|NCT02696902|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
219112104|NCT00000664|DRUG|Interleukin-2, Polyethylene Glycolated|
219698825|NCT03561194|DIETARY_SUPPLEMENT|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
219698826|NCT00381628|PROCEDURE|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
219112105|NCT00000664|DRUG|Zidovudine|
219698827|NCT02371681|DRUG|Treatment|Different Drug combinations
219698828|NCT02371681|RADIATION|PET/CT Scan|PET/CT Scans
219698829|NCT02371681|PROCEDURE|Sample Collection|Sample Collection
219698830|NCT03247777|OTHER|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
219698831|NCT03247777|OTHER|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
219698832|NCT00465530|DRUG|Saline|Intranasal Saline
219698833|NCT00465530|DRUG|Gentamycin|Intranasal irrigation
219698834|NCT00949442|DRUG|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
219112106|NCT02484079|PROCEDURE|Polypectomy|
219112107|NCT03421496|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219112108|NCT03421496|DRUG|Placebo|Matching oral solution
219112109|NCT03421496|DRUG|Vigabatrin|Powder suspension
219698835|NCT00949442|DRUG|Glimepiride|tablets of 1 and 2 mg
219698836|NCT00949442|DRUG|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
219698837|NCT02577536|OTHER|No Interventions|No Interventions will be conducted under this study.
219698838|NCT00310986|BEHAVIORAL|Breathing Meditation|
219698839|NCT02783638|DRUG|YHD1119|2 by 2
219698840|NCT02783638|DRUG|Lyrica|2 by 2
219112110|NCT01003600|BEHAVIORAL|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
219112111|NCT06035614|DEVICE|exciplex|exciplex, excimer lamp 308nm produced by clarteis
219112112|NCT06035614|DRUG|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
219112113|NCT01357330|DRUG|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
219112114|NCT01357330|DRUG|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
219112115|NCT04810039|OTHER|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
219698841|NCT01627665|DRUG|D->R->C+R|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
219698842|NCT01627665|DRUG|D->R->C+D|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
219698843|NCT01627665|DRUG|R->D->C+D|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
219698844|NCT01627665|DRUG|R->D->C+R|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
219698845|NCT01806181|OTHER|Exercise|
219698846|NCT05618223|DRUG|Dapagliflozin|Dapagliflozin 10 mg once daily in addition to standard therapy
219698847|NCT02238366|DRUG|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
219698848|NCT04688632|DRUG|Ampreloxetine <Dose A>|Ampreloxetine \<Dose A\> will be administered as 1 tablet of \<Dose A\> and 3 tablets of Ampreloxetine Placebo.
219698849|NCT04688632|DRUG|Ampreloxetine <Dose B>|Ampreloxetine \<Dose B\> will be administered as 4 tablets of \<Dose A\>
219112116|NCT05822921|BEHAVIORAL|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
219698850|NCT04688632|DRUG|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A\> tablet.
219698851|NCT04688632|DRUG|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
219698852|NCT04688632|DRUG|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
219698853|NCT00948090|DRUG|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
219698854|NCT03641976|DRUG|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
219698855|NCT03641976|DRUG|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
219698856|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
219698857|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
219698858|NCT00910234|DRUG|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
219698859|NCT01033838|PROCEDURE|rectosigmoid resection|
219698860|NCT00671268|BIOLOGICAL|AL0704rP|strict subcutaneous
219698861|NCT00671268|BIOLOGICAL|Placebo|strict subcutaneous
219698862|NCT05549596|DEVICE|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2\~L3
219698863|NCT05549596|DEVICE|Physical therapy with standard traction device|Physical therapy with standard traction device
219698864|NCT04045756|DEVICE|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
219698865|NCT02845674|DRUG|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
219698866|NCT05470452|OTHER|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
219698867|NCT05470452|OTHER|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
219698868|NCT03905733|DEVICE|Optiflow|supply of oxygen at 2 L / min/ kg through Optiflow
219698869|NCT00861133|DEVICE|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
219698870|NCT00843492|DRUG|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
219698871|NCT00843492|DRUG|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
219698872|NCT04482634|OTHER|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
219698873|NCT04482634|OTHER|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
219698874|NCT05724342|DRUG|rhTNK-tPA Thrombolysis|rhTNK-tPA Thrombolysis
219698875|NCT02110979|BEHAVIORAL|Use of a PDA to assist shared decision making|
219698876|NCT02553343|BIOLOGICAL|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
219698877|NCT02553343|BIOLOGICAL|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
219698878|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
219698879|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
219698880|NCT05660096|DEVICE|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
219698881|NCT00921323|BEHAVIORAL|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
219112117|NCT05822921|BEHAVIORAL|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
219224853|NCT04778670|DIAGNOSTIC_TEST|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
219698882|NCT00921323|BEHAVIORAL|Control|The control group will be advised to continue to be physically active and record daily steps
219698883|NCT04346316|DRUG|SHR0302|Oral tablets taken once daily (QD)
219698884|NCT01677741|DRUG|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
219698885|NCT01378208|BEHAVIORAL|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~* 28 days of dietary monitoring~* 28 days measurement by pedometer DAY 1, DAY 28 \& DAY 56: Test 1~* Oral glucose tolerance test with stable isotopes~* Fat and muscle biopsies DAY 2, DAY 29 \& DAY 57: Test 2~* DXA scanning~* Resting Metabolic Rate Measurement~* VO2max test on bicycle~* Cognitive testing~* MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 \& DAY 48: Test 3~* Actiheart for 3 days~* 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~* Fasting from 7am - 9pm~* 28 days of dietary monitoring~* 28 days measurement by pedometer"
219698886|NCT04329429|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
219698887|NCT02060500|PROCEDURE|Cardiaplication|
219698888|NCT00720499|DRUG|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
219698889|NCT00720499|DEVICE|Respimat® Inhaler|
219698890|NCT01492348|BEHAVIORAL|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
219698891|NCT01492348|BEHAVIORAL|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
219698892|NCT03651141|OTHER|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
219698893|NCT03651141|OTHER|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
219698894|NCT03651141|OTHER|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
219698895|NCT00800358|DRUG|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
219224854|NCT04778670|DIAGNOSTIC_TEST|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
219224855|NCT00010049|DRUG|imatinib mesylate|
219112118|NCT05822921|BEHAVIORAL|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
219112119|NCT05830435|BEHAVIORAL|Trier social stress test|TSST-VR-friendly: The assistant behind the desk asks the participant to prepare a small talk on their favourite holiday within 5 minutes. Then the participant is asked to tell about his holiday for 5 minutes. Then the participant is asked to do a simple math task: adding the number 5 to 0 for 5 minutes. The research assistant gives friendly gestures and verbal encouragements. TSST-VR-neutral: The assistant asks the participant to prepare a speech for a job interview in the upcoming 5 minutes. Then the participant is asked to deliver the speech for 5 minutes in front of two panelists and camera. Then the participant is asked to do a math task, subtracting the number 13 from 1022 for 5 minutes. During the performance the two panellist have neutral gestures and give neutral verbal instructions. TSST-VR unfriendly: The procedure of the TSST-VR unfriendly is the same as the neutral TSST-VR, with the addition that the two panellist give unfriendly gestures such as tapping on the table.
219112120|NCT00544544|DRUG|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
219112121|NCT02853266|OTHER|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
219112122|NCT00826163|DRUG|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
219112123|NCT03032354|DRUG|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
219112124|NCT03032354|OTHER|Placebo, (Placebo group)|Placebo during 6 months
219112125|NCT03406702|DRUG|CX-8998|T-type calcium channel blocker
219112126|NCT01228422|BIOLOGICAL|Interferon alpha 2a|3MUI
219112127|NCT03763955|BEHAVIORAL|MIRT|"4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)"
219224856|NCT05948774|DRUG|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
219698896|NCT00800358|DRUG|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
219698897|NCT00344695|DRUG|bupropion SR|
219698898|NCT01270477|OTHER|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
219698899|NCT00433472|DEVICE|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI
219698900|NCT04911348|OTHER|none (observational)|no intervention
219698901|NCT03021746|BEHAVIORAL|Diabetes Self Management Support (DSMS)|
219698902|NCT05171322|DEVICE|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
219698903|NCT01418443|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
219698904|NCT03638323|OTHER|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
219698905|NCT04245774|DRUG|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
219698906|NCT04245774|DRUG|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
219698907|NCT01769547|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
219698908|NCT01004939|DRUG|fondaparinux|fondaparinux
219698909|NCT06194916|OTHER|Education|A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.
219698910|NCT06194916|OTHER|CONTROL GROUP|THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
219698911|NCT05544097|OTHER|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
219112128|NCT06474689|OTHER|EMDR|EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.
219112129|NCT06474689|OTHER|CBT|CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
219112130|NCT00004390|DRUG|desipramine|
219112131|NCT00004390|DRUG|methadone|
219112132|NCT00004390|DRUG|morphine|
219112133|NCT00004390|DRUG|nortriptyline|
219112134|NCT04520555|DEVICE|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
219112135|NCT04520555|DEVICE|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
219112136|NCT00762021|DEVICE|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
219112137|NCT00762021|DEVICE|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
219112138|NCT01414426|DRUG|vandetanib|Given PO
219112139|NCT01414426|OTHER|placebo|Given PO
219112140|NCT01414426|OTHER|immunohistochemistry staining method|Correlative studies
219698912|NCT01621009|DRUG|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
219698913|NCT01621009|DRUG|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
219698914|NCT01621009|DRUG|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
219698915|NCT01621009|DRUG|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
219698916|NCT04509271|DIAGNOSTIC_TEST|MicRNAs battery kits|Novel peripheral blood diagnostic biomarker for MCI due to AD.
219112141|NCT01414426|OTHER|laboratory biomarker analysis|Correlative studies
219112142|NCT01414426|PROCEDURE|biopsy|Correlative studies
219112143|NCT01414426|OTHER|pharmacological study|Correlative studies
219112144|NCT00601003|DRUG|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
219112145|NCT00601003|DRUG|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
219698917|NCT03661775|DRUG|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
219698918|NCT06550921|PROCEDURE|ablation of oligometastasis|The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
219698919|NCT01589315|DEVICE|focal ECT|FEAST, ECT, unidirectional stimulation
219698920|NCT02147301|DEVICE|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
219112146|NCT00601003|DRUG|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
219112147|NCT04866862|DRUG|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
219112148|NCT04707911|BEHAVIORAL|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
219112149|NCT01857622|DRUG|DU-176b 15mg|oral DU-176b 15mg once daily
219112150|NCT01857622|DRUG|DU-176b 30mg|oral DU-176b 30mg once daily
219112151|NCT01857622|DRUG|DU-176b 60mg|oral DU-176b 60mg once daily
219112152|NCT05266014|DRUG|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
219112153|NCT05222035|DRUG|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
219112154|NCT05222035|DRUG|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
219112155|NCT00749801|DRUG|Nattokinase|2 capsules in the morning and before bed-time daily
219112156|NCT03341663|COMBINATION_PRODUCT|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
219112157|NCT06087562|DRUG|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
219112158|NCT06087562|DRUG|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
219112159|NCT04959149|DEVICE|AirTraq videolaryngoscope|intubation of morbidly obese patient using Airtraq videolaryngoscope
219112160|NCT01291225|OTHER|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
219112161|NCT01291225|BEHAVIORAL|Educational campaign|Educational materials will be developed and distributed in Ross County.
219112162|NCT06140563|OTHER|anticoagulation dosing|In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
219112163|NCT01267253|DRUG|Brivanib Alaninate|Given PO
219112164|NCT01267253|OTHER|Laboratory Biomarker Analysis|Correlative studies
219112165|NCT01450605|DRUG|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
219112166|NCT00014196|DRUG|cisplatin|
219698921|NCT01625468|BEHAVIORAL|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
219698922|NCT00151944|DRUG|SPD476 (mesalazine)|
219112167|NCT00014196|DRUG|docetaxel|
219698923|NCT04746638|DIAGNOSTIC_TEST|whole body study and SPECT with 99mTc-RM26|One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
219698924|NCT00144599|DRUG|MRA(Tocilizumab)|
219698925|NCT00144599|DRUG|placebo|
219112168|NCT00014196|RADIATION|radiation therapy|
219112169|NCT04444687|DIAGNOSTIC_TEST|Test for SARS-CoV-2|"* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
219112170|NCT05291182|DRUG|SY-4835|WEE1 inhibitor
219112171|NCT03470714|OTHER|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
219112172|NCT03470714|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
219112173|NCT04318093|DRUG|BMS-986259|Specified dose on specified days
219112174|NCT04318093|OTHER|Placebo|Specified dose on specified days
219112175|NCT02768558|RADIATION|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
219112176|NCT02768558|DRUG|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
219112177|NCT02768558|DRUG|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
219112178|NCT02768558|DRUG|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
219698926|NCT03400449|OTHER|Video counseling|Video counseling
219698927|NCT03400449|OTHER|Conversational counseling|Conversational counseling
219698928|NCT00004233|DRUG|fluorouracil|
219698929|NCT00004233|DRUG|leucovorin calcium|
219698930|NCT00004233|DRUG|triacetyluridine|
219112179|NCT02768558|OTHER|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
219112180|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: fortified spread|Provision of fortified spread
219112181|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
219112182|NCT02626221|OTHER|Non Interventional Study|Non Interventional Study
219112183|NCT03219268|BIOLOGICAL|tebotelimab 1 mg|1 mg IV every other week
219698931|NCT03641508|DRUG|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
219698932|NCT03641508|DRUG|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
219698933|NCT03642990|DRUG|Nicotinamide Riboside|Capsule
219698934|NCT03733236|DEVICE|ISS Active Stimulation|ISS SPG stimulation and standard of care
219698935|NCT05235438|DRUG|IMM27M|IMM27M injection
219698936|NCT03658551|DIAGNOSTIC_TEST|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
219112184|NCT03219268|BIOLOGICAL|tebotelimab 3 mg|3 mg IV every other week
219112185|NCT03219268|BIOLOGICAL|tebotelimab 10 mg|10 mg IV every other week
219112186|NCT03219268|BIOLOGICAL|tebotelimab 30 mg|30 mg IV every other week
219112187|NCT03219268|BIOLOGICAL|tebotelimab 120 mg|120 mg IV every other week
219112188|NCT03219268|BIOLOGICAL|tebotelimab 300 mg|300 mg IV every other wee
219112189|NCT03219268|BIOLOGICAL|tebotelimab 400 mg|400 mg IV every other wee
219112190|NCT03219268|BIOLOGICAL|tebotelimab 600 mg|600 mg IV every other week
219112191|NCT03219268|BIOLOGICAL|tebotelimab 800 mg|800 mg IV every other week
219112192|NCT03219268|BIOLOGICAL|tebotelimab 1200 mg|1200 mg IV every other week
219112193|NCT03219268|BIOLOGICAL|margetuximab|15 mg/kg IV every 3 weeks
219112194|NCT03018301|DRUG|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
219112195|NCT03018301|OTHER|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
219698937|NCT05355558|DIAGNOSTIC_TEST|[18F]FLT-PET/MRI body scan|"\[18F\]FLT-PET/MRI body scan will be done at~* Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~* Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~* Obtain vital signs and weight in kg before FLT administration.~* Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.)~* Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~* Perform a saline flush following the FLT injection.~* Body PET/MRI will be performed after FLT injection.~* Time of injection of FLT and time of scan will need to be recorded."
219698938|NCT04572373|DIETARY_SUPPLEMENT|SMOFlipid|
219698939|NCT00855218|DRUG|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
219698940|NCT00855218|DRUG|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
219698941|NCT04063839|DRUG|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
219698942|NCT04005040|PROCEDURE|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
219698943|NCT01542827|OTHER|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
219698944|NCT01542827|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
219112196|NCT03222544|COMBINATION_PRODUCT|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
219112197|NCT03222544|COMBINATION_PRODUCT|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
219112198|NCT03851913|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
219112199|NCT05719623|OTHER|CUEVAS MEDEK EXERCISES|stretchings/strengthening
219224857|NCT05948774|DRUG|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
219698945|NCT06036472|PROCEDURE|Standard periodontal therapy (steps 1 & 2)|participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
219698946|NCT06036472|PROCEDURE|supragingival debridement with anesthesia (step 1)|periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
219698947|NCT04173819|BIOLOGICAL|3BNC117-LS-J|300mg
219698948|NCT04173819|BIOLOGICAL|10-1074-LS-J|300mg
219698949|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
219698950|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
219698951|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
219112200|NCT05719623|OTHER|BALANCE AND POSTURAL|BALANCE AND POSTURAL
219112201|NCT02216747|DRUG|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
219112202|NCT02216747|DRUG|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
219112203|NCT02216747|DRUG|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
219112204|NCT01647308|DRUG|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
219112205|NCT01647308|DRUG|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
219112206|NCT03254953|BEHAVIORAL|self-monitoring of body weight|\- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
219112207|NCT03254953|BEHAVIORAL|self-monitoring of diet|"* track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm"
219112208|NCT03254953|BEHAVIORAL|weekly personalized feedback + lessons + action plans|\- these are additional evidence-based intervention components
219112209|NCT01664936|RADIATION|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
219112210|NCT00786890|OTHER|observational, no intervention needed|observational, no intervention needed
219112211|NCT01409421|BEHAVIORAL|motivational interviewing|counseling intervention
219112212|NCT01409421|BEHAVIORAL|three phone calls to remind patients to take their eye drops|reminder phone calls
219112213|NCT03308760|OTHER|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
219112214|NCT03308760|OTHER|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
219698952|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
219698953|NCT04173819|BIOLOGICAL|Placebo|0.9% Saline
219698954|NCT04173819|BIOLOGICAL|Placebo|Buffer Solution
219698955|NCT00764790|BIOLOGICAL|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
219698956|NCT00764790|BIOLOGICAL|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
219698957|NCT03191552|DEVICE|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
219698958|NCT03191552|OTHER|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
219698959|NCT03847961|DEVICE|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
219698960|NCT01441973|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|
219698961|NCT04993209|BIOLOGICAL|NDV-HXP-S 1μg|NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
219698962|NCT04993209|BIOLOGICAL|NDV-HXP-S 3μg|NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
219698963|NCT04993209|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
219112215|NCT03308760|OTHER|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
219112216|NCT03229434|BEHAVIORAL|Mountain hiking|Compare arm description
219112217|NCT01156077|DRUG|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
219698964|NCT04993209|OTHER|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
219698965|NCT02187549|DEVICE|HYMOVIS|Intra-articular injection
219698966|NCT02187549|DEVICE|Placebo|Intra-Articular Injection
219698967|NCT00632567|PROCEDURE|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
219698968|NCT00632567|PROCEDURE|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
219698969|NCT02391025|DRUG|Gallium-68 citrate|Given via IV at time of imaging
219698970|NCT02391025|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
219698971|NCT00528307|DEVICE|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
219698972|NCT01149655|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
219698973|NCT01149655|DRUG|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
219698974|NCT02031523|DRUG|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
219698975|NCT02031523|DRUG|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
219698976|NCT02823353|DRUG|Fenofibrate|Fenofibrate 200mg/day
219698977|NCT02823353|DRUG|UDCA|UDCA 13-15mg/kg/day
219698978|NCT01890655|DRUG|MT-1303-Low|
219698979|NCT01890655|DRUG|MT-1303-Middle|
219698980|NCT01890655|DRUG|MT-1303-High|
219112218|NCT01156077|DRUG|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
219224858|NCT04652869|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
219698981|NCT04195711|DIAGNOSTIC_TEST|"objective pediatric vision screen, blinq,"|hand-held birefringent screener for simultaneous foveation
219698982|NCT03720678|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
219112219|NCT02855164|DRUG|Tropifexor (LJN452)|Comparison of different doses of drug
219112220|NCT02855164|DRUG|Placebo|Comparator
219698983|NCT03720678|DRUG|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
219698984|NCT03874832|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
219112221|NCT05660915|PROCEDURE|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
219698985|NCT02664142|PROCEDURE|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
219112222|NCT05660915|PROCEDURE|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
219112223|NCT00876460|DRUG|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
219112224|NCT00876460|DRUG|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
219698986|NCT02664142|PROCEDURE|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
219698987|NCT02664142|DRUG|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
219698988|NCT06482164|DIAGNOSTIC_TEST|Dry Eye Disease|Corneal sensitivity in patients who also have dry eye.
219698989|NCT01298830|DRUG|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
219698990|NCT05576311|OTHER|Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.
219698991|NCT00624988|PROCEDURE|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
219698992|NCT04716985|DIETARY_SUPPLEMENT|MOLECULAR HYDROGEN|Magnesium Tablet
219698993|NCT04716985|DIETARY_SUPPLEMENT|PLACEBO MAGNESIUM|Magnesium carbonate tablet
219698994|NCT03477656|PROCEDURE|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
219698995|NCT03477656|PROCEDURE|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
219698996|NCT04640922|DEVICE|Gedea Pessary pHyph|Vaginal tablet
219698997|NCT04640922|DEVICE|Placebo|Vaginal tablet
219112225|NCT00876460|DRUG|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
219698998|NCT00471484|BIOLOGICAL|recombinant interferon alfa-2b|
219698999|NCT00471484|DRUG|doxorubicin hydrochloride|
219699000|NCT00471484|DRUG|fluorouracil|
219699001|NCT00471484|DRUG|oxaliplatin|
219699002|NCT00471484|OTHER|diagnostic laboratory biomarker analysis|
219699003|NCT00471484|OTHER|immunoenzyme technique|
219699004|NCT00471484|OTHER|immunohistochemistry staining method|
219699005|NCT00471484|PROCEDURE|adjuvant therapy|
219699006|NCT00471484|PROCEDURE|biopsy|
219699007|NCT00471484|PROCEDURE|neoadjuvant therapy|
219699008|NCT00471484|PROCEDURE|therapeutic conventional surgery|
219699009|NCT01738100|DRUG|Ticagrelor|
219699010|NCT01738100|DRUG|Clopidogrel|
219699011|NCT01738100|DRUG|Morphine Sulfate|
219699012|NCT01738100|DRUG|Saline|
219699013|NCT00000347|DRUG|Risperidone|
219699014|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
219699015|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
219699016|NCT00743756|BEHAVIORAL|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
219112226|NCT00876460|DRUG|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
219112227|NCT00876460|DRUG|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
219112228|NCT03004313|PROCEDURE|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
219112229|NCT03004313|PROCEDURE|MRI scan|
219112230|NCT03004313|PROCEDURE|Quantitative Sensory Testing (QST)|
219112231|NCT03101124|DRUG|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
219112232|NCT03101124|DRUG|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
219699017|NCT03557593|OTHER|Educational|Multi component educational intervention in long-term care
219699018|NCT06612632|DRUG|research drug in combination with Toripalimab|research drug in combination with Toripalimab
219699019|NCT06612632|DRUG|Toripalimab|Toripalimab
219699020|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
219699021|NCT06612697|OTHER|Radiology|A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records.
219699022|NCT05897671|OTHER|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
219699023|NCT01118078|GENETIC|DNA methylation analysis|Undergo DNA methylation analysis
219699024|NCT01118078|GENETIC|gene expression analysis|Undergo gene expression analysis
219699025|NCT01118078|GENETIC|microarray analysis|Undergo microarray analysis
219699026|NCT01118078|GENETIC|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
219699027|NCT01118078|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219112233|NCT03101124|DRUG|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
219112234|NCT03112200|PROCEDURE|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
219112235|NCT03112200|PROCEDURE|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
219112236|NCT03100994|DRUG|Bupivacaine|injecting anesthetics to different local
219112237|NCT03100994|DEVICE|Ultrasound|Ultrasound guided nerve block
219112238|NCT00715572|DRUG|thyroxine|monotherapy with thyroxine
219112239|NCT00715572|DRUG|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
219112240|NCT00446940|DRUG|rosuvastatin|
219112241|NCT00446940|DRUG|atorvastatin|
219112242|NCT04750993|DIAGNOSTIC_TEST|musculoskeletal ultrasonography|The presence of subclinic synovitis findings in the hand joints was evaluated with musculoskeletal ultrasonography.
219112243|NCT04381260|OTHER|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
219112244|NCT04381260|OTHER|Interview|Key Informant Interview
219112245|NCT04381260|OTHER|Survey|Stakeholder survey
219112246|NCT03313115|BEHAVIORAL|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
219112247|NCT00004430|DRUG|Dihematoporphyrin derivative|
219699028|NCT02969785|OTHER|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
219112248|NCT00004430|DRUG|prednisolone|
219699029|NCT02969785|OTHER|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
219112249|NCT00004430|PROCEDURE|Laser surgery|
219699030|NCT05550168|DEVICE|Low Level Laser therapy|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
219112250|NCT02042638|DRUG|hCG 1500 IU three times a week|
219112251|NCT02042638|DRUG|Pregnyl (hCG) ampule 1500 IU/three times a week|
219112252|NCT05437042|OTHER|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
219112253|NCT02989896|DEVICE|perfusion index|
219112254|NCT03842553|OTHER|No Intervention: anonymous online survey|
219112255|NCT02692950|OTHER|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
219112256|NCT02692950|BEHAVIORAL|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
219112257|NCT02495896|DRUG|Cisplatin|Given IV
219112258|NCT02495896|DRUG|Docetaxel|Given IV
219112259|NCT02495896|DRUG|Gemcitabine Hydrochloride|Given IV
219112260|NCT02495896|OTHER|Laboratory Biomarker Analysis|Correlative studies
219112261|NCT02495896|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219112262|NCT02495896|OTHER|Pharmacological Study|Correlative studies
219112263|NCT02495896|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219112264|NCT04282590|DRUG|TRK-750/Placebo|Powder for oral solution
219112265|NCT04282590|DRUG|Placebo/TRK-750|Powder for oral solution
219112266|NCT01234766|DRUG|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
219112267|NCT01234766|DRUG|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
219112268|NCT01234766|RADIATION|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
219112269|NCT02225821|DRUG|Cephalozin|1000 mg Cephalozin
219112270|NCT02225821|OTHER|Sodium chloride|10 cc of NaCl 0.9%
219112271|NCT00136032|DRUG|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
219112272|NCT00136032|DRUG|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
219112273|NCT02443506|DRUG|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
219112274|NCT02443506|DRUG|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
219112275|NCT05976113|OTHER|Observation only|Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
219112276|NCT06250543|DRUG|AbobotulinumtoxinA 300 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
219112277|NCT06250543|DRUG|IncobotulinumtoxinA 100 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
219112278|NCT06250543|DRUG|Lidocain|30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
219112279|NCT06250543|OTHER|placebo|30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
219112280|NCT00467064|BEHAVIORAL|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
219112281|NCT00467064|OTHER|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
219112282|NCT00610064|RADIATION|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
219112283|NCT00610064|RADIATION|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
219112284|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy - Pain|Pain treatment
219112285|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy-Integrated|Integrated treatment
219112286|NCT00127413|BEHAVIORAL|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
219112287|NCT00127413|BEHAVIORAL|Treat as Usual|Treatment as usual
219699031|NCT06593418|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
219699032|NCT06798207|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC).
219699033|NCT07043556|OTHER|Artificial Intelligence-Based ROTEM Interpretation|A structured artificial intelligence-based evaluation system that analyzes ROTEM (Rotational Thromboelastometry) parameters and provides treatment recommendations. ROTEM case data are converted into standardized clinical scenarios and evaluated by AI models using a predefined template. The AI output is compared to the consensus of expert clinicians regarding the presence and type of coagulopathy and the need for therapeutic intervention (e.g., fibrinogen, protamine, platelets, PCC, plasma). This intervention does not involve any patient-facing activity and is performed on de-identified data only.
219699034|NCT05079321|DEVICE|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
219699035|NCT05079321|DEVICE|Uncoated|Zen™ RC scleral lenses (non-coated)
219699036|NCT06726460|DIAGNOSTIC_TEST|Nova Stat Profile pHOx Ultra Analyzer System(Nova)|This group involves the use of Nova for measuring serum and whole blood samples. The results from Nova will be compared with those obtained from P1.
219699037|NCT06726460|DIAGNOSTIC_TEST|Novel POCT dry electrolyte analysis system(P1)|This group involves the use of P1 for measuring serum and whole blood samples. The results from P1 will be compared with those obtained from Nova.
219699038|NCT04610138|DRUG|CNM-ZnAg|ZnAg liquid solution
219699039|NCT04610138|DRUG|Placebo|Water
219699040|NCT02003144|BIOLOGICAL|eculizumab|
219699041|NCT06119165|BEHAVIORAL|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
219112288|NCT04100161|DIETARY_SUPPLEMENT|Protein supplementation|Daily dose of 40 g whey protein for 3 months
219112289|NCT04100161|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
219112290|NCT04100161|PROCEDURE|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
219112291|NCT01515345|DRUG|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
219112292|NCT01515345|DRUG|Clopidogrel|clopidogrel 75mg od for 12 month
219699042|NCT06894277|BEHAVIORAL|iTRAC-HERO|"iTRAC-HERO will consist of eight, approximately 45-minute, gamified digital modules of 4-6 activities (games, videos, etc.). No instruction is needed to use the program. Content will use gender- and sexuality-inclusive language and avoid heteronormative descriptions of risk. This content will include strategies for (and practice with) recognizing and managing emotions, particularly in relation to sexual health situations, to enhance the likelihood that the emotion regulation and sexual health education provided can be applied to experiences that are emotionally arousing and lead to risk."
219699043|NCT04354935|DEVICE|rTMS basic|1 session per day, for 4 or 6 weeks.
219112293|NCT06390930|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
219112294|NCT06390930|OTHER|Sham Acute Intermittent Hypoxia|During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
219112295|NCT05438225|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
219224859|NCT04652869|BEHAVIORAL|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
219699044|NCT04354935|DEVICE|rTMS VIIT|5 sessions per day, for 2 weeks.
219699045|NCT04354935|DEVICE|rTMS SAINT modified|8 sessions per day, for 1 week.
219699046|NCT04354935|DEVICE|rTMS SAINT|10 sessions per day, for 1 week.
219699047|NCT06339775|DRUG|Blinatumomab|"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
219699048|NCT00006320|PROCEDURE|determine blood levels of anti-HIV drugs|
219112296|NCT04394091|DEVICE|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
219112297|NCT00618462|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
219112298|NCT00618462|BEHAVIORAL|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
219112299|NCT00618462|BEHAVIORAL|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
219112300|NCT00618462|BEHAVIORAL|Case management|Case management will assist participants in obtaining additional services from the community as needed.
219699049|NCT05031442|DEVICE|RH1 (low waist)|Investigational product variant 1 low waist
219112301|NCT00618462|BEHAVIORAL|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
219112302|NCT00547911|DRUG|Droxidopa|
219699050|NCT05031442|DEVICE|Reference variant 1 (low waist)|Reference product variant 1
219699051|NCT05031442|DEVICE|RC2 (high waist)|Investigational product variant 2 high waist
219699052|NCT05031442|DEVICE|Reference variant 2 (high waist)|Reference product variant 2
219699053|NCT05628753|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
219699054|NCT01324947|DRUG|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
219699055|NCT00037986|DEVICE|Hearing Aids|Hearing aid use
219112303|NCT00547911|DRUG|Carbidopa|
219112304|NCT00547911|DRUG|Entacapone|
219112305|NCT04485650|OTHER|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
219112306|NCT04485650|OTHER|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
219112307|NCT04485650|OTHER|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
219112308|NCT01539174|BIOLOGICAL|rituximab|Given IV
219112309|NCT01539174|DRUG|cyclophosphamide|Given IV
219112310|NCT01539174|DRUG|doxorubicin hydrochloride|Given IV
219112311|NCT01539174|DRUG|vincristine sulfate|Given IV
219112312|NCT01539174|DRUG|prednisone|Given PO
219112313|NCT01539174|OTHER|laboratory biomarker analysis|Correlative studies
219699056|NCT06128018|PROCEDURE|Surgical gastrojejunostomy (S-GJ)|Surgical gastro-jejunostomy
219699057|NCT06128018|PROCEDURE|EUS-guided gastrojejunostomy (EUS-GJ)|Endoscopic Ultrasound guided gastro-jejunostomy
219699058|NCT01274351|DRUG|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
219699059|NCT00216593|DRUG|galantamine hydrobromide|
219699060|NCT00042913|BIOLOGICAL|epratuzumab|
219699061|NCT00535613|DRUG|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
219112314|NCT01539174|OTHER|pharmacological study|Correlative studies
219112315|NCT02254096|DRUG|BIRT 1696 BS|
219112316|NCT02254096|DRUG|Placebo|
219112317|NCT02254096|OTHER|Grapefruit juice (GFJ)|
219112318|NCT02254096|OTHER|High fat meal (HFM)|
219112319|NCT00655330|DRUG|Valsartan|Valsartan (160mg/day)
219112320|NCT00655330|DRUG|Placebo|Placebo
219112321|NCT00655330|DRUG|Probucol|Probucol (750mg/day)
219112322|NCT03241524|OTHER|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
219112323|NCT01483157|OTHER|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
219112324|NCT01483157|OTHER|high intensity resistance training|twelve weeks of resistance training twice a week
219112325|NCT01644474|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
219112326|NCT01644474|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
219699062|NCT02669706|DRUG|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
219699063|NCT04176224|DRUG|MT-1186|Suspension
219699064|NCT01296412|DRUG|sitagliptin|100 mg tablet, orally, once daily.
219699065|NCT01296412|DRUG|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
219699066|NCT01296412|DRUG|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
219699067|NCT01296412|DRUG|metformin|metformin tablets at a dose of ≥1500 mg per day
219112327|NCT01644474|DRUG|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
219112328|NCT01644474|DRUG|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
219112329|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
219699068|NCT04441346|RADIATION|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
219699069|NCT04454359|DIETARY_SUPPLEMENT|Multi-nutrient supplement|
219112330|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
219112331|NCT03787290|DRUG|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
219112332|NCT03787290|DRUG|Placebo|participants will receive a single subcutaneous injection of saline
219112333|NCT03787290|DEVICE|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
219112334|NCT04286230|BEHAVIORAL|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
219112335|NCT04286230|BEHAVIORAL|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
219112336|NCT05783674|OTHER|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
219112337|NCT05783674|OTHER|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
219699070|NCT04454359|DIETARY_SUPPLEMENT|Placebo|
219699071|NCT00776880|OTHER|ASA scale|ASA scale evaluation before operation
219699072|NCT00776880|OTHER|PPS scale|PPS scale evaluation before operation
219699073|NCT02160626|DRUG|A-101 Vehicle|Placebo control
219699074|NCT02160626|DRUG|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
219112338|NCT04453397|DRUG|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
219112339|NCT04213586|DIETARY_SUPPLEMENT|Whey protein supplementation|35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
219699075|NCT02160626|DRUG|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
219699076|NCT03918317|DEVICE|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
219112340|NCT04213586|DIETARY_SUPPLEMENT|Collagen supplementation|35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
219112341|NCT02751463|DRUG|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
219112342|NCT02751463|OTHER|Untreated skin|One site is patched without treatment as control
219112343|NCT01404611|DRUG|DF289|Ear drops
219112344|NCT01404611|DRUG|DF277|Ear drops
219112345|NCT01404611|DRUG|DF289 plus DF277|Ear drops
219112346|NCT03625505|DRUG|Venetoclax|tablet, oral
219112347|NCT03625505|DRUG|Gilteritinib|tablet, oral
219112348|NCT04138342|DRUG|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
219112349|NCT04138342|DRUG|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
219112350|NCT06382909|DIETARY_SUPPLEMENT|Inflammatory level|Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
219112351|NCT06382909|DIETARY_SUPPLEMENT|Cognitive assessment|Neurological assessment Psychiatric assessment
219112352|NCT06382909|DIETARY_SUPPLEMENT|Pedagogical assessment|Sociopedagogical assessment
219699077|NCT02632617|OTHER|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
219699078|NCT02888054|DRUG|lesinurad/allopurinol 200/300 FDC tablet|
219699079|NCT02888054|DRUG|lesinurad 200 mg|
219112353|NCT02044458|DEVICE|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
219112354|NCT00880308|DRUG|LDE225|
219112355|NCT03141710|DIETARY_SUPPLEMENT|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
219112356|NCT04667845|DEVICE|Home Ovulation Test|Digital read home ovulation test
219112357|NCT06512103|DIAGNOSTIC_TEST|Apical periodontitis group|Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
219112358|NCT02386917|PROCEDURE|Gastric bypass|Weight loss surgery
219699080|NCT02888054|DRUG|allopurinol 300 mg|
219699081|NCT04559984|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
219112359|NCT02386917|BEHAVIORAL|Very low calorie diet|Non-surgical weight loss procedure
219112360|NCT02625194|DRUG|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
219112361|NCT06625827|DRUG|Digoxin|Oral administration
219112362|NCT06625827|DRUG|Nemtabrutinib|Oral administration
219112363|NCT06625164|OTHER|exercise|core stabilization exercises
219112364|NCT06625996|DIETARY_SUPPLEMENT|carbohydrate loading|Preoperative carbohydrate loading
219112365|NCT06625749|DEVICE|Accurasee™ IOPCL|Intraocular pseudophakic capsular lens (IOPCL)
219112366|NCT02601937|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
219112367|NCT01133574|DRUG|SLV354 capsules|20 mg
219112368|NCT01133574|DRUG|SLV354 capsules|60 mg
219112369|NCT01133574|DRUG|SLV354 capsules|120 mg
219112370|NCT01133574|DRUG|SLV354 capsules|250 mg
219112371|NCT01133574|DRUG|SLV354 capsules|500 mg
219112372|NCT01133574|DRUG|SLV354 capsules|750 mg
219112373|NCT01133574|DRUG|SLV354 capsules|1000 mg
219112374|NCT01133574|DRUG|SLV354 capsules|1250 mg
219112375|NCT01133574|DRUG|Placebo capsules|placebo
219112376|NCT01133574|DRUG|SLV354 capsules|low dose group 1
219112377|NCT01133574|DRUG|SLV354 capsules|high dose group 1
219112378|NCT01133574|DRUG|SLV354 capsules|low dose group 2
219112379|NCT01133574|DRUG|SLV354 capsules|high dose group 2
219699082|NCT02215850|DRUG|SLC-0111|
219699083|NCT03451396|DRUG|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
219699084|NCT02172027|DEVICE|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
219699085|NCT04798157|RADIATION|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
219112380|NCT01133574|DRUG|Placebo capsules|placebo
219699086|NCT04371016|OTHER|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
219699087|NCT05959928|DEVICE|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
219699088|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
219699089|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)|A suitable size precontoured sectional matrix band (Saddle matrix, TORVM, Moscow, Russia) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges, TORVM, Moscow, Russia) and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
219699090|NCT05625243|OTHER|Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
219699091|NCT06122558|DIETARY_SUPPLEMENT|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
219699092|NCT06122558|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
219699093|NCT03767712|DIAGNOSTIC_TEST|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
219699094|NCT04239924|BEHAVIORAL|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
219699095|NCT04267497|DRUG|Amphotericin B Liposomal 50 MG|Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.
219699096|NCT04267497|OTHER|Placebo|Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
219699097|NCT07073560|PROCEDURE|Anthropometric Measurements|"1. Assessment of the accuracy of sex determination from hand indexes using anthropometric hand measurements.~2. Assessment of the accuracy of sex determination from the length of the metacarpals using x-ray radiographs on the same hand.~3. Determination of the best and least costly method for sex identification by comparing the effectiveness of the previous two methods."
219699098|NCT05498389|DRUG|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
219699099|NCT05498389|DRUG|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
219699100|NCT06275737|OTHER|Prehabilitation program|"Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)"
219699101|NCT06890611|DRUG|Bimagrumab|Administered SC
219699102|NCT06890611|DRUG|Tirzepatide|Administered SC
219699103|NCT06890611|DRUG|Bimagrumab + Tirzepatide Coformulation|Administered SC
219699104|NCT06757010|DRUG|NE3107|NE3107 20 mg BID
219699105|NCT06757010|DRUG|Placebo|Placebo BID
219699106|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
219699107|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
219699108|NCT06951009|DEVICE|Colli-Pee|The Colli-Pee device is a first void urine self-sampling device. Participants will collect urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
219112381|NCT02140346|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
219112382|NCT02140346|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
219224860|NCT05964426|OTHER|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
219224861|NCT01833455|DRUG|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
219112383|NCT06826066|OTHER|Blood samples|We propose to include patients who have been treated with radiotherapy and did not experience severe radiation-induced toxicity, after obtaining their informed consent. A blood sample will then be collected by the nursing staff from the Oncology-Radiotherapy department at Henri Mondor University Hospital. After the patient signs the consent form, each patient will have their clinical information recorded and a blood sample taken. The blood samples will be immediately transported, at room temperature, to the INSERM U955 i-Biot unit at Henri Mondor (serum, plasma, and PBMC). All samples will be frozen at -80°C for later analysis.
219112384|NCT06010511|OTHER|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
219699109|NCT06951009|DEVICE|standard of care 60 mL urine cup|Participants will collect clean catch urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
219112385|NCT06010511|OTHER|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
219112386|NCT06010511|BEHAVIORAL|Neuropsychological assessment|"* Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly"
219112387|NCT06010511|OTHER|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
219112388|NCT05929846|OTHER|Back to Living Well Program|The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
219112389|NCT01040780|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
219112390|NCT01040780|DRUG|Gefitinib|250 mg every 24 hours by mouth
219112391|NCT05407168|OTHER|Best Practice|Receive standard of care
219112392|NCT05407168|OTHER|Health Promotion and Education|View decision aid
219112393|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
219112394|NCT04876560|OTHER|Application of CDSS to provide nutritional care in breast cancer patients from home|A personalised dietary plan was implemented by the CDSS. The CDSS estimated body mass index (BMI) and Total daily Energy Expenditure (TEE) according to individual's incorporated data. For overweight and obese patients, the CDSS produced a hypocaloric diet, in which daily energy intake was less than TEE by approximately -500 kcal/day. Nutrient distribution was in line with the Mediterranean dietary pattern. Patients received individual login passwords to CDSS allowing access to their personal profile from home. During the trial, patients were instructed to record food diaries in the CDSS every week, which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes.
219112395|NCT04876560|OTHER|General lifestyle advice to breast cancer patients by phone|General lifestyle guidelines were provided by phone and food diaries were sent via emails.
219112396|NCT00802737|DRUG|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
219112397|NCT02711072|DRUG|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
219699110|NCT06951009|DIAGNOSTIC_TEST|Urinalysis|Participant samples will be analyzed by urinalysis to evaluate for leukocyte esterase (LE).
219699111|NCT06951009|DIAGNOSTIC_TEST|Sysmex UP-5000|Participant samples will be analyzed by the Sysmex UP-5000 to evaluate for white blood cells (WBCs) per microliter.
219699112|NCT00678457|DRUG|Ondansetron|ondansetron (4 μg/kg b.i.d.)
219699113|NCT00678457|DRUG|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
219699114|NCT00678457|DRUG|Placebo|placebo
219699115|NCT00502437|DRUG|GRANISETRON|
219699116|NCT00592111|DRUG|COPP/ABV|4 courses of COPP/ABV hybrid
219699117|NCT00592111|DRUG|COPP/ABV|6 courses of COPP/ABV hybrid
219699118|NCT00592111|DRUG|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
219699119|NCT04081181|PROCEDURE|Microwave ablation|CT\_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60\_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
219112398|NCT02711072|DRUG|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
219699120|NCT02441647|DEVICE|KL029 Intimate Lubricant Gel|
219699121|NCT03708146|DRUG|BIA 5-1058|"25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
219699122|NCT03708146|DRUG|Placebo|"matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
219699123|NCT04075175|DRUG|S315|Human monoclonal antibody against Diphtheria Toxin
219699124|NCT04075175|DRUG|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
219699125|NCT00068523|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
219699126|NCT00068523|DRUG|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
219699127|NCT00068523|DRUG|cyclosporine|oral cyclosporine on days -1 to 100
219699128|NCT00068523|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
219699129|NCT00068523|DRUG|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
219699130|NCT00068523|PROCEDURE|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
219699131|NCT00068523|PROCEDURE|allogeneic bone marrow transplantation|
219699132|NCT00068523|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
219699133|NCT04538105|OTHER|Control|Saline Articular Nerve Branch Block
219699134|NCT04538105|OTHER|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
219112399|NCT02955433|OTHER|Rideshare-based transportation|
219112400|NCT03677128|OTHER|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
219699135|NCT02936999|DRUG|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
219699136|NCT00753519|DEVICE|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
219699137|NCT00753519|DEVICE|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
219699138|NCT06197490|BIOLOGICAL|Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation|Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
219699139|NCT06197490|DRUG|Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation|Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
219699140|NCT03625024|BEHAVIORAL|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
219699141|NCT04432480|PROCEDURE|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
219699142|NCT03342768|OTHER|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
219699143|NCT01915316|OTHER|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
219699144|NCT01136590|DRUG|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
219699145|NCT01136590|DRUG|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
219112401|NCT00890643|DRUG|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
219699146|NCT00434252|DRUG|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
219699147|NCT00434252|DRUG|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
219699148|NCT00434252|DRUG|paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
219699149|NCT00434252|DRUG|placebo|Administered by IV infusion on the first day of each 3-week cycle
219699150|NCT04734613|BEHAVIORAL|Tai Chi exercise|Yang style Tai Chi 16 movements
219699151|NCT04734613|BEHAVIORAL|self management|health education and dietary counseling
219699152|NCT02820389|PROCEDURE|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
219699153|NCT02820389|PROCEDURE|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
219699154|NCT00747877|DRUG|cyclophosphamide|Given orally
219699155|NCT00747877|DRUG|melphalan|Given IV
219699156|NCT00747877|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
219699157|NCT05649501|OTHER|Proprioceptive neuromuscular facilitation techniques.|Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.
219699158|NCT05649501|OTHER|Traditional physical therapy|Conventional therapy (ROMs, stretching, strengthening) of lower limbs for 40 minutes.
219699159|NCT01008644|OTHER|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
219699160|NCT01008644|OTHER|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
219699161|NCT02807259|BEHAVIORAL|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
219112402|NCT00890643|DRUG|placebo|placebo
219112403|NCT01706211|DRUG|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
219112404|NCT01706211|DRUG|Placebo|
219112405|NCT04435795|DRUG|Normal Saline intranasal and placebo inhaler|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
219112406|NCT04435795|DRUG|Ciclesonide|Ciclesonide 600mcg BID inhaled with aero chamber
219112407|NCT04435795|DRUG|Ciclesonide nasal|intranasal ciclesonide 200 mcg DIE
219112408|NCT03864926|DRUG|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
219112409|NCT03864926|DRUG|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
219699162|NCT02059109|PROCEDURE|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
219699163|NCT03861039|DRUG|Tirzepatide|Administered SC
219699164|NCT03861039|DRUG|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
219699165|NCT06424353|PROCEDURE|Endoflas pulpectomy|obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
219699166|NCT02442908|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
219699167|NCT02442908|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
219699168|NCT05175625|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
219699169|NCT05175625|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
219112410|NCT00445601|DRUG|gemcitabine hydrochloride|Given intravesically
219224862|NCT01833455|DRUG|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
219699170|NCT01899092|DRUG|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
219699171|NCT03811938|PROCEDURE|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
219699172|NCT03811938|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
219699173|NCT00066456|RADIATION|3-Dimensional Conformal Radiation Therapy|
219699174|NCT00066456|DRUG|Chemosensitization/Potentiation Therapy|
219699175|NCT00066456|DRUG|Docetaxel|Given IV
219699176|NCT05395507|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
219699177|NCT05395507|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
219699178|NCT04852822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219699179|NCT04852822|OTHER|Electronic Health Record Review|Medical records are reviewed
219699180|NCT04675879|DEVICE|Shoulder arm bandage|Three different shoulder-arm bandage types
219699181|NCT03736018|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
219699182|NCT04321889|DEVICE|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
219224863|NCT04301206|BEHAVIORAL|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
219699183|NCT04321889|OTHER|Placebo|nanotechnological system loaded with placebo cream
219699184|NCT06133166|DRUG|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
219699185|NCT06133166|DRUG|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
219699186|NCT02868944|DRUG|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
219699187|NCT02868944|DRUG|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
219699188|NCT05679986|OTHER|no intervention|no intervention
219699189|NCT03816046|DRUG|botulinum toxin A|injection in hair bearing area of armpits
219699190|NCT00737178|DEVICE|CuT380A|Comparison of different timing of IUD insertion
219699191|NCT04735614|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
219699192|NCT05029531|COMBINATION_PRODUCT|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
219699193|NCT03346239|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
219699194|NCT03346239|DRUG|Escitalopram|10-20 mg of Escitalopram
219699195|NCT03346239|BEHAVIORAL|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
219699196|NCT04370496|PROCEDURE|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
219699197|NCT03422185|OTHER|No intervention|No intervention
219112411|NCT00445601|OTHER|placebo|Given intravesically
219112412|NCT05377710|PROCEDURE|sinus lift with lateral approach|Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material
219112413|NCT03764358|DEVICE|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
219112414|NCT03764358|DEVICE|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
219224864|NCT00247351|PROCEDURE|Cryoablation|
219112415|NCT02026713|OTHER|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
219112416|NCT00074074|BIOLOGICAL|infliximab|
219112417|NCT03260361|OTHER|Hypnosis, kinesitherapy, MEOPA|classical intervention
219112418|NCT03260361|OTHER|Usual practice|Usual practice with treatments and physio
219112419|NCT04683471|DEVICE|Stimulator|Neuromodulation
219112420|NCT04683471|DEVICE|Sham|Sham
219112421|NCT01150578|DRUG|No intervention|No intervention
219112422|NCT03340155|OTHER|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
219112423|NCT05638880|DRUG|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
219112424|NCT05638880|DRUG|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
219112425|NCT05638880|DRUG|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
219112426|NCT02895490|OTHER|educational intervention|Receive a DVD containing educational information and communication skills
219112427|NCT02895490|OTHER|communication skills training|Receive a DVD containing educational information and communication skills
219112428|NCT02895490|OTHER|educational intervention|Receive information about the LINC group
219699198|NCT05863442|DRUG|Soliris 300 MG in 30 ML Injection|Active Comparator
219699199|NCT05863442|DRUG|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
219699200|NCT02931461|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
219699201|NCT01477567|DRUG|LY3009385|
219112429|NCT02895490|OTHER|questionnaire administration|Ancillary studies
219112430|NCT02895490|OTHER|quality-of-life assessment|Ancillary studies
219112431|NCT03450213|DEVICE|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
219699202|NCT01477567|DRUG|Placebo|
219112432|NCT04481516|OTHER|Yoga|SKY Yoga
219112433|NCT05924490|BEHAVIORAL|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
219112434|NCT05924490|BEHAVIORAL|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
219112435|NCT02543723|BEHAVIORAL|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
219112436|NCT01300429|GENETIC|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
219112437|NCT02259920|DRUG|KUC 7483 CL, immediate release tablet|
219112438|NCT02259920|DRUG|KUC 7483 CL, particulate formulation|
219112439|NCT02259920|DRUG|KUC 7483 CL, solution formulation|
219112440|NCT02259920|DEVICE|Enterion™ capsule|
219112441|NCT01326793|OTHER|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
219112442|NCT02083003|DIETARY_SUPPLEMENT|Polyamine low-diet|
219112443|NCT02083003|DIETARY_SUPPLEMENT|Liberal alimentation|
219112444|NCT00273962|DRUG|ipratropium plus salbutamol UDV|
219224865|NCT02206867|BIOLOGICAL|LBAL|Anti-inflammatory agents
219112445|NCT00273962|DRUG|salbutamol UDV|
219112446|NCT02348437|PROCEDURE|Repair|An on-going suture technique with minimum four stitches.
219112447|NCT02348437|PROCEDURE|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
219112448|NCT00730990|OTHER|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
219112449|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
219224866|NCT02206867|BIOLOGICAL|Humira|Anti-inflammatory agents
219224867|NCT03900585|BEHAVIORAL|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
219699203|NCT04093271|DIETARY_SUPPLEMENT|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
219699204|NCT04093271|DRUG|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
219699205|NCT04093271|OTHER|Placebo|No active ingredients
219699206|NCT00485836|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
219699207|NCT00485836|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
219699208|NCT00485836|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
219699209|NCT06346158|DIAGNOSTIC_TEST|Cognitive testing|Preoperative cognitive battery test
219699210|NCT06346158|DEVICE|electroencephalogram|Preoperative 24 channel EEG
219699211|NCT06346158|DEVICE|High density electroencephalogram|preoperative 128-channel electroencephalogram
219699212|NCT06346158|PROCEDURE|General anesthesia|induction of general anesthesia using propofol 1%
219699213|NCT02880501|DEVICE|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
219699214|NCT06066775|OTHER|Observation study without intervention|Observation study without intervention
219699215|NCT00021164|BIOLOGICAL|aldesleukin|
219112450|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
219112451|NCT00730990|DRUG|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1\) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
219112452|NCT02450773|DRUG|Furosemide|40 mg furosemide on postpartum day 1-6
219112453|NCT02450773|DRUG|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
219112454|NCT02450773|DRUG|Placebo #1|Placebo (for furosemide)
219112455|NCT02450773|DRUG|Placebo #2|Placebo (for KCl)
219112456|NCT03840837|DRUG|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
219112457|NCT01877096|BEHAVIORAL|Motivational Interviewing|A brief motivational interviewing session
219112458|NCT01877096|BEHAVIORAL|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
219112459|NCT04157790|OTHER|CARE score|CARE score calculation
219112460|NCT00556348|DRUG|bevacizumab|1.25mg
219112461|NCT01506492|BEHAVIORAL|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
219112462|NCT01456858|OTHER|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
219112463|NCT01456858|OTHER|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
219224868|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
219224869|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
219224870|NCT00887224|DRUG|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
219224871|NCT03883828|DRUG|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
219224872|NCT03883828|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
219112464|NCT04861922|DRUG|Unfractionated Heparin|10 unit/kgBW/hour continuous infusion for 5 days
219112465|NCT06203444|DRUG|Tenapanor|The study drug will be administered in dose of 50 mg bid
219112466|NCT02064621|DRUG|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
219112467|NCT02064621|DRUG|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
219112468|NCT00966862|OTHER|Other: Dietary Fibers|
219112469|NCT04880915|OTHER|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
219224873|NCT05902936|PROCEDURE|Pulpotomy for mature permanent mandibular molars|Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.
219224874|NCT02915211|DIETARY_SUPPLEMENT|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
219112470|NCT02366208|DRUG|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
219112471|NCT02366208|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
219112472|NCT02366208|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
219112473|NCT05360758|OTHER|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow
219112474|NCT04399187|DRUG|Sodium hypochlorite gel application|Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
219112475|NCT02835443|DEVICE|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
219112476|NCT03917160|DEVICE|EMS device|EMS treatment will be performed
219112477|NCT00231270|DEVICE|Cordis Nitinol Stent|
219112478|NCT00231270|DEVICE|PRECISE tapered stent|
219112479|NCT00231270|DEVICE|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
219112480|NCT05828225|DRUG|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
219112481|NCT02930122|DRUG|anakinra (150mg)|intraarticular administration
219112482|NCT02930122|OTHER|Saline intraarticularly|intraarticular administration
219699216|NCT00021164|BIOLOGICAL|incomplete Freund's adjuvant|
219699217|NCT00021164|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
219699218|NCT01686893|DEVICE|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
219112483|NCT05857579|PROCEDURE|Microblepharoexfoliation|MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
219112484|NCT05857579|PROCEDURE|Intense pulse light|IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
219699219|NCT01686893|DEVICE|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
219699220|NCT04233684|DIAGNOSTIC_TEST|rapid urease test|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H\&E stain and Giemsa stain Gold standard is a immunohistochemistry."
219699221|NCT01737528|PROCEDURE|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
219112485|NCT05857579|PROCEDURE|Meibomian gland expression|Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
219112486|NCT05857579|DRUG|Home-based therapy|Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
219699222|NCT02359708|PROCEDURE|Surgical hand disinfection.|Bacterial recolonization
219112487|NCT05978648|DRUG|Trilaciclib|240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
219112488|NCT05978648|DRUG|Epirubicin|90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
219112489|NCT05978648|DRUG|Cyclophosphamide|600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
219699223|NCT04562909|DEVICE|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
219699224|NCT00140439|BEHAVIORAL|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~1. Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~2. Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~3. Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
219112490|NCT05978648|DRUG|Paclitaxel|80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.
219112491|NCT05978648|DRUG|Docetaxel|75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.
219112492|NCT05978648|DRUG|Carboplatin|area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.
219112493|NCT05978648|DRUG|Trastuzumab|8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
219112494|NCT05978648|DRUG|Pertuzumab|840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
219112495|NCT01465139|DRUG|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
219112496|NCT06349200|BEHAVIORAL|432 Hz music|Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality
219112497|NCT06349200|BEHAVIORAL|Binaural beats|Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds
219112498|NCT06349200|BEHAVIORAL|White noise|White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
219112499|NCT04971616|OTHER|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
219112500|NCT01745315|DEVICE|Advanced bipolar devices|
219699225|NCT01949545|DRUG|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
219699226|NCT01050153|DRUG|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
219112501|NCT06044220|BEHAVIORAL|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
219112502|NCT06044220|OTHER|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
219112503|NCT01681368|DRUG|Birinapant (TL32711)|47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
219112504|NCT03464214|DEVICE|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
219699227|NCT01050153|DRUG|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
219699228|NCT03520010|BEHAVIORAL|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
219112505|NCT03464214|BEHAVIORAL|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
219112506|NCT02140294|DIETARY_SUPPLEMENT|Polymeric nutritional supplements|
219699229|NCT03520010|BEHAVIORAL|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
219699230|NCT06199739|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
219699231|NCT05641571|BEHAVIORAL|The home-based extremity exercise program|Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
219699232|NCT02169882|DRUG|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
219699233|NCT02169882|DRUG|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
219224875|NCT02291406|PROCEDURE|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
219699234|NCT02169882|DRUG|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
219112507|NCT02140294|DIETARY_SUPPLEMENT|Standard Nutrional Treatment|
219112508|NCT03146481|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
219112509|NCT03146481|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
219112510|NCT04732715|BEHAVIORAL|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
219112511|NCT06449885|OTHER|patients receive optimal treatment or follow-up according to the characteristics of the disease|Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.
219224876|NCT02291406|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
219224877|NCT01399450|DRUG|paliperidone|paliperidone augmenting on ongoing medication
219224878|NCT00135018|DRUG|celecoxib and chemotherapy|
219224879|NCT01439906|PROCEDURE|Surgical correction of the deformity|"Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion"
219224880|NCT02860949|DRUG|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
219224881|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
219224882|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
219224883|NCT02386332|PROCEDURE|transplantation|
219112512|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
219112513|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
219112514|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
219112515|NCT05928715|OTHER|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
219112516|NCT04358419|DIAGNOSTIC_TEST|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
219112517|NCT04358419|DIAGNOSTIC_TEST|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
219112518|NCT04560205|DRUG|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
219112519|NCT01807221|DRUG|Finerenone (BAY94-8862)|
219699235|NCT02169882|DRUG|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
219699236|NCT02280434|DRUG|CBP-307|
219699237|NCT02280434|DRUG|Placebo|
219699238|NCT04699539|RADIATION|SBRT|SBRT: in 5-6fractions with Cyberknife.
219699239|NCT04699539|DRUG|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
219699240|NCT01675609|DRUG|Placebo|1 drop in each eye daily for up to 35 days
219699241|NCT01675609|DRUG|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
219699242|NCT04198168|DRUG|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
219699243|NCT00081003|GENETIC|gene expression analysis|
219112520|NCT01807221|DRUG|Placebo|
219112521|NCT01807221|DRUG|Inspra (eplerenone)|
219112522|NCT02609659|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219112523|NCT02609659|DRUG|ribavirin|Tablet
219112524|NCT00001955|DRUG|Etanercept|
219112525|NCT00001955|DRUG|Celecoxib|
219112526|NCT01004250|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
219112527|NCT01004250|DRUG|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
219112528|NCT01004250|DRUG|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
219112529|NCT04192214|DRUG|BC 007|1350 mg of BC 007
219112530|NCT04258085|OTHER|Early diagnosis program combined with electronic medical record|Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
219699244|NCT00081003|GENETIC|protein expression analysis|
219699245|NCT00081003|OTHER|cytology specimen collection procedure|
219699246|NCT00081003|OTHER|laboratory biomarker analysis|
219699247|NCT00081003|OTHER|physiologic testing|
219699248|NCT00081003|PROCEDURE|breast duct lavage|
219112531|NCT01875835|DEVICE|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
219112532|NCT01875835|DEVICE|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
219112533|NCT01658488|OTHER|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
219112534|NCT01658488|OTHER|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
219699249|NCT00081003|PROCEDURE|endoscopic biopsy|
219699250|NCT00081003|PROCEDURE|study of high risk factors|
219112535|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
219112536|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
219112537|NCT04122560|DRUG|Fluconazole 200mg tab|PO dose of 400mg
219112538|NCT04122560|DRUG|Fluconazole 2 MG/ML|IV dose of 400mg
219112539|NCT01281553|DRUG|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
219699251|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
219699252|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
219699253|NCT05200169|DRUG|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
219699254|NCT01855958|PROCEDURE|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
219699255|NCT01855958|PROCEDURE|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
219699256|NCT00320047|DRUG|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
219112540|NCT01281553|DRUG|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
219112541|NCT05909293|DRUG|Venclexta 100 MG Oral Tablet|"When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms."
219224884|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219224885|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219699257|NCT00296244|DRUG|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
219699258|NCT00296244|DRUG|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
219699259|NCT00296244|DRUG|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
219699260|NCT00296244|DRUG|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
219699261|NCT00053326|DRUG|fenretinide|Given orally
219699262|NCT00053326|OTHER|pharmacological study|Optional correlative studies
219699263|NCT03433235|DRUG|Edoxaban|"1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~\- NIHSS: National Institute of Health Stroke Scales"
219699264|NCT03052894|DEVICE|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
219699265|NCT03052894|DEVICE|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
219112542|NCT04375982|DIAGNOSTIC_TEST|Venepuncture|Blood tube will be collected from standard venepuncture
219112543|NCT04375982|DIAGNOSTIC_TEST|Fingerstick|Capillary blood will be collected by fingerstick
219112544|NCT04328558|OTHER|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219224886|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219224887|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219224888|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219224889|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219224890|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219699266|NCT01077557|OTHER|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
219699267|NCT01077557|DRUG|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
219699268|NCT01781897|DEVICE|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
219699269|NCT01781897|DRUG|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
219699270|NCT02378272|OTHER|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
219699271|NCT01905696|DRUG|Oral N-acetylcysteine|
219699272|NCT01973751|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
219699273|NCT04367298|BEHAVIORAL|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
219699274|NCT02815371|PROCEDURE|Needle Acupuncture|See above
219699275|NCT02815371|PROCEDURE|Laser Acupuncture|See above
219699276|NCT02815371|PROCEDURE|Sham Laser Acupuncture|See above
219112545|NCT01037959|DRUG|Norfloxacin|400 mg/day (per os) for 6 months
219112546|NCT01037959|DRUG|Placebo|1 pill/day (per os) for 6 months
219112547|NCT01231685|DRUG|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
219112548|NCT01231685|DRUG|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
219112549|NCT00861796|DRUG|CYR-101|Experimental arm
219112550|NCT00861796|DRUG|Placebo|Placebo comparator
219112551|NCT00902941|DRUG|Azilect 1mg|1 mg daily orally for 120 days
219112552|NCT00902941|DRUG|Placebo|1 mg daily orally for 120 days
219112553|NCT03492619|BEHAVIORAL|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
219112554|NCT03492619|BEHAVIORAL|Non-Intensive Intervention|Group sessions for healthy lifestyle
219112555|NCT00594906|DRUG|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
219699277|NCT05793658|PROCEDURE|Standard capnography|Patients undergoing colonoscopy under sedation were randomly assigned to receive standard capnography monitoring or modified capnography monitoring which can be achieved by tucking capnography probe under the face mask.74 patients were enrolled. Patient characteristics were well balanced between the two groups 37 patients in each group.
219112556|NCT00594906|DRUG|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
219112557|NCT00431002|BEHAVIORAL|Resistance training|See Detailed Description.
219112558|NCT05391321|OTHER|administration of the 4 quality of sexual life questionnaires|administration of the 4 quality of sexual life questionnaires
219112559|NCT03306186|DEVICE|HemoSpec|Blood sampling for analysis
219112560|NCT06220786|DEVICE|Low-level laser therapy|Low-level laser therapy ca. 72 Joules per cm2
219112561|NCT06220786|DEVICE|"Fake low-level laser therapy"|Identical laser pen without production of low-level laser therapy
219112562|NCT00079443|DRUG|romidepsin|Given IV
219112563|NCT00079443|BIOLOGICAL|rituximab|Given IV
219112564|NCT00079443|DRUG|fludarabine phosphate|Given IV
219112565|NCT00079443|OTHER|laboratory biomarker analysis|Correlative studies
219224891|NCT01279694|DRUG|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
219224892|NCT01279694|DRUG|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
219224893|NCT01279694|DRUG|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
219699278|NCT05793658|PROCEDURE|Modified capnography|If Respiratory rate below 14 b/m: more sedation isn't not advised and the patient may develop airway obstruction and needs airway intervention ( like jaw thrust or oral airway) If respiratory rate more than 20 b/m it means this patient is prone to awake or to move and this patient in need for incremental dose of sedative drug ( e.g 20 to 30 mg propofol) Also roughly speaking respiratory rate from 16 to 18 b/m is the target
219699279|NCT05241301|OTHER|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
219112566|NCT00867490|DRUG|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
219112567|NCT00867490|DRUG|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
219112568|NCT00867490|DRUG|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
219112569|NCT04773886|DRUG|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
219112570|NCT04773886|DRUG|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
219112571|NCT04773886|BIOLOGICAL|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
219112572|NCT03375684|OTHER|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
219112573|NCT03375684|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
219112574|NCT05521295|OTHER|no intervention|no intervention in this study
219112575|NCT02186080|DRUG|Gemigliptin|
219112576|NCT02186080|DRUG|Placebo|
219112577|NCT01810627|RADIATION|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
219112578|NCT06143657|DIAGNOSTIC_TEST|Automated Gram Staining Machine analysis|Measure urine and sputum specimens using this device.
219112579|NCT03786120|DRUG|Zolpidem|PO sleep aid in various doses
219112580|NCT02823964|DRUG|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
219112581|NCT03996941|BEHAVIORAL|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
219112582|NCT03996941|OTHER|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
219112583|NCT05973318|DRUG|Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
219112584|NCT05973318|DRUG|Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
219112585|NCT05408000|DRUG|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
219112586|NCT01737060|DEVICE|Reverse total shoulder arthroplasty|
219112587|NCT01324219|BEHAVIORAL|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
219112588|NCT01324219|BEHAVIORAL|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
219112589|NCT03577808|OTHER|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
219112590|NCT03424486|OTHER|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
219112591|NCT02489825|PROCEDURE|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
219112592|NCT02489825|PROCEDURE|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
219112593|NCT01211236|OTHER|application of wound dressing made of bio-bags (vitapads) containing maggots|
219112594|NCT01211236|OTHER|application of classical hydrogel/alginate wound dressing|
219112595|NCT04718714|DRUG|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
219112596|NCT04718714|DRUG|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
219112597|NCT04718714|DRUG|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
219112598|NCT05239416|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
219112599|NCT00334867|DRUG|cyclophosphamide|Given IV
219112600|NCT00334867|DRUG|dexrazoxane hydrochloride|Given IV
219112601|NCT00334867|DRUG|doxorubicin hydrochloride|Given IV
219112602|NCT00334867|DRUG|etoposide|Given IV
219112603|NCT00334867|DRUG|ifosfamide|Given IV
219112604|NCT00334867|DRUG|topotecan hydrochloride|Given IV
219112605|NCT00334867|DRUG|vincristine sulfate|Given IV
219112606|NCT00334867|PROCEDURE|conventional surgery|Patients undergo surgery in week 18
219112607|NCT00334867|PROCEDURE|radiation therapy|Patients undergo radiation therapy in week 19
219112608|NCT05013996|BEHAVIORAL|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
219699280|NCT03632824|DRUG|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
219699281|NCT05084391|DEVICE|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
219699282|NCT05084391|OTHER|Standard of Treatment|Standard of care
219112609|NCT05013996|BEHAVIORAL|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
219112610|NCT03394261|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
219112611|NCT05856240|BEHAVIORAL|Managing Stress & Emotions Group (MSEG)|The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
219112612|NCT00441051|DRUG|Diclofenac sodium 1mg/g|
219112613|NCT03940235|DRUG|Androgen deprivation therapy (ADT)|SBRT + ADT
219112614|NCT03940235|RADIATION|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
219699283|NCT06233786|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
219112615|NCT04506580|PROCEDURE|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
219112616|NCT00390455|DRUG|Fulvestrant|Given IM
219699284|NCT05766241|BEHAVIORAL|Sensory Strategies Training|In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
219699285|NCT00427934|DRUG|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
219699286|NCT00427934|DRUG|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
219699287|NCT04168957|DRUG|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
219699288|NCT06258252|OTHER|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
219699289|NCT05037604|OTHER|Questionnaire about associated factors|Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age\> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
219699290|NCT05037604|DIAGNOSTIC_TEST|Self questionnaire diagnostic tool|Self questionnaire of physical characteristics
219699291|NCT05037604|OTHER|Physical Examination|Physical Examination made by a dermatologist
219699292|NCT04576000|DRUG|Janus Kinase Inhibitor|Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
219699293|NCT03540459|DIAGNOSTIC_TEST|sleep polygraphy|sleep polygraphy (one night) in all included patients
219699294|NCT03673891|DEVICE|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
219699295|NCT03355144|DIETARY_SUPPLEMENT|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
219699296|NCT03966989|BEHAVIORAL|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
219699297|NCT03389165|DEVICE|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
219699298|NCT00134134|DRUG|efalizumab|
219699299|NCT00499122|DRUG|Cyclophosphamide|
219112617|NCT00390455|OTHER|Laboratory Biomarker Analysis|Correlative studies
219699300|NCT00499122|DRUG|Docetaxel|
219699301|NCT00499122|DRUG|Doxorubicin|
219699302|NCT00499122|DRUG|NOV 002|
219699303|NCT04399681|DEVICE|Bedside lung ultrasound|Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.
219112618|NCT00390455|DRUG|Lapatinib Ditosylate|Given PO
219224894|NCT00418119|DRUG|erythropoietin|
219224895|NCT00310609|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
219699304|NCT03699423|DRUG|0.01% atropine eye drops|0.01% atropine sulphate
219699305|NCT03699423|DRUG|0.02% atropine eye drops|0.02% atropine sulphate
219699306|NCT03699423|DRUG|0.03% atropine eye drops|0.03% atropine sulphate
219699307|NCT04168242|DEVICE|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
219699308|NCT04168242|OTHER|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
219699309|NCT03707002|DIETARY_SUPPLEMENT|scFOS|daily intake for 6 weeks
219112619|NCT00390455|OTHER|Placebo Administration|Given PO
219112620|NCT01148342|DRUG|MDMA|
219112621|NCT01148342|DRUG|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 \&amp; 1.6 mg/kg
219112622|NCT02891044|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
219112623|NCT03808441|OTHER|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
219224896|NCT01429454|DRUG|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
219112624|NCT04800757|BEHAVIORAL|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
219112625|NCT04800757|BEHAVIORAL|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
219112626|NCT04800757|BEHAVIORAL|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
219112627|NCT00539903|BEHAVIORAL|Physical activity (PA) and immigrants|
219112628|NCT00794820|DRUG|Fludarabine Phosphate|25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
219112629|NCT00794820|DRUG|Cyclophosphamide|250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
219112630|NCT00794820|DRUG|Rituximab|375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
219112631|NCT00671632|DRUG|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
219112632|NCT03542448|DEVICE|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
219112633|NCT02043262|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
219699310|NCT03707002|DIETARY_SUPPLEMENT|Maltodextrin|daily intake for 6 weeks
219699311|NCT06201104|OTHER|Patient empowerment education|"After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients."
219699312|NCT03176914|BEHAVIORAL|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
219699313|NCT03176914|BEHAVIORAL|conventional community interventions|community health programs as the sole source of health education
219699314|NCT02243748|OTHER|Palliative Therapy|Receive individualized palliative care
219112634|NCT02043262|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
219112635|NCT02474511|OTHER|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
219112636|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
219112637|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
219112638|NCT04708691|OTHER|Aerobic exercise|aerobic exercise
219112639|NCT04188483|DIETARY_SUPPLEMENT|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
219112640|NCT04188483|BIOLOGICAL|Influenza vaccination|Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
219699315|NCT02243748|OTHER|quality-of-life assessment|Ancillary studies
219699316|NCT02243748|OTHER|questionnaire administration|Ancillary studies
219699317|NCT03061942|OTHER|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
219699318|NCT03061942|OTHER|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
219112641|NCT04198532|OTHER|Contrast bath|Contrast bath (hot and cold therapy)
219112642|NCT00266474|OTHER|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
219112643|NCT02905019|BIOLOGICAL|R21 with Matrix-M1|Vaccine
219112644|NCT02905019|BIOLOGICAL|ChAd63 ME-TRAP|Vaccine
219112645|NCT02905019|BIOLOGICAL|MVA ME-TRAP|Vaccine
219112646|NCT02870504|PROCEDURE|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
219112647|NCT02870504|PROCEDURE|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
219112648|NCT02870504|PROCEDURE|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
219112649|NCT06172218|OTHER|Flo|sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
219112650|NCT06172218|OTHER|Saline|sterile, preservative free 0.9% NaCl
219112651|NCT04076020|BEHAVIORAL|Relational agent/AliveCor Kardia - Intervention|Use of the relational agent and Kardia daily for 120 days.
219112652|NCT04076020|BEHAVIORAL|Usual Care|Use of the WebMD app daily for 120 days.
219112653|NCT05022602|DEVICE|Imagio|Imagio - both ultrasound probe and Duplex OA probe
219112654|NCT00466258|DRUG|R-CHOP|"* Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5."
219112655|NCT00466258|DRUG|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
219112656|NCT00466258|DRUG|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
219112657|NCT00466258|DRUG|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
219112658|NCT02811289|DRUG|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
219112659|NCT02811289|OTHER|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
219112660|NCT02811289|RADIATION|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
219112661|NCT02811289|RADIATION|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
219112662|NCT02811289|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
219112663|NCT02811289|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
219112664|NCT02811289|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
219112665|NCT05542992|DIAGNOSTIC_TEST|CT-based deep learning model|CT-based deep learning model for pure-solid nodules classifications
219112666|NCT06445855|BEHAVIORAL|Interpersonal relationship-based intervention program|An interpersonal relations-based intervention program will be implemented with an online intervention platform.
219112667|NCT04064554|DEVICE|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
219112668|NCT04064554|DEVICE|BCG vaccination with conventional needle|BCG vaccination with conventional needle
219112669|NCT02300480|PROCEDURE|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
219112670|NCT02300480|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
219112671|NCT01210235|BEHAVIORAL|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
219112672|NCT03870178|DEVICE|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
219112673|NCT05444673|DRUG|Paprizumab combined with cisplatin and 5-FU|Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
219112674|NCT02310126|DEVICE|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
219112675|NCT02310126|DEVICE|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
219112676|NCT06451575|DIAGNOSTIC_TEST|Blood collection|Blood collection
219112677|NCT00590993|OTHER|MRI and MRSI|Compare treatment impact when using MRI and MRSI
219112678|NCT02524054|DRUG|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
219112679|NCT02524054|DRUG|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
219112680|NCT02220686|BEHAVIORAL|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
219112681|NCT00271869|PROCEDURE|Extracorporeal photoimmunotherapy|
219112682|NCT01578096|BEHAVIORAL|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
219112683|NCT00855868|DRUG|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
219112684|NCT00855868|DRUG|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB
219112685|NCT01948362|DRUG|Sulforadex|Active compound
219112686|NCT01948362|DRUG|Alpha cyclodextrin|Placebo control
219112687|NCT00000484|DRUG|chlorothiazide|
219112688|NCT00000484|DRUG|Rauwolfia alkaloids|
219112689|NCT05769270|BEHAVIORAL|Peer Navigation and Coping Skills|Participants will receive 6 sessions of peer navigation and coping skills
219112690|NCT05769270|BEHAVIORAL|Treatment as Usual|Participants will receive referrals for PrEP and services
219112691|NCT00932490|BEHAVIORAL|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
219112692|NCT03953729|DRUG|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
219112693|NCT03953729|DRUG|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
219112694|NCT05223842|BEHAVIORAL|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
219112695|NCT05223842|BEHAVIORAL|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
219112696|NCT02264496|BEHAVIORAL|Exercise|
219112697|NCT00654329|DRUG|Saline|Normal saline, given intranasally
219112698|NCT00654329|DRUG|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
219112699|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
219112700|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
219112701|NCT00974636|DIETARY_SUPPLEMENT|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
219699319|NCT05222867|PROCEDURE|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
219699320|NCT00049231|DRUG|EF5|
219699321|NCT00049231|OTHER|immunohistochemistry staining method|
219699322|NCT00049231|PROCEDURE|biopsy|
219699323|NCT01373164|DRUG|Galunisertib|Administered orally
219112702|NCT00974636|DIETARY_SUPPLEMENT|Usual Salt Diet|Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
219112703|NCT00074763|BIOLOGICAL|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
219112704|NCT04932720|BEHAVIORAL|chıld yoga programme|"Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes."
219112705|NCT04314063|OTHER|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
219112706|NCT05421520|DEVICE|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
219699324|NCT01373164|DRUG|Gemcitabine|Administered intravenously
219699325|NCT01373164|DRUG|Placebo|Administered orally
219699326|NCT02957552|BIOLOGICAL|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
219699327|NCT00612235|DRUG|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
219699328|NCT00612235|DRUG|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
219112707|NCT04876885|OTHER|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
219112708|NCT01581879|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
219112709|NCT02651285|OTHER|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
219112710|NCT02651285|OTHER|Control|incubation of IVF embryos with a medium without G-CSF
219112711|NCT02300389|RADIATION|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
219112712|NCT02300389|RADIATION|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
219112713|NCT03936413|DEVICE|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
219112714|NCT03936413|DEVICE|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
219112715|NCT03806504|OTHER|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
219112716|NCT03806504|OTHER|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
219112717|NCT00003288|BIOLOGICAL|filgrastim|
219112718|NCT00003288|DRUG|cyclophosphamide|
219112719|NCT00003288|DRUG|tirapazamine|
219112720|NCT01144221|PROCEDURE|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
219112721|NCT05812703|BEHAVIORAL|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR \> 50% HRmax.
219112722|NCT05812703|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
219112723|NCT05812703|BEHAVIORAL|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
219112724|NCT03537261|BEHAVIORAL|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
219224897|NCT01429454|DRUG|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
219224898|NCT01653652|DIETARY_SUPPLEMENT|Probiotic|
219224899|NCT01653652|DIETARY_SUPPLEMENT|Maltodextrin|
219224900|NCT01256359|DRUG|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
219699329|NCT00612235|DRUG|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
219699330|NCT00612235|OTHER|No Intervention|No intervention was given
219699331|NCT00843349|DRUG|Lanthanum Carbonate|Phosphorus binder
219699332|NCT00843349|OTHER|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
219699333|NCT00843349|DRUG|LC Placebo|Placebo for Lanthanum Carbonate
219699334|NCT00843349|OTHER|Ad Libitum Diet|Patients continued to eat their usual diet.
219699335|NCT03394937|BIOLOGICAL|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
219699336|NCT02526238|DEVICE|TMS and trunk rotation|TMS and trunk rotation
219699337|NCT02526238|DEVICE|Sham TMS and trunk rotation|Sham TMS and trunk rotation
219699338|NCT02254642|PROCEDURE|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
219699339|NCT02254642|PROCEDURE|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
219699340|NCT05902624|DRUG|Hepatitis B Virus Vaccine(HBV)|Hepatitis B Virus Vaccine(HBV)
219112725|NCT00123513|BEHAVIORAL|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
219112726|NCT00123513|BEHAVIORAL|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
219699341|NCT02120404|DRUG|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
219699342|NCT01605903|DRUG|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
219699343|NCT01605903|DRUG|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
219699344|NCT01559168|DEVICE|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
219699345|NCT01068236|BEHAVIORAL|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
219699346|NCT00218413|BIOLOGICAL|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
219699347|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
219699348|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182
219699349|NCT00218413|BIOLOGICAL|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
219699350|NCT00218413|BIOLOGICAL|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
219699351|NCT02037087|BEHAVIORAL|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
219699352|NCT02037087|BEHAVIORAL|Care seeking|"* Danger-sign recognition~* Reminders for government projects"
219699353|NCT02037087|BEHAVIORAL|Full bank of SMS|"* Danger-sign recognition~* Reminders for government projects~* Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
219699354|NCT04512495|OTHER|Blood samples will be collected at two times :|"* at Baseline,~* after surgery or at the time of post-chemotherapy evaluation."
219699355|NCT04828499|PROCEDURE|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
219699356|NCT04828499|PROCEDURE|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
219699357|NCT04596319|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
219699358|NCT04596319|OTHER|Placebo|Inactive Placebo administered via inhalation
219699359|NCT03437967|DEVICE|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
219112727|NCT00123513|BEHAVIORAL|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
219112728|NCT03760822|DRUG|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
219112729|NCT03760822|DRUG|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
219699360|NCT02609490|DRUG|Azilsartan tablets|20mg/tablet
219699361|NCT02609490|DRUG|Azilsartan placebo tablets|placebo tablet
219699362|NCT02609490|DRUG|Olmesartan medoxomil tablets|20mg/tablet
219699363|NCT02609490|DRUG|olmesartan medoxomil placebo tablets|placebo tablet
219699364|NCT04192682|DRUG|Anlotinib Hydrochloride|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
219699365|NCT04472572|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients with COVID-19 infection
219699366|NCT00171275|DRUG|Fluvastatin|
219699367|NCT03051711|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
219699368|NCT05669157|PROCEDURE|Radiography request by nurse|Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice
219699369|NCT05669157|PROCEDURE|Radiography request by physician|The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
219112730|NCT03237013|BEHAVIORAL|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
219112731|NCT03237013|BEHAVIORAL|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
219112732|NCT00288873|DRUG|Ergocalciferol|
219112733|NCT00288873|DRUG|Cholecalciferol|
219112734|NCT00237562|PROCEDURE|Large loop electrosurgical excision|
219699370|NCT06470581|DRUG|Botulinum toxin A|Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
219112735|NCT01359618|DRUG|TC-5214|Single dose, oral tablets
219112736|NCT01359618|OTHER|Placebo comparator|Single dose, oral tablets
219112737|NCT01359618|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
219224901|NCT01256359|DRUG|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
219699371|NCT02491762|PROCEDURE|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
219699372|NCT04140448|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
219699373|NCT04140448|DEVICE|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
219112738|NCT01359618|OTHER|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
219112739|NCT04266743|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
219112740|NCT05508347|DRUG|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
219112741|NCT02269618|OTHER|Home-based telehealth program|"Home-based telehealth program~* Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~* Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~* Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~* Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~* Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
219699374|NCT01170585|DRUG|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
219699375|NCT01170585|DRUG|Placebo|Placebo
219699376|NCT05729958|DIAGNOSTIC_TEST|CT scan|CT scan of the involved ankle
219699377|NCT03804619|DEVICE|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
219699378|NCT03563222|DRUG|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
219224902|NCT02000752|DEVICE|Acupuncture|
219224903|NCT02000752|DEVICE|Sham acupuncture|Sham point acupuncture
219224904|NCT02323776|OTHER|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
219224905|NCT00987324|DEVICE|Taxus stent|Implantation of paclitaxel-eluting stent
219224906|NCT00987324|DEVICE|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
219224907|NCT00987324|DEVICE|Conventional Balloon Catheter|Ryuijin, Trek
219112742|NCT02269618|OTHER|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~* Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~* Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
219112743|NCT02269618|OTHER|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
219224908|NCT01933100|OTHER|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
219224909|NCT03903692|DEVICE|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
219224910|NCT03903692|DEVICE|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
219224911|NCT03646266|DRUG|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
219112744|NCT01861756|OTHER|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
219112745|NCT00502996|DRUG|Methotrexate|\>=15 mg po/week
219112746|NCT00502996|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
219699379|NCT03563222|DRUG|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
219699380|NCT00259831|DRUG|CVT-E002 (Cold-FX); a natural health product|
219699381|NCT00194376|PROCEDURE|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
219699382|NCT04732793|DEVICE|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
219112747|NCT06228729|PROCEDURE|Endotracheal intubation|Inserting endotracheal tube into the trachea
219112748|NCT01729728|DRUG|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
219699383|NCT04732793|DEVICE|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
219699384|NCT01655875|DRUG|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
219699385|NCT03445169|DRUG|Belzutifan|Belzutifan Tablets
219699386|NCT01006629|BIOLOGICAL|palivizumab|palivizumab 15 mg/kg intramuscularly
219699387|NCT03738280|DIAGNOSTIC_TEST|Endoscopic ultrasound-fine needle biopsy|Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy
219699388|NCT04742218|DRUG|K-877|K-877 Tablet
219112749|NCT03569917|OTHER|Rectal swab collection|Rectab swab collection will be performed at inclusion and 5 and 30 days later.
219112750|NCT03688789|OTHER|Hydrocortisone supplementation|"* Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30"
219112751|NCT02500979|DRUG|Pramlintide acetate|Pramlintide acetate administered by a separate pump
219112752|NCT02500979|DRUG|Placebo|Placebo administered by separate pump
219112753|NCT02500979|DRUG|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
219112754|NCT02500979|DRUG|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
219699389|NCT04954872|BEHAVIORAL|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
219699390|NCT04954872|BEHAVIORAL|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
219699391|NCT00095329|BIOLOGICAL|sirolimus|
219699392|NCT04148404|PROCEDURE|Normothermic group|"1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
219699393|NCT04942600|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
219699394|NCT04661631|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
219699395|NCT06167902|OTHER|Ginseng oligopeptide (Ginseng extract）|The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
219112755|NCT04159116|OTHER|Prophylactic suctioning when clinically indicated|Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
219112756|NCT06500520|OTHER|Resisted Exercise group|The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.
219112757|NCT06500520|OTHER|Stretching Exercise group|The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
219112758|NCT02933463|OTHER|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
219112759|NCT02933463|OTHER|Clinpro sealant|
219112760|NCT01084590|BEHAVIORAL|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
219112761|NCT01084590|BEHAVIORAL|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
219112762|NCT02444299|DEVICE|Shoulder hemi-arthroplasty|
219112763|NCT04843813|DIETARY_SUPPLEMENT|Lutein|Participants will consume daily soft gels containing the lutein supplement.
219112764|NCT04843813|DIETARY_SUPPLEMENT|Placebo|Participants will consume daily soft gels containing the safflower oil.
219112765|NCT04039802|PROCEDURE|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
219112766|NCT04039802|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
219112767|NCT00238862|PROCEDURE|Amniotic membrane transplantation|
219699396|NCT06167902|OTHER|Maltodextrin|The control group was treated with placebo maltodextrin 1.2g/d
219699397|NCT01088555|DRUG|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
219699398|NCT00095979|DRUG|ixabepilone|Given IV
219699399|NCT04384900|PROCEDURE|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
219112768|NCT00238862|DRUG|Autologous serum/BSS 20%|
219112769|NCT05701722|DEVICE|Flourish HEC Vaginal Care System|BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
219699400|NCT04245761|DIETARY_SUPPLEMENT|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
219112770|NCT03326817|OTHER|Control Group|Patients receive standard care
219112771|NCT03326817|DEVICE|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
219112772|NCT02132533|DRUG|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
219112773|NCT02132533|DRUG|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
219112774|NCT02132533|OTHER|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
219112775|NCT03160300|DEVICE|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
219112776|NCT03160300|DEVICE|Music|Relaxing music without a binaural beat component
219112777|NCT01603563|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
219112778|NCT01603563|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
219112779|NCT00478764|DRUG|intraocular triamcinolone and gatifloxicin|
219112780|NCT00672958|DRUG|Vortioxetine|Encapsulated immediate-release tablets.
219112781|NCT00672958|DRUG|Placebo|Vortioxetine placebo-matching capsules.
219112782|NCT01380990|GENETIC|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously
219112783|NCT01380990|OTHER|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
219112784|NCT01380990|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
219112785|NCT01380990|DRUG|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
219112786|NCT01836627|OTHER|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
219112787|NCT03482817|DRUG|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
219112788|NCT03482817|DRUG|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
219112789|NCT02899871|OTHER|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies."
219112790|NCT00034645|DRUG|Posaconazole oral suspension|
219112791|NCT03121534|DRUG|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
219112792|NCT03121534|DRUG|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for \>4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
219699401|NCT00968162|DRUG|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
219699402|NCT01719250|DRUG|Buparlisib|Given PO
219699403|NCT01719250|OTHER|Laboratory Biomarker Analysis|Correlative studies
219112793|NCT03121534|DRUG|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
219112794|NCT03121534|DRUG|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
219112795|NCT02374593|DRUG|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
219112796|NCT02374593|DEVICE|Ultrasound|
219112797|NCT04267614|DRUG|Etanercept|Patients who received etanercept for RA
219112798|NCT02526056|OTHER|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
219112799|NCT02526056|OTHER|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
219112800|NCT03097003|DRUG|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
219699404|NCT01719250|OTHER|Questionnaire Administration|Ancillary studies
219112801|NCT01197989|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
219699405|NCT00912366|PROCEDURE|Lobectomy|Assessment of VATS versus open surgery.
219112802|NCT01197989|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
219112803|NCT04622137|PROCEDURE|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
219112804|NCT03118544|DEVICE|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
219112805|NCT02507882|BIOLOGICAL|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
219112806|NCT02507882|BIOLOGICAL|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
219112807|NCT03514407|DRUG|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
219112808|NCT03458559|DRUG|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
219112809|NCT03458559|DRUG|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
219112810|NCT02603315|OTHER|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
219699406|NCT02360332|BEHAVIORAL|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
219699407|NCT01994200|OTHER|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
219699408|NCT01994200|OTHER|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
219699409|NCT02251275|DRUG|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
219699410|NCT00761098|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
219112811|NCT00865891|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
219112812|NCT00865891|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
219112813|NCT01018641|BIOLOGICAL|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
219112814|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
219112815|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
219112816|NCT01018641|BIOLOGICAL|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
219112817|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
219112818|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
219112819|NCT01018641|BIOLOGICAL|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
219112820|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
219112821|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
219112822|NCT01018641|BIOLOGICAL|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
219112823|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
219112824|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
219112825|NCT01018641|PROCEDURE|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
219112826|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
219112827|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
219699411|NCT00761098|DRUG|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
219699412|NCT05246995|DRUG|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
219699413|NCT03314480|DIAGNOSTIC_TEST|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
219699414|NCT00266318|DRUG|Interferon Alfacon-1 and Ribavirin|
219699415|NCT01515124|BEHAVIORAL|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
219112828|NCT03684720|OTHER|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
219112829|NCT03847623|DIETARY_SUPPLEMENT|Curcumin|Natural compound, active ingredient of turmeric, in bi-daily dosing
219112830|NCT03847623|OTHER|Placebo|Placebo tablets at bi-daily dosing
219112831|NCT05404867|OTHER|fMRI|fMRI scan for 1 hour
219112832|NCT00003329|GENETIC|gene mapping|
219112833|NCT04827134|DRUG|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
219112834|NCT04827134|DRUG|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
219112835|NCT02861898|DRUG|Intra-arterial Cetuximab|
219112836|NCT02861898|DRUG|Intra-arterial Mannitol|
219112837|NCT01231243|PROCEDURE|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
219699416|NCT01515124|BEHAVIORAL|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
219699417|NCT05192642|DRUG|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
219699418|NCT05192642|DRUG|Data on other treatments|Real word data
219699419|NCT03164642|BEHAVIORAL|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
219112838|NCT00988351|DEVICE|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
219112839|NCT00988351|DEVICE|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
219112840|NCT04874324|DRUG|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
219112841|NCT04874324|OTHER|Placebo Oral|Subjects will receive matching placebo
219112842|NCT04845295|OTHER|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
219112843|NCT01306175|DRUG|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
219112844|NCT01306175|DRUG|Digoxin|Digoxin 0.5 mg as single dose
219112845|NCT01990820|DEVICE|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
219112846|NCT01990820|PROCEDURE|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
219112847|NCT00183456|BEHAVIORAL|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
219112848|NCT00183456|BEHAVIORAL|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
219699420|NCT03164642|BEHAVIORAL|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
219699421|NCT03733964|PROCEDURE|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
219699422|NCT03733964|PROCEDURE|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
219699423|NCT03733964|PROCEDURE|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
219699424|NCT03733964|PROCEDURE|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
219699425|NCT00686972|DRUG|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
219699426|NCT04256200|DRUG|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
219699427|NCT04256200|DRUG|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
219699428|NCT05141253|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
219699429|NCT02640560|OTHER|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
219699430|NCT02640560|OTHER|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
219699431|NCT02833909|OTHER|surgery|
219112849|NCT00004221|DRUG|Carboplatin|Given IV
219112850|NCT00004221|DRUG|Cyclophosphamide|Given IV
219112851|NCT00004221|BIOLOGICAL|Filgrastim|Given SQ
219112852|NCT00004221|DRUG|Paclitaxel|Given IV
219112853|NCT00004221|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
219112854|NCT00004221|DRUG|Topotecan Hydrochloride|Given IV
219112855|NCT03853122|OTHER|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
219112856|NCT03853122|OTHER|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
219112857|NCT00575068|DRUG|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
219112858|NCT06117748|OTHER|Pressure controlled ventilation-volume guaranteed|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
219112859|NCT06117748|OTHER|Volume controlled ventilation|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
219112860|NCT01693003|DRUG|Indacaterol|150 µg d.o. during the first 3 weeks
219112861|NCT01693003|DRUG|Tiotropium|150 µg d.o. during 3 weeks
219112862|NCT02731313|BIOLOGICAL|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
219112863|NCT05858489|OTHER|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
219112864|NCT01908673|BEHAVIORAL|HRV biofeedback|
219699432|NCT06163859|BEHAVIORAL|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
219699433|NCT04226157|DEVICE|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
219699434|NCT04226157|OTHER|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
219699435|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
219699436|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
219699437|NCT01462942|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
219699438|NCT01462942|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
219699439|NCT01462942|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
219699440|NCT05696067|BIOLOGICAL|Corfluvec component 1 low dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
219699441|NCT05696067|BIOLOGICAL|Corfluvec component 2 low dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
219699442|NCT05696067|BIOLOGICAL|Corfluvec component 1 high dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
219699443|NCT05696067|BIOLOGICAL|Corfluvec component 2 high dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
219699444|NCT05696067|BIOLOGICAL|Corfluvec low dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
219699445|NCT05696067|BIOLOGICAL|Corfluvec high dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
219112865|NCT01908673|BEHAVIORAL|ASTM|
219112866|NCT05752422|DEVICE|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
219112867|NCT03410238|BEHAVIORAL|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
219112868|NCT02861677|OTHER|pharmaceutical care|
219112869|NCT04357002|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
219112870|NCT04357002|DRUG|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
219112871|NCT04357002|DRUG|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
219112872|NCT06489054|OTHER|Peer education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the experimental group (peer-based education). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
219112873|NCT06489054|OTHER|Conventional education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the control group (dentist lecture). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
219112874|NCT01429519|DRUG|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
219112875|NCT00651443|DRUG|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
219112876|NCT03806946|DIAGNOSTIC_TEST|electroencephalography|diagnosis epileptic discharge
219112877|NCT03806946|DIAGNOSTIC_TEST|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
219112878|NCT03806946|OTHER|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
219112879|NCT04596787|PROCEDURE|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
219112880|NCT03562260|PROCEDURE|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
219112881|NCT05900219|DRUG|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
219112882|NCT05261503|OTHER|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
219112883|NCT05261503|OTHER|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
219112884|NCT02649322|DEVICE|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
219112885|NCT02649322|DEVICE|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
219112886|NCT00862953|DIETARY_SUPPLEMENT|Normal protein energy-restricted|Normal protein diet energy restricted
219112887|NCT00862953|DIETARY_SUPPLEMENT|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
219112888|NCT01042990|OTHER|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
219112889|NCT05833243|OTHER|modified diaphragmatic training|Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
219112890|NCT05833243|OTHER|standard diaphragmatic training|"standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist."
219112891|NCT04600297|DEVICE|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
219112892|NCT04974879|DRUG|Osimertinib Oral Tablet|Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
219112893|NCT01625624|OTHER|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
219112894|NCT01625624|OTHER|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
219112895|NCT01598428|PROCEDURE|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
219112896|NCT03380884|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
219112897|NCT00245336|BIOLOGICAL|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
219112898|NCT00245336|DRUG|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
219699446|NCT05696067|BIOLOGICAL|Placebo|Participants will receive two intranasal injections of placebo three weeks apart
219699447|NCT01027845|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
219699448|NCT01027845|BIOLOGICAL|DTPa|Subcutaneous injection, 4 doses
219699449|NCT04568200|DRUG|Durvalumab|Durvalumab 1500mg i.v. day 1-22-43-64
219699450|NCT04568200|DRUG|Carboplatin|Chemotherapy
219699451|NCT04568200|DRUG|Paclitaxel|Chemotherapy
219699452|NCT04568200|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy 23 x 1.8 Gy
219112899|NCT01618396|DRUG|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
219112900|NCT02708238|DIETARY_SUPPLEMENT|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
219112901|NCT02708238|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 (108 CFU)|
219112902|NCT02708238|DRUG|Simethicone|
219112903|NCT05134389|PROCEDURE|One Anastomosis Gastric Bypass|Exposure to One Anastomosis Gastric Bypass
219112904|NCT01898520|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
219112905|NCT01898520|DRUG|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
219112906|NCT04731103|DRUG|Abacavir (ABC)|Tablets or oral solution
219112907|NCT04731103|DRUG|Lamivudine (3TC)|Tablet or oral solution
219112908|NCT04731103|DRUG|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
219112909|NCT03675841|DRUG|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
219112910|NCT01927731|DRUG|Eltrombopag Olamine|Given PO
219112911|NCT01927731|OTHER|Laboratory Biomarker Analysis|Correlative studies
219112912|NCT00275496|PROCEDURE|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
219112913|NCT00275496|PROCEDURE|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
219112914|NCT00275496|PROCEDURE|Wide Excision|Subject has wide excision only for primary melanoma.
219112915|NCT04723251|BEHAVIORAL|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
219112916|NCT01388530|DEVICE|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
219112917|NCT01812005|DRUG|alisertib|Given PO
219699453|NCT03489564|BEHAVIORAL|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
219699454|NCT03489564|BEHAVIORAL|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
219699455|NCT06472479|BIOLOGICAL|LCAR-M61S cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
219112918|NCT01812005|BIOLOGICAL|rituximab|Given IV
219112919|NCT01812005|OTHER|laboratory biomarker analysis|Laboratory correlative studies will be performed
219112920|NCT05586854|PROCEDURE|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
219112921|NCT00432510|DRUG|C1 esterase inhibitor [human] (C1INH-nf)|
219112922|NCT00171405|DRUG|aliskiren|
219112923|NCT01435044|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
219112924|NCT01435044|DRUG|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
219112925|NCT01435044|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219112926|NCT01435044|DRUG|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
219112927|NCT01435044|DRUG|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
219112928|NCT02018237|BEHAVIORAL|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
219112929|NCT02018237|BEHAVIORAL|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
219112930|NCT02836613|BIOLOGICAL|Galcanezumab|Administered SC
219112931|NCT05071274|DEVICE|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
219112932|NCT03881059|OTHER|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
219699456|NCT06472479|BIOLOGICAL|LCAR-M61D cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
219112933|NCT03881059|DRUG|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
219112934|NCT03881059|DRUG|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
219112935|NCT03881059|DRUG|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
219112936|NCT03881059|OTHER|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
219699457|NCT03715062|OTHER|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
219699458|NCT00006152|DRUG|Ritonavir|
219699459|NCT00006152|DRUG|Abacavir sulfate|
219699460|NCT00006152|DRUG|Amprenavir|
219699461|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A|TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
219699462|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin|TMJ Arthrocentesis I-PRF Intra-articular Injection
219112937|NCT03499626|DRUG|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
219112938|NCT05284019|DRUG|Eptinezumab|Concentrate for solution for IV infusion
219112939|NCT05284019|DRUG|Erenumab|Solution for SC Injection
219112940|NCT05284019|DRUG|Onabotulinumtoxin-A|Solution for IM Injection
219112941|NCT05284019|DRUG|Fremanezumab|Solution for SC Injection
219112942|NCT05284019|DRUG|Galcanezumab|Solution for SC Injection
219112943|NCT05463614|DRUG|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
219699463|NCT06207955|DRUG|TMJ Arthrocentesis|TMJ Arthrocentesis By Saline
219699464|NCT01308619|DRUG|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
219112944|NCT02761889|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
219112945|NCT02761889|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
219112946|NCT02761889|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
219112947|NCT02761889|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
219699465|NCT01308619|OTHER|Placebo|Placebo, oral, one capsule daily in the morning
219699466|NCT00269724|DRUG|OROS® oxybutynin|
219699467|NCT00514085|BIOLOGICAL|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
219699468|NCT00514085|OTHER|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
219699469|NCT00514085|OTHER|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
219699470|NCT00514085|OTHER|pharmacological study|Starting dose of 50μg/kg/day as an IV push
219112948|NCT03989713|DRUG|MRD-triggered arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~3. Observation therapy:~No treatment"
219112949|NCT03989713|DRUG|Prophylactic Arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~3. Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o."
219112950|NCT01465503|DRUG|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
219112951|NCT01465503|DRUG|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
219699471|NCT03154086|DRUG|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
219699472|NCT03154086|DRUG|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
219699473|NCT05393596|BEHAVIORAL|Virtual Reality Software Intervention|Virtual Reality Software Intervention
219112952|NCT03627611|DRUG|Levothyroxin|3 months
219112953|NCT03627611|DRUG|Liothyronine|3 months
219112954|NCT02065570|DRUG|Adalimumab|
219699474|NCT02936973|DEVICE|Real catgut implantation at acupoints|"1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
219699475|NCT02936973|DEVICE|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
219699476|NCT03148262|DEVICE|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
219699477|NCT03148262|DEVICE|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
219699478|NCT05469945|DEVICE|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
219699479|NCT02522117|DRUG|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
219699480|NCT02522117|DRUG|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
219699481|NCT02936947|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
219699482|NCT02936947|OTHER|Free breathing|Free breathing
219699483|NCT02936947|OTHER|Active Breathing Control|Active Breathing Control
219112955|NCT02065570|DRUG|Placebo|
219112956|NCT04577742|RADIATION|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
219699484|NCT04900311|DRUG|pyrotinib + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
219699485|NCT04900311|DRUG|pertuzumab + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
219699486|NCT04465422|BEHAVIORAL|Occupational therapy based on the MOHO theory|"We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model."
219699487|NCT04465422|BEHAVIORAL|Occupational therapy|The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
219112957|NCT02325726|PROCEDURE|Renal Resistive Index compared with NephroCheckTM|
219112958|NCT01215708|DRUG|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
219112959|NCT05359731|DRUG|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
219112960|NCT05359731|DRUG|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
219112961|NCT00287469|BIOLOGICAL|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
219112962|NCT00287469|OTHER|Placebo|PBS buffer placebo containing alum
219112963|NCT03876938|DRUG|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
219112964|NCT03876938|DRUG|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
219112965|NCT03876938|DRUG|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
219112966|NCT02903589|OTHER|observational|
219112967|NCT00332215|DRUG|Inhaled Sodium Pyruvate|
219112968|NCT00259324|BEHAVIORAL|Diet and Activity|Diet and Activity
219112969|NCT04479293|OTHER|Post COVID-19 Functional Satus Scale|scale from 0-64 assessing functional limitation
219112970|NCT01436123|OTHER|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
219112971|NCT01436123|DEVICE|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
219112972|NCT02059772|DRUG|ranibizumab|
219112973|NCT02059772|PROCEDURE|micropulse diode laser|
219112974|NCT06187571|OTHER|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
219112975|NCT06187571|OTHER|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
219112976|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
219112977|NCT01648179|DRUG|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
219112978|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
219112979|NCT01648179|DRUG|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
219699488|NCT02668003|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
219699489|NCT03786640|RADIATION|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
219699490|NCT02147626|BEHAVIORAL|Web-based educational and motivational modules|
219699491|NCT02147626|BEHAVIORAL|Information and Screening Group|
219699492|NCT02415985|DRUG|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
219699493|NCT02415985|DRUG|Rifabutin|
219699494|NCT05899530|DEVICE|Invisalign|Expansion using Invisalign versus conventional expander
219112980|NCT01844193|DEVICE|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
219112981|NCT01266993|BIOLOGICAL|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
219112982|NCT01266993|BIOLOGICAL|Menjugate|Intramuscular, 1 dose
219112983|NCT02293837|DRUG|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
219699495|NCT05899530|DEVICE|Conventional expander|conventional expander
219699496|NCT00394641|BEHAVIORAL|listening to music / stories via stereophonic headphones|
219112984|NCT02293837|DRUG|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
219112985|NCT02293837|OTHER|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
219112986|NCT04779242|DRUG|Omadacycline|IV for injection, oral tablets
219112987|NCT04779242|DRUG|Moxifloxacin|IV solution, oral tablets
219112988|NCT01757067|DEVICE|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
219699497|NCT01244464|BIOLOGICAL|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
219699498|NCT00941551|DRUG|levothyroxine|levothyroxine 75-125 ug/day
219699499|NCT00941551|DRUG|no levothyroxine|observation only without prophylactic levothyroxine
219699500|NCT04562974|DEVICE|MRI-scanner|Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.
219112989|NCT03285113|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
219112990|NCT01223222|DRUG|LTX-109|Topical administration. 3 times daily. 5 days.
219112991|NCT00849680|OTHER|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
219112992|NCT00849680|BIOLOGICAL|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)
219112993|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)
219224912|NCT05108363|BEHAVIORAL|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
219699501|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
219699502|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
219699503|NCT03925896|DRUG|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
219699504|NCT01031290|DEVICE|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
219699505|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
219699506|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
219699507|NCT03359746|DRUG|Grazoprevir/Elbasvir|Medication for treatment of patient
219699508|NCT03233074|OTHER|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
219699509|NCT03720561|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
219699510|NCT01704261|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
219699511|NCT01704261|DRUG|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
219699512|NCT01704261|DRUG|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
219699513|NCT01704261|DRUG|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
219699514|NCT02061657|DRUG|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
219699515|NCT02061657|DRUG|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
219112994|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)
219112995|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)
219112996|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)
219224913|NCT01209156|DRUG|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
219224914|NCT03444415|OTHER|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
219224915|NCT03444415|OTHER|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
219699516|NCT06243445|DIAGNOSTIC_TEST|Transthoracic echocardiography for central venous catheter tip location|Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
219112997|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)
219112998|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)
219112999|NCT00849680|BIOLOGICAL|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
219113000|NCT02643979|DRUG|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
219113001|NCT02643979|DRUG|Propofol|100mg of Propofol
219113002|NCT02643979|DRUG|Saline|1mL of saline
219113003|NCT03398915|PROCEDURE|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
219113004|NCT02942004|DRUG|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
219113005|NCT02942004|DRUG|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
219113006|NCT02942004|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
219113007|NCT05233722|OTHER|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
219113008|NCT05233722|PROCEDURE|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
219113009|NCT05233722|DRUG|Placebo|Administration of 800 mg of calcium tablets
219113010|NCT05233722|DRUG|Rapamycin|Administration of 16 mg of Rapamycin tablets
219113011|NCT04103424|BEHAVIORAL|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
219113012|NCT05500027|DIAGNOSTIC_TEST|serum test|serum test of sCD58 and TGFbeta1
219224916|NCT06132009|PROCEDURE|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
219699517|NCT03196141|DIAGNOSTIC_TEST|StO2 and EndoPAT|"* StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand."
219699518|NCT02722967|DRUG|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
219699519|NCT01834547|DRUG|Drugs use: methylphenidate|40 mg tablets
219699520|NCT01834547|DRUG|Drug use: modafinil|40 mg tablets
219699521|NCT01834547|DRUG|caffeine|400 mg
219699522|NCT01834547|DRUG|placebo|placebo
219224917|NCT02052687|DRUG|LFX453 H1|LFX453 high dose cream 1
219113013|NCT02532322|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
219113014|NCT02532322|DRUG|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
219113015|NCT01272986|DEVICE|ALOA IgG-Elisa|measurement of IgG Level in blood
219113016|NCT01272986|DEVICE|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
219113017|NCT04262102|BEHAVIORAL|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
219113018|NCT04262102|BEHAVIORAL|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
219113019|NCT04262102|BEHAVIORAL|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
219113020|NCT04262102|BEHAVIORAL|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
219113021|NCT04001140|BEHAVIORAL|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
219113022|NCT04866914|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
219113023|NCT04866914|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
219113024|NCT00206388|DRUG|Zolendric acid|IV, 2mg/m2/dose on day 0
219113025|NCT00206388|DRUG|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
219113026|NCT06190574|OTHER|Telephone follow-up|Telephone follow-up
219113027|NCT04276818|PROCEDURE|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
219224918|NCT02052687|DRUG|LFX453 L1|LFX453 low dose cream 1
219699523|NCT04862338|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
219699524|NCT03779269|OTHER|meditation|meditation effect assessment using assessment tools.
219699525|NCT00706563|BIOLOGICAL|Fluarix™|Single intramuscular dose on Day 0
219699526|NCT03201991|OTHER|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
219699527|NCT03252626|DRUG|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline."
219699528|NCT03252626|DRUG|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
219699529|NCT02702544|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
219113028|NCT04276818|PROCEDURE|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
219113029|NCT03382600|BIOLOGICAL|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
219113030|NCT03382600|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
219113031|NCT03382600|DRUG|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
219113032|NCT03382600|DRUG|Cisplatin|60 mg/m\^2 Q3W on Day 1 by IV infusion
219113033|NCT04206137|OTHER|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
219113034|NCT04206137|OTHER|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
219113035|NCT01448044|DRUG|BMS-790052 (NS5A Replication Complex Inhibitor)|
219113036|NCT01448044|DRUG|Placebo matching BMS-790052|
219113037|NCT01448044|DRUG|Pegylated-interferon alfa 2a|
219113038|NCT01448044|DRUG|Ribavirin|
219113039|NCT03111758|DEVICE|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
219113040|NCT01000376|DRUG|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
219113041|NCT01000376|DRUG|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
219113042|NCT05235295|PROCEDURE|Ultrasound-guided sacroiliac joint injection|Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
219113043|NCT05235295|PROCEDURE|Flouroscopy-guided sacroiliac joint injection|Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
219113044|NCT02126436|OTHER|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
219224919|NCT02052687|DRUG|LFX453 H2|LFX453 high dose cream 2
219224920|NCT02052687|DRUG|LFX453 L2|LFX453 low dose cream 2
219699530|NCT02702544|DEVICE|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
219699531|NCT04283318|BEHAVIORAL|12h fasting|12h fasting (overnight)
219699532|NCT04283318|BEHAVIORAL|36h fasting|36h fasting ( one day and two nights fasting)
219113045|NCT02126436|OTHER|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
219113046|NCT00035945|DRUG|ISIS 14803|
219113047|NCT00715507|DEVICE|medication monitor|the medication monitor will aid in expertise and decision-making.
219113048|NCT00896454|DRUG|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
219113049|NCT06259162|PROCEDURE|LAG-3 expression / immune checkpoint protein expression|Evaluate the tissue and blood before and after chemotherapy
219113050|NCT02189096|OTHER|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
219224921|NCT02052687|DRUG|Imiquimod|Imiquimod cream
219224922|NCT02052687|DRUG|Placebo 1|Placebo cream 1
219224923|NCT02052687|DRUG|Placebo 2|Placebo cream 2
219224924|NCT02431741|DEVICE|Mepilex Transfer Ag|
219224925|NCT01945372|OTHER|EEG NeuroFeedback|
219224926|NCT06353620|DIAGNOSTIC_TEST|High Density EEG recording|Recording of resting state high density EEG (128 channels)
219224927|NCT06353620|DIAGNOSTIC_TEST|Rey Complex Figure Test|Memeory functioning evaluation
219699533|NCT03991039|RADIATION|Gamma knife|Microvascular decompression
219699534|NCT03310216|PROCEDURE|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
219699535|NCT03310216|PROCEDURE|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
219699536|NCT01445249|PROCEDURE|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
219699537|NCT01445249|PROCEDURE|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
219113051|NCT02189096|OTHER|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
219113052|NCT00397267|DRUG|inhalation of corticosteroids|
219113053|NCT01721395|DIETARY_SUPPLEMENT|Agave Syrup|
219113054|NCT04387838|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
219113055|NCT04387838|OTHER|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
219113056|NCT01902589|OTHER|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
219113057|NCT05759312|DRUG|Zimberelimab|Zimberelimab 240mg IV every 2 weeks
219113058|NCT05759312|DRUG|Metformin Hydrochloride|Metformin 2000mg PO QD
219113059|NCT03693599|DRUG|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
219113060|NCT03693599|DRUG|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
219699538|NCT00185315|DRUG|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
219113061|NCT05581238|OTHER|TRACK-TCT|An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
219113062|NCT03688711|DRUG|Dasiglucagon|Glucagon analogue
219113063|NCT03688711|DRUG|Placebo|Placebo for dasiglucagon
219699539|NCT04958876|DRUG|SP-104|oral capsule once daily
219699540|NCT04958876|DRUG|Naltrexone immediate release oral capsules|oral capsule once daily
219699541|NCT00467519|BIOLOGICAL|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
219699542|NCT00467519|BIOLOGICAL|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
219113064|NCT03041454|OTHER|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
219113065|NCT06122181|DRUG|HS-10384 tablets|Multiple dosing of HS-10384 orally in a fasting state
219113066|NCT06122181|DRUG|HS-10384-matched placebo tablets|Multiple dosing of HS-10384-matched placebo orally in a fasting state
219113067|NCT04864821|DRUG|Targeting CD276 CAR T cells|Targeting CD276 autologous chimeric antigen receptor T cells
219113068|NCT05039775|DEVICE|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
219113069|NCT05039775|BEHAVIORAL|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
219699543|NCT01028781|DRUG|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
219113070|NCT00253279|PROCEDURE|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
219113071|NCT02053545|DRUG|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
219699544|NCT05782153|DEVICE|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
219699545|NCT05782153|DEVICE|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
219699546|NCT00747214|DRUG|CRx-102|
219699547|NCT00747214|DRUG|Placebo|
219699548|NCT00747214|DRUG|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
219113072|NCT01410461|DEVICE|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
219113073|NCT01410461|DEVICE|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
219113074|NCT03262090|DRUG|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
219699549|NCT00171093|DRUG|valsartan + simvastatin|
219699550|NCT02346734|DEVICE|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
219699551|NCT03779555|OTHER|Medication Event Monitoring System|-Microchipped bottle cap
219699552|NCT00614510|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
219699553|NCT06184048|PROCEDURE|Intra-Articular knee injection of LC-PRP|Blood Collection 45mL, Processed Neutrophil-Poor PRP, 2 Injections at day 0 and 3 weeks.
219699554|NCT03931070|DRUG|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
219699555|NCT03931070|DRUG|Placebo - Cap|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
219699556|NCT05594082|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
219699557|NCT00833755|DRUG|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
219699558|NCT00833755|DRUG|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
219699559|NCT01457794|OTHER|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
219699560|NCT02439164|DRUG|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
219699561|NCT02343224|DRUG|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
219699562|NCT01776554|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
219699563|NCT02475369|DRUG|pancrelipase|
219113075|NCT03262090|DRUG|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
219113076|NCT03262090|DRUG|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
219699564|NCT02462265|DRUG|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
219699565|NCT02462265|DRUG|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
219699566|NCT06447636|DRUG|Surufatinib|Surufatinib: 250mg qd，d1-21, q3w
219699567|NCT06447636|DRUG|Sintilimab|Sintilimab：200mg ivdrip, d1, q3w
219699568|NCT06447636|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
219113077|NCT03262090|DRUG|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
219113078|NCT03262090|DRUG|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
219113079|NCT02441205|BEHAVIORAL|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
219113080|NCT05617547|DIAGNOSTIC_TEST|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
219699569|NCT06447636|DRUG|S1|S1：40\~60mg Bid，d1\~14, q3w
219699570|NCT05968105|PROCEDURE|Lateral Sagittal Infraclavicular Block|Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
219699571|NCT05968105|PROCEDURE|Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
219699572|NCT05968105|DIAGNOSTIC_TEST|Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
219699573|NCT06045117|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
219699574|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
219699575|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
219699576|NCT04386785|DEVICE|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
219699577|NCT03188575|BEHAVIORAL|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
219699578|NCT03188575|OTHER|Waiting List|8 week waiting list period.
219699579|NCT03874611|OTHER|electrophysiological data from DBS|For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
219699580|NCT02886351|DRUG|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
219699581|NCT04575870|OTHER|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
219699582|NCT02760888|DRUG|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
219699583|NCT02760888|DRUG|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
219699584|NCT02760888|DRUG|Placebo|Women will receive a Placebo 1 hour before the procedure
219699585|NCT02631681|BEHAVIORAL|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
219699586|NCT04254510|OTHER|Myofascial relaxation technique|"* Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
219699587|NCT03717571|DIAGNOSTIC_TEST|Glenohumeral translation assessment|amount of glenohumeral translation under load
219113081|NCT04396353|OTHER|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
219699588|NCT00306176|DRUG|Rosiglitazone|
219699589|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
219113082|NCT03454217|DRUG|Oxycodone|Postoperative pain treatment with oxycodone
219113083|NCT03454217|DRUG|Tramadol|Postoperative pain treatment with tramadol
219113084|NCT06369961|DRUG|transdermal fentanyl|Adult cancer pain patients switched from oral opioid to TDF
219113085|NCT00004811|DRUG|itraconazole|
219113086|NCT01110720|DRUG|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
219113087|NCT01110720|DRUG|Placebo|Placebo Nasal Spray BID IN 52 weeks
219113088|NCT04675242|DRUG|NCX 4251|NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily
219113089|NCT04675242|DRUG|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
219113090|NCT02903784|DEVICE|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
219113091|NCT02903784|PROCEDURE|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
219113092|NCT02903784|OTHER|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
219699590|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
219699591|NCT01369381|PROCEDURE|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
219699592|NCT05441007|OTHER|Hypoxic|Hypoxic gas mixture Gas mixture of 10% O2 and 90% N2 for six minutes.
219699593|NCT05441007|OTHER|Hypercapnic|Hypercapnic gas mixture Gas mixture of 21% O2, 5% CO2 74% N2 for six minutes.
219699594|NCT05441007|OTHER|Hypoxic and Hypercapnic|Hypoxic and Hypercapnic gas mixture Gas mixture of 10% O2, 5% CO2 85% N2 for six minutes.
219699595|NCT06082440|BIOLOGICAL|Human Umbilical Mesenchymal Stem Cells|Ntra-articular injection inject a corresponding dose of cells suspension into each joint cavity according to the lesion site.
219699596|NCT04585997|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
219699597|NCT04585997|DRUG|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
219113093|NCT03912220|DRUG|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
219699598|NCT04170413|DRUG|CeVUS|Contrast enhanced voiding urosonography
219699599|NCT02346864|BEHAVIORAL|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
219113094|NCT03912220|DRUG|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
219699600|NCT02346864|BEHAVIORAL|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
219699601|NCT03012737|DEVICE|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
219699602|NCT06006156|PROCEDURE|Dental implants placement|surgery for placement of two one-piece trans gingival implants
219113095|NCT05108727|DEVICE|Diode Laser|DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.
219113096|NCT05108727|PROCEDURE|Modified Widman Flap|Periodontal Surgery Technique
219113097|NCT00675545|DRUG|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
219113098|NCT03549611|DRUG|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
219113099|NCT03549611|DRUG|Acetaminophen|Acetaminophen 975mg
219113100|NCT02930564|OTHER|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
219113101|NCT00068666|DRUG|temozolomide|
219113102|NCT00068666|RADIATION|radiation therapy|
219113103|NCT03263182|BEHAVIORAL|Introduction of the Safe Childbirth Checklist|"1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
219699603|NCT02789371|PROCEDURE|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
219699604|NCT02789371|PROCEDURE|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
219699605|NCT03974282|BEHAVIORAL|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
219699606|NCT02174757|DRUG|Inersan|Probiotic
219699607|NCT02174757|DRUG|Doxycycline|Antibiotic
219699608|NCT01880827|PROCEDURE|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
219699609|NCT01880827|DRUG|GIP-infusion|Blood flow and volume during infusion
219699610|NCT01880827|DRUG|GLP-1|Blood flow and volume during infusion
219699611|NCT01880827|DRUG|MMS|Blood flow and volume after meal solution
219699612|NCT01880827|PROCEDURE|Sleeve gastrectomy|as in RYGS group
219699613|NCT01082744|DRUG|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
219699614|NCT01082744|DRUG|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
219699615|NCT00086671|DRUG|ABT-874/Human monoclonal antibody against IL-12|
219699616|NCT00086671|DRUG|Placebo|
219699617|NCT05056961|OTHER|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
219699618|NCT00871156|DRUG|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
219699619|NCT00871156|DRUG|Placebo|Placebo
219113104|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy|Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
219113105|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid|"• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~* Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (\<18); Medium (18-30); High (\>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~* Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place."
219113106|NCT04374929|DEVICE|Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)|"Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads."
219113107|NCT04374929|DEVICE|StealthTrac Lead Only (Control)|A single StealthTrac Lead is placed with no additional treatment.
219113108|NCT02221895|OTHER|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
219113109|NCT02221895|OTHER|Postpartum follow up 6-8wk after delivery|control arm
219224928|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
219699620|NCT04545073|DEVICE|PanOptix|Trifocal IOL with ORA in post refractive patients
219699621|NCT03608826|DEVICE|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
219699622|NCT00183079|BEHAVIORAL|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
219699623|NCT03817281|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
219699624|NCT03122171|OTHER|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
219699625|NCT04858152|PROCEDURE|Follicular Unit Extraction via punch biopsy|Follicular unit extraction will be performed using standard 0.7mm - 1mm punch biopsies. The donor site, which will be selected as a vitiligo-free, hair-bearing area that is not visible per patient's preference, will be harvested via punch biopsies and transplanted to the recipient site, which will be the glabrous skin of the hands or feet.
219699626|NCT04346953|BEHAVIORAL|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
219699627|NCT03035162|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
219699628|NCT05926609|DIETARY_SUPPLEMENT|EB-PA|1 capsule to be taken after breakfast once a day
219699629|NCT05926609|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken after breakfast once a day
219699630|NCT00953030|BEHAVIORAL|COACH|
219699631|NCT00953030|BEHAVIORAL|RealAge|
219699632|NCT06448052|BIOLOGICAL|umbilical cord mesenchymal stem cell|A total of 100 million single cells were suspended in 0.9% sterile saline solution and given intravenously at a 5-ml/min rate for 45 min. All patients will get two intravenous autologous infusions on days 0 (D0) and 90 (D90).
219699633|NCT06171893|BEHAVIORAL|Wavy stress application|"The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively."
219699634|NCT04105179|DEVICE|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
219699635|NCT04105179|DEVICE|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
219699636|NCT05665868|DEVICE|integrated care mode|The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model
219699637|NCT05665868|DEVICE|conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
219699638|NCT02139540|DRUG|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
219699639|NCT02139540|DRUG|Placebo|50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
219699640|NCT04440501|DEVICE|Virtual Reality Goggles to provide education a regarding the gluten free diet.|To watch and participate in a virtual reality educational experience regarding the gluten free diet.
219699641|NCT02139397|DRUG|DFMO|
219699642|NCT02139397|DRUG|Bortezomib|
219699643|NCT00349336|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
219699644|NCT00349336|DRUG|XELOX|As prescribed
219699645|NCT00349336|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
219699646|NCT00349336|DRUG|FOLFOX-4|As prescribed
219699647|NCT00100906|DRUG|IL-2|Immunotherapy with interleukin-2
219699648|NCT00100906|DRUG|ATRA|
219699649|NCT01550133|BEHAVIORAL|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
219699650|NCT01550133|BEHAVIORAL|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
219699651|NCT01550133|BEHAVIORAL|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
219699652|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
219699653|NCT01550133|BEHAVIORAL|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
219699654|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
219699655|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
219699656|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
219699657|NCT02643875|DEVICE|Orthokeratology|It is a kind of rigid permeable lens.
219699658|NCT03710512|PROCEDURE|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
219699659|NCT03951519|OTHER|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
219699660|NCT03951519|OTHER|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
219699661|NCT02866656|OTHER|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
219699662|NCT02866656|DEVICE|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
219699663|NCT02125552|PROCEDURE|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
219699664|NCT02125552|PROCEDURE|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
219699665|NCT02460016|DRUG|AK0529|AK0529 pellets for oral administration
219699666|NCT00975936|DRUG|[14C]-GSK706769|50µg \[14C\]-GSK706769 containing 250 nCi
219699667|NCT00975936|DRUG|Ketoconazole|200 mg Ketoconazole (Q12)
219699668|NCT04400461|OTHER|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
219699669|NCT03524716|BEHAVIORAL|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
219113110|NCT04401553|DRUG|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
219699670|NCT01450488|DRUG|masitinib|masitinib 3 mg/kg/day
219699671|NCT01450488|DRUG|masitinib|masitinib 6 mg/kg/day
219699672|NCT00061581|DEVICE|Isolex 300i Stem Cell Selection|
219699673|NCT04448119|DRUG|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
219699674|NCT04448119|DRUG|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
219699675|NCT06491498|DIAGNOSTIC_TEST|Supraclavicular Brachial Plexus Blockade|Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
219699676|NCT04541355|DRUG|Cisplatin|Given IV
219699677|NCT04541355|OTHER|Hearing Handicap Inventory for Adults - Screening|Patient self-assessment questionnaire to measure probability of hearing impairment
219699678|NCT04541355|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to the standard of care
219699679|NCT04541355|DRUG|Sodium Thiosulfate|Given IV
219699680|NCT03245281|DRUG|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
219113111|NCT04401553|DRUG|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
219699681|NCT03245281|DRUG|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
219699682|NCT03245281|DRUG|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
219113112|NCT03213015|DIAGNOSTIC_TEST|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
219113113|NCT04930458|OTHER|Nanosilver fluoride|Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
219113114|NCT04930458|OTHER|Sodium fluoride with casein phosphopeptides amorphous calcium phosphate|Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
219113115|NCT04930458|OTHER|Sodium fluoride varnish|Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
219113116|NCT03973138|DRUG|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
219113117|NCT02004743|BEHAVIORAL|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
219113118|NCT02004743|OTHER|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
219113119|NCT05963867|DRUG|BI 764532|BI 764532
219113120|NCT05963867|DRUG|[89Zr]Zr-BI 764532|\[89Zr\]Zr-BI 764532
219113121|NCT05514574|OTHER|Music|"hussoni duseni  music"
219699683|NCT06442605|DEVICE|single-channel uterine fibroid morcellation system|Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.
219699684|NCT06442605|DEVICE|Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator|In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
219699685|NCT01326871|DRUG|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
219699686|NCT01326871|DRUG|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
219699687|NCT01326871|BIOLOGICAL|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
219699688|NCT01449253|DRUG|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
219699689|NCT01449253|DRUG|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
219699690|NCT02510339|OTHER|Observation|Administration of two questionnairs during post operative visits.
219699691|NCT05696600|PROCEDURE|Scaling and root planing and open flap debridement|"Scaling and root planing involves removal of plaque and calculus.~Open Flap debridement involves reflection of full thickness mucoperiosteal flap, thorough debridement of the surgical site and approximation and suturing of the flap at the original position."
219699692|NCT05324917|DRUG|Rituximab|Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.
219699693|NCT05324917|DRUG|Rituximab (once a week)|"Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times."
219699694|NCT05901220|BEHAVIORAL|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
219699695|NCT04150315|DIAGNOSTIC_TEST|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
219699696|NCT02084823|BIOLOGICAL|cancer stem cell vaccine|
219699697|NCT03463083|DRUG|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
219113122|NCT05514574|OTHER|Stress ball|Stress ball squeeze
219113123|NCT00282360|DRUG|Trimetazidine|
219113124|NCT02885493|BEHAVIORAL|tests|
219113125|NCT00702182|DRUG|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
219113126|NCT00702182|DRUG|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
219113127|NCT00702182|DRUG|Erlotinib|Daily Oral Erlotinib 100 mg
219113128|NCT01609530|PROCEDURE|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
219113129|NCT01609530|PROCEDURE|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
219113130|NCT00224523|DRUG|GW685698X|
219113131|NCT00224523|DRUG|mometasone furoate|
219113132|NCT02384005|OTHER|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
219113133|NCT01421082|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
219113134|NCT04221061|DRUG|18F-FluorThanatrace|18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
219113135|NCT04415385|DRUG|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
219113136|NCT04415385|DRUG|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
219113137|NCT06033651|RADIATION|x-ray|AP view of pelvis
219113138|NCT05725187|DEVICE|MobiCare|It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
219113139|NCT03560245|DRUG|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
219113140|NCT03560245|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
219113141|NCT05401435|OTHER|Resting measurement of blood pressure and heart rate|Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
219113142|NCT03216902|DRUG|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
219113143|NCT03216902|DRUG|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
219113144|NCT03216902|DRUG|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
219113145|NCT03216902|DRUG|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
219113146|NCT03216902|DRUG|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
219113147|NCT03216902|DRUG|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
219113148|NCT03082833|DRUG|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
219113149|NCT04632732|DIAGNOSTIC_TEST|COVID-19 test|Nasal pharyngeal swab
219113150|NCT04632732|DIAGNOSTIC_TEST|Blood sampling|20cc of blood will be collected each 7 days during 28 days.
219113151|NCT03675074|DEVICE|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
219113152|NCT00150384|DRUG|Amlodipine/Atorvastatin|
219113153|NCT05053217|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
219113154|NCT02913521|DRUG|Diclofenac Sodium Gel 1%|
219113155|NCT02913521|DRUG|Voltaren Gel|
219113156|NCT02913521|DRUG|Placebo|
219113157|NCT03662360|OTHER|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
219113158|NCT00170937|DRUG|valsartan plus hydrochlorothiazide|
219113159|NCT06448455|OTHER|Observation|Collect relevant data of patients
219113160|NCT04356339|DRUG|Interferon-beta-1b (BETASERON, BAY 86-5046)|Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
219113161|NCT01424436|BIOLOGICAL|GSK933776|1mg/kg dose group
219113162|NCT01424436|BIOLOGICAL|GSK933776|3mg/kg dose group
219113163|NCT01424436|BIOLOGICAL|GSK933776|6mg/kg dose group
219113164|NCT05962593|OTHER|Telephone call|The patients will be randomized for a postoperative telephone call
219113165|NCT01850082|PROCEDURE|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
219113166|NCT03936140|DRUG|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
219113167|NCT03936140|DRUG|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
219113168|NCT04879316|OTHER|Resting Energy Expenditure measurement|Resting Energy Expenditure measurement using indirect calorimetry
219113169|NCT00005028|DRUG|bryostatin 1|
219699698|NCT03463083|DRUG|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
219699699|NCT03463083|DRUG|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
219113170|NCT00005028|DRUG|paclitaxel|
219113171|NCT00738452|OTHER|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
219113172|NCT00738452|OTHER|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
219113173|NCT00738452|PROCEDURE|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
219113174|NCT00738452|PROCEDURE|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
219113175|NCT00738452|RADIATION|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
219113176|NCT00738452|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
219113177|NCT03178084|DRUG|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
219113178|NCT03178084|DRUG|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
219699700|NCT03289078|OTHER|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
219113179|NCT03178084|DRUG|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
219113180|NCT02349724|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
219113181|NCT00819065|DRUG|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
219113182|NCT00819065|DRUG|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
219113183|NCT05666375|PROCEDURE|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
219113184|NCT03228017|DRUG|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
219113185|NCT01397565|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
219113186|NCT01397565|PROCEDURE|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
219113187|NCT03344822|DIAGNOSTIC_TEST|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
219113188|NCT03344822|DIAGNOSTIC_TEST|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
219113189|NCT02477397|DRUG|Spiromax Budesonide/formoterol|1\. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
219699701|NCT06515288|BEHAVIORAL|Nutrition Goes To School (NGTS) Program Intervention Package|"The NGTS Program intervention package in this project consists of four components:~1. A comprehensive Nutrition Education to improve healthy eating, physical activity, and hygiene-sanitation practices.~   This is a weekly interactive and fun nutrition and health promotion with different kinds of activities.~2. Healthy School Canteen to improve the availability of healthy food in school. This is an effort to strengthen the school canteen referring to the 4 Pillars of a Healthy School Canteen, including School Commitment and Management, Human Resources, Facilities and Infrastructure, and Food Quality.~3. School Garden. This is a gardening activity as a form of school garden as a media for nutrition education, character building, and contribute to supply vegetables during cooking class sessions in school.~4. Entrepreneurship nutrition. Entrepreneurship nutrition aims to foster entrepreneurial potential and skills among school members in providing healthy food at school."
219699702|NCT06515288|BEHAVIORAL|Nutrition Education Capacity Building for Teachers and Management|The intervention schools will receive Nutrition Education Capacity Building for Teachers and School Management, before the above four NGTS components is implemented in the respective school. Three representatives from each school will be invited to attend a 5-day training that include knowledge on adolescent nutrition and health issues, as well as skills in implementing the NGTS Program.
219699703|NCT03531749|DIETARY_SUPPLEMENT|HIV+ MRPJ|supplemented with (1g/d) MRPJ
219699704|NCT03531749|DIETARY_SUPPLEMENT|HIV+ ascorbic acid|Supplemented with (1g/d) AA
219699705|NCT01200329|DRUG|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
219699706|NCT01200329|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
219699707|NCT01200329|DRUG|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
219699708|NCT01200329|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
219699709|NCT01200329|DRUG|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
219699710|NCT04000178|DEVICE|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
219699711|NCT04000178|DEVICE|silicone stent|silicone stent
219699712|NCT00677898|BEHAVIORAL|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
219699713|NCT00677898|BEHAVIORAL|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
219699714|NCT03279042|PROCEDURE|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
219113190|NCT02477397|DRUG|Diskus Fluticasone/salmeterol|2\. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
219224929|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
219699715|NCT03279042|PROCEDURE|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
219699716|NCT02852460|OTHER|rapid recovery|
219224930|NCT01685268|DRUG|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
219699717|NCT01528410|DEVICE|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
219699718|NCT01528410|PROCEDURE|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
219699719|NCT04659005|OTHER|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
219113191|NCT06167551|OTHER|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
219113192|NCT06167551|OTHER|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
219113193|NCT06167551|OTHER|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
219113194|NCT06167551|OTHER|Contol Group|No intervation
219224931|NCT01685268|DRUG|abiraterone acetate|1000 mg PO daily.
219699720|NCT04659005|OTHER|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
219699721|NCT05684341|COMBINATION_PRODUCT|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
219699722|NCT00525837|DRUG|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
219699723|NCT00525837|DRUG|varenicline|up to 1 mg twice daily
219113195|NCT04545216|OTHER|Long-distance mountain running|Impact of a mountain race on the knee cartilage
219113196|NCT04456335|GENETIC|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
219113197|NCT01468532|DRUG|docetaxel|Given IV
219113198|NCT01468532|DRUG|pasireotide|Given IM
219699724|NCT04375163|OTHER|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
219699725|NCT04375163|OTHER|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
219699726|NCT00029822|DRUG|Alfuzosin (SL770499)|
219699727|NCT03517904|PROCEDURE|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
219699728|NCT03517904|PROCEDURE|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
219699729|NCT01813279|OTHER|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
219699730|NCT01940965|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
219699731|NCT01940965|DRUG|biguanide|Pharmaceutical form:tablet Route of administration: oral
219699732|NCT01940965|DRUG|TZD|Pharmaceutical form:tablet Route of administration: oral
219699733|NCT01940965|DRUG|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
219699734|NCT01940965|DRUG|glinide|Pharmaceutical form:tablet Route of administration: oral
219699735|NCT03087058|DRUG|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
219699736|NCT03087058|DRUG|Patiromer|2 g/day, 4 g/day and 8 g/day
219699737|NCT03087058|DRUG|Patiromer|1 g/day, 2 g/day and 4 g/day
219699738|NCT02717195|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
219699739|NCT02717195|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
219113199|NCT01468532|DRUG|prednisone|Given PO
219113200|NCT02332018|RADIATION|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
219113201|NCT03106519|DRUG|Liposome bupivacaine + bupivacaine|
219113202|NCT01476917|DEVICE|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
219113203|NCT05222425|DRUG|Xagrotin|A herbal compound
219113204|NCT05222425|DRUG|Green tea|Normal green tea
219113205|NCT05175534|PROCEDURE|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
219113206|NCT00589550|BIOLOGICAL|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
219113207|NCT00589550|DRUG|Sorafenib|
219113208|NCT00589550|GENETIC|gene expression analysis|
219113209|NCT00589550|GENETIC|polymerase chain reaction|
219699740|NCT02717195|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
219699741|NCT02717195|DRUG|Lu AF35700|20 mg/day, encapsulated tablets, orally
219699742|NCT00973258|DIETARY_SUPPLEMENT|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
219699743|NCT00973258|OTHER|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
219113210|NCT00589550|GENETIC|reverse transcriptase-polymerase chain reaction|
219113211|NCT00589550|OTHER|flow cytometry|
219113212|NCT00589550|OTHER|immunoenzyme technique|
219113213|NCT00589550|OTHER|laboratory biomarker analysis|
219113214|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
219113215|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
219113216|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
219113217|NCT01755520|DRUG|Ticagrelor|90mg twice daily dose
219113218|NCT01755520|DRUG|Aspirin|Aspirin 100mg once daily
219113219|NCT01755520|DRUG|Placebo - Ticagrelor|Placebo
219113220|NCT01755520|DRUG|Placebo - Aspirin|Placebo
219113221|NCT03441113|DRUG|MMB|Tablet(s) administered orally once daily
219113222|NCT04733196|DRUG|Essential oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219113223|NCT04733196|DRUG|Essential oils in combination with chlorhexidine 0,12%|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219699744|NCT00973258|OTHER|Cognitive Training|"The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
219699745|NCT00973258|OTHER|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
219699746|NCT00973258|OTHER|Placebo|Participants will receive their usual diet and placeboes.
219699747|NCT05437601|DRUG|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
219699748|NCT05437601|OTHER|Placebo|Oral placebo identical to astaxanthin
219699749|NCT03308552|RADIATION|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
219699750|NCT03308552|DRUG|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
219699751|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
219699752|NCT03308552|DRUG|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
219699753|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
219699754|NCT03912038|OTHER|No intervention.|No intervention
219113224|NCT04733196|DRUG|Placebo mouthwash|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219113225|NCT04733196|DRUG|Chlorhexidine 0,20 % in combination with aroma oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219113226|NCT04733196|DRUG|Prebiotic|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219113227|NCT04733196|DRUG|Hydrogen peroxide 0,8 %|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
219699755|NCT02577029|DRUG|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
219699756|NCT02577029|DRUG|entecavir|0.5 mg once daily; oral
219699757|NCT02577029|BIOLOGICAL|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
219699758|NCT02577029|DRUG|tenofovir disoproxil|300 mg once daily; oral
219699759|NCT02577029|DRUG|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
219699760|NCT00049244|DRUG|capecitabine|
219699761|NCT00049244|DRUG|ixabepilone|
219699762|NCT02980081|OTHER|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
219699763|NCT03500978|BEHAVIORAL|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
219699764|NCT02078817|DRUG|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
219699765|NCT01420536|PROCEDURE|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
219699766|NCT04344717|DRUG|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
219699767|NCT04344717|DRUG|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
219699768|NCT02650375|DRUG|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
219699769|NCT01162200|RADIATION|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
219113228|NCT03341650|BEHAVIORAL|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
219224932|NCT01685268|DRUG|Prednisone|5 mg PO twice daily.
219699770|NCT02283398|OTHER|without RIPC|the cuff will be placed around the left arm without being inflated
219113229|NCT03341650|BEHAVIORAL|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
219113230|NCT04398693|DIETARY_SUPPLEMENT|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
219113231|NCT01496508|DEVICE|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
219699771|NCT02283398|PROCEDURE|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
219699772|NCT04352348|OTHER|blood samples|"All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
219699773|NCT04352348|OTHER|feces samples (COVI-BIOME ancillary study)|"All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital"
219699774|NCT04352348|OTHER|sweat samples (COVIDOG ancillary study)|"All arms:~2 sweat samples at inclusion (T0)"
219699775|NCT04352348|OTHER|saliva samples|"All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
219699776|NCT04352348|OTHER|6 minutes walk test|"COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization."
219699777|NCT04352348|OTHER|Phone call|"All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection."
219699778|NCT04352348|OTHER|Urine samples|"All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
219699779|NCT02941640|PROCEDURE|E group|The securing the base of appendix by endoloop.
219113232|NCT02146222|DRUG|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
219113233|NCT02146222|DRUG|docetaxel|Given IV
219699780|NCT02941640|PROCEDURE|S group|The securing the base of appendix by Stapler.
219699781|NCT02941640|PROCEDURE|H group|The securing the base of appendix by Hem-o-lok clip.
219699782|NCT02941640|PROCEDURE|DS group|The securing the base of appendix by DS clip.
219699783|NCT02941640|DEVICE|Endoloop|
219699784|NCT02941640|DEVICE|Stapler|
219699785|NCT02941640|DEVICE|Hem-o-lok clip|
219699786|NCT02941640|DEVICE|DS clip|
219699787|NCT04192331|DRUG|nab-paclitaxel regimen1|nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.
219699788|NCT04192331|DRUG|nab-paclitaxel regimen2|nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
219699789|NCT01590108|DRUG|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
219699790|NCT01590108|DRUG|Saline|Saline
219699791|NCT00405418|DRUG|Insulin glargine|Subcutaneous injection, once a day in the evening
219699792|NCT00405418|DRUG|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
219699793|NCT00826553|DRUG|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
219699794|NCT00826553|DRUG|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
219113234|NCT02146222|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
219113235|NCT02146222|PROCEDURE|positron emission tomography/computed tomography|Undergo FLT PET/CT
219113236|NCT02146222|OTHER|pharmacological study|Correlative studies
219113237|NCT02146222|OTHER|laboratory biomarker analysis|Correlative studies
219113238|NCT02058290|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
219113239|NCT02058290|DRUG|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
219113240|NCT01625910|BEHAVIORAL|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
219113241|NCT02873299|OTHER|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
219113242|NCT02873299|OTHER|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
219113243|NCT02391038|DRUG|MLN0264|MLN0264 IV.
219113244|NCT02959138|DRUG|Lanraplenib.|20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
219113245|NCT03024320|BEHAVIORAL|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
219113246|NCT03024320|BEHAVIORAL|Attention Control|Telecoaching on health-based topics, not including physical activity.
219113247|NCT02158650|BEHAVIORAL|Video-Based Informed Consent|
219113248|NCT02880449|BEHAVIORAL|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
219113249|NCT01463917|DRUG|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
219113250|NCT01463917|DRUG|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
219113251|NCT00006040|BIOLOGICAL|filgrastim|
219113252|NCT00006040|DRUG|etoposide|
219113253|NCT00006040|PROCEDURE|autologous bone marrow transplantation|
219699795|NCT03040401|DRUG|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
219699796|NCT03040401|DRUG|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
219113254|NCT00006040|PROCEDURE|peripheral blood stem cell transplantation|
219113255|NCT00006040|RADIATION|yttrium Y 90 monoclonal antibody M195|
219113256|NCT06455761|DRUG|68Ga-DOTA-NI-FAPI04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
219113257|NCT06455761|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
219113258|NCT02464111|OTHER|Treatment 1: Control|No supplement provided.
219113259|NCT02464111|DIETARY_SUPPLEMENT|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
219113260|NCT02464111|DIETARY_SUPPLEMENT|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
219113261|NCT04213989|DEVICE|Flexitouch Plus and Conservative Care|A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
219113262|NCT04213989|OTHER|Conservative Care|May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
219113263|NCT03660722|OTHER|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
219113264|NCT03055585|BIOLOGICAL|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
219113265|NCT03055585|OTHER|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
219113266|NCT00150410|DRUG|Inhaled insulin|
219224933|NCT03408028|OTHER|Medical File consultation|Medical File consultation
219224934|NCT04921709|OTHER|Medical tests|Blood tests
219699797|NCT03040401|DRUG|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
219699798|NCT04505852|DEVICE|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
219113267|NCT04433793|BEHAVIORAL|Yoga therapy|"One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana)."
219113268|NCT05392387|OTHER|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
219113269|NCT01946243|DRUG|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
219113270|NCT03218761|DIAGNOSTIC_TEST|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
219113271|NCT03218761|DIAGNOSTIC_TEST|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
219113272|NCT03218761|DIAGNOSTIC_TEST|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
219113273|NCT03149263|BEHAVIORAL|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
219113274|NCT00008437|DEVICE|high-intensity focused ultrasound ablation|
219113275|NCT02023138|OTHER|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
219113276|NCT02023138|OTHER|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
219113277|NCT04788290|OTHER|Observational|Rabone D®, Once daily administered per the locally approved product information
219224935|NCT02124252|BEHAVIORAL|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
219224936|NCT02124252|BEHAVIORAL|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
219699799|NCT00296855|DRUG|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
219699800|NCT03513016|DRUG|UBX0101|Investigational drug intra-articular injection
219699801|NCT03513016|OTHER|Placebo|Diluent intra-articular injection
219699802|NCT00143338|DRUG|Inhaled insulin|
219699803|NCT03686553|OTHER|laboratory-based data collection|laboratory-based surveillance of SSI
219699804|NCT01265498|DRUG|obeticholic acid|25 mg daily for 72 weeks
219699805|NCT01265498|DRUG|placebo|placebo capsule, 25 mg daily for 72 weeks
219699806|NCT01502085|DRUG|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
219699807|NCT05171907|BEHAVIORAL|Teleobesity|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
219699808|NCT00968461|DRUG|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
219699809|NCT02055586|OTHER|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
219699810|NCT02055586|DEVICE|positron emission tomography|Undergo FLT-PET/MRI
219699811|NCT02055586|DEVICE|magnetic resonance imaging|Undergo FLT-PET/MRI
219699812|NCT03330509|OTHER|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
219699813|NCT04050033|DEVICE|Evoke Device|Subjects will undergo treatment with Evoke Device
219699814|NCT01652690|BIOLOGICAL|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
219699815|NCT06359899|DRUG|AK0901 capsule|Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
219113278|NCT01373710|DRUG|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
219113279|NCT05794919|DRUG|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
219113280|NCT05794919|DRUG|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
219113281|NCT05762536|DRUG|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
219113282|NCT05762536|DRUG|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
219113283|NCT05103813|DRUG|Beraprost Sodium Tablets|Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
219699816|NCT06359899|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
219699817|NCT05551390|OTHER|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
219113284|NCT02971384|DRUG|Echinaforce|
219113285|NCT00351923|BIOLOGICAL|MeMuRu-OKA (study vaccine)|
219113286|NCT06080230|BEHAVIORAL|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
219113287|NCT05172830|DEVICE|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
219113288|NCT03936296|PROCEDURE|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
219113289|NCT03936296|PROCEDURE|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
219113290|NCT00781742|DRUG|AZD6765|IV once per dosing day, multiple times during the treatment period
219699818|NCT05551390|OTHER|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
219113291|NCT00781742|DRUG|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
219113292|NCT04532151|DIAGNOSTIC_TEST|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
219113293|NCT01439087|DEVICE|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
219113294|NCT02256774|DRUG|BILR 355 BS|
219113295|NCT02256774|DRUG|Combivir®|
219113296|NCT02256774|DRUG|Ritonavir|
219224937|NCT00042965|DRUG|capecitabine|
219113297|NCT00003792|BIOLOGICAL|MART-1 antigen|
219113298|NCT00003792|BIOLOGICAL|filgrastim|
219113299|NCT00003792|BIOLOGICAL|flu matrix peptide p58-66|
219113300|NCT00003792|BIOLOGICAL|gp100 antigen|
219113301|NCT00003792|BIOLOGICAL|recombinant MAGE-3.1 antigen|
219113302|NCT00003792|BIOLOGICAL|tyrosinase peptide|
219113303|NCT00003792|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219113304|NCT02319343|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
219224938|NCT00042965|DRUG|gemcitabine hydrochloride|
219224939|NCT04996225|OTHER|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
219224940|NCT04497545|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
219113305|NCT02319343|DRUG|Isotonic Sodium Chloride|Placebo
219113306|NCT04284761|COMBINATION_PRODUCT|Bicalutamide implant|Biolen bicalutamide implant
219113307|NCT03414788|BIOLOGICAL|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
219113308|NCT03414788|BIOLOGICAL|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
219113309|NCT05827666|DIETARY_SUPPLEMENT|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
219113310|NCT05827666|DIETARY_SUPPLEMENT|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
219113311|NCT05827666|DIETARY_SUPPLEMENT|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
219113312|NCT05827666|DIETARY_SUPPLEMENT|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
219113313|NCT00000206|DRUG|Buprenorphine|
219113314|NCT01428921|BEHAVIORAL|Theory based education and brief motivation interview|"* Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media."
219699819|NCT02799147|PROCEDURE|Allogeneic stem cell transplantation|
219699820|NCT02799147|DRUG|Fludarabine monophosphate|
219699821|NCT02799147|DRUG|Busulfan|
219113315|NCT01189890|DRUG|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
219113316|NCT01189890|DRUG|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
219113317|NCT01189890|DRUG|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
219113318|NCT01189890|DRUG|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
219113319|NCT06542757|RADIATION|1.5 T Elekta Unity MR-Linac system|Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.
219113320|NCT06542757|DEVICE|Hydrogel rectal spacer (SpaceOAR)|A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.
219113321|NCT04384679|DEVICE|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
219113322|NCT06320522|DIETARY_SUPPLEMENT|Ketone Monoester|Commercial dietary supplement intended raise blood ketone body levels
219113323|NCT06320522|DIETARY_SUPPLEMENT|Placebo|Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
219113324|NCT01026909|DRUG|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
219699822|NCT02799147|DRUG|Bendamustine|
219699823|NCT00709332|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
219699824|NCT06139926|DRUG|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
219113325|NCT04691882|BEHAVIORAL|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
219113326|NCT04691882|BEHAVIORAL|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
219113327|NCT04896944|OTHER|No intervention|No intervention
219113328|NCT02831309|BEHAVIORAL|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
219113329|NCT02831309|BEHAVIORAL|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
219113330|NCT02831309|BEHAVIORAL|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
219113331|NCT02831309|BEHAVIORAL|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
219113332|NCT05063305|DIETARY_SUPPLEMENT|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
219113333|NCT05063305|DIETARY_SUPPLEMENT|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
219113334|NCT00542841|PROCEDURE|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
219113335|NCT00376441|PROCEDURE|Vaginal Surgery|patients undergoing vaginal surgery
219224941|NCT04497545|DEVICE|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
219224942|NCT01052766|PROCEDURE|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
219699825|NCT05239663|DRUG|Ganglioside-Monosialic Acid|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
219699826|NCT05239663|DRUG|250ml normal saline (NS)|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
219699827|NCT00617279|DEVICE|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
219699828|NCT00617279|PROCEDURE|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
219113336|NCT04963673|OTHER|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
219113337|NCT03093519|DRUG|KHK6640|Intravenous administration
219113338|NCT03093519|DRUG|Placebo|Intravenous administration
219113339|NCT04607915|BEHAVIORAL|Intervention for TECC Model|The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
219699829|NCT00545025|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
219699830|NCT00545025|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
219699831|NCT03880474|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
219699832|NCT03880474|DRUG|Saline|Sodium Chloride Placebo
219699833|NCT00921024|DRUG|CXA-101|intravenous
219699834|NCT00921024|DRUG|Ceftazidime|intravenous
219699835|NCT03328988|PROCEDURE|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
219699836|NCT03412214|DEVICE|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
219699837|NCT03412214|DEVICE|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
219699838|NCT02028598|DRUG|Treatment 1|An oral single dose administration
219699839|NCT02028598|DRUG|Treatment 2|An oral single dose administration
219699840|NCT02028598|DRUG|Treatment 3|Co-administration of oral single doses
219113340|NCT01662427|OTHER|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
219113341|NCT05534880|OTHER|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
219224943|NCT06475079|OTHER|• FHP app (Pyeongtaek, South Korea) mobile application|FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
219224944|NCT04938453|DRUG|nintedanib 25 mg|soft gelatin capsule
219699841|NCT03225287|DRUG|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
219699842|NCT02842528|BEHAVIORAL|Diagnostic Interview for Genetic Studies|
219699843|NCT02842528|BEHAVIORAL|Family Informant Schedule and Criteria|
219699844|NCT02842528|BEHAVIORAL|Temperament and Character Inventory|
219699845|NCT02842528|BEHAVIORAL|Barratt Impulsiveness Scale|
219113342|NCT03198793|DRUG|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
219699846|NCT02842528|BEHAVIORAL|Wisconsin Card Sorting Test|
219699847|NCT02842528|GENETIC|blood sample withdrawn|
219699848|NCT01749956|RADIATION|Radiation|
219699849|NCT01749956|DRUG|Aflibercept|
219699850|NCT01749956|PROCEDURE|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
219699851|NCT01749956|DRUG|FOLFOX6|
219699852|NCT02239211|DRUG|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
219699853|NCT06609122|OTHER|Animal Assisted Intervention|"Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support."
219699854|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
219699855|NCT03434210|OTHER|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
219699856|NCT03434210|OTHER|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
219113343|NCT00519259|DRUG|Lobeline|
219113344|NCT01155388|DRUG|Ferumoxytol|Experimental: Ferumoxytol
219113345|NCT01155388|DRUG|Oral Iron|Active Comparator: Oral iron
219224945|NCT04938453|DRUG|nintedanib 100 mg|soft gelatin capsule
219224946|NCT02509715|PROCEDURE|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
219699857|NCT03415178|DRUG|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
219699858|NCT03415178|DEVICE|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
219699859|NCT03415178|DEVICE|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
219699860|NCT03415178|DRUG|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
219699861|NCT03415178|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
219699862|NCT01689597|DRUG|Morphine|Comparison of different dosages of drug
219699863|NCT01689597|DRUG|Placebo|
219699864|NCT03062371|BEHAVIORAL|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
219699865|NCT00523432|DRUG|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
219699866|NCT00523432|DRUG|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
219699867|NCT06612658|DIETARY_SUPPLEMENT|A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids|This study will investigate the effect of the supplement on exercise performance.
219699868|NCT01138020|BEHAVIORAL|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
219699869|NCT01138020|BEHAVIORAL|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
219699870|NCT02471573|PROCEDURE|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
219699871|NCT02471573|PROCEDURE|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
219699872|NCT04030598|DRUG|Donidalorsen|Donidalorsen administered SC
219699873|NCT04030598|DRUG|Placebo|Placebo matching solution administered SC
219699874|NCT04258072|DRUG|Vactosertib|Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
219699875|NCT03150459|DRUG|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
219699876|NCT03150459|DRUG|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
219699877|NCT03150459|DRUG|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
219113346|NCT03710213|BEHAVIORAL|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
219113347|NCT02891239|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
219113348|NCT03943589|DRUG|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
219699878|NCT03150459|OTHER|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
219113349|NCT02710331|DRUG|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
219699879|NCT03150459|OTHER|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
219699880|NCT01872962|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
219699881|NCT01872962|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
219699882|NCT01916200|DRUG|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
219699883|NCT07045584|DEVICE|Transcranial Alternating Current Stimulation|Intervention Group（tACS）: Receive tACS stimulation targeting the temporal pole, with stimulation frequency of 40Hz, using adapter power supply: voltage 9V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
219113350|NCT02710331|DRUG|Placebo|Control: no alcohol, administered for \~80 minutes.
219113351|NCT02710331|DRUG|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
219113352|NCT02710331|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
219113353|NCT00889382|DRUG|OSI-906|Administered orally
219113354|NCT00889382|DRUG|Paclitaxel|Administered intravenously
219113355|NCT03675724|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
219113356|NCT03675724|DRUG|Placebo oral capsule|Placebo
219113357|NCT02338921|DRUG|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
219699884|NCT07045584|DEVICE|transcranial Temporal Interference Stimulation|Intervention Group（tTIS）: Receive tTIS targeting the temporal pole, with stimulation frequency of 2040/2000HZ, using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
219699885|NCT02377869|OTHER|No intervantion|
219699886|NCT01941394|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells infusion
219699887|NCT05418803|DRUG|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
219699888|NCT05418803|DRUG|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
219699889|NCT00747916|DEVICE|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
219113358|NCT02338921|DRUG|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
219113359|NCT02338921|DRUG|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
219113360|NCT02338921|DRUG|Glimepirde|
219113361|NCT02338921|DRUG|Metformin|
219699890|NCT02025283|PROCEDURE|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
219699891|NCT02107846|DRUG|PRX-112|
219699892|NCT02974933|DRUG|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
219699893|NCT05817162|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
219699894|NCT05817162|PROCEDURE|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
219699895|NCT05817162|DRUG|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
219699896|NCT05817162|DRUG|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
219699897|NCT03416348|DRUG|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
219699898|NCT03416348|DRUG|Alcohol|Placebo
219113362|NCT03806049|DRUG|Niraparib|given orally once daily
219113363|NCT03806049|DRUG|Bevacizumab|given as iv infusion every three weeks
219699899|NCT00168948|DRUG|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
219699900|NCT06107998|OTHER|stethoscope|endotracheal tube cuff will be inflated via stethoscope guidance
219699901|NCT06107998|OTHER|Audible leak/Balloon palpation|endotracheal tube cuff will be inflated via audible leak/balloon palpation method
219699902|NCT02394769|DRUG|Aspirin|
219699903|NCT02394769|DRUG|Placebo for Aspirin|
219699904|NCT04630184|BEHAVIORAL|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
219699905|NCT04630184|BEHAVIORAL|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
219699906|NCT04630184|BEHAVIORAL|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
219113364|NCT03806049|DRUG|TSR042|Given as IV infusion every three weeks
219699907|NCT03539094|OTHER|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
219699908|NCT01662544|PROCEDURE|Oxygen delivery|
219699909|NCT04277780|DEVICE|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
219699910|NCT04277780|OTHER|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
219699911|NCT00001475|DRUG|IL-2 plus Anti-TNF or Thalidomide|
219699912|NCT04378335|OTHER|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
219699913|NCT02461212|PROCEDURE|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
219113365|NCT03806049|DRUG|Carboplatin|given as iv infusion every three weeks
219113366|NCT03806049|DRUG|Paclitaxel|given as iv infusion every three weeks
219113367|NCT05599880|DRUG|Bortezomib|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
219113368|NCT04096807|OTHER|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
219113369|NCT03813095|DRUG|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
219113370|NCT03813095|DRUG|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
219113371|NCT03494374|DEVICE|UCBL orthosis|toe walking exercise
219113372|NCT00900627|DRUG|AZD8931|Tablet Oral bid
219113373|NCT00900627|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
219113374|NCT00900627|DRUG|Placebo|Oral bid (twice daily)
219113375|NCT04027790|DIAGNOSTIC_TEST|Epi proColon|Analysis of DNA methylation status for Septin9 and additional biomarkers
219113376|NCT03325335|DRUG|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
219699914|NCT01340690|DIETARY_SUPPLEMENT|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
219699915|NCT01340690|DIETARY_SUPPLEMENT|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
219699916|NCT05944640|PROCEDURE|Intraocular surgery|Pars plana vitrectomy or cataract surgery.
219113377|NCT03325335|DRUG|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
219113378|NCT03325335|DRUG|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
219113379|NCT00373295|DRUG|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
219113380|NCT00373295|DRUG|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
219113381|NCT00373295|DRUG|Placebo|
219113382|NCT00830947|DEVICE|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
219113383|NCT00830947|DEVICE|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
219113384|NCT01306565|DRUG|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
219113385|NCT01306565|DRUG|High dose atorvastatin|80mg daily atorvastatin for 72 hours
219699917|NCT00032591|PROCEDURE|Weekly patient self-testing of prothrombin time|
219699918|NCT00032591|OTHER|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
219113386|NCT05742724|DRUG|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
219113387|NCT04217070|OTHER|Questionnaire|Questionnaire including demographic data, data regarding poisoning substance and outcomes of suicidal attempts
219699919|NCT00367926|DRUG|American ginseng root / polysaccharides|
219699920|NCT00000972|BIOLOGICAL|MTP-PE/MF59|
219699921|NCT00000972|BIOLOGICAL|Env 2-3|
219699922|NCT05348304|DIETARY_SUPPLEMENT|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
219699923|NCT03614104|BEHAVIORAL|Mobile Health Technology (short message service)|Health education through mobile technology with Short Message Service (SMS)
219699924|NCT01953991|DEVICE|Dentures|Removable prosthesis to replace missing teeth
219699925|NCT05892237|PROCEDURE|bronchial artery interventional therapy|After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
219113388|NCT02025452|OTHER|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
219113389|NCT02025452|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
219113390|NCT02025452|OTHER|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
219699926|NCT05892237|DRUG|Chemotherapy drug|Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
219113391|NCT04039074|BEHAVIORAL|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
219113392|NCT04039074|BEHAVIORAL|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
219113393|NCT04039074|BEHAVIORAL|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
219113394|NCT03985163|OTHER|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
219113395|NCT02854306|PROCEDURE|Bariatric surgery|With mindfulness programm
219113396|NCT02854306|PROCEDURE|Bariatric surgery|Without mindfulness programm
219113397|NCT02137538|DRUG|Letrozole|
219113398|NCT02137538|DRUG|Anastrozole|
219113399|NCT01649596|DEVICE|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
219113400|NCT01649596|OTHER|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
219224947|NCT02966652|DRUG|DITEST|Lipid formulation of native oral testosterone.
219224948|NCT02966652|DRUG|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
219699927|NCT05892237|RADIATION|IMRT|60Gy/2Gy/30f
219699928|NCT05892237|DRUG|Immunotherapy|PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
219699929|NCT00660452|DRUG|Staloral|Sublingual immunotherapy with Staloral dust mites solution
219699930|NCT04494698|DEVICE|Duotherm VibraCool Back Device|Active New multimodal pain device
219699931|NCT04494698|DEVICE|TENS 8-channel unit|LG Smart TENS unit
219699932|NCT05519865|DRUG|Tucidinostat|30mg orally BIW
219699933|NCT05519865|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
219113401|NCT02702258|BEHAVIORAL|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
219113402|NCT00883103|DRUG|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
219113403|NCT00883103|DRUG|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
219113404|NCT00962585|DRUG|Placebo|
219113405|NCT00962585|DRUG|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)"
219113406|NCT06146309|DRUG|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
219113407|NCT05666700|BIOLOGICAL|Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent|Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
219113408|NCT03638856|DRUG|Misoprostol 200Mcg Tab|patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
219113409|NCT03503838|BEHAVIORAL|Online Yoga|12 weeks of online yoga; 60 min/week
219113410|NCT00415493|OTHER|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
219113411|NCT00415493|OTHER|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
219113412|NCT02254421|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
219113413|NCT02254421|DRUG|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
219113414|NCT02743286|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
219113415|NCT02743286|BEHAVIORAL|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
219113416|NCT02743286|BEHAVIORAL|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
219113417|NCT05346796|BEHAVIORAL|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
219113418|NCT02279147|DRUG|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
219113419|NCT05235763|OTHER|activity coach|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
219113420|NCT05235763|OTHER|sham activity coach|The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
219113421|NCT05464576|DIAGNOSTIC_TEST|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
219113422|NCT03896451|DEVICE|Total knee endoprothesis|Total knee endoprosthesis after knee joint osteoarthritis
219113423|NCT04037995|OTHER|No intervation|No intervation
219113424|NCT05253690|PROCEDURE|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
219113425|NCT06341517|DEVICE|iTBS|Intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses for up to 8 sessions daily for 5 days
219113426|NCT04375696|DRUG|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
219113427|NCT04375696|OTHER|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
219113428|NCT03092960|BEHAVIORAL|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
219113429|NCT03092960|BEHAVIORAL|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
219113430|NCT04621136|DRUG|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
219113431|NCT02415218|BIOLOGICAL|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
219113432|NCT00272766|DRUG|pegaptanib sodium|
219113433|NCT01033773|DRUG|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
219113434|NCT01033773|BEHAVIORAL|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
219699934|NCT06909240|OTHER|Progressive gait training|The focus of the intervention is on exercises that can improve venous return, and consists of progressive gait training at moderate and high intensity as well as guidance on progressive gait training. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to obtain 30 mins/day of gait training at moderate intensity. After 14 days, the patient receives physiotherapist guidance via telephone on progressive gait training and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achive 2 x 20 mins/week of muscle-strengtening activities at moderate or greater intensity. After one and two months of training, the patient will be guided via telephone on maintaining their current level of physical activity or possibly on further progression.
219699935|NCT06909240|OTHER|Standard Care (in control arm)|Standard care encompasses standard diagnostics with compression ultrasound examination, and a treatment procedure with anticoagulant medication, and compression stockings class III. Standard care also involves visits to the outpatient anticoagulation clinic, where patients with DVT are required to attend treatment sessions within the first 14 days and 90 days after diagnosis. Standard care will serve as a comparator to reflect the current treatment regimen.
219113435|NCT01972334|BIOLOGICAL|FMT|as explained in study arm
219113436|NCT01972334|BIOLOGICAL|placebo|salt water or saline will be given as placebo
219113437|NCT02701946|PROCEDURE|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
219113438|NCT02701946|PROCEDURE|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
219113439|NCT00839917|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
219113440|NCT00839917|BIOLOGICAL|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
219113441|NCT03246425|OTHER|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
219113442|NCT03246425|DEVICE|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
219224949|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety normal nebulizer and mask+ distraction|Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
219224950|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety a toy nebulizer and a toy mask|Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
219224951|NCT03169933|RADIATION|Combined, intensified and modulated adjuvant radiotherapy|
219224952|NCT02978066|OTHER|Spinal anaesthesia|
219699936|NCT01860859|PROCEDURE|Closure of the hysterotomy at the time of primary cesarean|
219699937|NCT07129096|BEHAVIORAL|Applied Relaxation|Applied relaxation method developed by psychologists from progressive relaxation is used. The method is trained using a web application (Relappy.app), which contains step-by-step instructions with self-instructed exercises and exercise diaries, in which the examinee records his/her level of tension before and after the exercise (on a scale of 0-100, where 0 means a completely relaxed state, 50 a normal state (neither relaxed nor tense) and 100 maximum tenseness.
219113443|NCT01770249|PROCEDURE|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
219113444|NCT01254565|DRUG|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
219113445|NCT01254565|DRUG|Placebo|Administered intravenously at the end of hemodialysis
219113446|NCT00472186|DRUG|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
219113447|NCT00472186|DRUG|Placebo|Placebo will also be administered based on weight.
219699938|NCT07129096|DEVICE|Occlusal splint|The splint group is treated with occlusal splint, which is a conventional treatment method in cases where the implementation of information and self-care methods has not given a sufficient treatment response. The splint is prepared for night use and controlled according to the usual protocol.
219699939|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with insertion of a plastic stent.|A plastic stent was placed during the initial ERCP, with elective stone removal scheduled 8-12 weeks later.
219113448|NCT01389063|DRUG|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
219113449|NCT05604287|DRUG|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
219113450|NCT05604287|DRUG|Placebo|The participant will receive a oral dose of Placebo.
219113451|NCT05872828|OTHER|No intervention|Observational study. No intervention will be adopted.
219113452|NCT02961855|DRUG|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
219113453|NCT02961855|DRUG|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
219113454|NCT05891418|BEHAVIORAL|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
219113455|NCT05891418|BEHAVIORAL|Standard notice of eligibility determination|No extra outreach during intervention period.
219113456|NCT03354637|DRUG|ATI-50002 high dose|Topical solution
219113457|NCT03354637|DRUG|ATI-50002 low dose|Topical solution
219113458|NCT03354637|DRUG|Placebo|Topical solution
219113459|NCT05334823|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219113460|NCT05571995|BEHAVIORAL|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
219113461|NCT02726399|DRUG|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
219113462|NCT02726399|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
219113463|NCT02726399|DRUG|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
219113464|NCT02726399|DRUG|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
219699940|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with immediate stone extraction attempts.|Immediate ERCP for stone removal, utilizing conventional techniques such as basket, balloon, or mechanical lithotripsy as needed.
219699941|NCT01320397|DRUG|Rostafuroxin|6 microgram capsules
219113465|NCT06073028|OTHER|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
219113466|NCT03202030|PROCEDURE|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
219113467|NCT03202030|PROCEDURE|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
219113468|NCT04238403|BEHAVIORAL|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
219113469|NCT04438096|DRUG|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
219699942|NCT01320397|DRUG|Rostafuroxin|50 micrograms capsules
219699943|NCT01320397|DRUG|Rostafuroxin|500 micrograms capsules
219699944|NCT01320397|DRUG|Losartan|Losartan 50 mg once a day
219699945|NCT01866254|DRUG|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
219699946|NCT01866254|DRUG|Morphine|Injection of 200 mcg of intrathecal morphine
219699947|NCT02603133|BEHAVIORAL|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
219699948|NCT02603133|BEHAVIORAL|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
219699949|NCT02603133|BEHAVIORAL|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
219699950|NCT02603133|BEHAVIORAL|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
219113470|NCT04438096|DRUG|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
219113471|NCT04438096|DRUG|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
219113472|NCT04438096|DRUG|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
219113473|NCT00433576|DRUG|resveratrol|Given orally
219113474|NCT00433576|OTHER|pharmacological study|Correlative studies
219113475|NCT00433576|OTHER|laboratory biomarker analysis|Correlative studies
219113476|NCT02693912|PROCEDURE|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
219113477|NCT06403241|OTHER|2000 meter ergometer test|Rowers performed 2000m ergometer test.A 2,000-m time trial is a standard test used to assess performance in rowers.
219113478|NCT05652764|OTHER|Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients|In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
219113479|NCT02438462|OTHER|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
219113480|NCT03110328|DRUG|MK3475|anti-PD1 immunotherapy
219113481|NCT00519675|DRUG|alitretinoin|
219699951|NCT02603133|BEHAVIORAL|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
219113482|NCT04253704|COMBINATION_PRODUCT|IDL lotion|IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
219113483|NCT04253704|COMBINATION_PRODUCT|Control lotion|Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
219699952|NCT00303043|PROCEDURE|Mixed venous saturation monitoring|Mixed venous saturation monitoring
219113484|NCT01327937|DEVICE|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
219699953|NCT01950702|PROCEDURE|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
219699954|NCT01950702|PROCEDURE|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
219699955|NCT02898467|OTHER|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
219113485|NCT01327937|OTHER|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
219699956|NCT02898467|OTHER|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
219699957|NCT03950804|DRUG|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
219699958|NCT00719667|OTHER|coronary artery bypass grafting|on pump off pump
219699959|NCT02733419|DRUG|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
219699960|NCT02733419|DRUG|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
219699961|NCT05252338|BIOLOGICAL|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
219699962|NCT00008697|DRUG|arsenic trioxide|
219699963|NCT04686032|OTHER|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
219699964|NCT04686032|OTHER|Early ambulation|Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
219699965|NCT00901641|DEVICE|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
219699966|NCT02349438|DEVICE|senofilcon A|A soft spherical contact lens
219699967|NCT02349438|DEVICE|lotrafilcon B|
219699968|NCT03029390|DIETARY_SUPPLEMENT|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
219699969|NCT03029390|DRUG|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
219699970|NCT03659344|DRUG|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
219113486|NCT04054895|DEVICE|Lead placed in the His-Purkinje system in order to achieve QRS shortening.|Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
219113487|NCT04054895|DEVICE|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
219699971|NCT01258374|DRUG|Raltegravir|Raltegravir, 400 mg bid
219113488|NCT02004860|DRUG|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
219113489|NCT02004860|DRUG|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
219113490|NCT01379820|DEVICE|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
219113491|NCT03871049|DRUG|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
219113492|NCT03871049|DRUG|Bupivacaine|bupivacaine
219113493|NCT04376411|DIAGNOSTIC_TEST|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
219699972|NCT01258374|DRUG|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
219224953|NCT00075998|DRUG|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
219699973|NCT06399159|PROCEDURE|Thyroidectomy and lymph node dissection|All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
219699974|NCT00079976|DRUG|Tigecycline|
219699975|NCT03932708|BEHAVIORAL|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
219699976|NCT00560963|DRUG|everolimus|
219699977|NCT02957201|OTHER|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
219113494|NCT04376411|DIAGNOSTIC_TEST|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
219113495|NCT04376411|DIAGNOSTIC_TEST|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
219113496|NCT02564055|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
219113497|NCT02564055|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
219113498|NCT02564055|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
219113499|NCT00697021|DRUG|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
219113500|NCT00697021|DRUG|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
219113501|NCT01599416|DIETARY_SUPPLEMENT|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
219113502|NCT04027205|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
219113503|NCT04027205|PROCEDURE|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation
219113504|NCT00773071|DEVICE|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
219113505|NCT00615602|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
219113506|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
219113507|NCT00615602|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
219113508|NCT00615602|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
219113509|NCT00615602|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
219113510|NCT00615602|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
219113511|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
219113512|NCT04747275|DRUG|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
219113513|NCT04747275|DRUG|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
219113514|NCT05351736|DRUG|Lurasidone|Treatment with lurasidone
219113515|NCT05912530|OTHER|no intervention|there is no intervention will done
219113516|NCT02360774|DRUG|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
219113517|NCT02360774|DRUG|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
219113518|NCT06002061|DEVICE|NovaResp MAPR System|"Baseline measurements will be taken while the subject is awake. Genioglossus activity with maximal tongue protrusion will be measured as well as the response to 1 to 2 pressure routines. Once the subject is sleeping, the operator will observe the PSG recording and determine sleep stage and respiratory phase (inspiration, expiration, between breaths). Test routines will be performed for each sleep stage and each respiratory phase. If the operator notices an apnea occurring, one of the routines will be applied. When all manual tests are complete, an automatic mode will be engaged for the remainder of the night. During this mode, a previously developed and trialled AI model will be used to predict if an obstructive apnea is upcoming. The operator will input which routine to test, and the routine will be automatically applied when a prediction occurs. There will be a minimum of 60 seconds between pressure routine applications."
219113519|NCT00447330|DRUG|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
219113520|NCT05498766|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
219113521|NCT05498766|DRUG|Oxaliplatin|Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
219113522|NCT05498766|DRUG|Tegafur, Gimeracil and Oteracil Potassium|Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
219113523|NCT00921297|PROCEDURE|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
219113524|NCT05675917|DEVICE|MacuTest platform|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
219224954|NCT01232166|OTHER|Auscultation|
219113525|NCT03268590|DRUG|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
219113526|NCT00531011|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
219113527|NCT00531011|DEVICE|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
219113528|NCT05719285|DRUG|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
219113529|NCT05719285|DRUG|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
219113530|NCT02139982|PROCEDURE|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
219699978|NCT04902781|DRUG|AT-007|Treatment with AT-007 given orally
219699979|NCT04902781|OTHER|Placebo|Placebo given orally
219699980|NCT04936893|BEHAVIORAL|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
219699981|NCT04936893|BEHAVIORAL|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
219699982|NCT04968704|OTHER|3D photography and computer modelling|3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
219699983|NCT04064268|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
219699984|NCT04064268|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
219699985|NCT02791269|DRUG|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
219699986|NCT04831710|DRUG|Sintilimab|Sintilimab,200mg, ivd, d1
219699987|NCT04831710|DRUG|Chidamide|Chidamide,30mg,po,biw,d1-21
219699988|NCT04546763|DEVICE|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
219113531|NCT02139982|DRUG|ropivacaine|Different concentration of ropivacaine
219113532|NCT02971891|DRUG|CLS006 (Furosemide) Topical Gel|
219113533|NCT02971891|DRUG|Vehicle Topical Gel|
219113534|NCT01777243|DRUG|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
219113535|NCT01777243|DRUG|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
219224955|NCT01232166|OTHER|Observation of symmetric chest movements|
219699989|NCT04546763|DEVICE|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
219699990|NCT05676658|BEHAVIORAL|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
219699991|NCT05676658|BEHAVIORAL|Placebo coherent breathing|Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
219699992|NCT01621074|DIETARY_SUPPLEMENT|Sodium bicarbonate|Ergogenic effect
219699993|NCT01621074|DIETARY_SUPPLEMENT|Placebo|Placebo effect
219699994|NCT02329158|DRUG|6% hydroxyethyl starch|
219699995|NCT04553419|DRUG|Cephalexin|Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin
219699996|NCT04553419|DRUG|Placebo|Cellulose capsules or suspension
219699997|NCT02950389|DEVICE|PMMA filter|
219699998|NCT02950389|DEVICE|HFR17 filter|
219699999|NCT02950389|DEVICE|F7 filter|
219700000|NCT03968809|DIAGNOSTIC_TEST|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
219700001|NCT02305316|DRUG|BIA 9-1067 non-micronized|
219700002|NCT02305316|DRUG|BIA 9-1067 micronized|
219113536|NCT04592536|DRUG|CVL-865 High dose|High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
219113537|NCT04592536|DRUG|Alprazolam 1mg XR|Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
219113538|NCT04592536|DRUG|Placebo|Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
219113539|NCT04592536|DRUG|CVL-865 low dose|Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
219113540|NCT05119413|DRUG|New trio de Kligman|Once daily application in addition to the same sunscreen
219113541|NCT05119413|DRUG|Trio Kligman|Once daily application in addition to the same sunscreen
219113542|NCT03262337|OTHER|none, this is an observational study|none, this is an observational study
219113543|NCT02786043|DRUG|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
219113544|NCT02919943|PROCEDURE|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
219700003|NCT04948918|PROCEDURE|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
219700004|NCT02474836|BIOLOGICAL|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
219700005|NCT02474836|BIOLOGICAL|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
219113545|NCT04117061|PROCEDURE|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
219113546|NCT02929342|DRUG|Pitolisant|
219113547|NCT02929342|RADIATION|[14C]-Pitolisant|
219113548|NCT06010121|DIETARY_SUPPLEMENT|Liposomal Vitamin D|2000 IU of cholecalciferol in liposomal formulation
219113549|NCT06010121|DIETARY_SUPPLEMENT|Traditional Vitamin D|2000 IU of cholecalciferol in traditional formulation
219113550|NCT06475196|DRUG|Sintilimab (PD-1 inhibitor)|to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
219113551|NCT02565355|OTHER|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
219113552|NCT02565355|OTHER|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
219113553|NCT05153278|BIOLOGICAL|Packed red blood cells|Standard treatment for iron deficiency anemia (control)
219113554|NCT05153278|DRUG|Intravenous drug|Experimental treatment for iron deficiency treatment
219113555|NCT02774343|DRUG|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
219113556|NCT02774343|DRUG|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
219113557|NCT02774343|BEHAVIORAL|Therapy|Cognitive-behavioral therapy 1 hour per week
219113558|NCT02774343|BEHAVIORAL|Contingency Management|Prize-based contingency management for attendance
219113559|NCT03477461|DRUG|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
219113560|NCT00179283|DRUG|sertraline|
219113561|NCT00179283|DRUG|venlafaxine XR|
219113562|NCT01705470|DRUG|furosemide|
219113563|NCT01705470|DRUG|placebo normal saline|
219113564|NCT00549419|DRUG|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
219113565|NCT00549419|DRUG|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
219113566|NCT00549419|DRUG|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
219113567|NCT03817346|DRUG|GT-002|Single ascending dose
219113568|NCT03817346|DRUG|Placebo oral capsule|Comparator single ascending dose
219113569|NCT03701009|PROCEDURE|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
219113570|NCT03701009|PROCEDURE|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
219113571|NCT03701009|PROCEDURE|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
219224956|NCT01232166|OTHER|Tube depth|
219113572|NCT04907487|DEVICE|MRI|"MRI of routine care includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~* SWI QSM 1.0iso 8 echoes (10 minutes)~* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)"
219113573|NCT00365495|PROCEDURE|Physical training (aerobic training)|
219700006|NCT02474836|BIOLOGICAL|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
219700007|NCT01138241|OTHER|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients"
219113574|NCT05552729|DRUG|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
219113575|NCT02173535|DEVICE|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
219113576|NCT02173535|DEVICE|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
219113577|NCT02173535|DEVICE|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
219113578|NCT02173535|DEVICE|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
219224957|NCT01232166|OTHER|All three|
219224958|NCT00284466|PROCEDURE|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
219113579|NCT02173535|DEVICE|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
219113580|NCT03208400|BEHAVIORAL|virtual reality exposure|one-session exposure conveyed via virtual reality technology
219113581|NCT06067529|DRUG|hormone replacement therapy|hormone replacement therapy
219113582|NCT03318952|DRUG|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
219113583|NCT03318952|DRUG|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
219113584|NCT04005547|BEHAVIORAL|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up
219700008|NCT05072808|OTHER|View PACCI-ED and referral recommendations|Results of parent completed PACCI-ED and referral recommendations
219700009|NCT01799941|DRUG|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
219700010|NCT01398241|DRUG|RO5267683|Multiple ascending doses
219700011|NCT01398241|DRUG|placebo|Multiple ascending doses
219700012|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
219700013|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
219700014|NCT04780399|DRUG|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
219700015|NCT00420745|BIOLOGICAL|Rotarix™|Two-dose oral vaccination.
219700016|NCT00420745|BIOLOGICAL|Placebo|Two-dose oral administration
219700017|NCT00818935|DIETARY_SUPPLEMENT|Low-Intermediate-Glycemic Index diets|
219700018|NCT00818935|DIETARY_SUPPLEMENT|High GI diet|
219700019|NCT03515408|DEVICE|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
219113585|NCT02821520|DRUG|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
219113586|NCT02821520|PROCEDURE|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
219113587|NCT02821520|PROCEDURE|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
219113588|NCT03064893|DEVICE|Alloderm|Reconstruction material
219113589|NCT03064893|DEVICE|Dermacell|Reconstruction material
219113590|NCT02682498|DRUG|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
219700020|NCT00247234|BEHAVIORAL|Schema Therapy|group based schema therapy
219700021|NCT00247234|BEHAVIORAL|standard care|standard psychiatric out-patient care
219700022|NCT01125930|DRUG|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
219700023|NCT01125930|DRUG|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
219700024|NCT00666770|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
219700025|NCT00666770|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
219700026|NCT00666770|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
219700027|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
219700028|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
219700029|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
219700030|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
219700031|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
219700032|NCT03098979|DRUG|Placebo|Orally once daily for 20 weeks
219700033|NCT02369653|DRUG|Apixaban|
219700034|NCT02369653|OTHER|No systemic anticoagulant prophylaxis|
219700035|NCT05634291|OTHER|Standard of care|Standard of care as prescribed by healthcare provider.
219700036|NCT05634291|DEVICE|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
219700037|NCT03847493|OTHER|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
219700038|NCT05092087|BEHAVIORAL|nutrition counseling|nutrition counseling
219700039|NCT03720587|OTHER|Semi-structured interviews|Semi-struuctured telephone interviews
219113591|NCT02682498|DRUG|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
219113592|NCT04192812|DRUG|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
219113593|NCT04192812|DRUG|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
219113594|NCT02763540|PROCEDURE|Lung cryobiopsy|Transbronchial cryobiopsy
219113595|NCT03100565|DRUG|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
219700040|NCT04989933|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
219700041|NCT02362022|DRUG|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
219700042|NCT00425919|DRUG|PPM-204|
219700043|NCT04363476|OTHER|SHRED Osteoarthritis program|Combined exercise and education intervention
219700044|NCT05510453|OTHER|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
219700045|NCT03595098|BEHAVIORAL|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
219700046|NCT03595098|BEHAVIORAL|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
219700047|NCT03434262|DRUG|Gemcitabine|Given intravenously (IV).
219700048|NCT03434262|DRUG|ribociclib|Given orally (PO).
219700049|NCT03434262|DRUG|sonidegib|Given PO.
219700050|NCT03434262|DRUG|trametinib|Given PO.
219700051|NCT03434262|BIOLOGICAL|filgrastim|Given subcutaneously (SQ).
219700052|NCT06190366|PROCEDURE|Bloodletting acupuncture at the fossa poplitea|This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
219700053|NCT06190366|PROCEDURE|Bloodletting acupuncture at the regio glutaea|This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
219113596|NCT03100565|OTHER|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
219113597|NCT03026569|OTHER|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
219113598|NCT01015261|PROCEDURE|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
219113599|NCT01015261|PROCEDURE|Chemotherapy|"1. Cyclophosphamide 1200 mg/m2 D15~2. Daunorubicin 45 mg/m2 D15-D18~3. Vincristine 1 mg/m2 D15, D22~4. Dexamethasone 24 mg/d D12-D28"
219113600|NCT04946305|OTHER|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
219113601|NCT03841344|DEVICE|MRI|Evaluation of the utility of candidate endpoints in PAH trials
219113602|NCT03317210|DRUG|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
219113603|NCT03317210|DRUG|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
219113604|NCT00165269|PROCEDURE|Mantle irradiation|Limited to above the diaphragm
219113605|NCT05931705|OTHER|questionnaire|questionnaire
219700054|NCT05255822|DRUG|INNA-051|Liquid for intra-nasal administration
219700055|NCT05255822|OTHER|Placebo|Liquid for intra-nasal administration
219113606|NCT02263144|PROCEDURE|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
219113607|NCT00018161|DRUG|Mecamylamine|
219113608|NCT00018161|DRUG|Nicotine Patch|
219113609|NCT00018161|BEHAVIORAL|Cigarette brand switching|
219113610|NCT01754779|DIETARY_SUPPLEMENT|Placebo|3 tablets twice daily of matching placebo during the placebo phase.
219113611|NCT01754779|DIETARY_SUPPLEMENT|Citric Acid|3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)
219113612|NCT01754779|DIETARY_SUPPLEMENT|Potassium Citrate|2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
219700056|NCT02827539|DEVICE|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
219700057|NCT02827539|DEVICE|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
219700058|NCT00202488|DRUG|H. pylori treatment|
219700059|NCT03157089|DRUG|Afatinib|Film-coated tablet
219700060|NCT03157089|DRUG|pembrolizumab|Solution for infusion
219700061|NCT05622903|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
219700062|NCT05622903|OTHER|No Cash Benefit|No monthly cash benefit.
219700063|NCT00487591|DRUG|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
219700064|NCT00487591|DRUG|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
219700065|NCT00250484|DEVICE|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
219700066|NCT00250484|DEVICE|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
219700067|NCT03661918|BEHAVIORAL|In-Person First Session|Conduct first session in person vs. over the phone
219700068|NCT03661918|BEHAVIORAL|Second Caregiver|Have second caregiver participate in three coaching calls
219700069|NCT03661918|BEHAVIORAL|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
219700070|NCT03661918|BEHAVIORAL|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
219700071|NCT06327594|DIAGNOSTIC_TEST|ultrasound scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.
219700072|NCT06327594|DIAGNOSTIC_TEST|CT/MRI scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
219700073|NCT04710121|OTHER|Virtual Reality Glasses|Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
219700074|NCT00345267|DEVICE|Integrated Care Pathway|
219700075|NCT02453607|DRUG|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
219700076|NCT02453607|DRUG|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
219700077|NCT02356120|OTHER|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
219700078|NCT01022333|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
219700079|NCT00329316|DRUG|Crinone Gel 8%|
219700080|NCT02106273|DEVICE|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
219700081|NCT02106273|DEVICE|LMA-ProsealTM|
219700082|NCT00163592|DRUG|Tissucol®|
219700083|NCT00163592|PROCEDURE|Control: Conventional treatment, i.e. compression with swabs|
219700084|NCT00257452|DRUG|tiotropium 18 mcg or 54 mcg qd|
219700085|NCT00257452|DRUG|placebo matching tiotropium qd|
219700086|NCT00257452|DRUG|moxifloxacin 200 mg|
219700087|NCT04453683|DEVICE|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
219700088|NCT04453683|DEVICE|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
219700089|NCT06508814|PROCEDURE|Lower Insufflation Pressure|Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.
219700090|NCT06508814|PROCEDURE|Standard Insufflation Pressure|Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
219700091|NCT06026436|BIOLOGICAL|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
219700092|NCT06026436|BIOLOGICAL|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
219224959|NCT01583868|DEVICE|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
219700093|NCT00546442|DRUG|Metformine|850-2550 mg/daily for 48 weeks
219700094|NCT00546442|OTHER|Placebo of metformine|850-2550 mg/daily for 48 weeks
219700095|NCT05706324|BIOLOGICAL|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
219700096|NCT02300610|DRUG|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
219700097|NCT02300610|DRUG|Cisplatin|Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
219700098|NCT02300610|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
219700099|NCT01626066|DRUG|LUM015|LUM015 assigned dose given once by IV push
219113613|NCT04254679|DRUG|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
219113614|NCT04254679|DRUG|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
219113615|NCT04999358|BEHAVIORAL|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
219700100|NCT04422886|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
219700101|NCT04422886|BEHAVIORAL|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
219700102|NCT04422886|DEVICE|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
219700103|NCT05983536|DIAGNOSTIC_TEST|HIV Ag +Ab Assay Kit (Sysmex)|Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.
219700104|NCT05828992|OTHER|No intervention administered|Survey only to gather people's experiences, opinions and needs.
219700105|NCT00001512|DRUG|Id-KLH Vaccine|
219700106|NCT00001512|DRUG|GM-CSF|
219113616|NCT04999358|BEHAVIORAL|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
219224960|NCT01583868|DEVICE|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
219700107|NCT00002438|DRUG|Itraconazole|
219700108|NCT05841511|BEHAVIORAL|"Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version"|"The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program."
219700109|NCT02654509|BIOLOGICAL|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
219700110|NCT05665998|DEVICE|ARC-BSI Cervical system|Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.
219700111|NCT01289522|BIOLOGICAL|cetuximab IV|"* Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~* Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~* Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
219113617|NCT03954158|DRUG|Crisaborole ointment 2%|BID regimen
219113618|NCT03954158|DRUG|Vehicle|BID regimen
219113619|NCT03954158|DRUG|Crisaborole ointment 2%|QD regimen
219113620|NCT03954158|DRUG|Vehicle|QD regimen
219113621|NCT00424853|DRUG|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
219224961|NCT01583868|DEVICE|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
219700112|NCT01289522|OTHER|Biopsies|No intervention, only biopsy for translational project.
219700113|NCT03547609|OTHER|No arm intervention|No arm intervention
219700114|NCT05279872|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
219700115|NCT00207168|BEHAVIORAL|Compliance|
219113622|NCT00424853|DRUG|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
219113623|NCT04412564|DRUG|TQ-B3101|TQ-B3101 is a ALK inhibitor.
219113624|NCT02206152|DRUG|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
219113625|NCT02206152|DRUG|Placebo|
219700116|NCT03113955|DEVICE|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
219700117|NCT05057520|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
219700118|NCT05141032|PROCEDURE|Endoscopic Submucosal Dissection with Pathfinder/Overtube device|Removal of gastrointestinal polyps via ESD
219700119|NCT01930591|DRUG|Ticagrelor|180 mg bolus followed by 90 mg BID
219113626|NCT00478608|DRUG|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
219113627|NCT02080520|DIETARY_SUPPLEMENT|Nattokinase|
219113628|NCT02080520|OTHER|Placebo|
219224962|NCT01583868|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
219224963|NCT00362219|OTHER|Placebo|Gel with no active ingredient.
219700120|NCT01930591|DRUG|Clopidogrel|300 mg bolus followed by 75 mg OD
219700121|NCT02136381|BEHAVIORAL|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
219700122|NCT02136381|BEHAVIORAL|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
219700123|NCT02943122|DEVICE|Ambulatory blood pressure monitor|
219700124|NCT04979871|PROCEDURE|Venous bleeding|Blood samples collected 5 times with approx. 2-4 weeks interval
219700125|NCT04222491|DRUG|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
219700126|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
219700127|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
219700128|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
219700129|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
219700130|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
219700131|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
219700132|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
219700133|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
219700134|NCT02739893|PROCEDURE|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
219700135|NCT02739893|PROCEDURE|Standard procedure for colonoscopy|
219700136|NCT02230163|BIOLOGICAL|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
219113629|NCT00658697|DRUG|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
219113630|NCT00658697|DRUG|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
219224964|NCT00362219|DRUG|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
219700137|NCT06293833|RADIATION|Low-dose CT scan|Participants get an annual low-dose CT scan in UZA
219700138|NCT06293833|BEHAVIORAL|Smoking Cessation|Smoking cessation campagnes
219700139|NCT05122481|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
219700140|NCT02484677|DRUG|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
219700141|NCT02484677|DRUG|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
219700142|NCT02484677|DRUG|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
219113631|NCT00658697|DRUG|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
219113632|NCT00658697|DRUG|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
219113633|NCT00004286|DRUG|immune globulin|
219113634|NCT03875495|DRUG|Temferon|Genetically modified autologous HSPCs
219113635|NCT04418713|OTHER|active video-games|An intervention with active video-games to increase physical activity and improve body composition
219113636|NCT03570125|DIETARY_SUPPLEMENT|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
219113637|NCT00486915|PROCEDURE|Left Atrial Appendage Ligation|
219700143|NCT05446285|OTHER|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
219700144|NCT03635918|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
219700145|NCT01099046|BEHAVIORAL|Lifestyle|water intake, tympanic tubing, regular sleep
219700146|NCT00170443|BIOLOGICAL|rHAO Trivalent Influenza Vaccine|
219700147|NCT05069467|DEVICE|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
219700148|NCT05069467|DEVICE|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
219700149|NCT01612013|DRUG|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
219700150|NCT01612013|DRUG|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
219700151|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
219700152|NCT01612013|DRUG|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
219700153|NCT01612013|DRUG|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
219700154|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
219700155|NCT00896259|OTHER|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
219700156|NCT05244200|OTHER|Pharmaceutical care and insulin staging.|Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
219700157|NCT03265561|DEVICE|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
219700158|NCT03265561|DEVICE|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
219113638|NCT06049693|DRUG|Ferrous Gluconate 300 MG|Ferrous Gluconate 300 MG twice a day
219113639|NCT05641077|OTHER|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
219113640|NCT05641077|OTHER|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
219700159|NCT00415467|DEVICE|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
219700160|NCT04617821|DRUG|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
219700161|NCT04617821|DRUG|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
219700162|NCT03139500|DRUG|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
219700163|NCT03139500|DRUG|Placebo|Participants will receive matching placebo.
219700164|NCT03139500|DRUG|Midazolam|Participants will receive single oral dose of midazolam.
219700165|NCT00880126|BEHAVIORAL|Community Development Teams|CDTs bring together counties who are implementing a new practice
219700166|NCT00858286|OTHER|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
219113641|NCT05398497|DEVICE|Cryoablation|Cryoablation will be performed under ultrasound guidance.
219113642|NCT02035215|DRUG|Atorvastatin 20mg|
219113643|NCT02035215|DRUG|Omega-3-acids ethylesters 90 4g|
219113644|NCT02035215|OTHER|Placebo(Omega-3-acids ethylesters 90)|
219113645|NCT03263143|OTHER|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
219113646|NCT00818909|OTHER|Systane|Systane prescription
219224965|NCT00362219|DRUG|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
219224966|NCT00362219|DRUG|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
219224967|NCT00474799|DRUG|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
219224968|NCT00797550|BIOLOGICAL|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
219700167|NCT05660876|PROCEDURE|standard fistulotomy|in a standard manner fistula tract was identified and laid open without doing marsupialization
219700168|NCT05660876|PROCEDURE|fistulotomy with marsupialization|in this arm fistulotomy was done in a standard manner and marsupialization was done
219700169|NCT03599960|DRUG|Chemotherapy|"* Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)"
219700170|NCT04638062|OTHER|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
219113647|NCT04860154|DRUG|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
219113648|NCT06294015|BIOLOGICAL|20% ASED + AT|Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.
219113649|NCT06294015|DRUG|0.9% NS + AT|Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
219113650|NCT00011830|DRUG|G-CSF|
219113651|NCT00011830|PROCEDURE|Apheresis|
219113652|NCT02208882|DRUG|BMS-986120|
219113653|NCT02208882|DRUG|Placebo|
219113654|NCT02208882|DRUG|Midazolam|
219113655|NCT03900312|BEHAVIORAL|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
219113656|NCT00634322|DRUG|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
219113657|NCT00634322|DRUG|leucovorin|IV or po given every 6 hours
219113658|NCT01394250|DEVICE|Buzzy|Cold, Vibrational Device
219113659|NCT01394250|DRUG|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
219113660|NCT00783120|OTHER|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
219113661|NCT00783120|OTHER|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
219113662|NCT05781386|DRUG|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
219113663|NCT01759680|DEVICE|Vibrosphère device|Vertical Sinusoidal vibration
219113664|NCT03680040|DIAGNOSTIC_TEST|Subjects previously implanted with a RESILIA aortic tissue valve.|Subjects to undergo multi-slice computed tomography and echocardiogram to assess predictors of valve durability in previously implanted Edwards aortic valves with RESILIA tissue.
219113665|NCT03860064|OTHER|Non intervention|Non
219113666|NCT01414218|BEHAVIORAL|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
219113667|NCT02951650|DEVICE|Cyberonics VNS|Vagus nerve stimulation
219113668|NCT03385057|DRUG|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
219113669|NCT03385057|DRUG|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
219224969|NCT00797550|PROCEDURE|Autologous bone graft|
219224970|NCT00307216|BEHAVIORAL|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
219113670|NCT01622101|DIETARY_SUPPLEMENT|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
219113671|NCT01443429|DRUG|beraprost sodium(BPS)|
219113672|NCT02282319|DRUG|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
219113673|NCT02282319|OTHER|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
219113674|NCT02282319|DRUG|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
219113675|NCT00601718|DRUG|vorinostat|Given PO
219113676|NCT00601718|BIOLOGICAL|rituximab|Given IV
219113677|NCT00601718|DRUG|ifosfamide|Given IV
219700171|NCT04638062|OTHER|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
219700172|NCT00447083|DEVICE|UVB|UVB exposure by a tanning bed
219700173|NCT00447083|PROCEDURE|Non-UVB|Non-UVB exposure by a tanning bed
219700174|NCT05512559|DEVICE|body composition analysis|Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
219700175|NCT02467244|DRUG|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
219700176|NCT01302899|DRUG|Aliskiren|Aliskiren 150 mg (Tablet)
219700177|NCT01302899|DRUG|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
219700178|NCT01302899|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
219700179|NCT01302899|DRUG|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
219700180|NCT01302899|DRUG|Ramipril|Ramipril 10mg (Tablet)
219700181|NCT05185804|DRUG|Dimolegin|60 mg orally, 1 time per day
219113678|NCT00601718|DRUG|carboplatin|Given IV
219113679|NCT00601718|DRUG|etoposide|Given IV
219113680|NCT00601718|OTHER|pharmacological study|Correlative studies
219700182|NCT05185804|DRUG|Clexane|40 mg subcutaneously, 1 time per day
219113681|NCT00601718|OTHER|laboratory biomarker analysis|Correlative studies
219113682|NCT00601718|GENETIC|gene expression analysis|Correlative studies
219113683|NCT05956938|DEVICE|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
219113684|NCT05956938|DEVICE|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
219113685|NCT06179589|DIETARY_SUPPLEMENT|VS002A|Amino acid based, glucose free ORS
219113686|NCT00865475|DRUG|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
219113687|NCT00865475|DRUG|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
219113688|NCT05539521|DRUG|Remimazolam Besylate|sedation drugs
219113689|NCT05539521|DRUG|Propofol|Propofol
219113690|NCT00037557|DRUG|BeneFIX|
219113691|NCT06207643|PROCEDURE|carotid endarterectomy|removing carotid artery atheromatous plaque surgically
219224971|NCT00307216|BEHAVIORAL|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
219113692|NCT04595734|OTHER|No intervention due to observational methods of study|No intervention due to observational methods of study
219113693|NCT00579982|DRUG|Lamotrigine|Experimental formulation
219113694|NCT01161004|DRUG|Sugammadex - Nacl 9/00|"* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~* Nacl 9/00: same volume as Sugammadex"
219224972|NCT04115553|DIAGNOSTIC_TEST|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
219700183|NCT00424242|DRUG|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
219700184|NCT00822848|DRUG|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
219700185|NCT00822848|DRUG|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
219113695|NCT01161004|DRUG|Nacl 9/00 - sugammadex|"* Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
219700186|NCT00822848|DRUG|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
219700187|NCT00822848|OTHER|immunoenzyme technique|
219700188|NCT00822848|OTHER|immunohistochemistry staining method|
219700189|NCT00822848|OTHER|laboratory biomarker analysis|
219700190|NCT00822848|PROCEDURE|adjuvant therapy|Preoperative administration has been the preference at our institution.
219700191|NCT00822848|PROCEDURE|neoadjuvant therapy|
219700192|NCT00822848|PROCEDURE|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
219113696|NCT01358448|BEHAVIORAL|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
219113697|NCT01358448|BEHAVIORAL|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
219113698|NCT02587689|BIOLOGICAL|anti-MUC1 CAR T Cells|
219113699|NCT01776684|DRUG|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
219113700|NCT04399239|COMBINATION_PRODUCT|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
219113701|NCT00110513|BIOLOGICAL|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is \> 80% and \< 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at \> 80% and \< 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
219224973|NCT04115553|DIAGNOSTIC_TEST|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
219700193|NCT00822848|RADIATION|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
219700194|NCT06228339|DRUG|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
219700195|NCT06228339|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (Reference Drug)
219700196|NCT05724290|GENETIC|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
219700197|NCT04271215|OTHER|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
219700198|NCT00855348|OTHER|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
219700199|NCT02834975|DRUG|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
219113702|NCT04830605|BEHAVIORAL|Internet-based treatment|The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
219113703|NCT02669303|DRUG|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
219113704|NCT02669303|DRUG|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
219113705|NCT02340754|BEHAVIORAL|Mindfulness-based Stress Reduction|
219113706|NCT02340754|BEHAVIORAL|MS Education Control|
219224974|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
219224975|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
219224976|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
219224977|NCT01776320|DRUG|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
219700200|NCT02834975|DRUG|Paclitaxel|"* NACT: Paclitaxel on Day 1 of each cycle;~* ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
219700201|NCT02834975|DRUG|Carboplatin|Carboplatin IV on Day 1 of each cycle.
219700202|NCT00023231|DRUG|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
219700203|NCT00023231|DRUG|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
219700204|NCT00023231|DRUG|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
219700205|NCT00023231|DRUG|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
219700206|NCT00023231|DRUG|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
219700207|NCT00023231|DRUG|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
219700208|NCT00023231|DRUG|Lipitor|Oral tablet taken daily
219700209|NCT01856933|DRUG|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
219700210|NCT02171624|DRUG|dabigatran etexilate|
219700211|NCT02171624|DRUG|quinidine|
219700212|NCT05327582|DRUG|Durvalumab|Administered intravenously, 1000 mg on day 1 in a 3-week cycle
219700213|NCT05327582|DRUG|Lenvatinib|Administered orally, 8mg/d once daily in a 3-week cycle
219700214|NCT05327582|DRUG|Nab paclitaxel|Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
219700215|NCT01741077|DIETARY_SUPPLEMENT|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
219700216|NCT00217490|BEHAVIORAL|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
219113707|NCT04037241|BIOLOGICAL|Anti-CEA CAR-T cells|Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
219700217|NCT00217490|BEHAVIORAL|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
219113708|NCT04037241|DRUG|gemcitabine/nab paclitaxel|systemic chemotherapy regimen
219113709|NCT04037241|DRUG|NLIR+FU/FA|systemic chemotherapy regimen
219113710|NCT04037241|DRUG|Capecitabine|systemic chemotherapy regimen
219113711|NCT05270317|PROCEDURE|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
219113712|NCT02795260|BIOLOGICAL|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
219113713|NCT02795260|BIOLOGICAL|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
219113714|NCT03069560|DEVICE|SMS|SMS contact from the caregiver with patient after discharge in intervention group
219113715|NCT01313923|DRUG|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
219700218|NCT00217490|BEHAVIORAL|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
219700219|NCT00217490|OTHER|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
219113716|NCT03352063|BEHAVIORAL|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
219113717|NCT03352063|BEHAVIORAL|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
219113718|NCT02471404|DRUG|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
219113719|NCT02471404|DRUG|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
219113720|NCT02471404|DRUG|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
219113721|NCT02471404|DRUG|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
219113722|NCT02471404|DRUG|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
219113723|NCT02471404|DRUG|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
219113724|NCT03417882|BIOLOGICAL|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
219113725|NCT00401674|DRUG|carboplatin|
219113726|NCT00401674|DRUG|paclitaxel|
219113727|NCT03418935|DRUG|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
219113728|NCT03418935|DRUG|Ringer's Solution|Intravenous infusion, 400 or 800 ml
219113729|NCT01676025|PROCEDURE|PRA|
219113730|NCT01676025|PROCEDURE|LA|
219113731|NCT06339125|OTHER|Fall prevention algorithm|Algorithm generates fall prevention alerts to nurses in real time, using evidenced based electronic health record information regarding changes in care that may suggest the need for additional fall prevention strategies
219113732|NCT06339125|OTHER|Inspiren camera visualization|The Inspiren computer camera visualization is an additional strategy for nurses to employ when there is a change in a patient's fall risk.
219224978|NCT02997410|DEVICE|Ozone|
219700220|NCT00962286|DRUG|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
219700221|NCT03558516|DRUG|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
219700222|NCT03558516|DRUG|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
219700223|NCT03363906|DRUG|Dulaglutide (Reference)|Administered SC
219113733|NCT00305864|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
219113734|NCT00305864|DRUG|Motexafin Gadolinium|Given IV
219113735|NCT00305864|DRUG|Temozolomide|Given orally
219113736|NCT02912156|DRUG|Vaway FC Tablets 200mg (Voriconazole)|
219113737|NCT02912156|DRUG|VFEND FC Tablets 200mg (Voriconazole)|
219113738|NCT02276378|DRUG|Telmisartan low|
219113739|NCT02276378|DRUG|Telmisartan high|
219113740|NCT02276378|DRUG|Hydrochlorothiazide (HCTZ)|
219113741|NCT02276378|OTHER|Japanese meal|
219113742|NCT00035503|DRUG|etiprednol dicloacetate|
219113743|NCT05335772|BEHAVIORAL|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
219113744|NCT05335772|BEHAVIORAL|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
219700224|NCT03363906|DRUG|Dulaglutide (Test)|Administered SC
219700225|NCT01513655|DEVICE|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
219700226|NCT05989425|DRUG|surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
219113745|NCT00114153|DRUG|capecitabine|
219113746|NCT00114153|DRUG|carboplatin|
219113747|NCT00114153|PROCEDURE|conventional surgery|
219113748|NCT00114153|RADIATION|radiation therapy|
219700227|NCT05541705|BEHAVIORAL|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
219700228|NCT06406504|OTHER|in-laboratory simulation group|The students in-laboratory group performed the simulation applications in the patient room in the simulation laboratory. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
219113749|NCT05280847|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
219113750|NCT03728114|DEVICE|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
219113751|NCT03728114|DEVICE|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
219113752|NCT01467258|DRUG|Amantadine|Single dose
219113753|NCT01013935|OTHER|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
219113754|NCT01013935|OTHER|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
219113755|NCT01674595|BIOLOGICAL|AVANZ olea|Immunotherapy Olea europaea
219113756|NCT04315246|BIOLOGICAL|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
219113757|NCT00004736|DRUG|Nelfinavir mesylate|
219113758|NCT00004736|DRUG|Ethambutol hydrochloride|
219113759|NCT00004736|DRUG|Isoniazid|
219113760|NCT00004736|DRUG|Pyrazinamide|
219113761|NCT00004736|DRUG|Lamivudine|
219113762|NCT00004736|DRUG|Rifabutin|
219113763|NCT00004736|DRUG|Stavudine|
219113764|NCT00004736|DRUG|Zidovudine|
219113765|NCT04870619|OTHER|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
219113766|NCT02247414|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
219113767|NCT02247414|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
219113768|NCT02247414|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
219113769|NCT02247414|DRUG|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
219113770|NCT05011916|DRUG|KDR2-2 suspension eye drops|All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
219113771|NCT01169181|DEVICE|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
219700229|NCT06406504|OTHER|in-situ simulation group|Students in the in-situ simulation group performed the simulation practices in a patient room in a clinic at a university hospital. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
219700230|NCT03282864|DEVICE|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
219700231|NCT06231524|OTHER|Analyse pathologic slides|HE-stained whole slide images were used for the validation of the PSN-AI model.
219700232|NCT02861313|DEVICE|CM LOC attachment|CM LOC attachment
219113772|NCT03741205|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
219700233|NCT02861313|DEVICE|ball attachment|Ball attachment
219700234|NCT06179459|PROCEDURE|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
219700235|NCT03764605|DRUG|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
219113773|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
219113774|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
219113775|NCT05699902|PROCEDURE|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
219113776|NCT05699902|PROCEDURE|Sham block|Female undergone mastectomy and have received conventional analgesic methods
219113777|NCT04745104|DRUG|SHR-1707|SHR-1707 will be administered through IV infusion
219113778|NCT04745104|DRUG|Placebo|Placebo will be administered through IV infusion
219113779|NCT04160611|DRUG|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
219224979|NCT02997410|DEVICE|Placebo (for Ozone)|
219224980|NCT02997410|DEVICE|Dental treatment with occlusal splint|
219224981|NCT05059106|BIOLOGICAL|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
219700236|NCT03764605|DRUG|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
219700237|NCT04272229|DIAGNOSTIC_TEST|Cognition|Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
219700238|NCT04272229|DIAGNOSTIC_TEST|Sympathetic Nervous System|The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
219113780|NCT03169270|OTHER|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
219113781|NCT04280471|DRUG|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
219113782|NCT03053674|OTHER|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
219113783|NCT03053674|OTHER|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
219113784|NCT02749695|DRUG|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
219113785|NCT02749695|OTHER|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
219113786|NCT03299062|DIAGNOSTIC_TEST|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
219113787|NCT02480686|DRUG|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
219113788|NCT03518164|PROCEDURE|Allograft|Bone graft
219113789|NCT01566786|DRUG|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
219113790|NCT01566786|DRUG|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
219113791|NCT03892369|OTHER|Ethanol|Ethanol administration
219113792|NCT01141335|DEVICE|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
219113793|NCT01141335|DEVICE|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
219113794|NCT04017741|DRUG|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
219113795|NCT04017741|DRUG|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
219113796|NCT01049074|OTHER|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
219700239|NCT04272229|DIAGNOSTIC_TEST|Concentratio and Attention|Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
219700240|NCT02640079|BEHAVIORAL|Cognitive behavioral therapy|
219700241|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
219700242|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract Placebo|Cocoa extract placebo
219700243|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
219700244|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
219700245|NCT03261999|DRUG|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
219113797|NCT01049074|OTHER|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
219113798|NCT00115362|DRUG|venlafaxine|
219113799|NCT01040286|DRUG|Flurbiprofen|2.0 mg
219113800|NCT01040286|DRUG|Chlorhexidine|2.5mg
219224982|NCT05059106|BIOLOGICAL|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
219224983|NCT03087890|DRUG|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
219224984|NCT03087890|DRUG|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
219700246|NCT00929669|DRUG|pasireotide LAR|pasireotide LAR 80 mg IM once a month
219113801|NCT02763891|OTHER|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
219113802|NCT02763891|OTHER|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
219113803|NCT03146858|DRUG|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
219113804|NCT02273505|DRUG|Asasantin (ER)|
219113805|NCT02273505|DRUG|Persantin|
219113806|NCT02273505|DRUG|Acetyl salicylic acid (ASA)|
219113807|NCT04864041|OTHER|Evaluation of global longitudinal strain using routinely recorded echocardiography images|There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
219113808|NCT05892835|OTHER|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
219113809|NCT02310893|BEHAVIORAL|Combined Contingency Management and Peer Navigation|
219113810|NCT02310893|BEHAVIORAL|Contingency Management|
219113811|NCT02310893|BEHAVIORAL|Peer Navigation|
219113812|NCT00543218|DRUG|teriparatide 20 micrograms/day subcutaneous|
219700247|NCT04285463|DIAGNOSTIC_TEST|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
219700248|NCT02714153|DEVICE|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
219700249|NCT01658839|DRUG|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
219113813|NCT00543218|DRUG|calcitonin 100 IU/day subcutaneous|
219113814|NCT00780442|DRUG|D-cycloserine|50 mg DCS
219113815|NCT00780442|DRUG|Placebo|Placebo
219113816|NCT00507026|DRUG|IV Diclofenac|IV Diclofenac q6h
219113817|NCT00507026|DRUG|IV ketorolac|IV ketorolac q6h
219113818|NCT00507026|DRUG|Placebo|Placebo q6h
219113819|NCT06381362|PROCEDURE|Minimally invasive pancreatic surgery|Minimally invasive pancreatic surgery
219113820|NCT05008159|BEHAVIORAL|3 month community-based mobility and health intervention|"12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support"
219113821|NCT02372058|DEVICE|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
219113822|NCT00658736|DRUG|Triamcinolone|Injection of bupivacaine and triamcinolone
219113823|NCT00658736|DRUG|Bupivicaine alone|Injection of bupivacaine
219113824|NCT00255697|PROCEDURE|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
219113825|NCT00255697|PROCEDURE|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
219113826|NCT03395938|BEHAVIORAL|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
219700250|NCT03749161|DEVICE|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
219113827|NCT03395938|BEHAVIORAL|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
219113828|NCT06274580|DEVICE|embolization of the middle meningeal artery|Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
219113829|NCT05193721|DRUG|SHR-1901|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
219113830|NCT05175482|OTHER|Virtual Education|health belief model based virtual education
219113831|NCT00253409|DRUG|chemotherapy|
219113832|NCT00253409|PROCEDURE|adjuvant therapy|
219700251|NCT03749161|DEVICE|Monofocal IOL|Lentis L-313, monofocal IOL
219700252|NCT04115813|BEHAVIORAL|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
219700253|NCT02363088|OTHER|Neutral text message reminder|"Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219700254|NCT02363088|OTHER|Messenger text message reminder|"\<GP NAME\>: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219700255|NCT02363088|OTHER|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219700256|NCT02363088|OTHER|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219700257|NCT02363088|OTHER|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219113833|NCT00253409|PROCEDURE|conventional surgery|
219113834|NCT00253409|PROCEDURE|neoadjuvant therapy|
219113835|NCT00253409|RADIATION|radiation therapy|
219113836|NCT02749058|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
219113837|NCT02749058|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
219113838|NCT00604929|DIETARY_SUPPLEMENT|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
219224985|NCT06412094|OTHER|Standard care|Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
219700258|NCT02363088|OTHER|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
219700259|NCT02196129|DRUG|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
219700260|NCT02196129|DRUG|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
219700261|NCT03271697|DRUG|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
219700262|NCT03271697|DRUG|Placebo|as a comparator comparing with AM group
219113839|NCT01400464|DRUG|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
219113840|NCT02061761|BIOLOGICAL|BMS-986016|Specified Dose on Specified Days
219113841|NCT02061761|BIOLOGICAL|BMS-936558|Specified Dose on Specified Days
219113842|NCT00918216|GENETIC|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
219113843|NCT00918216|OTHER|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
219113844|NCT00918216|OTHER|medical chart review|Patients' medical charts are reviewed to obtain clinical information
219113845|NCT00918216|PROCEDURE|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
219113846|NCT00918216|PROCEDURE|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
219113847|NCT00918216|PROCEDURE|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
219700263|NCT03130413|DEVICE|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
219113848|NCT02361593|PROCEDURE|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
219113849|NCT02361593|PROCEDURE|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
219113850|NCT01793246|DEVICE|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
219113851|NCT02327910|OTHER|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
219113852|NCT02327910|OTHER|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
219700264|NCT03130413|DEVICE|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
219113853|NCT02019433|DEVICE|Structan®|
219113854|NCT01037205|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
219113855|NCT01037205|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
219113856|NCT01594658|PROCEDURE|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
219113857|NCT01594658|PROCEDURE|conservative|This arm only has medical standard handling (healings performed by the nurse group)
219113858|NCT03141528|OTHER|Self-learning|Training without supervision
219113859|NCT03141528|OTHER|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
219113860|NCT01165346|RADIATION|Fiducials|Implantation of fiducials
219113861|NCT01165346|RADIATION|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
219113862|NCT04349761|DRUG|MyMD1|Isomyosamine 5mg capsules
219113863|NCT04349761|DRUG|Placebo|Placebo
219113864|NCT01924143|DRUG|TD-9855|radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)
219113865|NCT02667444|DRUG|SB204 4%|Applied topically once daily
219113866|NCT02667444|DRUG|Vehicle Gel|Applied topically one daily
219113867|NCT01575782|DRUG|Chloroquine|Daily intake of Chloroquine during radiotherapy
219113868|NCT05851911|BIOLOGICAL|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
219224986|NCT06412094|BEHAVIORAL|"Access to the AtopicApp mobile application"|"Access to the AtopicApp mobile application with 1 day after enrollment."
219113869|NCT04374565|DRUG|High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma|Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
219113870|NCT04015882|OTHER|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
219113871|NCT04982965|DRUG|Active Cannabis|400 mg of vaporized and inhaled active cannabis (5.1%)
219113872|NCT04982965|DRUG|Placebo Cannabis|400 mg of vaporized and inhaled placebo cannabis (\<.1%)
219113873|NCT04777188|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
219113874|NCT04291170|OTHER|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
219113875|NCT04291170|OTHER|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
219113876|NCT00972387|DIETARY_SUPPLEMENT|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
219113877|NCT00972387|DIETARY_SUPPLEMENT|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
219113878|NCT00972387|DIETARY_SUPPLEMENT|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
219113879|NCT00972387|DIETARY_SUPPLEMENT|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
219113880|NCT04719013|DEVICE|Evoke radiofrequency device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments,
219113881|NCT02647047|PROCEDURE|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
219113882|NCT02647047|PROCEDURE|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
219113883|NCT02647047|PROCEDURE|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
219113884|NCT02647047|PROCEDURE|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
219113885|NCT02647047|DRUG|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
219113886|NCT02647047|DRUG|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
219113887|NCT02647047|DRUG|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
219113888|NCT02647047|DRUG|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
219113889|NCT02647047|DRUG|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
219113890|NCT02647047|DRUG|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
219113891|NCT01298180|DRUG|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
219113892|NCT01298180|PROCEDURE|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
219113893|NCT01298180|PROCEDURE|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
219113894|NCT05018429|PROCEDURE|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
219113895|NCT01632332|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
219113896|NCT01632332|OTHER|laboratory biomarker analysis|Correlative studies
219224987|NCT06412094|BEHAVIORAL|Virtual oversight through the AtopicApp|Notification of doctor's virtual oversight through the AtopicApp mobile application.
219700265|NCT06082232|DRUG|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
219700266|NCT06082232|DRUG|Midazolam|1 mg midazolam intrathecal administration
219700267|NCT06082232|DRUG|Bupivacain|20 mg bupivacaine intrathecal administration
219700268|NCT00485823|DRUG|Olanzapine Hydrochloride|
219700269|NCT00485823|PROCEDURE|Weight Management Program|
219700270|NCT03453294|DEVICE|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
219113897|NCT06096220|PROCEDURE|Enucleation|Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
219113898|NCT06096220|DIAGNOSTIC_TEST|incisional biopsy|Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
219113899|NCT06096220|DRUG|Application of 5-fluorouracil|5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
219113900|NCT06096220|DRUG|Application of Carnoy solution|Carnoy solution will be applied during the enucleation as described previously
219113901|NCT02500316|DRUG|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
219113902|NCT03777865|BIOLOGICAL|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
219113903|NCT02611830|DRUG|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
219113904|NCT02611830|DRUG|Placebo IV|Vedolizumab intravenous infusion placebo
219113905|NCT02611830|DRUG|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
219113906|NCT02611830|DRUG|Placebo SC|Vedolizumab subcutaneous injection placebo
219113907|NCT03826134|DRUG|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
219700271|NCT03453294|DEVICE|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
219700272|NCT00516646|DRUG|ALT-711|200 mg bid
219700273|NCT00516646|DRUG|Placebo|bid
219700274|NCT02330341|DIETARY_SUPPLEMENT|Artemisia dracunculus|
219700275|NCT02330341|OTHER|Placebo|
219700276|NCT02192788|RADIATION|Stereotactic Body Radiation Therapy for Oligometastases|
219700277|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
219700278|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
219700279|NCT05363202|DRUG|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
219700280|NCT05363202|DRUG|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
219700281|NCT05363202|DRUG|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
219113908|NCT06144268|DEVICE|ZyMōt Multi (850µL)|An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.
219700282|NCT04599231|DIAGNOSTIC_TEST|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
219700283|NCT06551740|DRUG|HUC2-344|per oral
219700284|NCT06551740|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
219113909|NCT06144268|OTHER|Density Gradient Centrifugation|"The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure."
219224988|NCT02205515|DRUG|Everolimus|Everolimus is a novel derivative of rapamycin.
219224989|NCT00192959|DRUG|Xenon vs propofol|
219224990|NCT06269029|OTHER|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
219360889|NCT05374473|BEHAVIORAL|Lifestyle modification|Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.
219700285|NCT01869309|DRUG|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
219700286|NCT01869309|DRUG|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
219700287|NCT02532504|OTHER|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets"
219700288|NCT03798743|DRUG|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
219700289|NCT05951634|DEVICE|PerQseal ELITE|"Percutaneous ELITE Arterial Closure Device~The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
219113910|NCT05389527|DRUG|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
219113911|NCT04842396|OTHER|Experimental:Motorized cycle ergometer|Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
219113912|NCT00188318|PROCEDURE|hyperfractionated accelerated radiotherapy|
219113913|NCT02947607|PROCEDURE|Colon biopsies|
219113914|NCT00865111|DRUG|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
219113915|NCT00865111|DRUG|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
219113916|NCT03508336|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
219113917|NCT01706224|PROCEDURE|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
219113918|NCT01706224|OTHER|Data collection|Electronic Case Report Forms (eCRF)
219700290|NCT04186156|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
219700291|NCT03442452|OTHER|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
219700292|NCT04179682|PROCEDURE|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
219700293|NCT02346318|DRUG|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
219700294|NCT02760303|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
219113919|NCT01706224|OTHER|Data collection|Questionnaires, active questioning.
219113920|NCT04529603|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
219113921|NCT05228093|PROCEDURE|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
219224991|NCT06269029|OTHER|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
219113922|NCT05228093|PROCEDURE|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
219113923|NCT04694482|OTHER|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
219113924|NCT04410887|DRUG|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
219113925|NCT02798029|RADIATION|Frameless Fractionated Stereotactic Radiation Therapy|
219113926|NCT01931579|DEVICE|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
219113927|NCT00671996|DRUG|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
219113928|NCT00671996|DRUG|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
219113929|NCT01378520|DRUG|ketoconazole|600 mg capsule oral once
219113930|NCT01378520|DRUG|inert powder|oral once
219113931|NCT02653924|OTHER|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
219113932|NCT02653924|OTHER|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
219113933|NCT02653924|OTHER|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
219700295|NCT02760303|BEHAVIORAL|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
219700296|NCT02760303|BEHAVIORAL|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
219700297|NCT02423408|DRUG|TNX-201|TNX-201 capsule
219700298|NCT02423408|DRUG|Placebo|Placebo capsule
219700299|NCT04479046|OTHER|PMMA crowns|New type of pediatric crowns
219700300|NCT06250114|OTHER|Retreatment|manual k file, carrier based technique, Xrays, tooth build up, provisional and definitive crowns. Post if necessary will be placed
219700301|NCT06250114|OTHER|extraction implant|Flapless or flapped techniques, early, delayed and immediate implant insertions. Cement retrained restorations
219700302|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 1
219700303|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 180
219700304|NCT02655874|BIOLOGICAL|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
219700305|NCT02774083|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
219700306|NCT02774083|BEHAVIORAL|Adler Program|Social and emotional group program
219700307|NCT01687699|DRUG|Spironolactone|
219224992|NCT06959771|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|The study cell product is base edited autologous HSPCs which will be administered as a one-time infusion following myeloid conditioning.
219224993|NCT06959771|DRUG|Alemtuzumab|Serotherapy agent, 10 mg/m\^2 on days -21, -20 and -19
219700308|NCT05362201|PROCEDURE|therapeutic position of the anterior repositioning splints|the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
219700309|NCT06424808|OTHER|Consolidating content on a single website and providing access to it via QR codes in a brochure format|The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
219700310|NCT04573270|BIOLOGICAL|PrimePro|Intravenous Injection
219700311|NCT04573270|OTHER|Placebo|Intravenous Injection
219700312|NCT05612321|DEVICE|Vacuum application|vacuum-assisted delivery
219700313|NCT02891512|OTHER|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
219700314|NCT02891512|OTHER|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
219700315|NCT02891512|OTHER|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
219113934|NCT02653924|OTHER|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
219113935|NCT06192355|DEVICE|Endoscopic hemostasis using a Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
219113936|NCT00547105|DRUG|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
219113937|NCT00547105|RADIATION|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
219113938|NCT00594789|OTHER|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
219113939|NCT06420596|OTHER|Conventional Physiotherapy|Conventional physiotherapy is one prescription of 9 in person physiotherapy sessions (according to FMH Switzerland guidelines). The frequency of the physiotherapy sessions are at the discretion of the treating clinician, but the recommendation is 1 to 2 sessions per week.
219700316|NCT04020562|OTHER|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
219700317|NCT04020562|OTHER|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
219700318|NCT00225875|DRUG|Mabthéra|
219700319|NCT00005925|DRUG|Muscimol|
219700320|NCT05001607|DEVICE|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
219700321|NCT03194334|BEHAVIORAL|Vegetarian diet|
219700322|NCT03194334|DIETARY_SUPPLEMENT|creatine|1g creatine/day
219700323|NCT03194334|DIETARY_SUPPLEMENT|Placebo|pills
219700324|NCT03194334|DIETARY_SUPPLEMENT|Beta-alanine|0.8g beta-alanine per day
219700325|NCT00875316|DRUG|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
219700326|NCT00918983|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
219700327|NCT00918983|DRUG|Placebo|Single intraprostatic injection of placebo
219700328|NCT05459415|PROCEDURE|Reducing Excision Margins|Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
219700329|NCT04593381|RADIATION|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
219700330|NCT03918057|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
219700331|NCT03918057|OTHER|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
219113940|NCT06420596|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports therapeutic exercises in people with musculoskeletal disorders. It is the first app-supported physiotherapy solution available in Switzerland.
219224994|NCT06959771|DRUG|Sirolimus|Immunophilin drug, will start on day -1, targeting a trough level between 4-12 ng/mL.
219360890|NCT05374473|BEHAVIORAL|Standard-care|Content in standard-care arm was adapted from MS-related websites
219700332|NCT00318695|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
219700333|NCT00318695|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
219700334|NCT01100424|DEVICE|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
219700335|NCT01100424|DEVICE|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
219113941|NCT05544552|DRUG|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
219113942|NCT05745428|OTHER|molecular and cellular analyses|sample blood
219113943|NCT04437147|DIETARY_SUPPLEMENT|Placebo|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
219113944|NCT04437147|DIETARY_SUPPLEMENT|3 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
219113945|NCT04437147|DIETARY_SUPPLEMENT|8 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
219113946|NCT02014090|OTHER|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
219700336|NCT01100424|DEVICE|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
219700337|NCT01100424|OTHER|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
219700338|NCT00087178|DRUG|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
219700339|NCT00087178|DRUG|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
219113947|NCT05240833|DIAGNOSTIC_TEST|VExUS Score|"The VExUS-Guided Arm care team will be informed of the Day 0 VExUS immediately after the ultrasound is performed and given a suggested target for the following 48 hours as follows:~* VExUS 0: There is no evidence of venous congestion.~* VExUS 1: There is evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: There is evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis.~* If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
219113948|NCT04650971|BIOLOGICAL|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
219113949|NCT04650971|BIOLOGICAL|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
219224995|NCT06959771|DRUG|Palifermin|Mucositis prophylaxis agent, will be administered at 60 mcg/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
219224996|NCT06959771|DRUG|Busulfan|Myeloid conditioning agent, administered once daily (3 mg/kg) x 2 days, targeting a daily AUC of 4500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L for the 2 days of therapy, if levels are available
219700340|NCT00087178|DRUG|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
219700341|NCT00087178|DRUG|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
219700342|NCT04527588|OTHER|Questionaire Michigan|Patient-Reported Outcome Measures (PROMs) are important clinical items for evaluating injuries and recovery of the hand. The Michigan Hand Questionnaire is one of the most important.
219700343|NCT00746005|DIETARY_SUPPLEMENT|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
219700344|NCT00746005|DIETARY_SUPPLEMENT|placebo, sunflower oil|3 g of sunflower oil
219700345|NCT01012427|PROCEDURE|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase \> 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
219700346|NCT00226369|DRUG|CY-1503|
219700347|NCT01841372|OTHER|Second Life|Second Life is an online virtual reality environment.
219700348|NCT01841372|BEHAVIORAL|Group Phone Conference Call|
219113950|NCT04023097|DEVICE|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
219113951|NCT01755624|DEVICE|NovoTTF-100A device|
219113952|NCT01755624|OTHER|Best Standard of Care|
219113953|NCT00552773|DRUG|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
219113954|NCT03791385|BEHAVIORAL|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
219113955|NCT06823557|DIETARY_SUPPLEMENT|Psychobiotic treatment|The dietary supplementation will follow established guidelines, recommending an intake of 16 g of prebiotic per day, distributed across three meals, for a duration of 12 weeks.
219113956|NCT06823557|OTHER|Placebo treatment|The control group will receive identical packaging that matches the experimental treatment in taste and appearance and will follow the same guidelines for consuming the placebo. For ethical reasons, after the end of the RCT, the control group will be given the option to receive the same prebiotic supplement.
219113957|NCT05741905|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
219113958|NCT05741905|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
219113959|NCT00903786|DRUG|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
219113960|NCT00220961|DRUG|Pioglitazone|Pioglitazone tablets - 45 mg/day
219113961|NCT00220961|DRUG|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
219700349|NCT04149080|PROCEDURE|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
219700350|NCT04149080|PROCEDURE|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
219700351|NCT00622765|DRUG|placebo|Placebo capsule twice daily
219700352|NCT00622765|DRUG|R256918|5 mg capsule twice daily
219700353|NCT00622765|DRUG|R256918|10 mg capsule twice daily
219700354|NCT00622765|DRUG|R256918|15 mg capsule twice daily
219700355|NCT03017859|DEVICE|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
219700356|NCT02219256|DRUG|TAK-079|TAK-079 solution
219700357|NCT02219256|DRUG|Placebo to TAK-079|Placebo to TAK-079 solution
219700358|NCT02678819|DEVICE|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
219700359|NCT01710462|DRUG|Pantoprazole + Domperidone|
219700360|NCT01710462|DRUG|Pantozol®|
219700361|NCT06233708|DRUG|Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use|Non-selective blocker including Propranolol, Carvedilol PO was prescribed
219700362|NCT03893786|DEVICE|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
219700363|NCT01427140|OTHER|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
219700364|NCT01427140|OTHER|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
219700365|NCT00998153|BEHAVIORAL|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
219700366|NCT00833326|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
219700367|NCT00833326|DRUG|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
219700368|NCT00833326|DRUG|Prophylactic growth factors; subcutaneous|standard of care
219700369|NCT00988182|OTHER|dietary intervention|whey protein
219700370|NCT00988182|OTHER|water control|
219113962|NCT00006432|PROCEDURE|very low fat diet|
219113963|NCT03806868|OTHER|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
219113964|NCT03806868|OTHER|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
219113965|NCT03651232|BEHAVIORAL|yoga|once weekly group yoga class for 12 weeks
219113966|NCT03651232|BEHAVIORAL|support group|once weekly group support class for 12 weeks
219113967|NCT06017388|BEHAVIORAL|Hypnosis|We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).
219113968|NCT06017388|BEHAVIORAL|Control|We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
219113969|NCT02380508|DRUG|BCG SSI|Intradermal injection
219113970|NCT02380508|OTHER|No vaccination|
219113971|NCT02380508|DRUG|BCG Sii|intradermal injection
219113972|NCT04081519|DEVICE|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
219113973|NCT04081519|DEVICE|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
219700371|NCT00005649|DRUG|capecitabine|
219700372|NCT00005649|DRUG|paclitaxel|
219700373|NCT02667639|BIOLOGICAL|RPH-104|Anti-IL-1 Mab
219700374|NCT02667639|OTHER|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
219700375|NCT01692119|BEHAVIORAL|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
219700376|NCT00997893|DIETARY_SUPPLEMENT|Soy Phytoestrogen|Novasoy® pill (55 mg)
219700377|NCT00997893|DRUG|Estradiol|Estradiol pill (1 mg)
219700378|NCT00997893|DRUG|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
219700379|NCT00997893|DRUG|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
219700380|NCT00997893|DRUG|MPA Placebo|oral placebo pill (0mg MPA)
219113974|NCT04081519|DEVICE|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
219113975|NCT04081519|DEVICE|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
219113976|NCT01743794|DRUG|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
219113977|NCT01743794|DRUG|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
219113978|NCT03584776|DEVICE|Virtual Reality|Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
219113979|NCT03923010|DRUG|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
219113980|NCT00458913|DRUG|bortezomib|
219113981|NCT00458913|DRUG|cisplatin|
219113982|NCT06559943|OTHER|Traditional Physiotherapy + Placebo Kinesio Tape|"Following a total of 15 sessions of electrophysical agent and exercise training, 5 days a week, for 3 weeks, each session lasting 45 minutes, followed by traditional physiotherapy, 2 days a week, for 3 weeks, a total of 6 times, with 0% tension applied to the trapezius muscle in the neck region (I). Kinesiotape will be applied.~The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application."
219113983|NCT06559943|OTHER|Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method|In addition to a total of 15 sessions of electrophysical agents and exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, kinesio tape will be applied 6 times in total, 2 days a week. Kinesiotape will be cut into an (I) shape (15 cm) with 50% tension and adhered laterally to the C7 joint. In acute cases such as overuse and muscle spasm, it is recommended to apply an inhibition technique that will inhibit the muscle. In the inhibition technique, the direction of the tape should be from the entry point of the muscle to the starting point and the application should be done with very light or light (15 - 25%) tension. In chronic cases, a facilitation technique should be applied to stimulate the weak muscle. The direction of the tape should be from the starting point of the muscle to the attachment point and the application should be done with light or moderate tension (25 - 50%).
219113984|NCT03091101|DEVICE|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
219113985|NCT01629056|PROCEDURE|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
219113986|NCT01629056|PROCEDURE|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
219113987|NCT05240378|OTHER|Surgery|Surgery for cancer as per the stage of the disease and protocol
219113988|NCT00401102|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
219700381|NCT02989974|BEHAVIORAL|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
219700382|NCT00598091|DRUG|gemcitabine|1000mg/m2, Days 1, 8, 15
219113989|NCT00032344|PROCEDURE|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
219113990|NCT02571946|RADIATION|Proton beam therapy|
219113991|NCT01246180|DRUG|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
219700383|NCT00598091|DRUG|dasatinib|50mg, PO, QD
219113992|NCT01246180|DRUG|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
219113993|NCT05582096|DRUG|LY3457263|Administered SC.
219113994|NCT05582096|DRUG|Tirzepatide|Administered SC.
219113995|NCT05582096|DRUG|Placebo|Administered SC.
219113996|NCT05372679|DEVICE|Renal denervation|The TIVUS system will be used for renal denervation
219113997|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
219113998|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
219113999|NCT04898842|OTHER|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
219700384|NCT00598091|DRUG|gemcitabine|1000mg/m2, days 1, 8, 15
219700385|NCT00598091|DRUG|dasatinib|50mg, PO, BID
219700386|NCT02500498|DRUG|Nulojix|
219700387|NCT03444207|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
219114000|NCT03457272|OTHER|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
219114001|NCT01163747|BIOLOGICAL|tocilizumab|Intravenous repeating dose
219114002|NCT01163747|DRUG|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
219114003|NCT01163747|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
219114004|NCT01163747|BIOLOGICAL|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
219114005|NCT02392884|BEHAVIORAL|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
219114006|NCT04970095|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
219114007|NCT04970095|DEVICE|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
219700388|NCT03444207|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
219700389|NCT05572931|DEVICE|Fu's Subcutaneous Needling(FSN)|"Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity.~FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point."
219700390|NCT05572931|DEVICE|fine acupuncture needle|(36G, 0.5 inch, Wujiang city cloud \& dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.
219700391|NCT04158609|DIAGNOSTIC_TEST|Doppler flow indices assessment|Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
219700392|NCT04970082|DIAGNOSTIC_TEST|FFR DWP|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
219700393|NCT04970082|DIAGNOSTIC_TEST|FFR|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
219700394|NCT03641027|OTHER|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week)~* decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~* decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
219700395|NCT03641027|OTHER|Standard care|
219700396|NCT02247388|BEHAVIORAL|Computerized Alcohol Screening|iPad based automated alcohol screening
219700397|NCT02247388|BEHAVIORAL|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
219700398|NCT06265311|PROCEDURE|IDUS examination|for patients with high risks of bile duct stones recurrence using IDUS during ERCP
219700399|NCT00293592|DRUG|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
219114008|NCT03109340|OTHER|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
219224997|NCT06959771|BIOLOGICAL|Base-edited T lymphocyte cells|The secondary study cell product is base edited autologous which will be administered as a one-time infusion two weeks following the infusion of the base-edited autologous HSPCs.
219700400|NCT04861792|BEHAVIORAL|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
219700401|NCT04287348|DRUG|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
219114009|NCT03109340|DEVICE|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
219114010|NCT02244099|OTHER|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
219114011|NCT00554333|BIOLOGICAL|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
219114012|NCT00554333|BIOLOGICAL|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
219114013|NCT04418414|DRUG|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
219700402|NCT01707524|PROCEDURE|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
219700403|NCT04422067|OTHER|Fetal cephalometry|Fetal cephalometry
219114014|NCT04418414|OTHER|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
219114015|NCT00991822|DRUG|Dorzolamide 2%|
219114016|NCT00991822|DRUG|Timolol 0.5%|
219114017|NCT04906590|DRUG|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
219114018|NCT02101099|DEVICE|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
219114019|NCT00451568|DRUG|Metformin|500 mg 2 tablets 2 times a day
219224998|NCT01883193|DIETARY_SUPPLEMENT|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
219224999|NCT03642834|DRUG|ICP-105|25mg, 100mg capsule
219700404|NCT05423951|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
219700405|NCT05423951|DRUG|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
219700406|NCT05423951|DRUG|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
219700407|NCT05423951|DRUG|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
219700408|NCT05273983|BEHAVIORAL|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
219700409|NCT03998631|PROCEDURE|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
219700410|NCT03998631|PROCEDURE|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
219700411|NCT02668068|PROCEDURE|large volume whole-lung lavage (WLL)|Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
219700412|NCT02668068|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
219114020|NCT00451568|DRUG|Desorelle|1 tablet/day in 21 days
219114021|NCT05433402|DRUG|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
219225000|NCT06259032|OTHER|Mechanical alignment|Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
219225001|NCT06259032|OTHER|Functional alignment|Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
219225002|NCT01289600|DEVICE|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
219114022|NCT05433402|DRUG|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
219700413|NCT04503460|DRUG|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
219700414|NCT04503460|DRUG|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
219114023|NCT02758574|PROCEDURE|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
219114024|NCT02758574|PROCEDURE|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
219114025|NCT05929508|OTHER|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
219114026|NCT03363659|DRUG|Disulfiram|Disulfiram is taken orally, twice daily.
219114027|NCT03363659|DIETARY_SUPPLEMENT|Copper gluconate|Copper gluconate is taken orally, twice daily
219114028|NCT03363659|DRUG|Temozolomide|Temozolomide is taken once daily
219114029|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 1
219114030|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 2
219114031|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 3
219114032|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 1
219114033|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 2
219114034|NCT03417037|DRUG|BMS-986205|Administered orally daily, 100 mg
219114035|NCT03417037|BIOLOGICAL|Nivolumab|Specified dose on specified days
219114036|NCT03417037|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
219114037|NCT06625541|DRUG|AJ302-IM|7 cohorts (7 dose levels) of participants are planned to be dosed.
219114038|NCT06625541|DRUG|Placebo|Matching placebo
219114039|NCT03872388|DRUG|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
219114040|NCT03872388|DRUG|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
219225003|NCT02840045|DEVICE|high-density electroencephalography|Musical stimulation during electroencephalography recording
219225004|NCT06488742|OTHER|3% kanuka oil|To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
219225005|NCT03543332|DIAGNOSTIC_TEST|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
219225006|NCT06071052|PROCEDURE|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
219700415|NCT00610415|PROCEDURE|tumor biopsy|
219700416|NCT04976374|DRUG|Dexmedetomidine and Gabapentin|Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin
219700417|NCT04976374|OTHER|Saline|Intravenous Saline 0.9% for placebo purposes
219700418|NCT01836120|DRUG|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
219700419|NCT01836120|DRUG|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
219700420|NCT01687660|OTHER|acupuncture|apply acupuncture to prevent the migraine attack
219114041|NCT06625736|DRUG|Xenical|The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
219114042|NCT06625736|DIETARY_SUPPLEMENT|The dandelion extract|The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
219114043|NCT06624917|PROCEDURE|Green Breast Surgery Protocol|A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
219114044|NCT03455296|OTHER|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
219225007|NCT04270032|DIAGNOSTIC_TEST|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
219114045|NCT07032311|DEVICE|Behavioral Treatment|Description: ARM-2-G1: Patient subjects receiving standard care services without GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy. ARM-2-G2: Patient subjects receiving standard care services that includes GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy.
219700421|NCT04026425|OTHER|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
219700422|NCT00112957|BIOLOGICAL|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.
219700423|NCT00112957|BIOLOGICAL|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
219700424|NCT06467721|DEVICE|Self-adhesive silicone gel waterproof dressing|Self-adhesive silicone gel waterproof dressing is used after artificial joint replacement surgery.
219700425|NCT06467721|DEVICE|Sterile gauze dressing|Sterile gauze dressing is used after artificial joint replacement surgery.
219700426|NCT02165527|PROCEDURE|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
219700427|NCT00870142|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
219700428|NCT00870142|DRUG|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
219700429|NCT02182804|DEVICE|Olympus|narrow band imaging with magnification
219700430|NCT02182804|DEVICE|Cellvizio|probe-based confocal laser endomicroscopy
219700431|NCT02366871|DRUG|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
219700432|NCT02366871|DRUG|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
219700433|NCT06147674|DEVICE|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~* Pulmonary Blood Flow (PBF)~* Shunt Fraction (Qsi)~* Dead space (VD):~* Functional Residual Capacity (FRC)"
219700434|NCT00167700|BEHAVIORAL|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
219700435|NCT00167700|BEHAVIORAL|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
219700436|NCT00167700|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
219700437|NCT00167700|DIETARY_SUPPLEMENT|Probiotics|
219114046|NCT07032324|DRUG|CAR T cells|chimeric antigen receptor T cells
219225008|NCT06369532|DEVICE|Active tDCS|During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
219225009|NCT06369532|DEVICE|Sham tDCS|The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
219700438|NCT00167700|DIETARY_SUPPLEMENT|Prebiotics|
219700439|NCT02830139|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
219114047|NCT02527070|DEVICE|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
219700440|NCT02830139|PROCEDURE|Radical colorectal resection|radical colorectal resection with lymphadenectomy
219700441|NCT02830139|DRUG|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
219114048|NCT02527070|DEVICE|Quantum Warp10 (Red LED)|
219700442|NCT02830139|DRUG|Normal saline , Cisplatin , 5-Fu|
219114049|NCT02527070|DEVICE|Omnilux new-U (Near Infrared LED)|
219114050|NCT02527070|OTHER|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
219225010|NCT00486304|OTHER|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
219114051|NCT06718322|OTHER|Primary Cancer Prevention Implementation Toolkit (PCP-IT)|The PCP-IT is an online implementation support toolkit which aims to support implementation teams in improving the implementation of primary cancer prevention programs (PCPs). The PCP-IT builds upon the theory-base and the proven to be effective ItFits tool. The PCP-IT encompasses a total of six modules which are designed to guide implementers through the process of selecting and adapting PCP programs, identifying and addressing barriers, and developing and applying tailored implementation strategies. The toolkit includes: (1) a repository of PCP programs, (2) a repository of determinants of practice, (3) a repository of implementation strategies, (4) stakeholder consultation at all stages, (5) an online community of implementation practitioners, and (6) structured stepped process flows, instructions, examples and worksheets for working with the materials. https://global.itfits-toolkit.com/
219114052|NCT00141687|PROCEDURE|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
219114053|NCT00141687|PROCEDURE|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
219114054|NCT05084261|DRUG|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
219114055|NCT05084261|DRUG|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
219114056|NCT05084261|DRUG|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
219114057|NCT05084261|DRUG|Matching Placebo|Placebo Matching BT051
219114058|NCT00581113|RADIATION|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
219114059|NCT02810119|DRUG|LO2A|
219114060|NCT02810119|DRUG|Placebo|
219700443|NCT04871464|DRUG|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
219700444|NCT04871464|OTHER|Placebo|Oral
219114061|NCT06365606|DEVICE|iStatis Syphilis Ab Test|Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.
219114062|NCT02775747|BIOLOGICAL|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
219114063|NCT02775747|BIOLOGICAL|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
219114064|NCT04814017|PROCEDURE|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
219225011|NCT00486304|OTHER|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
219225012|NCT01271244|DRUG|Escitalopram|10-20mg daily for 12 weeks
219225013|NCT02234999|DRUG|CC-122|3mg \[14C\]-CC-122 will be administered as a single dose
219225014|NCT05532553|DEVICE|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
219700445|NCT02060409|GENETIC|spliceosome|spliceosome mutations
219700446|NCT02634255|DRUG|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
219700447|NCT02634255|DRUG|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
219700448|NCT02634255|DRUG|Propofol|
219700449|NCT02634255|DRUG|Fentanyl|
219700450|NCT02634255|OTHER|Ringer Lactate|
219114065|NCT04814017|PROCEDURE|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
219114066|NCT00619476|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
219114067|NCT00619476|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
219114068|NCT00619476|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
219225015|NCT04313699|DRUG|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
219700451|NCT02634255|DEVICE|Acceleromyography device|
219700452|NCT04808102|DEVICE|IER AG|The game is a web-based single-player adventure game with 3 levels created with the RPG Maker MV. Playtime is approximately 3 hours.
219700453|NCT04808102|DEVICE|BubbleShooter|A free-to-play arcade browser puzzle game called BubbleShooter.
219700454|NCT01258049|DRUG|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
219700455|NCT01258049|DRUG|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
219700456|NCT02715908|DRUG|LBEC0101|Etanercept 50mg
219700457|NCT05534542|OTHER|exercıse|ıntradıalıtıc core stabılızatıon
219700458|NCT06099535|DRUG|LNK01001 Dose A|Capsules taken orally
219114069|NCT00619476|DRUG|Placebo|placebo
219114070|NCT01062906|DRUG|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
219700459|NCT06099535|DRUG|LNK01001 Dose B|Capsules taken orally
219114071|NCT01062906|DRUG|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
219700460|NCT06099535|DRUG|placebo|Capsules taken orally
219700461|NCT04725669|DIAGNOSTIC_TEST|ELISA IgG Testkit|All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
219700462|NCT02049216|OTHER|Flexible tape|Flexible, elasticised, adhesive athletic tape
219700463|NCT02049216|OTHER|Fixomull|
219700464|NCT02049216|OTHER|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
219700465|NCT01641042|BIOLOGICAL|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
219700466|NCT03444584|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
219700467|NCT03444584|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382.
219700468|NCT03444584|DRUG|Dapaglifozin|Oral dose of dapaglifozin 10 mg tablet.
219700469|NCT03444584|DRUG|Metformin|Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
219700470|NCT02230215|DEVICE|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
219700471|NCT01142336|DRUG|Simvastatin|Simvastatin 40mg qHS for 1 year
219700472|NCT01142336|DRUG|Placebo|Placebo 1 tablet qHS for 1 year
219700473|NCT05232617|OTHER|Rheumatological rehabilitation training|Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
219700474|NCT05590338|DRUG|GSK1070806|Participants will receive GSK1070806
219700475|NCT05590338|DRUG|Placebo|Participants will receive placebo
219114072|NCT04444375|DIAGNOSTIC_TEST|balance test|balance test
219114073|NCT03753321|DIETARY_SUPPLEMENT|Whey protein|Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
219114074|NCT03753321|DIETARY_SUPPLEMENT|Soy protein|Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
219114075|NCT03753321|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
219114076|NCT06301659|BEHAVIORAL|routine rehabilitation therapy|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
219114077|NCT06301659|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
219114078|NCT01062815|DIETARY_SUPPLEMENT|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
219114079|NCT01820468|BEHAVIORAL|Adapted critical time intervention team|
219114080|NCT02711176|DRUG|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
219114081|NCT02711176|DRUG|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
219114082|NCT02711176|DRUG|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
219700476|NCT04503044|OTHER|Retrospective observational study|No intervention to occur
219700477|NCT01670370|DRUG|R-GemOx|Rituximab Gemcitabine Oxaliplatin
219700478|NCT03761316|OTHER|interview regarding goals|interview regarding goals
219700479|NCT04294537|PROCEDURE|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
219700480|NCT04294537|PROCEDURE|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
219700481|NCT04294537|PROCEDURE|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
219114083|NCT02711176|DRUG|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
219114084|NCT02711176|DRUG|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
219114085|NCT02711176|DRUG|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
219700482|NCT04294537|DRUG|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
219114086|NCT01783093|OTHER|Data Collection|Collection of data from existing medical records
219114087|NCT01564082|DEVICE|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
219114088|NCT04084743|OTHER|Virtual reality intervention|Virtual reality intervention includes: Maze game software
219114089|NCT04084743|OTHER|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
219700483|NCT01061996|DRUG|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
219700484|NCT04054830|DRUG|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
219114090|NCT04084743|OTHER|Conventional physiotherapy|"1. Gait training in parallel bar~2. Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
219114091|NCT02986737|DEVICE|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
219114092|NCT04218760|DRUG|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
219114093|NCT04218760|OTHER|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
219700485|NCT04054830|DRUG|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
219114094|NCT04170660|DIAGNOSTIC_TEST|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
219114095|NCT03673371|OTHER|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
219114096|NCT05398354|BEHAVIORAL|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
219114097|NCT06139484|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
219114098|NCT03715374|PROCEDURE|Periodontal Surgery with PRF+ABB|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
219114099|NCT03715374|PROCEDURE|Periodontal Surgery with Collagen Membrane +ABB|Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
219114100|NCT01801384|BEHAVIORAL|Voucher-based incentives|
219114101|NCT06121518|DRUG|D064 and D702, QD|Experimental Group Subjects assigned to this group are treated with D064, D702
219114102|NCT06121518|DRUG|D064 and Placebo of D702, QD|Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
219114103|NCT06121518|DRUG|Placebo of D064 and D702, QD|Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
219700486|NCT03704064|BEHAVIORAL|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
219700487|NCT03704064|BEHAVIORAL|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are \>10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
219700488|NCT05778344|BEHAVIORAL|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
219700489|NCT01369264|DEVICE|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
219700490|NCT01369264|DEVICE|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
219700491|NCT01090180|DRUG|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
219700492|NCT01090180|DRUG|Placebo (sugar pill)|inactive
219700493|NCT02378389|DRUG|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
219700494|NCT04534998|PROCEDURE|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
219700495|NCT00289276|DEVICE|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
219114104|NCT03079115|DRUG|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
219114105|NCT03079115|DRUG|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
219114106|NCT06458660|BEHAVIORAL|LPP+: Mindfulness Meditation Delivered|During the 6-week intervention period, participants will receive reminder SMS text messages at a time selected by the participant at 48 and 24-hrs before each scheduled study visit. Within 24 hours after every session, participants will receive an SMS text reminder to complete a session satisfaction survey. If the satisfaction surveys are not completed within 48 hours after each session, participants will receive an additional SMS text message once per day for three consecutive days after each planned study visit. Twenty-four hours before each scheduled study visit after study visit number 1, participants will an SMS text requiring a one-character response (1= yes, 2=no), asking if participants practiced any mindfulness meditation techniques since the last session. Participants who have not interacted with the app during the previous week will receive an accountability call to assess barriers to participation.
219225016|NCT00615368|DRUG|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
219700496|NCT03939104|DRUG|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
219700497|NCT03939104|DRUG|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
219700498|NCT03939104|DRUG|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
219700499|NCT03939104|DRUG|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
219700500|NCT04077892|DRUG|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
219700501|NCT05093582|DRUG|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
219700502|NCT05093582|DRUG|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
219700503|NCT01663389|DRUG|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
219700504|NCT01663389|DRUG|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
219700505|NCT02728323|DRUG|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
219700506|NCT02728323|DRUG|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
219225017|NCT00615368|DRUG|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
219225018|NCT04130490|DEVICE|ANTERION|3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
219225019|NCT01087710|OTHER|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
219225020|NCT01087710|OTHER|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
219114107|NCT06458660|BEHAVIORAL|LP|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
219114108|NCT02334319|DRUG|Ganetespib|Given IV
219114109|NCT02334319|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219114110|NCT02334319|OTHER|Laboratory Biomarker Analysis|Correlative studies
219700507|NCT04850651|DRUG|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
219700508|NCT01884948|DRUG|Omegaven™|
219700509|NCT00001091|DRUG|Ritonavir|
219700510|NCT00001091|DRUG|Nelfinavir mesylate|
219700511|NCT00001091|DRUG|Nevirapine|
219700512|NCT00001091|DRUG|Lamivudine|
219114111|NCT01912820|DIETARY_SUPPLEMENT|green tea extract|Given PO
219114112|NCT01912820|DRUG|quercetin|Given PO
219114113|NCT01912820|OTHER|placebo|Given PO
219225021|NCT01404000|DRUG|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
219114114|NCT01912820|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
219114115|NCT01912820|OTHER|laboratory biomarker analysis|Correlative studies
219114116|NCT03693820|DRUG|the infiltration group|"* 15-20 ml periportal,~* 50 ml in gallbladder bed,~* The rest (about 150 ml in 70 Kg patient) will be intraperitoneal"
219114117|NCT03693820|DRUG|the control group|the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.
219114118|NCT01811563|DEVICE|Zimmer|
219114119|NCT01811563|DEVICE|Stryker|
219114120|NCT05221203|BEHAVIORAL|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
219114121|NCT05221203|BEHAVIORAL|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
219114122|NCT00047710|DRUG|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
219114123|NCT00047710|DRUG|Capecitabine|650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
219114124|NCT00047710|RADIATION|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
219114125|NCT04989530|DEVICE|Extracorporeal Shock Wave Therapy|different energy levels of ESWT
219114126|NCT02816047|OTHER|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
219114127|NCT01327547|DRUG|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
219114128|NCT01327547|DRUG|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
219225022|NCT05469165|DRUG|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
219225023|NCT05469165|OTHER|Placebo|Placebo administration for 3months
219225024|NCT02697968|DEVICE|Electroacupuncture|
219225025|NCT04658784|DEVICE|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
219225026|NCT04658784|DEVICE|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
219700513|NCT00001091|DRUG|Stavudine|
219700514|NCT01382550|DRUG|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
219700515|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
219700516|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
219700517|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
219700518|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
219700519|NCT00496418|DEVICE|Mesh in permanent colostomy|
219114129|NCT03257488|DEVICE|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
219114130|NCT00329719|PROCEDURE|Conventional Surgery|Undergo surgery
219114131|NCT00329719|OTHER|Laboratory Biomarker Analysis|Correlative studies
219114132|NCT00329719|DRUG|Sorafenib Tosylate|Given PO
219114133|NCT00329719|DRUG|Temsirolimus|Given IV
219114134|NCT00832143|BEHAVIORAL|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
219700520|NCT03652896|PROCEDURE|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
219700521|NCT03961399|DEVICE|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
219700522|NCT03961399|DEVICE|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
219700523|NCT00091078|BIOLOGICAL|oblimersen sodium|Given IV
219700524|NCT00091078|DRUG|imatinib mesylate|Given orally
219114135|NCT05305937|DEVICE|MRI scan|All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
219700525|NCT00091078|OTHER|laboratory biomarker analysis|Correlative studies
219700526|NCT05029908|DIAGNOSTIC_TEST|Jaw Functional Limitation Scale|DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
219700527|NCT03720886|BIOLOGICAL|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
219700528|NCT03720886|BIOLOGICAL|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
219700529|NCT03720886|BIOLOGICAL|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
219700530|NCT02029417|DRUG|cytarabine|Given SC
219700531|NCT02029417|DRUG|omacetaxine mepesuccinate|Given SC
219700532|NCT02029417|DRUG|decitabine|Given IV
219700533|NCT02029417|OTHER|laboratory biomarker analysis|Correlative studies
219700534|NCT04582656|DEVICE|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
219700535|NCT04087512|OTHER|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
219700536|NCT04087512|OTHER|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
219114136|NCT05030935|DEVICE|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
219114137|NCT06783621|DRUG|OnabotulinumtoxinA|Intramuscular Injections
219114138|NCT06783621|DEVICE|JUVÉDERM|Injections
219114139|NCT06783621|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
219114140|NCT06783621|OTHER|SkinMedica Products|Skincare Product
219114141|NCT06783621|DRUG|KYBELLA|Injections
219114142|NCT03918915|DRUG|SYD-101 Dose 1|Sterile topical ophthalmic solution
219114143|NCT03918915|DRUG|SYD-101 Dose 2|Sterile topical ophthalmic solution
219114144|NCT03918915|DRUG|Vehicle|Sterile topical ophthalmic solution without active ingredient
219114145|NCT02552680|OTHER|Exercise|Physical Exercise
219114146|NCT02552680|OTHER|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
219114147|NCT02552680|OTHER|Brochure|Manual/brochure containing information about general health
219114148|NCT05271682|DRUG|FHND6091|FHND6091 capsules
219114149|NCT02809508|DIETARY_SUPPLEMENT|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
219114150|NCT02809508|DIETARY_SUPPLEMENT|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
219114151|NCT00440180|DRUG|Anastrozole|1 mg qd for 4 months
219114152|NCT00440180|DRUG|Placebo|Placebo Comparator
219114153|NCT04277741|DIETARY_SUPPLEMENT|RS4 bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
219114154|NCT04277741|DIETARY_SUPPLEMENT|Control bar|The control group will consume one native wheat starch bar per day.
219114155|NCT04846205|DIAGNOSTIC_TEST|systematic etiological|"Theses following tests are made as usual practice :~* Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~* Transoesophageal ultrasound"
219225027|NCT04574206|BEHAVIORAL|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
219700537|NCT03580018|DRUG|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
219700538|NCT03580018|PROCEDURE|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
219700539|NCT03168945|OTHER|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
219114156|NCT05303038|COMBINATION_PRODUCT|Cryoablation Combined with Tirelizumab and Bevacizumab|"Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation."
219114157|NCT05774496|OTHER|Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.|All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
219114158|NCT04545294|DEVICE|Theta tACS|See detail in arm/group descriptions regarding the intervention.
219114159|NCT05645289|DRUG|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
219114160|NCT05645289|DRUG|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
219114161|NCT01391143|BIOLOGICAL|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
219114162|NCT03751540|PROCEDURE|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
219114163|NCT03751540|PROCEDURE|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
219114164|NCT01807143|OTHER|laboratory biomarker analysis|Correlative studies
219700540|NCT03168945|OTHER|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
219700541|NCT01997658|DRUG|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
219700542|NCT01997658|DRUG|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
219114165|NCT02462083|DRUG|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
219114166|NCT03635138|OTHER|Metal nanoparticles ( O Zn and Cu)|Np of OZn nanoparticles mixed with dental adhesive
219700543|NCT04056169|DRUG|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
219700544|NCT04056169|DRUG|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
219700545|NCT05244096|OTHER|No intervention|Observational study
219700546|NCT02406820|DEVICE|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
219700547|NCT03578042|DRUG|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
219114167|NCT03635138|OTHER|Dental Adhesive pure|Dental Adhesive with commercial preparation
219114168|NCT01004419|DRUG|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
219700548|NCT03578042|DRUG|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
219700549|NCT01254370|DRUG|Latanoprost|0.005%
219700550|NCT01254370|DRUG|Travatan Z|0.004%
219700551|NCT06178692|DIAGNOSTIC_TEST|Validation of miRNA-serum signatures associated with IDH1 status|Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
219700552|NCT03401957|DRUG|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
219114169|NCT01004419|DRUG|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
219114170|NCT06232499|DEVICE|Intravenous Laser Irradiation of Blood|The different color lights for Intravenous Laser Irradiation of Blood are red light at 808nm and blue light at 415nm
219114171|NCT00696085|BEHAVIORAL|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
219700553|NCT03401957|DIAGNOSTIC_TEST|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
219700554|NCT05709613|DEVICE|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
219114172|NCT04908761|PROCEDURE|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
219114173|NCT04908761|PROCEDURE|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
219114174|NCT03244592|DRUG|Minocycline|200 mg/day
219114175|NCT03244592|DRUG|Sugar pill|Matched placebo
219114176|NCT02291289|DRUG|Cetuximab|500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
219114177|NCT02291289|DRUG|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
219114178|NCT02291289|DRUG|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
219114179|NCT02291289|DRUG|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
219114180|NCT02291289|DRUG|Vemurafenib|960 mg vermurafenib BID by mouth
219114181|NCT02291289|DRUG|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
219114182|NCT02291289|DRUG|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
219114183|NCT02291289|DRUG|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
219114184|NCT02291289|DRUG|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
219114185|NCT02291289|DRUG|5-FU/LV|1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
219114186|NCT02291289|DRUG|Capecitabine|1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
219114187|NCT01304524|BIOLOGICAL|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
219114188|NCT01304524|BIOLOGICAL|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
219114189|NCT01304524|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
219225028|NCT04574206|BEHAVIORAL|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
219225029|NCT05227898|DEVICE|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
219700555|NCT06478914|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES unit manufactured by Enraf-Holland was be used to administer the neuromuscular electrical stimulation (NMES) The study involved adjusting the patient's hips, knees, and ankles to achieve a comfortable position. Two electrodes of NMES were used in the first study group and a placebo in the control group. The electrodes were placed on the popliteal fossa and fibular head, and each session was conducted for 15 minutes daily for 2 months.
219700556|NCT06478914|DEVICE|low-intensity laser therapy (LILT)|"The laser unit is a small, hand-held, class III laser product manufactured by Laserex Technology Pty Ltd Australia. It offers continuous and pulsed laser therapy, with continuous therapy being the most effective. The device has a maximum average power of 5 milliwatts, a wavelength of 820 nm, and a power density of 0.39 W/cm2.~Patients were treated as outpatients, receiving full explanations about the purpose, therapeutic, and physiological benefits of low-intensity laser therapy (LILT). They were relaxed in supine position, with hips and knees adjusted. The patient was irradiated in a continuous mode and direct contact method, 3 times per week for 2 months, at 1-cm intervals and across the surface in grids. The laser applicator was applied to the surface, maintaining contact for maximum penetration."
219700557|NCT01767337|DEVICE|FLUGEN 101.2 device|
219700558|NCT05907447|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
219700559|NCT05856487|DRUG|NVP-2203|Take it once daily for 8 weeks orally.
219700560|NCT05856487|DRUG|NVP-2203-R1|Take it once daily for 8 weeks orally.
219700561|NCT05856487|DRUG|NVP-2203-R2|Take it once daily for 8 weeks orally.
219700562|NCT05856487|DRUG|NVP-2203-R3|Take it once daily for 8 weeks orally.
219700563|NCT05856487|DRUG|NVP-2203 Placebo|Take it once daily for 8 weeks orally.
219700564|NCT05856487|DRUG|NVP-2203-R1 Placebo|Take it once daily for 8 weeks orally.
219700565|NCT05856487|DRUG|NVP-2203-R2 Placebo|Take it once daily for 8 weeks orally.
219700566|NCT05856487|DRUG|NVP-2203-R3 Placebo|Take it once daily for 8 weeks orally.
219700567|NCT04873726|DEVICE|Magnetic Tape® aplication|Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
219700568|NCT04873726|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
219700569|NCT02783911|DEVICE|MTA|Mineral Trioxide Aggregate grey paste
219700570|NCT02783911|DRUG|Ferric Sulfate|Ferric Sulfate paste
219700571|NCT05583630|DEVICE|A gap plate with the function of knee joint pressure detection|A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
219700572|NCT03617302|DRUG|Experimental: Nitrate-containing|Experimental
219700573|NCT03617302|DRUG|Placebo: Nitrate-depleted|Placebo
219700574|NCT00006126|DRUG|busulfan|
219700575|NCT00006126|DRUG|cyclophosphamide|
219700576|NCT00006126|DRUG|etoposide|
219700577|NCT00006126|DRUG|fludarabine phosphate|
219700578|NCT00006126|PROCEDURE|peripheral blood stem cell transplantation|
219700579|NCT00006126|RADIATION|radiation therapy|
219700580|NCT01555593|DEVICE|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
219114190|NCT05290103|BEHAVIORAL|Game intervention|"Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations."
219114191|NCT00003238|DRUG|perillyl alcohol|
219114192|NCT01915147|DRUG|OXN PR followed by OxyPR tablets|
219114193|NCT01915147|DRUG|OxyPR followed by OXN PR tablets|
219114194|NCT02615756|BEHAVIORAL|Exercise|
219114195|NCT03076359|BEHAVIORAL|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
219114196|NCT03076359|DRUG|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
219114197|NCT01545362|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
219114198|NCT03891459|BEHAVIORAL|spray+ manipulation|Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);
219114199|NCT03891459|BEHAVIORAL|control manipulation|Participants in control group were told they sprayed saline (in fact, it was saline).
219114200|NCT06223477|OTHER|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
219700581|NCT00216372|DRUG|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
219114201|NCT06223477|OTHER|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
219114202|NCT02409160|PROCEDURE|Standard Roux-en-Y gastric bypass|
219114203|NCT05568485|OTHER|Telerehabilitation was applied to the group with rheumatism|Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
219114204|NCT06190158|DIAGNOSTIC_TEST|Oral sodium suppression test|Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
219114205|NCT06190158|DIAGNOSTIC_TEST|Saline suppression test|Saline suppression test (2 liters of saline)
219114206|NCT06190158|DIAGNOSTIC_TEST|Captopril suppression test|Captopril suppression test (50mg of captopril)
219114207|NCT06190158|DIAGNOSTIC_TEST|Dexamethasone suppression test|1mg of dexamethasone
219114208|NCT06190158|DIAGNOSTIC_TEST|Cosyntropin stimulation test|250mcg of cosyntropin
219114209|NCT01642186|DRUG|everolimus|
219114210|NCT01642186|DRUG|letrozole plus leuprolide|
219114211|NCT01642186|DRUG|combination of everolimus, letrozole and leuprolide|
219114212|NCT02336581|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
219114213|NCT02336581|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
219114214|NCT01511627|DRUG|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
219114215|NCT01511627|DRUG|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
219114216|NCT04802642|OTHER|Survey|Survey
219114217|NCT00321256|PROCEDURE|human pancreatic islet transplantation|
219700582|NCT00216372|OTHER|Placebo|A single intra-muscular injection on day 0.
219700583|NCT01703468|DRUG|Oxcarbazepine|
219700584|NCT04673500|DRUG|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
219114218|NCT02590133|DRUG|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
219114219|NCT02590133|DRUG|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
219114220|NCT02590133|DRUG|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
219114221|NCT04316455|OTHER|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
219114222|NCT03498755|BEHAVIORAL|Mobile phone audio messaging|"Audio messages will be pushed to participants' mobile phones twice weekly on a set schedule in discrete modules that include basic information related to each of the four behavioral domains followed by an integration of the information across behaviors through relatable, character-driven narratives that enable message recipients to engage with the content through a real-world context."
219114223|NCT03498755|BEHAVIORAL|Peer-to-peer learning|Women participants in each community will meet twice monthly for peer-to-peer learning sessions to reinforce the content of audio messages. These sessions will further use women's empowerment approaches including critical examination of gender dynamics, and discussions of solutions for equitable decision-making and control of resources within households. These discussions will be facilitated with male household members and grandmothers in separate learning sessions that will be held three times throughout the intervention period.
219114224|NCT03498755|BEHAVIORAL|Conditional cash transfer|Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.
219114225|NCT03498755|BEHAVIORAL|Entrepreneurship training|Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.
219114226|NCT03498755|BEHAVIORAL|Market price information|Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.
219114227|NCT03498755|BEHAVIORAL|Improved smoke ovens|Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
219114228|NCT02040792|DRUG|TD-4208|
219700585|NCT04673500|DRUG|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
219700586|NCT00071981|BIOLOGICAL|incomplete Freund's adjuvant|Given by injection
219114229|NCT02040792|DRUG|Placebo|
219700587|NCT00071981|BIOLOGICAL|melanoma helper peptide vaccine|Given by injection
219114230|NCT01842087|OTHER|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
219114231|NCT01842087|OTHER|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
219114232|NCT00451997|DRUG|Gleevec|600 mg (capsules) by mouth once daily
219114233|NCT00451997|DRUG|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
219114234|NCT05652855|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
219114235|NCT00124800|BEHAVIORAL|Tinnitus retraining therapy|Sound therapy and counseling
219114236|NCT00124800|DEVICE|Sound therapy|sound therapy and counselling
219114237|NCT01025661|OTHER|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
219114238|NCT03693261|PROCEDURE|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
219700588|NCT00071981|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given by injection
219700589|NCT00071981|BIOLOGICAL|sargramostim|Given by injection
219700590|NCT00071981|BIOLOGICAL|tetanus peptide melanoma vaccine|Given by injection
219700591|NCT05605990|DEVICE|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
219114239|NCT03693261|PROCEDURE|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
219114240|NCT03459820|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
219114241|NCT04107103|DRUG|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
219114242|NCT02802020|DEVICE|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
219114243|NCT00285090|DIETARY_SUPPLEMENT|Calcium, Vitamin D|
219700592|NCT04244539|DEVICE|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
219700593|NCT00802971|DIETARY_SUPPLEMENT|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
219700594|NCT01867255|DRUG|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
219700595|NCT00036426|BIOLOGICAL|FavId (Id-KLH) active immunotherapy|
219700596|NCT03448198|PROCEDURE|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
219700597|NCT04398836|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
219700598|NCT04398836|OTHER|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
219700599|NCT04398836|OTHER|Standard nutrition|Well nurished patients will receive a standard nutrition
219700600|NCT05673395|DEVICE|Electrolyzed alkaline reduced water generator|Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
219700601|NCT02937597|BEHAVIORAL|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
219700602|NCT02937597|BEHAVIORAL|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
219700603|NCT02937597|BEHAVIORAL|HSE|National HSE e-learning programme only
219700604|NCT01123655|DRUG|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
219700605|NCT01123655|DRUG|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
219700606|NCT05449665|OTHER|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
219700607|NCT05449665|OTHER|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
219700608|NCT05449665|OTHER|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
219114244|NCT00285090|DIETARY_SUPPLEMENT|Calcium,Vitamin D|
219114245|NCT00285090|DIETARY_SUPPLEMENT|Calcium, VitaminD|
219700609|NCT03456466|DRUG|TQB2303|375mg/m2 ，iv
219700610|NCT03456466|DRUG|Rituximab|375mg/m2 ，iv
219114246|NCT00285090|OTHER|Sugar Pill|
219114247|NCT01691989|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
219114248|NCT01691989|DRUG|placebo|oral doses once a day for 26 weeks
219114249|NCT05218122|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
219114250|NCT00506285|DRUG|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
219114251|NCT00506285|OTHER|placebo patch|This patch is designed to appear identical to the actual intervention patch
219114252|NCT06150677|OTHER|Voluntary apnoea|Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
219114253|NCT01089556|DRUG|Duloxetine|Administered orally
219700611|NCT00843466|OTHER|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
219114254|NCT01089556|DRUG|Pregabalin|Administered orally
219114255|NCT01089556|DRUG|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
219114256|NCT05054829|BEHAVIORAL|PEERS®: program for the education and enrichment of relational skills|providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
219114257|NCT01238575|OTHER|placebo|Administered for up to 8 weeks.
219114258|NCT01238575|DRUG|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
219114259|NCT02128503|OTHER|HBV DNA level monitoring|HBV DNV level being monitoring regularly
219114260|NCT04509765|RADIATION|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
219114261|NCT01577030|DIETARY_SUPPLEMENT|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
219114262|NCT01577030|DIETARY_SUPPLEMENT|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
219114263|NCT03294213|DEVICE|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
219700612|NCT01785381|OTHER|Added value of coordinator|Added value of coordinator
219700613|NCT06525467|PROCEDURE|radical nephrectomy|open radical nephrectomy and lymph node dissection.
219700614|NCT04194164|OTHER|Fluid intake app|Monitor fluid intake and interdialytic weight gain in patients using the fluid app
219700615|NCT02387086|DRUG|Thalidomide|
219700616|NCT02387086|DRUG|placebo|
219700617|NCT02387086|DRUG|Gefitinib|
219700618|NCT02387086|DRUG|Aspirin|
219700619|NCT00836732|PROCEDURE|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
219700620|NCT00815152|BEHAVIORAL|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
219700621|NCT00815152|BEHAVIORAL|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
219700622|NCT05120076|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
219700623|NCT05120076|DRUG|NaCl 0.9%|s. arm/group description
219700624|NCT05571111|DRUG|FE 999302|Subcutaneous injection as a single dose. 3 different doses
219700625|NCT05571111|DRUG|Ovitrelle|Subcutaneous injection as a single dose. 250 µg (0.5 mL)
219700626|NCT05571111|DRUG|Novarel|Subcutaneous injection as a single dose. 10,000 IU (1 mL)
219700627|NCT05613348|BIOLOGICAL|CD19 CAR T-Cell(CAT19T2)|Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
219700628|NCT00003261|DRUG|methotrexate|
219700629|NCT00003261|DRUG|zidovudine|
219700630|NCT00003261|PROCEDURE|neoadjuvant therapy|
219700631|NCT00003261|RADIATION|radiation therapy|
219700632|NCT02115100|PROCEDURE|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
219700633|NCT00707837|OTHER|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
219700634|NCT00707837|OTHER|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
219700635|NCT04042831|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219114264|NCT04376983|BEHAVIORAL|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
219114265|NCT05545462|DRUG|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
219114266|NCT05545462|OTHER|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
219114267|NCT05193942|BEHAVIORAL|Intervention Our Plan|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
219700636|NCT04042831|PROCEDURE|Computed Tomography|Undergo CT
219700637|NCT04042831|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219700638|NCT04042831|DRUG|Olaparib|Given PO
219700639|NCT02385786|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
219700640|NCT04165122|BIOLOGICAL|HDIT101|i.v. Infusion
219700641|NCT04165122|DRUG|Valaciclovir|oral application of encapsulated Valaciclovir tablets
219700642|NCT04165122|BIOLOGICAL|HDIT101 placebo|i.v. Infusion
219700643|NCT04165122|DRUG|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
219700644|NCT02429050|DRUG|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
219700645|NCT02429050|DRUG|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
219700646|NCT00171249|DRUG|STI571 400 mg|STI571 capsules and tablets
219700647|NCT00171249|DRUG|STI571 600 mg|STI571 capsules and tablets
219700648|NCT01041859|DRUG|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
219700649|NCT01041859|DRUG|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
219700650|NCT00595361|DRUG|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
219700651|NCT00981617|DRUG|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
219700652|NCT00981617|DRUG|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
219700653|NCT00981617|DRUG|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
219700654|NCT00981617|DRUG|Placebo|Matching placebo taken once daily for 12 weeks
219700655|NCT03889392|PROCEDURE|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
219700656|NCT03559816|OTHER|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
219700657|NCT03559816|PROCEDURE|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
219700658|NCT02075125|DRUG|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
219700659|NCT02075125|DRUG|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
219700660|NCT01642381|BEHAVIORAL|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
219700661|NCT01642381|BEHAVIORAL|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
219700662|NCT00982345|DRUG|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
219700663|NCT02101151|DIETARY_SUPPLEMENT|Vitamin D3(cholecalciferol)|
219700664|NCT02908347|DRUG|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
219700665|NCT02908347|DRUG|Placebo|hard gelatine capsules without active ingredient
219700666|NCT00393315|DEVICE|paclitaxel coated balloon catheter|
219114268|NCT05193942|BEHAVIORAL|Internation Informational Control|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
219114269|NCT03449459|DIETARY_SUPPLEMENT|oral probiotics|"Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time."
219114270|NCT03449459|DRUG|aerosol inhaled amikacin|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
219114271|NCT03449459|BIOLOGICAL|combined vaccination|"Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time."
219114272|NCT03498014|OTHER|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
219114273|NCT03498014|OTHER|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
219114274|NCT04288674|OTHER|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
219114275|NCT04288674|OTHER|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
219114276|NCT04288674|OTHER|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
219114277|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
219225030|NCT05227898|DEVICE|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
219700667|NCT05392400|DEVICE|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
219700668|NCT05392400|OTHER|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
219700669|NCT06516471|DEVICE|Conventinal Navigation System Group|The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
219700670|NCT02431429|DRUG|Miltefosine|
219700671|NCT00691379|DRUG|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
219700672|NCT00691379|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
219700673|NCT00691379|DRUG|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
219700674|NCT02905162|OTHER|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
219114278|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
219114279|NCT02165904|BIOLOGICAL|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
219114280|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0
219114281|NCT01450280|BIOLOGICAL|ChAd63 CS, MVA CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
219114282|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0
219114283|NCT01450280|BIOLOGICAL|ChAd63, MVA CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
219114284|NCT00252928|OTHER|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
219114285|NCT00252928|OTHER|Placebo|Placebo
219114286|NCT02662595|OTHER|SMS reminder message|
219114287|NCT02662595|OTHER|Voice call + SMS message|
219225031|NCT03624283|DRUG|Betahistine|Betahistine is used in the treatment of and vertigo.
219700675|NCT00235261|DRUG|Pregabalin|
219700676|NCT00235261|DRUG|Dexamethasone|
219225032|NCT03624283|BEHAVIORAL|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
219700677|NCT03798418|BEHAVIORAL|elastic band strengthening exercise|2-3days per week(150min per week)
219700678|NCT03798418|DIETARY_SUPPLEMENT|diet counseling|each patients in this group will receive4-5times diet counseling
219700679|NCT03428334|DRUG|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
219114288|NCT03389685|BIOLOGICAL|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
219114289|NCT03389685|OTHER|Saline Placebo|saline solution
219114290|NCT01398436|PROCEDURE|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
219114291|NCT01940653|DRUG|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
219114292|NCT01950273|DRUG|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
219114293|NCT01950273|DRUG|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
219114294|NCT00722813|OTHER|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
219114295|NCT01428674|OTHER|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
219114296|NCT01428674|OTHER|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
219114297|NCT05583851|DEVICE|Acceptance and Commitment Therapy|Smartphone app guided and manualized version of acceptance and commitment therapy.
219114298|NCT05583851|OTHER|Psychoeducation Active Control|Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
219114299|NCT02230150|BEHAVIORAL|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
219114300|NCT05238532|GENETIC|CT303|"Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg"
219114301|NCT02418299|DEVICE|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
219114302|NCT04345198|PROCEDURE|Adrenal Artery Ablation|Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
219114303|NCT02367014|DRUG|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
219114304|NCT02367014|DRUG|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
219114305|NCT02367014|DRUG|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
219114306|NCT02367014|DRUG|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
219114307|NCT02642718|DRUG|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
219700680|NCT01015027|BIOLOGICAL|REGN668|4 IV Cohorts (Dose 1, 2, 3, \& 4)
219114308|NCT02642718|OTHER|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
219114309|NCT06208072|DRUG|Irbesartan 150mg|Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
219114310|NCT06208072|DRUG|Eplerenone 25 mg|Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
219114311|NCT03545815|BIOLOGICAL|anti-mesothelin CAR-T cells|Cells will be infused on day 0.
219114312|NCT01074749|DEVICE|Accent Pacemaker|Implantation of pacemaker
219700681|NCT04145063|OTHER|no stent|following uretroscopy, no stent will be placed
219114313|NCT04554485|DRUG|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
219114314|NCT04615208|DIAGNOSTIC_TEST|suspected of COVID-19 infection|suspected of COVID-19 infection
219114315|NCT01154049|BIOLOGICAL|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
219114316|NCT02851836|BEHAVIORAL|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
219114317|NCT01594177|DRUG|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
219114318|NCT01594177|DRUG|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
219114319|NCT01594177|DRUG|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
219114320|NCT01594177|DRUG|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
219114321|NCT01594177|DRUG|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
219114322|NCT00469365|BEHAVIORAL|pharmacist contact with the patient via telephone|
219114323|NCT00469365|BEHAVIORAL|Pharmacist contact with the patient's physician via fax|
219114324|NCT00469365|BEHAVIORAL|Usual care|
219114325|NCT00999401|DRUG|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
219700682|NCT05409365|OTHER|Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)|Immunohistochemical staining
219700683|NCT04411615|DRUG|Omega 3|rTG form Omega-3
219700684|NCT00885118|DRUG|Placebo (middle dose)|Placebo tablets once a day
219700685|NCT00885118|DRUG|Placebo|Placebo tablets once a day
219114326|NCT02026973|DRUG|Fulvestrant|
219114327|NCT02026973|DRUG|Anastrozole|
219114328|NCT02026973|DRUG|Placebo|
219114329|NCT02026973|DRUG|Somatostatin|
219114330|NCT04315623|PROCEDURE|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
219114331|NCT04315623|PROCEDURE|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
219114332|NCT00317174|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
219114333|NCT05554146|OTHER|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
219225033|NCT04192357|BEHAVIORAL|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
219225034|NCT04192357|BEHAVIORAL|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
219700686|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
219700687|NCT00885118|DRUG|BI 10773|BI 10773 high dose tablets once a day
219700688|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
219700689|NCT00885118|DRUG|Placebo (high dose)|Placebo tablets once a day
219700690|NCT00885118|DRUG|BI 10773|BI 10773 low dose tablets once a day
219700691|NCT00885118|DRUG|Placebo (low dose)|Placebo tablets once a day
219700692|NCT02816723|BEHAVIORAL|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
219700693|NCT02816723|BEHAVIORAL|Brain Health|Brain Health Education
219700694|NCT00057135|BEHAVIORAL|Unit of use medication packaging|
219700695|NCT00057135|BEHAVIORAL|Mailed reminders to patient when medication refills are due|
219700696|NCT00057135|BEHAVIORAL|Note to Mental Health Provider when refill is overdue|
219700697|NCT00057135|PROCEDURE|Aligning all prescriptions to fall due on same date|
219700698|NCT05742334|PROCEDURE|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
219700699|NCT05742334|DEVICE|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
219700700|NCT02582476|DRUG|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
219700701|NCT02582476|DRUG|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
219700702|NCT00123344|DEVICE|AT501 pacemaker|
219114334|NCT05554146|OTHER|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
219114335|NCT05554146|OTHER|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
219114336|NCT05554146|OTHER|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
219114337|NCT05921721|DEVICE|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
219114338|NCT04376697|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment will be delivered by trained medical personnel.
219700703|NCT01646437|DRUG|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
219700704|NCT01646437|DRUG|Aspirin|75 mg daily
219700705|NCT01646437|DRUG|Vitamin D|60,000 IU monthly
219700706|NCT01646437|DRUG|Matching Placebo|Matching Placebo
219700707|NCT00218751|BEHAVIORAL|Home Visiting|
219700708|NCT00338780|DRUG|Lamivudine/ Placebo 100mg daily|
219700709|NCT05293795|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
219700710|NCT05293795|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
219700711|NCT04421417|PROCEDURE|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
219700712|NCT04421417|PROCEDURE|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
219700713|NCT01712711|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
219700714|NCT04132765|OTHER|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
219114339|NCT04063111|DEVICE|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
219700715|NCT04132765|OTHER|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
219700716|NCT04132765|OTHER|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
219700717|NCT04132765|OTHER|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
219700718|NCT04132765|OTHER|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
219700719|NCT04132765|OTHER|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
219700720|NCT04132765|OTHER|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
219700721|NCT04132765|OTHER|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
219700722|NCT04132765|OTHER|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
219700723|NCT04132765|OTHER|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
219700724|NCT04132765|OTHER|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
219700725|NCT04132765|OTHER|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
219700726|NCT05844540|PROCEDURE|harvesting bone block|Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.
219114340|NCT04063111|DEVICE|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
219114341|NCT03702101|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
219114342|NCT00432679|DRUG|Rosiglitazone (BRL49653C)|study drug
219114343|NCT03790930|DIAGNOSTIC_TEST|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
219114344|NCT03763396|DRUG|Ketoconazole (KCZ)|Oral Tablet
219114345|NCT03763396|DRUG|Posaconazole (PCZ)|Delayed Release Oral Tablet
219114346|NCT00431977|PROCEDURE|coronary computed tomography angiography|
219114347|NCT02312505|DEVICE|COPFX|cardiac Output by semi-invasive pulse contour analysis
219114348|NCT05948462|DRUG|Lorlatinib|Participants will receive assigned dose of daily oral lorlatinib continuously for each cycle. Each cycle is 3 weeks.
219114349|NCT05948462|DRUG|Cisplatin or Carboplatin|Participants will receive standard of care intravenous Cisplatin or Carboplatin, both chemotherapy medications, on day 1 of each cycle every 3 weeks, for Cycles 1-4. Each cycle is 3 weeks.
219114350|NCT05948462|DRUG|Pemetrexed|Participants will receive intravenous Pemetrexed, a chemotherapy medication, on day 1 of each cycle. Each cycle is 3 weeks.
219114351|NCT04131868|BEHAVIORAL|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
219114352|NCT04131868|BEHAVIORAL|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
219700727|NCT05844540|PROCEDURE|Recipient site preparation|At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.
219700728|NCT05844540|PROCEDURE|implant insertion|"Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion."
219114353|NCT01426906|DRUG|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
219114354|NCT01426906|DRUG|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
219700729|NCT02499016|PROCEDURE|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
219700730|NCT00109993|BIOLOGICAL|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
219700731|NCT00109993|DRUG|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
219114355|NCT03906981|OTHER|Plaque from each subject will be collected but there will be no intervention|No intervention
219114356|NCT00279279|DEVICE|Implanted Device|
219114357|NCT03075293|OTHER|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
219114358|NCT00600743|DRUG|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
219114359|NCT00600743|BEHAVIORAL|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
219114360|NCT00600743|BEHAVIORAL|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
219114361|NCT00600743|DRUG|Placebo|Drug one trial vs placebo
219114362|NCT02578420|OTHER|open-label placebo|"Placebo Cream, openly described as Placebo"
219114363|NCT02578420|OTHER|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
219114364|NCT02937844|BIOLOGICAL|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
219700732|NCT00109993|DRUG|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
219114365|NCT02937844|DRUG|Cyclophosphamide|250 mg/m\^2, d1-3
219114366|NCT02937844|DRUG|Fludarabine|25mg/m\^2, d1-3
219114367|NCT05674942|OTHER|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
219114368|NCT02787720|OTHER|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
219700733|NCT06523712|BEHAVIORAL|Smile Smarts|The interactive oral health care lessons provided to participants in Arm 1 would involve activities and discussions aimed at changing behaviors such as tooth brushing frequency, brushing techniques, and the use of interdental aids. The intervention aims to educate and motivate participants to adopt and maintain optimal oral hygiene habits through behavioral change strategies.
219700734|NCT05923996|DRUG|microbotox|Will be treated by single session of microbotox injection
219700735|NCT05923996|RADIATION|fractional carbon dioxide laser|Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
219700736|NCT01311219|OTHER|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
219700737|NCT01311219|PROCEDURE|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
219700738|NCT01311219|PROCEDURE|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
219700739|NCT00688441|DRUG|Nasal CO2|Twice daily during the 14 day Treatment Period
219700740|NCT00688441|DRUG|Placebo|Use of the study drug dispenser at the same frequency as the active arm
219700741|NCT01208285|DRUG|VX-770|150 mg oral tablet
219114369|NCT02787720|OTHER|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
219114370|NCT06418035|BEHAVIORAL|Video modeling by scanning Qr code|The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.
219114371|NCT06418035|BEHAVIORAL|Modeling traditional method|The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
219114372|NCT00664664|DRUG|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
219700742|NCT03684746|OTHER|No Intervention|It is an observational Study with staff
219114373|NCT00664664|DRUG|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
219114374|NCT00664664|DRUG|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
219114375|NCT02415075|BEHAVIORAL|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
219114376|NCT05063643|OTHER|High altitude|High altitude is defined as \>2000m.
219114377|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
219114378|NCT01177813|DRUG|BI 10773|BI 10773 low dose tablet once daily
219114379|NCT01177813|DRUG|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
219114380|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
219114381|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
219114382|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
219114383|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
219114384|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
219114385|NCT01177813|DRUG|BI10773|BI 10773 high dose tablets once daily
219114386|NCT01177813|DRUG|Sitagliptin|Sitagliptin tablets 100 mg once daily
219114387|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
219114388|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
219114389|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
219114390|NCT01225042|DIETARY_SUPPLEMENT|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
219700743|NCT02539251|BEHAVIORAL|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
219114391|NCT01225042|DIETARY_SUPPLEMENT|placebo|placebo consisting of carrier material powder of identical appearance
219114392|NCT05250804|OTHER|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
219114393|NCT00581256|RADIATION|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
219114394|NCT00581256|RADIATION|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
219114395|NCT06063655|DIETARY_SUPPLEMENT|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
219114396|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
219114397|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
219114398|NCT00109928|DRUG|cisplatin|
219114399|NCT00109928|DRUG|etoposide|
219700744|NCT03054428|DRUG|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
219700745|NCT03054428|DRUG|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
219700746|NCT01813747|DEVICE|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
219700747|NCT03036267|BEHAVIORAL|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
219114400|NCT00109928|DRUG|gemcitabine|
219114401|NCT00109928|DRUG|methylprednisolone|
219114402|NCT00003944|BIOLOGICAL|filgrastim|
219114403|NCT00003944|DRUG|carboplatin|
219700748|NCT03036267|OTHER|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
219700749|NCT05387876|DIETARY_SUPPLEMENT|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
219700750|NCT05387876|DIETARY_SUPPLEMENT|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
219700751|NCT05525260|DRUG|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
219114404|NCT00003944|DRUG|cyclophosphamide|
219700752|NCT05525260|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
219114405|NCT00003944|DRUG|paclitaxel|
219114406|NCT00003944|DRUG|topotecan hydrochloride|
219114407|NCT00003944|PROCEDURE|peripheral blood stem cell transplantation|
219114408|NCT01196104|DRUG|Technosphere® Insulin Inhalation Powder|
219114409|NCT01196104|DRUG|Insulin Aspart|Usual Care
219114410|NCT01196104|DRUG|Insulin Glargine|
219114411|NCT06359795|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT|Patients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
219114412|NCT04149262|DRUG|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
219114413|NCT04149262|DRUG|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
219114414|NCT04149262|DEVICE|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
219114415|NCT00610675|DRUG|Org 50081|One tablet daily
219114416|NCT00471575|PROCEDURE|ultra sound examination|
219114417|NCT05905887|DRUG|Rivoceranib Mesylate, Paclitaxel|"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."
219114418|NCT04126473|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
219114419|NCT04126473|DRUG|Ivacaftor|CFTR potentiator
219114420|NCT02688374|OTHER|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
219114421|NCT02688374|OTHER|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
219114422|NCT02688374|OTHER|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
219114423|NCT00799734|DRUG|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
219114424|NCT00267111|DRUG|Eucerin plus|1g, single application
219114425|NCT00267111|DRUG|Amethocaine gel 4%|1 g, single application
219114426|NCT06385912|PROCEDURE|lymphadenectomy|Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
219225035|NCT04751981|PROCEDURE|Patient Specific Guide|For lumbar fusion pedicle screws will be placed with the aid of patient specific guides.
219700753|NCT05158569|OTHER|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
219700754|NCT05158569|OTHER|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
219114427|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
219114428|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
219700755|NCT01628536|DIETARY_SUPPLEMENT|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
219700756|NCT01383278|BEHAVIORAL|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
219700757|NCT01383278|BEHAVIORAL|Screening and resource provision|Screening and resource provision
219700758|NCT02298972|BEHAVIORAL|Nurse support and selfmanagement intervention|
219700759|NCT05678361|BEHAVIORAL|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
219700760|NCT03717597|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
219700761|NCT01884597|DRUG|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
219700762|NCT01884597|DRUG|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
219700763|NCT03335345|OTHER|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
219700764|NCT03335345|OTHER|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
219700765|NCT05401721|DIAGNOSTIC_TEST|Serum copeptin|Blood test
219700766|NCT02097823|DRUG|Olanzapine|
219700767|NCT02097823|DRUG|Aprepitant|
219700768|NCT04078009|DIAGNOSTIC_TEST|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
219700769|NCT04078009|DIAGNOSTIC_TEST|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
219700770|NCT06115460|DRUG|oral sitagliptin supplementation|oral sitagliptin supplementation for three months
219700771|NCT04559113|DRUG|Methylprednisolone Injectable Product|"1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
219700772|NCT03685604|DRUG|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
219700773|NCT03685604|DRUG|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
219700774|NCT04245969|DEVICE|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
219114429|NCT01822028|DRUG|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
219114430|NCT01822028|DRUG|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
219114431|NCT01316692|OTHER|laboratory biomarker identification and analysis|Correlative studies
219114432|NCT01316692|PROCEDURE|biopsy|Correlative studies
219700775|NCT04245969|OTHER|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
219114433|NCT01316692|OTHER|immunohistochemistry/tissue microarrays|Correlative studies
219114434|NCT01316692|GENETIC|TdT-mediated dUTP nick end labeling assay|Correlative studies
219114435|NCT01316692|OTHER|mass spectrometry|Correlative studies
219114436|NCT00014950|PROCEDURE|CF newborn screening|
219114437|NCT04592328|OTHER|Bacterial cultures taken during surgery.|Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
219114438|NCT02368002|BEHAVIORAL|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
219114439|NCT02368002|BEHAVIORAL|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
219114440|NCT02368002|BEHAVIORAL|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
219114441|NCT03772314|DRUG|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
219114442|NCT03772314|DRUG|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
219700776|NCT04245969|OTHER|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
219700777|NCT03429101|DRUG|Poziotinib|Poziotinib is a tablet for oral administration.
219114443|NCT00749619|OTHER|Catheter Lock Solution Taurolidine and Citrate|
219114444|NCT00749619|OTHER|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
219114445|NCT00749619|OTHER|Catheter Lock Solution : Heparin|
219114446|NCT03708419|OTHER|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
219114447|NCT03708419|OTHER|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
219114448|NCT04967625|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
219700778|NCT03429101|DRUG|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
219700779|NCT03082729|DRUG|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
219700780|NCT01093846|DRUG|AIN457|300mg every 4 weeks
219700781|NCT01093846|DRUG|AIN457|300mg every 2 weeks
219700782|NCT01093846|DRUG|Placebo AIN457|Placebo to AIN457
219700783|NCT04328987|PROCEDURE|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
219114449|NCT04967625|DRUG|Anlotinib hydrochloride|A tyrosine kinase inhibitor selectively targeting VEGFR-2
219114450|NCT01333540|DRUG|TD-1211|Escalating doses
219700784|NCT02023827|BEHAVIORAL|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
219700785|NCT01683461|BEHAVIORAL|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
219114451|NCT01333540|DRUG|Placebo|Placebo once daily
219114452|NCT01536145|DRUG|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
219225036|NCT04751981|PROCEDURE|Navigation|Conventional navigation will be used to place pedicle screws.
219114453|NCT06393686|OTHER|yoga|The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
219114454|NCT01183650|DRUG|Tadalafil|5 mg, administered orally, daily for 10 days
219114455|NCT04683302|DEVICE|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
219114456|NCT04683302|DEVICE|2D US catheterization|2D short axis internal jugular vein catheterization
219114457|NCT05092243|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
219114458|NCT01257139|PROCEDURE|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
219114459|NCT00649493|DRUG|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
219114460|NCT00649493|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
219114461|NCT05743764|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
219114462|NCT05743764|DRUG|Restasis|cyclosporine 0.05%
219114463|NCT05743764|DRUG|Moisview Eye drop|trehalose 3%
219114464|NCT00466674|DRUG|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
219114465|NCT03869645|DEVICE|CAPERE Thrombectomy System|Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System
219700786|NCT01683461|BEHAVIORAL|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
219700787|NCT03434483|PROCEDURE|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
219700788|NCT03434483|GENETIC|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
219700789|NCT03434483|OTHER|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
219700790|NCT03434483|OTHER|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
219700791|NCT03434483|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
219114466|NCT02971059|DIETARY_SUPPLEMENT|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
219700792|NCT04102137|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
219114467|NCT01284140|BEHAVIORAL|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
219114468|NCT01284140|BEHAVIORAL|Usual care|Usual care.
219114469|NCT02556515|PROCEDURE|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
219114470|NCT02556515|PROCEDURE|Total joint replacement|Total joint replacement
219114471|NCT02556515|DEVICE|Elektra prosthesis|Elektra prosthesis
219114472|NCT03184090|DRUG|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
219114473|NCT03184090|DRUG|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
219114474|NCT01654822|DRUG|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
219114475|NCT01654822|DRUG|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
219114476|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
219114477|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
219114478|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
219114479|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
219114480|NCT00088205|DRUG|enzastaurin|500 milligrams (mg), oral, daily, up to six 28-day cycles
219114481|NCT06026722|BEHAVIORAL|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
219114482|NCT02361060|DRUG|Neostigmine|40mcg/kg
219114483|NCT02361060|DRUG|Sugammadex|4mg/kg
219114484|NCT02361060|DRUG|Atropine|10 mcg/kg
219700793|NCT04102137|BIOLOGICAL|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
219700794|NCT04102137|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
219700795|NCT00313872|DRUG|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
219700796|NCT00313872|DRUG|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
219700797|NCT04650737|DRUG|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
219700798|NCT04650737|DRUG|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
219700799|NCT01416571|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
219700800|NCT03184246|DEVICE|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
219700801|NCT03184246|DEVICE|Direct laryngoscopy|direct laryngoscopy will be used for intubation
219700802|NCT06307262|DEVICE|T-TEER|T-TEER using the PACAL or TriClip device
219700803|NCT02062138|OTHER|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
219700804|NCT02062138|OTHER|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
219700805|NCT02062138|OTHER|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
219700806|NCT06941610|DEVICE|Erchonia GVS Laser|405nm violet and 520nm green laser light therapy.
219700807|NCT07151469|OTHER|Kaltenborn mobilization|The therapist applies gentle traction to the mandible, maintained for approximately 20 to 30 seconds, to create space in the joint. This is done by pulling the jaw downward and slightly forward, which can help alleviate pressure and pain. This hand placement allowed the therapist to apply transverse force across the mandible as necessary, while at the same time allowing an anterior-inferior gliding force to the mandible on the side of restriction, while also controlling the unrestricted side inhibiting any excessive mandibular forward gliding with the other hand. The mobilization is then initiated with Grade I, which involves small-amplitude movements performed at the beginning of the range of joint play to reduce pain and muscle guarding. This is followed by Grade II mobilization, which consists of larger amplitude movements within the mid-range of joint play to enhance joint mobility and decrease pain without reaching the joint's full resistance barrier
219700808|NCT07151469|OTHER|active release technique|This deep tissue therapy technique is primarily used to break up adhesions and scar tissue on the surrounding muscle and ligaments. However, this technique has been proven to be a very effective method for treating TMD.While there are several muscles connected with the movement of the TMJ, it is thought that the major players are the digastricus, masseter, and lateral pterygoid muscles
219700809|NCT01150682|GENETIC|RNA analysis|
219700810|NCT01150682|GENETIC|reverse transcriptase-polymerase chain reaction|
219700811|NCT01150682|OTHER|enzyme-linked immunosorbent assay|
219700812|NCT01150682|OTHER|immunohistochemistry staining method|
219700813|NCT01150682|OTHER|laboratory biomarker analysis|
219114485|NCT06420102|DIAGNOSTIC_TEST|Biophysical and biochemical skin assessment|Measurements are taken from the skin surface including transepidermal water loss, skin hydration and pH. In addition, non-invasive biofluid (sebum) is sampled from the skin to profile local inflammation. Skin surface cells were also stripped to assess corneocyte properties over the pressure ulcer and surrounding healthy skin.
219114486|NCT03192215|DRUG|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
219114487|NCT03192215|DRUG|Aspirin|Aspirin 81 mg by mouth once daily.
219225037|NCT03260998|DIAGNOSTIC_TEST|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
219114488|NCT02593032|DEVICE|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
219114489|NCT01160120|DRUG|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
219114490|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
219114491|NCT00736073|DRUG|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
219114492|NCT00736073|DRUG|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
219114493|NCT03244241|DRUG|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
219114494|NCT01305096|OTHER|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
219114495|NCT01161693|DEVICE|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
219114496|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
219114497|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
219114498|NCT06226142|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
219114499|NCT01048606|BEHAVIORAL|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
219114500|NCT01048606|DIETARY_SUPPLEMENT|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
219114501|NCT01048606|OTHER|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
219114502|NCT01914978|OTHER|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
219114503|NCT01914978|OTHER|Food allergy treatment as usual|
219114504|NCT06545396|OTHER|Half-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.
219700814|NCT01765322|DEVICE|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
219700815|NCT06517199|DRUG|Olanzapine 2.5 MG|olanzapine 2.5 mg/day for 28 days
219700816|NCT06517199|DRUG|Olanzapine 5 MG|olanzapine 5 mg/day for 28 days
219700817|NCT06517199|DRUG|Placebo|placebo 1 tab/day for 28 days
219700818|NCT00959751|DRUG|NXN-188|200 mg capsules, 600 mg, PRN
219700819|NCT00959751|DRUG|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
219700820|NCT01735812|DEVICE|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
219700821|NCT06440512|OTHER|Dark chocolate Intervention|The intervention involves daily consumption of 50 grams of dark chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
219114505|NCT06545396|OTHER|Full-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
219114506|NCT03562455|OTHER|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
219114507|NCT03562455|BEHAVIORAL|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
219114508|NCT06207370|DRUG|Tafenoquine|Oral Tafenoquine
219114509|NCT06207370|OTHER|Placebo|Placebo
219114510|NCT05853874|OTHER|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
219114511|NCT05853874|OTHER|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
219114512|NCT03300375|OTHER|Home exercise program|Home-based, progressive exercise program using resistance bands
219114513|NCT03300375|OTHER|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
219114514|NCT02571621|DEVICE|Combitube|Intubation with Combitube
219114515|NCT00163891|BEHAVIORAL|Chest physiotherapy|
219700822|NCT06440512|OTHER|White chocolate Intervention|The intervention involves daily consumption of 40 grams of white chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
219700823|NCT01269294|DRUG|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
219700824|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
219700825|NCT01269294|DRUG|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
219700826|NCT01269294|DRUG|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
219700827|NCT01269294|DRUG|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
219700828|NCT01269294|DRUG|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
219700829|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
219700830|NCT04217759|BEHAVIORAL|Healthy lifestyle intervention|"The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention."
219700831|NCT01182025|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
219114516|NCT05765188|OTHER|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
219114517|NCT03681483|DRUG|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
219114518|NCT01601444|DEVICE|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
219114519|NCT01654237|OTHER|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
219114520|NCT02246829|PROCEDURE|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
219114521|NCT05771194|DRUG|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
219700832|NCT01182025|DRUG|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
219700833|NCT01182025|DRUG|Xiyanping Injection with western medicine|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
219114522|NCT05771194|DRUG|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
219114523|NCT05771194|PROCEDURE|Cleaning, hot compresses and massage of the meibomian gland|Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
219114524|NCT05989867|DIAGNOSTIC_TEST|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
219114525|NCT05989867|DEVICE|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
219114526|NCT00399425|DRUG|bemiparin (low molecular weight heparin)|
219114527|NCT00110760|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
219114528|NCT00110760|DRUG|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
219114529|NCT03614884|BEHAVIORAL|Gambling and Smoking Treatment|The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.
219114530|NCT03614884|BEHAVIORAL|Gambling only treatment|The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
219114531|NCT02443103|DRUG|Guanabenz acetate|
219114532|NCT03027505|DRUG|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day"
219114533|NCT05624723|DRUG|INCB054707|INCB054707 75 mg will be administered orally
219114534|NCT03669094|DIETARY_SUPPLEMENT|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1\*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
219114535|NCT03669094|DIETARY_SUPPLEMENT|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
219700834|NCT05401175|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
219700835|NCT06472921|BEHAVIORAL|Butylphthalide treatment initiation time|Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).
219700836|NCT00176735|DRUG|Capecitabine|
219700837|NCT02397746|DEVICE|total hip arthroplasty implant|
219700838|NCT03711721|DIETARY_SUPPLEMENT|Food basket|
219700839|NCT03711721|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|
219700840|NCT00459017|DEVICE|Portable blood pressure wrist manometer|
219700841|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
219700842|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
219700843|NCT05522478|DEVICE|Fall risk|Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
219700844|NCT06516224|OTHER|Liftactiv® B3 Serum|In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
219114536|NCT02878070|BEHAVIORAL|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
219114537|NCT01630590|DRUG|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
219114538|NCT01630590|DRUG|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
219114539|NCT02067351|BEHAVIORAL|Mindfulness|Meditation, body scan, yoga.
219114540|NCT02366936|DEVICE|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
219114541|NCT00287248|DRUG|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
219114542|NCT02978989|PROCEDURE|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
219114543|NCT02978989|PROCEDURE|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
219700845|NCT06516224|OTHER|Liftactiv® B3 retinol night cream|In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
219700846|NCT06516224|OTHER|Sunscreen UVAage® Inter SPF 50+|twice daily (morning and beginning of the afternoon)
219700847|NCT06516224|OTHER|Mineral 89 cream|2 drops in the morning before sunscreen application for 6 months
219700848|NCT02934685|RADIATION|hypofraction|70 Gy in 28 fractions over 5.6 weeks
219700849|NCT02934685|RADIATION|convention|80Gy in 40 fractions over 8 weeks
219700850|NCT03371550|DRUG|Docetaxel|Induction chemotherapy
219114544|NCT00656916|DRUG|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
219114545|NCT03358329|COMBINATION_PRODUCT|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
219225038|NCT05018156|BEHAVIORAL|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
219700851|NCT03371550|RADIATION|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
219700852|NCT03371550|DRUG|Cisplatin|Induction chemotherapy
219700853|NCT01715831|DRUG|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
219700854|NCT01715831|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
219700855|NCT02111018|DEVICE|CytoSorb Device|
219225039|NCT05722626|PROCEDURE|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
219225040|NCT05722626|OTHER|Normal Saline|NaCl 0.9%
219225041|NCT05030415|DRUG|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
219700856|NCT02111018|PROCEDURE|CVVH|
219700857|NCT03799861|OTHER|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
219700858|NCT03799861|OTHER|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
219700859|NCT03052777|BEHAVIORAL|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
219700860|NCT03257579|OTHER|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
219700861|NCT03257579|BEHAVIORAL|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
219700862|NCT00150696|DRUG|Risedronate|
219700863|NCT03502824|DEVICE|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
219114546|NCT06393218|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219114547|NCT06393218|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
219114548|NCT06393218|BEHAVIORAL|Routine rehabilitation|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219700864|NCT03502824|OTHER|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
219700865|NCT00900562|DRUG|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
219700866|NCT03496740|PROCEDURE|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
219700867|NCT03496740|PROCEDURE|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
219700868|NCT03496740|DRUG|Bupivacaine (Block Drug)|Block drug
219700869|NCT02426684|DRUG|IdeS® (Imlifidase)|0.24mg/kg IdeS
219700870|NCT00146068|DRUG|Avonex/Zocor|
219114549|NCT04994041|OTHER|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
219114550|NCT04994041|OTHER|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
219114551|NCT01682564|DRUG|Candemore tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
219114552|NCT01682564|DRUG|Atacand tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
219114553|NCT02088827|OTHER|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
219114554|NCT02088827|OTHER|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
219114555|NCT05197686|DEVICE|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
219114556|NCT05197686|DEVICE|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
219114557|NCT02982720|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
219114558|NCT02982720|DRUG|Sylatron|Sylatron will be administered subcutaneously.
219114559|NCT01952964|OTHER|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
219114560|NCT05993286|BEHAVIORAL|Exposure Therapy|"At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions."
219700871|NCT05598567|OTHER|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
219700872|NCT05598567|OTHER|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
219700873|NCT02661308|DEVICE|Litebook|
219700874|NCT02650739|PROCEDURE|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
219700875|NCT00047827|DRUG|Micafungin|IV
219700876|NCT00047827|DRUG|Liposomal Amphotericin B|IV
219700877|NCT03587636|DRUG|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
219700878|NCT03587636|DRUG|Bupivacaine|interscalene block with bupivacaine
219700879|NCT04660383|DEVICE|Inspiratory Muscle Training|Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
219700880|NCT03626896|DEVICE|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
219700881|NCT02663700|DRUG|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
219700882|NCT02663700|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
219700883|NCT02663700|OTHER|Placebo|Placebo
219114561|NCT05993286|OTHER|Sound Therapy|Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
219114562|NCT05993286|OTHER|Psychoeducation|A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
219114563|NCT02144519|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
219114564|NCT00633737|BEHAVIORAL|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
219114565|NCT05295563|OTHER|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
219114566|NCT05318846|DRUG|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
219114567|NCT05318846|DRUG|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
219114568|NCT03600038|BEHAVIORAL|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
219114569|NCT03600038|BEHAVIORAL|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
219114570|NCT05853757|DRUG|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
219700884|NCT06140134|PROCEDURE|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
219700885|NCT02499107|DIETARY_SUPPLEMENT|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
219700886|NCT02499107|DIETARY_SUPPLEMENT|Pasta treatment|
219700887|NCT02499107|DIETARY_SUPPLEMENT|Boiled and mashed potato treatment|
219114571|NCT06062576|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
219114572|NCT01381744|BIOLOGICAL|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
219114573|NCT01381744|OTHER|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
219700888|NCT02499107|DIETARY_SUPPLEMENT|Baked french fries treatment|
219114574|NCT00614198|OTHER|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
219114575|NCT04517370|DEVICE|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
219114576|NCT05690789|OTHER|No treatment given|No treatment given
219114577|NCT04048252|OTHER|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
219700889|NCT02499107|DIETARY_SUPPLEMENT|Fried french fries treatment|
219700890|NCT02253342|DRUG|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
219700891|NCT05429996|OTHER|Skin Biopsy|Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril
219700892|NCT02202252|PROCEDURE|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
219700893|NCT02202252|PROCEDURE|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
219700894|NCT02202252|PROCEDURE|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
219700895|NCT00779337|BIOLOGICAL|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
219700896|NCT01118299|DEVICE|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
219114578|NCT04048252|OTHER|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
219114579|NCT02088775|PROCEDURE|PET scan|Undergo PET-CT scan
219114580|NCT02088775|PROCEDURE|CT Scan|Undergo PET-CT scan
219114581|NCT02088775|PROCEDURE|hepatic artery embolization|Undergo standard radioembolization
219114582|NCT02578225|OTHER|Non interventional study|
219114583|NCT00827151|DRUG|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
219114584|NCT02666586|OTHER|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
219114585|NCT02666586|OTHER|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
219114586|NCT02666586|OTHER|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
219114587|NCT02666586|OTHER|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
219225042|NCT01083706|DRUG|azacitidine|Given SC or IV
219700897|NCT03965585|PROCEDURE|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
219114588|NCT02666586|OTHER|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
219700898|NCT01228045|DRUG|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
219114589|NCT00065468|DRUG|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
219114590|NCT00065468|DRUG|CCI-779|25 mg of CCI-779 given Intra Venously once per week
219114591|NCT00065468|DRUG|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
219114592|NCT03309124|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
219114593|NCT03309124|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
219114594|NCT03309124|OTHER|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
219114595|NCT03309124|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
219114596|NCT03309124|OTHER|Meal skipping|No food given
219114597|NCT01874574|DRUG|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
219114598|NCT01874574|DRUG|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
219114599|NCT01225835|DRUG|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
219114600|NCT01225835|DRUG|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
219114601|NCT01225835|DRUG|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
219114602|NCT01225835|DRUG|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.
219114603|NCT01225835|DRUG|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
219114604|NCT03085550|PROCEDURE|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
219114605|NCT03085550|PROCEDURE|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
219114606|NCT01479491|OTHER|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
219114607|NCT00307099|DRUG|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
219114608|NCT00307099|DRUG|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
219114609|NCT02589392|OTHER|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
219114610|NCT02589392|OTHER|Cetaphil® Restoraderm® body wash|
219114611|NCT04676009|OTHER|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
219114612|NCT02965144|OTHER|no treatment|no treatment
219114613|NCT03978026|BEHAVIORAL|Nap|Each participant is compared to himself in 4 conditions,
219225043|NCT01083706|OTHER|laboratory biomarker analysis|Correlative studies
219700899|NCT04459338|BIOLOGICAL|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
219700900|NCT04459338|OTHER|Saline|Placebo comparator
219700901|NCT01503047|DIETARY_SUPPLEMENT|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
219700902|NCT01503047|DIETARY_SUPPLEMENT|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
219700903|NCT04740853|BEHAVIORAL|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
219700904|NCT05731596|DRUG|Rosuvastatin 20 Mg Oral Tablet|Rosuvastatin 20 mg will be administered orally once daily for 3 Months
219700905|NCT05731596|DRUG|Coenzyme Q10 100 MG Oral Capsule|Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
219114614|NCT05987618|DEVICE|Oral appliance with elastic bands|"The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16)."
219114615|NCT05987618|DEVICE|Oral appliance without elastic bands|The oral appliance without the elastic bands.
219114616|NCT02938936|OTHER|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
219114617|NCT03572829|DRUG|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
219114618|NCT05515679|BEHAVIORAL|The BRAIN App|The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
219114619|NCT01579617|BEHAVIORAL|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
219114620|NCT01579617|BEHAVIORAL|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
219114621|NCT02522338|DRUG|iohexol|10 ml de l'iohexol (300 mgI/ml)
219114622|NCT00274170|DRUG|Octreotide|
219114623|NCT02989363|PROCEDURE|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
219700906|NCT01700803|DRUG|Povidone Iodine 10% vand cesarean section wound infections|
219700907|NCT01700803|DRUG|Povidone Iodine 7.5% vand cesarean section wound infections|
219700908|NCT04287179|DRUG|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
219700909|NCT01454284|DRUG|Glargine|
219700910|NCT01454284|DRUG|LY2605541|
219114624|NCT02989363|PROCEDURE|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
219114625|NCT02989363|PROCEDURE|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
219114626|NCT02989363|PROCEDURE|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
219114627|NCT03509376|PROCEDURE|Suture repair|The diastasis is repaired with continous nylon suture
219114628|NCT03509376|PROCEDURE|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
219114629|NCT05239871|DIAGNOSTIC_TEST|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
219114630|NCT03360279|DEVICE|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
219114631|NCT03360279|DEVICE|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
219114632|NCT01187290|RADIATION|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
219700911|NCT01454284|DRUG|Insulin Lispro|
219700912|NCT00255385|DRUG|Micronutrient (Zinc and Iron) fortification|
219700913|NCT00255385|DRUG|Pre and Probiotic fortification|
219700914|NCT03161054|DRUG|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
219700915|NCT03161054|DRUG|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
219114633|NCT05287334|DEVICE|Electrical impedance tomography measurement|During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
219114634|NCT02829710|BEHAVIORAL|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
219114635|NCT02207374|DRUG|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
219114636|NCT02207374|DRUG|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
219114637|NCT00807027|DRUG|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
219114638|NCT00124774|PROCEDURE|Nucleoplasty|
219114639|NCT02087150|DEVICE|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
219114640|NCT03862703|DEVICE|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
219114641|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
219225044|NCT02269852|BIOLOGICAL|trivalent seasonal influenza vaccine|"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"
219700916|NCT03161054|DRUG|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
219700917|NCT03161054|DRUG|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
219700918|NCT03161054|DRUG|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
219700919|NCT02665117|DRUG|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
219700920|NCT02665117|DRUG|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
219700921|NCT02665117|DRUG|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
219700922|NCT04176913|DRUG|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
219700923|NCT03686592|OTHER|Measurement of body awareness|Questionnaires+ interviews
219700924|NCT00574639|DRUG|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
219700925|NCT00574639|DRUG|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
219700926|NCT01245348|GENETIC|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
219700927|NCT04854746|BIOLOGICAL|VXA-GI.1.NN|GI.1 oral vaccine tablet
219700928|NCT04854746|BIOLOGICAL|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
219700929|NCT02178514|OTHER|Formula fed with BabyNes Nutrition System|
219700930|NCT00634556|DRUG|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
219700931|NCT00634556|DRUG|placebo|normal saline
219700932|NCT04943393|OTHER|nointervention|Nointervention
219700933|NCT05316870|BEHAVIORAL|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
219700934|NCT05316870|BEHAVIORAL|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
219700935|NCT04572035|BEHAVIORAL|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
219225045|NCT02930317|DRUG|Recombinant Factor VIII (50 IU/kg)|
219225046|NCT02930317|DRUG|Recombinant Factor VIII (On-demand treatment)|
219700936|NCT04572035|BEHAVIORAL|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
219700937|NCT04572035|OTHER|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
219700938|NCT00470548|DRUG|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
219700939|NCT00470548|DRUG|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
219700940|NCT02215902|DEVICE|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
219700941|NCT03248037|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
219700942|NCT03248037|DRUG|Placebo|Placebo eye drops
219700943|NCT04496232|DEVICE|PICSI|Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate
219700944|NCT04496232|OTHER|Second ejaculate|Semen processing by density gradient centrifugation for the second ejaculate
219114642|NCT06395389|BEHAVIORAL|Bloom|Bloom is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
219114643|NCT00955006|BIOLOGICAL|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
219114644|NCT00955006|BIOLOGICAL|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
219114645|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
219114646|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
219114647|NCT00688090|BIOLOGICAL|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
219114648|NCT00688090|BIOLOGICAL|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
219114649|NCT04531072|DRUG|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
219114650|NCT04531072|DRUG|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
219114651|NCT02501135|PROCEDURE|Femoral nerve block with ropivacaine or bupivacaine|
219700945|NCT02517723|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
219700946|NCT02517723|BEHAVIORAL|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
219700947|NCT02517723|BEHAVIORAL|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
219700948|NCT02517723|OTHER|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
219700949|NCT02669875|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
219700950|NCT02669875|DRUG|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
219700951|NCT03950882|DRUG|PXL770|Oral capsule
219700952|NCT03950882|DRUG|Placebo|Oral capsule
219700953|NCT01653691|PROCEDURE|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
219700954|NCT01653691|PROCEDURE|Sham|No treatment to one side of subject's scar.
219700955|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
219700956|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
219700957|NCT05460884|DIETARY_SUPPLEMENT|White bread|109g of white bread
219114652|NCT02342184|DRUG|GB-0998|
219114653|NCT01034241|DIETARY_SUPPLEMENT|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
219114654|NCT01034241|DIETARY_SUPPLEMENT|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
219114655|NCT01034241|DIETARY_SUPPLEMENT|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
219114656|NCT01034241|DIETARY_SUPPLEMENT|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
219114657|NCT01021163|DRUG|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
219114658|NCT04256590|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
219225047|NCT01833598|PROCEDURE|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
219114659|NCT06091618|PROCEDURE|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
219114660|NCT06091618|PROCEDURE|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
219114661|NCT01584830|DRUG|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
219114662|NCT01584830|DRUG|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
219114663|NCT01857830|BEHAVIORAL|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
219114664|NCT01857830|BEHAVIORAL|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
219114665|NCT05449574|DIAGNOSTIC_TEST|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
219114666|NCT03856021|PROCEDURE|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
219114667|NCT03856021|PROCEDURE|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
219114668|NCT01952301|DEVICE|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
219114669|NCT01952301|DEVICE|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
219114670|NCT03049657|DEVICE|Angiolite|Percutaneous coronary intervention
219114671|NCT03049657|DEVICE|Xience|Percutaneous coronary intervention
219225048|NCT01833598|PROCEDURE|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
219700958|NCT03035019|BEHAVIORAL|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
219700959|NCT01655160|BEHAVIORAL|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
219700960|NCT01655160|BEHAVIORAL|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
219700961|NCT01655160|BEHAVIORAL|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
219700962|NCT01655160|BEHAVIORAL|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
219700963|NCT02271113|DRUG|GMI-1271|
219700964|NCT02271113|DRUG|Placebo|
219700965|NCT02271113|DRUG|Enoxaparin Sodium (Lovenox®)|
219700966|NCT03720119|DRUG|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
219114672|NCT01642134|DRUG|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
219114673|NCT01482650|DEVICE|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
219114674|NCT00972179|DRUG|Placebo|Administered by subcutaneous or intravenous injection.
219114675|NCT00972179|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
219114676|NCT04166695|DEVICE|Monolithic / facially veneered zirconia fixed partial denture|Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
219700967|NCT04587804|DEVICE|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
219700968|NCT04182893|DIAGNOSTIC_TEST|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
219700969|NCT03743194|DRUG|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
219700970|NCT03743194|DRUG|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
219700971|NCT00129337|DRUG|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
219700972|NCT05648734|DRUG|Corticosteroids alone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)
219700973|NCT05648734|DRUG|Corticosteroids + Colchicine|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)
219225049|NCT02224469|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
219114677|NCT04166695|DEVICE|Completely veneered CoCr fixed partial denture|Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
219114678|NCT04695158|DRUG|COVID-19 group (Group I)|Routine COVID-19 treatment
219114679|NCT04695158|DRUG|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
219700974|NCT05648734|DRUG|Corticosteroids + Pirfenidone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
219700975|NCT05648734|DRUG|Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
219114680|NCT02054078|DRUG|Bevacizumab|Bevacizumab200mg by intrapleural administration
219700976|NCT03414632|DRUG|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
219700977|NCT01944423|DRUG|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
219700978|NCT01944423|DRUG|Pill Placebo|
219700979|NCT01944423|DRUG|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
219700980|NCT01944423|BEHAVIORAL|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
219700981|NCT01590615|DRUG|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
219114681|NCT02054078|DRUG|Pulvis talci|Pulvis talci 4g by intrapleural administration
219114682|NCT00100139|DRUG|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
219114683|NCT00100139|DRUG|Paclitaxel for injection (Taxol)|
219114684|NCT04610151|OTHER|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
219114685|NCT03696277|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
219114686|NCT05216926|OTHER|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
219114687|NCT05216926|OTHER|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
219114688|NCT04091776|RADIATION|CT scan|"1. Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~2. Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~3. Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~4. Assessment of fixation failure in fixed fractures if occurred.~5. Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
219114689|NCT05895968|PROCEDURE|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
219114690|NCT06211387|PROCEDURE|Resistance Exercise Training|Resistance Exercise Training for knee
219114691|NCT06211387|PROCEDURE|Joint Mobilization|Tibiofemoral and Patellofemoral Joint Mobilization
219700982|NCT02897349|DRUG|placebo|
219700983|NCT02897349|DRUG|linagliptin|
219114692|NCT03355105|OTHER|Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
219114693|NCT03355105|OTHER|Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|"The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient."
219114694|NCT03677882|BEHAVIORAL|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
219114695|NCT04415697|DIAGNOSTIC_TEST|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
219114696|NCT03479190|PROCEDURE|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
219114697|NCT03479190|PROCEDURE|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
219114698|NCT04809792|RADIATION|SBRT on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
219114699|NCT02640976|DRUG|Human menopausal gonadotrophin (HMG)|\[Merional® 75 IU ampoules, IBSA institut\]
219114700|NCT02640976|DRUG|GnRH antagonist Cetrorelix|\[Cetrotide® 0.25 mg syringes, Merck Serono\]
219114701|NCT02640976|DRUG|Human chorionic gonadotrophin (hCG)|\[Choriomon® 5000 IU ampoules, IBSA institut\]
219114702|NCT05909787|OTHER|Auto-questionnaire|MCH (Montreal Children's Hospital) self questionnaire completed by the parents
219114703|NCT03766893|DRUG|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
219114704|NCT03766893|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
219114705|NCT03766893|OTHER|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
219114706|NCT06330636|OTHER|D-Allulose|Test breakfast
219114707|NCT06330636|OTHER|Sodium Saccharin|placebo breakfast
219114708|NCT02210910|DEVICE|InSpace™ system over repair|
219114709|NCT02210910|PROCEDURE|Best Repair of torn Rotator Cuff|
219114710|NCT03978390|BEHAVIORAL|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
219114711|NCT03978390|BEHAVIORAL|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
219114712|NCT03978390|BEHAVIORAL|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
219114713|NCT03314623|BEHAVIORAL|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
219114714|NCT02475044|BEHAVIORAL|Cognitive-Behavioral Therapy|16 Sessions of CBT.
219114715|NCT06226428|OTHER|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
219114716|NCT06226428|OTHER|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
219114717|NCT06226428|OTHER|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
219114718|NCT00459303|DEVICE|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
219114719|NCT00459303|DEVICE|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
219114720|NCT00798356|OTHER|Yoga training|Yoga training for 12 weeks
219114721|NCT06493123|OTHER|Conventional Cardiopulmonary Rehabilitation|Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises
219114722|NCT06493123|OTHER|Bottle P.E.P. (Pozitive Expiratory Pressure)|"The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~\- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant."
219225050|NCT04634851|BEHAVIORAL|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
219225051|NCT03387826|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
219225052|NCT03387826|DRUG|Prasugrel 5mg|Prasugrel 5 mg once daily
219700984|NCT02897349|DRUG|background therapy|insulin with or without metformin
219700985|NCT00166400|DRUG|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
219114723|NCT06493123|OTHER|Early Mobilization|"The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)"
219114724|NCT04826874|BEHAVIORAL|Affect labeling|Short behavioral intervention teaching affect labeling
219114725|NCT01352702|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
219114726|NCT01352702|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
219114727|NCT02379065|DEVICE|The Aerogen Aeroneb Solo©|
219114728|NCT02379065|DEVICE|Phillips Respironic© mask|
219114729|NCT00811746|DRUG|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
219114730|NCT00811746|DRUG|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
219700986|NCT01829347|BIOLOGICAL|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
219700987|NCT01829347|OTHER|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
219700988|NCT03468504|DEVICE|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
219700989|NCT03468504|DEVICE|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
219700990|NCT03468504|DEVICE|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
219700991|NCT06279078|DRUG|Corticosteroid|oral/inhaled corticosteroid
219700992|NCT04222543|COMBINATION_PRODUCT|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
219700993|NCT01750437|DRUG|YH1885L(Revaprazan)|
219700994|NCT01750437|DRUG|Esomeprazole 20mg|
219700995|NCT01750437|DRUG|placebo|
219700996|NCT05890079|OTHER|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
219700997|NCT05890079|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
219700998|NCT06399042|DEVICE|SP5M002 inj|pre-filled syringe
219700999|NCT06399042|DEVICE|Synovian inj|pre-filled syringe
219114731|NCT00811746|OTHER|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
219114732|NCT04499339|DRUG|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
219114733|NCT04441424|BIOLOGICAL|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
219701000|NCT04662333|PROCEDURE|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
219701001|NCT04662333|PROCEDURE|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
219701002|NCT03189082|PROCEDURE|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
219701003|NCT05720637|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
219701004|NCT05720637|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
219114734|NCT04441424|DRUG|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
219114735|NCT02285595|DEVICE|Sonendo GentleWave™ System|
219114736|NCT00284908|DRUG|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
219114737|NCT06548789|DIETARY_SUPPLEMENT|Prebiotic Xnack Packouts|Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
219114738|NCT01058330|OTHER|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
219114739|NCT05716841|OTHER|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
219114740|NCT01535131|PROCEDURE|palatoplasty|procedure to close cleft palate
219114741|NCT04380896|OTHER|Blood test|Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
219701005|NCT05720637|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
219114742|NCT04380896|OTHER|Standardised questionnaires|It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
219114743|NCT05158881|DEVICE|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
219114744|NCT00195715|BIOLOGICAL|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
219114745|NCT00284999|DRUG|Soothe|
219114746|NCT00284999|DRUG|Refresh Tears|
219114747|NCT03844321|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
219114748|NCT03844321|BEHAVIORAL|Brief Mindfulness|3 sessions of online mindfulness therapy
219114749|NCT05140213|DEVICE|Anti-infectious prescription support tool|"implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
219114750|NCT00230815|DEVICE|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
219114751|NCT00230815|DEVICE|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (\>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
219114752|NCT00660920|DRUG|Ponatinib|Comparison of different dosages of drug given orally once per day.
219701006|NCT01708603|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
219114753|NCT05387486|PROCEDURE|Anatomical Landmark technique|anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin
219114754|NCT05387486|PROCEDURE|Ultrasound-guided pre location technique|In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.
219114755|NCT05387486|PROCEDURE|Ultrasound-guided real-time technique|In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
219114756|NCT00002015|DRUG|Ganciclovir|
219114757|NCT05088967|DRUG|IBI110|R2PD d1 IV every 3 weeks
219114758|NCT05088967|DRUG|sintilimab|200mg d1 IV every 3 weeks
219114759|NCT04773249|DEVICE|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
219114760|NCT04773249|DEVICE|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
219114761|NCT05752643|OTHER|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
219225053|NCT03210324|DRUG|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
219225054|NCT03466983|DRUG|Iron Isomaltoside|administered IV
219701007|NCT01708603|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
219701008|NCT01708603|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
219701009|NCT01708603|DRUG|placebo|Placebo administered SC
219701010|NCT05808985|DRUG|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
219701011|NCT04214743|DEVICE|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
219701012|NCT04214743|DEVICE|Fundus camera from Optomed|It allows to monitor retinal microvasculature
219701013|NCT01482832|BEHAVIORAL|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
219701014|NCT06207474|OTHER|Video + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
219225055|NCT03466983|DRUG|Ferric Carboxymaltose|administered IV
219225056|NCT05400759|OTHER|IOP monitoring data|
219225057|NCT02827201|DRUG|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
219701015|NCT06207474|OTHER|Video + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
219701016|NCT06207474|OTHER|Paper + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
219701017|NCT06207474|OTHER|Paper + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
219701018|NCT00001078|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
219701019|NCT04018066|DIETARY_SUPPLEMENT|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
219701020|NCT06157424|OTHER|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
219701021|NCT06157424|OTHER|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
219701022|NCT06157424|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
219701023|NCT05517590|DRUG|Tranexamic acid|1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
219114762|NCT01597661|DRUG|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
219114763|NCT01597661|DRUG|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
219114764|NCT01597661|OTHER|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
219114765|NCT05805306|BEHAVIORAL|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
219114766|NCT05805306|BEHAVIORAL|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
219114767|NCT02452866|DRUG|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
219114768|NCT06193759|BIOLOGICAL|Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)|Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.
219701024|NCT05517590|DRUG|Saline|100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
219701025|NCT03456323|BEHAVIORAL|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
219701026|NCT03456323|OTHER|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
219114769|NCT00845871|DRUG|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
219114770|NCT02076074|RADIATION|accelerated partial breast irradiation|Undergo HG-PBI
219114771|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
219114772|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
219114773|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
219701027|NCT01027156|BEHAVIORAL|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
219701028|NCT02924155|DRUG|SJP002|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
219701029|NCT02924155|DRUG|Placebo|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
219701030|NCT05051163|DRUG|Ceftriaxone Sodium|7 days of once daily dosing
219701031|NCT05051163|DRUG|Ampicillin|7 days of 6 hourly dosing
219701032|NCT05051163|DRUG|Gentamicin|7 days of once daily dosing
219701033|NCT03817528|DRUG|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
219701034|NCT06275399|DIAGNOSTIC_TEST|OCT examination|OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
219701035|NCT06275399|DIAGNOSTIC_TEST|Blood sampling|Blood sampling directly from coronary artery (proximal and distal segment) arteries
219701036|NCT06275399|DIAGNOSTIC_TEST|Assessment of vFFR and shear stress parameters|The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
219701037|NCT04568655|DEVICE|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
219701038|NCT04284254|DRUG|Autologous Plasmablasts|"Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~\- Maximum Tolerated Dose (MTD) established in Phase I"
219701039|NCT00244309|DRUG|tamsulosin and/or dutasteride|
219701040|NCT06064201|OTHER|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
219701041|NCT06064201|OTHER|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
219701042|NCT04054297|BEHAVIORAL|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
219701043|NCT04054297|BEHAVIORAL|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
219114774|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
219114775|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
219114776|NCT05080881|DIAGNOSTIC_TEST|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
219114777|NCT01542060|DRUG|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
219114778|NCT01374802|DRUG|Darunavir|400 mg tablet for oral administration
219114779|NCT01374802|DRUG|Ritonavir|tablet for oral administration
219114780|NCT01374802|DRUG|BI 201335|
219114781|NCT03061448|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
219114782|NCT00345787|DRUG|Placebo|Corresponding placebo is applied for 12weeks
219701044|NCT04794257|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
219701045|NCT02399332|OTHER|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
219701046|NCT00235807|PROCEDURE|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
219701047|NCT00235807|PROCEDURE|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
219701048|NCT00235807|PROCEDURE|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
219701049|NCT00388921|DRUG|Vitamin A|
219701050|NCT03620448|DEVICE|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
219701051|NCT03620448|OTHER|Oxygen Arm|Oxygen therapy from oxygen cylinders
219114783|NCT00345787|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
219114784|NCT03313258|DEVICE|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
219114785|NCT03313258|DEVICE|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
219114786|NCT03694314|DIETARY_SUPPLEMENT|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
219114787|NCT03694314|DIETARY_SUPPLEMENT|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
219114788|NCT04070677|COMBINATION_PRODUCT|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
219114789|NCT04424875|DRUG|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
219114790|NCT04424875|DRUG|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
219114791|NCT02500914|DRUG|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
219701052|NCT00033280|DRUG|temozolomide|
219701053|NCT00033280|PROCEDURE|neoadjuvant therapy|
219701054|NCT00033280|RADIATION|radiation therapy|
219114792|NCT00406458|DRUG|SB-509|60 mg dose
219114793|NCT00406458|OTHER|Normal Saline|
219114794|NCT01117753|BEHAVIORAL|OutPatient Treatment for Adolescents (OPT-A)|
219114795|NCT01117753|BEHAVIORAL|Treatment As Usual|
219114796|NCT01719900|DIETARY_SUPPLEMENT|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
219114797|NCT01719900|DIETARY_SUPPLEMENT|Control|Control biscuit with no yellow pea hull fibre.
219225058|NCT02827201|DRUG|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
219225059|NCT02407899|DRUG|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
219225060|NCT02407899|DRUG|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
219114798|NCT03380663|PROCEDURE|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
219114799|NCT03164915|BIOLOGICAL|LIV-GAMMA SN Inj.|
219701055|NCT05348252|OTHER|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
219701056|NCT05348252|OTHER|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
219701057|NCT03530891|PROCEDURE|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
219114800|NCT02559609|BEHAVIORAL|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
219114801|NCT02559609|BEHAVIORAL|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
219114802|NCT02559609|BEHAVIORAL|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
219701058|NCT03530891|PROCEDURE|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
219701059|NCT03791320|DIAGNOSTIC_TEST|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
219701060|NCT03287544|OTHER|Combined rehabilitation|Linguistic training as well as communication training.
219701061|NCT03287544|OTHER|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
219701062|NCT03177395|DRUG|PP100-01 (calmangafodipir)|PP100-01
219701063|NCT03177395|DRUG|Acetylcysteine|NAC
219701064|NCT00906243|BIOLOGICAL|CV9103|CV9103 encodes for 4 prostate specific antigens.
219701065|NCT04078386|BIOLOGICAL|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
219701066|NCT04078386|BIOLOGICAL|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
219114803|NCT03772951|OTHER|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
219114804|NCT03772951|DRUG|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
219701067|NCT04078386|BIOLOGICAL|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
219114805|NCT00841516|OTHER|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
219114806|NCT00841516|BIOLOGICAL|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
219114807|NCT02281396|BIOLOGICAL|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
219225061|NCT02407899|DRUG|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
219701068|NCT00834184|DRUG|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
219701069|NCT05021653|OTHER|no intervention|No intervention involved
219701070|NCT01027949|DRUG|Oral Treprostinil|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
219701071|NCT00937534|DRUG|Fimasartan|Fimasartan 240mg/day
219701072|NCT03398096|DEVICE|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
219701073|NCT03315949|DRUG|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
219114808|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
219114809|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
219114810|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
219114811|NCT02155959|DEVICE|toric intraocular lens|toric intraocular lens
219114812|NCT04908124|DEVICE|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
219114813|NCT04908124|DEVICE|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
219114814|NCT04908124|DEVICE|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
219114815|NCT04908124|DEVICE|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
219114816|NCT04908124|DEVICE|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
219114817|NCT03116503|OTHER|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
219114818|NCT04376294|DEVICE|Extracorporeal Shockwave Therapy(ESWT)|Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
219114819|NCT04376294|OTHER|Eccentric training of the calf muscle:|The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
219114820|NCT04376294|OTHER|Gastrocnemius, soleus, and hamstring stretch|Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
219114821|NCT01849796|DEVICE|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
219114822|NCT04152850|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
219114823|NCT01091896|DRUG|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
219114824|NCT01091896|DRUG|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
219114825|NCT04096989|OTHER|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
219114826|NCT04096989|OTHER|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
219114827|NCT01865123|BEHAVIORAL|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
219114828|NCT01865123|BEHAVIORAL|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
219114829|NCT01865123|BEHAVIORAL|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
219114830|NCT00354133|DEVICE|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
219114831|NCT00354133|DRUG|Best Medical Treatment|Patients in this arm get best medical treatment only
219114832|NCT02333734|OTHER|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
219114833|NCT00064025|OTHER|Laboratory Biomarker Analysis|Correlative studies
219701074|NCT00600522|PROCEDURE|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
219701075|NCT02426697|DRUG|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
219701076|NCT02426697|DRUG|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
219701077|NCT01416038|BIOLOGICAL|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
219701078|NCT01416038|DRUG|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
219701079|NCT03773874|OTHER|Assessment|Evaluation
219701080|NCT05945407|COMBINATION_PRODUCT|Indication-extended Fertility-sparing Therapy|"Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions."
219701081|NCT03258255|PROCEDURE|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
219701082|NCT03897335|DRUG|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
219701083|NCT03897335|DRUG|Placebo|The placebo group will not receive any aminophylline treatments for the first post-op five days
219701084|NCT05563558|DRUG|Pembrolizumab|Included in arm/group description
219701085|NCT05563558|DRUG|Carboplatin|Included in arm/group description
219701086|NCT05563558|DRUG|Cabazitaxel|Included in arm/group description
219701087|NCT00587665|DRUG|ketamine|Single IV dose of 0.1 mg/kg of ketamine
219701088|NCT00587665|DRUG|Placebo|Saline given of equal volume to drug
219114834|NCT00064025|DRUG|Medroxyprogesterone|Given IM
219114835|NCT00064025|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
219701089|NCT03353077|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219114836|NCT04641195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
219225062|NCT02407899|DRUG|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
219114837|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
219114838|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
219114839|NCT04641195|OTHER|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
219114840|NCT00095823|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
219114841|NCT00095823|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
219114842|NCT03277378|DEVICE|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
219225063|NCT04968509|DRUG|PCSK9 inhibitors and statins with or without ezetimibe|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
219225064|NCT04968509|DRUG|Statins with or without ezetimibe|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
219701090|NCT01771926|OTHER|potatoes|Daily intake of assigned treatment for 8 weeks
219701091|NCT01771926|OTHER|other carbohydrate|Daily intake of assigned treatment for 8 weeks
219701092|NCT03703895|DRUG|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
219114843|NCT02468934|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
219114844|NCT02500875|DEVICE|PTNiA|
219114845|NCT02500875|DEVICE|PTNiB|
219225065|NCT02279485|DRUG|Perampanel|
219225066|NCT02223728|BEHAVIORAL|Lifestyle|
219225067|NCT02223728|BEHAVIORAL|Health Education|
219225068|NCT02560961|OTHER|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
219701093|NCT03703895|DRUG|Topical Placebo|Placebo Comparator, Topical Placebo.
219701094|NCT00338117|DRUG|Galantamine hydrobromide|
219701095|NCT00671749|DRUG|adapalene gel, 0.3%|Applied once daily at bedtime
219701096|NCT00671749|DRUG|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
219701097|NCT05236530|DRUG|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219701098|NCT05236530|DRUG|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219701099|NCT05236530|DRUG|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219114846|NCT02500875|DEVICE|PTN|
219114847|NCT06024629|DEVICE|cOCT and LC-OCT|"cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)"
219114848|NCT04570813|OTHER|Artistic activies|12 workshops of artictic activities during 12 weeks
219114849|NCT00450515|DRUG|capecitabine|
219114850|NCT00450515|DRUG|vinflunine|
219114851|NCT00829608|BIOLOGICAL|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
219114852|NCT01370603|DRUG|Atorvastatin|40 mg tablet administered orally once daily
219225069|NCT02560961|OTHER|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
219225070|NCT02773862|DEVICE|HS-1000|
219225071|NCT01958385|DEVICE|placement of g-Cath EZ suture anchors|
219225072|NCT01958385|PROCEDURE|Sham procedure|
219225073|NCT01958385|BEHAVIORAL|Diet and Exercise|A structured diet and exercise plan
219701100|NCT05236530|DRUG|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219114853|NCT01370603|DRUG|Ezetimibe|10 mg tablet administered orally once daily
219114854|NCT01370603|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
219701101|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
219701102|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
219114855|NCT01370603|DRUG|Placebo to atorvastatin|Administered orally once daily
219114856|NCT01370603|DRUG|Placebo to ezetimibe|Administered orally once daily
219701103|NCT05236530|DRUG|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219701104|NCT05236530|DRUG|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
219114857|NCT01370603|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
219701105|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
219701106|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
219701107|NCT04694469|PROCEDURE|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
219701108|NCT00129636|PROCEDURE|Additional specific letter written to patient|
219701109|NCT02515227|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219701110|NCT02515227|DRUG|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
219114858|NCT01097213|DRUG|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
219114859|NCT01097213|DRUG|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
219114860|NCT04774822|PROCEDURE|Color Fundus Photography|Stereoscopic Fundus photography
219114861|NCT04774822|DRUG|Mydriatics Agent|Eye dilating agent
219114862|NCT04774822|PROCEDURE|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
219114863|NCT06177236|DIAGNOSTIC_TEST|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
219114864|NCT03723135|DRUG|CC-486|Oral azacitidine administered as directed by treating physician.
219114865|NCT00518713|DRUG|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
219114866|NCT00518713|DRUG|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
219114867|NCT00518713|DRUG|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
219701111|NCT00413517|PROCEDURE|Epi-Lasik|A vision correcting surgery
219701112|NCT03731013|BEHAVIORAL|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
219701113|NCT03731013|BEHAVIORAL|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
219114868|NCT00518713|DRUG|Placebo|tablets; orally; daily for 15-18 weeks
219114869|NCT01722136|BEHAVIORAL|Low Dosage|Exercise dose of 8kcal/kg/week
219701114|NCT03731013|BEHAVIORAL|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
219114870|NCT01722136|BEHAVIORAL|High Dosage|Exercise dose of 14kcal/kg/week
219114871|NCT04396925|OTHER|Point-of care Ultrasonography|GPs using POCUS and how it affects clinical judgement
219114872|NCT00391014|DRUG|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
219114873|NCT01939782|OTHER|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
219114874|NCT01939782|OTHER|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
219114875|NCT01991444|OTHER|TAVI|no Intervention planned, Observation only
219114876|NCT03027713|PROCEDURE|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
219114877|NCT00687661|DRUG|Bisphosphonate|35mg given orally once weekly for 24 months
219701115|NCT04489342|DEVICE|IMU sensor test|Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
219701116|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
219701117|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
219701118|NCT02437292|OTHER|Ischemic compression with stretching|
219114878|NCT00687661|DRUG|Placebo|identical placebo pill once weekly for 24 months
219114879|NCT03119337|OTHER|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
219114880|NCT00019006|DRUG|Detox-B adjuvant|
219114881|NCT00019006|DRUG|ras peptide cancer vaccine|
219114882|NCT01207050|DRUG|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
219114883|NCT01207050|DIETARY_SUPPLEMENT|Placebo|Control treatment
219225074|NCT04160559|OTHER|green tea|The investigators require patients to regularly drink green tea during the trial period.
219114884|NCT01235130|DRUG|OMEGA-3|600mg, 2 caps, twice a day
219114885|NCT01235130|DRUG|Placebo soybean oil|600mg, 2caps twice a day
219114886|NCT03240939|DRUG|Dutasteride 0.5 mg|single dose
219114887|NCT03240939|DRUG|Tadalafil 5 mg|single dose
219114888|NCT03240939|DRUG|YY-201|single dose
219114889|NCT00571779|DEVICE|AtriCure Bipolar System|
219225075|NCT05210309|PROCEDURE|Stem Cell Therapy|Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.
219701119|NCT00922311|DRUG|Aliskiren|Titrate from 150 mg daily to 300 mg daily
219701120|NCT05188105|DEVICE|Alpha tACS (12 Hz) over the occipital cortex|Single session of alpha tACS (12 Hz) over the occipital cortex
219701121|NCT03307135|DEVICE|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
219701122|NCT03307135|DEVICE|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
219701123|NCT03307135|DEVICE|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
219114890|NCT00798031|DEVICE|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
219114891|NCT00798031|DEVICE|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
219114892|NCT00798031|DEVICE|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
219114893|NCT02905123|BEHAVIORAL|Check Your Drinking|
219114894|NCT00417014|DRUG|chlorambucil|
219114895|NCT00417014|DRUG|prednisolone|
219114896|NCT00417014|DRUG|procarbazine hydrochloride|
219114897|NCT00417014|DRUG|vinblastine sulfate|
219114898|NCT00417014|RADIATION|radiation therapy|
219701124|NCT05998967|BEHAVIORAL|Mobile Mantram Repetition Program|Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
219114899|NCT06280456|DRUG|Tranexamic Acid Powder|10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
219114900|NCT03636035|DIETARY_SUPPLEMENT|Tregocel®|Coated tablet (oral)
219114901|NCT01630343|DRUG|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
219114902|NCT01630343|DRUG|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
219114903|NCT01278108|DRUG|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
219114904|NCT01278108|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
219114905|NCT01278108|DRUG|GLPG0778|multiple dose, capsule, 7 days
219114906|NCT01278108|DRUG|placebo|multiple dose, capsule, 7 days
219114907|NCT04703803|COMBINATION_PRODUCT|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
219114908|NCT03681639|DIAGNOSTIC_TEST|Serum Metal ion levels determined to monitor changes in chromium and cobalt levels|Analyses was performed pre-operatively, 6 months, 1 year, 2 years and 5 years post-operatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations was analysed by an approved Central Laboratory. The Central Laboratory provided specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory provided the results to the Investigators. The cobalt and chromium was measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
219114909|NCT00654940|DRUG|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
219114910|NCT00654940|DRUG|Placebo|Oral, matched capsules, BID
219701125|NCT01980758|PROCEDURE|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
219701126|NCT01777646|BIOLOGICAL|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
219701127|NCT04418947|OTHER|Communication type|Control letter vs. intervention letter
219701128|NCT02865161|DRUG|NISELAT|NISELAT 600MG BD
219701129|NCT01259245|OTHER|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
219701130|NCT01259245|OTHER|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
219114911|NCT06058689|DRUG|Pomalidomide 4 MG Oral Capsule|A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period
219114912|NCT00092170|DRUG|MK0826, ertapenem sodium|
219114913|NCT00092170|DRUG|Comparator: Ticarcillin/Clavulanate|
219114914|NCT05155280|OTHER|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
219701131|NCT01792232|OTHER|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
219701132|NCT01792232|OTHER|Saline|Saline will be placed in the lung on day 1 of each triad
219701133|NCT02152007|DRUG|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
219701134|NCT03277131|DEVICE|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
219701135|NCT02258061|PROCEDURE|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
219701136|NCT02258061|PROCEDURE|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
219701137|NCT03316105|DEVICE|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
219701138|NCT01146483|DRUG|Rosuvastatin, Pantoprazole|"Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study."
219114915|NCT05155280|BEHAVIORAL|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
219114916|NCT00994487|OTHER|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
219114917|NCT00994487|OTHER|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
219114918|NCT02965209|PROCEDURE|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
219114919|NCT05921630|OTHER|Education|Patient education before pulmonary function test
219114920|NCT05793762|DEVICE|Left virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
219114921|NCT05793762|DEVICE|Right virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
219114922|NCT06494553|OTHER|cervical stabilization exercises|Neck stabilization exercises included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction
219114923|NCT06494553|DEVICE|Ultrasound therapy|The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio
219114924|NCT06494553|OTHER|traditional treatment program|US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
219114925|NCT06494553|DEVICE|Infrared therapy|Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
219114926|NCT01941992|DRUG|SAMITAL®|
219701139|NCT03442062|OTHER|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
219701140|NCT03442062|OTHER|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
219701141|NCT03442062|OTHER|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
219701142|NCT03318172|DEVICE|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
219701143|NCT06479902|PROCEDURE|Core stability exercise|Core stability exercises featured moves such as planks and side planks.
219701144|NCT06479902|PROCEDURE|Diaphragmatic Strengthening Exercise|. Diaphragmatic exercises included diaphragmatic breathing in various positions.
219701145|NCT05569096|DIAGNOSTIC_TEST|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
219701146|NCT03451071|DRUG|Gardasil9|Gardasil 9
219701147|NCT02023489|DEVICE|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
219114927|NCT01941992|DRUG|Placebo sachets|
219114928|NCT00590070|DRUG|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
219114929|NCT00590070|DRUG|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
219114930|NCT00590070|DRUG|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
219225076|NCT05493488|BIOLOGICAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
219225077|NCT05493488|BIOLOGICAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
219225078|NCT05493488|BIOLOGICAL|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
219114931|NCT04714216|DEVICE|The Omnipod 5/Horizon HCL system|"The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or pod), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments."
219114932|NCT03541811|DIAGNOSTIC_TEST|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
219114933|NCT03541811|DIAGNOSTIC_TEST|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
219114934|NCT03541811|DIAGNOSTIC_TEST|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
219114935|NCT03541811|DIAGNOSTIC_TEST|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
219360891|NCT00993707|DRUG|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
219701148|NCT02023489|OTHER|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
219701149|NCT02023489|OTHER|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at \~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with \[1-13C\]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
219701150|NCT06004960|DRUG|[14C]CCX168|Administered orally.
219701151|NCT00129831|DRUG|QAB149|
219701152|NCT01530919|PROCEDURE|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
219114936|NCT03541811|DIAGNOSTIC_TEST|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
219114937|NCT01238783|DRUG|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
219701153|NCT04005872|DRUG|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
219701154|NCT04005872|DRUG|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
219701155|NCT04133389|OTHER|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
219701156|NCT04133389|OTHER|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
219701157|NCT01934179|OTHER|cytology specimen collection procedure|Undergo blood sample collection
219701158|NCT01934179|OTHER|laboratory biomarker analysis|Correlative studies
219701159|NCT01934179|OTHER|questionnaire administration|Ancillary studies
219701160|NCT02065557|BIOLOGICAL|Adalimumab|Subcutaneous (SC) injection
219701161|NCT02065557|BIOLOGICAL|Placebo|Subcutaneous (SC) injection
219701162|NCT00250588|BEHAVIORAL|Problem solving skills training|See description in Results
219701163|NCT00250588|BEHAVIORAL|Asthma care coordination|See description in Results
219701164|NCT00250588|OTHER|Usual Care|Usual clinical care
219701165|NCT01993199|PROCEDURE|deep biopsy via ESD technique|
219701166|NCT03025204|BIOLOGICAL|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
219701167|NCT03025204|PROCEDURE|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
219701168|NCT00706797|DRUG|etanercept (EnbrelTM)|
219701169|NCT00706797|DRUG|methotrexate|
219114938|NCT01238783|DRUG|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
219114939|NCT01238783|DRUG|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
219114940|NCT01238783|DRUG|Vehicle|Topical ocular dosed 3 times per day for 3 days
219114941|NCT04615858|DIETARY_SUPPLEMENT|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
219114942|NCT04615858|DIETARY_SUPPLEMENT|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
219225079|NCT06134557|PROCEDURE|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
219225080|NCT02095145|OTHER|Laboratory Biomarker Analysis|Correlative studies
219225081|NCT02095145|OTHER|Pharmacological Study|Correlative studies
219225082|NCT02095145|OTHER|Placebo|Given PO
219225083|NCT02095145|DRUG|Pomegranate-Extract Pill|Given PO
219360892|NCT02977104|OTHER|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
219360893|NCT04737473|DRUG|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
219701170|NCT03689517|OTHER|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
219701171|NCT03689517|DEVICE|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
219701172|NCT02039349|DRUG|PF-05190457|
219701173|NCT00568971|DRUG|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
219701174|NCT02902575|PROCEDURE|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
219701175|NCT02197156|DRUG|10 mg HC-ER|Single dose
219701176|NCT02197156|DRUG|20 mg HC-ER|Single dose
219701177|NCT02197156|DRUG|30 mg HC-ER|Single dose
219701178|NCT02197156|DRUG|40 mg HC-ER|Single dose
219114943|NCT06484764|PROCEDURE|CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions|"During the procedure, the participant first undergoes a CT scan the radiologist plans the needle trajectory based on the registered preoperative CECT (contrast-enhanced computed tomography~) and intraoperative CT. After the participant is manually sterilised and given local anaesthesia, the radiologist will remotely control the robot to finish the needle insertion process under the CT-fluoroscopy guidance and simultaneously adjust the angular needle if necessary. The radiologist confirms whether the needle has reached the target area by CT-fluoroscopy image."
219114944|NCT06484764|PROCEDURE|Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions|Radiologists following the current clinical practice guidance to finish the freehand biopsy procedure under the CT guidance.
219114945|NCT01924403|PROCEDURE|Staple Closure|
219114946|NCT01924403|PROCEDURE|Vertical Mattress Closure|
219114947|NCT01924403|PROCEDURE|Running Subcuticular Closure|
219114948|NCT03506217|DEVICE|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
219114949|NCT05764603|DRUG|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
219114950|NCT00608361|DRUG|Dasatinib|Given PO
219114951|NCT00608361|OTHER|Pharmacological Study|Correlative studies
219114952|NCT01884987|DRUG|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
219114953|NCT05291013|PROCEDURE|Gastric byspass|Test will be before and 9-12 month after gastric bypass
219701179|NCT02197156|DRUG|10 mg HC / 325 mg APAP|Single dose
219701180|NCT02197156|DRUG|Matching Placebo|Single dose
219701181|NCT03502798|DEVICE|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
219701182|NCT02737137|PROCEDURE|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
219701183|NCT02737137|PROCEDURE|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
219114954|NCT02112734|DRUG|Vitamin D|400 IU/daily until age 12 months
219701184|NCT05850715|DIAGNOSTIC_TEST|Disability Assessment for Dementia (DAD)|The scale consists of 40 items and assesses patients' independence in basic and instrumental activities. The scale is completed by the patient's caregiver with the assistance of the assessor-therapist.
219701185|NCT01391611|DRUG|Pazopanib|800 mg; PO
219701186|NCT02738502|DRUG|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
219701187|NCT00485303|DRUG|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
219701188|NCT00485303|DRUG|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
219114955|NCT02112734|DRUG|placebo|identical placebo daily
219114956|NCT05466474|BIOLOGICAL|Tislelizumab Injection|Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
219114957|NCT03428568|OTHER|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
219701189|NCT06232343|OTHER|Parachute Resistance Training|The training programmed duration is of four weeks.The groups will follow the training programmed three times a week. The daily schedule (training group) included four repetitions of maximum intensity 30 m \& 50 m dashes (4 × 30 m, 4 × 50 m). The duration of recovery time between the 30 m \& 50 m runs will be 4 and 6 minutes respectively. Between the last 30 m dash and the first 50 m dash, a 10-minute recovery will be applied. Moreover, sprint speed training should not exceed 400-500 meters in total . To this end, the training programmed of the present study consisted of 4x30m and 4x50m runs, at a frequency of 3 times a week.
219701190|NCT06232343|OTHER|Sprinters|control group perform sprinters without any external resistance training for four weeks.
219701191|NCT00591877|PROCEDURE|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus."
219114958|NCT03428568|DRUG|Nexium|omeprazole
219114959|NCT03428568|DRUG|Amoxil|Antibiotic
219114960|NCT03428568|DRUG|Clarithromycin|Antibiotic
219114961|NCT03428282|PROCEDURE|VR Box|Distraction will be made during the injection of the drug using this method.
219114962|NCT03428282|PROCEDURE|Tablet Device|Distraction will be made during the injection of the drug using this method
219114963|NCT03428282|DRUG|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
219114964|NCT06306950|DEVICE|Near infrared spectroscopy neuromonitor to prevent cerebral desaturation|patients were assigned into active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA) \[17\]. After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors.
219114965|NCT02471846|DRUG|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
219114966|NCT02471846|DRUG|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
219114967|NCT01625936|DRUG|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
219701192|NCT00591877|PROCEDURE|Sham Acupuncture|"The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
219701193|NCT00591877|OTHER|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
219701194|NCT03835039|DEVICE|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
219701195|NCT03253822|OTHER|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
219701196|NCT00445718|PROCEDURE|computed tomography|
219701197|NCT00445718|PROCEDURE|3-Tesla magnetic resonance imaging|
219701198|NCT00445718|PROCEDURE|Abdominal Sonogram|Sonogram of the abdomen area
219701199|NCT00156260|PROCEDURE|Ductal lavage|
219701200|NCT03341520|DRUG|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
219701201|NCT03341520|RADIATION|Low dose radiation Therapy (LDRT)|2 x 2 Gy
219701202|NCT05439564|DRUG|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
219701203|NCT05439564|DRUG|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
219701204|NCT05439564|DRUG|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
219114968|NCT01625936|DRUG|Bevacizumab|
219114969|NCT03139838|BEHAVIORAL|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
219114970|NCT03139838|BEHAVIORAL|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
219114971|NCT02104856|DEVICE|Alair System (Bronchial Thermoplasty)|
219114972|NCT02864511|PROCEDURE|Nefertiti lift|
219114973|NCT01818141|DRUG|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
219114974|NCT01818141|DRUG|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
219114975|NCT04329143|PROCEDURE|open completion cholecystectomy|open excision of cystic duct remnant
219114976|NCT04329143|PROCEDURE|lap completion cholecystectomy|lap excision of cystic duct stone
219701205|NCT03820401|DEVICE|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
219701206|NCT03820401|OTHER|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
219701207|NCT03820401|OTHER|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
219701208|NCT03820401|OTHER|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
219701209|NCT00412620|DRUG|ABT-925|
219701210|NCT00412620|DRUG|Placebo|
219701211|NCT01524315|DRUG|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
219701212|NCT01524315|DRUG|Placebo|100 ml normal saline, intravenous, preoperative
219701213|NCT03646539|BEHAVIORAL|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
219701214|NCT03646539|OTHER|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
219701215|NCT03073928|PROCEDURE|Interscalene Block|Regional Anesthesia procedure in the neck
219701216|NCT03073928|PROCEDURE|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
219701217|NCT03073928|DRUG|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
219114977|NCT04319003|BEHAVIORAL|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
219114978|NCT03444220|BIOLOGICAL|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
219114979|NCT03444220|BIOLOGICAL|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
219114980|NCT01554982|DRUG|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
219114981|NCT00678444|OTHER|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
219114982|NCT02127905|BIOLOGICAL|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
219701218|NCT04555148|BIOLOGICAL|GC5131|COVID19 Hyper-Immunoglobulin
219701219|NCT04555148|OTHER|Placebo|Placebo
219701220|NCT05595226|PROCEDURE|RT3D-TEE-guided mitral valve repair|RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
219114983|NCT04238221|DRUG|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
219114984|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
219114985|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
219114986|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
219114987|NCT03059693|DRUG|HAT1 topical cream|
219114988|NCT03059693|DRUG|Vehicle cream|
219114989|NCT00027690|DRUG|Gefitinib|Given orally
219114990|NCT00027690|OTHER|Laboratory Biomarker Analysis|Correlative studies
219114991|NCT03749382|OTHER|AprilAge- facial morphing appearance based intervention for smoking|"Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document."
219114992|NCT02011958|DRUG|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
219114993|NCT02011958|DRUG|Miltefosine|"Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
219114994|NCT03241043|DRUG|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
219114995|NCT03241043|DRUG|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
219114996|NCT04019600|OTHER|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
219114997|NCT04834362|DRUG|Analog Insulin|"For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG \>15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is \>10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG \>15 mmol/L."
219114998|NCT04834362|DRUG|Human insulin|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
219114999|NCT00081471|DRUG|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
219115000|NCT00081471|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
219115001|NCT03990714|PROCEDURE|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
219115002|NCT01868789|RADIATION|Weightbearing CT|
219115003|NCT00299689|DRUG|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
219701221|NCT03644732|PROCEDURE|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
219701222|NCT00296335|DRUG|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
219701223|NCT00296335|DRUG|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
219701224|NCT03331081|OTHER|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
219701225|NCT03331081|OTHER|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
219701226|NCT03331081|OTHER|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
219701227|NCT00012116|DRUG|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
219701228|NCT05508958|PROCEDURE|Anterior approach|Anterior approach
219701229|NCT05508958|PROCEDURE|Posterolateral approach|Posterolateral approach
219701230|NCT05230836|OTHER|High-frequency alternating current stimulation|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group"
219701231|NCT05230836|OTHER|Sham current stimulation|"Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
219701232|NCT01401322|DRUG|Lenalidomide|50 mg; po
219701233|NCT03980912|DIAGNOSTIC_TEST|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
219701234|NCT02737722|DRUG|Bisphosphocin Nu-3|
219701235|NCT02737722|DRUG|Placebo|
219701236|NCT06032663|DIAGNOSTIC_TEST|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
219701237|NCT01231217|OTHER|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
219701238|NCT01231217|OTHER|Coffee|Patients are recommended to drink as much coffee as they tolerate.
219701239|NCT00518570|DRUG|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
219701240|NCT06471439|OTHER|single leg exercise intervantion in COPD|"single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training"
219701241|NCT03880513|DIAGNOSTIC_TEST|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
219701242|NCT00454298|DRUG|AGG-523 (Aggrecanase Inhibitor)|
219701243|NCT02771964|OTHER|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
219701244|NCT06039163|DRUG|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
219701245|NCT06039163|DRUG|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
219701246|NCT02465450|DRUG|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
219701247|NCT02465450|OTHER|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
219701248|NCT02803463|PROCEDURE|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
219701249|NCT02803463|PROCEDURE|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
219115004|NCT05830916|DIAGNOSTIC_TEST|Antiphospholipid antibodies|Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
219115005|NCT00513019|DRUG|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
219115006|NCT00513019|DRUG|Placebo|daily
219115007|NCT05733923|PROCEDURE|Traditional Escavation|"Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling.~\- Group 6: 15 carious teeth will be excavated chemo-mechanically using Selecti-solve."
219115008|NCT05733923|PROCEDURE|Excavation with Sodium Hypochlorite Gel 2.5%.|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using Sodium Hypochlorite Gel 2.5%.
219115009|NCT05733923|PROCEDURE|Excavation with Papacarie Duo|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Papacarie Duo.
219115010|NCT05733923|PROCEDURE|Excavation with Brix3000|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Brix3000.
219115011|NCT05733923|PROCEDURE|Excavation with Selecti-solve|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Selecti-solve.
219701250|NCT02752477|DRUG|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
219701251|NCT02752477|DRUG|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
219701252|NCT05415878|DEVICE|RCW design form|"Tall RCW= a knee high removable cast walker with an offloading insole~Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb"
219701253|NCT00092001|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
219701254|NCT01578291|BEHAVIORAL|Parental information|An informational brochure indicating the study details
219701255|NCT01578291|BEHAVIORAL|Play therapy|Play therapy with a child life specialist
219701256|NCT01242787|DRUG|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
219701257|NCT01242787|DRUG|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
219701258|NCT02136693|DRUG|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
219701259|NCT02136693|DRUG|Placebo|3.5 g /day of inert compound for 180 days after STARR
219701260|NCT00386061|DRUG|rimonabant (SR141716)|
219701261|NCT01981083|DIETARY_SUPPLEMENT|Egg albumin-based protein supplement|
219701262|NCT01981083|DIETARY_SUPPLEMENT|Renal-specific oral supplement|
219701263|NCT00770406|DRUG|botulinum toxin type A|100 or 200 units intravesically
219701264|NCT03749200|OTHER|Obemat2.0 therapy|
219115012|NCT01096732|DRUG|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
219115013|NCT00807222|DRUG|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
219701265|NCT03749200|OTHER|Regular practise in primary care|
219701266|NCT05916209|PROCEDURE|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
219701267|NCT05297682|DEVICE|anesthesia with propofol|General anesthesia with propofol
219701268|NCT04451096|DIETARY_SUPPLEMENT|Probiotics with prebiotic|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
219701269|NCT04451096|DIETARY_SUPPLEMENT|Placebo|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
219701270|NCT00454870|DRUG|MEM 3454|
219701271|NCT02933814|DRUG|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
219701272|NCT06264713|DEVICE|Immersive Virtual Reality|Patients wear a head-mounted-display and will be immersed in a virtual environment. The stimuli will be provided in the left, center and right visual fields. Eye-tracking biofeedback will be provided about the real-time performance during each exercise.
219701273|NCT06264713|DEVICE|Sham Immersive Virtual Reality|The patients performed the same protocol of the experimental group, differently to the immersive virtual reality group, from session 2 to session 8 (7 sessions), the stimuli will be provided in the center and right visual fields.
219701274|NCT00290225|BEHAVIORAL|Breath Water Sound Course and Traumatic Incident Reduction|
219701275|NCT02889419|DEVICE|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
219115014|NCT04616274|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
219115015|NCT04934774|BIOLOGICAL|CD7 CAR T cells|Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219115016|NCT04641624|OTHER|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
219701276|NCT06000644|DEVICE|Combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.
219701277|NCT06000644|DEVICE|Cognitive group|The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .
219115017|NCT04535739|RADIATION|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
219115018|NCT02940769|DEVICE|light glasses|light glasses
219701278|NCT06000644|DEVICE|Rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
219701279|NCT06000644|DEVICE|Treadmill group|The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
219701280|NCT06140186|DRUG|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
219701281|NCT06140186|DRUG|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
219701282|NCT05776992|DEVICE|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
219701283|NCT05776992|DEVICE|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
219701284|NCT03955549|BEHAVIORAL|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
219701285|NCT03955549|BEHAVIORAL|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
219701286|NCT03955549|DRUG|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
219701287|NCT01131936|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
219701288|NCT00930618|DRUG|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
219701289|NCT00930618|DRUG|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
219701290|NCT04164238|DRUG|Toripalimab|Toripalimab Injection
219701291|NCT04164238|DRUG|Paclitaxel|Paclitaxel Injection
219701292|NCT04164238|DRUG|Carboplatin|Carboplatin Injection
219701293|NCT04164238|DRUG|Cisplatin|Cisplatin injection
219701294|NCT04164238|DRUG|5-fu|5-fu injection
219115019|NCT02940769|DEVICE|sham glasses (placebo)|sham light glasses
219115020|NCT02746536|OTHER|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
219115021|NCT02746536|OTHER|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
219115022|NCT01755689|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
219701295|NCT03207399|DRUG|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
219701296|NCT05836480|PROCEDURE|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
219115023|NCT01755689|BIOLOGICAL|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
219115024|NCT01755689|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
219115025|NCT00050414|DRUG|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
219115026|NCT00050414|DRUG|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
219115027|NCT05299489|OTHER|Direct restoration|Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration, bonding, applying composite and assessment of occlusion.
219115028|NCT05299489|OTHER|Indirect restoration|"Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. Preparation walls were vertical according to the longitudinal axis of the tooth and the occlusal depth 2 mm. The impressions were taken for both jaws and the bite were recorded for the using red wax. The cavity in example were painted with insulating material. Indirect composite resin were applied, finishined and polished.~Cementation:~Tooth surface: The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration: application of silane coupling agent to enhance the formation of resin tags.~Dual cure resin cement was used for final cementation followed by an assessment of occlusion."
219115029|NCT04800835|DEVICE|Gastric Balloon|implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
219115030|NCT00385905|DEVICE|Excel Drug-eluting stent|
219115031|NCT05926856|DRUG|Indocyanine green|Indocyanine Green 25mg kit for injection
219115032|NCT03864289|BEHAVIORAL|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
219115033|NCT01714596|OTHER|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
219115034|NCT02106689|DEVICE|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
219360894|NCT06265844|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219701297|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
219701298|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
219701299|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
219701300|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
219701301|NCT02595658|DIETARY_SUPPLEMENT|Meal composition|
219701302|NCT02595658|DRUG|Rapid-Acting Insulin Dose|
219701303|NCT06305845|PROCEDURE|Digital crowns|crowns fabricated digitally by CAD-CAM technology
219701304|NCT06305845|PROCEDURE|zirconia crowns|crowns that are ready made for primary teeth
219701305|NCT06060470|BEHAVIORAL|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
219701306|NCT06060470|BEHAVIORAL|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
219701307|NCT04809116|DRUG|Pimavanserin|open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
219115035|NCT02106689|DEVICE|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
219115036|NCT01054872|BIOLOGICAL|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
219115037|NCT01054872|BIOLOGICAL|HIV-1 recombinant Ad5 vaccine|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
219115038|NCT03923296|DEVICE|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
219115039|NCT03923296|BEHAVIORAL|Interviews|Focus group interviews
219701308|NCT02925468|DEVICE|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
219701309|NCT04668677|OTHER|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
219701310|NCT05414604|DIAGNOSTIC_TEST|3D spine CT|CT scan of the spine
219701311|NCT00477685|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
219701312|NCT02500251|DRUG|belimumab|Belimumab will be administered per study protocol.
219701313|NCT02500251|DRUG|Bortezomib|Bortezomib will be administered per study protocol.
219115040|NCT04575649|OTHER|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
219115041|NCT04461925|PROCEDURE|Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|i/v infusions
219115042|NCT04461925|DRUG|Antibiotics|per os
219115043|NCT04461925|DRUG|Hormones|a moderate amount of dexamethasone i/v
219115044|NCT04461925|DRUG|Anticoagulant Therapy|Sub-Q
219115045|NCT04461925|DEVICE|Оxygen therapy|Оxygen therapy, mechanical ventilation and other supportive therapies
219115046|NCT01995357|DEVICE|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
219115047|NCT01995357|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
219115048|NCT01995357|DEVICE|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
219115049|NCT04086979|BEHAVIORAL|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
219115050|NCT04086979|BEHAVIORAL|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
219115051|NCT05266105|DRUG|Palazestrant|Complete Estrogen Receptor Antagonist
219115052|NCT05266105|DRUG|Palbociclib|Palbociclib is an approved CDK 4/6 Inhibitor drug
219115053|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
219115054|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
219115055|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
219115056|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
219115057|NCT05107245|DIAGNOSTIC_TEST|1test1|Loss of bacterial diversity diagnosis
219115058|NCT06581640|BIOLOGICAL|CAR-T treatment|Peripheral blood lymphocyte collection, PBMC separation, BCMA CAR-T cell preparation/storage, lymphodepletion chemotherapy pretreatment for the subject, and BCMA CAR-T cell infusion.
219115059|NCT04082182|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
219115060|NCT04082182|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
219115061|NCT04082182|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
219115062|NCT03359681|DRUG|Metformin Hydrochloride|metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
219115063|NCT03359681|DRUG|Placebo oral capsule|placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
219115064|NCT00897611|PROCEDURE|DNA methylation analysis|
219115065|NCT00897611|PROCEDURE|polymerase chain reaction|
219115066|NCT00897611|PROCEDURE|computed tomography|
219115067|NCT00897611|PROCEDURE|magnetic resonance imaging|
219115068|NCT02955277|OTHER|TECH: Tablet Enhancement of Cognition and Health protocol|Cognitive training using touchscreen tablets (TECH protocol)
219115069|NCT02955277|OTHER|Standard care or active standard care|standard occupational therapy or 6-weekly group sessions playing board games and puzzles.
219115070|NCT00225420|DRUG|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
219115071|NCT00225420|DRUG|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
219115072|NCT00225420|RADIATION|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
219115073|NCT02748564|BIOLOGICAL|Aldesleukin|Given IV
219115074|NCT02748564|OTHER|Laboratory Biomarker Analysis|Correlative studies
219115075|NCT02748564|BIOLOGICAL|Pembrolizumab|Given IV
219115076|NCT03597893|DRUG|Oxytocin|intranasally administrated
219115077|NCT03597893|DRUG|Placebo|intranasally administrated
219115078|NCT03188328|DRUG|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX~\+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
219115079|NCT03188328|DRUG|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
219115080|NCT03188328|DRUG|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
219115081|NCT00005594|DRUG|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
219115082|NCT01668147|DRUG|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging
219115083|NCT01668147|OTHER|Control - no pretreatment|Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI
219115084|NCT01668147|DRUG|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
219701314|NCT02500251|DRUG|Rituximab|Rituximab will be administered per study protocol.
219701315|NCT02500251|DRUG|Plasmapheresis|Plasmapheresis will be administered per study protocol.
219115085|NCT01668147|DRUG|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
219115086|NCT01809210|DRUG|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
219115087|NCT01809210|DRUG|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
219115088|NCT01809210|DRUG|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
219115089|NCT01809210|DRUG|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
219115090|NCT01809210|DRUG|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
219701316|NCT03779646|DRUG|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
219701317|NCT03451045|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
219701318|NCT03451045|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
219701319|NCT03451045|OTHER|Placebo|Subjects will receive placebo twice daily.
219701320|NCT01553929|OTHER|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
219701321|NCT01553929|OTHER|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
219701322|NCT01553929|OTHER|control group|no physical training and no cognitive activity
219701323|NCT04581915|DRUG|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
219115091|NCT00791622|DRUG|Paliperidone ER|
219115092|NCT06168656|BEHAVIORAL|Mobile Application|"The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers."
219701324|NCT04581915|OTHER|Placebo|Placebo capsule
219701325|NCT00863707|DRUG|Regadenoson|IV
219701326|NCT00863707|DRUG|Placebo|IV
219115093|NCT03557983|DRUG|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
219115094|NCT03557983|DRUG|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
219115095|NCT01808443|OTHER|Cryotherapy|up to a maximum of four treatments every 21-28 days
219701327|NCT06374303|OTHER|NE + Meal Delivery (NE+MD) intervention|NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
219701328|NCT02291978|DEVICE|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
219701329|NCT00512590|BEHAVIORAL|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
219701330|NCT05415293|DIETARY_SUPPLEMENT|Expecta 200mg DHA|
219701331|NCT05415293|DIETARY_SUPPLEMENT|Promise 275mg DHA|
219115096|NCT01808443|OTHER|laser|up to a maximum of four treatments every 21-28 days
219701332|NCT04909944|DEVICE|i-gel Supraglottic insertion|i-gel Supraglottic insertion for oxygenation
219115097|NCT02717598|PROCEDURE|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
219115098|NCT02717598|PROCEDURE|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
219115099|NCT04141111|DEVICE|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
219115100|NCT03760315|DIAGNOSTIC_TEST|blood mNGS (IDSeqTM Ultra); blood Culture|take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
219115101|NCT00061100|BEHAVIORAL|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
219115102|NCT00061100|BEHAVIORAL|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
219115103|NCT06186505|DEVICE|AirGlove|AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
219115104|NCT04122053|BEHAVIORAL|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
219115105|NCT04122053|BEHAVIORAL|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
219115106|NCT05852769|DRUG|BMS-986196|Specified dose on specified days
219115107|NCT05852769|DRUG|Caffeine|Specified dose on specified days
219115108|NCT05852769|DRUG|Montelukast|Specified dose on specified days
219115109|NCT05852769|DRUG|Flurbiprofen|Specified dose on specified days
219115110|NCT05852769|DRUG|Omeprazole|Specified dose on specified days
219701333|NCT04909944|DEVICE|Laryngeal Tube Suction Disposable Supraglottic insertion|Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
219115111|NCT05852769|DRUG|Midazolam|Specified dose on specified days
219115112|NCT05852769|DRUG|Digoxin|Specified dose on specified days
219115113|NCT05852769|DRUG|Pravastatin|Specified dose on specified days
219701334|NCT06190028|DEVICE|Iridium A Gel|IRIDIUM® A gel is a sterile, preservative free ophthalmic gel, containing Carbopol, amino acids, Echinacea and Aloe extract. IRIDIUM® A gel is indicated for the protection of the eye surface particularly at night, even in the presence of changes in histological continuity and blepharitic conditions, including those of an iatrogenic nature, following the use of hypotonic eye drops and of the preservatives contained therein.
219701335|NCT00174824|DRUG|Insulin glargine|
219701336|NCT00514696|DRUG|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
219701337|NCT00217230|BIOLOGICAL|CAIV-T|
219701338|NCT01745510|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
219115114|NCT06040463|BEHAVIORAL|Diabetes Self-Management Training (DSMT)|The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education \& portion control; Session 3 - Tips \& Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.
219115115|NCT06040463|BEHAVIORAL|Remote Glucose Monitoring (RGM)|Remote Glucose Monitoring (RGM) is an automated process of transmitting glucose levels directly from a personal smartphone device to a healthcare provider using a remote data transmitter. Since 2020, Sinai has worked with Glooko Inc. to provide the RGM platform and technical assistance to patients and for Sinai providers to access data remotely. Via the app, patients can: document their glucose levels; sync data from a meter, insulin pump, pen or continuous glucose monitoring device; track their weight; log food and meals; access educational resources; track steps; and track blood pressure. Remotely uploading data provides patients with a direct line to their provider for regular feedback on progress and answers to questions between clinic visits. Patients also receive one one-hour education session on RGM and the Glooko application.
219115116|NCT06040463|BEHAVIORAL|Community Health Worker tailored support|CHWs are frontline public health workers who are trusted members of and/or have an unusually close understanding of the community served. The Center has two bilingual (Spanish/English) CHWs; additional bilingual CHWs will be added to the team to support the proposed study. While approaches will differ slightly depending on the patient and study condition, all patients paired with a CHW will be screened for social needs utilizing a standard social determinants of health (SDoH) screening tool, receive referrals to resources to address unmet social/health needs, and aided in navigating health and social systems.
219115117|NCT04640480|DRUG|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
219115118|NCT04399564|DEVICE|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
219115119|NCT04399564|DEVICE|long-term hemodialysis catheters|long-term hemodialysis catheters
219115120|NCT00401466|DEVICE|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
219115121|NCT03839472|PROCEDURE|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
219115122|NCT03699124|BIOLOGICAL|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
219115123|NCT01346761|BEHAVIORAL|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
219701339|NCT01745510|DIETARY_SUPPLEMENT|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
219701340|NCT04142242|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
219701341|NCT04142242|OTHER|Blood sample|Blood sample for assessment of antibody persistence.
219115124|NCT01346761|BEHAVIORAL|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
219115125|NCT05435183|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
219115126|NCT05435183|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
219115127|NCT00260156|DRUG|vildagliptin|
219115128|NCT00260156|DRUG|placebo|
219115129|NCT00699543|DEVICE|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
219701342|NCT05913362|BEHAVIORAL|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
219701343|NCT06351904|DRUG|RAG-01|RAG-01 is a therapeutic small activating RNA (saRNA) duplex molecule comprised of two partially chemically modified complementary oligonucleotide strands.
219701344|NCT05302011|DRUG|Pembrolizumab|Pembrolizumab 200mg i.v. day 1-22-43-64
219701345|NCT05302011|DRUG|Carboplatin or Cisplatin|Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
219701346|NCT05302011|DRUG|Docetaxel|75mg/m2 i.v. day 1-22-43-64
219701347|NCT00513929|DIETARY_SUPPLEMENT|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
219701348|NCT02051868|DRUG|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
219701349|NCT02051868|DRUG|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
219701350|NCT02051868|DRUG|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
219701351|NCT02051868|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
219701352|NCT03040726|DRUG|Netupitant|Given PO
219701353|NCT03040726|DRUG|Palonosetron|Given PO
219701354|NCT03040726|DRUG|Palonosetron Hydrochloride|Given PO
219701355|NCT03040726|OTHER|Placebo|Given PO
219701356|NCT03040726|OTHER|Questionnaire Administration|Ancillary studies
219701357|NCT03998072|OTHER|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
219115130|NCT00699543|DEVICE|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
219115131|NCT05484258|BEHAVIORAL|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
219115132|NCT04773002|OTHER|Different anesthesia methods|Total intravenous anesthesia (TIVA)and volatile anesthesia
219115133|NCT01118962|DRUG|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
219115134|NCT03708380|BEHAVIORAL|Dietary intervention|Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
219115135|NCT02127684|DRUG|ranibizumab|ranibizumab 0.3mg intravitreally monthly
219115136|NCT02127684|DRUG|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
219115137|NCT04689165|BIOLOGICAL|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
219115138|NCT04689165|BIOLOGICAL|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
219701358|NCT04749199|BEHAVIORAL|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
219701359|NCT04749199|BEHAVIORAL|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
219701360|NCT06466239|OTHER|PNF Stretching|PNF was applied to the hamstring muscle, with a 1-day washout period in between.
219701361|NCT06466239|OTHER|Static Stretching|Static stretching was applied to the hamstring muscle, with a 1-day washout period in between.
219115139|NCT05931562|OTHER|Fermented Foods|Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
219701362|NCT04382482|DEVICE|Tachidino|Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).
219701363|NCT05295589|PROCEDURE|Computed Tomography|Undergo CT scan
219115140|NCT05931562|OTHER|High Fibre|Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
219701364|NCT05295589|DRUG|Copanlisib Hydrochloride|Given IV
219701365|NCT05295589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219115141|NCT05931562|OTHER|Combined Diet|Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.
219115142|NCT05931562|OTHER|Control|Participants will recieve dietary education based on the Irish healthy food pyramid.
219701366|NCT05295589|DRUG|Olaparib|Given PO
219701367|NCT05295589|DRUG|Paclitaxel|Given IV
219701368|NCT05295589|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219701369|NCT05295589|DRUG|Topotecan Hydrochloride|Given IV
219701370|NCT03210766|DRUG|Nabilone|
219701371|NCT03210766|DRUG|THC/CBD|
219701372|NCT02328612|OTHER|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
219115143|NCT02749708|DRUG|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
219115144|NCT05373602|DIAGNOSTIC_TEST|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
219115145|NCT03671720|BIOLOGICAL|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
219115146|NCT05173051|OTHER|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
219115147|NCT06163716|BEHAVIORAL|Multidomain intervention (MD-Int) group|The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
219115148|NCT04708184|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
219115149|NCT04708184|DRUG|GLPG3970 tablet|GLPG3970 for oral administration
219115150|NCT06213012|DEVICE|Transcutaneous Spinal cord Stimulation|Delivered using a constant-current stimulator
219115151|NCT06213012|DEVICE|Epidural Spinal Stimulation (ESS)|"The device used for ESS, the CoverEdgeX 32 Surgical Lead system (Boston Scientific, USA), is a device approved by the FDA used in the treatment of severe pain and is approved for individuals to manage chronic pain when other treatments have not been effective.~If you are in the ESS group, you will have surgery to have the stimulator placed and the stimulator will be removed at an office visit towards the end of the study."
219115152|NCT00805636|DRUG|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|\[18F\]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for \[18F\]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of \[18F\]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
219115153|NCT00805636|RADIATION|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
219115154|NCT00805636|PROCEDURE|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of \[18F\]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
219115155|NCT00262743|BIOLOGICAL|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
219115156|NCT05594355|DRUG|TEBOFORTAN|TEBOFORTAN 240 mg is administrated 1 tablet per day
219115157|NCT05691569|OTHER|doll therapy|empathy dolls
219115158|NCT05887284|RADIATION|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
219115159|NCT05887284|RADIATION|mock radiation treatment|6 times 0.0 Gy
219115160|NCT05887284|RADIATION|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
219115161|NCT06176820|DRUG|Vaginal Gel|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
219115162|NCT06176820|DRUG|Vaginal lubricant|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
219115163|NCT02701582|DRUG|Phenylephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered
219115164|NCT02701582|DRUG|Epinephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
219115165|NCT02701582|OTHER|Albumin|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
219115166|NCT02701582|OTHER|Voluven|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
219115167|NCT02701582|OTHER|Normal Saline|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
219115168|NCT02701582|OTHER|Packed Red Blood Cells|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
219115169|NCT02701582|DEVICE|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
219115170|NCT00951860|OTHER|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
219115171|NCT02123290|DRUG|DSM265 400mg|
219115172|NCT02123290|DRUG|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
219701373|NCT03226795|OTHER|" Information-Motivation-Behavioral skills  intervention."|"* information -\> Reminders of medication: mobile application~* Motivation -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~* Behavioral skills -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
219701374|NCT01141816|OTHER|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
219701375|NCT02444026|BEHAVIORAL|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
219701376|NCT03297190|BEHAVIORAL|SMS|Receipt of SMS messages on nutrition and health topics
219701377|NCT03297190|BEHAVIORAL|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
219701378|NCT01894906|DRUG|Soluble Ferric Pyrophosphate|
219701379|NCT01894906|OTHER|Placebo|
219701380|NCT06525792|PROCEDURE|Oxygen|Oxygen and standard therapy were given
219701381|NCT06525792|PROCEDURE|Ozone|Ozone and standard therapy were given
219701382|NCT06525792|PROCEDURE|Standard therapy|Best standard of care
219701383|NCT04460053|PROCEDURE|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
219701384|NCT02673749|DRUG|RP-G28|Study drug taken orally
219701385|NCT02673749|OTHER|Placebo|Placebo taken orally
219701386|NCT01231269|OTHER|MRI|MRI scan without administration of contrast/without radiation
219701387|NCT02322996|OTHER|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
219701388|NCT04543864|DEVICE|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
219701389|NCT04543864|DEVICE|casting|casting the metal framework
219701390|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
219701391|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
219115173|NCT02123290|DRUG|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
219701392|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
219701393|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
219701394|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
219701395|NCT00877968|DIETARY_SUPPLEMENT|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
219701396|NCT00877968|DIETARY_SUPPLEMENT|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
219115174|NCT02161328|OTHER|EIT belt|
219115175|NCT02589041|PROCEDURE|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
219701397|NCT00877968|DIETARY_SUPPLEMENT|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --\> 250 g cooked Available CHO: 52.8 g"
219701398|NCT04369937|RADIATION|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
219701399|NCT04369937|DRUG|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
219115176|NCT02589041|DRUG|Ropivacaine 1%|
219115177|NCT02653040|OTHER|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
219115178|NCT00492843|DRUG|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
219701400|NCT04369937|DRUG|Cisplatin|Chemotherapy
219701401|NCT04369937|BIOLOGICAL|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
219701402|NCT04805528|RADIATION|Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)|Twice weekly ALTENS therapy for 12 weeks
219701403|NCT05219162|GENETIC|Gene Profile explore|The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.
219701404|NCT04632108|DRUG|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
219115179|NCT04684927|DEVICE|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
219115180|NCT04016051|DRUG|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
219115181|NCT04016051|DRUG|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
219115182|NCT04016051|DRUG|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
219115183|NCT04016051|DRUG|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
219115184|NCT04016051|DRUG|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
219115185|NCT04016051|DRUG|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
219225084|NCT02916576|DEVICE|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
219701405|NCT04154891|GENETIC|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
219115186|NCT02502305|BEHAVIORAL|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
219115187|NCT01182168|DRUG|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
219115188|NCT02490696|DEVICE|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
219115189|NCT02490696|DEVICE|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
219115190|NCT02774265|DRUG|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
219701406|NCT04154891|GENETIC|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
219701407|NCT04154891|GENETIC|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
219701408|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
219115191|NCT02774265|DRUG|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
219701409|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
219701410|NCT03506061|DRUG|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
219701411|NCT02143687|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
219701412|NCT02143687|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
219115192|NCT02678520|RADIATION|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
219115193|NCT02678520|RADIATION|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
219115194|NCT02678520|DRUG|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
219701413|NCT02143687|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
219701414|NCT02143687|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
219701415|NCT05929833|BEHAVIORAL|BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)|The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
219701416|NCT05929833|OTHER|Usual Care|Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
219701417|NCT01952652|DRUG|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
219701418|NCT01952652|DRUG|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
219701419|NCT04367805|DIAGNOSTIC_TEST|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
219701420|NCT04626505|DRUG|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
219115195|NCT01427621|PROCEDURE|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
219115196|NCT04910906|DEVICE|Ectoin® Vaginal Gel|"Ectoin® Vaginal Gel is a clear, non-hormonal moisturizing gel containing only active ingredient Ectoin® for the relief of vaginal dryness/vaginal atrophy.~Other excipients in the formulation include:~Hydroxyethylcellulose (Gelling agent) Lactic acid (90 %) (pH stabiliser) DL-Sodium lactate (Buffer substance) Sodium benzoate (preservative) Propylene glycol (Humectant)"
219115197|NCT04430335|BEHAVIORAL|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
219115198|NCT04430335|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
219115199|NCT02071563|DIETARY_SUPPLEMENT|CSB14|
219115200|NCT02071563|DIETARY_SUPPLEMENT|RUSF1|
219225085|NCT00786344|BEHAVIORAL|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
219225086|NCT01542255|DRUG|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
219701421|NCT04626505|DRUG|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
219701422|NCT01367691|DEVICE|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
219701423|NCT03246945|BEHAVIORAL|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
219115201|NCT02071563|DIETARY_SUPPLEMENT|SC+|
219115202|NCT04004793|BEHAVIORAL|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, \>15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
219115203|NCT04004793|DRUG|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
219115204|NCT04004793|DRUG|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
219115205|NCT04668287|BEHAVIORAL|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
219115206|NCT03748979|DRUG|TAK-925|TAK-925
219115207|NCT03748979|DRUG|Placebo|TAK-925 Placebo
219115208|NCT01335308|BEHAVIORAL|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
219115209|NCT01335308|BEHAVIORAL|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
219225087|NCT01542255|DRUG|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
219701424|NCT05711368|BEHAVIORAL|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
219701425|NCT06062992|DIAGNOSTIC_TEST|Contrast Enhanced Stereotactic Biopsy|Stereotactic breast biopsy using CEM as targeting modality
219701426|NCT00000498|BEHAVIORAL|diet, sodium-restricted|
219701427|NCT00000498|BEHAVIORAL|diet, reducing|
219701428|NCT00000498|BEHAVIORAL|alcohol restriction|
219701429|NCT00000498|DRUG|antihypertensive agents|
219701430|NCT02466503|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
219115210|NCT01335308|BEHAVIORAL|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
219115211|NCT00189176|DRUG|Tetrathiomolybdate|
219115212|NCT02809586|BEHAVIORAL|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
219115213|NCT02809586|BEHAVIORAL|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
219115214|NCT04127305|OTHER|No Intervention|No Intervention
219115215|NCT04397302|DIAGNOSTIC_TEST|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
219115216|NCT01064583|OTHER|cocoa|dissolved in water twice-daily intervention
219115217|NCT01650675|BEHAVIORAL|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
219225088|NCT01542255|DRUG|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
219225089|NCT02323945|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
219225090|NCT02323945|OTHER|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
219225091|NCT02323945|OTHER|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
219225092|NCT00670488|DRUG|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
219701431|NCT02466503|DRUG|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
219701432|NCT00761878|PROCEDURE|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
219115218|NCT01650675|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
219115219|NCT05475769|DRUG|Clinical evaluation|Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
219115220|NCT06359665|DRUG|Curcumin|500 mg capsule twice daily
219115221|NCT06359665|DRUG|Placebo|capsule twice daily
219115222|NCT00283738|DEVICE|BioSTAR Septal Repair Implant System|PFO Closure
219115223|NCT00283738|PROCEDURE|Sham Procedure|Catheterization
219225093|NCT06554184|DRUG|HR20013 + dexamethasone + palonosetron placebo|HR20013 + dexamethasone + palonosetron placebo
219701433|NCT01313754|PROCEDURE|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
219701434|NCT01313754|PROCEDURE|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
219115224|NCT03086122|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
219115225|NCT00655395|DRUG|Laromustine (VNP40101M) and Ara-C|"1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
219115226|NCT01979055|BEHAVIORAL|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
219115227|NCT01979055|BEHAVIORAL|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
219115228|NCT04789213|OTHER|Liver Transplantation|Liver Transplantation
219115229|NCT06038812|DIAGNOSTIC_TEST|GCF sample collection|collecting GCF from deepest sites by paper points
219115230|NCT06038812|PROCEDURE|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
219115231|NCT00005108|DRUG|Estradiol|
219115232|NCT00005108|DRUG|Progesterone|
219115233|NCT05275751|DRUG|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
219115234|NCT05275751|DRUG|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
219115235|NCT05275751|DRUG|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
219115236|NCT05275751|DRUG|Placebo|No pharmacological intervention
219115237|NCT05275751|DRUG|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
219115238|NCT02508766|PROCEDURE|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
219115239|NCT00850044|DRUG|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
219225094|NCT06554184|DRUG|Palonosetron + dexamethasone + HR20013 placebo|Palonosetron + dexamethasone + HR20013 placebo
219115240|NCT00850044|DRUG|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
219115241|NCT00850044|DRUG|placebo for ABT-450|capsules, QD, one dose
219115242|NCT00850044|DRUG|Placebo for ritonavir|capsules, QD, one dose
219115243|NCT04182607|PROCEDURE|kidney transplant|Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
219115244|NCT03039543|DRUG|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
219115245|NCT03039543|DRUG|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
219225095|NCT01455779|DEVICE|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
219225096|NCT00301054|DRUG|Ferrous sulphate|
219115246|NCT02561715|BEHAVIORAL|Questionnaires|Pre and post deep brain surgery questionnaires
219115247|NCT02941068|DRUG|fluconazole and caspofungin|
219115248|NCT03821415|DRUG|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
219225097|NCT00301054|DRUG|Sulphadoxine-Pyrimethamine|
219225098|NCT03677167|OTHER|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
219701435|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
219701436|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
219701437|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
219115249|NCT04266171|BEHAVIORAL|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
219115250|NCT04266171|BEHAVIORAL|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
219115251|NCT05511740|RADIATION|Afternoon Radiation|Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
219115252|NCT04142463|OTHER|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
219115253|NCT01591460|DRUG|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
219115254|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
219115255|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
219115256|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
219115257|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
219115258|NCT00524238|DRUG|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
219115259|NCT05473091|OTHER|no intervention|retrospective analysis
219115260|NCT00464035|BEHAVIORAL|high calcium intake|
219701438|NCT03180710|DRUG|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
219701439|NCT03156075|BEHAVIORAL|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
219701440|NCT04198935|DEVICE|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
219701441|NCT01061372|DRUG|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
219701442|NCT01061372|DRUG|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
219701443|NCT01061372|DRUG|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
219701444|NCT04425317|DIAGNOSTIC_TEST|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
219701445|NCT01620645|RADIATION|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
219701446|NCT00013507|PROCEDURE|Falls|
219701447|NCT04421755|OTHER|Produce delivery|weekly home delivery of fresh fruits and vegetables
219701448|NCT04421755|OTHER|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is \~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (\~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
219115261|NCT03230864|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
219115262|NCT03230864|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
219115263|NCT03230864|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
219115264|NCT03679013|DRUG|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
219115265|NCT03679013|DRUG|Opiate based pain regimen.|Standard of care opiate based pain regimen.
219701449|NCT01521000|DEVICE|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
219115266|NCT02780986|BEHAVIORAL|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
219115267|NCT02780986|BEHAVIORAL|Heterosexual men intervention group|"This will be delivered via 3 main activities:~1. Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~2. Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~3. Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
219115268|NCT01930643|DEVICE|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
219115269|NCT00859508|DEVICE|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
219701450|NCT05645926|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
219701451|NCT05645926|PROCEDURE|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
219115270|NCT00859508|DEVICE|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
219115271|NCT01528644|DIETARY_SUPPLEMENT|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
219115272|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
219115273|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
219225099|NCT03447912|BEHAVIORAL|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
219225100|NCT00221065|DEVICE|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
219225101|NCT02110914|BEHAVIORAL|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
219701452|NCT05212298|DIETARY_SUPPLEMENT|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
219701453|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
219701454|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
219701455|NCT03846375|BEHAVIORAL|Psychotherapy|DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
219701456|NCT03846375|OTHER|Pre-intervention testing|Pre-intervention testing for baseline measures.
219701457|NCT03279575|BEHAVIORAL|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
219701458|NCT03279575|BEHAVIORAL|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
219701459|NCT03279575|BEHAVIORAL|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
219701460|NCT03279575|BEHAVIORAL|Control|Physicians in this arm will serve as a no-contact control group.
219701461|NCT04730609|DRUG|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
219701462|NCT04987047|BIOLOGICAL|Blood collection|A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
219701463|NCT04987047|OTHER|Questionnaires|Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
219701464|NCT04987047|OTHER|Cognitive test battery (optional)|"For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French)."
219701465|NCT03684408|DEVICE|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
219701466|NCT03684408|DEVICE|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
219701467|NCT03684408|DEVICE|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
219701468|NCT05298241|OTHER|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
219701469|NCT01399307|PROCEDURE|Liposuction|Elective Liposuction
219701470|NCT03397017|OTHER|Transfusion|
219115274|NCT01528644|DIETARY_SUPPLEMENT|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
219115275|NCT00229476|DRUG|sertraline (Zoloft)|
219115276|NCT04171804|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
219701471|NCT02629783|OTHER|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
219701472|NCT02629783|OTHER|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
219701473|NCT02629783|DRUG|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
219701474|NCT02631447|DRUG|LGX818|LGX818 450 mg p.o. od
219701475|NCT02631447|DRUG|MEK162|MEK162 45 mg p.o. bid
219701476|NCT02631447|DRUG|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
219701477|NCT02631447|DRUG|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
219701478|NCT01526408|DRUG|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
219701479|NCT01526408|DRUG|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
219701480|NCT06413966|PROCEDURE|Partially absorbable mesh|\- In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).
219701481|NCT06413966|PROCEDURE|Apical pleurectomy|\- In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
219701482|NCT04155645|DRUG|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
219225102|NCT06346652|OTHER|Routine Physical Therapy|Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.
219701483|NCT04155645|DRUG|Placebo|Randomized subjects will receive SC dose of placebo injection.
219701484|NCT02062697|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
219701485|NCT02062697|PROCEDURE|Liquid-PAP smear|
219701486|NCT04763993|PROCEDURE|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
219701487|NCT04763993|PROCEDURE|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
219701488|NCT06296511|BEHAVIORAL|Exercise|60 min of treadmill exercise performed at 70% of peak oxygen uptake.
219701489|NCT02821533|PROCEDURE|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
219701490|NCT02821533|DRUG|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
219115277|NCT02037867|DEVICE|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
219115278|NCT01744496|DRUG|Rotigotine|Patches will contain 4 mg / 24 h (20 cm\^2), 6 mg/ 24 h (30 cm\^2), or 8 mg /24 h (40 cm\^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
219115279|NCT01744496|DRUG|Placebo|Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
219115280|NCT03987568|OTHER|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
219115281|NCT03987568|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
219115282|NCT02369315|BEHAVIORAL|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
219115283|NCT02369315|BEHAVIORAL|Control (Invited entry 2013)|Entry to music program offered in September 2013
219115284|NCT01038674|DRUG|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
219115285|NCT01038674|DRUG|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
219115286|NCT03630081|DRUG|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
219115287|NCT03630081|DRUG|Meropenem|1 g IV q8h, infused over 45 min
219115288|NCT03630081|DRUG|ciprofloxacin 500 mg Optional Oral Switch|ciprofloxacin 500 mg PO q12h
219115289|NCT03630081|OTHER|Infusion of normal saline|Infusion of normal saline over 45 min
219225103|NCT06346652|OTHER|Routine Physical Therapy+ PNF and Core Stregthening|Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
219701491|NCT06983678|BEHAVIORAL|Smoking as usual fMRI session|Participants in this condition will continue smoking as usual prior to the fMRI session
219701492|NCT06983678|BEHAVIORAL|Abstinent fMRI session|Participants in this condition will be asked to abstain from smoking or using any other tobacco products for 24 hours prior to the fMRI session
219701493|NCT06664567|BEHAVIORAL|Colorectal cancer screening test|delivery of colorectal cancer screening test by GP
219701494|NCT05978167|DRUG|Methylphenidate|Oral administration of 20 mg Methylphenidate
219701495|NCT05978167|BEHAVIORAL|Memory reconsolidation|Retrieval of drug-cue memories before extinction.
219701496|NCT05978167|DRUG|Placebo|Matching placebo pill
219701497|NCT06986148|OTHER|Immediate Antibiotic Prescribing Group Instructions|Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.
219115290|NCT05951699|DEVICE|minimally invasive preoperative image-guided vacuum-assisted biopsy|minimally invasive preoperative image-guided vacuum-assisted biopsy of the breast and needle biopsy of axillary lymph node
219115291|NCT03670147|DEVICE|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
219115292|NCT01567163|BIOLOGICAL|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
219115293|NCT01567163|DRUG|Docetaxel|docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
219115294|NCT03148080|PROCEDURE|Cognitive Assessment|Complete CogState
219115295|NCT03148080|OTHER|Questionnaire Administration|Complete Self-Report Questionnaire
219115296|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
219115297|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
219115298|NCT05349396|DRUG|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
219115299|NCT03405662|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
219115300|NCT03405662|OTHER|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
219115301|NCT00003009|BIOLOGICAL|aldesleukin|
219115302|NCT01608438|DEVICE|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
219225104|NCT01355809|DRUG|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
219701498|NCT06986148|OTHER|Safety Net Antibiotic Prescribing (SNAP) Group Instructions|For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.
219701499|NCT00161655|DRUG|Etanercept|
219701500|NCT00161655|DRUG|Methotrexate|
219115303|NCT05649488|DEVICE|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
219115304|NCT05649488|DEVICE|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
219115305|NCT06120062|OTHER|swaddled|the 1st experimental group were swaddled
219115306|NCT06120062|OTHER|mother's breast milk odor|the 2nd experimental group were made to inhale mother's breast milk odor
219115307|NCT06120062|OTHER|both swaddled and made to inhale mother's breast milk odor|the 3rd experimental group were both swaddled and made to inhale mother's breast milk odor
219115308|NCT06120062|OTHER|No procedure|No procedure was applied to the infants in the control group.
219115309|NCT05489029|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
219115310|NCT02676986|DRUG|Enzalutamide|Anti-androgen
219115311|NCT02676986|DRUG|Exemestane|Hormonal therapy (Licenced)
219115312|NCT00014339|DRUG|Wobe-Mugos E|
219115313|NCT00014339|DRUG|melphalan|
219115314|NCT00014339|DRUG|prednisone|
219225105|NCT01355809|DRUG|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
219225106|NCT01355809|DRUG|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
219225107|NCT05227092|DEVICE|3D OPTIMIZED WMN MPRAGE|"* At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
219701501|NCT03634319|DEVICE|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
219701502|NCT06513260|PROCEDURE|Surgical extraction of impacted lower third molars.|Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
219701503|NCT06993038|DRUG|adenosine|IV adenosine at standard doses for SVT (6 mg, 12 mg)
219115315|NCT00014339|PROCEDURE|quality-of-life assessment|
219115316|NCT04340674|OTHER|Telerehabilitation based on aerobic exercise|To perform different whole body aerobic exercises moderately intense according to Borg scale.
219115317|NCT05884021|OTHER|Postoperative analgesia|In patients who used intravenous PCA after surgery
219115318|NCT01023737|DRUG|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
219115319|NCT01023737|DRUG|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
219115320|NCT03763188|OTHER|Use of daily urinary urea excretion|Weaning dialysis catheter
219115321|NCT02862847|OTHER|stool samples|
219115322|NCT04537104|DEVICE|Coala Heart Monitor|ECG monitoring
219115323|NCT02856919|DRUG|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
219115324|NCT00983619|DRUG|MEDI-551|MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
219115325|NCT00983619|DRUG|Rituximab|Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
219115326|NCT05264233|DIETARY_SUPPLEMENT|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
219115327|NCT05264233|DIETARY_SUPPLEMENT|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
219115328|NCT05264233|DIETARY_SUPPLEMENT|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
219225108|NCT00074646|DRUG|CC-8490|
219225109|NCT05738434|DRUG|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
219701504|NCT06993038|DRUG|diltiazem|IV diltiazem at standard doses for SVT (0.25 mg/kg)
219115329|NCT02757222|RADIATION|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
219115330|NCT02757222|RADIATION|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
219115331|NCT02444234|DRUG|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
219115332|NCT02444234|DRUG|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
219115333|NCT05668364|OTHER|Outdoor cold air exposure|Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
219115334|NCT02092246|DEVICE|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
219115335|NCT02092246|DEVICE|Unguided injection|Needle placement will take place without ultrasound machine guidance
219115336|NCT01165710|OTHER|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
219115337|NCT02430922|DEVICE|iVolution nitinol stent|
219115338|NCT04328818|DIAGNOSTIC_TEST|indwelling device biofilm identification|performance of the NGS-based identification technique in comparison with the conventional culture-based one, for the same indwelling device biofilm sample
219115339|NCT00064272|DRUG|ginger extract|Given orally
219115340|NCT00064272|OTHER|placebo|Given orally
219115341|NCT04380818|RADIATION|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
219115342|NCT04380818|DRUG|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
219225110|NCT05738434|DRUG|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
219701505|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the PCR results|Patients receive treatment prescribed by a blinded clinician, based solely on the PCR diagnostic results
219115343|NCT04380818|DRUG|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
219115344|NCT04380818|DRUG|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
219115345|NCT04380818|DRUG|Azithromycin|500 mg/24h for 3 days
219115346|NCT04380818|DRUG|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
219115347|NCT04380818|DRUG|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
219115348|NCT04380818|DEVICE|Oxygen supply|Oxygen
219115349|NCT04730063|DEVICE|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
219115350|NCT02500485|DRUG|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
219115351|NCT01322438|DRUG|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
219115352|NCT02618057|DRUG|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
219115353|NCT02618057|DRUG|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
219225111|NCT02797743|OTHER|Whole blood|"* Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
219225112|NCT02331485|DEVICE|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
219225113|NCT05636111|DRUG|Paclitaxel|Given by (IV) vein
219225114|NCT05636111|DRUG|Bevacizumab|Given by (IV) vein
219225115|NCT05636111|DRUG|Lurbinectedin|Given by (IV) vein
219225116|NCT05660473|DRUG|Vincristine|Anti-tumor alkaloids
219225117|NCT05660473|DRUG|Daunorubicin|Anthracycline
219701506|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the C&S results|Patients receive treatment prescribed by a blinded investigator (clinician), based solely on the C\&S diagnostic results.
219701507|NCT03198845|OTHER|video game|20-min per session for 3 times per week for a 4-week duration
219701508|NCT03198845|OTHER|exercise|20-min per session for 3 times per week for a 4-week duration
219701509|NCT01042418|OTHER|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
219701510|NCT05356364|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
219115354|NCT03137602|DEVICE|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
219115355|NCT04435392|DRUG|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
219115356|NCT04435392|DRUG|Placebo|Placebo
219115357|NCT04716881|DRUG|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
219115358|NCT01369056|BEHAVIORAL|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
219115359|NCT01085565|DEVICE|ExAblate 2100|Conformal Bone System
219115360|NCT03173443|DEVICE|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
219115361|NCT03173443|DEVICE|double lumen tube|fiberoptic intubation with double umen tube
219115362|NCT04299633|DRUG|Vadadustat|2 x 150 mg oral tablets
219115363|NCT04299633|DRUG|Sevelamer carbonate|2 x 800 mg oral tablets
219115364|NCT04299633|DRUG|Calcium acetate|2 x 667 mg oral gelcaps
219115365|NCT04299633|DRUG|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
219115366|NCT01752413|DIETARY_SUPPLEMENT|Ferrous gluconate 325mg|Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
219115367|NCT01752413|BEHAVIORAL|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
219115368|NCT02561351|OTHER|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
219115369|NCT05943418|BEHAVIORAL|Wysa for Worry|"The Wysa for Worry cCBT program is a week-based cCBT programme consisting of specialised cognitive behavior therapy (CBT) interventions delivered through a conversational agent.~Each week of the programme focuses on a different CBT technique or intervention, which is explained in a short weekly video. Following each video, the technique or intervention is discussed and practiced with Wysa's AI chatbot."
219701511|NCT05356364|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
219701512|NCT07005973|BEHAVIORAL|mobile-based mindfulness intervention|"Patients will be provided with usual care by surgeon, anesthetist and perioperative team, and they will be asked to install a validated mindfulness based mobile app during the PAS session. Orientation and teaching on the use of the mobile app will be carried out by research team. Return demonstration by patients will be performed at the end to ensure they are capable to use the app at home independently.~A minimum of 4-week intervention duration with session lengths of 1 min, 3 days per week is set for this study.~Patients will be distributed a dairy log to record the frequency and duration of mindfulness practice and submit to the researcher on the day of admission. Follow up on patient's progress through phone call or whatsapp will be provided by the researcher to ensure patient's adherence to the intervention on a bi-weekly basis."
219701513|NCT03658980|BEHAVIORAL|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
219701514|NCT07014137|DRUG|ABSK043 single agent|ABSK043 BID continuously for 28 day cycle
219115370|NCT05943418|BEHAVIORAL|App-based Psychoeducation|The control will include the weekly delivery of active psychoeducational resources.
219115371|NCT02934113|BEHAVIORAL|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
219115372|NCT02934113|BEHAVIORAL|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
219115373|NCT02892682|OTHER|BLOOD TEST|
219115374|NCT01426490|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C, 100 mg/d
219115375|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6, 50mg/d
219115376|NCT01426490|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 microgram/d
219115377|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
219115378|NCT01558674|DRUG|MK-7145|
219115379|NCT01558674|DRUG|Furosemide|
219115380|NCT01558674|DRUG|Torsemide|
219115381|NCT04147260|DRUG|BI 730357|Film-coated tablet
219115382|NCT04147260|DRUG|Placebo to match BI 730357|Film-coated tablet
219115383|NCT04147260|DRUG|Ciprofloxacin|Film-coated tablet
219115384|NCT04454905|DRUG|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
219115385|NCT04454905|DRUG|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
219115386|NCT04980716|DRUG|"Multiple cardiovascular drugs related to Golden Triangle"|Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
219115387|NCT03479749|DEVICE|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
219115388|NCT01121718|DRUG|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
219115389|NCT01872780|DRUG|Rosiglitazone|single oral administration of 4mg of rosiglitazone
219115390|NCT01872780|GENETIC|CYP2C8 genotype|CYP2C8\*11.
219701515|NCT06682416|PROCEDURE|In the context of epidural analgesia, the temperature of the local anesthetic solution is elevated to 37°C utilizing a blood transfusion and infusion warmer.|"For the observation group, after reactivating the analgesic pump's exhaust procedure to clear the air from the tubing, the output tubing of the analgesic pump is first connected to the epidural catheter. Following this, a blood transfusion and infusion warmer (manufactured by Barkey GmbH \& Co. KG., Germany, model S-line, with the national medical device registration number 20182450063) is used to preheat the output tubing of the analgesic pump until it reaches the predetermined temperature of 37°C.~For the control group, after reactivating the analgesic pump's exhaust procedure to remove air from the tubing, the output tubing of the analgesic pump is connected to the epidural catheter without preheating the output tubing using a blood transfusion and infusion warmer, maintaining room temperature (23°C)."
219701516|NCT06686420|DIETARY_SUPPLEMENT|B. longum|On the first day of the intervention period, participants will be instructed to consume two capsules of the live B. longum strain daily with a glass of water before breakfast for the next eight weeks.
219701517|NCT06686420|DIETARY_SUPPLEMENT|Placebo|On the first day of the intervention period, participants will be instructed to consume two capsules, which are without any live bacteria, daily. They should take these before breakfast with a glass of water, for the following eight weeks.
219701518|NCT07017946|DRUG|MTP-101C|MTP-101C is a freeze-dried encapsulated formulation of fecal microbiota purified from the stool of healthy donors.
219701519|NCT05814107|DRUG|CT-996|Capsule of CT-996
219701520|NCT05814107|DRUG|Placebo|Capsule of placebo matching CT-996.
219701521|NCT03908411|PROCEDURE|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
219701522|NCT03908411|PROCEDURE|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
219701523|NCT07034950|DRUG|Intravenous esketamine using Dixon's up-and-down sequential method|Using Dixon's up-and-down sequential method, esketamine will be titrated intravenously from an initial 0.3 mg∙kg-1 dose with 0.02 mg∙kg-1 adjustments based on intraprocedural responses to pain (Positive: purposeful somatic movement or the complaint of pain; Negative: no movement or no complaint of pain). The titration sequence will continue until six crossover inflection points are observed.
219701524|NCT07034950|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
219701525|NCT07034950|DRUG|Intravenous fentanyl 1 μg∙kg-1|The control group will be injected with fentanyl 1 μg∙kg-1.
219115391|NCT06109844|OTHER|Standard of Care|Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
219115392|NCT01734850|DRUG|Busulfan|Intravenous busulfan
219115393|NCT01734850|BIOLOGICAL|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
219115394|NCT01734850|BIOLOGICAL|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
219701526|NCT02991001|PROCEDURE|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
219701527|NCT02991001|PROCEDURE|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
219701528|NCT02991001|DEVICE|Ultrasound|
219701529|NCT02991001|DRUG|Normal Saline|
219701530|NCT01585883|BEHAVIORAL|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
219701531|NCT00860275|DRUG|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
219701532|NCT00860275|DRUG|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
219115395|NCT00750893|BIOLOGICAL|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
219115396|NCT05955521|PROCEDURE|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
219115397|NCT03885856|OTHER|single row repair technique|single row repair technique
219115398|NCT03885856|OTHER|double row repair technique|double row repair technique
219115399|NCT03498326|DRUG|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
219115400|NCT03498326|DRUG|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
219115401|NCT02420327|DRUG|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
219115402|NCT02420327|DRUG|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
219115403|NCT02420327|DRUG|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
219225118|NCT05660473|DRUG|Cyclophosphamide|Alkylating agent
219115404|NCT02420327|DRUG|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
219115405|NCT02204293|DRUG|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
219115406|NCT02204293|DRUG|Placebo|Matching placebo administered subcutaneously.
219115407|NCT01196130|BEHAVIORAL|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
219115408|NCT01196130|OTHER|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
219115409|NCT01405794|DRUG|32ppm Silver Particle|Oral silver dose of 32ppm
219115410|NCT01405794|DRUG|Placebo|Sterile Water No Silver
219115411|NCT02462785|BEHAVIORAL|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
219115412|NCT02462785|BEHAVIORAL|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
219115413|NCT02576834|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
219115414|NCT02576834|OTHER|Services as Usual|Services as usually provided in the community
219115415|NCT04538807|DIAGNOSTIC_TEST|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
219115416|NCT04349410|DRUG|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
219115417|NCT04349410|DRUG|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
219115418|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
219115419|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
219115420|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
219115421|NCT04349410|DRUG|Remdesivir|FMTVDM Planar, SPECT, PET
219115422|NCT04349410|DRUG|Tocilizumab|FMTVDM Planar, SPECT, PET
219115423|NCT04349410|DRUG|Methylprednisolone|FMTVDM Planar, SPECT, PET
219701533|NCT00860275|DRUG|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
219701534|NCT00860275|DRUG|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
219701535|NCT00860275|DRUG|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
219115424|NCT04349410|DRUG|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
219115425|NCT04349410|DRUG|Losartan|FMTVDM Planar, SPECT, PET
219115426|NCT04349410|DRUG|Convalescent Serum|FMTVDM Planar, SPECT, PET
219115427|NCT04509830|OTHER|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
219115428|NCT04509830|OTHER|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
219115429|NCT06392061|DIETARY_SUPPLEMENT|Trilac|Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
219115430|NCT00393094|BIOLOGICAL|Bevacizumab|10 mg/kg intravenous injection
219115431|NCT00393094|DRUG|Irinotecan hydrochloride|125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
219115432|NCT02019602|PROCEDURE|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
219701536|NCT06417970|DIAGNOSTIC_TEST|Shoulder Proprioception, Palmar Touch Sensation and Psychometric Parameters|"Shoulder Proprioception: Proprioception will be measured with isokinetic device. The measurement reference angles are 30° and 60°.~Palmar Touch Sensation: Palmar tactile sensation will be measured with the Semmes-Weinstein Monofilament.~Psychometric Parameters: Athlete Psychological Strain Questionnaire, Tampa kinesiophobia questionnaire"
219701537|NCT02323074|PROCEDURE|Brain Computer Interface|
219701538|NCT05750758|DRUG|rivaroxaban|rivaroxaban 2.5mg bid for 1m
219701539|NCT04606758|PROCEDURE|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
219701540|NCT04606758|PROCEDURE|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
219701541|NCT02523352|PROCEDURE|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
219701542|NCT02523352|PROCEDURE|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
219701543|NCT04950400|DRUG|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
219115433|NCT02019602|PROCEDURE|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
219225119|NCT05660473|DRUG|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
219115434|NCT02019602|PROCEDURE|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
219115435|NCT02019602|BIOLOGICAL|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use"
219115436|NCT03124030|PROCEDURE|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
219115437|NCT00925782|DRUG|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
219115438|NCT00925782|DRUG|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
219115439|NCT03133468|DRUG|AJM347|Oral administration
219115440|NCT03133468|DRUG|Placebo|Oral administration
219115441|NCT03288389|DIETARY_SUPPLEMENT|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
219115442|NCT03288389|DIETARY_SUPPLEMENT|Placebo|Placebo wafers
219115443|NCT03523871|DRUG|Mavyret|Patients will be on 8 weeks of Mavyret
219115444|NCT02552849|OTHER|No intervention|
219115445|NCT05472220|DRUG|Alpelisib|Given orally
219115446|NCT05472220|DRUG|Carboplatin|Given IV during imaging
219701544|NCT04913831|DRUG|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
219115447|NCT05472220|DRUG|Hyperpolarized Carbon-13 (13C) Pyruvate|Given IV
219115448|NCT05472220|DEVICE|Continuous Glucose Monitor (CGM)|Self-applied devices that sit partially beneath the skin
219115449|NCT03266341|DIAGNOSTIC_TEST|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
219701545|NCT04913831|DRUG|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
219701546|NCT05689359|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
219701547|NCT02832778|DRUG|Efavirenz|Efavirenz 400mg
219701548|NCT02832778|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
219115450|NCT04406337|DEVICE|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.
219115451|NCT04406337|DEVICE|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
219115452|NCT06423586|DIETARY_SUPPLEMENT|Curcuma longa and Boswellia serrata extracts|Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
219701549|NCT02832778|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
219701550|NCT02832778|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
219115453|NCT05468671|DRUG|Remimazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
219115454|NCT05468671|DRUG|Propofol|Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
219115455|NCT05468671|DRUG|Rocuronium|Rocuronium is a non-depolarizing neuromuscular blocker
219115456|NCT05468671|DRUG|Remifentanil|Remifentanil is an esterase-metabolized opioid
219115457|NCT05468671|DRUG|oxycodone|Oxycodone is an opiate painkiller.
219115458|NCT05468671|DRUG|Sugammadex Sodium|Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
219115459|NCT05468671|DRUG|Flumazenil|Flumazenil is used to reverse the effects of a benzodiazepine
219115460|NCT03054974|OTHER|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
219115461|NCT03054974|OTHER|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
219115462|NCT03054974|OTHER|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
219115463|NCT03054974|OTHER|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
219115464|NCT02909361|DRUG|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
219115465|NCT04745858|OTHER|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
219701551|NCT02832778|DRUG|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
219701552|NCT00584389|DRUG|rimonabant|20mg/d (oral) once daily for 12 weeks
219701553|NCT00584389|BEHAVIORAL|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
219115466|NCT04745858|OTHER|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
219115467|NCT04285229|DRUG|Ixekizumab|Administered SC
219115468|NCT04285229|DRUG|Placebo|Administered SC
219701554|NCT04433104|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
219701555|NCT04433104|DRUG|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
219701556|NCT03321721|PROCEDURE|Suture for wound repair|Repair of wound with suture
219701557|NCT03321721|DEVICE|Suture for wound repair|Repair of wound with suture
219701558|NCT03783065|DRUG|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
219701559|NCT03783065|PROCEDURE|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
219701560|NCT03783065|PROCEDURE|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
219115469|NCT05490069|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
219115470|NCT00306514|BIOLOGICAL|CYT004-MelQbG10|
219115471|NCT01406717|DRUG|SPIL1033|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
219115472|NCT01406717|DRUG|Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
219115473|NCT01222611|DRUG|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
219115474|NCT01375894|DEVICE|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
219701561|NCT05767983|OTHER|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
219701562|NCT05767983|OTHER|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
219701563|NCT05767983|OTHER|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
219115475|NCT00596024|DIETARY_SUPPLEMENT|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
219115476|NCT00596024|DIETARY_SUPPLEMENT|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
219115477|NCT03257995|DRUG|Indacaterol maleate|150 μg via Concept1 device
219115478|NCT03257995|DRUG|Indacaterol acetate|150 μg via Concept1 device
219115479|NCT03257995|DRUG|Placebo|Capsule containing no active ingredients delivered via Concept1 device
219115480|NCT03120208|BEHAVIORAL|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
219115481|NCT03120208|BEHAVIORAL|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
219115482|NCT03120208|BEHAVIORAL|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
219115483|NCT03120208|BEHAVIORAL|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
219115484|NCT03120208|BEHAVIORAL|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
219701564|NCT05767983|OTHER|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
219115485|NCT00346996|DRUG|insulin levemir / aspart|for subcutaneous injection
219115486|NCT00346996|DRUG|human insulin /insulin isophane|for subcutaneous injection
219115487|NCT01112696|DEVICE|Sensor wear|All subjects to wear sensors
219115488|NCT03124628|OTHER|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
219115489|NCT03124628|OTHER|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
219115490|NCT04758234|DRUG|LY3549492|Administered orally.
219115491|NCT04758234|DRUG|Placebo|Administered orally.
219115492|NCT04478513|DRUG|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
219225120|NCT05660473|DRUG|Prednisone|Glucocorticoids
219701565|NCT05767983|OTHER|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
219115493|NCT04478513|DRUG|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
219115494|NCT05291884|DEVICE|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
219115495|NCT02969031|BEHAVIORAL|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
219115496|NCT02969031|BEHAVIORAL|Standard Communication training|Standard Communication training
219115497|NCT01642069|OTHER|laboratory biomarker analysis|Correlative studies
219701566|NCT05441189|PROCEDURE|Resection|radical R0 resection of pancreatic adenocarcinoma
219701567|NCT05502029|BEHAVIORAL|Extended translation|Translation extended beyond the preoperative area
219701568|NCT05502029|BEHAVIORAL|Standard translation|Translation in the preoperative area
219701569|NCT03795415|BEHAVIORAL|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
219115498|NCT04903834|DIAGNOSTIC_TEST|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
219115499|NCT04903834|DIAGNOSTIC_TEST|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
219115500|NCT03259529|DRUG|Bendamustine hydrochloride|70 mg/m2 by intravenous (IV) infusion for up to 2 cycles
219115501|NCT03259529|DRUG|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
219115502|NCT03259529|DRUG|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
219115503|NCT03259529|DRUG|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
219115504|NCT03259529|DRUG|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
219115505|NCT03259529|DRUG|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
219115506|NCT02973360|DRUG|Docosahexaenoic Acid|Oral Capsule
219115507|NCT02973360|DRUG|Placebo|Oral Capsule
219115508|NCT05401370|PROCEDURE|Methylene blue dye|For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
219115509|NCT01556763|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
219115510|NCT01556763|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
219115511|NCT01556763|DRUG|Placebo|Matching placebo was administered as one capsule per day for 21 days.
219225121|NCT05660473|DRUG|Cytarabine|Pyrimidine antimetabolites
219225122|NCT05660473|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
219225123|NCT05660473|DRUG|Dexamethasone|Glucocorticoids
219225124|NCT05660473|DRUG|Methotrexate|Antifolate antineoplastic drug
219225125|NCT05660473|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
219225126|NCT01477177|DEVICE|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
219701570|NCT01001741|OTHER|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
219115512|NCT01556763|DRUG|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
219115513|NCT00747318|DRUG|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
219115514|NCT02584855|DRUG|Ixekizumab|Administered SC
219115515|NCT02584855|DRUG|Placebo|Administered SC
219115516|NCT05208619|PROCEDURE|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
219115517|NCT02337478|DRUG|Vincristine Sulfate Liposome|Given via injection
219115518|NCT02337478|OTHER|Laboratory Biomarker Analysis|Correlative studies
219225127|NCT01505166|BIOLOGICAL|Vigil™ Vaccine|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
219701571|NCT04005768|DRUG|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
219701572|NCT04005768|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
219701573|NCT03353220|DRUG|Belviq|Belviq is an oral drug
219701574|NCT03353220|DRUG|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
219701575|NCT03680027|DIETARY_SUPPLEMENT|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
219701576|NCT05862012|DRUG|ISB 2001|Participants will receive escalating doses of ISB 2001
219701577|NCT05862012|DRUG|ISB 2001|Participants will receive injection of ISB 2001 as determined in Part 1.
219701578|NCT06908317|OTHER|floor rise training using backward chaining method|"Each session lasts for 40 minutes starting with a five minutes warming-up including flexibility exercises and ends with a five minutes cooling-down consisting of stretching and breathing exercises. Warming-up is followed by the practicing of getting up floor taught with BMC involving the following 7 steps:~Step 1: descending from a standing position to half kneeling on a wedge pillow. Step 2: descending from a standing position to half kneeling on the floor. Step 3: Like step 2, then descending both knees to the floor into a high kneeling position. Step 4: Like step 3, then descending both hands to the floor one at a time, to come to a prone kneeling position. Step 5: Like step 4, then descending of the body to half sitting. A pillow can be positioned under the hip to soften the floor surface. Step 6: Like step 5, then descending of the body to side lying position. Step 7: Like step 6, then turning from side-lying to supine"
219701579|NCT02868567|DRUG|dalfampridine|Pill open label
219701580|NCT05553405|DRUG|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
219701581|NCT01533259|DRUG|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
219701582|NCT02996383|DEVICE|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
219115519|NCT00039156|DRUG|ortataxel|
219115520|NCT02258464|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)
219115521|NCT02258464|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
219115522|NCT02258464|OTHER|Background hormonal therapy|Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
219115523|NCT04723160|DIAGNOSTIC_TEST|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
219115524|NCT05970835|OTHER|Control group|Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.
219115525|NCT05970835|OTHER|Experimental group|"Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement."
219115526|NCT02138747|DRUG|Mirabegron|Oral
219115527|NCT02138747|DRUG|Tolterodine ER|Oral
219115528|NCT04170296|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
219115529|NCT02833662|OTHER|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
219115530|NCT02779595|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
219701583|NCT02996383|DEVICE|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
219701584|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
219701585|NCT06315283|DRUG|Oral olanzapine|Administered orally
219115531|NCT00932646|DRUG|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
219115532|NCT00932646|DRUG|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
219115533|NCT00932646|DRUG|Placebo|Placebo Respimat once daily and placebo Foradil
219115534|NCT00932646|DRUG|Foradil|12 mcg twice daily and placebo Respimat
219115535|NCT04581902|DEVICE|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
219115536|NCT03012789|PROCEDURE|Surgery|Surgical excision
219701586|NCT06928116|BEHAVIORAL|Heat therapy|At home lower body heat therapy
219115537|NCT05112211|DRUG|Doxycycline Hyclate|patients administrated with doxycycline tablets 100mg orally per day
219115538|NCT04963972|BEHAVIORAL|Behavioral Intervention|Participate in Lucid Lane therapy program
219115539|NCT04963972|OTHER|Best Practice|Receive standard of care opioid education
219115540|NCT04963972|OTHER|Questionnaire Administration|Ancillary studies
219701587|NCT06928116|BEHAVIORAL|Sham Control|Sham Thermoneutral
219701588|NCT06928116|BEHAVIORAL|Walking|Walking intervention
219701589|NCT06928324|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane Block (ESPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
219701590|NCT06928324|PROCEDURE|Control|No intervention
219701591|NCT02707042|DRUG|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
219701592|NCT02707042|DRUG|Azithromycin|5-day oral course of once-daily azithromycin
219701593|NCT02707042|OTHER|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
219115541|NCT03381508|DEVICE|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
219115542|NCT02699541|BEHAVIORAL|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
219115543|NCT00183443|DRUG|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
219225128|NCT01505166|DRUG|Placebo|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
219225129|NCT06020352|DRUG|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
219225130|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
219225131|NCT00031941|DRUG|lenalidomide|
219701594|NCT06908707|DRUG|LAE102 SC|A single dose of LAE102 will be administered subcutaneously
219701595|NCT06908707|DRUG|Placebo SC|A single dose of placebo administered subcutaneously
219701596|NCT06908707|DRUG|LAE102 IV|A single dose of LAE102 administered intravenously
219701597|NCT06908707|DRUG|Placebo IV|A single dose of placebo administered intravenously
219701598|NCT06649409|DRUG|Vamorolone|vamorolone 20 mg/kg single dose on Day 2
219701599|NCT06649409|DRUG|Eplerenone|Eplerenone 200 mg single dose on Day 2
219701600|NCT06649409|DRUG|Fludrocortisone|"Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm."
219701601|NCT06188208|DRUG|VVD-130850|Oral tablets
219701602|NCT06188208|DRUG|Pembrolizumab|IV infusion
219701603|NCT04224974|OTHER|Usual Care|The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial
219115544|NCT00183443|DRUG|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
219115545|NCT00183443|DRUG|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
219115546|NCT05282849|PROCEDURE|ultrasound guided fascia iliaca block|ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
219115547|NCT05282849|PROCEDURE|ultrasound guided quadratus lumborum block|ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
219115548|NCT00737984|PROCEDURE|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
219115549|NCT01722318|DRUG|Plecanatide|
219115550|NCT01722318|DRUG|Placebo|
219115551|NCT06100380|OTHER|Survey|Questionnaire
219701604|NCT04224974|BEHAVIORAL|EASE-psy|"All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms."
219701605|NCT04709276|DRUG|Nivolumab|360 mg intravenously every 3 weeks
219701606|NCT04709276|DRUG|Ipilimumab|1 mg/kg intravenously every 6 weeks
219701607|NCT04709276|DRUG|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
219701608|NCT04709276|DRUG|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
219701609|NCT07101445|DRUG|Acetaminophen|Given by mouth (PO).
219701610|NCT07101445|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219701611|NCT07101445|DRUG|Dexamethasone|Given intravenously (IV).
219701612|NCT07101445|OTHER|Electronic Health Record Review|Ancillary studies
219701613|NCT07101445|DRUG|Famotidine|Given by mouth (PO).
219701614|NCT07101445|DRUG|Loratadine|Given by mouth (PO).
219701615|NCT07101445|DRUG|Methylprednisolone|Given intravenously (IV).
219701616|NCT07101445|DRUG|Montelukast|Given by mouth (PO).
219701617|NCT07101445|DRUG|Motixafortide|Given subcutaneously (SC).
219701618|NCT07101445|PROCEDURE|Pheresis|Undergo apheresis
219115552|NCT06189430|OTHER|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
219115553|NCT06189430|OTHER|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
219115554|NCT04265443|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
219115555|NCT01139905|OTHER|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
219115556|NCT05093751|OTHER|Observation|This study does not involve any intervention to subjects.
219115557|NCT00004220|DRUG|gemcitabine hydrochloride|
219115558|NCT00004220|DRUG|oxaliplatin|
219225132|NCT03205566|DRUG|Raltegravir 400Mg Tab|bd for 7 days
219225133|NCT03205566|DRUG|Lamivudine 150Mg Tablet|\+ Raltegravir 400Mg tablet bd for 7 days
219225134|NCT02973594|DRUG|Ivabradine|
219701619|NCT07101445|OTHER|Questionnaire Administration|Ancillary studies
219701620|NCT07101445|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Give Granulocyte Colony-Stimulating Factor (G-CSF).
219701621|NCT06410534|DRUG|nivolumab|Nivolumab will be dosed at 3 mg/kg and given as an IV over 30-60 minutes on day 1 of each cycle. It will be administered every 3 weeks (21 days) for up to 8 cycles
219701622|NCT06410534|DRUG|ipilimumab|Ipilimumab will be dosed at 1 mg/kg and given as an IV over approximately 30 minutes on day 1 of every other cycle (every 6 weeks or 42 days) for up to 4 doses
219701623|NCT06690281|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine)
219701624|NCT06690281|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 3 doses)
219701625|NCT06690281|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 4 days
219701626|NCT06690281|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
219701627|NCT04895436|DRUG|Venetoclax|Oral tablet
219701628|NCT04895436|DRUG|Obinutuzumab|Intravenous (IV) infusion
219701629|NCT06675955|DRUG|Ocrelizumab|Ocrelizumab will be administered according to the regimen in the parent study.
219701630|NCT06919991|DRUG|Casdatifan|Administered as a single dose in treatment Periods 1, 2, and 3
219115559|NCT06092541|DRUG|Intervention Group: pericervical anesthesia|"Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours."
219115560|NCT06092541|OTHER|Nitroux Oxide anesthesia|Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
219115561|NCT02800603|BEHAVIORAL|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
219115562|NCT03044262|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
219115563|NCT03044262|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
219701631|NCT06919991|DRUG|Itraconazole|Administered as multiple doses in treatment Period 2
219701632|NCT06919991|DRUG|Phenytoin|Administered as multiple doses in treatment Period 3
219701633|NCT01408693|PROCEDURE|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
219701634|NCT01408693|PROCEDURE|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
219701635|NCT01788761|DIETARY_SUPPLEMENT|Probiotic Supplemented Group|
219701636|NCT01788761|DIETARY_SUPPLEMENT|Control Group|
219701637|NCT02728908|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
219701638|NCT00315341|DRUG|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
219701639|NCT00315341|DRUG|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
219701640|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 1b|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.
219701641|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 2|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.
219701642|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
219701643|NCT01268995|DRUG|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
219701644|NCT01268995|DRUG|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
219701645|NCT06894810|OTHER|Decision-aid|Decision Aids (DA) are evidence-based clinical tools developed for patients to supplement clinicians' discussions and facilitate difficult preference-sensitive decisions. They are the gold standard approach (recommended by the Australian Commission of Safety and Quality in Healthcare) to facilitate complex healthcare decisions where there is more than one reasonable choice and where patients may value benefits and risks differently.
219701646|NCT06945250|OTHER|Experimental Audio Visual|Participants in this group will receive the audiovisual presentation
219701647|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
219701648|NCT07145229|DRUG|ABP-745 Dose A|ABP-745 Dose A + Colchicine placebo - tablets (PO)
219115564|NCT03567993|BEHAVIORAL|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
219225135|NCT02973594|DRUG|Placebo|
219225136|NCT01744808|DRUG|EB-1020 IR|Immediate release
219701649|NCT07145229|DRUG|ABP-745 Dose B|ABP-745 Dose B + Colchicine placebo - tablets (PO)
219701650|NCT07145229|DRUG|Colchicine|ABP-745 placebo + Colchicine - tablets (PO)
219701651|NCT07145229|DRUG|Placebo|ABP-745 placebo + Colchicine placebo - tablets (PO)
219225137|NCT01744808|DRUG|EB-1020 SR1|sustained release
219225138|NCT01744808|DRUG|EB-1020 SR2|Sustained release
219225139|NCT01744808|DRUG|EB-1020 SR3|Sustained release
219225140|NCT01744808|OTHER|Placebo|Placebo formulation
219115565|NCT03567993|BEHAVIORAL|Intervention|"Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
219115566|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
219115567|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
219701652|NCT07151079|BEHAVIORAL|Trans Adolescent Group ThErapy for Alleviating Minority stress|The intervention, Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM), is a group Cognitive Behavioural Therapy (CBT) program, originally developed using co-design methodology with trans and gender diverse young people. The 6 weekly, 2-hour session TAG TEAM program aims to improve mental health and wellbeing using evidence-based cognitive and behavioural strategies to target minority stressors discrimination and internalised stigma and facilitating community connection and pride. The intervention will be delivered by a psychologist facilitator and peer facilitator, who will both be trained and supervised by clinical psychologists, to groups of 8 participants from the same stratum.
219701653|NCT07153224|BEHAVIORAL|Peri-operative support measures [mentorship, intraoperative consult, surgical coaching, standard practice (no structured support)]|"Mentorship: Formal (assigned by an institution or via an official program) or informal (personal relationship built during the career pathway) professional guidance relationships that support early-career surgeons in clinical decision-making, technical development, and emotional processing.~Surgical Coaching: Structured, feedback-oriented discussions or sessions aimed at performance enhancement and reflective practice Intraoperative Consultation (IOC): Real-time assistance or second opinions provided by a more experienced surgeon or peers during a surgical procedure Standard practice: the surgeon performs the procedure supported by one or multiple assistants, as per internal hospital protocols and national/local regulations, receiving and providing natural feedback without a structured support system."
219701654|NCT07154628|DRUG|Lidocaine %2 ampoule|During general anesthesia, the anesthesiologist administers 1.5cc of lidocaine spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
219701655|NCT07154628|DRUG|Normal Saline (0.9% NaCl)|During general anesthesia, the anesthesiologist administers 1.5cc of normal saline spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
219701656|NCT07158060|BEHAVIORAL|Breathing Exercises|Breathing Exercises This intervention
219701657|NCT07155863|DEVICE|Earplugs and eye mask|Participants in the experimental group will use earplugs and eye mask during MRI. The use of these devices aims to decrease anxiety levels caused by noise and the MRI procedure. Physiological parameters and axiety scores will be monitored throughout the study.
219701658|NCT07151963|DEVICE|prolonged continuous TBS|prolonged continuous theta burst stimulation
219701659|NCT07151963|DEVICE|20 Hz rTMS|20 Hz repetitive transcranial magnetic stimulation
219701660|NCT02964871|DEVICE|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
219701661|NCT02964871|OTHER|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
219701662|NCT00195741|DRUG|divalproex sodium|
219701663|NCT02617095|DEVICE|T2762|One drop in each eye 3 to 6 times daily
219701664|NCT02617095|DEVICE|Optive|One drop in each eye 3 to 6 times daily
219701665|NCT05417750|DRUG|TIL therapy|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
219701666|NCT05360290|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
219701667|NCT05539131|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
219701668|NCT05681988|PROCEDURE|Early minimally invasive image guided endoscopic hematoma evacuation|The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
219115568|NCT02488382|DRUG|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
219115569|NCT00910806|DRUG|TMC207; nevirapine|
219225141|NCT05623033|OTHER|The study is an observational study without intervention|The study is an observational study without intervention
219115570|NCT05656638|BEHAVIORAL|Speech and language therapy|"The treatment focuses on grammatical time marking. The aim of the treatment is to train underlying grammatical time marking processes, which were identified as deficient during a preliminary evaluation. The intervention is composed of 4 steps inspired by models and hypotheses from the literature on the subject. Step 1: temporal adverbial selection, subject must identify the tense encoded in sentences and select the correct adverbial among those proposed. Step 2: selection of inflected verb forms, subject must identify the tense encoded in the sentence and select the correct verb form among those proposed. Step 3: production of inflected verb forms, subject must identify the tense encoded in the sentence and produce inflected verbs. Step 4: semantic narration, subject must describe scenes using verbs inflected according to the previously defined reference time."
219115571|NCT04505995|DRUG|Azacitidine and homoharringtonine|Concommitant use of azacitidine and homoharringtonine
219115572|NCT02348320|BIOLOGICAL|Personalized polyepitope DNA vaccine|
219115573|NCT05923177|DRUG|SPECT|One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
219115574|NCT05943275|DEVICE|Magnetic sensor|During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
219115575|NCT03948087|DEVICE|Vacuum Removable Rigid Dressing (VRRD)|Intra-operative application of device.
219701669|NCT05681988|PROCEDURE|Best medical treatment (BMT)|The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
219701670|NCT01950663|DEVICE|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
219701671|NCT01588275|DEVICE|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
219701672|NCT01588275|PROCEDURE|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
219701673|NCT03524001|DEVICE|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
219701674|NCT00895713|DRUG|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
219701675|NCT06217471|PROCEDURE|Carotid Endoarterectomy|Surgical removal of atherosclerotic plaque from the carotid artery, collection of blood samples
219701676|NCT04156659|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
219115576|NCT00416871|BIOLOGICAL|aldesleukin|
219115577|NCT00416871|BIOLOGICAL|recombinant interferon alfa|
219115578|NCT03018743|DRUG|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
219115579|NCT00316030|DRUG|Bexarotene|
219115580|NCT03129529|DEVICE|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
219115581|NCT03129529|DEVICE|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
219115582|NCT06442644|OTHER|Live music in the intensive care unit|To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
219115583|NCT01157741|BEHAVIORAL|C-C|Mx as H-C plus positioning follow up in the community clinic
219115584|NCT01157741|OTHER|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
219115585|NCT01157741|OTHER|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
219115586|NCT01157741|OTHER|As C-C but with both SF & PS (C-SF+PS)|Giving both SF \& PS
219115587|NCT01157741|OTHER|H-C|Follow-up at Hospital
219115588|NCT02290366|RADIATION|Focal prostate brachytherapy with Cesium-131|
219115589|NCT03698864|DRUG|PCS499|PCS499 900mg twice a day with food
219701677|NCT02934178|BIOLOGICAL|Shigella sonnei Strain WRSS1 Vaccine|Live attenuated, oral Shigella WRSS1 vaccine
219701678|NCT02934178|BIOLOGICAL|Placebo|Sterile saline solution
219701679|NCT02862509|DRUG|Budesonide nasal instillation|
219701680|NCT02862509|DRUG|Normal saline nasal instillation|
219701681|NCT03126149|DRUG|PF-06667272|Single ascending dose of PF-06667272
219701682|NCT03126149|OTHER|Placebo|Single dose of placebo
219701683|NCT04323592|DRUG|Methylprednisolone|Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 \> 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 \> 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
219115590|NCT04253197|DEVICE|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
219115591|NCT03380780|DRUG|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
219115592|NCT01209481|BEHAVIORAL|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
219115593|NCT03424720|DEVICE|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
219115594|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
219115595|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
219115596|NCT03032874|PROCEDURE|Colonoscopy|They all had screening colonoscopy
219115597|NCT00997256|DRUG|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
219115598|NCT00997256|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 3 days
219115599|NCT04623411|BEHAVIORAL|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
219115600|NCT04623411|BEHAVIORAL|Control Group|Neonatal resuscitation training with classical method
219115601|NCT03183557|DRUG|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
219115602|NCT03183557|DRUG|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
219701684|NCT04323592|OTHER|standard care|"usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins"
219701685|NCT02963324|DRUG|Ivermectin|
219701686|NCT00357942|DRUG|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
219701687|NCT00357942|DRUG|Placebo|Placebo mouthwash
219701688|NCT00357942|DRUG|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
219701689|NCT00357942|DRUG|Placebo|Placebo solution for injection every 3 hour for 24 hours
219701690|NCT01898078|DRUG|Alisertib|Alisertib ECT
219115603|NCT02922985|DRUG|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
219115604|NCT02922985|DRUG|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
219115605|NCT02922985|DRUG|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
219115606|NCT02922985|DRUG|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
219115607|NCT02218489|DRUG|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
219115608|NCT02218489|DRUG|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
219115609|NCT01099540|DRUG|Pazopanib|Pazopanib 800 mg qd daily
219115610|NCT05221749|DRUG|Nanosilver Fluoride (NSF)|Optimized synthesis of Nanosilver Fluoride
219115611|NCT05221749|DRUG|Silver diamine fluoride|Silver Diamine Fluoride
219115612|NCT00063817|DRUG|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
219701691|NCT00542308|DRUG|Zalutumumab|Individual dose titration weekly i.v. doses
219701692|NCT02588508|PROCEDURE|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
219701693|NCT02588508|PROCEDURE|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
219115613|NCT03085251|DEVICE|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
219115614|NCT00214032|DRUG|Pycnogenol|pycnogenol 300 mg daily
219115615|NCT00214032|DRUG|Placebo|placebo 3 capsules daily
219115616|NCT02404493|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
219115617|NCT02404493|DRUG|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
219115618|NCT06077435|DEVICE|AI|AI system
219115619|NCT02071550|DEVICE|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
219115620|NCT02071550|DEVICE|FORESIGHT and INVOS monitor|
219701694|NCT04176523|DRUG|Carglumic Acid|Maintenance therapy with carglumic acid
219701695|NCT00234741|DRUG|STA-5326 mesylate|
219701696|NCT05226377|DIAGNOSTIC_TEST|Atherogenic Index of Plasma|\- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
219701697|NCT05849805|PROCEDURE|Intracalvaria bone marrow injection|Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
219701698|NCT05849805|OTHER|Conventional treatment|standard treatment and management according to related guidelines
219701699|NCT06229938|OTHER|Passive leg raise manoeuvre|"Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia."
219701700|NCT05700864|DRUG|Cenegermin-Bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
219701701|NCT00631293|DIETARY_SUPPLEMENT|lactisole|administration of lactisole followed by placebo
219701702|NCT00631293|OTHER|placebo|administration of placebo followed by lactisole
219701703|NCT00171535|DRUG|valsartan/amlodipine|
219115621|NCT05179044|DEVICE|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
219115622|NCT03435601|DRUG|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
219115623|NCT03435601|DRUG|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
219115624|NCT00474721|DRUG|ibuprofen|
219115625|NCT00474721|DRUG|acetaminophen with codeine|
219115626|NCT01159639|DRUG|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
219115627|NCT03037879|OTHER|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
219115628|NCT03037879|OTHER|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
219115629|NCT03037879|OTHER|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
219701704|NCT00002844|DRUG|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
219701705|NCT00002844|PROCEDURE|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
219115630|NCT03037879|OTHER|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
219115631|NCT01487304|DRUG|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
219115632|NCT04840888|DRUG|LY3484356|Administered orally.
219115633|NCT04840888|DRUG|Omeprazole|Administered orally.
219115634|NCT04840888|DRUG|Itraconazole|Administered orally.
219115635|NCT04840888|DRUG|Carbamazepine|Administered orally.
219115636|NCT05172882|PROCEDURE|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
219115637|NCT05172882|PROCEDURE|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
219115638|NCT02388074|DEVICE|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
219115639|NCT05787938|DEVICE|MRI|A procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. A contrast agent, such as gadolinium, may be injected into a vein to help the tissues and organs show up more clearly in the picture. MRI may be used to help diagnose disease, plan treatment, or find out how well treatment is working. It is especially useful for imaging the brain and spinal cord, the heart and blood vessels, the bones, joints, and other soft tissues, the organs in the pelvis and abdomen, and the breast. Also called magnetic resonance imaging, NMRI, and nuclear magnetic resonance imaging.
219115640|NCT00000782|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
219115641|NCT00000782|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219115642|NCT01265589|DRUG|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
219701706|NCT00002844|PROCEDURE|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
219115643|NCT01265589|DRUG|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
219115644|NCT06493838|DRUG|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
219115645|NCT06493838|DRUG|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
219115646|NCT00915902|DRUG|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
219115647|NCT00915902|DRUG|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
219115648|NCT00003050|DRUG|cyclophosphamide|
219115649|NCT00003050|DRUG|doxorubicin hydrochloride|
219115650|NCT00003050|DRUG|paclitaxel|
219115651|NCT00003050|DRUG|tamoxifen citrate|
219115652|NCT00003050|PROCEDURE|surgical procedure|
219115653|NCT00003050|RADIATION|radiation therapy|
219701707|NCT00002844|RADIATION|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
219701708|NCT01075048|DRUG|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
219701709|NCT01075048|DRUG|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
219701710|NCT01075048|DRUG|Cetuximab|Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
219701711|NCT01075048|DRUG|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
219701712|NCT05816941|PROCEDURE|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
219701713|NCT05816941|PROCEDURE|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
219701714|NCT00193648|DRUG|Rosiglitazone (Avandia)|oral drug administration
219701715|NCT00193648|DRUG|Adalimumab (Humira)|Injection of drug biweekly
219701716|NCT00547144|DRUG|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
219701717|NCT00547144|PROCEDURE|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
219701718|NCT04483765|PROCEDURE|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
219701719|NCT04499885|DEVICE|Paraffin oil gastric lavage|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
219115654|NCT03464604|DIAGNOSTIC_TEST|active|Pre-screening for melanoma by qualified nurse
219115655|NCT02133924|DRUG|natalizumab|Natalizumab 300mg on days 0 and 14.
219115656|NCT02133924|DRUG|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
219115657|NCT00003458|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
219115658|NCT02773264|DEVICE|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
219115659|NCT01254890|DRUG|Azacitidine|75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
219115660|NCT01254890|DRUG|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
219115661|NCT03320460|DRUG|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
219115662|NCT03320460|DEVICE|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
219115663|NCT03320460|OTHER|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
219115664|NCT03320460|OTHER|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
219115665|NCT01213862|BEHAVIORAL|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
219115666|NCT01340911|DRUG|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
219115667|NCT01340911|DRUG|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
219115668|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
219115669|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
219115670|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
219115671|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
219115672|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
219701720|NCT04499885|DEVICE|Gastric lavage with saline and sodium bicarbonate 8.4%|Gastric lavage with saline and sodium bicarbonate 8.4%
219115673|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
219115674|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
219115675|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
219115676|NCT05178264|DRUG|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
219115677|NCT03746977|DIETARY_SUPPLEMENT|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
219115678|NCT03746977|BEHAVIORAL|Walking|Walking with a volume corresponding to 250 kcal/d
219115679|NCT03746977|BEHAVIORAL|WB-EMS application|WB-EMS application 1.5x 20 min/week
219115680|NCT04364321|DRUG|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
219115681|NCT04364321|DRUG|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
219115682|NCT04183673|PROCEDURE|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
219115683|NCT04183673|PROCEDURE|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
219115684|NCT01233167|DRUG|clopidogrel|clopidogrel 75 mg po per day for 12 months
219115685|NCT01233167|DRUG|placebo|placebo 75mg po per day for 12 months
219701721|NCT05041686|COMBINATION_PRODUCT|CADISS® System|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2.~2. Reusable stainless steel noncutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
219701722|NCT04933565|DRUG|ORG-129|ORG-129 oral capsules
219701723|NCT04933565|DRUG|Placebo|Placebo oral capsules
219701724|NCT04596293|DRUG|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
219701725|NCT00325169|DRUG|Tiotropium + SERETIDE 50/500|
219701726|NCT02776293|BEHAVIORAL|Relaxation|
219701727|NCT02776293|BEHAVIORAL|Music|
219701728|NCT01287936|BIOLOGICAL|SB623|SB623, a modified stem-cell product
219115686|NCT01233167|DRUG|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
219115687|NCT01185054|OTHER|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
219115688|NCT01185054|OTHER|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
219115689|NCT04039503|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
219115690|NCT04039503|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
219115691|NCT01097460|DRUG|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
219115692|NCT01398501|DRUG|Sorafenib|Oral, 200 to 400 mg QD or BID
219115693|NCT03176043|PROCEDURE|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
219115694|NCT01845948|BEHAVIORAL|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
219115695|NCT01845948|BEHAVIORAL|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
219115696|NCT02585791|OTHER|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
219115697|NCT02585791|OTHER|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
219115698|NCT02585791|OTHER|PG+VG|inhaled PG+VG by vaporing
219115699|NCT04157686|DRUG|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL area
219115700|NCT04157686|DRUG|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL area
219115701|NCT04157686|DRUG|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
219115702|NCT02881177|DRUG|Oxytocin|40 IU
219115703|NCT02881177|DRUG|Placebo|40 IU
219115704|NCT01615991|DRUG|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
219115705|NCT04112264|PROCEDURE|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
219115706|NCT04112264|PROCEDURE|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
219115707|NCT04156152|OTHER|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
219115708|NCT04156152|OTHER|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
219115709|NCT00651469|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
219115710|NCT00651469|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
219115711|NCT01564745|OTHER|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
219115712|NCT05867485|OTHER|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~1. Information about the spread of the virus and precautions to be taken.~2. Guidelines for cleanliness and disinfection of the environment.~3. Precautions regarding personal and wearable items.~4. Information about food and beverages.~5. Guidelines for personal hygiene practices.~6. Information about quarantine and isolation.~7. Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
219701729|NCT00681200|BEHAVIORAL|Enhanced health education|health education and social support
219701730|NCT00681200|BEHAVIORAL|Transcendental Meditation program|The TM program plus didactic-based health education classes
219701731|NCT02022358|DRUG|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
219701732|NCT02022358|DRUG|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
219701733|NCT02022358|DRUG|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
219115713|NCT05088837|OTHER|muscle energy technique|MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
219115714|NCT05088837|OTHER|ice and heat packs|Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
219115715|NCT00218803|BEHAVIORAL|Nurse asthma education intervention|Asthma Education
219115716|NCT00218803|BEHAVIORAL|Control Group|Asthma Education
219115717|NCT04823559|OTHER|ThinkCancer workshop|The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
219115718|NCT02377713|DRUG|KHK6640|Single ascending dose administration
219115719|NCT02377713|DRUG|Placebo|Single ascending dose administration
219115720|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
219115721|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
219115722|NCT01542021|DRUG|androgen deprivation therapy|
219115723|NCT03122756|DRUG|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
219115724|NCT03122756|OTHER|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
219115725|NCT05271838|DIETARY_SUPPLEMENT|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test \>25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
219115726|NCT05271838|DIETARY_SUPPLEMENT|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
219115727|NCT05835622|DEVICE|Keeogo|Keeogo is exoskeleton for walking assistance
219115728|NCT05835622|OTHER|adviced home practice|health tips for regular and appropriate physical activity
219115729|NCT05668936|DRUG|Cotadutide|Participants will receive a subcutaneous injection of cotadutide.
219115730|NCT05668936|DRUG|Cotadutide-placebo|Participants will receive a subcutaneous injection of cotadutide-placebo.
219115731|NCT05668936|DRUG|Moxifloxacin|Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
219115732|NCT05668936|DRUG|Moxifloxacin-placebo|Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
219115733|NCT03753776|DRUG|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
219115734|NCT03753776|DRUG|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
219115735|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
219115736|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
219115737|NCT03609554|OTHER|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
219115738|NCT02307747|OTHER|blood samples|Blood samples will be collected every 4 hours during 24 h
219115739|NCT04088474|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
219115740|NCT04088474|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
219115741|NCT03663777|OTHER|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
219115742|NCT03663777|OTHER|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
219115743|NCT01216293|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg capsules
219115744|NCT01216293|DRUG|Esomeprazole|Esomeprazole 40 mg capsules
219115745|NCT01216293|DRUG|Placebo|Placebo-matching capsules
219115746|NCT01080651|DRUG|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
219115747|NCT04496843|DIAGNOSTIC_TEST|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
219115748|NCT01243073|DRUG|Imetelstat|
219115749|NCT02679534|OTHER|hand massage|
219115750|NCT02679534|OTHER|hand holding|
219115751|NCT02679534|OTHER|application of unscented hypoallergenic cream|
219115752|NCT02679534|OTHER|environmental adjustments|
219701734|NCT03957993|OTHER|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
219701735|NCT03957993|OTHER|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
219701736|NCT05297357|DIETARY_SUPPLEMENT|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
219701737|NCT01118676|DRUG|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
219701738|NCT04512989|DIAGNOSTIC_TEST|Cognitive assesment using MOCA test|Cognitive assesment using MOCA test
219701739|NCT01140906|DRUG|Placebo|capsules, daily, orally
219701740|NCT01140906|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
219701741|NCT01140906|DRUG|Duloxetine|encapsulated capsules, daily, orally
219115753|NCT04676490|OTHER|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
219115754|NCT04676490|OTHER|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
219115755|NCT04590859|PROCEDURE|Block performed|Comparing block performed with penile blood flow
219115756|NCT04590859|DEVICE|LMA placement|Placement of LMA for airway securement
219115757|NCT06394661|DRUG|Serplulimab+NabPE|Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3）
219115758|NCT05280405|DRUG|Infliximab|Infliximab
219115759|NCT05632536|PROCEDURE|SACRAL ESP AND CAUDAL BLOCK|Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
219115760|NCT01671748|DEVICE|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
219115761|NCT01671748|OTHER|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
219115762|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -active|with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
219115763|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -sham|The sham stimulation was performed using the same procedures, with the sham coil.
219701742|NCT00703534|DRUG|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
219701743|NCT00703534|DRUG|Placebo|capsule. administered as a single dose twice daily for 4 weeks
219701744|NCT00703534|DRUG|Gelusil®|Chewable tablets taken as needed
219701745|NCT05729321|COMBINATION_PRODUCT|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
219701746|NCT05375916|DRUG|Hydromorphone|Sustained-release hydromorphone is a long-acting preparation opioid
219701747|NCT00038285|PROCEDURE|Amputation Prevention|
219701748|NCT05224830|OTHER|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
219701749|NCT01327768|PROCEDURE|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
219701750|NCT01309334|PROCEDURE|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
219115764|NCT06609330|BEHAVIORAL|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
219115765|NCT06376981|DRUG|Hyaluronic acid injection|An injection of 2 ml of Acid hyaluronic
219115766|NCT06376981|DRUG|Corticosteroid injection|An injection of 1 ml of corticosteroids
219115767|NCT06376981|DRUG|Placebo injection|An injection of 2 ml of placebo (physiological serum)
219701751|NCT01309334|PROCEDURE|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
219701752|NCT03667521|PROCEDURE|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
219701753|NCT00336544|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
219115771|NCT00697554|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
219115772|NCT00697554|BIOLOGICAL|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
219115773|NCT01974466|OTHER|Goal A|controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
219701754|NCT00336544|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
219701755|NCT03592628|OTHER|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
219701756|NCT03592628|OTHER|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
219701757|NCT02177994|DRUG|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
219701758|NCT01649765|DRUG|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
219701759|NCT01649765|OTHER|placebo|Normal Saline 250 ml
219701760|NCT02188550|DRUG|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
219701761|NCT01648764|DRUG|LY2334737|Administered orally
219115774|NCT01974466|OTHER|Goal B|"controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
219701762|NCT05197439|DRUG|Dexmedetomidine|The 4.8ug/kg dexmedetomidine will be diluted into 100ml and pump 2ml/h at the beginning of the second of DBS and last for 48 hours.
219701763|NCT05197439|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
219701764|NCT00715208|DRUG|rituximab|
219701765|NCT00715208|DRUG|cyclophosphamide|
219701766|NCT00715208|DRUG|doxorubicin|
219701767|NCT00715208|DRUG|VELCADE|
219701768|NCT00715208|DRUG|prednisone|
219115775|NCT04315415|DEVICE|Silk Voice|Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
219701769|NCT01316614|DEVICE|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
219701770|NCT00052338|DRUG|gemcitabine hydrochloride|Given IV
219701771|NCT00052338|DRUG|carboplatin|Given IV
219115776|NCT06474117|OTHER|Gait analysis coupled with ultrasound|Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle
219115777|NCT06474117|OTHER|Isokinetic dynamometer with simultaneous ultrasound|Measure the force/length profile of the gastrocnemius medialis muscle
219115778|NCT03403933|DRUG|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
219115779|NCT00913679|PROCEDURE|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
219115780|NCT01222832|DRUG|Bacitracin|Bacitracin soaked nasopore sponge
219701772|NCT00052338|DRUG|bortezomib|Given IV
219701773|NCT00052338|OTHER|laboratory biomarker analysis|Correlative studies
219701774|NCT01860209|PROCEDURE|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
219701775|NCT00076570|DRUG|Sirolimus|
219701776|NCT00076570|DRUG|Tacrolimus|
219701777|NCT05307393|BEHAVIORAL|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
219701778|NCT03427411|DRUG|M7824|Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
219701779|NCT05662969|DEVICE|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
219701780|NCT02106507|DRUG|apalutamide|apalutamide, 240 mg/day, oral
219701781|NCT02106507|DRUG|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
219115781|NCT01339325|PROCEDURE|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
219701782|NCT02939352|DEVICE|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
219701783|NCT02939352|DEVICE|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
219701784|NCT04548245|DEVICE|EEG|EEG
219225142|NCT05340231|DRUG|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
219701785|NCT00481663|DRUG|Sitagliptin|
219701786|NCT00481663|DRUG|Placebo to sitagliptin|
219701787|NCT00481663|DRUG|Metformin|
219701788|NCT00481663|DRUG|Rescue|Patients whose FPG \>240 mg/dL from Week 16 or HbA1C \>8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently \>240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C \>8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C \>7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
219701789|NCT00533338|BEHAVIORAL|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
219701790|NCT00533338|BEHAVIORAL|Questionnaire|Packet of questionnaires will be completed.
219701791|NCT05859230|DIETARY_SUPPLEMENT|Experimental: The probiotic drink study group|The 100 ml volume of milk drink containing 10 billion Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded by study team members and subjects. The milk drink bottles are coded by the manufacturing company.
219701792|NCT05859230|DIETARY_SUPPLEMENT|Placebo Comparator: The placebo drink study group|The 100 ml volume of milk drink without containing Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded to study team members and subjects. The milk drink bottles are coded by the manufacturing company.
219701793|NCT04069858|DRUG|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
219701794|NCT02186028|DRUG|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
219701795|NCT04044118|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet consisted of \~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
219701796|NCT00001891|PROCEDURE|Myocardial contrast echocardiography|
219701797|NCT00001891|PROCEDURE|Dobutamine echocardiography|
219701798|NCT04227912|OTHER|Transversus abdominis plane block|Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
219701799|NCT04227912|OTHER|Local anesthetic infiltration|Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
219701800|NCT04227912|OTHER|Intravenous dexketoprofen|Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
219701801|NCT04889040|DRUG|RO7496998|275 mg tablets
219701802|NCT04889040|DRUG|Placebo|Matching tablets
219701803|NCT02295137|PROCEDURE|Using pre-procedural CTA to guide advanced EVAR procedure|
219701804|NCT05500937|DRUG|UDCA|UDCA vs. placebo together with statin in ASCVD patients
219701805|NCT04897620|OTHER|Scanning the blood test results|"Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations were recorded. NLR was calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula platelet numberxneutrophil number/lymphocyte number"
219701806|NCT04941872|DIAGNOSTIC_TEST|68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
219701807|NCT04796974|DEVICE|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
219701808|NCT00128375|BEHAVIORAL|Financial incentives|
219701809|NCT00312442|DRUG|Treatment with WST09 Vascular Photodynamic therapy|
219701810|NCT04111302|OTHER|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
219701811|NCT04111302|OTHER|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
219115782|NCT03242603|BIOLOGICAL|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
219115783|NCT02358590|BEHAVIORAL|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
219115784|NCT02358590|BEHAVIORAL|Standard care|The treating physician will advice participants to take vitamin D
219115785|NCT02626403|DEVICE|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
219115786|NCT02626403|DEVICE|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
219115787|NCT05475938|OTHER|Painting therapy and psychoanalysis|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
219115788|NCT03204695|DEVICE|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
219115789|NCT03204695|DRUG|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
219115790|NCT04596527|DRUG|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
219115791|NCT03800966|OTHER|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
219115792|NCT06396195|OTHER|bioflx crown|The Bioflx crowns are characterized by their flexibility, durability, and adaptability. These crowns are preformed pediatric crowns designed for aesthetics, combining properties found in both stainless steel and zirconia crowns.
219115793|NCT06396195|OTHER|stainless steel crown|"Stainless steel crowns continue to be considered the Gold Standard for posterior full coverage restorations in primary molars"
219115794|NCT01316497|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
219115795|NCT01316497|PROCEDURE|Control|The cuff was applied on the leg without inflation in the control group.
219115796|NCT05536674|BEHAVIORAL|SMS reminder for the HPV vaccination|A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
219115797|NCT03788148|DEVICE|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
219115798|NCT01349829|BIOLOGICAL|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
219115799|NCT01349829|BIOLOGICAL|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
219115800|NCT02555371|BIOLOGICAL|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
219115801|NCT02555371|DRUG|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
219115802|NCT04784273|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
219115803|NCT04784273|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
219115804|NCT01859650|OTHER|MR and CT imaging|
219115805|NCT03095599|BIOLOGICAL|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
219115806|NCT03095599|OTHER|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
219115807|NCT00104182|DRUG|insulin detemir|
219115808|NCT00104182|DRUG|insulin NPH|
219115809|NCT03116763|BEHAVIORAL|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
219115810|NCT03116763|OTHER|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
219115811|NCT01379235|OTHER|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
219115812|NCT03184714|DEVICE|NIPPV|BiPAP treatment for 3 years
219115813|NCT00931203|DRUG|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
219115814|NCT00058903|DRUG|sertraline|
219115815|NCT00968838|PROCEDURE|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients \>50 years of age are randomized to receive either radiated or non radiated transfusions."
219115816|NCT00742885|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
219225143|NCT05340231|DRUG|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
219115817|NCT05180747|OTHER|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
219115818|NCT05071066|OTHER|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month \[T1\], and 6-month \[T2\]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
219115819|NCT04781647|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
219115820|NCT04781647|DRUG|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
219115821|NCT04781647|BIOLOGICAL|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
219115822|NCT00489723|DRUG|tamsulosin 0.4mg|
219115823|NCT05729815|OTHER|Relaxation|Sessions focused on relaxations activities (Jacques Choque Method).
219115824|NCT05729815|OTHER|Loose parts play|Loose parts play-based sessions, with open-ended materials.
219115825|NCT05729815|OTHER|Combined|Sessions focused on loose parts play and relaxation activities.
219115826|NCT01973465|BIOLOGICAL|Stool|Implanting fecal matter via colonscope
219225144|NCT04378894|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
219115827|NCT00360555|DRUG|flibanserin|flibanserin 25 mg b.i.d
219115828|NCT00360555|DRUG|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
219115829|NCT00360555|DRUG|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
219115830|NCT00360555|DRUG|placebo|placebo comparator
219115831|NCT01603940|DRUG|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
219701812|NCT04111302|OTHER|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
219701813|NCT04111302|OTHER|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
219701814|NCT02058095|DRUG|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
219115832|NCT01603940|DRUG|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
219115833|NCT02836977|DRUG|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
219115834|NCT02018861|DRUG|Parsaclisib|
219115835|NCT02018861|DRUG|Itacitinib|
219115836|NCT02018861|DRUG|Rituximab|
219115837|NCT02018861|DRUG|Ifosfamide|
219115838|NCT02018861|DRUG|Carboplatin|
219115839|NCT02018861|DRUG|Etoposide|
219115840|NCT00147979|DEVICE|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
219115841|NCT00147979|DEVICE|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
219115842|NCT05140993|BEHAVIORAL|extended emotional and orientation support|extended emotional and orientation support
219225145|NCT05123079|DRUG|Darigabat|Tablets
219225146|NCT04701372|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
219115843|NCT06228235|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings."
219115844|NCT01109303|PROCEDURE|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
219115845|NCT01109303|PROCEDURE|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
219115846|NCT02529865|BIOLOGICAL|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
219115847|NCT03135353|DEVICE|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
219115848|NCT03135353|DEVICE|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
219115849|NCT03567083|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
219115850|NCT00192283|BIOLOGICAL|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
219115851|NCT00192283|OTHER|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
219115852|NCT03664167|DIETARY_SUPPLEMENT|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
219115853|NCT04574245|PROCEDURE|Gastrectomy; Hepatectomy|
219115854|NCT00504348|DRUG|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
219115855|NCT05248464|OTHER|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
219115856|NCT05248464|OTHER|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
219115857|NCT02372331|OTHER|ERAS perioperative management|"* Preop Counseling~* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)~* Preop enteral nutrition~* Oral bowel preparation (mechanical bowel preparation ) (X)~* Preop fasting \< 6 hours~* Prevention of postoperative nausea and vomiting (PONV) (O)~* Nasogastric intubation (X)~* Near-zero fluid balance~* Somatostatin analogues (X)~* Postop routine artificial nutrition (X), soft diet at POD #2~* Audit~* Other items are same as conventional"
219115858|NCT03833011|PROCEDURE|Osteopathic Manipulation|Osteopathic manipulation
219115859|NCT00827944|DEVICE|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
219115860|NCT00827944|DEVICE|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
219115861|NCT00709891|DEVICE|cobas® 4800 HPV Test|
219115862|NCT04071691|DIAGNOSTIC_TEST|PET-MRI|SST2 PET-MRI scan
219115863|NCT05835492|DEVICE|myCOPD|myCOPD is a digital self-management application (app), that supports all elements of managing COPD by creating a supported self-help environment, and in turn reduce medical visits, and hospital admissions and re-admissions. myCOPD allows for key aspects of disease management, such as PR, to be provided remotely, based on a person's self-assessment. Furthermore, it can help people with COPD manage their condition at home, or anywhere away from a clinical setting. Successful implementation of myCOPD provides an opportunity to build capacity in primary and secondary care, and community teams where a blended approach with traditional PR and myCOPD is used. Studies have shown myCOPD is able to deliver similar improvements in symptoms and exercise tolerance compared to PR exercise-classes and helps patients admitted to hospital recover more quickly at home(5)(6). myCOPD is widely deployed across the NHS and is being used by patients in different areas of the UK.
219115864|NCT02353117|BEHAVIORAL|Congenital Syphilis Intervention Group|
219115865|NCT03644134|BEHAVIORAL|Assessment of physiological stress and sleep pattern|The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
219115866|NCT01474512|DRUG|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
219115867|NCT01474512|DRUG|Placebo|Administered SC
219115868|NCT03888885|BEHAVIORAL|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
219115869|NCT02187211|DRUG|Minocycline|
219115870|NCT02187211|DRUG|Placebo (for Minocycline)|
219115871|NCT02724072|DEVICE|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
219115872|NCT03478423|DRUG|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
219115873|NCT03478423|DRUG|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
219115874|NCT03478423|DRUG|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
219115875|NCT00514605|OTHER|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
219115876|NCT00514605|DEVICE|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
219115877|NCT00487422|DRUG|prucalopride|2 mg o.d.
219115878|NCT00487422|DRUG|Prucalopride|4 mg o.d.
219115879|NCT00487422|OTHER|Placebo|o.d.
219225147|NCT06014372|DRUG|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
219115880|NCT01635894|BEHAVIORAL|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
219115881|NCT01043731|PROCEDURE|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
219115882|NCT00772798|DRUG|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
219115883|NCT01305356|DEVICE|Augment® Injectable Bone Graft|Implantation of up to 9cc of Augment® Injectable Bone Graft
219115884|NCT01305356|PROCEDURE|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
219115885|NCT00000556|DRUG|amiodarone|
219115886|NCT00000556|DRUG|sotalol|
219115887|NCT00000556|DRUG|propafenone|
219115888|NCT00000556|DRUG|flecainide|
219115889|NCT00000556|DRUG|quinidine|
219115890|NCT00000556|DRUG|moricizine|
219115891|NCT00000556|DRUG|disopyramide|
219115892|NCT00000556|DRUG|procainamide|
219115893|NCT00000556|DRUG|adrenergic beta antagonists|
219115894|NCT00000556|DRUG|verapamil|
219115895|NCT00000556|DRUG|diltiazem|
219115896|NCT00000556|DRUG|digoxin|
219701815|NCT02058095|DRUG|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
219115897|NCT00000556|PROCEDURE|catheter ablation|
219115898|NCT00000556|DEVICE|pacemaker, artificial|
219115899|NCT01023308|DRUG|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
219701816|NCT05082480|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA)
219701817|NCT05082480|DEVICE|Saline|Saline
219701818|NCT04252729|PROCEDURE|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
219115900|NCT01023308|DRUG|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
219115901|NCT01023308|DRUG|Dexamethasone|Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
219115902|NCT01023308|DRUG|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
219115903|NCT00551213|BIOLOGICAL|Robatumumab|
219115904|NCT00551213|DRUG|Irinotecan|
219115905|NCT00551213|BIOLOGICAL|Cetuximab|
219115906|NCT00551213|DRUG|Capecitabine|
219115907|NCT00551213|DRUG|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
219115908|NCT00551213|DRUG|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
219115909|NCT00551213|DRUG|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
219115910|NCT02060253|DRUG|ganetespib|Given IV
219115911|NCT02060253|DRUG|paclitaxel|Given IV
219115912|NCT02060253|BIOLOGICAL|trastuzumab|Given IV
219115913|NCT02060253|BIOLOGICAL|pertuzumab|Given IV
219115914|NCT01409174|DRUG|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
219115915|NCT01409174|DRUG|Temozolomide|200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
219115916|NCT01409174|DRUG|Cisplatin|25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
219115917|NCT01409174|DRUG|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
219701819|NCT00144313|BIOLOGICAL|hepatitis B vaccine|
219701820|NCT00998946|DRUG|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
219701821|NCT00998946|DIETARY_SUPPLEMENT|Vitamin B12|1 mg intramuscular (IM) injection
219701822|NCT00998946|DIETARY_SUPPLEMENT|Folic Acid|Oral 1 mg tablet
219115918|NCT01409174|DRUG|Interleukin-2|9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
219115919|NCT01697761|OTHER|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
219115920|NCT01697761|OTHER|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
219115921|NCT02152436|OTHER|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
219115922|NCT00337415|DRUG|MK0354|
219115923|NCT00855192|BEHAVIORAL|mindful meditation|interpersonal and psycho-educational
219115924|NCT00855192|BEHAVIORAL|interpersonal therapy|psycho-educational
219701823|NCT00148798|DRUG|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
219701824|NCT00148798|DRUG|cisplatin + vinorelbine|cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
219701825|NCT01897116|DRUG|Hydroxychloroquine (HCQ)|
219701826|NCT01897116|DRUG|Vemurafenib (VEM)|
219115925|NCT02772250|BEHAVIORAL|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
219115926|NCT02772250|BEHAVIORAL|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
219701827|NCT03050567|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
219701828|NCT02139319|DRUG|Botulinum toxin|
219701829|NCT02139319|DRUG|Placebo|
219115927|NCT01093261|DRUG|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
219115928|NCT01093261|DRUG|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
219115929|NCT02687503|DIETARY_SUPPLEMENT|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
219115930|NCT04908163|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
219225148|NCT06014372|DRUG|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
219225149|NCT01034306|DRUG|CF101|orally q12h
219225150|NCT01034306|DRUG|Placebo control|orally q12 hours
219225151|NCT00836498|BIOLOGICAL|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
219701830|NCT00316004|DRUG|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
219701831|NCT00316004|DRUG|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
219701832|NCT00316004|DRUG|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
219701833|NCT01339169|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
219115931|NCT04908163|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
219115932|NCT05338983|DRUG|Topical anesthetic|20% Benzocaine gel will be applied on the area of infiltration
219115933|NCT05338983|DEVICE|Avent baby bottle warmer|Warming device
219115934|NCT05338983|DRUG|Sodium bicarbonate|0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
219115935|NCT05338983|DEVICE|Buzzy device|"Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic."
219115936|NCT05338983|DRUG|Mepivacaine Hydrochloride|Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
219115937|NCT03437798|OTHER|Disease status|Women who reported periodontal disease diagnosis/condition
219115938|NCT00900289|GENETIC|DNA methylation analysis|
219115939|NCT00900289|GENETIC|microarray analysis|
219115940|NCT00900289|GENETIC|polymerase chain reaction|
219115941|NCT00900289|OTHER|immunohistochemistry staining method|
219701834|NCT02254655|DRUG|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
219701835|NCT02254655|DRUG|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
219701836|NCT03483428|BEHAVIORAL|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
219701837|NCT03483428|BEHAVIORAL|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
219701838|NCT05106569|DIAGNOSTIC_TEST|Spirometry|All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
219701839|NCT03155698|COMBINATION_PRODUCT|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
219701840|NCT03155698|RADIATION|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
219115942|NCT00900289|OTHER|laboratory biomarker analysis|
219115943|NCT01890967|DRUG|LY3015014|Administered SC
219115944|NCT01890967|DRUG|Placebo|Administered SC
219115945|NCT01890967|DRUG|Statin|Administered orally
219115946|NCT01890967|DRUG|Ezetimibe|Administered orally
219115947|NCT05440799|DRUG|BI 1819479|BI 1819479
219115948|NCT05440799|DRUG|BI matching placebo|BI matching placebo
219115949|NCT01861301|OTHER|Laboratory Biomarker Analysis|Correlative studies
219115950|NCT01861301|DRUG|Tivantinib|Given PO
219701841|NCT00977197|DRUG|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
219701842|NCT00977197|DRUG|Placebo|A matching placebo will be administered twice a day
219115951|NCT02089451|DRUG|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
219115952|NCT03350477|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
219115953|NCT03350477|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
219115954|NCT00255814|RADIATION|radiation therapy|
219115955|NCT01015573|DEVICE|magnetic sensor system to measure the movements of finger tapping|
219115956|NCT04612114|DIAGNOSTIC_TEST|Belun Ring|Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
219225152|NCT00836498|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
219225153|NCT00836498|BIOLOGICAL|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
219701843|NCT01961492|OTHER|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
219161734|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
219701844|NCT02684929|DIETARY_SUPPLEMENT|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
219701845|NCT00784875|DRUG|LY2624803|1 mg, oral capsule, once nightly before bedtime
219701846|NCT00784875|DRUG|LY2624803|3 mg, oral capsule, once nightly before bedtime
219701847|NCT00784875|DRUG|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
219701848|NCT00784875|DRUG|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
219701849|NCT04345224|OTHER|Dynamic tape|A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
219701850|NCT04345224|OTHER|Rigid tape|The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
219701851|NCT04345224|OTHER|Sham tape|The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
219701852|NCT03524209|DEVICE|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
219701853|NCT03524209|OTHER|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
219701854|NCT01244659|DRUG|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
219701855|NCT01244659|DRUG|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
219701856|NCT04111315|DRUG|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
219701857|NCT04111315|DRUG|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
219701858|NCT04111315|BEHAVIORAL|Patient education|Leaflet and phone call
219701859|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
219701860|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
219701861|NCT06255483|OTHER|Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction|"A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node ."
219701862|NCT05755126|BEHAVIORAL|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
219701863|NCT05755126|BEHAVIORAL|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
219115957|NCT06373848|DRUG|Receive 30 mg of Coq10|A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
219115958|NCT03801720|OTHER|Ultrasound|Using ultrasound stimulation to induce micturition.
219115959|NCT04653896|DEVICE|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
219115960|NCT02809027|DRUG|Ginger|
219115961|NCT02809027|DRUG|Placebo|
219115962|NCT00675727|BIOLOGICAL|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
219115963|NCT06424379|OTHER|Histopathological analysis|"Morphological analysis will include the description of architectural patterns and cytological features on formalin-fixed and paraffin-embedded (FFPE) tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud.~A panel of immunohistochemical staining will be analyzed including CD20, CD3, CD10, Bcl-6, Bcl-2, CD5, CD23, CD38, MUM1, Ig kappa, Ig lambda, MEF2B, LMO2, MNDA, IRTA1, P53, CMYC and Ki67 . /MIB1. Diffuse large B-cells lymphomas will be classified into two distinct subgroups: centro-germinative (GC) and non-centro-germinative (nGC), using the Hans algorithm."
219701864|NCT04992247|BIOLOGICAL|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
219701865|NCT04992247|BIOLOGICAL|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
219115964|NCT06424379|GENETIC|Molecular analysis|"Next-generation sequencing (NGS) analysis will be performed on FFPE tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud. A panel of 73 genes dedicated to lymphoma diagnosis determined by a consensus of French Lysa experts will be used. The identification of genetic variants will be followed by the attribution of pathogenicity class in accordance with the guidelines for validation of NGS-based oncology panels.~RNA extraction will classify DLBCLs into two distinct subgroups: germinal-centre B-cell-like (GCB-DLBCL) and activated B-cell-like (ABC-DLBCL)."
219701866|NCT06366308|PROCEDURE|Transperineal Prostate Biopsy|The investigators plan to retrospectively review data from over 10000 men receiving transperineal prostate biopsy in our center.
219701867|NCT02118623|BEHAVIORAL|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
219115965|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
219115966|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
219115967|NCT03251404|OTHER|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
219115968|NCT02928094|BIOLOGICAL|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
219115969|NCT02928094|BIOLOGICAL|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
219115970|NCT05545969|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219225154|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
219225155|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
219115971|NCT05545969|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
219115972|NCT04689022|BEHAVIORAL|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
219115973|NCT04689022|DIAGNOSTIC_TEST|visual analogue scale (VAS)|pain intensity
219115974|NCT04689022|DIAGNOSTIC_TEST|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
219115975|NCT01093300|DEVICE|Paclitaxel-eluting balloon catheter|
219115976|NCT01093300|DEVICE|Everolimus-eluting stent|
219115977|NCT00414869|DRUG|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
219115978|NCT00414869|DRUG|Placebo|Inactive powder matching NCX-1000
219115979|NCT03544528|PROCEDURE|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
219701868|NCT02118623|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies."
219701869|NCT02118623|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
219701870|NCT00526617|DRUG|ABT-888|Oral capsules
219701871|NCT00526617|DRUG|Temozolomide|Oral capsules
219701872|NCT05531955|DRUG|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
219701873|NCT05531955|OTHER|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
219701874|NCT05531877|DIAGNOSTIC_TEST|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
219701875|NCT00676143|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
219701876|NCT00676143|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
219701877|NCT00001011|DRUG|Zidovudine|
219701878|NCT06403657|OTHER|An enhanced model of hepatitis B testing and linkage to care|Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
219115980|NCT03010735|DIETARY_SUPPLEMENT|probiotics|Daily take 4.0E+10 CFU of probiotics
219115981|NCT03010735|DIETARY_SUPPLEMENT|Placebo|
219115982|NCT00218985|BEHAVIORAL|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
219115983|NCT03572010|DIETARY_SUPPLEMENT|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
219115984|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
219115985|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L);
219115986|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
219115987|NCT01492855|PROCEDURE|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
219115988|NCT01492855|BEHAVIORAL|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
219115989|NCT03453632|DRUG|Botulinic toxin|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot"
219701879|NCT00787878|DRUG|somatropin|SGA previously treated with Norditropin®
219701880|NCT00787878|DRUG|No treatment given|Untreated SGA
219701881|NCT00787878|DRUG|No treatment given|AGA (Average gestational age)
219701882|NCT03862638|OTHER|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
219701883|NCT01144832|DRUG|ebastine|20 milligram capsule once daily
219115990|NCT03453632|DRUG|Placebo|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot"
219115991|NCT04524182|OTHER|control group|"There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
219115992|NCT04524182|OTHER|mobilization group|"Lumbosacral mobilization for 10 minutes in the study group (pelvis forward and backward distraction, passive rotation of the lower body, short lever rotation, long lever rotation, lumbar central posterior-anterior, lumbar unilateral posterior-anterior, anterior rotation-posterior superior iliac spine- down, posterior rotation-posterior superior iliac spine-up were applied.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
219115993|NCT04964765|DIAGNOSTIC_TEST|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
219115994|NCT04964765|DIAGNOSTIC_TEST|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
219115995|NCT04485780|BIOLOGICAL|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
219701884|NCT01144832|DRUG|placebo capsule|one capsule once daily
219701885|NCT06228989|PROCEDURE|Restorative therapy|Restorative treatment of first permanent molars affected with severe MIH
219701886|NCT06228989|PROCEDURE|Extraction therapy|Extraction treatment of first permanent molars affected with severe MIH
219701887|NCT01901185|DRUG|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
219701888|NCT02318264|DEVICE|Kinesio Tape|Elastic tape placed over the skin
219701889|NCT04525196|OTHER|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
219115996|NCT05536427|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
219115997|NCT02646553|OTHER|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
219115998|NCT01556841|BIOLOGICAL|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
219701890|NCT02914327|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
219701891|NCT00694772|PROCEDURE|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
219701892|NCT00694772|PROCEDURE|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
219701893|NCT05267717|OTHER|Non-interventional study, all patients being tested with AG Pregnolia System to assess the values of the Cervical Stiffness|Non-interventional study,
219701894|NCT06243302|PROCEDURE|OTSC Closure After VAAFT|Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
219115999|NCT01556841|BIOLOGICAL|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
219116000|NCT04559399|PROCEDURE|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
219116001|NCT05205447|DRUG|LY3410738|Oral LY3410738
219116002|NCT05205447|DRUG|Itraconazole|Oral Itraconazole
219701895|NCT03185078|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
219701896|NCT03185078|OTHER|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
219701897|NCT05803707|BEHAVIORAL|Home-based Adapted Physical Activity|There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
219701898|NCT02841046|DEVICE|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
219701899|NCT02841046|DEVICE|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
219701900|NCT02309359|BIOLOGICAL|ALX-0061|
219701901|NCT02309359|OTHER|Placebo|
219701902|NCT02309359|DRUG|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
219701903|NCT00067834|DEVICE|Pulsing electromagnetic field (PEMF)|
219701904|NCT03443648|PROCEDURE|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
219701905|NCT05055765|PROCEDURE|Microneedling|MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
219701906|NCT05055765|PROCEDURE|injectable- platelet rich fibrin|I-PRF will be prepared according to Choukroun PRF method.
219701907|NCT00626145|PROCEDURE|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
219701908|NCT00626145|PROCEDURE|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
219701909|NCT00701363|DRUG|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
219701910|NCT00060411|DRUG|erlotinib hydrochloride|Given IV
219701911|NCT00060411|DRUG|fluorouracil|Given IV
219701912|NCT00060411|DRUG|leucovorin calcium|Given IV
219701913|NCT00060411|DRUG|oxaliplatin|Given IV
219116003|NCT05205447|DRUG|Carbamazepine|Oral Carbamazepine
219116004|NCT03796689|DEVICE|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
219116005|NCT03796689|DEVICE|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
219116006|NCT04234243|PROCEDURE|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
219116007|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
219116008|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
219225156|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
219701914|NCT00060411|BIOLOGICAL|bevacizumab|Given IV
219701915|NCT00049569|DRUG|cytarabine|Given IT
219701916|NCT00049569|DRUG|methotrexate|Given IT
219701917|NCT00049569|DRUG|vincristine sulfate|Given IV
219701918|NCT00049569|DRUG|prednisone|Given PO
219701919|NCT00049569|DRUG|pegaspargase|Given IM
219701920|NCT00049569|DRUG|doxorubicin hydrochloride|Given IV
219701921|NCT00049569|DRUG|imatinib mesylate|Given PO
219701922|NCT00049569|DRUG|cyclophosphamide|Given IV
219701923|NCT00049569|DRUG|etoposide|Given IV
219701924|NCT00049569|BIOLOGICAL|filgrastim|Given SC
219701925|NCT00049569|DRUG|leucovorin calcium|Given IV
219701926|NCT00049569|DRUG|asparaginase|Given IM
219701927|NCT00049569|DRUG|therapeutic hydrocortisone|Given IT
219701928|NCT00004921|BIOLOGICAL|filgrastim|
219701929|NCT00004921|DRUG|carboplatin|
219701930|NCT00004921|DRUG|cyclophosphamide|
219701931|NCT00004921|DRUG|melphalan|
219701932|NCT00004921|DRUG|paclitaxel|
219701933|NCT00004921|PROCEDURE|adjuvant therapy|
219701934|NCT00004921|PROCEDURE|bone marrow ablation with stem cell support|
219701935|NCT00004921|PROCEDURE|peripheral blood stem cell transplantation|
219701936|NCT00284856|DRUG|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
219701937|NCT00284856|DRUG|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
219701938|NCT00284856|DRUG|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
219701939|NCT00284856|DRUG|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
219701940|NCT03019380|DEVICE|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
219701941|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
219701942|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
219701943|NCT05598697|OTHER|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
219701944|NCT05047900|DIAGNOSTIC_TEST|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
219701945|NCT01192815|DRUG|erlotinib hydrochloride|Given orally or via gastronomy tube
219701946|NCT01192815|RADIATION|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
219701947|NCT01192815|OTHER|pharmacogenomic studies|Optional correlative studies
219701948|NCT01192815|OTHER|gene expression analysis|Correlative studies
219701949|NCT01192815|RADIATION|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
219701950|NCT01192815|OTHER|biopsy|Optional correlative studies
219701951|NCT01192815|OTHER|pharmacological study|Optional correlative studies
219701952|NCT01192815|OTHER|laboratory biomarker analysis|Optional correlative studies
219701953|NCT01192815|OTHER|questionnaire administration|Optional ancillary studies
219701954|NCT01192815|OTHER|enzyme-linked immunosorbent assay|Optional correlative studies
219116009|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
219116010|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
219116011|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
219701955|NCT01192815|OTHER|polymorphism analysis|Optional correlative studies
219701956|NCT05312996|OTHER|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
219701957|NCT05312996|OTHER|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
219701958|NCT05473845|PROCEDURE|Acupressure intervention|Acupressure
219701959|NCT05473845|PROCEDURE|Reiki intervention|Reiki
219701960|NCT03350919|DEVICE|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
219701961|NCT03350919|DEVICE|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
219116012|NCT05572151|PROCEDURE|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
219701962|NCT03879031|DIAGNOSTIC_TEST|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT)."
219701963|NCT05966103|OTHER|Exercises|For control group; Cervical conventional exercises. For treatment group; scapulothoracic exercises including strengthening, proprioceptive and stabilization exercises in addition to cervical conventional exercises
219701964|NCT05642676|OTHER|Clinics remodeling|changes to the clinics will be planned based on baseline surveys
219701965|NCT02574585|BIOLOGICAL|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
219701966|NCT01286129|PROCEDURE|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
219701967|NCT04071379|BIOLOGICAL|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
219701968|NCT04071379|BIOLOGICAL|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
219701969|NCT00466830|OTHER|questionnaire administration|
219701970|NCT00466830|PROCEDURE|management of therapy complications|
219701971|NCT00466830|PROCEDURE|psychosocial assessment and care|
219701972|NCT00466830|PROCEDURE|quality-of-life assessment|
219701973|NCT06468956|DRUG|SHR-1819|SHR-1819 injection
219701974|NCT06468956|DRUG|Placebo|placebo
219701975|NCT02816359|OTHER|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
219701976|NCT00477009|DEVICE|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
219701977|NCT02373267|BIOLOGICAL|Technozyme|determination of ADAMTS13 activity
219701978|NCT04134039|DEVICE|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
219701979|NCT04134039|DEVICE|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
219701980|NCT04140110|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
219701981|NCT04113135|OTHER|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
219116013|NCT00839228|DRUG|Perhexiline|100mg o bd for 3 months
219116014|NCT00839228|DRUG|Placebo|Placebo one tablet bd for 3 months
219116015|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
219116016|NCT04201522|OTHER|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
219116017|NCT04201522|OTHER|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
219116018|NCT02561455|DRUG|Gilteritinib|oral tablet
219116019|NCT01050075|OTHER|acupuncture therapy|acupuncture therapy
219116020|NCT01050075|OTHER|questionnaire administration|Ancillary study
219116021|NCT01050075|OTHER|management of therapy complications|To be determined by the treating physician
219116022|NCT05049044|OTHER|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
219116023|NCT06187181|PROCEDURE|implant overdenture|. Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
219116024|NCT06187181|RADIATION|videofluroscopy|videofluroscopy evaluation of swallowing function
219701982|NCT04113135|OTHER|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
219701983|NCT05692440|DEVICE|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
219701984|NCT03860688|DRUG|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
219701985|NCT06298734|BEHAVIORAL|Exercise Program|A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
219701986|NCT06298734|BEHAVIORAL|Diet Program|A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
219701987|NCT02837926|OTHER|questionnaire|
219701988|NCT02837926|BIOLOGICAL|Gardasil vaccine|
219701989|NCT02837926|BIOLOGICAL|Cervarix®|
219701990|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
219701991|NCT05882877|OTHER|Placebo|SC injection
219116025|NCT03677024|PROCEDURE|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
219701992|NCT04108390|OTHER|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
219116026|NCT01290016|BEHAVIORAL|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
219116027|NCT01290016|BEHAVIORAL|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
219116028|NCT01290016|BEHAVIORAL|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
219701993|NCT01862042|OTHER|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
219701994|NCT05283434|DRUG|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
219701995|NCT05283434|DRUG|Placebo|Sugar pill placebo
219701996|NCT05615077|OTHER|Combined exercise-education intervention|"Combined exercise and education intervention by fall risk state for 12 months during intervention period.~Exercise intervention includes balance exercise and strength exercise according to protocol.~Education intervention includes medication review, nutrition intervention, and home hazard modification.~The key to medication review is paying special attention to medications known to increase the risk of falls. Reduction of these medications is recommended, and redundant psychotropic medications are withdrawn. Nutrition intervention includes investigating dietary habits and calculate insufficient protein intake to provide customized diet and high protein drink. If vitamin D necessary, supplements are prescribed. Home hazard modification includes providing instructions to reduce and modify the home hazards that increase the risk of falls."
219701997|NCT04451083|DRUG|FOY-305|Multiple-dose of FOY-305 will be administered orally at 4 times/day.
219701998|NCT00465179|DRUG|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
219701999|NCT01366716|BEHAVIORAL|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
219702000|NCT01366716|BEHAVIORAL|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
219702001|NCT02123381|RADIATION|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
219116029|NCT01330043|DRUG|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
219116030|NCT01330043|DRUG|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
219116031|NCT01330043|DRUG|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
219702002|NCT02123381|DRUG|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
219702003|NCT00112749|BIOLOGICAL|infliximab|A single infusion of 1mg/kg will be administered.
219702004|NCT00112749|OTHER|Clinical Assessment|Medical, psychiatric, and immune evaluation.
219702005|NCT00112749|OTHER|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
219702006|NCT00112749|OTHER|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
219702007|NCT00976339|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
219702008|NCT05150691|BIOLOGICAL|DB-1303/BNT323|Administered IV
219702009|NCT05150691|DRUG|Pertuzumab Injection|Administered IV
219116032|NCT06117995|OTHER|Assessment the pre-washed sperm motility before IUI|The pre-washed sperm motility will be assessed by using WHO 2021 guidelines, stratified into four groups.
219116033|NCT05969522|DRUG|GlucoCorticoid|The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
219116034|NCT03482674|BEHAVIORAL|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
219702010|NCT05150691|DRUG|Ritonavir|Administered oral
219702011|NCT05150691|DRUG|Itraconazole|Administered oral
219702012|NCT02907827|OTHER|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
219702013|NCT06255457|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement of mitral regurgitation
219702014|NCT04485949|COMBINATION_PRODUCT|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
219702015|NCT04485949|COMBINATION_PRODUCT|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
219702016|NCT04485949|PROCEDURE|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
219702017|NCT04485949|DRUG|SOC: Temozolomide|Temozolomide administered orally.
219702018|NCT05010265|OTHER|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
219702019|NCT05010265|OTHER|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
219702020|NCT05399875|OTHER|Augmented reality virtual ruler|Use of augmented reality virtual ruler to measure catheter length
219702021|NCT06823037|OTHER|HAPPI software|"We will enroll 15 community pharmacies. These 15 pharmacies will continue to provide birth control services as normal for several months (control).~Then, we will introduce the intervention: the HAPPI software. The pharmacies will continue to provide birth control services while using the HAPPI software in place of any paper or electronic processes that they were previously using. The results will then be compared between the control and the intervention period."
219702022|NCT06827236|DRUG|BNT323|Intravenous infusion
219702023|NCT06827236|DRUG|BNT327|Intravenous infusion
219702024|NCT02187783|DRUG|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
219702025|NCT03622567|BEHAVIORAL|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
219702026|NCT03010072|DRUG|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
219702027|NCT03010072|DRUG|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
219702028|NCT00121056|DRUG|Enbrel®|
219702029|NCT00121056|DRUG|Kineret®|
219702030|NCT05334394|OTHER|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
219702031|NCT05334394|OTHER|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
219702032|NCT00888875|DEVICE|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
219702033|NCT00888875|DEVICE|ILMA|Insertion after Induction. Insertion of tracheal tube over device
219702034|NCT00309517|DRUG|Fluourouracil|
219702035|NCT00309517|DRUG|Leucovorin|
219702036|NCT00309517|DRUG|MAb 17-1A|
219702037|NCT01654276|DRUG|Febuxostat|One 40 mg tablet once a day for 6 months
219702038|NCT05054634|BEHAVIORAL|Psycho-oncological Intervention Based on Counselling (PIBC)|Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
219702039|NCT03832556|OTHER|CT scan|CT scan with biphasic injection of contrast product
219702040|NCT03832556|OTHER|MRI examination|MRI with injection of contrast
219702041|NCT00236626|DRUG|topiramate|
219702042|NCT02990052|PROCEDURE|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
219702043|NCT02990052|PROCEDURE|Conservative treatment|Closed reduction \& casting of distal radius fracture
219702044|NCT00774085|OTHER|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
219702045|NCT05880719|OTHER|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~* 15 minutes of music improvisation~* 20 minutes of harmony and rythm exercices~* 20 minutes of Lesson about the software and musical interfaces~* 5 minutes of debrief."
219702046|NCT02484521|DEVICE|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
219702047|NCT02484521|OTHER|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~1. GAF- Global assessment of functioning~2. PANSS- Positive and negative syndrome scale~3. SANS- Scale for the Assessment of Negative Symptoms~4. The Calgary Depression Scale for schizophrenia~5. Demographic Questionnaire~6. Hamilton Anxiety scale"
219702048|NCT05041465|OTHER|Clay mask|Clay mask powders- French green, Rhassul and bentonite
219702049|NCT03890965|OTHER|Reflex locomoction therapy|"The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation."
219702050|NCT04716543|DIAGNOSTIC_TEST|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
219702051|NCT05126316|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
219702052|NCT05126316|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
219702053|NCT02587208|DEVICE|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
219702054|NCT02587208|PROCEDURE|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
219702055|NCT05949840|OTHER|Expressive Interviewing|Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
219702056|NCT02954081|DRUG|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
219702057|NCT01618877|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
219702058|NCT01618877|OTHER|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
219702059|NCT06851858|DRUG|AZD6234|Weekly SC injections of AZD6234
219116035|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
219116036|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
219116037|NCT00521872|PROCEDURE|STARR Operation|
219161735|NCT05486052|OTHER|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
219161736|NCT03110549|DRUG|TMB-607|
219161737|NCT03110549|DRUG|Placebo|
219702060|NCT06851858|DRUG|Placebo to match|Weekly SC injections of matching placebo
219702061|NCT03418519|OTHER|Constraint Induced Movement Therapy|Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
219702062|NCT05948579|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
219702063|NCT05948579|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
219702064|NCT02933853|DRUG|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
219702065|NCT02933853|DRUG|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
219702066|NCT01356420|DIETARY_SUPPLEMENT|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
219702067|NCT02642705|OTHER|High intensity interval training N|Exercise training and ambient air breathing
219702068|NCT02642705|OTHER|High intensity interval training H|Exercise training and hypoxic breathing
219116038|NCT06174974|OTHER|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
219116039|NCT04925921|DEVICE|SR-1 Laser|3-4 treatments at 4-6 week intervals
219116040|NCT06478823|OTHER|Stools donation|"Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.~Donors will be followed from their selection until 6 months after their last valid stool donation."
219116041|NCT02341911|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
219225157|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
219225158|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
219225159|NCT02082652|DRUG|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
219702069|NCT02642705|OTHER|Constant load exercise training N|Exercise training and ambient air breathing
219702070|NCT02642705|OTHER|Constant load exercise training H|Exercise training and hypoxic breathing
219702071|NCT02642705|OTHER|Hypoxic conditioning at rest|Hypoxic breathing at rest
219702072|NCT02642705|OTHER|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
219702073|NCT04609514|DEVICE|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
219702074|NCT04609514|BEHAVIORAL|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
219702075|NCT04609514|DRUG|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
219702076|NCT04609514|BEHAVIORAL|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
219702077|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch|NSAIDs+narcotic analgesics
219702078|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
219702079|NCT00989222|PROCEDURE|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
219702080|NCT00989222|PROCEDURE|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
219702081|NCT00943436|OTHER|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
219702082|NCT00943436|OTHER|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
219702083|NCT01316575|DEVICE|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
219702084|NCT01316575|DEVICE|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
219702085|NCT05830760|BIOLOGICAL|Myocardium biopsy|The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
219702086|NCT02164292|PROCEDURE|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
219702087|NCT04534751|BIOLOGICAL|Fibrinogen + PCC|"Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units)."
219116042|NCT02341911|DRUG|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
219116043|NCT00337116|DRUG|iso sorbide dinitrate iv bolus or s/l|
219116044|NCT04443920|DRUG|Tranexamic acid (TXA)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
219116045|NCT04443920|DRUG|Placebo Normal Saline (NS)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
219116046|NCT01395771|BEHAVIORAL|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
219116047|NCT02580682|DRUG|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
219116048|NCT02580682|DRUG|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
219225160|NCT02923479|DEVICE|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
219702088|NCT04534751|BIOLOGICAL|Frozen Plasma|"4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician."
219702089|NCT00001104|DRUG|Zidovudine|
219702090|NCT03181152|DIAGNOSTIC_TEST|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
219702091|NCT05911217|DRUG|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
219702092|NCT05906849|BEHAVIORAL|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
219702093|NCT05637502|OTHER|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
219116049|NCT02580682|DRUG|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
219116050|NCT03112122|BIOLOGICAL|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
219225161|NCT02923479|OTHER|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
219225162|NCT02923479|OTHER|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
219225163|NCT02923479|DEVICE|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
219225164|NCT02923479|DEVICE|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
219225165|NCT01939249|DEVICE|Abbott Laboratories Xience|
219225166|NCT01939249|DEVICE|Biotronik Orsiro|
219225167|NCT02195856|DIETARY_SUPPLEMENT|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
219225168|NCT02195856|DIETARY_SUPPLEMENT|Placebo|
219702094|NCT00402831|BIOLOGICAL|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
219702095|NCT03927170|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
219702096|NCT03927170|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
219116051|NCT03112122|BIOLOGICAL|bone substitute i-FactorTM|subchondral injections of i-FactorTM
219116052|NCT03112122|PROCEDURE|core decompression|subchondral anterograde drilling
219116053|NCT03623711|DRUG|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
219116054|NCT03623711|DRUG|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
219116055|NCT03623711|DRUG|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
219116056|NCT03623711|OTHER|Healthy control|Healthy control take placebo tablets
219225169|NCT01619059|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
219225170|NCT01619059|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
219225171|NCT01619059|DRUG|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
219116057|NCT03749356|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
219116058|NCT03503994|DRUG|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid"
219116059|NCT03206294|OTHER|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
219702097|NCT03553147|OTHER|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
219702098|NCT05354297|DEVICE|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
219702099|NCT05354297|DEVICE|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
219702100|NCT05354297|DEVICE|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
219702101|NCT05354297|DEVICE|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
219116060|NCT05656313|DEVICE|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
219116061|NCT05656313|DEVICE|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
219116062|NCT05656313|DEVICE|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
219116063|NCT05656313|DEVICE|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
219116064|NCT04372511|DEVICE|Binaural Beats|Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
219225172|NCT01619059|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
219702102|NCT03043053|DRUG|oxytocin nasal spray|oxytocin intranasal spray
219702103|NCT03043053|DRUG|Placebo|Placebo nasal spray
219702104|NCT00808223|BIOLOGICAL|alefacept|IM injection
219116065|NCT05727683|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
219116066|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1(0.5mL)
219702105|NCT02524938|DIETARY_SUPPLEMENT|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
219702106|NCT02524938|DIETARY_SUPPLEMENT|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
219702107|NCT01436734|OTHER|Fasting glycemia|no intervention
219702108|NCT01436734|OTHER|Hypoglycemia|Insulin induced hypoglycemia
219702109|NCT01114724|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
219702110|NCT02873975|DRUG|LY2606368|
219702111|NCT03891225|PROCEDURE|Amniotic Membrane implantation|Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
219702112|NCT04655417|DRUG|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
219702113|NCT01860196|DRUG|Meditoxin|
219702114|NCT01860196|DRUG|Normal saline|
219702115|NCT03699748|BEHAVIORAL|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
219702116|NCT03699748|OTHER|Usual Care|Usual care as provided by Unite Here Health and local oncologists
219702117|NCT00687700|DRUG|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
219702118|NCT00687700|DRUG|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
219702119|NCT00687700|DRUG|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
219702120|NCT00687700|DRUG|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
219702121|NCT02473497|DRUG|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
219702122|NCT01700491|DRUG|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
219702123|NCT01700491|DRUG|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
219702124|NCT00287430|DRUG|Growth Hormone|
219702125|NCT00287430|PROCEDURE|Whole body Protein Turnover Study|
219116067|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2(0.5mL)
219116068|NCT06550830|BIOLOGICAL|Prevenar13®|One dose of PCV13 manufactured by Pfizer
219116069|NCT03172741|DRUG|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
219116070|NCT03172741|DRUG|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
219225173|NCT03080805|DRUG|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
219702126|NCT00287430|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
219702127|NCT00800046|DEVICE|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
219702128|NCT06377423|PROCEDURE|Direct technique|The composite was placed directly using free-hand technique
219702129|NCT06377423|PROCEDURE|Indirect technique|The ceramic was placed using indirect method via laboratory casts
219702130|NCT00720135|BIOLOGICAL|DI-Leu16-IL2 immunocytokine|Given IV
219702131|NCT00720135|BIOLOGICAL|rituximab|Given IV
219702132|NCT00720135|OTHER|flow cytometry|Correlative studies
219702133|NCT00720135|OTHER|immunohistochemistry staining method|Correlative studies
219702134|NCT00720135|OTHER|pharmacological study|Correlative studies
219225174|NCT03080805|DRUG|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
219225175|NCT02381132|DRUG|Norco 7.5mg/325|
219225176|NCT02381132|DRUG|MNK155|
219225177|NCT00649857|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
219702135|NCT00720135|OTHER|laboratory biomarker analysis|Correlative studies
219702136|NCT00720135|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219702137|NCT00720135|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
219702138|NCT00864110|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
219702139|NCT00864110|RADIATION|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
219702140|NCT00864110|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
219702141|NCT03883386|DRUG|Loratadine|10 mg in a capsule
219116071|NCT05828784|DEVICE|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
219116072|NCT00895479|PROCEDURE|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
219116073|NCT04218136|BIOLOGICAL|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
219116074|NCT02040233|DRUG|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
219116075|NCT02040233|DRUG|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
219702142|NCT03883386|DRUG|Placebo|Administered via capsule
219702143|NCT02814526|BEHAVIORAL|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
219702144|NCT02814526|BEHAVIORAL|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
219702145|NCT00889304|DEVICE|Position HTO system|open wedge high tibial osteotomy
219702146|NCT00914368|DRUG|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
219702147|NCT06389617|DRUG|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone|Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
219116076|NCT02040233|DRUG|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
219116077|NCT02040233|DRUG|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
219116078|NCT02818816|DRUG|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
219116079|NCT02818816|OTHER|Carboxymethylcellulose Eye Drops|Ocular lubricants
219116080|NCT00372307|DRUG|Application of pimecrolimus|
219702148|NCT03002402|BEHAVIORAL|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
219702149|NCT03945630|PROCEDURE|anterior Quadratus Lumborum Block|Interfascial plane block
219702150|NCT03945630|PROCEDURE|Standard of Care|No QLB
219702151|NCT06088693|OTHER|Electroacupuncture and Standard Therapy|Acupuncture Needle Insertion with Electroacupuncture machine.
219702152|NCT05782517|DEVICE|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
219702153|NCT05782517|DEVICE|Endotracheal Tube|Placement of an Endotracheal Tube.
219116081|NCT04966156|BEHAVIORAL|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
219116082|NCT06431698|DEVICE|Custom-made silicone device|Correction of deformation using the custom-made silicone device
219116083|NCT06431698|DEVICE|adjustable Earwell device|Correction of deformation using the adjustable Earwell device
219225178|NCT00649857|DRUG|Zyrtec® 10 mg|10mg, single dose fed
219702154|NCT02723240|DRUG|NUC-3373|
219702155|NCT05442008|DRUG|Erenumab 70/140 mg s.c.|Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)
219702156|NCT00908934|DRUG|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
219702157|NCT00908934|DRUG|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
219702158|NCT00908934|DRUG|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
219702159|NCT00908934|DRUG|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
219702160|NCT04596904|OTHER|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
219702161|NCT04596904|OTHER|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
219702162|NCT01409668|DIETARY_SUPPLEMENT|L. Amylovorus|L. Amylovorus
219702163|NCT01409668|DIETARY_SUPPLEMENT|L. Fermentum|L. Fermentum
219702164|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
219702165|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
219702166|NCT00251758|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
219702167|NCT02426099|DRUG|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
219702168|NCT02426099|OTHER|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
219116084|NCT04708821|DRUG|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
219116085|NCT04708821|DRUG|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
219116086|NCT04708821|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
219116087|NCT02733133|DRUG|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
219116088|NCT02702349|OTHER|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
219116089|NCT03030547|DEVICE|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
219116090|NCT02640651|DEVICE|DC-Stimulator (PLUS version)|transcranial direct current stimulation
219702169|NCT05650502|DRUG|saisonal malaria chimoprevention|Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
219702170|NCT01576614|BEHAVIORAL|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
219702171|NCT03252158|BEHAVIORAL|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
219702172|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
219702173|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
219702174|NCT05076734|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
219702175|NCT03514953|BEHAVIORAL|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
219702176|NCT01518062|DRUG|somatropin|4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
219702177|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
219702178|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
219702179|NCT01518062|DRUG|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
219702180|NCT00102323|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
219702181|NCT00102323|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
219116091|NCT02291224|BEHAVIORAL|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
219116092|NCT02291224|BEHAVIORAL|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
219702182|NCT06807346|DIETARY_SUPPLEMENT|Kids Plus Multi & Omega|Participants will be instructed to take two gummies of Kids Plus Multi and Omegas with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
219702183|NCT06807346|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to take two gummies of placebo with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
219702184|NCT01387269|DRUG|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
219702185|NCT01387269|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
219702186|NCT00006362|DRUG|bortezomib|
219702187|NCT01471626|DEVICE|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
219702188|NCT01066572|DRUG|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
219702189|NCT01066572|DRUG|Placebo|Matched placebo; identical tablets to Lisinopril.
219702190|NCT00851149|DEVICE|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
219702191|NCT04058509|COMBINATION_PRODUCT|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
219702192|NCT06018090|OTHER|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
219702193|NCT01222299|DRUG|bepotastine besilate nasal product - low dose|sterile nasal product
219702194|NCT01222299|DRUG|bepotastine besilate nasal product - medium dose|sterile nasal product
219702195|NCT01222299|DRUG|bepotastine besilate nasal product - high dose|sterile nasal product
219116093|NCT02291224|BEHAVIORAL|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
219116094|NCT04672109|DEVICE|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
219702196|NCT01222299|DRUG|placebo comparator nasal product|sterile nasal product
219702197|NCT03999255|PROCEDURE|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
219702198|NCT01981616|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
219702199|NCT01981616|DRUG|Placebo|Placebo intravenous infusion
219702200|NCT01981616|BIOLOGICAL|Hepatitis B vaccine|
219702201|NCT01981616|BIOLOGICAL|Oral cholera vaccine|
219702202|NCT03619278|OTHER|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
219702203|NCT03619278|OTHER|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
219702204|NCT04092413|DEVICE|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
219702205|NCT06269835|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
219702206|NCT06269835|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
219116095|NCT00912821|DRUG|6 L dialysate|6 L peritoneal dialysis solution
219702207|NCT06269835|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
219702208|NCT02160938|OTHER|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)"
219702209|NCT01924598|DEVICE|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
219702210|NCT00513214|DRUG|XOMA 052|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
219702211|NCT00513214|DRUG|Placebo|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
219702212|NCT01213238|DRUG|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
219702213|NCT01213238|DRUG|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
219702214|NCT01213238|DRUG|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
219702215|NCT01716273|OTHER|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
219702216|NCT01716273|OTHER|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
219702217|NCT06380283|DEVICE|Virtual reality headset|Use of a virtual reality headset during pediatric dental care
219702218|NCT01367041|PROCEDURE|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
219116096|NCT00912821|DRUG|8 L dialysate|8 L peritoneal dialysis solution
219702219|NCT01911741|DRUG|MDV3100|Oral
219702220|NCT01020123|DRUG|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
219702221|NCT01020123|DRUG|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
219702222|NCT01020123|DRUG|Glipizide|Glipizide administered to 1 group of patients
219702223|NCT01178788|DRUG|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
219702224|NCT01178788|DRUG|micronized Progesterone|daily administration of vaginal progesterone
219702225|NCT01178788|PROCEDURE|Control|
219702226|NCT00336908|DRUG|a combination of MCT, LCT , and Fish Oil|
219702227|NCT01576848|DIETARY_SUPPLEMENT|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
219702228|NCT01576848|DIETARY_SUPPLEMENT|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
219702229|NCT05287815|BEHAVIORAL|training/observation|In the study, elderly individuals who met the sampling criteria and accepted to participate in the study were 30 in the experimental group and 30 in the control group, using the stratified randomization method to control and balance the effects of age (65-75 years, 76 and over) and gender (female and male) variables. It will be planned to be an elderly individual. Computer-assisted randomization, which is one of the simple randomization methods, was assigned to the groups according to the determined.
219702230|NCT06257888|OTHER|patient navigation|two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
219116097|NCT01284777|GENETIC|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
219116098|NCT03249376|DRUG|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate)
219116099|NCT03249376|OTHER|Placebo|Placebo
219116100|NCT00002813|DRUG|cisplatin|
219116101|NCT00002813|DRUG|vinorelbine tartrate|
219225179|NCT02024217|RADIATION|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
219225180|NCT01431118|OTHER|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
219702231|NCT04646382|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
219702232|NCT04646382|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
219702233|NCT01376219|OTHER|asthma control test|results of asthma control testing collected
219702234|NCT01141608|OTHER|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
219702235|NCT01141608|OTHER|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
219702236|NCT00175227|DRUG|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
219702237|NCT00175227|DRUG|intravenous saline hydration|500 mls half-normal saline
219702238|NCT02087098|DRUG|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
219116102|NCT05530967|OTHER|TT|"This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating.~The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark Yes if they are willing to participate in the study or No if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol."
219116103|NCT05530967|OTHER|VE|A randomly selected sub-group of participants (n=30) will also receive an animated education video that provides targeted information and encouragement for self-managing your PAP problem(s). Patients in this sub-group will be asked to view a maximum of 2 different videos that are less than 2 minutes in duration. These videos are aligned with practice guideline recommendations for addressing PAP problems early in treatment. The videos will be sent digitally from Somnoware™.
219116104|NCT01958762|OTHER|Invitation for oral cavity cancer screening|
219116105|NCT01235273|DRUG|Growth Hormone|growth hormone administration
219116106|NCT01235273|OTHER|Placebo|standard placebo
219702239|NCT04434508|PROCEDURE|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
219702240|NCT04434508|PROCEDURE|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
219702241|NCT02638532|PROCEDURE|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
219116107|NCT04963764|DRUG|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
219116108|NCT04963764|DRUG|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
219702242|NCT06039202|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
219702243|NCT06039202|DRUG|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
219702244|NCT06039202|BIOLOGICAL|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
219702245|NCT06422533|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days
219116109|NCT03086915|DRUG|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
219116110|NCT01611103|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
219116111|NCT04676230|PROCEDURE|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
219116112|NCT04676230|PROCEDURE|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
219116113|NCT02339389|OTHER|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
219116114|NCT05952115|OTHER|lumbar motor control exercises|"the patients will receive lumbar motor control exercises in the form of three exercises (Abdominal draw in maneuver, side-bridge, and quadruped) and the level of difficulty increased each week. For all exercises, the number of repetitions stayed the same, but the difficulty increased each week, and we progressed to the advanced level of each of the three exercises.~This training achieves co-contraction of the local/deep stabilizing muscles (Transversus abdominis and multifidus) and strengthening the global/large spinal stabilizers (erector spinae and obliques)."
219225181|NCT01431118|OTHER|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
219702246|NCT06422533|DRUG|Piperacillin/tazobactam|Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
219702247|NCT04919707|BEHAVIORAL|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
219702248|NCT04919707|PROCEDURE|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
219116115|NCT05952115|OTHER|Cervical stabilization exercises|The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.
219702249|NCT03721354|OTHER|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
219702250|NCT02339337|OTHER|Abbreviation of treatment duration|
219702251|NCT02866643|DRUG|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
219702252|NCT02866643|DRUG|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
219702253|NCT05769972|DEVICE|Immersive Virtual Reality (Parkinson's disease)|This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.
219702254|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Parkinson's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
219702255|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Huntington's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
219116116|NCT01010893|BIOLOGICAL|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
219116117|NCT01010893|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
219116118|NCT06034574|DEVICE|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
219116119|NCT02265380|DEVICE|Placement of IV catheter|
219116120|NCT00187317|BEHAVIORAL|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
219116121|NCT00187317|OTHER|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
219116122|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
219116123|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
219225182|NCT03500523|DIAGNOSTIC_TEST|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
219225183|NCT02108704|DRUG|Helicobacter pylori eradication therapy|
219225184|NCT02108704|DRUG|Placebo|
219702256|NCT05769972|BEHAVIORAL|Music-therapy (Huntington's disease)|The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory
219116124|NCT06235164|DRUG|immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab|"Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time"
219116125|NCT05293535|OTHER|Prognostic study|No intervention... as it is a prognostic study and no intervention done on patients.
219116126|NCT00176865|PROCEDURE|Stem Cell Transplant|IV on Day 0
219702257|NCT01531426|DEVICE|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
219702258|NCT03523637|BEHAVIORAL|Interoceptive Exposure|The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
219702259|NCT03007875|BIOLOGICAL|high-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219116127|NCT00176865|DRUG|Fludarabine|30mg/m\^2 IV Day -7 through Day -3
219116128|NCT00176865|DRUG|Melphalan|140 mg/m\^2 IV Day -1
219116129|NCT00176865|DRUG|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
219116130|NCT00176865|DRUG|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
219116131|NCT00176865|DRUG|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
219116132|NCT00176865|DRUG|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
219116133|NCT00176865|DRUG|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
219116134|NCT05397938|DRUG|JMT103|JMT103, subcutaneous injection, once every 6 months (Q6M)
219116135|NCT05397938|DRUG|Alendronate sodium|Alendronate sodium tablet, once every week (QW)
219116136|NCT05397938|DRUG|JMT103 placebo|JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
219116137|NCT05397938|DRUG|Alendronate sodium placebo|Alendronate sodium tablet placebo, once every week (QW)
219116138|NCT05218564|DRUG|Oxygen Therapy|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
219116139|NCT05218564|OTHER|Compressed Medical Air|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
219116140|NCT02542514|DRUG|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
219116141|NCT06121115|DRUG|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
219116142|NCT05676398|DIAGNOSTIC_TEST|Ambulatory rhythm recording|Ambulatory rhythm recording by use of a wearable patch-type device.
219116143|NCT00534911|BEHAVIORAL|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
219225185|NCT02944123|DRUG|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
219702260|NCT04711005|DRUG|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
219702261|NCT04711005|DRUG|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
219702262|NCT05576896|DRUG|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
219116144|NCT00534911|BEHAVIORAL|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
219116145|NCT04153513|DRUG|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
219116146|NCT04153513|OTHER|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
219116147|NCT00654693|OTHER|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
219116148|NCT03490890|OTHER|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
219116149|NCT06343441|DEVICE|intraoral scan|intraoral scanning of the edentulous arch and scan body
219116150|NCT06343441|DEVICE|open tray impression|conventional method of impression making with silicone rubber material
219116151|NCT02426385|DEVICE|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
219702263|NCT03024567|DIETARY_SUPPLEMENT|Salt|10 capsules daily for 14 days
219702264|NCT03024567|DIETARY_SUPPLEMENT|Placebo|10 capsules daily for 14 days
219702265|NCT02753881|DRUG|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
219702266|NCT02753881|DRUG|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
219702267|NCT00506675|DEVICE|Patching|42 hours per week of patching
219702268|NCT00506675|DRUG|Atropine|daily atropine (1%)
219702269|NCT00506675|DEVICE|Patching|two hours of daily patching for 4 weeks, then no treatment
219702270|NCT00506675|DRUG|Atropine|once weekly atropine for 4 weeks, then no treatment
219702271|NCT05672875|DIAGNOSTIC_TEST|Anthrax LF Dx System|Lateral flow immunoassay for the detection of the LF biomarker in whole blood samples.
219116152|NCT03857581|DRUG|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
219116153|NCT03857581|DRUG|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
219116154|NCT00279422|DRUG|visilizumab|
219116155|NCT00279422|DRUG|visilizumab|
219702272|NCT02858908|DRUG|Tideglusib|Tideglusib for oral suspension,
219702273|NCT04236778|DRUG|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
219702274|NCT04236778|DRUG|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
219702275|NCT03524378|BEHAVIORAL|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
219702276|NCT06355349|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
219702277|NCT06395727|DRUG|Fentanyl|traditional fentanyl dose
219702278|NCT06395727|DRUG|Lidocain|lidocaine nebuliser and lidocaine spray targeting difficult swallowing
219702279|NCT01800370|DRUG|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
219702280|NCT01800370|DRUG|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
219702281|NCT01800370|OTHER|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
219702282|NCT01800370|PROCEDURE|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
219702283|NCT01800370|OTHER|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
219702284|NCT06500702|DRUG|frexalimab|frexalimab treatment
219702285|NCT06500702|DRUG|SAR442970|SAR442970 treatment
219702286|NCT06500702|DRUG|rilzabrutinib|rilzabrutinib treatment
219116156|NCT01190384|OTHER|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
219116157|NCT01190384|DIETARY_SUPPLEMENT|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
219116158|NCT01190384|OTHER|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
219116159|NCT02334943|BIOLOGICAL|Blood test|Blood test
219702287|NCT06500702|DRUG|placebo|placebo treatment
219116160|NCT06024499|DRUG|HY209GEL Active|Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
219116161|NCT06024499|OTHER|Placebo|Placebo
219116162|NCT01686932|DRUG|Vildagliptin|vildagliptin 50mg BID for 8 weeks
219116163|NCT01686932|DRUG|Sitagliptin|sitagliptin 100mg QD for 8 weeks
219116164|NCT01782040|OTHER|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
219116165|NCT06081530|DRUG|BI 3802876|BI 3802876
219116166|NCT06081530|DRUG|Placebo matching BI 3802876|Placebo matching BI 3802876
219116167|NCT03568721|DRUG|Ibuprofen|prescription of ibuprofen 400 mg
219116168|NCT03568721|DRUG|Acetaminophen|prescription of acetaminophen 500 mg
219116169|NCT03568721|OTHER|Chewing gum|prescription of one tablet of chewing gum
219116170|NCT02338518|DRUG|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
219116171|NCT02338518|DRUG|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
219116172|NCT02338518|DRUG|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
219116173|NCT02338518|DRUG|S-1|80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
219116174|NCT01423864|DRUG|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
219116175|NCT01423864|DRUG|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
219116176|NCT01965964|PROCEDURE|Questionnaire|
219116177|NCT00472537|PROCEDURE|Retromuscular Mesh repair of midline incisional hernia|
219702288|NCT03824561|DRUG|Vedolizumab|Vedolizumab IV infusion
219116178|NCT00472537|PROCEDURE|Laparoscopic repair of midline incisional hernia|
219116179|NCT03951935|OTHER|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
219116180|NCT03951935|DIAGNOSTIC_TEST|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
219116181|NCT00057603|PROCEDURE|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
219116182|NCT02563834|DRUG|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
219116183|NCT02563834|DRUG|Saline|Saline infusion for control
219116184|NCT02563834|DRUG|Insulin|Insulin infusion for insulin/glucose clamp procedure
219116185|NCT00319605|DRUG|Levetiracetam|
219116186|NCT01364727|DRUG|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
219116187|NCT05072522|DRUG|SKLB1028|SKLB1028 capsules, oral, once daily in continuous 28-day cycles
219116188|NCT00005973|DRUG|BMS-214662|Given IV
219116189|NCT00005973|OTHER|laboratory biomarker analysis|Correlative studies
219116190|NCT01219595|OTHER|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
219116191|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
219116192|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
219116193|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
219702289|NCT07133828|DRUG|BIIB142|Administered Orally
219702290|NCT07133828|DRUG|BIIB142-Matching Placebo|Administered Orally
219702291|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
219702292|NCT03393182|PROCEDURE|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
219116194|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
219116195|NCT01219595|OTHER|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
219116196|NCT04513457|OTHER|Liver resection and Neoadjuvant chemotherapy|
219116197|NCT04513457|OTHER|Liver resection and Adjuvant chemotherapy|
219116198|NCT04513457|OTHER|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
219116199|NCT04513457|PROCEDURE|Liver resection|
219225186|NCT02944123|DRUG|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
219225187|NCT02944123|DRUG|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
219116200|NCT02343588|BEHAVIORAL|The Health Lifestyles Interventions|"1. Creating supportive school and family environment, whole intervention periods;~2. Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~3. Instruct and promote school physical education, whole intervention periods;~4. The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
219116201|NCT01927718|DRUG|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
219702293|NCT03393182|PROCEDURE|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
219702294|NCT05724758|PROCEDURE|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~* Oncoplastic reconstruction with round-block technique~* Oncoplastic reconstruction using J-Plastic~* Oncoplastic reconstruction using V-Plastic~* Oncoplastic reconstruction using Grisotti~* Oncoplastic reconstruction using Batwing~* Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~* Oncoplastic perforator flap surgery"
219702295|NCT04953195|DRUG|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
219702296|NCT06984627|DRUG|Rilzabrutinib dose 1|Pharmaceutical form:Tablet-Route of administration:Oral
219702297|NCT06984627|DRUG|Rilzabrutinib dose 2|Pharmaceutical form:Tablet-Route of administration:Oral
219702298|NCT06819878|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
219702299|NCT06819878|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
219702300|NCT04259138|BIOLOGICAL|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
219702301|NCT04259138|BIOLOGICAL|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
219702302|NCT04259138|BIOLOGICAL|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
219702303|NCT01899911|DEVICE|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
219702304|NCT03573297|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily
219116202|NCT01927718|DRUG|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
219116203|NCT01927718|BEHAVIORAL|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
219116204|NCT01101139|DRUG|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
219116205|NCT01101139|DRUG|Placebo|Placebo: single intravenous injection Saline 0.9%
219116206|NCT02984956|DEVICE|pleth variability index|
219116207|NCT01009047|DRUG|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
219702305|NCT03573297|DRUG|Placebo|Matching placebo capsules, oral administration, once daily
219702306|NCT03501251|DRUG|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
219702307|NCT03501251|DRUG|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
219702308|NCT03501251|DRUG|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
219702309|NCT03501251|DRUG|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
219702310|NCT03501251|DRUG|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
219702311|NCT03501251|DRUG|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
219702312|NCT03501251|OTHER|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
219702313|NCT04223947|PROCEDURE|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
219116208|NCT01009047|DRUG|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
219116209|NCT06303336|OTHER|NMES with Dynamic Bracing|The group will receive NMES along with dynamic bracing
219116210|NCT06303336|OTHER|NMES without Dynamic Bracing|The participants will receive NMES on the lower extremity
219702314|NCT01508988|DRUG|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
219702315|NCT01508988|DRUG|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
219702316|NCT01508988|DRUG|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
219702317|NCT01508988|DRUG|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
219702318|NCT01508988|DRUG|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
219702319|NCT01508988|DRUG|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
219702320|NCT01508988|DRUG|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
219702321|NCT06983249|PROCEDURE|Rhomboid intercostal and Sub-serratus nerve block in nephrectomy|That block was performed when the patient was in the lateral position. A high frequency linear ultrasound transducer was placed longitudinally on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe was slightly rotated to obtain an oblique parasagittal plane. The following landmarks were identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). Under ultrasound guidance, a 22 mm gauge spinal needle was directed to the plane by using high frequency ultrasound guidence (Sono SiteTM, Inc., Bothell, WA 98021, USA) between the rhomboid major and the underlying intercostal muscles and 15 ml bupivacaine (0.25%) was delivered into that plane (after repeated negative aspiration of blood), and its spread was manifested by the hydrodissection and widening of the plane visualized by ultrasound
219702322|NCT06983249|PROCEDURE|Quadratus lumborum nerve block in nephrectomy|"Ultrasound guided posterior quadrates lumborum block was done in lateral decubitus position and linear probe according to the depth was placed in the midaxillary line in the transverse plane immediately above the iliac crest and then it was slided dorsally until the Shamrock sign was clearly identified. In Shamrock sign The quadratus lumborum (QL) muscle is seen as a superior leaf of the Shamrock at the apex of the transverse process (TP) of L4"
219116211|NCT06303336|OTHER|Dynamic Bracing Only|This group will receive dynamic bracing only on the lower limb.
219116212|NCT05758363|DIETARY_SUPPLEMENT|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
219116213|NCT05758363|OTHER|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
219116214|NCT04398784|DIETARY_SUPPLEMENT|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
219116215|NCT04398784|DIETARY_SUPPLEMENT|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
219116216|NCT03575637|DRUG|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
219702323|NCT02714933|OTHER|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
219702324|NCT06193889|DRUG|Standard of Care Treatment|Standard of Care Medications Optional Crossover to receive KYV-101 treatment
219116217|NCT04394741|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
219116218|NCT04394741|DEVICE|Control-Dry Needling|"Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times."
219702325|NCT06193889|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219702326|NCT06193889|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
219702327|NCT04715087|OTHER|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
219116219|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
219116220|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
219116221|NCT04100460|DIETARY_SUPPLEMENT|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
219116222|NCT04100460|DIETARY_SUPPLEMENT|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
219702328|NCT04715087|OTHER|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
219702329|NCT06986590|BEHAVIORAL|ADHINCRA Program|The ADHINCRA Program is a nurse-led intervention that includes the use of home blood pressure monitoring, a mobile health app, lifestyle counselling, and a simplified hypertension treatment protocol to achieve blood pressure control among people diagnosed with hypertension.
219702330|NCT03847402|BEHAVIORAL|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
219702331|NCT03847402|BEHAVIORAL|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
219702332|NCT03847402|BEHAVIORAL|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
219702333|NCT03847402|BEHAVIORAL|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
219702334|NCT03847402|BEHAVIORAL|Community intervention for GDD|community intervention based on developmental approaches
219702335|NCT03847402|BEHAVIORAL|community intervention for ADHD|School and family education
219116223|NCT04100460|DIETARY_SUPPLEMENT|Control - No Arabinoxylan|Participants are given no Arabinoxylan
219116224|NCT04288362|OTHER|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
219116225|NCT04288362|OTHER|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
219116226|NCT02223247|DRUG|TVB-2640|
219116227|NCT00158522|DRUG|pegylated interferon alpha2a|
219116228|NCT06275672|OTHER|Adapted version of the mhGAP-IG|An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
219116229|NCT05918315|PROCEDURE|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
219116230|NCT01555021|GENETIC|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
219116231|NCT02242240|DRUG|Formoterol twice daily|
219116232|NCT02242240|DRUG|Formoterol once daily|
219116233|NCT02242240|DRUG|Tiotropium once daily|
219116234|NCT02242240|DRUG|Placebo|
219116235|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.
219702336|NCT06861244|RADIATION|Radiotherapy (RT)|Undergo RT
219116236|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
219116237|NCT04136652|PROCEDURE|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
219116238|NCT01531192|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
219116239|NCT01531192|DRUG|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
219702337|NCT06861244|DRUG|Chemotherapy Drug, Cancer - Physician's Choice|One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
219702338|NCT06861244|PROCEDURE|Non-Investigational Surgical Resection|Undergo surgery directly before study enrollment as part of planned care.
219702339|NCT06861244|DRUG|Temozolomide|Participants assigned to or whom receive optional RT will receive concurrent temozolomide
219702340|NCT06861244|PROCEDURE|Tumor Tissue Sample|Tumor tissue will be collected for correlative studies
219702341|NCT06861244|PROCEDURE|Blood Sample|Blood samples will be collected for correlative studies
219702342|NCT06861244|PROCEDURE|Cerebrospinal Fluid (CSF) Sample|CSF samples will be collected for correlative studies
219702343|NCT01499810|PROCEDURE|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
219702344|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
219702345|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
219702346|NCT02256865|DRUG|Ketoconazole|Ketoconazole is taken 4 times a day
219702347|NCT02256865|DRUG|Hydrocortisone|Hydrocortisone is taken 3 times a day
219702348|NCT02256865|DRUG|Testosterone|Testosterone gel is applied once a day
219702349|NCT02256865|DRUG|Placebo for ketoconazole|Placebo for ketoconazole
219702350|NCT02256865|DRUG|Placebo for hydrocortisone|Placebo for hydrocortisone
219702351|NCT02256865|DRUG|Placebo for testosterone|Placebo for testosterone
219702352|NCT06443827|DRUG|Amantadine Sulfate|intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
219702353|NCT06673628|DRUG|Pembrolizumab plus Lenvatinib|"One course is fixed at 21 days, and the length of course is not extended or shortened.~Participants receive 200 mg of pembrolizumab injection intravenously over approximately 30 minutes on day 1 of each course, and take 20 mg of lenvatinib capsules orally once daily, preferably at the same time each day.~Treatment with pembrolizumab and lenvatinib will be continued for up to 35 courses unless the criteria for termination of protocol treatment are met."
219702354|NCT02144558|OTHER|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
219702355|NCT06868186|DEVICE|RUS NE|The RUS NE is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the intra-abdominal surgical environments, allowing for the visualization of tumor, vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS NE utilizes preoperative CT images of the patients to segment tumor, organs, and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS NE as a surgical navigation tool to simulate the surgery before performing the actual procedure.
219702356|NCT06870838|DIAGNOSTIC_TEST|7T MRI scan|MRI-scanning of the brain using a 7T MRI scanner
219702357|NCT06870838|DIAGNOSTIC_TEST|CSF|CSF collection via lumbar puncture
219702358|NCT06870838|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
219116240|NCT06339151|DRUG|Dexamethasone before surgery|Dexamethasone 0.15 mg/kg IV before surgery
219702359|NCT06870838|DIAGNOSTIC_TEST|Neuropsychological assessment|Tests for memory, language, attention, executive functions, praxis, social cognition, visuoconstructive skills
219702360|NCT06870838|DIAGNOSTIC_TEST|Clinical measures|Medical history, neurological assessment, neuropsychiatric inventory
219702361|NCT00275652|DRUG|LdT (Telbivudine) and lamivudine|
219702362|NCT04467021|OTHER|Best Practice|Receive usual blood pressure management
219702363|NCT04467021|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
219702364|NCT04467021|OTHER|Clinical Management|Undergo intensive systolic BP management
219702365|NCT04467021|OTHER|Quality-of-Life Assessment|Ancillary studies
219702366|NCT04467021|OTHER|Questionnaire Administration|Ancillary studies
219116241|NCT06339151|DRUG|Dexamethasone before and 12 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 12 hours post operation
219702367|NCT01647178|PROCEDURE|TORQ assisted sternal closure|
219702368|NCT01647178|PROCEDURE|Conventional closure|
219702369|NCT06094816|DRUG|Furosemide (Diuretic)|The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
219702370|NCT06094816|OTHER|Hypertonic Saline Infusion|3% Hypertonic saline infusion to acutely increase sodium and osmolality
219702371|NCT03308669|DRUG|Lasmiditan|Administered orally
219702372|NCT03308669|DRUG|Placebo|Administered orally
219702373|NCT03308669|DRUG|Topiramate|Administered orally
219702374|NCT03251365|DRUG|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
219702375|NCT07030088|DEVICE|Dual-Headed Manual Toothbrush|A novel toothbrush with a dual-headed design intended to clean both upper and lower buccal/ or upper and lower lingual/ palatal surfaces simultaneously. Participants were instructed to use this toothbrush on one side of the mouth only, twice daily using the Bass brushing technique. This intervention is evaluated for plaque removal efficacy, gingival health, brushing time, and patient comfort
219702376|NCT07030088|DEVICE|Conventional Single-Headed Manual Toothbrush|A standard single-headed manual toothbrush used as the active control. Participants used this toothbrush on the other side of the mouth, with the same brushing technique (Bass method), frequency (twice daily). It serves as the comparator for assessing the performance of the dual-headed design.
219702377|NCT06324617|PROCEDURE|Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap|"Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap The previous incision is reopened and extended, Neurolysis begins proximally preserving the palmar cutaneous branch. The subcutaneous tissue is exposed, leaving part of the superficial venous plexus with the adipofascial flap. Flap elevation is begun by incising the subcutaneous tissue through the deep fascia along the radial border of FCU and ECU .~When the flap reaches a suitable length (10-12 cm from the wrist), it is cut proximally and along the ulnar side. The flap is dissected proximally to distally in continuity with the underlying fascia . When the dissected flap is (2-5) cm proximal to the wrist. Ulnar retraction of the flexor carpi ulnaris permits identification of the perforator. the pivot point of the flap is localized (2-5) cm proximal to the pisiform.~The adipofascial flap is turned 180 degrees and anchored with a few absorbable stitches around the median nerve."
219702378|NCT03668210|PROCEDURE|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
219702379|NCT00173628|PROCEDURE|blood drawing|
219702380|NCT03456245|DEVICE|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
219116242|NCT06339151|DRUG|Dexamethasone before and 24 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 24 hours post operation
219116243|NCT00259493|PROCEDURE|Off-Pump Coronary Artery Bypass Graft Surgery|
219116244|NCT00445263|DRUG|TIROFIBAN|intravenous infusion
219116245|NCT00445263|PROCEDURE|CORONAROGRAPHY|standard procedure of coronarography
219116246|NCT01191684|OTHER|laboratory biomarker analysis|Correlative studies
219116247|NCT01191684|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219116248|NCT01191684|OTHER|flow cytometry|Correlative studies
219116249|NCT01191684|OTHER|immunoenzyme technique|Correlative studies
219116250|NCT01191684|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
219116251|NCT00000719|DRUG|Zidovudine|
219116252|NCT00000719|DRUG|Zalcitabine|
219116253|NCT04093141|PROCEDURE|IRE|in situ irreversible electroporation
219702381|NCT02649010|DEVICE|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
219116254|NCT01448525|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
219116255|NCT01448525|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
219116256|NCT03875911|DRUG|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
219116257|NCT02869113|DRUG|BAY98751 (Y65-110)|10 µL in one eye
219116258|NCT02869113|DRUG|BAY 98751 (Y65-102)|10 µL in one eye
219116259|NCT02869113|DRUG|BAY 98751 (Y65-106)|10 µL in one eye
219225188|NCT01595269|OTHER|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
219702382|NCT05328960|OTHER|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
219702383|NCT02367300|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
219702384|NCT03798314|BIOLOGICAL|Nivolumab|Given IV
219702385|NCT03798314|DRUG|Pomalidomide|Given PO
219702386|NCT02511301|DEVICE|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
219116260|NCT02869113|DRUG|Standard shampoo mixture (Control)|10 µL in other eye
219116261|NCT02117674|PROCEDURE|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
219116262|NCT02117674|PROCEDURE|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
219116263|NCT02117674|PROCEDURE|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
219116264|NCT03519698|OTHER|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
219116265|NCT03519698|OTHER|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
219116266|NCT03519698|OTHER|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
219116267|NCT03508804|DRUG|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
219116268|NCT03508804|DRUG|Placebo Cream|10ml of vaginally self-administered placebo cream
219116269|NCT03508804|DRUG|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
219116270|NCT00119119|DRUG|pentoxyphilline|
219116271|NCT00119119|DRUG|tocopherol|
219116272|NCT02343575|DRUG|Valproic Acid|"1\.~Start:~VPA PO/NGT 500 mg BID~2\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
219116273|NCT02343575|DRUG|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
219116274|NCT02343575|DRUG|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
219116275|NCT02374190|OTHER|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
219225189|NCT03627637|DIETARY_SUPPLEMENT|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
219225190|NCT06134193|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
219225191|NCT06134193|DRUG|Surufatinib|250mg PO d1, Q3W
219225192|NCT06134193|DRUG|Tislelizumab|200mg IV d1, Q3W
219225193|NCT03418545|DEVICE|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
219225194|NCT03074032|DRUG|ONC1-0013B|ONC1-0013B per os daily
219116276|NCT05595330|BEHAVIORAL|Lymphedema prevention protocols|"Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room."
219116277|NCT05480033|BEHAVIORAL|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
219225195|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
219225196|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day placebo capsule|Once per day, 12 weeks
219702387|NCT02273167|DRUG|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
219702388|NCT02273167|DRUG|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
219702389|NCT02273167|DRUG|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
219702390|NCT04670120|DRUG|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
219702391|NCT06448962|DRUG|AD-2021|PO, Once daily(QD), 8weeks
219702392|NCT06448962|DRUG|AD-2022|PO, Once daily(QD), 8weeks
219702393|NCT06448962|DRUG|AD-2021 Placebo|PO, Once daily(QD), 8weeks
219116278|NCT03824938|DRUG|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
219116279|NCT03824938|DRUG|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
219702394|NCT06448962|DRUG|AD-2022 Placebo|PO, Once daily(QD), 8weeks
219116280|NCT03824938|OTHER|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
219225197|NCT05268991|OTHER|Geriatric Assessments and Frailty Indices|Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
219702395|NCT04079504|PROCEDURE|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
219702396|NCT04079504|PROCEDURE|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
219702397|NCT00576511|DRUG|prucalopride|4 mg o.d.
219702398|NCT00576511|DRUG|placebo|Placebo o.d.
219702399|NCT03311867|OTHER|Ethibond Suture|Cerclage placement with ethibond
219702400|NCT03311867|OTHER|Prolene Suture|Cerclage placement with prolene
219702401|NCT02781324|PROCEDURE|Posterior Spinal Fusion|
219702402|NCT02781324|DEVICE|Ultrasonic Bone Scalpel|
219702403|NCT04724746|BEHAVIORAL|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
219702404|NCT03415152|DRUG|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
219702405|NCT01537172|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
219702406|NCT01537172|DRUG|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
219116281|NCT05126459|COMBINATION_PRODUCT|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
219116282|NCT05126459|COMBINATION_PRODUCT|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
219116283|NCT05126459|COMBINATION_PRODUCT|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
219116284|NCT00747058|DRUG|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
219116285|NCT00747058|DRUG|Placebo|Placebo
219116286|NCT01304043|DRUG|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
219116287|NCT04874064|OTHER|Liquid Biopsy|Blood collection and access to residual tumor.
219116288|NCT01990300|DRUG|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
219702407|NCT00666237|PROCEDURE|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
219702408|NCT00666237|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
219702409|NCT00666237|DRUG|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
219702410|NCT02615886|OTHER|Observational Control|Participants will be observed and not provided any dietary supplementation.
219116289|NCT00720005|DEVICE|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
219116290|NCT00953420|DRUG|Docetaxel|60 mg/m2 IV on Day 1
219702411|NCT02615886|DIETARY_SUPPLEMENT|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
219702412|NCT07086820|DRUG|Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided to all participants.
219702413|NCT07086820|DRUG|Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided only to participants with a positive IGRA result at baseline.
219702414|NCT06907667|OTHER|Vaccine injection|Injection of the vaccine in chronic renal insufficiency patients.
219702415|NCT06906809|DRUG|BGB-16673|Administered orally
219702416|NCT06906809|DRUG|Itraconazole|Administered orally
219702417|NCT06906809|DRUG|Phenytoin|Administered orally
219702418|NCT06908083|OTHER|Analytical Treatment Interruption|Participants will stop their ART (Antiretroviral therapy) on Week 0 and will remain off of their ART for up to 48 weeks or until they meet restart criteria.
219702419|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
219702420|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
219702421|NCT07091032|OTHER|Treatment as Usual|This is the comparison condition, in which participants will receive treatment as usual for their conditions at the clinic.
219116291|NCT00953420|DRUG|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
219116292|NCT00953420|DRUG|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
219116293|NCT00953420|BIOLOGICAL|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
219116294|NCT00953420|BIOLOGICAL|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for \> 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC \> 2500 cells/ul x 2 days after nadir.
219116295|NCT04976569|DEVICE|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
219116296|NCT00255229|DRUG|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
219116297|NCT00255229|OTHER|Placebo|Glutamine placebo
219116298|NCT03296618|DRUG|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
219116299|NCT02571439|PROCEDURE|Surgical TAP block|surgeon administered TAP block
219116300|NCT02571439|PROCEDURE|Conventional TAP block|Anesthesiologist administered TAP block
219116301|NCT02571439|DRUG|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
219116302|NCT03160482|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
219116303|NCT04607473|DEVICE|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
219116304|NCT04537338|GENETIC|1. Characterize the immune response after infection with SARS-CoV-2|1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
219116305|NCT05407532|PROCEDURE|Group with oral management|The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
219116306|NCT05407532|PROCEDURE|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
219116307|NCT00652925|DRUG|Celecoxib|Higher dose, 6 mg/kg/dose BID
219116308|NCT00652925|DRUG|Celecoxib|Active drug at lower dose
219702422|NCT07091032|BEHAVIORAL|Building Connections Intervention|The combined Building Connections intervention incorporates three areas. Participants take part in those for which they are eligible. The obesity/weight management intervention offers coaching and support for education on evidence-based anti-obesity medications (AOM) and a lifestyle behavioral intervention offered by Community Health Workers focused on diet and physical activity. The cancer screening intervention focuses on developing workflows and systems to offer a CHW-delivered population-based intervention to improve colorectal and cervical cancer, focusing on newer screening modalities and monitoring adherence for individuals with a positive screening test result. The mental health intervention uses the evidence-based Strong Minds intervention, a 10-session psychoeducational program provided by trained community health workers with clinical supervision. The skills-based intervention uses an integrative approach aimed at improving depression, anxiety, and trauma-related symptoms.
219702423|NCT07136441|DIAGNOSTIC_TEST|Lower Limb Neurodynamic Test (LLNT) with Shear Wave Elastography|"Participants underwent sciatic nerve stiffness assessment using shear wave elastography during two distinct sequences of the lower limb neurodynamic test. Each participant received:~Proximal-to-distal sequence: Starting with hip flexion, followed by knee extension, then ankle dorsiflexion with toe extension.~Distal-to-proximal sequence: Starting with ankle dorsiflexion and toe extension, followed by knee extension, then hip flexion."
219116309|NCT00652925|DRUG|Naproxen|Control comparator, 15 mg/kg/dy target dose
219116310|NCT00555789|DRUG|AEB071|200mg oral b.i.d.
219116311|NCT00555789|DRUG|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
219116312|NCT00322374|DRUG|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
219116313|NCT00322374|DRUG|Epirubicin|Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
219116314|NCT03085121|PROCEDURE|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
219116315|NCT01710774|PROCEDURE|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
219116316|NCT06531148|OTHER|Chemo-mechanical caries removal|Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.
219116317|NCT00925340|BEHAVIORAL|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
219116318|NCT00925340|BEHAVIORAL|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
219116319|NCT02712840|PROCEDURE|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
219116320|NCT02712840|PROCEDURE|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
219116321|NCT06381037|BEHAVIORAL|"How to improve your strengths and quality of life."|"The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop."
219116322|NCT03386760|DEVICE|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
219116323|NCT03386760|DEVICE|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
219116324|NCT03869060|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
219116325|NCT04311242|OTHER|Diet|Ketogenic diet
219116326|NCT04598737|PROCEDURE|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
219116327|NCT04598737|PROCEDURE|Lithium disilicate|Lithium disilicate laminate veneer treatment
219116328|NCT03559439|BIOLOGICAL|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
219116329|NCT02298205|OTHER|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
219116330|NCT02298205|OTHER|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
219225198|NCT03333824|DRUG|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
219225199|NCT03333824|DRUG|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
219702424|NCT07098169|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities. i
219702425|NCT07098169|BEHAVIORAL|Active Control|Behavioral: Mobile cognitive tests will be administered to control subjects. Participants will receive feedback regarding their performance but not on the accuracy of their self-ratings. Coaching will also be coupled with mobile cognitive tests and will include goal-setting without specific mention of Introspective Accuracy (IA). in place of content related to IA, participants will receive psychoeducation about the benefits of sleep, physical activity, and social connection to overall cognitive health
219702426|NCT06891820|OTHER|Physical effort|The examined athletes will be subjected to an effort on a rowing ergometer, covering a designated distance in the shortest possible time.
219702427|NCT07095075|BIOLOGICAL|LUCAR-DKS1 NK cells|Prior to the infusion of the LUCAR-DKS1 cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219702428|NCT06842485|OTHER|Telerehabilitation|The experimental group will be given a tailored program of telerehabilitation consisting of stretching and strengthening exercises for six weeks (three times per week)
219702429|NCT06842485|OTHER|Patient education|Patient education will be given to both the experimental and control groups. Patient education and telerehabilitation will be given to the experimental group. To the control group, patient education alone will be provided
219116331|NCT03001401|OTHER|iDesign|One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
219116332|NCT03001401|OTHER|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
219116333|NCT02503462|DRUG|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
219116334|NCT02503462|DRUG|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
219116335|NCT02503462|DRUG|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
219116336|NCT05956977|DEVICE|resection with help of 3D ultrasound|see above
219116337|NCT03615625|BEHAVIORAL|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
219116338|NCT00463541|DRUG|solifenacin succinate|oral
219116339|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
219116340|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
219116341|NCT01162941|OTHER|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
219116342|NCT05349318|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
219116343|NCT05349318|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
219116344|NCT02329990|DIETARY_SUPPLEMENT|phosphorus|phosphorus supplement
219116345|NCT02514980|DRUG|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
219702430|NCT07103889|BEHAVIORAL|Spartacus Test|The Spartacus test was conducted on a 750 m (75 × 10 m) rectangular course marked with cones at regular intervals to indicate different speeds (from 7 to 18 km/h). Each participant began running at 7 km/h, with speed increasing by 1 km/h every three minutes.During the 3-minute intervals (for each speed stage), participants had 15 seconds to reach the corresponding marker, followed by 15 seconds of rest. Participants had to adjust their running pace to reach the target cone in synchrony with an audio signal. The test ended when a participant failed to reach the next cone within the given time. This test is validated for assessing maximal aerobic capacity (MAS) in obese adolescents. During the Spartacus test, maximal heart rate (HRmax) was recorded using a heart rate monitor (S810; Polar, Kempele, Finland).
219702431|NCT04207671|PROCEDURE|Complete omission of chest tube|No chest tube implacement
219702432|NCT04207671|PROCEDURE|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
219702433|NCT05441306|DEVICE|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
219702434|NCT05441306|DEVICE|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
219702435|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
219702436|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
219702437|NCT06662409|OTHER|Nature-based healing meditation (NBHM) intervention|6 nature-based healing meditation (NBHM) auditory modules available via the study website to facilitate bereavement (grief) recovery and assessed on parameters of directed attention, grief, and QOL (including parameters of depression/anxiety)
219702440|NCT07112443|BIOLOGICAL|NVD003|Bone correction and grafting surgery
219702441|NCT07112443|PROCEDURE|Iliac Crest Bone Graft|"Either a single-stage Grafting Surgery with internal fixation and cross-union or the 2-stage induced membrane Grafting Surgery approach, depending on the surgeon's own standard of care."
219702442|NCT07118046|DEVICE|Pulmonary vein isolation|Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation
219702443|NCT07117058|DIAGNOSTIC_TEST|New rapid screening tool for anxiety and depressive disorders|New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
219116346|NCT02514980|DRUG|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
219116347|NCT03548636|BEHAVIORAL|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of \>50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
219116348|NCT03335891|PROCEDURE|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
219116349|NCT03335891|PROCEDURE|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
219116350|NCT01058863|DRUG|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
219116351|NCT01058863|DRUG|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
219116352|NCT01058863|OTHER|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
219116353|NCT04668664|DEVICE|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
219116354|NCT06460415|DEVICE|photobiomidulação|The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.
219116355|NCT06460415|OTHER|Placebo|The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
219116356|NCT03753607|OTHER|No intervention|No intervention
219116357|NCT05043311|BIOLOGICAL|SCTV01C|intramuscular injection
219116358|NCT05043311|OTHER|Placebo|intramuscular injetion
219702444|NCT07117058|DIAGNOSTIC_TEST|SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
219702445|NCT07117058|DIAGNOSTIC_TEST|HADS (Hospital Anxiety and Depression Scale)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.
219702446|NCT07130786|DRUG|Levetiracetam (Keppra)|Patients will be randomized to receive levetiracetam/ASM or to receive no ASM therapy
219702447|NCT07129486|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is the standard treatment for moderate to severe OSA in clinical practice.
219702448|NCT06934785|PROCEDURE|IUI or intercourse|5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) and 50 milligrams CC (Duinum 50 milligrams, Medochemie, Cyprus) or 5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) will be started on the second to the fourth day of the cycle, for five consecutive days. An ultrasound will be carried out three days after the last dose of medicine (day 8 of OI) to evaluate ovarian follicles' growth and the endometrium's thickness. If the follicular diameter reach ≥14 millimetres, check-up will be planned every two days until it reaches 18 millimetres. If there is the appearance of at least one follicle reaching 18 millimetres or more, a human chorionic gonadotropin (hCG) injection (IVF-C 5000 IU, LG Life Science, Korea) will be administered on the same day of the ultrasound in order to induce ovulation. IUI will be scheduled 36 - 38 hours after hCG injection or intercourse will be scheduled in the next day.
219702449|NCT07140770|DEVICE|Fitbit|"You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate.~Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet."
219702450|NCT07140770|OTHER|Questionnaire|Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.
219702451|NCT05162742|DRUG|Colchicine|ATC: M04AC01
219702452|NCT05162742|DRUG|Placebo|Placebo tablets
219702453|NCT06941194|DEVICE|PICO 14|PICO 14 application after neoadjuvant radiotherapy followed by surgery
219702454|NCT06949774|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
219702455|NCT06949774|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to (draw a prize in monthly prize group) or get a monthly prize (monthly escalated group) if they take their medication within +/-one hour of the stated existing routine to which pill-taking is anchored on at least 80% of days for 3-months.
219702456|NCT07146698|BEHAVIORAL|daily Interruption of Sedation|The patients will be managed by DIS. Richmond agitation and sedation score (RASS) will be used for monitoring the depth of sedation
219702457|NCT06952699|DRUG|TAK-360|TAK-360 tablet.
219702458|NCT06952699|OTHER|Placebo|TAK-360 matching placebo tablet.
219116359|NCT00681187|DRUG|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
219116360|NCT02254850|PROCEDURE|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
219116361|NCT02254850|DRUG|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
219116362|NCT02254850|DRUG|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
219116363|NCT02254850|DRUG|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
219116364|NCT02254850|DRUG|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
219116365|NCT03653416|DEVICE|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
219116366|NCT03653416|DRUG|Bupivacaine|20 cc of bupivacaine(o.25%) injection
219116367|NCT03653416|PROCEDURE|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
219116368|NCT02712112|DRUG|Imatinib Mesylate|
219116369|NCT03508102|DRUG|remifentanil|the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
219116370|NCT03557489|DEVICE|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
219116371|NCT00086086|DRUG|Darbepoetin Alfa|
219116372|NCT06309095|DEVICE|use of VDW Silver Endodontic motor|All patients will be subjected to local anesthesia with articaine hydrochloride (Maxicaine, Istanbul) containing 1:100,000 adrenaline. After the entrance cavities of the teeth are opened, a rubber dam will be applied to the relevant teeth for isolation from the oral environment. After the entrance cavity is opened, the working length of the canals will be determined with the help of a No. 10 K-file (Dentsply Maillefer, Ballaigues, Switzerland) canal file and an electronic apex finder (Woodpex III, Woodpecker Medical Instrument Co, Guilin, China). In both groups, it was planned to use the NiTi rotary instrument system using V Taper Gold (Fanta Dental Material, Shanghai, China) files with the help of VDW.Silver endomotor (VDW, München, Germany). The endodontic motor will be used to adjust different speed and torque values during root canal treatment. Post-operative pain caused by different speed and torque values will be compared.
219116373|NCT02210962|DIETARY_SUPPLEMENT|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
219116374|NCT02210962|DIETARY_SUPPLEMENT|olive oil|Yellow capsules containing olive oil (placebo)
219116375|NCT04388930|OTHER|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
219116376|NCT04388930|OTHER|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
219116377|NCT04388930|OTHER|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
219116378|NCT04388930|OTHER|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
219116379|NCT04388930|OTHER|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
219116380|NCT04388930|OTHER|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
219116381|NCT03867708|RADIATION|ASD device closure|transcatheter secundum ASD device closure
219116382|NCT06410378|PROCEDURE|Erector Spinae Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach
219116383|NCT06410378|PROCEDURE|Serratus Anterior Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
219116384|NCT06410378|PROCEDURE|controll group|patient will receive general anesthesia
219116385|NCT04893070|OTHER|Questionnaires COVID+|"* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms"
219225200|NCT03333824|DRUG|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
219225201|NCT03333824|DRUG|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
219225202|NCT03333824|DRUG|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
219225203|NCT04781868|DRUG|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
219225204|NCT04781868|DRUG|Placebo|Placebo
219225205|NCT01249638|DRUG|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
219225206|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
219116386|NCT04893070|OTHER|Questionnaires COVID-|"* 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment"
219116387|NCT04230980|DRUG|Gabapentin|Gabapentin 600mg tablet
219116388|NCT04230980|DRUG|Placebo|Placebo tablet
219116389|NCT02839135|DRUG|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
219116390|NCT02839135|DRUG|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
219116391|NCT03647839|DRUG|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
219116392|NCT03647839|DRUG|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
219225207|NCT01249638|DRUG|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
219225208|NCT01249638|DRUG|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
219116393|NCT03647839|DRUG|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
219116394|NCT02157415|DEVICE|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
219116395|NCT00166634|PROCEDURE|Ambulatory Blood Pressure Monitoring (ABPM)|
219116396|NCT05345912|DRUG|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
219702459|NCT07157163|BEHAVIORAL|Phase 1: standardized nudge messages|Participants receive uniform messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake.
219702460|NCT07157163|BEHAVIORAL|Phase 1: personalized nudge messages + chatbot|Participants receive tailored messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. Additionally, they have access to an interactive chatbot to address questions and provide decision-making support for influenza vaccination.
219702461|NCT07157163|BEHAVIORAL|Phase 2: motivational Interviewing|Unvaccinated participants engage in one-on-one motivational interviewing sessions with a trained interviewer.
219702462|NCT07158216|DEVICE|TMS|Active TMS + sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
219116397|NCT05345912|DRUG|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
219116398|NCT05345912|OTHER|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
219702463|NCT07158216|DEVICE|tDCS|sham TMS + active tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
219702464|NCT07158216|DEVICE|Sham TMS|Sham TMS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
219702465|NCT07158216|DEVICE|Sham tDCS|Sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
219702466|NCT07149727|OTHER|Standard Care|Environmental temperature control, preoperative psychological counseling, and parent-guided distraction.
219702467|NCT07149727|BEHAVIORAL|Immersive Game Experience (IGE)|Standard care plus immersive game experience, including role-playing scenarios (e.g., using dolls to simulate IV puncture), parent-child interactive games, environmental adjustments (children's music, colorful objects), and post-intervention rewards (cartoon stickers).
219116399|NCT05345912|OTHER|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
219702468|NCT07155096|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): Participants will each receive Default Mode Network-targeted continuous theta burst stimulation (cTBS) administered at 100% Active Motor Threshold
219702469|NCT07158801|BEHAVIORAL|Project EMPOWER-OCD|"Project EMPOWER-OCD is a web-based intervention for caregivers that takes about 20-25 minutes to complete that reduces accommodation. The program is drawing from an empirically supported intervention, Project EMPOWER, and will be adapted for the OCD population pending stakeholder input during phase 1 and include 5 elements: (1) an introduction to the program's rationale; (2) psychoeducation around OCD-driven avoidance, along with how caregiver accommodation can inadvertently maintain these avoidance patterns; (3) information on how caregivers can better identify patterns of avoidance, validate, and encourage approach behaviors instead; (4) creation of an action plan to promote approach behavior and reducing avoidance; (5) a vignette exercise in which caregivers read about another case and provide possible solutions based on what they learned. Resources for finding mental health treatment for OCD are presented at the end."
219702470|NCT07158801|BEHAVIORAL|Project CARE|To evaluate the effects of Project EMPOWER-OCD, we will compare it to an active psychoeducation-based SSI that provides general information on caregiving and caregiver mental health. The intervention includes 5 elements that mirror Project EMPOWER: (1) introduction to the rationale for the program; (2) introduce the concept of caregiving across relationships and situations; (3) present broad information on typical development processes; (4) helping caregivers identify their own role and reflect on how caregiving looks like in their life (5) vignette exercise where caregivers identify caregiving roles, prompting reflection on roles. This active comparator intentionally does not include any psychoeducational components explicitly designed to reduce accommodation of anxiety, OCD, and its related disorders.
219702471|NCT07167056|BEHAVIORAL|Standard of Care Psychotherapy|Participants will receive six psychotherapy sessions over the course of approximately 3 months.
219116400|NCT00416923|BIOLOGICAL|rituximab|
219116401|NCT04019119|BEHAVIORAL|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
219225209|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
219225210|NCT04273672|DIAGNOSTIC_TEST|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
219116402|NCT00549822|DRUG|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
219702472|NCT07167056|BEHAVIORAL|WYSA App|Participants will have access to the WYSA mental health support artificial intelligence app over the course of the 3 months that they are participating in psychotherapy sessions per standard of care. The app will contain features intended to manage symptoms of depression and anxiety in individuals with cancer. The app will include an AI-powered chatbot with Cognitive Behavioral Therapy (CBT) and mindfulness techniques, visual progress elements (a progress roadmap, a weekly progress report, etc.), and a customizable tool library. Participants are instructed to use the app whenever they feel like it, if they are in distress, or if the app prompts them to use it. App prompts (notifications) will occur once daily.
219702473|NCT07167355|PROCEDURE|POEM|Children randomised to POEM arm will undergo a single session of POEM following an overnight fast. The procedure will be done in supine position under general anaesthesia. A gastroscope (Olympus GIF-HQ190) with a transparent tapered cap fit at its distal end will be used. A mucosal bleb will be created using a 21G sclerotherapy needle and a solution of saline with indigo-carmine dye. A posterior approach will be followed in all patients. A small mucosal incision (2-3mm) will be made using a needle knife and enlarged using an insulated tip knife (2-3cm). The submucosal tunned will then be entered and the submucosal fibres will be cleared using a triangular tip knife (TriangularTipKnife J, Olympus). Full thickness will be performed in all patients. Length of the myotomy will be \~3cm in the oesophagus and \~2cm in the cardia of the stomach. Minor bleeding will be controlled using coagulation forceps. Mucosal injury and resistance at the gastroesophageal junction will be examined. Mucosal i
219702474|NCT07167355|PROCEDURE|BALLOON DILATATION|"Children randomised to BD arm will undergo BD of 30mm (Rigiflex II, Achalasia balloon dilators, Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 30mm with a pressure of 5psi initially and gradually the pressure will be increased to a maximum of 15 psi till the disappearance of waist fluoroscopically. A note will be made at the pressure at which the waist disappears and will be maintained for 1 minute. One month after the initial session, if the Eckardt score \>3 or if the TBE shows a barium column of \>5cm at 5 minutes, a second session of BD will be done using a 35mm balloon.~These children will be kept nil per oral for 4 hours post procedure. They will be observed for signs of perforation (crepitus, hemodynamic instability, chest pain). If they are stable, a clear liquid (water) will be provided. If there is no pain, they will be discharged with an advise to follow soft diet for a day"
219702475|NCT07167004|BEHAVIORAL|Marketing Nudges Only|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives
219702476|NCT07167004|BEHAVIORAL|Marketing Nudges + Dynamically Adapted Financial Incentives|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives, plus personalized financial incentives with individual incentive amounts optimized weekly based on prior whole grain purchasing behavior and engagement
219702477|NCT07168200|DRUG|SHR-1316 Injection|SHR-1316 injection.
219702478|NCT07168200|DRUG|Cisplatin Injection|Cisplatin injection.
219702479|NCT07168200|DRUG|Carboplatin Injection|Carboplatin injection.
219702480|NCT07168200|DRUG|Paclitaxel Injection|Paclitaxel injection.
219702481|NCT07168200|DRUG|SHR-1316 Placebo Injection|SHR-1316 placebo injection.
219702482|NCT07168148|DRUG|Oxymetazoline + Triamcinolone|"Participants will be stratified according to this usage and placed into a titration schedule.~* Titration 1: 0.05% 5x/day,~* Titration 2: 0.05% 4x/day,~* Titration 3: 0.05 3x/day,~* Titration 4: 0.05% 2x/day.~Participants with twice daily use, will then be placed in a titration schedule for oxymetazoline concentration which will stop when the oxymetazoline concentration is set to zero.~* Titration 5: 0.0375% Afrin/Nasacort 2x/day,~* Titration 6: 0.025% Afrin/Nasacort 2x/day,~* Titration 7: 0.0125% Afrin/Nasacort 2x/day,~* Titration 8: 0.0% Afrin/Nasacort 2x/day."
219702483|NCT07168239|BEHAVIORAL|ENHANCING VASCULAR ACCESS SELF-CARE IN HEMODIALYSIS PATIENTS|A set of health education sessions were developed for patients who did not exhibit fully adequate behaviour in the first assessment of the Scale of Assessment of Self-Care with AVF in HD. The sessions were conducted individually through an expository method and providing an informative leaflet. The sessions focused on the areas presented by the scale, i.e. prevention of thrombosis and infection, signs and symptoms of intra/interdialytic complications, haemostasis care, protection of the AV limb and correct assessment of signs and symptoms suggestive of complications with the AVF, evaluation of AVF functionality and detection of thrombosis, changes in colour and sensitivity of the hand corresponding to the AV, pain in the AV limb
219702484|NCT07169175|DRUG|SNUG01|AAV (adeno-associated virus) Gene therapy
219702485|NCT07167342|DRUG|Clostridium butyricum capsules, Live|Oral Clostridium butyricum capsules, Live: take 3 capsules twice daily (bid) for the first 3 months after adenoma resection, then continue with 3 capsules once daily (qd) until 3 years post-resection (each capsule contains ≥6.3 × 10⁶ CFU of Clostridium butyricum).
219702486|NCT07167342|OTHER|Control (placebo)|Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the treatment group.
219702487|NCT07168785|DRUG|[18F]-AraG radiotracer|\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.
219702488|NCT07168785|DRUG|Chemotherapy|Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.
219702489|NCT07168785|DEVICE|Radiotherapy|Concurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.
219116403|NCT00743522|DEVICE|ICD/ CRT-D|Cardiac device
219702490|NCT07167420|PROCEDURE|RISE (Revolute Insert Side-End ileocecal valve reconstruction)|After performing a conventional right hemicolectomy, an additional step is carried out in which sutures are used to artificially reconstruct an ileocecal valve structure at the ileal stump before proceeding with the ileocolic anastomosis.
219702491|NCT07168304|DRUG|S. boulardii|Participants received zinc plus S. boulardii supplementation according to the World Health Organization recommendations.
219116404|NCT05521594|PROCEDURE|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
219225211|NCT04273672|BEHAVIORAL|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
219702492|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 3|Prednisolone 0.5-1 mg/kg orally for grade 3 IR-hepatitis; adjusted based on liver function; treatment per local standard of care.
219702493|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 2|Hold immunotherapy and reassess liver function at the treating physician's discretion. If liver function tests persistently worsen or continue to rise, consider administering prednisolone at 0.5 mg/kg body weight
219702494|NCT00788385|DEVICE|ShuntCheck test|
219702495|NCT07167368|DRUG|Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction|Participants receive standardized basic drug therapy for HFrEF and chronic kidney dysfunction in accordance with clinical practice guidelines. Medications include but are not limited to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and diuretics, with dosage adjustments based on individual patient conditions.
219702496|NCT07167368|BEHAVIORAL|Home-based Personalized Exercise Rehabilitation|On the basis of basic drug treatment, participants in the exercise rehabilitation group receive personalized home-based exercise prescriptions. Prescriptions are developed according to cardiopulmonary exercise test results (using heart rate at anaerobic threshold) or 6MWT (for those unable to complete cardiopulmonary exercise tests). The 6-month exercise program includes aerobic exercises (e.g., brisk walking, cycling), with intensity, duration, and frequency adjusted based on individual tolerance and progress.
219702497|NCT07167277|DIETARY_SUPPLEMENT|Whey Protein|24g of whey protein will be given to the participant to be consumed daily. Participants will be asked to consume 1 serving per day for 3 months.
219702498|NCT07167277|DIETARY_SUPPLEMENT|Placebo|A calorie matched serving of carbohydrate powder will be given to participants to consume daily. Participants will be asked to consume 1 serving per day for 3 months.
219702499|NCT07166991|DRUG|Volatile anesthetic|"In the volatile anesthetic group, sevoflurane will be administrated during the organ procurement procedure. Administration will be initiated progressively after moving in the operating room and will be pursued until aortic clamping (targeted end-expiratory concentration suggested between 1 and 2%).~No opioid agent (or intravenous hypnotic agent) will be allowed in this group."
219702500|NCT07166991|DRUG|Opioid Anesthesia|In the opioid anesthetic group, intravenous sufentanil will be administrated during the organ procurement procedure. Continuous administration will be initiated after moving in the operating room (suggested dosage : 0,3 µg/kg/h) with supplemental dose if needed (at the discretion of the anesthesia team) and will be pursued until aortic clamping. No hypnotic drug administration will be allowed in this group.
219702501|NCT07166991|OTHER|Intraoperative brain-dead donor management|"In all groups (experimental and control groups), neuromuscular blocking agents will be administered during the entire procedure, according to national guidelines. In all groups, hemodynamic management (use of vasoactive agents as vasopressors or anti-hypertensive drugs) will be done according to the discretion of the anesthesia team.~In all groups, all the others aspects of the donor management will be not modified by the study protocol."
219702502|NCT07168070|OTHER|physical therapy and exercise|"Participants will receive one-on-one physiotherapy sessions, 45 minutes each, three times per week for 6 weeks. Sessions will include range of motion, strengthening, balance, and gait training.~Home-based Exercise Participants will be instructed to perform a structured home exercise program to complement in-clinic sessions."
219702503|NCT07168070|BEHAVIORAL|group physical therapy vs individualized physical therapy|group physical therapy vs individualized physical therapy
219702504|NCT07168070|OTHER|Group Physical therapy|Participants will attend group physiotherapy sessions, where several patients receive treatment at the same time. Each session lasts 45 minutes, three times per week for 6 weeks, and includes range of motion, strengthening, balance, and gait training.
219702505|NCT07167459|DEVICE|ndividualized Stereotactic Body Radiotherapy (SBRT) System|The individualized SBRT system employs advanced image-guided radiation delivery to deliver highly conformal, ablative doses to early-stage peripheral non-small-cell lung cancer while minimizing exposure to surrounding normal tissues. Treatment is delivered via a state-of-the-art robotic radiosurgery platform (e.g., CyberKnife M6) according to patient-specific fractionation schedules based on tumor size and proximity to critical structures, following standard indications and institutional protocols for medically inoperable or surgically refused cases.
219116405|NCT02951299|DRUG|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
219116406|NCT02788006|DRUG|Regorafenib 160 mg|
219116407|NCT06279754|DRUG|Recombinant Human Endostatin Injection|Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle Evafolimab Injection：Subcutaneous injection on day 1, 8, and 15, once every three weeks cycle
219225212|NCT04273672|BEHAVIORAL|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
219225213|NCT04273672|GENETIC|DNA Analysis|Participants will have their blood drawn for DNA analysis.
219116408|NCT05047562|OTHER|Pilates Group|16 Pilates exercise sessions twice a week for 2 months.
219116409|NCT05047562|OTHER|Segmental Stabilization group|16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
219116410|NCT04948879|PROCEDURE|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
219116411|NCT04141579|DRUG|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
219116412|NCT04141579|DRUG|Placebo|Matching placebo
219116413|NCT03859336|DEVICE|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
219116414|NCT05375136|OTHER|Non-interventional|No intervention will be administered.
219116415|NCT04696848|DRUG|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
219116416|NCT03927872|OTHER|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
219116417|NCT02694614|BEHAVIORAL|smartphone-assisted dietary coaching|
219116418|NCT02145481|BEHAVIORAL|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
219116419|NCT02145481|BEHAVIORAL|CAD Education|Education for patients with coronary artery disease
219116420|NCT01925261|DRUG|TPX-100 50mg|
219116421|NCT01925261|DRUG|TPX-100 100mg|
219116422|NCT01925261|DRUG|TPX-100 200mg|
219116423|NCT01925261|DRUG|TPX-100 20mg|
219116424|NCT01925261|DRUG|Placebo|
219116425|NCT00570258|DRUG|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
219116426|NCT00570258|DRUG|erlotinib|150 mg PO QD
219116427|NCT00570258|DRUG|Fulvestrant|250 mg IM Q 4 weeks
219116428|NCT00570258|DRUG|Placebo|Placebo 150 mg PO QD
219116429|NCT05540691|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
219116430|NCT06309030|DRUG|Bushen quhan zhiwang decoction|Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
219116431|NCT06309030|DRUG|Bushen quhan zhiwang decoction placebo|Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
219116432|NCT03050398|DRUG|Ribociclib|ribociclib + letrozole
219116433|NCT03050398|DRUG|letrozole|ribociclib + letrozole
219116434|NCT00598481|GENETIC|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
219116435|NCT00598481|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
219116436|NCT01723553|DRUG|C-11 PiB|One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
219116437|NCT00457613|DRUG|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
219116438|NCT04455334|OTHER|Error-augmented treadmill training|walk on split-belt treadmill
219116439|NCT04455334|OTHER|active control group|walk on tie-belt treadmill
219116440|NCT04455334|OTHER|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
219116441|NCT04455334|OTHER|conventional physical therapy group|conventional physical therapy
219116442|NCT04455334|OTHER|NO INTERVENTION|NO INTERVENTION
219116443|NCT00673634|PROCEDURE|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
219116444|NCT00673634|PROCEDURE|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
219116445|NCT04387539|DRUG|SOF/SMV/DCV/RBV|SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
219116446|NCT04726475|BEHAVIORAL|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
219116447|NCT04726475|DIETARY_SUPPLEMENT|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
219116448|NCT04726475|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of MCT coconut oil.
219116449|NCT02778282|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
219116450|NCT04479098|OTHER|Resistance exercise training|The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
219702506|NCT07169461|DEVICE|The blue MY MASK-E|"Device-Specific Protocol Blue MyMask® LLLT (Espansione): Emits monochromatic photobiomodulation therapy at 633 nm, distinct from conventional red or near-infrared LLLT used in other studies.~Espansione IPL: Uses a patented Optimal Power Energy (OPE®) system with a polychromatic spectrum of 590-1200 nm, allowing sub-threshold energy pulses for selective thermal effects on abnormal telangiectasia and Demodex-related inflammation."
219116451|NCT04479098|OTHER|Exercise detraining|The exercise detraining will last 12 weeks without exercise.
219116452|NCT02838225|DRUG|Docetaxel, Doxorubicin|
219116453|NCT02838225|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|
219116454|NCT05538299|BEHAVIORAL|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
219116455|NCT01071889|DRUG|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
219116456|NCT01071889|DRUG|Placebo|Placebo - only excipients with no API
219116457|NCT05740475|DRUG|9MW3811 injection|Single dose intravenously infused on day 1
219116458|NCT05740475|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
219116459|NCT01397929|DRUG|BAL101553|Intravenous administration
219116460|NCT05758155|OTHER|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
219116461|NCT05758155|OTHER|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
219116462|NCT03416504|BEHAVIORAL|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
219116463|NCT03416504|BEHAVIORAL|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
219116464|NCT04456582|PROCEDURE|Shear wave elastography|The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
219116465|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome Hansatome 160 microns
219116466|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome K 3000 130 microns
219116467|NCT00558324|PROCEDURE|LASIK|Femtoseconds laser 100 microns
219702507|NCT07169461|DEVICE|IPL|"IPL : The Eye-light device (Espansione Marketing S.p.A., Bologna, Italy,waveleggths 1,200-1,500 nm, Delivery system 12cm2) (Thai FDA No 66-2-2-2-0012685) :~* Protective eye shields~* 5 flashes of light were applied for each eye (3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim)~* Therapeutic energy level (10-16 joules/ cm2) based on the degree of skin pigmentation."
219702508|NCT07169461|PROCEDURE|Mechanical with pharmacological treatment|"Mechanical with pharmacological treatment : Warm compression 15 minutes + Lid hygiene + 1% TTO 2 times per day for 90 days~1%TTO : OCuSOFT Oust Demodex Eyelid Cleanser Foam Bottle 50ml (OCuSOFT, Richmond, TX) is the only commercially available medication in Thailand that contains 1% tea tree oil."
219702509|NCT07169461|DEVICE|ShamIPL|the Eye-light device (Espansione Marketing S.p.A., Bologna, Italy) - Protective eye shields, 5 time for each eye with flashes of light off , but flashes sound on.
219702510|NCT07169461|DEVICE|ShamLLLT|the MY MASK-E (Espansione Marketing S.p.A., Bologna, Italy) - No eye shields, applying a power off special mask for 15 minutes but light on , once a week for 4 weeks
219702511|NCT07169409|DRUG|Telemedicine Buprenorphine Treatment|With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.
219702512|NCT07169227|DRUG|Lidocaine %2 ampoule|Patients who were administered 40 mg lidocaine.
219116468|NCT00126685|BIOLOGICAL|autologous tumor cell vaccine|
219116469|NCT00126685|BIOLOGICAL|therapeutic autologous dendritic cells|
219116470|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
219116471|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
219702513|NCT07169227|DRUG|Dexmedetomidine|Patients who were administered 0.25 mg/kg dexmedetomidine.
219116472|NCT02309606|OTHER|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
219116473|NCT05461560|DIETARY_SUPPLEMENT|Sucrose solution|50 g of sucrose dissolved in 500 ml of tap water
219116474|NCT05461560|DIETARY_SUPPLEMENT|Seaweed extract in sucrose solution|1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
219116475|NCT04515563|BEHAVIORAL|Stretching exercise|Control Group
219116476|NCT04515563|BEHAVIORAL|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
219116477|NCT04515563|BEHAVIORAL|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
219116478|NCT04515563|BEHAVIORAL|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
219116479|NCT04515563|BEHAVIORAL|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
219116480|NCT02306395|PROCEDURE|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
219116481|NCT01274130|DRUG|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
219116482|NCT01994720|DRUG|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
219116483|NCT01994720|DRUG|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
219116484|NCT03108287|DRUG|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
219116485|NCT03108287|DRUG|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
219702514|NCT07169227|DRUG|paracetamol|Patients who were administered 50 mg paracetamol.
219116486|NCT00443469|DEVICE|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
219702515|NCT07167680|PROCEDURE|Individualized reduction of falls (iROLL)|The iROLL program is a 6-week fall prevention and management program for people living with spinal cord injury (SCI) and multiple sclerosis (MS) who use wheelchairs and scooters. The program's overall goals are to reduce fall frequency, improve functional mobility skills, decrease fear of falling, increase quality of life, and increase community participation. It uses many active learning strategies such as: goal setting, journaling, small group discussions, practicing skills, and homework to apply content to one's daily life.
219702516|NCT07167680|PROCEDURE|Stopping Elderly Accidents, Deaths & Injuries (STEADI)|The CDC's Stopping Elderly Accidents, Deaths \& Injuries (STEADI) initiative is a coordinated approach to fall prevention for older adults. It focuses on helping healthcare providers implement clinical fall prevention strategies, including screening for fall risk, assessing modifiable risk factors, and intervening to reduce risk.
219116487|NCT00443469|DEVICE|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
219116488|NCT03217734|BIOLOGICAL|Adalimumab|Subcutaneous Injection
219116489|NCT03217734|DRUG|Methotrexate|Oral Tablet
219116490|NCT03217734|DRUG|Placebo|Oral Tablet
219116491|NCT03450421|DEVICE|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
219225214|NCT01279707|BIOLOGICAL|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
219702517|NCT07168486|BIOLOGICAL|CD19.20.22 CAR T cells|CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).
219116492|NCT00801424|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
219702518|NCT07168486|DRUG|Fludarabine and Cyclophosphamide|Lymphodepletion with Flu-Cy prior to CAR T cell therapy
219702519|NCT07167537|BIOLOGICAL|OL-CD19-GDT|OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol
219225215|NCT01279707|BIOLOGICAL|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
219225216|NCT01279707|BIOLOGICAL|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
219702520|NCT06348147|BIOLOGICAL|Daratumumab|Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.
219702521|NCT06348147|DRUG|Lenalidomide|Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
219702522|NCT06348147|DRUG|Bortezomib|Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
219116493|NCT06380595|PROCEDURE|Complex endovascular aortic repair (cEVAR)|Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.
219116494|NCT03073629|DIAGNOSTIC_TEST|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
219116495|NCT03949751|DRUG|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
219116496|NCT05552690|PROCEDURE|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
219702523|NCT06348147|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid.
219702524|NCT01022606|OTHER|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
219702525|NCT03386981|OTHER|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
219702526|NCT04211714|BIOLOGICAL|EXG34217|Single infusion
219702527|NCT03370172|DRUG|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1 and 2 Day 0.
219702528|NCT04941274|DRUG|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
219702529|NCT05896332|DEVICE|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
219702530|NCT06814730|DRUG|THN391|THN391, IV infusion, 3\*Q4W (every 4 weeks)
219702531|NCT06814730|DRUG|Placebo|Placebo for comparison with THN391, IV infusion, 3\*Q4W
219702532|NCT06952998|DRUG|Topical application of Plasma Rich in Growth Factors (PRGF)|Topical application of PRGF will be maintained each time the patient undergoes the conventional treatment. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. The treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months).
219702533|NCT06952998|PROCEDURE|Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).|"Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic). The TIME dynamic wound closure strategy will be followed, which summarizes the four key points to stimulate the natural healing process: control of non-viable tissue, control of inflammation and infection, control of exudate and stimulation of the edges. After healing, chlorhexidine spray will be applied topically to these patients. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. Treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months)."
219702534|NCT06952153|PROCEDURE|Phacoemulsification with Goniosynechialysis|This procedure involves standard phacoemulsification cataract surgery combined with goniosynechialysis, which mechanically separates peripheral anterior synechiae to open the anterior chamber angle. It aims to both remove the cataractous lens and restore aqueous outflow in patients with primary angle-closure glaucoma.
219702535|NCT06952153|PROCEDURE|Trabeculectomy with 5FU|Trabeculectomy is a glaucoma filtration procedure designed to lower intraocular pressure by creating a new drainage pathway from the anterior chamber to the sub-conjunctival space. It is considered the standard surgical intervention for medically uncontrolled glaucoma.
219702536|NCT04765904|PROCEDURE|SDF|1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
219702537|NCT04765904|PROCEDURE|Hall technique|Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
219702538|NCT03139162|OTHER|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
219702539|NCT05502887|DIAGNOSTIC_TEST|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
219116497|NCT01991197|DRUG|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
219116498|NCT01991197|DRUG|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
219702540|NCT02987868|DRUG|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
219702541|NCT02987868|DRUG|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
219702542|NCT02987868|DRUG|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
219702543|NCT02987868|DRUG|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
219116499|NCT01991197|DRUG|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
219116500|NCT01991197|DRUG|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
219116501|NCT05474443|OTHER|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
219116502|NCT05474443|OTHER|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
219116503|NCT03709875|DEVICE|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
219116504|NCT01276249|DEVICE|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
219116505|NCT04305899|DRUG|BMS-986165 Tablet formulation 1|Specified dose on specified days
219116506|NCT04305899|DRUG|BMS-986165 Tablet formulation 2|Specified dose on specified days
219116507|NCT05580640|PROCEDURE|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
219116508|NCT06071975|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219116509|NCT06071975|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
219702544|NCT03286790|OTHER|Data collection on pneumonia events|
219702545|NCT00479752|DRUG|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
219702546|NCT04363814|BIOLOGICAL|Bactek-R|BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
219702547|NCT01587313|DRUG|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
219702548|NCT01931605|DEVICE|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
219702549|NCT05367999|DIAGNOSTIC_TEST|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
219702550|NCT04639440|OTHER|Adipose tissue|Adipose tissue sampling
219702551|NCT00498550|DRUG|Clozapine|Clozapine up to 550mg per day
219702552|NCT00498550|DRUG|Treatment as usual|Remain on pre-study antipsychotic treatment
219702553|NCT02382302|DEVICE|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
219702554|NCT03007940|OTHER|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
219702555|NCT03007940|OTHER|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
219116510|NCT02216422|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
219116511|NCT02216422|DRUG|Dasabuvir|Tablet
219116512|NCT02216422|DRUG|Ribavirin (RBV)|Tablet
219116513|NCT05814757|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
219116514|NCT05814757|DRUG|Controlled Insertion|Collagen Punctal Plug 0.2mm (Controlled Insertion)
219116515|NCT05814757|DRUG|Collagen Punctal Plug|Collagen Punctal Plug 0.2mm (Full Insertion)
219116516|NCT00792428|DEVICE|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
219116517|NCT00792428|DEVICE|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
219116518|NCT01171365|DRUG|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
219702556|NCT03007940|OTHER|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
219702557|NCT03007940|OTHER|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
219702558|NCT03007940|OTHER|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
219702559|NCT02918344|OTHER|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
219702560|NCT02918344|PROCEDURE|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
219702561|NCT00067340|DRUG|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
219702562|NCT00067340|OTHER|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
219702563|NCT00863122|DRUG|lapatinib|1500 mg lapatinib by mouth per day for 10 days
219702564|NCT01171534|DEVICE|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
219702565|NCT01171534|DEVICE|Vessel loop|Vessel loops and staples for fasciotomy closure
219702566|NCT03991975|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
219116519|NCT01171365|DRUG|Placebo|Matched placebo inhaler two inhalations twice daily
219116520|NCT03640689|DEVICE|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
219116521|NCT03640689|DEVICE|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
219116522|NCT03654586|BEHAVIORAL|Sugary drink warning labels|The description of each intervention appears in the descriptions of the experimental arms.
219116523|NCT00004189|BIOLOGICAL|filgrastim|
219116524|NCT00004189|DRUG|becatecarin|
219116525|NCT00004189|DRUG|cisplatin|
219116526|NCT02677103|DEVICE|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
219116527|NCT02677103|PROCEDURE|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
219116528|NCT02677103|PROCEDURE|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
219116529|NCT03870503|DRUG|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
219116530|NCT03870503|DRUG|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
219116531|NCT03870503|DRUG|Carbetocin|The patient received Carbetocin 100 mic gm
219116532|NCT02674243|DRUG|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
219116533|NCT02674243|DRUG|Talc|In this group, Talc will be used as pleurodesis substance
219116534|NCT02059317|OTHER|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
219116535|NCT02059317|OTHER|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
219116536|NCT02059317|OTHER|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
219116537|NCT02397460|DRUG|Gefapixant|Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
219116538|NCT02397460|DRUG|Placebo|
219116539|NCT01759875|DRUG|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
219116540|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
219702567|NCT03991975|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219702568|NCT00849056|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
219702569|NCT00849056|DRUG|placebo|placebo weekly subcutaneous injection
219702570|NCT02711137|DRUG|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
219702571|NCT02711137|DRUG|Gemcitabine|Standard of Care (SOC) agents
219702572|NCT02711137|DRUG|Paclitaxel|Standard of Care (SOC) agents
219702573|NCT02711137|DRUG|Rucaparib|Standard of Care (SOC) agents
219702574|NCT02711137|DRUG|Abiraterone|Standard of Care (SOC) agents
219702575|NCT02711137|DRUG|Ruxolitinib|Standard of Care (SOC) agents
219702576|NCT02711137|DRUG|Azacitidine|Standard of Care (SOC) agents
219702577|NCT00389389|DRUG|AZD4877|intravenous infusion
219702578|NCT03770819|PROCEDURE|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
219116541|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
219225217|NCT04945538|OTHER|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
219225218|NCT00545311|DRUG|NVA237|
219225219|NCT00545311|DRUG|NVA237|
219225220|NCT00545311|DRUG|NVA237|
219702579|NCT00548327|DRUG|Atomoxetine|Comparison between Atomoxetine and Placebo
219702580|NCT00548327|PROCEDURE|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
219702581|NCT00548327|PROCEDURE|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
219702582|NCT00548327|DRUG|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
219702583|NCT01855022|BEHAVIORAL|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
219702584|NCT01673386|DRUG|Tivozanib|
219702585|NCT01673386|DRUG|Sunitinib|
219116542|NCT03906487|BEHAVIORAL|Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~* the last to characterize the SDM by defining 5 personal memories"
219116543|NCT03906487|BEHAVIORAL|Assessment measures MINI and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~* the last to characterize the SDM by and defining 5 personal memories"
219116544|NCT03810079|DEVICE|Anodal transcranial direct current stimulation|Neuromodulation of bilateral prefrontal areas using 2 mA tDCS delivered during 20 minutes via sponge electrodes on the scalp
219116545|NCT01168674|DRUG|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
219116546|NCT01168674|DRUG|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
219702586|NCT06209918|DEVICE|bioptron light therapy|patient will be sitting on comfortable chair with the hand placed on an armrest in an extended and supinated position. Firstly, the skin over the wrist area will be exposed and cleaned by alcohol to achieve maximal penetration of light. Then, the bioptron device will be held perpendicular to the surface of the treated area, at a distance of 10 cm.
219702587|NCT06209918|DEVICE|wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
219702588|NCT00534651|DRUG|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
219702589|NCT01212510|OTHER|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
219702590|NCT00629577|GENETIC|microarray analysis|
219702591|NCT00629577|OTHER|flow cytometry|
219702592|NCT00629577|PROCEDURE|biopsy|
219702593|NCT00629577|PROCEDURE|colposcopy|
219702594|NCT03231176|DRUG|Varlitinib|oral tablets, twice daily
219702595|NCT03231176|DRUG|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
219702596|NCT04571489|DRUG|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
219702597|NCT04571489|DRUG|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
219702598|NCT04571489|DRUG|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
219702599|NCT04800796|OTHER|Audiovisual|Receive blended learning before and reading the Standard operating procedure
219702600|NCT01026935|DEVICE|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
219702601|NCT05726253|DRUG|Supportive Care + Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
219702602|NCT05726253|DRUG|Supportive Care + Placebo (no antibiotics)|Participants will be randomized to receive oral placebo for a standard course (7 days)
219702603|NCT01104649|DRUG|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
219702604|NCT01104649|DRUG|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
219702605|NCT00000204|DRUG|Buprenorphine|
219702606|NCT02576600|DEVICE|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
219702607|NCT02576600|OTHER|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
219702608|NCT02576600|DRUG|Propofol|TCI
219702609|NCT02576600|DRUG|Remifentanil|TCI
219702610|NCT02983123|PROCEDURE|1-hour hs-cTnT|
219702611|NCT04326374|DRUG|TransCon hGH|Once weekly subcutaneous injection
219702612|NCT04326374|DRUG|daily hGH|Once daily subcutaneous injection
219702613|NCT04858464|OTHER|Survey study|Patients will complete the mentioned questionnaires.
219702614|NCT03380156|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
219702615|NCT03380156|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
219702616|NCT06426745|PROCEDURE|Bowel preparation|to compare bowel cleanliness, compliance, tolerability, and patient satisfaction of a single regimen versus a split regimen for colonoscopy.
219702617|NCT04555447|DIETARY_SUPPLEMENT|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
219702618|NCT04555447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
219116547|NCT00127972|DRUG|stavudine|
219116548|NCT00127972|DRUG|lamivudine|
219116549|NCT00127972|DRUG|nevirapine|
219116550|NCT00127972|DRUG|efavirenz|
219116551|NCT00127972|DRUG|trizivir|
219225221|NCT00545311|DRUG|NVA237|
219225222|NCT00545311|DRUG|Placebo|
219702619|NCT05759871|OTHER|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
219702620|NCT03069664|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
219702621|NCT03069664|DEVICE|Covered Self-expandable Metal Stent|Pancreatic duct stent
219702622|NCT04663113|OTHER|Control Group/1st group ( standard physiotherapy|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
219116552|NCT05509712|BEHAVIORAL|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
219116553|NCT05509712|BEHAVIORAL|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
219116554|NCT02107248|BEHAVIORAL|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
219116555|NCT02107248|BEHAVIORAL|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
219702623|NCT04663113|OTHER|2nd group- Standard physiotherapy + bicycle ergometer|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given."
219702624|NCT04663113|OTHER|3rd group- Standard physiotherapy + exercise protocol to be developed|"Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction"
219702625|NCT04638244|BEHAVIORAL|Music|Brief Online Music
219702626|NCT04638244|BEHAVIORAL|Reading messages|Reading psychoeducational messages
219702627|NCT02967029|DRUG|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
219702628|NCT02967029|DRUG|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
219702629|NCT04155554|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
219702630|NCT04155554|DRUG|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
219702631|NCT05528952|DRUG|Atezolizumab|1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
219702632|NCT05528952|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
219702633|NCT05528952|DRUG|UCPVax|UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
219702634|NCT05188508|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
219702635|NCT05188508|COMBINATION_PRODUCT|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
219702636|NCT06422780|OTHER|Maternal Role Preparation Training|Maternal Role Preparation Training: Maternal Role Preparation Training (MRHE) is an occupational training programme aimed at increasing the competence of first-time mothers regarding motherhood. In this four-session programme, pregnant women will be provided with written materials, face-to-face talks and practical training covering topics related to their babies (maternal attachment, training on the sensory and developmental abilities of babies) and themselves (training on adopting a new role as a mother).The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions.
219116556|NCT01272713|OTHER|Oxygen therapy|"* Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol"
219116557|NCT01272713|OTHER|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
219116558|NCT00049686|DRUG|laromustine|
219116559|NCT00776100|OTHER|clinical observation|Patients undergo observation for 6 weeks.
219116560|NCT00776100|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
219225223|NCT05486494|OTHER|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
219116561|NCT03687450|BEHAVIORAL|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
219116562|NCT02126787|BEHAVIORAL|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
219116563|NCT02126787|BEHAVIORAL|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
219116564|NCT04196374|GENETIC|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
219116565|NCT05858203|OTHER|ATAC-seq and ChIP-seq|CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.
219702637|NCT06422780|OTHER|Awareness Centred Occupational Therapy Group|Awareness Centred Occupational Therapy (FME); In FME, areas that affect the occupational performance of pregnant women in their daily lives will be identified and appropriate occupational therapy interventions will be applied. Awareness training on the applications will be given before starting the sessions. The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions. Awareness training will be given before starting the sessions.
219702638|NCT06471010|OTHER|Blended Dynamic Interpersonal Therapy (B-DIT)|The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
219702639|NCT03746496|DIAGNOSTIC_TEST|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
219702640|NCT00668616|DRUG|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
219702641|NCT00668616|DRUG|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
219702642|NCT04037605|DRUG|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
219702643|NCT04037605|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
219702644|NCT04037605|DRUG|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
219225224|NCT02333318|DRUG|VVZ-149 injection|Colorless, transparent liquid in water for injection
219225225|NCT02333318|OTHER|Placebo|water for injection
219702645|NCT04037605|DRUG|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
219702646|NCT04037605|DRUG|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
219702647|NCT04037605|DRUG|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
219702648|NCT04037605|DRUG|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
219702649|NCT04037605|DRUG|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
219702650|NCT04037605|DRUG|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
219702651|NCT04037605|DRUG|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
219702652|NCT04037605|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
219702653|NCT04037605|DRUG|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
219702654|NCT01721798|DEVICE|Mirena levonorgestrel IUD|Intrauterine contraception system
219702655|NCT01721798|DEVICE|Copper T-380a IUD|intrauterine contraception system
219702656|NCT01308515|DEVICE|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
219702657|NCT01308515|DEVICE|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
219702658|NCT03174639|PROCEDURE|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
219702659|NCT06150820|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
219702660|NCT04040699|BIOLOGICAL|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
219702661|NCT05781802|OTHER|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~* In case of P0.1\<2, the clinically selected level of pressure support will be considered High Pressure support.~* In case of P0.1\>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
219702662|NCT02397616|OTHER|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
219702663|NCT00577408|DRUG|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
219702664|NCT00577408|DRUG|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
219702665|NCT01625767|BEHAVIORAL|AAT experiment|Smokers and nonsmokers complete AAT experiment
219702666|NCT05009550|PROCEDURE|Group ESP|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
219702667|NCT05009550|OTHER|Non-blocked Group|This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
219702668|NCT03400189|DRUG|Sulthiame|Single dose (50, 100, 200 mg)
219702669|NCT00656617|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)
219702670|NCT00656617|DRUG|Cytarabine|1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
219702671|NCT00656617|DRUG|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
219702672|NCT01544036|DRUG|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
219702673|NCT02301455|BEHAVIORAL|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
219702674|NCT01604772|DRUG|Akt Inhibitor MK2206|Given PO
219702675|NCT01604772|OTHER|Laboratory Biomarker Analysis|Correlative studies
219702676|NCT05684107|PROCEDURE|IPACK block|the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
219116566|NCT04793464|BEHAVIORAL|Promotores de Salud|The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
219702677|NCT05684107|PROCEDURE|adductor canal block|"the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn"
219702678|NCT05684107|PROCEDURE|sciatic nerve block|patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
219702679|NCT00255580|DRUG|Smoked cannabis|
219702680|NCT02349386|DRUG|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
219702681|NCT02349386|DRUG|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
219702682|NCT01712178|BIOLOGICAL|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
219702683|NCT01712178|BIOLOGICAL|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
219702684|NCT04104971|DIAGNOSTIC_TEST|blood tests , abdominal US and doppler|
219702685|NCT05270356|OTHER|MRI|Magnet Resonance Imaging of the Brain without Contrast
219702686|NCT00091819|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
219702687|NCT00091819|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
219702688|NCT02278653|OTHER|Questionnaires for the evaluation of Quality of Life|"1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~2. Short Form (36) health survey~3. EORTC CR38~4. Vaizey score~5. Low Anterior Resection Syndrome (LARS) score~6. International Index of Erectile Function for men~7. International Prostate Symptom Score for men~8. Female Sexual Function Index for women"
219702689|NCT02278653|OTHER|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
219702690|NCT05844423|BIOLOGICAL|0.5 ml dose of 1.1 mcg VAX-24|24 valent pneumococcal conjugate vaccine
219702691|NCT05844423|BIOLOGICAL|0.5 ml dose of PCV20|20 valent pneumococcal conjugate vaccine
219702692|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2 mcg VAX-24|24 valent pneumococcal conjugate vaccine
219702693|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2/4.4 mcg VAX-24|24 valent pneumococcal conjugate vaccine
219116567|NCT04793464|BEHAVIORAL|Services as usual|Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
219116568|NCT02337205|DRUG|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
219702694|NCT03879330|DEVICE|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
219116569|NCT02513992|PROCEDURE|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
219116570|NCT02513992|DRUG|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
219702695|NCT02900716|DRUG|DTRMWXHS-12|DTRMWXHS-12
219702696|NCT02900716|DRUG|DTRM-505|DTRMWXHS-12 and everolimus
219702697|NCT02900716|DRUG|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
219702698|NCT05510492|OTHER|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
219702699|NCT05510492|OTHER|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
219702700|NCT00275613|DRUG|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
219702701|NCT01503424|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
219116571|NCT02513992|DEVICE|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
219116572|NCT02513992|DEVICE|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
219116573|NCT02624206|DIETARY_SUPPLEMENT|Juice A|Subjects to be given juice daily for 3 weeks.
219225226|NCT04007705|BEHAVIORAL|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
219702702|NCT01516099|OTHER|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
219702703|NCT01516099|OTHER|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
219702704|NCT02682758|DRUG|Xenon|Wash-in of xenon for maintenance of anaesthesia
219702705|NCT00919672|DEVICE|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
219702706|NCT02112201|BEHAVIORAL|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
219702707|NCT01451073|BIOLOGICAL|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
219702708|NCT00091429|DRUG|Ranolazine|
219702709|NCT04772443|DRUG|DWJ1506|DWJ1506
219702710|NCT04772443|DRUG|DWJ1507|DWJ1507
219702711|NCT04772443|DRUG|DWC202011|DWC202011
219702712|NCT04772443|DRUG|DWJ1177|DWC202011
219702713|NCT03581006|DIETARY_SUPPLEMENT|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
219702714|NCT03581006|COMBINATION_PRODUCT|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
219116574|NCT02624206|DIETARY_SUPPLEMENT|Juice B|Subjects to be given juice daily for 3 weeks.
219702715|NCT03581006|OTHER|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
219702716|NCT02597608|BEHAVIORAL|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
219116575|NCT02075190|OTHER|Therapeutic Computerized intervention|Remediation training intervention
219116576|NCT02075190|OTHER|Nontherapeutic computerized intervention|Online gaming intervention
219116577|NCT00188396|DRUG|Citalopram|
219116578|NCT05274308|PROCEDURE|Blood sampling|Blood sampling from all eligible transplantation patients according to the protocol
219702717|NCT02597608|DIETARY_SUPPLEMENT|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
219702718|NCT02597608|BEHAVIORAL|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
219702719|NCT02597608|DIETARY_SUPPLEMENT|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
219702720|NCT02597608|BEHAVIORAL|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
219702721|NCT02597608|DIETARY_SUPPLEMENT|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
219702722|NCT02597608|OTHER|UPPR: Control|No interventions provided.
219702723|NCT02474186|RADIATION|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
219702724|NCT02474186|DRUG|Xeloda|chemotherapy agent daily for two weeks
219702725|NCT02474186|DRUG|paclitaxel|chemotherapy agent weekly for two weeks
219702726|NCT03528941|DRUG|Lamivudine|Patients who received lamivudine to prevent hepatitis B
219702727|NCT03528941|OTHER|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
219702728|NCT03889288|DEVICE|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
219702729|NCT01963871|OTHER|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
219702730|NCT00382356|DRUG|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
219702731|NCT03659630|BEHAVIORAL|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
219702732|NCT03659630|BEHAVIORAL|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
219702733|NCT05813561|DRUG|DWP14012|DWP14012 40mg
219702734|NCT00110708|DRUG|Oralgam (human immunoglobulin)|
219702735|NCT05100563|DRUG|50 mg naltrexone|Medication combined with twice a week psychotherapy
219702736|NCT00167791|DRUG|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
219702737|NCT00390715|DRUG|chemotherapy|
219116579|NCT02934477|OTHER|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
219116580|NCT03467308|GENETIC|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods."
219116581|NCT04660019|OTHER|Scalp and auricular acupuncture|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.
219116582|NCT04660019|OTHER|Seed acupressure|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
219116583|NCT01212406|DRUG|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
219116584|NCT02963051|DRUG|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
219116585|NCT02963051|DRUG|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
219116586|NCT02963051|DRUG|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
219702741|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
219702742|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
219702743|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
219702744|NCT04042792|OTHER|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
219702745|NCT02912052|DRUG|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
219702746|NCT02912052|DRUG|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
219702747|NCT04410393|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
219702748|NCT04258956|DRUG|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
219702749|NCT02852759|PROCEDURE|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
219702750|NCT02852759|DEVICE|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
219702751|NCT01379612|OTHER|Ultrasonic Elastography|Non-invasive
219702752|NCT03638791|BEHAVIORAL|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
219702753|NCT01414296|DRUG|PSMA ADC|PSMA ADC administered IV
219702754|NCT02548546|DEVICE|ECHO|Imaging
219116587|NCT00641186|DRUG|sodium oxybate|4.5 to 9.0 grams per night
219116588|NCT06622278|BEHAVIORAL|Flipped Classroom|The flipped classroom educational model requires participants to independently review educational material before class, and class time with the health educator is spent engaging in group and individual skills-based activities and problem-solving assignments. The theoretical basis for the development of active learning is to elicit higher cognitive learning, according to the revised Bloom's taxonomy and shift independent student time to passive learning (remembering and understanding) and collaborative student and educator time to active learning (applying, analyzing, evaluating, and creating). Thus, the weight management education will include: case vignettes, group debates/discussions, think-pair-share activities, gamification of health-related topics, creation of meal and physical activity, problem-solving barriers to a healthy diet and physical activity, and hands-on worksheets.
219116589|NCT06624423|OTHER|corn silk tea|Corn Silk Tea
219225227|NCT04007705|BEHAVIORAL|General healthy eating|Healthy eating counseling according to the World Health Organization
219225228|NCT03133299|DRUG|Glucocorticoids|Oral prednisolone for four months
219702755|NCT02548546|DEVICE|ECG-gated MRA|Imaging
219702756|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
219702757|NCT06462287|DRUG|Aprepitant 125 and 80Mg Oral Capsule|Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
219702758|NCT06462287|DRUG|Placebo|Placebo:1 oral capsule time a day for 4 days
219702759|NCT06291363|DRUG|Esmolol Hydrochloride|Patients in the experimental group will receive esmolol during general anesthesia
219702760|NCT06291363|DRUG|Saline|Patients in the standard of care group will receive saline as placebo during general anesthesia
219702761|NCT00696033|DRUG|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
219702762|NCT00696033|DRUG|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
219702763|NCT00696033|DRUG|placebo|lorazépam placebo or Diazépam placebo
219702764|NCT04249843|DRUG|BGB-3245|administered orally (PO)
219702765|NCT04764292|DEVICE|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
219116590|NCT06625294|PROCEDURE|Task -oriented training with bilateral functional task training exercises|"Task oriented training approach with BFTT will consists of different tasks including:~Hand Movements:~1. Fold a small cloth towel with both hands with initially putting the towel flat on the table and gradually folding it into a large towel roll.~2. Put a small amount of putty on patient's table and instruct to roll it with the help of rolling pin moving it back and forth using both the hands.~3. Place a jar with a removable lid on the table and instruct the patient to remove lid from the jar completely by holding the jar with either hand and remove the lid with the alternate hand.~4. Pouring water: Pour water from jug while holding the jug in unaffected hand to cup/glass that is held in affected hand and activity can be done the other way round as well.~5. Pour water from one hard plastic cup to another while alternatively involving both the hands (we must not allow deformation of the cup)~6. Plunging action with coffee maker against water resistance:Fill the coffee maker with water."
219116591|NCT06625294|PROCEDURE|Task Oriented Training with CIMT|"• Hand Movements:~1. Sitting at a table (Wrist Extension): Affected forearm resting on table. Place cylindrical object in palm of patient's hand. Patient asked to move the hand towards the forearm (dorsiflexion) by extending the wrist - no elbow flexion allowed.~2. Sitting at a table (Radial Deviation of Wrist): Therapist should place forearm with ulnar side on table in mid-pronation / supination position. Thumb in line with forearm and wrist in extension. Fingers around cylindrical object. Patient is asked to lift hand off table. No wrist flexion or extension.~Advanced Hand Activities:~1. Have the patient reach forward to pick up the top of a pen with their affected hand, bring the affected arm back to their side and put the pen cap down in front of them.~2. Place (beans), in a teacup an arm's length away on the affected side. Place another teacup an arm's length away on the intact side. Have the patient pick up one beans with their affected hand and place the beans in the cup on the"
219225229|NCT03133299|DRUG|Vitamin D|Oral vitamin D for two months
219225230|NCT05522309|DRUG|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
219225231|NCT05380115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
219702766|NCT04764292|DRUG|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
219702767|NCT04126525|DRUG|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
219702768|NCT04759131|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
219702769|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
219702770|NCT06568237|DRUG|Placebo|Matching placebo administered orally
219702771|NCT05144945|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
219702772|NCT05144945|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
219702773|NCT00000965|DRUG|Zidovudine|
219702774|NCT06390345|OTHER|FOCuSEd Integrated Intervention|"Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach."
219702775|NCT06390345|OTHER|Enhanced Usual Care|"Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider."
219702776|NCT06401603|DRUG|Decitabine|Given by IV
219702777|NCT06401603|DRUG|Listaftoclax|Given by PO
219702778|NCT06401603|DRUG|Olverembatinib|Given by PO
219702779|NCT04226170|DRUG|DAS-001|ondansetron + pyridostigmine
219702780|NCT04228289|DRUG|Oxytocin|40 IU intranasal spray
219702781|NCT04228289|OTHER|Placebo|matching intranasal spray
219702782|NCT02580812|OTHER|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
219702783|NCT06209242|PROCEDURE|Percutaneous pinning|Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol
219702784|NCT06209242|PROCEDURE|Cast immobilization|Using sugar tong slab and then replace to short arm casting within 1 week
219702785|NCT03692949|DRUG|LY3451838|Administered IV Part A
219702786|NCT03692949|DRUG|LY3451838|Administered IV Part A
219702787|NCT03692949|DRUG|LY3451838|Administered IV Part A
219702788|NCT03692949|DRUG|LY3451838|Administered IV Part A
219116592|NCT06687148|OTHER|Manual manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
219702789|NCT03692949|DRUG|LY3451838|Administered IV Part A
219702790|NCT03692949|DRUG|LY3451838|Administered IV Part A
219702791|NCT03692949|DRUG|LY3451838|Administered SC Part B
219702792|NCT03692949|DRUG|Placebo|Administered IV in Part A and SC in Part B
219702793|NCT03454620|DRUG|irinotecan|GC1118 combination with irinotecan
219702794|NCT03454620|DRUG|FOLFIRI|GC1118 combination with FOLFIRI
219702795|NCT00937196|DRUG|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
219702796|NCT00937196|DRUG|Histaminum hydrochloricum globuli|
219702797|NCT06274827|DIAGNOSTIC_TEST|Superficial Electromyography|For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
219702798|NCT04855136|BIOLOGICAL|BB2121|CAR T Cell Therapy
219702799|NCT04855136|DRUG|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
219702800|NCT04855136|DRUG|BMS-986405|gamma secretase inhibitor (GSI)
219702801|NCT00572845|OTHER|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
219702802|NCT05213780|OTHER|No intervention is involved|No intervention is involved
219702803|NCT01850316|RADIATION|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
219702804|NCT01449565|DRUG|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
219702805|NCT01449565|DRUG|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
219702806|NCT02749409|DRUG|Parecoxib|
219702807|NCT02749409|DRUG|Morphine|
219702808|NCT02592824|DRUG|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
219702809|NCT02592824|DRUG|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
219702810|NCT04074811|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.
219702811|NCT05266768|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
219702812|NCT04971655|OTHER|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
219116593|NCT06687148|OTHER|Sham manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
219116594|NCT05244148|DEVICE|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
219116595|NCT05244148|DEVICE|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
219116596|NCT05244148|BEHAVIORAL|Standard of Care|hydration + rest at home + if needed paracetamol
219702813|NCT04388423|OTHER|simulated puncture training|The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
219702814|NCT04388423|OTHER|traditional bedside teaching|The residents are trained by traditional bedside teaching
219702815|NCT00490308|DRUG|Treatment with estradiol valerate|
219702816|NCT01781247|BEHAVIORAL|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
219702817|NCT01781247|BEHAVIORAL|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
219702818|NCT01840631|BEHAVIORAL|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
219702819|NCT05868161|DEVICE|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
219702820|NCT04704050|DRUG|dronedarone 400 mg Oral Tablet|"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
219702821|NCT04704050|DRUG|Placebo|Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
219702822|NCT05769816|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
219702823|NCT05769816|DRUG|NAs|Once/day, 1 capsule/time, oral
219702824|NCT02204943|DEVICE|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
219702825|NCT02204943|DRUG|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
219702826|NCT00634478|RADIATION|Pre-lemniscal Radiation Deep Brain Stimulation|
219702827|NCT06098508|OTHER|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
219702828|NCT06098508|OTHER|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
219702829|NCT05785169|BEHAVIORAL|All-facility Training|The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To change clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. The training is modeled on these principles and supports the development of multiple stigma-reduction strategies to improve patient and staff wellbeing.
219702830|NCT06546345|DEVICE|KeriFlex®|The KeriFlex® finger joint prothesis MCP is designed to replace a damaged metacarpophalangeal (MCP) joint and the KeriFlex® finger joint prothesis PIP is designed to replace a damaged proximal interphalangeal (PIP) joint.
219702831|NCT02398773|PROCEDURE|Computed Tomography|Undergo PET/CT
219702832|NCT02398773|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
219702833|NCT02398773|OTHER|Laboratory Biomarker Analysis|Correlative studies
219702834|NCT02398773|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219116597|NCT06710535|OTHER|Manual Manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
219116598|NCT06710535|OTHER|Sham Manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
219225232|NCT00850915|OTHER|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
219225233|NCT00001930|DRUG|Amantadine|
219702835|NCT04128917|DRUG|Tegoprazan|Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
219702836|NCT04128917|DRUG|RAPAE01|RAPAE01/Clarithromycin/Amoxicillin BID peroral
219702837|NCT00998569|BEHAVIORAL|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
219702838|NCT00998569|BEHAVIORAL|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
219702839|NCT00869960|DRUG|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
219702840|NCT00869960|DRUG|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
219702841|NCT00869960|DRUG|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
219702842|NCT00869960|DRUG|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
219702843|NCT05720598|PROCEDURE|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (\>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
219702844|NCT05720598|PROCEDURE|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
219702845|NCT05720598|PROCEDURE|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
219702846|NCT04478617|DRUG|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
219116599|NCT05438615|OTHER|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
219116600|NCT05438615|OTHER|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
219116601|NCT06328062|DRUG|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
219116602|NCT06328062|DRUG|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
219116603|NCT06893055|OTHER|Strength-Endurance Training|"The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down.~The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions."
219116604|NCT06893055|OTHER|Endurance Training|The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
219116605|NCT05574374|DRUG|DWP14012|Potassium-competitive acid blocker
219116606|NCT05574374|DRUG|DWC202202|Clopidogrel Bisulfate
219116607|NCT05574374|DRUG|DWC202203|Proton pump inhibitor
219116608|NCT05018650|DEVICE|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
219116609|NCT05359900|OTHER|Pain neuroscience education|Pain neuroscience education lecture
219116610|NCT05359900|OTHER|Red Flag Education|Red Flag education lecture
219702847|NCT03911531|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
219702848|NCT03911531|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
219702849|NCT05578053|DRUG|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
219116611|NCT02229903|DEVICE|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
219116612|NCT02229903|DEVICE|Sham Treatment|29 treatments over 6 weeks.
219116613|NCT06180252|DIAGNOSTIC_TEST|PET with 11C MP4|Each subject will undergo a PET exam using 11C MP4 as a tracer. This is a specific ligand for the acetyl-choline esterase enzyme already used abroad both in healthy volunteers and in various patient groups.
219116614|NCT03670186|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
219116615|NCT02725281|OTHER|Stress ball|"The patients in this group were given stress ball into both their palms 5 minutes before ESWL. Participants were instructed to squeeze the balls twice after counting up to ten and repeat it until the end of the procedure. This ball was medium hard and has been made of high quality silicon."
219116616|NCT02725281|OTHER|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
219116617|NCT05400720|BEHAVIORAL|Mentoring|At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
219116618|NCT02358460|DEVICE|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
219116619|NCT01461616|DRUG|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
219116620|NCT01461616|DRUG|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
219116621|NCT01461616|DRUG|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
219116622|NCT05188963|PROCEDURE|Intermittent catheterization|Intermittent catheterization is performed as treatment for urinary retention. Treatment is stopped when postvoid urinary retention volume is below the threshold of each group.
219116623|NCT02169830|DRUG|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
219116624|NCT02169830|DRUG|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
219702850|NCT06646302|OTHER|Personalized 40 Hz Broadband Stimulation|Broadband acoustic stimulus (125 Hz-12 kHz) amplitude-modulated at 40 Hz with a 50% duty cycle. A polynomial regression and FFT-based algorithm applies individualized frequency weighting, combining population data (70%) and patient-specific responses (30%). Delivered for 60 seconds at 10 dB above the individual minimum masking level (MML).
219702851|NCT06646302|OTHER|40 Hz Pure Tone Stimulation|Pure tone stimulus at the optimized frequency (matched to tinnitus characteristics or high-frequency carrier), amplitude-modulated at 40 Hz with a 50% duty cycle. Delivered for 60 seconds at 10 dB above MML.
219116625|NCT02169830|BEHAVIORAL|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
219116626|NCT03493113|DIAGNOSTIC_TEST|EEG|
219116627|NCT06508099|DRUG|Vitamin A|300 000 IU single dose orally
219116628|NCT06508099|DRUG|Vitamin D3|100 000 IU single dose orally
219116629|NCT06003101|BIOLOGICAL|Bone marrow aspirate concentrate (BMAC)|Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.
219116630|NCT06003101|PROCEDURE|Control|Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
219116631|NCT06224426|OTHER|Normobaric high-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
219116632|NCT06224426|OTHER|Normobaric low-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
219116633|NCT06330818|DIAGNOSTIC_TEST|MRI|Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.
219116634|NCT06330818|DIAGNOSTIC_TEST|H2 15O PET/CT|Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images
219225234|NCT03690804|DEVICE|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
219225235|NCT03316690|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
219225236|NCT03316690|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
219225237|NCT03316690|BEHAVIORAL|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
219225238|NCT01824849|PROCEDURE|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
219225239|NCT01824849|PROCEDURE|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
219225240|NCT03096470|PROCEDURE|anesthesia|no anesthesia
219225241|NCT00516399|DRUG|povidone-iodine 1.25% ophthalmic solution|
219116635|NCT06330818|OTHER|Biosampling|Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis
219116636|NCT04860128|BEHAVIORAL|Sports technology application|Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
219116637|NCT04201951|DRUG|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
219116638|NCT04201951|OTHER|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
219116639|NCT04793932|DRUG|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
219116640|NCT04793932|DRUG|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
219116641|NCT04793932|DRUG|short-course chemotherapy|other two months of chemotherapy after surgery
219116642|NCT04793932|DRUG|long-course chemotherapy|other two months of chemotherapy before surgery
219116643|NCT06116110|OTHER|Long-term Follow-Up|No intervention
219116644|NCT02455479|BIOLOGICAL|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
219116645|NCT02455479|BIOLOGICAL|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
219116646|NCT06452706|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
219116647|NCT01490515|PROCEDURE|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
219116648|NCT01490515|OTHER|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
219116649|NCT00130650|DEVICE|Pain Ease|
219116650|NCT02156362|OTHER|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
219116651|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
219116652|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
219116653|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
219116654|NCT03750279|OTHER|Exercise therapy|"* 5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~* Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
219116655|NCT03750279|OTHER|LLLT|\- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
219116656|NCT03750279|OTHER|Sham LLLT|\- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
219702852|NCT06646302|OTHER|Continuous Broadband Noise|Continuous broadband noise spanning 125 Hz-12 kHz without 40 Hz modulation. Delivered for 60 seconds at 10 dB above MML as an active control condition.
219702853|NCT03630848|OTHER|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
219702854|NCT01948245|DEVICE|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
219702855|NCT01948245|DEVICE|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
219702856|NCT06046950|OTHER|Treatment target DAS28CRP-LDA|Aiming for DAS28CRP-low disease activity
219702857|NCT06046950|OTHER|Treatment target SDAI-remission|Aiming for SDAI-remission
219702858|NCT02458066|OTHER|IRS: bendiocarb|carbamate insecticide
219702859|NCT02458066|OTHER|IRS: deltamethrin|Pyrethroid insecticide
219702860|NCT06524258|DIAGNOSTIC_TEST|testicular elastography|testicular elastography for predicting non obstructive azoospermia
219702861|NCT05263193|DRUG|Caplacizumab|as in real world practice
219702862|NCT04622566|DRUG|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
219116657|NCT06267274|DRUG|Bimatoprost Ophthalmic Solution, 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
219116658|NCT06267274|DRUG|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
219116659|NCT00798395|DRUG|Org 50081|1.5 mg on day 1-7
219225242|NCT00516399|DRUG|natamycin ophthalmic suspension, USP 5%|
219702863|NCT02857504|DEVICE|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
219702864|NCT02857504|DEVICE|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
219702865|NCT01434511|BIOLOGICAL|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
219702866|NCT03993912|DRUG|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression"
219702867|NCT03993912|DRUG|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
219702868|NCT03993912|DRUG|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
219116660|NCT00798395|DRUG|Org 50081|4.5 mg on Day 1-7
219116661|NCT00798395|DRUG|Placebo|Once daily on Day 1-7
219116662|NCT00798395|DRUG|zopiclone|Single dose of 7.5 mg
219116663|NCT01548443|DEVICE|Medifoam H dressing|"Cover medifoam H on the wound for a week."
219116664|NCT01548443|DEVICE|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
219116665|NCT00005611|DRUG|BMS-188797|
219116666|NCT03615482|BIOLOGICAL|V114|Single 0.5 mL injection
219116667|NCT03615482|BIOLOGICAL|QIV|Single 0.5 mL injection
219116668|NCT03615482|BIOLOGICAL|Matching Placebo for V114|Single 0.5 mL injection
219116669|NCT03987035|DEVICE|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
219116670|NCT05798728|PROCEDURE|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
219225243|NCT04017104|DIAGNOSTIC_TEST|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
219702869|NCT00262925|BIOLOGICAL|alemtuzumab|Given subcutaneously
219116671|NCT05798728|PROCEDURE|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
219116672|NCT02845505|OTHER|Intravascular Ultrasound, coronary computed tomography angiography|
219116673|NCT03521921|DEVICE|Mitraclip|Edge-to edge mitral valve repair
219116674|NCT03248570|DRUG|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
219116675|NCT03248570|DRUG|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
219116676|NCT04576780|OTHER|Integrated Large Complex Polyp Referral Pathway|"The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection."
219116677|NCT02309528|OTHER|Educational computerized digital stories|computerized digital stories made by American Indians
219116678|NCT01295346|OTHER|Head CT scan and blood draw|
219116679|NCT02922413|BIOLOGICAL|Hemin for injection|Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
219116680|NCT02922413|OTHER|Placebo|Saline infusion
219116681|NCT00979173|DRUG|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
219116682|NCT03078387|DIAGNOSTIC_TEST|imaging|imaging before and after treatment
219116683|NCT01492517|OTHER|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
219116684|NCT01492517|OTHER|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
219116685|NCT01492517|OTHER|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
219116686|NCT01492517|OTHER|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
219702870|NCT00262925|DRUG|asparaginase|Given IM
219702871|NCT00262925|DRUG|methotrexate|Given IV or orally
219116687|NCT01161017|DRUG|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
219116688|NCT01161017|DRUG|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
219702872|NCT00262925|DRUG|dexamethasone|Given orally
219702873|NCT00262925|DRUG|leucovorin calcium|Given IV
219702874|NCT00262925|DRUG|mercaptopurine|Given orally
219702875|NCT00262925|DRUG|vincristine|Given IV
219702876|NCT04682301|BEHAVIORAL|Behavioral Intervention|Receive SDM intervention
219702877|NCT04682301|OTHER|Discussion (focus group)|Attend focus group
219702878|NCT04682301|OTHER|Discussion (feedback on SDM)|Provide feedback on SDM
219116689|NCT02377765|DEVICE|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
219116690|NCT02377765|PROCEDURE|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
219116691|NCT05491005|BEHAVIORAL|Total diet replacement|Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
219116692|NCT05491005|BEHAVIORAL|eHealth|All follow-up through an eHealth application and video meetings.
219702879|NCT04682301|OTHER|Interview|Attend a telephone interview
219702880|NCT04682301|OTHER|Survey Administration|Ancillary studies
219702881|NCT00560404|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
219702882|NCT00560404|DRUG|Epoetin alfa|As prescribed
219702883|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
219116693|NCT05491005|BEHAVIORAL|Face-to-face|All follow-up through face-to-face meetings.
219116694|NCT05616182|OTHER|LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
219116695|NCT01500226|DRUG|Rolapitant|(4 X 50 mg capsule) 200 mg PO
219116696|NCT01500226|DRUG|Granisetron|2 mg PO
219116697|NCT01500226|DRUG|Dexamethasone|20 mg PO
219116698|NCT01500226|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
219116699|NCT06176456|DIAGNOSTIC_TEST|rTMS|Active regiment
219116700|NCT06176456|OTHER|Placebo|Tactile artefacts without magnetic pulses
219116701|NCT05096390|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
219116702|NCT05096390|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
219116703|NCT02754609|OTHER|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
219116704|NCT02754609|OTHER|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
219225244|NCT04017104|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
219225245|NCT04017104|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
219225246|NCT01953679|DRUG|Ulipristal Acetate|
219225247|NCT02336802|BEHAVIORAL|Avoidance experiment|Participants complete an avoidance task
219116705|NCT02754609|OTHER|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
219116706|NCT02754609|OTHER|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
219116707|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
219116708|NCT02754609|OTHER|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
219225248|NCT00003654|DRUG|patent blue V dye|
219225249|NCT00003654|PROCEDURE|lymphangiography|
219116709|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
219116710|NCT02754609|OTHER|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
219116711|NCT03620071|OTHER|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
219116712|NCT03620071|OTHER|Standard Care|Standard Clinical Care
219116713|NCT00387192|DRUG|Optivate|Plasma-derived Factor VIII
219116714|NCT04212169|DRUG|MEDI3506|multiple doses
219116715|NCT04212169|DRUG|Placebo|multiple doses
219116716|NCT02500511|BIOLOGICAL|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
219225250|NCT00003654|PROCEDURE|radionuclide imaging|
219225251|NCT00003654|PROCEDURE|sentinel lymph node biopsy|
219225252|NCT00003654|RADIATION|technetium Tc 99m sulfur colloid|
219225253|NCT03672032|DEVICE|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
219225254|NCT03672032|DEVICE|Franseen Needle|Franseen Needle will be used to obtain biopsy
219116717|NCT05210140|DRUG|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
219116718|NCT02938728|OTHER|Biopsies|
219116719|NCT04463082|PROCEDURE|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
219116720|NCT04027569|OTHER|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
219702884|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Control Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
219116721|NCT04027569|OTHER|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
219116722|NCT05348330|PROCEDURE|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
219116723|NCT05348330|PROCEDURE|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
219116724|NCT04236128|OTHER|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
219116725|NCT04474964|RADIATION|Low dose Craniospinal Irradiation plus Focal Radiotherapy|The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
219116726|NCT05361746|DEVICE|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
219116727|NCT05361746|DEVICE|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
219116728|NCT06040645|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
219225255|NCT02134626|DRUG|Simvastatin|40mg / pill, one pill orally once a day for three months
219225256|NCT02134626|DRUG|Placebo pill|
219225257|NCT04440540|BEHAVIORAL|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
219225258|NCT04440540|BEHAVIORAL|Conventional care (control)|receive routine care
219116729|NCT06040645|OTHER|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
219116730|NCT06388070|DRUG|HUC3-053|drops in each eye five to six times a day for 12 weeks
219116731|NCT06388070|DRUG|Hyalein Mini Drops|drops in each eye five to six times a day for 12 weeks.
219116732|NCT06518499|PROCEDURE|Pilonidal sinus surgery|Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
219116733|NCT05584657|DRUG|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
219225259|NCT01080404|PROCEDURE|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
219116734|NCT05584657|DRUG|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
219116735|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
219116736|NCT05070650|DRUG|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
219116737|NCT05070650|DRUG|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
219116738|NCT05070650|DRUG|Phenylephrine|500 mg/10 mg granules for oral solution
219116739|NCT00002730|DRUG|buthionine sulfoximine|
219116740|NCT00002730|DRUG|melphalan|
219116741|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
219702885|NCT05716893|BEHAVIORAL|Adaptive Aerobic Training/AT Dosing|o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
219116742|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
219116743|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
219116744|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
219116745|NCT03585114|DRUG|[F-18] DCFPyL|\[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
219116746|NCT03585114|PROCEDURE|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
219116747|NCT02268318|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
219116748|NCT02268318|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
219116749|NCT00684268|DRUG|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
219116750|NCT00684268|DRUG|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
219225260|NCT01080404|DEVICE|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
219225261|NCT06285812|DEVICE|OtoSight Middle Ear Scope|Subjects will be evaluated with the OtoSight Middle Ear Scope
219116751|NCT00005991|DRUG|gemcitabine hydrochloride|
219116752|NCT00005991|DRUG|pegylated liposomal doxorubicin hydrochloride|
219116753|NCT00778063|DRUG|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
219116754|NCT00778063|DRUG|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
219116755|NCT05582213|DIAGNOSTIC_TEST|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
219116756|NCT01406860|DRUG|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
219116757|NCT01406860|DRUG|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
219116758|NCT00931450|DRUG|exemestane|Given orally
219116759|NCT00931450|DRUG|sunitinib malate|Given orally
219116760|NCT00931450|OTHER|placebo|Given orally
219225262|NCT03170050|DEVICE|YYD701-2|HA Filler
219225263|NCT03170050|DEVICE|Restylane Perlane Lidocaine|HA Filler
219225264|NCT00462072|DRUG|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
219225265|NCT05199506|DEVICE|RAP|Treatment of cellulite with RAP device
219225266|NCT04190485|OTHER|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
219225267|NCT04190485|OTHER|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
219225268|NCT04190485|OTHER|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
219225269|NCT02384382|DRUG|Enzalutamide|
219225270|NCT05847452|DRUG|Benralizumab|30mcg ever month for 3 months
219116761|NCT02391285|DEVICE|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
219116762|NCT00763932|BIOLOGICAL|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
219116763|NCT06385210|OTHER|Semi structured interviews|Participants will be interviewed concerning perceived barriers to routine surgical video recording
219116764|NCT02727868|GENETIC|blood samples|
219116765|NCT04572490|DIAGNOSTIC_TEST|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
219116766|NCT01734837|DEVICE|DS-Ligature Clip|
219116767|NCT00126204|DRUG|Doxycycline|
219116768|NCT05730218|DRUG|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
219116769|NCT05730218|DRUG|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
219702886|NCT05716893|BEHAVIORAL|Standard (fixed) Aerobic Training/AT dosing|In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
219702887|NCT03609047|DRUG|Palbociclib|CDK4/6 inhibitor
219702888|NCT03609047|DRUG|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
219116770|NCT00061360|DRUG|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
219702889|NCT03609047|DRUG|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
219702890|NCT03609047|DRUG|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
219116771|NCT00061360|DRUG|ATG+cyclosporine|ATG+cyclosporine
219116772|NCT03930966|DIAGNOSTIC_TEST|PDEQ, PCL-5 and demographic survey|Questionnaires
219702891|NCT03609047|DRUG|paclitaxel|Adjuvant Chemotherapy
219702892|NCT04155307|DEVICE|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
219116773|NCT02922673|DRUG|Aspirin|
219116774|NCT02922673|DRUG|Placebo|
219116775|NCT04507672|DRUG|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
219116776|NCT00948259|DRUG|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
219702893|NCT04155307|DIAGNOSTIC_TEST|Anal Manometry|Anal Manometry done in standard care
219702894|NCT04155307|DIAGNOSTIC_TEST|Defecography|Defecographydone in standard care
219702895|NCT04155307|DIAGNOSTIC_TEST|Electromyogram|Electromyogram done in standard care
219702896|NCT05468307|BIOLOGICAL|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
219702897|NCT02310542|DEVICE|MARS albumin dialysis system|
219702898|NCT02310542|DEVICE|SPAD albumin dialysis system|
219116777|NCT00948259|DRUG|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
219116778|NCT02151019|RADIATION|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
219116779|NCT06378502|DRUG|Amoxicillin Short|Short Span
219116780|NCT06378502|DRUG|Amoxicillin Long|Long span
219116781|NCT01613820|DRUG|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
219116782|NCT01613820|DRUG|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
219116783|NCT05640076|OTHER|24/7 Telephonic Palliative Care Service availability|"Metropolitan Palliative Care Service-implemented 24/7 telephonic availability service for the patients, their relatives, the EMS and Primary Care physicians taking care of them.~After consultation, if the information and medical suggestions are not sufficient, an urgent ambulatory or home visit could be planned."
219116784|NCT00573950|DRUG|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
219116785|NCT00573950|DRUG|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
219116786|NCT00245596|DRUG|sildenafil|
219116787|NCT01388374|OTHER|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
219702899|NCT06293248|OTHER|musical application|Rast, Acemasiran, and Huseyni from Classical Turkish Music modes were optionally offered to the patients in the music group, and the patient's preferred music was listened to through headphones for 15-20 minutes before the CAG procedure. Following the interviews, musical genres were arranged as instrumental, without words, at 70 decibels in terms of rhythm and duration, at approximately 60 metronomes per minute, and were played according to the person's preference. Instrumental music was loaded onto the portable MP3 player provided by the researchers.
219702900|NCT06106256|DEVICE|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
219702901|NCT06106256|OTHER|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
219702902|NCT06106256|OTHER|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
219116788|NCT05586191|OTHER|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
219225271|NCT05036434|DRUG|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
219225272|NCT03695549|PROCEDURE|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
219702903|NCT06217302|DRUG|Sotagliflozin|Oral sotagliflozin (200 mg per day)
219702904|NCT06217302|DRUG|Placebo|Inactive tablets identical to sotagliflozin tablets
219702905|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
219702906|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
219116789|NCT05586191|OTHER|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
219702907|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
219116790|NCT03373474|OTHER|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
219116791|NCT03373474|OTHER|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
219116792|NCT00002214|DRUG|Capravirine|
219702908|NCT06271590|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
219116793|NCT03685708|BIOLOGICAL|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
219116794|NCT01300559|DEVICE|Tissuelink device|Tissuelink device plus Unipolar electrocautery
219116795|NCT03565770|OTHER|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
219116796|NCT03565770|OTHER|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
219116797|NCT00936494|PROCEDURE|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
219702909|NCT06271590|DEVICE|Drug eluting stents (DES)|For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
219702910|NCT06015490|OTHER|Sucrose drink|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
219702911|NCT06015490|OTHER|Glucose drink|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
219702912|NCT06015490|OTHER|Fructose drink|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
219116798|NCT00065416|PROCEDURE|massage|
219225273|NCT03695549|PROCEDURE|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
219702913|NCT05579015|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
219702914|NCT05579015|OTHER|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
219702915|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 1|A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.
219702916|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 2|A Flu mRNA vaccine composition in combination with Dose 2 of a COVID-19 component will be administered.
219702917|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal mRNA|An investigational mRNA Flu Seasonal vaccine will be administered.
219702918|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 1|Dose 1 of an investigational mRNA COVID-19 vaccine will be administered.
219702919|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 2|Dose 2 of an investigational mRNA COVID-19 vaccine will be administered.
219702920|NCT06680375|COMBINATION_PRODUCT|Licensed Flu Seasonal|A licensed Flu Seasonal vaccine will be administered.
219702921|NCT06680375|COMBINATION_PRODUCT|Licensed COVID-19 mRNA|A licensed mRNA COVID-19 vaccine will be administered.
219702922|NCT06680375|DRUG|Placebo|A placebo will be administered.
219702923|NCT04340076|DRUG|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
219702924|NCT04340076|DRUG|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
219702925|NCT04340076|DRUG|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
219702926|NCT04340076|DRUG|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
219116799|NCT05188391|DIAGNOSTIC_TEST|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
219702927|NCT04340076|DRUG|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
219702928|NCT04340076|DRUG|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
219702929|NCT04340076|DRUG|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
219702930|NCT05519254|DIETARY_SUPPLEMENT|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
219702931|NCT05519254|DIETARY_SUPPLEMENT|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
219702932|NCT05519254|COMBINATION_PRODUCT|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
219702933|NCT05519254|OTHER|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
219702934|NCT06510504|DRUG|225 mg BNC210|225 mg BNC210
219702935|NCT06510504|DRUG|Placebo|Placebo
219702936|NCT06850922|DRUG|RO7446603|Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.
219702937|NCT06850922|DRUG|Aflibercept|Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.
219702938|NCT06850922|DRUG|Faricimab|Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.
219702939|NCT01739140|BEHAVIORAL|Yoga|
219702940|NCT04352673|DIAGNOSTIC_TEST|Elbow flexion and extension strength measurements using a hand-held dynamometer|Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
219702941|NCT02283879|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
219702942|NCT00997945|DRUG|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
219702943|NCT05605353|DIAGNOSTIC_TEST|Faecal microbiota sampling and blood sampling|There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
219116800|NCT04773574|DEVICE|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
219116801|NCT01286974|DRUG|[14C]linifanib|\[14C\]linifanib, single administration, oral liquid
219116802|NCT01286974|DRUG|ABT-869, linifanib|linifanib once a day (QD), oral tablet
219116803|NCT04006366|BEHAVIORAL|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
219116804|NCT05313893|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
219116805|NCT01080196|BEHAVIORAL|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
219116806|NCT03988374|DRUG|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
219116807|NCT05743192|OTHER|Stop performing an antibiotic susceptibility test|Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
219225274|NCT04284085|OTHER|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
219702944|NCT00471497|DRUG|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
219702945|NCT00471497|DRUG|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
219702946|NCT05074901|BEHAVIORAL|digital behavioral intervention|interaction with a conversational agent to implement physical and cognitive programs
219702947|NCT04163874|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
219702948|NCT04163874|DRUG|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
219702949|NCT04163874|DRUG|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
219702950|NCT04163874|DEVICE|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
219702951|NCT06492629|DRUG|Toripalimab|Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
219702952|NCT06492629|DRUG|chidamide|Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
219702953|NCT03904654|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
219225275|NCT02447666|DRUG|Azacitidine|
219702954|NCT02339688|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
219702955|NCT02243657|DRUG|ASP3652|oral
219702956|NCT02243657|DRUG|Placebo|oral
219702957|NCT00605020|DRUG|insulin detemir|
219702958|NCT00605020|DRUG|insulin aspart|
219702959|NCT00605020|DEVICE|biphasic insulin aspart|
219702960|NCT01631942|DRUG|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
219702961|NCT04334369|DEVICE|Proclear Single Vision Contact Lenses manufactured by CooperVision|FDA approved single vision contact lenses.
219225276|NCT01030263|OTHER|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
219225277|NCT01030263|OTHER|Random four-quadrant biopsies.|Random four-quadrant biopsies.
219702962|NCT04334369|DEVICE|Proclear Multifocal Contact Lenses manufactured by CooperVision|FDA Approved Multifocal Contact Lenses
219702963|NCT04926168|OTHER|Delay of TMZ|Delay of TMZ to analyze the current standard of care practice of prescribing TMZ post combination (RT and TMZ).
219702964|NCT04926168|OTHER|Standard of Care (SOC) Adjuvant TMZ (no intervention|SOC in Adjuvant Setting no intervention
219116808|NCT02698280|DRUG|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
219116809|NCT02698280|DRUG|Nimustine|Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
219225278|NCT03338166|OTHER|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
219225279|NCT06263673|DRUG|Sitagliptin|100 mg once daily, oral
219225280|NCT06263673|DRUG|Dapagliflozin|10 mg once daily, oral
219225281|NCT06263673|DRUG|Placebo|Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
219225282|NCT01455948|DEVICE|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
219702965|NCT00003858|DRUG|mitoxantrone hydrochloride|
219702966|NCT00392223|DRUG|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
219702967|NCT00392223|DRUG|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
219702968|NCT00392223|DRUG|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
219702969|NCT00392223|DRUG|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
219702970|NCT03332537|BEHAVIORAL|Personalized IBS Pain SM|
219702971|NCT01492959|DRUG|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
219702972|NCT01763229|PROCEDURE|transthoracic echocardiography|
219702973|NCT03966066|DRUG|erythromycin|3-5mg/kg.d orally for 6 months
219116810|NCT06395077|DIAGNOSTIC_TEST|CBCT low-dose protocol|The patient underwent two CBCT examinations (Accuitomo 170; J Morita Corp., Kyoto, Japan): one examination followed the clinical standard-dose protocol (exposure settings: 90 kV, 5 mA, and 9.4 s), and one, the low-dose protocol (90 kV, 2 mA, 9.4 s).
219116811|NCT01151982|BEHAVIORAL|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
219116812|NCT03767478|DEVICE|Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
219225283|NCT01455948|PROCEDURE|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
219702974|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
219702975|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
219702976|NCT04683575|DRUG|Selenium Yeast|oral medication
219702977|NCT04683575|DRUG|Placebo|oral medication
219702978|NCT01991795|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
219702979|NCT01991795|DRUG|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
219702980|NCT03318458|OTHER|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
219702981|NCT06024460|PROCEDURE|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
219702982|NCT06024460|PROCEDURE|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
219702983|NCT04618913|DRUG|Apixaban|Anticoagulant
219116813|NCT03767478|DEVICE|Sham Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
219116814|NCT03887104|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
219116815|NCT05674968|BEHAVIORAL|Managing Challenging Behaviors in ADHD; Psychosocial program|MCB-ADHD is a brief Behavioral Parent Training (BPT) program delivered to caregivers and children together. THe researchers have specially designed this program to be flexible so that it can be delivered over telehealth and/or in-person. All sessions are guided by web-based tool to provide parent support materials and direct the work to be completed in session. MCB-ADHD combines brief BPT skills modules adapted from an established evidence-based BPT called Helping the Noncompliant Child (HNC; McMahon \& Forehand, 2003) with high quality psychoeducation and advocacy training that were developed by the investigators specifically for use in this project. Families receive 4 sessions adapted from HNC focused on behavior management and 2 sessions focused on education and empowerment.
219225284|NCT00630500|DRUG|Memantine|Tablets, 5 or 10 mg, twice daily
219225285|NCT00630500|DRUG|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
219225286|NCT00407888|DRUG|doxorubicin hydrochloride|Given IV
219225287|NCT00407888|DRUG|cyclophosphamide|Given orally
219225288|NCT00407888|BIOLOGICAL|filgrastim|Given SC
219225289|NCT00407888|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219225290|NCT00407888|BIOLOGICAL|trastuzumab|Given IV
219225291|NCT00407888|OTHER|laboratory biomarker analysis|Correlative studies
219225292|NCT00407888|PROCEDURE|quality-of-life assessment|Ancillary studies
219225293|NCT03187548|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
219225294|NCT02941692|DRUG|Oxytocin|
219225295|NCT02941692|DRUG|Placebo|Placebo for Oxytocin
219225296|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2.5 grams
219225297|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
219116816|NCT00627042|BIOLOGICAL|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
219702984|NCT04618913|DRUG|Rivaroxaban|Anticoagulant
219702985|NCT04618913|DRUG|Edoxaban|Edoxaban
219225298|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
219702986|NCT04618913|DRUG|Dabigatran|Dabigatran
219702987|NCT04618913|DRUG|VKA|Vitamin K antagonist
219116817|NCT02268552|DRUG|branaplam|
219116818|NCT04266990|OTHER|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
219116819|NCT04266990|OTHER|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
219116820|NCT04266990|OTHER|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
219116821|NCT02728518|DRUG|Nebulized Amikacin|400mg twice daily nebulized amikacin
219116822|NCT02728518|DRUG|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
219116823|NCT04916899|DRUG|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
219116824|NCT05506267|DEVICE|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
219360895|NCT06265844|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219702988|NCT04618913|DRUG|LMWH|Low Molecular Weight Heparin
219116825|NCT04121221|DRUG|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
219116826|NCT04121221|OTHER|Placebo|IM injection once every 4 weeks
219116827|NCT00000836|DRUG|Sevirumab|
219116828|NCT00146211|DRUG|Ethyl-EPA (Miraxion™)|
219116829|NCT02375763|OTHER|Software instruction|
219702989|NCT03854110|DRUG|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
219702990|NCT06472739|DRUG|GM-CSF|GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase
219702991|NCT03989544|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
219702992|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole"
219702993|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade
219116830|NCT03692988|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
219702994|NCT04896671|BEHAVIORAL|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
219702995|NCT01413802|PROCEDURE|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
219702996|NCT02644746|DEVICE|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
219702997|NCT02644746|DEVICE|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
219702998|NCT02323243|DEVICE|"Allium  Bulbar Urethral Stent  (BUS) system"|
219702999|NCT06472622|DEVICE|Thermal Pain Stimulation|Thermal pain will be administered during fMRI neuroimaging via a thermal stimulation device (Medoc Ltd., Advanced Medical System, Israel; 510K: K052357; K041908; K922052) to examine brain activity corresponding to the experience of this stimulus. This device and associated system carries an FDA 510 (K) clearance.
219703000|NCT06472622|DEVICE|Physical Effort Stimulation|Physical effort will be administered during fMRI neuroimaging via a hand dynamometer attachment for a physiological monitoring system (BIOPAC Systems, Inc., Goleta, CA, USA) to examine brain activity corresponding to the experience of this stimulus. This device has not received pre-marked approval or 510 (K) clearance by the FDA.
219703001|NCT06301438|DRUG|dalpiciclib|dalpiciclib oral day 1-21, every 28 days
219116831|NCT01154036|DRUG|ezetimibe 10 mg|
219116832|NCT01154036|DRUG|atorvastatin|
219116833|NCT01154036|DRUG|Comparator: rosuvastatin|
219116834|NCT00583180|DRUG|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
219116835|NCT06352515|DIAGNOSTIC_TEST|Flow cytometry|flow cytometry to study distribution of T lymphocyte subsets in ulcerative colitis patients
219360931|NCT01418001|DRUG|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
219116836|NCT00623415|DRUG|Flupirtine|300 mg daily (divided in two doses)
219116837|NCT00623415|DRUG|Placebo|twice daily
219116838|NCT00165620|DRUG|Iomeprole|
219116839|NCT05679700|OTHER|Rigid Taping|Rigid taping was applied to stroke patients with knee hyperextension.
219116840|NCT01537653|DRUG|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
219360932|NCT02027740|DIETARY_SUPPLEMENT|almond|
219116841|NCT01537653|DRUG|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
219116842|NCT00997243|BIOLOGICAL|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
219116843|NCT00997243|DRUG|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
219116844|NCT06048874|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
219116845|NCT06048874|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
219116846|NCT06048874|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
219116847|NCT01985698|PROCEDURE|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
219116848|NCT01985698|PROCEDURE|Laparoscopic resection|Laparoscopic abdominoperineal resection
219116849|NCT03069794|DIAGNOSTIC_TEST|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
219116850|NCT02602249|BIOLOGICAL|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
219116851|NCT02602249|BIOLOGICAL|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
219116852|NCT03641833|DIAGNOSTIC_TEST|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
219116853|NCT03756779|OTHER|Dietary intervention|Dietary intervention with dietary modification of fat intake.
219116854|NCT01842243|PROCEDURE|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
219116855|NCT01842243|PROCEDURE|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
219116856|NCT01842243|DEVICE|Pacemaker|MR conditional Pacemaker implanted in all study patients
219116857|NCT00321477|DRUG|GW679769 oral tablets|
219116858|NCT04499742|RADIATION|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
219116859|NCT01349907|DRUG|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
219225299|NCT05654285|OTHER|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
219225300|NCT05654285|OTHER|Cola beverage with sucrose and stevia|
219225301|NCT00490789|DRUG|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
219116860|NCT01349907|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
219116861|NCT02557906|PROCEDURE|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
219116862|NCT02557906|PROCEDURE|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
219116863|NCT02557906|PROCEDURE|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
219116864|NCT02460081|DRUG|PDA-002|
219116865|NCT02460081|DRUG|Placebo|
219116866|NCT03993899|DEVICE|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
219116867|NCT00344370|DRUG|Pitavastatin|Pitavastatin 4 mg QD
219116868|NCT00344370|DRUG|Atorvastatin|Atorvastatin 40 mg
219225302|NCT03049332|BEHAVIORAL|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
219703002|NCT03344757|BEHAVIORAL|Cultural CBSM|The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
219116869|NCT03226457|DRUG|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
219116870|NCT03226457|DRUG|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
219703003|NCT03344757|BEHAVIORAL|Standard CBSM|The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
219116871|NCT03226457|DRUG|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
219116872|NCT03413358|DRUG|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
219116873|NCT03413358|DRUG|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
219116874|NCT04980235|DIAGNOSTIC_TEST|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
219116875|NCT05886686|DEVICE|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
219116876|NCT00739635|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
219116877|NCT00739635|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo
219116878|NCT03583541|BEHAVIORAL|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
219703004|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
219703005|NCT04511013|DRUG|Binimetinib|Given PO
219703006|NCT04511013|DRUG|Encorafenib|Given PO
219703007|NCT04511013|BIOLOGICAL|Ipilimumab|Given IV
219116879|NCT03583541|BEHAVIORAL|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
219225303|NCT02865785|DRUG|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
219703008|NCT04511013|BIOLOGICAL|Nivolumab|Given IV
219703009|NCT06119854|BEHAVIORAL|Attitudinal inoculation|A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
219116880|NCT03583541|BEHAVIORAL|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
219116881|NCT03583541|BEHAVIORAL|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (\~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
219225304|NCT02865785|DRUG|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
219225305|NCT05939505|OTHER|Su Jok therapy|Sujok therapy will be applied with Mexican bean seeds 14 times with an interval of one day.
219703010|NCT06119854|BEHAVIORAL|Cognitive-behavioral therapy-informed intervention|A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
219116882|NCT05316168|DRUG|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
219116883|NCT05316168|DRUG|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
219116884|NCT05316168|PROCEDURE|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
219116885|NCT05316168|DRUG|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
219116886|NCT01541618|OTHER|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
219116887|NCT04102540|OTHER|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
219116888|NCT03507829|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
219703011|NCT06119854|BEHAVIORAL|Conventional public health messaging|A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
219703012|NCT04887688|DEVICE|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
219703013|NCT06473532|BEHAVIORAL|TEXT4HF|In addition to usual care, participants in the intervention group will receive 5 TMs/week for 12 weeks at a time of their preference. Tailoring of the TMs is performed based on participants' responses to validated questionnaires (health beliefs scales, HF-knowledge scale, and self-efficacy about HF self-care scale), administered at baseline and 4 weeks. They will also receive an AHA HF discharge informational packet.
219703014|NCT06968637|OTHER|care recommendations|Provision of specific care recommendations for diabetes management. Based on existing guidelines, when any DR is present, the PIS will prompt diabetologists to check, and if necessary, change medicines to optimize, blood sugar, blood pressure and lipids.
219116889|NCT03507829|DRUG|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
219116890|NCT03507829|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
219116891|NCT00649974|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
219116892|NCT00649974|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
219116893|NCT02460471|RADIATION|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
219225306|NCT05939505|OTHER|placebo|Instead of the Mexican bean seed applied in sujok therapy, plastic beans will be applied 14 times with an interval of one day.
219225307|NCT05939505|OTHER|routine interventions|routine applications in the hemodialysis unit
219225308|NCT01607320|DRUG|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
219703015|NCT06194825|DRUG|Eplontersen|Eplontersen by subcutaneous injection
219703016|NCT06194825|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
219703017|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
219703018|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
219703019|NCT05135091|PROCEDURE|Sham Comparator|Sham Comparator
219703020|NCT03958877|DRUG|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
219703021|NCT03958877|DRUG|Interferon beta type 1a|Administered as specified in the treatment arm
219703022|NCT06851533|PROCEDURE|Standard Analgesia (No Block)|Participants receive standard perioperative analgesia (including intravenous paracetamol/tramadol), but no additional regional block is applied.
219703023|NCT06851533|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) Block|In addition to standard perioperative analgesia, a TLIP block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the thoracolumbar fascial plane, and spread is confirmed via ultrasound.
219703024|NCT06851533|PROCEDURE|Quadro Iliac Plane Block|In addition to standard perioperative analgesia, a Quadro Iliac Plane Block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the quadro iliac plane at the level of the iliac crest, and spread is confirmed via ultrasound.
219703025|NCT05942885|OTHER|anxiety questionnaire|Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
219225309|NCT01607320|DRUG|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
219225310|NCT03784898|OTHER|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
219703026|NCT06395012|DRUG|LY3985297|Administered either IV or SC.
219703027|NCT06395012|DRUG|Placebo|Administered either IV or SC.
219703028|NCT06061952|BEHAVIORAL|Customized Adherence Enhancement for Schizophrenia (CAE-S)|6-session series spaced out over approximately 6-10 weeks
219703029|NCT06061952|OTHER|Enhanced Treatment as Usual (eTAU)|eTAU participants will view a pre-taped series of 6 videos
219703030|NCT06970080|DRUG|Inhaled corticosteroid (ICS)|In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.
219360933|NCT00374803|DRUG|Mycophenolic Acid (Myfortic)|"* Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
219703031|NCT06970080|DRUG|Oral Corticosteroid (OCS)|In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.
219116894|NCT05140174|OTHER|Radical Healing and Internalized Stigma (RHIS) Training|8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
219116895|NCT05220124|DRUG|Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
219116896|NCT06363435|DEVICE|AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans|Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients
219703032|NCT06554665|BEHAVIORAL|High-intensity Interval Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
219703033|NCT06554665|BEHAVIORAL|Moderate-Intensity Continuous Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
219703034|NCT06554665|BEHAVIORAL|Stretching|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
219703035|NCT05787574|DRUG|Emapalumab|Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
219703036|NCT05787574|DRUG|Fludarabine and Dexamethasone|Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
219225311|NCT02320097|OTHER|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
219225312|NCT01198314|PROCEDURE|immunosuppression withdrawal|tapering off immunosuppressant
219225313|NCT01198314|PROCEDURE|continue of taking immunosuppressant|maintain immunosuppression
219703037|NCT05787574|PROCEDURE|Stem Cell Transplant|Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
219703038|NCT06971445|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (PUFA n-3)|1280 mg of omega-3 polyunsaturated fatty acids (650mg EPA, 450mg DHA, and 179mg ALA) per day for 8 weeks
219703039|NCT06971445|DIETARY_SUPPLEMENT|Olive oil (placebo)|Softgels containing extra virgin olive oil, with a similar appearance to the experimental group, were given to participants for 8 weeks.
219703040|NCT06431841|DRUG|Atropine 0,025%|Atropine 0,025% (1 drop per day)
219703041|NCT06431841|DEVICE|DIMS Lenses|Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.
219703042|NCT06431841|DEVICE|Monofocal lenses|Use of monofocal lenses.
219703043|NCT05837195|DEVICE|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
219703044|NCT06666283|DRUG|AP303 150μg|AP303 Tablet 150μg QD
219703045|NCT06666283|DRUG|Placebo 150μg|Placebo Tablet 150μg QD
219703046|NCT06022354|DRUG|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
219703047|NCT06684990|OTHER|POC testing|POC testing for HbA1c and cystatin C
219703048|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
219116897|NCT04273503|BEHAVIORAL|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
219116898|NCT00001450|DRUG|paclitaxel|
219116899|NCT00001450|DRUG|cisplatin|
219225314|NCT04870788|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
219225315|NCT04870788|OTHER|Quality-of-Life Assessment|Ancillary studies
219225316|NCT04870788|OTHER|Questionnaire Administration|Ancillary studies
219225317|NCT04870788|OTHER|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program together or separately, depending on their preference, as in Group I beginning 12 weeks after starting the study and completing the third study visit.
219225318|NCT01263522|OTHER|different training programs|two different endurance programs and one strength endurance program
219225319|NCT01263522|OTHER|control condition|unchanged lifestyle
219703049|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
219703050|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
219703051|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg\*2 single dose
219225320|NCT01031056|PROCEDURE|Blood Draw|
219225321|NCT01031056|PROCEDURE|Frozen Tumor Specimens|
219225322|NCT01784744|OTHER|Hydroworx Pool at 98 degrees Fahrenheit|
219703052|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
219703053|NCT06020508|DEVICE|Group 1 - Lumoptik BrightPoint Epidural Device|Participants will undergo a neuraxial procedure to measure loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device.
219703054|NCT01581450|DRUG|Nitrous Oxide|35%
219703055|NCT01581450|DRUG|Nitrous Oxide|50%
219703056|NCT03104374|DRUG|Placebo|Oral tablet
219703057|NCT03104374|DRUG|Upadacitinib|Oral tablet
219703058|NCT06079424|OTHER|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
219116900|NCT05950048|OTHER|The web-based breastfeeding counseling|To the web-based breastfeeding counseling/experimental group (n =33), during the first 6 months after birth, they will be directed to the web-based breastfeeding consultancy website. On this page, mothers will receive counseling on breastfeeding (written, visual, audio materials and telephone counseling) from birth. In addition, the Web-based breastfeeding counseling/experimental group will fill out data collection forms in the first 24 hours, 1st, 2nd, 4th and 6th months after delivery.
219116901|NCT02244593|OTHER|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
219116902|NCT03113162|BIOLOGICAL|Autologous Hematopoietic Stem Cell|
219703059|NCT04210284|DIETARY_SUPPLEMENT|Ensure|"Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~* 160 Calories, 20 from fat~* 2g Total fat~* 0.5g Saturated fat~* 20mg Cholesterol~* 135mg Sodium~* 170mg Potassium~* 19g Total carbohydrate~* \<1g Fiber~* 4g Sugar~* 16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables"
219703060|NCT05899023|OTHER|Telehealth Bridge Visits|Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
219703061|NCT05899023|OTHER|Standard of Care|Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
219116903|NCT03113162|DRUG|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
219116904|NCT04079374|DRUG|Etanercept|Subcutaneous injections
219116905|NCT04079374|DRUG|Enbrel|Subcutaneous injections
219116906|NCT01821443|OTHER|Stereotactic radiosurgery (SRS)|"Dose \& prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% \[maximum=100%\]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
219703062|NCT03686124|BIOLOGICAL|IMA203 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
219703063|NCT03686124|BIOLOGICAL|IMA203 product- flat dose|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
219225323|NCT01784744|OTHER|Hydroworx Pool at 102 degrees Fahrenheit|
219225324|NCT03475264|DIAGNOSTIC_TEST|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
219703064|NCT03686124|BIOLOGICAL|IMA203CD8 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
219703065|NCT03686124|DRUG|Nivolumab|Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
219703066|NCT03686124|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
219703067|NCT04233866|DRUG|Fluorouracil|Given IV
219703068|NCT04233866|DRUG|Gemcitabine|Given IV
219116907|NCT00479037|DRUG|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
219116908|NCT00479037|DRUG|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
219116909|NCT05655481|OTHER|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
219116910|NCT05655481|OTHER|Health education|Telehealth and guidelines for the practice of physical activity and health education
219703069|NCT04233866|DRUG|Gemcitabine Hydrochloride|Given IV
219703070|NCT04233866|DRUG|Leucovorin|Given IV
219703071|NCT04233866|DRUG|Leucovorin Calcium|Given IV
219703072|NCT04233866|DRUG|Liposomal Irinotecan|Given IV
219703073|NCT04233866|DRUG|Nab-paclitaxel|Given IV
219703074|NCT04233866|OTHER|Quality-of-Life Assessment|Ancillary studies
219703075|NCT04233866|OTHER|Questionnaire Administration|Ancillary studies
219703076|NCT06105749|DEVICE|contrast-enhanced mammography|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
219116911|NCT00280293|DRUG|Lamotrigine|Lamotrigine
219225325|NCT04826211|DIAGNOSTIC_TEST|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
219703077|NCT04802057|DRUG|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
219116912|NCT00280293|DRUG|Placebo|Placebo
219116913|NCT02158624|DRUG|Intravitreal Lucentis 0.5mg|
219116914|NCT00588003|DRUG|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
219116915|NCT00588003|OTHER|Placebo|No medication before surgery
219116916|NCT05350085|DRUG|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
219116917|NCT05350085|DRUG|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
219116918|NCT00178022|BEHAVIORAL|Case management and problem solving therapy|
219116919|NCT01375712|DIETARY_SUPPLEMENT|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of Lactobacillus casei strain Shirota.
219116920|NCT01375712|DIETARY_SUPPLEMENT|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
219116921|NCT06302790|OTHER|Molli Suit Apply|Exopulse Mollii Suit is a neuromodulation application that has been extensively evaluated and is a reliable technique in patients with spasticity. Unlike many neurostimulation techniques that focus only on symptomatic muscles, Suit relieves spasticity and associated pain by stimulating the weakened antagonist of the spastic muscle. Its wearable structure is designed to manage spasticity and associated pain in both upper and lower extremities.
219116922|NCT03012217|OTHER|Observational Study|
219116923|NCT04450433|DIAGNOSTIC_TEST|aortic dissection and healthy people|Differential expression of metabolites in patients with aortic dissection and healthy people
219116924|NCT02834715|DIETARY_SUPPLEMENT|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
219116925|NCT03252678|OTHER|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
219116926|NCT03252678|OTHER|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
219116927|NCT01273649|DEVICE|cryotherapy|cryotherapy is given with other physical training
219116928|NCT01458249|DRUG|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
219116929|NCT01824082|DRUG|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
219116930|NCT05993871|DIAGNOSTIC_TEST|Clinical Evaluation/Questionnaires|Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
219116931|NCT05993871|DIAGNOSTIC_TEST|Nerve Conduction Study|Routine Nerve Conduction Study.
219703078|NCT04622345|DRUG|VSJ-110|ophthalmic solution
219116932|NCT05993871|DIAGNOSTIC_TEST|Small fiber electrodiagnostic tests|R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
219703079|NCT04622345|DRUG|Placebo|ophthalmic solution
219703080|NCT04047264|PROCEDURE|Microdialysis|Undergo microdialysis
219703081|NCT04047264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219703082|NCT06622187|DRUG|Desmopressin (DDAVP)|Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
219703083|NCT06622187|DRUG|Sodium Chloride|Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
219703084|NCT04931342|DRUG|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
219116933|NCT05993871|DIAGNOSTIC_TEST|Nerve Ultrasound|Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
219116934|NCT05993871|DIAGNOSTIC_TEST|Skin Biopsy|distal leg 3mm punch skin biopsy
219116935|NCT02116140|OTHER|[C11]Acetate and HED PET|
219703085|NCT04931342|DRUG|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
219116936|NCT01348854|DEVICE|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
219703086|NCT04931342|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
219703087|NCT04931342|DRUG|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
219703088|NCT04931342|DRUG|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
219703089|NCT04931342|DRUG|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
219116937|NCT04583319|DIAGNOSTIC_TEST|EasyCov POC|Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
219116938|NCT01345461|DEVICE|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
219116939|NCT04798105|BEHAVIORAL|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
219116940|NCT03366883|COMBINATION_PRODUCT|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
219703090|NCT04931342|DRUG|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
219703091|NCT04931342|DRUG|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
219703092|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
219703093|NCT04931342|DRUG|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
219703094|NCT04931342|DRUG|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
219703095|NCT04931342|DRUG|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
219703096|NCT04931342|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
219703097|NCT04931342|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
219703098|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
219703099|NCT04270838|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
219703100|NCT04270838|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
219116941|NCT03366883|RADIATION|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
219116942|NCT06364319|DRUG|anti-CD25 rhMAb|1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
219116943|NCT06364319|DRUG|Prednisone|Maintain pre-screening dose
219116944|NCT06364319|DRUG|Ruxolitinib|10mg, BID PO
219116945|NCT06364319|DRUG|Cyclosporine|1.25mg/kg, BID PO/IV, target:150-250ng/ml
219360934|NCT04280354|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
219360935|NCT04280354|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
219703101|NCT06973863|DRUG|PEP08|PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.
219703102|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
219703103|NCT06455449|OTHER|Placebo|Matched placebo delivered subcutaneously, once weekly for 52 weeks
219703104|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
219703105|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
219703106|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
219703107|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
219703108|NCT02330952|DRUG|Prednisone|40mg/day per os for 5 days
219703109|NCT02330952|DRUG|Placebo|40mg/day per os for 5 days
219703110|NCT05012124|OTHER|Collaborative care|Receive u-CoCM
219703111|NCT05012124|OTHER|Interview or Focus Group|Participate in an interview or focus group
219703112|NCT05012124|OTHER|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
219703113|NCT05012124|OTHER|Survey Administration|Complete surveys
219703114|NCT05678738|DIETARY_SUPPLEMENT|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
219703115|NCT05678738|OTHER|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
219116946|NCT05015777|OTHER|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
219116947|NCT05452629|BEHAVIORAL|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
219116948|NCT05452629|BEHAVIORAL|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
219116949|NCT04463043|DEVICE|SelfBACK app|The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
219703116|NCT05678738|DIETARY_SUPPLEMENT|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
219703117|NCT04393701|PROCEDURE|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
219703118|NCT05385497|OTHER|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
219703119|NCT05385497|DEVICE|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
219703120|NCT04421573|PROCEDURE|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
219703121|NCT04421573|PROCEDURE|Waiting period with usual care|Same as previous group description
219703122|NCT05370391|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
219703123|NCT03207997|OTHER|unenhanced MR sequences|2 additional unenhanced MR sequences
219703124|NCT06279013|OTHER|Counseling|Receive TIPC
219703125|NCT06279013|BEHAVIORAL|Health Education|Receive handbook
219703126|NCT06279013|OTHER|Interview|Ancillary studies
219703127|NCT06279013|OTHER|Medical Chart Review|Ancillary studies
219703128|NCT06279013|OTHER|Monitoring|Receive IVR symptom monitoring
219703129|NCT06279013|OTHER|Questionnaire Administration|Ancillary studies
219703130|NCT01316718|DRUG|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
219703131|NCT01316718|DRUG|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
219703132|NCT02970383|BEHAVIORAL|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
219703133|NCT02970383|BEHAVIORAL|Inital prescription for 30 narcotic tabs|
219703134|NCT02121210|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
219703135|NCT02664675|PROCEDURE|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
219703136|NCT02664675|PROCEDURE|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
219703137|NCT04108078|BEHAVIORAL|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
219703138|NCT04108078|BEHAVIORAL|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
219703139|NCT04108078|BEHAVIORAL|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
219703140|NCT04405336|DRUG|tab block|injection of tab block to women who are doing cs
219703141|NCT04405336|DRUG|PCA|giving women PCA
219703142|NCT04405336|DRUG|women who will not receive tab block or PCA|no tab block or PCA will be given
219703143|NCT04054401|DEVICE|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
219360936|NCT00446914|BEHAVIORAL|Systems Change (High Blood Pressure Strategy)|
219703144|NCT00909870|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
219703145|NCT00909870|DEVICE|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
219703146|NCT03070873|DEVICE|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
219116950|NCT04463043|OTHER|e-Help webpage|The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
219116951|NCT04463043|OTHER|Usual care|Usual care refers to seeking care or receiving treatments or help as usual.
219116952|NCT06396390|DRUG|Progestin|In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
219116953|NCT06396390|DRUG|GnRH antagonist|In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
219116954|NCT00514072|BIOLOGICAL|BCG vaccine|given intradermally
219225326|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
219225327|NCT03665532|BEHAVIORAL|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
219703147|NCT03070873|DEVICE|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
219703148|NCT03070873|PROCEDURE|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
219703149|NCT02923765|OTHER|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
219703150|NCT03043196|DRUG|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
219703151|NCT03043196|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
219703152|NCT02590458|PROCEDURE|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
219703153|NCT02590458|BEHAVIORAL|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
219703154|NCT00000320|DRUG|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
219703155|NCT02102555|DRUG|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
219703156|NCT02102555|DRUG|placebo|placebo (IV normal saline)
219703157|NCT00053625|PROCEDURE|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
219116955|NCT00514072|BIOLOGICAL|prostate cancer vaccine ONY-P1|given intradermally
219116956|NCT00514072|OTHER|placebo|given intradermally
219116957|NCT04011384|BEHAVIORAL|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
219116958|NCT01094171|BIOLOGICAL|Poliorix TM|Intramuscular administration, 3 doses
219116959|NCT01094171|BIOLOGICAL|Infanrix TM|Intramuscular administration, 3 doses
219225328|NCT01989793|DRUG|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
219225329|NCT01989793|DRUG|Placebo|Placebo will be given to those in placebo arm
219225330|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
219703158|NCT01232283|DRUG|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
219703159|NCT01232283|DRUG|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
219703160|NCT01232283|OTHER|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
219703161|NCT03728569|OTHER|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
219703162|NCT03728569|OTHER|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
219703163|NCT03137810|PROCEDURE|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
219703164|NCT03137810|PROCEDURE|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
219703165|NCT01565213|BEHAVIORAL|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
219703166|NCT01565213|BEHAVIORAL|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
219703167|NCT01565213|BEHAVIORAL|CAU|Care as usual by the GPs
219703168|NCT01226329|BEHAVIORAL|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
219703169|NCT01226329|BEHAVIORAL|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
219116960|NCT06564025|BEHAVIORAL|Pilot program study|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
219703170|NCT06195644|DEVICE|Galvanic vestibular stimulation|galvanic current generated by Gymna DUO 200 and delivered through conductive medium (electrode gel) by two small carbon rubber electrodes 3 cm 2 each bilaterally over two mastoid processes for 30 minutes, two times per week for 12 weeks .
219703171|NCT06195644|DEVICE|MovAlyzeR® software from Neuroscript|MovAlyzeR® movement analysis software from Neuroscript turns a pen tablet or mouse into a high-quality system for examining movements by a pen, mouse or finger. Hence, it can train and analyze hand dexterity and handwriting using pen tablets such as sentence parameters.
219703172|NCT06195644|DEVICE|BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)|stationary upper body pedaling as a moderate intensity aerobic training
219116961|NCT06566482|DRUG|Dexmedetomidine-esketamine combination|Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
219116962|NCT06566482|DRUG|Placebo|Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
219116963|NCT04571632|DRUG|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
219116964|NCT04571632|DRUG|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
219116965|NCT04571632|DRUG|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
219116966|NCT04571632|OTHER|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
219116967|NCT05426382|DEVICE|A digital care solution for patients with NAFLD|A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
219116968|NCT06237868|DEVICE|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
219116969|NCT06237868|DEVICE|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
219116970|NCT00730301|PROCEDURE|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
219116971|NCT01676220|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
219116972|NCT01676220|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
219116973|NCT01250249|BIOLOGICAL|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
219116974|NCT00026637|DRUG|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
219116975|NCT00026637|BEHAVIORAL|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
219116976|NCT06344611|OTHER|Other|It is an observational study. Subjects will receive the treatment as per institute protocol.
219116977|NCT00422396|DRUG|Fenofibrate (drug)|
219703173|NCT02776566|OTHER|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
219703174|NCT01219023|DRUG|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
219703175|NCT04393649|OTHER|ESOGER|Questionnaire
219703176|NCT06477978|DIAGNOSTIC_TEST|Hand grip function testing|The use of Bio-impedance to measure the skeletal muscle mass
219116978|NCT02269943|DRUG|CC-486|
219116979|NCT03863899|PROCEDURE|Nerve block|drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
219116980|NCT03863899|PROCEDURE|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
219116981|NCT03863899|PROCEDURE|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
219116982|NCT03863899|DRUG|Additional intraoperative analgesia|Administration of any analgesics during the operation
219116983|NCT03863899|DRUG|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
219116984|NCT05535686|OTHER|Rheumatoid Arthritis|Rheumatoid Arthritis Disease (R.A)
219116985|NCT03527693|DEVICE|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
219116986|NCT00391456|BEHAVIORAL|Animal-assisted Therapy|
219116987|NCT04471883|PROCEDURE|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
219703177|NCT02986464|DEVICE|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
219703178|NCT02986464|OTHER|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
219703179|NCT03662412|DRUG|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
219703180|NCT02483884|DRUG|[68Ga]RM2|\[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
219703181|NCT02483884|PROCEDURE|PET/CT|Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min
219703182|NCT03068104|OTHER|No intervention|
219703183|NCT02203266|DEVICE|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
219703184|NCT02203266|BEHAVIORAL|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
219703185|NCT04773028|OTHER|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
219703186|NCT03122795|PROCEDURE|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
219703187|NCT01725672|DRUG|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703188|NCT01725672|DRUG|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703189|NCT01725672|DRUG|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703190|NCT01725672|DRUG|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703191|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703192|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703193|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703194|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
219703195|NCT01577797|BEHAVIORAL|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
219116988|NCT00003175|DRUG|fluorouracil|
219116989|NCT02628847|DRUG|sildenafil citrate|
219116990|NCT02628847|DRUG|Placebo|
219116991|NCT03706729|DEVICE|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
219116992|NCT00746317|DRUG|GC33|IV administration at 4 escalating dose levels.
219225331|NCT00361907|PROCEDURE|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
219703196|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
219116993|NCT06285617|DRUG|1-week predisone+1-week celecoxib|20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
219116994|NCT06285617|DRUG|6-weeks predisone|20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
219116995|NCT00372333|DRUG|IDEA-033|
219116996|NCT05286515|OTHER|Hybrid Peroperative PT|The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
219116997|NCT05286515|OTHER|Standard Clinical Practice PT|This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
219116998|NCT00649480|DRUG|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
219116999|NCT00649480|DRUG|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
219703197|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
219703198|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
219703199|NCT04405752|DEVICE|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
219703200|NCT04405752|DEVICE|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
219117000|NCT02213055|DRUG|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
219117001|NCT02213055|DRUG|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
219117002|NCT00747981|PROCEDURE|Thoracic CT Scan|Perform a CT Scan and an endoscopy
219117003|NCT00231894|DRUG|Pioglitazone|pioglitazone 30-45 mg/day
219117004|NCT00231894|BEHAVIORAL|Life style diet group|life style diet education group 1x/week
219117005|NCT00231894|OTHER|Placebo|placebo comparator capsules
219117006|NCT04268836|DEVICE|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
219117007|NCT02631083|OTHER|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
219117008|NCT02986828|DRUG|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
219117009|NCT02986828|DRUG|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
219117010|NCT02986828|DEVICE|Ultrasound|
219117011|NCT01531140|DRUG|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
219117012|NCT01531140|DRUG|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
219117013|NCT01531140|DRUG|Sennosides|Sennosides 1tbl/8kg for 2 days
219117014|NCT04447443|DIETARY_SUPPLEMENT|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
219703201|NCT01535924|DRUG|gemcitabine hydrochloride|Given IV
219703202|NCT01535924|DRUG|bendamustine hydrochloride|Given IV
219703203|NCT01737736|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
219703204|NCT04721418|RADIATION|11C-UCB-J|11C-UCB-J PET scan
219703205|NCT05916547|PROCEDURE|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
219703206|NCT00848497|DRUG|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
219703207|NCT00848497|OTHER|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
219703208|NCT00848497|DRUG|Viagra®|Viagra 25mg was the dose given to the patient which he started.
219703209|NCT03647592|DRUG|Erlotinib/Gefitinib combined with Bevacizumab|Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
219703210|NCT05149339|DRUG|Cholecalciferol 2800 I.U. ml oral drops|"(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3)."
219703211|NCT00469131|DRUG|tacrolimus + steroid|
219703212|NCT00469131|DRUG|tacrolimus + mycophenolate mofetil|
219703213|NCT02342626|BEHAVIORAL|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
219117015|NCT04447443|DIETARY_SUPPLEMENT|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
219117016|NCT06381635|DIETARY_SUPPLEMENT|Manuka honey mixed with aloe vera gel|a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
219117017|NCT02025205|DEVICE|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
219117018|NCT04239365|DIAGNOSTIC_TEST|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
219117019|NCT02153294|PROCEDURE|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
219117020|NCT02153294|PROCEDURE|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
219703214|NCT01990326|DRUG|XAF5 Gel|
219703215|NCT01990326|DRUG|Placebo Gel|
219703216|NCT00176449|DRUG|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
219703217|NCT00176449|DRUG|Placebo Oral Tablet|Comparable placebo
219703218|NCT04538508|DEVICE|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
219703219|NCT04538508|OTHER|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
219703220|NCT03406520|DEVICE|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
219703221|NCT02966834|DRUG|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
219703222|NCT02966834|DRUG|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
219117021|NCT04181541|PROCEDURE|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
219117022|NCT04181541|PROCEDURE|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
219117023|NCT03753217|DEVICE|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
219117024|NCT03375814|DRUG|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
219117025|NCT03375814|DRUG|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
219703223|NCT04929015|PROCEDURE|Biospecimen Collection - blood and tissue sample collection|The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
219703224|NCT04929015|OTHER|Electronic Health Record Review|Medical record reviewed
219703225|NCT02450643|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
219117026|NCT04415892|OTHER|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
219117027|NCT06320275|BEHAVIORAL|Storytelling Intervention|A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.
219117028|NCT04110873|DRUG|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
219117029|NCT04110873|DRUG|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
219117030|NCT04110873|DRUG|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
219117031|NCT00962663|DRUG|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
219117032|NCT00962663|DRUG|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
219117033|NCT00962663|DRUG|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
219117034|NCT00111254|PROCEDURE|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
219117035|NCT04575675|DRUG|Dapagliflozin|Dapagliflozin 10mg once daily
219117036|NCT04575675|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
219703226|NCT02450643|OTHER|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
219703227|NCT05858983|GENETIC|FT-001 Low Dose|Comparison of different dosages of FT-001
219703228|NCT05858983|GENETIC|FT-001 Mid Dose|Comparison of different dosages of FT-001
219703229|NCT05858983|GENETIC|FT-001 High Dose|Comparison of different dosages of FT-001
219703230|NCT00333528|DRUG|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
219703231|NCT00333528|DRUG|Placebo: Normal saline|Intramuscular administration
219703232|NCT01542762|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
219703233|NCT02344823|DRUG|Vardenafil|per oral intake of 10mg Vardenafil once daily
219703234|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
219703235|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
219703236|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
219703237|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
219117037|NCT04575675|DRUG|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
219117038|NCT04575675|DRUG|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
219117039|NCT04575675|DEVICE|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
219117040|NCT05181943|DEVICE|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
219117041|NCT05181943|DRUG|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
219117042|NCT00743743|DIETARY_SUPPLEMENT|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
219117043|NCT00743743|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo daily for 52 weeks
219117044|NCT05040490|DRUG|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
219117045|NCT05517720|OTHER|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
219703238|NCT02344823|DRUG|Placebo intake once daily|
219703239|NCT02600260|DRUG|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
219703240|NCT02600260|OTHER|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
219703241|NCT00094445|DRUG|Curcumin|Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
219703242|NCT01714115|DRUG|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
219703243|NCT04660045|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
219703244|NCT03962829|DRUG|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
219703245|NCT03962829|DRUG|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
219117046|NCT00114842|PROCEDURE|MR colonography|
219117047|NCT01767129|DRUG|AVP-923-45|One capsule twice daily for 14 days
219117048|NCT01767129|DRUG|Placebo|One capsule twice daily for 14 days
219117049|NCT02166086|PROCEDURE|Endoscopy|Endoscopy involving advanced imaging techniques
219117050|NCT00747773|DEVICE|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
219117051|NCT04165161|DIAGNOSTIC_TEST|search for a patent foramen ovale|Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
219117052|NCT03308903|DIAGNOSTIC_TEST|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
219703246|NCT05981846|BIOLOGICAL|BIMERVAX|One dose of booster vaccine
219117053|NCT01471067|DRUG|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
219117054|NCT01471067|DRUG|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
219117055|NCT01471067|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
219225332|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
219703247|NCT05981846|BIOLOGICAL|SIIV|One dose
219703248|NCT04368169|DIETARY_SUPPLEMENT|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
219703249|NCT04368169|OTHER|Placebo|Emulsifier carrier without active supplement ingredients.
219703250|NCT03665870|BEHAVIORAL|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
219703251|NCT00117416|PROCEDURE|controlling the MAP|
219703252|NCT00769561|BEHAVIORAL|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
219703253|NCT00769561|DEVICE|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
219703254|NCT01773928|BIOLOGICAL|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
219703255|NCT01773928|BIOLOGICAL|VCIV manufactured with the current manufacturing process (VCIV current)|
219703256|NCT01773928|BIOLOGICAL|Fluzone®, licensed trivalent influenza vaccine (TIV)|
219703257|NCT03092752|DRUG|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
219703258|NCT00217945|BEHAVIORAL|Shared-Decision Making|
219703259|NCT04499703|DEVICE|RHMS-RTM|Assessment of retinal thickness
219703260|NCT04499703|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure
219703261|NCT00792285|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
219703262|NCT05745623|DRUG|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
219703263|NCT03974464|DIAGNOSTIC_TEST|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
219703264|NCT06819891|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
219703265|NCT06819891|DRUG|Placebo|Placebo matching IV afimkibart.
219703266|NCT06818825|BEHAVIORAL|Automated interactive messages|High ED utilizers will be sent SMS text messages guiding them through ED-alternative resources, with different guidance (including a follow-up phone call from a healthcare worker) depending on patient responses.
219703267|NCT06818825|BEHAVIORAL|Live outreach|High ED utilizers will be called (and possibly visited) by a CHW/CMA guiding them through ED-alternative resources.
219703268|NCT06814275|BEHAVIORAL|ARTEMIS|The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
219117056|NCT01471067|DRUG|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
219117057|NCT01471067|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
219117058|NCT01471067|DRUG|Rituximab|375 mg/m\^2 by vein on Day -10 for B cell malignancy.
219117059|NCT01471067|DRUG|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
219225333|NCT00973505|DRUG|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
219225334|NCT03385031|OTHER|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
219117060|NCT01471067|DRUG|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
219117061|NCT01471067|DRUG|Clofarabine|30 mg/m\^2 IV Day -7 to Day -4;
219117062|NCT01471067|RADIATION|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
219117063|NCT00804869|DEVICE|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
219117064|NCT00804869|DEVICE|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
219117065|NCT02702934|OTHER|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
219117066|NCT00197912|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
219117067|NCT03389893|DRUG|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
219117068|NCT03389893|DRUG|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
219117069|NCT01146808|DRUG|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
219117070|NCT05424861|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
219117071|NCT05424861|OTHER|Control group|No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
219117072|NCT01833117|OTHER|FID 119515A|topical ocular drops
219703269|NCT06814275|BEHAVIORAL|Contingency management for Antiretroviral (ARV) adherence|All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.
219117073|NCT01833117|OTHER|Blink® Tears|topical ocular drops
219117074|NCT00636714|BEHAVIORAL|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
219117075|NCT00636714|BEHAVIORAL|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
219703270|NCT06331351|OTHER|control group|2 times a day, 1 sachet each time.
219703271|NCT06331351|OTHER|Jing Si herbal tea liquid packets|2 times a day, 1 sachet each time.
219703272|NCT04399642|PROCEDURE|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
219703273|NCT06822738|DEVICE|XEN63 Glaucoma Treatment System|Gel Stent
219117076|NCT00569361|PROCEDURE|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
219117077|NCT00004074|BIOLOGICAL|recombinant interleukin-12|Given IV
219225335|NCT00332319|DRUG|GW679769|
219225336|NCT05313412|DEVICE|Lens A (comfilcon A lens)|6 hours
219225337|NCT05313412|DEVICE|Lens B (lehfilcon A lens)|6 hours
219225338|NCT03567616|DRUG|Venetoclax|Tablet; oral
219225339|NCT03567616|DRUG|Pomalidomide|Capsule; oral
219225340|NCT03567616|DRUG|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
219703274|NCT06994299|RADIATION|Radiation Therapy|Hypofractionated radiotherapy - 8Gy x3 fractions (week 0)
219703275|NCT06994299|DRUG|Tremelimumab|Tremelimumab - single dose of 300 mg IV (week 0).
219703276|NCT06994299|DRUG|Durvalumab|Durvalumab-500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection
219225341|NCT01253213|DRUG|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
219225342|NCT04675684|BEHAVIORAL|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
219225343|NCT02426229|DRUG|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
219703277|NCT06994299|PROCEDURE|Surgery|Hepatic resection
219703278|NCT07001800|DRUG|Ataciguat|Ataciguat will be administrated daily for up to 156 weeks
219703279|NCT07001800|DRUG|Placebo|Placebo will be administrated daily for up to 156 weeks
219117078|NCT00004074|BIOLOGICAL|ABI-007/carboplatin/trastuzumab|Given IV
219225344|NCT03177941|OTHER|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
219703280|NCT04719897|BEHAVIORAL|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
219703281|NCT05382897|OTHER|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
219703284|NCT06624085|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
219703285|NCT06624085|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
219703286|NCT06624085|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab pretreatment
219703287|NCT06624085|DRUG|Gemcitabine|Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
219703288|NCT06624085|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
219703289|NCT06428825|DRUG|BAY3283142|oral administration
219703290|NCT06428825|DRUG|Placebo to BAY3283142|oral administration
219703291|NCT07011459|BEHAVIORAL|Cooking class|3-month community teaching kitchen-based culinary education of MedDiet
219703292|NCT07011459|OTHER|Standard of care|Participants will continue to receive clinical care recommendations from their physicians
219703293|NCT03244488|DRUG|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
219703294|NCT03244488|DRUG|Mecamylamine Pill|10 or 20mg of mecamylamine orally
219703295|NCT00676949|BIOLOGICAL|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
219703296|NCT04291040|BEHAVIORAL|Decision Aid|Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
219703297|NCT04291040|BEHAVIORAL|Routine Care|The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
219703298|NCT05947253|OTHER|Buyteko breathing technique|group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
219703299|NCT05947253|OTHER|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
219703300|NCT01220284|DRUG|Satraplatin in combo with vinorelbine|"* Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
219703301|NCT04539990|BEHAVIORAL|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
219703302|NCT01721538|OTHER|Weight reduction program|
219703303|NCT01721538|OTHER|Lecture on healthy nutrition|
219703304|NCT03404245|BEHAVIORAL|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
219117079|NCT01232556|DRUG|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
219117080|NCT01232556|DRUG|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
219117081|NCT01232556|DRUG|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
219117082|NCT01232556|DRUG|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
219117083|NCT02448719|DRUG|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
219703305|NCT03404245|BEHAVIORAL|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
219703306|NCT00763360|DEVICE|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
219703307|NCT00763360|DRUG|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
219703308|NCT00763360|DRUG|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
219703309|NCT04066374|DEVICE|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
219703310|NCT00505635|DRUG|Temozolomide|250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
219703311|NCT00505635|DRUG|Velban|1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
219703312|NCT00505635|DRUG|Cisplatin|20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
219703313|NCT00505635|DRUG|Interleukin-2|9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
219703314|NCT00505635|DRUG|Intron-A|5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
219703315|NCT00505635|DRUG|Thalidomide|400 mg By Mouth Daily
219703316|NCT03011996|DRUG|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
219703317|NCT03011996|DRUG|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
219703318|NCT03011996|DRUG|CJ-12420 50mg|Cohort 2: bid for 7 days
219703319|NCT03011996|DRUG|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
219703320|NCT03011996|DRUG|Pantoprazole 40mg|Cohort 2: bid for 7 days
219703321|NCT01989858|OTHER|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
219703322|NCT01989858|OTHER|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
219703323|NCT01989858|OTHER|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
219703324|NCT01989858|OTHER|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
219117084|NCT02448719|DRUG|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
219117085|NCT02448719|DRUG|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
219703325|NCT03000946|DRUG|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
219117086|NCT02448719|DRUG|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
219225345|NCT04613713|OTHER|Somatocognitive physiotherapy|"The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
219703326|NCT03000946|DRUG|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
219703327|NCT00834041|DRUG|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
219703328|NCT06753396|PROCEDURE|Platelet rich fibrin|The injectable platelet rich fibrin will be integrated into the tissue by subgingival and submucosal application to the keratinized gingiva of the implant sites with insufficient peri-implant soft tissue phenotype. Then, the prepared injectable platelet rich fibrin will be injected into the mucogingival junction apical to the keratinized gingival site. This procedure will be repeated 3 times in total, 1 time in 30 days for 3 months.
219117087|NCT02448719|DRUG|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
219117088|NCT02448719|DRUG|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
219117089|NCT02448719|DRUG|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
219117090|NCT02448719|DRUG|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
219117091|NCT02448719|DRUG|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
219117092|NCT02448719|DRUG|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
219117093|NCT02448719|DRUG|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
219117094|NCT02448719|DRUG|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
219117095|NCT01024751|DEVICE|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
219117096|NCT01024751|DEVICE|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
219117097|NCT04779164|DIAGNOSTIC_TEST|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
219117098|NCT04237480|DIAGNOSTIC_TEST|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
219117099|NCT04622020|PROCEDURE|Cervical Plexus Block with Local Anaesthesia|Ultrasound guided intermediate cervical plexus block
219117100|NCT04622020|PROCEDURE|Cervical Plexus Block with Depot Steroids|Ultrasound guided intermediate cervical plexus block
219117101|NCT02225275|DRUG|Lenalidomide|Given PO
219117102|NCT02225275|BIOLOGICAL|Obinutuzumab|Given IV
219117103|NCT02200393|DEVICE|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.~Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
219117104|NCT01153256|DRUG|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
219117105|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
219117106|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
219117107|NCT00369811|DRUG|Oxycodone, fentanyl|
219117108|NCT04243161|OTHER|Experimental|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
219117109|NCT04243161|OTHER|Control|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
219117110|NCT01564719|BEHAVIORAL|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
219117111|NCT05382858|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
219117112|NCT05125016|DRUG|REGN4336|Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
219117113|NCT05125016|DRUG|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
219117114|NCT05125016|DRUG|REGN5678|Administered concomitantly QW by IV infusion
219117115|NCT05125016|DRUG|Sarilumab|Administered once by IV infusion as prophylaxis prior to REGN4336 IV
219117116|NCT01544621|OTHER|Smoking cessation|Smoking cessation
219117117|NCT06348537|DIETARY_SUPPLEMENT|Olive Polyphenols|Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.
219703329|NCT02634177|GENETIC|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
219703330|NCT02634177|OTHER|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
219703331|NCT05831878|DRUG|Disitamab vedotin|2.0mg/kg, iv, day1, every 2 weeks
219117118|NCT06348537|DIETARY_SUPPLEMENT|Placebo|Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
219117119|NCT05796960|PROCEDURE|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
219703332|NCT06040619|BEHAVIORAL|Therapy Together|8-week caregiver-led pediatric constraint-induced movement therapy program
219703333|NCT06040619|BEHAVIORAL|Usual Care|8 weeks of usual care received in an early intervention therapy program
219117120|NCT00992160|DRUG|GW597599|GW597599 15mg tablet
219117121|NCT00992160|DRUG|Placebo|Placebo to match GW597599 15mg tablet
219117122|NCT02040090|DRUG|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
219117123|NCT01005628|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
219117124|NCT03037229|DEVICE|Smartphone ECG|
219117125|NCT03037229|DEVICE|Standard 12-lead ECG|
219117126|NCT03086824|DEVICE|magnetic resonance-guided focused ultrasound|
219117127|NCT03936309|OTHER|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
219117128|NCT03936309|OTHER|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
219117129|NCT03936309|OTHER|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
219225346|NCT04613713|OTHER|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
219225347|NCT06028308|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
219703334|NCT07069426|DIETARY_SUPPLEMENT|20 grams protein|20 grams of whey protein provided as beverage
219703335|NCT07069426|DIETARY_SUPPLEMENT|40 grams protein|40 grams of whey protein provided as beverage
219703336|NCT07062679|OTHER|Maitland Oscillatory Glides/Mobilization|"Hot pack for 15 minutes Ultrasound for 5 minutes Maitland Mobilization Oscillatory Glides inferiorly during normal abduction. Glenohumeral caudal glide mobilization was given at the rate of 2-3 glides per second for 30 seconds for each glide, 5 sets were given.~(3 sessions per week for 4 weeks)"
219225348|NCT03972046|DRUG|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
219225349|NCT03972046|DRUG|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
219225350|NCT03972046|DRUG|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
219225351|NCT01006538|DEVICE|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
219225352|NCT01006538|DRUG|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
219225353|NCT00894894|DRUG|MP-470|escalating daily doses of amuvatinib
219703337|NCT07062679|OTHER|Mulligan Mobilization with Movement (MWM)|"Hot pack for 15 minutes Ultrasound for 5 minutes Mobilization with Movement (MWM) Patient sitting with therapist posterolateral to him/her. Therapist places the Mulligan belt across the humeral head and to his waist. Patient movement (Flexion, extension, \& abduction respectively) combined with therapist-applied joint gliding (postero-lateral Glide) MWM will be performed.~3 sets of 10 reps per session (30 seconds rest between sets)~(3 sessions per week for 4 weeks)"
219703338|NCT06901297|DRUG|Raphamin|Oral administration
219117130|NCT04474223|DRUG|Dexamethasone|"In mother in whom 2° AVB or AV interval \>170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery"
219117131|NCT04474223|DRUG|IVIG|"In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval \> 170 ms will not be treated with maternal IVIG, only dexamethasone."
219225354|NCT00894894|DRUG|amuvatinib (MP-470)|escalating doses of daily amuvatinib
219703339|NCT06901297|DRUG|Placebo|Oral administration
219117132|NCT05837975|DEVICE|FREE Walk Exoskeleton|Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.
219117133|NCT05837975|OTHER|Traditional Rehabilitation|Traditional rehabilitation refers to the use of conventional therapeutic methods.
219225355|NCT06452069|OTHER|IMMUNO19|"280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time."
219225356|NCT03777566|DIAGNOSTIC_TEST|sonohysterography|sonohysterography with measuring the uterine cavity volume
219225357|NCT06218758|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
219225358|NCT05075421|PROCEDURE|Gastrectomy|Any type of gastrectomy for gastric cancer
219703340|NCT06805175|DEVICE|vestibular implant|vestibular implant
219703341|NCT06717308|DEVICE|Comfort Release® NPWT drape|Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.
219703342|NCT06765980|GENETIC|VV-14295|VV-14295 will be administered as a single suprachoroidal injection.
219703343|NCT07080775|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
219703344|NCT06682013|DEVICE|Virtual agent|"The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. choose 1 for appointments, choose 2 for questions about your bill, etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate."
219703345|NCT06682013|OTHER|Human agent|The human agent will onboard the patient on use of the RPM devices.
219703346|NCT07080619|DRUG|SC-101|Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).
219703347|NCT06903104|OTHER|Mindfulness closed program|MAEva program will be proposed with meditative practices and three different themes will be addressed (one theme per session): Meditation, Acceptance and Commitment to values.
219703348|NCT06903104|DIAGNOSTIC_TEST|Quality of life evaluation|The assessment will be carried out at inclusion and after completion of the program.
219703349|NCT06903104|DIAGNOSTIC_TEST|Perceived Stress Scale|The assessment will be carried out at inclusion and after completion of the program.
219703350|NCT06903104|DIAGNOSTIC_TEST|Multidimensional Psychological Flexibility Inventory|The assessment will be carried out at inclusion and after completion of the program.
219703351|NCT06903104|OTHER|satisfaction questionnaire and semi-structured interview|The assessments will be carried out after completion of the program.
219703352|NCT06924541|DIETARY_SUPPLEMENT|Choline|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
219703353|NCT06924541|DIETARY_SUPPLEMENT|Placebo|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
219703354|NCT06846606|DRUG|AUTX-703|AUTX-703 administered orally
219225359|NCT04070963|OTHER|HbA1C|To take additional blood test of HbA1C once patient consented to the study
219225360|NCT03492021|OTHER|Diet Intervention_AP-CPT|Adequate Protein\_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
219225361|NCT03492021|OTHER|Diet Intervention_PP-PPT|Optimal Protein\_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
219225362|NCT00562614|DRUG|SLx-2101|
219225363|NCT01203943|DRUG|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
219225364|NCT01203943|OTHER|Placebo|Placebo
219225365|NCT01203943|DRUG|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
219703355|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
219703356|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
219703357|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
219703358|NCT06776159|OTHER|Active Control|Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.
219703359|NCT06776159|OTHER|Standardized injection protocol|Nurses administer LMWH according to the standardized evidence-based protocol.
219703360|NCT07084948|DRUG|Flavonoid|"The daily maintenance, Tenofovir 150mg + SB Flavon 1345mg dose is to be taken 2 times a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma at an early stage. The product is Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin.~Use these ingredients to protect liver cell membranes, preventing the growth of HBV in the body."
219225366|NCT01203943|DRUG|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
219225367|NCT00004805|BEHAVIORAL|CPR instruction|
219225368|NCT02139813|PROCEDURE|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
219225369|NCT02139813|PROCEDURE|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
219703361|NCT07084948|DRUG|Tenofovir|"The daily maintenance, Tenofovir 300mg dose is to be taken 1 time a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma."
219703362|NCT06902077|BEHAVIORAL|low carb diet|diet based on low carb with max 50-80 grams of carbohydrates daily
219703363|NCT06902077|BEHAVIORAL|diabetic diet|Balanced diet based on standard of care recommendations for type 2 diabetes
219703364|NCT06742801|DEVICE|Onyx™ Liquid Embolic System|The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
219703365|NCT06826768|DRUG|REGN5678|Given by IV infusion
219703366|NCT06826768|DRUG|Cemiplimab|Given by IV infusion
219703367|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
219703368|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
219703369|NCT07117968|OTHER|Standard-of-care|Management of the first year post-CI follow-up according to current center practices
219703370|NCT07117968|OTHER|Experimental hybrid care pathway|First year post-CI follow-up including early activation of the implant and hybrid follow-up, including remote or in-center monitoring visits, adjustable according to the evolution of their hearing performance and comfort. In this new care pathway, compared with the Standard-of-care, the 2-week visit and the 9-month visit are omitted, due to early activation and remote follow-up. Visits at 1 and 6 months are the same as those in the conventional, on-site routine. Visits at 3 and 12 months will be carried out remotely by default via the remote monitoring application.
219703371|NCT07126535|DIAGNOSTIC_TEST|Radiofrequency ablation alone|If there is no evidence of nodularity, these patients will undergo RFA. Clinical biopsies utilizing a large-capacity biopsy forceps (Radial Jaw 4, Boston Scientific, Marlborough, MA) are obtained. RFA may be delivered through several devices under the BarrX RFA System (Medtronic USA, Minnetonka, MN), including a circumferential balloon catheter (Halo 360; figure 1), or over the scope focal catheter (Halo 90 or 60). The Halo 360 treats a circumferential 4 cm segment at a time, whereas the focal catheters treat a 1.3x2 cm (Halo 90) or 1.0x1.5 cm (Halo 60) area.
219703372|NCT02177500|DRUG|Telmisartan + hydrochlorothiazide|
219703373|NCT02177500|DRUG|Telmisartan|
219703374|NCT02177500|DRUG|Placebo|
219703375|NCT07133607|OTHER|education about pain and physical excersice|"The sessions will be conducted in groups of 10 to 15 patients.~* 4 pain science education sessions, each lasting 1.5 hours (6 hours), with one session per week, for 4 weeks.~* 12 therapeutic physical exercise program sessions, each lasting 1 hour, to be conducted over 6 weeks (12 hours), with two sessions per week. Although the intervention is group-based, individual instructions will be given to patients. Reference will be made to the content learned in the neuroeducation sessions. The exercise dose must be adjusted to the patient's condition, keeping in mind that, due to the inhibition of the descending pain modulation system, they may experience an initial increase in pain during the first sessions, so as not to alarm the patient and prevent the activity from being discontinued. The main objective is to increase the patient's functionality, an aspect that will be constantly reinforced.~The session structure will be as recommended by the American College of Sports Medicine, with se"
219703376|NCT07133607|OTHER|education about pain and physical excersice with somatosensorial treatment|"Patients assigned to this group will receive, in addition to the same intervention as the AADC study group intervention type 2 (education about pain), somatosensory and body schema treatment for the changes observed in an initial assessment during the 4 weeks prior.~The prescribed treatment will be repeated daily at home. To facilitate~the progress of the treatment, it is recommended that a companion participate in the first session, when possible, where the daily intervention to be performed at home will be explained.~If the participation of a companion is not possible, the patient will attend the Health Center's physiotherapy room once a day to be accompanied by the physiotherapist and offered the same treatment opportunities.~As a control and monitoring measure, the patient will attend the physiotherapy room once a week and will be called again weekly to verify that the treatment is being performed correctly. They will also be provided with a form to record their home treatment."
219703377|NCT07133607|OTHER|Classic physiotherapy treatment with physical exercise, analgesic electrotherapy and thermotherapy|The patients will receive the usual physiotherapy treatment provided in Primary Care Physiotherapy units, supported by the current Primary Care Physiotherapy protocols of Castilla y León, since Andalusia does not currently have any published. The patient will receive 12 sessions of thermotherapy (Infrared/Microwave) and analgesic electrotherapy (analgesic Tens currents) in the painful area(s), and will be prescribed exercises recommended by the Spanish Society of Physical Medicine and Rehabilitation (SERMEF). The learning and execution of the exercises will be supervised by a Primary Care physiotherapist. The sessions will be with a frequency of 2 per week on alternate days for 6 weeks.
219703378|NCT06507553|BIOLOGICAL|Trivalent-Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219703379|NCT06507553|BIOLOGICAL|Augment-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219703380|NCT06507553|BIOLOGICAL|TIV-2X Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219703381|NCT06507553|BIOLOGICAL|Trivalent-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219703382|NCT05998135|DRUG|Atovaquone|Given PO
219225370|NCT04547764|DRUG|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
219703383|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
219703384|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
219703385|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
219117134|NCT01997502|DEVICE|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
219117135|NCT01997502|OTHER|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
219703386|NCT06943963|BEHAVIORAL|Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder|"The Self Stigma Tailored Cognitive Behavioral Therapy for Gambling Disorder (SSCBT) is a novel intervention designed specifically for this study and has not been previously used or named in existing literature. This 4-session protocol can be integrated into any part of GD treatment. Each session was accompanied by materials specifically designed for that session's content, and assignments related to the session's topics were given at the end of each session.~Session 1: Gambling Disorder from a bio-psycho-social perspective, stigma and self-stigma, CBT introduction, cognitive-behavioral model of self-stigmatization, impact of emotions and cognitive distortions.~S. 2: Self-stigmatizing thoughts and behaviors, identifying automatic thoughts with cognitive techniques, cognitive awareness, and restructuring with evidence examination.~S. 3: Aligning behaviors with values, cognitive restructuring, behavior change, and self-awareness.~S. 4: Prevention strategies, relapse prevention planning."
219703387|NCT06943963|DRUG|standart pharmacotherapy|All participants continued to receive standard pharmacotherapy from their respective psychiatrists.
219703388|NCT06943963|BEHAVIORAL|motivational intervention|All participants continued to receive the standard motivational interviewing intervention for addiction from their psychiatrist.
219703389|NCT07150884|DIETARY_SUPPLEMENT|Lactase|The lactase drops that will be used in the study will be Delictase®, which is a dietary supplement that helps the proper digestion of lactose through its breakdown. Delictase® lactase drops offer an exogenous source of the lactase enzyme, which is essential for the proper absorption and digestion of lactose, can be administered from birth, mixed into the administered milk and contain high levels of lactase (\>3,000 ALU\*). The supply of Delictase® lactase preparations will be carried out by Galenic Pharmacy, every 2 months at the study site.
219703390|NCT07153913|OTHER|Intensive growth support|For women in the intervention group, we will develop a nutritional plan for the child in collaboration with the mother. Mothers will then receive a visit every other week - during this visit, children's health and nutrition will be discussed, and height and weight will be measured by field officers. Detailed food recommendations will be made based on national and international infant and young child feeding guidelines. To ensure appropriate foods are available, field workers will drop off local foods on a weekly basis.
219703391|NCT07157176|BEHAVIORAL|Daily 3-Minute Laughter Practice (Laughie Prescription)|"The intervention will consist of 3-minutes of laughter (joyful and natural laughter is recommended) per day. Each day participants will laugh for one minute in a group (virtual and/or actual) guided by a professional laughter practitioner who is not going to be involved in the analysis of the data. That laughter will be recorded. The recording (the Laughie) will then be prescribed for participants to laugh with (with others - family, friends, colleagues, or alone) twice a day. This will result in 3 minutes of laughter per day (the first in a group, the second two prompted by the Laughie)"
219703392|NCT07168252|DRUG|Rocuronium dosing|Rocuronium doses of 0.6ng/kg, 1.2mg/kg, 1.6mg/kg and 2.0 mg/kg will be compared for onset speed of muscle relaxation and information on speed, cardiac output and patient body size entered into a computer model
219703393|NCT07169201|DIAGNOSTIC_TEST|Angiography based RWS and OCT based plaque characteristcis|Angiography based RWS and OCT based plaque characteristcis
219703394|NCT07168265|DRUG|androgen replacement therapy|intramuscular testosterone
219703395|NCT07169019|DRUG|Probiotics and methotrexate|weekly oral methotrexate 15-25 mg/week, along with an oral daily dose of probiotics.
219703396|NCT07169019|DRUG|Methotrexate|weekly oral methotrexate 15-25 mg/week
219703397|NCT07169383|DRUG|Melatonin tablet|Group A will receive oral melatonin 5mg every night for 3 months
219703398|NCT07169383|DRUG|Tranexamic Acid (TXA)|Group B will receive oral tranexamic acid 250mg twice daily for 3 months.
219703399|NCT07169253|OTHER|GAP Index|For each patient in the IPF, fibrotic HP, and non-fibrotic HP groups, the GAP index was calculated based on age, gender, FVC, and DLCO values. According to the GAP index, patients were classified as Stage 1 (0-3 points), Stage 2 (4-5 points), and Stage 3 (6-8 points).
219703400|NCT07169253|OTHER|ILD-GAP Index|In addition to the GAP parameters, the index was calculated to include the ILD subtype as well.
219117136|NCT06041763|PROCEDURE|Meniscal Repair Procedure|All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.
219117137|NCT06041763|DEVICE|BEAR Implant|The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
219117138|NCT04813146|OTHER|SLP|Synchronization of dietary intake with circadian rhythm of the body
219703401|NCT07169253|OTHER|Composite Physiologic Index (CPI)|"The CPI (Composite Physiologic Index) was calculated using the following formula:~CPI = 91 - (0.65 × %DLCO) - (0.53 × %FVC) + (0.34 × %FEV1).~DLCO: Diffusing Capacity of the Lung for Carbon Monoxide FVC: Forced Vital Capacity FEV₁: Forced Expiratory Volume in One Second"
219703402|NCT07167849|BEHAVIORAL|UKADO Content - problem-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is problem-focused
219703403|NCT07167849|BEHAVIORAL|UKADO Content - resource-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is resource-focused.
219703404|NCT07167849|BEHAVIORAL|Human support|Human support is provided as two weeks of guidance for study participants
219703405|NCT07167849|BEHAVIORAL|Expectation fostering elements|Patient in the expectation-fostering condition receive elements in UKADO that are meant to foster expectations.
219703406|NCT07167511|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
219703407|NCT07169474|PROCEDURE|Isolated trapeziometacarpal arthroplasty with double mobility|Isolated trapeziometacarpal arthroplasty with double mobility in all cases, using a MAIA or TOUCH prosthesis depending on the operator's habits.
219703408|NCT07167160|DRUG|Camrelizumab combined with chemotherapy|Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
219703409|NCT06472362|DIAGNOSTIC_TEST|HRCT biomarkers|HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
219703410|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
219703411|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
219117139|NCT04813146|OTHER|SLP along with Physiotherapy|Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)
219117140|NCT04813146|OTHER|Physiotherapy|Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
219703412|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
219703413|NCT02414126|DEVICE|CPAP|
219703414|NCT06514989|DIETARY_SUPPLEMENT|Low-residue full nutrition formula podwer|The day before the colonoscopy, subjects were given a low-residue full nutrition formula podwer instead of a traditional self-prepared low-residue diet. Subjects were given 6 packs (60g/pack) pre-packaged FNFP and asked to use the FNFP according to individual needs. The 2 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 1 liter taken 3-5 hours before the colonoscopy.
219703415|NCT06514989|DIETARY_SUPPLEMENT|Self-prepared low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liter taken 4-6 hours before the colonoscopy.
219703416|NCT05954312|DRUG|VVD-130037|Oral tablets
219703417|NCT05954312|DRUG|Docetaxel|IV infusion
219703418|NCT05954312|DRUG|Paclitaxel|IV infusion
219703419|NCT00322322|DRUG|L-Carnitine|L-Carnitine
219703420|NCT02530840|BEHAVIORAL|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
219703421|NCT02530840|BEHAVIORAL|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
219703422|NCT02530840|BEHAVIORAL|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
219703423|NCT05608434|BEHAVIORAL|Floreo Virtual Reality application|Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
219703424|NCT03427892|DRUG|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
219703425|NCT05096377|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
219703426|NCT00274456|DRUG|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
219703427|NCT00274456|DRUG|Docetaxel|Docetaxel dosed q3w at 100 mg/m\^2
219117141|NCT04619368|OTHER|Follow up calls|The follow-up will consist in phone call with an intensive care doctor. These visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder PTSD. A review would be sent to the patients' General Practitioners at the end of each visit.
219117142|NCT01227408|DRUG|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
219117143|NCT05095129|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219117144|NCT02894320|BEHAVIORAL|Behavioral observation|
219117145|NCT02836327|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
219117146|NCT03587844|DRUG|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
219117147|NCT03587844|DRUG|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
219117148|NCT03587844|DRUG|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
219703428|NCT02314546|DRUG|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
219703429|NCT02314546|DRUG|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
219703430|NCT02314546|DRUG|saline placebo|Placebo - Control patients will receive intranasal saline.
219703431|NCT03255187|DIETARY_SUPPLEMENT|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].
219703432|NCT03255187|DIETARY_SUPPLEMENT|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
219703433|NCT02664688|OTHER|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
219703434|NCT02664688|OTHER|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
219703435|NCT00375752|DRUG|Letrozole|2.5 mg.tablet.
219703436|NCT00375752|DRUG|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
219117149|NCT00895843|DRUG|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
219117150|NCT00895843|DRUG|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
219225371|NCT04547764|DRUG|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
219703437|NCT06094036|BEHAVIORAL|Structured and personalized program of physical exercise|"In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality."
219703438|NCT04167813|DRUG|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
219703439|NCT01933724|DRUG|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
219703440|NCT01933724|DRUG|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
219117151|NCT00895843|DRUG|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
219117152|NCT05957757|DRUG|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
219117153|NCT05957757|DRUG|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
219117154|NCT00284765|PROCEDURE|flector|
219225372|NCT03110536|DIAGNOSTIC_TEST|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
219225373|NCT03110536|OTHER|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
219225374|NCT04897633|DEVICE|transcranial electric stimulation|Simon's task assessment when under tDCS
219225375|NCT06282354|OTHER|Type of post-operative appointment|remote post-operative appointment for small or medium urooncology procedures
219225376|NCT02233998|OTHER|Mouth Rinse 1|
219703441|NCT03369782|DRUG|Rocuronium|rocuronium is administered in bolus and continuous infusion
219703442|NCT03369782|DRUG|Sugammadex|Sugammadex is administered just before reduction of the joint
219703443|NCT03369782|DRUG|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
219703444|NCT02034006|DRUG|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
219703445|NCT03042546|DRUG|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
219703446|NCT03042546|DRUG|PMMA|PMMA with abx will be used in the defect
219703447|NCT03042546|OTHER|No treatment|The defect will not be treated
219703448|NCT00109343|BIOLOGICAL|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
219703449|NCT00109343|BIOLOGICAL|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
219703450|NCT00750269|RADIATION|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
219703451|NCT00750269|RADIATION|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
219703452|NCT00750269|RADIATION|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
219703453|NCT00750269|RADIATION|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
219703454|NCT00750269|RADIATION|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
219117155|NCT05106985|DEVICE|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
219703455|NCT00750269|RADIATION|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
219703456|NCT00750269|RADIATION|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
219703457|NCT00750269|RADIATION|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
219703458|NCT00750269|RADIATION|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
219703459|NCT03227588|DIAGNOSTIC_TEST|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
219703460|NCT03889132|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
219703461|NCT00185159|DRUG|Olmesartan medoxomil|tablets
219703462|NCT00185159|DRUG|Placebo Tablets|Tablets
219703463|NCT06469086|OTHER|Clinical data collection|The clinical significance of appendicoliths in the conservative management of acute complicated appendicitis with abscesses.
219703464|NCT04084704|DEVICE|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
219703465|NCT05054387|DRUG|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
219703466|NCT05596175|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
219703467|NCT00297011|DRUG|valacyclovir+clobetasol gel|
219703468|NCT03625674|BEHAVIORAL|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
219117156|NCT02637050|OTHER|Standard of care|At the discretion of the attending physician.
219117157|NCT04334785|DEVICE|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
219225377|NCT02233998|OTHER|Mouth Rinse 2|
219225378|NCT02233998|OTHER|Mouth Rinse 3|
219703469|NCT02746861|BEHAVIORAL|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
219703470|NCT05848284|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
219703471|NCT06492837|DRUG|Mosunetuzumab in combination with Zanubrutinib|Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
219703472|NCT05425979|DRUG|Mepivacaine|Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
219703473|NCT05425979|DRUG|Bupivacaine|Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
219703474|NCT02361931|DRUG|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
219117158|NCT05966376|DEVICE|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
219117159|NCT06489093|DRUG|NSF|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
219117160|NCT06489093|DRUG|SDF+KI|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
219117161|NCT06489093|OTHER|Control group|Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
219117162|NCT00039182|DRUG|erlotinib hydrochloride|Given orally
219117163|NCT00039182|OTHER|laboratory biomarker analysis|Correlative studies
219117164|NCT01260857|DRUG|Aldazide|Aldazide 25 mg OD
219117165|NCT02304328|OTHER|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
219117166|NCT03587350|DEVICE|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
219117167|NCT00115375|DRUG|Clopidogrel (SR25990)|
219117168|NCT02329600|DRUG|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
219117169|NCT02329600|DRUG|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
219117170|NCT02406118|PROCEDURE|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
219117171|NCT01977001|DEVICE|MigraineBoxTM|
219703475|NCT02361931|DRUG|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
219703476|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
219703477|NCT03588624|DEVICE|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
219703478|NCT05138575|DRUG|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
219703479|NCT05138575|DRUG|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
219117172|NCT02988206|BEHAVIORAL|Personalized Objects|personalized objects are based on the observation or the reports from family
219117173|NCT02988206|BEHAVIORAL|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
219117174|NCT04395768|DIETARY_SUPPLEMENT|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
219117175|NCT04395768|DRUG|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
219117176|NCT04395768|DRUG|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
219117177|NCT04395768|DIETARY_SUPPLEMENT|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
219117178|NCT04395768|DIETARY_SUPPLEMENT|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
219117179|NCT04395768|DIETARY_SUPPLEMENT|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
219117180|NCT06379230|OTHER|This study is purely descriptive study.|This study is purely descriptive study.
219117181|NCT05681403|DRUG|Improved BEAM regimen|Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
219117182|NCT02868437|DEVICE|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
219117183|NCT06029530|DRUG|Atropine Ophthalmic|eye drops to be administered once daily
219117184|NCT00850720|OTHER|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
219117185|NCT04374500|DRUG|Leptin infusion plus vasodilators in healthy men|This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
219703480|NCT05138575|DRUG|Potassium Chloride + Placebo for Empagliflozin|Active control.
219703481|NCT05051839|PROCEDURE|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
219703482|NCT04060836|DRUG|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
219117186|NCT04374500|DRUG|Leptin infusion in healthy men|This applies only to protocol 1 when only leptin was given
219117187|NCT04374500|DRUG|Vasodilators in CAD patients|This applies only to protocol 3
219117188|NCT02950935|DRUG|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
219117189|NCT02950935|DRUG|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
219117190|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization|Imaging, blood tests, LV pressure measurement
219117191|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)|Imaging and Blood tests
219117192|NCT01482949|DRUG|AGS-003|Autologous Dendritic Cell Immunotherapy
219117193|NCT04963062|DEVICE|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
219117194|NCT04963062|DEVICE|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
219117195|NCT06529211|DIETARY_SUPPLEMENT|Low caloric diet|Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.
219703483|NCT04060836|DRUG|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
219703484|NCT04823104|OTHER|Home visitation|Home visitation for pregnancy follow-up
219703485|NCT02871596|OTHER|Placebo|A combination of maltodextrins and red and blue food colors.
219703486|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
219703487|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
219117196|NCT06529211|DEVICE|Ultrasound cavitation|"Ultrasound cavitation + Low caloric diet Low caloric diet program (1500 Kcal/ day): for 6 weeks.~Ultrasound cavitation: It will be on abdomen for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will be in supine lying position and the abdomen is divided into two sides right and left from the midline.~* The Ultrasound pulsed waves will be set with power input (AC100/ 240V), frequency (40 KHz), and Power output (45W). This will be for 15 minutes on each abdominal side."
219117197|NCT06529211|DEVICE|Whole body vibration|"Whole body vibration + Low caloric diet Low caloric diet program (1500 Kcal/ day) for 6 weeks.~Whole body vibration: for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will begin with a brief warm-up for 5 minutes by doing deep breathing exercises.~* Then they will stand with feet shoulder-width apart on the platform while holding handrails to maintain balance and stability. They will be instructed to relax and allow the vibrations to pass through her body. This will be applied for 20 minutes per session.~* The vibration will be started with lower settings and gradually will be increased till the desired frequency and amplitude (45 HZ) will be reached.~* After the session will be completed, the participant will be instructed to cool down gradually by doing deep breathing for 5 minutes to help their body to return to a resting state. They will be advised to drink plenty of water to be hydrated and recovered after the WBV session."
219117198|NCT03873246|DRUG|OC-01 0.1% 0.6 mg/ml|OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
219117199|NCT03873246|DRUG|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
219117200|NCT03873246|OTHER|placebo comparator|vehicle control
219225379|NCT03914885|GENETIC|ATLCAR.CD30|Administered at a dose of 2 x 10\^8 cells/m2
219225380|NCT03914885|DRUG|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
219703488|NCT06784193|DRUG|OP-3136|OP-3136
219703489|NCT06784193|DRUG|Fulvestrant|Fulvestrant
219703490|NCT06721247|DRUG|Magnesium|oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024
219703491|NCT06721247|DRUG|ICS+LABA|inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily
219703492|NCT02340676|PROCEDURE|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
219703493|NCT02340676|DRUG|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
219703494|NCT04533581|DRUG|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
219117201|NCT03752736|BEHAVIORAL|"I wear sunscreen everyday song-based video"|"All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet."
219117202|NCT03250598|DRUG|AG-348|50 mg single-dose
219117203|NCT03250598|DRUG|AG-348|5 mg single-dose
219225381|NCT03914885|DRUG|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
219225382|NCT02245529|DRUG|Tamsulosin|
219225383|NCT01957163|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
219703495|NCT06074835|DEVICE|Gamete preparation, ICSI, embryo culture and vitrification robot assistant|Patients undergoing an assisted conception treatment with medical indication to perform ICSI may be recruited in this study. The study will follow a sibling-oocyte and/or sibling embryo study design where oocytes and/or embryos obtained from a specific patient or couple will be randomly distributed across two groups (test and control) and undergo one or more elements of an automated assisted conception laboratory workflow (for the test group) or a standard assisted conception laboratory workflow (for the control group). Before distributing the samples, an embryologist will slightly blur the vision of the samples so that their morphology can no longer be clearly assessed. Robotic automation may include any of the following steps: robotic sperm preparation, robotic oocyte selection and denudation, robotic sperm injection, automated embryo culture, and automated cryopreservation. The resulting embryos may be employed for embryo transfer.
219703496|NCT06074835|OTHER|Routine Manual ICSI Workflow|Routine Manual Icsi Workflow
219703497|NCT03944616|BEHAVIORAL|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
219225384|NCT01957163|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
219225385|NCT01957163|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
219703498|NCT03944616|BEHAVIORAL|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
219117204|NCT03250598|DRUG|AG-348|200 mg single-dose
219117205|NCT05128292|DIETARY_SUPPLEMENT|CoQ10 plus Selenium|400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
219225386|NCT01957163|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
219225387|NCT02498145|OTHER|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
219225388|NCT02498145|OTHER|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
219703499|NCT01614652|DEVICE|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
219225389|NCT03960957|BIOLOGICAL|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
219225390|NCT03960957|OTHER|Placebo|Treatment of glabellar facial lines with placebo
219225391|NCT01296230|PROCEDURE|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
219225392|NCT01264172|PROCEDURE|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
219225393|NCT01264172|PROCEDURE|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
219117206|NCT01857323|DRUG|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
219117207|NCT00541957|BEHAVIORAL|behavior therapy|10 sessions over 4 months
219117208|NCT00541957|DRUG|Medication prescribed by PCP|Can include any antidepressant medication
219117209|NCT05357807|PROCEDURE|Standard RYGB|Roux-en-Y Gastric bypass
219117210|NCT05357807|PROCEDURE|Extended Pouch RYGB|Roux-en-Y gastric bypass with an extended pouch
219117211|NCT05357807|PROCEDURE|Banded extended pouch RYGB|Roux-en-Y gastric bypass with a banded extended pouch
219117212|NCT00404482|DRUG|Cyclosporine A|
219117213|NCT03922828|DIAGNOSTIC_TEST|CT scans|CT surveillance, Lung biopsy, Lung resection
219117214|NCT01140022|OTHER|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
219703500|NCT05707221|OTHER|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
219703501|NCT05707221|OTHER|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
219703502|NCT05707221|OTHER|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
219703503|NCT00070434|DRUG|capecitabine|825mg/m2 BID, PO, daily
219703504|NCT00070434|DRUG|fluorouracil|Bolus + IV for 46 hrs on Day 1
219117215|NCT04678869|DRUG|Ciprofloxacin|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
219117216|NCT04678869|DRUG|Antibiotic|Standard of care antibiotic as per local policy
219117217|NCT06291077|DRUG|Belatacept|Changing of anticalcineurins by Belatacept
219117218|NCT06291077|DRUG|anticalcineurins|Keeping of anticalcineurins
219117219|NCT03854240|OTHER|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
219117220|NCT05379140|BEHAVIORAL|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
219703505|NCT00070434|DRUG|irinotecan hydrochloride|IV infusion over 90 min on Day 1
219703506|NCT00070434|DRUG|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
219703507|NCT00070434|DRUG|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
219703508|NCT00070434|RADIATION|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
219117221|NCT05379140|BEHAVIORAL|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
219117222|NCT03888508|OTHER|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
219117223|NCT04436081|DRUG|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
219117224|NCT04436081|DRUG|Placebo|Placebo Gelcaps
219117225|NCT05697432|DIAGNOSTIC_TEST|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
219117226|NCT05697432|DIAGNOSTIC_TEST|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
219117227|NCT05697432|DIAGNOSTIC_TEST|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
219703509|NCT00070434|DRUG|Pyridoxine|50mg TID, PO daily
219703510|NCT00478621|BIOLOGICAL|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
219703511|NCT00478621|BIOLOGICAL|Cervarix TM|Intramuscular administration
219703512|NCT00090532|DRUG|AG-013,958|
219703513|NCT06958042|OTHER|Questionnaire and Physical Exam|\- St George Respiratory Questionnaire (SGRQ): The SGRQ developed by Jones (2000), which is used specifically for respiratory diseases, consists of 50 questions. In the questionnaire, there are three categories in which symptom, activity and the effect of the disease on quality of life are questioned and each category is evaluated within itself and there is an evaluation scale between 0-100 points. In the evaluation, high scores indicate an inadequate and low quality of life.
219703514|NCT00219609|DRUG|UK-390,957|
219703515|NCT02144909|BEHAVIORAL|Partners in Care with Semi-Structured Support Group|
219703516|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
219703517|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
219703518|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
219117228|NCT05697432|DIAGNOSTIC_TEST|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
219117229|NCT05697432|BEHAVIORAL|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
219117230|NCT03658811|DEVICE|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
219117231|NCT00184613|DEVICE|pump|
219117232|NCT00184613|DRUG|insulin glargine|
219117233|NCT00184613|DRUG|insulin aspart|
219117234|NCT02739243|BEHAVIORAL|Tailored group intervention (PREPARE)|
219117235|NCT02739243|BEHAVIORAL|Individual treatment as usual|
219117236|NCT04381702|PROCEDURE|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
219117237|NCT05165875|DRUG|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
219117238|NCT05165875|OTHER|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
219117239|NCT02093143|DRUG|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
219117240|NCT00988585|DIETARY_SUPPLEMENT|EPA 600|EPA 600 mg/day for 6 weeks
219117241|NCT00988585|DIETARY_SUPPLEMENT|EPA 1800|1800 mg/day for 6 weeks
219117242|NCT00988585|DIETARY_SUPPLEMENT|Olive Oil|600 mg/day for 6 weeks
219117243|NCT00988585|DIETARY_SUPPLEMENT|DHA|600 mg/day for 6 weeks
219117244|NCT01920776|OTHER|ultrasound examination|
219117245|NCT01920776|OTHER|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
219117246|NCT03262701|DRUG|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
219117247|NCT03262701|DRUG|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
219117248|NCT03262701|OTHER|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
219117249|NCT03423459|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
219117250|NCT00946647|DRUG|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
219117251|NCT00946647|DRUG|5-Azacytidine|
219117252|NCT02031744|DRUG|erlotinib [Tarceva]|150 mg oral administration once daily
219117253|NCT02031744|DRUG|Placebo|15 mg/kg intravenous administration every 3 weeks
219117254|NCT02031744|DRUG|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
219117255|NCT05991050|DIETARY_SUPPLEMENT|energy-restricted diet|Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
219117256|NCT05991050|DEVICE|Whole body vibration|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
219117257|NCT03868319|PROCEDURE|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
219117258|NCT03868319|PROCEDURE|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
219117259|NCT01349660|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
219117260|NCT01349660|DRUG|BKM120|BKM120 orally (PO) once daily
219117261|NCT03746756|BEHAVIORAL|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
219117262|NCT03746756|BEHAVIORAL|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
219117263|NCT03281278|OTHER|standard treatment|standard medical treatment
219117264|NCT05200637|DEVICE|Orsiro stent|Orsiro stent
219117265|NCT05200637|DEVICE|Xience stent|Xience stent
219117266|NCT05200637|DEVICE|Any drug-eluting stent|Any drug-eluting stent
219117267|NCT02535559|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
219117268|NCT02826304|PROCEDURE|Vaginal hysterectomy|"All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and"
219117269|NCT02826304|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|"1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
219117270|NCT05353543|DRUG|SSRIs|In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
219117271|NCT05353543|PROCEDURE|acupuncture (strong reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219117272|NCT05353543|PROCEDURE|acupuncture (weak reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219117273|NCT05353543|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
219117274|NCT05906303|DRUG|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
219117275|NCT05906303|DRUG|Normal Saline|Provide normal saline to serve as a placebo
219117276|NCT05666102|BEHAVIORAL|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
219225394|NCT01264172|PROCEDURE|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
219117277|NCT03240341|BEHAVIORAL|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
219117278|NCT02337712|RADIATION|q.d. RT|65 Gy in 26 fractions
219117279|NCT02337712|RADIATION|b.i.d.RT|45 Gy in 30 fractions
219117280|NCT02337712|DRUG|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
219117281|NCT03449537|DIETARY_SUPPLEMENT|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
219117282|NCT03449537|DIETARY_SUPPLEMENT|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
219117283|NCT00519636|DRUG|FPNS|fluticasone propionate nasal spray
219117284|NCT00519636|DRUG|FFNS|fluticasone furoate nasal spray
219117285|NCT00519636|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
219703519|NCT03821129|DEVICE|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
219117286|NCT00519636|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
219117287|NCT01611818|OTHER|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
219117288|NCT01611818|OTHER|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
219117289|NCT01611818|OTHER|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
219117290|NCT04436796|DEVICE|interoperable Artificial Pancreas System (iAPS)|Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.
219117291|NCT04436796|OTHER|Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)|Use of personal pump with study CGM \& glucometer at home for 13 weeks.
219117292|NCT03136835|DRUG|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
219117293|NCT00462644|DRUG|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
219117294|NCT00462644|DRUG|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
219117295|NCT03407261|PROCEDURE|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
219117296|NCT02964715|DRUG|Empagliflozin|25 mg daily for 6 months
219117297|NCT02846558|OTHER|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
219117298|NCT02846558|BEHAVIORAL|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
219225395|NCT01307254|PROCEDURE|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
219703520|NCT01131273|DRUG|methadone|12 weeks of methadone maintenance with counseling
219117299|NCT02846558|DEVICE|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
219117300|NCT01728805|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
219117301|NCT01728805|DRUG|Vorinostat|
219117302|NCT00744081|DRUG|Glivec|
219117303|NCT00744081|DRUG|Mitoxantrone|
219117304|NCT00744081|DRUG|Topotecan|
219117305|NCT00744081|DRUG|AraC|
219117306|NCT05264493|DRUG|NaxRedy ™|5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
219117307|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg IM (2mg/2 mL) injection into gluteal muscle
219117308|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg bolus IV (2mg/2 mL)
219117309|NCT04228328|DIAGNOSTIC_TEST|The 6-minutes Walk Test|To walk for 6 minutes
219117310|NCT06236581|BEHAVIORAL|GEM Intervention|Lifestyle coaching
219117311|NCT06109415|DRUG|HTX-011|400 mg
219117312|NCT06109415|DRUG|Bupivacaine Hydrochloride|100 mg
219117313|NCT06109415|DRUG|Ibuprofen|400 mg
219117314|NCT06109415|DRUG|Acetaminophen|1 g
219117315|NCT06109415|DEVICE|Luer lock applicator|Applicator for instillation
219117316|NCT03799679|DRUG|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
219117317|NCT04174235|DEVICE|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
219117318|NCT00205231|DRUG|etanercept|
219703521|NCT01131273|DRUG|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
219703522|NCT06450288|BEHAVIORAL|GO|"Green Oasis wellness program: include physical exercises, gardening, interaction with the developed website. Participants' general health status and website evaluation will be measured at T0 (baseline), T1 (3 months), T2 (9 months), using standardized questionnaires.~Study Design: pre-post study, 50 participants will be recruited from the Concordia Tsat Sing Kong transitional housing estate."
219117319|NCT06307340|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)|Adapted version of evidence-based behavioral PTSD intervention.
219117320|NCT06307340|BEHAVIORAL|Treatment as Usual|Treatment as usual.
219117321|NCT00000561|DEVICE|pacemaker, artificial|
219117322|NCT05728593|OTHER|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
219117323|NCT05728593|OTHER|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
219117324|NCT03776994|BIOLOGICAL|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
219117325|NCT06858436|DRUG|Canagliflozin 100mg|receiving Canagliflozin 100mg QD
219117326|NCT05064111|DIAGNOSTIC_TEST|TRUS biopsy|The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
219117327|NCT01017978|PROCEDURE|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
219703523|NCT06833697|PROCEDURE|erector spinae plane block|"the ESP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed in the lateral position with the surgical side up, and a sterile ultrasound probe cover will be used.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be placed transversely at the T5 thoracic vertebra.~Anatomy Identification: The erector spinae muscle and transverse processes will be visualized.~Needle Insertion: Using an in-plane technique, the needle will be advanced to the transverse process.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected between the erector spinae muscle and transverse process, with spread monitored via ultrasound."
219703524|NCT06833697|PROCEDURE|serratus posterior superior intercostal plane block|"In Group 3, SPSIP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed laterally with the surgical side up, using a sterile ultrasound probe cover.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be positioned sagittally at the scapula's upper corner to visualize the rhomboid major, trapezius, serratus posterior superior muscles, and the third rib.~Anatomy Identification: The third rib and serratus posterior superior muscle will be identified.~Needle Insertion: Using an in-plane technique, the needle will be advanced between the serratus posterior superior muscle and the third rib.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected into the space, with spread monitored via ultrasound."
219703525|NCT06833697|DRUG|0.25% bupivacaine|0.25% bupivacaine
219703526|NCT00961064|DRUG|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
219703527|NCT00574314|OTHER|No Intervention|Participants will be consented.
219703528|NCT02397525|DRUG|LIPO-202|
219117328|NCT01338558|DRUG|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
219117329|NCT01338558|DRUG|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
219117330|NCT01338558|DRUG|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
219117331|NCT05443100|OTHER|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
219225396|NCT01982994|BEHAVIORAL|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
219117332|NCT05443100|OTHER|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
219117333|NCT06918691|BEHAVIORAL|technology addiction prevention program|technology addiction prevention program
219117334|NCT01779713|GENETIC|Case-control transcriptomic study|No intervention
219117335|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
219117336|NCT06618105|DRUG|Test Placebo|Matching Placebo of T inhalation aerosol
219117337|NCT06618105|DRUG|Reference Placebo|Matching Placebo of R inhalation aerosol
219117338|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
219117339|NCT05516017|DEVICE|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
219117340|NCT05516017|DEVICE|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
219117341|NCT06625853|OTHER|Mtwo R files with Xp-Endo finisher file|"XP-endo Finisher file will be inserted without rotation into the root canals filled with 2.5% NaOCl and will be activated (800 rpm; torque of 1 N.cm) for~1 min in each canal using slow and gentle 7-8 mm lengthwise movements."
219117342|NCT06625853|OTHER|Mtwo R files|obturation material will be removed using Mtwo R (VDW, Munich, Germany)files attached to an endodontic motor (Ecube, seachin, Korea) with a constant speed of 280 rpm, as suggested by the manufacturer. Mtwo R 25/0.05 will be used to empty the coronal and middle thirds of the root. Mtwo R 15/0.05 will be used to reach the working length.
219117343|NCT06626217|OTHER|Resting conditions|The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch
219117344|NCT06626217|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.
219117345|NCT06626217|OTHER|Circulation constriction|The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.
219703529|NCT04753801|BEHAVIORAL|Thinking, writing and imagination|All participants are asked to take some time to think and write about the respective intervention group's content. In some groups (after the writing exercise (approx. 15min)), participants are also asked to imagine that content or engage in a mindfulness activity or recall task for about 5 minutes.
219703530|NCT00576758|DRUG|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
219703531|NCT00576758|DRUG|rituximab|375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
219703532|NCT01262586|DRUG|Vildagliptin|
219703533|NCT01262586|DRUG|Glimepiride|
219703534|NCT04023968|BEHAVIORAL|YESplus workshop|"See description in Arms section."
219703535|NCT04023968|BEHAVIORAL|WOW! workshop|"See description in Arms section."
219703536|NCT02456311|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
219703537|NCT02866981|OTHER|Observation|
219117346|NCT06626217|OTHER|Physical exercise|The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
219117347|NCT06626178|DIAGNOSTIC_TEST|Computed tomography (CT) scan low dose|The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.
219117348|NCT06626178|PROCEDURE|Blood sampling|Peripheral venous blood sampling (20 ml)
219117349|NCT06626178|PROCEDURE|Tissue sampling (lung)|sampling of tumor and healthy tissue during surgery
219117350|NCT06626178|OTHER|Spirometry|Spirometry measurement using spirometer
219117351|NCT06626178|OTHER|Questionnaires|Compilation of epidemiological questionnaire, quality of life questionnaires
219117352|NCT06626178|OTHER|Smoking cessation program|Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases
219117353|NCT06626178|OTHER|Carbon monoxide measurment|Measurment of Carbon monoxide (CO)
219117354|NCT06626178|OTHER|Cardiovascular primary prevention|Intervention done in order to find the presence of coronary calcifications
219117355|NCT06863662|DRUG|Etoricoxib + Tizanidine fixed dose|One sachet with 120 mg / 4 mg, dissolved in 100 mL of water
219117356|NCT06863662|DRUG|Etoricoxib fixed dose|One sachet with 120 mg, dissolved in 100 mL of water
219117357|NCT06624852|OTHER|Screening for coronary artery revascularization based on TMT-ECG|Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT
219117358|NCT06626386|DIAGNOSTIC_TEST|PSA testing|PSA Testing in venipunctate and capillary blood
219117359|NCT05314556|BEHAVIORAL|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
219117360|NCT01803841|PROCEDURE|Transradial coronary angiography and intervention|
219703538|NCT02166112|PROCEDURE|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
219703539|NCT01294046|DEVICE|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
219703540|NCT00026130|DRUG|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
219703541|NCT00026130|DRUG|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
219703542|NCT00026130|RADIATION|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
219117361|NCT01803841|PROCEDURE|Transfemoral coronary angiography and intervention|
219117362|NCT04147767|DIETARY_SUPPLEMENT|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols"
219117363|NCT04147767|DIETARY_SUPPLEMENT|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
219117364|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
219703543|NCT05721313|PROCEDURE|root resection|It will be carried out under local anestesia. Intra-crevicular or para-marginal gingival incision will be carried out and full-tickness mucoperiostal flaps will be raised to expose the affected roots. Whit the use (if possible) of a surgical stent an incision will be performed on the root to be removed. Biodentine will be used for retrogade obturation. The flaps will be sutured.
219703544|NCT00761319|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
219703545|NCT00761319|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
219703546|NCT00123136|DEVICE|foot energizer|
219703547|NCT02556749|DIETARY_SUPPLEMENT|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
219703548|NCT02556749|DIETARY_SUPPLEMENT|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
219703549|NCT04454606|DEVICE|Fit test|"Bitrex Fit Test The Bitrex test uses a person's ability to test a bitter solution to determine whether a respirator fits properly\[11\]. Each subject was given a taste-threshold screening test prior to each fit test to ensure that he or she could taste. This process was done without subject wearing a respirator. After passing the sensitivity test, the subject will process to 7 steps of fit test as following~* Breathe normally~* Breathe deeply~* Head side to side~* Head up and down~* Bent over wrist, jogging~* Talking~* Breath normally Each step took 60 seconds and the Bitrex solution was refilled into the hood every 30 seconds with half dosage of the amount of the previously test. We asked the participant if he / she could taste the solution during each steps of the test . The test was considered a failure, otherwise, a pass."
219703550|NCT04454606|DEVICE|Filtration Test|"Respirator Performance~The real time respirator performance test method was developed using MT-05U machine (SIBATA model, Saitama, Japan), which measure particle concentrations of diameter 0.03 - 0.06 µm using and particle generator laser beam scattering particle counter that measure particles outside and inside the mask. The ratio between these two values reflected % leak as following:~* leak=((Paticle inside the filter))/((Paticle inside the filter)) x 100 And calculate % filter performance = 100 - % leak We tested at the airflow rate of 40L/min which is 3-4 times higher than normal physiology, assuming that there should be no leakage through the filter. We tested 2 types of filter is CareStar and SafeStar that was incorporated with the silicone mask. CareStar is limited for 24 hour usage and SafeStar is for 72 hour duration.~Study protocol"
219703551|NCT06074510|DRUG|Piflufolastat F 18 Intravenous Solution [PYLARIFY]|Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
219703552|NCT02101567|DRUG|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
219703553|NCT02101567|DRUG|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
219703554|NCT00623610|PROCEDURE|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
219703555|NCT04922281|DEVICE|Insertable Cardiac Monitor or external non-invasive LT-ECG patch|"Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection."
219703556|NCT06098183|OTHER|Whey Protein Isolate|Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving
219703557|NCT06098183|OTHER|Non-caloric Placebo water|Non-caloric placebo
219703558|NCT02335281|PROCEDURE|FMT|Standardized FMT once
219703559|NCT02335281|DRUG|Mesalazine|2g Po perday
219703560|NCT03890575|PROCEDURE|Airway stent implantation|The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
219117365|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
219117366|NCT03239405|DEVICE|Suction callibrated system|One-step suction callibrated SG system
219117367|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
219117368|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
219117369|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
219117370|NCT02841267|DRUG|PF 06252616|
219117371|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
219117372|NCT06692452|DRUG|Tazemetostat|EZH2 inhibitor, 200 mg tablet, taken orally per protocol.
219117373|NCT06692452|DRUG|Doxorubicin|Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.
219117374|NCT06692452|DRUG|Vincristine|Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.
219117375|NCT06692452|DRUG|Prednisone|Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.
219117376|NCT06692452|DRUG|Cytoxan|Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.
219117377|NCT06692452|DRUG|Carmustine|Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.
219703561|NCT00407875|PROCEDURE|Intensity Modulated External Beam Radiation Therapy|
219703562|NCT01902667|PROCEDURE|Magnetic Resonance Imaging|
219703563|NCT04319224|DRUG|Vopratelimab|Specified dose on specified days
219703564|NCT04319224|DRUG|Ipilimumab|Specified dose on specified days
219703565|NCT04319224|DRUG|Nivolumab|Specified dose on specified days
219703566|NCT04319705|DRUG|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
219703567|NCT04319705|DRUG|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
219703568|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using V technique
219703569|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using palpation technique
219703570|NCT05105685|DRUG|recombinant human growth hormone|RhGH treatment was started at 0.1 IU/kg once daily
219703571|NCT05105685|DRUG|Saline|Saline was started at 0.1 IU/kg once daily as the placebo
219703572|NCT05226429|BIOLOGICAL|UNAIR Inactivated COVID-19 Vaccine|UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
219117378|NCT06692452|DRUG|Etoposide|Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.
219117379|NCT06692452|DRUG|Cytarabine|Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care
219117380|NCT06692452|DRUG|Melphalan|Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
219117381|NCT06695195|DRUG|Cannabidiol (CBD)|25 mg capsule twice daily
219117382|NCT06695195|DRUG|Placebo|25 mg capsule twice daily
219117383|NCT06686303|OTHER|High frequency Segmental Vibrator|Segmental vibrations of high frequency was used on each flexor and extensor interspersed with a 1 minute break.
219117384|NCT06686303|OTHER|Combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.|Segmental vibrations of high frequency with Neuromuscular Electrical Stimulation was given on each flexor and extensor.
219117385|NCT06710379|DRUG|ADRX-0405|Antibody Drug Conjugate targeting STEAP1
219117386|NCT06698809|DEVICE|Active tPBM|tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.
219703573|NCT05226429|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
219703574|NCT02705430|DIETARY_SUPPLEMENT|EPA and DHA capsules of 2 g/day|EPA and DHA capsules of 2 g/day
219703575|NCT02705430|BEHAVIORAL|Stress management phone application (Eco Fusion Mentally)|Stress management phone application (Eco Fusion Mentally)
219703576|NCT02705430|BEHAVIORAL|life style program using a mobile phone (Eco Mentally and NewMe)|life style program using a mobile phone (Eco Mentally and NewMe)
219703577|NCT02705430|DEVICE|mobile phone|mobile phone
219703578|NCT02882971|BEHAVIORAL|Pain Assessment|To create an objective observational pain scoring system and validate.
219703579|NCT03831022|OTHER|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
219703580|NCT04044508|DIETARY_SUPPLEMENT|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
219117387|NCT05623137|DEVICE|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
219117388|NCT05623137|DEVICE|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy \& Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
219117389|NCT05623137|OTHER|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
219117390|NCT04894578|PROCEDURE|reverse distal metatarsal minimal-invasive osteotomy|minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
219117391|NCT04894578|PROCEDURE|tarsometatarsal fusion|open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
219117392|NCT04321993|DRUG|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
219117393|NCT04321993|DRUG|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
219117394|NCT04321993|DRUG|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
219117395|NCT04321993|DRUG|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
219117396|NCT02635087|DEVICE|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
219117397|NCT06744933|COMBINATION_PRODUCT|Self-administered auricular acupressure integrated with a smartphone application|"6 to 8 Vaccariae Semen ear patches will be affixed on one ear of the patient. The patient will be required to press on the ear patches 3 times a day, and 30 minutes before a meal. Every 3 to 4 days, the patient will visit the clinic to change a new set of ear patches on the same auricular acupoints of the opposite ear alternately. The whole course of intervention will be 8 weeks. The smartphone app will send scheduled pop-up notifications to remind patients to press on the ear patches. The patient will be required to enter the number of times pressing and of defaecation every day on the smartphone application. The smartphone application will send more notifications to the patient if he/ she has a low compliance. When the participants record the number of times pressing on the auricular acupoints, positive reinforcement messages will pop-up, such as Excellent job! for those with good compliance while You are almost there! Keep going! for those with poor compliance."
219117398|NCT06909708|PROCEDURE|SIRT|Y-90 administered
219117399|NCT06909708|PROCEDURE|cTACE|cTACE administered
219117400|NCT06910969|BEHAVIORAL|HORIZONS Intervention|Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions
219117401|NCT06910969|BEHAVIORAL|Minimally enhanced usual care|Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations
219117402|NCT06912308|OTHER|Active Physiotherapy|Involves patient-driven exercises such as verticalization, sitting on the edge of the bed, and active breathing exercises.
219225397|NCT04913103|DRUG|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
219117403|NCT06912308|OTHER|Passive Physiotherapy|Employs methods like passive movements and electrostimulation of the diaphragm, providing therapeutic benefits without requiring active patient engagement.
219117404|NCT06919913|DIETARY_SUPPLEMENT|Culturelle Digestive Daily Probiotic Capsule|Each capsule contains 10 billion colony-forming units (CFU) of Lactobacillus rhamnosus GG. Subjects will self-administer 1 oral capsule daily for 6 weeks post operatively.
219117405|NCT06917807|PROCEDURE|Pericapsuler nerve group block|A single shot pericapsular nerve group block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
219117406|NCT06917807|PROCEDURE|Quadratus lumborum block|A single shot Quadratus lumborum block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
219117407|NCT00528190|DRUG|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
219117408|NCT01870817|DIETARY_SUPPLEMENT|Home jejunostomy feeding|
219117409|NCT04129580|DEVICE|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
219117410|NCT06788236|DRUG|AVTR101|three times daily
219117411|NCT06788236|DRUG|Placebo|three times daily
219117412|NCT03757169|OTHER|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
219117413|NCT03757169|OTHER|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
219117414|NCT00394875|PROCEDURE|Treated and educated by nurses specialized in diabetes.|
219117415|NCT03159650|DEVICE|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
219117416|NCT02435511|OTHER|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
219117417|NCT01766518|DRUG|Mycophenolate mofetil|MY-REPT capsule 500\~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
219117418|NCT01332240|PROCEDURE|Endoscopic ultrasonography|in order to stage the mediastinum
219117419|NCT02875678|DRUG|ABX-1431|Single-dose ABX-1431
219117420|NCT02875678|DRUG|Placebo|Single-dose matching placebo
219117421|NCT05488379|OTHER|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
219117422|NCT00483821|OTHER|medical chart review|medical chart review
219117423|NCT02629445|DEVICE|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
219703581|NCT04044508|DIETARY_SUPPLEMENT|Fortini multifibre Nutrica (placebo)|Placebo diet
219117424|NCT03739385|OTHER|Exercise Intervention|The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
219117425|NCT02606747|OTHER||routine blood sugar control
219117426|NCT05187598|OTHER|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
219117427|NCT02079207|BIOLOGICAL|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
219117428|NCT02079207|BIOLOGICAL|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
219117429|NCT05148624|PROCEDURE|embryo transfer|immediate ambulation after embryo transfer
219117430|NCT02078310|DRUG|ITI-007|ITI-007 for Part 1
219117431|NCT02078310|DRUG|Placebo|ITI-007 for Part 1
219117432|NCT02078310|DRUG|ITI-007|ITI-007 for Part 2
219117433|NCT02078310|DRUG|Placebo|Placebo for Part 2
219117434|NCT04911114|BEHAVIORAL|Be-Balanced|The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).
219117435|NCT04227925|BIOLOGICAL|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
219703582|NCT01724268|DRUG|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
219703583|NCT01724268|DRUG|Anti TNF + Meth|
219703584|NCT01620424|DRUG|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
219703585|NCT01620424|DRUG|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
219703586|NCT06522425|OTHER|mindfulness-based serious games|The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.
219703587|NCT01859039|BIOLOGICAL|Administration of Live attenuated influenza vaccine|
219703588|NCT02995148|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
219703589|NCT02995148|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219117436|NCT00224133|DRUG|Silodosin|8 mg daily
219117437|NCT06258239|OTHER|Communication between nursing staff and participants|The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.
219117438|NCT02372175|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
219117439|NCT00000764|DRUG|Isotretinoin|
219117440|NCT00000764|DRUG|Interferon alfa-2a|
219117441|NCT00151008|DRUG|Bexarotene/NBUVB vs placebo NBUVB|
219117442|NCT01639261|DRUG|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever \>38,5 dose increase: 50µg/m² BSA three times/week
219117443|NCT02468505|BEHAVIORAL|STEPS|time-limited behavioral counseling, online materials, training
219117444|NCT02968940|BIOLOGICAL|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
219117445|NCT02968940|RADIATION|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
219703590|NCT00674726|OTHER|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
219703591|NCT05024448|DRUG|Prednisone|oral administration, 60mg/d for 10d
219117446|NCT03869710|DEVICE|Ultrasound-guided Dry-Needling Therapy|The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
219117447|NCT04896905|OTHER|Rehabilitation|Rehabilitative procedures in isolation ward
219117448|NCT02718417|DRUG|carboplatin|Given Q3W during chemotherapy phase
219117449|NCT02718417|DRUG|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
219117450|NCT02718417|DRUG|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
219117451|NCT02718417|DRUG|Avelumab|Given as single agent in maintenance portion Q2W
219117452|NCT05881083|BEHAVIORAL|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
219117453|NCT05881083|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
219117454|NCT01220674|OTHER|cognitive testing|computer-based cognitive assessment
219117455|NCT05854940|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Intelligent diagnostic system based on Raman spectrum of serum
219117456|NCT06029218|RADIATION|Proteus ONE one daily beam|A single daily beam is used, doubling the dose delivered for this treatment incidence.
219117457|NCT06029218|RADIATION|Proteus ONE two daily beam|two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
219117458|NCT01938664|DRUG|Candesartan with CBT|8 mg, po (by mouth)
219117459|NCT01938664|OTHER|Placebo with CBT|
219117460|NCT05894759|BEHAVIORAL|Psychological stress relief techniques|Psychological stress relief techniques
219117461|NCT02486705|BEHAVIORAL|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
219117462|NCT02486705|BEHAVIORAL|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
219117463|NCT06501300|BEHAVIORAL|Emotion-focused: Tuning in to Kids in School|The aim of the TIKiS is to improve emotion coaching and reduce emotion dismissing in elementary school teachers through six x 90-minute group sessions.
219117464|NCT03985098|BEHAVIORAL|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
219117465|NCT00790829|DRUG|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
219117466|NCT00386711|BEHAVIORAL|training on identification of suicide risk and depression|
219117467|NCT03040219|DRUG|Folic Acid|Tablets
219117468|NCT01668875|OTHER|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
219117469|NCT01668875|OTHER|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
219117470|NCT04270513|OTHER|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
219117471|NCT00004645|PROCEDURE|Plasma exchange|
219117472|NCT03685747|DRUG|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
219117473|NCT01962064|BEHAVIORAL|Cognitive assessment|
219117474|NCT01962064|OTHER|Brain imaging examination MRI|
219117475|NCT00795132|DRUG|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
219703592|NCT05240690|BIOLOGICAL|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
219703593|NCT00815529|DEVICE|Acupuncture, Pak-sham needle|25\*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
219703594|NCT01715298|DRUG|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
219703595|NCT01715298|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
219117476|NCT00795132|DRUG|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
219117477|NCT00795132|DRUG|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
219117478|NCT00795132|DRUG|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
219117479|NCT00795132|DRUG|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
219117480|NCT00002956|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
219117481|NCT03082300|DRUG|naquotinib|Oral
219117482|NCT02883322|OTHER|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
219117483|NCT01547104|DRUG|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
219117484|NCT01547104|DRUG|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
219117485|NCT05523622|DEVICE|Tono-Vera tonometer|The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
219117486|NCT05523622|DEVICE|Goldman Applanation Tonometry|This is the current gold standard for measuring eye pressure.
219117487|NCT05799924|DEVICE|Transcutaneous electrical acupoint stimulation|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
219117488|NCT05799924|DRUG|non steroidal anti inflammatory drugs|Hormonal contraception can suppress ovulation, NSAIDS can ease pain
219117489|NCT00042393|DRUG|Adefovir Dipivoxil|
219117490|NCT02451930|DRUG|Necitumumab|Administered IV
219117491|NCT02451930|DRUG|Pembrolizumab|Administered IV
219703596|NCT00193635|DRUG|mycophenolate mofetil|oral drug administration
219117492|NCT05616208|BIOLOGICAL|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
219117493|NCT05156801|DEVICE|ArchSinus stent|Post FESS unilateral placement of the ArchSinus stent into the randomized ethmoid sinus cavity.
219117494|NCT00835874|DRUG|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
219225398|NCT04913103|DRUG|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
219225399|NCT04913103|DRUG|Rituximab|treatment by a study drug rituximab, i.v.
219225400|NCT01920126|DRUG|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
219703597|NCT00910975|DRUG|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
219703598|NCT00910975|DRUG|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
219225401|NCT01920126|DRUG|Saline|
219225402|NCT02317172|OTHER|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
219225403|NCT04528914|OTHER|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
219703599|NCT05764499|OTHER|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
219703600|NCT03837847|BEHAVIORAL|Health Coaching Calls|Participants in this group will receive 12 weekly health coaching calls
219703601|NCT03837847|BEHAVIORAL|Control|Participants in this group will receive 6 educational guides
219703602|NCT00953433|DEVICE|Endoflex tube|Size decided upon gender.
219703603|NCT00953433|DEVICE|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
219703604|NCT00187434|DEVICE|Infant Flow System|
219703605|NCT00187434|DEVICE|Bubble CPAP|
219117495|NCT03681340|OTHER|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
219117496|NCT03681340|OTHER|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
219117497|NCT00000286|DRUG|Nefazodone|
219117498|NCT03406429|DEVICE|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
219117499|NCT03406429|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
219703606|NCT06109298|OTHER|Cold spray|Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
219703607|NCT06109298|OTHER|Refrigerated gel ice|Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
219703608|NCT04652089|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 7 days
219117500|NCT05483842|OTHER|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
219117501|NCT05483842|OTHER|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
219117502|NCT02991287|PROCEDURE|Inguinal hernia repair|
219117503|NCT02991287|PROCEDURE|Abdominal hysterectomy|
219117504|NCT02991287|PROCEDURE|Vaginal hysterectomy|
219117505|NCT02991287|PROCEDURE|Thoracotomy|
219117506|NCT03704311|PROCEDURE|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
219117507|NCT04344834|DIAGNOSTIC_TEST|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
219550767|NCT00905008|PROCEDURE|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
219703609|NCT04652089|DRUG|Placebo|Placebo once a day for 7 days
219703610|NCT02508792|DEVICE|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
219703611|NCT02508792|DEVICE|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
219703612|NCT01283347|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
219225404|NCT03776760|DEVICE|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
219225405|NCT03776760|DRUG|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
219225406|NCT03776760|DRUG|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
219225407|NCT04730726|DEVICE|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
219117508|NCT03655496|DEVICE|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
219117509|NCT03826563|DRUG|oral melatonin tablets (NatureMade brand)|melatonin tablets
219117510|NCT03826563|OTHER|Placebo|pill placebo
219117511|NCT01387256|DRUG|medical abortion|pregnancy termination with drugs
219117512|NCT06279429|DIETARY_SUPPLEMENT|Sideral® Sucrosomial Iron|Sucrosomial Iron 30mg
219117513|NCT06279429|DIETARY_SUPPLEMENT|Iron chewable tablet|Iron chewable tablet 100mg
219117514|NCT00788424|DRUG|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
219703613|NCT03860753|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
219703614|NCT03860753|DRUG|Placebo|Pill capsules will look same as that of active drug.
219703615|NCT06076590|DRUG|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
219117515|NCT06036394|DIAGNOSTIC_TEST|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
219117516|NCT00886470|BIOLOGICAL|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
219117517|NCT02807246|BIOLOGICAL|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
219117518|NCT02807246|OTHER|drops of saline|Dietary Supplement: Breast milk +drops of saline
219117519|NCT04128033|OTHER|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
219117520|NCT04128033|OTHER|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
219117521|NCT04763083|DRUG|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
219117522|NCT05961813|BEHAVIORAL|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
219117523|NCT05961813|BEHAVIORAL|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
219225408|NCT06428656|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule of postbiotics supplement per day
219225409|NCT06428656|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule of placebo per day
219550768|NCT00905008|DEVICE|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
219550769|NCT03600753|OTHER|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
219703616|NCT05733338|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
219550770|NCT03600753|OTHER|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
219550771|NCT04711057|OTHER|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
219550772|NCT04711057|OTHER|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
219550773|NCT02702895|BEHAVIORAL|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
219550774|NCT05756218|OTHER|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
219550775|NCT06462495|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
219117524|NCT06413550|BIOLOGICAL|Hibiscus Sabdariffa|The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
219117525|NCT00980109|DRUG|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
219225410|NCT06002087|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
219703617|NCT05733338|OTHER|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
219117526|NCT00980109|DRUG|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
219117527|NCT00980109|DRUG|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
219117528|NCT00980109|DRUG|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
219117529|NCT05843630|DIAGNOSTIC_TEST|without|without
219117530|NCT03479060|PROCEDURE|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
219117531|NCT04936490|DRUG|Crocin|15 mg/d
219117532|NCT04936490|DRUG|Placebo|15 mg/d
219117533|NCT06446843|COMBINATION_PRODUCT|(Arthrocentesis followed by i-PRF +HA)|Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
219117534|NCT05721027|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg PO every 8 hours as needed for 7 days
219117535|NCT05721027|DRUG|Dexamethasone Oral|Dexamethasone 16 mg PO during ED visit and next day
219703618|NCT03424304|DEVICE|Excel V™ Laser With Green Genesis|Subject(s) will receive treatments with a Cutera Excel V™ Laser
219703619|NCT03415880|BEHAVIORAL|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
219703620|NCT03415880|DEVICE|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
219703621|NCT03415880|DEVICE|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
219117536|NCT05721027|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
219117537|NCT05609019|DRUG|SYHX2005|Tablets. Take orally.
219117538|NCT02260089|DRUG|Low dose of telmisartan|
219703622|NCT03415880|BEHAVIORAL|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
219117539|NCT02260089|DRUG|High dose of telmisartan|
219117540|NCT02260089|DRUG|Placebo|
219117541|NCT01700504|DRUG|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
219117542|NCT03908281|BEHAVIORAL|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
219117543|NCT03908281|BEHAVIORAL|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
219225411|NCT04863365|DRUG|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
219225412|NCT04863365|DRUG|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
219225413|NCT02131922|PROCEDURE|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
219225414|NCT02131922|PROCEDURE|Dental Hygienization Treatment|
219225415|NCT02131922|DRUG|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
219360937|NCT01345500|OTHER|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
219703623|NCT03415880|BEHAVIORAL|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
219117544|NCT03215121|PROCEDURE|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
219117545|NCT03215121|PROCEDURE|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
219117546|NCT03215121|PROCEDURE|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
219117547|NCT04403061|DIAGNOSTIC_TEST|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
219703624|NCT01104844|DRUG|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
219703625|NCT01104844|DRUG|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
219703626|NCT01104844|DRUG|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
219703627|NCT01104844|DRUG|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
219703628|NCT01104844|DRUG|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
219703629|NCT01104844|DRUG|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
219703630|NCT01104844|DRUG|Placebo|2 placebo tablets
219703631|NCT00667264|PROCEDURE|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
219703632|NCT02348333|DRUG|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
219703633|NCT02348333|DRUG|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
219703634|NCT00726453|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
219703635|NCT00635713|DRUG|Fulvestrant|125mg
219703636|NCT00635713|DRUG|Anastrozole|ARIMIDEX
219703637|NCT00635713|DRUG|Fulvestrant|250mg
219703638|NCT04128553|BEHAVIORAL|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
219703639|NCT03507101|OTHER|No intervention|No particular intervention or exposure is of particular interest
219703640|NCT03951389|OTHER|Non-interventional|Non-interventional
219703641|NCT02865291|DEVICE|ForConti device|
219703642|NCT03171259|OTHER|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
219703643|NCT03750565|DRUG|TD-1473 - Dose A|oral capsule/tablet, QD
219703644|NCT03750565|DRUG|TD-1473 - Dose B|oral capsule/tablet, QD
219703645|NCT03750565|DRUG|TD-1473 - Dose C|oral capsule/tablet, QD
219703646|NCT03750565|DRUG|Placebo|oral capsule/tablet, QD
219703647|NCT03310840|OTHER|others|others
219703648|NCT05707676|DRUG|LB4330|LB4330
219703649|NCT01395719|OTHER|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
219703650|NCT01374386|BEHAVIORAL|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
219117548|NCT04403061|DIAGNOSTIC_TEST|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
219117549|NCT04403061|DIAGNOSTIC_TEST|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
219117550|NCT04403061|DIAGNOSTIC_TEST|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
219117551|NCT03950219|OTHER|Group course|Education and support
219117552|NCT01440049|OTHER|Prospective Observational|this is an observational study non interventional
219117553|NCT05226845|OTHER|prescribed exercise|the therapist chooses the five exercises to do
219117554|NCT05226845|OTHER|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
219117555|NCT00540605|DRUG|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
219117556|NCT03433092|OTHER|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
219117557|NCT04314128|DIAGNOSTIC_TEST|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
219117558|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
219117559|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
219117560|NCT05126446|DEVICE|the Aorta Arch Stent Graft System combined with the Endovascular Needle System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with device
219117561|NCT00671541|DRUG|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
219117562|NCT00671541|DRUG|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
219117563|NCT04329052|BEHAVIORAL|Adventure-based training with health educational talk|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
219117564|NCT01476579|DEVICE|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
219117565|NCT01386840|OTHER|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
219117566|NCT02537353|DEVICE|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
219117567|NCT02537353|DRUG|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
219703651|NCT01963806|BEHAVIORAL|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
219117568|NCT02537353|PROCEDURE|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
219703652|NCT01963806|BEHAVIORAL|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
219117569|NCT02537353|DRUG|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
219117570|NCT02184897|DRUG|lenograstim 10 microgram/kg/day|
219117571|NCT02261415|DRUG|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
219117572|NCT02261415|DRUG|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
219117573|NCT03617874|OTHER|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
219117574|NCT03617874|OTHER|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
219117575|NCT01999660|DEVICE|SpaceOAR™ implantation|
219117576|NCT01587729|DRUG|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
219117577|NCT02602457|BEHAVIORAL|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
219117578|NCT02602457|BEHAVIORAL|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
219117579|NCT02273011|PROCEDURE|caesarean section|elective caesarean section under regional anesthesia
219117580|NCT02948946|PROCEDURE|NETest|5 mL of blood will be drawn from participants for testing.
219117581|NCT02900781|DEVICE|Steprite™|Steprite™ Device shoe insert monitoring device
219117582|NCT02900781|OTHER|Standard of care|No Device. Standard of care physical therapy
219117583|NCT03795805|PROCEDURE|total knee arthroplasty|Total knee arhroplasty
219117584|NCT03795805|PROCEDURE|Tourniquet limb cuff|Tourniquet limb cuff and regular anesthesia
219117585|NCT03795805|DRUG|Intaarticular lidocain|20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
219117586|NCT02453087|DRUG|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
219117587|NCT02453087|DRUG|Rituximab|Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
219117588|NCT02453087|DRUG|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
219117589|NCT02862704|BIOLOGICAL|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
219117590|NCT02472314|DRUG|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
219117591|NCT02472314|DRUG|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
219117592|NCT03149211|DRUG|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
219117593|NCT03149211|DRUG|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
219117594|NCT06417905|OTHER|Supervised exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
219117595|NCT06417905|OTHER|video based exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
219117596|NCT03631147|DRUG|Rifaximin|400mg bid for 8 weeks
219117597|NCT03391713|BEHAVIORAL|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
219117598|NCT02889042|OTHER|MRI and biological assessment|performing a MRI and a biological assessment
219117599|NCT06357364|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
219117600|NCT06357364|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
219117601|NCT06357364|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
219117602|NCT00090272|DRUG|MK0826, ertapenem sodium|
219117603|NCT00090272|DRUG|Comparator: cefotetan|
219117604|NCT03415022|BEHAVIORAL|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
219117605|NCT01702389|DRUG|Remifentanil|
219117606|NCT04466618|BIOLOGICAL|Saline|Saline infused during the study
219117607|NCT04466618|BIOLOGICAL|Exendin-9,39|Exendin-9,39 infused during the study
219117608|NCT04466618|BIOLOGICAL|Saline + Intralipid/Heparin|Saline infused during acute insulin resistance
219117609|NCT04466618|BIOLOGICAL|Exendin-9,39 + Intralipid/Heparin|Exendin-9,39 infused during acute insulin resistance
219117610|NCT04730934|OTHER|Perceived stress scale|Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
219117611|NCT04730934|OTHER|Fibromyalgia impact questionnaire|Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
219117612|NCT04730934|OTHER|The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status|"Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better."
219117613|NCT04947969|DEVICE|laser acupuncture|This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
219117614|NCT01433653|BEHAVIORAL|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
219117615|NCT01897857|DEVICE|duplex Doppler ultrasonography|
219117616|NCT05543421|DEVICE|TMS|rTMS (30sessions) or iTBS (40sessions)
219117617|NCT02949518|OTHER|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
219117618|NCT00906503|DRUG|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
219703653|NCT01963806|OTHER|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
219117619|NCT00906503|PROCEDURE|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
219117620|NCT00906503|RADIATION|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
219117621|NCT03142217|OTHER|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
219703654|NCT01345799|DRUG|TRK-170|
219703655|NCT01345799|DRUG|Placebo|
219703656|NCT01432951|DRUG|Enzastaurin|Administered orally
219703657|NCT03969537|OTHER|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
219703658|NCT04464460|DRUG|TAK-671|TAK-671 intravenous infusion.
219703659|NCT04464460|DRUG|TAK-671 Placebo|TAK-671 placebo-matching intravenous infusion.
219703660|NCT00853385|DRUG|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
219703661|NCT00853385|DRUG|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
219703662|NCT00853385|OTHER|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
219703663|NCT00853385|OTHER|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
219703664|NCT00853385|BIOLOGICAL|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
219703665|NCT06265025|DRUG|GM103 (Part A)|dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
219703666|NCT06265025|DRUG|GM103 (Part B)|dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
219117622|NCT03372486|DRUG|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
219117623|NCT03372486|DRUG|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
219117624|NCT06504576|DRUG|Cilostazol 50 MG Oral Tablet|Two consecutive weeks of Cilostazol (50mg BID) two days after admission
219703667|NCT06265025|DRUG|GM103 and Pembrolizumab (Part C)|dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
219703668|NCT01951950|DRUG|Nicardipine|
219703669|NCT01951950|DRUG|Esmolol|
219703670|NCT00915525|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
219703671|NCT06436859|BEHAVIORAL|stress ball group|"According to randomization, pregnant women in the intervention group will receive stress ball therapy during labor."
219703672|NCT00176046|DRUG|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
219703673|NCT00176046|DRUG|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
219703674|NCT05550181|BEHAVIORAL|intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)|A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
219703675|NCT06216340|DRUG|Henagliflozin|10mg of Henagliflozin and diet-exercise therapy
219703676|NCT06216340|DRUG|Placebo|Placebo and diet-exercise therapy
219703677|NCT02955927|DRUG|0.01% atropine eye drops|
219117625|NCT06504576|PROCEDURE|Conventional internal medicine treatment|Receives only conventional internal medicine treatment
219117626|NCT02981485|DEVICE|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
219117627|NCT00004767|DRUG|Sodium Benzoate|
219117628|NCT00004767|DRUG|Sodium Phenylacetate|
219117629|NCT00004767|DRUG|Sodium Phenylbutyrate|
219117630|NCT00004767|BEHAVIORAL|Dietary Intervention|
219117631|NCT06478875|COMBINATION_PRODUCT|[68Ga]Ga-PentixaFor PET imaging|PET imaging of adrenal glands
219703678|NCT02955927|DEVICE|ortho-k|
219703679|NCT00126945|BIOLOGICAL|Meningococcal Vaccine|
219703680|NCT05250869|DIAGNOSTIC_TEST|HPLC/MS|Quantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions
219703681|NCT05164211|OTHER|Didgeridoo|the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
219703682|NCT02650817|DRUG|RAD1901|RAD1901, a novel selective ER degrader (SERD)
219703683|NCT05716464|BEHAVIORAL|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
219225416|NCT05014607|BIOLOGICAL|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
219703684|NCT05716464|BEHAVIORAL|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
219703685|NCT03006120|PROCEDURE|Retroperitoneal hematoma due to cardiac catheterization|
219703686|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
219703687|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
219117632|NCT04934319|BEHAVIORAL|Balance and Proprioceptive Training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks"
219117633|NCT03757611|DIETARY_SUPPLEMENT|Tabetri capsule|1,000 mg/capsule (Taheebo extract 600 mg/day)
219703688|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
219117634|NCT03757611|DIETARY_SUPPLEMENT|Placebo capsule|1,000 mg/capsule
219225417|NCT01939509|DRUG|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
219225418|NCT01939509|DRUG|Bisoprolol|
219225419|NCT03735381|DEVICE|Pedometer watch 'Xiomi mi band2'|"1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
219703689|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
219703690|NCT03613298|DEVICE|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
219703691|NCT03587597|PROCEDURE|socket shield technique|socket shield technique with immediate temporization
219117635|NCT01684488|BEHAVIORAL|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
219117636|NCT01684488|OTHER|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
219225420|NCT03176056|DIETARY_SUPPLEMENT|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
219225421|NCT03176056|DIETARY_SUPPLEMENT|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
219225422|NCT03011047|PROCEDURE|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
219703692|NCT03587597|PROCEDURE|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
219703693|NCT01055912|DRUG|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
219703694|NCT01055912|DRUG|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
219703695|NCT02337582|OTHER|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
219703696|NCT02337582|OTHER|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
219225423|NCT03011047|PROCEDURE|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
219225424|NCT00953355|DRUG|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
219225425|NCT00953355|DRUG|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
219550776|NCT06462495|DRUG|[18F]F-PSMA-1007|Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
219550777|NCT00052949|DRUG|imatinib mesylate|Given orally
219550778|NCT00052949|OTHER|laboratory biomarker analysis|Correlative studies
219550779|NCT06292364|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
219550780|NCT06292364|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
219550781|NCT01588743|DRUG|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
219550782|NCT04727164|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
219550783|NCT00088608|DRUG|SOM230 s.c.|
219550784|NCT05232487|OTHER|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
219550785|NCT05232487|OTHER|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
219550786|NCT01533038|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
219550787|NCT01533038|PROCEDURE|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
219550788|NCT05456438|OTHER|İntervention 1|Group 1 applied coconut oil to the nipple
219550789|NCT05456438|OTHER|İntervention 2|Group 2 applied tea tree oil to the nipple
219550790|NCT00635687|DEVICE|Fibroscan|transient elastography measure - Liver stiffness
219550791|NCT02646800|DRUG|Micafungin|Injection
219550792|NCT05568849|DIAGNOSTIC_TEST|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
219550793|NCT00770952|DRUG|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
219550794|NCT00770952|DRUG|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
219550795|NCT05336487|OTHER|Physical activity|2 hours of physical activity per day, 5 days per week, for the intervention period
219550796|NCT03324815|DRUG|Morphine|Pain Treatment
219550797|NCT03324815|DRUG|Methadone|Pain Treatment
219117637|NCT03430128|DIETARY_SUPPLEMENT|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
219117638|NCT03430128|DIETARY_SUPPLEMENT|ENSURE|Liquid milk formula available over the counter
219703697|NCT00869180|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
219117639|NCT03518736|BEHAVIORAL|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
219117640|NCT00264043|DEVICE|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
219117641|NCT05611619|RADIATION|Tyre noise - continuous flow|Tyre noise from continuous traffic, throughout the night
219117642|NCT05611619|RADIATION|Tyre noise - discrete events|Tyre noise from few, discrete traffic events, occurring throughout the night
219117643|NCT05611619|RADIATION|High noise level|Tyre noise corresponding up to 65 dB LAEq,24h
219117644|NCT05611619|RADIATION|Moderate noise level|Tyre noise corresponding up to 60 dB LAEq,24h
219117645|NCT05611619|RADIATION|Low noise level|Tyre noise corresponding up to 55 dB LAEq,24h
219703698|NCT00869180|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
219703699|NCT03797053|PROCEDURE|Biological sample|"Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment"
219703700|NCT06317974|BEHAVIORAL|Breastfeeding education based on the Health Belief model|Training was given face to face with the participant, lasting approximately 40 minutes. One week after the training presentation, three short messages about the training were sent to the couples (both the pregnant woman and her partner) every other day. Two weeks after the training was given, a phone call was made for feedback. Post-test data were taken four weeks later.
219703701|NCT06551844|DRUG|Molnupiravir 400 mg|"This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.~In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed."
219117646|NCT05611619|RADIATION|Air-filled tyres|Tyre noise from traditional, air-filled tyres
219117647|NCT05611619|RADIATION|Composite tyres|Tyre noise from newly designed, airless composite tyres
219117648|NCT03645486|GENETIC|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight
219117649|NCT01041508|DRUG|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
219117650|NCT01041508|RADIATION|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
219117651|NCT01041508|OTHER|Stem Cell Transplantation|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
219117652|NCT01041508|DRUG|Cyclosporine|"Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age \> 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml."
219117653|NCT01041508|DRUG|Mycophenolate Mofetil|MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
219117654|NCT03033121|DRUG|Growth Hormone|
219117655|NCT06479993|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with chlorella (6g/day for 3-weeks)
219117656|NCT06479993|DIETARY_SUPPLEMENT|Placebo supplementation|Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)
219117657|NCT04690296|DEVICE|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
219117658|NCT05981729|OTHER|Technology enriched stroke rehabilitation|In order to increase time spent in rehabilitation activity, participants will be prescribed and supported to use (by NHS staff) commercially available technology, such as robotics, adapted treadmills, virtual reality, and mobile digital devices such as smartphones, tablets, and wearable sensors.
219117659|NCT05625841|OTHER|Honey product|Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
219117660|NCT05625841|OTHER|propolis|propolis
219117661|NCT05625841|OTHER|Usual care|Usual care
219117662|NCT00503828|DRUG|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
219117663|NCT00503828|DRUG|naproxen|Naproxen 500 mg/day for 4 weeks
219117664|NCT01285219|DRUG|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
219117665|NCT01285219|DRUG|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
219360938|NCT01345500|OTHER|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
219117666|NCT02056119|DEVICE|Vibrating Mesh Nebulizer Arm|"* Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
219117667|NCT02056119|DEVICE|Jet Nebulizer Arm|"* Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
219117668|NCT05089110|PROCEDURE|blood sample|5 cm blood sample from COVID-19 patients
219117669|NCT06460012|BEHAVIORAL|STELLA-R Curriculum|The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.
219117670|NCT06460012|BEHAVIORAL|Unrestricted Access|Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.
219117671|NCT06460012|BEHAVIORAL|Limited Access|Experimental and Waitlist Control group will experience 8 consecutive weeks of limited access to the STELLA-R website and resources. Waitlist Control will experience this from Week 1 to Week 8 while the Experimental Group will reach this phase from Week 17 to Week 24.
219117672|NCT04280328|DRUG|Ciforadenant|100 mg orally twice daily for 28-day cycles
219117673|NCT04280328|DRUG|daratumumab|"16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1"
219117674|NCT03220737|BIOLOGICAL|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
219117675|NCT03220737|OTHER|Placebo|Placebo control for this study is normal (0.9%) saline.
219117676|NCT02064725|DRUG|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
219117677|NCT00684983|DRUG|Capecitabine|Given PO
219117678|NCT00684983|BIOLOGICAL|Cixutumumab|Given IV
219225426|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
219703702|NCT06551844|DRUG|VIS513 (a monoclonal antibody)|VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.
219703703|NCT05737511|DRUG|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
219703704|NCT05737511|DRUG|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
219703705|NCT05799950|DEVICE|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
219703706|NCT05799950|DEVICE|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
219703707|NCT05207358|DRUG|Rituximab|2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
219703708|NCT05207358|DRUG|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
219703709|NCT05207358|DRUG|Cyclophosphamide|All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
219117679|NCT00684983|DRUG|Lapatinib Ditosylate|Given PO
219117680|NCT00684983|OTHER|Quality-of-Life Assessment|Ancillary studies
219117681|NCT03807193|BEHAVIORAL|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
219117682|NCT03807193|BEHAVIORAL|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
219117683|NCT03807193|BEHAVIORAL|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
219117684|NCT03807193|BEHAVIORAL|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
219117685|NCT02973126|PROCEDURE|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
219117686|NCT03093090|DIETARY_SUPPLEMENT|Water|6 oz
219117687|NCT03093090|DIETARY_SUPPLEMENT|Parmalat™ Whole Milk|6 oz
219117688|NCT03093090|DIETARY_SUPPLEMENT|Similac Pro-Advance™|6 oz
219117689|NCT03093090|DIETARY_SUPPLEMENT|Ensure Plus™|6 oz
219117690|NCT03093090|DRUG|Furosemide 20 MG|Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
219225427|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
219225428|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
219225429|NCT03055559|DIETARY_SUPPLEMENT|Globifer Forte|
219225430|NCT03948438|PROCEDURE|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
219225431|NCT04496388|BEHAVIORAL|exercise|different type of exercise
219225432|NCT04496388|BEHAVIORAL|No exercise intervention|No exercise intervention
219225433|NCT03543631|OTHER|Survey|Online survey
219225434|NCT02736422|OTHER|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
219703710|NCT05207358|DRUG|Corticosteroids|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
219703711|NCT01608594|DRUG|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
219703712|NCT01608594|DRUG|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
219117691|NCT00050401|DRUG|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
219117692|NCT00050401|DRUG|vancomycin I.V. 1 g every 12 hours|
219117693|NCT00050401|DRUG|tobramycin I.V. 5 mg/kg every 24 hours|
219117694|NCT00050401|DRUG|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
219225435|NCT02093169|DRUG|Part A: Lu AF35700|One 30 mg single dose for one day; orally
219225436|NCT02093169|DRUG|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
219225437|NCT03590899|DEVICE|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
219225438|NCT04486703|OTHER|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
219117695|NCT00050401|DRUG|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
219117696|NCT00594932|DRUG|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
219117697|NCT00594932|OTHER|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
219117698|NCT06641219|DRUG|One single intravenous injection of [177Lu]Lu-BQ7876|One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
219117699|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
219117700|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
219117701|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
219117702|NCT06255847|DRUG|Pomalidomide, cyclophosphamide combined with dexametha|The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
219117703|NCT03511079|BEHAVIORAL|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
219117704|NCT01719640|DRUG|infusion of MSCs|infusion of MSCs
219117705|NCT01719640|DRUG|infusion MCs|infusion of MCs
219117706|NCT01719640|DRUG|insulin|intensive insulin care
219117707|NCT04056728|BIOLOGICAL|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
219117708|NCT04496167|DRUG|EN3835|Collagenase clostridium histolyticum
219225439|NCT06566690|DEVICE|Addition of ORi monitoring to SpO2 monitoring|Integration of Oxygen Reserve Index (ORi) monitoring into standard SpO2 monitoring
219550798|NCT03088007|OTHER|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
219117709|NCT04496167|DRUG|Placebo|Placebo comparator
219117710|NCT00182663|DRUG|clarithromycin|Given PO
219117711|NCT00182663|DRUG|thalidomide|Given PO
219117712|NCT00182663|DRUG|dexamethasone|Given PO
219117713|NCT03436121|DRUG|Ketamine|"Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment."
219550799|NCT02979132|DRUG|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
219550800|NCT02979132|DRUG|Ferinject(R)|Single-dose Ferinject(R) administration
219550801|NCT02979132|DIETARY_SUPPLEMENT|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
219550802|NCT05118607|DEVICE|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
219550803|NCT00073632|BEHAVIORAL|Acceptance Based Behavioral Therapy|
219550804|NCT00948909|DRUG|Placebo|Placebo intervention
219550805|NCT00948909|DRUG|ABT-126|Experimental intervention
219550806|NCT00948909|DRUG|donepezil|Active comparator intervention
219550807|NCT04037488|DIAGNOSTIC_TEST|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
219550808|NCT03337893|DIAGNOSTIC_TEST|blood pressure|it will be done both right and left arms
219550809|NCT02670551|DRUG|Cariprazine|
219550810|NCT02670551|DRUG|Placebo|
219550811|NCT00490932|DRUG|Hypo-osmolar ORS|
219550812|NCT00139815|DRUG|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
219550813|NCT00139815|DRUG|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
219550814|NCT05485051|OTHER|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
219550815|NCT05485051|OTHER|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
219550816|NCT05650151|DIETARY_SUPPLEMENT|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
219550817|NCT05650151|DIETARY_SUPPLEMENT|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
219550818|NCT04736537|DEVICE|4DCT|CT imaging conceptually similar to time-lapse photography.
219550819|NCT02961205|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
219550820|NCT01962298|DRUG|sugammadex 2mg/kg|
219550821|NCT01962298|DRUG|neostigmine|
219550822|NCT01962298|DRUG|sugammadex 4mg/kg|
219550823|NCT01962298|DRUG|placebo|
219550824|NCT01962298|DRUG|Single rocuronium dose|
219550825|NCT01962298|DRUG|Repeated rocuronium dose|
219550826|NCT01962298|DRUG|Continuous rocuronium infusion|
219550827|NCT01971645|DRUG|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
219550828|NCT01971645|DRUG|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
219550829|NCT04476277|DRUG|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
219550830|NCT03840577|DEVICE|Monitorization of sedation by Bispectral Index|The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
219550831|NCT04020445|OTHER|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
219117714|NCT03436121|DRUG|Midazolam|In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
219117715|NCT03436121|DRUG|Placebo|In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
219117716|NCT02136485|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
219117717|NCT02136485|OTHER|waiting list control|
219117718|NCT02498743|PROCEDURE|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
219117719|NCT02498743|BEHAVIORAL|Watching Animated cartoons|
219117720|NCT05015673|DRUG|SEP363856|
219117721|NCT05015673|DRUG|Placebo|
219117722|NCT02433093|DRUG|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
219117723|NCT02433093|DRUG|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
219225440|NCT04333485|OTHER|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
219550832|NCT01940445|DEVICE|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
219550833|NCT01940445|DEVICE|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
219550834|NCT03076645|BEHAVIORAL|Facilitator support and education|Group engaged with facilitator support and education
219550835|NCT03284697|PROCEDURE|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
219550836|NCT03284697|PROCEDURE|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
219550837|NCT04173923|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
219550838|NCT04173923|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219550839|NCT04173923|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
219550840|NCT04173923|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219550841|NCT04173923|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219550842|NCT04173923|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219550843|NCT04173923|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
219550844|NCT05062564|DEVICE|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
219550845|NCT05062564|PROCEDURE|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
219550846|NCT00533507|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
219550847|NCT00533507|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
219550848|NCT00533507|BIOLOGICAL|Rotarix|Oral, 2 doses.
219550849|NCT02708758|BEHAVIORAL|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
219550850|NCT01022879|PROCEDURE|vitrectomy|
219550851|NCT03783897|DRUG|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
219117724|NCT05629442|OTHER|ctDNA|initial research biopsy, quality of life assessments and ctDNA collection
219117725|NCT00303082|DRUG|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
219117726|NCT03870087|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
219117727|NCT04612049|DEVICE|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
219117728|NCT02522546|OTHER|nasopharyngeal swab|nasopharyngeal swab
219117729|NCT00101569|DRUG|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
219117730|NCT00101569|DRUG|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
219117731|NCT04049721|PROCEDURE|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
219117732|NCT04049721|OTHER|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
219117733|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
219117734|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
219117735|NCT03584685|DEVICE|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
219225441|NCT04333485|OTHER|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
219225442|NCT05843552|OTHER|no intervention|no intervention, this is an observational study
219225443|NCT06040294|OTHER|DDS program|dementia virtual reality and disability simulation of activity design for seniors
219225444|NCT06040294|OTHER|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
219550852|NCT03783897|DRUG|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
219550853|NCT04955158|DRUG|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
219117736|NCT03584685|PROCEDURE|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
219117737|NCT05586074|DRUG|Clifutinib|tablet, oral
219117738|NCT05586074|DRUG|LoDAC|subcutaneous (SC) or intravenous (IV) injection
219117739|NCT05586074|DRUG|Azacitidine|SC or IV
219117740|NCT05586074|DRUG|Decitabine|IV
219117741|NCT05586074|DRUG|Ara-C±IDA|SC and IV
219117742|NCT05586074|DRUG|FLAG-IDA|SC and IV
219117743|NCT05249296|OTHER|Nature based solution for stress reduction|participation in nature activities: daily 30 min walking in nature
219117744|NCT05553574|BEHAVIORAL|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
219550854|NCT04955158|DRUG|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
219550855|NCT04955158|OTHER|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
219550856|NCT00249197|DRUG|levofloxacin|
219550857|NCT04184947|DRUG|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
219550858|NCT04184947|DRUG|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
219550859|NCT03825198|PROCEDURE|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
219550860|NCT03825198|DRUG|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
219550861|NCT03825198|PROCEDURE|spine fusion|fusion of lumbar vertebral body on 1 or two levels
219550862|NCT03825198|DRUG|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
219550863|NCT03825198|DRUG|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
219550864|NCT03825198|DRUG|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
219550865|NCT03825198|DRUG|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
219550866|NCT03825198|DRUG|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
219550867|NCT03825198|DRUG|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
219550868|NCT03825198|DRUG|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
219550869|NCT03825198|DRUG|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
219550870|NCT03825198|DRUG|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
219550871|NCT03825198|DRUG|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
219550872|NCT03917758|DRUG|SGLT2 inhibitor|Start of the treatment with SGLT2i.
219550873|NCT01032590|BEHAVIORAL|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
219550874|NCT00213551|DRUG|Glutamine|
219117745|NCT03018106|DRUG|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
219117746|NCT03018106|DRUG|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
219117747|NCT05034510|DEVICE|Deep Brain Stimulation|modification in stimulation parameters
219225445|NCT03165734|DRUG|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
219117748|NCT00136916|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
219117749|NCT00136916|DRUG|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
219225446|NCT03165734|DRUG|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
219225447|NCT06461286|DRUG|PYC-001|Single Group Assignment
219225448|NCT05508464|RADIATION|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
219225449|NCT05508464|RADIATION|Arm 1: Standard of Care|Standard of care palliative radiotherapy
219225450|NCT06463340|DRUG|SGR-3515|SGR-3515 will be administered orally with an intermittent schedule.
219550875|NCT00213551|DRUG|Glucose|
219550876|NCT00213551|DRUG|glutamine-antioxidants containing solution|
219550877|NCT01828203|DRUG|Minocycline|
219550878|NCT01828203|DRUG|Placebo|
219550879|NCT01828203|PROCEDURE|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
219550880|NCT01828203|PROCEDURE|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
219550881|NCT00904280|DRUG|Oxymorphone ER|Open label
219550882|NCT01445860|DRUG|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
219550883|NCT03548480|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo
219550884|NCT03548480|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic
219550885|NCT05002660|BEHAVIORAL|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
219550886|NCT05002660|BEHAVIORAL|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
219550887|NCT03788876|OTHER|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
219550888|NCT03788876|OTHER|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
219550889|NCT01083329|BEHAVIORAL|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
219550890|NCT01083329|DRUG|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
219550891|NCT01083329|DRUG|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
219550892|NCT04316962|OTHER|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support."
219550893|NCT06357416|DEVICE|MV-POCT Sub-study|Point of care blood testing
219550894|NCT06357416|OTHER|Main Man Van Group Sub-study (MV-Eco)|Consent for long-term follow-up of patients
219550895|NCT06357416|OTHER|MV-QualQ Sub-study|Qualitative questionnaire and interview sub-study
219550896|NCT06357416|DIAGNOSTIC_TEST|MV-PRS Sub-study|Patients consenting to polygenic risk score testing
219550897|NCT06357416|OTHER|MV-DNA and MV-UctDNA Sub-study|Patients consenting to collection of DNA and urine for further study.
219550898|NCT06357416|OTHER|Man Van patients|All patients seen in Man Van
219550899|NCT06357416|OTHER|MV-SSI Sub-study|Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
219550900|NCT06357416|OTHER|MV-TPP Sub-study|Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
219550901|NCT01589835|BEHAVIORAL|Lifestyle changes|Green prescription with support from facilitator
219550902|NCT00881426|DRUG|Cefprozil 500 mg Tablets (Sandoz GmbH)|
219117750|NCT00897728|OTHER|laboratory biomarker analysis|
219117751|NCT04739683|DEVICE|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
219117752|NCT04739683|DEVICE|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
219117753|NCT03505411|DIETARY_SUPPLEMENT|melatonin supplementation|
219117754|NCT03619174|DEVICE|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
219117755|NCT00312975|DRUG|CP-675,206|Given intravenously every 3 months
219117756|NCT00312975|DRUG|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
219117757|NCT03354988|OTHER|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
219117758|NCT03354988|OTHER|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
219117759|NCT00059254|DIETARY_SUPPLEMENT|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
219117760|NCT00059254|DIETARY_SUPPLEMENT|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
219117761|NCT03779451|DRUG|17-OHPC|received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
219117762|NCT03779451|DRUG|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
219117763|NCT01850966|DRUG|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
219117764|NCT05331820|OTHER|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
219117765|NCT00283465|DRUG|Epoetin alfa|
219117766|NCT05608733|DRUG|Epidural catheter|Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.
219117767|NCT05608733|DRUG|Continuous sciatic nerve block|The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
219117768|NCT04763538|OTHER|Standard of care|Patients are treated according to the standard of care for each individual disease.
219117769|NCT02938741|DRUG|Anti-human Thymoglobulin|r-ATG 2.5MG/KG\*4days were used in the conditioning
219117770|NCT02938741|DRUG|Placebo|r-ATG 2.5MG/KG\*4days were not used in the conditioning
219117771|NCT00620165|DRUG|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
219550903|NCT00881426|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
219550904|NCT05575557|PROCEDURE|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
219550905|NCT01062490|DRUG|Treosulfan|14 g/m2/d, day -6 to -4
219550906|NCT01576705|DRUG|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
219550907|NCT01140607|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
219550908|NCT00268216|DRUG|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
219550909|NCT05560139|DEVICE|a-tDCS|Transcranial direct current stimulation
219550910|NCT06297408|DRUG|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
219550911|NCT03021876|DRUG|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
219550912|NCT03021876|OTHER|usual intake|baseliner
219550913|NCT01068704|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
219117772|NCT00620165|DRUG|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
219117773|NCT03963882|DRUG|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
219117774|NCT03963882|DIAGNOSTIC_TEST|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
219117775|NCT03963882|DIAGNOSTIC_TEST|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
219117776|NCT03963882|DRUG|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
219117777|NCT03963882|PROCEDURE|RH|Radical hysterectomy
219117778|NCT03963882|RADIATION|Radiochemotherapy|Concurrent radiochemotherapy
219117779|NCT03963882|DIAGNOSTIC_TEST|Pathologic evaluation|Pathologic evaluation for RH patients
219117780|NCT03938948|DEVICE|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
219117781|NCT03486899|DRUG|BMS-986036|Specified dose on specified days.
219117782|NCT03486899|OTHER|Placebo|Specified dose on specified days.
219117783|NCT00949962|DRUG|antiandrogen therapy|Given systemically
219117784|NCT00949962|DRUG|leuprolide acetate|Given subcutaneously
219117785|NCT00949962|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
219703713|NCT04571593|BEHAVIORAL|Yoga Nidra|The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
219703714|NCT01107015|DEVICE|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
219703715|NCT01107015|DEVICE|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
219117786|NCT03553940|BIOLOGICAL|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
219117787|NCT03553940|OTHER|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
219117788|NCT03553940|BIOLOGICAL|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
219117789|NCT00082290|OTHER|massage therapy|
219117790|NCT00082290|OTHER|visit with a volunteer|
219117791|NCT00082290|OTHER|period of quiet time|
219117792|NCT00082290|BEHAVIORAL|questionaire about pain|
219117793|NCT01010217|DRUG|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
219117794|NCT01010217|DRUG|Fludarabine|40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
219117795|NCT01010217|DRUG|Melphalan|140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
219117796|NCT01010217|DRUG|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
219117797|NCT01010217|DRUG|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
219117798|NCT01010217|PROCEDURE|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
219117799|NCT01010217|DRUG|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
219117800|NCT01010217|DRUG|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
219117801|NCT01010217|DRUG|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
219117802|NCT01010217|DRUG|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
219117803|NCT02212938|DRUG|BI 14332 CL|
219117804|NCT02212938|OTHER|high fat breakfast|
219117805|NCT00941278|DRUG|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
219117806|NCT01439711|DRUG|letrozole|
219117807|NCT01439711|PROCEDURE|MRI|
219117808|NCT01439711|PROCEDURE|conventional surgery|
219117809|NCT00605371|DRUG|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
219117810|NCT00605371|DRUG|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
219117811|NCT02366585|DRUG|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
219117812|NCT04431687|DRUG|CKD 501|QD, PO
219117813|NCT04431687|DRUG|D759, D150|QD, PO
219117814|NCT04431687|DRUG|CKD-501, D759, D150|QD, PO
219703716|NCT01107015|DEVICE|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
219703717|NCT06518291|DRUG|Nitrofurantoin 100 MG|Comparing two drugs in UTI treatment
219703718|NCT06518291|DRUG|Fosfomycin|treatment of UTI
219703719|NCT03409965|DEVICE|Lutronic Infini System|A microneedle radiofrequency device
219703720|NCT03409965|DEVICE|Lutronic LaseMD System|A fractional thulium laser device
219117815|NCT05212493|DRUG|Cannabis oil|Cannabis oil 20:1 CBD:THC ratio
219117816|NCT04242875|DIAGNOSTIC_TEST|Angle Kappa|Angle kappa will be measured using the OPD III scan.
219117817|NCT04242875|OTHER|Visual disturbance questionnaire.|Questionnaire evaluating visual disturbances.
219703721|NCT02765035|DEVICE|C-Leg 4|Microprocessor Controlled Knee
219117818|NCT02025348|DRUG|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
219117819|NCT01164163|DRUG|ruxolitinib phosphate|
219117820|NCT01164163|OTHER|laboratory biomarker analysis|
219117821|NCT01164163|OTHER|pharmacological study|
219117822|NCT03913728|OTHER|Drug level blood tests|All information included previously.
219117823|NCT03913728|OTHER|Telephone Interview|All information included previously.
219117824|NCT01046461|DRUG|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
219117825|NCT05914428|OTHER|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
219117826|NCT02362113|OTHER|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
219117827|NCT03504865|DRUG|Liposomal bupivacaine|Given at the end of the operation.
219117828|NCT03504865|DRUG|Standard bupivacaine|Given at the end of the operation.
219117829|NCT03504865|OTHER|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
219117830|NCT01012973|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
219117831|NCT01012973|OTHER|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
219117832|NCT05994599|COMBINATION_PRODUCT|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
219117833|NCT05994599|COMBINATION_PRODUCT|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
219117834|NCT01773668|DEVICE|Integrated sensor and infusion set.|
219117835|NCT00479596|DRUG|Botox|
219117836|NCT04729140|DRUG|Ivermectin Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
219117837|NCT04729140|DRUG|Doxycycline Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
219117838|NCT04729140|DRUG|Placebo|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
219117839|NCT01449214|PROCEDURE|Ultrasound|Ultrasound-guided technique
219117840|NCT01449214|PROCEDURE|Landmarking|Landmark-guided technique
219117841|NCT02501759|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
219703722|NCT02765035|DEVICE|C-Leg 3|Microprocessor Controlled Knee
219703723|NCT03104413|DRUG|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
219703724|NCT03104413|DRUG|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
219703725|NCT03104413|DRUG|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
219703726|NCT01575990|BEHAVIORAL|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
219703727|NCT01575990|BEHAVIORAL|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
219703728|NCT03997877|OTHER|Physical activity|Increase physical activity Balanced diet
219117842|NCT02501759|RADIATION|Gadodiamide|Given IV
219117843|NCT02501759|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
219117844|NCT02501759|PROCEDURE|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
219703729|NCT04147156|PROCEDURE|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
219703730|NCT04147156|PROCEDURE|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
219703731|NCT04147156|PROCEDURE|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
219703732|NCT03931564|PROCEDURE|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
219703733|NCT03931564|PROCEDURE|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
219703734|NCT02236377|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
219703735|NCT04772976|OTHER|Observational study, not applicable|Observational study, not applicable
219703736|NCT04782141|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
219703737|NCT04782141|PROCEDURE|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
219703738|NCT04782141|PROCEDURE|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
219703739|NCT03423771|DRUG|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
219703740|NCT05031351|DRUG|Withania somnifera|Nuclear Factor Kappa Beta Inhibitor
219703741|NCT05031351|DRUG|Placebo|Placebo Comparator
219703742|NCT00984867|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
219117845|NCT02501759|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
219117846|NCT02887560|PROCEDURE|transoesophageal echocardiography|
219117847|NCT03190083|DEVICE|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
219117848|NCT03190083|DEVICE|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
219117849|NCT00394511|PROCEDURE|low-LET photon therapy|
219117850|NCT06234137|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
219703743|NCT00984867|DRUG|Placebo|Matching placebo tablet
219703744|NCT05115396|OTHER|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
219703745|NCT05115396|OTHER|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
219703746|NCT05664906|DRUG|Chinese Medicine Oral Rinse Formula-I (CMORF-I)|"* Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT."
219703747|NCT05664906|OTHER|Standard Care|• Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
219703748|NCT05664906|OTHER|Placebo|Placebo granules, instruction is the same as CMORF-I.
219703749|NCT03582683|BEHAVIORAL|Chronic Pain Self-Management Program (CPSMP)|Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
219117851|NCT06234137|DRUG|Carboplatin|AUC=6 min/mL iv 3-weekly
219117852|NCT06234137|DRUG|Inetetamab|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
219117853|NCT06234137|DRUG|Pyrotinib|400mg orally daily
219117854|NCT01782326|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
219117855|NCT01782326|DRUG|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
219117856|NCT02278575|DRUG|Atenativ|intravenous transfusion
219117857|NCT03685279|BEHAVIORAL|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
219117858|NCT02445885|PROCEDURE|PCI|Guideline directed Percutaneous Coronary Intervention
219117859|NCT00399178|DRUG|Transdermal delivery system|
219703750|NCT05668559|PROCEDURE|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
219703751|NCT05668559|PROCEDURE|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
219117860|NCT05390892|DRUG|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
219117861|NCT05390892|DRUG|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
219117862|NCT01843452|RADIATION|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
219117863|NCT01843452|BIOLOGICAL|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
219117864|NCT01843452|DRUG|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
219117865|NCT01843452|DRUG|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
219703752|NCT03273972|OTHER|Written Informed Consent|To be completed prior to conducting any study related procedures
219703753|NCT03273972|OTHER|Inclusion/Exclusion check|Eligibility check
219703754|NCT03273972|OTHER|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
219703755|NCT03273972|OTHER|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
219703756|NCT03273972|OTHER|Pregnancy Test|If applicable for women of child bearing potential
219117866|NCT04437771|OTHER|Safety and efficacy assessments|Long term disease and gene therapy specific safety evaluations and efficacy assessments
219117867|NCT00503568|BIOLOGICAL|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
219703757|NCT03273972|OTHER|12 Lead ECG|participant resting supine
219703758|NCT03273972|OTHER|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
219117868|NCT04239287|DIAGNOSTIC_TEST|Lung function + exercise tests|Lung function + exercise tests
219117869|NCT03415087|PROCEDURE|sequential intrathecal injection|intrathecal injection of fentanyl and hyperbaric bupivacaine
219117870|NCT03415087|DRUG|hyperbaric bupivacaine|intrathecal injection of intrathecal bupivacaine
219225451|NCT05699174|DRUG|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to PO (oral) antibiotics for up to 6 weeks post hospitalization. The exact type of oral antibiotic will be depended on the patient's infection diagnosis.
219703759|NCT03273972|OTHER|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
219703760|NCT03273972|OTHER|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
219703761|NCT03273972|OTHER|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
219703762|NCT03273972|OTHER|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
219703763|NCT03273972|OTHER|Concomitant medication check|Review of medication taken by the participant
219703764|NCT03273972|OTHER|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
219703765|NCT03273972|OTHER|Physical examination|Check overall health
219117871|NCT03415087|DRUG|fentanyl|intrathecal injection of fentanyl
219703766|NCT03273972|OTHER|Medical history|Review of volunteers medial history
219117872|NCT00107874|DRUG|misoprostol|
219117873|NCT04558086|DEVICE|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
219703767|NCT03273972|OTHER|AE/SAE review & reporting|Monitor safety from the point of consent
219703768|NCT03273972|DRUG|Dosing|To be performed at the end of the visit following completion all other study visits
219703769|NCT00513799|DRUG|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
219703770|NCT00513799|GENETIC|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
219703771|NCT00513799|PROCEDURE|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
219703772|NCT00513799|BEHAVIORAL|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
219703773|NCT01922453|OTHER|Music and Sound|
219703774|NCT03655431|OTHER|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
219703775|NCT03655431|OTHER|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
219703776|NCT00634504|DRUG|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
219703777|NCT00634504|DRUG|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
219117874|NCT04558086|DEVICE|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
219117875|NCT00349102|RADIATION|Free breathing|Free breathing during conformal radiation
219117876|NCT00349102|RADIATION|Breath holding|Breath holding during conformal radiation
219117877|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide|
219117878|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
219117879|NCT06047873|DEVICE|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
219117880|NCT03713814|OTHER|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
219703778|NCT05224375|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
219703779|NCT00204737|DRUG|prednisone|20mg x 2 weeks
219703780|NCT00204737|DRUG|placebo|placebo
219703781|NCT03727165|OTHER|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
219703782|NCT03727165|OTHER|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
219703783|NCT05001620|OTHER|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
219703784|NCT01456923|OTHER|Treatment with chemotherapy|
219703785|NCT01456923|OTHER|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
219703786|NCT01456923|PROCEDURE|surgery|
219703787|NCT01873144|DRUG|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
219703788|NCT01873144|DRUG|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
219117881|NCT05315219|PROCEDURE|Endoscopic Thyroidectomy Bilateral Areola Approach|The endoscopic thyroidectomy achieves better cosmetic effects than open thyroidectomy, and is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
219117882|NCT03291600|BEHAVIORAL|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
219117883|NCT01473420|BIOLOGICAL|Epoetin Hospira|Variable dose
219117884|NCT01473420|BIOLOGICAL|Epogen Amgen|Variable dose
219703789|NCT01873144|DEVICE|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
219117885|NCT06483412|BEHAVIORAL|Healthy Futures: Alternative-to-Suspension Curriculum|Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.
219703790|NCT01873144|DRUG|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
219703791|NCT00469794|PROCEDURE|stress test|
219703792|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food|The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
219703793|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher|The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
219703794|NCT02593240|BEHAVIORAL|Human Performance Institute©|The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
219703795|NCT02036918|DRUG|Sipuleucel-T|
219703796|NCT02036918|PROCEDURE|Lymph Node Biopsy|
219703797|NCT06249230|DIAGNOSTIC_TEST|Hematologic features|Hematologic features include coagulation indicators, autoimmune indicators, and endocrine indicators.
219703798|NCT06249230|DIAGNOSTIC_TEST|Ultrasound indices of uterine artery blood flow|Ultrasound indices of uterine artery blood flow include endometrial thickness, endometrial artery blood flow parameters , and bilateral uterine artery blood flow parameters.
219703799|NCT06249230|OTHER|Demographic characteristics|Demographic characteristics include age, the number of previous spontaneous abortions (including biochemical pregnancies), BMI, fertility history, past disease history, chromosomal status, family and genetic history, etc.
219703800|NCT02104102|OTHER|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
219225452|NCT05699174|DRUG|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. The exact type of IV antibiotic will be depended on the patient's infection diagnosis.
219360939|NCT01345500|OTHER|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
219703801|NCT02104102|OTHER|Kinesiotherapy|Hands movements.
219703802|NCT00481676|DRUG|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
219703803|NCT00481676|DRUG|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
219703804|NCT00481676|DRUG|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
219117886|NCT04895787|BEHAVIORAL|Gait + aerobic exercise|Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.
219117887|NCT04895787|BEHAVIORAL|Gait + resistance exercises|Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.
219117888|NCT04895787|BEHAVIORAL|Gait + conventional physical therapy|Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
219117889|NCT04895787|BEHAVIORAL|Gait + rest|Following skill-based gait training, the participants will sit and rest on a chair.
219117890|NCT06458387|DIETARY_SUPPLEMENT|Active protein supplementation|The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day. NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active protein supplementation arm were protein supplementation at over 1.5 g/kg/day during first 3 days after ICU admission. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.
219117891|NCT06458387|DIETARY_SUPPLEMENT|Conventional protein supplementation|The participants in conventional protein supplementation arm received conservative nutritional management without specific protein targets.
219117892|NCT01811017|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
219117893|NCT00955903|BEHAVIORAL|Exercise|Participants will participate in supervised exercise sessions
219117894|NCT00955903|BEHAVIORAL|Reduced Calorie Diet|Participants will follow a reduced calorie diet
219117895|NCT00955903|BEHAVIORAL|Weight Maintenance Diet|Participants will follow a weight maintenance diet
219117896|NCT02308501|DRUG|Lastacaft ®|
219117897|NCT02308501|DRUG|Tears Naturale ® (Placebo)|
219117898|NCT04172987|DRUG|Tirzepatide|Administered SC
219117899|NCT04172987|DRUG|EE/NGM|Combination oral contraceptive administered orally
219117900|NCT01190033|DEVICE|Neurotome OFF|In this intervention the neurotome will be unconnected.
219117901|NCT01190033|PROCEDURE|neurolysis|In this procedure the neurotome will be connected
219703805|NCT00481676|DRUG|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
219117902|NCT00030875|DRUG|bortezomib|
219703806|NCT03806816|DIETARY_SUPPLEMENT|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
219703807|NCT03806816|OTHER|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
219703808|NCT04226443|DRUG|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
219117903|NCT00712855|BIOLOGICAL|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
219117904|NCT00712855|DRUG|sorafenib|400 mg orally, twice a day continuously in each cycle
219117905|NCT03020095|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
219117906|NCT03020095|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
219117907|NCT03020095|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
219117908|NCT03020095|DRUG|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally
219117909|NCT04033991|DRUG|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
219117910|NCT04033991|DRUG|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
219117911|NCT00134524|PROCEDURE|MME procedure|
219360940|NCT02246257|OTHER|Simvastatin|LDL \> 2.5 is treated with 40 mg
219360941|NCT02246257|OTHER|Losartan|BT \> 140/90 mmHg treated with 50 mg OD
219360942|NCT02246257|OTHER|Losartan|DM BT \> 130/80 mmHg treated with 50 mg OD
219360943|NCT02246257|OTHER|Losartan|Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD
219703809|NCT04226443|DRUG|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
219703810|NCT00413803|PROCEDURE|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
219703811|NCT00413803|PROCEDURE|8-hour thrice weekly in center hemodialysis|long dialysis
219117912|NCT02410161|DIETARY_SUPPLEMENT|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
219117913|NCT01470378|PROCEDURE|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
219117914|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
219703812|NCT03937778|BEHAVIORAL|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
219703813|NCT01687803|BEHAVIORAL|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
219117915|NCT03862482|DEVICE|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
219117916|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
219117917|NCT01121640|PROCEDURE|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
219117918|NCT01121640|PROCEDURE|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
219117919|NCT01121640|PROCEDURE|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
219117920|NCT03574701|DIETARY_SUPPLEMENT|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
219117921|NCT05607966|DEVICE|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
219117922|NCT01224561|BEHAVIORAL|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
219117923|NCT00738530|DRUG|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
219117924|NCT00738530|DRUG|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
219117925|NCT00738530|DRUG|Placebo|IV every 2 weeks
219117926|NCT04101864|PROCEDURE|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
219117927|NCT04101864|PROCEDURE|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
219117928|NCT00200421|DRUG|Nebivolol and Atenolol|
219360944|NCT02246257|OTHER|Metformin|HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
219360945|NCT02246257|OTHER|Outpatient rheumatology department|(4 times yearly)
219360946|NCT02246257|OTHER|Refered to general practice|
219360947|NCT00168831|DRUG|Tiotropium Inhalation Solution|
219360948|NCT00168831|OTHER|Placebo|
219703814|NCT01687803|BEHAVIORAL|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
219703815|NCT05207501|BEHAVIORAL|Exercise|Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
219117929|NCT05503680|BEHAVIORAL|Yoga|In this study, the researcher will provide participants with two month of Hatha yoga as an experimental intervention for managing stress. All participants who belong to the intervention group will be required to complete 120 minutes per week of home-based, online streaming yoga for eight weeks with our certified yoga instructor. The intervention will be conducted online by Zoom video; participants will be sent a link to join a scheduled live online yoga session twice every week. The data collection will be undertaken in three times: baseline (before the intervention begins), posttest one ( after two month intervention), and posttest two (one month after yoga intervention finish) to evaluate the lasting effect of yoga.
219117930|NCT01628510|DEVICE|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
219117931|NCT01628510|OTHER|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
219117932|NCT04501458|OTHER|Training of youth, community health assistants and community health workers.|Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
219117933|NCT04501458|OTHER|Training clinicians in basic critical care and the management of severe COVID-19 cases|Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
219117934|NCT05685680|PROCEDURE|total mesorectal excision in rectal carcinoma|total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
219117935|NCT06445920|OTHER|No Intervention|No Intervention
219117936|NCT06276413|DEVICE|GORE TAG Thoracic Branch Endoprosthesis|deployment of the GORE TAG Thoracic Branch Endoprosthesis fro thoraci aorta pathologies
219117937|NCT04179461|DRUG|Cholecalciferol|Oral administration
219117938|NCT04179461|DRUG|antihistamine|Oral administration
219703816|NCT04816344|PROCEDURE|Outpatient Anesthesia|The inclusion criteria were children aged between 2 and 10 years, undergoing outpatient anaesthesia for elective MRI under sedation, and classified as American Society of Anesthesiologists (ASA) grade I-II. The study exclusion criteria were defined as difficult airway, allergies to the study drugs, asthma, severe central nervous system disease (eg, brain tumour, uncontrolled seizures), mental motor retardation, the application of another procedure after MRI sedation, and those whose parents declined to participate in the study.
219703817|NCT04909723|COMBINATION_PRODUCT|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
219703818|NCT04909723|BIOLOGICAL|NB1000S|A recombinant live biotherapeutic product.
219703819|NCT04909723|DRUG|NB2000P|A botanically derived polysaccharide.
219703820|NCT04909723|DRUG|Placebo|Placebo
219117939|NCT04179461|DRUG|Azithromycin|Oral administration
219117940|NCT04179461|DRUG|emollient cream|Topical
219117941|NCT04179461|DRUG|Fluticasone Propionate|Nasal spray
219117942|NCT04179461|DRUG|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
219117943|NCT06285526|PROCEDURE|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
219117944|NCT06285526|PROCEDURE|Cephalic DuodenoPancreatectomy|Cephalic DuodenoPancreatectomy
219117945|NCT01474408|BEHAVIORAL|interval training day 1|
219117946|NCT01474408|BEHAVIORAL|Moderate exercise day 2|
219117947|NCT01474408|BEHAVIORAL|Control day 3|
219117948|NCT01653847|DRUG|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
219703821|NCT03748667|DIAGNOSTIC_TEST|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
219703822|NCT03748667|DIAGNOSTIC_TEST|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
219703823|NCT02699164|DEVICE|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
219703824|NCT02699164|OTHER|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
219703825|NCT02699164|OTHER|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
219703826|NCT00089388|DRUG|cilengitide|Given IV
219360949|NCT02298933|DRUG|Eculizumab|300 mg single-use vials
219360950|NCT02009878|DRUG|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
219360951|NCT01964066|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
219703827|NCT01703156|PROCEDURE|Stress Test|
219703828|NCT01703156|PROCEDURE|No Stress Test|
219703829|NCT00819039|DRUG|Aprepitant|Aprepitant administered orally or intraveously.
219703830|NCT00819039|DRUG|Ondansetron|Ondansetron administered intravenously.
219117949|NCT01653847|DRUG|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
219117950|NCT00915070|DRUG|BQ-123|60 mcg/min, infusion period: 60 min
219117951|NCT00915070|DRUG|Physiological saline solution|infusion period 60 minutes
219117952|NCT00915070|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
219117953|NCT00915070|DEVICE|Goldmann Applanation Tonometer|intraocular pressure measurements
219117954|NCT00915070|OTHER|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
219117955|NCT01889160|DRUG|AZD4721 Solution|1-9 mg/mL liquid solution
219117956|NCT01889160|DRUG|AZD4721 Placebo|Liquid solution
219117957|NCT01889160|DRUG|AZD4721 Suspension|9 mg/g liquid suspension
219117958|NCT04400708|PROCEDURE|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
219117959|NCT04400708|PROCEDURE|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
219117960|NCT05676073|DRUG|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
219117961|NCT05676073|DRUG|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
219117962|NCT05676073|DRUG|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
219117963|NCT00136903|DRUG|Prochymal® - 2 Million cells/kg|2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
219117964|NCT00136903|DRUG|Prochymal®- 8 Million cells/kg|8 million hMSCs/kg actual body weight IV on study Days 1 and 4
219117965|NCT00136903|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg administered intravenously.
219117966|NCT00136903|DRUG|Prednisone|Prednisone 2.5 mg/kg administered orally.
219117967|NCT00136903|DRUG|Cyclosporine|Administered as prescribed by the caregiver.
219117968|NCT00136903|DRUG|Tacrolimus|Administered as prescribed by the caregiver.
219117969|NCT00136903|DRUG|Mycophenolate Mofetil|Administered as prescribed by the caregiver.
219117970|NCT02011308|DEVICE|Green light Laser|Laser vs TURP
219703831|NCT05529433|PROCEDURE|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
219117971|NCT02011308|DEVICE|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
219117972|NCT02509351|DRUG|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
219117973|NCT02509351|DRUG|placeboo|women will recive 2 identical tablets as placeboo
219117974|NCT01944943|DRUG|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
219117975|NCT01627847|DRUG|Ropinirole|
219117976|NCT01013220|OTHER|Depression Product Detailing|"1. two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~2. technical assistance in purchasing high quality depression management products"
219117977|NCT01013220|OTHER|Depression HEDIS detailing|"1. academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~2. technical assistance"
219117978|NCT06247085|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
219117979|NCT06247085|OTHER|Placebo|volume-matched saline SC BIW
219117980|NCT01198925|DRUG|piperacillin continuous infusion|piperacillin continuous infusion
219117981|NCT01198925|DRUG|piperacillin extended infusion|piperacillin extended infusion
219117982|NCT03750773|DRUG|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
219117983|NCT03750773|DRUG|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
219117984|NCT02471508|DEVICE|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
219117985|NCT00169741|OTHER|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
219117986|NCT00669747|DRUG|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
219703832|NCT05529433|PROCEDURE|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
219703833|NCT05529433|PROCEDURE|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
219703834|NCT01693952|BIOLOGICAL|blood draw|
219703835|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
219703836|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
219117987|NCT00669747|DRUG|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
219117988|NCT00669747|DRUG|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
219117989|NCT02264392|PROCEDURE|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
219117990|NCT02264392|PROCEDURE|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
219703837|NCT00375661|DRUG|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
219703838|NCT04985162|OTHER|Intervention group|Differential learning based physiotherapy to improve torso control, balance and gait
219703839|NCT04985162|OTHER|Control group|Ordinary physiotherapy program
219117991|NCT00632528|DRUG|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
219117992|NCT00632528|DRUG|Medicinal air|Administration of medical air during postoperative physical therapy
219117993|NCT04707391|COMBINATION_PRODUCT|MenABCWY vaccine|2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
219117994|NCT04707391|COMBINATION_PRODUCT|Placebo|1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
219117995|NCT04707391|BIOLOGICAL|MenACWY vaccine|1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
219117996|NCT04707391|COMBINATION_PRODUCT|MenB vaccine|2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
219703840|NCT01240694|DRUG|CEP-33457|CEP-33457 will be administered subcutaneously per dose specified in the arm description.
219703841|NCT02494024|DRUG|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
219703842|NCT02494024|DRUG|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
219703843|NCT01513590|DRUG|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
219703844|NCT00005996|DRUG|cisplatin|
219703845|NCT00005996|DRUG|gemcitabine hydrochloride|
219703846|NCT00005996|DRUG|semaxanib|
219703847|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
219703848|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
219703849|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
219703850|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
219703851|NCT02442128|DRUG|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
219703852|NCT02442128|DRUG|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
219703853|NCT00573924|DRUG|Proton pump inhibitor (lansoprazole)|"1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
219117997|NCT01019356|DRUG|Rosiglitazone|4 mg twice daily for 8 weeks orally
219117998|NCT01019356|DRUG|Acarbose|100 mg three times daily for 8 weeks orally
219360952|NCT01964066|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
219703854|NCT03834350|OTHER|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
219117999|NCT04598880|DRUG|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
219118000|NCT04598880|DRUG|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
219118001|NCT05123716|DRUG|MDMA|Participants will be given 100 mg of MDMA
219703855|NCT03834350|DEVICE|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
219703856|NCT02141932|PROCEDURE|Bed-side pocket size ultrasound imaging|
219703857|NCT02141932|DEVICE|GE Ultrasound Vscan|
219703858|NCT05675800|DRUG|Psilocybin|Psilocybin administered with psychological support
219703859|NCT04789122|OTHER|Attitude assessment|The study covered a representative group of 1000 people. Own questionnaire and standardized tools sent online via the Statistical Research and Analysis Office, in compliance with the privacy policy and personal data protection of the General Data Protection Regulation.
219703860|NCT04698434|DRUG|Esketamine|each group was given a single intravenous dose of the corresponding esketamine.
219703861|NCT02059837|PROCEDURE|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
219703862|NCT03365180|DEVICE|Starter Kit Algorithm|Long acting insulin titration to target
219118002|NCT05123716|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
219118003|NCT03059836|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
219118004|NCT03059836|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
219118005|NCT06363955|DEVICE|Carbamide Peroxide Mouthwash|The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
219118006|NCT06363955|DEVICE|Placebo mouthwash|Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
219118007|NCT06175663|DRUG|Antihypertensive medication withdrawal|To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
219118008|NCT00000926|DRUG|Nonoxynol-9|
219118009|NCT02062411|BEHAVIORAL|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
219118010|NCT02062411|BEHAVIORAL|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
219118011|NCT03246672|BEHAVIORAL|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
219118012|NCT04635787|DEVICE|ANNE One|Wireless vital sign monitoring device
219118013|NCT02548195|DRUG|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
219118014|NCT02548195|DRUG|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
219118015|NCT01913964|DRUG|Acetylcarnitine|
219118016|NCT01913964|DRUG|Placebo|(sugar pill)
219118017|NCT05167526|DRUG|ASP8731|Oral
219118018|NCT05167526|DRUG|ASP8731 Matching Placebo|Oral
219118019|NCT06261944|DEVICE|Near-infrared (NIR)|Near-infrared assessment of glycated keratin in middle fingernail
219118020|NCT02420275|OTHER|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
219225453|NCT04111510|DRUG|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
219703863|NCT03609463|BEHAVIORAL|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
219703864|NCT03609463|BEHAVIORAL|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
219703865|NCT03609463|OTHER|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
219703866|NCT02765165|DRUG|USL311|Administered once weekly in a 21-day cycle
219703867|NCT02765165|DRUG|USL311|Administered once daily in a 21-day cycle
219703868|NCT02765165|DRUG|USL311|Administered once daily in a 42-day cycle
219703869|NCT02765165|DRUG|Lomustine|Administered once every 6 weeks in a 42-day cycle
219703870|NCT03732378|DIETARY_SUPPLEMENT|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
219703871|NCT01206764|DRUG|RAD001|
219703872|NCT04824001|OTHER|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
219703873|NCT02528448|DRUG|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
219703874|NCT02528448|DRUG|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
219703875|NCT06414863|DEVICE|IPE|"Invisalign palatal expander system:~The Invisalign® Palatal Expander System (AlignTechnology, inc.) is 3D-printed orthodontic device for maxillary expansion."
219703876|NCT06414863|DEVICE|HE|"Hyrax expander:~The Hyrax-type maxillary expander will include a midline self-locking screw. The expansion screw is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician"
219118021|NCT02420275|DEVICE|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
219703877|NCT02567188|OTHER|MIRCERA|
219118022|NCT02617420|DEVICE|Propeller Health Monitoring Device|
219118023|NCT03666065|DRUG|Aspart insulin|Standard insulin
219118024|NCT03613779|COMBINATION_PRODUCT|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
219225454|NCT03395080|DRUG|Paclitaxel|Administered by IV infusion
219225455|NCT03395080|DRUG|300mg DKN-01|Administered by IV infusion
219225456|NCT03395080|DRUG|600mg DKN-01|Administered by IV infusion
219118025|NCT03613779|OTHER|Standard of Care|Standard of care will be provided.
219118026|NCT03667235|OTHER|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
219118027|NCT03667235|OTHER|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
219118028|NCT04840953|DEVICE|Vçac|VAC THERAPY vs SURGICAL DREINAGE
219118029|NCT00401921|DRUG|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
219118030|NCT00401921|DRUG|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
219118031|NCT00002087|DRUG|Alvircept sudotox|
219225457|NCT04799301|BEHAVIORAL|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
219118032|NCT02430636|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
219118033|NCT02430636|DEVICE|NanoKnife|
219118034|NCT04920461|DEVICE|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
219118035|NCT04920461|OTHER|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
219118036|NCT05725343|DRUG|Canakinumab|Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
219703878|NCT05893238|PROCEDURE|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
219703879|NCT05893238|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in serum
219703880|NCT05893238|DIAGNOSTIC_TEST|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
219703881|NCT05893238|DIAGNOSTIC_TEST|Sperm samples for analysis|Oxidation-reduction potential
219703882|NCT05893238|PROCEDURE|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
219703883|NCT03052686|OTHER|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
219703884|NCT00774917|DEVICE|Numen|Numen Co-Cr coronary stent implant
219703885|NCT02502370|DRUG|observation alone|
219703886|NCT02502370|DRUG|LV5FU2|
219703887|NCT02502370|DRUG|FOLFOX|
219703888|NCT02427009|OTHER|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
219703889|NCT02427009|PROCEDURE|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
219703890|NCT03384199|RADIATION|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
219118037|NCT05725343|DRUG|Placebo|placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
219118038|NCT00615082|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
219118039|NCT00615082|BEHAVIORAL|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
219118040|NCT05401682|OTHER|Cox chiropractic care|Manual distraction of spine in a prone position using specially assisted table
219118041|NCT01347645|DRUG|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
219360953|NCT01964066|PROCEDURE|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
219703891|NCT01408069|DRUG|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
219703892|NCT01408069|DRUG|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
219703893|NCT00047762|DRUG|Erlotinib (aka Tarceva or OSI-774)|
219703894|NCT00047762|DRUG|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
219703895|NCT05986110|PROCEDURE|A training intervention on clinical ultrasound|To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
219703896|NCT06002191|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
219703897|NCT06002191|BEHAVIORAL|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
219703898|NCT02373527|OTHER|No Fasting prior to catheterization|No restriction for oral intake
219703899|NCT00366496|DEVICE|Acrysof single piece (SA60AT)|
219703900|NCT00366496|DEVICE|Acrysof IQ (SN60WF)|
219703901|NCT02844478|BEHAVIORAL|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
219703902|NCT02844478|BEHAVIORAL|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
219118042|NCT01347645|DRUG|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
219118043|NCT00178243|PROCEDURE|3D Conformal Radiation Therapy and Radiosurgery|
219118044|NCT00388362|DRUG|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
219118045|NCT00388362|DRUG|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
219118046|NCT01141660|DEVICE|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
219118047|NCT01141660|DEVICE|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
219118048|NCT06845683|OTHER|Group A|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Cognitive tasks during the intervention, including the recall of words and counting forward (1, 4, 7, 10...) and backward (...10, 7, 4, 1) by adding 3 to the digits. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
219118049|NCT06845683|OTHER|Group B|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
219118050|NCT00305201|DRUG|pravastatin|
219118051|NCT00515164|DRUG|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
219118052|NCT01219621|PROCEDURE|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
219118053|NCT01448837|DRUG|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
219118054|NCT01448837|DRUG|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
219118055|NCT01438229|DEVICE|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
219118056|NCT05186844|BEHAVIORAL|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
219118057|NCT00209027|OTHER|fMRI|fMRI scanning during behavioral reward task
219225458|NCT04799301|BEHAVIORAL|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
219118058|NCT00209027|DRUG|Aripiprazole|30 mg by mouth once daily
219118059|NCT01643395|OTHER|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
219225459|NCT04799301|BEHAVIORAL|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
219225460|NCT05824871|DRUG|Sudapyridine|Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
219225461|NCT05824871|DRUG|Bedaquiline|Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
219550914|NCT01068704|DRUG|Lapatinib|Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
219550915|NCT01068704|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
219550916|NCT03224663|OTHER|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
219550917|NCT03224663|OTHER|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
219550918|NCT06173050|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
219118060|NCT01643395|OTHER|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
219118061|NCT03487003|DRUG|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
219118062|NCT03487003|DRUG|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
219118063|NCT05158257|DEVICE|balloon and Stent|balloon dilatation combined stent angioplasty
219118064|NCT05158257|DEVICE|endovascular debulking and DCB|endovascular debulking combined drug-coated balloon
219118065|NCT04943900|DRUG|BMS-986416|Specified dose on specified days
219118066|NCT04943900|DRUG|Nivolumab|Specified dose on specified days
219118067|NCT02758678|BIOLOGICAL|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
219118068|NCT06029361|DEVICE|Selfit Device group|During 21 days, intervention group will receive physical therapy of 45 minutes which 15 minutes out of the 45 minutes will be with the SELFIT system
219118069|NCT06029361|OTHER|Control Group|Conventional physical therapy of 45 minute
219118070|NCT01932996|DRUG|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
219703903|NCT02411643|DRUG|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
219118071|NCT01932996|BEHAVIORAL|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
219703904|NCT04793945|COMBINATION_PRODUCT|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
219118072|NCT04457622|OTHER|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
219118073|NCT05616949|BEHAVIORAL|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
219118074|NCT05616949|BEHAVIORAL|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
219118075|NCT00338715|DEVICE|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
219225462|NCT06097091|OTHER|Self-management education|A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
219225463|NCT06097091|BEHAVIORAL|pain neuroscience education|"Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content."
219703905|NCT04832035|OTHER|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
219703906|NCT04832035|BEHAVIORAL|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
219703907|NCT02827526|DRUG|Ketamine|
219703908|NCT02827526|DRUG|Control|
219703909|NCT00321763|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
219703910|NCT00321763|BIOLOGICAL|Fluarix TM|Single dose, Intramuscular injection
219703911|NCT00267540|BEHAVIORAL|cholecalciferol (D3) (vitamin)|
219703912|NCT00405769|DRUG|red yeast rice|600 mg 3 caps bid
219703913|NCT00405769|DRUG|placebo|3 caps bid
219703914|NCT00481039|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
219703915|NCT00410163|DRUG|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
219118076|NCT05608941|OTHER|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
219703916|NCT00410163|DRUG|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
219703917|NCT00410163|DRUG|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
219703918|NCT00410163|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
219703919|NCT03147963|DRUG|Docetaxel|Docetaxel will be given until progression or patient intolerance
219703920|NCT03601676|OTHER|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
219703921|NCT00021242|DRUG|docetaxel|Continuous IV infusion
219118077|NCT05608941|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
219118078|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
219118079|NCT06195241|DRUG|DaxibotulinumtoxinA|Patients with Benign Essential Blepharospasm (BEB) or Hemifacial spasms (HFS) will be treated with DaxibotulinumtoxinA-Lanm (Daxxify) using a 2:1 conversion rate of Daxxify to Botox.
219118080|NCT05577065|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
219118081|NCT05577065|DIETARY_SUPPLEMENT|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
219118082|NCT01929005|OTHER|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
219225464|NCT05683990|DRUG|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
219360954|NCT00394849|PROCEDURE|suture one tonsillar fossa|one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
219703922|NCT03612219|DRUG|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
219703923|NCT03612219|RADIATION|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
219703924|NCT03612219|DRUG|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
219703925|NCT00742937|DIETARY_SUPPLEMENT|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
219703926|NCT00742937|DIETARY_SUPPLEMENT|Placebo|second capsule with vitamin E, eight days after delivery.
219225465|NCT06461234|BEHAVIORAL|Pelvic floor muscle training|A therapist will instruct the patient to contract the anus, perineum as well as the urethra, until the patient masters the correct method.
219550919|NCT06173050|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
219225466|NCT06461234|OTHER|Biofeedback electrical stimulation|The therapist will place the electrodes of the instrument into the vagina, adjust the current value until the woman feels obvious contraction of the pelvic floor muscles but no pain, and instructs the patient to refer to the biofeedback mode for vaginal and anal contraction and relaxation.
219550920|NCT04392934|PROCEDURE|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
219550921|NCT00829894|DRUG|Risperidone|1 mg Tablet
219550922|NCT00829894|DRUG|Risperidone|1 mg Tablet
219550923|NCT02896296|DRUG|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
219550924|NCT02790658|DIETARY_SUPPLEMENT|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
219550925|NCT00380796|DRUG|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
219550926|NCT02010034|DRUG|Omegaven|Omegaven will be used in place of soy oil Intralipid
219550927|NCT02246296|DIETARY_SUPPLEMENT|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
219550928|NCT02246296|DIETARY_SUPPLEMENT|Modified F75 Milk|This is the experimental group
219550929|NCT01751854|DRUG|SSRI|SSRI alone or with training
219550930|NCT01751854|DRUG|Placebo|Placebo alone or with training
219550931|NCT03545334|DIAGNOSTIC_TEST|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
219550932|NCT03667963|OTHER|Glucose|50g glucose dissolved in 250ml water
219550933|NCT03667963|OTHER|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
219118083|NCT04517656|OTHER|Blood samples|"A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment."
219118084|NCT05125211|DRUG|GB001 recombinant peptide spray|administrated oral spray
219118085|NCT05125211|DRUG|Placebo|administrated oral spray
219703927|NCT05824026|DEVICE|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
219703928|NCT01610518|DIETARY_SUPPLEMENT|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
219703929|NCT01610518|DIETARY_SUPPLEMENT|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
219703930|NCT05109715|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
219703931|NCT05109715|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
219703932|NCT04443192|DRUG|ZF874|ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
219703933|NCT04443192|DRUG|Placebo|Placebo to ZF874
219703934|NCT06579300|DRUG|ABBV-1088|Oral Capsule
219703935|NCT06579300|DRUG|Placebo for ABBV-1088|Oral Capsule
219703936|NCT06579300|DRUG|Itraconazole (ITZ)|Oral Capsule
219703937|NCT03534674|DIETARY_SUPPLEMENT|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
219703938|NCT05287789|OTHER|Squatting position by footstool|"Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation."
219703939|NCT05215288|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219703940|NCT03428373|DRUG|Rivaroxaban|Rivaroxaban 10mg daily
219703941|NCT03428373|DRUG|ASA|ASA 81mg
219703942|NCT06369688|OTHER|IDEAL SKIIN CARES bundles|The investigators developed a specialized PIP care bundle, named IDEAL SKIIN CARES, through extensive review of literature and expert insights, which will be utilized for training WSNs and patients in the intervention group. This comprehensive bundle comprises 15 key components aimed at effectively preventing PIs: (1) Incontinence care status; (2) Dehydration status; (3) Elevate at-risk surfaces; (4) Attention to attached devices to skin; (5) Lotion use; (6) Skin assessment; (7) Keeping repositioning; (8) Individualized up-to-date knowledge; (9) Individualized medical devices selection; (10) Nutrition status; (11) Caregiver (formal and informal) participation; (12) Activity assessment; (13) Reducing friction/shear forces; (14) Evaluate hemodynamic instability; (15) and Scrutinizing comorbidities.
219703943|NCT06369688|OTHER|IDEAL SKIIN CARES bundles workshop|IDEAL SKIIN CARES bundles will be explained in detail by a trained research assistant in a workshop. This workshop is different from clinical training and following up about the IDEAL SKIIN CARES bundles.
219703944|NCT06369688|OTHER|Respiratory care workshop|An unrelated topic, specifically respiratory care will be held in a workshop. This training will involve the distribution of educational pamphlets, brochures, and visual posters outlining key aspects of respiratory care
219118086|NCT06275035|DRUG|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
219118087|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
219118088|NCT06610682|DRUG|Plixorafenib|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
219118089|NCT06610682|DRUG|Cobicistat 150 MG [Tybost]|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
219118090|NCT04025372|DRUG|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
219118091|NCT04025372|DRUG|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
219118092|NCT04025372|RADIATION|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
219118093|NCT04025372|DRUG|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
219118094|NCT06218589|DIAGNOSTIC_TEST|Velacur|Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
219118095|NCT06218589|DIAGNOSTIC_TEST|MRI|Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
219118096|NCT06218589|DIAGNOSTIC_TEST|Blood sample collection for biomarkers|Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
219118097|NCT06218589|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
219118098|NCT01083966|DRUG|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
219118099|NCT02210819|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
219118100|NCT02210819|DRUG|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
219225467|NCT06461234|OTHER|Magnetic Stimulation|The therapist will use the magnetic stimulator to intermittently stimulate the and adjust the stimulation intensity at any time according to the patient\&amp;amp;amp;#39;s condition, adjusting it until there is a clear sense of contraction and feel comfortable.
219118101|NCT01824914|DEVICE|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
219118102|NCT01848834|BIOLOGICAL|Pembrolizumab|IV infusion
219118103|NCT02257255|PROCEDURE|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
219118104|NCT02257255|PROCEDURE|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
219118105|NCT01342029|DRUG|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks"
219118106|NCT01342029|DRUG|Placebo|500-1,000 mg po bid for 2 weeks
219118107|NCT02865057|PROCEDURE|Vaginal assessment|Vaginal assessment of position prior to delivery
219118108|NCT03981536|DRUG|AP-101|Administered by intravenous infusion (IV)
219118109|NCT01050101|DIETARY_SUPPLEMENT|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
219225468|NCT06461234|OTHER|Magnetic stimulation combined with biofeedback electrical stimulation|Pelvic floor magnetic stimulation for 30 minutes followed by biofeedback electrical stimulation.
219225469|NCT03697603|DRUG|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
219225470|NCT03697603|DRUG|Placebo|Tablets, Oral, once daily, 14 weeks
219225471|NCT00828126|PROCEDURE|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
219550934|NCT03667963|OTHER|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
219550935|NCT03667963|OTHER|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
219550936|NCT02421653|DIETARY_SUPPLEMENT|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
219550937|NCT02421653|DIETARY_SUPPLEMENT|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
219550938|NCT02421653|DIETARY_SUPPLEMENT|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
219550939|NCT02421653|DIETARY_SUPPLEMENT|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
219550940|NCT02421653|DIETARY_SUPPLEMENT|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
219550941|NCT02421653|DIETARY_SUPPLEMENT|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
219118110|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
219118111|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
219118112|NCT05851690|PROCEDURE|Surgical treatment of pilonidal sinus disease|Advancement flap techniques in surgical treatment of pilonidal sinus disease.
219118113|NCT00435903|DEVICE|Palm Pilot|
219118114|NCT00001493|GENETIC|peripheral blood progenitor cells carrying MDR1|
219118115|NCT00999973|DRUG|Mitomycin C 0.02%|
219118116|NCT00999973|DRUG|Placebo|
219118117|NCT04915703|PROCEDURE|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
219118118|NCT01978275|DEVICE|stimulong 100, pajunk, germany|simulating catheter
219118119|NCT01978275|DEVICE|plexolong 100, pajunk, germany|nonstimulating catheter
219118120|NCT04648891|DRUG|Lidocaine|Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
219118121|NCT04648891|DEVICE|Vibrating wand|a vibrating instrument held adjacent to the cricothyroid space
219118122|NCT04908436|DRUG|Finerenone (BAY94-8862)|10 mg BAY94-8862 immediate release (IR) tablet, administered orally
219118123|NCT00972946|BIOLOGICAL|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
219118124|NCT00972946|DRUG|Administration of Endorem|single dose, intravenous
219118125|NCT05822297|DEVICE|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
219118126|NCT03591861|PROCEDURE|Ketogenic diet|"* Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~* Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
219118127|NCT03591861|DRUG|BCNU|-Standard of care
219118128|NCT02890056|BEHAVIORAL|H2GO!|
219118129|NCT03259373|BEHAVIORAL|Early Patient-Level and Provider-Level Educational Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
219118130|NCT03259373|BEHAVIORAL|Delayed Provider-Level Educational Intervention|Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
219225472|NCT06971861|BEHAVIORAL|Acceptance and Commitment Therapy|The current program is based on ACT and consists of four one-hour sessions covering the six core components of psychological flexibility. The four sessions respectively focus on Cognitive Defusion, Being Present and Acceptance, Self-as-Context and Values, and Committed Action. All sessions involve experiential learning activities and reflective discussions. Each participant also receives a workbook to facilitate post-session home practice.
219225473|NCT06647498|DRUG|Remternetug|Administered subcutaneously every 12 weeks
219225474|NCT06647498|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
219225475|NCT01800305|DRUG|Pegylated rhEPO|
219225476|NCT01800305|DRUG|EPIAO®|
219550942|NCT04550013|OTHER|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
219550943|NCT04550013|OTHER|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
219550944|NCT01385163|BEHAVIORAL|Treatment as usual|Standard psychosocial counseling
219550945|NCT01385163|BEHAVIORAL|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
219550946|NCT01385163|BEHAVIORAL|Cognitive Processing Therapy|group 12 session intervention
219550947|NCT04350697|PROCEDURE|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
219550948|NCT04674072|OTHER|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
219550949|NCT04674072|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
219118131|NCT05576259|OTHER|oVRcome phone app with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
219118132|NCT03567356|OTHER|"MAT-PLUS Helping Hands"|"1\) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
219118133|NCT05850286|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
219118134|NCT05850286|DRUG|VRD-based Regimen|Bortezomib, Lenalidomide and Dexamethasone
219118135|NCT04919434|OTHER|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
219550950|NCT00838188|OTHER|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
219550951|NCT02611323|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
219118136|NCT04798378|DEVICE|Neurosleeve|Myoelectric devices for restoration of independent arm function
219118137|NCT06634056|DRUG|Pentoxifylline|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
219118138|NCT06634056|OTHER|Placebo|One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
219118139|NCT06634056|OTHER|α-Tocopherol|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
219118140|NCT05879120|DRUG|Pembrolizumab|Given by IV (vein)
219118141|NCT05879120|DEVICE|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
219550952|NCT02611323|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m\^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
219550953|NCT02611323|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
219550954|NCT02611323|DRUG|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
219550955|NCT03676790|OTHER|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
219550956|NCT03676790|OTHER|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
219550957|NCT03676790|OTHER|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
219703945|NCT03716960|OTHER|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
219703946|NCT03716960|OTHER|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
219703947|NCT02421042|DRUG|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
219703948|NCT03171090|OTHER|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
219118142|NCT06282549|DRUG|Telmisartan/Amlodipine/Chlorthalidone(Truset)|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg
219118143|NCT00514007|DRUG|OSI-906|OSI-906 administered orally
219118144|NCT06250309|DIETARY_SUPPLEMENT|Dietary assignment|A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
219118145|NCT03466151|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
219118146|NCT03466151|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
219118147|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
219118148|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
219118149|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
219703949|NCT03171090|OTHER|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
219118150|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
219118151|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
219118152|NCT05205720|PROCEDURE|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
219118153|NCT05205720|DRUG|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
219118154|NCT02196961|DRUG|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
219118155|NCT06413849|OTHER|Telephone coached graphic narrative bibliotherapy|Eight weekly sessions of telephone coached graphic narrative bibliotherapy
219118156|NCT06413849|OTHER|Control group|Reading educational booklet
219703950|NCT03163966|DRUG|CR6086|oral CR6086 capsules
219703951|NCT03163966|DRUG|Methotrexate|oral Methotrexate tablets
219703952|NCT03163966|DRUG|Placebo|oral CR6086 Placebo capsules
219703953|NCT04375046|DRUG|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
219703954|NCT04677257|PROCEDURE|PCI, invasive coronary physiology and CMR|Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
219703955|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.
219118157|NCT05216666|PROCEDURE|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
219118158|NCT05216666|PROCEDURE|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
219118159|NCT05960604|DIAGNOSTIC_TEST|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
219118160|NCT03967405|DEVICE|MolecuLight PID|Hand-held, real-time fluorescence imaging device
219118161|NCT04894903|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
219118162|NCT06386653|DRUG|Diagnostic injection of [123I]I-DARPIN-Ec1|A single intravenous injection of \[123I\]I-DARPIN-Ec1
219118163|NCT06386653|DIAGNOSTIC_TEST|Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1|Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
219118164|NCT06386653|DIAGNOSTIC_TEST|Whole-body SPECT with [123I]I-DARPIN-Ec1|Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
219118165|NCT06238648|PROCEDURE|Biopsy|Undergo biopsy
219118166|NCT06238648|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219118167|NCT06238648|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
219118168|NCT06238648|BIOLOGICAL|Epcoritamab|Given SC
219118169|NCT06238648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219118170|NCT06238648|OTHER|Patient Observation|Undergo observation
219118171|NCT06238648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219118172|NCT06247826|PROCEDURE|Blood sampling|Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
219118173|NCT04925700|DIETARY_SUPPLEMENT|ProDentis Lozenge|1-2 ProDentis Lozenges per day
219118174|NCT04925700|OTHER|Placebo Lozenge|1-2 Placebo Lozenges per day
219118175|NCT05742230|DRUG|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
219118176|NCT05742230|DRUG|blank control|standard treatment
219118177|NCT01540396|BEHAVIORAL|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
219118178|NCT05580159|BIOLOGICAL|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
219118179|NCT05580159|BIOLOGICAL|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
219118180|NCT02172456|DRUG|99mTc-radiolabelled tiotropium|
219118181|NCT02172456|DRUG|non-radiolabelled tiotropium|
219703956|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), placebo condition|"Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task"
219703957|NCT04369417|BEHAVIORAL|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
219703958|NCT05094427|PROCEDURE|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
219703959|NCT02739126|PROCEDURE|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
219703960|NCT02739126|DEVICE|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
219703961|NCT00797563|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
219118182|NCT06343337|DIAGNOSTIC_TEST|Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman|Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
219118183|NCT04451343|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
219703962|NCT06113978|PROCEDURE|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
219703963|NCT06113978|PROCEDURE|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
219703964|NCT06113978|PROCEDURE|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
219703965|NCT06412822|OTHER|Blood sampling|Blood sampling
219703966|NCT06412822|OTHER|Urine sampling|Urine sampling
219118184|NCT02875561|DEVICE|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
219118185|NCT02875561|DEVICE|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
219118186|NCT01770990|BEHAVIORAL|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
219118187|NCT01770990|BEHAVIORAL|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
219118188|NCT03329430|OTHER|Foot orthoses|Customized foot orthoses
219118189|NCT05408923|DRUG|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
219118190|NCT05408923|DRUG|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
219118191|NCT05763992|DIETARY_SUPPLEMENT|Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)|Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
219118192|NCT04669912|OTHER|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
219118193|NCT02409303|BEHAVIORAL|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
219118194|NCT04657523|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
219118195|NCT04717063|DRUG|Peroxyl Oral Product|mouth wash
219118196|NCT04717063|DRUG|Placebo|placebo mouth wash
219118197|NCT03989791|DIETARY_SUPPLEMENT|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
219118198|NCT03989791|DIETARY_SUPPLEMENT|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
219118199|NCT00563849|DRUG|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
219118200|NCT06842927|OTHER|data collection|"An additional collection of peritoneal dialysate and spot urine samples will be collected.~Participants randomized to the training/validation arm will have their data used for model development, including the training and validation phases."
219118201|NCT06842927|OTHER|data report|An additional collection of peritoneal dialysate and spot urine samples will be collected. Participants randomized to the test arm will have their data isolated and reserved exclusively for evaluating the performance of the final AI model
219118202|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Tropical Fruits|flavour Tropical Fruits
219118203|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Cappuccino|flavour Cappuccino
219118204|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Pineapple-Coconut|flavour Pineapple-Coconut
219118205|NCT05971823|OTHER|Tobacco product administration and assessment|Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
219118206|NCT06583122|PROCEDURE|Ultrasound Guided Approach|All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
219118207|NCT07102628|DRUG|Placebo|The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90
219225477|NCT06965348|DEVICE|Application of kinesio tape|"The facilitating taping technique for the quadriceps and hamstring muscle group described by Kase et al. will be applied to the kinesio tape group. The tape will be applied from the muscle origin to the insertion (proximal to distal) for facilitation.~The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending on the undersurface of the patella.~The physiotherapist places the tape base without tension in the first 5 centimeters of the starting point of the hamstring muscles and quadriceps muscle. Light to moderate tension (25-50%) is applied for facilitation. The tail parts of the tape are placed on the skin without tension at a distance of 2 to 5."
219225478|NCT06965348|OTHER|Placebo Group|The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will also be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending at the lower surface of the patella.The placebo group will have tape applied to the quadriceps and hamstring muscle groups without any tension.
219225479|NCT03749187|DRUG|PARP Inhibitor BGB-290|Given PO
219225480|NCT03749187|DRUG|Temozolomide (TMZ)|Given PO
219225481|NCT04560946|BEHAVIORAL|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
219118208|NCT07102628|DRUG|Inclisiran|The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90
219118209|NCT06918717|PROCEDURE|Direct Laryngoscopy-to-VideoLaryngoscopy sequence|Participants will proceed with a double intubation technique sequence, first performing an initial direct laryngoscopy without looking at the video screen until they reached the epiglottis, then performing an indirect lryngoscopy for intubation.
219118210|NCT06918717|PROCEDURE|Free use of videolaryngoscopy|Participants are free to use of the videolaryngoscope as they intended
219118211|NCT06919900|BEHAVIORAL|Perturbation Training|Unexpected slips blended with trips and unperturbed walking trials on a treadmill. A safety harness will be worn at all times.
219118212|NCT06919900|BEHAVIORAL|Treadmill Walking|Treadmill walking for the same amount of time as the training group without perturbation. A safety harness will be worn at all times.
219118213|NCT06918470|OTHER|Standard monitoring techniques|（3）atients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
219118214|NCT06918470|OTHER|noise cancelling headphones|The treatment group started wearing noise cancelling headphones until the end of the surgery in the general anesthesia induction group to isolate intraoperative environmental noise,patients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
219118215|NCT06918197|PROCEDURE|PAS Technique|"PAS Technique Protocol:~The following steps outline the PAS Technique. While the example below uses 6 injection sites, the approach can be adapted for different pain management procedures with a different number of needle injection sites as needed.~Timer: Begin stopwatch for entire procedure from start to medication insertion. Positioning: The patient is placed in a prone position on the fluoroscopic table. Time out was performed.~Skin Preparation: Clean the injection site with an antiseptic solution and drape it to maintain sterility.~Anesthesia: Administer intravenous sedation Identification of Anatomical Landmark:The spinous process was located and marked as the reference point (SP), which was then used as a guide for the following steps.~Marking Target Points: Using the spinous process (SP) as the anatomical landmark and X-ray guided fluoroscopy, Target Point 1 (TP1) was identified and its position verified. The X value (the horizontal distance from the SP to TP1) was measured."
219118216|NCT06918197|PROCEDURE|Standard Technique|"In the Standard or Traditional technique, the spinal needles are used to localize the anatomical objective using fluoroscopic guidance for each needle placement. Traditionally, each needle is placed individually with a spot radiological view before placement and after placement of each needle to confirm the localization."
219118217|NCT06919328|DIETARY_SUPPLEMENT|Niagen®|nicotinamide riboside
219118218|NCT06919328|OTHER|NAD+|Nicotinamide adenine dinucleotide
219118219|NCT06919328|OTHER|Placebo|bacteriostatic water
219118220|NCT00035958|DRUG|Prednisone|
219118221|NCT00035958|DRUG|Methotrexate|
219118222|NCT00035958|DRUG|Etanercept|
219118223|NCT05956834|DEVICE|PAMSys|Wearable accelerometer and gyroscope for measuring movement
219118224|NCT05956834|DEVICE|LEGSys|Wearable accelerometer and gyroscope for measuring movement
219118225|NCT05041634|BEHAVIORAL|IHOPE|Integrating Healthy Habits Optimized by Community Participation and Engagled Learning
219703967|NCT03776279|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
219703968|NCT05378503|DRUG|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
219703969|NCT05378503|DRUG|Qsymia 7.5Mg-46Mg Extended Release Capsule|"1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
219703970|NCT05378503|DRUG|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
219703971|NCT05378503|DRUG|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
219703972|NCT05378503|DRUG|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
219703973|NCT00453687|DRUG|GSK233705|investigational drug
219118226|NCT04068727|OTHER|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
219703974|NCT05493631|BIOLOGICAL|MG1113|MG1113 subcutaneous (SC) injection
219703975|NCT04777513|PROCEDURE|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
219703976|NCT04777513|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
219703977|NCT04777513|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
219703978|NCT04777513|DEVICE|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
219703979|NCT04777513|DEVICE|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
219703980|NCT04908501|OTHER|Intervention|The program intervention has three focuses : the prioritization of appropriateness indicators, the automation and visualization of the prioritized indicators, and support for practice analysis groups (PAG) based on e-feedback from automated indicators
219703981|NCT00896831|DRUG|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
219703982|NCT00896831|DRUG|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
219703983|NCT00688597|DRUG|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
219118227|NCT03133143|BEHAVIORAL|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
219118228|NCT03133143|BEHAVIORAL|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
219118229|NCT00895973|OTHER|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
219118230|NCT02654067|PROCEDURE|photograph|photograph of airway
219118231|NCT03038074|DEVICE|Pulse Oximeter with respiration rate sensor|
219118232|NCT01361815|DEVICE|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
219225482|NCT04560946|BEHAVIORAL|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
219225483|NCT02686658|DRUG|Avacincaptad Pegol|Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection
219118233|NCT05923268|DRUG|[99mTc]Tc-G3-(G3S)3C|One single injection of \[99mTc\]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
219118234|NCT06268353|OTHER|blood sampling|Measure CAPGDF15 in plasma of 3 pregnant and 3 non-pregnant women
219703984|NCT00259103|DRUG|Serelaxin|
219703985|NCT00259103|DRUG|Placebo|
219118235|NCT04351490|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate capsule 15 mg x 2 per day during 2 months
219118236|NCT04351490|DIETARY_SUPPLEMENT|25-OH cholecalciferol|25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
219118237|NCT01710293|BEHAVIORAL|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
219118238|NCT02643771|PROCEDURE|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
219118239|NCT00322868|DRUG|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
219118240|NCT03565861|DRUG|Placebo|Intravenous vehicle
219703986|NCT03980678|DIETARY_SUPPLEMENT|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
219703987|NCT03980678|DIETARY_SUPPLEMENT|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
219118241|NCT03565861|DRUG|NP10679|NP10679
219118242|NCT03290469|OTHER|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
219118243|NCT00309335|DRUG|Phentolamine Mesylate (NV-101)|
219118244|NCT00862875|DRUG|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
219118245|NCT04125511|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of IgG4-RD by PET/CT.
219118246|NCT06082128|BEHAVIORAL|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
219118247|NCT04646447|DIETARY_SUPPLEMENT|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
219118248|NCT02752152|BEHAVIORAL|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
219118249|NCT02752152|BEHAVIORAL|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
219118250|NCT02752152|BEHAVIORAL|Standard counseling|The counselor gives face-to-face general information/education
219118251|NCT02752152|BEHAVIORAL|Appointment + reminder|Has an appointment and receive reminders for further testing
219118252|NCT02752152|BEHAVIORAL|Reminder|Only receive reminders for further testing
219118253|NCT02752152|BEHAVIORAL|No appointment and no reminder|No appointment and no reminders for further testing
219118254|NCT04404257|RADIATION|ControlRad System|Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
219118255|NCT04404257|RADIATION|Without ControlRad System|Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
219118256|NCT02176928|DEVICE|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
219118257|NCT02176928|DEVICE|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
219118258|NCT01917734|OTHER|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
219118259|NCT02162693|BIOLOGICAL|Mesenchymal progenitor cells|Administrated for intra-articular injection
219118260|NCT02162693|BIOLOGICAL|Sodium Hyaluronate|
219118261|NCT03114995|DRUG|Tirofiban|
219118262|NCT04223154|DEVICE|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
219118263|NCT04223154|DEVICE|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
219118264|NCT00900536|GENETIC|mutation analysis|
219118265|NCT00900536|GENETIC|polymorphism analysis|
219118266|NCT00900536|GENETIC|protein expression analysis|
219118267|NCT00900536|OTHER|immunohistochemistry staining method|
219118268|NCT00900536|OTHER|laboratory biomarker analysis|
219118269|NCT05151861|OTHER|Complete removal of pharmacological treatment|Removal of treatment
219118270|NCT05151861|DRUG|Control|Maintenance of pharmacological treatment
219118271|NCT00739583|DRUG|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
219118272|NCT00739583|DRUG|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
219118273|NCT00973947|OTHER|questionnaire administration|
219118274|NCT00973947|RADIATION|3-dimensional conformal radiation therapy|
219118275|NCT00973947|RADIATION|radiation therapy treatment planning/simulation|
219225484|NCT02686658|OTHER|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
219225485|NCT00485693|DRUG|Bupivacaine HCl|150 mg Bupivacaine HCl
219118276|NCT01668485|PROCEDURE|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
219118277|NCT04699448|OTHER|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
219118278|NCT01155726|DEVICE|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
219118279|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
219118280|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
219118281|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
219118282|NCT01155726|DEVICE|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
219118283|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
219118284|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
219703988|NCT04524156|OTHER|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
219703989|NCT01902069|DIETARY_SUPPLEMENT|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
219118285|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
219118286|NCT01549691|DRUG|Zopiclone|7.5 mg before sleep, the evening before surgery
219118287|NCT01549691|DRUG|Alprazolam|0.5 mg at awakening, the day of surgery
219118288|NCT01549691|DRUG|placebo|given night before surgery and at awakening, the day of surgery
219118289|NCT06696612|DIAGNOSTIC_TEST|Dermoscopy|Dermoscopic examination of the nails
219118290|NCT06242509|DIAGNOSTIC_TEST|Biological samples|"Plasma sampling ans stool sampling~* at inclusion~* at 1 month~* at 3 months~* at progression within the 3 months"
219703990|NCT01902069|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
219703991|NCT02749825|DRUG|Trelstar|As labeled
219118291|NCT04464941|BEHAVIORAL|a composite intervention with both group and individual components for oral health promotion program|"The group intervention consisted of:~1\. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1\. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method"
219118292|NCT00157586|DRUG|Delapril, Delapril-Manidipine Fixed combination|
219118293|NCT02580825|BEHAVIORAL|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
219225486|NCT00485693|DRUG|SKY0402|600 mg SKY0402 (study drug)
219703992|NCT02749825|DRUG|Lupron|As labeled
219703993|NCT02749825|DRUG|Zoladex|As labeled
219703994|NCT03756675|OTHER|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
219703995|NCT01355965|BIOLOGICAL|Autologous T cells|
219118294|NCT02580825|BEHAVIORAL|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
219118295|NCT05389358|BEHAVIORAL|Asiphephe health worker training|Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).
219118296|NCT05389358|BEHAVIORAL|Asiphephe therapeutic sessions|Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.
219118297|NCT05389358|OTHER|IPV assessment|IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
219118298|NCT05389358|OTHER|Referral for IPV or Mental Health|Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
219118299|NCT00677456|PROCEDURE|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
219118300|NCT00677456|PROCEDURE|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
219118301|NCT00677456|PROCEDURE|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
219118302|NCT00677456|PROCEDURE|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
219118303|NCT02459587|BEHAVIORAL|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
219118304|NCT02459587|BEHAVIORAL|Enhanced Usual Care (EUC)|Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).
219118305|NCT02696720|DRUG|Lidocaine|
219118306|NCT02696720|OTHER|Sham|
219118307|NCT02224014|DRUG|Lendormin D tablets|
219118308|NCT02794961|BIOLOGICAL|CD22 CAR-T|Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight
219118309|NCT03090217|BEHAVIORAL|Pelvic Physiotherapy|1\) daily pelvic floor muscle training (PFMT).
219118310|NCT03090217|BEHAVIORAL|Standard care (SC)|1\) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
219118311|NCT00110201|DRUG|Nesiritide|
219118312|NCT04572542|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
219118313|NCT04572542|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
219118314|NCT04572542|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
219118315|NCT00412867|DRUG|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
219118316|NCT04439487|DIAGNOSTIC_TEST|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
219118317|NCT04439487|OTHER|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
219118318|NCT04027920|DRUG|Shenghua Decoction|Three days' shenghua decoction treatment
219225487|NCT02348866|OTHER|method of laundering and donning scrubs|
219225488|NCT01565187|BEHAVIORAL|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
219118319|NCT04897087|OTHER|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
219118320|NCT02096081|DRUG|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
219118321|NCT02096081|DRUG|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
219118322|NCT00884286|DRUG|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
219118323|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
219118324|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
219118325|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
219118326|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
219703996|NCT04278313|PROCEDURE|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
219703997|NCT04278313|PROCEDURE|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
219703998|NCT00961415|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
219703999|NCT00961415|DRUG|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
219704000|NCT00961415|DRUG|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
219704001|NCT03186664|DEVICE|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
219118327|NCT03100695|OTHER|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
219118328|NCT02424331|OTHER|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
219118329|NCT02424331|OTHER|Quiet Breathing|
219118330|NCT04600622|BEHAVIORAL|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
219118331|NCT04600622|BEHAVIORAL|Diabetes Education Materials|Diabetes Education Materials
219118332|NCT02395705|DRUG|cisplatin and paclitaxel|"1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
219118333|NCT01720797|DEVICE|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
219118334|NCT01720797|DRUG|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
219118335|NCT01720797|OTHER|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
219118336|NCT00178620|DRUG|Reteplase 10 Units (U) plus a second dose of reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
219118337|NCT00178620|DRUG|Reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
219118338|NCT00178620|PROCEDURE|Urgent Percutaneous Coronary Intervention (PCI)|
219118339|NCT00178620|PROCEDURE|Primary Percutaneous Coronary Intervention (PCI)|
219118340|NCT00675961|BEHAVIORAL|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
219118341|NCT00675961|DRUG|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
219118342|NCT00675961|OTHER|BCI + Naltrexone|Combination of the two previous interventions
219118343|NCT00675961|BEHAVIORAL|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
219118344|NCT02243072|BEHAVIORAL|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
219118345|NCT03781960|DRUG|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
219118346|NCT03781960|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
219118347|NCT05565222|DRUG|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
219118348|NCT05565222|DRUG|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
219225489|NCT00467272|DRUG|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
219118349|NCT00591747|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
219704002|NCT03186664|DRUG|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
219704003|NCT02424695|DRUG|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
219704004|NCT02424695|DRUG|Placebo|
219704005|NCT01560117|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
219704006|NCT00808925|OTHER|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
219704007|NCT05354934|OTHER|quetionnaire|"The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
219704008|NCT01045278|DRUG|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
219704009|NCT00544271|BIOLOGICAL|INFANRIX|
219704010|NCT00544271|BIOLOGICAL|BOOSTRIX|
219704011|NCT00544271|BIOLOGICAL|HAVRIX|
219704012|NCT00300729|DRUG|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
219704013|NCT00300729|DRUG|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
219704014|NCT01543191|DRUG|PUR118|low dose and high dose for 3 doses, BID
219704015|NCT02678533|DRUG|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
219118350|NCT00591747|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
219118351|NCT03821701|DRUG|Entresto|Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
219118352|NCT03821701|DRUG|ACEI/ARB|Choose one of ACEI/ARB according to the clinical condition among the whole study.
219118353|NCT00249093|DRUG|oxygen|
219118354|NCT04028115|DRUG|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
219118355|NCT00678990|PROCEDURE|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
219225490|NCT05094011|BIOLOGICAL|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
219225491|NCT04275167|DEVICE|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
219118356|NCT05125120|OTHER|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
219118357|NCT01994733|DRUG|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
219118358|NCT01994733|DRUG|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
219118359|NCT04047004|DRUG|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
219118360|NCT04047004|DRUG|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
219118361|NCT04539379|DRUG|Magnesium sulfate|intravenous infusion
219118362|NCT04539379|DRUG|Labetolol|intravenous infusion
219118363|NCT05345093|DEVICE|Ialuxid gel|"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."
219704016|NCT02678533|DRUG|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
219704017|NCT05545501|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
219704018|NCT05545501|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
219704019|NCT05545501|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
219704020|NCT01151436|DEVICE|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
219704021|NCT02038192|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
219704022|NCT02038192|BEHAVIORAL|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
219704023|NCT05247320|DRUG|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
219118364|NCT03753971|OTHER|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
219704024|NCT03454035|DRUG|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
219704025|NCT03454035|DRUG|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
219704026|NCT05470504|DRUG|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
219704027|NCT05469490|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.
219704028|NCT05469490|DRUG|navoximod|A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
219704029|NCT05469490|DRUG|NLG802 (indoximod Prodrug)|An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
219704030|NCT02547831|OTHER|Observational approach|Patients will be placed under wait and see approach without any specific treatment
219118365|NCT00113698|DRUG|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
219118366|NCT00113698|OTHER|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
219118367|NCT06312527|DEVICE|Silicone dressing|"Participant will apply silicone dressing at 2 weeks after TKA on one side of knee.~Silicone dressing will change every week until 12 week postoperative."
219118368|NCT02339701|RADIATION|IMRT|
219118369|NCT02339701|RADIATION|SBRT|
219118370|NCT02550275|BEHAVIORAL|neuropsychological test|
219118371|NCT02550275|RADIATION|MRI|
219118372|NCT00982982|DRUG|THC and Iomazenil|"* Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
219118373|NCT00982982|DRUG|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
219118374|NCT02255630|OTHER|Cycling Exercise|
219118375|NCT00002750|DRUG|melphalan|
219118376|NCT03541642|BEHAVIORAL|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
219118377|NCT03541642|BEHAVIORAL|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
219118378|NCT02682563|DRUG|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
219118379|NCT02682563|DRUG|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
219118380|NCT05898737|DEVICE|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
219118381|NCT03088137|DRUG|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
219118382|NCT03088137|DRUG|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
219118383|NCT06126419|DRUG|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
219118384|NCT03699046|PROCEDURE|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
219118385|NCT03699046|PROCEDURE|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
219118386|NCT03699046|BIOLOGICAL|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
219118387|NCT01026675|PROCEDURE|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
219118388|NCT06341257|RADIATION|Stereotactic Central/Core Ablative Radiation Therapy (SCART)|The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
219118389|NCT03070314|DRUG|Echinaforce junior|Echinacea Purpurea Extract Pill, sweetened and with orange flavour
219118390|NCT03265379|OTHER|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
219118391|NCT00274911|DRUG|cisplatin|
219118392|NCT00274911|DRUG|lomustine|
219118393|NCT00274911|DRUG|vincristine sulfate|
219118394|NCT00274911|PROCEDURE|adjuvant therapy|
219118395|NCT00274911|RADIATION|radiation therapy|
219704031|NCT05728411|OTHER|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
219118396|NCT03198260|OTHER|Fascial manipulation|Deep frictional massage
219118397|NCT02826564|DRUG|pembrolizumab|
219118398|NCT00918749|DRUG|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
219118399|NCT00918749|DRUG|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
219118400|NCT00918749|DRUG|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
219118401|NCT01951092|OTHER|Text messaging|
219118402|NCT05058586|OTHER|The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients|Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
219704032|NCT05728411|OTHER|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
219118403|NCT04698889|DIETARY_SUPPLEMENT|natural cow|
219704033|NCT04497961|DRUG|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
219118404|NCT04698889|DIETARY_SUPPLEMENT|high protein cow milk|
219118405|NCT04698889|DIETARY_SUPPLEMENT|natural human|
219118406|NCT04698889|DIETARY_SUPPLEMENT|low protein cow milk|
219118407|NCT01712789|DRUG|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
219118408|NCT01712789|DRUG|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
219118409|NCT04786470|DRUG|Ropivacaine|Ropivacaine infusion via transversus abdominis plane catheter.
219225492|NCT04198467|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
219704034|NCT04497961|DRUG|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
219704035|NCT04497961|BEHAVIORAL|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
219704036|NCT04497961|OTHER|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
219118410|NCT04786470|DRUG|Saline|Saline infusion via transversus abdominis plane catheter.
219118411|NCT04199715|BIOLOGICAL|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
219118412|NCT00072163|DRUG|temozolomide|Given orally
219118413|NCT00072163|DRUG|thalidomide|Given orally
219118414|NCT03729349|BIOLOGICAL|Golimumab|Participants will receive golimumab as a part of clinical practice.
219118415|NCT04592133|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography Examination
219118416|NCT03587987|DEVICE|Neopff|manual ventilation
219118417|NCT03587987|DEVICE|rPap|Manual ventilation
219118418|NCT06529562|RADIATION|Surgery combined with Target-reduction intensity-modulated radiotherapy|in control arm
219118419|NCT06529562|RADIATION|Surgery combined with Dose-reduction intensity-modulated radiotherapy|in experimental arm
219118420|NCT01708187|BIOLOGICAL|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
219118421|NCT00873093|DRUG|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
219118422|NCT00873093|DRUG|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
219118423|NCT00873093|DRUG|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
219118424|NCT00873093|DRUG|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
219118425|NCT00873093|DRUG|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
219118426|NCT00873093|DRUG|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
219118427|NCT00873093|DRUG|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
219118428|NCT00873093|DRUG|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
219118429|NCT00873093|DRUG|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
219118430|NCT00873093|DRUG|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
219118431|NCT00873093|DRUG|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
219118432|NCT00873093|BIOLOGICAL|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
219118433|NCT00873093|DRUG|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
219118434|NCT00873093|OTHER|laboratory biomarker analysis|Correlative studies
219225493|NCT04198467|DRUG|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
219225494|NCT01572805|DRUG|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
219118435|NCT00873093|DRUG|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
219118436|NCT00788255|DRUG|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
219118437|NCT00788255|DRUG|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
219704037|NCT02365779|PROCEDURE|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
219118438|NCT00788255|DRUG|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
219704038|NCT02365779|DEVICE|endomicroscopy Cellvizio® system|
219704039|NCT05960695|OTHER|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
219704040|NCT05960695|OTHER|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
219704041|NCT06470438|DRUG|JNJ-88998377|JNJ-88998377 will be administered.
219118439|NCT02053779|DRUG|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
219118440|NCT00459511|PROCEDURE|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
219118441|NCT00734890|BIOLOGICAL|bevacizumab|
219704042|NCT06511076|DRUG|Zilucoplan|Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
219704045|NCT05138562|DRUG|Placebo Comparator: Placebo|4 x placebo capsules, QD
219704046|NCT05138562|DRUG|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
219704047|NCT05138562|DRUG|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
219704048|NCT05138562|DRUG|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
219704049|NCT05567341|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
219704050|NCT05567341|PROCEDURE|Sham-control|A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
219704051|NCT05347628|DRUG|PLB1004|PLB1004 is a capsule in the form of 10mg and 40mg.
219704052|NCT05914376|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
219118442|NCT00734890|DRUG|vandetanib|
219118443|NCT00734890|OTHER|laboratory biomarker analysis|
219704053|NCT06638125|DEVICE|3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
219704054|NCT06638125|DEVICE|3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
219704055|NCT05595577|OTHER|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
219704056|NCT05595577|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
219118444|NCT00734890|OTHER|pharmacological study|
219118445|NCT00917228|DEVICE|recordings with device equipped|
219118446|NCT00917228|DEVICE|Control|Recording without device equipped
219118447|NCT03509922|DRUG|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
219225495|NCT01572805|DRUG|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
219225496|NCT01572805|DRUG|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
219225497|NCT01841515|DRUG|Desmopressin administration|
219118448|NCT03509922|DRUG|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
219118449|NCT01898975|OTHER|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
219118450|NCT06304311|PROCEDURE|Routine Obstetrics care & Lamaze breathing techniques and backside massage|"Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist."
219118451|NCT03055832|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
219118452|NCT03055832|DEVICE|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
219118453|NCT00904228|OTHER|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
219118454|NCT00904228|OTHER|placement of routine cap during delivery room stabilization|
219118455|NCT01529190|DRUG|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
219225498|NCT00570505|DEVICE|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
219225499|NCT01695291|DRUG|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
219225500|NCT01695291|OTHER|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
219118456|NCT01529190|DRUG|Placebo|placebo
219225501|NCT03051568|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
219225502|NCT02045498|DEVICE|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
219225503|NCT00614614|BIOLOGICAL|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
219225504|NCT00614614|BIOLOGICAL|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
219225505|NCT00614614|BIOLOGICAL|Infanrix®|One dose as intramuscular injection
219225506|NCT00614614|BIOLOGICAL|ActHIB®|Three doses in the priming phase as intramuscular injection
219225507|NCT00614614|BIOLOGICAL|Pediarix®|Three doses in the priming phase as intramuscular injection
219225508|NCT04990856|PROCEDURE|Exercise|Tumor blood flow after acute exercise
219225509|NCT05426109|OTHER|Peanut snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal peanut-containing (whole peanuts or peanut butter) snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
219225510|NCT05426109|OTHER|No peanut-containing snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal non-peanut-containing high carbohydrate snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
219225511|NCT06354985|DRUG|Modafinil 200mg|Modafinil 200mg daily for 8 weeks.
219118457|NCT01585922|PROCEDURE|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
219118458|NCT01585922|PROCEDURE|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
219225512|NCT06354985|DRUG|Placebo|Placebo daily for 8 weeks.
219225513|NCT06354985|BEHAVIORAL|Exercise|Exercise three times per week for 8 weeks.
219704057|NCT05595577|DIAGNOSTIC_TEST|MRI scan|Images of the heart will be taken.
219118459|NCT01854333|OTHER|ADOS module 1-4 or ADI-R|
219118460|NCT04212481|PROCEDURE|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
219118461|NCT04212481|PROCEDURE|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
219118462|NCT04212481|PROCEDURE|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
219118463|NCT00002354|DRUG|Indinavir sulfate|
219118464|NCT00002354|DRUG|Stavudine|
219118465|NCT04323319|DEVICE|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
219118466|NCT03066388|OTHER|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
219118467|NCT03508128|OTHER|surgical procedure|Surgical procedure
219118468|NCT00309920|BIOLOGICAL|darbepoetin alfa|
219118469|NCT00309920|DRUG|cyclophosphamide|
219118470|NCT00309920|DRUG|docetaxel|
219704058|NCT05595577|BEHAVIORAL|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
219118471|NCT00309920|DRUG|doxorubicin hydrochloride|
219118472|NCT00309920|DRUG|epirubicin hydrochloride|
219118473|NCT00309920|DRUG|fluorouracil|
219118474|NCT03725943|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
219118475|NCT04026282|PROCEDURE|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
219118476|NCT04026282|PROCEDURE|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
219118477|NCT06386224|BEHAVIORAL|Internet-delivered pain self-management (CBT Condition)|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focused on different skills delivered over 8 weeks (e.g., symptom identification, changing negative thoughts, activity pacing)
219118478|NCT06386224|BEHAVIORAL|Education Program|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focusing on pancreatitis pain topics, including: an introduction to pancreatitis, treatment options, specific therapies, surgical procedures.
219118479|NCT05825729|DIAGNOSTIC_TEST|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
219118480|NCT05825729|DIAGNOSTIC_TEST|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
219118481|NCT05825729|DIAGNOSTIC_TEST|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
219118482|NCT05946382|BEHAVIORAL|RNT-ACT Protocol|Swedish Translation of the 2\*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.
219118483|NCT05946382|BEHAVIORAL|iCBT Treatment|Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
219704059|NCT05595577|BEHAVIORAL|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
219118484|NCT04207684|DRUG|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
219118485|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 3 mg administered SC
219704060|NCT05595577|OTHER|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
219704061|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
219704062|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
219704063|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
219704064|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
219704065|NCT06252480|DEVICE|tDCS|4 variance of different intensities of tDCS (0.5mA, 1 mA, 1.5mA and 2mA). At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment.
219118486|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 6 mg administered SC
219118487|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 12 mg administered SC
219118488|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 24 mg administered SC
219118489|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.1 mg/kg administered IV
219118490|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.2 mg/kg administered IV
219118491|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.4 mg/kg administered IV
219118492|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.8 mg/kg administered IV
219118493|NCT04183192|BIOLOGICAL|Placebo|Placebo (administered either IV or SC)
219118494|NCT05962840|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
219118495|NCT05962840|OTHER|Placebo of Telitacicept|Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
219118496|NCT05447247|OTHER|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
219118497|NCT02492217|DRUG|Adalimumab|
219118498|NCT06340529|OTHER|Clinical Simulation|Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
219118499|NCT06441019|DRUG|HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab|The patient will receive combined treatment with HAIC, TQB2868, and Ramucirumab. After enrollment, the patient will undergo routine hepatic artery angiography via femoral artery catheterization and placement of a hepatic artery catheter，they will then receive 150ml of 5% sodium bicarbonate + Oxaliplatin (85mg/m2) for 4-6 hours + Raltitrexed (2mg/m2) for 2-4 hours . This will be done every 3-4 weeks for at least 2 cycles. Systemic treatment will be administered every 21 days, with TQB2868 injection given on the first day of each cycle (1-7 days after HAIC). The fixed dose of TQB2868 will be 300mg, and Ramucirumab will be given at a dose of 500mg (initial intravenous infusion for 60 minutes, followed by 30 minutes if tolerated).
219225514|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
219704066|NCT05091190|OTHER|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
219118500|NCT01539434|BEHAVIORAL|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
219704067|NCT05439655|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
219704068|NCT02745106|PROCEDURE|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
219225515|NCT05212285|DEVICE|Inbody 570|Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
219118501|NCT01539434|BEHAVIORAL|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
219118502|NCT03377075|DEVICE|AL measurement|IOL Master 500 (Carl Zeiss AG, Germany)
219118503|NCT03377075|DEVICE|OCT|Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
219118504|NCT02459340|OTHER|therapeutic treatment (inpatient and outpatient setting)|
219118505|NCT02181205|DRUG|bupivacaine|
219118506|NCT02181205|DRUG|placebo|
219118507|NCT05359159|OTHER|Data collection|Data collection
219118508|NCT01163149|DRUG|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
219704069|NCT02745106|DEVICE|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
219704070|NCT02745106|DEVICE|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)"
219704071|NCT04850105|OTHER|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
219118509|NCT01163149|DRUG|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
219118510|NCT01968161|DRUG|Asenapine|
219118511|NCT05197075|DRUG|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
219118512|NCT01517022|DRUG|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
219118513|NCT05210842|OTHER|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
219118514|NCT04685473|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
219118515|NCT02806336|BEHAVIORAL|Multi Modal Balance Training (MMBI)|Group balance class, obstacle course, strengthening exercises
219225516|NCT05212285|DEVICE|JAMAR Dynamometer|Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
219225517|NCT05212285|RADIATION|CT scan|Chest and abdominal CT scan during each follow-up
219118516|NCT02806336|BEHAVIORAL|Weight Loss (WL)|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
219118517|NCT01916317|DRUG|0.5% lignocaine 60mM|
219118518|NCT06222554|DEVICE|MoveMend Health|Software-based therapeutic tool that offers gamified exercises and activities. The device is designed for deployment on tablets. The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
219118519|NCT04225949|OTHER|survey 1|survey with one version of depiction
219118520|NCT04225949|OTHER|survey 2|survey with one version of depiction
219118521|NCT06088420|PROCEDURE|Intrathcal Morphine Group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
219118522|NCT06088420|PROCEDURE|Quadratus Lumborum nerve block(QL) group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
219118523|NCT06088420|PROCEDURE|Erector Spinae nerve block (ESP)group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
219118524|NCT01874093|DEVICE|The Ischemic Stroke System|SPG stimulation and standard of care
219118525|NCT01874093|DEVICE|Sham control|Sham stimulation and standard of care
219704072|NCT05186480|DIETARY_SUPPLEMENT|Neo Mune|"Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)"
219118526|NCT04221477|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
219118527|NCT04221477|DRUG|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
219118528|NCT04221477|DRUG|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
219118529|NCT04221477|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
219118530|NCT04221477|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
219118531|NCT04221477|DRUG|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
219118532|NCT04221477|DRUG|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
219118533|NCT06074653|OTHER|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
219118534|NCT06074653|OTHER|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
219118535|NCT03983993|DRUG|Niraparib|Given PO
219118536|NCT03983993|BIOLOGICAL|Panitumumab|Given IV
219118537|NCT03867474|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
219118538|NCT01107730|DRUG|Vitamin C|VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
219118539|NCT01107730|DRUG|L-Carnitine|L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
219118540|NCT01107730|DRUG|Placebo|Placebo
219118541|NCT01504451|DEVICE|ILR insertion|Insertion of implantable loop recorder
219704073|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
219118542|NCT01504451|PROCEDURE|AF ablation|AF ablation
219225518|NCT06346886|BEHAVIORAL|FAITH! HTN app|Participants will remain in the intervention for 11 weeks. The app-based intervention is a tailored program to promote HTN self-management and knowledge through an 11-module educational video series with a focus on HTN. Participants will also be provided with at home Blood Pressure (BP) monitoring system to allow for self-tracking of BP measurements(automatically synchronized with the app). The app will include pre-post module quizzes, a tracking component for participants to input self-monitored measures (medication adherence, diet, physical activity, etc.). The app sharing board will be a moderated discussion platform and feed for participant interaction by posting healthy lifestyle practices through text, photographs and video to foster discussion on HTN management barriers/facilitators. The project team will post weekly to the sharing board on HTN-related topics to generate discussion among patients.
219225519|NCT05591534|RADIATION|Endorectal brachytherapy|Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
219225520|NCT06305962|DRUG|177Lu-RAD204|177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
219704074|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
219704075|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
219118543|NCT02774213|OTHER|Questionnaires completion|
219118544|NCT02774213|OTHER|Clinical Pain Assessments|
219118545|NCT02999971|OTHER|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
219225521|NCT01421836|PROCEDURE|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
219704076|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
219704077|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
219704078|NCT05719961|DRUG|INS062 injection|Part I: A single dose of 1.2noml/kg is administered.
219704079|NCT05719961|DRUG|Insulin Aspart|Part I: A single dose of 0.2U/kg is administered.
219118546|NCT02999971|OTHER|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
219118547|NCT02543593|DEVICE|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
219118548|NCT00892268|PROCEDURE|acupuncture therapy|Undergo acupuncture
219118549|NCT00892268|PROCEDURE|pain therapy|Receive standard care
219118550|NCT00043095|DRUG|gemcitabine hydrochloride|
219118551|NCT00043095|DRUG|ixabepilone|
219118552|NCT00487786|DRUG|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
219118553|NCT00487786|DRUG|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study
219118554|NCT05495061|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
219118555|NCT05495061|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
219118556|NCT03795779|BIOLOGICAL|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
219118557|NCT02595229|PROCEDURE|Pronator quadratus repair|Suturing of the pronator quadratus muscle
219118558|NCT02638064|PROCEDURE|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
219118559|NCT04807829|DRUG|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
219118560|NCT04807829|DRUG|Placebo|Inactive placebo comparator
219118561|NCT02554435|DEVICE|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
219118562|NCT02554435|BEHAVIORAL|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
219118563|NCT02554435|DEVICE|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
219118564|NCT06428253|DEVICE|HMM1-022|intradermal injection
219118565|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
219118566|NCT05951296|DRUG|Leramistat|Drug: Leramistat
219118567|NCT05951296|DRUG|Placebo|Placebo comparator
219118568|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
219704080|NCT05719961|DRUG|HR20014 injection|Part II: Ascending single doses at three dose levels
219704081|NCT05719961|DRUG|Insulin Aspart 30 Injection|Part II: A single dosewas administered
219118569|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
219118570|NCT06084429|OTHER|pre and post test (health educational intervention)|"The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution"
219118571|NCT06509464|DEVICE|High intensity interval training|High intensity interval training on treadmill
219118572|NCT06509464|DIETARY_SUPPLEMENT|Caloric restricted diet|Caloric restricted diet
219118573|NCT05814861|DIAGNOSTIC_TEST|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
219704082|NCT04762186|DRUG|human SARS-CoV 2 specific T lymphocytes|"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
219704083|NCT00844311|DRUG|rFSH|150 iu/day of rFSH
219118574|NCT03213002|DRUG|Capecitabine|Capecitabine at 1500 mg/m2
219118575|NCT03213002|DRUG|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
219118576|NCT05687071|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
219118577|NCT05421650|OTHER|CCRT|CCRT
219704084|NCT00844311|DRUG|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
219704085|NCT00844311|DRUG|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
219704086|NCT00844311|DRUG|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
219704087|NCT06546306|DEVICE|TOUCH® CMC 1|TOUCH® prosthesis is a total CMC 1 (1st Carpo-metacarpal) joint replacement prosthesis.
219704088|NCT06468358|DRUG|LB1410|anti-PD-1/TIM3 bispecific antibody
219704089|NCT06468358|DRUG|LB4330|anti-claudin18.2/IL-10 fusion protein
219118578|NCT05421650|PROCEDURE|Surgical debulking of lymph nodes + CCRT|Surgical debulking of lymph nodes + CCRT
219118579|NCT05407311|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
219118580|NCT05995431|PROCEDURE|scaling and root planing|All the participants will undergo scaling and root planing
219118581|NCT05995431|PROCEDURE|Subgingival instrumentation|All the participants will undergo subgingival instrumentation
219118582|NCT04259775|DEVICE|Automated Insulin Dose Adjustment|The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
219118583|NCT04259775|DEVICE|Control|Standard Care - change in therapy settings effected at regularly scheduled patient visits
219118584|NCT01614574|BIOLOGICAL|velaglucerase alfa|60 U/kg every other week intravenous infusion
219118585|NCT03786484|DRUG|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
219118586|NCT00492934|DRUG|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
219118587|NCT01792362|OTHER|Weight loss diet|Control the patients diet to make them loosing weight
219118588|NCT01923428|DRUG|AZD1722|
219118589|NCT01923428|DRUG|Placebo|
219118590|NCT03230422|DEVICE|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
219118591|NCT03230422|DEVICE|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
219118592|NCT05323214|DRUG|Control Analgesic regimen|testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
219118593|NCT05323214|DRUG|Fentanyl Analgesic regimen|testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
219118594|NCT05323214|DRUG|Dexmedetomidine Analgesic regimen|testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
219118595|NCT01822353|DIETARY_SUPPLEMENT|Dietary supplement|Milk, egg or nut oral immunotherapy
219704090|NCT01072591|DRUG|MEDI-578|intravenous infusion, once
219118596|NCT02550873|BIOLOGICAL|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
219118597|NCT02550873|OTHER|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
219118598|NCT05625919|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
219118599|NCT04653298|OTHER|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
219118600|NCT05409196|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
219118601|NCT05409196|DRUG|Placebo|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
219118602|NCT01354275|OTHER|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
219118603|NCT01354275|OTHER|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
219118604|NCT00306904|DRUG|bevasiranib|
219118605|NCT03684005|OTHER|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
219118606|NCT04702100|OTHER|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
219704091|NCT01072591|DRUG|Placebo for MEDI-578|Intravenous infusion, once
219704092|NCT05077800|DRUG|FOLFIRNINOX|Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
219704093|NCT05077800|DRUG|Losartan|Taken Orally
219704094|NCT05077800|DRUG|9-ING-41|Administered by intravenous infusion
219704095|NCT05146336|DEVICE|CytoSorb|Sorbent hemoperfusion system
219704096|NCT05853120|DRUG|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
219704097|NCT05834179|OTHER|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
219118607|NCT04702100|OTHER|integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
219118608|NCT04702100|OTHER|conventional therapy|the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
219118609|NCT02425475|DEVICE|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
219118610|NCT04159961|DRUG|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
219118611|NCT03171558|PROCEDURE|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
219704098|NCT04159142|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
219704099|NCT04159142|DRUG|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
219704100|NCT05555732|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219704101|NCT05555732|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219704102|NCT05555732|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219704103|NCT05555732|DRUG|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
219118612|NCT03171558|PROCEDURE|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
219118613|NCT01907412|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
219118614|NCT01469793|DRUG|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
219704104|NCT05555732|DRUG|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
219704105|NCT02484248|DRUG|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
219704106|NCT02484248|DRUG|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
219704107|NCT05612594|DRUG|Bexagliflozin 20 mg|15mg once daily
219118615|NCT00579540|DIETARY_SUPPLEMENT|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
219118616|NCT00579540|DIETARY_SUPPLEMENT|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
219118617|NCT00579540|DIETARY_SUPPLEMENT|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
219225522|NCT01421836|PROCEDURE|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
219225523|NCT05089461|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
219704108|NCT05612594|DRUG|Placebo|matching placebo once daily
219704109|NCT06525935|DRUG|Placebo|Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
219704110|NCT06525935|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
219704111|NCT06961877|BEHAVIORAL|Cannabis Conversation Skills for Families (CCSF)|The purpose of the intervention is to train family members in communication skills that may increase contemplation of change in their loved one with first episode psychosis to reduce cannabis use, decrease conflict surrounding these discussions, and provide skills to understand when and how to approach their loved one about cannabis use and encourage treatment. Because families report confusion from the mixed messages they receive about cannabis and also desire research-based information, CCSF will involve psychoeducation on the risks and relationship of cannabis to psychosis to increase participants motivation to engage in the intervention. frequency of cannabis use as it relates to psychosis treatment outcomes.
219704112|NCT06425237|OTHER|music therapy|standard patient care in interventional radiology associated with a well-being atmosphere with the implementation of music therapy (soothing sound environment) in the preparation box and in the examination room.
219704113|NCT06425237|OTHER|aromatherapy|standard patient care in interventional radiology associated with a well being atmosphere with the implementation of aromatherapy (essential oil of Ylang Ylang) in the preparation box and in the examination room.
219704114|NCT05933083|BEHAVIORAL|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
219118618|NCT05810675|BEHAVIORAL|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
219118619|NCT02168920|DRUG|2 mg/day|Once daily for 10 weeks
219704115|NCT05933083|BEHAVIORAL|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
219118620|NCT02168920|DRUG|3 mg/day|Once daily for 10 weeks
219118621|NCT02168920|DRUG|6 mg/day|Once daily for 10 weeks
219118622|NCT02168920|DRUG|Placebo (0 mg/day)|Once daily for 10 weeks
219118623|NCT06139263|DEVICE|a percussion massage gun (Compex Fix 2.0)|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
219118624|NCT06139263|OTHER|conventional treatment program|In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
219118625|NCT01607411|DRUG|Fluoride|Fluoride Toothpaste
219118626|NCT01607411|DRUG|Placebo|Fluoride free toothpaste
219118627|NCT03208309|DRUG|Diacerein|
219118628|NCT03208309|DRUG|Placebo|
219118629|NCT01839643|DRUG|Meloxicam 2.4 g|2.4 g in Vaginal Ring
219225524|NCT03005119|DRUG|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
219225525|NCT03005119|DRUG|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
219704120|NCT05689645|DRUG|F573 for injection|"The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit.~The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit.~The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest ."
219704121|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
219118630|NCT01839643|DRUG|Meloxicam 3.0 g|3.0 g in Vaginal Ring
219118631|NCT01368211|BIOLOGICAL|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
219118632|NCT01368211|BIOLOGICAL|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
219118633|NCT05770596|DRUG|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
219118634|NCT05770596|OTHER|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
219118635|NCT05553132|COMBINATION_PRODUCT|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
219225526|NCT04313816|OTHER|questionnaire|no intervention at all apart from filling a brief questionnaire
219225527|NCT00558454|DRUG|Iron|Ferrous succinate mixture
219704122|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
219118636|NCT05763732|BEHAVIORAL|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
219118637|NCT05989321|PROCEDURE|PVI alone|pulmonary vein isolation
219704123|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
219704124|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
219704125|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
219704126|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
219704127|NCT04431206|DRUG|Oxytocin|Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
219704128|NCT00621101|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
219704129|NCT00621101|DRUG|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
219704130|NCT00621101|DRUG|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
219704131|NCT01032928|BEHAVIORAL|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
219704132|NCT04836377|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
219704133|NCT04290104|DRUG|1gr oral ampicillin/sulbactam group|Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
219118638|NCT05989321|PROCEDURE|PVI + SPs ablation|pulmonary vein isolation + SPs ablation
219118639|NCT03749460|BIOLOGICAL|Nivolumab|Given IV
219118640|NCT03749460|BIOLOGICAL|Ipilimumab|Given IV
219704134|NCT02559167|DRUG|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
219704135|NCT00820378|OTHER|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
219704136|NCT03163732|GENETIC|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
219704137|NCT03426878|OTHER|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
219704138|NCT03426878|OTHER|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
219118641|NCT03749460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219118642|NCT03315819|PROCEDURE|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
219704139|NCT05910398|DRUG|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
219704140|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
219704141|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
219118643|NCT03315819|PROCEDURE|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
219225528|NCT02222493|BIOLOGICAL|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
219225529|NCT02222493|BIOLOGICAL|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
219225530|NCT00900341|GENETIC|DNA analysis|
219225531|NCT00900341|GENETIC|gene expression analysis|
219225532|NCT00900341|GENETIC|protein expression analysis|
219118644|NCT03883958|PROCEDURE|Erector Spinae Plane Block|ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
219118645|NCT03883958|PROCEDURE|Paravertebral Block|TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
219118646|NCT05884190|OTHER|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
219118647|NCT05884190|OTHER|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
219118648|NCT05884190|OTHER|SoC|SoC for Postpartum Hypertension
219118649|NCT05138484|DRUG|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
219118650|NCT02169037|PROCEDURE|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
219118651|NCT02169037|PROCEDURE|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
219704142|NCT05791643|BEHAVIORAL|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
219704143|NCT05791643|BEHAVIORAL|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
219704144|NCT05791643|BEHAVIORAL|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
219704145|NCT05791643|BEHAVIORAL|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
219704146|NCT05791643|BEHAVIORAL|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
219118652|NCT03930134|PROCEDURE|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
219118653|NCT03930134|PROCEDURE|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
219118654|NCT01674257|OTHER|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
219118655|NCT01674257|RADIATION|18f-Fluoride PET/CT scan|
219118656|NCT01674257|RADIATION|18F-Flurodeoxyglucose PET/CT scan|
219118657|NCT02806284|BIOLOGICAL|PPSV23, Act-HIB|"described in Arm description"
219118658|NCT01987830|DEVICE|MRI-PET|"* \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide"
219225533|NCT00900341|GENETIC|reverse transcriptase-polymerase chain reaction|
219118659|NCT01987830|DEVICE|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
219225534|NCT00900341|GENETIC|western blotting|
219225535|NCT00900341|OTHER|immunohistochemistry staining method|
219225536|NCT00900341|OTHER|laboratory biomarker analysis|
219118660|NCT03990363|DRUG|Verinurad|"Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9"
219118661|NCT03990363|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
219118662|NCT03990363|DRUG|Placebo for Verinurad|Matching Capsule
219118663|NCT03990363|DRUG|Placebo for Allopurinol|Matching tablet
219118664|NCT02171182|DRUG|Qutenza|capsaicin patch
219118665|NCT04299802|DRUG|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
219118666|NCT04299802|PROCEDURE|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
219118667|NCT02406209|DRUG|NS2|NS2 ophthalmic drops (0.5%)
219118668|NCT02406209|DRUG|Prednisolone acetate ophthalmic suspension (1%)|
219118669|NCT02283437|BEHAVIORAL|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
219118670|NCT02283437|BEHAVIORAL|Behavioral Management and Education Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
219118671|NCT06353659|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
219118672|NCT04193748|DRUG|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
219704147|NCT05791643|BEHAVIORAL|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
219704148|NCT05791643|BEHAVIORAL|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
219704149|NCT05791643|BEHAVIORAL|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
219704150|NCT05791643|BEHAVIORAL|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
219704151|NCT03331380|DEVICE|MRI scan - obj 1|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
219704152|NCT03331380|DEVICE|MRI scans - obj 2|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
219704153|NCT03331380|DEVICE|MRI scans - obj 3|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
219118673|NCT05266651|DRUG|Tadalafil 5mg|oral tablets for one month duration
219118674|NCT05266651|DRUG|Placebo|oral tablets for one month duration
219118675|NCT02334527|DRUG|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
219118676|NCT05216224|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
219118677|NCT05216224|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
219118678|NCT02099435|DEVICE|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
219118679|NCT00488215|DRUG|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
219118680|NCT00488215|OTHER|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
219118681|NCT05764239|DRUG|SYNB1934v1|SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
219118682|NCT05764239|DRUG|Placebo|Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
219118683|NCT00518141|DRUG|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
219118684|NCT02797223|BEHAVIORAL|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
219118685|NCT00028314|DRUG|Abacavir sulfate|
219118686|NCT00028314|DRUG|Atazanavir/Ritonavir|
219118687|NCT00028314|DRUG|Lopinavir/Ritonavir|
219118688|NCT00028314|DRUG|Nevirapine|
219118689|NCT00057811|DRUG|doxorubicin hydrochloride|Given IV, IT, or orally
219118690|NCT00057811|DRUG|cyclophosphamide|Given IV
219118691|NCT00057811|DRUG|methotrexate|Given IV or IT
219118692|NCT00057811|DRUG|rasburicase|Given IV
219118693|NCT00057811|DRUG|leucovorin calcium|Given IV or orally
219118694|NCT00057811|DRUG|prednisone|Given IV or orally
219118695|NCT00057811|DRUG|methylprednisolone|Given IV or orally
219118696|NCT00057811|BIOLOGICAL|filgrastim|Given subcutaneously
219704154|NCT03331380|DEVICE|MRI scans - obj 4|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
219704155|NCT02679846|OTHER|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
219704156|NCT02610010|DRUG|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
219704157|NCT02610010|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
219704158|NCT05563324|GENETIC|DNA extraction and genotyping of candidate genetic polymorphisms|
219704159|NCT05563324|OTHER|self-assessment questionnaires|
219704160|NCT06546332|DEVICE|KeriFuse®|The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.
219704161|NCT06486844|DRUG|Vericiguat (Verquvo, BAY1021189)|Vericiguat was given following routine clinical practice.
219118697|NCT00057811|BIOLOGICAL|rituximab|Given IV
219118698|NCT00057811|DRUG|cytarabine|Given IT
219118699|NCT00057811|DRUG|etoposide|Given IV
219118700|NCT00057811|DRUG|vincristine sulfate|Given IV
219118701|NCT00057811|DRUG|hydrocortisone sodium succinate|Given IT
219118702|NCT00057811|OTHER|laboratory biomarker analysis|Correlative studies
219118703|NCT00556374|DRUG|Placebo|
219118704|NCT00556374|BIOLOGICAL|Denosumab|Administered as a subcutaneous injection
219118705|NCT00556374|DRUG|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
219118706|NCT00556374|DRUG|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
219118707|NCT00556374|OTHER|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
219118708|NCT04039880|DRUG|Olorofim|single oral dose (120 mg, 3.7 MBq)
219118709|NCT03857711|PROCEDURE|Conventional CABG|Coronary artery bypass grafting
219118710|NCT03857711|PROCEDURE|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
219118711|NCT03857711|PROCEDURE|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
219118712|NCT03857711|PROCEDURE|CABG+amiodarone|
219118713|NCT05075655|DEVICE|Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration|"Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance."
219118714|NCT05721339|BEHAVIORAL|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
219118715|NCT04562779|DRUG|Naltrexone 380 MG|XR naltrexone to be given once prior to hospital discharge
219225537|NCT05987774|DEVICE|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
219704162|NCT05691543|PROCEDURE|sacrospinous fixation Using Posterior Vaginal wall flap|"* Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
219704163|NCT05667441|COMBINATION_PRODUCT|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
219704164|NCT05667441|COMBINATION_PRODUCT|Risk profiling|Personalized risk profiling for lifestyle and genetics.
219704165|NCT05667441|BEHAVIORAL|Coaching|Coaching
219704166|NCT06552260|DRUG|Troriluzole|Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.
219704167|NCT02803489|DEVICE|medical device intervention|
219704168|NCT02855268|DRUG|lademirsen (SAR339375)|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
219704169|NCT02855268|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
219704170|NCT02607813|DRUG|LXH254|pan-RAF inhibitor
219704171|NCT02607813|DRUG|PDR001|Biological: PDR001 anti-PD1 antibody
219704172|NCT04634188|DIAGNOSTIC_TEST|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
219704173|NCT03504618|DRUG|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
219704174|NCT03028311|PROCEDURE|Angiography|Undergo angiography
219704175|NCT03028311|PROCEDURE|Computed Tomography|Undergo SPECT-CT
219704176|NCT03028311|PROCEDURE|Planar Imaging|Undergo planar imaging
219704177|NCT03028311|RADIATION|Radioembolization|Undergo radioembolization
219704178|NCT03028311|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
219225538|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
219225539|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
219704179|NCT03028311|RADIATION|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
219704180|NCT03028311|OTHER|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
219704181|NCT06115174|DRUG|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\]."
219704182|NCT06115174|RADIATION|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
219704183|NCT06115174|RADIATION|XELOX|(oxaliplatin + capecitabine)
219704184|NCT06115174|DRUG|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
219704185|NCT00465517|DRUG|Ganaxolone|Oral suspension 200-500 mg 3x/day
219704186|NCT00465517|OTHER|Placebo|non-active placebo
219704187|NCT04737733|OTHER|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
219704188|NCT01657396|PROCEDURE|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
219118716|NCT04562779|DRUG|Ketamine Hydrochloride|IV ketamine infusion to be given once prior to hospital discharge
219118717|NCT04562779|BEHAVIORAL|Enhanced linkage|Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
219118718|NCT05332951|OTHER|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
219118719|NCT00333138|DRUG|FTY720|FTY720 capsule was taken orally once a day
219225540|NCT06190132|DRUG|Omega 3 fatty acid, gabapentin|To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
219704189|NCT01657396|PROCEDURE|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
219118720|NCT00333138|DRUG|Placebo|Placebo 1.25 mg capsule was given once daily
219118721|NCT05103254|DRUG|Bempedoic Acid|Bempedoic Acid 180 MG
219704190|NCT01657396|PROCEDURE|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
219704191|NCT03735823|OTHER|No intervention, just collect blood samples and CSF samples|No intervention
219704192|NCT06277674|DRUG|Cadonilimab plus Pemetrexed and Anlotinib|Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
219704193|NCT04486261|OTHER|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
219704194|NCT00713076|OTHER|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
219118722|NCT05103254|DRUG|Bempedoic Acid / Ezetimibe|Bempedoic Acid 180 MG / Ezetimibe 10 MG
219118723|NCT04581239|OTHER|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
219225541|NCT02627391|OTHER|Early surgical aortic valve replacement|
219225542|NCT02627391|OTHER|Delayed Surgical aortic valve replacement|
219704195|NCT04390165|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
219118724|NCT04581239|OTHER|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
219704196|NCT02111200|DRUG|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
219704197|NCT02111200|DRUG|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
219118725|NCT02721199|OTHER|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
219118726|NCT04630756|DRUG|AZD4573|AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
219118727|NCT04630756|DRUG|Acalabrutinib|Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
219118728|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT)|Diagnostic test
219704198|NCT00346437|GENETIC|Ad5FGF-4 vs. Placebo|Intracoronary infusion
219704199|NCT02823886|OTHER|MRI at D7|The infarct size measured on MRI at 7 days.
219704200|NCT02823886|BIOLOGICAL|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
219704201|NCT05033041|DRUG|Study drug metoclopramide|Intravenous administration of 10 mg metoclopramide
219704202|NCT05033041|DRUG|Study drug placebo administration|Intravenous administration of placebo (sterile normal saline)
219704203|NCT05146739|DRUG|Cytarabine|Given IV and IT
219704204|NCT05146739|DRUG|Fludarabine|Given IV
219118729|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat|Diagnostic test - repeat for biological variability deterination
219118730|NCT04925596|BEHAVIORAL|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
219118731|NCT04925596|BEHAVIORAL|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
219225543|NCT00219466|OTHER|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
219225544|NCT00219466|OTHER|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
219225545|NCT03951259|DRUG|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
219225546|NCT03951259|DRUG|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
219704205|NCT05146739|DRUG|Leucovorin|Give PO or IV
219704206|NCT05146739|DRUG|Triple Intrathecal Chemotherapy|Given IT
219118732|NCT06327763|PROCEDURE|ilioinguinal nerve section|patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
219118733|NCT03764423|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
219704207|NCT05146739|DRUG|Uproleselan|Given IV
219704208|NCT05259709|DRUG|89Zr˗DFO˗REGN5054|Administered by intravenous (IV) infusion during Part A and B.
219704209|NCT05259709|DRUG|cemiplimab|Administered by IV infusion every 3 weeks (Q3W).
219704210|NCT04497116|DRUG|RP-3500 (camonsertib)|Oral ATR inhibitor
219704211|NCT04497116|DRUG|Talazoparib|Oral PARP inhibitor
219704212|NCT04497116|DRUG|Gemcitabine Injection|Gemcitabine
219704213|NCT05233761|DRUG|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
219704214|NCT05233761|DRUG|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
219704215|NCT06802445|OTHER|Self-Management Therapy|Participants in this group will receive self management therapy. The self-administered therapy programme will consist of prevention of parafunctional activities, information about sleep hygiene and home exercise programmes, the effectiveness of which has been reported in the literature and is in line with the International Delphi Guidelines. Home exercises will start with 2 times a day, 8 repetitions and progress will be made weekly according to the patient's condition.
219704216|NCT06802445|DEVICE|Placebo Non-Invasive Vagal Nerve Stimulation|Participants in this group will receive self managemenet therapy and placebo vagal nerve stimulation. For Placebo Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, the technique will be similar to active stimulation. The VaguStim device will be set to 0 Hz by the practitioner, indicating that no actual stimulation is being delivered. Patients will be told that they will not be able to feel the current due to its lower intensity during the intervention, without explaining the true nature of the placebo stimulation.
219704217|NCT06802445|DEVICE|Non-Invasive Vagal Nerve Stimulation|Participants will receive Non-Invasive Vagal Nerve Stimulation and self management therapy. : Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, CE certified (CE No: 2460) non-invasive stimulation device will be applied with. The application will be performed with 3 different sized electrodes (small, medium, large) specially designed according to the size of the inner ear. The stimulation will be delivered bilaterally from the symba concha and tragus regions innervated by the auricular branch of the n.vagus, which guarantees effective and targeted vagal modulation. With reference to the studies in the literature; VaguStim application frequency will be 25 Hz, pulse width 250 µs, current level 0.5 mA with biphasic waveform. The treatment will continue 3 days a week for a total of 6 weeks, with each session lasting 20 minutes.
219704218|NCT05685342|DRUG|Acetaminophen/Ibuprofen fixed-dose combination|Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
219704219|NCT05073705|BEHAVIORAL|Empowerment and personal transformation intervention|The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
219704220|NCT02118285|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion
219704221|NCT02118285|DRUG|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
219704222|NCT02118285|BIOLOGICAL|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
219118734|NCT03764423|DIETARY_SUPPLEMENT|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
219118735|NCT02862041|DEVICE|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
219118736|NCT02862041|DEVICE|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
219704223|NCT02118285|BIOLOGICAL|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
219704224|NCT02118285|DRUG|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
219704225|NCT01604785|DRUG|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
219704226|NCT01604785|DRUG|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
219704227|NCT02793986|DRUG|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
219704228|NCT02793986|DRUG|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
219704229|NCT02938780|OTHER|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
219118737|NCT05593211|DEVICE|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
219118738|NCT00859092|DIETARY_SUPPLEMENT|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
219704230|NCT02938780|OTHER|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
219118739|NCT03077620|DRUG|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
219118740|NCT03077620|DRUG|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
219118741|NCT05092425|OTHER|no intervention|no intervention
219704231|NCT01332825|OTHER|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
219704232|NCT05646914|OTHER|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
219704233|NCT05646914|OTHER|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
219704234|NCT05398627|DEVICE|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
219704235|NCT01563783|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
219704236|NCT01563783|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
219704237|NCT01563783|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
219704238|NCT02960451|OTHER|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
219704239|NCT02960451|OTHER|Usual care|Medication and psychotherapy as available form community providers
219704240|NCT06486883|DRUG|Trastuzumab deruxtecan (T-DXd, DS-8201a)|Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
219704241|NCT06486883|DRUG|CDK4/6i plus ET|Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
219704242|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
219704243|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
219704244|NCT06422208|BIOLOGICAL|Autologous midbrain dopamine neurons|The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
219704245|NCT05190770|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
219704246|NCT05190770|DRUG|Oleogel-S10|Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
219704247|NCT05710575|BIOLOGICAL|probiotic|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
219704248|NCT05710575|OTHER|placebo|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
219118742|NCT00454428|PROCEDURE|pulsatile intra-aortic balloon pump|
219118743|NCT03225846|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
219118744|NCT03225846|DRUG|Placebo|0.9% Sodium Chloride
219118745|NCT00996580|DRUG|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
219118746|NCT04756011|OTHER|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
219118747|NCT02718534|BEHAVIORAL|stroke rehabilitation|Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
219118748|NCT02980796|BEHAVIORAL|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
219118749|NCT02980796|BEHAVIORAL|Practice|Each experimental day participants will complete a session of skilled motor practice.
219118750|NCT05708846|OTHER|Telemonitoring|"All patients will be telemonitored in order to create a labeled and diverse dataset that will include the following data:~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes"
219118751|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
219118752|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
219118753|NCT01157143|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
219704249|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
219704250|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
219704251|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
219704252|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
219704253|NCT01430377|PROCEDURE|SB predilatation|Initial SB \[predilatation.
219704254|NCT01430377|PROCEDURE|No SB predilatation|Without SB predilatation
219118754|NCT00253539|DRUG|arzoxifene hydrochloride|Given orally
219118755|NCT00253539|DRUG|tamoxifen citrate|Given orally
219118756|NCT00253539|OTHER|placebo|Given orally
219704255|NCT04139252|OTHER|No intervention|No intervention
219118757|NCT02036515|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
219118758|NCT02036515|DRUG|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
219704256|NCT01132508|DEVICE|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
219704257|NCT05105347|DRUG|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
219704258|NCT03567681|DRUG|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
219704259|NCT06001879|OTHER|Simulation in basic life support training (SBLST)|The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation, and clinical simulation training.
219118759|NCT02036515|DRUG|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
219118760|NCT02036515|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
219118761|NCT02036515|DRUG|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
219118762|NCT02036515|DRUG|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
219118763|NCT02036515|BIOLOGICAL|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
219118764|NCT02036515|DRUG|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
219118765|NCT01028521|DRUG|CM3.1-AC100|Solution for sc injection, single ascending doses
219118766|NCT01028521|DRUG|Placebo|Solution for sc injection
219704260|NCT06001879|OTHER|standard treatment by using an AHA-BLS 2020 brochure|The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test
219704261|NCT00486681|DEVICE|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
219118767|NCT03722719|OTHER|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
219118768|NCT03722719|OTHER|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
219118769|NCT03722719|OTHER|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
219118770|NCT00026520|BIOLOGICAL|recombinant interferon alfa|
219118771|NCT00026520|DRUG|thalidomide|
219118772|NCT02089815|BEHAVIORAL|Home based exercise|modified Otago exercise program to simple designed home based exercise program
219118773|NCT02089815|OTHER|fall prevention education and counseling|
219118774|NCT02231372|DRUG|Berodual® Respimat® solution for inhalation|
219118775|NCT05427513|DRUG|Tranexamic acid injection|will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss
219118776|NCT05427513|OTHER|normal saline|normal saline will be injected to ensure placebo
219118777|NCT06013332|DEVICE|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
219118778|NCT06013332|DEVICE|Sculptra®|Sculptra®
219118779|NCT05217823|DEVICE|Er:YAG laser|
219118780|NCT05217823|OTHER|hand instruments|
219704262|NCT02284100|BEHAVIORAL|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
219704263|NCT01706562|DRUG|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
219704264|NCT04887649|DRUG|Morphine|morphine 3 mg
219118781|NCT05559437|DRUG|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
219118782|NCT04088318|DRUG|OQL011|OQL011 is an ointment containing active ingredient.
219118783|NCT04088318|DRUG|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
219118784|NCT03434613|DRUG|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
219118785|NCT03434613|DRUG|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
219118786|NCT02934516|PROCEDURE|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
219118787|NCT00338793|DRUG|prednisolone|
219118788|NCT00108121|DRUG|PEP005|
219118789|NCT00238420|DRUG|Paclitaxel|Given IV
219118790|NCT00238420|RADIATION|Radiation Therapy|Undergo radiation therapy
219118791|NCT00238420|BIOLOGICAL|Trastuzumab|Given IV
219118792|NCT06195124|DRUG|RGL-193（low-dose）|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.
219118793|NCT06195124|DRUG|RGL-193（high-dose）|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
219704265|NCT04887649|DRUG|saline solution|4 cc of saline solution in epidural cateter in postpartum
219704266|NCT04887649|DRUG|Morphine|morphine 2 mg for epidural cateter in postpartum
219704267|NCT04400266|DRUG|Buspirone|Buspirone 15mg once daily
219161738|NCT01370330|DRUG|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Jubilant DraxImage (Quebec, Canada) with specific activities of 9-18 Ci/mmole, or at Progenics with specific activity of 2,500 mCi/mg. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25-50 ml of normal saline for either preparation, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present.If Azedra is used, the dose will be infused over 30-60 minutes; the low specific activity preparation from Draximage will be infused over 90-120 minutes. For patients with pheochromocytoma or paraganglioma, the recommended maximum dose is 500 mCI or 12 mCi/kg.
219704268|NCT04400266|DRUG|Mealatonin|Melatonin 3mg once nightly
219118794|NCT05768516|OTHER|Implementation of best practice for low back pain in primary care|"1. Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~2. Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~3. Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~4. Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
219118795|NCT02450019|PROCEDURE|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
219118796|NCT02450019|PROCEDURE|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
219118797|NCT03666910|DIAGNOSTIC_TEST|Audiometer|detection of hearing problems
219118798|NCT00663962|DRUG|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
219118799|NCT00663962|DRUG|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
219118800|NCT05364619|DRUG|Qingre Huashi Granules combined the modified dual therapy|Qingre Huashi Granules combined the modified dual therapy for 14 days
219118801|NCT05364619|DRUG|Bismuth containing quadruple therapy|Bismuth containing quadruple therapy for 14 days
219704269|NCT06983743|DRUG|ERAS-0015|ERAS-0015 Administered orally
219704270|NCT06983743|DRUG|ERAS-0015 in combination|ERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
219704271|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
219704272|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
219704273|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
219704274|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
219704275|NCT07004764|DRUG|Nitroglycerin Ointment 2%|Patients will have pre- and post-nitropaste tissue perfusion measurement with the LA-ICG system.
219704276|NCT06939036|DRUG|225Ac-SSO110 + SoC|Dose Level -2-7
219704277|NCT06939036|DRUG|Atezolizumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
219704278|NCT06939036|DRUG|Durvalumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
219704279|NCT06939036|DRUG|Avelumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
219704280|NCT06939036|DRUG|Pembrolizumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
219118802|NCT00425217|DRUG|Rituximab|
219704281|NCT06939036|DRUG|Retifanlimab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
219704282|NCT07156760|DIAGNOSTIC_TEST|Ultrasound diagnostics|Non-invasive ultrasound evaluation of the upper limb on the hemiplegic side (Ekipomed Portable Ultrasound) to determine its pathological morphology (thickness, fiber orientation, and echogenicity) using the modified Heckmatt scale. This procedure will be performed by a physician who is an expert in muscle ultrasound.
219704283|NCT07168668|PROCEDURE|Transarterial chemoembolization|"1. Targeting 1-3 prognostically relevant tumor nodules.~2. Administration of anti-cancer drugs (doxorubicin 20 mg in each section of TACE).~3. Embolization with Drug-Eluting Beads (doxorubicin 20 mg loaded Hepasphere 20 mg of TACE)~4. Embolization was done when there was a slight decrease in blood flow for each tumor feeder."
219704284|NCT07168668|DRUG|durvalumab and tremelimumab|Combine TACE with immunotherapy
219704285|NCT07166926|DEVICE|Mobile CT|SOMATOM On.site
219704286|NCT07169487|DRUG|Methylene Blue|Intravenous infusion of methylene blue once daily for 3-5 consecutive days at doses of 1 mg/kg, 2 mg/kg, or 3 mg/kg, administered over 20 minutes, following CAR-T or bispecific antibody infusion in patients who develop Grade ≥1 CRS or ICANS.
219704287|NCT07167771|OTHER|No intervention|There is not intervention in these patients, appart from their normal dental check-up visits.
219704288|NCT07168759|OTHER|VR game -based education program|The schoolchildren in the intervention group participate in an innovative VR game-based educational programme featuring: (1) Web-based health education on (i) SARS-CoV-2 and Influenza virus transmission, (ii) proper hand and respiratory hygiene practices and (iii) the importance of rapid screening and vaccination in the prevention of upper respiratory tract infections.
219704289|NCT05800015|DRUG|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
219704290|NCT05800015|DRUG|cemiplimab|Administered IV Q3W
219704291|NCT05800015|DRUG|Pemetrexed|IV Infusion, Q3W
219118803|NCT02754414|PROCEDURE|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
219118804|NCT02754414|OTHER|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
219118805|NCT02754414|RADIATION|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
219118806|NCT02754414|OTHER|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
219161739|NCT02949375|DRUG|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
219704292|NCT05800015|DRUG|Paclitaxel|IV Infusion, Q3W
219704293|NCT05800015|DRUG|Carboplatin|IV Infusion, Q3W
219704294|NCT05800015|DRUG|Cisplatin|IV infusion, Q3W
219704295|NCT05800015|DRUG|Placebo|IV infusion, Q3W
219704296|NCT04585750|DRUG|rezatapopt|First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
219704297|NCT04585750|DRUG|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
219704298|NCT06385041|OTHER|Multicomponent training group|Additional exercise program with balance and strength trainings will include 3 times/week. Patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights up to 2kg 30-50% 1RM) and balance training (with unstable surfaces). The program will be performed by 3 sets with 10 repetitions 3 times/week 30-45 minutes.
219704299|NCT06385041|OTHER|Computer-based interactive training group|Additional exercise program with balance and strength trainings will include 3 times/week 30-45 minutes. Patients will get an individualized program for frailty syndrome, with interactive technologies: gait training with Biodex GaitTrainerTM3 with visual, audio feedback and incline up to 10-15 min, Zebris FDM-T, with virtual barriers, thus simulating real environment for the patient, while performing a cognitive task up to 10-15 min, for balance training investigators used a computerized Biodex board. Exercises will be performed with the programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training. For strength training investigators used equipment HUR based on pneumatic (air pressure) technology. For strength training intensity 30-50% 1-RM, 10 repetitions with 3 sets. Leg press, leg extension, leg abduction, leg adduction will be performed with pneumatic technology.
219704300|NCT04799288|DRUG|Teriflunomide|Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
219704301|NCT05852860|OTHER|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
219704302|NCT05852860|OTHER|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
219118807|NCT03509792|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
219118808|NCT03509792|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
219704303|NCT03729362|BIOLOGICAL|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
219704304|NCT03729362|DRUG|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
219704305|NCT03729362|BIOLOGICAL|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
219704306|NCT03729362|DRUG|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
219704307|NCT06784934|DEVICE|NeuroSky Mindfulness-Based Neurofeedback|NeuroSky will monitor participants' brain response to the intervention and provide feedback based on the participants' performance. Neurofeedback Intervention: When practicing the mindfulness-based intervention, NeuroSky will provide instructions before beginning the sessions. Dr. Saul will assist with set up and answer any questions. The apps audio and visual feedback will assist the participants as they practice mindfulness meditation. Participants in the experimental group will practice for 10 minutes in the lab during Sessions 1 and 5 and then at home for 10-20 minutes daily for 4 weeks with weekly 10-minute virtual check-ins with Dr. Saul to ensure acceptability and feasibility. Dr. Saul will also monitor participants' progress using the secure participant portal and de-identified usernames available through NeuroSky.
219704308|NCT02967445|DEVICE|Arabin Pessary|Arabin silicon pessary
219704309|NCT02967445|DEVICE|Cervical cerclage|
219704310|NCT01701310|DRUG|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
219704311|NCT01701310|DRUG|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
219704312|NCT04861298|DRUG|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
219704313|NCT04861298|DIETARY_SUPPLEMENT|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
219704314|NCT06425640|BEHAVIORAL|24-hour movement behavior|Cross-sectional observational study investigating the 24-hour movement behaviors and glucose control
219118809|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 1, once daily
219118810|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 2, once daily
219704315|NCT01113749|OTHER|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
219704316|NCT05702632|DEVICE|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
219118811|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 3, once daily
219118812|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 4, once daily
219118813|NCT01119339|DRUG|LAS 41004|LAS 41004 , dosage 5, once daily
219118814|NCT01119339|DRUG|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
219118815|NCT01119339|DRUG|Placebo|Placebo, once daily
219118816|NCT01119339|DRUG|Reference|Reference, once daily
219118817|NCT05343117|DRUG|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
219118818|NCT05343117|DRUG|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
219118819|NCT05896917|DEVICE|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
219118820|NCT05896917|DEVICE|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
219118821|NCT02933190|PROCEDURE|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
219118822|NCT02102464|DEVICE|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
219704317|NCT05702632|DEVICE|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
219704318|NCT05702632|PROCEDURE|traditional physical therapy program|Facilitation of balance and gait training
219704319|NCT04134390|DRUG|Cabozantinib|Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
219704320|NCT06964815|DIETARY_SUPPLEMENT|Silibinin as STAT3 inhibitor|Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.
219704321|NCT06964815|OTHER|Placebo|Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.
219704322|NCT04723862|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
219704323|NCT04723862|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
219118823|NCT04140890|BEHAVIORAL|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
219118824|NCT04140890|BEHAVIORAL|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
219118825|NCT01700348|DEVICE|Airflosser|Use of Philips Airflosser
219118826|NCT01700348|DEVICE|Manual Floss|Active Comparator
219118827|NCT03580460|BEHAVIORAL|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
219118828|NCT03713255|PROCEDURE|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
219118829|NCT03713255|PROCEDURE|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
219118830|NCT03713255|PROCEDURE|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
219118831|NCT03530046|COMBINATION_PRODUCT|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
219118832|NCT03530046|COMBINATION_PRODUCT|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
219118833|NCT04814875|DRUG|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
219118834|NCT05222438|DRUG|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
219118835|NCT03655873|DRUG|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
219704324|NCT04431544|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
219704325|NCT05413317|OTHER|Color Doppler Ultrasound|Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
219704326|NCT04429542|DRUG|BCA101|EGFR/TGFβ fusion monoclonal antibody
219118836|NCT03655873|DRUG|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
219118837|NCT04729283|PROCEDURE|Sigmoidectomy|The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
219118838|NCT01270763|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
219118839|NCT01270763|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
219704327|NCT04429542|DRUG|Pembrolizumab|anti-PD-1
219704328|NCT01691651|PROCEDURE|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
219704329|NCT01691651|DRUG|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
219704330|NCT00362232|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
219704331|NCT00362232|DRUG|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
219704332|NCT00362232|DRUG|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
219704333|NCT00362232|DRUG|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
219704334|NCT01043419|DRUG|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
219704335|NCT02287428|RADIATION|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
219704336|NCT02287428|BIOLOGICAL|Personalized NeoAntigen Peptides|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
219704337|NCT02287428|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
219704338|NCT02287428|DRUG|Temozolomide|Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT
219704339|NCT02287428|DRUG|Temozolomide|Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
219704340|NCT02287428|BIOLOGICAL|Poly-ICLC|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
219704341|NCT04475276|DRUG|Placebo|Lifestyle modification with placebo for 12 weeks
219704342|NCT04475276|DRUG|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
219118840|NCT05552274|DRUG|ECC4703|ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
219118841|NCT05552274|DRUG|Placebo|Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
219118842|NCT03427086|DRUG|Biotin|High dose biotin
219118843|NCT03427086|DRUG|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
219118844|NCT05433896|DRUG|Dasatinib ASD|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
219118845|NCT05433896|DRUG|Omeprazole 40 MG|Omeprazole Delayed Release Capsules, USP 40 mg
219704343|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
219704344|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
219704345|NCT06088979|OTHER|Placebo|Placebo
219704346|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
219704347|NCT03549026|DRUG|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
219704348|NCT03549026|DRUG|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
219704349|NCT00121875|DRUG|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period"
219704350|NCT04262349|BEHAVIORAL|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
219704351|NCT01259999|DIETARY_SUPPLEMENT|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
219704352|NCT03740893|DRUG|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.~AZD6738 was removed as intervention under investigation as of 06 August 2024 (due to formal closure of cohort B)"
219704353|NCT03740893|DRUG|Olaparib|"PART 1 (cohort C, and cohorts E-G): Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2 (cohort C, and cohorts F and G): 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.~Cohort C was formally closed to recruitment since 06 August 2024."
219704354|NCT03740893|DRUG|Durvalumab|"PART 1 (cohort D): Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2 (cohorts A and D, and cohorts F and G): 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.~Cohorts A and D were formally closed to recruitment since 06 August 2024."
219704355|NCT03729284|DRUG|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
219704356|NCT03729284|DRUG|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
219704357|NCT01799889|DRUG|Entospletinib MM|Entospletinib MM tablet administered orally
219704358|NCT01799889|DRUG|Entospletinib SDD|Entospletinib SDD tablet administered orally
219704359|NCT01636843|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
219704360|NCT01636843|DRUG|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
219704361|NCT01447966|BEHAVIORAL|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
219704362|NCT03186352|PROCEDURE|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
219704363|NCT03471819|DIAGNOSTIC_TEST|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
219704364|NCT00662337|DRUG|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
219704365|NCT04294823|DIAGNOSTIC_TEST|Helicobacter Pylori Diagnostic|"Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C\^13 urea)~\+ The C\^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28."
219704366|NCT04294823|DEVICE|Vital signs measurments|No description;
219704367|NCT04294823|DIAGNOSTIC_TEST|endoscopy|Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin \& Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.
219704368|NCT04294823|DRUG|Nexium Pill|patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
219704369|NCT01499407|DEVICE|ClearWay RX catheter|
219704370|NCT01499407|DRUG|Abciximab|
219704371|NCT05105256|DRUG|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
219704372|NCT05105256|DRUG|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
219118846|NCT03958630|DRUG|11C-ER176|PET biomarker for inflammation
219118847|NCT03958630|DRUG|11C-PIB|PET biomarker for amyloid
219118848|NCT03958630|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
219118849|NCT01941004|DRUG|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
219118850|NCT01941004|DRUG|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
219704373|NCT01679470|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
219704374|NCT00938938|OTHER|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
219704375|NCT05514990|DRUG|Bortezomib|Given SC or IV
219704376|NCT05514990|DRUG|Dexamethasone|Given PO, IV, or IM
219704377|NCT05514990|BIOLOGICAL|Pelareorep|Given IV
219704378|NCT05514990|BIOLOGICAL|Pembrolizumab|Given IV
219704379|NCT05530018|BEHAVIORAL|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
219704380|NCT01889381|DRUG|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
219704381|NCT03117127|BEHAVIORAL|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
219704382|NCT03117127|OTHER|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
219704383|NCT03117127|OTHER|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
219704384|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
219704385|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
219704386|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
219118851|NCT00670696|DRUG|Rapydan|Topical anaesthetic plaster
219118852|NCT00670696|DRUG|tetracaine gel|Topical tetracaine gel
219118853|NCT04370743|OTHER|No intervention|
219118854|NCT01628380|PROCEDURE|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
219118855|NCT01628380|PROCEDURE|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
219118856|NCT05409274|OTHER|No Intervention|No Intervention
219118857|NCT01824472|DEVICE|CPAP|Treatment for sleep apnea
219118858|NCT01824472|BEHAVIORAL|CBT|Treatment for insomnia
219118859|NCT01824472|DEVICE|sham CPAP|Placebo for sleep apnea
219118860|NCT01824472|BEHAVIORAL|CC|Placebo (sham) for insomnia
219118861|NCT06328920|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
219118862|NCT06328920|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
219118863|NCT01736358|DRUG|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
219118864|NCT01736358|DRUG|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
219161740|NCT02949375|DRUG|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
219161741|NCT02949375|DRUG|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
219161742|NCT02612233|DRUG|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
219704387|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
219704388|NCT04896775|BEHAVIORAL|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
219704389|NCT04896775|BEHAVIORAL|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
219704390|NCT01237730|DRUG|cefuroxime|Use the cefuroxime as prophylaxis.
219704391|NCT01237730|DRUG|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
219704392|NCT02939391|DRUG|KW-6356|Oral administration
219704393|NCT02939391|DRUG|KW-6356|Oral administration
219704394|NCT02939391|DRUG|Placebo|Oral administration
219704395|NCT03628326|OTHER|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
219704396|NCT01544881|DRUG|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
219118865|NCT04956263|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
219118866|NCT04956263|DRUG|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
219118867|NCT05181813|PROCEDURE|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
219118868|NCT05181813|PROCEDURE|Metapex|Fill the infected root canal of of primary teeth with Metapex
219118869|NCT04969744|DEVICE|ICE|Intermittent Cooling Exposure using cooling garment for 1-2 hours
219704397|NCT01544881|DRUG|Rapid Acting Analog|Subcutaneous Injection
219704398|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
219704399|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
219704400|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
219704401|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
219704402|NCT02857920|DRUG|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
219704403|NCT02857920|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
219704404|NCT02686255|OTHER|complete blood count|complete blood count during follow up in the heart institute
219704405|NCT05767970|BEHAVIORAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
219704406|NCT01527669|DRUG|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
219704407|NCT01527669|DRUG|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
219118870|NCT04939311|DRUG|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
219118871|NCT04939311|DRUG|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
219118872|NCT03760471|OTHER|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
219118873|NCT01695122|DRUG|Valproic Acid|
219704408|NCT02100631|BIOLOGICAL|PXVX0200|
219704409|NCT02100631|BIOLOGICAL|Placebo|
219704410|NCT04786574|DRUG|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
219704411|NCT03000972|PROCEDURE|Cement augmentation|
219704412|NCT03000972|PROCEDURE|PFN-A Nail|
219704413|NCT06478212|DRUG|Vorasidenib|To be taken by mouth once daily in 28-day cycles with no break between cycles
219704414|NCT06478212|DRUG|Temozolomide (TMZ)|To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
219704415|NCT04804644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219704416|NCT04804644|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219704417|NCT04804644|DRUG|Memantine Hydrochloride|Given PO
219704418|NCT04804644|OTHER|Neurocognitive Assessment|Ancillary studies
219704419|NCT04804644|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219704420|NCT04804644|OTHER|Survey Administration|Ancillary studies
219704421|NCT04804644|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
219704422|NCT01446185|DEVICE|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
219704423|NCT05049005|BEHAVIORAL|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
219704424|NCT03705325|DEVICE|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
219118874|NCT01132196|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
219704425|NCT01528085|DRUG|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
219704426|NCT00113165|DRUG|LAMICTAL extended-release|
219704427|NCT02071537|DRUG|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
219704428|NCT02071537|DRUG|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
219704429|NCT02071537|DRUG|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
219704430|NCT01242319|BEHAVIORAL|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
219704431|NCT04065308|DRUG|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
219118875|NCT01147211|DRUG|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
219118876|NCT01815736|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
219118877|NCT01815736|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
219704432|NCT03328065|OTHER|Interviews|Semi-directed interviews, recorded and transcribed for analysis
219704433|NCT03328065|OTHER|Questionnaires|economic and psycho-social questionnaires
219118878|NCT01815736|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
219118879|NCT01815736|DRUG|RTV|100 mg tablet administered orally once daily
219118880|NCT01815736|DRUG|ATV|300 mg capsule administered orally once daily
219118881|NCT01815736|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
219118882|NCT01815736|DRUG|COBI|150 mg tablet administered orally once daily
219118883|NCT05389969|OTHER|digital arch scanning|"Scanning of the maxillary and mandibular dental arch will be performed for the same group of patients twice. The first time is before bracket positioning using two different scanners and the three different techniques. The second time is after brackets positioning using the same two different scanners and the same three different scanning techniques.~Then these scans will be compared to by superimposition techniques and linear measurement techniques."
219118884|NCT03694457|PROCEDURE|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
219118885|NCT03694457|PROCEDURE|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
219118886|NCT06204328|OTHER|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique \& mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
219118887|NCT02912429|DEVICE|Patellofemoral Arthroplasty|
219118888|NCT02413684|BEHAVIORAL|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
219118889|NCT00429260|DRUG|Saredutant|
219118890|NCT05211375|PROCEDURE|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
219118891|NCT05211375|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
219118892|NCT01518114|BEHAVIORAL|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
219118893|NCT02398162|PROCEDURE|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
219118894|NCT02398162|PROCEDURE|Single Blood Collection|On the enrollment day
219118895|NCT04005729|DRUG|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
219704434|NCT02564341|BEHAVIORAL|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
219704435|NCT02564341|BEHAVIORAL|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
219704436|NCT02564341|BEHAVIORAL|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
219704437|NCT04260165|PROCEDURE|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
219704438|NCT04260165|PROCEDURE|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
219704439|NCT02480296|DRUG|MYK-461|
219704440|NCT02480296|DRUG|Placebo|Placebo comparator
219704441|NCT04265001|DRUG|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
219704442|NCT00726245|BIOLOGICAL|PRGF|3-6mg IM (to area of muscle tear)
219118896|NCT02429921|DIETARY_SUPPLEMENT|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
219118897|NCT02429921|DIETARY_SUPPLEMENT|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
219118898|NCT04681430|BIOLOGICAL|Convalescent plasma|transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)
219118899|NCT04681430|DRUG|Camostat Mesilate|Tablets over 7 days, daily dose of 600 mg split into 3 doses
219118900|NCT04681430|DRUG|Placebo for Camostat Mesilate|Placebo Tablets over 7 days, split into 3 doses
219118901|NCT04681430|OTHER|Standard of Care (SoC)|Control Arm for convalescent plasma (CP)
219225547|NCT06426966|DIETARY_SUPPLEMENT|Berberine|Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
219118902|NCT06119906|DEVICE|Hyper-Spectral Endoscopy|We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
219118903|NCT01438671|PROCEDURE|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
219118904|NCT01438671|PROCEDURE|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
219225548|NCT06426966|DIETARY_SUPPLEMENT|Gymnema sylvestre|"Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity."
219225549|NCT05851495|PROCEDURE|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
219704443|NCT00726245|BIOLOGICAL|Placebo|3cc IM of physiological saline
219704444|NCT00744341|DRUG|SLV320|1.25mg i.v. bid
219704445|NCT00744341|DRUG|SLV320|3.75mg i.v. bid
219704446|NCT00744341|DRUG|SLV320|7.5mg i.v. bid
219704447|NCT00744341|DRUG|SLV320|15.0mg i.v. bid
219704448|NCT00744341|DRUG|Placebo|
219225550|NCT02433444|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
219225551|NCT03924869|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
219704449|NCT05243706|DRUG|Loratadine|Intervention is given to study its' effect on vinca alkaloids induced neuropathy
219704450|NCT05243706|DRUG|Diosmin/ Hesperidin|Intervention is given to study its effect on vinca alkaloids induced neuropathy
219704451|NCT00197743|DIETARY_SUPPLEMENT|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
219704452|NCT00197743|DIETARY_SUPPLEMENT|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
219704453|NCT00197743|OTHER|Placebo|Placebo pill
219704454|NCT06293820|DRUG|TL-925|TL-925 is an eye drop.
219225552|NCT03924869|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
219704455|NCT06293820|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
219704456|NCT01115270|OTHER|Non-invasive measures|assessment of cerebrovascular fluid movement
219704457|NCT03208153|PROCEDURE|Invasive|Coronary angiogram and revascularization if anatomically feasible
219704458|NCT03208153|PROCEDURE|Conservative|Conservative
219704459|NCT00846599|OTHER|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
219704460|NCT00846599|OTHER|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
219704461|NCT05080985|PROCEDURE|TPVB|20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
219704462|NCT05080985|PROCEDURE|ESPB|20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
219704463|NCT05080985|DRUG|Bupivacain|20 ml 0.375 % bupivacaine was injected
219704464|NCT04454502|OTHER|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
219704465|NCT01653418|DRUG|Bortezomib|
219704466|NCT01653418|DRUG|Carmustine|
219704467|NCT01653418|DRUG|Etoposide|
219704468|NCT01653418|DRUG|Cytarabine|
219704469|NCT01653418|DRUG|Melphalan|
219704470|NCT01653418|PROCEDURE|Stem cell infusion|
219704471|NCT01668043|DRUG|Antibody UB-421|UB-421 is administered by intravenous infusion
219704472|NCT02331732|BEHAVIORAL|Virtually Observed Treatment|
219118905|NCT01369173|OTHER|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
219118906|NCT03040687|BIOLOGICAL|Anti CS6 BSIgG product (Lot PD1601105CS)|
219118907|NCT03040687|BIOLOGICAL|Anti B7A BSIgG product (Lot PD1601132ET)|
219118908|NCT03040687|BIOLOGICAL|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
219118909|NCT03040687|BIOLOGICAL|B7A- CS6-expressing ETEC challenge strain|
219118910|NCT03241264|DRUG|ND-L02-s0201|Specified dose on specified day
219118911|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
219118912|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
219118913|NCT00872014|DRUG|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
219225553|NCT03924869|DRUG|Placebo|Placebo (normal saline solution) will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
219225554|NCT02734355|DRUG|Telmisartan 80 mg and amlodipine 5 mg|
219118914|NCT00003384|OTHER|Cervical Papanicolaou Test|Undergo Pap smear
219118915|NCT00003384|PROCEDURE|Conization|Undergo cone biopsy
219118916|NCT00003384|OTHER|Laboratory Biomarker Analysis|Correlative studies
219118917|NCT01635361|OTHER|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
219118918|NCT00550173|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
219118919|NCT00550173|DRUG|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
219704473|NCT02331732|OTHER|Directly Observed Treatment|
219704474|NCT02856217|PROCEDURE|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
219704475|NCT02856217|PROCEDURE|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
219704476|NCT05570422|DRUG|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
219704477|NCT05570422|RADIATION|External Beam Radiation Therapy|"* Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~* Intensity-modulated radiotherapy (IMRT) must be used.~* IMRT should be given once daily Monday-Friday, 5 fractions per week."
219704478|NCT05570422|DRUG|cisplatin|"* Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
219704479|NCT05570422|RADIATION|brachytherapy|"* BT treatment planning will be based on 3D-image-guided BT by MRI.~* Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
219704480|NCT03284554|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
219704481|NCT03284554|DIETARY_SUPPLEMENT|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
219118920|NCT04408001|OTHER|Clinical interview|At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
219118921|NCT04408001|BIOLOGICAL|Blood collection|"At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected."
219118922|NCT04408001|BIOLOGICAL|Saliva collection|At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
219118923|NCT05967104|OTHER|Education based on the PLISSIT model|Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
219118924|NCT02359383|OTHER|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
219118925|NCT02522975|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
219225555|NCT02734355|DRUG|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
219225556|NCT04976764|OTHER||
219225557|NCT00910832|DRUG|Eductyl suppository|one suppository every morning during 21 days
219225558|NCT00910832|DRUG|Placebo suppository|placebo suppository every morning during 21 days
219704482|NCT03284554|DIETARY_SUPPLEMENT|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
219704483|NCT03564262|OTHER|Low Sodium Meal (138 mg sodium)|One Low Sodium Meal
219704484|NCT03564262|OTHER|High Sodium Meal (1,495 mg sodium)|One High Sodium Meal
219118926|NCT02522975|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
219118927|NCT04366570|OTHER|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
219118928|NCT02610712|DRUG|Ketamine|
219118929|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
219118930|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
219118931|NCT00721331|DRUG|nortriptyline HCl|Topical
219118932|NCT00721331|DRUG|mometasone furoate|Topical
219118933|NCT00721331|DRUG|Active ingredient free vehicle cream of CRx-197|Topical
219118934|NCT03499574|BEHAVIORAL|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
219118935|NCT03499574|BEHAVIORAL|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
219118936|NCT03911193|DRUG|Cabozantinib|Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
219118937|NCT01899495|OTHER|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
219704485|NCT04130087|DRUG|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
219704486|NCT04130087|DRUG|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
219704487|NCT03049566|OTHER|preoperative questionnaires|no intervention, cross-sectional survey in a single group
219704488|NCT04826562|DRUG|Dolutegravir/Lamivudine|single tablet antiretroviral
219118938|NCT01843075|DRUG|Liraglutide|Daily subcutaneous injection
219118939|NCT01843075|DRUG|Placebo|Daily subcutaneous injection
219118940|NCT00810641|PROCEDURE|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
219118941|NCT00810641|PROCEDURE|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
219118942|NCT00810641|PROCEDURE|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
219118943|NCT03160911|DEVICE|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
219118944|NCT03160911|DEVICE|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
219118945|NCT01388543|DRUG|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
219118946|NCT01556243|PROCEDURE|therapeutic conventional surgery|
219118947|NCT01556243|RADIATION|whole breast irradiation|
219118948|NCT03540979|PROCEDURE|endometrial preparation for frozen blastocyst transfer|medical endometrial preparation for frozen blastocyte transfer
219118949|NCT03540979|DRUG|Letrozole|Aromatase inhibitor - 2.5mg/d for 5 days
219704489|NCT02820415|OTHER|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
219118950|NCT03540979|DRUG|Ovidrel|recommbinant hCG 250 mcg- single sc injection to induce ovulation
219118951|NCT03540979|DRUG|Estrofem|Estrofem 2mg\*3/d for endometrial preparation
219704490|NCT06535659|DEVICE|VitaFlow Liberty™ Transcatheter Aortic Valve System|"Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.~Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care."
219704491|NCT01526980|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
219704492|NCT01526980|DRUG|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
219704493|NCT01526980|DRUG|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
219704494|NCT05572918|DIAGNOSTIC_TEST|Urodynamics aka filling cystometry|Participants will be undergoing a routine diagnostic test to characterise bladder function and volume
219704495|NCT01021384|BEHAVIORAL|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
219118952|NCT03540979|DRUG|Endometrin 100Mg Vaginal Insert|vaginal tab for lutheal support
219118953|NCT03703206|DRUG|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
219118954|NCT02325713|DRUG|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
219118955|NCT02325713|DRUG|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
219118956|NCT02325713|DRUG|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
219704496|NCT01611675|DRUG|Vemurafenib|take orally, twice daily
219704497|NCT01611675|DRUG|Leflunomide|take orally, once daily
219704498|NCT05301634|PROCEDURE|infraorbital block|the patients will receive bilateral infraorbital block
219704499|NCT05301634|PROCEDURE|topical intranasal bupivacaine|the patients will receive topical intranasal application of bupivacaine
219118957|NCT02325713|DRUG|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
219118958|NCT02325713|DRUG|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
219118959|NCT02325713|DRUG|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
219118960|NCT02948543|BIOLOGICAL|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
219118961|NCT02948543|DRUG|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
219118962|NCT03492996|DRUG|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
219118963|NCT04532437|OTHER|artificial intelligence-based skin aging simulation|Photographs of the volunteers' facial skin will be taken in the Department of Dermatology at baseline using a modern skin analysis photo system (VISIA®, Canfield Scientific, Parsippany, NJ, USA) and afterwards a simulation of the participants' facial skin aging will be performed with the VISIA® photo analysis System.
219118964|NCT04532437|OTHER|electronic questionnaire 1|Electronic questionnaire about current sun-related knowledge and protective behaviours via link with smartphone before and after the skin aging simulation.
219118965|NCT04532437|OTHER|electronic questionnaire 2|Participants report their perception of the interventions and their motivation for improved sun protection by completing an electronic questionnaire after the skin aging simulation.
219118966|NCT05967676|DIAGNOSTIC_TEST|Turkish adaptation, validity and reliability|"This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes"
219118967|NCT01947595|BEHAVIORAL|intensified lifestyle intervention|"* physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
219118968|NCT01947595|BEHAVIORAL|normal lifestyle intervention|"* physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
219118969|NCT01947595|BEHAVIORAL|Single lifestyle advice|"\- Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25\> kg/m²)"
219118970|NCT00761917|DEVICE|Tear Film Analyzer|tear film images
219704500|NCT00355641|DRUG|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
219704501|NCT02690129|DRUG|Vaginal Progesteron|
219118971|NCT02359019|BIOLOGICAL|Pembrolizumab|Given IV
219118972|NCT02359019|OTHER|Laboratory Biomarker Analysis|Correlative studies
219118973|NCT01337830|OTHER|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
219118974|NCT01337830|OTHER|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
219118975|NCT00012181|DRUG|alvocidib|Given IV
219118976|NCT00012181|OTHER|pharmacological study|Correlative studies
219704502|NCT00941928|DRUG|Epratuzumab|360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
219118977|NCT05774028|DRUG|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
219118978|NCT06050291|DRUG|Fixed-Dose Combination (FDC) Tablet|Obicetrapib/Ezetimibe FDC tablet
219704503|NCT00941928|DRUG|Fludarabine|25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
219704504|NCT00941928|DRUG|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
219704505|NCT00941928|DRUG|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
219704506|NCT00941928|PROCEDURE|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
219118979|NCT04912622|DIAGNOSTIC_TEST|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
219118980|NCT02398682|OTHER|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1\) Rapidly establish a credible diagnosis of the cause of AKI including:~1. Improved assessment of volume status~2. Standardised use of urine dipstick .~3. Appropriate sepsis investigations.~4. Urgent ultrasound with suspected obstruction."
219118981|NCT02398682|OTHER|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
219704507|NCT00941928|DRUG|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
219704508|NCT03562130|DRUG|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
219704509|NCT04686331|DIAGNOSTIC_TEST|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~* Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
219118982|NCT02398682|OTHER|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
219118983|NCT02398682|OTHER|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
219118984|NCT02398682|OTHER|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
219118985|NCT02398682|OTHER|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
219118986|NCT04493918|COMBINATION_PRODUCT|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
219118987|NCT04493918|COMBINATION_PRODUCT|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
219118988|NCT02870946|PROCEDURE|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
219118989|NCT02870946|PROCEDURE|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
219118990|NCT05790564|OTHER|Almond|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
219704510|NCT04247971|PROCEDURE|Blood draw|23 ml of blood collected
219704511|NCT04247971|PROCEDURE|Sputum collection|Induced sputum sample collected
219704512|NCT04247971|PROCEDURE|Pulmonary function test|Pulmonary function testing
219704513|NCT02805998|BEHAVIORAL|Web-based CBT-I|
219704514|NCT02805998|OTHER|Treatment as Usual|
219704515|NCT00651846|DRUG|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
219704516|NCT00651846|DRUG|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
219704517|NCT03416101|PROCEDURE|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification \[39\] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
219118991|NCT05790564|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
219704518|NCT01214122|DRUG|AZD9668|60 mg orally twice daily for 11 days
219704519|NCT01214122|DRUG|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
219704520|NCT00879216|DRUG|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
219704521|NCT00879216|DRUG|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
219704522|NCT05306704|OTHER|placebo Oil|participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4
219704523|NCT05306704|DRUG|25-Hydroxyvitamin D|Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4
219704524|NCT02214810|DRUG|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
219704525|NCT05432817|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
219704526|NCT03482024|DRUG|Tirzepatide|Administered SC.
219118992|NCT06652737|BIOLOGICAL|PfSPZ-LARC2 Vaccine|The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)
219118993|NCT06652737|BIOLOGICAL|Normal Saline (Placebo)|Normal Saline Placebo
219118994|NCT06331299|DRUG|UGN-103|UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
219118995|NCT00001125|BIOLOGICAL|Varicella Virus Vaccine (Live)|
219118996|NCT06654986|DRUG|Salmeterol + amino acid availability|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
219118997|NCT06654986|DRUG|Salmeterol + placebo|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
219704527|NCT03518684|DRUG|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
219704528|NCT06393231|OTHER|acupuncture|Acupuncture is applied to ST8, GB14, BL12, SJ23, ST2, SI18, ST4, ST7, RN24, Ex-HN16, SJ17 and LI4 on the affected side and needles are retained for half an hour.Add infrared irradiation therapy in the same time
219704529|NCT01513499|DRUG|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
219704530|NCT01513499|DRUG|Placebo|Intranasal Placebo single-dose administration
219704531|NCT02921165|DRUG|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
219704532|NCT02921165|DRUG|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
219704533|NCT01555814|DRUG|Amisulpride|4-week open label amisulpride treatment
219704534|NCT04452175|OTHER|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
219704535|NCT05902065|DEVICE|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
219704536|NCT05902065|DEVICE|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
219704537|NCT00305526|DEVICE|Contak Renewal (CRT-D)|
219704538|NCT04636047|OTHER|The method of gene mutation detection|All samples were detected by NGS CGP panel.
219704539|NCT00251472|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
219704540|NCT02819128|OTHER|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
219118998|NCT06654986|DRUG|Placebo + placebo|The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
219118999|NCT06812221|DRUG|Sublingual administration|Participants will receive a sublingual dose of 5-MeO-DMT or placebo, once a week for four consecutive weeks.
219119000|NCT06812221|PROCEDURE|Electroencephalography|Conducting baseline electroencephalography and during the consumption of the corresponding dose.
219704541|NCT02819128|OTHER|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
219704542|NCT01056276|DRUG|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
219704543|NCT01056276|DRUG|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
219704544|NCT01056276|DRUG|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
219119001|NCT06812221|DIAGNOSTIC_TEST|Biochemical mesurements|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
219119002|NCT06812221|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
219119003|NCT06812221|DIAGNOSTIC_TEST|Vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment.
219119004|NCT06812221|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will complete the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) to measure attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to monitor any cognitive changes in response to either a 6 mg dose of 5-MeO-DMT or placebo. This will help determine how the intervention may affect cognitive processing, memory, and attention.
219119005|NCT06812221|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
219119006|NCT05694975|DRUG|Vitamin C|The total dosage of vitamin C for the treatment group is 24 g per day.
219119007|NCT05694975|DRUG|Placebo|The total dosage of placebo(5% glucose) for the control group is 24 g per day.
219119008|NCT02684903|BEHAVIORAL|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
219119009|NCT03617159|DEVICE|Magnetic Resonance Imaging|Diagnostic Modality
219119010|NCT01222221|BIOLOGICAL|glioblastoma multiforme multipeptide vaccine IMA950|
219119011|NCT01222221|BIOLOGICAL|sargramostim|
219704545|NCT01881425|PROCEDURE|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
219704546|NCT01881425|DEVICE|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
219704547|NCT01710423|BEHAVIORAL|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
219119012|NCT01222221|DRUG|temozolomide|
219119013|NCT01222221|OTHER|laboratory biomarker analysis|
219119014|NCT01222221|OTHER|pharmacological study|
219119015|NCT01222221|PROCEDURE|adjuvant therapy|
219119016|NCT01222221|RADIATION|radiation therapy|
219119017|NCT00216762|DRUG|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
219119018|NCT06603961|DEVICE|CPG-EB group|Customized-pressure guided elastic bandage group
219119019|NCT03726021|DRUG|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
219704548|NCT00521495|DEVICE|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
219119020|NCT06918951|RADIATION|Stereotactic ablative radiotherapy (SABR)|SABR is a safe and effective modality for metastasis-directed therapy, delivering a high dose of radiotherapy to a small target using conformal techniques. Emerging evidence suggests that SABR for oligoprogressive cancer may extend the duration of systemic therapy, and result in improvements in Progression Free Survival (PFS) and Overall Survival (OS) compared to historic controls.
219704549|NCT00521495|DEVICE|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
219704550|NCT00521495|DEVICE|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
219704551|NCT06351176|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
219704552|NCT06351176|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
219704553|NCT06351176|DIAGNOSTIC_TEST|DXA scan with TBS and VFA|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.
219704554|NCT06351176|DIAGNOSTIC_TEST|AGEReader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
219704555|NCT00537836|DRUG|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
219704556|NCT00537836|DRUG|Placebo|Placebo, once daily p.o. over 8 weeks
219704557|NCT00537836|DRUG|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
219704558|NCT03493971|PROCEDURE|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
219704559|NCT03493971|PROCEDURE|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
219704560|NCT04057092|DIETARY_SUPPLEMENT|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
219704561|NCT02832713|DRUG|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
219704562|NCT02832713|DEVICE|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
219704563|NCT06456307|BEHAVIORAL|Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)|The intervention includes systematic screening for PMAD symptoms using PHQ-2 and GAD-2, non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) and in-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to PM+
219704564|NCT00745602|PROCEDURE|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
219704565|NCT03421587|BEHAVIORAL|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
219704566|NCT00397579|DRUG|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
219704567|NCT00351247|PROCEDURE|Postconditioning|
219119021|NCT06918951|RADIATION|Palliative radiotherapy|"Radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression.~Participants will continue their current systemic therapy (if already on systemic therapy at the time of oligoprogression event) or continue off systemic therapy (if the participant was not on systemic therapy at the time of the oligorecurrence event)."
219704568|NCT00034632|DRUG|Posaconazole oral suspension|
219704569|NCT00620906|PROCEDURE|Manipulation|HVLA manipulation to Sacroiliac Joint
219704570|NCT04892160|OTHER|Guided Imagery|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
219704571|NCT04892160|OTHER|Virtual Reality|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
219704572|NCT02524119|DRUG|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
219704573|NCT02524119|PROCEDURE|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
219704574|NCT02054156|DRUG|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
219704575|NCT02054156|DRUG|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
219704576|NCT02054156|DRUG|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
219360955|NCT02146287|OTHER|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
219704577|NCT05106478|DEVICE|AuraGain|Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
219704578|NCT02821845|BEHAVIORAL|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
219704579|NCT04640896|DRUG|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
219704580|NCT04640896|DRUG|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
219704581|NCT04640896|DRUG|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
219704582|NCT02237664|PROCEDURE|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
219704583|NCT02237664|PROCEDURE|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
219704584|NCT01928849|DRUG|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
219704585|NCT01928849|OTHER|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
219704586|NCT03704077|BIOLOGICAL|Relatlimab + Nivolumab|Specified dose on specified days
219704587|NCT03704077|BIOLOGICAL|Nivolumab|Specified dose on specified days
219704588|NCT03704077|DRUG|Paclitaxel|Specified dose on specified days
219704589|NCT03704077|DRUG|Ramucirumab|Specified dose on specified days
219704590|NCT01649219|BEHAVIORAL|Exercise|
219704591|NCT06022575|PROCEDURE|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
219704592|NCT06022575|PROCEDURE|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
219704593|NCT01200355|DRUG|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
219704594|NCT01200355|DRUG|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
219704595|NCT04383678|DEVICE|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
219704596|NCT05098561|OTHER|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
219704597|NCT02641821|DRUG|Nifedipine GITS|
219704598|NCT00724776|BIOLOGICAL|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
219704599|NCT01404481|DEVICE|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
219704600|NCT01502553|DEVICE|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
219704601|NCT01490710|OTHER|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
219225559|NCT04602728|BEHAVIORAL|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
219704602|NCT01490710|OTHER|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
219704603|NCT00005988|DRUG|cyclophosphamide|
219704604|NCT00005988|DRUG|cyclosporine|
219704605|NCT00005988|DRUG|leucovorin calcium|
219704606|NCT00005988|DRUG|methotrexate|
219704607|NCT00005988|DRUG|methylprednisolone|
219704608|NCT00005988|PROCEDURE|in vitro-treated bone marrow transplantation|
219704609|NCT00005988|RADIATION|radiation therapy|
219704610|NCT06436417|DEVICE|Analgesia Nociception Index (ANI) Monitor|Non-invasive monitoring of HRV to evaluate autonomic nervous system activity using the indices of Energy (SDNN) and ANI (HFnu).
219704611|NCT06436417|BEHAVIORAL|Trimodal Prehabilitation|Program of physical exercise, nutritional supplementation, and psychological support according to the RICA guidelines of the Spanish Group for Multimodal Rehabilitation.
219704612|NCT04991584|DRUG|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
219704613|NCT05489575|DEVICE|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
219704614|NCT05489575|DEVICE|Sham CPAP|Sham continuous positive airway pressure applied at \<4 cm H2O
219704615|NCT05489575|OTHER|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
219704616|NCT06192732|BEHAVIORAL|A more plant-based diet during weight loss|Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
219704617|NCT02191501|PROCEDURE|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
219704618|NCT02993276|DEVICE|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
219704619|NCT05526768|DEVICE|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
219704620|NCT04424901|DRUG|Placebo|Daily dose while hospitalized up to 9 days
219704621|NCT04424901|DRUG|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
219704622|NCT00128427|DRUG|Colchicine (for 1 month)|
219704623|NCT03697590|DRUG|No curettage|Standard PDT without curettage
219704624|NCT03697590|DRUG|Curettage|Standard PDT
219704625|NCT00147238|DRUG|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
219704626|NCT00147238|PROCEDURE|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
219704627|NCT04735302|OTHER|Radiographic Feature|Radiographic rewiev
219704628|NCT00102973|DRUG|TLK286 in Combination with Carboplatin|Experimental Arm
219704629|NCT00102973|DRUG|Doxorubicin HCl Liposome Injection|Active Comparator
219704630|NCT03874962|OTHER|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
219704631|NCT02572154|OTHER|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
219704632|NCT01242007|OTHER|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
219704633|NCT03491488|OTHER|Brain Games|The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
219704634|NCT02857153|DRUG|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
219704635|NCT02857153|DRUG|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
219704636|NCT02857153|PROCEDURE|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
219704637|NCT02857153|PROCEDURE|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
219119022|NCT06544096|BEHAVIORAL|intervention group (WeChat platform + healthcare)|The study will implement the WeChat-based Neonatal Home Skin Care Management System, designed based on neonatal skin characteristics and evidence-based care guidelines. The intervention materials included a WeChat platform functional module (comprising a newborn information registration interface, online consultation, and questionnaire features) along with standard educational brochures used in the control group. During hospitalization, study group healthcare providers will deliver standard health education (identical to the control group) while additionally guiding mothers through platform registration and data entry, with demonstrations of system functionality. Post-discharge, the system automatically will deliver stage-appropriate skin care recommendations based on neonatal age with read reminders prompting parental engagement. Parents can access educational materials or submit queries at any time, while researchers utilize the platform for survey distribution.
219119023|NCT06544096|BEHAVIORAL|control group (routine health education)|When the parturient is discharged from the hospital, the medical staff of the control unit will give the parturient health education about the discharge of the newborn. The contents of the education include neonatal jaundice, umbilical care, vaccination, 42-day follow-up, breastfeeding and so on, which are not included in the system.
219119024|NCT05204550|DRUG|unfractionated heparin|intranasal
219119025|NCT05204550|DRUG|0.9%sodium chloride|intranasal
219119026|NCT02800486|DRUG|Intra-arterial Cetuximab|
219704638|NCT00937807|DRUG|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
219704639|NCT00937807|DRUG|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
219704640|NCT02955693|DRUG|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
219704641|NCT04034472|OTHER|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
219119027|NCT02800486|DRUG|Intra-arterial Mannitol|
219119028|NCT02800486|RADIATION|Hypofractionated re-irradiation|
219704642|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
219119029|NCT02902029|DRUG|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
219119030|NCT02902029|DRUG|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
219119031|NCT02902029|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
219119032|NCT04031430|DEVICE|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
219225560|NCT06870630|DEVICE|Per oral endoscopy myotomy|Poem procedure is meant for cutting of circular and longitudinal muscle fibers in esophagus to reduce the symptoms of dysphagia, regurgitation and chestpain, weight loss.
219225561|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
219225562|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
219225563|NCT07012655|DEVICE|Colour Doppler Ultrasound|All study participants will undergo abdominal Ultrasound and Colour doppler ultrasound study of the superior and inferior mesenteric arteries and the resistance index and peak systolic velocity (cm/s) of radial and ulnar arteries measured by ultrasonography color Doppler with spectral wave analysis.
219119033|NCT04031430|OTHER|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
219119034|NCT04031430|OTHER|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
219360956|NCT05801237|DRUG|PE0116&PE0105|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
219704643|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
219704644|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
219704645|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
219704646|NCT00178373|DRUG|Modafinil|
219704647|NCT00178373|DRUG|sugar pill|
219704648|NCT04232137|BEHAVIORAL|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
219704649|NCT04120818|PROCEDURE|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
219704650|NCT04120818|PROCEDURE|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
219704651|NCT05584345|OTHER|Conventional Treatment and manual therapy|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. In addition, participants will receive manual therapy techniques, including Glenohumeral joint (GH) distraction, glenohumeral joint inferior gliding, anterior gliding, and posterior gliding, scapulothoracic joint distraction, scapulothoracic joint superior, inferior, medial, and lateral gliding. Each manual therapy technique was performed with 10 repetitions per participant
219704652|NCT05584345|OTHER|Manual therapy and Respiratory Exercises|In addition to the treatment program applied in conventional therapy and manual therapy,, participants in this group also will perform diaphragmatic breathing exercises, pursed-lip breathing exercises, and relaxation breathing exercises. Each breathing exercise will be performed with 10 repetitions under physiotherapist supervision. Participants were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
219704653|NCT00145561|DRUG|Saquinavir and Ritonavir|
219704654|NCT01927588|DRUG|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
219704655|NCT01927588|DRUG|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
219704656|NCT00754923|DRUG|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
219704657|NCT02448082|OTHER|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
219704658|NCT02448082|OTHER|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
219704659|NCT00815074|OTHER|No intervention|no intervention
219119035|NCT02344394|DEVICE|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
219119036|NCT02344394|DEVICE|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
219119037|NCT02344394|DEVICE|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
219119038|NCT06625580|PROCEDURE|transverse thoracic muscle plane and serratus anterior plane block|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with 0.25% bupivacaine
219119039|NCT06625580|PROCEDURE|erector spinae plane block|ultrasound guided erector spinae plane block will be performed with 0.25% bupivacaine
219360957|NCT05646108|DEVICE|Endovascular treatment|Endovascular treatment
219119040|NCT06625866|BEHAVIORAL|Feedback and information|"The healthcare professionals in the intervention arm will be exposed to feedback and information behavioral strategies. Namely, interns, residents, obstetricians/gynecologists, and nurses will receive written feedback about the episiotomy rates in the hospital each month during the study period. Moreover, at least two academic sessions will be designed to outline the indications, surgical technique, complications, and surgical ethics for the procedure (i.e., episiotomy). Likewise, each session will also include a patient testimonial about their experience during delivery and their follow-up when an episiotomy was performed.~The feedback intervention will be provided for 2 months, and the feedback intervention + the information intervention will be provided for 2 additional months."
219119041|NCT06625450|DRUG|Tofacitinib|Tofacitinib alone will be continued at a dose of 11 mg once a day
219119042|NCT06625450|DRUG|Tofacitinib plus mesalamine|Both tofacitinib 11 mg once a day and mesalamine will be continued
219119043|NCT06625879|PROCEDURE|Serratus Anterior Plane Block (SAPB)|"Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection."
219360958|NCT06340009|OTHER|mime therapy|"1. Facial Massage~2. Frowning~3. Close eyes~4. Smile~5. Fish Face~6. Eyebrow raising~7. Breathing exercise~8. Blow cheeks~9. Mouth opening and closing.~10. Moving lips side to side~11. Blow a candle.~12. Nasal flaring~13. Chewing exercise~14. Rinse mouth~15. Speaking vowels~16. Fill mouth with water~17. Fill rubber balloon~18. Sucking water with straw"
219704660|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
219704661|NCT04736433|DRUG|ACE inhibitor|ACE inhibitor dispensing claim is used as the reference
219704662|NCT04736433|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan dispensing claim is used as the reference
219704663|NCT05404841|DIETARY_SUPPLEMENT|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
219704664|NCT05404841|DIETARY_SUPPLEMENT|Placebo|Placebo
219704665|NCT03083041|BIOLOGICAL|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
219704666|NCT03083041|DRUG|Apatinib|Apatinib tablet will be administered orally,once daily until progression
219704667|NCT03185208|DRUG|Lithium Carbonate|See lithium carbonate arm
219704668|NCT03185208|DRUG|Placebo oral capsule|See placebo arm
219704669|NCT05364424|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
219704670|NCT05364424|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
219704671|NCT05364424|DRUG|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
219704672|NCT05364424|DRUG|Rituximab|Participants will receive up to 2 doses of IV rituximab.
219704673|NCT05364424|DRUG|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
219704674|NCT05364424|DRUG|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
219704675|NCT05364424|DRUG|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
219704676|NCT04960267|DEVICE|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
219704677|NCT04541121|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
219704678|NCT04541121|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
219704679|NCT01855269|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
219704680|NCT01855269|DIETARY_SUPPLEMENT|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
219704681|NCT01855269|DIETARY_SUPPLEMENT|placebo sterile water|
219704682|NCT06134388|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
219704683|NCT02410629|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
219704684|NCT02410629|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
219704685|NCT04909788|BEHAVIORAL|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
219704686|NCT04121143|BIOLOGICAL|IL-17A Antagonist|SHR-1314 subcutaneous injection
219704687|NCT04121143|BIOLOGICAL|Placebos|placebo subcutaneous injection to maintain consistency and to prevent blindness
219119044|NCT06625879|PROCEDURE|Midpoint transverse process to pleura (MTP) block|In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
219119045|NCT06625125|BEHAVIORAL|Mindfulness-based intervention|"The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
219119046|NCT06625125|BEHAVIORAL|Progressive muscle relaxation|"he progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
219119047|NCT06874413|BEHAVIORAL|Prehabilitation|Physical prehabilitation or exercise conducted through the YMCA's Silver Sneaker's program prior to receiving surgery that will be assessed through the use of wearable activity monitors.
219119048|NCT06874413|OTHER|Standard of Care (SOC)|Patients will receive standard of care preoperative instructions.
219119049|NCT06875895|OTHER|Traditional Physiotherapy|Hotpack, Tens and Ultrasound application
219119050|NCT06875895|OTHER|Motor Imagery Training|Kinesthetic and visual motor imagery will be applied.
219704688|NCT02751229|BEHAVIORAL|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~1. Considering pros and cons of disclosing:~   * hurtful and helpful attitudes about mental illness~  * identify beliefs participants hold about themselves~  * explore five-step process to challenge their personally hurtful beliefs~  * weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~2. Different ways to disclose:~   * different levels of (non-) disclosure and how to weigh the cons and pros~  * disclosure via social media versus disclosing face to face~  * how to find people that are better to disclose to than others and how to 'test them out'~  * participants will discuss how others might respond to their disclosure and how that will affect them~3. Telling your story:~   * how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
219704689|NCT02701634|DRUG|ENTO|Tablets administered orally
219704690|NCT02701634|DRUG|Placebo|Tablets administered orally
219704691|NCT02458495|BEHAVIORAL|Diabetes MAP Intervention|
219704692|NCT03523286|OTHER|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
219704693|NCT00006032|DRUG|etoposide|
219704694|NCT00006032|DRUG|ifosfamide|
219704695|NCT00006032|DRUG|topotecan hydrochloride|
219704696|NCT00006032|PROCEDURE|peripheral blood stem cell transplantation|
219704697|NCT06551753|OTHER|virtual reality app|virtual reality app
219119051|NCT03873636|OTHER|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
219119052|NCT06703580|DRUG|Hyperbaric prilocaine 2% 40 mg|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
219119053|NCT06703580|DRUG|hyperbaric prilocaine 2% 50 mg|comparison of 3 different doses of prilocaine
219119054|NCT06703580|DRUG|hyperbaric prilocaine 2% 60 mg|this study compare 3 different doses of prilocaine
219360959|NCT06340009|OTHER|motor imagery|"1. Raising your eyebrows~2. Showing angry face~3. Closing and opening eyes~4. Pouting~5. Blowing cheeks~6. Smiling~7. Nasal flaring~8. Blowing candle~9. Deviating lips side to side~10. Chewing something~11. Speaking vowels"
219704698|NCT05337761|BEHAVIORAL|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
219704699|NCT01186770|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
219704700|NCT01186770|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
219704701|NCT02689960|DRUG|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
219704702|NCT02511717|OTHER|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
219704703|NCT02511717|OTHER|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
219704704|NCT02964624|OTHER|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
219704705|NCT02686411|OTHER|Survey Administration|Complete survey
219704706|NCT05342571|OTHER|Behavioral, Psychological or Informational Intervention|Participate in ABC session
219704707|NCT05342571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219704708|NCT05342571|OTHER|Electronic Health Record Review|Medical records reviewed
219704709|NCT05342571|OTHER|Informational Intervention|Receive patient guidebook
219119055|NCT05650307|DIAGNOSTIC_TEST|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
219119056|NCT06883006|BEHAVIORAL|Sleep Extension|A 1.5-hour nap opportunity compared to a neutral 1.5 hour waking activity (e.g., puzzle completion) prior to task. Participants will either nap or not prior to the emotion regulation task. These two conditions will be counter-balanced within gender and participants will complete them 1 week apart. If they are in the nap condition, they will nap for 1.5 hours with PSG in a dark, soundproofed room with optional fan, white noise, or music. If they are in the no nap condition, they will work on puzzles for 1.5 hours in the same room but with the lights on.
219119057|NCT06920446|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
219119058|NCT06918821|BEHAVIORAL|Healthy Toddler Parent Group (HTPG)|Parent education class
219119059|NCT06918821|BEHAVIORAL|Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup|Family playgroup
219119060|NCT06500611|OTHER|Sensory Integration and Vestibular Exercise with Routine Physical Therapy|"1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1\. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2\. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times"
219119061|NCT06500611|OTHER|Vestibular Exercise with Routine Physical Therapy|"Vestibular exercise~1\. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2\. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group"
219119062|NCT06739590|BEHAVIORAL|Learning with CT scans|The average performance improvement in this group will serve as the baseline for learning achievable through conventional CT and MR imaging alone.
219119063|NCT06739590|BEHAVIORAL|Learning with 3D visualization models|Learning anatomical structures using three-dimensional visualization models displayed on a computer.
219119064|NCT06739590|RADIATION|Learning with 3D-MR visualization models|Viewing and manipulating 3D visualization models to learn anatomical structures using the MR headset.
219119065|NCT06744062|DRUG|BR1015|One tablet administered alone
219119066|NCT06744062|DRUG|BR1015-1|One tablet administered alone
219119067|NCT06744062|DRUG|BR1015-2|One tablet administered alone
219225564|NCT07043491|DIAGNOSTIC_TEST|Endoscopy|We first observed the residual esophagus to evaluate the mucosal color. We then reached the top of the anastomosis to obtain a full view of the anastomosis to exclude obvious leakage around that site. We next conducted a more detailed endoscopic examination at a close focal distance, circumferentially around the anastomosis. During this process, we utilized saline solution to meticulously remove white fibrin coverings and bloodstains to the greatest extent possible to ensure a thorough evaluation of anastomotic integrity. Finally, we inspected the staple line of the tubularized stomach to exclude gastric fistula and assessed the perfusion of the gastric graft. Endoscopic findings were assessed by an additional endoscopist and 3 esophageal surgeons during the examination, as well as by reviewing captured images or videos after endoscopy.
219225565|NCT07043101|OTHER|Extended Reality based Gait Rehabilitation|XR headset augmenting traditional Vector based gait rehabilitation.
219704710|NCT05342571|OTHER|Survey Administration|Complete surveys
219704711|NCT01337934|DRUG|Lactated Ringer|Lactated Ringer
219704712|NCT01337934|DRUG|Albumin|Albumin 4%
219704713|NCT04519190|DIAGNOSTIC_TEST|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
219704714|NCT04519190|DIAGNOSTIC_TEST|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
219704715|NCT04519190|DIAGNOSTIC_TEST|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
219704716|NCT05335616|OTHER|Guideline|Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
219119068|NCT06887517|DRUG|Antimalarial with or without oral glucocorticosteroid|"Intervention one: Antimalarial and Oral Glucocorticosteroid, Prednisone or equivalent dose of glucocorticoid tapering: 0.5\~0.6mg/kg/d(week 0\~2), 0.3\~0.4mg/kg/d(week 3\~4), 15 mg/d(week 5\~6), 10 mg/d(week 7\~8), 7.5 mg /d(week 9\~10), 5 mg/d(week 11\~12), 2.5 mg/d(week 13\~24), \<2.5 mg/d(after week 24)；Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy~Intervention two: Antimalarial only. Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy"
219119069|NCT05940298|DRUG|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
219119070|NCT06914960|PROCEDURE|2-point Radiofrequency Ablation|"For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used.~In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. Patients in 2 nerve groups (SM and IM) will undergo 2-point RFA at 42°C using a 120-second pulse RFA generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany).~To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1 cc) will be injected into the points where RFA is applied, after aspiration."
219119071|NCT06914960|PROCEDURE|3-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 3-point RFA will be applied to patients in 3 nerve groups (SM, SL and IM) using a generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany) in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
219119072|NCT06914960|PROCEDURE|5-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 5-point RFA will be applied to patients in 5 nerve groups (SM, SL and IM, recurrent fibular nerve-RFN, infrapatellar branch of saphenous nerve-IPBSN) via same generator in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2cc of betamethasone (5mg+2mg/1cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
219119073|NCT07102602|DEVICE|high intensity laser therapy|The high-intensity laser used in this study is approved by the Ministry of Health and Welfare, Taiwan (No. 032670). It operates at a wavelength of 940 nm. For the active treatment (HILT), the laser delivers 900 joules to the quadriceps at a power output of 3 W for 5 minutes and is applied along the length of the quadriceps muscle
219119074|NCT07102602|DEVICE|Sham laser therapy|In the sham condition (SHAM), the output is set to 0 W for 5 minutes, resulting in no energy delivery.
219119075|NCT06920173|PROCEDURE|Experiemental: Peripheral Venous Catheter|Patients older than 18 years of age who present with shock requiring vasopressors at the following minimum doses: norepinephrine 5 mcg/min, phenylephrine 50 mcg/min, epinephrine 5 mc/min, dobutamine 5 mcg/kg/min. Vasopressors are infused through a peripheral venous catheter (18 gauge or larger); however, patients are crossed over to the central venous catheter group if the maximum vasopressor dose is reached or more than two vasopressors.
219119076|NCT06919874|BEHAVIORAL|Thinking out Loud Session|Participants will complete one thinking out loud session (approx. 60 minutes). The session will be led by a yoga therapist (see below) either in person at the hospital or via Zoom. Individual patients, caregivers or patient-caregiver dyads will attend the session. Each participant will need to either bring their own device or will use an institutional loaner device if no personal device is available. During the session, participants will be asked to download the app from the device appropriate app store and open the app. Then, we will implement the thinking out loud methods asking participants to continuously think out loud, meaning verbalizing their thoughts as they move through the user interface of the app. The sessions will be audio recorded with permission obtained during the consent process. Specific feedback will be requested using a semi-structured interview approach
219360960|NCT02690623|OTHER|Pediatric hospitalist program|In-house hospitalists available at all hours
219360961|NCT02690623|OTHER|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
219704717|NCT05335616|OTHER|Treatment fee item|Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
219704718|NCT00772837|DRUG|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
219704719|NCT00772837|DRUG|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
219704720|NCT01033136|BEHAVIORAL|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
219704721|NCT01033136|BEHAVIORAL|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
219704722|NCT00930462|DEVICE|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
219704723|NCT00025402|BIOLOGICAL|filgrastim|
219704724|NCT00025402|BIOLOGICAL|recombinant interferon alfa|
219704725|NCT00025402|DRUG|busulfan|
219704726|NCT00025402|DRUG|cyclophosphamide|
219704727|NCT00025402|DRUG|cytarabine|
219704728|NCT00025402|DRUG|etoposide|
219119077|NCT06915051|DIAGNOSTIC_TEST|Determining the relationship between the coiling number and fetal echocardiography findings.|Fetal echocardiography findings to be performed simultaneously with the determination of the coiling number.
219360962|NCT00814957|DRUG|GSK618334|D3 receptor antagonist
219119078|NCT06917924|DIAGNOSTIC_TEST|lumbar puncture|Standard of care of LP
219119079|NCT06915155|DEVICE|Swing-Mesh™|A lightweight, macroporous, three-dimensional polypropylene mesh implant developed by THT BioScience™ and distributed by B. Braun™, used in laparoscopic-endoscopic inguinal hernia repair without fixation. The mesh is designed to conform to the anatomical shape of the myopectineal orifice and is available in two sizes (15×11 cm or 16×12 cm).
219119080|NCT06919523|DRUG|Dapagliflozin 5mg|Dapagliflozin 5m orally once daily for 3 months plus standard care (diuretics and Large volume paracentesis)
219119081|NCT06919523|DRUG|Standard care treatment|Diuretics and Large volume paracentesis as indicated
219119082|NCT06917911|PROCEDURE|Biospecimen Collection|Undergo optional buccal cell collection and/or blood sample collection
219704729|NCT00025402|DRUG|hydroxyurea|
219119083|NCT06917911|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219119084|NCT06917911|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219119085|NCT06917911|DRUG|Cytarabine|Given IV
219704730|NCT00025402|DRUG|idarubicin|
219119086|NCT06917911|DRUG|Daunorubicin Hydrochloride|Given IV
219119087|NCT06917911|PROCEDURE|Echocardiography Test|Undergo echocardiography
219119088|NCT06917911|DRUG|Gemtuzumab Ozogamicin|Given IV
219119089|NCT06917911|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219119090|NCT06917911|DRUG|Venetoclax|Given PO
219119091|NCT06918171|PROCEDURE|Clinical Efficacy of Open Reduction and Anchor Suture Bridge Fixation|Under general anesthesia, patients were positioned prone, and a midline posterior incision was made at the level of the popliteal fossa. After incising the fascia, careful dissection was undertaken to expose the posterior joint capsule and fracture fragment, with particular attention to safeguarding the neurovascular structures. Once the fracture site was fully exposed, hematoma and any interposing soft tissue were meticulously cleared to prepare for reduction. The avulsed bone fragment, located at the PCL insertion site, was identified and prepared for fixation. A suture anchor (Johnson \& Johnson, USA) was carefully implanted into the prepared osseous bed. The suture threads were passed anteriorly around the PCL and configured in a figure-of-eight pattern to achieve precise anatomical reduction of the fracture fragment. To enhance fixation stability, two extracortical anchors (Johnson \& Johnson, USA) were additionally positioned approximately 2 cm distal to the fracture site, securing
219119092|NCT00153387|BEHAVIORAL|Women's health|
219704731|NCT00025402|PROCEDURE|allogeneic bone marrow transplantation|
219704732|NCT00025402|PROCEDURE|peripheral blood stem cell transplantation|
219704733|NCT00025402|RADIATION|radiation therapy|
219704734|NCT04342169|DRUG|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
219704735|NCT04342169|DRUG|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
219704736|NCT03781271|DEVICE|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
219119093|NCT06919575|COMBINATION_PRODUCT|Multicomponent frailty intervention|"First, the underlying causes of the patient's frailty should be analyzed. Individualized goals should be established using Goal Attainment Scaling (GAS), followed by implementation of tailored measures. For patients presenting with malnutrition or mood-related disorders, comprehensive nutritional and psychological assessments must be conducted, with subsequent nutritional support or pharmacological treatment initiated when clinically indicated.~The patients of the intervention group with poor physical function would receive exercise prescription tailored to the subjects' physical ability from a trained specialist. For Participants requiring exercise-based interventions, a moderate and gradually increasing intensity exercise regimen home-basethree times a week, over a 12-week duration will be administer under telehealth-based monitoring."
219119094|NCT04627103|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
219704737|NCT02456896|DRUG|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
219704738|NCT04096131|PROCEDURE|cataract surgery|phacoemulsification
219119095|NCT00583505|DEVICE|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
219119096|NCT00107380|BIOLOGICAL|rituximab|
219119097|NCT00107380|DRUG|cyclophosphamide|
219119098|NCT00107380|DRUG|doxorubicin hydrochloride|
219119099|NCT00107380|DRUG|prednisone|
219119100|NCT00107380|DRUG|vincristine sulfate|
219119101|NCT00107380|RADIATION|tositumomab and iodine I 131 tositumomab|
219119102|NCT03673098|BEHAVIORAL|Adapted 3RP|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
219119103|NCT06431802|OTHER|Conventional intervention|A nursing specialist with extensive clinical and teaching experience will provide on-site course training. The training will cover topics related to pain and pain assessment, such as: pain definition, types, physiological mechanisms, performance, pain assessment tools, and frequency of pain assessment. Interventions will be provided once a week for 4 weeks.
219119104|NCT06431802|BEHAVIORAL|Platform intervention|Using a pre-assigned account to log in to the platform, read the guidance instructions and enter the platform to start training. Basic knowledge of pain and pain assessment can be learnt through the Learning Resources module on the platform, and pain assessment training can be conducted through the Pain Assessment Exercise module. During pain assessment training the platform provides instant feedback based on the participant's exercises. Interventions will be completed in 4 weeks.
219119105|NCT04307602|OTHER|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
219119106|NCT04307602|OTHER|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
219119107|NCT01781611|DRUG|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
219119108|NCT01781611|DRUG|81mg aspirin|half a tablet twice daily for 24 weeks
219119109|NCT03639675|DRUG|Aflibercept (EYLEA, BAY86-5321)|2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
219119110|NCT03639675|DRUG|Topical IOP-lowering drugs|A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
219704739|NCT06516770|DEVICE|Transcranial direct current stimulation|The subject will receive the tDCS using 5X7 cm electrodes. The anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes
219704740|NCT06516770|DEVICE|Neuromuscular electrical stimulation|The participants will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes.
219704741|NCT06516770|OTHER|Motor control exercise|The participant will be instructed to perform co-contraction of transverse abdominis and lumbar multifidus muscle, while performing self-selected pace forward bend. Emphasis will be given to move in control manner (smooth and symmetrical movement). The participant will perform 4 minutes of continuous movement for 4 sets with 1 minute rest between sets.
219704742|NCT06516770|OTHER|Isometric exercise|The participant will be instructed to perform isometric back extension exercise in modified Sorensen position. The participant will hold 60 seconds in neutral position for 5 repetitions with 3 minutes rest between repetitions.
219119111|NCT01212263|DRUG|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
219119112|NCT01212263|DRUG|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
219119113|NCT00938899|DRUG|TMC435350; Placebo|
219119114|NCT00507611|PROCEDURE|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
219119115|NCT03454932|OTHER|Blood sampling|
219119116|NCT00311792|BEHAVIORAL|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
219119117|NCT00311792|BEHAVIORAL|Traditional clinical education|
219119118|NCT01477749|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
219119119|NCT02915380|BIOLOGICAL|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
219119120|NCT02915380|BEHAVIORAL|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
219119121|NCT02915380|BEHAVIORAL|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
219119122|NCT00107185|BIOLOGICAL|therapeutic autologous dendritic cells|
219119123|NCT05527470|DRUG|Gemcitabine,Cisplatin|Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
219119124|NCT05527470|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
219119125|NCT05527470|DRUG|Cisplatin|Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
219119126|NCT04841044|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid ( C22:1n-11)
219119127|NCT04841044|DIETARY_SUPPLEMENT|Control Oil|Control oil consisting of: mix of anchovy oil, olive oil, high-oleic sunflower oil and rapeseed oil
219119128|NCT00479947|DRUG|Probiotics (Natural product)|
219119129|NCT00479947|DRUG|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
219119130|NCT00647413|BEHAVIORAL|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
219704743|NCT04409613|OTHER|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
219704744|NCT01776957|DEVICE|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
219704745|NCT00627692|DRUG|Prucalopride|0.5 mg o.d.
219704746|NCT00627692|OTHER|Placebo|o.d.
219704747|NCT00627692|DRUG|Prucalopride|1 mg o.d.
219704748|NCT00627692|DRUG|Prucalopride|2 mg o.d.
219704749|NCT00627692|DRUG|Prucalopride|4 mg o.d.
219704750|NCT00300599|DEVICE|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
219704751|NCT00300599|OTHER|Placebo|Placebo
219704752|NCT03807024|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
219704753|NCT03094156|DRUG|Placebo|1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
219704754|NCT03094156|DRUG|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
219704755|NCT03094156|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
219119131|NCT03794349|BIOLOGICAL|Dinutuximab|Given IV
219119132|NCT03794349|DRUG|Eflornithine Hydrochloride|Given PO or via NG or G tube
219119133|NCT03794349|DRUG|Irinotecan Hydrochloride|Given IV
219119134|NCT03794349|BIOLOGICAL|Sargramostim|Given SC or IV
219119135|NCT03794349|DRUG|Temozolomide|Given PO or via NG or G tube
219704756|NCT03094156|DRUG|Comtan®|Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
219704757|NCT01640977|PROCEDURE|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
219704758|NCT01640977|PROCEDURE|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
219119136|NCT04704401|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
219119137|NCT00939796|DEVICE|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
219119138|NCT02118714|DRUG|Atrasentan|Atrasentan
219119139|NCT01220141|DRUG|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
219119140|NCT00109551|DRUG|zinc sulphate dietary supplement|
219119141|NCT00109551|DRUG|iron sulphate-folic acid dietary supplement|
219119142|NCT05602337|OTHER|Observational Study Only|Non-invasive Skin Sampling
219119143|NCT05170035|PROCEDURE|MMS + Autologous patch|A patch of consisting of platelets, leucocytes and fibrin, formed by the patients own blood sample.
219704759|NCT01493713|OTHER|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
219704760|NCT02645890|DRUG|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
219119144|NCT05170035|PROCEDURE|MMS and secondary intention healing|Mohs micrographic surgery (standard of care) (wounds will heal by secondary intention healing)
219119145|NCT03943303|RADIATION|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
219119146|NCT03943303|RADIATION|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
219119147|NCT02488694|DRUG|Afatinib|40 mg/d
219119148|NCT02488694|DRUG|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
219704761|NCT02645890|DRUG|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
219704762|NCT02372461|DRUG|Placebo|This is an non inferiority trial, the intervention is a placebo
219704763|NCT02372461|DRUG|Amoxicillin|Amoxicillin Liquid
219704764|NCT06094465|OTHER|Different phase of the learning curve of RPD|Different phases of the learning curve of RPD (learning phase or proficiency phase)
219704765|NCT04270188|OTHER|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
219704766|NCT01005381|DIETARY_SUPPLEMENT|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
219704767|NCT01005381|DIETARY_SUPPLEMENT|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
219704768|NCT01005381|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
219704769|NCT01005381|DIETARY_SUPPLEMENT|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
219704770|NCT05107037|DRUG|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
219704771|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
219704772|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
219704773|NCT01572792|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
219119149|NCT03529903|BEHAVIORAL|Health Coaching|Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
219119150|NCT03904342|BEHAVIORAL|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
219704774|NCT01572792|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
219704775|NCT01572792|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
219704776|NCT03607318|BEHAVIORAL|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
219704777|NCT03932357|RADIATION|CBCT|measuring soft tissue thickness using a CBCT
219704778|NCT03530696|DRUG|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
219119151|NCT03904342|BEHAVIORAL|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
219119152|NCT01112150|DEVICE|NormaTec Pump|Normatec Pump
219225566|NCT06754956|DEVICE|The patient will receive two intravenous injections of the same gadoterate meglumine contrast agent.|Each patient will undergo two different field strength HR-VWIs with enhancement, and on each occasion the patient will be injected with contrast DOTAREM (gadoterate meglumine) .
219225567|NCT07066657|DRUG|MRG007|MRG007 will be administrated as specified in the protocol.
219225568|NCT06771115|DRUG|VTX3232 Dose A|VTX3232 Dose A
219225569|NCT06771115|DRUG|Placebo|Placebo
219225570|NCT06771115|DRUG|VTX3232 Dose A in combination with semaglutide|VTX3232 Dose A in combination with semaglutide
219225571|NCT06771115|DRUG|Placebo in combination with semaglutide|Placebo in combination with semaglutide
219704779|NCT03530696|DRUG|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
219704780|NCT05326516|DRUG|Revumenib|Participants will receive revumenib until meeting criteria for discontinuation.
219704781|NCT05326516|DRUG|Chemotherapy Regimen 1|Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
219704782|NCT05326516|DRUG|Chemotherapy Regimen 2|Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
219704783|NCT02472353|DRUG|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
219704784|NCT02472353|DRUG|Doxorubicin|Standard of care treatment with doxorubicin
219704785|NCT02297126|OTHER|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
219704786|NCT06080126|OTHER|Control: per usual practice|160 patients were included as per usual practice.
219119153|NCT04562506|DEVICE|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
219119154|NCT04562506|DEVICE|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
219119155|NCT04543370|DRUG|Edasalonexent 2000 mg TID|CAT-1004 capsules
219119156|NCT04543370|DRUG|Midazolam 2 MG/ML|2 mg/ml syrup
219119157|NCT04543370|DRUG|Deflazacort 36Mg Tab|36 mg tablets
219119158|NCT04945343|PROCEDURE|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
219119159|NCT01628874|DEVICE|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
219119160|NCT01628874|DRUG|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
219119161|NCT01628874|DRUG|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
219119162|NCT00248443|PROCEDURE|Fiberoptic bronchoscopy and bronchoalveolar lavage|
219119163|NCT00545142|DRUG|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
219119164|NCT00545142|DRUG|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
219119165|NCT03722212|DIAGNOSTIC_TEST|METAglut1|A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
219704787|NCT06080126|OTHER|Intervention MAF|160 patients were included with MAF intervention.
219704788|NCT04769297|DRUG|Sublingual Micro-Dose Ketamine|daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
219704789|NCT05956743|OTHER|progressive relaxation exercise sessions|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~1. week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2. ,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6\. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
219704790|NCT05956743|OTHER|Sham|"1\. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6\. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
219704791|NCT01334359|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
219119166|NCT05414721|DRUG|Low flow desflurane anesthesia (Group D)|When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
219119167|NCT01866241|DRUG|Misoprostol|Is a prostaglandin
219119168|NCT01899248|DRUG|Sevoflurane|
219119169|NCT01899248|DRUG|Desflurane|
219119170|NCT05307900|OTHER|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
219119171|NCT00655070|DEVICE|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
219119172|NCT00232843|DEVICE|stent|Cordis SMART™ nitinol self-expanding stent.
219119173|NCT00232843|DEVICE|angioplasty|balloon angioplasty
219119174|NCT00006085|DRUG|CP-609,754|
219119175|NCT01152554|DRUG|TC-5214|Tablet, oral, twice daily for 52 weeks
219119176|NCT01152554|DRUG|Placebo|Tablet, oral, twice daily for 52 weeks
219119177|NCT00029627|DRUG|Yohimbine|
219119178|NCT06355908|BIOLOGICAL|IL13Rα2 CAR-T|The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.
219119179|NCT00801593|PROCEDURE|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
219119180|NCT00268229|DRUG|cytarabine|300 mg/m2/day
219119181|NCT00268229|DRUG|daunorubicin hydrochloride|45 mg/m2/day
219119182|NCT00268229|DRUG|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
219119183|NCT01071265|PROCEDURE|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
219119184|NCT01071265|PROCEDURE|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
219119185|NCT01620736|DRUG|Raltegravir|Raltegravir 400 mg po bid
219119186|NCT04783324|BEHAVIORAL|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
219119187|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（Low Dose）
219119188|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（High Dose）
219119189|NCT05459220|DRUG|Placebo|Placebo for SHR0410 Injection.
219119190|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses (new)|
219119191|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses|
219119192|NCT02967211|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219119193|NCT02967211|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219119194|NCT02967211|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219119195|NCT02967211|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219119196|NCT02967211|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219119197|NCT01693939|DEVICE|FS200 Femtosecond Laser|
219119198|NCT02718352|OTHER|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
219119199|NCT04957940|DRUG|SMOFlipid|Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
219119200|NCT04957940|OTHER|0.9% saline|Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
219119201|NCT03682822|PROCEDURE|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
219119202|NCT03682822|PROCEDURE|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
219119203|NCT05905471|OTHER|Interview|Interview study
219119204|NCT02769611|DRUG|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
219119205|NCT03911375|OTHER|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
219119206|NCT03289546|BEHAVIORAL|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
219119207|NCT03289546|BEHAVIORAL|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
219119208|NCT02321085|PROCEDURE|Sinus Rhythm control|
219119209|NCT02321085|PROCEDURE|Pulse Rate control|
219119210|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
219119211|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
219119212|NCT05856474|OTHER|pancreatectomy|pancreaserving surgery, using end to side or end to end, pancreaticojejunostomy
219119213|NCT05620017|DRUG|BAT8008 for Injection|Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
219119214|NCT01236027|OTHER|no intervention|not applicable-no intervention
219119215|NCT03781011|BEHAVIORAL|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
219119216|NCT00030654|DRUG|bicalutamide|
219119217|NCT00030654|DRUG|docetaxel|
219119218|NCT00030654|DRUG|doxorubicin hydrochloride|
219119219|NCT00030654|DRUG|estramustine phosphate sodium|
219119220|NCT00030654|DRUG|flutamide|
219119221|NCT00030654|DRUG|ketoconazole|
219119222|NCT00030654|DRUG|paclitaxel|
219119223|NCT00030654|DRUG|releasing hormone agonist therapy|
219119224|NCT00030654|DRUG|vinblastine sulfate|
219119225|NCT04858620|DRUG|Xlear Nasal Spray|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
219119226|NCT04858620|DRUG|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
219119227|NCT01029600|PROCEDURE|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
219119228|NCT01029600|PROCEDURE|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
219225572|NCT06749327|BEHAVIORAL|High UPF, high hPDI diet|High ultra-processed foods (UPFs) and healthy plant based diet
219119229|NCT02703285|OTHER|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
219119230|NCT02129569|OTHER|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
219119231|NCT02129569|BEHAVIORAL|behavioral intervention|Receive individualized walking prescription and wear pedometer
219119232|NCT02129569|OTHER|counseling intervention|Receive supplemental counseling support over the phone
219119233|NCT02129569|OTHER|educational intervention|Receive NCI educational booklets and a link to the ACS website
219225573|NCT06749327|BEHAVIORAL|Low UPF, high hPDI diet|Low ultra-processed foods (UPFs) and high healthy plant-based diet
219225574|NCT06778278|BEHAVIORAL|Transition Health and Resilience through Valued Experiences (THRiVE) Program|Six (6) total weekly, 90-minute, small-group, peer-led sessions delivered virtually
219225575|NCT06899607|OTHER|Fibre arm|Increasing daily fibre intake by 10 grams
219119234|NCT02129569|OTHER|telephone-based intervention|Receive calls that are primarily social in nature
219119235|NCT02129569|OTHER|questionnaire administration|Ancillary studies
219119236|NCT02129569|OTHER|quality-of-life assessment|Ancillary studies
219119237|NCT01944982|BIOLOGICAL|Expanded haploidentical natural killer cells (NKAEs)|
219119238|NCT04019821|DRUG|Insulin Glulisine|A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
219119239|NCT04019821|DRUG|Insulin Aspart|A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
219119240|NCT04019821|DRUG|Insulin Lispro|A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
219119241|NCT05145556|DEVICE|Videolarygoscopy|In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
219119242|NCT05145556|DEVICE|conventional laryngoscopy|In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
219119243|NCT00184028|DRUG|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
219119244|NCT00184028|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
219119245|NCT02760862|DRUG|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
219119246|NCT02760862|DRUG|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
219119247|NCT00191685|DRUG|duloxetine|
219119248|NCT00908856|BIOLOGICAL|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
219119249|NCT00908856|BIOLOGICAL|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
219119250|NCT00908856|DRUG|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
219119251|NCT00256139|DRUG|Raptiva|
219119252|NCT02179645|DRUG|GRC 27864|
219119253|NCT02179645|DRUG|Celecoxib|
219119254|NCT02179645|DRUG|Placebo|
219119255|NCT01803932|BEHAVIORAL|Male-focused group violence prevention intervention|
219119256|NCT06252389|PROCEDURE|Achilles Tendon Repair augmented with Bioinductive Collagen Patch|Standard Achilles Tendon Repair augmented with Bioinductive Collagen Patch. Standard Rehabilitation Protocol.
219119257|NCT00037700|DRUG|anakinra|
219119258|NCT00037700|DRUG|pegsunercept|
219119259|NCT04879355|DEVICE|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
219119260|NCT04879355|DEVICE|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
219704792|NCT06519630|DEVICE|Rehabotics Physiotherapy|The intervention will be consisted of sessions for participants in the intervention group which includes a repetition of each of the four Sollerman AR Games named, Wallet, Key, Jar, Screwdriver and one repetition of Balloon Pop. Participants will interact with the AR Box and Block Test (BBT) and the serious games under controlled conditions. A clinician will be present throughout the whole session providing help if participants encounter any difficulties. Following the games, the clinician will initiate a stretching program using the Active Exoskeletal Aid, performing 3 sets of 10 repetitions on the finger flexors of the patient's hand. Each rehabilitation session will last 30 minutes and will be conducted three times a week. Similarly, the traditional physiotherapy training program will be prescribed for the control group and will be consisted of sessions lasting 30 minutes per day, three days per week. Both programs duration will be five weeks.
219119261|NCT03691584|DRUG|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
219119262|NCT03691584|PROCEDURE|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
219119263|NCT01354938|DRUG|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
219225576|NCT06461962|OTHER|Treatment as Usual|Peer-facilitated referral to a local primary care provider to follow-up their screening results.
219704793|NCT06519630|OTHER|Traditional Physiotherapy|Similarly, the hand functional training program prescribed for the control group consisted of sessions lasting 30 minutes per day, three days per week. Both programs lasted for five weeks and were designed by two clinical experts.
219704794|NCT05209919|DIAGNOSTIC_TEST|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
219704795|NCT00710658|BEHAVIORAL|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
219704796|NCT01129128|BIOLOGICAL|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
219704797|NCT01129128|BIOLOGICAL|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
219704798|NCT01129128|BIOLOGICAL|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
219704799|NCT04587908|DRUG|TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]|・Treatment period：oral administration for 52 weeks, BID after meal
219704800|NCT04587908|DRUG|Placebo [Ambulatory Cohort] only|"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"
219119264|NCT06488729|OTHER|Foot massage|Foot massage
219119265|NCT04424485|PROCEDURE|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
219119266|NCT04424485|PROCEDURE|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
219119267|NCT04424485|DIAGNOSTIC_TEST|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
219119268|NCT04424485|DIAGNOSTIC_TEST|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
219119269|NCT04785183|DIETARY_SUPPLEMENT|Melatonin drops|Melatonin oral administration
219119270|NCT04785183|OTHER|Placebo|Oral 5% glucose
219119271|NCT01133509|DRUG|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
219119272|NCT05843175|OTHER|Exercise and meal testing (acute stimuli)|"Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake"
219119273|NCT02424461|DRUG|Ceftriaxone|1 injection 1 g per day for 2 days
219119274|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
219119275|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
219119276|NCT02424461|DRUG|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
219119277|NCT04047069|BEHAVIORAL|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
219119278|NCT04047069|BEHAVIORAL|Awareness Training|"Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)"
219119279|NCT03112278|PROCEDURE|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
219704801|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
219704802|NCT05523596|DRUG|ICM20|small molecules
219704803|NCT05523596|DRUG|Benznidazole|small molecule
219704804|NCT06275087|DRUG|Propofol|The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
219704805|NCT06275087|DRUG|Sevoflurane|The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
219704806|NCT05043324|DRUG|AntiCov-220|The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.
219704807|NCT05043324|DRUG|AntiCov-220 (placebo)|The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.
219704808|NCT05171686|DRUG|Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
219704809|NCT06830109|DRUG|Oxymetazoline Nasal Spray|Intra-nasal alpha-adrenergic agonist and vasoconstrictor that is available over-the-counter (OTC)
219704810|NCT06830109|DRUG|Budesonide nasal spray|Intranasal corticosteroid that is available over-the-counter (OTC)
219704811|NCT03456934|OTHER|Modified infant formula|Test formula with lower protein content than standard formula
219704812|NCT03456934|OTHER|Standard infant formula|Standard infant formula
219119280|NCT03112278|PROCEDURE|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
219119281|NCT06116643|DIETARY_SUPPLEMENT|Soluble protein hydrolysate (SPHi)|Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.
219225577|NCT06461962|OTHER|Telehealth-Cardiology|"Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer~Referral for a locally performed testing including echocardiogram~Transitional care management facilitated by a remote nurse care manager and the peer"
219225578|NCT05711719|DRUG|Vericiguat|Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
219225579|NCT05711719|DRUG|Placebo|Administered the same way
219704813|NCT06829485|BEHAVIORAL|Community health workers (CHW)|Participants will meet with a Community Health Worker (CHW) who will help facilitate and provide personalized navigation to existing resources for addressing health challenges such as food insecurity and access to care. CHW will meet with participants in person or virtually at least three times for approximately 15-60 minutes for over the six month period
219704814|NCT06829485|BEHAVIORAL|Educational Materials|Participants will receive one time educational materials including information of existing health resources. Participants will be able to review materials at participant discretion.
219704815|NCT05156008|OTHER|Ultrasound-guided vascular access|Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
219704816|NCT01911949|DRUG|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
219704817|NCT06846281|DRUG|Remibrutinib oral treatment|Remibrutinib tablet taken daily
219704818|NCT06846281|DRUG|Ocrelizumab|Ocrelizumab 600mg infusion or 920mg injection
219704819|NCT06850402|DEVICE|DeepDOF Images|Women referred for consultation for cervical biopsy(ies) and/or LEEP will be recruited into the experimental group of the study.
219704820|NCT06041789|DRUG|Donepezil|10 mg tablet
219704821|NCT06041789|DRUG|Memantine|10 mg tablet
219704822|NCT04727619|BEHAVIORAL|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
219704823|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
219119282|NCT01016990|DRUG|valproic acid|
219119283|NCT01016990|GENETIC|western blotting|
219119284|NCT01016990|OTHER|laboratory biomarker analysis|
219119285|NCT01016990|OTHER|pharmacological study|
219119286|NCT02335268|DRUG|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
219225580|NCT06780553|DIAGNOSTIC_TEST|Proteomic profiling|Proteomic profiling as a diagnostic tool in the face of suspected extrahepatic cholangiocarcinoma stenosis
219225581|NCT07077395|DRUG|fezolinetant - reference formulation|fezolinetant 45 mg daily x 12 weeks
219225582|NCT07077395|DRUG|placebo|placebo daily x 12 weeks
219119287|NCT05465694|PROCEDURE|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
219119288|NCT05465694|PROCEDURE|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
219119289|NCT00000195|DRUG|Naltrexone|
219119290|NCT02706626|DRUG|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
219119291|NCT00843362|DRUG|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
219119292|NCT00843362|DRUG|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
219119293|NCT03670745|BEHAVIORAL|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
219119294|NCT03670745|BEHAVIORAL|Control group|No planning tool
219225583|NCT03671967|DRUG|Piperacillin/tazobactam|4.5 grams QID
219704824|NCT04497883|DRUG|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
219704825|NCT04497883|DRUG|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
219119295|NCT01879878|DIETARY_SUPPLEMENT|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
219119296|NCT01879878|DIETARY_SUPPLEMENT|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
219119297|NCT03065790|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)|2-Deoxy-2-\[18F\]fluoro-D-glucose (FDG)
219225584|NCT03671967|DRUG|Meropenem|1 gram TID
219225585|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
219225586|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
219225587|NCT05062980|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
219225588|NCT05062980|DRUG|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
219225589|NCT05062980|DRUG|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
219704826|NCT04497883|DRUG|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
219704827|NCT01840111|BEHAVIORAL|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
219225590|NCT05062980|DRUG|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
219225591|NCT05062980|DRUG|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
219704828|NCT01840111|BEHAVIORAL|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
219704829|NCT01850992|DEVICE|Active CPAP|Effective CPAP will be administered
219704830|NCT01850992|DEVICE|Sham CPAP|This is placebo CPAP
219119298|NCT00547664|DRUG|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
219119299|NCT00547664|OTHER|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
219119300|NCT02938390|PROCEDURE|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
219119301|NCT03207425|DRUG|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
219119302|NCT04889885|DEVICE|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
219704831|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
219704832|NCT06309394|DRUG|INCB099280|INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
219119303|NCT04889885|DEVICE|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
219119304|NCT03423901|OTHER|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
219119305|NCT00190346|DEVICE|Humidification devices: HH vs HME|
219225592|NCT06903052|DEVICE|Nurse parental support using a proactive mobile App|Nurse parental support using a proactive mobile App in symptom management for child with mechanical ventilation
219704833|NCT03570788|PROCEDURE|Amputation|Major amputation defined as at or above ankle
219704834|NCT06645158|DEVICE|Transcutaneous bilirubin level monitoring|self-monitoring by parents long-term: from birth to 30 days of age
219704835|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
219704836|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
219704837|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
219704838|NCT00888745|DRUG|placebo|Intravenous and subcutaneous ascending dose
219704839|NCT00888745|DRUG|PRO283698|Intravenous and subcutaneous ascending dose
219704840|NCT03136198|OTHER|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours"
219704841|NCT03136198|OTHER|Usual Care|Patients will receive usual AHF care
219704842|NCT03136198|DRUG|Intravenous Loop Diuretic|IV loop diuretic
219704843|NCT03136198|DRUG|Vasodilator|IV, topical, or SL Vasodilator
219704844|NCT03136198|DEVICE|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
219704845|NCT03639415|DRUG|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
219704846|NCT05774951|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
219704847|NCT05774951|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
219704848|NCT05774951|DRUG|Anastrozole|Anastrozole. Comparator. Administered per local approved label
219704849|NCT05774951|DRUG|Letrozole|Letrozole. Comparator. Administered per local approved label
219704850|NCT05774951|DRUG|Exemestane|Exemestane. Comparator. Administered per local approved label
219119306|NCT01192295|DRUG|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
219119307|NCT03460717|OTHER|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
219119308|NCT02859597|DEVICE|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
219119309|NCT02859597|DEVICE|Nasal Cannula|Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
219119310|NCT03785340|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
219225593|NCT06147063|BIOLOGICAL|AZD9838|Intramuscular (IM) injection.
219225594|NCT06147063|BIOLOGICAL|Licensed mRNA vaccine|Intramuscular (IM) injection.
219225595|NCT06147063|BIOLOGICAL|AZD6563|Intramuscular (IM) injection.
219225596|NCT06192927|DRUG|TenoMiR|Single intralesional injection
219704851|NCT04156529|BEHAVIORAL|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
219704852|NCT04156529|BEHAVIORAL|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
219704853|NCT01503788|DRUG|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
219704854|NCT06555796|DRUG|Xaluritamig|IV infusion
219704855|NCT05692726|OTHER|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
219704856|NCT05871801|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylenglycol (PEG) solution, 2 Liters of PEG-Asccorbic acid or 2L sodium picosulphate.
219704857|NCT05871801|DEVICE|Colonoscopic examination|Colonoscopy will be performed to every patient included in the study
219704858|NCT04512105|DRUG|Pitavastatin|Given PO
219704859|NCT04512105|DRUG|Venetoclax|Given PO
219704860|NCT05642208|DRUG|Dupilumab step-down|step down dupilumab injections
219704861|NCT00435617|DEVICE|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
219704862|NCT02309021|OTHER|Sport|
219704863|NCT02309021|OTHER|Non-sport activities|
219704864|NCT03142893|DRUG|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
219704865|NCT03142893|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
219704866|NCT03142893|DRUG|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
219704867|NCT03142893|DRUG|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
219704868|NCT03142893|DRUG|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
219704869|NCT03142893|DRUG|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
219119311|NCT03785340|DRUG|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
219119312|NCT04682574|DRUG|Vitamin C|mega dose is given to the selected critically ill patients
219119313|NCT01444976|DRUG|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
219704870|NCT03142893|DRUG|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
219704871|NCT03142893|DRUG|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
219704872|NCT03142893|DRUG|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
219704873|NCT03142893|DRUG|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
219704874|NCT03142893|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
219704875|NCT03142893|DRUG|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
219704876|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
219704877|NCT05570253|DRUG|Eribulin|Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
219704878|NCT05570253|DRUG|SDX-7320|SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
219704879|NCT05570253|OTHER|Placebo|Placebo
219704880|NCT05110664|DRUG|PYY (3-36) Peptide|oral PYY3-36 solution
219704881|NCT05110664|DRUG|Placibo|oral placebo solution
219704882|NCT02687802|OTHER|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
219704883|NCT01052948|OTHER|Retrospective study-|
219704884|NCT01052948|OTHER|Retrospective study-|
219119314|NCT01444976|BEHAVIORAL|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
219119315|NCT01444976|DRUG|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
219119316|NCT02605499|OTHER|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
219119317|NCT02519179|BEHAVIORAL|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
219119318|NCT02519179|BEHAVIORAL|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
219119319|NCT00461448|DIETARY_SUPPLEMENT|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
219704885|NCT01052948|OTHER|Retrospective study-|
219704886|NCT01052948|OTHER|Retrospective study-|
219704887|NCT02244632|DRUG|Modufolin (arfolitixorin)|IV injection every second week for 8 weeks.
219704888|NCT02244632|DRUG|Fluorouracil|IV injection every second week for 8 weeks.
219704889|NCT02244632|DRUG|Oxaliplatin|IV infusion every second week for 8 weeks.
219704890|NCT02244632|DRUG|Irinotecan|IV infusion every second week for 8 weeks.
219704891|NCT02244632|DRUG|Bevacizumab|IV infusion every second week for 8 weeks.
219704892|NCT01935115|DRUG|Propofol|Propofol anesthesia for ECT
219704893|NCT01935115|DRUG|Ketamine|Ketamine anesthesia for ECT
219704894|NCT00797758|OTHER|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
219119320|NCT03281564|OTHER|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
219119321|NCT06417645|DRUG|fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)|after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
219704895|NCT00557232|DRUG|bevacizumab|1.25mg/month
219704896|NCT00639509|BIOLOGICAL|cixutumumab|Given IV
219704897|NCT00639509|PROCEDURE|computed tomography|Undergo contrast-enhanced computed tomography
219704898|NCT00639509|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
219704899|NCT00295802|DEVICE|Integrated Imaging High Intensity Focused Ultrasound|
219704900|NCT00295802|DEVICE|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
219704901|NCT04773132|OTHER|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
219704902|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
219704903|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
219704904|NCT00683137|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
219704905|NCT03510000|DRUG|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
219119322|NCT06086808|OTHER|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
219704906|NCT03510000|DEVICE|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
219119323|NCT06086808|OTHER|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
219119324|NCT00737308|OTHER|ceramic crown|Zirconia
219119325|NCT04127344|BEHAVIORAL|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
219119326|NCT04253821|OTHER|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
219119327|NCT03746444|OTHER|General Anesthesia|The patients in general anesthesia group will undergo general anesthesia
219119328|NCT03746444|OTHER|Regional Anesthesia|The patients in Group R will be given combined spinoepidural anesthesia
219119329|NCT05049525|DRUG|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
219119330|NCT05049525|DRUG|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
219225597|NCT06192927|DRUG|0.9% Sodium Chloride Injection|Single subcutaneous injection
219119331|NCT02452229|OTHER|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
219704907|NCT03510000|BEHAVIORAL|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
219704908|NCT05818787|BEHAVIORAL|Roll Tilt Training|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
219704909|NCT05818787|BEHAVIORAL|Translation Training|The participants will be translated and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the translation stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
219704910|NCT05818787|BEHAVIORAL|Both Tilt and Translation Training|The participants will be equally tilted and translated and asked to indicate their perceived direction of self-motion (e.g., left or right) . Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds. After each trial, a three second period of rest will be given. Each day of training will include four blocks; 2 blocks of roll tilt and 2 blocks of translation - one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
219704911|NCT05818787|BEHAVIORAL|Placebo Control|Participants will complete home-based exercises that are not associated with improving vestibular perception or balance (e.g. saccades, smooth pursuit). Participants will sit in a comfortable chair facing out into a living space. They will then find a stationary object to the right and to the left of themselves as well as above and below their line of sight. Without moving their heads, they will look back and forth and up and down between the objects. Participants will complete a total of 400 eye motions per day for six days.
219704912|NCT00327327|DRUG|imexon|30-60 minutes IV, days 1,8,15 every 28 days
219704913|NCT00327327|DRUG|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
219704914|NCT05579132|DRUG|MK-1045|MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Each 4 week treatment cycle is followed by a 2-week treatment-free interval
219704915|NCT06524375|DRUG|Venetoclax|Venetoclax tablets will be administered as per the schedule specified in the arm.
219704916|NCT06524375|DRUG|cBTKi Monotherapy|Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
219704917|NCT06003400|DEVICE|Study treatment administration (TriO FITT)|Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).
219704918|NCT06003400|DIAGNOSTIC_TEST|Physical Examination|physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.
219704919|NCT06003400|DIAGNOSTIC_TEST|Vital Signs|vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.
219119332|NCT04044079|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
219119333|NCT04044079|DRUG|Misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
219119334|NCT04044079|DRUG|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
219119335|NCT02923895|OTHER|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
219119336|NCT02923895|OTHER|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
219119337|NCT02463162|OTHER|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
219704920|NCT06003400|DIAGNOSTIC_TEST|Hematology Blood Tests|complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,
219704921|NCT06003400|DIAGNOSTIC_TEST|Biochemistry Blood Test|urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).
219119338|NCT06206044|DRUG|Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine|Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.
219119339|NCT06184477|OTHER|PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION|we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon
219119340|NCT01627236|DRUG|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
219119341|NCT03589482|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
219119342|NCT03589482|OTHER|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
219704922|NCT06003400|DIAGNOSTIC_TEST|Wound Digital Photography|3 photographs of the wound taken before wash, after wash and after treatment.
219704923|NCT06003400|DIAGNOSTIC_TEST|Urine pregnancy test|for women with childbearing potential
219704924|NCT06003400|OTHER|Visual Analogue Scale|Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.
219704925|NCT06003400|OTHER|SF-36|SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.
219704926|NCT06003400|DIAGNOSTIC_TEST|Wounds evaluation|including size measurements and visual description.
219704927|NCT03202303|DRUG|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
219704928|NCT03202303|DRUG|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
219704929|NCT03789877|OTHER|Physical Activity|Participate in home-based walking program
219704930|NCT03789877|OTHER|Questionnaire Administration|Ancillary studies
219704931|NCT03789877|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
219119343|NCT06063317|BIOLOGICAL|CF33-CD19 IT Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
219704932|NCT03789877|PROCEDURE|Sham Intervention|Undergo sham rTMS
219704933|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
219704934|NCT01745588|DRUG|Pomalidomide|
219704935|NCT01745588|PROCEDURE|stem cell|
219704936|NCT01745588|DRUG|Dexamethasone|
219119344|NCT06063317|BIOLOGICAL|CF33-CD19 IV Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
219119345|NCT06063317|BIOLOGICAL|CF33-CD19 IT Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28 day cycle.
219704937|NCT01745588|DRUG|Clarithromycin|
219704938|NCT05295719|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
219119346|NCT06063317|BIOLOGICAL|CF33-CD19 IV Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28 day cycle.
219704939|NCT05295719|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
219704940|NCT05295719|DIETARY_SUPPLEMENT|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
219704941|NCT05295719|BEHAVIORAL|Low-intensity training|A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min.
219704942|NCT02325778|PROCEDURE|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
219704943|NCT03039075|DRUG|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
219704944|NCT06520891|DRUG|Statin and SGLT2i|Statin as atrovastatin SGLT2i as dapagliflozin
219704945|NCT03547570|OTHER|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
219704946|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
219119347|NCT06063317|DRUG|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
219119348|NCT06063317|DRUG|Hydroxyurea|Hydroxyurea will be orally administered daily.
219119349|NCT05832580|DRUG|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
219119350|NCT05832580|DRUG|Placebo|Placebo in similar capsules
219119351|NCT00813111|DRUG|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
219704947|NCT06154278|DRUG|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
219704948|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
219119352|NCT00813111|DRUG|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
219119353|NCT04776447|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
219119354|NCT04776447|DRUG|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
219119355|NCT04776447|DRUG|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
219119356|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
219119357|NCT05087095|BEHAVIORAL|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
219119358|NCT03998462|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
219119359|NCT03998462|BEHAVIORAL|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
219119360|NCT05940844|DRUG|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
219119361|NCT03588026|DRUG|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
219119362|NCT03588026|OTHER|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
219704949|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
219704950|NCT02974582|BEHAVIORAL|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
219704951|NCT02974582|BEHAVIORAL|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
219704952|NCT02974582|BEHAVIORAL|Exposure to non health related images|Control group
219704953|NCT05722015|BIOLOGICAL|Pembrolizumab Formulated with Berahyaluronidase Alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
219704954|NCT05722015|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
219119363|NCT06368687|OTHER|Anorexia nervosa plus autism|In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
219119364|NCT06443697|OTHER|No intervention|This is a secondary analysis and no intervention is implemented.
219119365|NCT06110117|DEVICE|Sterimar Stop & Protect Irritation & Dryness|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for seven days.
219119366|NCT03175575|BEHAVIORAL|Access to a community garden in deprived neighborhoods|
219704955|NCT05722015|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
219704956|NCT05722015|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
219704957|NCT05722015|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
219704958|NCT05722015|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
219704959|NCT05722015|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
219704960|NCT05722015|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
219704961|NCT05722015|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
219119367|NCT04489693|BEHAVIORAL|Ambulatory Care Coordinator Team (ACCT)|See arm description
219119368|NCT04489693|BEHAVIORAL|Comprehensive Care Physician Program (CCP)|see arm description
219119369|NCT04489693|BEHAVIORAL|Comprehensive Care Community & Culture Program (C4P)|see arm description
219119370|NCT02120885|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
219119371|NCT04780217|BIOLOGICAL|T3011|T3011 will be administered through IV drip or pumping.
219119372|NCT04029558|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
219119373|NCT04029558|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
219119374|NCT00469781|DRUG|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
219119375|NCT00469781|DRUG|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
219119376|NCT00211601|BEHAVIORAL|Disease Management Assessment|
219119377|NCT03997058|OTHER|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
219119378|NCT03997058|DRUG|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
219704962|NCT05740618|DRUG|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
219704963|NCT04513366|DRUG|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
219119379|NCT02076685|DRUG|isoniazid|dose adjustment according to the pharmacogenomic results
219119380|NCT03675243|DIAGNOSTIC_TEST|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
219119381|NCT04320615|DRUG|Tocilizumab (TCZ)|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
219119382|NCT04320615|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
219119383|NCT04268953|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
219704964|NCT04513366|DRUG|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
219704965|NCT04513366|OTHER|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
219119384|NCT03003546|OTHER|Laboratory Biomarker Analysis|Correlative studies
219119385|NCT03003546|DRUG|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
219119386|NCT03003546|OTHER|Pharmacological Study|Correlative studies
219225598|NCT06876623|DRUG|dabigatran etexilate mesylate capsules 150mg|Oral dabigatran etexilate mesylate capsules，150mg Once every seven days，two cycle T drug, two cycles R drug
219704966|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219704967|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 2|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219704968|NCT06237296|BIOLOGICAL|RSV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219704969|NCT06237296|BIOLOGICAL|hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
219119387|NCT06206980|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
219119388|NCT06206980|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
219119389|NCT01226628|BIOLOGICAL|CNTO 2476|
219119390|NCT01226628|PROCEDURE|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
219119391|NCT01427335|DRUG|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
219119392|NCT01427335|DRUG|0.9 % saline|0.9 % saline intravenous infusion
219119393|NCT01435057|PROCEDURE|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
219119394|NCT03269448|DIAGNOSTIC_TEST|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
219119395|NCT01023880|DRUG|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
219119396|NCT03356860|DRUG|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
219119397|NCT03356860|DRUG|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
219119398|NCT03356860|DRUG|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
219119399|NCT03356860|DRUG|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
219119400|NCT03752762|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
219119401|NCT03752762|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
219704970|NCT05768646|BEHAVIORAL|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
219119402|NCT01449721|DRUG|Intravenous fluid|0.9% Sodium chloride intravenous fluid
219119403|NCT06316505|BEHAVIORAL|Oral hygiene motivation with individual oral photograps|Oral photograps was taken at control sessions.
219119404|NCT05229172|DEVICE|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
219119405|NCT03490903|DEVICE|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
219119406|NCT03490903|DRUG|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
219119407|NCT03490903|DRUG|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
219119408|NCT03822624|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
219119409|NCT03822624|OTHER|Placebo|Placebo comparator with maltodextrin as a carrier.
219119410|NCT02915718|PROCEDURE|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
219704971|NCT00892021|DRUG|NSA-789|
219704972|NCT00892021|DRUG|Placebo|
219704973|NCT02835716|DRUG|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
219704974|NCT02835716|BIOLOGICAL|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
219704975|NCT04745728|DRUG|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
219704976|NCT04745728|DRUG|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
219119411|NCT01216982|DRUG|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
219119412|NCT01216982|DRUG|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
219119413|NCT02793635|DEVICE|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
219119414|NCT05748782|OTHER|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
219119415|NCT05748782|DEVICE|Endotracheal tube|BASKA Mask
219119416|NCT05683522|OTHER|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
219119417|NCT05683522|OTHER|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
219119418|NCT05683522|OTHER|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
219119419|NCT00491725|DRUG|repaglinide|
219704977|NCT04745728|DRUG|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
219704978|NCT02713672|OTHER|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
219704979|NCT01426581|BEHAVIORAL|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
219704980|NCT01426581|BEHAVIORAL|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
219704981|NCT03424278|OTHER|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
219704982|NCT03424278|OTHER|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
219704983|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
219704984|NCT05227716|DRUG|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
219704985|NCT06200103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219704986|NCT06200103|PROCEDURE|Bone Scan|Undergo bone scan
219704987|NCT06200103|OTHER|Clinical Observation|Undergo active monitoring
219119420|NCT00491725|DRUG|metformin|
219119421|NCT04600401|OTHER|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
219119422|NCT02654795|RADIATION|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
219119423|NCT05441358|PROCEDURE|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
219119424|NCT03734159|DRUG|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
219704988|NCT06200103|PROCEDURE|Computed Tomography|Undergo SPECT/CT or PET/CT
219704989|NCT06200103|OTHER|Gallium Ga 68 Gozetotide|Given IV
219704990|NCT06200103|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
219704991|NCT06200103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219704992|NCT06200103|OTHER|Questionnaire Administration|Ancillary studies
219704993|NCT06200103|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219119425|NCT03734159|DRUG|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
219119426|NCT03334760|OTHER|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
219119427|NCT02658292|DRUG|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
219704994|NCT06360484|DIAGNOSTIC_TEST|investigations for Hepatitis D virus|Investigations included liver function tests, abdominal ultrasounds to identify features of chronic liver disease, and evidence of decompensation. ELISA for Ant-HDV-IgG was conducted.
219704995|NCT01498549|DRUG|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
219704996|NCT01498549|DRUG|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
219704997|NCT04478266|DRUG|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
219119428|NCT02658292|DRUG|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
219119429|NCT06058143|PROCEDURE|CLIF-LP|CLIF-LP surgery method was applied
219119430|NCT06058143|PROCEDURE|TLIF|TLIF surgery method was applied
219119431|NCT00003509|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219119432|NCT05270382|OTHER|cetylpyridinium chloride|The mouthwash is used to see the effects on wound healing and the oral microbiome.
219119433|NCT05353738|BIOLOGICAL|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
219704998|NCT04478266|DRUG|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
219704999|NCT04478266|DRUG|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
219705000|NCT04478266|DRUG|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
219705001|NCT04478266|DRUG|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
219705002|NCT04478266|DRUG|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
219705003|NCT05385770|DRUG|AZM X mg + AML Y mg|tablet, single dose, QD, oral administration
219705004|NCT05385770|DRUG|AZM X mg + AML Y' mg|tablet, single dose, QD, oral administration
219119434|NCT05353738|OTHER|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
219119435|NCT04055285|PROCEDURE|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
219119436|NCT04055285|DEVICE|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
219225599|NCT06826703|OTHER|Experimental Group|Individuals will receive diabetes education with motivational interviewing technique based on health belief model.
219705005|NCT05385770|DRUG|AZM X' mg + AML Y mg|tablet, single dose, QD, oral administration
219705006|NCT05385770|DRUG|AZM X' mg + AML Y' mg|tablet, single dose, QD, oral administration
219705007|NCT05385770|DRUG|AZM X mg|tablet, single dose, QD, oral administration
219705008|NCT05385770|DRUG|AZM X' mg|tablet, single dose, QD, oral administration
219705009|NCT05385770|DRUG|AML Y mg|tablet, single dose, QD, oral administration
219705010|NCT05385770|DRUG|AML Y' mg|tablet, single dose, QD, oral administration
219705011|NCT06123117|PROCEDURE|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
219705012|NCT06123117|PROCEDURE|local trocar site ropivacaine infiltration|please see arm/group descriptions
219705013|NCT04058717|OTHER|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
219705014|NCT04058717|OTHER|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
219705015|NCT04058717|OTHER|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
219705016|NCT04058717|OTHER|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
219705017|NCT01937468|OTHER|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
219705018|NCT01937468|DRUG|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
219225600|NCT06476509|DRUG|LV232 40mg|oral
219225601|NCT06476509|DRUG|Escitalopram 20 mg|oral
219225602|NCT06476509|DRUG|LV232 60mg|oral
219225603|NCT06476509|DRUG|LV232 20mg|oral
219705019|NCT06222697|DRUG|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
219705020|NCT06967454|OTHER|Water|Participants will receive 600ml water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
219705021|NCT06967454|OTHER|Semi-skimmed milk|Participants will receive 600ml semi skimmed milk with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
219705022|NCT06967454|OTHER|Whey permeate|Participants will receive 600ml whey permeate with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
219705023|NCT06967454|OTHER|'Low dose' water|Participants will receive 150ml water with a strawberry flavour, across 30 minutes
219705024|NCT06222762|OTHER|Experimental arm|Personalized follow-up in adapted physical activities
219705025|NCT01842295|OTHER|Blood and sperm samples|Blood and sperm samples will be done in each visit
219705026|NCT03915431|BIOLOGICAL|NCS-01|single infusion
219705027|NCT05999747|DRUG|pudexacianinium chloride|Intravenous
219705028|NCT04513717|DRUG|Apalutamide|Given PO
219705029|NCT04513717|DRUG|Bicalutamide|Given bicalutamide
219705030|NCT04513717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219705031|NCT04513717|PROCEDURE|Bone Scan|Undergo bone scan
219705032|NCT04513717|DRUG|Buserelin|Given buserelin
219705033|NCT04513717|PROCEDURE|Computed Tomography|Undergo CT scan
219119437|NCT01672450|DRUG|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
219119438|NCT04333173|PROCEDURE|endovascular procedure|Endovascular therapies for erectile dysfunction
219119439|NCT02120989|BEHAVIORAL|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
219119440|NCT05515029|COMBINATION_PRODUCT|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
219119441|NCT03285711|DRUG|Filgotinib|200 mg tablet administered orally once daily
219119442|NCT03285711|DRUG|Lanraplenib|30 mg tablet administered orally once daily
219119443|NCT03285711|DRUG|Filgotinib placebo|Tablet administered orally once daily
219119444|NCT03285711|DRUG|Lanraplenib placebo|Tablet administered orally once daily
219705034|NCT04513717|DRUG|Degarelix|Given degarelix
219705035|NCT04513717|DRUG|Flutamide|Given flutamide
219705036|NCT04513717|DRUG|Goserelin|Given goserelin
219705037|NCT04513717|DRUG|Histrelin|Given histrelin
219705038|NCT04513717|DRUG|Leuprolide|Given leuprolide
219705039|NCT04513717|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219705040|NCT04513717|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219705041|NCT04513717|OTHER|Quality-of-Life Assessment|Ancillary studies
219705042|NCT04513717|OTHER|Questionnaire Administration|Ancillary studies
219705043|NCT04513717|RADIATION|Radiation Therapy|Undergo radiation therapy
219705044|NCT04513717|DRUG|Relugolix|Given relugolix
219705045|NCT04513717|DRUG|Triptorelin|Given triptorelin
219705046|NCT03068741|DRUG|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
219705047|NCT03068741|DRUG|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
219705048|NCT03068741|DRUG|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
219705049|NCT03068741|DRUG|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
219705050|NCT06334198|DRUG|Naldemedine|Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
219705051|NCT06334198|DRUG|Placebo|Placebo is administered orally once daily in the morning.
219705052|NCT06334198|DRUG|Tramadol|In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
219705053|NCT05388656|DRUG|Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release|0.1 mg/day transdermal patch administered for 3 weeks
219705054|NCT05388656|DRUG|Placebo|Estradiol-matched placebo patch administered for 3 weeks
219705055|NCT05388656|DRUG|Progesterone 200 mg|200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study
219705056|NCT06933069|DRUG|CMAB017|CMAB017 was administered at a preset dose, and body weight was measured before each study dose; if body weight changed ≥10% from baseline, the dose should be recalculated. Administration was by intravenous infusion: for doses ≤1000 mg, intravenous infusion lasted 60±5 min; for doses \>1000 mg, intravenous infusion lasted 90±5 min.
219705057|NCT00671788|DRUG|Dasatinib|Given orally
219705058|NCT00671788|OTHER|Laboratory Biomarker Analysis|Correlative studies
219705059|NCT03290625|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
219119445|NCT00865644|DRUG|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
219705060|NCT03290625|DRUG|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
219705061|NCT04331106|DIAGNOSTIC_TEST|Online Questionnaire|Online Questionnaire via SoSci Survey
219705062|NCT01832766|DRUG|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
219705063|NCT01832766|OTHER|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
219705064|NCT02066571|DRUG|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
219705065|NCT02066571|DRUG|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
219705066|NCT00646724|BIOLOGICAL|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
219705067|NCT02493959|BIOLOGICAL|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
219705068|NCT02493959|BIOLOGICAL|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
219705069|NCT02493959|BIOLOGICAL|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
219705070|NCT02493959|BIOLOGICAL|placebo|Infusion of saline for 2 hrs.
219705071|NCT04562376|OTHER|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
219705072|NCT04562376|OTHER|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
219119446|NCT03964025|DEVICE|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
219705073|NCT03169439|PROCEDURE|Irreversible electroporation|minimal invasive ablative technique for tumors
219705074|NCT00960427|DRUG|systemic chemotherapy|
219705075|NCT00960427|GENETIC|RNA analysis|
219705076|NCT00960427|GENETIC|gene expression analysis|
219119447|NCT00085059|DRUG|boronophenylalanine-fructose complex|
219119448|NCT02935855|DRUG|Dabigatran|
219119449|NCT02935855|DRUG|Apixaban|
219119450|NCT02935855|DRUG|Rivaroxaban|
219119451|NCT02935855|DRUG|Edoxaban|
219119452|NCT02935855|DRUG|Warfarin|
219119453|NCT02935855|DRUG|Acenocumarole|
219119454|NCT00122161|BEHAVIORAL|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
219705077|NCT00960427|GENETIC|reverse transcriptase-polymerase chain reaction|
219705078|NCT00960427|OTHER|immunohistochemistry staining method|
219119455|NCT00122161|BEHAVIORAL|Profiling performance|
219119456|NCT02431533|DIETARY_SUPPLEMENT|PX0612|PX0612 is a probiotic contained in a veggie capsule.
219119457|NCT02431533|DIETARY_SUPPLEMENT|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
219119458|NCT06520033|DEVICE|humanoid robot|"The humanoid robot will execute an educational hydration plan that will be integrated into the usual dynamics of the residence. In order to increase the fluid intake of the residents, stimulation activities will be proposed that will be carried out by the robot such as reminders, interactive activities and positive reinforcement. It will also allow the daily recording fluid intake of each residents.~This intervention will last two months."
219119459|NCT06520033|OTHER|Usual care|The center's usual hydration plan
219119460|NCT00281944|DRUG|oxaliplatin|Given IV
219119461|NCT00281944|DRUG|fluorouracil|Given IV
219119462|NCT00281944|DRUG|leucovorin calcium|Given IV
219119463|NCT00281944|OTHER|pharmacological study|Correlative studies
219119464|NCT00281944|PROCEDURE|positron emission tomography|Undergo PET scan
219119465|NCT00281944|PROCEDURE|computed tomography|Undergo PET/CT scan
219119466|NCT00885495|DRUG|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
219119467|NCT00885495|DRUG|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
219119468|NCT02107443|BEHAVIORAL|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
219119469|NCT02107443|BEHAVIORAL|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
219119470|NCT02107443|BEHAVIORAL|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
219225604|NCT06825091|RADIATION|SBRT|Standard of care SBRT (36.25 Gy in 5 fractions or 42.7 Gy in 7 fractions) for localized prostate cancer, delivered either via an adaptive or a non-adaptive image-guided treatment. Androgen deprivation therapy use and duration is at the discretion of the treating physician and patient, in accordance with standard practice based on patients' prostate cancer risk group.
219705079|NCT00960427|OTHER|laboratory biomarker analysis|
219705080|NCT00960427|PROCEDURE|endoscopic biopsy|
219705081|NCT00960427|PROCEDURE|neoadjuvant therapy|
219705082|NCT00960427|PROCEDURE|sigmoidoscopy|
219705083|NCT00960427|RADIATION|radiation therapy|
219705084|NCT05203185|OTHER|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
219705085|NCT05063240|BEHAVIORAL|Mobile phone text messaging plus prospective motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
219705086|NCT05063240|BEHAVIORAL|Standard infant feeding counselling|Standard infant feeding counselling as part of routine practice at primary healthcare facility
219705087|NCT04646278|DRUG|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
219119471|NCT01400893|DEVICE|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
219119472|NCT02528955|RADIATION|A: De-Intensification RT primary tumor region|"A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides"
219119473|NCT02528955|RADIATION|B: De-Intensification RT contralateral lymph nodes|"B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
219705088|NCT03349307|DEVICE|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
219119474|NCT02528955|RADIATION|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
219119475|NCT05560516|DRUG|Qutenza|Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
219119476|NCT05560516|DRUG|Duloxetine|Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
219119477|NCT05806099|DRUG|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
219119478|NCT03615209|DEVICE|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
219119479|NCT03615209|DEVICE|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
219119480|NCT05183009|DEVICE|eXciteOSA|eXciteOSA
219119481|NCT00471263|DRUG|Casigold|
219119482|NCT00471263|DRUG|Casimax|
219119483|NCT00471263|DRUG|Placebo|
219119484|NCT03724461|BEHAVIORAL|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
219705089|NCT05771402|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
219119485|NCT03724461|BEHAVIORAL|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
219119486|NCT03724461|BEHAVIORAL|Control (12 weeks)|No resistance training during the intervention period.
219119487|NCT03724461|BEHAVIORAL|One High Intensity resistance training session|High intensity resistance training, 1 training session
219119488|NCT03724461|BEHAVIORAL|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
219119489|NCT02589925|DEVICE|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
219119490|NCT02589925|PROCEDURE|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
219119491|NCT02589925|PROCEDURE|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
219225605|NCT07075705|PROCEDURE|Biopsy of Prostate|Undergo standard of care prostate biopsy
219705090|NCT05771402|DRUG|NAs|Once/day, 1 capsule/time, oral
219705091|NCT05771402|DRUG|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
219705092|NCT06978127|BEHAVIORAL|Technology Assisted Stepped Collaborative Care|The TĀCcare 2.0 intervention will provide pharmacotherapy recommendations and/or CBT for pain, fatigue and depression. A stepped-treatment approach will be used to intensify treatment. CBT will be provided through 12 weekly telehealth sessions (done during dialysis treatment or from home) with the behavioral specialist. Booster sessions will be used to enhance the maintenance of effect following the initial intervention to complete a total 12 month intervention. A collaborative care approach will be used so that patients' symptom management will be integrated with their dialysis treatment. Throughout the study, participants will be asked to complete phone surveys about their symptoms and health.
219705093|NCT06978127|OTHER|Usual Care Arm|Participants in the Usual Care Arm will continue with their usual care.
219119492|NCT02589925|PROCEDURE|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
219705094|NCT06615908|DRUG|Psilocybin|See treatment arm description.
219705095|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
219705096|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
219705097|NCT03879070|DEVICE|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
219705098|NCT05784051|DRUG|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
219705099|NCT05784051|DRUG|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
219705100|NCT01420159|DRUG|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
219705101|NCT05058989|DIAGNOSTIC_TEST|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
219705102|NCT05058989|OTHER|Clinical interventions and procedures|"First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
219705103|NCT04092478|OTHER|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
219705104|NCT01586052|DRUG|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
219119493|NCT04769882|DEVICE|Er:YAG Laser|"Selected Er:YAG settings: enamel removal program for adult, with normal modality (frequency: 20 Hz, energy: 400 mJ, power: 8.0 W, air: 80%, water: 60%) and dentin removal program for adult, with normal modality (frequency: 20 Hz, energy: 200 mJ, power: 4.0 W, air: 90%, water: 30%)"
219705105|NCT06804824|DRUG|VVD-159642|Oral capsules
219705106|NCT06804824|DRUG|Sotorasib|Oral tablets
219705107|NCT06804824|DRUG|Trametinib|Oral tablets
219705108|NCT06593938|DRUG|HRS-5965 capsule|HRS-5965 capsule for 24 weeks
219705109|NCT06593938|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
219705110|NCT03485599|DIAGNOSTIC_TEST|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
219705111|NCT04697797|OTHER|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
219119494|NCT03862443|BEHAVIORAL|Fixed Incentive|The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
219119495|NCT03862443|BEHAVIORAL|Drawing Incentive|The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
219119496|NCT06310122|DEVICE|Extracorporeal shockwave therapy|"Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks"
219225606|NCT07075705|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219119497|NCT06310122|DEVICE|ultrasound|"Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks"
219119498|NCT06312631|DEVICE|Putting on the gripping glove|taking measurements and putting the gripping glove on the patient
219119499|NCT06312631|OTHER|ULPA questionnaire|"The evaluation of the effectiveness of the gripping glove on the performance of the upper limb in daily life will be evaluated using the ULPA score.~The investigator asks the patient to perform a task and the ULPA collects the total number of errors made by the patient (inability/omission, imprecision, repetition, time to complete the task)"
219119500|NCT06312631|OTHER|Motor Activity Log (MAL) Questionnaire|"The MAL is a self-assessment of the integration of the upper limb into daily life. This measurement allows a quantified evaluation of the perceived performance of the use of the upper limb in the actions of daily life.~The patient will answer 30 questions about daily life and for each item, rate the quantity from 0 to 5: 0 = never uses the hemiplegic arm and 5 = uses as much as before the accident"
219119501|NCT06312631|OTHER|Fugl-Meyer Assessment Upper Extremity (FMA-UE) questionnaire|This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum).
219119502|NCT06312631|OTHER|Score Action Arm Research Test|"This questionnaire evaluates 4 different actions: Grasping an object (6 different objects to grasp), holding an object (4 different objects), pinching an object (6 different objects) and the overall movements made by the patient (3 different overall movements).~For each item, each object or each movement evaluated, the patient must rate the task on a scale of 0 to 3 (0=cannot perform any part of the test and 3=performs the test normally)"
219119503|NCT06312631|OTHER|EuroQol five-level (EQ-5D-5L) questionnaire|This questionnaire assesses the patient's state of health. 5 items are proposed (mobility, autonomy, current activity, pain, anxiety) and for each the patient must check one of the 5 propositions (no problem, mild problems, moderate problems, severe problems, incapable). The patient must also rate their state of health on a scale of 0 to 100.
219119504|NCT06312631|OTHER|Quebec User Evaluation of Satisfaction with Assistive Technology|This questionnaire assesses satisfaction with the technical aid (here the gripping glove) and the related services. The technique and related services will be evaluated by items provided to the patient and he will have to rate for each of them a score between 1 and 5 (1 = not satisfied at all and 5 = very satisfied)
219225607|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transperineal micro-ultrasound imaging
219225608|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transrectal micro-ultrasound imaging
219705112|NCT01549665|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
219705113|NCT05408364|DIETARY_SUPPLEMENT|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
219705114|NCT05408364|PROCEDURE|SRP|Scalling and root planing
219705115|NCT02396667|OTHER|5D ultrasound|Measure the femur length by 5DLB to calculate fetal weight
219705116|NCT07037082|OTHER|Self-saliva sampling|Self-saliva samples are taken every day from D1 inclusive over 1 consecutive cycle, to measure progesterone (P4) and estradiol (E2) concentrations.
219705117|NCT07037082|OTHER|Self-collection of dried blood spots|Self-blood sampling is done 5 times during the cycle to measure protéine C-Réactive (CRP) concentrations.
219705118|NCT07037082|OTHER|Wearing the connected ring|A connected ring is worn every day of the observed cycle, while maintaining lifestyle habits, to measure daily body temperature, assess heart rate variability and resting heart rate, evaluate physical activity and energy expenditure, assess stress level, and evaluate sleep quality.
219705119|NCT07037082|OTHER|Ovulation test|An ovulation test (Ovulatest®) is carried out from day 7 until a test is positive, or until day 39 if ovulation is not detected
219705120|NCT06711926|OTHER|Distilled water|Participants will receive 600ml distilled water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
219705121|NCT06711926|OTHER|Semi-skimmed milk|Participants will receive \~600ml semi-skimmed milk with a strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
219705122|NCT06711926|OTHER|Whey permeate|Participants will receive \~600ml whey permeate (30g sachet, rehydrated with distilled water)with strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
219705123|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by surgical resection.
219705124|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by using radiofrequency ablaion.
219705125|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy by coblation of the surface of the course of the nerve
219705126|NCT07057388|DEVICE|continous wave compaction|post operative pain measurement using continous wave compaction
219705127|NCT06747507|DRUG|Dolutegravir Pill|Dose will be based on weight; brand names will be as supplied through the respective national programs
219705128|NCT06747507|DRUG|Darunavir+Ritonavir|Dose will be based on weight
219705129|NCT07059091|DRUG|Omalizumab (Xolair®)|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
219705130|NCT07059091|DRUG|Sodium Chloride (NaCl) 0.9 %|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
219119505|NCT06312631|OTHER|Psychosocial Impact of Assistive Devices Scale (PIADS)|This questionnaire measures the effect of technical aids on the psychosocial level. 26 sentences or words are offered to the patient concerning his psychological state and the patient must evaluate them between -3 and 3 (-3 = decreased and +3: increased)
219705131|NCT06580470|BEHAVIORAL|Tailored Cognitive Behavioral Therapy for Menopause|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
219705132|NCT03074500|DEVICE|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
219705133|NCT03074500|OTHER|Sham taping|Sham taping will be performed without using any technique
219705134|NCT03074500|OTHER|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
219705135|NCT05881629|BEHAVIORAL|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
219705136|NCT05881629|BEHAVIORAL|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
219705137|NCT05668273|OTHER|education with simulated patient|Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
219705138|NCT05668273|OTHER|education with simulator|Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
219705139|NCT05668273|OTHER|control group|Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
219705140|NCT06843447|BIOLOGICAL|Raludotatug Deruxtecan|IV infusion on Day 1 of every 3-week cycle.
219119506|NCT06312631|OTHER|Goal Attainment Scale (GAS)|Carrying out an activity in the patient's real context is assessed using the Goal Attainment Scale (GAS). The doctor gives the patient objectives to achieve and the patient must give the quotation for each objective between initial state (-2), expected result (0) and best possible result (2)
219119507|NCT06312631|OTHER|installation and collection of accelerometers|The accelerometer quantitatively reports the spontaneous use of the upper limb in daily life. It counts the number of voluntary movements of the upper limbs. The amount of movement of the paretic upper limb will be expressed as a percentage of the movements of the non-paretic limb.
219705141|NCT06843447|DRUG|Carboplatin|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
219705142|NCT06843447|DRUG|Paclitaxel|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
219705143|NCT06843447|BIOLOGICAL|Bevacizumab|IV infusion on Day 1 of every 3-week cycle.
219705144|NCT06771219|DRUG|SLV-154|SLV-154
219119508|NCT06129695|PROCEDURE|Zygomatic implants|the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
219119509|NCT03318211|DRUG|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
219119510|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
219119511|NCT04222309|PROCEDURE|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
219119512|NCT03227484|DRUG|Empagliflozin 25mg|Once daily over 8 weeks
219119513|NCT03227484|DRUG|Placebo Oral Tablet|Once daily over 8 weeks
219119514|NCT04430296|PROCEDURE|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
219119515|NCT05012423|DRUG|Placebo|Matching Placebo will be administered as oral capsules.
219119516|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
219119517|NCT05012423|DRUG|Placebo|Matching Placebo will be given orally during each dosing day.
219119518|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules
219119519|NCT01638468|DEVICE|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
219119520|NCT03171168|DEVICE|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
219119521|NCT03171168|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
219705145|NCT07070895|BEHAVIORAL|Cough Management|"CoughPro is a smartphone wellness application that uses algorithms to detect and count coughs continuously and passively (similar to a step counter, but for cough). CoughPro also includes a Cough Management (CM) component, which delivers short, structured behavioral lessons (based on BCST) designed to help users recognize their urge to cough and apply cough suppression strategies in real-world settings. The Cough Management wellness feature is the key area of investigation in this study.~The novel CM program is delivered entirely through participants' devices. The application aims to help users better understand and manage their cough by coupling real-time cough detection with self-management BCST resources:~* Reduce cough frequency (coughs per hour).~* Reduce cough intensity (as measured by cough bouts).~* Improve cough-related quality of life (as reported by patients and its correlation with cough-free time as measured objectively)."
219705146|NCT07070895|DEVICE|CoughMonitor Suite|CoughMonitor Suite's smartwatch is used in this study to continuously, automatically, and passively monitor cough frequency in a fully privacy-preserving way - no audio is recorded, stored, or synced to the cloud, and no human is in the loop.
218985730|NCT02946944|DRUG|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
219119522|NCT05672004|OTHER|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
219119523|NCT05672004|OTHER|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
219119524|NCT01090037|DRUG|TRK-100STP high dose|
219119525|NCT01090037|DRUG|TRK-100STP low dose|
219119526|NCT01090037|DRUG|Placebo|
219119527|NCT03786094|DRUG|Eribulin|Eribulin alone
219119528|NCT03786094|DRUG|Balixafortide|Balixafortide + Eribulin
219119529|NCT00670982|DRUG|bevacizumab|Given intravenously every 2 weeks
219119530|NCT00670982|DRUG|vinorelbine|Given intravenously once a week
219119531|NCT00670982|DRUG|trastuzumab|Given intravenously once a week
219119532|NCT05398263|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
219119533|NCT05398263|OTHER|Placebo|Placebo subcutaneous injection
219119534|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
219119535|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
219225609|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
219705147|NCT07073963|BEHAVIORAL|Virtual Mindfulness Based Cognitive Therapy Group|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week, group-based psychological intervention that integrates principles of cognitive behavioral therapy (CBT) with training in mindfulness meditation. The intervention is designed to help participants develop greater awareness of thoughts, emotions, and bodily sensations, with the goal of preventing depressive relapse and reducing psychological distress. Each weekly session includes guided mindfulness practices (e.g., body scan, sitting meditation, mindful movement), group discussion, and cognitive-behavioral exercises focused on recognizing and disengaging from unhelpful thought patterns. Participants are assigned daily home practice using audio recordings and written materials. The MBCT intervention will be delivered over a video platform for this trial.
219705148|NCT07073963|BEHAVIORAL|Virtual sarcoidosis support group|Participants attend a once-monthly, virtual support group via secure video conferencing. Each session includes a brief didactic presentation on topics relevant to living with chronic illness (e.g., symptom management, coping strategies, navigating healthcare) followed by a facilitated group discussion. The discussion emphasizes peer support, shared experiences, and emotional processing in a safe, respectful environment. Groups are led by an experienced facilitator with experience in chronic illness care. No home practice is required.
219705149|NCT06469151|DRUG|AZD5148|Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus
219705150|NCT06469151|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
219705151|NCT06603155|BEHAVIORAL|Time restricted eating (TRE)|TRE is defined as limiting daily food intake to 10 hour period with a nightly fasting period of 14 hours.
219705152|NCT07075159|DEVICE|Hydrocolloid Wound Dressing|one time hydrocolloid dressing application
219705153|NCT06943859|DRUG|Treatment with Ketamine|Participants will receive four doses of ketamine spaced 1-6 days apart of 0.75 mg/kg intramuscular ketamine (n=25) for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
219705154|NCT06943859|DRUG|Treatment with Active Placebo|Participants will receive four doses of an active placebo (diphenhydramine 50 mg) (n=25) spaced 1-6 days apart for two weeks (first placebo session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
219705155|NCT07150078|DIAGNOSTIC_TEST|test|Descriptive tests will be applied
219705156|NCT07155070|DRUG|Kera Sol Eye Drops|Eye drops
219705157|NCT07167485|OTHER|Assessment of sleep quality|Sleep quality will be assessed each night in intensive care using a Richards-Campbell sleep questionnaire and an intensive care sleep questionnaire, completed by the patient.
219119536|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
219119537|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
219119538|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
219119539|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
219119540|NCT06827496|DRUG|Oral antibiotic treatment|"Initial antibiotics:~Below 5 years: High-dose amoxicillin-clavulanate (8:1 ratio; 100/12.5 mg/kg/day in 3 doses) until clinical improvement and decrease in CRP, followed by dose reduction (4:1 ratio) to 50/12.5 mg/kg/day in 3 doses).~5 years and above: High-dose anti-staphylococcal penicillin (200 mg/kg/day in 4 doses) until clinical improvement and decrease in CRP, with dose reduction (100 mg/kg/day in 4 doses) after clinical improvement~Treatment duration of follow-up therapy (after initial high-dose antibiotics): One week for uncomplicated joint infections, three weeks for bone infections, and four weeks for spondylodiscitis"
219119541|NCT05895058|DEVICE|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
219119542|NCT05895058|DEVICE|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
219225610|NCT04224272|DRUG|Palbociclib|Administered orally
219225611|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
219225612|NCT04425473|DRUG|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
219225613|NCT04425473|DRUG|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
219225614|NCT06766838|PROCEDURE|1. Conventional dissection technique (group A) :|In this group, circumcision is performed by the dorsal slit technique. A slit is made dorsally to the level of about 5 mm from the coronal sulcus, and the redundant foreskin and mucosa were excised circumferentially. Hemostasis is secured with ligation , and the cut edges are sutured with absorbable suture. Then, dressing is applied.
219225615|NCT06766838|PROCEDURE|2. Bone cutting forceps technique (Group B)|Two mosquito forceps are used to grasp the foreskin. The glans penis is squeezed back to avoid its injury. After that, bone cutting forceps is applied to the foreskin for 3 minutes, at the level of the mark, then the foreskin is excised by scalpel at the same level. Bleeding points are ligated and the cut edges are sutured with absorbable suture. Then, a dressing is applied
219705158|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.03 mg/kg.
219705159|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.07 mg/kg.
219705160|NCT07169240|DRUG|BT-114143|3 subjects will receive a single dose of BT-114143 injection at 0.15 mg/kg.
219705161|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.3 mg/kg.
219705162|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.6 mg/kg.
219119543|NCT03396536|OTHER|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
219119544|NCT04367194|BEHAVIORAL|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
219119545|NCT01513967|DRUG|RPh201, botanical drug product|SC administration at varying doses
219119546|NCT01513967|DRUG|Placebo|SC administration at varying doses
219119547|NCT00389090|DRUG|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
219119548|NCT06004752|DRUG|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
219119549|NCT06004752|DRUG|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
219225616|NCT06766838|PROCEDURE|3. Electro-cauterization (bipolar) assisted circumcision (Group C)|"The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by scissor with hemostasis by bipolar cauterization.~The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane."
219705163|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 1.2 mg/kg.
219705164|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 2.4 mg/kg.
219705165|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 4.8 mg/kg.
219705166|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 8.4 mg/kg.
219705167|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 12.6 mg/kg.
219705168|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 15 mg/kg.
219119550|NCT03400904|OTHER|Patients with brain injury and mechanical ventilation exposed to extubation/tracheostomy|Extubation and/or tracheostomy if applicable
219119551|NCT04752540|DRUG|Olorofim|single oral dose
219119552|NCT01548859|DRUG|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
219705169|NCT07169240|DRUG|0.9% Sodium Chloride Injection as Placebo|Except that the S1 dose group was a pilot study group with 1 subject matched to receive a placebo, all other dose groups were each matched with 2 subjects who received placebo treatment as controls.
219705170|NCT07169331|DRUG|Zanubrutinib|Administered orally
219705171|NCT07166978|BEHAVIORAL|Social story|Social story is a training method constituting of short stories to convey information in a step-by-step manner, so that ASD children can understand what to expect and how to behave in different situations in daily lives. Social stories have been implemented to introduce dentistry and improve oral hygiene to individuals diagnosed with ASD with promising results. However, the certainty of evidence for its effectiveness in reducing dental fear during dental visit was low as the results were derived from small-scaled non-randomized controlled studies.
219119553|NCT01548859|DRUG|Sevoflurane|end tidal concentration of % 0,5-8
219119554|NCT02711826|BIOLOGICAL|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
219119555|NCT02711826|DRUG|Everolimus|
219119556|NCT02711826|DRUG|Tacrolimus|
219119557|NCT02711826|DRUG|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
219119558|NCT02711826|DRUG|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
219705172|NCT07167264|OTHER|PGHD's AI intelligent model(APP)|To collect patient PRO (physical strength, pain, defecation, appetite, weight, etc.) data through the PGHD's AI intelligent model(APP), and use corpus collection cards, facial photography and other technologies to collect PGHD characteristic phenotypes.
219705173|NCT07168902|DRUG|BL1107 Low dose|Dosed twice daily for 28 days.
219705174|NCT07168902|DRUG|BL1107 High dose|Dosed twice daily for 28 days.
219705175|NCT07168902|DRUG|Timolol maleate 0.5%|Dosed twice daily for 28 days.
219705176|NCT07168941|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
219705177|NCT07168811|PROCEDURE|Hyaluronic Acid (HA)|"• After achieving complete hemostasis:~1. Mix HA (0,5% gengigel teething) with ZO powder until a mixture, then apply it on pulp stumps.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
219705178|NCT07168811|PROCEDURE|TheraCal|"• After achieving complete hemostasis:~1. TheraCal L.C will be applied directly to the radicular pulp by a disposable syringe tip and light cure will be done for 20 seconds.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
219119559|NCT02711826|DRUG|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
219119560|NCT02711826|DRUG|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
219119561|NCT02711826|PROCEDURE|Biopsy, Kidney|
219119562|NCT02711826|PROCEDURE|Blood Draw|
219119563|NCT02711826|PROCEDURE|Leukapheresis|
219119564|NCT02711826|PROCEDURE|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
219119565|NCT02710994|DRUG|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
219119566|NCT02710994|DRUG|Losec|Losec 40 mg
219705179|NCT07168811|PROCEDURE|Mineral Trioxide Aggregate|"• After achieving complete hemostasis:~1. mix MTA with sterile saline and put on pulp stumps. A moist cotton pellet was placed for initial setting.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
219705180|NCT07168135|DRUG|propofol (drug)|Withholding the continuous propofol intravenous drip upon intubating the cecum during the colonoscopy.
219705181|NCT07167615|BEHAVIORAL|Caring Connections|Participants receive the Caring Connections intervention.
219119567|NCT02906202|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
219119568|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
219119569|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
219119570|NCT01791634|PROCEDURE|proximal chevron osteotomy|
219705182|NCT07167615|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive treatment as usual.
219705183|NCT07169552|DRUG|HC010|HC010 Q3W intravenous infusion
219705184|NCT07168421|DRUG|Landiolol|The main dose range is 1-40 mcg/kg/min, titrated to the effect on heart rate aiming for a heart rate of below 90 beats per minute throughout. This dose can be decreased to 0 if heart rate stays below target.
219705185|NCT07167602|BEHAVIORAL|Positional Release Therapy|A manual therapy technique applied to the medial and lateral hamstrings after conventional physiotherapy. In PRT, the affected muscle is placed in a position of maximal comfort and relative shortening, while gentle pressure and controlled joint movements are applied. This position is held for approximately 30 seconds and repeated three times per session. The method aims to decrease neuromuscular tension, reduce pain, and promote muscle relaxation through a reflexive response. Distinct from Active Release Therapy, PRT does not involve active contractions or longitudinal tension but instead relies on positioning and relaxation to achieve therapeutic effects.
219119571|NCT01791634|PROCEDURE|proximal open wedge osteotomy with LPS system|
219119572|NCT01521325|DRUG|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
219119573|NCT02085343|BEHAVIORAL|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
219119574|NCT02085343|BEHAVIORAL|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
219119575|NCT02085343|BEHAVIORAL|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
219119576|NCT01248520|OTHER|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
219119577|NCT01248520|OTHER|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
219119578|NCT04968028|PROCEDURE|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
219119579|NCT04968028|PROCEDURE|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
219119580|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
219705186|NCT07167602|BEHAVIORAL|Active Release Therapy|A manual therapy technique applied to the hamstrings after conventional physiotherapy. ART combines therapist-applied longitudinal tension with patient movement and brief isometric contractions of both hamstrings and quadriceps. The limb is guided through specific ranges of motion to break down adhesions, restore tissue mobility, and improve flexibility. Unlike Positional Release Therapy, ART is an active technique requiring patient engagement through contractions and controlled movement against resistance, targeting scar tissue and myofascial restrictions.
219119581|NCT01194882|DRUG|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
219119582|NCT01194882|DRUG|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
219119583|NCT05039034|OTHER|Advice according to primary prevention guidelines on stroke of China|
219119584|NCT06199947|OTHER|Biopsies and Blood collection|Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
219119585|NCT00566358|PROCEDURE|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
219119586|NCT02601586|DRUG|PR Oxycodone|PR Oxycodone
219119587|NCT02601586|DRUG|Levodopa|Levodopa
219119588|NCT02601586|DRUG|Oxycodone Placebo|Placebo of PR Oxycodone
219119589|NCT02601586|DRUG|Levodopa placebo|
219119590|NCT06392685|OTHER|Silane coupling agent|Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done
219119591|NCT06392685|OTHER|Adhesive containing silane.(Intervention 1 )|Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
219119592|NCT06392685|OTHER|Acid resistance silane containing adhesive.(Intervention 2)|Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
219705187|NCT07167602|OTHER|Conventional Physiotherapy|Hot pack, TENS, hamstring stretching, ankle pumps (common to both groups).
219705188|NCT07166952|DEVICE|SPRINT PNS System|This study will evaluate patient-reported outcomes, including pain and function, following standard clinical use of the SPRINT PNS System for posterior sacroiliac joint complex (PSIJC) pain.
219705189|NCT07167381|DIAGNOSTIC_TEST|xDRIVE Tumor Profiling|Patients and physicians will receive tumor profiling data via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment.
219119593|NCT04453059|DRUG|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
219119594|NCT04672356|BIOLOGICAL|IBI939|IBI939 injection
219119595|NCT04672356|BIOLOGICAL|Sintilimab|Sintilimab injection
219119596|NCT02766998|PROCEDURE|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
219119597|NCT00043888|DRUG|fosamprenavir|
219119598|NCT00043888|DRUG|COMBIVIR|
219119599|NCT00043888|DRUG|ritonavir|
219119600|NCT00043888|DRUG|TRIZIVIR|
219119601|NCT00008047|DRUG|fluorouracil|
219119602|NCT00008047|DRUG|hydroxyurea|
219119603|NCT00008047|DRUG|paclitaxel|
219705190|NCT07169305|PROCEDURE|Deep Margin Elevation|The tooth preparation is performed using conventional diamond burs. The extent of caries decides the group into which the participant falls. A precontoured sectional matrix (Palodent) with a properly sized plastic diamond wedge (Bioclear Matrix Systems) is applied and stabilized using a separating ring to ensure closure of deep cervical margins, adaptation of the matrix cervically and attain contact tightness. A 37% phosphoric acid etch gel is used for Selective Enamel Etching technique for 15-20 seconds. Two coats of adhesive are applied to both enamel and dentin using a microbrush and light cured. Flowable bulkfill composite (SDR plus, Dentsply, Sirona) restorative composite is placed using teflon coated hand instruments to perform DME till the level of CEJ and light cured for 20s. Further build up of proximal box is done using packable composite. The restoration is finished using fine grit yellow coded tapered diamond stones. Polishing done by using Composite Polishing kits.
219705191|NCT07168278|DRUG|TNK|a dose of 0.25 mg/kg (max 25 mg) administered as a bolus
219119604|NCT00008047|PROCEDURE|conventional surgery|
219119605|NCT00008047|RADIATION|radiation therapy|
219705192|NCT07168278|DRUG|Standard medical treatment|antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.
219705193|NCT07169344|RADIATION|preoperative|The radiotherapy will be delivered 2.85 Gy x 15 for both x-ray or proton radiotherapy. A comparative doseplan will decide if the patient will receive proton og x-ray radiotherapy.
219705194|NCT07169344|OTHER|Quality of life|Questionnaire
219705195|NCT07169344|OTHER|Functional outcome|Questionnaire
219705196|NCT07168356|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219705197|NCT07169006|DRUG|Group 1|Will receive a single dose of gabapentin 300 mg preoperatively before standard general anesthesia
219119606|NCT00428064|DRUG|Sirolimus|
219119607|NCT00428064|DRUG|cyclosporine|
219119608|NCT03881033|OTHER|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
219119609|NCT03881033|OTHER|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
219119610|NCT02313896|BEHAVIORAL|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
219119611|NCT04478227|DRUG|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
219705198|NCT07169006|DRUG|Group 2|will receive a placebo before standard general anesthesia
219705199|NCT07169097|BIOLOGICAL|free ceftriaxone concentration dosage|The proportion of patients with UTI for whom the time spent with a free ceftriaxone concentration above 1x MIC is 100% will be determined by calculating the ratio of the total number of patients meeting this criterion to the total number of patients included. Plasma ceftriaxone dosages will be integrated into a structural model from the scientific literature using the MonolixSuite 2023R1® package (Lixoft - Saclay) including a modeling module (Monolix) and a simulation module (Simulx). T. Individual pharmacokinetic parameters will be determined by Bayesian estimation by integrating the dosage performed in the protocol.
219705200|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter
219119612|NCT02476097|DRUG|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
219119613|NCT02476097|OTHER|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
219119614|NCT02476097|DRUG|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
219119615|NCT01799772|BEHAVIORAL|Comprehensive Behavioral Intervention|"1. Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~2. Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~3. Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~4. Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
219119616|NCT01799772|OTHER|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
219119617|NCT01133860|DRUG|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
219119618|NCT03017144|OTHER|Pit crew model education|A pit crew model for resuscitation is educated to all resuscitation team members.
219119619|NCT01079624|OTHER|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
219119620|NCT01500746|PROCEDURE|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
219119621|NCT01500746|OTHER|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
219119622|NCT03195920|DEVICE|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
219119623|NCT04052230|OTHER|ultrasound measure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
219119624|NCT05322135|DRUG|18F-FSPG|Given by vein (IV)
219705201|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter
219705202|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter
219705203|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter
219705204|NCT07167329|DRUG|Belzutifan|Patients with Von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan.
219705205|NCT07167563|OTHER|Lithium (LI) based on clinical indication|Participants have for 4 weeks a pill box registering the time for lithium intake. Weekly phone calls will assess whether patients can remember the time for lithium intake.
219705206|NCT07167303|OTHER|VR Training)|Participants were first introduced to the VR simulator and briefed on the current scenario. Through the VR headset, nurses experienced the CPR scenario in real time in an interactive environment. Each nurse had sufficient time to practice the skill steps in the given scenario. Participants used the scenario-based VR CPR training game until they felt ready (approximately 30 minutes)
219705207|NCT07167303|OTHER|Traditional Training|Nurses in the control group received traditional training in a hospital training room using an adult plastic CPR manikin
219705208|NCT07168395|DRUG|Non-selective beta blockers|Non-selective beta blockers are used in patients who have not had a previous variceal bleed to prevent bleeding by reducing blood pressure in the liver. These drugs also work by blocking beta receptors that reduce cardiac output and by causing vessel constriction in the abdominal organs, which lowers blood flow to the liver and the existing varices.
219705209|NCT07168395|PROCEDURE|Retrograde transvenous obliteration|Pre-emptive retrograde transvenous obliteration will be performed in patients randomized to this arm to evaluate the effectiveness in decreasing gastric variceal bleeding. Either CARTO or PARTO (coil or plug-assisted retrograde transvenous obliteration) will be performed using EMBOLIZATION COILS or VASCULAR PLUGS of different sizes based on the size of the shunt. Additionally, Gelfoam (collagen sponges) slurry will be injected into the shunt and varices to completely obliterate them.
219705210|NCT07167394|PROCEDURE|Interactive Virtual Reality Guidance with Restorative Dental Treatment|"Participants in this group will undergo a standardized restorative dental procedure on mandibular primary molars involving local anesthesia, caries excavation, and compomer restoration. Prior to the treatment, children will wear a virtual reality (VR) headset through which they will experience an interactive, animated educational game.~The VR content simulates the treatment steps-including sitting in the chair, receiving local anesthesia, caries removal, filling, and polishing-using engaging characters and storytelling. The aim is to reduce anxiety and perceived pain through immersive visual and cognitive distraction while standard dental procedures are being performed."
219705211|NCT07167394|PROCEDURE|Tell-Show-Do Guidance with Restorative Dental Treatment|Participants in this group will also receive a standardized restorative dental procedure identical to the VR group, including local anesthesia, caries removal, and compomer filling of mandibular primary molars. Behavioral preparation will be conducted using the conventional Tell-Show-Do technique. The clinician will verbally explain each step, demonstrate the procedure using visual and tactile tools in a child-friendly manner, and then proceed with the actual intervention. This method aims to reduce dental fear and increase compliance by familiarizing the child with the clinical environment before the surgical procedure.
219705212|NCT07167927|BEHAVIORAL|Decision support tool|Decision support tool developed for patients, parents, and providers of children with neuromuscular scoliosis
219119625|NCT05322135|DRUG|11C-Glutamine|Given by vein (IV)
219705213|NCT07168499|BEHAVIORAL|Diet Management|Visit with IBD dietician for diet management specifically for IBD
219705214|NCT07168499|BEHAVIORAL|Stress Management|Visit with IBD GI psychologist for stress management
219705215|NCT07169565|DRUG|Ibrutinib|Oral Bruton's tyrosine kinase (BTK) inhibitor administered at a fixed dose of 420 mg once daily. Capsules must be swallowed whole with water; do not open, break, or chew. If a dose is missed by ≤6 hours, take immediately; if \>6 hours, skip the dose and resume normal schedule the next day. Avoid grapefruit and Seville oranges (moderate CYP3A inhibitors). Treatment duration: 3 cycles (28 days/cycle) or until disease progression/unacceptable toxicity. Dose reduction is mandated for specific toxicities: 420 mg → 280 mg → 140 mg → discontinuation (per protocol-specified criteria). Use with caution in hepatic impairment (Child-Pugh A: reduce to 80 mg/day; Child-Pugh B/C: contraindicated).
219119626|NCT01622712|DEVICE|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
219119627|NCT02092818|DRUG|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
219119628|NCT03677063|OTHER|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
219119629|NCT00099216|DRUG|Rivastigmine|
219119630|NCT02431728|DIETARY_SUPPLEMENT|Melatonin|5 mg capsule p.o. at bedtime daily
219119631|NCT02431728|DIETARY_SUPPLEMENT|Matched Placebo|5 mg capsule p.o. at bedtime daily
219119632|NCT05470413|DRUG|SHR0302|SHR0302 4 mg
219225617|NCT06766838|PROCEDURE|4. Thermal cauterization assisted circumcision (Group D)|The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by thermal cauterization. The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane.
219119633|NCT05470413|DRUG|SHR0302|SHR0302 8 mg
219119634|NCT05470413|DRUG|Placebo|Placebo
219119635|NCT01706965|DRUG|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
219119636|NCT01706965|DRUG|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
219119637|NCT00884520|DRUG|[F-18] VM4-037|"The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
219705216|NCT07169565|DRUG|Bendamustine|Intravenous alkylating agent dosed via a 3+3 dose de-escalation design (70 mg/m² → 60 mg/m² → 50 mg/m²). Infused over 60-120 minutes on Days 1-2 of each 28-day cycle for 3 cycles. Starting dose: 70 mg/m² (Dose Level 1); dose reduction triggered by Dose-Limiting Toxicity (DLT) events per protocol. In the dose-expansion phase, all subjects receive the MTD/RP2D established in Part 1. Concomitant live vaccines are prohibited. Dose delays (≤4 weeks) and reductions are required for Grade ≥3 hematologic/non-hematologic toxicities.
219705217|NCT07169565|DRUG|Rituximab|Intravenous anti-CD20 monoclonal antibody administered at a fixed dose of 375 mg/m² on Day 0 of each 28-day cycle for 3 cycles. Initial infusion starts at 50 mg/hour; if tolerated, increase by 50 mg/hour every 30 minutes (maximum: 400 mg/hour). Subsequent infusions start at 100 mg/hour with the same escalation. Premedication with acetaminophen and an antihistamine is required prior to each infusion. Permanently discontinue for Grade 4 infusion-related reactions or severe/life-threatening toxicity.
219705218|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
219705219|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
219705220|NCT02709902|DRUG|Adapalene/BP gel, 0.3%/2.5%|Gel
219705221|NCT02709902|DRUG|EPIDUO® FORTE|Gel
219705222|NCT02709902|DRUG|Placebo|Gel
219705223|NCT03344393|DRUG|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
219705224|NCT03344393|DRUG|Normal saline|intravenous normal saline infusion intraoperatively
219705225|NCT03997305|DEVICE|AltaValve|Transcatheter Mitral Valve Replacement
219705226|NCT03990428|BEHAVIORAL|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
219705227|NCT03244995|PROCEDURE|Mind-Body Intervention Procedure|Undergo CBMB program
219705228|NCT03244995|OTHER|Quality-of-Life Assessment|Ancillary studies
219705229|NCT03244995|OTHER|Questionnaire Administration|Ancillary studies
219705230|NCT04235764|DEVICE|modified resectoscope|The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
219705231|NCT04235764|PROCEDURE|TURBT|All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
219705232|NCT06108674|OTHER|Pharmaceutical care via telepharmacy and usual care|Pharmacotherapeutic monitoring via telephone consultation
219705233|NCT06108674|OTHER|Pharmaceutical care in-person and usual care|Face-to-face pharmacotherapeutic monitoring
219705234|NCT05751655|OTHER|Prehospital care following drowning accident|Prehospital care provided by the emergency medical service 83 (SAMU 83)
219705235|NCT02320435|DRUG|Pertuzumab|In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
219705236|NCT02320435|DRUG|Trastuzumab|If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
219119638|NCT03944980|DRUG|Docetaxel|Docetaxel injection
219119639|NCT03944980|BIOLOGICAL|PD1-T cells|PD1-T cells injection
219119640|NCT02451813|PROCEDURE|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
219119641|NCT06161103|PROCEDURE|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
219119642|NCT06161103|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
219119643|NCT05925738|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
219705237|NCT02320435|DRUG|Other Combination Anti-Cancer Therapies|If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
219705238|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
219705239|NCT04367246|OTHER|No Intervention|No intervention is assigned.
219705240|NCT04716829|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
219119644|NCT02814110|DRUG|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
219119645|NCT02506621|DEVICE|R test|
219119646|NCT02506621|DEVICE|Nuubo|
219119647|NCT02506621|DEVICE|TECHNOMED pocket ECG|
219119648|NCT02506621|DEVICE|ZIO xt patch|
219705241|NCT04594187|OTHER|Immunotherapy|All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
219119649|NCT02506621|DEVICE|MoMe|
219119650|NCT05502224|OTHER|Ergospirometry|Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
219119651|NCT05551429|BEHAVIORAL|Invitation to the CR|"1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later."
219119652|NCT06083311|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
219119653|NCT06083311|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
219119654|NCT02908854|OTHER|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
219705242|NCT04594187|OTHER|Quality-of-Life Assessment|Ancillary studies
219705243|NCT04594187|RADIATION|Radiation Therapy|Undergo nodal radiation therapy
219119655|NCT01563978|DRUG|fostamatinib|fostamatinib 100 mg twice daily
219119656|NCT01563978|DRUG|placebo|placebo
219705244|NCT06953323|DRUG|Paclitaxel/Paclitaxel-albumin|"WJB001 Capsules:120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles；"
219705245|NCT06953323|DRUG|Carboplatin/Nedaplatin|"WJB001 Capsules: 80mg(or 60mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18), Every 21 days;~Carboplatin: AUC 5 mg/ml\*min(or 4mg/ml\*min,3mg/ml\*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Nedaplatin: 100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
219705246|NCT06953323|DRUG|Paclitaxel+Carboplatin|"WJB001 Capsules: 40mg,Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel: 60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Carboplatin: AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
219705247|NCT06953323|DRUG|Niraparib|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Niraparib:Niraparib:300mg(or 200mg,100mg),Oral QD Every 21 days;"
219119657|NCT00729690|DRUG|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
219119658|NCT00729690|DRUG|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
219119659|NCT00729690|DRUG|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
219119660|NCT05800119|BEHAVIORAL|Brain-level condition|Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
219119661|NCT05800119|OTHER|Mind-level condition|Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
219705248|NCT06953323|DRUG|Bevacizumab|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Bevacizumab: 15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects；"
219705249|NCT04935632|BEHAVIORAL|prevention training|Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
219705250|NCT06290102|DRUG|TEV-56248|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
219705251|NCT06290102|DRUG|Fp MDPI|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
219119662|NCT03832725|OTHER|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
219119663|NCT03832725|OTHER|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
219119664|NCT00003639|BIOLOGICAL|recombinant interferon alfa|
219119665|NCT00003639|DRUG|chlorambucil|
219119666|NCT00003639|DRUG|dexamethasone|
219119667|NCT00003639|DRUG|idarubicin|
219119668|NCT03314649|OTHER|Observational study|Lavage of the Peritoneal Cavity
219225618|NCT06766838|PROCEDURE|5. Gomco clamp technique (Group E):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
219705252|NCT05423743|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
219705253|NCT05423743|OTHER|Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
219705254|NCT01583361|DRUG|Oxaliplatin+S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
219705255|NCT01583361|DRUG|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
219705256|NCT01246167|DEVICE|Philos|"Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group."
219705257|NCT01246167|DEVICE|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
219705258|NCT01246167|OTHER|Control group|Conservative control group
219705259|NCT01800253|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
219705260|NCT01800253|PROCEDURE|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
219705261|NCT01800253|PROCEDURE|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
219705262|NCT01800253|PROCEDURE|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
219705263|NCT01800253|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
219705264|NCT02233413|DEVICE|Active LLLT helmet application|LED helmet applied with light activated
219705265|NCT02233413|DEVICE|Non-active LLLT helmet application|LED helmet applied without light activated
219705266|NCT00090103|DRUG|dutasteride 0.5mg once daily for 4 years|combination or single agent
219705267|NCT00090103|DRUG|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
219705268|NCT00675480|PROCEDURE|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
219705269|NCT00675480|PROCEDURE|Primary angioplasty|Standard primary angioplasty with stent implantation
219705270|NCT00890162|DRUG|Epinephrine|
219705271|NCT00890162|DRUG|Omalizumab (Xolair)|
219705272|NCT00890162|DRUG|Placebos|
219705273|NCT02196103|DEVICE|Double balloon cervical catheter|
219705274|NCT05666024|OTHER||Prospective observational study
219705275|NCT05220423|OTHER|sms and emails reminders|6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
219705276|NCT05220423|OTHER|No reminders|no reminders on top of the National annual communication campaign organized by the French Health System authorities
219705277|NCT05267704|DEVICE|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
219705278|NCT01467752|PROCEDURE|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
219705279|NCT01923558|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
219705280|NCT04763967|DEVICE|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
219705281|NCT04763967|DEVICE|Standard of Care|Current Standard of Care for pediatric patients
219705282|NCT05151185|OTHER|Case Management Service Program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
219705283|NCT01082471|DRUG|Morphine 6-glucuronide|
219119669|NCT02465333|PROCEDURE|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
219119670|NCT00324012|DRUG|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
219119671|NCT00168051|DRUG|ReFacto|
219119672|NCT00168051|DRUG|Advante|
219119673|NCT01621282|OTHER|Education|A 6-month interactive course on critical appraisal
219119674|NCT01621282|OTHER|Conventional|Conventional method/no intervention
219705284|NCT01082471|DRUG|Morphine|
219705285|NCT02194465|DRUG|LY2623091|Administered orally
219705286|NCT02194465|DRUG|Tadalafil|Administered orally
219705287|NCT02194465|DRUG|Spironolactone|Administered orally
219705288|NCT02194465|DRUG|Placebo|Administered orally
219705289|NCT01408641|DRUG|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
219705290|NCT01408641|DRUG|Placebo|Placebo capsules without topiramate
219705291|NCT00279929|PROCEDURE|DHEA Replacement|
219705292|NCT02764736|DRUG|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
219705293|NCT05530005|OTHER|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
219705294|NCT01687439|DRUG|Endostar|7.5mg/m2, D1-14
219705295|NCT01687439|DRUG|Vinorelbine|25-30mg/m2, D1,8
219705296|NCT01687439|DRUG|Cisplatin|25 mg/m2, D1-3
219705297|NCT01687439|RADIATION|Radiotherapy|
219705298|NCT02232230|DRUG|Provenge|
219705299|NCT03979313|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
219705300|NCT03979313|DRUG|Placebo|Commercially available 0.9% (w/v) saline
219705301|NCT00089648|DRUG|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
219119675|NCT06016374|OTHER|telerehabilitation|"During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available."
219119676|NCT03358212|DRUG|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
219119677|NCT02788136|DRUG|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
219119678|NCT02492061|BEHAVIORAL|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
219705302|NCT01443884|DIETARY_SUPPLEMENT|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
219705303|NCT01443884|DIETARY_SUPPLEMENT|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
219705304|NCT01454752|DRUG|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
219705305|NCT01454752|OTHER|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
219705306|NCT00872118|BEHAVIORAL|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
219705307|NCT00872118|BEHAVIORAL|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
219705308|NCT03758508|DEVICE|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
219705309|NCT03758508|DEVICE|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
219119679|NCT05760430|COMBINATION_PRODUCT|PVE+cTACE+Camrelizumab+Apatinib|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
219119680|NCT05760430|COMBINATION_PRODUCT|cTACE+Atirizumab+Bevacizumab|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
219119681|NCT02999893|DRUG|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
219119682|NCT01591161|DRUG|Mapracorat|1 drop of study medication into the study eye QID for 14 days
219119683|NCT01591161|DRUG|Placebo|1 drop of vehicle into the study eye QID for 14 days.
219119684|NCT04860843|DRUG|Thoracic paravertebral block|Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
219119685|NCT04860843|DRUG|Pecs block|Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
219119686|NCT04860843|DRUG|Sham Pecs block|Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
219119687|NCT01048203|DRUG|ABR-215050|1 mg ABR-215050
219119688|NCT04239456|DEVICE|RehaCom (software)|RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
219119689|NCT02117336|DRUG|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
219119690|NCT06183515|PROCEDURE|CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash|The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
219119691|NCT03356873|DRUG|Vitamin D|Vitamin D supplementation
219705310|NCT02224417|BEHAVIORAL|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
219119692|NCT03356873|OTHER|Placebo|Placebo
219119693|NCT05085743|DIAGNOSTIC_TEST|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
219119694|NCT05278923|DEVICE|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
219119695|NCT03524274|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
219119696|NCT03524274|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
219119697|NCT02169219|DRUG|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week"
219119698|NCT02169219|DRUG|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
219119699|NCT02672163|PROCEDURE|CABG surgery|Elective CABG surgery
219119700|NCT02672163|PROCEDURE|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
219119701|NCT05733806|OTHER|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
219705311|NCT02224417|BEHAVIORAL|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~* SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~* SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~* SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
219705312|NCT02224417|BEHAVIORAL|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~* SGD 2 weekly if one glucose readings falls within the normal range,~* SGD 7 weekly if two glucose readings fall within the normal range,~* SGD 14 weekly if all three glucose readings fall within the normal range."
219705313|NCT00300053|BIOLOGICAL|CLBS14 (low-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
219705314|NCT00300053|BIOLOGICAL|CLBS14 (high-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
219705315|NCT00300053|BIOLOGICAL|placebo injection|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
219705316|NCT03347591|GENETIC|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
219705317|NCT03347591|DIAGNOSTIC_TEST|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
219705318|NCT00771108|BEHAVIORAL|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
219705319|NCT01445340|DRUG|Romidepsin (FR901228)|
219705320|NCT00423605|DRUG|Xyrem®|flexible dosing
219119702|NCT00255567|DRUG|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
219119703|NCT00255567|DRUG|Paromomycin sulphate|Paromomycin sulphate
219705321|NCT00396292|DRUG|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
219705322|NCT00396292|DRUG|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
219705323|NCT05203315|DRUG|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
219705324|NCT05203315|DRUG|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
219705325|NCT06078982|DRUG|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
219705326|NCT06078982|DRUG|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
219705327|NCT03183908|BIOLOGICAL|FLUAD®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
219705328|NCT03183908|BIOLOGICAL|Fluzone® High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
219705329|NCT02156258|DEVICE|FFDM Mammography|Standard mammography image collection
219119704|NCT00255567|DRUG|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
219119705|NCT02688920|PROCEDURE|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
219119706|NCT03881540|OTHER|tDNA-MI group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
219119707|NCT03881540|OTHER|tDNA-CC group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
219119708|NCT03881540|OTHER|UC group|Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
219705330|NCT02156258|DEVICE|DBT Mammography|Collection of breast images using DBT mammography
219119709|NCT03524313|DIAGNOSTIC_TEST|End tidal carbon monoxide|"* Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~* Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~* Evaluation of femoral veinous velocity"
219705331|NCT05031767|OTHER|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
219705332|NCT05031767|OTHER|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
219705333|NCT05031767|OTHER|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
219705334|NCT02934594|OTHER|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
219119710|NCT06227325|DRUG|RC48 combined with Sintilimab and XELOX|RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
219119711|NCT00518505|OTHER|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
219119712|NCT04019561|DRUG|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
219705335|NCT01060501|DRUG|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
219705336|NCT04413045|OTHER|Prevalence of COVID-19|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
219705337|NCT01749371|DRUG|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
219705338|NCT03290651|DIETARY_SUPPLEMENT|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
219705339|NCT03290651|DIETARY_SUPPLEMENT|Placebo|Participants will take the probiotic or placebo daily for 90 days.
219705340|NCT00132626|DRUG|[123I]ß-CIT and SPECT imaging|
219705341|NCT03977480|DRUG|Hemay007|Hemay007 will be orally administered.
219705342|NCT03977480|DRUG|Placebo|Placebo
219705343|NCT04159376|DIAGNOSTIC_TEST|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
219705344|NCT01562990|DRUG|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
219705345|NCT03920800|OTHER|Data extraction from medical files|Data extraction from medical files
219705346|NCT03920800|BIOLOGICAL|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
219119713|NCT04019561|DRUG|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
219119714|NCT04019561|DRUG|MEDI0382 low dose|MEDI0382 low dose administered subcutaneously
219119715|NCT04019561|DRUG|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
219119716|NCT04628416|DEVICE|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
219119717|NCT04628416|DEVICE|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
219119718|NCT01034761|BEHAVIORAL|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
219119719|NCT04842279|OTHER|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
219119720|NCT02344836|BEHAVIORAL|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
219705347|NCT01688713|DRUG|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
219705348|NCT01278368|PROCEDURE|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
219705349|NCT01278368|PROCEDURE|Pancreatic resection|Pancreatic resection
219705350|NCT01240746|BIOLOGICAL|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
219705351|NCT01240746|BIOLOGICAL|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
219705352|NCT01240746|BIOLOGICAL|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
219705353|NCT05393219|OTHER|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
219705354|NCT05393219|OTHER|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
219705355|NCT05393219|OTHER|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
219705356|NCT05393219|OTHER|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
219705357|NCT03738696|DRUG|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
219705358|NCT03738696|DRUG|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
219705359|NCT02049203|DRUG|Ataciguat|
219705360|NCT02049203|DRUG|Placebo|
219705361|NCT05739071|DIETARY_SUPPLEMENT|JING SI HERBAL TEA|JING SI HERBAL TEA is a food, contain with herbal extracts
219705362|NCT05739071|DIETARY_SUPPLEMENT|Placebo|Placebo will have the same appearance as JING SI HERBAL TEA
219705363|NCT05127460|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
219705364|NCT01060462|DRUG|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
219705365|NCT00559260|DEVICE|Passive monitoring with pulse-oximetry, NIBP and ECG|
219705366|NCT01595828|DRUG|Pitavastatin|
219705367|NCT00861081|BEHAVIORAL|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
219705368|NCT00861081|BEHAVIORAL|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
219705369|NCT02566005|DEVICE|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
219705370|NCT02566005|DEVICE|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
219705371|NCT02472405|DEVICE|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
219705372|NCT02472405|DEVICE|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
219705373|NCT05491577|OTHER|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
219705374|NCT00080054|DRUG|Motexafin Gadolinium Injection|
219119721|NCT02344836|BEHAVIORAL|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
219119722|NCT00290082|DRUG|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
219119723|NCT00290082|BIOLOGICAL|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
219705375|NCT02834273|BEHAVIORAL|stroke education workshops|
219705376|NCT02905708|DEVICE|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
219705377|NCT02905708|DEVICE|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
219119724|NCT00290082|OTHER|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
219119725|NCT00290082|DRUG|Loxapine|Loxapine 1 mL / 10 kg
219119726|NCT00290082|DRUG|Midazolam|Midazolam 1 mL / 10 Kg
219119727|NCT03390361|DEVICE|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
219119728|NCT03390361|PROCEDURE|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
219119729|NCT04946448|OTHER|FIT diet|Dietary intervention as add-on therapy to biologicals
219119730|NCT02044419|DRUG|lomitapide|
219119731|NCT03816592|PROCEDURE|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
219705378|NCT03246178|OTHER|MSD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
219705379|NCT03246178|OTHER|HFD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
219705380|NCT06307379|OTHER|no intervention|only observational
219705381|NCT03332342|OTHER|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
219705382|NCT03617588|DRUG|Gallium-68 THP-PSMA|Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
219705383|NCT06452550|DIAGNOSTIC_TEST|Logistic regression (LR) prediction models|Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
219705384|NCT02381691|OTHER|maternal breast milk odor|
219705385|NCT02381691|OTHER|no odor|
219705386|NCT05424120|PROCEDURE|Manual aspiration|One option from standard of care
219705387|NCT05424120|PROCEDURE|Wall suction|One option from standard of care
219705388|NCT05424120|PROCEDURE|Vacuum bottle drainage|One option from standard of care
219705389|NCT00732914|DRUG|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
219705390|NCT00732914|DRUG|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
219705391|NCT00152048|DRUG|Eflornithine hydrochloride|
219705392|NCT01184911|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
219705393|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
219705394|NCT03261401|DRUG|Placebo|Participants received placebo matched to M5717
219705395|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
219119732|NCT03816592|PROCEDURE|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
219119733|NCT06307483|BEHAVIORAL|Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
219705396|NCT02934646|DEVICE|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
219705397|NCT06305481|DEVICE|P200TE|SLO and OCT imaging
219705398|NCT03734341|DEVICE|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
219119734|NCT06307483|BEHAVIORAL|Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
219119735|NCT02886936|DEVICE|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
219119736|NCT02886936|DEVICE|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
219119737|NCT06396962|OTHER|WANG DAORONG|surgery
219119738|NCT01933347|DRUG|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
219119739|NCT02654379|BIOLOGICAL|Rituximab|Rituximab use in non-oncology indications
219119740|NCT02320721|DRUG|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
219705399|NCT03734341|DEVICE|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
219705400|NCT01451658|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
219705401|NCT03808246|OTHER|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
219705402|NCT01366391|DRUG|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
219705403|NCT00806065|DRUG|ENMD-2076|
219705404|NCT02503046|OTHER|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
219705405|NCT02503046|GENETIC|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
219705406|NCT05262179|DRUG|CTO0101|1 drop/ once or three times a day/ for 17 days divided into stage2
219705407|NCT05262179|OTHER|Placebo (vehicle)|1 drop/ once or three times a day/ for 17 days divided into stage2
219705408|NCT00599001|DRUG|SD-101|Single subcutaneous escalating dose
219705409|NCT00599001|DRUG|placebo|placebo
219705410|NCT03873584|OTHER|Fatigue|Iron deficiency anemia with fatigue symptoms
219705411|NCT06078670|DRUG|CVL218|Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
219705412|NCT00668239|DRUG|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
219705413|NCT00668239|PROCEDURE|laser therapy|pan fotocoaglulation by laser therapy
219705414|NCT00439439|RADIATION|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
219705415|NCT06158945|DIAGNOSTIC_TEST|urinary endothelin 1|assesment of endothelin 1 in urinary sample
219705416|NCT04719559|DEVICE|Laser-assisted drug delivery|All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion \& BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
219705417|NCT05110612|BEHAVIORAL|Episodic Future Thinking|Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
219119741|NCT02320721|DRUG|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
219705418|NCT05110612|BEHAVIORAL|Control Episodic Thinking|Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
219119742|NCT02320721|DRUG|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
219119743|NCT02541539|DIETARY_SUPPLEMENT|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
219119744|NCT02541539|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
219705419|NCT00102635|DRUG|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
219705420|NCT00102635|DRUG|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
219705421|NCT03871413|DEVICE|TRV-chair|Repositioning maneuvers in TRV-chair
219705422|NCT03871413|PROCEDURE|Manual repositioning maneuver|Treatment with manual repositioning maneuver
219119745|NCT03839121|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
219119746|NCT05190068|DRUG|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
219119747|NCT05654272|DIAGNOSTIC_TEST|MRI|Cardiac MRI
219119748|NCT06373588|BEHAVIORAL|Patient Navigator|The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
219119749|NCT05004064|DRUG|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
219119750|NCT05004064|DRUG|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
219119751|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
219119752|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
219119753|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
219119754|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
219119755|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
219119756|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
219119757|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
219119758|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
219119759|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
219119760|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
219705423|NCT00838851|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
219119761|NCT05289934|BEHAVIORAL|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
219119762|NCT05965167|DRUG|EBP05|Oral tablets
219119763|NCT05965167|DRUG|Forteo 20 mg|Subcutaneous injection
219119764|NCT05965167|DRUG|EBP11|Oral tablets
219119765|NCT05965167|DRUG|EBP22|Oral tablets
219119766|NCT06219486|DIAGNOSTIC_TEST|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
219705424|NCT06249971|PROCEDURE|Dermal subsitute Glyaderm + skin graft|A human donor-derived dermal substitute will be implanted together with a skin graft
219705425|NCT06249971|PROCEDURE|Skin graft alone|Skin graft alone with no dermal substitute
219705426|NCT00454077|PROCEDURE|radioiodine therapy after rhTSH|
219705427|NCT01173250|PROCEDURE|adding diverting ileostomy|
219705428|NCT01173250|PROCEDURE|omitting diverting ileostomy|
219705429|NCT04087447|PROCEDURE|Thyroidectomy|Thyroidectomy
219705430|NCT00442793|DRUG|Epoetin beta|As prescribed, 3 times weekly
219119767|NCT03841708|DEVICE|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above\>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
218985731|NCT02946944|DRUG|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
218985732|NCT04621630|DRUG|PN-235|Active Drug
218985733|NCT04621630|DRUG|Placebo|Matching Placebo
218985734|NCT03372096|DEVICE|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
218985735|NCT00329004|DRUG|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
218985736|NCT02040493|RADIATION|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
218985737|NCT06455644|OTHER|CT group|After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
218985738|NCT06455644|OTHER|DSA group|After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
218985739|NCT05317182|OTHER|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
218985740|NCT05317182|OTHER|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
218985741|NCT05317182|OTHER|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
218985742|NCT02200432|OTHER|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
218985743|NCT00040365|DRUG|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
218985744|NCT00040365|RADIATION|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
218985745|NCT03198572|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
218985746|NCT03198572|DRUG|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
218985747|NCT03198572|DRUG|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
218985748|NCT06352489|PROCEDURE|Posterior component separation technique.|By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
218985749|NCT00541931|DRUG|Dietary Supplement: LifePak Nano|Daily use
218985750|NCT01460888|DRUG|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
218985751|NCT01460888|RADIATION|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
218985752|NCT00680017|DRUG|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
218985753|NCT00680017|DRUG|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
218985754|NCT04313218|DRUG|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
218985755|NCT05297396|OTHER|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
218985756|NCT06480708|OTHER|Ketogenic diet|The ketogenic diet consisting of fats (70%), protein (20%) and carbohydrates (10%) will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
218985757|NCT06480708|OTHER|Control diet|The control diet consisting of a Mediterranean diet, at 25% fat, 20% protein and 55% carbohydrates will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
218985758|NCT03385902|OTHER|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
218985759|NCT03385902|OTHER|late start time|patients will start hemodialysis when their DIFE less than 30
218985760|NCT05402345|DRUG|GlcNAc-GlcN|GlcNAc powder - weight-dependent dose
218985761|NCT05402345|OTHER|Placebo|Placebo xylose
219705431|NCT00442793|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
219705432|NCT01160302|DRUG|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
219705433|NCT06042075|OTHER|Questionnaire on congenital birthmarks|Questions will be put to health professionals on representation using a semi-quantitative questionnaire.
219705434|NCT02234271|OTHER|Mobile Health Application|Mobile Health application for contraception information
219705435|NCT02234271|OTHER|Health Educator Counseling|Counseling via health educator
219705436|NCT03259893|OTHER|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
219705437|NCT03259893|BEHAVIORAL|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
219705438|NCT03259893|OTHER|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
219705439|NCT05124548|DIAGNOSTIC_TEST|Sleep diagnostics|On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
218985762|NCT00526513|DRUG|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
218985763|NCT01562418|BEHAVIORAL|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
218985764|NCT01562418|BEHAVIORAL|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
218985765|NCT01562418|BEHAVIORAL|control group|general instructions no intervention
218985766|NCT05595096|PROCEDURE|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
218985767|NCT06428422|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis Bl-04|4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks
218985768|NCT06428422|OTHER|Plasebo|1 g/day maltodextrin for 12 weeks
218985769|NCT05238402|DRUG|Statin|Statin on COVID 19 patienst
218985770|NCT00899574|DRUG|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
218985771|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
218985772|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
218985773|NCT01724918|DRUG|Lacosamide|
218985774|NCT04396678|BEHAVIORAL|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
218985775|NCT06312345|DRUG|Drug: ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
218985776|NCT01511198|DRUG|liraglutide|Injected subcutaneously once daily
218985777|NCT01511198|DRUG|metformin|1000 mg twice daily, administered orally
218985778|NCT06345105|DEVICE|Endoscreener QC|Artificial intelligence monitoring of effective withdrawal time
218985779|NCT06025097|DRUG|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
218985780|NCT02813824|DRUG|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
218985781|NCT02813824|DRUG|Placebo (for Aspirin 300)|Daily dose during 4 years
218985782|NCT02813824|DRUG|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
218985783|NCT02813824|DRUG|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
218985784|NCT04868162|DRUG|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg.
218985785|NCT04868162|DRUG|MRG003+HX008|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or the recommended dose by SMC; and HX008 will be administered via intravenous infusion at 3.0 mg/kg
219119768|NCT03841708|DEVICE|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
219119769|NCT01412814|DEVICE|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
219119770|NCT01412814|OTHER|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
219119771|NCT01717183|DEVICE|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
219119772|NCT01717183|DEVICE|Placebo URGO 310 3113 dressing|
219119773|NCT03027687|DEVICE|tDCS|tDCS is an electrical brain stimulation method
219119774|NCT04464837|DEVICE|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
219119775|NCT04533776|BEHAVIORAL|Celiac Disease Definition, Symptoms and Treatment|"* Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
219119776|NCT04533776|BEHAVIORAL|Difficulties Due to Celiac Disease|"* Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
219119777|NCT04533776|BEHAVIORAL|Gluten Free Diet in Celiac Disease|"* Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
219119778|NCT04533776|BEHAVIORAL|Difficulties Related to Disease in School and Social Life|"* Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
219119779|NCT04533776|BEHAVIORAL|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"* Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
219119780|NCT04533776|BEHAVIORAL|Celiac Diseae anf Future Goals|"* General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
219705440|NCT03815513|OTHER|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
219705441|NCT02145819|DRUG|hCG|
219119781|NCT04533776|OTHER|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
219119782|NCT04343222|DRUG|Bromfenac|An NSAID used to treat eye pain and swelling
219705442|NCT02145819|OTHER|LH peak|
219705443|NCT03629301|BEHAVIORAL|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
219119783|NCT04343222|DRUG|Artificial tears|eye drops to lubricate the eye and maintain moisture
219705444|NCT03629301|OTHER|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
219705445|NCT04554251|OTHER|Survey|invited questionnaire
219705446|NCT04571203|BIOLOGICAL|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
219705447|NCT05997745|DIETARY_SUPPLEMENT|study group|Patients will receive early enteral locally nutrition postoperatively following surgery for peritonitis
219705448|NCT04129541|OTHER|Same Day Discharge|Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
219705449|NCT04129541|OTHER|Overnight Hospitalization|Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
219705450|NCT04017377|DRUG|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
219705451|NCT03773783|DEVICE|Button and Bead appliance|Button and Bead appliance
219705452|NCT03773783|DEVICE|Twin Block appliance|Twin Block appliance
219705453|NCT02332642|OTHER|Immuno-monitoring|
219705454|NCT04275037|OTHER|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
219705455|NCT04275037|OTHER|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
219705456|NCT01067391|DRUG|tadalafil|20 mg tablet, administered once per study protocol
219705457|NCT01067391|DRUG|placebo|placebo tablet administered once per study protocol
219705458|NCT02690727|DRUG|RP6530|Single oral dose
219705459|NCT00097435|DRUG|Albuferon|
219705460|NCT00097435|DRUG|Ribavirin|
219705461|NCT04032938|PROCEDURE|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
218985786|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
218985787|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
218985788|NCT05929885|DRUG|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status."
218985789|NCT05059470|DRUG|Pembrolizumab|Given by IV
218985790|NCT04607746|DEVICE|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
218985791|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
218985792|NCT05154578|BIOLOGICAL|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
218985793|NCT05154578|BIOLOGICAL|Placebo|0.5 mL normal saline given by intramuscular injection
218985794|NCT06395714|OTHER|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation."
218985795|NCT06395714|OTHER|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy"
218985796|NCT05880251|BEHAVIORAL|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
219705462|NCT04416789|OTHER|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
219705463|NCT01295411|DEVICE|Magnetic Resonance Imaging|
219705464|NCT01295411|OTHER|EVALUATION NEUROPSYCHOLOGICAL|
219705465|NCT03345797|DRUG|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
219705466|NCT04649723|DRUG|Rifampin|single oral dose, 600 mg, fasted.
219705467|NCT04649723|DRUG|SHR1459|single oral dose, 200 mg, fasted.
219119784|NCT03072758|BEHAVIORAL|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
219119785|NCT03655522|DRUG|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
219119786|NCT03655522|DRUG|Placebo|There were two Placebos per group.
219225619|NCT06766838|PROCEDURE|6. Plastibell device technique (Group F):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
219705468|NCT01603147|BIOLOGICAL|normal saline|saline 225 ml
219705469|NCT01603147|BIOLOGICAL|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
219705470|NCT06094647|DEVICE|Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
218985797|NCT05880251|BEHAVIORAL|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
218985798|NCT06090604|OTHER|High intensity gait training in a balance challenging Movement amplification environment|For Aim 2, each participant will engage in ten 45-min high-intensity gait training sessions performed in a Movement Amplification Environment (MAE). Training sessions will occur 2x/week and led by a licensed Physical Therapist. The goal of each training session is to achieve 40-min of stepping practice within a targeted range of heart rate (HR) of 70 to 80% of estimated age-predicted HR max and perceived excursion (RPE) in a MAE. Each session will begin and end with a 2.5-min warm-up and cool down, with 40-min of training using two 10-min Speed-training blocks and two 10-min Balance-training blocks. Balance training activities will include lateral maneuvers, head turns, obstacle negotiation, and backward walking. The MAE gain, training speeds and balance activities will be progressively increased within and across sessions to challenge the participant.
219705471|NCT05413642|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
219705472|NCT05413642|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
219705473|NCT01782092|OTHER|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
219705474|NCT01814085|DRUG|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
219705475|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
219705476|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
218985799|NCT03631745|BEHAVIORAL|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
219119787|NCT00354367|DRUG|Certolizumab pegol|
219119788|NCT04248465|DRUG|Placebo|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
219119789|NCT04248465|BIOLOGICAL|Ravulizumab|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
219705477|NCT05876065|DRUG|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
219705478|NCT05876065|DRUG|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
219705479|NCT03229603|OTHER|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
219705480|NCT01062191|DEVICE|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
219705481|NCT01062191|DEVICE|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
219705482|NCT06055582|DIETARY_SUPPLEMENT|Bread|81g (3 slices) harvest gold white bread as standard food.
219705483|NCT06055582|DIETARY_SUPPLEMENT|Mango|250g of mango pulp of each mango variety was given to the subjects.
219705484|NCT02320409|DRUG|Sulfatinib|250mg Sulfatinib ,single dose,oral
219705485|NCT00795340|DRUG|carboplatin|Given IV
219705486|NCT00795340|DRUG|cediranib maleate|Given orally
219705487|NCT00795340|DRUG|paclitaxel|Given IV
219705488|NCT00795340|OTHER|placebo|Given orally
219705489|NCT00869596|DRUG|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
219705490|NCT00869596|DRUG|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
219705491|NCT00869596|DRUG|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
218985800|NCT06258785|DRUG|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
218985801|NCT01832649|BEHAVIORAL|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
218985802|NCT01832649|BEHAVIORAL|Health education|Supervised groups 2 times per week during 8 weeks.
218985803|NCT06083142|BIOLOGICAL|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
218985804|NCT06833268|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol.
218985805|NCT05999799|DRUG|GSK1070806|GSK1070806 will be administered.
218985806|NCT05999799|DRUG|Placebo|Placebo will be administered.
218985807|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
218985808|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
218985809|NCT04417803|BIOLOGICAL|Blood sampling|plasmatic sampling
218985810|NCT06466109|BEHAVIORAL|social robot intervention|"In the first and second courses, the patients and their parents freely interact with the social robot PARO for 30 minutes.~In the third course, patients and their parents interact with PARO for 30 minutes using a worksheet that includes naming and recording characteristics of PARO.~In the last course, patients and their parents interact with PARO for 30 minutes using a worksheet that freely recorded their observations about PARO and say goodbye to it."
218985811|NCT06105151|DRUG|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
218985812|NCT06105151|DRUG|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
218985813|NCT06105151|DRUG|VV119(FE)|A：2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2；
218985814|NCT06112808|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
218985815|NCT06112808|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
218985816|NCT04781998|DRUG|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
218985817|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
218985818|NCT02924571|DEVICE|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
218985819|NCT02924571|DEVICE|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
218985820|NCT02924571|PROCEDURE|Autograft|Autograft with bone marrow aspirate.
218985821|NCT00434954|DRUG|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
218985822|NCT00434954|DRUG|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
218985823|NCT06556511|DRUG|Zinc Sulfate|Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
218985824|NCT06556511|DRUG|Placebo|Placebo is administered with standard therapy in the placebo group for a period of 10 days.
218985825|NCT00836030|OTHER|No treatment given|No treatment given
218985826|NCT00991120|DEVICE|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
218985827|NCT02927886|PROCEDURE|Per-oral endoscopy pyloromyotomy|
218985828|NCT02927886|PROCEDURE|Intrapyloric injection of Botulinum toxin|
219119790|NCT00553020|DRUG|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
219119791|NCT03084939|BIOLOGICAL|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
219119792|NCT03084939|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
219119793|NCT03084939|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
219119794|NCT00696163|DRUG|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
219705492|NCT00869596|DRUG|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
219705493|NCT00775034|DRUG|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
219705494|NCT00775034|PROCEDURE|Drainage|Mesh repair for open incisional hernia repair with drainage
219705495|NCT03850626|BIOLOGICAL|Immunotherapy|subcutaneous injection
219705496|NCT03134807|OTHER|Observation prospective|No intervention
219119795|NCT04013490|DIETARY_SUPPLEMENT|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
219119796|NCT03621982|DRUG|ADCT-301|intravenous infusion
219705497|NCT02233257|DRUG|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
219705498|NCT00818844|DRUG|Nepafenac 0.1%|NSAID
219705499|NCT00818844|OTHER|BSS|BSS
219705500|NCT01788514|OTHER|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
219119797|NCT03621982|BIOLOGICAL|Pembrolizumab|intravenous infusion
219119798|NCT04547426|OTHER|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
219119799|NCT02166151|DRUG|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
219119800|NCT00442286|DEVICE|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
219119801|NCT04772690|OTHER|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
219119802|NCT05733819|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
219119803|NCT05733819|BEHAVIORAL|Active Walking|Walking without RAS cueing
219119804|NCT00859131|DRUG|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
219119805|NCT00859131|DRUG|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
219119806|NCT03428815|DEVICE|Prosthesis suspension liner|Liners out of phase change material will be fitted
219119807|NCT05709691|OTHER|Oculomotor therapy|Visual exercise to improve oculomotor behavior.
219119808|NCT05709691|OTHER|Adapted yoga|Muscular Stretching Therapy, postural control, respiratory physiotherapy.
219119809|NCT03691285|PROCEDURE|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
219119810|NCT01053637|DRUG|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
219119811|NCT01053637|DRUG|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
219119812|NCT04499417|DEVICE|Electromyostimulation Whole-Body-Workout|Electromyostimulation - intensity 5 (muscle stimulation)
219119813|NCT04499417|DEVICE|Electromyostimulation Sham Whole-Body-Workout|Electromyostimulation - intensity 0 (no muscle stimulation)
219705501|NCT03403049|RADIATION|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
219705502|NCT03403049|DRUG|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
219705503|NCT03403049|DRUG|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
219705504|NCT03403049|DRUG|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
219119814|NCT02378818|BEHAVIORAL|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
219119815|NCT00822315|DRUG|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
219119816|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
219119817|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
219705505|NCT03403049|DRUG|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
219705506|NCT03403049|RADIATION|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
219705507|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
219705508|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
218985829|NCT03403088|DEVICE|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
218985830|NCT03403088|DEVICE|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
219119818|NCT02722317|BEHAVIORAL|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
219119819|NCT02181972|DRUG|Gingko biloba|
219119820|NCT02181972|DRUG|Placebo|
218985831|NCT03403088|OTHER|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
218985832|NCT03403088|OTHER|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
218985833|NCT03403088|OTHER|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
218985834|NCT03403088|OTHER|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
219119821|NCT01346670|DRUG|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
219119822|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
219705509|NCT05598970|OTHER|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
219705510|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
219119823|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
219119824|NCT04201496|DEVICE|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
219119825|NCT04201496|DEVICE|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
219119826|NCT01209338|BEHAVIORAL|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
219119827|NCT01715623|BIOLOGICAL|a blood sample|Dosage of Ig
219119828|NCT03676036|DRUG|DS107E|
219119829|NCT03676036|DRUG|Vehicle|
219119830|NCT03796013|DRUG|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
219119831|NCT03796013|DRUG|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
219119832|NCT04250961|OTHER|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
219119833|NCT05471258|OTHER|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
219119834|NCT05471258|OTHER|Control: Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
219119835|NCT06159296|DEVICE|Hydroxy gas|Hydroxy gas is a combination of hydrogen and oxygen together.
219119836|NCT03758924|DRUG|ANAVEX2-73|Liquid oral solution
219705511|NCT05598970|OTHER|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
219119837|NCT03758924|DRUG|Placebo|Liquid oral solution
219119838|NCT00799071|DRUG|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
219119839|NCT03656393|DRUG|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
219119840|NCT03656393|DRUG|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
219119841|NCT03656393|DRUG|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
219119842|NCT01282320|BEHAVIORAL|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
219119843|NCT01954524|DRUG|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
219119844|NCT03993405|OTHER|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
219119845|NCT02202694|BEHAVIORAL|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
219119846|NCT05744882|PROCEDURE|coronectony|root canal treatment
219119847|NCT05744882|PROCEDURE|root canal treatment|root canal treatment
219119848|NCT02427555|OTHER|Barley kernel bread|3 days intervention with barley kernel bread
219119849|NCT02427555|OTHER|white wheat bread|3 days intervention with white wheat bread
219119850|NCT04701593|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
219119851|NCT00245011|BIOLOGICAL|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
219119852|NCT00245011|DRUG|ifosfamide|Ifosfamide administered IV.
219119853|NCT00245011|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
219119854|NCT00245011|RADIATION|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
219119855|NCT00245011|RADIATION|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
219705512|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
219705513|NCT01478646|OTHER|conventional breathing therapy|duration: 60 minutes.
219705514|NCT01478646|OTHER|reflectory breathing therapy|duration: 60 minutes.
219705515|NCT01548235|DRUG|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
219705516|NCT00527995|DRUG|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
219705517|NCT01110941|DRUG|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
219705518|NCT05042492|DEVICE|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
219705519|NCT00635505|DRUG|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
219705520|NCT00635505|DRUG|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
219705521|NCT00635505|DRUG|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
218985835|NCT06357858|DRUG|INQOVI (decitabine and cedazuridine)|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
218985836|NCT06357858|DRUG|Nivolumab|Nivolumab will be administered on D8 with every 4 week cycle.
218985837|NCT06366100|BEHAVIORAL|Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)|"In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation"
218985838|NCT06366100|BEHAVIORAL|Unified Protocol (UP)|"In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress"
218985839|NCT05310838|BEHAVIORAL|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
218985840|NCT05310838|BEHAVIORAL|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
218985841|NCT02194855|DRUG|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
218985842|NCT02194855|DRUG|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
218985843|NCT03057678|OTHER|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
218985844|NCT00687895|PROCEDURE|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides."
218985845|NCT00454623|BEHAVIORAL|drawing serum adiponectin level|
218985846|NCT00894166|DRUG|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
219119856|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for CSII users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal"
219705522|NCT05052905|DEVICE|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
219705523|NCT00847028|OTHER|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
219119857|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL"
219705524|NCT00847028|OTHER|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
219119858|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL"
219119859|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for MDI users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal"
219119860|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal"
219119861|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal"
219119862|NCT05028010|BEHAVIORAL|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
219119863|NCT04877574|PROCEDURE|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.
219119864|NCT04877574|PROCEDURE|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
219119865|NCT03050437|DRUG|Cisplatin|cisplatin is added to Pem/cis arm
219119866|NCT03050437|DRUG|Pemetrexed|Pem is applied to both arms
219119867|NCT00075803|DRUG|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.
219119868|NCT00075803|DRUG|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
219119869|NCT00650494|DRUG|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
219119870|NCT00650494|DRUG|Valtrex® 1000 mg|1000mg, single dose fed
219119871|NCT03496025|DEVICE|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
219119872|NCT06336499|OTHER|Multi-parametric MRI and image analysis by deep learning or machine learning algorithms|Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
219119873|NCT00438867|GENETIC|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
219119874|NCT00438867|GENETIC|Placebo|Control group
219119875|NCT05107778|DRUG|ASC42 10mg|ASC42 10mg orally once daily;
219119876|NCT05107778|DRUG|ASC42 15mg|ASC42 15mg orally once daily.
219119877|NCT05107778|DRUG|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
219119878|NCT05107778|DRUG|Entecavir|Entecavir 0.5 mg orally once daily.
219119879|NCT05107778|DRUG|Placebo|Placebo orally once daily.
219119880|NCT05631990|DRUG|AD-209|PO, Once daily(QD), 8weeks
219119881|NCT05631990|DRUG|AD-209-1A|PO, Once daily(QD), 8weeks
219119882|NCT05631990|DRUG|AD-209-1B|PO, Once daily(QD), 8weeks
219119883|NCT05631990|DRUG|AD-209-1C|PO, Once daily(QD), 8weeks
219119884|NCT05631990|DRUG|AD-209 placebo|PO, Once daily(QD), 8weeks
219119885|NCT05631990|DRUG|AD-209-1 placebo|PO, Once daily(QD), 8weeks
219119886|NCT04261361|BEHAVIORAL|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
219119887|NCT04261361|BEHAVIORAL|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
219119888|NCT04261361|BEHAVIORAL|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
219705525|NCT00847028|OTHER|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
219705526|NCT00847028|OTHER|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
219705527|NCT00785629|DRUG|Calcium acetate|
219705528|NCT00785629|DRUG|Lanthanum Carbonate|
219705529|NCT00785629|DRUG|Sevelamer Carbonate|
219705530|NCT00785629|DRUG|Placebo|
219705531|NCT00014014|DRUG|Lamivudine/Zidovudine|
219705532|NCT00006039|BIOLOGICAL|pegylated interferon alfa|
219705533|NCT05062473|BEHAVIORAL|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
219705534|NCT05318326|DRUG|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
219705535|NCT05318326|DRUG|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
219705536|NCT05318326|DRUG|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
219705537|NCT00851591|DRUG|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
219705538|NCT00851591|DRUG|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
219705539|NCT01114555|DRUG|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
219705540|NCT05413772|OTHER|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
219705541|NCT02458417|DEVICE|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
219705542|NCT02458417|DEVICE|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
219705543|NCT02458417|DEVICE|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
219705544|NCT02458417|DEVICE|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
219705545|NCT01543854|DRUG|RLX030|Intravenous infusion of RLX030 over 20 hrs
219705546|NCT01543854|DRUG|Placebo|Intravenous infusion of placebo over 20 hours
219119889|NCT03317379|BEHAVIORAL|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
219119890|NCT03317379|BEHAVIORAL|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
219705547|NCT00225030|DRUG|antihypertensive drugs according to current guidelines|
219705548|NCT01789268|DEVICE|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
219705549|NCT01319968|DRUG|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
219705550|NCT03200223|BEHAVIORAL|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
219705551|NCT02502500|DRUG|Celecoxib|
219705552|NCT02502500|DRUG|AKB-6548|
219705553|NCT04796415|BEHAVIORAL|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
219705554|NCT03045172|BIOLOGICAL|Platelet Rich Plasma|PRP
219705555|NCT03045172|DRUG|Placebo|Saline
219705556|NCT02469857|DRUG|AB103 0.5 mg/kg|
219119891|NCT03317379|BEHAVIORAL|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
219705557|NCT02469857|OTHER|NaCl 0.9%|
219119892|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
219119893|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
219119894|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
219119895|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
219705558|NCT06340659|BEHAVIORAL|HbAEx|Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.
219705559|NCT06340659|BEHAVIORAL|HbExergame|Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
219705560|NCT02110693|OTHER|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
219705561|NCT01489423|GENETIC|RNA analysis|
219705562|NCT01489423|GENETIC|in situ hybridization|
219705563|NCT01489423|GENETIC|polymerase chain reaction|
219705564|NCT01489423|OTHER|enzyme-linked immunosorbent assay|
219705565|NCT01489423|OTHER|flow cytometry|
219705566|NCT01489423|OTHER|immunohistochemistry staining method|
219705567|NCT01489423|OTHER|laboratory biomarker analysis|
219705568|NCT05801692|PROCEDURE|Weaning of mechanical ventilation|Weaning of mechanical ventilation is the time when the patient is ready for separation from ventilatory support until breathing without invasive support
219705569|NCT02205138|DRUG|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
219705570|NCT00002302|DRUG|Epoetin alfa|
219705571|NCT02768155|OTHER|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
219119896|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
219119897|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
219119898|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
219119899|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
219705572|NCT02768155|OTHER|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
219705573|NCT02768155|OTHER|Placebo Control|Normal Saline
219119900|NCT02661854|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
219119901|NCT02661854|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
219705574|NCT03111433|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
219705575|NCT03111433|DRUG|Insulin|multiple dose insulin injection therapy
219705576|NCT02041572|BEHAVIORAL|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
219705577|NCT05136638|BEHAVIORAL|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
219705578|NCT05136638|BEHAVIORAL|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
219119902|NCT03066570|BEHAVIORAL|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
219119903|NCT03067103|DRUG|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
219119904|NCT03067103|DRUG|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
219119905|NCT03067103|DRUG|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
219705579|NCT05136638|BEHAVIORAL|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
219705580|NCT05136638|BEHAVIORAL|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
219705581|NCT05136638|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
219119906|NCT02018315|DRUG|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
219705582|NCT03287765|DRUG|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219119907|NCT06250166|BEHAVIORAL|iPLANT diet plan and diet counselling|A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).
219705583|NCT06485505|DRUG|ISOtretinoin 10 MG|Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis
219705584|NCT06485505|DEVICE|excimer light|excimer light as an adjuvant for itraconazole in treating onychomycosis
219705585|NCT06485505|DRUG|Itraconazole 200 mg|Itraconazole alone
219705586|NCT02315183|OTHER|This is an observational Study|THis study has no intervention
219705587|NCT05169905|COMBINATION_PRODUCT|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
219119908|NCT06250166|BEHAVIORAL|Usual diet counselling|General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
219705588|NCT05169905|COMBINATION_PRODUCT|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV\_dTpa-P and RSV\_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
219119909|NCT04998695|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
219119910|NCT04998695|OTHER|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
219119911|NCT00107744|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
219119912|NCT00107744|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
219119913|NCT00107744|DIETARY_SUPPLEMENT|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
219119914|NCT02769299|RADIATION|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
219119915|NCT01725997|PROCEDURE|hook plate|Surgery with hook plate followed by physiotherapy
219119916|NCT01725997|OTHER|Physiotherapy|Patients will be following a program specific for AC joint dislocations
219119917|NCT05934097|DRUG|FT596|Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
219119918|NCT05934097|DRUG|Cyclophosphamide|750 mg/m\^2 intravenously
219119919|NCT05934097|DRUG|Doxorubicin|50 mg/m\^2 intravenously
219119920|NCT05934097|DRUG|Vincristine|1.4 mg/m\^2 (maximum dose 2 mg) intravenously
219119921|NCT05934097|DRUG|Prednisone|100 mg orally
219119922|NCT05934097|DRUG|Rituximab|375 mg/m\^2 intravenously
219119923|NCT05934097|DRUG|Bendamustine|90 mg/m\^2 IV infusion
219119924|NCT05690022|PROCEDURE|sleeve gastrectomy|Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
219119925|NCT01835561|DRUG|Pomalidomide|Single oral dose of 4-mg capsule
219119926|NCT01835561|DRUG|Pomalidomide|4-mg capsule
219119927|NCT03292042|BEHAVIORAL|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)"
219119928|NCT00408161|BEHAVIORAL|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
219705589|NCT02027493|DRUG|Reiferon R|subcutaneous injection of 100 μg/m2
219705590|NCT02027493|DRUG|Ribavirin|15 mg/kg daily on two divided doses
219705591|NCT05265754|BEHAVIORAL|sujok therapy|sujok therapy
219119929|NCT00408161|BEHAVIORAL|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
219119930|NCT00099450|DRUG|INS50589 Intravenous Infusion|
219119931|NCT05727033|BEHAVIORAL|Participatory teaching group|"The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence."
219119932|NCT05727033|BEHAVIORAL|Sham control group|"The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective."
219119933|NCT05538481|OTHER|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
219119934|NCT05538481|OTHER|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
219119935|NCT05538481|OTHER|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
219119936|NCT06662695|DIETARY_SUPPLEMENT|Ginger-based supplement|Ginger-based supplement in a dosage of 1500 mg
219119937|NCT06662695|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn flour
219119938|NCT01354106|DEVICE|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
219119939|NCT06609473|BEHAVIORAL|CHEF Intervention Program|Poverty-targeted intervention utilizing direct resource provision of healthy meal kits and groceries, as well as assisted referral and enrollment in government nutrition assistance benefits, SNAP (Supplement Nutrition Assistance Program) and/or WIC (Woman, Infants, and Children Program). Meal kits will be delivered by a commercial meal kit vendor. Grocery gift cards will be delivered via email, mail, or in-person. Kitchen equipment will be delivered to caregiver residence.
219119940|NCT01421485|BEHAVIORAL|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
219119941|NCT01421485|BEHAVIORAL|Treatment as Usual|Treatment in community, case management
219119942|NCT06918054|DIETARY_SUPPLEMENT|Dietary modification|Patients will follow Mediterranean Diet (MD), this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat was extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein
219119943|NCT06918054|DIETARY_SUPPLEMENT|Supplementation of omega 3 fatty acids|Supplementation of omega 3 fatty acids ( dose based on weight: \<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day)
219119944|NCT06916585|DRUG|AS1501 for injection|Single administration, after 20 days of elution, enter continuous administration, once a week for 4 consecutive weeks
219119945|NCT06624501|OTHER|Observational cohort study|
219119946|NCT03824535|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
219119947|NCT03824535|DRUG|Fludeoxyglucose F-18|Given IV
219119948|NCT03824535|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
219119949|NCT03824535|DIAGNOSTIC_TEST|Positron Emission Tomography (PET/CT)|Undergo PET/CT
219119950|NCT06624332|BEHAVIORAL|e-SBI main session|Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.
219119951|NCT06624332|BEHAVIORAL|e-SBI Booster Session|A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.
219119952|NCT06624332|BEHAVIORAL|Text messaging|4 weeks of daily automated text messages that reinforce content from the e-SBI main session.
219705592|NCT01537588|OTHER|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
219705593|NCT01537588|OTHER|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
219705594|NCT04831554|PROCEDURE|single chest tube drainage|place single chest tube after surgery of PSP
219705595|NCT04186273|DRUG|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
219705596|NCT04186273|OTHER|Vehicle moisture balancing base|Vehicle base without FS2.
219705597|NCT04687397|BEHAVIORAL|Rehabilitation|Multidisciplinary rehabilitation
219705598|NCT04292886|DRUG|Tamoxifen and femoston|oral
219705599|NCT04292886|DRUG|Vitamin C and femoston|Vitamin C and femoston
219705600|NCT03183440|DIETARY_SUPPLEMENT|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
219119953|NCT06744127|DRUG|BR1015|One tablet administered alone
219119954|NCT06744127|DRUG|BR1015-1|One tablet administered alone
219705601|NCT03183440|OTHER|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
219705602|NCT04968236|OTHER|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
219705603|NCT04968236|OTHER|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
219119955|NCT06744127|DRUG|BR1015-2|One tablet administered alone
219119956|NCT05196633|OTHER|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
219119957|NCT05196633|OTHER|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
219119958|NCT04305678|DRUG|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
219119959|NCT01682538|DRUG|Nitisinone, capsule|
219119960|NCT01682538|DRUG|Nitisinone, suspension|
219119961|NCT01686594|DRUG|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
219119962|NCT05455463|BEHAVIORAL|Online aphasia-adapted physical activity class|Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
219119963|NCT02283099|BIOLOGICAL|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10\^6 pfu, 2x10\^7 pfu or 3x10\^5)
219119964|NCT03575442|BEHAVIORAL|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
219119965|NCT02929290|DRUG|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
219119966|NCT00542945|DEVICE|ICD|Implantation of an ICD
219119967|NCT00542945|OTHER|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
219119968|NCT03312985|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
219119969|NCT03312985|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
219119970|NCT00283309|DRUG|Memantine|
219119971|NCT00283309|DRUG|Riluzole|
219119972|NCT05786586|DEVICE|650 nm low-level red-light|650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina
219119973|NCT04339218|DEVICE|Cryoablation|"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."
219705604|NCT04968236|OTHER|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
219705605|NCT02636621|DEVICE|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
219705606|NCT02636621|OTHER|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
219705607|NCT01842204|DEVICE|Magnetic field therapy device|Therapy device for 1 week.
219705608|NCT01842204|DEVICE|Non magnetic field therapy device.|Non-active device for 1 week.
219705609|NCT01849614|OTHER|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
219705610|NCT05273359|DRUG|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
219705611|NCT05273359|OTHER|Benralizumab placebo|15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
219705612|NCT05273359|OTHER|Comparison (control) group; no intervention|15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
219705613|NCT04009837|BEHAVIORAL|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
219225620|NCT04725266|BEHAVIORAL|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
219119974|NCT04339218|DRUG|Pembrolizumab|Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
219225621|NCT04725266|OTHER|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
219225622|NCT02556918|DRUG|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
219225623|NCT02556918|DRUG|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
219705614|NCT04009837|BEHAVIORAL|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
219705615|NCT02674659|BEHAVIORAL|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
219705616|NCT02674659|BEHAVIORAL|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
219705617|NCT06329596|DIETARY_SUPPLEMENT|Xylitol gum|Two pieces of xylitol gum after meals, thrice a day.
219705618|NCT06329596|DIETARY_SUPPLEMENT|Sorbitol gum|Two pieces of sorbitol gum after meals, thrice a day.
219119975|NCT04339218|DRUG|Pemetrexed|Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
219119976|NCT04339218|DRUG|Carboplatin|Carboplatin will be prescribed and administered at the dose recommended by market authorization.
219119977|NCT00731042|DRUG|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
219119978|NCT00731042|DRUG|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
219119979|NCT03104569|PROCEDURE|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
219119980|NCT00149721|PROCEDURE|Ventriculo-peritonal shunting|
219119981|NCT03878082|DRUG|Propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
219119982|NCT03878082|DRUG|Propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
219119983|NCT03878082|DRUG|IVPCA|pain control with IVPCA
219225624|NCT02556918|DRUG|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
219705619|NCT01066377|DIETARY_SUPPLEMENT|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
219705620|NCT06568679|OTHER|No intervention; observational|No intervention; observational
219119984|NCT05365074|DRUG|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
219119985|NCT00906295|OTHER|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
219119986|NCT00906295|OTHER|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
219119987|NCT01419301|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
219119988|NCT02692235|DIETARY_SUPPLEMENT|carnitine|1500 mg/d l-carnitine-l-tartrate
219119989|NCT02692235|DIETARY_SUPPLEMENT|placebo|isonitrogenous
219705621|NCT05530694|BEHAVIORAL|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
219705622|NCT05530694|BEHAVIORAL|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
219705623|NCT05530694|BEHAVIORAL|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
219705624|NCT04556747|OTHER|VR - Distraction|Participants will be instructed to use any application.
219705625|NCT04556747|OTHER|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
219705626|NCT00117234|DRUG|darbepoetin alfa|
219705627|NCT02266524|DRUG|Tamsulosin hydrochloride, very low dose|
219705628|NCT02266524|DRUG|Tamsulosin hydrochloride, low dose|
219705629|NCT02266524|DRUG|Tamsulosin hydrochloride, medium dose|
219705630|NCT02266524|DRUG|Tamsulosin hydrochloride, high dose|
219705631|NCT03173274|BEHAVIORAL|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
219705632|NCT03173274|BEHAVIORAL|Contingency Management|Contingent Reinforcement for negative breath CO samples
219705633|NCT03173274|BEHAVIORAL|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
219705634|NCT00970580|DRUG|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
219705635|NCT06356493|PROCEDURE|caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries|Preoperative placement of prophylactic occlusion balloons of both internal iliac arteries (OBIIA) was performed at radiology department. Access to the internal iliac arteries was achieved by retrograde transcutaneous introduction of hydrophilic sheath kits of 8.5 mm under fluoroscopic guidance from both femoral arteries. Once in the lumens of the two internal iliac arteries, the radiologist inflated the balloons until blood flow ceased. The pressure at which occlusion of both internal iliac arteries was achieved was recorded for subsequent replication in the operating room. The radiologist secured the two kits to the skin and applied a compressive dressing. The patient was then directly transferred to the operating room.
219705636|NCT06356493|PROCEDURE|caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries|"Caesarean hysterectomy was performed through a midline infraumbilical incision. The bladder-uterine peritoneum was dissected, followed by a vertical fundal hysterotomy away from the placenta, and the baby was delivered This was followed by clamping the umbilical cord and closure of the hysterotomy while leaving the placenta in situ without any attempt at traction or delivery and without oxytocin administration.~We proceeded with the remaining steps of hysterectomy."
219705637|NCT03097263|OTHER|Physical Rehabilitation program|
219705638|NCT05001048|DRUG|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
219119990|NCT01034475|DRUG|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is \>Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
219119991|NCT01219465|BIOLOGICAL|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
219119992|NCT00802841|DRUG|nilotinib|Supplied as 200 mg tablets
219119993|NCT00802841|DRUG|imatinib|Supplied as 100 mg and 400 mg tablets
219705639|NCT05001048|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
219705640|NCT05001048|OTHER|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
219225625|NCT02556918|DRUG|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal"
219705641|NCT05001048|OTHER|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
219705642|NCT03727867|DRUG|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
219705643|NCT03727867|DEVICE|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
219705644|NCT02030873|OTHER|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
219705645|NCT04995159|DRUG|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
219705646|NCT04995159|DRUG|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
219705647|NCT03417960|DEVICE|iTBS|"The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method."
219119994|NCT04312828|PROCEDURE|Orthopedic management of the Z-foot|Orthopedic treatment with femoropedic plasters and slotted splints in 1st intention
219119995|NCT05498974|OTHER|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
219119996|NCT05090982|OTHER|Audio recordings during the consultations|50 patients with audio recordings of the consultation
219119997|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
219119998|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
219119999|NCT02391220|OTHER|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
219705648|NCT06386601|OTHER|Ergonomics Knowledge|Participants will participate in a lecture/module on surgical ergonomics
219705649|NCT06386601|OTHER|Ergonomics Feedback/Guided Practice|Participants will practice minimally invasive surgical skills while receiving feedback on ergonomic positioning/practice
219120000|NCT02391220|OTHER|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
219120001|NCT02174198|DEVICE|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
219120002|NCT06410443|DRUG|Dexamethasone|Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.
219120003|NCT06410443|DRUG|Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation|Treatment according to guideline of radiation-induced intestinal injury.
219120004|NCT06423261|DRUG|GB002 Recombinant Peptide Inhalation Solution|Inhalation administration
219705650|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
219705651|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
219120005|NCT06423261|DRUG|Placebo|Inhalation administration
219120006|NCT02720887|PROCEDURE|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
219120007|NCT02711995|DRUG|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
219120008|NCT02711995|DRUG|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
219120009|NCT00377741|DRUG|valganciclovir [Valcyte]|900mg po
219120010|NCT06314191|OTHER|blood sampling|blood sampling with analyses
219120011|NCT06314191|OTHER|knee radiography|radiography of both knees in Schuss
219120012|NCT00940134|BIOLOGICAL|PYY 3-36|0.8 pmol/kg/min x 3 hours
219120013|NCT00940134|BIOLOGICAL|GLP-1|1.0 pmol/kg/min x 3 hours
219120014|NCT00940134|BIOLOGICAL|saline infusion|saline infusion x 3 hours
219120015|NCT04006795|OTHER|Serum|Participants will be topically applied adhesive patch containing developmental serum
219120016|NCT04006795|OTHER|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
219120017|NCT04006795|OTHER|Cream|Participants will be topically applied adhesive patch containing developmental cream
219120018|NCT04006795|OTHER|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
219120019|NCT04192942|OTHER|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
219120020|NCT02703961|DRUG|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
219120021|NCT02703961|DRUG|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
219120022|NCT02703961|RADIATION|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
219120023|NCT02703961|RADIATION|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
219120024|NCT02703961|DRUG|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
219705652|NCT05934019|DEVICE|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
219120025|NCT04058210|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
219120026|NCT04058210|DRUG|IVA|150-mg tablet for oral administration.
219120027|NCT00987792|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
219120028|NCT01454336|BIOLOGICAL|Cell injection|MSCs introduced into portal vein
219120029|NCT02249481|PROCEDURE|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
219705653|NCT05305859|DRUG|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
219120030|NCT02249481|PROCEDURE|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
219120031|NCT02662244|DEVICE|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
219120032|NCT00548275|BEHAVIORAL|Enhanced Sexual Risk Management|management of sexual risk
219120033|NCT00548275|BEHAVIORAL|Standard Sexual Risk Management|management of sexual risk
219120034|NCT05645913|DRUG|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
219120035|NCT03138083|DRUG|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
219120036|NCT02110927|DEVICE|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
219120037|NCT02110927|DEVICE|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
219120038|NCT00029809|BEHAVIORAL|Chinese exercise modalities|
219120039|NCT02135393|DIETARY_SUPPLEMENT|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
219120040|NCT02578602|DRUG|Gadoxetate Disodium|Given IV
219120041|NCT02578602|DEVICE|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
219120042|NCT03531905|DRUG|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
219120043|NCT03531905|DRUG|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
219120044|NCT03531905|DRUG|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
219120045|NCT03531905|DRUG|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
219120046|NCT02477943|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
219120047|NCT02477943|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
219120048|NCT00624104|DIETARY_SUPPLEMENT|Food (fat free meal)|Fat free meal (40% of REE)
219120049|NCT02516579|DRUG|Siklos|
219120050|NCT03905811|DRUG|Terazosin 5 MG|5 milligrams by mouth daily at bedtime
219120051|NCT03905811|DRUG|Placebo oral capsule|1 capsule by mouth daily at bedtime
219120052|NCT04975789|OTHER|InfoViz|The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
219705654|NCT04230434|BEHAVIORAL|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
219705655|NCT02763566|DRUG|Abemaciclib|Administered orally
219705656|NCT02763566|DRUG|Anastrozole|Administered orally
219120053|NCT04610424|BEHAVIORAL|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
219120054|NCT04610424|BEHAVIORAL|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
219120055|NCT05935280|OTHER|Room temperature|Room temperature injection
219120056|NCT05935280|OTHER|Cold temperature|Cold temperature injection
219120057|NCT05935280|DRUG|Lidocain|Unspecific sodium channel blocker
219120058|NCT05935280|DRUG|PF-05105679|Specific antagonist of the TRPM8 ion channel
219120059|NCT05935280|DRUG|A967079|Specific antagonist of the TRPA1 ion channel
219120060|NCT05935280|DRUG|PF-05089771|Specific antagonist of the Nav1.7 sodium channel
219120061|NCT05935280|DRUG|PF-06305591|Specific antagonist of the Nav1.8 sodium channel
219120062|NCT04460443|DRUG|sofosbuvir|Sofosbuvir once daily
219120063|NCT04460443|DRUG|Sofosbuvir ledipsavir|Sofosbuvir ledipsavir once daily
219120064|NCT04460443|DRUG|Daclatasvir|Daklatasuvir tablets
219705657|NCT02763566|DRUG|Letrozole|Administered orally
219705658|NCT02763566|DRUG|Placebo|Administered orally
219705659|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
219705660|NCT01837745|DRUG|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
219705661|NCT01837745|DRUG|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
219705662|NCT01837745|OTHER|Follow up|"* 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
219705663|NCT03008044|DEVICE|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
219120065|NCT06696950|OTHER|Mutimodal gait training includes unilateral step training, inclined treadmill training, over ground training with rhythmic auditory stimulation|Unilateral step training, inclined treadmill training, over ground training, repetitive isochronous pulses via metronome
219120066|NCT06696950|OTHER|Multimodal gait training|Unilateral step training, inclined treadmill training, over ground training,
219120067|NCT05980221|DIAGNOSTIC_TEST|Metabolomics|Plasma samples taken for the investigation of the metabolome
219120068|NCT05980221|DIAGNOSTIC_TEST|13C MTGT|sequential breath samples taken for investigation of PEI (reference test)
219120069|NCT06696846|BIOLOGICAL|CD70 CAR-NK|"CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors.~Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival."
219120070|NCT01540435|DRUG|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
219120071|NCT05417997|DIETARY_SUPPLEMENT|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
219120072|NCT05417997|DRUG|Favipiravir|Antiviral medication used to treat influenza
219120073|NCT05417997|DRUG|Enoxaparin|Anticoagulant medication
219120074|NCT05417997|DRUG|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
219120075|NCT05417997|DRUG|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
219120076|NCT05417997|DRUG|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
219120077|NCT05417997|DRUG|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
219120078|NCT02333851|DRUG|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
219120079|NCT02333851|DRUG|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
219120080|NCT04737590|DEVICE|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
219120081|NCT02106767|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
219120082|NCT02106767|DRUG|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
219120083|NCT06712498|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 22-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
219120084|NCT06712498|DRUG|control group|No intervention
219120085|NCT01732575|BEHAVIORAL|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
219120086|NCT00549497|DRUG|GW870086X|
219120087|NCT04953104|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219120088|NCT04953104|BIOLOGICAL|Nivolumab|Given IV
219120089|NCT04953104|DRUG|Relatlimab|Given IV
219120090|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
219120091|NCT01536262|DEVICE|Respimat|Respimat inhaler
219120092|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
219120093|NCT01536262|DRUG|Olodaterol|Olodaterol once daily inhalation
219120094|NCT01536262|DEVICE|Respimat|Respimat inhaler
219120095|NCT01536262|DEVICE|Respimat|Respimat inhaler
219120096|NCT00412516|BIOLOGICAL|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
219120097|NCT03673202|DIAGNOSTIC_TEST|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
219120098|NCT01355120|DRUG|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
219120099|NCT00318825|DRUG|Nitrous oxide|
219120100|NCT01760655|DRUG|Fludarabine phosphate|Given IV
219120101|NCT01760655|DRUG|Busulfan|Given IV
219120102|NCT01760655|RADIATION|Total-Body Irradiation|Undergo TBI
219120103|NCT01760655|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo DLI
219120104|NCT01760655|DRUG|Cyclophosphamide|Given IV
219120105|NCT01760655|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
219120106|NCT01760655|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219120107|NCT01760655|DRUG|Tacrolimus|Given IV
219120108|NCT01760655|DRUG|Mycophenolate Mofetil|Given IV
219120109|NCT01760655|OTHER|Laboratory Biomarker Analysis|Correlative studies
219225626|NCT02556918|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro"
219120110|NCT04078100|PROCEDURE|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
219120111|NCT03701425|DIETARY_SUPPLEMENT|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
219120112|NCT05599633|DIETARY_SUPPLEMENT|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
219120113|NCT05599633|DIETARY_SUPPLEMENT|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
219120114|NCT02719951|DRUG|[18F]FPEB PET imaging|PET exam
219705664|NCT04674956|DRUG|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
219120115|NCT02719951|OTHER|Biological samples|blood sample and urine sample
219120116|NCT02719951|OTHER|MRI|MRI exam
219120117|NCT02485353|DRUG|Vosaroxin and Cytarabine|
219120118|NCT06011967|OTHER|Intubation using C-MAC D blade videolariyngoscope|all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
219120119|NCT02883504|PROCEDURE|Echo-Doppler examination and left heart catheterization|
219120120|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
219120121|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
219120122|NCT01746394|BEHAVIORAL|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
219120123|NCT01746394|BEHAVIORAL|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
219120124|NCT01358916|OTHER|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
219120125|NCT06297096|DRUG|Tocilizumab|Tocilizumab 162 mg s.c./week
219120126|NCT06297096|DRUG|Nintedanib|Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
219120127|NCT06297096|DRUG|Standard therapy|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
219120128|NCT06109259|DRUG|DWJ1567|One tablet of DWJ1567
219120129|NCT06109259|DRUG|DWC202312|One tablet of DWC202312
219225627|NCT02556918|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart"
219225628|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
219705665|NCT04674956|DRUG|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
219705666|NCT04674956|DRUG|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
219705667|NCT06693765|DRUG|AZD4144|AZD4144 will be administered orally.
219705668|NCT06338566|OTHER|Follow-up|Follow-up at D45, 3 months and 6 months, with scoring, radiological monitoring and assessment of wound healing
219705669|NCT03864081|DEVICE|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
219120130|NCT04489784|DEVICE|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
219120131|NCT05845073|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
219120132|NCT05845073|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
219120133|NCT04744662|DRUG|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
219120134|NCT04744662|PROCEDURE|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
219120135|NCT03487666|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
219120136|NCT03487666|DRUG|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
219120137|NCT06434051|OTHER|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
219120138|NCT06434051|OTHER|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
219120139|NCT04545593|BEHAVIORAL|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
219120140|NCT04545593|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
219225629|NCT04837937|BEHAVIORAL|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
219225630|NCT04837937|BEHAVIORAL|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
219225631|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
219225632|NCT04128514|DEVICE|Panoptix Toric|Cataract surgery and IOL implantation
219225633|NCT05465954|PROCEDURE|Biospecimen Collection|Correlative studies
219705670|NCT03492203|BEHAVIORAL|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
219705671|NCT03492203|BEHAVIORAL|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
219225634|NCT05465954|BIOLOGICAL|Efineptakin alfa|Given IM
219225635|NCT05465954|BIOLOGICAL|Pembrolizumab|Given IV
219225636|NCT05465954|PROCEDURE|Biopsy|Undergo tumor biopsy
219705672|NCT03492203|BEHAVIORAL|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
219120141|NCT05929807|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
219120142|NCT04600180|PROCEDURE|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
219120143|NCT04411940|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
219120144|NCT04411940|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
219120145|NCT05061771|DRUG|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
219120146|NCT05061771|OTHER|Placebo|Placebo
219120147|NCT00002896|DRUG|chemotherapy|
219120148|NCT00002896|DRUG|fluorouracil|
219120149|NCT00002896|DRUG|leucovorin calcium|
219120150|NCT00002896|PROCEDURE|conventional surgery|
219120151|NCT00002896|RADIATION|low-LET cobalt-60 gamma ray therapy|
219120152|NCT00002896|RADIATION|low-LET photon therapy|
219120153|NCT03498040|OTHER|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
219120154|NCT04864496|DRUG|Prescribe N-acetylcysteine tablets|N-acetylcysteine tablets ,1200 mg two times daily
219120155|NCT04864496|DRUG|Prescribe placebo tablets|manufactured by Daroo Salamat Pharmed, two times daily
219120156|NCT04761419|BEHAVIORAL|Parents' longer presence beside their infant|They are not intervention. We will collect data about these items.
219705673|NCT03492203|BEHAVIORAL|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
219705674|NCT03492203|BEHAVIORAL|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
219705675|NCT03713918|OTHER|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
219705676|NCT03713918|OTHER|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
219120157|NCT02722941|DRUG|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
219120158|NCT04223596|DRUG|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
219120159|NCT04171726|DRUG|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
219705677|NCT03084237|BIOLOGICAL|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
219705678|NCT03084237|BIOLOGICAL|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
219705679|NCT03084237|DRUG|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
219705680|NCT00213681|DEVICE|Boussignac CPAP - bilevel ventilation support|
219705681|NCT02016326|DEVICE|HD Colon|High Definition White Light
219705682|NCT02016326|DEVICE|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
219705683|NCT02016326|DEVICE|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
219705684|NCT00914069|DEVICE|RIVS vascular access|Access to peripheral vasculature
219705685|NCT00914069|DEVICE|Conventional vascular access|Vascular access using conventional venous access device
219120160|NCT00027768|PROCEDURE|adjuvant therapy|
219120161|NCT00027768|RADIATION|iodine I 131 ethiodized oil|
219120162|NCT00003928|DRUG|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219120163|NCT00003928|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219120164|NCT02510066|DEVICE|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
219120165|NCT02510066|DEVICE|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
219120166|NCT06526208|DRUG|MB-IMP|MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
219120167|NCT06526208|OTHER|Placebo|Does not contain CBD or THC
219705686|NCT04795349|PROCEDURE|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
219705687|NCT02517788|DRUG|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
219705688|NCT02517788|DRUG|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
219705689|NCT02517788|DRUG|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
219705690|NCT04087772|BEHAVIORAL|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
219705691|NCT04087772|BEHAVIORAL|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
219705692|NCT06511778|DRUG|Hemoblast Bellows application|Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
219705693|NCT02656030|OTHER|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
219120168|NCT05149079|DIETARY_SUPPLEMENT|Cod protein hydrolysate|Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
219120169|NCT05149079|DIETARY_SUPPLEMENT|Placebo|Whey protein powder, commercially available
219705694|NCT02656030|OTHER|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
219705695|NCT02656030|OTHER|usual care|usual care, 2 time per week, 6 weeks duration
219705696|NCT00519350|PROCEDURE|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
219705697|NCT04124133|DEVICE|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
219705698|NCT01933594|DRUG|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
219705699|NCT01933594|DRUG|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
219705700|NCT04222049|DEVICE|Vibro Tactile Gadget|The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
219705701|NCT04796701|OTHER|Follow-Home-intervention|x
219705702|NCT03012646|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
219705703|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
219120170|NCT03589924|PROCEDURE|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
219120171|NCT03589924|PROCEDURE|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
219120172|NCT02977975|OTHER|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
219120173|NCT02977975|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
219120174|NCT02748512|DRUG|FAI Insert administered using the Mk II inserter|
219120175|NCT02748512|DRUG|FAI Insert administered using the Mk I inserter|
219120176|NCT03344614|DRUG|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
219705704|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
219705705|NCT05729347|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
219705706|NCT03678077|OTHER|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
219705707|NCT00004261|DRUG|EF5|
219705708|NCT00004261|OTHER|flow cytometry|
219705709|NCT00004261|OTHER|fluorescent antibody technique|
219120177|NCT02990728|DRUG|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
219120178|NCT02990728|DEVICE|Mirena®|
219120179|NCT04012320|OTHER|No intervention, observational study|No intervention, observational study
219120180|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
219120181|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
219120182|NCT05034575|OTHER|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
219120183|NCT05830461|BEHAVIORAL|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
219120184|NCT05830461|BEHAVIORAL|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
219120185|NCT04003311|DEVICE|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
219120186|NCT04003311|DEVICE|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
219120187|NCT02585310|OTHER|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
219120188|NCT00950209|DIETARY_SUPPLEMENT|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
219120189|NCT00950209|OTHER|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
219120190|NCT00950209|DIETARY_SUPPLEMENT|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
219705710|NCT00004261|OTHER|immunohistochemistry staining method|
219705711|NCT00004261|PROCEDURE|biopsy|
219120191|NCT00950209|OTHER|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
219120192|NCT06367062|OTHER|MRI|MRI is used to assess of brain development.
219705712|NCT04289038|OTHER|Autogenic Relaxation|Autogenic relaxation
219120193|NCT04415593|DIETARY_SUPPLEMENT|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
219120194|NCT04415593|DIETARY_SUPPLEMENT|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
219120195|NCT01837043|DRUG|Belatacept|
219120196|NCT01837043|DRUG|Calcineurin Inhibitor|
219120197|NCT02264574|DRUG|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
219120198|NCT02264574|DRUG|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
219705713|NCT04289038|OTHER|virtual reality game application|virtual reality game application,
219705714|NCT04289038|OTHER|kidney function narration|kidney function narration
219705715|NCT02504164|DRUG|midazolam 0.02mg/kg|
219705716|NCT02504164|DRUG|No premedication|No premedication before sedation for endoscopic submucosal dissection
219705717|NCT02105090|DRUG|Anesthetics, Local|
219705718|NCT02105090|DRUG|Sodium Chloride 0.9%|
219705719|NCT03419468|OTHER|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
219705720|NCT05735340|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
219120199|NCT02264574|DRUG|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
219120200|NCT01697137|BEHAVIORAL|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
219120201|NCT02593175|DRUG|Carboplatin|Given IV
219120202|NCT02593175|DRUG|Paclitaxel|Given IV
219120203|NCT02593175|BIOLOGICAL|Panitumumab|Given IV
219120204|NCT01587833|DRUG|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
219120205|NCT00641953|DRUG|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
219120206|NCT00641953|DRUG|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
219120207|NCT00641953|DRUG|Placebo|0.5 g topically BID to each foot for 4 weeks
219120208|NCT03219437|DRUG|risankizumab|subcutaneous (SC) injection
219120209|NCT03219437|DRUG|methotrexate|capsule
219705721|NCT05735340|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
219120210|NCT03259347|BEHAVIORAL|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
219120211|NCT03291275|OTHER|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
219120212|NCT02354248|PROCEDURE|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
219120213|NCT02658721|DRUG|Lidocaine|
219120214|NCT02658721|DRUG|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
219120215|NCT02658721|DRUG|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
219225637|NCT05689502|DEVICE|Treatment|Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.
219705722|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
219705723|NCT06285825|DRUG|Emapalumab|Given by Infusion
219120216|NCT02658721|DRUG|Fentanyl|If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
219120217|NCT02658721|DRUG|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR \<50/min), 0.5 mg intravenous atropine was administered."
219120218|NCT02658721|DRUG|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
219120219|NCT02658721|DRUG|Diclofenac sodium|The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
219120220|NCT02658721|DRUG|Ephedrine|In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
219120221|NCT02658721|DRUG|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
219120222|NCT01356030|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
219120223|NCT01356030|PROCEDURE|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
219120224|NCT03403569|DRUG|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
219120225|NCT03403569|DRUG|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
219705724|NCT03869268|DRUG|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
219705725|NCT03869268|DRUG|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
219120226|NCT03501238|OTHER|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
219120227|NCT03501238|OTHER|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
219120228|NCT03501238|OTHER|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
219120229|NCT04436003|BEHAVIORAL|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
219120230|NCT02690402|BEHAVIORAL|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
219120231|NCT06063369|DRUG|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
219120232|NCT04551703|DRUG|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
219120233|NCT04271592|DRUG|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
219120234|NCT04271592|DRUG|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
219120235|NCT04271592|DRUG|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
219705726|NCT06234228|BEHAVIORAL|Bluetooth Haptic Device (BHD)|The BHD will deliver constant low-frequency vibration (CF).
219705727|NCT06234228|BEHAVIORAL|BHD synced with mobile game|The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
219705728|NCT06109922|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
219705729|NCT06109922|DIETARY_SUPPLEMENT|Placebo|Around 40g pea protein powder not containing phospholipids
219120236|NCT04271592|DRUG|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
219120237|NCT06358742|OTHER|ZCT toothpaste|
219120238|NCT06358742|OTHER|Control toothpaste|
219120239|NCT03383185|DEVICE|Intrauterine device|Use of Intrauterine device during the follow-up period
219120240|NCT03383185|DRUG|Combined Oral Contraceptive|Use of combined oral contraceptive during the follow-up period
219120241|NCT03383185|DRUG|Progestin-only pills|Use of progestin-only pills during the follow-up period
219120242|NCT03383185|DRUG|Depot-Medroxyprogestereone Acetate|Use of depot-medroxyprogesterone acetato during the follow-up period
219120243|NCT04499040|BIOLOGICAL|Blood sample|Blood samples to assess biological parameters such as:
219120244|NCT04499040|OTHER|Fecal samples|Microbiota analysis
219120245|NCT04499040|BEHAVIORAL|Neuropsychological|Neuropsychological assessment
219120246|NCT05528887|BIOLOGICAL|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
219120247|NCT05528887|DRUG|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
219120248|NCT05528887|DRUG|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
219120249|NCT02716597|DRUG|25% Albumin|
219120250|NCT02716597|DRUG|Placebo|
219120251|NCT03548545|DEVICE|tDCS|subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
219705730|NCT04208230|DEVICE|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
219705731|NCT03678025|DRUG|Abiraterone|Given PO
219705732|NCT03678025|DRUG|Bicalutamide|Given PO
219705733|NCT03678025|DRUG|Degarelix|Given via injection
219705734|NCT03678025|DRUG|Docetaxel|intravenous
219705735|NCT03678025|DRUG|Flutamide|Given PO
219705736|NCT03678025|DRUG|Goserelin Acetate|Given SC
219705737|NCT03678025|DRUG|Histrelin Acetate|Receive SC
219120252|NCT04105985|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
219120253|NCT04105985|DRUG|Articaine Injection|Local anesthetic
219120254|NCT02886728|DRUG|Filgotinib|Tablet(s) administered orally once daily
219120255|NCT02886728|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
219120256|NCT02886728|DRUG|MTX|Capsule(s) administered orally once weekly
219120257|NCT02886728|DRUG|Placebo to match MTX|Capsule(s) administered orally once weekly
219120258|NCT04770597|DEVICE|Aranet4 Home CO2 monitor|The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
219705738|NCT03678025|DRUG|Leuprolide Acetate|Receive SC or IM
219705739|NCT03678025|DRUG|Nilutamide|Given PO
219705740|NCT03678025|PROCEDURE|Orchiectomy|Undergo bilateral orchiectomy
219705741|NCT03678025|DRUG|Prednisone|Given PO
219705742|NCT03678025|OTHER|Quality-of-Life Assessment|Ancillary studies
219705743|NCT03678025|RADIATION|Radiation Therapy|Standard radiation
219705744|NCT03678025|PROCEDURE|Radical Prostatectomy|Standard surgery
219705745|NCT03678025|DRUG|Triptorelin|injection
219705746|NCT05084495|DIAGNOSTIC_TEST|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
219120259|NCT03650738|DRUG|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
219120260|NCT02029703|DEVICE|Synvisc-One Injection|
219120261|NCT02029703|OTHER|Sham Injection|
219120262|NCT06073964|BEHAVIORAL|Trauma Resilience & Understanding Self-help Therapy|A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
219120263|NCT00074243|DRUG|CC-8490|
219120264|NCT01785641|DRUG|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
219120265|NCT01785641|DRUG|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
219120266|NCT01785641|DRUG|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
219120267|NCT01785641|DRUG|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
219120268|NCT05059574|BEHAVIORAL|Breast Crawling|The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
219705747|NCT00455871|DRUG|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
219705748|NCT00455871|DRUG|Lucentis|Lucentis intravitreal injection
219705749|NCT04157179|OTHER|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
219705750|NCT05388591|OTHER|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
219705751|NCT00370617|DRUG|metformin|
219705752|NCT02750722|DEVICE|Flutter®|Acute exercise with Flutter® breathing therapy.
219705753|NCT02750722|DEVICE|No Flutter®|Acute exercise without Flutter® breathing therapy.
219705754|NCT04698811|BEHAVIORAL|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
219705755|NCT02410330|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
219705756|NCT02410330|PROCEDURE|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
219705757|NCT03774446|DRUG|Seliciclib|Drug: Seliciclib
219705758|NCT02657551|DRUG|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
219705759|NCT01314729|DEVICE|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
219705760|NCT01314729|DEVICE|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
219705761|NCT01010178|DRUG|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
219705762|NCT04679207|PROCEDURE|Vacuum-assisted excision|Vacuum-assisted biopsy (VAB) is a minimally invasive technique performed under local anaesthetic as an outpatient procedure by radiologists using x-ray or ultrasound guidance. It was developed in the USA in the mid 1990s and has become well established as a diagnostic test for suspected breast disease. It uses the combination of a large gauge biopsy needle and suction to allow larger pieces of tissue to be removed than can be obtained with a standard needle biopsy device. The technique is used widely for diagnostic purposes and, in some centres, for the therapeutic removal of benign breast lumps such as fibroadenomas and papillomas.
219120269|NCT04934553|BEHAVIORAL|Amplification of Positivity Training|12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
219120270|NCT04934553|BEHAVIORAL|Cognitive-behavioral Therapy|12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
219120271|NCT03839563|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
219120272|NCT01015183|DRUG|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
219120273|NCT01015183|DRUG|Placebo|Placebo: as the same of intervention group
219120274|NCT04990440|DRUG|Bermekimab|Participants will receive bermekimab IV.
219120275|NCT04990440|DRUG|Placebo|Participants will receive placebo IV.
219120276|NCT02724761|DRUG|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
219120277|NCT02724761|DRUG|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
219120278|NCT04814485|DRUG|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
219120279|NCT04524104|BEHAVIORAL|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
219120280|NCT01013480|DRUG|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
219705763|NCT00034866|DRUG|Protease inhibitor tipranavir|
219120281|NCT05103774|DIAGNOSTIC_TEST|T3-T4-TSH|thyroid function tests
219120282|NCT05284188|PROCEDURE|Open or arthroscopic Modified Broström operation|Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
219120283|NCT00724061|BIOLOGICAL|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
219120284|NCT00724061|OTHER|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
219120285|NCT00724061|OTHER|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
219705764|NCT04105270|DRUG|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
219705765|NCT04105270|DRUG|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
219705766|NCT04105270|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
219120286|NCT00409240|OTHER|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
219120287|NCT06204523|DIAGNOSTIC_TEST|investigated biomarkers regarding the efficacy of first-line chemotherapy|The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC
219120288|NCT02620189|DRUG|Anti-TNF Biologics Therapy|
219225638|NCT04572451|DRUG|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
219225639|NCT04572451|DRUG|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
219705767|NCT04105270|OTHER|Placebo|Sixteen doses of oral placebo capsules given weekly
219705768|NCT06968611|OTHER|Education/information of risk|Participant will receive a message underscoring risk of vision loss from poorly controlled DM, and how this risk can be largely eliminated with excellent compliance with mediations and clinical visits.
219705769|NCT06968611|OTHER|Free eye glasses|Participants will receive a free pair of reading glass at their first appointment
219705770|NCT05445141|BEHAVIORAL|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
219120289|NCT04655313|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
219120290|NCT04798703|DRUG|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
219120291|NCT01060566|DRUG|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
219120292|NCT01060566|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
219120293|NCT06339047|OTHER|Projector Kaleidoscope|Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction in the operating room.
219120294|NCT06339047|OTHER|Cartoon|Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
219120295|NCT05866250|DIAGNOSTIC_TEST|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
219120296|NCT00878358|OTHER|Hydrotherapy|
219120297|NCT00878358|OTHER|Physiotherapy|
219120298|NCT00060463|BEHAVIORAL|Increased access to emergency contraceptive pills|
219120299|NCT00192621|DRUG|Combivir (zidovudine [AZT] / lamivudine [3TC])|
219120300|NCT00192621|DRUG|Kaletra (lopinavir [LPVr])|
219120301|NCT00688259|BEHAVIORAL|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
219120302|NCT00688259|BEHAVIORAL|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
219120303|NCT05403359|DRUG|Steroids|"Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
219120304|NCT05983471|DRUG|ME-015 (Suplatast Tosilate)|Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)
219120305|NCT05983471|OTHER|Identical placebo|Without active component
219120306|NCT01310868|DRUG|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
219120307|NCT01310868|DRUG|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
219120308|NCT01310868|RADIATION|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
219120309|NCT01310868|DRUG|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
219120310|NCT01310868|DRUG|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
219120311|NCT00023439|OTHER|Nucleic Acid Amplification Methods for diagnosis|no intervention
219120312|NCT02496494|DRUG|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
219120313|NCT05539690|BEHAVIORAL|Balance training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks"
219120314|NCT02544737|DRUG|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
219120315|NCT02411591|DRUG|Necitumumab|Administered IV.
219120316|NCT02411591|DRUG|Abemaciclib|Administered orally.
219120317|NCT00963703|DRUG|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
219120318|NCT02131714|BEHAVIORAL|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
219120319|NCT02131714|BEHAVIORAL|lifestyle counseling|
219120320|NCT00280475|DEVICE|Whole brain radiation therapy arm|Whole brain radiation therapy arm
219120321|NCT00280475|DEVICE|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
219120322|NCT00000736|DRUG|Zidovudine|
219120323|NCT03994575|OTHER|Guideline recommended feedback|The ACS Reflective III Pilot program is a quality assurance program where the decision to follow the recommendations and all treatment decisions related to patient care are left to the physician's discretion and feedback to the physician with their aggregate and individual patient data is intended as a quality assurance undertaking
219120324|NCT02954575|DRUG|Wilate|
219120325|NCT00229619|DRUG|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
219120326|NCT02491892|DRUG|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
219120327|NCT04227340|DEVICE|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
219120328|NCT04227340|OTHER|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
219705771|NCT05445141|BEHAVIORAL|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
219705772|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
219705773|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
219705774|NCT05445843|DRUG|JDQ443|JDQ443 per os (PO) 200 mg twice a day continuously
219705775|NCT03563573|DRUG|Potassium Gluconate Oral Capsule|Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
219705776|NCT03563573|DRUG|Placebo oral capsule|Each subject will receive a dose of \~8 mg/kg of a placebo capsule
219120329|NCT04227340|OTHER|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
219120330|NCT04681677|RADIATION|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
219120331|NCT04681677|DRUG|Bevacizumab|Bevacizumab
219120332|NCT01154803|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
219120333|NCT01154803|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
219705777|NCT04062695|DRUG|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
219120334|NCT06027775|DRUG|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
219120335|NCT01066156|DRUG|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
219120336|NCT01018823|DRUG|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
219120337|NCT01018823|DRUG|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
219705778|NCT04062695|DRUG|Placebo oral tablet|tablets containing placebo
219705779|NCT04140409|DRUG|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
219705780|NCT05350020|DRUG|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
219705781|NCT05350020|DRUG|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
219705782|NCT03837717|BEHAVIORAL|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
219705783|NCT03837717|OTHER|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
219705784|NCT03837717|BEHAVIORAL|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
219705785|NCT03736655|DEVICE|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
219120338|NCT01820533|OTHER|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
219120339|NCT02809274|OTHER|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
219705786|NCT00713804|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
219705787|NCT00713804|BEHAVIORAL|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
219705788|NCT06230263|DIAGNOSTIC_TEST|Visual acuity test|"Assess near high-contrast visual acuity (40cm) using EyeChart PRO on an iPad.~Use the MNREAD app to measure:~Reading Acuity: Smallest font size read without errors. Critical Print Size: Smallest font size for peak reading speed. Maximum Reading Speed: Time to read comfortable font size, in words per minute. Reading Accessibility Index: Single metric summarizing visual access to print. Assess near visual function with the Near Activity Visual Questionnaire.~Evaluate distance visual acuity, both high and low contrast, using logMAR and the E-ETDRS (NIDEK SC-2000)."
219705789|NCT02573714|DRUG|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
219705790|NCT02573714|DRUG|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
219705791|NCT02573714|OTHER|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
219705792|NCT02573714|OTHER|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
219705793|NCT02573714|OTHER|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
219705794|NCT04091165|OTHER|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
219705795|NCT06083129|DRUG|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
219705796|NCT06083129|DRUG|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
219705797|NCT00315445|DRUG|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
219705798|NCT00315445|DRUG|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
219705799|NCT00315445|DRUG|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
219705800|NCT00315445|DRUG|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
219120340|NCT00658671|DRUG|ENMD-2076|Capsules, daily dosing in 28 day cycles
219120341|NCT05925959|OTHER|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
219705801|NCT03851575|OTHER|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
219705802|NCT03851575|OTHER|Usual guideline therapy|Usual guideline therapy
219705803|NCT01833676|DRUG|Sevoflurane|
219705804|NCT01833676|DRUG|Desflurane|
219120342|NCT03537053|BEHAVIORAL|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
219120343|NCT01700673|DRUG|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
219120344|NCT01700673|BIOLOGICAL|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
219705805|NCT03113734|OTHER|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
219705806|NCT00636727|PROCEDURE|arthrocentesis|Irrigate the TMJ with lactated ringers
219705807|NCT00636727|PROCEDURE|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
219705808|NCT00636727|PROCEDURE|arthroplasty|The disc will be surgically repositioned with open surgery
219705809|NCT03468621|PROCEDURE|Wound closure|Method of wound closure
219705810|NCT01035138|DRUG|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
219705811|NCT06283355|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
219705812|NCT06283355|BIOLOGICAL|Placebo|Placebo sterile swab
219705813|NCT01518101|DRUG|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
219705814|NCT01518101|DRUG|Liraglutide|1.2 mg once daily by commercially available injection pens
219705815|NCT01518101|DRUG|Metformin|1000 mg tablets twice daily
219705816|NCT06032806|OTHER|moderate intensity|"* Arm circles~* Leg swings~* Lunges"
219705817|NCT06032806|OTHER|High intensity|"* Arm circles~* Leg swings~* Lunges~* Butt kicks"
219705818|NCT02916927|DRUG|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
219705819|NCT02916927|DRUG|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
219705820|NCT04938336|BEHAVIORAL|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
219120345|NCT04729049|PROCEDURE|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
219705821|NCT00492011|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
219705822|NCT00492011|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
219705823|NCT00492011|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
219705824|NCT00492011|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
219705825|NCT05446103|OTHER|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
219705826|NCT05446103|OTHER|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
219705827|NCT06235554|PROCEDURE|Renal Stimulation|Renal Denervation procedure as per hospital routine practice
219705828|NCT06532305|BEHAVIORAL|HOPE empowerment classes|A three-month empowerment course.
219705829|NCT01154660|OTHER|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
219705830|NCT00392106|DRUG|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
219120346|NCT04729049|DRUG|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
219120347|NCT00305682|BIOLOGICAL|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
219120348|NCT00305682|DRUG|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
219120349|NCT00305682|DRUG|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
219120350|NCT00305682|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
219120351|NCT00305682|PROCEDURE|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
219120352|NCT00305682|RADIATION|total body irradiation|Administered Day -1, 200 cGy
219705831|NCT00392106|DRUG|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
219705832|NCT00392106|DRUG|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
219705833|NCT00392106|DRUG|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
219705834|NCT00392106|DEVICE|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
219705835|NCT00392106|DRUG|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
219705836|NCT06160271|DRUG|PET scan of 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
219705837|NCT04909060|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
219120353|NCT00305682|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
219120354|NCT00661258|BEHAVIORAL|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
219120355|NCT04895020|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
219120356|NCT03890120|DRUG|Cilofexor|100 mg tablet administered orally once daily
219120357|NCT03890120|DRUG|Placebo|Tablet administered orally once daily
219120358|NCT01259336|DRUG|Itraconazole|Tablet 200 mg twice daily for 6 months
219120359|NCT01259336|DRUG|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
219120360|NCT02622971|OTHER|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
219120361|NCT02622971|OTHER|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
219120362|NCT03496415|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
219120363|NCT03496415|DEVICE|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
219120364|NCT02696278|OTHER|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
219120365|NCT02696278|OTHER|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
219225640|NCT04572451|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
219225641|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
219705838|NCT04440488|BIOLOGICAL|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
219705839|NCT03153657|DRUG|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
219705840|NCT03153657|DRUG|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
219120366|NCT02696278|OTHER|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
219705841|NCT00655889|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of biopsy from palate~2. Papillary priming procedure~3. Seven injection treatments to target sites~4. Performance of study assessments (investigator and subject)"
219120367|NCT01080963|DRUG|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
219120368|NCT01080963|DRUG|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
219120369|NCT02796443|PROCEDURE|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
219120370|NCT03952455|PROCEDURE|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
219120371|NCT04802863|DRUG|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
219120372|NCT03553862|BEHAVIORAL|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
219120373|NCT01253382|BIOLOGICAL|ecallantide|10 - 30mg subcutaneous injection.
219120374|NCT00683449|DRUG|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
219120375|NCT00683449|DRUG|MN-221 placebo|i.v. infusion of placebo for 15 minutes
219120376|NCT00683449|DRUG|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
219120377|NCT00683449|DRUG|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
219120378|NCT01200719|DEVICE|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: \< 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity \~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
219120379|NCT04831762|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
219120380|NCT04831762|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
219120381|NCT04831762|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
219120382|NCT04831762|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
219120383|NCT04831762|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
219120384|NCT01991717|DEVICE|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
219120385|NCT01991717|DEVICE|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
219120386|NCT01600950|DRUG|LY2963016|Single 0.3 U/kg dose administered subcutaneously
219120387|NCT01600950|DRUG|Lantus|Single 0.3 U/kg dose administered subcutaneously
219120388|NCT00007930|PROCEDURE|conventional surgery|
219120389|NCT00007930|PROCEDURE|laparoscopic surgery|
219120390|NCT00156338|PROCEDURE|fluid management|volume and sodium restriction
219705842|NCT02255747|DRUG|Lactulose|
219705843|NCT02721784|DEVICE|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
219705844|NCT02721784|RADIATION|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
219120391|NCT00156338|PROCEDURE|fluid management|volume restriction
219120392|NCT00156338|PROCEDURE|fluid management|liberal fluid management
219120393|NCT00451815|DRUG|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
219120394|NCT00451815|DRUG|placebo|
219120395|NCT02711722|DEVICE|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
219120396|NCT02711722|DEVICE|PScli1|Pressure support set by clinicians prior to inclusion
219120397|NCT02711722|DEVICE|PScli2|Pressure support at the same level as prior to the study
219120398|NCT06264934|DEVICE|Breast scan using the Z-scanner|Four repeated scans of both breasts using the Z-scanner.
219120399|NCT06264934|DEVICE|Breast scan using the Z-scanner|A scan of both breasts using the Z-scanner.
219120400|NCT01987375|DRUG|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
219120401|NCT00000242|DRUG|Carbamazepine|
219705845|NCT01281696|DRUG|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
219705846|NCT01281696|DRUG|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
219120402|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
219120403|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Alpha (British) variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
219120404|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
219120405|NCT05968521|BEHAVIORAL|Cardiac Rehabilitation (CR): Experimental|CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
219120406|NCT05968521|BEHAVIORAL|Treatment as usual: Control|Treatment as usual will include routine clinical outpatient management.
219705847|NCT04945811|DIAGNOSTIC_TEST|Interlukein 6 and procalcitonin serum levels|Blood tests
219705848|NCT06381232|OTHER|No Intervention|This is an observational study, there are no interventions.
219705849|NCT02688790|DRUG|Dalbavancin|
219705850|NCT00439998|PROCEDURE|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
219705851|NCT03164824|OTHER|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
219120407|NCT03369288|DIAGNOSTIC_TEST|PET MRI|18F-fluoride PET-MRI
219120408|NCT05752578|OTHER|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
219120409|NCT04123873|DRUG|Paracetamol|1g x 4 p.o.
219120410|NCT04123873|DRUG|Ibuprofen|400mg x 4 p.o.
219120411|NCT04123873|DRUG|Dexamethasone|24mg IV x 1 after induction om anaesthesia
219705852|NCT03922373|DRUG|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
219705853|NCT03922373|DRUG|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
219705854|NCT03922373|DRUG|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
219705855|NCT01093508|DRUG|APD916|
219705856|NCT03475238|PROCEDURE|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
219705857|NCT01811719|BEHAVIORAL|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
219705858|NCT01811719|BEHAVIORAL|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
219705859|NCT04270877|DRUG|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
219120412|NCT04123873|DRUG|Placebo oral capsules|p.o. x 4
219120413|NCT04123873|DRUG|Placebo IV|IV x 1
219120414|NCT03908242|DRUG|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
219120415|NCT03908242|DRUG|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
219120416|NCT06337539|DRUG|SSRI|"Outpatients with a diagnosis of major depression in the Psychiatry Outpatient Clinics will be evaluated for recruitment.~* Recruitment visit: It will be carried out by one of the psychiatrists participating in the study. The patient will be informed about the study and written consent will be requested. Subsequently, the inclusion and exclusion criteria will be reviewed, and all demographic and clinical variables will be collected.~* Baseline visit: One of the psychiatrists will interview the patient and apply the semi-structured clinical interview and the psychopathological evaluation questionnaires. In addition, a blood draw will be performed for serum collection, spectral cytometric analysis of lymphocyte subpopulations and obtaining peripheral blood mononuclear cells (PBMCs).~* Follow-up visit after 3 months of treatment: Clinical variables will be collected and the same procedures will be performed as during the baseline visit. Not in the control group."
219120417|NCT01398761|OTHER|Signout tool|Electronic signout tool
219120418|NCT01720017|OTHER|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
219120419|NCT01720017|OTHER|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
219120420|NCT05542017|PROCEDURE|Surgical Ablation for Atrial Fibrillation|Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.
219120421|NCT01018043|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
219120422|NCT06128317|OTHER|no intervention is intended.|no intervention is intended.
219120423|NCT03302533|PROCEDURE|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
219120424|NCT02559817|DRUG|Linaclotide Dose A|
219120425|NCT02559817|DRUG|Linaclotide Dose B|
219120426|NCT02559817|DRUG|Linaclotide Dose C|
219120427|NCT02559817|DRUG|Linaclotide Approved Adult Dose|
219120428|NCT02559817|DRUG|Matching Placebo|
219120429|NCT01739556|DRUG|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
219120430|NCT00003840|BIOLOGICAL|DTGM fusion protein|
219120431|NCT04887961|DRUG|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
219120432|NCT03328052|DEVICE|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
219120433|NCT03328052|OTHER|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
219120434|NCT03374345|DRUG|Sipjeondaebo-tang Granule|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219120435|NCT03374345|DRUG|Placebo|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219120436|NCT00004643|DRUG|cytarabine|
219120437|NCT03059160|DRUG|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
219120438|NCT05188365|OTHER|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
219225642|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
219705860|NCT04270877|DRUG|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
219705861|NCT04376567|PROCEDURE|One stage approach|Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
219705862|NCT04585893|DRUG|Rituximab|375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
219705863|NCT04585893|DRUG|Etoposide|Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
219705864|NCT02598661|DRUG|Imetelstat Sodium|Imetelstat sodium IV infusion.
219705865|NCT02598661|DRUG|Placebo|Imetelstat sodium-matching placebo IV infusion.
219705866|NCT03332615|BEHAVIORAL|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
219120439|NCT05188365|OTHER|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
219120440|NCT00597870|DEVICE|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
219120441|NCT01882894|DEVICE|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
219120442|NCT01882894|OTHER|Faux orthosis|Foam cut out
219225644|NCT05064306|DRUG|131I-omburtamab|50 mCi 131I-omburtamab
219120443|NCT01806415|DRUG|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
219120444|NCT01806415|DRUG|Placebo|Oral administration of placebo or lactose 150 mg
219120445|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
219120446|NCT01056211|PROCEDURE|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
219120447|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
219120448|NCT05711329|OTHER|Accuracy|We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
219120449|NCT00070629|DRUG|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
219705867|NCT03332615|BEHAVIORAL|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
219120450|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
219705868|NCT01665742|DIETARY_SUPPLEMENT|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
219705869|NCT01665742|DIETARY_SUPPLEMENT|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
219120451|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
219120452|NCT04422821|DEVICE|Flash Glucose Monitoring|Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
219120453|NCT04422821|DEVICE|Self-Monitoring of Blood Glucose|Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
219705870|NCT03112551|DRUG|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
219705871|NCT03942770|BEHAVIORAL|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
219705872|NCT03942770|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
219120454|NCT01925170|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
219120455|NCT01925170|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
219120456|NCT01925170|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
219120457|NCT01403844|OTHER|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
219120458|NCT01403844|OTHER|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
219120459|NCT01403844|OTHER|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
219120460|NCT01403844|OTHER|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
219120461|NCT03888703|DEVICE|Fractional ablative CO2 laser|Three treatments with a fractional ablative CO2 laser 8 weeks apart
219120462|NCT03042442|DIAGNOSTIC_TEST|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
219120463|NCT03042442|OTHER|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
219120464|NCT03042442|OTHER|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
219120465|NCT00577720|DRUG|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
219120466|NCT00577720|DRUG|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
219120467|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
219120468|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
219120469|NCT01340833|DRUG|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
219120470|NCT02742909|DRUG|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
219120471|NCT02742909|DRUG|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
219705873|NCT05614063|DRUG|XEN1101|XEN1101 Capsules
219705874|NCT05614063|DRUG|Placebo|Placebo Capsules
219120472|NCT02682017|OTHER|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
219120473|NCT02682017|OTHER|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
219120474|NCT02839681|DRUG|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
219705875|NCT05923632|BEHAVIORAL|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
219705876|NCT06562153|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
219705877|NCT02750293|DRUG|Cholecalciferol|Vitamin D preparation
219705878|NCT02750293|DRUG|Placebo|placebo
219705879|NCT01499589|PROCEDURE|regional anesthesia|regional anesthesia procedure
219705880|NCT03803137|OTHER|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
219705881|NCT00757653|DEVICE|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
219120475|NCT02839681|DEVICE|Blood test|Research blood test for eligibility
219120476|NCT01539941|BEHAVIORAL|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
219120477|NCT01000870|DRUG|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
219120478|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
219120479|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
219120480|NCT03327675|OTHER|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
219120481|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
219120482|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
219120483|NCT03100838|DRUG|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
219120484|NCT03100838|DEVICE|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
219120485|NCT06021210|DRUG|Letermovir Pill|Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
219705882|NCT00757653|DEVICE|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
219705883|NCT00757653|DEVICE|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
219705884|NCT00988780|DRUG|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
219705885|NCT00988780|DRUG|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
219705886|NCT05047744|DEVICE|Touch Dual Mobility CMC I Prosthesis|Surgery
219705887|NCT05157373|DIAGNOSTIC_TEST|Endometrial sampling and Peripheral blood collection|The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.
219705888|NCT05157373|BEHAVIORAL|FSFI Scale|"The participants will fill up the Female Sexual Function Index (FSFI) questionnaire.~The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration)."
219705889|NCT07015541|OTHER|NMES and BFR|NMES is applied when patients perform quadriceps strengthening exercises. BFR is applied during compound exercises.
219705890|NCT07015541|OTHER|Standard physical therapy|Standard physical therapy (week 1-16) includes interventions for typical impairments following ACLR. The initial phase will focus on pain and effusion control, restoration of knee range of motion, followed by gait normalization, lower extremity strength training, then running and plyometrics.
219705891|NCT06626828|DEVICE|Electroacupuncture|Disposable sterilized needles are inserted into selected acupoints at a depth of approximately 17-25 mm and an angle of 15-30° along the scalp. Acupoints are then stimulated by the SDZ-II electroacupuncture device, with a dilatational wave pattern at 4/20 Hz. The intensity of the stimulation was adjusted to the patient\&#39;s tolerance.
219705892|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
219120486|NCT05678153|DIAGNOSTIC_TEST|Nordic Orofacial Test-Screen (NOT-S)|screening tool to detect orofacial dysfunction
219120487|NCT01182922|BEHAVIORAL|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
219705893|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
219120488|NCT01845636|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
219120489|NCT01845636|DRUG|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
219120490|NCT04734041|BEHAVIORAL|Anti-inflammatory (Mediterranean-style) diet|Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.
219120491|NCT04734041|BEHAVIORAL|Behavioral and psychosocial support|Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
219120492|NCT02093585|DRUG|abacavir (600 mg QD)|
219120493|NCT02093585|DRUG|tenofovir (245 mg QD)|
219120494|NCT02053311|DRUG|Orteronel|300mg orteronel
219120495|NCT02053311|DRUG|Placebo|Placebo
219120496|NCT03092544|DRUG|dimethyl fumarate|Active drug
219120497|NCT02554513|DEVICE|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
219120498|NCT02554513|BEHAVIORAL|SPT|A treatment hierarchy involving integral stimulation
219120499|NCT05702203|OTHER|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
219120500|NCT06086002|DEVICE|Microwave ablation|Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
219120501|NCT05565755|OTHER|Motivational interview|Motivational interview Training
219120502|NCT04055480|DEVICE|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
219120503|NCT04055480|DEVICE|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
219120504|NCT06337643|BIOLOGICAL|MVX01|Pneumococcal Vaccine Candidate
219120505|NCT06337643|BIOLOGICAL|MVX01 Placebo|Placebo
219120506|NCT02295982|PROCEDURE|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
219120507|NCT03985722|DRUG|Olaratumab and Trabectedin|"Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0\*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. \* Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3\*\*: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~\*\*In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
219120508|NCT04992442|DRUG|TAK-935 Oral Tablet|TAK-935 tablet
219120509|NCT04992442|DRUG|[14C]TAK-935 IV Infusion|\[14C\]TAK-935 IV infusion
219120510|NCT04992442|DRUG|[14C]TAK-935 Oral Solution|\[14C\]TAK-935 oral solution
219120511|NCT02114827|BEHAVIORAL|Video|23-minute video
219120512|NCT02114827|BEHAVIORAL|FAQ Sheet|
219120513|NCT00393627|BEHAVIORAL|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
219120514|NCT00630162|GENETIC|amoeba|
219120515|NCT04389255|OTHER|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
219120516|NCT04389255|DEVICE|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
219120517|NCT00147654|DRUG|Tolterodine ER 4 mg QD|
219120518|NCT00147654|DRUG|Tamsulosin 0.4 mg QD|
219120519|NCT03708068|OTHER|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
219120520|NCT04187534|OTHER|Albumin Fluid Resuscitation Optimization Intervention|Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
219120521|NCT04187534|OTHER|Usual Practice|Albumin fluid resuscitation according to usual practice
219120522|NCT02883543|DRUG|icotinib|Icotinib is orally administered three times per day.
219120523|NCT02883543|DRUG|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
219120524|NCT02883543|RADIATION|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
219120525|NCT05727059|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
219120526|NCT03838159|DRUG|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
219120527|NCT03838159|DRUG|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
219120528|NCT03838159|DRUG|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
219120529|NCT04245033|DRUG|Dihydroartemisinin-Piperaquine (DP)|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
219120530|NCT06094933|BEHAVIORAL|Mobile Anger Reduction Intervention (MARI)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
219120531|NCT06094933|BEHAVIORAL|Health Education Condition (HED)|This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
219120532|NCT05526235|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
219120533|NCT05526235|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
219120534|NCT05526235|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
219120535|NCT03175991|DIAGNOSTIC_TEST|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
219120536|NCT05377086|OTHER|Schroth 3-Dimensional scoliosis exercise|Schroth 3-Dimensional scoliosis exercises
219120537|NCT05377086|OTHER|conventional scoliosis exercise|conventional scoliosis exercise
219120538|NCT06013488|BEHAVIORAL|Character Strengths Based Coaching Support|Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
219120539|NCT06013488|BEHAVIORAL|Routine Supervision|Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
219120540|NCT03552978|BEHAVIORAL|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS \&Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
219120541|NCT03552978|BEHAVIORAL|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
219120542|NCT05601232|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
219120543|NCT03892785|DRUG|Prednisone treatment|tapering prednisone regimen
219120544|NCT03892785|DRUG|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
219705894|NCT07022093|DEVICE|Custom made insoles|For the production of insoles using the CAD-CAM method; In the production of insoles, medial longitudinal arch support will be added so that the subtalar joints are in a neutral position, and additionally, transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger-under supports to assist with palmar grip will be designed in three dimensions using the EasyCad modelling interface. Using a Vulcan Computer Numerical Control (CNC) milling machine, the insoles will be machined from Ethylene Vinyl Acetate (EVA) material placed in blocks. After this process, the insoles will be adjusted on the milling machine to fit the patient's shoes.For the production of insoles using the 3D printing method, the Elegoo Neptune 4 Max 3D printer will be used. Using TPU material, medial longitudinal arch support will be added, along with transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger support to aid palmar grip.
219705895|NCT06871553|OTHER|Self management education program|"After returning home, patients will be encouraged to practice their self-management behaviors and record the behavior and data to the self-monitoring notebook.~At their next hemodialysis session, patients will bring their self-monitoring notebook, and the nurse will review the behavior and data, and offering feedback. The nurses will provide additional videos and education, and request the patients to share their experiences with other patients in the hemodialysis room. This cycle of education, self-monitoring, and feedback will continue with each hemodialysis session."
219705896|NCT07025369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219705897|NCT07025369|PROCEDURE|Computed Tomography|Undergo PET/CT
219705898|NCT07025369|OTHER|Flotufolastat F-18 Gallium|Given flotufolastat F 18
219705899|NCT07025369|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic assisted radical prostatectomy
219705900|NCT07025369|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymph node dissection
219705901|NCT07025369|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219705902|NCT07025369|DRUG|Relugolix|Given PO
219120545|NCT03892785|DRUG|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
219120546|NCT03892785|OTHER|Questionnaires|HAQ, SF-36, FACIT-fatigue
219120547|NCT03892785|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
219120548|NCT06668285|BEHAVIORAL|parental presence|parental presence in PICU
219120549|NCT01670500|DRUG|Cisplatin|administered intravenously every 3 weeks for 4 doses
219120550|NCT01670500|DRUG|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
219705903|NCT07024589|DRUG|AN2-502998|Oral Capsule
219705904|NCT07024589|DRUG|Placebo|Oral Capsule
219705905|NCT07027813|OTHER|Telemedicine|Provision of Telemedicine support to pediatric patients during ambulance transport.
219705906|NCT07027813|OTHER|Control|Provision of ambulance transport without any telemedicine support.
219120551|NCT01670500|DRUG|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
219120552|NCT04702022|DIAGNOSTIC_TEST|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
219705907|NCT07027345|DRUG|5% TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).
219705908|NCT07027345|DRUG|Topical Placebo Gel|Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).
219705909|NCT06810193|OTHER|Aerobic exercise|After the end-of-season assessments, participants in the Intervention (Exercise or Stretching) arm will be randomized to 2 weeks of daily aerobic exercise for 30 minutes or to 30-minutes of prescribed stretching.
219705910|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
219120553|NCT06318663|OTHER|Survivor Mom Companion|Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
219120554|NCT06136312|DEVICE|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
219120555|NCT03473756|DRUG|Rogaratinib (BAY1163877)|Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
219120556|NCT03473756|DRUG|Atezolizumab|Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
219120557|NCT03514264|PROCEDURE|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
219120558|NCT03514264|PROCEDURE|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
219120559|NCT02148718|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
219120560|NCT04827290|BEHAVIORAL|Low-AGE diet|Low-AGE diet during 24 months
219120561|NCT04827290|BEHAVIORAL|High-AGE diet|High-AGE diet during 24 months
219120562|NCT00129675|DRUG|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
219120563|NCT02053194|BEHAVIORAL|Pharmacist-led educational intervention|1\) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
219120564|NCT04129632|BEHAVIORAL|IEPF Wellness Tool|A daily 5 minute mindfulness exercise over 28 days
219120565|NCT03276702|PROCEDURE|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
219120566|NCT03276702|OTHER|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
219120567|NCT04354311|DEVICE|ANI|Under steady state total intravenous anaesthesia with propofol and remifentanil at constant dosage, tetanus stimulation of the ulnar nerve was performed followed by orotracheal intubation. The variation of ANI and hemodynamic parameters as well as the somatic response associated with both maneuvers were collected.
219120568|NCT02351895|OTHER|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
219120569|NCT03956576|OTHER|[Pyr]apelin-13|Peptide \[Pyr\]apelin-13 infusion
219120570|NCT05763459|DRUG|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
219705911|NCT06705660|OTHER|WEB-based progressive relaxation training|"WEB-based progressive relaxation training will be given for 8 weeks, 2 days a week for 30-45 minutes (16 sessions), following the menstrual cycles of women. Measurements will be taken before and after (at the end of) the intervention. Measurements will be taken 4 weeks after the next menstrual cycle to ensure follow-up.~Progressive relaxation training is an easy-to-learn, non-invasive and side-effect free method. PGE beginners will be trained for at least 30 minutes and practitioners who have learned the basics of the method will be trained to introduce PGE for 15 minutes. Prior to the PGE, individuals will be informed that they should not come overly hungry or overly full (eating should be finished 2 hours before), wear loose and comfortable clothes, avoid clothes that tightly wrap the abdomen (pants, dresses, belts), remove contact lenses, glasses, jewelry and tight shoes. PGE will be administered in a quiet, comfortable and dimly lit place. Women will perform PCI in the supine posit"
219705912|NCT06705660|OTHER|The WEB-based lifestyle interventions|The WEB-based lifestyle interventions will be administered to women by monitoring their menstrual cycles for 8 weeks, with sessions held twice a week for 30-45 minutes each (totaling 16 sessions). Measurements will be taken both before the intervention and after its completion. An additional measurement will be conducted during the following menstrual cycle, 4 weeks later, to ensure follow-up.In this study, telehealth and counseling services will be provided. Through telehealth and counseling, women will have the opportunity to communicate online with healthcare professionals and receive guidance on health goals, nutrition, exercise, and stress management
219705913|NCT01366092|DRUG|Interleukin-2|Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
219705914|NCT06715891|DRUG|Raphamin|Tablet for oral use.
219705915|NCT06715891|DRUG|Placebo|Tablet for oral use.
219120571|NCT03656016|DEVICE|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
219120572|NCT00333788|BIOLOGICAL|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
219225645|NCT02883361|BEHAVIORAL|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
219225646|NCT02883361|BEHAVIORAL|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
219705916|NCT07039617|DEVICE|AIDANET + FCL|All participants will use AIDANET in fully closed loop (FCL) mode with instructions to avoid announcing meal boluses whenever possible during the four weeks.
219705917|NCT07039617|DEVICE|AIDANET + HCL|All participants will use AIDANET in hybrid closed loop (HCL) mode with instructions to announce all meal boluses using carbohydrate counting or easy bolus during the four weeks. All components of AIDANET will remain active during this phase but BPS in particular is expected to be triggered less often due to meal announcements.
219705918|NCT07039617|DEVICE|AIDANET in FCL-HCL-mixed mode|All participants will use AIDANET with instructions to choose whether to use fully closed loop (FCL) or hybrid closed loop (HCL) mode with meal announcements (carb counting or easy bolus) per their discretion each day.
219705919|NCT07039617|OTHER|Automated Insulin Delivery (AID) (usual care)|Participants will manage their diabetes as they normally do at home.
219705920|NCT06883279|OTHER|Intraplexus|The block needle will be advanced from the middle scalene muscle in a posterior-anterior direction and advanced between the C5-C6 nerve roots and the injection will be performed
219705921|NCT06883279|OTHER|Extraplexus|The block needle will first be advanced above the C5 nerve root and towards the anterior part of the brachial plexus and 10 ml of local anesthetic will be injected. Then, the needle will be withdrawn to the posterior surface of the brachial plexus and 10 ml of local anesthetic will be administered.
219705922|NCT07037875|DRUG|Linaprazan glurate 50 mg Twice Daily (BID)|"Participants in this group will receive a total daily dose of 100 mg of linaprazan glurate, administered as 50 mg in the morning and 50 mg in the evening.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that matches the appearance of the lansoprazole capsule. In the evening, they take another 50 mg linaprazan glurate tablet, without any additional placebo."
219120573|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
219120574|NCT03954496|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
219120575|NCT03954496|BEHAVIORAL|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
219120576|NCT04341155|DRUG|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
219120577|NCT04341155|DRUG|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
219120578|NCT00277589|DRUG|Levothyroxin-Na|1 tablet 30 minutes before breakfast
219120579|NCT00277589|DRUG|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
219120580|NCT00277589|DRUG|Iodide|1 tablet 30 minutes before breakfast
219120581|NCT00277589|DRUG|Placebo|1 tablet 30 minutes before breakfast
219120582|NCT00161096|DRUG|pantoprazole 20 mg (drug)|
219120583|NCT00063674|BEHAVIORAL|Nutrition Education|
219705923|NCT07037875|DRUG|Linaprazan Glurate 50 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 50 mg of linaprazan glurate, taken once daily in the morning.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that mimics the lansoprazole capsule. In the evening, they take a placebo tablet that mimics the appearance of the linaprazan glurate tablet."
219705924|NCT07037875|DRUG|Lansoprazole 30 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 30 mg of lansoprazole, taken once daily in the morning.~In the morning, they take one 30 mg lansoprazole capsule along with a placebo tablet that mimics the linaprazan glurate tablet. In the evening, they take another placebo tablet resembling linaprazan glurate."
219705925|NCT07042451|BEHAVIORAL|Pink Cloud|Participants randomized to the Pink Cloud condition will receive a subscription code to access the Pink Cloud mobile application for approximately 365 days. The app includes features such as a searchable database of over 245,000 12-Step meetings (in-person and virtual), a sobriety counter, customizable daily planners, personal inventory tools, and a resentment journal. Participants are encouraged to use the app as they see fit throughout the study period. No prompts or required usage schedules will be imposed; instead, engagement will be self-directed to reflect real-world usage patterns.
219705926|NCT07042451|BEHAVIORAL|Active Control|Participants randomized to the control condition will receive a code to access recovery-related resources hosted on a private study website. These materials include links to mutual-help groups, crisis support services, and educational content and treatment options. Participants may access the website at their discretion and engage with the resources as often and in whatever ways they choose. No prompts or required usage schedules will be imposed.
219705927|NCT06712563|DRUG|Budesonide/glycopyrrolate/formoterol fumarate|Budesonide/glycopyrrolate/formoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist
219120584|NCT00063674|BEHAVIORAL|After-school dance class|
219120585|NCT02175160|OTHER|Braking and functionality|
219120586|NCT00519987|DRUG|intranasal ketamine|intranasal ketamine
219120587|NCT05012254|DRUG|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
219120588|NCT05012254|DRUG|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
219705928|NCT07045974|OTHER|Group A-Mulligan Mobilization|"Group A will receive Mulligan mobilizations (SNAGs). Mulligan SNAGs mobilization technique was applied at level C4/5. Subjects were placed in sitting position and therapist stood behind the patient with therapist's thumbs on spinous process of particular vertebra. Mobilization was given by active movement followed by passive overpressure based on the movement restricted. The duration of treatment was three sets of ten repetitions each.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), and manual traction along with deep neck flexor, and isometric neck strengthening."
219705929|NCT07045974|OTHER|Group B-Stretching Exercises|"Group B will receive stretching exercises. Subject was asked to lie supine on the plinth and the head was held at the edge of the plinth by the therapist. Then with one hand the therapist held the neck in cervical lateral flexion to the opposite side so as to achieve the stretching of the trapezius muscle. Myofascial release by applying sustained finger pressure for 5-10 s on the involved trapezius was given. A gentle myofascial stretching force was applied to take up slack and sustained until a release occurred. This protocol comprised four sets of 15 stretches with 3 min rest.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), manual traction along with deep neck flexor, and isometric neck strengthening."
219705930|NCT07045948|DIAGNOSTIC_TEST|Blood eosinophil Count|Blood sample for blood eosinophil count
219705931|NCT07045727|PROCEDURE|Accelerometry|Ancillary studies
219705932|NCT07045727|OTHER|Aerobic Exercise|Participate in aerobic training program
219705933|NCT07045727|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219705934|NCT07045727|OTHER|Electronic Health Record Review|Ancillary studies
219705935|NCT07045727|OTHER|Exercise Counseling|Receive health coaching check-in calls
219705936|NCT07045727|OTHER|Internet-Based Intervention|Use Connected mHealth app
219705937|NCT07045727|OTHER|Interview|Ancillary studies
219705938|NCT07045727|OTHER|Physical Performance Testing|Ancillary studies
219705939|NCT07045727|OTHER|Resistance Training|Participate in resistance training program
219705940|NCT07045727|OTHER|Survey Administration|Ancillary studies
219705941|NCT07045727|PROCEDURE|Tailored Intervention|Receive personalized exercise plan
219705942|NCT06709534|OTHER|Exercise Intervention|Participate in an individualized online home-based exercise intervention
219705943|NCT06709534|OTHER|Functional Assessment|Complete functional capacity assessment
219120589|NCT05012254|DRUG|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
219705944|NCT06709534|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
219705945|NCT06709534|OTHER|Questionnaire Administration|Ancillary studies
219705946|NCT06709534|OTHER|Supportive Care|Receive social support
219705947|NCT06883292|DIETARY_SUPPLEMENT|Tyrosol|phenolic compound found in olive oil
219705948|NCT06883292|DIETARY_SUPPLEMENT|Creatine|chemical produced naturally by the body used to rapidly regenerate ATP
219705949|NCT06883292|DIETARY_SUPPLEMENT|Resistant Dextrin|A type of soluble dietary fiber that is resistant to digestion in the small intestine. It is a byproduct of the starch hydrolysis process, where starch is broken down into smaller chains of glucose molecules
219705950|NCT06732193|PROCEDURE|On-site respiratory physiotherapy|The patient attends face-to-face physiotherapy sessions prescribed by the doctor.
219705951|NCT06732193|DEVICE|Fissios App|The patient uses the Fissios App to perform respiratory physiotherapy exercises.
219705952|NCT07047716|DRUG|Lenacapavir Injection|Administered intramuscularly
219705953|NCT07047716|DRUG|Lenacapavir Tablet|Administered orally
219705954|NCT05554341|PROCEDURE|Biopsy Procedure|Undergo biopsy
219705955|NCT05554341|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219705956|NCT05554341|PROCEDURE|Computed Tomography|Undergo CT
219705957|NCT05554341|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219705958|NCT05554341|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
219705959|NCT05554341|DRUG|Paclitaxel|Given IV
219705960|NCT06341205|DRUG|RiTUXimab Injection|Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
219705961|NCT06745024|OTHER|Best Practice|Given SOC systemic anti-cancer therapy
219705962|NCT06745024|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219705963|NCT06745024|OTHER|Bone Metastases Treatment|Given bone modifying agent
219705964|NCT06745024|PROCEDURE|Computed Tomography|Undergo CT
219705965|NCT06745024|PROCEDURE|Conventional Radiotherapy|Undergo conventional RT
219705966|NCT06745024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219705967|NCT06745024|OTHER|Patient Observation|Undergo SOC observation
219705968|NCT06745024|OTHER|Questionnaire Administration|Ancillary studies
219120590|NCT05012254|DRUG|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
219120591|NCT05012254|DRUG|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
219120592|NCT05012254|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
219120593|NCT05942079|OTHER|REİKİ|Reiki is applied as an alternative and complementary treatment method.
219120594|NCT01433393|DRUG|TAK-875|
219120595|NCT01433393|DRUG|TAK-875|
219120596|NCT01433393|DRUG|Placebo|
219120597|NCT01305928|OTHER|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~* Assess withdrawal, need for medication change~* Describe warm hand-off process~* Provide 2-page flyer~* Perform call, leave room~* Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~* Collect minimum data set~* Explore thoughts/feelings toward quitting~* Provide medication education~* Build plan to stay quit~* Schedule next call~Staff check-back (5 min):~* Ask patient how session went~* Ask if patient requests cessation medication script on discharge"
219120598|NCT01305928|OTHER|Fax|"Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge"
219120599|NCT01758874|PROCEDURE|phlebotomy|repeated phlebotomy for 4 weeks
219120600|NCT02600182|DEVICE|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
219120601|NCT00510796|BEHAVIORAL|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
219120602|NCT03713645|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
219120603|NCT03826433|BIOLOGICAL|Peripheral iv|6\*10\^7 cells
219120604|NCT02514564|BEHAVIORAL|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
219120605|NCT05557383|BEHAVIORAL|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
219120606|NCT03439371|OTHER|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
219705969|NCT06745024|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219120607|NCT00110682|DRUG|Imiquimod used as an adjunct to cryotherapy|
219120608|NCT05824221|DEVICE|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
219120609|NCT05893563|OTHER|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
219120610|NCT05893563|OTHER|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
219120611|NCT04131907|DEVICE|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
219705970|NCT06868797|OTHER|Biological sample for the measurement of suPAR levels.|Biological sample for the measurement of plasminogen activator receptor (suPAR) level at baseline and at 6 months follow up to assess the evolution of cardio-renal interaction in HF patients listed for heart transplant treated by GDMT including dapagliflozin.
219120612|NCT04131907|DEVICE|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
219120613|NCT01297530|DRUG|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
219705971|NCT06796114|OTHER|blood sample|"A total of 48 ml of blood will be collected at baseline (before STRIDE initiation):~* 6 EDTA 6 ml tubes for PBMC collection~* 2 EDTA 6 ml tube for plasma collection"
219705972|NCT04983888|DRUG|Obinutuzumab|1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
219705973|NCT06343402|DRUG|BBO-8520|Participants will receive assigned dose of BBO-8520 orally (PO), QD
219705974|NCT06343402|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
219120614|NCT01874327|BEHAVIORAL|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
219120615|NCT01874327|BEHAVIORAL|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
219120616|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
219120617|NCT01730014|DRUG|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
219120618|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
219120619|NCT01730014|DRUG|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
219120620|NCT01730014|DRUG|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
219705975|NCT04386447|DRUG|Oxytocin|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
219705976|NCT04386447|DRUG|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients."
219120621|NCT01730014|DRUG|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
219120622|NCT01670227|BEHAVIORAL|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
219120623|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II)|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II)."
219120624|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II), Famitinib|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib."
219120625|NCT02023216|DEVICE|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
219120626|NCT01082146|DRUG|Lurasidone|40 mg suspension, PO, for 7 days
219120627|NCT00871793|OTHER|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
219120628|NCT03975387|DRUG|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
219120629|NCT03276663|OTHER|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
219120630|NCT03331627|DRUG|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
219120631|NCT03532893|OTHER|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
219120632|NCT02357680|OTHER|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
219705977|NCT04724135|OTHER|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
219120633|NCT06210763|BEHAVIORAL|Threshold IMT and traditional physical therapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
219120634|NCT06210763|BEHAVIORAL|traditional physiotherapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
219120635|NCT01778062|DRUG|Indacaterol|Indacaterol 150µg once daily oral inhalation
219120636|NCT01778062|DRUG|Control|Placebo once daily oral inhalation
219120637|NCT05667259|OTHER|Surgical resection for cancer rectum|Curative resection for cancer recum
219120638|NCT01117597|RADIATION|low RF exposure level|Exposure with 1.5 W/kg
219120639|NCT01117597|RADIATION|sham exposure|intervention with sham RF exposure
219120640|NCT01117597|RADIATION|high RF exposure|intervention with high RF exposure
219120641|NCT01632358|DRUG|TAP311 capsules|
219120642|NCT01632358|DRUG|Placebo|
219120643|NCT02834572|BEHAVIORAL|All About Me|Assessment and algorithm to determine recommended HIV testing approach
219120644|NCT02834572|BEHAVIORAL|Control|HIV testing information
219705978|NCT02804217|OTHER|Genetic: mutation profile|
219705979|NCT06783907|BEHAVIORAL|Non-invasive blood glucose monitoring|"Non-invasive wearable glucose monitoring device for capturing participants' blood glucose.~The intervention will include:~1. Training for self-management of diabetes and phone consultation.~2. Follow-up through phone calls or WhatsApp for hypoglycaemic or hyperglycaemic events.~3. Personalized care guided by sensor data.~The Investigator will monitor the health data from the device regularly. A mobile app will track and record compliance with blood glucose monitoring."
219705980|NCT06783907|BEHAVIORAL|Traditional blood glucose monitoring|"Traditional blood glucose monitoring~Participants will engage in traditional self-monitoring of blood glucose at home over the course of 8 weeks. They are recommended to check their blood glucose levels one to two times per week and record all results. This will allow for the collection of data using traditional monitoring methods."
219705981|NCT05835999|DRUG|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
219705982|NCT05835999|DRUG|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
219705983|NCT05835999|DRUG|Placebo once per day|No therapeutic effect
219705984|NCT05835999|DRUG|Placebo once per week|No therapeutic effect
219705985|NCT03608163|DRUG|Naloxone|Naloxone Nasal Spray
219705986|NCT03608163|DRUG|Diazoxide|Diazoxide (oral)
219705987|NCT03608163|DRUG|Placebo (for Naloxone)|Sterile water nasal spray
219705988|NCT03608163|DRUG|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
219705989|NCT06735469|OTHER|Discrete choice experiment|Participants will state their preferences for 1) return of full versus limited results to participants (trust/personal benefit), 2) balancing a study's participant burden with the study's ability to address multiple research aims (burden/knowledge generation), 3) incentivizing clinical assessments vs. conducting home-based assessments (personal benefit/burden), and 4) results generalizable to specific social groups versus the broader population. Participants will evaluate these attributes within a hypothetical trial to prevent chronic diseases.
219705990|NCT06755736|DRUG|superficial cervical plexus block|In anterior cervical discectomy surgeries, superficial cervical block will be used for analgesia.
219705991|NCT06503146|DRUG|[18F]FAPI-74|Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
219120645|NCT04323644|PROCEDURE|Surgery|Emergency or elective surgery
219705992|NCT06503146|DRUG|[18F]FDG|18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
219705993|NCT03335046|BEHAVIORAL|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
219120646|NCT03418896|DRUG|human chorionic gonadotropin|a single injection of a standard dose
219705994|NCT03335046|BEHAVIORAL|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
219120647|NCT04421937|BEHAVIORAL|Procedure: Traditional Dysphagia Therapy (TDT)|"Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks."
219120648|NCT04421937|DEVICE|Procedure: Neuromuscular Electrical Stimulation with TDT|The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
219120649|NCT01372358|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
219120650|NCT05724524|OTHER|Stool sample collection|50mg stool sample taken for protein extraction
219120651|NCT05724524|OTHER|Blood sample collection|Venous blood sample taken for analysis of serum and plasma
219120652|NCT01740011|PROCEDURE|Laparoscopic surgery|
219120653|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
219120654|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
219120655|NCT01910558|DIETARY_SUPPLEMENT|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
219120656|NCT01443975|PROCEDURE|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
219120657|NCT02812212|DEVICE|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
219120658|NCT02812212|DEVICE|diuretic renography|diuretic renography to measure the cortical transit time.
219120659|NCT01625039|BEHAVIORAL|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
219225647|NCT03580629|BEHAVIORAL|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
219705995|NCT07147790|DRUG|After successful revacularization, We will categorize patients into two groups : groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the woun|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
219120660|NCT01625039|BEHAVIORAL|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
219120661|NCT03044496|DRUG|Supraclavicular nerve block|Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
219120662|NCT05050370|BEHAVIORAL|Brief messaging and personalized support|Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
219120663|NCT04445155|BEHAVIORAL|Modified DECIDE Parent and Provider Intervention|The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
219120664|NCT03079505|DRUG|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
219705996|NCT07147790|DRUG|Silver Nanoparticles Irrigant|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
219705997|NCT00523211|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
219705998|NCT00523211|DRUG|Placebo|One tablet of placebo once daily.
219705999|NCT07168629|BEHAVIORAL|Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation|The CHW will perform: 1) patient outreach 2) patient-centered shared-decision making, 3) smoking cessation counseling, and 4) navigation of logistical barriers
219706000|NCT07168629|OTHER|Enhanced Usual Care|After randomization, the control group will receive the same mailed LCS educational materials as the intervention group and encouraged to discuss screening with their PCP, the typical pathway through which patients enter the LCS program.
219706001|NCT07169500|BIOLOGICAL|CAR-T|Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.
219706002|NCT07168473|DRUG|Experimental|"1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
219706003|NCT07168473|DRUG|Comparator|"1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
219706004|NCT07169513|DRUG|Aspirin 75 mg daily|For group 1 patients
219706005|NCT07169513|DRUG|Clopidogrel 75 mg daily|For group 2 patients
219706006|NCT07169513|DRUG|Clopidgrel 75 mg daily|For group 1 patients
219706007|NCT07169513|DRUG|Aspirin 75 mg daily + Clopidgrel 75 mg daily|For group 2 patients
219706008|NCT07167576|OTHER|Catinfo tool and discussion with physician|Patients in the study group watch a computer presentation with information about the cataract surgery
219120665|NCT03079505|DRUG|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
219120666|NCT01103986|BEHAVIORAL|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
219706009|NCT07167576|OTHER|discussion with physician|Patients in the control group have a discussion with the physician
219706010|NCT07167095|OTHER|Retrospective Data Collection and Analysis|This intervention refers to retrospective evaluation of clinical and laboratory data of advanced cancer patients who presented to the emergency department between December 2022 and March 2025. Data will be extracted from the hospital information system (HBYS) and national death registry (e-Nabız). Parameters include demographics, ECOG performance status, primary tumor type, metastatic sites, laboratory markers (e.g., NLR, CRP, albumin, LDH), and outcomes such as 90-day mortality, re-admissions, and re-hospitalizations. No experimental treatment, drug, or device is administered as part of the study.
219706011|NCT07167888|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
219706012|NCT07167888|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
219120667|NCT00366262|DRUG|PLA-695|
219120668|NCT00366262|DRUG|Naproxen|
219120669|NCT00366262|DRUG|Placebo|
219120670|NCT01473511|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
219120671|NCT05532020|DRUG|DCCR (diazoxide choline) extended-release tablets|All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
219120672|NCT01875861|OTHER|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
219120673|NCT06198660|OTHER|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
219120674|NCT06198660|OTHER|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
219120675|NCT06198660|OTHER|conventional therapy only|conventional therapy two sessions for 6 weeks
219120676|NCT04425993|DRUG|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
219706013|NCT07169110|OTHER|SPIN-NA Developmental Observation Grid Assessment via Home-Based Standardized Video Recording|The SPIN-NA intervention consists of an analytical developmental assessment using a standardized clinical observation grid. Infants are filmed once between 1 and 6 months corrected age in their home environment by the grid's creators. Each video includes structured observation scenarios designed to evaluate eight developmental domains (e.g., stress signals, tonic regulation, sensory perception, emotional expressiveness, and parent-infant interaction). The videos are independently assessed by five experienced psychomotor therapists trained in the use of the SPIN-NA grid. No treatment or physical intervention is administered; the intervention is observational and non-invasive, aiming to validate the grid's reproducibility in a real-life setting.
219120677|NCT04425993|DRUG|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
219706014|NCT07167290|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Focused Acceptance and Commitment Therapy will be delivered following a facilitators guide. The intervention is adapted for Spinal Cord Injury patients and is to be delivered on an inpatient neurorehabilitation setting over the course of 1-3 sessions.
219706015|NCT07169071|OTHER|Home-based chest physiotherapy program|he program will include breathing exercises, teaching of relaxation positions, cough training, breathing control strategies, and physical activity recommendations.
219120678|NCT04425993|DRUG|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
219706016|NCT07169071|OTHER|Expiratory Muscle Training|Participants perform expiratory muscle training (EMT) using a threshold device at 30% of their maximum expiratory pressure (MEP). The program consists of twice daily sessions, each lasting 20 minutes, at least 5 days per week, for 8 weeks. Resistance will be increased by 10% each week, adjusted according to tolerance and the presence of any complaints for experimental group.
219706017|NCT07168434|DRUG|Saccharomyces Boulardii 250 MG|Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day
219120679|NCT04425993|DRUG|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
219120680|NCT02062190|DRUG|resveratrol|"100mg 2x/day~1 month"
219120681|NCT02635282|DRUG|intranasal ketamine|
219120682|NCT02635282|DRUG|intranasal fentanyl|
219120683|NCT02635282|DRUG|intranasal midazolam|
219120684|NCT00000582|DRUG|factor ix|
219120685|NCT06476340|OTHER|No intervention|None, questionnaires/CBCT/3D photography/physical examination
219120686|NCT03491124|OTHER|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
219120687|NCT03491124|OTHER|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
219120688|NCT04789200|DRUG|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
219120689|NCT04278430|DEVICE|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
219120690|NCT04278430|DEVICE|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
219120691|NCT02150265|BEHAVIORAL|SMART manual cognitive behavioral therapy|
219120692|NCT04927039|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
219120693|NCT04927039|DRUG|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
219120694|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
219120695|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
219120696|NCT05125692|PROCEDURE|vaginal surgical repair of isthmocele|after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
219120697|NCT03162965|OTHER|Oraquick HIV Self Test|This is an oral swab in home HIV test.
219120698|NCT03162965|OTHER|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
219120699|NCT01186861|DRUG|OSI-906|Tablet administered with food and with up to 200 mL of water
219706018|NCT07168434|DRUG|Placebo 250 mg|Placebo, 250mg, 2 capsules/day
219706019|NCT07168681|OTHER|Control group|"Active Comparator: Control group The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week.~The control group will perform the exercises under normal visual conditions. The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week. Previous research has shown that the SHRed injury prevention neuromuscular training program reduces ankle and knee injuries in youth basketball players by 36% \[35\]. The program consists of balance, agility, strength, and aerobic exercises."
219706020|NCT07169539|DEVICE|SerenApp Digital Psychological Intervention|SerenApp is a co-created, personalized digital intervention designed to support the mental health of women in breast cancer follow-up or survivorship. The app includes modules targeting stress coping, anxiety, and depression, delivered via smartphone or computer. Content and functionalities were developed collaboratively with patients and healthcare professionals, ensuring usability, clinical relevance, and adherence to regulatory and ethical standards. The intervention is intended for self-guided use over eight weeks, with monitoring of engagement, completion, and user satisfaction.
219706021|NCT07169396|OTHER|RNA extraction and gene expression|RNA extraction and gene expression
219706022|NCT07168187|OTHER|Reflexology|Reflexology, a complementary therapy rooted in ancient practices, involves applying pressure to specific points on the feet, hands, or ears thought to stimulate nerve pathways, potentially promoting relaxation and reducing stress. Evidence supporting reflexology's role in obstetrics is growing, with studies highlighting its ability to reduce anxiety, alleviate pain, and influence the duration of labor. Moreover, when reflexology was applied during the active phase of labor it was related to a significant reduction in labor pain intensity and improvements in maternal satisfaction.
219706023|NCT07167524|BIOLOGICAL|Dosage concentration of piperacillin and tazobactam|The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.
219706024|NCT07167901|PROCEDURE|Free Gingival Graft|All patients will undergo free gingival graft surgery by the same surgeon using the same surgical protocol.
219706025|NCT07167134|RADIATION|D1-3-5 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D3, and D5
219120700|NCT01186861|DRUG|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
219120701|NCT01186861|DRUG|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
219120702|NCT06655012|DRUG|Salmeterol|Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
219120703|NCT06655012|DRUG|Placebo|Participants are administered placebo (8 puffs) from a MDI device
219706026|NCT07167134|RADIATION|D1-2-3 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D2, and D3
219120704|NCT00852137|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
219120705|NCT00852137|DRUG|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
219120706|NCT03253770|DEVICE|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
219120707|NCT02353832|DEVICE|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
219120708|NCT06555133|COMBINATION_PRODUCT|yttrium-90 radioembolization|yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
219120709|NCT01244139|DRUG|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
219120710|NCT01244139|DRUG|Placebo|IV infusion dummy drug
219120711|NCT04788030|OTHER|Nerve reconstruction|Nerve bridging with muscle-in-vein conduits
219120712|NCT02881190|DRUG|RC48-ADC|
219120713|NCT05151042|PROCEDURE|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
219120714|NCT05151042|PROCEDURE|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
219120715|NCT04880161|BIOLOGICAL|Ampion|Inhaled Ampion
219120716|NCT04880161|OTHER|Placebo|Inhaled Placebo
219120717|NCT04419532|DRUG|DS-1055a|"Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions"
219120718|NCT00723333|PROCEDURE|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
219120719|NCT05151562|BEHAVIORAL|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
219120720|NCT00250172|DRUG|[C-11](R)-rolipram|
219120721|NCT03194074|DRUG|Propofol|In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
219706027|NCT07169292|PROCEDURE|Wet-cupping|"The intervention consists of three sessions of wet cupping therapy (Hijama), administered once every month over three consecutive months. This study's protocol is distinguished by its standardized, medically supervised approach, designed to align traditional Hijama practices with modern clinical trial standards.~Key features that distinguish this intervention include:~Standardized Procedure: The Hijama protocol follows a detailed, consistent method including suction, superficial skin incisions, and reapplication of suction, followed by honey dressing. All sessions use disposable, single-use instruments and follow strict infection control measures.~Timing Based on Prophetic Recommendation: Cupping is performed on the 17th, 19th, or 21st day of the Islamic lunar month, which is rooted in Islamic tradition and rarely standardized in scientific studies.~Certified Practitioner and Setting: Procedures are conducted by a licensed Hijama practitioner with"
219120722|NCT03194074|DRUG|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
219120723|NCT05591469|DEVICE|IR Camera|the respiration parameters are measured using an IR camera.
219120724|NCT05591469|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
219120725|NCT06991283|DEVICE|transcutaneous vagus nerve stimulation|The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions. The device is set with a pulse width of 200 microseconds and a pulse frequency of 20 hertz. The stimulation intensity is individually adjusted to above the perception threshold and below the discomfort level of 1 milliampere.
219120726|NCT06991283|DEVICE|Sham (no implant)|Vagus nerve stimulation is delivered through a transcutaneous electrical nerve stimulation device by attaching an ear clip to the tragus. But no stimulation will be delivered. The sham stimulation will be performed twice daily, each session lasting for half an hour. The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions.
219706028|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
219706029|NCT07168980|DRUG|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
219706030|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
219120727|NCT06991231|PROCEDURE|Total knee arthroplasty (TKA)|Administered as part of patient standard of care.
219120728|NCT06991231|DEVICE|Cryoablation|Cryoablation will be administered on the leg of the knee indicated for surgery.
219120729|NCT06991218|PROCEDURE|cardiac surgery|Adult patients (age ≥18 years) who underwent cardiac surgery with cardiopulmonary bypass were included.
219120730|NCT05218980|DIETARY_SUPPLEMENT|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
219120731|NCT06674265|BIOLOGICAL|Allogenic NK cells infusion|Natural Killer (NK) cells are extracted from a healthy donor through apheresis and processed in a clean room using the CLINIMACS device. After quality assessment, these cells are stored at -198°C until needed. When required, the cells are thawed, washed, and evaluated for viability and sterility before being administered to the patient at a dosage of 5 × 10\^6 cells per kilogram of body weight. Two further injections may be considered based on the patient's response and confirmed improvement via MRI MIBG. Injections are scheduled seven to ten days after each chemotherapy course according to the standard treatment protocol.
219120733|NCT06918639|PROCEDURE|Pulpotomy|VPT: Partial pulpotomy: 2 mm of pulp tissue is removed with a high speed 014 diamond round bur different from the one used to remove carious tissue. In those cases in which access to the pulp tissue induces a painful sensation due to failure of the anaesthetic technique, intrapulpal anaesthesia shall be used, and this parameter shall be recorded.Cotton wool impregnated with 2.5% stabilised sodium hypochlorite shall be held over the pulp exposure to achieve haemostasis. If it is not possible to control bleeding, proceed to a complete pulpotomy procedure. If in this case it is impossible to achieve haemostasis, the possibility of performing a TPV is ruled out and the RCT is excluded from the study. Once haemostasis has been achieved, BiodentineXp is applied according to the manufacturer's instructions and a material thickness of 2-3 mm is ensured. Full pulpotomy: The same anterior procedure .Complete removal of the tissue from the pulp chamber. Maximum haemostasis time: 10 minutes
219120734|NCT06624813|PROCEDURE|Robot-assisted partial prostatectomy|Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
219120735|NCT06697990|DRUG|Iruplinalib|60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.
219706031|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1
219706032|NCT07168980|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4; Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,4(CNS2-3),8
219706033|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8
219120736|NCT06897215|DEVICE|Hyaluronic acid hydrogel|Assigned to the Experimental Cohort once OM grade 2.0 presents, Gelclair is a hyaluronic acid hydrogel that acts as a protective film in the management of OM. This product is used internationally and has been recently approved by Health Canada as a Class 2 Medical Device with an indication to manage the symptoms of OM caused by radiotherapy and chemotherapy.
219120737|NCT05182892|OTHER|Change of stimulation amplitudes in dopaminergic OFF drug state|Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
219120738|NCT05091684|DRUG|Fibrinogen Concentrate Human|Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours. Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if \< 24 hours.
219120739|NCT06910514|COMBINATION_PRODUCT|Mucopolysaccharide saline solution 0.9%|Injectable solution designed for submucosal elevation in endoscopic mucosal resection. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
219120740|NCT06910514|COMBINATION_PRODUCT|Saline solution 0.9%|Control injectable solution composed of saline 0.9 %. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
219120741|NCT06911515|OTHER|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum
219120742|NCT06908278|BEHAVIORAL|Suture Simulation Training for Episiotomy Repair|"This intervention involves training participants to perform episiotomy repairs using a suture simulator. Participants will practice suturing techniques in a controlled, safe environment to improve their self-efficacy in performing the procedure. The training includes both theoretical learning and hands-on practice. The goal is to enhance the participants' confidence and competence in performing episiotomies.~(This description outlines the nature of the intervention and the learning objectives.)"
219120743|NCT06919120|DRUG|Simethicone is mixed into the final packet of compound polyethylene glycol electrolyte powder|The patients added one bottle of simethicone when taking the final packet of compound polyethylene glycol electrolyte powder.
219120744|NCT06919120|DRUG|Take simethicone separately|Take one bottle of simethicone orally after finishing the last sip of compound polyethylene glycol electrolyte solution.
219120745|NCT04939207|DIAGNOSTIC_TEST|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
219120746|NCT04939207|DIAGNOSTIC_TEST|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
219120747|NCT04939207|DIAGNOSTIC_TEST|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
219706034|NCT07168980|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1
219706035|NCT07168525|DEVICE|Ultrasound spa|Each participant will sit in a bathtub which has been fitted with an ultrasound device which produces low frequency sound waves within the water.
219120748|NCT05696730|OTHER|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
219120749|NCT02408419|DRUG|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
219120750|NCT02408419|DRUG|Saline|Saline is injected as a placebo
219120751|NCT00252681|PROCEDURE|laparotomy|
219120752|NCT00252681|PROCEDURE|primary peritoneal drainage|
219120753|NCT05339906|DEVICE|ZOV.ai digital therapy candidate|ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
219120754|NCT04635878|OTHER|Blood collection|Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
219120755|NCT02990221|DRUG|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
219120756|NCT02990221|PROCEDURE|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
219120757|NCT04106687|PROCEDURE|Ultrasound Guided Caudal Block|Postoperative pain procedure
219120758|NCT04106687|PROCEDURE|Sacral Erector Spinae Block|Postoperative pain procedure
219120759|NCT04288973|DIAGNOSTIC_TEST|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
219706036|NCT07168525|OTHER|Sham ultrasound spa|The control group will sit in the same tub for 45 minutes, 3 times per week for 8 weeks but without the ultrasound being turned on.
219706037|NCT07168460|BEHAVIORAL|Dog-assisted support|Children in the intervention group received dog-assisted support for 30 minutes per session, twice per week for 10-12 weeks. The process began with children meeting school dog with dog handlers either at their home or at school. During the intervention, children had physical contact with dogs as much as they wished and on consideration of dogs' welfare. The dog handler carried out some pedagogical tasks, such as children reading to the dog while the dog was next to the child or when its head was on the child's lap. The dog handler documented the process of each session in a protocol filled in after each session and observed the children on their educational tasks.
219706038|NCT07168460|BEHAVIORAL|Special education teacher support|Children in the control group met special education teachers and received pedagogical tasks involving Swedish, mathematics, etc. Similar to the dog team, special education teachers documented the process and observed the performance of children's educational tasks.
219120760|NCT06244147|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha Root Extract|Participants will take KSM-66 Ashwagandha root extract 300mg twice a day for the duration of the study.
219120761|NCT06440174|PROCEDURE|endoscopic ultrasound|EUS is an invasive procedure combining upper gastrointestinal endoscopy with ultrasonography. An ultrasound probe located at the end of the endoscope allows direct visualisation of the oesophageal wall layers and adjacent tissues providing local assessment of the depth of tumour invasion and lymph nodes. This assessment informs local tumour (T-) and node (N-) staging which are important prognostic indicators of survival. Patients undergoing EUS require sedation and there are risks of complication. EUS is a specialist investigation requiring many years of dedicated training to perform competently.
219120762|NCT01329120|PROCEDURE|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
219120763|NCT01329120|PROCEDURE|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
219120764|NCT05370989|OTHER|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
219120765|NCT05370989|OTHER|ongoing treatment|Health service of the control group will ongoing.
219120766|NCT03064503|BIOLOGICAL|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
219120767|NCT03064503|DEVICE|MRI|MRI will be performed to measure interstitial fibrosis
219120768|NCT03064503|BIOLOGICAL|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
219120769|NCT06349486|DRUG|vonoprazan, amoxicillin, tripotassium dicitrate bismuthate|bismuth-amoxicillin-vonoprazan triple therapy
219120770|NCT06349486|DRUG|vonoprazan, amoxicillin|vonoprazan-amoxicillin dual therapy
219120771|NCT06349486|DRUG|rabeprazole, amoxicillin, clarithromycin|proton pump inhibitor-based standard triple therapy
219120772|NCT05229510|DRUG|50 mg/mL Virazole Inhalant Product|50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
219120773|NCT05229510|DRUG|100 mg/mL Virazole Inhalant Product|100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
219120774|NCT05229510|DRUG|Placebo|Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
219120775|NCT05501132|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
219120776|NCT00315627|DRUG|Islet transplantation|Islet transplantation
219120777|NCT01115998|OTHER|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
219120778|NCT01115998|OTHER|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
219120779|NCT00915850|DRUG|DCF|docetaxel, Cisplatin and 5-FU
219120780|NCT04428970|PROCEDURE|Invasive ICP monitoring|Insertion of a parenchymal pressure measuring probe
219120781|NCT06270290|OTHER|Exposure to contact sports or history of concussions|History of contact sports practices or of concussions
219120782|NCT01268059|DRUG|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
219706039|NCT07167069|RADIATION|Radiation Therapy|Standard of Care Chemoradiation for Cervical cancer patients in India.
219706040|NCT07167498|BEHAVIORAL|Intermittent midwife absence during remote monitoring of remifentanil PCA in labour|"Midwife absence during remifentanil PCA for labour analgesia.~We aim to include a total of 80 participants. All will receive remifentanil PCA for labour analgesia and be monitored with remote monitoring equipment. First a group of 40 parturients will be included, and the attending midwife will not be allowed to leave the parturient (Group 1). A following group of 40 parturients will then be included and the attending midwife can leave the room in intervals up to 10 minutes (Group 2)."
219706041|NCT01682525|OTHER|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
219706042|NCT03978767|DRUG|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
219706043|NCT03978767|DRUG|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
219120783|NCT01268059|DRUG|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
219706044|NCT03978767|DRUG|Acetaminophen|Analgesic medication to be used in both treatment arms
219706045|NCT03978767|DRUG|Oxycodone|Analgesic medication to be used in both treatment arms
219120784|NCT01268059|DRUG|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
219706046|NCT05084456|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
219706047|NCT04898556|DRUG|Prasterone 6.5 MG|The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
219120785|NCT01214447|OTHER|No intervention|Observational study - no intervention
219120786|NCT02819479|DRUG|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
219120787|NCT02819479|DRUG|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
219120788|NCT03114943|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
219706048|NCT04898556|OTHER|Placebo|Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.
219706049|NCT02953691|DRUG|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
219706050|NCT02953691|DRUG|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
219706051|NCT01754649|DRUG|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
219120789|NCT03114943|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
219120790|NCT02174679|DRUG|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
219120791|NCT00196911|PROCEDURE|Implantation of stimulation electrodes in the STN|
219706052|NCT03395964|PROCEDURE|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
219706053|NCT03395964|PROCEDURE|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
219706054|NCT03070652|BEHAVIORAL|NBO, Newborn behavioral observation|
219706055|NCT03070652|BEHAVIORAL|Practice as usual|
219706056|NCT01331434|DRUG|exemestane|25 mg tablet
219706057|NCT04403633|OTHER|mobile health educational tool|Interactive educational tool delivered on iPad
219706058|NCT06116851|OTHER|MRI scan and laboratory visit|Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
219120792|NCT01097980|DRUG|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
219120793|NCT01097980|DRUG|Placebo|Placebo
219120794|NCT02294162|DRUG|Ketamine i.v|
219120795|NCT01120574|OTHER|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
219120796|NCT05732948|DRUG|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
219120797|NCT06292702|PROCEDURE|Traditional Burch colposuspension|Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
219120798|NCT06292702|PROCEDURE|Modified Burch colposuspension|Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
219120799|NCT01142999|DRUG|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
219120800|NCT01142999|DRUG|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
219120801|NCT01142999|DRUG|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
219120802|NCT01142999|DRUG|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
219120803|NCT03147092|DRUG|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
219120804|NCT03147092|DRUG|Atenolol|Treatment of hypertensive subjects
219120805|NCT03147092|DRUG|Losartan potassium 50mg|Treatment of hypertensive subjects
219120806|NCT03147092|DRUG|Clonidine|Treatment of hypertensive subjects
219120807|NCT03805360|DRUG|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
219120808|NCT03805360|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
219120809|NCT02343614|DRUG|Celecoxib|
219120810|NCT06490094|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|"The 8-week IBSR program is a clinical intervention based on The Work method, developed by Byron Katie and run in the US and Europe for 35 years. The IBSR intervention will involve weekly group meetings (3 hours/meeting) throughout 8 weeks. Home practice between sessions will be supported by facilitator assistants (1-hour session per week). All sessions will be standardized according to the IBSR certification program guidelines and will be assessed to maintain consistency in the program, as in previous studies. ."
219120811|NCT03348826|DRUG|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
219120812|NCT03348826|DRUG|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
219120813|NCT01646320|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
219120814|NCT01646320|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
219120815|NCT01646320|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
219120816|NCT01646320|DRUG|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
219120817|NCT06449235|DRUG|Omarigliptin|"Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing."
219120818|NCT06449235|DRUG|Sulphonylureas|"Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs."
219120819|NCT06449235|DRUG|Metformin|"Chemical Name: Metformin Class: Biguanide~Mechanism of Action:~Decreases hepatic glucose production. Improves insulin sensitivity in peripheral tissues. Enhances peripheral glucose uptake and utilization. Reduces intestinal absorption of glucose. Administration: Administered orally, usually once or twice daily with meals."
219120820|NCT06449235|DRUG|Other DPP4-i|"Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs."
219120821|NCT06449235|DRUG|Thiazolidinediones|"Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
219706059|NCT06116851|PROCEDURE|Prostate biopsies|The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
219706060|NCT06116851|PROCEDURE|Radical prostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
219706061|NCT06116851|PROCEDURE|TURP and blood, urine and tissue sampling|Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
219706062|NCT06116851|PROCEDURE|Radical cystoprostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
219706063|NCT02050204|BEHAVIORAL|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
219706064|NCT02930447|DEVICE|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
219706065|NCT01111669|DRUG|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
219120822|NCT06449235|DRUG|Alpha-Glucosidase Inhibitor|"Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response."
219120823|NCT06449235|DRUG|Glucagon-Like Peptide-1|"Chemical Name: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: GLP-1 Receptor Agonists~Mechanism of Action:~Mimics the action of endogenous GLP-1. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
219120824|NCT06449235|DRUG|Receptor Agonists (GLP1RA)|"Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
219120825|NCT06449235|DRUG|SGLT2 inhibitors|"Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors~Mechanism of Action:~Inhibits SGLT2 in the proximal renal tubules. Reduces reabsorption of filtered glucose from the renal tubules. Increases urinary glucose excretion. Lowers blood glucose levels independently of insulin. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
219120826|NCT01489020|BIOLOGICAL|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
219120827|NCT01489020|BIOLOGICAL|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
219120828|NCT00258713|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
219120829|NCT00375856|DEVICE|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
219120830|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
219120831|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
219120832|NCT04103047|OTHER|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
219120833|NCT04027361|DRUG|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
219120834|NCT00069719|DRUG|Glaucoma therapy|
219706066|NCT01111669|DRUG|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
219706067|NCT02634463|DRUG|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
219706068|NCT02634463|OTHER|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
219120835|NCT02814760|OTHER|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
219120836|NCT00099918|DRUG|vildagliptin|
219120837|NCT04252937|DRUG|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
219120838|NCT03128203|DRUG|Oxytocin|Oxytocin, intranasally administrated
219120839|NCT03128203|DRUG|Placebos|Saline, intranasally administrated
219120840|NCT01411280|DRUG|methylphenidate|Ritalin 10mg, Ritalin 20mg
219120841|NCT00414414|DRUG|Prednisone|
219120842|NCT00414414|DRUG|placebo|placebo
219120843|NCT00083564|DRUG|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
219120844|NCT04609540|DRUG|Trastuzumab|Dual anti-HER2 therapy
219120845|NCT01174550|PROCEDURE|Coronary Angiography|Use of standard equipment for usual-care testing
219120846|NCT01174550|PROCEDURE|Stress Echocardiogram|Use of standard equipment for usual-care testing
219120847|NCT01174550|PROCEDURE|Nuclear Stress Test|Use of standard equipment for usual-care testing
219120848|NCT01174550|PROCEDURE|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
219120849|NCT04509284|OTHER|Training|The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
219120850|NCT04509284|OTHER|Control|The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
219120851|NCT06268925|OTHER|Exercises|number of exercises will be guided to do through zoom
219120852|NCT00846209|OTHER|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
219120853|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
219120854|NCT03115775|DIETARY_SUPPLEMENT|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
219120855|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
219120856|NCT03115775|OTHER|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
219120857|NCT02821312|DRUG|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
219120858|NCT02821312|DRUG|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
219120859|NCT03572413|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
219120860|NCT03572413|DRUG|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
219120861|NCT05080595|OTHER|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
219120862|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
219120863|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
219120864|NCT05036694|DEVICE|FUJILAM KIT|Urine based test to detect LAM
219120865|NCT06783673|PROCEDURE|Upper GIT endoscopy|upper GIT endoscopy of suspected cases and multiple biopsies will be taken for histopathological examination
219120866|NCT05835050|DIAGNOSTIC_TEST|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
219120867|NCT04061161|DRUG|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
219120868|NCT00000568|BEHAVIORAL|smoking cessation|
219120869|NCT00000568|DRUG|ipratropium|
219120870|NCT05588882|PROCEDURE|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
219120871|NCT05588882|PROCEDURE|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
219120872|NCT03504605|OTHER|Online self-compassion intervention|Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
219120873|NCT02087033|DIETARY_SUPPLEMENT|ritmonutra|2 tablets a day by mouth for 4 weeks
219120874|NCT02087033|DIETARY_SUPPLEMENT|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
219120875|NCT05257837|BEHAVIORAL|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
219120876|NCT05257837|OTHER|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
219120877|NCT00164593|BEHAVIORAL|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
219120878|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
219120879|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
219120880|NCT01625338|DRUG|SOF|SOF 400 mg tablet administered orally once daily
219120881|NCT01625338|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219120882|NCT01625338|DRUG|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
219120883|NCT04565314|DIETARY_SUPPLEMENT|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
219120884|NCT05767164|PROCEDURE|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
219120885|NCT00234559|DEVICE|VAC® Therapy System|
219706069|NCT02634463|DRUG|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent \[eq.\] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
219706070|NCT02634463|DRUG|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
219706071|NCT06086795|OTHER|Whole eggs|3 large whole eggs per day for 4 weeks
219706072|NCT06086795|OTHER|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
219120886|NCT05636436|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
219120887|NCT05636436|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
219120888|NCT05636436|BIOLOGICAL|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
219120889|NCT05636436|BIOLOGICAL|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
219706073|NCT06086795|OTHER|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
219120890|NCT05636436|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
219120891|NCT05636436|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
219120892|NCT04731714|DEVICE|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
219120893|NCT04731714|DEVICE|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
219120894|NCT04758403|RADIATION|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
219120895|NCT04758403|RADIATION|Cone beam computed tomography (CBCT)|Per Protocol
219120896|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
219120897|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
219120898|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
219120899|NCT05493722|OTHER|PS and OS stimulation order 1|PS, OS, OS
219706074|NCT00359684|DRUG|Cysteamine|Cystine-depleting agent
219120900|NCT05493722|OTHER|PS and OS stimulation order 2|OS, PS, OS
219120901|NCT05493722|OTHER|PS and OS stimulation order 3|OS, OS, PS
219120902|NCT05343455|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
219120903|NCT05343455|DRUG|Doxycycline|Doxycycline 40 mg capsules
219120904|NCT05343455|DRUG|Placebo|Placebo capsules
219120905|NCT06121791|OTHER|Normal values of abdominal level muscle areas of Turkish children|age, sex, L3-L4 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area, L4-L5 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area
219120906|NCT05138796|DRUG|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
219120907|NCT05138796|DRUG|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
219120908|NCT02451904|OTHER|Observation|
219120909|NCT05441475|DRUG|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w|All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
219120910|NCT03826212|DIETARY_SUPPLEMENT|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
219120911|NCT03826212|DIETARY_SUPPLEMENT|Placebo|Placebo 1,600 mg/day for 12 weeks.
219120912|NCT06438393|DIAGNOSTIC_TEST|CT coronary angiography and non-contrast CT|"A CTCA is an X-ray computed tomography of the coronary arteries that allows visualization of coronary plaques with high temporal and spatial resolution, however, it implies the use of iodine contrast and exposition to clinically significant ionizing radiation.~Non-contrast ECG-gated CT (calcium score - CCS image). A non-contrast cardiac CT for CCS can be performed very quickly with significantly lower radiation (\~6 times lower) than CTCA and without the need for contrast."
219120913|NCT05969106|DEVICE|Tandem Control-IQ|AID-system
219120914|NCT00765362|DEVICE|Encore Mobile-Bearing Knee|Used for primary total knee replacement
219706075|NCT04955691|OTHER|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
219706076|NCT04955691|OTHER|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
219706077|NCT06420271|DEVICE|Real (real iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 190 seconds with a frequency of 5 Hz coupled with iTBS (coil positioned tangentially with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
219706078|NCT06420271|DEVICE|Sham (sham iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 10 seconds with a frequency of 5 Hz coupled with sham iTBS (coil positioned perpendicularly with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
219706079|NCT05399680|DEVICE|S.M.A.R.T. RADIANZ™ Vascular Stent System|The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
219706080|NCT05399680|DEVICE|BRITE TIP RADIANZ™ Guiding Sheath|BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
219120915|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
219120916|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
219120917|NCT00298935|PROCEDURE|Osteopathic manipulative treatment (OMT)|
219120918|NCT04066543|DEVICE|TACE|The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.
219120919|NCT04066543|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
219120920|NCT03930186|DRUG|Apremilast|Tablets for oral administration
219120921|NCT03930186|DRUG|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
219120922|NCT06343961|PROCEDURE|Intraoperative Fluorescein Angiography|Targeted laser photocoagulation under the guidance of intraoperative fluoroscopy
219120923|NCT04525300|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
219120924|NCT04525300|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
219120925|NCT05471921|BEHAVIORAL|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
219120926|NCT05471921|BEHAVIORAL|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
219120927|NCT06273189|DEVICE|Conventional|In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)
219120928|NCT06273189|DEVICE|Bone Scalpel|In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
219120929|NCT04576195|OTHER|Real PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session."
219120930|NCT04576195|OTHER|Sham PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One single session"
219120931|NCT04187911|BEHAVIORAL|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
219706081|NCT05399680|DEVICE|SABERX RADIANZ™ PTA Balloon Catheter|SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
219706082|NCT02659865|DRUG|Placebo|Administered orally
219706083|NCT02659865|DRUG|LY3039478 Capsule Formulation (Formulation 3)|Administered orally
219706084|NCT02659865|DRUG|LY3039478 Drug-in Capsule (Reference, Formulation 1)|Administered orally
219706085|NCT02659865|DRUG|LY3039478 Formulated Capsule (Test, Formulation 3)|Administered orally
219706086|NCT05084404|DRUG|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
219706087|NCT05084404|DRUG|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
219120932|NCT04187911|BEHAVIORAL|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
219120933|NCT01639274|OTHER|COPD prevalence|Determine prevalence of COPD
219120934|NCT00379249|DRUG|Rosuvastatin|
219120935|NCT02033993|DRUG|Nab-Paclitaxel|
219120936|NCT02033993|DRUG|Paclitaxel|
219120937|NCT02332317|BEHAVIORAL|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
219120938|NCT03140293|DRUG|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
219120939|NCT03140293|DRUG|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
219120940|NCT04302090|OTHER|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
219120941|NCT06459362|DIAGNOSTIC_TEST|Serum cystatin C|Diagnostic test for detection of acute kidney injury
219120942|NCT04710693|DIAGNOSTIC_TEST|CAD polyp-detection system|Software will be used during the procedure to aid the detection of polyps during the procedure.
219120943|NCT01800409|DEVICE|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
219120944|NCT00375128|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
219120945|NCT00375128|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
219120946|NCT05173493|DRUG|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
219120947|NCT05173493|DRUG|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
219120948|NCT05173493|DRUG|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
219120949|NCT05665309|PROCEDURE|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
219120950|NCT01636362|DEVICE|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
219120951|NCT06090435|BEHAVIORAL|Therapeutic exercise plus motor imagery|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).
219120952|NCT06090435|BEHAVIORAL|Therapeutic exercise plus action observation|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).
219120953|NCT06090435|BEHAVIORAL|Therapeutic exercise|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
219120954|NCT00926965|DRUG|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
219120955|NCT00926965|DRUG|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
219120956|NCT00926965|DRUG|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
219120957|NCT00003431|BIOLOGICAL|recombinant flt3 ligand|
219120958|NCT02181959|DRUG|Pharmaton® with DMAE|
219120959|NCT02181959|DRUG|Pharmaton® without DMAE|
219120960|NCT02181959|DRUG|Placebo|
219120961|NCT00021398|DRUG|fluorouracil|
219120962|NCT00021398|DRUG|leucovorin calcium|
219120963|NCT00021398|PROCEDURE|conventional surgery|
219120964|NCT00021398|RADIATION|radiation therapy|
219120965|NCT04621071|DIETARY_SUPPLEMENT|Probiotics (2 strains 10x10^9 UFC)|Probiotic vs Placebo (1:1)
219120966|NCT04621071|DIETARY_SUPPLEMENT|Placebo (potato starch and magnesium stearate)|Probiotic vs Placebo (1:1)
219120967|NCT02622425|DIETARY_SUPPLEMENT|Placebo|maltodextrin
219120968|NCT02622425|DIETARY_SUPPLEMENT|PD01|Carotenoid-producing Bacillus strain PD01
219120969|NCT02521259|DEVICE|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
219550958|NCT03676790|OTHER|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
219120970|NCT04313387|DIAGNOSTIC_TEST|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
219120971|NCT04082455|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
219120972|NCT01244009|DRUG|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
219120973|NCT05719636|OTHER|Conventional treatment|Conventional protocol that involves simple active and passive range of motion exercises of lower limb with positioning for assistive devices was provided
219120974|NCT05719636|OTHER|Progressive resistance exercise|The protocol that was applied on the members of (experimental group) are progressive resistance exercises. These passive resistance exercises included Flexion, Extension, Abduction, Adduction of hip; Flexion, Extension of knee; with minimum time in start and minimum quantity of loads, with Thera bands and sandbags,.
219120975|NCT02900911|OTHER|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
219120976|NCT02900911|OTHER|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
219120977|NCT00765661|DRUG|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
219120978|NCT00765661|DRUG|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
219120979|NCT01214564|DRUG|PEP005 (ingenol mebutate) Gel|0.05%
219120980|NCT03569969|PROCEDURE|device: Tympanoplasty with Membrane Amniotic|amniotic membrane Tympanoplasty
219120981|NCT03569969|PROCEDURE|Tympanoplasty With Autologous Fascia|Autologous Temporalis fascia Tympanoplasty
219120982|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
219120983|NCT05874999|OTHER|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
219120984|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
219120985|NCT05722171|BIOLOGICAL|gdT cell injection targeting B7-H3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
219120986|NCT05004779|PROCEDURE|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
219120987|NCT05004779|PROCEDURE|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
219120988|NCT05460130|BEHAVIORAL|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
219120989|NCT00440674|DEVICE|CoStar Paclitaxel-eluting coronary stent system|
219120990|NCT00238199|DIETARY_SUPPLEMENT|calcitriol|
219120991|NCT00238199|DRUG|docetaxel|
219120992|NCT03522428|DIETARY_SUPPLEMENT|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
219120993|NCT00457080|DEVICE|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
219120994|NCT05368506|DRUG|Wee1 Inhibitor ZN-c3|Given PO
219120995|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Active DBS Therapy
219120996|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Implanted system but no stimulation
219120997|NCT03044093|DRUG|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
219120998|NCT03044093|DRUG|Placebo|The group that will only get Misoprostol
219120999|NCT03044093|DRUG|Misoprostol|Both groups will get think drug
219121000|NCT03076658|RADIATION|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
219121001|NCT05915871|DRUG|Tegoprazan|Tablet for oral administration
219121002|NCT05915871|DRUG|Bismuth|Capsule for oral administration
219121003|NCT05915871|DRUG|Amoxicilli|Capsule for oral administration
219706088|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
219706089|NCT00133796|DRUG|Herceptin|IV
219706090|NCT06502158|DRUG|Mifepristone|200 milligrams (mg)
219706091|NCT06502158|DRUG|Misoprostol|600 micrograms (ug)
219121004|NCT05915871|DRUG|Clarithromycin|Tablet for oral administration
219121005|NCT05724212|DIAGNOSTIC_TEST|Interferon gamma release assay (IGRA)|in vitro test
219121006|NCT00421694|DRUG|Bicalutamide|
219121007|NCT03897166|DEVICE|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
219121008|NCT00311428|BIOLOGICAL|Influenza|
219121009|NCT01969162|PROCEDURE|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
219121010|NCT01521949|DRUG|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
219121011|NCT05804864|DRUG|KM501|1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
219706092|NCT01288430|DRUG|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
219706093|NCT04131803|DRUG|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
219121012|NCT00422721|PROCEDURE|realization of a family tree|
219121013|NCT00422721|PROCEDURE|refractometry|
219121014|NCT00422721|PROCEDURE|evaluation of the presence of a nystagmus|
219121015|NCT00422721|PROCEDURE|ocular behavior|
219121016|NCT00422721|PROCEDURE|test of baby vision|
219121017|NCT00422721|PROCEDURE|test of keenness|
219121018|NCT00422721|PROCEDURE|reading test|
219121019|NCT00422721|PROCEDURE|visual field|
219121020|NCT00422721|PROCEDURE|color vision|
219121021|NCT00422721|PROCEDURE|electroretinographical activity|
219121022|NCT00422721|PROCEDURE|biomicroscopical test|
219121023|NCT00422721|PROCEDURE|retinal imaging|
219121024|NCT00422721|PROCEDURE|retinal autofluorescence|
219121025|NCT00422721|PROCEDURE|genotyping|
219121026|NCT06169761|OTHER|Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea|"The following items will be assessed:~1. Risk for sleep apnea, through the STOP-BANG Questionnaire.~2. Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~3. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~4. Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~5. Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~6. Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~7. Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements."
219121027|NCT01429961|DRUG|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1\~14
219121028|NCT03819569|PROCEDURE|Small Renal Mass Biopsy|Subjects will receive a small renal mass biopsy prior to making a treatment decision
219121029|NCT03819569|OTHER|No Small Renal Mass Biopsy|Subjects will not receive a small renal mass biopsy prior to making a treatment decision
219121030|NCT04525274|DRUG|normal saline|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
219121031|NCT04525274|DRUG|dexmedetomidine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
219121032|NCT04525274|DRUG|Ketamine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
219121033|NCT03084952|DRUG|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
219121034|NCT03084952|DRUG|Glucantime|Leishmaniasis standard drug in Brazil
219121035|NCT00933062|DRUG|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
219121036|NCT00933062|DRUG|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
219121037|NCT02958761|BIOLOGICAL|intraarticular injections of platelet lysate|
219121038|NCT02958761|DRUG|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
219706094|NCT04131803|DRUG|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
219706095|NCT04607096|BEHAVIORAL|Intermittent fasting|The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
219706096|NCT04607096|BEHAVIORAL|Control diet|Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
219121039|NCT05645042|BEHAVIORAL|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
219706097|NCT02970864|DEVICE|Polynerve|Polymer biomaterial nerve conduit
219121040|NCT05645042|BEHAVIORAL|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
219121041|NCT00538408|PROCEDURE|Whole body magnetic resonance angiography (dotarem)|
219121042|NCT00538408|DEVICE|Whole body magnetic resonance angiography (vasovist)|
219121043|NCT03566589|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
219121044|NCT02270073|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
219706098|NCT05795335|DRUG|CDK4/6 inhibitor|CDK4/6 inhibitors
219706099|NCT04639063|OTHER|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
219706100|NCT04853290|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
219706101|NCT04853290|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
219706102|NCT06832878|DRUG|Oral Tranexamic Acid|Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3
219121045|NCT00180687|DRUG|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
219121046|NCT00180687|DRUG|Normal Saline|Nebulised Normal Saline
219121047|NCT00180687|DRUG|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
219121048|NCT00180687|OTHER|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
219121049|NCT04394819|OTHER|electromyography-triggered electrical stimulation|All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
219121050|NCT03847168|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
219121051|NCT02055911|DRUG|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
219121052|NCT04252703|PROCEDURE|Percutaneous coronary intervention (PCI)|Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
219121053|NCT03352050|DIETARY_SUPPLEMENT|mushroom|
219121054|NCT03352050|OTHER|ground beef|
219121055|NCT01084122|DRUG|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
219121056|NCT03048110|DRUG|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
219121057|NCT03048110|DRUG|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
219121058|NCT03048110|DRUG|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
219121059|NCT02075983|BIOLOGICAL|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
219121060|NCT04537351|BIOLOGICAL|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
219121061|NCT03712098|DRUG|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
219121062|NCT03712098|DRUG|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
219121063|NCT03712098|BEHAVIORAL|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
219121064|NCT03605017|BEHAVIORAL|Virtual Reality Executive Function Training (VREFT)|
219121065|NCT01609153|DRUG|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
219121066|NCT01609153|DRUG|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
219121067|NCT01609153|DRUG|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
219121068|NCT00498277|PROCEDURE|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
219121069|NCT02303340|RADIATION|Dual Energy X-ray Absorptiometry|
219121070|NCT00043940|DRUG|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
219121071|NCT02790762|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
219121072|NCT05000775|DIETARY_SUPPLEMENT|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
219121073|NCT05000775|DIETARY_SUPPLEMENT|Placebo|Placebo
219121074|NCT00994136|DRUG|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
219121075|NCT06304844|DIAGNOSTIC_TEST|transient elastography (Fibroscan)|conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)
219121076|NCT04157764|DEVICE|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
219121077|NCT00000816|DRUG|Sulfamethoxazole-Trimethoprim|
219121078|NCT01612364|PROCEDURE|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
219121079|NCT04032457|DEVICE|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
219121080|NCT04032457|DEVICE|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
219121081|NCT02328456|OTHER|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
219121082|NCT03291795|OTHER|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
219121083|NCT02310490|DEVICE|DA-13-007 right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
219121084|NCT02310490|DEVICE|DA-13-007 left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
219121085|NCT00513903|BEHAVIORAL|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
219706103|NCT06833788|DRUG|Ferric carboxymaltose IV|Single dose of Ferric carboxymaltose 1000 mg (20mL) IV infusion (20ml vial of 1000mg iron or two 10ml vials of 500mg)
219706104|NCT06833788|DRUG|TIMOFÉROL®|100 mg once a day (2 pills of TIMOFÉROL® 50mg)
219706105|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
219121086|NCT00513903|BEHAVIORAL|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
219706106|NCT03768999|DIAGNOSTIC_TEST|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
219706107|NCT05802940|BEHAVIORAL|Electronic health record best practice alert|The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
219121087|NCT01342653|OTHER|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
219121088|NCT01601743|BEHAVIORAL|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
219121089|NCT01601743|BEHAVIORAL|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
219121090|NCT01601743|BEHAVIORAL|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
219706108|NCT05652101|OTHER|collection of medical data|"The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available"
219706109|NCT05652101|OTHER|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
219706110|NCT06125743|BEHAVIORAL|Usual Care|Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
219706111|NCT06125743|BEHAVIORAL|In-Person LEF-SMP|Participants will receive the in-person LEF-SMP intervention.
219706112|NCT06125743|BEHAVIORAL|Telehealth LEF-SMP|Participants will receive the telehealth LEF-SMP intervention.
219706113|NCT06056102|DRUG|Cyclophosphamide|"* Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3"
219121091|NCT01536782|PROCEDURE|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
219121092|NCT01536782|PROCEDURE|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
219121093|NCT01536782|DEVICE|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
219121094|NCT05648955|DIETARY_SUPPLEMENT|an enriched high protein and high energy oral nutrition supplement (ONS)|NA (see intervention name)
219121095|NCT02034084|PROCEDURE|left radial approach|Coronary diagnostic procedures performed through left radial approach
219121096|NCT02034084|PROCEDURE|Right radial approach|coronary diagnostic procedures performed through right radial approach
219121097|NCT02783482|BIOLOGICAL|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
219121098|NCT05847764|DRUG|RC48+Tislelizumab+carboplatin|RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations
219121099|NCT05847764|DRUG|RC48+Furmonertinib, 1L|RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
219121100|NCT05847764|DRUG|RC48+Furmonertinib, 2L+|RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
219121101|NCT02539758|OTHER|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
219121102|NCT02539758|DEVICE|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
219121103|NCT02539758|DEVICE|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
219121104|NCT00953160|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
219121105|NCT05374083|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket
219121106|NCT05374083|PROCEDURE|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
219121107|NCT05121870|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
219121108|NCT05121870|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo intravenously at week 0, week 4, week 8.
219121109|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
219121110|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
219121111|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
219121112|NCT03937271|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
219121113|NCT03937271|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
219121114|NCT02537444|DRUG|Acalabrutinib|
219121115|NCT02537444|DRUG|acalabrutinib and pembrolizumab combination|
219706114|NCT06056102|BIOLOGICAL|CART-BCMA|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
219706115|NCT06056102|BIOLOGICAL|huCART19|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
219706116|NCT06056102|DRUG|Fludarabine|• Cohort 3: 24mg/m\^2 daily x 3
219121116|NCT05168644|DRUG|Niclosamide Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
219121117|NCT05168644|DRUG|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
219121118|NCT01686269|PROCEDURE|blood collecting|
219121119|NCT02724020|DRUG|Everolimus|Everolimus capsules.
219121120|NCT02724020|DRUG|MLN0128|MLN0128 capsules.
219121121|NCT02724020|DRUG|MLN1117|MLN1117 capsules.
219121122|NCT00425503|DRUG|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
219121123|NCT04808869|OTHER|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
219121124|NCT05466903|DIETARY_SUPPLEMENT|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
219121125|NCT03337880|OTHER|instrumental delivery|the birth was assisted with an extractor.
219121126|NCT05081375|DRUG|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
219121127|NCT05081375|DRUG|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
219121128|NCT00444717|DRUG|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
219121129|NCT03093311|OTHER|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
219121130|NCT06022874|OTHER|Phoilex Releaf Gel|"Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day."
219121131|NCT00792129|DEVICE|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
219121132|NCT03904082|PROCEDURE|Erector Spinae Plane block ( Group ı)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219121133|NCT03904082|PROCEDURE|Serratus Anterior Plane block ( Group ıı)|SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219121134|NCT03904082|PROCEDURE|Control Group (GROUPIII)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
219121135|NCT00876122|DRUG|GDC-0941|Escalating oral dose
219121136|NCT05180812|DEVICE|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
219121137|NCT01615861|PROCEDURE|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
219121138|NCT01615861|DEVICE|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
219121139|NCT02600858|BEHAVIORAL|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
219121140|NCT03729206|DIAGNOSTIC_TEST|intravital microscopy|intravital microscopy with sidestream dark-field imaging
219121141|NCT04584606|DIAGNOSTIC_TEST|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
219121142|NCT01226173|DEVICE|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
219121143|NCT02724787|BEHAVIORAL|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
219121144|NCT06392516|DRUG|Ketoacid|250 ml ketoacid two hours before the hemodialysis session ended
219121145|NCT01761786|GENETIC|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
219121146|NCT04081298|BEHAVIORAL|Health Education|Attend nutrition and PA classes, and cooking sessions
219121147|NCT04081298|OTHER|Physical Activity|Participate in physical activities
219121148|NCT04081298|OTHER|Health Promotion and Education: Text Messages|Receive motivational text messages
219121149|NCT04081298|OTHER|Health Promotion and Education: Web Site|Given access to nutrition website
219121150|NCT04081298|OTHER|Quality-of-Life Assessment|Ancillary studies
219121151|NCT04081298|OTHER|Questionnaire Administration|Ancillary studies
219121152|NCT01305057|OTHER|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
219121153|NCT01242943|DRUG|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
219121154|NCT01537354|DRUG|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
219121155|NCT01537354|DRUG|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
219121156|NCT02787538|BEHAVIORAL|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
219121157|NCT02787538|BEHAVIORAL|Control group (Online medication guide)|Standard online medication guide.
219121158|NCT00479674|DRUG|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
219121159|NCT00479674|DRUG|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
219121160|NCT00479674|DRUG|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
219121161|NCT02145793|BEHAVIORAL|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
219121162|NCT03497182|DEVICE|Breath sample collection|Subject exhales into breath collection container.
219121163|NCT00282321|BEHAVIORAL|High Protein diet|
219121164|NCT00282321|BEHAVIORAL|High carbohydrate diet|
219121165|NCT05471193|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
219121166|NCT00643500|DRUG|Levetiracetam|
219706117|NCT05874271|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total) (Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
219121167|NCT04368195|PROCEDURE|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
219121168|NCT01980979|DRUG|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
219121169|NCT01138319|GENETIC|DNA analysis|
219121170|NCT01138319|GENETIC|mutation analysis|
219121171|NCT01138319|GENETIC|polymerase chain reaction|
219121172|NCT01138319|OTHER|laboratory biomarker analysis|
219121173|NCT03150680|GENETIC|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
219121174|NCT04018443|DIAGNOSTIC_TEST|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: \[(dia-mpost/dia-mpre) × 100\] - 100 \[11\].
219121175|NCT02071095|DRUG|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
219121176|NCT02071095|DRUG|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
219121177|NCT04555629|OTHER|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
219121178|NCT03983902|PROCEDURE|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
219121179|NCT03983902|PROCEDURE|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
219121180|NCT03983902|PROCEDURE|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
219121181|NCT02059161|DRUG|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
219121182|NCT02059161|DRUG|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
219121183|NCT02059161|DRUG|Prandial Insulin|Participants will continue their prandial insulin during the study.
219121184|NCT00980707|DRUG|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
219121185|NCT00324532|DRUG|ProBactrix|
219121186|NCT00905060|BIOLOGICAL|HSPPC-96|Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
219121187|NCT00905060|DRUG|Temozolomide|Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
219121188|NCT00905060|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
219121189|NCT01306708|DRUG|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
219121190|NCT03790293|DRUG|Rituximab|Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
219121191|NCT03790293|DRUG|corticosteroids'therapy|Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
219121192|NCT01364961|DIETARY_SUPPLEMENT|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
219121193|NCT01325987|DIETARY_SUPPLEMENT|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
219121194|NCT01325987|OTHER|Sugar pill|"1. group: vitamin D2 50000 IU weekly once for 8 weeks~2. nd group: placebo weekly once for 8 weeks"
219121195|NCT01228383|BIOLOGICAL|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
219121196|NCT01228383|BIOLOGICAL|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
219121197|NCT01228383|BIOLOGICAL|Placebo|Placebo intramuscularly on Day 0.
219121198|NCT01228383|BIOLOGICAL|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
219121199|NCT01228383|BIOLOGICAL|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
219121200|NCT02821390|DRUG|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
219121201|NCT02821390|DRUG|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
219550959|NCT03676790|OTHER|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
219121202|NCT05050487|PROCEDURE|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
219121203|NCT05050487|PROCEDURE|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
219121204|NCT03127592|DRUG|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
219121205|NCT03127592|DRUG|Etodolac|Individual drug
219121206|NCT03127592|DRUG|Cyclobenzaprine|Individual drug
219121207|NCT05728983|OTHER|Sleep levels|Sleep levels are what the experimenter prescribes to participants in the study.
219121208|NCT01840761|DRUG|herbal drug|
219121209|NCT01840761|DRUG|placebo|
219121210|NCT02633319|BEHAVIORAL|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
219121211|NCT02633319|OTHER|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
219121212|NCT02958228|BEHAVIORAL|Positive Mental Imagery Training (PMIT)|
219121213|NCT02958228|BEHAVIORAL|Cognitive Control Training (CCT)|
219121214|NCT02958228|OTHER|Treatment as Usual|
219121215|NCT03040193|DRUG|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
219121216|NCT03040193|DRUG|Saline Nebulization|Normal Saline Delivered via Nebulization
219121217|NCT02511561|DRUG|OTO-201 (ciprofloxacin)|
219121218|NCT03404869|DRUG|ORL-1M - D-mannose|Oral ORL-1M
219121219|NCT03511183|DRUG|XELIRI + bevacizumab|Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
219121220|NCT03511183|DRUG|XELOX + bevacizumab|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
219706118|NCT03166709|BEHAVIORAL|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
219121221|NCT01723826|DRUG|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
219121222|NCT04184024|OTHER|Massage|"Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist."
219121223|NCT04184024|OTHER|Kinesio tape|Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
219121224|NCT04184024|OTHER|Neck stabilization exercise|Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
219121225|NCT05455944|DRUG|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
219121226|NCT05455944|DRUG|Placebo|Two identical placebo capsules is administered orally to patients
219121227|NCT02086799|DRUG|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
219121228|NCT02086799|DRUG|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
219121229|NCT02460744|RADIATION|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
219121230|NCT05018962|DEVICE|Cutting balloon followed by paclitaxel coated balloon|Cutting balloon followed by paclitaxel coated balloon
219706119|NCT03166709|BEHAVIORAL|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
219706120|NCT00003720|DRUG|semaxanib|
219121231|NCT03405181|OTHER|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
219121232|NCT03405181|OTHER|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
219121233|NCT03939221|BEHAVIORAL|Infrared Lamp and Acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
219121234|NCT00000390|DRUG|Imipramine hydrochloride|
219121235|NCT00739193|DRUG|amiodarone|
219121236|NCT01043536|RADIATION|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
219121237|NCT01043536|DRUG|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
219121238|NCT03550729|BEHAVIORAL|Endurance training|Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
219706121|NCT05942313|DRUG|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
219706122|NCT03836053|DRUG|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
219121239|NCT04919681|OTHER|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
219121240|NCT00191048|DRUG|Atomoxetine|
219121241|NCT01699893|OTHER|unique arm|blood, nasal swab, skin biopsy, stool samples
219121242|NCT03513211|DRUG|SUBA-itraconazole|150mg PO BD
219121243|NCT03513211|DRUG|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
219121244|NCT02013687|BIOLOGICAL|Pfs25 VLP- FhCMB|
219121245|NCT01627340|BIOLOGICAL|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219121246|NCT01272011|OTHER|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
219121247|NCT01272011|OTHER|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
219121248|NCT04859049|PROCEDURE|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
219121249|NCT04859049|PROCEDURE|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
219706123|NCT05357651|DRUG|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
219706124|NCT04006457|DRUG|PF-06651600|50 mg oral tablets/capsules
219706125|NCT04006457|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
219706126|NCT04006457|BIOLOGICAL|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
219706127|NCT05172960|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
219706128|NCT04669197|DRUG|Paclitaxel protein bound|combination therapy
219706129|NCT04669197|DRUG|Gemcitabine|combination therapy
219121250|NCT01657032|DIETARY_SUPPLEMENT|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
219121251|NCT01657032|DIETARY_SUPPLEMENT|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
219121252|NCT01657032|DIETARY_SUPPLEMENT|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
219121253|NCT01694875|DEVICE|APTIMA HPV Assay|In Vitro Diagnostics Assay
219121254|NCT03178305|BEHAVIORAL|Do CHANGE|"Besides the behavior change programme (Do Something Different)~1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~3. Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
219121255|NCT03633903|BEHAVIORAL|Mindfulness|Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
219121256|NCT05968482|DRUG|Diclofenac Sodium Gel|Topical application on both knees
219121257|NCT03062150|DRUG|Placebo|Placebo
219121258|NCT03062150|DRUG|Fludrocortisone|Fludrocortisone
219121259|NCT03062150|DRUG|D-Cycloserine|D-Cycloserine
219121260|NCT02046538|DRUG|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
219706130|NCT04669197|DRUG|Cisplatin|combination therapy
219706131|NCT04669197|DRUG|Hydroxychloroquine|combination therapy
219121261|NCT02046538|DRUG|Oxaliplatin|85 mg/m2 IV over two hours
219121262|NCT02046538|DRUG|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
219706132|NCT06049212|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.
219706133|NCT06049212|BIOLOGICAL|Pembrolizumab|Pembrolizumab solution for IV infusion.
219706134|NCT06049212|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
219706135|NCT04486716|DRUG|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
219706136|NCT05165368|OTHER|Intraneural Facilitation® Therapy (INF® Therapy)|INF® Therapy plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.
219121263|NCT02046538|DRUG|Irinotecan|180 mg/m2 IV over 90 minutes
219121264|NCT05653180|DRUG|IBI310|2mg/kg IV,3 weeks later, 1mg/kg IV Q6W
219121265|NCT05653180|DRUG|sintilimab|200mg IV Q3W
219121266|NCT00189280|DRUG|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
219121267|NCT06278389|DRUG|ACC017 tablets|ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
219121268|NCT06278389|DRUG|Emtricitabine and Tenofovir Alafenamide Fumarate Tablets|Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
219121269|NCT02848235|OTHER|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
219121270|NCT00431743|DRUG|Hydroxyethylstarch 130/0,4|
219121271|NCT00431743|DRUG|Lactated Ringer's solution|
219121272|NCT05767138|BEHAVIORAL|HPV Vaccine Acceptance Survey|
219121273|NCT02685592|DRUG|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
219121274|NCT05312619|OTHER|Cross sectional survey|A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19
219121275|NCT02314455|OTHER|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
219121276|NCT02839083|OTHER|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
219121277|NCT02839083|OTHER|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
219121278|NCT04305236|DRUG|Abemaciclib|Given PO
219121279|NCT04305236|DRUG|Fulvestrant|Given Intramuscularly
219121280|NCT04086173|DIETARY_SUPPLEMENT|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
219121281|NCT04086173|OTHER|Placebo|Placebo
219121282|NCT05269511|DRUG|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
219121283|NCT02202590|DEVICE|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
219121284|NCT04542447|DRUG|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
219121285|NCT00813007|BEHAVIORAL|Questionnaires|5 Questionnaires at differing times before and after surgery.
219121286|NCT01047943|DRUG|Topical application of STA-21 ointment for treatment of psoriasis|
219121287|NCT04724174|PROCEDURE|pancreaticogastrostomy|Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
219121288|NCT04724174|PROCEDURE|pancreaticojejunostomy|Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
219121289|NCT02885532|OTHER|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
219550960|NCT01158313|DIETARY_SUPPLEMENT|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
219550961|NCT00748787|DRUG|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
219550962|NCT00748787|DRUG|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
219550963|NCT03853187|RADIATION|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
219550964|NCT03853187|DRUG|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
219550965|NCT02597049|DRUG|Dulaglutide|Administered SC
219550966|NCT02597049|DRUG|Placebo|Administered SC
219550967|NCT02597049|DRUG|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
219550968|NCT02597049|DRUG|Metformin|Administered orally as standard of care for type 2 diabetes
219550969|NCT05119049|OTHER|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
219550970|NCT02463487|DEVICE|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
219550971|NCT02463487|DEVICE|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
219550972|NCT01613937|BEHAVIORAL|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
219550973|NCT04021407|DEVICE|LMA group|patients were ventilated with LMA
219550974|NCT04021407|DEVICE|AirQ group|patients were ventilated with AirQ airway
219121290|NCT04377997|DRUG|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
219121291|NCT00680693|BEHAVIORAL|Mindfulness training|8 weekly 2-hour classes
219706137|NCT05165368|OTHER|INF® Therapy|"INF® Therapy only (INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)"
219706138|NCT05633550|DIAGNOSTIC_TEST|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
219706139|NCT05518162|DEVICE|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
219121292|NCT00680693|BEHAVIORAL|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
219121293|NCT04273685|BEHAVIORAL|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
219706140|NCT05518162|BEHAVIORAL|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
219706141|NCT02602262|OTHER|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
219706142|NCT05479461|OTHER|Digital Hypertension Management System|Mobile health technology using physician- directed, semi-automated management of hypertension
219706143|NCT05479461|OTHER|Usual Care|The participants will receive usual care
219121294|NCT04273685|OTHER|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
219121295|NCT03894943|DIAGNOSTIC_TEST|PET/CT scan|Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
219121296|NCT03894943|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
219121297|NCT01580527|PROCEDURE|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
219121298|NCT01580527|PROCEDURE|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
219121299|NCT03905382|OTHER|Qualitative|Focus group and 1:1 telephone interviews
219121300|NCT05911074|DIAGNOSTIC_TEST|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
219121301|NCT01634711|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
219121302|NCT00005864|DRUG|chloroquinoxaline sulfonamide|
219706144|NCT05685303|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
219706145|NCT05685303|OTHER|Sham-Control|Cardiac imaging
219706146|NCT06565559|DEVICE|Wearable Wireless Sensor|Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
219706147|NCT03637543|DRUG|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
219121303|NCT01773538|DRUG|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
219121304|NCT01773538|DIETARY_SUPPLEMENT|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
219121305|NCT01773538|OTHER|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
219121306|NCT02916472|BEHAVIORAL|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
219121307|NCT02916472|BEHAVIORAL|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
219121308|NCT02916472|BEHAVIORAL|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
219121309|NCT03082209|DRUG|ABBV-621|Intravenous (IV)
219121310|NCT03082209|DRUG|Venetoclax|tablet, oral
219121311|NCT03082209|DRUG|Bevacizumab|IV infusion
219121312|NCT03082209|DRUG|FOLFIRI|IV infusion
219121313|NCT05530954|OTHER|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
219706148|NCT06814236|BEHAVIORAL|Three-Stage Informed Consent Conversation Model for Anaesthesia Risk profiling|"Stage 1 Pre-information queries~Do you know about the risks involved in Anaesthesia?~If yes, where did you get information about the risks involved with Anaesthesia??~Which of these do you already know of and what concerns you most?~Why are you concerned more about that particular risk factor?~Stage 2 Informing Risks~The probability or chances of supposed anaesthesia risks could be:~Probable risk Possible risk Remote risk~We have the following risk management strategy in place for your reassurance and safety:~Employing ERAS protocol~The surgery you are going to undergo, also may have its own set of risks~Stage 3 Post-information Informing Risks~In view of the above conversation we had, do you have other point of concern or query on what we have talked about."
219706149|NCT06775379|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
219706150|NCT06775379|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
219706151|NCT06110624|OTHER|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
219706152|NCT06788262|OTHER|Cerebral MRI|Cerebral MRI
219706153|NCT00488878|PROCEDURE|Biospecimen Collection|Patients' residual tissue samples are collected
219706154|NCT00488878|OTHER|Electronic Health Record Review|Medical records are reviewed
219706155|NCT05292313|PROCEDURE|Single distal femur implant|Single implant fixation
219706156|NCT05292313|PROCEDURE|Dual distal femur implants|Dual implant fixation
219706157|NCT04864171|DEVICE|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
219706158|NCT06835530|DRUG|Rituximab + Golcadomide (CC-99282)|A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA).
219706159|NCT04184050|DRUG|MK-4002|IV infusion
219121314|NCT05530954|OTHER|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
219121315|NCT02186938|DEVICE|FloTrac|
219121316|NCT03165383|DRUG|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
219121317|NCT03165383|DRUG|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
219706160|NCT06063538|COMBINATION_PRODUCT|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
219706161|NCT00879177|DRUG|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
219706162|NCT00879177|BEHAVIORAL|behavioral therapy|confirmed negative smoking status at different time points
219121318|NCT00761774|DRUG|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
219121319|NCT06009783|OTHER|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
219121320|NCT05539404|PROCEDURE|Endovascular treatment in addition of best medical treatment.|Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
219121321|NCT04900883|OTHER|survey|anonymous survey
219121322|NCT01077024|OTHER|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
219121323|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
219121324|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler with patient application|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
219121325|NCT04500743|DRUG|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
219121326|NCT04500743|DRUG|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
219706163|NCT00714818|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
219706164|NCT00714818|BEHAVIORAL|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
219706165|NCT02332707|DRUG|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
219121327|NCT04755868|DRUG|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
219121328|NCT04755868|DRUG|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
219121329|NCT01603121|DRUG|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
219121330|NCT04651231|PROCEDURE|releasable sutures in punch trabeculectomy|punch trabeculectomy,scleral flap suturing
219121331|NCT01238029|DRUG|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
219121332|NCT02932111|PROCEDURE|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
219121333|NCT02932111|PROCEDURE|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
219121334|NCT00628628|DRUG|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
219121335|NCT00628628|DRUG|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
219121336|NCT04344990|PROCEDURE|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
219121337|NCT04344990|PROCEDURE|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
219121338|NCT04344990|PROCEDURE|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
219121339|NCT01218685|BIOLOGICAL|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
219121340|NCT05170542|DRUG|Camrelizumab+S-1|Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
219121341|NCT03131141|DRUG|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
219706166|NCT02332707|DRUG|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
219121342|NCT02300311|DRUG|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
219121343|NCT02300311|DRUG|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
219121344|NCT01989715|OTHER|analyzing the position of the body, muscle activity|
219121345|NCT05250479|BEHAVIORAL|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
219706167|NCT02332707|DRUG|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
219706168|NCT02332707|DRUG|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
219706169|NCT02332707|DRUG|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
219706170|NCT02332707|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
219121346|NCT02687919|OTHER|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
219121347|NCT00125775|BIOLOGICAL|Engerix-B|Engerix-B at 0, 1, 6 months
219121348|NCT01656759|DRUG|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
219121349|NCT00419003|DRUG|Lamotrigine|anticonvulsant medication
219121350|NCT00419003|DRUG|Ketamine|subanesthetic dose of NMDAR antagonist
219121351|NCT00419003|DRUG|Riluzole|glutamate release inhibitor
219121352|NCT03848312|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
219706171|NCT02887001|OTHER|Pharmacist consultation|
219706172|NCT05848063|OTHER|Global hip muscles strengthening exercises|Strengthening exercises will be given to all hip muscles
219706173|NCT05848063|OTHER|Hip abductors strengthening exercises|Strengthening exercises will be given to hip abductor muscles
219706174|NCT05695287|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
219706175|NCT05695287|DRUG|Isoflurane|Isoflurane
219706176|NCT05695287|DRUG|Sevoflurane|Sevoflurane
219121353|NCT03848312|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
219706177|NCT05435508|OTHER|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
219706178|NCT05435508|OTHER|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
219706179|NCT02700841|DRUG|Melphalan|Given IV
219121354|NCT02531438|DRUG|Omadacycline|Injection for IV; Oral tablets
219706180|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
219706181|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
219706182|NCT02700841|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
219121355|NCT02531438|DRUG|Moxifloxacin|IV solution; Oral tablets
219121356|NCT03259698|DRUG|nPEP|Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
219121357|NCT03259698|BEHAVIORAL|Text Messaging Support|"Text messaging support service ('WelTel'): community-based counselors will provides standardized weekly 'check-in' messages during the participants 12-week course of nPEP follow-up. Participants in the text-message arm will also have the option of receiving generic non-specific automated text reminders of their upcoming appointments in the form of Don't forget about tomorrow."
219121358|NCT03259698|OTHER|Nurse-Led nPEP|nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
219706183|NCT02700841|BIOLOGICAL|Tetanus Toxoid Vaccine|Given IM
219706184|NCT06136585|DRUG|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
219706185|NCT06136585|DRUG|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
219706186|NCT05644834|OTHER|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
219706187|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~30 seconds|Care team will wait to clamp the umbilical between 1-\<60 seconds after birth. 30 seconds is the ideal time of clamping.
219706188|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~120 seconds|Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping
219706189|NCT06153459|PROCEDURE|Umbilical Cord Milking|"For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times. Cord milking should NOT be performed if the delay meets or exceeds 60 seconds.~Umbilical cord milking will not be provided among participant-infant dyads in the DCC-30 group."
219121359|NCT00217100|DIETARY_SUPPLEMENT|Multivitamin|1 tablet a day
219121360|NCT00217100|DIETARY_SUPPLEMENT|Placebo|1 tablet a day
219121361|NCT03730298|DIETARY_SUPPLEMENT|American Ginseng|cpr
219121362|NCT03730298|OTHER|Placebo|cpr
219121363|NCT06425705|DRUG|Silymarin|140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
219121364|NCT06425705|DRUG|Placebo|placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
219121365|NCT02667691|DIETARY_SUPPLEMENT|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
219121366|NCT02667691|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
219121367|NCT02667691|OTHER|caloric restriction|Caloric recommendation reduced by 20%
219121368|NCT05099887|BIOLOGICAL|Procenta conformable barrier|Wound care dressing biologic allograft
219121369|NCT04917692|DRUG|Empagliflozin|2.5 mg daily
219121370|NCT05463211|DEVICE|Trexo Plus Pediatric Exoskeleton|Wearable pediatric robotic walker for the lower extremities
219121371|NCT05040061|BEHAVIORAL|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
219121372|NCT05040061|BEHAVIORAL|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
219121373|NCT02165124|DEVICE|Artificial Embolization Device|Embosphere Microspheres
219121374|NCT01693146|DEVICE|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
219121375|NCT01693146|DEVICE|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
219121376|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
219121377|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
219121378|NCT02843022|BEHAVIORAL|standardized electronic messages|supportive and educational short messages
219121379|NCT02843022|BEHAVIORAL|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
219121380|NCT02843022|BEHAVIORAL|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
219706190|NCT04521452|DRUG|Evogliptin|Subjects will receive evogliptin 5 mg daily
219706191|NCT03265964|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
219706192|NCT03265964|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
219121381|NCT00325559|PROCEDURE|Normoinsulinemic eu- or hyperglycemic clamp|
219121382|NCT00768599|DRUG|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
219121383|NCT00768599|DRUG|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
219121384|NCT00768599|DRUG|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
219121385|NCT02874846|DRUG|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
219121386|NCT02874846|OTHER|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
219121387|NCT01233102|DRUG|Conserved Therapy|Conserved Therapy
219121388|NCT01233102|PROCEDURE|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
219121389|NCT04288466|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin solution 450ml
219121390|NCT00803140|PROCEDURE|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
219121391|NCT00305890|BEHAVIORAL|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
219121392|NCT00305890|BEHAVIORAL|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
219121393|NCT00305890|OTHER|Standard Care|Standard care will include routine medical care.
219121394|NCT00801242|DRUG|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
219121395|NCT02781064|DRUG|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
219121396|NCT02781064|DRUG|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
219121397|NCT06171048|BIOLOGICAL|CM310|CM310 injection
219121398|NCT04042662|OTHER|no intervention|no intervention
219121399|NCT06012838|BEHAVIORAL|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
219706193|NCT03238534|DEVICE|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
219706194|NCT03238534|DRUG|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
219706195|NCT03238534|OTHER|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
219706196|NCT03238534|OTHER|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
219121400|NCT02381899|DRUG|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
219121401|NCT03660072|OTHER|Non-Interventional|Non-Interventional
219121402|NCT04322487|DIAGNOSTIC_TEST|Lung ultrasound|A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.
219121403|NCT02015195|OTHER|Acetic Acid (5%)|
219121404|NCT02015195|OTHER|Sodium Bicarbonate Slurry (50%)|
219121405|NCT02015195|OTHER|Papain Slurry (70%)|
219121406|NCT02015195|OTHER|Ammonia (10%)|
219121407|NCT02015195|DRUG|Lidocaine (4%)|
219121408|NCT02015195|OTHER|Isopropyl Alcohol (70%)|
219121409|NCT02015195|OTHER|Hot Tap Water (40 degrees Celsius)|
219121410|NCT02015195|OTHER|No treatment|
219121411|NCT03233165|PROCEDURE|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
219121412|NCT03233165|PROCEDURE|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
219121413|NCT05122754|DRUG|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
219706197|NCT05251428|PROCEDURE|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
219706198|NCT05251428|PROCEDURE|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
219706199|NCT06172660|DRUG|Nirsevimab|Immunoprophylaxis against RSV
219706200|NCT05718674|PROCEDURE|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
219121414|NCT05122754|DRUG|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
219121415|NCT01318811|DRUG|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
219121416|NCT01318811|DRUG|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
219706201|NCT05205811|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
219706202|NCT05205811|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
219121417|NCT00811187|DRUG|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
219121418|NCT00811187|DRUG|Normal Saline|5cc Normal Saline injection in each paracervical region
219121419|NCT03618303|DIAGNOSTIC_TEST|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
219121420|NCT00209729|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
219121421|NCT00209729|DRUG|TS-1|Day 1-14, P.O. everyday
219121422|NCT00131911|DRUG|sorafenib tosylate|400 mg given orally
219121423|NCT00329303|DRUG|Certolizumab Pegol (Cimzia®)|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"
219706203|NCT05205811|DRUG|Placebo bupropion|Placebo bupropion for 7 weeks.
219706204|NCT05205811|DRUG|Placebo zonisamide|Placebo zonisamide for 7 weeks.
219706205|NCT05205811|OTHER|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
219706206|NCT02977351|PROCEDURE|Non-surgical periodontal treatment|
219706207|NCT06517381|OTHER|Digital Online Warning Signs of Mental Illness Literacy Program|Digital Online Warning Signs of Mental Illness Literacy Program is comprised of 30-minute pre-recorded video and question-and-answer sessions. The videos were followed by case studies, success stories, and interactive question-and-answer sessions
219706208|NCT04213261|BIOLOGICAL|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
219706209|NCT04658355|OTHER|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
219706210|NCT04658355|OTHER|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
219706211|NCT01898416|DRUG|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
219706212|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
219706213|NCT03283917|DRUG|Dexamethasone|Given IV or PO
219706214|NCT03283917|DRUG|Ixazomib|Given PO
219706215|NCT03349463|DRUG|Fluciclovine F18|All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
219706216|NCT00947544|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
219706217|NCT00947544|DRUG|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
219706218|NCT04542941|BIOLOGICAL|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
219706219|NCT01563939|DRUG|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
219706220|NCT03095235|DIETARY_SUPPLEMENT|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
219706221|NCT01922999|DRUG|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
219706222|NCT04920669|PROCEDURE|erector spinae block with bupivacaine|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
219706223|NCT04920669|PROCEDURE|erector spinae block with bupivacaine + dexmedetomidine|Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
219706224|NCT01204242|DRUG|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
219706225|NCT01204242|DRUG|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
219706226|NCT06550908|OTHER|Lutetia Training Plattform - real images|Training platform Lutetia offers training the Paris classification using real images of colon polyps.
219706227|NCT06550908|OTHER|Lutetia Training Plattform - artifical images|Training platform Lutetia offers training the Paris classification using artificial images of colon polyps.
219706228|NCT04841889|DIAGNOSTIC_TEST|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
219706229|NCT01795612|OTHER|physical activity|
219121424|NCT02877953|BEHAVIORAL|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
219121425|NCT00747279|OTHER|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
219121426|NCT00747279|DRUG|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
219706230|NCT02631057|DRUG|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
219706231|NCT02631057|DRUG|Warfarin|Warfarin tablet (adjustment by each patients)
219706232|NCT02398344|DEVICE|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
219706233|NCT02398344|DEVICE|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
219706234|NCT00409825|DRUG|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
219706235|NCT00409825|PROCEDURE|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
219121427|NCT04326985|BIOLOGICAL|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
219121428|NCT04326985|DRUG|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
219706236|NCT03173339|PROCEDURE|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
219121429|NCT05585762|OTHER|Ketone ester|75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
219121430|NCT05585762|OTHER|Non-ketone placebo|75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
219121431|NCT01367587|DRUG|IV Methylnaltrexone|
219121432|NCT00162539|OTHER|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
219121433|NCT01359410|DEVICE|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
219121434|NCT01359410|DEVICE|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
219706237|NCT03173339|DRUG|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
219121435|NCT01697787|DRUG|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
219121436|NCT01697787|DRUG|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
219121437|NCT04142125|DRUG|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
219121438|NCT04142125|DRUG|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
219121439|NCT03695289|BEHAVIORAL|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
219121440|NCT03695289|BEHAVIORAL|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
219121441|NCT04427722|DEVICE|MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
219121442|NCT05590910|OTHER|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
219121443|NCT02848495|GENETIC|Non-Interventional|
219121444|NCT00994279|BEHAVIORAL|Yoga|Yoga sessions
219121445|NCT00994279|BEHAVIORAL|Education|Educational Wellness Group
219121446|NCT01791426|DEVICE|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
219121447|NCT01791426|DEVICE|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
219706238|NCT03173339|DRUG|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
219706239|NCT03173339|DRUG|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
219706240|NCT03173339|DRUG|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
219121448|NCT01606189|DRUG|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
219121449|NCT01606189|DRUG|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
219121450|NCT01606189|DRUG|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
219121451|NCT00162942|DEVICE|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
219121452|NCT00162942|DEVICE|Sham|Sham, ten apheresis sessions within 9 weeks
219121453|NCT05635266|DIAGNOSTIC_TEST|Specimen sample|The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
219121454|NCT02162732|DEVICE|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
219121455|NCT00287638|DEVICE|CPAP|Continuous positive pressure device with a time clock
219121456|NCT00287638|DEVICE|placebo|no CPAP
219121457|NCT01649102|DEVICE|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard"
219121458|NCT01167023|DRUG|Prasugrel|Administered orally, once daily for 30 days.
219706241|NCT04610775|OTHER|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
219706242|NCT06153550|OTHER|preparation in Respiratory Physiotherapy|"preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery."
219121459|NCT01167023|DRUG|Placebo|Administered orally, once daily for 30 days.
219706243|NCT03642314|DIAGNOSTIC_TEST|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
219706244|NCT02965482|DEVICE|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
219706245|NCT02965482|DEVICE|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
219706246|NCT01926210|OTHER|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
219706247|NCT01926210|OTHER|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
219706248|NCT04521868|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
219706249|NCT04521868|DIETARY_SUPPLEMENT|placebo|Placebo is made of starch
219706250|NCT00293891|DRUG|Tacrolimus Cream|
219706251|NCT00187551|OTHER|Interruption of enfuvirtide|treatment interruption
219706252|NCT00187551|OTHER|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
219706253|NCT00128843|DRUG|Exemestane|25mg/day until progression disease
219706254|NCT00128843|DRUG|Anastrozole|1mg/day until progression disease
219706255|NCT03636633|OTHER|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
219706256|NCT03636633|OTHER|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
219706257|NCT00793975|BIOLOGICAL|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
219706258|NCT00793975|BIOLOGICAL|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
219706259|NCT00793975|BIOLOGICAL|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
219706260|NCT00793975|BIOLOGICAL|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
219121460|NCT00080002|DRUG|Pegamotecan|
219121461|NCT03186937|DIETARY_SUPPLEMENT|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
219121462|NCT00108784|BEHAVIORAL|Reduced-energy-density diet|
219706261|NCT00793975|BIOLOGICAL|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
219706262|NCT00793975|BIOLOGICAL|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
219706263|NCT00793975|BIOLOGICAL|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
219706264|NCT01632319|BEHAVIORAL|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
219706265|NCT01632319|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
219706266|NCT02598310|DRUG|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
219706267|NCT02598310|DRUG|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
219706268|NCT05727644|DRUG|NNC0194-0499|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
219706269|NCT00527059|DRUG|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
219706270|NCT00527059|DRUG|spironolactone, beta-blockers,ecc|
219121463|NCT04121273|BIOLOGICAL|CAR-T cell immunotherapy|"Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10\^7/m2~Dose 2: 3x10\^7/m2~Dose 3: 1x10\^8/m2~The cell numbers are calculated according to CAR-positive T cells."
219706271|NCT03778632|BEHAVIORAL|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
219121464|NCT05651880|DRUG|Baricitinib 4 MG|4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
219121465|NCT02049437|DRUG|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
219706272|NCT02471183|DRUG|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
219706273|NCT00532467|DRUG|SRX251|
219121466|NCT02049437|DRUG|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
219121467|NCT04392258|DIAGNOSTIC_TEST|TSH determination|Determination of serum concentration of thyrotropin (TSH)
219121468|NCT04392258|DIAGNOSTIC_TEST|FT4 determination|Determination of serum free thyroxine (FT4) concentration
219121469|NCT04392258|DIAGNOSTIC_TEST|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
219121470|NCT04392258|DIAGNOSTIC_TEST|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
219121471|NCT04392258|DIAGNOSTIC_TEST|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
219121472|NCT04121208|DRUG|JNJ-40346527|Active study drug
219121473|NCT04121208|OTHER|Placebo|Non-active study drug
219121474|NCT02217995|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams \& Teasdale, 2002)."
219121475|NCT00705640|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously and intradermally
219121476|NCT00705640|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
219121477|NCT00705640|BIOLOGICAL|tetanus toxoid helper peptide|Given subcutaneously and intradermally
219121478|NCT00705640|PROCEDURE|biopsy|Patients undergo surgical biopsy at replicate vaccine site
219121479|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
219121480|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
219706274|NCT01905072|OTHER|Education Home Visits|"Intervention will include educational home visits on:~1. Growth monitoring and feedback~2. Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~3. Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~4. Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~5. Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
219706275|NCT00657566|OTHER|duration of antibiotics|4 +/- 1 days of antibiotics
219706276|NCT00657566|OTHER|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
219706277|NCT03784495|DRUG|Melatonin 1mg|1 mg/day 30 minutes before sleep
219706278|NCT03784495|DIETARY_SUPPLEMENT|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
219121481|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
219121482|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
219121483|NCT01831414|OTHER|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
219121484|NCT01831414|OTHER|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
219121485|NCT02641951|OTHER|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
219121486|NCT02641951|OTHER|Pecs II block|Ultrasound guided Pecs II block
219706279|NCT03784495|COMBINATION_PRODUCT|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
219121487|NCT06077669|DRUG|Methylphenidate|Single oral dose of methylphenidate (5mg or 10 mg)
219121488|NCT06077669|DRUG|Placebo|oral placebo
219121489|NCT06398028|DRUG|Indocyanine green|Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
219121490|NCT06529601|DEVICE|CAD/CAM mandibular fixed retainer|Keeppy is a Class IIa custom-made medical device manufactured by Digital Service Leone s.r.l. - via Pratese 160/b, Florence, Italy. The Keeppy is an individualized fixed retainer, made of a Nickel-free Chrome Cobalt alloy, produced with a CAD-CAM procedure starting from a digital impression made with an intraoral optical scanner (3 Shape), which allows a perfect adaptation to the lingual surfaces of the 6 lower anterior teeth on which it is bonded. The device is characterized by the presence of applicators that can be placed temporarily on the buccal surface of the canines, which facilitate the clinician in the precise application of the device and which are removed as soon as the bonding phase of the retainer is complete. Bonding is performed using classic composite resins following a preparation phase of the lingual surface of the tooth consisting of the application of etchant (37% orthophosphoric acid) for 30 seconds and adhesive (primer-bonding).
219121491|NCT06529601|DEVICE|Conventional mandibular fixed retainer|The standard control device, which is among the most commonly used in routine clinical practice, consists of a steel braided wire. The device selected for the Class IIa investigation is the Ortho Flex Tech manufactured by Reliance Orthodontic Products, Inc. 1540 West Thorndale Ave. Itasca, IL 60143 USA. The Ortho Flex Tech steel braided wire is manually shaped by the clinician and cut with a wire cutter so that it has the proper length to extend over the 6 dental elements. Once the correct length has been defined, it is then held in place on the lingual surface of the teeth by the use of 2 interdental wires passing doubly through the interdental area (between the lateral incisor and canine on one side and the other). This allows the device to be bonded using composite resin after etching the lingual surfaces of the lower anterior teeth.
219121492|NCT03387514|DRUG|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
219121493|NCT00118144|DRUG|bortezomib|Given IV
219121494|NCT04069221|DRUG|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
219121495|NCT04069221|DRUG|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
219121496|NCT04069221|DRUG|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
219121497|NCT04069221|DRUG|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
219121498|NCT01159535|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
219121499|NCT01159535|BEHAVIORAL|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
219121500|NCT01159535|BEHAVIORAL|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
219121501|NCT03377673|DIAGNOSTIC_TEST|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
219706280|NCT03784495|OTHER|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
219706281|NCT01983930|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
219706282|NCT01983930|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
219706283|NCT06535568|DEVICE|Drug-coated balloon|Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
219706284|NCT06535568|DRUG|Single antiplatelet therapy (SAPT)|The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
219706285|NCT06535568|DRUG|Dual antiplatelet therapy (DAPT)|The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
219121502|NCT02708602|GENETIC|β2AR polymorphism|
219121503|NCT03461250|DIAGNOSTIC_TEST|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
219121504|NCT02218021|DRUG|Samidorphan|
219121505|NCT02218021|DRUG|Placebo|
219121506|NCT02218021|DRUG|Oxycodone|
219706286|NCT00158613|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
219706287|NCT01859819|DRUG|Rituximab|
219706288|NCT01859819|DRUG|IT Cytarabine|
219706289|NCT03399344|OTHER|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
219706290|NCT02082951|BEHAVIORAL|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
219706291|NCT02082951|BEHAVIORAL|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
219706292|NCT05302050|DEVICE|BT-001|"BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
219121507|NCT03740074|BEHAVIORAL|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
219121508|NCT04308538|PROCEDURE|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
219121509|NCT04308538|PROCEDURE|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
219121510|NCT02868580|DRUG|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
219121511|NCT01287793|DRUG|tigecycline|intravenous, 200 mg, single dose
219121512|NCT01287793|DRUG|tigecycline|intravenous, 50 mg, single dose
219121513|NCT01287793|DRUG|moxifloxacin|oral tablet, 400 mg, single dose
219121514|NCT01287793|DRUG|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
219121515|NCT01287793|DRUG|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
219121516|NCT04131283|DRUG|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
219121517|NCT00488241|DEVICE|Zarzenda|Topically applied daily for 2 weeks
219121518|NCT00564590|DRUG|Melatonin|4 mg of Melatonin once a day for 3 months
219121519|NCT00564590|OTHER|omeprazole|omeprazole 20 mg once a day
219121520|NCT00564590|DRUG|Placebo|Placebo once a day
219121521|NCT02385617|DRUG|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
219121522|NCT02385617|DRUG|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
219121523|NCT05261750|BIOLOGICAL|Auto-Dendritic Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
219121524|NCT05261750|BIOLOGICAL|Allo-Dendritic-Secretome Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
219121525|NCT05919667|DIETARY_SUPPLEMENT|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
219706293|NCT05302050|DEVICE|Control Mobile Application|The app asks patients brief questions about their health but does not include any behavioral therapy.
219121526|NCT05397808|OTHER|Pilates Training|The group that received pilates training.
219121527|NCT05397808|OTHER|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
219121528|NCT01656928|BEHAVIORAL|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
219121529|NCT06488768|OTHER|Radial nerve block|Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
219121530|NCT06824246|BEHAVIORAL|Water conservation education|The programme of training for participants will be based on the Health Belief Model, and will consist of two sessions on individuals' water footprints and water consumption habits. Support for the sessions will be provided by brochures and videos that have been prepared for this purpose. Women will be given brochures and a list of things to do to save water. They will also be informed that their monthly water bill will be monitored during the process.
219706294|NCT03710811|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion
219121531|NCT06824246|BEHAVIORAL|Monitoring water bill|Participants in the control group will be informed that their water bills will be monitored for water savings.
219121532|NCT01813032|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
219121533|NCT01813032|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
219121534|NCT05259553|OTHER|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
219550975|NCT02709057|BEHAVIORAL|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
219550976|NCT03124758|DEVICE|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
219706295|NCT03491592|BEHAVIORAL|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
219121535|NCT06625281|PROCEDURE|Epleys Maneuver|"* The patient begins in an upright sitting posture, with the legs fully extended and the head rotated 45 degrees towards the affected side.~* The patient is then quickly and passively forced down backwards by the therapist performing the treatment into a supine position with the head held approximately in a 30-degree neck extension~* The therapist observes the patient's eyes for primary stage nystagmus. The patient remains in this position for 1-2 minutes.~* The patient's head is then turned 90 degrees to the opposite direction so that the unaffected ear faces the ground, for 1-2 minutes.~* Keeping the head and neck in a fixed position relative to the body, the individual rolls onto their shoulder, rotating the head another 90 degrees in the direction they are facing. The patient is now looking downwards at a 45-degree angle.~* The eyes should be immediately observed by the therapist for secondary stage nystagmus. The patient remains in this position for 1-2 minutes."
219706296|NCT03491592|BEHAVIORAL|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
219706297|NCT02730130|DRUG|Pembrolizumab|
219121536|NCT06625281|PROCEDURE|Semont-plus maneuver|"* The Semont-plus maneuver includes the upright position with turning of the head by 45° toward the non-affected side.~* Then movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move and since the clot is beyond the vertex, the movement of body by 240° moves the clot into the direction of the vestibulum."
219121537|NCT06625281|PROCEDURE|Brandt-Daroff exercises|"* Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes."
219706298|NCT02730130|RADIATION|Radiotherapy|
219706299|NCT00141921|DRUG|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
219706300|NCT05665647|DRUG|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
219706301|NCT05665647|DRUG|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
219706302|NCT05665647|DRUG|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
219706303|NCT00358488|DRUG|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
219121538|NCT06625359|DRUG|Thiotepa in conditioning before transplantation|"For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen."
219121539|NCT03008720|DEVICE|Transcranial direct current stimulation (tDCS)|
219121540|NCT03008720|DEVICE|Functional electrical stimulation (FES)|
219121541|NCT03008720|DEVICE|Sham stimulation|
219121542|NCT06687681|BIOLOGICAL|NK cell therapy|Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type
219121543|NCT06624826|DEVICE|Emmetropic modality|PureSee IOL, emmetropic modality
219121544|NCT06624826|DEVICE|Monovision modality|PureSee IOL, monovision modality
219121545|NCT06917820|PROCEDURE|Interscalene brachial plexus block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the C5 and C6 nerve roots and between C6 and C7 nerve roots.
219121546|NCT06917820|PROCEDURE|Clavipectoral fascia plane block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the periosteum of clavicle and the surrounding clavipectoral fascia.
219121547|NCT06918535|OTHER|Progressive Muscle Relaxation Technique|Progressive Muscle Relaxation (PMR) is a relaxation technique that involves systematically tensing and then relaxing different muscle groups in the body to reduce physical tension and stress. Developed by Edmund Jacobson in the 1930s, PMR aims to promote deep relaxation by increasing awareness of muscle tension and learning to release it. The technique is typically performed in a quiet environment, starting from the feet and progressing upward or vice versa. It is commonly used for stress management, pain relief, anxiety reduction, and improving overall well-being.
219121548|NCT06918535|OTHER|Muscle Energy Technique|Muscle Energy Technique (MET) is a manual therapy approach that uses the patient's voluntary muscle contractions against a controlled resistance provided by the therapist to improve musculoskeletal function. It is commonly used to lengthen shortened muscles, improve joint mobility, and reduce pain. MET works by engaging the target muscles in an isometric or isotonic contraction, followed by a relaxation phase, allowing for a greater stretch or repositioning of the joint. It is frequently used in physiotherapy for conditions such as muscle tightness, joint restrictions, and postural imbalances.
219121549|NCT06918418|DRUG|Salbutamol (Ventolin®)|Children were given 0.5% salbutamol aerosol solution (0.15 mg/kg weight, up to a maximum of 5 mg) in 5mL of normal saline solution for 7 min every 20 min for 2 h, and then every 30 min for two more hours. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
219121550|NCT06918418|DRUG|salbutamol + ipratropium bromide nebules|In addition to Salbutamol nebulization, children received ipratropium bromide nebulization. Ipratropium bromide solution (250 mcg in children \<20 kg weight or 500 mcg in children \>=20 kg) every 20 min for the first 2 hours then every 30 min for 2 hours more will be given in between the salbutamol nebulization. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
219121551|NCT06918028|OTHER|With fundus diseases|With fundus diseases
219121552|NCT06918028|OTHER|Without fundus diseases|Without fundus diseases
219121553|NCT06378762|BEHAVIORAL|Endurance Exercise|30 minutes of running at an intensity corresponding to the heavy-domain (between the first and second ventilatory thresholds)
219121554|NCT06378762|BEHAVIORAL|Strength Exercise|Combination of strength and power exercises Weeks 1-5 focus on building maximal strength Weeks 6-11 focus on maintaining maximal strength and improve muscle power
219121555|NCT06378762|BEHAVIORAL|Concurrent Exercise|Combining both strength and endurance training programs, with strength preceding endurance, incorporating a 20-min rest period between each modality
219121556|NCT05904106|DRUG|Venetoclax plus Azacitidine|"Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7"
219121557|NCT05904106|DRUG|standard of care chemotherapy plus gemtuzumab ozogamicin|"Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3"
219121558|NCT04267146|DRUG|Nivolumab|"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"
219121559|NCT04267146|DRUG|Temozolomide|Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
219121560|NCT04267146|RADIATION|Radiotherapy|Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
219121561|NCT03923673|PROCEDURE|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
219706304|NCT00358488|DRUG|salbutamol|salbutamol
219706305|NCT00358488|DRUG|salmeterol 50mcg|salmeterol 50mcg
219706306|NCT00358488|DRUG|placebo|placebo
219121562|NCT05902403|OTHER|invasive mechanical ventilation|Invasive mechanical ventilation for patients admitted to the ICU
219121563|NCT03179540|PROCEDURE|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
219121564|NCT00394095|DRUG|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
219706307|NCT02490163|DEVICE|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
219121565|NCT00394095|DRUG|Placebo|Matched placebo to Experimental arm
219121566|NCT05820074|DIAGNOSTIC_TEST|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
219121567|NCT05820074|DIAGNOSTIC_TEST|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
219121568|NCT05820074|OTHER|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
219121569|NCT04660968|BEHAVIORAL|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
219121570|NCT04660968|BEHAVIORAL|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
219121571|NCT03606135|OTHER|The Pneumonia Group|
219121572|NCT03606135|OTHER|The Control Group|
219706308|NCT00880217|DRUG|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
219706309|NCT00880217|DRUG|Placebo|Placebo capsule once daily for 42 days
219121573|NCT00413608|DRUG|Clopidogrel|Clopidogrel
219121574|NCT04049201|PROCEDURE|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
219121575|NCT04049201|DRUG|Midazolam|Oral Midazolam
219121576|NCT04049201|DEVICE|Interactive Tablet|interactive Tablet containing many cartoon's videos
219121577|NCT02114281|OTHER|Care|
219121578|NCT02114281|OTHER|Not care|
219121579|NCT02187822|DRUG|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m\^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
219121580|NCT02187822|PROCEDURE|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
219121581|NCT01941914|DRUG|Calcium chloride|
219121582|NCT06224595|DRUG|CS32582 capsule|Participants receive CS32582 orally single or multiple doses
219121583|NCT06224595|DRUG|Placebo capsule|Participants receive placebo matching CS32582 orally single or multiple doses
219121584|NCT03564938|DRUG|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
219121585|NCT01982071|DRUG|Micafungin|Intravenous (IV)
219121586|NCT06287450|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
219121587|NCT06287450|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219121588|NCT03381794|PROCEDURE|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
219121589|NCT05474664|DRUG|Camostat mesylate|"1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day"
219121590|NCT06068738|OTHER|Biological sample collection|Collection of ascites, blood and fresh tumour tissues (if available)
219706310|NCT00880217|DRUG|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
219706311|NCT00880217|DRUG|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
219706312|NCT00880217|DRUG|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
219706313|NCT00880217|DRUG|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
219121591|NCT05417204|BEHAVIORAL|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
219121592|NCT04213846|BEHAVIORAL|Experimental: Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
219121593|NCT04423393|BIOLOGICAL|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
219121594|NCT04423393|OTHER|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
219121595|NCT02867839|DRUG|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
219121596|NCT02867839|DRUG|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
219225648|NCT05281588|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
219121597|NCT02459509|DRUG|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
219121598|NCT01277237|DRUG|Omacor|Active comparator: omacor 4g/day
219121599|NCT01277237|DRUG|lactose tablet|placebo: lactose tablet 4g/day
219121600|NCT03302065|DRUG|Tiotropium|
219121601|NCT04769024|DEVICE|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
219121602|NCT04769024|BEHAVIORAL|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes…). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
219121603|NCT03613584|DRUG|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
219550977|NCT00243347|DRUG|AZD2171|oral tablet
219550978|NCT00866476|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
219550979|NCT00866476|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
219550980|NCT02286479|PROCEDURE|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
219550981|NCT02286479|PROCEDURE|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
219550982|NCT02380534|PROCEDURE|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
219550983|NCT01298050|PROCEDURE|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
219550984|NCT00045162|DRUG|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
219550985|NCT00045162|DRUG|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
219550986|NCT00045162|DRUG|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
219550987|NCT00702793|DRUG|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
219550988|NCT01044433|DRUG|lapatinib ditosylate|Given orally
219550989|NCT01044433|DRUG|capecitabine|Given orally
219550990|NCT06520683|DRUG|Tislelizumab|\- Tislelizumab 200mg (day 1 and day 22), administered after surgery
219121604|NCT03613584|DRUG|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
219121605|NCT03374072|BEHAVIORAL|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
219121606|NCT03374072|BEHAVIORAL|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
219121607|NCT01968005|DRUG|Etoreat®(Etodolac-Lidocaine Topical Patch)|
219121608|NCT01968005|DRUG|Placebo|
219121609|NCT01939860|OTHER|Written and verbal patient education on hypertension and its treatment|
219706314|NCT02585206|BEHAVIORAL|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
219706315|NCT02585206|BEHAVIORAL|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
219706316|NCT02585206|BEHAVIORAL|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
219121610|NCT03303274|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
219121611|NCT01901549|PROCEDURE|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
219121612|NCT01901549|DRUG|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
219225649|NCT05943054|OTHER|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
219225650|NCT06703476|PROCEDURE|Stent placement|Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.
219706317|NCT02585206|BEHAVIORAL|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
219706318|NCT02585206|BEHAVIORAL|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
219706319|NCT03085303|DEVICE|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
219121613|NCT01901549|DRUG|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
219121614|NCT03094897|DRUG|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
219121615|NCT03094897|DEVICE|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
219121616|NCT02783105|OTHER|Musical intervention|
219121617|NCT02783105|OTHER|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
219121618|NCT03850444|BIOLOGICAL|pembrolizumab|
219121619|NCT03850444|DRUG|carboplatin|
219121620|NCT03850444|DRUG|paclitaxel|
219121621|NCT03850444|DRUG|pemetrexed|
219121622|NCT05154344|DRUG|Capmatinib|Available through expanded access
219121623|NCT06216028|BIOLOGICAL|Autologous Bone Marrow Aspirate Concentrate|Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)
219121624|NCT04096365|DEVICE|Subcostal Temporary Extracardiac Pacing Lead|The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
219121625|NCT01452672|RADIATION|Radiotherapy|RT 40 Gy in 15 fractions
219121626|NCT01452672|RADIATION|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
219121627|NCT05310084|BIOLOGICAL|BNT162b2|Intramuscular injection
219121628|NCT05310084|OTHER|Placebo|Saline intramuscular injection
219121629|NCT05310084|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
219121630|NCT04727710|BEHAVIORAL|Mindfulness-based Intervention|A self-directed, web-based mindfulness training. Investigators recommend one module a week for 6 weeks. Each module is approximately 1 hour long and consists of didactic components as well as meditation and mindfulness exercises.
219121631|NCT04727710|BEHAVIORAL|Usual Care|Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.
219121632|NCT05373901|DRUG|Dinutuximab Beta|Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
219121633|NCT05373901|DRUG|13-cis-Retinoic Acid|13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
219121634|NCT04440228|BEHAVIORAL|TeamSTEPPS|"TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals."
219121635|NCT05628662|DEVICE|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
219121636|NCT01598987|DRUG|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
219121637|NCT00006221|DRUG|ixabepilone|
219121638|NCT01144117|DRUG|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
219121639|NCT04497311|DIAGNOSTIC_TEST|Thoraxic computed tomography|Diagnostic lung CT.
219121640|NCT02107274|DRUG|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
219550991|NCT06520683|DRUG|Adjuvant chemotherapy|"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."
219706320|NCT02181595|OTHER|Group reading and discussion|
219706321|NCT04103840|OTHER|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
219706322|NCT02721069|DRUG|NRL-1|
219706323|NCT02122419|OTHER|lateral|spinal anesthesia performed during lateral position
219706324|NCT02122419|OTHER|sitting|spinal anesthesia performed during sitting position
219121641|NCT02107274|DRUG|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
219121642|NCT05878353|PROCEDURE|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
219121643|NCT05878353|PROCEDURE|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
219121644|NCT02293707|BIOLOGICAL|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
219121645|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
219550992|NCT03595254|BEHAVIORAL|Thrive|Computerized Cognitive Behavior Therapy program
219550993|NCT03329209|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
219550994|NCT03882762|DRUG|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
219550995|NCT00483145|DEVICE|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
219550996|NCT00483145|DEVICE|Long-pulsed dye laser|
219550997|NCT00483145|DEVICE|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
219550998|NCT05953987|OTHER|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
219121646|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
219121647|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
219121648|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
219121649|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
219121650|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
219121651|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
219121652|NCT05899049|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
219121653|NCT05899049|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
219121654|NCT05899049|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
219225651|NCT06703476|DRUG|Alvimopan|Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
219706325|NCT03448848|DRUG|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
219706326|NCT03448848|DRUG|sterile normal saline|sterile normal saline in a volume equal to the study drug
219706327|NCT02742207|OTHER|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
219706328|NCT02742207|OTHER|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
219706329|NCT04286880|PROCEDURE|PRP injection|"Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003."
219706330|NCT04286880|PROCEDURE|Dry needling|In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
219706331|NCT02471339|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
219706332|NCT06394258|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy to the vaginal cuff with the aim to reproduce adjuvant high dose rate (HDR) brachytherapy dose distribution by means of external beam radiotherapy in patients operated for intermediate risk endometrial carcinoma
219706333|NCT05356663|OTHER|Mulligan Mobilization|Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
219706334|NCT05356663|OTHER|Hold Relax|Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
219706335|NCT00025337|BIOLOGICAL|bevacizumab|Given IV
219706336|NCT00025337|DRUG|oxaliplatin|Given IV
219706337|NCT00025337|DRUG|leucovorin calcium|Given IV
219706338|NCT00025337|DRUG|fluorouracil|Given IV
219706339|NCT05662813|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
219121655|NCT05899049|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
219121656|NCT01178242|PROCEDURE|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
219225652|NCT04640805|DIETARY_SUPPLEMENT|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
219706340|NCT00318396|PROCEDURE|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
219706341|NCT00318396|PROCEDURE|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
219121657|NCT03940469|DRUG|Saline|2 ml normal saline
219121658|NCT03940469|DRUG|Dexamethasone Injection|8 mg dexamethasone
219121659|NCT03940469|DRUG|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
219121660|NCT03412838|PROCEDURE|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
219121661|NCT02763098|DRUG|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
219225653|NCT04640805|OTHER|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
219225654|NCT06449378|DEVICE|Transorb™ Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for repair of open ventral hernia.
219706342|NCT03786393|DIAGNOSTIC_TEST|ACR 1990 fibromyalgia critters|ACR 1990 fibromyalgia critters
219706343|NCT03934775|DEVICE|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
219706344|NCT03340883|BIOLOGICAL|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
219121662|NCT02763098|DRUG|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
219121663|NCT02763098|DRUG|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
219121664|NCT02298374|OTHER|Homecare reablement|
219121665|NCT02298374|OTHER|usual care|
219121666|NCT02941146|DEVICE|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
219121667|NCT00767715|DRUG|olanzapine|physician determined dose, oral, daily, 5 months
219121668|NCT00767715|DRUG|haloperidol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
219121669|NCT00767715|DRUG|zuclopentixol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
219121670|NCT05838612|OTHER|Heat acclimation|Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (\~40°C) for 1 hour over 7 consecutive days.
219121671|NCT01972087|BEHAVIORAL|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
219225655|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
219706345|NCT00564356|PROCEDURE|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
219706346|NCT03552406|BIOLOGICAL|ISU104|Intravenous Infusion for 1 hour.
219706347|NCT03552406|DRUG|Cetuximab|Intravenous Infusion for 1 hour (2 hours at initial dose)
219706348|NCT01675778|DRUG|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
219706349|NCT03453736|OTHER|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
219706350|NCT00626639|DRUG|Placebo|Administered by intravenous (IV) bolus injection
219706351|NCT00626639|DRUG|palifermin|Administered by intravenous (IV) bolus injection
219706352|NCT00626639|RADIATION|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
219706353|NCT00626639|DRUG|Cisplatin|100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
219706354|NCT05142735|DIETARY_SUPPLEMENT|N-Acetylcysteine|2000 mg (4 x 500-mg tablets) every morning
219706355|NCT05142735|DIETARY_SUPPLEMENT|Placebo|4 placebo tablets every morning
219706356|NCT06437756|OTHER|Theraband resistance training|Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.
219121672|NCT01660295|DRUG|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
219706357|NCT06437756|OTHER|Conventional Resistance Training|The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
219706358|NCT00827567|DRUG|RAD 001|RAD 001-10 mg by mouth once everyday
219121673|NCT01660295|DRUG|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
219121674|NCT01660295|DRUG|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
219121675|NCT01660295|DRUG|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
219121676|NCT02394886|BIOLOGICAL|ALLO-ASC-DFU|
219121677|NCT03281265|OTHER|standard treatment|
219121678|NCT02180711|DRUG|acalabrutinib|
219121679|NCT02180711|DRUG|rituximab (IV)|
219121680|NCT02180711|DRUG|Lenalidomide|
219121681|NCT01036087|DRUG|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
219121682|NCT01036087|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
219121683|NCT01036087|DRUG|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
219121684|NCT01036087|DRUG|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
219121685|NCT01036087|DRUG|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
219121686|NCT01036087|DRUG|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
219121687|NCT00134810|BIOLOGICAL|Botulinum toxin type A|
219121688|NCT00406809|DRUG|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~\- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
219121689|NCT02595307|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
219121690|NCT05151133|BIOLOGICAL|Low dose UCMSCs|Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
219121691|NCT05151133|BIOLOGICAL|Moderate dose UCMSCs|Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
219121692|NCT05151133|BIOLOGICAL|High dose UCMSCs|Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
219706359|NCT01946867|DEVICE|NBTXR3 activated by IMRT|
219706360|NCT01461551|DRUG|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
219121693|NCT00512408|DRUG|testosterone|
219121694|NCT04376476|BIOLOGICAL|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
219121695|NCT04376476|BIOLOGICAL|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
219121696|NCT04376476|BIOLOGICAL|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
219121697|NCT04376476|OTHER|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
219121698|NCT06356181|DEVICE|Respiratory Maximus Training Device|Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.
219121699|NCT06356181|DEVICE|No Respiratory Training Device|Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
219121700|NCT03961256|DRUG|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
219121701|NCT05310721|BEHAVIORAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
219121702|NCT05310721|BEHAVIORAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
219121703|NCT05310721|BEHAVIORAL|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
219121704|NCT02708641|DRUG|pembrolizumab|200 mg IV given every three weeks
219121705|NCT04591184|BIOLOGICAL|Covigenix VAX-001 placebo|Placebo vaccine
219121706|NCT04591184|BIOLOGICAL|Covigenix VAX-001|Active Covigenix VAX-001
219121707|NCT00345462|BIOLOGICAL|Trivalent virosomal influenza vaccine|
219121708|NCT06390553|DEVICE|Task-Oriented Virtual Reality Application with Crowd Simulation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
219121709|NCT06390553|PROCEDURE|Conventional Parkinson Rehabilitation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
219121710|NCT02424344|DRUG|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
219121711|NCT02424344|DRUG|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
219121712|NCT00003802|DRUG|pyrazoloacridine|
219121713|NCT06450184|DRUG|Pimavanserin 34 mg|1 capsule of Pimavanserin Capsule 34mg
219121714|NCT06450184|DRUG|NUPLAZID 34 MG Oral Capsule|1 capsule of Pimavanserin Capsule 34mg
219706361|NCT01461551|DRUG|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
219706362|NCT01461551|DRUG|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
219706363|NCT00989300|DRUG|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
219121715|NCT01445639|DRUG|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
219121716|NCT01445639|DRUG|Normal saline|as placebo
219121717|NCT00335543|DRUG|cisplatin|
219121718|NCT00335543|DRUG|gemcitabine hydrochloride|
219121719|NCT00335543|PROCEDURE|adjuvant therapy|
219121720|NCT00335543|PROCEDURE|conventional surgery|
219121721|NCT00335543|PROCEDURE|neoadjuvant therapy|
219121722|NCT00335543|RADIATION|radiation therapy|
219706364|NCT00989300|DRUG|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
219706365|NCT00989300|OTHER|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
219706366|NCT01155141|DRUG|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
219706367|NCT02007772|DEVICE|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
219706368|NCT02007772|DEVICE|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
219706369|NCT04507113|OTHER|DTI sequence acquisition|DTI sequence acquisition
219706370|NCT04055883|DRUG|DA-1229|All participants are administered one tablet per day for 96 weeks
219121723|NCT05476822|DIAGNOSTIC_TEST|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
219121724|NCT06439953|DEVICE|Chlorhexidine gluconate solution|Evaluating the prophylactic use of Irrisept irrigation alone
219121725|NCT06439953|DRUG|Vancomycin|Evaluating the use of versus vancomycin-saline irrigation with or without topical vancomycin
219121726|NCT04018781|OTHER|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
219121727|NCT03947957|DIAGNOSTIC_TEST|collection of expectoration, stools and blood|collection of expectoration, stools and blood
219121728|NCT01426620|DIETARY_SUPPLEMENT|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
219706371|NCT02240329|BEHAVIORAL|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
219706372|NCT02240329|BEHAVIORAL|Respiratory measures|We will collect measures of cough airflow and breathing strength.
219706373|NCT02240329|DRUG|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
219706374|NCT01694134|DRUG|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
219706375|NCT01694134|DRUG|Lidocaine|
219121729|NCT03701100|DEVICE|tDCS|tDCS
219121730|NCT03626974|BIOLOGICAL|Venipuncture|Venipuncture for blood collection
219121731|NCT03626974|DEVICE|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
219121732|NCT03109717|DRUG|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
219121733|NCT04502667|DRUG|Cholecalciferol|1000U or 2000U every 24 hours orally
219121734|NCT05178394|DEVICE|Weightlifting belts and wrist straps|"The participants wore a weightlifting belt (Heavywear Nylon Contour Belt H9, North Carolina, USA) for the with weightlifting belt conditions and/or put on a pair of wrist straps (Versa Gripps Professional Series, Versa Gripps, Maine, USA) for the with wrist strap conditions. The steps involved in completing a conventional deadlift have been detailed in Holmes."
219121735|NCT05247840|DIAGNOSTIC_TEST|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
219225656|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
219225657|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
219225658|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
219706376|NCT01720966|PROCEDURE|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
219706377|NCT00733434|DRUG|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
219706378|NCT00733434|OTHER|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
219706379|NCT02016118|DEVICE|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
219706380|NCT03473197|DRUG|Diacerein 1% ointment|During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
219121736|NCT05247840|DIAGNOSTIC_TEST|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
219121737|NCT05247840|DIAGNOSTIC_TEST|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
219121738|NCT01421771|DRUG|Antihypertensive Agents|"Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator"
219121739|NCT01421771|OTHER|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
219121740|NCT01421771|DIETARY_SUPPLEMENT|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
219121741|NCT02091063|DRUG|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
219121742|NCT06629129|DRUG|Latanoprost (0.005%)|MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
219121743|NCT02863159|DEVICE|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
219121744|NCT03367364|BEHAVIORAL|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
219706381|NCT00440843|DRUG|Olanzapine (Zyprexa)|OLZ
219121745|NCT03367364|BEHAVIORAL|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
219121746|NCT03259971|DIETARY_SUPPLEMENT|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
219121747|NCT03259971|DIETARY_SUPPLEMENT|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
219121748|NCT04953156|DRUG|Nitroglycerin|data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion
219121749|NCT04953156|DRUG|Dexmedetomidine|All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.
219121750|NCT04751513|OTHER|auricular acupressure|Pressure on auricular point of Shenmen (TF4), Sympathesis (AH6a), Subcortex (AT4), Endocrine (CO18), finger (SF1), and toe (AH2) of the ear.
219121751|NCT00252785|DRUG|Budesonide/Formoterol|
219121752|NCT00252785|DRUG|Budesonide|
219121753|NCT00252785|DRUG|Theophylline|
219225659|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
219706382|NCT00440843|DRUG|Typicals|Stay on typicals regimen
219706383|NCT01946945|GENETIC|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
219706384|NCT00482833|DRUG|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
219706385|NCT00482833|DRUG|idarubicin|"Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
219225660|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
219706386|NCT00482833|DRUG|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
219121754|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
219706387|NCT00482833|DRUG|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
219121755|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
219121756|NCT05169021|DRUG|Amlodipine+intensive antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
219121757|NCT05169021|DRUG|Amlodipine+standard antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
219706388|NCT00482833|DRUG|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
219706389|NCT00482833|DRUG|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
219706390|NCT01828658|OTHER|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
219706391|NCT00267670|DRUG|Pentoxifylline|400mg PO TID
219706392|NCT00267670|DRUG|Placebo|1 pill PO TID
219706393|NCT03200821|BIOLOGICAL|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
219706394|NCT03200821|DRUG|Gemcitabine|1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
219706395|NCT06397482|DIETARY_SUPPLEMENT|Encapsulated Calcium Butyrate|Contains at minimum 35% butyric acid
219121758|NCT01391156|DRUG|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
219121759|NCT01391156|DRUG|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
219706396|NCT01384656|DRUG|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
219706397|NCT05241951|OTHER|Structured hand-off|Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams
219706398|NCT05241951|OTHER|Medication reconciliation during transitional period|Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)
219706399|NCT05241951|OTHER|Transitional medication monitoring|Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery
219706400|NCT05241951|OTHER|Teleconsultation|Ad hoc consultation to provide additional clarification to SNF clinical teams
219706401|NCT03797729|DRUG|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
219706402|NCT03797729|DRUG|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
219706403|NCT02671968|DEVICE|Continuous Glucose Monitoring System|
219706404|NCT03320915|DRUG|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
219121760|NCT05557019|DEVICE|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
219121761|NCT01102478|DRUG|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
219706405|NCT02326883|BEHAVIORAL|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
219121762|NCT02408562|OTHER|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
219121763|NCT02408562|OTHER|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
219121764|NCT05186090|BEHAVIORAL|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
219121765|NCT05337969|DRUG|Metformin and Vildagliptin 850/50 mg|50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
219121766|NCT03234621|OTHER|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
219121767|NCT03344289|DIAGNOSTIC_TEST|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
219121768|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
219121769|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
219121770|NCT02360345|DRUG|ONX-0801|
219121771|NCT05974826|BEHAVIORAL|the SI! Program for Secondary Schools (NCT03504059)|The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.
219121772|NCT05974826|BEHAVIORAL|the Fifty-Fifty Program (NCT02367963)|"1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts."
219121773|NCT06534463|OTHER|All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.|The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
219706406|NCT02326883|BEHAVIORAL|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
219706407|NCT02326883|BEHAVIORAL|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
219706408|NCT02460003|BEHAVIORAL|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
219706409|NCT02460003|OTHER|Home exercise program|Home exercise program
219706410|NCT03921983|OTHER|Oxygen supplementation|short term O2 supplementation during 1 hour
219706411|NCT00722696|OTHER|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
219706412|NCT05627687|BEHAVIORAL|Heart Rate Variability Biofeedback|Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
219706413|NCT05627687|BEHAVIORAL|Music Listening Control|Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
219706414|NCT02339207|DRUG|AL-335 matching placebo|
219706415|NCT02339207|DRUG|AL-335|
219706416|NCT05173311|BEHAVIORAL|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
219706417|NCT04024137|DRUG|ZSP1273 200 mg|1 X 200-mg tablet taken orally
219706418|NCT04024137|DRUG|Placebo|2 tablets taken orally
219706419|NCT04024137|DRUG|ZSP1273-400 mg|2 X 200-mg tablet taken orally
219706420|NCT04024137|DRUG|Placebo|1 tablet taken orally
219121774|NCT00635843|DEVICE|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
219121775|NCT00635843|DEVICE|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
219121776|NCT03554187|DEVICE|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
219121777|NCT03554187|BIOLOGICAL|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
219121778|NCT03554187|GENETIC|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
219121779|NCT03554187|BIOLOGICAL|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
219121780|NCT03554187|DEVICE|Halitosis measure|With appropriate device : halimeter
219121781|NCT03327506|DRUG|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
219121782|NCT05329389|DEVICE|StoneMD|StoneMD - is an app from App Store (for iOS) or Google Play (for Android).
219121783|NCT05329389|BEHAVIORAL|Schools of Patients|"The Schools for Patients with Urolithiasis is an online course for patients with urinary stone disease."
219121784|NCT05329389|BEHAVIORAL|Standard recommendation|Only fluid balance recommendations given at the day of discharge.
219121785|NCT01511536|DRUG|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
219121786|NCT01511536|DRUG|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
219121787|NCT01511536|DRUG|Prednisone 5 mg|Route of administration: oral
219121788|NCT01800344|DEVICE|LMA|
219121789|NCT01800344|DEVICE|Ultra|Ultra
219121790|NCT00928460|PROCEDURE|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
219121791|NCT02357758|DRUG|Antibiotic Prophylaxis|Approved clinical dosage or antibiotics
219121792|NCT00688506|DEVICE|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
219121793|NCT00688506|DEVICE|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
219121794|NCT06486935|DEVICE|IoT sensors|The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.
219121795|NCT06486935|OTHER|Traditional/Manual elderly monitoring|Traditional elderly care without the use of IoT sensors.
219121796|NCT02688036|RADIATION|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
219121797|NCT02688036|RADIATION|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
219121798|NCT02318225|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
219121799|NCT02318225|DRUG|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
219121800|NCT05701943|BEHAVIORAL|Home-Based|During the home-based intervention, aerobic training was performed using body weight exercises such as jumping jacks, standing box, side shift with floor touch, high knees, half burpee, and hook box (Borrega-Mouquinho et al., 2021).
219121801|NCT05701943|BEHAVIORAL|Gym-Based|During the gym-based intervention, aerobic training was performed on cycle ergometers (Star Trac Spinner Blade ION 7220, Vancouver, WA).
219121802|NCT00671593|BIOLOGICAL|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
219121803|NCT00671593|BIOLOGICAL|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
219121804|NCT03681821|BEHAVIORAL|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
219121805|NCT05564182|DEVICE|High intensity laser therapy|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). It will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect.
219121806|NCT05564182|OTHER|Therapeutic Exercise|Therapeutic Exercise As therapeutic exercise program; A multidisciplinary stroke rehabilitation program will be implemented in the presence of a specialist physiotherapist. In addition, a therapeutic exercise program including passive, actively supported and active ROM exercises, stretching, strengthening and mobilization exercises will be applied to all patients by physiotherapists according to the level of pain and limitation.It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes.
219121807|NCT03337347|DEVICE|CTC/DTC count|The presence of CTCs/DTCs in the peripheral blood and/or bone marrow may identify colorectal cancer patients with high risk of disease recurrence who may benefit from adjuvant therapy.
219121808|NCT03351361|DRUG|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
219121809|NCT03351361|DRUG|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
219121810|NCT02022514|OTHER|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
219121811|NCT02022514|DRUG|Conventional medical treatment|
219121812|NCT04365413|DEVICE|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
219121813|NCT04365413|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
219121814|NCT03046303|PROCEDURE|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
219121815|NCT06580834|DEVICE|Cergenx Wave|Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.
219121816|NCT03941938|PROCEDURE|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
219706421|NCT04024137|DRUG|ZSP1273-600 mg|3 X 200-mg tablet taken orally
219706422|NCT04024137|DRUG|Placebo|3 tablets taken orally
219706423|NCT04024137|DRUG|Placebo|Subjects will receive matching placebo of ZSP1273
219706424|NCT05689437|OTHER|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
219706425|NCT05689437|OTHER|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
219706426|NCT05689437|OTHER|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
219121817|NCT03941938|PROCEDURE|No reinforcement|Nothing applied on the anastomosis line
219121818|NCT02037061|DRUG|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
219121819|NCT02037061|OTHER|Normal Saline|
219121820|NCT03019458|DIETARY_SUPPLEMENT|MINGO|6 20oz sachets will be taken daily by intervention group
219121821|NCT00557505|DRUG|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
219121822|NCT05608720|BEHAVIORAL|Information Booklet|Information Booklet prior to the dental visit
219225661|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
219225662|NCT05980598|DRUG|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
219121823|NCT04099953|DIAGNOSTIC_TEST|Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels|Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
219121824|NCT02782429|DRUG|Ketamine|
219121825|NCT02782429|OTHER|Saline|
219121826|NCT04873713|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension over low back
219121827|NCT04873713|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
219121828|NCT06352190|DRUG|[14C] SY-5007|Carbon-14 labeled SY-5007
219121829|NCT03457194|BIOLOGICAL|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
219121830|NCT03457194|BIOLOGICAL|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
219121831|NCT03914339|PROCEDURE|Periodontal and orthodontic treatment|Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
219706427|NCT05689437|OTHER|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
219706428|NCT05689437|OTHER|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
219706429|NCT05689437|OTHER|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
219121832|NCT03914339|PROCEDURE|periodontal treatment|Eighteen periodontally compromised patients who give be given periodontal treatment alone.
219121833|NCT02945202|DEVICE|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
219121834|NCT02945202|DEVICE|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
219121835|NCT02945202|DEVICE|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
219121836|NCT06270511|DRUG|S-337395|Administered as an oral suspension.
219225663|NCT05980598|DRUG|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
219225664|NCT05980598|DRUG|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
219225665|NCT03258866|DRUG|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
219706430|NCT02419950|DEVICE|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
219706431|NCT06216496|OTHER|dynamic test for amino acid metabolism|"Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate."
219121837|NCT06270511|DRUG|Placebo|Administered as an oral suspension.
219121838|NCT00426374|PROCEDURE|echocardiography and blood test|
219121839|NCT02046642|BEHAVIORAL|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
219121840|NCT02046642|BEHAVIORAL|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
219121841|NCT03244137|OTHER|Pulmonary rehabilitation|See group description.
219121842|NCT05675774|DIAGNOSTIC_TEST|Dual Energy CT|Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
219225666|NCT03258866|DRUG|Rituximab|given with a single dose of 375mg/m2
219225667|NCT02423005|DEVICE|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
219225668|NCT02423005|DEVICE|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
219706432|NCT06557681|DEVICE|Virtual Reality-Treadmill Training Group (VTT)|The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.
219121843|NCT05420987|DIETARY_SUPPLEMENT|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
219121844|NCT01241578|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
219121845|NCT01330121|OTHER|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity"
219121846|NCT05148767|DRUG|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）."
219121847|NCT00099424|BEHAVIORAL|High-intensity exercise training|
219706433|NCT06557681|OTHER|Conventional Therapy Group (CT)|The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
219706434|NCT00471965|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
219706435|NCT00471965|DRUG|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
219706436|NCT04335864|PROCEDURE|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
219706437|NCT04335864|PROCEDURE|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
219706438|NCT03698461|DRUG|Atezolizumab|"* 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
219706439|NCT03698461|DRUG|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
219121848|NCT02548793|OTHER|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
219706440|NCT03698461|DRUG|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
219706441|NCT03698461|DRUG|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
219706442|NCT03698461|DRUG|5-FU|"* 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
219706443|NCT03337126|DRUG|Metronidazole Tablet|Comparator Drug
219706444|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
219706445|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
219706446|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
219706447|NCT06412003|BEHAVIORAL|Home-based balance training|This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
219706448|NCT03012776|DEVICE|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
219706449|NCT03012776|PROCEDURE|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
219706450|NCT06425016|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG)|Bariatric Surgery
219706451|NCT06425016|PROCEDURE|Robotic Sleeve Gastrectomy (RSG)|Bariatric Surgery
219121849|NCT02548793|OTHER|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
219121850|NCT01418092|DRUG|ALKS 37|Capsules for oral administration
219121851|NCT01418092|DRUG|Placebo|Capsules for oral administration
219706452|NCT00005663|DRUG|Valacyclovir hydrochloride|
219706453|NCT00315367|DRUG|Donepezil HCI (drug)|
219706454|NCT04877002|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
219706455|NCT04794998|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
219121852|NCT02744274|OTHER|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
219121853|NCT00518752|PROCEDURE|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
219121854|NCT00518752|PROCEDURE|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
219121855|NCT00031447|DRUG|Acyclovir|Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.
219121856|NCT00031447|DRUG|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
219121857|NCT02786979|DRUG|Beraprost|Oral
219121858|NCT02786979|DRUG|Aspirin|Oral
219121859|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant D
219121860|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant E
219706456|NCT04794998|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
219706457|NCT02736617|DRUG|Ibrutinib|Given PO
219706458|NCT02736617|BIOLOGICAL|Obinutuzumab|Given IV
219706459|NCT04657913|OTHER|cold water spray application|It will be sprayed into the mouth of patients every hour.
219121861|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant F
219121862|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant G
219121863|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant H
219121864|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 µg/capsule inhaled via Handihaler
219121865|NCT04850144|DRUG|Tiotropium Easyhaler with oral activated charcoal|The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
219121866|NCT01244763|DRUG|Roxadustat|Oral capsule
219121867|NCT04457271|BEHAVIORAL|Goal Management Training (GMT)|GMT is a structured, short-term cognitive remediation program with an emphasis on mindfulness and practice in planning and completion of goal-oriented behaviours. The main objective of GMT is to help participants regain executive control in order to better define goals and monitor performance in achieving them. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Mindfulness meditation is also incorporated for the purpose of developing the skill of bringing one's mind to the present to monitor ongoing behaviour, goal states, and the relationship between them, and for the development of attentional control. The program incorporates real-life examples to illustrate goal attainment failures and successes, as well as in-session practice of complex tasks that mimic real-life tasks - typically a challenge for individuals with executive function deficits (e.g., planning and set-shifting tasks).
219121868|NCT04990687|DEVICE|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
219121869|NCT02947711|DRUG|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
219706460|NCT04657913|OTHER|cold saline spray application|It will be sprayed into the mouth of patients every hour.
219706461|NCT01718691|DRUG|SyB L-0501|A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
219706462|NCT01718691|DRUG|rituximab|A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
219706463|NCT03318562|DRUG|eFT508|200 mg eFT508 dosed BID for 3 week cycles
219706464|NCT02494011|OTHER|traditional exercise|mobilization stretching exercise
219706465|NCT02494011|OTHER|Russian current stimulation|stimulation to wrist flexors for 15 minutes
219706466|NCT02494011|OTHER|closed kinetic chain exercise|wall press exercise plyometric exercise
219121870|NCT02947711|DRUG|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
219121871|NCT05466708|DRUG|Esketamine combined with dexmedetomidine|"Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
219121872|NCT05466708|DRUG|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
219121873|NCT00862511|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
219121874|NCT00862511|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
219121875|NCT02044198|BIOLOGICAL|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
219121876|NCT05731375|DIAGNOSTIC_TEST|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
219121877|NCT01446029|DEVICE|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
219121878|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and a connective tissue graft|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft
219121879|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and platelet rich fibrin membranes|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
219121880|NCT00376480|BIOLOGICAL|anti-thymocyte globulin|
219706467|NCT05348434|PROCEDURE|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
219706468|NCT04383132|DEVICE|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
219706469|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
219706470|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
219706471|NCT02952417|OTHER|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
219706472|NCT02911116|DRUG|Ustekinumab|Subcutaneous Injection
219706473|NCT02911116|DRUG|Ustekinumab|Intravenous Infusion
219706474|NCT03974958|GENETIC|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
219706475|NCT03555552|DEVICE|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
219121881|NCT00376480|BIOLOGICAL|peripheral blood lymphocyte therapy|
219121882|NCT00376480|DRUG|fludarabine phosphate|
219121883|NCT00376480|DRUG|methylprednisolone|
219706476|NCT03555552|DEVICE|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
219706477|NCT02368392|OTHER|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
219121884|NCT00376480|DRUG|thiotepa|
219121885|NCT00376480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219121886|NCT00376480|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219121887|NCT00376480|RADIATION|total-body irradiation|
219121888|NCT00519779|DIETARY_SUPPLEMENT|omega-3 supplementation|2.5 g/day omega-3
219121889|NCT00519779|DIETARY_SUPPLEMENT|Oral omega-3 fish oil placebo|to match experimental dosage
219121890|NCT01561079|DRUG|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
219121891|NCT06113029|DIAGNOSTIC_TEST|The Hamilton Rating Scale for Anxiety|The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
219121892|NCT06113029|DIAGNOSTIC_TEST|The Beck Depression inventory|one of the most widely used instruments for measuring the severity of depression
219225669|NCT03954106|DRUG|Defibrotide|"* Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
219225670|NCT06280469|DEVICE|Single-Balloon Enteroscopy|The inflated balloon is supposed to fix the intestine to the endoscope system.Pushing the endoscope deeper into the small bowel with the balloon and enteroscope.
219121893|NCT06113029|DIAGNOSTIC_TEST|Rand SF-36 Questionnaire|The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Component analyses showed that there are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales do contribute in different proportions to the scoring of both PCS and MCS measures
219121894|NCT04561414|DEVICE|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
219121895|NCT04561414|DEVICE|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
219121896|NCT03330119|DRUG|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
219121897|NCT03330119|DRUG|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
219706478|NCT02590783|PROCEDURE|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
219706479|NCT02590783|PROCEDURE|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
219706480|NCT05190133|DRUG|UIC201602 and co-administration of UIC201601 and UIC201602|"* UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
219706481|NCT05190133|DRUG|UIC201601 and co-administration of UIC201601 and UIC201602|"* UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
219706482|NCT00004059|DRUG|7-hydroxystaurosporine|
219706483|NCT00004059|DRUG|fluorouracil|
219706484|NCT00956189|DRUG|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
219706485|NCT00956189|DRUG|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
219706486|NCT00777842|DEVICE|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
219121898|NCT05908448|DEVICE|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
219161475|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh used:1. Parietex™ Composite Mesh (Medtronic, USA): A multifilament polyester mesh with an anti-adhesive collagen barrier to minimize visceral adhesions."
219225671|NCT04458597|RADIATION|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
219225672|NCT02064699|BIOLOGICAL|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
219225673|NCT06239012|DEVICE|Position measurement with BePow|14 measurements taken with the device
219225674|NCT06239012|OTHER|Position measurement with MCPAA scale|MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
219121899|NCT03969602|BEHAVIORAL|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
219121900|NCT03969602|OTHER|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
219121901|NCT03215225|PROCEDURE|Root canal orthograde treatment|
219121902|NCT05284422|PROCEDURE|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
219121903|NCT05284422|PROCEDURE|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
219706487|NCT03036943|RADIATION|Fluciclovine|Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer
219121904|NCT00917189|BEHAVIORAL|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
219121905|NCT01930617|PROCEDURE|Burr hole surgery with various drainage techniques|"Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain"
219121906|NCT01212705|DEVICE|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
219121907|NCT02781155|OTHER|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
219121908|NCT06429566|DRUG|GB001 recombinant peptide spray low dose group、high dose group|Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
219121909|NCT06429566|DRUG|GB001 recombinant peptide spray placebo|Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
219121910|NCT01971307|OTHER|SGE-PsyScan|
219225675|NCT02610439|OTHER|Laboratory Biomarker Analysis|Correlative studies
219225676|NCT03702777|DRUG|ASP8302|Oral Capsule
219225677|NCT03702777|DRUG|Placebo|Oral Capsule
219225678|NCT00551421|BIOLOGICAL|pertuzumab|Given IV
219225679|NCT00551421|BIOLOGICAL|cetuximab|Given IV
219706488|NCT03763981|PROCEDURE|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
219706489|NCT03763981|PROCEDURE|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
219706490|NCT03873532|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
219706491|NCT03873532|DRUG|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
219706492|NCT04810962|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
219706493|NCT04810962|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
219706494|NCT02475668|DEVICE|Pulse oximeter|Hypoxia
219121911|NCT05408650|OTHER|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~* The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~* The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
219121912|NCT05315804|OTHER|MINSD and amelogenins|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied to the intraosseous periodontal pockets using a sterile syringe with plasticized needle.
219121913|NCT05315804|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
219121914|NCT01349855|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
219121915|NCT00227747|DRUG|capecitabine|
219121916|NCT00227747|DRUG|oxaliplatin|
219121917|NCT00227747|PROCEDURE|conventional surgery|
219225680|NCT00551421|DRUG|irinotecan hydrochloride|Given IV
219225681|NCT00551421|OTHER|immunohistochemistry staining method|Correlative study
219225682|NCT00551421|OTHER|fluorescence in situ hybridization|Correlative study
219225683|NCT00551421|OTHER|gene expression analysis|Correlative study
219225684|NCT00551421|OTHER|mutation analysis|Correlative study
219225685|NCT00551421|OTHER|polymerase chain reaction|Correlative study
219225686|NCT00551421|OTHER|laboratory biomarker analysis|Correlative study
219225687|NCT02271906|DRUG|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
219225688|NCT05421572|DIAGNOSTIC_TEST|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
219121918|NCT00227747|PROCEDURE|neoadjuvant therapy|
219121919|NCT00227747|RADIATION|radiation therapy|
219121920|NCT04860700|DRUG|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
219121921|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
219121922|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
219121923|NCT03394664|BEHAVIORAL|Feeding Study|Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
219121924|NCT00058851|PROCEDURE|Manual lymph drainage|
219706495|NCT04899037|OTHER|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
219706496|NCT03349047|BEHAVIORAL|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
219706497|NCT03349047|BEHAVIORAL|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
219121925|NCT00058851|PROCEDURE|Combined physiotherapy|
219121926|NCT00058851|PROCEDURE|Compression bandaging|
219121927|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
219121928|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
219121929|NCT06556030|DRUG|Botulinum Toxin A|Botulinum Toxin
219121930|NCT06556030|OTHER|CONTROL|Saline Solution
219121931|NCT01605331|DRUG|sustained-release recombinant human GH (SR-rhGH)|
219121932|NCT02647918|DRUG|Sotagliflozin|Single dose
219121933|NCT02647918|DRUG|Sotagliflozin|2 single doses
219121934|NCT04521205|DRUG|fecal microbiota capsule|a capsule full of fecal microbiota extracting from the health
219225689|NCT00978718|DIETARY_SUPPLEMENT|high-selenium baker's yeast|Given orally
219225690|NCT00978718|DIETARY_SUPPLEMENT|selenium|Given orally
219706498|NCT03419650|DRUG|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
219706499|NCT00088855|DRUG|Bortezomib|Given IV
219706500|NCT00088855|OTHER|Laboratory Biomarker Analysis|Correlative studies
219706501|NCT00088855|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219706502|NCT02478333|DRUG|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
219706503|NCT02478333|DRUG|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
219121935|NCT04982380|DRUG|Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
219121936|NCT04982380|DRUG|Siliankang simulating tablets|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
219121937|NCT05205941|DRUG|MMV688533|Not exceeding 200mg
219121938|NCT03748264|OTHER|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
219121939|NCT03748264|DEVICE|DreamMapper Application|The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
219225691|NCT00978718|OTHER|placebo|Given orally
219225692|NCT01039610|DRUG|GSK945237|Dose detailed in Arm description
219225693|NCT01039610|DRUG|Placebo|matching placebo tablet
219225694|NCT01039610|DRUG|Linezolid|600 mg BID, 14 Days
219225695|NCT01039610|DRUG|Moxifloxacin|40 mg single dose
219225696|NCT03919851|DRUG|Antibiotics|Administration of antibiotics
219225697|NCT03377049|DRUG|Acetazolamide|1 g acetazolamide through a peripheral IV line
219706504|NCT02478333|DRUG|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
219706505|NCT02478333|OTHER|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
219706506|NCT05655871|OTHER|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
219706507|NCT05655871|OTHER|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
219121940|NCT03748264|DEVICE|DreamMapper Application with Therapist Assist|The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
219121941|NCT05248360|DEVICE|Hydrogen-oxygen mixed gas(H2-O2) inhalation|H2-O2 inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
219121942|NCT05248360|DEVICE|Air inhalation|Air inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
219121943|NCT04138628|DRUG|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
219121944|NCT03454243|DRUG|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
219121945|NCT00039208|DRUG|fluorouracil|
219121946|NCT00039208|DRUG|irinotecan hydrochloride|
219121947|NCT00039208|DRUG|leucovorin calcium|
219121948|NCT00039208|DRUG|oxaliplatin|
219121949|NCT04089176|DRUG|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
219121950|NCT04089176|DRUG|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
219121951|NCT00664521|BIOLOGICAL|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
219706508|NCT00630292|OTHER|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
219706509|NCT03602001|BEHAVIORAL|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
219706510|NCT03602001|BEHAVIORAL|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
219706511|NCT03099525|OTHER|ILD|This is an observational study without any intervention.
219706512|NCT00142415|DRUG|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
219121952|NCT00664521|DRUG|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
219121953|NCT00664521|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
219121954|NCT05506644|OTHER|HRV-Biofeedback/Mind-Body Therapy|A 7-week protocol using real-time feedback on heart rate variability
219121955|NCT03818997|DRUG|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
219121956|NCT03818997|DRUG|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
219121957|NCT03818997|DRUG|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
219121958|NCT04979390|DRUG|SHR-1316|SHR-1316 administrated intravenously (IV) at protocol defined dose levels
219121959|NCT05362526|DEVICE|HFOT using AIRVO2|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases. The subjects in this group will receive HFOT at a flow rate of 60-30L liters per minute, maximum concentration of 40%, which will be titrated by bedside nurse to maintain an oxygen saturation of 92% or greater (unless there is a history of COPD and then the clinician can recommend \>88%)
219121960|NCT05362526|DEVICE|COT|Subjects will be placed on aerosolized trach mask with cool humidification, and titrated to keep oxygen saturation \>92% (unless there is a history of COPD and then the clinician can recommend \>88%)
219121961|NCT03667326|DRUG|Aspirin tablet|Low dose aspirin, 81mg tablets, PO
219121962|NCT03667326|DRUG|Placebo oral capsule|Placebo oral capsule, PO
219121963|NCT03558113|DIAGNOSTIC_TEST|light induced fluorescence intraoral camera|intraoral oral light induced fluorescence diagnostic camera
219121964|NCT00125983|DRUG|Lopinavir/ritonavir|
219121965|NCT00125983|DRUG|Ortho Novum 1/35|
219121966|NCT00125983|DRUG|Ortho Evra|
219121967|NCT02459964|DRUG|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
219121968|NCT02459964|DRUG|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
219121969|NCT02459964|BEHAVIORAL|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
219121970|NCT03835520|DRUG|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
219121971|NCT03835520|DRUG|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
219121972|NCT02383550|OTHER|Observational Cognitive assessments|Observational
219121973|NCT01409226|DEVICE|3.0-T MRI|Participants undergo MRI prior to biopsy.
219121974|NCT01409226|PROCEDURE|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
219706513|NCT00142415|DRUG|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
219121975|NCT01960361|DEVICE|ICE dental implant|ICE- Implant Classical Esthetic implant
219550999|NCT05953987|OTHER|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
219551000|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
219121976|NCT05883579|PROCEDURE|percutaneous coronary intervention|doing percutaneous revascularization of chronic coronary total occlusion.
219121977|NCT04559308|DRUG|Metformin|first-line anti-diabetic drug
219121978|NCT04559308|DRUG|Chemotherapy|First line neoadjuvant chemotherapy protocol
219121979|NCT00423644|DRUG|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
219121980|NCT00367237|DRUG|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
219121981|NCT00367237|DRUG|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
219121982|NCT02785055|PROCEDURE|Thoracic Epidural Placement|Thoracic Epidural Placement
219121983|NCT02785055|DRUG|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
219121984|NCT02785055|DRUG|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
219121985|NCT05878743|BEHAVIORAL|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
219121986|NCT05972616|BIOLOGICAL|Natural Matrix Protein (NMP)|human bone allograft
219121987|NCT06493084|DRUG|LAE102 intravenous administration|A single dose of LAE102 administered intravenously
219121988|NCT06493084|DRUG|placebo intravenous administration|A single dose of placebo administered intravenously
219121989|NCT06493084|DRUG|LAE102 subcutaneous administration|Single dose of LAE102 administered subcutaneously
219121990|NCT06493084|DRUG|placebo subcutaneous administration|single dose of placebo administered subcutaneously
219121991|NCT06493084|DRUG|LAE102 multiple subcutaneous administration|Multiple dose of LAE102 administered subcutaneously
219706514|NCT03742596|DIETARY_SUPPLEMENT|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
219706515|NCT03742596|DRUG|Control|The Placebos will be coded in a specific label by a researcher.
219706516|NCT00139529|BEHAVIORAL|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
219706517|NCT00139529|BEHAVIORAL|Educational Intervention|Educational intervention will be completed during pregnancy.
219121992|NCT06493084|DRUG|Placebo multiple subcutaneous administration|Multiple dose of placebo administered subcutaneously
219121993|NCT05318014|DIETARY_SUPPLEMENT|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
219121994|NCT05318014|OTHER|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
219121995|NCT06131073|OTHER|speed endurance production (SEP) training along with conventional training.|this include speed endurance training for 3 days in a week for 8 weeks.
219121996|NCT06131073|OTHER|conventional training|this include conventional training for 3 days in a week for 8 weeks.
219121997|NCT04010175|BEHAVIORAL|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
219121998|NCT04010175|BEHAVIORAL|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
219121999|NCT04010175|BEHAVIORAL|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
219122000|NCT00221130|PROCEDURE|surgical operation of cell transplantation|
219122001|NCT02162940|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
219122002|NCT02162940|OTHER|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
219706518|NCT01189266|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
219706519|NCT01189266|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
219706520|NCT01189266|OTHER|Laboratory Biomarker Analysis|Correlative studies
219706521|NCT01189266|DRUG|Vorinostat|Given PO
219706522|NCT02294266|DRUG|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
219706523|NCT02294266|DRUG|Mephedrone|Single oral dose mephedrone
219706524|NCT02294266|DRUG|Alcohol|Single oral dose alcohol
219706525|NCT02294266|DRUG|Placebo|Single oral dose placebo
219122003|NCT03826602|DRUG|Tucatinib|150mg administered orally twice daily
219122004|NCT03826602|DRUG|Metformin|850mg administered orally
219122005|NCT03826602|DRUG|Iohexol|1500 mg administered intravenously (IV)
219122006|NCT02697721|BEHAVIORAL|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
219122007|NCT02697721|OTHER|Control with delayed intervention|Control with delayed intervention
219122008|NCT00550732|DRUG|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
219122009|NCT03455413|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
219122010|NCT05326373|DRUG|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
219122011|NCT00415155|DRUG|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
219122012|NCT04135495|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
219122013|NCT04135495|DRUG|Ivacaftor|CFTR potentiator
219122014|NCT06021990|DRUG|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
219122015|NCT00320866|DEVICE|syringe driver|
219706526|NCT02146183|DIETARY_SUPPLEMENT|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
219706527|NCT02146183|DIETARY_SUPPLEMENT|Placebo Corn Starch|500 mg/day
219706528|NCT04779177|DRUG|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
219706529|NCT04779177|DRUG|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
219706530|NCT04729517|DRUG|AI201901|Twice daily inhaled AI201901 for 4 weeks
219706531|NCT04729517|DRUG|Azelastine Hydrochloride|Twice daily inhaled Azelastine Hydrochloride for 4 weeks
219706532|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
219706533|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
219122016|NCT05571800|OTHER|Mango|120g of fresh Mango
219122017|NCT05571800|OTHER|Placebo|200g isocaloric Granola Bar
219122018|NCT04689698|DIAGNOSTIC_TEST|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
219122019|NCT06475599|DRUG|Anlotinib hydrochloride capsule + TQB2450 injection|"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
219122020|NCT06475599|DRUG|Chemotherapy drug|Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
219122021|NCT00866216|DRUG|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
219122022|NCT00866216|DRUG|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
219122023|NCT05256043|DIAGNOSTIC_TEST|Diabetes Diagnosis|HbA1c \> 6.5%
219122024|NCT01207934|DIETARY_SUPPLEMENT|placebo|saline placebo
219122025|NCT01207934|DRUG|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
219122026|NCT01207934|DRUG|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
219122027|NCT01966536|PROCEDURE|CD133+ cells transplantation into ovarian artery of one ovary|
219122028|NCT03302910|OTHER|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
219122029|NCT03302910|OTHER|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
219706534|NCT05624853|DRUG|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
219706535|NCT05624853|DRUG|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
219706536|NCT00003297|DRUG|mitoxantrone hydrochloride|
219706537|NCT00003297|DRUG|thiotepa|
219706538|NCT00003297|DRUG|topotecan hydrochloride|
219706539|NCT00003297|PROCEDURE|peripheral blood stem cell transplantation|
219706540|NCT06401291|DEVICE|Transcutaneous Electrical Nerve Stimulation|Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
219706541|NCT03620162|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
219706542|NCT03620162|BIOLOGICAL|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
219706543|NCT03620162|BIOLOGICAL|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
219706544|NCT03620162|BIOLOGICAL|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
219706545|NCT03620162|BIOLOGICAL|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
219706546|NCT03620162|BIOLOGICAL|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
219706547|NCT03620162|BIOLOGICAL|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
219122030|NCT00707863|DRUG|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
219122031|NCT05255263|OTHER|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
219122032|NCT05255263|OTHER|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
219122033|NCT04902170|PROCEDURE|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
219122034|NCT04027335|DEVICE|leva|Vaginal device used for pelvic floor muscle exercises
219122035|NCT02800928|DRUG|CERC-501|CERC-501
219122036|NCT02800928|DRUG|Placebo|Placebo
219225698|NCT05817513|OTHER|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
219706548|NCT03620162|BIOLOGICAL|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
219706549|NCT00952198|DRUG|ARRY-403, glucokinase activator; oral|multiple dose, escalating
219706550|NCT00952198|DRUG|Placebo; oral|matching placebo
219706551|NCT06447974|BEHAVIORAL|Exposure mitigations|Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure
219122037|NCT03231449|OTHER|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
219122038|NCT01853163|PROCEDURE|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
219122039|NCT00861978|DRUG|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
219122040|NCT00861978|DRUG|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
219122041|NCT05677867|DRUG|Formulation A (PF-07081532 20 mg plus 60 mg)|Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
219122042|NCT05677867|DRUG|Formulation B (PF-07081532 80 mg)|Formulation B: administered as a 80 mg immediate release tablet
219122043|NCT06303830|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium Nitrate
219122044|NCT00576602|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
219122045|NCT00576602|DRUG|Supportive treatment|As prescribed
219122046|NCT04289285|DRUG|IBI306 450mg SC Q4W|Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
219122047|NCT04289285|DRUG|Placebo SC Q4W|Subjects will receive placebo every 4 weeks subcutaneously.
219122048|NCT04289285|DRUG|IBI306 600mg SC Q6W|Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
219122049|NCT04289285|OTHER|Placebo SC Q6W|Subjects will receive placebo every 6 weeks subcutaneously.
219122050|NCT03114046|BEHAVIORAL|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
219122051|NCT03505359|OTHER|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
219122052|NCT03505359|OTHER|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
219122053|NCT04237454|DEVICE|Thermal Imaging Camera|To develop a non-ionising radiation-based method of excluding fractures in children with suspected physical abuse
219122054|NCT00799461|OTHER|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
219122055|NCT00799461|OTHER|questionnaire administration|Completion of questions in an online format
219122056|NCT00799461|PROCEDURE|psychosocial assessment and care|Assessment and care of psychosocial aspects
219122057|NCT00799461|PROCEDURE|assessment of therapy complications|Evaluation of complications of treatment
219122058|NCT00799461|PROCEDURE|management of therapy complications|Managing therapy complications
219122059|NCT00799461|PROCEDURE|fatigue assessment and management|Assessing and managing fatigue
219122060|NCT00799461|OTHER|counseling intervention|Counseling provided via telephone
219122061|NCT03172793|DRUG|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
219122062|NCT04792983|OTHER|No intervention|This is an observational study with no interventions.
219122063|NCT01336335|DEVICE|CPAP|CPAP
219122064|NCT01817543|DEVICE|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
219551001|NCT05341492|BIOLOGICAL|EGFR/B7H3 CAR-T|2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
219551002|NCT02838953|BEHAVIORAL|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
219551003|NCT01899053|DRUG|TAK-228|TAK-228 Capsules
219551004|NCT01899053|DRUG|TAK-117|TAK-117 Capsules
219551005|NCT00471094|DRUG|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
219551006|NCT00471094|DRUG|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
219551007|NCT00471094|DRUG|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
219551008|NCT00471094|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
219551009|NCT03105297|DEVICE|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
219551010|NCT03105297|OTHER|No strip|
219551011|NCT06445478|OTHER|Blood Flow Restrictive Exercise and Isokinetic Exercise|"Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants."
219551012|NCT01859260|DEVICE|CPAP/autopap|
219122065|NCT02106221|OTHER|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
219122066|NCT02106221|OTHER|Control|Will receive payments based on achievement in meeting goals.
219122067|NCT04004208|DRUG|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
219706552|NCT03777241|BEHAVIORAL|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
219706553|NCT03777241|BEHAVIORAL|Standard of care|Participants in this group will receive standard of care.
219122068|NCT04004208|PROCEDURE|Laser photocoagulation|Transpupillary conventional laser ablative therapy
219122069|NCT04463615|DRUG|Leflunomide|Given PO
219122070|NCT00839982|DRUG|clofarabine|Given PO
219122071|NCT00839982|DRUG|cytarabine|Given SC
219122072|NCT05010382|PROCEDURE|Implant placement surgery|Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
219122073|NCT03738579|DEVICE|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
219122074|NCT03738579|DEVICE|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
219122075|NCT03738579|DEVICE|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
219122076|NCT05382455|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in Ai in healthcare.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the AI reporting standards in systematic reviews and objectively identify critical aspects of reporting methodology and results.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
219122077|NCT04267653|DRUG|Lactoferrin Bovine|treatment for 30 days
219706554|NCT00437463|DRUG|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
219706555|NCT02515474|PROCEDURE|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
219122078|NCT04267653|DRUG|Ferrous Sulfate|treatment for 30 days
219122079|NCT03793855|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
219122080|NCT03793855|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
219122081|NCT06164353|BIOLOGICAL|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
219122082|NCT05720000|DEVICE|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
219122083|NCT05720000|PROCEDURE|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
219122084|NCT01341080|DRUG|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
219122085|NCT01341080|DRUG|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
219706556|NCT02515474|PROCEDURE|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
219122086|NCT04387890|DIAGNOSTIC_TEST|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
219122087|NCT01637558|DRUG|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
219122088|NCT01637558|DRUG|Nevirapine|
219122089|NCT01637558|DRUG|Lopinavir/Ritonavir|
219122090|NCT03022266|BEHAVIORAL|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
219122091|NCT03656900|DEVICE|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
219122092|NCT03656900|DEVICE|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
219122093|NCT03656900|RADIATION|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
219122094|NCT03656900|OTHER|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
219122095|NCT03656900|OTHER|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
219122096|NCT04145336|DEVICE|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
219122097|NCT04145336|DEVICE|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
219122098|NCT04145336|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
219706557|NCT06462677|DIAGNOSTIC_TEST|Babesia NAT|Blood donors will be tested with Babesia NAT
219706558|NCT03336346|DRUG|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
219706559|NCT03336346|DEVICE|ENG implant|Reversible contraception implant
219706560|NCT03336346|DRUG|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
219706561|NCT01019993|PROCEDURE|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.
219122099|NCT00766857|DRUG|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
219122100|NCT00766857|DRUG|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
219122101|NCT04830514|OTHER|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
219122102|NCT04830514|OTHER|Habitual protein intake|1.0 g/kg/day protein intake
219122103|NCT04830514|OTHER|Optimal Protein Intake|1.5 g/kg/day protein intake
219122104|NCT02476643|OTHER|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
219122105|NCT01275053|DRUG|leptin|0.01mg/kg
219122106|NCT03393910|DIAGNOSTIC_TEST|Experimental Pelvic Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam."
219122107|NCT05198453|BIOLOGICAL|vaccination|patients who received COVID-19 vaccine
219122108|NCT01924481|DIETARY_SUPPLEMENT|High Caffeine|
219122109|NCT01924481|DIETARY_SUPPLEMENT|Low caffeine|
219122110|NCT01924481|DIETARY_SUPPLEMENT|High theobromine|
219122111|NCT01924481|DIETARY_SUPPLEMENT|low theobromine|
219225699|NCT05817513|OTHER|Traditional exercises for scoliosis treatment.|"The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises."
219225700|NCT05983939|DRUG|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
219122112|NCT01924481|DIETARY_SUPPLEMENT|No theobromine|
219122113|NCT02926300|BIOLOGICAL|stem cells|IV infusion
219122114|NCT00201253|OTHER|Bronchoalveolar lavages and venipunctures only|
219122115|NCT03016013|BIOLOGICAL|Placebo plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
219122116|NCT03016013|BIOLOGICAL|RC18 160 mg plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
219122117|NCT03743012|OTHER|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
219122118|NCT03743012|OTHER|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
219122119|NCT02785601|DRUG|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
219122120|NCT05510401|OTHER|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
219122121|NCT03434535|DEVICE|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
219122122|NCT02945293|OTHER|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
219122123|NCT00570661|DRUG|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
219122124|NCT06048796|OTHER|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
219122125|NCT01734382|DRUG|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
219122126|NCT01932138|OTHER|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
219122127|NCT01932138|OTHER|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
219122128|NCT00131560|GENETIC|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
219122129|NCT04664335|OTHER|questionnaire|if no Reply to questionnaire, telephone interview
219122130|NCT01823120|OTHER|Supportive and interactive text messages|
219122131|NCT02500927|DRUG|ASP8273 Capsules|oral
219122132|NCT02500927|DRUG|ASP8273 Capsules A|oral
219122133|NCT00795418|BIOLOGICAL|Placebo|Placebo comparator
219122134|NCT00795418|BIOLOGICAL|CAD106|
219225701|NCT05983939|DRUG|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
219706562|NCT04367896|OTHER|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
219706563|NCT02767531|DRUG|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
219706564|NCT04429958|OTHER|GDM|different degrees of hyperglycaemia during pregnancy
219706565|NCT04865809|OTHER|Peribioma Toothpaste and Mousse|Use of Peribioma Toothpaste and Mousse for home oral care.
219706566|NCT04865809|OTHER|Standard toothpaste|Use of Biorepair Plus Parodontgel for home oral care
219122135|NCT01663675|GENETIC|karyotype|
219122136|NCT04672746|BEHAVIORAL|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
219122137|NCT04672746|BEHAVIORAL|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
219225702|NCT01087346|BEHAVIORAL|Reading Information|Reading information about risk factors for obesity among children
219225703|NCT06563505|DRUG|Mosunetuzumab|Given by IV
219225704|NCT06563505|DRUG|Zanubrutinib|Given by IV
219706567|NCT04264741|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
219122138|NCT06201013|BEHAVIORAL|urotherapy|Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.
219122139|NCT06201013|DRUG|Solifenacin Succinate|In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day
219122140|NCT06201013|DRUG|Vitamin D3|In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
219122141|NCT05079880|DRUG|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
219122142|NCT05079880|DRUG|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
219122143|NCT02400307|DRUG|Bictegravir|75 mg tablet administered orally
219122144|NCT00925028|DRUG|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
219122145|NCT00925028|DRUG|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
219122146|NCT03248440|DRUG|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
219122147|NCT03248440|DRUG|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
219122148|NCT04737174|DRUG|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
219122149|NCT01052662|DRUG|Memantine|30mg/day Memantine orally everyday for 12 weeks
219122150|NCT01052662|DRUG|Memantine|15 mg/day Memantine orally everyday for 12 weeks
219122151|NCT01052662|DRUG|Placebo|Placebo orally everyday for 12 weeks
219122152|NCT04558099|BEHAVIORAL|MBSR|Described previously
219122153|NCT00816140|DRUG|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
219122154|NCT00816140|DRUG|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
219122155|NCT01148043|DRUG|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
219122156|NCT01148043|DRUG|cellulose|capsule, 2 capsules QD for 24 weeks
219122157|NCT02818608|DEVICE|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
219225705|NCT06569836|OTHER|12-week intervention|"Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)"
219122158|NCT02818608|DEVICE|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
219122159|NCT00401817|DRUG|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
219122160|NCT00401817|DRUG|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
219551013|NCT02594527|OTHER|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
219551014|NCT04139941|DIAGNOSTIC_TEST|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
219551015|NCT03293719|DEVICE|BPK-S Integration UC|Primary Knee Endoprosthesis
219551016|NCT06678386|BEHAVIORAL|50% sugar reduction|Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
219551017|NCT05065619|BIOLOGICAL|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
219551018|NCT05065619|DRUG|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
219551019|NCT05065619|BIOLOGICAL|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
219551020|NCT03831490|DIAGNOSTIC_TEST|history|combining these 4 interventions will great an algorithm predicting preeclampsia
219122161|NCT00401817|DRUG|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
219122162|NCT02015663|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
219122163|NCT01113463|DRUG|TPI 287|Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
219122164|NCT03285451|DIAGNOSTIC_TEST|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
219122165|NCT01150851|OTHER|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
219122166|NCT01150851|OTHER|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
219122167|NCT00533247|DRUG|Celecoxib|
219122168|NCT01054911|DRUG|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
219122169|NCT01054911|PROCEDURE|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
219706568|NCT04264741|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
219706569|NCT04877964|DEVICE|Ultrasound|Using ultrasound with transverse median and paramedian sagittal oblique approach, the screens that show the target epidural space in the center are obtained and stored for evaluation.
219706570|NCT03579667|BEHAVIORAL|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
219122170|NCT04232748|DRUG|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
219122171|NCT04531683|OTHER|electroacupuncture|same as described in experimental arm.
219122172|NCT04531683|OTHER|sham electroacupuncture|same as described in sham comparator.
219122173|NCT04531683|BEHAVIORAL|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
219122174|NCT00436787|DRUG|Fondaparinux Sodium|
219122175|NCT00060021|PROCEDURE|acupuncture therapy|
219122176|NCT00060021|PROCEDURE|management of therapy complications|
219122177|NCT00060021|PROCEDURE|pain therapy|
219122178|NCT05562843|BIOLOGICAL|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
219122179|NCT00146640|DRUG|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams \[mg\] prednisone per day) at bed time.
219122180|NCT00146640|DRUG|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
219122181|NCT00146640|DRUG|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
219122182|NCT00146640|DRUG|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
219122183|NCT02319447|BEHAVIORAL|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
219122184|NCT01356238|OTHER|MRC media|Culture media
219122185|NCT01356238|OTHER|Sydney IVF media|Culture media
219122186|NCT00280449|BEHAVIORAL|strengths-based case managed proactive service model|
219122187|NCT03293485|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
219122188|NCT01451060|DRUG|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
219122189|NCT01451060|DRUG|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
219122190|NCT03180411|BEHAVIORAL|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
219122191|NCT03180411|BEHAVIORAL|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
219122192|NCT01798082|OTHER|Pelvic organ prolapse decision aid|
219122193|NCT03023332|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
219122194|NCT03023332|BEHAVIORAL|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
219122195|NCT03023332|BEHAVIORAL|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
219122196|NCT02567474|BEHAVIORAL|5 A model|self management program based on 5A model
219122197|NCT05281393|BEHAVIORAL|PrEPresent|PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
219122198|NCT01852955|DRUG|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
219122199|NCT01852955|DRUG|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
219122200|NCT03295006|DEVICE|TheraSphere|Patients who had received TheraSphere
219122201|NCT01729897|DRUG|Etomidate|
219122202|NCT01729897|DRUG|Fentanyl|
219122203|NCT01729897|DRUG|Propofol|
219122204|NCT02408549|DRUG|Lacosamide Tablet|"* Active substance: Lacosamide~* Pharmaceutical form: Tablet~* Concentration: 50 mg and 100 mg~* Route of Administration: Oral administration"
219122205|NCT02408549|DRUG|Lacosamide Oral Solution|"* Active substance: Lacosamide~* Pharmaceutical form: Oral solution~* Concentration: 10 mg/ml~* Route of Administration: Oral administration"
219122206|NCT04994574|DRUG|tiotropium/olodaterol|From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.
219122207|NCT00526305|DRUG|Vincristine|1,5 mg/m2 i.v., days 1 and 8
219122208|NCT00526305|DRUG|Daunorubicin|60 mg/m2, i.v., days 1 and 8
219122209|NCT00526305|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
219122210|NCT00526305|DRUG|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
219122211|NCT00526305|DRUG|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
219122212|NCT00526305|DRUG|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
219122213|NCT00526305|DRUG|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
219122214|NCT00526305|DRUG|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
219122215|NCT00526305|DRUG|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
219122216|NCT00526305|DRUG|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
219122217|NCT05706662|PROCEDURE|inguinal hernia repair with mesh|inguinal hernia repair with mesh
219122218|NCT05415059|DEVICE|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
219706571|NCT04632121|DRUG|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
219706572|NCT04561791|DEVICE|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
219706573|NCT02232347|DRUG|Ketamine|
219706574|NCT02232347|DRUG|Sufentanil|
219122219|NCT04179994|OTHER|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
219122220|NCT04179994|OTHER|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
219122221|NCT04179994|OTHER|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
219122222|NCT03230487|DRUG|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
219122223|NCT03230487|DRUG|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
219122224|NCT02485795|OTHER|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
219122225|NCT05549024|DRUG|68Ga-RM26-RGD|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
219122226|NCT05549024|DRUG|18F-FDG|18F-FDG injection
219122227|NCT05549024|DRUG|68Ga-RM26|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
219122228|NCT05549024|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
219122229|NCT03232190|OTHER|Web Application|Parents receive a web application that offers information and support until the age of 2.
219122230|NCT04317170|OTHER|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
219122231|NCT00812630|DRUG|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
219122232|NCT03110679|BIOLOGICAL|injection of autologous bone marrow concentrate|
219122233|NCT03110679|BIOLOGICAL|injection of hyaluronic acid.|
219122234|NCT01513356|DRUG|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
219122235|NCT04730180|DEVICE|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
219122236|NCT04730180|DEVICE|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
219122237|NCT00410384|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
219122238|NCT00410384|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
219122239|NCT00410384|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
219122240|NCT00429702|DRUG|Decadron®|Given IV
219706575|NCT03315260|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
219706576|NCT03416179|DRUG|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
219122241|NCT00429702|DRUG|Benadryl®|Given IV
219122242|NCT00429702|DRUG|Ativan®|Given IV
219122243|NCT00429702|DRUG|ondansetron hydrochloride|Given IV
219122244|NCT03496961|BEHAVIORAL|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
219122245|NCT01111890|DRUG|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
219122246|NCT01111890|DRUG|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
219122247|NCT05168969|OTHER|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
219122248|NCT01253200|DEVICE|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
219706577|NCT03416179|DRUG|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
219122249|NCT01253200|DEVICE|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
219122250|NCT04502927|PROCEDURE|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
219122251|NCT06221774|DRUG|TT-00420 + Toripalimab|TT-00420 tablets in combination with Toripalimab injection
219122252|NCT00740519|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
219122253|NCT06492538|PROCEDURE|various types of angle interventions|procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor. Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
219122254|NCT05987150|RADIATION|Variation in anisotropy of the Spinal Cord using diffusion tensor imaging|All examinations were performed on a 3.0-T MRI machine with a 12-channel spine special coil (Ingenia CX, Philips Healthcare, Best, the Netherlands). The multi-sequence MRI protocol included conventional T1-weighted (sag \& tra), T2-weighted (sag \& tra), and DTI sequence.
219122255|NCT01649726|PROCEDURE|Apnea test - control|
219122256|NCT01649726|PROCEDURE|Apnea test - CPAP|
219122257|NCT02235610|PROCEDURE|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
219122258|NCT01096095|DRUG|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
219122259|NCT01096095|DRUG|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
219122260|NCT04970238|DRUG|Levosimendan|Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.
219122261|NCT04970238|OTHER|placebo|Control drug: 5% glucose injection, intravenous injection method is the same as the experimental group pump dose, the initial load dose of treatment is 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg / kg / min for 24 hours.
219122262|NCT01505075|RADIATION|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
219122263|NCT03459495|DEVICE|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
219122264|NCT03459495|DEVICE|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
219122265|NCT04700319|DRUG|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
219122266|NCT04338529|DRUG|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
219706578|NCT03416179|DRUG|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
219706579|NCT03416179|DRUG|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
219706580|NCT03416179|DRUG|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
219706581|NCT03416179|DRUG|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
219706582|NCT03416179|DRUG|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
219122267|NCT05569005|OTHER|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
219122268|NCT05569005|OTHER|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
219122269|NCT05569005|OTHER|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
219122270|NCT02065011|DRUG|Blood draw for the laboratory assessment|
219122271|NCT06494072|DRUG|Ampicillin for Injection|Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
219122272|NCT06494072|DRUG|Ceftriaxone for Injection|Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
219122273|NCT06494072|DRUG|Amoxicillin|Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
219122274|NCT06494072|DRUG|Ampicillin / Sulbactam Injection|Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
219122275|NCT06494072|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
219122276|NCT06494072|DRUG|Clindamycin|Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
219706583|NCT03416179|PROCEDURE|HSCT|If required, and done per standard of care post Induction(s).
219122277|NCT06494072|DRUG|Cefprozil|Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
219122278|NCT06494072|DRUG|Levofloxacin|Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
219122279|NCT05913778|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
219122280|NCT04883346|DRUG|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
219122281|NCT04712565|DEVICE|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
219122282|NCT04712565|DEVICE|Astra Tech Implant System EV|dental implant with a conventional neck configuration
219706584|NCT00042211|BEHAVIORAL|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
219706585|NCT00042211|BEHAVIORAL|Control|No treatment control
219706586|NCT05445089|DRUG|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
219122283|NCT04002479|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219122284|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
219122285|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
219122286|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
219122287|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
219122288|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
219122289|NCT04599478|DRUG|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
219706587|NCT05445089|OTHER|Control group|Placebo
219706588|NCT02481700|PROCEDURE|Third molar removal|The surgical removal of third molars
219706589|NCT02295319|OTHER|Individual discharge|"See previous description in Arms"
219706590|NCT06330415|OTHER|The SME tool|The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
219706591|NCT01348243|DRUG|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
219122290|NCT04599478|BEHAVIORAL|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
219122291|NCT04599478|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
219122292|NCT00204035|BEHAVIORAL|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
219122293|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
219122294|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
219122295|NCT02498379|DRUG|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
219706592|NCT01348243|DRUG|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
219706593|NCT04640116|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
219706594|NCT04640116|PROCEDURE|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
219706595|NCT00475332|DRUG|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm\^3) total body radiation dose can be calculated."
219706596|NCT00475332|PROCEDURE|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
219706597|NCT03134768|OTHER|This is not an interventional study|This is an observational study
219706598|NCT00058032|OTHER|screening questionnaire administration|
219706599|NCT00058032|PROCEDURE|annual screening|
219706600|NCT01682031|DIETARY_SUPPLEMENT|selenomethionine|Given PO
219122296|NCT00461214|OTHER|Participation in laparoscopic training curriculum|General Surgery Training Outcome
219122297|NCT04293809|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
219122298|NCT04293809|DRUG|Bupivacaine Hydrochloride|1.3%, 13.3 mg/mL
219122299|NCT00159510|DRUG|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
219122300|NCT00159510|DRUG|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
219122301|NCT00159510|DRUG|Methylene blue & nitric oxide|See the dosage in the previous arms
219706601|NCT01682031|OTHER|placebo|Given PO
219122302|NCT02303743|DEVICE|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
219122303|NCT02303743|DEVICE|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
219122304|NCT02899598|BIOLOGICAL|Extra blood draw samples|NEVER STARTED
219122305|NCT02899598|BIOLOGICAL|extra amniotic fluid samples|NEVER STARTED
219122306|NCT00884819|DRUG|Fenofibrate|fenofibrate 200 mg daily for 6-months
219122307|NCT00884819|OTHER|Placebo|Placebo match for 6 months
219122308|NCT00235495|BIOLOGICAL|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
219122309|NCT00235495|DRUG|Saline|equivalent volume of isotonic saline control
219122310|NCT02234310|BIOLOGICAL|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
219122311|NCT01739387|DEVICE|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
219122312|NCT02242461|DRUG|Rhodiola placebo capsules|Corn starch
219122313|NCT02242461|DRUG|Rhodiola Crenulata|Rhodiola Crenulata
219122314|NCT05211830|DRUG|SXR1096 cream|Skin cream to be applied twice a day to a predefined area of the skin
219706602|NCT01682031|DRUG|cisplatin|Given IV
219706603|NCT01682031|RADIATION|radiation therapy|Undergo radiotherapy
219706604|NCT01682031|PROCEDURE|quality-of-life assessment|Ancillary studies
219706605|NCT01286350|BEHAVIORAL|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
219706606|NCT00325637|DRUG|cilnidipine|Cilnidipine 10\~20mg, qd, po for 4 weeks.
219706607|NCT04841291|BEHAVIORAL|Diabetes Foot Care Education (DFCE)|Virtual simulation-based DFCE sessions on seven topics (the reasons for inspecting one's feet, risk factors and prevention strategies of diabetic foot ulcer, how to wash and moisturize feet, comfortable sock and shoe choices, what to look for, and what to do during feet inspection, how to trim fingernails, and how to maintain foot health) at University of Gondar computer lab for 30 minutes.
219706608|NCT01809067|OTHER|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
219706609|NCT00025467|DRUG|thalidomide|Given orally
219706610|NCT00025467|OTHER|laboratory biomarker analysis|Correlative studies
219122315|NCT05211830|DRUG|Placebo cream|Skin cream to be applied twice a day to a predefined area of the skin
219122316|NCT01226264|PROCEDURE|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
219122317|NCT05350995|OTHER|No intervention|No intervention
219122318|NCT01577732|BIOLOGICAL|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
219122319|NCT01164787|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
219122320|NCT01164787|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
219706611|NCT00435058|DRUG|timolol maleate 0,5%|
219706612|NCT00435058|DRUG|brimonidine tartrate 0,2%|
219122321|NCT03289455|BIOLOGICAL|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
219122322|NCT01305824|DRUG|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
219122323|NCT01305824|DRUG|Placebo|Placebo administered at the time of AVF creation.
219122324|NCT01305824|DRUG|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
219706613|NCT00435058|DRUG|travoprost 0,004%|
219706614|NCT01369550|OTHER|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
219706615|NCT01369550|OTHER|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
219706616|NCT01369550|OTHER|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
219706617|NCT01101100|DRUG|AMG 827|210 mg SC or 140 mg SC
219706618|NCT01481467|BEHAVIORAL|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
219706619|NCT03080285|DEVICE|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
219706620|NCT03080285|DEVICE|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
219122325|NCT05445687|BEHAVIORAL|Narrative language intervention program|"Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program"
219122326|NCT05445687|BEHAVIORAL|Conventional language intervention|Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
219122327|NCT00330213|BEHAVIORAL|red wine and cognac consumption|
219122328|NCT06492941|DRUG|Docetaxel for Injection (Albumin bound)|Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
219122329|NCT06492941|DRUG|Placebo|Placebo was human blood albumin without the active ingredient docetaxel
219122330|NCT06492941|DRUG|Best supportive care|Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
219122331|NCT05623969|DIAGNOSTIC_TEST|Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)
219122332|NCT04298684|DRUG|METFORMIN|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
219122333|NCT04298684|DRUG|Sitagliptin|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
219122334|NCT04216160|OTHER|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
219122335|NCT04216160|OTHER|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
219122336|NCT04751864|DEVICE|Cranial Electrotherapy Stimulator (CES) Device|Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
219122337|NCT06433466|OTHER|Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities|Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
219122338|NCT03888365|DRUG|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
219122339|NCT03888365|DRUG|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
219122340|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
219122341|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup|Source of polyphenols
219122342|NCT03577145|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
219122343|NCT02219594|DEVICE|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
219122344|NCT06498674|DIAGNOSTIC_TEST|Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, supplementary fine needle aspiration biopsy or intraoperative biopsy will be performed to clarify the nature of the nodule.
219122345|NCT06498674|OTHER|No Need for Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, there is no need for supplementary fine needle aspiration biopsy or intraoperative biopsy.
219122346|NCT02192359|BIOLOGICAL|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
219122347|NCT02192359|DRUG|Irinotecan|Given IV
219122348|NCT02192359|DRUG|Irinotecan Hydrochloride|Given IV
219122349|NCT02192359|OTHER|Laboratory Biomarker Analysis|Correlative studies
219122350|NCT02192359|OTHER|Pharmacological Study|Correlative studies
219122351|NCT00315224|BEHAVIORAL|heart-rate controlled 12 week exercise program|
219122352|NCT03157011|OTHER|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
219122353|NCT04912141|DRUG|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
219122354|NCT01049061|DRUG|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
219706621|NCT01911247|DRUG|Metformin|Metformin 850 mg once daily
219122355|NCT03877263|DIAGNOSTIC_TEST|Endocervical swab for detection of STI|After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
219122356|NCT03877263|DIAGNOSTIC_TEST|Vaginal swab for detection of STI|"After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups"
219706622|NCT01056536|BEHAVIORAL|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
219122357|NCT06487767|OTHER|Surgery|Surgery for operable cervical cancer
219706623|NCT01056536|DEVICE|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
219122358|NCT03781713|OTHER|KDIGO|Interventions to prevent renal replacement therapy
219122359|NCT03781713|OTHER|Delta SOFA|interventions to improve SOFA score
219122360|NCT03781713|COMBINATION_PRODUCT|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
219122361|NCT03781713|DRUG|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
219122362|NCT03781713|DRUG|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
219122363|NCT05299879|DIAGNOSTIC_TEST|Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization|Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
219122364|NCT03735810|DRUG|LBS-008|LBS-008 oral capsules
219706624|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
219706625|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
219706626|NCT01582204|DRUG|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
219706627|NCT05881811|DRUG|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
219122365|NCT03735810|DRUG|Placebos|Oral capsules
219122366|NCT03325621|BIOLOGICAL|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
219122367|NCT03325621|BIOLOGICAL|PRS-080-Placebo#001|Placebo Comparator
219122368|NCT05567952|DRUG|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
219122369|NCT05567952|DRUG|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
219122370|NCT05567952|DRUG|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
219122371|NCT03299374|OTHER|Pilates Intervention|Intervention based on Pilates principles
219122372|NCT03299374|OTHER|Fall prevention intervention|Intervention based on principles to prevent falls
219122373|NCT01907399|OTHER|Blood samples|
219122374|NCT00777803|DRUG|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
219122375|NCT00777803|DRUG|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
219122376|NCT01759992|DEVICE|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
219122377|NCT04680910|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.
219122378|NCT04680910|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
219122379|NCT04680910|DIAGNOSTIC_TEST|Slow-Wave Activity|Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
219122380|NCT04707794|DRUG|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
219122381|NCT04707794|DRUG|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
219706628|NCT02729233|OTHER|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
219706629|NCT05456672|OTHER|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
219706630|NCT06307548|DRUG|Aminolevulinic Acid|Given PO
219706631|NCT06307548|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219122382|NCT05139160|DIETARY_SUPPLEMENT|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
219122383|NCT06158347|DEVICE|hyperbaric oxygen chamber|Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
219122384|NCT03549806|DIAGNOSTIC_TEST|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
219122385|NCT03282019|DEVICE|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
219122386|NCT03282019|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
219122387|NCT06542705|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
219122388|NCT06542705|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace. ACLR technique will be standardized to standard anteromedial (AM) portal femoral drilling to ensure consistency between surgeons.
219122389|NCT05468567|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
219122390|NCT05468567|DIAGNOSTIC_TEST|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
219122391|NCT05468567|BEHAVIORAL|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
219706632|NCT06307548|PROCEDURE|Computed Tomography|Undergo CT
219122392|NCT06042127|PROCEDURE|POEM-F|POEM-F would be performed as described in the arms section
219122393|NCT06042127|PROCEDURE|Conventional POEM|Anterior POEM performed as described in the arms section
219122394|NCT04230694|DEVICE|Dexcom Generation 6 CGM (Dexcom Gen6) device|Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
219706633|NCT06307548|PROCEDURE|Fluorescence-Guided Surgery|Undergo fluorescence-guided surgery
219706634|NCT06307548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219706635|NCT06307548|DRUG|Photodynamic Therapy|Undergo PDT
219706636|NCT06307548|PROCEDURE|Surgical Procedure|Undergo surgery
219706637|NCT05115929|PROCEDURE|Decompressive Laparotomy|As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
219706638|NCT05115929|PROCEDURE|Decompressive Craniectomy|As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
219122395|NCT02697799|BEHAVIORAL|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
219122396|NCT02697799|BEHAVIORAL|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
219122397|NCT05931198|OTHER|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
219122398|NCT05931198|OTHER|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
219122399|NCT04569708|OTHER|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
219122400|NCT05610410|OTHER|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
219122401|NCT02193633|DRUG|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
219122402|NCT02193633|DRUG|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
219122403|NCT03337503|DRUG|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
219122404|NCT03337503|DRUG|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
219122405|NCT03337503|DRUG|High CBD with trace THC oil|capsule containing cannabis oil
219706639|NCT05840445|DRUG|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
219122406|NCT03337503|OTHER|placebo|carrier oil capsule
219122407|NCT01005771|DRUG|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
219122408|NCT01005771|DRUG|Placebo|Matching placebo
219122409|NCT03672760|DEVICE|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
219122410|NCT03672760|DEVICE|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
219122411|NCT03672760|DEVICE|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
219122412|NCT04494321|DRUG|Budesonide|Inhaled corticosteroid
219122413|NCT04494321|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
219122414|NCT03685188|DRUG|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
219122415|NCT03685188|DRUG|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
219122416|NCT03425136|OTHER|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
219122417|NCT03869034|COMBINATION_PRODUCT|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
219122418|NCT03869034|DRUG|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
219122419|NCT00421421|DRUG|Dutasteride|
219122420|NCT05202236|DRUG|pemigatinib|The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
219122421|NCT01672983|DRUG|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
219122422|NCT03768661|PROCEDURE|Single-incision Laparoscopic cholecystectomy|laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
219122423|NCT03768661|PROCEDURE|Laparoscopic Cholecystectomy|laparoscopic cholecystectomy performed using three-trocars standard technique
219706640|NCT05840445|DRUG|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
219706641|NCT00911911|PROCEDURE|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
219706642|NCT00911911|PROCEDURE|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
219706643|NCT00911911|PROCEDURE|SURGERY|Surgery after neoadjuvant chemotherapy
219706644|NCT01830517|DRUG|Amlodipine, Losartan|
219706645|NCT03747471|BEHAVIORAL|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
219122424|NCT05247879|DIETARY_SUPPLEMENT|Glucose containing Oral Rehydration Solution (ORS)|Oral rehydration solution
219706646|NCT02474641|RADIATION|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
219706647|NCT02474641|RADIATION|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
219122425|NCT05247879|DIETARY_SUPPLEMENT|Sugar free - amino acid and electrolyte ORS|Glucose free oral rehydration solution
219122426|NCT06532552|DRUG|VACl|Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.
219122427|NCT06532552|DRUG|VACh|Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
219122428|NCT06532552|DRUG|VACl Alternating With VACh|"VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days"
219122429|NCT06532552|DRUG|VA|Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
219122430|NCT03410485|DEVICE|BIS index/NoL index|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55."
219122431|NCT03410485|DEVICE|Variation of baseline mean arterial pressure|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC."
219122432|NCT05829941|BEHAVIORAL|Smartwatch app to deliver binge-eating CBT strategies|Participants will receive a smartwatch with a pre-loaded app that will alert the participant to relevant binge-eating strategies based on their previous detected behavior.
219122433|NCT05829941|BEHAVIORAL|Reminder control condition|Participants will receive a smartwatch that vibrates randomly, and will be instructed the vibration is a cue not to binge eat.
219122434|NCT00611637|BIOLOGICAL|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
219122435|NCT00432159|DEVICE|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
219122436|NCT00432159|DEVICE|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
219122437|NCT00002374|DRUG|Ritonavir|
219122438|NCT00002374|DRUG|Nelfinavir mesylate|
219122439|NCT00002374|DRUG|Saquinavir|
219706648|NCT05406089|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
219706649|NCT01865019|DEVICE|mechanical ventilation|
219706650|NCT00581191|DRUG|SLV-351|SLV-351 capsules taken once
219225706|NCT06569836|OTHER|12-week attention control|The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
219225707|NCT05453435|DRUG|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
219706651|NCT03805841|DRUG|tarloxotinib bromide|weekly intravenous infusion
219122440|NCT00002374|DRUG|Stavudine|
219122441|NCT02522052|OTHER|Blue mussel diet|5 meals a week containing blue mussels
219122442|NCT02522052|OTHER|Meat/Control diet|5 meals a week containing meat
219122443|NCT03516149|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
219122444|NCT06242496|OTHER|Retrospective follow-up|Data collection
219122445|NCT05160025|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
219122446|NCT03610217|OTHER|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
219122447|NCT03610217|OTHER|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
219706652|NCT03765606|DIETARY_SUPPLEMENT|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
219706653|NCT03765606|DIETARY_SUPPLEMENT|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
219706654|NCT01470716|DRUG|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
219122448|NCT03610217|OTHER|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
219122449|NCT03610217|OTHER|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
219122450|NCT03610217|OTHER|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
219122451|NCT03610217|OTHER|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
219122452|NCT03610217|OTHER|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
219122453|NCT03610217|OTHER|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
219122454|NCT03610217|OTHER|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score \>32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
219122455|NCT03610217|OTHER|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
219122456|NCT03437434|OTHER|Visual Acuity|Ocular Examination
219122457|NCT05516342|BEHAVIORAL|LEAD IT! Programming|LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
219122458|NCT04643743|DEVICE|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
219122459|NCT03952065|DRUG|PD1/PDL1/CTLA4 inhibitors|Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
219122460|NCT01852162|DRUG|Dabigatran|Dabigatran 150mg
219122461|NCT01852162|DRUG|Placebo|Matching placebo tablets
219122462|NCT03224338|DRUG|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B\*5701 allele screening assessment.
219122463|NCT03679702|DEVICE|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
219122464|NCT00347659|DRUG|BLVR System|Treatment is administered in a single treatment session.
219122465|NCT04176614|OTHER|cereal-legume snack|cereal-legume biscuit
219122466|NCT04176614|OTHER|cereal snack|cereal biscuit
219122467|NCT06055777|DRUG|SZEY-2108 for injetion|Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
219122468|NCT06055777|DRUG|Placebo|Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
219122469|NCT02153385|OTHER|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
219706655|NCT02164916|BIOLOGICAL|cetuximab|Given IV
219122470|NCT00002563|PROCEDURE|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
219122471|NCT00002563|PROCEDURE|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
219706656|NCT02164916|DRUG|irinotecan hydrochloride|Given IV
219706657|NCT02164916|DRUG|vemurafenib|Given PO
219706658|NCT04366674|PROCEDURE|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
219122472|NCT03904719|DRUG|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
219122473|NCT01866475|DEVICE|EZ-IO|To have an EZ-IO placed up to 48 hours
219122474|NCT02991885|BIOLOGICAL|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
219122475|NCT02991885|DRUG|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
219122476|NCT04727775|DRUG|Favipiravir|Antiviral drugs
219122477|NCT04727775|DRUG|Remdesivir|Antiviral drugs
219122478|NCT03871933|OTHER|Measurement of lung function, electrocardiography, echocardiography and autonomic function|Measurement of lung function, electrocardiography, echocardiography and autonomic function
219122479|NCT04333836|DEVICE|Removable Clear Aligners|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction."
219122480|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
219122481|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
219122482|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
219122483|NCT02466126|BEHAVIORAL|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
219122484|NCT00244361|DRUG|rituximab|
219122485|NCT03081208|DRUG|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
219122486|NCT03081208|DRUG|Placebo|Placebo dispersible tablets for single oral administration
219122487|NCT03329833|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
219706659|NCT03229499|DRUG|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
219122488|NCT03329833|BEHAVIORAL|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
219122489|NCT04019522|OTHER|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
219122490|NCT04577820|DRUG|garetosmab|Repeated doses administered intravenously (IV) every four weeks (Q4W)
219122491|NCT00839202|OTHER|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
219122492|NCT04729543|BIOLOGICAL|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
219122493|NCT05192512|DRUG|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
219122494|NCT00864565|DRUG|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
219122495|NCT00864565|DRUG|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
219122496|NCT04921995|DRUG|Tislelizumab|"1. Chemotherapy (including but not limited to following):~   GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~   Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~2. anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities."
219122497|NCT05406986|OTHER|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
219122498|NCT03645603|DRUG|Dexmedetomidine|intravenous infusion
219122499|NCT03645603|DRUG|Placebo|intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
219122500|NCT04129762|OTHER|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
219225708|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
219706660|NCT03229499|DRUG|Placebo Oral Tablet|matching placebo tablet
219122501|NCT04129762|OTHER|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
219122502|NCT03097211|DRUG|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
219122503|NCT03097211|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
219122504|NCT03097211|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
219122505|NCT03097211|DRUG|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
219122506|NCT05475223|DIAGNOSTIC_TEST|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
219122507|NCT01501916|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
219122508|NCT01501916|DIETARY_SUPPLEMENT|Placebo|daily intake of placebo
219122509|NCT02347449|OTHER|Questionnaires, Oncotype Dx Assay|"1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire"
219122510|NCT01021878|OTHER|icodextrin|glucose sparing dialysis solution
219122511|NCT01021878|OTHER|Dianeal|glucose based dialysis solution
219122512|NCT03251144|DRUG|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
219122513|NCT02213679|DIETARY_SUPPLEMENT|Guanidinoacetic acid|Dietary supplement
219122514|NCT02213679|OTHER|Placebo|Placebo
219122515|NCT02651103|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
219706661|NCT04501900|DRUG|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
219706662|NCT06522113|DRUG|Cilostazol|patients were given cilostazol 100mg twice a day with aspirin
219706663|NCT06522113|DRUG|Clopidogrel|patients were given clopidogrel 75mg with aspirin
219122516|NCT05175443|OTHER|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
219122517|NCT05737563|DRUG|PD-1 Inhibitors|Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.
219122518|NCT05737563|DRUG|Irinotecan|Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1\*6 or UGT1A1\*28 or UGT1A1\*6 and UGT1A1\*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).
219122519|NCT05737563|DRUG|Capecitabine tablets|Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
219122520|NCT01049750|OTHER|type 2 diabetic patients|males; type 2 diabetic patients
219122521|NCT05305040|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
219122522|NCT05305040|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
219122523|NCT01532050|DEVICE|Mandibular Advancement Device ( MAD)|
219122524|NCT00184561|DRUG|biphasic insulin aspart|
219122525|NCT03700255|PROCEDURE|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
219122526|NCT04442672|PROCEDURE|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
219225709|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
219225710|NCT06634927|DRUG|Ozempic®|Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
219225711|NCT06634927|DRUG|HDG1901|Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
219225712|NCT05616039|PROCEDURE|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
219122527|NCT04442672|PROCEDURE|sham|surrounding the cuff but not inflate it.
219122528|NCT03356743|DEVICE|Spectrum Analysis|The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
219225713|NCT05616039|DIAGNOSTIC_TEST|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
219706664|NCT00483665|PROCEDURE|Computed tomography angiography|Computed tomography angiography
219706665|NCT00483665|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
219706666|NCT00596635|DIETARY_SUPPLEMENT|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
219706667|NCT00596635|DIETARY_SUPPLEMENT|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
219706668|NCT04903301|PROCEDURE|Contoura Vision LASIK|Topography-Guided LASIK using Phorcides Analytic Software
219706669|NCT02630030|DRUG|Ixazomib|Given PO
219706670|NCT01010763|DEVICE|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
219706671|NCT05218694|DIAGNOSTIC_TEST|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
219706672|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule and Oral Supplement of Yuyikang|
219706673|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
219706674|NCT02771756|RADIATION|chemotherapy|
219706675|NCT02771756|OTHER|nutrition education|
219706676|NCT04184141|DRUG|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
219706677|NCT04184141|DRUG|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
219706678|NCT04184141|DRUG|Placebo|Placebo candy
219706679|NCT06125665|DRUG|Aminophylline-Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
219706680|NCT06125665|DRUG|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
219706681|NCT03852511|BIOLOGICAL|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
219225714|NCT06073587|DIAGNOSTIC_TEST|Scintigraphy scan|Scans will be performed as specified in the arm description.
219225715|NCT05739136|DRUG|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
219706682|NCT00236717|DRUG|Topiramate; Carbamazepine; Valproate|
219706683|NCT01101178|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
219706684|NCT01101178|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
219706685|NCT00221780|DEVICE|left ventricular pacing|
219122529|NCT00868205|DIETARY_SUPPLEMENT|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
219122530|NCT02008058|BEHAVIORAL|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
219122531|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
219122532|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
219225716|NCT05779631|DIAGNOSTIC_TEST|mpMRI plus a same-day cystoscopic bladder biopsy|mpMRI plus a same-day cystoscopic bladder biopsy
219225717|NCT05779631|PROCEDURE|TURBT|Transurethral resection of the bladder tumor
219225718|NCT03774849|DEVICE|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
219225719|NCT03774849|DEVICE|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
219225720|NCT03774849|DEVICE|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
219706686|NCT04700865|DIAGNOSTIC_TEST|AF screening|Continous ECG monitoring for minimum 3 days
219706687|NCT04237363|BEHAVIORAL|Exercise|Underwater treadmill training and supplemental overground walk training
219706688|NCT01850641|DRUG|PA21|
219706689|NCT05968235|OTHER|Collecting blood samples|Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
219706690|NCT04131296|DIAGNOSTIC_TEST|influenza screening|positive influenza screening
219706691|NCT00141817|DRUG|pantoprazole for approximately 9 weeks.|
219706692|NCT05672719|DIAGNOSTIC_TEST|Right Heart Catheterization|Procedure
219706693|NCT01643213|DEVICE|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
219122533|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
219122534|NCT02488772|DEVICE|Sleep mask|
219122535|NCT02488772|OTHER|Standard of care|Standard of care as decided by treating emergency physician
219122536|NCT02488772|DEVICE|Ear Plugs|
219122537|NCT01421043|DRUG|triazolam liquid oral drops|0.25 mg single dose oral drops
219122538|NCT01421043|DRUG|triazolam tablets|0.25 mg single oral dose
219122539|NCT05661526|OTHER|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
219122540|NCT05661526|OTHER|Text-to-speech group|Blood transfusion training given by text-to-speech
219122541|NCT05372003|DRUG|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
219122542|NCT05372003|OTHER|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
219122543|NCT02123966|DRUG|Sirolimus|
219122544|NCT00593164|DEVICE|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
219122545|NCT00593164|DEVICE|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
219122546|NCT03152565|DRUG|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
219122547|NCT02920398|DRUG|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
219122548|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
219122549|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
219122550|NCT04721509|DEVICE|Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'|Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
219122551|NCT06305988|DEVICE|Transcranial direct current stimulation|The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
219122552|NCT01460381|DRUG|LY2216684|
219122553|NCT01460381|DRUG|Quinidine|
219122554|NCT06102343|DEVICE|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
219122555|NCT00378872|DRUG|IV Tranexamic acid 10mg/kg pt body weight|
219122556|NCT00378872|DRUG|Quixil topical sealant|
219122557|NCT06036030|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
219122558|NCT06036030|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
219122559|NCT06036030|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
219122560|NCT06036030|OTHER|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
219122561|NCT03738657|OTHER|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
219122562|NCT03738657|OTHER|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
219122563|NCT01824446|DRUG|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
219122564|NCT05976490|BEHAVIORAL|Information and Support Intervention|Information guide and four one-on-one coaching sessions
219122565|NCT05976490|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
219122566|NCT02944903|OTHER|Audit|Questionnair
219122567|NCT00262444|PROCEDURE|Different turning frequencies|
219122568|NCT02442414|DRUG|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
219122569|NCT05037656|BEHAVIORAL|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
219122570|NCT04430517|DRUG|Nicotinamide riboside|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
219122571|NCT05663892|DRUG|Biktarvy 50/200/25 Tab|As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
219122572|NCT05663892|DRUG|Estradiol Tablets|"Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking \> 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher."
219122573|NCT05992233|DEVICE|Dual wavelength low level laser|Application of double wavelength low level laser to the related area after tooth extraction.
219122574|NCT05992233|DEVICE|Placebo|Only red light applied.
219122575|NCT05144386|BIOLOGICAL|EBT-101|EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
219122576|NCT03844516|OTHER|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
219122577|NCT03844516|OTHER|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
219122578|NCT04359056|OTHER|Clinical pharmacy activities along the care pathways|"PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses.~Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs.~Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge~* Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary~* Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary~* Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected."
219122579|NCT04351750|OTHER|general exercise|The participants will receive training sessions twice a week for 8 weeks. General exercise includes aerobic exercise (stationary bike) and resistance training (thera-band, sandbags, dumbbell and swiss ball), and the intensity and progression of both aerobic and resistance exercises will be provided as recommended by the ACSM, and the exercise will individualized based on participant's HRR, 1 RM weight and Borg Scale of Perceived Exertion Scale (Borg RPE scale). An oximeter will be utilized to monitor the heart rate and SPO2 of the participants to ensure safety during the training session.
219122580|NCT04351750|OTHER|pelvic floor muscle training|Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
219122581|NCT03623412|DIAGNOSTIC_TEST|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
219122582|NCT03623412|DIAGNOSTIC_TEST|75g GTT|post-partum GTT
219122583|NCT01462201|DEVICE|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
219706694|NCT01643213|DEVICE|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
219122584|NCT05942404|PROCEDURE|mechanical bowel preparation|mechanical bowel preparation before surgery
219122585|NCT01333943|PROCEDURE|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
219122586|NCT01333943|PROCEDURE|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
219706695|NCT00522834|DRUG|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
219706696|NCT00522834|DRUG|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
219706697|NCT00127803|BIOLOGICAL|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
219706698|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
219706699|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
219706700|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
219706701|NCT06208501|DIAGNOSTIC_TEST|Urine sample for proteomic analysis|Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
219706702|NCT06208501|DIAGNOSTIC_TEST|ABPM|ABPM in screen visit and 3 months after renal denervation procedure.
219122587|NCT01414530|DRUG|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
219122588|NCT01414530|DRUG|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
219122589|NCT02751099|OTHER|transplanted patients|bone biopsy, echocardiogram, blood samples
219122590|NCT01353235|DRUG|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
219122591|NCT01353235|DRUG|usual care|no drug administered
219122592|NCT06103461|PROCEDURE|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
219122593|NCT04135144|OTHER|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
219122594|NCT04135144|OTHER|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
219122595|NCT01551589|RADIATION|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33\~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33\~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33\~35F，once a day, 5 times per week.
219122596|NCT01551589|DRUG|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
219122597|NCT01551589|RADIATION|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
219122598|NCT01062984|PROCEDURE|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVH; the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
219122599|NCT01062984|PROCEDURE|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
219122600|NCT03696979|OTHER|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
219122601|NCT03696979|OTHER|Therapeutic pain education|Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
219225721|NCT00895596|DRUG|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
219706703|NCT06208501|DIAGNOSTIC_TEST|OBPM|OBPM in screen visit and 3 months after renal denervation procedure.
219706704|NCT01950962|OTHER|Sampling of blood|
219706705|NCT01551667|BIOLOGICAL|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
219706706|NCT01551667|BIOLOGICAL|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
219706707|NCT03077217|DRUG|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
219706708|NCT00944554|DRUG|Varenicline|Varenicline given twice a day or five weeks.
219706709|NCT00944554|DRUG|Placebo|Placebo given twice a day or five weeks.
219225722|NCT06014671|BEHAVIORAL|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
219706710|NCT02251847|DRUG|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
219706711|NCT02525523|DRUG|Alicaforsen|
219706712|NCT02525523|DRUG|Placebo|
219706713|NCT00894192|DEVICE|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
219706714|NCT00894192|DEVICE|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
219122602|NCT03205020|DIAGNOSTIC_TEST|serum amyloid a test|"* Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
219122603|NCT04656002|DRUG|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
219122604|NCT00950053|PROCEDURE|Achilles decompression & debridement|Surgical intervention
219122605|NCT00950053|PROCEDURE|Achilles decompression and debridement with FHL transfer|surgical intervention
219122606|NCT04974502|PROCEDURE|Nonsurgical periodontal treatment|Oral hygiene instructions, scaling and root planning.
219122607|NCT00740662|PROCEDURE|Distal gastric bypass|Distal gastric bypass
219122608|NCT04547803|OTHER|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
219122609|NCT04547803|OTHER|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
219122610|NCT03654989|DRUG|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
219122611|NCT03654989|DEVICE|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~* Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
219122612|NCT02644538|DRUG|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA \<1000copies/ml, and HBsAg\<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
219122613|NCT01269398|DEVICE|GO-LIF and SpineAssist SYSTEMS|
219122614|NCT02274246|DRUG|gadobutrol|Gadobutrol administration in healthy volunteers
219706715|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
219122615|NCT03809884|BEHAVIORAL|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
219122616|NCT03809884|DRUG|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
219122617|NCT02718443|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
219122618|NCT00183573|BEHAVIORAL|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
219122619|NCT00183573|BEHAVIORAL|Brief Informational Intervention|15 minute informational DVD on safer sex
219122620|NCT00183573|BEHAVIORAL|Intensive Informational Intervention|4-hour, information-only intensive group workshop
219122621|NCT00183573|BEHAVIORAL|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
219122622|NCT02664220|DRUG|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
219122623|NCT02664220|PROCEDURE|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
219122624|NCT01841840|OTHER|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
219122625|NCT01841840|OTHER|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
219122626|NCT00310713|BIOLOGICAL|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
219122627|NCT00060827|DEVICE|Head Impact Recording Technology (HIRT)|
219122628|NCT01276535|DEVICE|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
219122629|NCT00305760|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
219122630|NCT00305760|BIOLOGICAL|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
219706716|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
219122631|NCT00305760|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
219122632|NCT01960205|DRUG|Saxagliptin|5mg a day for 6 months
219122633|NCT01960205|DRUG|saxagliptin|2.5 mg a day for 6 months
219122634|NCT01960205|DRUG|metformin|500mg three times a day for 6 months
219122635|NCT01960205|OTHER|lifestyle intervention|lifestyle intervention for 6 months
219706717|NCT00846365|DRUG|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
219122636|NCT03560141|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
219122637|NCT03560141|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
219122638|NCT02628522|OTHER|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
219122639|NCT02628522|DEVICE|Celution|Adipose derived regenerative cell isolation
219122640|NCT02628522|DEVICE|Tulip cannulas|Lipoaspiration
219706718|NCT05836623|DRUG|Radiolabelled CB307|CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)
219706719|NCT05836623|DRUG|CB307|Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
219706720|NCT04583501|BIOLOGICAL|Omalizumab|Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
219706721|NCT05079971|DIAGNOSTIC_TEST|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
219122641|NCT02628522|OTHER|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
219122642|NCT06014567|PROCEDURE|Magnetic Resonance Imaging|"1. A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~2. A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2\*, perfusion imaging and cine imaging to assess the heart dynamically."
219122643|NCT01591395|PROCEDURE|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
219122644|NCT03941782|DRUG|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
219122645|NCT05067959|BIOLOGICAL|Covid-19 vaccine|blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
219122646|NCT03990025|DIAGNOSTIC_TEST|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
219122647|NCT03990025|DIAGNOSTIC_TEST|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
219122648|NCT00145262|PROCEDURE|Autologous Bone Marrow Mononuclear Cell Implantation|
219122649|NCT05592652|OTHER|Survey|Survey including demographic, clinical and psychopathological questions
219122650|NCT03318120|BEHAVIORAL|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
219122651|NCT03035240|BEHAVIORAL|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
219122652|NCT03486743|BEHAVIORAL|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
219122653|NCT02527850|DEVICE|B-cure laser|
219706722|NCT04337788|OTHER|telehealth applications|telehealth applications during 30 days/patient
219706723|NCT01535885|BIOLOGICAL|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
219122654|NCT01445756|DRUG|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
219122655|NCT01445756|DRUG|Placebo|Placebo; no topical lidocaine administered
219122656|NCT01378897|DEVICE|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
219122657|NCT01237678|DRUG|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
219122658|NCT01237678|DRUG|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
219122659|NCT06413615|DRUG|FDA022-BB05|Monoclonal antibody-drug conjugate for injection
219122660|NCT03789903|DIAGNOSTIC_TEST|amniotic fluid lactate|AF lactate
219122661|NCT04889781|DRUG|Dexamethasone injection|Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery
219122662|NCT04889781|PROCEDURE|Piezosurgery|Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
219122663|NCT04889781|PROCEDURE|Conventional Rotatory instruments|Surgical extraction using conventional rotatory instruments to perform osteotomy
219122664|NCT00170235|OTHER|Prehabilitation|Exercise class pre-surgery
219122665|NCT00170235|OTHER|Usual care|Exercise booklet, physiotherapy if needed
219122666|NCT02447679|DRUG|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
219122667|NCT02447679|DRUG|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
219122668|NCT01818700|DRUG|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
219122669|NCT00003650|DRUG|asparaginase|
219122670|NCT00003650|DRUG|cyclophosphamide|
219122671|NCT00003650|DRUG|cytarabine|
219122672|NCT00003650|DRUG|daunorubicin hydrochloride|
219122673|NCT00003650|DRUG|dexamethasone|
219122674|NCT00003650|DRUG|etoposide|
219122675|NCT00003650|DRUG|mercaptopurine|
219122676|NCT00003650|DRUG|methotrexate|
219122677|NCT00003650|DRUG|methylprednisolone|
219122678|NCT00003650|DRUG|mitoxantrone hydrochloride|
219122679|NCT00003650|DRUG|prednisone|
219122680|NCT00003650|DRUG|vincristine sulfate|
219706724|NCT02109757|OTHER|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
219706725|NCT02109757|OTHER|Education only|
219706726|NCT03640819|PROCEDURE|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
219706727|NCT04270461|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
219706728|NCT01047449|PROCEDURE|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
219706729|NCT01047449|DIETARY_SUPPLEMENT|Fish oil supplementation vs placebo|Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op
219122681|NCT00003650|RADIATION|radiation therapy|
219122682|NCT04974320|BIOLOGICAL|blood biomarkers|All patients were obtained blood biomarkers: troponin, ST2, copeptin
219122683|NCT04751175|DRUG|Ketamine|Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
219122684|NCT04751175|DRUG|Dexamethasone|"A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration"
219122685|NCT04751175|DRUG|Physiologic saline|placebo
219122686|NCT05715450|PROCEDURE|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
219122687|NCT02058342|BEHAVIORAL|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
219122688|NCT00004108|DRUG|exatecan mesylate|
219122689|NCT02237378|RADIATION|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
219122690|NCT05531903|DEVICE|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
219122691|NCT01333761|DEVICE|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
219122692|NCT04186169|PROCEDURE|Catheter ablation|Catheter ablation
219122693|NCT01657682|DRUG|Crenolanib besylate|"Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy."
219122694|NCT01719861|DRUG|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
219122695|NCT04849728|DRUG|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
219122696|NCT04849728|DRUG|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
219122697|NCT00725582|DRUG|IMA-026|
219122698|NCT00725582|OTHER|Placebo|
219122699|NCT00087490|DRUG|linezolid|
219122700|NCT00087490|DRUG|vancomycin|
219122701|NCT02034435|OTHER|Low Salt diet plus Placebo tablet|
219122702|NCT02034435|OTHER|Low Sodium diet plus Salt tablet|
219122703|NCT02034435|DRUG|Epleronone|50mg daily
219122704|NCT02034435|DRUG|Amlodipine|5mg daily
219122705|NCT03208556|BIOLOGICAL|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg"
219122706|NCT03208556|DRUG|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
219122707|NCT05495451|BEHAVIORAL|Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting|Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
219122708|NCT01192087|DRUG|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
219122709|NCT01166087|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
219122710|NCT02651402|BEHAVIORAL|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
219122711|NCT02651402|BEHAVIORAL|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
219122712|NCT02651402|BEHAVIORAL|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
219122713|NCT02651402|BEHAVIORAL|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
219122714|NCT06277128|DRUG|WS016 3g|Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
219122715|NCT06277128|DRUG|WS016 6g|Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
219122716|NCT06277128|DRUG|WS016 12g|Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
219706730|NCT05504525|PROCEDURE|Fascia Iliaca block|Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
219122717|NCT06277128|DRUG|Matching Placebo|Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
219225723|NCT00663611|DRUG|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
219706731|NCT05504525|PROCEDURE|Quadratus lumborum block|The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
219706732|NCT03320811|OTHER|Data record|
219706733|NCT01925417|BIOLOGICAL|RBX2660 (microbiota suspension)|
219706734|NCT02332759|DEVICE|Materna Medical|
219706735|NCT03479905|OTHER|Salter nasal cannula|Oxygen will be delivered via standard nasal cannula during colonoscopy
219706736|NCT03479905|OTHER|Face mask|Oxygen will be delivered via face mask during colonoscopy
219706737|NCT03479905|DEVICE|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
219706738|NCT01089179|DRUG|Metformin|
219706739|NCT01548365|OTHER|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
219706740|NCT02057341|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
219706741|NCT06014645|OTHER|Rehabilitation|The study group will be given a core stabilization program in addition to education.
219706742|NCT06014645|OTHER|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
219706743|NCT03704740|BIOLOGICAL|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
219706744|NCT03704740|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains (trivalent)
219706745|NCT00720759|DRUG|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
219706746|NCT00720759|BEHAVIORAL|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
219706747|NCT00720759|DRUG|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
219706748|NCT00720759|BEHAVIORAL|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
219706749|NCT06308783|OTHER|Diaphragmatic Breathing|10 minutes each day during 6 weeks, before sleeping.
219706750|NCT06308783|OTHER|Global Postural Reeducation|10 minutes each day during 6 weeks, before sleeping.
219706751|NCT02837159|OTHER|mHealth application|Dietary and physical activity recommendations trough a mobile application
219706752|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter ultrasound guided
219706753|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter landmark guided
219706754|NCT01047319|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
219706755|NCT03513419|BEHAVIORAL|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
219706756|NCT01977833|OTHER|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
219706757|NCT01977833|OTHER|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
218985847|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
219122718|NCT01386216|DEVICE|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
219122719|NCT00374621|DRUG|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
219225724|NCT00663611|DRUG|Placebo|0.9% normal saline
219122720|NCT04569214|DRUG|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
219122721|NCT04569214|OTHER|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
219706758|NCT03443297|OTHER|breast milk|Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight \<1200 grams and \>1200 grams respectively. gradually volume of milk should be increased
219706759|NCT04084015|DEVICE|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
219706760|NCT00857389|DRUG|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
219706761|NCT00857389|DRUG|Clofarabine|40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
219706762|NCT00857389|DRUG|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
219706763|NCT00857389|PROCEDURE|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
219706764|NCT00857389|DRUG|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
219706765|NCT00857389|DRUG|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
219706766|NCT00857389|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
219706767|NCT00857389|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
219706768|NCT00857389|DRUG|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
219706769|NCT00857389|DRUG|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
219706770|NCT02251639|BEHAVIORAL|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
219706771|NCT02251639|DEVICE|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
219706772|NCT02251639|PROCEDURE|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
219706773|NCT03226587|PROCEDURE|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
219706774|NCT03226587|PROCEDURE|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
219706775|NCT05297383|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
219706776|NCT05297383|DIETARY_SUPPLEMENT|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
218985848|NCT00894166|DRUG|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
218985849|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
218985850|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
218985851|NCT00894166|DRUG|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
218985852|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
218985853|NCT00354887|DRUG|Capecitabine|Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
218985854|NCT00354887|DRUG|Oxaliplatin|130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
218985855|NCT00944671|DRUG|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
218985856|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
218985857|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
218985858|NCT03892187|BEHAVIORAL|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
219122722|NCT03918018|DEVICE|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
219122723|NCT03950908|OTHER|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
219122724|NCT03950908|OTHER|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
219122725|NCT00625274|DRUG|Esomeprazole|40mg Oral
219122726|NCT00625274|DRUG|Lansoprazole|30mg Oral
219122727|NCT00625274|DRUG|Pantoprazole|40mg Oral
219122728|NCT00910884|OTHER|laboratory biomarker analysis|No supplements are given
219122729|NCT00910884|PROCEDURE|therapeutic dietary intervention|Given orally daily for 12 months
219122730|NCT05880693|DRUG|Dexmedetomidine|Group 1 received dexmedetomidine
219706777|NCT05297383|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
219706778|NCT05297383|BEHAVIORAL|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
219706779|NCT06701825|DRUG|Tacrolimus|"Tacrolimus at the dosage reccomended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing based on the subjects pharmacogenetic phenotype."
219706780|NCT06701825|DRUG|Tacrolimus|Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.
219706781|NCT03673644|OTHER|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
219706782|NCT02056678|DRUG|acetaminophen, IV preparation|
219122731|NCT05880693|DRUG|Magnesium sulfate|the group 2 received magnesium sulfate
219122732|NCT01506921|DRUG|Racemic ketamine|0.6 mg/kg
219122733|NCT01506921|DRUG|S-ketamine|0.3 mg/kg
219122734|NCT04462913|OTHER|no intervention|This is an observation study, with no intervention
219122735|NCT03943186|DEVICE|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
219122736|NCT03943186|DEVICE|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
219122737|NCT00630539|DRUG|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
219122738|NCT00630539|DRUG|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
219122739|NCT00630539|DRUG|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
219122740|NCT00630539|DRUG|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
219122741|NCT01253980|DRUG|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
219122742|NCT01253980|DRUG|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
219122743|NCT01700530|DRUG|Statin|Statins (40mg/day)for 12 weeks
219122744|NCT01700530|OTHER|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
219122745|NCT01700530|OTHER|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
219122746|NCT06488066|OTHER|Data collection|Collection of clinical data from groups of patients already implanted with the light adjustable lens (LAL) and have completed light treatments.
219122747|NCT02250144|DEVICE|Foot orthoses|
219122748|NCT05300880|OTHER|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
219122749|NCT02420587|DRUG|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
219122750|NCT02420587|BEHAVIORAL|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
219122751|NCT01023178|DRUG|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
219122752|NCT01023178|DRUG|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
219122753|NCT01023178|DRUG|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
219122754|NCT01023178|DRUG|Progesterone, micronized|Given starting at 18 months
219225725|NCT01850342|PROCEDURE|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
219706783|NCT05532878|DRUG|Apixaban|Apixaban 2.5 mg daily
219122755|NCT04569279|DRUG|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
219122756|NCT04569279|DRUG|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
219706784|NCT03546127|GENETIC|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
219706785|NCT07055399|DRUG|neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles|"Neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab, cisplatin, and nab-paclitaxel for 1 cycle, then Iparomlimab and tuvonralimab continued for 2 cycles at 3-week intervals. Details:~Iparomlimab and tuvonralimab 5 mg/kg, IV infusion, Q3W for 3 cycles Cisplatin：75-80 mg/m2, IV infusion, (cycle 1) Nab-paclitaxel 260 mg/m2，30min，IV infusion,(cycle 1)"
219706786|NCT02970084|OTHER|Nutraceutical product based on vitamin K2 (PLAK2)|
219706787|NCT05146752|DEVICE|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
219706788|NCT05146752|OTHER|routine care|routine care
219706789|NCT06107114|DRUG|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
219706790|NCT06107114|DRUG|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
219706791|NCT06107114|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
219706792|NCT06107114|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
219706793|NCT01157845|DEVICE|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
219706794|NCT05041400|OTHER|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
219706795|NCT03311555|DRUG|Apalutamide|240mg tablet daily for 36 weeks
219706796|NCT03311555|DRUG|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
219706797|NCT03311555|RADIATION|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
219122757|NCT01616719|DEVICE|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
219122758|NCT00310362|BEHAVIORAL|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
219122759|NCT00715286|OTHER|timing of surgery|Surgery is followed by chemotherapy
219122760|NCT00715286|OTHER|timing of surgery|Chemotherapy is followed by surgery
219122761|NCT05365867|BEHAVIORAL|iCAN Group|See description in iCAN study arm.
219706798|NCT03311555|DRUG|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
219706799|NCT05685121|DEVICE|Apollo Neuro|The device is a wearable nerve stimulator.
219706800|NCT03966625|DIAGNOSTIC_TEST|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
219706801|NCT02164617|OTHER|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
219122762|NCT03453385|BEHAVIORAL|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
219122763|NCT00419068|DRUG|Cholecalciferol|
219706802|NCT03186755|DRUG|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
219706803|NCT03186755|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
219706804|NCT02830711|OTHER|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
219706805|NCT05883514|BEHAVIORAL|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
219122764|NCT00419068|DRUG|Migliol Placebo Oil|
219122765|NCT04308616|OTHER|Blood samples|Blood samples
219122766|NCT02055859|RADIATION|Radiosurgery|
219122767|NCT03912103|OTHER|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
219122768|NCT05561855|BEHAVIORAL|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
219122769|NCT04284748|OTHER|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
219122770|NCT04284748|OTHER|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
219122771|NCT04284748|OTHER|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
219122772|NCT06336746|DEVICE|Esophageal Doppler|Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
219122773|NCT04863105|DRUG|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
219122774|NCT01716832|BEHAVIORAL|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
219706806|NCT04309331|DIETARY_SUPPLEMENT|Motion|Amino acid based protein substitute
219706807|NCT06159582|BEHAVIORAL|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
219706808|NCT06159582|BEHAVIORAL|Usual Care|Usual HIV testing and PrEP clinical care
219706809|NCT01580956|OTHER|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
219122775|NCT02117115|RADIATION|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
219122776|NCT02117115|DRUG|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
219122777|NCT01126021|BEHAVIORAL|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
219122778|NCT01126021|BEHAVIORAL|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
219122779|NCT04455724|DEVICE|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
219122780|NCT04455724|DEVICE|Standard sterile dressing|A standard, sterile island dressing
219225726|NCT05996900|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
219225727|NCT05996900|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
219706810|NCT01580956|OTHER|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
219706811|NCT06774235|DRUG|Interferon Gamma 1-b|injection of interferon gamma 1-b
219706812|NCT06774235|DRUG|Placebo|Injection of placebo in the same condition of experimental traitment
219122781|NCT06224075|BEHAVIORAL|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
219122782|NCT06224075|OTHER|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
219706813|NCT05789485|BEHAVIORAL|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
219706814|NCT03020368|BIOLOGICAL|Leeches|
219706815|NCT03020368|DRUG|Diclofenac|
219706816|NCT03857256|DRUG|CP105F|Natural Health Product
219706817|NCT03857256|DRUG|Placebo|tablet manufactured to mimic the CP105F beta-glucan
219706818|NCT07155538|OTHER|Assesment test for Validity and Reliability|Assesment test
219706819|NCT07168707|OTHER|Group-based Emotional Awareness & Expression Therapy - Hebrew|"This pilot study will use the eight-session group EAET manual developed by Mark A. Lumley and Howard Schubiner. Several adaptations to this manual were made: a) Manual's translation to the Hebrew language; b) Adaptations to the Israeli context and setting; c) Manual's language was changed from fibromyalgia to chronic pain and adaptations were made accordingly. Group participants will receive a class syllabus and an educational booklet of the EAET approach. Each group meeting will be led by two instructors, a psychologist and a physiotherapist."
219706820|NCT07167667|OTHER|Paraffin Bath|Patients' hands will be dipped into the paraffin bath 8-10 times.
219706821|NCT07167667|OTHER|Extracorporeal Shock Wave Therapy|The patients will be treated with a sound wave pulse frequency of 15 Hz, an intensity of 1.5 bar, and a total number of pulses of 2000 for one session.
219706822|NCT07168226|DRUG|Active Comparator|Megace F suspension 20mL, intake daily for 12weeks
219706823|NCT07168226|DRUG|ASCA101 24.32mg/kg|ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks
219706824|NCT07168226|DRUG|ASCA101 32.43mg/kg|ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks
219706825|NCT07168226|DRUG|Placebo|0.9% normal saline injection
219706826|NCT07168512|OTHER|Exercises (Endurance and strengthening)|"Neck Strengthening and Endurance Exercises with Hot Packs~Preparation: A moist hot pack will be applied for 10-15 minutes to the cervical region before exercise to reduce stiffness and enhance tissue extensibility.~Exercise program:~Deep cervical flexor training: Chin tucks in supine and sitting, progressing to sustained isometric holds.~Extensor and scapular stabilizer training: Prone head lifts and shoulder retraction exercises with light resistance.~Endurance training: Low-load, high-repetition exercises focusing on maintaining cervical posture against gravity.~Progression: Intensity and duration will gradually increase, emphasizing endurance over maximal strength to correct postural deficits.~Frequency: 40 minutes per session, 3 times per week for 6 weeks~Rationale: The combined use of heat and targeted exercises improves neuromuscular control, enhances cervical stability, and supports better cervical curvature correction. Myofascial Release Technique"
219706827|NCT07168512|OTHER|Myofascial release technique|"Myofascial Release Technique~Target areas: Suboccipital muscles, upper trapezius, levator scapulae, and deep cervical fascia.~Method: A physiotherapist will perform gentle, sustained manual pressure and low-load, long-duration stretching on restricted cervical and upper thoracic fascia to reduce tension and improve soft tissue mobility.~Duration and frequency: Each session will include 30'to 50 minutes of myofascial release, delivered 3 times per week for the study period for 6 weeks.~Rationale: This technique aims to decrease myofascial restrictions contributing to abnormal cervical alignment and pain, thereby facilitating improved posture and muscle activation."
219706828|NCT07167914|DRUG|SFG-02|Transdermal Formulation (SFG-02)
219706829|NCT07167914|DRUG|Placebo|Transdermal Formulation (Placebo)
219706830|NCT07167654|OTHER|Smartphone Application|"The Intervention: Serene Motherhood Application The Serene Motherhood application was a newly developed Android-based application created specifically for this study by the research team in collaboration with professional software developers. The content was adapted from authoritative guidelines provided by the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), the World Health Organization, and the American Psychological Association (APA, 2023; Mota \& Bø, 2021; NICE, 2016; WHO, 2022). The application was developed using the research project budget and was provided free of charge to all participants.~The app aimed to integrate emotional and behavioral strategies, social support, and education for women with symptoms of PPD. The application combines evidence-based therapeutic techniques with user-friendly features supporting daily engagement with the app and self-management. Content and activities were grounded"
219706831|NCT07167979|BEHAVIORAL|Combining neck muscle strengthening with oculomotor saccade tasks.|"he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session.~Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.~After neck training, participants in the intervention group perform oculomotor saccade tasks while maintaining a neutral head position. Five visual targets appear randomly in front of the participant for 1 second each. The task lasts 40 seconds, followed by 1-2 minutes of rest, and is repeated three times."
219122783|NCT06422026|DIETARY_SUPPLEMENT|APCP I|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.
219122784|NCT06422026|DIETARY_SUPPLEMENT|APCP II|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.
219122785|NCT06422026|DIETARY_SUPPLEMENT|Placebo|Each subject takes one active bottle per day for 24 weeks.
219122786|NCT02656940|DIETARY_SUPPLEMENT|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
219122787|NCT02656940|DIETARY_SUPPLEMENT|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
219122788|NCT02656940|DIETARY_SUPPLEMENT|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
219122789|NCT04833855|BIOLOGICAL|Tezepelumab Dose 1|Subcutaneous injection.
219122790|NCT04833855|BIOLOGICAL|Tezepelumab Dose 2|Subcutaneous injection.
219122791|NCT04833855|BIOLOGICAL|Omalizumab|Subcutaneous injection.
219122792|NCT04833855|BIOLOGICAL|Placebo|Subcutaneous injection.
219122793|NCT04654351|DRUG|TAK-667|TAK-667 single SC administration
219122794|NCT03364816|PROCEDURE|TDR|total artificial disc replacement
219122795|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
219122796|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
219122797|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
219122798|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
219122799|NCT05073081|OTHER|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
219122800|NCT05073081|OTHER|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
219122801|NCT03306615|DRUG|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
219122802|NCT03306615|DRUG|Placebo|0.9% Sodium Chloride Injection
219122803|NCT03682536|DRUG|Luspatercept|Specified dose on specified days
219706832|NCT07167979|BEHAVIORAL|Neck Strengthening Only|he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session. Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.
219122804|NCT03682536|DRUG|Epoetin alfa|Specified dose on specified days
219122805|NCT04385342|DRUG|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
219122806|NCT04385342|DRUG|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
219122807|NCT05786313|PROCEDURE|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
219122808|NCT05115955|DRUG|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
219122809|NCT05115955|DRUG|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
219122810|NCT01269853|DRUG|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
219122811|NCT01269853|DRUG|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
219122812|NCT03903835|DRUG|Enzalutamide Oral Capsule|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
219122813|NCT03903835|DRUG|Abiraterone Oral Tablet|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
219122814|NCT03903835|DRUG|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
219122815|NCT03903835|DRUG|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
219122816|NCT03903835|DRUG|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
219122817|NCT03903835|DRUG|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
219122818|NCT03903835|DRUG|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
219122819|NCT03903835|DRUG|Capivasertib plus Docetaxel|Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
219706834|NCT07167446|DRUG|Cannabidiol (CBD)|Oral hemp-derived CBD capsules, 150 mg twice daily (with titration in Cycle 1; dose reductions permitted for tolerability). Administered starting the day before oxaliplatin infusion and continued for 7 days after each chemotherapy cycle.
219706835|NCT07167446|DRUG|oxaliplatin-based chemotherapy|Standard of care oxaliplatin-based regimens per NCCN guidelines (e.g., FOLFOX or CAPEOX), administered in 2-3 week cycles for a maximum of 6 months.
219122820|NCT03903835|DRUG|Apalutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
219122821|NCT03903835|DRUG|Darolutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
219122822|NCT06629025|DIAGNOSTIC_TEST|High-resolution impedance manometry|High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
219122823|NCT05370768|BEHAVIORAL|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
219122824|NCT05144802|PROCEDURE|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
219122825|NCT04952987|DRUG|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
219122826|NCT02057380|DRUG|linsitinib|oral
219122827|NCT02057380|DRUG|erlotinib|oral
219122828|NCT02057380|DRUG|paclitaxel|Intravenous (IV) infusion
219706836|NCT07168655|DRUG|Mavacamten|According to the product label
219706837|NCT07167940|DEVICE|Transcranial magnetic stimulation|iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
219706838|NCT07167940|DEVICE|Sham transcranial magnetic stimulation|Sham iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
219706839|NCT07167784|OTHER|Ecological Momentary Assessment|Participants will be complete four daily EMA surveys via the Avicenna Research app (morning, 11 a.m., 3 p.m., and evening). Participants will be instructed to complete and submit each survey as soon as they see the app notification. If no response is provided within 15 minutes, a reminder notification will be sent. At the end of the 14-day period, devices will be returned using a prepaid envelope provided by the study team and participants will complete an end-of-study questionnaire to assess the acceptability of the study and will be invited to participate in a debriefing interview with a member of the research team.
219122829|NCT02057380|DRUG|Bortezomib|Subcutaneous or IV
219122830|NCT02057380|DRUG|Dexamethasone|IV, Oral
219122831|NCT03852615|DIAGNOSTIC_TEST|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
219122832|NCT03852615|DIAGNOSTIC_TEST|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
219122833|NCT06345872|BEHAVIORAL|CBT-I|Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
219122834|NCT06345872|BEHAVIORAL|Treatment as usual|Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
219122835|NCT06345872|OTHER|Tapered Withdrawal|Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
219122836|NCT01912326|DEVICE|Pacemaker Implantation|Implantation of a dual chamber pacemaker
219122837|NCT04607252|DRUG|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
219122838|NCT04607252|DRUG|Megestrol Acetate|megestrol acetate 160mg per day, oral
219122839|NCT03008122|OTHER|Placebo|Placebo
219122840|NCT03008122|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
219122841|NCT03050281|OTHER|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
219122842|NCT03050281|OTHER|Lectures|Standard Anatomy lectures were offered.
219122843|NCT03862521|OTHER|Low carbohydrate diet|Low carbohydrate diet
219122844|NCT03862521|OTHER|Very low carbohydrate diet|Very low carbohydrate diet
219122845|NCT05297123|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
219122846|NCT05297123|DRUG|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
219122847|NCT05297123|DRUG|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
219122848|NCT02338609|DRUG|Everolimus|At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
219122849|NCT04872062|DEVICE|NIV cards|Reading the data available on the NIV cards
219122850|NCT04872062|OTHER|Medical file|Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
219122851|NCT02519556|DRUG|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
219122852|NCT02519556|DRUG|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
219122853|NCT02116387|OTHER|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
219122854|NCT02116387|DEVICE|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
219122855|NCT03547505|PROCEDURE|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
219122856|NCT03547505|PROCEDURE|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
219122857|NCT03547505|PROCEDURE|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
219122858|NCT04460079|DRUG|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
219706840|NCT07166965|DIETARY_SUPPLEMENT|Hawthorn supplement|Hawthorn oral supplement
219122859|NCT02655653|DRUG|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
219122860|NCT02655653|DRUG|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
219122861|NCT03985579|OTHER|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
219122862|NCT05953753|BEHAVIORAL|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
219122863|NCT06493929|OTHER|Chest ultrasound|to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT.
219122864|NCT06493929|OTHER|Calculation of Mechanical Power on the first day of intubation and before First trial of weaning:|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
219122865|NCT05877560|DEVICE|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
219122866|NCT05877560|BEHAVIORAL|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
219706841|NCT07166965|DIETARY_SUPPLEMENT|Ketones|ketone oral supplement
219706842|NCT07166965|OTHER|Placebo Control|Placebo Control, oral supplement
219706843|NCT07168954|DEVICE|Lumos Glasses|The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.
219122867|NCT05877560|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
219122868|NCT06774248|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to medication adherence in this vulnerable young adult population. The YORS intervention primary components are (as detailed below):~1. Low barrier access to MOUD, including home delivery, ride-share app transportation and mobile van delivery and low barrier access to MOUD in general~2. Engagement of families in collaborative treatment planning and monitoring with a focus on medication adherence~3. Assertive continuing care: actively tracking and communicating with youth and families by text and social media to promote engagement and adherence~4. Contingency management: to provide incentives for medication adherence"
219122869|NCT02633943|OTHER|Safety and efficacy assessments|"Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study."
219122870|NCT04707716|OTHER|conometric concept Acuris system|implant crown retention type using friction only
219122871|NCT04707716|OTHER|screw retention|screw retained implant crown
219122872|NCT04707716|OTHER|cementation|cement retained implant crown
219122873|NCT05190549|PROCEDURE|CAV regimen bridging to HSCT|The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
219122874|NCT06458543|DRUG|Longidaza|Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
219122875|NCT06458543|DRUG|Metronidazole 500 mg|Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
219122876|NCT05930756|PROCEDURE|Radiofrequency ablation|Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
219122877|NCT06379893|DRUG|Voltaren Gel 1% (diclofenac sodium) (US only)|Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
219122878|NCT06379893|DRUG|Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
219706844|NCT07169279|DRUG|Infigratinib is provided as a single dose of minitablets for oral administration|"* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria.~* The target dose is the dose that will provide similar exposure to the dose of 0.25 mg/kg/day in participants 3 years old and older.~* The dose and number of minitablets will be calculated based on individual participant age and weight."
219706845|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
219706846|NCT07169279|DRUG|Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
219122879|NCT06379893|DRUG|Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
219122880|NCT02223182|BIOLOGICAL|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
219122881|NCT02223182|BIOLOGICAL|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
219122882|NCT02223182|BIOLOGICAL|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
219122883|NCT02223182|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
219122884|NCT00924989|DRUG|OSI-906|Administered orally
219122885|NCT00924989|OTHER|Placebo|Matching placebo administered orally
219122886|NCT05039450|DRUG|EFX|Investigational drug, Efruxifermin
219122887|NCT05039450|DRUG|Placebo|Placebo
219122888|NCT00180947|DRUG|Vinorelbine, cyclofosfamide|
219122889|NCT06391034|DRUG|hyperpolarized pyruvate +/-urea (13C/15N)|Given IV
219122890|NCT06391034|RADIATION|Non-investigational Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy given outside of this study
219122891|NCT06391034|PROCEDURE|Radiotherapy (RT)|Radiation therapy given outside of this study
219122892|NCT06391034|PROCEDURE|Multi-parametric magnetic resonance imaging (mpMRI)|Imaging scan
219122893|NCT06391034|BIOLOGICAL|Non-interventional hormone therapy|Therapy given outside of this study as part of standard of care
219122894|NCT06391034|PROCEDURE|Prostate Biopsy|Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
219122895|NCT05653310|DRUG|Tradipitant|Tradipitant Capsule
219122896|NCT05653310|DRUG|Placebo|Placebo Capsule
219706847|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter."
219122897|NCT05138536|PROCEDURE|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
219122898|NCT06301399|DRUG|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
219122899|NCT05649332|DEVICE|Argogen (silver zeolite powder)|The medical device will be self-administered by each patient twice daily without interruption for the duration of the study (4 weeks) or until complete healing. Application is carried out by spraying at short intervals, lightly pressing the dispenser button and directing the spray onto the area to be treated.
219122900|NCT06499207|DIAGNOSTIC_TEST|Photon-counting detector computed tomography (PCD-CT)|Patients undergoing follow-up coronary angiography with IVI after percutaneous coronary intervention (PCI) as part of routine clinical practice will additionally receive coronary computed tomography angiography (CCTA) with PCD as part of this study.
219122901|NCT05349136|OTHER|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
219122902|NCT05349136|OTHER|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
219122903|NCT05604235|OTHER|Therapeutic upper limb strength exercise treatment|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
219122904|NCT05604235|OTHER|Treatment with passive and active mobilization of the upper limb.|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
219122905|NCT03909139|BIOLOGICAL|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
219122906|NCT05970731|DRUG|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
219122907|NCT05970731|OTHER|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
219122908|NCT05970731|DEVICE|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
219122909|NCT03069469|DRUG|Vimseltinib|Colony-stimulating factor 1 receptor (CSF1R) inhibitor
219122910|NCT04940546|DRUG|Sintilimab|Mode of administration: Intravenously
219122911|NCT04940546|DRUG|Oxaliplatin|Mode of administration: Intravenously
219122912|NCT04940546|DRUG|Capecitabine|Mode of administration: Orally
219122913|NCT04940546|DRUG|Bevacizumab|Mode of administration: Intravenously
219122914|NCT06119087|DEVICE|Mechanical insufflation|"Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.~Mechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient's own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one cycle. Prior literature has used a dose of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place."
219122915|NCT06397885|DEVICE|Milli Vaginal Dilator|Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion
219122916|NCT06442189|DIETARY_SUPPLEMENT|Mediterranean Diet|The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month of patients with a body mass index of 25 and more who were treated in our clinic due to a diagnosis of PCOS.
219706848|NCT07167043|DIAGNOSTIC_TEST|AI-assisted diagnostic systems|Diagnosing neurological diseases on CT/MRI with and without AI-assisted tools
219122917|NCT03431805|DRUG|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
219122918|NCT03431805|DRUG|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
219122919|NCT05804396|DEVICE|Relivion®|Active stimulation device
219706849|NCT07166900|PROCEDURE|Modified Thoracolumbar Interfascial Plane Block|The TLIP block, introduced as a modification of the lumbar interfascial plane block, targets the dorsal rami of the thoracolumbar nerves by injecting local anesthetic into the fascial plane between the multifidus and longissimus muscles. This technique is designed to provide analgesia to the posterior elements of the spine, which are often the primary sources of pain after laminectomy
219122920|NCT03714022|DRUG|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
219122921|NCT04685733|DEVICE|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
219122922|NCT06352268|PROCEDURE|Pallidal, subthalamic or thalamic lesioning|Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders
219122923|NCT00367393|DRUG|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
219122924|NCT02005003|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
219122925|NCT02005003|PROCEDURE|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
219122926|NCT02005003|BIOLOGICAL|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
219122927|NCT02005003|PROCEDURE|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
219122928|NCT02005003|BEHAVIORAL|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
219122929|NCT02005003|BEHAVIORAL|Memory task|Participants perform short memory tasks on each visit
219122930|NCT02005003|BEHAVIORAL|Food consumption task|Participants are given a selection of food items to consume on each visit
219122931|NCT04616118|OTHER|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
219122932|NCT04616118|OTHER|Video Visit|Participants randomized to this arm will receive usual care via video call
219122933|NCT05121675|BEHAVIORAL|Neuroflow app: Mental health and wellbeing resources for adults|"The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app."
219122934|NCT00165867|DRUG|E7070|
219122935|NCT01907152|OTHER|Protein enriched yoghurt drink and bread|
219122936|NCT03157102|DEVICE|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 \>92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
219122937|NCT03157102|DEVICE|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
219122938|NCT00197301|BIOLOGICAL|Vaccination|
219122939|NCT04625478|OTHER|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
219122940|NCT06157775|DIAGNOSTIC_TEST|Shear-wave elastography|Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
219706850|NCT07168005|BEHAVIORAL|Informative Video on LMWH|A short (up to 5 minutes) informative video presented to postpartum women prior to their first LMWH (Clexane) injection. The video explains the rationale, process, and safety of LMWH use for thrombopr
219706851|NCT07168005|BEHAVIORAL|Standard Verbal Explanation|Participants receive the routine verbal explanation regarding postpartum LMWH (Clexane) administration, covering its purpose and method of injection
219122941|NCT00859417|PROCEDURE|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
219122942|NCT00859417|DEVICE|Perigee® prosthesis|Surgical method with Perigee® prosthesis
219122943|NCT03864133|DRUG|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
219122944|NCT00927628|PROCEDURE|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
219122945|NCT02668432|DRUG|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
219122946|NCT04391075|PROCEDURE|Pudendal nerve block|Pudendal nerve block provided during last fase of delivery
219122947|NCT06410911|PROCEDURE|Subcostal Transversus Abdominis Plane block in patients undergoing open cholecystectomy surgery.|"Subcostal Transversus Abdominis Plain block will be performed under ultrasound guidance using a 5-10 MHz linear transducer. The needle will be inserted perpendicular to the skin 2 fingers below the costal~margin, just lateral to the rectus abdominis muscle. After confirming the needle tip's location within the TAP, 20 mL of 0.25% bupivacaine will be injected on both sides in patients undergoing open cholicystectomy surgery."
219122948|NCT06410911|PROCEDURE|Erector Spinae Block in patients undergoing open cholecystectomy|Ultrasound-guided Erector Spinae block using 20 mL of 0.25% bupivacaine will be injected bilaterally at the T7- T8 vertebral level in patients undergoing open cholecystectomy The probe will be advanced 3 cm to the right lateral direction and rotated 90 degrees, and the transverse processes will be determined . Next, 5 mL of 2% lidocaine will be administered to the predicted needle entry point. A 22-gauge, peripheral nerve block needle will cephalocaudally advanced by the in-plane technique. The needle tip will be continuously advanced toward the transverse process to 1-2 mm before contact with the transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine will be injected with intermittent negative aspirations into the fascia of the erector spinae muscle.
219122949|NCT06410911|DRUG|Sbcostal transversus Abdominis block and erector spinae block for both groups|Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
219122950|NCT04447820|DRUG|K-877-ER (Dose A)|Dose A Oral Administration
219122951|NCT04447820|DRUG|K-877-ER (Dose B)|Dose B Oral Administration
219122952|NCT04447820|DRUG|K-877-IR|K-877-IR Oral Administration
219706852|NCT07169058|BEHAVIORAL|Vagus Nerve Fascial Mobilization|"Reference Points of the Body Regions for Mobilization~1. Occipito-Mastoid Suture (OM) The occipitomastoid suture is the cranial suture located between the occipital bone and the mastoid part of the temporal bone. The condylus squamosa mastoidea serves as the pivot point. The patient lies in the supine position while the physiotherapist sits at the head of the patient. One hand is placed under the occiput at the suture, while the other hand is placed on the mastoid portion of the temporal bone. The patient's head is turned toward the direction of mobilization, and mobilization is performed using the weight of the head (25). Each application is planned as a single repetition lasting 120 seconds.~2. Anterior Cervical Region (Triangle) Topographically, this region is located at the anterior part of the neck, extending along the seven cervical vertebrae (C1-C7). The anterior triangle is bordered superiorly by the lower margin of the mandible, laterally by the anterior median line of the s"
219706853|NCT07168993|OTHER|Standard medical treatment|Standard of care follow up per institution
219706854|NCT07168993|OTHER|Standard medical treatment|SOC per institution
219706855|NCT07168850|DEVICE|Exablate MR-guided Focused Ultrasound Pallidotomy|Active Pallidotomy
219706856|NCT07168850|DEVICE|Sham Sham Exablate MRgFUS Pallidotomy|Sham procedure. Identical setup without thermal lesioning. Participants cross over to Active Pallidotomy after 3 months.
219706857|NCT07168603|DRUG|aNPC|Eligible subjects must be diagnosed with disc herniation and scheduled for discectomy, nucleus pulposus tissue will be collected for cell culture. Cultured cells will be then reintroduced into the degenerated disc via injection. Subjects will undergo multiple follow-up visits after surgery to evaluate safety and efficacy, supplemented with imaging studies to assess disc height, tissue regeneration, and water-retention capacity.
219706858|NCT07168031|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|High definition tDCS will be applied, using a Soterix Medical device and 4x1 ring electrodes. A centre ring electrode overlying the target cortical region (left dlPFC at position F3 according to the 10-20 system) will be surrounded by four return electrodes (position F1, FC3, F5, and AF3).
219706859|NCT07168031|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|The same setup and device as in the active tDCS group will be used, but in this case stimulation will be turned off after a ramp-up phase of 30 seconds. This mimics the same sensory feeling as active tDCS.
219122953|NCT04850742|PROCEDURE|Cryopreserved aorta|After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.
219122954|NCT01766583|DRUG|CC-292 + lenalidomide|CC-292 + lenalidomide
219122955|NCT03753880|DEVICE|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
219122956|NCT00183924|DRUG|Estramustine|
219122957|NCT00183924|DRUG|Docetaxel|
219122958|NCT00183924|DRUG|Carboplatin|
219122959|NCT03513198|DIAGNOSTIC_TEST|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes."
219122960|NCT03513198|OTHER|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
219122961|NCT03513198|OTHER|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
219122962|NCT03513198|DIAGNOSTIC_TEST|Contrast-enhanced computed tomography (CT)|"* Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
219122963|NCT02789163|DEVICE|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
219122964|NCT02838004|DEVICE|IOL MINI WELL READY|IOL MINI WELL READY
219122965|NCT05080621|DRUG|Ripretinib|50 mg tablets
219122966|NCT05080621|DRUG|binimetinib|15 mg tablets
219122967|NCT02355405|DEVICE|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
219122968|NCT02355405|RADIATION|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
219122969|NCT02810808|PROCEDURE|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
219122970|NCT02810808|PROCEDURE|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
219122971|NCT02810808|DRUG|Ranibizumab|Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
219122972|NCT00248521|DRUG|alvespimycin hydrochloride|
219122973|NCT00374387|DRUG|Nuvaring|
219122974|NCT00374387|DRUG|low-dose combination pill|
219122975|NCT00374387|DRUG|minipill|
219122976|NCT06077825|OTHER|postoperative rehabilitation|30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
219122977|NCT05756842|DIETARY_SUPPLEMENT|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
219122978|NCT05051787|BIOLOGICAL|Blood and milk samples|"2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~* 3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~* 3 blood samples of approximately 5 ml each."
219122979|NCT02490384|PROCEDURE|Physical exam indicated cerclage|Cervical cerclage
219122980|NCT05194007|DRUG|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
219122981|NCT05194007|DRUG|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
219122982|NCT06162819|DRUG|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
219122983|NCT06162819|DRUG|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
219122984|NCT06094140|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
219122985|NCT06094140|DRUG|Oxaliplatin|85mg/m2 intravenously on day 1
219122986|NCT06094140|DRUG|Irinotecan|150mg/m2 intravenously on day 1
219122987|NCT06094140|DRUG|Calcium folinate (leucovorin)|50mg as an intravenous bolus
219122988|NCT06094140|DRUG|Fluorouracil|2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
219122989|NCT06094140|DRUG|Pegylated G-CSF|6mg by subcutaneous injection to be given on day 3 of each cycle.
219122990|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
219122991|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
219122992|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
219225728|NCT05856682|PROCEDURE|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
219225729|NCT04529928|DEVICE|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
219225730|NCT03605082|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
218985859|NCT05086926|COMBINATION_PRODUCT|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
218985860|NCT03750955|DEVICE|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
219225731|NCT03605082|OTHER|Placebo|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
219225732|NCT02596061|BEHAVIORAL|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
219225733|NCT02596061|OTHER|Incentives|Patients receive incentives for completing smoking cessation activities.
219225734|NCT05819294|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
218985861|NCT03750955|DEVICE|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
219706860|NCT07167082|OTHER|Hand Grip Strength Measurement|Hand grip strength will be measured within the first 24 hours of hospitalization using a calibrated hand dynamometer. Measurements will be performed on the dominant hand, with patients seated, following standardized international procedures. Three consecutive measurements will be obtained, and the average value will be recorded. The test is non-invasive, quick, and performed by oncology clinicians trained in the protocol.
219706861|NCT07168538|PROCEDURE|TAP Block Group|Bilateral ultrasound-guided transversus abdominis plane block performed at the end of surgery using 20 mL of 0.25% bupivacaine per side.
219706862|NCT07168538|PROCEDURE|Control Group|Standard ERAS-based multimodal analgesia protocol without regional block.
218985862|NCT00261469|DRUG|topiramate|
218985863|NCT05568823|OTHER|Blood sampling|Measurement of markers of disease evolution
218985864|NCT04286750|DRUG|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
219225735|NCT04468191|DEVICE|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
218985865|NCT04286750|DRUG|Placebo|Matching placebo administered as hard capsules for oral use.
218985866|NCT04403360|PROCEDURE|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
219225736|NCT04468191|DEVICE|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
219225737|NCT01748864|DRUG|Etarfolatide (EC20)|
219225738|NCT01767688|DRUG|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
218985867|NCT04403360|PROCEDURE|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
218985868|NCT00815698|PROCEDURE|suture|suture for mesh fixation
218985869|NCT00815698|PROCEDURE|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
218985870|NCT00440414|DRUG|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
218985871|NCT00440414|DRUG|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
219122993|NCT00114959|DRUG|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m\^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
219122994|NCT00114959|DRUG|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
219122995|NCT01067495|BEHAVIORAL|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
219122996|NCT04069910|OTHER|Quality-of-Life Assessment|Ancillary studies
219122997|NCT04069910|OTHER|Questionnaire Administration|Ancillary studies
219122998|NCT04069910|RADIATION|Stereotactic Radiosurgery|Undergo SRS/SRT
219122999|NCT04069910|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219123000|NCT05256303|OTHER|Home Hospital care|Patients receive hospital-level care in their home
219123001|NCT05256303|OTHER|Traditional Hospital care|Patients receive hospital-level care in the hospital.
219123002|NCT04931173|OTHER|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
219123003|NCT06229886|OTHER|Application of positive-end-expiratory pressure|Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
219123004|NCT03298815|BIOLOGICAL|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
219123005|NCT03298815|OTHER|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
219123006|NCT03251378|DRUG|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
219706863|NCT07167693|DRUG|Arginine hydrochloride|Single intravenous infusion of arginine hydrochloride 30 g in 300 mL 10% solution (R-Gene® 10), administered over 30 minutes via infusion pump. Given as early as feasible after recognition of DKA and in addition to standard DKA care (fluids, insulin, electrolytes) at the treating clinician's discretion. Investigational pharmacy prepares and dispenses blinded study drug; containers are covered to mask appearance and infusion parameters match placebo. Continuous safety monitoring with prespecified stop criteria. Study blood draws at 0 (pre-infusion), 10, 30, and 90 minutes for C-peptide/glucose and amino acids; clinical labs track β-hydroxybutyrate clearance and total insulin over 24 hours.
219123007|NCT03572764|DRUG|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
219123008|NCT03572764|PROCEDURE|Research skin biopsy|"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
219123009|NCT03572764|PROCEDURE|Research blood draw|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
219123010|NCT03572764|PROCEDURE|Research bone marrow aspirate|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
218985872|NCT00395681|DRUG|Diprivan|Propofol 200 mg versus 350 mg
219123011|NCT03083743|BIOLOGICAL|Recombinant human Apo-2 ligand for Injection|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
219123012|NCT03083743|BIOLOGICAL|Placebo|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
219123013|NCT05051540|DEVICE|Sigvaris Compreflex Inelastic Compression Wrap|Compreflex compression system using wraps to apply compression of 30-40 mmHg.
219123014|NCT05765110|OTHER|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
219123015|NCT05765110|OTHER|DBS OFF state|Turning off the stimulation during experiment
219123016|NCT05765110|OTHER|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
219123017|NCT05765110|OTHER|DBS ON state|Experiment will be performed with stimulation (ON condition)
219123018|NCT00081029|PROCEDURE|management of therapy complications|
219123019|NCT00081029|RADIATION|radiation therapy|
219123020|NCT00995358|BIOLOGICAL|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
219123021|NCT05413564|OTHER|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months|optimized self-exclusion procedure A
219123022|NCT04725968|PROCEDURE|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
219225739|NCT00686257|DEVICE|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
219225740|NCT00686257|DEVICE|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
219123023|NCT03931005|OTHER|Collaboration Decision Support Guide|Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
219123024|NCT01402258|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
219123025|NCT02076867|BEHAVIORAL|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
219706864|NCT07167693|DRUG|Sodium Chloride 0.9%|Placebo comparator: 0.9% sodium chloride administered as a single 30-minute intravenous infusion using identical tubing, pump settings, and covered container as the active arm to preserve blinding. Initiated as early as feasible after recognition of DKA and provided in addition to standard DKA care at the treating clinician's discretion. Study assessments occur on the same schedule as the active arm (0, 10, 30, and 90 minutes) with continuous safety monitoring during and after infusion and follow-up through 90 days.
219706865|NCT07167550|DRUG|Dimephosphon®|1 g/ml, concentrate for solution for intravenous infusion
219123026|NCT02076867|BEHAVIORAL|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
219123027|NCT05581797|OTHER|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
219706866|NCT07167550|DRUG|Placebo|Placebo IV solution
219706867|NCT07168837|DRUG|Letrozole tablets|to compare between Letrozole withncabergoline and letrozole alone in ovulation induction among PCOS female patients.
219706868|NCT07169370|BEHAVIORAL|SPIRIT Club CBI Pathway|A tailored, on-demand exercise and education program delivered via the SPIRIT Club virtual streaming platform. Content includes progressive adaptive workouts, safety videos, screening checkpoints, and prompts for a support person. Participants choose classes designed specifically for adults ≥9 months post-brain injury and after being placed in the appropriate archetype, complete activity surveys, and earn incentives for adherence. They are instructed on current physical activity guidelines (≥150 min moderate or ≥75 min vigorous activity per week) and to follow the CBI Pathway at their comfort level. Content was co-developed with clinical experts and survivors to ensure both usability and safety.
219706869|NCT05094336|DRUG|AMG 193|AMG 193: Orally via tablet
219706870|NCT05094336|DRUG|Docetaxel|Docetaxel: Intravenous infusion
219123028|NCT05802550|OTHER|Ocular Surface Disease Index|Questionnaire on ocular surface disorders
219123029|NCT05802550|OTHER|Interferometry|Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
219123030|NCT05802550|OTHER|Oxford score|Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
219123031|NCT05802550|OTHER|Conjunctival collection|Two conjunctival prints: one for metabolomic and one for lipidomic
219123032|NCT05802550|OTHER|Aqueous humor collection|Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
219123033|NCT05802550|OTHER|Quantification of Tyndall and flare|Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
219123034|NCT06306430|DEVICE|STANDARDTM F TB LAM FIA|STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.
219123035|NCT02538679|OTHER|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
219123036|NCT02538679|DRUG|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
219123037|NCT02538679|DRUG|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
219706871|NCT05094336|DRUG|Comparator AMG 193 Test Tablet|Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
219706872|NCT05767359|DRUG|Ciltacabtagene Autoleucel|Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
219706873|NCT05767359|DRUG|Cyclophosphamide|Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
219706874|NCT05767359|DRUG|Fludarabine Phosphate|Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
219706875|NCT05528848|DRUG|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
219225741|NCT01579799|DRUG|L-lysine|Dose finding study for L-lysine
219225742|NCT05732727|DRUG|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
219706876|NCT05528848|DRUG|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
219123038|NCT02006303|PROCEDURE|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
219706877|NCT05528848|DRUG|Loperamide Hydrochloride|Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
219123039|NCT02006303|PROCEDURE|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
219123040|NCT01691443|PROCEDURE|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
219123041|NCT02556723|DRUG|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
219123042|NCT00866710|OTHER|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
219123043|NCT06161649|BEHAVIORAL|accepting the operation process of automated intelligent education software system|"1. Execute registration and qualification review~2. Automated smart education interaction"
219123044|NCT04770818|DEVICE|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
219123045|NCT04770818|DEVICE|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
219123046|NCT00102193|DEVICE|Adacolumn Apheresis System|
219123047|NCT04130906|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
219123048|NCT04130906|DEVICE|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
219123049|NCT04361630|DRUG|FGF 2|Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
219123050|NCT02451423|DRUG|Atezolizumab|1200 mg Given IV
219123051|NCT02209207|DEVICE|Treadmill|
219123052|NCT02209207|OTHER|walking training|
219123053|NCT00881010|BEHAVIORAL|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
219123054|NCT00881010|BEHAVIORAL|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
219123055|NCT04482855|DEVICE|Low-level laser|Low-level laser therapy
219123056|NCT05157204|PROCEDURE|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
219706878|NCT00962767|DRUG|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
219123057|NCT00899002|GENETIC|comparative genomic hybridization|
219123058|NCT00899002|GENETIC|molecular genetic technique|
219123059|NCT00899002|GENETIC|mutation analysis|
219123060|NCT00899002|GENETIC|polymerase chain reaction|Not noted
219123061|NCT00899002|GENETIC|proteomic profiling|
219123062|NCT00899002|OTHER|immunohistochemistry staining method|not noted
219706879|NCT00962767|DRUG|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
219123063|NCT00899002|OTHER|laboratory biomarker analysis|not noted
219123064|NCT00899002|OTHER|mass spectrometry|not noted
219123065|NCT00899002|OTHER|medical chart review|not noted
219225743|NCT05732727|DRUG|Standard of care|standard of care management for antihypertensive therapy intensification
219706880|NCT00672009|DRUG|Ixabepilone|Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
219706881|NCT05538845|DEVICE|Screw fixation|Screw fixation to patients
219706882|NCT05538845|DEVICE|Suture button|Suture button for patients
219706883|NCT02702856|OTHER|ExoIntelliScore Prostate|
219706884|NCT03892200|BEHAVIORAL|Aim2 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim2 the intervention training is delivered by a research dental hygienist."
219706885|NCT03892200|BEHAVIORAL|Aim3 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim3 the intervention training is delivered by state public health dental hygienists."
219706886|NCT05139173|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
219706887|NCT04484441|OTHER|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
218985873|NCT05764421|BEHAVIORAL|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
219706888|NCT05444062|BEHAVIORAL|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
218985874|NCT04815681|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
219706889|NCT03737994|DRUG|Alectinib|Given PO
218985875|NCT04815681|BEHAVIORAL|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
218985876|NCT01180985|DEVICE|galyfilcon A prototype lens|silicone hydrogel contact lens
218985877|NCT01180985|DEVICE|comfilcon A|silicone hydrogel contact lens
218985878|NCT03214146|BIOLOGICAL|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
218985879|NCT04423276|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
218985880|NCT04423276|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
218985881|NCT01431989|DRUG|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
218985882|NCT01431989|DRUG|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
218985883|NCT05781620|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
218985884|NCT05781620|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
218985885|NCT00316472|DRUG|Niacinamide|
218985886|NCT06145672|PROCEDURE|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
218985887|NCT02542904|PROCEDURE|mesenteric excision|
218985888|NCT03525171|DIAGNOSTIC_TEST|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
218985889|NCT06557590|DIAGNOSTIC_TEST|18F-FAPI-04|18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
218985890|NCT00319995|DRUG|loratadine; montelukast|
218985891|NCT03172169|OTHER|no Intervention|no Intervention
218985892|NCT00578708|DEVICE|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
218985893|NCT06444971|PROCEDURE|Post isometric Relaxation|"Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid"
218985894|NCT03345914|DRUG|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
218985895|NCT03345914|DRUG|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
218985896|NCT03345914|OTHER|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
218985897|NCT03345914|OTHER|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
218985898|NCT04798963|PROCEDURE|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
218985899|NCT04798963|PROCEDURE|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
218985900|NCT03754569|PROCEDURE|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
218985901|NCT01358851|PROCEDURE|Cryotherapy|1-2 times during the treatment time
218985902|NCT01358851|DRUG|LAS41005|once daily
219123066|NCT01373853|PROCEDURE|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
219706890|NCT03737994|DRUG|Brigatinib|Given PO
219706891|NCT03737994|DRUG|Carboplatin|Given IV
219706892|NCT03737994|DRUG|Ceritinib|Given PO
219706893|NCT03737994|DRUG|Cisplatin|Given IV
219706894|NCT03737994|DRUG|Crizotinib|Given PO
219123067|NCT01373853|PROCEDURE|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
219123068|NCT05976594|DIAGNOSTIC_TEST|serology and virology detection of hepatitis E virus|Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.
219123069|NCT01593735|DRUG|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
219123070|NCT01593735|DRUG|Placebo|Placebo tablets, orally, once daily for 7 days
219123071|NCT01140659|PROCEDURE|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
219123072|NCT03212365|DRUG|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
219123073|NCT03212365|DRUG|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
219123074|NCT06481930|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|The enrolled patients underwent fluorescence photoelectric cervical lesion image detection, followed by colposcopy and biopsy to obtain histopathological results. The results of fluorescence photoelectric image detection were compared with histopathological results, and at the same time compared with HPV and TCT results at the time of enrollment.
219123075|NCT02434952|DRUG|Dihydroartemisinin piperaquine (DHA PP)|
219123076|NCT02434952|DRUG|Primaquine|
219123077|NCT05162118|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab|Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
219123078|NCT03050294|BEHAVIORAL|Phone calls|Phone calls twice daily
219123079|NCT03050294|DRUG|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
219123080|NCT01156415|DRUG|AGO178|
219123081|NCT01156415|DRUG|AGO178|
219123082|NCT00333515|DRUG|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
219225744|NCT03066921|DIETARY_SUPPLEMENT|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
219706895|NCT03737994|DRUG|Ensartinib|Given PO
219706896|NCT03737994|DRUG|Lorlatinib|Given PO
219706897|NCT03737994|DRUG|Pemetrexed|Given IV
219706898|NCT02340325|DRUG|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
219706899|NCT02340325|DRUG|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
219706900|NCT04661228|DIAGNOSTIC_TEST|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
219123083|NCT00333515|DRUG|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
219123084|NCT03982940|DEVICE|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
219123085|NCT00216320|DEVICE|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
219123086|NCT00216320|DEVICE|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
219123087|NCT00216320|DEVICE|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
219123088|NCT01015014|DRUG|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
219123089|NCT01015014|DRUG|Placebo|0.9% sodium chloride for injection
219123090|NCT02221323|DRUG|Insulin LISPRO|
219123091|NCT02100618|PROCEDURE|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
219123092|NCT03074110|DEVICE|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
219123093|NCT04997967|DRUG|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
219123094|NCT04997967|DRUG|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
219225745|NCT03066921|DIETARY_SUPPLEMENT|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
219123095|NCT02517333|OTHER|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
219123096|NCT02753530|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
219123097|NCT02753530|OTHER|Placebo|2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
219123098|NCT01797796|DRUG|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
219123099|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
219123100|NCT01797796|DRUG|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
219123101|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
219123102|NCT02818075|OTHER|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
219123103|NCT02818075|OTHER|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
219123104|NCT00816660|BIOLOGICAL|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
219123105|NCT00816660|BIOLOGICAL|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
219123106|NCT01493830|GENETIC|fluorescence in situ hybridization|
219123107|NCT01493830|GENETIC|gene expression analysis|
219123108|NCT01493830|GENETIC|microarray analysis|
219123109|NCT01493830|GENETIC|mutation analysis|
219123110|NCT01493830|GENETIC|protein analysis|
219123111|NCT01493830|OTHER|immunohistochemistry staining method|
219706901|NCT05536908|BEHAVIORAL|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx \& Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
219123112|NCT01493830|OTHER|laboratory biomarker analysis|
219123113|NCT01493830|OTHER|microscopy|
219123114|NCT05249764|OTHER|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
219123115|NCT05249764|OTHER|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
219123116|NCT02941185|DRUG|Devit-3 Oral Drop|
219123117|NCT04845438|DIAGNOSTIC_TEST|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
219123118|NCT00752570|DRUG|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
219123119|NCT00752570|DRUG|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
219123120|NCT00752570|DRUG|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
219123121|NCT01125774|DRUG|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
219123122|NCT01125774|DRUG|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
219123123|NCT02344303|DRUG|TRV130|
219123124|NCT02344303|DRUG|Moxifloxacin|
219123125|NCT02344303|DRUG|Placebo|
219123126|NCT00971516|PROCEDURE|Implant placement|dental implant placement
219123127|NCT00971516|PROCEDURE|Implants surgery|dental implant surgery
219123128|NCT04855487|BEHAVIORAL|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
219123129|NCT03271619|OTHER|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
219123130|NCT05698654|BEHAVIORAL|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
219123131|NCT05698654|BEHAVIORAL|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI \>25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
219123132|NCT03886675|OTHER|CO2 flushing|As above
219706902|NCT05536908|BEHAVIORAL|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
219706903|NCT01473134|DEVICE|Oxford Cementless Partial Knee|Oxford Partial Knee applied without bone cement.
219706904|NCT01473134|DEVICE|Oxford Cemented Partial Knee|Oxford Partial Knee applied with bone cement.
219706905|NCT06217809|BEHAVIORAL|The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.|The intervention is youth-co-led, and targets youth in Detroit, Out-Wayne County or geographically similar areas through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to abstinence, and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
219706906|NCT03643848|BEHAVIORAL|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
219123133|NCT03886675|OTHER|Saline flushing|As above
219123134|NCT01134211|DEVICE|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
219123135|NCT01134211|DEVICE|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
219123136|NCT01055106|DRUG|GW05|vaginal gel once daily regimen A
219123137|NCT01055106|DRUG|GW05|vaginal gel once daily regimen B
219123138|NCT01055106|DRUG|GW05|vaginal gel once daily regimen C
219123139|NCT01055106|DRUG|Metronidazole|vaginal gel 0.75% once daily for 5 days
219123140|NCT01807078|DRUG|Ezetimibe|10 mg p.d. of ezetimibe
219123141|NCT01807078|DIETARY_SUPPLEMENT|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
219123142|NCT02521519|OTHER|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
219123143|NCT02521519|OTHER|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
219123144|NCT00002735|DRUG|Induction chemotherapy|Cisplatin and 5-Fluorouracil
219123145|NCT00002735|DRUG|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
219123146|NCT00002735|DRUG|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
219123147|NCT00002735|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
219706907|NCT03643848|BEHAVIORAL|Sleep with Sham Cues|Sham manipulation
219706908|NCT06957275|PROCEDURE|Nasal packing|group c will not receive pharyngeal packing
219706909|NCT06957275|PROCEDURE|Nasal packing|Group (P): will include the patients who will receive pharyngeal packing
219123148|NCT06083675|DRUG|Semaglutide|Administered as oral tablets.
219123149|NCT06083675|DRUG|Empagliflozin|Administered as oral tablets.
219123150|NCT06083675|DRUG|Metformin|Administered as oral tablets.
219123151|NCT03580720|OTHER|Inspiratory threshold loading protocol|Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
219123152|NCT05573919|DEVICE|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
219123153|NCT02346487|DRUG|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day"
219123154|NCT00429793|DRUG|temsirolimus|Given IV
219123155|NCT00403988|DRUG|Oxaliplatin|
219123156|NCT00403988|DRUG|vinorelbine|
219123157|NCT05375565|OTHER|weight bearing exercises|"* Standing knee raise 10 rep x 2sets~* Standing knee bend 10 rep x 2sets~* Standing hip extension 10 rep x 2sets~* Shallow squats 5 rep x 2 sets After 4 week gradually restricting the use of assistive device when patient become able to walk and stand for 10 mins then add stair climbing and descending with a step height not higher than 7 inch.~The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
219123158|NCT05375565|OTHER|non weight bearing exercises|"* Seated knee flexion 10 rep x 2sets~* Seated knee extension 10 rep x2sets~* Use of stationary bicycle 10 mins~* Side lying leg lift 10 rep x2sets~* Straight leg raise 10 rep x 2sets The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
219706910|NCT06244160|OTHER|High flow oxygen therapy|High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
219706911|NCT04761822|BIOLOGICAL|Moderna COVID-19 Vaccine|Intramuscular injection
219706912|NCT04761822|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
219706913|NCT04761822|BIOLOGICAL|Placebo|Intramuscular injection
219706914|NCT05231668|DRUG|SAR439459|Powder for solution for infusion; IV infusion
219706915|NCT05231668|DRUG|Placebo|Solution for infusion; IV infusion
219706916|NCT04570410|PROCEDURE|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
219706917|NCT04570410|DRUG|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
219123159|NCT01667120|DRUG|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
219123160|NCT01667120|DRUG|placebo|0.9% normal saline 1ml/kg
219123161|NCT03754738|DEVICE|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
219123162|NCT03754738|DEVICE|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
219123163|NCT00831246|OTHER|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
219123164|NCT00831246|OTHER|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
219123165|NCT05185700|BEHAVIORAL|post covid 19 symtoms|observation
219706918|NCT04570410|DRUG|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
219706919|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection(LILRB4 dual STAR-T Cell Injection/BCMA LILRB4 Dual STAR-T Cell Injection)) is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
219706920|NCT04598113|DEVICE|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
219706921|NCT04864054|BIOLOGICAL|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
219706922|NCT04864054|DRUG|Regorafenib (STIVARGA®, BAY73-4506)|Regorafenib pretreatment before an ECT204 infusion.
219706923|NCT04646434|PROCEDURE|Electroencephalography|Undergo EEG
219706924|NCT04646434|PROCEDURE|Electromyography|Undergo EMG
219123166|NCT00052559|BIOLOGICAL|bevacizumab|Given IV
219123167|NCT00052559|DRUG|fluorouracil|Given IV
219123168|NCT00052559|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
219123169|NCT00052559|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219123170|NCT00052559|OTHER|laboratory biomarker analysis|Correlative studies
219706925|NCT04646434|OTHER|Questionnaire Administration|Complete questionnaire
219706926|NCT04646434|PROCEDURE|Urodynamics (UDS)|Undergo UDS
219706927|NCT06531109|DRUG|Ritlecitinib|As provided in the real world practice.
219706928|NCT04521296|OTHER|Part 1|\- DWJ1248 600mg PO (100mg 2 tab, TID)
219706929|NCT04521296|OTHER|Part 2|\- DWJ1248 600mg PO (200mg 1 tab, TID)
219706930|NCT04865705|DRUG|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
219706931|NCT06021522|DRUG|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
219123171|NCT02663258|DRUG|Pembrolizumab|
219123172|NCT05823779|OTHER|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
219123173|NCT06089876|BEHAVIORAL|STRAVA mobile application|The adolescents in the intervention group will use the STRAVA mobile application for a period of 10 weeks. To do so, they will follow the instructions provided by the researchers on the frequency of use, the distance to be covered and how to record it.
219123174|NCT01641861|DEVICE|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
219123175|NCT01641861|PROCEDURE|Conventional method|caries removal by using rotary instrument.
219706932|NCT05658237|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
219706933|NCT03991143|DRUG|ATH3G10|intravenous
219706934|NCT03991143|DRUG|Placebo|intravenous
219123176|NCT04858789|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
219123177|NCT03174964|DRUG|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
219123178|NCT04125017|DEVICE|ICSI with laser pulse|Using laser pulse before ICSI
219706935|NCT01908244|OTHER|Music|Pentatonic music
219123179|NCT04125017|DEVICE|ICSI with micro needle technique|Using micro needle technique before ICSI
219123180|NCT06031662|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT
219123181|NCT06031662|DEVICE|Sham Intermittent Theta-Burst Stimulation|Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
219123182|NCT04248075|DEVICE|Electroencephalogram|Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
219123183|NCT02914106|OTHER|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
219123184|NCT05162768|DRUG|Elamipretide|60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
219706936|NCT04451538|DIETARY_SUPPLEMENT|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoons, 440 kcal\]/day, twice a day).
219706937|NCT04451538|DIETARY_SUPPLEMENT|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
219706938|NCT05611801|DRUG|marstacimab|marstacimab
219706939|NCT06087211|DRUG|Magnesium sulphate and Duloxetine|Patients received Duloxetine 30mg orally and an intravenous infusion of magnesium sulphate 50mg/kg mixed with 200 ml of normal saline.
219706940|NCT06087211|DRUG|Duloxetine|Patients received Duloxetine 30mg orally and 200 ml of normal saline.
219706941|NCT06087211|DRUG|Placebo and normal saline|Patients received a placebo capsule and an intravenous infusion of 200 mL of normal saline.
219706942|NCT05978323|BEHAVIORAL|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
219706943|NCT02534480|DRUG|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
219123185|NCT05162768|DRUG|Placebo|Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
219123186|NCT05002361|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
219123187|NCT05002361|DRUG|Isotonic saline|6 ml of isotonic saline
219123188|NCT03230929|DEVICE|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
219123189|NCT05168865|DRUG|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
219123190|NCT02173353|DEVICE|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
219123191|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
219123192|NCT06697470|DEVICE|Ultrasound and Bioelectrical Impedance Analysis for Muscle Thickness and Fluid Balance Assessment Translation|This intervention involves the use of ultrasound and bioelectrical impedance analysis (BIA) to monitor changes in muscle thickness and assess fluid balance in critically ill patients. Measurements will be taken daily during the patients' ICU stay, with a focus on rectus femoris, tibialis anterior, and biceps brachii muscles, as well as total body fluid compartments. The study aims to explore correlations between muscle thickness variations, fluid balance, and patient outcomes.
219123193|NCT06919549|PROCEDURE|mini anchor|arthroscopic repair of triangular fibrocartilage complex tears using mini anchor
219706944|NCT05149105|PROCEDURE|Argon plasma coagulation|On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
219123194|NCT06918769|DIAGNOSTIC_TEST|Sysmex UF-5000 system|Provide real time bacterial count in urine samples and Gram-staining results. High bacterial count suggests likelihood of active UTI and indicated for antibiotics treatment; while low bacterial count suggests UTI not likely.
219123195|NCT06918769|DRUG|Empirical antibiotics|Empirical antibiotics per local guideline/ investigator's discretion for urinary tract infection
219123196|NCT06919978|BEHAVIORAL|The Position to Prevent Pleural Irritation (PPPI)|The Position to Prevent Pleural Irritation (PPPI) was administered once before sleep on the first night of the day the participant arrived at the clinic.
219706945|NCT05413941|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
219706946|NCT04476043|DRUG|INCB054707|Oral; Tablet
219706947|NCT04476043|DRUG|Placebo|Oral; Tablet
219706948|NCT00211367|DRUG|Anecortave Acetate|
219123197|NCT02239653|BEHAVIORAL|Physician communication|
219706949|NCT05296278|DRUG|IBI-323 combined with bevacizumab plus Platinum|IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
219706950|NCT06215911|DRUG|Tovinontrine (CRD-750)|Tablets administered orally
219706951|NCT06215911|DRUG|Placebo|Tablets administered orally
219706952|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
219706953|NCT03170297|OTHER|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
219706954|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma|"* Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
219123198|NCT04722224|OTHER|Home-based pulmonary rehabilitation|The reabilitAR program includes the self-management educational program Living Well with COPD. The exercise training will include endurance, resistance/strength, flexibility and balance training.
219123199|NCT03511989|DEVICE|Bone borne distractor|Bone borne distraction device
219123200|NCT03511989|DEVICE|Tooth borne distractor|Tooth borne distraction device
219123201|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 1|
219123202|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 2|
219123203|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 3|
219123204|NCT03049982|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
219123205|NCT01427387|DRUG|ASP0456|oral
219123206|NCT01427387|DRUG|Placebo|oral
219123207|NCT05104762|DEVICE|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
219123208|NCT05104762|DRUG|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
219123209|NCT06522672|DIETARY_SUPPLEMENT|My Happy Flo|The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.
219123210|NCT05177081|DEVICE|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
219123211|NCT02522520|BEHAVIORAL|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
219123212|NCT02522520|BEHAVIORAL|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
219123213|NCT02522520|DEVICE|Omron Walking Style pro. 20|
219123214|NCT04650347|PROCEDURE|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
219123215|NCT06395363|PROCEDURE|fixation method|The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
219123216|NCT05879640|BEHAVIORAL|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
219123217|NCT00465361|PROCEDURE|performance feedback with an educational module|individual performance feedback with an educational module
219123218|NCT06755710|BEHAVIORAL|Introductory PTSD module|The Introductory PTSD module consist of four session focusing on motivation
219123219|NCT06755710|BEHAVIORAL|Shared Decision Making|A patient-centred shared decision making session where one of four standardised treatments can be chosen
219123220|NCT06755710|BEHAVIORAL|Treatment as Usual|Treatment as usual
219123221|NCT06755710|BEHAVIORAL|Standardised treatments|One of four treatments Treatment as ususal Sessions with psychologists Sessions with nurses Sessions with medical doctors
219123222|NCT03596424|DRUG|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
219123223|NCT03596424|DRUG|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
219123224|NCT03596424|COMBINATION_PRODUCT|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
219123225|NCT05406791|OTHER|VIRA App|Support from coach and using the VIRA app
219706955|NCT06217380|DEVICE|Masimo SafetyNet Alert (MSNA)|This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.
219706956|NCT04539236|DRUG|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
219706957|NCT04539236|DRUG|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
219123226|NCT05406791|OTHER|Mood Education App|Support from mood education app
219123227|NCT03674593|PROCEDURE|Mitral valve chordae prosthesis|"The method consists of five stages:~1. Measure the required length of the chords~2. Forming loops~3. Fixation of the loop group to the papillary muscles~4. Fixation of chordal loops to the free edge of the valve~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
219123228|NCT03674593|PROCEDURE|Mitral valve chordae translocation|"The method consists essentially of three stages:~1. Selection of the secondary chord.~2. Fixation of secondary chords to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
219123229|NCT06796049|BEHAVIORAL|Information pamphlet + social norm driver|"The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 Colorectal cancer (CRC) screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.~The information pamphlet will also contain a social norm driver that displays the sub-par screening rate the clinic compared to a collective New York State screening rate and a national screening rate goal set by the CDC."
219123230|NCT06796049|BEHAVIORAL|Information pamphlet|The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 CRC screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.
219123231|NCT03927365|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
219706958|NCT04109963|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
219706959|NCT05539170|BEHAVIORAL|Immediate positive parenting feedback|Individual positive feedback concerning their parenting and their child's behavior.
219706960|NCT06582524|DRUG|Pegzilarginase|SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
219706961|NCT03054896|DRUG|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
219706962|NCT03054896|OTHER|DA-EPOCH-R|Intensive chemotherapy regiment
219706963|NCT03054896|OTHER|R-CHOP|Intensive chemotherapy regiment
219706964|NCT04848961|BEHAVIORAL|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
219123232|NCT05836662|OTHER|CrashCourse Concussion Education in Virtual Reality|The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
219123233|NCT06527105|DEVICE|Eye masks and ear plugs|Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
219123234|NCT05825820|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
219123235|NCT01289704|OTHER|TreSPE|"1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
219123236|NCT01289704|OTHER|SPE|"1. Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~2. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~3. Proprioceptive and postural kinesitherapy according to the neurocognitive method.~4. Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
219123237|NCT01189253|DRUG|doxorubicin hydrochloride|
219123238|NCT01189253|DRUG|trabectedin|
219123239|NCT01189253|OTHER|laboratory biomarker analysis|
219123240|NCT01189253|PROCEDURE|quality-of-life assessment|
219123241|NCT04502719|DIAGNOSTIC_TEST|Nutritional screening.|Nutritional screening with the RFH-NPT and LDUST questionnaires.
219123242|NCT02144324|DEVICE|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
219123243|NCT01561690|DRUG|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
219123244|NCT01561690|DRUG|Placebo; oral|matching placebo
219706965|NCT02912312|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
219123245|NCT03232177|DRUG|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
219123246|NCT05640921|BEHAVIORAL|Gi-CBT|Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
219123247|NCT05640921|OTHER|Media Orientation|The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
219706966|NCT02912312|OTHER|Laboratory Biomarker Analysis|Correlative studies
219706967|NCT02912312|OTHER|Quality-of-Life Assessment|Ancillary studies
219706968|NCT02912312|OTHER|Questionnaire Administration|Ancillary studies
219706969|NCT02912312|RADIATION|Radiation Therapy|Undergo standard RNI
219123248|NCT03861728|DEVICE|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
219123249|NCT03861728|OTHER|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
219123250|NCT02652130|BIOLOGICAL|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
219123251|NCT00354029|DRUG|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
219123252|NCT00354029|DRUG|Placebo|isotonic saline
219123253|NCT00826280|DRUG|regadenoson|IV
219123254|NCT00826280|DRUG|overencapsulated caffeine|oral
219123255|NCT00826280|RADIATION|technetium|IV
219123256|NCT00826280|DRUG|placebo|oral
219706970|NCT00005584|BIOLOGICAL|bleomycin sulfate|
219706971|NCT00005584|DRUG|ABVD regimen|
219706972|NCT00005584|DRUG|BEACOPP regimen|
219706973|NCT00005584|DRUG|epirubicin hydrochloride|
219706974|NCT00005584|DRUG|prednisone|
219706975|NCT00005584|DRUG|vinblastine sulfate|
219706976|NCT00005584|RADIATION|radiation therapy|
219706977|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
219123257|NCT03831438|DRUG|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
219123258|NCT03201757|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
219123259|NCT05098600|OTHER|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
219123260|NCT06022809|BEHAVIORAL|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
219123261|NCT06022809|BEHAVIORAL|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
219123262|NCT01424163|DRUG|Single dose reduced|Treatment 1 (Part A)
219123263|NCT01424163|DRUG|Single dose standard|Treatment 2 (Part A)
219123264|NCT01424163|DRUG|Multiple Dose|Treatment 3 (Part A)
219123265|NCT01424163|DRUG|Multiple Dose|Part B
219123266|NCT06418373|BEHAVIORAL|Get Ready with My Heart Program|"In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program."
219123267|NCT06418373|BEHAVIORAL|Conventional intervention|Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
219123268|NCT05578924|OTHER|" women group "|women aged more than 18 years old
219123269|NCT02297503|DRUG|Azzalure|Glabellar lines
219123270|NCT02297503|DEVICE|Restylane/Emervel filler|Facial tissue augmentation
219123271|NCT02297503|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
219123272|NCT00203138|DRUG|rasagiline mesylate|
219123273|NCT00809432|DEVICE|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
219123274|NCT00809432|OTHER|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
219123275|NCT00351221|DRUG|rhIGF-1/rhIGFBP-3|
219123276|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules150mg oral administration, BIW in every 28d
219706978|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
219123277|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 200mg oral administration, BIW in every 28d
219123278|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 250mg oral administration, BIW in every 28d
219123279|NCT02021461|DRUG|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
219123280|NCT02021461|DRUG|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
219123281|NCT02021461|DRUG|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
219123282|NCT00353054|DRUG|Caltrate® 600 + D|
219123283|NCT00353054|BEHAVIORAL|Weight loss intervention|
219123284|NCT00105885|PROCEDURE|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
219123285|NCT06148259|OTHER|International prostate symptom score|Questionnaire of 8 questions to be administered to all patients about prostate symptoms
219123286|NCT06148259|DIAGNOSTIC_TEST|Assessment of prostate volume|Measurements using ultrasound
219123287|NCT06148259|OTHER|Pittsburgh sleep quality Index|Questionnaire to assess quality of sleep
219123288|NCT06148259|DIAGNOSTIC_TEST|Glycated hemoglobin|Measures control of diabetes
219123289|NCT03941301|DEVICE|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
219123290|NCT05470062|DEVICE|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
219123291|NCT06283602|DIAGNOSTIC_TEST|oral health status|the dentists examined the dried teeth with a probe and mount mirror in a dental unit.
219123292|NCT02263885|DEVICE|ExAblate Transcranial System|Transcranial MRgFUS
219123293|NCT02402972|DRUG|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
219123294|NCT02402972|DRUG|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
219123295|NCT02695043|BEHAVIORAL|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
219123296|NCT02695043|BEHAVIORAL|Multimedia Multicultural Educational Program for TBI (MMEPT)|
219123297|NCT01724203|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
219123298|NCT01724203|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
219123299|NCT01724203|DIETARY_SUPPLEMENT|Placebo|
219706979|NCT04661904|DEVICE|Continuous theta burst stimulation (cTBS)|Our active treatment consisted of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group received 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1and 2, respectively.
219706980|NCT04661904|DEVICE|Sham stimulation|The sham stimulation group received a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 3 days) with the coil set at 90 against the skull. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1 and 2, respectively.
219706981|NCT06529159|PROCEDURE|HEAPE|The stomach is filled with sodium chloride solution which is then treated with APC to activate it into an antibacterial solution.
219706982|NCT06529159|PROCEDURE|Pre-HEAPE|Plasma activated sodium chloride solution (prepared outside of the body) is administered into the patients stomach through an endoscope channel using a syringe.
219123300|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
219123301|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
219123302|NCT06297980|OTHER|Personalized modifications to treatment to address menstrual cycle effects on glycemia|The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
219123303|NCT05708820|BEHAVIORAL|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
219123304|NCT05708820|BEHAVIORAL|Standard education programme|Face-to-face educacion programme in a group session
219123305|NCT03659487|PROCEDURE|Nissen|Laparoscopic total (Nissen) fundoplication
219123306|NCT03659487|PROCEDURE|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
219123307|NCT01813955|DRUG|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
219123308|NCT05113589|DEVICE|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
219123309|NCT05113589|DEVICE|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
219123310|NCT00821925|PROCEDURE|bone densitometry|All patients do a bone densitometry after the inclusion.
219123311|NCT01444066|PROCEDURE|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
219123312|NCT04816682|DRUG|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
219123313|NCT03664661|DRUG|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
219123314|NCT00112723|DRUG|alvocidib|Given IV
219123315|NCT04975581|BIOLOGICAL|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
219123316|NCT05121155|DEVICE|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak \[TTP\] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care\[B4c\]). Intracranial hypertension was defined as an invasively measured ICP \> 20 mmHg for at least five minutes
219706983|NCT05581030|DRUG|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
219123317|NCT06055907|DIAGNOSTIC_TEST|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
219123318|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
219123319|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
219123320|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
219123321|NCT02205879|DRUG|Pregabalin|
219123322|NCT02205879|DRUG|Placebo|
219706984|NCT05581030|DRUG|Calaspargase Pegol|Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
219706985|NCT05581030|DRUG|Rituximab|Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
219706986|NCT06257550|BEHAVIORAL|THRIVE Intervention|"THRIVE Intervention includes:~1. Weekly Pulse Surveys~2. Adaptive culturally tailored messages~3. Personalized Dietitian Coaching~4. Produce Prescription FARMacy Mobile Market~5. Linkages to Social Services"
219706987|NCT06257550|BEHAVIORAL|Active Comparator|The Active Comparator arm will receive standard produce bags through our food is medicine partner, and will receive the linkages to needed social and health resources intervention components.
219706988|NCT06506344|BEHAVIORAL|5S Trial|Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.
219706989|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
219706990|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
219225746|NCT04320914|OTHER|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
219225747|NCT04320914|OTHER|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
219225748|NCT02634307|DRUG|ALKS 8700|Administered as specified in the treatment arm.
219706991|NCT06438211|PROCEDURE|superficial or deep serratus anterior plane block for mastectomy|group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy
219706992|NCT06645041|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
219706993|NCT06645041|DIETARY_SUPPLEMENT|Placebo Capsule(s)|The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
219706994|NCT06295250|BEHAVIORAL|Manualized Group Based Psychotherapy|Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.
219706995|NCT06295250|OTHER|Poverty Alleviation|Modeled on the well-known Graduation Program, a poverty alleviation strategy widely used in low income countries, this intervention includes an asset transfer (agricultural animals), financial literacy education, a 6 month stipend, savings accounts, veterinary support, feed, and agricultural training
219225749|NCT02698475|DRUG|Ustekinumab 0.75 mg/kg|Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
219225750|NCT02698475|DRUG|Ustekinumab 45 mg|Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
219706996|NCT06323954|PROCEDURE|tVNS stimulation|Electrical stimulation to the vagus nerve area.
219706997|NCT06323954|PROCEDURE|Sham stimulation|Electrical stimulation to the non-vagus nerve area.
219706998|NCT03991169|DRUG|Ferrous Sulfate|Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
219706999|NCT04232631|DEVICE|SnapshotNIR, Kent Imaging|Vascular imaging device
219707000|NCT06958380|BEHAVIORAL|Corrective exercise and rehabilitation|This is a longitudinal single-subject case study in which one adult patient diagnosed with Fanconi anemia will undergo a structured, supervised corrective exercise and rehabilitation program. The subject will serve as their own control, with baseline measurements compared to post-intervention outcomes.
219707001|NCT03143452|DRUG|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
219707002|NCT03143452|DRUG|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
219707003|NCT00634517|DRUG|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
219707004|NCT00634517|DRUG|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
218985903|NCT03473171|DEVICE|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
218985904|NCT01347229|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
218985905|NCT04396301|DRUG|Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).|Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
219707005|NCT02517749|DEVICE|Chest Drain Insertion and Talc Pleurodesis|
218985906|NCT03992014|DRUG|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
219707006|NCT02517749|DEVICE|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
219707007|NCT05106907|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
219707008|NCT05129696|BEHAVIORAL|Treatment (T)|Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
219123323|NCT03074981|DEVICE|Combined TopClosure & Vcare Alpha|"Combined TopClosure \& Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
219123324|NCT00825474|OTHER|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
219123325|NCT04215744|BEHAVIORAL|Ice water immersion|Ice water immersion of the left hands
219123326|NCT03706963|OTHER|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
219123327|NCT02536690|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
219123328|NCT02536690|DRUG|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
219123329|NCT02536690|DRUG|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
219123330|NCT04961216|BEHAVIORAL|OPTIMISE|Self-regulation intervention
219123331|NCT02438774|BEHAVIORAL|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
219123332|NCT02438774|BEHAVIORAL|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
219123333|NCT01472627|PROCEDURE|Blood draws|Blood draws
219123334|NCT04488172|DIETARY_SUPPLEMENT|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
219123335|NCT01203241|PROCEDURE|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
219123336|NCT01203241|PROCEDURE|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
219123337|NCT04871087|DEVICE|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
219123338|NCT05439265|OTHER|Electronic medical record order panel and resident involvement|Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
219123339|NCT04943835|OTHER|Observational - No intervention|
219123340|NCT05265988|DRUG|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
219123341|NCT00157053|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
219123342|NCT01822158|OTHER|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
219707009|NCT05129696|BEHAVIORAL|Treatment + (T+)|Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
219707010|NCT02549118|DRUG|Tenoxicam|
219707011|NCT02549118|DRUG|Pethidine|
219707012|NCT01408472|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
219707013|NCT03112538|DEVICE|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
219707014|NCT03112538|DRUG|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
219707015|NCT05453721|PROCEDURE|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
219123343|NCT04901728|BEHAVIORAL|Cultural Domain Analysis|80 and up to a maximum of 120 participants
219123344|NCT04901728|BEHAVIORAL|Focus Group Discussion|At least 18 and up to a maximum of 60 participants
219123345|NCT04901728|BEHAVIORAL|In-depth interview|At least 18 and up to a maximum of 36 participants
219123346|NCT00568347|DRUG|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
219123347|NCT00568347|DRUG|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
219123348|NCT00568347|DRUG|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
219123349|NCT00568347|DRUG|Salmeterol|salmeterol 50mcg bid X 3months
219123350|NCT00568347|DRUG|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
219123351|NCT03717545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb"
219123352|NCT05971641|OTHER|progressive relaxation exercise|Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
219123353|NCT01427907|DRUG|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
219123354|NCT01427907|DRUG|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
219225751|NCT02698475|DRUG|Ustekinumab 90 mg|Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
219707016|NCT05453721|PROCEDURE|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
219707017|NCT05812404|DRUG|DWP14012|Potassium-competitive acid blocker
219707018|NCT05812404|DRUG|DWC202201|Atorvastatin Calcium Trihydrate
219707019|NCT05322486|PROCEDURE|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
219707020|NCT05322486|DRUG|chemotherapy|Chemotherapy with or without biological drugs.
219707021|NCT02385318|DRUG|Ingenol Mebutate (Perrigo)|
219707022|NCT02385318|DRUG|Ingenol Mebutate (Reference)|
219707023|NCT02385318|DRUG|Placebo gel|
219707024|NCT05683067|OTHER|Hand Held Capillary Microscopy|The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.
219707025|NCT05683067|OTHER|Mobile 'O' Graph|The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.
219707026|NCT05683067|OTHER|quality of life using questionnaires|The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
219707027|NCT01080261|DEVICE|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
219707028|NCT00004497|DRUG|UT-15|
219707029|NCT05668455|DRUG|Hydrocortisone|1 drops 4 times a day
219707030|NCT05668455|DRUG|Dexamethasone|1 drops 4 times a day
219707031|NCT05668455|OTHER|Povidone|1 drops 4 times a day
219707032|NCT05080491|DIAGNOSTIC_TEST|immuno analysis and neuropsychological tests|"A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London)."
219707033|NCT03023501|DRUG|Gabapentin|
219707034|NCT03023501|DRUG|Placebo Oral Capsule|
219707035|NCT04146701|OTHER|Blood draw|venous blood withdraw (ca. 40ml)
219707036|NCT01409473|RADIATION|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
219707037|NCT03773588|DEVICE|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
219123355|NCT02377219|OTHER|hormonal and blood analysis|
219123356|NCT03676556|DRUG|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
219123357|NCT03676556|DRUG|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
219123358|NCT00502281|DRUG|highly purified urinary FSH|
219123359|NCT00502281|BEHAVIORAL|timed intercourses, intrauterine insemination|
219123360|NCT03628079|DRUG|ReposMBZ|Capsules 50mg, 100mg, 200mg
219707038|NCT03773588|DEVICE|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
219707039|NCT03245606|PROCEDURE|Liver biopsy|Measurement of liver fibrosis
219707040|NCT03245606|DEVICE|Abdominal MRI|Measurement of liver fibrosis
219707041|NCT03245606|DEVICE|Transient elastography|Measurement of liver fibrosis
219707042|NCT02594111|DRUG|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
219707043|NCT05926921|OTHER|music|Brahms' Lullaby will be played from a speaker at 50 decibels
219123361|NCT05864768|DIETARY_SUPPLEMENT|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
219123362|NCT05864768|DIETARY_SUPPLEMENT|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
219123363|NCT04361747|BEHAVIORAL|nursing counseling|The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
219123364|NCT01442168|DRUG|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
219123365|NCT01442168|DRUG|atovaquone/proquanil|malanil according to label
219123366|NCT01668342|BEHAVIORAL|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
219123367|NCT04994262|OTHER|Menthol Lozenge|"In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant."
219123368|NCT00684502|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
219123369|NCT00684502|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
219123370|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
219123371|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
219123372|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
219123373|NCT01663337|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
219123374|NCT01663337|BEHAVIORAL|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
219707044|NCT04132713|DRUG|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
219707045|NCT01241929|BEHAVIORAL|video decision aid|video of CPR
219707046|NCT01963611|DRUG|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
219707047|NCT01963611|DRUG|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
219707048|NCT01963611|DRUG|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
219707049|NCT01963611|DRUG|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
219707050|NCT01963611|DRUG|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
219707051|NCT00750334|DRUG|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
219707052|NCT00750334|DRUG|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
219707053|NCT01318434|DRUG|EB-1010 25mg BID|capsule once daily
219707054|NCT01318434|DRUG|SSRI Active|Active Comparator
219707055|NCT01318434|DRUG|EB-1010 50mg BID|Experimental Active
219707056|NCT01318434|DRUG|Placebo|Placebo comparator
219707057|NCT03526705|DEVICE|NB-UVB|Phototherapy
219707058|NCT04791176|RADIATION|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
219707059|NCT01759927|BEHAVIORAL|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
219707060|NCT02580656|BEHAVIORAL|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
219707061|NCT04700943|PROCEDURE|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
219707062|NCT01126424|DRUG|Solifenacin|tablet
219707063|NCT01126424|DRUG|Oxybutynin|capsule
219707064|NCT01126424|DRUG|Placebo|tablet
219707065|NCT05090254|OTHER|Treatment algorithms targeting cardiac output|Treatment algorithms targeting maximization or personalization of cardiac output
219707066|NCT05627596|BEHAVIORAL|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
219707067|NCT05627596|DRUG|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
219707068|NCT05627596|DRUG|Nicotine lozenge|4mg nicotine lozenge
219707069|NCT05970458|OTHER|Quality of life assessment|EQ5D-5L and Stoma QoL
219707070|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
219707071|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
219707072|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
219707073|NCT02425553|OTHER|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
219707074|NCT02425553|OTHER|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
219707075|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
219707076|NCT02429466|DRUG|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
219707077|NCT04292951|PROCEDURE|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
219707078|NCT03478280|DRUG|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
219707079|NCT03478280|DRUG|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
219707080|NCT04013464|DRUG|Escitalopram|Escitalopram 10-20mg/d
219707081|NCT00248560|DRUG|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
219707082|NCT00248560|DRUG|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
219707083|NCT01462604|OTHER|non-drug intervention educational programme|educational programme
219707084|NCT03782597|BEHAVIORAL|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
219707085|NCT03336970|OTHER|EDTA|
219707086|NCT03336970|OTHER|NaOCl|
219707087|NCT03336970|OTHER|CHX|
219707088|NCT03336970|OTHER|Calcium hydroxide|
219707089|NCT00200382|DRUG|PS-341 (Velcade-drug)|
219707090|NCT06302036|OTHER|EFT|EFT
219707091|NCT03801252|DRUG|Cefazolin|intravenous drugs used as prophylactic antibiotics
219707092|NCT03801252|DRUG|Placebo|Intravenous saline
219707093|NCT03801252|DRUG|Azithromycin|prophylactic antibiotic
219707094|NCT04356651|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, physician will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin from anterior superior iliac spine(ASIS) to 1/3 superior border of patella. Then the physician will push forward the needle parallel to the skin surface. The physician will sway the needle 45 times in 30 seconds. After swaying the needle, the physician will instruct the subject to do sole dorsiflexion for 10 seconds resisting the physician's opposite force, then the subject take a rest for 10 seconds. The above actions are 3 repetitions. Then the subject do knee flexion and extension for 10 seconds, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the physician will take out the needle to finish the treatment.
219123375|NCT00815321|BIOLOGICAL|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
219123376|NCT04036240|OTHER|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
219123377|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 150mg|leaves of the mango food plant
219225752|NCT03876184|OTHER|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
219707095|NCT04356651|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction.
219707096|NCT01134042|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
219707097|NCT01134042|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
219707098|NCT01134042|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
219707099|NCT01134042|OTHER|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
219707100|NCT01134042|OTHER|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
219707101|NCT06541015|DEVICE|InTENSity 10 TENS Stimulator|InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
219707102|NCT04085016|DEVICE|Keratograph 5M, Oculus, Wetzlar, Germany|
219707103|NCT05525468|DRUG|TDM-180935|TDM-180935 topical ointment
219707104|NCT05525468|DRUG|Placebo|Placebo for TDM-180935 topical ointment
219707105|NCT01060488|OTHER|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
219707106|NCT01060488|OTHER|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
219707107|NCT04208932|DRUG|SSRIs|Selective Serotonin Reuptake Inhibitors
219707108|NCT00393367|DRUG|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
219123378|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 300mg|leaves of the mango food plant
219123379|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 600mg|leaves of the mango food plant
219123380|NCT05580146|DIETARY_SUPPLEMENT|Placebo|Sunflower oil matched for appearance
219123381|NCT04864561|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
219123382|NCT04864561|BIOLOGICAL|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
219123383|NCT04864561|BIOLOGICAL|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
219123384|NCT04864561|BIOLOGICAL|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
219707109|NCT00393367|DRUG|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
219707110|NCT00393367|DRUG|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
219707111|NCT00393367|DRUG|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
219707112|NCT05330949|DIAGNOSTIC_TEST|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
219123385|NCT01571921|DIETARY_SUPPLEMENT|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
219707113|NCT03286504|BEHAVIORAL|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
219707114|NCT06109740|DIETARY_SUPPLEMENT|lactobacillus GG|probiotic
219707115|NCT05708664|PROCEDURE|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
219707116|NCT01459926|DRUG|TD-1211|once daily
219707117|NCT01459926|DRUG|TD-1211|Once daily
219707118|NCT01459926|DRUG|TD-1211|Once daily
219707119|NCT01459926|DRUG|Placebo|Once daily
219707120|NCT06060366|PROCEDURE|Pulmonary endarterectomy|removal of chronic thrombus from pulmonary arterial system
219707121|NCT01965795|DIETARY_SUPPLEMENT|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
219707122|NCT01965795|DIETARY_SUPPLEMENT|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
219707123|NCT01432327|DEVICE|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
219707124|NCT01432327|DEVICE|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
219707125|NCT01432327|DEVICE|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
219707126|NCT01432327|BEHAVIORAL|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
219123386|NCT02392338|PROCEDURE|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
219123387|NCT05892575|BEHAVIORAL|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
219707127|NCT04729712|PROCEDURE|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
219707128|NCT04729712|PROCEDURE|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
219707129|NCT04706221|DEVICE|CM-1500|Blood volume monitor CM-1500
219707130|NCT05231967|OTHER|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
219123388|NCT02388555|PROCEDURE|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
219123389|NCT05215652|OTHER|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~* an electronic monitoring device,~* data management and data analysis,~* feedback on patient's performance,~* clinical-pharmaceutical evaluation of medication adherence,~* transmission of an adherence report."
219123390|NCT03690856|OTHER|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
219123391|NCT04268563|DRUG|placebo|Oral rehydration solution
219123392|NCT04268563|DRUG|metformin|metformin tablet
219123393|NCT04268563|DRUG|Sitagliptin|Sitagliptin tablet
219123394|NCT04268563|DRUG|Sitagliptin/metformin|Sitagliptin/metformin tablet
219707131|NCT02497014|DEVICE|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
219707132|NCT02497014|DEVICE|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
219707133|NCT05791110|DIAGNOSTIC_TEST|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
219707134|NCT01255020|DRUG|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
219707135|NCT01255020|DRUG|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
219707136|NCT05608863|OTHER|Lifestyle - group sessions|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
219707137|NCT05608863|OTHER|Lifestyle - individual coaching|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
219707138|NCT06843551|RADIATION|Stereotactic Body Radiation Therapy|"The radiation therapy (RT) prescription biologically effective dose (BED10) goal for tumor (α/β=10) aims to achieve at least BED10= 60 Gy for a single fraction plan and at least BED10=100 Gy for a multi-fraction plan. This equates to a prescription dose of at least 20 Gy in a single fraction, 42 Gy over 3 fractions, 50 Gy over 5 fractions, and 62 Gy over 10 fractions.~Radiation therapy must be completed for up to 10 daily treatments within a 15-day course."
219707139|NCT06843551|DRUG|Botensilimab|Participants will be receive 75mg of Botensilimab immunotherapy administered via intravenous infusion, every six weeks for up to 4 doses, about 24 weeks. Botensilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
219707140|NCT06843551|DRUG|Balstilimab|Participants will receive 240mg of Balstilimab immunotherapy, administered via intravenous infusion, every 2 weeks for up to one (1) year. Balstilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
219123395|NCT03813056|DRUG|Glanatec|Rho kinase Inhibitor
219123396|NCT03813056|DRUG|Optive, Ophthalmic Solution|artificial tears (placebo)
219123397|NCT03813056|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
219225753|NCT03876184|OTHER|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
219225754|NCT03263611|DRUG|Placebo|single intradiscal injection
219225755|NCT03263611|DRUG|AMG0103|single intradiscal injection
219225756|NCT01942954|OTHER|Mobile health cognitive stimulation|
219225757|NCT06360276|BEHAVIORAL|Seated Exercises|A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
219123398|NCT02485743|OTHER|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
219123399|NCT02485743|OTHER|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
219123400|NCT02783157|DEVICE|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
219123401|NCT02783157|DEVICE|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
219123402|NCT00239161|DRUG|Levofloxacin|
219123403|NCT01065272|DRUG|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
219123404|NCT01065272|DRUG|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
219123405|NCT03317353|DEVICE|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
219123406|NCT03317353|DEVICE|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
219707141|NCT05849077|OTHER|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
219707142|NCT05849077|OTHER|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
219123407|NCT03317353|OTHER|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
219123408|NCT02873676|BEHAVIORAL|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
219123409|NCT02873676|BEHAVIORAL|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
219707143|NCT05594160|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
219707144|NCT00888082|DRUG|Goserelin acetate|3.6 mg depot injectable preparation
219123410|NCT02873676|BEHAVIORAL|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
219123411|NCT02873676|BEHAVIORAL|control|The intervention involve dietary pattern modification and protein intake standardization
219123412|NCT05930899|OTHER|Genetics|TOmAS is a biobank and all patients will be genotyped
219123413|NCT04617600|DRUG|MTA|Survival rate using MTA in cariously exposed vital primary molars
219123414|NCT04617600|DRUG|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
219123415|NCT02179918|DRUG|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
219123416|NCT02179918|DRUG|MK-3475|2 mg/kg q3wks, IV
219123417|NCT03429387|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET performed with low dose CT
219123418|NCT03429387|DIAGNOSTIC_TEST|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
219123419|NCT04814940|OTHER|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
219123420|NCT05602116|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
219707145|NCT01951066|DRUG|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
219707146|NCT01951066|DRUG|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
219707147|NCT04608864|PROCEDURE|varicocelectomy|microsurgical subinguinal varicocelectomy
219707148|NCT03427281|BEHAVIORAL|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
219123421|NCT02774252|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
219225758|NCT06360276|BEHAVIORAL|Psychoeducational Rehabilitation|Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
219123422|NCT04118699|DRUG|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
219123423|NCT04118699|DRUG|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
219123424|NCT06183918|DRUG|Tranexamic acid|"1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
219123425|NCT06183918|OTHER|Saline|3\. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
219123426|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis and elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.
219123427|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis without elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
219123428|NCT00276250|DRUG|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
219123429|NCT00276250|DRUG|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
219707149|NCT04195412|DEVICE|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
219707150|NCT04195412|DEVICE|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
219707151|NCT00177489|BEHAVIORAL|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
219707152|NCT00177489|OTHER|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
219707153|NCT03881774|BIOLOGICAL|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
219707154|NCT03818568|DIETARY_SUPPLEMENT|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
219707155|NCT02130609|DEVICE|Skintel|
219707156|NCT03316781|DRUG|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
219123430|NCT00276250|DRUG|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
219707157|NCT03316781|DRUG|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
219123431|NCT03189134|DRUG|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
219123432|NCT03189134|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
219123433|NCT06018194|DEVICE|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
219123434|NCT06023550|OTHER|Treatment with surgery and/or conservative measures|Patients will be treated according to established clinical practice with surgery and/or conservative measures.
219707158|NCT05627804|OTHER|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
219707159|NCT05627804|OTHER|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
219707160|NCT05627804|OTHER|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
219707161|NCT05627804|OTHER|Control|No exercise will be performed.
219707162|NCT02030600|DRUG|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
219707163|NCT02030600|DRUG|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
219707164|NCT03272152|GENETIC|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
219707165|NCT01155323|DEVICE|etafilcon A|1-day soft contact lens
219707166|NCT01155323|DEVICE|omafilcon A|1-day soft contact lens
219707167|NCT02250638|OTHER|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
219707168|NCT03953716|DEVICE|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
219707169|NCT03953716|DRUG|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
219707170|NCT03953716|DRUG|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
219707171|NCT03953716|DRUG|Marvelon|Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
219707172|NCT03805139|DIETARY_SUPPLEMENT|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
219707173|NCT04530071|BIOLOGICAL|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10\^7 cells)
219123435|NCT02678052|DRUG|Vedolizumab|Vedolizumab exposure
219123436|NCT02678052|BIOLOGICAL|Other Biological Agent|Other Biological Agent exposure
219123437|NCT05793892|DRUG|Lidocaine tetracaine cream|The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
219707174|NCT04530071|BIOLOGICAL|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10\^7 cells)
219707175|NCT04530071|BIOLOGICAL|Placebo|HA + saline + placebo comparator
219707176|NCT00406237|DRUG|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
219707177|NCT02052635|DRUG|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
219707178|NCT02052635|DRUG|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
219707179|NCT06283017|DEVICE|Hypoglossal nerve stimulation|Device stimulation of the hypoglossal nerve
219707180|NCT04732585|PROCEDURE|Physiotherapy or Surgery|"Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction"
219707181|NCT04440384|OTHER|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
219707182|NCT05466058|DIAGNOSTIC_TEST|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
218985907|NCT03992014|DRUG|[14C]-linerixibat intravenous infusion|\[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
218985908|NCT03992014|DRUG|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
218985909|NCT04224480|DRUG|Pembrolizumab|200mg of intravenous infusion every 3 weeks
218985910|NCT05520112|BIOLOGICAL|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
218985911|NCT05520112|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
218985912|NCT02403856|DRUG|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
218985913|NCT02403856|DRUG|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
218985914|NCT02403856|PROCEDURE|Ultrasound-guided Needling and Lavage|
218985915|NCT03217656|OTHER|No intervention|
218985916|NCT03584178|DEVICE|Budesonide via MAD device|Delivery through Mucosal Atomization Device
218985917|NCT03584178|DEVICE|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
218985918|NCT02569658|DRUG|Tranexamic Acid|
218985919|NCT02569658|DRUG|Placebo|
218985920|NCT05163977|PROCEDURE|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
219123438|NCT04337489|DEVICE|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
219123439|NCT01615627|DRUG|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
219123440|NCT01615627|DRUG|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
219123441|NCT04890132|BEHAVIORAL|VOR precision training|Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.
219123442|NCT04866342|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
219123443|NCT06339112|OTHER|Playing with toy nebulizer|The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the toy nebulizer is introduced to the child. The toy nebulizer is shown to the child as an example and allowed to play, thus reducing the level of fear. Inhaler medication is given through a mask for 10 minutes. Vital signs (pulse) before and after the application. , blood pressure, SPo2, respiration), the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
219707183|NCT05513911|OTHER|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
219707184|NCT05144243|DRUG|Venetoclax|Tablet: Oral
219707185|NCT05144243|DRUG|Azacitidine|Subcutaneous Injection (SC)
219123444|NCT06339112|OTHER|Cartoon|"Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure.~Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher."
219225759|NCT06360276|BEHAVIORAL|Routine Care|Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
219225760|NCT01444365|DRUG|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
219225761|NCT01444365|DRUG|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
219225762|NCT02315014|OTHER|whey protein|whey protein.
219225763|NCT02315014|OTHER|placebo|placebo.
219225764|NCT03528915|OTHER|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
219707186|NCT05675670|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
219707187|NCT05225662|DIAGNOSTIC_TEST|radiofrequency ablation|Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation
219123445|NCT03711838|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
219123446|NCT03711838|DIETARY_SUPPLEMENT|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
219123447|NCT06042985|DRUG|The absorption effect between calcium citrate and calcium carbonate|Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
219123448|NCT02817490|OTHER|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
219123449|NCT06510517|OTHER|Calculation of Mechanical Power.|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
219123450|NCT06510517|OTHER|Measurement Diaphragmatic Excursion after first SBT|Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)
219123451|NCT01719146|OTHER|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
219123452|NCT05465421|OTHER|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
219123453|NCT00974103|OTHER|exercise advise|Exercises
219123454|NCT00974103|OTHER|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
219123455|NCT00972543|BIOLOGICAL|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
219123456|NCT00972543|BIOLOGICAL|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
219123457|NCT03413605|BEHAVIORAL|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
219123458|NCT01888562|DRUG|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
219123459|NCT02981225|DIETARY_SUPPLEMENT|Phytostandard® Rhodiola-Saffron|
219225765|NCT03528915|OTHER|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
219225766|NCT02795741|DEVICE|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
219225767|NCT03528213|DRUG|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
219707188|NCT01622322|DRUG|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
219707189|NCT01622322|OTHER|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
219707190|NCT04067999|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
219707191|NCT03736304|DEVICE|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
219707192|NCT03736304|OTHER|Usual care|Patients will receive standard clinical care by the doctor in charge.
219707193|NCT02619188|OTHER|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
219707194|NCT02619188|OTHER|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
219707195|NCT02619188|OTHER|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
219707196|NCT02619188|OTHER|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
219707197|NCT04029844|DEVICE|Colibri TAVI System|Implantation of Colibri heart valve
219707198|NCT03183206|PROCEDURE|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
219707199|NCT03183206|BIOLOGICAL|γδ T cells|γδ T cells will be used against
219707200|NCT03183206|OTHER|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
219707201|NCT06326047|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219707202|NCT06326047|DRUG|Placebo|Placebo will be administered subcutaneously.
219123460|NCT06140667|DEVICE|LarysealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
219123461|NCT06140667|DEVICE|Ambu Aura Gain|The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: \>100 kg) with maximum suction catheter size of 16 Fr.
219123462|NCT02954718|OTHER|activity training|
219123463|NCT04404140|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
219123464|NCT04404140|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
219123465|NCT04404140|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
219123466|NCT04533217|PROCEDURE|Vertebroplasty|Injection of cement into vertebral lesion(s)
219707203|NCT06326047|DRUG|Trizepatide|Trizepatide will be administered subcutaneously.
219123467|NCT04537949|BIOLOGICAL|BNT162b3|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
219123468|NCT03381014|DRUG|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
219225768|NCT03528213|DRUG|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
219225769|NCT03528213|DRUG|Normal saline|normal saline at physician discretion
219225770|NCT02042703|DEVICE|anterior segment OCT|
219707204|NCT01285544|DRUG|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
219225771|NCT01158248|BIOLOGICAL|panitumumab|
219225772|NCT01158248|DRUG|cisplatin|
219225773|NCT01158248|RADIATION|brachytherapy|
219707205|NCT01285544|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
219707206|NCT00937950|OTHER|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
219707207|NCT03409380|DIETARY_SUPPLEMENT|Arginine Drink|10 g of arginine in a formulated drink
219707208|NCT03409380|DIETARY_SUPPLEMENT|Plain Drink|formulated drink
219707209|NCT00448799|RADIATION|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of \[123I\] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
219707210|NCT04807413|DRUG|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
219123469|NCT04560907|PROCEDURE|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
219123470|NCT04560907|PROCEDURE|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
219123471|NCT01882062|DRUG|Triheptanoin 1g/kg/day|
219123472|NCT04003974|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
219123473|NCT04003974|DRUG|Placebo oral tablet|Placebo will be administered with food when possible
219123474|NCT02705326|DEVICE|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
219123475|NCT02710006|PROCEDURE|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
219123476|NCT04296942|BIOLOGICAL|Brachyury-TRICOM|Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.
219123477|NCT04296942|DRUG|Entinostat|5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
219225774|NCT01158248|RADIATION|external beam radiation therapy|
219707211|NCT04807413|OTHER|standard of care treatment|standard of care treatment
219123478|NCT04296942|BIOLOGICAL|M7824|1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
219123479|NCT04296942|BIOLOGICAL|Ado-trastuzumab emtansine|3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
219123480|NCT00519363|DRUG|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
219123481|NCT02372448|OTHER|ALK analysis on CTCs detected by ISET|
219123482|NCT01680120|PROCEDURE|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
219225775|NCT04580004|OTHER|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
219225776|NCT05537532|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
219707212|NCT04820504|DEVICE|Augmented Infant Resuscitator (AIR)|Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
219707213|NCT04820504|DEVICE|AIR device without feedback|Device provides no visual feedback to clinician but records data on ventilation effectiveness
219707214|NCT03555799|DIAGNOSTIC_TEST|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
219123483|NCT06305507|OTHER|Focussed laser therapy|"Others: Spot laser therapy~Other names:~Spot laser therapy Low Level Laser Therapy (LLLT) - Local Spot~The intervention involves the precise and focused application of low-power laser on specific areas related to plantar fasciitis. The local point technique is characterized by directing the laser directly to the painful point, seeking optimal stimulation in the affected region. This approach allows for targeted delivery of treatment to the area where pain is experienced, with the goal of maximizing the effectiveness of the therapy in reducing the symptoms associated with plantar fasciitis."
219707215|NCT01799694|DRUG|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
219707216|NCT04154956|DRUG|SAR408701|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
219123484|NCT06305507|OTHER|Shower laser therapy|"Laser Therapy Sweeping~The intervention involves constantly moving the low-power laser over the areas affected by plantar fasciitis in a sweeping pattern. The sweeping technique seeks to cover a greater extent of the painful area during each treatment session. This approach differs by providing broader stimulation across the affected area, exploring the possibility of additional benefits compared to the local spot technique."
219707217|NCT04154956|DRUG|Docetaxel|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
219707218|NCT06135038|OTHER|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
219123485|NCT06421974|PROCEDURE|DaVinci si or xi system|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
219225777|NCT05537532|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
219123486|NCT06421974|PROCEDURE|laparoscopic radical resection|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
219123487|NCT04038099|DRUG|Water-Based Vaginal Lubricant|5cc water based jelly applied intraurethral
219123488|NCT04038099|DRUG|lidocaine topical|5cc 2% lidocaine jelly applied intraurethral
219707219|NCT06135038|OTHER|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
219707220|NCT00257530|DRUG|Imiquimod|
219707221|NCT00070525|DRUG|tipifarnib|Given orally
219707222|NCT01586325|DRUG|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
219707223|NCT01586325|DRUG|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
219707224|NCT01586325|DRUG|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
219707225|NCT01586325|DRUG|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
219707226|NCT01344564|DRUG|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
219707227|NCT05079087|PROCEDURE|Pericapsular nerve group blockade|The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.
219707228|NCT05079087|DRUG|Midazolam Ketamine arm|Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
219707229|NCT03791931|DIAGNOSTIC_TEST|oxidative stress measurement|oxidative stress measurement
219123489|NCT05489861|BEHAVIORAL|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
219123490|NCT05489861|BEHAVIORAL|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
219123491|NCT03891680|DRUG|Botox Injectable Product|Intra articular Botox injection
219707230|NCT00310518|DRUG|ARQ 501|
219707231|NCT05959291|OTHER|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
219707232|NCT00805532|BEHAVIORAL|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
219707233|NCT00805532|OTHER|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
219123492|NCT03891680|DEVICE|Radiofrequancy|Genicular nerves radiofrequancy
219123493|NCT04315038|PROCEDURE|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
219225778|NCT05537532|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
219225779|NCT05440240|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
219123494|NCT02336893|BEHAVIORAL|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
219123495|NCT02069587|DIETARY_SUPPLEMENT|pomegranate|
219123496|NCT04487028|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
219123497|NCT02412761|DRUG|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
219123498|NCT02412761|DRUG|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
219123499|NCT02412761|DRUG|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
219123500|NCT04987710|DEVICE|intracranial rescue stenting|use of intracranial rescue stenting as re-perfusion technique after failed thrombectomy
219123501|NCT01220440|DRUG|Methylphenidate|Methylphenidate:10mg x 3 for one week
219123502|NCT01220440|DRUG|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
219123503|NCT01220440|DRUG|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
219123504|NCT02553941|DRUG|Azacitidine|Given intravenous or subcutaneous
219707234|NCT01761188|PROCEDURE|Ablation|electrophysiology substrate mapping is the critical difference between both groups
219707235|NCT00452569|DRUG|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
219707236|NCT00452569|DRUG|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
219707237|NCT01859741|DRUG|OMP-59R5|OMP-59R5 administered intravenously
219707238|NCT01859741|DRUG|Etoposide|administered intravenously
219707239|NCT01859741|DRUG|Placebo|administered IV
219707240|NCT01859741|DRUG|Cisplatin or Carboplatin|administered intravenously
219707241|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
219707242|NCT03974906|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
219123505|NCT02553941|DRUG|Ibrutinib|Given by mouth once daily
219123506|NCT05992155|DRUG|TAK-279|TAK-279 capsules.
219123507|NCT00688961|DRUG|Aspirin|generic aspirin
219123508|NCT00688961|DRUG|omega-3 acid ethyl esters|4, 1 g capsules q.d.
219123509|NCT03195582|DRUG|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
219123510|NCT00347867|DRUG|Viagra administration in IUGR/PET pregnancies|
219123511|NCT06108492|DRUG|SHR-2005|"In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy."
219123512|NCT02240680|DRUG|placebo|placebo matching linagliptin 5 mg
219123513|NCT02240680|DRUG|linagliptin|5 mg once a day
219123514|NCT05700708|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
219225780|NCT05440240|DRUG|Corticosteroid injection|Depo-Medrol
219123515|NCT05575843|OTHER|Neurostatus-SMARTCARE|The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.
219707243|NCT03988647|DRUG|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
219707244|NCT03988647|RADIATION|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
219707245|NCT05202405|DRUG|AD-221|AD-221 Oral Tablet
219707246|NCT05202405|DRUG|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
219707247|NCT04681300|OTHER|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
219123516|NCT05575843|OTHER|Standard Neurostatus-EDSS|The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
219707248|NCT04681300|OTHER|Plastic surgery remnants|healthy skin from plastic surgery interventions
219707249|NCT04447365|DIAGNOSTIC_TEST|device interrogation|All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
219707250|NCT02412657|DRUG|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
219707251|NCT02412657|DRUG|Normal Saline|
219707252|NCT01913184|DEVICE|AKITA|
219707253|NCT03101345|OTHER|Peptamen® 1.5 vanilla|Administration orally
219123517|NCT06429371|OTHER|Quantitative Sensory Testing|Participants will undergo heat pain threshold, cold pain threshold, pressure pain threshold, temporal summation, and conditioned pain modulation to characterize pain sensitivity.
219123518|NCT06429371|OTHER|Pain-Related Psychological Factors|Participants will complete psychological questionnaires to characterize these factors.
219123519|NCT04924582|OTHER|Capacity Coaching|Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
219123520|NCT04448327|DEVICE|active tVNS|non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
219123521|NCT04448327|DEVICE|Sham tVNS|Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
219123522|NCT03668782|PROCEDURE|Umbilical cord milking|The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
219123523|NCT02034721|DIETARY_SUPPLEMENT|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
219707254|NCT00550004|DRUG|RP101|190 mg oral tablet
219707255|NCT00550004|DRUG|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
219707256|NCT00460798|OTHER|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
219707257|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
219707258|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
219707259|NCT01898130|BIOLOGICAL|bevacizumab|Given IV
219707260|NCT01898130|PROCEDURE|quality-of-life assessment|Ancillary studies
219707261|NCT00154466|BEHAVIORAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
219225781|NCT05440240|OTHER|Saline injection|Isotonic saline
219225782|NCT02132949|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
219225783|NCT02132949|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
219707262|NCT02724436|PROCEDURE|TACE|
219707263|NCT02724436|PROCEDURE|radioembolization with Y-90|radioembolization with Y-90
219707264|NCT05508802|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
219707265|NCT05508802|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
219123524|NCT02034721|DIETARY_SUPPLEMENT|Placebo|Placebo
219123525|NCT02809638|OTHER|ultrasound elastography|
219123526|NCT01235429|BEHAVIORAL|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
219123527|NCT01235429|BEHAVIORAL|Partners in Care|Diabetes self-management education
219225784|NCT02132949|DRUG|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
219123528|NCT06059053|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
219123529|NCT00562965|DRUG|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
219123530|NCT00562965|DRUG|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
219123531|NCT00562965|DRUG|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
219123532|NCT00562965|DRUG|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
219123533|NCT00562965|DRUG|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
219123534|NCT00562965|DRUG|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
219123535|NCT00562965|DRUG|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
219123536|NCT00562965|DRUG|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
219123537|NCT00562965|DRUG|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
219123538|NCT05275270|OTHER|oxytocin gel|The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
219707266|NCT02871427|DRUG|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
219707267|NCT03927391|DRUG|Enzalutamide|enzalutamide treatment
219707268|NCT04922762|BEHAVIORAL|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
219707269|NCT04922762|BEHAVIORAL|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
219123539|NCT05275270|OTHER|placebo gel|The placebo gel (B) consisted of the gel alone
219123540|NCT06201065|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219123541|NCT06201065|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
219123542|NCT06201065|DRUG|Toripalimab|240 mg iv.drip Q3W
219123543|NCT06201065|DRUG|oxaliplatin , fluorouracil, and leucovorin|FOLFOX-HAIC
219123544|NCT00847093|DRUG|LMX4|One inch every six hours
219123545|NCT00847093|DRUG|LMX4 Placebo|One inch every six hours
219123546|NCT06036979|PROCEDURE|Paravertebral plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
219123547|NCT06036979|PROCEDURE|Erector spinae plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
219123548|NCT06036979|DRUG|Intravenous morphine, ketorlac and paracetamol|• In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
219123549|NCT02402179|OTHER|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
219123550|NCT00525057|DRUG|Dalteparin|Given SC
219123551|NCT01911221|BIOLOGICAL|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
219123552|NCT05071573|OTHER|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
219123553|NCT03007342|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
219123554|NCT03007342|DRUG|Placebo|
219123555|NCT03464396|OTHER|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
219225785|NCT02132949|DRUG|Doxorubicin|Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
219707270|NCT04922762|BEHAVIORAL|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
219707271|NCT04747002|DRUG|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
219707272|NCT01476072|OTHER|MRI scan|MRI scan only, methodology study with no other intervention
219707273|NCT05316493|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
219707274|NCT05316493|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
219707275|NCT05316493|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
219707276|NCT03823131|DEVICE|ImmunoPulse|Intratumoral
219707277|NCT03823131|DRUG|Epacadostat|Given PO
219707278|NCT03823131|DRUG|Pembrolizumab|Given IV
219707279|NCT03823131|BIOLOGICAL|CORVax|Intratumoral
219123556|NCT03464396|OTHER|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
219123557|NCT03464396|OTHER|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate \[HR\] \< 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
219123558|NCT03464396|OTHER|Hypoxia Challenge Test|"A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of \> 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% \< 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped."
219225786|NCT02132949|DRUG|Epirubicin|Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
219707280|NCT03823131|DRUG|Tavokinogene telseplasmid|Intratumoral
219707281|NCT02846402|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
219707282|NCT02866383|DRUG|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
219707283|NCT02866383|DRUG|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
219707284|NCT02866383|RADIATION|Radiotherapy|15 Gy x 1 fraction given on day 1
219707285|NCT02909647|PROCEDURE|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
219707286|NCT02909647|PROCEDURE|Osteosynthesis|osteosynthesis using volar locking plate
219707287|NCT01281306|DRUG|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
219707288|NCT01281306|DRUG|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
219707289|NCT01281306|DRUG|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
219707290|NCT01281306|DRUG|Placebo|Placebo was supplied as tablets in blister cards.
219707291|NCT02054195|BEHAVIORAL|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
219707292|NCT02054195|BEHAVIORAL|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
219707293|NCT06418815|OTHER|Concept map group|The intervention group will create a concept map regarding neonatal toxic stress.
219707294|NCT03719664|DRUG|Albuvirtide|Intravenous infusion of Albuvirtide
219707295|NCT03719664|DRUG|3BNC117|Intravenous infusion of 3BNC117
219707296|NCT03719664|DRUG|Baseline ART|Subjects continuing on baseline ART
219707297|NCT03174522|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
219707298|NCT03174522|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
219707299|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) IV|Intravenous Injection
219707300|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) SC|Subcutaneous Injection
219707301|NCT04494815|DRUG|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
219123559|NCT03464396|OTHER|Effects of Nasal Cannula Flow|"Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~1. 28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~2. Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~3. Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops."
219123560|NCT03464396|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
219225787|NCT02132949|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
219707302|NCT04494815|DRUG|active control|Each participant will receive 1 dose of 300 mg active control capsule.
219707303|NCT04494815|DRUG|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
219707304|NCT04494815|DRUG|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
219707305|NCT05803343|BEHAVIORAL|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
219707306|NCT05803343|BEHAVIORAL|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
219707307|NCT03188471|DRUG|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
219707308|NCT03188471|DRUG|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
219707309|NCT01609192|DRUG|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
219707310|NCT03150186|OTHER|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
219707311|NCT03150186|OTHER|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
219707312|NCT03150186|OTHER|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
219707313|NCT03419871|OTHER|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
219225788|NCT02132949|DRUG|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
219123561|NCT03464396|DIAGNOSTIC_TEST|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
219707314|NCT03419871|OTHER|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
219123562|NCT03464396|OTHER|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
219123563|NCT02298543|OTHER|coronary spasm|
219123564|NCT00563654|DRUG|Alfuzosin GITS (Xatral XL)|
219123565|NCT05556005|DRUG|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
219123566|NCT05556005|DRUG|Placebo|Starch tablets used twice daily
219707315|NCT05551988|OTHER|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
219123567|NCT04795141|DRUG|ABY-035|ABY-035 Solution for injection
219123568|NCT04795141|DRUG|Placebo|Normal Saline for injection
219123569|NCT03505645|PROCEDURE|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule"
219707316|NCT02428153|OTHER|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
219707317|NCT00051506|DRUG|ALIMTA|
219707318|NCT00051506|DRUG|carboplatin|
219707319|NCT00051506|DRUG|cisplatin|
219707320|NCT01597362|PROCEDURE|laparoscopy|Trocar access in laparoscopy
219707321|NCT01597362|PROCEDURE|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
219707322|NCT01597362|PROCEDURE|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
219707323|NCT01597362|PROCEDURE|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
219707324|NCT02320396|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
219707325|NCT02320396|DRUG|Placebo|Placebo tablets
219707326|NCT00977977|DRUG|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
219123570|NCT03505645|PROCEDURE|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
219123571|NCT01894958|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
219123572|NCT01894958|DRUG|Placebo|Strawberry flavored solution
219123573|NCT00942240|DRUG|ACU-4429|administered orally once a day for 14 days
219123574|NCT00942240|DRUG|matching placebo tablet|administered orally once a day for 14 days
219123575|NCT06039891|DRUG|Nimotuzumab、Tislelizumab|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
219707327|NCT00977977|DRUG|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
219123576|NCT04701502|DIETARY_SUPPLEMENT|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
219707328|NCT03171870|DIAGNOSTIC_TEST|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
219123577|NCT04701502|DIETARY_SUPPLEMENT|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
219123578|NCT04701502|DRUG|Standard Care|Standard care for COVID-19
219123579|NCT03782948|DEVICE|Standard gait training on BART without pelvic perturbations|The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
219707329|NCT03331562|DRUG|Pembrolizumab|pembrolizumab solution for infusion
219707330|NCT03331562|DRUG|paricalcitol|Paricalcitol solution for injection
219123580|NCT03782948|DEVICE|Robotised gait training with BART with pelvic perturbations|In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
219123581|NCT00965484|DEVICE|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
219123582|NCT02288715|OTHER|no interventions|
219123583|NCT00315211|DRUG|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
219123584|NCT00315211|DRUG|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
219123585|NCT00848211|OTHER|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
219123586|NCT00848211|BIOLOGICAL|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
219707331|NCT03331562|DRUG|placebo|normal saline solution for injection
219707332|NCT03718000|DEVICE|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
219707333|NCT02623712|OTHER|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
219707334|NCT02623712|OTHER|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
219707335|NCT05906862|DRUG|AMT-253|Administered intravenously
219707336|NCT00322036|DRUG|MPC-7869|Oral 800 mg BID
219123587|NCT00848211|BIOLOGICAL|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
219123588|NCT00848211|BIOLOGICAL|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
219123589|NCT01124617|DRUG|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
219123590|NCT01124617|DRUG|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
219707337|NCT00322036|DRUG|MPC-7869|Oral BID dosing
219707338|NCT00141609|DRUG|Slow Sodium|
219707339|NCT04970940|DRUG|Treatment A|AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
219707340|NCT04970940|DRUG|Treatment B|AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
219707341|NCT04970940|DRUG|Treatment C|AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
219707342|NCT01478659|DIETARY_SUPPLEMENT|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
219707343|NCT01478659|DIETARY_SUPPLEMENT|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
219707344|NCT00769418|DRUG|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
219707345|NCT00769418|DRUG|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
219707346|NCT00382616|DRUG|Phosphatidylserine-Omega3|
219707347|NCT05557214|BEHAVIORAL|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
219707348|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. \- MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
219707349|NCT02935387|OTHER|Taper|Taper
219707350|NCT01838876|DRUG|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
219123591|NCT00945477|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
219123592|NCT00669695|DRUG|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
219123593|NCT00669695|OTHER|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
219123594|NCT00669695|OTHER|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
219123595|NCT02724267|BIOLOGICAL|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
219123596|NCT02013232|DRUG|Aripiprazole|
219123597|NCT03675204|OTHER|No intervention|No intervention
219123598|NCT01210053|DRUG|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
219123599|NCT00619151|DEVICE|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
219123600|NCT00619151|DEVICE|Regent|Implant of the St. Jude Medical Regent mechanical valve
219123601|NCT06042998|PROCEDURE|Robotic radical gastrectomy|Laparoscopic gastrectomy
219123602|NCT02461511|OTHER|Therapeutic Education|participation in a therapeutic education program on diabetes
219123603|NCT05328440|DRUG|Pyrotinib Maleate|once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
219123604|NCT05328440|DRUG|Dalpiciclib Isethionate Tablets|400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
219123605|NCT05328440|DRUG|Inetetamab|the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
219123606|NCT05328440|DRUG|Fulvestrant|fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
219123607|NCT04358471|BIOLOGICAL|Intravitreal AAVCAGsCD59|AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
219707351|NCT01838876|DRUG|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
219123608|NCT04358471|OTHER|Intravitreal Sham Injection|Sham injection mimics a real injection in the enrolled eye
219123609|NCT02825043|DEVICE|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
219123610|NCT06215729|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
219123611|NCT06215729|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
219123612|NCT06215729|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
219707352|NCT02101294|DEVICE|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout \[actual home row placement order: asdeihotlrn\], plus substitutions on the upper row \[qwfgjyuk;p\] and bottom row \[zxcvb'm,.\] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
219707353|NCT02101294|DEVICE|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
219707354|NCT01241149|PROCEDURE|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
219707355|NCT02646163|DRUG|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
219707356|NCT04179214|OTHER|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
219707357|NCT04179214|OTHER|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
219707358|NCT05502731|DRUG|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
219707359|NCT05502731|DRUG|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
219707360|NCT03001102|DEVICE|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
219707361|NCT03001102|DEVICE|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
219707362|NCT03001102|DEVICE|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
219707363|NCT04562558|DRUG|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
219707364|NCT04562558|DRUG|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
219707365|NCT04562558|DRUG|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
219707366|NCT04000113|DEVICE|laser acupuncture|low level laser emission on specific acupuncture points
219707367|NCT04000113|DEVICE|Sham laser|Sham laser
219707368|NCT03199690|DRUG|Dolutegravir|Antiviral (integrase inhibitor)
218985921|NCT05163977|PROCEDURE|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
218985922|NCT03326544|OTHER|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
218985923|NCT03326544|OTHER|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
219707369|NCT03199690|DRUG|Rifampicin|Antibiotic
219707370|NCT00658853|BEHAVIORAL|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
219707371|NCT02950571|BEHAVIORAL|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
219707372|NCT02950571|BEHAVIORAL|Standard Care|High level of support from an interdisciplinary team.
219707373|NCT02684175|DEVICE|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
219707374|NCT02684175|OTHER|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
219123613|NCT05482568|DRUG|SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316|"Drug: SHR-A1811 \& Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 \& SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"
219123614|NCT02444143|DRUG|tacrolimus extended release|
219123615|NCT05805540|PROCEDURE|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times
219123616|NCT05805540|PROCEDURE|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
219123617|NCT05805540|PROCEDURE|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)
219123618|NCT05805540|PROCEDURE|Placebo|Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
219123619|NCT06088901|PROCEDURE|Autologous Blood Patch|2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
219123620|NCT03582137|DRUG|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
219123621|NCT03582137|OTHER|Placebo|Subjects randomized to this arm will receive Placebo
219123622|NCT05391204|OTHER|Functional Tests|Various physical exercices of inferior members
219123623|NCT02402764|DRUG|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2).
219123624|NCT01982760|DRUG|DDAVP|Patients Receiving DDAVP prior to operation
219123625|NCT05569655|DRUG|Tolvaptan|Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
219123626|NCT05569655|DRUG|Furosemide|Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
219123627|NCT00377598|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
219123628|NCT00377598|DRUG|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
219123629|NCT00377598|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
219123630|NCT00377598|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
219123631|NCT00377598|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
219123632|NCT02726555|DRUG|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
219225789|NCT02132949|DRUG|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
219123633|NCT02726555|DRUG|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
219123634|NCT03704298|DRUG|Cyclophosphamide|Administered according to package insert
219123635|NCT03704298|DRUG|Fludarabine|Administered according to package insert
219123636|NCT03704298|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
219123637|NCT03704298|BIOLOGICAL|Utomilumab|Administered as an IV infusion
219123638|NCT04554498|DEVICE|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
219123639|NCT03123640|OTHER|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
219123640|NCT00483262|DRUG|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
219123641|NCT00483262|DRUG|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
219123642|NCT03766828|PROCEDURE|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
219123643|NCT03766828|PROCEDURE|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
219123644|NCT05789355|DIETARY_SUPPLEMENT|NUV001|Daily supplementation with NUV001 at 1000 mg (4 tablets of 250 mg each) for 90 days with a prolonged follow-up of 1 month (30 days) after stopping the supplementation
219123645|NCT02453529|DRUG|WCK 4873|Oral tablets
219225790|NCT00549666|DRUG|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
219225791|NCT00549666|DRUG|Placebo 40 mg|Placebo 40 mg once daily during treatment period
219225792|NCT00549666|DRUG|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
219707375|NCT02819817|DRUG|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
219707376|NCT02819817|OTHER|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
219707377|NCT02266485|DRUG|BIBB 515 BS|
219707378|NCT02266485|DRUG|Pravastatin|
219707379|NCT02266485|DRUG|Placebo|
219123646|NCT05084300|OTHER|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
219123647|NCT05084300|OTHER|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
219123648|NCT01607970|DRUG|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
219123649|NCT00918190|DRUG|Placebo|Saline
219123650|NCT00918190|DRUG|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
219123651|NCT00918190|DRUG|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
219123652|NCT02303574|DRUG|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
219123653|NCT02303574|DRUG|Placebo, oral solution|Matching placebo
219123654|NCT04875260|OTHER|Critical Care|Critical care in the intensive care units
219707380|NCT01545336|DRUG|Anastrozole|1 mg tablet to be taken 1 time daily
219707381|NCT01545336|DRUG|Placebo|1 mg tablet to be taken 1 time daily
219123655|NCT01873677|DRUG|M518101|
219123656|NCT01873677|DRUG|Vehicle|
219123657|NCT05943587|OTHER|culture-sensitive PNE4kids|Culturally adapted PNE4kids used by physiotherapists worldwide in chronic pain rehabilitation.
219123658|NCT05943587|OTHER|standard education|Standard education used by physiotherapists worldwide in chronic pain rehabilitation.
219123659|NCT04002089|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
219707382|NCT02826213|DEVICE|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
219707383|NCT02826213|DEVICE|Waves perfusion device|Renal Perfusion with Waves perfusion device
219707384|NCT06465056|DRUG|Botulinum toxin type A|Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.
219123660|NCT04002089|DRUG|Bupivacaine|1.3%, 13.3 mg/mL
219123661|NCT00859014|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
219123662|NCT05030376|DIETARY_SUPPLEMENT|intraileal infusion|intraileal glucose or intraileal saline infusion
219123663|NCT02731404|PROCEDURE|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
219123664|NCT02731404|PROCEDURE|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
219123665|NCT01863966|OTHER|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
219707385|NCT02341079|DRUG|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
219707386|NCT02341079|DRUG|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
219707387|NCT01869374|DEVICE|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
219707388|NCT01869374|BIOLOGICAL|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
219707389|NCT01680796|DRUG|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
219123666|NCT01863966|PROCEDURE|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
219123667|NCT04796935|DEVICE|Tactile Imaging (VerTouch)|VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
219123668|NCT04796935|OTHER|Control (palpation)|Control, palpation used to identify and mark an insertion site.
219123669|NCT03431519|PROCEDURE|VP|Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
219123670|NCT00599677|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
219123671|NCT00599677|DRUG|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
219123672|NCT02854891|OTHER|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
219707390|NCT01680796|DRUG|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
219707391|NCT01680796|DRUG|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
219707392|NCT03942588|BEHAVIORAL|High-intensity interval training|
219707393|NCT00844519|DRUG|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
219123673|NCT02888795|DRUG|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
219123674|NCT00783718|DRUG|vedolizumab|Vedolizumab for intravenous infusion
219707394|NCT00844519|DRUG|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
219707395|NCT01757132|DEVICE|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
219707396|NCT06108921|DRUG|Xylitol Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
218985924|NCT00560781|DRUG|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
218985925|NCT01459471|PROCEDURE|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
218985926|NCT04966832|DRUG|XW10508|XW10508 capsules or tablets
218985927|NCT04966832|OTHER|Placebo|Placebo capsules or tablets
218985928|NCT00523562|OTHER|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
218985929|NCT04465110|DIETARY_SUPPLEMENT|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
218985930|NCT01952145|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
218985931|NCT01952145|DRUG|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
218985932|NCT00168870|DRUG|Gemcitabine|
218985933|NCT00168870|DRUG|Treosulfan|
219123675|NCT00783718|OTHER|Placebo|Placebo intravenous infusion
219707397|NCT06108921|DRUG|Salt Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
219707398|NCT06438601|DEVICE|Lens A (omafilcon A)|15 minutes of daily wear.
219123676|NCT01575145|BEHAVIORAL|Quitline facilitation intervention|brief quitline facilitation intervention
219123677|NCT01575145|BEHAVIORAL|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
219123678|NCT00602901|OTHER|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
219123679|NCT00602901|OTHER|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
219123680|NCT00602901|DRUG|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
219123681|NCT06394336|OTHER|Muscle strengthening|Strengthening exercises for the intrinsic muscles of the foot and hips
219123682|NCT06394336|DRUG|Standard treatment (oral analgesic/anti-inflammatory drug)|oral analgesic/anti-inflammatory drug. Education.
219707399|NCT06438601|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
219707400|NCT05548907|BEHAVIORAL|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
219707401|NCT05548907|BEHAVIORAL|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
219707402|NCT02262871|DEVICE|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
219707403|NCT02262871|DEVICE|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
219707404|NCT05579834|PROCEDURE|posterior correction surgery|Cases of hemothorax developing after posterior correction surgery for spinal deformities
219707405|NCT05893641|BEHAVIORAL|A regular training volume|Participate will maintain their training volume of 35 h/week
219707406|NCT05893641|BEHAVIORAL|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
219707407|NCT05893641|BEHAVIORAL|A longer rest group|Participate will maintain the 35 h/week of exercise training
219707408|NCT04934358|BEHAVIORAL|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
219707409|NCT04934358|BEHAVIORAL|Usual care|Usual rehabilitation program
219707410|NCT00970554|OTHER|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
219123683|NCT05868499|BIOLOGICAL|EXG34217|Single infusion
219123684|NCT01632865|DEVICE|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
219123685|NCT02482909|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor
219123686|NCT02482909|PROCEDURE|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
219123687|NCT02668835|DEVICE|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
219123688|NCT02668835|GENETIC|Non intervention-Genetic testing|
219123689|NCT00315965|DRUG|Nitric oxide, Carbon monoxide, Helium|
219123690|NCT02007447|DRUG|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
219123691|NCT02135783|PROCEDURE|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
219123692|NCT02135783|PROCEDURE|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
219707411|NCT00970554|OTHER|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
219123693|NCT05254730|DEVICE|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
219123694|NCT01783457|OTHER|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
219707412|NCT01952860|OTHER|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
219707413|NCT01952860|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
219123695|NCT01783457|OTHER|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
219123696|NCT00000989|DRUG|Zidovudine|
219123697|NCT00000989|DRUG|Sargramostim|
219123698|NCT00000989|DRUG|Ganciclovir|
219123699|NCT00696293|DRUG|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
219123700|NCT01687192|BIOLOGICAL|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
219123701|NCT00651677|PROCEDURE|HAL proctectomy|Hand-assisted laparoscopic proctectomy
219123702|NCT00651677|PROCEDURE|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
219123703|NCT00651677|PROCEDURE|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
219707414|NCT01637168|DRUG|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
219707415|NCT01637168|DRUG|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
219707416|NCT05043935|PROCEDURE|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
219707417|NCT05043935|PROCEDURE|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
219707418|NCT01138735|DRUG|adapalene/benzoyl peroxide|daily topical application for 12 weeks
219123704|NCT00651677|PROCEDURE|SL Proctectomy|Straight laparoscopic proctectomy
219123705|NCT00586274|PROCEDURE|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
219123706|NCT00586274|DRUG|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m\^2
219123707|NCT00586274|BIOLOGICAL|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)"
219123708|NCT00586274|BIOLOGICAL|Campath 1h|10 mg iv over 4 hours day-8 through day-6
219123709|NCT00586274|BIOLOGICAL|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
219123710|NCT02133274|BEHAVIORAL|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
219123711|NCT02133274|OTHER|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
219707419|NCT01138735|DRUG|Topical Gel Vehicle|daily topical application for 12 weeks
219707420|NCT02744586|BEHAVIORAL|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
219707421|NCT02744586|BEHAVIORAL|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
219123712|NCT01759121|RADIATION|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
219123713|NCT01759121|RADIATION|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
219123714|NCT02374502|BEHAVIORAL|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
219123715|NCT00647140|OTHER|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
219123716|NCT01027871|DRUG|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
219123717|NCT01027871|DRUG|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
219123718|NCT00140881|DRUG|MK0476; montelukast sodium|
219123719|NCT00140881|DRUG|Comparator: placebo|
219123720|NCT06234397|DRUG|BH3120|BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
219123721|NCT06234397|DRUG|pembrolizumab|Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
219123722|NCT05873803|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
219123723|NCT05873803|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
219123724|NCT02405390|PROCEDURE|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
219707422|NCT05542563|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
219707423|NCT02287077|PROCEDURE|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
219707424|NCT05653843|DEVICE|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
219707425|NCT00722020|DEVICE|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
219707426|NCT06463678|DRUG|IVIEW-1201|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
219707427|NCT06463678|DRUG|NATACYN®|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
219123725|NCT02405390|PROCEDURE|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
219123726|NCT02405390|DEVICE|Storz C-Mac® laryngoscope|
219123727|NCT05773898|OTHER|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
219123728|NCT05994235|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
219707428|NCT01260129|DRUG|Silodosin|Silodosin 8 mg orally, once daily after morning meal
219707429|NCT01260129|DRUG|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
219707430|NCT02232867|BEHAVIORAL|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
219707431|NCT05558371|OTHER|No intervention.|No intervention administered as part of this study; observational only.
219707432|NCT00668928|OTHER|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
219123729|NCT05994235|DRUG|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
219123730|NCT06087692|OTHER|Exercise|-based game therapy applied in addition to aerobic exercise
219123731|NCT04869657|BEHAVIORAL|Coaches with Children's Hospital of Philadelphia (CHOP) Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices, while themselves being remotely supported by CHOP research consultants.
219123732|NCT04869657|BEHAVIORAL|Coaches without CHOP Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.
219123733|NCT05877547|DRUG|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
219123734|NCT05877547|DRUG|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
219123735|NCT05877547|DRUG|Placebo|SC injection of matching placebo
219123736|NCT04536025|OTHER|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
219123737|NCT04536025|OTHER|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
219707433|NCT01998360|PROCEDURE|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
219707434|NCT01998360|PROCEDURE|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
219707435|NCT01113242|OTHER|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
219707436|NCT00302900|BEHAVIORAL|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
219707437|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
219707438|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
219707439|NCT00924898|DRUG|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
219707440|NCT02138383|DRUG|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
219707441|NCT02138383|DRUG|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
219707442|NCT02138383|DRUG|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
219707443|NCT05253014|PROCEDURE|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
219707444|NCT05253014|DRUG|paracetamol|intravenous paracetamol every 8 hours
219707445|NCT01285518|DRUG|PF-05231023|0.5 mg QD IV x 1 day
219707446|NCT01285518|DRUG|PF-05231023|1.5 mg QD IV x 1 day
219707447|NCT01285518|DRUG|PF-05231023|5 mg QD IV x 1 day
219707448|NCT01285518|DRUG|PF-05231023|15 mg QD IV x 1 day
219123738|NCT04159896|DRUG|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Given PO
219707449|NCT01285518|DRUG|PF-05231023|50 mg QD IV x 1 day
219707450|NCT01285518|DRUG|PF-05231023|100 mg QD IV x 1 day
219123739|NCT04159896|BIOLOGICAL|Nivolumab|Given IV
219123740|NCT02156791|BIOLOGICAL|gpASIT+TM|
219123741|NCT02413788|OTHER|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
219123742|NCT02413788|OTHER|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
219123743|NCT02413788|DEVICE|treadmill|
219123744|NCT02877537|DRUG|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
219123745|NCT02877537|PROCEDURE|Forced oscillation technique|before and after bronchodilation
219123746|NCT02877537|PROCEDURE|Plethysmography|
219123747|NCT05055375|OTHER|questionnaire survey|We will conduct a questionnaire survey of outpatients.
219123748|NCT04285502|PROCEDURE|SURGICAL DRAIN|A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
219123749|NCT02887651|RADIATION|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
219707451|NCT01285518|DRUG|PF-05231023|200 mg QD IV x 1 day
219707452|NCT01285518|OTHER|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
219707453|NCT04975425|DIAGNOSTIC_TEST|Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement
219707454|NCT00504400|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
219123750|NCT05209399|PROCEDURE|Ultrasound guided injection|All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
219123751|NCT05705167|DRUG|Plitidepsin|IV infusion over 60-minutes
219123752|NCT05499585|OTHER|Whole Dairy|2 1/2 servings of whole dairy per day
219123753|NCT05806554|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
219123754|NCT06624189|OTHER|Auto-pended bot liver ultrasound order|This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
219123755|NCT04238455|PROCEDURE|Sham serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
219123756|NCT04238455|PROCEDURE|Serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
219123757|NCT06648096|DRUG|Afatinib|Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
219707455|NCT02991079|OTHER|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
219707456|NCT02991079|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
219707457|NCT01417169|DRUG|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
219707458|NCT05389267|DRUG|Kinezodianone R hydrochloride|Eyedrops
219707459|NCT05389267|DRUG|Placebo|Placebo
219707460|NCT00199173|DEVICE|SIR Spheres intra-arterial hepatic|
219707461|NCT04194632|PROCEDURE|Temporary right ventricular pacing|As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
219707462|NCT01242982|PROCEDURE|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
219707463|NCT01242982|PROCEDURE|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
219707464|NCT01471990|DRUG|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
219707465|NCT01471990|DRUG|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
219707466|NCT00836108|BEHAVIORAL|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
219707467|NCT00764114|DRUG|antibiotic|6 or 12 weeks
219707468|NCT00570947|OTHER|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
219707469|NCT02808988|PROCEDURE|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
219707470|NCT02808988|PROCEDURE|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
219707471|NCT02808988|OTHER|zoledronic acid|5 mg/year zoledronic acid (i.v.)
219707472|NCT01719653|DRUG|MiraLAX|MiraLAX consumed as described in each arm.
219707473|NCT01719653|OTHER|Gatorade|Gatorade consumed as described in each arm.
219123758|NCT03959098|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
219707474|NCT01719653|DRUG|MoviPrep|MoviPrep consumed as described in each arm.
219707475|NCT01719653|DRUG|SUPREP|SUPREP consumed as described in each arm.
219707476|NCT01757548|PROCEDURE|open operation|high ligation of spermatic vein by open operation
219707477|NCT01757548|PROCEDURE|microsurgery|high ligation of spermatic vein by microsurgery
219707478|NCT01910441|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
219707479|NCT01910441|DRUG|Glimepiride|Glimepiride 1-6 mg once daily
219707480|NCT01910441|DRUG|Metformin|Metformin (1000-1500 mg daily)
219707481|NCT04711577|BEHAVIORAL|Track clinician-determined symptoms|Participants will track clinician-determined symptoms
219707482|NCT04711577|BEHAVIORAL|Track clinician-determined and self-determined symptoms|Participants will track clinician-determined symptoms and a self-determined symptom
219707483|NCT00478959|DRUG|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
219123759|NCT03959098|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219123760|NCT03959098|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
219123761|NCT03959098|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
219123762|NCT03959098|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219123763|NCT03959098|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219123764|NCT03959098|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219123765|NCT03959098|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
219123766|NCT02099539|BIOLOGICAL|N-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
219123767|NCT05515874|DRUG|Feraheme|"Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use."
219123768|NCT05787652|BEHAVIORAL|ARTEMIS mobile app|Access to a self-regulation based mobile application.
219123769|NCT05812794|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention."
219707484|NCT01807533|BEHAVIORAL|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
219707485|NCT01807533|BEHAVIORAL|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
219707486|NCT05975489|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
219707487|NCT03744832|DIAGNOSTIC_TEST|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
219707488|NCT03744832|DIAGNOSTIC_TEST|Throat culture|Standard bacterial throat culture.
219123770|NCT06101927|DRUG|Whole body study and SPECT with [99mTc]Tc-BQ0413|One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
219123771|NCT00250419|BIOLOGICAL|V930|
219707489|NCT01811238|DRUG|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
219707490|NCT02217956|DRUG|Cisplatin|
219707491|NCT02217956|DRUG|Bevacizumab|
219707492|NCT00067080|DRUG|ICL670, deferoxamine|
219707493|NCT02644018|DRUG|Imidazolyl ethanamide pentandioic acid|
219707494|NCT02644018|DRUG|placebo|
219123772|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
219123773|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
219123774|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
219123775|NCT05299086|DRUG|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
219123776|NCT02679651|OTHER|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
219123777|NCT02679651|OTHER|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
219123778|NCT02679651|OTHER|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
219707495|NCT02879058|PROCEDURE|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
219123779|NCT06851156|DEVICE|tTIS|CM-pf tTIS
219123780|NCT04289987|BIOLOGICAL|CVI-HBV-002|Investigational Product
219123781|NCT04289987|BIOLOGICAL|Normal Saline(placebo)|Investigational Product
219123782|NCT04996069|DEVICE|Crest Whitening Emulsions|Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
219123783|NCT06160921|OTHER|Standard therapy|Individualized blood pressure reduction program
219123784|NCT05115656|BEHAVIORAL|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
219123785|NCT05115656|BEHAVIORAL|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
219707496|NCT03297632|BEHAVIORAL|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
219707497|NCT03995563|DRUG|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
219707498|NCT03995563|DRUG|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
219707499|NCT05730426|PROCEDURE|Deep dry needling|Method to decrease pain and improve function in musculoskeletal disorders.
219707500|NCT05730426|PROCEDURE|Muscle energy technique|Method to decrease pain and improve function in musculoskeletal disorders.
219707501|NCT05730426|PROCEDURE|Neck stability exercise|Method to decrease pain and improve function in musculoskeletal disorders.
219707502|NCT04003909|PROCEDURE|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
219123786|NCT05355597|DRUG|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
219123787|NCT05355597|DRUG|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
219123788|NCT04060680|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
219123789|NCT06662448|DEVICE|SAVIR Alpha Synch mobile (SASm)|The SAVIR Alpha Synch mobile is a device first used in office and then intended to be used for the home therapy of the visual system with non-invasive electrical stimulation.
219123790|NCT00935792|DRUG|alemtuzumab|Given subcutaneously
219123791|NCT00935792|DRUG|everolimus|Given orally
219123792|NCT02322775|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
219123793|NCT02322775|BIOLOGICAL|Placebo|Placebo administered subcutaneously every 4 weeks
219123794|NCT05711238|OTHER|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
219123795|NCT05711238|OTHER|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
219123796|NCT02719197|DRUG|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
219123797|NCT02719197|DRUG|Placebo|Placebo capsules matching AC-083 capsules
219123798|NCT01273532|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
219707503|NCT04003909|PROCEDURE|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
219707504|NCT01737801|PROCEDURE|Lung function test|Lung function test.
219123799|NCT01273532|DRUG|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
219123800|NCT03656458|OTHER|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
219123801|NCT03656458|OTHER|Conventional Balance Training|"Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training"
219123802|NCT03656458|OTHER|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
219707505|NCT01774526|OTHER|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
219707506|NCT01192178|DRUG|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
219123803|NCT05553158|DEVICE|Compression pants|Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.
219123804|NCT05553158|DEVICE|Embolization coils|Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.
219123805|NCT00135746|DRUG|nicotine transdermal system|
219123806|NCT00870025|BIOLOGICAL|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
219123807|NCT00870025|BIOLOGICAL|placebo|diluent, every 5 days, s.c., 4 doses
219123808|NCT00796536|BEHAVIORAL|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
219123809|NCT00796536|BEHAVIORAL|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
219123810|NCT05274776|DEVICE|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
219123811|NCT00615433|DRUG|Lurasidone|120mg/day
219123812|NCT00615433|DRUG|Olanzapine|15mg/day
219123813|NCT00615433|DRUG|Placebo comparator|Placebor Comparator
219123814|NCT00615433|DRUG|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
219123815|NCT04739423|DRUG|clenbuterol (CST-103), nadolol (CST-107), matching placebo|clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
219707507|NCT01192178|DRUG|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
219707508|NCT01579214|OTHER|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
219123816|NCT04360226|OTHER|Non-interventional|Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.
219123817|NCT01007552|DRUG|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
219123818|NCT01448174|DRUG|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
219123819|NCT00294996|DRUG|Myocet|
219123820|NCT01682707|PROCEDURE|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
219707509|NCT02351921|DEVICE|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
219707510|NCT02460289|DRUG|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
219707511|NCT03783637|OTHER|Whole grain oats|A meal containing whole grain oats
219707512|NCT03783637|OTHER|Whole grain wheat|A meal containing whole grain wheat
219707513|NCT04722406|OTHER|This item is not applicable to our observational study.|This item is not applicable to our observational study.
219707514|NCT03303222|DIAGNOSTIC_TEST|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
219707515|NCT01931384|DRUG|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
219707516|NCT01931384|DRUG|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
219707517|NCT00395577|DRUG|VX-702|
219123821|NCT01682707|PROCEDURE|track light|
219123822|NCT00236028|DRUG|Infliximab|
219123823|NCT05781490|DRUG|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
219123824|NCT01521143|BIOLOGICAL|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
219123825|NCT01521143|BIOLOGICAL|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
219123826|NCT02851043|DEVICE|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
219123827|NCT02851043|DEVICE|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
219123828|NCT01714089|DRUG|RNS60 125 ml|
219123829|NCT01714089|DRUG|RNS60 250 ml|
219123830|NCT01714089|DRUG|Interferon beta 1a|
219123831|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
219123832|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
219123833|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
219123834|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
219123835|NCT05029856|BIOLOGICAL|SII B.1.617.2|"Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
219123836|NCT02507219|DRUG|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
219123837|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
219123838|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
219707518|NCT04315402|OTHER|prospective, descriptive study via survey|"* Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review."
219707519|NCT03505346|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
219707520|NCT04830280|PROCEDURE|posterior quadratus lumborum block|administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
219707521|NCT01824667|DIETARY_SUPPLEMENT|B-GOS|
219707522|NCT01824667|DIETARY_SUPPLEMENT|Maltodextrin|
219707523|NCT03869099|OTHER|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
219707524|NCT03434288|OTHER|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
219123839|NCT03853590|PROCEDURE|Roux-en-Y gastric bypass|Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
219123840|NCT03853590|PROCEDURE|Laparoscopic adjustable gastric banding|Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
219123841|NCT01443143|OTHER|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
219123842|NCT01443143|DIETARY_SUPPLEMENT|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
219123843|NCT02656043|DRUG|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
219123844|NCT02656043|DRUG|Placebo|
219123845|NCT00005982|DRUG|nelarabine|Given IV
219123846|NCT00005982|OTHER|pharmacological study|Correlative studies
219123847|NCT00649129|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
219123848|NCT00649129|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
219123849|NCT04948073|OTHER|Dynamic neuromuscular stabilization approach|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment.
219123850|NCT04948073|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration).
219123851|NCT04843319|DRUG|VERU-100|GnRH antagonist
219123852|NCT01149603|DEVICE|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
219123853|NCT03176745|DIAGNOSTIC_TEST|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
219123854|NCT06561230|OTHER|Chart review|Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
219123855|NCT00232076|DRUG|ciclosporin|
219123856|NCT05395143|DRUG|Zinc sulfate|Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
219123857|NCT05395143|DRUG|Placebo|Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
219123858|NCT04912557|OTHER|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
219123859|NCT05174065|DRUG|Apremilast|Oral tablets
219123860|NCT05174065|DRUG|Placebo|Oral tablets
219123861|NCT06357741|DRUG|Denosumab|Desumumab, 60mg single injection
219123862|NCT05314283|DEVICE|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
219123863|NCT06218134|BIOLOGICAL|human Wharton's jelly-derived mesenchymal stem cells|human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
219123864|NCT02710058|BEHAVIORAL|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
219123865|NCT00593320|RADIATION|Stereotactic Radiosurgery|
219123866|NCT05922163|DEVICE|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
219707525|NCT01715051|DRUG|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
219123867|NCT01342887|DRUG|cyclosporine|Given IV
219123868|NCT01342887|DRUG|pravastatin sodium|Given PO
219123869|NCT01342887|DRUG|mitoxantrone hydrochloride|Given IV
219123870|NCT01342887|DRUG|etoposide|Given IV
219123871|NCT01342887|PROCEDURE|bone marrow aspiration|Correlative studies
219123872|NCT00209274|DEVICE|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
219123873|NCT00209274|PROCEDURE|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
219123874|NCT05827822|DEVICE|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
219123875|NCT03470285|PROCEDURE|Multiparametric MR imaging (mpMRI)|The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
219123876|NCT05229874|DRUG|carbon nanoparticles|Endoscopic injection
219123877|NCT05229874|DRUG|Indocyanine green|Endoscopic injection
219123878|NCT06376318|DRUG|Inotrope|Vasopressors: Norepinephrine, vasopressin Inotropes: Epinephrine, Dobutamine, Milrinone
219123879|NCT06376318|DEVICE|Mechanical circulatory support|Intra-aortic balloon pump Extracorporeal membrane oxygenation (ECMO)
219123880|NCT06376318|DRUG|anti-bodies|Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
219123881|NCT05794282|PROCEDURE|the robot assisted total hip arthroplasty|the robot assisted total hip arthroplasty
219123882|NCT05794282|PROCEDURE|the conventional total hip arthroplasty|the conventional total hip arthroplasty
219123883|NCT06145022|BEHAVIORAL|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
219707526|NCT01715051|BEHAVIORAL|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
219707527|NCT01715051|DRUG|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
219707528|NCT00774475|DRUG|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
219707529|NCT00774475|DRUG|doubled therapy|clopidogrel 150 mg/day
219707530|NCT01867775|DRUG|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
219707531|NCT04398472|BEHAVIORAL|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
219707532|NCT05232890|OTHER|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
219707533|NCT05232890|OTHER|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
219707534|NCT03385538|DRUG|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
219123884|NCT06145022|BEHAVIORAL|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
219123885|NCT03202875|DRUG|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219123886|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219123887|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219707535|NCT01484340|DRUG|Nicotine|"The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
219707536|NCT01484340|BEHAVIORAL|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
219707537|NCT02258672|OTHER|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
219707538|NCT00164359|DRUG|Amodiaquine plus artesunate|
219123888|NCT03323151|DRUG|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
219123889|NCT03323151|DRUG|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
219123890|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
219123891|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
219123892|NCT04578028|DRUG|ONO-2808|Investigational drug
219123893|NCT04578028|DRUG|Placebo|Placebo drug
219123894|NCT01258218|DEVICE|Implantation of an Accent MRI device|Implantation of an Accent MRI device
219123895|NCT01339494|DIETARY_SUPPLEMENT|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
219123896|NCT01620411|OTHER|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
219123897|NCT01620411|PROCEDURE|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
219123898|NCT03748537|DRUG|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
219707539|NCT00164359|DRUG|chlorproguanil-dapsone plus artesunate|
219707540|NCT02815761|OTHER|NO intervention, just observation|No intervention.
219707541|NCT03059368|DEVICE|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
219707542|NCT01584934|DRUG|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
219707543|NCT01584934|DRUG|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
219707544|NCT04745117|BEHAVIORAL|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
219707545|NCT01348841|OTHER|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
219707546|NCT02258581|DRUG|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
219707547|NCT02258581|DRUG|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
219707548|NCT02258581|DRUG|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
219707549|NCT04224116|DRUG|Tranexamic acid injection|to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
219707550|NCT04224116|DRUG|SSI|Serum Salin isotonic injected
219707551|NCT01357772|DRUG|Tamoxifen|
219707552|NCT01357772|DRUG|placebo|
219707553|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
219707554|NCT00063453|DIETARY_SUPPLEMENT|Selenium|selenium (200 μg/d L-selenomethionine)
219707555|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E placebo|placebo
219707556|NCT00063453|DIETARY_SUPPLEMENT|Selenium placebo|placebo
219123899|NCT00903773|DRUG|telaprevir|
219123900|NCT00465712|PROCEDURE|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
219123901|NCT05027750|BEHAVIORAL|Application of The Theory of Planned Behaviour For Weight Control|The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
219123902|NCT02784652|DRUG|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
219123903|NCT02784652|RADIATION|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
219123904|NCT05943483|OTHER|CCMQ questionnaire|Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.
219123905|NCT01355783|DRUG|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
219123906|NCT03013361|DRUG|Bupivacaine|Post operative pain control
219123907|NCT03013361|DRUG|Ropivacaine|Post operative pain control
219123908|NCT03013361|OTHER|Normal Saline|Acts as comparator
219707557|NCT04788134|DIAGNOSTIC_TEST|Post-rotatory nystagmus test|The test is administrated with the person sit down with cross legs at a rotatory board, with the head positioned by the examiner in 30° of forward flexion. The position was maintained by the administration of the test. The administration consist in two administrations separate by one minute. Each administration consist in rotate the person 10 times in 20 seconds (the first 10 rotations in a counterclockwise direction in 20 s and the second 10 rotations in a clockwise direction in 20 s). After each administration the examiner counts the duration of the reflex in seconds.
219707558|NCT00262379|DRUG|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
219123909|NCT02733107|DRUG|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
219707559|NCT00217451|DRUG|Fosmidomycin-clindamycin|
219707560|NCT01731548|RADIATION|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
219707561|NCT05623527|DEVICE|cardiac electronic implants|Cardiac electronic implants(CIED) includes permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), three-chamber pacemaker for cardiac resynchronization therapy defibrillator, lead free pacemaker, etc.
219123910|NCT02733107|DRUG|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
219123911|NCT00097370|DRUG|mepolizumab|Study Drug
219123912|NCT04595695|BEHAVIORAL|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
219123913|NCT04595695|BEHAVIORAL|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
219123914|NCT02337361|BEHAVIORAL|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1\) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
219123915|NCT01031043|DRUG|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
219123916|NCT01300793|DRUG|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 \& 11 q. 28 days.
219123917|NCT03354299|DIETARY_SUPPLEMENT|coconut milk|50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
219123918|NCT02419755|DRUG|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
219123919|NCT02419755|DRUG|Vorinostat|Vorinostat should be taken orally (PO) with food.
219123920|NCT02419755|DRUG|Mitoxantrone|Given by intravenous (IV) injection.
219123921|NCT02419755|DRUG|Cytarabine|Given by intravenous (IV) injection.
219123922|NCT02419755|DRUG|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
219123923|NCT02419755|DRUG|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
219123924|NCT02419755|DRUG|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
219123925|NCT02419755|DRUG|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
219123926|NCT02419755|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
219123927|NCT02419755|DRUG|Mercaptopurine|Given orally (PO).
219123928|NCT02419755|DRUG|Doxorubicin|Given intravenously (IV).
219123929|NCT02203097|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
219123930|NCT02203097|DRUG|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
219123931|NCT02472561|OTHER|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
219123932|NCT02472561|OTHER|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
219123933|NCT02472561|OTHER|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
219225793|NCT06340191|OTHER|Pilates with cueing|"The Pilates with a cueing component of the intervention involved a specialized approach to Pilates training. Participants in this group underwent an initial phase of training before the main sessions began, which consisted of two smaller group sessions focused on learning explicit verbal and tactile cues. These cues were designed to assist participants in maintaining proper body alignment, engaging specific muscle groups more effectively, and refining their movement techniques to enhance the overall efficacy of the Pilates exercises.~During the actual Pilates sessions, the instructors, who were certified and brought extensive experience to the program, provided real-time feedback to the participants. This feedback was based on the cueing instructions, aiming to optimize the execution of the Pilates exercises."
219551021|NCT02261181|DEVICE|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
219707562|NCT03795948|OTHER|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
219707563|NCT02629770|DRUG|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
219707564|NCT03702699|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
219707565|NCT01978756|OTHER|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
219707566|NCT00091858|DRUG|Darbepoetin Alfa|6.75 mcg/kg Q4W
219707567|NCT00091858|DRUG|Placebo|Placebo Q4W
219707568|NCT06222307|OTHER|Game-Based Exercises|Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
219707569|NCT06427499|DRUG|Stannous fluoride toothpaste|brush 2 min morning \& night daily
219707570|NCT06427499|DRUG|Colgate Cavity Protection Toothpaste|brush 2 min morning \& night daily
219123934|NCT03432039|BEHAVIORAL|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
219123935|NCT03432039|BEHAVIORAL|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
219123936|NCT01091285|DEVICE|Foley Catheter|Foley Catheter 16-19 H
219123937|NCT01091285|DEVICE|Double Balloon Catheter|Double Balloon Catheter for 16-19H
219707571|NCT02587936|OTHER|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
219707572|NCT03654417|DRUG|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
219707573|NCT03654417|DRUG|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
219707574|NCT00177125|DEVICE|ErectAid|
219707575|NCT02937441|OTHER|Ultrasonic Measurement|"How we measure;~1. First measurement shall be taken in 4 hours.~2. Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~3. Third measurement shall be taken after fluid treatment.~4. Fourth measurement shall be taken at patients polyclinic control."
219707576|NCT01134666|DRUG|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
219707577|NCT04131972|DEVICE|REGENERA|REGENERA breast implant
219707578|NCT00404313|DRUG|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
219707579|NCT00404313|DRUG|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
219707580|NCT00146471|DRUG|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
219707581|NCT00146471|DRUG|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
219707582|NCT03241693|OTHER|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
219707583|NCT03241693|OTHER|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
219707584|NCT04002986|GENETIC|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
219123938|NCT00553111|OTHER|educational video|educational video
219707585|NCT00862992|DRUG|Cariprazine 3 mg|
219707586|NCT00862992|DRUG|Cariprazine 6 mg|
219707587|NCT00862992|DRUG|Cariprazine 12.5 mg|
219707588|NCT02094040|BEHAVIORAL|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
219707589|NCT02872441|BIOLOGICAL|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
219123939|NCT04022642|OTHER|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of \>=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
219123940|NCT03608020|DRUG|BMX-001|Manganese butoxyethyl pyridyl porphyrin
219123941|NCT03608020|RADIATION|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
219123942|NCT02427646|DRUG|BoNT-A|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
219123943|NCT01553786|DRUG|Lenalidomide|Lenalidomide
219123944|NCT01932944|DEVICE|No treatment|
219123945|NCT04136028|DRUG|Kineret|Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
219123946|NCT00989170|BEHAVIORAL|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
219707590|NCT02912936|DIETARY_SUPPLEMENT|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
219707591|NCT02912936|DIETARY_SUPPLEMENT|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
219707592|NCT02880618|DEVICE|Barostim Neo™ System|
219707593|NCT00910585|BEHAVIORAL|Coaching, providing social support|Active telephone and in person coaching
219707594|NCT02697045|DRUG|Aripiprazole 400mg LAI|Aripiprazole 400mg, IM, Once a month
219707595|NCT04626076|OTHER|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
219123947|NCT00989170|BEHAVIORAL|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
219123948|NCT02288858|DIETARY_SUPPLEMENT|Viviscal Oral Supplement Tablets|Tablet (512 mg)
219123949|NCT03946657|DRUG|Inhalational anesthetic|Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
219123950|NCT03946657|DRUG|Intravenous anesthetic|Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
219707596|NCT05987384|DIETARY_SUPPLEMENT|Arachidonic acid|D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
219707597|NCT05987384|DIETARY_SUPPLEMENT|Sunflower oil|The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
219707598|NCT05987384|BIOLOGICAL|Rabies Vaccine (Vero Cell) for Human Use|Every participant will receive three doses of rabies vaccination.
219707599|NCT00430326|DRUG|Avotermin|
219707600|NCT02072200|DRUG|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
219707601|NCT00374478|DRUG|Scopolamine|
219707602|NCT05503498|OTHER|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
219123951|NCT05263453|DRUG|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
219123952|NCT05263453|DRUG|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
219707603|NCT03199105|OTHER|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
219707604|NCT04913922|DRUG|Azacitidine Injection|s.c. 75 mg/m2 BSA for 7 days
219707605|NCT04913922|DRUG|Nivolumab|480 mg i.v.
219123953|NCT01040663|OTHER|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
219123954|NCT05335135|OTHER|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
219123955|NCT05335135|OTHER|Usual Care|Clinical care without decision support provided by TriageGo-MDW
219123956|NCT01101542|BIOLOGICAL|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
219123957|NCT01101542|OTHER|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
219123958|NCT04606888|DEVICE|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
219707606|NCT04913922|DRUG|Relatlimab|80-160mg i.v.
219707607|NCT03311906|DRUG|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
219707608|NCT03311906|PROCEDURE|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
219707609|NCT01277861|DRUG|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
219707610|NCT02696798|DRUG|Ixekizumab|Administered SC
219707611|NCT02696798|DRUG|Placebo|Administered SC
219707612|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
219707613|NCT03879694|DRUG|Octreotide Acetate|Given IM
219707614|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
219707615|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
219707616|NCT03537833|OTHER|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
219707617|NCT04399447|RADIATION|Echocardiography|left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS
219707618|NCT02735564|PROCEDURE|Bariatric Surgery|
219707619|NCT00847314|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
219707620|NCT03451370|DRUG|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
219707621|NCT03451370|DRUG|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
219707622|NCT03451370|DRUG|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
219707623|NCT04853485|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
219707624|NCT06751433|DEVICE|Scar gel|Health care product (scar gel)
219707625|NCT06751433|DEVICE|Scar gel comparator|Health care product (Scar gel comparator)
219707626|NCT05159934|DRUG|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
219707627|NCT05159934|DRUG|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
219707628|NCT00805259|BEHAVIORAL|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
219707629|NCT01831843|DEVICE|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
219707630|NCT01831843|DEVICE|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
219123959|NCT04803084|OTHER|Tempus assay|Blood collection
219123960|NCT04803084|OTHER|Advanced pathology 1|Tissue procurement (from diagnostic biopsy)
219123961|NCT04803084|OTHER|Advanced pathology 2|Tissue procurement (from research biopsy)
219123962|NCT04187703|DRUG|5-azacytidine|5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
219123963|NCT04187703|DRUG|Decitabine|Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
219707631|NCT01831843|DEVICE|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
219707632|NCT03025321|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
219707633|NCT05777421|PROCEDURE|Conventional Physical Therapy for Knee Osteoarthriths|Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week
219707634|NCT05777421|PROCEDURE|Virtual Reality-Based Therapeutic Exercise regimes|"* Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~* Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total."
219707635|NCT00267436|BEHAVIORAL|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
219123964|NCT05823337|DIETARY_SUPPLEMENT|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
219123965|NCT05823337|DIETARY_SUPPLEMENT|only diet|diet suitable for pregnancy
219123966|NCT05459818|DEVICE|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
219123967|NCT00324714|DRUG|risedronate sodium|
219123968|NCT00324714|OTHER|diagnostic laboratory biomarker analysis|
219123969|NCT05230550|DRUG|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
219123970|NCT06613659|DRUG|traditional Chinese medicine (TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
219707636|NCT05349305|DRUG|continuous renal replacement therapy|continuous renal replacement therapy
219707637|NCT06054711|OTHER|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
219707638|NCT01273259|DRUG|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
219707639|NCT01273259|DRUG|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
219707640|NCT04481139|DRUG|SHR0302|SHR0302, oral, once daily
219707641|NCT04481139|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
219707642|NCT04324229|DRUG|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
219123971|NCT06613659|DRUG|non traditional Chinese medicine (non-TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
219123972|NCT00901485|DEVICE|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
219123973|NCT00901485|DEVICE|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
219123974|NCT06918262|DIAGNOSTIC_TEST|local treatment|Tumour somatic mutations were identified by 1021 panel sequencing of tumour tissues from cancer patients, and up to 20 mutations were selected as follow-up monitoring loci based on the tumour somatic variants of the patients, and a personalised panel was designed and customised.Post-operative blood from patients was analysed for recurrence risk stratification and drug indications using a combination of personalised panel and a cancer-specific core panel (\~5 kb) stacked on top of each other. The postoperative blood of patients was subjected to cfDNA targeted capture and ultra-high depth NGS sequencing (\&gt;100,000×) to analyse the status of the surveillance loci in the peripheral blood for recurrence risk stratification and medication advice.
219123975|NCT06696196|DEVICE|smart watches(wearable devices)|Participants will be asked to wear two smart watches simultaneously. The first smart watch is a dedicated prototype for validating algorithm developed by MediaTek. The second smart watch is Basis Peak. These watches are going to acquire PPG, body movements, skin temperature, and skin conductance.
219123976|NCT06744439|DRUG|BR1015|One tablet administered alone
219123977|NCT06744439|DRUG|BR1015-2|One tablet administered alone
219123978|NCT06744439|DRUG|BR1015-3|One tablet administered alone
219707643|NCT04324229|DRUG|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
219707644|NCT05407883|BEHAVIORAL|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
219707645|NCT01044524|RADIATION|SLV 334|2000 mg via i.v. solution
219707646|NCT07152704|DEVICE|Active therapy with non-ablative Er:YAG laser|three intravaginal and vulvar/clitoral treatments within 60 days
219707647|NCT07168096|OTHER|Psychosocial and clinical assessment|Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.
219707648|NCT07168798|DEVICE|Pulse oximeter|OLV-4201 pulse oximeter with sensors: TL-272T3, TL-274T3 and TL-273T3
219123979|NCT06748911|DEVICE|NaviCam Detachable String Capsule|Subjects will swallow the NaviCam capsule with 20 ml water while positioned in the upright position. Once the capsule reaches the gastric cardia, the string will slowly be pulled up to systematically inspect the Z-line and upper, middle, and lower thirds of the esophagus guided by real-time viewing and by moving the capsule solely with the tether. Images will be captured at a rate of 2 frames per second.
219123980|NCT06919822|DEVICE|Personalized SCAN Electrical Stimulation|"* Stage 1: iTBS Intervention (14 days) and Washout Period (3-6 months)~  * All enrolled participants undergo:~    * Baseline clinical assessments~   * Structural and functional MRI with pBFS mapping~   * Resting motor threshold determination~ * Daily iTBS sessions targeting individualized SCAN coordinates:~    * Treatment duration: 14 consecutive days~   * Post-intervention evaluation at Day 14-21~ * Mandatory observation window:~    * No neuromodulation therapies permitted~   * Stable PD medication regimen maintained~   * Monthly safety monitoring~* Stage 2: Surgical Intervention and Follow-up (12 months)~  * Surgical Procedure:~    * Epidural electrode implantation~   * 7-day externalized stimulation testing~   * Pulse generator internalization~ * Chronic Stimulation Stage:~    * Parameter optimization visits~   * Scheduled follow-ups at Months 1, 3, 6, 9, 12"
219123981|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Fentanyl|25 mcg Fentanyl 12.5 mg Bupivacaine
219123982|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Midazolam|2 Mg Midazolam 12.5 mg Bupivacaine
219123983|NCT06919484|OTHER|RCexp|patients received different RCexp
219123984|NCT06918587|DEVICE|TPI-120 with On body injector|6mg Subcutaneous injection
219225794|NCT06340191|OTHER|Pilates without cueing|"The Pilates without cueing portion of the study involved participants following the same comprehensive Pilates program as the Pilates with cueing group, with a significant distinction: they did not receive any additional training on cueing. This group engaged in 60-minute Pilates sessions twice a week for 8 weeks, under the supervision of certified and highly experienced Pilates instructors. The program included a variety of exercises, both mat-based and utilizing props, designed to improve participants\&#39; physical condition and wellness.~However, unlike their counterparts in the first group, these participants were not given explicit instructions on how to enhance their body alignment, muscle engagement, or movement techniques through verbal and tactile cues. They performed the Pilates exercises following the standard regimen, without the nuanced guidance and real-time feedback focused on optimizing exercise execution through cueing."
219707649|NCT07168382|BEHAVIORAL|DAPHNE Chatbot Intervention|The DAPHNE intervention consists of a conversational, AI-powered chatbot designed to identify and address health-related social needs (HRSNs) among caregivers of pediatric patients. Delivered via a secure mobile and web-based application, the chatbot facilitates natural language interactions to assess needs, generate personalized resource recommendations, and support real-time navigation to community-based services. Participants assigned to the intervention arm will have continuous access to the chatbot over a six-month period, including automated nudges, tailored prompts, and context-aware suggestions. The intervention is non-invasive and participant-driven.
219707650|NCT07168382|OTHER|Standard HRSN Screening and Referral (Usual Care)|Participants randomized to the control group will receive the standard-of-care HRSN screening and referral services as currently implemented in Nationwide Children's Hospital Primary Care Clinics. These services include in-clinic social needs assessments conducted during routine visits and referrals to internal or external resources, such as social work or care coordination teams. Participants in this group will not receive access to the DAPHNE chatbot.
219707651|NCT07169422|OTHER|Usual care for diabetic kidney disease management without primary care provider.|Participants in the control group will receive usual care for diabetic kidney disease which includes virtual care, walk-in clinics, or mobile health clinics for people without a primary care provider.
219707652|NCT07169422|OTHER|Pharmacist-led validated diabetic kidney disease decision support algorithm.|Pharmacist working in community pharmacy primary care clinic in Nova Scotia will utilize previously validated diabetic kidney disease decision support algorithms for renin-angiotensin system inhibitors (RASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or nonsteroidal mineralocorticoid receptor antagonists (nsMRA).
219707653|NCT07167108|OTHER|Conventional program, with addition to Mulligan technique|The Mulligan Concept is a manual therapy approach developed by New Zealand physiotherapist Brian Mulligan in the 1980s. It includes techniques such as Mobilization with Movement (MWM) and the Sustained Natural Apophyseal Glide (SNAG), which have attracted significant attention for their effectiveness in treating neck pain. Recent research has supported the benefits of physiotherapy interventions like SNAGs in improving cervical range of motion (ROM) and reducing pain.
219707654|NCT07167108|OTHER|Conventional Physical Therapy Program|Included exercises, electrical stimulation, and massage.
219707655|NCT07168317|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
219225795|NCT05741450|DEVICE|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
219123985|NCT06918587|DRUG|Fylntera|6mg subcutaneous
219123986|NCT02861495|DEVICE|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
219123987|NCT06360601|DRUG|Labetalol Injection|Labetalol intravenous infusion 20ml/hr
219123988|NCT06360601|DRUG|HydrALAZINE Injection|Hydralazine intravenous infusion 5mg/hr
219123989|NCT02993029|DRUG|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
219123990|NCT02993029|DRUG|Celecoxib|Celecoxib capsule 200mg qd by mouth.
219123991|NCT06120751|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
219123992|NCT06120751|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
219123993|NCT03177564|PROCEDURE|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
219123994|NCT03177564|PROCEDURE|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
219707656|NCT03365648|DIETARY_SUPPLEMENT|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~* Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~* Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~* Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
219707657|NCT03365648|OTHER|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
219707658|NCT01191749|DRUG|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
219707659|NCT03454555|BEHAVIORAL|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. Participants in the SDM arm received their regular pain care visits with a designated SDM-trained clinician over a 12-month period. SDM intervention participants scheduled pain visits as often as needed for pain management (typically quarterly). SDM participants also received an electronic and physical packet of educational materials after randomization.
219707660|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. MI + CBT-CP participants received one MI session plus up to eight weekly CBT-CP group sessions.
219707661|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
219707662|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
219707663|NCT04530630|DRUG|BIC/F/TAF 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
219707664|NCT00850642|DRUG|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
219707665|NCT00850642|DRUG|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
219707666|NCT03675308|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous injection
219707667|NCT03675308|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous injection
219707668|NCT06128954|DRUG|900mg TETA 4HCl Once Daily Formulation|3x300mg trientine base tablets as a single AM dose
219707669|NCT06128954|DRUG|900mg TETA 4HCl Cuprior®|6 x150mg trientine base tablets in two equally divided doses
219707670|NCT06548750|OTHER|Intrinsic and Ectrinsic Exercise|Intrinsic and extrinsic muscle strengthening exercises
219707671|NCT06548750|OTHER|Intrinsic Exercise|Intrinsic muscle strengthening exercises
219707672|NCT03360721|DRUG|Abiraterone Acetate|Given PO
219707673|NCT03360721|DRUG|Apalutamide|Given PO
219707674|NCT03360721|DRUG|Prednisone|Given PO
219707675|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
219707676|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
219707677|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
219707678|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
219707679|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
219707680|NCT01775098|DRUG|allopurinol|No arms will not be change as the study as been closed.
219225796|NCT05741450|DEVICE|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
219123995|NCT03177564|PROCEDURE|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
219123996|NCT06028841|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
219123997|NCT00823589|OTHER|Blood test and clinical test|Blood test and clinical test
219123998|NCT02794116|PROCEDURE|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
219123999|NCT02794116|PROCEDURE|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
219124000|NCT01929993|PROCEDURE|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
219707681|NCT04742179|OTHER|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
219707682|NCT03077867|PROCEDURE|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
219707683|NCT01386385|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
219124001|NCT01929993|PROCEDURE|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
219124002|NCT00378521|DRUG|MQX-503|
219124003|NCT04071080|DRUG|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
219124004|NCT04071080|DRUG|Placebo|500mL Gatorade
219124005|NCT06507969|OTHER|The Effect of Body Composition on Respiratory Parameters, Functional Capacity and Sleep in Healthy Young Adults|Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded
219124006|NCT01965080|DRUG|Exemestane|One tablet Exemestane 25 mg daily
219124007|NCT01256476|DRUG|pitavastatin|pitavastatin 4 mg once daily (QD)
219124008|NCT01256476|DRUG|pravastatin|Pravastatin 40 mg once daily (QD)
219124009|NCT04941417|DRUG|PD-1 inhibitor|Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
219124010|NCT05226481|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
219225797|NCT06488794|DRUG|colistimethate sodium|100 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for a maximum of 7 days for eligible ventilated children starting from day 3 of mechanical ventilation.
219225798|NCT06488794|DRUG|0.9% Saline|Nebulization of 3 ml of 0.9% saline twice a day for a maximum of 7 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
219225799|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
219225800|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
219707684|NCT01386385|DRUG|Carboplatin|Given IV
219707685|NCT01386385|OTHER|Laboratory Biomarker Analysis|Correlative studies
219707686|NCT01386385|DRUG|Paclitaxel|Given IV
219707687|NCT01386385|OTHER|Placebo Administration|Given PO
219707688|NCT01386385|DRUG|Veliparib|Given PO
219707689|NCT02617251|OTHER|No intervention|
219707690|NCT02927626|DRUG|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
219707691|NCT02927626|DRUG|Routine medical care|Routine medical care
219707692|NCT05347355|OTHER|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
219124011|NCT02115854|OTHER|labial biopsy|
219124012|NCT01796665|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
219124013|NCT01796665|DRUG|Acanya Gel|
219124014|NCT01796665|DRUG|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
219225801|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
219124015|NCT05603962|BEHAVIORAL|Visual training|Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.
219124016|NCT02268396|DRUG|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
219124017|NCT04840147|DEVICE|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
219124018|NCT04840147|PROCEDURE|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
219124019|NCT04529057|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
219124020|NCT02342912|BEHAVIORAL|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
219124021|NCT00163215|DRUG|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
219124022|NCT02836145|OTHER|Differentiation of hiPSCs to skeletal muscle progenitors|
219124023|NCT05202379|DRUG|CC-42344|CC-42344 capsules
219124024|NCT05202379|DRUG|Placebo|Placebo capsules
219124025|NCT05915130|BEHAVIORAL|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
219124026|NCT01620827|OTHER|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
219124027|NCT01620827|OTHER|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
219707693|NCT05347355|OTHER|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
219707694|NCT05032183|DRUG|Cyclophosphamide|Given IV
219124028|NCT02985697|DRUG|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
219124029|NCT02985697|DRUG|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
219124030|NCT02985697|DRUG|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
219124031|NCT03556826|BEHAVIORAL|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
219124032|NCT00535197|BIOLOGICAL|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
219124033|NCT06401850|OTHER|Education Group|The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.
219225802|NCT00628706|DRUG|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
219707695|NCT05032183|DRUG|Cytarabine|Given IT
219707696|NCT05032183|DRUG|Dexamethasone|Given IV or PO
219707697|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
219707698|NCT05032183|DRUG|Leucovorin|Given IV
219707699|NCT05032183|DRUG|Mercaptopurine|Given PO
219707700|NCT05032183|DRUG|Mesna|Give IV
219707701|NCT05032183|DRUG|Methotrexate|Given IT
219707702|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
219707703|NCT05032183|DRUG|Prednisone|Given PO
219225803|NCT03360513|OTHER|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
219707704|NCT05032183|BIOLOGICAL|Rituximab|Given IV
219707705|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219707706|NCT05032183|DRUG|Vincristine|Given IV
219707707|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
219707708|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
219707709|NCT03199209|BEHAVIORAL|Patient Visit|Attend study visit with research staff
219707710|NCT03199209|OTHER|Questionnaire Administration|Ancillary studies
219707711|NCT03199209|OTHER|Text Message|Receive information about healthy lifestyles
219707712|NCT03199209|OTHER|Text Message|Receive texts about healthy homes
219707713|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
219707714|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
219707715|NCT03550885|OTHER|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
219707716|NCT03550885|OTHER|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
219707717|NCT06480565|DRUG|ADI-270|Anti-CD70 CAR-T
219707718|NCT06480565|DRUG|Fludarabine|Chemotherapy for Lymphodepeletion
219707719|NCT06480565|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
219707720|NCT06122272|OTHER|Test Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
219707721|NCT06122272|OTHER|Control Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.
219707722|NCT06368778|OTHER|Verbal Advice|The participant will receive verbal instructions following the standard physical therapy.
219707723|NCT06368778|OTHER|Bathroom Scale|The participant is given a sense of what a 20 kg load feels like using a scale.
218985934|NCT02025322|BEHAVIORAL|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
219707724|NCT06368778|DEVICE|Loadsol Biofeedback|Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
219707725|NCT05183347|DRUG|BI 1291583|BI 1291583
219707726|NCT05183347|DRUG|Placebo|Placebo
219707727|NCT06357182|DRUG|Azacitidine|Given SC
219707728|NCT06357182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219707729|NCT06357182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219707730|NCT06357182|PROCEDURE|Echocardiography Test|Undergo ECHO
219707731|NCT06357182|DRUG|Iadademstat|Given PO
219707732|NCT06357182|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219707733|NCT06357182|OTHER|Questionnaire Administration|Ancillary study
219707734|NCT06357182|DRUG|Venetoclax|Given PO
219707735|NCT04254263|DRUG|pyrotinib|pyrotinib 400 mg, orally once daily for one year
219707736|NCT06552234|DRUG|Repotrectinib|Repotrectinib 160 mg BID, until progression or unacceptable toxicity
219707737|NCT05165433|BIOLOGICAL|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion
219707738|NCT05960175|DEVICE|New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application|"The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary.~If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram."
219707739|NCT03768063|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
219707740|NCT03768063|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
219707741|NCT03768063|DRUG|Alectinib|Alectinib will be administered as directed per the parent study.
219707742|NCT03768063|DRUG|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
219124034|NCT06401850|OTHER|Control Group|No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
219124035|NCT04240119|OTHER|According to current clinical care standards|Enrolled subjects may be treated with medical management or surgically using indirect revascularization surgery.
219124036|NCT06114329|DRUG|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
219124037|NCT04902742|PROCEDURE|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
219124038|NCT04902742|PROCEDURE|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
219124039|NCT01913756|DIETARY_SUPPLEMENT|Gamalost (Norwegian traditional cheese)|
219124040|NCT01913756|DIETARY_SUPPLEMENT|Gouda-type cheese|
219124041|NCT00003372|DRUG|topotecan hydrochloride|
219124042|NCT00001538|BIOLOGICAL|APL 400-003|
219124043|NCT04602364|OTHER|Noninterventional|Not applicable; Noninterventional study
219124044|NCT03660943|DRUG|Placebo|Receiving Placebo Injection
219124045|NCT03660943|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 Injection
219707743|NCT03768063|DRUG|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
219707744|NCT03768063|DRUG|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
219707745|NCT03768063|DRUG|Venetoclax|Venetoclax will be administered as directed per the parent study.
219124046|NCT00115180|OTHER|No intervention|No intervention
219124047|NCT04859556|DEVICE|Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
219707746|NCT03768063|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
219707747|NCT03768063|DRUG|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
219707748|NCT03768063|DRUG|Sunitinib|Sunitinib will be administered as directed per the parent study.
219225804|NCT02132039|OTHER|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
219225805|NCT02132039|OTHER|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
219225806|NCT00326196|DEVICE|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
219707749|NCT03768063|DRUG|Niraparib|Niraparib will be administered as directed per the parent study.
219707750|NCT03768063|DRUG|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
219707751|NCT03768063|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
219707752|NCT03768063|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
219707753|NCT03768063|DRUG|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
219707754|NCT03768063|DRUG|Rucaparib|Rucaparib will be administered as directed per the parent study.
219707755|NCT05895643|DRUG|Semaglutide Injectable Product|Once weekly injections s.c with semaglutide (Wegovy)
219707756|NCT05895643|DRUG|Placebo|Once weekly injections s.c with placebo (BD Posiflush)
219707757|NCT02310594|OTHER|cytology specimen collection procedure|Undergo blood sample collection
219124048|NCT04859556|DEVICE|Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
219124049|NCT04730336|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
219124050|NCT05484024|DRUG|Sintilimab|PD-1 inhibitor
219124051|NCT05484024|RADIATION|Short-course radiotherapy|Pelvic radiation
219124052|NCT05484024|COMBINATION_PRODUCT|CAPOX/mFOLFOX|chemotherapy regimen
219707758|NCT02310594|OTHER|laboratory biomarker analysis|Correlative studies
219707759|NCT01184807|DRUG|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
219707760|NCT00135655|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
219124053|NCT00003195|BIOLOGICAL|recombinant interferon alfa|
219124054|NCT00003195|DRUG|busulfan|
219124055|NCT00003195|PROCEDURE|allogeneic bone marrow transplantation|
219124056|NCT00003195|PROCEDURE|peripheral blood stem cell transplantation|
219124057|NCT00003195|RADIATION|radiation therapy|
219124058|NCT00231179|BEHAVIORAL|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
219124059|NCT00231179|OTHER|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
219707761|NCT05750082|DEVICE|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
219707762|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
219707763|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
219707764|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
219707765|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
219707766|NCT06274021|DEVICE|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
219707767|NCT06047119|PROCEDURE|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
219707768|NCT06047119|PROCEDURE|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
219707769|NCT06047119|PROCEDURE|Tidal volume|Tidal volume during general anesthesia
219707770|NCT06047119|PROCEDURE|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
219124060|NCT02028910|DRUG|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child"
219124061|NCT00408668|BIOLOGICAL|PEV3A|
219124062|NCT00408668|BIOLOGICAL|FP9 ME-TRAP|
219124063|NCT00408668|BIOLOGICAL|MVA ME-TRAP|
219124064|NCT00920374|BIOLOGICAL|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
219124065|NCT04438811|OTHER|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
219124066|NCT04438811|OTHER|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
219124067|NCT02583074|PROCEDURE|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
219124068|NCT02583074|PROCEDURE|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
219124069|NCT01884974|OTHER|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
219124070|NCT02491411|DRUG|Dexamethasone|Given PO
219124071|NCT02491411|DRUG|Enzalutamide|Given PO
219124072|NCT02491411|OTHER|Laboratory Biomarker Analysis|Correlative studies
219124073|NCT02491411|OTHER|Quality-of-Life Assessment|Ancillary studies
219124074|NCT04034238|DRUG|LMB-100|Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
219124075|NCT04034238|DRUG|Tofacitinib|Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
219124076|NCT04034238|DEVICE|Mesothelin Expression|Test for mesothelin expression in tumor tissues for study eligibility
219124077|NCT03968887|OTHER|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
219124078|NCT01039090|DRUG|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
219124079|NCT01039090|DRUG|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
219124080|NCT01939158|BIOLOGICAL|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
219124081|NCT01939158|BIOLOGICAL|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
219124082|NCT01182870|DRUG|choleclaciferol|800-6000 IU cholecalciferol per day
219124083|NCT05274789|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
219124084|NCT05274789|OTHER|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
219124085|NCT03294265|BEHAVIORAL|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
219124086|NCT03294265|BEHAVIORAL|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups."
219124087|NCT06212921|DIAGNOSTIC_TEST|Sequential blood samples|Sequential blood samples for diagnostic tests is the only intervention in thei study
219124088|NCT02953275|DRUG|vedolizumab|standard of care
219124089|NCT02953275|DRUG|Pentoxifylline|added to vedolizumab
219124090|NCT02953275|DRUG|placebo|added to vedolizumab
219124091|NCT03296579|DEVICE|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
219225807|NCT00326196|PROCEDURE|Coronary artery bypass graft (CABG)|coronary bypass
219225808|NCT05532501|DRUG|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
219707771|NCT06468033|BIOLOGICAL|Ropeginterferon alfa-2b|"Pre-filled Syringe.~Dosage: up to 500mcg"
219707772|NCT06468033|OTHER|Placebo|Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
219707773|NCT04058405|BEHAVIORAL|Observational|Cross-sectional observations
219707774|NCT00788671|OTHER|Laboratory Biomarker Analysis|Correlative studies
218985935|NCT03758066|DEVICE|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
218985936|NCT01216761|DRUG|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
218985937|NCT01216761|DRUG|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
219124092|NCT03296579|DEVICE|CPAP|The patient breathes against a constant pressure delivered by face mask.
218985938|NCT01216761|DRUG|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
219225809|NCT05532501|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
219124093|NCT03296579|DRUG|Ipratropium|Nebulized q6h
219124094|NCT03296579|DRUG|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
219124095|NCT03296579|DRUG|Aminophylline|6mg/kg IV (if no progress)
219124096|NCT03296579|DRUG|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
219124097|NCT03936062|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
219124098|NCT03936062|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
219124099|NCT00691158|DRUG|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
219124100|NCT00691158|DRUG|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
219124101|NCT00691158|DRUG|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
219124102|NCT00691158|DRUG|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
219124103|NCT05266196|DRUG|Seclidemstat|Treatment assigned as per parent protocol
219124104|NCT05972083|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219124105|NCT02705911|OTHER|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
219124106|NCT02705911|OTHER|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
219124107|NCT00575978|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
219124108|NCT05376605|OTHER|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
219124109|NCT06189716|DEVICE|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
219707775|NCT00788671|DEVICE|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
219707776|NCT00788671|OTHER|Quality-of-Life Assessment|Ancillary studies
219707777|NCT05542147|DRUG|Fenofibrate 145 mg|1 tablet per day
219707778|NCT05542147|DRUG|Placebo|1 tablet per day
219707779|NCT05489588|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
219707780|NCT04069897|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
219707781|NCT04069897|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
219707782|NCT06469801|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 36 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course. Patients will also undergo a portable MRI within 24 hours of clinical head imaging, if applicable.
219124110|NCT02065245|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
219124111|NCT02065245|BIOLOGICAL|Placebo|Placebo administered by peripheral intravenous infusion.
219124112|NCT02065245|BIOLOGICAL|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
219124113|NCT01304706|DRUG|Fluocinolone Acetonide|0.2 μg/day
219124114|NCT05895656|OTHER|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
219124115|NCT04073355|BEHAVIORAL|Physical Activity|Smartphone-delivered physical activity intervention
219124116|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
219124117|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
219124118|NCT04638777|DEVICE|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
219124119|NCT00286689|DRUG|Growth Hormone|
219124120|NCT00286689|PROCEDURE|Whole body Protein turnover|
219124121|NCT00286689|PROCEDURE|DEXA scan|
219124122|NCT03766919|DEVICE|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
219124123|NCT04639154|PROCEDURE|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
219124124|NCT02379364|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
219124125|NCT02892409|DRUG|Clarithromycin|Clarithromycin tablets
219124126|NCT02892409|DRUG|Amoxicillin|Amoxicillin capsules
219225810|NCT05532501|DRUG|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
219707783|NCT04799470|DEVICE|Novel DBS stimulation patterns|Stimulation patterns
219707784|NCT06114849|BEHAVIORAL|Treatment as usual|Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.
219124127|NCT02892409|DRUG|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
219124128|NCT02892409|DRUG|Lansoprazole|Lansoprazole capsules
219124129|NCT02892409|DRUG|TAK-438|TAK-438 tablets
219124130|NCT02331940|DRUG|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
219225811|NCT05532501|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
219124131|NCT02331940|DEVICE|Handihaler|Inhalation via the HandiHaler once daily
219124132|NCT02331940|DEVICE|Respimat|Inhalation via the Respimat once daily
219124133|NCT00903045|DRUG|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
219124134|NCT00903045|DRUG|Placebo|Identical placebo twice a day
219124135|NCT05665855|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid ketone monoester supplement.
219124136|NCT05665855|OTHER|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
219124137|NCT04940390|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
219124138|NCT04940390|DRUG|Placebo|Placebo for STS101
219124139|NCT00304811|DRUG|Vancomycin|
219124140|NCT00304811|DRUG|Vancomycin plus Gentamicin|
219124141|NCT00304811|DRUG|Vancomycin plus Rifampin|
219124142|NCT00304811|DRUG|Vancomycin plus Gentamicin plus Rifampin|
219124143|NCT01747161|DRUG|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
219124144|NCT01747161|DRUG|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
219124145|NCT05640817|DRUG|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
219124146|NCT05640817|DRUG|cisplatin with standard hydration with normal saline|chemotherapy
219225812|NCT02890524|DEVICE|night guard|60 days before and after intervention with the night guard
219225813|NCT02890524|DEVICE|placebo night guard|60 days before and after intervention with the placebo night guard
219225814|NCT00047125|RADIATION|radiation therapy|
219225815|NCT02148705|DRUG|NexoBrid|
219124147|NCT03679130|BEHAVIORAL|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
219124148|NCT03679130|BEHAVIORAL|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
219124149|NCT04291521|DRUG|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
219124150|NCT04291521|DRUG|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
219124151|NCT04291521|DRUG|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
219225816|NCT02148705|PROCEDURE|Standard of Care (SOC)|
219707785|NCT06114849|BEHAVIORAL|Barrier Reduction Intervention|"After a post is identified in real-time by the risk algorithm, participants will be shown a pop-up message offering information on mental health resources (e.g., crisis line). Participants will be asked about their likelihood of using these resources. For participants who indicate they are not likely to use these resources, they will then be presented with a list of common barriers to help-seeking, drawing from research in this area (e.g., Treatment is too expensive or I'm concerned about the police or paramedics getting involved.). Participants will be asked to click on any reason that resonates with them. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns and encourage professional help-seeking."
219707786|NCT06398158|DRUG|Ravulizumab|All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
219707787|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
219707788|NCT05611307|DIAGNOSTIC_TEST|Lipid profile|Advanced lipid profile
219707789|NCT05611307|DIAGNOSTIC_TEST|Coronary artery assessment|Coronary artery assessment via CT scans
218985939|NCT04138810|OTHER|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
218985940|NCT04138810|OTHER|Survey|Measure of satisfaction regarding post-op visit.
218985941|NCT01500577|DRUG|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
218985942|NCT01500577|DRUG|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
218985943|NCT01500577|OTHER|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
218985944|NCT01983813|OTHER|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
218985945|NCT01983813|OTHER|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
218985946|NCT05001256|OTHER|questionnaire study|Participants will be surveyed through face-to-face interviews.
218985947|NCT05014789|DEVICE|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
218985948|NCT03019783|DRUG|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
218985949|NCT03019783|OTHER|Placebo|The control group will stay on their baseline regimen
218985950|NCT04516174|PROCEDURE|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
218985951|NCT04516174|DRUG|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
218985952|NCT04516174|PROCEDURE|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
218985953|NCT04516174|DRUG|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
218985954|NCT03760978|DRUG|Dexmedetomidine|
218985955|NCT04010058|DEVICE|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
218985956|NCT04969575|OTHER|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
219124152|NCT01345292|DEVICE|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
219225817|NCT02148705|DRUG|Gel Vehicle|
219225818|NCT01462175|DRUG|RO5503781|
219707790|NCT05611307|DIAGNOSTIC_TEST|Hormone levels for hypogonadism|Hormone levels for hypogonadism
219707791|NCT05388474|OTHER|No ibalizumab or Pre-ibalizumab treatment|Patient registry
219707792|NCT05388474|BIOLOGICAL|On ibalizumab treatment|Patient registry
219707793|NCT03970720|DRUG|Metoclopramide|10 mg metoclopramide four times a day
219707794|NCT03970720|DRUG|Placebo|10 mg matching placebo capsules four times a day
219707795|NCT05037812|DRUG|Saline injection|Saline
219707796|NCT05037812|DRUG|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
219707797|NCT03405870|DRUG|Smoflipid|Administration of lipid injectable emulsion
219707798|NCT06621251|DRUG|TRL1068 (calpurbatug), a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
219707799|NCT06621251|PROCEDURE|DAIR|DAIR procedure will be performed between days 15-22
219707800|NCT06431763|DRUG|Inclisiran sodium|300 mg s.c. administered at day 1 and day 90
219707801|NCT06431763|DRUG|BPA|180 mg daily per oral
219707802|NCT04310930|DRUG|Amikacin|Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
219707803|NCT04310930|DRUG|Tigecycline|Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
218985957|NCT04969575|OTHER|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
218985958|NCT04969575|OTHER|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
218985959|NCT04969575|OTHER|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
218985960|NCT04969575|OTHER|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
218985961|NCT04447300|PROCEDURE|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
218985962|NCT04447300|PROCEDURE|Standard power application|Standard power application
218985963|NCT06065397|PROCEDURE|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
218985964|NCT03874637|DEVICE|Treament|Placement of the FemPulse System with therapy delivery
218985965|NCT03874637|DEVICE|Sham Control|Placement of the FemPulse System without therapy delivery
218985966|NCT02407860|OTHER|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
218985967|NCT02407860|OTHER|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
218985968|NCT00762385|DEVICE|galyfilcon A|galyfilcon A
218985969|NCT00762385|DEVICE|comfilcon A|comfilcon A
218985970|NCT06383078|DRUG|HR070803|HR070803 60 mg/\^2 D1 over 90 minutes.
218985971|NCT06383078|DRUG|Oxaliplatin|Oxaliplatin 85 mg/\^2 D1 over 2 hours.
218985972|NCT06383078|DRUG|Tegafur|initial dose of S-1 is determined according to the body surface area，orally, D1-7.
218985973|NCT06383078|DRUG|Folinic acid|Folinic acid 400 mg/\^2 D1
218985974|NCT06383078|DRUG|5-Fluorouracil|5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
218985975|NCT03129750|DEVICE|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
218985976|NCT02787096|DEVICE|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
218985977|NCT01786083|BEHAVIORAL|Application of Problem Solving Technique|
218985978|NCT00398580|DRUG|Nanomilled testosterone|
218985979|NCT00398580|DRUG|Nanomilled dutasteride|
218985980|NCT00398580|DRUG|commercially available dutasteride|
218985981|NCT03274024|DEVICE|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
218985982|NCT03274024|PROCEDURE|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
218985983|NCT05961332|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
218985984|NCT05961332|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
219707804|NCT04310930|DRUG|Imipenem|Adults: Intravenous Imipenem (≥50kg) 500mg twice daily (\<50kg) 15 mg/kg twice daily. Children: intravenous imipenem Day 1- 2- 25mg/kg (maximum 1g) twice daily. DAY 3- 25mg/kg (maximum 1g) four times daily (drop to 3 if not tolerated).
219707805|NCT04310930|DRUG|Cefoxitin|Adults: If imipenem is poorly tolerated intravenous cefoxitin 200 mg/kg thrice daily. Children: if imipenem is poorly tolerated intravenous cefoxitin 50mg/kg (maximum 4g) four times daily.
219707806|NCT04310930|DRUG|Azithromycin|"Adults: Oral azithromycin 500mg (≥40kg) once daily, (\<40kg) 250mg once daily.During consolidaiton: 500mg (≥40kg) thrice weekly, (\<40kg) 250mg thrice weekly.~Children: Oral azithromycin:10mg/kg (maximum 500mg) once daily. During consolidation 10mg/kg once daily maximum 500mg."
219707807|NCT04310930|DRUG|Clarithromycin|Adult: If azithromycin is poorly tolerated use oral clarithromycin 500mg twice daily.Children: If azithromycin is poorly tolerated use oral clarithromycin. In children 1 month old- 11years of age the following dosing applies: \<8kg: 7.5mg/kg twice daily, maximum dose 62.5mg, 8-11kg: 62.5mg twice daily, maximum dose 62.5mg, 12-19 kg: 125mg twice daily, maximum dose 125mg, 20-29 kg: 187.5mg twice daily, maximum dose 187.5mg, 30-40 kg: 250mg twice daily, maximum dose 250mg, Children 12-18 years of age: 500 mg twice daily
219707808|NCT04310930|DRUG|Clofazimine|Adult: Oral clofazimine 100mg once daily. Children: Oral clofazimine: 3-5mg/kg once daily. Maximum dose of 50mg once daily if \<40kg or 100mg if ≥40kg once daily.
219707809|NCT04310930|DRUG|Ethambutol|Adults: with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at either 15 mg/kg once daily or 25mg/kg thrice weekly. Children with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at 20 mg/kg once daily.
219707810|NCT04310930|DRUG|Amikacin|adult: Inhaled amikacin 500mg twice daily. Children: Inhaled amikacin 500mg twice daily
219707811|NCT04310930|DRUG|Linezolid|"Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral linezolid 600mg once daily.~Children: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Age 1 week - 9 years 10mg/kg twice daily maximum dose of 300mg. Age 10-12 years 10mg/kg twice daily maximum dose of 600mg. \>12 years 600mg once daily."
219707812|NCT04310930|DRUG|co-trimoxazole|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral Co-trimoxazole (TMP-SMX) 160/800mg twice daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral co-trimoxazole 5mg TMP/kg maximum dose of 160mg TMP/ 800mg SMX twice daily.
219707813|NCT04310930|DRUG|Doxycycline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline 100mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline (ages ≥ 8 years) 2mg/kg once daily maximum dose 100mg.
219707814|NCT04310930|DRUG|Moxifloxacin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 400mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 10-15mg/kg once daily, maximum dose 400mg
219707815|NCT04310930|DRUG|Bedaquiline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral bedaquiline (18-64 years of age) 400mg once daily for the first two weeks followed by 400mg thrice weekly for 22 weeks (maximum duration of 6 months).
219707816|NCT04310930|DRUG|Rifabutin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin: 5mg/kg once daily, maximum 300-450mg. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin 5mg/kg once daily
219707817|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will complete a virtual reality exercise (i.e., Supernatural) tutorial (YouTube instruction and in-headset gameplay instruction/practice) and will complete a 18-20 minute affect measurement medium intensity virtual reality exercise (i.e., Supernatural) session in the Behavioural Medicine Lab (UVic).
218985985|NCT05961332|DEVICE|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
218985986|NCT04550208|OTHER|3D analysis of different landing tasks|General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
218985987|NCT01540838|DRUG|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
218985988|NCT01540838|DRUG|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
218985989|NCT01816204|BEHAVIORAL|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
218985990|NCT01816204|BEHAVIORAL|face-to-face individual therapy|weekly individual counseling as usual.
218985991|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
218985992|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
218985993|NCT04007081|PROCEDURE|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
219124153|NCT01345292|DRUG|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
219124154|NCT01345292|DRUG|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
219124155|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2 and 4 months
219124156|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2, 4 and 11 months
219124157|NCT03742843|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
219124158|NCT05119933|DRUG|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
219124159|NCT04511663|COMBINATION_PRODUCT|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
219124160|NCT04511663|COMBINATION_PRODUCT|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
219124161|NCT03412942|DEVICE|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
219124162|NCT05240859|DRUG|Geleli|Adalimumab Biosimilar
219124163|NCT03397160|BEHAVIORAL|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
219124164|NCT02023944|OTHER|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
219124165|NCT06355817|DEVICE|Vibration|Vibration Assist Device, held to the forehead
219124166|NCT06355817|OTHER|Tapping|Tapping on the forehead
219124167|NCT06076759|DRUG|Intrathecal morphine or dexmedetomidine|Intrathecal injection
219124168|NCT05400980|DEVICE|Urocross implant|Urocross implant inserted via delivery catheter
219124169|NCT05400980|DIAGNOSTIC_TEST|Sham-control|Cystoscopy
219124170|NCT05241795|OTHER|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises"
219124171|NCT05241795|OTHER|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
219225819|NCT01475266|DRUG|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
219225820|NCT01475266|DRUG|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
219707818|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will be provided a virtual reality headset (Meta Quest 3 Headset) and subscription to a virtual reality exercise game (i.e., Supernatural) for 10 weeks. Participants will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity (equivalent to 75 minutes of vigorous physical activity) per week in their own home.
219707819|NCT05713071|PROCEDURE|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
219707820|NCT00463814|DRUG|AZD6244|Participants will receive single oral dose of AZD6244 as described in arm description.
219707821|NCT06955403|DEVICE|Precision 7 contact lenses|Acuvue Oaysis contact lens wearers have will be refit into precision 7 contact lenses.
219707822|NCT06025539|BEHAVIORAL|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
219707823|NCT05172609|BEHAVIORAL|Exposure Based Implementation Strategy (EBIS)|EBIS will include psychoeducation, assessment/hierarchy building. guided practice, and guidance for application to clinical practice.
219707824|NCT05172609|BEHAVIORAL|Implementation as Usual (IAU)|IAU will consist of standard didactic training and ongoing consultation activities for enrolled clinicians
219707825|NCT05119907|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219707826|NCT05975216|OTHER|Contact the patient|Phone call, email or letter to contact the patient to relink them.
219707827|NCT06955598|DRUG|SHR-2173|SHR-2173
219707828|NCT06782542|DRUG|Olutasidenib|Olutasidenib will be supplied as 150 mg capsules to be administered orally, twice per day (BID) on an empty stomach (fasting at least 1 hour before or 2 hours after a meal), starting on Cycle 1 Day 1, and will be given continuously.
219707829|NCT06782542|DRUG|Venetoclax|"Participants will receive Venetoclax as a 100mg tablet to be self-administered orally with a meal and water once daily, two hours after starting Olutasidenib administration, starting on Cycle 1 Day 1. The dosing regimen of Venetoclax is as follows:~* Cycle 1: Days 1 - 21 over a 28-day cycle~* Cycle 1 Week 1: Ramp-up dosing schedule up to 400mg (4 x 100mg/tablet)~* For participants with blast clearance: Cycle 2 and beyond: Days 1 - 14 over a 28-day cycle~* For participants with persistent clearance: Cycle 2 through 4: Days 1 - 21"
219707830|NCT06782542|DRUG|Azacitidine|Participants will receive Azacitidine 75 mg/m2 per day via subcutaneous (SC) injection or intravenous (IV) infusion on Days 1-7 of each cycle.
219707831|NCT06274489|DRUG|Setanaxib|Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.
219707832|NCT06274489|DRUG|Placebo|Matching film-coated placebo tablets, containing only excipients
219707833|NCT05654012|DEVICE|MRI|Grey Matter Volume (T1) Resting state BOLD
219707834|NCT05654012|DEVICE|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
219707835|NCT05654012|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
219707836|NCT05654012|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
219707837|NCT05654012|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
219707838|NCT05654012|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
219707839|NCT05654012|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
218985994|NCT04007081|DIAGNOSTIC_TEST|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
218985995|NCT04007081|OTHER|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
218985996|NCT04007081|OTHER|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
218985997|NCT06125522|DRUG|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
218985998|NCT06125522|DRUG|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
218985999|NCT02570360|BEHAVIORAL|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
218986000|NCT02570360|BEHAVIORAL|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
218986001|NCT03120234|DRUG|Dexmedetomidine|
218986002|NCT03120234|DRUG|Ketamine|
218986003|NCT03120234|DRUG|Fentanyl|
218986004|NCT03120234|DRUG|Placebos|o.9% normal saline will be used instead of ketamine
218986005|NCT02107404|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
218986006|NCT00871533|DRUG|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
218986007|NCT00871533|DRUG|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
218986008|NCT00871533|DRUG|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
219225821|NCT01583166|DRUG|Bupivacaine|10ml 0.5% bupivacaine
219225822|NCT01583166|DRUG|Saline|10ml 0.9% sodium chloride
219707840|NCT05654012|BEHAVIORAL|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
219707841|NCT05654012|BEHAVIORAL|Neural assessments|MRI and fMRI scans
219707842|NCT05654012|DIAGNOSTIC_TEST|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
219707843|NCT02903108|DRUG|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
219707844|NCT02903108|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
219707845|NCT03846479|DRUG|Itacitinib|for up to 56 days
219707846|NCT04599140|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
219707847|NCT04599140|BIOLOGICAL|Nivolumab|Given IV
219707848|NCT05461209|DRUG|Talquetamab|Talquetamab will be administered as subcutaneous injection.
219707849|NCT05461209|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
218986009|NCT00871533|DRUG|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
218986010|NCT05799170|OTHER|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
218986011|NCT02000583|OTHER|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
218986012|NCT02000583|OTHER|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
219707850|NCT06956586|OTHER|Therapeutic communication techniques|"Therapeutic communication techniques will be applied to children in the intensive care unit for two days."
219707851|NCT05020015|BIOLOGICAL|TAK-007|TAK-007 intravenous injection.
219707852|NCT05020015|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
219707853|NCT05612490|DRUG|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
219707854|NCT03994159|DEVICE|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
219707855|NCT02921100|PROCEDURE|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
218986013|NCT03641339|OTHER|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
218986014|NCT03641339|OTHER|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
218986015|NCT00493025|DRUG|cisplatin|Cisplatin IV
218986016|NCT00493025|DRUG|gefitinib|Gefitinib IV
218986017|NCT00493025|DRUG|paclitaxel|Paclitaxel IV
218986018|NCT00493025|PROCEDURE|adjuvant therapy|Postoperative ZD1839
218986019|NCT00493025|RADIATION|radiation therapy|Radiotherapy
218986020|NCT04033575|DRUG|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
219707856|NCT02921100|PROCEDURE|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
219707857|NCT02921100|PROCEDURE|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
219707858|NCT02921100|DEVICE|EUS-guided fine needle|
219707859|NCT02795143|DRUG|Isotretinoin|
219707860|NCT02795143|OTHER|Placebo|
219707861|NCT02358629|DEVICE|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
219707862|NCT00345306|DRUG|Comparison between two different progesterone administration|
219707863|NCT00908700|PROCEDURE|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
219707864|NCT00908700|PROCEDURE|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
219707865|NCT02515253|OTHER|Bra prescription|
219707866|NCT02515253|OTHER|Standard Care|
219707867|NCT06400810|DEVICE|Analog Devices Inc.|Wearable wrist device that collects Photoplethysmography, accelerometer data among other parameters.
219707868|NCT01954615|DRUG|5 mg ACT-281959 prodrug formulation I (Group A)|
219707869|NCT01954615|DRUG|20 mg ACT-281959 prodrug formulation I (Group B)|
219707870|NCT01954615|DRUG|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
219707871|NCT01954615|DRUG|ACT-281959 prodrug formulation II (Group G dose to be defined)|
219707872|NCT01954615|DRUG|ACT-246475 (Group G dose to be defined)|
219124172|NCT04822298|DRUG|AMG 160|AMG 160 administered as an intravenous (IV) infusion
219124173|NCT00453089|DRUG|VG101|
219124174|NCT01033643|DRUG|MK-3614|Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
219124175|NCT01033643|DRUG|Placebo for MK-3614|Participants were administered dose matched placebo tablets according to randomization.
219124176|NCT01430702|DEVICE|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
219124177|NCT01893320|DRUG|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
219124178|NCT01893320|DRUG|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
219124179|NCT02823743|DRUG|Aspirin|Daily medication
219124180|NCT02823743|DRUG|Placebo|Daily intake
219225823|NCT01583166|DRUG|Epinephrine|1:200,000 epinephrine
219707873|NCT01954615|DRUG|Placebo (Groups A to F)|
219707874|NCT05917379|BIOLOGICAL|fecal microbiota|FMT utilizes stool from a healthy donor and puts them into capsules after processing
219707875|NCT05917379|OTHER|Placebo|Starch into the same outlook capsule with fecal microbiota
219707876|NCT05917379|DIETARY_SUPPLEMENT|synbiotics|Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
218986021|NCT04033575|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
219707877|NCT02625740|DEVICE|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
219707878|NCT02625740|DEVICE|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
219707879|NCT02625740|DEVICE|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
218986022|NCT02126995|DRUG|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
218986023|NCT02989545|DEVICE|Anal Tape|
218986024|NCT04149379|DRUG|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
218986025|NCT01934946|OTHER|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
218986026|NCT01934946|OTHER|home rehabilitation|6 times home rehabilitation services within 3 months
218986027|NCT03173313|DEVICE|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
218986028|NCT01876420|DEVICE|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
218986029|NCT06032468|DEVICE|ARC Intellicare|wearable devices to guide rehabilitation exercise
218986030|NCT06032468|OTHER|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
218986031|NCT04352712|OTHER|blood sampling|blood sampling
218986032|NCT00067405|DRUG|Intravenous micronutrient therapy|
218986033|NCT04603456|DRUG|Lacteol fort|Lacteol fort is a drug containing lactobacilli
218986034|NCT04603456|DRUG|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
218986035|NCT04603456|DRUG|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
218986036|NCT03863197|BEHAVIORAL|Progressive strength training|Progressive Supervised Home-based Strength Training
218986037|NCT03832036|DIAGNOSTIC_TEST|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
218986038|NCT05188014|BEHAVIORAL|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
218986039|NCT05188014|BEHAVIORAL|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
218986040|NCT05338216|BEHAVIORAL|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
218986041|NCT05338216|BEHAVIORAL|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
218986042|NCT03891953|DRUG|DKY709|Novel immunomodulatory agent
219707880|NCT02625740|DRUG|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
219707881|NCT02625740|PROCEDURE|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
219707882|NCT00223574|DRUG|Control - high carbohydrate, high glycemic index foods|
219707883|NCT00223574|DRUG|high carbohydrate, low glycemic index foods|
219707884|NCT00223574|DRUG|low carbohydrate, high monounsaturate fat foods|
219707885|NCT01798290|BEHAVIORAL|narrative medicine: reading workshop|
219707886|NCT01798290|BEHAVIORAL|critical reading|
219707887|NCT04148456|PROCEDURE|Covered Endovacular Reconstruction of Aortic Bifurcation|"* The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~* After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~* A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~* The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
219707888|NCT02127853|DRUG|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
219707889|NCT02127853|DRUG|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
219707890|NCT00954876|DRUG|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
219707891|NCT02758470|DRUG|Acetazolamide|250 mg, taken orally three times per day
219707892|NCT02758470|DRUG|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
219707893|NCT02758470|OTHER|Placebo|A placebo will be taken three times per day
219707894|NCT02630654|OTHER|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
219707895|NCT05546762|DRUG|Povidone-iodine solution|Pleural irrigation with 2% povidone iodine
219707896|NCT05546762|DRUG|Normal saline|Pleural irrigation with normal saline
219707897|NCT05076929|DIAGNOSTIC_TEST|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
219707898|NCT00689741|BIOLOGICAL|Cervarix|3 doses of IM injection
219707899|NCT00689741|BIOLOGICAL|placebo|3 doses of IM injection of Al(OH)3 placebo
219707900|NCT05939167|DRUG|mesenchymal stem cell|Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
219707901|NCT05939167|OTHER|saline|saline is used as placebo in the placebo comparator group
219707902|NCT04089319|OTHER|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
218986043|NCT03891953|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
218986044|NCT06390397|OTHER|Produce prescription program|"Boxes of fresh fruit and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks. Participants will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
218986045|NCT06390397|OTHER|Standard of care|Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.
218986046|NCT06015451|OTHER|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
218986047|NCT06174649|DIAGNOSTIC_TEST|Reveal|Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
219707903|NCT04089319|OTHER|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
219707904|NCT05203016|OTHER|Hipotermia/Normotermia|The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
219707905|NCT01659905|DRUG|Montelukast|Chewable Tablet
219707906|NCT01659905|DRUG|Singulair|5 mg Chewable Tablet
219707907|NCT01324752|DRUG|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
219124181|NCT06633796|DEVICE|AMADEO|304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
219124182|NCT06633796|PROCEDURE|Standard of care|The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
219707908|NCT01324752|DRUG|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
219707909|NCT01324752|DRUG|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
219707910|NCT05884619|DEVICE|Dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
219707911|NCT01627717|DRUG|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
219707912|NCT01627717|DRUG|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
219707913|NCT02521480|DEVICE|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
219707914|NCT02521480|DEVICE|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
219707915|NCT02451878|BEHAVIORAL|E-Couch|e-couch is an online CBT based intervention
219707916|NCT04448808|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
219707917|NCT04448808|DRUG|Placebo|Placebo of BX-1, oral solution
219707918|NCT04189523|OTHER|SOC Pain Management|Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
219707919|NCT04189523|PROCEDURE|Early US Guided Nerve Block Administration|US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
219707920|NCT03113097|OTHER|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
219707921|NCT04118972|BEHAVIORAL|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
219707922|NCT04943783|DRUG|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
219707923|NCT00804271|DRUG|memantine|memantine tablets, OD, 12 weeks
219707924|NCT05282784|OTHER|Hyperthermia|"Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week."
219707925|NCT05282784|RADIATION|Radiotherapy|Patients will be treated with radiotherapy 5 times a week.
219707926|NCT02478671|DEVICE|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
219707927|NCT04799990|DRUG|Risankizumab|Subcutaneous Injection
219707928|NCT04799990|BIOLOGICAL|Comparator 1|Subcutaneous or Intravenous Injection
219707929|NCT04799990|DRUG|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
219707930|NCT00766220|DRUG|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
219707931|NCT00766220|DRUG|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
219707932|NCT00766220|DRUG|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
219124183|NCT01456663|DRUG|AFQ056|
219124184|NCT04484064|BEHAVIORAL|Adherence program|This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
219124185|NCT05946876|DRUG|XH-S003 (A)|IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
219124186|NCT05946876|OTHER|Placebo (B)|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
219124187|NCT04506671|PROCEDURE|Renal biopsy|Renal biopsy will be performed prior to the cryoablation on the basis of the center and according to the current protocols
219124188|NCT04506671|PROCEDURE|Cryoablation|Cryoablation under CT guidance will be performed on the basis of the center and according to the current protocols
219124189|NCT04506671|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be performed on the basis of the center and according to the current protocols
219124190|NCT04290429|DRUG|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
219124191|NCT01789203|DRUG|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
219707933|NCT03726476|BEHAVIORAL|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
219707934|NCT03726476|BEHAVIORAL|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
219707935|NCT02840565|DRUG|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
219707936|NCT02840565|DRUG|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
219124192|NCT01789203|DRUG|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
219707937|NCT02534961|DRUG|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
219707938|NCT02019069|DRUG|liposomal cytarabine-daunorubicin CPX-351|Given IV
219707939|NCT00614393|BIOLOGICAL|dalotuzumab|IV infusion
219707940|NCT00614393|DRUG|irinotecan hydrochloride|IV infusion
219707941|NCT00614393|BIOLOGICAL|cetuximab|IV infusion
219707942|NCT00614393|DRUG|placebo|IV infusion
219707943|NCT00000629|DRUG|Valproic acid|
219707944|NCT00000629|DRUG|Zidovudine|
219707945|NCT02328105|DRUG|Carboplatin|Dosing: AUC = 6; on Day 1
219707946|NCT02328105|DRUG|Abraxane|100 mg/m\^2; Days 1, 8, 15
219707947|NCT03132389|OTHER|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
219707948|NCT02544789|DRUG|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
219707949|NCT05796453|DEVICE|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
219707950|NCT05796453|DEVICE|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
219707951|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
219707952|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
219707953|NCT05442112|BEHAVIORAL|Wellness Patient Message|The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
219707954|NCT00739232|DRUG|HSD-016|
219707955|NCT00739232|OTHER|placebo|
219707956|NCT02612857|DRUG|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
219707957|NCT02612857|DRUG|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
219707958|NCT02612857|DRUG|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
219707959|NCT01588509|DRUG|Romosozumab|Administered by subcutaneous injection
219707960|NCT03870386|PROCEDURE|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
219707961|NCT03870386|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
219707962|NCT03276143|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
219707963|NCT03276143|DRUG|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
219707964|NCT03276143|DRUG|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
219707965|NCT00855582|DRUG|Tadalafil|tablet once daily by mouth for 12 weeks.
219707966|NCT00855582|DRUG|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
219707967|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
219707968|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
218986048|NCT06113003|DIETARY_SUPPLEMENT|Prebiotic|Wheat dextrin fiber
218986049|NCT06113003|DIETARY_SUPPLEMENT|Probiotic|Probiotic packet
218986050|NCT06195605|DEVICE|Restylane-L|Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
218986051|NCT06195605|DEVICE|Vehicle|Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
218986052|NCT05803785|DRUG|BBC1501|BBC1501 solution for Intravitreal injection
218986053|NCT00550121|DRUG|vitamin C|
218986054|NCT00550121|DRUG|placebo|
218986055|NCT02891694|OTHER|in vitro immuno-histo-chemical analysis of corneal epithelium|
218986056|NCT05904912|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
219707969|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
219707970|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
219707971|NCT03345004|BIOLOGICAL|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
219707972|NCT03345004|DIETARY_SUPPLEMENT|Vitamin D|Oil suspension of Vitamin D
219707973|NCT03345004|BIOLOGICAL|Placebo for Diamyd|Alhydrogel® only
219707974|NCT03345004|DIETARY_SUPPLEMENT|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
219707975|NCT03238469|DEVICE|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
219707976|NCT00165074|DRUG|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
219707977|NCT03070145|OTHER|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
219707978|NCT01531179|DRUG|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
219707979|NCT01531179|DRUG|Placebo|Placebo for 3 months
219707980|NCT01013753|DRUG|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
219707981|NCT01013753|DRUG|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
219707982|NCT01013753|DRUG|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
219707983|NCT01013753|DRUG|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
218986057|NCT05904912|DRUG|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
218986058|NCT05904912|DRUG|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
218986059|NCT00411528|DRUG|Patupilone|
218986060|NCT00411528|DRUG|prednisone|
218986061|NCT00411528|DRUG|docetaxel|
218986062|NCT01610531|OTHER|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
218986063|NCT01212458|DRUG|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
218986064|NCT00575991|DIETARY_SUPPLEMENT|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
219707984|NCT01013753|DRUG|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
219707985|NCT01013753|DRUG|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
219707986|NCT00539474|PROCEDURE|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
219707987|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
218986065|NCT02498132|OTHER|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
218986066|NCT02498132|OTHER|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
218986067|NCT02498132|OTHER|Treatment as Usual|Individuals will be provided with one on one therapy sessions
218986068|NCT01596478|BEHAVIORAL|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
218986069|NCT01596478|BEHAVIORAL|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
218986070|NCT01596478|BEHAVIORAL|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
219225824|NCT00457119|DRUG|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
219225825|NCT05543109|DRUG|Fentanyl|1 mic/kg during induction of anesthesia
219225826|NCT05543109|DRUG|Propofol|3mg/kg during induction of anesthesia
219707988|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
219707989|NCT05886881|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
219707990|NCT05886881|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
219707991|NCT05886881|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
219124193|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation."
219124194|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital."
219707992|NCT06583460|OTHER|Early and systematic oncosexological supporting care|"Each patient included in the study will be cared by an anthropologist and a sexologist.~This therapeutic support care will be based on :~* 2 qualitative semi-directive interviews (Baseline and M18),~* 2 individual consultations with questionnaires (Baseline and M18).~The qualitative semi-structured interviews will be conducted with the anthropologist, and the individual consultations with the sexologist.~At the end of the first oncosexology consultation, patients will be given the opportunity to decide whether or not to accept further systematic oncosexology support care, which will be based on :~* 3 individual and/or couple consultations,~* 3 group workshops.~Patients are under no obligation to accept this additional oncosexology support care."
219124195|NCT00001061|DRUG|Sevirumab|
219124196|NCT00001061|DRUG|Foscarnet sodium|
219124197|NCT00001061|DRUG|Ganciclovir|
219124198|NCT02174211|DRUG|Ranibizumab|Intravitreal injection of ranibizumab
219124199|NCT02174211|DRUG|Aflibercept|Intravitreal injection of aflibercept
219124200|NCT06629870|DEVICE|virtual reality|patients who received distraction using virtual reality glasses
219124201|NCT06629870|OTHER|control group|no any anxiety-reducing application
219124202|NCT06629870|OTHER|hypnotherapy|patients receiving hypnotherapy
219124203|NCT06629870|OTHER|mindfulness|patients who underwent mindfulness-based meditation
219124204|NCT03432221|DRUG|Desvenlafaxine|Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
219124205|NCT03350321|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
219124206|NCT03350321|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
219707993|NCT05201001|DRUG|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
219124207|NCT05515094|BEHAVIORAL|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
219124208|NCT05876936|DEVICE|contact lens sensor (CLS) SENSIMED Triggerfish®|contact lens sensor CLS placing and fitting evaluation, 24h recording
219124209|NCT00515086|DRUG|Everolimus|Tablets taken once a day with a full glass of water.
219124210|NCT00515086|PROCEDURE|Surgery|Salvage surgical resection
219124211|NCT02028884|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
219124212|NCT02028884|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
219124213|NCT02028884|DRUG|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
219124214|NCT02711982|PROCEDURE|Optic canal and optic nerve sheath decompression|within 5 days from trauma
219124215|NCT02711982|DRUG|methylprednisolone|within 5 days from trauma
219124216|NCT03810482|DEVICE|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
219124217|NCT03810482|OTHER|6 minute walking test|Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
219124218|NCT00121940|BEHAVIORAL|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
219124219|NCT02373813|DRUG|etanercept pre-filled syringe subcutaneous injection|etanercept for injection in pre-filled syringes
219124220|NCT02373813|DRUG|Oral methotrexate|"During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules."
219124221|NCT02373813|DRUG|Placebo for etanercept subcutaneous injection|etanercept placebo for injection in pre-filled syringes
219124222|NCT02373813|DRUG|Placebo for methotrexate|methotrexate placebo capsules
219707994|NCT05841550|BIOLOGICAL|TG01|All participants will receive the same treatment as described under arm
219707995|NCT05742295|DRUG|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
219707996|NCT02456558|DRUG|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
219124223|NCT02373813|DIETARY_SUPPLEMENT|Folic acid (non-investigational product)|Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
219124224|NCT04577248|DEVICE|edge-to-edge valve repair|edge-to-edge valve repair
219124225|NCT05000450|GENETIC|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
219124226|NCT05000450|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
219124227|NCT05000450|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219124228|NCT05000450|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219124229|NCT01969890|DRUG|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
219124230|NCT02547805|DRUG|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
219124231|NCT02547805|DRUG|Placebo|Placebo 5 capsules PO TID with meals
219124232|NCT03783455|PROCEDURE|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
219124233|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
219124234|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
219124235|NCT03783455|PROCEDURE|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
219124236|NCT03783455|PROCEDURE|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
219124237|NCT00723294|PROCEDURE|cryosurgery|
219124238|NCT00723294|PROCEDURE|therapeutic conventional surgery|
219707997|NCT02456558|DRUG|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
219124239|NCT06281717|DEVICE|Fetal Endotracheal Occlusion (FETO)|The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
219124240|NCT04202575|PROCEDURE|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
219707998|NCT00580099|OTHER|assisted exercise|4 weeks of passive range of motion exercise
219707999|NCT00580099|OTHER|cuddle|cuddle infant for 20 minutes
219708000|NCT01733953|DRUG|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
219708001|NCT01733953|DRUG|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
219708002|NCT00494312|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
219708003|NCT00494312|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
219124241|NCT06400056|DRUG|Terbinafine|FDA approved
219708004|NCT06080815|DEVICE|CAD/CAM Complete denture|four implant-supported CAD/CAM complete overdenture
219708005|NCT02560467|DRUG|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
219708006|NCT01784263|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
219124242|NCT01530009|DRUG|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
219124243|NCT01530009|OTHER|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
219124244|NCT05708417|BEHAVIORAL|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
219124245|NCT05708417|OTHER|Placebo|No lifestyle intervention within the study, only test/datacollection
219124246|NCT01974921|DEVICE|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
219124247|NCT04778371|OTHER|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
219124248|NCT04778371|OTHER|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
219124249|NCT05811208|DEVICE|automated pupillometry|Automated pupillometry every 6 hours
219124250|NCT05811208|DIAGNOSTIC_TEST|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
219124251|NCT02810743|DRUG|ddAC-CP-Olaparib|ddAC-CP-Olaparib
219124252|NCT02810743|DRUG|ddAC-mini CTC|ddAC - mini CTC
219124253|NCT06540287|OTHER|Observational|No intervention
219225827|NCT05543109|DRUG|Rocuronium|0.9 mg/kg during induction of anesthesia
219708007|NCT01784263|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
219708008|NCT00191919|DRUG|Duloxetine Hydrochloride|
219708009|NCT00191919|DRUG|Placebo|
219708010|NCT00674297|DRUG|Fluvastatin|Fluvastatin 40 mg daily for 3 months
218986071|NCT01065597|DEVICE|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
218986072|NCT02300246|PROCEDURE|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
218986073|NCT02081287|DRUG|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
218986074|NCT02081287|DRUG|Lamotrigine|Dose up to 200 mg per day over 10 weeks
218986075|NCT03766568|DEVICE|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
218986076|NCT05075460|DRUG|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
218986077|NCT00397345|BIOLOGICAL|Trovax|1ml IM injection 2-8 weeks apart.
218986078|NCT00397345|BIOLOGICAL|Placebo|Placebo
218986079|NCT00397345|BIOLOGICAL|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
218986080|NCT00734175|BIOLOGICAL|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
218986081|NCT02985372|DRUG|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
218986082|NCT02985372|DRUG|Cytarabine|
218986083|NCT03725137|OTHER|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
218986084|NCT01284101|DEVICE|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
218986085|NCT01284101|DEVICE|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
218986086|NCT04067882|OTHER|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
218986087|NCT01197261|DRUG|Oxycodone naloxone prolonged release tablets|2 tablets/ day
218986088|NCT01197261|DRUG|Placebo tablets|2 tablets/ day
218986089|NCT05013489|BEHAVIORAL|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
218986090|NCT01319890|PROCEDURE|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
218986091|NCT02167087|PROCEDURE|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
218986092|NCT05373277|DRUG|Placebo|one tablet of placebo twice daily for two days
218986093|NCT05373277|DRUG|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
218986094|NCT05373277|DRUG|Rosuvastatin|10 mg tablet, single dose
218986095|NCT00446251|DRUG|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
218986096|NCT00446251|DRUG|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
218986097|NCT05975307|DRUG|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
218986098|NCT05975307|DRUG|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
218986099|NCT05975307|DRUG|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
218986100|NCT05975307|DRUG|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
219124254|NCT05797311|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.
219225828|NCT05543109|DRUG|Sevoflurane|2-3% during maintanance of anesthesia
219124255|NCT05797311|OTHER|Shoulder Stabilization Exercises|Scapular stabilization exercise and stabilization exercise for the shoulder joints
219124256|NCT01254305|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
219225829|NCT05543109|DRUG|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
219708011|NCT02487121|BEHAVIORAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
219708012|NCT02487121|BEHAVIORAL|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
219708013|NCT00512668|DRUG|leuprolide acetate|Given intramuscularly
219708014|NCT00512668|DRUG|goserelin acetate|Given subcutaneously
219708015|NCT00512668|DRUG|bicalutamide|Given PO
219708016|NCT00512668|DRUG|nilutamide|Given PO
219708017|NCT00512668|DRUG|flutamide|Given PO
219708018|NCT00512668|DRUG|temsirolimus|Given IV
219708019|NCT00512668|OTHER|laboratory biomarker analysis|Optional correlative studies
218986101|NCT05975307|RADIATION|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
218986102|NCT01021722|PROCEDURE|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
218986103|NCT04083196|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
218986104|NCT04083196|BIOLOGICAL|Placebo|Placebo
218986105|NCT06030050|BEHAVIORAL|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
218986106|NCT05916027|BEHAVIORAL|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
218986107|NCT04509869|PROCEDURE|varicocelectomy|operation for varix ligation
218986108|NCT06069505|DIAGNOSTIC_TEST|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
218986109|NCT01642979|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
218986110|NCT01642979|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
218986111|NCT01642979|DRUG|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
218986112|NCT03185871|DRUG|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
218986113|NCT05235451|OTHER|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
218986114|NCT01042678|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye
219708020|NCT01271972|DRUG|nesvacumab (REGN910/ SAR307746)|
219708021|NCT03398135|DRUG|risankizumab|subcutaneous (SC) injection
219708022|NCT03398135|DRUG|placebo for risankizumab|subcutaneous (SC) injection
219708023|NCT00742456|DIETARY_SUPPLEMENT|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
219708024|NCT00742456|DIETARY_SUPPLEMENT|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
219708025|NCT00195325|DRUG|TTI-237|
219708026|NCT06847360|DEVICE|Home-based taVNS intervention|Home-based taVNS intervention will be administered using the non-invasive taVNS device, Parasym system (Parasym Health, Inc, London, UK).
219708027|NCT00002265|DRUG|Zalcitabine|
218986115|NCT03694587|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
218986116|NCT03694587|DRUG|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
218986117|NCT01235624|GENETIC|genetic analysis|
218986118|NCT04846296|OTHER|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
218986119|NCT00408460|DRUG|imatinib mesylate|Given PO
218986120|NCT00408460|DRUG|paclitaxel|Given IV
218986121|NCT04125888|DRUG|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
218986122|NCT02653872|DRUG|AZD7986|Oral solution, single dose, dilution from concentrate
218986123|NCT02653872|DRUG|Verapamil|Extended release tablet for oral use
218986124|NCT02653872|DRUG|Itraconazole|Oral solution
218986125|NCT02653872|DRUG|Diltiazem|Extended release capsule
218986126|NCT03617185|OTHER|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
218986127|NCT03617185|OTHER|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
218986128|NCT03617185|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
218986129|NCT01611610|OTHER|Functional tests|"The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module"
218986130|NCT01611610|OTHER|Functional tests|"The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module"
218986131|NCT06009692|OTHER|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
218986132|NCT06009692|OTHER|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
218986133|NCT06558461|DRUG|3% Sodium Chloride|4ml nebulized three times daily
218986134|NCT06558461|OTHER|Standard care|Standard care
219124257|NCT01254305|DRUG|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
219708028|NCT03320369|OTHER|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
219708029|NCT04890990|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
218986135|NCT00311844|DRUG|desloratadine|
218986136|NCT06362577|DIAGNOSTIC_TEST|EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG|Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
218986137|NCT04076475|DEVICE|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
218986138|NCT02506465|DEVICE|iTIND|Temporary Implantable Nitinol Device (iTIND)
218986139|NCT02506465|PROCEDURE|Sham Arm|Foley catheter will be placed and immediately removed.
218986140|NCT04102787|OTHER|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
219124258|NCT01254305|DRUG|Placebo|Matching placebo capsules, oral administration, once daily dosing
219124259|NCT04184102|BEHAVIORAL|education|The intervention group received pre-surgery education and training on therapeutic exercises in addition to the routine hospital care. The educational material was developed by the principal investigator (PI) and included a power point and a booklet with instructions on the exercises as well as information about the surgery and what to expect after the surgery. The educational material was based on previous research and adopted to our population after consultation with a panel of experts including two nurses and three physicians. Eligible women were approached while waiting for their appointment with their surgeon. If they showed interest in participating they signed a consent form. The PI explained the study and what is involved in participating including the weekly phone calls for women in the intervention group. Participants were told that they will visited at home by the PI to assess their ROM and to fill out a questionnaire.
219124260|NCT05349877|BEHAVIORAL|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
219124261|NCT05349877|BEHAVIORAL|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
219124262|NCT05349877|BEHAVIORAL|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
219124263|NCT02272465|OTHER|No intervention|Observational study
219708030|NCT06554236|OTHER|physical therapy and sensory training|Physical therapy standard of care and 5 minutes of sensory training.
219124264|NCT00004225|BIOLOGICAL|Ad5CMV-p53 gene|
219124265|NCT00004225|RADIATION|radiation therapy|
219124266|NCT03514589|DRUG|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
219124267|NCT03514589|DRUG|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
219124268|NCT03273803|DIAGNOSTIC_TEST|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
219124269|NCT04786886|OTHER|VIrtual Reality Visual Field Exam|Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.
219124270|NCT01426815|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
219124271|NCT01426815|DRUG|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
219124272|NCT02440906|BEHAVIORAL|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
219124273|NCT02440906|BEHAVIORAL|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
219124274|NCT03803917|PROCEDURE|Injection with freshly collected autologous adipose tissue|
219124275|NCT01238796|DRUG|telavancin|Intravenous
219124276|NCT04638699|OTHER|OptiScreen training|Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
219124277|NCT04255875|BIOLOGICAL|Placebo|Participants will receive matching placebo
219124278|NCT04255875|BIOLOGICAL|PF-07209326|Participants will receive SC or IV single ascending doses
219124279|NCT04255875|BIOLOGICAL|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
219124280|NCT03029338|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
219124281|NCT02788656|DEVICE|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
219124282|NCT02788656|DRUG|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
219124283|NCT02788656|DRUG|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
219124284|NCT02788656|DRUG|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
219124285|NCT04446975|OTHER|BPA|At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
219225830|NCT02310581|DRUG|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
219225831|NCT02310581|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
219708031|NCT04948125|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
219708032|NCT04948125|DRUG|Apatinib Mesylate|250 mg qd
219708033|NCT01485835|DRUG|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
219708034|NCT01485835|DRUG|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
219708035|NCT01485835|DRUG|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
219708036|NCT01732692|DRUG|MOVIPREP|MOVIPREP solution
219708037|NCT04841174|OTHER|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
219708038|NCT01617213|DRUG|Melphalan|200 mg/m2/IV
219708039|NCT01617213|DRUG|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
219708040|NCT04892667|OTHER|Intervention|"Evaluation of the sensitivity of the cardiac uptake of 18F-FDG measured on D28 +/- 7 days, D42 +/- 7 days ou D56 + 4 days of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop of more than 10 units of the LVEF and LVEF \&lt; 53%.~The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation."
219708041|NCT01051804|OTHER|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
219708042|NCT01051804|OTHER|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
219708043|NCT00507572|OTHER|Medical Chart Review|Medical records are reviewed
219708044|NCT04035083|DEVICE|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
219708045|NCT04035083|DEVICE|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
219708046|NCT04502277|DRUG|Fluconazole Powder|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
219708047|NCT04159064|DIAGNOSTIC_TEST|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
219708048|NCT05283837|BIOLOGICAL|Pertuzumab (ZRC-3277)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
219708049|NCT05283837|BIOLOGICAL|Pertuzumab (Perjeta®)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
219708050|NCT03243019|DRUG|rapamycin|oral administration
219708051|NCT03243019|DEVICE|MRI|cervicofacial MRI
219708052|NCT03243019|BIOLOGICAL|Rapamycin dosage|Biological dosage of Rapamycin level
219708053|NCT01137786|DRUG|Non ionic contrast media comparator|One time administration for PCI
219708054|NCT01137786|DRUG|Non ionic contrast media comparator|one time administration for PCI
219708055|NCT02711787|DEVICE|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
219708056|NCT02711787|DEVICE|Control group|Physiotherapy and occupational therapy.
219708057|NCT02711787|DEVICE|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
219708058|NCT01186081|RADIATION|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
219708059|NCT01186081|RADIATION|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
219708060|NCT02385890|OTHER|Control|Non pulse ingredient bagel
218986141|NCT04136340|OTHER|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
219225832|NCT03926702|DRUG|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
219225833|NCT01673594|DRUG|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
219708061|NCT02385890|OTHER|Pea flour|Pulse ingredient bagel
219708062|NCT02385890|OTHER|Pea fibre|Pulse ingredient bagel
219708063|NCT02385890|OTHER|Pea protein|Pulse ingredient bagel
219708064|NCT02385890|OTHER|Pea flour + pea protein|Pulse ingredient bagel
219708065|NCT02385890|OTHER|Pea fibre + pea protein|Pulse ingredient bagel
219708066|NCT03323762|DEVICE|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
219708067|NCT00435942|DEVICE|Relay Thoracic Stent-Graft|implant
219708068|NCT00435942|PROCEDURE|Open Repair|Open surgery
219708069|NCT05134844|OTHER|Hydrotherapy- Snoezelen|Multi sensory approach in water
219708070|NCT05134844|OTHER|Snoezelen|Multu Sensory approach on land
219708071|NCT00635284|DRUG|ABI-009|nab-rapamycin
219708072|NCT01859000|OTHER|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
219708073|NCT01859000|OTHER|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
219124286|NCT03174093|BEHAVIORAL|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
219124287|NCT04818879|OTHER|Vojta|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
219124288|NCT04818879|OTHER|Control|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg."
219124289|NCT04768062|DRUG|Viltolarsen|Received during weekly intravenous infusions
219124290|NCT02467374|BEHAVIORAL|Behavior Therapy|"BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors)."
219124291|NCT00864058|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
219708074|NCT03837834|OTHER|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
219708075|NCT05113303|DEVICE|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
219708076|NCT05113303|DEVICE|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
219708077|NCT05516069|OTHER|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
219708078|NCT00255333|DRUG|INNO-105|
219708079|NCT06125990|OTHER|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
219708080|NCT06125990|OTHER|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
219708081|NCT02251392|OTHER|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
219708082|NCT02251392|OTHER|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
219708083|NCT02251392|DRUG|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
219708084|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
219708085|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
219708086|NCT01967875|DRUG|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
219708087|NCT01967875|DRUG|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
219708088|NCT04491994|DRUG|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
219708089|NCT03589703|OTHER|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
219708090|NCT03589703|OTHER|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
219708091|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
219708092|NCT04622956|DRUG|Methotrexate Injectable Solution|"Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
219708093|NCT02941003|DEVICE|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
219708094|NCT02941003|OTHER|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
219708095|NCT02941003|DEVICE|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
219708096|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
219708097|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
219708098|NCT02619513|DRUG|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
219708099|NCT02619513|DRUG|Ropivacaine|Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
219708100|NCT02619513|DEVICE|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
219708101|NCT03755076|BEHAVIORAL|Perceptual cuing|Participants were provided four perceptual cues (or feedback) in a pseudorandom order: (a) indiscriminate, (b) Altered gain, (c) Coordination, (d) Dual: altered gain and coordination
218986142|NCT04136340|OTHER|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
218986143|NCT04188587|DRUG|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
218986144|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
219708102|NCT04033536|RADIATION|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
219124292|NCT00864058|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
219124293|NCT00268411|DRUG|gemcitabine hydrochloride|
219124294|NCT00268411|DRUG|oxaliplatin|
219124295|NCT03765697|DRUG|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
219708103|NCT04033536|RADIATION|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
219708104|NCT04547439|DRUG|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
219708105|NCT04547439|OTHER|Placebo|Placebo will be given nightly for 8 weeks
219708106|NCT04740970|DRUG|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
219708107|NCT04740970|DRUG|Placebo|Matching placebo injection will be administered subcutaneously.
219708108|NCT01953237|BEHAVIORAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
219708109|NCT01953237|DEVICE|Smartphone|
219708110|NCT04167462|DRUG|BMS-986165|Specified dose on Specified Days
219708111|NCT04167462|OTHER|Placebo|Specified dose on Specified days
219708112|NCT03936127|PROCEDURE|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
219708113|NCT05993169|OTHER|Body Composition optimization visits|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
219124296|NCT00230451|PROCEDURE|Radiation|
219124297|NCT00230451|DRUG|Paclitaxel|
219124298|NCT00230451|DRUG|Cisplatin|
219124299|NCT00230451|DRUG|5-Fluorouracil|
219124300|NCT03665506|DRUG|Trifluridin/Tipiracil|QoL assessment
219708114|NCT05408221|DRUG|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
219124301|NCT06497985|DRUG|Tucidinostat|30mg orally BIW
219124302|NCT06497985|DRUG|Sintilimab|200 mg intravenously (IV) Q3W
219124303|NCT06497985|DRUG|Bevacizumab|7.5mg/kg intravenously (IV) Q3W
219124304|NCT06497985|DRUG|Fruquintinib|5mg orally QD
219708115|NCT05408221|DRUG|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
219708116|NCT01125553|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
219708117|NCT04803500|DRUG|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
219708118|NCT04803500|DRUG|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
219708119|NCT03955445|DRUG|LNP023|LNP023 capsules
219708120|NCT02606253|DRUG|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
219708121|NCT02606253|DRUG|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
219708122|NCT02606253|DRUG|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
219708123|NCT03411538|OTHER|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
219124305|NCT00051415|BEHAVIORAL|Flaxseed-supplemented diet|
219124306|NCT02725203|BEHAVIORAL|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
219124307|NCT04550156|PROCEDURE|Colorectal Bundle|"1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
219225834|NCT01673594|DRUG|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
219124308|NCT03683355|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
219124309|NCT00249223|DRUG|Risperidone Long acting injectable|
219124310|NCT03881657|BEHAVIORAL|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
219124311|NCT03881657|BEHAVIORAL|Usual Care|Behavioral health services without primary care or integrated care services
219124312|NCT05009446|PROCEDURE|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
219124313|NCT05009446|RADIATION|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
219124314|NCT05009446|DRUG|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
219124315|NCT02455687|DRUG|Hi-dose iv MgSO4|
219124316|NCT02455687|DRUG|Nebulized budesonide|
219124317|NCT02455687|DRUG|Std-dose iv MgSO4|
219124318|NCT02455687|DRUG|Nebulized normal saline|
219708124|NCT06344949|DRUG|Ciprofol|The sedation before tracheal intubation with Ciprofol
219708125|NCT06344949|DRUG|Propofol|The sedation before tracheal intubation with Propofol
219124319|NCT02891369|OTHER|No intervention. Descriptive study|
219124320|NCT02728219|PROCEDURE|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
219124321|NCT02728219|PROCEDURE|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
219124322|NCT00002556|DRUG|vincristine sulfate|Given IV
219124323|NCT00002556|DRUG|carmustine|Given IV
219124324|NCT00002556|DRUG|melphalan|Given PO
219124325|NCT00002556|DRUG|cyclophosphamide|Given IV
219124326|NCT00002556|DRUG|prednisone|Given PO
219124327|NCT00002556|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
219124328|NCT00002556|OTHER|laboratory biomarker analysis|Correlative studies
219124329|NCT01530074|PROCEDURE|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
219708126|NCT05987280|OTHER|eDelphi method|eDelphi method
219708127|NCT00003969|DRUG|tanespimycin|
219708128|NCT06306391|DRUG|Intravenous naloxone|Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
219124330|NCT05154916|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
219124331|NCT04222244|OTHER|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
219124332|NCT00108524|BEHAVIORAL|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
219124333|NCT00108524|DRUG|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
219124334|NCT00108524|BEHAVIORAL|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
219124335|NCT04166968|DEVICE|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
219124336|NCT04166968|DEVICE|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
219124337|NCT04166968|DEVICE|Sham stimulation (sham-tDCS)|placebo stimulation
219124338|NCT04166968|BEHAVIORAL|Neuromotor training|conventional neuromotor treatment
219124339|NCT03132714|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
219124340|NCT03132714|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
219124341|NCT03132714|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
219124342|NCT03132714|DRUG|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
219124343|NCT03132714|PROCEDURE|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
219124344|NCT03132714|PROCEDURE|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
219124345|NCT04838821|BIOLOGICAL|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
219124346|NCT04838821|BIOLOGICAL|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
219225835|NCT05377918|OTHER|Diary|spiritual diary group and diary gruop will write a diary
219124347|NCT05748795|PROCEDURE|bronchoscopy brochoalveolar lavage|"* 2%lidocaine gel will be used to anaesthesize nasal mucosa.6ml lidocaine 2%diluted in 5cc normal saline lidocaine spray solution will be used for anaesthesizing the vocal cords and mucosa of the bronchial tree(13).~* Intravenous midazolam (0.01-0.1mg\\kg) will be given to achieve conscious sedation in selected cases(13).~* Flexible Bronchoscopy will be done under continuous monitoring for O2 saturation, heart rate, blood pressure and respiratory rate.~* The bronchoscope will be introduced into the nasal cavity and advanced to the level of the vocal cords. Lidocaine will be instilled through the bronchoscope to the vocal cords and tracheobronchial tree.~* Using sterile bronchoscope in the lobar bronchus of tumor location,100 mL of sterile normal saline in fractionated doses will be injected and then BAL will be removed by suction to be collected in sterile side-way bottles."
219124348|NCT05692843|DRUG|Cyclosporin A|"Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~2. Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
219124349|NCT05692843|OTHER|Follow-up of Cyclospoin treatment already started|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
219124350|NCT01896011|BIOLOGICAL|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
219124351|NCT01896011|OTHER|Placebo|Placebo 20 mcg injection pen
219124352|NCT05095155|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219708129|NCT06306391|DRUG|Intranasal naloxone|Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
219708130|NCT06367179|OTHER|Virtual reality and AI use|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
219708131|NCT06367179|OTHER|Health education leaflet|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
219124353|NCT01363947|DRUG|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
219124354|NCT06629623|OTHER|No intervention|No intervention
219124355|NCT00355667|DRUG|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
219124356|NCT00355667|DRUG|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
219708132|NCT06569238|DIAGNOSTIC_TEST|Conventional bacterial culture|Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).
219708133|NCT06569238|DEVICE|Rapid diagnostic group using mNGS technology|Participants will have DFU ulcer tissue collected and have metagenomics sequencing performed. The name of the devices listed for this study are the Illumina MiSeq System with MiSeq Reagent Kit V2 from Illumina and the MinION sequencer (Oxford Nanopore Technologies).
219708134|NCT05970757|DIAGNOSTIC_TEST|Extended MRI|Extension of the brain tumor MRI-protocol
219708135|NCT02171455|DRUG|Dabigatran etexilate low dose|
219708136|NCT02171455|DRUG|Dabigatran etexilate medium dose|
219708137|NCT02171455|DRUG|Dabigatran etexilate high dose|
219708138|NCT02171455|DRUG|Placebo|
219124357|NCT03047603|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
219124358|NCT02677246|DRUG|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils \> 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
219124359|NCT01403987|BEHAVIORAL|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
219124360|NCT01403987|BEHAVIORAL|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
219124361|NCT01403987|OTHER|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
219124362|NCT01403987|BEHAVIORAL|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
219124363|NCT02083640|DRUG|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
219124364|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
219124365|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
219124366|NCT00180440|DEVICE|ICD|all models of Guidant/Bsc ICD's
219124367|NCT02307123|PROCEDURE|Intubation|HEMS physician prehospital intubation
219124368|NCT04937075|OTHER|No intervention|No intervention
219708139|NCT03641729|OTHER|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
219708140|NCT03401047|DRUG|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
219708141|NCT00815737|DRUG|rhubarb|14 days of rhubarb
219708142|NCT00815737|DRUG|Placebo|14 days of Placebo
219708143|NCT05561062|DRUG|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
219708144|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
219708145|NCT06018012|DEVICE|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
219708146|NCT02653105|BIOLOGICAL|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
219708147|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 1|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
219708148|NCT02475213|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
219708149|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 2|Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses
219708150|NCT02475213|BIOLOGICAL|retifanlimab|Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses
219708151|NCT04432623|DRUG|Benserazide Only Product|Investigational drug
219708152|NCT05453539|DRUG|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
219708153|NCT05236010|DEVICE|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
219708154|NCT05236010|DEVICE|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
219708155|NCT05236010|OTHER|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
219124369|NCT06391203|PROCEDURE|Long-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 7 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
219124370|NCT06391203|PROCEDURE|Short-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 2 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
219124371|NCT01614756|BIOLOGICAL|BMS-981164|
219124372|NCT01614756|BIOLOGICAL|Placebo matching with BMS-981164|
219124373|NCT00237367|DRUG|rabeprazole and pantoprazole|
219124374|NCT00751790|DRUG|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
219124375|NCT00917254|DRUG|YM150|oral
219124376|NCT00917254|DRUG|Placebo|oral
219124377|NCT00917254|DRUG|Enoxaparin|injection
219124378|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
219124379|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
219124380|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
219124381|NCT00800124|PROCEDURE|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
219124382|NCT00361309|DRUG|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
219124383|NCT00220935|DEVICE|Orthotrac Pneumatic Vest|
219124384|NCT05638659|BEHAVIORAL|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
219124385|NCT05638659|BEHAVIORAL|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
219124386|NCT00020189|DRUG|acetylsalicylic acid|
219124387|NCT00020189|DRUG|alvocidib|
219124388|NCT00020189|DRUG|clopidogrel bisulfate|
219124389|NCT04571073|PROCEDURE|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
219124390|NCT01278693|DRUG|L-carnitine|500 mg,twice daily, 16 weeks
219124391|NCT01278693|DRUG|placebo|500 mg,twice daily, 16 weeks.
219124392|NCT04313348|BEHAVIORAL|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
219708156|NCT04571138|BIOLOGICAL|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
219708157|NCT00505921|DRUG|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
219708158|NCT00505921|DRUG|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
219708159|NCT00505921|DRUG|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
219708160|NCT00505921|DRUG|BCNU|300 mg/m2 IV over 1 hour on day -6
219708161|NCT00505921|DRUG|Stem Cell Transplant|Stem cell infusion on Day 0.
219708162|NCT00505921|DRUG|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
219708163|NCT00505921|DRUG|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
219708164|NCT00505921|DRUG|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
219708165|NCT00505921|DRUG|Melphalan|140 mg/m2 IV on day -1.
219124393|NCT04962100|OTHER|Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry|"After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry."
219124394|NCT00180674|DRUG|Warfarin|
219124395|NCT02194218|DRUG|Nevirapine, low dose|50 mg
219124396|NCT02194218|DRUG|Nevirapine, high dose|100 mg
219124397|NCT05428579|PROCEDURE|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
219124398|NCT05181306|PROCEDURE|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
219124399|NCT05181306|PROCEDURE|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
219124400|NCT01192490|DRUG|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
219124401|NCT01192490|DRUG|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
219124402|NCT06056154|DEVICE|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
219124403|NCT00649662|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
219124404|NCT00649662|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
219124405|NCT01899560|PROCEDURE|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated \[9\]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
219708166|NCT00505921|DRUG|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
219708167|NCT00505921|DRUG|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
219708168|NCT00505921|DRUG|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
219708169|NCT00505921|RADIATION|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
219708170|NCT05732714|BEHAVIORAL|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
219708171|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
219708172|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, high bioavailability|Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
219708173|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
219708174|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, high bioavailability|Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
219708175|NCT06142084|DIETARY_SUPPLEMENT|Protein-free meal|Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
219708176|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
219708177|NCT02441283|DRUG|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
219708178|NCT02441283|DRUG|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
219708179|NCT01458626|DRUG|mirtazapine|mirtazapine 30mg QD
219708180|NCT01458626|DRUG|paroxetine 20mg QD|paroxetine 20mg QD
219708181|NCT06547554|DRUG|Xeruborbactam|Experimental
219708182|NCT06547554|DRUG|Cefiderocol|Experimental
219708183|NCT06547554|DRUG|Xeruborbactam/Cefiderocol|A combination of Xeruborbactam and Cefiderocol.
219124406|NCT01899560|OTHER|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
219124407|NCT03950401|PROCEDURE|Monocryl|subcuticular Monocryl wound closure
219708184|NCT06547554|DRUG|Dextrose 5% in water|Placebo
219124408|NCT03950401|PROCEDURE|Nylon|wound closure using nylon suture on the skin
219124409|NCT03089372|DEVICE|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
219124410|NCT02490930|DRUG|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
219124411|NCT01553162|GENETIC|DNA analysis|
219124412|NCT01553162|GENETIC|RNA analysis|
219124413|NCT01553162|GENETIC|gene expression analysis|
219124414|NCT01553162|OTHER|laboratory biomarker analysis|
219124415|NCT02099032|OTHER|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
219124416|NCT02099032|OTHER|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
219124417|NCT02099032|OTHER|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
219124418|NCT01831492|DEVICE|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
219124419|NCT01831492|DEVICE|cellulose|given for 14 weeks
219124420|NCT03391167|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
219124421|NCT03391167|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
219124422|NCT04428086|DRUG|Apatinib in arm1|Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
219124423|NCT04428086|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
219124424|NCT04428086|DRUG|Apatinib in arm2|Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
219708185|NCT05169983|DIAGNOSTIC_TEST|iPad-Based Visual Field Test|In this study, the investigators aim to teach the participants to use the the visualFields easy App . The investigators will be using the app in the clinic with the patients watching, demonstrating its use and discussing and explaining its functions. Having observed how to use the application, the participant will then complete the visual field assessment.
219708186|NCT01325441|DRUG|BBI608|
219708187|NCT01325441|DRUG|Paclitaxel|
219708188|NCT06415721|DEVICE|Active Transcranial Magnetic Simulation|1 session of active continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. TMS will be delivered using the Magventure MagPro X100.
219708189|NCT06415721|DEVICE|Sham|1 session of sham continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. The MagVenture MagPro x100 is capable of administering a sham stimulation. The reverse side of the TMS coil is plated with a magnetic shield such that electromagnetic energy cannot stimulate the brain. The device offers compatibility with Transcutaneous Electrical Nerve Stimulation devices such that titrated electrical pulses can be delivered to the scalp location to mimic the sensation of a TMS pulse without stimulating the brain.
219708190|NCT02040220|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
219708191|NCT04641351|DRUG|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
219708192|NCT05779748|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
219708193|NCT02382939|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
219708194|NCT02382939|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
219708195|NCT06399718|DRUG|BOTOX|Intramuscular Injections
219708196|NCT06399718|DRUG|Placebo|Intramuscular Injections
219124425|NCT04428086|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
219124426|NCT03415490|OTHER|Folded technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
219708197|NCT06133257|PROCEDURE|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
219708198|NCT06133257|PROCEDURE|standard fluid management|standard fluid management
219708199|NCT05822752|DRUG|Budigalimab|Intravenous (IV) Infusion
219708200|NCT05822752|DRUG|Livmoniplimab|Intravenous (IV) Infusion
219708201|NCT05822752|DRUG|Lenvatinib|Oral: Capsule
219708202|NCT05822752|DRUG|Sorafenib|Oral: Tablet
219708203|NCT02026297|DRUG|Tranexamic Acid|1 gram IV over 10 minutes
219708204|NCT02026297|DRUG|Placebo; Normal Saline|0.9% Normal Saline
219708205|NCT00537277|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
218986145|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
218986146|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
218986147|NCT04495933|OTHER|Placebo|sterile saline
218986148|NCT00299351|DRUG|Depsipeptide|
218986149|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
218986150|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
218986151|NCT05763212|OTHER|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
218986152|NCT05763212|OTHER|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
218986153|NCT02063711|BEHAVIORAL|Yoga intervention|
218986154|NCT02146664|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
218986155|NCT02146664|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
218986156|NCT03427671|DEVICE|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
218986157|NCT00000488|DRUG|cholestyramine|
218986158|NCT00000488|BEHAVIORAL|diet, fat-restricted|
218986159|NCT00787761|BIOLOGICAL|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
218986160|NCT00787761|DRUG|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
218986161|NCT00787761|DRUG|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
218986162|NCT00787761|DRUG|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
219124427|NCT03415490|OTHER|Classic technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
219124428|NCT00618670|BEHAVIORAL|Walking Exercise|Three times per week for 3 months
219124429|NCT00618670|BEHAVIORAL|Control--Resistance Training|Three times per week for 3 months
219124430|NCT03250312|OTHER|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
219124431|NCT00004287|GENETIC|H5.001CBCFTR|
219708206|NCT05383209|DRUG|EYP-1901|EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.
219708207|NCT05383209|OTHER|Sham IVT|Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.
219708208|NCT06411067|DRUG|Erenumab|Monthly injection of erenumab for fibromyalgia
219708209|NCT06411067|DRUG|Saline|Monthly injection of 0.9% saline for control
219708210|NCT05114174|OTHER|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
219708211|NCT01298258|DRUG|Aliskiren|Aliskiren 150mg
219708212|NCT02229838|DRUG|BIBB 1464 MS tablet|
219124432|NCT02223689|PROCEDURE|Skin Affix|
219124433|NCT04349111|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
219124434|NCT02219828|DRUG|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
219124435|NCT02219828|DRUG|Placebo|Placebo
219708213|NCT02229838|DRUG|BIBB 1464 MS solution|
219708214|NCT02229838|DRUG|BIBB 1464 MS placebo|
219708215|NCT02229838|OTHER|Standard dinner|
219708216|NCT02035124|DRUG|BKM 120|
219708217|NCT02035124|DRUG|Cabazitaxel|
219708218|NCT01805999|DIETARY_SUPPLEMENT|7 g Ispaghula|
219708219|NCT01805999|DIETARY_SUPPLEMENT|7 g placebo|
219708220|NCT01805999|DIETARY_SUPPLEMENT|3.5g Ispaghula + 3.5 g placebo|
219708221|NCT00474019|DRUG|esomeprazole|IV qd for 4 days
219708222|NCT05849922|DRUG|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
219124436|NCT06309303|OTHER|Clinical evaluation|Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome
219124437|NCT03164733|OTHER|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
219124438|NCT05108389|DIAGNOSTIC_TEST|Viscoelastic haemostasis monitor output|Observational
219124439|NCT00455468|PROCEDURE|Day-care treatment vs. hospital care|
219124440|NCT00482105|OTHER|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
219708223|NCT05849922|DRUG|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
219124441|NCT00238043|DRUG|Biogeneric Epoetin|
219124442|NCT06077019|DRUG|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
219124443|NCT06077019|DRUG|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
219124444|NCT06077019|DRUG|Placebo|Participants inhale placebo daily
219124445|NCT00181779|DRUG|aripiprazole (Abilify)|
219708224|NCT01200641|DRUG|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
219708225|NCT01200641|DRUG|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
219708226|NCT01200641|DRUG|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
219708227|NCT00716417|DRUG|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
219708228|NCT00716417|DRUG|BIBW 2992|low to high dose, daily
219708229|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
219708230|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
219708231|NCT01520753|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
219708232|NCT01553851|DRUG|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
219708233|NCT04224467|OTHER|Intravenous ICG and Real-Time Near-infrared Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
219124446|NCT03997942|OTHER|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
219124447|NCT03406234|OTHER|No intervention.|Cross-sectional observation without interventions.
219124448|NCT02147860|DEVICE|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
219124449|NCT02147860|OTHER|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
219708234|NCT01369433|DRUG|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
219708235|NCT01369433|DRUG|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
219708236|NCT01369433|DRUG|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
219708237|NCT01369433|DRUG|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
219708238|NCT01369433|DRUG|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
219708239|NCT01369433|DRUG|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
219708240|NCT04429880|DRUG|Oxytocin|Oxytocin given by intravenous route
219708241|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
219708242|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
219708243|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
219124450|NCT03250780|PROCEDURE|indigo-carmine 0.2% using a spray catheter|
219124451|NCT03250780|PROCEDURE|0.03% using a foot pump|
219124452|NCT04317768|BEHAVIORAL|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
219124453|NCT04317768|BEHAVIORAL|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
219124454|NCT01779921|DRUG|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124455|NCT01779921|DRUG|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124456|NCT01779921|DRUG|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124457|NCT01779921|DRUG|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124458|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124459|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
219124460|NCT03230955|BEHAVIORAL|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
219124461|NCT03230955|OTHER|Brief counselling session|Brief counselling session
219124462|NCT04643730|OTHER|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
219124463|NCT04643730|OTHER|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
219124464|NCT04643730|OTHER|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
219124465|NCT02988375|BEHAVIORAL|dCBTI|
219124466|NCT02988375|BEHAVIORAL|Sleep Education|
219124467|NCT01147549|DRUG|[C14]AZD9668|Oral Solution 60 mg Single Dose
219124468|NCT05258617|DEVICE|LLLT Photobiomodulation|Treatment with red LED light using UltraSlim device.
219124469|NCT03791528|OTHER|Kinesio-taping treatment group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
219708244|NCT01399996|DIETARY_SUPPLEMENT|A capsule containing the probiotic|A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
219708245|NCT04144816|OTHER|Not applicable (no intervention)|Not applicable (no intervention)
219708246|NCT01200914|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
219708247|NCT01200914|PROCEDURE|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
219708248|NCT05312203|OTHER|the App|The App provides content for mobile-based stress relief that can be used on most Android and iOS-based mobile devices. Content for stress relief consists of three modules; meditation, cognitive approach, and relaxation sounds. Additionally, the App includes the module for objective stress monitoring. The APP was originally designed and developed in Korean, but English, Chinese, and Japanese versions are also available. For use in the treatment environment, the manufacturer also provides a service that allows therapists to check their patients' application usage and their stress level measured by the stress monitoring module.
219124470|NCT06272955|DEVICE|Spinal Cord Stimulator (SCS)|"Patients are already implanted with device from the H-49023 study.~The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
218986163|NCT00787761|DRUG|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
218986164|NCT00787761|DRUG|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
219124471|NCT04922099|DEVICE|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
219708249|NCT04402242|DEVICE|Bispectral index|Anesthesia monitoring
219708250|NCT04402242|DEVICE|Bispectral index + NOL index|Anesthesia monitoring
219708251|NCT01882452|BEHAVIORAL|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
219708252|NCT01882452|BEHAVIORAL|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
219708253|NCT02196831|DRUG|tesamorelin|
219708254|NCT02196831|DRUG|Placebo|inactive substance that looks like tesamorelin
219708255|NCT00149643|DRUG|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
219708256|NCT00149643|OTHER|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
219708257|NCT02632318|DEVICE|Light|30 minutes of dawn simulation
219708258|NCT02722109|OTHER|No intervention|No intervention will be done
219708259|NCT04051580|DRUG|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
219708260|NCT02875457|DRUG|apatinib;etoposide and cisplatin|
219708261|NCT02875457|DRUG|placebo;etoposide and cisplatin|
219124472|NCT02797483|OTHER|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
219124473|NCT02797483|OTHER|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
219124474|NCT02797483|OTHER|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
219124475|NCT00309816|DRUG|sildenafil|
219124476|NCT03606460|DRUG|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
219124477|NCT03606460|DRUG|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
219124478|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of either 1.5 mA electrical stimulation for 20 minutes each day over 10 consecutive days.
219124479|NCT06401928|DEVICE|transcranial direct current stimulation combined with cognitive training|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on 10 consecutive days. Each session is followed by 30 minutes cognitive training in which patients conduct several computerized cognitive tests.
219124480|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of sham (placebo) electrical stimulation for 20 minutes each day over 10 consecutive days.
219124481|NCT04170023|DRUG|ALXN2050|Oral FD inhibitor
219124482|NCT02613780|PROCEDURE|Crosslinking|corneal collagen crosslinking with riboflavin
219124483|NCT02613780|PROCEDURE|Photorefractive keratectomy|
219124484|NCT02613780|DEVICE|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
219124485|NCT01307852|DEVICE|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
219124486|NCT03963479|COMBINATION_PRODUCT|Magnesium and Vitamin B6|Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
219124487|NCT03818308|DRUG|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
219124488|NCT02398838|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
219124489|NCT02398838|DRUG|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
219124490|NCT01153854|DRUG|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
219124491|NCT01153854|DRUG|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
219124492|NCT05225454|OTHER||
219124493|NCT04402671|OTHER|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
219708262|NCT04587713|DRUG|TD-1473 [Tablet A]|TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
219708263|NCT04587713|DRUG|TD-1473 [Tablet B]|TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
219708264|NCT01658410|DRUG|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
219708265|NCT01658410|DRUG|NaCl|NaCl, Route: intracoronary
219708266|NCT05342844|DRUG|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
219708267|NCT05342844|DRUG|Dexmedetomidine 1 mcg|1 mcg/kg
219708268|NCT06525727|OTHER|Falls Decision Rule|The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss, newly developing neurological examination disorder, or frailty score lower than 5 after a fall.
219708269|NCT01567410|OTHER|e-learning|Braden scale and pressure ulcer classification
219708270|NCT01567410|OTHER|traditional classroom training|Braden scale and pressure ulcer classification
219708271|NCT05002803|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
219708272|NCT04480879|DRUG|AZD8154 nebuliser|Nebuliser suspension
219708273|NCT04480879|DRUG|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
219708274|NCT04480879|DRUG|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
219708275|NCT02682121|DRUG|Metformin|Metformin 850 mg twice daily
219708276|NCT02682121|DRUG|Placebo|Placebo twice daily
219708277|NCT05775653|OTHER|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
219708278|NCT05775653|OTHER|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
219708279|NCT05704712|BEHAVIORAL|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
219708280|NCT04666298|DRUG|Inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270.
219708281|NCT04666298|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
219708282|NCT00226655|DRUG|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
219124494|NCT04402671|OTHER|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
219124495|NCT03770377|DEVICE|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
219124496|NCT03770377|DEVICE|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
219124497|NCT05144815|OTHER|IPC + Exercise protocol|"The intervention consists of two parts: IPC and endurance training protocol.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
219124498|NCT05144815|OTHER|Sham IPC + Exercise protocol|"The intervention consists of two parts: sham IPC and endurance training protocol.~Sham IPC: the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
219124499|NCT04426487|DRUG|Progesterone|Intramusculer progesterone
219124500|NCT04928989|OTHER|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
219124501|NCT00537862|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219124502|NCT06275880|OTHER|Intra-articular infiltration of PVP Collagen|Intra-articular collagen injection plus physiotherapy program
219124503|NCT06275880|OTHER|Rehabilitation|Patients who received conservative treatment through rehabilitation with a home program for one month
219124504|NCT03836664|DRUG|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
219124505|NCT03836664|DRUG|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
219708283|NCT06281249|DEVICE|Ultrasound placement device|Device to assist in placement of epidural procedure
219124506|NCT04514042|PROCEDURE|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
219708284|NCT05490082|DRUG|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
219124507|NCT04514042|PROCEDURE|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
219124508|NCT01575470|BIOLOGICAL|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
219124509|NCT02920593|DRUG|Vitamin D3|Vitamin D prophylaxis
219124510|NCT00840320|DRUG|1278863|15mg, 25mg, 50mg, 150mg
219124511|NCT00840320|DRUG|Placebo|matching placebo
219124512|NCT00335153|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
219708285|NCT06034184|OTHER|Virtual Reality|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
219708286|NCT04076683|DEVICE|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
219708287|NCT03803826|DEVICE|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
219708288|NCT03803826|DIAGNOSTIC_TEST|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
219124513|NCT00335153|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219124514|NCT00335153|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
219124515|NCT00335153|DEVICE|J-tube|jejunal tube
219124516|NCT05913323|DEVICE|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
219124517|NCT05913323|DIAGNOSTIC_TEST|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
219124518|NCT05913323|DIAGNOSTIC_TEST|Standard pulmonary function test|Standard-of-care respiratory test.
219708289|NCT00397124|DEVICE|PET/CT imaging|
219124519|NCT04164160|OTHER|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
219124520|NCT03992911|DRUG|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
219124521|NCT03992911|DRUG|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
219124522|NCT03992911|DRUG|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
219124523|NCT03992911|DRUG|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
219124524|NCT00166660|BEHAVIORAL|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
219124525|NCT03688542|OTHER|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
219124526|NCT03264196|PROCEDURE|Open Reduction and Internal Fixation|Surgical treatment of fracture
219124527|NCT00033956|DRUG|M40403|
219124528|NCT01349751|DRUG|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
219124529|NCT01349751|DRUG|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
219708290|NCT06448780|DRUG|Caffeine citrate 20 mg/kg|Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
219708291|NCT06448780|DRUG|Caffeine citrate 30 mg/kg|Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
219124530|NCT02478359|BEHAVIORAL|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
219124531|NCT00996086|DEVICE|CRT device implant|CRT device-recipients
219124532|NCT05224687|OTHER|Retroactive review of patient data of those receiving a dose of daptomycin|A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
219124533|NCT01800149|PROCEDURE|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
219124534|NCT03794778|DRUG|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
219124535|NCT03794778|DRUG|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
219124536|NCT03794778|DRUG|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
219124537|NCT00372528|DRUG|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
219708292|NCT03149770|DRUG|Naloxone then placebo|naloxone intranasal 4mg, then placebo
219708293|NCT03149770|DRUG|Placebo then Naloxone|placebo then naloxone intranasal 4mg
219708294|NCT02993809|BIOLOGICAL|BM-ECs and PRPE|
219708295|NCT02993809|BIOLOGICAL|BM-ECs|
219124538|NCT05513521|OTHER|High-velocity interval training|For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
219124539|NCT05513521|OTHER|Resistance training|For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
219708296|NCT00090688|BIOLOGICAL|meCS6 + LT(R192G)|
219708297|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
219708298|NCT01311661|DRUG|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
219708299|NCT01311661|DRUG|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
219124540|NCT05808647|BEHAVIORAL|5-day controlled metabolic dietary intake|Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
219124541|NCT02830789|DIETARY_SUPPLEMENT|Calcium Carbonate|
219124542|NCT02830789|DIETARY_SUPPLEMENT|Calcium Citrate|
219124543|NCT02830789|DIETARY_SUPPLEMENT|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
219124544|NCT02830789|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
219124545|NCT02184884|DEVICE|MACE after OPCAB|
219124546|NCT02184884|DEVICE|without MACE after OPCAB|
219124547|NCT01455740|BEHAVIORAL|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
219124548|NCT01455740|BEHAVIORAL|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
219708300|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
219708301|NCT01311661|DRUG|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
219708302|NCT01311661|DRUG|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
218986165|NCT00787761|PROCEDURE|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
218986166|NCT00788073|DRUG|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
218986167|NCT00788073|DRUG|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
218986168|NCT05249699|DRUG|Isoniazid|prevent the development of tuberculosis
218986169|NCT05249699|OTHER|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
218986170|NCT05649566|DEVICE|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
218986171|NCT05856188|DIETARY_SUPPLEMENT|Glutamine|Biologic
218986172|NCT00375037|BEHAVIORAL|feedback|
218986173|NCT00375037|BEHAVIORAL|Education|
218986174|NCT00375037|OTHER|usual care|
218986175|NCT03527030|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
218986176|NCT03527030|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
218986177|NCT04730687|DEVICE|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
218986178|NCT04730687|DEVICE|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
218986179|NCT04730687|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
218986180|NCT02808793|DRUG|AK002|
218986181|NCT02083614|PROCEDURE|to clamp or release the catheter for 2 days before removal|
218986182|NCT05901454|DRUG|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
218986183|NCT01589978|DEVICE|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
219124549|NCT05146011|PROCEDURE|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
219124550|NCT05122403|PROCEDURE|MRgFUS central lateral thalamotomy|MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
219124551|NCT05397015|OTHER|No intervention will be done|No intervention will be done
219708303|NCT03390153|OTHER|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
219708304|NCT03390153|OTHER|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
219708305|NCT01465269|BEHAVIORAL|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
219708306|NCT01465269|BEHAVIORAL|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
219708307|NCT01041911|DRUG|Euphorbia tablets|50 mg, tablet, once daily, 14 days
219708308|NCT01041911|DRUG|Euphorbia tablets|100 mg, tablet, once daily, 14 days
219708309|NCT01041911|DRUG|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
219708310|NCT01041911|DRUG|Placebo tablets|placebo, tablet, once daily, 14 days
219708311|NCT02459626|OTHER|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
219708312|NCT04490460|DIETARY_SUPPLEMENT|WBF-0031|Medical food formulation WBF-0031
219708313|NCT01346098|PROCEDURE|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
219124552|NCT06479473|RADIATION|Radiotherapy to all residual lesions|Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
219124553|NCT06479473|DRUG|Chemoimmunotherapy|atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
219124554|NCT05960279|DEVICE|MD100|"The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform."
219124555|NCT02842879|OTHER|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
219124556|NCT01289405|DEVICE|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
219124557|NCT05508516|DRUG|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
219708314|NCT01346098|PROCEDURE|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
219708315|NCT00207740|DRUG|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
219708316|NCT00207740|DRUG|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
219708317|NCT02585440|DRUG|CMX157|Oral tablet
219708318|NCT02585440|DRUG|placebo|Oral tablet
219708319|NCT00624208|DRUG|droperidol and saline|droperidol 20 mcg.kg-1 and saline
219708320|NCT00624208|DRUG|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
219708321|NCT00624208|DRUG|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
219708322|NCT00624208|DRUG|saline and saline|saline and saline
219708323|NCT05426473|OTHER|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
219708324|NCT05372367|DRUG|BI 907828|BI 907828
219708325|NCT05372367|DRUG|Rifampicin|Rifampicin
219708326|NCT05372367|DRUG|Itraconazole|Itraconazole
219708327|NCT02591810|PROCEDURE|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
219708328|NCT02591810|PROCEDURE|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
219708329|NCT02591810|PROCEDURE|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
219708330|NCT04815356|BIOLOGICAL|CD22CART cell infusion|The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 participants will be evaluated for response at Day 28 post-CD22CART infusion.
218986184|NCT01589978|DRUG|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
219124558|NCT05508516|DRUG|Duloxetine Hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
219124559|NCT03513861|OTHER|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
219124560|NCT06450535|PROCEDURE|Autogenous onlay bone block harvesting from retromolar bone in anterior maxilla|"Surgical protocol ( retromolar bone harvesting) After injecting local anesthesia a crestal incision is done, from a point on the occlusal surface along the external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa, parallel to the gingival margin of the mandibular molars.~The subperiosteal dissection extend to expose the ascending ramus and the retromolar region With the aid of surgical carbide burs, two proximal vertical cuts penetrating the cortex of the external oblique ridge.~The depth of penetration of the posterior cut did not exceed 2.5 mm to avoid injury to the inferior alveolar nerve.~By using microsaw , an inferior cut of 3.2 mm in depth joining the anterior and posterior vertical cuts was done.~Small perforations of 3-4 mm in depth were performed on the superior aspect of the external oblique ridge using 1 mm drill bur.~Finally, the block was sheared off using a chisel."
219708331|NCT05790135|DEVICE|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
219708332|NCT05203172|DRUG|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
219708333|NCT05203172|DRUG|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
219708334|NCT05203172|DRUG|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
219708335|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
219708336|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
219708337|NCT00390013|DRUG|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
219708338|NCT00390013|DRUG|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
219708339|NCT03188822|DEVICE|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
219708340|NCT03188822|DEVICE|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
219708341|NCT01883167|DRUG|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
219708342|NCT01883167|DRUG|Febuxostat 40 mg|Febuxostat 40 mg qd
219708343|NCT01883167|DRUG|placebo|placebo qd
219708344|NCT05318664|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
219708345|NCT03509558|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
219708346|NCT03509558|OTHER|Physical Therapy|physical therapy to improve walking and standing functions
219708347|NCT05760599|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
219708348|NCT05760599|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
219708349|NCT05745168|DIAGNOSTIC_TEST|OraQuick|The intervention is based on respondent-driven sampling approach. Each selected seed from hotspots and on social networks is provided with two types of coupons for HIVST kit at partner pharmacy: electronic coupons (e-coupons) consisting of a pictured unique anonymous QR code and identifier and the address of pharmacies; paper coupons consisting of similar information to e-coupon. The seeds will then distribute coupons to their networks physically, via social media, and smart phone applications. Each recruited participant will bring the coupon to be scanned at the pharmacies to receive a free access HIVST kit. There, trained community worker will do the study visit including information/consent, e-CRF filling and providing link to send the test results. These recruited individuals will be considered as wave 1 and will each receive 10 additional coupons to recruit new members in the networks. The next round of individuals recruited and enrolled will be considered as wave 2, and so on.
219708350|NCT01211249|DRUG|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
219708351|NCT01211249|DRUG|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
219708352|NCT01211249|DRUG|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
219708353|NCT01211249|DRUG|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
219708354|NCT03129646|DRUG|Miltefosine|Miltefosine 10mg and 50mg capsules
219708355|NCT03129646|DRUG|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
219708356|NCT03129646|DRUG|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
219708357|NCT02540304|BEHAVIORAL|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
219708358|NCT01307072|PROCEDURE|Vitrectomy|Vitrectomy. Diabetic retinopathy
219708359|NCT06284161|DIAGNOSTIC_TEST|Quadriceps Combined Test|The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
219124561|NCT06450535|PROCEDURE|Autogenous cortical shell technique from retromolar bone in anterior maxilla|"The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~The plate was fixed at a distance from the residual ridge with 2 screws. Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site."
219124562|NCT05101109|DRUG|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
219124563|NCT04124991|DRUG|Durvalumab|Radioembolization with Yttrium-90 Microspheres
219124564|NCT04124991|RADIATION|Radioembolization|Radioembolization with Yttrium-90 Microspheres
219124565|NCT04626921|DRUG|CNM-Au8|30 mg of CNM-Au8
219124566|NCT04890665|BEHAVIORAL|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
219124567|NCT05078021|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.
219124568|NCT04560582|PROCEDURE|Blood Draw|Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
219124569|NCT06028256|DRUG|Norepinephrine Hydrochloride|"Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision."
219124570|NCT06028256|DRUG|Placebo|Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
219124571|NCT00977028|DRUG|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
219708360|NCT02035540|OTHER|Decellularized human valves|
219708361|NCT04132219|BEHAVIORAL|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
219708362|NCT04111835|DIAGNOSTIC_TEST|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -\> colposcopy~Normal reflex LBC -\> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
219708363|NCT00294658|PROCEDURE|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
219708364|NCT00294658|DRUG|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
219708365|NCT02726347|BIOLOGICAL|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
219708366|NCT01500980|BIOLOGICAL|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
219708367|NCT01500980|DRUG|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
219124572|NCT00977028|PROCEDURE|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
219124573|NCT04311073|DRUG|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
219124574|NCT04311073|DRUG|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
219124575|NCT02015533|DRUG|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
219124576|NCT02015533|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
219124577|NCT03923608|DIAGNOSTIC_TEST|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
219124578|NCT03923608|DIAGNOSTIC_TEST|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
219708368|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
219124579|NCT01026415|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
219124580|NCT01026415|DRUG|rifampin|600 mg/day PO
219124581|NCT01026415|DRUG|midazolam|1 mg IV
219124582|NCT01026415|DRUG|ketoconazole|400 mg/day PO
219124583|NCT01026415|DRUG|brentuximab vedotin|1.2 mg/kg IV every 21 days
219124584|NCT01447355|DRUG|cholecalciferol|Given PO
219124585|NCT04651738|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
219124586|NCT06080217|DEVICE|study group|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
219124587|NCT06080217|DEVICE|placebo (sham control)|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,"
219708369|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
219124588|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|tablets
219124589|NCT00755755|DRUG|PGL4001 matching placebo and iron|tablets
219124590|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|Tablets
219124591|NCT02947763|DRUG|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
219124592|NCT03637595|PROCEDURE|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
219124593|NCT03637595|PROCEDURE|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
219124594|NCT03637595|PROCEDURE|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
219124595|NCT00646867|DEVICE|Tetrix|Twice daily topical application
219225836|NCT04178213|DEVICE|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
219124596|NCT00646867|DEVICE|Placebo|Twice daily topical application
219124597|NCT04108338|OTHER|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
219708370|NCT02525068|DRUG|AZD5363|Until confirmed disease progression.
219708371|NCT02525068|DRUG|Enzalutamide|Until confirmed disease progression.
219708372|NCT04501250|DRUG|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
219708373|NCT04501250|DRUG|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
219708374|NCT03048786|BEHAVIORAL|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
219708375|NCT03048786|BEHAVIORAL|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
219708376|NCT04642222|BEHAVIORAL|APOLO-Teens web-based intervention|The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
219708377|NCT04642222|OTHER|Treatment as Usual for Pediatric Obesity|Treatment as Usual for pediatric obesity in portuguese public hospitals.
219124598|NCT04458389|DRUG|TY101|"Dose escalation: TY101 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg Intravenous Q3W, 2 years depending on response.~Dose expansion: Subjects received TY101 injection for a maximum of 2 years until progressive disease, intolerant toxicity, death, or withdrawal from the study occurred."
219124599|NCT06187870|OTHER|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
219225837|NCT00650169|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
219708378|NCT03727282|PROCEDURE|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
218986185|NCT01589978|DRUG|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
218986186|NCT05075902|BEHAVIORAL|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
218986187|NCT03267017|OTHER|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
218986188|NCT02628470|PROCEDURE|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
218986189|NCT02628470|PROCEDURE|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
218986190|NCT02628470|PROCEDURE|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
218986191|NCT02260544|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
218986192|NCT00768950|PROCEDURE|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
218986193|NCT00768950|PROCEDURE|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
218986194|NCT04158752|DRUG|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
218986195|NCT03026361|GENETIC|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
218986196|NCT05213481|DRUG|Tepotinib|Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
218986197|NCT05213481|DRUG|Carbamazepine|Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
218986198|NCT02256592|DRUG|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
218986199|NCT06220773|DRUG|BR1019A|Subjects take the investigational products once a day for 12 weeks.
219124600|NCT00592748|RADIATION|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
219124601|NCT00083174|DRUG|exemestane|one 25 mg tablet daily in am
219124602|NCT00938561|DRUG|Inulin|
219124603|NCT00056368|DRUG|Anidulafungin|
219124604|NCT00056368|DRUG|Fluconazole|
219124605|NCT03605875|BEHAVIORAL|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
219124606|NCT03605875|BEHAVIORAL|Paper|Contains similar questions to the Web-App tool
219124607|NCT03791177|OTHER|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
219225838|NCT00650169|DRUG|Plavix® Tablets 75 mg|75mg, single dose fed
219225839|NCT04627896|DEVICE|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
219124608|NCT05895773|DRUG|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
219124609|NCT05895773|DRUG|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
219124610|NCT04007809|OTHER|Glucagon|Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
219124611|NCT05212948|DRUG|S-268019-b|Solution for IM injection
219708379|NCT03727282|PROCEDURE|adjust dobutamine according to the attending physician|adjust dobutamine dose
219708380|NCT00152022|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
219708381|NCT05474001|DRUG|Fentanyl|10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
219708382|NCT05474001|DRUG|Bupivacain|10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
219708383|NCT05474001|DRUG|intravenous graniseton|10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
219708384|NCT02340949|DRUG|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
219708385|NCT02340949|DRUG|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
219708386|NCT02340949|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
219708387|NCT02340949|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
218986200|NCT06220773|DRUG|BR1019B|Subjects take the investigational products once a day for 12 weeks.
219708388|NCT01104961|DEVICE|Contact lens packaging solution|These test solutions are the intervention being tested.
219708389|NCT01104961|DEVICE|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
219708390|NCT00122603|DRUG|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
218986201|NCT06220773|DRUG|BR1019C|Subjects take the investigational products once a day for 12 weeks.
218986202|NCT06220773|DRUG|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
218986203|NCT06220773|DRUG|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
218986204|NCT06220773|DRUG|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
218986205|NCT03115086|DRUG|Cholbam|Cholbam prescribed according to the approved label.
218986206|NCT05114070|OTHER|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
218986207|NCT03791138|OTHER|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
218986208|NCT00415168|DRUG|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
218986209|NCT00415168|DRUG|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
218986210|NCT06132295|OTHER|Nursing care|"1. Consistent Schedule for the Replacement of Positioning Line Pens~2. Tailored Educational Content~3. Hypoallergenic Adhesive Patches~4. Enriched Treatment Care Platform~5. Participants with BMI \> 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI \< 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~6. Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
218986211|NCT03382275|DRUG|Iron Supplement|any oral or intravenous prescription iron supplement
218986212|NCT05837585|DEVICE|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
218986213|NCT02505906|RADIATION|Simultaneous Integrated Boost Technique|
218986214|NCT00776724|DRUG|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
218986215|NCT00776724|DRUG|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
218986216|NCT00332280|DRUG|AMT2003|
219124612|NCT05212948|DRUG|Placebo|Saline solution for IM injection
219124613|NCT03697226|DRUG|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
219708391|NCT00122603|DRUG|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
219708392|NCT06294470|DIAGNOSTIC_TEST|Ballon expulsion test|Rectal latex balloon probe filled with saline solution. Patients expelled balloon and time recorded (\<1 or \>1 min).
219708393|NCT06294470|DIAGNOSTIC_TEST|Colonic transit time|Patients ingested capsules with 24 radiopaque markers and underwent standing abdominal radiographs on Day 3 and Day 5. Over 80% expulsion within five days was considered normal, while retention indicated defecatory obstruction.
219708394|NCT06294470|PROCEDURE|Stapled hemorrhodopexy|Circumferential stapled hemorrhoidopexy with a 34mm circular stapler is a surgical procedure used to treat mucohemorrhoidal prolapse.
219708395|NCT01943617|DRUG|Entecavir|anti-viral therapy
219708396|NCT01943617|DRUG|Thymosin-α|anti-viral and antitherapy
219124614|NCT00220103|DRUG|epirubicin, capecitabine, cisplatin|
219124615|NCT00220103|PROCEDURE|Surgical resection|
219124616|NCT03753087|DRUG|Empagliflozin|10 mg tablet
219124617|NCT03753087|OTHER|Standard care|Standard care with no SGLT-2 inhibitors
219124618|NCT04135924|OTHER|Rehabilitation|physical exercise and respiratory muscle training
219124619|NCT00626600|DRUG|Oxycodone Hydrochloride|
219124620|NCT05630339|DIETARY_SUPPLEMENT|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
219124621|NCT05630339|DIETARY_SUPPLEMENT|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
219124622|NCT05630339|DIETARY_SUPPLEMENT|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
219124623|NCT04541225|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
219124624|NCT06102785|DRUG|Fruquintinib, TAS102|Fruquintinib combined with TAS102
219124625|NCT02953548|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219124626|NCT00696904|DRUG|ABT-333|Capsule, see arms for intervention description
219708397|NCT04546841|BIOLOGICAL|multipeptide cocktail|"Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening"
219708398|NCT02868515|OTHER|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
219708399|NCT06213116|DEVICE|MADgic Atomizer|Device to deliver directly lignocaine
219708400|NCT06213116|DEVICE|Lignocaine pump spray|Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
219708401|NCT02812784|DEVICE|Nephrocheck TM|
219708402|NCT00244179|DRUG|interferon-gamma|
219124627|NCT00696904|DRUG|Placebo|Capsule, see arms for intervention description
219124628|NCT01899209|PROCEDURE|STARR|
219124629|NCT01899209|PROCEDURE|Laparoscopic Ventral Rectopexy|
219124630|NCT00430378|PROCEDURE|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
219124631|NCT00430378|OTHER|Standard Care|No Acupuncture.
219124632|NCT00555347|DRUG|Armodafinil|Dosage 150-250 mg
219124633|NCT00555347|DRUG|Placebo|Placebo
219124634|NCT00565318|DRUG|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
219124635|NCT00565318|DRUG|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
219124636|NCT06193330|PROCEDURE|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
219124637|NCT06193330|PROCEDURE|external fixator|external fixators are applied to participants with severe long bone fractures
219124638|NCT00318513|DRUG|Bevacizumab|
219124639|NCT01664234|OTHER|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
219708403|NCT00244179|DRUG|infliximab|
219708404|NCT00244179|DRUG|dmard|
219708405|NCT02683629|BIOLOGICAL|NTCELL Implantation|NTCELL Implantation
219708406|NCT02683629|OTHER|Sham Surgery|Sham Surgery
219124640|NCT01664234|OTHER|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
219124641|NCT06466668|DIAGNOSTIC_TEST|Sleep study|All subjects will undergo a polysomnography at home
219124642|NCT06466668|DIAGNOSTIC_TEST|stress-related biomarkers and microbiome composition will be assessed using saliva samples|stress and stress-related inflammatory biomarkers will be tested using saliva sample
219124643|NCT06466668|DIAGNOSTIC_TEST|Audiological tests|Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
219124644|NCT01414166|DRUG|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
219124645|NCT01414166|DRUG|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
219124646|NCT04096313|DIAGNOSTIC_TEST|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
219124647|NCT05407194|DIETARY_SUPPLEMENT|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
219124648|NCT04268264|PROCEDURE|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
219124649|NCT04268264|PROCEDURE|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
219124650|NCT06356207|DIAGNOSTIC_TEST|Tilt Table Test|The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
219124651|NCT06511934|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into arm-hand motor-related cortex.
219124652|NCT02084082|DRUG|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
219708407|NCT00611052|BEHAVIORAL|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
219708408|NCT00611052|BEHAVIORAL|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
219708409|NCT00611052|OTHER|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
219708410|NCT02825823|DIETARY_SUPPLEMENT|Ketone Salt|
219708411|NCT02825823|DIETARY_SUPPLEMENT|Placebo|
219124653|NCT02084082|DRUG|Linagliptin|1x Linagliptin tablet
219124654|NCT02084082|DRUG|Metformin ER|2x Metformin ER tablets
219124655|NCT02977156|BIOLOGICAL|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
219124656|NCT02977156|DRUG|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
219124657|NCT05266261|DRUG|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
219124658|NCT00522184|PROCEDURE|intra-articular injection of etanercept|
219124659|NCT00522184|PROCEDURE|intra-articular injection of steroid|
219124660|NCT01799954|BIOLOGICAL|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
219124661|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
219124662|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
219124663|NCT01799954|BIOLOGICAL|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
219124664|NCT01799954|BIOLOGICAL|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
219124665|NCT01799954|BIOLOGICAL|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
219124666|NCT05860543|DIAGNOSTIC_TEST|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
219124667|NCT06340880|OTHER|Serratus anterior plane block|ultrasound guided SAPB vs anatomical landmark guided SAPB
219124668|NCT04842968|OTHER|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
219708412|NCT01207193|BIOLOGICAL|cell injection|injection of mesenchymal cells to bone cyst defect
219708413|NCT00296517|DRUG|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
219708414|NCT00296517|DRUG|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
219708415|NCT02517658|OTHER|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
219124669|NCT03168880|DRUG|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
219124670|NCT03168880|DRUG|Paclitaxel only|
219124671|NCT05675696|OTHER|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
219124672|NCT04736056|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
219124673|NCT04348370|BIOLOGICAL|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
219124674|NCT04348370|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
219124675|NCT04231110|BIOLOGICAL|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
219124676|NCT03163511|COMBINATION_PRODUCT|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
219124677|NCT03921905|DIAGNOSTIC_TEST|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
219124678|NCT05002478|OTHER|Prone positioning|Turn patient in prone position after surfactant administration.
219124679|NCT06099015|DEVICE|Cera™ Vascular Plug System|The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
219708416|NCT02517658|OTHER|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
219708417|NCT03905083|OTHER|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
219708418|NCT06251804|OTHER|Water exercise program|The exercise program includes a short foot exercise and will be given in water.
219708419|NCT06251804|OTHER|Land-based-program|The exercise program includes a short foot exercise and will be given on land.
219124680|NCT03886181|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219124681|NCT03437668|DRUG|WSE|WSE tablets
219124682|NCT03437668|DRUG|Placebo Oral Tablet|Placebo tablet
219124683|NCT04456738|BEHAVIORAL|Parent Training|16 weeks of of parent training led by a trained group facilitator
219124684|NCT02956967|OTHER|Overall satisfaction questionnaires of home use of Nivestim|
219124685|NCT01435408|OTHER|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
219124686|NCT01435408|OTHER|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
219708420|NCT00742950|PROCEDURE|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
219708421|NCT00742950|PROCEDURE|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
219124687|NCT01435408|OTHER|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
219124688|NCT05395572|DEVICE|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
218986217|NCT03273270|RADIATION|transcranial magnetic stimulation|transcranial magnetic stimulation
219124689|NCT04921605|DEVICE|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
219124690|NCT01648218|DRUG|Neutral protamine hagedorn (NPH) insulin|
219124691|NCT01648218|DRUG|Regular human insulin or Insulin Aspart|
218986218|NCT06405958|OTHER|gut microbiome|Obtaining new gut microbiome data in organ transplantation
218986219|NCT03623841|OTHER|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
219124692|NCT01648218|DRUG|Insulin glargine|
219124693|NCT00177879|BEHAVIORAL|website comparison|
219124694|NCT00819234|DRUG|Placebo|placebo pramlintide and placebo metreleptin twice daily
219124695|NCT00819234|DRUG|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
219124696|NCT05392426|DEVICE|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
219124697|NCT05392426|DEVICE|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
219124698|NCT05564988|OTHER|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
219124699|NCT00765089|PROCEDURE|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
219708422|NCT00742950|PROCEDURE|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
219708423|NCT02359240|PROCEDURE|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
218986220|NCT03623841|OTHER|Treadmill training|Participants in control group will do treadmill training only
218986221|NCT05353361|DRUG|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
218986222|NCT05353361|DRUG|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
218986223|NCT05353361|DRUG|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
218986224|NCT05353361|DRUG|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
218986225|NCT03528707|DIETARY_SUPPLEMENT|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
218986226|NCT03528707|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
218986227|NCT06044389|DEVICE|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
218986228|NCT04765982|DIAGNOSTIC_TEST|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
218986229|NCT05093140|DRUG|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
219124700|NCT01498874|DRUG|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
219708424|NCT02359240|PROCEDURE|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
219124701|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
219708425|NCT03342066|DIAGNOSTIC_TEST|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
219708426|NCT00587093|OTHER|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
219124702|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
219124703|NCT01823341|DEVICE|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
219124704|NCT01230034|DRUG|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
219124705|NCT01230034|DRUG|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
219124706|NCT00217711|DRUG|Capecitabine|capecitabine
219124707|NCT00217711|DRUG|irinotecan hydrochloride|irinotecan hydrochloride
219124708|NCT00217711|DRUG|oxaliplatin|oxaliplatin
219124709|NCT01548391|DRUG|HX-1171|20mg, 200mg, 500mg
219124710|NCT06251908|OTHER|Rewritalize|"REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text."
219124711|NCT06251908|OTHER|Standard mental health care|"F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs."
219124712|NCT06839274|OTHER|transvaginal Ultrasound|The only additional measure will be the measurement of the follicle volumes on the day of trigger and before oocyte pick up procedure. This will be performed at the same time as the pre Oocyte pick up ultrasound prior to the patient admission to the recovery room for preparation. The ultrasound that will be used already has a pre build program that calculates the follicular volume automatically and hence not extending the ultrasound time.
219124713|NCT06576193|BEHAVIORAL|Safe Dates for Young Parents (SDYP)|"SDYP is a healthy relationship and intimate partner violence (IPV) prevention program, adapted from Safe Dates (Foshee et al., 1998; Foshee et al., 1996) designed for teens, that focuses on pregnant or parenting females. The program consists of ten group-based sessions (50 minutes each) led by a trained facilitator which include interactive discussions, analysis of scenarios, games, role-plays, brainstorming, and a poster contest and theatrical play."
219124714|NCT04057833|DRUG|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
219124715|NCT05620472|DRUG|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
219124716|NCT05130138|OTHER|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
219124717|NCT04474600|DRUG|Propofol|The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
219124718|NCT04474600|DRUG|Desflurane|The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
219708427|NCT06472648|OTHER|Proprioception training exercise plan with BOSU|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises."
219708428|NCT06472648|OTHER|Proprioception training exercise plan with Blackboard (BB)|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises."
219708429|NCT02554396|DRUG|PRX-100|ophthalmic solution
219708430|NCT02554396|DRUG|Placebo|saline ophthalmic solution
219708431|NCT00964782|DRUG|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
219708432|NCT00964782|DRUG|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
219708433|NCT00964782|DRUG|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
219708434|NCT00964782|DRUG|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
219124719|NCT00924560|DRUG|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
219124720|NCT00924560|DRUG|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
219124721|NCT01114620|BIOLOGICAL|Arepanrix™|Intramuscular administration, one dose
219124722|NCT04635501|DEVICE|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
219124723|NCT06397287|OTHER|Observation of patients undergoing sugery|All patients undergoing urological surgery or treatment receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up,
219124724|NCT02696226|DRUG|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
219124725|NCT02696226|DRUG|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
219124726|NCT02696226|DRUG|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
219124727|NCT02696226|DRUG|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
219124728|NCT03564054|PROCEDURE|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
219124729|NCT03564054|PROCEDURE|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
219124730|NCT04477850|DRUG|Luspatercept|Specified dose on specified days
219124731|NCT03658629|BIOLOGICAL|NanoFlu (Quad-NIV)|2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
219124732|NCT03658629|OTHER|Matrix-M Adjuvant|Adjuvant
219124733|NCT03658629|OTHER|Placebo|Placebo
219124734|NCT03658629|BIOLOGICAL|Fluzone HD|2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
219124735|NCT03658629|BIOLOGICAL|Flublok Quadrivalent|2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
219708435|NCT02033512|DRUG|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
219708436|NCT02033512|DRUG|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
219708437|NCT02033512|DRUG|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
219708438|NCT05442658|OTHER|Microbiota|
219708439|NCT03513952|DRUG|Atezolizumab|Given IV
219124736|NCT03658629|BIOLOGICAL|Influenza Vaccine|2018-19 Licensed Seasonal Influenza Vaccine
219124737|NCT00415740|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
219124738|NCT02909101|DEVICE|Active Cognitive Training (ACT)|Cognitive training games
219124739|NCT02909101|DEVICE|Control Training (CON)|Cognitive training games
219124740|NCT06270420|DEVICE|Technological Motor Rehabilitation|Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
219124741|NCT02005614|PROCEDURE|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
219124742|NCT06827912|PROCEDURE|Interscalene Nerve Block|After sterile conditions are provided with the patient in the supine position, the brachial plexus will be identified in the supraclavicular fossa above the clavicle with ultrasonography. The transducer will be directed cephalad and 20 cc 0.5% bupivacaine will be applied to the interscalene space with a 50 mm block needle from the point where the C 5-6-7 nerve roots give the impression of a rosary bead between the anterior and medial scalene muscles.
219124743|NCT06827912|PROCEDURE|Shoulder Anterior Capsule Block|In pericapsular nerve block application, the patient will be placed in a supine position and the arm will be externally rotated and abducted to 45 degrees. After sterile conditions are provided, the humerus head, the tendon of the subscapularis muscle and the deltoid muscle above it will be identified with ultrasonography. 15 cc of 0.5% bupivacaine will be injected into the interfascial space between the deltoid muscle and the subscapularis muscle with a 22gauge 50 mm block needle. Then, the block needle will be directed deep into the subscapularis muscle and another 5 cc of 0.5% bupivacaine will be injected under the subscapularis muscle.
219708440|NCT03513952|PROCEDURE|Biopsy|Undergo biopsy of tumor
219708441|NCT03513952|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
219708442|NCT03513952|PROCEDURE|Computed Tomography|Undergo CT
219708443|NCT03513952|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given IM
219708444|NCT03513952|OTHER|Laboratory Biomarker Analysis|Correlative studies
219708445|NCT03513952|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219708446|NCT03513952|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
219708447|NCT05553717|DRUG|Carvedilol|Carvedilol 12.5mg\\12hr
219708448|NCT01583881|PROCEDURE|renal denervation|Renal denervation
219708449|NCT02938663|BEHAVIORAL|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
219708450|NCT01093417|DRUG|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
219708451|NCT01093417|OTHER|Placebo|Placebo pills will be administered to enrollees in this arm
219708452|NCT02703766|BEHAVIORAL|overfeeding induced weight gain|
219708453|NCT01143324|DEVICE|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
219708454|NCT04793568|DRUG|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
219124744|NCT03242044|PROCEDURE|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
219124745|NCT04245046|DRUG|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
219124746|NCT03439696|PROCEDURE|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
219124747|NCT01095718|BEHAVIORAL|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
219124748|NCT01095718|BEHAVIORAL|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
219124749|NCT01095718|BEHAVIORAL|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
219124750|NCT05886075|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
219124751|NCT03024242|DEVICE|Tight vaginoscope|
219708455|NCT04793568|DRUG|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
219708456|NCT01091610|OTHER|no intervention|purely observational retrospective study. no interventions are planned.
219708457|NCT00447408|BEHAVIORAL|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
219708458|NCT00447408|BEHAVIORAL|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
219708459|NCT01694680|DIETARY_SUPPLEMENT|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
219708460|NCT01694680|DIETARY_SUPPLEMENT|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
219708461|NCT06026397|DRUG|SK10|Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
219708462|NCT06026397|DRUG|Placebo|Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
219708463|NCT02530541|DRUG|CHG|Varied application times
219708464|NCT04872283|PROCEDURE|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
219708465|NCT04872283|DRUG|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
219708466|NCT04872283|DRUG|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
219708467|NCT04872283|DRUG|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
219708468|NCT04872283|DRUG|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
219708469|NCT02353780|DRUG|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
219708470|NCT02353780|DRUG|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
219708471|NCT02353780|DRUG|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
219708472|NCT03133013|DEVICE|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
219708473|NCT03265795|DEVICE|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
219708474|NCT00056680|BEHAVIORAL|Psychoeducational video|
219708475|NCT00056680|BEHAVIORAL|Infant massage|
219708476|NCT00056680|BEHAVIORAL|Brazelton Neonatal Behavioral Assessment Scale|
219708477|NCT02608619|RADIATION|F-choline PET Scan|
219708478|NCT02608619|DEVICE|FDG-PET|
219708479|NCT02608619|PROCEDURE|biopsy|
219708480|NCT02774889|BEHAVIORAL|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources"
219708481|NCT04025424|GENETIC|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
219708482|NCT04155801|DIETARY_SUPPLEMENT|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
219708483|NCT00858988|DRUG|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
219708484|NCT00858988|DRUG|Placebo|twice daily for 7 consecutive days
219708485|NCT00416273|DRUG|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
219708486|NCT00416273|DRUG|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
219708487|NCT01349595|DRUG|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
219708488|NCT01885065|OTHER|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
219708489|NCT00337883|DRUG|Erlotinib HCl (OSI-774)|
219708490|NCT01692574|BEHAVIORAL|Behavior Modification for Weight Loss|
219708491|NCT01692574|BEHAVIORAL|Alternative Approach to Weight Loss|
218986230|NCT00938236|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
218986231|NCT01067937|PROCEDURE|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
219708492|NCT01692574|BEHAVIORAL|Cognitive-Behavior Therapy for Depression|
219708493|NCT01692574|BEHAVIORAL|Depression Support and Education|
218986232|NCT04150055|BEHAVIORAL|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
218986233|NCT01634334|BEHAVIORAL|Real-Time Intervention|Lights and Sound Brief Coaching
218986234|NCT01634334|BEHAVIORAL|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
219708494|NCT00492869|DRUG|AEB071|
219708495|NCT05257616|OTHER|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
219124752|NCT03073005|OTHER|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
219124753|NCT01992198|DRUG|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
219124754|NCT01992198|PROCEDURE|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
219124755|NCT01992198|PROCEDURE|enteral nutrition|
219124756|NCT01992198|DRUG|Somatostatin|
219124757|NCT01992198|DRUG|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
219124758|NCT04374617|DIAGNOSTIC_TEST|Duplex ultrasound and Computed Tomography Angiography|All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
219124759|NCT02380521|DRUG|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
219124760|NCT04757558|DEVICE|C-MAC video-stylet|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
219124761|NCT04757558|DEVICE|Macintosh laryngoscope|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
219124762|NCT05104411|OTHER|Rehabilitative intervention|Active rehabilitation programs were done for all patients. Participants were asked to attend exercise program at PT room or bedside. Exercise program was offered once or twice daily on weekdays, by trained kinesiologists. In PT programs, most patients performed strengthening exercise of lower extremities, balance training, sit-up training, sit-to-stand training and gait training for about 30 minutes. Each program was individualized to participants' current physical function. In bedside programs, patients also underwent strengthening exercise and balance training without gait training for about 10 minutes. The duration of exercise program at PT room depends on the patient's condition(upto 1 month).
219124763|NCT05104931|DRUG|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
219124764|NCT05104931|DRUG|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
219124765|NCT05104931|DRUG|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
219124766|NCT01290094|DRUG|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
219124767|NCT04563052|BEHAVIORAL|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
219708496|NCT05257616|OTHER|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
219708497|NCT00355927|PROCEDURE|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
219124768|NCT06224270|BIOLOGICAL|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
219124769|NCT05988489|BEHAVIORAL|Dynamic Deconstructive Psychotherapy (DDP)|DDP treatment with an assigned therapist for up to 12 months
219124770|NCT05988489|BEHAVIORAL|Brief Intervention and Contact (BIC)|BIC treatment with an assigned therapist for up to 12 months
219124771|NCT04666454|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
219124772|NCT04666454|DRUG|Dipyridamole 200 mg|200 mg b.i.d
219124773|NCT04666454|DRUG|Apixaban 5 mg Oral Tablet|5mg b.i.d
219708498|NCT03955315|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
219708499|NCT03955315|PROCEDURE|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
219708500|NCT05578339|DEVICE|Biometry|Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
219708501|NCT02857868|DRUG|ABL001|
219708502|NCT00559078|OTHER|Interview|Hour-long, qualitative, phone interview
219708503|NCT02515929|DIETARY_SUPPLEMENT|Oligomeric Proanthocyanidins|
219124774|NCT04666454|OTHER|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
219124775|NCT03621553|DRUG|Ergocalciferol|Vitamin D2 50,000 units
219124776|NCT03621553|DRUG|Placebo|Sugar pill manufactured to mimic ergocalciferol 50,000 units
219124777|NCT03621553|DRUG|Calcium Citrate with Vitamin D2|To meet the recommended minimum daily dietary requirements
219124778|NCT01266044|PROCEDURE|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
219124779|NCT01266044|PROCEDURE|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
219124780|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
219124781|NCT01266044|OTHER|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
219708504|NCT02515929|DIETARY_SUPPLEMENT|Placebo|
219708505|NCT05071924|BEHAVIORAL|PLH Teens Original: In-person PLH programme for parents and teens by community-based workers|This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
219708506|NCT05071924|BEHAVIORAL|PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators|The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
219708507|NCT03133676|DRUG|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
219708508|NCT03133676|DRUG|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
219708509|NCT05346029|BEHAVIORAL|Lifestyle intervention|Resistance training and nutritional counseling
219708510|NCT05968378|BEHAVIORAL|Standard healthy eating advice|Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
219708511|NCT05968378|BEHAVIORAL|eTRE plus Mediterranean diet|Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
219708512|NCT02715453|OTHER|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge"
219708513|NCT04696198|OTHER|Manual Therapy Intervention|Manual Therapy Interventions to improve range of motion and decrease pain
219708514|NCT04696198|OTHER|Standard care|standard care
219708515|NCT04161196|PROCEDURE|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
219708516|NCT04161196|PROCEDURE|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
218986235|NCT02364726|PROCEDURE|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
218986236|NCT02364726|BEHAVIORAL|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
219124782|NCT05737550|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
219124783|NCT00125151|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|
218986237|NCT02364726|BEHAVIORAL|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
219124784|NCT04465890|DRUG|ASC22|200mg/1ml/1bottle
219124785|NCT04465890|DRUG|sodium chloride|90mg/10ml/1 bottle
219708517|NCT03000153|OTHER|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
219708518|NCT00002846|BIOLOGICAL|aldesleukin|
219708519|NCT00002846|PROCEDURE|conventional surgery|
219708520|NCT00602485|OTHER|Action Control Education|30 minute educational intervnetion
219708521|NCT04901624|BEHAVIORAL|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
219708522|NCT04901624|BEHAVIORAL|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
219708523|NCT04901624|BEHAVIORAL|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
219708524|NCT04901624|BEHAVIORAL|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
219708525|NCT00012909|BEHAVIORAL|Hormone Replacement Therapy Decision-Aid|
219708526|NCT04488952|DEVICE|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
219708527|NCT04488952|DEVICE|spinal anesthesia|Patients in this group receive spinal anesthesia.
219708528|NCT02655003|OTHER|TIME|
219708529|NCT02655003|OTHER|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
219708530|NCT05673122|DEVICE|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
219708531|NCT03667287|PROCEDURE|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
219708532|NCT01009567|DRUG|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
219708533|NCT01009567|DRUG|Control|Receive human albumin 20% infusion
219124786|NCT03395587|BIOLOGICAL|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
219124787|NCT03395587|DRUG|standard therapy|temozolomide, fractionated radiochemotherapy
219124788|NCT04091672|PROCEDURE|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
219124789|NCT04091672|DEVICE|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
219124790|NCT03416218|BEHAVIORAL|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
219124791|NCT04709731|DRUG|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
219124792|NCT04709731|DRUG|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
219708534|NCT02692079|PROCEDURE|T-PRF|Flap Surgery
219708535|NCT02692079|PROCEDURE|Allograft|Flap Surgery
219708536|NCT05046704|DEVICE|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
219708537|NCT02538991|DEVICE|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
219708538|NCT02538991|DEVICE|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
218986238|NCT04741711|PROCEDURE|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
218986239|NCT04741711|PROCEDURE|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
218986240|NCT04721730|BEHAVIORAL|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
218986241|NCT04721730|BEHAVIORAL|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
218986242|NCT02056938|DRUG|Anti-Thymocyte Globulins treatment|
218986243|NCT02056938|DRUG|Basiliximab treatment|
219124793|NCT06403644|DEVICE|NovoTHOR XL Photobiomodulation Full Body Light Bed|Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
219708539|NCT03004040|BIOLOGICAL|Flu Vaccine|
219708540|NCT02428400|BIOLOGICAL|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
219708541|NCT02428400|BIOLOGICAL|Placebo|Placebo: adenovirus reference material (ARM) buffer
219708542|NCT03100747|PROCEDURE|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
219708543|NCT03100747|PROCEDURE|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
219708544|NCT03100747|PROCEDURE|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
219708545|NCT05475145|PROCEDURE|Resin based sealing [RBS]|
219708546|NCT05545917|OTHER|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
219708547|NCT05545917|OTHER|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
219708548|NCT00658619|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
218986244|NCT02898805|OTHER|Placebo|
218986245|NCT02898805|OTHER|Prescribed Diet|
218986246|NCT02898805|DIETARY_SUPPLEMENT|LopiGLIK®|
218986247|NCT02898805|DIETARY_SUPPLEMENT|Armolipid Plus|
218986248|NCT00006111|DRUG|cisplatin|
218986249|NCT00006111|DRUG|fluorouracil|
218986250|NCT00006111|PROCEDURE|conventional surgery|
218986251|NCT00006111|RADIATION|radiation therapy|
218986252|NCT00532558|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
218986253|NCT00532558|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
218986254|NCT04470141|DRUG|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
218986255|NCT03668275|PROCEDURE|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
218986256|NCT00677131|OTHER|Reading the package insert of the drug|package insert of the drug
218986257|NCT00677131|OTHER|Reading the education information provided by the Pharmacy of NTUH|education information
218986258|NCT00677131|OTHER|Oral education provided by the pharmacist|Oral education provided by the pharmacist
218986259|NCT02418650|DRUG|ODM-201 300 mg tablet|
218986260|NCT02418650|DRUG|intravenous14C-ODM-201|
218986261|NCT02418650|DRUG|300 mg 14C-ODM-201 oral solution|
218986262|NCT04798755|DRUG|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
218986263|NCT04798755|DRUG|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
218986264|NCT04798755|DRUG|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
218986265|NCT04905966|BEHAVIORAL|Nutrition education and Physical activity intervention|Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
218986266|NCT02827227|BIOLOGICAL|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
218986267|NCT04783818|RADIATION|Adjuvant Radiotherapy|PMRT
218986268|NCT02850601|DRUG|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
218986269|NCT03864978|DRUG|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
218986270|NCT03864978|DRUG|Placebo|Placebo
218986271|NCT05212922|DRUG|YH001 + Toripalimab|YH001 + Toripalimab
219708549|NCT00658619|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
219708550|NCT00658619|OTHER|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
218986272|NCT03658239|OTHER|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
218986273|NCT02925117|DRUG|Upadacitinib|Tablet for oral use
219124794|NCT06403644|DEVICE|ARRC LED Photobiomodulation Full Body Light Bed|High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
219124795|NCT03037060|OTHER|[11C]-(+)-PHNO PET scan|PET scan
219124796|NCT03037060|OTHER|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
219124797|NCT03037060|OTHER|Craving Task|Cue exposure paradigm
219124798|NCT03037060|OTHER|MRI scan|MRI scan scan to analyze the PET data will be administered.
219124799|NCT03037060|OTHER|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
219124800|NCT05296629|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
219124801|NCT05296629|DRUG|Doxycycline|Doxycycline 40 mg capsules
219124802|NCT05296629|DRUG|Placebo|Placebo capsules
219124803|NCT03720015|BEHAVIORAL|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
219708551|NCT06403371|OTHER|Fluoride varnsh|Fluoride varnish was applied to the teeth surfaces before aligner therapy
218986274|NCT02925117|DRUG|Placebo|Tablet
218986275|NCT05582473|BEHAVIORAL|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
219124804|NCT03720015|DIETARY_SUPPLEMENT|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
219124805|NCT02272023|BEHAVIORAL|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
219124806|NCT02272023|BEHAVIORAL|Single session of Motivational Interviewing|
219124807|NCT01579656|DIETARY_SUPPLEMENT|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
219225840|NCT04464031|OTHER|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
219225841|NCT03183349|PROCEDURE|deprotienized bovine bone (tutogen)|
219708552|NCT06403371|OTHER|Normal saline|Normal saline was applied to the teeth surfaces before aligner therapy
219708553|NCT00000552|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219708554|NCT00000552|PROCEDURE|coronary artery bypass|
219708555|NCT00000552|DRUG|thrombolytic therapy|
219708556|NCT06055374|DRUG|BxC-I17e|Pharmaceutical form : solution for injection
219225842|NCT03183349|PROCEDURE|platelet rich fibrin|
219225843|NCT04843449|DRUG|ASC40|Oral tablets
219708557|NCT06055374|DRUG|Placebo|Pharmaceutical form : solution for injection
219225844|NCT04843449|DRUG|Itraconazole|Oral capsules
219225845|NCT04843449|DRUG|rifampicin|Oral capsules
219225846|NCT04681794|OTHER|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
219708558|NCT03261193|DRUG|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
219708559|NCT03261193|DRUG|ITM + Bupivacaine QLB|QL plane block with local anesthesia
219708560|NCT03750721|OTHER|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
219708561|NCT00055562|DRUG|CC 5013|
219708562|NCT01866670|BEHAVIORAL|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
219708563|NCT01866670|BEHAVIORAL|relaxation therapy|Relaxation Therapy: deep breathing
219708564|NCT00497107|DRUG|UFT, Calcium Folinate, PSK|
219708565|NCT00497107|DRUG|UFT, Calcium Folinate|
219124808|NCT01579656|DIETARY_SUPPLEMENT|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
219708566|NCT06737380|DIAGNOSTIC_TEST|Physical examination|The physical examination will be performed at the Screening visit and at each subsequent study and safety in clinic follow-up visit. The exam will include: measurement of vital signs (heart rate, peripheral arterial blood pressure, respiratory rate, and temperature), weight, height (at Screening visit only), cardiovascular and respiratory systems, abdominal examination, skin evaluation, mouth and eye evaluation, and neurological assessment. Abnormal findings will be recorded in the CRF.
219708567|NCT06737380|DIAGNOSTIC_TEST|Electrocardiogram|A twelve-lead electrocardiogram (ECG), including corrected QT interval (QTc interval), will be performed in all participants at the Screening visit.
219708568|NCT06737380|OTHER|SF-36 questionnaire|Patients will fill out the SF 36 survey, assessing physical and mental health outcomes prior to dosing and/or any other clinical assessments, on visits 1 (baseline), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
219124809|NCT01579656|DIETARY_SUPPLEMENT|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
219124810|NCT01579656|DIETARY_SUPPLEMENT|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
219124811|NCT01579656|DIETARY_SUPPLEMENT|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
219124812|NCT04330443|PROCEDURE|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
219225847|NCT03272412|DIAGNOSTIC_TEST|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
218986276|NCT04067674|BIOLOGICAL|Blood sampling|Blood sampling for biomarker measurement
218986277|NCT00956969|BEHAVIORAL|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
218986278|NCT00956969|BEHAVIORAL|Relaxation Training|Teaches patients relaxation training
218986279|NCT03254875|BEHAVIORAL|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
218986280|NCT04341077|DRUG|SHR3162|A single oral dose of fluzoparib on Day 1
218986281|NCT02027207|BIOLOGICAL|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
218986282|NCT02027207|BIOLOGICAL|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
219124813|NCT04925050|DRUG|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
219124814|NCT04925050|OTHER|Matching Placebo for VB0004|Matching Placebo
219124815|NCT06256302|PROCEDURE|Transverses Abdominis Plane Block|Transverses abdominis plane block will be provided randomly using prospective double-blinding.
219124816|NCT06256302|PROCEDURE|Local wound infiltration|Local wound infiltration will be provided randomly using prospective double-blinding.
219124817|NCT06477939|DRUG|Administration of L-TC|"Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
219124818|NCT06477939|OTHER|Radiotherapy plus Temozolomide|"Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
219124819|NCT05245656|DRUG|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"
219124820|NCT05245656|DRUG|RB|"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"
219124821|NCT00142064|BEHAVIORAL|observed levels of pain|
219124822|NCT05629598|BIOLOGICAL|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
219124823|NCT05629598|BIOLOGICAL|Human erythropoietin injection|Refer to the product instructions
219124824|NCT02401529|DRUG|IV dexamethasone|0.15 mg/kg
219708569|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Serology|Serologic testing for HIV, HBV, HCV, TB, and CMV will be performed; HBV and HCV PCR will be done only if serology is positive. Autoimmune tests (ANA, anti-ENA, total IgG, anti-nucleosome) will be done at Day 0 and end of study; ANA only at Screening if no positive ANA or anti-dsDNA in prior 6 months. Inflammatory markers (hs-CRP, ESR) will be tested at Day 0 and end of study. CBC with differential, biochemistry, anti-dsDNA, and complement C3/C4 will be assessed at each scheduled visit.
219708570|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Biochemistry|The panel will include analysis of albumin, blood urea nitrogen (BUN), creatinine, glucose, uric acid, calcium, phosphorus, potassium, sodium, lactate dehydrogenase (LDH), total protein, magnesium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and hs-CRP. For biochemistry, 3 mL blood will be collected at each study visit. Results relating to inclusion criteria must be confirmed within 7 days prior to Day 1.
219124825|NCT02401529|DRUG|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
219124826|NCT02401529|DRUG|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
219124827|NCT02401529|DRUG|IV saline|IV saline
219124828|NCT00323089|PROCEDURE|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
219124829|NCT03939520|DRUG|pirfenidone and nintedanib|The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
219124830|NCT03939520|DRUG|pirfenidone or nintedanib|The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
219124831|NCT03939520|DRUG|pirfenidone or nintedanib|The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
219708571|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Hematology|The complete blood count (CBC) will include: hemoglobin, hematocrit, white blood cells (WBCs) with complete manual or automated differential (total neutrophils, lymphocytes, monocytes, eosinophils, basophils; absolute or percentage will be acceptable), red blood cells (RBCs), platelet count. For CBC, 1mL blood will be collected at each study visit.
219708572|NCT06737380|DIAGNOSTIC_TEST|Pregnancy Test|"A serum b-hCG pregnancy test will be performed for women of child-bearing potential at the Screening visit;urine pregnancy tests will be performed for women of child-bearing potential at each study visit noted above, including on Day 0 prior to study treatment.~Pregnancy tests are not required for women unable to become pregnant for one of the following reasons: Menopause confirmed by healthcare provider, verbally reported by a participant that she has had her uterus or both ovaries or both fallopian tubes removed."
219708573|NCT06737380|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will include analysis of pH, specific gravity, protein, glucose, ketones, bilirubin, urobilinogen, leukocytes, erythrocytes. In addition samples will be assessed for presence of urinary casts. Spot urine protein/creatinine measure will be done at each visit. If no casts are observed at Screening, then machine assessment of further urinary samples is allowed. For urinalysis, 10mL urine will be collected at each study visit.
219708574|NCT06737380|DIAGNOSTIC_TEST|SLE activity evaluation|SLE status will be assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment- SLE Disease Activity Index (SLEDAI 2K scale).SLE activity will also be assessed using British Isles Lupus Assessment Group (BILAG), physician global and participant global assessment allowing use of the Systemic Lupus Responder Index (SRI 4) and the BILAG-based Composite Lupus Assessment (BICLA) instruments to assess clinical response.
219708575|NCT06737380|DIAGNOSTIC_TEST|SLE biomarker profiling|"SLE biomarkers will be profiled at the study visit (Day 1) and at every subsequent follow up visit. For this purpose, urine and 10 ml blood will be collected.~Anti-ENA, Anti-dsDNA antibodies, total serum IgG levels, CBC, C3, C4, anti-nucleosome antibodies, erythrocyte sedimentation rate, CRP, protein/creatinine ratio in spot urine, 24-hour urine protein - Day 1 - Baseline and at end of study visit only; Mononuclear cell changes. This analysis includes lymphocyte subsets and innate immune cell subsets"
219708576|NCT06737380|DIAGNOSTIC_TEST|Cytokines and chemokine profiling|Samples will be analyzed for the following cytokines/chemokines: IFNγ, IL-6, IL-10, IL-18, TNFα, TGFβ1, CXCL10, CCL2, N-GAL, urine endothelin, KIM1. Serum and urine samples will be collected on Days 0, 28, 56, 140, 168, and early termination visit.
218986283|NCT00456248|DRUG|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
218986284|NCT01446315|BEHAVIORAL|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
218986285|NCT01446315|BEHAVIORAL|Asthma APGAR tools|Usual care
218986286|NCT03117920|DRUG|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
218986287|NCT02235805|DIETARY_SUPPLEMENT|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
218986288|NCT02235805|DIETARY_SUPPLEMENT|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
218986289|NCT05719662|OTHER|Weight bearing exercises|Weight bearing exercises
218986290|NCT05719662|OTHER|Jaffrey's core stability exercises|Jaffrey's core stability exercises
218986291|NCT03717246|BEHAVIORAL|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
218986292|NCT03717246|BEHAVIORAL|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
218986293|NCT01853423|DRUG|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
218986294|NCT05161767|DIAGNOSTIC_TEST|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
218986295|NCT03504254|DIAGNOSTIC_TEST|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
218986296|NCT02043080|OTHER|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
218986297|NCT04035109|DRUG|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
218986298|NCT04035109|DRUG|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
218986299|NCT04035109|BIOLOGICAL|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
218986300|NCT04035109|BIOLOGICAL|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
218986301|NCT01533077|DRUG|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
218986302|NCT01533077|DRUG|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
218986303|NCT00651391|DRUG|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
218986304|NCT00651391|DRUG|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
218986305|NCT00651391|DRUG|Placebo|oral placebo once daily in the evening for 12 weeks
218986306|NCT04773756|DRUG|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
219124832|NCT05727995|DEVICE|PICO7|"The use of PICO is contraindicated in the presence of:~* Patients with malignancy in the wound bed or margins of the wound~* Previously confirmed and untreated osteomyelitis~* Nonenteric and unexplored fistulas~* Necrotic tissue with eschar present~* Exposed arteries, veins, nerves or organs~* Exposed anastomotic sites~* Emergency airway aspiration~* Pleural, mediastinal or chest tube drainage~* Surgical suction."
219124833|NCT05727995|OTHER|usual care dressing|usual care dressing
219124834|NCT03688295|OTHER|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
219124835|NCT03688295|DRUG|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
219124836|NCT01031693|DEVICE|Transcranial Magnetic Stimulation|daily sessions for 5 days
219124837|NCT05373290|OTHER|there is no intervention in the study|there is no intervention in the study
219708577|NCT06737380|BIOLOGICAL|single dose of UC-MSCs|participants will be treated on Baseline Day 1 with a UC-MSCs product administered subcutaneously. Participants will be observed for 2 to 3 hours after end of study treatment and then followed up for safety assessments over the subsequent 6-month period.
219708578|NCT06737380|OTHER|PROMIS instruments|PROMIS Fatigue, PROMIS, Depression, PROMIS Pain prior to dosing and/or any other clinical assessments, on visits 1 (baseline, day 0), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
219708579|NCT02965651|BEHAVIORAL|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
219708580|NCT00001305|DRUG|Humatrope|Patients receive a subcutaneous injection.
219708581|NCT02811770|OTHER|kidney biopsy|
219708582|NCT03510065|DEVICE|Prevision®|One time Evaluation with documentation of one follow-up visit
219708583|NCT01235221|DRUG|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
219708584|NCT04584788|DEVICE|Masimo O3 Regional Oximeter|Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
219708585|NCT05619133|DEVICE|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~1. A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~2. a presence sensor~3. ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
219708586|NCT04480528|OTHER|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
219708587|NCT04480528|OTHER|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
219124838|NCT03324685|DRUG|BIIB074|BIIB074 is administered as specified in the treatment arm.
219124839|NCT03324685|DRUG|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
219124840|NCT02272699|DRUG|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
219124841|NCT02272699|DRUG|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
219124842|NCT02272699|DRUG|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
219124843|NCT02272699|RADIATION|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
219124844|NCT02272699|PROCEDURE|Surgery|Esophagectomy
219124845|NCT03243760|DRUG|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
219124846|NCT03243760|DRUG|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
219124847|NCT03243760|DRUG|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
219124848|NCT01419847|DRUG|Ciclopirox|
219124849|NCT01419847|DRUG|Placebo|
219124850|NCT01518257|BIOLOGICAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
219708588|NCT04877600|OTHER|dual task performance|dual task performance measurement
219708589|NCT06387303|DRUG|Methadone|Intravenous Methadone
219708590|NCT06387303|DRUG|Morphine|Intrathecal Morphine
219708591|NCT02002663|DRUG|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
219708592|NCT02002663|DRUG|Methylprednisolone 1mg/kg|
219708593|NCT02002663|DRUG|saline 0.9%|
219708594|NCT04874311|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
219708595|NCT04874311|DRUG|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
219708596|NCT05399485|DRUG|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
219708597|NCT05399485|DRUG|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
219708598|NCT05063916|DRUG|AK104|Given By IV
219708599|NCT06830590|PROCEDURE|Molecular characterisation|All patients treated by surgery were included without any neoadjuvant therapy
219708600|NCT02818257|OTHER|Strip A|Adhesive strip A
219708601|NCT02818257|OTHER|Strip B|Adhesive strip B
219124851|NCT01518257|DRUG|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
219124852|NCT03185429|BIOLOGICAL|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
219124853|NCT03185429|DRUG|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
219124854|NCT00924664|BIOLOGICAL|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
219124855|NCT00924664|BIOLOGICAL|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
219708602|NCT02818257|OTHER|Strip C|Adhesive strip C
219124856|NCT05213403|DIAGNOSTIC_TEST|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
219708603|NCT03105401|OTHER|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
219708604|NCT06111625|DRUG|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
219708605|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
219708606|NCT03068910|DRUG|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
219708607|NCT03068910|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
219708608|NCT03068910|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
219708609|NCT06387979|OTHER|Non-Interventional Study|Non-Interventional Study
219708610|NCT01120197|OTHER|Exercise group|Weekly exercises
219708611|NCT01120197|OTHER|Control Group|No Intervention, control group only
219124857|NCT00449423|DRUG|acipimox|
219124858|NCT03139175|DEVICE|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
219708612|NCT05900245|OTHER|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
219708613|NCT03632447|DEVICE|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
219708614|NCT03632447|DEVICE|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
219708615|NCT06463275|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument).
219708616|NCT04178018|DEVICE|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
219708617|NCT04178018|DEVICE|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
219708618|NCT03115710|DIAGNOSTIC_TEST|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
219708619|NCT06096870|DRUG|Enzalutamide|Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
219708620|NCT06096870|DRUG|PDS01ADC|PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)
219124859|NCT03446508|DEVICE|Active frontal|1\) active HD-tDCS will be administered
219124860|NCT03446508|DEVICE|Active parietal|2\) active HD-tDCS will be administered
219124861|NCT03446508|DEVICE|Sham|3\) sham HD-tDCS - no current
219124862|NCT03293862|DEVICE|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
219124863|NCT03293862|PROCEDURE|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
219124864|NCT03293862|DEVICE|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
219124865|NCT01394770|DRUG|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
219124866|NCT04907448|OTHER|Physical Therapy|"The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks."
219124867|NCT06713161|DIAGNOSTIC_TEST|NIR-II Probe(i.e ICG-POL6326) incubation solution|After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.
219124868|NCT06705530|BIOLOGICAL|Hem101|CAR-T lymphocytes specific to CD19 B-cell antigen
219708621|NCT06394882|BEHAVIORAL|Family-Centered Healthy Lifestyle Program (FamCe-HLP)|A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
219708622|NCT06376526|BIOLOGICAL|Linvoseltamab|"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"
219708623|NCT03910959|OTHER|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
219708624|NCT03910959|OTHER|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
219708625|NCT06791291|DRUG|Teplizumab|Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion
219708626|NCT04482062|DEVICE|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
219708627|NCT04482062|DRUG|Optimal Medical Therapy|Optimal Medical Therapy
219708628|NCT06111586|DRUG|Frexalimab|Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
219708629|NCT06111586|DRUG|Placebo|IV Infusion at Day 1 and SC Injection from W2 to W102
219708630|NCT06111586|DRUG|Insulin|SC injection, dose and frequency will be established and/or adjusted by investigator
219708631|NCT00549055|DRUG|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
219708632|NCT06406309|BEHAVIORAL|Power Down manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for children with ADHD). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep during the 2-week intervention phase. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
219708633|NCT02655341|DEVICE|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
219708634|NCT02655341|PROCEDURE|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
219708635|NCT02655341|PROCEDURE|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
219124869|NCT05125861|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
219124870|NCT05125861|PROCEDURE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
219124871|NCT04448743|OTHER|Blood sample|20 Ml blood sample
219124872|NCT00093795|DRUG|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
219708636|NCT02655341|PROCEDURE|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
219124873|NCT00093795|DRUG|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
219124874|NCT00093795|DRUG|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
219124875|NCT00093795|DRUG|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
219124876|NCT00093795|DRUG|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
219124877|NCT02054247|DEVICE|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
219708637|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
219708638|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
219708639|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
219124878|NCT02054247|DEVICE|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
219124879|NCT02054247|DEVICE|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
219124880|NCT02582203|DRUG|Ceftaroline|
219124881|NCT02582203|DRUG|Vancomycin|
219124882|NCT01392755|DRUG|danoprevir|oral doses of danoprevir
219124883|NCT01392755|DRUG|omeprazole|oral doses of omeprazole
219124884|NCT01392755|DRUG|ranitidine|oral dose of ranitidine
219124885|NCT01392755|DRUG|ritonavir|oral doses of ritonavir
219124886|NCT04669613|OTHER|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
219124887|NCT01106287|DRUG|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
219124888|NCT01106287|DRUG|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
219124889|NCT03545490|DIETARY_SUPPLEMENT|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
219124890|NCT04591899|DEVICE|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
219708640|NCT00770809|OTHER|Laboratory Biomarker Analysis|Correlative studies
219124891|NCT04730947|DRUG|Dapagliflozin|10 mg orally once a day
219124892|NCT04730947|DRUG|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
219124893|NCT03060187|OTHER|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
219124894|NCT03916614|BEHAVIORAL|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
219124895|NCT03916614|BEHAVIORAL|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
219124896|NCT06300398|DRUG|IAMA-6|IAMA-6 liquid suspension
219124897|NCT06300398|DRUG|Placebo|Placebo-to-match IAMA-6 liquid suspension
219124898|NCT05883800|RADIATION|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
219124899|NCT01461356|PROCEDURE|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
219124900|NCT01461356|PROCEDURE|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
219124901|NCT03597308|DRUG|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
219708641|NCT00770809|DRUG|Lapatinib Ditosylate|Given PO
219124902|NCT03597308|DRUG|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
219124903|NCT03597308|DRUG|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
219124904|NCT05623280|DRUG|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
219124905|NCT06487026|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
219124906|NCT01189955|PROCEDURE|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
219124907|NCT01189955|PROCEDURE|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
219708642|NCT00770809|DRUG|Paclitaxel|Given IV
219708643|NCT00770809|BIOLOGICAL|Trastuzumab|Given IV
219708644|NCT03748329|DEVICE|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
219708645|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
219708646|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
219708647|NCT03187470|DEVICE|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
219124908|NCT00940017|DRUG|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
219124909|NCT04018729|DEVICE|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
219124910|NCT04018729|BIOLOGICAL|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
219124911|NCT05507697|BIOLOGICAL|HUC-MSCs|5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
219124912|NCT05507697|BIOLOGICAL|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
219124913|NCT02201030|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
219124914|NCT02201030|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
219124915|NCT01618331|BEHAVIORAL|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
219124916|NCT01618331|DIETARY_SUPPLEMENT|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
219708648|NCT04957394|BEHAVIORAL|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
219708649|NCT00001956|PROCEDURE|Blood draw|
219708650|NCT00001956|PROCEDURE|Oral surgery|
219708651|NCT00001956|PROCEDURE|Tissue biopsy|
219708652|NCT02806076|PROCEDURE|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
219708653|NCT02806076|PROCEDURE|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
219708654|NCT04301284|DRUG|CAD-1883|150 mg filled capsules
219708655|NCT04301284|DRUG|Placebos|capsules
219708656|NCT03618277|PROCEDURE|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
219708657|NCT06267391|DEVICE|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
219124917|NCT00175240|BEHAVIORAL|Evidence summaries endorsed by local opinion leaders|
219124918|NCT00031291|DRUG|Anthrax Immune Globulin|
219708658|NCT06267391|DEVICE|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
219708659|NCT05194930|BEHAVIORAL|The ABC of Insomnia (Acceptance and the Behavioral Changes to treat Insomnia)|5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) provided by a trained instructor.
219708660|NCT05194930|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
219708661|NCT05651256|DRUG|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
219124919|NCT04580654|BIOLOGICAL|CSL312|Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
219124920|NCT04764019|DIAGNOSTIC_TEST|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
219124921|NCT02074566|OTHER|Cryoballoon ablation|PVI using cryoballoon
219124922|NCT02688972|OTHER|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
219124923|NCT02688972|OTHER|Control group|The volunteers stayed in rest about 10 minutes
219124924|NCT02824289|BEHAVIORAL|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
219124925|NCT02824289|BEHAVIORAL|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
219124926|NCT02949271|OTHER|Programmed Intermittent Epidural Bolus|
219124927|NCT02949271|OTHER|Continuous Epidural Infusion|
219124928|NCT02949271|DRUG|Ropivacaine|
219124929|NCT02949271|DRUG|Fentanyl|
219124930|NCT01293461|DRUG|CBX129801|Subcutaneous injection
219124931|NCT01293461|DRUG|Placebo|Subcutaneous injection
219124932|NCT05448261|BEHAVIORAL|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
219124933|NCT05448261|OTHER|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
219708662|NCT05944718|DEVICE|Continuous glucose monitor|"Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.~CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.~CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels."
219708663|NCT06963606|DIAGNOSTIC_TEST|Artificial intelligence-assisted chest X-ray in TB screening|After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
219708664|NCT06963606|OTHER|Routine doctors analyze the process of chest X-rays|After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system
219708665|NCT01566370|DRUG|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
219708666|NCT01566370|DRUG|Placebo|placebo
219124934|NCT06500286|DRUG|Marciane|Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
219124935|NCT06500286|DRUG|Marcaine|Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
219708667|NCT02323009|DEVICE|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
219708668|NCT02323009|OTHER|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
219708669|NCT06214741|DRUG|survodutide|once weekly subcutaneous injection
219708670|NCT06214741|DRUG|Placebo matching BI 456906|Once weekly subcutaneous injection
219708671|NCT06098846|DIETARY_SUPPLEMENT|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
219708672|NCT06098846|DIETARY_SUPPLEMENT|Placebo transdermal patch|Application of a placebo transdermal patch
219708673|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
219708674|NCT03147612|DRUG|Cyclophosphamide|Given IV
219124936|NCT04878042|DEVICE|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
219124937|NCT04878042|DEVICE|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
219124938|NCT03893591|DIAGNOSTIC_TEST|Anti Xa levels|one Blood sample
219124939|NCT02817633|DRUG|TSR-022|TSR-022 will be administered.
219124940|NCT02817633|DRUG|Nivolumab|Nivolumab will be administered.
219124941|NCT02817633|DRUG|TSR-042|TSR-042 will be administered.
219124942|NCT02817633|DRUG|TSR-033|TSR-033 will be administered.
219124943|NCT02817633|DRUG|Docetaxel|Docetaxel will be administered.
219124944|NCT02817633|DRUG|Pemetrexed|Pemetrexed will be administered.
219124945|NCT02817633|DRUG|Cisplatin|Cisplatin will be administered.
219708675|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
219708676|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
219708677|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
219708678|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
219708679|NCT03147612|DRUG|Ponatinib|Given PO
219708680|NCT03147612|BIOLOGICAL|Rituximab|Given IV
219708681|NCT03147612|DRUG|Vincristine|Given IV
219708682|NCT06023563|DEVICE|Virtual reality active video gaming using Nintendo switch sports|Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
219708683|NCT06023563|BEHAVIORAL|Standard physical therapy balance exercises|Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
219708684|NCT06320652|OTHER|Cardiac telerehabilitation (video consultation and home monitoring)|Patients with cardiac disease and earlier experiences with cardiac rehabilitation, family members, and nurses in the Departments of Cardiology at Amager and Hvidovre Hospital will be invited to work in a partnership and through a course of innovative co-creative workshops. It is recommended that usability studies have 5-15 participants, which is why we plan to enroll 3 cardiac patients, 3 relatives and 3 nurses from the outpatient clinic. Through the workshops, a rehabilitation program offering cardiac telerehabilitation will be co-created to comply with the preferences and perspectives of patients and family members and nurses from the outpatient clinic. Through these workshops we will learn which important components and elements should be prioritized when offering cardiac telerehabilitation (how, when, and why?).
219708685|NCT00328536|DRUG|Omacor|
219708686|NCT02505061|BEHAVIORAL|Hospital-based Program|"The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team."
219708687|NCT02505061|BEHAVIORAL|Regular Therapy Program|"The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase"
219708688|NCT05824585|DRUG|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
219708689|NCT00145067|BEHAVIORAL|Disease Management Assessment|
219708690|NCT06378476|BEHAVIORAL|IMPaCT Community Health Worker Program|The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.
218986307|NCT04315883|BEHAVIORAL|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
218986308|NCT04315883|RADIATION|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate"
218986309|NCT05158465|BEHAVIORAL|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
218986310|NCT02059408|OTHER|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
218986311|NCT02059408|OTHER|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
219708691|NCT06378476|OTHER|Trauma-Informed Care Training|Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
219708692|NCT06775782|DEVICE|Remote Ischemic Conditioning (RIC) treatment|RIC will be given twice a day for 10-14 days. RIC will be applied using an automated RIC device. The cuff of the RIC medical device will be placed around the bilateral upper limbs. Five cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes) for a total procedure time of 50 minutes.
219708693|NCT06775782|DRUG|Medical Management|Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.
219708694|NCT06782386|DEVICE|OneStep Foot Scanner|Daily scans with the OneStep Foot scanner will provide thermal and visual data of the soles of the feet to assist in early identification of risk factors associated with Diabetic Foot Ulcers
219708695|NCT05631899|BIOLOGICAL|KRAS-EphA-2-CAR-DC|5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.
219708696|NCT05631899|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
219708697|NCT05631899|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
219708698|NCT05631899|DRUG|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
219708699|NCT05631899|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
219708700|NCT03154606|OTHER|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
219708701|NCT03154606|OTHER|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
219708702|NCT03154606|OTHER|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
219708703|NCT03154606|OTHER|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
219708704|NCT03154606|OTHER|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
219708705|NCT03154606|OTHER|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
219708706|NCT03154606|OTHER|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
218986312|NCT01153074|DEVICE|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
218986313|NCT01538511|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
218986314|NCT01538511|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
218986315|NCT04084431|RADIATION|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
218986316|NCT04084431|OTHER|OSC|optimal supportive Care (OSC) alone
218986317|NCT06171295|DIAGNOSTIC_TEST|Blood draw|The blood draws in specified time points
218986318|NCT04571320|BEHAVIORAL|Summer STRIPES|See arm description.
218986319|NCT04571320|OTHER|Enhanced School Services as Usual|see arm description.
218986320|NCT02586129|DRUG|YH14755|20/1500mg, QD
218986321|NCT02586129|DRUG|Metformin|1500mg, QD
218986322|NCT02586129|DRUG|Rosuvastatin|20mg, QD
218986323|NCT02399722|DEVICE|WICVAC|combined wound therapy
218986324|NCT02399722|DEVICE|VAC mono therapy|mono therapy
218986325|NCT03748784|BIOLOGICAL|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
218986326|NCT01752270|DRUG|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
218986327|NCT01752270|DRUG|Diane-35 pretreatment|
218986328|NCT01160315|DRUG|Triptorelin|Triptorelin: intramusculAR injection every 3 months
218986329|NCT01160315|DRUG|Norethisterone acetate|5 mg/day per os until during chemotherapy
218986330|NCT00567372|DRUG|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
218986331|NCT05686889|OTHER|Patient self-report|Simulated patient following structured script
218986332|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
218986333|NCT01681472|DRUG|Levoleucovorin 200 mg/m2|i.v. bolus injection
218986334|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
219708707|NCT03154606|OTHER|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
219708708|NCT03154606|OTHER|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
219708709|NCT03154606|OTHER|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
219708710|NCT03154606|OTHER|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
219708711|NCT03154606|OTHER|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
219708712|NCT03987048|OTHER|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
219708713|NCT02235740|DRUG|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
219708714|NCT02235740|DRUG|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
219708715|NCT05843565|DEVICE|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
219708716|NCT05843565|DEVICE|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
219708717|NCT04781673|DRUG|Ketamine|Will receive titratable infusion.
219708718|NCT04781673|DRUG|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
219708719|NCT04968106|DRUG|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
219708720|NCT04968106|DRUG|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
219708721|NCT04968106|DRUG|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
219708722|NCT04278690|OTHER|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.
218986335|NCT01681472|DRUG|Levoleucovorin 60 mg/m2|i.v. bolus injection
218986336|NCT00092612|DRUG|MK0653, ezetimibe|
218986337|NCT00092612|DRUG|Comparator: ezetimibe, placebo|
218986338|NCT04311775|DEVICE|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
218986339|NCT04311775|OTHER|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
218986340|NCT05600452|OTHER|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
218986341|NCT03260101|OTHER|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
218986342|NCT01237743|DEVICE|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
219124946|NCT02817633|DRUG|Carboplatin|Carboplatin will be administered.
219124947|NCT01131247|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
219225848|NCT05069038|DRUG|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
219225849|NCT06522139|PROCEDURE|Implantation of Episealer Talus Implant|Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
219708723|NCT04278690|OTHER|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
219708724|NCT03712943|DRUG|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
219708725|NCT03712943|DRUG|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
219708726|NCT05955651|DIAGNOSTIC_TEST|Peritoneal washings|"Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab.~1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus.~2. Second washing will be done after the hysterectomy and containment of the uterus in the bag.~3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff."
219708727|NCT06133140|DEVICE|Unblinded postoperative vital sign monitoring|Unblinded postoperative GE Portrait monitoring
219708728|NCT06133140|DEVICE|Blinded postoperative vital sign monitoring|Blinded postoperative GE Portrait monitoring
219708729|NCT06045611|DIETARY_SUPPLEMENT|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
219708730|NCT06045611|DIETARY_SUPPLEMENT|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
219708731|NCT06045611|DIETARY_SUPPLEMENT|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
219708732|NCT06045611|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
219708733|NCT04923542|RADIATION|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
219708734|NCT04923542|DRUG|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
219225850|NCT06509230|OTHER||The fibrosis grades were grouped without drug intervention
219708735|NCT04923542|DRUG|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
219708736|NCT05897788|BEHAVIORAL|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
219708737|NCT05897788|BEHAVIORAL|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
219708738|NCT04625647|DRUG|Sotorasib|Given PO
219708739|NCT01606475|BIOLOGICAL|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
219708740|NCT03862950|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
219708741|NCT03862950|DRUG|Metformin|Active medication
219124948|NCT00279474|BEHAVIORAL|cognitive-behavior groups|
219124949|NCT03756389|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of rosacea.
219124950|NCT00984178|OTHER|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
219124951|NCT00984178|OTHER|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
219124952|NCT01386086|DRUG|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
219124953|NCT01359137|BEHAVIORAL|Probation as usual|Routine probation with do deferred jail condition.
219124954|NCT01359137|BEHAVIORAL|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
219124955|NCT01359137|BEHAVIORAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
219124956|NCT02161510|DRUG|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
219124957|NCT01385280|BIOLOGICAL|therapeutic estradiol|Given orally (PO)
219124958|NCT01385280|DRUG|exemestane|Given PO
219124959|NCT01385280|OTHER|laboratory biomarker analysis|Correlative studies
219124960|NCT01385280|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219124961|NCT05458102|DRUG|Vesatolimod|Administered orally
219124962|NCT05458102|DRUG|Cobicistat|Administered orally
219124963|NCT05458102|DRUG|Voriconazole|Administered orally
219124964|NCT05458102|DRUG|Rifabutin|Administered orally
219124965|NCT04358861|PROCEDURE|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
219124966|NCT04358861|DEVICE|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
219124967|NCT06199687|OTHER|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
219124968|NCT00668174|BEHAVIORAL|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
219124969|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
219708742|NCT06838962|DRUG|Daratumumab Injection|"intravenous Daratumumab administration~This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
219708743|NCT03819322|DRUG|sofosbuvir/velpatasvir|12 week, oral, fixed dose
219124970|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
219124971|NCT05428436|DRUG|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
219124972|NCT05428436|DRUG|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
219708744|NCT03624543|DRUG|CFI-400945|32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
219708745|NCT00392353|DRUG|Azacitidine|Given SC
219708746|NCT00392353|OTHER|Laboratory Biomarker Analysis|Correlative studies
219124973|NCT02828930|DRUG|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
219124974|NCT02828930|DRUG|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
219124975|NCT02828930|DRUG|[13C]-radiolabeled Idasanutlin|\[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
219708747|NCT00392353|OTHER|Pharmacological Study|Correlative studies
219124976|NCT02828930|DRUG|[14C]-radiolabeled Idasanutlin|\[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
219124977|NCT02627625|DRUG|Tiotropium|4 inhalations
219124978|NCT01785420|DRUG|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
219708748|NCT00392353|DRUG|Vorinostat|Given PO
219124979|NCT01785420|DRUG|Placebo|A 90 minute intravenous infusion of saline as placebo
219124980|NCT03321760|RADIATION|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
219124981|NCT03014102|DRUG|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
219124982|NCT03666429|DEVICE|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
219124983|NCT03666429|DEVICE|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
219124984|NCT04920214|DIAGNOSTIC_TEST|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
219124985|NCT03860246|DIAGNOSTIC_TEST|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
219225851|NCT01189552|BEHAVIORAL|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
219708749|NCT06839794|BEHAVIORAL|Cognitively challenging physical activity for paediatric cancer patients|"The intervention is a structured cognitively challenging physical activity (PA) program specifically designed for pediatric cancer patients undergoing acute therapy. It stands out from other interventions by combining motor and cognitive tasks simultaneously. Therefore, the target executive functions are inhibition, shifting, and updating. Additionally, the whole body is addressed by enhancing PA.~The PA program spans 12 weeks, with each participant engaging in guided, supervised 45-minute sessions three times weekly. Each session includes a warm-up, the cognitive challenging PA task and a subsequent multimodal sports programme with a cool-down. Exercises are adaptive and tailored to each participant's physical and health condition by offering three levels of intensity in both cognitive and physical difficulty. In addition, exercise counselling in maintenance therapy or aftercare supports young patients to reintegrate into the life after the disease."
219708750|NCT06839794|OTHER|Physical activity recommendations|The children and adolescents receive general physical activity recommendations at the baseline measurement (t0). At the end of the intervention (after 12 weeks), i.e. after the final measurement (t3), they receive individualised and tailored exercise recommendations based on the test results from t0-t3.
219708751|NCT03420963|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
219708752|NCT03420963|DRUG|Cyclophosphamide|Given IV
219708753|NCT03420963|DRUG|Etoposide|Given IV
219708754|NCT01212250|DRUG|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
219708755|NCT01212250|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
219708756|NCT03764124|DIAGNOSTIC_TEST|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
219708757|NCT03595397|DRUG|Bupivacaine|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
219708758|NCT03595397|DRUG|Magnesium Sulfate|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
219708759|NCT03595397|DRUG|Fentanyl|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
219708760|NCT03595397|PROCEDURE|Thoracic epidural|All patients will receive mid-thoracic epidural analgesia
219708761|NCT04092075|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
219708762|NCT04092075|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
218986343|NCT01972113|DIETARY_SUPPLEMENT|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
218986344|NCT01972113|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
218986345|NCT01972113|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
218986346|NCT03250221|DEVICE|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
218986347|NCT03250221|DEVICE|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
218986348|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
218986349|NCT00795145|DRUG|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
218986350|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
218986351|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
218986352|NCT00795145|DRUG|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
218986353|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
218986354|NCT00795145|DRUG|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
218986355|NCT05797675|PROCEDURE|prf + osseodensification|prf+ osseodensification in close sinus lift
218986356|NCT03651869|DRUG|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
218986357|NCT03651869|DRUG|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
218986358|NCT03651869|DRUG|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
218986359|NCT03651869|DRUG|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
218986360|NCT00119834|DEVICE|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
218986361|NCT01470937|DRUG|Acarbose|acarbose 100 mg PO once daily
218986362|NCT01470937|DRUG|Placebo|acarbose placebo
218986363|NCT05195671|OTHER|Review|Reviewing all protocols
219124986|NCT06629974|BEHAVIORAL|Parental empowerment program|"The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes."
219124987|NCT06298630|OTHER|Assessments|Safety and efficacy assessments
219708763|NCT03233256|PROCEDURE|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
219124988|NCT02208323|DEVICE|Bubble CPAP|Respiratory assistance
219124989|NCT01576510|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
219708764|NCT06422871|DEVICE|HeRO® Graft System or Super HeRO® System|Treatment attempted with the HeRO® or Super HeRO® device.
219708765|NCT06832891|OTHER|Survey|Patients complete survey
219708766|NCT01224704|OTHER|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
219708767|NCT01224704|OTHER|Water deprivation|24 hour water deprivation
219708768|NCT06792019|BIOLOGICAL|CM313(SC) injection-low dose|Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
219124990|NCT02092987|OTHER|Social work support|All study participants were provided access to social support services at Riverstone Senior Life services
219124991|NCT02092987|OTHER|Educational material|All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
219124992|NCT02092987|BEHAVIORAL|NYU caregiver counseling intervention|"The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers."
219124993|NCT02092987|BEHAVIORAL|REACH OUT counseling intervention|All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed
219124994|NCT00951561|DEVICE|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
219124995|NCT00951561|DRUG|Ibuprofen|400 mg daily
219124996|NCT00852475|DIETARY_SUPPLEMENT|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
219124997|NCT00852475|DIETARY_SUPPLEMENT|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
219124998|NCT02538640|OTHER|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
219708769|NCT06792019|BIOLOGICAL|CM313(SC) injection-high dose|Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
219124999|NCT02538640|OTHER|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
219708770|NCT03474107|DRUG|Enfortumab Vedotin|Intravenous infusion
219708771|NCT03474107|DRUG|Docetaxel|Intravenous infusion
219708772|NCT03474107|DRUG|Vinflunine|Intravenous infusion
219708773|NCT03474107|DRUG|Paclitaxel|Intravenous infusion
219708774|NCT05359237|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219708775|NCT05359237|DRUG|Vincristine|Given IV per standard of care
219708776|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
219125000|NCT01979978|OTHER|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
219125001|NCT00589212|DEVICE|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
219551022|NCT06168903|PROCEDURE|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
219551023|NCT04976023|DRUG|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
219551024|NCT04976023|OTHER|Placebo|14.5 5 g twice daily for 8 weeks
219551025|NCT04391517|DIAGNOSTIC_TEST|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
219551026|NCT03614455|DRUG|Milademetan|Milademetan 100 mg capsule for oral administration
219551027|NCT03614455|DRUG|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
219551028|NCT03614455|DRUG|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
219551029|NCT02970149|OTHER|NA (observational)|
219551030|NCT04903652|DRUG|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
219551031|NCT04903652|DRUG|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
219551032|NCT05364606|DEVICE|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
219551033|NCT03786770|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
219551034|NCT02069951|OTHER|Practice a procedural module on a simulator|
219551035|NCT05819437|OTHER|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
219551036|NCT00714051|BEHAVIORAL|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
219551037|NCT00714051|BEHAVIORAL|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
219551038|NCT04293354|PROCEDURE|Serratus Plane Block|Serratus Plane Block was performed
219551039|NCT04293354|PROCEDURE|Control|No block was performed
219551040|NCT00141505|DRUG|Bifeprunox|
219551041|NCT02583698|DRUG|Carvedilol|
219551042|NCT02583698|DRUG|Placebo|
219551043|NCT04474145|PROCEDURE|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
219551044|NCT04474145|PROCEDURE|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
219125002|NCT03434743|OTHER|Rehabilitative|Non-nutritive sucking on emptied breast
219125003|NCT03434743|OTHER|Active Comparator|Non-nutritive sucking on pacifier
219125004|NCT03279198|BEHAVIORAL|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
219125005|NCT03279198|BEHAVIORAL|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
219125006|NCT03279198|BEHAVIORAL|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
219125007|NCT03279198|BEHAVIORAL|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
219125008|NCT02693626|BEHAVIORAL|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
219125009|NCT02693626|BEHAVIORAL|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
219125010|NCT00185484|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
219551045|NCT03727945|OTHER|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
219551046|NCT03727945|OTHER|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
219125011|NCT00274989|DRUG|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
219125012|NCT00274989|BIOLOGICAL|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
219551047|NCT04385745|PROCEDURE|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
219125013|NCT04931680|OTHER|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
219125014|NCT01071694|DRUG|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
219125015|NCT05557422|DIAGNOSTIC_TEST|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
219125016|NCT00135967|DRUG|mycophenolate mofetil orally 1000 mg twice a day (BID)|
219125017|NCT00135967|DRUG|prednisone 0,5 mg/kg orally on alternate days|
219125018|NCT00135967|DRUG|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
219551048|NCT00907205|DRUG|SF1126|Dose Escalating with 3+ patients in each cohort
219551049|NCT00858416|DEVICE|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
219551050|NCT00858416|DEVICE|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
219551051|NCT05745636|DIETARY_SUPPLEMENT|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
219551052|NCT05745636|DIETARY_SUPPLEMENT|Placebo|2 capsules per day for 4 weeks.
219551053|NCT03545399|DIETARY_SUPPLEMENT|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
219551054|NCT03545399|DIETARY_SUPPLEMENT|Placebo|The dose was taken with a glass of water during the evening meal once daily
219551055|NCT03868631|DIETARY_SUPPLEMENT|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
219551056|NCT03868631|DIETARY_SUPPLEMENT|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
219551057|NCT03458364|DEVICE|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
219551058|NCT03458364|DEVICE|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
219125019|NCT05153954|OTHER|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
219125020|NCT02403674|DRUG|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
219125021|NCT02403674|DRUG|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
219125022|NCT02403674|DRUG|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
219125023|NCT02714803|BEHAVIORAL|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
219125024|NCT02714803|BEHAVIORAL|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
219225852|NCT01189552|BEHAVIORAL|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
219225853|NCT03890653|BEHAVIORAL|Performance-Based Financing|Incentive-based payments
219125025|NCT02714803|BEHAVIORAL|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
219125026|NCT02877199|OTHER|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
219125027|NCT04874610|DRUG|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
219125028|NCT00273455|DRUG|bimatoprost 0.03%|
219125029|NCT00273455|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
219125030|NCT00273455|DRUG|placebo|
219125031|NCT06492577|OTHER|Pulmonary rehabilitation protocol|In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
219225854|NCT03890653|BEHAVIORAL|Decentralized Facility Financing|Financing not linked to service delivery.
219551059|NCT01420614|PROCEDURE|Femoral approach|diagnostic and interventional procedures by femoral artery access
219551060|NCT01420614|PROCEDURE|Radial approach|diagnostic and interventional procedures by radial artery access
219551061|NCT02928458|DRUG|Omnipaque|
219551062|NCT02928458|DRUG|MD-Gastroview|
219551063|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
219125032|NCT06492577|OTHER|Progressive muscle relaxation protocol|Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
219125033|NCT03037190|OTHER|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
219125034|NCT02256787|DRUG|BILB 1941 ZW - single rising dose part|
219125035|NCT02256787|DRUG|Placebo|
219125036|NCT02256787|DRUG|BILB 1941 ZW - solution|
219125037|NCT02256787|DRUG|BILB 1941 ZW - tablet|
219125038|NCT02256787|OTHER|standardized breakfast|
219125039|NCT02906306|BEHAVIORAL|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
219125040|NCT02906306|BEHAVIORAL|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
219551064|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
219551065|NCT03910361|DRUG|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
219125041|NCT06628505|OTHER|Speech in Noise Training|The active controls will receive frequency discrimination training that uses the same visual landscape and basic task of controlling the wisp based on judgments about acoustic cues. The task requires participants to avoid obstacles by swiping upward or downward on the touchscreen to indicate whether a test frequency associated with the obstacle was higher or lower, respectively, than a target sound presented slightly before the test sound.
219125042|NCT06628505|OTHER|Spatial Hearing Training Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are given feedback about how their perceived location related to the actual sound location."
219225855|NCT01386372|DRUG|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
219225856|NCT01386372|OTHER|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
219225857|NCT01349998|DRUG|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
219225858|NCT01509183|DEVICE|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
219708777|NCT05666973|PROCEDURE|Open Mesh Hernioplasty|"* Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture"
219708778|NCT03095287|BIOLOGICAL|Alphanate|Bolus IV injection.
219708779|NCT04118400|PROCEDURE|NIV-NAVA|NAVA mode during Non-invasive ventilation
219708780|NCT04118400|PROCEDURE|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
219708781|NCT00055237|BIOLOGICAL|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
219708782|NCT03276299|OTHER|six minute walking test|six minute walking test
219708783|NCT03276299|OTHER|six minute walking test|six minute walking test with encouragement
219708784|NCT02625584|BEHAVIORAL|Reading Together - Pausing for Reading|
219708785|NCT02625584|BEHAVIORAL|Reading Together - Dialogic Reading|
219708786|NCT02625584|BEHAVIORAL|Reading Together - Shared Reading Control|
219708787|NCT03829176|GENETIC|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
219708788|NCT04980729|DEVICE|Acetabular reconstruction after tumor resection.|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
219708789|NCT02705170|PROCEDURE|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
219125043|NCT06628505|OTHER|Spatial Hearing Control Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are NOT given feedback about how their perceived location related to the actual sound location."
219125044|NCT06191536|OTHER|Pilates|
219125045|NCT06191536|OTHER|Pelvic floor exercises|
219125046|NCT06572462|DRUG|individualized ATG dosing strategy|Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
219125047|NCT03387917|DRUG|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
219125048|NCT03387917|DRUG|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
219125049|NCT04950751|BIOLOGICAL|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
219225859|NCT00343083|DRUG|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
219225860|NCT00343083|RADIATION|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
219225861|NCT03075683|BEHAVIORAL|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
219225862|NCT03075683|BEHAVIORAL|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
219225863|NCT03783936|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
219225864|NCT03783936|DRUG|Leucovorin|Leucovorin 400 mg/m2
219225865|NCT03783936|DRUG|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
219125050|NCT02141347|DRUG|Tremelimumab|Tremelimumab administered intravenously
219125051|NCT02141347|DRUG|MEDI4736|MEDI4736 administered intravenously.
219125052|NCT03043066|PROCEDURE|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
219125053|NCT03043066|DRUG|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
219125054|NCT05986487|DEVICE|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
219125055|NCT05986487|DEVICE|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
219225866|NCT03783936|DRUG|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
219225867|NCT03783936|DRUG|Avelumab|Avelumab 800 mg
219225868|NCT03043443|DRUG|Melatonin|Natural health product for sleep problems treatment
219225869|NCT03043443|DRUG|Placebo|Lactose containing pills
219225870|NCT00454194|DRUG|pemetrexed disodium|given IV
219225871|NCT00454194|DRUG|sorafenib tosylate|given orally
219125056|NCT05967442|DRUG|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
219125057|NCT05967442|DRUG|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
219125058|NCT05967442|DRUG|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
219125059|NCT05950906|DRUG|PDM608|PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
219125060|NCT05950906|DRUG|Placebo|Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
219125061|NCT01440244|PROCEDURE|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
219225872|NCT04187482|OTHER|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
219225873|NCT00396487|DRUG|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
219125062|NCT04609150|OTHER|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
219125063|NCT02703532|BEHAVIORAL|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
219125064|NCT02703532|BEHAVIORAL|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
219125065|NCT02703532|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
219125066|NCT05481034|DEVICE|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
219125067|NCT05481034|DEVICE|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
219125068|NCT03980756|DRUG|AD-206 20mg|1 tablet administered before the breakfast during 7 days
219125069|NCT03980756|DRUG|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
219708790|NCT02545192|DEVICE|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
219125070|NCT03980756|DRUG|AD-206 40mg|1 tablet administered before the breakfast during 7 days
219125071|NCT03980756|DRUG|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
219125072|NCT01725867|OTHER|PT program|manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
219125073|NCT01725867|DEVICE|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
219125074|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
219125075|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
219125076|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
219125077|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
219125078|NCT01387646|BEHAVIORAL|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
219125079|NCT00632762|DRUG|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
219125080|NCT04669080|BEHAVIORAL|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
219125081|NCT05886738|OTHER|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
219708791|NCT02127671|OTHER|IDEAL intervention|
219708792|NCT02127671|OTHER|Control|
219708793|NCT04825522|DRUG|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
219708794|NCT03426150|DRUG|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
219708795|NCT03426150|DRUG|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
219125082|NCT05711628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219125083|NCT05711628|DRUG|Bendamustine|Given IV
219125084|NCT05711628|DRUG|Brentuximab Vedotin|Given IV
219125085|NCT05711628|DRUG|Carboplatin|Given IV
219125086|NCT05711628|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
219125087|NCT05711628|DRUG|Etoposide|Given IV
219125088|NCT05711628|DRUG|Gemcitabine|Given IV
219125089|NCT05711628|DRUG|Ifosfamide|Given IV
219125090|NCT05711628|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219125091|NCT05711628|BIOLOGICAL|Pembrolizumab|Given IV
219125092|NCT05711628|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219125093|NCT05711628|RADIATION|Radiation Therapy|Undergo RT
219125094|NCT05711628|OTHER|Transplant Conditioning|Receive standard preparative chemotherapy regimen
219125095|NCT05711628|DRUG|Vinorelbine|Given IV
219125096|NCT01608893|DRUG|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
219125097|NCT01608893|DRUG|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
219125098|NCT01174992|BIOLOGICAL|Evicel|EVICEL is a human plasma derived fibrin sealant
219125099|NCT01174992|OTHER|Sutures only|Standard of care
219125100|NCT04870164|DRUG|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
219125101|NCT04870164|DRUG|Placebo|One administration at day 1 by infusion.
219125102|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
219125103|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
219125104|NCT01161160|BIOLOGICAL|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
219125105|NCT01161160|BIOLOGICAL|GSK Biologicals' - GSK2340272A|Intramuscular injection
219125106|NCT04222647|DRUG|WO533|Intravaginal application
219125107|NCT03738241|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inactivated Influenza Virus Vaccine containing the Hemagglutinin (HA) and Neuraminidase (NA) from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The HA content of the 2017 A/H7N9 vaccine formulations were determined by Single Radial Immunodiffusion (SRID) assay to be approximately two times higher (14.45 mcg of HA per 0.5 mL dose) than the targeted HA content on the label (7.5 mcg of HA per 0.5 mL dose).
219125108|NCT03738241|DRUG|AS03|AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
219125109|NCT03738241|OTHER|Phosphate Buffered Saline (PBS) diluent|0.006M PBS diluent for Influenza Virus Vaccine.
219125110|NCT04430374|OTHER|No interverntion|No intervention will be done, registry only
219125111|NCT04230161|OTHER|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
219125112|NCT04230161|OTHER|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
219125113|NCT04230161|OTHER|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
219125114|NCT05032235|DRUG|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
219125115|NCT05032235|DRUG|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
219125116|NCT05032235|DRUG|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
219125117|NCT04155099|BIOLOGICAL|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
219125118|NCT04155099|BIOLOGICAL|Placebo|Capsule with cellulose filler
219125119|NCT03625011|DRUG|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
219125120|NCT01593878|OTHER|TV|test taken with TV on
219125121|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
219125122|NCT00554164|DRUG|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
219551066|NCT03910361|DRUG|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
219125123|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
219125124|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
219125125|NCT01188122|DEVICE|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
219125126|NCT03871881|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
219125127|NCT03871881|OTHER|Neuropsychological assessment|A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
219125128|NCT03169361|DRUG|Ixazomib|Ixazomib capsules
219125129|NCT00670995|BEHAVIORAL|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
219708796|NCT04250480|DIETARY_SUPPLEMENT|beta-alanine|beta-alanine tablet
219708797|NCT04250480|DIETARY_SUPPLEMENT|placebo|rice powder tablet
219708798|NCT05422508|BIOLOGICAL|MG1111 (BARICELA)|0.5ml, single dose, subcutaneous injection
219708799|NCT05422508|BIOLOGICAL|VARIVAX|0.5ml, single dose, subcutaneous injection
219708800|NCT05422508|BIOLOGICAL|Suduvax|0.5ml, single dose, subcutaneous injection
219708801|NCT05284253|OTHER|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
219708802|NCT05284253|OTHER|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
219125130|NCT02271594|BEHAVIORAL|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
219125131|NCT02271594|BEHAVIORAL|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
219125132|NCT05551962|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Sampling of free connective tissue graft from the maxilla tuber area~4. Fixation of the graft to the vestibular flap~5. Suturing the wound tightly"
219125133|NCT05551962|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
219551067|NCT04035954|OTHER|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
219551068|NCT03231345|PROCEDURE|US guided IJ|IV catheter placement
219551069|NCT03231345|DEVICE|Ultrasound|Ultrasound-guided Internal Jugular vein
219551070|NCT00691756|PROCEDURE|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
219551071|NCT00691756|PROCEDURE|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
219551072|NCT01711567|DRUG|tenofovir|tenofovir 300 mg qd
219551073|NCT01711567|DRUG|entecavir|entecavir 0.5 mg qd
219551074|NCT01910831|DRUG|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
219551075|NCT01910831|DRUG|Non-active placebo control|Non-active placebo control
219551076|NCT01007019|DRUG|YH4808 30mg|YH4808 30mg (single dose)
219551077|NCT01007019|DRUG|YH4808 50mg|YH4808 50mg (single dose)
219551078|NCT01007019|DRUG|YH4808 100mg|YH4808 100mg (single dose)
219551079|NCT01007019|DRUG|YH4808 200mg|YH4808 200mg (single dose)
219551080|NCT01007019|DRUG|YH4808|YH4808 400mg (single dose)
219551081|NCT01007019|DRUG|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
219551082|NCT01007019|DRUG|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
219551083|NCT01007019|DRUG|YH4808 600mg|YH4808 600mg
219551084|NCT01007019|DRUG|YH4808 800mg (single dose)|YH4808 800mg (single dose)
219551085|NCT01007019|DRUG|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
219551086|NCT01007019|DRUG|Placebo|10 volunteers will be administered matched placebo.
219551087|NCT01007019|DRUG|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
219708803|NCT05395585|PROCEDURE|Manual placental separation|Manual separation of the placenta from uterus
219708804|NCT02394275|BIOLOGICAL|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
219708805|NCT05751967|DRUG|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
219708806|NCT05751967|DRUG|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
219708807|NCT03834168|OTHER|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
219708808|NCT04678674|PROCEDURE|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
219125134|NCT03464253|DEVICE|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
219125135|NCT02594696|OTHER|Proactive Psychiatry Consultation (PPC)|"* The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~* The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~* The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~* The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~* Recommendations are documented in the medical record and communicated directly to the oncology team"
219125136|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
219125137|NCT01631903|DRUG|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
219125138|NCT01631903|DRUG|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
219125139|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
219125140|NCT01631903|DRUG|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
219125141|NCT00088465|DRUG|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
219125142|NCT03845764|DIAGNOSTIC_TEST|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
219125143|NCT06104540|OTHER|Experimental I liquid vaseline groups|Patients in the liquid vaseline group will apply liquid vaseline twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
219125144|NCT06104540|OTHER|Experimental II extra virgin olive oil groups|Patients in the extra virgin olive oil group will apply extra virgin olive oil twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
219125145|NCT06104540|OTHER|Control Croup|No intervention will be made other than the recommendations of the institution's physicians and nurses.
219125146|NCT03337750|BEHAVIORAL|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
219125147|NCT05979194|BEHAVIORAL|Labor Care Guide|Identifying information and labor characteristics at admission, supportive care, care of the baby, care of the woman, labor progress, medication, and shared decision-making
219125148|NCT00495469|DRUG|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
219125149|NCT00495469|DRUG|Placebo|Available as Placebo matching tablet to GSK189075
219125150|NCT03405298|BEHAVIORAL|Educational Material|Educational material is in the form of a brochure
219125151|NCT03405298|BEHAVIORAL|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
219125152|NCT06476899|DRUG|orelabrutinib|orelabrutinib tablets
219125153|NCT06476899|DRUG|FCR/BR|FCR/BR
219125154|NCT06476899|DRUG|BTK inhibitor|BTK inhibitor choose by physican
219551088|NCT06346106|GENETIC|Male Rett|This study does not have an intervention. Participants of this study must be parents or caregivers to boys with Rett syndrome.
219551089|NCT04613167|DRUG|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
219551090|NCT04613167|DRUG|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
219551091|NCT04613167|DRUG|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
219551092|NCT05920486|DEVICE|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
219125155|NCT04302675|BEHAVIORAL|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
219125156|NCT02062905|DRUG|Dexamethasone|
219125157|NCT02062905|OTHER|Placebo Vehicle|
219125158|NCT02303119|DRUG|Rituximab IV|intra-venous, 375 mg/m²
219125159|NCT02303119|DRUG|Rituximab SC|sub-cutaneous, 1400 mg
219125160|NCT04610203|DIETARY_SUPPLEMENT|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
219125161|NCT04610203|DIETARY_SUPPLEMENT|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
219125162|NCT04610203|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
219125163|NCT03578562|OTHER|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
219708809|NCT06343701|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
219708810|NCT06343701|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
219708811|NCT03725007|DRUG|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
219708812|NCT06139653|DEVICE|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
219125164|NCT01491529|DRUG|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
219125165|NCT01491529|DRUG|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
219125166|NCT00410995|DRUG|Naproxen|
219125167|NCT01757080|OTHER|Cardiorespiratory performance assessment with ergospirometry test|
219125168|NCT01757080|OTHER|Biochemical analysis|
219125169|NCT00448864|DRUG|Ecallantide|
219125170|NCT00448864|DRUG|Placebo|
219125171|NCT04189328|PROCEDURE|dental implant placement using magnifying loupes and microsurgical instruments|microsurgical dental implant placement employin splt finger technique by Misch
219125172|NCT04189328|PROCEDURE|macrosurgical dental implant placement|macrosurgical placement of single dental implants
219125173|NCT04069390|DEVICE|CARDIOSKIN - Short record|A short record (max 2H15) is performed with Cardioskin
219125174|NCT04069390|DEVICE|Cardioskin - long record|A long record (max 8H) is performed with Cardioskin
219125175|NCT04069390|DEVICE|Neuronaute - long record|A long record (max 8H) is performed with Neuronaute
219225874|NCT05388045|OTHER|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
219125176|NCT04069390|DEVICE|Neuronaute -short record|A short record (max 2H15) is performed with Neuronaute
219125177|NCT02616354|DRUG|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
219125178|NCT04679584|OTHER|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
219125179|NCT00892229|DRUG|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
219125180|NCT00892229|DRUG|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
219125181|NCT03312803|PROCEDURE|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
219708813|NCT06139653|DEVICE|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
219708814|NCT05038254|OTHER|Best Practice|Receive standard of care telemedicine
219708815|NCT05038254|PROCEDURE|Patient Monitoring|Undergo remote monitoring
219708816|NCT05038254|OTHER|Questionnaire Administration|Ancillary studies
219708817|NCT03556683|DEVICE|3% Hypertonic Saline|4 mL of 3% hypertonic saline
219708818|NCT03556683|DEVICE|7% Hypertonic Saline|4 mL of 7% hypertonic saline
219708819|NCT03556683|DRUG|Salbutamol|4 puffs (90 mcg/actuation)
219708820|NCT01599962|DRUG|Cinacalcet|single administration, 90mg
219708821|NCT01599962|DRUG|Placebo|single administration
219708822|NCT03127059|OTHER|Breathing Exercises|"Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX."
219708823|NCT03127059|OTHER|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
219708824|NCT04163263|DRUG|BOS-356|topical gel
219708825|NCT04163263|DRUG|Vehicle|topical gel
219708826|NCT03175458|PROCEDURE|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
219708827|NCT03175458|PROCEDURE|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
219708828|NCT01656499|DIETARY_SUPPLEMENT|Arabinoxylanoligosaccharides|
219708829|NCT01656499|DIETARY_SUPPLEMENT|Maltodextrine|
219708830|NCT06240182|PROCEDURE|conventional surgery|Surgery performed using conventional rotary burs
219708831|NCT06240182|PROCEDURE|piezoelectric device|surgery performed using piezoelectric device.
219708832|NCT04757636|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
219708833|NCT04757636|BIOLOGICAL|2.0 aflibercept|intravitreal injection
219708834|NCT04757636|PROCEDURE|Sham|intravitreal injection
219708835|NCT00142753|BIOLOGICAL|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
219708836|NCT00142753|BIOLOGICAL|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
219708837|NCT00142753|BIOLOGICAL|Recombivax|Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
219708838|NCT00142753|BIOLOGICAL|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
219708839|NCT03555786|OTHER|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
219708840|NCT04381715|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
219708841|NCT03600792|GENETIC|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
219708842|NCT04452838|DRUG|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
219708843|NCT04452838|DRUG|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
219708844|NCT04452838|DRUG|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
219708845|NCT04452838|DRUG|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
219708846|NCT04452838|DRUG|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
219708847|NCT03173963|DRUG|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
219708848|NCT03173963|OTHER|Placebo|1placebo tablet per day
219708849|NCT02825810|BEHAVIORAL|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
219708850|NCT03972917|DIAGNOSTIC_TEST|Transvaginal ultrasonographic examination|Evaluation of endometrial thickness; myoma size and volume
219708851|NCT04261166|DRUG|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
219708852|NCT04261166|DRUG|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
219708853|NCT04261166|DRUG|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
219708854|NCT04261166|DRUG|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
219225875|NCT06227988|PROCEDURE|patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
219225876|NCT06227988|PROCEDURE|patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
219225877|NCT02808832|BEHAVIORAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
219225878|NCT05785325|DRUG|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
219708855|NCT04261166|DRUG|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
219708856|NCT04261166|DRUG|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
219708857|NCT04261166|DRUG|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
219708858|NCT04261166|DRUG|B3|Sublingual tablets. CBD 40 mg (1 tablet)
219708859|NCT04261166|DRUG|B4|Sublingual tablets. CBD 40 mg (1 tablet)
219708860|NCT02018107|DIAGNOSTIC_TEST|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
219708861|NCT02018107|DIAGNOSTIC_TEST|PET scan|PET scan
219708862|NCT04596423|DIAGNOSTIC_TEST|Fetal echocardiography|fetal heart examination by medical ultrasound
219708863|NCT05173636|OTHER|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
219708864|NCT05173636|OTHER|thoracic mobilization technique|Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
219708865|NCT01308710|DIETARY_SUPPLEMENT|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
219708866|NCT02090257|BEHAVIORAL|TRANSIT|Educational Modules, staff follow up.
219708867|NCT05350423|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
219708868|NCT05350423|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
219708869|NCT01433913|DRUG|metformin hydrochloride|Given PO
219708870|NCT01433913|OTHER|placebo|Given PO
219708871|NCT01433913|OTHER|laboratory biomarker analysis|Correlative studies
219708872|NCT05499936|DRUG|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
219708873|NCT03243799|BEHAVIORAL|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
219708874|NCT03115970|PROCEDURE|capillary and venous lactate level measurement|capillary and venous lactate level measurement
219708875|NCT05743855|DIETARY_SUPPLEMENT|Nutritional Supplement|Nutritional Supplement + Chiropract sessions
219708876|NCT05743855|OTHER|Placebo|Placebo + Chiropractic sessions
219708877|NCT00820300|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
219708878|NCT02097277|BIOLOGICAL|BMS-986036|
219125182|NCT05900999|BEHAVIORAL|Feasibility of idle time exercise|The experiments in this proposal will assess the utility and subjective patient experience performing idle time exercise intervention designed to reduce learned non-use of the hemiparetic arm in the days, and weeks immediately following stroke. Exercise will be cued by wearable technology that provides vibrotactile cues similar to those provided by FitBit devices. Participants will be asked to perform simple exercises after receiving a vibration cue. In the first four sessions they will tap the more-involved wrist; in the second four sessions they will passively move the more-involved elbow through a range of motion; in the final four sessions they will actively move the more-involved elbow through a range of motion. Accelerometers in the wearable devices will monitor motion of the wrist during the exercise sessions. We will interview the participants two months later regarding how well they use the more-involved arm to perform daily activities.
219125183|NCT06296251|OTHER|Placebo treatment|Microcrystaline cellulose (MCC)
219125184|NCT06296251|DIETARY_SUPPLEMENT|Plant derived phenolics|Dietary supplement containing plant derived phenolics
219225879|NCT03946956|BEHAVIORAL|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
219225880|NCT03946956|BEHAVIORAL|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
219708879|NCT02097277|BIOLOGICAL|Placebo (Matching with BMS-986036)|
219708880|NCT06847230|DEVICE|Dailies total 1 contact lenses|successful refit into dt1 will be determined
219708881|NCT01091259|DRUG|Irinotecan|
219708882|NCT01091259|DRUG|Bevacizumab|
219708883|NCT00092729|DRUG|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
219708884|NCT00092729|DRUG|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
219708885|NCT00092729|DRUG|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
219125185|NCT04056156|BEHAVIORAL|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
219225881|NCT00005799|DRUG|fludarabine phosphate|Given IV
219225882|NCT00005799|RADIATION|total-body irradiation|Undergo low-dose TBI
219708886|NCT04753112|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
219708887|NCT01044667|BEHAVIORAL|GI and Quality of Life Assessment|
219708888|NCT01719302|DRUG|Gemcitabine|1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
219708889|NCT01719302|DRUG|Docetaxel|50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
219708890|NCT01719302|DRUG|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
219708891|NCT03609840|DRUG|Thiotepa|Given IV
219708892|NCT00026338|DRUG|erlotinib hydrochloride|150 mg po daily
219708893|NCT00026338|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
219708894|NCT05609227|OTHER|mobile application|The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
219708895|NCT04649424|DEVICE|CanSwab|New nasopharyngeal swab design.
219708896|NCT04330872|DRUG|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
219708897|NCT04330872|DRUG|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
219708898|NCT04991961|DIAGNOSTIC_TEST|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
219125186|NCT04056156|BEHAVIORAL|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
219125187|NCT02942901|PROCEDURE|PET-CT|
219125188|NCT02275936|DRUG|N91115|S Nitrosoglutathione Reductase Inhibitor
219125189|NCT04637464|OTHER|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
219125190|NCT04927052|DEVICE|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
219125191|NCT04927052|DEVICE|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
219125192|NCT03318744|DRUG|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
219125193|NCT03318744|DRUG|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
219125194|NCT02633891|BEHAVIORAL|Balance exercise|tailored balance exercise program
219125195|NCT02633891|BEHAVIORAL|Standard care|general health education and fall prevention classes
219125196|NCT03238482|DRUG|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
219125197|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
219125198|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
219708899|NCT05632523|OTHER|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
219708900|NCT05632523|OTHER|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
219125199|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
219125200|NCT05091762|BEHAVIORAL|exercise|Upper limb resistance training with blood flow obstruction
219125201|NCT04162366|DRUG|Aprocitentan 25 mg|Tablet, oral use once daily
219708901|NCT04690426|BIOLOGICAL|PRV-101|Coxsackie Virus B vaccine
219708902|NCT04690426|OTHER|Placebo|Placebo
219708903|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 1|1 dose of Flu mRNA Formulation 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219708904|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 2|1 dose of Flu mRNA Formulation 2 is administered intramuscularly in the non-dominant upper deltoid to YA at Day 1.
219708905|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 3|1 dose of Flu mRNA Formulation 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219125202|NCT04162366|DRUG|Placebo|Matching placebo tablet, oral use once daily
219125203|NCT05090423|OTHER|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
219125204|NCT05090423|OTHER|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
219125205|NCT06458738|DEVICE|Printable denture base material|The newly developed printable denture base material will be used for the production of dentures.
219125206|NCT06480656|PROCEDURE|Rehabilitation with eccentric cycling exercise|Instead of normal cycling, patients will exercise on the eccentric bike.
219125207|NCT06480656|PROCEDURE|normal rehabilitation|Normal rehabilitation will be conducted
219708906|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 4|1 dose of Flu mRNA Formulation 4 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219708907|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 5|1 dose of Flu mRNA Formulation 5 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219708908|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 6|1 dose of Flu mRNA Formulation 6 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219708909|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 7|1 dose of Flu mRNA Formulation 7 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219125208|NCT04196985|DIAGNOSTIC_TEST|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
219125209|NCT04196985|DIAGNOSTIC_TEST|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
219125210|NCT03465111|DRUG|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
219125211|NCT00041262|DRUG|cisplatin|
219125212|NCT00041262|DRUG|epirubicin hydrochloride|
219125213|NCT00041262|DRUG|fluorouracil|
219708910|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 8|1 dose of Flu mRNA Formulation 8 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219708911|NCT06431607|COMBINATION_PRODUCT|Active Comparator 1|1 dose of active comparator 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219125214|NCT00041262|PROCEDURE|conventional surgery|
219125215|NCT00041262|PROCEDURE|neoadjuvant therapy|
219125216|NCT04668183|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
219125217|NCT04668183|PROCEDURE|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
219708912|NCT06431607|COMBINATION_PRODUCT|Active Comparator 2|1 dose of active comparator 2 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219125218|NCT01885364|DRUG|Normal saline|intravenous injection with normal saline before injection of propofol
219125219|NCT01885364|DRUG|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
219125220|NCT01885364|DRUG|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
219125221|NCT01885364|DRUG|propofol|intravenous injection after pretreatment
219125222|NCT02107001|PROCEDURE|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
219125223|NCT01323660|DRUG|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
219125224|NCT01323660|DRUG|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
219125225|NCT01323660|DRUG|GSK573719 125|125mcg QID
219125226|NCT01323660|DRUG|GSK573719 62.5|62.5mcg QID
219125227|NCT01323660|DRUG|GW642444 25|25mcg QID
219125228|NCT01323660|DEVICE|placebo|Comparator QID
219708913|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 9|1 dose of Flu mRNA Formulation 9 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219708914|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 10|1 dose of Flu mRNA Formulation 10 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
219708915|NCT06431607|COMBINATION_PRODUCT|Active Comparator 3|1 dose of active comparator 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
219708916|NCT06431607|COMBINATION_PRODUCT|Active Comparator 4|1 dose of active comparator 4 is administered intramuscularly in the non-dominant upper deltoid to OA at Day1.
219708917|NCT02646059|OTHER|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
219708918|NCT02646059|OTHER|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
219708919|NCT03268187|DEVICE|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
219708920|NCT03268187|BEHAVIORAL|Self-Alert Training|Self-Alert Training
219708921|NCT03268187|BEHAVIORAL|Relaxation Training|Relaxation Training
219708922|NCT02433717|DRUG|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
219125229|NCT05287932|BEHAVIORAL|Brief physical activity intervention|See arm/group descriptions
219125230|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
219225883|NCT00005799|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
219708923|NCT05897554|DRUG|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
219125231|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
219125232|NCT05379127|OTHER|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
219125233|NCT05379127|OTHER|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
219125234|NCT02474615|PROCEDURE|ENDODONTIC SURGERY|ENDODONTIC SURGERY
219125235|NCT04531540|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
219125236|NCT02688621|BEHAVIORAL|Internet Only|18 month behavioral weight loss intervention delivered online
219125237|NCT02688621|BEHAVIORAL|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
219125238|NCT02512146|PROCEDURE|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
219125239|NCT06504875|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
219125240|NCT06504875|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
219125241|NCT06504875|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
219708924|NCT00472238|BEHAVIORAL|endurance training|control group.
219708925|NCT00472238|BEHAVIORAL|exercise training|Treadmill exercise training to optimize physical endurance
219125242|NCT06504875|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
219125243|NCT00270114|DRUG|epoetin alfa|
219125244|NCT00223054|DRUG|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
219125245|NCT00223054|DRUG|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
219708926|NCT01555775|DIETARY_SUPPLEMENT|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
219708927|NCT01555775|DIETARY_SUPPLEMENT|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
219708928|NCT06548490|DRUG|Semaglutide Pen Injector|Semaglutide will be provided using an injection pen
219125246|NCT00223054|DRUG|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
219125247|NCT00223054|DRUG|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
219125248|NCT05698940|PROCEDURE|Infundibultomy|Infundibultomy on one side of patient
219125249|NCT03239210|DRUG|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
219125250|NCT03239210|DRUG|Placebo|placebo equivalent
219708929|NCT06548490|DRUG|Placebo|Placebo will be a dry needle stick; no substances will be injected
219708930|NCT01534793|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
219708931|NCT01285089|DRUG|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
219708932|NCT06372236|BIOLOGICAL|UTAA06 injection for treatment of advanced malignant solid tumors|The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.
219125251|NCT05634213|DRUG|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
219708933|NCT03406468|RADIATION|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
219708934|NCT05075369|DIAGNOSTIC_TEST|water drinking test|Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
219708935|NCT00770367|DRUG|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
219225884|NCT00005799|PROCEDURE|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
219708936|NCT00770367|DRUG|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
219708937|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
219708938|NCT02786966|OTHER|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
219125252|NCT06502015|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
219125253|NCT00476203|BEHAVIORAL|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
219125254|NCT00476203|OTHER|Delayed yoga classes|Delayed yoga classes (after 6 months) offered \[wait list control group\]
219125255|NCT06192706|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
219125256|NCT01575860|DRUG|Lenalidomide|Lenalidomide, 10mg, oral tablets, daily
219125257|NCT00188929|PROCEDURE|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
219125258|NCT04648306|DEVICE|Prophylactic Impella support for a non-emergent PCI|Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
219225885|NCT00005799|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
219225886|NCT00005799|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
219225887|NCT00005799|DRUG|cyclosporine|Given PO
219225888|NCT00005799|DRUG|mycophenolate mofetil|Given PO
219225889|NCT00005799|OTHER|pharmacological study|Correlative studies
219708939|NCT05614076|PROCEDURE|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
219708940|NCT05614076|PROCEDURE|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
219708941|NCT01756755|DEVICE|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
219708942|NCT00820092|DRUG|Xerecept 1.0|24 hour infusion
219708943|NCT00820092|DRUG|Xerecept 2.0|24 hour infusion
219708944|NCT00820092|DRUG|Xerecept 3.0|24 hour infusion
219708945|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
219708946|NCT04862208|DIETARY_SUPPLEMENT|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
219708947|NCT04862208|DIETARY_SUPPLEMENT|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
219708948|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
219708949|NCT00243321|PROCEDURE|high dose-rate brachytherapy|High dose-rate brachytherapy
219708950|NCT00243321|PROCEDURE|intensity-modulated radiation therapy|intensity-modulated radiation therapy
219708951|NCT00994539|DRUG|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
219708952|NCT00920816|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
219708953|NCT00920816|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
219708954|NCT05758792|OTHER|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
219708955|NCT05029947|PROCEDURE|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
219708956|NCT03976128|BEHAVIORAL|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
219708957|NCT03976128|BEHAVIORAL|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
219708958|NCT01180777|DEVICE|etafilcon A (A)|Daily wear contact lens
219225890|NCT00005799|OTHER|laboratory biomarker analysis|Correlative studies
219708959|NCT01180777|DEVICE|etafilcon A (B)|Daily wear contact lens
219708960|NCT01180777|DEVICE|etafilcon A (C)|Daily wear contact lens
219708961|NCT05956093|RADIATION|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
219708962|NCT00350220|OTHER|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl
219708963|NCT00350220|OTHER|Low Hb transfusion group|RBCs will not be transfused unless the Hb \< 9.0 g/dl
219708964|NCT02369926|PROCEDURE|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
219708965|NCT02369926|PROCEDURE|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
219708966|NCT04329455|PROCEDURE|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
219708967|NCT00624260|OTHER|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
219708968|NCT00624260|OTHER|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
219708969|NCT05009420|OTHER|Avocado|avocado served with crackers as breakfast
219125259|NCT06200038|OTHER|Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)|"Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
219125260|NCT06200038|OTHER|Conventional physical therapy and sham manual therapy|"A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
219125261|NCT06200038|OTHER|Conventional physical therapy|Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
219125262|NCT03311854|DRUG|Emapalumab|Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
219125263|NCT06085196|BEHAVIORAL|Mindful walking activity|Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
219125264|NCT03700606|PROCEDURE|High flow nasal cannula|8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
219125265|NCT03700606|PROCEDURE|Nasal CPAP|Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
219225891|NCT05499767|BEHAVIORAL|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
219225892|NCT04927078|OTHER|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
219225893|NCT00620854|DRUG|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
219225894|NCT00620854|DRUG|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
219708970|NCT03209960|DIAGNOSTIC_TEST|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
219708971|NCT03209960|OTHER|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
219708972|NCT06573528|DRUG|CS060380|Tablets administered orally
219708973|NCT05474820|OTHER|Samples collection and ELISA analyses|"The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.~For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged."
219708974|NCT05474820|DIAGNOSTIC_TEST|Evaluating periodontal paramètres|The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
219708975|NCT04504760|DRUG|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
219708976|NCT04504760|DRUG|Placebo|Single dose of placebo will be administered orally.
219708977|NCT04504760|DRUG|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
219708978|NCT04504760|DRUG|Placebo|Multiple dose of placebo will be administered orally.
219708979|NCT05492435|DEVICE|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
219708980|NCT05651737|BEHAVIORAL|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
219708981|NCT02638441|OTHER|hospital anxiety and depression scale|Detection of infertility effect on emotional status
219225895|NCT00620854|DRUG|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
219125266|NCT04658719|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
219125267|NCT04658719|DEVICE|Standard Care|Uncoated Foley Catheter
219125268|NCT00278564|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
219125269|NCT00278564|DRUG|Cyclophosphamide|
219125270|NCT00278564|DRUG|Mesna|
219125271|NCT00278564|DRUG|ATG(rabbit)|
219125272|NCT00278564|DRUG|Methylprednisolone|
219125273|NCT00278564|DRUG|G-CSF|
219125274|NCT00278564|DRUG|Rituxan|
219125275|NCT02985333|DRUG|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
219125276|NCT02985333|DRUG|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
219125277|NCT02985333|DRUG|Dexamethasone|Dexamethasone 20mg iv d1-4
219125278|NCT02143674|OTHER|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
219125279|NCT02143674|OTHER|Educated about physical exercises|
219125280|NCT06140160|PROCEDURE|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
219125281|NCT01094743|DEVICE|galyfilcon A prototype lens|Silicone hydrogel contact lens
219125282|NCT01094743|DEVICE|lotrafilcon B lens|Silicon Hydrogel contact lens
219125283|NCT02851511|BEHAVIORAL|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
219125284|NCT02851511|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
219708982|NCT02820636|BEHAVIORAL|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
219708983|NCT02820636|BEHAVIORAL|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
219708984|NCT04976257|PROCEDURE|Angiogram|Undergo angiogram
219708985|NCT04976257|PROCEDURE|Catheterization|Undergo prostatic arterial catheterization
219125285|NCT02851511|DEVICE|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
219125286|NCT02851511|BEHAVIORAL|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
219125287|NCT05323929|PROCEDURE|ESD|Endoscopic Submucosal Dissection for early gastric cancer
219125288|NCT02687386|DRUG|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
219125289|NCT03909464|DEVICE|Neurosensory testing with Pressure-Specified Sensory Device|Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
219125290|NCT05487469|DRUG|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
219125291|NCT05487469|OTHER|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
219125292|NCT00004136|PROCEDURE|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
219125293|NCT04494373|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
219125294|NCT04494373|DRUG|Xgeva®|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
219125295|NCT00970411|DRUG|KRN951|Orally once daily administration
219125296|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
219125297|NCT01246648|PROCEDURE|biopsy|dental extraction and gingival epithelial biopsy
219125298|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
219125299|NCT06206681|PROCEDURE|Ultra-pulsed Carbon Dioxide Laser|Excision of eyelid lesion
219125300|NCT06142240|OTHER|exercise programe|"The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions."
219125301|NCT00914017|DRUG|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
219125302|NCT00914017|DRUG|Placebo|sugar pill daily for 1 year
219125303|NCT02095600|RADIATION|Radiosurgical thalamotomy|
219125304|NCT01326585|DRUG|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
219125305|NCT01326585|DRUG|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
219125306|NCT02487719|DRUG|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
219125307|NCT02286440|OTHER|AssureRx GeneSight genotyping results|
219125308|NCT02286440|OTHER|Treatment as usual|
219125309|NCT00051311|PROCEDURE|Stem cell transplantation|Recipients will receive donor stem cells 3 days after conditioning therapy is completed.
219125310|NCT00051311|DRUG|Fludarabine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219125311|NCT00051311|DRUG|Cyclophosphamide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219125312|NCT00051311|DRUG|Etoposide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219708986|NCT04976257|DRUG|Gallium Ga-labeled PSMA-11|Given IV and IA
219125313|NCT00051311|DRUG|Doxorubicin|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219708987|NCT04976257|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219125314|NCT00051311|DRUG|Vincristine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219125315|NCT00051311|DRUG|Prednisone|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
219125316|NCT00051311|DRUG|Methotrexate|Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
219125317|NCT00051311|DRUG|Cyclosporine|Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
219708988|NCT00169325|PROCEDURE|Magnetic resonance imaging|
219708989|NCT05700838|BEHAVIORAL|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
219708990|NCT04657900|OTHER|Observational|Observational - no intervention given
219125318|NCT00051311|PROCEDURE|Apheresis|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
219125319|NCT06382545|PROCEDURE|Fanta (Pepsi gold) (FPG)|endodontic treatment of posterior teeth with Fanta (Pepsi gold) (FPG)
219125320|NCT06382545|PROCEDURE|M3-pro+ Gold (assorted) (MPG)|endodontic treatment of posterior teeth with M3-pro+ Gold (assorted) (MPG) rotary files.
219125321|NCT03675711|DEVICE|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
219125322|NCT03675711|DEVICE|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
219125323|NCT03671538|DRUG|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
219125324|NCT03671538|DRUG|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
219125325|NCT03671538|DRUG|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
219125326|NCT03951376|BEHAVIORAL|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
219225896|NCT00620854|DRUG|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
219708991|NCT02508064|DRUG|BMS-663068|BMS-663068
219708992|NCT03650075|DRUG|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
219708993|NCT00383825|PROCEDURE|Anterior segment indocyanine green angiography|
219125327|NCT02050789|BEHAVIORAL|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
219125328|NCT01132911|DRUG|Vorinostat (SAHA)|
219125329|NCT01132911|DRUG|Velcade (PS-341, Bortezomib)|
219125330|NCT00350181|DRUG|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
219125331|NCT00350181|DRUG|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
219125332|NCT00350181|DRUG|BCNU|15 mg/kg, IV
219125333|NCT00350181|DRUG|VP-16|60 mg/kg, IV
219125334|NCT00350181|DRUG|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
219125335|NCT00350181|DRUG|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
219125336|NCT00350181|DRUG|BU|BU 1 mg/kg every 6hr x 4 doses, IV
219708994|NCT06494163|BEHAVIORAL|Exercise|The MICT and HIIT intervention groups will complete supervised virtual exercise sessions for 12 weeks using Zoom care or Microsoft Teams as a backup resource. The appointments will be scheduled and conducted 2 days per week. Initially, exercise intensity will be determined from participants' peak HR achieved during a baseline CPET.
219708995|NCT00890721|DRUG|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
219708996|NCT00890721|DRUG|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
219708997|NCT01772771|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
219708998|NCT01772771|OTHER|Genetic Testing|Correlative studies
219708999|NCT01772771|OTHER|Medical Chart Review|Review of medical records
219709000|NCT06306742|OTHER|Open-label placebo|Light pressure manual therapy
219709001|NCT06306742|OTHER|Osteopathic manipulative treatment|Manual therapy
219709002|NCT03885388|DRUG|MTX|multicourse methotrexate chemotherapy
219709003|NCT03885388|DRUG|MTX+ACTD|combination use of methotrexate and actinomycin
219709004|NCT02234180|OTHER|Placebo|Given PO
219709005|NCT02234180|DRUG|Regorafenib|Given PO
219709006|NCT04951960|OTHER|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
219709007|NCT04951960|OTHER|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
219709008|NCT02374983|OTHER|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
219125337|NCT00972712|DRUG|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
219125338|NCT02721758|BEHAVIORAL|Brief Motivational Intervention|
219125339|NCT01468415|DRUG|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
219225897|NCT01586416|BEHAVIORAL|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
219709009|NCT02022917|DRUG|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
219709010|NCT05522751|DEVICE|DBS|Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
219709011|NCT02251353|PROCEDURE|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
219709012|NCT02251353|DRUG|systemic treatment|Systemic therapy
219709013|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
219709014|NCT06110793|DRUG|Lenvatinib|20mg orally PO daily
219125340|NCT02584790|DEVICE|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
219125341|NCT05142228|DRUG|Erenumab-Aooe|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
219125342|NCT05142228|OTHER|Placebo|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
219225898|NCT03345979|COMBINATION_PRODUCT|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
219709015|NCT06110793|DRUG|Pembrolizuma|400mg IV Q6W
219709016|NCT06110793|DRUG|Fulvestrant|500mg IM Q4W
219709017|NCT03441061|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219709018|NCT02537548|OTHER|Laboratory Biomarker Analysis|Correlative studies
219225899|NCT03345979|DRUG|Paliperidone Palmitate|Intramuscular injection
219125343|NCT04884698|DEVICE|Stimit Activator|"The Stimit Activator Device is composed of three components.~1. A magnetic stimulator generating current pulses~2. A novel Stimit coil design optimized for phrenic nerve stimulation~3. A coil positioning device for quick, easy and reproducible coil positioning"
219125344|NCT05049629|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
219125345|NCT05049629|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
219125346|NCT04878172|DEVICE|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
219125347|NCT02333773|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
219125348|NCT00372567|DRUG|sunitinib malate|37.5 mg daily
219125349|NCT00372567|DRUG|imatinib mesylate|800mg daily
219125350|NCT01902901|GENETIC|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
219125351|NCT01902901|GENETIC|Carrier status testing|Carrier status testing
219125352|NCT00083421|DRUG|ONO-2506PO|
219125353|NCT01079598|DEVICE|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
219125354|NCT06202937|BEHAVIORAL|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
219125355|NCT06202937|OTHER|No intervention:control|the control group received the usual care
219125356|NCT03261635|DRUG|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
219125357|NCT03261635|DRUG|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
219125358|NCT00303303|BIOLOGICAL|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
219125359|NCT00303303|BIOLOGICAL|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
219125360|NCT00303303|BIOLOGICAL|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
219125361|NCT05675631|OTHER|Suspension training|This group will perform training using suspension devices.
219125362|NCT05675631|OTHER|Strength training|This group will perform training using weights and elastic bands.
219125363|NCT01330355|DRUG|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
219125364|NCT01330355|DRUG|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
219125365|NCT02832765|RADIATION|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
219125366|NCT02832765|RADIATION|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
219125367|NCT02832765|RADIATION|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
219125368|NCT02832765|RADIATION|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
219125369|NCT05826548|BEHAVIORAL|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
219125370|NCT05826548|BEHAVIORAL|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
219125371|NCT06530667|DEVICE|broadband collaborative pulse ablation|Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
219125372|NCT06068166|COMBINATION_PRODUCT|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
219125373|NCT06068166|DRUG|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
219125374|NCT04950543|BEHAVIORAL|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
219125375|NCT00582790|DRUG|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
219125376|NCT00582790|DRUG|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
219225900|NCT05478096|BEHAVIORAL|GetStarted|Guided internet-based intervention for procrastination.
219125377|NCT02699801|DRUG|propofol|propofol for post-sternal closure sedation
219125378|NCT02699801|DRUG|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
219125379|NCT03301922|BEHAVIORAL|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
219125380|NCT03301922|OTHER|Waiting list|Waiting list
219125381|NCT01941264|OTHER|community based screening and treatment|Already described in intervention arm description.
219125382|NCT00480441|DRUG|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
219125383|NCT00480441|BEHAVIORAL|BRENDA therapy|weekly therapy sessions for 6 weeks
219125384|NCT00480441|DRUG|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
219125385|NCT05039918|BEHAVIORAL|Affective touch|Gentle stroking at CT-optimal speed
219125386|NCT00165360|DRUG|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
219125387|NCT01719120|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
219125388|NCT04643249|DRUG|KL1333|Tablet
219709019|NCT02537548|PROCEDURE|Retroperitoneal Lymph Node Dissection|Undergo RPLND
219709020|NCT05433467|PROCEDURE|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
219709021|NCT06031272|DRUG|3BNC117-LS-J|Administered by intravenous (IV) infusion
219709022|NCT06031272|DRUG|10-1074-LS-J|Administered by intravenous (IV) infusion
219709023|NCT06031272|DRUG|Placebo for 3BNC117-LS-J|Administered by intravenous (IV) infusion
219709024|NCT06031272|DRUG|Placebo for 10-1074-LS-J|Administered by intravenous (IV) infusion
219709025|NCT05555017|PROCEDURE|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
219125389|NCT04643249|DRUG|Flurbiprofen|Tablet
219125390|NCT04643249|DRUG|Dextromethorphan|Syrap
219125391|NCT04643249|DRUG|Bupropion|Tablet
219125392|NCT04643249|DRUG|Midazolam injection|solution for injection
219125393|NCT04643249|DRUG|Omeprazole|Capsule
219125394|NCT04643249|DRUG|Caffeine|Tablet or capsule
219125395|NCT04643249|DRUG|Repaglinide|Tablet
219125396|NCT02865434|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219125397|NCT02865434|PROCEDURE|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
219709026|NCT05555017|DRUG|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
219709027|NCT00119639|DRUG|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
219709028|NCT02355223|OTHER|FAST|See information in arm description
219709029|NCT04011852|DEVICE|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
219125398|NCT02865434|PROCEDURE|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
219125399|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
219125400|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
219125401|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
219125402|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
219125403|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
219125404|NCT02865434|PROCEDURE|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
219125405|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
219125406|NCT02865434|PROCEDURE|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
219125407|NCT02865434|PROCEDURE|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
219125408|NCT02865434|PROCEDURE|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
219125409|NCT02865434|PROCEDURE|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
219125410|NCT05407363|PROCEDURE|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
219125411|NCT05407363|PROCEDURE|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
219709030|NCT05255107|COMBINATION_PRODUCT|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution \[0.23%\], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
219709031|NCT05255107|OTHER|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
219709032|NCT01644214|OTHER|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
219709033|NCT04892407|DEVICE|Algeness® DF 3.5%|dermal filler CE Mark approved for treatment of cheek and midface volume loss
219709034|NCT04892407|DEVICE|Juvéderm Voluma|dermal filler CE Mark approved for treatment of cheek and midface volume loss
219709035|NCT00642486|OTHER|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
219709036|NCT00642486|OTHER|Standard polysomnography (PSG)|laboratory-based testing
219709037|NCT02438579|OTHER|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
219125412|NCT05407363|PROCEDURE|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
219709038|NCT04512690|DEVICE|Epidural electrical stimulation (EES) of the cervical spinal cord|All participants enrolled in this group will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days.
219709039|NCT04068532|DRUG|Placebo|Administered as specified in the treatment arm.
219709040|NCT04068532|DRUG|BIIB104|Administered as specified in the treatment arm.
219125413|NCT02689271|OTHER|MRI|VERDICT diffusion-weighted microstructure imaging sequence
219125414|NCT03887962|DEVICE|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
219125415|NCT03887962|DEVICE|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
219125416|NCT00067145|BEHAVIORAL|Face-to-face maintenance program|
219125417|NCT00067145|BEHAVIORAL|Internet maintenance program|
219125418|NCT00508976|DRUG|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
219125419|NCT00508976|DRUG|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
219225901|NCT01705366|PROCEDURE|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
219225902|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
219225903|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
219125420|NCT00508976|DRUG|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
219125421|NCT00508976|DRUG|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
219125422|NCT03670381|OTHER|Psychiatric diagnosis|
219125423|NCT01004263|DRUG|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
219125424|NCT06143020|PROCEDURE|Erector spinae plane block|In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
219125425|NCT04679883|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
219125426|NCT04679883|DRUG|Placebo|Placebo as eye drops
219125427|NCT02861261|DRUG|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
219125428|NCT02861261|DRUG|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
219125429|NCT02861261|DRUG|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
219709041|NCT06342882|DIAGNOSTIC_TEST|dysphagia assessment|Twenty-one patients underwent the Modified Barium Swallowing Study and Swallowing Ability and Function Evaluation (SAFE) assessments. The Penetration Aspiration Scale (PAS) and SAFE physical examination, oral phase and pharyngeal phase domains was used to determine the dysphagia severity.
219709042|NCT06342882|DIAGNOSTIC_TEST|functional independence level|Functional independence was evaluated by the Functional Independence Measurement (FIM) motor and cognitive domains.
219709043|NCT05093868|DEVICE|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
219709044|NCT02321527|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
219709045|NCT02321527|DEVICE|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
219125430|NCT02861261|DRUG|1. Berberine placebo tablets; 2. Probiotics placebo powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
219125431|NCT06043804|OTHER|Doppler ultrasound measurement of changes in uterine artery blood flow|Doppler ultrasound measurement of changes in uterine artery blood flow
219125432|NCT00936013|DRUG|oseltamivir|75mg p.o Bid for 5 days
219125433|NCT00936013|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
219125434|NCT02444442|DEVICE|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
219125435|NCT02444442|OTHER|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
219125436|NCT05791721|DRUG|Etoricoxib 90 Mg Oral Tablet|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
219125437|NCT05791721|DRUG|Dexamethasone 4mg|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
219125438|NCT03528135|BEHAVIORAL|Project PRIDE|See arms section.
219125439|NCT02635061|DRUG|ACY-241|Specified dose on specified days
219125440|NCT02635061|DRUG|Nivolumab|Specified dose on specified days
219125441|NCT03247062|OTHER|Quality improvement - sleep bundle|implementation of a sleep bundle
219125442|NCT04534855|DRUG|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
219125443|NCT05366387|DEVICE|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
219125444|NCT05366387|RADIATION|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
219125445|NCT03756194|DEVICE|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
219125446|NCT03756194|DEVICE|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
219125447|NCT00958009|DEVICE|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
219125448|NCT00009958|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
219125449|NCT00009958|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
219125450|NCT00009958|BIOLOGICAL|sargramostim|Given SC
219125451|NCT00009958|OTHER|laboratory biomarker analysis|Correlative studies
219125452|NCT00353145|DRUG|Gemcitabine (Gemox)|1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).
219125453|NCT00353145|DRUG|Oxaliplatin|100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
219125454|NCT00353145|BEHAVIORAL|Questionnaire|Quality of Life Surveys
219125455|NCT05420662|PROCEDURE|Manipulation of vagina during abdominal hysterectomy operation|The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
219125456|NCT05420662|PROCEDURE|Classical conventional abdominal hysterectomy operation|Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
219125457|NCT00527085|DRUG|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
219125458|NCT00527085|DRUG|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
219225904|NCT01705366|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
219709046|NCT02321527|PROCEDURE|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
219709047|NCT02321527|BEHAVIORAL|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
219125459|NCT00558753|DRUG|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
219125460|NCT00558753|DRUG|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
219125461|NCT04056104|DIAGNOSTIC_TEST|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
219125462|NCT04058314|DEVICE|Gemini IV|Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
219125463|NCT04058314|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
219125464|NCT01855308|PROCEDURE|Single site robotic chole|Cholecystectomy
219225905|NCT01705366|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
219709048|NCT03315637|PROCEDURE|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
219709049|NCT03335527|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
219125465|NCT01855308|DEVICE|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
219125466|NCT04805151|OTHER|No intervention|No intervention
219125467|NCT05434442|OTHER|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
219125468|NCT05434442|OTHER|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
219125469|NCT05434442|OTHER|control group|Clinical routine training will be given to caregivers in this group.
219125470|NCT00693030|DEVICE|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
219125471|NCT00693030|DEVICE|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
219709050|NCT03335527|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
219709051|NCT05340699|DEVICE|Defocus Distributed Multi-point lens|Wear DDM lens
219125472|NCT00693030|DEVICE|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
219125473|NCT00693030|DEVICE|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
219125474|NCT00889564|DEVICE|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
219125475|NCT00789061|DRUG|Proton pump inhibitor|One dosage/day/year
219125476|NCT01055782|DEVICE|Endoguide|Use of endoguide to facilitate completion of endoscopy
219125477|NCT00686621|DRUG|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
219125478|NCT00578227|BIOLOGICAL|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
219125479|NCT00578227|BIOLOGICAL|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
219125480|NCT02350361|DRUG|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
219125481|NCT02350361|DRUG|Placebo|Placebo
219125482|NCT02353611|OTHER|6% hydrogen peroxide|
219125483|NCT02353611|OTHER|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
219709052|NCT05340699|DEVICE|Single vision lens|Wear single vision lens
219709053|NCT01654887|OTHER|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
219125484|NCT01293162|DRUG|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
219225906|NCT01705366|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
219125485|NCT04668144|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
219125486|NCT04668144|DRUG|Prasugrel|Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
219125487|NCT00723320|DRUG|Atorvastatin|atorvastatin 10mg/d
219125488|NCT00723320|BEHAVIORAL|Aggressive lifestyle intervention|aggressive lifestyle intervention
219125489|NCT00577629|DRUG|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
219125490|NCT00577629|DRUG|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
219125491|NCT00577629|DRUG|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
219125492|NCT00577629|DRUG|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
219125493|NCT00577629|DRUG|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
219225907|NCT01962597|OTHER|aerobic exercise|
219225908|NCT01962597|OTHER|resistance training|
219709054|NCT01654887|RADIATION|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
219709055|NCT01730313|DRUG|Pyridoxine|
219709056|NCT01730313|DRUG|Sodium Valproate|
219709057|NCT01730313|DRUG|Phenytoin|
219709058|NCT01730313|DRUG|Placebo|
219709059|NCT01375101|DRUG|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
219125494|NCT00577629|DRUG|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
219125495|NCT03351829|GENETIC|Gene-modified autologous stem cells|1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
219125496|NCT04878380|DEVICE|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
219125497|NCT04878380|BEHAVIORAL|Sleep education tips|Sleep tips will be provided before the intervention phase
219125498|NCT04878380|BEHAVIORAL|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
219125499|NCT00364598|DRUG|Anginera, a human tissue replacement therapy|
219125500|NCT02871765|OTHER|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
219709060|NCT01375101|DRUG|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
219709061|NCT06053944|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine.
219125501|NCT02929108|BEHAVIORAL|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
219709062|NCT05867875|OTHER|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
219709063|NCT05867875|OTHER|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
219709064|NCT04882800|DEVICE|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
219125502|NCT02929108|BEHAVIORAL|ACCESS|"Intervention will have two components.~1. Participants will be enrolled in a Secret Facebook group for social support and education~2. Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
219125503|NCT00244257|BIOLOGICAL|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
219125504|NCT00244257|BIOLOGICAL|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
219125505|NCT00244257|BIOLOGICAL|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
219125506|NCT00244257|BIOLOGICAL|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
219125507|NCT00244257|BIOLOGICAL|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
219125508|NCT00800371|PROCEDURE|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
219709065|NCT04882800|DEVICE|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
219709066|NCT03139513|DRUG|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
219709067|NCT03139513|DRUG|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
219709068|NCT02305979|DRUG|Loratadine|
219709069|NCT04809753|DEVICE|Eustachian tube dilation|Dilation of the eustachian tube with an endovascular balloon
219125509|NCT00116740|DRUG|APD356|
219125510|NCT00019318|DRUG|romidepsin|
219125511|NCT03033914|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
219125512|NCT03033914|DRUG|Bleomycin|Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
219125513|NCT03033914|DRUG|vinblastine|Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
219125514|NCT03033914|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
219709070|NCT05707169|PROCEDURE|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
219709071|NCT05707169|DEVICE|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
219709072|NCT05707169|DRUG|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
219709073|NCT05509504|OTHER|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for \~45 minutes. Participants will attend these sessions once a week.
219709074|NCT06219239|GENETIC|KL003 cell injection Drug Product|No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
219709075|NCT02597114|DRUG|AGT-181|intravenous infusion over 3-4 hours
219709076|NCT02924961|DEVICE|Triathlon PS total knee system with mobile-bearing|
219709077|NCT02924961|DEVICE|Triathlon PS total knee system with fixed-bearing|
219709078|NCT00785889|PROCEDURE|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
219709079|NCT02011178|PROCEDURE|Optimal medical treatment and surgery|
219125515|NCT03033914|DRUG|Nivolumab|nivolumab 240mg q14 days
219125516|NCT03177187|DRUG|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
219709080|NCT02011178|PROCEDURE|Optimal medical treatment|
219709081|NCT01138046|DRUG|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
219709082|NCT00809198|OTHER|Sodium Hyaluronate|
219709083|NCT00809198|OTHER|Carboxymethylcellulose sodium|
219125517|NCT03177187|DRUG|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
219709084|NCT01034423|DIETARY_SUPPLEMENT|Omega-3|Capsules with omega-3 fatty acids.
219125518|NCT06015646|BEHAVIORAL|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
219125519|NCT06015646|BEHAVIORAL|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
219125520|NCT05895630|BEHAVIORAL|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
219125521|NCT05895630|BEHAVIORAL|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
219225909|NCT02673359|DRUG|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
219709085|NCT01034423|DIETARY_SUPPLEMENT|sun flower oil|Capsules with sun flower oil.
219709086|NCT04952896|DIAGNOSTIC_TEST|Synovitis diagnosis|
219709087|NCT01510639|BIOLOGICAL|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
219125522|NCT03549988|OTHER|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
219125523|NCT06408246|DRUG|Guanfacine|Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
219125524|NCT06408246|DRUG|Sertraline|Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
219125525|NCT05147987|DEVICE|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
219125526|NCT00203775|DRUG|risperidone|
219125527|NCT03194776|DRUG|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
219125528|NCT03194776|DRUG|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
219125529|NCT00014690|DRUG|plevitrexed|
219125530|NCT00014690|DRUG|topotecan hydrochloride|
219125531|NCT00185367|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
219709088|NCT05855720|OTHER|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
219709089|NCT05441904|DRUG|PXL770|A single dose of 500 and 750 mg was administered to each subject.
219709090|NCT03846791|OTHER|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
219709091|NCT01986998|DRUG|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
219709092|NCT01986998|DRUG|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
219709093|NCT01294540|DRUG|Drug: E2609|E2609 orally at varying ascending doses
219125532|NCT00185367|DRUG|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
219125533|NCT00894751|DRUG|dexmedetomidine|dexmedetomidine general anesthesia for MRI
219709094|NCT01294540|DRUG|Placebo|Matching Placebo
219709095|NCT05891444|DEVICE|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219125534|NCT00894751|DRUG|propofol|propofol general anesthesia for MRI
219125535|NCT00958529|DIETARY_SUPPLEMENT|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
219125536|NCT01984125|OTHER|Point-of-Care Prompt|
219125537|NCT06038071|OTHER|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
219125538|NCT06038071|OTHER|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
219125539|NCT06038071|OTHER|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
219125540|NCT03701464|PROCEDURE|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
219125541|NCT03701464|PROCEDURE|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
219125542|NCT04327596|PROCEDURE|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
219125543|NCT03347838|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219125544|NCT06576908|DEVICE|HyperSight Imaging|Subjects receive both HyperSight imaging and conventional imaging, on their first day of radiation treatment, on their second day of treatment, and on their last day of treatment.
219125545|NCT05546099|BEHAVIORAL|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
219125546|NCT05546099|BEHAVIORAL|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
219125547|NCT05421273|DEVICE|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
219125548|NCT05421273|DEVICE|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
219125549|NCT00184119|PROCEDURE|Psychiatric Intensive Care Unit|
219125550|NCT00184119|PROCEDURE|Care in whole acute unit|psychiatric acute care as usual
219125551|NCT01307280|BEHAVIORAL|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
219125552|NCT01307280|BEHAVIORAL|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
219709096|NCT05891444|DEVICE|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
219709097|NCT06201325|OTHER|virtual reality based exercises|play VR games
219125553|NCT01307280|BEHAVIORAL|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
219125554|NCT00153335|BEHAVIORAL|patient-provider interaction|
219125555|NCT02249871|DRUG|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
219709098|NCT06201325|OTHER|conventional physical therapy|streching and strengthening exercises
219125556|NCT02249871|DRUG|Omeprazole|Will be given daily with oral semaglutide.
219125557|NCT03590743|DRUG|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
219125558|NCT03590743|OTHER|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
219125559|NCT00734513|BEHAVIORAL|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
219709099|NCT06201325|OTHER|home exercises program|home exercises
219709100|NCT01900314|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
219125560|NCT00734513|BEHAVIORAL|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
219125561|NCT00000316|DRUG|Cocaine|
219125562|NCT00671684|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
219125563|NCT04223921|OTHER|Comparison of patient's medicines|"Comparison of patient's medicines:~* between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~* between patient's admission and discharge from hospital (acute geriatric care unit"
219225910|NCT02673359|PROCEDURE|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
219225911|NCT00487240|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
219709101|NCT05926713|DIETARY_SUPPLEMENT|Sarcojoint®|All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
219709102|NCT05926713|BEHAVIORAL|supervised exercise|All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
219709103|NCT04277585|OTHER|Telehealth|Early Psychosis Coordinated Specialty Care Services via telehealth.
219709104|NCT03318068|OTHER|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
219225912|NCT00487240|DRUG|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
219225913|NCT01487954|DIETARY_SUPPLEMENT|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
219125564|NCT01046747|PROCEDURE|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
219125565|NCT00530179|PROCEDURE|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
219125566|NCT00530179|DRUG|R-CHOP|6 - 21 DAY Cycles of R-CHOP
219125567|NCT03174795|DRUG|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
219125568|NCT03174795|DRUG|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
219125569|NCT00604786|DRUG|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
219125570|NCT00604786|DRUG|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
219125571|NCT00001416|DRUG|CEREDASE™|
219125572|NCT01221181|DRUG|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
219709105|NCT05257187|DEVICE|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
219125573|NCT00253903|DRUG|eplivanserin (SR46349)|oral administration
219125574|NCT00253903|DRUG|placebo|oral administration
219709106|NCT03005756|DEVICE|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
219709107|NCT01104766|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219709108|NCT01104766|DRUG|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219709109|NCT01104766|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
219709110|NCT02753673|BEHAVIORAL|qualitative interviews with patients|
219709111|NCT02753673|BEHAVIORAL|questionnaires|
219125575|NCT02698436|DEVICE|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
219125576|NCT02698436|DRUG|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
219125577|NCT01233635|OTHER|no drug|none, no drug
219125578|NCT01233635|DRUG|start cozaar|start cozaar
219125579|NCT01233635|DRUG|continue cozaar|continue cozaar
219125580|NCT06008535|PROCEDURE|Open inguinal hernia repair|Lichtenstein hernioplasty or open inguinal hernia repair with self-gripping mesh
219125581|NCT03732586|DIETARY_SUPPLEMENT|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
219125582|NCT03732586|OTHER|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
219125583|NCT01020565|DRUG|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
219125584|NCT04435886|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with maltodextrin as a carrier.
219125585|NCT04435886|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
219125586|NCT04279028|BEHAVIORAL|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
219709112|NCT02095288|PROCEDURE|Blood draw|This is a single blood donation, no drugs or devices administered
219709113|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
219709114|NCT04057235|DEVICE|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
219125587|NCT04279028|BEHAVIORAL|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
219709115|NCT03047252|DEVICE|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
219709116|NCT03047252|OTHER|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
219709117|NCT04276220|DIAGNOSTIC_TEST|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
219709118|NCT04225832|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
219709119|NCT05526417|PROCEDURE|Computed Tomography|Undergo CT
219709120|NCT05526417|OTHER|Educational Intervention|Receive educational materials
219709121|NCT05526417|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219709122|NCT05526417|PROCEDURE|Physical Therapy|Receive prehabilitation physical therapy
219709123|NCT05526417|OTHER|Questionnaire Administration|Ancillary studies
219125588|NCT04750408|DEVICE|Standard oxygen|COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).
219709124|NCT05526417|OTHER|Telemedicine|Attend telemedicine visits
219709125|NCT03076463|DIETARY_SUPPLEMENT|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
219709126|NCT05730205|DRUG|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
219709127|NCT05698823|DEVICE|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
219709128|NCT02578797|DRUG|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
219709129|NCT04443413|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219709130|NCT04443413|OTHER|Questionnaire Administration|Ancillary studies
219709131|NCT04443413|RADIATION|X-ray Therapy|Undergo x-ray therapy
219709132|NCT06640426|BEHAVIORAL|Two Messaging Nudges|This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
219709133|NCT06640426|BEHAVIORAL|Five messaging nudges|This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
219709134|NCT06492993|OTHER|Education|The CHN meets with DDBHH participant over sessions to provide navigation support through the cancer screening process.
219709135|NCT05865314|OTHER|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care."
219709136|NCT05865314|OTHER|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
219709137|NCT05836077|OTHER|Education with pecha kucha method|Education with pecha kucha method
219709138|NCT05635006|OTHER||No special intervention, randomly classify the subjects
219709139|NCT06619444|BEHAVIORAL|Aerobic exercise only|Aerobic exercise training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year trial
219125589|NCT04750408|DEVICE|Nasal high-flow|F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
219125590|NCT05541419|DRUG|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
218986364|NCT03473483|OTHER|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~* Sealed and disposable~* Minimum 350 puffs per tank~* Volume of e-liquid per tank \~ 3ml~E-Liquid Characteristics:~* Tobacco flavored~* Nicotine concentration: 15 mg/ml~* Propylene Glycol:\~ 50% (wt / wt)~* Glycerin: \~ 50% (wt / wt)~* Cotinine: \<1 μg/g~* Nornicotine: 5 μg/g~* Myosmine : 3 μg/g~* Anabasine: \<1 μg/g~* Anatabine: \<1 μg/g~* Beta:nicotyrine: \<1 μg/g~* Diacetyl: \<2 μg/g~* 2,3:Pentanedione: \<1 μg/g~* Arsenic: \<0.1 μg/g~* Cadmium: \<0.1 μg/g~* Chromium: \<0.1 μg/g~* Lead: \<0.1 μg/g~* Nickel: \<0.1 μg/g~* Mercury: \<0.05 μg/g"
219225914|NCT01487954|DIETARY_SUPPLEMENT|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
219225915|NCT01487954|RADIATION|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
219709140|NCT06619444|BEHAVIORAL|30 min of resistance exercise|30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 15 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
218986365|NCT03314194|OTHER|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
218986366|NCT00952042|OTHER|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
218986367|NCT00952042|OTHER|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
218986368|NCT01234831|DEVICE|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
218986369|NCT01234831|OTHER|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
218986370|NCT00569608|OTHER|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
218986371|NCT01686061|OTHER|No intervention- only one time survey|
219225916|NCT03829553|RADIATION|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
219225917|NCT03829553|RADIATION|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
219125591|NCT05541419|DRUG|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
219709141|NCT06619444|BEHAVIORAL|60 min of resistance exercise|60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
219709142|NCT06619444|BEHAVIORAL|120 min of resistance exercise|120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
219709143|NCT02754453|BEHAVIORAL|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
219709144|NCT03965923|DRUG|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
219709145|NCT03965923|DRUG|Truvada Tablet|Tablet taken orally
219709146|NCT04491799|DIAGNOSTIC_TEST|Fecal calprotectin|Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
219709147|NCT03963388|OTHER|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
219709148|NCT02712853|OTHER|Saliva collection|Collection of saliva via swab for miRNA processing
219709149|NCT02712853|OTHER|Vineland Adaptive Behavior Scale-II Assessment|
219709150|NCT06095193|BEHAVIORAL|menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
219709151|NCT03368430|DIETARY_SUPPLEMENT|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
219709152|NCT03368430|DRUG|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
219709153|NCT05322343|OTHER|Questionnaires|"Participants will complete a series of three questionnaires at the V1 (at home, by a trained interviewer) repeated at V7 for the follow up phase:~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5, V6 visits. and V7, V9, V10 et V11 for the follow-up phase~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
219709154|NCT05322343|OTHER|Fasting blood sampling.|"In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.~The blood collection is repeated at V8 during the follow-up phase (21 mL)."
219709155|NCT05322343|OTHER|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
219709156|NCT05322343|OTHER|Urine and stool samples|During the V2 visit, the nurse will collect urine and stool samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator. Stool sampling os repeated at V8 during the follow-up phase.
219709157|NCT05322343|OTHER|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope. The hair collection is repeated at V8 during the follow-up phase.
219709158|NCT05322343|OTHER|Nasal microbiota|Nasal or nasopharyngeal swab
219709159|NCT05322343|OTHER|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit. Some of these measures (blood pressure, grip strength, screening of sarcopenia and Parkinson's syndromes) are repeated at V8 during the follow-up visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
219125592|NCT03116451|BEHAVIORAL|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
219125593|NCT03780205|OTHER|Prescription glasses for bilateral amblyopia|Correction of refractive error with prescription glasses both eyes
219125594|NCT03780205|OTHER|Prescription glasses for unilateral amblyopia|Correction of asymmetric refractive errors with lenses
219125595|NCT05420532|OTHER|Exergaming|A video game-based physical activity training applied using a commercial game console.
219125596|NCT05929456|DRUG|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
219125597|NCT00219401|BIOLOGICAL|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
219709160|NCT05322343|OTHER|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
219709161|NCT05322343|OTHER|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
219709162|NCT03282097|BEHAVIORAL|DECAD decision aid|A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.
219709163|NCT03282097|OTHER|Home safety guide|The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
219709164|NCT02226159|DRUG|Lidocaine|
219125598|NCT03766594|DRUG|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
219125599|NCT03766594|DRUG|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
219125600|NCT03766594|DRUG|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
219125601|NCT05781529|PROCEDURE|Alveolar ridge augmentation with injectable platelets rich fibrin|Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
219225918|NCT01814605|PROCEDURE|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
219709165|NCT02226159|DRUG|Lidocaine with Dexamethasone|
219709166|NCT02120326|DEVICE|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
219709167|NCT02120326|DEVICE|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
219125602|NCT05781529|PROCEDURE|Alveolar ridge augmentation with hyaluronic acid|Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
219125603|NCT05781529|PROCEDURE|Alveolar ridge augmentation with xenograft|Xenograft is added alone as a active compatator
219125604|NCT02729792|DEVICE|rTMS|intermittent theta burst stimulation (iTBS)
219125605|NCT01630499|BEHAVIORAL|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
219125606|NCT01630499|BEHAVIORAL|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
219125607|NCT05203731|BEHAVIORAL|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
219125608|NCT05203731|BEHAVIORAL|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
219125609|NCT06697652|PROCEDURE|adrenalectomy|adrenalectomy
219125610|NCT06697535|DRUG|JYP0061|Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.
219125611|NCT06697535|DRUG|Intravenous Glucocorticoids|Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.
219709168|NCT01410825|BIOLOGICAL|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
219709169|NCT06050993|OTHER|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
219125612|NCT06697535|DRUG|Oral Glucocorticoids|Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
219125613|NCT04811651|BIOLOGICAL|Umbilical Cord-derived Mesenchymal Stem Cells|umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.
219125614|NCT04811651|DRUG|Placebo|intravenous placebo solution with the same appearance as the treatment group.
219125615|NCT06846034|OTHER|Hypoxia administration study group|Acute 2-hour hypoxia (14.5%FiO2 corresponding to 3000m altitude)
219125616|NCT06846034|COMBINATION_PRODUCT|Renal clairance study|"Assessment of renal clearance by measuring Glomerular Filtration Rate (GFR) after two agents infusion:~* Aminohippurate Sodium (or or para-aminohippuric acid \[PAH\]) Inj 20% Diagnostic agent used to measure effective renal plasma flow (ERPF)~* Iohexol Inj 300 MG/ML Diagnostic agent used to measure glomerular filtration rate (GFR)"
219125617|NCT06913114|DIAGNOSTIC_TEST|Lafayette|The Lafayette handheld dynamometer data correlates with the measurements taken using the 10-Meter Walk Test (10MWT) or not.
219125618|NCT06913114|DIAGNOSTIC_TEST|Lafayette|Lafayette handheld dynamometer.
219125619|NCT06918080|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|Daily doses of Ursodeoxycholic acid (UCD) Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks will be assigned to arm(1)
219125620|NCT06918080|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day) will be assigned to children in arm (1). Side effect such as gastrointestinal upset and allergy will be monitored, compliance will be monitored by weekly phone call
219125621|NCT06918080|BEHAVIORAL|Physical exercise|Patients assigned to arm (1) will participate in a 12-week exercise program for 30-45 min/day for 3 days/week. in the first two weeks and for 60 min/day for 4-5 days/week in the following weeks
219125622|NCT06918080|BEHAVIORAL|Mediterrenean diet|"Patients in arm (1) will follow Mediterranean Diet (MD) for 12 weeks, this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat is extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein.( Plaz et al., 2019) Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age.~Compliance to the MD will be assessed in all patients using the KIDMED index at 4 ,8 and 12 weeks.Those who prove to be non-compliant will be excluded from the study."
219125623|NCT06918080|BEHAVIORAL|Diet according to NASPGHAN guidelines|Patients in arm (2) will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age, with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours.
219125624|NCT06919510|DRUG|lvonescimab|lvonescimab, DS1, D1,q3w, intravenous infusion
219125625|NCT06919510|DRUG|CAPOX (oxaliplatin/capecitabine)|Oxaliplatin 130 mg / m2, D1, intravenous infusion, q3w, Capecitabine 1000 mg / m2,twice a day, oral,1-14 days, then rest for 7 days, q3w.
219125626|NCT06919510|RADIATION|radiotherapy|5\* 5Gy, once a day, 5Gy each time, for 5 days
219125627|NCT06919510|PROCEDURE|Surgery or watch&wait|The surgical method is selected by the investigator. Watch and Wait (only for patients with clinical complete response after neoadjuvant therapy)
219125628|NCT06918444|DEVICE|WARIFA app with AI|"Participants will be given access to the WARIFA app on their mobile phones during the study.~This app will collect activity data as well as questionnaires and diaries. Using this data and artificial intelligence, it will provide participants with personalised information and recommendations about their lifestyle and risk of chronic non-communicable diseases."
219225919|NCT01814605|PROCEDURE|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
219709170|NCT01732211|BIOLOGICAL|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
219709171|NCT01732211|OTHER|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
219709172|NCT05753800|DEVICE|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
219709173|NCT05404100|PROCEDURE|Aortic valve replacement|SAVR or TAVR
219709174|NCT03575169|DEVICE|BIS Monitor|Unilateral BIS electrode
219709175|NCT00363740|DRUG|GW685698X Aqueous Nasal Spray|
219709176|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
219709177|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
219125629|NCT06918444|DEVICE|WARIFA app without AI|"Participants will be given access to the WARIFA app on their cell phones during the study.~This app will collect activity data, as well as through questionnaires and diaries. With this data, it will give information and general recommendations to the participants related to their lifestyle habits and risks of chronic non-communicable diseases, following the WHO guidelines. This version will not use artificial intelligence or personalized messages."
219125630|NCT06918600|OTHER|Virtual Reality-Supported Early Mobilization Program|"The intervention involves the use of a virtual reality (VR)-supported mobilization program specifically designed for patients recovering from open-heart surgery. Participants wear a VR headset that delivers guided sessions comprising:~Breathing Exercises: Deep breathing and coughing techniques to support respiratory function and prevent complications.~Lower Limb Exercises: Interactive movements aimed at improving circulation and preventing venous stasis.~Mobilization Strategies: Gradual and guided steps to assist patients in transitioning from bed to ambulation, tailored to their recovery stage.~This intervention is unique because it integrates an immersive and engaging digital environment to promote physical activity, reduce anxiety, and enhance motivation during the critical early postoperative phase. Unlike standard rehabilitation practices, the VR program provides real-time feedback and visual cues to ensure correct execution of movements."
219709178|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
219709179|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
219709180|NCT02755090|DRUG|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
219709181|NCT02755090|DRUG|IV Saline|
219709182|NCT06019078|DEVICE|SedLine|Continuous 4 channel processed neurological monitor
219709183|NCT04940221|BEHAVIORAL|Shared Decision Making|Telephone delivered non-persuasive shared decision-making for lung cancer screening.
219709184|NCT00512434|PROCEDURE|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
219709185|NCT00758888|PROCEDURE|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
219709186|NCT00758888|PROCEDURE|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
219709187|NCT00758888|OTHER|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
219709188|NCT02926014|DEVICE|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
219709189|NCT02926014|OTHER|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
219709190|NCT02926014|OTHER|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
219709191|NCT04696471|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
219709192|NCT04696471|DEVICE|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
219709193|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
219709194|NCT05577000|DRUG|Fludarabine|Given IV
219709195|NCT05577000|DRUG|Cyclophosphamide|Given IV
219709196|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
219709197|NCT04928599|OTHER|Interview|Complete interview
219709198|NCT04928599|OTHER|Survey Administration|Complete survey
219709199|NCT05735834|DRUG|Rituximab|Truxima concentrate for solution for infusion 500 mg/50 ml
219709200|NCT05735834|DRUG|Zanubrutinib|Zanubrutinib 80 mg hard capsules
219709201|NCT06083896|PROCEDURE|Photodynamic nails|stab incision is made at the entry site
219709202|NCT01938326|PROCEDURE|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
219709203|NCT03515746|DEVICE|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
219125631|NCT06919406|BEHAVIORAL|Mindfulness Intervention for emotional distress(MIED）|MIED is an eight-week program developed based on MBSR and the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. MIED consists of weekly group sessions with daily interactive materials delivered via a WeChat-based mini-program. The group sessions, conducted online, provide structured content and interactive discussions aligned with the weekly themes, for example including psychoeducation on mindfulness, emotions, and emotional distress. Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks).
219125632|NCT06918288|DEVICE|High flow nasal canula|All patients assigned to the HFNC group will receive HFNC immediately after extubation. Researchers will need to choose the suitable size nasal catheter. The initial airflow will be set to 50 L/min and adjusted according to patient tolerance with an absolute humidity setting to 44 mgH2O/L and the temperature setting to 37 °C.The patient's respiratory rate will be maintained below 30 beats/min or the baseline level before extubation with a SpO2 at 88-92%. HFNC failure is defined as escalation to NIV or invasive mechanical ventilation due to respiratory failure.
219225920|NCT02318628|DEVICE|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
219225921|NCT05072002|OTHER|no intervention / observational study|no intervention / observational study
219225922|NCT02539576|DRUG|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
219709204|NCT01943604|OTHER|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
219709205|NCT01943604|OTHER|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
219709206|NCT05389904|OTHER|Arm 1: Routine care|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.
219709207|NCT05389904|OTHER|Arm 2: Preemptive C. difficile infection prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
219709208|NCT03913039|PROCEDURE|Transperineal biopsy Protocol|"1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
219709209|NCT01853865|OTHER|Instruction in self-referral|
219709210|NCT04797169|BEHAVIORAL|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
219709211|NCT04797169|BEHAVIORAL|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
219709212|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
219709213|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
219709214|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
219709215|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
219709216|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
219709217|NCT05631626|DRUG|Placebo|Placebo
219709218|NCT04109924|DRUG|Irinotecan|Given IV
219709219|NCT04109924|BIOLOGICAL|Bevacizumab|Given IV
219709220|NCT04109924|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219709221|NCT03498261|DRUG|Gabapentin|Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
219709222|NCT03498261|DRUG|Placebos|Placebo
219709223|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
219709224|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
219125633|NCT06918288|DEVICE|Non-invasive positive pressure mechanical ventilation|All patients assigned to the control group will receive NIV immediately after extubation. Researchers will use a standard oronasal mask to connect the patient to the ventilator. The patients will be on Spontaneous/Timed (S/T) mode, with the initial end-expiratory pressure setting to 4 cmH2O. The pressure level will gradually increase to ensure that the patients can trigger the ventilator with each inhalation. The initial inspiratory pressure will be set at 8 cmH2O and adjusted according to the tidal volume with 6-8 ml/kg and tolerance of patients. The pres- sure level and the fraction of inspiration oxygen will be adjusted in order to maintain the respiratory rate ≤ 30/ min or the baseline level before extubation, a partial pressure of carbon dioxide (PaCO2) at 45-60 mmHg or the last PaCO2 level recorded before extubation, and a pulse oxygen saturation at 88-92%. NIV treatment failure is defined as a return to invasive mechanical ventilation.
219125634|NCT06919302|BEHAVIORAL|Digital Heart Health Program|The digital heart health program will include the web-based app, which will deliver the intervention through interactive features (dashboard, goal setting, gamification, nudges, etc.) and will be supported by a 16-session synchronous online behaviour change program and provision of key study foods.
219125635|NCT06919679|DRUG|BrECADD|Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone
219125636|NCT06920511|DEVICE|Cognitve rehabilitation with virtual reality and robotic arm|The intervention consists of a cognitive rehabilitation program using the PRoBio platform, a bio-cooperative robotic system integrating virtual reality and real-time multisensory feedback. The PRoBio platform includes a robotic arm (TIAGo), a virtual reality interface (VRRS), and sensors to monitor biomechanical, cognitive, and emotional parameters during training.
219125637|NCT06918405|DRUG|Tirzepatide|"All the included patients in both the diabetic and nondiabetic groups will receive the same intervention of tirzepatide at a dose of 15 mg administered subcutaneously once a week in addition to lifestyle modification.~Initially, tirzepatide will be started with a dose of 2.5 mg once weekly subcutaneous injection for the first 4 weeks. After the stabilization period of the drug, the dose will be increased to 5 mg after 4 weeks, 7.5 mg after 8 weeks, 10 mg after 12 weeks, 12.5 mg after 16 weeks and finally 15 mg after 20 weeks."
219125638|NCT06918301|DIAGNOSTIC_TEST|Measurement of cardiac performance|Measurement of cardiac performance by different devices
219125639|NCT06919029|DEVICE|Advanced Hybrid Closed Loop from onset of type 1 diabetes in children|The objective of this study is to evaluate glycemic control of users of the AHCL system MiniMed 780G with GS4 calibration-free sensor in children and adolescents with newly diagnosed T1D implemented directly upon T1D diagnosis in combination with continuous glucose monitoring system (CGMS) compared with those treated with MDI retrieved from historical data- in a single- arm open-label prospective observational study, assessed at 3 months. After the initial study period there will be a 3month extension phase of the study.
219709225|NCT06450925|DRUG|Vitamin A|Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
219709226|NCT06450925|OTHER|Placebo|Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
219709227|NCT04921943|DRUG|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
219709228|NCT04921943|DRUG|Azithromycin|Standard of care
219709229|NCT04921943|DRUG|Ethambutol|Standard of care
219709230|NCT04921943|DRUG|Rifampin|Standard of care
219709231|NCT06033846|DRUG|Minocycline|treatment with minocycline combined with first-line drugs for autoimmune encephalitis
219709232|NCT05963113|BEHAVIORAL|Pharyngeal Swallowing Exercises|12-weeks of proactive pharyngeal swallowing exercises conducted 5 times per week. The exercise program will include the following four exercises: effortful saliva swallows, tongue-hold swallows, effortful pitch glides and posterior lingual resistance. Each exercise set will include 10 repetitions of each exercise (40 reps per set). The number of sets will be gradually increased as tolerance builds.
219709233|NCT05963113|DIETARY_SUPPLEMENT|Protein Supplementation|12-week supply of the commercially-available Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink). Participants will be asked to consume one drink per day for the 12-week intervention period.
219709234|NCT05963113|DEVICE|MRI|Participants will be scanned using a 3T MRI scanner and a 16-channel phased array neck coil.
219709235|NCT05092451|DRUG|Cyclophosphamide|Given by IV
219709236|NCT05092451|DRUG|CAR.70/IL15-transduced CB-NK cells|Given by IV
219709237|NCT05092451|DRUG|Fludarabine phosphate|Given by IV
219709238|NCT04919408|OTHER|telephone survey|telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
219709239|NCT06850051|BIOLOGICAL|TIV-HA Vaccine formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
219709240|NCT06850051|BIOLOGICAL|TIV-HA formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
219709241|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
219709242|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
219709243|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
219709244|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
219709245|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
219709246|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
219709247|NCT06850051|BIOLOGICAL|RIV4 (Supemtek®)|Solution for injection in a prefilled syringe. Route of administration: IM injection
219709248|NCT05037370|DEVICE|Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation|Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
219709249|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1, Day 8, Day 15, Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
219709250|NCT05718219|DRUG|SIM0348 + Sintilimab|Selected doses from Part 1A will be evaluated for SIM0348 when they were combined with Sintilimab (200mg once every 3 weeks).
219709251|NCT02236364|DEVICE|Photographic Image Capture System|Collection of images of the iris along with corresponding fingerstick blood glucose
219709252|NCT02535312|DRUG|Cisplatin|Given IV
219709253|NCT02535312|DRUG|Methoxyamine|Given PO
219709254|NCT02535312|DRUG|Pemetrexed Disodium|Given IV
219709255|NCT06385132|OTHER|Psychological Tests' administration|to assess global psychological and psychiatric profile of patients affected by GBM and H\&N-C by means of standardized questionnaires
219709256|NCT04688736|DRUG|Placebo|The tablet resembles chlorpheniramine but has no therapeutic value.
219709257|NCT04688736|DRUG|Chlorpheniramine|An antihistamine that reduces the natural chemical histamine in the body.
219709258|NCT06441214|DRUG|Zanubrutinib|Patients will be treated with Zanubrutinib as per routine clinical practice.
219709259|NCT06260904|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
219709260|NCT06260904|DRUG|Apremilast|Apremilast 30 mg twice daily orally
219709261|NCT06260904|DRUG|Methotrexate|Methotrexate 15 mg weekly orally
219709262|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
219709263|NCT05343013|DRUG|TAS-102|GIven by PO
219709264|NCT03839641|OTHER|High fat meal|60% fat meal
219709265|NCT03839641|OTHER|Low fat meal|20% fat meal
219709266|NCT00029237|BEHAVIORAL|Cognitive-behavioral relaxation (Positively Living)|
219709267|NCT00029237|BEHAVIORAL|Spiritual growth group|
219709268|NCT00029237|BEHAVIORAL|Focused Tai Chi|
219709269|NCT04221490|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
219709270|NCT02942290|DRUG|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
219709271|NCT02942290|DRUG|Venetoclax|Oral; Tablet
219709272|NCT05123625|PROCEDURE|Reduce surgical procedures|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
219709273|NCT05940012|OTHER|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
219709274|NCT05776888|OTHER|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
219709275|NCT06350318|DRUG|Zanubrutinib|Zanubrutinib is an anti-cancer medication administered orally.
219709276|NCT06350318|DRUG|Rituximab|Rituximab is a biologic medication administered intravenously or subcutaneously.
219709277|NCT00837889|DRUG|diuretics, inotropica|
219709278|NCT05898204|OTHER|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
219709279|NCT05898204|OTHER|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
219709280|NCT05761171|PROCEDURE|Biospecimen Collection|Undergo collection of blood and CSF samples
219709281|NCT05761171|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219709282|NCT05761171|DRUG|Calaspargase Pegol|Given IV
219709283|NCT05761171|DRUG|Cytarabine|Given IV and IT
219709284|NCT05761171|PROCEDURE|Echocardiography Test|Undergo ECHO
219709285|NCT05761171|DRUG|Fludarabine Phosphate|Given IV
219709286|NCT05761171|DRUG|Hydrocortisone Sodium Succinate|Given IT
219709287|NCT05761171|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219709288|NCT05761171|DRUG|Methotrexate|Given IT
219709289|NCT05761171|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219709290|NCT05761171|DRUG|Prednisolone|Given PO or via NG, NJ, ND or G-tube
219709291|NCT05761171|DRUG|Prednisone|Given PO or via NG, NJ, ND or G-tube
219709292|NCT05761171|DRUG|Revumenib|Given PO or via NG, NJ, ND or G-tube
219709293|NCT05761171|DRUG|Vincristine Sulfate|Given IV
219709294|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
219709295|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
219709296|NCT00998192|BIOLOGICAL|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
219709297|NCT00998192|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
219709298|NCT00998192|DRUG|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
219709299|NCT04903522|BEHAVIORAL|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
219125640|NCT06914206|DRUG|esketamine group|in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.
219125641|NCT06914206|DRUG|PRF group|In the control group, patients will receive PRF+standardized drug treatment. Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center. They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy
219125642|NCT06920095|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
219125643|NCT06917833|OTHER|compare infant hypoxic events in both groups|early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all this will be compared between two groups.
219125644|NCT06934148|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
219125645|NCT06934148|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials
219125646|NCT00929305|DEVICE|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
219125647|NCT00929305|DEVICE|Placebo laser|Inactive laser light
219125648|NCT06508723|PROCEDURE|Dental implant placement|The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
219125649|NCT04827017|OTHER|follow up|follow up population
219125650|NCT00188409|PROCEDURE|CT scan|
219125651|NCT03624595|DRUG|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
219125652|NCT03624595|DRUG|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
219125653|NCT03739879|DEVICE|Inspiratory Muscle Trainer Philips Respironics|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
219125654|NCT06309043|DRUG|recombinant anti-EGFR human/murine chimeric monoclonal antibody injection|a single dose，250 mg/m2
219125655|NCT05311475|DRUG|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
219125656|NCT05311475|DRUG|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
219125657|NCT05311475|DRUG|Placebo|Placebo nasal spray
219125658|NCT02600429|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
219125659|NCT02600429|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
219125660|NCT05924893|DRUG|Naltrexone Hydrochloride|naltrexone film
219125661|NCT05924893|DRUG|Carboxy methyl cellulose|Carboxy methyl cellulose drops
219125662|NCT03746275|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
219125663|NCT03746275|DRUG|Acetylsalicylic acid|75 - 100 mg once daily according to local label
219125664|NCT03427229|BIOLOGICAL|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
219125665|NCT03427229|DRUG|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
219125666|NCT03427229|BIOLOGICAL|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
219125667|NCT01414036|OTHER|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
219125668|NCT01414036|BEHAVIORAL|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
219125669|NCT02182882|DRUG|GINSANA|
219125670|NCT02182882|DRUG|Placebo|
219125671|NCT03863717|OTHER|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
219125672|NCT03863717|OTHER|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
219125673|NCT01955382|DRUG|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
219125674|NCT01955382|DRUG|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
219125675|NCT01955382|DRUG|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
219125676|NCT02077738|DEVICE|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
219125677|NCT04417556|DIAGNOSTIC_TEST|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
219125678|NCT02029053|DEVICE|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
219125679|NCT05404113|OTHER|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
219709300|NCT04909762|OTHER|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
219709301|NCT03034967|DRUG|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
219709302|NCT03034967|DRUG|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
219709303|NCT03034967|DRUG|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
219709304|NCT03034967|DRUG|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
219225923|NCT05907070|OTHER|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
219709305|NCT00334308|PROCEDURE|Barley protein bread or control (casein) bread|
219709306|NCT06533449|DEVICE|Couplet Care Bassinet|Couplet Care Bassinet
219709307|NCT06533449|DEVICE|Standard Bassinet|Standard Bassinet
219709308|NCT00007748|BEHAVIORAL|Aerobic exercise|
219709309|NCT00007748|BEHAVIORAL|Cognitive behavioral therapy|
219709310|NCT06641570|OTHER|Aquatic Exercise Program|This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.
218986372|NCT06680700|DEVICE|Perin Health Patch|The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
219125680|NCT05404113|OTHER|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
219709311|NCT06641570|OTHER|Land-based Exercise Program|This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
218986373|NCT07012876|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|The intervention is a guided mental health chatbot - STARS - developed by the World Health Organization (WHO). It consists of 10 sessions which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Supportive Self-talk (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained and supervised non-specialists (called e-helpers) provide weekly calls (five calls lasting approximately 15 minutes) to support participants individually and increase motivation and adherence to the intervention.
218986374|NCT07012876|BEHAVIORAL|Basic psychoeducation|The control group will receive basic psychoeducation. The content of the psychoeducation is very similar to the content of session 2 of the STARS chatbot and includes psychoeducation about emotions, a personal story about a fictional character who talks about her emotions, and information about where to access mental health support. It also includes a list of organizations and clinics providing mental health care in Lithuania.
218986375|NCT07008417|DRUG|Cabergoline tablets test formulation|Single oral administration
218986376|NCT07008417|DRUG|Cabergoline tablets reference formulation|Single oral administration
218986377|NCT06684964|OTHER|asciminib|This is an observational study. There is no treatment allocation. The decision to initiate asciminib will be based solely on clinical judgement.
218986378|NCT06684457|BEHAVIORAL|Atrial Fibrillation Education|Atrial fibrillation education rendered through a generative AI chatbot, using an iPAD. The intervention itself is an approximately 1 hour long interaction with the chatbot or approximately 10 questions about atrial fibrillation, for 1 single interaction.
218986379|NCT06680882|OTHER|Auricular Acupoint Stimulation +prucapride|The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
218986380|NCT06680882|DRUG|prucapride|was administered prucapride as a monotherapy
218986381|NCT06873841|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
218986382|NCT06873841|BEHAVIORAL|Cognitive psychophysiological and Biofeedback|Biofeedback refers to visual exercises that help improve movement control.
218986383|NCT07020052|DRUG|temozolomide/anlotinib/pembrolizumab|"Starting from 30 days after radiotherapy, adjuvant temozolomide was orally administered at a dose of 150mg/m2. The dosage of temozolomide was adjusted to 200mg/m2 starting from the second cycle, with continuous use for 5 days per week and a 23 day hiatus. Oral administration for a total of 6 cycles.~The start time of oral administration of anlotinib after radiotherapy follows the cycle of radiotherapy, with continuous oral administration for 2 weeks and cessation for 1 week. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months.~Begin treatment with bemarituzumab 24 hours after radiotherapy, with a body weight of\>=45kg, intravenous injection of 200mg, once every 3 weeks. Weight\<45kg, 100mg intravenous injection, once every 3 weeks. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months."
218986384|NCT06229210|DRUG|Lumateperone|Lumateperone 5 mg - 42 mg capsules or orally disintegrating tablets administered orally, once daily based on age and indication
218986385|NCT03389230|BIOLOGICAL|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
218986386|NCT03389230|OTHER|Laboratory Biomarker Analysis|Correlative studies
218986387|NCT03389230|PROCEDURE|Leukapheresis|Undergo leukapheresis
218986388|NCT02039336|DRUG|Dacomitinib|
218986389|NCT02039336|DRUG|PD-0325901|
218986390|NCT02039336|DRUG|Docetaxel|
219225924|NCT05907070|OTHER|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
219225925|NCT04019067|DIAGNOSTIC_TEST|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
218986393|NCT06704776|PROCEDURE|"The medially pedicled IPFP flap group"|"In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures."
218986394|NCT06704776|PROCEDURE|"Complete IPFP removal group"|The entire IPFP was resected from below the patellar tendon prior to femoral preparation.
218986395|NCT05213338|DEVICE|Wear-documentation microchip|Microchip embedded in the appliance
219125681|NCT00069862|DRUG|Deferitrin (GT56-252)|
219125682|NCT00069862|DRUG|desferoxamine (DFO)|
219709312|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
219709313|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
219709314|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
219709315|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
219125683|NCT05219045|OTHER|Ohio RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
219709316|NCT04279483|BEHAVIORAL|Tobacco retailer|Assigned to make a small (\~$3.00) purchase from a tobacco retail store(s) using a study-provided debit card during each retail environment visit
219709317|NCT04279483|BEHAVIORAL|Non-tobacco retailer|Assigned to make a small (\~$3.00) purchase from a store that does not sell tobacco (non-tobacco retailer) using a study-provided debit card during each retail environment visit.
219709318|NCT00643175|BEHAVIORAL|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
219709319|NCT02077699|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
219709320|NCT03160950|DEVICE|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
219709321|NCT06406972|OTHER|Brief Admission by self-referral (BA)|Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
219709322|NCT02255864|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
219709323|NCT03474575|OTHER|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
219125684|NCT05597098|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
219125685|NCT00764179|OTHER|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
219125686|NCT00764179|OTHER|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
219125687|NCT05626283|DRUG|transforaminal epidural injection.|transforaminal epidural steroid injection.
219125688|NCT05626283|OTHER|micro RNA-155 serum level|Estimation of miR-155 expression level:
219125689|NCT02401399|DIETARY_SUPPLEMENT|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
219709324|NCT00125944|BIOLOGICAL|FluMist|
219125690|NCT02401399|DIETARY_SUPPLEMENT|High protein formula|The patients receive high protein formula during 15 days before surgery
219125691|NCT02401399|DIETARY_SUPPLEMENT|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
219125692|NCT02395185|OTHER|Milk bottle administration|Patients are given a bottle of milk during the casting process.
219125693|NCT02395185|OTHER|Water bottle administration|Patients are given a bottle of water during the casting process.
219125694|NCT02395185|OTHER|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
219125695|NCT03134456|DRUG|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
219125696|NCT05427357|OTHER|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
219125697|NCT02949817|DEVICE|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
219125698|NCT02949817|OTHER|Conventional OT group|2\. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
219125699|NCT03940261|OTHER|High Intensity Interval Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
219125700|NCT03940261|OTHER|Continuous Moderate Intensity Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
219125701|NCT06080711|OTHER|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
219125702|NCT01095224|BIOLOGICAL|rAd35 Env A|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
219125703|NCT01095224|BIOLOGICAL|rAd5 Env A|1 x 10\^10 PU administered as 1 mL IM in deltoid
219125704|NCT01095224|BIOLOGICAL|rAd5 Env B|1 x 10\^10 PU administered as 1 mL IM in deltoid
219125705|NCT01739517|DRUG|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
219125706|NCT01400100|DRUG|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
219125707|NCT01400100|DRUG|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
219125708|NCT05491161|OTHER|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
219125709|NCT04478175|OTHER|multidisciplinary assessment and intervention|early multidisciplinary assessment and intervention in addition to usual patient care
219125710|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Block|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of 0.375% ropivacaine was administered in close proximity to the targeted vagal branch.
219125711|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Injection|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of normal saline was administered in close proximity to the targeted vagal branch.
219709325|NCT06086249|PROCEDURE|Regeneration using Injectable platelet-rich fibrin|root canals of affected molars will be cleaned and shaped chemo-mechanically, after two weeks I-PRF will be applied.
219125712|NCT00029523|DRUG|Intrathecal (injected into the spinal fluid) DepoCyt|
219125713|NCT00029523|DRUG|Intrathecal methotrexate|
219125714|NCT00029523|DRUG|Intrathecal cytarabine (also known as ara-C)|
219709326|NCT06086249|PROCEDURE|Root canal treatment|Conventional root canal treatment using gutta-percha obturation
219709327|NCT04289948|DRUG|Phage|The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
219709328|NCT05693220|DEVICE|Zymot Multi sperm separation device|Sperm preparation with Zymot Multi sperm preparation device
219709329|NCT05693220|OTHER|Density gradient centrifugation|Sperm preparation with density gradient centrifugation
219709330|NCT02838355|DEVICE|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
219709331|NCT02838355|OTHER|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
219709332|NCT00843973|PROCEDURE|iliac crest bone graft|iliac crest bone graft procedure
219709333|NCT00843973|PROCEDURE|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
219709334|NCT04926233|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
219709335|NCT04926233|DEVICE|Sp(t)iolto® Respimat®|Sp(t)iolto® Respimat®
219709336|NCT05395442|DIAGNOSTIC_TEST|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
219709337|NCT02550795|DRUG|Dexmedetomidine|administration of dexmedetomidine only
219709338|NCT02550795|DRUG|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
219709339|NCT02550795|DRUG|Control|administration of normal saline
219709340|NCT01887808|OTHER|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
219709341|NCT01971177|DEVICE|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
219709342|NCT01971177|PROCEDURE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
219709343|NCT01113099|OTHER|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
219709344|NCT03983031|DRUG|Rituximab|Infusion
219709345|NCT00889434|DIETARY_SUPPLEMENT|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
219709346|NCT00889434|DIETARY_SUPPLEMENT|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
219709347|NCT00889434|DIETARY_SUPPLEMENT|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
219709348|NCT01868672|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
219709349|NCT04844320|DIAGNOSTIC_TEST|Cobb angle measurements|PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
219709350|NCT05932888|DRUG|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
219709351|NCT05932888|DRUG|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
219709352|NCT00879658|DRUG|BAF312|
219709353|NCT00879658|DRUG|Placebo|
219709354|NCT02727712|PROCEDURE|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4)program
219709355|NCT02727712|DEVICE|Transesophageal Echocardiography（TEE）|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management"
219709356|NCT02727712|DEVICE|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
219709357|NCT02727712|DRUG|Anesthesia drugs during the surgery|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
219709358|NCT02727712|PROCEDURE|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml\*2)program
219709359|NCT01794468|OTHER|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
219709360|NCT04529694|OTHER|Psychotherapy|
219709361|NCT03907215|DRUG|ACT541468|50 mg; film-coated tablet for oral use
219709362|NCT03907215|DRUG|ACT541468 placebo|film-coated tablet for oral use
219709363|NCT03907215|DRUG|Citalopram|20 mg; tablet tor oral use; for single- or repeated dosing
219125715|NCT03141164|OTHER|computerized training|Computerized training
219125716|NCT04609293|COMBINATION_PRODUCT|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
219125717|NCT05599360|DRUG|Vyxeos|Vyxeos (daunorubicin and cytarabine) liposome for injection
219125718|NCT05599360|DRUG|Mylotarg|Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
219125719|NCT00563277|PROCEDURE|combined pterygium and cataract operation|
219709364|NCT05255419|DEVICE|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
219709365|NCT00580840|DRUG|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
219709366|NCT00580840|DRUG|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
219709367|NCT00580840|OTHER|Placebo|placebo (saline) administered as two injections every 2 weeks
219709368|NCT02659904|OTHER|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
218986396|NCT06709183|OTHER|Intervention-Control|Nurses in this group will start the first oral care practice by using the oral care retractor on the model. Before starting the procedure, the nurses will fill in the 'Beck Mouth Assessment Guide' and after the procedure, they will fill in the 'Oral Care Practices Evaluation Form'. A rest period of at least 10 minutes will be provided before the second oral care application. Standard oral care will be applied during the second application. Similarly, nurses will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Assessment Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to collect nurses' experiences and opinions about the oral care procedure. During the interview, audio recordings will be made with the knowledge of the nurses.
219709369|NCT02659904|OTHER|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
219709370|NCT01955304|DRUG|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
219709371|NCT01258868|DRUG|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
219709372|NCT01258868|BIOLOGICAL|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
219709373|NCT01046942|DRUG|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
218986397|NCT06709183|OTHER|Control - intervention|In the first oral care procedure, nurses in this group will perform standard oral care on the model without using the oral care retractor. They will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. There will be a rest period of at least 10 minutes before the second oral care procedure. During this procedure, the second group of nurses who initially perform standard oral care will perform oral care using an oral care retractor. Similarly, they will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to obtain nurses' experiences and opinions regarding oral care practices..
219709374|NCT01046942|DRUG|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
219709375|NCT01551173|DRUG|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
218986398|NCT07048158|DIETARY_SUPPLEMENT|Perfect Heartio Drink|Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.
218986399|NCT07053592|BEHAVIORAL|Geriatric Ｂeauty and Ｈealth Care Learning Program|An educational course on geriatric care designed to enhance students' attitudes toward older adults and learning outcomes. The intervention includes lectures, group discussions, and interactive learning activities. Effectiveness is measured using pre- and post-course surveys and focus group interviews.
218986400|NCT07053488|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver|Donor liver tissue is perfused outside the body with a CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA, to create a hypoimmunogenic graft. After confirming successful gene knockout, the liver is transplanted into the patient following standard surgical techniques. Post-operative care includes routine immunosuppressive therapy with planned adjustments based on the patient's tolerance and evidence of graft immunogenicity.
218986401|NCT04006613|OTHER|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
218986402|NCT04006613|OTHER|Usual Care|Exercises aimed at improving mobility and balance
218986403|NCT03800914|OTHER|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
219709376|NCT00974454|DRUG|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
219709377|NCT00974454|DRUG|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
219709378|NCT01719276|OTHER|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
219709379|NCT01719276|OTHER|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
219709380|NCT02632942|PROCEDURE|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin."
219709381|NCT02632942|PROCEDURE|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
219709382|NCT05920239|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
218986404|NCT03800914|OTHER|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
218986405|NCT06919666|DRUG|NT219|NT219 is a first-in-class small molecule targeting IRS 1/2 and STAT3. Preclinical studies in melanoma have shown NT219 induces PD-L1 expression in vitro and in vivo, resulting in increased efficacy of PD-1 inhibition via synergistic antitumor effect in PD-1 sensitive models and restoration of sensitivity in resistant models. NT219 also synergized with cetuximab in vitro and reversed cetuximab resistance in a head and neck cancer xenograft platform.
218986406|NCT06913764|DEVICE|class I compression stockings of the RAL-GZ 387 standard: 1 month using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) above-knee graduated compression stockings
218986407|NCT06913764|DEVICE|class II compression stockings of the RAL-GZ 387 standard: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
219125720|NCT00563277|PROCEDURE|pterygium excision followed by cataract operation|
219125721|NCT02339727|DIETARY_SUPPLEMENT|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
219125722|NCT05395208|BEHAVIORAL|Therapeutic touch group accompanied by white noise|During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
219709383|NCT05920239|DIAGNOSTIC_TEST|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
219709384|NCT04317027|DEVICE|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
219709385|NCT02998112|DRUG|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
219709386|NCT02998112|DRUG|Saline|
219709387|NCT05237050|OTHER|Sound therapy associated with relaxation|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest."
219709388|NCT05237050|OTHER|Relaxation alone|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session)."
219709389|NCT04530344|DRUG|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
218986408|NCT06933017|DEVICE|Portable mask for respiratory gas analysis|This is a portable mask, which is connected to the SplendoHealth app. The Polar sens 10 heartrate monitor and TrainRed NIRS device are also connected to this app. The three devices (mask, heartrate monitor and NIRS) are measuring respiratory gases, heart rate and muscle tissue oxygenation simultanuously and at the end of the 6 min step test, you get an individual cardiorespiratory fitness report.
218986409|NCT06933017|DEVICE|Cardio-pulmonary exercise test|Golden standard for measuring PEM: the double cardio-pulmonary exercise test on a bike.
218986410|NCT06772532|DRUG|BI 456906 - Formulation A|Formulation A
218986411|NCT06772532|DRUG|BI 456906 - Formulation B|Formulation B
218986412|NCT06772532|DRUG|BI 456906 - Formulation C|Formulation C
218986413|NCT03740633|BEHAVIORAL|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
218986414|NCT03740633|BEHAVIORAL|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
218986415|NCT03740633|COMBINATION_PRODUCT|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
218986416|NCT02346552|DEVICE|AutoLap|
218986417|NCT06384690|DIETARY_SUPPLEMENT|Micro-vegetable blend|The intervention in this study is 6 weeks with a daily proprietary blend micro-vegetables that has been freeze-dried
218986418|NCT06384690|DIETARY_SUPPLEMENT|Placebo|The intervention in this study is 6 weeks with a placebo supplement
218986419|NCT06709573|DRUG|vasopressin - early initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min
218986420|NCT06709573|DRUG|vasopressin - standard initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min
218986421|NCT03128047|DEVICE|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.
218986422|NCT04805541|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
218986423|NCT04805541|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
218986424|NCT04805541|DEVICE|EyeCheckup - AI Based DR Screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
218986425|NCT02033616|BIOLOGICAL|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
219125723|NCT03882489|DRUG|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
219125724|NCT00550472|DIETARY_SUPPLEMENT|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
219125725|NCT04364945|DRUG|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
219125726|NCT04364945|DRUG|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
219125727|NCT04364945|DRUG|Sevoflurane|Anesthesia is maintained using sevoflurane.
219125728|NCT04356066|DIAGNOSTIC_TEST|serum cxcl10 by ELISA|serum sample
219125729|NCT03158948|DRUG|Nangibotide 0.3 mg/kg|Formulated LR12 peptide
219125730|NCT03158948|DRUG|Placebo|placebo
219125731|NCT03158948|DRUG|Nangibotide 1 mg/kg|Formulated LR12 peptide
219709390|NCT04530344|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219709391|NCT04616521|PROCEDURE|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
219709392|NCT05031221|BEHAVIORAL|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
219709393|NCT01402700|DEVICE|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
219709394|NCT05814835|DRUG|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
219125732|NCT03158948|DRUG|Nangibotide 3 mg/kg|Formulated LR12 peptide
219125733|NCT02391909|BIOLOGICAL|Vivotif|
219125734|NCT00288769|DRUG|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
219709395|NCT05814835|DRUG|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
219709396|NCT05814835|DRUG|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
219709397|NCT00936819|BIOLOGICAL|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
219709398|NCT00936819|BIOLOGICAL|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
219709399|NCT00936819|BIOLOGICAL|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
219125735|NCT02338037|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
219125736|NCT02338037|PROCEDURE|Biopsy|Undergo biopsy
219125737|NCT02338037|DRUG|Eribulin Mesylate|Given IV
219125738|NCT02338037|PROCEDURE|Microdialysis|Undergo intracerebral microdialysis
219125739|NCT02338037|OTHER|Pharmacological Study|Correlative studies
219125740|NCT05978661|DRUG|FKC288|Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
219125741|NCT02683824|DIAGNOSTIC_TEST|Computed Tomography|Undergo CT scan
219125742|NCT02683824|OTHER|Laboratory Biomarker Analysis|Correlative studies
219125743|NCT02683824|DIAGNOSTIC_TEST|PET/MRI scan|Undergo PET/MRI scan
219125744|NCT02683824|DRUG|[18F]FP-R01-MG-F2|radioactive tracer
219125745|NCT01876043|DRUG|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising."
219125746|NCT01730417|DRUG|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
219125747|NCT00713934|BIOLOGICAL|CD133|portal vein infusion of CD133+ cells
219125748|NCT00713934|BIOLOGICAL|BM-MNC|portal vein infusion of BM-MNC
219125749|NCT03573362|DEVICE|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
219125750|NCT03573362|DEVICE|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
219125751|NCT04965883|PROCEDURE|Excision and Grafting|reconstruction of deep burn by grafting
219125752|NCT04965883|PROCEDURE|dressing then delayed grafting|multiple dressing and delayed grafting
219125753|NCT00079937|DRUG|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
219125754|NCT00079937|DRUG|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
219125755|NCT00079937|DRUG|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
219125756|NCT02206685|DRUG|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
219125757|NCT02206685|DRUG|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
219709400|NCT03453216|BEHAVIORAL|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
219709401|NCT04442048|BIOLOGICAL|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
219709402|NCT04442048|OTHER|Observation|No active treatment. Observation only
219709403|NCT04638517|DRUG|Danazol|Danazol up to 800mg daily in two-divided doses.
219709404|NCT04638517|DRUG|Placebo|Matching placebo.
219709405|NCT05449002|BEHAVIORAL|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
219125758|NCT02813499|OTHER|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
219125759|NCT01616563|BEHAVIORAL|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
219125760|NCT01616563|BEHAVIORAL|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
219125761|NCT01195675|DRUG|BI 10773 (low)|single oral dose
219125762|NCT01195675|DRUG|Moxifloxacin|single oral dose
219709406|NCT05449002|OTHER|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
219709407|NCT05484804|OTHER|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
219709408|NCT05484804|OTHER|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
219709409|NCT05783323|DRUG|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
219709410|NCT05783323|RADIATION|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
219709411|NCT06008587|DEVICE|AIRVO3 TM|A device that provides high flows of heated and humidified respiratory gases to patient who breath spontaneously. Patients will be treated with the device up to 15 days or until the occurrence of respiratory acidosis defined by pH\<7.35, whichever come first.
219709412|NCT06008587|OTHER|Standard therapy|Standard therapy depends on the acute respiratory failure etiology. Treatments will be administered at the investigator's discretion in accordance with the standard of care.
219709413|NCT06304792|PROCEDURE|Immediate FET in a stimulated or programmed cycle|Patients will undergo FET in the cycle immediately following oocyte retrieval and a failed fresh embryo transfer or freeze all.
219709414|NCT03279952|DRUG|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
219709415|NCT06208878|OTHER|Non Interventional|Safety and Efficacy Assessment
219709416|NCT06582849|OTHER|Standard assistance|Standard assistance includes all community and institutional resources currently available for which the participant qualifies.
219709417|NCT06582849|OTHER|Enhanced assistance|Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
219709418|NCT03868540|DRUG|BI 1291583|tablet
219709419|NCT03868540|DRUG|Placebo|tablet
219125763|NCT01195675|DRUG|BI 10773 Placebo|2 times single dose
219125764|NCT01195675|DRUG|BI 10773 (high)|single oral dose
219125765|NCT03299387|DRUG|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
219125766|NCT03299387|DRUG|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
219125767|NCT05727956|PROCEDURE|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
219125768|NCT00072475|DRUG|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
219709420|NCT01883674|OTHER|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
219125769|NCT03093610|PROCEDURE|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
219125770|NCT03093610|PROCEDURE|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
219125771|NCT05916885|OTHER|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
219125772|NCT05916885|OTHER|conventional therapy alone|a control group receiving conventional therapy alone.
219125773|NCT00031343|DRUG|highly active antiretroviral therapy (HAART)|
219125774|NCT04559932|OTHER|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
219125775|NCT06052982|PROCEDURE|Drainage|At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result
219125776|NCT05153174|DRUG|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
219709421|NCT00808704|DRUG|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
219709422|NCT02080416|DRUG|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
219709423|NCT05148728|PROCEDURE|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
219709424|NCT06354608|BEHAVIORAL|Audio Book Group|Audiobook will be applied during the entire IM injection procedure and until the end of the procedure. After the procedure is over, the children will be taken to the waiting area. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior, and the same nurse who is independent from the study, will independently rate the child's pain and fear level during the procedure.
219709425|NCT06354608|DEVICE|Local Vibration Group|In the local vibration group, IM injection will be performed with a vibrating massage device. After the procedure is finished, the children will be taken to the waiting section. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior and the same nurse who is independent from the study will independently rate the pain and fear level of the child during the procedure.
219709426|NCT06550648|PROCEDURE|Right Heart Catheterization (Swan Ganz Catheter)|Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer
219709427|NCT00040638|DRUG|TLK286|
219709428|NCT00002470|BIOLOGICAL|recombinant interferon alfa|
219709429|NCT00002470|DRUG|fluorouracil|
219709430|NCT06434350|DRUG|Enfortumab Vedotin|Given by IV
219709431|NCT06434350|RADIATION|Radiation Therapy|Given by Radiation Therapy
219709432|NCT06378047|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that will be administered via IV infusion.
219709433|NCT06378047|DEVICE|Irreversible Electroporation|Participants will undergo IRE as standard of care treatment.
219709434|NCT06468137|BEHAVIORAL|Swedish I-ACE|Rehabilitative programme with focus on communication strategies and problem solving for people with hearing loss.
219709435|NCT06468137|BEHAVIORAL|Clinical visit|Visit in the clinic with focus on audiologic rehabilitation.
219709436|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
219709437|NCT05827835|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
219709438|NCT05827835|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
219709439|NCT05325034|BEHAVIORAL|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
219125777|NCT01450943|DEVICE|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
219125778|NCT01450943|PROCEDURE|debridement, irrigation|debridement, irrigation
219125779|NCT01450943|DEVICE|Dermagraft|Dermagraft per company protocol
219125780|NCT01450943|DEVICE|Oasis|Oasis per company protocol
219125781|NCT02689375|DEVICE|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
219125782|NCT01439425|BEHAVIORAL|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
219125783|NCT06376890|DIETARY_SUPPLEMENT|Red chili peppers|2.4 grams/day of powdered red chili pepper
219125784|NCT06376890|DIETARY_SUPPLEMENT|Green Chili Pepper|2.4 grams/day of powdered green chili peppers
219125785|NCT06376890|DIETARY_SUPPLEMENT|Placebo|2.4 grams of a metabolically equivalent placebo
219125786|NCT00618280|DRUG|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
219125787|NCT06249789|PROCEDURE|Spinal Anesthesia|Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
219125788|NCT06249789|PROCEDURE|General Anesthesia|Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
219125789|NCT05176353|OTHER|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
219125790|NCT06508346|BIOLOGICAL|anti-CD19-CAR-T cells|Intravenous injection
219125791|NCT06313684|OTHER|Comprehensive Initial Assessment|"Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.~* Functional capacity with 6MWT~* Assessment of skeletal muscle strength, flexibility, and balance.~* Assessment of function~* Assessment of dietary habits~* Assessment of self-efficacy and barriers to CR adherence.~* Screening for depression."
219125792|NCT06313684|OTHER|Continuous evaluation|Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.
219125793|NCT06313684|OTHER|Interval Exercise|"High-intensity interval training prescribed by physical therapist:~* According to an adapted Wisloff protocol.~* Borg scale to monitor intensity.~* Training 3 times per week."
219125794|NCT06313684|BEHAVIORAL|Psychosocial support|"Based on social-cognitive theory, with self-efficacy as a focus:~* Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.~* Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring~* Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program."
219125795|NCT06313684|OTHER|Diet management|A dietary plan supported by a nutritionist will be made together with the patient.
219125796|NCT06313684|OTHER|Resistance exercise|"Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week."
219125797|NCT06313684|OTHER|Continuous exercise|"Moderate-intensity continuous exercise prescribed by physical therapist :~* The intensity will be moderate, as tolerated~* Borg scale to monitor intensity.~* Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks."
219125798|NCT06313684|OTHER|Initial Assessment|"Includes all those necessary to plan exercise training, as usual:~* Functional capacity with 6MWT.~* Assessment of skeletal muscle strength."
219709440|NCT05019638|DRUG|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
219709441|NCT05019638|DRUG|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
219125799|NCT05121207|DEVICE|Terahertz scanning|Short scans using Terahertz device
219125800|NCT06321172|DEVICE|FES Bike|Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
219125801|NCT00652574|DRUG|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
219125802|NCT02213900|DRUG|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
219125803|NCT02213900|DRUG|Placebo|
219125804|NCT03442920|OTHER|Exercise|This group made exercise for 12 week/3 times a week.
219125805|NCT06051162|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
219125806|NCT03815916|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
219125807|NCT04454567|DRUG|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
219125808|NCT04454567|DRUG|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
219125809|NCT04454567|DRUG|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
219709442|NCT04862286|DRUG|Risankizumab|Subcutaneous (SC) injection.
219709443|NCT06366269|OTHER|Acupuncture|traditional and electroacupuncture
219709444|NCT06366269|BEHAVIORAL|Behavioral management|based on American urologic association guidelines
219709445|NCT06366269|OTHER|Physical therapy|pelvic floor with biofeedback
219709446|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
219709447|NCT05402761|BEHAVIORAL|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
219709448|NCT05402761|BEHAVIORAL|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
219709449|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
219709450|NCT06466187|DRUG|PF-08052666|Given into the vein (IV; intravenously)
219709451|NCT06242795|DRUG|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
219709452|NCT06275477|DIAGNOSTIC_TEST|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
219709453|NCT06505811|BEHAVIORAL|Guaranteed Income ($500/monthly)|Participants receive $500 monthly for up to 18 months.
219709454|NCT06505811|BEHAVIORAL|Active Comparison ($20/monthly)|Participants receive $20 monthly for up to 18 months.
219709455|NCT04467593|DEVICE|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
219709456|NCT04467593|DRUG|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
219125810|NCT02114008|OTHER|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
219125811|NCT01685580|DEVICE|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
219125812|NCT04282902|DRUG|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
219709457|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
219709458|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
219709459|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention|"Focus of the SEMC-protocol is on increasing PA gradually towards the national recommendations. Emphasis of counseling is on incidental exercise, endurance, and strength training. Techniques of motivational interviewing are utilized.~Baseline; MD+PT counseling, medical clearance, mapping lifestyle \& life situation, goal setting, measurements, questionnaires, feedback. weeks 1-6: guided group resistance training 1hr, 1x/week. 5-10-minute warm-up, 9 exercises with weight stack equipment on large muscle groups. 2-3 sets, 12-15 repetitions. Modified individually, e.g. according to musculoskeletal problems. Emphasis on learning the basics and safety aspects. After 6 weeks unsupervised training. 3-month: MD counseling and questionnaires. 6-month: MD+PT counseling, assessing safety of PA, measurements, questionnaires, feedback. 12-month: MD+PT counseling (feedback, ensuring continuity of lifestyle changes; redirecting to municipality/NGO activities), measurements, questionnaires, feedback"
219125813|NCT03197311|OTHER|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
219125814|NCT01600703|DRUG|Sitagliptin|Sitagliptin, 100mg, oral, single dose
219125815|NCT01600703|DRUG|Placebo|Placebo, oral, single dose
219125816|NCT04261920|DRUG|Huangqi Guizhi Wuwu decoction|"The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)."
219125817|NCT03450876|OTHER|Non-Interventional|Non-Interventional
219709460|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention combined with enhanced behavioral support -intervention (EBS)|"In addition to the SEMC-protocol, the participants will be contacted 3 times during the first 3 months (live / online as preferred). Themes:~Session 1: Motivation and illness perceptions. Exploring CPAP use, PA, and SB. Session 2: Self-regulation (feedback, goal setting, self-monitoring, action planning, problem solving), activating social support, prompts/cues, and preparatory behaviors. (Included BCTs from Michie et al 2013 taxonomy: 3.2, 12.2, 8.3,) Session 3: Assessing progress and agenda setting, self-regulation, maintenance of PA.~Measurements and questionnaires as with SEMC-protocol."
219709461|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
219709462|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
219709463|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
219709464|NCT06665217|DRUG|Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
219709465|NCT06350526|DIAGNOSTIC_TEST|Complete Blood Count|blood sample
219709466|NCT06350526|DIAGNOSTIC_TEST|C-reactive protein|serum sample
219709467|NCT06350526|DIAGNOSTIC_TEST|O2 saturation|blood sample
219709468|NCT06350526|DIAGNOSTIC_TEST|Serum ferritin and D-dimer|Blood sample
219709469|NCT06350526|DIAGNOSTIC_TEST|Liver and renal function tests|Blood sample
219709470|NCT06350526|DIAGNOSTIC_TEST|Lactate dehydrogenase|Blood sample
219709471|NCT06350526|DIAGNOSTIC_TEST|coronavirus (SARS-CoV-2) swab|Throat swab
219709472|NCT06350526|RADIATION|CT chest|Radiation
219709473|NCT00764517|DRUG|Cladribine|Given IV
219709474|NCT00764517|OTHER|Laboratory Biomarker Analysis|Correlative studies
219709475|NCT00764517|BIOLOGICAL|Rituximab|Given IV
219709476|NCT00764517|DRUG|Vorinostat|Given PO
219709477|NCT00520468|DRUG|Erythropoietin|40,000 units injected under the skin (SQ) weekly
219709478|NCT00520468|DRUG|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
219709479|NCT00520468|DRUG|G-CSF|300 mcg injected under the skin (SQ) two times per week
219709480|NCT00520468|DRUG|Prednisone|60 mg per day for 7 days, taper over 1 month
219709481|NCT02556450|DRUG|Spironolacton|Administration of Spironolacton 25 mg per day
219709482|NCT01890577|DRUG|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
219709483|NCT04159155|RADIATION|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
219709484|NCT04159155|DRUG|Niraparib|Oral drug
218986426|NCT02033616|BIOLOGICAL|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
218986427|NCT05038189|DIAGNOSTIC_TEST|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
218986428|NCT05038189|DIAGNOSTIC_TEST|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
218986429|NCT05038189|DIAGNOSTIC_TEST|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
218986430|NCT05812456|OTHER|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
218986431|NCT02364479|DRUG|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
218986432|NCT02364479|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
218986433|NCT02364479|DRUG|Placebo|The injection method and frequency of placebo is the same as the other arms.
219125818|NCT06323330|OTHER|Speech rehabilitation|Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
219709485|NCT04159155|RADIATION|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
219709486|NCT04159155|OTHER|Observation - no drugs|Observation
219709487|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
219709488|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
219125819|NCT04602962|PROCEDURE|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
219709489|NCT05229081|BEHAVIORAL|vaccine education|The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
219709490|NCT00469547|OTHER|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
219709491|NCT00469547|DRUG|Placebo|15% ethanol in emollient gel used as a topical male microbicide
219709492|NCT00469547|OTHER|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
219709493|NCT04433598|BEHAVIORAL|Nutrition Education Intervention|Each participant were interviewed by face- to- face using Arabic language, after 1 hour when they finish their assessment by medical doctors. The researcher was collected the data from the participants in a special room for 10-15 minutes, after only one hour of completing the necessary tests with the treating physician to allow participants to go for a meal before the nutrition education starts.12 classes (1:30 hour each session):- 100 participants / 5 days = 20 participants each class was offered twice per day to cover the number of participants and to enhance attendance for them can not attend at first morning. the classes was designed according to health belief model (HBM). The topics were about the type 2 diabetes and its complications,the benefits of diabetes plate and eating vegetables before carbohydrates.
219709494|NCT06844110|DRUG|68GA-DOTA-dPNE|Intravenous administration of 68GA-DOTA-dPNE tracer
219709495|NCT05360953|DRUG|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
219709496|NCT05360953|DRUG|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
219709497|NCT05360953|DRUG|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
219709498|NCT00621530|DRUG|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
219709499|NCT00621530|DRUG|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
219709500|NCT00811408|DRUG|carboplatin|
219709501|NCT00811408|DRUG|cidofovir|
219709502|NCT00811408|GENETIC|protein expression analysis|
219709503|NCT00811408|OTHER|laboratory biomarker analysis|
219709504|NCT00811408|RADIATION|brachytherapy|
219709505|NCT00811408|RADIATION|radiation therapy|
219709506|NCT06182085|DRUG|PRI-002|Oral administration
219709507|NCT06182085|DRUG|Placebo|Oral administration
219709508|NCT05941936|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
219709509|NCT00693264|DIETARY_SUPPLEMENT|Hoodia Gordonii|750 mg capsule will be taken one time
219709510|NCT00693264|DIETARY_SUPPLEMENT|Placebo|Placebo capsule to be taken one time
219709511|NCT03813654|BEHAVIORAL|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
219125820|NCT04294082|BEHAVIORAL|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises"
219709512|NCT03813654|BEHAVIORAL|8-h Free Sleep|8 consecutive hours time in bed at any time.
219709513|NCT04302285|OTHER|PKU type meal and Exercise|"* Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
219709514|NCT04302285|OTHER|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
219709515|NCT00748800|BEHAVIORAL|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
219709516|NCT00748800|BEHAVIORAL|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
219709517|NCT04607551|PROCEDURE|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
219709518|NCT04607551|PROCEDURE|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
219709519|NCT04398966|DEVICE|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
219709520|NCT02884648|DRUG|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
219709521|NCT04106037|OTHER|Data extraction from medical files|Data extraction from medical files
219709522|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
219125821|NCT05550974|DEVICE|Minimally Invasive Surgery|gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
219125822|NCT00224796|DEVICE|V.A.C. ® System|
219125823|NCT04925180|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
219125824|NCT05243992|OTHER|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
219125825|NCT01805856|DRUG|PIPC piperacillin sodium|
219709523|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
219709524|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
219709525|NCT00177411|DRUG|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
219709526|NCT01868568|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin).
219709527|NCT01868568|DRUG|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
219709528|NCT01868568|DRUG|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
219709529|NCT01868568|DRUG|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
219709530|NCT01868568|DRUG|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
219709531|NCT01868568|DRUG|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
219125826|NCT01805856|DRUG|CEZ, cefazolin sodium|
219709532|NCT01868568|DRUG|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
219709533|NCT01868568|DRUG|placebo|A single dose administered subcutaneously (s.c., under the skin).
219709534|NCT03353051|OTHER|Observational study|Observational study
219709535|NCT01208051|DRUG|Cediranib|Given PO
219709536|NCT01208051|DRUG|Cediranib Maleate|Given PO
219709537|NCT01208051|OTHER|Laboratory Biomarker Analysis|Correlative studies
219709538|NCT01208051|DRUG|Lenalidomide|Given PO
219709539|NCT06519331|DEVICE|Research FibroScan (FS)|"Patients #1 to #25:~Exam 1: Examination with Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #26 to #75:~Exam 1: Examination with the Research or Reference FibroScan. Exam 2: Examination with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #76 to #114:~Exams 1 \& 2: 2 consecutive examinations with the Research or Reference FibroScan.~Exams 3 \& 4: 2 consecutive examinations with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exams 1 \& 2."
219709540|NCT02033798|DRUG|Tamsulosin|Once Daily 0.2mg per oral for 6 months
219709541|NCT00255177|DRUG|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
219709542|NCT00255177|DRUG|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
219125827|NCT01779882|DRUG|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
219125828|NCT01779882|DRUG|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
219709543|NCT00973973|DRUG|Placebo|Matching placebo tablets taken orally once a day
219709544|NCT00973973|DRUG|Elagolix|Immediate release (IR) tablets taken orally once a day
219125829|NCT00182416|DEVICE|pacemaker|
219125830|NCT01175707|DRUG|Daptomycin|
219125831|NCT01175707|DRUG|Vancomycin|
219125832|NCT03320109|OTHER|Vitamin D|
219125833|NCT01497444|DRUG|hypoxia-activated prodrug TH-302|
219125834|NCT01497444|DRUG|sorafenib tosylate|
219125835|NCT00186680|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
219709545|NCT02984137|OTHER|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
219709546|NCT05775705|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
219709547|NCT06398938|RADIATION|Interventional Radiotherapy|The patients will undergo four IRT fractions in one week
219709548|NCT04197960|PROCEDURE|Microwave ablation|Use thermal energy to destroy tumor
219709549|NCT04197960|PROCEDURE|Surgical resection|Resect tumors
219709550|NCT00988338|BIOLOGICAL|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
219709551|NCT05985759|DRUG|N acetyle cystiene|N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
219709552|NCT03079830|DRUG|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
219709553|NCT03079830|DRUG|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
219709554|NCT01571791|DRUG|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
219709555|NCT01571791|DRUG|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
219125836|NCT05877404|OTHER|Surveys|Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
219125837|NCT02461238|OTHER|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
219125838|NCT02461238|OTHER|Nutrition education|Nutrition education workshops taught by a dietician
219125839|NCT01178515|OTHER|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
219125840|NCT01178515|OTHER|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
219125841|NCT01178515|OTHER|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
219125842|NCT05985291|COMBINATION_PRODUCT|SCS in combination with CMM|Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
219125843|NCT02142439|BEHAVIORAL|Strength training|Three times per week with strength training
219125844|NCT00003743|BIOLOGICAL|aldesleukin|
219125845|NCT03790397|DRUG|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
219125846|NCT03677726|BEHAVIORAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
219125847|NCT03677726|OTHER|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
219125848|NCT06469892|OTHER|Detect the expression level of miR-185 in salivary and plasma exosomes.|"Participants were instructed to refrain from eating, drinking, brushing their teeth, rinsing their mouth, or taking medications for one hour before saliva collection. They were then asked to bend over, lower their head, open their mouth, and allow saliva to flow naturally without chewing or spitting. Using a specialized container, 2 mL of unstimulated saliva was collected.~Participants fasted overnight before blood collection. Researchers used plasma tubes containing anticoagulant (EDTA) to obtain venous blood (4-5 mL) from the participants\&#39; upper arm. Subsequently, the blood was gently inverted to ensure optimal contact with the anticoagulant before centrifugation at 2000 rpm and 4°C for 10 minutes. Following centrifugation, the supernatant was extracted."
219709556|NCT03641365|DEVICE|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
219709557|NCT03641365|DEVICE|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
219125849|NCT02435901|DRUG|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
219709558|NCT00671060|DRUG|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
219709559|NCT00671060|DRUG|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
219125850|NCT02435901|DRUG|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
219125851|NCT02435901|DRUG|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
219125852|NCT02435901|DRUG|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
219125853|NCT02435901|DRUG|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
219125854|NCT02435901|DRUG|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
219125855|NCT02435901|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
219125856|NCT01598025|RADIATION|total-body irradiation (TBI)|
219125857|NCT01598025|DRUG|thiotepa|
219125858|NCT01598025|DRUG|fludarabine phosphate|
219125859|NCT01598025|DRUG|melphalan|
219125860|NCT01598025|BIOLOGICAL|anti-thymocyte globulin|
219125861|NCT01598025|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219125862|NCT01598025|BIOLOGICAL|peripheral blood stem cell transplantation|
219125863|NCT01598025|OTHER|laboratory biomarker analysis|
219125864|NCT05482386|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
219125865|NCT04582357|BEHAVIORAL|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
219125866|NCT01501630|DEVICE|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
219125867|NCT00629512|DRUG|Esomeprazole|20mg oral daily
219125868|NCT00629512|DRUG|Esomeprazole|40mg oral daily
219125869|NCT00629512|DRUG|Placebo|
219125870|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
219125871|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
219125872|NCT01408680|DIETARY_SUPPLEMENT|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
219125873|NCT00081809|DRUG|autologous human tumor-derived HSPPC-96|
219125874|NCT04286022|OTHER|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
219709560|NCT06290817|DRUG|Orelabrutinib combined with R-CDOP regimen|All participants were treated with the orelabrutinib combined with R-CHOP regimen (O-RCDOP). The treatment plan involved orelabrutinib tablets at 150mg QD (once daily) from day 1 to day 21, Rituximab at 375mg/m2 on day 1; Cyclophosphamide at 750mg/m2 on day 1; Liposomal Doxorubicin at 30mg/m2 on day 0; Vincristine at 25mg/m2 on day 1 (maximum dose 40mg); and Prednisone at 100mg from day 1 to day 5. The treatment cycles were set every 21 days for a total of 6-8 cycles. Dose adjustments were made for elderly patients for Cyclophosphamide and Liposomal Doxorubicin based on age: 70-80% of the dose for those aged 70-80 years old, and 50-60% of the dose for those older than 80 years.
219709561|NCT03277040|OTHER|CSA membership|Bi-weekly fresh food delivery
219709562|NCT02515786|OTHER|oxygen humidification|humidification for oxygen delivered by nasal catheter
219709563|NCT00120939|DRUG|Motexafin Gadolinium|
219709564|NCT01273961|DEVICE|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
219709565|NCT03695081|PROCEDURE|Patient Pathway Pharmacist intervention|"1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge"
219709566|NCT00455624|DRUG|Androgen deprivation therapy|According to standard medical care
219709567|NCT06057064|BIOLOGICAL|Biological: AZD3152|300 mg single dose of AZD3152 IM
219709568|NCT06057064|BIOLOGICAL|Biological: Placebo|Single dose of Placebo IM (0.9% sodium chloride)
219125875|NCT04286022|OTHER|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
219125876|NCT06489171|PROCEDURE|Received laparoscopic-assisted vaginal radical trachelectomy|"The LAVRT procedure began with laparoscopic pelvic lymphadenectomy, and all lymph nodes were removed for frozen pathological analysis. The laparoscopic-assisted vaginal radical trachelectomy procedure was continued only if the nodes were negative. The pararectal pouch was revealed, and the uterine arteries were divided from their origin to the internal iliac artery. The ureters were freed from the posterior leaf of the broad ligament down to the level where they entered the ureteral tunnel and then displaced laterally. The uterosacral ligaments, cardinal ligaments, and parametrial portions were then divided and dissected. The section of the procedure was performed laparoscopically. The vaginal epithelium was circumferentially incised approximately 3 cm distal to the endocervix. Frozen section analysis confirmed no cancer involvement at the endocervical or vaginal margin. The vaginal mucosa was sutured to the cervical stump to form a new cervical os."
219125877|NCT05939622|OTHER|Structural and functional MRI|MRI using a Siemens MAGNETOM Prisma 3T scanner before and after a course of therapy, using resting state fMRI and with cognitive paradigm.
219125878|NCT05939622|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration)
219125879|NCT05939622|DRUG|Placebo|Placebo was used in the same way
219125880|NCT01359098|DRUG|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
219125881|NCT01359098|DRUG|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
219709569|NCT01541748|OTHER|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
219709570|NCT01691664|RADIATION|Only radiation therapy|Patients only radiation therapy after surgery
219125882|NCT06263985|DEVICE|Axis Dermis biologic mesh repair for pelvic organ prolapse|Subjects with pelvic organ prolapse will undergo a pelvic organ prolapse repair with the use of Axis Dermis biologic mesh.
219125883|NCT06009380|OTHER|Physiotherapy and Rehabilitation|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
219125884|NCT01616290|DRUG|PRT-201|0.03, 1, or 3 mg single adventitial administration
219125885|NCT06335758|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
219125886|NCT00003377|DRUG|cisplatin|
219125887|NCT00003377|DRUG|paclitaxel|
219125888|NCT00003377|RADIATION|brachytherapy|
219125889|NCT00003377|RADIATION|radiation therapy|
219125890|NCT03928561|DEVICE|Active intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
219125891|NCT03928561|DEVICE|Placebo Intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
219709571|NCT01691664|OTHER|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
219709572|NCT00227916|BEHAVIORAL|Behavior Therapy|
219709573|NCT01821313|OTHER|Moderate exercise|
219125892|NCT04318964|BIOLOGICAL|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
219125893|NCT02759003|PROCEDURE|Nightime NIV initiation|In-hospital vs home
219225926|NCT04148885|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219709574|NCT01821313|OTHER|High Intensity Interval Exercise|
219709575|NCT05361759|DEVICE|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
219709576|NCT02020941|DRUG|carfilzomib|Given IV
219709577|NCT02020941|DRUG|dexamethasone|Given IV or PO
219709578|NCT02020941|OTHER|laboratory biomarker analysis|Correlative studies
219709579|NCT01016002|DRUG|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
219709580|NCT03483090|DIETARY_SUPPLEMENT|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
219709581|NCT03483090|OTHER|Placebo|No therapeutic effect
219709582|NCT04422132|RADIATION|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
219709583|NCT04422132|RADIATION|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
219709584|NCT06494956|PROCEDURE|Implant device|A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
219709585|NCT00436761|BIOLOGICAL|anti-thymocyte globulin|
219709586|NCT00436761|BIOLOGICAL|graft-versus-tumor induction therapy|
219709587|NCT00436761|BIOLOGICAL|sargramostim|
219225927|NCT04148885|DRUG|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
219709588|NCT00436761|DRUG|busulfan|
219709589|NCT00436761|DRUG|cyclosporine|
219709590|NCT00436761|DRUG|melphalan|
219709591|NCT00436761|DRUG|methylprednisolone|
219709592|NCT00436761|OTHER|flow cytometry|
219709593|NCT00436761|OTHER|immunologic technique|
219709594|NCT00436761|OTHER|laboratory biomarker analysis|
219709595|NCT00436761|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219709596|NCT00436761|PROCEDURE|umbilical cord blood transplantation|
219709597|NCT03572296|DIETARY_SUPPLEMENT|Placebo|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
219709598|NCT03572296|DIETARY_SUPPLEMENT|Polyphenol and fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
219709599|NCT03572296|DIETARY_SUPPLEMENT|Fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
219709600|NCT02832037|DRUG|BI 425809 dose 1|
219709601|NCT02832037|DRUG|BI 425809 dose 2|
219709602|NCT02832037|DRUG|BI 425809 dose 3|
219709603|NCT02832037|DRUG|BI 425809 dose 4|
219709604|NCT02832037|DRUG|Placebo|
219709605|NCT00131300|DEVICE|Synvisc (hylan G-F 20)|
219709606|NCT04127929|OTHER|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
219709607|NCT04127929|OTHER|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
219709608|NCT01820832|DRUG|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
219709609|NCT05604300|DIETARY_SUPPLEMENT|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
219709610|NCT05604300|DIETARY_SUPPLEMENT|Oat supplement|A twice daily supplementation of oat for 12 weeks
219709611|NCT05951686|DRUG|Desflurane|In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
219709612|NCT05951686|DRUG|Remifentanil infusion|Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
219709613|NCT05951686|OTHER|Fresh gas|Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
219709614|NCT05951686|DRUG|Propofol infusion|Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
219225928|NCT04027985|OTHER|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
219709615|NCT02476162|DEVICE|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
219709616|NCT00189514|DRUG|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
219709617|NCT00189514|DRUG|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
219709618|NCT04139135|DRUG|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
219709619|NCT04139135|DRUG|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
219709620|NCT03396562|OTHER|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
219709621|NCT04773795|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
219709622|NCT05564923|DRUG|there is no intervention|there is no intervention
219709623|NCT06486701|BEHAVIORAL|have a sing|Singing
219709624|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 7g|Xylitol 7g in 300mL tap water
219709625|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 10g|Erythritol 10g in 300mL tap water
219709626|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 17g|Xylitol 17g in 300mL tap water
219709627|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 35g|Xylitol 35g in 300mL tap water
219709628|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 25g|Erythritol 25g in 300mL tap water
218986434|NCT05191524|OTHER|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
218986435|NCT05191524|OTHER|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
218986436|NCT05055362|OTHER|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
218986437|NCT06089499|BEHAVIORAL|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
218986438|NCT03930680|DRUG|Dexrazoxane|One dose of dexrazoxane
218986439|NCT03783949|DRUG|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
218986440|NCT03783949|DRUG|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
218986441|NCT03783949|DRUG|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
218986442|NCT03783949|DRUG|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
218986443|NCT03783949|DRUG|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
218986444|NCT01428271|OTHER|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
218986445|NCT06260124|OTHER|Slow tempo|A single Greek traditional dance of slow tempo lasting 3-4 minutes.
218986446|NCT06260124|OTHER|Moderate tempo|A single Greek traditional dance of moderate tempo lasting 3-4 minutes.
218986447|NCT06260124|OTHER|Fast tempo|A single Greek traditional dance of fast tempo lasting 3-4 minutes.
218986448|NCT00997880|DRUG|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
219125894|NCT05646069|DEVICE|Storz Flex-XC1 Disposable Flexible Ureteroscope|Patients will receive flexible ureteroscopy with the Storz Flex-XC1 disposable flexible ureteroscope.
219125895|NCT05646069|DEVICE|Storz Flexible Digital Ureteroscope|Patients will receive flexible ureteroscopy with the Storz flexible Digital ureteroscope.
219125896|NCT03002987|BEHAVIORAL|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
219125897|NCT02949310|DRUG|Nefopam|
219125898|NCT02949310|DRUG|Normal Saline|
219709629|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 50g|Erythritol 50g in 300mL tap water
219709630|NCT02214472|BEHAVIORAL|Biofeedback|
219125899|NCT02856529|OTHER|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
219125900|NCT02856529|OTHER|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
219125901|NCT00098943|BIOLOGICAL|CNGRC peptide-TNF alpha conjugate|
219125902|NCT04880343|DIETARY_SUPPLEMENT|Group (A)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months
219125903|NCT04880343|DIETARY_SUPPLEMENT|Group (B)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months
219125904|NCT02256969|DRUG|Blephamide|
219709631|NCT02214472|DRUG|Placebo|
219709632|NCT06150547|DIAGNOSTIC_TEST|FDG Positron Emission Tomography|Imaging using an FDG radioactive tracer to look at the head.
219709633|NCT06150547|DIAGNOSTIC_TEST|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
219709634|NCT03931122|DEVICE|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
219709635|NCT01038765|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
219709636|NCT03864432|DRUG|Gemigliptin 25mg|Gemigliptin 50mg 1/2T
219709637|NCT03864432|DRUG|Gemigliptin 50mg|Gemigliptin 50mg 1T
219709638|NCT03864432|DRUG|Gemigliptin 100mg|Gemigliptin 50mg 2T
219709639|NCT03864432|DRUG|Gemiglptin 50mg multiple dose|Gemigliptin 50mg 1T \* 10days
219125905|NCT02256969|DRUG|GenTeal PM Night-Time|
219125906|NCT02256969|PROCEDURE|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
219125907|NCT02256969|PROCEDURE|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
219125908|NCT04516811|BIOLOGICAL|COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
219125909|NCT04516811|BIOLOGICAL|Standard of care (SOC) plus placebo|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
219125910|NCT05238779|OTHER|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
219125911|NCT02920944|DEVICE|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
219125912|NCT02920944|DEVICE|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
219125913|NCT04882462|DRUG|Nimotuzumab|Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
219125914|NCT04882462|DRUG|Sintilimab|Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
219125915|NCT04882462|DRUG|Chemotherapy drug|Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
219709640|NCT00552838|BEHAVIORAL|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
219709641|NCT00107588|BEHAVIORAL|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
219709642|NCT00107588|BEHAVIORAL|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
219709643|NCT00107588|BEHAVIORAL|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
219709644|NCT00855608|DRUG|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
219709645|NCT02107898|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
219709646|NCT02107898|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
219709647|NCT02107898|DRUG|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
218986449|NCT00997880|DRUG|Rosuvastatin calcium10mg|Rosuvastatin 10mg
218986450|NCT00478946|DRUG|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
218986451|NCT00478946|DRUG|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
218986452|NCT00478946|DRUG|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
218986453|NCT06324383|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
218986454|NCT01210131|DRUG|[18F]HX4|Intravenous injection
218986455|NCT04790773|OTHER|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
218986456|NCT02324257|DRUG|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
218986457|NCT02324257|DRUG|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
218986458|NCT02324257|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
218986459|NCT04267822|DRUG|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
218986460|NCT04267822|DRUG|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
218986461|NCT03967301|DIETARY_SUPPLEMENT|Probiotic|Intervention: defined as probiotic consumption
218986462|NCT03967301|DIETARY_SUPPLEMENT|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
218986463|NCT03681665|OTHER|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
218986464|NCT02027961|BIOLOGICAL|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
218986465|NCT02027961|DRUG|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
218986466|NCT02027961|DRUG|Trametinib|Oral dose of 2 mg trametinib tablet.
218986467|NCT06557044|DRUG|Ropivacaine|PENG block with ropivacaine
218986468|NCT06557044|OTHER|Physiological saline|Placebo control
218986469|NCT03265639|DIETARY_SUPPLEMENT|P-inulin|
218986470|NCT00767962|OTHER|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
218986471|NCT00767962|OTHER|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
218986472|NCT03556735|DEVICE|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
218986473|NCT01315665|DIETARY_SUPPLEMENT|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
218986474|NCT05490810|OTHER|Trunk stabilization|"Trunk stabilization exercises with~* Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~* Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~* Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~* Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~* SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
219125916|NCT00660166|BIOLOGICAL|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
219709648|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
219125917|NCT02396030|DRUG|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
219125918|NCT02396030|DRUG|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
219709649|NCT03868800|OTHER|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
219709650|NCT03329989|BIOLOGICAL|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
219709651|NCT02569983|OTHER|Observational cohort|No intervention - observational study
219709652|NCT06433726|DRUG|BY101921 tablets|An oral PARP7 Inhibitor
219709653|NCT02011399|PROCEDURE|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.~Arms: Brain Computer Interface Keyboard"
219709654|NCT00193986|DEVICE|Arbitrary Waveform Defibrillator|
219709655|NCT02708056|DRUG|Sugammadex|
219709656|NCT03344211|DRUG|Enzalutamide|Given PO
219709657|NCT03344211|OTHER|Laboratory Biomarker Analysis|Correlative studies
219709658|NCT03344211|RADIATION|Radium Ra 223 Dichloride|Given IV
219709659|NCT04272515|OTHER|blood sampling|collection of blood sample for preparation of DNA
219709660|NCT04272515|OTHER|skin biopsy sampling|preparation of primary cultures of dermal fibroblasts from skin biopsy sample
219125919|NCT02981134|PROCEDURE|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
219125920|NCT04599452|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15."
219709661|NCT04272515|OTHER|explanted liver of BA patients sampling|cryoconservation of liver tissue for molecular analyses
219709662|NCT00002818|DRUG|cytarabine|
219709663|NCT00002818|DRUG|deoxycytidine|
219709664|NCT01426126|DRUG|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
219709665|NCT03520530|DEVICE|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
219125921|NCT00301379|OTHER|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
219225929|NCT04027985|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
219709666|NCT03573856|BEHAVIORAL|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
219709667|NCT03573856|OTHER|Health and Safety|Participants will be provided with education related to general health and safety topics.
219709668|NCT00525304|BEHAVIORAL|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
219709669|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
219709670|NCT04358523|DRUG|ravidasvir and sofosbuvir|RDV 200 mg and SOF 400 mg
219709671|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
219125922|NCT02858934|RADIATION|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
219125923|NCT00402883|DRUG|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
219125924|NCT00402883|DRUG|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
219125925|NCT00402883|PROCEDURE|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
219125926|NCT00402883|OTHER|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
219125927|NCT00402883|OTHER|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
219125928|NCT00402883|DRUG|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
219125929|NCT03566680|DEVICE|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
219125930|NCT00824785|DRUG|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
219709672|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
219709673|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
219709674|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
219709675|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
219125931|NCT00824785|DRUG|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
219125932|NCT06396845|PROCEDURE|robotic surgery|robotic surgery
219125933|NCT06396845|PROCEDURE|laparoscopic surgery|laparoscopic surgery
219125934|NCT00336921|DRUG|Alfuzosin|Once daily
219125935|NCT00336921|DRUG|Placebo|Once daily
219709676|NCT05135533|DEVICE|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
219709677|NCT05135533|DEVICE|Sham|The Sham group will not receive electrical stimulation.
219709678|NCT05135533|OTHER|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
219709679|NCT06063928|PROCEDURE|Archive Sample Retrieval|Undergo collection of archival tumor tissue
219709680|NCT06063928|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
219709681|NCT06063928|OTHER|Electronic Health Record Review|Medical records reviewed
219709682|NCT06063928|OTHER|Genetic Testing|Undergo genetic testing
219709683|NCT06063928|OTHER|Questionnaire Administration|Complete questionnaires
219125936|NCT06204185|DRUG|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
219125937|NCT06204185|DRUG|Placebo|Placebo gel consist of drug without the active component.
219125938|NCT00451698|DRUG|acyanotic erythropoietin|Single dose IV push
219125939|NCT00451698|DRUG|acyanotic placebo|Single dose IV push
219125940|NCT02862054|PROCEDURE|splenectomy|
219125941|NCT01209676|DRUG|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
219125942|NCT05401916|DRUG|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
219125943|NCT05401916|DRUG|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
219225930|NCT04027985|OTHER|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
219125944|NCT05401916|DRUG|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
219125945|NCT06132321|BEHAVIORAL|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
219125946|NCT04437108|PROCEDURE|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
219125947|NCT04437108|PROCEDURE|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
219125948|NCT04437108|PROCEDURE|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
219709684|NCT03662568|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
219709685|NCT03662568|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
219709686|NCT03662568|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
219709687|NCT03662568|DRUG|TDF|Administered TDF 300 mg orally once daily in fasted state
219709688|NCT01283386|DRUG|Chlorambucil|10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
219125949|NCT04437108|PROCEDURE|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
219125950|NCT04437108|DRUG|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
219125951|NCT03458897|DIAGNOSTIC_TEST|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
219709689|NCT01283386|DRUG|Cyclophosphamide|150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
219709690|NCT01283386|DRUG|Fludarabine|20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
219709691|NCT01283386|DRUG|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
219709692|NCT03901300|BEHAVIORAL|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
219125952|NCT02374957|DRUG|Cilostazol|100 mg twice daily for 90 days
219125953|NCT01495195|DRUG|High-dose donepezil|Donepezil titrated to 22.5 mg daily
219125954|NCT01495195|DRUG|Low-dose donepezil|Donepezil titrated to 10 mg daily
219125955|NCT01495195|DRUG|Selegiline|Transdermal selegiline, 6 mg daily
219709693|NCT03901300|BEHAVIORAL|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
219709694|NCT06361108|DRUG|YJ001 for Spray Use|Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
219709695|NCT06361108|DRUG|Placebo of YJ001 for Spray Use|Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
219709696|NCT02689778|DRUG|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
219125956|NCT01495195|DRUG|Placebo|microcrystalline cellulose
219125957|NCT01687270|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
219125958|NCT01687270|DRUG|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
219125959|NCT05094115|BEHAVIORAL|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~* An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~* Questions from the attendees about applying the concepts in their lives.~* Comments and questions from the booster session facilitators to encourage application of the concepts."
219125960|NCT05349084|DIAGNOSTIC_TEST|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
219125961|NCT03307746|DRUG|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
219125962|NCT03500705|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.
219225931|NCT02630186|DRUG|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
219709697|NCT02689778|DRUG|Placebo|Identical tablets without active substance
219225932|NCT02630186|DRUG|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
219709698|NCT02078167|OTHER|nutraceutical combination (red yeast rice, policosanols and berberine)|
219709699|NCT03436719|DRUG|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
219709700|NCT03436719|DRUG|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
219709701|NCT03436719|DRUG|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
219709702|NCT05994807|DRUG|DC-806|Oral tablets
219709703|NCT05994807|DRUG|Itraconazole|Oral capsules
219125963|NCT03500705|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
219125964|NCT05072990|DRUG|Chinese herb medicine|Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
219125965|NCT02810561|OTHER|No Intervention|No intervention was completed with this study.
219125966|NCT00657774|DRUG|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
219125967|NCT00657774|DRUG|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
219125968|NCT00657774|DRUG|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
219125969|NCT00657774|DRUG|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
219125970|NCT02150044|DEVICE|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
219125971|NCT01581853|DRUG|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
219125972|NCT01223859|PROCEDURE|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
219125973|NCT06294951|DIAGNOSTIC_TEST|fMRI|The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
219125974|NCT02847585|DIETARY_SUPPLEMENT|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
219709704|NCT05994807|DRUG|Carbamazepine|Oral tablets
219709705|NCT03853928|DIETARY_SUPPLEMENT|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
219125975|NCT02846818|PROCEDURE|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
219709706|NCT03339362|PROCEDURE|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
219709707|NCT03339362|PROCEDURE|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
219125976|NCT04166461|OTHER|Not application, observational study|Not application, observational study
219125977|NCT00821236|DEVICE|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
219125978|NCT00821236|DEVICE|AMO/VISX CustomVue™|Excimer Laser
219125979|NCT00821236|DEVICE|LADARVision 4000 excimer laser|Excimer Laser
219125980|NCT05649579|DRUG|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
219709708|NCT05884450|OTHER|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
219125981|NCT03599115|BEHAVIORAL|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
219125982|NCT04415840|DIAGNOSTIC_TEST|acetic acid test|using acetic acid to unmask dysplastic lesions on the cervix uteri
219709709|NCT01531153|DRUG|Galantamine|8mg or 16mg
219709710|NCT01531153|DRUG|Placebo|Placebo dose.
219709711|NCT00494117|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
219125983|NCT04415840|DIAGNOSTIC_TEST|Lugol's solution test|using Lugol's solution after acetic acid test to unmask dysplastic lesions on the cervix uteri
219125984|NCT06340243|RADIATION|radiotherapy|radiotherapy
219125985|NCT06180798|PROCEDURE|cold snare endoscopic mucosal resection (C-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation."
219125986|NCT06180798|PROCEDURE|Hot snare endoscopic mucosal resection (H-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps."
219125987|NCT02467153|OTHER|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
219125988|NCT02467153|DIETARY_SUPPLEMENT|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
219125989|NCT02467153|DIETARY_SUPPLEMENT|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
219125990|NCT04990882|OTHER|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
219125991|NCT01051778|DRUG|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
219709712|NCT00435643|PROCEDURE|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
219709713|NCT02695459|DRUG|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
219709714|NCT05766748|DRUG|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
219709715|NCT02189824|BIOLOGICAL|Partially HLA-matched unrelated donor cells|
219709716|NCT03406676|DRUG|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
219125992|NCT01051778|DRUG|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
219125993|NCT01605136|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
219125994|NCT01605136|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months
219125995|NCT01072929|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
219125996|NCT01072929|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
219125997|NCT01366196|DRUG|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
219709717|NCT02908230|BEHAVIORAL|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
219709718|NCT02908230|BEHAVIORAL|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
219709719|NCT02908230|BEHAVIORAL|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
219709720|NCT00463424|DEVICE|NeuFlex metacarpophalangeal implant|
219709721|NCT00463424|DEVICE|Swanson metacarpophalangeal implant|
219709722|NCT01161888|DRUG|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
219709723|NCT06627803|DRUG|Alcohol (Oral)|Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
219125998|NCT01366196|DRUG|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
219125999|NCT06053593|DEVICE|Testing of self collected urine|Each PWD will test their self-collected urine.
219126000|NCT06053593|DEVICE|Labeling Evaluation|Each PWD will complete a labeling evaluation.
219126001|NCT06053593|DEVICE|Urine Control testing|Each PWD will test four urine control solutions.
219126002|NCT04308447|DEVICE|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
219126003|NCT00052962|PROCEDURE|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
219126004|NCT00052962|PROCEDURE|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
219126005|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
219126006|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
219126007|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
219126008|NCT02240875|BIOLOGICAL|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
219126009|NCT02240875|BIOLOGICAL|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
219126010|NCT02240875|BIOLOGICAL|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
219709724|NCT01618591|DRUG|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
219709725|NCT01618591|DRUG|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
219709726|NCT01618591|DRUG|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
219126011|NCT05227313|DIETARY_SUPPLEMENT|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
219126012|NCT05227313|DIETARY_SUPPLEMENT|Placebo oral solution|oral solution matched placebo
219709727|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
219709728|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
219225933|NCT03730688|DEVICE|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
219225934|NCT03730688|DEVICE|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
219225935|NCT03492853|GENETIC|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
219709729|NCT05428865|OTHER|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
219126013|NCT00550108|OTHER|Ethanol lavage|Ethanol lavage of pancreatic cysts.
219126014|NCT04971694|OTHER|No interventions or procedures|This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
219126015|NCT02453724|DEVICE|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
219126016|NCT03213470|OTHER|magnetic resonance imaging|
219126017|NCT02374333|BIOLOGICAL|huCART19|
219126018|NCT06228703|DEVICE|High-flow nasal cannula device with flow setting at 40 L/min or higher|Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
219709730|NCT03988660|DIAGNOSTIC_TEST|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
219709731|NCT02022930|DEVICE|Hydros|
219709732|NCT02022930|DEVICE|Hydros-TA|
219709733|NCT02022930|DRUG|Triamcinolone Acetonide|
219709734|NCT00360204|BEHAVIORAL|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
219126019|NCT05113927|DEVICE|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
219126020|NCT05380739|BEHAVIORAL|Working Memory Training|A 10-session working memory (WM) training program
219126021|NCT01101906|DRUG|OSI-906|OSI-906 administered orally
219126022|NCT01101906|DRUG|Placebo|Matching placebo administered orally
219126023|NCT05935267|PROCEDURE|thoracic irrigation|We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
219126024|NCT06431022|BEHAVIORAL|webSTAIR|WebSTAIR is a self-paced, brief skills-focused treatment for PTSD that focused on improving one's ability to manage emotions and relationships.
219126025|NCT06431022|BEHAVIORAL|CHW coaching|CHWs will provide webSTAIR coaching, which includes motivational, problem solving, and cognitive-behavioral strategies to enhance skills practice and engagement.
219126026|NCT01688102|DIETARY_SUPPLEMENT|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
219126027|NCT01688102|RADIATION|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
219126028|NCT06570785|DEVICE|Intra-Operative Positioning System (IOPS)|This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
219126029|NCT06570785|DEVICE|Conventional group|This group will be treated using standardised materials (wires, catheters) during EVAR.
219126030|NCT01723774|DRUG|PD0332991|
219126031|NCT01723774|DRUG|Anastrozole|
219126032|NCT01723774|DRUG|Goserelin|
219709735|NCT03479151|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
219709736|NCT02595710|OTHER|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
219126033|NCT01723774|PROCEDURE|Surgery (standard of care)|-Breast and axillary lymph node surgery
219709737|NCT02595710|OTHER|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
219709738|NCT02595710|OTHER|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
219126034|NCT01723774|PROCEDURE|Tumor biopsy|
219126035|NCT00739453|DRUG|OSI-906|administered orally
219126036|NCT00739453|DRUG|erlotinib|administered orally
219126037|NCT03663712|BIOLOGICAL|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
219126038|NCT05768555|OTHER|Whole body vibration intervention at 40 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
219126039|NCT05768555|OTHER|Whole body vibration intervention at 25 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
219126040|NCT05768555|OTHER|Whole body vibration intervention at 0 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
219126041|NCT05842343|OTHER|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
219126042|NCT05842343|OTHER|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
219709739|NCT03934801|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
219126043|NCT05914324|DEVICE|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
219126044|NCT05914324|DEVICE|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
219126045|NCT00202397|DRUG|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
219126046|NCT00202397|OTHER|placebo|capsule-shaped tablet bid for 8 weeks
219126047|NCT05211531|OTHER|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
219126048|NCT01016353|DEVICE|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
219126049|NCT01016353|DEVICE|BVPT|Barker's Vacuum Packing Technique
219709740|NCT03934801|OTHER|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219126050|NCT05018273|BIOLOGICAL|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
219126051|NCT02518932|DRUG|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
219126052|NCT02518932|DRUG|placebo saline|
219126053|NCT01839825|DEVICE|QuietCare|
219126054|NCT06010485|OTHER|Serial Casting|A short leg cast is applied to the serial casting group by an orthopedic specialist once every three days for three weeks.
219126055|NCT06010485|OTHER|Exercise|Stretching exercises, strengthening exercises, balance exercises, proprioception exercises, and heel walking exercises are applied to the physical therapy group for 3 weeks with a physiotherapist for 3 sessions a week.
219126056|NCT06330831|OTHER|Intensive, Group Based Constraint Induced Therapy (CIMT)|See arm description. Children who were in study 2 received two consecutive episodes of the intensive, group based CIMT intervention (episode 1 during the first summer, episode 2 during the following summer).
219126057|NCT02487446|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
219126058|NCT02487446|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
219126059|NCT02487446|DRUG|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
219126060|NCT02487446|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
219126061|NCT02509403|DRUG|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
219126062|NCT01822821|DRUG|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
219126063|NCT01822821|DRUG|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
219709741|NCT03934801|OTHER|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219709742|NCT03934801|OTHER|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
219709743|NCT06571045|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
219709744|NCT06571045|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
219126064|NCT05780047|DIAGNOSTIC_TEST|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
219126065|NCT05221398|DRUG|Immune Checkpoint Inhibitors Based Adjuvant therapy|Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
219126066|NCT05221398|OTHER|Active surveillance|Patients in this group only receive active surveillance
219126067|NCT02907697|BEHAVIORAL|Life Steps-Drug Use|
219126068|NCT02907697|BEHAVIORAL|General Health Education|
219126069|NCT05039424|PROCEDURE|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
219126070|NCT05039424|PROCEDURE|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
219709745|NCT05787223|OTHER|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
219709746|NCT05787223|OTHER|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side \&tandem walking, step up and down, jumping \&hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
219709747|NCT03517137|DRUG|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
219709748|NCT03517137|DRUG|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
219709749|NCT03517137|DRUG|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
219709750|NCT03517137|DRUG|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
219709751|NCT03517137|DRUG|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
219709752|NCT03517137|DRUG|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
219709753|NCT03517137|RADIATION|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
219709754|NCT04836936|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
219709755|NCT04836936|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
219709756|NCT05653271|DRUG|Cyclophosphamide|Lymphodepleting agent
219709757|NCT05653271|DRUG|Fludarabine|Lymphodepleting agent
219126071|NCT04568096|COMBINATION_PRODUCT|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
219126072|NCT04568096|OTHER|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219126073|NCT04473859|DRUG|FSR Peptide 20μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
219126074|NCT04473859|DRUG|FSR Peptide 50μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
219126075|NCT04473859|DRUG|FSR Peptide 100μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
219126076|NCT04473859|DRUG|FSR Peptide 200μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
219126077|NCT04473859|DRUG|Placebo|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
219126078|NCT06214806|BEHAVIORAL|Grocery Vouchers|Participants will be given vouchers to buy groceries each month for five months.
219126079|NCT04838093|DIAGNOSTIC_TEST|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
219126080|NCT01659138|DRUG|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
219126081|NCT01659138|OTHER|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219126082|NCT05617235|DEVICE|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
219709758|NCT05653271|DRUG|ACE1831|Allogeneic gamma delta T (gdT) cell therapy
219709759|NCT05653271|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
219709760|NCT05681819|DRUG|SHR-1707|Multiple-ascending Dose
219709761|NCT05681819|DRUG|SHR-1707 placebo|Multiple-ascending Dose
219709762|NCT05983952|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
219126083|NCT03557255|DRUG|Levosimendan|Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.
219126084|NCT03557255|DRUG|Saline|Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
219126085|NCT00308061|BIOLOGICAL|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
219126086|NCT00308061|BIOLOGICAL|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, \<150g of neomycin sulfate, and \>2.5 IU of rabies antigen.
219126087|NCT02963597|DEVICE|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
219126088|NCT02963597|OTHER|Standard Medical Therapy|Standard medical therapy according to current guidelines.
219126089|NCT05040243|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
219126090|NCT05040243|OTHER|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
219126091|NCT05470660|PROCEDURE|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.
219709763|NCT01582451|DRUG|LY2605541|
219709764|NCT01582451|DRUG|Insulin glargine|
219709765|NCT03658525|DEVICE|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
219709766|NCT06193382|BEHAVIORAL|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
219126092|NCT05470660|PROCEDURE|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
219126093|NCT00595283|BEHAVIORAL|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
219126094|NCT00595283|BEHAVIORAL|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
219126095|NCT03810885|OTHER|Bread with reduced salt content|Bread with gradually lowered salt content
219126096|NCT03810885|BEHAVIORAL|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
219126097|NCT03810885|OTHER|Bread with standard salt content|Bread with normal salt content
219225936|NCT01263132|DRUG|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
219709767|NCT03318341|DEVICE|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
219709768|NCT03318341|DEVICE|Sham Stimulation|The device applies no vibration.
219709769|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
219709770|NCT05472974|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of pressure injury, without pressure injury, up during the day, will ly a on a specific P-APAM (DOMUS 4 /AUTO)
219126098|NCT05612529|DEVICE|US , Echocardiography|"* Carotid ultrasonography: Parameters will be measured by single blinded independent examiner using an ultrasound device. Baseline carotid FTc, ΔVpeak, will be measured.~* Echocardiography: Stroke Volume will be measured by transthoracic echocardiography.~* Renal and splenic Doppler resistivity index.~* Inferior vena cava collapsibility and distensibility indices.~* Central venous pressure estimation by central venous catheter, and central - Lung ultrasound for detection of lung congestion~* Lung ultrasound for detection of lung congestion."
219126099|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with air|After endotracheal intubation, the endotracheal tube cuff is inflated with air
219126100|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with saline|After endotracheal intubation, the endotracheal tube cuff is inflated with saline
219126101|NCT05136742|OTHER|aerobic exercise and diet program|It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
219126102|NCT05136742|OTHER|diet program|balanced restricted diet
219126103|NCT05981456|OTHER|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
219126104|NCT05981456|OTHER|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
219126105|NCT00771628|DEVICE|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
219126106|NCT00771628|DEVICE|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
219126107|NCT04438785|DEVICE|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
219126108|NCT04011033|BIOLOGICAL|iNKT cells|5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
219126109|NCT04011033|DRUG|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
219126110|NCT04011033|PROCEDURE|TAE/TACE|TAE/TACE will be conducted to all patients at 0th week and 4th week.
219126111|NCT06065774|PROCEDURE|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
219126112|NCT06065774|DRUG|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
219225937|NCT01263132|DRUG|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
219225938|NCT02353507|DEVICE|Opticell Ag+|
219225939|NCT02353507|DEVICE|Aquacel Ag+|
219225940|NCT02027584|OTHER|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
219709771|NCT04885608|OTHER|PReGe|There will be two weekly sessions of 45 minutes, outdoors in outdoor fitness parks. The components of balance, gait, resistance, strength and elasticity will be worked on and breathing exercises will be performed. The sessions will be guided and dosed by physiotherapists, considering the level of perception of effort. Indications will be given to carry out other sessions of 60 to 120 minutes of therapeutic walking (minimum speed of 4 km/hour) during the week, to complete the 150-300 minutes per week of physical activity recommended by the WHO.
219709772|NCT04210518|OTHER|Neuromuscular training|This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
219709773|NCT04210518|OTHER|Stroboscopic glasses|Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
219709774|NCT00717886|RADIATION|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
219709775|NCT00540917|PROCEDURE|cooling spray during laser treatment|skin temperature measurement
219709776|NCT06210685|DEVICE|Automatic Continuous Effusion Shunt implantation|The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
219126113|NCT06065774|PROCEDURE|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
219126114|NCT06065774|DRUG|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
219126115|NCT02027935|BIOLOGICAL|Aldesleukin|Given SC
219126116|NCT02027935|BIOLOGICAL|Autologous CD8+ Melanoma Specific T Cells|Given IV
219126117|NCT02027935|DRUG|Cyclophosphamide|Given IV
219126118|NCT02027935|BIOLOGICAL|Ipilimumab|Given IV
219126119|NCT02027935|OTHER|Laboratory Biomarker Analysis|Correlative studies
219126120|NCT00689104|DRUG|Mirabegron|Tablets
219126121|NCT00689104|DRUG|Tolterodine|Capsules
219709777|NCT03479827|DEVICE|Monofocal Contact Lens|A monofocal contact lens will be used for this measurement.
219709778|NCT03479827|DEVICE|Bifocal Contact Lens|A bifocal contact lens will be used for this measurement.
219709779|NCT01807455|DEVICE|Restylane Vital Lidocaine|
219126122|NCT00689104|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
219126123|NCT00689104|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
219126124|NCT04692714|DEVICE|Knee prosthesis implementation with additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot with additional cement.
219126125|NCT04692714|DEVICE|Knee prosthesis implementation without additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot without additional cement.
219126126|NCT06203262|DEVICE|FieldForce™ Ablation System Ventricular Tachycardia|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
219225941|NCT04094207|DRUG|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
219709780|NCT00487188|DRUG|Enfuvirtide|90 mg subcutaneous injection twice a day
219709781|NCT00487188|DRUG|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
219709782|NCT04098835|BEHAVIORAL|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
219709783|NCT02759640|DRUG|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
219709784|NCT04718701|DRUG|Anlotinib+Toripalimab+Nab-paclitaxel|Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
219709785|NCT04818801|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
219709786|NCT04818801|OTHER|Placebo|Normal saline (0.9% sodium chloride solution),
219709787|NCT00484510|DRUG|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
219709788|NCT00484510|DRUG|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
219126127|NCT06203262|DEVICE|FieldForce™ Ablation System Premature Ventricular Contractions|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
219126128|NCT06226870|PROCEDURE|root canal tretment|traditional therapy
219126129|NCT06226870|PROCEDURE|biodentin VPT|Alternative therapy
219126130|NCT06226870|PROCEDURE|PRF|Alternative therapy
219126131|NCT05047094|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219126132|NCT05047094|DRUG|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
219709789|NCT00000935|BIOLOGICAL|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
219709790|NCT02412943|OTHER|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
219709791|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
219709792|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
219709793|NCT04426032|DIAGNOSTIC_TEST|Renal Doppler Ultrasound|Measurement of Renal resistive index
219126133|NCT06252662|DRUG|Dexmedetomidine|block duration extension additive
219126134|NCT06252662|DRUG|Liposomal bupivacaine|Control arm, comparison for block duration with dexmedetomidine
219126135|NCT04873817|DEVICE|IonicRF Generator and compatible accessories|Participants will receive IonicRF lesion generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator
219126136|NCT01925781|DRUG|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
219126137|NCT01925781|OTHER|STAM 1100mAh CE4 eGo Clearomizer|
219126138|NCT01579019|DRUG|RO5024048|1500 mg po bid, 24 or 26 weeks
219126139|NCT01579019|DRUG|RO5024048|1000 mg po bid, 24 or 26 weeks
219126140|NCT01579019|DRUG|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
219126141|NCT01579019|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
219126142|NCT01579019|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
219126143|NCT01579019|DRUG|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
219126144|NCT03606096|BIOLOGICAL|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
219126145|NCT03606096|BIOLOGICAL|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
219126146|NCT03606096|BIOLOGICAL|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
219709794|NCT01932606|DRUG|Nitrite|Study drug (NaNO\_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
219709795|NCT01932606|DRUG|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
219709796|NCT02598115|OTHER|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
219709797|NCT04315324|DRUG|AKR1C3-activated Prodrug AST-3424|Given IV
219709798|NCT04315324|PROCEDURE|Biopsy Procedure|Undergo biopsy
219126147|NCT03606096|BIOLOGICAL|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
219126148|NCT01667315|DRUG|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
219126149|NCT03282175|OTHER|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
219126150|NCT03282175|OTHER|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
219709799|NCT04315324|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219709800|NCT04315324|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
219709801|NCT04315324|PROCEDURE|Computed Tomography|Undergo CT scan
219126151|NCT03282175|OTHER|Control group|The control group did not receive any treatment.
219126152|NCT03789643|DRUG|JTT-251|Active drug tablets containing JTT-251
219126153|NCT03789643|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
219126154|NCT00591357|DRUG|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
219126155|NCT00591357|DRUG|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
219126156|NCT04447781|BIOLOGICAL|INO-4800|\- Manufacturer: Inovio Pharmaceuticals Inc.
219126157|NCT04447781|DEVICE|CELLECTRA® 2000|\- Manufacturer: Inovio Pharmaceuticals Inc.
219126158|NCT04447781|OTHER|Saline-sodium citrate (SSC) buffer|\- Manufacturer: Inovio Pharmaceuticals Inc.
219126159|NCT00530192|OTHER|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
219126160|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
219126161|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
219126162|NCT03607903|BIOLOGICAL|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
219126163|NCT03607903|BIOLOGICAL|Adalimumab SC|Adalimumab subcutaneous using regular needle
219709802|NCT03881371|DRUG|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
219709803|NCT03881371|OTHER|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
219126164|NCT03607903|OTHER|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
219126165|NCT03607903|OTHER|Saline SC|Saline subcutaneous using regular needle
219126166|NCT02250495|DEVICE|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
219126167|NCT00415974|BEHAVIORAL|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
219709804|NCT06115122|OTHER|Pre-eclampsia screening program|Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
219709805|NCT05565807|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
219126168|NCT00415974|BEHAVIORAL|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
219126169|NCT00415974|BEHAVIORAL|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
219225942|NCT04094207|DRUG|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
219225943|NCT05087407|PROCEDURE|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
219225944|NCT05087407|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
219126170|NCT00415974|BEHAVIORAL|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
219126171|NCT02403531|DRUG|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
219709806|NCT02508389|DRUG|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219709807|NCT02508389|DRUG|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219126172|NCT02403531|DRUG|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
219126173|NCT02403531|RADIATION|Radiotherapy|definitive radiotherapy
219126174|NCT05419674|DRUG|Vonoprazan|Potassium-competitive acid blocker
219126175|NCT05419674|DRUG|Rabeprazole|Proton pump inhibitor
219126176|NCT05419674|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219126177|NCT05419674|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
219126178|NCT05419674|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
219126179|NCT02846662|BEHAVIORAL|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
219126180|NCT00019890|DRUG|dendritic cell-gp100-MART-1 antigen vaccine|
219126181|NCT00019890|DRUG|sargramostim|
219126182|NCT04355676|DRUG|Selinexor|20 mg selinexor oral tablet.
219709808|NCT02508389|DRUG|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219126183|NCT02355704|DRUG|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
219225945|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
219709809|NCT02508389|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
219126184|NCT02355704|DRUG|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
219126185|NCT04774185|DEVICE|New hearing aid loudspeaker|The new hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
219126186|NCT04774185|DEVICE|Standard hearing aid loudspeaker|The standard hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
219126187|NCT04884984|BIOLOGICAL|anti-CLL1 CART|Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
219126188|NCT00158080|PROCEDURE|hemofiltration|
219126189|NCT02006043|DRUG|Erlotinib 150mg|
219225946|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
219225947|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
219709810|NCT02508389|DRUG|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
219709811|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
219709812|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
219709813|NCT00080418|DRUG|Liposome Entrapped Paclitaxel Easy to Use|
219709814|NCT03822416|DRUG|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
219709815|NCT03822416|DRUG|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
219709816|NCT03822416|BEHAVIORAL|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
219709817|NCT03822416|OTHER|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
219709818|NCT00080340|DRUG|TLK286 (Telcyta) HCl for Injection|
219709819|NCT00080340|DRUG|gefitinib (Iressa)|
219709820|NCT04700436|DRUG|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
219709821|NCT04700436|DRUG|Suvast tablet 10 mg (Rosuvastatin 10 mg)|\- Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
219709822|NCT03057418|DRUG|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
219709823|NCT01809652|OTHER|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
219709824|NCT01823900|DRUG|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
219709825|NCT01823900|DRUG|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
219709826|NCT04293536|OTHER|Cases study|Patients with a retained device or almost
219709827|NCT03033888|BEHAVIORAL|Health-Literacy Focused Education Session|
219709828|NCT02032485|DRUG|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
219709829|NCT04916678|OTHER|R-TEP EMDR intervention|"During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment."
219709830|NCT01532089|BIOLOGICAL|Bevacizumab|Given IV
219709831|NCT01532089|DRUG|Erlotinib|Given PO
219709832|NCT01532089|DRUG|Erlotinib Hydrochloride|Given PO
219709833|NCT01532089|OTHER|Laboratory Biomarker Analysis|Correlative studies
219709834|NCT02806999|DRUG|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
219709835|NCT02806999|DRUG|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
219709836|NCT06003764|OTHER|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
219709837|NCT06003764|OTHER|traditional skin care|traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
219126190|NCT04346303|OTHER|Short-term Interactive Video Games|"1. Collect basic information through a structured questionnaire, which includes basic information, disease status, life style and other related information.~2. Three data collections were performed, namely the baseline period (T0) and the pre-program (T1) two weeks later. Three weeks of intervention activities were provided twice a week, followed by a post-test ( post-program, T2).~3. After a total of six times mentioned above, each 60 minutes of interactive video game intervention, the patient completed the activity feedback form, reflecting the feelings and feedback of participating in the activity."
219126191|NCT03004599|DEVICE|SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System|Transcatheter Aortic Valve Implantation via Transfemoral Approach
219709838|NCT01995201|DRUG|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
219126192|NCT01429714|DEVICE|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
219126193|NCT01429714|DEVICE|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
219126194|NCT06026787|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
219126195|NCT05597683|PROCEDURE|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
219126196|NCT01397487|PROCEDURE|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
219126197|NCT02841722|PROCEDURE|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
219126198|NCT04632966|BIOLOGICAL|Biological: PTP-001|allogeneic placental tissue particulate
219126199|NCT01047072|DRUG|fludarabine phosphate|Given IV
219126200|NCT01047072|RADIATION|total-body irradiation|Undergo total-body irradiation
219126201|NCT01047072|DRUG|tacrolimus|Given orally
219126202|NCT01047072|DRUG|mycophenolate mofetil|Given orally
219709839|NCT01995201|DRUG|methotrexate|stable dose
219709840|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
219709841|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
219709842|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
219709843|NCT04994964|DIAGNOSTIC_TEST|Electromyography|Needle vocal cord electromyography using Medtronic NIM monitor
219126203|NCT01047072|BIOLOGICAL|rituximab|Given IV
219225948|NCT00637858|DIETARY_SUPPLEMENT|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
219126204|NCT01047072|DRUG|cyclophosphamide|Given orally
219126205|NCT01047072|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
219126206|NCT01047072|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
219126207|NCT01862211|OTHER|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
219126208|NCT00665561|DRUG|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
219225949|NCT00637858|OTHER|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
219709844|NCT04619537|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
219709845|NCT00137319|DEVICE|Impedance threshold device|
219709846|NCT01001156|OTHER|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
219709847|NCT03329001|DRUG|Niraparib Tablet|Niraparib tablet formulation
219709848|NCT03329001|DRUG|Niraparib Capsule|Niraparib capsule formulation
219709849|NCT01568541|DRUG|Regular toothpastes|One tooth brushing
219709850|NCT01568541|DRUG|Children's toothpastes|One tooth brushing
219709851|NCT02178956|DRUG|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
219709852|NCT02178956|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
219709853|NCT02178956|OTHER|Placebo|Orally two times daily
219709854|NCT02513875|DIETARY_SUPPLEMENT|vitamin D|60,000 IU per week for 8 weeks
219709855|NCT02513875|DIETARY_SUPPLEMENT|Placebo|placebo +diet and lifestyle
219709856|NCT00782444|PROCEDURE|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
219709857|NCT00782444|PROCEDURE|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
219709858|NCT00022373|DRUG|iseganan HCl oral solution|
219709859|NCT00022373|PROCEDURE|management of therapy complications|
219709860|NCT00134576|BEHAVIORAL|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
219709861|NCT00622518|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
219709862|NCT01592838|OTHER|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
219126209|NCT00665561|DRUG|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
219126210|NCT04780438|DRUG|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
219126211|NCT04780438|DRUG|Placebo|Patients rendomized in this arm will receive placebo.
219126212|NCT02851199|DEVICE|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
219126213|NCT05678595|DEVICE|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
219709863|NCT03769493|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
219709864|NCT04557774|OTHER|Cognitive function test|"Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
219709865|NCT06467734|DEVICE|Joint aspiration|Joint puncture to extract joint fluid.
219709866|NCT02456064|BEHAVIORAL|Lifestyle counseling|"* Group medical visits~* Telephone medical consultations~* Expert patient~* Training workshops"
219709867|NCT00084630|DRUG|imatinib mesylate|Given orally
219709868|NCT00084630|OTHER|laboratory biomarker analysis|Correlative studies
219126214|NCT05678595|DEVICE|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
219126215|NCT03980405|DIETARY_SUPPLEMENT|Group 1- Control Diet|Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
219126216|NCT03980405|DIETARY_SUPPLEMENT|Group 2- UCD Diet|Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
219709869|NCT04010305|DRUG|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
219126217|NCT01283217|DRUG|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
219126218|NCT01283217|DRUG|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
219126219|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
219126220|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
219225950|NCT06470386|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
219225951|NCT06470386|DRUG|Carvedilol|taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
219709870|NCT04010305|DRUG|Placebo film|Placebo film for BXCL501
219709871|NCT05316467|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|"* dietary guidance~* exercise guidance~* lifestyle intervention"
219709872|NCT05316467|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
219709873|NCT00884988|DRUG|Lymphomyosot|20 drops X3/day, until discharge
219709874|NCT00884988|DRUG|Placebo remedy|20 drops X3/day, until discharge
219126221|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
219126222|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
219126223|NCT02081365|BEHAVIORAL|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
219126224|NCT00001084|DRUG|Indinavir sulfate|
219126225|NCT00001084|DRUG|Lamivudine|
219126226|NCT00001084|DRUG|Stavudine|
219126227|NCT00001084|DRUG|Zidovudine|
219126228|NCT02850328|OTHER|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%."
219126229|NCT02621788|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
219126230|NCT00489073|DRUG|duloxetine|
219126231|NCT00489073|DRUG|placebo|
219126232|NCT02230579|DRUG|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
219225952|NCT05738785|OTHER|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
219709875|NCT04228939|BEHAVIORAL|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
219709876|NCT04228939|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
219709877|NCT03692806|DIETARY_SUPPLEMENT|Stablor|Stablor sachet
219709878|NCT03692806|DIETARY_SUPPLEMENT|placebo|placebo sachet
219709879|NCT03510936|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
219709880|NCT01431742|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
219126233|NCT02230579|DRUG|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
219709881|NCT04732676|OTHER|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
219709882|NCT04837170|DRUG|Conventional therapy + S (+)-Ketamine|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
219126234|NCT02230579|DRUG|MMV390048 40mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
219126235|NCT02230579|DRUG|MMV390048 80mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
219126236|NCT02230579|DRUG|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
219126237|NCT02230579|DRUG|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
219126238|NCT01081353|DRUG|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
219126239|NCT01081353|DRUG|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
219709883|NCT04837170|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
219709884|NCT02957448|DRUG|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
219709885|NCT02957448|DRUG|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
219709886|NCT02709369|DEVICE|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
219709887|NCT00963235|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
219709888|NCT00963235|PROCEDURE|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
219709889|NCT02749890|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219709890|NCT02749890|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219126240|NCT01081353|DRUG|Aspirin Migraine|One effervescent tablet under fasting conditions
219126241|NCT01081353|DRUG|Aspirin Aspro|One effervescent tablet under fasting conditions
219126242|NCT04345211|OTHER|Group1, walking group|The walking group includes a weekly walking goal of 75 minutes.
219126243|NCT04345211|OTHER|Group 2, Walking plus manual therapy|Walking plus self-administered thorax manual therapy
219126244|NCT04345211|OTHER|Group 3; Walking plus exercises with Theraband|Walking plus thorax exercises with Theraband
219126245|NCT00002915|DRUG|penclomedine|
219126246|NCT06407479|OTHER|proprioceptive neuromuscular facilitation technique group|Proprioceptive Neuromuscular Facilitation Technique group; In addition to the exercises applied to the participants and the control group, combined isotonic contractions and dynamic stabilization will be used as facilitation techniques, and hold-relax technique will be used as an inhibition technique.
219126247|NCT06407479|OTHER|eccentric muscle training technique application group|Eccentric Muscle Training Technique: Participants will receive eccentric muscle training in addition to the exercises given to the control group. Before the application, 5-minute warm-up exercises will be given to the neck area. Eccentric muscle training will be applied to the muscles of the participants in the cervical region. Eccentric exercise will be strengthened in the cervical region muscles in the direction of movement in each plane, that is, flexion / extension and lateral flexion. The movements will first be explained and demonstrated to the patient.
219126248|NCT06407479|OTHER|Control|No intervention will be made.
219126249|NCT01734811|BIOLOGICAL|Biological vaccine|daily spray (2 puff of 100 µL) for six months
219126250|NCT04141163|DRUG|Metformin|Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
219126251|NCT04141163|DRUG|Placebo oral tablet|No therapeutic effect
219126252|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126253|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126254|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126255|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126256|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126257|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
219126258|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2"
219126259|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
219709891|NCT02749890|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
219709892|NCT05182437|RADIATION|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
219709893|NCT03104803|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
219709894|NCT05378152|DEVICE|Pipelle biopsy catheter|A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
219709895|NCT05378152|DEVICE|Sham procedure|A speculum is inserted into the vagina and then removed
219709896|NCT05958303|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
219709897|NCT05958303|OTHER|Placebo|Placebo
219709898|NCT03797612|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
219709899|NCT03797612|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
219225953|NCT04179526|BEHAVIORAL|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
219225954|NCT04413526|PROCEDURE|radiofrequency|radiofrequency combined with liver resection
219225955|NCT04413526|PROCEDURE|TACE|only TACE treatment
219225956|NCT04413526|PROCEDURE|TACE+radiofrequency|TACE followed by radiofrequency
219225957|NCT00439218|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
219225958|NCT03063021|DRUG|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
219225959|NCT02558543|DRUG|Stromal Vascular fraction|
219225960|NCT02558543|DRUG|Ringer lactate|
219225961|NCT05073822|DRUG|Tacrolimus|reduction of both standard Tacrolimus \& Mycophenolate mofetil does in one arm
219225962|NCT05260866|OTHER|national population-based study|No intervention
219709900|NCT04582071|BEHAVIORAL|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
219709901|NCT06009874|DRUG|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
219709902|NCT06009874|DRUG|Placebo|patients will be treated with a placebo tab once daily for three months
219709903|NCT00585182|DRUG|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
219709904|NCT01642316|OTHER|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
219709905|NCT01642316|OTHER|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
219709906|NCT00366769|DEVICE|Wavefront-guided LASIK using CustomVue platform|
219709907|NCT02222324|DRUG|Placebo|8 placebo tablets matching E2609
219709908|NCT02222324|DRUG|E2609|E2609 will be administered as 8 tablets
219709909|NCT02222324|DRUG|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
219126260|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
219126261|NCT01324882|DEVICE|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
219126262|NCT01324882|DEVICE|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
219126263|NCT04560361|OTHER|Electroacupuncture treatment|Continue the electroacupuncture treatment as described above for 30 minutes.
219709910|NCT01341470|DRUG|LY2495655|administered intravenously or subcutaneously
219709911|NCT01341470|DRUG|Placebo|administered intravenously or subcutaneously
219126264|NCT04560361|OTHER|Sham electroacupuncture treatment|Continue the sham electroacupuncture treatment as described above for 30 minutes.
219126265|NCT06385470|BEHAVIORAL|Dynamic Temporal and Tactile Cueing treatment|"DTTC is a motor-based treatment designed for children with CAS who may have limited verbal output. It applies the principles of motor learning and focuses on speech movement gestures in the context of functional words and phrases.~The participants will receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]), where probe data will be collected before, during, between and after the treatment intervention."
219709912|NCT04905277|DRUG|Atenolol 50 MG|50 mg Atenolol daily
219126266|NCT00725010|DRUG|Temozolomide|Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
219126267|NCT00725010|RADIATION|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
219126268|NCT06478771|DEVICE|Essix retainer|A clear plastic removable retainer.
219126269|NCT06478771|DEVICE|Lingual retainer|A fixed retainer placed on the lingual side of the teeth.
219126270|NCT06075888|DIAGNOSTIC_TEST|Metagenomic diagnosis (mNGS, DISQVER)|Blood sample taken for metagenomic sequencing at inclusion visit.
219225963|NCT03342261|DRUG|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
219225964|NCT03176407|DIAGNOSTIC_TEST|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
219709913|NCT04905277|DRUG|Placebo|one placebo daily
219709914|NCT03716427|DRUG|CT1812|
219709915|NCT03716427|DRUG|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
219709916|NCT03716427|DRUG|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
219709917|NCT03716427|DRUG|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
219225965|NCT03339544|DRUG|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
219709918|NCT03716427|DRUG|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
219709919|NCT05969561|PROCEDURE|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
219709920|NCT05969561|DRUG|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
219225966|NCT03339544|DRUG|Placebo|placebo is given as a tablet before initiation of endodontic treatment
219709921|NCT04744181|DRUG|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
219225967|NCT05579184|DRUG|[177Lu]Ludotadipep|"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
219225968|NCT02263105|DRUG|CDDP|
219709922|NCT04744181|DRUG|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
219709923|NCT04744181|DRUG|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
219709924|NCT03907436|OTHER|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
219709925|NCT03907436|OTHER|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
219709926|NCT00389870|BIOLOGICAL|panitumumab|
219709927|NCT00389870|DRUG|cyclosporine|
219709928|NCT00389870|DRUG|irinotecan hydrochloride|
219709929|NCT01699828|DRUG|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
219709930|NCT01699828|DRUG|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
219709931|NCT01136915|DRUG|Iopamidol 370|one time administration for PCI
219709932|NCT01136915|DRUG|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
219709933|NCT01579864|DRUG|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
219709934|NCT01579864|DRUG|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
219126271|NCT02239185|PROCEDURE|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
219126272|NCT02239185|PROCEDURE|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
219126273|NCT05391802|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
219126274|NCT02619708|BEHAVIORAL|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
219126275|NCT06443671|DRUG|CapeOX|"Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
219126276|NCT06443671|DRUG|Fruquintinib and Tislelizumab combined with mCapeOX|"Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
219126277|NCT02970747|DRUG|Carfilzomib|In accordance with SmPC.
219126278|NCT06021119|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
219126279|NCT00202826|PROCEDURE|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
219126280|NCT02414828|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
219126281|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
219126282|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
219126283|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
219709935|NCT02205645|DEVICE|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
219709936|NCT05486468|DRUG|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
219709937|NCT05486468|OTHER|Sham Injection|Sham injection
219709938|NCT05646992|PROCEDURE|Uterine Allotransplantation|Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
219126284|NCT02669719|BIOLOGICAL|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
219126285|NCT02669719|DRUG|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
219126286|NCT01423357|OTHER|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
219126287|NCT04688021|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
219126288|NCT04688021|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
219126289|NCT04688021|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
219126290|NCT04688021|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
219126291|NCT04688021|DRUG|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
219126292|NCT04688021|DRUG|Tocilizumab|8mg/kg administered IV on day -1.
219126293|NCT04688021|PROCEDURE|Allogeneic HSCT|Day 0
219709939|NCT05646992|DRUG|Tacrolimus|Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
219709940|NCT05646992|DRUG|Imuran|Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
219126294|NCT04688021|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
219126295|NCT04688021|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
219126296|NCT04688021|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
219126297|NCT03635177|PROCEDURE|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
219126298|NCT00875147|DRUG|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
219126299|NCT04680936|DRUG|Dextrose 5% in water|low dose dextrose solution
219126300|NCT04680936|DRUG|Dextrose 15 % in Water|high dose dextrose solution
219126301|NCT04680936|DRUG|Isotonic sodium chloride solution|isotonic saline solution
219126302|NCT03916380|DIETARY_SUPPLEMENT|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
219126303|NCT01938417|DRUG|tobramycin|
219126304|NCT01786343|DRUG|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
219126305|NCT00906880|DRUG|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
219126306|NCT03530020|OTHER|monolithic zirconia crowns|full anatomical monolithic crowns
219126307|NCT03530020|OTHER|lithium silicate crowns|lithium silicate glass ceramics are highly resistance to chipping
219126308|NCT03186807|DIAGNOSTIC_TEST|ultrasonographic scan of fetal brain|"1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6\. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
219126309|NCT03429309|DRUG|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
219709941|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
219709942|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
219709943|NCT06449014|DEVICE|Mini-implants assisted maxillary expansion|The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
219709944|NCT02959762|DIETARY_SUPPLEMENT|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
219709945|NCT02959762|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
219126310|NCT06231082|PROCEDURE|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
219225969|NCT02263105|DRUG|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
219126311|NCT06231082|PROCEDURE|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique."
219126312|NCT02817373|OTHER|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
219126313|NCT05661760|BEHAVIORAL|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
219126314|NCT01484106|OTHER|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
219225970|NCT04301713|OTHER|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
219225971|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
219225972|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
219225973|NCT01482325|DEVICE|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
219225974|NCT03591588|OTHER|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
219126315|NCT01484106|OTHER|Standard of Care|Standard of Care
219126316|NCT06033131|DRUG|Metformin ER|Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
219225975|NCT01428583|DRUG|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
219709946|NCT02959762|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
219225976|NCT05197452|BEHAVIORAL|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
219225977|NCT01375699|DRUG|Doxorubicin|As prescribed by treating provider.
219225978|NCT01375699|DRUG|Sildenafil|Given PO, by mouth
219225979|NCT02983721|PROCEDURE|transradial|transradial route for coronary angiography and PCI
219225980|NCT02983721|PROCEDURE|Transfemoral|transfemoral route for coronary angiography and PCI
219225981|NCT00033748|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
219709947|NCT04574713|DRUG|Candesartan Oral Tablet 8 mg|1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).
219709948|NCT04574713|DRUG|Candesartan Oral Tablet 16 mg|1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).
219709949|NCT04574713|DRUG|Placebo oral tablet|1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
219709950|NCT04153136|DRUG|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
219709951|NCT04153136|DRUG|Placebo oral tablet|Placebo oral tablet By mouth twice daily
219709952|NCT03225482|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
219126317|NCT06033131|DRUG|Placebo|Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
219126318|NCT06325943|DRUG|Rituximab|Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6
219225982|NCT00033748|BIOLOGICAL|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
219225983|NCT00529009|DRUG|UDCA|
219225984|NCT05360537|DRUG|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
219225985|NCT05360537|DRUG|Insulin Glargine|Administration of glargine insulin
219709953|NCT03225482|BEHAVIORAL|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
219709954|NCT05376358|DEVICE|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
219709955|NCT05376358|OTHER|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
219709956|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
219126319|NCT06325943|OTHER|Placebo|Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6
219126320|NCT00048854|DRUG|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
219126321|NCT00048854|OTHER|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
219225986|NCT00655213|DEVICE|Symphony D 2450|
219225987|NCT00655213|DEVICE|Symphony DR 2550|
219225988|NCT00523900|DIETARY_SUPPLEMENT|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
219709957|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
219709958|NCT03841981|DIAGNOSTIC_TEST|Anthropometric and physical examination|"* Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\]."
219709959|NCT03841981|DIAGNOSTIC_TEST|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
219709960|NCT03841981|DIAGNOSTIC_TEST|Biochemical, hormonal and metabolic phenotyping|"* Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers."
219225989|NCT06836479|OTHER|NOURISH Diet|NOURISH meals will be prepared by NOURISH chefs for seven days. Both South Asian and Filipino meal plans will be prepared, vegetarian, vegan and non-vegetarian options available for all. Participants will pick-up NOURISH meals at a Stanford facility and consume three meals (breakfast, lunch, and dinner) and two snacks over one week. There will be no caloric restriction, the calories in each meal will be informed by the average intake for the participants gender and BMI.
219225990|NCT06836479|OTHER|Self-Selected Diet (Control)|The participants will eat their routine meals without any involvement of the investigators. Participants will be required to wear the CGM during this time and keep a detailed food log through Tastermonial.
219126322|NCT03418779|DRUG|The Yi-Qi-Qing-Jie herbal compound|The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
219126323|NCT03418779|DRUG|Immunosuppressants|Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 109/L and platelets \< 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
219709961|NCT03841981|DIAGNOSTIC_TEST|Sonographic studies|"* Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
219709962|NCT03841981|DIAGNOSTIC_TEST|24-hour Ambulatory blood pressure monitoring|A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).
219225991|NCT06835985|OTHER|Chatbot Intervention|Participants screened for suicidality during the ETUDES Center Primary Care Study and who disclose experiencing online victimization will be onboarded by a research clinician on how to use SMILEY, the web-based intervention that delivers psychoeducation, basic concepts of social media self-efficiency, and guidance on how to respond to and cope with online victimization. The chatbot and/or research clinician will send out periodic reminders to users to remind them to engage with the chatbot over four weeks. Technical troubleshooting concerns will be carried out by research clinician and chatbot developer team.
219709963|NCT03841981|PROCEDURE|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
219709964|NCT03841981|DIAGNOSTIC_TEST|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
219709965|NCT03841981|DIAGNOSTIC_TEST|Oral smear and feces specimen|Microbiome studies.
219709966|NCT03811561|DRUG|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
219709967|NCT03811561|DRUG|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
219709968|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
219709969|NCT05736848|DEVICE|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
219709970|NCT02997293|OTHER|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
219709971|NCT00311168|DEVICE|Intervention/treatment|"Device: VIP On~Device: VIP Off"
219709972|NCT05712772|OTHER|Blue Light|Blue light exposure
219709973|NCT05712772|OTHER|Red Light|Red light exposure
219709974|NCT04302025|DRUG|Alectinib|Participants will receive oral alectinib twice per day (BID)
219709975|NCT04302025|DRUG|Entrectinib|Participants will receive oral entrectinib daily
219709976|NCT04302025|DRUG|Vemurafenib (Enrollment closed)|Participants will receive oral vemurafenib BID
219709977|NCT04302025|DRUG|Cobimetinib (Enrollment closed)|Participants will receive oral cobimetinib daily
219709978|NCT04302025|DRUG|Pralsetinib (Enrollment closed)|Participants will receive oral pralsetinib daily
219709979|NCT04302025|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
219709980|NCT04302025|DRUG|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
219709981|NCT04302025|PROCEDURE|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
219709982|NCT04302025|DRUG|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
219709983|NCT04302025|DRUG|Divarasib|Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
219709984|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
219709985|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
219709986|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
219126324|NCT03418779|OTHER|Optimized Supportive Care|"The optimized supportive care included:~1. Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~2. The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~3. Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~4. Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid \<6 mg/dL in female, \<7 mg/dL in male"
219126325|NCT03418779|OTHER|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
219709987|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
219126326|NCT04601376|BEHAVIORAL|Mobile Monitoring Tool|a text-messaged based outcomes collection system
219709988|NCT02981693|PROCEDURE|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
219126327|NCT05791877|DEVICE|pneuRIP|Respiratory sensor to measure pulmonary function
219126328|NCT04890145|DEVICE|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
219126329|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
219126330|NCT06067100|DRUG|Placebo|Participants are administered placebo
219126331|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
219126332|NCT03230006|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion over 16 sessions, in a minimum of 16- and a maximum of 21-weeks, following the published therapist guide with minor refinements for application in the proposed comorbid population.
219126333|NCT03230006|BEHAVIORAL|Take Control|TC will be conducted over 12 sessions, in a minimum of 12- and a maximum of 16-weeks. Therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
219126334|NCT05593458|DRUG|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
219126335|NCT05593458|DRUG|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
219126336|NCT05593458|DRUG|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
219126337|NCT05593458|PROCEDURE|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
219126338|NCT05593458|DRUG|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
219126339|NCT05593458|DRUG|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
219126340|NCT04949399|DRUG|OnabotulinumtoxinA|Injection
219126341|NCT04949399|DRUG|Placebo|Saline Injection
219126342|NCT04778488|DEVICE|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
219126343|NCT00271414|DRUG|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
219126344|NCT04210193|DRUG|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
219126345|NCT04210193|DRUG|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
219126346|NCT03412981|OTHER|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
219126347|NCT01974687|DRUG|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
219126348|NCT01974687|DRUG|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
219126349|NCT01974687|DRUG|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
219126350|NCT00236821|DRUG|levofloxacin|
219126351|NCT00124605|DRUG|pamidronate disodium|Given IV
219126352|NCT00124605|DRUG|arsenic trioxide|Given IV
219126353|NCT00124605|OTHER|laboratory biomarker analysis|Correlative studies
219126354|NCT00124605|OTHER|pharmacological study|Correlative studies
219126355|NCT00005305|OTHER|No interventions - observational study|
219126356|NCT00814489|BIOLOGICAL|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
219126357|NCT00814489|BIOLOGICAL|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
219126358|NCT03773055|DRUG|NPC-06|Patients will receive once a day for 7 days.
219126359|NCT04453787|OTHER|Arch support orthoses with forefoot medial wedge|The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
219126360|NCT04453787|OTHER|Arch support orthoses|The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
219126361|NCT04453787|OTHER|Flat insole|The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
219126362|NCT02748239|BEHAVIORAL|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
219126363|NCT02748239|BEHAVIORAL|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
219126364|NCT06117475|PROCEDURE|Posterior corpectomy|Removal of posterior portion of vertebrae by posterior approach
219225992|NCT06835985|OTHER|Brief Psychoeducation|When youth onboard the study, a research clinician will deliver psychoeducation for youth and caregivers supported by web-based resources. Content will introduce basic concepts of social media self-efficacy (screen time guidance, technological coping skills, and encouragement of positive online interactions) and guidance on how to respond to and cope with online victimization.
219225993|NCT02232997|OTHER|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
219225994|NCT02232997|OTHER|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
219225995|NCT02823340|DEVICE|Fractional microneedle RF(United, Peninsula Medical, China)|
219225996|NCT01760005|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
219225997|NCT01760005|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
219225998|NCT01760005|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
219225999|NCT01760005|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
219709989|NCT02483403|OTHER|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
219709990|NCT02483403|DEVICE|MRI|
219226000|NCT01760005|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
219226001|NCT01760005|DRUG|E2814|Administered intravenously in a blinded fashion
219709991|NCT06314568|RADIATION|Radiochemotherapy plus interventional radiotherapy|All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
219709992|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
219709993|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
219709994|NCT04041648|OTHER|Placebo Solution|Single ascending dose
219709995|NCT04559230|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
219709996|NCT05551741|BIOLOGICAL|IBC-Ab002|An anti-PD-L1 monoclonal antibody
219709997|NCT05551741|OTHER|Placebo|Normal Saline
219709998|NCT06060873|OTHER|Non-Interventional Study|Non-interventional study
219709999|NCT05658887|DRUG|Gabapentin|One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure
219710000|NCT05658887|DRUG|Gabapentin Placebo|Gabapentin Placebo
219710001|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
219126365|NCT03591965|DRUG|ATG-008|Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
219226002|NCT01760005|DRUG|Lecanemab|Administered intravenously
219226003|NCT01760005|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
219226004|NCT04482556|DEVICE|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
219226005|NCT04482556|DEVICE|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
219226006|NCT02294994|DRUG|tirofiban|
219226007|NCT00108589|DRUG|S-adenosylmethionine|
219226008|NCT05600439|BEHAVIORAL|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
219226009|NCT05271045|DIETARY_SUPPLEMENT|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
219226010|NCT05271045|DIETARY_SUPPLEMENT|Active comparator|30 g fortified canola oil with vitamins A and D
219126366|NCT05696808|DIETARY_SUPPLEMENT|IHPD|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
219126367|NCT05696808|DIETARY_SUPPLEMENT|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
219126368|NCT03031639|PROCEDURE|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
219126369|NCT06556004|BIOLOGICAL|TRIMELVAX|The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
219126370|NCT05644405|DIAGNOSTIC_TEST|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
219126371|NCT02613897|DRUG|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
219126372|NCT02613897|DRUG|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
219126373|NCT02613897|DRUG|Placebo|Placebo
219126374|NCT03896230|DRUG|Ketamine Injectable Product|Three different doses of ketamine will be administered.
219126375|NCT05476211|DEVICE|BTL-785F|Radiofrequency
219126376|NCT00972985|DRUG|modafinil|oral tablet, 100 mg, single acute dose
219126377|NCT00972985|DRUG|methylphenidate|oral tablet, 20 mg, single acute dose
219710002|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
219710003|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
219710004|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
219710005|NCT06641089|DRUG|Sonelokimab|Sonelokimab
219710006|NCT06641089|DRUG|Placebo|Placebo
219710007|NCT06641089|DRUG|Risankizumab|Active comparator
219710008|NCT06476379|PROCEDURE|Testicular sperm extraction (TESE)|Surgical procedure used to retrieve sperm directly from the testicles of men who have low sperm production or no sperm in their ejaculate
219126378|NCT00972985|DRUG|lorazepam|oral tablet, 1 mg, single, acute dose
219126379|NCT00972985|DRUG|placebo|oral tablet, single acute dose
219126380|NCT01866917|DRUG|Ropivacaine 0.5% 20cc injectate bilaterally|
219126381|NCT01866917|DRUG|Placebo|
219126382|NCT01712685|DRUG|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
219126383|NCT01712685|PROCEDURE|PET/CT|
219126384|NCT00232934|DRUG|Thalidomide|
219226011|NCT05271045|DIETARY_SUPPLEMENT|Placebo|30 g fortified sunflower oil with vitamins A and D
219710009|NCT06476379|OTHER|Ejaculate|Ejaculate processing for ICSI
219126385|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
219126386|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
219226012|NCT04022421|DRUG|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
219226013|NCT04530370|BIOLOGICAL|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
219710010|NCT06639217|OTHER|a comprehensive nursing care protocol|a comprehensive nursing care protocol provided for nurses who provide direct care for women with pelvic organ prolapse and urinary incontinence on their knowledge and practices as well as its impact on the women quality of life
219710011|NCT06952751|OTHER|Differential ultracentrifugation|Differential ultracentrifugation
219710012|NCT06952751|OTHER|OptiPrep™ density gradient ultracentrifugation|OptiPrep™ density gradient ultracentrifugation
219710013|NCT06952751|OTHER|Size-exclusion chromatography|Size-exclusion chromatography
219710014|NCT06952751|OTHER|Combined techniques|Combined techniques
219126387|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
219126388|NCT06811532|OTHER|Blood perfusion analysis using SPY-Q software|Use of the SPY-Q analysis software during surgery to calculate bone profusion scores on several areas of the scapular tip flap (endosteum of scapula bone segments and latissimus dorsi muscle component).
219126389|NCT02773251|DRUG|hyaluronic acid-carboxymethylcellulose|
219126390|NCT03406442|PROCEDURE|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
219126391|NCT01194505|OTHER|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
219126392|NCT01194505|OTHER|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
219126393|NCT06608888|DIAGNOSTIC_TEST|MRI|"Multimodal MRI technology is a method that combines various magnetic resonance imaging techniques, providing more comprehensive images and information about human tissues and organs. These different imaging techniques include, but are not limited to:~Structural MRI (sMRI): Provides information about the types of brain tissues, such as gray matter, white matter, and cerebrospinal fluid.~Functional MRI (fMRI): Dynamically measures the hemodynamic response related to brain neural activity, commonly used to study brain functional activities.~Diffusion Tensor Imaging (DTI): Offers information on the structural connections between brain regions, which can be used to study the neural fiber pathways of the brain"
219126394|NCT01703533|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
219126395|NCT01703533|DRUG|Placebo|Strawberry flavored solution and Water for Injection
219126396|NCT06006130|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires 11 minutes in total.
219126397|NCT06006130|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
219126398|NCT06615141|DEVICE|Oculus Quest 3|Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.
219126399|NCT06615141|DEVICE|Neofect Smartboard and Tyromotion Myro|"Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills."
219226014|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
219226015|NCT06117891|DRUG|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
219226016|NCT06117891|DRUG|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
219226017|NCT06117891|DRUG|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
219226018|NCT06117891|DRUG|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
219226019|NCT02994524|PROCEDURE|Rerouting technique for transsphincteric perianal fistula|
219226020|NCT05804357|BEHAVIORAL|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
219710015|NCT03909477|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
219710016|NCT03909477|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
219710017|NCT03909477|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
219126400|NCT05504343|DEVICE|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
219126401|NCT06401993|PROCEDURE|"The dao qi tong luo group"|"The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi."
219126402|NCT06401993|PROCEDURE|The acupuncture group|The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
219126403|NCT06602752|BEHAVIORAL|Food system and demand generation|The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
219126404|NCT04831164|OTHER|NA (not an interventional study)|(not an interventional study)
219126405|NCT05468658|OTHER|Designing the birthing unit according to the philosophy of Feng Shui|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
219126406|NCT06918860|OTHER|Analysis|Analysis and review of imaging and clinical data
219126407|NCT06303778|OTHER|Stand Down mobile app|The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.
219126408|NCT06303778|OTHER|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
219126409|NCT04854486|OTHER|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
219126410|NCT04854486|DRUG|Control Placebo|Saline
219126411|NCT06693024|DRUG|neratinib|neratinib 240mg qd for 1 year
219126412|NCT04207255|DRUG|Opaganib|500mg of Opaganib orally twice a day continuously.
219126413|NCT04207255|DRUG|Abiraterone|IV as directed by SOC
219126414|NCT04207255|DRUG|Enzalutamide|IV as directed by SOC
219126415|NCT04207255|DRUG|Opaganib|250mg of Opaganib orally twice a day continuously.
219126416|NCT06698224|DEVICE|Spinal cord transcutaneous stimulation|Physical therapy combined with spinal cord transcutaneous stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord stimulation is a non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
219126417|NCT06698224|DEVICE|Paired spinal cord and peripheral nerve stimulation|Physical therapy combined with paired spinal cord-peripheral nerve stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord and peripheral nerve stimulation are both non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
219126418|NCT06713772|DEVICE|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
219126419|NCT06713772|DEVICE|Steri-StripsTM (3M, St. Paul, Minnesota, USA|Steri-StripsTM (3M, St. Paul, Minnesota, USA
219126420|NCT06713772|DEVICE|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
219126421|NCT06696872|OTHER|core exercises|The core muscle strength training program were lasted for 8 weeks and comprised of 3 training sessions per week, with a total of 24 sessions. Each session were lasted for 30 to 45 minutes, starting with a brief warm-up exercise program consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program
219226021|NCT05804357|BEHAVIORAL|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
219710018|NCT03909477|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
219710019|NCT03909477|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
219710020|NCT03909477|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
219710021|NCT03909477|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
219710022|NCT05778539|PROCEDURE|Lateral retinacular release|During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
219710023|NCT06637332|DRUG|Daptomycin for Injection|Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
219710024|NCT06637332|DRUG|Vancomycin (IV)|Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
219126422|NCT06696872|OTHER|Proprioceptive Neuromuscular Facilitation|The hold-relax proprioceptive neuromuscular facilitation stretching protocol consisted of passively moving the dominant leg into a position where the subjects felt mild discomfort and holding that position for 30 seconds. Subjects were then asked to isometrically contract the stretched muscle for 10 seconds; this were followed by muscle relaxation in the same posi¬tion for 30 seconds, before being stretched to a new point of mild discomfort. The leg were then released
219126423|NCT06696391|OTHER|Venous Excess Ultrasound (VEXUS)-Guided Management|"Expert operators will perform VEXUS within 6 hours of randomization and repeat the assessment every 24 hours for 3 days, or until ICU discharge or death. After each assessment, investigators will grade the severity of venous congestion using a modified version of the VEXUS score and provide updated management recommendations.~Patients without congestion will receive standard fluid management. For mild congestion, investigators will implement fluid restriction (e.g., minimizing maintenance fluids) while maintaining nutrition and blood product administration as clinically indicated. For moderate to severe congestion, investigators will 1. target negative fluid balance (-1 to -2L/24h) through fluid restriction and diuretics, 2. perform cardiac ultrasound to guide inotrope administration and optimize RV physiology, and 3. optimize PEEP for ventilated patients.~All patients will receive the standard of care based on Surviving Sepsis Campaign guidelines."
219126424|NCT06711367|BEHAVIORAL|tell show do behavior management technique|tell show do behavior management technique about the the diagnosis and procedures of dental restoration
219126425|NCT06711367|BEHAVIORAL|a costume-designed storybook|a costume-designed storybook explaining the diagnosis and procedures of dental restoration
219126426|NCT06712472|DRUG|Olaparib (300 mg BID)|Olaparib 300mg Bid during one year.
219126427|NCT06918210|PROCEDURE|Indocyanine Green|Visualization of the bile ducts with ICG
219126428|NCT06918210|PROCEDURE|Cholangiography|Visualization of the bile ducts with intraoperative cholangiography
219126429|NCT06740357|OTHER|Tumor response monitoring program|three steps of tumor response evaluation (STEP 1 at 2 months, STEP 2 at 4 months, STEP 3 at 6 months after completion of neoadjuvant treatment): STEP 1: digital rectal examination, pelvic MRI, rectoscopy, TAP scan STEP 2: DRE, pelvic MRI, rectoscopy STEP 3: DRE, pelvic MRI, rectoscopy, TAP or PET scan
219126430|NCT06740357|OTHER|Standard evaluation of tumor response|Assessment at 2 months (+/- 7 days) after neoadjuvant treatment: digital rectal exam, pelvic MRI, rectoscopy, TAP scan
219126431|NCT06740357|OTHER|Shared decision-making|At each stage of the monitoring program and depending on the clinical and oncological results, the decision to preserve the rectum will be discussed with the patient according to a shared-decision program.
219126432|NCT06740357|OTHER|Decision-making according to national recommendations|The decision to preserve the rectum is based on assessment at 2 months after completion of neoadjuvant treatment (standard of care since the GRECCAR2 trial).
219126433|NCT06740357|OTHER|Follow-up|Every 3 months for 2 years, then every 6 months for the third year
219126434|NCT04754061|DRUG|Psilocybin|"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
219126435|NCT06818071|BEHAVIORAL|Points and Leaderboards|"Participants will have the opportunity to gain points if they meet their self-set daily step goal throughout the experiment period.~Participants will also compete with others in their own respective groups on a leaderboard in regards to each day's daily step count."
219226022|NCT05816707|BIOLOGICAL|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
219710025|NCT06950398|OTHER|NMP viability testing|NMP viability testing before transplantation of discarded livers
219710026|NCT05401201|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
219710027|NCT05401201|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
219710028|NCT04928391|DRUG|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
219710029|NCT04928391|DRUG|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
219710030|NCT04928391|OTHER|0.9% saline|Same volume of saline placebo IV at the end of surgery
219710031|NCT05905536|DEVICE|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
219710032|NCT06328712|DRUG|EN001|"* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals."
219710033|NCT04472299|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
219710034|NCT00431418|DRUG|Sildenafil|Sildenafil oral solution
219710035|NCT00431418|DRUG|Placebo|Placebo solution
219710036|NCT03679793|PROCEDURE|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
219126436|NCT06818071|BEHAVIORAL|Social Aspects|Participants will be randomly assigned into groups of three to compete with other groups based on their daily step count. Each day, one participant will be randomly selected to represent the group against their opponent. If they walked more than their randomly selected opponent, the participant's group will receive a positive, encouraging message congratulating them for winning that day. If they did not walk more than their randomly selected opponent, they will receive a motivational message to encourage them to walk more.
219126437|NCT06818071|BEHAVIORAL|Health Messages|Experiment participants will receive messages that encourage healthy behaviors. These include topics such as: nutrition, sleep, physical activity, and decreased consumption/use of unhealthy products (tobacco, alcohol, etc.).
219126438|NCT06818071|BEHAVIORAL|Pikmin Bloom|Participants will play the mobile game Pikmin Bloom, which encourages users to increase their daily step count and allows them to utilize various gamified elements to do so. The game has many gamified elements included, such as personalization and avatar, social aspects, competition, collaboration, progression, and many more.
219126439|NCT06760533|DRUG|Psilocybin 25 mg|Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
219126440|NCT06760533|BEHAVIORAL|Psychotherapy Treatment Session|The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.
219126441|NCT06760533|DRUG|Niacin 100 mg|Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
219126442|NCT06766981|PROCEDURE|Infiltration with Articain 4%|The experimental group of patients that are diagnosed for tooth extraction of mandibular 1st. molar will undergo extraction using an infiltration technique for local anaesthesia. In contrast to the conventional group that will receive Inferior alveolar nerve block
219126443|NCT06766981|PROCEDURE|Inferior Alveolar Nerve Block|This group will receive a conventional inferior alveolar nerve block (IANB) technique with 2% lidocaine with epinephrine (1:80,000) for tooth extraction.
219126444|NCT06891703|OTHER|[18F]ACI-15916|\[18F\]ACI-15916 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
219126445|NCT05700214|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine
219126446|NCT05700214|DRUG|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
219126447|NCT06780293|OTHER|Laser acupuncture (LA)|The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.
219126448|NCT06780293|DIAGNOSTIC_TEST|Numerical Rating Scale (NRS)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Numerical Rating Scale (NRS).
219126449|NCT06780293|DIAGNOSTIC_TEST|Schirmer's test|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Schirmer's test.
219710037|NCT03679793|PROCEDURE|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
219710038|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
219710039|NCT00332397|DEVICE|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
219710040|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
219710041|NCT00516607|DRUG|enzastaurin hydrochloride|
219710042|NCT00516607|DRUG|temozolomide|
219710043|NCT00516607|OTHER|pharmacological study|
219710044|NCT05497128|DEVICE|Ultrahigh-speed cut rate 27-gauge system|The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
219126450|NCT06780293|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the OSDI test.
219710045|NCT05497128|DEVICE|Standard cut rate 27-gauge system|The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
219710046|NCT05398588|OTHER|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
219710047|NCT05398588|OTHER|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
219710048|NCT03586193|PROCEDURE|Pars plana vitrectomy|pars plana vitrectomy without ICG staining and ILM peeling
219126451|NCT06780293|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the ESSPRI.
219126452|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) tongue diagnosis.
219126453|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) pulse diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) pulse diagnosis.
219126454|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) constitution questionnaire|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) constitution questionnaire.
219126455|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) heart rate variability analysis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) heart rate variability analysis.
219126456|NCT06780293|DIAGNOSTIC_TEST|nailfold microcirculation assessment|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the nailfold microcirculation assessment.
219126457|NCT06780293|DIAGNOSTIC_TEST|iris examination|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the iris examination.
219126458|NCT06780293|OTHER|Sham Laser Acupuncture|"The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.~The sham laser acupuncture procedure follows the same process as the true laser acupuncture protocol, including the positioning, cleaning of acupoints, and wearing of protective goggles. However, no laser emission is delivered during the treatment. This ensures a consistent experience for the patient while maintaining the blinding integrity of the study."
219126459|NCT06907030|OTHER|No intervention|No intervention
219126460|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
219126461|NCT06325670|BEHAVIORAL|BED treatment|A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.
219126462|NCT06325670|OTHER|Waitlist|A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.
219126463|NCT06913738|BEHAVIORAL|GPM-Extended|GPM-extended is a dimensional adaptation of Good Psychiatric Management (GPM) that retains its core principles-validation, real-life focus, alliance building-while enhancing flexibility and personalization. It emphasizes diagnostic clarity, treatment prioritization, and individualized psychoeducation based on three key personality dilemmas: fear of abandonment, self-esteem dysregulation, and control dependency. These dilemmas guide the focus of therapy and case management. Treatment goals are collaboratively set and regularly reassessed to align with the patient's evolving needs. The intervention includes weekly individual therapy and tailored group programs, with clinical strategies adapted to each dominant dilemma.
219226023|NCT05816707|BIOLOGICAL|Curcuma Longa gel|Curcuma Longa gel
219226024|NCT05816707|OTHER|extraction socket|extraction socket
219226025|NCT03233997|OTHER|FT21018|An electronic cigarette
219710049|NCT01829607|OTHER|Functional electrical stimulation of peripheral muscles|
219710050|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
219710051|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
219710052|NCT05874141|DIAGNOSTIC_TEST|HBA1C|blood sample on EDTA
219710053|NCT05874141|DIAGNOSTIC_TEST|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
219710054|NCT05874141|DIAGNOSTIC_TEST|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
219710055|NCT05874141|DIAGNOSTIC_TEST|Serum creatinine and estimated glomerular filtration rate|serum sample
219710056|NCT05874141|DIAGNOSTIC_TEST|Complete blood count|blood sample on EDTA
219226026|NCT03233997|OTHER|FT21033|An electronic cigarette
219226027|NCT03233997|OTHER|FT21034|An electronic cigarette
219226028|NCT03233997|OTHER|FT21035|An electronic cigarette
219710057|NCT05874141|DIAGNOSTIC_TEST|Thyroid-stimulating hormone|serum sample
219710058|NCT05874141|DIAGNOSTIC_TEST|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
219710059|NCT05874141|PROCEDURE|Electrocardiography (ECG)|by electrocardiogram
219710060|NCT05874141|PROCEDURE|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
219710061|NCT05874141|PROCEDURE|Arterial duplex ultrasound of both lower limbs|imaging
219710062|NCT05874141|DIAGNOSTIC_TEST|Random blood glucose|serum sample
219710063|NCT05874141|DIAGNOSTIC_TEST|AST, ALT, albumin|serum sample
219710064|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
219710065|NCT04651673|OTHER|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
219710066|NCT05633355|DRUG|Rocatinlimab|Subcutaneous (SC) injection
219710067|NCT01698788|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
219710068|NCT03410420|DRUG|Pimonidazole hydrochloride|administration of pimonidazole-HCl
219710069|NCT06087627|DRUG|Dupilumab SAR231893 (REGN668)|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
219710070|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Imatinib|
219126464|NCT06913738|BEHAVIORAL|Classic GPM|The classic GPM group follows the validated and manualized version of Good Psychiatric Management (GPM) for BPD. It emphasizes symptom stabilization through weekly individual therapy and pragmatic case management every 3 weeks. Unlike GPM-extended, it uses a uniform therapeutic framework rather than tailoring treatment to individual personality dilemmas,.The intervention includes weekly individual therapy and standardized group programs, with clinical strategies applied uniformly across patients, centered on interpersonal hypersensitivity and building stable life roles.
219126465|NCT06914453|DEVICE|Air Q-3 Supraglottic Airway Device|Oropharyngeal leak pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
219126466|NCT06914453|DEVICE|Ambu AuraGain Supraglottic Airway Device|Oropharyngeal Leak Pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
219126467|NCT06920264|DRUG|Tranexamic acid|A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. .
219126468|NCT06920264|OTHER|placebo|saline
219126469|NCT06919263|BEHAVIORAL|Influencer marketing|Participants viewed survey-imbedded promotional images featuring influencers
219126470|NCT06918496|DEVICE|Surgical placement of a prosthetic or biologic graft (patch), or an allograft for cardiac and (cardio)vascular repair.|"Suture line bleeding in cardiac and vascular reconstruction poses significant risks, including morbidity, mortality, and complications related to blood loss and transfusion. Advances in surgical techniques have improved hemostasis but may not suffice, especially in patients on anticoagulant or antiplatelet medications or those using synthetic graft materials.~Surgical adhesives are valuable adjuncts to standard hemostatic techniques, aiming to prevent postoperative bleeding and its associated complications. NE'X Glue R-eco, a novel surgical adhesive, utilizes recombinant human serum albumin (rHSA) and glutaraldehyde (GA) for suture line sealing. It is similar to BioGlue®, which uses bovine serum albumin (BSA) and GA, and has proven safety and benefits.~Distinguishing Features of NE'X Glue R-eco:~Composition: Uses rHSA expressed in plants, offering improved biocompatibility and reduced risk of allergic reactions.~Bonding Strength: Demonstrates high bonding strength in tests, comparab"
219126471|NCT06919146|BEHAVIORAL|Physical Activity|EG participated in AGPAP (4:00 pm-5:00 pm) twice a week, every Wednesday and Friday, for a total of 60 minutes, for 12 weeks. EG and CG did not participate in any additional physical activity programs after-school.
219126472|NCT06918249|OTHER|No intervention|
219126473|NCT06914557|DEVICE|Scrambler Therapy|Scrambler therapy will be administered by the staff of the Supportive Oncology and Palliative Care team who have been trained in Scrambler therapy and have extensive experience providing it to patients with neuropathic cancer-related pain. Patients who meet the study criteria will be treated daily, Monday through Friday, for up to 10 sessions. The treatment may be terminated sooner if a patient experiences complete pain relief or if it is ineffective after five sessions. Patients will be closely monitored during the treatment. The treatment is non-painful and not associated with any significant adverse effects.
219710071|NCT01771458|PROCEDURE|Tumor biopsy|
219126474|NCT06914557|OTHER|Questionnaire and Physical Exam|15-minute-long questionnaires evaluating Pain and degree of pain.
219126475|NCT06919848|DRUG|TORIPALIMAB INJECTION(JS001 )|Toripalimab will be administered by IV, 240 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219710072|NCT01771458|DRUG|Standard Chemotherapy|
219710073|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Everolimus|
219710074|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Vemurafenib|
219710075|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Sorafenib|
219710076|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Erlotinib|
219126476|NCT06919848|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219710077|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
219710078|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Dasatinib|
219710079|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
219710080|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Abiraterone|
219710081|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
219710082|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
219710083|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
219710084|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
219710085|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
219710086|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
219710087|NCT05869552|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
219710088|NCT05869552|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
219710089|NCT04957095|DRUG|Apomorphine Injectable Solution|Apomorphine injected for therapeutic relief
219710090|NCT04957095|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
219710091|NCT05086315|DRUG|SAR443579|Powder for solution for infusion; by IV infusion
219710092|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
219710093|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
219710094|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
219710095|NCT06301035|DEVICE|Asymmetric High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
219710096|NCT06301035|DEVICE|Standard(symmetric) High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
219710097|NCT05850494|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
219126477|NCT06919848|DRUG|H101|H101 will be percutaneously injected into tumor on day 1 of every 21-day cycle. Lenvatinib plus Toripalizumab will be administered 1-3 days after H101 injection.
219710098|NCT05850494|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
219126478|NCT06919848|DRUG|FOLFOX|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
219126479|NCT06920329|DRUG|Peginterferon α-2b based injection|Peginterferon α-2b injection, 180 μg administered subcutaneously in the abdomen or thigh once weekly, with regular follow-up for HBV recurrence. Patients will be followed up every 12 weeks.
219126480|NCT06918652|PROCEDURE|Transmural ultrasound-guided gallbladder drainage|TUGD will be performed using the bi-flanged LAMSs mounted on an electrocautery-enhanced delivery system (Hot-AXIOS™) by an experienced endoscopist defined as \> 10 LAMS positioning per year. The diameter and length of the stent and the modality of placing the stent (under complete EUS view or with endoscopic or fluoroscopic guidance) will be chosen at the discretion of the endoscopist performing the procedure
219126481|NCT06918652|PROCEDURE|Laparoscopic cholecystectomy|LC will be performed by the four-trocar technique with transection of the cystic duct and cystic artery after reaching the critical view of safety. ELC will be performed by a surgeon trained and experienced in laparoscopic surgery defined as \> 5 laparoscopic procedures for ACC on a yearly basis
219126482|NCT06918756|OTHER|Questionnaires|Completion of new questionnaire in addition to other patient reported outcome measures that measure cough severity and cough-related quality of life.
219126483|NCT06918756|OTHER|Focus group interviews|Semi-structured focus group interviews for patients with refractory chronic cough
219126484|NCT06918756|OTHER|Objective cough measures|Cough monitoring and cough sensitivity testing.
219126485|NCT06917859|DRUG|Methylprednisolone group|In this study patients will be given a single intra-venous dose of methylprednisolone (2 mg/kg) after the induction of anesthesia, and before the initiation of CPB.
219126486|NCT06918678|DEVICE|Tai Chi intervention|The Tai Chi program was delivered virtually via Zoom by a certified Tai Chi instructor for 12 weeks. Tai Chi forms employed in the class was adapted from an evident-based fall prevention program - Tai Ji Quan: Moving for Better Balance. This program is a research-based Tai Chi balance training regimen. The program composed of core adapted Tai Chi movements and various therapeutic movements as well as breathing exercises
219126487|NCT06918678|OTHER|Usual care condiition|In the usual care condition, the investigators requested that participants maintain their regular activities during their time in the usual care condition. The participants were encouraged to refrain from Tai Chi, but not prohibited from engaging in Tai Chi, in the usual care period.
219126488|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
219126489|NCT04308551|DRUG|Indobufen|Indobufen Tablets
219126490|NCT04308551|DRUG|Aspirin|Aspirin Tablets
219126491|NCT06914193|DRUG|esketamine+PRF treatment group|In the esketamine group, in addition to receiving PRF treatment+pregabalin, patients will also undergo a single intravenous infusion of esketamine.
219126492|NCT06914193|DRUG|PRF treatment group|In the control group, patients will receive PRF treatment. PRF will be performed on DRG by an designated physician in each participating center. The patients will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which will be carefully inserted until the needle tip reached the upper edge of the intervertebral foramen under the guidance of three-dimensional (3D) CT. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to DRG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
219226029|NCT03843606|OTHER|Modified ketogenic diets|Different diet composition
219226030|NCT04266626|OTHER|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
219710099|NCT01426451|OTHER|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
219710100|NCT01426451|OTHER|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
219710101|NCT04325386|OTHER|ECHO Intervention|Project ECHO (Extension for Community Healthcare Outcomes) based intervention 26 CME educational sessions. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes. 1.25 hour long. Also consultation line and ATHELAS device.
219710102|NCT04325386|OTHER|eTAU|Consultation Line and ATHELAS device only
219710103|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
219710104|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
219710105|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
219710106|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
219710107|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
219710108|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
219710109|NCT03751813|DIETARY_SUPPLEMENT|Supplement|Supplement will be given to this group to take daily for 8 weeks
219710110|NCT00392041|DRUG|Eszopiclone|3mg qpm for 12 weeks
219710111|NCT00392041|DRUG|placebo|1 pill qpm for 12 weeks
219710112|NCT06465667|BEHAVIORAL|Dashboard|The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
219710113|NCT06465667|BEHAVIORAL|Precision Feedback Push|"The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data."
219710114|NCT05300282|DRUG|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
219226031|NCT04266626|OTHER|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
219226032|NCT01037868|OTHER|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
219226033|NCT00000178|DRUG|Prednisone|
219226034|NCT01427816|DRUG|KCT-0809|
219226035|NCT01427816|DRUG|KCT-0809|
219226036|NCT01427816|DRUG|Placebo|
219126493|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using hemostatic sealant|"* A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary.~* The hemostatic sealant as Surgicel original, Surgicel Fibrillar (ETHICON, USA) which is an absorbable hemostat (oxidized regenerated cellulose) will be applied directly to the bleeding surface 1:5sheets of hemostat will be used."
219126494|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using electrosurgical energy|"A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary In the electrosurgical energy using group the hemostasis method will be different and will be achieved using electrosurgical energy.~* After the cyst removal and cyst bed examination, any bleeding will be carefully coagulated using bipolar electrosurgical energy~* Minimal energy will be applied for short durations to reduce collateral thermal"
219126495|NCT06920563|OTHER|Video|Those in the intervention arm will watch a short educational video.
219126496|NCT06920563|OTHER|Text Reminder|Those in the intervention group will receive regular text message reminders to check their blood pressures
219126497|NCT06920563|OTHER|Blood pressure threshold|Those in the intervention group will have a lower blood pressure threshold to titrate their BP medications towards
219126498|NCT06918314|DEVICE|Blood Flow Restriction Kaatsu Training Device|"The Blood Flow Restriction (BFR) intervention uses a pneumatic cuff to partially restrict arterial and fully restrict venous blood flow, creating a hypoxic environment that enhances muscle activation and strength at low exercise intensities. In this study, BFR will be applied intermittently during low-intensity treadmill walking with controlled pressure adjustments.~The Moxy Muscle Oxygen Monitor is a non-invasive NIRS device that measures muscle oxygen saturation (SmO₂) and total hemoglobin (THb). Placed on the quadriceps femoris muscle, it will track oxygenation changes before, during, and after BFR exercise, helping assess muscle metabolism and performance adaptations."
219126499|NCT06919211|PROCEDURE|Perfluorocarbon Liquid vs. Posterior Retinotomy during Pars-plana Vitrectomy for The Surgical Repair of Rhegmatogenous Retinal Detachment|This study compares outcomes of perfluorocarbon liquid (PFCL) versus posterior retinotomy (PR) during Pars plana vitrectomy (PPV) for Rhegmatogenous retinal detachment (RRD), focusing on anatomical success, visual acuity, intraocular pressure (IOP), and complications
219126500|NCT06919367|OTHER|age estimation using orthopantomography|Dental age estimation will be performed with 3 different methods based on orthopantomographic images obtained during routine examinations of patients.
219126501|NCT06918145|PROCEDURE|Lymphaticovenous Anastomosis|The basic principle of LVA surgery is to anastomose the deep cervical lymphatic vessels of the brain with adjacent small veins, effectively enabling the direct reflow of accumulated Aβ and tau proteins in the brain's lymphatic circulation into the venous system, thereby improving the symptoms of Alzheimer's Disease (AD).
219126502|NCT06919731|OTHER|whole blood flow cytometry analisys|Evaluation of platelet prothrombotic potential through a flow-cytometry analysis of platelet activation marker expression, including P-selectin, aGPIIbIIIa and TF, as well as platelet-leukocyte aggregate formation.
219126503|NCT06920355|OTHER|Produce Prescription|Each month, participants will receive a fixed amount of funds on the PRx card. Participants will be able to use these funds to purchase fruits, vegetables, beans, nuts, nut butters, seeds, plant-based oils, seafood, and yogurts from participating grocery stores. These funds will be provided through an electronic PRx benefit card that is activated after the initial baseline in-person visit is completed. The card will be reloaded monthly for a period of 6 months.
219126504|NCT06920355|BEHAVIORAL|Nutrition Education|Participating pharmacies/grocery chains will have Registered Dietitians (RD/RDN) on staff who can provide participants with nutrition education programs, coaching, and/or nudges.
219126505|NCT06934213|BEHAVIORAL|Choice|The observer gets to make a choice about the sequence of trials they see
219126506|NCT06934213|BEHAVIORAL|Mixed trials|The search tasks are either intermixed. Otherwise trials are run in blocks
219126507|NCT04216225|OTHER|pre-hospital tourniquet placement|patients with extremity injuries presenting with or without pre-hospital tourniquet placement.
219126508|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
219126509|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
219126510|NCT00662909|DRUG|Mirabegron|Oral
219126511|NCT00662909|DRUG|Placebo|Oral
219226037|NCT06055491|DRUG|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
219710115|NCT05300282|COMBINATION_PRODUCT|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
219710116|NCT02272270|DRUG|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
219710117|NCT06556862|DRUG|Dalpiciclib|100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
219710118|NCT06556862|DRUG|Chidamide|25 mg/BIW, po. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
219710119|NCT06556862|DRUG|Enitinostat|5mg/QW，po.
219710120|NCT05879432|DRUG|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
219710121|NCT05879432|DRUG|Placebo|0.9% saline solution
219710122|NCT06557460|DEVICE|Surgical implantation of the CPCB-RPE1 implant|Surgical implantation of the CPCB-RPE1 implant
219710123|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
219710124|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
219126512|NCT06163222|BEHAVIORAL|Additional message with behavioural science-informed content and associated web pages|Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
219126513|NCT06163222|OTHER|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
219126514|NCT04406779|DEVICE|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
219126515|NCT04610684|DRUG|Carboplatin|Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
219710125|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
219126516|NCT04610684|DRUG|Etoposide|Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
219126517|NCT04610684|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
219126518|NCT05079217|BIOLOGICAL|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219126519|NCT05079217|BIOLOGICAL|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219126520|NCT02190838|DRUG|Metformin|per os 850 mg BID
219126521|NCT02190838|DRUG|Melatonin|per os 3 mg daily
219126522|NCT02190838|DRUG|Dacarbazine|IV 1 hour 1000 mg/m\^2 once in 28 days
219126523|NCT03494699|BEHAVIORAL|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
219126524|NCT02998827|DRUG|Thalidomide|
219710126|NCT05090891|DRUG|Placebo|Placebo will be administered QD orally.
219710127|NCT05989048|DRUG|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
219126525|NCT02998827|DRUG|infliximab, azathioprine|other treatment include infliximab, azathioprine
219126526|NCT02998827|OTHER|enteral nutrition|
219126527|NCT02655692|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
219126528|NCT02655692|DRUG|Placebo/Saline|This is a saline placebo/non-active solution.
219126529|NCT03768245|BEHAVIORAL|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
219710128|NCT05989048|DRUG|Placebo|Single dose of matching placebo taken within Treatment Phase.
219126530|NCT03768245|DIETARY_SUPPLEMENT|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
219126531|NCT02721511|DRUG|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
219126532|NCT01084161|DRUG|N1539|5 mg IV once per day
219126533|NCT01084161|DRUG|N1539|7.5 mg IV once per day
219226038|NCT03367416|BEHAVIORAL|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
219226039|NCT02782000|OTHER|lessons,long-term supervision and message|
219710129|NCT04297917|BIOLOGICAL|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
219710130|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
219710131|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
219126534|NCT01084161|DRUG|N1539|15 mg IV once per day
219710132|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
219710133|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
219710134|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219126535|NCT01084161|DRUG|N1539|30 mg IV once per day
219126536|NCT01084161|DRUG|placebo|IV placebo once per day
219126537|NCT01084161|DRUG|Morphine|morphine 10-15 mg IV once per day
219126538|NCT01084161|DRUG|N1539|60 mg IV once per day
219126539|NCT01217580|DRUG|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
219126540|NCT01217580|DRUG|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
219126541|NCT02728245|DRUG|Dienogest|Dienogest 2mg po qd
219226040|NCT02782000|OTHER|lessons,short-term supervision and message|
219226041|NCT04263714|BEHAVIORAL|Exercise|Aerobic exercise and resistance exercise
219226042|NCT03516877|BEHAVIORAL|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
219710135|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
219126542|NCT02728245|DRUG|Placebo drug|Placebo 1 table po qd
219126543|NCT02728245|PROCEDURE|Surgery|conservative surgery without intent to oophorectomy
219126544|NCT00017277|BIOLOGICAL|epoetin alfa|
219126545|NCT00017277|RADIATION|radiation therapy|
219710136|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
219710137|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
219710138|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
219710139|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
219710140|NCT06643442|DRUG|Empagliflozin Tablets|Empagliflozin 10mg p.o. once daily (commercially available tablet)
219710141|NCT06645236|DEVICE|therascreen® KRAS RGQ PCR Kit|The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
219710142|NCT06492460|DRUG|Drug：Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
219710143|NCT04225039|DRUG|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
219710144|NCT04225039|DRUG|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
219710145|NCT04225039|DRUG|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
219710146|NCT04225039|PROCEDURE|Brain surgery|maximal safe surgical resection of the tumor.
219710147|NCT06343324|BEHAVIORAL|Web-based education|Patients using noninvasive ventilation at home will receive detailed information about accessing, logging in and using web-based training. Pretest data will be collected, then week 4 and week 8 data will be collected.
219710148|NCT05453383|DRUG|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
219710149|NCT00434486|DRUG|SKI-606|
219710150|NCT02620280|DRUG|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
219710151|NCT02620280|DRUG|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
219126546|NCT03959709|PROCEDURE|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
219126547|NCT03959709|PROCEDURE|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
219126548|NCT03764345|DRUG|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
219126549|NCT04376164|RADIATION|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
219126550|NCT00038792|DRUG|Recombinant Human Keratinocyte Growth Factor|
219126551|NCT00312078|DIETARY_SUPPLEMENT|Yogurt Supplementation|
219710152|NCT02620280|DRUG|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
219710153|NCT02620280|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
219710154|NCT02620280|DRUG|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
219710155|NCT05743894|DEVICE|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
219710156|NCT05884593|DEVICE|Pedicle screw instrumentation using Mazor X robotic system|Pedicle screw instrumentation using Mazor X robotic system
219710157|NCT00734565|BIOLOGICAL|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
219710158|NCT00384631|OTHER|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
219710159|NCT00384631|DRUG|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
219710160|NCT02869035|DRUG|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
219710161|NCT02869035|DRUG|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
219710162|NCT03658772|DRUG|grapiprant|Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
219710163|NCT03658772|DRUG|grapiprant and pembrolizumab|Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
219710164|NCT02020642|PROCEDURE|Renal transplantation|Renal transplantation from cadaveric or live donor
219710165|NCT00000640|DRUG|Primaquine|
219710166|NCT00000640|DRUG|Sulfamethoxazole-Trimethoprim|
219710167|NCT00000640|DRUG|Dapsone|
219710168|NCT00000640|DRUG|Clindamycin|
219710169|NCT05004025|DEVICE|Novocure Optune|Novacure Optune with Opdivo and Yervoy
219710170|NCT05004025|DRUG|Opdivo|Novacure Optune with Opdivo and Yervoy
219710171|NCT05004025|DRUG|Yervoy|Novacure Optune with Opdivo and Yervoy
219710172|NCT05991375|DRUG|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
219710173|NCT05991375|OTHER|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
219126552|NCT00690456|DRUG|Rimonabant|Tablet, oral administration
219126553|NCT00690456|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
219126554|NCT00690456|DRUG|Metformin|Metformin continued at stable dose as background therapy
219126555|NCT01334541|BEHAVIORAL|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol"
219126556|NCT04978363|DEVICE|BOOT|A walking boot is a common type of brace/boot that restricts ankle and foot movement.
219126557|NCT04978363|DEVICE|HFC|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.
219126558|NCT04978363|DEVICE|SAC|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.
219126559|NCT04978363|DEVICE|HFC+BOOT|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
219126560|NCT04978363|DEVICE|SAC+BOOT|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
219126561|NCT01251614|BIOLOGICAL|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
219126562|NCT01251614|DRUG|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
219126563|NCT01251614|BIOLOGICAL|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
219126564|NCT01251614|DRUG|Placebo to Methotrexate|Orally once a week
219126565|NCT02387203|DRUG|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
219710174|NCT06131021|DRUG|Amoxicillin|Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
219710175|NCT06131021|DRUG|Metronidazole|Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
219126566|NCT02153788|DRUG|Temazepam|Temazepam 15 mg orally at bedtime
219126567|NCT02153788|DRUG|Placebo|
219126568|NCT04672460|DRUG|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
219126569|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
219126570|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
219126571|NCT03575962|DRUG|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
219226043|NCT01124045|DRUG|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
219126572|NCT03575962|DRUG|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
219126573|NCT05247853|PROCEDURE|Blood collection|Blood collection at enrollment visit
219126574|NCT05247853|PROCEDURE|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
219126575|NCT05247853|PROCEDURE|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
219126576|NCT05247853|PROCEDURE|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
219126577|NCT05247853|PROCEDURE|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
219126578|NCT05247853|PROCEDURE|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
219126579|NCT00059917|DRUG|polyglutamate camptothecin|
219126580|NCT00418847|DRUG|miglustat|Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
219226044|NCT01124045|DRUG|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
219226045|NCT00729547|BEHAVIORAL|Neurofeedback|enhance relative activity level of left frontal activity
219226046|NCT00729547|BEHAVIORAL|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
219710176|NCT06131021|OTHER|Placebo|Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
219710177|NCT06245499|BEHAVIORAL|Aging Brain Care Virtual Program|The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
219710178|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
219710179|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
219126581|NCT05322161|BEHAVIORAL|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation"
219126582|NCT03286725|BEHAVIORAL|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
219126583|NCT01032850|DRUG|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
219126584|NCT03426514|PROCEDURE|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
219126585|NCT03426514|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
219126586|NCT00530374|DIETARY_SUPPLEMENT|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
219126587|NCT00530374|DIETARY_SUPPLEMENT|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
219126588|NCT06231628|PROCEDURE|Percutaneous cementoplasty|"Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely"
219126589|NCT03952481|DRUG|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
219126590|NCT00049517|BIOLOGICAL|sargramostim|Given IV or as an injection
219226047|NCT03939416|OTHER|Experimental|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes."
219710180|NCT04733534|DRUG|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
219126591|NCT00049517|DRUG|busulfan|Given IV
219126592|NCT00049517|DRUG|cyclophosphamide|Given IV
219126593|NCT00049517|DRUG|cytarabine|Given as a continuous infusion
219710181|NCT04733534|DRUG|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
219126594|NCT00049517|DRUG|gemtuzumab ozogamicin (GO)|Given IV
219126595|NCT00049517|DRUG|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
219126596|NCT00049517|PROCEDURE|Autologous HCT|Autologous hematopoietic cell transplantation
219126597|NCT00049517|PROCEDURE|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
219126598|NCT03044769|PROCEDURE|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
219126599|NCT02487290|DEVICE|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
219126600|NCT05955599|OTHER|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
219226048|NCT03939416|OTHER|Control|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
219710182|NCT05220046|DRUG|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
219710183|NCT04675710|PROCEDURE|Conventional Surgery|Undergo surgery
219710184|NCT04675710|DRUG|Dabrafenib|Given PO
219710185|NCT04675710|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219710186|NCT04675710|BIOLOGICAL|Pembrolizumab|Given IV
219710187|NCT04675710|OTHER|Quality-of-Life Assessment|Ancillary studies
219710188|NCT04675710|DRUG|Trametinib|Given PO
219710189|NCT06538337|RADIATION|External beam Radiotherapy|Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
219710190|NCT06538246|BEHAVIORAL|Blueprint|This is a mobile app-based adaptive coping skills intervention that lasts 1 month
219126601|NCT05955599|OTHER|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
219126602|NCT06454292|DRUG|Oliceridine Fumarate|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
219126603|NCT06454292|DRUG|Remifentanil|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
219126604|NCT00961805|BEHAVIORAL|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
219126605|NCT00961805|OTHER|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
219126606|NCT05218603|DRUG|Bortezomib|Maintenance: Administration as per routine clinical practice.
219126607|NCT05218603|DRUG|Daratumumab|Maintenance: Administration as per routine clinical practice.
219126608|NCT02746900|PROCEDURE|Cervical cerclage|McDonald cervical cerclage
219126609|NCT03089346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
219126610|NCT03089346|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
219126611|NCT04094012|DRUG|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
219710191|NCT06538246|BEHAVIORAL|Education program|This is a mobile app-based education program that lasts 1 month
219710192|NCT04546646|OTHER|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
219710193|NCT01670006|DEVICE|Cochlear Nucleus Cochlear Implant System|
219710194|NCT06019754|PROCEDURE|one point combined Lumbar and sacral plexus block|performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
219710195|NCT05988138|BEHAVIORAL|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
219710196|NCT05988138|BEHAVIORAL|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
219710197|NCT05050383|OTHER|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
219126612|NCT01684046|DEVICE|Opti-Free® PureMoist® MPDS|
219126613|NCT01684046|DEVICE|RevitaLens MPDS|
219710198|NCT05050383|OTHER|Submental Ultrasound|Ultrasound of airway soft tissues
219710199|NCT06189352|OTHER|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
219710200|NCT02477449|DRUG|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
219710201|NCT02477449|DRUG|9% Saline (NS)|infusion for 24 hours
219710202|NCT00359476|DRUG|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
219710203|NCT00988026|DRUG|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
219710204|NCT01642368|OTHER|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
219710205|NCT02845804|DEVICE|Alpine|
219710206|NCT04800627|BIOLOGICAL|Pembrolizumab|Given IV
219126614|NCT01684046|DEVICE|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
219126615|NCT04074551|DRUG|HCP1701|HCP1701
219126616|NCT04074551|DRUG|Losartan|Losartan
219126617|NCT04074551|DRUG|Amlodipine|Amlodipine
219126618|NCT04074551|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
219126619|NCT00082485|DRUG|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
219126620|NCT00082485|OTHER|Placebo|Placebo
219126621|NCT04616365|PROCEDURE|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
219126622|NCT00515840|OTHER|Physiotherapist|Physiotherapist administered breathing retraining programme
219126623|NCT05709548|DRUG|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
219126624|NCT02562014|OTHER|Glucose|75g glucose
219126625|NCT02562014|OTHER|Inulin|75g glucose plus 24g inulin
219126626|NCT02562014|OTHER|Resistant Starch|75g glucose plus 28.2g resistant starch
219126627|NCT03837925|DRUG|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
219126628|NCT03837925|DRUG|Placebo comparator|Patient participation for 6 weeks of treatment
219710207|NCT04800627|DRUG|Pevonedistat|Given IV
219710208|NCT03542760|DRUG|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
219226049|NCT06029842|OTHER|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
219710209|NCT00177697|BEHAVIORAL|behavioral weight loss program|
219710210|NCT02064062|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
219710211|NCT02084797|DRUG|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
219710212|NCT04544917|BEHAVIORAL|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
219710213|NCT04544917|BEHAVIORAL|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
219710214|NCT00166699|PROCEDURE|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
219710215|NCT02802228|DRUG|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
219710216|NCT02802228|DRUG|Placebo|matched placebo delivered as infusion and oral capsule
219710217|NCT01879267|BEHAVIORAL|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
219126629|NCT00318968|DRUG|Esomeprazole|
219126630|NCT00049114|DRUG|doxorubicin hydrochloride|
219126631|NCT00049114|DRUG|cyclophosphamide|Given IV
219126632|NCT00049114|DRUG|tipifarnib|Given orally
219226050|NCT05414201|DRUG|Adalimumab|Subcutaneous Injection
219126633|NCT00049114|BIOLOGICAL|filgrastim|Given subcutaneously
219126634|NCT00049114|PROCEDURE|therapeutic conventional surgery|Undergo complete resection
219126635|NCT00049114|OTHER|laboratory biomarker analysis|Correlative studies
219126636|NCT03521323|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
219126637|NCT03521323|DRUG|Placebos|Placebos: Saline，Sham operation
219126638|NCT05336123|BEHAVIORAL|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
219126639|NCT05336123|BEHAVIORAL|Health Education|Weekly health education classes lasting 10 weeks.
219126640|NCT05520827|DRUG|BI 1584862|BI 1584862
219126641|NCT05520827|DRUG|Placebo|Placebo
219126642|NCT04902586|DEVICE|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
219126643|NCT00536666|DRUG|Iron oligosaccharide|
219226051|NCT00515060|OTHER|Sensory Tests|Tests to find the threshold at which perceive stimuli.
219710218|NCT04620200|DRUG|Nivolumab|3mg/kg
219710219|NCT04620200|DRUG|Ipilimumab|1mg/kg
219710220|NCT00695019|DRUG|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
219710221|NCT00695019|DRUG|placebo lozenges|200 mg matching placebo lozenges
219710222|NCT03410316|OTHER|No intervention|
219710223|NCT05580120|BEHAVIORAL|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
219126644|NCT05777057|DIAGNOSTIC_TEST|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
219126645|NCT06063330|COMBINATION_PRODUCT|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
219126646|NCT06063330|OTHER|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
219126647|NCT03614130|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
219126648|NCT03614130|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
219126649|NCT00421915|DRUG|Enbrel (etanercept)|
219126650|NCT02111343|OTHER|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
219126651|NCT03371108|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
219126652|NCT03371108|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
219126653|NCT04108910|DIAGNOSTIC_TEST|Guidance UTI|
219126654|NCT02563600|BEHAVIORAL|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
219126655|NCT02563600|BEHAVIORAL|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
219710224|NCT05580120|BEHAVIORAL|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
219126656|NCT04416139|BIOLOGICAL|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
219126657|NCT02836665|PROCEDURE|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
219126658|NCT05978609|DRUG|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
219126659|NCT05978609|DRUG|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
219126660|NCT05978609|DRUG|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
219126661|NCT02714829|DEVICE|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
219126662|NCT02714829|DEVICE|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
219226052|NCT06229418|OTHER|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
219226053|NCT06113692|BIOLOGICAL|mRNA-1273|intramuscular injection
219710225|NCT00340483|BEHAVIORAL|Smoking cessation|
219710226|NCT01796522|DRUG|progesterone 200 mg / day vaginally|
219710227|NCT01796522|DRUG|nifedipine (60 mg / day orally)|
219710228|NCT06375993|DRUG|ADI-001|Anti-CD20 CAR-T
219710229|NCT06375993|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
219710230|NCT06375993|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
219710231|NCT04463706|OTHER|Predictors adverse evolution|Predictors adverse evolution in all hospital participant admitted patients
219710232|NCT04463706|OTHER|Predictors of health care provide|Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
219710233|NCT04373941|DRUG|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
219126663|NCT05190185|BIOLOGICAL|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
219126664|NCT05626543|BEHAVIORAL|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
219126665|NCT00521716|DEVICE|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
219226054|NCT05298423|BIOLOGICAL|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
219226055|NCT05298423|BIOLOGICAL|durvalumab|Administered as an IV infusion
219710234|NCT04525820|DRUG|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
219710235|NCT04525820|DRUG|Placebo|Patient receives a single dose of a placebo solution
219710236|NCT04525820|DRUG|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
219710237|NCT05634369|BIOLOGICAL|GEM/DOX + TGFBi expanded NK cells|"8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~  1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)"
219710238|NCT06026813|DEVICE|test pressure alternating shoes|test pressure alternating shoes
219710239|NCT02368509|OTHER|Perform sensory tests|
219710240|NCT02879695|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219710241|NCT02879695|BIOLOGICAL|Blinatumomab|Given IV
219710242|NCT02879695|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219710243|NCT02879695|BIOLOGICAL|Ipilimumab|Given IV
219710244|NCT02879695|BIOLOGICAL|Nivolumab|Given IV
219710245|NCT06787599|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in non-peritoneal dialysis (PD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of teleexercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
219710246|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
219710247|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
219710248|NCT05595915|DIETARY_SUPPLEMENT|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
219710249|NCT04298541|DRUG|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
219710250|NCT04298541|DRUG|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
219710251|NCT04442724|PROCEDURE|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
219710252|NCT04442724|DIAGNOSTIC_TEST|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
219710253|NCT04272060|DIAGNOSTIC_TEST|CT angiography|Diagnostic CT angiography
219710254|NCT04272060|DIAGNOSTIC_TEST|Invasive coronary angiography|Diagnostic invasive coronary angiography
219710255|NCT06688864|BEHAVIORAL|EPIO App|Participants will receive access to the app-based cognitive-behavioral pain self-management intervention program (EPIO) for 3 months.
219710256|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
219226056|NCT05298423|DRUG|cisplatin|Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
219710257|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
219710258|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
219126666|NCT00521716|DEVICE|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
219126667|NCT05668091|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours.
219126668|NCT05668091|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours.
219226057|NCT05298423|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
219126669|NCT05668091|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
219126670|NCT05805059|DEVICE|Control Contact Lens (stenfilcon A)|one week wear
219126671|NCT05805059|DEVICE|Test Contact Lens (senofilcon A)|one week of wear
219126672|NCT04042467|BEHAVIORAL|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
219126673|NCT04042467|BEHAVIORAL|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
219126674|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
219126675|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
219126676|NCT05905458|DRUG|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
219126677|NCT06219785|DEVICE|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
219126678|NCT05882032|DRUG|LY3502970|Administered orally.
219126679|NCT03892850|BEHAVIORAL|Nurse prescription|Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
219126680|NCT03892850|BEHAVIORAL|Medical prescription|Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
219126681|NCT04188288|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
219126682|NCT04188288|DEVICE|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
219126683|NCT04188288|DEVICE|fMRI|fMRI will be used to assess brain activity
219126684|NCT02790606|DEVICE|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
219126685|NCT02735915|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
219126686|NCT05356403|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
219126687|NCT05356403|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
219710259|NCT06496607|BIOLOGICAL|Placebo|Placebo
219710260|NCT02401295|DRUG|ATRA|
219710261|NCT02401295|DRUG|Celecoxib|
219126688|NCT05328973|OTHER|ELEQUIL|patch placed on skin
219126689|NCT06331962|OTHER|remote home-based exercise therapy group|"Location and Frequency: Four times per week at the individual's ownhome. Exercise Duration: Eight weeks (subject to adjustments based onactual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory exercises.~Note: The participant will receive a customized exercise plan based ontheir capabilities, including guidelines and exercise instructions (exercisenames, required equipment, movement sequences, repetitions,precautions)."
219126690|NCT06331962|OTHER|supervised exercise therapy group|"Exercise Location and Frequency: Physiotherapy Center (twice a week)and individual's home (twice a week).~Exercise Duration: Eight weeks (subject to adjustments based on actualprogress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory training exercises. The home-based exercise trainingcontent is partially the same as the remote home-based exercise group."
219126691|NCT06331962|OTHER|regular care group|Perform regular care for eight consecutive weeks. After the trackingperiod ends (8 weeks), provide home-based education on resistanceexercises, cardiovascular endurance exercises, and sensory trainingexercises.
219126692|NCT02680769|DIETARY_SUPPLEMENT|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
219126693|NCT02680769|OTHER|Placebo|This group will take a placebo
219126694|NCT03203161|PROCEDURE|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
219126695|NCT00227981|BEHAVIORAL|Interpersonal Psychotherapy|
219126696|NCT00227981|DRUG|Fluoxetine|
219126697|NCT06630923|DRUG|Human albumin|Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
219126698|NCT01218828|OTHER|LVEDP -Based hydration strategy|
219126699|NCT01218828|OTHER|Standard hydration|
219710262|NCT02401295|DRUG|Itraconazole|
219710263|NCT04606446|DRUG|PF-07248144|KAT6 Inhibitor
219710264|NCT04606446|DRUG|Fulvestrant|Endocrine Therapy
219710265|NCT04606446|DRUG|Letrozole|Endocrine Therapy
219710266|NCT04606446|DRUG|Palbociclib|CDK4/6 Inhibitor
219710267|NCT04606446|DRUG|PF-07220060|CDK4 inhibitor
219710268|NCT04606446|DRUG|PF-07850327, ARV-471, vepdegestrant|PROTAC (PROteolysis Targeting Chimera) ER degrader
219710269|NCT05217810|OTHER|Atectura inhalation capsule (150/80ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
219710270|NCT05217810|OTHER|Atectura inhalation capsule (150/160ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
219710271|NCT05217810|OTHER|Atectura inhalation capsule (150/320ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
219126700|NCT02728271|BIOLOGICAL|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
219126701|NCT03422978|DRUG|Dexmedetomidine|Single dose dexmedetomidine administered over 60 seconds post-induction.
219126702|NCT03422978|DRUG|Normal saline|Single dose normal saline administered over 60 seconds post-induction.
219126703|NCT01525433|BEHAVIORAL|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
219126704|NCT01525433|BEHAVIORAL|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
219126705|NCT00486733|DEVICE|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
219710272|NCT05045963|OTHER|Electronic Health Record Review|Medical record reviewed
219710273|NCT05536011|DRUG|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
219710274|NCT05536011|DRUG|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
219710275|NCT04627688|BEHAVIORAL|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
219710276|NCT04627688|BEHAVIORAL|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
219126706|NCT00946114|DRUG|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
219126707|NCT00946114|DRUG|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
219126708|NCT04833192|DIAGNOSTIC_TEST|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
219126709|NCT06163521|OTHER|Education|A training consisting of 8 sessions of 40 minutes each will be applied to the children. One session will be done every week. The training will consist of activities including information, discussion and role-playing about children with special needs. The training topics consist of; Children with Special Needs Empathy Differences, Respect for Differences Contact Activity Awareness Benevolence Social Acceptance and Behaviour What can we do?
219126710|NCT00517478|PROCEDURE|Blood Sample|
219126711|NCT00316784|DRUG|IDEA-033 (and rescue medication)|
219126712|NCT01841827|DRUG|Cilostazol|
219126713|NCT01841827|DRUG|Placebo|
219126714|NCT02304822|DRUG|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
219126715|NCT02304822|DRUG|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
219126716|NCT02304822|DRUG|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
219126717|NCT03299491|OTHER|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
219126718|NCT03299491|OTHER|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
219226058|NCT05298423|DRUG|etoposide|Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
219226059|NCT05298423|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
219226060|NCT05298423|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
219226061|NCT05298423|RADIATION|thoracic radiotherapy|60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
219226062|NCT05553366|DRUG|SUZ|Tablets for oral administration.
219226063|NCT05553366|DRUG|HB/APAP|Capsules for oral administration.
219226064|NCT05553366|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
219226065|NCT05553366|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
219226066|NCT04289571|DIAGNOSTIC_TEST|VR Mobility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
219126719|NCT01387490|BEHAVIORAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
219126720|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
219126721|NCT03728738|PROCEDURE|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
219126722|NCT02024308|DRUG|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
219126723|NCT02024308|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
219126724|NCT05302843|DRUG|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
219126725|NCT01447914|DRUG|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
219126726|NCT01447914|OTHER|Diagnostic laboratory biomarker analysis|Correlative studies
219126727|NCT01447914|OTHER|Questionnaire administration|Ancillary studies
219126728|NCT01447914|PROCEDURE|Quality-of-life assessment|Ancillary studies
219126729|NCT02888613|PROCEDURE|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
219710277|NCT03318198|OTHER|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
219710278|NCT03318198|OTHER|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
219710279|NCT05455775|DEVICE|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
219710280|NCT02373865|DRUG|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
219710281|NCT02373865|DRUG|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
219126730|NCT02888613|PROCEDURE|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
219710282|NCT02373865|DRUG|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
219710283|NCT02373865|DRUG|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
219710284|NCT06034743|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm."
219710285|NCT06034743|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
219710286|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
219710287|NCT04098003|DRUG|Placebo|Matched placebo control
219710288|NCT06344364|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
219126731|NCT01483287|DIETARY_SUPPLEMENT|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
219126732|NCT06629415|DRUG|Indocyanine Green|"injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image"
219126733|NCT06629415|DRUG|Indocyanine Green Drug|1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
219710289|NCT00432822|DRUG|tetrahydrobiopterin (BH4)|
219710290|NCT04808921|DIAGNOSTIC_TEST|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
219710291|NCT05277207|BEHAVIORAL|Personalized Smoking Cessation Facilitation Meetings|Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
219710292|NCT05277207|DRUG|Personalized Smoking Cessation Pharmacotherapy|Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
219710293|NCT05277207|BEHAVIORAL|Personalized Text Messaging Support|If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
219710294|NCT05277207|BEHAVIORAL|SmokefreeVET|Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
219710295|NCT05277207|BEHAVIORAL|VA Quitline|Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
219710296|NCT05277207|OTHER|Education about pharmacotherapy|Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
219710297|NCT02770703|DEVICE|DynaMesh visible mesh|Implantation of a MRI visible mesh
219710298|NCT06377514|DEVICE|Test IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
219710299|NCT06377514|DEVICE|Control IOL Model DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
219710300|NCT06645093|OTHER|Fasting|Fasting implies 0 kilojoule. Water ad libitum is permitted.
219710301|NCT05523297|DRUG|Octaplex|Prothrombin complex concentrate
219710302|NCT05523297|DRUG|Frozen Plasma Product, Human|If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
219710303|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 1
219710304|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 2
219710305|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 3
219710306|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 4
219710307|NCT04847024|DRUG|Parecoxib|40 mg IV
219710308|NCT04847024|DRUG|Dexketoprofen|50 mg IV
219710309|NCT03347643|DEVICE|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
219710310|NCT03347643|DEVICE|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
219710311|NCT03462680|DIETARY_SUPPLEMENT|niacin|Niacin or nicotinic acid 250 mg tablets
219710312|NCT03462680|OTHER|placebo|placebo tablet
219710313|NCT04225975|DIAGNOSTIC_TEST|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
219710314|NCT04225975|DIAGNOSTIC_TEST|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
219710315|NCT03203785|DIETARY_SUPPLEMENT|Carbohydrate (maltodextrin)|maltodextrin flavored
219710316|NCT03203785|OTHER|Placebo|non-caloric drink
219710317|NCT05345080|BEHAVIORAL|Exposure-Reduction Intervention|The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
219126734|NCT06461741|DEVICE|Integrated Dual-task EMG Biofeedback Training (EMG-BF)|"The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of \>1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the device is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles. In this trail is the Explore+ ExG amplifier which is sold by Mentalab."
219126735|NCT06461741|BEHAVIORAL|Traditional Balance Exercise Training (BAL-EX)|This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.
219126736|NCT03588975|BIOLOGICAL|MACI|autologous cultured chondrocytes on porcine collagen membrane
219126737|NCT03588975|PROCEDURE|microfracture|Arthroscopic microfracture treatment
219126738|NCT05036772|DEVICE|Virtual reality|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
219126739|NCT01764386|DRUG|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
219126740|NCT01764386|BEHAVIORAL|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
219126741|NCT01764386|BEHAVIORAL|Usual Care|Usual Care is a self-directed lifestyle intervention program
219126742|NCT03377036|DIAGNOSTIC_TEST|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
219710318|NCT02270268|DIETARY_SUPPLEMENT|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
219126743|NCT03377036|DIAGNOSTIC_TEST|2D-FFDM|2D full-field digital mammography
219126744|NCT03929302|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
219126745|NCT04113837|DIETARY_SUPPLEMENT|food range|"The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week"
219126746|NCT01123161|DEVICE|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
219126747|NCT01123161|DRUG|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
219226067|NCT02915432|BIOLOGICAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
219710319|NCT02270268|DIETARY_SUPPLEMENT|maltodextrin|
219710320|NCT02333643|DRUG|CLS003|
219710321|NCT02333643|DRUG|Furosemide|
219710322|NCT02333643|DRUG|Digoxin|
219710323|NCT02333643|DRUG|Vehicle topical|
219710324|NCT02576496|DRUG|Tinostamustine|
219710325|NCT05844046|BIOLOGICAL|durvalumab, tremelimumab, bevacizumab|durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
219710326|NCT02246777|DEVICE|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
219710327|NCT00182819|DRUG|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
219710328|NCT00182819|RADIATION|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
219710329|NCT00439621|BIOLOGICAL|RP 01|Active immunotherapy
219126748|NCT02757885|PROCEDURE|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
219710330|NCT00825006|DEVICE|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
219126749|NCT02757885|DRUG|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.
219126750|NCT02757885|DRUG|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.
219126751|NCT02757885|DRUG|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
219126752|NCT02757885|DRUG|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
219126753|NCT02757885|OTHER|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
219126754|NCT02757885|RADIATION|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
219710331|NCT00498303|BIOLOGICAL|trivalent split influenza vaccine|
219710332|NCT00870701|RADIATION|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
219710333|NCT00870701|OTHER|absence of radiotherapy|absence of radiotherapy
219710334|NCT03076879|BEHAVIORAL|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
219710335|NCT02401230|DRUG|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
219710336|NCT02401230|DEVICE|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
219710337|NCT00683995|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
219710338|NCT00916734|PROCEDURE|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
219710339|NCT00916734|PROCEDURE|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
219710340|NCT04133909|BIOLOGICAL|Mepolizumab|Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.
219710341|NCT04133909|DRUG|Placebo|Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.
219710342|NCT03505775|DIAGNOSTIC_TEST|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
219126755|NCT05998590|DIETARY_SUPPLEMENT|High protein supplement|The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
219126756|NCT05998590|DIETARY_SUPPLEMENT|Moderate protein supplement|The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
219226068|NCT02915432|BIOLOGICAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
219710343|NCT06376136|DRUG|BAT8010 for Injection|Intravenous
219710344|NCT06376136|DRUG|BAT1006 for Injection|Intravenous
219710345|NCT05402059|DRUG|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
219126757|NCT05998590|DIETARY_SUPPLEMENT|Carbohydrate placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
219126758|NCT05998590|OTHER|Control: No supplementation|The participants did not receive any supplementation but instead acted as a control group doing BT only
219126759|NCT06340789|DRUG|Sodium Benzoate 2gram/day|the add-on sodium benzoate with conventional pharmacological treatment
219226069|NCT02915432|BIOLOGICAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
219226070|NCT05808595|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
219710346|NCT00830765|DRUG|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
219710347|NCT00830765|DRUG|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
219710348|NCT06201312|OTHER|COP exercise|crossover point intensity exercise
219710349|NCT03959657|OTHER|No intervention performed by authors|Observational and retrospective study, no intervention performed
219710350|NCT01087060|PROCEDURE|partial or radical nephrectomy|
219710351|NCT01299909|BEHAVIORAL|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
219710352|NCT01299909|BEHAVIORAL|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
219710353|NCT01299909|BEHAVIORAL|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
219710354|NCT03023995|PROCEDURE|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
219710355|NCT03023995|PROCEDURE|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
219710356|NCT02435134|OTHER|no intervention|
219710357|NCT06405919|DIAGNOSTIC_TEST|Histopathology|Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
219710358|NCT01256515|BEHAVIORAL|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
219126760|NCT06340789|DRUG|Placebo|the add-on placebo with conventional pharmacological treatment
219126761|NCT04704960|OTHER|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
219226071|NCT05808595|OTHER|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
219226072|NCT03877575|OTHER|No specific intervention. Collection of clinical data|
219226073|NCT02022657|DRUG|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
219226074|NCT06434064|PROCEDURE|Biopsy|Undergo tumor biopsy
219226075|NCT06434064|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219226076|NCT06434064|PROCEDURE|Computed Tomography|Undergo CT scan
219710359|NCT01256515|BEHAVIORAL|Health Education Training|8 weeks of group training regarding health education techniques.
219710360|NCT00493675|PROCEDURE|endoscopic bile duct stenting|
219710361|NCT00460967|DEVICE|Rheopheresis|8 rheopheresis treatments over 10 wks.
219710362|NCT00460967|DEVICE|Rheopheresis|Sham treatment
219710363|NCT03305718|OTHER|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
219710364|NCT03305718|OTHER|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
219710365|NCT03305718|OTHER|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
219710366|NCT03305718|OTHER|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
219710367|NCT03305718|OTHER|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
219126762|NCT03783533|BEHAVIORAL|Behavioral Activation|Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
219126763|NCT01492309|DEVICE|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
219226077|NCT06434064|PROCEDURE|Echocardiography|Undergo echocardiography
219226078|NCT06434064|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219226079|NCT06434064|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219226080|NCT06434064|DRUG|Tamoxifen|Given PO
219710368|NCT03305718|OTHER|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
219710369|NCT03305718|OTHER|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
219710370|NCT03305718|OTHER|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
219126764|NCT01492309|DEVICE|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
219126765|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
219126766|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
219126767|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
219126768|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
219126769|NCT02414230|DRUG|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219126770|NCT06564831|OTHER|SLAM + SOC|Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219126771|NCT06564831|OTHER|SOC|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219710371|NCT03305718|OTHER|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
219710372|NCT03305718|OTHER|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
219710373|NCT03305718|OTHER|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
219710374|NCT03305718|OTHER|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
219710375|NCT04130841|PROCEDURE|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
219710376|NCT00873652|BIOLOGICAL|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
219710377|NCT03087240|PROCEDURE|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
219126772|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
219126773|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
219126774|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
219126775|NCT00973141|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
219710378|NCT02860052|DRUG|SB208 2%|Apply once daily to one or both feet for 14 days
219710379|NCT02860052|DRUG|SB208 4%|Apply once daily to one or both feet for 14 days
219710380|NCT02860052|DRUG|SB208 16%|Apply once daily to one or both feet for 14 days
219710381|NCT02860052|DRUG|Vehicle Gel|Apply once daily to one or both feet for 14 days
219710382|NCT04019639|DEVICE|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
219126776|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
219126777|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
219710383|NCT04019639|DEVICE|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
219710384|NCT00112229|BIOLOGICAL|group 1|Melan-A analog peptide + CpG + Montanide
219226081|NCT06108635|PROCEDURE|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
219226082|NCT06108635|PROCEDURE|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
219226083|NCT06108635|PROCEDURE|Heat Therapy|Moist heat therapy with hot pack.
219710385|NCT00112229|BIOLOGICAL|group 2|Melan-A natural peptide + CpG + Montanide
219126778|NCT05482919|BEHAVIORAL|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
219126779|NCT05482919|BEHAVIORAL|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
219710386|NCT00112229|BIOLOGICAL|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
219710387|NCT00112229|BIOLOGICAL|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
219710388|NCT03882632|DEVICE|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
219710389|NCT01740206|DRUG|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
219710390|NCT01740206|OTHER|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
219710391|NCT04705090|DRUG|YY-20394 treatment|Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
219710392|NCT03194477|BEHAVIORAL|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
219710393|NCT06252207|DRUG|Desflurane|General anesthesia with desflurlane
219710394|NCT06252207|DRUG|Isoflurane|General anesthesia with isoflurane
219710395|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|"Patients in the rt-PA group received the first dose as soon as possible after registration.~Initial dosing regime: 10 mg of rt-PA dissolved in 5 ml of diluent given every 6 hrs (resulting in a total daily dose of 40mg) for a maximum of 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). Following protocol amendment, dosing duration was increased from 3 days to up to 14 days of rt-PA treatment."
219710396|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV received 60mg daily over three doses for up to 14 days
219710397|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients received 60mg daily over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
219710398|NCT06207799|DRUG|Elranatamab|Given by SC
219710399|NCT06207799|DRUG|Lenalidomide|Given by PO
219710400|NCT06207799|DRUG|Plerixafor|Given by SC
219710401|NCT06207799|DRUG|Melphalan|Given by IV
219710402|NCT06207799|DRUG|Busulfan|Given by PO
219710403|NCT06207799|DRUG|G-CSF|Given by IV
219710404|NCT06207799|PROCEDURE|Stem cell transplant|Given by IV
219126780|NCT05482919|BEHAVIORAL|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
219226084|NCT03177824|DRUG|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
219710405|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
219710406|NCT01985984|RADIATION|Radiation alone|Radiation alone
219710407|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
219710408|NCT06517576|DEVICE|Blood glucose monitor with Digital Platform and Health Coaching|Blood glucose monitors will be used daily to measure blood glucose measurements.
219710409|NCT06517576|DEVICE|Continuous glucose monitor|Continuous glucose monitors will be used daily to measure blood glucose measurements.
219710410|NCT06517576|OTHER|Usual Care|Usual care for type 2 diabetes
219710411|NCT05504070|DEVICE|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
219710412|NCT05504070|DEVICE|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
219710413|NCT06327100|DRUG|Ruxolitinib|Given by PO
219710414|NCT06327100|DRUG|Tasquinimod|Given by PO
219126781|NCT02111148|PROCEDURE|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
219126782|NCT02111148|PROCEDURE|Nitrazine|Nitrazine detection in vaginal wash
219126783|NCT02111148|DRUG|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
219126784|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
219126785|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
219126786|NCT01360840|OTHER|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
219126787|NCT01360840|OTHER|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
219126788|NCT04521192|DRUG|Fluzoparib|the first period: test preparation; the second period: reference preparation
219126789|NCT04521192|DRUG|Fluzoparib|the first period: reference preparation the second period: test preparation
219126790|NCT05657067|BEHAVIORAL|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
219710415|NCT06776510|DRUG|nicotinamide adenine dinucleotid/nicotinamide mononucleotide|"Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide adenine dinucleotide (100mg/d) for 1 week.~Drug: oral nicotinamide mononucleotide administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide mononucleotide 450mg BID for 2 weeks.~The first stage is the main research stage (d0-w2), which is the core treatment period. The aim is to observe the safety and efficacy during treatment.~The second stage (w2-w8) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after treatment."
219710416|NCT01509105|BIOLOGICAL|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
219126791|NCT03801772|DEVICE|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
219126792|NCT04644861|OTHER|Program of adapted physical activity|3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
219126793|NCT05718297|DRUG|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
219126794|NCT05718297|DRUG|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
219126795|NCT00959803|DRUG|PF-04447943|3 mg solution, oral single dose.
219126796|NCT00959803|DRUG|PF-04447943|10 mg solution, oral single dose.
219126797|NCT00959803|DRUG|PF-04447943|25 mg solution, oral single dose.
219226085|NCT03177824|DRUG|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
219226086|NCT04122885|COMBINATION_PRODUCT|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
219226087|NCT04122885|PROCEDURE|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
219226088|NCT05618951|OTHER|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
219710417|NCT03363035|DRUG|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
219710418|NCT03363035|DRUG|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
219710419|NCT03363035|DRUG|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
219710420|NCT03595748|BEHAVIORAL|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
219710421|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
219710422|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
219710423|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
219710424|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
219710425|NCT05595460|DRUG|Atezolizumab|Atezolizumab
219710426|NCT05595460|DRUG|Carboplatin|Carboplatin
219710427|NCT05595460|DRUG|Etoposide|Etoposide
219126798|NCT00959803|DRUG|Placebo|Solution, oral single dose.
219126799|NCT00959803|DRUG|PF-04447943|25 mg solution, oral twice daily for 7 days.
219126800|NCT00959803|DRUG|Placebo|Solution, oral twice daily for 7 days.
219126801|NCT01328587|DRUG|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
219126802|NCT00463151|DRUG|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
219126803|NCT05173571|COMBINATION_PRODUCT|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
219126804|NCT03417973|DEVICE|dorsal root ganglion neuromodulation|stimulation for neuromodulation of the dorsal root ganglion
219710428|NCT05934084|BEHAVIORAL|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
219710429|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
219710430|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
219710431|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
219710432|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
219710433|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
219710434|NCT05352763|DRUG|simufilam|simufilam 100 mg oral tablet, twice daily
219710435|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
219710436|NCT03687359|OTHER|Standard of care|Treatment as per standard practice
219126805|NCT01221077|DRUG|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
219126806|NCT01221077|DRUG|Erlotinib|Erlotinib administered orally
219126807|NCT01221077|DRUG|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
219126808|NCT02425683|DRUG|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
219126809|NCT02453230|BEHAVIORAL|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
219126810|NCT02300779|DIETARY_SUPPLEMENT|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
219226089|NCT05208034|DRUG|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
219710437|NCT05019430|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
219710438|NCT05019430|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
219710439|NCT05019430|DRUG|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
219710440|NCT00805688|BEHAVIORAL|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
219710441|NCT00805688|PROCEDURE|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
219710442|NCT00805688|DEVICE|Pedometer|Worn daily to measure physical activity.
219226090|NCT00797212|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
219226091|NCT03220334|DRUG|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
219226092|NCT03220334|DRUG|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
219126811|NCT02300779|DIETARY_SUPPLEMENT|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
219126812|NCT00293462|BIOLOGICAL|sargramostim|
219126813|NCT00293462|OTHER|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
219126814|NCT03471468|PROCEDURE|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
219126815|NCT04007003|BEHAVIORAL|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
219126816|NCT00688688|DRUG|Mirabegron|Tablets
219126817|NCT00688688|DRUG|Tolterodine|Extended release capsules
219126818|NCT00688688|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
219126819|NCT00688688|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
219126820|NCT06290232|DEVICE|Fetoscopic Laser Photocoagulation|Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
219126821|NCT06146738|BEHAVIORAL|Palliative Care|Best supportive care without surgical intervention
219126822|NCT06146738|PROCEDURE|Tumor biopsy|Tumor biopsy
219126823|NCT06146738|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
219710443|NCT05486169|PROCEDURE|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
219710444|NCT00003871|BIOLOGICAL|fowlpox virus vaccine vector|
219710445|NCT00003871|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
219710446|NCT05814510|BEHAVIORAL|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
219126824|NCT02442544|DIETARY_SUPPLEMENT|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
219126825|NCT02442544|DIETARY_SUPPLEMENT|Placebo|maltodextrin 3.3g orally/day
219126826|NCT01950260|DRUG|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
219710447|NCT05814510|BEHAVIORAL|Asthma CHAMPS Wait List Control|Stepped wedge design
219710448|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention employing Neurofeedback|Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
219710449|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention|Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
219710450|NCT05708521|DRUG|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
219710451|NCT05708521|DRUG|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
219710452|NCT06433310|DRUG|L-Phenylalanine 500 mg Veg Capsule product|500 mg Veg Capsule product
219710453|NCT05415215|DRUG|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
219126827|NCT01950260|OTHER|Placebo|Placebo to start at 4 weeks after RAI
219126828|NCT00930189|DRUG|intravitreal injection of ranibizumab|
219710454|NCT05415215|DRUG|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
219710455|NCT05415215|DRUG|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
219126829|NCT00930189|DRUG|intravitreal injection of triamcinolone|
219126830|NCT00930189|PROCEDURE|photodynamic therapy|
219126831|NCT03283553|OTHER|Checklist, MyChart, OpenNotes|1\) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
219126832|NCT03283553|OTHER|Usual Care|Routine medical oncology care
219126833|NCT04132284|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus \& Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
219126834|NCT04132284|BEHAVIORAL|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
219126835|NCT02460887|DRUG|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
219126836|NCT02460887|DRUG|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
219126837|NCT02460887|DRUG|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
219126838|NCT02460887|RADIATION|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
219710456|NCT05415215|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
219710457|NCT05415215|DRUG|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
219126839|NCT00207649|BEHAVIORAL|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
219226093|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
219226094|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
219226095|NCT03103048|DIAGNOSTIC_TEST|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
219226096|NCT03103048|DIAGNOSTIC_TEST|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
219226097|NCT03103048|DIAGNOSTIC_TEST|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
219226098|NCT03103048|DIAGNOSTIC_TEST|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
219226099|NCT06375759|PROCEDURE|Subarachnoid-Subarachnoid (S-S) Bypass|"The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long."
219226100|NCT06375759|PROCEDURE|Intradural Adhesion Lysis|Intradural spinal cord Adhesion Lysis
219226101|NCT01408394|DRUG|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
219226102|NCT01408394|DRUG|90 mg controlled release form|This is the 90 mg controlled release form
219226103|NCT01408394|DRUG|180 mg controlled release form|This is the 180 mg controlled release capsule
219226104|NCT02108171|DRUG|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
219226105|NCT02108171|DRUG|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
219710458|NCT05415215|PROCEDURE|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
219710459|NCT05415215|RADIATION|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
219126840|NCT00574678|OTHER|Tear collection|"A tear sample (\~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
219126841|NCT03686683|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
219126842|NCT03199885|DRUG|Atezolizumab|Given IV
219126843|NCT03199885|PROCEDURE|Biopsy|Undergo biopsy
219126844|NCT03199885|PROCEDURE|Bone Scan|Undergo bone scan
219126845|NCT03199885|PROCEDURE|Computed Tomography|Undergo CT scan
219126846|NCT03199885|DRUG|Docetaxel|Given IV
219126847|NCT03199885|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219126848|NCT03199885|DRUG|Paclitaxel|Given IV
219126849|NCT03199885|BIOLOGICAL|Pertuzumab|Given IV
219126850|NCT03199885|OTHER|Placebo Administration|Given IV
219126851|NCT03199885|OTHER|Quality-of-Life Assessment|Ancillary studies
219126852|NCT03199885|BIOLOGICAL|Trastuzumab|Given IV
219126853|NCT06209359|DRUG|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
219126854|NCT06209359|DRUG|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
219126855|NCT06356272|OTHER|Non-Interventional Study|Non-interventional study
219126856|NCT04704102|BEHAVIORAL|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
219126857|NCT04704102|BEHAVIORAL|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
219126858|NCT04704102|BEHAVIORAL|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
219126859|NCT03639441|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
219126860|NCT03639441|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
219126861|NCT04304469|OTHER|surveys|delivery of the survey at a domestic violence consultation
219710460|NCT05493111|DRUG|0.003% AR-15512 ophthalmic solution|Active ingredients administered via topical ocular instillation
219710461|NCT05493111|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
219710462|NCT05886842|OTHER|Test-retest|Test-retest
219126862|NCT04304469|OTHER|follow-up|follow-up of women 6 months after their consultation
219126863|NCT03255941|DRUG|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
219126864|NCT03255941|DRUG|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
219126865|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
219126866|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
219126867|NCT05876910|BEHAVIORAL|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
219126868|NCT02311192|DEVICE|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
219126869|NCT05323721|DRUG|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
219126870|NCT05323721|DRUG|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
219126871|NCT03229889|DRUG|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
219126872|NCT03229889|DRUG|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
219126873|NCT03229889|COMBINATION_PRODUCT|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
219126874|NCT03229889|DRUG|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
219710463|NCT06125964|BEHAVIORAL|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
219710464|NCT06125964|BEHAVIORAL|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
219710465|NCT06125964|BEHAVIORAL|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
219710466|NCT06125964|BEHAVIORAL|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
219710467|NCT02462096|DEVICE|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
219710468|NCT05306340|DRUG|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
219710469|NCT05306340|DRUG|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
219710470|NCT05306340|DRUG|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
219710471|NCT05306340|DRUG|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
219126875|NCT00372060|DRUG|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
219126876|NCT00372060|DRUG|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
219126877|NCT00372060|DRUG|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
219126878|NCT00372060|DRUG|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
219126879|NCT05023720|OTHER|nonintervention|
219126880|NCT00961493|BEHAVIORAL|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
219126881|NCT00961493|BEHAVIORAL|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
219126882|NCT02476630|DEVICE|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
219126883|NCT02476630|OTHER|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
219226106|NCT04734600|DEVICE|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+\_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
219126884|NCT01579578|DRUG|AZD8931|40 mg, oral dose twice daily
219226107|NCT04734600|OTHER|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
219226108|NCT02616276|OTHER|Control breakfast|It consists of 350 ml of water at room temperature.
219710472|NCT05306340|DRUG|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
219710473|NCT05306340|DRUG|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
219710474|NCT05306340|DRUG|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
219710475|NCT04573920|DRUG|Atrasentan|Film-coated tablet
219126885|NCT01579578|DRUG|Placebo|Placebo, oral dose twice daily
219126886|NCT01579578|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
219710476|NCT06551805|DRUG|Safety assessment of Ferumoxytol.|"Observe the injection site for skin invagination, rash, or urticaria during injection. Patients and their relatives were asked about any subjective adverse events before, during, and after drug injection, and all adverse events were recorded on the case report forms, and adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) from Grade 1 mild to Grade 5 death, Observe the vital signs of patients. Patients undergoing MRI underwent electrocardiogram (ECG) monitoring before and within 60 minutes after ferumoxytol administration, specifically including: biochemical panel, iron metabolism, liver and kidney function, cytokines, blood routine, urine routine, 24-hour urine volume, glycosylated hemoglobin and so on. All patients received a total of 3 blood and urine collections at 7 days before injection, 48 hours after injection, 1month to 3months after injection."
219126887|NCT00984074|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
219126888|NCT00984074|PROCEDURE|diffusion tensor imaging|
219226109|NCT02616276|OTHER|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
219710477|NCT06551805|DRUG|Assessment of the diagnostic value of Ferumoxytol for MR angiography.|steady-state, high-spatial-resolution, three-dimensional fast low-angle shot acquisition technique, T2W-MDIR imaging, polysaccharide superparamagnetic iron oxide injection enhanced T1W and T2W, T2\* mapping, and Steady state free precession sequence, T2 weighted black blood sequence, T2 preparation single shot steady state free precession sequence, T2\* weighted multi-echo/gradient echo sequence, polysaccharide superparamagnetic iron oxide injection enhanced imaging, Breath-triggered Transverse 3D Balance-Vortex Field Echo (b-TFE) Magnetic Resonance Angiography, iMSDE-SPGR Sequence, 4D Flow MRI. the MRI anxiety questionnaire.
219710478|NCT02308878|BEHAVIORAL|Mobile health cognitive stimulation|
219126889|NCT00984074|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219126890|NCT00984074|PROCEDURE|functional magnetic resonance imaging|
219126891|NCT00984074|RADIATION|intensity-modulated radiation therapy|
219126892|NCT00984074|RADIATION|radiation therapy treatment planning/simulation|
219226110|NCT02616276|OTHER|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
219226111|NCT03680638|OTHER|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
219226112|NCT03680638|DRUG|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
219226113|NCT03680638|DRUG|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
219226114|NCT03680638|DRUG|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
219126893|NCT02703727|BEHAVIORAL|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
219126894|NCT00285688|PROCEDURE|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
219126895|NCT02201563|DRUG|Minocycline|Oral minocycline (100mg twice a day) for 3 months
219126896|NCT00037999|PROCEDURE|Testosterone supplement|
219126897|NCT05377099|DIAGNOSTIC_TEST|CORVIS|Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
219126898|NCT03394963|BEHAVIORAL|Food-based dietary guidelines for healthier diet|Develop and validate food-based dietary guideline and a healthy eating index
219126899|NCT04108689|BEHAVIORAL|I-ACT|An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
219126900|NCT03640013|PROCEDURE|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
219126901|NCT00249483|DRUG|Venlafaxine|Venlafaxiine 300mg/day
219126902|NCT00249483|DRUG|Placebo|Placebo
219126903|NCT01235325|DIETARY_SUPPLEMENT|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
219126904|NCT01235325|DIETARY_SUPPLEMENT|placebo|placebo oil capsule
219710479|NCT04997733|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit)."
219126905|NCT05927961|DIAGNOSTIC_TEST|histopathology|There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
219126906|NCT05159882|DRUG|THR-1442 and Dapagliflozin placebo|THR-1442 tablets 20mg and Dapagliflozin tablets placebo
219226115|NCT00843050|DRUG|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
219226116|NCT04559074|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
219226117|NCT02328144|DRUG|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
219226118|NCT02328144|DRUG|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
219226119|NCT02821299|OTHER|Laryngeal transplantation|Laryngeal transplantation
219710480|NCT04997733|DRUG|Sham-transplantation (placebo)|"The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo)."
219710481|NCT05962957|DRUG|carbidopa-levodopa|Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
219126907|NCT05159882|DRUG|Dapagliflozin 10mg and THR1442 placebo|Dapagliflozin tablets 10mg and THR-1442 tablets placebo
219126908|NCT03464643|OTHER|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
219126909|NCT03423264|DRUG|Gabapentin|"Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg"
219126910|NCT01893528|DRUG|REGN2009|
219126911|NCT01893528|OTHER|placebo|
219126912|NCT01988519|PROCEDURE|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
219126913|NCT01988519|PROCEDURE|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
219126914|NCT02803840|RADIATION|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
219126915|NCT02271282|DRUG|Toremifene|
219126916|NCT02271282|DRUG|Placebo|
219710482|NCT05962957|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
219126917|NCT02271282|DRUG|GHRH/Ghrelin combined Injection|
219126918|NCT01120171|DRUG|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
219126919|NCT01120171|DRUG|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
219126920|NCT00657111|DRUG|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
219126921|NCT00657111|OTHER|Placebo|placebo capsules containing 25 mg lactose
219126922|NCT05504694|DRUG|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
219126923|NCT05352529|DEVICE|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
219710483|NCT05962957|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
219126924|NCT05352529|DEVICE|Dementia educational videos|Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
219126925|NCT06475170|PROCEDURE|proximal gastrectomy combined with 'λ+α' double-tract anastomosis|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；"
219126926|NCT06305273|OTHER|Head position for face mask ventilation during induction supine|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in supine position. Participants will be crossed over to the head elevated position after the first measurement is obtained.
219126927|NCT06305273|OTHER|Head position for face mask ventilation during induction head elevated|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in head elevated position. Participants will be crossed over to the supine position after the first measurement is obtained.
219126928|NCT01528709|DRUG|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
219710484|NCT04534153|DRUG|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
219710485|NCT04534153|DRUG|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
219710486|NCT05358938|OTHER|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
219710487|NCT05358938|DRUG|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
219710488|NCT06034470|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219710489|NCT06034470|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
219710490|NCT06034470|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219126929|NCT01528709|DRUG|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
219126930|NCT01034111|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
219126931|NCT01034111|DRUG|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
219126932|NCT00386594|DRUG|852A|
219126933|NCT03682354|DRUG|Intercostal Nerve Block with PCIA|Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
219126934|NCT03682354|DRUG|Erector Spinae Plane Block (ESPB)|Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
219126935|NCT04163471|DEVICE|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
219126936|NCT01314495|DRUG|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
219126937|NCT01314495|DRUG|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
219126938|NCT03254069|DEVICE|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
219126939|NCT02726178|DRUG|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
219126940|NCT02726178|DRUG|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
219710491|NCT06034470|DRUG|Cytarabine|Given IV
219710492|NCT06034470|PROCEDURE|Echocardiography|Undergo ECHO
219710493|NCT06034470|DRUG|Fludarabine|Given IV
219710494|NCT06034470|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
219710495|NCT06034470|DRUG|Idarubicin|Given IV
219710496|NCT06034470|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219710497|NCT06034470|DRUG|Pivekimab Sunirine|Given IV
219710498|NCT00002462|BIOLOGICAL|bleomycin sulfate|
219710499|NCT00002462|DRUG|doxorubicin hydrochloride|
219710500|NCT00002462|DRUG|mechlorethamine hydrochloride|
219710501|NCT00002462|DRUG|prednisone|
219710502|NCT00002462|DRUG|procarbazine hydrochloride|
219710503|NCT00002462|DRUG|vinblastine sulfate|
218986475|NCT05490810|OTHER|Activation exercises|"Activation exercises with~* Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~* External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~* Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
218986476|NCT04858633|DRUG|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
218986477|NCT04858633|OTHER|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
219710504|NCT00002462|DRUG|vincristine sulfate|
219710505|NCT00002462|RADIATION|low-LET cobalt-60 gamma ray therapy|
219710506|NCT00002462|RADIATION|low-LET photon therapy|
218986478|NCT04858633|OTHER|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
218986479|NCT00129272|DRUG|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
219126941|NCT04778384|BEHAVIORAL|Micro-training to promote self-management in pain therapy|Micro-training according to the checklist \& targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire) In this discussion, the nurses give their opinion on any patient-related barriers that become apparent after completing the second part of the questionnaire. This is not done according to a fixed template, but with the specialist knowledge and everyday experience of the nurse.
219126942|NCT04778384|OTHER|Sham intervention|An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
219126943|NCT05841160|DRUG|Ecopipam Hydrochloride|oral tablets
219710507|NCT00002462|RADIATION|radiation therapy|
219126944|NCT05841160|DRUG|Moxifloxacin|oral tablet
219710508|NCT05478304|DEVICE|AtriClip LAA Exclusion System|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
219710509|NCT05389293|DRUG|Mosunetuzumab|During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
219710510|NCT05389293|DRUG|Zanubrutinib|In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
219710511|NCT05895604|BEHAVIORAL|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
219710512|NCT04693403|PROCEDURE|HFNC|40-60l/min humidified oxygen by nasal cannula
219710513|NCT04693403|PROCEDURE|CPAP|Oxygen therapy by boussignac Continuous positive airway pressure face mask
219710514|NCT04693403|PROCEDURE|Standard Oxygen|Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
219710515|NCT06831188|OTHER|daily life exercise group|random games which includes physical activity
219710516|NCT06831188|OTHER|specific type exercise group|10 minutesTreadmill Walk, Playdough or ball squeeze, Towel wring,Throwing to target, catching the tennis ball, bouncing a ball inside borders without losing control, dribbling a ball inside borders without losing control, tandem walk, Single leg stance balance on balance pad or pillow, rolling forward, Jumping exercises, Side stepping, etc
219710517|NCT05030441|DRUG|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
219710518|NCT06830642|DRUG|MTR-601|Capsule
219710519|NCT06830642|DRUG|Placebo|Capsule
219710520|NCT02469233|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
219126945|NCT05841160|DRUG|Placebo|oral tablet
219126946|NCT05124899|DRUG|CAP UnScented|Sunscreen lip balm.
219226120|NCT04970732|PROCEDURE|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
219226121|NCT00861991|BEHAVIORAL|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
219126947|NCT05124899|DRUG|CAP Herbal Mint|Sunscreen lip balm.
219126948|NCT05124899|DRUG|CAP Mountain Berry|Sunscreen lip balm.
219126949|NCT05124899|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
219126950|NCT01068054|DRUG|tacrolimus|0.1% ointment,apply bid, 8 weeks
219126951|NCT01068054|DRUG|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
219126952|NCT00438971|DRUG|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
219126953|NCT05426291|OTHER|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
219126954|NCT01833975|BIOLOGICAL|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell \[MNCs\],100millions per dose in 3 divided doses at interval of 10 days.
219126955|NCT05712811|DRUG|CRYOTHERAPY|Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
219126956|NCT05712811|DRUG|Tricholoracetic acid|Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
219126957|NCT05080920|DIETARY_SUPPLEMENT|Rosmalip®|Nutritional Supplement+Usual Care
219126958|NCT05080920|OTHER|Placebo|Placebo+Usual Care
219126959|NCT01677039|DRUG|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
219710521|NCT04131829|DRUG|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
219710522|NCT04131829|DRUG|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
219710523|NCT03617432|DRUG|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219710524|NCT03617432|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219710525|NCT03617432|DRUG|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219710526|NCT03617432|DRUG|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219710527|NCT03617432|DRUG|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219126960|NCT01677039|DRUG|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
219126961|NCT01677039|DRUG|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
219126962|NCT02688361|DRUG|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
219126963|NCT02688361|DRUG|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
219226122|NCT03114215|DRUG|MD1003|capsules 100mg 3 times per day
219226123|NCT03114215|DRUG|Placebo oral capsule|capsules 100mg lactose 3 times per day
219226124|NCT00659373|DRUG|Tamoxifen|
219226125|NCT00659373|DRUG|triptorelin|
219226126|NCT00659373|DRUG|Exemestane|
219226127|NCT04364230|DRUG|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219126964|NCT02481882|DEVICE|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
219126965|NCT02481882|DRUG|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
219126966|NCT04438551|BEHAVIORAL|Standard dietary counseling|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.
219126967|NCT04438551|BEHAVIORAL|Mobile app|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
219126968|NCT01278537|BEHAVIORAL|Information|Booklet, motivational interviewing, brief advice
219126969|NCT00716573|DRUG|everolimus|0,75 mg bid, 24 months
219226128|NCT04364230|DRUG|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
219226129|NCT04364230|DRUG|PolyICLC|polyICLC, local adjuvant
219226130|NCT04364230|DRUG|CDX-1140|CDX-1140, local adjuvant
219226131|NCT04353856|OTHER|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
219226132|NCT01098409|DRUG|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
219226133|NCT01098409|DRUG|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
219226134|NCT00060502|DRUG|Infliximab; Gemcitabine|
219226135|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
219226136|NCT00070642|DRUG|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
219226137|NCT00070642|DRUG|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
219226138|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
219226139|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
219226140|NCT00351026|DRUG|Methadone|short-term methadone maintenance
219226141|NCT02382640|DRUG|Febuxostat XR|Febuxostat extended-release (XR) capsules
219710528|NCT03617432|DRUG|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
219710529|NCT04932109|OTHER|No intervention|No intervention in this group
219710530|NCT04574518|BEHAVIORAL|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
219710531|NCT04574518|BEHAVIORAL|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
219710532|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
219710533|NCT01787838|OTHER|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
219710534|NCT06284109|DEVICE|Cryoanalgesia|Participants will receive cryoanalgesia with the The iovera° system. . The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Cryoanalgesia will result from an 8-minute-long percutaneous cryoneuroablation procedure consisting of several freeze/defrost cycles. Per routine, all patients will have a nerve block with single shot ropivacaine.
218986480|NCT00129272|OTHER|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
218986481|NCT00092638|DRUG|MK0653, ezetimibe|
218986482|NCT00092638|DRUG|Comparator: ezetimibe, placebo|
218986483|NCT05679219|PROCEDURE|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
218986484|NCT05679219|PROCEDURE|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
218986485|NCT05679219|PROCEDURE|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
218986486|NCT06262880|DIETARY_SUPPLEMENT|plant derived phenolics|Dietary supplement containing plant derived phenolics
218986487|NCT06262880|OTHER|Microcrystaline cellulose (MCC)|Placebo treatment: Microcrystaline cellulose
218986488|NCT01655771|DRUG|TD-1211 Dose 1|
218986489|NCT01655771|DRUG|TD-1211 Dose 2|
218986490|NCT03365492|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
219126970|NCT05535036|DRUG|Dexamethasone 4mg|all patients had standard non-invasive monitoring including an electrocardiogram, non invasive blood pressure and pulse oxymetry. An 18-gauge intravenous cannula was inserted into the nondominant arm or hand and 500 ml of a saline solution (0.9 %) was infused. The prevention of postoperative nausea and vomiting (PONV) was assured to all patients by administering 4 mg of IV Ondansetron. Spinal anesthesia was performed according to our department protocol: L4-L5 or L3-L4 intervertebral space puncture using a 25 gauges needle, with injection of 0.5% hyperbaric Bupivacaine mixture (dose depending on patient height) associated with 2.5 ug Sufentanil and 100 ug Morphine. Before surgical incision, patients received either an intravenous injection of 8 mg (2 ml) Dexamethasone (DG) or 2 ml of a Saline solution (PG).
219126971|NCT05535036|DRUG|Placebo|patients received 2ml of intravenous saline solution
219126972|NCT00002569|DRUG|lomustine|
219126973|NCT00002569|DRUG|procarbazine hydrochloride|
219126974|NCT00002569|DRUG|vincristine sulfate|
219126975|NCT00002569|RADIATION|radiation therapy|
219226142|NCT02382640|DRUG|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
219126976|NCT03869242|DEVICE|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
219126977|NCT04635436|OTHER|Split-belt treadmill walking.|"The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
219126978|NCT04850365|PROCEDURE|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
219126979|NCT05883319|OTHER|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
219126980|NCT05883319|OTHER|exercises|approaches will be applied for 3 days / week for 6 weeks.
219126981|NCT03906474|BIOLOGICAL|Blood-stage controlled human P. falciparum malaria infection|Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
219126982|NCT03155191|BIOLOGICAL|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
219126983|NCT01495780|BEHAVIORAL|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
219126984|NCT05410535|DRUG|Patients who continued UDCA 300mg medication|patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
219126985|NCT05410535|OTHER|Patients who discontinued UDCA 300mg prescription|patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
219126986|NCT02987829|DRUG|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
219226143|NCT02697656|BEHAVIORAL|IPS|Individualized job support provided by an employment specialist
219226144|NCT02697656|BEHAVIORAL|Self-help|Self-help resources on obtaining employment and coping with chronic pain
219226145|NCT02697656|BEHAVIORAL|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
219226146|NCT02356198|DRUG|EXPAREL|transversus abdominis plane injection
219226147|NCT02356198|DRUG|Intrathecal hydromorphone|Intrathecal opioid administration
219226148|NCT05850793|BEHAVIORAL|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
219126987|NCT02117869|OTHER|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
219126988|NCT02117869|OTHER|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
219126989|NCT02117869|OTHER|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
219126990|NCT01417000|BIOLOGICAL|GVAX Pancreas|
219126991|NCT01417000|BIOLOGICAL|CRS-207|
219126992|NCT01417000|DRUG|Cyclophosphamide|
219126993|NCT00647348|DRUG|Simvastatin|80mg simvastatin oral once daily for 24 months
219126994|NCT00647348|DRUG|Placebo|Oral placebo tablet once daily for 24 months
219710535|NCT06284109|DEVICE|Sham Cryoanalgesia|Participants will receive Sham cryoanalgesia with the The iovera° system. The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Per routine, all patients will have a nerve block with single shot ropivacaine.
219710536|NCT04336683|DEVICE|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
219710537|NCT00058981|DRUG|DiaPep277|
219126995|NCT04837950|PROCEDURE|Diaphragmatic traction-suture|Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture
219126996|NCT00714233|DRUG|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
219126997|NCT00714233|DRUG|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
219710538|NCT02367560|PROCEDURE|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
219710539|NCT02367560|PROCEDURE|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
219710540|NCT02367560|DRUG|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
219710541|NCT02367560|DEVICE|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
219710542|NCT00526175|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
219710543|NCT00526175|DRUG|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
219710544|NCT00526175|DRUG|Daunorubicin|30 mg/m2, i.v., days 8 and 15
219126998|NCT00714233|BEHAVIORAL|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
219126999|NCT00714233|DRUG|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
219127000|NCT02554175|DRUG|Propofol|Propofol was administered to achieve target propofol Ce
219127001|NCT00699933|OTHER|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
219127002|NCT00890474|PROCEDURE|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
219127003|NCT05004480|DEVICE|Treadmill|Electronic treadmill, Hammer T-2000 Treadmill, 2,5 HP - 140 Kilograms
219127004|NCT03487874|PROCEDURE|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
219127005|NCT03487874|PROCEDURE|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
219127006|NCT03487874|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
219127007|NCT03967561|OTHER|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
219127008|NCT03967561|OTHER|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
219127009|NCT01743651|DRUG|arbaclofen|40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
219127010|NCT01743651|DRUG|baclofen|80 mg/day as 20 mg baclofen administered orally 4 times per day
219127011|NCT01743651|DRUG|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
219127012|NCT02284464|DRUG|Prednisone withdrawal|Withdrawal of steroids
219127013|NCT02284464|DRUG|Prednisone continuation|Continuation of steroids
219710545|NCT00526175|DRUG|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
219710546|NCT00526175|DRUG|Cyclophosphamide|1000 mg/m2, i.v., day 22.
219710547|NCT00526175|DRUG|Methotrexate|Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
219710548|NCT00526175|DRUG|Cytosine Arabinoside|Edad \<1 year 1-2 years 2-3 years \> 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
219710549|NCT00526175|DRUG|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
219710550|NCT00526175|DRUG|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
219710551|NCT01431976|DRUG|Lamictal|No comparison
219127014|NCT02849262|DRUG|Omiganan (CLS001) topical gel|
219127015|NCT02849262|DRUG|Vehicle topical gel|
219127016|NCT04788017|DRUG|Ziresovir|"Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir"
219127017|NCT04788017|OTHER|Placebo|"Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo"
219127018|NCT02741843|BEHAVIORAL|Patient Education|
219226149|NCT05850793|BEHAVIORAL|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
219226150|NCT05850793|BEHAVIORAL|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
219226151|NCT00000892|DRUG|Ritonavir|
219226152|NCT00000892|DRUG|Nelfinavir mesylate|
219226153|NCT00000892|DRUG|Levocarnitine|
219226154|NCT00000892|DRUG|Adefovir dipivoxil|
219127019|NCT01160991|PROCEDURE|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
219127020|NCT01160991|DRUG|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
219127021|NCT01160991|DRUG|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
219127022|NCT01160991|DRUG|Placebo|Placebo capsules are given at 8:00 a.m.
219127023|NCT05078385|DRUG|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
219127024|NCT05165069|DRUG|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
219127025|NCT05165069|DRUG|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
219710552|NCT00608920|OTHER|Single Photon Emission Computed Tomography (SPECT)|
219710553|NCT00867932|DRUG|Eculizumab|5 mg/mL solution in 5% Dextrose
219710554|NCT05688228|OTHER|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
219710555|NCT03197727|DIAGNOSTIC_TEST|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
219710556|NCT05897151|DRUG|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
219710557|NCT05897151|DRUG|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
219710558|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
219710559|NCT04736875|DIAGNOSTIC_TEST|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
219710560|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
219127026|NCT03096119|OTHER|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
219127027|NCT02397889|DRUG|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
219127028|NCT02397889|DRUG|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
219127029|NCT04942470|OTHER|Aloe vera and propolis applied|Suitable of sterile pads containing aloe vera and propolis to the area with pressure sores
219127030|NCT02775617|DRUG|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
219127031|NCT02775617|DRUG|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
219127032|NCT02775617|DRUG|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
219226155|NCT00000892|DRUG|Saquinavir|
219226156|NCT00000892|DRUG|Delavirdine mesylate|
219226157|NCT00917098|BEHAVIORAL|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
219226158|NCT00917098|BEHAVIORAL|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
219226159|NCT06425289|OTHER|Macrohemodynamic parameters|"Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)"
219226160|NCT03162614|BIOLOGICAL|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
219226161|NCT03162614|BIOLOGICAL|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
219127033|NCT04547543|OTHER|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
219226162|NCT03162614|PROCEDURE|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
219226163|NCT01607697|BEHAVIORAL|Mindfulness Training|Mindfulness Training
219226164|NCT01920191|BIOLOGICAL|IMA 950|
219226165|NCT01920191|BIOLOGICAL|Poly ICLC|
219226166|NCT01920191|OTHER|Immunomonitoring|Blood samples, DTH analysis
219226167|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
219226168|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
219226169|NCT00432016|DRUG|zidovudine|
219226170|NCT00432016|DRUG|amdoxovir|
219226171|NCT00432016|PROCEDURE|pharmacokinetic sampling|
219226172|NCT02251301|DIETARY_SUPPLEMENT|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
219226173|NCT02251301|BEHAVIORAL|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
219226174|NCT02251301|OTHER|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
219226175|NCT02251301|DIETARY_SUPPLEMENT|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
219226176|NCT01350167|PROCEDURE|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
219226177|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
219226178|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
219226179|NCT03470805|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
219226180|NCT02630966|DRUG|Vedolizumab|Vedolizumab 300 mg IV infusion
219226181|NCT02630966|DRUG|Placebo|0.9% sodium chloride IV infusion
219226182|NCT01334840|DIETARY_SUPPLEMENT|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
219226183|NCT01334840|DIETARY_SUPPLEMENT|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
219710561|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
219710562|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
219127034|NCT06008067|RADIATION|tricuspid annular plane systolic excursion (TAPSE)|Echocardiography
219127035|NCT05356026|OTHER|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
219710563|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
219127036|NCT01454362|DRUG|Nicotine|Inhalation of nicotine.
219710564|NCT01136954|DRUG|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
219710565|NCT00782067|DRUG|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
219710566|NCT04262843|DRUG|Cyclophosphamide|Given IV
219710567|NCT04262843|DRUG|Fludarabine|Given IV
219710568|NCT04262843|DRUG|Fludarabine Phosphate|Given IV
219710569|NCT04262843|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Growth factor therapy
219710570|NCT04262843|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
219710571|NCT04262843|PROCEDURE|Intensity-Modulated Radiation Therapy|Undergo TMLI
219127037|NCT00797225|DRUG|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
219226184|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
219226185|NCT00641537|DRUG|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
219710572|NCT04262843|DRUG|Mycophenolate Mofetil|Immunosuppressive therapy
219710573|NCT04262843|DRUG|Tacrolimus|Immunosuppressive therapy
219710574|NCT01949272|DEVICE|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
219710575|NCT05883488|OTHER|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
219710576|NCT05883488|OTHER|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
219710577|NCT02703363|DRUG|Minocycline|
219710578|NCT02703363|DRUG|Celecoxib|
219710579|NCT02703363|DRUG|Placebo|
219710580|NCT04681378|PROCEDURE|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
219710581|NCT06161948|OTHER|Time-restricted enteral nutrition therapy group|Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 \~ 08:00, end time: 16:00 \~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.
219127038|NCT00797225|DRUG|Elagolix|Elagolix tablets administered orally
219127039|NCT00797225|DRUG|Placebo to Elagolix|Placebo tablet administered orally
219710582|NCT06161948|OTHER|Continuous enteral nutrition control group|The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
219127040|NCT00797225|DRUG|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
219127041|NCT02905513|BEHAVIORAL|Contraceptive app instant messages|
219127042|NCT02905513|OTHER|Mobile phone app|
219127043|NCT04307979|DIETARY_SUPPLEMENT|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
219127044|NCT04307979|DIETARY_SUPPLEMENT|Black coffee|A regular black coffee with no added caloric content.
219127045|NCT02408965|DRUG|Methergine|0.2 mg of methylergonovine maleate
219127046|NCT02408965|OTHER|placebo|saline placebo to maintain blinding
219226186|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
219710583|NCT04629833|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
219710584|NCT04629833|BIOLOGICAL|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
219710585|NCT02115152|DRUG|fluorouracil|
219710586|NCT02115152|DRUG|capecitabine|
219710587|NCT02115152|DRUG|cyclophosphamide|
219710588|NCT02115152|DRUG|Epirubicin|
219710589|NCT05568290|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
219710590|NCT05568290|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
219710591|NCT02210195|DRUG|aprepitant|125 mg daily for 8 weeks.
219710592|NCT02210195|DRUG|Placebo|Placebo daily for 8 weeks.
219710593|NCT02210195|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
219710594|NCT01422109|DRUG|YH14659|YH14659 capsule by oral
219710595|NCT01422109|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
219710596|NCT02388009|BIOLOGICAL|Flexyn2a|Intramuscular doses of 0.5 mL
219710597|NCT02388009|BIOLOGICAL|Placebo|Intramuscular doses of 0.5 mL
219710598|NCT02388009|BIOLOGICAL|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
219710599|NCT04320875|OTHER|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
219127047|NCT02248142|DRUG|Pramipexole|
219127048|NCT05478122|DEVICE|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
219127049|NCT00250224|DEVICE|Radiotherapy stent|
219127050|NCT00246298|DRUG|epoetin alfa|
219127051|NCT03956199|PROCEDURE|pulpotomy|removal of the pulp from pulp chamber
219127052|NCT03956199|PROCEDURE|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
219127053|NCT05972239|OTHER|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
219127054|NCT05972239|OTHER|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
219127055|NCT01313598|DRUG|GLPG0187|continuous IV infusion
219127056|NCT01352507|DRUG|Tadalafil|Administered Orally
219127057|NCT01352507|DRUG|Sildenafil|Administered Orally
219127058|NCT06219603|OTHER|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
219127059|NCT00279058|PROCEDURE|Immunotherapy treatment for melanoma|
219127060|NCT00409864|PROCEDURE|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
219127061|NCT03968237|DRUG|Buprenorphine/Naloxone|Controlled substances
219127062|NCT03018145|DEVICE|Wagon|
219127063|NCT03018145|DEVICE|Standard stretcher car|
219127064|NCT02729324|DRUG|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
219127065|NCT02729324|DRUG|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
219127066|NCT00607516|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
219226187|NCT00641537|DRUG|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
219710600|NCT04320875|OTHER|Conventional Physiotherapy|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
219710601|NCT05770310|DRUG|JS015|Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
219127067|NCT00607516|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
219127068|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
219127069|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
219127070|NCT02096003|DRUG|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
219710602|NCT06323382|PROCEDURE|Locoregional therapy|"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."
219710603|NCT06323382|DRUG|Bevacizumab|15mg/kg or 7.5mg/kg intravenously every 3 weeks
219710604|NCT06323382|DRUG|Atezolizumab|1200mg intravenously every 3 weeks
219127071|NCT02096003|DRUG|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
219127072|NCT02078830|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
219127073|NCT02078830|DEVICE|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
219127074|NCT01511250|BIOLOGICAL|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
219127075|NCT01511250|BIOLOGICAL|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
219127076|NCT01636440|DEVICE|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
219127077|NCT01636440|DEVICE|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
219127078|NCT00980278|PROCEDURE|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
219127079|NCT00980278|BIOLOGICAL|Aastrom BRCs|sinus augmentation, BRC application, dental implant
219127080|NCT00142766|BEHAVIORAL|Nurse Implemented Goal-Directed Comfort Algorithm|See description
219127081|NCT06107920|DRUG|Neoadjuvant chemotherapy|Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
219127082|NCT03610633|DRUG|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
219127083|NCT03610633|DRUG|Placebo|Saline solution.
219127084|NCT03795701|DRUG|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
219127085|NCT03795701|OTHER|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
219127086|NCT03243656|DRUG|Eltrombopag|An oral thrombopoietin receptor agonist
219127087|NCT00611065|DEVICE|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
219127088|NCT04616482|BEHAVIORAL|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
219127089|NCT01619254|BEHAVIORAL|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
219127090|NCT04015986|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
219127091|NCT04015986|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
219710605|NCT06323382|DRUG|Tislelizumab|200mg intravenously every 3 weeks
219127092|NCT02148809|RADIATION|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
219127093|NCT06188260|DRUG|Systane COMPLETE Lubricant Eye Drops|Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
219127094|NCT00916006|DRUG|PEP005 Gel|0.015%, three day treatment
219127095|NCT00916006|DRUG|Vehicle gel|Vehicle gel, three day treatment
219127096|NCT01253915|DRUG|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
219127097|NCT01253915|DRUG|Placebo|10 sec/nostril up to 4 times to treat a migraine
219127098|NCT04293991|DEVICE|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
219710606|NCT06323382|DRUG|Toripalimab|220mg intravenously every 3 weeks
219710607|NCT06323382|DRUG|Sintilimab|200mg intravenously every 3 weeks
219710608|NCT06323382|DRUG|Camrelizumab|200mg intravenously every 3 weeks
219127099|NCT04293991|DEVICE|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
219127100|NCT01763736|BEHAVIORAL|Music|playlist per patient preference
219127101|NCT06108141|BEHAVIORAL|Resident Education And Counseling on Household Firearm Safety|An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
219710609|NCT00689832|DRUG|Tacrolimus 0.03%|ointment
219127102|NCT06108141|BEHAVIORAL|Modified American Academy of Pediatrics Safer|An intervention that includes a self-directed online curriculum.
219127103|NCT03148938|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test"
219226188|NCT00641537|DRUG|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
219710610|NCT00689832|DRUG|Fluticasone 0.005%|ointment
219710611|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
219710612|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
219710613|NCT00082316|DRUG|Capsaicin Dermal Patch|
219710614|NCT06205589|BIOLOGICAL|ID93 + GLA-SE vaccine|At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
219710615|NCT06205589|BIOLOGICAL|Placebo vaccine|At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
219127104|NCT02915809|BIOLOGICAL|GC3110B vaccine|0.5mL, Intramuscular
219127105|NCT02915809|BIOLOGICAL|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
219127106|NCT02483299|DRUG|Metformin|
219127107|NCT02483299|DRUG|Glucophage tablets and Victoza|
219127108|NCT03627962|OTHER|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2\) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
219127109|NCT00912587|DRUG|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
219127110|NCT00138632|DRUG|PTK787|Visudyne® + PTK787, 500 mg/day
219127111|NCT00138632|DRUG|PTK787|Visudyne® + PTK787 1000 mg/day
219127112|NCT00138632|DRUG|Placebo|Visudyne® + Placebo
219127113|NCT05068713|OTHER|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
219127114|NCT05068713|OTHER|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
219226189|NCT02704416|PROCEDURE|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
219226190|NCT01801007|DEVICE|Flow Re-Direction Endoluminal Device (FRED)|
219710616|NCT01525771|OTHER|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days"
219710617|NCT06003036|DEVICE|sham stimulation|sham delivery of transcranial magnetic stimulation
219710618|NCT06003036|DEVICE|transcranial magnetic stimulation|accelerated intermittent theta burst stimulation
219710619|NCT01970371|DRUG|plazomicin|
219710620|NCT01970371|DRUG|colistin|
219710621|NCT01970371|DRUG|meropenem|
219710622|NCT01970371|DRUG|tigecycline|
219710623|NCT01970371|DRUG|antibiotic of Investigator's choice|
219710624|NCT03483103|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
219710625|NCT00004855|DRUG|Lopinavir/Ritonavir|
219710626|NCT00004855|DRUG|Abacavir sulfate|
219710627|NCT00004855|DRUG|Nevirapine|
219710628|NCT00004855|DRUG|Lamivudine|
219710629|NCT00004855|DRUG|Stavudine|
219127115|NCT05248035|OTHER|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
219127116|NCT01102322|BEHAVIORAL|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
219127117|NCT00857142|DRUG|oxymorphone hydrochloride|
219127118|NCT00857142|DRUG|Opana|
219127119|NCT05794373|PROCEDURE|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
219710630|NCT01481779|DRUG|Glargine|Administered by SC injection via a pen device.
219127120|NCT02744508|DRUG|palonosetron|
219710631|NCT01481779|DRUG|LY2605541|Administered by SC injection with a pen device.
219710632|NCT01481779|DRUG|Insulin Lispro|Administered by SC injection with a pen device.
219127121|NCT02744508|DRUG|palonosetron with dexamethasone|
219127122|NCT06020417|DEVICE|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
219127123|NCT06020417|PROCEDURE|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
219127124|NCT06112704|DRUG|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219710633|NCT04622995|DRUG|Benzodiazepine|Benzodiazepine prescribing
219710634|NCT03186365|DRUG|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
219710635|NCT01199770|OTHER|Control, small|control pasta, small portion
219710636|NCT01199770|OTHER|Experimental B, small|experimental pasta, small portion
219710637|NCT01199770|OTHER|Experimental pasta C, small|experimental pasta C, small portion
219710638|NCT01199770|OTHER|control, medium|control pasta, medium portion
219710639|NCT01199770|OTHER|experimental pasta B, medium|experimental pasta B, medium portion
219710640|NCT01199770|OTHER|experimental pasta C, medium|experimental pasta C, medium portion
219710641|NCT01199770|OTHER|NL|no pasta, water only
219710642|NCT04547699|COMBINATION_PRODUCT|A single step culture medium|A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
219127125|NCT04519450|DEVICE|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
219127126|NCT06645249|DRUG|Amiodarone (Antiarrhythmic drug)|Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
219127127|NCT06268860|DRUG|Rocatinlimab vial injection|Vial solution for SC injection administered on Day 1
219127128|NCT06268860|COMBINATION_PRODUCT|Rocatinlimab prefilled syringe|Prefilled syringe solution for SC injection administered on Day 1
219127129|NCT06640894|OTHER|MegaPower training|See arm/group descriptions
219127130|NCT06640894|OTHER|Usual Care|See arm/group descriptions
219127131|NCT06640751|BEHAVIORAL|Health behavior intervention|The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
219127132|NCT06644014|BEHAVIORAL|Exercise|"Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient)."
219127133|NCT06644014|BEHAVIORAL|Exercise|Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
219710643|NCT02378181|BEHAVIORAL|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
219710644|NCT02378181|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
219710645|NCT05355207|DRUG|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
219710646|NCT04890613|DRUG|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
219710647|NCT02664883|PROCEDURE|Computed Tomography|Correlative studies
219710648|NCT02664883|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
219127134|NCT06644014|DEVICE|Smart Ring|Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
219127135|NCT05328505|RADIATION|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
219127136|NCT04824131|DRUG|Oral cabotegravir (CAB)|30 mg tablets
219710649|NCT02664883|OTHER|Laboratory Biomarker Analysis|Correlative studies
219710650|NCT02664883|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
219710651|NCT05285969|BEHAVIORAL|Motivational interview|The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change
219710652|NCT05285969|BEHAVIORAL|Active Comparator: Standard care group|All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
219710653|NCT02145676|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
219710654|NCT02145676|DRUG|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
219710655|NCT00042146|BEHAVIORAL|Cognitive-behavior therapy|
219710656|NCT00042146|DRUG|zolpidem|
219710657|NCT05524129|OTHER|rehabilitation exercise|Conventional rehabilitation exercise.
219127137|NCT04824131|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
219710658|NCT05524129|OTHER|electrotherapy|A middle frequency electro-therapy
219127138|NCT04824131|DRUG|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
219127139|NCT05429021|DRUG|IMM-BCP-01|Single dose of IMM-BCP-01
219127140|NCT05429021|DRUG|Placebo|Placebo matching single dose of IMM-BCP-01
219127141|NCT05489224|BIOLOGICAL|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
219127142|NCT05489224|BIOLOGICAL|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
219127143|NCT02130492|RADIATION|FDG|The intervention arm consists of treatment with increasing doses of \[18F\]-Fluorodeoxyglucose.
219127144|NCT04651348|DRUG|Recombinant Humanized Monoclonal Antibody MIL95|"PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days."
219127145|NCT06148753|OTHER|Manuka Health Eternal Renewal Regenerating Face Serum with Royal Jelly and Bee Venom|Face serum containing manuka honey, royal bee jelly, and bee venom.
219127146|NCT06577857|DEVICE|Inferonasal Minimally Invasive Micro Sclerostomy|The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
219127147|NCT06522867|OTHER|Intraocular pressure measure|The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
219127148|NCT04887285|DEVICE|Virtual reality|Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
219127149|NCT04887285|DRUG|Intravenous sedation|Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
219127150|NCT04887285|OTHER|Standard care|Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
219127151|NCT04640571|DRUG|pravastatin and chenodeoxycholic acid, after metformin and placebo|single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
219127152|NCT04640571|DRUG|valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo|single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
219127153|NCT04515797|DRUG|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
219127154|NCT06298032|DRUG|Olamkicept Part A|"Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg"
219127155|NCT06298032|DRUG|Olamkicept Part B|"Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg"
219127156|NCT06298032|DRUG|Placebo|Intravenous infusion
219127157|NCT06268301|DRUG|Budesonide|Budesonide oral suspension
219127158|NCT05408455|OTHER|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
219127159|NCT05408455|OTHER|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
219710659|NCT04115059|DRUG|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
219710660|NCT05593640|OTHER|biological samples|blood and synovial liquid will be sampled
219127160|NCT06068153|DRUG|Sotorasib|Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
219127161|NCT06068153|DRUG|Lenvatinib|Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
219710661|NCT01635179|PROCEDURE|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
219710662|NCT04599985|OTHER|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
219710663|NCT04599985|OTHER|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
219710664|NCT01088789|DRUG|Cyclophosphamide|Cohort 1 (J0810 Arm B), Cohort 3, Cohort 4, and Cohort 5 patients will receive 200mg/m\^2 CY administered IV on day 0 of each Cycle (every 6 months). Cohort 2 patients will receive 200mg/m\^2 CY administered IV on Day 0 of the first 3 cycles (every 28 days) and Day 0 of subsequent Cycles (every 6 months).
219710665|NCT01088789|DRUG|Cyclophosphamide Pill|Cohort 1 patients (J0810 Arm C) will receive 50mg oral CY once a day starting 28 days prior to GVAX and for 28 days post-GVAX (every 6 months).
219127162|NCT03934905|DRUG|sulforaphane|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
219127163|NCT03934905|DRUG|Placebo Oral Tablet|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
219127164|NCT05633771|OTHER|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
219127165|NCT06220474|DEVICE|The Thermage FLX System|The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction
219127166|NCT06220474|DEVICE|Sham treatment|Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System
219127167|NCT00170911|DRUG|AAE581|
219127168|NCT00525694|OTHER|Glucose tolerance test|10 ounces glucose tolerance test solution
219127169|NCT00525694|OTHER|glucose tolerance test solution|75 grams glucose load
219226191|NCT03298295|DEVICE|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
219226192|NCT02024854|BEHAVIORAL|skin-to-skin|
219226193|NCT02024854|BEHAVIORAL|standard care|
219226194|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
219226195|NCT06041386|DRUG|Mepolizumab|Mepolizumab will be prescribed based on physician decision.
219710666|NCT01088789|BIOLOGICAL|GVAX Pancreas Vaccine|Cohort 1, 3, 4, and 5 patients will receive GVAX on day 1 of each Cycle (every 6 months). Cohort 2 patients will receive GVAX on Day 1 of the first 3 cycles (every 28 days) and Day 1 of subsequent Cycles (every 6 months).
219127170|NCT00525694|OTHER|Diet Coke|10 ounces of Diet Coke
219226196|NCT06041386|OTHER|Spirometry|Lung function via spirometry will be collected.
219226197|NCT06524648|DIAGNOSTIC_TEST|niPGT-A|"Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active."
219226198|NCT00243867|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion
219226199|NCT00243867|DRUG|Carboplatin|Administered by intravenous infusion over 30 minutes. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate (GFR) + 25).
219226200|NCT00243867|DRUG|Paclitaxel|Administered by intravenous infusion over 3 hour infusion
219226201|NCT02159716|BIOLOGICAL|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
219226202|NCT06798701|OTHER|Best Practice|Undergo standard care
219226203|NCT06798701|OTHER|Interview|Ancillary studies
219226204|NCT06798701|OTHER|Survey Administration|Ancillary studies
219226205|NCT06798701|PROCEDURE|Virtual Reality|Use VR device
219226206|NCT06501001|BEHAVIORAL|High-Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.
219127171|NCT00525694|OTHER|Coke Zero|10 ounces of Coke Zero
219127172|NCT00610883|DRUG|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
219127173|NCT01827280|DRUG|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
219127174|NCT04625855|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
219127175|NCT04269070|BEHAVIORAL|Standing condition|Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.
219127176|NCT04269070|BEHAVIORAL|Light physical activity (LPA) condition|Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.
219127177|NCT04269070|BEHAVIORAL|Usual behavior condition|Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.
219127178|NCT01037543|DRUG|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
219127179|NCT04349579|DRUG|Rifamycine|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, extraction socket was irrigated with the solution which contains 250 mg rifamycine and the mucoperiosteal flap was repositioned by 3.0 silk sutures.
219127180|NCT04349579|DRUG|Saline Solution|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
219127181|NCT02028975|OTHER|Measure the threshold of detection for linoleic acid|
219127182|NCT02028975|OTHER|Oral stimulation tests|
219127183|NCT02028975|OTHER|Venous blood samples|
219127184|NCT02028975|OTHER|Samples for genetic studies (ancillary study)|
219127185|NCT04119245|DEVICE|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
219710667|NCT06571006|OTHER|music|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB"
219710668|NCT00075231|DRUG|Kaletra® (lopinavir/ritonavir)|
219710669|NCT00075231|DRUG|Combivir® (lamivudine, zidovudine)|
219127186|NCT00832780|RADIATION|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
219127187|NCT02396940|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
219127188|NCT02396940|DEVICE|2D HD laparoscopy|Placebo
219127189|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
219127190|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
219127191|NCT06028048|BEHAVIORAL|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
219127192|NCT03421444|OTHER|No intervention|No intervention
219127193|NCT02635659|OTHER|Encapsulated nutrients|
219127194|NCT02635659|OTHER|Placebo|
219127195|NCT03569813|BEHAVIORAL|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
219226207|NCT06501001|BEHAVIORAL|Experimental: Time-Restricted Eating|Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
219226208|NCT04982926|DRUG|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
219226209|NCT04982926|DRUG|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
219226210|NCT06143709|OTHER|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
219710670|NCT00075231|DRUG|Sustiva® (efavirenz)|
219710671|NCT04152590|DEVICE|Uincare|Interactive digital healthcare system
219710672|NCT01866592|DRUG|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
219710673|NCT06420232|DEVICE|weighted blanket|Blanket weighted with 10% or less of body weight applied to child prior to meals for duration no more than 15 minutes
219710674|NCT06281392|DEVICE|CADe system|Colonoscopy assisted by an artificial intelligence system (CADe).
219710675|NCT06281392|DEVICE|NBI|Virtual colonoscopy assisted by NBI
219710676|NCT06033469|DRUG|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
219710677|NCT06033469|DRUG|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
219710678|NCT05302999|DRUG|Gabapentin|Generic gabapentin
219127196|NCT03569813|OTHER|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
219127197|NCT06646926|OTHER|Body tempering|Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.
219127198|NCT06646926|OTHER|Foam rolling self-myofascial release|Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
219127199|NCT02783950|OTHER|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
219127200|NCT03184545|DEVICE|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
219127201|NCT03184545|OTHER|Physical therapy|Standard physical therapy exercises
219226211|NCT01321073|DEVICE|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
219226212|NCT05253846|DRUG|Irinotecan|chemotherapy treatment
219226213|NCT05253846|DRUG|Oxaliplatin|chemotherapy treatment
219710679|NCT05302999|DRUG|Placebo|Inert cellulose
219710680|NCT06465810|DRUG|Treatment of transthyretin (ATTR) amyloidosis in observational study setting|Data will be collected on patients with ATTR amyloidosis in a real-world setting
219710681|NCT04194112|DIAGNOSTIC_TEST|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
219710682|NCT00002703|RADIATION|high-LET heavy ion therapy|
219710683|NCT00002703|RADIATION|low-LET photon therapy|
219710684|NCT06451120|DRUG|Platelet-Rich Plasma (PRP) Injections|Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection
219710685|NCT06451120|DEVICE|Centrifuge|The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.
219226214|NCT05253846|DRUG|Lederfolin|treatment
219226215|NCT05253846|DRUG|5-Fluorouracil|chemotherapy treatment
219226216|NCT05253846|RADIATION|Short-course radiotherapy|RT
219226217|NCT05253846|PROCEDURE|TME|surgery
219226218|NCT06268015|DRUG|Botensilimab|75 mg IV every 6 weeks for up to 4 doses
219226219|NCT06268015|DRUG|Balstilimab|240 mg IV every 2 weeks
219226220|NCT06268015|DRUG|Oxaliplatin|85 mg/m2 IV every 2 weeks
219226221|NCT06268015|DRUG|Leucovorin|400 mg/m2 IV every 2 weeks
219226222|NCT06268015|DRUG|Fluorouracil|400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
219710686|NCT06451120|DRUG|Control saline injection|A placebo injection of 6 mL of 0.9% saline will be prepared by the unblinded research assistant in an adjacent room. The syringed will be prepared in a 10 mL syringe and covered with Aluminum foil, such that the investigator performing the injection cannot tell if there is PRP or saline to be injected.
219710687|NCT04285086|BIOLOGICAL|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
219710688|NCT04285086|DRUG|Anagrelide|Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
219710689|NCT03979417|OTHER|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
219127202|NCT05129800|OTHER|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
219127203|NCT05129800|OTHER|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
219127204|NCT06370351|COMBINATION_PRODUCT|SENS-501 administration|Administration of SENS-501 with a dedicated administration system
219127205|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
219127206|NCT06515184|DRUG|PharmaNord Placebo|"Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
219127207|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
219127208|NCT04672408|DEVICE|His bundle pacing|Pacing with capture of the His bundle
219127209|NCT04672408|DEVICE|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
219127210|NCT06583837|DRUG|Orelabrutinib|Orelabrutinib was administrated for 12 weeks
219127211|NCT06583837|RADIATION|response-adapted radiation|response-adapted ultra-low dose 4Gy radiation
219127212|NCT02399995|BEHAVIORAL|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
219127213|NCT05417698|OTHER|Exercise Only (Ex only)|Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
219226223|NCT06268015|DRUG|Bevacizumab|5 mg/kg IV every 2 weeks
219226224|NCT06268015|DRUG|Panitumumab|6 mg/kg IV every 2 weeks
219226225|NCT03396107|DRUG|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
219226226|NCT03396107|DRUG|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
219710690|NCT05866224|OTHER|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
219710691|NCT02313155|DRUG|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
219710692|NCT02313155|DRUG|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
219710693|NCT01979900|DRUG|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
219710694|NCT01979900|DRUG|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
219710695|NCT02190201|DEVICE|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
219710696|NCT02190201|DEVICE|Direct laryngoscope|A kind of traditional laryngoscopes
219710697|NCT05971589|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
219710698|NCT00689936|DRUG|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
219127214|NCT05417698|OTHER|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale."
219127215|NCT06302062|DRUG|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
219127216|NCT06302062|DRUG|cyclophosphamide|A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
219127217|NCT06302062|DRUG|IL-2|The IL-2 treatment will be continued for 5 days.
219127218|NCT06302062|DRUG|Serplulimab Injection|In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .
219127219|NCT05407220|DRUG|HCP1904-1|take it once per period
219127220|NCT05407220|DRUG|HCP1904-3|take it once per period
219127221|NCT05869838|DEVICE|Colonoscopy|Screening or surveillance colonoscopy
219127222|NCT06233630|DRUG|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
219127223|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
219127224|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
219127225|NCT06095206|DRUG|GenSci094|On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
219127226|NCT04058392|BIOLOGICAL|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
219710699|NCT00689936|DRUG|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
219710700|NCT00689936|DRUG|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
219710701|NCT04684316|OTHER|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
219710702|NCT00386828|DRUG|Bevacizumab:|
219710703|NCT00636571|BEHAVIORAL|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
219127227|NCT06351267|OTHER|Core Stability Exercises|Core stability exercises will be used to strengthen the core muscles, which includes sets of exercises like pelvic tilts, wall squatting, bridging, bird dog and heel walking which targets core muscles.
219127228|NCT06351267|OTHER|Back Strengthening exercises|Back strengthening exercises will be used to strengthen the back muscles which include sets of exercises that target back muscles like cat-cow exercise, child pose, heel sits, and kegels.
219127229|NCT04319094|BEHAVIORAL|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
219127230|NCT04319094|OTHER|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
219127231|NCT05112315|DEVICE|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
219127232|NCT04956692|BIOLOGICAL|Pembrolizumab SC|SC injection
219710704|NCT04876937|DRUG|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
219127233|NCT04956692|BIOLOGICAL|Pembrolizumab IV|IV injection
219127234|NCT04956692|DRUG|Paclitaxel|IV injection
219127235|NCT04956692|DRUG|Nab-Paclitaxel|IV infusion
219127236|NCT04956692|DRUG|Carboplatin|IV infusion
219127237|NCT04956692|DRUG|Cisplatin|IV infusion
219127238|NCT04956692|DRUG|Pemetrexed|IV infusion
219127239|NCT06362837|BEHAVIORAL|Education intervention on nutrition, gender equity, WASH, sexual and reproductive health rights|Educational training on nutrition, gender equity, WASH, sexual and reproductive health rights will take place in communities (including schools) for women, men, and adolescents
219127240|NCT06362837|DIETARY_SUPPLEMENT|school-based iron-folic acid supplement program|The program will help support and promote the school-based programs of weekly iron and folic acid supplementation for adolescent girls, in countries where it is allowed.
219127241|NCT06362837|BEHAVIORAL|Health service training on equitable access to nutrition, health, and sexual and reproductive services|Training and support activities to make gender-equitable nutrition, health, and sexual and reproductive services in the health facilities
219127242|NCT06362837|DIETARY_SUPPLEMENT|bio-fortified crops|The program promotes and distributes bio-fortified crops, including orange-fleshed sweet potatoes, rice, beans, and corn
219127243|NCT06536036|DRUG|SIM0270|Use according to the prescribed protocol
219127244|NCT05305911|DRUG|SGLT-2 inhibitors|SGLT2 inhibitor once daily for six months
219127245|NCT05305911|DRUG|Placebo|Placebo once daily for six months
219127246|NCT03969277|OTHER|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
219127247|NCT03969277|OTHER|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
219127248|NCT03969277|OTHER|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
219127249|NCT03969277|OTHER|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
219127250|NCT06054828|BEHAVIORAL|mHELP@ICU|"The 14-day mHELP@ICU consists of the following three components:~1. Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~2. Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~3. Feeding monitor daily: The exact feeding data will be abstracted from medical records."
219710705|NCT04876937|DRUG|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
219710706|NCT00166816|DRUG|sirolimus, cyclosporine, tacrolimus|
219710707|NCT02392910|DRUG|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
219710708|NCT02392910|DRUG|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
219710709|NCT01396564|DRUG|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
219710710|NCT01396564|DRUG|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
219710711|NCT04144829|PROCEDURE|HIFU|Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
219710712|NCT04144829|PROCEDURE|Fibrin|Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
219710713|NCT00691964|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
219710714|NCT00691964|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
219710715|NCT00691964|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
219710716|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
219710717|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
219710718|NCT05375305|DRUG|Saline Solution|Saline Solution
219710719|NCT05375305|DRUG|Morphine|Morphine
219710720|NCT01303419|DEVICE|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
219127251|NCT03057132|DEVICE|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
219127252|NCT06148766|OTHER|Manuka Health Eternal Renewal Regenerating Face Cream with Royal Jelly and Bee Venom|Face cream containing manuka honey, royal bee jelly, and bee venom.
219127253|NCT05493371|DRUG|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
219127254|NCT04863898|BEHAVIORAL|Drug-use stigma reduction intervention for HIV care and treatment clinic staff|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
219127255|NCT00770211|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
219710721|NCT01303419|DEVICE|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
219710722|NCT00141375|DRUG|Pregabalin|
219710723|NCT04758338|OTHER|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
219710724|NCT04758338|OTHER|Interview|25-30 participants will be interviewed
219710725|NCT04758338|OTHER|Educational materials|Participants will be provided educational materials
219710726|NCT03697746|DRUG|paracetamol|paracetamol 1000 mg vial
219710727|NCT03697746|DRUG|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
219710728|NCT03697746|DRUG|Ibuprofen|ıbuprofen 400 mg vial
219710729|NCT06168214|DRUG|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
219710730|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
219710731|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
219710732|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
219710733|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
219127256|NCT00770211|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
219127257|NCT05705050|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
219127258|NCT05705050|OTHER|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
219127259|NCT02911272|DEVICE|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
219127260|NCT02911272|DRUG|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
219127261|NCT02911272|PROCEDURE|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
219127262|NCT02911272|DEVICE|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
219127263|NCT05547802|BIOLOGICAL|BBIBP-CorV and/or BNT162b2 vaccine|Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
219127264|NCT03109106|DEVICE|PCT Arm|PCT-guided antibiotic therapy per study protocol
219127265|NCT03362619|BIOLOGICAL|CC-EIEs|2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
219127266|NCT00764868|DRUG|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
219710734|NCT06168214|DRUG|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
219127267|NCT05571930|PROCEDURE|Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.
219127268|NCT05716633|DIAGNOSTIC_TEST|MRI|Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
219127269|NCT06148714|DIETARY_SUPPLEMENT|Provitalize Natural Menopause Probiotic|Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.
219710735|NCT06168214|DRUG|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
219710736|NCT06168214|DRUG|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
219710737|NCT06168214|DRUG|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
219710738|NCT05740202|DRUG|SHR-7367|The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.
219710739|NCT05676437|DIAGNOSTIC_TEST|Stress radiography|Radiographic examination during clinical stress test of knee laxity
219710740|NCT04229576|DEVICE|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
219710741|NCT01260506|DRUG|VB-111|
219127270|NCT06148714|OTHER|Placebo|Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.
219127271|NCT05736770|OTHER|Respiratory rehabilitation and out of bed mobilization|The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery
219127272|NCT05736770|OTHER|conventional treatment|The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
219127273|NCT05993208|DIAGNOSTIC_TEST|optical coherence tomography,multifocal electroretinogram. VA measurment|retinal photography
219127274|NCT02453646|DEVICE|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
219127275|NCT00741273|DRUG|Proellex|Proellex 25 mg capsule, single dose
219127276|NCT03605186|OTHER|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
219710742|NCT01260506|DRUG|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
219226227|NCT02010957|OTHER|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
219226228|NCT02010957|OTHER|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
219226229|NCT06176443|PROCEDURE|One anastomosis gastric bypass with combined fundoplication|FundoRingOAGB
219127277|NCT03605186|OTHER|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
219127278|NCT01077661|DRUG|Nebivolol|patients administrated Nebivolol according to the prescribing information
219710743|NCT05842291|DEVICE|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
219710744|NCT05842291|DEVICE|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
219127279|NCT01091181|PROCEDURE|hysterotomy at cesarean|incision to open the uterus at cesarean.
219127280|NCT01515319|DRUG|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
219127281|NCT01515319|DRUG|0.9% saline|Identical volume to that of Y242
219226230|NCT06176443|PROCEDURE|One anastomosis gastric bypass without combined fundoplication|OAGB
219226231|NCT00346320|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
219710745|NCT05842291|DEVICE|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
219710746|NCT06475001|DRUG|VER-01|"Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil."
219710747|NCT06475001|DRUG|Placebo|Comparator without active ingredient
219710748|NCT01644838|DRUG|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
219710749|NCT01644838|DRUG|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
219127283|NCT06667856|OTHER|Asynchronous exercise group|Application of foot core training combined with lower extremity exercises using asynchronous telerehabilitation method.
219226232|NCT03506945|BEHAVIORAL|mPEP|Behavioral Activation Therapy
219226233|NCT03506945|BEHAVIORAL|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
219226234|NCT01852006|DEVICE|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
219226235|NCT03000257|DRUG|Venetoclax|Tablet taken orally
219226236|NCT03000257|DRUG|Rovalpituzumab Tesirine|Intravenous infusion
219710750|NCT00594555|DRUG|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
219127284|NCT06667856|OTHER|Synchronous exercise group|Application of foot core training combined with lower extremity exercises using synchronous telerehabilitation method.
219127285|NCT06610370|OTHER|Group 1|95 children with spastic cerebral palsy were included. Gross Motor Function Measure-88 (GMFM-88) and Gross Motor Function Classification System (GMFCS) were applied to the cases before and after the Selective Dorsal Rhizotomy (SDR) surgery.
219226237|NCT03000257|DRUG|ABBV-181|Intravenous infusion
219127286|NCT04428164|OTHER|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
219127287|NCT04428164|OTHER|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
219127288|NCT06426771|BEHAVIORAL|Dietary Inflammatory Index|The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
219127289|NCT06426771|DIAGNOSTIC_TEST|hormone profile|In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
219710751|NCT00594555|DRUG|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
219710752|NCT04652648|DRUG|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
219127290|NCT06615583|DEVICE|Surgical device|The C-REX device consists of an invasive surgical part, including two anastomotic rings, and surgical instruments for assisting the placement of the anastomotic ring to intestine. The rings are loosen from the inside of the intestinal wall and expelled with faeces per rectum once the anastomosis is healed in approximately ten days.
219127291|NCT06615596|BEHAVIORAL|discontinue anticoagulation therapy|Participants in the discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
219127292|NCT06615596|DRUG|Anticoagulant drugs|Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
219226238|NCT02804815|DRUG|Aspirin 100mg|Aspirin 100mg
219226239|NCT02804815|DRUG|Aspirin 300mg|Aspirin 300mg
219226240|NCT02804815|DRUG|Placebo 100mg|Placebo 100mg
219710753|NCT00158730|DRUG|AmBisome|
219710754|NCT06197282|PROCEDURE|Major surgery involving general anesthesia|EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
219710755|NCT03788330|DEVICE|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
219710756|NCT05707325|DRUG|engineered red blood cell|engineered red blood cell
219226241|NCT02804815|DRUG|Placebo 300mg|Placebo 300mg
219226242|NCT03692845|PROCEDURE|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
219226243|NCT03511612|DIAGNOSTIC_TEST|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
219226244|NCT02568553|BIOLOGICAL|Blinatumomab|Given IV
219226245|NCT02568553|DRUG|Lenalidomide|Given PO
219226246|NCT04784715|DRUG|Trastuzumab deruxtecan|Administered by intravenous infusion
219226247|NCT04784715|DRUG|Placebo|Administered by intravenous infusion
219226248|NCT04784715|DRUG|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
219226249|NCT04784715|DRUG|Pertuzumab|Administered by intravenous infusion
219226250|NCT04784715|DRUG|Trastuzumab|Administered by intravenous infusion
219226251|NCT02674841|OTHER|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
219226252|NCT02674841|OTHER|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
219226253|NCT02674841|OTHER|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
219127293|NCT06615596|PROCEDURE|Catheter Ablation|Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
219710757|NCT02013414|DEVICE|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
219127294|NCT03035071|PROCEDURE|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
219127295|NCT03035071|PROCEDURE|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
219127296|NCT06613646|PROCEDURE|Ultrasound-guided injection of the subacromial bursa and pectoralis minor|"Patients will first receive an ultrasound-guided injection of the subacromial bursa. After the subacromial bursa injection, patients will be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the Numeric Rating Scale (NRS), and passive range of motion will be measured.~Following the subacromial bursa injection, patients will receive an ultrasound-guided injection of the pectoralis minor muscle. After the pectoralis minor muscle injection, patients will again be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the NRS, and passive range of motion will be measured."
219127297|NCT06613646|DRUG|Lidocaine (drug)|5 mL of 2% lidocaine will be used as a local anesthetic for the subacromial bursa injection, and 4 mL of 2% lidocaine will be used for the pectoralis minor muscle injection.
219127298|NCT01959880|DEVICE|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
219127299|NCT06614088|DIAGNOSTIC_TEST|serum calprotectin|A blood sample is collected at time of admission to detect serum level of calprotectin
219127300|NCT06613620|OTHER|Standard Treatment|"All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
219226254|NCT01227421|DRUG|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
219226255|NCT01227421|DRUG|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
219226256|NCT01227421|DRUG|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
219226257|NCT02847520|BEHAVIORAL|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
219226258|NCT03395600|DRUG|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
219226259|NCT03395600|DRUG|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
219226260|NCT03395600|DRUG|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
219710758|NCT01056679|DRUG|Doxorubicine|50mg/m2 day 1 + 15
219710759|NCT01056679|DRUG|DTIC|375mg/m2 day 1 + 15
219710760|NCT01056679|DRUG|Lenalidomide|day 1 - 21
219710761|NCT01056679|DRUG|Vinblastine|6mg/m2 day 1 + 15
219127301|NCT06613620|OTHER|Visual and auditory feedback on SEMG biofeedback unit|Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.
219127302|NCT06613620|OTHER|Electrical muscle stimulation|Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.
219127303|NCT06614075|BEHAVIORAL|Questionnaire and anthropometric measurement|Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
219127304|NCT06613555|OTHER|Retinal imaging|"the retinal imaging work-up includes:~* OCT-angiography~* Retinophotography~* Adaptive optics~performed at inclusion, at 6 months and then once a year for 10 years for patients Only performed at inclusion for controls"
219127305|NCT06613555|BIOLOGICAL|Biological check-up|"it is performed at inclusion and then once a year for 10 years for patients~Only performed at inclusion for controls"
219226261|NCT06233552|PROCEDURE|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
219226262|NCT06233552|PROCEDURE|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
219226263|NCT02499328|DRUG|AZD9150|AZD9150
219226264|NCT02499328|DRUG|MEDI4736|MEDI4736
219226265|NCT02499328|DRUG|AZD5069|AZD5069
219226266|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
219226267|NCT06435169|DIAGNOSTIC_TEST|Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.|The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
219226268|NCT04847375|DRUG|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
219710762|NCT06278168|OTHER|Awareness training with using Oculus.|"The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest."
219226269|NCT04603508|DRUG|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
219226270|NCT04603508|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
219127306|NCT06613581|OTHER|Home-based follow-up|Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines
219127307|NCT01919619|BIOLOGICAL|Ipilimumab|Given IV
219127308|NCT01919619|DRUG|Lenalidomide|Given PO
219127309|NCT06682624|DEVICE|MRI|Magnetic Resonance Imaging in recognition of pediatric neurodegenerative disease patterns
219226271|NCT04603508|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
219226272|NCT04603508|OTHER|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
219226273|NCT04603508|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
219226274|NCT04603508|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
219127310|NCT06682117|DRUG|DC Vaccine|"Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons."
219127311|NCT06137755|BIOLOGICAL|CVI-VZV-001|Investigational Product
219127312|NCT06137755|BIOLOGICAL|Shingrix|Investigational Product
219127313|NCT06696235|DEVICE|Early initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
219127314|NCT06696235|DEVICE|Standard initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
219127315|NCT04323735|DRUG|Culturelle 10 Billion CFU Capsule|"LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group."
219127316|NCT06697275|DEVICE|Hypnotic Virtual reality|Hypnotic Virtual reality mask Deepsen® with age-appropriate software Birdy®
219127317|NCT06697275|DEVICE|Interactive virtual reality|Interactive virtual reality mask Deepsen® with age-appropriate software Birdy®
219127318|NCT06697275|OTHER|Standard method|Use of local anesthesic cream + Nurse and/or parents distraction +/- anxioloytic gas
219127319|NCT06697795|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic neck pain.
219127320|NCT06697795|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
219226275|NCT03350698|BIOLOGICAL|Gardasil-9|3 vaccine series
219226276|NCT00934817|DRUG|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
219226277|NCT00934817|DRUG|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
219127321|NCT06696495|DIAGNOSTIC_TEST|Measurement of the size and width of the foot|Assessment of the height of the plantar arch using a podoscope, and application of functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, the distribution of plantar pressure and the centre of pressure (COP)
219127322|NCT06710977|DRUG|Safety of intracameral levofloxacin in cataract surgery|Intracameral levofloxacin (0.1ml/0.5mg)
219127323|NCT06710977|DRUG|Use of intracameral cefazolin in cataract surgery|Intracameral cefazolin (0.1ml/1mg)
219127324|NCT06696755|DRUG|Icalcaprant|Oral Capsules
219127325|NCT06696755|DRUG|Placebo for Icalcaprant|Oral Capsules
219127326|NCT06698081|OTHER|Video Multimedia|The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia. In addition to the standard consent process, we planned to show a 6-minute video multimedia presentation containing information about undescended testis and orchiopexy.
219127327|NCT05846087|BEHAVIORAL|sleep retraining therapy|Sleep retraining therapy improves sleep efficiency (total sleep time/total time in bed) by reducing the amount of time spent in bed awake. The digitally designed version which SleepFix delivers uses an algorithm which requires the users current sleep times and ideal wake-up time to determine when one should get into bed to fall asleep and when one should get out of bed.
219127328|NCT05846087|OTHER|sleep health education modules|educational modules about sleep and insomnia; its causes; and its impact on various aspects of life. This information is arranged into three modules which will be provided to participants over three weeks.
219710763|NCT06278168|OTHER|Awareness training without using Oculus|The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
219710764|NCT02543411|DRUG|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
219710765|NCT02543411|DRUG|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
219710766|NCT05944952|DRUG|buprenorphine/naloxone|Participants will be dosed with buprenorphine/ naloxone strips
219127329|NCT06166511|PROCEDURE|Laparoscopic liver resection|Using Laparoscopy in liver resection
219226278|NCT05631808|OTHER|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
219226279|NCT02036177|DEVICE|SCu300A IUB intrauterine device|Spherical copper IUD
219226280|NCT02036177|DEVICE|T380A IUD|T-shaped copper IUD
219226281|NCT06328868|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219226282|NCT06328868|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219710767|NCT01580644|DRUG|GLPG0187 prodrug|
219710768|NCT03232944|DEVICE|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
219710769|NCT06378970|OTHER|Audio Book Application|The Audio Book Application Preference Form asked about book preferences other than horror and thriller genres. The selected audiobook was played with headphones via tablet/smartphone. Separate headphones were used for each patient. Patient Follow-up Form and Facial Anxiety Scale evaluations; the initial measurement (M0) was evaluated before the intervention, the first measurement (M1) at the 15th minute of the intervention, the second measurement (M2) at the 30th minute of the intervention, and the third measurement (M3) 30 minutes after the end of the intervention. Care was taken to ensure that there was no deterioration in the comfort of individuals due to the intervention. In the selection of audio books, language fluency, spelling rules and accessibility were taken into consideration and audiobook platforms to which the researchers were members were used.
219710770|NCT02792127|BEHAVIORAL|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
219710771|NCT02342730|BEHAVIORAL|Weight Loss Specialist|Referred to a weight loss specialist
219710772|NCT02342730|OTHER|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
219127330|NCT01201564|PROCEDURE|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
219127331|NCT01201564|PROCEDURE|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
219127332|NCT06829238|DRUG|Metformin|Participants will receive Metformin ER (500mg increasing to 1000mg) or placebo for 16 weeks to assess immune restoration and inflammatory response.
219127333|NCT06829238|DRUG|Placebo|Participants will receive placebo for 16 weeks and assess immune restoration and inflammatory response.
219127334|NCT06829238|BIOLOGICAL|Jynneos|All participants will take a Jynneos (MPOX) vaccine.
219127335|NCT06829238|BIOLOGICAL|Capvaxvie|All participants will take a Capvaxvie (PCV21, pneumococcal) vaccine.
219127336|NCT06779149|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Participants in this treatment group will receive CBT-I. CBT-I sessions will occur weekly for the first 4 sessions and biweekly for the last 2 sessions (treatment phase is thus 8 weeks). : Graduate level students in clinical psychology will serve as therapists for this project.
219127337|NCT06779149|DRUG|Lemborexant|Participants assigned to this group will be prescribed 5 to 10 mg of lemborexant to be taken at bedtime in 5 mg capsules. Lemborexant (Dayvigo) is a Dual Orexin Receptor Antagonist approved by Health Canada for the treatment of adult with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
219127338|NCT06779149|DRUG|Placebo|Participants assigned to this group will be prescribed 5 to 10 mg of placebo to be taken at bedtime in 5 mg capsules identical to lemborexant. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
219127339|NCT03253653|DEVICE|Differential effects of waterpipe smoking practices on toxicity of waterpipe tobacco smoke|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
219127340|NCT06750965|DIAGNOSTIC_TEST|Serum M protein screening|Using highly sensitivity test to screen serum M protein of all participants.
219127341|NCT06621563|DRUG|HS-20117 combined HS-20093|HS-20117 + HS-20093
219127342|NCT06621563|DRUG|HS-20117 combined Platinum-containing chemotherapy|HS-20117 + cisplatin/carboplatin + pemetrexed
219127343|NCT06621563|DRUG|HS-20117 combined HS-20093 and 5-FU|HS-20117 + HS-20093 + 5-FU
219127344|NCT06621563|DRUG|HS-20117+CAPEOX|CAPOEX: Oxaliplatin+Capecitabine
219710773|NCT02342730|OTHER|Medical Chart Review|Chart reviews are performed
219710774|NCT04521140|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
219710775|NCT04521140|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
219127345|NCT06621563|DRUG|HS-20117+FOLFIRI|FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU
219127346|NCT06621563|DRUG|HS-20117+mFOLFOX6|mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU
219127347|NCT06906094|PROCEDURE|Selective meniscectomy|involves the partial removal of the damaged meniscus.
219127348|NCT06908564|DEVICE|Experimental: Interactive balance rehabilitation based on serious games.|The intervention of the Experimental Group consists of 30 minutes (16 sessions, 4 days/week, for 4 weeks) of balance rehabilitation exercises using non-immersive virtual reality through the OAK device (Khymeia Group, Italy). The system includes exercises that require the patient to reach visual targets by shifting their Center of Pressure (COP). The exercises are categorized based on the direction of COP displacement and can be performed with increasing difficulty, as determined by the physiotherapist during the rehabilitation process.
219127349|NCT06908564|OTHER|Active Comparator: conventional balance rehabilitation without the use of technological devices.|"Intervention of the Control Group (CG) consists of 30 minutes (4 days/week, for 4 weeks) of conventional balance rehabilitation treatments without the use of technological devices. The motor exercises will focus on the rehabilitation of balance, the trunk, and the lower limbs and will be carried out with a physiotherapist who will tailor the treatment according to the patient's characteristics and needs. Primary attention will be given to recovering trunk control and seated posture. This phase will focus on restoring and maintaining muscle trophism in the anterior and posterior kinetic chains of the thigh and lower leg, as well as the hip's range of motion, through isometric exercises and gentle joint mobilizations while adhering to anti-dislocation guidelines.~The process will continue with the reacquisition of the upright stance, emphasizing proprioceptive, coordination, and balance abilities. Once the upright position is stabilized, gait re-education will be introduced."
219127350|NCT05968079|DEVICE|Masimo W1™ and Apple Watch Series 8|Noninvasive wearable health monitoring device
219127351|NCT05031936|PROCEDURE|cervical spinal injection with 0.2% ropivacaine|spinal injections performed in cervical pillar area to relieve chronic neck pain
219127352|NCT06920394|OTHER|Survey using a questionnaire.|In the present study, no intervention will be carried out, and only the patients recruited will complete the questionnaires set out below.
219127353|NCT06918730|PROCEDURE|U-POEM|Water immersion for luminal distension of the GI tract as opposed to carbon dioxide insufflation
219127354|NCT06918730|PROCEDURE|CO2-POEM|POEM is routinely performed under carbon dioxide insufflation (CO2-POEM) as this gas is more rapidly absorbed than air.
219127355|NCT06920082|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
219710776|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
219710777|NCT04584671|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
219127356|NCT06918782|DRUG|Osimertinib plus platinum doublet chemotherapy|Based on the FLAURA2 study (which was not subdivided into ctDNA clearance subgroups), it is hypothesized that adding systemic chemotherapy to osimertinib will prolong PFS and OS and increase objective response rate even among the poor prognostic subgroup with failed ctDNA clearance after initial osimertinib monotherapy. By incorporating systemic chemotherapy (pemetrexed/carboplatin) to first-line osimertinib treatment among the poor prognostic group of metastatic EGFR-mutant lung adenocarcinoma with failure of plasma ctDNA EGFR mutant clearance despite initial osimertinib treatment.
219710778|NCT04584671|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
219710779|NCT04584671|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
219710780|NCT04584671|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
219710781|NCT04584671|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
219710782|NCT04584671|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
219710783|NCT04584671|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
219710784|NCT06403839|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
219710785|NCT05290649|DIAGNOSTIC_TEST|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
219710786|NCT04392206|DRUG|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
219710787|NCT05835882|BIOLOGICAL|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~1. Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~2. Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~3. Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
219710788|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
219710789|NCT04287062|DRUG|Placebos|Weight and color matched placebo
219127357|NCT06919289|DRUG|Infiltration of papaverine|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
219127358|NCT06919289|DRUG|Lidocaine infiltration|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
219710790|NCT06640920|BIOLOGICAL|Cohort A|Administered IV High dose
219710791|NCT06640920|BIOLOGICAL|Cohort B|Administered SC Low Dose
219710792|NCT06640920|BIOLOGICAL|Cohort C|Administered SC Mid Dose
219710793|NCT06640920|BIOLOGICAL|Cohort D|Administered SC High Dose
219710794|NCT02213926|DRUG|ACP-196 (acalabrutinib)|
219710795|NCT05810948|BIOLOGICAL|efgartigimod IV|Intravenous (IV) infusion of efgartigimod
219710796|NCT05810948|OTHER|Placebo|Intravenous (IV) infusion of placebo
219710797|NCT06415630|PROCEDURE|Type A aortic dissection surgery|Patients with type A aortic dissection undergone surgery.
219710798|NCT04518085|BEHAVIORAL|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
219710799|NCT04518085|BEHAVIORAL|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
219710800|NCT04518085|BEHAVIORAL|Mindfulness session|Single session mindfulness session delivered by audio file
219710801|NCT04518085|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
219710802|NCT01234116|DRUG|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
219710803|NCT05690828|BEHAVIORAL|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
219127359|NCT06918912|DRUG|Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)|Loncastuximab Tesirine is an antibody-drug conjugate specifically targeting CD19, a protein found on the surface of B-cells. It is designed to deliver a cytotoxic pyrrolobenzodiazepine dimer directly to CD19-expressing malignant B-cells. Unlike traditional chemotherapies, Loncastuximab Tesirine combines the precision of an anti-CD19 monoclonal antibody with a potent chemotherapy agent, offering targeted therapy for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma (HGBCL) after failure of CAR-T therapy. It is administered intravenously every 3 weeks, with an initial higher dose of 150 μg/kg followed by a reduced dose of 75 μg/kg for up to 8 cycles, distinguishing it from other treatments by its specific targeting mechanism and dosage regimen tailored to this patient population.
219127360|NCT06920316|DEVICE|Gro Health digital application|The Gro Health digital application is a personalised treatment platform proven to support sustainable weight loss. It is non-MHRA regulated as MASLD is within the device's UKCA/CE UKNI/CE marked indication. Gro Health reports 7% weight loss at 52 weeks in patients with Type 2 Diabetes Mellitus. We can set up the application so patients follow a Mediterranean diet. Over 1000 recipes of different cuisines will be available, along with weekly diet plans and shopping lists. Based on the patient's body mass index, daily calories and macronutrient targets will be calculated in line with the Mediterranean diet. Aerobic exercise can be tracked by daily step count linked by compatible smartwatches and smartphones. Physical activity can also be logged manually. Gro Health provides educational videos on aerobic and resistance exercise, along with 'follow along' videos of exercises for patients. These videos range from ones for beginners to those who have more experience with exercise.
219127361|NCT06919250|OTHER|Patients with systemic lupus erythematosus|Population: Patients with systemic lupus erythematosus. Intervention: Identification of the degree of physical activity of patients with systemic lupus erythematosus.
219127362|NCT04060784|PROCEDURE|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
219127363|NCT03709784|DRUG|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
219127364|NCT03709784|OTHER|One time survey|One time survey
219127365|NCT03802773|PROCEDURE|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
219127366|NCT03478579|OTHER|observational|No intervention, it is observational study
219127367|NCT02253186|DEVICE|Auto-Adjustable MOBIDERM Armsleeve|
219127368|NCT04181801|PROCEDURE|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
219127369|NCT00948844|DEVICE|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
219127370|NCT03881254|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
219710804|NCT02587416|DRUG|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
219710805|NCT02587416|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
219127371|NCT03881254|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
219710806|NCT02587416|DRUG|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
219710807|NCT04635345|OTHER|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
219710808|NCT04635345|OTHER|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
219710809|NCT00954083|BEHAVIORAL|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
219710810|NCT00954083|BEHAVIORAL|Routine care|Routine care
219710811|NCT00743093|DRUG|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
219710812|NCT00743093|DRUG|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
219710813|NCT03831997|DRUG|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
219710814|NCT02327078|DRUG|Nivolumab|specified dose and dosing schedule
219127372|NCT03881254|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
219127373|NCT03881254|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
219127374|NCT03610477|DIETARY_SUPPLEMENT|Medium chain triglycerides|Gel capsules, each containing 1 gram
219127375|NCT03610477|DIETARY_SUPPLEMENT|Long chain triglycerides|Gel capsules, each containing 1 gram
219127376|NCT02098902|BEHAVIORAL|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
219127377|NCT06278857|DRUG|Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]|The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
219127378|NCT04746859|OTHER|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
219710815|NCT02327078|DRUG|Epacadostat|oral twice daily continuous at the protocol-defined dose
219127379|NCT04746859|BEHAVIORAL|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
219127380|NCT01551836|DRUG|Paracetamol formulation 1|formulation 1
219710816|NCT02327078|DRUG|Chemotherapy|Specified dose on specified days
219710817|NCT06579612|OTHER|Personalized follow-up and support|After a pulmonary rehabilitation program, an interview with a professional will enable the professional to identify the barriersand enablers of physical activity engagement, and to identify (with the patient) a plan for maintaining a physical activities adapted in daily life. Adapted solutions will then be proposed.
219710818|NCT05496998|DEVICE|Medtronic Intrepid™ TMVR TF System|Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
219710819|NCT02115698|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
219710820|NCT02115698|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
219710821|NCT02115698|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
219710822|NCT02115698|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
219710823|NCT02115698|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
219710824|NCT06366841|OTHER|Psychological tests administration|Psychological tests administration to evaluate stigma, personality characteristics and quality of life of rectal and anal cancer patients.
219710825|NCT04987879|BEHAVIORAL|Exercise|Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
219710826|NCT04949776|DIAGNOSTIC_TEST|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
219710827|NCT05428917|BEHAVIORAL|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
219127381|NCT01551836|DRUG|Paracetamol formulation 2|Formulation 2
219127382|NCT05232136|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
219710828|NCT05428917|BEHAVIORAL|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
219710829|NCT03540940|OTHER|PEEP|7cmH2O positive end expiratory pressure
219710830|NCT03540940|OTHER|ZEEP|0 cmH2O positive end expiratory pressure
219710831|NCT05052008|DRUG|Erenumab|Erenumab is monoclonal antibody used for management of migraine
219710832|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
219710833|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
219710834|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
219710835|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
219710836|NCT04963920|DEVICE|Cytosorb® 300 ml|patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
219127383|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
219127384|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
219127385|NCT03076801|BEHAVIORAL|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
219127386|NCT00498186|DRUG|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
219127387|NCT05846711|DIAGNOSTIC_TEST|BPPV diagnostic|Supine Roll Test and Dix-Hallpike Test
219127388|NCT05846711|DEVICE|TRV chair|Mechanical rotational chair
219127389|NCT05846711|DEVICE|VNG goggles|Goggles for video nystagmography
219710837|NCT05756153|DRUG|GFH925|GFH925 tablets administered orally daily.
219710838|NCT05756153|DRUG|Cetuximab|Cetuximab administered intravenously Q2W.
219710839|NCT04147494|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219710840|NCT04147494|RADIATION|Gallium Ga 68 FAPi-46|Given IV
219127390|NCT05846711|DEVICE|IMU sensor|A sensor that measures triaxial acceleration and triaxial angular velocity.
219127391|NCT05846711|PROCEDURE|Manual BPPV diagnostics|Bedside BPPV diagnostics
219127392|NCT05039736|DRUG|Cabozantinib|Given by PO
219127393|NCT05039736|DRUG|Nivolumab|Given by IV
219127394|NCT05247216|DRUG|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
219127395|NCT05247216|DRUG|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
219127396|NCT05247216|DRUG|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
219127397|NCT05247216|DRUG|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
219127398|NCT05928182|BEHAVIORAL|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]."
219127399|NCT05165914|DRUG|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
219127400|NCT05165914|DRUG|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
219127401|NCT05091164|PROCEDURE|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
219127402|NCT04551417|PROCEDURE|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
219226283|NCT06328868|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219226284|NCT03150446|DEVICE|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
219710841|NCT04147494|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
219710842|NCT04147494|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219710843|NCT04147494|RADIATION|18F-FDG|Given IV
219710844|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
219710845|NCT06062108|OTHER|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
219710846|NCT05884983|PROCEDURE|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
219710847|NCT05513950|BIOLOGICAL|CHF10067 starting dose -- 1000mg (Cohort A)|Intravenous administration of a starting dose of the monoclonal antibody
219710848|NCT05513950|BIOLOGICAL|CHF10067 intermediate dose -- 2000mg (Cohort B)|Intravenous administration of an intermediate dose of the monoclonal antibody
219710849|NCT05513950|BIOLOGICAL|CHF10067 high dose -- 3000mg (Cohort C)|Intravenous administration of a high dose of the monoclonal antibody
219710850|NCT05513950|DRUG|Placebo|Intravenous administration of a physiological solution as placebo
219710851|NCT04871477|OTHER|Communication Intervention|Audio record part of clinic visit
219710852|NCT04871477|OTHER|Questionnaire Administration|Ancillary studies
219127403|NCT05387928|DRUG|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
219127404|NCT05343884|RADIATION|Myocardial perfusion imaging|Myocardial perfusion imaging
219710853|NCT06504446|DRUG|NOC-110|Inhalation powder
219710854|NCT06504446|OTHER|Placebo|Inhalation powder
219127405|NCT01565161|BEHAVIORAL|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
219127406|NCT01565161|BEHAVIORAL|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
219127407|NCT01641276|DEVICE|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
219127408|NCT02963220|BEHAVIORAL|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
219127409|NCT02458846|OTHER|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
219226285|NCT04554108|OTHER|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
219226286|NCT00468156|BEHAVIORAL|written materials only|related to fruit/vegetable servings/day
219226287|NCT00468156|BEHAVIORAL|written materials|related to fruit/vegetable servings/day
219226288|NCT00468156|BEHAVIORAL|telephone support|related to fruit/vegetable servings/day
219710855|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Spaced Retrieval condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated spaced retrieval condition consists of study and retrieval trials. At the start of the sessions, retrieval trials immediately follow study trials. Thereafter, retrieval trials are spaced for each verb, occurring after 3 other words have intervened between the retrieval trial and the last study trial for that verb."
219710856|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Study condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated study condition consists of study trials only (with no retrieval practice)."
219226289|NCT03759249|OTHER|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
219226290|NCT05224557|OTHER|No intervention|No intervention
219226291|NCT03563690|OTHER|treatment1|"1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
219226292|NCT03563690|OTHER|treatment2|"1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
219226293|NCT03563690|OTHER|treatment3|"1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
219226294|NCT03563690|OTHER|treatment4|"1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
219710857|NCT02903914|DRUG|INCB001158|Arginase Inhibitor
219710858|NCT02903914|DRUG|Pembrolizumab|PD-1 Inhibitor
219710859|NCT03817970|DRUG|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
219710860|NCT03817970|DRUG|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
219127410|NCT02458846|OTHER|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
219127411|NCT02458846|DEVICE|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
219127412|NCT02458846|OTHER|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
219127413|NCT02462655|OTHER|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
219127414|NCT02462655|OTHER|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
219127415|NCT00512824|DIETARY_SUPPLEMENT|low calcium milk of 180 ml|twice daily for 24 weeks
219127416|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml|twice daily for 24 weeks
219127417|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
219127418|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
219127419|NCT00886613|BIOLOGICAL|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
219127420|NCT00886613|BIOLOGICAL|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
219710861|NCT03817970|DRUG|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
219710862|NCT05777408|PROCEDURE|Conventional Physical Therapy|"* 15 mins of TENS (frequency 100 Hz, phase duration 50 μs) with moist heat over the area of pain~* Isomeric Stretching of neck muscles followed by neck isometrics"
219710863|NCT05777408|PROCEDURE|Natural Apophyseal glides|-Will be applied in sitting position Therapist right hand would cradle the head such that the little finger would rest on the spinous process of the vertebra that is to be mobilized. The other hands thumb would be used to apply over pressure. Direction of force will be parallel to highly irritable-grossly restricted cervical facet joints. Intervention would involve 3 sets of 20 repetitions in 15minutes, 3 days a week for 2 weeks comprising of total 6 session.
219127421|NCT00886613|BIOLOGICAL|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
219127422|NCT00886613|OTHER|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
219710864|NCT05777408|PROCEDURE|Cranial Base Release|Will be performed in lying position. therapist fingers will contact the sub occipital muscles and upward pressure would be given until the tissues and muscles relax. it will be given once daily for 3 days a week and will continue for 2 weeks
219127423|NCT00886613|OTHER|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
219127424|NCT06631365|DEVICE|PrEPsmart mobile app|"The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging"
219127425|NCT06631365|DRUG|Truvada|Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
219127426|NCT06630481|DRUG|neoadjuvant therapy|Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
219710865|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
219710866|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
219127427|NCT06629467|BEHAVIORAL|Cognitive-behavioral therapy for smoking cessation|Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
219127428|NCT06629467|BEHAVIORAL|Personalized PA plan|The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
219127429|NCT06629467|DEVICE|Fitbit Versa 3|Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
219127430|NCT03349190|DRUG|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
219127431|NCT03874975|DRUG|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
219127432|NCT01760681|DEVICE|H- Coil DTMS|20 daily deep rTMS treatments
219710867|NCT04955249|DRUG|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
219710868|NCT04955249|DRUG|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
219710869|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
219710870|NCT04341636|RADIATION|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
219127433|NCT01760681|DEVICE|Sham|
219127434|NCT06479460|DIAGNOSTIC_TEST|ctDNA-MRD|This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.
219127435|NCT01515956|DRUG|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
219127436|NCT04767230|OTHER|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
219127437|NCT02741479|OTHER|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
219127438|NCT02821598|OTHER|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
219127439|NCT02821598|OTHER|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
219226295|NCT03563690|OTHER|treatment5|"1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm."
219127440|NCT02821598|OTHER|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
219127441|NCT02821598|OTHER|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
219127442|NCT02821598|OTHER|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
219127443|NCT04106440|BEHAVIORAL|Application Use|Use applications after initial diagnosis to share information with study team.
219127444|NCT05205993|DRUG|Intrauterine infusion|A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
219127445|NCT05205993|DRUG|Oral administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
219226296|NCT03563690|DRUG|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
219226297|NCT00145470|DRUG|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
219127446|NCT03089619|DRUG|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
219127447|NCT03089619|DEVICE|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
219127448|NCT02470624|OTHER|treatment following current guideline|
219226298|NCT00145470|DRUG|Placebo|Placebo fast dissolving SL tablets, BID
219226299|NCT02540525|DEVICE|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
219226300|NCT02540525|DEVICE|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
219710871|NCT04491643|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
219127449|NCT05518513|DRUG|Bupivacain|adductor canal block with 0.25% bupivacaine
219127450|NCT04541186|DRUG|Pegozafermin|Subcutaneous injection
219127451|NCT04541186|DRUG|Placebo|Matching placebo
219226301|NCT03355534|DRUG|Intravenous dexmedetomidine|drug is intravenously infused to patients
219710872|NCT04491643|DRUG|Rosuvastatin|At a dosage of 10 mg/day
219710873|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
219710874|NCT06294106|DEVICE|Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)|EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
219710875|NCT06374537|OTHER|Muscle Therapy|Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
219710876|NCT06018428|DRUG|bempikibart (ADX-914)|Subcutaneous administration of bempikibart (ADX-914)
219710877|NCT06200961|DEVICE|Transnasal Endoscopy|Unsedated endoscopic evaluation through the nose.
219226302|NCT03355534|DRUG|nasal dexmedetomidine|drug is nasally given to patients
219226303|NCT03355534|DRUG|intravenous saline|saline is given to patients intravenously
219226304|NCT03355534|DRUG|nasal saline|normal saline is given to patients nasally
219226305|NCT04800042|DIAGNOSTIC_TEST|Diagnostic test|Blood iron status : ferritin and transferrin saturation factor
219226306|NCT02628106|DRUG|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
219226307|NCT00073255|DRUG|hokt3g1 (ALA-ALA)|
219226308|NCT06396975|PROCEDURE|robotic surgery|robotic surgery
219710878|NCT06200961|PROCEDURE|Esophagogastroduodenoscopy|Sedated endoscopic evaluation through the mouth.
219710879|NCT04914338|OTHER|Health Promotion|Participate in MDT-intervention
219710880|NCT04914338|OTHER|Quality-of-Life Assessment|Ancillary studies
219710881|NCT04914338|OTHER|Questionnaire Administration|Ancillary studies
219127452|NCT06445231|DIAGNOSTIC_TEST|Implementation of echocardiography in nursing homes|An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
219127453|NCT00094250|BEHAVIORAL|Resistance and Aerobic Training|
219710882|NCT06836414|PROCEDURE|Low-dose Computerized tomography (CT) of Chest|Undergo CT for lung cancer screening
219127454|NCT04370236|DRUG|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
219127455|NCT04370236|DRUG|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
219127456|NCT04543344|DRUG|Recifercept|recifercept powder for solution for injection
219127457|NCT04543344|OTHER|Placebo|solution for injection
219127458|NCT02224833|BEHAVIORAL|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
219127459|NCT05954169|DRUG|SHR4640|SHR4640 single-dose
219127460|NCT00691028|DRUG|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
219127461|NCT00691028|DRUG|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
219127462|NCT00691028|DRUG|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
219127463|NCT02349113|DRUG|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
219127464|NCT00233129|BEHAVIORAL|Top Down|Six months
219127465|NCT00233129|OTHER|cognitive rehabilitation day treatment program|six months
219127466|NCT06300840|DEVICE|BalanceBelt|The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
219127467|NCT03382743|DRUG|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
219127468|NCT06141746|DEVICE|Lung ultrasound|Early detection of fluid accumulation in alveolar, interstitial and intracellular compartments of the lung due to intravascular absorption of irrigation fluid of PNL guided by lung ultrasound by detection of sonographic B lines.
219127469|NCT02874261|DEVICE|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
219127470|NCT06042114|BEHAVIORAL|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
219127471|NCT00360126|DRUG|lamotrigine|
219127472|NCT03049696|BEHAVIORAL|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
219226309|NCT04185961|DEVICE|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
219226310|NCT04185961|DEVICE|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
219226311|NCT02499601|DEVICE|CORolla™ TAA device|
219226312|NCT04402736|BEHAVIORAL|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
219226313|NCT04402736|BEHAVIORAL|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
219226314|NCT04773431|DRUG|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
219226315|NCT01183598|DRUG|tocilizumab [RoActemra/Actemra]|maintenance dose
219710883|NCT06836414|OTHER|Questionnaires|Participants will complete questionnaires on or before the day of the scan.
219710884|NCT06836414|OTHER|Medical History|Medical history will be obtained in person and via medical record review
219710885|NCT06836258|OTHER|AI assisted documentation|This study will use Gosta Aide AI-assisted documentation platform
219710886|NCT04301154|BIOLOGICAL|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
219127473|NCT02596906|DEVICE|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
219127474|NCT02596906|DEVICE|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
219127475|NCT04647162|PROCEDURE|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
219127476|NCT04647162|PROCEDURE|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
219127477|NCT04647162|PROCEDURE|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
219127478|NCT04647162|OTHER|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
219127479|NCT03255018|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
219127480|NCT03379415|DEVICE|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
219127481|NCT03379415|PROCEDURE|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
219127482|NCT01105494|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
219127483|NCT03381430|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
219127484|NCT04986540|DRUG|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
219127485|NCT00450892|DRUG|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
219226316|NCT01237496|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
219226317|NCT04379869|DRUG|NNZ-2591|Single dose of NNZ-2591
219226318|NCT04379869|DRUG|Placebo|Comparator for double-blind MAD
219710887|NCT04301154|BIOLOGICAL|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
219226319|NCT04931524|DRUG|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
219226320|NCT05750043|DRUG|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
219710888|NCT04301154|BIOLOGICAL|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
219710889|NCT05143671|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
219710890|NCT05143671|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
219710891|NCT05143671|PROCEDURE|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
219710892|NCT05143671|PROCEDURE|Carotid artery stenting|Carotid artery stenting.
219710893|NCT06118411|DRUG|Upadacitinib|Oral Tablets
219710894|NCT06118411|DRUG|Placebo|Oral Tablets
219127486|NCT00450892|DRUG|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
219127487|NCT00450892|DRUG|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
219127488|NCT05262972|OTHER|Conservatory treatment|Personalized plantar orthosis
219127489|NCT05262972|OTHER|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
219127490|NCT03601143|OTHER|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
219127491|NCT01495507|PROCEDURE|MPFL- Reconstruction|
219127492|NCT03504449|OTHER|neoadjuvant chemoradiotherapy|
219127493|NCT03539159|OTHER|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
219226321|NCT05194696|BEHAVIORAL|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
219226322|NCT04851743|OTHER|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
219226323|NCT02697305|DIETARY_SUPPLEMENT|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
219226324|NCT02697305|DIETARY_SUPPLEMENT|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
219226325|NCT02697305|OTHER|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
219226326|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
219226327|NCT05545306|DIETARY_SUPPLEMENT|fasting|Fasting for at least 24 hours
219710895|NCT06118411|OTHER|NB-UVB (narrow-band ultraviolet B) Phototherapy|NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
219710896|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
219710897|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
219127494|NCT03539159|OTHER|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
219127495|NCT00874796|DRUG|GS-9450|Taken as one capsule by mouth once daily
219127496|NCT00874796|DRUG|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
219127497|NCT05553561|PROCEDURE|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
219127498|NCT05553561|PROCEDURE|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
219127499|NCT02157714|DRUG|PRX002|
219226328|NCT05545306|DIETARY_SUPPLEMENT|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
219710898|NCT06559267|BEHAVIORAL|Remaking Recess|Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
219710899|NCT06559267|OTHER|TEAM|Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
219710900|NCT06850610|DIAGNOSTIC_TEST|Pulse oximeter accuracy under hypoxic conditions|This study will specifically evaluate the accuracy of the Owlet pulse oximeter sensor, currently FDA cleared for infants 1-18 months of age in an expanded hypoxia lab trial.
219710901|NCT01696721|OTHER|No intervention|
219710902|NCT05565560|DRUG|Apremilast|Oral tablets
219710903|NCT06263946|DEVICE|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
219710904|NCT05935722|BEHAVIORAL|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
219710905|NCT05935722|BEHAVIORAL|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
219710906|NCT04197440|DRUG|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
219710907|NCT04197440|DRUG|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
219710908|NCT04197440|DRUG|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
219710909|NCT04197440|DRUG|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
219710910|NCT04197440|DRUG|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
219710911|NCT04197440|DRUG|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
219710912|NCT04197440|DRUG|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
219127500|NCT02157714|OTHER|Placebo|
219127501|NCT04151121|BEHAVIORAL|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
219127502|NCT01343173|DRUG|Imatinib stop|To stop imatinib after inclusion.
219127503|NCT03298464|BIOLOGICAL|NGM313|Subcutaneous injection
219127504|NCT03298464|DRUG|Pioglitazone|White to off-white round tablet
219127505|NCT05506709|DEVICE|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
219127506|NCT00748969|DRUG|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
219127507|NCT06426082|BEHAVIORAL|Thermoneutral condition|Participants will be exposed 2 hours/day at 32ºC for 5 days/week
219127508|NCT06426082|BEHAVIORAL|Cold condition|Participants will be exposed 2 hours/day at 18ºC for 5 days/week
219226329|NCT05545306|DIETARY_SUPPLEMENT|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
219127509|NCT06426082|BEHAVIORAL|Aerobic exercise condition|Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
219710913|NCT04197440|DRUG|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
219710914|NCT05019677|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
219710915|NCT03765073|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
219710916|NCT03765073|BIOLOGICAL|Placebo|Saline control
219710917|NCT02924870|OTHER|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~* Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~* Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~* Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~* Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
219710918|NCT02924870|OTHER|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
219710919|NCT06015581|BEHAVIORAL|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
219710920|NCT06015581|BEHAVIORAL|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
219710921|NCT00452595|DRUG|DVS-233 SR (desvenlafaxine sustained release )|
219710922|NCT06086275|DRUG|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
219710923|NCT05622149|BEHAVIORAL|Diet Only|Food tracking based on macronutrient goals.
219710924|NCT05622149|BEHAVIORAL|Training Only|Subjects completed 16 weeks of supervised resistance training
219710925|NCT05622149|BEHAVIORAL|Diet plus Training|Food tracking plus resistance training.
219710926|NCT05039710|DRUG|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
219710927|NCT05039710|OTHER|Placebo|Matching placebo will be administered as SC injection.
219710928|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
219710929|NCT05998642|DRUG|Methotrexate|3.5mg/m2 IV
219710930|NCT05998642|DRUG|Rituximab (where available)|375mg/m2 / 1400mg IV or SC
219710931|NCT05998642|DRUG|Ibrutinib|Dose and schedule assigned at enrollment
219710932|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
219127510|NCT06426082|DRUG|Salbutamol|Participants will take salbutamol 12 mg/day. 7 days week
219127511|NCT04679363|OTHER|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
219710933|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
219710934|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
219127512|NCT04679363|OTHER|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
219127513|NCT01912001|OTHER|Telephone follow-up|
219127514|NCT01912001|OTHER|Sympton Assessment|
219127515|NCT05163756|DRUG|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
219127516|NCT05163756|DRUG|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
219710935|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
219127517|NCT02334306|BIOLOGICAL|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
219226330|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
219710936|NCT00957359|DRUG|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
219710937|NCT00957359|DRUG|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
219127518|NCT02334306|OTHER|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
219127519|NCT01153750|DRUG|Glivec|
219127520|NCT00465985|DRUG|ACZ885|
219127521|NCT00465985|DRUG|Placebo|
219127522|NCT00285558|BEHAVIORAL|CBT with peer-enhanced activities|
219127523|NCT00285558|BEHAVIORAL|CBT with supervised aerobic exercise|
219127524|NCT01385865|DIETARY_SUPPLEMENT|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
219127525|NCT01385865|DIETARY_SUPPLEMENT|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
219127526|NCT05939557|PROCEDURE|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
219127527|NCT05939557|DEVICE|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
219127528|NCT04417712|DEVICE|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
219127529|NCT03532178|DRUG|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
219226331|NCT05545306|DIETARY_SUPPLEMENT|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
219226332|NCT05545306|DIETARY_SUPPLEMENT|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
219710938|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
219710939|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
219710940|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
219710941|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
219226333|NCT03440645|OTHER|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
219226334|NCT05656066|BEHAVIORAL|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
219226335|NCT05656066|BEHAVIORAL|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
219127530|NCT03532178|DRUG|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
219127531|NCT03302156|DRUG|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
219127532|NCT06103240|OTHER|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
219127533|NCT03206931|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
219127534|NCT03180190|DRUG|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
219127535|NCT05392764|DRUG|Empagliflozin 10 MG|once-daily oral empagliflozin 10 mg
219127536|NCT05392764|DRUG|Placebo|Placebo matching empagliflozin 10 mg
219127537|NCT04077684|DRUG|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
219127538|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - fast release|
219127539|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - slow release|
219226336|NCT06477679|PROCEDURE|• Furlow with buccinators myomucosal flap|• Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
219710942|NCT05470010|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
219226337|NCT06477679|PROCEDURE|• Two flap palatoplasty as von langenbeck technique|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
219226338|NCT06046196|DRUG|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
219226339|NCT06046196|DRUG|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
219710943|NCT00600496|DRUG|AZD6244|twice daily oral dose
219226340|NCT04378036|OTHER|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
219710944|NCT00600496|DRUG|Dacarbazine|intravenous infusion
219710945|NCT00600496|DRUG|Erlotinib|daily oral dose
219710946|NCT00600496|DRUG|Docetaxel|intravenous infusion
219710947|NCT00600496|DRUG|Temsirolimus|intravenous infusion
219710948|NCT05912244|DRUG|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
219710949|NCT05912244|DRUG|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
219710950|NCT01407263|PROCEDURE|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.
219710951|NCT01407263|PROCEDURE|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
219127540|NCT02636413|DRUG|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
219127541|NCT02636413|DIETARY_SUPPLEMENT|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
219127542|NCT04031417|OTHER|Hypoxia|
219127543|NCT04031417|OTHER|Low Humidity|
219127544|NCT02543450|OTHER|Cardiovascular and task-oriented training|
219127545|NCT02543450|OTHER|Upper limb strength training program|
219127546|NCT00552734|DEVICE|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
219127547|NCT02824367|BEHAVIORAL|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
219127548|NCT01121783|OTHER|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
219127549|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
219127550|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
219127551|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
219127552|NCT06351280|OTHER|Standardised Physiotherapy Plan|"Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time."
219127553|NCT00628940|RADIATION|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
219127554|NCT02390557|OTHER|Survey|PDQS survey reports only
219127555|NCT02390557|OTHER|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
219127556|NCT01376141|DRUG|Sumatriptan|
219127557|NCT00440986|PROCEDURE|Eritrocytoapheresis|
219127558|NCT01711918|DRUG|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
219127559|NCT01612754|BEHAVIORAL|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
219127560|NCT01612754|BEHAVIORAL|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
219127561|NCT03278028|DRUG|A-101 Topical Solution|A-101 Topical Solution
219127562|NCT03278028|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
219127563|NCT00247156|PROCEDURE|Acupressure treatments and NAET treatments|
219127564|NCT02114840|PROCEDURE|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
219710952|NCT01407263|DRUG|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
219710953|NCT01407263|DRUG|Hemostatic Agent|For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
219710954|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
219710955|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
219710956|NCT06637527|DRUG|Placebo|Placebo
219710957|NCT02734771|DRUG|Brentuximab vedotin|
219127565|NCT02114840|PROCEDURE|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
219127566|NCT02114840|PROCEDURE|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
219127567|NCT04900155|DRUG|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
219127568|NCT04900155|DRUG|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
219127569|NCT01004328|OTHER|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
219127570|NCT04124068|OTHER|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
219127571|NCT04124068|DEVICE|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
219127572|NCT04124068|DEVICE|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
219127573|NCT04124068|DEVICE|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
219127574|NCT05054400|DRUG|F18 Fluciclovine|Given by IV
219127575|NCT05054400|OTHER|Standard of Care|Standard of care
219127576|NCT06132919|DRUG|MC2-25 cream|Topical application
219127577|NCT06132919|DRUG|MC2-25 vehicle|Topical application
219710958|NCT02734771|DRUG|Rituximab|
219710959|NCT02734771|DRUG|Cyclophosphamide|
219710960|NCT02734771|DRUG|Doxorubicin|
219710961|NCT02734771|DRUG|Prednisone|
219710962|NCT05457556|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219710963|NCT05457556|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219710964|NCT05457556|DRUG|Busulfan|Given intravenously (IV)
219710965|NCT05457556|DRUG|Cyclophosphamide|Given IV
219710966|NCT05457556|PROCEDURE|Echocardiography Test|Undergo ECHO
219710967|NCT05457556|DRUG|Fludarabine|Given IV
219710968|NCT05457556|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo haploHCT
219710969|NCT05457556|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
219127578|NCT03578640|DRUG|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
219127579|NCT04201015|DEVICE|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
219127580|NCT01554254|DRUG|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
219127581|NCT01570777|PROCEDURE|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
219127582|NCT01570777|PROCEDURE|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
219127583|NCT05204784|PROCEDURE|Rheopheresis treatment|After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
219127584|NCT05204784|DRUG|Intravenous Infusion|Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
219127585|NCT01351038|DRUG|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
219127586|NCT03405415|DEVICE|Blood glucose monitoring system and continuous interstitial glucose monitoring system|"At enrolment, participants are provided with BGM (Blood Glucose Monitoring) and CGM (Continuous Glucose Monitoring) systems. They will use the systems throughout the study. Participants will visit the study site three times. During the first visit, a standardized oral glucose tolerance test will be performed to ensure that participants do not have diabetes mellitus and to obtain glucose concentration data from people without diabetes mellitus during a glucose challenge. On another two days, participants will visit the study site for standardized breakfast and lunch meals to provide glucose concentration data under standardized conditions.~Outside of the study site visits, participants are asked to eat similar meals on two days to obtain glucose concentration data under repeated conditions that represent daily life.~During the study, participants are asked to document meals, physical activity and addition comments to provide context to the recorded glucose concentration data."
219127587|NCT00264680|DRUG|lamotrigine|
219127588|NCT00264680|DRUG|valproic acid|
219127589|NCT02700685|DIETARY_SUPPLEMENT|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
219127590|NCT02700685|DRUG|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
219127591|NCT02700685|OTHER|Placebo|Placebo treatment (identical capsules containing excipients only)
219127592|NCT05421845|BEHAVIORAL|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
219127593|NCT00252993|DRUG|DDP225|
219127594|NCT01145144|DRUG|dehydroepiandrosterone crystalline fine powder|
219710970|NCT05457556|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219710971|NCT05457556|PROCEDURE|Matched Unrelated Donor Hematopoietic Cell Transplantation|Undergo MUD-HCT
219710972|NCT05457556|DRUG|Melphalan|Given IV
219127595|NCT03122964|DIAGNOSTIC_TEST|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
219127596|NCT00462553|DRUG|sunitinib malate|Given orally
219127597|NCT00462553|DRUG|gemcitabine hydrochloride|Given IV
219127598|NCT05102903|DRUG|BR1016A|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
219710973|NCT05457556|DRUG|Methotrexate|Given IV
219710974|NCT05457556|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219710975|NCT05457556|DRUG|Mycophenolate Mofetil|Given IV
219710976|NCT05457556|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning regimen
219127599|NCT05102903|DRUG|BR1016B|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
219710977|NCT05457556|OTHER|Quality-of-Life Assessment|Ancillary studies
219710978|NCT05457556|OTHER|Questionnaire Administration|Ancillary studies
219710979|NCT05457556|BIOLOGICAL|Rituximab|Given IV
219710980|NCT05457556|PROCEDURE|T-Cell Depletion Therapy|Undergo haploHCT with alpha beta T cell depletion
219710981|NCT05457556|DRUG|Tacrolimus|Given IV
219710982|NCT05457556|DRUG|Thiotepa|Given IV
219710983|NCT05457556|RADIATION|Total-Body Irradiation|Undergo TBI
219710984|NCT04776525|DRUG|Ifosfamide|3 g/m2 each day for three days
219710985|NCT04776525|DRUG|Doxorubicin|80 mg/m2 over four hours day 1
219710986|NCT02226770|DEVICE|Implantable Cardioverter Defibrillator (ICD)|
219710987|NCT04764045|DRUG|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
219710988|NCT01496742|DRUG|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
219710989|NCT01496742|DRUG|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
219710990|NCT01496742|DRUG|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
219710991|NCT01496742|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
219710992|NCT01496742|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
219710993|NCT01496742|DRUG|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
219710994|NCT06564389|DRUG|PF-07832837|escalated doses of PF-07832837
219710995|NCT06564389|OTHER|Placebo|placebo
219710996|NCT05567458|DRUG|Luspatercept|Specified dose on specified days
219127600|NCT00746928|OTHER|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
219127601|NCT02743663|PROCEDURE|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
219127602|NCT02743663|PROCEDURE|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
219127603|NCT02743663|PROCEDURE|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.
219127604|NCT02743663|PROCEDURE|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
219710997|NCT05567458|DRUG|Placebo|Specified dose on specified days
219710998|NCT05524532|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
219710999|NCT05524532|DIETARY_SUPPLEMENT|Placebo|Placebo is an inert form of cellulose acetate.
219711000|NCT02225587|BIOLOGICAL|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
219127605|NCT02743663|PROCEDURE|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
219711001|NCT02225587|BIOLOGICAL|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
219711002|NCT02225587|BIOLOGICAL|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
219711003|NCT04447729|DRUG|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
219711004|NCT01031082|PROCEDURE|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
219711005|NCT02066454|DRUG|Apixaban|2.5mg x 2 per day during 6 months
219711006|NCT01925794|DEVICE|COBRA PzF|
219711007|NCT03181997|DEVICE|Native aortic valve|Native valve, with any transcatheter heart valve type
219127606|NCT02743663|DRUG|salbutamol|Given during bronchodilator response.
219711008|NCT03181997|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
219711009|NCT06616818|OTHER|DASH-FV|12weeks of fruit and vegetable delivery to the home
219711010|NCT06616818|OTHER|nutrition counselling only|nutrition counselling as part of standard of care
219711011|NCT03033615|DEVICE|PixelShine|Machine learning algorithm
219711012|NCT03033615|DEVICE|Conventional processing|Iterative reconstruction software
219711013|NCT05789797|DRUG|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
219711014|NCT01542281|DIETARY_SUPPLEMENT|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
219711015|NCT01542281|OTHER|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
219127607|NCT02743663|PROCEDURE|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
219127608|NCT02743663|PROCEDURE|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
219127609|NCT02743663|PROCEDURE|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
219127610|NCT02743663|PROCEDURE|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
219127611|NCT01813422|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219127612|NCT01813422|DRUG|Placebo|Administered by subcutaneous injection
219127613|NCT06231485|BEHAVIORAL|STEPS2|One of the two health education curricula as described in arm/group descriptions.
219127614|NCT06231485|BEHAVIORAL|STYH|One of the two health education curricula as described in arm/group descriptions.
219127615|NCT06528977|OTHER|Western Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
219127616|NCT02212886|DRUG|GA Depot 80 mg|Recruitment completed
219127617|NCT02212886|DRUG|GA Depot 40 mg|Recruitment completed
219127618|NCT02734368|DRUG|Hyperpolarized Helium-3|
219127619|NCT01653743|DRUG|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
219127620|NCT01653743|DRUG|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
219127621|NCT01653743|DRUG|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
219127622|NCT05769374|DEVICE|cooperative versus competitive AVG play|The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors
219127623|NCT04807179|DEVICE|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
219127624|NCT03068286|BEHAVIORAL|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
219127625|NCT03068286|BEHAVIORAL|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
219127626|NCT03068286|BEHAVIORAL|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
219711016|NCT00000964|DRUG|Ranitidine hydrochloride|
219711017|NCT00000964|DRUG|Foscarnet sodium|
219711018|NCT03390660|OTHER|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
219711019|NCT01014091|BIOLOGICAL|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
219711020|NCT06217549|OTHER|ozone therapy|Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
219711021|NCT03197129|OTHER|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
219711022|NCT05998447|DRUG|GEN-001|The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
219711023|NCT05998447|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
219711024|NCT05998447|DRUG|mFOLFOX|mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
219711025|NCT05145114|PROCEDURE|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
219711026|NCT04226677|OTHER|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
219127627|NCT03748771|DEVICE|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
219127628|NCT04889118|BIOLOGICAL|Pembrolizumab|IV infusion
219127629|NCT04889118|DRUG|Lenvatinib|Oral capsule
219127630|NCT04889118|DRUG|Placebo for lenvatinib|Oral capsule
219127631|NCT00372970|DRUG|Botulinum toxin A|200 U given by injection into the pylorus.
219127632|NCT00372970|DRUG|Placebo|saline injection into pylorus.
219127633|NCT05761067|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
219127634|NCT00562393|OTHER|Nutritional|Overfeeding high fat diet for 28 days
219127635|NCT05053308|DRUG|Intravenous Infusion|IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
219127636|NCT05053308|DRUG|Sublingual Tablet|subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
219127637|NCT00828620|OTHER|Imaging study|PET-CT
219711027|NCT04226677|OTHER|Video based exercise|Exergame training include virtual reality games by xbox kinect.
219127638|NCT02817503|DRUG|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
219127639|NCT02817503|DRUG|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
219127640|NCT02817503|DRUG|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
219226341|NCT04378036|DEVICE|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
219711028|NCT04226677|OTHER|Control group|first and last evaluations will be made
219711029|NCT02943759|DRUG|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
219711030|NCT02943759|DRUG|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
219711031|NCT01564407|DRUG|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
219127641|NCT04846062|BEHAVIORAL|nutrition behavior intervention|Iodized salt utilization and iron dietary intake behavior
219127642|NCT01631708|PROCEDURE|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to \~100 ug/L in accordance with current guidelines."
219127643|NCT01631708|PROCEDURE|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
219127644|NCT02899637|DEVICE|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
219127645|NCT02899637|DEVICE|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
219127646|NCT03768544|BEHAVIORAL|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
219127647|NCT03768544|BEHAVIORAL|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
219127648|NCT05238597|DRUG|A197 Ophthalmic Solution|A197 Ophthalmic Solution
219127649|NCT05238597|DRUG|A197 Vehicle Control|A197 Vehicle Control
219127650|NCT05238597|DRUG|Active Comparator|Active Comparator
219127651|NCT05906329|RADIATION|Low-dose radiotherapy combined with conventional fractionated radiotherapy|Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total.
219711032|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
219711033|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
219127652|NCT01438437|PROCEDURE|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
219127653|NCT01438437|PROCEDURE|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
219127654|NCT04582045|DEVICE|silver impregnated dressing|comparison of Mepilex versus our standard techniques
219127655|NCT03917212|OTHER|No intervention|No intervention, observational study with metabolic characterisation
219127656|NCT01827228|OTHER|Assays|May vary across sites
219127657|NCT01827228|OTHER|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
219127658|NCT01827228|OTHER|Social network and venue tracing|This is described in Arms 1 and 2
219127659|NCT01827228|OTHER|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
219127660|NCT01827228|OTHER|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
219127661|NCT01827228|BEHAVIORAL|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
219127662|NCT00487721|DRUG|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
219127663|NCT00004870|BIOLOGICAL|oblimersen sodium|
219127664|NCT00004870|DRUG|irinotecan hydrochloride|
219127665|NCT01800955|DEVICE|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
219127666|NCT01800955|OTHER|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
219127667|NCT04208737|PROCEDURE|recruitment maneuver|30 cmH2O pressure 15 seconds
219226342|NCT06569771|DIAGNOSTIC_TEST|Functional assessments|"* Computer Adaptive Test for Fugl-Meyer (CAT-FM)~* Action Research Arm Test (ARAT)~* Measurement of Functional Independence~* Star cancellation test~* Stroke Impact Scale~* ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)"
219226343|NCT01522014|DEVICE|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
219226344|NCT01522014|DEVICE|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
219127668|NCT05765032|DRUG|SHR-A1921；|Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
219226345|NCT05558683|OTHER|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
219127669|NCT02723357|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
219127670|NCT02723357|BEHAVIORAL|Access to Social Service Referrals|Access to referrals for common social needs.
219127671|NCT03738358|DIETARY_SUPPLEMENT|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
219127672|NCT03738358|OTHER|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
219127673|NCT00257777|PROCEDURE|Myocardial protection techniques|
219127674|NCT02745769|DRUG|Ramucirumab|Administered IV
219127675|NCT02745769|DRUG|Merestinib|Administered orally
219127676|NCT02745769|DRUG|Abemaciclib|Administered orally
219127677|NCT00602160|DRUG|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
219127678|NCT01154686|BEHAVIORAL|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
219127679|NCT04088994|OTHER|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
219127680|NCT04088994|OTHER|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
219127681|NCT02143531|DRUG|4 mg of Ondansetron IV|
219127682|NCT02143531|DRUG|1mg of Haloperidol IV|
219127683|NCT03351309|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
219127684|NCT06096129|PROCEDURE|Spy PTC|Percutaneous transhepatic cholangioscopy with SpyGlass DS system
219127685|NCT00255021|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
219226346|NCT04336618|DEVICE|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
219711034|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
219711035|NCT03729479|BEHAVIORAL|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
219711036|NCT03729479|BEHAVIORAL|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
219711037|NCT03729479|BEHAVIORAL|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
219711038|NCT06496243|DRUG|obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks|10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
219711039|NCT05682378|DRUG|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution administered subcutaneously in pre-filled syringe
219711040|NCT06087718|DEVICE|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
219127686|NCT00119587|DRUG|darbepoetin alfa|
219127687|NCT06137313|OTHER|questionnaire|completion of a questionnaire
219127688|NCT02493790|OTHER|Cognitive and motor performances|
219127689|NCT02309840|BEHAVIORAL|choice architecture|"1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
219127690|NCT02309840|OTHER|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
219127691|NCT05945082|OTHER|biopsy|biopsy of a colorectal cancer site
219127692|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implant, Nanobone with PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
219127693|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implantand PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
219127694|NCT02803294|PROCEDURE|transcatheter aortic valve replacement|
219127695|NCT05603026|DEVICE|Self-expanding valve (Medtronic Evolut FX)|Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
219127696|NCT05603026|DEVICE|Balloon-expanding valve (Edwards Sapien 3 Ultra)|Bioprosthesis Edwards Sapien 3 Ultra valve
219127697|NCT03098264|PROCEDURE|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
219127698|NCT03098264|PROCEDURE|staged surgery|staged surgery in complicated hepatolithiasis
219127699|NCT04690283|DRUG|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
219711041|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
219127700|NCT04690283|DRUG|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
219127701|NCT04690283|DRUG|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
219127702|NCT02994550|DRUG|FSH/LH|
219127703|NCT01757509|OTHER|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
219127704|NCT05077631|DRUG|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
219127705|NCT05077631|DRUG|Placebo|Placebo oral solution
219127706|NCT05077631|DRUG|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
219127707|NCT05057754|BEHAVIORAL|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
219127708|NCT05057754|BEHAVIORAL|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
219127709|NCT05057754|BEHAVIORAL|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
219127710|NCT05057754|BEHAVIORAL|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
219127711|NCT05057754|BEHAVIORAL|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
219127712|NCT05057754|BEHAVIORAL|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
219711042|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
219711043|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
219711044|NCT04978636|OTHER|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
219127713|NCT00508885|DRUG|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
219127714|NCT00508885|DRUG|Placebo|Placebo
219127715|NCT02723656|BEHAVIORAL|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
219127716|NCT02723656|BEHAVIORAL|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
219127717|NCT00253214|DRUG|galantamine hydrobromide|
219127718|NCT02215798|DRUG|Cymbalta|
219226347|NCT06100744|DRUG|Adalimumab|SC Injection
219226348|NCT06100744|DRUG|Risankizumab|Subcutaneous (SC) Injection
219226349|NCT01866800|DEVICE|Renal Guard|Renal Guard
219711045|NCT04978636|OTHER|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
219127719|NCT04768790|OTHER|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
219127720|NCT04768790|OTHER|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
219127721|NCT03668067|DEVICE|2WIN photoscreener|conventional infrared off-axis photoscreener
219127722|NCT01125202|BEHAVIORAL|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
219127723|NCT01125202|BEHAVIORAL|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
219127724|NCT03270930|PROCEDURE|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
219127725|NCT06044961|RADIATION|CT scan|All pre-operative CT scan collected
219127726|NCT01101919|DRUG|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
219127727|NCT01112072|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
219127728|NCT05298670|DRUG|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
219127729|NCT05298670|DRUG|Interferon beta-1a|Disease Modifying Therapies (DMTs)
219127730|NCT00000988|DRUG|Stavudine|
219127731|NCT03332966|DIAGNOSTIC_TEST|Psychiatric questionnaires|"Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale"
219127732|NCT03332966|DIAGNOSTIC_TEST|Semi-structured psychiatric interview|Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
219711046|NCT04978636|OTHER|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
219711047|NCT05328908|DRUG|Nivolumab-relatlimab FDC|Specified dose on specified days
219711048|NCT05328908|DRUG|Regorafenib|Specified dose on specified days
219711049|NCT05328908|DRUG|TAS-102|Specified dose on specified days
219127733|NCT00875641|OTHER|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
219127734|NCT04656470|DRUG|Dexmedetomidine|Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
219226350|NCT01866800|DRUG|Conventional Treatment|Saline and N-acetylcysteine
219226351|NCT05604547|DIAGNOSTIC_TEST|Non-Invasive Infrared Spectroscopy|NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
219127735|NCT04055896|OTHER|Medication Reduction|Systematic approach to reduction in polypharmacy
219127736|NCT01857453|DRUG|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
219127737|NCT01857453|DRUG|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
219226352|NCT00276276|DRUG|topotecan|
219127738|NCT01857453|RADIATION|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
219127739|NCT02800161|DRUG|Trehalose|Trehalose 70g/die
219127740|NCT02800161|DRUG|Maltose|Maltose 70g/die
219127741|NCT04706247|OTHER|thoracic combined spinal epidural anesthesia|A combined spinal-epidural anesthesia set will be used for the block. Using the loss of resistance to saline technique, an 18 G Tuohy needle will be advanced to the T2-3 vertebral interspace with the mid-line approach. After confirming the epidural space, a 26 G pencil point spinal needle will be inserted slowly through the Tuohy needle to puncture the dura. After free flow of cerebrospinal fluid will be observed, local anesthetic wil be injected into the subarachnoid space over 15 secs. Then, an epidural catheter will be inserted into the epidural space.
219127742|NCT04500821|DEVICE|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
219226353|NCT07012486|DRUG|Oral DHA + Topical minoxidil 5%|DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
219226354|NCT07012486|DRUG|Topical Minoxidil 5%|Topical minoxidil 5% daily for 180 days
219226355|NCT03365622|DRUG|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
219226356|NCT03365622|DRUG|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
219711050|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
219711051|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
219711052|NCT04129515|DEVICE|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
219711053|NCT04129515|DRUG|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
219711054|NCT05952648|PROCEDURE|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
219711055|NCT05952648|DIAGNOSTIC_TEST|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
219711056|NCT05952648|DIAGNOSTIC_TEST|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
219226357|NCT03365622|DRUG|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
219711057|NCT05952648|DIAGNOSTIC_TEST|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
219711058|NCT04893798|COMBINATION_PRODUCT|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
219711059|NCT02442349|DRUG|AZD9291|Once daily tablet 80 mg
219711060|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
219127743|NCT00447915|DRUG|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
219127744|NCT00447915|DRUG|RIS placebo|0 mg(p.o.)/day for 36 months
219127745|NCT00447915|DRUG|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
219127746|NCT00447915|DRUG|ibandronic acid placebo|0mg(i.v.)/month for 35 months
219127747|NCT00447915|DRUG|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
219226358|NCT03365622|DRUG|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
219226359|NCT07042711|DIETARY_SUPPLEMENT|Placebo|Patients are given capsules that can contain either a placebo or Vitamin D.
219127748|NCT00447915|DIETARY_SUPPLEMENT|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
219226360|NCT07042711|DIETARY_SUPPLEMENT|Vitamin D 5,000IU Oral Tablet|Patients are given capsules that can contain either a placebo or Vitamin D.
219226361|NCT07044167|DIETARY_SUPPLEMENT|Polyphenol-enriched functional product|Polyphenol-enriched functional product
219226362|NCT07044167|DIETARY_SUPPLEMENT|Control without active polyphenols|Product with identical characteristics to the experimental product, but without active polyphenols.
219711061|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
219711062|NCT05342519|DRUG|Rapamycin|While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
219127749|NCT02609555|PROCEDURE|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
219127750|NCT02267980|DRUG|Sevoflurane|Inhalation anesthetic agent
219127751|NCT02267980|DRUG|Ketamine|Intravenous anesthetic agent
219127752|NCT02267980|DRUG|Saline|Isotonic solution for placebo group
219127753|NCT06170060|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
219127754|NCT06107621|BEHAVIORAL|iCBT for Gambling Disorder and psychiatric comorbidities|The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
219127755|NCT00534755|OTHER|Breast Cancer database|prospective breast cancer database
219127756|NCT02922972|DEVICE|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
219127757|NCT04231461|PROCEDURE|Cardiac Surgery|Routine or urgent cardiac surgery
219127758|NCT02673008|BIOLOGICAL|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
219127759|NCT01802203|DEVICE|truFreeze Spray Cryotherapy|spray cryotherapy
219127760|NCT01763047|DEVICE|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
219127761|NCT01763047|DEVICE|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
219127762|NCT04241796|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
219127763|NCT03381391|BEHAVIORAL|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
219226363|NCT07042971|DEVICE|Pre-operative BiPAP Training|Seven consecutive nights (≥ 4 h/night) of BiPAP use at home or on ward, pressure ladder EPAP 6→8 cmH₂O / IPAP 12→16 cmH₂O, recorded on SD card; devices: ResMed AirCurve 10 ST or Philips A40.
219711063|NCT05342519|DRUG|Rapamycin|Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
219711064|NCT05342519|DRUG|Placebo|All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
219711065|NCT06219226|PROCEDURE|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
219711066|NCT06219226|PROCEDURE|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
219711067|NCT06439225|DRUG|Docetaxel|75mg/m2 q21 days
219711068|NCT06439225|DRUG|Carboplatin|AUC5 q21 days
219127764|NCT05854628|PROCEDURE|skin biopsy|Skin biopsies will be obtained at different time points.
219127765|NCT03999944|DEVICE|positive airway pressure system|Positive Airway Pressure System
219127766|NCT00479180|BIOLOGICAL|Vascugel|One time implant on the day of surgery
219127767|NCT00479180|BIOLOGICAL|Placebo Comparator|One time implant on the day of surgery
219127768|NCT02759198|DRUG|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
219127769|NCT02759198|DRUG|Celecoxib|Drug: Celecoxib 200mg
219127770|NCT02759198|DRUG|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
219127771|NCT03124108|DRUG|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
219127772|NCT03124108|DRUG|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
219127773|NCT03124108|DRUG|Placebo|Two coated tablets daily for 12 weeks
219127774|NCT05912751|OTHER|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
219127775|NCT05912751|OTHER|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
219226364|NCT07042971|DEVICE|Post-extubation BiPAP Support|Same BiPAP device started immediately after tracheal extubation; EPAP 8 cmH₂O / IPAP 14 cmH₂O (or patient's final training setting) maintained ≥ 48 h, then weaned when SpO₂ ≥ 94 % off-BiPAP for 24 h.
219226365|NCT07042971|OTHER|Standard Peri-operative Care|Routine oxygen, nebulized steroids, airway monitoring; rescue re-intubation or tracheostomy per institutional protocol; no planned BiPAP unless crossover criteria met.
219226366|NCT06773208|DRUG|Azacitidine (AZC)|75 mg/m2 daily, on days 1-7, given IV or SC
219127776|NCT02396992|OTHER|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
219711069|NCT05609331|OTHER|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
219127777|NCT04963621|BEHAVIORAL|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
219226367|NCT06773208|DRUG|Venetoclax|Venetoclax 400 mg orally daily on days 1-28
219226368|NCT06577662|BEHAVIORAL|individual and family self-management (IFSM) fall prevention program|"The IFSM program will last for ten weeks, two weeks in the hospital, and follow up at eight weeks after patients discharge to home. It will include 11 sessions, including ten sessions developed in the inpatient department within two weeks and one online booster session developed in the first month (week 4) after discharge in home. There will be also one session just for caregivers.~Session 1 : PRST combined with GRI (one) Session 2 : Environment safety Session 3 : Assistant technology Session 4 : PRST combined with GRI (two) Session 5 : Medication review Session 6 : Safety in daily activities Session 7 : How to keep loved one safety Session 8 : Review of PRST combined with GRI Session 9 : Review of other five fall prevention skills Session 10 : Summary of the program and setting goals Session 11 : Booster session Week 10: Evaluation"
219711070|NCT05609331|RADIATION|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
219127778|NCT06247098|PROCEDURE|Sinus Lift augmentation|Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)
219127779|NCT06247098|DEVICE|Cone-beam computed tomography systems (CBCT)|An research only use of CBCT at visit 2 to review healing status.
219127780|NCT06324955|BEHAVIORAL|Standard/common language during induction|The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.
219127781|NCT06324955|BEHAVIORAL|Positive language during induction|The anesthesiologist taking care of the patient will use scripted positive language during the induction.
219127782|NCT05882318|DEVICE|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
219226369|NCT06745986|DRUG|ultrasound guided fascia iliaca compartment block ( bupivacaine 0.25% )|Fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.
219226370|NCT06745986|DRUG|Spinal Anesthesia (bupivacaine)|spinal anesthesia by 2.5 ml bupivacaine 0.5%
219226371|NCT06778538|DIAGNOSTIC_TEST|Immunohistochemistry; WB; PCR|The intervention will specifically focus on evaluating the role of HPGD in patients with clear cell renal cell carcinoma by classifying them into high-low expression groups based on median HPGD expression values by immunohistochemical scores for prognostic analysis. Protein and RNA were extracted from collected ccRCC tissues for expression verification.
219226372|NCT07084337|BEHAVIORAL|Bodypump Training Program|Participants in this group performed a structured 8-week Bodypump program consisting of three sessions per week (Monday, Wednesday, and Friday), each lasting 45 minutes. The sessions followed the official Les Mills format, incorporating choreographed resistance exercises using barbells, weight plates, and a step platform. All movements were synchronized with music and led by certified instructors. Participants completed high-repetition, low-load exercises (\~20% of 1RM) targeting major muscle groups. Exercises were adapted to individual capabilities to ensure safety and promote adherence.
219226373|NCT06931028|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
219226374|NCT06931028|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
219226375|NCT05511207|DEVICE|RECOM - hBCI training|The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
219226376|NCT05511207|OTHER|CTRL - upper limb training with FES|An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
219711071|NCT04041154|BEHAVIORAL|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
219711072|NCT04041154|BEHAVIORAL|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
219711073|NCT04041154|BEHAVIORAL|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
219711074|NCT05982730|BEHAVIORAL|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
219127783|NCT04872959|OTHER|HealthReveal|"In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed."
219127784|NCT06632093|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
219127785|NCT06632093|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
219127786|NCT06630507|BEHAVIORAL|Educational module|1 hour pre-recorded educational module created by Dr. Sharma.
219711075|NCT05401487|OTHER|Pre-hospital and hospital care|Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
219711076|NCT04386005|DEVICE|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age \>2 years).
219711077|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
219711078|NCT00314145|BIOLOGICAL|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
219711079|NCT00314145|BIOLOGICAL|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
219711080|NCT00128063|DRUG|succinylated human serum albumin|
219711081|NCT00922584|DRUG|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
219711082|NCT05179629|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
219711083|NCT03335176|BEHAVIORAL|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
219711084|NCT02511756|DEVICE|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
219711085|NCT06525818|OTHER|Tube weaning therapy intervention|Participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in individual virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Therapies intervention group participants are already receiving or who begin to receive during the study period will not be stopped during this intervention. The Speech Therapist and Occupational Therapist will be utilized as needed for the child's individualized care plan. They will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.
219711086|NCT06525818|OTHER|Feeding Group|All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
219127787|NCT04685343|BEHAVIORAL|Quantitative Sensory Testing|Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).
219127788|NCT04685343|OTHER|fMRI|Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
219127789|NCT05390645|DRUG|MFA-370|MFA-370 is a treatment with a combination of two approved pharmaceuticals
219127790|NCT02513914|DEVICE|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
219127791|NCT02513914|DEVICE|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
219127792|NCT02862418|OTHER|UTE MRI|One MRI with UTE settings will be acquired.
219127793|NCT03686384|DRUG|SVT-15652|1 vial twice daily
219127794|NCT03686384|DRUG|Placebo|1 vial twice daily
219127795|NCT06030089|OTHER|Pharmacokinetic sampling|4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2
219127796|NCT06030089|OTHER|Vital status determination|Survival situation 12 months after start of treament
219127797|NCT06030089|OTHER|Toxicity assessments|Toxicity events
219711087|NCT01402726|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
219711088|NCT05672056|PROCEDURE|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
219127798|NCT06030089|DRUG|Venetoclax and azacitidine combination|Response to treatment
219711089|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
219711090|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
219127799|NCT06058637|DEVICE|Eye screening|Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
219127800|NCT05939947|DRUG|ALE.F02|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
219127801|NCT05939947|DRUG|Placebo|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
219127802|NCT05861089|DIAGNOSTIC_TEST|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
219127803|NCT05876585|DRUG|Ondansetron 8 mg ampoule|Study drug
219127804|NCT05876585|DRUG|Metoclopramide 10 mg ampoule|Comparator drug
219127805|NCT03643965|DRUG|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
219127806|NCT03643965|DRUG|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
219127807|NCT05676996|OTHER|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
219127808|NCT05913739|OTHER|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
219127809|NCT06306274|DRUG|Tacrolimus|Tacrolimus (0,1%) ointment
219711091|NCT00382512|DRUG|Raptiva (efalizumab)|
219711092|NCT01776229|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
219711093|NCT03669471|OTHER|Testing of performance|"The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
219711094|NCT05608655|DEVICE|DKutting LL balloon|After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
219711095|NCT05608655|DEVICE|Chocolate balloon|After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
219711096|NCT01694238|PROCEDURE|Cruciate incision|
219711097|NCT01694238|PROCEDURE|Circular incision|
219711098|NCT01694238|OTHER|Mesh enforced cruciate incision|
219711099|NCT00914212|DRUG|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
219711100|NCT00914212|DRUG|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
219127810|NCT06306274|DRUG|Placebo|Placebo ointment
219127811|NCT04761393|PROCEDURE|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
219226377|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
219127812|NCT06178315|PROCEDURE|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
219127813|NCT06178315|PROCEDURE|Sham procedure|Celiac plexus will not be performed in this arm.
219127814|NCT05683301|DRUG|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
219127815|NCT05683301|DRUG|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
219127816|NCT05683301|DRUG|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
219127817|NCT03593759|DRUG|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
219127818|NCT03593759|DRUG|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
219226378|NCT02831049|BEHAVIORAL|Retrieval-extinction|Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
219711101|NCT01767220|PROCEDURE|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
219711102|NCT01767220|PROCEDURE|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
219711103|NCT05166642|DEVICE|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
219711104|NCT05166642|DEVICE|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
219711105|NCT03724331|BEHAVIORAL|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
219711106|NCT03724331|BEHAVIORAL|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
219711107|NCT03724331|BEHAVIORAL|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
219127819|NCT02820051|DEVICE|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
219127820|NCT02820051|DRUG|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
219127821|NCT02820051|DRUG|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
219127822|NCT02820051|DRUG|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
219127823|NCT02820051|DRUG|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
219127824|NCT01222247|DRUG|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
219711108|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
219711109|NCT02371811|DEVICE|uterine manipulator (v care)|
219711110|NCT00005849|DRUG|bryostatin 1|
219127825|NCT01222247|DRUG|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
219127826|NCT01851109|BEHAVIORAL|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~1. A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~2. Discuss how the results - positive or negative - affect cancer risk~3. Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~4. Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~5. Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
219127827|NCT03674840|PROCEDURE|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
219226379|NCT02831049|BEHAVIORAL|Alcohol-related cues|Alcohol related cues
219226380|NCT02831049|BEHAVIORAL|Soft-drink related cues|Soft drink related cues
219226381|NCT06907823|DRUG|propofol|propofol anesthesia
219226382|NCT06907823|DRUG|Sevoflurane|sevoflurane anesthesia
219711111|NCT00005849|DRUG|paclitaxel|
219127828|NCT03674840|PROCEDURE|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
219127829|NCT05000190|DIETARY_SUPPLEMENT|Active capsule|1 capsule daily for 28 days
219226383|NCT04434092|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
219127830|NCT05000190|OTHER|Placebo capsule|1 capsule daily for 28 days
219127831|NCT05446389|DEVICE|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
219226384|NCT04434092|DRUG|Eculizumab|Eculizumab will be administered as specified in the respective arm.
219226385|NCT07091981|DEVICE|OneCurve Rotary File|A single-file NiTi system (25/.04) operated at 300 rpm and 2.5 Ncm torque. Applied directly to the MB2 canal without prior hand instrumentation.
219127832|NCT04968782|OTHER|Patients with acute appendicitis|No intervention, single survey
219127833|NCT06222619|PROCEDURE|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
219127834|NCT02938650|DRUG|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
219127835|NCT01149135|DEVICE|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
219127836|NCT01149135|DEVICE|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
219226386|NCT07091981|DEVICE|Perfect Minimally Invasive Kit|Two-file system using 10/.06 Shaper for coronal/middle thirds and 25/.04 Finisher for apical third. Operated at 300 rpm and 2.0-2.5 Ncm torque.
219226387|NCT07091981|DEVICE|VDW Rotate|Three-file NiTi rotary system (15/.04, 20/.05, 25/.04) used sequentially for coronal, middle, and apical thirds. Applied with brushing-pecking motion in 2-3 mm increments under continuous irrigation. Operated at 300 rpm and 1.8 Ncm torque.
219711112|NCT04883853|PROCEDURE|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
219711113|NCT04947501|DRUG|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
219226388|NCT07091981|DEVICE|Perfect Advanced Kit|NiTi rotary file system including 10/.07 Opener, 10/.04, 17/.05, and 25/.04 files. Used in crown-down sequence with rpm and torque settings ranging from 250-300 rpm and 2.0-2.5 Ncm. Brushing-pecking motion and continuous irrigation were applied during instrumentation.
219711114|NCT04947501|DRUG|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
219127837|NCT01683695|DRUG|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
219127838|NCT01683695|DRUG|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
219127839|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
219127840|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
219127841|NCT03141658|DRUG|Placebo|Multiple doses of placebo once daily for 6 days
219127842|NCT03141658|OTHER|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
219127843|NCT06494423|BEHAVIORAL|Work Support (WorkS)|The WorkS intervention entails two structured visits with a research team member initiated 6-months post-HSCT, which is the earliest point at which most HSCT survivors can safely consider returning to work. The sessions are focused on 1) identifying challenges of navigating work and illness; 2) linking survivors with psychological, rehabilitative, governmental, and community resources that can promote recovery and well-being; and 3) communicating with employers regarding the necessary work modifications to achieve mutual goals.
219127844|NCT00480805|DRUG|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
219127845|NCT00480805|DRUG|Comparator : ramipril /Duration of Treatment : 8 Weeks|
219127846|NCT06174896|PROCEDURE|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
219127847|NCT06174896|PROCEDURE|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
219127848|NCT06174896|PROCEDURE|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
219127849|NCT03374046|PROCEDURE|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
219127850|NCT01767909|DRUG|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
219127851|NCT01767909|DRUG|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
219127852|NCT05653570|DIAGNOSTIC_TEST|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
219127853|NCT05653570|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
219127854|NCT04939428|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
219127855|NCT04939428|DRUG|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
219711115|NCT04947501|DRUG|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
219711116|NCT04947501|DRUG|Doxorubicin|"Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
219711117|NCT04947501|DRUG|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
219711118|NCT04947501|DRUG|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
219711119|NCT04947501|DRUG|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
219711120|NCT04947501|DRUG|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
219711121|NCT03296683|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
219127856|NCT05938868|DEVICE|Low intensity pulsed ultrasound (LIPUS)|LIPUS will be delivered intra-orally using a probe applied on the buccal aspect of the implant site. The probe is in contact with the buccal attached gingiva with a thin film of intra oral gel intervening between them, acting as a transmitting medium. It will be applied twice a week for 20 minutes each session that commenced after surgery on the second day and continued for 10 weeks. The intensity of ultrasound therapy used was 30 mW/cm2 with a frequency of 1.5 MHz and temporal average power of 20 Mw
219711122|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
219360963|NCT06528470|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when direct motor stimulation ceases and sensory stimulation is comfortable. Continuous stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
219711123|NCT02099058|DRUG|Osimertinib|It is administered orally everyday.
219711124|NCT02099058|DRUG|Nivolumab|It is an intravenous infusion administered every 14 days.
219226389|NCT07090252|OTHER|Group I zinc oxide Neem|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points. 2\\ After complete excavation of all pulp tissue, saline irrigation is done then the canals will be obturated zinc-oxide with Neem ( Zinc oxide powder(Prime Dental Pvt. Ltd.Thane, Maharashtra, India) and 100% Neem oil with mixing ratio of 1:3 will be mixed on a glass slab with a stainless- steel spatula) and then the rest of the pulp chamber will be filled with Zinconol. (reinforced zinc oxide eugenol)3\\ Tooth will be restored with stainless steel crown.
219226390|NCT07090252|OTHER|Group II zinc oxide eugenol|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points 2\\ After complete removed of coronal and radicular pulp zinc oxide eugenol will be manipulated in the ratio of 3:1 (powder: liquid) to obtain semisolid mix.This mix will be placed in the canals. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of Zinconol.3\\ Tooth will be restored with stainless steel crown.
219711125|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
219226391|NCT06482814|BEHAVIORAL|Partial sleep deprivation (sleep restriction)|During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.
219226392|NCT06482814|BEHAVIORAL|Normal sleep|During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
219711126|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
219711127|NCT02099058|DRUG|Erlotinib|It is administered orally everyday.
219711128|NCT05041127|BIOLOGICAL|Cetuximab|Given IV
219711129|NCT05041127|OTHER|Questionnaire Administration|Ancillary studies
219127857|NCT05938868|DEVICE|low level diode laser therapy|The patients will be irradiated with low level diode laser therapy (GaAs) (Chattanooga, model 27841, USA) .Patient will be irradiated with low level diode laser therapy with parameters: wavelength 850 nm and power of 200 mw in continuous mode will be applied in six points in non-contact method 10 mm away from the peri-implant soft tissue after suturing. The laser irradiations will be administered at six sites that included mesiobuccally, distobuccal, midbuccal, midlingual, mesial, and distal areas around implant for a duration of 10 seconds for each site. The total energy delivered was 6 J per session. And is based on a previous study by Gulati et al., 2020
219127858|NCT05938868|OTHER|Standard Care|Patients in all three groups will receive the standard care which includes: (1) Extra-oral ice packs during the first 2 days every two hour; (2) maintain daily routine oral hygiene after surgery; (3) Patients will be instructed to eat a soft diet for one weeks; (4) Broad spectrum oral antibiotics in a dose of one capsule every twelve hours for a week; (5) Non-steroidal anti-inflammatory drugs at a dose of one tablet every 8 hours for four days; (6) Warm chlorhexidine gluconate solution as a mouthwash for a period of 2 weeks to enhance plaque control.
219127859|NCT06291701|DIAGNOSTIC_TEST|Assessment of scapular endurance|For the assessment of scapular endurance, participants will be instructed to bend their arms and elbows while keeping a wooden rod placed between their elbows, pull a spring dynamometer placed between thei
219127860|NCT06291701|DIAGNOSTIC_TEST|Prone Bridge Test|"For the Prone Bridge Test, participants will be instructed to lie face down with their hands and feet shoulder-width apart and then raise their bodies off the ground by lifting themselves up on their hands, forearms, and toes. A stopwa"
219127861|NCT06291701|DIAGNOSTIC_TEST|Side Bridge Test|"For the Side Bridge Test, participants will be asked to lie on their right side, supporting themselves on their forearm and elbow, and lift themselves off the ground. A stopwatch will be started, and the test will be terminated if there is any deviation from the position. The elapsed time will be recorded in seconds. The test will then be repeated on the left side."
219711130|NCT04406792|BEHAVIORAL|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
219711131|NCT04406792|BEHAVIORAL|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
219711132|NCT03884998|DRUG|Copanlisib|Given IV
219711133|NCT03884998|BIOLOGICAL|Nivolumab|Given IV
219711134|NCT03507790|DRUG|CT1812|Active Study Drug
219711135|NCT03507790|DRUG|Placebo|Non-active study drug
219711136|NCT06181799|DIAGNOSTIC_TEST|Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).|"Once enrolled in the study, all participants are scheduled to undergo the following tests:~Analysis of the exhaled breath volatile organic compounds using real-time analytical methods (PTR-TOF-MS-1000; real-time mass spectrometer with ionization by the proton transfer method) before and after the physical exertion test, during 1 minute. Machine learning models will be employed to analyze the patterns identified in the exhaled air volatilome data.~Before and immediately after the physical exertion test, all participants are scheduled to record a single-lead ECG and pulse wave for 3 minutes, using a portable single-lead recorder (Cardio-Qvark) (Russia, Moscow). Single-lead ECG and pulse wave parameters will be analyzed using machine learning models."
219127862|NCT06291701|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|For the Closed Kinetic Chain Upper Extremity Stability Test, participants will be asked to assume a push-up position on a flat surface with their hands placed on two parallel lines drawn 90 cm apart. They will then be instructed to touch one hand to the other hand's side as many times as possible within 15 seconds. The test will be repeated three times, and the average of the scores will be calculated.
219127863|NCT06291701|DIAGNOSTIC_TEST|Seated Medicine Ball Throw Test|"For the Seated Medicine Ball Throw Test, participants will be asked to sit on the ground with their back, shoulders, and head against the wall. Holding a 2 kg medicine ball with both hands, they will start with their elbows bent and arms at their sides, then extend their elbows to throw the ball forward as far as possible. The distance between the wall and the point where the ball lands will be recorded. The test will be performed three times, and the average will be calculated."
219127864|NCT03669042|DEVICE|PhotoFix|PhotoFix Patch Implantation
219127865|NCT05995171|OTHER|Questionnaire|Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
219127866|NCT06204666|DIETARY_SUPPLEMENT|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
219127867|NCT06204666|DIETARY_SUPPLEMENT|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
219127868|NCT06204666|DIETARY_SUPPLEMENT|Placebo|Placebo bar with other ingredients
219127869|NCT05302791|DEVICE|Muscle Cooling|Cooling wrap will be set to 10°C
219127870|NCT05302791|OTHER|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
219127871|NCT06505265|DRUG|Povorcitinib|Oral; Tablet
219127872|NCT05736367|DRUG|U-13C-glucose|Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
219127873|NCT04486638|BIOLOGICAL|Dengue Tetravalent Vaccine, Live|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
219127874|NCT06008678|DEVICE|RXiBreeze PAP System, Model RXiBreeze 20A|The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.
219127875|NCT03099785|DRUG|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
219127876|NCT03099785|DRUG|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
219127877|NCT03099785|DRUG|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
219127878|NCT06401005|DRUG|Cadonilimab (AK104)|8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
219127879|NCT04639947|DEVICE|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
219127880|NCT04639947|DEVICE|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
219711137|NCT06294548|DRUG|Valemetostat|Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).
219127881|NCT06339983|OTHER|Manual Scar Mobilization Therapy:|In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin and will be followed by skin rolling
219127882|NCT06339983|OTHER|Myofascial Cupping Therapy:|A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect
219127883|NCT04178005|DRUG|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
219127884|NCT03541603|DRUG|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
219127885|NCT03541603|DRUG|Matching Placebo|A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
219711138|NCT06294548|DRUG|Atezolizumab|Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
219711139|NCT06294548|DRUG|Bevacizumab|Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
219711142|NCT01426529|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
219711143|NCT01426529|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
219127886|NCT05183555|DRUG|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
219127887|NCT05837026|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
219127888|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
219127889|NCT06555432|DRUG|LIVTENCITY|LIVTENCITY tablet.
219127890|NCT04425148|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
219127891|NCT04425148|DEVICE|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
219127892|NCT05801042|DIETARY_SUPPLEMENT|Maltodextrin|Placebo product
219127893|NCT05801042|DIETARY_SUPPLEMENT|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
219127894|NCT05801042|DIETARY_SUPPLEMENT|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
219127895|NCT02735252|OTHER|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
219127896|NCT02735252|DEVICE|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
219127897|NCT01733134|DRUG|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
219711144|NCT01426529|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
219711145|NCT06403943|DRUG|BaiDiZiYin Pill, ShenQiYiFei Pill|"Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating."
219127898|NCT01733134|DRUG|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
219127899|NCT05821907|BEHAVIORAL|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
219127900|NCT02691065|DRUG|Integrase Inhibitor|Raltegravir
219226393|NCT06821451|DEVICE|Bronchoscopic navigation robot|Preoperative CT data creates a 3D image of the lung anatomy to plan the navigation path. The surgeon controls the robotic arm in real-time to reach staining marker points for pulmonary nodule localization. After placing the staining catheter in the working channel, 1 ml of indocyanine green is injected at the site. Then the patient is positioned laterally for video-assisted thoracoscopic surgery for nodule resection, initially focusing on sub-lobar resection. More extensive resection is determined based on intraoperative frozen section results.
219711146|NCT06403943|DRUG|Anti tuberculosis chemotherapy|2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
219711147|NCT01155765|DRUG|Prasugrel|Prasugrel 10 mg/day for 15 days
219127901|NCT01464294|DEVICE|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
219127902|NCT01464294|DEVICE|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
219711148|NCT01155765|DRUG|Clopidogrel|Clopidogrel 150 mg/day for 15 days
219711149|NCT05076838|DRUG|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
219711150|NCT03662373|RADIATION|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
219711151|NCT03662373|RADIATION|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
219711152|NCT02296125|DRUG|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219127903|NCT05087732|DEVICE|STYLAGE® M Lidocaïne|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
219127904|NCT05087732|DEVICE|STYLAGE® M|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
219127905|NCT02696785|DRUG|Ixekizumab|Administered SC
219127906|NCT02696785|DRUG|Placebo|Administered SC
219127907|NCT02696785|DRUG|Adalimumab|Administered SC
219127908|NCT05478863|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
219127909|NCT05478863|DRUG|Oral THC|THC will be orally self-administered by study participants.
219127910|NCT05478863|DRUG|Oral CBD|CBD will be orally self-administered by study participants.
219127911|NCT05478863|DRUG|Oral Caffeine|Caffeine will be orally self-administered by study participants.
219127912|NCT03486197|OTHER|Laboratory Biomarker Analysis|Correlative studies
219127913|NCT03486197|BIOLOGICAL|Pembrolizumab|Given IV
219711153|NCT02296125|DRUG|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219711154|NCT02296125|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219711155|NCT02296125|DRUG|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
219711156|NCT02296125|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
219711157|NCT02296125|DRUG|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219711158|NCT05456503|DRUG|FPI-2620|Radiotracer
219711159|NCT03611738|DRUG|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
219127914|NCT03486197|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
219127915|NCT06321159|OTHER|mobile application|mobile application for diet, exercises and medication adherence
219127916|NCT05990881|DRUG|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
219127917|NCT05990881|DRUG|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
219127918|NCT02155582|DRUG|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
219127919|NCT01011790|BEHAVIORAL|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
219127920|NCT03093363|OTHER|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:~* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~* Explanation of asthma and inflammation~* Explanation of triggers and how to avoid it~* Explanation of asthma treatments~* Explanation of the inhalation technique with a physical demonstration~* Emphasis on treatment adherence~* Assessment of comorbidities and their treatment~* Emphasis on influenza vaccination"
219127921|NCT03093363|OTHER|Questionnaires for control group|\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
219127922|NCT03941574|DRUG|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
219127923|NCT03328520|BEHAVIORAL|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
219127924|NCT03166592|DEVICE|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
219711160|NCT03611738|DRUG|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
219711161|NCT05935787|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
219711162|NCT05935787|DRUG|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
219711163|NCT00481546|GENETIC|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
219711164|NCT03543163|PROCEDURE|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
219711165|NCT03543163|PROCEDURE|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
219711166|NCT02098772|DRUG|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
219711167|NCT02098772|DRUG|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
219711168|NCT00457353|DRUG|Bacillus Clausii|For 5 days
219711169|NCT00457353|OTHER|Oral rehydration therapy|For 5 days
219711170|NCT01160614|DRUG|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
218986491|NCT04564261|BEHAVIORAL|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
219711171|NCT06433648|DEVICE|Ottobock CLeg4 + Ottobock foot|Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.
219711172|NCT06433648|DEVICE|SRALAB Hybrid Knee + Polycentric Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.
219711173|NCT06433648|DEVICE|SRALAB Hybrid Knee + Passive Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and passive ankle.
219711174|NCT06433648|DEVICE|Ottobock CLeg 4 + Polycentric Ankle|Commercially available Ottobock CLeg 4 prosthetic knee and SRALAB powered polycentric ankle.
219711175|NCT06262438|DRUG|Quizartinib|"Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of FMS-like tyrosine kinase FLT3. The dose will be adjusted for the patient's body weight (BW) as measured at the start of each course. Quizartinib will be administered orally once daily and is taken for 14 consecutive days during induction and consolidation courses.~Induction course 1: Start on day 13; Induction course 2: Start on day 9; Consolidation course 1: Start on day 6; Consolidation courses 2 and 3 (only if no allo-SCT is done): Start on day 6.~Continuation courses 1-6: patients will receive quizartinib for six 28-day courses. For the first 15 days of course 1 a starting dose will be applicable. On course 1 Day 16, the dose will be increased if the average QTc of the triplicate Electrocardiograms is ≤450 msec on course 1 Day 15. Once the dose is increased, the patient may continue on this dose as long as dose reduction is not needed."
219711176|NCT06262438|DRUG|Etoposide|"Induction course 1: 150 mg/m2 once daily by Intravenous (IV) infusion over 2 hours (+/- 30 mins) on days 1-5 inclusive (total 5 doses).~Induction course 2: 150 mg/m2 once daily by IV infusion over 2 hours (+/- 30 mins) on days 6-8 inclusive (total 3 doses).~Consolidation course 2 (only if no allo-SCT is done): 100 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 1-5 inclusive (total 5 doses)."
219127925|NCT00614744|PROCEDURE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
219127926|NCT00614744|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
219127927|NCT05634889|RADIATION|De-escalation|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
219127928|NCT05282342|DIAGNOSTIC_TEST|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
219127929|NCT03302806|OTHER|Non interventional Study|
219127930|NCT02451280|PROCEDURE|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
219226394|NCT06821451|DEVICE|Conventional electromagnetic navigation bronchoscope|Based on preoperative CT data, a three-dimensional image of the virtual bronchi is created to plan the navigation path, and manual registration is completed by selecting registration points using a conventional electromagnetic bronchoscope. After registration, the target position is reached under the guidance of the magnetic navigation positioning system, and when the positioning sensor indicates that it has arrived at the staining marker point, a staining catheter is inserted through the working channel to inject 1 ml of indocyanine green at the marker site, followed by thoracoscopic resection of the pulmonary nodule.
219127931|NCT02451280|PROCEDURE|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
219127932|NCT02451280|PROCEDURE|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
219127933|NCT00320476|DRUG|Velcade|
219226395|NCT07089641|PROCEDURE|Biospecimen Collection|Undergo urine, blood, and CSF sample collection
219711177|NCT06262438|DRUG|Dexrazoxane|"Induction course 1: 250 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on day 6-10 inclusive (total 5 days), per investigator discretion and per institutional guidelines and availability.~Induction course 2: 600 mg/m2 once daily by 15 mins IV infusion shortly before daunorubicin on day 2,4,6 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability.~Consolidation course 1: 500 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on 3-5 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability."
219711178|NCT06262438|DRUG|Mitoxantrone|"Induction course 1: 5 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 6-10 inclusive (total 5 doses). Please note that mitoxantrone and cytarabine should not be given concomitantly. Mitoxantrone should be completed before cytarabine is given.~Consolidation course 1: 10 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 3-5 inclusive (total 3 doses)."
219711179|NCT06262438|DRUG|Cytarabine|"Induction course 1: 200 mg/m2 once daily by IV infusion over 12 hours (+/- 1 hour) on days 6-12 inclusive (total 7 doses), following mitoxantrone. Induction course 2: 100 mg/m2 once daily by continuous IV infusion on days 1-2 inclusive. And 100 mg/m2 twice daily as a 30min (+/- 10 mins) IV infusion every 12 hours on days 3-8 inclusive (total 12 doses). Consolidation course 1: 1000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 min) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 2 (only if no allo-SCT is done): 3000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 mins) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 3 (only if no allo-SCT is done): 2000 mg/m2 once daily by IV infusion over 3 hours (+/- 1 hour) starting 4 hours after fludarabine on days 1-5 inclusive (total 5 doses), following fludarabine."
219127934|NCT00317538|DRUG|infliximab, etanercept|
219127935|NCT00877851|BEHAVIORAL|Computer-based Program|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
219226396|NCT07089641|PROCEDURE|Echocardiography Test|Undergo ECHO
219226397|NCT07089641|DRUG|EGFR Inhibitor ERAS-801|Given PO
219226398|NCT07089641|OTHER|Fludeoxyglucose F-18|Given FDG
219226399|NCT07089641|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
219226400|NCT07089641|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
219226401|NCT07089641|PROCEDURE|Surgical Procedure|Undergo surgical resection
219226402|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule
219226403|NCT02609048|DRUG|Experimental: Seladelpar 50 mg|Seladelpar 50 mg capsule
219226404|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|Seladelpar 100 mg capsules
219226405|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
219226406|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
219226407|NCT07094893|DRUG|Cetuximab (EGFR inhibitor)|Administration according to the labels of each IMP.
219226408|NCT07094893|DRUG|Bevacizumab|Administration according to the labels of each IMP.
219127936|NCT03662893|BEHAVIORAL|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
219127937|NCT03662893|DRUG|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
219127938|NCT03662893|BEHAVIORAL|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
219127939|NCT06167382|OTHER|Questionnare|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Goniometric Measurements, Digital Dynamometer Measurements, Hand Grip Measurements, Hand Reaction Measurements, Dexterity and Function Measurements, Jamar Handheld Dynomometer Measurement, Pinchmeter Measurement, Purdue Pegbord Test, Minnesota Manuel Skill Test, Nelson Hand Reaction Test, Modified Borg Scale
219127940|NCT06167382|OTHER|Device: Arm Ergometer|Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
219127941|NCT01861782|OTHER|Dead Sea Solar and Water Treatment|
219711180|NCT06262438|DRUG|Methotrexate|"Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently."
219711181|NCT06262438|DRUG|Daunorubicin|Induction course 2: 60 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 2,4,6 inclusive (total 3 doses).
219127942|NCT01861782|OTHER|Sulfur Pool & Medicinal Mud|
219127943|NCT04021056|OTHER|No intervention|
219127944|NCT02800811|DRUG|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
219127945|NCT02800811|DRUG|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
219127946|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
219127947|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
219127948|NCT01537250|DRUG|Nemonoxacin 3 tablets|oral form,once daily,7\~10 days
219127949|NCT03424239|DRUG|Zoledronic Acid|5mg zoledronic acid
219127950|NCT03424239|DIETARY_SUPPLEMENT|Calcium citrate + vitamin D|Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3
219711182|NCT06262438|DRUG|Fludarabine|Consolidation course 3 (only if no allo-SCT is done): 30 mg/m2 once daily by IV infusion over 30 mins (+/- 10 mins) on days 1-5 inclusive (total 5 doses).
219711183|NCT06262438|OTHER|allo-SCT|The SCT procedure is left to the discretion of the investigator and not part of this protocol.
219711184|NCT05950711|OTHER|Combination use of MBCT and IV Ketamine|Group with Major Depression who will receive a single dose of IV Ketamine embedded within a course of MBCT.
219711185|NCT05107375|BIOLOGICAL|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
219711186|NCT05107375|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
219711187|NCT01738958|BIOLOGICAL|L. retueri|two tablets a day for 6 weeks
219711188|NCT01738958|BIOLOGICAL|Placebo|
219127951|NCT03424239|DIETARY_SUPPLEMENT|Vitamin D3|1000IU Vitamin D3 gummy
219127952|NCT02618629|DRUG|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
219711189|NCT00157755|DEVICE|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
219711190|NCT01680614|BEHAVIORAL|CASI|
219127953|NCT01258387|DRUG|Glial growth factor 2/ Neuregulin 1β3|
219127954|NCT01258387|OTHER|Placebo|
219711191|NCT02141555|DRUG|Vaginal Misoprostol|Misoprostol inserted into vagina
219127955|NCT04871373|BEHAVIORAL|Motivational interviewing|A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.
219127956|NCT04871373|BEHAVIORAL|Oral Hygiene Instructions|A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
219127957|NCT02121704|DEVICE|Magnetic Endoscope Imaging (Scope Guide)|
219127958|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
219127959|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
219127960|NCT00168181|PROCEDURE|Submandibular gland Transfer|
219127961|NCT00168181|DRUG|Salagen|
219127962|NCT02496988|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
219127963|NCT02496988|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
219127964|NCT01364220|DRUG|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
219127965|NCT01364220|OTHER|Placebo tablet|Placebo tablet, once daily, for 14 days
219127966|NCT02641210|PROCEDURE|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
219127967|NCT02641210|DRUG|Albendazole|All participants took Albendazole 400 mg before the intervention.
219127968|NCT01988987|OTHER|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
219127969|NCT06528132|BEHAVIORAL|Mindfulness-based intervention (MBI) (enhanced with peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
219127970|NCT06528132|BEHAVIORAL|Experimental: social worker-led MBI (without peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
219127971|NCT03889899|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219127972|NCT04544540|OTHER|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
219127973|NCT01939938|DEVICE|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
219127974|NCT02460029|OTHER|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
219127975|NCT05764512|OTHER|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
219127976|NCT04488874|DRUG|Sodium Lactate|"Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose"
219127977|NCT04488874|DRUG|Mannitol 20% Infusion|Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
219127978|NCT00165152|PROCEDURE|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
219127979|NCT00165152|PROCEDURE|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
219711192|NCT02141555|DRUG|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
219127980|NCT03005288|DRUG|BYM338 10 mg/kg|intravenous infusion every four weeks
219127981|NCT03005288|OTHER|Placebo|intravenous infusion every four weeks
219127982|NCT02393261|OTHER|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
219127983|NCT02393261|OTHER|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
219127984|NCT06346145|PROCEDURE|Bariatric surgery|Type of surgery assigned by surgeon in consultation with patient
219127985|NCT06346145|PROCEDURE|Standard care|Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
219127986|NCT04783415|DRUG|Acalabrutinib|Given PO
219127987|NCT04783415|BIOLOGICAL|Ublituximab|Given IV
219127988|NCT04783415|DRUG|Umbralisib|Given PO
219127989|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
219127990|NCT01033396|DRUG|Allegra|Fexofenadine single dose 60 mg
219127991|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
219127992|NCT01033396|DRUG|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
219711193|NCT01217346|OTHER|no intervention is involved in this study|no intervention is involved in this study
219711194|NCT02149134|DIETARY_SUPPLEMENT|TeHF2013-01|
219127993|NCT01033396|DRUG|Placebo|Placebo single dose
219127994|NCT02269436|DRUG|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
219226409|NCT07094893|DRUG|Irinotecan (CPT-11)|Administration according to the labels of each IMP.
219226410|NCT07094893|DRUG|Oxaliplatin|Administration according to the labels of each IMP.
219226411|NCT07094893|DRUG|Leucovorin and 5-FU|Administration according to the labels of each IMP.
219226412|NCT07094893|DRUG|Capecitabine|Administration according to the labels of each IMP.
219226413|NCT06524570|DEVICE|HIFU-HT|High-Intensify Focused Ultrasound Histotripsy
219226414|NCT06524570|DRUG|ICI|Ipilimumab and nivolumab
219127995|NCT02659644|DRUG|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
219127996|NCT03824236|BIOLOGICAL|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
219127997|NCT02662738|DIETARY_SUPPLEMENT|Natural fruit extract|
219127998|NCT02662738|OTHER|Placebo|
219127999|NCT02662738|OTHER|Glucose solution|
219128000|NCT02912039|DEVICE|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
219128001|NCT02912039|DEVICE|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
219128002|NCT01416909|OTHER|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
219128003|NCT01416909|OTHER|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
219128004|NCT01416909|OTHER|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
219128005|NCT05014620|OTHER|Semi-directive interview|semi-structured exploratory interview
219128006|NCT05477862|BEHAVIORAL|Clinically Designed Improvisatory Music|Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
219128007|NCT03727360|OTHER|Exercise Training|Supervised exercise conducted four days per week for six months.
219128008|NCT03727360|OTHER|Flexibility Control|Supervised exercise conducted four days per week for six months.
219128009|NCT06093529|DIAGNOSTIC_TEST|complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.|"1. Full history~2. Thorough clinical examinations~3. Laboratory investigations will include:~   1. complete blood count with focus on platelet count, platelet distribution width and mean platelet volume. Platelet count will be confirmed by direct blood film and blood smear.~  2. Measurements of CD3+, CD4+, CD8+ and natural killer cells (CD16+, CD56+) will be conducted using flow cytometry.~  3. Serum IFN-γ levels will be determined using an ELISA kit.~4. Response to the treatment will be assessed according to The International Working Group criteria which defines Response as platelet count ≥ 30 x 10⁹/L and \>2-fold increase in platelet count from baseline and absence of bleeding, measured on 2 occasions greater than 7 days apart. No response is characterized by a platelet count \<30 x 10⁹/L or a less than 2-fold increase in platelet count from baseline, or the presence of bleeding."
219128010|NCT00701311|DRUG|CC-10004|CC-10004 20 mg per day
219128011|NCT01702038|DRUG|Rituximab|1000 mg administered intravenously
219128012|NCT05910931|DRUG|ICG angiography|"* A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
219128013|NCT01133613|DRUG|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
219128014|NCT01076218|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
219128015|NCT03236233|DRUG|PC786 - Single doses|Safety and tolerability of single doses
219128016|NCT03236233|DRUG|Placebo - Single doses|Safety and tolerability of single doses
219128017|NCT03236233|DRUG|PC786 - Repeat doses|Safety and tolerability of repeat doses
219128018|NCT03236233|DRUG|Placebo - Repeat doses|Safety and tolerability of repeat doses
219128019|NCT01024205|DRUG|sunitinib malate|
219128020|NCT01024205|OTHER|laboratory biomarker analysis|
219128021|NCT01024205|PROCEDURE|adjuvant therapy|
219128022|NCT01024205|PROCEDURE|neoadjuvant therapy|
219128023|NCT01024205|PROCEDURE|therapeutic conventional surgery|
219128024|NCT04549051|DEVICE|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
219128025|NCT04549051|DRUG|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
219128026|NCT04837495|PROCEDURE|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
219128027|NCT04244591|DRUG|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
219128028|NCT04244591|OTHER|Standard care|Standard care
219226415|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
219128029|NCT04435730|DIAGNOSTIC_TEST|serum level of Mac 2 binding protein|"Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment."
219128030|NCT04435730|DEVICE|musculoskeletal ultrasound|MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
219128031|NCT04007887|OTHER|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
219128032|NCT00710723|PROCEDURE|vitrification|Vitrification using Hemi-straw carrier system.
219128033|NCT04307550|DRUG|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
219711195|NCT06525168|DRUG|DA414 Granules|DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
219711196|NCT06525168|DRUG|DA414 placebo|DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
219711197|NCT02998853|OTHER|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
219711198|NCT03314935|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
219711199|NCT03314935|DRUG|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
219711200|NCT03314935|DRUG|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
219711201|NCT03314935|DRUG|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
219711202|NCT03314935|DRUG|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
219711203|NCT03314935|DRUG|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
219711204|NCT03314935|DRUG|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
219711205|NCT04597450|DRUG|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
219711206|NCT04597450|DRUG|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
219711207|NCT04529408|DEVICE|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
219711208|NCT03437954|OTHER|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
219711209|NCT06202820|BEHAVIORAL|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
219711210|NCT05884580|DEVICE|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
219711211|NCT05667506|BIOLOGICAL|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
219711212|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
219128034|NCT04307550|OTHER|Placebo|10 inhalations of a sterile saline pad
219128035|NCT04767646|PROCEDURE|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
219128036|NCT04677465|DEVICE|RheOx Bronchial Rheoplasty|bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
219128037|NCT04677465|DEVICE|Sham Procedure|staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
219128038|NCT01924234|DRUG|Morphine|
219128039|NCT01924234|DRUG|Remifentanil|
219128040|NCT05267834|PROCEDURE|Conization and/or Hysterectomy|Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
219128041|NCT00674947|DRUG|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
219128042|NCT00670540|OTHER|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
219128043|NCT06132776|DEVICE|HiToP 191 PNP|High tone therapy
219128044|NCT06132776|DEVICE|Placebo device|Placebo therapy
219128045|NCT03882463|DEVICE|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
219128046|NCT03316443|DEVICE|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).~For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.~Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
219128047|NCT03316443|DEVICE|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
219128048|NCT01140347|BIOLOGICAL|Placebo|8 mg/kg IV every 2 weeks
219128049|NCT01140347|BIOLOGICAL|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
219128050|NCT01140347|OTHER|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
219128051|NCT00828919|DRUG|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
219711213|NCT05979883|RADIATION|Machine Learning Assisted Radiation (MLAP) RapidPlan|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.
219711214|NCT05979883|RADIATION|Radiation Therapy Standard of Care (SOC)|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.
219128052|NCT00828919|DRUG|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
219128053|NCT06169436|PROCEDURE|Nephroureterectomy|Removal of cancer mass by urether and kidney complete resection.
219128054|NCT00761254|DRUG|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
219128055|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
219711215|NCT04217980|DIAGNOSTIC_TEST|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
219711216|NCT00168298|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
219711217|NCT00168298|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
219711218|NCT00168298|OTHER|Sham Injection|Sham injection on Day 0.
219711219|NCT03283878|DRUG|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
219128056|NCT06603402|RADIATION|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
219128057|NCT00442663|DEVICE|Transcervical Foley Catheter|
219128058|NCT00442663|DEVICE|Transcervical Foley Catheter with an EASI|
219128059|NCT00565682|DRUG|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
219711220|NCT04253730|OTHER|Cold Stress|60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
219128060|NCT06423599|DRUG|Semaglutide Injectable Product|Weight loss using Semaglutide
219128061|NCT06423599|DIETARY_SUPPLEMENT|Calorie-restricted diet|Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
219128062|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in neutral position
219128063|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in sniffing position
219128064|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in beyond sniffing position
219226416|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
219128065|NCT06659887|DEVICE|nasal cannula|After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be \>90%, saturation of oxygen was 100%, and end tidal carbon dioxide was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
219128066|NCT05573113|DIAGNOSTIC_TEST|Bowel Ultrasound|Bowel Ultrasound
219128067|NCT05573113|DIAGNOSTIC_TEST|Abdominal radiograph|Abdominal radiograph
219128068|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
219128069|NCT00759824|DRUG|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
219128070|NCT01449929|DRUG|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
219128071|NCT01449929|DRUG|darunavir 800mg OAD|2 x 400mg tablets OAD
219128072|NCT01449929|DRUG|ritonavir 100mg OAD|1 x 100mg tablet OAD
219711221|NCT03636477|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
219711222|NCT03636477|DRUG|veledimex|"* 2 doses (10mg/day, 20mg/day)~* 15 oral daily doses of veledimex"
219711223|NCT03636477|DRUG|Nivolumab|"* 2 doses (1mg/kg, 3mg/kg)~* Every 2 weeks"
219711224|NCT05705557|DEVICE|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
219711225|NCT02617277|DRUG|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
219711226|NCT02617277|DRUG|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
219711227|NCT06270394|DRUG|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
219711228|NCT06011239|BEHAVIORAL|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
219711229|NCT04086264|DRUG|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
219128073|NCT06611137|COMBINATION_PRODUCT|SBRT+Toripalimab Plus Docetaxel and Cisplatin|All participants will receive SBRT (18Gy/3 fractions, QOD ) to gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab (240mg) Plus Docetaxel (75mg/m2, q3w) and Cisplatin (75mg/m2, q3w) for 3 cycles. If tumor has complete or partial response at 2 weeks after the last course of neoadjuvant chemotherapy, participants will then receive intensity modulated radiotherapy (54Gy/27 fractions). If tumor is stable or progressive, participants will receive radical resection with or without postoperative intensity modulated radiotherapy when necessary.
219128074|NCT05707182|DRUG|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
219128075|NCT06611761|PROCEDURE|Shoulder arthroscopy|Shoulder arthroscopy in procedures that cause intense postoperative pain
219128076|NCT05641467|OTHER|virtual reality glasses|OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
219128077|NCT06614283|BEHAVIORAL|Diabetes self management @ click|A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
219226417|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
219711230|NCT04086264|DRUG|IMGN632|Study formulation given intravenously (IV)
219711231|NCT04086264|DRUG|Venetoclax|Commercially available formulation administered orally
219711232|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
219711233|NCT04762992|OTHER|standard of care|Obsteric standard of care.
219711234|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
219128078|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation combined slow breathing|The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.
219128079|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation|Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
219128080|NCT06613386|OTHER|The information-based discharge preparation service (IBDPS)|"The main modules of the IBDPS platform include:~* Establishing information records for infants and parents.~* Collaboratively identifying existing or potential caregiving challenges.~* Assessing parents' emotional and psychological states, providing support and intervention.~* Collaboratively establishing caregiving objectives with parents.~* Collaboratively formulating and executing caregiving plans.~* Assessing parental support resources, offering analysis, assistance, and necessary referrals.~* Conducting outcome assessments."
219128081|NCT06613607|OTHER|Core Strengthening|"Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch"
219128082|NCT06614153|DRUG|HRG2010(I)|HRG2010(I)
219128083|NCT06614153|DRUG|HRG2010(II)|HRG2010(II)
219711235|NCT06461403|DEVICE|Inhaler Trainer System|The system consists of an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. The inhaler trainer system consists of a detachable/disposable mouthpiece and a reusable electronics module. The electronics module measures flow/pressure achieved by the patient and wirelessly transmits this data to a PC. The PC software analyzes the real-time inhalation flow data to enable the monitoring of the following quantities: Flow Rate, Duration, and Maximum Pressure Slope. These quantities will be used in the computation of the assessment metric, providing the user with real-time feedback about their inhalation technique. In addition, the software includes features to support the human study and provides fully functional inhaler education features for the expert test evaluators.
219711236|NCT06461403|OTHER|Initial Inhaler Use Assessment|Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists
219128084|NCT06614153|DRUG|Sustained-release Carbidopa/Levodopa|Sustained-release Carbidopa/Levodopa
219128085|NCT06613503|DEVICE|AI-supporter|rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot. This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process. When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper. The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis. This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
219128086|NCT06668480|PROCEDURE|Conventional Physical Therapy|It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors
219128087|NCT06668480|PROCEDURE|Strengthening Exercise|Strengthening exercises of lower fibers of trapezius
219128088|NCT06668480|PROCEDURE|SNAG'S|Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks
219128089|NCT06118710|DRUG|Dexamethasone|Dexamethasone prior to paclitaxel infusion according to local care standards.
219128090|NCT06118710|DRUG|H1 Antihistaminics|Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
219128091|NCT04313530|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
219128092|NCT01871285|DRUG|Buprenorphine|
219711237|NCT06461403|OTHER|Inhaler Use Instruction|Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.
219711238|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
219128093|NCT01871285|DRUG|Placebo film|Matching placebo buccal film
219128094|NCT01871285|DRUG|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
219128095|NCT01871285|DRUG|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
219128096|NCT01871285|DRUG|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
219128097|NCT02359968|DRUG|FOLFOX|radiochemotherapy before surgery
219128098|NCT02359968|DRUG|CarboP-pacliT|radiochemotherapy before surgery
219128099|NCT06615687|PROCEDURE|Inverted T shape Free Gingival Graft|"the preparation of the recipient site commenced by making a horizontal incision at the mucogingival junction (MGJ) as well as two vertical incisions extending to the adjacent teeth and about 3-4 mm beyond the MGJ. A sharp split-thickness flap will be reflected, and the surfaces between these incisions will be de-epithelialized. Also, all the surfaces of the interdental papilla up to the lingual side will be de-epithelized using a 15c blade and microsurgical scissor .(Harvesting of the palatal donor site will be designed 2 mm away from the gingival margin using a template in the form of an inverted T-shape, taking into consideration the position of the greater palatine blood vessels at 5 mm. 2 mm is required for the width of the interproximal extension with 3 mm length to obtain an even thickness of 1-1.5 mm .~Placement of the graft : The Inverted T FGG will be inserted between the teeth to cover interproximal tissue defect and sutured lingually into the lingual marginal gingiva"
219128100|NCT06615687|PROCEDURE|Free Gingival Graft|"Preparation of the recipient site :Following an intrasulcular incision, 2 mm-long horizontal incisions at the level of the CEJ will be performed bilaterally. From these, vertical releasing incisions will be placed in a diverging manner, extending well into the alveolar mucosa, a thin partial thickness flap will be subsequently raised then excised. The dimension of the resulting site will be measured to obtain a rectangular foil template .~Harvesting of the Graft :Using the foil template, graft dimensions will be outlined in the palate adjacent to the premolars and first molar. A partial thickness graft consisting of epithelium and a thin layer of underlying connective tissue will be harvested (intended total thickness of graft: 1.5 mm), maintaining a distance of ≥2 mm to the maxillary teeth."
219128101|NCT06615414|OTHER|participants are not assigned an intervention as part of the study|participants are not assigned an intervention as part of the study
219711239|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
219711240|NCT06482346|BIOLOGICAL|MT-3534|Solution for infusion; Intravenous (IV)
219711241|NCT06482346|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
219711242|NCT04261192|OTHER|Constitution of tumor and blood samples|Constitution of tumor and blood samples
219711243|NCT04940065|OTHER|Kesimpta|Prospective observational cohort study. There is no treatment allocation.
219711244|NCT05797506|DRUG|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
219711245|NCT05797506|DIETARY_SUPPLEMENT|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
219711246|NCT03621592|DEVICE|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
219711247|NCT03621592|DEVICE|Acticoat®|Silver impregnated contact layer dressing
219711248|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
219711249|NCT02382380|DRUG|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
219711250|NCT02382380|OTHER|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
219711251|NCT02984410|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
219711252|NCT02984410|PROCEDURE|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
219711253|NCT05555043|DEVICE|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
219128102|NCT06917937|OTHER|Exercise Program|Our exercise program in our study; (i) foot intrinsic muscle strengthening exercise (with a load of 3 kg), (ii) plantar fascia stretching with finger extension, (iii) standing gastrocnemius muscle stretching, (iv) sitting achilles tendon stretching, (v) plantar fascia and gastrocnemius stretch on the step, (vi) cold massage exercise in the arch of the foot. We stated that the group to which exercise was added should do the exercises regularly for 6 weeks, in the specified number and time.
219226418|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
219711254|NCT05555043|DEVICE|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
219711255|NCT05555043|DEVICE|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
219711256|NCT06166992|DRUG|BI 1291583|BI 1291583
219711257|NCT06166992|DRUG|[14C]-BI 1291583|\[14C\]-BI 1291583
219711258|NCT04401748|DRUG|Venetoclax|Tablet: Oral
219711259|NCT04401748|DRUG|Azacitidine|Subcutaneous (SC) or Intravenous (IV) injection
219711260|NCT04401748|DRUG|Placebo|Tablet; Oral
219128103|NCT06917937|OTHER|Corticosteroid injection|"The orthopedic physician administered the corticosteroid injection as a mixture of 1 ml of arthropane (5 mg of triamcinolone hexacetonide) and 4 ml of citanest. Before the application, the physician cleaned the area to be treated with 10% povidone iodine. He made a single dose injection by entering the painful point determined by palpation around the calcaneal spur and plantar fascia from the percutaneous foot-heel lateral. The patients were in the prone position with the ankle in a neutral position.~After the application, he covered the area with a sterile cloth and said to remove it after 3 hours. He stated that patients could apply ice to the injected area if necessary for pain control, and advised patients to avoid all jogging and other high-impact activities on the day of injection. No additional treatments, including NSAIDs, orthoses, and night splints, were allowed during the study period."
219128104|NCT06919042|DEVICE|Pulsed Acoustic Cellular Expression therapy|The therapy involves the delivery of targeted acoustic energy that initiates cellular mechanotransduction pathways, inducing beneficial biological responses such as enhanced angiogenesis, modulation of fibroblast proliferation and differentiation, and reorganization of aberrant extracellular matrix components.
219128105|NCT06615648|BEHAVIORAL|PMT|7-minute PMT intervention video
219128106|NCT06615648|BEHAVIORAL|Non-contact Control|6-minute alternative video
219128107|NCT06613776|DRUG|Amoxicillin|4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
219128108|NCT06613776|DRUG|Placebo|4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
219128109|NCT06612606|OTHER|observational study|This was an observational study with no intervention.
219128110|NCT06671327|DRUG|Preemptive Dexmedetomidine injection|The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
219711261|NCT04008602|DEVICE|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
219711262|NCT04008602|DEVICE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
219711263|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
219711264|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
219711265|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
219711266|NCT05168800|BEHAVIORAL|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
219711267|NCT05168800|BEHAVIORAL|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
219711268|NCT05168800|OTHER|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
219711269|NCT04751890|BEHAVIORAL|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
219711270|NCT04751890|BEHAVIORAL|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
219711271|NCT01744587|OTHER|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
219711272|NCT01744587|DIETARY_SUPPLEMENT|Placebo|Placebo qd (2# bid) for 3 years
219711273|NCT06472271|DRUG|Polymyxin e|Increased starting colistin dose
219128111|NCT06671327|DRUG|Sodium Chloride 0.9% Inj|The Placebo group was infused with equal amounts of isochronous normal saline.
219128112|NCT06685276|DRUG|Fruquintinib|Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.
219128113|NCT06685276|DRUG|Sintilimab|Sintilimab: 200mg, iv, d1, q3w.
219128114|NCT06685276|DRUG|Chidamide|Chidamide: 30mg/m2, po, biw.
219711274|NCT05514535|DRUG|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
219711275|NCT05514535|DRUG|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
219128115|NCT06628466|DRUG|Nuberol Forte|Quality of Life study
219128116|NCT06697561|BEHAVIORAL|patient education program|"The intervention for the experimental group was an evidence-based educational program for hand dysfunction in patients with systemic sclerosis, which included a health education manual and multimedia videos developed through evidence translation. Additionally, individual education and consultation were provided."
219128117|NCT06697886|DRUG|Antiwei Granules|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
219128118|NCT06697886|DRUG|Antiwei Granules Placebo|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
219128119|NCT06697080|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells
219128120|NCT06697067|PROCEDURE|modified smead jones|interrupted suture technique
219128121|NCT06697067|PROCEDURE|conventional comtinuous suture techniques|continuous suture technique
219128122|NCT04000893|OTHER|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
219128123|NCT06918626|PROCEDURE|ELC + Spyglass cholangiography|Study group (Spyglass Discover). Patients will undergo ELC surgery as soon as the ACC diagnosis has been confirmed. During surgery, intra-operative cholangiograpy (IOC) will be performed in order to exclude the presence of CBDS and in case of confirmation or still suspicion of CBDS, the exploration of the common bile duct and its eventual clearance via Spyglass Discover is carried out during ELC.
219128124|NCT06918626|PROCEDURE|ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures|Control group (ELC sequential treatment after possible clearance of CBDS via ERCP). Following the diagnosis of ACC, patients with CBDS high/intermediate risk are introduced either directly, in case of high risk, or after performing second-level diagnostics (MNR cholangiography or endoscopic ultrasound), in the case of intermediate risk, to the ERCP with the aim of eliminating CBDS preoperatively and then the ELC will be performed.
219128125|NCT04286555|OTHER|DASH4D diet|"DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate."
219128126|NCT04286555|OTHER|comparison diet|The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
219128127|NCT04286555|OTHER|higher sodium|3700 mg/day sodium (at the 2000 kilocalorie level)
219128128|NCT04286555|OTHER|lower sodium|1500 mg/day sodium (at the 2000 kilocalorie level)
219128129|NCT06914180|DRUG|esketamine group|In the esketamine group, in addition to receiving PRF treatment+pregabalin for rescue analgesia, patients will also undergo a single intravenous infusion of esketamine. A total of 0.5 mg/kg of esketamine will be diluted in 50 mL of normal saline. The infusion will commence with an intravenous injection of 10 mg of esketamine over 1 minute, followed by a maintenance dose of 8 mg/h. The infusion rate will be adjusted based on the patients' tolerance levels.
219128130|NCT06914180|DRUG|control group|In the control group, patients will receive PRF+pregabaline treatment. Pulsed radiofrequency (PRF) will be performed on GG by a designated physician in each participating center. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to GG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
219128131|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
219128132|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
219128133|NCT06918743|DRUG|RSS0393 ointment placebo|RSS0393 ointment placebo
219128134|NCT06918184|BEHAVIORAL|Specific Exercise Therapy|The exercise protocol includes mobilisation and stretching with 40-minute sessions twice weekly for 8 weeks post-initiation, transitioning to a home-based maintenance phase for 4 months. All sessions will be supervised by certified physiotherapists.
219128135|NCT06920121|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 2-3 minute before the start of the procedure, the patients will be watched (5 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
219128136|NCT06920121|OTHER|Stress ball|Patients will be instructed to continue squeezing and relaxing the stress ball (squeezing and relaxing once, counting from one to three) for 5 minutes before and throughout the AVF cannulation procedure. Patients will be instructed to focus their attention on the stress ball and focus on squeezing the stress ball.
219128137|NCT06920277|DEVICE|Ultrasound scans|10 seconds scanning for one block region
219128138|NCT06933693|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials.
219128139|NCT06933693|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
219128140|NCT04834024|DRUG|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
219128141|NCT04834024|DRUG|lenalinomide|The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
219128142|NCT06297564|OTHER|Progesterone primed endometrial protocol|The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.
219128143|NCT06297564|OTHER|Gonadotropin-releasing hormone antagonist protocol|The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
219711276|NCT05514535|DRUG|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
219711277|NCT05507866|OTHER|CSNEI|CSNEI is a policy intervention designed to address childhood obesity by modifying lunch and breakfast meal/menu items, changing the school cafeteria environments, and making changes to purchasing and procurement practices.
219128144|NCT05640128|OTHER|Aldosterone in HPLC-MS/MS|Aldosterone in HPLC-MS/MS
219128145|NCT04259970|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each 4 visits.
219128146|NCT06393634|DRUG|Testosterone injection|A single injection of testosterone
219128147|NCT06393634|DRUG|Testosterone gel|A daily dose of testosterone gel
219128148|NCT06393634|DRUG|Testosterone Oral|A twice-daily pill of testosterone pill to swallow
219128149|NCT04541901|OTHER|Massage|12 minutes of effleurage and petrissage on the upper limbs
219711278|NCT05129150|OTHER|Ultrasound examination|Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
219128150|NCT04541901|OTHER|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
219128151|NCT05512260|DEVICE|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
219128152|NCT00699738|BEHAVIORAL|Breastfeeding|Breastfeeding
219128153|NCT00699738|BEHAVIORAL|Bottlefeeding|Bottlefeeding
219128154|NCT01471262|PROCEDURE|Right hepatectomy|Right liver resection
219128155|NCT01471262|PROCEDURE|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
219128156|NCT01260974|DRUG|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
219128157|NCT01663610|BEHAVIORAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
219128158|NCT06306859|BEHAVIORAL|Using m-health for monitoring and education provision|The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
219128159|NCT06306859|OTHER|Standard care|The comparator group will be given standard and routine care
219128160|NCT04094064|DEVICE|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
219128161|NCT06629948|DEVICE|x ray|whole spine x ray posterioanterior and lateral views
219128162|NCT06629948|DIAGNOSTIC_TEST|the cranio-cervical flexion test|measure of deep neck flexors muscles endurance
219128163|NCT06172595|DIAGNOSTIC_TEST|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
219128164|NCT01249300|OTHER|No intervention|No intervention
219128165|NCT00027612|DRUG|carmustine|IV
219128166|NCT00027612|DRUG|irinotecan hydrochloride|IV
219128167|NCT00027612|RADIATION|radiation therapy|
219711279|NCT00647816|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
219711280|NCT00647816|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fasting
219711281|NCT05552339|DRUG|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
219711282|NCT05552339|DRUG|Type 2 DM drugs|Following the physicians' decision
219128168|NCT01895140|DEVICE|Renal denervation device|
219128169|NCT04859777|DRUG|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
219128170|NCT04859777|DRUG|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
219128171|NCT03960255|OTHER|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
219128172|NCT04751747|PROCEDURE|Computed Tomography|Undergo CT simulation
219128173|NCT04751747|OTHER|Contrast Agent|Given IV
219128174|NCT01554592|DRUG|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
219128175|NCT01554592|DRUG|Statin therapy|Participants will continue on stable statin therapy.
219128176|NCT04701060|DRUG|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
219128177|NCT06277622|DEVICE|PFUN|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
219128178|NCT06277622|DEVICE|PFNA|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
219128179|NCT03273530|OTHER|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
219128180|NCT03631563|DRUG|Immunosuppressive Agent|ATG-Fresenius versus ATG
219128181|NCT02967016|BEHAVIORAL|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
219128182|NCT06145256|DEVICE|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
219226419|NCT07098624|OTHER|ACV Moringa Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
219128183|NCT03423394|BEHAVIORAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
219128184|NCT03423394|BEHAVIORAL|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
219128185|NCT03176030|DIETARY_SUPPLEMENT|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
219128186|NCT02764307|DEVICE|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
219128187|NCT02764307|DEVICE|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
219128188|NCT02764307|DEVICE|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
219128189|NCT02764307|DEVICE|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
219128190|NCT06411145|DRUG|OXERVATE® 0.002%|Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
219128191|NCT02770040|DRUG|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
219128192|NCT01211665|DRUG|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
219128193|NCT01211665|DRUG|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
219128194|NCT04550650|OTHER|Training groupe|Using virtual training
219128195|NCT04550650|OTHER|PNF|PNF technique was used
219711283|NCT03399773|BIOLOGICAL|Dilanubicel|Given IV
219711284|NCT03399773|DRUG|Cyclophosphamide|Given IV
219128196|NCT04550650|OTHER|Spinning grp|They only worked with spinning bikes.
219128197|NCT04550650|OTHER|Balance|Balance development was done
219128198|NCT01576315|DRUG|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
219128199|NCT04675411|DEVICE|Smart care|Home based nursing intervention with smart assisted technology
219128200|NCT04675411|DEVICE|usual care|Routine hospital care with only in-hospital rehabilitation
219128201|NCT01459315|DRUG|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
219128202|NCT02685293|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
219128203|NCT02685293|DRUG|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
219128204|NCT04093128|OTHER|herbal tea intervention|herbal tea intervention for 7 weeks
219128205|NCT05406492|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
219711285|NCT03399773|DRUG|Fludarabine|Given IV
219711286|NCT03399773|DRUG|Thiotepa|Given IV
219711287|NCT03399773|RADIATION|Total-Body Irradiation|Undergo TBI
219711288|NCT03399773|PROCEDURE|Umbilical Cord Blood Transplantation|Given IV
219711289|NCT03399773|OTHER|Laboratory Biomarker Analysis|Correlative studies
219711290|NCT03399773|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219711291|NCT03399773|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
219711292|NCT03399773|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
219711293|NCT03399773|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219711294|NCT03399773|PROCEDURE|Electrocardiography|Undergo ECHO
219128206|NCT00672152|BIOLOGICAL|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~* WT peptide #1: HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
219128207|NCT01390857|DRUG|Valaciclovir|
219128208|NCT04029740|BEHAVIORAL|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
219128209|NCT04029740|OTHER|No intervention|Healthy controls will not receive any intervention.
219128210|NCT03712293|DEVICE|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
219128211|NCT06184789|DIAGNOSTIC_TEST|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
219128212|NCT03155204|DRUG|tiotropium pMDI|inhalation
219128213|NCT06218186|DEVICE|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
219128214|NCT02197871|DIETARY_SUPPLEMENT|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
219711295|NCT03399773|PROCEDURE|Computed Tomography|Undergo CT
219711296|NCT04556097|BEHAVIORAL|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
219711297|NCT05566171|DIETARY_SUPPLEMENT|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
219711298|NCT02516241|DRUG|MEDI4736 (Durvalumab)|IV infusion
219711299|NCT02516241|DRUG|Tremelimumab|IV infusion
219711300|NCT02516241|DRUG|Cisplatin|IV infusion
219128215|NCT06634537|DEVICE|Active Comparator: insoles hard, soft and barefoot|"Primary Outcome Measure:~1\. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]"
219128216|NCT00291707|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
219128217|NCT00291707|DRUG|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
219711301|NCT02516241|DRUG|Carboplatin|IV infusion
219711302|NCT02516241|DRUG|Gemcitabine|IV infusion
219711303|NCT05330897|PROCEDURE|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
219711304|NCT05330897|DEVICE|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
219711305|NCT03425526|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
219711306|NCT06551155|DIAGNOSTIC_TEST|Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)|Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders
219711307|NCT05067387|DRUG|Placebo|Oral placebo
219711308|NCT05067387|DRUG|THC|Oral THC (20 mg)
219711309|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
219711310|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
219711311|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath) + Scapular Training|The Bobath concept for 40 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed with 20 minutes scapular training including scapular exercise such as Proprioceptive Neuromuscular Facilitation (PNF), dynamic hug, towel-wall slide, scapular punch exercises etc. 3 days a week for 8 weeks.
219128218|NCT00291707|PROCEDURE|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
219128219|NCT02579512|OTHER|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
219128220|NCT05879666|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
219128221|NCT04267094|DEVICE|Iterative reconstruction at reduced radiation dose|Evaluating Agatston coronary calcium score using reduced dose acquisitions reconstructed using iterative reconstruction
219128222|NCT00398502|DRUG|MOA-728|
219128223|NCT04501224|DRUG|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
219128224|NCT04501224|DRUG|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
219226420|NCT07098624|OTHER|Placebo Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
219711312|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath)|The Bobath concept for 60 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed 3 days a week for 8 weeks.
219711313|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
219711314|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
219711315|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
219711316|NCT05776277|BIOLOGICAL|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.
219711317|NCT05776277|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
219711318|NCT05493046|BEHAVIORAL|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
219128225|NCT03737175|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting
219128226|NCT03737175|PROCEDURE|Carotid Endarterectomy|Carotid Endarterectomy
219128227|NCT03797235|PROCEDURE|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
219128228|NCT03797235|PROCEDURE|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
219226421|NCT07098039|OTHER|Semi-presential or hybrid group|The hybrid format will consist of 4 in-person sessions (every two weeks) complemented by a home program until completing 3 sessions of the full program at home.
219711319|NCT05493046|BEHAVIORAL|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
219711320|NCT04430218|DEVICE|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
219711327|NCT06360289|OTHER|Standard of Care|This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
219711328|NCT06239116|DRUG|Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)|Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
219128229|NCT00403884|PROCEDURE|Selective RPE laser treatment|interventional SRT laser treatment
219711329|NCT06239116|DRUG|Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)|Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
219711330|NCT06239116|DRUG|Part C: RM-718|Multiple ascending doses of RM-718 (specific to Part C single cohort)
219226422|NCT07098039|OTHER|Hospital Cardiac Rehabilitation|The hospital cardiac rehabilitation group will attend the hospital 3 days a week for the same, for eight weeks.
219711331|NCT06354777|DEVICE|Atrial Ablation|Left atrial radiofrequency ablation for the treatment of atrial fibrillation; this may include Pulmonary Vein Isolation (PVI) with or without additional ablation lesions as warranted during the procedure
219711332|NCT05975983|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
219711333|NCT05975983|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
219128230|NCT01450878|DRUG|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
219128231|NCT02933320|BIOLOGICAL|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
219128232|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
219128233|NCT02933320|BIOLOGICAL|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
219711334|NCT06546813|OTHER|scales and questionnaire administration|evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
219128234|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
219128235|NCT01436409|OTHER|echography|echography during labor
219711335|NCT05864144|DRUG|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
219711336|NCT05864144|DRUG|Cemiplimab|Cemiplimab IV every 21 days.
219128236|NCT05455346|DIAGNOSTIC_TEST|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
219128237|NCT05455346|OTHER|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
219128238|NCT05455346|OTHER|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
219128239|NCT05455346|OTHER|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
219128240|NCT05455346|OTHER|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
219128241|NCT01642940|DRUG|Prasugrel|Prasugrel 10mg/day
219128242|NCT01642940|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
219128243|NCT01996644|DRUG|Placebo vs Setraline|Placebo
219128244|NCT01996644|DRUG|Setraline|250mg DCS
219128245|NCT06429410|DIETARY_SUPPLEMENT|fortified formula milk powder|Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
219128246|NCT06429410|DIETARY_SUPPLEMENT|formula milk powder|Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.
219128247|NCT06429410|DIETARY_SUPPLEMENT|regular milk powder|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
219711337|NCT05040568|DRUG|Cetuximab|Given IV
219711338|NCT05040568|DRUG|Expanded CB-NK cells|Given IV
219711339|NCT05040568|DRUG|Fludarabine phosphate|Given IV
219711340|NCT05040568|DRUG|Cyclophosphamide|Given IV
219711341|NCT06487195|BEHAVIORAL|Peer-facilitated, Recovery-based Self-illness-management programme|The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.
219711342|NCT06487195|BEHAVIORAL|Psycho-education group|The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.
219711343|NCT06487195|BEHAVIORAL|Treatment-as-usual only|Participants in the TAU group will receive routine community mental healthcare services.
219711344|NCT03182335|OTHER|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
219711345|NCT05093634|DRUG|Setmelanotide|Subcutaneous Injection
219711346|NCT05093634|DRUG|Placebo|Subcutaneous Injection
219711347|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
219711348|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
219711349|NCT05818709|DEVICE|HAC 22L|Subcutaneous and/or Supraperiosteal injection
219711350|NCT05720130|DRUG|[²¹²Pb]Pb-ADVC001|"Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~\- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~\- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~\- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~\- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~\- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3c~\- Optional cohort of 160 MBq, 4 to 6 cycles every week~Dose Level 4a~* 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~\- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4c~\- Optional cohort of 200MBq, 4 to 6 cycles every week~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule"
219711351|NCT05380947|DRUG|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
219711352|NCT05380947|DRUG|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
219711353|NCT05380947|DRUG|Rabeprazole sodium|Rabeprazole sodium
219711354|NCT05394116|DRUG|Garetosmab|Garetosmab is supplied as a liquid drug product and will be administered IV.
219711355|NCT05394116|DRUG|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
219128248|NCT02844764|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
219128249|NCT04205032|DEVICE|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~* Electrocardiogram~* Vascular Doppler~* LaserDoppler and iontophoresis~* Brachial blood pressure~* Continuous blood pressure recorded at the finger level~* Ultrasound~* Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
219128250|NCT05818813|DEVICE|Renal denervation|Renal denervation (ReCor Medical)
219128251|NCT01954043|DRUG|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
219128252|NCT01954043|DRUG|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
219711356|NCT00724945|DEVICE|balafilcon A|multifocal contact lens
219711357|NCT00724945|DEVICE|senofilcon A|multifocal contact lens
219128253|NCT01954043|DRUG|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
219128254|NCT06497634|PROCEDURE|25 PP|Spinal anesthesia will be performed in sitting position, with 25 G pencil point needle (Whitacre -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
219711358|NCT04262219|BEHAVIORAL|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
219711359|NCT02546570|DRUG|Oxytocin|See arm/group descriptions for dosage amount and procedure.
219711360|NCT02546570|DRUG|Placebo|See arm/group descriptions for dosage amount and procedure.
219711361|NCT01772082|BEHAVIORAL|Internet mediated walking program|
219711362|NCT06403800|OTHER|No intervention|No intervention
219711363|NCT00467766|BEHAVIORAL|Psychosocial information, counseling, and support|
219711364|NCT00467766|DRUG|Donepezil (Aricept)|
219711365|NCT03088397|BEHAVIORAL|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
219711366|NCT03088397|BEHAVIORAL|Website|Patient directed to website with information on various contraceptive methods.
219711367|NCT03088397|BEHAVIORAL|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
219711368|NCT03069989|DRUG|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
219128255|NCT06497634|PROCEDURE|25 Q|Spinal anesthesia will be performed in sitting position, with 25 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
219128256|NCT06497634|PROCEDURE|27 Q|Spinal anesthesia will be performed in sitting position, with 27 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
219128257|NCT06497634|OTHER|Optic Nerve Sheath Measurement|Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.
219128258|NCT04442659|DIAGNOSTIC_TEST|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
219711369|NCT03069989|DRUG|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
219711370|NCT03069989|DRUG|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
219711371|NCT03579511|PROCEDURE|External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities
219711372|NCT01303484|DIETARY_SUPPLEMENT|Bi2muno® GOS|5.5g/day for 10 weeks
219711373|NCT01303484|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily for 10 weeks
219711374|NCT06514859|PROCEDURE|Laparoscopic repair of inguinal hernia|Laparoscopic repair of inguinal hernia
219711375|NCT06514859|PROCEDURE|Open repair of inguinal hernia|Repair of inguinal hernia by open technique-mesh hernioplasty -
219711376|NCT06018103|BEHAVIORAL|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
219711377|NCT00569491|DEVICE|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
219711378|NCT00155987|PROCEDURE|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
219711379|NCT04801095|DRUG|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
219711380|NCT01277029|OTHER|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
219711381|NCT02478827|BEHAVIORAL|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
219711382|NCT00369083|PROCEDURE|Hospital at home treatment|
219711383|NCT05367505|DEVICE|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
219711384|NCT06478589|BEHAVIORAL|Adapted Patient Priorities Care (PPC) approach|Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
219711385|NCT06478589|OTHER|Usual Care|Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
219711386|NCT04132999|BEHAVIORAL|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
219711387|NCT04132999|BEHAVIORAL|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
219711388|NCT06797245|DEVICE|RiSolve App|Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.
219711389|NCT06797245|BEHAVIORAL|AUGS Patient Handouts|"AUGS Overactive Bladder and Pelvic Floor Muscles and Bladder Training Patient Fact Sheets will be provided and reviewed."
219711390|NCT05329623|DRUG|JDQ443|All the participants will receive a single oral dose of JDQ443.
219711391|NCT06793475|BIOLOGICAL|anti-BCMA/GPRC5D bispecific CAR-T|Autologous BCMA/GPRC5D bispecific CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA/GPRC5D bispecific CAR-T cells/kg.
219711392|NCT06793475|DRUG|Apornemin|Apornemin 10mg/kg will be administered by i.v. infusion. Apornemin will be administered on Days 1-5, 15-19 during bridging therapy, and on Days 1-5 every 28-day cycle during maintanance treatment.
219711393|NCT06793475|DRUG|Carfilzomib|Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.
219128259|NCT03647475|COMBINATION_PRODUCT|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
219711394|NCT06793475|DRUG|Thalidomide|Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.
219128260|NCT02286661|PROCEDURE|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
219711395|NCT06793475|DRUG|Dexamethasone|Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy.
219711396|NCT06775626|DEVICE|Implanon NXT® subdermal implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
219711397|NCT06775626|DRUG|Etonogestrel 68mg implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
219711398|NCT04601506|BEHAVIORAL|Choice Architecture Nudge|"Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order."
219128261|NCT02286661|PROCEDURE|Casting (short arm)|
219128262|NCT02741011|OTHER|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
219711399|NCT04601506|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
219128263|NCT05157334|DEVICE|Non-invasive auricular electrical transcutaneous vagus nerve stimulation|"A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study."
219128264|NCT05157334|OTHER|Deep breathing|The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
219128265|NCT06268210|DRUG|Lazertinib+Pemetrexed+Carboplatin|Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
219128266|NCT06268210|DRUG|Lazertinib|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
219128267|NCT01262495|OTHER|cryopreservation|cryopreservation of testicular tissue
219128268|NCT05014724|DRUG|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
219128269|NCT04575805|BEHAVIORAL|Internet-delivered Combined Cognitive Bias Modification (iCBM-C)|The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
219128270|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)|The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
219128271|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)|The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
219128272|NCT01079455|DRUG|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
219226423|NCT07099755|BEHAVIORAL|Intervention Group: Name: Dynamic Neuromuscular Stabilization (DNS) Exercises|"Distinguishing Description for DNS Intervention~This intervention consists of a structured Dynamic Neuromuscular Stabilization (DNS) exercise program specifically tailored for post-partum women with mechanical low back pain. DNS emphasizes restoring functional motor patterns through:~Breathing-based core activation techniques~Developmental positions mimicking infant motor milestones (e.g., supine 90/90, quadruped, side-lying)~Coordination of the diaphragm, pelvic floor, and transverse abdominis muscles~Progressive motor control retraining over 6 weeks, 3 sessions/week~What distinguishes this intervention:~It integrates developmental kinesiology principles with respiratory-pelvic-lumbar coordination.~DNS is performed under supervised sessions by a physiotherapist, ensuring precision and progression.~This protocol replaces standard strengthening/stretching exercises and focuses on neuromuscular re-patterning, not just symptom relief."
219128273|NCT04721392|OTHER|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
219226424|NCT07099755|DEVICE|Control Group:Name: Conventional Physiotherapy (Ultrasound and Infrared Therapy)|"1-Therapeutic Ultrasonic: comparison group also received treatment through therapeutic ultrasound, which was applied three times per week. The ultrasound therapy was delivered to the paraspinal muscles of the lumbar region, using a stroking technique where each stroke overlapped by about 50% with the preceding stroke. The ultrasound used a frequency of 3 MHz and an intensity range of 1.0 to 1.5 W/cm²,The ultrasound head was placed over the L4 to L5 and L5 to S1 regions and moved in a circular motion for a total duration of 5 minutes per treatment session (Shobari et al., 2024).~infra red the infrared lamp was placed at 75 cm distance from the patient's back so that the radiation struck the surface at or near a right angle to achieve maximum penetration. The treatment duration was 15 minutes. Each woman with post-partum low back pain was treated by 20 minutes infrared irradiation 40 cm away from the low back region, from prone3 sessions per week for 6 weeks (El-Lassy and Madian, 2018"
219226425|NCT07098455|PROCEDURE|GNRFT- genicular nerve radiofrequency ablation|Ultrasound-guided genicular nerve radiofrequency ablation will be performed
219226426|NCT07098455|PROCEDURE|IAPRF- Intraarticular pulsed radiofrequency|Intra-articular pulsed radiofrequency will be applied under fluoroscopy guidance.
219711400|NCT00440687|DRUG|Fluticasone 500mcg BD via accuhaler or identical placebo|
219711401|NCT02215759|DRUG|BI 44370 TA|
219711402|NCT02215759|DRUG|Placebo|
219128274|NCT04721392|OTHER|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
219128275|NCT01827410|PROCEDURE|Ventral hernia repair|
219128276|NCT03574909|DRUG|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
219128277|NCT03574909|DRUG|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
219128278|NCT05414565|DEVICE|Vivity IOL|Commercially available extended vision IOL
219128279|NCT05414565|DEVICE|Aspheric monofocal IOL|Commercially available aspheric IOL
219128280|NCT00427973|DRUG|cediranib maleate|Given orally
219128281|NCT00427973|OTHER|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
219128282|NCT00427973|PROCEDURE|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
219128283|NCT00427973|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
219128284|NCT00427973|OTHER|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
219128285|NCT02708459|DEVICE|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
219128286|NCT02708459|DRUG|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
219711403|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
219128287|NCT02708459|DRUG|Bupevecaine|
219128288|NCT02708459|DRUG|Dexmedetomedine|
219128289|NCT01287338|DRUG|Olopatadine|low dose
219128290|NCT01287338|DRUG|Olopatadine|high dose
219128291|NCT01245777|DRUG|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
219128292|NCT04698291|PROCEDURE|Blood Donation|The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
219128293|NCT00045695|DRUG|bortezomib|PS-341 bolus intravenous injection twice weekly\* for 2 out of every 3 weeks
219128294|NCT02893540|DRUG|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
219128295|NCT01719289|BEHAVIORAL|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
219128296|NCT01868867|BEHAVIORAL|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
219128297|NCT05331495|DEVICE|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
219128298|NCT03085017|DEVICE|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
219711404|NCT00408226|DRUG|MKC-1|capsules, twice daily for 14 days in 21 day cycle
219128299|NCT03085017|DEVICE|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
219128300|NCT01528124|DRUG|LY3025876|Given as a subcutaneous injection
219128301|NCT01528124|DRUG|Placebo|Given as a subcutaneous injection
219128302|NCT00058058|PROCEDURE|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
219128303|NCT00743405|DRUG|GSK1034702|Oral or liquid
219711405|NCT00408226|DRUG|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
219128304|NCT00743405|DRUG|Placebo|To match GSK1034702
219128305|NCT05939726|OTHER|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
219128306|NCT05939726|OTHER|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
219128307|NCT05939726|OTHER|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
219128308|NCT06492356|DEVICE|Tripolar radiofrequency therapy|Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
219128309|NCT06492356|DRUG|medical treatment|Twenty patients will receive medical treatment by dermatologist.
219128310|NCT04378582|OTHER|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
219128311|NCT02375321|BEHAVIORAL|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
219128312|NCT04472871|DEVICE|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
219128313|NCT05337072|DIAGNOSTIC_TEST|Microbiome study|Investigation of the vaginal and endometrial microbiome
219128314|NCT01995370|DRUG|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
219128315|NCT01995370|DRUG|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
219128316|NCT01995370|DRUG|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
219128317|NCT01695343|BIOLOGICAL|KB001-A|
219128318|NCT01695343|DRUG|Placebo Comparator|
219128319|NCT04835584|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
219128320|NCT04835584|DRUG|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
219128321|NCT04835584|DRUG|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
219128322|NCT05693662|BEHAVIORAL|Session 1|"* Ensuring group interaction, allowing parents to meet each other,~* Providing information in line with the Awareness-Based Self-Compassion Training Booklet for Parents of Children with Autism Spectrum Disorder prepared as training material,"
219711406|NCT05900284|DRUG|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
219128323|NCT05693662|BEHAVIORAL|Session 2|"* Making explanations about the contents of the training sessions to be held with parents,~* Teaching proper breathing techniques,~* Visual demonstration and application of relaxation techniques"
219128324|NCT05693662|BEHAVIORAL|Session 3|"* Breathing break with kindness application,~* Thinking and evaluating how threat, impulse and soothing systems develop in individuals' own lives,~* Safe place application,~* Applying kindness meditation,"
219128325|NCT05693662|BEHAVIORAL|Session 4|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with resistance,~* Kindness meditation: a do-gooder application,~* A hand on the heart application,~* A compassionate companion application,"
219128326|NCT05693662|BEHAVIORAL|Session 5|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,"
219128327|NCT05693662|BEHAVIORAL|Session 6|"* Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,"
219128328|NCT05693662|BEHAVIORAL|Session 7|"* A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,"
219128329|NCT05693662|BEHAVIORAL|Session 8|"* Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,"
219128330|NCT05693662|BEHAVIORAL|Session 9|"* The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,"
219128331|NCT05693662|BEHAVIORAL|Session 10|"* Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye."
219128332|NCT03583437|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
219128333|NCT00790062|DRUG|Oxytocin|See arms
219128334|NCT02365896|PROCEDURE|TLDG or LADG|
219128335|NCT03107702|DIAGNOSTIC_TEST|melatonin|the relationship between melatonin level and analgesia requirement.
219128336|NCT03988062|DEVICE|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
219128337|NCT00886808|DRUG|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
219128338|NCT00073970|DRUG|celecoxib|400mg, given twice daily
219128339|NCT03681691|DRUG|Estradiol patch|transdermal 17β-estradiol patch
219128340|NCT00387062|DEVICE|Computer-based Cognitive Training|
219128341|NCT03983343|DEVICE|exofin®|Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
219128342|NCT06027112|OTHER|musculoskeletal injuries|This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
219128343|NCT00280033|BIOLOGICAL|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
219128344|NCT00280033|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
219128345|NCT00280033|BIOLOGICAL|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
219128346|NCT00280033|DRUG|Placebo|Saline placebo.
219128347|NCT01701154|OTHER|respiratory muscle strength training|
219128348|NCT05392738|DEVICE|I-Stent implantation|I-Stent implantation
219128349|NCT00147355|DRUG|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
219128350|NCT00147355|DRUG|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
219128351|NCT00147355|DRUG|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
219128352|NCT00147355|DRUG|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
219128353|NCT00465751|DRUG|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
219128354|NCT00465751|DRUG|placebo capsules|placebo capsules containing mannitol tid po
219128355|NCT04399707|DEVICE|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
219128356|NCT04399707|DEVICE|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
219128357|NCT02771418|DRUG|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
219128358|NCT02771418|DRUG|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
219128359|NCT02771418|PROCEDURE|Elective carotid endarterectomy|
219128360|NCT06421090|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
219128361|NCT02192034|BEHAVIORAL|Navigation|
219711407|NCT05900284|DRUG|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
219711408|NCT05900284|DRUG|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
219128362|NCT05886751|OTHER|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
219711409|NCT05130827|DRUG|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
219128363|NCT05886751|OTHER|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
219128364|NCT05886751|OTHER|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
219128365|NCT05886751|OTHER|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
219128366|NCT05886751|OTHER|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
219128367|NCT05886751|OTHER|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
219128368|NCT05886751|OTHER|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
219128369|NCT05886751|OTHER|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
219128370|NCT01227642|OTHER|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
219711410|NCT02584296|BEHAVIORAL|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
219128371|NCT01227642|OTHER|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
219128372|NCT01227642|OTHER|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
219128373|NCT05579080|DEVICE|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
219128374|NCT05165030|GENETIC|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
219128375|NCT00507208|DEVICE|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
219128376|NCT00507208|OTHER|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
219128377|NCT01221142|DEVICE|"Cincinnati Sub-Zero, Blanketrol III"|
219128378|NCT02082405|DRUG|bortezomib|Given SC or IV
219128379|NCT02082405|DRUG|cyclophosphamide|Given PO
219128380|NCT02082405|DRUG|dexamethasone|Given PO
219128381|NCT02082405|OTHER|laboratory biomarker analysis|Optional correlative studies
219128382|NCT02082405|OTHER|quality-of-life assessment|Ancillary studies
219128383|NCT00067639|DRUG|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
219711411|NCT04474002|DRUG|4L Klean Prep®|Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
219128384|NCT00067639|PROCEDURE|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
219128385|NCT06581926|OTHER|Behavioral assessment|nutrition knowledge reward-related eating body awareness
219128386|NCT05550480|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
219226427|NCT07099040|BEHAVIORAL|Social support|Psychoeducation will be provided for enrolled participants and their caregivers by Community Resource, Engagement \& Support Team (CREST). Visits from CREST teams will be provided on an ad hoc basis, based on older adult participants' needs and circumstances.
219226428|NCT07099040|BEHAVIORAL|Health coaching|"Health coaching aims to control risk factors of dementia by community nurses (CMNs) and wellbeing coordinators (WBCs). These include addressing chronic conditions and lifestyle aspects (diet, exercise, habits stress management, and sleep). Care recipients are encouraged to proactively manage their health journey and establish Specific, Measurable, Achievable, Relevant, and Time-bound (SMART) goals with the support of WBCs and CMNs. This multi-faceted approach has the potential to not only address older individuals' immediate health concerns but also foster long-term lifestyle changes. The frequency of visits are once or twice a month, depending on recipients' health status and cognitive functions.~Flexible scheduling is based on individual needs and community nurses' usual practice at the Community Health Post at AACs."
219226429|NCT07099040|BEHAVIORAL|Physical Activity|Physical Activity that focuses on improving resistance and balance for care recipients. Physical activity will be conducted 2 times/week at the Active Ageing Centres (AACs) with care recipients for a duration of 1-hour and 1-2 times/week at home.
219226430|NCT07099040|BEHAVIORAL|Cognitive activity|"Cognitive activity will be delivered to enrolled care recipients by Community Resource, Engagement \& Support Team (CREST) and AAC staff. With the incorporation of using SilverPad as part of the cognitive activities, care recipients will undergo 1-hour weekly cognitive activity. Youth volunteers will also be engaged to help facilitate the sessions.~This will be augmented with additional 1-2 times weekly home-based training sessions supervised by caregivers."
219226431|NCT07099625|DEVICE|Adaptive Indoor Rowing Seat|Light weight adjustable indoor rowing seat for Veterans with limited trunk stability.
219226432|NCT07099625|DEVICE|Paddle Sport adaptive seating system|On market comparator (discontinued) adaptive indoor rowing seat for individuals with limited trunk stability.
219226433|NCT07098884|DIAGNOSTIC_TEST|AI model|AI model developed by smartphone photos of resected tumor specimens
219226434|NCT07098897|DRUG|Telitacicept 160mg|Currently monoclonal antibodies, that may affect the main axis of pathogenesis of IgA nephropathy and biological therapy such as Telitacicept, provides a new treatment option and altering or depletion or modulation of Gd-IgA1 producing B cells and plasma cells. At present, Telitacicept are used for clinical treatment in IgA nephropathy patient inside China, but still clear data on safety and effect, and patient's complete remission, repeated relapse data are unclear.
219226435|NCT07098897|DRUG|Corticosteroid|Standard Supportive Care plus Corticosteroid(≤1mg/kg/d) without immunosuppressants
219226436|NCT07098897|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|Drug: ACE Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization Drug: ARB Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization
219226437|NCT07098052|DRUG|HDM2020|FGFR2b-ADC
219226438|NCT07096037|OTHER|Urtica dioica cataplasm|Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.
219711412|NCT04474002|DRUG|1L Klean prep® and 2 sachets Picoprep®|Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
219226439|NCT07096037|OTHER|Placebo|Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.
219226440|NCT07096037|DRUG|Vitamin D|Participants will receive oral vitamin D.
219128387|NCT02575235|DRUG|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
219128388|NCT02575235|DRUG|placebo|Control group takes the placebo for the same period.
219128389|NCT04096157|DRUG|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
219128390|NCT04096157|DRUG|Isavuconazonium sulfate capsules|Oral
219128391|NCT01989637|DIETARY_SUPPLEMENT|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
219128392|NCT01989637|DIETARY_SUPPLEMENT|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
219128393|NCT00343798|DRUG|cyclophosphamide|Given IV
219128394|NCT00343798|DRUG|fludarabine phosphate|Given IV
219128395|NCT00343798|DRUG|cyclosporine|Given IV
219128396|NCT00343798|DRUG|mycophenolate mofetil|Given IV or PO
219128397|NCT00343798|OTHER|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
219226441|NCT07096037|BEHAVIORAL|Resting conditions|Reduction in physical activity based on orthopedic advice.
219226442|NCT07099937|OTHER|Observational cross-sectional study with no intervention.|"This study does not involve any intervention. It is a cross-sectional observational study. The term intervention here refers to laboratory investigations and clinical assessments conducted as part of data collection only."
219711413|NCT06420908|DRUG|Adebrelimab+TP/FP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
219128398|NCT00343798|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
219128399|NCT00343798|PROCEDURE|biopsy|Optional correlative studies
219128400|NCT00343798|OTHER|immunologic technique|Correlative studies
219128401|NCT00343798|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219128402|NCT03881358|DEVICE|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
219128403|NCT03881358|DEVICE|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
219128404|NCT06026358|DRUG|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
219128405|NCT04680702|DIAGNOSTIC_TEST|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
219128406|NCT04471987|DRUG|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
219128407|NCT04471987|DRUG|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
219128408|NCT05650294|DIETARY_SUPPLEMENT|PL+ omega 3 fatty acids|PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
219128409|NCT05650294|DIETARY_SUPPLEMENT|FO EE fatty acids|A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
219128410|NCT01373047|BIOLOGICAL|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
219711414|NCT06420908|DRUG|Adebrelimab+FP/TP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
219711415|NCT05374460|BEHAVIORAL|Explanatory diagram|Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
219711416|NCT05374460|BEHAVIORAL|Direct vision|Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.
219711417|NCT05374460|BEHAVIORAL|Movement feedback, target hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
219711418|NCT05374460|BEHAVIORAL|Movement feedback, pointing hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.
219128411|NCT01883765|BEHAVIORAL|Neurofeedback active|
219128412|NCT01883765|BEHAVIORAL|Neurofeedback sham|
219128413|NCT01883765|BEHAVIORAL|Metacognitive Training|
219711419|NCT05374460|BEHAVIORAL|No movement feedback|The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.
219128414|NCT04038281|OTHER|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
219128415|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
219128416|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
219128417|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
219128418|NCT02742051|DRUG|Everolimus|Neoadjuvant endocrine therapy
219128419|NCT02742051|DRUG|Letrozole|Neoadjuvant endocrine therapy
219128420|NCT02742051|DRUG|Fluorouracil|Neoadjuvant chemotherapy
219128421|NCT02742051|DRUG|Epirubicin|Neoadjuvant chemotherapy
219128422|NCT02742051|DRUG|Cyclophosphamide|Neoadjuvant chemotherapy
219128423|NCT01781910|DIETARY_SUPPLEMENT|Branched Chain Amino Acid drink supplement|
219128424|NCT01781910|DIETARY_SUPPLEMENT|Placebo|
219128425|NCT06118619|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
219128426|NCT05127395|OTHER|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
219128427|NCT05087238|BEHAVIORAL|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
219128428|NCT05284058|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
219128429|NCT05357196|DRUG|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
219128430|NCT02527889|OTHER|Exercise training|8-week resistive exercise training
219128431|NCT00257816|DRUG|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
219128432|NCT00257816|DRUG|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
219128433|NCT02312440|DRUG|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
219128434|NCT02312440|DRUG|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
219128435|NCT02312440|DRUG|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
219711420|NCT05374460|BEHAVIORAL|Attend to the targets|Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
219711421|NCT00620542|DRUG|Rosuvastatin|capsule, oral, once daily
219711422|NCT00620542|DRUG|Atorvastatin|capsule, oral, one daily
219711423|NCT01582347|DRUG|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
219128436|NCT01853358|BIOLOGICAL|NK Cell infusion|"* level 1: 1 x 10e6 NK cells /kg;~* level 2: 5 x 10e6 NK cells /kg;~* level 3: \> 5.10e6 and ≤ 5.10e7 cellules NK/kg"
219128437|NCT05009485|DEVICE|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
219128438|NCT01582243|DRUG|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
219711424|NCT01582347|DRUG|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
219711425|NCT01582347|DRUG|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
219711426|NCT01582347|DRUG|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
219711427|NCT02208440|PROCEDURE|Best Repair of torn Rotator Cuff|
219711428|NCT02208440|DEVICE|InSpace™ system|
219711429|NCT02353663|OTHER|Echocardiography|Echocardiography examination
219711430|NCT01359423|DRUG|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
219128439|NCT01805323|DRUG|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
219128440|NCT05823987|DRUG|H101|a modified human recombinant type 5 adenovirus with genetic modifications
219128441|NCT05823987|DRUG|Tislelizumab|a PD-1 immune check inhibitor
219128442|NCT05823987|DRUG|Lenvatinib|Lenvatinib capsules
219711431|NCT01359423|DRUG|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
219711432|NCT00432120|DRUG|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
219711433|NCT01348269|DRUG|Aclasta|1 x intravenous non-current drip (infusion)
219711434|NCT01348269|DRUG|Placebo|NaCl Solution
219711435|NCT05690243|BEHAVIORAL|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
219711436|NCT04727749|BEHAVIORAL|Therapy Dog Team Visit|For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
219711437|NCT02827968|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
219128443|NCT03354533|DRUG|L-fucose|Oral ORL-1F
219128444|NCT02967666|RADIATION|FDG ligand|
219128445|NCT02967666|RADIATION|DOTANOC ligand|
219128446|NCT02896608|DEVICE|measure of neuronal excitability|
219128447|NCT02747264|DEVICE|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
219711438|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219711439|NCT05229588|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
219711440|NCT03575364|DEVICE|ClotTriever|Thrombectomy
219711441|NCT04849741|DRUG|zilganersen|zilganersen will be administered by ITB injection.
219711442|NCT04849741|DRUG|Placebo|zilganersen-matching placebo will be administered by ITB injection.
219711443|NCT00977145|BIOLOGICAL|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
219711444|NCT01577121|DRUG|indomethacin|50 mg / 6 hours during 5 days
219711445|NCT01577121|DRUG|placebo|50 mg / 6 hours during 5 days
219128448|NCT04198961|OTHER|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
219128449|NCT03404609|DEVICE|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
219128450|NCT01441778|DRUG|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
219128451|NCT01441778|DRUG|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
219128452|NCT02931162|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
219128453|NCT02931162|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
219128454|NCT02507310|OTHER|thermostat|ambient temperature as modified by thermostat
219128455|NCT00240643|DRUG|SB424323|
219128456|NCT04827225|BEHAVIORAL|questionnaires|Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
219128457|NCT05905289|OTHER|observational study|no intervention as it is an observational study
219128458|NCT06183047|DIAGNOSTIC_TEST|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
219128459|NCT03931603|OTHER|MRI|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
219128460|NCT00618358|DEVICE|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
219128461|NCT00618358|OTHER|Gelfoam/Thrombin|
219711446|NCT00448045|BEHAVIORAL|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
219711447|NCT00448045|BEHAVIORAL|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
219711448|NCT04115722|OTHER|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
219711449|NCT06635447|DRUG|Capivasertib|400 mg, oral, twice daily; 4 days on and 3 days off
219711450|NCT06635447|DRUG|Fulvestrant|Fulvestrant IV
219711451|NCT05123924|OTHER|Evaluation of respiratory capacity, respiratory muscle strength and fatigue|"The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time."
219711452|NCT05972135|DRUG|Teclistamab|Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
219711453|NCT05972135|DRUG|Talquetamab|Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
219711454|NCT05972135|DRUG|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
219711455|NCT04391907|PROCEDURE|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
219711456|NCT05508906|DRUG|Palazestrant|Complete estrogen receptor antagonist (CERAN)
219711457|NCT05508906|DRUG|Ribociclib|All subjects in Treatment Group 1 will receive palazestrant in combination with ribociclib.
219711458|NCT05508906|DRUG|Alpelisib|All subjects in Treatment Group 2 will receive palazestrant in combination with alpelisib.
219711459|NCT05508906|DRUG|Everolimus|All subjects in Treatment Group 3 will receive palazestrant in combination with everolimus.
219128462|NCT04612595|OTHER|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
219128463|NCT02955862|OTHER|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
219128464|NCT05717985|PROCEDURE|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
219128465|NCT05717985|PROCEDURE|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
219128466|NCT06371482|DRUG|Durvalumab|Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.
219128467|NCT06371482|DRUG|Chemotherapy drug of EP regimen|"Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks."
219128468|NCT06371482|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
219128469|NCT06121570|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
219128470|NCT06121570|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219711460|NCT01319370|DRUG|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
219711461|NCT01319370|DRUG|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
219128471|NCT06121570|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219128472|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
219128473|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
219128474|NCT06121570|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
219128475|NCT06121570|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
219128476|NCT06121570|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
219128477|NCT06121570|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
219128478|NCT04921761|PROCEDURE|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
219128479|NCT04921761|PROCEDURE|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
219128480|NCT00498537|DRUG|spironolactone|
219128481|NCT01928940|DRUG|dabrafenib|150 mg twice daily
219128482|NCT01928940|DRUG|trametinib|2 mg once daily
219711462|NCT05733689|COMBINATION_PRODUCT|FLOT|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
219711463|NCT05733689|COMBINATION_PRODUCT|FOLFOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
219711464|NCT05733689|COMBINATION_PRODUCT|FOLFIRI|"* Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
219711465|NCT05733689|COMBINATION_PRODUCT|FOLFIRINOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
219711466|NCT05733689|COMBINATION_PRODUCT|PACLITAXEL with or without CARBOPLATIN|"* Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~\- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
219711467|NCT05733689|COMBINATION_PRODUCT|DOCETAXEL and IRINOTECAN (alone or combined)|"* Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
219128483|NCT03054220|DRUG|Dextromethorphan 5 MG|
219128484|NCT03054220|DRUG|Tramadol 10 mg|
219128485|NCT03054220|DRUG|Duloxetine 60mg|
219128486|NCT03054220|DRUG|Paroxetine 20 mg|
219128487|NCT02954055|DRUG|Paclitaxel|Arm A
219128488|NCT02954055|DRUG|Cyclophosphamide|Arm B
219128489|NCT02954055|DRUG|Capecitabine|Arm B
219128490|NCT02954055|DRUG|Vinorelbine|Arm B
219128491|NCT06456931|BEHAVIORAL|Traditional Buddhist mindfulness|Details are provided in the arm/group descriptions.
219128492|NCT06456931|BEHAVIORAL|secular mindfulness based cognitive therapy|Details are provided in the arm/group descriptions.
219128493|NCT03063307|PROCEDURE|Atraumatic Restorative Treatment|
219128494|NCT03063307|OTHER|Silver Diamine Fluoride|
219128495|NCT01363479|DRUG|Oral palonosetron|
219128496|NCT01363479|DRUG|I.V. palonosetron|
219128497|NCT01363479|DRUG|Dexamethasone|
219128498|NCT06416280|OTHER|Assessment of the TRiP(cast) score|"In patients presenting to the emergency department with trauma to a lower limb, the TRiP(cast) score is assessed in accordance with the recommendations. If the patient does not object. The attending physician will then be asked to fill in his implicit assessment of the risk of venous thromboembolism on a paper CRF and then to complete his assessment of the TRiP(cast) score. He will then be free to decide whether or not to anticoagulate the patient.~At the same time, a doctor not involved in the patient's care will assess the TRiP(cast) score and record it on a paper CRF. The second doctor's assessment will be independent and will have no impact on the patient's management.~The CRFs will then be analysed and stored. Data will be anonymised during data collection and each patient will be assigned an anonymity number."
219128499|NCT00363285|BIOLOGICAL|gonadotrophin releasing hormone|
219128500|NCT00363285|DRUG|cyproterone acetate|
219226443|NCT07098637|BEHAVIORAL|Self-Compassionate Mindfulness Psychoeducation Program|"The researcher completed the internationally accredited institutional and practical training program titled All About Compassion in 12 Weeks: A Thousand Faces of Compassion, offered by the School of Compassion. Expert opinions were sought from the planning phase of the study for the content of the program, which was designed by the researchers. In developing the content of the Self-Compassionate Mindfulness Psychoeducation Program for Delinquent Adolescents, the opinions of three academic faculty members were consulted. Based on the suggestions received, the session titles of the psychoeducation program were determined as follows:~1. Holding Our Own Hand: Discovering Self-Compassion~2. Discovering Awareness of Thought~3. Understanding Pain, Approaching with Compassion~4. Facing Reality: Acceptance~5. Calm Waters: Forgiveness~6. Moving Forward, Farewell, and a New Beginning."
219226444|NCT07098065|BEHAVIORAL|Graphical health warnings|This group will receive only graphical health warnings (GHWs) featuring images proposed by the Bangladesh Tobacco Control Cell, explicitly illustrating smoking-related harms, such as mouth diseases, damaged teeth and gums, lung diseases and cancer, heart diseases and cardiovascular damage, and throat and oral cancer. Additionally, these warnings will clearly highlight the benefits of quitting smoking-including improved overall health, reduced disease risks, financial savings, and enhanced quality of life-as well as practical cessation techniques. Participants will receive these GHW materials at baseline and again at the six-month follow-up to reinforce these critical health messages; however, this intervention group will not receive any counselling services. Monthly SMS reminders will also be sent to participants, prompting them to review the GHW leaflet and reinforcing the negative health impacts of smoking and the benefits of quitting.
219226445|NCT07098065|BEHAVIORAL|Graphical health warnings plus pharmacist-led counselling|Participants in this group will receive graphical health warnings (GHWs) featuring Bangladesh Tobacco Control Cell-approved images clearly depicting smoking-related harms (e.g., mouth diseases, damaged teeth and gums, lung cancer, heart disease, and oral cancer). Additionally, they will receive personalized counselling from community pharmacists, focused on the specific health and financial benefits of quitting, practical cessation techniques, strategies for overcoming barriers, and relapse prevention. This combined intervention will be provided at baseline and reinforced at a six-month follow-up. Monthly SMS reminders will also be sent, reinforcing key messages on the harmful effects of smoking and benefits of cessation.
219226446|NCT07098065|OTHER|Routine pharmacy services (no intervention)|Participants in this group will receive only routine pharmacy services based on standard pharmacy practice guidelines applicable in each country. They will not receive any additional graphical health warnings or counselling interventions. Outcomes will be assessed at baseline, 6 months, and 12 months, consistent with the intervention groups.
219226447|NCT06910956|OTHER|CXR-LC|Alert to provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool.
219128501|NCT00363285|PROCEDURE|quality-of-life assessment|
219128502|NCT06459661|OTHER|Diet|Intake of unrefined, intact plant foods
219128503|NCT03084861|DRUG|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
219128504|NCT03084861|DRUG|Conventional treatment|"1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day"
219128505|NCT01119703|BIOLOGICAL|Tetanus & Diphtheria booster vaccine (Td)|Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
219128506|NCT01119703|BIOLOGICAL|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
219128507|NCT01119703|BIOLOGICAL|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
219128508|NCT04623723|OTHER|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
219128509|NCT04623723|OTHER|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
219128510|NCT00438906|PROCEDURE|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
219128511|NCT00438906|DRUG|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
219128512|NCT02923128|DRUG|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
219128513|NCT02923128|DRUG|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
219128514|NCT02923128|DRUG|Saline|Saline is used to dilute other drugs
219128515|NCT03178201|DRUG|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
219128516|NCT04517994|BEHAVIORAL|Active Treatment|See arm description.
219128517|NCT04517994|BEHAVIORAL|Supportive Treatment|See arm description.
219711468|NCT05733689|DRUG|NIVOLUMAB (alone or when added to a regimen above)|"* 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days"
219711469|NCT05733689|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|"* 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days"
219711470|NCT05733689|DRUG|Durvalumab|\- 1500 mg IV on Day 1 every 28 days
219711471|NCT05733689|DRUG|Trastuzumab|"* 8 mg/kg on Day 1, then 6 mg/kg IV every 21 days, or~* 6 mg/kg on Day 1, then 4 mg/kg IV every 14 days"
219711472|NCT02724579|DRUG|Cisplatin|Given IV
219128518|NCT04069546|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
219128519|NCT00205894|DEVICE|bion microstimulator|
219128520|NCT05647356|DRUG|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
219128521|NCT00846781|DRUG|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
219128522|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
219128523|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
219128524|NCT00438425|DIETARY_SUPPLEMENT|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
219128525|NCT02550054|DRUG|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
219226448|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
219226449|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
219711473|NCT02724579|DRUG|Cyclophosphamide|Given IV
219711474|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
219711475|NCT02724579|DRUG|Lomustine|Given PO
219711476|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219711477|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
219711478|NCT02724579|DRUG|Vincristine|Given IV or via minibag
219711479|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
219711480|NCT06641869|DIETARY_SUPPLEMENT|procyanidin C1|Proprietarily extracted procyanidin C1
219711481|NCT06641869|DIETARY_SUPPLEMENT|Placebo|Placebo
219711482|NCT06641869|DIETARY_SUPPLEMENT|PCC1 complex|5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.
219711483|NCT06582433|OTHER|Intervention|"1. Process: implementation of pre-tests~2. Process: Solution-focused counseling, 60 minutes once a week for a total of 6 sessions~3. Final test after 2 months"
219711484|NCT05472142|OTHER|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
219711485|NCT05472142|OTHER|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
219711486|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
219711487|NCT00107289|DRUG|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year. Once patients are off treatment on this protocol, they will begin long term follow up through 5 years from enrollment."
219711488|NCT05096715|DRUG|Atezolizumab|Intravenous Infusion
219711489|NCT05096715|DRUG|Bevacizumab|Intravenous Infusion
219711490|NCT05096715|RADIATION|Stereotactic body radiation therapy (SBRT)|External Beam Radiation
219711491|NCT01697579|DRUG|Fosaprepitant|Administered intravenously (IV) as a single dose
219711492|NCT01697579|DRUG|Fosaprepitant Placebo|Administered IV as a single dose
219711493|NCT01697579|DRUG|Ondansetron|Administered IV according to local labeling and/or local standard of care
219711494|NCT01697579|DRUG|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
219711495|NCT02452190|DRUG|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
219128526|NCT02550054|DRUG|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
219128527|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
219128528|NCT01121874|PROCEDURE|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
219128529|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
219128530|NCT03127345|DRUG|Omegaven|Intravenous omega 3 fatty acid administration
219128531|NCT03127345|DRUG|Intralipid|Standard of care
219128532|NCT00263679|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus and pertussis|
219128533|NCT06339905|PROCEDURE|Sonic Activation with EndoActivator|sonic activation
219128534|NCT06339905|PROCEDURE|Control Needle Irrigation|control group
219711496|NCT02452190|DRUG|Placebo|Matching Placebo
219711497|NCT03159637|PROCEDURE|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
219128535|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
219128536|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm OFF|
219128537|NCT06280729|OTHER|AI-Analyis|The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
219128538|NCT02763553|DIETARY_SUPPLEMENT|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
219128539|NCT02763553|DIETARY_SUPPLEMENT|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
219128540|NCT03061344|BIOLOGICAL|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
219128541|NCT00598013|DRUG|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
219128542|NCT01270789|DRUG|Liraglutide|Liraglutide administered as once daily sc injection
219128543|NCT01270789|DRUG|placebo|placebo administered as once daily sc injection
219128544|NCT03693755|PROCEDURE|In-plane Group|Placement of femoral nerve catheter under ultrasound control
219711498|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
219711499|NCT01044498|DRUG|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
219711500|NCT01044498|DRUG|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
219711501|NCT00767871|DRUG|Lexapro|12 week treatment with lexapro
219711502|NCT04593602|BEHAVIORAL|Early Mobilization|Nurse-driven early mobilization activities twice daily
219711503|NCT04593602|BEHAVIORAL|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
219711504|NCT04361175|DRUG|Letrozole|Each group will be followed up for ovulation by day 12 ovulation monitoring by Transvaginal ultrasound for mature griffian follicle and measure endometrial thickness and volume then day 21 test serum progesterone level to confirm ovulation and if pregnancy occurred confirm by serum pregnancy test at day 35 of the cycle and follow pregnancy till confirmed by fetal pulsation by ultrasound.
219711505|NCT04361175|DRUG|Clomiphine Citrate|Clomiphine Citrate
219711506|NCT06052124|DEVICE|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
219711507|NCT00820534|DRUG|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
219711508|NCT00820534|DRUG|Placebo|Placebo every 2 hous during waking hours for 96 hours
219226450|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
219226451|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
219226452|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
219226453|NCT04181788|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
219226454|NCT06831227|DEVICE|High power Laser Therapy|"A total course protocol: 18 sessions, for 6 weeks ,3 sessions per week. Patients will receive High power Laser treatment. manually set to bio stimulation mode with high peak power (5 - 6 W), energy per impulse 150 mJ/c2, wavelength measuring 1064 nm, and spot beam diameter area of 1 cm2.~The hand piece was positioned in contact with and perpendicular to the treated area with the patient inside lying position with knee to chest. Scanning will perform transversely and longitudinally paravertebral region on the lower lumbar area at the level of the disc concerned. Each session included three phases (fast scan, sensitive trigger points, slow scan) and had a total duration of 20 minutes. During each session, a total energy of 3000 J was applied through three phases of treatment."
219226455|NCT06831227|DEVICE|physical therapy exercise program and hot pack|this group will receive the same selected physical therapy exercise program (45 minutes) and hot pack (10 min) for 18 session. All patients will attend the physical therapy clinic three times weekly for 6 weeks
219128545|NCT03693755|PROCEDURE|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
219128546|NCT01567059|DRUG|tosedostat|Given PO
219128547|NCT01567059|DRUG|cytarabine|Given IV
219128548|NCT01567059|DRUG|decitabine|Given IV
219128549|NCT01594060|DRUG|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
219128550|NCT01594060|DRUG|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
219128551|NCT04216303|DIAGNOSTIC_TEST|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
219128552|NCT02282527|BIOLOGICAL|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
219128553|NCT02282527|BIOLOGICAL|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
219128554|NCT00941031|DRUG|AIN457|
219128555|NCT00941031|DRUG|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
219128556|NCT00941031|DRUG|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
219128557|NCT00941031|DRUG|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
219128558|NCT01872611|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|
219128559|NCT01872611|OTHER|Vehicle|Inactive ingredients used as placebo comparator
219128560|NCT01872611|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
219128561|NCT03645356|DEVICE|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
219128562|NCT03645356|DEVICE|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
219128563|NCT00276328|DRUG|Diosmectite (Smecta®)|
219128564|NCT01090609|DEVICE|Stent implantation|Stent implantation
219128565|NCT04750629|DEVICE|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
219128566|NCT05191251|DIAGNOSTIC_TEST|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
219128567|NCT06226987|DIAGNOSTIC_TEST|68Ga-DOTATATE PET/MRI|PET/MRI scanning
219128568|NCT00631917|DRUG|Aliskiren|Aliskiren 300 mg once a day
219128569|NCT00631917|DRUG|Ramipril|Ramipril 10 mg once a day
219128570|NCT00631917|OTHER|Placebo to Ramipril|Placebo capsules to match ramipril.
219128571|NCT00631917|OTHER|Placebo to Aliskiren|Placebo tablets to match aliskiren.
219128572|NCT01954940|DEVICE|Whole Body Vibration Therapy|
219128573|NCT03433261|DIETARY_SUPPLEMENT|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
219128574|NCT00145535|DEVICE|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, \~50 spots over 180°
219128575|NCT00145535|DEVICE|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, \~50 spots over 180°
219128576|NCT01167036|DEVICE|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
219128577|NCT01167036|OTHER|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
219128578|NCT06183710|BEHAVIORAL|Contingency management|Psychosocial intervention
219128579|NCT06389318|DRUG|buccal midazolam +oral placebo syrup|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
219128580|NCT06389318|DRUG|oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
219128581|NCT05481294|OTHER|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
219128582|NCT05481294|OTHER|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
219128583|NCT05650333|DRUG|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
219711509|NCT05679505|DEVICE|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
219711510|NCT04528498|OTHER|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
219128584|NCT06518837|DRUG|Tirzepatide|The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
219128585|NCT03703479|OTHER|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
219128586|NCT04795089|PROCEDURE|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
219128587|NCT03677947|BEHAVIORAL|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
219128588|NCT03677947|OTHER|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
219128589|NCT02271607|DEVICE|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
219128590|NCT06200636|DEVICE|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
219128591|NCT02616263|OTHER|Foot exercise|
219128592|NCT02616263|OTHER|Shoulder exercise|
219128593|NCT04805346|DEVICE|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
219128594|NCT06631599|OTHER|Physical training|The intervention consisted of physical exercise according to various protocols
219128595|NCT02098031|OTHER|Improving nutrition knowledge among mothers|
219128596|NCT06570551|DEVICE|i3 CGM(continuous glucose monitor)|The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.
219128597|NCT03298113|DEVICE|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
219128598|NCT03298113|DEVICE|IAD Hospital Standard Care|Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
219128599|NCT06546696|BEHAVIORAL|Competency Based Approaches to Community Health (COACH)|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
219128600|NCT02939183|DRUG|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
219128601|NCT02939183|DRUG|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
219128602|NCT02939183|DRUG|Dexamethasone|Dexamethasone
219128603|NCT02939183|DRUG|Pomalidomide|Pomalidomide
219711511|NCT04467489|OTHER|observational|There is no intervention for any group in this observational study.
219711512|NCT06138275|DRUG|Elranatamab|subcutaneous (under the skin) injection
219711513|NCT04716998|BIOLOGICAL|MesenCure|Three administrations of MesenCure in addition to standard care
219128604|NCT05096117|DRUG|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
219128605|NCT05096117|DRUG|Placebo|1 x per day for 6 weeks
219128606|NCT06122935|DEVICE|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
219128607|NCT06122935|DEVICE|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
219128608|NCT05896306|OTHER|No intervention|No intervention
219128609|NCT05962125|OTHER|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
219711514|NCT06277063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The vagus nerve's auricular branch is primarily distributed in the tragus, tragus sulcus, and concha cavity. It can activate the nucleus tractus solitarius through the vagus afferent fibers, thereby activating various areas of the vagus nerve in the central nervous system. This stimulation technique involves applying a constant current of around 2-3mA to the epidermal terminals of the ear using an electrode. It aims to regulate the vagus nerve, modulate the autonomic nervous system, release neurotransmitters, improve cerebral blood flow, and alleviate headache symptoms. In the implementation, non-invasive transcutaneous vagus nerve stimulation was performed by having the subject wear a vagus stimulator and adjusting the appropriate stimulation intensity.
219711515|NCT06121011|BIOLOGICAL|Cipaglucosidase alfa|Enzyme Replacement Therapy (ERT) via intravenous infusion
219711516|NCT06121011|DRUG|Miglustat|Participants received ATB200 co-administered with AT2221 (Miglustat)
219711517|NCT06121011|BIOLOGICAL|Alglucosidase alfa or Avalglucosidase alfa|Patients prescribed other commercially available ERT after local regulatory approval
219711518|NCT06121011|OTHER|Untreated|Patients who are not currently receiving any medical therapy for Pompe disease.
219711519|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
219711520|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
219128610|NCT05962125|OTHER|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
219128611|NCT04001114|COMBINATION_PRODUCT|Sampling Research Cigarettes|Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
219128612|NCT06041997|BEHAVIORAL|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
219128613|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
219128614|NCT05683262|PROCEDURE|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
219128615|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
219128616|NCT00003957|BIOLOGICAL|filgrastim|
219128617|NCT00003957|BIOLOGICAL|recombinant human stem cell factor|
219128618|NCT00003957|DRUG|cyclophosphamide|
219128619|NCT00003957|DRUG|cytarabine|
219128620|NCT00003957|DRUG|etoposide|
219128621|NCT00003957|DRUG|melphalan|
219128622|NCT00003957|DRUG|mitoxantrone hydrochloride|
219128623|NCT00003957|DRUG|paclitaxel|
219128624|NCT00003957|PROCEDURE|peripheral blood stem cell transplantation|
219128625|NCT01446003|DRUG|MK-8457|10 x 10-mg capsule BID for 10 days
219128626|NCT01446003|DRUG|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
219128627|NCT00318656|DRUG|rosiglitazone-metformin fixed dose combination|
219128628|NCT00318656|DRUG|metformin + glimepiride|
219128629|NCT05498311|RADIATION|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
219128630|NCT05498311|PROCEDURE|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
219128631|NCT05498311|RADIATION|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
219128632|NCT03356015|DRUG|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
219128633|NCT03356015|DRUG|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
219128634|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
219711521|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
219711522|NCT04002180|DRUG|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
219711523|NCT03401398|DRUG|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
219711524|NCT03401398|DRUG|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
219711525|NCT04980794|BEHAVIORAL|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
219711526|NCT04980794|BEHAVIORAL|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
219711527|NCT03968406|OTHER|Quality-of-Life Assessment|Ancillary studies
219711528|NCT03968406|RADIATION|Radiation Therapy|Undergo radiation therapy
219711529|NCT03968406|DRUG|Talazoparib|Given PO
219711530|NCT06199726|BEHAVIORAL|REFLECT web-based tool|Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
219711531|NCT05287113|DRUG|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
219711532|NCT05287113|DRUG|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
219711533|NCT05287113|DRUG|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
219711534|NCT05287113|DRUG|Placebo|Placebo will be administered intravenously.
219711535|NCT00181025|DRUG|Tasonermine (TNFa)|
219711536|NCT00181025|DRUG|Melphalan|
219711537|NCT04038424|OTHER|Art therapy|Art therapy including coloring, painting and listening to music
219711538|NCT04705831|DRUG|Ruconest|C1 Esterase Inhibitor
219711539|NCT06566118|DEVICE|Auricular Vagus Nerve Stimülation|After exercise loading, active ear VSS was applied to Group 1. Application was made simultaneously in both ears, with a 300 microsecond pulse duration, a biphasic asymmetric waveform, and a frequency of 25 Hz, for a total of 20 minutes. All assessments were recorded 3 times: at the beginning of the test, after exercise loading, and after active VSS application.
219711540|NCT06566118|DEVICE|Sham Auricular Vagus Nerve Stimülation|After the exercise challenge, Group 2 underwent sham VSS. Device parameters were set to the same as Group 1 (300 microsecond pulse duration, biphasic asymmetric waveform, and 25 Hz frequency). Both headphones were worn for a total of 20 minutes. However, the participant heard only the device's power-on tone and received no current. All assessments were recorded three times: at the beginning of the test, after the exercise challenge, and after sham VSS.
219711541|NCT06220435|RADIATION|Ultra-hypofractionated radiotherapy regimen.|"* Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions"
219711542|NCT06374550|BEHAVIORAL|Jump Start on the Go|Centers will receive the Jump Start On The Go mental health program via a mobile app. This will entail receiving 12-24 mental health consultation sessions in which a licensed mental health consultant will use a mobile app that will provide directors and teachers with access to information such as videos, infographics, and an Artificial Intelligence Chatbot on how to work with children with challenging behaviors. Participants will receive the intervention once per week for up to 1 hour.
219711543|NCT06374550|BEHAVIORAL|Jump Start Plus Coronavirus Support|The Jump Start Plus Coronavirus Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
219128635|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
219128636|NCT03905135|BIOLOGICAL|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
219128637|NCT01102296|BIOLOGICAL|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
219128638|NCT03888911|DIETARY_SUPPLEMENT|High dose IQP-LU-104 (5120mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
219128639|NCT03888911|DIETARY_SUPPLEMENT|Low dose IQP-LU-104 (2560mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
219128640|NCT03888911|DIETARY_SUPPLEMENT|Placebo|1 sachet to be taken 2 times daily orally, together with 2 main meals
219128641|NCT02138513|BEHAVIORAL|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
219128642|NCT05457361|DRUG|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
219128643|NCT05457361|DRUG|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
219128644|NCT03533855|DIAGNOSTIC_TEST|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
219128645|NCT02919085|PROCEDURE|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
219128646|NCT05577962|DRUG|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
219128647|NCT00490555|DRUG|Testosterone gel|Testosterone gel 10 g
219128648|NCT00490555|DRUG|Dutasteride|dutasteride 0.5 mg orally
219128649|NCT00490555|DRUG|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
219128650|NCT00490555|OTHER|Placebo Testosterone gel|Place gel applied daily for 12 weeks
219128651|NCT00490555|OTHER|Placebo dutasteride|placebo pill for 12 weeks
219128652|NCT00490555|OTHER|Placebo DMPA|placebo DMPA injection Once
219128653|NCT03782038|DEVICE|MCD|Micro coring skin removal with automated coring device
219128654|NCT03313089|BEHAVIORAL|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
219128655|NCT06061484|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
219128656|NCT06061484|DRUG|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
219128657|NCT02185664|PROCEDURE|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
219128658|NCT02185664|DEVICE|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
219128659|NCT00671463|PROCEDURE|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
219128660|NCT02540941|OTHER|non|
219128661|NCT02806895|DRUG|JZP-110|
219128662|NCT02806895|DRUG|Placebo|
219128663|NCT00568503|DRUG|QAX028|
219128664|NCT00568503|DRUG|Placebo|
219128665|NCT00568503|DRUG|Tiotropium bromide|
219128666|NCT00568503|DRUG|QAX028|
219128667|NCT00568503|DRUG|QAX028|
219128668|NCT02949648|DEVICE|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
219128669|NCT04071522|OTHER|no intervention|no intervention
219128670|NCT03222284|DEVICE|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
219128671|NCT01890161|DRUG|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
219128672|NCT01890161|DRUG|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
219128673|NCT02042443|DRUG|Capecitabine|Given PO
219128674|NCT02042443|DRUG|Fluorouracil|Given IV
219128675|NCT02042443|OTHER|Laboratory Biomarker Analysis|Correlative studies
219128676|NCT02042443|DRUG|Leucovorin Calcium|Given IV
219128677|NCT02042443|DRUG|Trametinib|Given PO
219128678|NCT00272285|DRUG|Ramosetron|IV, concomitant administration with dexamethasone
219128679|NCT00272285|DRUG|Granisetron|IV, concomitant administration with dexamethasone
219128680|NCT03000712|BIOLOGICAL|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
219128681|NCT02897284|BEHAVIORAL|Mindfulness 8 weeks|8 sessions of mindfulness
219128682|NCT02897284|BEHAVIORAL|Mindfulness 2 weeks|2 sessions of mindfulness
219226456|NCT04886960|BIOLOGICAL|Amniotic Fluid Injection|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
219226457|NCT04886960|OTHER|Standard of Care|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
219711544|NCT05238675|DRUG|BI 1291583|BI 1291583
219128683|NCT05350436|BEHAVIORAL|Balance Conditions|"Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
219128684|NCT05350436|BEHAVIORAL|Singing|"Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21"
219128685|NCT03106376|OTHER|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
219128686|NCT03106376|OTHER|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
219128687|NCT02112929|DRUG|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
219128688|NCT06100029|DRUG|Lavender|The lavender aroma (L. angustifolia ssp. Angustifolia) is provided by Pranarom International, Ghislenghien, Belgium. Lavender aroma will be contained in a 10 ml glass bottle with a drop stopper and place the bottle within 20 cm of the patient's pillow so that the aroma can reach the patient. The entire course of treatment lasts 5 days.
219128689|NCT06100029|BEHAVIORAL|A2F bundle|A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
219711545|NCT05238675|DRUG|Placebo|Placebo
219128690|NCT00205530|BEHAVIORAL|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
219128691|NCT04357418|OTHER|it is a survey|this interview can be carried out face to face or remotely.
219128692|NCT02735187|DEVICE|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
219128693|NCT02735187|DRUG|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
219128694|NCT03595943|DIETARY_SUPPLEMENT|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
219128695|NCT03595943|DIETARY_SUPPLEMENT|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
219128696|NCT01105572|DEVICE|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
219128697|NCT01105572|OTHER|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
219128698|NCT03049436|OTHER|Program of adapted physical activity|
219128699|NCT01007149|DRUG|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
219128700|NCT01007149|DRUG|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
219128701|NCT00431795|DRUG|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
219128702|NCT00431795|DRUG|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
219128703|NCT01913340|DRUG|Erythropoietin|1000 U/kg/dose IV x 5 doses
219128704|NCT01913340|DRUG|Normal saline|placebo: NS IV x 5 doses
219128705|NCT02784704|DRUG|Eravacycline|
219128706|NCT02784704|DRUG|Meropenem|
219711546|NCT06176235|DRUG|Teriflunomide|Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.
219711547|NCT06176235|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
219711548|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
219711549|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
219711550|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219711551|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
219711552|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control 6.1|Participants will use their Placebo Control 6.1 as directed for a period of 6 weeks.
219711553|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 6.1 Usage|Participants will use their Radicle Calm Active Study Product 6.1 as directed for a period of 6 weeks.
219128707|NCT02784704|DRUG|Placebo|
219128708|NCT01403792|DRUG|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
219128709|NCT05398120|BEHAVIORAL|Skills Group|Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
219128710|NCT00793806|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
219128711|NCT03620929|DRUG|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
219128712|NCT05946746|DIETARY_SUPPLEMENT|PeptiStrong|PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.
219128713|NCT05946746|DIETARY_SUPPLEMENT|Placebo SMCC silicated micro-crystalline cellulose|Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
219128714|NCT02320253|BEHAVIORAL|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
219128715|NCT02320253|BEHAVIORAL|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
219128716|NCT02320253|BEHAVIORAL|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
219128717|NCT01235585|DRUG|Placebo|Oral doses, once a day for 52 weeks
219128718|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
219128719|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
219128720|NCT05425797|OTHER|In-Person Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place in-person at the PP's office.
219128721|NCT05425797|OTHER|Video-Call Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place virtually via a secure video system.
219128722|NCT05425797|OTHER|Phone Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place via telephone.
219128723|NCT06134505|PROCEDURE|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
219128724|NCT06134505|PROCEDURE|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
219128725|NCT06134505|PROCEDURE|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
219226458|NCT04937504|BEHAVIORAL|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
219226459|NCT04937504|BEHAVIORAL|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
219128726|NCT05717075|BEHAVIORAL|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
219128727|NCT00603538|DRUG|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
219226460|NCT06832449|DEVICE|PNS|Retrospective study investigating PNS
219226461|NCT05182177|DEVICE|SurgiMend PRS|SurgiMend® PRS and SurgiMend® PRS Meshed are intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend® PRS and SurgiMend® PRS Meshed are specifically indicated for plastic and reconstructive surgery, including breast reconstruction.
219128728|NCT05010304|DRUG|Amoxicillin|Two-dose amoxicillin challenge
219128729|NCT05975996|DRUG|Cyclophosphamide added to standard immunosuppressive therapy with herombopag|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
219128730|NCT05750745|DRUG|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
219128731|NCT05750745|DRUG|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
219128732|NCT05750745|DRUG|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
219128733|NCT05064761|DEVICE|Sculptra new dilution|Treatment to improve appearance of cellulite.
219226462|NCT02881554|PROCEDURE|Computed Tomography|Undergo SC SPECT/CT
219226463|NCT02881554|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
219226464|NCT02881554|DRUG|Technetium Tc-99m Sulfur Colloid|Given IV
219226465|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
219128734|NCT05654649|DRUG|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
219128735|NCT05654649|DRUG|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
219128736|NCT05060471|DRUG|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
219128737|NCT04423731|DRUG|Folfirinox|Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
219128738|NCT03848481|DRUG|CBDV Compound|CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
219711554|NCT05142774|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
219128739|NCT03848481|DRUG|Placebo|Placebo oral solution contains matching excipients.
219128740|NCT06141668|OTHER|Neurostimulation|Electrical stimulation
219226466|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
219226467|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
219226468|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
219226469|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
219711555|NCT06651177|DRUG|Tirzepatide|The tirzepatide pen is a pre-filled, disposable, injection device designed for subcutaneous administration. Each pen is pre-filled with a single dose of tirzepatide and is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A UMC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
219711556|NCT06651177|OTHER|Placebo|"Saline administered subcutaneously with a syringe will be used as the placebo for the trial. The placebo which will be administered by a study UMC. The process for deciding on dose increases will be the same for placebo and tirzepatide."
219711557|NCT00967785|DRUG|Mozobil (TM)|twice daily subcutaneous injection or via continuous subcutaneous infusion
219711558|NCT01903226|OTHER|High intensity training|
219711559|NCT01903226|OTHER|Moderate intensity training|
219711560|NCT03112603|DRUG|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
219226470|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
219711561|NCT03112603|DRUG|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
219711562|NCT03112603|DRUG|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711563|NCT03112603|DRUG|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711564|NCT03112603|DRUG|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219128741|NCT05825417|DRUG|Selexipag|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
219128742|NCT05825417|DRUG|Riociguat|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
219128743|NCT05825417|DEVICE|CardioMEMS pulmonary artery pressure monitor|Implantation and remote monitoring established with patient initiated daily readings
219128744|NCT05825417|DEVICE|Confirm Rx|Implantation and remote monitoring established with automated daily readings / downloads
219128745|NCT02389426|DEVICE|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
219128746|NCT02389426|DEVICE|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
219128747|NCT02389426|DEVICE|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
219128748|NCT02389426|DEVICE|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
219128749|NCT06544928|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
219128750|NCT05669833|DRUG|Guselkumab|Guselkumab (GUS) subcutaneous injection
219711565|NCT03112603|DRUG|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711566|NCT03112603|DRUG|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711567|NCT03112603|DRUG|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219128751|NCT05669833|DRUG|Golimumab|Golimumab (GOL) subcutaneous injection
219226471|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
219226472|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
219226473|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
219128752|NCT05803824|OTHER|exercise therapy program|"patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises"
219128753|NCT00518375|DRUG|Rapamune® (Sirolimus)|
219226474|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
219226475|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
219226476|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
219226477|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
219226478|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
219128754|NCT00518375|DRUG|Neoral® (Cyclosporine)|
219128755|NCT00518375|DRUG|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
219128756|NCT06585540|DRUG|Amisulpride IV Prevention|Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
219128757|NCT06585540|DRUG|Amisulpride IV Treatment|Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
219128758|NCT06585540|DRUG|Placebo Preventative|Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
219128759|NCT06585540|DRUG|Placebo Treatment|Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
219128760|NCT06197880|OTHER|Anterior teeth retraction|En masse retraction of the upper and lower anterior segments using maximum anchorage
219128761|NCT03796494|PROCEDURE|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
219128762|NCT03796494|PROCEDURE|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
219128763|NCT02994706|PROCEDURE|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
219711568|NCT03112603|DRUG|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711569|NCT03112603|DRUG|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
219711570|NCT05733286|DRUG|Suvorexant 20 mg|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
219711571|NCT05733286|DRUG|Placebo|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
219711572|NCT02817880|DEVICE|rTMS|
219711573|NCT02817880|DEVICE|tDCS|
219711574|NCT02817880|DEVICE|tsDCS|
219711575|NCT05497401|BIOLOGICAL|MesenCure|Enhanced mesenchymal cell-based product
219711576|NCT05497401|OTHER|Placebo|Saline
219711577|NCT03410121|DEVICE|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
219128764|NCT02994706|OTHER|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
219128765|NCT00219921|DRUG|Intrathecal morphine at surgery, 0.1mg and placebo|
219128766|NCT00219921|DRUG|Patient Controlled Analgesia with iv morphine and placebo|
219128767|NCT00219921|DRUG|intrathecal morphine AND patient controlled analgesia with iv morphine|
219128768|NCT04493437|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
219226479|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
219226480|NCT06922643|DRUG|Peginterferon Alfa-2A|180 mcg, subcutaneous injection, once weekly
219226481|NCT06922643|DRUG|Ribavirin Oral Product|15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)
219226482|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
219711578|NCT03410121|DEVICE|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
219128769|NCT04958187|DRUG|ANG-3777|Arm assigned to this intervention will receive 2 mg/kg, IV
219128770|NCT05983692|DEVICE|Magnesium based wire|Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
219128771|NCT00783692|DRUG|vedolizumab|Vedolizumab for intravenous infusion
219128772|NCT00783692|OTHER|Placebo|Placebo intravenous infusion
219128773|NCT03750656|DRUG|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
219128774|NCT03750656|DRUG|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
219128775|NCT01536353|DRUG|AGSAV301|tablet, q.d.
219128776|NCT01536353|DRUG|Exforge 10/160|Tablet, q.d.
219128777|NCT04569578|OTHER|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
219128778|NCT00198874|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
219128779|NCT00198874|OTHER|Education|Drug education curriculum was delivered to participants assigned to this condition.
219128780|NCT01258361|PROCEDURE|echocardiography|Echocardiography is performed for all patients
219128781|NCT02283645|DRUG|3 % minoxidil lotion|
219128782|NCT02283645|DRUG|Placebo|
219128783|NCT03986606|BIOLOGICAL|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
219128784|NCT05688371|DRUG|standard dose morphine|Receiving 0.05 mg morphine/kg as a bolus.
219128785|NCT05688371|DRUG|low dose morphine plus dexmedetomidine|Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
219128786|NCT04150835|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
219226483|NCT06247774|BEHAVIORAL|Cardiac Rehabilitation|Participation in a 12-week cardiac rehabilitation program
219226484|NCT06247774|BEHAVIORAL|Attention Control|Participants will receive regular phone calls in place of cardiac rehabilitation visits
219711579|NCT05247047|DEVICE|TENA SmartCare Change Indicator|The intervention is a medical device system that consists of a reusable electronic sensor and an application installed on one or more smart phones. The device estimates the saturation level of an absorbing incontinence product used by a study subject. The device is non-invasive and does not have any effect on the function of the absorbing incontinence product.
219226485|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
219226486|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
219226487|NCT06762600|DRUG|HRS-4729 injection|HRS-4729 injection
219711580|NCT04624230|DRUG|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
219711581|NCT06278259|OTHER|Telerehabilitation program bases aerobic and Baduanjin exercises|It is an interventional study in which 68 stroke patients are estimated to enroll according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on aerobic exercises, guided by video. The telerehabilitation program is aerobic exercise 3 times per week for 3 months. With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
219128787|NCT04150835|DRUG|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
219128788|NCT04150835|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
219226488|NCT06762600|DRUG|HRS-4729 injection placebo|HRS-4729 injection placebo
219226489|NCT06762600|DRUG|HRS9531 injection|HRS9531 injection
219226490|NCT06762600|DRUG|HRS9531 injection placebo|HRS9531 injection placebo
219128789|NCT01650337|OTHER|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
219226491|NCT06762600|DRUG|Acetaminophen|Acetaminophen
219226492|NCT03426059|OTHER|No Intervention|No Intervention. This is an observational study.
219128790|NCT05251285|PROCEDURE|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
219128791|NCT00002620|DRUG|carmustine|
219128792|NCT00002620|DRUG|chemotherapy|
219128793|NCT00002620|DRUG|mitolactol|
219226493|NCT06354387|DRUG|Alectinib (Alecensa), Nivolumab (Opdivo)|Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
219226494|NCT06932874|DRUG|Glucophage (Metformin Hydrochloride Tablets)|Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.
219226495|NCT06932874|DRUG|New sustained-release metformin tablets (Ⅲ)|The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.
219226496|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
219226497|NCT06330610|OTHER|Intermittent enteral nutrition|Patients will receive intermittent enteral nutrition, defined as 3 60-minute administrations every 8 hours.
219226498|NCT02337985|DRUG|Prednisone|Given PO
219226499|NCT02337985|BIOLOGICAL|Rituximab|Given IV
219226500|NCT02337985|DRUG|Etoposide|Given IV
219128794|NCT00002620|RADIATION|low-LET cobalt-60 gamma ray therapy|
219128795|NCT00002620|RADIATION|low-LET photon therapy|
219128796|NCT01231282|OTHER|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
219128797|NCT05892913|DRUG|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
219128798|NCT05892913|DRUG|Ephedrine|For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
219226501|NCT02337985|DRUG|Doxorubicin Hydrochloride|Given IV
219226502|NCT02337985|DRUG|Vincristine Sulfate|Given IV
219226503|NCT02337985|DRUG|Cyclophosphamide|Given IV
219226504|NCT02337985|BIOLOGICAL|Filgrastim|Given SC
219226505|NCT02337985|BIOLOGICAL|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
219226506|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
219128799|NCT00768066|BIOLOGICAL|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
219128800|NCT00768066|BIOLOGICAL|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
219128801|NCT00768066|BIOLOGICAL|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
219128802|NCT03071497|DIAGNOSTIC_TEST|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
219128803|NCT04631549|DRUG|SHR3680|SHR3680, PO, single dose
219128804|NCT00548964|DRUG|Lithium|600-900mg of Li carbonate
219128805|NCT00548964|DRUG|Ketamine|0.5mg/kg of ketamine
219128806|NCT04831775|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
219128807|NCT04831775|BEHAVIORAL|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
219128808|NCT04838210|BEHAVIORAL|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
219128809|NCT04838210|BEHAVIORAL|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
219128810|NCT05159908|DRUG|NBI-921352|Tablets for oral administration
219128811|NCT05159908|DRUG|Placebo|Matching placebo tablets for oral administration
219128812|NCT06030687|OTHER|Ad libitum data collection|Food purchase, prep, eat and toss data
219128813|NCT03230591|OTHER|Echocardiography|LV vortex flow in Echocardiography
219128814|NCT03001986|BIOLOGICAL|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
219128815|NCT04455048|OTHER|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
219711582|NCT06278259|OTHER|Telerehabilitation program bases aerobic exercises|The telerehabilitation program is aerobic exercise 3 times per week for 3 months.
219711583|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711584|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711585|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711586|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711587|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711588|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
219711589|NCT05924594|DRUG|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
219711590|NCT05618067|BEHAVIORAL|breathing exercise training|Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
219711591|NCT02329717|DRUG|PBI 05204|PBI 05204 daily dosing
219128816|NCT04455048|OTHER|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
219128817|NCT05984641|DEVICE|CONAN® Proctological Cream|The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
219128818|NCT01205750|OTHER|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
219128819|NCT02477826|DRUG|Nivolumab|
219128820|NCT02477826|DRUG|Ipilimumab|
219128821|NCT02477826|DRUG|Carboplatin|
219128822|NCT02477826|DRUG|Cisplatin|
219128823|NCT02477826|DRUG|Gemcitabine|
219128824|NCT02477826|DRUG|Pemetrexed|
219128825|NCT02477826|DRUG|Paclitaxel|
219128826|NCT00597883|PROCEDURE|Carotid endarterectomy|(non-experimental) carotid endarterectomy (CEA) for treatment of carotid artery stenosis
219128827|NCT00597883|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
219128828|NCT05550337|DRUG|Trifarotene 0.005 % Topical Cream|Cream
219128829|NCT05550337|DRUG|AKLIEF®|Cream
219128830|NCT05550337|DRUG|Placebo|Cream
219128831|NCT05950113|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219128832|NCT05950113|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219226507|NCT06951035|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"The repeated stimulations will be carried out using an eight-part probe detected by the infrared camera (eight shaped tracked coil), connected to a Rapid 2 stimulator (Magstim Company, Whitland, UK). The stimulation will be performed manually or with robotic assistance using TMS-Robot (Axilum Robotics, SCHILTIGHEIM, France)"
219711592|NCT04433572|DRUG|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
219711593|NCT04433572|DRUG|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
219711594|NCT02097706|DRUG|NMDA receptor antagonist (active drug)|
219711595|NCT02097706|OTHER|Lactose packed capsule (inert/inactive arm)|
219711596|NCT05752539|DEVICE|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
219128833|NCT05950113|PROCEDURE|Computed Tomography|Undergo PET/CT
219128834|NCT05950113|DRUG|Cyclophosphamide|Receive IV
219128835|NCT05950113|PROCEDURE|Echocardiography|Undergo ECHO
219128836|NCT05950113|DRUG|Fludarabine|Receive IV
219128837|NCT05950113|OTHER|Fludeoxyglucose F-18|Receive IV
219128838|NCT05950113|OTHER|Immunotherapy|Receive CART-BCMA/CS1 cells IV
219128839|NCT05950113|PROCEDURE|Leukapheresis|Undergo leukapheresis
219128840|NCT05950113|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219128841|NCT05950113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219128842|NCT06006091|DRUG|Letrozole|Different endothelial preparations according to groups, see arm descriptions for details
219128843|NCT06576895|OTHER|No intervention|No intervention
219128844|NCT04989439|OTHER|Electrical impedance tomography and ultrasonography of the lung|Both EIT and LUS are non-invasive methods and do not pose any additional risk for the patient. The LuMon System with pediatric EIT belts (LuMon Belt, Sentec, Landquart, Switzerland) will be used. The belt will be placed on the thorax circumference of the infant and connected to the LuMonConnector (Sentec, Landquart, Switzerland). Small electrical currents (3 mA, 198 kHz) will be repetitively injected in rotation through adjacent electrode pairs, and voltage changes will be measured by all passive electrodes pairs (scan rate 48 Hz). Changes in lung electrical impedance will be continuously recorded for 5 minutes. EIT data will be analyzed off-line using Matlab (Mathworks, Natick, Massachusetts, USA). The regional tidal volume distribution, the homogeneity of tidal ventilation distribution, regional respiratory system compliance, and alveolar overdistension and collapse will be assessed. LUS will be performed by experienced users, with a 10 MHz linear transducer.
219128845|NCT06506240|OTHER|Acupuncture|Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 (Quchi), SP10 (Xuehai), ST36 (Zusanli), SP6 (Sanyinjiao), LR3 (Taichong), LI4 (Hegu), ST25 (Tianshu), CV4 (Guanyuan), GV20 (Baihui), and superior GV29 (superior Yintang). Patients will receive acupuncture or sham acupuncture three times weekly for 6 weeks.
219128846|NCT03115346|OTHER|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
219128847|NCT05457244|DEVICE|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
219128848|NCT05117034|DRUG|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
219128849|NCT05117034|DRUG|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
219128850|NCT05506345|BEHAVIORAL|Creative Drama Workshop|"* The host introduces the theme and stressor scene of this workshop~  * Nursing students group discussion~    * Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
219128851|NCT04816526|BIOLOGICAL|Descartes 08|Car T-cells
219128852|NCT01737268|DRUG|FK949E|Oral tablet
219128853|NCT03743922|DRUG|Calciferol|calciferol capsule
219128854|NCT03743922|DRUG|Placebo|placebo capsule
219128855|NCT04160585|OTHER|There is no intervention.|There is no intervention.
219128856|NCT06419946|DRUG|Temozolomide|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
219128857|NCT06419946|DRUG|Lomustine|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
219711597|NCT04696692|OTHER|Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.|"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
219711598|NCT04418960|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
219711599|NCT05604417|DRUG|TAZEMETOSTAT|Dosage and treatment timings per protocol
219711600|NCT05604417|DRUG|Zandelisib|Dosage and treatment timings per protocol
219128858|NCT03788291|DRUG|Acalabrutinib|100 mg by mouth twice a day starting on day 8 of cycle 1
219128859|NCT03788291|DRUG|Rituximab|Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
219128860|NCT03869853|BEHAVIORAL|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
219128861|NCT03869853|BEHAVIORAL|control|no intervention
219128862|NCT05588791|DIAGNOSTIC_TEST|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
219128863|NCT06118736|PROCEDURE|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
219128864|NCT05503420|DEVICE|Masticatory muscle training exerciser|In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
219128865|NCT00461565|DRUG|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
219128866|NCT00461565|DRUG|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
219128867|NCT00461565|DRUG|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
219128868|NCT00461565|DRUG|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
219128869|NCT01155999|DRUG|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
219128870|NCT01155999|DRUG|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
219128871|NCT04636697|DRUG|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
219128872|NCT04636697|BIOLOGICAL|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
219128873|NCT00609141|BIOLOGICAL|cixutumumab|Given IV
219128874|NCT00609141|OTHER|pharmacological study|Correlative studies
219128875|NCT00609141|OTHER|laboratory biomarker analysis|Correlative studies
219128876|NCT04271384|COMBINATION_PRODUCT|nivolumab|Combined neoadjuvant therapy consisting of nivolumab + SABR
219128877|NCT01442974|DRUG|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
219128878|NCT01668979|DEVICE|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
219128879|NCT00943423|RADIATION|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
219128880|NCT00943423|OTHER|No further treatment|
219128881|NCT02555007|DRUG|Vinorelbine|
219128882|NCT03341806|DRUG|Avelumab|Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
219128883|NCT03341806|COMBINATION_PRODUCT|MRI-guided LITT therapy|(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
219128884|NCT04218643|OTHER|Ultrasound-guided technique|IV inserted via ultrasound guidance
219128885|NCT04218643|OTHER|Standard technique|IV inserted via standard technique
219128886|NCT01576237|OTHER|blood donation|blood donation with preparative hemapheresis
219128887|NCT02765243|BIOLOGICAL|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
219128888|NCT04973618|BIOLOGICAL|APVO436|"APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly"
219128889|NCT04742244|DIETARY_SUPPLEMENT|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
219128890|NCT04742244|DIETARY_SUPPLEMENT|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
219128891|NCT02266329|DRUG|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
219128892|NCT02266329|DRUG|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
219128893|NCT04703699|DEVICE|Myval Transcatheter Heart Valve Series|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
219128894|NCT02894307|DRUG|Rivaroxaban|In patients with mechanical valves and unstable INR
219711601|NCT04376671|DEVICE|Electroencephalography|The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
219128895|NCT04868396|PROCEDURE|Tumor biopsy|Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
219711602|NCT06285643|DRUG|AAV2-GDNF Gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
219128896|NCT06483022|BEHAVIORAL|BELIEVE IPE Training|The IPC training will be delivered to health team members who provide intrapartum and/or postpartum maternity care at each facility. Individuals with roles as maternity care providers, nurses, lactation consultants or doulas whose primary inpatient clinical assignment is maternity care will be included in the training. The training will consist of a pre-session module (about 60 minutes), a 90-minute interprofessional collaboration session, delivered using virtual reality head-sets, and post-session modules (about 60 minutes). The pre- and post-session modules will be delivered through an online learning platform.
219128897|NCT06483022|OTHER|Usual Care|Prior to implementation of the IPC training, birthing people at the facilities will receive treatment-as-usual
219128898|NCT04124822|DRUG|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
219128899|NCT04124822|DRUG|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
219128900|NCT05567159|DRUG|Donanemab|Administered IV.
219128901|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
219128902|NCT03719677|BEHAVIORAL|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
219711603|NCT06285643|PROCEDURE|Control Surgery|Bilateral partial burr/twist holes without dural penetration
219128903|NCT06605677|OTHER|Questionnaire|An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
219128904|NCT03314337|DEVICE|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
219128905|NCT06650696|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
219128906|NCT06650696|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
219128907|NCT06650696|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
219128908|NCT01423903|DRUG|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
219128909|NCT06601907|BEHAVIORAL|alivis|alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
219128910|NCT06607965|DIETARY_SUPPLEMENT|Whey Protein and Carbohydrates|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
219128911|NCT06608121|OTHER|Upper limb isokinetic forces measurements|The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.
219128912|NCT06601387|PROCEDURE|choledochoduodonostomy|surgical drainage procedures
219128913|NCT06601387|PROCEDURE|hepaticojejunostomy|surgical intervention
219711604|NCT06419270|OTHER|Observation|Observational
219711605|NCT03093844|DEVICE|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
219711606|NCT06791187|DRUG|dabigatran etexilate|dabigatran etexilate
219711607|NCT06791187|DRUG|BI 1291583|BI 1291583
219711608|NCT04123197|OTHER|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
219711609|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
219711610|NCT06273618|OTHER|Micro-Learning|Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
219711611|NCT06207305|DRUG|Dexamethasone|Given by PO
219711612|NCT06207305|DRUG|Diphenhydramine|Given by PO
219711613|NCT06207305|DRUG|Famotidine|Given by PO
219711614|NCT06207305|DRUG|Paclitaxel|Given by PO
219711615|NCT01336270|OTHER|biological collection|to collect some human cell samples in melanoma
219711616|NCT06551272|DRUG|EXL01|EXL01 contains an unmodified single strain of F. prausnitzii
219711617|NCT06833294|DEVICE|GentleFit Mask, Gentlefit Prong, Standard of Care Interface|The subject will be randomized to sequence of interfaces. The subject will wear each of three NIV interfaces for 8 cumulative hours, for a total of 24 hours. Pressure achieved using each GentleFit interface will be compared to pressure achieved by standard of care interface.
219128914|NCT01953510|BIOLOGICAL|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
219128915|NCT01953510|BIOLOGICAL|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
219128916|NCT06070597|DRUG|Iclepertin|Iclepertin
219128917|NCT06070597|DRUG|Iclepertin Placebo|Placebo to Iclepertin
219128918|NCT06070597|DRUG|Moxifloxacin|Moxifloxacin
219128919|NCT06070597|DRUG|Moxifloxacin Placebo|Placebo Moxifloxacin
219128920|NCT06610357|OTHER|Group 1|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
219128921|NCT00117377|DRUG|Pimecrolimus|Pimecrolimus cream 1 % bid
219128922|NCT00117377|DRUG|Placebo|Placebo application bid
219128923|NCT05402579|GENETIC|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
219128924|NCT06615440|DRUG|Alpha blocker|prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs
219128925|NCT06615180|BEHAVIORAL|Transcultural Nursing Course (new curriculum)|"Multinational Collaboration: Developed with input from institutions across five countries, ensuring a broad, international perspective on transcultural nursing.~Comprehensive Theoretical Framework: Integrates multiple cultural competence models (Purnell, Campinha-Bacote, Papadopoulos) with Leininger's Culture Care Theory, offering a thorough approach.~Extensive Practical Training: Includes 17 hours of hands-on experience, featuring hospital visits and interactions with healthcare professionals.~Interactive Learning Methods: Combines role-playing, reflective essays, and cultural activities (e.g., traditional clothing, dances) for dynamic, multimodal education.~Peer Education: Incorporates peer education and evaluation, enhancing collaborative learning and critical thinking.~Standardized Materials: Educational materials and teaching methods are standardized across institutions to ensure consistency and quality in instruction."
219128926|NCT06613594|OTHER|Conventional physical therapy|Patients will receive hot pack, Broom stick ROM exercises, Codman and strengthening exercises. A total of 10 sessions, 5 sessions per week for 2 consecutive weeks.
219128927|NCT06613594|OTHER|Kaltenborn traction mobilization|kaltenborn direction non specific traction mobilization for (1 minute), 3 sets of 10 reps with 1 minute rest in between will be given.
219128928|NCT06613594|OTHER|Kaltenborn translatoric glides|Kaltenborn direction specific linear tranlatoric glides, rhtymic 5reps of each glide, such anterior glide for extension and external rotation, caudal glide for abduction,post glide for flexion and internal roation,these3 sets of painless glides will performed with 10 reps,rest of 1 minutes between these sets.
219128929|NCT06616506|DEVICE|newly-invented AI model|Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
219128930|NCT01273090|DRUG|imetelstat sodium|
219128931|NCT01273090|OTHER|laboratory biomarker analysis|
219128932|NCT01273090|OTHER|pharmacological study|
219128933|NCT06688708|DEVICE|Using vibrating foot orthosis with tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis in conjunction with a random 0-100 Hz square wave pulse stimulus and pseudorandom white noise via a stochastic resonance approach.
219128934|NCT06688708|DEVICE|Using vibrating foot orthosis without tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis with only vibration 100 Hz freqency.
219128935|NCT06631573|OTHER|fixed all-on-four prosthesis reinforced with PEEK framework.|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
219128936|NCT06631573|OTHER|Fixed all-on-four prosthesis reinforced with Co-Cr framework|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
219128937|NCT06697639|BEHAVIORAL|Rehabilitation Group|In addition to routine postpartum care, small-sized WAFF air cushions will be issued during the hospitalization period to guide patients in performing the WAFF pelvic-abdominal mechanical rehabilitation exercises. Patients will also be instructed to join the experimental group's WeChat group. After discharge, researchers will upload WAFF pelvic-abdominal mechanical rehabilitation instructional videos. Patients are required to complete their rehabilitation exercises twice daily, each session lasting 10-15 minutes. Patients need to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination. The abdominal rectus muscle, pelvic floor muscle function, and adherence to rehabilitation exercises will be assessed for patients in both groups at 6-8 weeks and 6 months postpartum.
219128938|NCT06698029|OTHER|VIM Targeting|Targeting with the use of VIMRS-LAT-1.0
219711618|NCT06837857|DRUG|Opioid|Subjects will receive oral oxycodone as needed for pain which will be titrated weekly based on pain response, adverse effects, and patient preference. Subjects with intolerance to oxycodone will receive the equivalent dosing of morphine as an alternative.
219711619|NCT06837857|DRUG|Opioid Placebo|Subjects will receive a placebo capsule identical to oxycodone, which will similarly be titrated weekly. Subjects with intolerance to the first placebo will receive another placebo capsule identical to morphine.
219128939|NCT06696976|OTHER|Telerehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
219128940|NCT06696976|OTHER|Clinical rehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
219128941|NCT06696937|OTHER|Tai chi|Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.
219128942|NCT06696937|OTHER|full body vibrator|Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
219128943|NCT06698315|OTHER|Observation|Medical Records Chart Review
219128944|NCT06696144|DIAGNOSTIC_TEST|Skin swabs for multi drug resistant bacteria|Swabs from personal items or skin will be obtained from stuff and analyzed to detect CVE or VRE bacteria using Automated Susceptibility Testing
219128945|NCT06697548|OTHER|Pain Neuroscience Education|Participants will watch and discuss a short (5-minute) standardized pain neuroscience education video with their treating provider. The video explains and illustrates how chronic pain is different than acute pain in that it concerns nervous system hypersensitivity more than local tissue damage. Pain neuroscience education principles from the video will then be used to throughout all interventions to coach the participants through graded exposure of activities that may have previously been painful or provoked anxiety.
219128946|NCT06697548|OTHER|Lumbopelvic and Hip Therapeutic Exercise|These motor control exercises will focus on proprioception, coordination, and sensorimotor control training and include progressive exercises that focus on transversus abdominis, lumbar multifidus, diaphragmatic, pelvic floor muscles, and deep hip stabilizers. Exercises will progress from more stabilized (e.g., pelvic tilt, cat and cow) to less stabilized and more dynamic and functional (e.g., forward bending, eccentric squat) to mimic the demands of work duty. Exercise will be trained and progressed during the clinical visits and be performed daily at home.
219128947|NCT06697548|OTHER|Extrapelvic Manual Therapy|Thrust and non-thrust manual therapy will be applied to the lumbar facet, sacroiliac, and hip joints based upon the clinical exam in a semi-standardized manner
219128948|NCT06697548|OTHER|Extrapelvic Dry Needling|Dry needling treatment to muscles of the lumbopelvic and upper thigh regions in a semi-standardized manner based upon a palpatory examination. The palpatory examination will include the erector spinae, lumbar multifidi, gluteus medius/minimus, piriformis, illiacus, and hip adductor muscles.
219128949|NCT06697548|OTHER|Deep Paced Diaphragmatic Breathing Training|The breathing intervention will start with education describing the link between the diaphragm and the pelvic floor to include awareness of any breath holding patterns and finding positions that facilitate expansion of the ribs, abdominals, and pelvic floor muscles with inhalation. Then progressive training will be given to encourage deep breathing at a pace of approximately 6 breaths per minute.
219128950|NCT06697548|OTHER|Chronic Pelvic Pain Education|During the first visit, participants will receive and briefly discuss the 2023 standardized patient educational handout created by the International Pelvic Pain Society with their treating provider. The educational handout describes chronic pelvic pain etiology, typical symptoms, examination, and treatments.
219128951|NCT06697548|OTHER|Intravaginal and intrarectal pelvic floor physical therapy|Superficial vulvar, perineal and intravaginal manual therapy and biofeedback utilizing commonly used techniques in previous research selected based on identified impairments from the pelvic floor examination will be performed.
219128952|NCT06632262|DRUG|ABSK061 + ABSK043|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
219128953|NCT06632262|DRUG|ABSK061+ABSK043 in combination with CAPOX|Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
219128954|NCT03853798|DRUG|AG-348|Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
219128955|NCT00147043|PROCEDURE|Leukapheresis|
219128956|NCT00147043|PROCEDURE|Infusion of stem cells via image guided scan|
219128957|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
219128958|NCT06697119|OTHER|Fecal Microbial Transplantation|Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy
219128959|NCT05108051|DRUG|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
219128960|NCT05108051|DRUG|Oseltamivir|Oseltamivir 75mg administered orally twice daily
219128961|NCT04794621|DEVICE|Electroceutical Dressing Technology-EDThi|Use of EDThi for 3 weeks post enrollment
219128962|NCT04794621|DEVICE|Adding EDTlo (Procellera®) for 3 weeks after use of EDThi|Use of EDTlo (Procellera®) for additional 3 weeks
219128963|NCT06919276|OTHER|Vaping Device Labeling|"Participants will view one vape image (experimental stimulus) and are randomized to a label presented and the color/flavor of the vaping device presented.~The label conditions are:~1. plain (i.e., no labeling on device)~2. contains THC~3. contains 80% THC~4. contains 80% THC - HIGH POTENCY~5. contains nicotine~6. contains 5% nicotine~7. contains 5% nicotine - HIGH STRENGTH The color/flavor conditions are: mint/mint, white/original, blue/blueberry."
219128964|NCT05096299|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
219128965|NCT02501811|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219128966|NCT02501811|BIOLOGICAL|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219128967|NCT02501811|BIOLOGICAL|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219128968|NCT06478654|PROCEDURE|Bilateral Modified Pectoral Nerve Block (PECS II).|"The procedure will be done bilateral with the patient lying in the supine position and the ipsilateral arm will be abducted and externally rotated, and the elbow flexed 90°.~The block will be managed by in-plane technique. After confirming the location of the needle with 2-3 mL of saline, 10 mL of 0.25% bupivacaine will be injected. Then, the needle will be advanced to the interfascial plane between the pectoralis minor and serratus anterior muscle, and 20 mL of 0.25% bupivacaine will be administered with the same procedure. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine"
219128969|NCT06478654|PROCEDURE|Bilateral Thoracic Erector spinae plane block (ESPB).|Under all aseptic precautions and sonar guided, ESP block will be managed at T4 or T5 bilateral using a high-frequency linear ultrasound probeWe will inject 20ml of bupivacaine 0.25% into interfacial plane below to erector spinae, a manifest linear pattern will be visualized uplifting the muscle. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine.
219128970|NCT05601466|DRUG|QN-023a|NK cell therapy
219128971|NCT05601466|DRUG|Cyclophosphamid|Lympho-conditioning Agent
219128972|NCT05601466|DRUG|Fludarabine|Lympho-conditioning Agent
219128973|NCT05601466|DRUG|Cytarabine|Lympho-conditioning Agent
219128974|NCT05763004|DRUG|IOS-1002|monotherapy
219128975|NCT05763004|DRUG|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
219128976|NCT04504903|BEHAVIORAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
219128977|NCT04504903|BEHAVIORAL|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
219128978|NCT03992638|PROCEDURE|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
219128979|NCT03992638|PROCEDURE|CAF|Completing root coverage by coronally advanced flap technique alone
219128980|NCT04191161|DEVICE|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
219128981|NCT06329804|OTHER|Isometric Handgrip Exercise Training (IHGT)|Each IHGT session will consist of 4 x 2-minute contractions at 30% maximal voluntary contraction, with 2-minutes of rest in between, performed with the dominant hand. Training will be performed using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong).
219128982|NCT01565538|DRUG|Erlotinib|150 mg Given orally
219128983|NCT01565538|DRUG|Pemetrexed|500mg/m2 Given IV
219128984|NCT05263141|PROCEDURE|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
219128985|NCT05263141|PROCEDURE|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
219128986|NCT04074954|PROCEDURE|Cataract surgery|Patients will receive cataract surgery
219128987|NCT00361998|DRUG|NITROFURANTOIN MACROCRYSTALS|
219128988|NCT00359619|BIOLOGICAL|CervarixTM|Subjects were administered three doses of HPV vaccine
219128989|NCT00359619|BIOLOGICAL|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
219128990|NCT04774406|DRUG|olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib|All patients treated at least with 1 PARPi (alone or in combination)
219128991|NCT00716079|OTHER|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
219128992|NCT00117611|DRUG|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
219128993|NCT05759221|PROCEDURE|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
219128994|NCT06518005|DRUG|Imlifidase|Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
219128995|NCT06518005|DRUG|GNT0003|GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
219128996|NCT00878384|DRUG|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
219128997|NCT00878384|PROCEDURE|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
219128998|NCT06710561|DRUG|SPN01 for Injection|After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
219128999|NCT06710561|OTHER|Placebo|After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered
219129000|NCT06710561|DRUG|SPN01 for Injection|Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
219129001|NCT05406934|BIOLOGICAL|Infliximab|obseravation with investigation
219129002|NCT02807753|OTHER|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
219129003|NCT02807753|OTHER|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
219129004|NCT03919617|DRUG|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
219129005|NCT00256308|DRUG|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
219129006|NCT00256308|PROCEDURE|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
219129007|NCT01419717|DRUG|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
219129008|NCT02857283|OTHER|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
219129009|NCT02857283|OTHER|Filtered Air|Participants will be exposed to filtered clean air
219129010|NCT02857283|DEVICE|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
219129011|NCT04885595|PROCEDURE|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
219129012|NCT03698136|OTHER|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
219129013|NCT04740255|DEVICE|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
219129014|NCT01626274|DEVICE|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
219129015|NCT05949372|OTHER|Giving a biological breastfeeding position|The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother.
219129016|NCT05949372|OTHER|Giving a football ( armpit) position|The mother sits upright, leaning back, and the baby's bottom and the right or left side of the mother is supported by pillows from whichever side she will breastfeed. The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side. While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.
219129017|NCT02018666|DEVICE|NAVA endotracheal tube|
219129018|NCT00114803|DRUG|Calcitonin nasal spray (salmon)|
219129019|NCT04444180|DIAGNOSTIC_TEST|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
219129020|NCT04107519|BEHAVIORAL|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
219129021|NCT01207908|DRUG|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
219129022|NCT05080192|DRUG|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
219711621|NCT06078683|DIETARY_SUPPLEMENT|C8 Ketone Supplement|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch."
219711622|NCT06078683|DIETARY_SUPPLEMENT|Placebo|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil."
219711623|NCT06078683|DIETARY_SUPPLEMENT|Ketone Ester Acute|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein."
219711624|NCT06078683|DIETARY_SUPPLEMENT|Placebo Acute|Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
219129023|NCT05080192|DRUG|Placebo|Matching placebo (once/day) for 10 days
219129024|NCT05074498|DRUG|TB006|intravenous infusion
219129025|NCT05074498|DRUG|Placebo|intravenous infusion
219129026|NCT04944693|OTHER|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
219129027|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
219129028|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
219129029|NCT00287573|DEVICE|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
219129030|NCT00287573|PROCEDURE|Brachytherapy (beta source)|Brachytherapy (beta source)
219129031|NCT00161447|DRUG|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
219129032|NCT00161447|DRUG|Testosterone Gel|Testosterone Gel (10 g daily
219129033|NCT00161447|DRUG|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 \& month 3
219129034|NCT02756104|OTHER|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
219129035|NCT02756104|OTHER|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
219129036|NCT06306846|RADIATION|SBRT+immunochemotherpy|SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy
219129037|NCT06306846|DRUG|Immunochemotherapy|PD-1 monoclonal antibody and TP chemotheapy
219129038|NCT06306846|DRUG|cetuximab+immunochemotharpy|PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
219129039|NCT01106703|DIETARY_SUPPLEMENT|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
219129040|NCT01106703|OTHER|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
219129041|NCT00578435|PROCEDURE|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
219129042|NCT04911686|DEVICE|rod distraction|Our study entails the application of a simple method for correction of FKFD in younger children using a simple cast distraction technique. This conservative method aims at avoiding the complications of surgery in children while achieving a reasonable amount of correction.
219129043|NCT06479564|OTHER|free weight training and machine training|20 participants will be in control group who will only perform free weight and machine training
219129044|NCT06479564|OTHER|Aerobic Exercises|20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
219129045|NCT04599114|BEHAVIORAL|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
219129046|NCT04844099|DRUG|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
219711625|NCT03579888|BIOLOGICAL|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
219711626|NCT03579888|DRUG|Cyclophosphamide|Given IV
219711627|NCT03579888|DRUG|Fludarabine|Given IV
219711628|NCT04912687|DIAGNOSTIC_TEST|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
219711629|NCT06485245|DRUG|CS060304|Tablets administered orally
219129047|NCT03470987|PROCEDURE|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
219711630|NCT04590326|DRUG|REGN5668|Administer per the protocol
219129048|NCT03470987|DIETARY_SUPPLEMENT|Metabolic control|Calorie restricted diet
219129049|NCT05224362|DEVICE|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
219129050|NCT03972293|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.
219129051|NCT03972293|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
219129052|NCT04004702|DRUG|Levetiracetam|Levetiracetam 500mg twice a day
219129053|NCT01218503|BEHAVIORAL|CHOICES - obese|Standard group behavioral weight loss treatment
219129054|NCT04759339|DRUG|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
219129055|NCT00306683|DRUG|DIAZOXIDE|
219129056|NCT02886988|DRUG|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
219129057|NCT02886988|DRUG|normal saline|0.1mlof normal saline will be injected with a 30G needle.
219129058|NCT04879134|DRUG|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
219129059|NCT04879134|DRUG|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
219129060|NCT00450502|DRUG|Batracylin|
219129061|NCT06098027|DRUG|[14C]CS0159|Single oral administration of 4mg \[14C\]CS0159
219711631|NCT04590326|DRUG|Cemiplimab|Administer per the protocol
219711632|NCT04590326|DRUG|Ubamatamab|Administer per the protocol
219711633|NCT04590326|DRUG|Sarilumab|Administer per the protocol
219711634|NCT04590326|DRUG|Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]|Administer per the protocol
219129062|NCT04248764|OTHER|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
219129063|NCT04248764|OTHER|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
219129064|NCT06631963|BEHAVIORAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
219129065|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in CT|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
219711635|NCT05219552|BEHAVIORAL|personalized lactation support|Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
219711636|NCT03916926|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
219711637|NCT03916926|DEVICE|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
219711638|NCT05412394|DRUG|Prednisolone|Liquid, 5mg/kg per week, for one year
219711639|NCT05359484|DIAGNOSTIC_TEST|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
219711640|NCT06333769|RADIATION|Short-course Radiotherapy|Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.
219129066|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in CT|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
219129067|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in CT|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
219129068|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in MRI|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
219129069|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in MRI|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
219129070|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in MRI|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
219129071|NCT06631859|OTHER|Cosmetic products containing 0% Assam tea|Cosmetic products containing 0% Assam tea
219129072|NCT06631859|OTHER|Cosmetic products containing 2.5% Assam tea|Cosmetic products containing 2.5% Assam tea
219129073|NCT05507463|DRUG|KBP-7072|KBP-7072
219129074|NCT05507463|DRUG|Placebo|Placebo
219129075|NCT02404454|PROCEDURE|Hysteroscopic metroplasty|
219129076|NCT02404454|DEVICE|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
219711641|NCT06333769|DRUG|Tislelizumab|Tislelizumab：200mg，d1，q3w，2 cycles.
219129077|NCT02404454|PROCEDURE|Office second look hysteroscopy|Second-look hysteroscopy after three months
219129078|NCT00362193|BEHAVIORAL|Telephonic diabetes care|
219129079|NCT04471467|PROCEDURE|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
219129080|NCT03660605|OTHER|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
219129081|NCT03613129|DRUG|CT38|Infusion
219129082|NCT00608348|PROCEDURE|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
219129083|NCT00608348|PROCEDURE|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
219129084|NCT00363116|DRUG|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
219129085|NCT05309486|OTHER|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
219711642|NCT06333769|DRUG|Capecitabine|Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.
219711643|NCT06333769|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2, d1, q3w, 2 cycles
219711644|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|Conditioning regimen consisted of the following1)Severe aplastic anemia(SAA):FC-ATG:Flu 30 mg/m\^2/d ×4d (- 7d- -4d), CTX 22.5 -25mg/kg/d × 4d (-7d- -4d), ATG 7.5mg in total（- 5d- -2d).2)Transfusion-dependent non-severe aplastic anemia（TD-NSAA) and Paroxysmal nocturnal hemoglobinuria (PNH) acquired clonal-aplastic anemia(AA):BU/FC-ATG:Bu 0.8mg/kg(q6h -8d）+FC-ATG. The GVHD prophylaxis program was Application of Anti-CD25 Humanized Monoclonal Antibody 50mg (+1d,+4d);cyclosporine A + mycophenolate mofetil (MMF)+short course methotrexate (MTX).The infusion time of umbilical cord blood (UCB) stem cells in the UCB-assisted haploidentical hematopoietic stem cell transplantation (UCB-Haplo-HSCT) group: 4 hours before the infusion of peripheral blood stem cells.In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
219711645|NCT00950001|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219711646|NCT04680988|DRUG|SHR-1210|SHR-1210 intravenously every 3 weeks
219711647|NCT04680988|DRUG|SHR-1020|SHR-1020 Orally once daily
219711648|NCT04680988|DRUG|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
219129086|NCT03255642|DRUG|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
219129087|NCT03255642|DRUG|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
219129088|NCT00180518|DEVICE|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
219226508|NCT06951958|BEHAVIORAL|Cardiac Rehabilitation Program Based on Health Action Process Approach Model|The intervention program will start in the hospital setting and continue at home. A work schedule will be created with each individual in intervention group 1 by determining the times when they are available separately. Individuals are planned to receive 60-minute home visits once a week. In the following weeks, care interventions such as home visits, training, counseling and monitoring will be organized according to the specific needs and requirements of each individual. In the face-to-face preparation phase, the patient's health needs will be identified, health status will be assessed, daily activities will be reviewed, incompatibility between activity levels and recommended exercise guidelines will be examined, and individualized exercise goals and a behavior-specific exercise program will be created for behavioral changes. In the intervention phase, the parts that the patient lacks will be determined and the trainings needed will be given.
219226509|NCT06951139|DIAGNOSTIC_TEST|Ultrasound and Shear Wave Elastography|Non-invasive diagnostic imaging techniques used to assess the stomatognathic system. Ultrasound was performed to measure the thickness of the masseter, temporalis, and sternocleidomastoid muscles, as well as the articular disc of the temporomandibular joint. Shear Wave Elastography was used to evaluate the elasticity (stiffness) of the same muscles and joint structures in kilopascals. All evaluations were conducted at rest, using standardized positioning, and by the same experienced operator.
219226510|NCT05429632|DRUG|mocravimod|S1PR modulator
219226511|NCT06950242|DEVICE|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
219129089|NCT03956173|OTHER|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
219129090|NCT03349684|DRUG|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
219129091|NCT03349684|DRUG|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
219129092|NCT03349684|DRUG|Placebo|Acarbose matching placebo, oral
219129093|NCT06047262|DRUG|Dapansutrile|Patients receive investigational product.
219129094|NCT06047262|DRUG|Placebo|Patients receive placebo.
219129095|NCT03355053|DRUG|Dexmedetomidine|"Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL."
219129096|NCT03355053|DRUG|Placebo|"From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O."
219129097|NCT01770860|DEVICE|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
219129098|NCT01770860|DEVICE|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
219129099|NCT01770860|DEVICE|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
219129100|NCT01770860|DEVICE|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
219129101|NCT02369523|DRUG|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
219711649|NCT03884413|OTHER|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
219711650|NCT04725188|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
219711651|NCT04725188|DRUG|Docetaxel|Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
219711652|NCT04725188|DRUG|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
219711653|NCT05639556|DIAGNOSTIC_TEST|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
219711654|NCT05639556|DIAGNOSTIC_TEST|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
219711655|NCT05639556|DIAGNOSTIC_TEST|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
219711656|NCT05639556|DIAGNOSTIC_TEST|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
219711657|NCT05639556|DIAGNOSTIC_TEST|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
219711658|NCT05639556|DIAGNOSTIC_TEST|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
219711659|NCT05639556|DIAGNOSTIC_TEST|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
219711660|NCT05639556|DIAGNOSTIC_TEST|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
219129102|NCT02369523|DRUG|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
219711661|NCT05639556|OTHER|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
219129103|NCT02369523|DRUG|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
219129104|NCT03432533|DRUG|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
219711662|NCT05639556|OTHER|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
219129105|NCT03432533|DEVICE|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
219129106|NCT04880070|DEVICE|Shockwave Treatment|Self-controlled, single-arm group using the Shockwave device.
219129107|NCT05531825|DEVICE|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
219129108|NCT00547261|DRUG|SSR97225|every 3 weeks
219711663|NCT05639556|OTHER|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
219129109|NCT05207787|DRUG|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
219129110|NCT03365856|OTHER|observational study|as clinical practice
219129111|NCT03867864|DEVICE|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
219129112|NCT03867864|DEVICE|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
219129113|NCT03867864|OTHER|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
219129114|NCT03867864|DEVICE|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
219129115|NCT03867864|DEVICE|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
219129116|NCT05587140|DEVICE|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
219226512|NCT06950242|DEVICE|Boston Scientific Corporation|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
219711664|NCT05639556|OTHER|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
219711665|NCT05639556|OTHER|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
219711666|NCT05639556|OTHER|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
219129117|NCT05587140|DEVICE|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
219711667|NCT05639556|OTHER|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
219711668|NCT05639556|OTHER|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
219711669|NCT05639556|DEVICE|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
219129118|NCT05587140|DEVICE|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
219129119|NCT04484688|DRUG|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
219129120|NCT04596761|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
219129121|NCT04596761|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
219129122|NCT01447797|DRUG|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
219129123|NCT00138164|BIOLOGICAL|denileukin diftitox|
219129124|NCT03881631|BEHAVIORAL|Mindfulness Based Stress Reduction Program|Group-based intervention
219129125|NCT03881631|BEHAVIORAL|Living Well Program|Group-based intervention
219129126|NCT03214887|BIOLOGICAL|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
219129127|NCT05092932|OTHER|Normal Foot Force|LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
219129128|NCT04173845|DRUG|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
219129129|NCT04173845|DRUG|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
219129130|NCT04651244|DIAGNOSTIC_TEST|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
219129131|NCT04651244|DIAGNOSTIC_TEST|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
219129132|NCT04651244|DIAGNOSTIC_TEST|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
219129133|NCT01380119|BIOLOGICAL|V7|experimental arm
219129134|NCT01380119|OTHER|placebo|placebo pill
219711670|NCT05639556|DIAGNOSTIC_TEST|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
219129135|NCT01460992|PROCEDURE|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
219129136|NCT06001684|BIOLOGICAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
219129137|NCT01784380|DRUG|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
219129138|NCT01112735|BIOLOGICAL|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
219129139|NCT01112735|PROCEDURE|Standard of care|Standard of care
219129140|NCT05161702|OTHER|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
219711671|NCT05639556|DIAGNOSTIC_TEST|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
219711672|NCT05639556|DIAGNOSTIC_TEST|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
219129141|NCT05161702|OTHER|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
219129142|NCT03529864|OTHER|Exercise Therapy|
219129143|NCT05536284|DRUG|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
219129144|NCT03542708|PROCEDURE|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
219129145|NCT03771326|BIOLOGICAL|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
219711673|NCT05639556|DIAGNOSTIC_TEST|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
219711674|NCT05639556|OTHER|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
219711675|NCT05639556|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
219129146|NCT03419780|BIOLOGICAL|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
219129147|NCT04315220|OTHER|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
219129148|NCT04315220|OTHER|No Intervention|No Intervention
219129149|NCT04749693|DEVICE|DBLG1 System|Use of DBLG1 System in real life condition
219129150|NCT02980380|OTHER|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
219129151|NCT03680014|DIAGNOSTIC_TEST|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
219129152|NCT03017456|BEHAVIORAL|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
219129153|NCT02095158|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
219129154|NCT04866056|DRUG|Jaktinib|Jaktinib PO BID
219129155|NCT04866056|DRUG|azacitidine|Azacytidine SC
219129156|NCT05171933|BEHAVIORAL|Survey|This study is based on a survey made on COVID-19
219129157|NCT04161222|OTHER|Experimental group|Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
219129158|NCT04161222|OTHER|Control group|Control group will perform a typical warm-up of competitive football
219129159|NCT03095209|DRUG|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
219129160|NCT03095209|DRUG|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
219129161|NCT03095209|RADIATION|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
219129162|NCT01008748|DRUG|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
219129163|NCT01008748|BEHAVIORAL|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
219129164|NCT01008748|BEHAVIORAL|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
219129165|NCT01008748|BEHAVIORAL|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
219129166|NCT02616367|DRUG|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
219129167|NCT02616367|DRUG|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
219129168|NCT00870259|DIETARY_SUPPLEMENT|Optifast VLCD|Meal replacement, three times daily for 8 weeks
219129169|NCT01787994|GENETIC|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
219129170|NCT00514332|PROCEDURE|stent|stent placement for colorectal cancer obstruction
219129171|NCT03518983|DEVICE|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
219129172|NCT03518983|DEVICE|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
219129173|NCT02887378|DEVICE|hot clamps|reusable hot biopsy forceps
219129174|NCT02887378|DEVICE|normal clamps|
219129175|NCT06444009|DRUG|Ivonescimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
219129176|NCT06444009|DRUG|Cadonilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
219129177|NCT06444009|DRUG|Penpulimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
219129178|NCT00062062|DRUG|carboplatin|
219129179|NCT00062062|DRUG|gefitinib|
219129180|NCT00062062|DRUG|paclitaxel|
219129181|NCT02775435|BIOLOGICAL|Pembrolizumab|IV infusion
219129182|NCT02775435|DRUG|Paclitaxel|IV infusion
219129183|NCT02775435|DRUG|Nab-paclitaxel|IV infusion
219129184|NCT02775435|DRUG|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
219129185|NCT02775435|DRUG|Saline placebo for pembrolizumab|IV infusion
219129186|NCT05811728|RADIATION|Low level laser therapy|The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
219129187|NCT05811728|OTHER|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
219129188|NCT03681730|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219129189|NCT03059082|BEHAVIORAL|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
219129190|NCT03059082|BEHAVIORAL|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
219129191|NCT03059082|OTHER|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
219129192|NCT03198546|BIOLOGICAL|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
219129193|NCT04056221|OTHER|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
219129194|NCT04056221|OTHER|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
219129195|NCT01501214|DRUG|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
219129196|NCT01501214|DRUG|Normal saline|Normal saline given
219129197|NCT03840070|DEVICE|Potenfill|Maximum: 22ml
219129198|NCT02516176|BEHAVIORAL|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
219129199|NCT05082883|DIAGNOSTIC_TEST|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
219129200|NCT02637544|OTHER|acupuncture|classical acupuncture therapy
219129201|NCT00097253|BEHAVIORAL|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
219129202|NCT06239662|BEHAVIORAL|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
219129203|NCT06239662|BEHAVIORAL|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
219129204|NCT01513642|BEHAVIORAL|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
219129205|NCT04159948|DIETARY_SUPPLEMENT|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
219129206|NCT05989737|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
219129207|NCT00841282|PROCEDURE|Colonoscopy for colorectal cancer screening|
219129208|NCT00841282|PROCEDURE|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
219129209|NCT00841282|PROCEDURE|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
219129210|NCT00623922|BEHAVIORAL|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
219129211|NCT05793099|OTHER|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
219129212|NCT05793099|OTHER|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
219129213|NCT00690469|OTHER|Laboratory Biomarker Analysis|Correlative studies
219129214|NCT00690469|OTHER|Questionnaire Administration|Ancillary studies
219129215|NCT01495637|DRUG|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
219129216|NCT04882722|OTHER|Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session
219129217|NCT00533416|DRUG|ON 01910 Na|
219129218|NCT03699735|DEVICE|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
219129219|NCT00385658|DRUG|Fluvastatin extended release, fenofibrate|
219129220|NCT00385658|DRUG|Fixed combination simvastatin/ezetimibe|
219129221|NCT01646502|BIOLOGICAL|Esp protein|
219129222|NCT01646502|OTHER|Standard wound care|
219129223|NCT03452306|DRUG|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
219129224|NCT03452306|DRUG|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
219129225|NCT03452306|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
219129226|NCT03452306|DRUG|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
219129227|NCT02766504|DEVICE|airway ultrasound|airway assessment using ultrasound
219129228|NCT02196012|BEHAVIORAL|Intervention group|
219129229|NCT02196012|BEHAVIORAL|attention control condition|
219129230|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
219129231|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
219129232|NCT01219855|DRUG|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
219129233|NCT01219855|DRUG|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
219129234|NCT01219855|DRUG|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
219129235|NCT04097899|OTHER|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay."
219129236|NCT00064571|PROCEDURE|vocal fold medialization|
219129237|NCT00064571|PROCEDURE|vocal fold reinnervation|
219129238|NCT04088513|DRUG|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
219129239|NCT04088513|DRUG|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
219129240|NCT02634216|DIETARY_SUPPLEMENT|Capros|250 mg BID
219129241|NCT04766437|DRUG|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
219129242|NCT04766437|DRUG|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
219129243|NCT00590603|DRUG|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
219129244|NCT04808635|OTHER|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
219129245|NCT00883350|BEHAVIORAL|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
219129246|NCT03061955|BIOLOGICAL|influenza vaccination|administration of influenza vaccination
219129247|NCT05200650|COMBINATION_PRODUCT|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
219129248|NCT02191852|DRUG|Seresis®|
219129249|NCT03392337|DEVICE|Narrowband UVB phototherapy|Ultraviolet B phototherapy
219129250|NCT00956449|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
219129251|NCT02952950|OTHER|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
219129252|NCT04392349|DEVICE|Haag-Streit EYESTAR 900|The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
219711676|NCT05639556|OTHER|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
219711677|NCT05639556|OTHER|CF Management Questionnaire|Assessment of prior 12-month management of cystic fibrosis, including treatments, medication intake and hospitalizations. This questionnaire will only be completed at 24- and 36- month visits.
219711678|NCT05639556|OTHER|Food Frequency Questionnaire|Assessment of prior 12-month nutritional intake being completed at Baseline (no later than 6-month visit) and 12-month visit.
219711679|NCT06442033|OTHER|High intensity stationary cycling|All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
219129253|NCT04392349|DEVICE|Tomey CASIA 2|The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
219129254|NCT04392349|DEVICE|Oculus PENTACAM HR|The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
219129255|NCT04392349|DEVICE|Zeiss ATLAS 9000|ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
219129256|NCT05468333|OTHER|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
219129257|NCT00994149|DRUG|Diazoxide|10mg/kg/d divide every 8 hours
219129258|NCT00994149|DRUG|Ora-plus|placebo, give every 8 hours.
219129259|NCT00005106|DRUG|Lamivudine/Zidovudine|
219129260|NCT00005106|DRUG|Abacavir sulfate|
219129261|NCT00005106|DRUG|Nelfinavir mesylate|
219129262|NCT00005106|DRUG|Lamivudine|
219129263|NCT00005106|DRUG|Stavudine|
219129264|NCT01738867|DRUG|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
219129265|NCT01738867|DRUG|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
219129266|NCT01738867|DRUG|Placebo|Matching placebo capsules to GSK1521498 or NTX
219711680|NCT06558487|OTHER|Cancer Admission Score Prediction Model|A prediction model that calculates the chance for a patient to be admitted after triage and after first blood results
219711681|NCT03422302|DEVICE|Biphasic Positive Airway Pressure|Receive BiPAP
219711682|NCT03422302|PROCEDURE|Computed Tomography|Undergo CT simulation scans
219129267|NCT04793139|DRUG|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
219129268|NCT03058783|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
219129269|NCT03058783|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
219129270|NCT03537651|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
219711683|NCT03422302|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP
219711684|NCT03422302|PROCEDURE|Deep Inspiration Breath Hold|Complete DIBH
219129271|NCT03537651|DRUG|IVA|Tablet for oral administration.
219129272|NCT05553041|DRUG|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
219129273|NCT04688411|BEHAVIORAL|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
219129274|NCT04348331|DIAGNOSTIC_TEST|Dual echo MRI sequence|new MRI sequences for imaging of joints
219129275|NCT06029751|OTHER|No intervention|No intervention
219129276|NCT02403323|DRUG|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
219129277|NCT00340613|DRUG|glargine insulin|
219129278|NCT05764824|DIETARY_SUPPLEMENT|Blueberry powder|20 g per day of blueberry powder
219129279|NCT05764824|OTHER|Controlled and matched powder|20 g per day
219129280|NCT00018525|PROCEDURE|Lung Volume Reduction Surgery|
219129281|NCT03852433|DRUG|Bulevirtide|Administered via subcutaneous injections
219129282|NCT03852433|DRUG|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
219129283|NCT06234280|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
219129284|NCT01076335|DRUG|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
219129285|NCT01076335|DRUG|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
219711685|NCT03422302|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
219711686|NCT03422302|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219711687|NCT06358885|OTHER|Facilitation (FAC)|The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
219711688|NCT06358885|BEHAVIORAL|Experiential Brief Alcohol Intervention (EBAI)|Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
219711689|NCT05658549|DRUG|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
219129286|NCT03092557|OTHER|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
219129287|NCT00731380|DRUG|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
219129288|NCT06067490|DRUG|RC1416(SAD)|RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
219129289|NCT06067490|DRUG|Placebo(SAD)|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
219129290|NCT05154799|BEHAVIORAL|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
219129291|NCT06323668|PROCEDURE|Cardiac implantable electronic device extraction|The CIED removal will be done as soon as possible within 7 days.
219129292|NCT05832723|DEVICE|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
219129293|NCT03444779|DEVICE|Tibial Tuberoplasty|Kyphoplasty ballon
219711690|NCT06798974|OTHER|Three-dimensional video|Patients who meet the criteria for inclusion in the study will be randomly assigned to intervention and control groups. The intervention group will be shown a 3D lemon video with virtual reality glasses. The video will be created by a company that shoots 3D videos. Opinions of three experts will be obtained for the suitability of the video. The video will be shown to patients for 5 minutes. In order to control the effects that may arise from the practitioner during the study, the virtual reality glasses application will be applied to all patients by the same clinic nurse. The control group will not receive any intervention and will receive standard care. Data collection forms will be given to the patient by the researcher and will be collected after the patient fills them out.
219129294|NCT03444779|DEVICE|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
219129295|NCT03461042|DRUG|Ramelteon 8mg|Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
219129296|NCT03461042|DRUG|Placebo|Placebo capsule once daily before bedtime for 12 weeks since informed consent
219711691|NCT03330197|BIOLOGICAL|Ad-RTS-hIL-12|2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
219226513|NCT06947434|OTHER|Laughter Yoga|Laughter yoga is a behavioral intervention that combines intentional laughter exercises with yogic breathing techniques. In this study, the intervention consisted of 10 sessions delivered over five weeks (two sessions per week), each lasting approximately 40 minutes. Sessions were conducted live via Zoom and included components such as rhythmic clapping, deep breathing (pranayama), playful movements, and guided laughter exercises. The aim was to promote relaxation, reduce stress, and enhance psychological well-being in individuals with multiple sclerosis.
219711692|NCT03330197|DRUG|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
219711693|NCT03330197|DRUG|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
219129297|NCT00715806|DEVICE|Open MRI scanner.|Imaging in an Open MRI scanner.
219129298|NCT00715806|DEVICE|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
219226514|NCT06953986|DRUG|Vonoprazan|Vonaprazon is potassium competitive acid blockers
219226515|NCT06953986|DRUG|Esomeprazole 40mg|esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
219129299|NCT05037994|PROCEDURE|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
219129300|NCT04081545|DRUG|Opioid Anesthetics|see arm/group description
219129301|NCT04081545|DRUG|Non Opioid Analgesics|see arm/group description
219129302|NCT03528629|DRUG|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
219226516|NCT04118894|DEVICE|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
219226517|NCT03685305|BEHAVIORAL|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
219226518|NCT03685305|BEHAVIORAL|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
219226519|NCT06325280|DIAGNOSTIC_TEST|Exercise cardiac MRI Assessment|Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.
219226520|NCT06325280|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
219226521|NCT02872532|PROCEDURE|Testicular tissue cryopreservation|Testicular tissue will be removed
219226522|NCT06299462|DRUG|ATG 5.0|ATG 2.5 mg/kg on days -3 and -2
219129303|NCT00654238|DRUG|sorafenib|400mg PO BID daily
219226523|NCT06299462|DRUG|Cyclophosphamide injection|Cyclophosphamide 50 mg/kg on days +3 and +4
219226524|NCT06299462|DRUG|ATG 4.0|ATG 2.5 mg/kg on day -2 + 1.5 mg/kg on day -3
219226525|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
219226526|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
219226527|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
219226528|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
219226529|NCT06507930|OTHER|Telehealth Hospice Visits|Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
219226530|NCT02678455|BIOLOGICAL|TV005 vaccine|Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
219226531|NCT02678455|BIOLOGICAL|Placebo|Delivered by subcutaneous injection
219226532|NCT03532139|DRUG|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
219711694|NCT02654574|OTHER|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
219129304|NCT00906490|DEVICE|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
219129305|NCT06168604|BEHAVIORAL|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
219129306|NCT06168604|BEHAVIORAL|Health Promotion Program|The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
219129307|NCT03664323|BIOLOGICAL|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
219711695|NCT06042140|DEVICE|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
219711696|NCT04030559|DRUG|Niraparib|Given PO
219129308|NCT05871242|DIETARY_SUPPLEMENT|Probiotic Lactobacillus crispatus M247|Patient who have received probiotic Lactobacillus crispatus M247
219129309|NCT01538446|DRUG|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
219129310|NCT01538446|DRUG|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
219129311|NCT01538446|DEVICE|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
219129312|NCT03318913|OTHER|Placebo|5g of the sucralose administered as white plastic capsules
219129313|NCT03318913|OTHER|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
219129314|NCT04890756|OTHER|observational|"The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed."
219129315|NCT05133167|PROCEDURE|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
219129316|NCT02301234|DRUG|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
219129317|NCT02301234|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
219129318|NCT02301234|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
219129319|NCT02301234|DRUG|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
219129320|NCT02301234|DRUG|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
219129321|NCT03031704|PROCEDURE|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
219129322|NCT03276364|DIAGNOSTIC_TEST|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
219129323|NCT01740557|BIOLOGICAL|Aldesleukin|Given IV
219129324|NCT01740557|BIOLOGICAL|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
219129325|NCT01740557|DRUG|Cyclophosphamide|Given IV
219129326|NCT01740557|DRUG|Fludarabine Phosphate|Given IV
219129327|NCT01740557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219711697|NCT04030559|DRUG|Niraparib Tosylate Monohydrate|Given PO
219129328|NCT01740557|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
219129329|NCT01740557|OTHER|Quality-of-Life Assessment|Ancillary studies
219129330|NCT01481935|OTHER|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
219129331|NCT01481935|OTHER|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
219129332|NCT02998489|OTHER|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
219129333|NCT02998489|OTHER|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
219129334|NCT03394248|DEVICE|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
219129335|NCT01248221|DRUG|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
219129336|NCT00142220|DRUG|Defined percentage of omega-3-fatty acids|
219129337|NCT03724474|BEHAVIORAL|Be SMART|The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
219129338|NCT03563781|PROCEDURE|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
219129339|NCT05922436|DRUG|QLG2071|intravenous injection
219129340|NCT05922436|DRUG|Cleviprex®|intravenous injection
219129341|NCT02429609|DEVICE|Moorfields Acuity Chart|
219711698|NCT04030559|PROCEDURE|Radical Prostatectomy|Undergo standard of care surgery
219711699|NCT04667234|DRUG|AMG 510|Administered as an oral tablet.
219711700|NCT02436707|DRUG|Ibrutinib|
219711701|NCT02436707|DRUG|Rituximab|
219711702|NCT02436707|DRUG|Gemcitabine|
219129342|NCT02521064|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
219129343|NCT02521064|DRUG|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
219711703|NCT02436707|DRUG|Dexamethasone|
219129344|NCT01268566|DRUG|MEDI-575|MEDI-575 as an IV infusion.
219129345|NCT00928200|DRUG|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
219129346|NCT00928200|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
219711704|NCT02436707|DRUG|Cisplatin|
219711705|NCT02436707|DRUG|Mesna|
219711706|NCT02436707|DRUG|Cyclophosphamide|
219711707|NCT02436707|DRUG|Etoposide|
219711708|NCT02436707|DRUG|G-CSF|
219711709|NCT02436707|DRUG|Selinexor|
219711710|NCT04315142|DEVICE|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
219711711|NCT04315142|DEVICE|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
219129347|NCT00928200|DRUG|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
219129348|NCT00928200|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
219129349|NCT00928200|DRUG|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
219129350|NCT00928200|DRUG|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
219129351|NCT00928200|DRUG|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
219129352|NCT00928200|DRUG|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
219129353|NCT03537885|DIAGNOSTIC_TEST|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
219711712|NCT04981613|DRUG|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
219711713|NCT06485258|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
219711714|NCT06485258|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
219711715|NCT06485258|OTHER|Placebo|0.5 mL sterile saline administered via IM injection
219711716|NCT05261425|DEVICE|Monocryl buried|Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
219711717|NCT05261425|DEVICE|Nylon (FDA Approved) not buried|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
219711718|NCT06236516|RADIATION|One fraction stereotactic body radiotherapy|Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.
219711719|NCT06236516|DEVICE|HyperSight|HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.
219711720|NCT06236516|DEVICE|Ethos|Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
219711721|NCT06409156|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.
219129354|NCT03537885|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
219129355|NCT03537885|DIAGNOSTIC_TEST|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
219129356|NCT03982420|PROCEDURE|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
219129357|NCT01273558|DRUG|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
219129358|NCT00601965|DRUG|Escitalopram|20 mg daily oral escitalopram
219129359|NCT00601965|DRUG|Placebo|Placebo pill of daily oral escitalopram
219129360|NCT00601965|BEHAVIORAL|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
219129361|NCT06187974|OTHER|observation|observation
219129362|NCT06217029|OTHER|physiotherapy and maxillary traction|"1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release"
219129363|NCT03661554|BIOLOGICAL|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
219129364|NCT02138916|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219129365|NCT02138916|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
219711722|NCT06409156|PROCEDURE|External Oblique Intercostal Fascial Plane block|With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
219711723|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
219711724|NCT02404142|DRUG|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
219711725|NCT02404142|DRUG|saline isotonic solution|
219711726|NCT02222467|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
219711727|NCT02290418|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
219711728|NCT02290418|PROCEDURE|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
219711729|NCT01416662|DRUG|gemcitabine hydrochloride|
219711730|NCT01650428|BIOLOGICAL|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
219711731|NCT01650428|DRUG|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
219711732|NCT01650428|DRUG|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
219711733|NCT01650428|DRUG|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
219129366|NCT02138916|DRUG|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
219129367|NCT06265168|OTHER|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
219129368|NCT01348087|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
219129369|NCT03034733|DRUG|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
219129370|NCT03034733|DRUG|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
219129371|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
219129372|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
219129373|NCT03057561|DRUG|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
219129374|NCT03057561|DRUG|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
219129375|NCT03929731|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
219129376|NCT01420367|DRUG|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
219129377|NCT04794179|DEVICE|Naida Link CROS|Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
219711734|NCT05438511|BEHAVIORAL|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
219711735|NCT05438511|BEHAVIORAL|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
219711736|NCT06961851|OTHER|aTMS utilizing the MagVenture TMS device|Participants will complete 6 MagVenture TMS sessions per day for 5 days at the SLP Clinic. Sessions will take place with at least 30 minutes between each session. The first session will determine the baseline motor threshold for delivering aTMS. We will be stimulating the dorsolateral prefrontal cortex (DLPFC) which is within the FDA approved uses. Participants will complete a PHQ9 on all 5 treatment days and 1, 2, 4, and 6 weeks post treatment via REDCap Participants will complete daily adverse event logs via REDCap
219711737|NCT06962345|DEVICE|Hormone-free vulvovaginal gel with tested composition XCM® INTIM and PROMs questionnaire.|"Management of GSM in post-menopausal women will be measured with the combination of the application of the hormone-free vulvovaginal gel along the 8 weeks of the study and the use of a PROMs questionnaire. PROMS questionnaire will be delivered to the women at baseline and at the end of the study. Daily living quality of life domains of activities of daily living, emotional well-being, sexual functioning, self-perception and body image will be evaluated."
219711738|NCT06963177|DRUG|GenSci048|Administered SC.
219711739|NCT06963177|DRUG|Placebo|Administered SC.
219711740|NCT02854462|BEHAVIORAL|Language comprehension intervention|
218986492|NCT04564261|BEHAVIORAL|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
218986493|NCT00137579|PROCEDURE|Influenza vaccine intramuscular administration route|
218986494|NCT02085083|BEHAVIORAL|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
218986495|NCT02085083|BEHAVIORAL|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
218986496|NCT05705388|DEVICE|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
218986497|NCT05705388|DRUG|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
218986498|NCT01786668|DRUG|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
218986499|NCT01786668|DRUG|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
218986500|NCT01786668|DRUG|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
218986501|NCT01786668|DRUG|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
218986502|NCT02129998|OTHER|IVF/ICSI treatment|
218986503|NCT01471470|DRUG|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
218986504|NCT01530360|DEVICE|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
218986505|NCT01376284|DRUG|Dutasteride|Collection of safety data
218986506|NCT04103658|RADIATION|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
218986507|NCT03213522|PROCEDURE|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
218986508|NCT03213522|PROCEDURE|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
218986509|NCT04465474|OTHER|Non Intervention|It's an observational study, no intervention involves.
218986510|NCT02762357|DEVICE|Novosyn® Quick|Episiotomy closure
218986511|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
219129378|NCT05227469|BEHAVIORAL|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
219129379|NCT06383884|DRUG|Patritumab Deruxtecan|Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
219129380|NCT05785897|DEVICE|Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation|"'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age \>75 years or weight \<60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis \<30% by visual estimation or 20% by QCA."
219129381|NCT04181775|DIAGNOSTIC_TEST|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
219129382|NCT02636881|PROCEDURE|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
219129383|NCT02636881|PROCEDURE|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
219129384|NCT06180382|DRUG|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
219129385|NCT06180382|DRUG|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
219129386|NCT06411665|DRUG|Oliceridine|Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
219129387|NCT06411665|DRUG|Morphine|Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
219129388|NCT05433948|DIAGNOSTIC_TEST|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
219711741|NCT02854462|BEHAVIORAL|Counting intervention|
219711742|NCT02843308|BEHAVIORAL|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
219711743|NCT06379321|DEVICE|Triathlon Hinge Knee (THK) System|Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
219711744|NCT03765177|BIOLOGICAL|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
219711745|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
219711746|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
219129389|NCT01573143|DRUG|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
219129390|NCT01573143|DRUG|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
219129391|NCT06104865|BEHAVIORAL|Tinnitus Sound Therapy using (Resound Tinnitus relief) mobile application|Patient exposure to relieving sound(wind, rain, ocean waves, etc) of his own choice from the mobile phone application and using this effect with time to accommodate the brain to neglect the negative effects of tinnitus.
219129392|NCT03968991|DIAGNOSTIC_TEST|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
219129393|NCT02977143|PROCEDURE|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
219129394|NCT05585112|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale
219129395|NCT05585112|DRUG|Articaine 4%|The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
219129396|NCT03050840|BEHAVIORAL|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
219129397|NCT00444574|DRUG|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
219129398|NCT00444574|DRUG|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
219711747|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
219711748|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
219711749|NCT05985785|OTHER|Autologous bone marrow aspirate concentrate (BMAC)|Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.
219711750|NCT05985785|DRUG|Corticosteroid injections|Current standard of treatment for OA of the knee is corticosteroid injection.
218986512|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
218986513|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
218986514|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
218986515|NCT00939497|DRUG|Risperidone|
218986516|NCT02579187|PROCEDURE|tooth extraction|The study tooth will be removed
218986517|NCT02579187|RADIATION|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
218986518|NCT02579187|DRUG|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
218986519|NCT02579187|OTHER|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
218986520|NCT02579187|DRUG|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
218986521|NCT02579187|DRUG|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
218986522|NCT02579187|PROCEDURE|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
218986523|NCT02579187|DRUG|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
218986524|NCT02579187|DRUG|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
218986525|NCT02579187|PROCEDURE|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
218986526|NCT02579187|OTHER|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
218986527|NCT02579187|PROCEDURE|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 \& 4 weeks post extraction
218986528|NCT02579187|PROCEDURE|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
218986529|NCT02579187|RADIATION|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
218986530|NCT02579187|OTHER|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
218986531|NCT01970046|DRUG|Placebo/Metformin|"* Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
218986532|NCT01970046|DRUG|SP2086 50 mg b.i.d/Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
218986533|NCT01970046|DRUG|SP2086 50 mg q.d./Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
218986534|NCT06318169|BIOLOGICAL|Pegozafermin|Subcutaneous injection
218986535|NCT06318169|OTHER|Placebo|Subcutaneous injection
218986536|NCT03570697|DRUG|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
218986537|NCT03570697|DRUG|Placebo|Participants will receive matching placebo subcutaneous monthly.
218986538|NCT03570697|DRUG|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
219129399|NCT00444574|DRUG|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
219129400|NCT02125513|DRUG|carboplatin and paclitaxel followed by surgery|
219129401|NCT03194061|RADIATION|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
219129402|NCT03194061|DRUG|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
219129403|NCT03563638|DIAGNOSTIC_TEST|75gOGTT|oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
219129404|NCT00913432|DRUG|masitinib|3 mg/kg/day oral route
219129405|NCT00913432|DRUG|masitinib|masitinib 6 mg/kg/day oral route
219129406|NCT02809911|DEVICE|Provant|
219129407|NCT03688854|DIETARY_SUPPLEMENT|SCFA mixture|Intracolonic administration
219129408|NCT00818025|BEHAVIORAL|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
219129409|NCT03297983|DRUG|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
219129410|NCT00589862|DRUG|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
219129411|NCT04732039|OTHER|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
219711751|NCT05985785|OTHER|Crossover Autologous bone marrow aspirate concentrate (BMAC)|Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
219711752|NCT06553872|DRUG|Pirtobrutinib|Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
219129412|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
219129413|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
219129414|NCT04242394|PROCEDURE|ERCP|Routine ERCP procedures with gallbladder in situ patient
219129415|NCT02266420|PROCEDURE|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
219129416|NCT05502380|DRUG|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
219129417|NCT06404762|PROCEDURE|tSCTG+ CAF|In the tSCTG group, at the distal end of a second maxillary molar, an incision will be made using a double-bladed scalpel (SKU 10-130-05D; Hu-Friedy, Chicago, IL, USA) bucco-palatally, forming a 1,5 mm thick parallel line. Secondary incisions will be made to separate the graft using a 15c blade on the buccal and palatal sides. Later, the graft will be de-epithelialized extra-orally using a blade
219129418|NCT06404762|PROCEDURE|pSCTG+ CAF|In pSCTG group; the graft will be harvested through a single-incision approach at the lateral palatal mucosa
219711753|NCT06553872|DRUG|Brexucabtagene Autoleucel|Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
219129419|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
219129420|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
219129421|NCT02221479|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
219129422|NCT02221479|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
219711754|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
219711755|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
219711756|NCT04993846|DIAGNOSTIC_TEST|Dental plaque sampling|Dental plaque sampling
219711757|NCT04993846|DIAGNOSTIC_TEST|qPCR|qPCR
219711758|NCT03258242|DRUG|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
219711759|NCT03258242|DRUG|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
219711760|NCT02320175|BEHAVIORAL|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
219129423|NCT01092624|DRUG|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
219129424|NCT01092624|DRUG|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
219129425|NCT01092624|DEVICE|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
219129426|NCT00791531|DRUG|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
219129427|NCT03226730|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
219129428|NCT03226730|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
219711761|NCT05498727|DIAGNOSTIC_TEST|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
219711762|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
219711763|NCT01246284|DRUG|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
219711764|NCT01246284|OTHER|Normal saline|
219711765|NCT02242630|DRUG|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
219711766|NCT02242630|DRUG|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
219711767|NCT02242630|DRUG|Triamcinolone, 20 mg|Compared with methylprednisolone
219711768|NCT02242630|DRUG|Triamcinolone, 40 mg|Compared with methylprednisolone
219129429|NCT03237221|DRUG|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
219129430|NCT02237079|DRUG|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
219129431|NCT02237079|DRUG|Placebo Oral Tablet|Daily placebo tablet
219129432|NCT03020355|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
219711769|NCT05310136|BEHAVIORAL|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
219129433|NCT03020355|PROCEDURE|not Placental Blood Drainage|In the control group, the clamped cord will not released.
219129434|NCT01542619|BIOLOGICAL|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
219129435|NCT01542619|BIOLOGICAL|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
219129436|NCT06470776|BEHAVIORAL|Chatbot counselling|Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.
219129437|NCT06470776|BEHAVIORAL|Peer counselling|Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline
219129438|NCT01289743|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
219129439|NCT04380844|OTHER|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
219129440|NCT01110174|DIAGNOSTIC_TEST|HD PET/CT|imaging
219129441|NCT04827459|BEHAVIORAL|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
219129442|NCT02801929|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72\_V27-010).
219129443|NCT00002784|BIOLOGICAL|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
219129444|NCT00002784|DRUG|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
219711770|NCT06001645|DIAGNOSTIC_TEST|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
219711771|NCT06001645|DIAGNOSTIC_TEST|Chest CT scan|Computed Tomography Scan per normal clinical practice
219129445|NCT00002784|DRUG|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
219711772|NCT01311791|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
219711773|NCT01311791|DRUG|Standard medical therapy|as defined per protocol
219711774|NCT04070534|OTHER|PALS|patient activated learning system
219711775|NCT05483647|PROCEDURE|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
219129446|NCT00002784|DRUG|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
219129447|NCT00002784|DRUG|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
219129448|NCT00002784|DRUG|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
219129449|NCT00002784|DRUG|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
219129450|NCT00002784|DRUG|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
219129451|NCT00002784|DRUG|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
219129452|NCT00002784|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
219129453|NCT00002784|RADIATION|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
219129454|NCT00002784|RADIATION|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
219129455|NCT04678830|DRUG|Placebos|Placebos
219129456|NCT04678830|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
219129457|NCT05900453|OTHER|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
219129458|NCT03310229|RADIATION|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
219129459|NCT01190176|PROCEDURE|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
219129460|NCT01190176|BIOLOGICAL|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
219129461|NCT01190176|BIOLOGICAL|Placebo control|Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
219129462|NCT03697460|DRUG|INCB018424|INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
219129463|NCT05567666|DEVICE|Optilume Catheter System|Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
219129464|NCT06081101|DRUG|Methylprednisolone Injection|Medication will be injected into SI joint under ultrasound guidance
219129465|NCT06081101|DRUG|Ketorolac Injection|Medication will be injected into SI joint under ultrasound guidance
219129466|NCT04004858|RADIATION|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
219129467|NCT00365417|DRUG|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
219129468|NCT00365417|DRUG|Doxorubicin|60 mg/m\^2 IV every 21 days x 4 cycles
219129469|NCT00365417|DRUG|Cyclophosphamide|600 mg/m\^2 IV every 21 days x 4 cycles
219711776|NCT05483647|PROCEDURE|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
219129470|NCT00365417|DRUG|Capecitabine|Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
219129471|NCT00365417|DRUG|Docetaxel|Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
219129472|NCT03272646|PROCEDURE|surgery|gastric resection or total gastrectomy
219129473|NCT03524820|DRUG|Cetuximab|Administration of drug
219129474|NCT04807660|OTHER|middle ear fluid sample|middle ear fluid sample for each enrrolled children
219129475|NCT02023203|PROCEDURE|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
219129476|NCT01188317|DRUG|aleglitazar|repeated daily doses
219129477|NCT01188317|DRUG|placebo|repeated daily doses
219129478|NCT01188317|DRUG|ibuprofen|repeated daily doses
219129479|NCT01051011|DRUG|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
219129480|NCT01051011|DRUG|metformin|as prescribed
219129481|NCT01051011|DRUG|taspoglutide|10mg sc weekly, 24 (-52) weeks
219129482|NCT01051011|DRUG|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
219129483|NCT03499600|BEHAVIORAL|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
219129484|NCT03499600|BEHAVIORAL|Clinical Assessment|CA families will participate their standard intake procedures.
219129485|NCT06109532|OTHER|hyponatremia|hyponatremia at admission in dengue infected patients
219129486|NCT00258479|DRUG|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
219129487|NCT00258479|DRUG|Modafinil|See Modafinil Intervention Description above.
219129488|NCT00445692|DRUG|Clarithromycin|Given Orally (PO)
219129489|NCT00445692|DRUG|Dexamethasone|Given PO
219129490|NCT00445692|DRUG|Lenalidomide|Given Orally (PO)
219711777|NCT03220789|PROCEDURE|Drilling at low speed|
219711778|NCT03220789|PROCEDURE|Drilling at conventional or high speed|
219711779|NCT06265636|PROCEDURE|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
219711780|NCT06265636|OTHER|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
219129491|NCT01796977|DEVICE|OxyGenesys Dissolved Oxygen Dressing|
219129492|NCT01796977|DEVICE|Standard Gauze Dressing|
219129493|NCT01525979|BEHAVIORAL|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
219129494|NCT01525979|BEHAVIORAL|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
219129495|NCT01525979|BEHAVIORAL|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
219129496|NCT01525979|BEHAVIORAL|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
219711781|NCT06265636|OTHER|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
219129497|NCT05008341|DRUG|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
219129498|NCT04614077|OTHER|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
219129499|NCT06434428|DRUG|dexmedetomidine (IV)|Administration of IV dexmedetomidine
219129500|NCT06434428|DRUG|dexmedetomidine (IN)|Administration of IN dexmedetomidine
219711782|NCT06700447|BEHAVIORAL|Enhanced inoculation message|"Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: Inoculation message with a BE boost for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime."
219711783|NCT06700447|BEHAVIORAL|Nutrition information|Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
219711784|NCT00876343|DRUG|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
219129501|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
219129502|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
219129503|NCT03883685|DIETARY_SUPPLEMENT|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
219129504|NCT03883685|DIETARY_SUPPLEMENT|Placebo|Placebo
219129505|NCT01821911|BIOLOGICAL|Zagreb2-1-1|Injection on day 0、7、21
219129506|NCT01821911|BIOLOGICAL|Essen|Injection on day 0、3、7、14、28
219129507|NCT01155245|DRUG|Forteo|Forteo pen
219129508|NCT04952272|COMBINATION_PRODUCT|CpG-ODN|CAR-T cells secreting scFv against OX40
219711785|NCT00876343|DRUG|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
219711786|NCT00876343|DRUG|Placebo|administered orally once daily, 6 weeks
219711787|NCT06792825|DRUG|Tafasitamab|Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.
219711788|NCT06792825|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
219711789|NCT06792825|DRUG|Lenalidomide|Lenalidomide 20 mg PO Day 1 through Day 21
219711790|NCT04582526|BEHAVIORAL|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
219711791|NCT06158828|DRUG|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
219711792|NCT06158828|DRUG|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
219129509|NCT05792046|DEVICE|Visual field|test for detecting loss in visual function
219129510|NCT03331328|DEVICE|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
219129511|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
219129512|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
219129513|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
219129514|NCT00880490|DRUG|Inhaled placebo|single dose, inhaled
219129515|NCT00880490|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
219129516|NCT02928939|OTHER|drug-drug or drug-disease interaction|
219711793|NCT06158828|DRUG|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
219711794|NCT06158828|DRUG|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
219129517|NCT00607035|DRUG|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
219226533|NCT03532139|DRUG|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
219129518|NCT00607035|DRUG|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
219129519|NCT02939001|DEVICE|iris recognition scanner|
219129520|NCT03425539|DRUG|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
219129521|NCT03425539|DRUG|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
219226534|NCT03532139|OTHER|Thromboprophylaxis|standard of care therapy
219129522|NCT01137292|DRUG|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
219129523|NCT02040844|DRUG|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
219129524|NCT02040844|DRUG|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
219129525|NCT02040844|DRUG|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
219129526|NCT03663101|DRUG|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
219360578|NCT05300516|PROCEDURE|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
219711795|NCT06158828|DRUG|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
219711796|NCT06158828|BIOLOGICAL|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
219711797|NCT06158828|BIOLOGICAL|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
219711798|NCT06158828|BIOLOGICAL|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
219711799|NCT06158828|DRUG|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
219711800|NCT06158828|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
219711801|NCT06158828|DEVICE|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
219711802|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
219711803|NCT06695247|OTHER|Exercise Training|Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
219711804|NCT05357495|BEHAVIORAL|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
219711805|NCT03539510|BEHAVIORAL|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
219129527|NCT03663101|BIOLOGICAL|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
219129528|NCT03663101|DRUG|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
219129529|NCT03663101|DRUG|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
219129530|NCT05472649|BIOLOGICAL|Gene-Modified Cell Therapy|No investigational cell product will be administered
219129531|NCT03661970|OTHER|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
219711806|NCT05802355|OTHER|Manual Diaphragm Release|The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.
219711807|NCT05802355|OTHER|control group|Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
219711808|NCT05316220|DRUG|Mesalamine|Oral Capsules
219711809|NCT05316220|DRUG|Placebo|Oral Capsule
219711810|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
219711811|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
219711812|NCT04126070|DRUG|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
219711813|NCT04126070|DRUG|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
219711814|NCT04126070|DRUG|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
219711815|NCT05217446|DRUG|Encorafenib|capsule
219711816|NCT05217446|BIOLOGICAL|Cetuximab|IV
219711817|NCT05217446|BIOLOGICAL|Pembrolizumab|IV
219129532|NCT05765591|OTHER|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
219129533|NCT04122924|OTHER|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
219129534|NCT01353638|DRUG|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
219129535|NCT00609648|BEHAVIORAL|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
219711818|NCT05211700|OTHER|This is an observational study, there is no intervention in this study.|There is no intervention in this study
219711819|NCT04194840|OTHER|physical therapy consult|Physical therapy consult to assess physical functioning on a separate office visit prior to attending the Transplant Wellness Clinic. Full evaluation that incorporates several tools to measure the risk of falling and to assess mobility and strength
219711820|NCT04194840|OTHER|Cognitive Assessment|Montreal cognitive assessment (MoCA) and the Blessed Orientation-Memory-Concentration Test (BOMC)
219711821|NCT04194840|OTHER|Cancer Aging Research Group (CARG) assessment|CARG assessment - utilized to capture information about a participant's medical history as well as functional, cognitive, and psychosocial status
219711822|NCT04194840|OTHER|Medication Review|Medication Review via Beers Assessment
219711823|NCT04194840|OTHER|Nutrition assessment|Nutrition assessment Via Mini Nutrition Assessment (MNA)
219711824|NCT04194840|OTHER|Laboratory studies|Laboratory studies including urine toxicology screen, C-reactive protein, albumin, pre-albumin, vitamin D
219711825|NCT04194840|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
219711826|NCT04194840|OTHER|Physician Questionnaire|"Physician Questionnaire:~Questionnaire to learn about physician satisfaction with information received from reports and participant questionnaires."
219711827|NCT04194840|OTHER|Patient follow-up questionnaire|"Patient follow-up questionnaire:~Questionnaire to learn more about participant opinions concerning the clinic and the quality of care received during visits with specialists"
219711828|NCT01081990|DRUG|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
219711829|NCT00646516|DRUG|budesonide/formoterol (Symbicort)|
219711830|NCT05984030|OTHER|PrEP Navigation Services|Trained professional PrEP navigators will connect with intervention arm participants following study onboarding. Primary navigator responsibilities include helping participants engage in PrEP care, assisting with completing necessary paperwork for insurance, referral to PrEP care, and application for drug assistance programs, as needed. Navigation services will be available to participants for the first 6 months of participation (active intervention period). Navigation services are tailored to the individual needs of each intervention arm participant
219129536|NCT00609648|BEHAVIORAL|Pamphlet|A pamphlet reassuring patients about dental injections.
219711831|NCT05984030|OTHER|Telehealth PrEP Services Referral|PrEP Navigators can link interested intervention arm participants to telehealth PrEP services via self-referral. The study facilitates referral for intervention arm participants to pre-existing telehealth PrEP services. The telehealth PrEP services participants receive are not provided, financed, or staffed by the study. Participants will receive telehealth PrEP services via the technology platform or service that the provider typically employs. PrEP clinical eligibility, visit frequency, monitoring labs, and all other PrEP management will be at the discretion of the established PrEP provider. PrEP navigators can assist with appointment scheduling, reminders, and other provider-access issues, as requested, for the first 6 months of study participation.
219711832|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Enhanced|The Enhanced version of the HealthMpowerment Digital Health Intervention includes all features from the Basic version, plus the following additional features: Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.
219711833|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Basic|The Control Arm version of the HealthMpowerment Digital Health Intervention includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.
219711834|NCT06627569|BEHAVIORAL|Exercise|12 weeks of aerobic exercise, with 4 sessions per week.
219711835|NCT01508000|DRUG|FOLFOX6|5-FU, folinic acid, oxaliplatin
219711836|NCT01508000|BIOLOGICAL|Bevacizumab|Targeted therapy
219711837|NCT01508000|BIOLOGICAL|Panitumumab|Targeted therapy
219711838|NCT01508000|PROCEDURE|Surgery|
219711839|NCT05250232|OTHER|onlays conservative|Partial coverage of cusps with shoulder finish line
219711840|NCT05250232|OTHER|onlays conventional|all coverage of cusps as overlay with shoulder finish line
219711841|NCT01983631|OTHER|Whole body vibration training|
219711842|NCT05155358|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
219711843|NCT06294561|DRUG|Itraconazole+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11
219711844|NCT06294561|DRUG|Efavirenz+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20
219711845|NCT02323256|OTHER|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
219711846|NCT02323256|OTHER|Speech-ABR|
219711847|NCT02323256|OTHER|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
219711848|NCT02323256|OTHER|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
219711849|NCT03116230|DEVICE|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
219711850|NCT03116230|DEVICE|Knee Sleeve|Commercially-available knee sleeve.
219711851|NCT06197204|OTHER|Blood sampling|"* at first visit in the reference center~* at each follow-up visit ( once a year)~* before and after specific treatment~* in case of flare"
219711852|NCT06197204|OTHER|Biopsy|In case of flare
219711853|NCT06197204|OTHER|Blood sampling|Once at inclusion visit
219711854|NCT00207428|DRUG|Carbamazepine|
219711855|NCT03220893|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
219711856|NCT03220893|RADIATION|Scintimammography|Undergo MBI
219711857|NCT06487962|DEVICE|CGM Intervention|The intervention has 4 components with CGM uptake and maintenance as a primary focus. (1) Participants will visit their primary care provider (PCP) at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of CGM data and insulin therapy adjustments as indicated. Intervention providers received rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes). (2) After each PCP visit, the CDCES will follow-up with participants to ensure participant understanding of the education/instructions provided at the PCP visit. (3) Next, participants will receive 4-weekly sessions of culturally sensitive, intensive CGM education and training led by a CDCES with accompaniment of a supportive family member or friend. (4) Virtual group support sessions, led by a peer educator, will follow over 5 months. During this period, the peer-led sessions will take place every two weeks and then move to every three weeks.
219129537|NCT02014558|DRUG|Gilteritinib|Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
219129538|NCT02014558|DRUG|Voriconazole|Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
219129539|NCT02014558|DRUG|Midazolam|Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
219129540|NCT02014558|DRUG|Cephalexin|Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
219360579|NCT01625273|OTHER|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10\^8 CFU per day from 28 days to 6 months of infant age
219711858|NCT06487962|OTHER|SMBG Control Condition|The SMBG control condition consists of 3 components delivered over 6 months. (1) Participants will visit their PCP at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of SMBG data and insulin therapy adjustments as indicated. Control providers received rigorous training in T1D management via Project ECHO. (2) Commencing after the first PCP visit, participants will have 4-weekly telehealth visits for knowledge and skills reinforcement for SMBG. (3) CDCES support phone calls will follow over 5 months. During this period, the support phone calls will take place every two weeks and then move to every three weeks.
219711859|NCT01933932|DRUG|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
219129541|NCT00186810|DRUG|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
219129542|NCT00186810|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
219129543|NCT04784013|PROCEDURE|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
219711860|NCT01933932|DRUG|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
219129544|NCT04784013|PROCEDURE|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
219129545|NCT05579886|DEVICE|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
219129546|NCT05579886|DEVICE|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
219129547|NCT01472536|BEHAVIORAL|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
219129548|NCT01560949|DRUG|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
219129549|NCT01560949|DRUG|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
219129550|NCT01560949|DRUG|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
219129551|NCT01560949|DRUG|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
219129552|NCT01560949|RADIATION|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
219129553|NCT04756050|DRUG|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
219129554|NCT04756050|DRUG|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
219360580|NCT03551743|COMBINATION_PRODUCT|PRT064445/Edoxaban|
219360581|NCT03551743|COMBINATION_PRODUCT|Placebo/Edoxaban|
219360582|NCT03551743|DRUG|Placebo|
219129555|NCT04756050|DRUG|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
219129556|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
219129557|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
219129558|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
219129559|NCT04756050|PROCEDURE|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
219129560|NCT04580407|BIOLOGICAL|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
219129561|NCT03861455|DRUG|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
219711861|NCT01933932|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
219711862|NCT01933932|DRUG|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
219711863|NCT06636214|BEHAVIORAL|CHATO-I|Online communication education program
219711864|NCT06634706|DEVICE|RefleXion X1 Radiotherapy System [Imaging Only]|kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
219711865|NCT04315558|DRUG|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
219711866|NCT04315558|DRUG|Ipratropium Bromide|nebulized drug comparison
219129562|NCT03861455|DRUG|placebo|patient receive placebo
219129563|NCT03181724|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
219360583|NCT01929304|OTHER|Survey|
219711867|NCT03823027|DEVICE|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
219711868|NCT06634979|PROCEDURE|Selective lymph node dissection|For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
219711869|NCT00858546|DEVICE|Repetitive transcranial stimulation|Repetitive transcranial stimulation
219711870|NCT06520163|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
219711871|NCT06520163|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
219711872|NCT06520163|DRUG|PEG-rhG-CSF|Day 6: 6mg
219711873|NCT06520163|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
219711874|NCT06520163|COMBINATION_PRODUCT|CHOP|\[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
219711875|NCT06520163|COMBINATION_PRODUCT|Hyper-CVAD|\[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
219711876|NCT06520163|COMBINATION_PRODUCT|ID-MTX + Ara-C|\[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
219360584|NCT02319044|DRUG|MEDI4736|MEDI4736 monotherapy
219360585|NCT02319044|DRUG|Tremelimumab|Tremelimumab monotherapy
219360586|NCT02319044|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
219711877|NCT06520163|COMBINATION_PRODUCT|DA-EPOCH|\[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
219711878|NCT06520163|COMBINATION_PRODUCT|GDP|\[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
219711879|NCT06520163|COMBINATION_PRODUCT|GDPE|\[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
219711880|NCT06520163|COMBINATION_PRODUCT|ICE|\[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
219711881|NCT06520163|COMBINATION_PRODUCT|DICE|\[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
219711882|NCT06520163|DRUG|G-CSF|From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
219711883|NCT06635213|OTHER|Desensitisation|This technique is utilized to decrease, or normalize, the body's response to particular sensations.
219711884|NCT06635213|OTHER|Pain neuroscience education|PNE is an educational intervention aiming to alter a patient's beliefs and cognitions regarding their pain experience.
219711885|NCT06548035|BEHAVIORAL|Adapted Relaxation Response Resiliency Program (3RP)|The 3RP intervention is an integrated program of relaxation response (RR) eliciting meditation and mindfulness exercises, social support, cognitive skills training, and positive psychology focused on developing skills to reduce the stress response, elicit the relaxation response and enhance resiliency.
218986539|NCT00816920|OTHER|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
219711886|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
219711887|NCT03938389|DRUG|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
219711888|NCT03938389|DRUG|Valsartan 160mg|Participant will take Valsartan for 26 weeks
219711889|NCT03938389|DRUG|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
219711890|NCT05109650|DRUG|BAT6026|IV infusions
219711891|NCT05109650|DRUG|BAT1308|Ⅳ infusions
219711892|NCT01635088|DRUG|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
219711893|NCT01635088|DEVICE|KoKo Spirometry|
218986540|NCT04851457|DRUG|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
218986541|NCT05857059|DRUG|Misoprostol 25 mcg|Misoprostol 50 mcg every 2 hours
218986542|NCT05857059|DRUG|Misoprostol 50 mcg|Misoprostol 50 mcg every 2 hours
218986543|NCT01849783|DRUG|dexamethasone|Given PO
218986544|NCT01849783|DRUG|cisplatin|Given IV
218986545|NCT01849783|DRUG|doxorubicin|Given IV
218986546|NCT01849783|DRUG|cyclophosphamide|Given IV or PO
218986547|NCT01849783|DRUG|etoposide|Given IV
218986548|NCT01849783|DRUG|bortezomib|Given IV
218986549|NCT01849783|DRUG|thalidomide|Given PO
218986550|NCT01849783|DRUG|melphalan|Given IV
218986551|NCT01849783|PROCEDURE|autologous stem cell transplant|
218986552|NCT01044628|DEVICE|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%
218986553|NCT01044628|DEVICE|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
218986554|NCT01776840|DRUG|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
218986555|NCT01776840|DRUG|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
218986556|NCT01776840|DRUG|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
218986557|NCT01776840|DRUG|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
218986558|NCT06006741|BIOLOGICAL|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
218986559|NCT04961931|DRUG|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
218986560|NCT01152697|DRUG|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
218986561|NCT01152697|DRUG|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
218986562|NCT01152697|BEHAVIORAL|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
218986563|NCT02974478|DIETARY_SUPPLEMENT|Orange juice with meals|orange juice (20% of energy requirement/day)
218986564|NCT02974478|DIETARY_SUPPLEMENT|Orange juice between meals|orange juice (20% of energy requirement/day)
219129564|NCT04865302|PROCEDURE|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
219129565|NCT03032159|BEHAVIORAL|Text2Breathe Study Group|
219711894|NCT01635088|DRUG|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
219129566|NCT03902340|DEVICE|ActiTENS|ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
219129567|NCT03902340|DRUG|Level 2 Analgesic Treatments|"There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~* Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~* Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~* Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~* Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h."
219129568|NCT00137956|DEVICE|Emphasys Endobronchial Valve (EBV) Device and Procedure|
219129569|NCT00681811|DRUG|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
219129570|NCT01642264|BEHAVIORAL|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
219129571|NCT02068885|BEHAVIORAL|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
219129572|NCT00928109|BEHAVIORAL|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
219129573|NCT00928109|BEHAVIORAL|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
219129574|NCT01365338|DRUG|Placebo|Administered as specified in the treatment arm
219711895|NCT01635088|DEVICE|Oscillometry|
219711896|NCT04468061|DRUG|Sacituzumab Govitecan|Intravenous Infusion
219711897|NCT04468061|DRUG|Pembrolizumab|Intravenous Infusion
219711898|NCT05843994|OTHER|online survey|Participants will complete an online survey and submit photographs.
219711899|NCT06071442|DRUG|Vemircopan|Participants will receive oral tablets of Vemircopan.
219711900|NCT06071442|DRUG|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
219711901|NCT06071442|DRUG|Metformin|Participants will receive oral film-coated tablets of Metformin.
219711902|NCT06071442|DRUG|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
219711903|NCT06071442|DRUG|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
219129575|NCT01365338|DRUG|PF-04958242|Administered as specified in the treatment arm
219129576|NCT03921528|BIOLOGICAL|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
219129577|NCT04928157|DEVICE|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
219129578|NCT00747929|DRUG|S-2367 Placebo|four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
219711904|NCT05258721|DRUG|ClōSYS® Sensitive Fluoride Toothpaste|ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
219711905|NCT05258721|OTHER|ClōSYS® Sensitive Rinse|ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
219711906|NCT05973214|BEHAVIORAL|Cognitive Behavioral Therapy|CBT for IEI
219711907|NCT02818673|RADIATION|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
219711908|NCT02818673|RADIATION|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
219711909|NCT00230737|DRUG|Melatonin 0.4 mg|
219711910|NCT00230737|DRUG|Melatonin 4.0 mg|
219711911|NCT00230737|DRUG|Placebo|
219711912|NCT02721888|DRUG|Liraglutide|
218986565|NCT02974478|DIETARY_SUPPLEMENT|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
218986566|NCT05012033|OTHER|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
218986567|NCT00214110|DRUG|Tamoxifen|
218986568|NCT06440902|DRUG|Cetuximab|Cetuximab is given In patients with NeoRAS WT
218986569|NCT03948581|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
218986570|NCT03068455|BIOLOGICAL|nivolumab|Specified Dose on Specified Days
218986571|NCT03068455|BIOLOGICAL|ipilimumab|Specified Dose on Specified Days
218986572|NCT04635228|DEVICE|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
219711913|NCT02721888|DRUG|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
219711914|NCT02721888|BIOLOGICAL|Blood sample|
219711915|NCT02721888|OTHER|Kinetic substudy (10 patients)|
219129579|NCT00747929|DRUG|S-2367 800 mg|two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
219129580|NCT00747929|DRUG|S-2367 1600 mg|four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
219129581|NCT00747929|OTHER|Reduced Calorie Diet|A diet with restricted calorie content
219711916|NCT04508816|DRUG|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
219711917|NCT03146390|DRUG|Essential oils|all subjects will perform all interventions of all arms
219711918|NCT03146390|DRUG|Alcohol free essential oils|all subjects will perform all interventions of all arms
219711919|NCT03146390|OTHER|Water|all subjects will perform all interventions of all arms
219711920|NCT05810662|OTHER|Lactated ringer and dextrose 5%|Fluid use perioperative
219711921|NCT05496764|DRUG|Dexamethasone|we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
218986573|NCT02527135|BEHAVIORAL|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
218986574|NCT03204578|DRUG|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
218986575|NCT03204578|DRUG|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
218986576|NCT01390129|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
218986577|NCT01390129|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
218986578|NCT03604484|PROCEDURE|Tricuspid annuloplasty|Tricuspid annuloplasty
219129582|NCT01245413|DEVICE|SenSura|Adhesive to stoma bag
219129583|NCT01245413|DEVICE|Athena|Adhesive to stoma bag
219129584|NCT02530151|DRUG|Morphine with clonidine|see arm description
219129585|NCT02530151|OTHER|Normal saline|see arm description
219129586|NCT01268761|DRUG|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
219129587|NCT01268761|DRUG|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
219129588|NCT06713187|BIOLOGICAL|interleukin 23|assessment of interleukin 23 in Sera of patients using ELIZA
219129589|NCT01562743|DRUG|SPM 962|Tansdermal patch
219129590|NCT00179608|DRUG|CC-5013|
219129591|NCT05348824|DIETARY_SUPPLEMENT|Moringa oleifera leaf|Leaf extract preparation
219129592|NCT05348824|DRUG|Sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
219129593|NCT00117754|DRUG|Terbinafine hydrochloride|
219129594|NCT01374490|DRUG|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
219129595|NCT05714670|DRUG|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
219129596|NCT03466840|PROCEDURE|The coronally advanced lingual flap|": A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured."
219129597|NCT03466840|PROCEDURE|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured."
219129598|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Baseline Scans|The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
219711922|NCT05496764|DRUG|Glucose Injection|inject10 ml glucose 5% into the carpal tunnel in group B
219711923|NCT00754780|DRUG|Pirfenidone|Capsule 800 mg TID, oral
219711924|NCT03923920|PROCEDURE|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
219711925|NCT00790036|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
219711926|NCT00790036|DRUG|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
219711927|NCT02598908|DIAGNOSTIC_TEST|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
219711928|NCT02511353|DRUG|ivermectin|
219711929|NCT02511353|DRUG|placebo|Placebo for ivermectin.
219711930|NCT02511353|DRUG|dihydroartemisinin-piperaquine|
219226535|NCT06524232|OTHER|Practice Facilitation (PF)|Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.
219711931|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
219711932|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
219711933|NCT03073759|DEVICE|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
219711934|NCT03073759|DEVICE|Sham device|The device will administer a sham.
219711935|NCT05926960|DRUG|encorafenib|encorafenib
219711936|NCT05926960|DRUG|binimetinib|binimetinib
219711937|NCT05926960|DRUG|pembrolizumab|pembrolizumab
219711938|NCT05926960|DRUG|ipilimumab|ipilimumab
219711939|NCT05926960|DRUG|nivolumab|nivolumab
219711940|NCT05869955|DRUG|CC-97540|Specified dose on specified days
219711941|NCT05869955|DRUG|Fludarabine|Specified dose on specified days
219711942|NCT05869955|DRUG|Cyclophosphamide|Specified dose on specified days
219711943|NCT05869955|DRUG|Tocilizumab|Specified dose on specified days
219711944|NCT02973620|DRUG|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
219711945|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
219711946|NCT04003285|DRUG|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
219711947|NCT04003285|DRUG|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
219711948|NCT04003285|DRUG|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
219711949|NCT06330675|OTHER|Early mobilization|Short-term bed-rest and immobilization
219711950|NCT06330675|OTHER|Standard of care|Bed-rest and immobility until the day-after procedure
219711951|NCT05841056|DRUG|Amiodarone Hydrochloride 200 MG|200 mg daily for 4 weeks
218986579|NCT00214344|BEHAVIORAL|family preparation for withdrawing life support|
218986580|NCT02275637|DEVICE|implantable cardioverter defibrillator|
218986581|NCT05870124|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
218986582|NCT05870124|OTHER|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
218986583|NCT01965613|BIOLOGICAL|Xilonix|IV
218986584|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
218986585|NCT04616248|DRUG|Poly ICLC|Given IT
218986586|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
218986587|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
218986588|NCT04616248|DRUG|Pembrolizumab|Given IV
218986589|NCT04616248|DRUG|Tocilizumab|Given SC
218986590|NCT06025825|DRUG|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
218986591|NCT06025825|DRUG|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
218986592|NCT04515394|DRUG|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
218986593|NCT04515394|BIOLOGICAL|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
218986594|NCT05133752|DRUG|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
218986595|NCT05901428|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
218986596|NCT05901428|DRUG|Carboplatin|Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
218986597|NCT05901428|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
218986598|NCT05901428|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
218986599|NCT00318123|DRUG|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
218986600|NCT00999232|DRUG|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
218986601|NCT00999232|DRUG|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
218986602|NCT03223142|DEVICE|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
219129599|NCT05674643|DIAGNOSTIC_TEST|Acetaminophen Absorption Test (AAT)|"Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying."
219129600|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Serial Scans|Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
219129601|NCT03067051|DRUG|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
219129602|NCT03067051|DEVICE|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
219129603|NCT05286541|PROCEDURE|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
219711952|NCT05703373|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
219711953|NCT06433960|DIAGNOSTIC_TEST|Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~Instruct the patient to clench their wrist while the examiner occlude with three fingers the patients ulnar and radial arteries; instruct the patient to unclench their wrist; release the ulnar artery. The MAT result is negative or positive considering in how long the palm flushes:~≤5 seconds: negative MAT; good collateral hand circulation (suggesting harvestable radial artery).~greater than 5 seconds: positive MAT; poor collateral hand circulation (suggesting not-harvestable radial artery)."
219711954|NCT06433960|DIAGNOSTIC_TEST|Pulse-oximetry guided Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~A pulse-oximetry probe is positioned on the patients index finger; both radial and ulnar arteries are occluded by the examiner (with three fingers) until flattening of pulse waveform is obtained. Pressure on the ulnar artery is released and the result of the assessment is calculated considering in how long the pulse waveform returns to baseline:~≤5 seconds: negative result (suggesting harvestable radial artery). greater than 5 seconds: positive result (suggesting not harvestable radial artery).~(Busti and Kellogg, 2015)"
219711955|NCT06433960|DIAGNOSTIC_TEST|Barbeau Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 2 minutes.~A pulse-oximetry probe is positioned on the patients thumb; the radial artery is then compressed by the examiner, and the pulse waveform is analysed for up to 120 seconds, providing four result patterns of ulno-palmar patency:~1. No damping of the pulse tracing immediately after compression (suggesting harvestable radial artery)~2. Damping of the pulse tracing (suggesting harvestable radial artery)~3. Loss of the pulse tracing, followed by recovery within 120 sec (suggesting harvestable radial artery)~4. Loss of the pulse tracing, without recovery within 120 sec (suggesting not harvestable radial artery).~(Zalocar et al., 2020)"
219711956|NCT06433960|DIAGNOSTIC_TEST|Ultrasound examination of the forearm arteries|"Pre-operative intervention aimed at evaluating morphological characteristics (diameter, presence of calcifications) of the radial and ulnar arteries. Duration: 5 minutes.~The radial artery is surgically exposed (negative result) when the following apply:~1. ulnar artery inner diameter ≥2 mm~2. radial artery inner diameter ≥2 mm~3. absence of radial artery intraluminal calcifications and plaques.~(Vukovic et al., 2017)"
219711957|NCT06433960|DIAGNOSTIC_TEST|Measurement of oxygen saturation|"Intra-operative intervention aimed at evaluating the blood oxygen level in the hand if the radial artery was harvested. Duration: 1 minute.~The radial artery is surgically harvested when the oxygen saturation reading (SpO2) from the thumb through pulse-oximetry remains at 95% or above when an occlusive atraumatic clamp is applied on the mobilised radial artery."
219711958|NCT06433960|OTHER|Radial Artery Quality Evaluation Survey|"Intra-operative intervention (validated structured questionnaire) aimed at evaluating anatomical and physiological characteristics of the radial artery and suitability for coronary graft implantation.~The radial artery is surgically harvested when its morphology and pathology (diameter, calcifications, presence of pulsatile flow), quality of harvesting technique and surgical accessibility are considered satisfactory, good or optimal.~The Radial Artery Quality Evaluation Survey is completed by surgical care practitioners."
219711959|NCT06433960|OTHER|Follow-up Radial Artery Harvesting Scale|"Postoperative intervention (ordinal symptoms scale) aimed at evaluating patients finger movements, cold tolerance sensitivity and tactile/touch perception at post-operative day 2 to 5 and at follow-up appointment (3-6 weeks after surgery). Bilateral comparison between hands and forearms is undertaken. Tactile perception is assessed through monofilaments (single touch). Cold sensitivity is assessed through the use of ice-pack.~The Follow-up Radial Artery Harvesting Scale was developed from a verbal rating scale (VRS) questionnaire documented in the literature. The VRS questionnaire was re-adapted to appreciate people postoperative experience with their finger movements, cold sensitivity and tactile/touch perception of their forearm."
219129604|NCT05286541|PROCEDURE|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
219129605|NCT02299921|OTHER|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
219129606|NCT06614322|DRUG|Pregabalin|300mg/day pregabalin capsule
219711960|NCT03126110|DRUG|INCAGN01876|In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().
219711961|NCT03126110|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
219711962|NCT03126110|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
219711963|NCT06305676|DIAGNOSTIC_TEST|combined HPV 16 DNA and host gene methylation oral biomarker panel|DNA Methylation Profiling
219711964|NCT05029869|DIAGNOSTIC_TEST|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
219711965|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
219711966|NCT05050799|DEVICE|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
219711967|NCT02368496|DEVICE|HR-pQCT|
219711968|NCT04744623|DRUG|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
219711969|NCT04171622|DRUG|Lenvatinib|Given PO
219711970|NCT04171622|BIOLOGICAL|Pembrolizumab|Given IV
219711971|NCT01926158|DRUG|Denosumb|Prefilled syringe of 1 mL denosumab solution
219711972|NCT01926158|DRUG|Placebo (for denosumab)|
219711973|NCT04732234|PROCEDURE|Superior Hypogastric Plexus Block|Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
219711974|NCT02339636|OTHER|PDUS examination|
219711975|NCT04834596|OTHER|retrospectives analysis on hepatic scanner|hepatic scanner will be analysed by two radiologist and by the software
219711976|NCT05778565|PROCEDURE|Extraocular muscle stretching|Extraocular muscle stretching to test its efficacy as a weakening procedure
219711977|NCT02072616|OTHER|Pancreatic adenocarcinoma diagnosis|
219711978|NCT01641536|GENETIC|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
219129607|NCT06614322|DRUG|Duloxetine|60mg/day duloxetine capsule
219129608|NCT06614322|OTHER|Placebo|Placebo capsule
219129609|NCT06615167|DEVICE|ALZGUARD|A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.
219711979|NCT01799083|DRUG|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
219711980|NCT01799083|BIOLOGICAL|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
219711981|NCT05223127|OTHER|Aloe vera|The leaves of Aloe vera (Aloe barbadensis) will be identified and verified by Selçuk University Faculty of Agriculture. Aloe vera leaves will be washed with antiseptic solution and cut crosswise using gloves and sterile knife. The thick epidermis will be removed from the middle of the leaf. The gel will be obtained from the parenchyma of the thick juicy leaves of aloe vera.
219129610|NCT06615466|RADIATION|Partial Breast Irradiation|26Gy/5.2Gy/5f
219711982|NCT05434702|BEHAVIORAL|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
219711983|NCT05434702|BEHAVIORAL|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
219129611|NCT06614140|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect."
219711984|NCT05434702|BEHAVIORAL|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
219711985|NCT05434702|BEHAVIORAL|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
219129612|NCT06614439|PROCEDURE|proximal gastrectomy|proximal gastrectomy
219226536|NCT06524232|OTHER|Learning Collaborative (LC)|Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.
219226537|NCT06524232|OTHER|Performance Incentives (PI)|We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
219226538|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
219226539|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
219226540|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
219226541|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
219129613|NCT06614439|PROCEDURE|total gastrectomy|total gastrectomy
219226542|NCT04922307|PROCEDURE|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
219226543|NCT04922307|PROCEDURE|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
219226544|NCT03508700|DRUG|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
219226545|NCT05680259|OTHER|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
219226546|NCT05680259|OTHER|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
219226547|NCT03900286|DIETARY_SUPPLEMENT|Total Dietary Replacement|Total Dietary Replacement
219226548|NCT03736889|DRUG|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
219226549|NCT05714774|DEVICE|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
219711986|NCT05434702|BEHAVIORAL|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
219711987|NCT05434702|BEHAVIORAL|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
219711988|NCT05434702|BEHAVIORAL|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
219711989|NCT05495997|BEHAVIORAL|Mental Imagery Training|Participants will practice mental imagery of everyday tasks daily for 6 weeks.
219711990|NCT05495997|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation on cognition and brain health.
219711991|NCT00909467|OTHER|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
219711992|NCT02804893|PROCEDURE|VATS|Thorax thoracoscopic surgery (lobectomy)
219711993|NCT02804893|PROCEDURE|RATS|Thorax robotic surgery (lobectomy)
219711994|NCT03120273|DRUG|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
219711995|NCT03120273|DRUG|Lansoprazole Injection|30 mg q12h for 5 days.
219711996|NCT01284543|DEVICE|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
219711997|NCT01284543|DEVICE|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
219711998|NCT00998283|DRUG|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
219129614|NCT06615362|PROCEDURE|preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant|tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
219129615|NCT06615362|PROCEDURE|Collagen Membrane for Guided Bone Regeneration in Immediate Implant|like group one but with application of collagen membrane
219129616|NCT06615336|BEHAVIORAL|Intensive Sleep retraining|Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period
219129617|NCT06615336|BEHAVIORAL|Total Sleep Deprivation|Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
219129618|NCT06615193|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
219129619|NCT06614452|DEVICE|EUS-FNB|"Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the slow-pull, the dry suction, or the wet suction, will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.~The rapid-on site cytological evaluation (ROSE) will not be available in this study."
219129620|NCT06613997|DRUG|Albendazole 400mg|Albendazole 400mg per days for 21 consecutive days
219129621|NCT06613997|DRUG|Placebo|Placebo for 21 consecutive days
219129622|NCT06271200|OTHER|Strategic lifestyle and drug interventions|"Participants in the Intensive Lifestyle Intervention (ILI) group will follow a program including:~1. time-restricted eating with a 16:8 pattern (eating within an 8-hour window, fasting for 16 hours),~2. walking over 10,000 steps daily, and~3. a daily calorie reduction of 500 kcal (with macronutrient distribution: 40-55% carbohydrates, 15-20% protein, 20-30% fat).~Participants in the Usual Lifestyle Intervention (ULI) group will maintain their habitual meal timing.~After the initial 24-week lifestyle program, ILI participants will be randomized (1:1) to receive either a GLP-1 receptor agonist (Rybelsus) or an SGLT-2 inhibitor (Forxiga) for 26 weeks, while continuing their lifestyle regimen. This phase will assess the impact of medication-with or without prior lifestyle intervention-on weight loss and liver fat. All participants will then be followed for an additional 52 weeks to evaluate long-term weight maintenance."
219129623|NCT06271200|OTHER|Control|"Participants in the ULI group will maintain their usual lifestyle without intervention during the first 24 weeks.~After the initial 24-week usual lifestyle intervention, participants in the ULI group will be randomly assigned in a 1:1 ratio to receive either Rybelsus (GLP-1 receptor agonist) or Forxiga (SGLT-2 inhibitor) for a duration of 26 weeks. This phase aims to assess the effects of these medications on weight reduction and liver fat content without prior intensive lifestyle intervention. All participants will be followed for an additional 52 weeks to evaluate the long-term sustainability of weight loss."
219129624|NCT06614530|DEVICE|Chilipad Docker Pro|The Chilipad Dock Pro is an advanced sleep system designed to optimize sleep by dynamically adjusting the bed\&#39;s surface temperature. It consists of a mesh mattress pad and a Dock Pro control unit that circulates water through the pad, allowing users to customize the temperature between 55°F and 115°F. The system offers both single and dual control, making it ideal for individual or shared use. Equipped with AI-driven features, the Dock Pro can monitor sleep patterns and environmental factors to make real-time adjustments, ensuring optimal sleep conditions throughout the night. This intelligent temperature management system is enhanced when paired with the optional Sleepme Tracker, creating a personalized sleep experience.
219129625|NCT05471232|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
219129626|NCT05471232|OTHER|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
219129627|NCT06528782|OTHER|Pecha Kucha method|The Pecha Kucha method will be prepared in the form of a presentation consisting of 20 slides each shown for 20 seconds. The Pecha Kucha presentation lasts 6 minutes and 40 seconds, and most slides present only images. This method is planned to be used in breastfeeding education as it will be more memorable because it contains more visual, auditory and short information.
219129628|NCT05039203|DEVICE|Indwelling urinary catheter|Removal of indwelling urinary catheter
219129629|NCT06919107|OTHER|Survey of athletes|Data will be collected on the number of injuries (muscle and tendon), lower limb injuries in the last 3 athletic seasons, as well as age, sex, weekly training load with and without AFT, weekly training frequency, completion of a complementary toning program and foot size.
219129630|NCT06919393|OTHER|"Triple negative adul B-cell ALL"|"Samples will be studied with conventional techniques to classify and define properly the disease: morphology, immunophenotype, immunohistochemistry (IHC), conventional Cytogenetic Fluorescence in Situ Hybridization (FISH) will be used when appropriate.~● Isolation of Mononuclear cells~The following research methodologies will be applied:~* Next Generation Sequencing~* Flow cytometry analysis of 3C-up B-ALL top three markers~* Gene expression profile analysis~* Copy number Alterations analysis~* In vitro studies"
219711999|NCT00998283|DRUG|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
219712000|NCT00998283|DRUG|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
219712001|NCT00998283|DRUG|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
219712002|NCT00998283|DRUG|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
219712003|NCT00998283|DRUG|Placebo|Subcutaneously administrate at 0 hour on Day 1
219712004|NCT04817982|DRUG|Perineural dexamethasone|Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
219712005|NCT04817982|DRUG|Lidocaine|Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
219712006|NCT04817982|DRUG|Placebo|Saline will be added perineurally to an ulnar nerve block with bupivacaine.
219712007|NCT04817982|DRUG|Systemic dexamethasone|Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
219712008|NCT02135198|DRUG|2 mg AZD7325|A single 2 mg oral dose of AZD7325
219712009|NCT02135198|DRUG|10 mg AZD7325|A single 10 mg oral dose of AZD7325
219712010|NCT02135198|DRUG|Placebo|A single oral dose
219712011|NCT05162092|OTHER|Conventional physiotherapy|Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
219712012|NCT05162092|OTHER|Vestibular stimulation with conventional physiotherapy|Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
219712013|NCT06549985|BEHAVIORAL|PEEPS|Participants will participate in the PEEPS program in addition to usual care.
219712014|NCT06549985|BEHAVIORAL|Education|Participants will receive an educational handout on endometriosis in addition to usual care.
219712015|NCT02767973|OTHER|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
219712016|NCT05561543|DIETARY_SUPPLEMENT|Peppermint oil|Peppermint oil
219712017|NCT05561543|OTHER|Placebo|Placebo
219129631|NCT06614556|OTHER|Resistance Training|Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.
219129632|NCT06614816|BIOLOGICAL|Oka strain varicella attenuated live vaccine|lyophilized powder, subcutaneous injection
219129633|NCT06614569|DRUG|AXO-AAV-GM2|Participants who received AXO-AAV-GM2 will be tracked in long term follow up
219129634|NCT06614686|DRUG|U87 autologous CAR T-cell|Treatment with U87 chimeric antigen receptor T-cell infusion.
219129635|NCT05531370|OTHER|Breathing Retraining|"Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist.~BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity."
219129636|NCT04918108|BIOLOGICAL|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
219129637|NCT06453109|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
219129638|NCT05854992|DRUG|Acute migraine treatment with any prescribed triptans|Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
219129639|NCT05854992|DRUG|Standard of care management of acute migraine without triptans|Any standard of care management without triptans
219129640|NCT03015740|OTHER|Laboratory Biomarker Analysis|Correlative studies
219129641|NCT03015740|BIOLOGICAL|Nivolumab|Given IV
219129642|NCT03015740|OTHER|Quality-of-Life Assessment|Ancillary studies
219129643|NCT03015740|OTHER|Questionnaire Administration|Ancillary studies
219129644|NCT03015740|DRUG|Sitravatinib|Given PO
219129645|NCT05965362|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
219129646|NCT06615323|BEHAVIORAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to play the Dandini Dandini Dastana lullaby by vocal artist Mircan Kaya, which they downloaded from the YouTube application, and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by switching the phone to airplane mode just before sleep. In the event of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be played at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effects of confounding factors, mothers in the polyphonic lullaby group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the study.
219129647|NCT06615323|OTHER|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
219129648|NCT01981161|PROCEDURE|biological samples and clinical data|
219129649|NCT06614244|PROCEDURE|Oral immunotherapy (OIT)|OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
219129650|NCT06614244|DIETARY_SUPPLEMENT|Culprit food elimination diet|The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
219129651|NCT06687460|OTHER|Brief electrical stimulation|During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
219129652|NCT06687460|OTHER|no nerve electrical stimulation|only nerve microsurgical reconstruction, no nerve electrical stimulation
219712018|NCT06569667|BEHAVIORAL|PRC supported text + AI driven SDH-enhanced text|This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
219712019|NCT06569667|BEHAVIORAL|AI driven SDH-enhanced text only|This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
219712020|NCT06569667|BEHAVIORAL|Treatment as Usual (TAU)|Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
219712021|NCT05406167|DEVICE|Registry - Observational|Observation Registry for Medical Device
219712022|NCT05621772|OTHER|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
219712023|NCT00619528|BIOLOGICAL|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (\>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
219712024|NCT04526054|DIAGNOSTIC_TEST|ENT exam|ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
219712025|NCT04526054|DIAGNOSTIC_TEST|Olfactometry|Olfactometry test using odorous pens (Sniffin's stick test).
219129653|NCT05513235|OTHER|Digital personal health record|The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
219129654|NCT04895345|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219129655|NCT04895345|RADIATION|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
219129656|NCT02449044|DRUG|Tolvaptan|Once Daily
219129657|NCT04086758|DRUG|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
219129658|NCT06629285|PROCEDURE|Continuous compression cryotherapy|Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
219129659|NCT06629285|PROCEDURE|Conventional ice treatment|Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
219129660|NCT06628479|OTHER|interleukin, enzyme, hormone|Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
219129661|NCT06631794|BEHAVIORAL|A short talk about the importance of HPV vaccination|"Investigator plan to set up a short talk to 3rd grade classes in addition to the usual sexual health training. The issue of HPV vaccination will be systematically addressed for 10 minutes to encourage catch-up vaccination.~The usual training include different themes such us : definition of sexual health, anatomy, sexually transmitted infections contraception/condoms, menstrual cycles, voluntary interruption of pregnancy, consent, sexual abuse/violence/harassment, pornography, anti-discrimination....~A 45-minute talk will include 2 or 3 topics from the above list. A ten minutes of talk will be added to the usual training to explain the HPV vaccination (a topic not usually addressed in sexual health training), covering the following elements: definition of HPV infection"
219129662|NCT06631196|PROCEDURE|Jacobson's PMRT|each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
219129663|NCT06629194|DIAGNOSTIC_TEST|interferon gamma releasing assay (IGRA)|All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
219129664|NCT06629337|GENETIC|H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)|Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
219129665|NCT06630182|OTHER|Bortner self-questionnaire|14 items
219129666|NCT06630182|OTHER|Self-questionnaire BFI-10|10 items
219712026|NCT04526054|DIAGNOSTIC_TEST|Brain MRI|Brain MRI focused on the olfactory bulbs (3 teslas).
219712027|NCT03870490|DRUG|VNRX-5133 + cefepime|IV infusion (3 doses)
219129667|NCT06629428|DRUG|Ublituximab|The participants will receive 48 weeks of treatment with ublituximab.
219129668|NCT06629883|BEHAVIORAL|REPS w/BANDS|This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
219129669|NCT06696248|DRUG|Carvedilol and alverine|On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
219129670|NCT06698016|DRUG|Nemtabrutinib|Oral administration
219712028|NCT05117996|OTHER|capsule endoscopy|capsule endoscopy
219712029|NCT05117996|OTHER|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
219712030|NCT05117996|OTHER|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
219712031|NCT05784675|DEVICE|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
219712032|NCT02523209|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
219712033|NCT02523209|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
219129671|NCT06698016|DRUG|Efavirenz|Oral administration
219129672|NCT06696625|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution."
219129673|NCT06696625|DRUG|0.1% sodium hyaluronate eye drop|Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).
219129674|NCT06697366|DRUG|Irinotecan liposome injection Ⅱ|56.6 mg/m2，Q3W
219129675|NCT06697366|DRUG|Sintilimab|200mg，Q3W
219129676|NCT06697288|OTHER|Tested product group|Apply the test product per zone at least twice a day on the face, neck (neck \& nape), décolleté and back of the hand in the morning and at midday whatever the weather conditions and the activities of the day
219129677|NCT06697288|OTHER|Control group|Maintain their normal routine of using cosmetics (cleansers and moisturizers) and normal sun protection habits (if applicable)
219129678|NCT06696859|DRUG|Antibiotics|Bacterial culture (sputum ,blood and pleural fluid) Antibiotics sensitivity tests
219712034|NCT06627764|BEHAVIORAL|SER Familia|SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
219129679|NCT06698211|DRUG|Posaconazole tablet|Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
219129680|NCT06697665|BIOLOGICAL|LM103|Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.
219129681|NCT06697249|OTHER|Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation|CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.
219129682|NCT06696885|OTHER|Mobile based video games and task based training|The experimental group received a mobile-based applications for 20 minutes and tasks-based training for 20 minutes per day (a total of 40 minutes), 6 days a week for 17 weeks. The time between each game was divided accordingly to work on improving hand function. The games and tasks were divided into three broad categories, Easy, Moderate, Difficult. Each category is applied for 6 weeks
219129683|NCT06698185|DEVICE|Materna Prep Device|Materna Prep Device
219129684|NCT06698185|DEVICE|Sham Control|Sham Control
219712035|NCT06387069|DRUG|HMPL-306 Regimen|Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
219712036|NCT06387069|DRUG|Salvage Chemotherapy Regimen|"Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10).~* Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7)."
219712037|NCT03534323|DRUG|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
219712038|NCT03534323|DRUG|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
219712039|NCT06174207|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
219129685|NCT06697613|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
219129686|NCT05118932|BEHAVIORAL|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
219129687|NCT06711224|BEHAVIORAL|Digital intervention for adolscents with ADHD|The aim of the digital intervention is to promote coping of ADHD. The intervention has a duration of 6 weeks and will be delivered as a mobile app including weekly phone calls from a therapist. The intervention includes text, interactive exercises, animations, and coping skills. The themes of the intervention includes psychoeducation on ADHD, healthy habits (sleep, exercise, food), social skills, and emotion regulation. The adolescents have the possibility to choose some of the themes they want to work on during the intervention.
219129688|NCT06711653|DIAGNOSTIC_TEST|Vestibular evoke myogenic potential|routine Vestibular test
219129689|NCT06713018|PROCEDURE|Three cannulated compression screws by navigation system|Patients with femoral neck fractures treated with three cannulated compression screws assisted by a navigation system
219129690|NCT06713018|PROCEDURE|Traditional three cannulated compression screws|Patients with femoral neck fractures treated with traditional three cannulated compression screws
219129691|NCT06711978|DRUG|Mirogabalin|Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.
219129692|NCT06711978|DRUG|Duloxetine|Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.
219129693|NCT06711471|DRUG|trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab|Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
219712040|NCT03303248|BEHAVIORAL|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
219129694|NCT06711289|DIAGNOSTIC_TEST|Carotid ultrasound measurement|Pulsed-wave Doppler acquisition of the carotid artery. One acquisition will be made with the slow-speed setting (33 mm/s) and one with the medium-speed setting (66 mm/s).
219129695|NCT06711289|DIAGNOSTIC_TEST|Vital sign measurement|Measurement of noninvasive blood pressure, at different time points before and after the induction of spinal anesthesia.
219129696|NCT06711289|DRUG|Spinal anesthesia|Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
219712041|NCT05242211|OTHER|exercise test|Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
219712042|NCT05754710|DRUG|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
219712043|NCT03435419|DIAGNOSTIC_TEST|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
219712044|NCT03435419|DIAGNOSTIC_TEST|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
219712045|NCT04928300|DRUG|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
219712046|NCT04928300|DRUG|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
219712047|NCT04928300|OTHER|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
219129697|NCT06713291|PROCEDURE|Sliding compression locking plate|The patients with femoral neck fracture were treated with three cannulated compression screws or sliding compression locking plate.
219129698|NCT06713291|PROCEDURE|Three cannulated compression screws|The patients with femoral neck fracture were treated with three cannulated compression screws.
219129699|NCT06713044|DEVICE|Murottal Therapy Intervention Name: Murottal (Islamic verse recitation)|To evaluate whether murottal recitations can reduce postoperative pain intensity and lower interleukin 6 levels, which are indicative of inflammation.
219129700|NCT06713044|DEVICE|Classical Music Therapy Intervention Name: Classical Music Listening|To evaluate the impact of classical music on reducing postoperative pain intensity and interleukin 6 levels in the body, thereby managing inflammation.
219129701|NCT06713044|OTHER|Standard Care (in control arm)|To serve as a control group no intervention
219129702|NCT06137469|DRUG|Acetaminophen/SHR20004|SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
219129703|NCT06137469|DRUG|Acetaminophen/Placebo|Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
219129704|NCT06712979|PROCEDURE|Adapted Lee Silverman Method|Exercise protocol with 6 steps that the voice professionals adapted from Lee Silverman Method
219129705|NCT06712979|DEVICE|Lung volume recruitment technique - LVRT|The adapted Lee Silverman Method will have a addiction of LVRT technique. Lung inflation begins, reaching an optimal inspiratory peak of 30 cmH2O. From this point, the sound /HA/ begins to be emitted until the most comfortable low sound, where the emission should be maintained for as long as possible, making sure that this time is not less than 12 seconds, trying to emit a high and comfortable vocal intensity. When performing the emissions, the mouth should be kept wide open with the tongue, jaw and neck relaxed, repeating 5 emissions in 3 series. Between series, the participant will be instructed to drink 50 ml of water exactly as in the previous emissions.
219129706|NCT03717259|PROCEDURE|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
219129707|NCT03717259|PROCEDURE|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
219129708|NCT03717259|PROCEDURE|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
219129709|NCT06805058|OTHER|comedy therapy|Patients will be shown 10-minute Turkish comedy films prepared by the researchers
219712048|NCT06129734|DRUG|Venetoclax|Venetoclax is a BCL2 inhibitor. It is administered at low doses and used in combination with other hypomethylating agents such as decitabine to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants will initiate therapy with decitabine that will be followed by venetoclax 400 mg oral 6-8 hours later. Participants will continue this dose each week. The venetoclax dose will be reduced to 100 mg once per week if the participant is being treated with posaconazole or voriconazole (strong CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). The venetoclax dose will be reduced 200 mg once per week if the participant is being treated with fluconazole or isavuconazole (moderate CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). This clinical trial is administering venetoclax well below the current FDA approved dosing.
219129710|NCT06744426|DRUG|BR1015|One tablet administered alone
219129711|NCT06744426|DRUG|BR1015-2|One tablet administered alone
219129712|NCT06744426|DRUG|BR1015-3|One tablet administered alone
219712049|NCT06129734|DRUG|Decitabine|Decitabine is a hypomethylating agent. It is administered at low doses and used in combination with venetoclax to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants initiate therapy with 5 mg/m2 decitabine subcutaneous every week followed by venetoclax.
219712050|NCT03776630|OTHER|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
219129713|NCT06824402|DEVICE|Forceps Biopsy|10-12 transbronchial lung biopsies will be obtained using standard of care biopsy forceps: Olympus disposable EndoJaw (FB-211), Olympus, USA
219129714|NCT06824402|DEVICE|Cryoprobe Biopsy|3 transbronchial lung biopsies of two separate lobes will be obtained using a flexible cryoprobe: single-use, ø 1.1 mm (Erbe Elektromedizin GmbH, 20402-401) used with ERBECRYO 2 (Erbe Elektromedizin GmbH, 10402-000
219129715|NCT06911827|DRUG|QLP2117|Specified dose on specified days
219129716|NCT06911827|DRUG|QL2107|Specified dose on specified days
219129717|NCT06917976|BEHAVIORAL|to compare the effect of environment and attitude of dentist in children visiting specialized pediatric dental clinic and general dental clinic .|the investigators will measure salivary cortisol and salivary alpha amylase and using children fear dental survey schedule - dental subscale
219129718|NCT06920212|PROCEDURE|FMT capsule|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
219129719|NCT06919237|OTHER|HIIT Intervention|Over the first 4 weeks, participants will perform 4 bouts of 2 min of high-intensity exercise at 80-90% heart rate reserve (HRR), during the next 4 weeks, participants will perform 6 bouts of 2 min of high-intensity exercise at 80-90%HRR, while in the last 4 weeks participants will perform 6 bouts of 2 min of high-intensity exercise at 90%HRR). Exercise bouts will be interspersed by 2 min of active recovery at 50-60% HRR.
219129720|NCT06919237|OTHER|MICT Intervention|Over the first 4 weeks participants in MICT will perform continuous exercise at 50-60% HRR (2x10'), during the next 4 weeks participants will perform continuous exercise at 50-60% HRR (2x12'), while in the last 4 weeks participants will perform continuous exercise at 60-70% HRR (2x15').
219129721|NCT06919237|OTHER|HRV-Guided Intervention|"Following a 10-day initial characterization period, where the HRV is measured with plethysmography continually during the night, with Whoop (https://www.whoop.com) device, the individual HRV profile is defined, still, participants will use the Whoop during all intervention to allow the updating of HRV profile. Then, considering the daily individual autonomic regulation, following a decision-making schema modiﬁed from Kiviniemi et al., (2007) \[21\], exercise intensity will be defined for the training session, i.e., if LnRMSSD7day-roll-avg remained inside the smallest worthwhile change (SWC) (SWC = 0.5 × standard deviation), high intensity or moderate-intensity training sessions is prescribed, if LnRMSSD7day-roll-avg fell outside SWC, low intensity or rest is prescribed, leading to different workloads from the predefined training programs."
219129722|NCT05396547|DEVICE|Treated with Ledinbio device|Treated with Ledinbio device
219129723|NCT05397106|DEVICE|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
219129724|NCT06211257|OTHER|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
219226550|NCT04939012|BEHAVIORAL|MyPath Intervention|MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
219226551|NCT04939012|BEHAVIORAL|Usual care|Standard of Care
219226552|NCT06093490|DEVICE|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
219226553|NCT06132984|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
219129725|NCT01169805|DRUG|Ondansetron|Ondansetron/single injection/4 mg/IV
219129726|NCT01169805|DRUG|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
219129727|NCT01169805|DRUG|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
219129728|NCT01169805|DRUG|Normal saline inj|normal saline injection 2ml
219129729|NCT05881785|BIOLOGICAL|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
219129730|NCT05881785|BIOLOGICAL|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
219129731|NCT05881785|BIOLOGICAL|placebo|"* Core treatment period:placebo~* Maintenance treatment period: GR1501 injection"
219129732|NCT05541497|DRUG|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
219129733|NCT05541497|DRUG|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
219129734|NCT04513028|DIETARY_SUPPLEMENT|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
219129735|NCT00587288|BIOLOGICAL|Reslizumab|
219129736|NCT00587288|OTHER|Saline|
219129737|NCT03910543|DRUG|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
219129738|NCT05060614|PROCEDURE|Hip fracture surgery|Hip fracture surgery
219129739|NCT05809076|DEVICE|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
219226554|NCT04820088|OTHER|Computer based role play trianing|Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
219712051|NCT02588365|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
219712052|NCT02588365|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
219712053|NCT02588365|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
219712054|NCT06292663|DEVICE|Virtual Reality|The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
219712055|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
219712056|NCT05373680|DRUG|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
219712057|NCT05373680|DRUG|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
219712058|NCT05373680|OTHER|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
219712059|NCT05143255|BEHAVIORAL|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
219712060|NCT05568511|OTHER|App-based exercise program|Remotely-controlled, app-guided exercise program
219712061|NCT05568511|OTHER|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
219712062|NCT04458194|OTHER|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
219712063|NCT04458194|BEHAVIORAL|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
219712064|NCT05746325|OTHER|Digital Photography|Digital photographs taken of array placement
219712065|NCT05746325|PROCEDURE|Lumbar Puncture|Undergo LP
219712066|NCT05746325|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219712067|NCT05746325|DEVICE|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
219712068|NCT05746325|PROCEDURE|Biospecimen Collection|Undergo collection of cerebrospinal fluid (CSF) during screening if no CSF testing for malignancy has been done previously
219712069|NCT01149083|PROCEDURE|Biopsy|Undergo biopsy
219712070|NCT01149083|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219129740|NCT05809076|DEVICE|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
219129741|NCT01287052|DRUG|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
219129742|NCT04045366|OTHER|Sample collection|Plasma and BAL sample collection
219129743|NCT02723851|DEVICE|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
219226555|NCT06405451|OTHER|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.
219712071|NCT01149083|DRUG|Carboplatin|Given IV
219712072|NCT01149083|PROCEDURE|Computed Tomography|Undergo CT
219712073|NCT01149083|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219712074|NCT01149083|DRUG|Veliparib|Given PO
219712075|NCT03785366|DRUG|VeraCept|VeraCept Intrauterine Device (IUD)
219712076|NCT03785366|DRUG|ParaGard|ParaGard intrauterine copper contraceptive
219712077|NCT06340633|DRUG|Ebselen|Glutathione peroxidase mimetic
219712078|NCT06340633|DRUG|Placebo|Matching placebo containing excipients
219712079|NCT05568719|DIAGNOSTIC_TEST|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
219712080|NCT05477069|DEVICE|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
219712081|NCT03240874|BEHAVIORAL|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
219712082|NCT03240874|BEHAVIORAL|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
219129744|NCT05137951|DEVICE|Rebee sensor|Rebee is a wearable motion sensor package of sensor with its own mobile application, which measures range of joint movement in different planes easily which the patient able to wear the sensor and move easily to measure ROM and record the measurement at the application software Digital goniometer Goniometry has been described as a tool to measure angle. It gives the physician a useful method to diagnose musculoskeletal function in terms of ROM, monitor the progress of an intervention, record the data for future follow-up, and meet statutory and legal requirements for impairment rating and disability determinations where applicable
219129745|NCT00731107|PROCEDURE|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
219129746|NCT00731107|PROCEDURE|laparoscopic surgery|Veress Needle laparoscopic entry
219129747|NCT06021574|DRUG|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
219129748|NCT06021574|DRUG|Placebo|Placebo
219129749|NCT03401788|DRUG|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
219129750|NCT04760444|BEHAVIORAL|Peer Leader Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
219129751|NCT04760444|BEHAVIORAL|Virtual Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
219129752|NCT04664777|DEVICE|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
219129753|NCT02510534|DRUG|Menopur 150 international units|Menopur 150 international units given x 1 dose
219129754|NCT02510534|DRUG|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
219129755|NCT01244984|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
219129756|NCT01244984|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
219129757|NCT04097886|OTHER|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
219129758|NCT04097886|OTHER|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
219129759|NCT05293301|DEVICE|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
219129760|NCT05293301|DEVICE|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
219129761|NCT06161883|OTHER|Soffritto|The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
219129762|NCT05396495|DEVICE|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
219129763|NCT06233955|DEVICE|Low Level laser therapy|is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation
219129764|NCT06233955|OTHER|Maitland mobilization technique|is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
219129765|NCT02072226|DRUG|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
219129766|NCT02072226|DRUG|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
219129767|NCT02072226|DRUG|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
219129768|NCT02072226|DRUG|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
219129769|NCT01335789|DRUG|Oxytocin|40 IUs
219129770|NCT01335789|DRUG|Saline|40 IUs
219129771|NCT03720340|DRUG|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
219129772|NCT03720340|DRUG|Saline|saline was administed through respiratory tract
219129773|NCT00119743|BIOLOGICAL|undecavalent pneumococcal-protein D conjugate vaccine|
219712083|NCT03240874|BEHAVIORAL|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
219129774|NCT04157842|PROCEDURE|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
219129775|NCT04157842|PROCEDURE|total hip replacement with no osteotomy|just total hip replacement
219129776|NCT05951595|DRUG|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
219129777|NCT05951595|DRUG|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
219129778|NCT05951595|DRUG|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
219129779|NCT03559361|DIETARY_SUPPLEMENT|EPA-rich|6 months omega 3 supplementation
219129780|NCT03559361|DIETARY_SUPPLEMENT|DHA-rich|6 months omega 3 supplementation
219129781|NCT03559361|DIETARY_SUPPLEMENT|Olive oil Placebo|6 months placebo supplementation
219129782|NCT04222387|DEVICE|OCT-B scan|OCT-B scan (Optical coherence tomography)
219129783|NCT02850627|DRUG|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
219129784|NCT02850627|DRUG|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
219129785|NCT01214902|DEVICE|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
219129786|NCT01214902|BEHAVIORAL|play|play which encourages the use of the hemiplegic hand
219129787|NCT03220139|OTHER|fat intake|Observational study on fat intake and mortality
219129788|NCT06328946|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
219129789|NCT06328946|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219129790|NCT06328946|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219129791|NCT02387346|DEVICE|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
219129792|NCT02387346|DEVICE|Magstim Rapid 2 Sham Stimulation|
219129793|NCT05695573|DIAGNOSTIC_TEST|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
219129794|NCT06240039|OTHER|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
219712084|NCT04153864|BEHAVIORAL|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
219129795|NCT03422510|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
219129796|NCT03450109|DRUG|LY01005|One gluteal IM injection
219129797|NCT03450109|DRUG|Zoladex|One Subcutaneous injection in the abdominal wall
219129798|NCT04053829|DEVICE|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
219129799|NCT04053829|OTHER|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
219129800|NCT05334082|OTHER|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
219129801|NCT03888820|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
219129802|NCT03888820|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
219129803|NCT01364519|DRUG|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
219129804|NCT01364519|DRUG|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
219129805|NCT00197457|PROCEDURE|serum pepsinogen|
219129806|NCT00197457|PROCEDURE|urea breath test|
219129807|NCT05114044|OTHER|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
219129808|NCT05114044|OTHER|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
219129809|NCT02157402|BEHAVIORAL|Social marketing activities and pop-up events to promote healthy lifestyles|
219226556|NCT06405451|OTHER|Experimental treatment|"Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set."
219226557|NCT06341309|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
219712085|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
219712086|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
219712087|NCT06287385|DIETARY_SUPPLEMENT|Goat-milk Based Formula|Provided Goat-milk Based Formula for babies 1-2 years old
219712088|NCT06460116|BEHAVIORAL|School-Based Community Health Worker (SB-CHW) intervention|The school-based community health worker will support students with chronic poor attendance and their parent/guardian for a minimum of two 30-minute encounters focused on addressing social determinants needs, understanding the range/student encounter varies greatly due to the intensity of the social need(s) (e.g., crisis/noncrisis) and the number of needs being jointly addressed. The SB-CHW will build relationships across encounters and apply trauma-informed best practices.
219712089|NCT06460116|BEHAVIORAL|Enhanced Usual Care (EUC) Methods|The network of school-based health centers without school-based community health workers will receive reminders of the the existing online social services directory.
219712090|NCT05717348|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219712091|NCT05922202|OTHER|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
219712092|NCT04958707|OTHER|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
219712093|NCT04958707|OTHER|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
219129810|NCT02831114|OTHER|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
219129811|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
219129812|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
219129813|NCT00810303|DRUG|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
219129814|NCT00810303|DRUG|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
219129815|NCT03241498|OTHER|Medicines optimisation|
219129816|NCT06059313|OTHER|Submission of the NEO-PI-3 questionnaire|The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
219129817|NCT06059313|OTHER|Submission of the Interpersonal Reactivity Index questionnaire (IRI)|The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
219129818|NCT00010881|DRUG|antioxidants|
219129819|NCT00010881|BEHAVIORAL|stress reduction|
219129820|NCT05137912|BIOLOGICAL|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
219129821|NCT02731521|DEVICE|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
219129822|NCT02731521|DEVICE|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
219129823|NCT03002844|DRUG|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
219129824|NCT03002844|DRUG|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
219129825|NCT03002844|DRUG|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
219129826|NCT05773612|OTHER|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
219712094|NCT04222751|DEVICE|Ankle Splint|Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
219712095|NCT04938830|BIOLOGICAL|Clesrovimab|IM injection
219129827|NCT03465007|DRUG|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
219129828|NCT03465007|DRUG|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
219129829|NCT01005992|PROCEDURE|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
219129830|NCT01005992|PROCEDURE|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
219129831|NCT05186545|DRUG|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
219712096|NCT04938830|BIOLOGICAL|Palivizumab|IM injection
219129832|NCT04101123|OTHER|Non-Interventional|Non-Interventional
219129833|NCT00021112|DRUG|cisplatin|
219129834|NCT00021112|DRUG|etoposide|
219129835|NCT00021112|PROCEDURE|conventional surgery|
219129836|NCT00021112|RADIATION|radiation therapy|
219129837|NCT03570255|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
219129838|NCT05753137|OTHER|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
219129839|NCT05753137|OTHER|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
219712097|NCT04938830|BIOLOGICAL|Placebo|IM injection
219712098|NCT02282969|BEHAVIORAL|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
219129840|NCT04927598|DEVICE|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
219129841|NCT04550416|OTHER|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
219129842|NCT05980468|OTHER|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
219226558|NCT06341309|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
219226559|NCT00455104|OTHER|No intervention|This is an observational, voluntary registry.
219712099|NCT02282969|BEHAVIORAL|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
219712100|NCT04698967|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
219712101|NCT04698967|BEHAVIORAL|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
219712102|NCT04447222|OTHER|Quality-of-Life Assessment|Ancillary studies
219712103|NCT04447222|OTHER|Questionnaire Administration|Ancillary studies
219712104|NCT04447222|OTHER|Survey Administration|Complete survey
219712105|NCT05457855|DRUG|Montelukast|Montelukast claim is used as the exposure group.
219712106|NCT05457855|DRUG|Fluticasone|Fluticasone claim is used as the reference group.
219712107|NCT02629159|DRUG|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
219712108|NCT02629159|DRUG|Adalimumab|Administered by subcutaneous injection once every other week
219712109|NCT02629159|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
219712110|NCT02629159|DRUG|Upadacitinib|Tablets taken orally once a day
219712111|NCT04383223|BEHAVIORAL|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
219712112|NCT05355272|DRUG|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
219712113|NCT04245514|DRUG|Durvalumab|Immunotherapy
219712114|NCT04245514|RADIATION|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
219712115|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
219712116|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
219712117|NCT02127398|BIOLOGICAL|fecal microbiota|fecal microbiota in capsule form
219712118|NCT04544462|OTHER|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
219712119|NCT05233228|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
219712120|NCT05233228|BEHAVIORAL|Self-help materials (to support smoking cessation)|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
219712121|NCT05233228|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
219129843|NCT05461924|OTHER|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
219129844|NCT00140166|DRUG|niacinamide|
219129845|NCT00140166|DRUG|pyridoxine|
219226560|NCT04323800|BIOLOGICAL|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
219129846|NCT00140166|DRUG|ascorbate|
219129847|NCT01124162|DRUG|Losartan|100 mg Tablet
219129848|NCT01124162|DRUG|Cozaar®|100 mg Tablet
219226561|NCT04323800|BIOLOGICAL|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
219226562|NCT00489554|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
219226563|NCT00489554|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
219226564|NCT00489554|BIOLOGICAL|Rotarix|Oral, 2 doses.
219129849|NCT04586192|OTHER|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
219129850|NCT04586192|OTHER|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
219129851|NCT00707590|DRUG|BMS-767778 or Placebo|
219129852|NCT04451889|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
219129853|NCT04371926|DRUG|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
219129854|NCT02680756|DRUG|Ferric Maltol|
219129855|NCT02680756|DRUG|Ferric Carboxy Maltose|
219712122|NCT06436651|OTHER|Digital Storytelling|4 stages of digital storytelling will be implemented.
219712123|NCT03331341|DRUG|Dacarbazine|Given IV
219712124|NCT03331341|DRUG|Doxorubicin Hydrochloride|Given IV
219712125|NCT03331341|OTHER|Laboratory Biomarker Analysis|Correlative studies
219712126|NCT03331341|BIOLOGICAL|Pembrolizumab|Given IV
219712127|NCT03331341|DRUG|Vinblastine|Given IV
219712128|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
219712129|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
219712130|NCT06452719|DRUG|Letrozole|Letrozole 10 mg orally daily for three consecutive days
219712131|NCT06452719|DRUG|Misoprostol|Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
219712132|NCT06106360|DEVICE|Locus Health iPhone App|In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
219712133|NCT03463408|DRUG|nivolumab|240 mg every 2 weeks
219712134|NCT03463408|DRUG|ipilimumab|1 mg/kg every 6 weeks
219712135|NCT05738213|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
219712136|NCT05738213|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
219129856|NCT04744597|BEHAVIORAL|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
219129857|NCT04744597|BEHAVIORAL|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
219129858|NCT04744597|BEHAVIORAL|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
219129859|NCT02560103|OTHER|Transmeridian travel across multiple time zones|
219129860|NCT02210702|DRUG|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
219129861|NCT02210702|DRUG|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
219129862|NCT00779571|BEHAVIORAL|Crispbread|8 week low calorie diet
219129863|NCT01702896|DRUG|Interleukin-2|Interleukin-2
219129864|NCT02805387|DIETARY_SUPPLEMENT|Treatment|Bicarbonate was ingested
219129865|NCT04281264|BEHAVIORAL|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
219129866|NCT04281264|BEHAVIORAL|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
219712137|NCT05738213|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
219712138|NCT05738213|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
219712139|NCT05738213|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
219712140|NCT05738213|BEHAVIORAL|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
219712141|NCT05738213|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
219129867|NCT04281264|BEHAVIORAL|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
219129868|NCT04281264|BEHAVIORAL|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
219129869|NCT04281264|BEHAVIORAL|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
219129870|NCT00447434|DRUG|Natto extract (Nattokinase)|
219129871|NCT01516892|BIOLOGICAL|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
219129872|NCT04475224|DRUG|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
219129873|NCT05390476|DRUG|Capecitabine|500mg orally three times a day (continuously)
219129874|NCT05390476|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
219129875|NCT05125367|PROCEDURE|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
219129876|NCT05125367|PROCEDURE|bypass grafting|coronary artery bypass graft
219129877|NCT04278820|DRUG|TQA3526|Tablet(s) administered orally once daily
219129878|NCT04278820|DRUG|Placebo to match TQA3526|Tablet(s) administered orally once daily
219129879|NCT02323386|DEVICE|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
219129880|NCT05580796|DRUG|KSH01 injection|TCR-T cell injection
219129881|NCT03136263|DRUG|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
219129882|NCT03136263|DRUG|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
219129883|NCT04037735|DEVICE|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
219129884|NCT04037735|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
219129885|NCT05584046|OTHER|CDAM|Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
219129886|NCT00387491|DRUG|MOA-728|
219129887|NCT03635112|DRUG|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
219129888|NCT03635112|DRUG|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
219129889|NCT03086512|DEVICE|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
219129890|NCT03086512|DEVICE|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
219129891|NCT00456274|PROCEDURE|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
219129892|NCT06097429|DIAGNOSTIC_TEST|blood sample for platelet aggregation|evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)
219226565|NCT06571695|PROCEDURE|Anatomic Long Head of Biceps Tensioning Technique|The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
219226566|NCT06571695|PROCEDURE|Traditional Long Head of Biceps Tensioning Technique|Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
219712142|NCT05738213|OTHER|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
219712143|NCT06327555|OTHER|telerehabilitation|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform telerehabilitation at home. Both sets of training sessions are identical.
219712144|NCT06327555|OTHER|in-person rehabilitation|The in-person rehabilitation group uses a face-to-face approach, with therapists providing outpatient rehabilitation guidance to patients three times a week for six weeks. After that, patients exercise at home according to the rehabilitation manual.
219712145|NCT00278408|BIOLOGICAL|filgrastim|
219712146|NCT00278408|BIOLOGICAL|rituximab|
219712147|NCT00278408|DRUG|cyclophosphamide|
219712148|NCT00278408|DRUG|doxorubicin hydrochloride|
219712149|NCT00278408|DRUG|prednisone|
219712150|NCT00278408|DRUG|vincristine sulfate|
219712151|NCT00278408|RADIATION|radiation therapy|
219129893|NCT02128789|OTHER|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
219712152|NCT05285891|DRUG|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
219712153|NCT05285891|DRUG|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 30 through Month 48.
219712154|NCT05280730|OTHER|No intervention|There is no intervention
219712155|NCT05599490|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
219129894|NCT02881125|DRUG|Nortriptyline Hydrochloride|Given PO
219129895|NCT02881125|DRUG|Paclitaxel|Given IV
219129896|NCT01520350|DRUG|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
219129897|NCT01520350|DRUG|placebo|Placebo
219129898|NCT03142646|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
219129899|NCT01023919|DEVICE|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
219129900|NCT00698191|BIOLOGICAL|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
219129901|NCT02446223|DRUG|Inggenol Mebutate 0.015%|
219129902|NCT03199417|DRUG|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
219712156|NCT03741127|DRUG|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
219712157|NCT03033355|DRUG|Intra-detrusor injection of Onabotulinumtoxin-A|Using cystoscopy, Onabotulinumtoxin-A is injected into the bladder.
219712158|NCT06387394|DRUG|BOTOX|Intramuscular Injections
219712159|NCT06387394|DRUG|Placebo|Intramuscular Injections
219712160|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
219129903|NCT03199417|OTHER|Placebo|An identically packaged placebo cream
219129904|NCT02148406|BEHAVIORAL|Yoga Skills Training (YST)|Undergo YST
219129905|NCT02148406|OTHER|questionnaire administration|Ancillary studies
219129906|NCT02148406|OTHER|fatigue and depressive symptom assessment and management|Ancillary studies
219129907|NCT02148406|OTHER|psychological stress assessment|Ancillary studies
219129908|NCT02148406|OTHER|laboratory biomarker analysis|Correlative studies
219129909|NCT02148406|OTHER|Attention Control|
219129910|NCT04087044|DEVICE|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"1. Oculo-Motility and Positional Testing,~2. Caloric Testing"
219129911|NCT06554964|PROCEDURE|performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube|Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
219129912|NCT05304390|BEHAVIORAL|Patient Navigation|Receive patient navigation intervention
219129913|NCT05304390|OTHER|Questionnaire Administration|Ancillary studies
219129914|NCT05304390|BEHAVIORAL|Smoking Cessation Intervention|Receive an intervention for smoking cessation
219129915|NCT05304390|PROCEDURE|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
219129916|NCT02243007|DRUG|FOLFIRINOX|
219129917|NCT02243007|DRUG|Gemcitabine/nab-Paclitaxel|
219129918|NCT02243007|RADIATION|Radiation therapy|
219129919|NCT02243007|DRUG|Capecitabine|
219129920|NCT01187303|DRUG|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
219129921|NCT02950545|DEVICE|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
219129922|NCT02950545|DEVICE|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
219129923|NCT02950545|DEVICE|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
219129924|NCT06405074|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
219129925|NCT03101592|OTHER|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
219129926|NCT03101592|OTHER|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
219129927|NCT00003543|BIOLOGICAL|monoclonal antibody A33|
219129928|NCT00003543|DRUG|carmustine|
219129929|NCT00003543|DRUG|fluorouracil|
219129930|NCT00003543|DRUG|streptozocin|
219129931|NCT00003543|DRUG|vincristine sulfate|
219129932|NCT04741971|DIETARY_SUPPLEMENT|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
219129933|NCT04741971|DIETARY_SUPPLEMENT|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
219129934|NCT06179095|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
219129935|NCT04555330|DEVICE|Physical activity measurement|"To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking."
219129936|NCT04555330|DEVICE|Visual Feedback|The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
219129937|NCT05766163|DEVICE|DaVinci RARP|Assisted-robotic radical prostatectomy.
219129938|NCT05766163|DEVICE|Hugo RARP|Assisted-robotic radical prostatectomy.
219129939|NCT05766163|DEVICE|Versius RARP|Assisted-robotic radical prostatectomy.
219129940|NCT00413491|PROCEDURE|MR mammography|MR mammography
219129941|NCT00413491|PROCEDURE|MR|MR
219712161|NCT04717557|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
219712162|NCT03745287|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
219129942|NCT01728389|PROCEDURE|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
219129943|NCT01351610|BIOLOGICAL|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC\_Apceth
219129944|NCT01351610|PROCEDURE|PTA|percutaneous transluminal angioplasty only
219129945|NCT02694679|BEHAVIORAL|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
219129946|NCT02276131|DEVICE|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
219129947|NCT03461887|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
219129948|NCT02341534|DEVICE|BioMonitor|Patients will be implanted with the BioMonitor + Home Monitoring feature
219129949|NCT04100954|DEVICE|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
219129950|NCT04100954|DEVICE|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
219129951|NCT03398356|DRUG|Metformin|"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."
219129952|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A|Participants will engage in a modified version of the Iowa Gambling Task with visual stimuli that are aligned with the Pé-de-Meia program's requirements. Advantageous cards will display images that are congruent with the program's criteria, while disadvantageous cards will feature images that are contrary to the Pé-de-Meia program's requirements.
219129953|NCT06344455|BEHAVIORAL|Iowa Gambling Task|The participants will play the unmodified Iowa Gambling Task.
219129954|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B|"The participants will play the modified IGT (Iowa Gambling Task). For the disadvantageous cards, images that align with the requirements of the Pé-de-Meia program will be presented, while for the advantageous cards, images that contradict the criteria of the Pé-de-Meia program will be shown."
219129955|NCT05237193|DIAGNOSTIC_TEST|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
219129956|NCT01048151|BIOLOGICAL|TNFerade™ Biologic|AdGVEGR.TNF.11D
219129957|NCT03091712|DEVICE|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
219129958|NCT04643353|DEVICE|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
219129959|NCT04643353|OTHER|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
219129960|NCT05101330|DEVICE|Bilingual prescription medication labels|The bilingual PML contains English and Chinese medication-related instructions for participants.
219129961|NCT04034121|DEVICE|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
219129962|NCT00740285|DRUG|Lidocaine 2% without vessel constrictor|"* first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
219129963|NCT00740285|OTHER|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
219129964|NCT01522339|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
219129965|NCT01738711|BEHAVIORAL|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
219129966|NCT06310564|RADIATION|SABR|"A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data.~In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered.~SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest."
219129967|NCT02362633|DEVICE|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
219129968|NCT02362633|DEVICE|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
219226567|NCT01219153|DRUG|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
219712163|NCT05776719|BEHAVIORAL|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
219129969|NCT04170426|BIOLOGICAL|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
219129970|NCT01648283|DRUG|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
219129971|NCT01648283|DRUG|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
219129972|NCT01942083|DRUG|OPB-111077|
219129973|NCT00226200|DRUG|Omalizumab|
219129974|NCT05543096|DEVICE|Adroit Guiding Catheter, Cordis Transradial Access Devices, Cordis Diagnostic Catheters, Cordis Guidewires|Observation
219129975|NCT06526728|DRUG|Hyperbaric oxygen|Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
219129976|NCT03983161|DRUG|Fedratinib|Fedratinib
219129977|NCT02113111|BEHAVIORAL|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
219129978|NCT01257165|DRUG|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
219129979|NCT01257165|DRUG|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
219129980|NCT01257165|DRUG|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
219129981|NCT01257165|DRUG|Placebo drink|Placebo drink, given orally as a single dose
219129982|NCT03281343|BEHAVIORAL|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
219129983|NCT03281343|BEHAVIORAL|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
219129984|NCT03907605|OTHER|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
219129985|NCT04512742|OTHER|biting by Phlebotomus duboscqi infected with Leishmania major|The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed.
219712164|NCT05776719|BEHAVIORAL|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
219129986|NCT03364959|OTHER|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
219712165|NCT06265220|DRUG|AB-101|NK Cell Therapy
219712166|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
219129987|NCT03364959|OTHER|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
219129988|NCT04865562|DRUG|testosterone propionate|1mg/0.1mL solution, to be administered intranasally
219129989|NCT04865562|DRUG|0.5% cholorbutanol, saline|125 mg 0.5% cholorbutanol, 50mg saline
219129990|NCT02060279|OTHER|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
219129991|NCT02060279|OTHER|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
219129992|NCT03506490|OTHER|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
219712167|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
219129993|NCT04582175|PROCEDURE|angioplasty|angioplasty of all non-culprit lesions
219129994|NCT01134809|PROCEDURE|Major abdominal surgery|All adult patients having major abdominal surgery
219129995|NCT03587194|DRUG|Otezla|Otezla 30mg BID
219129996|NCT00407940|DEVICE|Lower extremity Atherectomy and Cryoplasty|
219129997|NCT00073957|BIOLOGICAL|rituximab|
219129998|NCT00073957|DRUG|cytarabine|to be used for CNS prophylaxis
219129999|NCT00073957|DRUG|liposomal cytarabine|to be used as CNS prophylaxis
219130000|NCT00073957|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219130001|NCT00423774|BEHAVIORAL|Problem-Solving Education|
219130002|NCT05304520|DRUG|Natalizumab|Administered as specified in the treatment arm.
219712168|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
219712169|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
219712170|NCT04184895|BIOLOGICAL|ASP2390|Intradermal
219712171|NCT04184895|BIOLOGICAL|Placebo|Intradermal; normal saline solution
219130003|NCT02823496|OTHER|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
219130004|NCT02823496|OTHER|Untreated skin|One site is patched without treatment as control
219130005|NCT00601640|DRUG|Diclofenac Na gel|Given topically twice daily on days 1-90
219130006|NCT00601640|DRUG|Eflornithine HCL ointment|Given topically twice daily on days 1-90
219130007|NCT00530777|DRUG|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
219130008|NCT00530777|DRUG|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
219130009|NCT04066998|OTHER|Tears sampling|Tears sampling
219130010|NCT04066998|OTHER|Lashes sampling|Lashes sampling
219130011|NCT02992665|DRUG|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
219712172|NCT03964116|OTHER|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
219712173|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
219712174|NCT06401980|DRUG|Darolutamide|Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
219712175|NCT06401980|OTHER|Standard of care|"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."
219712176|NCT06549413|OTHER|Non-Interventional Study|Non-interventional study
219712177|NCT04258319|DIAGNOSTIC_TEST|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
219712178|NCT03731000|DEVICE|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
219130012|NCT02992665|OTHER|Placebo|Placebo is used to control Ca ionophore group
219130013|NCT05192824|DEVICE|Orthokeratology lens|The intervention was according to the design of different optical zone and peripheral reverse curve
219130014|NCT06426654|DRUG|sintiliman plus LDRT|"All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
219130015|NCT02359058|DRUG|Ramucirumab|Administered IV
219130016|NCT02359058|DRUG|Capecitabine|Administered orally
219130017|NCT02359058|DRUG|Cisplatin|Administered IV
219130018|NCT02359058|DRUG|S-1|Administered orally
219130019|NCT02359058|DRUG|Oxaliplatin|Administered IV
219130020|NCT05660850|DRUG|GDC-6599|GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
219130021|NCT05660850|OTHER|GDC-6599-matching placebo|GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
219130022|NCT05660850|DIAGNOSTIC_TEST|Mannitol|Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
219130023|NCT02926742|DEVICE|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
219130024|NCT03829280|BEHAVIORAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
219130025|NCT03829280|BEHAVIORAL|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
219130026|NCT04830254|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
219130027|NCT03163992|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
219130028|NCT01104103|DEVICE|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
219130029|NCT01104103|DEVICE|Standard elastic constricting band|Standard therapy
219130030|NCT02060097|DIETARY_SUPPLEMENT|Cocoa flavanol beverage|
219130031|NCT02060097|DIETARY_SUPPLEMENT|Placebo beverage|
219130032|NCT03267147|OTHER|no intervention is given|no intervention is given
219130033|NCT02833454|PROCEDURE|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
219130034|NCT02833454|PROCEDURE|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
219130035|NCT02833454|PROCEDURE|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
219130036|NCT03771235|BEHAVIORAL|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
219130037|NCT03771235|BEHAVIORAL|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
219130038|NCT00151619|DRUG|Amlodipine|
219130039|NCT00577447|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
219130040|NCT00577447|DIETARY_SUPPLEMENT|Placebo|Placebo capsule containing corn and soybean oil
219130041|NCT03382821|PROCEDURE|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
219712179|NCT03727880|DRUG|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
219712180|NCT03727880|DRUG|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
219712181|NCT02213003|BIOLOGICAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
219712182|NCT06242470|BIOLOGICAL|MGC026 Dose Escalation|Escalating doses of MGC026
219712183|NCT06242470|BIOLOGICAL|MGC026 Dose for Expansion|MGC026 recommended dose for expansion
219712184|NCT04837716|BIOLOGICAL|Bevacizumab|Given IV
219712185|NCT04837716|DRUG|Carboplatin|Given IV
219130042|NCT03382821|PROCEDURE|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
219130043|NCT03382821|DRUG|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
219130044|NCT03382821|DRUG|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
219130045|NCT03382821|DRUG|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
219712186|NCT04837716|DRUG|Ensartinib|Given PO
219712187|NCT04837716|DRUG|Pemetrexed|Given IV
219712188|NCT05808920|GENETIC|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
219712189|NCT05352399|OTHER|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
219712190|NCT06618885|BIOLOGICAL|SUM-101|Three immunizations every 4 weeks for 3 months (total 3 immunizations)
219712191|NCT06374485|DRUG|AU409|Oral administration
219712192|NCT05484778|PROCEDURE|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
219130046|NCT04296240|DRUG|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
219130047|NCT04296240|PROCEDURE|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
219130048|NCT00578695|DRUG|lixivaptan|Oral Capsule
219130049|NCT00578695|DRUG|Placebo|Oral Capsule
219130050|NCT03247348|BEHAVIORAL|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
219130051|NCT04438915|BEHAVIORAL|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
219130052|NCT00282438|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
219130053|NCT00282438|BIOLOGICAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
219712193|NCT05609435|OTHER|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
219712194|NCT06432517|OTHER|Power Bike（Ergoselect 100P）|Changes in the participants' energy balance will be measured through moderate to high intensity exercise. Observation of food intake, body composition, metabolic rate, food assimilation rate.
219226568|NCT01219153|DRUG|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
219226569|NCT06092307|DIAGNOSTIC_TEST|Bioelectrical impedance|Resistance, reactance, phase angle,free-fat mass, body cell mass, body cell mass index and total body will be recorded
219226570|NCT06092307|DIAGNOSTIC_TEST|Handgrip strength test|Handgrip strength test using a hydraulic hand dynamometer and sit-to-stand test will be performed.
219226571|NCT06092307|DIAGNOSTIC_TEST|muscle ultrasound.|The following ultrasound parameters will be evaluated: radial, ulnar, rectus femoris, rectus abdominis and medial gastrocnemius muscle thickness and echo intensity with gray-scale-index; rectus femoris muscle cross sectional area; gastrocnemius muscle fiber length and pennation angle.
219226572|NCT00773344|DRUG|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
219712195|NCT03370224|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219712196|NCT03370224|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219712197|NCT06220656|PROCEDURE|Biopsy|Local anesthetic is usually given and a small needle is used to take cells from the thyroid under ultrasound guidance through several 'passes' and placed into specialized media for pathology evaluation.
219712198|NCT06220656|PROCEDURE|Active Monitoring|Ultrasound and a check-up at 6 months. Depending on ultrasound results, either biopsy and further care (as for the treatment arm called 'biopsy'), or continue with active monitoring.
219712199|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
219130054|NCT02793609|OTHER|Intervention is to let patient to go home.|Intervention is to let patient to go home.
219130055|NCT02793609|OTHER|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
219130056|NCT06048341|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
219226573|NCT01349270|DRUG|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
219226574|NCT01349270|DRUG|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
219226575|NCT00989742|DRUG|Doxycycline|50mg od
219130057|NCT06048341|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
219130058|NCT06048341|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
219130059|NCT00471211|DRUG|PBT2|
219130060|NCT06331754|OTHER|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program.
219130061|NCT03864484|DEVICE|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
219130062|NCT03864484|BEHAVIORAL|Usual rehabilitation|The control group receives usual rehabilitation.
219130063|NCT00106808|DRUG|Muraglitazar|
219130064|NCT00106808|DRUG|Pioglitazone|
219130065|NCT02831400|BEHAVIORAL|Walking test|Walking test to increase cardiac output, maximum 12 minutes
219226576|NCT00989742|DRUG|Placebo|50mg od
219226577|NCT05075200|DRUG|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
219130066|NCT02831400|BEHAVIORAL|Standard Meal|After the walking test, volunteers eat a standard warm meal
219130067|NCT05831280|BEHAVIORAL|Laughter Yoga|"* Warm-up exercises (5 minutes),~* Deep breathing exercises (5 minutes),~* Childlike playfulness (5 minutes),~* Laughter exercises (15 minutes)."
219130068|NCT04144985|OTHER|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
219130069|NCT02778308|DRUG|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
219130070|NCT04155853|PROCEDURE|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
219130071|NCT04155853|PROCEDURE|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
219130072|NCT04818320|DRUG|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
219130073|NCT00188240|DRUG|Pegasys; Copegus.|
219130074|NCT02742142|OTHER|water as placebo|topical application of water as a placebo in the control arm
219712200|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
219712201|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
219712202|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
219130075|NCT02742142|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
219130076|NCT01572077|RADIATION|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
219130077|NCT06366893|DIETARY_SUPPLEMENT|DHA/AA emulsion supplement for preterm infant|Enteral supplementation of DHA/AA emulsion
219130078|NCT04548609|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
219130079|NCT04390464|DRUG|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
219130080|NCT04390464|DRUG|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
219130081|NCT04390464|OTHER|Standard of care|Regular standard of care for COVID-19 patients
219130082|NCT04422925|PROCEDURE|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
219130083|NCT05249179|OTHER|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
219130084|NCT05249179|OTHER|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
219130085|NCT00006265|DRUG|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
219130086|NCT00006265|BIOLOGICAL|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)
219130087|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
219130088|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
219130089|NCT01674569|DRUG|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
219130090|NCT01674569|DRUG|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
219130091|NCT03244566|DIAGNOSTIC_TEST|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
219130092|NCT02419521|DEVICE|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
219130093|NCT04888455|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
219226578|NCT03030651|BEHAVIORAL|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
219226579|NCT00237926|BEHAVIORAL|Exercise|aerobic or resistance training
219130094|NCT00587132|DRUG|Synthetic Human Secretin|0.2mcg/kg one time dose.
219130095|NCT06418906|OTHER|Self-reported questionnaires|After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
219226580|NCT01380145|BIOLOGICAL|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
219226581|NCT06075641|PROCEDURE|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
219226582|NCT02118311|BIOLOGICAL|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
219226583|NCT02118311|DRUG|Fludarabine|Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
219226584|NCT02118311|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
219226585|NCT02118311|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
219226586|NCT05080257|DEVICE|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
219226587|NCT06211998|DEVICE|Group 1|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
219226588|NCT06211998|DEVICE|Group 2|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
219226589|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
219226590|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an IV infusion.
219130096|NCT06478043|DRUG|ivonescimab|20mg/kg, IV, D1, Q3W
219130097|NCT06478043|DRUG|irinotecan liposome|56.5mg/m\^2, IV, D1, Q2W
219130098|NCT00908674|DRUG|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
219130099|NCT04670575|PROCEDURE|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
219226591|NCT05139615|DRUG|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
219712203|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
219712204|NCT02846623|DRUG|Atezolizumab|Given IV
219712205|NCT02846623|OTHER|Laboratory Biomarker Analysis|Correlative studies
219712206|NCT02846623|BIOLOGICAL|Obinutuzumab|Given IV
219130100|NCT02782988|OTHER|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
219130101|NCT02347917|DRUG|BBI608|480 mg orally twice daily (960 mg total daily dose)
219130102|NCT02347917|DRUG|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
219712207|NCT02846623|DRUG|Venetoclax|Given PO
219712208|NCT06195228|DRUG|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
219712209|NCT06195228|DRUG|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
219712210|NCT06195228|DRUG|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
219712211|NCT06195228|DRUG|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
219712212|NCT06195228|DRUG|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
219712213|NCT06195228|DRUG|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
219712214|NCT01802281|PROCEDURE|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
219712215|NCT01802281|PROCEDURE|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
219712216|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
219712217|NCT05484115|DEVICE|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
219130103|NCT02347917|DRUG|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
219130104|NCT03033732|DRUG|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
219130105|NCT03033732|DRUG|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
219226592|NCT01672684|PROCEDURE|support group therapy|Complete at-home group video calling support sessions
219226593|NCT01672684|OTHER|educational intervention|Receive an educational workbook journal
219226594|NCT02174146|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
219712218|NCT05484115|DEVICE|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
219712219|NCT03314181|DRUG|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
219712220|NCT03314181|DRUG|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
219712221|NCT03314181|DRUG|Venetoclax|Tablet; Oral
219712222|NCT03314181|DRUG|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
219712223|NCT05639231|BEHAVIORAL|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~* Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~* Customizable diary to document mobility goals, results, difficulties and needs.~* Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing).~* iPad 10.2'' with videos of the exercises.~HCPs (physicians \& nursing staff):~* E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation.~* Oral presentation on the intervention.~* Checklist to remind HCPs to address mobility.~ENVIRONMENT:~* Posters in the wards about mobility and other topics of interest to older adults.~* Walking itineraries in the wards."
219130106|NCT03605329|OTHER|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH \<15 / hour."
219130107|NCT03771027|OTHER|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
219130108|NCT03771027|OTHER|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
219226595|NCT04918394|OTHER|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor"
219130109|NCT06095310|BEHAVIORAL|New computer vision methods|Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
219130110|NCT01941316|DRUG|Carfilzomib|20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
219130111|NCT01941316|DRUG|Irinotecan|125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
219130112|NCT05998668|OTHER|Genital hygiene training|In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
219130113|NCT00372216|DRUG|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
219130114|NCT04545606|BEHAVIORAL|In-Person CBT for insomnia in children with autism|"7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
219130115|NCT04545606|BEHAVIORAL|Remote CBT for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
219130116|NCT04545606|BEHAVIORAL|Remote sleep hygiene and related education (SHARE) for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle"
219130117|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
219130118|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
219130119|NCT02960542|BEHAVIORAL|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
219712224|NCT05884411|DEVICE|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
219712225|NCT05884411|DIAGNOSTIC_TEST|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
219712226|NCT05049837|OTHER|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
219712227|NCT05049837|OTHER|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
219712228|NCT05049837|OTHER|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
219712229|NCT05049837|OTHER|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
219130120|NCT06555029|BEHAVIORAL|EHR Changes|"Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources"
219130121|NCT06555029|BEHAVIORAL|Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training|"Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR."
219130122|NCT06555029|BEHAVIORAL|Standard ADA Oral Health Training|"Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter."
219130123|NCT03885596|DRUG|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
219130124|NCT03885596|DRUG|Ketorolac|30 mg IV at the onset of anesthesia
219130125|NCT03885596|DRUG|Acetaminophen IV|1 g at the onset of anesthesia
219130126|NCT03885596|DRUG|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
219130127|NCT03885596|DRUG|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
219130128|NCT03885596|DRUG|Lidocaine HCl|1.5% 12 mL at the end of surgery
219130129|NCT03885596|DRUG|Celecoxib|200 mg PO bid each day postoperative
219130130|NCT03885596|DRUG|Acetaminophen Oral|1 g postoperative
219130131|NCT03885596|DRUG|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
219130132|NCT03885596|DRUG|Exparel|Bupivacaine liposome injection suspension
219130133|NCT03419208|OTHER|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
219130134|NCT04903002|DRUG|24-IU oxytocin|Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
219712230|NCT05049837|OTHER|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
219712231|NCT05049837|OTHER|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
219712232|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
219712233|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
219712234|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
219712235|NCT05674929|DRUG|BPL-003|A single dose administered intranasally
219712236|NCT02685735|DRUG|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
219712237|NCT02685735|DRUG|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
219712238|NCT06827782|BIOLOGICAL|anti-CD19 CAR-NK cells|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
219712239|NCT06590792|OTHER|exhaustive exercise training session|Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.
219712240|NCT04282616|OTHER|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
219712241|NCT04282616|OTHER|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
219712242|NCT04282616|OTHER|In-hospital structured supervised physical activity program|Supervised exercise training program
219712243|NCT06843720|BEHAVIORAL|HR-HPV Testing|Given by Interview and focus groups
219712244|NCT06849726|PROCEDURE|Standard Epidural Analgesia|Administration of conventional epidural analgesia using an 18G Tuohy needle for catheter placement and subsequent administration of a standardized dose of bupivacaine with fentanyl.
219130135|NCT04903002|DRUG|48-IU oxytocin|Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
219130136|NCT04903002|DRUG|Placebo|Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
219130137|NCT03749291|OTHER|Obemat2.0 therapy|"Lifestyle (diet \& physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month \& 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight \& physical activity are defined to be accomplished until the next visit."
219130138|NCT03749291|OTHER|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians \& nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity \[Spanish Ministry of Science and Innovation\], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
219130139|NCT05842850|BEHAVIORAL|Caloric restriction intervention|The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.
219130140|NCT05842850|OTHER|No intervention|No intervention
219712245|NCT06849726|PROCEDURE|Dural Puncture Epidural Analgesia|Administration of epidural analgesia that incorporates a dural puncture with a 27G spinal needle prior to epidural catheter placement, followed by the same standardized dose of bupivacaine with fentanyl.
219712246|NCT05157386|OTHER|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
219712247|NCT05560685|OTHER|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
219712248|NCT05560685|OTHER|Semi-structured interview|Team member participants will complete a semi-structured interview.
219712249|NCT05965427|OTHER|No intervention|Study is retrospective data collection only
219712250|NCT05620212|BEHAVIORAL|Recovery College participation|Recovery College participation in any way (visitors, course/retreat participants, volunteers, employees).
219130141|NCT06219213|OTHER|Glyceryl Eicosapentaenoate serum|Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.
219130142|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream A|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
219130143|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream B|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
219130144|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream C|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
219130145|NCT03276793|OTHER|MRI scan|Patients will undergo an MRI scan
219226596|NCT03531242|BIOLOGICAL|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
219130146|NCT03276793|BEHAVIORAL|Behavioral testing|Patients will complete a series of cognitive tasks
219130147|NCT04398459|DRUG|Ibrutinib|Each recruited subject will accept Ibrutinib treatment.
219130148|NCT06466473|DRUG|Phenytoin (Ascoli)|Phenytoin 50mg chewable tablets
219130149|NCT06466473|DRUG|Phenytoin (Vega Baja)|Phenytoin 50mg chewable tablets
219130150|NCT05980793|PROCEDURE|PIP joint denervation|Surgical denervation of the PIP joint
219130151|NCT05980793|PROCEDURE|Patient education plus exercise|An education plus exercise program
219712251|NCT02101788|DRUG|Letrozole|Given PO
219712252|NCT02101788|DRUG|Paclitaxel|Given IV
219712253|NCT02101788|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219712254|NCT02101788|OTHER|Quality-of-Life Assessment|Ancillary studies
219712255|NCT02101788|OTHER|Questionnaire Administration|Ancillary studies
219712256|NCT02101788|DRUG|Tamoxifen Citrate|Given PO
219712257|NCT02101788|DRUG|Topotecan|Given IV
219712258|NCT02101788|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219712259|NCT05466929|BEHAVIORAL|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
219130152|NCT02911571|DEVICE|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
219130153|NCT04087096|DRUG|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
219130154|NCT04087096|DRUG|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
219130155|NCT04087096|DRUG|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
219226597|NCT04997798|DRUG|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
219226598|NCT04746404|BEHAVIORAL|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
219712260|NCT05770479|BEHAVIORAL|Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules|ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
219712261|NCT05770479|OTHER|Treatment As Usual|Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
219712262|NCT05768685|BEHAVIORAL|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
219712263|NCT03943173|DRUG|Chemotherapy|Given standard chemotherapy
219712264|NCT03943173|DRUG|Olaparib|Given PO
219712265|NCT03943173|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219130156|NCT04436029|BIOLOGICAL|Descartes 11|Car T-cells
219130157|NCT05455996|DRUG|MDMA|MDMA-assisted therapy
219130158|NCT02749331|DRUG|AdVince|Virus solution for infusion in intrahepatic artery
219130159|NCT05413928|BEHAVIORAL|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
219130160|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
219130161|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
219130162|NCT05413928|OTHER|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
219130163|NCT06444347|DEVICE|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
219130164|NCT06444347|PROCEDURE|Hiatal Hernia Repair|The non-mesh group will undergo hiatal hernia repair with permanent suture only.
219130165|NCT01515358|DRUG|Placebo|Administered orally
219712266|NCT01292408|DRUG|Hydrochloroquine|800 mg per os once, and then 400 mg per day
219712267|NCT01092377|DIETARY_SUPPLEMENT|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
219130166|NCT01515358|DRUG|LY3000328|Administered orally
219130167|NCT04252820|DEVICE|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
219130168|NCT05165238|BEHAVIORAL|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
219130169|NCT03957980|OTHER|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
219226599|NCT00724737|PROCEDURE|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
219226600|NCT00724737|PROCEDURE|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
219226601|NCT03848975|OTHER|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
219226602|NCT03848975|OTHER|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
219712268|NCT01092377|DIETARY_SUPPLEMENT|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
219130170|NCT02292667|PROCEDURE|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
219130171|NCT02292667|DRUG|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
219130172|NCT02292667|DRUG|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
219130173|NCT05837780|OTHER|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
219130174|NCT05717335|DRUG|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
219130175|NCT00555581|DRUG|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
219130176|NCT05964257|DRUG|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
219130177|NCT05964257|DRUG|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
219130178|NCT05822440|DRUG|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
219130179|NCT05822440|DRUG|Itraconazole|Interacting drug which will be given for 7 days in period 2
219130180|NCT01609894|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
219130181|NCT01609894|DIETARY_SUPPLEMENT|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
219130182|NCT05805124|DIAGNOSTIC_TEST|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~* renal function tests~* hematologic tests~* coagulation tests~* hepatic function tests~* ECG~* cardiac function tests~* pulmonary function tests~* endocrine function tests"
219130183|NCT05365386|DEVICE|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
219130184|NCT06440850|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219130185|NCT06440850|DRUG|Cobimetinib|Given PO
219130186|NCT06440850|PROCEDURE|Computed Tomography|Undergo CT scan
219130187|NCT06440850|PROCEDURE|Diagnostic Imaging|Undergo I-123 diagnostic scan
219130188|NCT06440850|PROCEDURE|I-131 Uptake Test|Undergo I-131 whole body scan
219130189|NCT06440850|RADIATION|Iodine I-131|Given PO
219130190|NCT06440850|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219130191|NCT06440850|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219130192|NCT06440850|BIOLOGICAL|Recombinant Thyrotropin Alfa|Given IM
219130193|NCT06440850|PROCEDURE|Ultrasound Imaging|Undergo neck ultrasound
219130194|NCT06440850|DRUG|Vemurafenib|Given PO
219130195|NCT02387749|GENETIC|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
219130196|NCT00117988|DRUG|tanespimycin|
219130197|NCT02196051|OTHER|one bout of 45 minutes exercise|45 minutes of exercise on an elliptical exercise machine
219130198|NCT02525510|OTHER|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
219130199|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
219130200|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
219130201|NCT02525510|OTHER|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
219130202|NCT02525510|OTHER|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
219130203|NCT05196737|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
219130204|NCT05096884|DRUG|Metoprolol Succinate|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
219130205|NCT06585020|DRUG|Arikayce|Treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin with ARIKAYCE® during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
219130206|NCT06585020|DRUG|standard treatment|treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
219712269|NCT01092377|OTHER|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
219130207|NCT03310463|DRUG|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
219226603|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
219226604|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
219226605|NCT05687214|OTHER|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum."
219226606|NCT04552457|BEHAVIORAL|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
219226607|NCT04552457|BEHAVIORAL|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
219226608|NCT02038049|DRUG|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
219226609|NCT02038049|DRUG|Placebo|Placebo to VAY736
219712270|NCT01092377|OTHER|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
219226610|NCT05364840|DRUG|STI-1558|Orally available protease inhibitor capsule
219226611|NCT05364840|DRUG|Placebo|Placebo product capsule
219226612|NCT01691716|DRUG|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
219226613|NCT01691716|BEHAVIORAL|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
219226614|NCT03540329|DEVICE|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
219226615|NCT03540329|DEVICE|External Osteogenesis distractor|External distraction osteogenesis in mandible
219130208|NCT01605968|DEVICE|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
219130209|NCT01605968|DEVICE|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
219130210|NCT05214794|DRUG|nemolizumab|nemolizumab will be administered subcutaneous injection
219226616|NCT02656147|BIOLOGICAL|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
219226617|NCT01378884|DRUG|Domperidone|Patient to receive treatment with Domperidone
219226618|NCT00586755|PROCEDURE|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
219226619|NCT02454556|DRUG|FOLITIME®|
219226620|NCT02454556|DRUG|Gonal-F®|
219226621|NCT04540926|DRUG|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
219226622|NCT02905292|OTHER|evaluation and treatment maneuver for BPPV|
219226623|NCT01030315|DRUG|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
219226624|NCT01808534|DRUG|palifosfamide|Given IV
219226625|NCT05186402|PROCEDURE|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
219226626|NCT00002599|BIOLOGICAL|filgrastim|
219226627|NCT00002599|BIOLOGICAL|recombinant interferon alfa|
219226628|NCT00002599|BIOLOGICAL|sargramostim|
219226629|NCT00002599|DRUG|carmustine|
219226630|NCT00002599|DRUG|cyclophosphamide|
219226631|NCT00002599|DRUG|doxorubicin hydrochloride|
219226632|NCT00002599|DRUG|melphalan|
219712271|NCT04925635|BEHAVIORAL|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
219712272|NCT04925635|BEHAVIORAL|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
219226633|NCT00002599|DRUG|methylprednisolone|
219226634|NCT00002599|DRUG|prednisone|
219226635|NCT00002599|DRUG|vincristine sulfate|
219226636|NCT00002599|RADIATION|low-LET cobalt-60 gamma ray therapy|
219226637|NCT00002599|RADIATION|low-LET photon therapy|
219130211|NCT01249742|BEHAVIORAL|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
219226638|NCT01823224|DRUG|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
219712273|NCT04646629|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
219130212|NCT03265704|OTHER|AGA - Control group|Data processing from Patient Medical Files
219130213|NCT03265704|OTHER|SGA - Control group|Data processing from Patient Medical Files
219712274|NCT04646629|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
219130214|NCT03265704|OTHER|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
219130215|NCT03265704|OTHER|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
219712275|NCT03866694|BEHAVIORAL|BRIGHT|Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.
219712276|NCT03866694|OTHER|STAR/TAU+|Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
219130216|NCT03591289|DRUG|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
219130217|NCT05042063|DEVICE|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
219226639|NCT01823224|DRUG|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
219226640|NCT00188747|PROCEDURE|Thromboelastograph, Point of Care|
219226641|NCT05174520|OTHER|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
219226642|NCT05174520|OTHER|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
219226643|NCT06486610|BEHAVIORAL|Fish-shaped nebulizer and fish-shaped toy|In order to reduce the child's fear and anxiety, it is planned to apply inhalation therapy using a nebulizer with a red fish figure and an amigurumi toy with a red fish figure.
219712277|NCT03653481|DIETARY_SUPPLEMENT|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
219712278|NCT03653481|DIETARY_SUPPLEMENT|Maltodextrin|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
219712279|NCT05839977|OTHER|Individual telerehabilitation|The exercise will consist of strength and balance exercises using the Homebalance ® system
219712280|NCT05839977|OTHER|Home exercises based on videos|intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
219712281|NCT05853263|DRUG|paracetamol|paracetamol IV to substitute morphine IV.
219712282|NCT05853263|DRUG|Morphine|standard care
219130218|NCT05042063|DEVICE|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
219130219|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
219226644|NCT06486610|DEVICE|Silent nebulizer|It is planned to apply inhalation therapy using a silent nebulizer to reduce the child's fear and anxiety.
219226645|NCT05302076|DEVICE|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
219712283|NCT01470170|DRUG|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
219712284|NCT01470170|DRUG|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
219130220|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
219130221|NCT01096056|BIOLOGICAL|Fluarix|Intramuscular administration, 1 dose
219130222|NCT05167747|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
219130223|NCT05167747|OTHER|Placebo|Oral administration: 2 tablets/day at evening meal
219130224|NCT02484365|OTHER|No treatment|Attach adhesive probe on thumb or index finger
219130225|NCT03571243|OTHER|no intervention|observational study
219130226|NCT05536466|PROCEDURE|bariatric surgery|bariatric surgery
219130227|NCT02594176|DEVICE|FLEXISEQ®|applicable gel
219712285|NCT01470170|DEVICE|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
219712286|NCT01470170|DRUG|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
219712287|NCT00927472|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
219712288|NCT00927472|DRUG|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
219712289|NCT00055146|DRUG|ONTAK|
219712290|NCT02641041|BIOLOGICAL|BIIB033|single or multiple dose
219712291|NCT02641041|OTHER|Placebo|single or multiple dose
219130228|NCT02594176|DEVICE|Placebo|applicable gel
219130229|NCT00000821|DRUG|Aldesleukin|
219130230|NCT01793272|OTHER|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
219130231|NCT02471391|DRUG|ABT-199|
219130232|NCT02471391|DRUG|Ibrutinib|
219130233|NCT03781804|DRUG|OPN-375|OPN-375, BID
219130234|NCT00925730|DRUG|Pimecrolimus|
219130235|NCT04355130|DIETARY_SUPPLEMENT|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
219130236|NCT03994146|DRUG|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
219130237|NCT03994146|DRUG|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
219130238|NCT01668212|PROCEDURE|Doppler ultrasound|Doppler Ultrasound
219130239|NCT06519370|DRUG|FDA018-ADC|Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
219712292|NCT01373619|DRUG|Ivabradine|ivabradine titrated to 7.5 mg BID
219712293|NCT01991951|DRUG|warfarin|
219712294|NCT05973448|OTHER|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
219712295|NCT05973448|OTHER|Control Lighting Condition|Standard night light plugged into wall socket
219712296|NCT06530329|OTHER|Classical massage|Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.
219712297|NCT06530329|OTHER|Ischemic compression|Ischemic compression was applied to the trigger points in the upper trapezius muscle using an average pressure of 1 kg at a right angle, and after compression, passive stretching was applied to the upper trapezius muscle 3 times in 20-second periods. The application was performed 3 times a week for 2 weeks to evaluate the short-term effect.
219712298|NCT03897621|DRUG|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
219712299|NCT03897621|DRUG|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
219712300|NCT03997136|PROCEDURE|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
219130240|NCT06519370|DRUG|Eribulin|1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
219130241|NCT06519370|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
219130242|NCT06519370|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle
219712301|NCT01091207|DRUG|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
219712302|NCT03882099|DIAGNOSTIC_TEST|Determination of Vitamin D by ELISA|Blood samples
219712303|NCT06468046|BEHAVIORAL|Mama Empoderada [Mom Power]|'Mamá Empoderada' \[Mom Power\] is a theory-based, trauma-informed group intervention to promote mental health and positive parenting among mothers with young children (0-5 years). It has been adapted for migrant mothers, and will conduct a pilot randomized controlled trial (RCT) of the intervention with migrant mothers with young children (MMC). The intervention group (IG) will receive 10 group and 3 individual sessions addressing attachment theory, hands-on parenting skills, linkage to resources (e.g., food, shelter), social support, and self-care and resilience.
219712304|NCT06510296|BEHAVIORAL|Digital Mind Body Intervention mobile application|A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.
219712305|NCT04812015|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
219712306|NCT04812015|DEVICE|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
219712307|NCT04812015|DEVICE|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
219712308|NCT04812015|DEVICE|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
219712309|NCT04812015|DEVICE|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
219712310|NCT04812015|DEVICE|taVNS 0 minutes|Sham taVNS 75 minutes
219712311|NCT05725239|DEVICE|Vagus Nerve Stimulation|All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
219712312|NCT05725239|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
219130243|NCT06519370|DRUG|Vinorelbine|25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
219130244|NCT05694507|OTHER|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
219712313|NCT05831579|RADIATION|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
219712314|NCT05239403|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
219712315|NCT05239403|OTHER|Questionnaire Administration|Complete questionnaires
219712316|NCT05442047|DRUG|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
219712317|NCT05442047|DRUG|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
219712318|NCT05404490|DRUG|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
219712319|NCT05404490|DRUG|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
219712320|NCT06275282|DEVICE|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
219130245|NCT01836458|DRUG|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
219130246|NCT05547659|DRUG|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
219130247|NCT05547659|DRUG|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
219712321|NCT02273375|DRUG|MEDI4736|
219712322|NCT02273375|DRUG|Placebo|
219130248|NCT05547659|DRUG|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
219130249|NCT00339625|OTHER|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
219712323|NCT02169232|DEVICE|Videolaryngoscope|
219712324|NCT02169232|DEVICE|Fiberoptic|
219712325|NCT03678740|OTHER|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
219130250|NCT05347537|OTHER|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
219130251|NCT05347537|OTHER|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
219130252|NCT02189863|DEVICE|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
219130253|NCT02189863|DEVICE|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
219130254|NCT02189863|DEVICE|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
219712326|NCT01858961|DRUG|BI 201335|Once a day
219130255|NCT02189863|DEVICE|Comfilcon A MF|Multifocal contact lenses worn in both eyes
219130256|NCT02189863|DEVICE|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
219130257|NCT01458275|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
219712327|NCT01858961|DRUG|ribavirin|Twice a day
219712328|NCT01858961|DRUG|BI 207127|Twice a day
219712329|NCT01858961|DRUG|Telaprevir|Three times a day
219712330|NCT01858961|DRUG|ribavirin|Twice a day
219712331|NCT01858961|DRUG|Pegylated Interferon|Once a week
219712332|NCT03424148|DEVICE|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
219712333|NCT06057857|OTHER|conventional oral examination|conventional oral examination
219712334|NCT06810973|BEHAVIORAL|SUCCESS-E|"SUCCESS-E is a previously developed intervention based on the evidence-based Antiretroviral Treatment and Access to Services (ARTAS) intervention, modified for those detained within a jail system. It is a manualized six-session program delivered by a case management team, composed of a professional case manager and paraprofessional peer navigators.~In Jail Sessions:~1. Build Trust~2. Assess Strengths~3. Explore life on ART~   Post-Release Sessions:~4. Link with care~5. Enhance self-efficacy for HIV care/PrEP~6. Future transitions"
219130258|NCT01458275|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
219130259|NCT01458275|DRUG|Placebo|Placebo - one actuation per nostril
219130260|NCT01190670|DRUG|Tacrolimus|Oral and Intravenous
219130261|NCT01190670|DRUG|ASP015K|Oral
219130262|NCT01743274|PROCEDURE|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
219130263|NCT03184428|OTHER|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
219130264|NCT01819090|DEVICE|Elysee 150 ventilator|
219130265|NCT01819090|DEVICE|Elysee 150 ventilator with a ventilation switch control|
219130266|NCT03369951|DRUG|Minocycline|Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
219130267|NCT02451293|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|
219712335|NCT06810973|BEHAVIORAL|Enhanced Standard of Care|A list of referral sites for follow-up SUD care will be shared. This information sharing without strength-based, longitudinal case management will be an enhancement to treatment as usual. Also, information about HIV/PrEP follow-up in the community will be placed around the jail, such as affixed to the nurses' medication carts that they push from housing unit to unit, twice a day when residents are due for prescription medications.
219712336|NCT06810973|BEHAVIORAL|Key Informant Interviews|Key informant interviews (KII) will be conducted with jail staff and community stakeholders in the R61 phase to examine perceptions, barriers, and facilitators to SUD and HIV/PrEP service and treatment utilization, as well as document the experiences of SUCCESS-E participants from the pilot phase.
219712337|NCT06811636|PROCEDURE|Lesion sterilization and tissue repair|Lesion sterilization and tissue repair therapy performed with a triple antibiotic mixture.
219130268|NCT02451293|DRUG|Placebo|
219130269|NCT06097104|OTHER|electrolytes - serum blood samples|"CBC - Kidney function tests - liver function tests - ABG - levels of serum sodium, potassium, magnesium, phosphorus, ionized calcium and chloride, with maximum 5 mm blood sampling per day"
219130270|NCT02569229|OTHER|Diagnostics for glucose tolerance with 3 different methods.|"1. A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~2. An oral glucose tolerance test done within the 7 day period of CGMS.~3. Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
219130271|NCT01807819|OTHER|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
219130272|NCT02178436|DRUG|gemcitabine hydrochloride|Given IV
219712338|NCT06811636|PROCEDURE|Conventional pulpectomy|Conventional pulpectomy with calcium hydroxide-iodoform based root canal paste.
219712339|NCT05630066|DRUG|Alogabat|Alogabat will be administered QD with dose depending on cohort and age of the participant.
219712340|NCT06412601|BEHAVIORAL|RPM|remote patient monitoring by clinic staff
219712341|NCT06412601|BEHAVIORAL|app|use of Happy Bob phone app
219712342|NCT06794112|OTHER|Animated Educational Video|Both arms will receive standard care (written instructions), with the experimental arm receiving an additional animated video intervention.
219712343|NCT06794112|OTHER|Written Instructions|Standard written instructions for bowel preparation before colonoscopy
219712344|NCT05714293|RADIATION|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
219130273|NCT02178436|DRUG|Selinexor|Given IV
219130274|NCT02178436|OTHER|Pharmacological Study|Correlative studies
219130275|NCT02178436|OTHER|Laboratory Biomarker Analysis|Correlative studies
219130276|NCT02178436|DRUG|Nab paclitaxel|Given IV
219130277|NCT02926937|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet;~Route of administration: oral"
219712345|NCT06666257|BEHAVIORAL|Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy|The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be discussed with participants during motivational interviewing. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data
219712346|NCT00068185|DRUG|Black cohosh|
219712347|NCT06597240|DEVICE|AMCOR|Participants will collect biometric and quality of life data for 9 or 10 weeks at home, depending on treatment schedule. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.
219130278|NCT02926937|DRUG|Placebo|"Pharmaceutical form: tablet;~Route of administration: oral"
219130279|NCT01317017|DRUG|Actimmune|"* All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~* Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~* Patients will return at one to two weeks for suture removal.~* Clinical assessments done at every visit.~* Patients will also be evaluated at each visit for any adverse events."
219130280|NCT00350961|DRUG|Gemcitabine|
219130281|NCT00350961|DRUG|Oxaliplatin|
219130282|NCT00350961|DRUG|Capecitabine|
219130283|NCT05697965|DRUG|Vancomycin|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty to prevent periprosthetic joint infection
219130284|NCT05697965|PROCEDURE|Total knee or total hip arthroplasty|Primary total knee or total hip arthroplasty without using local vancomycin
219130285|NCT03805958|PROCEDURE|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
219130286|NCT03805958|PROCEDURE|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
219130287|NCT05586217|OTHER|INCENTIVE SPIROMETRY|"* Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
219130288|NCT05586217|OTHER|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
219130289|NCT05518825|DIETARY_SUPPLEMENT|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
219130290|NCT03571594|DRUG|ONO-5788|Investigational drug
219130291|NCT03571594|DRUG|ONO-5788 Placebo|Placebo Comparator
219130292|NCT03571594|DRUG|Octreotide|Active Comparator in Part D
219130293|NCT02165423|BEHAVIORAL|myFAMI iPad application|
219130294|NCT02653274|OTHER|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
219130295|NCT03677375|DEVICE|INVSENSOR00026|Noninvasive pulse oximeter sensor
219130296|NCT03795974|BIOLOGICAL|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
219130297|NCT03795974|BIOLOGICAL|MSC|Mesenchymal cells derived from allogenic umbilical cord
219130298|NCT03795974|PROCEDURE|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
219130299|NCT06254599|DRUG|SY-3505 Capsules|A third-generation ALK tyrosine kinase inhibitor
219130300|NCT06254599|DRUG|Crizotinib Capsules|An oral ALK tyrosine kinase inhibitor
219130301|NCT00901056|DEVICE|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
219130302|NCT00974298|PROCEDURE|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
219130303|NCT02723877|DRUG|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
219130304|NCT02723877|DRUG|Eribulin|non.taxane microtubule dynamics inhibitor
219226646|NCT05302076|DEVICE|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
219226647|NCT01419210|OTHER|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
219130305|NCT00264589|BEHAVIORAL|8 weeks individualized training program|no drugs added
219226648|NCT01419210|OTHER|Educational Presentations|Attend a two-hour presentation each week for four weeks
219712348|NCT02324751|BIOLOGICAL|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
219712349|NCT02324751|BIOLOGICAL|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
219130306|NCT02141581|BIOLOGICAL|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
219226649|NCT01419210|OTHER|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
219226650|NCT01419210|OTHER|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
219712350|NCT02324751|BIOLOGICAL|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
219712351|NCT06857448|PROCEDURE|Split Thickness Skin Graft (STSG)|Partial thickness skin in STSGs are performed by harvesting via dermatome the donor site. Donor sites are typically taken from a flat surface on the thigh, lower back, or gluteal region to allow for a graft of even thickness and the selection of donor site is to be based on clinical standard practice. These grafts are placed on the prepared recipient site.
219712352|NCT06857448|PROCEDURE|Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
219712353|NCT06538220|BEHAVIORAL|Questionnaires and focus group|"To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group."
219226651|NCT01337141|OTHER|Control|7 face-to-face visits.
219226652|NCT01337141|DEVICE|Telecare system|5 telematic visits and 2 face-to-face visits.
219226653|NCT05566249|DEVICE|ArtiSential|Articulating laparoscopic instrument
219712354|NCT06624046|BEHAVIORAL|Sleep stability intervention|The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.
219712355|NCT07103239|BEHAVIORAL|Video Based Visits|Video based visit with Heart Failure team
219712356|NCT07103239|BEHAVIORAL|Remote Self-Care Education|Self Guided Training
219226654|NCT05040828|BEHAVIORAL|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
219130307|NCT02141581|BIOLOGICAL|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
219130308|NCT02141581|BIOLOGICAL|2011-2012 FluMist®|This vaccine is given intranasally
219130309|NCT02134275|BEHAVIORAL|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
219130310|NCT02134275|BEHAVIORAL|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
219226655|NCT05040828|BEHAVIORAL|Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
219226656|NCT05040828|DRUG|No oral drug therapy throughout the pollen period|Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
219226657|NCT00481572|DRUG|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
219226658|NCT00481572|DRUG|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
219226659|NCT00481572|DRUG|Norepinephrine|titrated norepinephrine over a period of 48 hrs
219130311|NCT03031028|OTHER|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
219130312|NCT00126113|BEHAVIORAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
219130313|NCT00126113|BEHAVIORAL|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
219130314|NCT03008343|DEVICE|Irreversible Electroporation|One kind of electric ablation machine from Angiodynamic company (USA)
219130315|NCT03008343|BIOLOGICAL|Natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
219130316|NCT06143761|DRUG|PD-1 inhibitor+carboplatin+albumin-bound paclitaxel|A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
219130317|NCT03356067|PROCEDURE|Gastric endoscopic peroral pyloromyotomy|"G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~1. Mucosal incision at the greater curvature 3-5 cm from the pylorus~2. Submucosal tunnelling~3. Finding pyloric sphincter~4. Myotomy (2-3 cm) of the pyloric muscle~5. Incision closure (endoclips or suture device)"
219130318|NCT03356067|PROCEDURE|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope
219130319|NCT01061905|BEHAVIORAL|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
219130320|NCT01061905|BEHAVIORAL|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
219130321|NCT01061905|BEHAVIORAL|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
219130322|NCT03918135|DRUG|Paracetamol|"1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~* Perfalgan~* Paracerol"
219130323|NCT03918135|DRUG|Ibuprofen|"400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen"
219130324|NCT00524147|PROCEDURE|Pigtail drainage|
219130325|NCT06217731|COMBINATION_PRODUCT|Laser+clonazepam|treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month
219130326|NCT06217731|DEVICE|Laser Sham|INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
219130327|NCT06217731|DEVICE|Laser|Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
219130328|NCT06217731|DRUG|Clonazepam|Rivotril 0.25mg once every 24 hours for a month
219130329|NCT05687942|DEVICE|REBUILD|3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
219130330|NCT00616161|DRUG|Istaroxime|0.5 microgram/kg/min IV for 6 hours
219130331|NCT00616161|DRUG|Istaroxime|1.0 microgram/kg/min IV for 6 hours
219130332|NCT00616161|DRUG|Istaroxime|1.5 microgram/kg/min IV for 6 hours
219130333|NCT00616161|DRUG|Placebo|Placebo
219130334|NCT04415268|BEHAVIORAL|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
219130335|NCT04415268|BEHAVIORAL|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
219130336|NCT04415268|DRUG|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
219130337|NCT05437471|DRUG|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
219130338|NCT01750996|BEHAVIORAL|Strongest Families|Behavioural intervention
219130339|NCT00503074|BEHAVIORAL|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
219130340|NCT00503074|BEHAVIORAL|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
219130341|NCT01085487|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
219130342|NCT01085487|DRUG|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
219130343|NCT01085487|DRUG|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
219130344|NCT03604861|OTHER|Not applicable - no defined intervention|Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
219130345|NCT00561574|DRUG|Esmirtazapine|One tablet daily
219130346|NCT03055845|DRUG|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
219130347|NCT03055845|DRUG|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
219130348|NCT05399979|PROCEDURE|Labor Neuraxial Analgesia|Labor Neuraxial Analgesia
219130349|NCT05260840|OTHER|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
219130350|NCT03971357|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
219130351|NCT03971357|DRUG|Placebo|Placebo eye drops
219712357|NCT07103239|BEHAVIORAL|Remote Patient Monitoring|Participant will use home devices to monitor blood pressure and weight; Participant will then send results to RN educator
219130352|NCT04314661|BIOLOGICAL|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
219130353|NCT04314661|BIOLOGICAL|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
219130354|NCT04314661|BIOLOGICAL|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
219130355|NCT04314661|BIOLOGICAL|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
219130356|NCT05196594|DIAGNOSTIC_TEST|collection of stools for genetic analysis|Intestinal microbiome analysis
219130357|NCT06103422|DIAGNOSTIC_TEST|Whole mouth taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.
219130358|NCT06103422|DIAGNOSTIC_TEST|Localized taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
219130359|NCT04157166|DIAGNOSTIC_TEST|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
219226660|NCT05764057|DRUG|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
219226661|NCT05764057|DRUG|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
218986603|NCT01377883|OTHER|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
219226662|NCT00729794|DRUG|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
219226663|NCT00729794|DRUG|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
219226664|NCT02094534|BIOLOGICAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
219226665|NCT02094534|OTHER|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
219226666|NCT01737021|OTHER|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
219226667|NCT03069391|BEHAVIORAL|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
219712358|NCT05904886|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
219712359|NCT05904886|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
219712360|NCT05904886|DRUG|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
219712361|NCT05904886|OTHER|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
219712362|NCT04700124|BIOLOGICAL|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
219226668|NCT03069391|DEVICE|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
219130360|NCT02064751|DEVICE|CRT with MultiPoint Pacing|
219130361|NCT02064751|PROCEDURE|Hemodynamic measurements for CRT device programming|
219130362|NCT02376933|PROCEDURE|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
219226669|NCT03069391|DEVICE|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
219226670|NCT05973773|DRUG|TAS6417|oral tablets
219226671|NCT03155100|DRUG|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
219226672|NCT03155100|DRUG|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
219226673|NCT03155100|DRUG|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
219712363|NCT04700124|BIOLOGICAL|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
219712364|NCT04700124|PROCEDURE|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
219712365|NCT04700124|DRUG|Gemcitabine|1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
219712366|NCT04700124|DRUG|Cisplatin|70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
219712367|NCT06234462|DRUG|Amantadine|Participants that have been randomized to the study group will be instructed to begin taking amantadine on the day after this study visit. They will self-administer amantadine 100 mg twice daily (morning and noon) for four weeks
219712368|NCT06234462|OTHER|Physical, Occupational, Speech Therapy|Physical Therapy (PT) and Occupational Therapy (OT) train patients on breathing exercises and gradual reconditioning. Patients are referred to speech therapy (SLP) for cognitive remediation and metacognitive strategies.
219712369|NCT06234462|OTHER|Provider Counseling|Clinic providers will provide counseling/education on Long-COVID.
219712370|NCT06234462|OTHER|Medications for symptoms management|Clinic providers may recommend targeted pharmacologic management for symptoms the patient is experience. As an example, if a patient reports a headache the provider may recommend over-the-counter or prescription medications to target this particular symptom.
219712371|NCT06229145|BIOLOGICAL|Pegloticase|IV infusion
219712372|NCT06229145|DRUG|Methotrexate|Oral
219712373|NCT06027957|BIOLOGICAL|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~* Dose: 1-2.10e6 cells/kg of weight~* Route: intravenous infusion~For Chemotherapy Drug:~* Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~* Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~* Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
219130363|NCT02376933|RADIATION|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
219130364|NCT04287751|DEVICE|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
219130365|NCT02646046|BEHAVIORAL|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
219226674|NCT03768466|DRUG|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
219712374|NCT06161519|DRUG|PLX038|PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
218986604|NCT01377883|BEHAVIORAL|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
218986605|NCT02389062|OTHER|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
218986606|NCT04314726|DRUG|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
218986607|NCT04314726|DRUG|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
218986608|NCT03301701|PROCEDURE|Radical prostatectomy|Radical prostatectomy
218986609|NCT03301701|RADIATION|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
218986610|NCT00647361|DEVICE|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
218986611|NCT04239859|BIOLOGICAL|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
219130366|NCT02646046|BEHAVIORAL|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
219130367|NCT03860077|DRUG|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
219130368|NCT03860077|DRUG|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
219130369|NCT01546571|BIOLOGICAL|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
219130370|NCT01546571|BIOLOGICAL|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
219130371|NCT06168123|BEHAVIORAL|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
219130372|NCT02793882|DRUG|18F-Fluorocholine PET/CT|
219226675|NCT04295642|DRUG|CVL-751|Oral tablet
219712375|NCT06253520|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
219712376|NCT06253520|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
219712377|NCT06253520|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
219712378|NCT06253520|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
219712379|NCT06253520|BIOLOGICAL|GRT-C903/GRT-R904|Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
219712380|NCT05136677|BIOLOGICAL|Nivolumab|Specified dose on specified days
219712381|NCT05136677|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219712382|NCT05136677|DRUG|Pemetrexed|Specified dose on specified days
219712383|NCT05136677|DRUG|Cisplatin|Specified dose on specified days
219712384|NCT05136677|DRUG|Carboplatin|Specified dose on specified days
219712385|NCT05162443|DRUG|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
219712386|NCT06332534|DRUG|Upadacitinib|Oral Solution/ Extended-Release Tablets
219712387|NCT05756543|BEHAVIORAL|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
219712388|NCT06104917|DRUG|High Dose Maolactin|Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
219712389|NCT06104917|DRUG|Low Dose Maolactin|Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
218986612|NCT04239859|DRUG|Methotrexate|Oral tablet up to 15mg per week
218986613|NCT04239859|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
218986614|NCT04239859|DRUG|Acitretin|Oral capsule up to 25mg per day
218986615|NCT06126926|BEHAVIORAL|group therapy|32 weeks of group therapy
218986616|NCT06126926|OTHER|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
218986617|NCT02432482|BEHAVIORAL|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
218986618|NCT02432482|BEHAVIORAL|Standard care|Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
218986619|NCT01820065|PROCEDURE|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
218986620|NCT01723657|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
218986621|NCT01723657|OTHER|Autologous peripheral blood stem cell transplantation.|"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
218986622|NCT01723657|OTHER|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
218986623|NCT01723657|DRUG|G-CSF|"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
218986624|NCT01723657|OTHER|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
218986625|NCT01723657|OTHER|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
218986626|NCT00032955|DRUG|Buprenorphine/naloxone|
218986627|NCT01058655|DRUG|Everolimus|
218986628|NCT01058655|DRUG|Tivozanib|
218986629|NCT02984111|DRUG|normal saline|
218986630|NCT02984111|DRUG|erythropoietin|
218986631|NCT01117948|DRUG|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
218986632|NCT01117948|DRUG|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
218986633|NCT00381550|DRUG|fludarabine phosphate|Given IV
218986634|NCT00381550|DRUG|triapine|Given IV
219712390|NCT06104917|DRUG|Maltodextrin|Once daily dose of 2 capsules
219130373|NCT02831153|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
219712391|NCT06537401|BEHAVIORAL|Hypercaloric, High Fat Diet|Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
219712392|NCT04035005|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300 milligrams (mg), IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusion, should be maintained between each infusion.
218986635|NCT00381550|PROCEDURE|laboratory biomarker analysis|Correlative study
218986636|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
218986637|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
218986638|NCT04875169|DRUG|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
218986639|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
218986640|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
219130374|NCT02147990|DRUG|Rociletinib|Rociletinib will be administered to patients orally
219130375|NCT03693222|DRUG|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
219130376|NCT03693222|DRUG|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
219130377|NCT02924454|DRUG|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
219130378|NCT02924454|DRUG|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
219130379|NCT02924454|DRUG|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
219130380|NCT02924454|DRUG|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
219130381|NCT03638219|OTHER|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
219130382|NCT02942147|DEVICE|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
219130383|NCT02942147|PROCEDURE|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
219130384|NCT05991505|OTHER|Physical exercise|Multimodal exercises twice a week
219130385|NCT00124982|DRUG|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
219130386|NCT00124982|DRUG|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
219130387|NCT00124982|DRUG|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
219130388|NCT03034382|DRUG|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
219130389|NCT03034382|DRUG|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
219130390|NCT03034382|DRUG|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
219130391|NCT03034382|DRUG|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
219130392|NCT01237392|DEVICE|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
219130393|NCT00630864|DRUG|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
219130394|NCT04813211|PROCEDURE|mobile artificial cervical vertebrae replacement|"1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
219712393|NCT04035005|DRUG|Placebo|The first dose of placebo will be administered as two IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusions, maintained between each infusion.
219712394|NCT02378246|DIETARY_SUPPLEMENT|Iodine|
219712395|NCT02378246|DIETARY_SUPPLEMENT|Placebo|
219130395|NCT04813211|PROCEDURE|anterior cervical corpectomy and fusion|"1. Position: The patient is in a supine position with the neck hyperextended.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
219130396|NCT02393664|DRUG|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
219130397|NCT02393664|DRUG|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
219130398|NCT02439255|OTHER|Laboratory Biomarker Analysis|Correlative studies
219130399|NCT02439255|DIETARY_SUPPLEMENT|Phytochemical|Given black raspberry (BRB) nectar per oral (PO)
219130400|NCT02439255|OTHER|Placebo|Given PO
219712396|NCT05307666|OTHER|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
219712397|NCT06514157|COMBINATION_PRODUCT|budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)|BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)
218986641|NCT03118648|DIAGNOSTIC_TEST|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
218986642|NCT05617950|OTHER|salicylic acid|Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
218986643|NCT05617950|OTHER|cryotherapy|Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
218986644|NCT00809393|DRUG|tranexamic acid|10 mg/kg
219130401|NCT02439255|OTHER|Screening Questionnaire Administration|Ancillary studies
218986645|NCT00809393|DRUG|tranexamic acid|30 mg/kg
218986646|NCT04472429|DRUG|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
218986647|NCT04472429|DRUG|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
219130402|NCT03687385|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
219130403|NCT03687385|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
219130404|NCT00254475|DRUG|simvastatin|
219130405|NCT00254475|DRUG|valsartan|
219130406|NCT02770664|DRUG|Placebo|Placebo
219130407|NCT02770664|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
219130408|NCT02770664|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
219130409|NCT02770664|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
219130410|NCT01853917|OTHER|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
219130411|NCT06083714|OTHER|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
219130412|NCT06083714|OTHER|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
219130413|NCT00430677|DRUG|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
219130414|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
219130415|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
219130416|NCT00430677|DRUG|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
219130417|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
219226676|NCT03622710|OTHER|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
219226677|NCT03733275|DRUG|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
219226678|NCT03398668|DEVICE|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
219226679|NCT03398668|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
218986648|NCT04472429|DRUG|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
218986649|NCT01172522|DRUG|Fexofenadine|Fexofenadine 1%
218986650|NCT01172522|DRUG|Placebo|Placebo
218986651|NCT01477593|PROCEDURE|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
218986652|NCT01477593|PROCEDURE|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
218986653|NCT01477593|PROCEDURE|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
218986654|NCT04795011|OTHER|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
218986655|NCT04795011|OTHER|exercise|range of motion and walking exercise
218986656|NCT05938491|DIAGNOSTIC_TEST|OCT and OCT-A|OCT and OCT angiography for the macula
218986657|NCT03195764|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
218986658|NCT02035930|DRUG|dexmedetomidine|
218986659|NCT04767594|DRUG|Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
218986660|NCT02846571|BIOLOGICAL|Human Pancreatic Islet Transplantation|Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
218986661|NCT01313312|BIOLOGICAL|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
218986662|NCT03396705|PROCEDURE|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
218986663|NCT03023787|DRUG|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
218986664|NCT03023787|DRUG|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
218986665|NCT00383461|BEHAVIORAL|smoking cessation intervention|
218986666|NCT00383461|OTHER|counseling intervention|
218986667|NCT04088942|OTHER|High-intensity smoking cessation intervention|"1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
218986668|NCT04088942|DRUG|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
218986669|NCT00892047|DRUG|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
218986670|NCT00892047|DRUG|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
218986671|NCT03354078|PROCEDURE|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
218986672|NCT03354078|PROCEDURE|continous sutures|The way of closure of subcutanous tissue is by continous sutures
218986673|NCT02135770|DRUG|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
218986674|NCT01864655|DRUG|saracatinib|oral drug given to experimental group
218986675|NCT01864655|DRUG|Placebo|Placebo given to placebo group
219130418|NCT05058794|OTHER|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
219130419|NCT05058794|OTHER|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
219130420|NCT04535375|DIAGNOSTIC_TEST|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
219130421|NCT05013164|DRUG|Folinic Acid|Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
219130422|NCT01333514|DRUG|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
219130423|NCT01333514|DRUG|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
219130424|NCT02851147|DEVICE|SL-D301|Slit Lamp
219130425|NCT02851147|DEVICE|DC-4|Digital Camera Attachment
219130426|NCT02851147|DEVICE|SL-3G|Slit Lamp
219130427|NCT04733300|BEHAVIORAL|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
219130428|NCT04733300|OTHER|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
219130429|NCT00836810|DRUG|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
219130430|NCT00836810|DRUG|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
219130431|NCT00112112|BIOLOGICAL|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
219130432|NCT00112112|BIOLOGICAL|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
219130433|NCT06054789|DRUG|68Ga-PSMA-33|Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
219130434|NCT02286856|BEHAVIORAL|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
219712398|NCT05889910|PROCEDURE|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
219712399|NCT06003803|BEHAVIORAL|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
219712400|NCT06585891|BIOLOGICAL|VRC-HIVMAB0121-00-AB|The CAP256J3LS bispecific antibody (bsAbs) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of the light chain of CAP256V2LS, linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
219130435|NCT00895024|BEHAVIORAL|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
219130436|NCT00389519|DRUG|ramipril|once a day oral ramipril capsules given for 4 weeks
219130437|NCT00389519|DRUG|placebo|once a day oral placebo capsule for 4 weeks
219712401|NCT05706116|BIOLOGICAL|Trichuris trichiura Egg Inoculum|Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
219712402|NCT06352606|DIAGNOSTIC_TEST|Spinal anesthesia|Oxygen supply will be done via nasal prong (2 L/min) when necessary. The local anesthetic used will be bupivacaine 0.6 mg/kg.
219712403|NCT06352606|DIAGNOSTIC_TEST|General anesthesia|Patients will receive sevoflurane for induction and maintenance in an air/oxygen mixture along. Endotracheal tube will be inserted. No opioids or nitrous oxide was used intraoperatively.
219712404|NCT03935048|DIETARY_SUPPLEMENT|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
219130438|NCT04692948|OTHER|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
219712405|NCT06343792|DRUG|RLS-0071|RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
219712406|NCT06409260|OTHER|Acceleromyography (AMG)|Philips IntelliVue NMT Module
219712407|NCT06409260|OTHER|Electromyography (EMG)|Senzime TetraGraph
219712408|NCT04855851|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
219712409|NCT04855851|PROCEDURE|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
219712410|NCT01081951|DRUG|olaparib|Tablets Oral BID
219712411|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
219712412|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
219712413|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
219712414|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
219712415|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
219130439|NCT05843656|OTHER|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
219130440|NCT00946192|DRUG|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
219226680|NCT04090476|OTHER|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
219226681|NCT03540524|DRUG|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
219712416|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
219712417|NCT05320042|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
219712418|NCT05320042|DEVICE|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
219712419|NCT03456778|DEVICE|Shear Wave Elastography|An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
219712420|NCT05776966|BEHAVIORAL|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
219712421|NCT05776966|OTHER|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
219712422|NCT04553718|OTHER|experimental group|provide mHealth program, which has pregnant women using wearable device and app
219712423|NCT01963234|BEHAVIORAL|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
219712424|NCT06962904|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
219712425|NCT06962904|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
219130441|NCT00946192|DRUG|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
219130442|NCT00946192|DIETARY_SUPPLEMENT|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
219130443|NCT00146978|PROCEDURE|intra-arterial treatment|
219130444|NCT03924245|DRUG|Entinostat|Given by mouth
219226682|NCT03540524|DRUG|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
219226683|NCT03540524|DRUG|GLPG2222|GLPG2222 tablet for oral use, daily.
219712426|NCT06962904|OTHER|Placebo|Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally
219712427|NCT04466293|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
219712428|NCT03054519|DRUG|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
219226684|NCT03540524|DRUG|GLPG2737|GLPG2737 capsules for oral use, daily.
219712429|NCT03054519|DRUG|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
219130445|NCT03924245|DRUG|Olaparib|Given by mouth
219130446|NCT04001504|BIOLOGICAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
219130447|NCT04001504|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
219130448|NCT04362319|DIAGNOSTIC_TEST|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
219130449|NCT02959151|DRUG|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
219226685|NCT00495144|DRUG|TH-302|
219226686|NCT01849107|BIOLOGICAL|Plasma citrulline|
219226687|NCT04288388|BEHAVIORAL|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
219226688|NCT00006350|BIOLOGICAL|daclizumab|
219226689|NCT00006350|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219712430|NCT03806296|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning
219712431|NCT03806296|OTHER|Decrease evening blue light|Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
219712432|NCT03806296|BEHAVIORAL|Sleep scheduling|Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
219712433|NCT03806296|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
219712434|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
219712435|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
219712436|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
219712437|NCT04578756|DRUG|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
219712438|NCT04578756|DRUG|Cariprazine Flexible Dose|Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
219130450|NCT01080131|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
219130451|NCT01080131|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
219130452|NCT01080131|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
219130453|NCT01080131|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
219226690|NCT00006350|DRUG|mycophenolate mofetil|
219226691|NCT00006350|DRUG|tacrolimus|
219226692|NCT00006350|PROCEDURE|peripheral blood stem cell transplantation|
219226693|NCT00293761|DRUG|Travoprost, Investigational|One drop in study eye once daily for 13 days
219226694|NCT00293761|DRUG|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
219130454|NCT03518541|PROCEDURE|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
219130455|NCT03677206|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
219130456|NCT03677206|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
219130457|NCT05139732|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
219226695|NCT04638049|OTHER|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
219226696|NCT04638049|OTHER|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
219226697|NCT00532350|DRUG|QAT370|
219226698|NCT00532350|DRUG|Placebo|
219226699|NCT00532350|DRUG|Tiotropium|
219226700|NCT00706888|DIETARY_SUPPLEMENT|Vitamins B6, B9 and B12 and polyphenols|
219226701|NCT00706888|DIETARY_SUPPLEMENT|placebo|
219226702|NCT03510195|OTHER|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
219226703|NCT05647759|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
219226704|NCT06293066|DIAGNOSTIC_TEST|Ultrasound|Usefulness of transvaginal ultrasound
219226705|NCT04397185|DEVICE|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
219226706|NCT04397185|DEVICE|Wire Localized (WL) partial mastectomy|Standard of care procedure
219226707|NCT05984667|BEHAVIORAL|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
219226708|NCT01179100|DRUG|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
219226709|NCT06435481|DRUG|3D printed chewable formulation of hydrocortisone|Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
219226710|NCT06435481|DRUG|Oral suspension of hydrocortisone|Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
219226711|NCT00669474|PROCEDURE|Suction curettage|Suction curettage
219712439|NCT05823805|OTHER|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
219712440|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
219712441|NCT02890017|OTHER|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
219712442|NCT02890017|OTHER|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
219712443|NCT01070680|DRUG|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
219712444|NCT01070680|DRUG|sodium chlorid 0,9%|continuous intravenous infusion
219712445|NCT03304236|DEVICE|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
219712446|NCT03747003|OTHER|No intervention is provided|No intervention is provided
219712447|NCT02646085|DRUG|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
219712448|NCT00497510|PROCEDURE|Chiropractic manipulation|
218986676|NCT03881475|OTHER|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
218986677|NCT05306977|DEVICE|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by \~50 min rest intervals.
218986678|NCT01783431|DRUG|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
218986679|NCT01783431|PROCEDURE|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
218986680|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
218986681|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
218986682|NCT00487175|DRUG|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
218986683|NCT00076206|DRUG|CCI-779|
218986684|NCT00076206|DRUG|Placebo|
218986685|NCT01672008|DRUG|NOX-100|
218986686|NCT00578383|DEVICE|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
219226712|NCT00669474|DRUG|Treatment with Botox|Treatment with Botox
219226713|NCT02431442|DRUG|RM-493|
219226714|NCT02431442|DRUG|Placebo|
219226715|NCT02575365|DRUG|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
219226716|NCT05109598|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
219226717|NCT01928875|DEVICE|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
219226718|NCT01928875|DEVICE|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
219130458|NCT02572778|PROCEDURE|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
219130459|NCT02914067|OTHER|Neurocognitive testing|
219130460|NCT02914067|DEVICE|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
219712449|NCT05793723|DIAGNOSTIC_TEST|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
219712450|NCT04897243|DRUG|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
219712451|NCT04897243|BEHAVIORAL|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
219712452|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
219712453|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
219712454|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
219712455|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
219712456|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
218986687|NCT05026411|DIAGNOSTIC_TEST|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
218986688|NCT05026411|DIAGNOSTIC_TEST|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
218986689|NCT05026411|DIAGNOSTIC_TEST|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
218986690|NCT03402113|DRUG|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
218986691|NCT03402113|DRUG|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
218986692|NCT04961294|DEVICE|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
218986693|NCT04767763|DIAGNOSTIC_TEST|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
218986694|NCT04846842|DRUG|Gimatecan|Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.
218986695|NCT00154635|DRUG|DCB-AD1|
218986696|NCT05401357|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
218986697|NCT05401357|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
218986698|NCT00547495|DRUG|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
218986699|NCT00547495|DRUG|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
218986700|NCT00547495|DRUG|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
218986701|NCT00547495|DRUG|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
218986702|NCT02898129|OTHER|Questionnaire|
218986703|NCT02898129|DEVICE|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
218986704|NCT05274880|DRUG|CKD-393|PO, QD
218986705|NCT00124228|DRUG|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
218986706|NCT00807170|DRUG|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
218986707|NCT00807170|RADIATION|Whole Brain Radiotherapy (WBRT)|
218986708|NCT00807170|DRUG|ZD6474|200 mg as a once daily oral dose, 21 days
219712457|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
219712458|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
219712459|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
219712460|NCT00036400|DRUG|epoetin alfa|
219712461|NCT01344928|BEHAVIORAL|HIT exercise intervention|
219712462|NCT01344928|BEHAVIORAL|Aerobic exercise intervention|
219712463|NCT04125459|PROCEDURE|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
219712464|NCT06280716|DRUG|Placebo|Subcutaneous injection
219712465|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
219712466|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
219712467|NCT04935606|BEHAVIORAL|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
219712468|NCT04935606|BEHAVIORAL|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
218986709|NCT00807170|DRUG|ZD6474|300 mg as a once daily oral dose, 21 days
218986710|NCT01518348|BIOLOGICAL|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
218986711|NCT02050841|BIOLOGICAL|octaplas|Octaplas S/D Plasma
218986712|NCT04340648|DEVICE|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
218986713|NCT06015464|DRUG|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
218986714|NCT02432495|OTHER|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
218986715|NCT02432495|OTHER|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
218986716|NCT01138774|DIETARY_SUPPLEMENT|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
218986717|NCT04850001|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
218986718|NCT02698046|DIETARY_SUPPLEMENT|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
218986719|NCT02698046|DIETARY_SUPPLEMENT|Placebo starch|200mg of placebo starch three times a day for 4 months
218986720|NCT03918148|DRUG|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
218986721|NCT03918148|DRUG|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
219130461|NCT03759171|OTHER|Guitars for Vets Intervention|This was an active intervention providing veterans with an acoustic guitar, guitar pick, tuning instruments, a music book, practice CDs, and individual and group sessions of music instruction during a 6-week intervention period. Six tailored 1-hour individual guitar instruction sessions were scheduled (1 session per week). In addition to the 6 tailored individual lessons, the intervention provided 3 group sessions. Veterans were given a guitar that they could keep upon completion of the program. The same instructor was assigned to a subject for the duration of the study, and group sessions were supervised by the Education Director of Guitars for Vets.
219130462|NCT01698671|DEVICE|InterGard Synergy Vascular Graft|
219130463|NCT03526445|DRUG|Glucagon|Glucagon (4 ng/kg/min)
219130464|NCT03526445|DRUG|Saline|Placebo
219226719|NCT03392194|BEHAVIORAL|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
219226720|NCT03392194|BEHAVIORAL|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
219226721|NCT03865732|DRUG|Ganaxolone|active drug
219712469|NCT04935606|BEHAVIORAL|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
219712470|NCT04428671|BIOLOGICAL|Cemiplimab|Given IV
219712471|NCT04428671|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219712472|NCT04428671|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219712473|NCT06801704|BEHAVIORAL|Top Set Resistance Training|Participants will receive four warm-up sets at increasingly higher resistance, followed by three sets of eight repetitions per set on six resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
219712474|NCT06801704|BEHAVIORAL|Power Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set on six power resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
219712475|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
219712476|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
219712477|NCT03674138|DIAGNOSTIC_TEST|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
219712478|NCT03674138|OTHER|Clinical management|Clinical management to identify best antidepressant therapy
219712479|NCT06121674|PROCEDURE|Shaeer-II|"SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
219712480|NCT06121674|PROCEDURE|PPI|Penile Prosthesis Implantation will be performed
219712481|NCT00001647|PROCEDURE|White blood cell infusion|
218986722|NCT03078244|OTHER|N/A, observational study|
218986723|NCT01204437|DRUG|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
218986724|NCT01204437|DRUG|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
218986725|NCT01204437|DRUG|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
218986726|NCT00181155|DRUG|Allopurinol|intravenous infusion of allopurinol (300mg)
218986727|NCT00181155|DRUG|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
218986728|NCT01788228|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
218986729|NCT02077478|DEVICE|Remifentanil and propofol administration using TCI|
218986730|NCT02077478|DEVICE|Remifentanil and propofol administration using MCI|
218986731|NCT00002982|BIOLOGICAL|filgrastim|
218986732|NCT00002982|DRUG|carboplatin|
218986733|NCT00002982|DRUG|carmustine|
218986734|NCT00002982|DRUG|cytarabine|
218986735|NCT00002982|DRUG|etoposide|
218986736|NCT00002982|DRUG|ifosfamide|
218986737|NCT00002982|DRUG|melphalan|
218986738|NCT00002982|PROCEDURE|autologous bone marrow transplantation|
218986739|NCT00002982|PROCEDURE|peripheral blood stem cell transplantation|
218986740|NCT00002982|RADIATION|radiation therapy|
218986741|NCT02358681|DRUG|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
218986742|NCT02358681|DRUG|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
219130465|NCT01634919|DEVICE|chronic hepatitis C|acoustic radiation force impulse ultrasonography
219130466|NCT04684342|DIAGNOSTIC_TEST|Routine Laboratory investigations|"1. Complete blood picture~2. Liver function test and prothrombine time \& concentration.~3. Blood urea and creatinine~4. Blood glucose, serum Na and K~5. CRP and ESR~6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
219130467|NCT06141239|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
219130468|NCT06141239|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
219130469|NCT06141239|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
219130470|NCT06664112|DEVICE|AIDA Analysis|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
219130471|NCT06612554|DIETARY_SUPPLEMENT|zinc acetate|Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).
219130472|NCT06612554|OTHER|Placebo|participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
219130473|NCT06613750|DRUG|Sitagliptin and Gliclazide|Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
219130474|NCT06613750|DRUG|Metformin|Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
219130475|NCT06361940|DRUG|Aromatase inhibitors or tamoxifen|Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
219130476|NCT06615271|PROCEDURE|Neurosurgery|Patients who have undergone neurosurgery form more than 3 hours.
219130477|NCT03250325|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
219130478|NCT03250325|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
219130479|NCT06617065|DRUG|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.|"The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio."
219226722|NCT03865732|DRUG|Placebo|inactive
219226723|NCT02345551|BEHAVIORAL|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
219712482|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
219712483|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
219130480|NCT06920290|DEVICE|Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence|"1. Natural Eye Movement To the best of our knowledge, this is the first visual field perimeter software that allows users to move their eyes naturally during the test. Previous visual field tests required that patients maintain a central gaze throughout the test as test points flashed in the periphery of their vision; our test allows patients to look directly at these test points.~2. Simplified Data Capture To the best of our knowledge, this is the first visual field perimeter software that reliably eliminates the need for a hand-held clicker to register test points as the user sees them.~3. Attention Monitoring In previous tests, staring at a central spot could induce sleepiness and inattention; our test employs a software monitor that pauses the test, gives encouragement when appropriate, and allows the patient to regain focus. This allows for far greater accuracy in data reporting.~4. Artificial Intelligence (AI) Our test uses AI to optimize the test parameters."
219130481|NCT04155424|DRUG|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
219130482|NCT06621329|COMBINATION_PRODUCT|Transnasal sphenopalatine ganglion block|Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
219226724|NCT04973306|PROCEDURE|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
219712484|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
219712485|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
219130483|NCT05322980|DIAGNOSTIC_TEST|Microcephaly|Those with a z score of birth head circumference \< -2 (primary microcephaly) are classified into the Microcephaly group.
219130484|NCT04209127|PROCEDURE|Microwave treatment via needle antenna|Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
219130485|NCT04209127|PROCEDURE|Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)|Embolization via percutaneous catheter
219130486|NCT06625762|OTHER|Nantes bariatric surgery cohort|The participants will be individuals living with obesity undergoing bariatric surgery
219130487|NCT06685107|OTHER|Standard of Care Analgesia|Analgesia as determined by the treating physician
219130488|NCT06685107|OTHER|Standard of Care Analgesia + Virtual Reality|Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
219130489|NCT05436054|DRUG|Picoprep|200 patients will be randomised to this arm
219130490|NCT05436054|DRUG|Plenvu|200 patients will be randomised to this arm
219130491|NCT02338622|DRUG|olaparib|olaparib BD
219130492|NCT02338622|DRUG|AZD5363|AZD5363 BD
219130493|NCT04861051|DRUG|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
219130494|NCT06627439|BEHAVIORAL|Comadres Saludables|Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.
219130495|NCT06627439|BEHAVIORAL|Control|Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
219226725|NCT04973306|DRUG|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
219226726|NCT04973306|PROCEDURE|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
219226727|NCT00797056|DRUG|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
219226728|NCT00797056|DRUG|Placebo|Saline SQ daily for 10 days
219226729|NCT00797056|DRUG|Aspirin|Aspirin 75 mg/day for 14 days
219226730|NCT00797056|DRUG|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
219226731|NCT05361356|RADIATION|Spectral CT scanning|Volunteer accept spectral CT scanning
219130496|NCT06627907|OTHER|fluid challenge|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
219130497|NCT06627907|DIAGNOSTIC_TEST|end-expiratory occlusion test|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
219712486|NCT05433688|DEVICE|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
219712487|NCT06176066|PROCEDURE|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
219130498|NCT06692985|OTHER|Clinical and epidemiological data|Collection of clinical and epidemiological data on day 0
219130499|NCT06692985|OTHER|Parasitological samples|Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0
219130500|NCT06692985|OTHER|Assessment of clinical course and response to treatment|Follow-up visit with assessment of clinical course and response to treatment at M6
219130501|NCT06692985|OTHER|DLQI questionnaire|DLQI questionnaire at M6
219130502|NCT06693882|DEVICE|EYETRONIC Nextwave System|"Eyetronic Nextwave is a neurostimulation device that stimulates the optic nerve non-invasively using transcranial alternating current stimulation delivered through goggles in patients presenting with glaucoma.~Eyetronic is approved in Europe for the treatment of glaucoma to possibly delay progression of visual field (VF) loss for at least 12 months. The indication for use in Europe includes all patients suffering from neuropathies of the optic nerve resulting in loss of VF. Two studies conducted in Europe have demonstrated improvement in visual fields following 10-days of optic nerve stimulation treatment with this device. In the current study, the Eyetronic system will be used to treat only those individuals who have visual field loss from glaucoma."
219130503|NCT04159506|BEHAVIORAL|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
219130504|NCT02662192|OTHER|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
219130505|NCT02662192|OTHER|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
219130506|NCT06631066|RADIATION|neoadjuvant chemoradiation|Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
219130507|NCT06629532|OTHER|medical management, surgical interventions, and rehabilitative strategies|By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.
219130508|NCT06696807|DRUG|glucocorticosteroids and/or intravenous immunoglobulin|methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
219130509|NCT06696742|DRUG|Clostridium Butyricum Tablets|Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets
219130510|NCT06696742|DRUG|Cisplatin|Gemcitabine and Cisplatin
219130511|NCT05336552|OTHER|Validated questionnaire : Social Phobia Inventory ( SPIN ) questionnaire|Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. . The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ). The total score will be calculated to determine the severity of the problem .
219712488|NCT04620499|DEVICE|EEG|PEER EEG
219712489|NCT00002791|BIOLOGICAL|filgrastim|
219712490|NCT00002791|DRUG|dacarbazine|
219712491|NCT00002791|DRUG|doxorubicin hydrochloride|
219712492|NCT00002791|DRUG|ifosfamide|
219712493|NCT00002791|DRUG|mesna|
219712494|NCT00002791|PROCEDURE|conventional surgery|
219712495|NCT00002791|RADIATION|brachytherapy|
219712496|NCT00002791|RADIATION|intraoperative radiation therapy|
219712497|NCT00002791|RADIATION|radioisotope therapy|
219712498|NCT05355337|DRUG|Pramipexole|9 weeks of treatment with Pramipexole
219712499|NCT05355337|DRUG|Placebo|9 weeks of treatment with Placebo
219712500|NCT05512390|DRUG|ABBV-319|Intravenous (IV); Infusion
219130512|NCT03315221|OTHER|Test product|HMF with added lipids - Intervention group
219130513|NCT03315221|OTHER|Control product|Commercially available HMF (without lipids) - control group
219130514|NCT06698159|DEVICE|Cryoablation with cryoballoon 28 mm|Pulmonary vein isolation using 28 mm balloon cryoablation
219130515|NCT06698159|DEVICE|Cryoablation with cryoballoon 31 mm|Pulmonary vein isolation using 31 mm balloon cryoablation
219130516|NCT06697769|OTHER|virtual reality|breastfeeding simulation with virtual reality glasses
219130517|NCT06697210|DEVICE|• Dental Floss (Vitis®, Dentaid, Barcelona, Spain).|Dental Floss: A piece of dental floss approximately 40-50 cm in length was taken and placed between the index and middle fingers of each hand, leaving about 2-3 cm free in the middle. The floss was then inserted, embracing the mesial and distal surfaces, and moved up and down three times on each side
219226732|NCT02517385|DRUG|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
219226733|NCT04069806|DIETARY_SUPPLEMENT|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
219226734|NCT05329519|BEHAVIORAL|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
219130518|NCT06697210|DEVICE|• Superfloss (Oral B®, Procter & Gamble, USA)|Superfloss: The stiffened end was used to introduce the thread and the spongy-floss into the interproximal area on both the mesial and distal parts, and a gentle back-and-forth motion was applied to remove bacterial plaque. The spongy-floss was then pulled through to the regular floss section and gently slid under the gumline, followed by an up-and-down motion. These movements were repeated three times on each side.
219130519|NCT06697210|DEVICE|• Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)|Oral Irrigator: The finest tip was selected and placed in the mesiobuccal, distobuccal, mesiolingual, and distolingual interproximal spaces. The irrigator was activated at medium power (2/3), and the process was repeated three times on each side for five seconds.
219130520|NCT06697210|DEVICE|• Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)|Interproximal Brush Group: According to the interproximal space, the appropriate size was selected for each case. The brush was then placed horizontally in the interproximal space mesially and distally, and a back-and-forth movement was performed three times on each side.
219226735|NCT01336842|DRUG|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
219226736|NCT02125292|DRUG|Mesalamine|
219712501|NCT05686694|OTHER|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
219712502|NCT04613453|DRUG|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
219712503|NCT04613453|DRUG|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
219712504|NCT06229730|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
219712505|NCT06229730|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219712506|NCT06229730|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219130521|NCT06697834|PROCEDURE|Histotripsy ultrasound session|The study will be performed with the MINDRAY DP-10 ultrasound device equipped with a linear probe and histotripsy functionality.
219226737|NCT00776139|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
219226738|NCT03068312|DRUG|Ivacaftor|IVA 150 mg tablet.
219226739|NCT03068312|DRUG|Placebo|Placebo matched to IVA tablet.
219226740|NCT06140888|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
219226741|NCT02551224|OTHER|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
219712507|NCT06229730|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
219226742|NCT00986869|PROCEDURE|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
219130522|NCT06697834|OTHER|VAS questionnaire|Pain assessment with the EVA questionnaire
219712508|NCT06229730|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
219712509|NCT03776045|OTHER|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted \~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
219712510|NCT06636448|PROCEDURE|the effect of body mass index during low-flow anesthesia|The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
219712511|NCT06785636|DRUG|Pocenbrodib|Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.
218986743|NCT02358681|DRUG|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
218986744|NCT02358681|DRUG|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
218986745|NCT05193370|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
218986746|NCT05193370|DRUG|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
218986747|NCT06274320|OTHER|Group A: holistic approach|2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
218986748|NCT06274320|OTHER|Group B: Tolak® Standard of use|4-week Tolak® alone treatment (once daily in the evening)
218986749|NCT04792008|BIOLOGICAL|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
218986750|NCT04792008|BIOLOGICAL|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
218986751|NCT00004857|BIOLOGICAL|alemtuzumab|30 mg subQ injection tiw for 6 weeks
218986752|NCT00004857|DRUG|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
218986753|NCT06154187|DRUG|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
218986754|NCT06154187|DRUG|Placebo|Placebo was formulated similar to abaloparatide-SC.
218986755|NCT05964101|DRUG|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
218986756|NCT06391320|OTHER|other|Observational studies do not involve intervention
218986757|NCT05000281|DRUG|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
218986758|NCT04628741|BEHAVIORAL|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
218986759|NCT04628741|BEHAVIORAL|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
218986760|NCT00003257|BIOLOGICAL|Ad5CMV-p53 gene|
218986761|NCT06050148|BIOLOGICAL|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
218986762|NCT06050148|OTHER|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
218986763|NCT01323959|BIOLOGICAL|BoostrixTM Polio|Single dose, intramuscular administration.
218986764|NCT01215565|DRUG|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
218986765|NCT01548287|DRUG|AZD5213|AZD5213 doseA daily
218986766|NCT01548287|DRUG|AZD5213|AZD5213 doseB daily
218986767|NCT01548287|DRUG|AZD5213|AZD5213 doseC daily
218986768|NCT01548287|OTHER|Placebo|Placebo tablet daily
218986769|NCT04067700|PROCEDURE|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
218986770|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
218986771|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
218986772|NCT02993757|BIOLOGICAL|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
218986773|NCT05708170|DRUG|Ferinject|"Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject)."
218986774|NCT05708170|DRUG|Ferrous Sulfate 200 MG|Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
218986775|NCT02500160|DEVICE|Patient specific instrumentation (MRI)|
218986776|NCT02500160|DEVICE|Patient specific instrumentation (CT)|
218986777|NCT02886832|DIETARY_SUPPLEMENT|Prostate Health formulation|
219130523|NCT06697834|OTHER|AOFAS questionnaire|AOFAS questionnaire at visit 1 and visit 4 (75 days after the first visit).
219130524|NCT06697574|BEHAVIORAL|Hypnosis aimed at stress reduction and health of the oral mucosa|"* Induction.~* Hypnotic relaxation and escalating deepening of hypnotic trance.~* Suggestions for healing and wellness of the oral mucosa and for balanced and optimal performance of the immune system, tailoring metaphors and images based on interview with patients.~…the interior of the mouth is soft, healthy pink, intact and whole. It functions optimally as it should - enabling joyful eating and tasting, speaking with ease for any needed expression, any function of the mouth that needs to be used can be done so easily.~The immune system is very wise - it knows perfectly how to function in a balanced and harmonious way. Its wisdom enables it to act if the body needs defense and to standby and rest if it does not.~* Ego strengthening.~* Anchoring - using a predetermined mark selected by the patient.~* Dehypnotisation."
219130525|NCT06697574|BEHAVIORAL|Psychoeducation|A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
219130526|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing|Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
219130527|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing (negative control)|Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
219130528|NCT06918457|DIAGNOSTIC_TEST|AI EEG analysis system|The first stage, physicians independently diagnose pediatric epilepsy with EEG; the second stage, Artificial intelligence EEG analysis system assisted physicians to diagnose pediatric epilepsy
219130529|NCT05859997|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
219130530|NCT04377633|PROCEDURE|Oral handover|Anesthesia handover during surgery will be performed as usual, i.e., oral exchange of pertinent clinical information.
219130531|NCT04377633|PROCEDURE|Checklist handover|Anesthesia handover during surgery will be performed according to a structured handover checklist.
219130532|NCT05927480|BEHAVIORAL|Audio distraction|Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
219130533|NCT01489176|DRUG|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
219130534|NCT02624778|BIOLOGICAL|LY3002813|Administered IV
219130535|NCT02624778|DRUG|Placebo|Administered IV
219130536|NCT06026189|DIAGNOSTIC_TEST|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
219130537|NCT00982254|DRUG|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
219130538|NCT00982254|DRUG|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
219130539|NCT03618095|DEVICE|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
219130540|NCT05300555|DRUG|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
219130541|NCT05300555|DRUG|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
219130542|NCT04587479|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
219130543|NCT05094284|DEVICE|BioFreedom Ultra|this is a registry only
219130544|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
219130545|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
219130546|NCT01286415|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
219130547|NCT01286415|BEHAVIORAL|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
219130548|NCT01537133|DRUG|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
219130549|NCT01537133|DRUG|Placebo|Dry Powder Inhaler: Placebo
219226743|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
219130550|NCT00610753|BEHAVIORAL|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
219130551|NCT00610753|BEHAVIORAL|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
219130552|NCT00606866|DRUG|placebo|Placebo for four weeks
219130553|NCT00606866|DRUG|Sorafenib|Sorafenib 200 mg twice daily
219130554|NCT00606866|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
219130555|NCT02324114|DEVICE|Hsp90|Detect plasma Hsp90α concentration
219130556|NCT04702503|DRUG|WP1220|Topical administration 2x daily for 84 consecutive days
219130557|NCT05169281|OTHER|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
219130558|NCT06550193|DEVICE|Ultrasound-guided procedure using AR/VR technology|Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
219130559|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
219130560|NCT00531479|DRUG|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
219130561|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
219130562|NCT01898676|DRUG|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
219130563|NCT01898676|DRUG|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
219130564|NCT04442984|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
219130565|NCT04442984|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
219130566|NCT04442984|DRUG|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
219226744|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
219712512|NCT06785636|DRUG|Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617|Pocenbrodib alone or in combination
219712513|NCT02455622|DRUG|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
219712514|NCT06216158|DRUG|Iberdomide|Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
219130567|NCT04442984|DRUG|5-FU|d1 5-FU 250 mg/m² every two weeks
219130568|NCT04442984|DRUG|Leucovorin|d1 Leucovorin 400 mg every two weeks
219130569|NCT04442984|DRUG|5-FU|d1 5-FU 400 mg/m² every two weeks
219226745|NCT00606216|PROCEDURE|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
219226746|NCT00608699|DRUG|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
219226747|NCT01070537|DEVICE|Bonfils fiberscope intubation|
219226748|NCT02110407|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
219226749|NCT02110407|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
219226750|NCT04455204|DIAGNOSTIC_TEST|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
219226751|NCT04455204|DIAGNOSTIC_TEST|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
219712515|NCT06216158|DRUG|Isatuximab|Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
219226752|NCT04455204|DIAGNOSTIC_TEST|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
219226753|NCT04455204|DIAGNOSTIC_TEST|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
219226754|NCT04305340|DEVICE|Myant SKIIN Device|"1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes"
219226755|NCT03620955|OTHER|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
219226756|NCT00273052|DRUG|Carvedilol Phosphate modified release formulation|
219226757|NCT00273052|DRUG|metoprolol succinate|
219712516|NCT06216158|DRUG|Dexamethasone|Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
219712517|NCT04161898|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet
219712518|NCT04161898|DRUG|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
219712519|NCT04161898|DRUG|Prednisolone|Prednisolone will be administered as oral tablet
219712520|NCT06496620|DRUG|Biological: Solrikitug low dose|Solrikitug subcutaneous injection
219712521|NCT06496620|DRUG|Biological: Solrikitug high dose|Solrikitug subcutaneous injection
219712522|NCT06496620|OTHER|Placebo|Placebo subcutaneous injection
219712523|NCT05482022|DEVICE|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
219712524|NCT05482022|OTHER|control|no intervention
219712525|NCT04896385|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219712526|NCT04896385|DRUG|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
219130570|NCT04442984|DRUG|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
219130571|NCT03742219|BEHAVIORAL|Lifestyle Modification|"1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
219130572|NCT05642000|BEHAVIORAL|SASEA HUB|SASEA HUB website, an intervention tool to increase COVID-19 testing
219130573|NCT03193346|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
219130574|NCT03193346|DRUG|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
219130575|NCT02008864|DRUG|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
219130576|NCT02008864|DRUG|Placebo|Placebo tablet/ 2 times per day
219226758|NCT05099562|DEVICE|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
219712527|NCT01940588|BEHAVIORAL|Neuropsychoanalytic therapy|Psychotherapy, medication management
219712528|NCT03386227|OTHER|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
219130577|NCT00535977|DIETARY_SUPPLEMENT|Broccoli|400g ITC-enriched broccoli per week for 12 months
219130578|NCT00535977|DIETARY_SUPPLEMENT|Peas|400g frozen garden peas per week for 12 months
219130579|NCT06630403|OTHER|Demographic Data|Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
219226759|NCT01951703|DEVICE|senofilcon A|Control, senfilcon A
219226760|NCT01951703|DEVICE|senofilcon A|Test, senofilcon A
219226761|NCT03086226|DRUG|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
219226762|NCT03086226|DRUG|Itraconazole|This will be the active comparator
219712529|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
219712530|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
219712531|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
219712532|NCT06492252|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
219712533|NCT06492252|BEHAVIORAL|Adaptation|Auditory adaptation in speech
219712534|NCT06492252|BEHAVIORAL|Adaptation|Auditory baseline in speech
219712535|NCT06466551|OTHER|intravenous catheterization|This randomized experimental study was planned to examine the effect of virtual reality goggles and squeezing a stress ball as a distraction method during intravenous catheter application on pain and fear in children aged 6-12 years.
219712536|NCT05034289|BEHAVIORAL|PINPOINT Digital Educational Tool|"The intervention prototype called the PINPOINT Digital Educational Tool will be comprised of four main sections that include information about: 1) precision oncology; 2) clinical trials; 3) Learn More screens; and 4) discussion points and questions for the treating clinician. The intervention prototype will also include a search function, short videos of patient testimonials, patient-provider interaction about immunotherapy and clinical trials, as well as a list of questions/concerns that the patient could print (or save electronically) and take with them to their provider visit. An optional chatbot will be available in the corner of the screen. Users can ask the chatbot questions about any of the material on the website or request additional information. The chatbot will also be able to help patients search for molecularly targeted and immunotherapy clinical trials and offer additional resources (such as websites and online support groups)."
219712537|NCT04960618|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
219712538|NCT04960618|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
219712539|NCT03255694|DRUG|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
219712540|NCT05543941|DEVICE|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
218986778|NCT03948672|DEVICE|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
218986779|NCT02762578|DRUG|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
218986780|NCT02762578|DRUG|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
218986781|NCT00828412|DEVICE|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
218986782|NCT00828412|DRUG|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
218986783|NCT00259610|DRUG|methotrexate|varies
218986784|NCT00259610|DRUG|sulfasalazine|varies
218986785|NCT00259610|DRUG|hydroxychloroquine|varies
218986786|NCT00259610|DRUG|etanercept|varies
218986787|NCT03726944|BEHAVIORAL|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
218986788|NCT03726944|BEHAVIORAL|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
218986789|NCT03726944|OTHER|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
218986790|NCT02028754|DRUG|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
218986791|NCT02028754|DRUG|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
218986792|NCT02028754|DRUG|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
218986793|NCT06220565|DEVICE|"sensor and wearable device Graded Exercise"|"The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management."
218986794|NCT06220565|OTHER|exercise|exercise
218986795|NCT06220565|OTHER|Educational Manual|Educational Manual
218986796|NCT04841538|DRUG|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
218986797|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
218986798|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
218986799|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
219226763|NCT05461755|COMBINATION_PRODUCT|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
219712541|NCT05543941|DEVICE|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
219712542|NCT04457258|PROCEDURE|Computed Tomography|Undergo PET/CT
219712543|NCT04457258|DRUG|Gallium Ga 68 FAPi-46|Given IV
219712544|NCT04457258|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219712545|NCT04457258|RADIATION|18F-FDG|Given IV
219712546|NCT06307665|COMBINATION_PRODUCT|BDA MDI|Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
219712547|NCT06307665|COMBINATION_PRODUCT|AS MDI|Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
219712548|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care and education|Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.
219712549|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care, education and support resources|Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
219712550|NCT01931098|DRUG|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
219712551|NCT01931098|DRUG|pazopanib|600 mg orally, daily until progression, up to one year.
219712552|NCT03246932|BEHAVIORAL|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
219712553|NCT03246932|BEHAVIORAL|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
219226764|NCT05461755|DRUG|Topical Tretinoin|Treatment of striae with topical tretinoin alone
219226765|NCT05461755|DEVICE|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
219226766|NCT01009645|BEHAVIORAL|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
219226767|NCT01009645|BEHAVIORAL|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
219712554|NCT03246932|OTHER|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
219712555|NCT00340093|BEHAVIORAL|Managing Diabetes|
219712556|NCT05091242|DRUG|Clonidine|Clonidine injection 3 mcg/kg once
219712557|NCT05091242|DRUG|Sodium chloride|Sodium chloride 0.9 % injection 0.2 mL/kg once
219712558|NCT04649307|BEHAVIORAL|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
219712559|NCT00559000|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children
219712560|NCT03295851|DRUG|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
219712561|NCT03295851|DRUG|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
219712562|NCT06530550|DRUG|PI3K inhibitor|Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
219712563|NCT02278354|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
219712564|NCT02278354|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post injection
219712565|NCT04194970|DEVICE|With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations|"Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off"
218986800|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
219226768|NCT01009645|BEHAVIORAL|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
219226769|NCT01009645|BEHAVIORAL|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
219226770|NCT05085704|DEVICE|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
219226771|NCT00407706|PROCEDURE|blood test|
219712566|NCT04529174|DIETARY_SUPPLEMENT|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
219130580|NCT06630403|OTHER|Disease History|The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
219130581|NCT06630403|OTHER|Pulmonary Function Test|Pulmonary Function Test will be performed with a spirometer.
219130582|NCT06630403|OTHER|Reaction Time|Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
219130583|NCT06630403|OTHER|Functional Capacity|Functional capacity will be evaluated with 6 minute walk test
219130584|NCT06630403|OTHER|Dyspnea Perception|Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
219130585|NCT06630403|OTHER|Quality of Life|"Quality of life will be assessed with the Quality of Life Scale for Children\&#34;"
219226772|NCT05672485|DIAGNOSTIC_TEST|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
219226773|NCT00141232|DRUG|Atorvastatin and Omega-3 fatty acids|
219712567|NCT04529174|DIETARY_SUPPLEMENT|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
219712568|NCT01901562|DEVICE|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
219712569|NCT05930288|BEHAVIORAL|Walking exercise|The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
219130586|NCT06630403|OTHER|Fear of movement|Fear of movement will be evaluated with Tampa Kinesiophobia Scale
219226774|NCT05533905|DIAGNOSTIC_TEST|Lumbar puncture|A thin needle is inserted between the bones in the spine.
219226775|NCT05533905|DIAGNOSTIC_TEST|MRI|A scan of the head.
219130587|NCT06630403|OTHER|Ability of Motor Imagery|Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
219130588|NCT06630403|OTHER|Cognitive Functions|Cognitive functions will be assessed with Trail Making Test and Stroop Test
219130589|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation according to body weight every other day
219130590|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation dose according to body weight daily
219226776|NCT03918005|OTHER|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
219226777|NCT05494658|DIETARY_SUPPLEMENT|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
219130591|NCT06631612|DRUG|Albendazole.|both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
219226778|NCT05494658|DIETARY_SUPPLEMENT|water|600ml water was consumed by patients 2-4h before suegery.
219130592|NCT00713739|DRUG|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
219226779|NCT03755115|DRUG|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
219226780|NCT01019135|BEHAVIORAL|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
219226781|NCT03192501|DRUG|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
219226782|NCT03690466|DEVICE|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
219226783|NCT03690466|DEVICE|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
219712570|NCT04767750|OTHER|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
219712571|NCT04510415|DRUG|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
219712572|NCT00169832|DRUG|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
219712573|NCT05750706|OTHER|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
219712574|NCT04512287|DRUG|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
219712575|NCT04512287|OTHER|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
219130593|NCT00713739|DRUG|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
219130594|NCT00713739|DRUG|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
219130595|NCT00713739|DRUG|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
219130596|NCT02653079|OTHER|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
219130597|NCT02222415|DIETARY_SUPPLEMENT|Exercise + Protein drink|
219130598|NCT00432653|DRUG|rituximab|
219130599|NCT00887640|DRUG|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
219130600|NCT00887640|DRUG|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
219130601|NCT01711047|PROCEDURE|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
219130602|NCT01711047|PROCEDURE|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
219130603|NCT00208104|BEHAVIORAL|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
219130604|NCT05908799|DRUG|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
219130605|NCT05908799|DRUG|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
219130606|NCT06067178|BEHAVIORAL|Health Dialogue Intervention|"1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
219226784|NCT05154955|DRUG|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
219226785|NCT05154955|DRUG|10XB-101 Vehicle Solution for Injection|This is the placebo control
219226786|NCT00010959|DRUG|Cimicifuga racemosa|
219226787|NCT00010959|DRUG|Trifolium pratense|
219226788|NCT02064283|PROCEDURE|Diffusion MRI|
219712576|NCT04724668|DIETARY_SUPPLEMENT|Melatonin (3hrs before DLMO)|Melatonin 3mg (3hrs before DLMO)
219712577|NCT04724668|DIETARY_SUPPLEMENT|Placebo (3hrs before DLMO)|Placebo capsule (3hrs before DLMO)
219712578|NCT04724668|DEVICE|Morning light version 1|Morning light version
219712579|NCT04724668|DEVICE|Morning light version 2|Morning light version
219712580|NCT06489483|BEHAVIORAL|Action Regulation Movement Task|A joystick is utilized to trace the movement of a visual stimulus on a computer screen. In stop signal task, the subjects are required to move a reference dot to reach to a target dot by controlling a joystick and stop their movements when the target turns red. During the switch task, subjects will be required to switch their joystick movement trajectory when the target location is switched to one of the other target locations.
219130607|NCT06067178|OTHER|Opportunistic Screening|"1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
219130608|NCT00328523|DRUG|MK-0653, ezetimibe|
219130609|NCT00328523|DRUG|Duration of Treatment: 3 months|
219130610|NCT04618458|BEHAVIORAL|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
219130611|NCT00202358|DRUG|atenolol|
219130612|NCT00202358|DRUG|placebo|
219130613|NCT06037187|DIAGNOSTIC_TEST|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
219130614|NCT04653350|OTHER|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
219712581|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
219712582|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
219712583|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
219712584|NCT04235374|BEHAVIORAL|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
219712585|NCT05785845|RADIATION|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
219712586|NCT05785845|DEVICE|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
219712587|NCT04825132|OTHER|Geriatric assessment tools|Multidimensional Prognostic Index (Living status, medications, ADL, IADL, MMSE mental evaluation, ESS pressure sores, chronic disease, nutritional assessment)
219712588|NCT03426865|DRUG|Axumin PET scan|PET scan prior to RPLND
218986801|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
218986802|NCT01766596|PROCEDURE|Optical Coherence Tomography|
218986803|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
218986804|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
218986805|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
218986806|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
218986807|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
218986808|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
218986809|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
218986810|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
218986811|NCT00731627|DRUG|placebo|one tablet a day for up to 21 days
218986812|NCT00731627|DRUG|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
218986813|NCT00268359|BIOLOGICAL|bevacizumab|
218986814|NCT00268359|DRUG|irinotecan hydrochloride|
218986815|NCT03538002|DEVICE|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
218986816|NCT00002711|DRUG|chemotherapy|
218986817|NCT00002711|DRUG|cisplatin|
218986818|NCT00002711|DRUG|paclitaxel|
218986819|NCT00002711|RADIATION|low-LET electron therapy|
218986820|NCT00002711|RADIATION|low-LET photon therapy|
218986821|NCT01796509|OTHER|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
218986822|NCT03113071|DRUG|Decitabine|Decitabine will be administered in combination with Digoxin
218986823|NCT03113071|DRUG|Digoxin|Decitabine will be administered in combination with Digoxin
218986824|NCT04716907|GENETIC|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
218986825|NCT04716907|BIOLOGICAL|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
218986826|NCT04716907|DIAGNOSTIC_TEST|CT Scan|Thymus and lung imaging
218986827|NCT04716907|BIOLOGICAL|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
218986828|NCT05586893|DEVICE|Acupuncture therapy and Electroacupuncture|"We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
218986829|NCT01802801|OTHER|embryo development|intra- and inter-observator analysis
218986830|NCT01611155|DRUG|venlafaxine|Given PO
218986831|NCT01611155|DRUG|placebo|Given PO
218986832|NCT01611155|OTHER|questionnaire administration|Ancillary studies
218986833|NCT01611155|OTHER|quality-of-life assessment|Ancillary studies
218986834|NCT01602120|DRUG|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
218986835|NCT04861909|DEVICE|AT LISA tri 839MP|Non interventional study
218986836|NCT03219138|DEVICE|Acceleromyography|Use of an uncalibrated acceleromyography
218986837|NCT03325127|DRUG|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
218986838|NCT03325127|DRUG|Zytiga|Abiraterone 1000 mg per day orally
218986839|NCT03325127|DRUG|Xtandi|Enzalutamide 160 mg per day orally
218986840|NCT05849701|DEVICE|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
219130615|NCT04653350|OTHER|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
219130616|NCT01606384|DRUG|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
219130617|NCT01606384|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
219130618|NCT00697892|DRUG|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
219130619|NCT00697892|DRUG|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
219130620|NCT00697892|DRUG|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
219130621|NCT02007083|PROCEDURE|Bilateral laminotomy (BL)|
219712589|NCT06179069|DRUG|ZL-1310|Drug: ZL-1310
219712590|NCT06179069|DRUG|Atezolizumab|Drug Atezolizumab
219712591|NCT06179069|DRUG|Carboplatin|Drug Carboplatin
219712592|NCT06141135|OTHER|Preimplantation genetic testing for aneuploidy (PGTA)|24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
219130622|NCT02007083|PROCEDURE|Unilateral laminotomy with crossover (UL)|
219130623|NCT02007083|PROCEDURE|Spinous Process Osteotomy (SPO)|
219130624|NCT02039700|DRUG|Lesinurad 400 mg|
219130625|NCT02039700|DRUG|[14C]lesinurad (100 μg per 10 mL)|
219130626|NCT06080958|DEVICE|NPWT|the NPWT dressing applied to fasciocutaneous flap
219130627|NCT06080958|OTHER|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
219130628|NCT01809379|DRUG|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
219226789|NCT03903978|BEHAVIORAL|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
219712593|NCT06337552|OTHER|FEED-FF|3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.
219712594|NCT06337552|OTHER|Standard of Care (SUC)|Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.
219712595|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally.
219712596|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally
219712597|NCT03733535|DRUG|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
219130629|NCT04792099|PROCEDURE|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
219130630|NCT04792099|PROCEDURE|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
219130631|NCT02055482|DRUG|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
219130632|NCT02055482|BIOLOGICAL|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
219130633|NCT06368180|DEVICE|Robotic assisted gait training|is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
219712598|NCT03733535|DRUG|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
219712599|NCT04907266|OTHER|Structured Questionnaire|A structured proforma to assess outcome
219712600|NCT05917340|DRUG|High dose rifampicin (25mg/kg)|Given for 2 months
219712601|NCT05917340|DRUG|Moxifloxacin 400mg|Given for 2 months
219712602|NCT05917340|DRUG|Aspirin 150 mg|Given for 2 months
219712603|NCT05917340|DRUG|Isoniazid|Given for 6 months
219712604|NCT05917340|DRUG|Pyrazinamide|Given for 6 months
219712605|NCT05917340|DRUG|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
219712606|NCT05917340|DRUG|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
219130634|NCT06368180|DEVICE|Body weight supported treadmill training|The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
219130635|NCT00782041|DRUG|Oxaliplatin|85 mg/m²
219712607|NCT05917340|DRUG|HRZE|2 months
219712608|NCT05917340|DRUG|HRE|7-10 months as per TB program guidelines
219712609|NCT03274817|DRUG|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
219712610|NCT03274817|DRUG|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
219712611|NCT03274817|DRUG|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
219712612|NCT05107115|DRUG|rilzabrutinib|Tablet, oral use
219130636|NCT00782041|DRUG|5-FluoroUracil|2,000 mg/m²
219130637|NCT00782041|DRUG|Folinic acid|20 mg/m²
219130638|NCT06268028|BEHAVIORAL|Training|Discharge training
219130639|NCT03392662|DEVICE|Hemopatch|Patients received product at the discretion of their surgeon.
219130640|NCT02501629|DRUG|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
219130641|NCT02501629|DRUG|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
219130642|NCT02501629|DRUG|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
219130643|NCT02501629|DRUG|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
219130644|NCT02004613|DRUG|Dexmedetomidine|Dexmedetomidine
219130645|NCT02004613|DRUG|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
219130646|NCT03007459|OTHER|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
219130647|NCT03007459|OTHER|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
219130648|NCT00868231|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
219130649|NCT00868231|DRUG|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
219130650|NCT00868231|DRUG|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
219130651|NCT00004209|DRUG|cisplatin|
219130652|NCT00004209|DRUG|mitomycin C|
219130653|NCT00004209|DRUG|vinblastine sulfate|
219130654|NCT02359838|OTHER|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
219226790|NCT03903978|BEHAVIORAL|Healthy lifestyle|"1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
219712613|NCT05107115|DRUG|placebo|Tablet, oral use
219130655|NCT02359838|OTHER|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
219712614|NCT02497066|OTHER|Neuropathic pain cream|Subjects will apply the cream to the painful area.
219712615|NCT02497066|OTHER|Nociceptive pain cream|Subjects will apply the cream to the painful area.
219712616|NCT02497066|OTHER|Mixed pain cream|Subjects will apply the cream to the painful area.
219712617|NCT03179384|DRUG|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
219712618|NCT05145972|OTHER|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
219712619|NCT00747604|BIOLOGICAL|mecasermin [rDNA origin] injection|As prescribed by the physician.
219130656|NCT00971009|BEHAVIORAL|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
219712620|NCT03588338|DRUG|Perfalgan|For postoperative pain
219712621|NCT03588338|DRUG|Control|For postoperative nausea and vomiting
219712622|NCT04049461|DIAGNOSTIC_TEST|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
219130657|NCT00971009|BEHAVIORAL|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
219130658|NCT03451643|PROCEDURE|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
219130659|NCT05245487|DIAGNOSTIC_TEST|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
219130660|NCT00931229|DRUG|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
219712623|NCT04049461|RADIATION|Abdominal CT scan|Observe whether HOAI occurs.
219712624|NCT02440867|DEVICE|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
219130661|NCT02851030|BEHAVIORAL|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
219130662|NCT04585347|DRUG|ALZ-801 170 mg Fasting|
219130663|NCT04585347|DRUG|ALZ-801 205 mg Fasting|
219712625|NCT02440867|DEVICE|Sham TBS|Sham stimulation
219712626|NCT05262101|DRUG|TQB2858 injection|TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
219712627|NCT00888836|PROCEDURE|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
219712628|NCT00888836|PROCEDURE|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
219712629|NCT00888836|BEHAVIORAL|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
219712630|NCT06572033|BEHAVIORAL|Simulation|Observational study with simulations.
219712631|NCT03833310|DIAGNOSTIC_TEST|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
219712632|NCT05324189|DIAGNOSTIC_TEST|Referable versus Non Referable Diabetic Retinopathy diagnostic test|Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy
219712633|NCT06357767|BEHAVIORAL|Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence|A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
219712634|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
219712635|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
219712636|NCT04609696|DRUG|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
219712637|NCT03301259|OTHER|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
219712638|NCT05167539|PROCEDURE|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
219712639|NCT00088153|DRUG|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
219712640|NCT00088153|OTHER|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
219712641|NCT00107497|RADIATION|Radiation therapy|
219130664|NCT04585347|DRUG|ALZ-801 205 mg After Food|
219130665|NCT04585347|DRUG|ALZ-801 342 mg Fasting|
219130666|NCT00814853|DEVICE|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
219130667|NCT05709457|BEHAVIORAL|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
219130668|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
219130669|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
219712642|NCT04589767|BEHAVIORAL|CAPD scale|Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
219712643|NCT00208975|DRUG|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|"Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
219712644|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
219712645|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
219712646|NCT00073931|BIOLOGICAL|filgrastim|5 µg/kg/day subcutaneously
219130670|NCT05496049|DEVICE|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
219130671|NCT05496049|DEVICE|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
219130672|NCT04355637|DRUG|Inhaled budesonide|adding budesonide to standard of care for pneumonia in COVID19 positive patients
219130673|NCT00353067|DRUG|veliflapon (DG-031)|
219130674|NCT00174720|DRUG|Ciclesonide (XRP1526)|
219130675|NCT03315403|DIAGNOSTIC_TEST|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
219130676|NCT04163666|BEHAVIORAL|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
219130677|NCT04163666|BEHAVIORAL|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
219130678|NCT02870543|DRUG|Phytolacca decandra|Treatment of bruxism
219130679|NCT02870543|DRUG|Melissa officinalis|Treatment of bruxism
219130680|NCT02870543|DRUG|Phyt.decandra + Melissa offic.|Treatment of bruxism
219130681|NCT03152799|PROCEDURE|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
219130682|NCT03152799|OTHER|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
219130683|NCT00333541|BEHAVIORAL|Using internet/E-mail for follow-up|follow-up via email link to survey
219712647|NCT00073931|BIOLOGICAL|sargramostim|250µg/m2/d subcutaneously
219130684|NCT01759979|PROCEDURE|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
219130685|NCT01759979|PROCEDURE|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
219712648|NCT00073931|PROCEDURE|autologous bone marrow transplantation|autologous stem cells given via central catheter
219712649|NCT00073931|PROCEDURE|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
219130686|NCT02551354|DEVICE|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
219130687|NCT02793297|OTHER|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
219130688|NCT02793297|OTHER|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
219130689|NCT02793297|OTHER|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
219130690|NCT02135809|DEVICE|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
219226791|NCT01229384|DEVICE|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
219226792|NCT01229384|DEVICE|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
219226793|NCT01244997|PROCEDURE|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
219712650|NCT00073931|RADIATION|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with \~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
219712651|NCT00261040|PROCEDURE|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
219130691|NCT06106659|DEVICE|Mini Midline|"The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector."
219130692|NCT03997006|DRUG|IV Aminophylline|IV Aminophylline (100 mg/8h)
219130693|NCT03997006|DRUG|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
219130694|NCT04691544|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Delivered by enema
219130695|NCT02611648|OTHER|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
219130696|NCT02611648|OTHER|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
219130697|NCT00192192|BIOLOGICAL|CAIV-T|
219130698|NCT04185519|DEVICE|AI (model)|The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose. Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl. Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated. There will be three periods, namely ry 3 months.
219130699|NCT04841486|OTHER|Data collection|evaluation of women's stress
219130700|NCT04488653|DIETARY_SUPPLEMENT|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
219130701|NCT04488653|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219130702|NCT05095623|OTHER|Natural History Observation|This is a natural history study.
219130703|NCT05963776|DEVICE|spirometry|pulmonary function tests using spirometry
219130704|NCT03613103|DEVICE|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
219130705|NCT03613103|DEVICE|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
219130706|NCT02416635|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
219130707|NCT02416635|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
219130708|NCT04439513|DEVICE|Hemostasis|Compression device to achieve hemostasis.
219130709|NCT03748732|PROCEDURE|sclerectomy|scleral flap
219130710|NCT02856711|BEHAVIORAL|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
219130711|NCT02329041|DEVICE|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
219130712|NCT02329041|DEVICE|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
219130713|NCT02950194|PROCEDURE|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
219130714|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (EnzySystem HemA version A - whole blood)|Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
219130715|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)|Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
219130716|NCT06357572|DIAGNOSTIC_TEST|Additional coagulation tests|"Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay"
219130717|NCT04518566|BEHAVIORAL|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
219130718|NCT00106431|DRUG|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
219130719|NCT05324631|DRUG|SHR0302|SHR0302, oral, once daily
219130720|NCT05324631|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
219130721|NCT04395755|BEHAVIORAL|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
219130722|NCT04395755|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
219130723|NCT00030381|DRUG|4'-iodo-4'-deoxydoxorubicin|Given IV
219226794|NCT03971552|PROCEDURE|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
219712652|NCT00261040|PROCEDURE|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
219712653|NCT05791331|OTHER|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
219712654|NCT05791331|OTHER|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
219712655|NCT01349387|DRUG|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
219712656|NCT04065620|DIAGNOSTIC_TEST|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration \<24 hours, those without one good reading per hour and those with \<70% of satisfactory readings will be excluded
219712657|NCT05289882|BEHAVIORAL|PASS Program Condition:|Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
219712658|NCT05251870|DRUG|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
219712659|NCT03354377|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
219712660|NCT03354377|BEHAVIORAL|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
219712661|NCT03354377|BEHAVIORAL|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
219712662|NCT04680039|DEVICE|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
219712663|NCT05967091|DEVICE|Targeted Lung Denervation|Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System
219130724|NCT00030381|OTHER|pharmacological study|Correlative studies
219130725|NCT00523731|PROCEDURE|Angiogenic Cell Precursors (ACPs) or Vescell TM|
219130726|NCT00233740|DEVICE|OPTEASE Vena Cava Filter|
219712664|NCT04612400|OTHER|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
219130727|NCT06053788|DIAGNOSTIC_TEST|PocDoc|Point of care digital lipid test
219130728|NCT03946813|OTHER|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
219130729|NCT05759585|BEHAVIORAL|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
219130730|NCT00623506|DRUG|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
219226795|NCT02142595|DRUG|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
219226796|NCT02142595|DRUG|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
219712665|NCT04435626|DRUG|Finerenone (BAY94-8862)|"For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets."
219226797|NCT02052167|DEVICE|methotrexate prefilled pen|
219226798|NCT01255800|DRUG|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
219712666|NCT04435626|OTHER|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
219130731|NCT00623506|DRUG|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
219130732|NCT06491095|DIETARY_SUPPLEMENT|0 g Flax|175 g yogurt with no flax product
219130733|NCT06491095|DIETARY_SUPPLEMENT|40 g whole ground flaxseed|175 g yogurt with 40 g whole ground flaxseed
219130734|NCT06491095|DIETARY_SUPPLEMENT|40 g roasted then ground whole flaxseed|175 g yogurt with 40 g roasted then ground whole flaxseed
219712667|NCT00427596|DRUG|Solabegron|
219130735|NCT06491095|DIETARY_SUPPLEMENT|40 g of whole intact flaxseeds|175 g yogurt with 40 g of whole intact flaxseeds
219712668|NCT00643253|BEHAVIORAL|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
219712669|NCT05486728|DRUG|SHJ002/Vehicle|Topical ophthalmic
219712670|NCT05129085|DRUG|Dexamethasone 4mg|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).
219712671|NCT05129085|PROCEDURE|epidural platelet rich plasma injection|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
219130736|NCT06491095|DIETARY_SUPPLEMENT|28 g flax hulls|175 g yogurt with 28 g flax hulls
219130737|NCT03675139|DRUG|Medroxyprogesterone Acetate|At a dosage of 10mg/day
219130738|NCT03675139|DRUG|Dydrogesterone 10 MG|At a dosage of 20 mg/day
219226799|NCT02596737|BEHAVIORAL|wittyFit concept|
219712672|NCT01023321|DRUG|GLPG0555|single ascending doses, oral solution
219712673|NCT01023321|DRUG|placebo|single dose, oral solution
219712674|NCT01023321|DRUG|GLPG0555|multiple dose, oral solution, 7 or 14 days
219712675|NCT01023321|DRUG|placebo|multiple dose, oral solution, 7 or 14 days
219712676|NCT06310135|DEVICE|Filtered Eyewear|Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.
219712677|NCT06310135|DEVICE|Unfiltered Eyewear|For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.
219712678|NCT06310135|OTHER|No Filters|Dim lights with no filters.
219712679|NCT01976208|DRUG|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.
219712680|NCT01976208|DRUG|placebo|
219130739|NCT04661670|DEVICE|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
219130740|NCT04579510|BIOLOGICAL|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
219130741|NCT04579510|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
219130742|NCT01756417|DRUG|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
219226800|NCT05124210|BIOLOGICAL|Sotrovimab|Sotrovimab will be administered.
219226801|NCT01817491|OTHER|American Heart Association Diet|
219226802|NCT01817491|OTHER|Reduced Fat Vegan Diet|
219130743|NCT01756417|DRUG|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
219130744|NCT05122312|DRUG|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
219130745|NCT05122312|DRUG|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
219130746|NCT06480409|OTHER|VR Mindfulness and Stress Reduction Program|"Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds.~Physiological Monitoring: Throughout the sessions, participants' physiological responses will be monitored using Polar H-10 sensors to measure heart rate variability (HRV), providing data on autonomic nervous system activity.~Psychological Assessment: Participants will complete the Perceived Stress Scale (PSS-10) before and after the intervention to evaluate changes in stress levels.~Cybersickness Monitoring: The occurrence of any adverse effects, such as cybersickness, will be monitored and recorded."
219130747|NCT04364880|DEVICE|TBS|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
219130748|NCT04364880|DEVICE|Sham|The sham-TBS coil produced a similar sound without a magnetic pulse.
219130749|NCT04311619|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
219130750|NCT04311619|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
219130751|NCT02321540|DRUG|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
219712681|NCT03739931|BIOLOGICAL|mRNA-2752|Solution for intratumoral injection
219712682|NCT03739931|BIOLOGICAL|Durvalumab|Solution for infusion after dilution
219712683|NCT04426656|BEHAVIORAL|Phone application|"The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders."
219712684|NCT05664789|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N
219712685|NCT05664789|DRUG|Placebo|matched placebo
219712686|NCT04754074|BEHAVIORAL|Education|Weekly education related to behavior change
219712687|NCT04754074|BEHAVIORAL|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
219712688|NCT04754074|BEHAVIORAL|Weekly behavior modification challenges|Weekly challenges to address behavior change
219712689|NCT01410942|OTHER|Placebo|Capsules by mouth twice daily.
219712690|NCT01410942|DRUG|Methylphenidate|Starting dose 5 mg by mouth twice daily.
219712691|NCT01410942|BEHAVIORAL|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
219226803|NCT05512299|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
219226804|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po
219226805|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
219226806|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
219712692|NCT01410942|OTHER|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
219712693|NCT01410942|OTHER|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
219130752|NCT00530335|DRUG|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
219130753|NCT04577183|DEVICE|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
219130754|NCT04477798|DIAGNOSTIC_TEST|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
219130755|NCT03374111|DRUG|Colla corii asini|15 g Colla corii asini granule daily for 8 weeks
219130756|NCT03374111|DRUG|a Simulate Agent of Colla corii asini granule|15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
219226807|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
219130757|NCT00816335|PROCEDURE|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
219130758|NCT00816335|DRUG|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
219130759|NCT00816335|PROCEDURE|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
219130760|NCT00816335|DRUG|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
219130761|NCT00816335|PROCEDURE|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
219130762|NCT00816335|PROCEDURE|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
219130763|NCT01205282|DRUG|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
219130764|NCT01205282|DRUG|Placebo|There will be a 2 week period of placebo run-in.
219226808|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
219226809|NCT02134782|BEHAVIORAL|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
219226810|NCT02134782|OTHER|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
219226811|NCT04037072|DRUG|Mitomycin C|Topical application of Mytomycin C (MMC)
219226812|NCT04037072|OTHER|Control|Topical application of Normal Saline
219226813|NCT02222506|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
219226814|NCT06176014|PROCEDURE|implant placement|5 implant were placed in intraforaminal area using surgical guide
219130765|NCT04440969|BEHAVIORAL|Multi-domain intervention|"Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app."
219130766|NCT04857450|DRUG|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by Etomidate 0.05 mg/kg IV and repeated when needed.
219226815|NCT00546156|DRUG|Doxorubicin|Standard chemotherapy regimen
219226816|NCT00546156|DRUG|Cyclophosphamide|Standard chemotherapy regimen
219226817|NCT00546156|DRUG|Paclitaxel|Standard chemotherapy regimen
219712694|NCT01410942|OTHER|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
219712695|NCT02605239|DRUG|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
219712696|NCT02156661|DRUG|Oxytocin|
219712697|NCT03952741|BEHAVIORAL|Physical Therapy|
219712698|NCT06504862|DRUG|Zongertinib|Zongertinib
219712699|NCT06504862|DRUG|Dabigatran-etexilate|Dabigatran-etexilate
219712700|NCT06504862|DRUG|Rosuvastatin|Rosuvastatin
219712701|NCT06504862|DRUG|Metformin hydrochloride|Metformin hydrochloride
219130767|NCT04857450|DRUG|Ketamine Hydrochloride|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
219226818|NCT00546156|DRUG|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
219226819|NCT05193175|BEHAVIORAL|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
219226820|NCT05837689|DRUG|Blinatumomab|IV
219712702|NCT06504862|DRUG|Furosemide|Furosemide
219712703|NCT05462873|BIOLOGICAL|QEQ278|Intravenous dosing of QEQ278
219130768|NCT03972423|OTHER|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
219130769|NCT02763020|OTHER|Fruit extracts high in polyphenols|
219130770|NCT02763020|OTHER|placebo|
219130771|NCT04651179|OTHER|observation|not applicable, observational study
219130772|NCT00710164|DRUG|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
219226821|NCT03717207|OTHER|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
219226822|NCT03717207|DIAGNOSTIC_TEST|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
219130773|NCT00710164|DRUG|Placebo|14 days of Placebo
219226823|NCT03579875|DRUG|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
219226824|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
219712704|NCT05120271|BIOLOGICAL|CAR-GPC3 T Cells|Five dose levels each with LD chemotherapy
219712705|NCT03757923|DRUG|TAB METFORMIN|INSULIN SENSITIZING AGENTS
219712706|NCT03757923|DRUG|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
219712707|NCT05991453|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
219712708|NCT05991453|OTHER|Anesthetic technique inhaled agent|Must administer inhaled agent.
219712709|NCT06526429|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
219712710|NCT02393625|DRUG|Ceritinib (LDK378)|
219712711|NCT02393625|DRUG|Nivolumab|
219130774|NCT01259687|DEVICE|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
219130775|NCT05619887|DRUG|Fentanyl|Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
219226825|NCT03579875|DRUG|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
219712712|NCT03830606|DRUG|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
219712713|NCT02517489|DRUG|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
219712714|NCT02517489|DRUG|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
219712715|NCT04451785|BIOLOGICAL|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
219712716|NCT04451785|DIAGNOSTIC_TEST|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
219712717|NCT03837704|OTHER|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
219712718|NCT03837704|OTHER|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
219712719|NCT03837704|OTHER|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
219712720|NCT06416644|DEVICE|Supera Vasculomimetic Stent|Femoral-popliteal revascularization with Supera Stent
219712721|NCT04208529|BIOLOGICAL|CTX001|CTX001 infusion.
219712722|NCT04132778|DEVICE|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
219712723|NCT05033054|DRUG|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
219712724|NCT05128383|DRUG|Dupilumab|Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
219130776|NCT05619887|OTHER|Saline|An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
219130777|NCT02492594|OTHER|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent"
219712725|NCT03838354|DRUG|Chidamide|In the 2.5 mg group, chidamide will be administered orally at an initial dose of 2.5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients in 2.5 mg group were allowed to increase dose to 5 mg if platelet counts were less than 30×10\^9 cells per L or less than two-times increase from baseline platelet count at week 12 according to investigators' advice and the patients' decision.
219130778|NCT03871998|OTHER|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
219226826|NCT03579875|DRUG|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
219226827|NCT03579875|DEVICE|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
219712726|NCT03838354|DRUG|Chidamide|In the 5 mg group, chidamide will be administered orally at an initial dose of 5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients who did not respond to chidamide at 5 mg for 12 weeks would stop the allocated treatment and were continuously followed up.
219712727|NCT05275426|DRUG|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
219130779|NCT04686643|DRUG|AGSAVI|S-amlodipine, Valsartan, Indapamide
219130780|NCT04686643|DRUG|AGLS|S-amlodipine, Valsartan
219130781|NCT04683497|OTHER|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
219130782|NCT00932919|BEHAVIORAL|Thought field therapy|5 sessions with Thought field therapy
219130783|NCT00932919|BEHAVIORAL|Cognitive therapy|12 sessions of Cognitive therapy
219130784|NCT00932919|BEHAVIORAL|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
219130785|NCT03614858|BIOLOGICAL|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).
219130786|NCT01168401|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
219130787|NCT01168401|BIOLOGICAL|Saline|Two doses 28 days apart
219130788|NCT02999282|DEVICE|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
219130789|NCT02999282|DEVICE|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
219130790|NCT01260662|DRUG|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
219712728|NCT05275426|DRUG|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
219712729|NCT04379050|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
219130791|NCT01260662|DRUG|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
219130792|NCT01260662|DRUG|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
219130793|NCT04219293|DEVICE|Microneedling w/ and w/o PRP|i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
219130794|NCT03049111|BIOLOGICAL|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
219130795|NCT06235879|OTHER|Control Group (Interscalene brachial plexus block)|"Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride)."
219130796|NCT06235879|PROCEDURE|Pericapsular nerve group (PENG) block|"Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected."
219130797|NCT02518906|BEHAVIORAL|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
219130798|NCT02518906|BEHAVIORAL|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
219130799|NCT03218956|DIETARY_SUPPLEMENT|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
219130800|NCT04461223|DIAGNOSTIC_TEST|contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)|CMR T1 mapping, T2mapping, T2\* mapping, LGE, ECV
219712730|NCT02275533|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219712731|NCT02275533|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219712732|NCT02275533|OTHER|Clinical Observation|Undergo standard of care clinical observation
219712733|NCT02275533|PROCEDURE|Echocardiography Test|Undergo ECHO
219712734|NCT02275533|BIOLOGICAL|Nivolumab|Given IV
219712735|NCT05550350|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
219712736|NCT05550350|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
219130801|NCT02335021|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
219130802|NCT02335021|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
219130803|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
219130804|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
219130805|NCT06549894|PROCEDURE|Performing endoscopic examinations|Performing endoscopic examinations in the conventional framework of patient follow-up. No patient data is collected. The physician performing the act is the subject of the study.
219130806|NCT03463811|DIAGNOSTIC_TEST|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
219130807|NCT04107337|OTHER|Vocal work session with straw exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
219130808|NCT04107337|OTHER|Vocal work session with open mouth exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
219130809|NCT00000772|DRUG|Ribavirin|
219130810|NCT00000772|DRUG|Didanosine|
219130811|NCT02980679|DRUG|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
219130812|NCT02980679|DRUG|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
219226828|NCT03579875|DRUG|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)
219712737|NCT04528134|DEVICE|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
219130813|NCT03352388|DIETARY_SUPPLEMENT|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
219130814|NCT00483912|DEVICE|Molecular adsorbent recirculating system|
219130815|NCT01288638|OTHER|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
219712738|NCT04528134|DEVICE|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
219130816|NCT01288638|OTHER|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
219130817|NCT03832660|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
219130818|NCT03832660|DRUG|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
219130819|NCT00672256|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
219226829|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
219226830|NCT03579875|DRUG|Rituximab|200 mg/m2 IV once on day -1
219226831|NCT03579875|DRUG|Busulfan|Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
219226832|NCT03579875|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
219226833|NCT03579875|DRUG|Melphalan|If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
219712739|NCT04650581|DRUG|Ipatasertib|400 mg PO QD days 1-21 every 28 days
219712740|NCT04650581|DRUG|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
219712741|NCT04650581|OTHER|Placebo|PO QD days 1-21 every 28 days
219712742|NCT01771107|DRUG|Brentuximab Vedotin|Given IV
219712743|NCT01771107|DRUG|Dacarbazine|Given IV
219712744|NCT01771107|DRUG|Doxorubicin Hydrochloride|Given IV
219226834|NCT03579875|DRUG|Rituximab|Rituximab will be given once on treatment plans 1-3 on day -1.
219712745|NCT01771107|OTHER|Pharmacological Study|Correlative studies
219712746|NCT01771107|DRUG|Vinblastine|Given IV
219712747|NCT00700765|DRUG|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
219712748|NCT06543173|PROCEDURE|Prophylactic Catheter-based VT Ablation|Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
219130820|NCT06480422|OTHER|Segmental breathing technique|To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.
219130821|NCT06480422|OTHER|autogenic drainage|"To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes."
219130822|NCT03151421|BEHAVIORAL|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
219130823|NCT01721564|DRUG|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
219130824|NCT02909751|DRUG|Epirubicin 90 mg/m2 iv|Max. 3 months
219130825|NCT02909751|DRUG|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
219130826|NCT02909751|DRUG|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
219130827|NCT02909751|DRUG|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
219130828|NCT02909751|DRUG|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
219130829|NCT02909751|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily|Max. 6 months
219712749|NCT04780321|BIOLOGICAL|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
219712750|NCT04780321|DRUG|Placebo|30 patients receipt placebo intravenous infusion on day 1
219712751|NCT04357795|DRUG|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
219712752|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
219712753|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
219712754|NCT05644925|DEVICE|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
219712755|NCT05644925|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
219712756|NCT05248386|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
219712757|NCT05248386|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
219712758|NCT02571985|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
219130830|NCT03016897|OTHER|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
219712759|NCT02312843|BEHAVIORAL|Exercise/Aerobic|
219712760|NCT02312843|BEHAVIORAL|Exercise/Stretching|
219712761|NCT05348317|BEHAVIORAL|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
219712762|NCT00077818|DRUG|Enoxaparin sodium|
219712763|NCT05100667|OTHER|Hypoxia|altitude (3800m)
219712764|NCT05100667|OTHER|Normoxia|sea level
219712765|NCT00287820|DRUG|Olanzapine|olanzapine 5-40 mg/day
219130831|NCT03661190|OTHER|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
219712766|NCT00287820|DRUG|olanzapine|olanzapine 5-40 ,mg/day
219712767|NCT00287820|DRUG|risperidone|risperidone 1-12 mg/day
219712768|NCT04909138|DEVICE|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
219712769|NCT04909138|DEVICE|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
219712770|NCT06000670|PROCEDURE|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
219712771|NCT06551675|DIETARY_SUPPLEMENT|Silkworm pupa tablets|Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
219712772|NCT06551675|DIETARY_SUPPLEMENT|Control product|The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
219130832|NCT03661190|OTHER|Card Pairs|A basic picture-matching task.
219130833|NCT03106025|DEVICE|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
219130834|NCT03106025|OTHER|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
219130835|NCT02126397|PROCEDURE|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
219130836|NCT02126397|PROCEDURE|polyps resection with bipolar electrode|
219130837|NCT03297749|OTHER|Observational study (no intervention)|No interventions
219130838|NCT04298840|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
219130839|NCT04298840|DIETARY_SUPPLEMENT|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
219130840|NCT06196528|DEVICE|WristArt implant|implantation of the WristArt implant
219130841|NCT06211140|DEVICE|tACS|tACS in 4 weeks, once per weekday for 40 minutes each, 20 sessions. The treatment group will receive transcranial alternating current stimulation at a gamma frequency (77.5Hz) with a peak amplitude of 15mA.
219130842|NCT06211140|OTHER|Control|Without the tACS stimulation in this group.
219130843|NCT02260739|OTHER|Blood samples|
219130844|NCT00395434|DRUG|Combretastatin A4 Phosphate (CA4P)|
219130845|NCT00395434|DRUG|Bevacizumab (Avastin)|
219130846|NCT06343155|OTHER|Therapeutic Group|Pelvic tilt exercise:Participant will be supine position on the floor with your knees bent. Flatten your back against the floor by tightening your abdominal muscles and bending your pelvis up slightly. Lumbar flexion(single knee to chest): Participants will be supine position with knees bent and feet flat on the floor. The right knee will be brought closer to your chest and held with the hands. Lumbar flexion(double knee to chest) : Participants will be supine position with both legs flat on the floor. One hip and knee will be bent first to the chest, then the other to the chest. The knees will be grasped with the hands. Straight Leg Raise: Participants will be supine position with hips and legs comfortably on the floor. By contracting the quadriceps muscle the straight leg will be fixed. Inhaling slowly, the straight leg will be lifted six inches off the floor. Spine twist: Participants will turn their hips and knees to one side as much as possible in a supine position.
219130847|NCT06343155|OTHER|Rocabado's Group|Rest position of tongue: Making a 'clucking' sound positions the tongue against the hard palate in the correct resting position for appropriate nasal and diaphragmatic breathing. Once the activity is practiced, the patient is to attempt to maintain appropriate tongue / jaw resting position throughout normal activity. Shoulder retraction:Sitting up nice and tall, squeeze your shoulder blades back and together. Stabilized head posture:Place your hands behind your hand with fingers interlocked.Gently bring head forward with gentle overpressure from hands.Axial extension of the neck: Sitting up nice and bring your chin backward as if trying to make a double chin. Rotation control of temporomandibular joint: Place tongue at the roof of your mouth just behind your front teeth and place fist underneath chin. Gently open mouth into fist and hold for a few seconds. Rhythmic stabilization:Patients apply resistance to opening, closing, and lateral deviation with the jaw in a resting position.
219130848|NCT03841019|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
219130849|NCT03841019|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
219130850|NCT05044130|DIETARY_SUPPLEMENT|High-fat mixed-meal tolerance test (HF-MMTT)|The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
219130851|NCT02988596|OTHER|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
219130852|NCT02988596|OTHER|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
219130853|NCT00272610|DRUG|0.4% Retinol Cream|
219130854|NCT04483882|DEVICE|Tactile Labels for Drug identity and dose frequency|The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
219130855|NCT01268891|DRUG|Placebo|Once daily; tablet; orally; 18 weeks
219130856|NCT01268891|DRUG|Azilect®|1 mg daily; tablet; orally; 18 weeks
219226835|NCT03298087|PROCEDURE|radical prostatectomy|surgical removal of the prostate
219226836|NCT03298087|RADIATION|stereotactic body radiotherapy|Highly targeted radiation
219130857|NCT02553382|DIETARY_SUPPLEMENT|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
219226837|NCT03298087|DRUG|Leuprolide|Lowers serum testosterone
219226838|NCT03298087|DRUG|apalutamide|antiandrogen
219226839|NCT03298087|DRUG|abiraterone|Inhibits androgen synthesis
219130858|NCT02553382|DIETARY_SUPPLEMENT|Positive Control|Oat bran blend and wheat bran capsules
219130859|NCT03172403|DIAGNOSTIC_TEST|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
219130860|NCT03172403|DIAGNOSTIC_TEST|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
219130861|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
219226840|NCT03089905|DRUG|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
219226841|NCT03089905|DRUG|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
219226842|NCT03089905|DRUG|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
219130862|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
219130863|NCT03172403|DIAGNOSTIC_TEST|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
219130864|NCT05526508|DEVICE|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
219130865|NCT02634008|DRUG|Paritaprevir/ritonavir/ombitasvir|
219130866|NCT02634008|DRUG|Dasabuvir|
219130867|NCT02634008|DRUG|Ribavirin|
219226843|NCT05107869|OTHER|High Saturated Fat|High saturated fat meal
219226844|NCT03935152|DRUG|Dydrogesterone|dydrogesterone capsule
219712773|NCT06172361|DRUG|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
219130868|NCT02634008|DRUG|Glecaprevir/pibrentasvir|
219130869|NCT03615001|DEVICE|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
219226845|NCT03935152|DRUG|placebo|placebo capsule
219226846|NCT04874493|OTHER|Electronic Health Record Review|Review of medical records
219226847|NCT04874493|OTHER|Questionnaire Administration|Complete questionnaire
219226848|NCT06130605|OTHER|Data collection|Data collection
219130870|NCT00403208|PROCEDURE|Analgesia based sedation in ICU patients|
219130871|NCT06185400|DRUG|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
219130872|NCT06185400|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
219130873|NCT06185400|DRUG|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
219130874|NCT00533039|DRUG|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
219130875|NCT00533039|DRUG|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
219130876|NCT04660084|DIAGNOSTIC_TEST|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
219130877|NCT02931149|DRUG|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
219226849|NCT05864625|DRUG|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
219226850|NCT05864625|DRUG|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
219226851|NCT06489353|BEHAVIORAL|Video-watching|Participants will watch age-appropriate and engaging videos.
219226852|NCT06489353|BEHAVIORAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure
219226853|NCT02054000|DRUG|Tirofiban|Intracoronary administering of Tirofiban
219226854|NCT02054000|OTHER|Placebo|Intracoronary serum physiologic
219226855|NCT04228952|COMBINATION_PRODUCT|Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK|American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
219226856|NCT05552157|DRUG|Remternetug (SC)|Administered subcutaneously every 12 weeks
219226857|NCT05552157|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
219226858|NCT04419519|DRUG|Venetoclax monotherapy|Venetoclax monotherapy
219226859|NCT04419519|DRUG|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
219226860|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
219226861|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
219226862|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
219226863|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
219226864|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
219226865|NCT05925036|OTHER|Placebo|Controls
219226866|NCT01979393|DRUG|Cabozantinib|
219712774|NCT06172361|DRUG|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
219130878|NCT05189587|DEVICE|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
219130879|NCT03129035|PROCEDURE|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
219130880|NCT03129035|PROCEDURE|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
219130881|NCT01720043|DRUG|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
219130882|NCT06045637|BEHAVIORAL|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
219130883|NCT00762658|DRUG|AN2728 Ointment, 5%|
219130884|NCT00762658|DRUG|AN2728 Ointment, 2%|
219130885|NCT00762658|DRUG|AN2728 Ointment, 0.5%|
219130886|NCT00762658|DRUG|AN2728 Ointment Vehicle|
219130887|NCT00762658|DRUG|Betnesol®-V Creme, 0.1%|
219712775|NCT04324112|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
219712776|NCT04324112|DRUG|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
219712777|NCT04657991|DRUG|Encorafenib|Encorafenib
219712778|NCT04657991|DRUG|Binimetinib|Binimetinib
219712779|NCT04657991|DRUG|Pembrolizumab|Pembrolizumab
219712780|NCT02627807|RADIATION|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
219712781|NCT02627807|RADIATION|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
219712782|NCT02627807|DRUG|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
219712783|NCT02627807|DRUG|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
219712784|NCT02627807|DRUG|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
219712785|NCT02627807|DRUG|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
219712786|NCT04765631|OTHER|Patients with Type 2 diabetes|No intervention
219712787|NCT04765631|OTHER|Placebo|Placebo comparator
219712788|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
219130888|NCT00762658|DRUG|Protopic® Ointment, 0.1 %|
219712789|NCT04913298|DEVICE|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
219130889|NCT02022462|BEHAVIORAL|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
219712790|NCT02595892|DRUG|Berzosertib|Given IV
219712791|NCT02595892|DRUG|Gemcitabine|Given IV
219130890|NCT02090309|DRUG|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
219130891|NCT02090309|DRUG|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
219712792|NCT02595892|DRUG|Gemcitabine Hydrochloride|Given IV
219712793|NCT04869280|OTHER|No Intervention|This is a non-interventional study.
219712794|NCT01139879|DEVICE|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
219130892|NCT02212717|PROCEDURE|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
219712795|NCT03859297|BEHAVIORAL|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
219712796|NCT03859297|BEHAVIORAL|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
219712797|NCT04321512|OTHER|There is no intervention given to the subjects|Not appicable
219712798|NCT03867084|BIOLOGICAL|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
219130893|NCT02212717|PROCEDURE|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
219130894|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
219130895|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
219130896|NCT04660370|DRUG|CKD-348|QD, PO
219130897|NCT04660370|DRUG|CKD-828, D097, D337|QD, PO
219130898|NCT05283369|DEVICE|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
219130899|NCT05283369|OTHER|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
219130900|NCT00182520|DRUG|Topiramate|25 mg - 400 mg/day x 12 weeks
219130901|NCT00182520|DRUG|placebo|25 - 400 mg/day x 12 weeks
219130902|NCT05015517|PROCEDURE|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
219130903|NCT05015517|PROCEDURE|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
219130904|NCT03988387|BEHAVIORAL|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
219226867|NCT01979393|DRUG|Placebo|
219226868|NCT03416959|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
219712799|NCT03867084|DRUG|Placebo|IV infusion of 0.9% normal saline.
219712800|NCT02864992|DRUG|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
219712801|NCT06297668|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.
219712802|NCT06297668|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
219130905|NCT03988387|BEHAVIORAL|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
219130906|NCT03988387|DRUG|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
219130907|NCT04285125|OTHER|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
219130908|NCT01054430|DRUG|avanafil|200 mg avanafil tablets QD
219130909|NCT01551615|DRUG|Metformin 1000 mg|2 x 500 mg oral tablets
219130910|NCT01551615|DRUG|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
219130911|NCT04642261|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
219130912|NCT04642261|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
219130913|NCT04832646|PROCEDURE|atrial fibrillation ablation|persistent atrial fibrillation ablation with both AF and sinus rhythm map available
219130914|NCT06214468|COMBINATION_PRODUCT|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
219712803|NCT06297668|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
219712804|NCT06297668|DEVICE|AeroChamber Plus Flow-Vu spacer|Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.
219712805|NCT03191058|DEVICE|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
219130915|NCT06214468|DRUG|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
219130916|NCT00364442|DRUG|fluticasone propionate/salmeterol|investigational drug
219130917|NCT00123747|PROCEDURE|Positron Emission Tomography (PET) scan Imaging|
219130918|NCT02700867|DEVICE|NIO|Intraosseous access device NIO (Defibtech)
219130919|NCT02661035|DRUG|Allopurinol|300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
219130920|NCT02661035|DRUG|Fludarabine|30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
219130921|NCT02661035|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
219130922|NCT02661035|DRUG|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
219130923|NCT02661035|RADIATION|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
219130924|NCT02661035|DRUG|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
219226869|NCT04745156|DEVICE|RNS System Implantation|Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
219226870|NCT06800404|DRUG|Autologous HB-adMSCs|Autologous HB-adMSCs
219130925|NCT02661035|DRUG|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated."
219130926|NCT02661035|BIOLOGICAL|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
219130927|NCT02661035|BIOLOGICAL|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
219130928|NCT04658849|DRUG|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
219130929|NCT04658849|DRUG|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
219130930|NCT01176799|DRUG|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
219712806|NCT03191058|DEVICE|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
219712807|NCT04967222|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .
219130931|NCT01176799|DRUG|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
219130932|NCT00413868|PROCEDURE|LASIK|
219130933|NCT00413868|PROCEDURE|PRK|
219130934|NCT00413868|BEHAVIORAL|Small target contrast sensitivity and disability glare|
219130935|NCT01360190|DRUG|fluoxetine|fluoxetine 20 mg. daily
219130936|NCT03557385|DRUG|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
219130937|NCT03557385|DRUG|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
219130938|NCT03557385|DEVICE|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
219130939|NCT03557385|DEVICE|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
219130940|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
219130941|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
219130942|NCT00000871|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219130943|NCT00000871|BIOLOGICAL|rgp120/HIV-1 SF-2|
219130944|NCT01769781|DRUG|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
219130945|NCT01769781|DRUG|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
219130946|NCT04122807|PROCEDURE|Cardiac catheter ablation|Cryoablation
219130947|NCT04290585|OTHER|Questionnaire Administration|Ancillary studies
219130948|NCT04290585|BEHAVIORAL|Telephone-Based Intervention|Receive text message reminders
219130949|NCT03688828|DRUG|Saccharomyces boulardii|500mg bid
219130950|NCT03688828|DRUG|Esomeprazole|20mg bid
219130951|NCT03688828|DRUG|Amoxicillin|1.0g bid
219130952|NCT03688828|DRUG|Clarithromycin|0.5g bid
219130953|NCT03688828|DRUG|Bismuth potassium citrate|0.22g bid
219130954|NCT05836935|RADIATION|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
219130955|NCT05836935|RADIATION|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
219130956|NCT00580437|PROCEDURE|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
219130957|NCT05560828|OTHER|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
219130958|NCT01145456|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219130959|NCT01145456|DRUG|gemcitabine hydrochloride|Given IV
219130960|NCT01145456|OTHER|pharmacological study|Correlative studies
219130961|NCT01145456|OTHER|laboratory biomarker analysis|Correlative studies
219130962|NCT00088673|DRUG|3APS|
219130963|NCT02702024|PROCEDURE|Double uterine incision technique in uterus preserving surgery for placenta percreta|
219130964|NCT05817331|OTHER|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
219130965|NCT05817331|OTHER|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
219712808|NCT04967222|BEHAVIORAL|Control Downregulate Condition|Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
219712809|NCT05776069|DRUG|VGA039|Single doses of VGA039
219130966|NCT05817331|OTHER|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
219130967|NCT00857480|DRUG|NRL972|Single intravenous administration of 2 mg NRL972
219712810|NCT05776069|OTHER|Placebo|Single doses of Placebo
219712811|NCT05776069|DRUG|VGA039|Multiple doses of VGA039
219712812|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
219712813|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
219130968|NCT00857480|DRUG|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
219130969|NCT00857480|DRUG|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
219130970|NCT00002937|DRUG|paclitaxel|
219130971|NCT00002937|DRUG|valspodar|
219130972|NCT03761654|DIAGNOSTIC_TEST|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
219130973|NCT00938340|DIETARY_SUPPLEMENT|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
219130974|NCT00938340|DIETARY_SUPPLEMENT|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
219130975|NCT00938340|DIETARY_SUPPLEMENT|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
219130976|NCT00938340|DIETARY_SUPPLEMENT|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
219130977|NCT05795829|DEVICE|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
219130978|NCT02594215|DRUG|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
219712814|NCT05139602|BIOLOGICAL|Lutikizumab|Subcutaneous Injection
219712815|NCT05139602|DRUG|Placebo|Subcutaneous Injection
219712816|NCT05018221|DRUG|Vitamin K1|Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
219712817|NCT05018221|DRUG|Magnesium citrate|Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
219712818|NCT05018221|DRUG|Sodium Thiosulfate|Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
219712819|NCT05018221|DEVICE|High Flux Dialyser|Hemodialysis using a high flux dialyser.
219712820|NCT05018221|DEVICE|Medium Cut-off Dialyser|Hemodialysis using a medium cut-off dialyser.
219712821|NCT05018221|DRUG|Placebo injection (normal saline)|Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
219712822|NCT05018221|DRUG|Placebo capsule (Vitamin K1)|Placebo to be administered 3 times per week following the subject's hemodialysis session.
219130979|NCT01600911|OTHER|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
219130980|NCT01923857|DRUG|Androxal 25 mg|
219130981|NCT02534896|DRUG|Treatment I|Sunpharma1505 and Placebo
219130982|NCT02534896|DRUG|Treatment II|Sunpharma1505 and Placebo
219130983|NCT02534896|DRUG|Treatment III|Reference1505 and Placebo
219130984|NCT02796092|DEVICE|Fibered platinum coils|
219130985|NCT02796092|DEVICE|Vascular plugs|
219130986|NCT03594331|DRUG|Low-dose PvP001|Low-dose PvP001
219130987|NCT03594331|DRUG|Medium-dose PvP001|Medium-dose PvP001
219712823|NCT05018221|DRUG|Placebo tablet (Magnesium citrate)|Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
219712824|NCT05467215|DRUG|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
219712825|NCT01962415|DRUG|Hydroxyurea|Oral administration
219712826|NCT01962415|DRUG|Alemtuzumab|Intravenous (IV) administration.
219712827|NCT01962415|DRUG|Fludarabine|IV administration
219712828|NCT01962415|DRUG|Melphalan|IV administration
219712829|NCT01962415|DRUG|Thiotepa|IV administration
219712830|NCT05382091|DRUG|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
219130988|NCT03594331|DRUG|High-dose PvP001|High-dose PvP001
219130989|NCT03594331|DRUG|Placebo|100 mL liquid with no drug
219130990|NCT04288492|BEHAVIORAL|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
219130991|NCT01141933|OTHER|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
219130992|NCT01141933|OTHER|Usual care|This group receive the usual treatment only.
219130993|NCT02135458|OTHER|Telemonitoring|
219130994|NCT02135458|OTHER|Conventional care|
219130995|NCT05779514|DRUG|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
219130996|NCT04346524|OTHER|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
219130997|NCT01365403|DRUG|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
219130998|NCT01365403|DRUG|carbamazepine|multiple oral doses, Days 1-24 of study period 2
219130999|NCT00268606|BEHAVIORAL|cognitive-behavioral therapy|
219131000|NCT00469300|DRUG|Iontophoretic delivery of acyclovir|
219131001|NCT01180621|BIOLOGICAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
219131002|NCT02702921|DEVICE|Surgeon's 'standard of care' stapler|
219131003|NCT02702921|DEVICE|Ethicon Powered Vascular Stapler|
219131004|NCT03751878|BEHAVIORAL|Evaluation of reporting inconsistencies|"1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports."
219131005|NCT03751878|BEHAVIORAL|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
219131006|NCT05961670|DEVICE|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
219131007|NCT01107626|DRUG|Paclitaxel|Given IV
219131008|NCT01107626|DRUG|Carboplatin|Given IV
219131009|NCT01107626|BIOLOGICAL|Bevacizumab|Given IV
219131010|NCT01107626|DRUG|Pemetrexed Disodium Heptahydrate|Given IV
219131011|NCT03992495|OTHER|Exercise|All participants will be exposed to aerobic/strengthening exercises
219131012|NCT04238000|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
219131013|NCT04381494|DEVICE|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
219131014|NCT04310579|DRUG|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
219131015|NCT04310579|DRUG|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
219131016|NCT00102414|DRUG|Gemcitabine|
219131017|NCT05975294|DRUG|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
219131018|NCT05975294|DRUG|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
219131019|NCT05190913|OTHER|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
219131020|NCT05190913|OTHER|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
219131021|NCT04884399|DRUG|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
219131022|NCT04884399|DRUG|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
219131023|NCT04353037|DRUG|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
219131024|NCT04353037|DRUG|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
219226871|NCT03833440|DRUG|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
219131025|NCT05830604|PROCEDURE|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
219131026|NCT04147416|DRUG|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
219131027|NCT04147416|DRUG|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
219131028|NCT00241540|DRUG|Esomeprazole|
219131029|NCT02540135|OTHER|fluorescein|fluorescein and conventional neuro-navigation
219131030|NCT02540135|OTHER|intraoperative MRI|conventional neuro-navigation and iMRI
219712831|NCT05763797|BEHAVIORAL|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
219712832|NCT05763797|BEHAVIORAL|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
219131031|NCT01949909|BIOLOGICAL|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
219131032|NCT01949909|BIOLOGICAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
219131033|NCT01949909|BIOLOGICAL|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
219131034|NCT01949909|BIOLOGICAL|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
219131035|NCT01949909|BIOLOGICAL|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
219131036|NCT01949909|BIOLOGICAL|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
219131037|NCT01949909|BIOLOGICAL|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
219131038|NCT03710564|BIOLOGICAL|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
219131039|NCT03710564|BIOLOGICAL|Aflibercept|2 mg/0.05mL solution for intravitreal injection
219131040|NCT00000676|DRUG|Clotrimazole|
219131041|NCT00000676|DRUG|Fluconazole|
219131042|NCT06392932|DEVICE|QDOT Micro ablation catheter|QDOT Micro ablation catheter
219131043|NCT06392932|DEVICE|ST SF ablation catheter|ST SF ablation catheter
219131044|NCT00225719|DRUG|rHDL|
219131045|NCT03837769|DEVICE|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
219131046|NCT00533234|DEVICE|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
219131047|NCT05593822|PROCEDURE|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
219131048|NCT04667065|OTHER|Physical activity|Physical activity with the remotely guidance of physical activity teachers
219131049|NCT05082649|OTHER|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
219131050|NCT05082649|OTHER|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
219226872|NCT03833440|DRUG|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
219226873|NCT03833440|DRUG|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
219226874|NCT03833440|DRUG|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
219712833|NCT04140656|OTHER|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
219712834|NCT04140656|OTHER|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
219712835|NCT05884203|DEVICE|Caregiver socket|A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
219131051|NCT01133132|BEHAVIORAL|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
219131052|NCT01133132|OTHER|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
219131053|NCT02375581|DRUG|Icotinib|125mg, Po, TID during RT
219131054|NCT02375581|RADIATION|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
219712836|NCT05884203|DEVICE|Prosthetist socket|A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
219712838|NCT05621733|OTHER|ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
219712839|NCT06391918|BIOLOGICAL|GEN2 + Valganciclovir|Gene therapy vector product
219712840|NCT04235686|DRUG|Mydayis Extended-Release Capsule|Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
219712841|NCT04235686|DRUG|Placebo|Matching placebo
219712842|NCT05252702|DEVICE|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
219712843|NCT05322005|PROCEDURE|partial meniscectomy|Arthroscopic procedure
219712844|NCT05322005|DEVICE|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
219712845|NCT06271681|DRUG|21-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment
219712846|NCT05706051|OTHER|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
219712847|NCT05504967|DRUG|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
219712848|NCT05504967|DRUG|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
219712849|NCT05504967|DRUG|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
219131055|NCT04009226|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
219131056|NCT01320436|DIETARY_SUPPLEMENT|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
219131057|NCT01320436|DRUG|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
219131058|NCT03241654|PROCEDURE|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
219131059|NCT04572672|OTHER|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
219131060|NCT00134511|DRUG|Torcetrapib/atorvastatin|
219131061|NCT06347952|PROCEDURE|Use of Acoustic and color imaging doppler during surgery for breast cancer|The intervention (post pilot study) is to systematically record the effect of routine use of acoustic as well as color imaging doppler during mammoplasty for breast cancer (for both the therapeutic and symmetrising breast reduction).
219131062|NCT03138473|DIAGNOSTIC_TEST|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
219131063|NCT03138473|DIAGNOSTIC_TEST|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
219131064|NCT02715063|BEHAVIORAL|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219131065|NCT02715063|BEHAVIORAL|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219226875|NCT03833440|DRUG|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
219712850|NCT05052957|BIOLOGICAL|P140K-MGMT|Ex Vivo Cultured P140K MGMT CD34+ Cells. The transduced cells are a biological product and production is detailed in the Cellular Therapy Lab standard operating procedures and IND 14099
219226876|NCT03833440|DRUG|Savolitinib|"600 mg QD~1 cycle = 28 days"
219226877|NCT04726449|OTHER|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
219712851|NCT05052957|DRUG|O6-benzylguanine|O6BG is a low molecular-weight purine analog which selectively and irreversibly inactivates the DNA-repair enzyme, O6- alkylguanine DNA-alkyltransferase.
219712852|NCT05052957|RADIATION|Photon Based Radiotherapy|Standard of care, photon-based radiotherapy (60Gy in 30 fractions) will be performed in both arms without concomitant TMZ between to 6 weeks post-operatively. Radiotherapy will be performed at UH-SCC.
219712853|NCT05052957|DRUG|temozolomide|Temozolomide is not directly active but undergoes rapid non-enzymatic conversion at physiologic pHto the reactive compoundMTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylationof DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine
219712854|NCT05052957|DRUG|Filgrastim|Filgrastim is a 175 amino acid protein manufactured by recombinant DNA technology. Endogenous filgrastim is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells, which regulates the production of neutrophils within the bone marrow.
219712855|NCT05052957|DRUG|carmustine|BCNU is a lipid soluble agent which has alkylating properties, plus an isocyanate metabolite which interferes with DNA and RNA synthesis.
219712856|NCT05111015|DEVICE|Concomitant Open Heart Surgical Ablation Procedures|AtriCure's Concomitant Open Heart Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
219712857|NCT05111015|DEVICE|Hybrid (Convergent) Ablation Procedures|AtriCure's Hybrid (Convergent) Ablation Devices used for the treatment of Atrial Fibrillation.
219712858|NCT05111015|DEVICE|AtriCure Hybrid Totally Thoracoscopic Ablation Procedures|AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
219712859|NCT05111015|DEVICE|AtriCure LAA Exclusion Procedures|AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the treatment of Atrial Fibrillation.
219712860|NCT05441917|DEVICE|Sanae method with LED|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
219712861|NCT05441917|DEVICE|Sanae method with Radiofrecuency|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
219131066|NCT02715063|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
219131067|NCT02715063|OTHER|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
219131068|NCT03923101|DIAGNOSTIC_TEST|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
219131069|NCT03006341|DRUG|Dabigatran etexilate|observed upto 12 months
219131070|NCT03006341|DRUG|Warfarin|Observed upto 12 months
219131071|NCT03617107|OTHER|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
219131072|NCT00003656|BIOLOGICAL|recombinant interferon alfa|
219131073|NCT00003656|DRUG|tretinoin liposome|
219131074|NCT03275896|OTHER|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
219131075|NCT03393520|DRUG|Placebo|oral capsules
219131076|NCT03393520|DRUG|AVP-786|oral capsules
219131077|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
219131078|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
219131079|NCT00939848|DRUG|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
219131080|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
219131081|NCT00939848|DRUG|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
219131082|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
219131083|NCT00630513|DRUG|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
219131084|NCT00630513|DRUG|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
219712862|NCT05385861|DRUG|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
219712863|NCT05316935|DRUG|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
219712864|NCT05316935|DRUG|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
219712865|NCT05316935|DRUG|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
219712866|NCT05316935|DRUG|MET|500mg po tid
219712867|NCT04891640|OTHER|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
219712868|NCT04891640|OTHER|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks"
219712869|NCT04891640|OTHER|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
219131085|NCT03936829|DRUG|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
219131086|NCT01073098|OTHER|Vascular occlusion test|Reperfusion slope after vascular occlusion test
219131087|NCT04892810|PROCEDURE|Percutaneous ablation|Hepatic Percutaneous Ablation with radiofrequency or microwave
219131088|NCT01904357|DRUG|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and \< 50 kg will receive the 1g dose.
219131089|NCT01904357|DRUG|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
219131090|NCT02327039|DRUG|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
219131091|NCT02327039|DRUG|Placebo|Tables of Dapagliflozin placebo
219131092|NCT01894347|OTHER|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
219131093|NCT01273701|BEHAVIORAL|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
219131094|NCT01273701|BEHAVIORAL|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
219131095|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
219712870|NCT06123052|OTHER|Interview|"This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy."
219712871|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
219131096|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
219131097|NCT04379986|DEVICE|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
219131098|NCT00998816|DRUG|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
219131099|NCT03431779|PROCEDURE|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
219131100|NCT03431779|PROCEDURE|Surgical excision|Excision of painful areas
219131101|NCT04358328|OTHER|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
219131102|NCT04358328|OTHER|Standard care|Standard pre-, peri- and post operative care.
219131103|NCT03780309|BEHAVIORAL|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
219131104|NCT03780309|BEHAVIORAL|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
219131105|NCT03288350|DRUG|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
219712872|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
219712873|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
219712874|NCT05847504|BEHAVIORAL|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
219712875|NCT06493253|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
219712876|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
219712877|NCT06193512|DEVICE|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
219131106|NCT00478556|DRUG|Omnipaque|Oral CT contrast
219131107|NCT00478556|DRUG|Gastroview|Oral CT contrast
219131108|NCT02718469|BIOLOGICAL|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
219131109|NCT02718469|BIOLOGICAL|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
219131110|NCT02718469|BIOLOGICAL|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
219131111|NCT02718469|BIOLOGICAL|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
219131112|NCT03142789|DRUG|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
219131113|NCT03142789|DRUG|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
219712878|NCT06193512|PROCEDURE|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
219712879|NCT05239728|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
219131114|NCT03142789|DRUG|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
219131115|NCT03142789|DRUG|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
219131116|NCT05540990|DEVICE|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
219131117|NCT05540990|OTHER|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
219131118|NCT04238104|OTHER|no intervention|it's only observational study. No interventions.
219131119|NCT02722356|DRUG|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
219131120|NCT05457842|DRUG|pudexacianinium chloride|Intradermal injection
219131121|NCT05692258|OTHER|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
219131122|NCT00445406|DRUG|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
219131123|NCT00445406|DRUG|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
219131124|NCT04590794|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
219131125|NCT04135209|DIAGNOSTIC_TEST|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
219131126|NCT01405235|DRUG|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
219131127|NCT01405235|DRUG|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
219131128|NCT03360422|OTHER|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
219131129|NCT03360422|OTHER|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
219131130|NCT03360422|OTHER|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
219131131|NCT02664194|DEVICE|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
219712880|NCT05239728|BIOLOGICAL|Pembrolizumab|400 mg via IV infusion
219712881|NCT05239728|DRUG|Placebo|Oral tablet
219712882|NCT03653338|BIOLOGICAL|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
219131132|NCT02664194|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
219131133|NCT01521624|DRUG|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
219131134|NCT04807517|DRUG|Buspirone|All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
219131135|NCT05889390|DEVICE|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
219712883|NCT03653338|BIOLOGICAL|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
219712884|NCT03653338|DRUG|Hydroxyurea|Sickle Cell Disease Conditioning
219712885|NCT03653338|DRUG|Rituximab|Sickle Cell Disease Conditioning
219712886|NCT03653338|DRUG|Alemtuzumab|Sickle Cell Disease Conditioning
219131136|NCT05889390|DRUG|Paclitaxel|weekly paclitaxel for 12 weeks
219131137|NCT05889390|DRUG|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
219131138|NCT05889390|DRUG|Cyclophosphamide/Doxorubicin|according to the AC protocol
219131139|NCT05889390|PROCEDURE|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
219131140|NCT06628544|BIOLOGICAL|BCG vaccination|BCG vaccination
219712887|NCT03653338|DRUG|Fludarabine|Sickle Cell Disease Conditioning
219712888|NCT03653338|DRUG|Thiotepa|Sickle Cell Disease Conditioning
219712889|NCT00569127|BIOLOGICAL|Bevacizumab|Given IV
219712890|NCT00569127|OTHER|Laboratory Biomarker Analysis|Correlative studies
219712891|NCT00569127|DRUG|Octreotide Acetate|Given IM
219131141|NCT06628544|DRUG|Metformin is administered on the day 0|Metformin is administered on the day 0
219131142|NCT06628544|OTHER|Placebo|Placebo
219131143|NCT06628544|DRUG|Metformin is administered on the day 9|Metformin is administered on the day 9
219131144|NCT06628544|DRUG|Metformin is administered on the day 85|Metformin is administered on the day 85
219131145|NCT03480971|DRUG|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
219131146|NCT03480971|DRUG|Placebo Solution|The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
219131147|NCT06250816|OTHER|The hospital gown with cartoon characters|The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
219131148|NCT03168438|DRUG|Letetresgene autoleucel|Letetresgene autoleucel (GSK3377794) as an IV infusion
219131149|NCT03168438|DRUG|Letetresgene autoleucel with pembrolizumab|Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
219131150|NCT03168438|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
219131151|NCT03168438|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
219131152|NCT03168438|DRUG|Pembrolizumab|Pembrolizumab is available as an IV infusion
219712892|NCT00569127|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
219712893|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
219131153|NCT06629246|DRUG|Conventional heart failure treatment|Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
219226878|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
219226879|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
219712894|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
219712895|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
219712896|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
219712897|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
219712898|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
219712899|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
219712900|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
219712901|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
219712902|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
219712903|NCT04279522|DEVICE|Relivion®DP- Active|Relivion®DP- Active stimulation device
219712904|NCT04279522|DEVICE|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
219131154|NCT06629246|DRUG|Pogejiuxin decoction combined with conventional heart failure treatment|In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
219712905|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
219712906|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
219712907|NCT04587830|DRUG|Placebo|Investigational Medicine
219712908|NCT05470920|BEHAVIORAL|Electronic Decision Aid|Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
219712909|NCT05470920|BEHAVIORAL|Pre-Test Genetic Counseling|Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
219226880|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
219131155|NCT06629792|OTHER|Gentle Cleanser|The cleanser was instructed to be used twice daily over the course of 12 weeks
219131156|NCT06629792|OTHER|Facial Moisturizer|The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
219131157|NCT06629792|OTHER|sunscreen SPF 30|The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
219226881|NCT05342246|PROCEDURE|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
219131158|NCT05015478|DEVICE|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
219131159|NCT05015478|DEVICE|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered at randomly varying frequencies of 20 Hz and 50 Hz, specifically avoiding the frequency of 40 Hz. The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
219131160|NCT03966716|DEVICE|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
219131161|NCT03966716|DEVICE|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
219131162|NCT02341989|DRUG|Bleomycin Etoposide and Cisplatin|
219131163|NCT02341989|DRUG|Carboplatin|
219712910|NCT05893511|PROCEDURE|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
219712911|NCT05893511|DRUG|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
219131164|NCT05191797|DRUG|Bomedemstat|Given PO
219131165|NCT05191797|BIOLOGICAL|Atezolizumab|Given IV
219131166|NCT06030427|BEHAVIORAL|Behavioral Dietary Intervention|Participate in weight management program
219131167|NCT06030427|OTHER|Educational Intervention|Receive patient education handouts
219131168|NCT06030427|OTHER|Health Promotion and Education|View behavioral educational PowerPoint presentation
219131169|NCT06030427|OTHER|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
219131170|NCT06030427|OTHER|Interview|Ancillary studies
219131171|NCT06030427|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
219131172|NCT06030427|BEHAVIORAL|Mindfulness Relaxation|Complete mindfulness components
219131173|NCT06030427|OTHER|Physical Performance Testing|Ancillary studies
219131174|NCT06030427|OTHER|Questionnaire Administration|Ancillary studies
219131175|NCT05278988|DRUG|PRS Regimen V|PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
219226882|NCT02967861|BEHAVIORAL|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
219226883|NCT02967861|PROCEDURE|Scaling and root planing|It is a mechanical debridement of dental plaque.
219131176|NCT05278988|DRUG|MDR-TB Treatment Regimen(WHO)|Treatment according to WHO MDR-TB treatment guidelines (2019)
219131177|NCT01786746|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
219131178|NCT01786746|BEHAVIORAL|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
219131179|NCT00658411|DRUG|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
219131180|NCT03082885|DRUG|Thymosin-α1|1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
219226884|NCT04725136|BIOLOGICAL|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
219226885|NCT00081913|GENETIC|Cell Therapy - Autologous CD34 Positive Cells|
219226886|NCT01786876|DRUG|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
219131181|NCT02684084|DRUG|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
219131182|NCT02684084|DRUG|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
219131183|NCT06548477|DRUG|Human albumin|Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
219131184|NCT02739568|DRUG|Pitolisant (BF2.649)|
219131185|NCT02739568|DRUG|Placebo|
219131186|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
219131187|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
219131188|NCT05630495|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
219712912|NCT04880824|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
219712913|NCT03834688|DRUG|Venetoclax|"Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days)."
219131189|NCT06174480|OTHER|Cryostimulation|Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
219131190|NCT00441675|PROCEDURE|Symptom Score|Symptom Score
219226887|NCT00741650|BEHAVIORAL|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
219712914|NCT03834688|DRUG|Bendamustine|Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
219712915|NCT03834688|DRUG|Rituximab|Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
219712916|NCT06023498|OTHER|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~* Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~* Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~* Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~* Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
219712917|NCT06023498|OTHER|Intramuscular Electroacupuncture|As described previously
219712918|NCT05728450|DEVICE|Light amplification by stimulated emission of radiation (LASER)|"* The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
219131191|NCT00441675|PROCEDURE|Symptom Score and PD20|Symptom Score and PD20
219131192|NCT06087068|DRUG|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
219226888|NCT00741650|BEHAVIORAL|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
219226889|NCT05080036|OTHER|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
219226890|NCT05683834|DRUG|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
219712919|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
219131193|NCT06566586|DRUG|TQB3702 tablets+Chemotherapy regimen|"TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；"
219131194|NCT05066451|OTHER|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
219131195|NCT05066451|OTHER|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
219131196|NCT02787967|DRUG|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
219131197|NCT02787967|DRUG|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
219131198|NCT04927975|DRUG|Upadacitinib|Oral tablets
219226891|NCT05683834|DRUG|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
219712920|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
219712921|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
219712922|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
219131199|NCT04927975|DRUG|Placebo|Oral tablets
219131200|NCT05365607|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
219131201|NCT05365607|DEVICE|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
219131202|NCT03548922|OTHER|Tanner stage|a scale of pubertal development in children, adolescents
219226892|NCT05683834|OTHER|Placebo Comparator|Normal Saline
219226893|NCT01530334|DRUG|Gefitinib 250mg|Gefitinib 250mg once daily
219712923|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
219712924|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
219226894|NCT00262015|BIOLOGICAL|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
219226895|NCT01105988|OTHER|Radiologic exams|FLT PET scan x 2 MRI scan x 2
219131203|NCT03548922|OTHER|Risser stage|a measure showing the growth left in the spine
219131204|NCT03548922|OTHER|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
219131205|NCT03548922|OTHER|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
219131206|NCT04942054|DRUG|Part 1|Dose escalation cohort
219131207|NCT04942054|DRUG|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
219131208|NCT04942054|DRUG|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
219226896|NCT01485887|DRUG|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
219226897|NCT02895659|PROCEDURE|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
219226898|NCT00476736|DRUG|Effect on small airways (N-Acetylcystein)|
219131209|NCT03906747|OTHER|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
219131210|NCT03906747|OTHER|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
219226899|NCT04332094|DRUG|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
219226900|NCT04332094|DRUG|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
219226901|NCT04332094|DRUG|Azithromycin|500 mg / day v.o. for 3 days
219226902|NCT05879705|OTHER|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
219226903|NCT00140725|DRUG|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
219226904|NCT00140725|DRUG|Lamivudine|
219226905|NCT04278755|DRUG|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
219226906|NCT05925699|OTHER|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
219226907|NCT03154736|OTHER|Interview|Individual interview and group interview Socio-economic questionnaire
219226908|NCT04257799|OTHER|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
219712925|NCT03537690|OTHER|Laboratory Biomarker Analysis|Correlative studies
219712926|NCT03537690|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
219712927|NCT03537690|OTHER|Pharmacokinetic Study|Correlative studies
219712928|NCT06052956|DRUG|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
219131211|NCT00420472|DRUG|mycophenolate mofetil [CellCept]|
219226909|NCT03340909|DRUG|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
219226910|NCT03340909|OTHER|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
219226911|NCT06438237|PROCEDURE|Bowel preparation before colonoscopy|Patients use purgative for bowel cleansing before colonoscopy.
219226912|NCT02013700|BIOLOGICAL|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
219226913|NCT02013700|BIOLOGICAL|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
219226914|NCT02304757|DRUG|99Tc-MDP|99Tc-MDP, H20000218
219226915|NCT02304757|DRUG|Fosamax|H20080172
219226916|NCT02541318|BEHAVIORAL|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
219226917|NCT04437043|OTHER|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
219226918|NCT03184987|DRUG|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
219712929|NCT06052956|DRUG|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
219712930|NCT06052956|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
219712931|NCT06052956|DEVICE|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
219131212|NCT06329869|DRUG|Sacituzumab govitecan|Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
219131213|NCT04327037|BIOLOGICAL|Expanded Haploidentical Natural Killer cells|One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells
219131214|NCT04327037|DRUG|IL-2|6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
219131215|NCT00362752|DRUG|Norfloxacin|400 mg po bid
219131216|NCT00362752|DRUG|Placebo|Placebo 400 mg po bid
219131217|NCT05492890|DEVICE|Dexcom G6|Continuous glucose monitoring
219131218|NCT02708862|DEVICE|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
219131219|NCT02113163|DRUG|Metformin Eicosapentaenoate|
219131220|NCT02113163|DRUG|Metformin HCl and Vascepa|
219131221|NCT05239702|BIOLOGICAL|CD7 CAR T-cells|Each subject receive CD7 CAR T-cells by intravenous infusion
219712932|NCT06052956|DEVICE|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
219131222|NCT02758262|DEVICE|Noninvasive brain stimulation|
219131223|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
219131224|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
219131225|NCT03568162|DRUG|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
219131226|NCT03568162|DRUG|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
219131227|NCT03568162|DRUG|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
219226919|NCT03184987|DRUG|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
219712933|NCT06052956|DEVICE|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
219712934|NCT06052956|PROCEDURE|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
219712935|NCT04529655|DEVICE|Capillary Refill Assessment|Device to quantify capillary refill time
219131228|NCT03568162|DRUG|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
219131229|NCT03568162|DRUG|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
219131230|NCT03568162|DRUG|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
219226920|NCT03184987|DRUG|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
219712936|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
219712937|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219131231|NCT04914312|DIETARY_SUPPLEMENT|Maqui berry/omeg-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
219131232|NCT04914312|DIETARY_SUPPLEMENT|Placebos|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
219131233|NCT01368120|DEVICE|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
219131234|NCT01368120|DEVICE|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
219131235|NCT01368120|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
219131236|NCT03717194|DRUG|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
219131237|NCT03717194|DRUG|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
219131238|NCT00337818|BIOLOGICAL|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
219131239|NCT00725413|DRUG|etonogestrel implant (Implanon)|subdermal etonogestrel implant
219131240|NCT00333060|DRUG|OT-551 ophthalmic solution|
219131241|NCT00336232|DRUG|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
219131242|NCT06152029|DEVICE|Temporary PNS system|This system remains in place up to 60 days, then removed.
219131243|NCT06044948|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel spherical contact lenses
219131244|NCT04216433|PROCEDURE|endovascular surgery|"an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or ballooning of the blood vessel. The surgery involves making a small incision near each hip to access the blood vessels."
219131245|NCT05590871|DEVICE|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
219131246|NCT05590871|OTHER|Sham|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
219712938|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
219712939|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
219712940|NCT04654312|DRUG|Hydrochlorothiazide|Please see arm descriptions
219712941|NCT04654312|DRUG|Placebo|Please see arm descriptions
219131247|NCT03563053|COMBINATION_PRODUCT|EryDex System|"EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data."
219131248|NCT03137316|DIAGNOSTIC_TEST|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
219131249|NCT01013974|DRUG|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
219131250|NCT01013974|DRUG|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
219131251|NCT01013974|DRUG|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
219131252|NCT01013974|DRUG|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
219131253|NCT04530474|DRUG|Ivermectin Pill|Ivermecin as a one-time dose
219131254|NCT04530474|DRUG|Placebo|Inactive medication as a one time dose
219131255|NCT06629480|DRUG|Bictegravir|The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
219131256|NCT02479867|DRUG|Cefadroxil|1 tablet from test vs 1 tablet from reference
219131257|NCT00399282|DRUG|Omega-3 and Vitamin E supplementation|
219131258|NCT03807505|PROCEDURE|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
219131259|NCT03807505|PROCEDURE|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
219131260|NCT02081391|DRUG|Tapentadol oral solution 4 mg/mL|"Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold."
219712942|NCT04289142|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20-60 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
219712943|NCT03036254|DEVICE|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
219712944|NCT03036254|DEVICE|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
219712945|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
219131261|NCT02081391|DRUG|Tapentadol oral solution 20 mg/mL|Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.
219131262|NCT02081391|OTHER|Placebo|Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
219226921|NCT03184987|OTHER|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
219226922|NCT04758949|DRUG|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
219226923|NCT04758949|DRUG|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
219226924|NCT04758949|DRUG|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
219712946|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
219712947|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
219712948|NCT02250352|OTHER|cytology specimen collection procedure|Correlative studies
219712949|NCT06484114|DEVICE|Revita Duodenal Mucosal Resurfacing (DMR)|DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.
219712950|NCT06484114|DEVICE|Sham|An endoscopic review with non active catheter introduction
219712951|NCT06378398|DRUG|Omeprazole|Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
219712952|NCT06378398|DRUG|Aspirin|Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
219712953|NCT06571838|DEVICE|DAISY system|DAISY is a The humanoid robot with an ipad and attached peripheral devices capable of taking blood pressure and temperature
219712954|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
219712955|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
218986841|NCT05849701|DEVICE|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
219131263|NCT04504084|OTHER|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
219131264|NCT05143242|PROCEDURE|Hard tissue augmentation at the buccal aspect of single implants.|One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
219131265|NCT05143242|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants.|A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
219131266|NCT05830695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
219131267|NCT05830695|DRUG|Mineral Trioxide Aggregate|mineral trioxide aggregate was used as control
219131268|NCT01339221|PROCEDURE|Stool samples|Stool samples collected and checked for the presence of rotavirus
219131269|NCT02659995|OTHER|No intervention|No interventions will be performed on these patients.
219131270|NCT01084421|BEHAVIORAL|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
219131271|NCT03413774|PROCEDURE|vaginal swab|high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
219131272|NCT05441020|OTHER|Administration of patient questionnaire|Patients undergoing maintenance hemodialysis complete electronic questionnaires on a tablet computer during this study to assess patient reported outcomes.
219131273|NCT00041795|DRUG|leteprinim potassium (Neotrofin)|
219131274|NCT03251651|DRUG|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
219131275|NCT03251651|DRUG|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
219131276|NCT04629144|DRUG|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
219131277|NCT04629144|DRUG|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
219131278|NCT03213041|DRUG|Carboplatin|Given IV
219131279|NCT03213041|OTHER|Laboratory Biomarker Analysis|Correlative studies
219131280|NCT03213041|BIOLOGICAL|Pembrolizumab|Given IV
219131281|NCT03087721|BEHAVIORAL|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
219131282|NCT03087721|BEHAVIORAL|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
219131283|NCT02404246|BEHAVIORAL|Peer support program|
219712956|NCT02783274|DEVICE|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
218986842|NCT02617381|OTHER|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
219226925|NCT05054270|OTHER|Chest examination with Ultrasound device|Chest examination with Ultrasound device
219712957|NCT05386914|DRUG|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
218986843|NCT01358045|DRUG|Diclofenac|Application on the lesion 2 times a day 8 weeks.
218986844|NCT01358045|DRUG|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
218986845|NCT01358045|DRUG|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
219712958|NCT06273865|DIAGNOSTIC_TEST|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
219712959|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
219712960|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
219712961|NCT06114875|BEHAVIORAL|Peer support intervention|"Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress."
219712962|NCT05477277|DIAGNOSTIC_TEST|MAsS|Add MAsS to standard of care MRI scan
219712963|NCT06003166|DRUG|4-Aminopyridine|Study drug will be a one time, 10mg dose of 4-aminopyridine
219712964|NCT06003166|OTHER|Placebo|Matched placebo
219712965|NCT06268808|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
218986846|NCT03963596|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
218986847|NCT00145522|DRUG|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
218986848|NCT00145522|DRUG|Tibolone|2,5 mg/day for 12 cycles of 28 days
218986849|NCT03555916|DRUG|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
218986850|NCT03555916|DRUG|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
218986851|NCT01010373|DRUG|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
218986852|NCT06161870|DRUG|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
218986853|NCT06161870|DRUG|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
218986854|NCT05009654|DIETARY_SUPPLEMENT|L-carnitine|
218986855|NCT05009654|DIETARY_SUPPLEMENT|L-leucine|
218986856|NCT04997083|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
218986857|NCT04997083|DEVICE|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
218986858|NCT05116878|DIETARY_SUPPLEMENT|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
218986859|NCT05116878|DIETARY_SUPPLEMENT|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
218986860|NCT00991731|BEHAVIORAL|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
218986861|NCT00991731|BEHAVIORAL|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
218986862|NCT02566486|DEVICE|Reciprocating system|Different root canal instrumentation systems
218986863|NCT02566486|DEVICE|Rotational system|Different root canal instrumentation systems
218986864|NCT01540266|PROCEDURE|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
219226926|NCT04826406|DRUG|Camrelizumab combined Apatinib regimen|Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
219712966|NCT06388213|DEVICE|Gastric Ultrasonography|Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
219226927|NCT03353961|BEHAVIORAL|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
219226928|NCT03353961|BEHAVIORAL|Treatment as usual|Treatment as usual as provided in the community.
219226929|NCT05500352|OTHER|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
219226930|NCT05500352|OTHER|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
219226931|NCT05500352|OTHER|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
219226932|NCT05500352|OTHER|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
219226933|NCT05500352|OTHER|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
219226934|NCT05500352|OTHER|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
218986865|NCT01540266|PROCEDURE|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
218986866|NCT00330070|DRUG|IPL512,602 20 mg once daily|
218986867|NCT00330070|DRUG|IPL512,602 Matching Placebo once daily|
219712967|NCT06069908|OTHER|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
219712968|NCT06069908|OTHER|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
218986868|NCT00868608|DRUG|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
218986869|NCT03454542|DEVICE|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
218986870|NCT03844100|DRUG|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
218986871|NCT03363997|DRUG|Estriol 0.125 mg/day|Application of one vaginal ring
218986872|NCT03363997|DRUG|Estriol 0.250 mg/day|Application of one vaginal ring
218986873|NCT03363997|DRUG|Estriol 0.500 mg/day|Application of one vaginal ring
218986874|NCT06308367|DRUG|Betaine|50mg/kg for 12 weeks
218986875|NCT06308367|DRUG|Placebo|Placebo
218986876|NCT02012283|OTHER|Food consumption|Cooked vegetables with spices or without spices
218986877|NCT04916431|DRUG|mRNA-6231|Sterile frozen liquid dispersion for injection
218986878|NCT01007539|DIETARY_SUPPLEMENT|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
218986879|NCT01007539|DIETARY_SUPPLEMENT|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
218986880|NCT02423759|DRUG|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
218986881|NCT02423759|DRUG|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
218986882|NCT02423759|DRUG|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
218986883|NCT00981201|DRUG|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
218986884|NCT00981201|DRUG|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
218986885|NCT00981201|DRUG|Placebo|"Months 1-3:~By mouth twice daily."
218986886|NCT00981201|DRUG|Placebo|"Months 4-6:~By mouth twice daily."
218986887|NCT04204343|DRUG|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
218986888|NCT04204343|DRUG|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
218986889|NCT00180622|PROCEDURE|Spirometry|
219131284|NCT01111591|DRUG|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
219131285|NCT04505124|BEHAVIORAL|FutureMe App|The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
219226935|NCT05500352|OTHER|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
219712969|NCT06069908|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
219712970|NCT06069908|OTHER|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
219712971|NCT04838444|BIOLOGICAL|VLA1553|Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
219712972|NCT05749822|DRUG|Fenofibrate 200mg|Fenofibrate 200mg/day
219712973|NCT05749822|DRUG|Placebo|1 tablet/ day
219712974|NCT05749822|DRUG|UDCA|UDCA 13-15mg/kg/day
219712975|NCT03568617|DEVICE|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
218986890|NCT00180622|PROCEDURE|Exhaled Nitric Oxide and Carbon Monoxide|
218986891|NCT00180622|PROCEDURE|Exhaled Breath Condensate|
218986892|NCT00180622|PROCEDURE|Induced Sputum|
218986893|NCT00180622|PROCEDURE|CT Scan|
218986894|NCT00180622|PROCEDURE|Blood test|
218986895|NCT00180622|PROCEDURE|St Georges Questionnaire|
218986896|NCT00180622|PROCEDURE|Bodypletysmography|
218986897|NCT01810731|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (QIV)|
218986898|NCT01810731|BIOLOGICAL|Inactivated Polio Vaccine|
218986899|NCT01810731|BIOLOGICAL|Double Dose QIV|
218986900|NCT05693948|OTHER|Other: Serum X|Serum X contain arbutin and glutathione
218986901|NCT01725711|DEVICE|OPRA Implant System|
218986902|NCT06556381|PROCEDURE|TAP block|Women will receive TAP block.
218986903|NCT00626223|DRUG|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
218986904|NCT00626223|DRUG|folic acid|5 mg per day of oral folic acid
218986905|NCT00579137|BIOLOGICAL|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg"
218986906|NCT00579137|DRUG|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
218986907|NCT00579137|BIOLOGICAL|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
218986908|NCT00579137|PROCEDURE|Stem cell infusion|stem cells are infused on day 0
218986909|NCT03756077|DIAGNOSTIC_TEST|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
218986910|NCT01400763|DIETARY_SUPPLEMENT|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
218986911|NCT01400763|DIETARY_SUPPLEMENT|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
218986912|NCT01400763|DIETARY_SUPPLEMENT|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
218986913|NCT01400763|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
218986914|NCT05531383|DRUG|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
218986915|NCT00635674|DEVICE|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
218986916|NCT03011710|DEVICE|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
218986917|NCT03011710|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
218986918|NCT03011710|DEVICE|Cigarette tip|Placebo device
218986919|NCT01999179|DRUG|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
218986920|NCT01981980|OTHER|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
218986921|NCT01981980|OTHER|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
218986922|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
218986923|NCT01890369|DIETARY_SUPPLEMENT|3g Leucine|Dissolved in 250ml water.
219131286|NCT04505124|BEHAVIORAL|Conventional TrackingApp|The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
219131287|NCT00425542|OTHER|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
219131288|NCT06232161|DEVICE|Red-light therapy device|Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
219131289|NCT06232161|DEVICE|Spectacles|Single focus spectacles, that is to say, wearing glasseses with minus power lens
219131290|NCT02513433|DRUG|Bupivacaine|Local anesthetic
219131291|NCT02513433|DRUG|Levobupivacaine|Local anesthetic
219131292|NCT02513433|DRUG|Ropivacaine|Local anesthetic
219131293|NCT02622139|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
219131294|NCT04145102|OTHER|hesperidine|used for antibacterial and reminerlization assesment
219131295|NCT04145102|OTHER|propolis|used for antibacterial and reminerlization assesment
219131296|NCT04145102|OTHER|silver diamine fluoride|used for antibacterial and reminerlization assesment
219131297|NCT01781702|DRUG|Pelubiprofen 30 mg|
219131298|NCT01781702|DRUG|Celebrex 200 mg|
219131299|NCT00056641|DRUG|tipranavir|
219131300|NCT00056641|DRUG|ritonavir|
219131301|NCT00056641|DRUG|saquinavir|
219131302|NCT00056641|DRUG|amprenavir|
219131303|NCT00056641|DRUG|lopinavir|
219131304|NCT05975320|DRUG|Warfarin|Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) \& (ORBIT) SCORES will be calculated and compared for all cases .
219131305|NCT01021644|BEHAVIORAL|aerobic exercise-training|3 times per week for 6 months
219131306|NCT01021644|BEHAVIORAL|stretch exercise|3 times per week for 6 months
219131307|NCT02228603|BEHAVIORAL|high-intensity exercise training|
219131308|NCT02228603|BEHAVIORAL|web-based follow-up program|
219131309|NCT02228603|BEHAVIORAL|usual care|
219131310|NCT03411811|OTHER|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
219226936|NCT05500352|OTHER|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
219226937|NCT05500352|OTHER|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
219131311|NCT03411811|PROCEDURE|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
219131312|NCT01779375|DRUG|Metformin|
219131313|NCT01779375|DRUG|Glargine|
219131314|NCT04459832|PROCEDURE|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
219131315|NCT06341374|BIOLOGICAL|Influvac Tetra|All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
219131316|NCT00013650|DRUG|Cyclophosphamate|
219131317|NCT04451733|PROCEDURE|Endotracheal intubation|Perform the endotracheal intubation during CPR
219131318|NCT02216786|DRUG|AZD2014|Oral tablet
219131319|NCT02216786|DRUG|Everolimus|Oral tablet
219226938|NCT00275444|DRUG|Tipranavir|
219226939|NCT02851498|OTHER|Food product: high-protein pasta and cereal|
219131320|NCT02216786|DRUG|Fulvestrant|Im injection
219131321|NCT02121574|DEVICE|Zero flux and ingestible thermometers|
219131322|NCT03102242|DRUG|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
219131323|NCT02957292|DRUG|Levonorgestrel (13,5 mg) intrauterine device|
219131324|NCT02957292|DEVICE|Cooper (380mm2) intrauterine device|
219131325|NCT03357224|DRUG|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
219131326|NCT00733460|DRUG|BFPET|
219131327|NCT01994161|PROCEDURE|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~\--------------------------------------------------------------------------------"
219131328|NCT02639429|DRUG|Vaginal Misoprostol|
219131329|NCT02639429|DEVICE|Foley Balloon + Vaginal Misoprostol|
219131330|NCT03920163|OTHER|Enhanced Recovery Measures|Perioperative measures
219131331|NCT04566874|DEVICE|ALIF|Anterior Lumbar Interbody Fusion
219131332|NCT02441075|OTHER|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
219131333|NCT01311713|DRUG|CEP-9722|CEP-9722 will be administered per dose and schedule specified in the arm description.
219131334|NCT05616221|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
219131335|NCT05616221|OTHER|Placebo|Inactive Placebo administered via inhalation
219226940|NCT01727570|DIETARY_SUPPLEMENT|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
219226941|NCT06002035|DIETARY_SUPPLEMENT|Binom Vitamin D drops|Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
219226942|NCT05884567|OTHER|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
219226943|NCT05884567|OTHER|Mobilization|These exercises are used to increase ROM and used for pain reduction
219712976|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
219131336|NCT04543513|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
219131337|NCT03416751|BIOLOGICAL|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
219131338|NCT03416751|OTHER|Placebo|Placebo enemas
219226944|NCT00826826|PROCEDURE|Catheter ablation|(Pulmonary vein isolation)
219131339|NCT02990858|DRUG|PRO 140 SC injections|
219131340|NCT05553119|BEHAVIORAL|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
219131341|NCT05553119|BEHAVIORAL|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
219131342|NCT05652608|BEHAVIORAL|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
219131343|NCT06622499|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
219131344|NCT06631261|OTHER|No intervention; Observational study|No intervention
219131345|NCT06698302|BEHAVIORAL|Questionnaires|Administer translated COMPAT-SF questionnaires to Spanish-speaking CP patients
219131346|NCT06696664|DRUG|PEG-IFN-α|chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
219226945|NCT00826826|DRUG|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
219226946|NCT00826826|DRUG|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
219226947|NCT00259766|DRUG|Budesonide|
219226948|NCT00259766|DRUG|Formoterol|
219226949|NCT00259766|DRUG|Terbutaline|
219226950|NCT02003872|DEVICE|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
219226951|NCT05381090|DIAGNOSTIC_TEST|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
219712977|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
219712978|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
219131347|NCT06630572|DRUG|Rifaximin|Patients randomized to receive Rifaximin for 14 days
219131348|NCT06630572|DRUG|Placebo|Patients randomized to receive Placebo for 14 days
219131349|NCT00116870|DRUG|lovastatin|
219226952|NCT02767674|DRUG|Rituximab|375 mg/m2 IVD day0
219226953|NCT02767674|DRUG|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
219226954|NCT02767674|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
219226955|NCT02767674|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
219226956|NCT02767674|DRUG|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
219226957|NCT02767674|DRUG|Vindesine|Vindesine 2 mg IVP d1
219226958|NCT02767674|DRUG|Prednisone|Prednisone 40mg/m2 PO d1-5
219226959|NCT01750424|PROCEDURE|Autologous Fat Grafting|
219226960|NCT01750424|OTHER|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
219226961|NCT00853411|DRUG|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
219226962|NCT01553266|BEHAVIORAL|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
219226963|NCT02286869|PROCEDURE|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
219226964|NCT01629420|DRUG|KLH-2109|
219226965|NCT01629420|DRUG|KLH-2109|
219712979|NCT04930991|DRUG|Omeprazole|Treatment will consist of Omeprazole 12-14 days prior to surgical therapy of pancreatectomy.
219712980|NCT02176967|PROCEDURE|Biopsy|Undergo biopsy
219712981|NCT02176967|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219712982|NCT02176967|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219712983|NCT02176967|DRUG|Carboplatin|Given IV
219712984|NCT02176967|OTHER|Clinical Observation|Undergo clinical observation
219712985|NCT02176967|PROCEDURE|Computed Tomography|Undergo CT
219712986|NCT02176967|DRUG|Cyclophosphamide|Given IV
219712987|NCT02176967|DRUG|Doxorubicin Hydrochloride|Given IV
219712988|NCT02176967|DRUG|Etoposide|Given IV
219712989|NCT02176967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219712990|NCT02176967|PROCEDURE|Ultrasound|Undergo ultrasound
219712991|NCT05822544|DRUG|TLC-6740 Oral Solution|Oral solution of TLC-6740
219712992|NCT05822544|OTHER|Placebo Oral Solution|Placebo-to-match oral solution TLC-6740
219712993|NCT05822544|DRUG|TLC-6740 Tablet|Tablet formulation of TLC-6740
219712994|NCT05822544|DRUG|Drug Metabolizing Enzyme|Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin
219226966|NCT01756599|BIOLOGICAL|blood samples|
219712995|NCT05822544|DRUG|Tirzepatide|Subcutaneous injection of tirzepatide
219712996|NCT05822544|OTHER|Placebo Tablet|Placebo-to-match tablet formulation of TLC-6740
219712997|NCT05311527|DEVICE|Urolift|Urolift Implant
219712998|NCT05311527|RADIATION|SABR|Stereotactic Body Radiation Therapy for prostate cancer
219712999|NCT06138821|DEVICE|ESG + lifestyle modification|Endoscopic sleeve gastroplasty - an endoscopic weight loss procedure where an endoscopic suturing device is utilized to reduce the size of the stomach by 70%.
219713000|NCT06138821|BEHAVIORAL|Lifestyle modification|Lifestyle modification program consisting of diet and exercise therapy
219713001|NCT02095366|DRUG|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
219713002|NCT02095366|DRUG|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
219713003|NCT02095366|DRUG|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
219713004|NCT02095366|DRUG|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
219713005|NCT06974175|OTHER|Deprox_HP|Use of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy
219713006|NCT06974175|OTHER|Peacist|Use of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract
219713007|NCT06966375|OTHER|WYSH Web Application|Worldwide Yearly Screening for Hypospadias (WYSH) Web Application
219713008|NCT06347315|DIETARY_SUPPLEMENT|BrainXpert|sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.
218986924|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
218986925|NCT05164185|PROCEDURE|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
218986926|NCT01778972|OTHER|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
218986927|NCT01778972|OTHER|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
218986928|NCT01176383|GENETIC|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
218986929|NCT00880997|DRUG|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
218986930|NCT00880997|OTHER|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
218986931|NCT02530684|OTHER|insole|Insoles available on the market without prescription
218986932|NCT06509139|DRUG|Drug: Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218986933|NCT06509139|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218986934|NCT06509139|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218986935|NCT06509139|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
218986936|NCT03006107|PROCEDURE|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
218986937|NCT03006107|PROCEDURE|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
219131350|NCT06696989|OTHER|Frenkel's exercises|In this group, participants will receive Frenkel's exercises, and the total treatment session will be 60 minutes of routine physical therapy, i.e., breathing, stretching, ROM's, and joint mobility, with rest intervals in between for 20 minutes. To begin the intervention, the investigator will perform Frenkel's exercises for 40 minutes in total, with rest intervals between each exercise, initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively, after 2 weeks.
219131351|NCT06696989|OTHER|Core stability exercises|This group participants will receive core stability exercises, and the total treatment session will also be 60 minutes. The routine physical therapy includes breathing, stretching, joint rotations, ROM's, and frequent periods of rest in between the treatment sessions. To begin the intervention the investigator will perform core stability exercises for 40 minutes in total with rest intervals between each exercise and initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively after 2 weeks.
219131352|NCT06697860|DEVICE|Radial Shockwave Therapy|In Group A, Radial Shockwave Therapy (RST) was given to the plantar fascia for 5 minutes, with each session consisting of 5-10 shock wave pulses of varied intensity. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each stretch. This therapy procedure was followed out in weekly sessions for 8 weeks, each lasting 40 minutes in total.
219131353|NCT06697860|DEVICE|Graston Instrument|Group B employed Graston Instrument-Assisted Soft Tissue Mobilization (IASTM) for 5-10 minutes to target and break down plantar fascia adhesions. The therapist used a specialized device to apply controlled, precise pressure to the fascia. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each. The entire therapy procedure was carried out in weekly sessions for 8 weeks, each lasting 40 minutes in total..
219131354|NCT06698055|OTHER|Flywheel Resistance Exercise|FW is conducted in a leg extension machine (LegExx, Exxentric, Stockholm, Sweden) and leg press machine (YoYo™ Leg Press, nHANCE, Sweden).
219131355|NCT06698055|OTHER|Weight Stack Resistance Exercise|WS is conducted in a leg extension machine (Seated leg press, Nordic Gym, Bollnäs, Sweden) and a leg press machine (Seated leg extension, Nordic Gym, Bollnäs, Sweden)
219131356|NCT06705023|BIOLOGICAL|Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)|Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.
219131357|NCT06705023|OTHER|Continuation of patient's best guideline based medical treatment|Patients will receive continuation of their best guideline based medical treatment.
219131358|NCT06711562|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
219131359|NCT06711159|DEVICE|continuous positive airway pressure|Initiation of treatment with continuous positive airway pressure for obstructive sleep apnea
219131360|NCT06706063|OTHER|Ultrasonography of muscles|The biceps brachii, flexor digitorum superficialis and profundus muscles and gastrocnemius muscles of the participants on the affected and unaffected sides will be evaluated ultrasonographically. Two researchers (with at least 5 years of experience in ultrasound imaging) blinded to the clinical evaluations of the patients and previous measurements will evaluate the same patients at two different times to test interobserver reproducibility. Muscle thickness, fascicle length and pennation angle will be recorded on B-mode imaging. In addition, elastographic evaluation will be performed on the same muscles and strain rate will be recorded.
219226967|NCT03655366|OTHER|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
219226968|NCT03655366|OTHER|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
219226969|NCT02203799|BIOLOGICAL|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
219226970|NCT01433185|OTHER|Text message|Text messages sent to women before and after delivery
219226971|NCT03658252|BEHAVIORAL|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
219713009|NCT06347315|OTHER|Placebo|high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
219713010|NCT06973785|DRUG|dispense of study drug|• Cohort Group 1 (Experimental): ketorolac 10mg with rescue medication oxycodone 5mg All patients will be given acetaminophen
219226972|NCT03658252|BEHAVIORAL|Online disease specific forum|An invitation to join an online moderated disease specific social forum
219713011|NCT06973785|DRUG|Ketorolac|Patients will be randomized to either Ketorolac or Oxycodone
219131361|NCT06712303|DEVICE|MRI ,ct|"Every patient will be subjected to~1\. MSCT examination: All patients will undergo MSCT (Siemens somatom 32 slice ,16 slice ,GE bright speed 16 slice ) Non contrast high-resolution CT of the temporal bone with the following parameters:{ 0.75-mm collimation, 130 kvp, 20 mA, topogram length 265}. Patients will be scanned in the supine position with craniocaudal direction. Scanning will be parallel to the orbito-meatal line from the lower margin of the external auditory meatus and extended upward to the arcuate eminence of the superior semicircular canal, as seen on the lateral topogram. Followed by image reconstruction in both the axial and coronal planes to evaluate the inner ear and its malformations, The initial data sets will be reconstructed at 0.6 mm slice thickness. The raw axial image data set can be reconstructed with a section thickness of as little as 0.3 mm to obtain high-quality coronal reformatted images. A 512 × 512 matrix is used, and all the images are reviewed wit"
219131362|NCT06713629|PROCEDURE|cardiac surgery via median sternotomy|For both groups, the same median sternotomy cardiac surgery procedure
219131363|NCT06713785|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution
219131364|NCT04571333|DEVICE|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
219131365|NCT02799706|DRUG|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
219131366|NCT02799706|DRUG|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
219131367|NCT02799706|RADIATION|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
219131368|NCT04990674|BEHAVIORAL|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
219131369|NCT04990674|BEHAVIORAL|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
219131370|NCT00797862|DRUG|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
219131371|NCT00797862|DRUG|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
219131372|NCT00797862|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
219131373|NCT01743729|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
219131374|NCT01743729|DRUG|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
219131375|NCT05753293|OTHER|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
219131376|NCT01693094|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
219131377|NCT04167709|OTHER|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
219131378|NCT04300933|BEHAVIORAL|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
219131379|NCT06313723|OTHER|Prenatal education management delivered via podcast|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
219131380|NCT03127358|DEVICE|AiCure|Smartphone App
219131381|NCT03127358|DEVICE|AiCure with gamification|Smartphone App with gaming.
219131382|NCT00409708|DRUG|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
219131383|NCT00409708|BEHAVIORAL|Behavior Therapy|
219131384|NCT04899284|OTHER|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
219131385|NCT00785772|DRUG|Gabapentin|100-200mg once a day
219131386|NCT00785772|DRUG|Gabapentin|200-500mg once a day
219131387|NCT00785772|DRUG|Gabapentin|400-1000mg (200-500 mg twice a day)
219131388|NCT04632368|BEHAVIORAL|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
219131389|NCT04477538|OTHER|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
219131390|NCT00328393|DRUG|Pioglitazone|45 mg 8 weeks
219131391|NCT00328393|DRUG|Placebo|Placebo
219131392|NCT05925712|DEVICE|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
219226973|NCT01847768|BIOLOGICAL|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
219131393|NCT05925712|DEVICE|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
219226974|NCT01847768|PROCEDURE|Bronchoalveolar Lavage|
219226975|NCT01847768|DRUG|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
219226976|NCT01847768|PROCEDURE|Nasal Lavage|
219226977|NCT01847768|PROCEDURE|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
219226978|NCT01847768|PROCEDURE|Bronchial Brushings|
219226979|NCT01847768|PROCEDURE|Lung Mucosal Biopsy|
219226980|NCT01847768|PROCEDURE|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
219226981|NCT01847768|PROCEDURE|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
219713012|NCT05011656|DEVICE|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
219713013|NCT05011656|DEVICE|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
219226982|NCT01847768|PROCEDURE|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
219226983|NCT01847768|PROCEDURE|Spirometry|
219226984|NCT00349232|BEHAVIORAL|lifestyle intervention (diet and physical activity)|
219713014|NCT06543576|BIOLOGICAL|Bevacizumab|Given IV
219713015|NCT06543576|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219131394|NCT05471167|BIOLOGICAL|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
219226985|NCT01581099|PROCEDURE|Digestive Adaptations III surgery|
219226986|NCT04105751|DEVICE|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
219713016|NCT06543576|RADIATION|Brachytherapy|Undergo brachytherapy
219713017|NCT06543576|DRUG|Cisplatin|Given IV
219713018|NCT06543576|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219131395|NCT03872297|DIETARY_SUPPLEMENT|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
219131396|NCT03872297|DIETARY_SUPPLEMENT|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
219131397|NCT01306669|BIOLOGICAL|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
219226987|NCT03556410|BEHAVIORAL|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
219226988|NCT03556410|BEHAVIORAL|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
219226989|NCT02562612|DRUG|SM-88|Daily SM-88 in multiple ascending doses over 6 months
219713019|NCT06543576|DRUG|Paclitaxel|Given IV
219226990|NCT01178372|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
219226991|NCT01178372|DRUG|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
219226992|NCT03346733|DIETARY_SUPPLEMENT|Psyllium Fibre|Viscous soluble psyllium fibre
219226993|NCT00681109|DRUG|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
219226994|NCT00681109|DRUG|Placebo|custom eye drop to be applied three times a day in both eyes for three months
219226995|NCT00681109|DRUG|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
219226996|NCT02599025|DEVICE|Innowalk cycling system|Innowalk is a unique, motorized medical device
219713020|NCT06543576|BIOLOGICAL|Pembrolizumab|Given IV
219713021|NCT06543576|OTHER|Questionnaire Administration|Ancillary study
219713022|NCT06138743|DRUG|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
219713023|NCT06138743|DRUG|Placebo|calculated volume to match active treatment by IV infusion
219131398|NCT01306669|BIOLOGICAL|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
219131399|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant immunotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
219131400|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant chemotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
219131401|NCT01159158|DRUG|Nateglinide|Nateglinide Tablets 120 mg
219131402|NCT03211598|PROCEDURE|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
219713024|NCT05748626|DEVICE|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
219713025|NCT05748626|PROCEDURE|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
219713026|NCT06573229|DIETARY_SUPPLEMENT|Aminolife Plus by Piemme Pharmatech, Italy|A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)
219131403|NCT01348321|DRUG|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
219131404|NCT04510337|DRUG|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
219131405|NCT04510337|DRUG|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
219131406|NCT04236713|OTHER|Dietary intervention 1|Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.
219131407|NCT04236713|OTHER|Dietary intervention 2|Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
219131408|NCT02485964|OTHER|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
219713027|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
219713028|NCT03562572|PROCEDURE|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
219131409|NCT01474538|DRUG|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
219131410|NCT01474538|DRUG|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
219713029|NCT03562572|OTHER|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
219713030|NCT06179667|BEHAVIORAL|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
219713031|NCT05094128|DRUG|Upadacitinib|Tablet; Oral
219713032|NCT06496477|DEVICE|Ayo wearable|Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
219713033|NCT05030818|DRUG|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
219713034|NCT05030818|DRUG|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
219713035|NCT05046353|DRUG|D-serine|Auditory remediation +/-D-serine
219713036|NCT05046353|OTHER|Placebo|Auditory remediation +/-D-serine
219713037|NCT05813288|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
219713038|NCT05813288|DRUG|Placebo|Oral administration of placebo tablet
219713039|NCT04336943|BIOLOGICAL|Durvalumab|Given IV
219713040|NCT04336943|DRUG|Olaparib|Given PO
219131411|NCT06282835|DRUG|Eravacycline Injection|Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
219131412|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment|Compound level meeting
219131413|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
219713041|NCT04336943|OTHER|Quality-of-Life Assessment|Ancillary studies
219713042|NCT04336943|OTHER|Questionnaire Administration|Ancillary studies
219713043|NCT05119569|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
219713044|NCT05119569|DRUG|Placebo|Placebo will be administered orally.
219713045|NCT05045612|OTHER|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
219131414|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
219131415|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
219131416|NCT03645174|DEVICE|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
219131417|NCT03645174|DEVICE|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
219131418|NCT00009685|DRUG|VRC4302|
219131419|NCT01456780|DRUG|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
219226997|NCT02599025|DEVICE|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
219226998|NCT02504801|DRUG|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
219713046|NCT00434434|DRUG|omalizumab|Aged Liquid; subcutaneous repeating dose
219226999|NCT04016207|DRUG|Guanfacine|regular treatment
219227000|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
219227001|NCT04660799|DRUG|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
219713047|NCT00434434|DRUG|omalizumab|Lyophilized; subcutaneous repeating dose
219713048|NCT00434434|DRUG|placebo|Subcutaneous repeating dose
219713049|NCT04312100|OTHER|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
219713050|NCT03495518|OTHER|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
219713051|NCT03495518|OTHER|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
219713052|NCT06032637|PROCEDURE|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
219131420|NCT01456780|DRUG|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
219131421|NCT01456780|DRUG|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
219131422|NCT03298932|PROCEDURE|Aortic valve surgery|Aortic valve surgery
219131423|NCT04285996|PROCEDURE|PET Scan|
219131424|NCT03095911|OTHER|News items with spin|Interpretation of news items with spin
219131425|NCT03095911|OTHER|News items without spin|Interpretation of news items without spin
219131426|NCT04413279|PROCEDURE|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
219131427|NCT04413279|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
219131428|NCT04372992|OTHER|Timing of stoma closure|Defining the best timing of stoma closure in relation to adjuvant therapy compliance
219131429|NCT01601314|DRUG|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
219131430|NCT01601314|OTHER|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
219131431|NCT06435572|OTHER|Suction|Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
219131432|NCT02416674|PROCEDURE|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
219227002|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
219227003|NCT04660799|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
219227004|NCT04660799|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m\^2
219227005|NCT04660799|DRUG|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m\^2
219227006|NCT04660799|DRUG|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
219227007|NCT04660799|DRUG|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
219713053|NCT06032637|PROCEDURE|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
219131433|NCT02416674|DRUG|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
219131434|NCT02214667|BEHAVIORAL|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
219131435|NCT02214667|BEHAVIORAL|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
219131436|NCT02214667|BEHAVIORAL|Jail and community-based behavioral health services|Existing behavioral health service programs
219131437|NCT01501929|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
219131438|NCT01501929|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
219131439|NCT01501929|PROCEDURE|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
219131440|NCT01501929|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
219131441|NCT01501929|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
219713054|NCT00608179|DRUG|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
219713055|NCT00608179|DRUG|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
219713056|NCT00608179|OTHER|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
219713057|NCT00608179|OTHER|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
219713058|NCT02422654|DRUG|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
219713059|NCT01053455|DEVICE|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
219713060|NCT04235946|OTHER|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
219713061|NCT05081687|DRUG|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
219713062|NCT04004182|DIETARY_SUPPLEMENT|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
219131442|NCT03239925|RADIATION|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
219131443|NCT03239925|RADIATION|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
219131444|NCT02873884|BEHAVIORAL|Case-management|
219131445|NCT05507281|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
219131446|NCT05507281|PROCEDURE|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
219131447|NCT05507281|PROCEDURE|Control|General anesthesia
219131448|NCT04813393|OTHER|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
219131449|NCT03120676|DRUG|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
219131450|NCT02271048|DEVICE|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
219713063|NCT02290184|BEHAVIORAL|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
219131451|NCT00326027|DRUG|Pantoprazole|Efficacy of Pantoprazole
219131452|NCT00926393|DRUG|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
219131453|NCT00926393|DRUG|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
219131454|NCT00716664|OTHER|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
219131455|NCT00716664|OTHER|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
219131456|NCT01935258|OTHER|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
219131457|NCT01935258|OTHER|care as usual|usual care of the general practitioner
219131458|NCT00415675|PROCEDURE|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
219131459|NCT06628492|DEVICE|stainless steel printed surgical guide|the patient will wear the stainless steel surgical guide for the insertion of one implant
219131460|NCT06628492|DEVICE|resin printed surgical guide|the patient will wear the resin surgical guide for insertion of adjacent another implant implant
219131461|NCT05349864|DRUG|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
219713064|NCT02290184|BEHAVIORAL|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
219713065|NCT06184282|DRUG|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
219131462|NCT05349864|DRUG|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
219131463|NCT05349864|DRUG|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
219131464|NCT02333630|OTHER|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
219131465|NCT02333630|OTHER|Asthma education|A website with links to written asthma education and videos
219131466|NCT03425292|DRUG|Temozolomide|concomitant and 5-day adjuvant temozolomide
219131467|NCT03425292|RADIATION|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
219131468|NCT03425292|DRUG|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
219713066|NCT06184282|DRUG|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
219713067|NCT03345823|DRUG|Upadacitinib|Oral; Tablet
219713068|NCT03345823|DRUG|Placebo for Upadacitinib|Oral; Tablet
219713069|NCT01180062|DRUG|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
219713070|NCT01180062|DRUG|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
219131469|NCT03425292|DRUG|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
219131470|NCT03425292|DRUG|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
219131471|NCT03425292|DRUG|5-day Temozolomide|150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
219131472|NCT03425292|DRUG|5-day Temozolomide|100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
219131473|NCT03425292|DRUG|Lomustine|100 mg/m\^2 oral, on Day 1 of each 6 week course
219131474|NCT03425292|DRUG|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
219131475|NCT02223793|BEHAVIORAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
219131476|NCT02223793|BEHAVIORAL|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
219131477|NCT02223793|BEHAVIORAL|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
219131478|NCT05312541|PROCEDURE|pre emptive local anaesthetic wound infiltration|Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
219131479|NCT02287649|OTHER|blood sample|
219131480|NCT00165139|DRUG|Vincristine|Described under detailed description
219131481|NCT00165139|DRUG|Cyclophosphamide|Described under detailed description
219131482|NCT00165139|DRUG|Adriamycin|Described under detailed description
219131483|NCT00165139|DRUG|Etoposide (VP-16)|Described under detailed description
219227008|NCT04660799|DRUG|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
219227009|NCT05017909|BEHAVIORAL|Face to face education|Face to face education techniques on the acquisition of the mothering Role
219131484|NCT00165139|DRUG|Cisplatin|Described under detailed description
219131485|NCT00165139|DRUG|Carboplatin|Described under detailed description
219131486|NCT00165139|DRUG|Melphalan|Described under detailed description
219131487|NCT00165139|DRUG|Ifosfamide|Described under detailed description
219131488|NCT00165139|DRUG|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
219131489|NCT00165139|DRUG|Mesna|Described under detailed description
219131490|NCT05822271|PROCEDURE|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
219131491|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
219131492|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
219227010|NCT05017909|BEHAVIORAL|Web based education|web based education techniques on the acquisition of the mothering Role
219227011|NCT05017909|BEHAVIORAL|No education|Control group will not be educated
219227012|NCT03941509|BEHAVIORAL|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
219227013|NCT05652907|DRUG|FSD201|Tablets for oral administration.
219227014|NCT05652907|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
219713071|NCT01180062|DRUG|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
219131493|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
219131494|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
219131495|NCT02611414|DEVICE|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
219131496|NCT02611414|DEVICE|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
219131497|NCT03083522|DRUG|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219131498|NCT03083522|DRUG|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219131499|NCT00248612|DRUG|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
219131500|NCT00248612|BEHAVIORAL|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
219131501|NCT00248612|OTHER|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
219131502|NCT00248612|OTHER|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
219131503|NCT00660374|DRUG|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
219131504|NCT00660374|DRUG|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
219131505|NCT03818061|DRUG|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
219131506|NCT03818061|DRUG|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
219131507|NCT02321748|DRUG|Montelukast|
219131508|NCT02321748|DRUG|ASP2151|
219227015|NCT02449785|DEVICE|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
219227016|NCT02449785|DEVICE|CT measurements of lung morphological changes in cystic fibrosis|
219227017|NCT01714076|OTHER|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
219227018|NCT04406532|BEHAVIORAL|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
219227019|NCT04406532|BEHAVIORAL|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
219227020|NCT01354288|OTHER|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
219227021|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
219131509|NCT03353272|BEHAVIORAL|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
219131510|NCT06417489|DRUG|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
219227022|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
219131511|NCT06417489|DRUG|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
219131512|NCT06548334|COMBINATION_PRODUCT|Advanced Physiotherapy|The physiotherapist used the regression techniques for 1 hour of session 2 times for 8 weeks. The caudal component involved the spinous process of the treated segment touching the therapist's hand and not applying force as though mobilising the segment at grade 2. These were applied if there is a suspected case of a posterolateral disc prolapse where the aim is to increase the diameter of the foramen and decrease the tension exerted on the nerve root. Applied posteroanterior was used to distract the anterior intervertebral end plate and to approximate the posterior end plates so as to pull back the protruded nuclear material by creating a negative pressure.
219131513|NCT06548334|OTHER|Conventional Physiotherapy Techniques|In traditional physiotherapy, the patient underwent two sessions per week for eight weeks. Each session lasted one hour and included 20minutes of TENS treatment. The flexibility exercises consisted of hamstring stretches and single and double knee-to-chest stretches. The strengthening exercises were partial sit-ups, quadruped lifts, and double leg hold; pelvic tilts were performed with 10-15 repetitions, each held for 20-30 seconds and repeated three times.
219227023|NCT05589415|DEVICE|High-definition Transcranial Direct Current Stimulation|"High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps."
219227024|NCT05589415|DEVICE|Conventional Transcranial Direct Current Stimulation|Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
219227025|NCT02652845|BEHAVIORAL|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
219227026|NCT03471117|DRUG|Pioglitazone|Pioglitazone 15mg daily for 1 month
219227027|NCT03471117|OTHER|Placebo|Placebo pills for 1 month
219227028|NCT00647465|DRUG|vaccine|IFNalpha 2b
219227029|NCT00647465|DRUG|Placebo|Placebo
219227030|NCT04188522|DIAGNOSTIC_TEST|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
219713072|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
219713073|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
219713074|NCT01069939|DRUG|Esomeprazole|20mg, capsule, 72 weeks
219227031|NCT04127513|DRUG|Ammonium Lactate|12% ammonium lactate moisturizing cream
219227032|NCT04127513|DRUG|Urea|10% urea moisturizing cream
219713075|NCT01069939|DRUG|Placebo|Placebo, capsule, 72 weeks
219713076|NCT03755817|DEVICE|SCENAR application|Active SCENAR application on the painful area
219713077|NCT03755817|DEVICE|SCENAR application with the device off|Placebo SCENAR application on the painful area
219227033|NCT00461656|DRUG|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
219713078|NCT01994031|DRUG|Paclitaxel liposome injection|
219713079|NCT01994031|DRUG|Paclitaxel injection|
219713080|NCT01890993|DRUG|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
219713081|NCT01390506|DRUG|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
219713082|NCT01390506|DRUG|Placebo|0,9% sodium chloride is administered intravenously
219713083|NCT00555854|BEHAVIORAL|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
219713084|NCT04923451|DEVICE|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
219131514|NCT01688973|DRUG|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
219131515|NCT01688973|OTHER|Laboratory Biomarker Analysis|Correlative studies
219131516|NCT01688973|DRUG|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
219131517|NCT02606292|PROCEDURE|Photoacoustic endoscopy|
219131518|NCT02606292|PROCEDURE|Endoscopic ultrasound (standard of care)|
219131519|NCT02606292|PROCEDURE|Endoscopic surgery (standard of care)|
219131520|NCT04697251|DIAGNOSTIC_TEST|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
219131521|NCT06080373|BEHAVIORAL|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
219131522|NCT06080373|BEHAVIORAL|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
219227034|NCT05732142|OTHER|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
219131523|NCT03789799|OTHER|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
219131524|NCT03789799|OTHER|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
219131525|NCT03771846|DRUG|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219131526|NCT03771846|DRUG|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
219713085|NCT04923451|DEVICE|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
219713086|NCT00385840|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
219131527|NCT02306564|DRUG|Cabergoline|given to patients at high risk for OHSS
219131528|NCT00017004|RADIATION|External Beam Radiation Therapy|Undergo radiation
219131529|NCT00017004|DRUG|Cisplatin|Given IV
219131530|NCT00017004|RADIATION|Internal Radiation Therapy|Undergo radiation
219131531|NCT00017004|BIOLOGICAL|Epoetin Alfa|Given SC
219227035|NCT01028976|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
219227036|NCT01028976|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
219227037|NCT06111014|DRUG|Latozinemab|All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
219713087|NCT00385840|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
219713088|NCT04227834|BEHAVIORAL|Health hygiene education|A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
219713089|NCT04587817|COMBINATION_PRODUCT|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
219713090|NCT02823119|DEVICE|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
219131532|NCT00186420|DRUG|Taxotere|
219131533|NCT01149681|DRUG|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
219131534|NCT05612659|PROCEDURE|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
219131535|NCT05612659|PROCEDURE|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
219131536|NCT04484402|BIOLOGICAL|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
219131537|NCT04484402|BIOLOGICAL|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
219131538|NCT04484402|OTHER|standard treatment|Standard treatment according to the Clinical protocols
219131539|NCT02993471|DRUG|Drug Cocktail|Administered orally
219131540|NCT02993471|DRUG|Ixekizumab|Administered SC
219131541|NCT03426696|BEHAVIORAL|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
219131542|NCT05001828|DRUG|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
219131543|NCT04531488|PROCEDURE|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
219131544|NCT04531488|OTHER|Training with Powered Wheel Chair|Training with Powered Wheel Chair
219131545|NCT03510091|BEHAVIORAL|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
219131546|NCT00304980|DRUG|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
219131547|NCT05025124|DEVICE|Entia Liberty|Home monitoring system
219131548|NCT02013986|DRUG|etomidate|0.3mg/kg IV only once during induction of general anesthesia
219131549|NCT02013986|DRUG|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
219131550|NCT02013986|DRUG|propofol|2mg/kg IV only once during induction of general anesthesia
219131551|NCT02321813|BEHAVIORAL|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
219131552|NCT02321813|OTHER|placebo control|Quality of life measurement
219131553|NCT00449657|DRUG|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
219131554|NCT00449657|PROCEDURE|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
219131555|NCT00449657|DRUG|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 \& 9
219131556|NCT00449657|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 \& 9
219131557|NCT03487042|DRUG|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
219131558|NCT03318536|DRUG|Granisetron Hydrochloride|Patients received Granisetron.
219131559|NCT03318536|DRUG|No Granisetron|Patients who did not receive Granisetron.
219131560|NCT06169904|DRUG|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
219131561|NCT02740530|DEVICE|Magstim® Rapid 2 machine|See Arms description
219131562|NCT02000999|OTHER|brushing of bile duct strictures for cytology|
219131563|NCT04097626|OTHER|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
219131564|NCT04097626|OTHER|no nutrition education|This group will not receive nutrition education.
219131565|NCT01916889|OTHER|RACY test|
219131566|NCT06106087|OTHER|Mixed methods quality improvement intervention|Quality improvement training for frontline PCH staff
219131567|NCT00248391|BEHAVIORAL|upright feeding|
219131568|NCT05949554|OTHER|Ketamine infusion|"Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA).~EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused.~The duration varies depending on patient's weight.~Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours."
219131569|NCT03172533|DRUG|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
219131570|NCT03172533|DRUG|Placebo oral capsule|placebo
219131571|NCT00016913|DRUG|carboplatin|AUC=6 week one of each 4 week cycle
219131572|NCT00016913|DRUG|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
219131573|NCT00016913|DRUG|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
219131574|NCT00016913|RADIATION|radiation therapy|77.4 Gy in 1.8 Gy fractions
219131575|NCT00016913|DRUG|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
219131576|NCT01971788|DEVICE|Optical Coherence Tomography of the infarct related artery|
219131577|NCT05348226|DIAGNOSTIC_TEST|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
219131578|NCT00588666|DRUG|Bevacizumab|
219131579|NCT00588666|DRUG|Carboplatin|
219131580|NCT00588666|DRUG|Gemcitabine|
219131581|NCT00964314|OTHER|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
219131582|NCT05522699|BEHAVIORAL|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
219131583|NCT05522699|BEHAVIORAL|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
219131584|NCT03804086|PROCEDURE|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
219131585|NCT03804086|PROCEDURE|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
219131586|NCT06350045|COMBINATION_PRODUCT|PCNL|percutaneous nephrolithotomy
219131587|NCT01693419|DRUG|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
219131588|NCT03150563|OTHER|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
219131589|NCT02823548|DRUG|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
219227038|NCT05353296|BEHAVIORAL|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
219227039|NCT05353296|BEHAVIORAL|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
219227040|NCT05353296|DEVICE|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
219131590|NCT02823548|DRUG|Placebo|Placebo
219131591|NCT02002819|DRUG|levetiracetam|
219131592|NCT03856541|DRUG|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
219131593|NCT05622188|OTHER|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
219131594|NCT05622188|OTHER|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
219131595|NCT05622188|OTHER|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
219131596|NCT05634317|BEHAVIORAL|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
219713091|NCT02823119|DEVICE|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
219713092|NCT03982537|DRUG|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
219131597|NCT05634317|BEHAVIORAL|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
219713093|NCT03982537|RADIATION|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
219713094|NCT00692796|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
219713095|NCT02970045|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
219131598|NCT04662840|PROCEDURE|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
219131599|NCT04662840|PROCEDURE|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
219131600|NCT04662840|PROCEDURE|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
219131601|NCT04582877|DEVICE|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
219131602|NCT04630652|DRUG|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
219131603|NCT04630652|PROCEDURE|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
219227041|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
219227042|NCT05681351|DRUG|Olezarsen|Administered as SC injection.
219227043|NCT04349436|BIOLOGICAL|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
219227044|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
219713096|NCT02970045|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
219713097|NCT02970045|OTHER|Medical Chart Review|Review of medical chart
219713098|NCT02970045|OTHER|Quality-of-Life Assessment|Ancillary studies
219131604|NCT04630652|PROCEDURE|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
219131605|NCT01501435|DRUG|CJ-30039|single dose
219131606|NCT01501435|DRUG|fenofibric acid|single dose
219131607|NCT03055767|DRUG|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
219131608|NCT03055767|OTHER|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
219131609|NCT02759731|DRUG|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
219227045|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
219227046|NCT06302439|OTHER|No Intervention for this observational study|No Intervention for this observational study
219227047|NCT02329639|GENETIC|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
219713099|NCT02970045|OTHER|Questionnaire Administration|Ancillary studies
219713100|NCT02414061|DIETARY_SUPPLEMENT|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
219713101|NCT02414061|OTHER|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
219227048|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
219713102|NCT03504553|OTHER|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
219713103|NCT01785901|OTHER|without interventions|without interventions
219713104|NCT00002129|DRUG|Vesnarinone|
219713105|NCT01017250|RADIATION|Stereotactic Radiosurgery (SRS)|Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
219713106|NCT01017250|DRUG|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
219713107|NCT05548894|DEVICE|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
219713108|NCT05548894|DEVICE|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
219713109|NCT05548894|DEVICE|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
219713110|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
219227049|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
219227050|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
219131610|NCT03121131|OTHER|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
219131611|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
219131612|NCT03121131|OTHER|No clinical exam findings|No clinical exam findings are given to the radiologists
219131613|NCT05982600|DIAGNOSTIC_TEST|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
219131614|NCT05982600|DIAGNOSTIC_TEST|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
219131615|NCT05982600|DIAGNOSTIC_TEST|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
219131616|NCT05982600|DIAGNOSTIC_TEST|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
219131617|NCT02661997|BEHAVIORAL|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
219131618|NCT02661997|BEHAVIORAL|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
219131619|NCT00763282|BEHAVIORAL|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
219131620|NCT00763282|BEHAVIORAL|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
219131621|NCT00763282|BEHAVIORAL|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
219131622|NCT04370782|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
219131623|NCT04370782|DRUG|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
219131624|NCT04370782|DRUG|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
219131625|NCT04370782|DRUG|Doxycycline|Doxycycline 200 mg once daily for 5 days
219131626|NCT06495411|OTHER|pranayama-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
219227051|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
219227052|NCT02276599|PROCEDURE|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
219227053|NCT02426255|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
219131627|NCT06495411|OTHER|deep breathing-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
219131628|NCT06495411|OTHER|control|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
219131629|NCT03245060|BEHAVIORAL|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
219131630|NCT01912703|OTHER|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
219131631|NCT00507637|DRUG|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
219131632|NCT02364518|PROCEDURE|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
219131633|NCT02427737|BEHAVIORAL|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
219131634|NCT06189742|BIOLOGICAL|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
219227054|NCT04693741|PROCEDURE|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
219713111|NCT06978842|DEVICE|Wearable EEG headband for passive brain signal acquisition|This intervention involves the use of non-invasive, consumer-grade wearable EEG headbands to passively record brain activity from individuals with epilepsy in their natural home environments. The devices include BrainBit Headband, BrainBit Mindo, BrainBit Headphones, Muse 2, and Muse S. These devices transmit EEG signals via Bluetooth to a mobile application developed by the sponsor. The app provides real-time feedback on signal quality and securely uploads data to the cloud for offline analysis. The wearable devices are used solely for passive data acquisition and are not being evaluated for safety or therapeutic effectiveness in this study. No changes are made to clinical care or treatment.
219713112|NCT05406232|PROCEDURE|Biopsy|Undergo tumor punch biopsy
219713113|NCT05406232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219713114|NCT05406232|RADIATION|Radiation Therapy|Undergo RT
219713115|NCT06827457|DRUG|GenSci120|Administered SC.
219713116|NCT06827457|DRUG|Placebo|Administered SC.
218986938|NCT04795960|DIETARY_SUPPLEMENT|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
219131635|NCT06378879|DRUG|Propofol 100 MG in 10 ML Injection|Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
219131636|NCT00297765|DRUG|Tacrolimus, Prograf®|
219131637|NCT02258295|DRUG|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
219131638|NCT02258295|DRUG|Saline|Saline
219131639|NCT02782182|DRUG|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
219713117|NCT03603613|BEHAVIORAL|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
219131640|NCT01281761|DRUG|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
219131641|NCT00335556|DRUG|Doxorubicin Hydrochloride|Given IV
219131642|NCT00335556|DRUG|Irinotecan Hydrochloride|Given IV
219131643|NCT00335556|PROCEDURE|Conventional Surgery|Patients undergo resection
219131644|NCT00335556|DRUG|Cyclophosphamide|Given IV
218986939|NCT04795960|DIETARY_SUPPLEMENT|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
219131645|NCT00335556|DRUG|Etoposide|Given IV
219131646|NCT00335556|DRUG|Carboplatin|Given IV
219131647|NCT00335556|BIOLOGICAL|Dactinomycin|Given IV
219131648|NCT00335556|DRUG|Vincristine Sulfate|Given IV
219131649|NCT00335556|RADIATION|Radiation Therapy|Undergo radiotherapy
219131650|NCT00335556|OTHER|Laboratory Biomarker Analysis|Correlative studies
219131651|NCT03898687|DEVICE|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
219227055|NCT04693741|PROCEDURE|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
219227056|NCT04693741|PROCEDURE|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
219227057|NCT03175159|BEHAVIORAL|IMPACT|Ten counseling sessions
219227058|NCT03175159|BEHAVIORAL|Standard of Care|Two counseling sessions
219227059|NCT02111551|DRUG|DMXB-A 150 mg|
219227060|NCT02111551|OTHER|placebo|
219131652|NCT05893043|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
219131653|NCT05893043|OTHER|Placebo|Participants will receive matching placebo oral capsules.
219131654|NCT04018417|DRUG|Amphotericin B|Drug concentration: 0.255 μg/mL
219227061|NCT02111551|DRUG|DMXB-A 75 mg|
219227062|NCT04806100|DEVICE|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
219227063|NCT00391170|DRUG|Topical Dexamethasone|dexamethasone 0.01%
219227064|NCT00391170|DRUG|Placebo|Placebo
219713118|NCT03603613|BEHAVIORAL|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
219713119|NCT00535470|DRUG|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
219713120|NCT01235377|OTHER|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
219713121|NCT01416779|BEHAVIORAL|Writing Intervention|Finding Balance Writing Intervention
219131655|NCT02155686|DEVICE|Biosensors|Device: Biometric sensors; Home automation; telecare
219131656|NCT02155686|DEVICE|Home automation|
219131657|NCT06446674|PROCEDURE|mini monaka|mini monaka,perforated plugs
219131658|NCT06099821|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
219131659|NCT06099821|DRUG|Regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
219227065|NCT02494336|PROCEDURE|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
219227066|NCT02494336|PROCEDURE|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
219227067|NCT02494336|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
219227068|NCT04644887|OTHER|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA \< 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) \>2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
219227069|NCT04644887|OTHER|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (\~2%), normal fat cheese (\~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
219227070|NCT02911961|DRUG|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
219227071|NCT06030817|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
219131660|NCT06099821|DRUG|Apatinib|Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
219131661|NCT05767073|BEHAVIORAL|Lifestyle InterVEntion (LIVE)|"The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people."
219131662|NCT01339702|OTHER|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
219131663|NCT03545789|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
219713122|NCT00872742|BEHAVIORAL|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
219713123|NCT00872742|BEHAVIORAL|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
219713124|NCT03860155|BIOLOGICAL|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
219713125|NCT03913247|OTHER|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
219713126|NCT06512987|OTHER|technology-driven, interactive ICU diary|Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
219713127|NCT02056132|OTHER|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
219713128|NCT05626088|OTHER|No Intervention|This is a non-interventional study.
219713129|NCT02647177|OTHER|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
219131664|NCT04872712|PROCEDURE|Press needles|Manual acupuncture using press needles
219131665|NCT04872712|PROCEDURE|Filiform Needles|Manual acupuncture using filiform needles
219131666|NCT05753709|PROCEDURE|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
219131667|NCT05753709|PROCEDURE|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
219713130|NCT05899114|OTHER|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~1. A structured pharmacotherapeutic analysis~2. A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~3. An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~4. A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
219713131|NCT03684889|BIOLOGICAL|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
219713132|NCT03684889|BIOLOGICAL|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
219131668|NCT05753709|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
219131669|NCT03114722|DRUG|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
219131670|NCT03114722|DRUG|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
219131671|NCT01878890|DRUG|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
219131672|NCT01878890|DRUG|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
219131673|NCT01878890|DRUG|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
219131674|NCT01878890|DRUG|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
219131675|NCT02506426|PROCEDURE|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
219713133|NCT06443632|BEHAVIORAL|WASPE Sleep Adjustment Protocol|Parents are instructed to implement the WASPE protocol (Watching videos, Activities outdoors, Stimulation to stay awake, Playing with toys, and Eating snacks) to keep the child awake from morning until the scheduled RT slot (14:00-16:00), thereby inducing natural deep sleep during RT without pharmacologic sedation. Treatment setup is verified with CBCT and monitored in real time using OSMS with a 5-mm motion threshold.
219713134|NCT06443632|DRUG|Chloral Hydrate|Oral or rectal chloral hydrate (typically 30-50 mg/kg, maximum 1 g) administered approximately 30 minutes before each RT fraction per institutional pediatric sedation protocol. Vital signs are monitored continuously. CBCT and OSMS are used as in the experimental arm.
219713135|NCT06815692|BEHAVIORAL|Psychoeducation|Focus on understanding mechanisms of concussion
219713136|NCT06815692|BEHAVIORAL|Physiotherapy|Gradual training and physical exercises
219713137|NCT06815692|BEHAVIORAL|Treatment of tinnitus and increased sound sensitivity|Treatment given individually or in groups
219713138|NCT06815692|BEHAVIORAL|Vision training and examination|Training and examination by a neuro-optometrist
219713139|NCT06815692|BEHAVIORAL|Sleep guidance and education|Counselling to achieve better sleep and reduce fatigue.
219713140|NCT06815692|BEHAVIORAL|Mindfulness with a cognitive therapeutic approach|Training by certified mindfulness instructor
219713141|NCT06815692|BEHAVIORAL|Employment-oriented intervention|The Concussion Team therapists work with a patient's employer to facilitate a gradual return to normal working hours.
219131676|NCT02506426|PROCEDURE|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
219131677|NCT04636086|DRUG|Cholecalciferol|Vitamin D supplementation
219131678|NCT04636086|OTHER|Placebo|Placebo comparator
219713142|NCT06815692|BEHAVIORAL|Energy management and graded exercise|Counselling to achieve more energy and vitality.
219713143|NCT06815692|OTHER|Neuropsychological counseling|Talks with a neuropsychologist about mTBI sequelae.
219713144|NCT06811038|DEVICE|iCanQuit Smartphone App Smoking Cessation Program|Receive access to iCanQuit app, with daily push notifications
219713145|NCT06811038|DRUG|Nicotine Gum|Receive nicotine replacement therapy gum
219713146|NCT06811038|DRUG|Nicotine Patch|Receive nicotine replacement therapy patch(es)
219713147|NCT06811038|DRUG|Nicotine Lozenge|Receive nicotine replacement therapy lozenge(s)
219713148|NCT06811038|OTHER|Survey Administration|Ancillary studies
219713149|NCT06811038|OTHER|Interview|Ancillary studies
219713150|NCT06597058|DRUG|MAR|Once-daily tablet
219713151|NCT06086054|BEHAVIORAL|Navigation and EMR referral to childcare facility|See arm description
219713152|NCT06983210|DRUG|Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy|To explore the efficacy and safety of the combination of tamivarotene (AM80), gemcitabine, cisplatin, and nivolumab in the treatment of patients with untreated unresectable or recurrent urothelial cancer
219713153|NCT06614127|DEVICE|Dexcom G7® sensor placed in upper arm and positioned over deltoid|"For the subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh."
219713154|NCT06614127|DEVICE|Dexcom G7® sensor placed in anterior thigh|"For the subjects with Dexcom G7® sensor place in anterior thigh cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh."
219713155|NCT06132802|PROCEDURE|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
219131679|NCT01886469|DRUG|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
219131680|NCT01886469|DRUG|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
219131681|NCT01886469|DRUG|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
219131682|NCT02974010|DRUG|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
219131683|NCT02974010|DRUG|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
219131684|NCT02974010|DRUG|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
219131685|NCT02974010|DRUG|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
219131686|NCT05062590|OTHER|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
219131687|NCT00154713|BIOLOGICAL|CEA pulsed dendritic cells|
219131688|NCT02519296|BEHAVIORAL|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
219131689|NCT02519296|BEHAVIORAL|Observation|fMRI.
219131690|NCT02519296|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the brain
219131691|NCT06076343|BEHAVIORAL|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
219131692|NCT02214108|OTHER|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
219131693|NCT04745702|COMBINATION_PRODUCT|Low Calorie Meals Rich in Plant Components|Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
219131694|NCT04745702|COMBINATION_PRODUCT|Low Calorie Balanced Meals|Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
219131695|NCT00320489|DRUG|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
219131696|NCT00320489|DRUG|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
219131697|NCT03363256|BEHAVIORAL|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
219131698|NCT03363256|BEHAVIORAL|TAU|Standard outpatient addiction treatment
219131699|NCT06368609|DIAGNOSTIC_TEST|IgG RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
219131700|NCT06368609|DIAGNOSTIC_TEST|IgG4 RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
219131701|NCT00854139|DRUG|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
219131702|NCT00854139|PROCEDURE|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
219131703|NCT00854139|RADIATION|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
219131704|NCT00854139|PROCEDURE|Bone marrow transplant from a related donor|• Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
219131705|NCT02380729|GENETIC|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
219713156|NCT06132802|PROCEDURE|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
219713157|NCT02101853|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
219713158|NCT02101853|DRUG|Asparaginase|Given IM or IV
219713159|NCT02101853|BIOLOGICAL|Blinatumomab|Given IV
219713160|NCT02101853|DRUG|Cyclophosphamide|Given IV
219713161|NCT02101853|DRUG|Cytarabine|Given IT and IV or SC
219713162|NCT02101853|DRUG|Dexamethasone|Given PO or IV
219713163|NCT02101853|DRUG|Etoposide|Given IV
219713164|NCT02101853|DRUG|Leucovorin Calcium|Given IV or PO
219713165|NCT02101853|DRUG|Mercaptopurine|Given PO
219713166|NCT02101853|DRUG|Methotrexate|Given IT, IV, and PO
219713167|NCT02101853|DRUG|Mitoxantrone|Given IV
219713168|NCT02101853|DRUG|Mitoxantrone Hydrochloride|Given IV
219713169|NCT02101853|DRUG|Pegaspargase|Given IV
219713170|NCT02101853|OTHER|Pharmacological Study|Correlative studies
219713171|NCT02101853|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
219713172|NCT02101853|DRUG|Therapeutic Hydrocortisone|Given IT
219131706|NCT02380729|GENETIC|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
219131707|NCT00124956|DRUG|Doxorubicin|
219713173|NCT02101853|DRUG|Thioguanine|Given PO
219713174|NCT02101853|DRUG|Vincristine|Given IV
219713175|NCT02101853|DRUG|Vincristine Sulfate|Given IV
219713176|NCT03412032|OTHER|assessment|different assessments in both arms
219713177|NCT03966651|DRUG|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
219713178|NCT06371274|DRUG|ATRA|ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
219713179|NCT06371274|DRUG|Toripalimab|Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
219713180|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
219713181|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
219713182|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
219713183|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
219713184|NCT04409002|DRUG|Niraparib|Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
219713185|NCT04409002|DRUG|Dostarlimab|Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
219713186|NCT04409002|RADIATION|Radiation|Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
219713187|NCT05337241|DEVICE|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
219131708|NCT00100659|DRUG|Pegylated Interferon/ribavirin|
219131709|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
219131710|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
219131711|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
219131712|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
219131713|NCT04059562|COMBINATION_PRODUCT|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
219131714|NCT05750095|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
219131715|NCT05750095|BEHAVIORAL|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
219131716|NCT02718118|DEVICE|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
219131717|NCT02718118|DEVICE|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
219131718|NCT00390403|DRUG|R-(-)-gossypol acetic acid|
219131719|NCT00390403|DRUG|temozolomide|
219131720|NCT00390403|GENETIC|gene expression analysis|
219131721|NCT00390403|GENETIC|mutation analysis|
219131722|NCT00390403|GENETIC|protein expression analysis|
219131723|NCT00390403|OTHER|laboratory biomarker analysis|
219131724|NCT00390403|OTHER|pharmacological study|
219131725|NCT00390403|PROCEDURE|adjuvant therapy|
219131726|NCT00390403|RADIATION|radiation therapy|
219131727|NCT02180087|DRUG|Ketoprofen|
219131728|NCT05043818|OTHER||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
219131729|NCT05776576|BEHAVIORAL|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
219131730|NCT05776576|BEHAVIORAL|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
219131731|NCT05776576|OTHER|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
219131732|NCT05685758|OTHER|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
219131733|NCT04555044|DRUG|Clinolipid|Lipid injectable emulsion, USP 20%
219131734|NCT04555044|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
219131735|NCT00013026|BEHAVIORAL|CHF Self-management Education (Web-based Education)|
219131736|NCT01675830|DEVICE|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
219131737|NCT02639962|RADIATION|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
219131738|NCT05402228|DIAGNOSTIC_TEST|temporomandbular joint disorders|no intervention
219131739|NCT04017884|COMBINATION_PRODUCT|Remin Pro Forte|a combination of chemicals with natural products cream .
219131740|NCT04017884|COMBINATION_PRODUCT|Remin Pro|a combination of chemicals
219131741|NCT03192085|DIAGNOSTIC_TEST|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
219131742|NCT03192085|DIAGNOSTIC_TEST|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
219131743|NCT05492474|PROCEDURE|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
219131744|NCT04088188|DRUG|Cisplatin|Given IV
219131745|NCT04088188|DRUG|Gemcitabine|Given IV
219131746|NCT04088188|DRUG|Ivosidenib|Given PO
219131747|NCT04088188|DRUG|Pemigatinib|Given PO
219131748|NCT06510283|DRUG|Taitacept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
219131749|NCT06079593|PROCEDURE|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
219713188|NCT06816186|BEHAVIORAL|multimedia|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, the researcher explained the motivation and process of the research. After the women and their spouses agreed to join the study, they were randomly assigned to the experimental group and the control group. The control group will be given general care guidance, while the experimental group will receive general care and multimedia birth control education intervention, and the mothers and their spouses will download and watch the video through Line, an instant messaging software on their mobile phones.
219713189|NCT06816186|BEHAVIORAL|Usual Care|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, The control group will be given general care guidance,
219713190|NCT04468711|DRUG|Vitamin D|Vitamin D plus topical 1% hydrocortisone cream twice daily
219713191|NCT04468711|DRUG|Placebo|placebo plus topical 1% hydrocortisone cream twice daily
219713192|NCT06656845|DEVICE|Genus, a self-management app for patients with knee osteoarthritis|The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
219713193|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
219713194|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
219713195|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
219713196|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
219713197|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
219713198|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
219713199|NCT02712515|PROCEDURE|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
219713200|NCT02712515|DEVICE|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
219131750|NCT06079593|PROCEDURE|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
219131751|NCT01949584|DEVICE|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
219131752|NCT03588065|DIAGNOSTIC_TEST|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
219131753|NCT03588065|OTHER|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
219713201|NCT02712515|DEVICE|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
219713202|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
219713203|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
219713204|NCT02850835|OTHER|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
219713205|NCT05676554|OTHER|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
219713206|NCT04166019|BEHAVIORAL|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
219713207|NCT04166019|BEHAVIORAL|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
219713208|NCT04166019|BEHAVIORAL|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
219713209|NCT03923075|DRUG|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
219713210|NCT03923075|OTHER|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
219713211|NCT05710679|BIOLOGICAL|Blood sample|"The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the radiochemotherapy in case of incomplete response (PET-CT)"
219713212|NCT04835441|DRUG|ALPN-101|Intravenous infusion via an infusion pump.
219713213|NCT04835441|DRUG|Placebo|Intravenous infusion via an infusion pump.
219227072|NCT04572867|DEVICE|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
219713214|NCT06590454|DRUG|Pyrvinium|Pyrvinium (2 mg/kg) per day for 14 days
219713215|NCT06590454|DRUG|Placebo|Placebo for 14 days
219713216|NCT06590350|OTHER|Clinical nutrition counseling|"In the first phase, all patients admitted to the Departmental Simple Operating Unit Admission Room of Policlinico Universitario A. Gemelli will be screened for NRS-2002 upon admission.~Only patients with NRS-2002 ≥ 3 will subsequently be tracked via the Foundation's computer system (TrackCare®).~The patients will be managed by caregivers who may spontaneously request nutritional counseling, as is currently the case.~Patient data (laboratory tests, medical history, reason for admission, any instrumental test reports) and clinical outcomes (average length of hospitalization, complications, antibiotic therapy use, intensive care admission, mortality, re-hospitalization within 30 days) will be obtained from the Foundation's computer system (TrackCare®) and recorded in a dedicated Excel® spreadsheet.~Costs related to hospitalization and management of any complications will also be assessed."
219713217|NCT06827938|DEVICE|YY-WRY-V01 Infrared thermotherapy apparatus|Infrared hyperthermia（44±1℃） device for 3 consecutive days (times / day), each treatment for 30 minutes After 7-10 days, the lesions of the same target were treated continuously for 2 days (times / day), and then treat every 7-10 days, the method was the same as before. Lesion changes were assessed after 15 treatments.
219713218|NCT06592352|DRUG|Modafinil Generis 100 mg|All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration
219713219|NCT03778671|DRUG|Levobupivacaine|Patients will receive Levobupivacaine 5%
219713220|NCT03778671|DRUG|Dexmedetomidine Injection [Precedex]|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
219713221|NCT03778671|DRUG|fentanyl|Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
219713222|NCT06839989|BIOLOGICAL|Mpox vaccination with MVA-BN|All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.
219713223|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
219713224|NCT05101226|BEHAVIORAL|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
219713225|NCT05101226|BEHAVIORAL|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
219131754|NCT03588065|OTHER|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
219131755|NCT00679276|PROCEDURE|Prolift|surgical repair of vaginal prolapse
219131756|NCT02199145|PROCEDURE|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
219131757|NCT02266810|DEVICE|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
219713226|NCT06366347|DRUG|Abemaciclib|CDK inhibitor, tablet taken orally per protocol.
219713227|NCT06366347|DRUG|Letrozole|Aromatase inhibitor, tablet taken orally per protocol.
219713228|NCT06366347|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
219713229|NCT02900651|DRUG|MAK683|Drug: MAK683
219713230|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
219713231|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
219713232|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
219131758|NCT02266810|PROCEDURE|Sinus Surgery alone|Sinus surgery only, without implant placement
219131759|NCT02266810|DEVICE|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
219131760|NCT05338242|DEVICE|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
219131761|NCT05805345|DEVICE|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
219227073|NCT04572867|DRUG|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
219227074|NCT02436694|DRUG|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
219713233|NCT06248268|OTHER|(Neuro-)psychological assessment|The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
219713234|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
219713235|NCT05032196|DRUG|SAD: 30mg WVE-003|Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
219713236|NCT05032196|DRUG|SAD: 60mg WVE-003|Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
219713237|NCT05032196|DRUG|SAD: 90mg WVE-003|Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
219713238|NCT05032196|DRUG|SAD: Pooled Placebo|Single dose of placebo
219713239|NCT05032196|DRUG|MD: 30mg WVE-003|Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)
219713240|NCT05032196|DRUG|MD: Placebo|Three doses of placebo Q8WK
219713241|NCT06983470|DEVICE|SNM based on visual-motor responses (VMRs)|SNM using parameters that elicited the best VMRs in the stage-1 implant procedure
219713242|NCT06983470|DEVICE|SNM based on sacral evoked responses (SERs)|SNM using parameters that elicited the best SERs in the stage-1 implant procedure
219131762|NCT05805345|DEVICE|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
219131763|NCT05805345|DEVICE|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
219131764|NCT05805345|DEVICE|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
219131765|NCT02648425|DRUG|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
219131766|NCT02648425|DRUG|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
219131767|NCT02648425|DRUG|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
219131768|NCT05286424|PROCEDURE|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
219131769|NCT05112250|DEVICE|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
219131770|NCT04898322|DRUG|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
219131771|NCT04898322|DRUG|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
219131772|NCT04898322|DRUG|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
219131773|NCT04898322|DRUG|Placebo|Placebo
219131774|NCT01496209|BIOLOGICAL|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
219131775|NCT01496209|BIOLOGICAL|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
219713243|NCT03997422|PROCEDURE|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
219713244|NCT06614374|DIETARY_SUPPLEMENT|Low-dose fish oil capsules|Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
219713245|NCT06614374|DIETARY_SUPPLEMENT|High-dose fish oil capsules|Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
219713246|NCT06614374|DIETARY_SUPPLEMENT|Refined olive oil|Participants in the control group will receive 4 g refined olive oil daily
219713247|NCT06670976|PROCEDURE|Biopsy|Undergo tissue biopsy sample collection
219713248|NCT06670976|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219131776|NCT02606734|DEVICE|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
219131777|NCT02702674|DRUG|propranolol|propranolol 20 mg given before induction of labor
219131778|NCT02702674|DRUG|placebo|starch tablet containing no active drug material given before induction of labor
219131779|NCT02702674|DRUG|Oxytocin|intravenous infusion of oxytocin
219227075|NCT02436694|DRUG|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
219227076|NCT00958321|PROCEDURE|computed tomography|
219227077|NCT00958321|RADIATION|3-dimensional conformal radiation therapy|
219713249|NCT06670976|PROCEDURE|Computed Tomography|Undergo CT scan
219131780|NCT05046158|DEVICE|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
219131781|NCT05046158|OTHER|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
219131782|NCT00548119|BIOLOGICAL|NeoCart|autologous tissue implant
219131783|NCT00548119|PROCEDURE|microfracture|microfracture
219131784|NCT01269606|DRUG|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
219227078|NCT00958321|RADIATION|fludeoxyglucose F 18|
219227079|NCT00958321|RADIATION|radiation therapy treatment planning/simulation|
219227080|NCT01360918|DEVICE|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
219227081|NCT01360918|OTHER|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
219713250|NCT06670976|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219713251|NCT06670976|DRUG|Propranolol|Given PO
219713252|NCT06670976|RADIATION|Radiation Therapy|Undergo RT
219713253|NCT06670976|PROCEDURE|Surgical Procedure|Undergo surgery
219713254|NCT06991530|DRUG|Low Molecular Weight Heparine|the LMWH group received injections of 4100 IU/d LMWH from the day of transplant
219713255|NCT04740593|OTHER|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
219227082|NCT00556478|DRUG|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
219131785|NCT01269606|DRUG|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
219131786|NCT01269606|DRUG|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
219131787|NCT01269606|DRUG|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
219131788|NCT04904757|DEVICE|Contrast-enhanced spectral mammography (CESM)|CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
219360587|NCT05634759|DRUG|Azithromycin for Routine Community-wide MDA|"Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan."
219713256|NCT04740593|OTHER|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
219713257|NCT04740593|OTHER|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
219713258|NCT05288985|DEVICE|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
219713259|NCT05288985|DRUG|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
219131789|NCT00580801|DRUG|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
219131790|NCT00580801|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
219131791|NCT00580801|DRUG|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
219131792|NCT00580801|DRUG|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
219131793|NCT01670019|DRUG|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
219131794|NCT01670019|DRUG|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
219131795|NCT05495646|PROCEDURE|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
219131796|NCT00502593|BIOLOGICAL|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
219131797|NCT00502593|BIOLOGICAL|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
219131798|NCT00479141|BEHAVIORAL|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
219131799|NCT00479141|BEHAVIORAL|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
219131800|NCT00516711|DRUG|Sevoflurane|
219131801|NCT01877616|OTHER|diagnostic test|Polysomnography
219131802|NCT01877616|OTHER|Diagnostic test|overnight polysomnography
219131803|NCT05222750|OTHER|Pre-COVID-19|Pre-COVID-19
219131804|NCT05222750|OTHER|COVID-19|COVID-19
219131805|NCT05222750|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
219131806|NCT05603442|PROCEDURE|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
219131807|NCT00988286|PROCEDURE|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
219131808|NCT01724255|OTHER|questionnaire|
219131809|NCT01062880|BEHAVIORAL|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
219131810|NCT02586454|PROCEDURE|Transmuscular quadratus lumborum block|
219131811|NCT02586454|DRUG|morphine|
219131812|NCT02586454|DRUG|ropivacaine|
219131813|NCT06096428|DEVICE|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
219713260|NCT06994988|DEVICE|A-Band (Smart Band-Aid)|The A-Band is a smart band-aid placed on the forearm or other designated site that collects interstitial fluid (ISF) from participants using a microneedle patch. ISF is a natural fluid found between your cells that can inform us on your bodily readings and health. A microneedle patch is a safe alternative to standard fluid collection which uses tiny needles to collect the ISF. The patches consist of single-use, sterile (clean) microneedles created from biocompatible materials. These microneedles penetrate the outermost skin layer without causing significant discomfort, pain, or bleeding.
219713261|NCT06994988|COMBINATION_PRODUCT|Empatica Smartwatch|A commercial smart band will be worn by participants for 22+ hours a day for approximately 7 days. The smart band collects biophysical data from the participant. This includes data on biomarkers, heart rate and heart rate variability, galvanic skin response, step count, and temperature fluctuations, among other biophysical data.
219131814|NCT06096428|DEVICE|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
219131815|NCT01771887|BEHAVIORAL|education program|education program in 6 hours and monitoring phone every 15 days
219131816|NCT05105152|BIOLOGICAL|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
219131817|NCT05407519|DRUG|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
219131818|NCT03802786|DRUG|Imeglimin|Single administration dose of imeglimin
219131819|NCT03601507|DRUG|Alpelisib|Given PO
219131820|NCT03601507|OTHER|Laboratory Biomarker Analysis|Correlative studies
219131821|NCT03601507|OTHER|Pharmacodynamic Study|Correlative studies
219131822|NCT03601507|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219131823|NCT00073138|DRUG|ABT-751|
219131824|NCT00243334|OTHER|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
219131825|NCT01664104|DRUG|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
219131826|NCT03807102|BIOLOGICAL|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
219131827|NCT01043549|DEVICE|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
219131828|NCT01043549|DEVICE|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
219131829|NCT03061513|DRUG|Ubiquinol|Ubiquinol caplets 600mg/day
219131830|NCT03061513|DIETARY_SUPPLEMENT|Placebo|placebo
219131831|NCT02939495|DRUG|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
219131832|NCT02540642|DIETARY_SUPPLEMENT|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
219131833|NCT03478501|BEHAVIORAL|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
219131834|NCT02107014|DRUG|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
219131835|NCT00370799|DRUG|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
219131836|NCT00370799|DRUG|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
219131837|NCT00370799|DRUG|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
219131838|NCT00370799|DRUG|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
219131839|NCT03237936|DRUG|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
219131840|NCT03761784|DRUG|S6G5T-3|Once a day topical cream
219131841|NCT03761784|DRUG|S6G5T-8|Once a day topical cream
219131842|NCT04245319|DRUG|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
219131843|NCT04245319|OTHER|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
219131844|NCT00104754|DRUG|liposomal SN-38|
219131845|NCT02992275|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
219131846|NCT02992275|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
219131847|NCT00478855|DRUG|Tazocin (Piperacillin/Tazobactem)|
219131848|NCT00586339|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
219131849|NCT00586339|BIOLOGICAL|Placebo Control|Intramuscular injection, 3 doses
219131850|NCT03588845|OTHER|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
219131851|NCT03588845|OTHER|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
219131852|NCT06556134|DRUG|Intravenous Iron Sucrose|Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
219131853|NCT06556134|DRUG|Oral Iron|One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
219131854|NCT04428320|PROCEDURE|Pelvic floor injection|Injection of 10 cc of bupivacaine
219131855|NCT03697213|OTHER|Online study|20 hypothetical patient summaries
219131856|NCT02092844|BEHAVIORAL|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
219131857|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
219131858|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
219131859|NCT03462199|DIETARY_SUPPLEMENT|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
219131860|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
219360588|NCT05634759|DRUG|Two Additional Rounds of Azithromycin for Children|An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
219360589|NCT05634759|DRUG|Azithromycin for Second Community-wide MDA|A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
219131861|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
219131862|NCT03462199|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
219131863|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
219131864|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
219131865|NCT05130060|BIOLOGICAL|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
219131866|NCT05130060|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219131867|NCT00295867|DRUG|Zoledronic Acid|Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
219131868|NCT05379868|PROCEDURE|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
219131869|NCT05379868|PROCEDURE|No osteotomies|Standard treatment
219131870|NCT03643042|OTHER|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
219131871|NCT02734628|DRUG|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
219131872|NCT02734628|DRUG|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
219131873|NCT06555523|OTHER|Ultrasound guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
219131874|NCT06555523|OTHER|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
219131875|NCT00143936|BEHAVIORAL|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
219131876|NCT00143936|BEHAVIORAL|Low Calorie Diet|Maintain a low calorie diet
219131877|NCT03610958|DEVICE|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
219131878|NCT05893303|OTHER|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
219131879|NCT05893303|OTHER|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
219131880|NCT05875350|PROCEDURE|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
219131881|NCT05880732|DRUG|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
219131882|NCT05880732|DRUG|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
219131883|NCT00896948|GENETIC|Southern blotting|
219131884|NCT00896948|GENETIC|TdT-mediated dUTP nick end labeling assay|
219131885|NCT00896948|GENETIC|gene expression analysis|
219131886|NCT00896948|GENETIC|protein expression analysis|
219131887|NCT00896948|OTHER|flow cytometry|
219131888|NCT00896948|OTHER|fluorescent antibody technique|
219131889|NCT00896948|OTHER|immunoenzyme technique|
219713262|NCT06994988|BEHAVIORAL|Questionnaires: Hospital Anxiety & Depression Scale, Central Sensitization Inventory, Pain Catastrophizing Scale, Somatic Symptom Scale-8, Pain Self-Efficacy Questionnaire-10, Athens Insomnia Scale|HADS- measures anxiety and depression (0-21, higher scores signify greater pathology); CSI- measures central sensitization (0-100, higher scores signify greater central sensitization, PCS- measures catastrophizing (0-52, higher scores signify greater catastrophization), SSS-8- measures somatization (0-32, higher scores signify greater somatization), PSEQ-10- measures self-efficacy (0-60, with lower scores signifying low self-efficacy), AIS- measures sleep (0-28, with higher scores signifying greater sleep dysfunction)
219713263|NCT06748066|BEHAVIORAL|RISE-ACL development|A meeting will be organized with all expert panel members to select relevant items. Before the meeting, experts will review a literature on ACL reconstruction return to sport processes. During round 1, the chairperson will ask panel members to suggest items to be included in the scale. Items with agreement from 5 or more members will be included in round 2. In round 2, redundant items will be identified and grouped, and new items will be added based on the literature and expert experience. Selected items will be randomly ordered to create a preliminary 6-level Likert scale (0 = strongly disagree, 5 = strongly agree).
219131890|NCT00896948|OTHER|immunohistochemistry staining method|
219131891|NCT00896948|OTHER|immunologic technique|
219131892|NCT00029926|DRUG|2-deoxy-2 [F-18] fluoro-2-d-glucose|
219360590|NCT02317562|DRUG|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
219131893|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
219131894|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
219131895|NCT05121506|COMBINATION_PRODUCT|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
219360591|NCT00987363|OTHER|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
219360592|NCT03319862|PROCEDURE|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
219131896|NCT02642419|DRUG|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
219131897|NCT02642419|DRUG|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
219131898|NCT05582057|BEHAVIORAL|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
219131899|NCT00223314|BEHAVIORAL|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
219131900|NCT03350737|OTHER|Physical rehabilitation|Standard treadmill exercise session
219131901|NCT03350737|DRUG|Heparin|Heparin i.v.
219131902|NCT03350737|OTHER|Placebo|Sodium Chloride 0.9% i.v.
219131903|NCT06313138|OTHER|The Individual and Family Enhancement Program|The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
219131904|NCT02050958|DRUG|OXP001|
219131905|NCT02050958|DRUG|Ibuprofen|
219131906|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
219131907|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
219131908|NCT00197236|BIOLOGICAL|Havrix™|2 intramuscular injections, 6 months apart
219131909|NCT00197236|BIOLOGICAL|Infanrix™|1 intramuscular injection
219131910|NCT00197236|BIOLOGICAL|ActHIB™|1 intramuscular injection
219131911|NCT04034901|DEVICE|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2"
219131912|NCT00746330|DRUG|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
219131913|NCT00746330|DRUG|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
219131914|NCT00746330|DRUG|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
219131915|NCT00746330|DRUG|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
219227083|NCT00556478|DRUG|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
219227084|NCT02733484|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
219227085|NCT02733484|DIETARY_SUPPLEMENT|Placebo|the patients in this arm will receive placebo intervention
219227086|NCT04864782|DRUG|QL1604|Intravenous Infusion
219131916|NCT00746330|DRUG|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
219131917|NCT02733250|BIOLOGICAL|Pembrolizumab|200mg IV Day 1 of each 21 cycles
219131918|NCT02733250|DRUG|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
219131919|NCT01114919|BEHAVIORAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
219131920|NCT01114919|BEHAVIORAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
219227087|NCT04864782|DRUG|Paclitaxel injection|Intravenous Infusion
219227088|NCT04864782|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
219131921|NCT04851730|PROCEDURE|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
219131922|NCT04851730|DEVICE|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
219131923|NCT01981850|BIOLOGICAL|RO7490677|IV infusion
219131924|NCT01981850|DRUG|Ruxolitinib|IV infusion
219131925|NCT00909935|DRUG|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
219131926|NCT03250104|OTHER|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
219131927|NCT03250104|OTHER|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
219131928|NCT01649635|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
219131929|NCT01649635|DRUG|Prednisone|Pharmaceutical form: tablet Route of administration: oral
219131930|NCT01649635|DRUG|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
219131931|NCT01649635|DRUG|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
219131932|NCT03761966|OTHER|Pregnant women|
219131933|NCT06530875|BEHAVIORAL|training on hesitations regarding childhood vaccinations|Training will be given to expectant mothers on childhood vaccination hesitations
219131934|NCT03641950|DRUG|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
219131935|NCT04753463|OTHER|Survey|The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
219131936|NCT04854993|DRUG|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
219131937|NCT04854993|DRUG|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
219131938|NCT05723991|DRUG|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
219131939|NCT06227286|DEVICE|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
219131940|NCT06227286|DEVICE|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
219131941|NCT01958099|BEHAVIORAL|Education|
219227089|NCT01570894|DRUG|Quetiapine Fumarate|25 mg tablet
219131942|NCT02524288|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
219131943|NCT02107378|BIOLOGICAL|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
219131944|NCT02107378|DRUG|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
219131945|NCT00517933|DRUG|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
219131946|NCT00517933|OTHER|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
219131947|NCT04868799|BIOLOGICAL|Mass spectrometry|Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
219131948|NCT02732314|DRUG|Investigational OTC Cream|
219131949|NCT02732314|OTHER|Cosmetic Eczema Cream|
219131950|NCT02732314|DRUG|0.05% Desonide Cream|
219131951|NCT02732314|OTHER|Placebo Cream|
219131952|NCT00380705|DRUG|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
219131953|NCT01022489|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
219131954|NCT01022489|DEVICE|Placebo (sham coil) treatment|Sham coil treatment
219131955|NCT01835899|DRUG|Placebo|Placebo to BI 1015550
219131956|NCT01835899|DRUG|BI 1015550|medium dose 1 powder for oral solution
219131957|NCT01835899|DRUG|BI 1015550|medium dose 2 powder for oral solution
219131958|NCT01835899|DRUG|BI1015550|low dose 2 powder for oral solution
219131959|NCT01835899|DRUG|BI 1015550|low dose 1 powder for oral solution
219131960|NCT05412030|BIOLOGICAL|AFX3772|AFX3772 administered intramuscularly 4 times within 12 months
219131961|NCT05412030|BIOLOGICAL|Prevnar 13|PCV13 administered intramuscularly 4 times within 12 months
219131962|NCT05412030|BIOLOGICAL|Prevnar 20|PCV 20 administered intramuscularly 4 times within 12 months
219131963|NCT03114904|OTHER|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
219131964|NCT02993510|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
219131965|NCT02993510|DEVICE|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
219131966|NCT02993510|DEVICE|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
219131967|NCT05598528|OTHER|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
219131968|NCT05598528|OTHER|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
219131969|NCT04795544|PROCEDURE|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
219131970|NCT06094205|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
219131971|NCT04077281|OTHER|Medication Coordinated care|"* Clinical Pharmacology \& Toxicology consult~* CPT team completes detailed circle of care communication~* Telemedicine followup by CPT team (approximately 48 hrs post-discharge \& 1 week to1 month post-discharge)"
219131972|NCT04478305|DRUG|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
219131973|NCT06032234|OTHER|This is an observational study|This is an observational study
219131974|NCT05560399|DRUG|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
219131975|NCT05560399|DRUG|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
219131976|NCT05560399|DRUG|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
219131977|NCT03246581|DRUG|Tiotropium|inhalation
219131978|NCT06630429|OTHER|Biospecimen Collection|Undergo collection of blood and stool samples
219131979|NCT06628739|DRUG|Imatinib|The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.
219131980|NCT06631495|OTHER|Observation|not available-observation study
219131981|NCT06630962|OTHER|Financial Navigation Program|"A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies."
219131982|NCT06630702|DEVICE|SCS electrode stimulation 1|300Hz/300us
219131983|NCT06630702|DEVICE|SCS electrode stimulation 2|130Hz/300us
219131984|NCT06630702|DEVICE|SCS electrode stimulation 3|60Hz/300us
219131985|NCT05926271|DRUG|Clopidogrel|See arm description earlier.
219131986|NCT06489249|DRUG|Placebo|Oral placebo tablet
219131987|NCT06489249|DRUG|Salsalate 750 MG Oral Tablet [DISALCID]|Oral salsalate tablet
219131988|NCT06631352|OTHER|Hepatopancreatoduodenectomy|Pancreatoduodenectomy with liver resection
219131989|NCT06253325|DIAGNOSTIC_TEST|Measuring tissue oxygenation|Measuring oxygen content of arteries, capillaries and veins
219131990|NCT06253325|DIAGNOSTIC_TEST|Procalcitonin|Blood test
219131991|NCT06253325|DIAGNOSTIC_TEST|Mid-regional proadrenomedullin|Blood test looking at inflammation in the body
219131992|NCT06253325|DIAGNOSTIC_TEST|Hand-held video microscope|A handheld video microscope that looks at blood flow through the capillaries of the tongue
219131993|NCT03618472|DRUG|Metformin Hydrochloride 850 MG|Regular strength metformin (850 mg/tab)
219131994|NCT03618472|DRUG|Placebo Oral Tablet|Starch based placebo manufatured to mimic Metformin 850 mg
219131995|NCT06104657|OTHER|Non-Interventional Study|Non-interventional study
219227090|NCT00065000|BEHAVIORAL|Water, Cafeteria and Staff Health Promotion|
219227091|NCT01190852|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
219360593|NCT06312072|OTHER|No intervention; observational study|No intervention; observational study
219713264|NCT06748066|BEHAVIORAL|RISE-ACL scale validation|"The scale validation phase will involve 162 participants who have undergone ACL reconstruction within the past two years and are in the 'Return to Sport' process, with follow-up in the sports medicine department.~These participants will complete the final version of the RISE-ACL Scale in addition with the ACL-RSI scale and the IKDC Subjective Knee Form.~Validation will consist of testing face validity, construct validity, criterion validity (concurrent validity), and reliability, including internal consistency and test-retest reliability."
219713265|NCT03132792|GENETIC|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
219713266|NCT06249919|BIOLOGICAL|NS101|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
219713267|NCT06249919|BIOLOGICAL|Placebo|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
219713268|NCT00575081|DEVICE|Stereotactic brain procedures|Stereotactic brain procedures
219713269|NCT06747247|DRUG|MT1013|MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.
219713270|NCT06747247|DRUG|Placebo|Appear similar to MT1013, but has no treatment effect.
219713271|NCT07008976|DRUG|TQB2102 Injection|TQB2102 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody-drug conjugate.
219131996|NCT06533254|OTHER|Predicting choice of dialysis|"Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD."
219131997|NCT06533254|BEHAVIORAL|Behavioral nudges|"Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses."
219131998|NCT06150885|BIOLOGICAL|HLA-G-CAR.BiTE allogeneic γδ T cells|"Phase I is a multiple escalating dose, single arm, open-label and 3+3 design that implemented with five cohorts: low dose for single administration, low dose for twice administrations for 2 weeks, low, middle and high dose for 4 repeated administrations for 4 weeks.~Phase IIa is a single-arm, open-label and dose-expansion study and the effective dose of CAR-positive cells will be administered to 27 evaluable subjects with TNBC, NSCLC, CRC or GBM via intravenous infusion weekly for 4 weeks."
219131999|NCT05464108|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
219132000|NCT02632916|DRUG|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
219132001|NCT02632916|DRUG|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
219132002|NCT01870609|DRUG|defactinib (VS-6063)|
219132003|NCT01870609|DRUG|Placebo|Sugar pill manufactured to mimic defactinib tablet
219132004|NCT04548232|PROCEDURE|Laparoscopic sleeve gastrectomy|bariatric surgery
219132005|NCT01639443|OTHER|Predictive no-show overbooking|"During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot."
219132006|NCT03400098|DRUG|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
219713272|NCT07008976|DRUG|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection is HER2-targeting antibody-drug conjugate (ADC).
219713273|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
219713274|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
219713275|NCT05260008|DRUG|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
219713276|NCT07060755|OTHER|Peppermint oil footbath|This includes a footbath with peppermint oil for 30 minutes each day for 2 weeks
219713277|NCT07060755|OTHER|Warm Water Footbath|This includes a warm water footbath for 30 minutes each day dor 2 weeks
219713278|NCT05742360|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
219713279|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with low dose PA-001|Multivalent pneumococcal conjugate vaccine
219227092|NCT01190852|DRUG|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
219227093|NCT01190852|DRUG|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
219713280|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with low dose PA-002|Multivalent pneumococcal conjugate vaccine
219713281|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with high dose PA-001|Multivalent pneumococcal conjugate vaccine
219713282|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with high dose PA-002|Multivalent pneumococcal conjugate vaccine
219713283|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 2|Multivalent pneumococcal conjugate vaccine
219713284|NCT07086677|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|(20vPnC)
219713285|NCT07086677|BIOLOGICAL|Saline injection|Placebo
219713286|NCT06551649|OTHER|Venous blood draw and skin biopsy|The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
219713287|NCT06340685|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
219713288|NCT06840535|DRUG|[68Ga]Ga-OncoACP3|Single intravenous bolus injection.
219713289|NCT06781788|OTHER|Making room for climate emotions in the classroom|"The Making room for climate emotions in the classroom program is designed to address emotions as students learn (formally or informally) about climate change. Each session features a drawing, photography, Lego sculpture, rock painting or collage/drawing workshop to address themes, explore emotions/feelings/experiences and initiate discussions on topics related to climate change."
219713290|NCT07091435|BEHAVIORAL|ChatGPT|Phase 2 Involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
219713291|NCT07091435|BEHAVIORAL|community social|Phase 2 involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
219713292|NCT06107946|OTHER|USD questionnaire|After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
219713293|NCT07095660|DEVICE|Recana procedure|recanalization and debulking of obstructions and occlusions within stented and non-stented segments in veins
219713294|NCT06109272|DRUG|Livmoniplimab|Intravenous (IV) Solution
219713295|NCT06109272|DRUG|Budigalimab|Intravenous (IV) Solution
219713296|NCT06109272|DRUG|Durvalumab|Intravenous (IV) Solution
219713297|NCT06109272|DRUG|Atezolizumab|Intravenous (IV) Solution
219713298|NCT06109272|DRUG|Bevacizumab|Intravenous (IV) Solution
219713299|NCT06109272|DRUG|Tremelimumab|Intravenous (IV) Solution
219713300|NCT00000352|DRUG|Dextromethorphan|
219713301|NCT04943861|BEHAVIORAL|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
219713302|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
218986940|NCT02564796|DRUG|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
218986941|NCT02564796|DRUG|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
218986942|NCT04456946|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy
218986943|NCT04456946|DEVICE|Occlusal Splint Treatment|Occlusal Splint Treatment
218986944|NCT02378259|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
218986945|NCT02378259|PROCEDURE|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
218986946|NCT02014571|DRUG|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
218986947|NCT02014571|DRUG|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
218986948|NCT01545804|DRUG|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
218986949|NCT02257307|PROCEDURE|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
218986950|NCT01869517|OTHER|intrastromal corneal ring segments (Keraring) implantation|
218986951|NCT01869517|OTHER|Intrastromal corneal continuous ring (Myoring) implantation|
218986952|NCT02620657|OTHER|Non interventional study|Non interventional study
219132007|NCT04887272|OTHER|Supervised Exercise Training Protocol|EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.
219132008|NCT04887272|OTHER|Inspiratory Muscle and Exercise Training|Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
219132009|NCT04305912|DEVICE|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
219132010|NCT04305912|DEVICE|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
219132011|NCT04340245|OTHER|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
219132012|NCT02882503|DEVICE|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
219132013|NCT01649427|DRUG|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
219132014|NCT01649427|DRUG|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
219132015|NCT00740272|PROCEDURE|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
219132016|NCT00740272|PROCEDURE|Pacemaker implantation|regular pacemaker implantation
219132017|NCT01147770|DRUG|progesterone|duration
219227094|NCT04002349|DRUG|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
219227095|NCT04002349|DRUG|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
219713303|NCT07097324|BEHAVIORAL|Video- and Game-Based Oral Health Education|A video- and game-based oral health education intervention will be delivered to the participants in the intervention group over three weekly sessions. In the first session, participants will watch a video that highlights key messages on oral health, including the importance of oral health, the consequences of poor oral health and recommended oral health practices. This will be followed by an interactive quiz to reinforce the content of the video. In the second session, a video demonstrating proper tooth brushing and flossing techniques will be shown. Participants will then practice these techniques using tooth models. The third session will feature a video on cariogenic food consumption, followed by an interactive educational game in which participants identify non-cariogenic foods.
219713304|NCT07097324|BEHAVIORAL|Conventional Oral Health Talk|A conventional oral health talk will be delivered to participants in both the control and intervention groups. The talk will cover key messages on oral health, including the importance of oral health, consequences of poor oral health and recommended oral health practices.
219713305|NCT07102459|DRUG|Experimental: LTG-001 High Dose|High Dose Active
219227096|NCT04002349|DRUG|0.9% natural saline|Detailed in arm descriptions
219713306|NCT07102459|DRUG|Experimental: LTG-001 Low Dose|Lower Dose Active
219713307|NCT07102459|DRUG|Active Comparator: HB/APAP|Active Comparator
219713308|NCT07102459|DRUG|Placebo Comparator|Placebo
219713309|NCT07101783|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneously.
219227097|NCT01896843|DRUG|STX107|
219227098|NCT05878106|DIETARY_SUPPLEMENT|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
219227099|NCT05878106|OTHER|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
219227100|NCT03224806|OTHER|Wholegrain bread|156.8g wholegrain bread
219227101|NCT03224806|OTHER|White bread|122.6g white bread
219713310|NCT06774144|DRUG|Rezafungin|Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.
219713311|NCT06774144|DRUG|Standard of care antifungal prophylaxis|UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
219227102|NCT03224806|OTHER|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
219713312|NCT07103395|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.
219132018|NCT05803330|DRUG|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
219132019|NCT02842658|OTHER|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
219132020|NCT02842658|OTHER|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
219132021|NCT06217354|DRUG|Carbetocin 100 Microgram/mL Solution for Injection|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
219132022|NCT05216237|DRUG|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
219132023|NCT00964717|PROCEDURE|real chiropractic|real chiropractic manipulation
219132024|NCT00964717|PROCEDURE|Sham Chiropractic|Placebo stimulation using 'activator' thumper
219132025|NCT05586451|BEHAVIORAL|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
219227103|NCT03224806|OTHER|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
219227104|NCT00262366|DEVICE|Comparison of automatic CPAP versus fixed CPAP|
219227105|NCT01228500|DEVICE|PriMatrix|Dermal Repair Scaffold
219227106|NCT03035942|DRUG|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
219713313|NCT07103395|RADIATION|Radiotherapy|Definitive dose of hypofractionated radiotherapy was delivered to patients, with concurrent chemotherapy.
219713314|NCT07103395|DRUG|Consolidative therapy|Consolidation therapy consists of iparomlimab and tuvonralimab and thymosin alpha 1, for a total duration of 1 year.
219713315|NCT07103538|BEHAVIORAL|Reflective practices|The intervention was implemented as part of a nursing course consisting of 4 hours of theoretical instruction, 4 hours of laboratory practice, and 8 hours of clinical practice. For 14 weeks, reflective practice was integrated into both the laboratory and clinical components. In the laboratory sessions, clinical scenarios were developed based on five common topics (e.g., infection control, vital signs) that students are likely to encounter during clinical practice. Students performed these scenarios by taking on different roles. Following each role-play, structured reflection sessions were conducted with the students. In the clinical setting, the final hour of each practice day was allocated for reflection. After completing an online reflection form, students had the opportunity to engage in group discussions if they wished to reflect further.
219713316|NCT07104916|COMBINATION_PRODUCT|Psilocybin + MBCT therapy|The experimental arm has psilocybin with support and MBCT sessions.
219713317|NCT07104916|COMBINATION_PRODUCT|Active Comparator: Psilocybin with Support Only|The active comparator has psilocybin with support only.
219713318|NCT07105358|DEVICE|transcranial random noise stimulation (tRNS)|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: 1 mA current intensity, with a frequency range of 101-640 Hz.
219713319|NCT07105358|DEVICE|Sham Stimulation|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: Ramp up stimulation at 1mA with a frequency range of 101-640Hz for the first 30 seconds followed by no current for the remainder of the duration.
219132026|NCT05586451|BEHAVIORAL|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
219132027|NCT05586451|BEHAVIORAL|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
219132028|NCT03603418|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
219132029|NCT03603418|OTHER|Distilled water|Distilled water
219132030|NCT05689216|BEHAVIORAL|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
219713320|NCT07105358|BEHAVIORAL|Perceptual learning-based training|A motion discrimination task, judging the global direction of moving dot stimuli with two different coherence levels.
219713321|NCT07108777|DRUG|L-Carnitine Tartrate|L-carnitine 350 mg three times daily by oral.
219713322|NCT07108777|DRUG|Placebo|placebo tablet three times daily by oral.
219713323|NCT07142005|OTHER|Interviews|"* Questionnaires/Survey Measures~* Qualitative Instruments"
219713324|NCT07142590|DIETARY_SUPPLEMENT|Stable Isotopes|15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
219713325|NCT07141589|DRUG|Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU diluted in normal saline to a total volume of 8 ml.
219713326|NCT07141589|DRUG|Fentanyl + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU and fentanyl 20 μg diluted in normal saline to a total volume of 8 ml.
219713327|NCT07141589|DRUG|Ketorolac + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, hyaluronidase 60 IU, and ketorolac 15 mg diluted in normal saline to a total volume of 8 ml.
219713328|NCT04021433|DRUG|Ketamine|Repeated doses of IM/SC ketamine up to 3 times a week
219713329|NCT06323291|BEHAVIORAL|Coaching Sessions|"Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email."
219713330|NCT06831409|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Coronary Computed Tomography Angiography (CCTA) is a non-invasive medical imaging test that uses X-rays to create detailed 3D images of the heart and its blood vessels, specifically the coronary arteries.
219713331|NCT04322383|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
219713332|NCT04307667|BIOLOGICAL|Whole lung antigen challenge (WLAC)|Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
219713333|NCT04307667|RADIATION|[18F]FEPPA|\[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
219713334|NCT03333343|DRUG|EGF816|Study Drug
219713335|NCT03333343|DRUG|trametinib|Study Drug
219713336|NCT03333343|DRUG|ribociclib|Study Drug
219713337|NCT03333343|DRUG|LXH254|Study Drug
218986953|NCT00453063|DRUG|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
218986954|NCT00453063|DRUG|Placebo|Two sprays in each nostril once daily in the morning
218986955|NCT00043901|DRUG|lamotrigine|
218986956|NCT05560360|DRUG|SHR1459 tablet|100 mg/tablet; administered orally
218986957|NCT05560360|DRUG|Efavirenz tablet|600 mg/tablet; administered orally
218986958|NCT05840380|DEVICE|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
218986959|NCT06556342|DRUG|FRD001|FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
218986960|NCT00728793|DRUG|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
218986961|NCT03812471|DEVICE|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
218986962|NCT03812471|DEVICE|2D standard measurements and 3D volumes acquisitions|"* 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume"
218986963|NCT02403986|DEVICE|Restylane Vital Skinboosters Lidocaine|
218986964|NCT03726411|PROCEDURE|non-surgical periodontal therapy|scaling and root planing
218986965|NCT00289783|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
218986966|NCT00289783|BIOLOGICAL|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
218986967|NCT00289783|BIOLOGICAL|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
218986968|NCT00289783|BIOLOGICAL|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
218986969|NCT00289783|BIOLOGICAL|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
218986970|NCT00289783|BIOLOGICAL|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
218986971|NCT00289783|BIOLOGICAL|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
218986972|NCT00566995|DRUG|ZACTIMA (Vandetanib) (ZD6474)|
218986973|NCT02732756|BEHAVIORAL|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
218986974|NCT02732756|BEHAVIORAL|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
218986975|NCT03013738|BEHAVIORAL|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
218986976|NCT03013738|OTHER|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
219713338|NCT03333343|DRUG|INC280|Study Drug
219132031|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
219132032|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
219132033|NCT05756998|PROCEDURE|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
219713339|NCT03333343|DRUG|gefitinib|Study Drug
219713340|NCT05677139|OTHER|None (Observational Study)|Not applicable since it's an observational study.
219713341|NCT03850574|DRUG|Tuspetinib|Daily (QD), continuous dosing
219713342|NCT03850574|DRUG|Venetoclax Oral Tablet|Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
219713343|NCT03850574|DRUG|Azacitidine for Intravenous Infusion|Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
219713344|NCT04375332|DEVICE|HARPOON™ Beating Heart Mitral Valve Repair System|Repair of the chordae tendinae in the mitral valve.
219713345|NCT05337553|DRUG|taldefgrobep alfa|DB Phase: 35 mg/50 mg weekly subcutaneous injection
219713346|NCT05337553|DRUG|Placebo|DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
219713347|NCT05337553|DRUG|taldefgrobep alfa|Extension Phase: 35 mg/50 mg weekly subcutaneous injection
219713348|NCT04070703|BEHAVIORAL|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
219132034|NCT02431663|DRUG|Ketamine|Intravenous administration in continuous
219132035|NCT06550115|BEHAVIORAL|Time-restricted eating|Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
219132036|NCT06550115|BEHAVIORAL|Control eating|Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
219132037|NCT05899764|DRUG|Brivaracetam|"* Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~* Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."
219132038|NCT05450783|OTHER|Biocollection|serum
219132039|NCT04714411|DRUG|Omadacycline|Omadacycline monotgherapy
219713349|NCT05783817|DRUG|3,4-Methyl enedioxy methamphetamine|MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.
219713350|NCT05783817|DRUG|Methamphetamine|Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.
219713351|NCT05783817|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.
219713352|NCT05962424|DRUG|Ketamine Hydrochloride|Ketamine is an FDA-approved dissociative anesthetic.
219713353|NCT06123377|DIAGNOSTIC_TEST|Angiogenic factor|sFLt-1/PGIF below or equal to 33
219713354|NCT03539536|DRUG|Telisotuzumab vedotin|Intravenous (IV) infusion
219713355|NCT02664753|DRUG|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
219713356|NCT02664753|DRUG|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
219713357|NCT06963580|DRUG|MI078 capsule dose 1|MI078 capsule dose 1 for 3 days
219713358|NCT06963580|DRUG|MI078 capsule dose 2|MI078 capsule dose 2 for 3 days
219713359|NCT06963580|DRUG|placebo|placebo for 3 days
219713360|NCT05977868|DRUG|Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid|COpAT (oral antimicrobial therapy) on hospital discharge
219713361|NCT05977868|DRUG|Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem|Standard of care (IV antimicrobial therapy) on hospital discharge
219713362|NCT05388006|DRUG|Acalabrutinib|Given PO
219132040|NCT02735265|BEHAVIORAL|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
219132041|NCT02735265|BEHAVIORAL|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
219132042|NCT02694848|DRUG|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
219132043|NCT02694848|DRUG|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
219132044|NCT04888585|DRUG|ABBV-154|Subcutaneous Injection
219132045|NCT04888585|DRUG|Placebo|Subcutaneous Injection
219132046|NCT02882646|DEVICE|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
219132047|NCT04784741|OTHER|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
219132048|NCT04784741|DEVICE|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
219132049|NCT04784741|DEVICE|Biodex Balance System|Pre and post balance assessment by Biodex balance system
219132050|NCT04784741|PROCEDURE|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
219132051|NCT05093712|OTHER|Educational Intervention|Watch educational video
219132052|NCT05093712|OTHER|Survey Administration|Complete surveys
219132053|NCT02454907|OTHER|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
219132054|NCT00044928|DRUG|Piperacillin/Tazobactam|
219132055|NCT05756439|DRUG|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
219132056|NCT05756439|DRUG|No IV sedation|Participants having dental surgery without conscious intravenous sedation
219132057|NCT01888718|DRUG|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
219132058|NCT04035759|BEHAVIORAL|APPEAL|Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
219713363|NCT05388006|BIOLOGICAL|Durvalumab|Given IV
219713364|NCT05388006|DRUG|Venetoclax|Given PO
219713365|NCT05388006|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219713366|NCT05388006|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219713367|NCT05388006|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219713368|NCT05388006|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/CT
219132059|NCT01559090|DRUG|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
219132060|NCT01559090|DRUG|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
219132061|NCT01559090|DRUG|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
219132062|NCT03909581|PROCEDURE|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
219132063|NCT03909581|PROCEDURE|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
219132064|NCT02768805|BIOLOGICAL|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
219132065|NCT02768805|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
219132066|NCT02768805|BIOLOGICAL|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
219132067|NCT04463953|DRUG|Zanubrutinib,Ixazomib and Dexamethasone|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
219713369|NCT05388006|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219713370|NCT06784024|DRUG|Lidocaine topical|Topical lidocaine (SPRAY SOLUTION 10 g) 10% will be applied to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml/spray).
219713371|NCT06784024|OTHER|Saline solution|Placebo (0.9% saline) will be applied topically to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml / spray).
219713372|NCT05048797|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
219713373|NCT05048797|DRUG|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
219713374|NCT05048797|DRUG|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
219713375|NCT05048797|DRUG|Pembrolizumab|Pembrolizumab administered by intravenous infusion
219713376|NCT05048797|DRUG|Pemetrexed|Pemetrexed administered by intravenous infusion
219132068|NCT04705974|PROCEDURE|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
219132069|NCT04705974|PROCEDURE|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
219132070|NCT04705974|PROCEDURE|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
219132071|NCT04120337|DEVICE|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
219713377|NCT04385888|BEHAVIORAL|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
219713378|NCT02716441|DEVICE|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
219713379|NCT06229600|OTHER|Standard rehabilitation|Respiratory rehabilitation
219132072|NCT04120337|PROCEDURE|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
219132073|NCT04120337|DEVICE|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
219132074|NCT01234194|DRUG|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
219713380|NCT06299189|BEHAVIORAL|MinADHD|Guided self-help, 7 modules Interventions
219713381|NCT05431101|PROCEDURE|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
219713382|NCT04912869|DRUG|Crovalimab|Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
219713383|NCT04912869|DRUG|Placebo|Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
219713384|NCT06847100|DIAGNOSTIC_TEST|Blood withdrawal|Optional collection of 5 mL of blood to assess the contribution of 16 gene polymorphisms AF-associated
219713385|NCT06165016|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
218986977|NCT04720066|DIAGNOSTIC_TEST|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
218986978|NCT05307146|DEVICE|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
218986979|NCT06356519|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
218986980|NCT05469191|OTHER|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
219132075|NCT01234194|DRUG|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
218986981|NCT05469191|OTHER|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
218986982|NCT01760629|DEVICE|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
218986983|NCT04896541|BIOLOGICAL|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
218986984|NCT04896541|BIOLOGICAL|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
218986985|NCT04896541|BIOLOGICAL|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
218986986|NCT04896541|BIOLOGICAL|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
218986987|NCT01289080|DRUG|OPC-34712|administered orally
219132076|NCT05617339|BEHAVIORAL|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
219132077|NCT04805645|OTHER|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
219132078|NCT02675855|OTHER|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
219132079|NCT02675855|PROCEDURE|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
219132080|NCT02675855|DEVICE|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
219227107|NCT03035942|DRUG|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
219132081|NCT03455361|PROCEDURE|Stark Implant with low primary stability|
219227108|NCT03035942|DRUG|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
219227109|NCT05022615|DIAGNOSTIC_TEST|Topcon Camera|Standard 7 field imaging
219227110|NCT05022615|DIAGNOSTIC_TEST|Optos Camera|Ultrawide field imaging
219227111|NCT05022615|DIAGNOSTIC_TEST|Clarus Camera|Ultrawide field imaging
219227112|NCT04987528|DIAGNOSTIC_TEST|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
219227113|NCT04987528|DIAGNOSTIC_TEST|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
219227114|NCT05270460|DRUG|PCS12852|PCS12852 oral tablet administered once daily
219227115|NCT05270460|DRUG|Placebo|Placebo comparator oral tablet administered once daily
219227116|NCT00380250|DRUG|Lubiprostone|
219713386|NCT06165016|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
219713387|NCT06330701|DEVICE|Robotic-assisted mini-PCNL|This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
219713388|NCT06540170|BEHAVIORAL|A personalised self-care support program|A personalized care program consists of three 30-minute face-to-face sessions (once every 2 weeks) after patients' routine wound dressings to enhance self-efficacy, support emotional adjustments, and DFU self-care.
219713389|NCT05451862|DEVICE|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
219713390|NCT05451862|DEVICE|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
219713391|NCT04803279|DEVICE|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
219713392|NCT04803279|DEVICE|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
219713393|NCT04803279|DEVICE|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
219713394|NCT04803279|DEVICE|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB\[s\] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
219713395|NCT04803279|DEVICE|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
219132082|NCT00002589|BIOLOGICAL|aldesleukin|
219132083|NCT00002589|BIOLOGICAL|muromonab-CD3|
219132084|NCT00002589|BIOLOGICAL|therapeutic autologous lymphocytes|
219227117|NCT00380250|DRUG|Placebo|
219227118|NCT02765126|BIOLOGICAL|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
219132085|NCT00002589|PROCEDURE|adjuvant therapy|
219132086|NCT05423080|DRUG|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
219132087|NCT05423080|DRUG|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
219132088|NCT00547976|DRUG|[C-11]PBR28|
219227119|NCT02765126|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
219227120|NCT05972252|DEVICE|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
219227121|NCT03579407|PROCEDURE|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
219227122|NCT03156738|DRUG|MT-2990|Subjects will receive a single IV dose of MT-2990
219227123|NCT03156738|DRUG|Placebo|Subjects will receive a single IV dose of placebo
219227124|NCT00729209|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
219227125|NCT00729209|DRUG|Placebo; oral|matching placebo
219360594|NCT00626093|DEVICE|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"* Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~* Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
219360595|NCT02059590|DRUG|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
219713396|NCT04803279|DEVICE|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
219713397|NCT04803279|DEVICE|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
219713398|NCT05826873|BEHAVIORAL|Discharge antibiotic stewardship intervention|Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
219713399|NCT05511324|BEHAVIORAL|Questionnaires|Participants will be asked to complete this assessment on your own time, and it should take about 40 minutes.
219713400|NCT05511324|BEHAVIORAL|Caregiver Assessment|These sessions will involve simulation-based, caregiving skill training, and your caregiver will be taught skills to help support you (such as feeding, hygiene, mobility, medication administration, and care coordination).
219713401|NCT01809808|PROCEDURE|Surgery for acromegaly|(non-experimental) standard procedure
219713402|NCT01809808|DRUG|Medications for acromegaly|(non-experimental) standard procedure
219713403|NCT01809808|DIAGNOSTIC_TEST|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
219713404|NCT01809808|PROCEDURE|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
219132089|NCT01585181|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
219132090|NCT01585181|BIOLOGICAL|Placebo|Approx 2 grams of lactose reconstituted in water
219132091|NCT00002179|DRUG|Indinavir sulfate|
219132092|NCT00002179|DRUG|Lamivudine|
219132093|NCT00002179|DRUG|Zidovudine|
219132094|NCT01113229|DRUG|Misoprostol|two misoprostol tablets taken orally (400µg)
219132095|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
219713405|NCT05696847|DRUG|Tirzepatide|Administered SC
219713406|NCT05696847|DRUG|Placebo|Administered SC
219713407|NCT04167748|PROCEDURE|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
219713408|NCT03323502|BEHAVIORAL|APPROACHES ACP Specialist Program|The APPROACHES Advance Care Planning (ACP) Specialist will work with nursing home leaders (in intervention arm facilities) to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP Specialist Program with patients who have Alzheimer's disease/related dementias and their family caregivers.
219713409|NCT03323502|OTHER|Standard of care|Standard of care Advance Care Planning (ACP) procedures
219713410|NCT06638619|BEHAVIORAL|Biofeedback Fixation Training|This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.
219713411|NCT06638619|BEHAVIORAL|Saccadic Reading Training|Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
219713412|NCT06300996|DEVICE|Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)|Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
219713413|NCT05943678|DEVICE|Siemens Magnetom 7T Plus|Magnetic Resonance Spectroscopy
219713414|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
219713415|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
219132096|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
219132097|NCT03722446|DEVICE|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
219132098|NCT03722446|DEVICE|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
219132099|NCT04107649|BEHAVIORAL|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
219132100|NCT04107649|BEHAVIORAL|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.
219360596|NCT01889979|DRUG|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
219713416|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
219360597|NCT01889979|DRUG|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
219360598|NCT05841095|DRUG|ISA104|SLP vaccine
219360599|NCT05841095|DRUG|Placebo|Saline solution (0.9% NaCl)
219132101|NCT04107649|OTHER|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
219132102|NCT05803967|BEHAVIORAL|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
219132103|NCT01577043|DRUG|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
219132104|NCT01577043|OTHER|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
219132105|NCT01141140|BEHAVIORAL|Healthy|Favourable nutritional characteristics.
219132106|NCT01141140|BEHAVIORAL|Diet|Benefits of an ingredient/nutrient for weight management
219132107|NCT01141140|BEHAVIORAL|Unhealthy|Hedonic characteristics and less healthy ingredients.
219132108|NCT01049139|BEHAVIORAL|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
219132109|NCT01049139|BEHAVIORAL|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
219132110|NCT05464589|OTHER|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
219132111|NCT05464589|OTHER|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
219132112|NCT02908464|DEVICE|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
219132113|NCT05209542|PROCEDURE|Hysterosalpingo-Foam Ultrasonography|"* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
219132114|NCT05209542|PROCEDURE|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
219132115|NCT01571089|BEHAVIORAL|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
219132116|NCT02727621|DRUG|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
219713417|NCT05524883|DRUG|DYNE-251|Administered by IV infusion
219713418|NCT05524883|DRUG|Placebo|Administered by IV infusion
219713419|NCT04492670|PROCEDURE|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
219713420|NCT04492670|DRUG|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
219713421|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
219713422|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
219713423|NCT03293524|GENETIC|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
219713424|NCT03293524|DRUG|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
219713425|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
219713426|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
219713427|NCT05918640|DRUG|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
219132117|NCT02727621|DRUG|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
219132118|NCT02214459|BEHAVIORAL|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
219132119|NCT06244108|OTHER|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
219132120|NCT00140673|BIOLOGICAL|Rotavirus|
219132121|NCT06058182|DIAGNOSTIC_TEST|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
219132122|NCT00069459|DRUG|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
219132123|NCT04129424|DEVICE|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
219132124|NCT06250075|DIETARY_SUPPLEMENT|Formulation with probiotics|Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
219132125|NCT06250075|OTHER|Non-intervention for Clinical Outcomes -G5|only observation of clinical outcomes in the postoperative period
219132126|NCT02017106|PROCEDURE|Endovenous Laser ablation and concomitant phlebectomies|
219132127|NCT02017106|PROCEDURE|Endovenous Laser ablation and sequential phlebectomies|
219132128|NCT06146985|COMBINATION_PRODUCT|20 mg Famitinib & 1200 mg Adebrelimab|Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
219132129|NCT04215913|OTHER|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
219132130|NCT00070954|DRUG|ginkgo biloba|EgB 761
219132131|NCT00070954|OTHER|matched placebo|Inactive look-alike placebo
219132132|NCT01710150|PROCEDURE|CTI ablation alone|
219132133|NCT01710150|PROCEDURE|CTI ablation and Pulmonary vein isolation (PVI)|
219132134|NCT02180113|DEVICE|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
219132135|NCT04018118|BIOLOGICAL|Biological sample|Additional blood samples for biobanking
219132136|NCT02840994|BIOLOGICAL|CV301|
219132137|NCT02840994|BIOLOGICAL|Pembrolizumab|
219132138|NCT02840994|BIOLOGICAL|Nivolumab|
219132139|NCT04720599|DIAGNOSTIC_TEST|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
219132140|NCT06486974|DRUG|NaF|Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
219132141|NCT06486974|DRUG|Na MFP|Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
219132142|NCT05273801|DEVICE|Heart Rate Recording from Multiple Participants, No Visual Feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
219132143|NCT05273801|DEVICE|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
219132144|NCT06611722|OTHER|Psychological and Functional Assessment|Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.
219713428|NCT04092777|BEHAVIORAL|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
219713429|NCT04092777|OTHER|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
219132145|NCT06611514|DRUG|Prasterone (DHEA)|Prasterone 6.5 mg vaginal tablets
219360600|NCT03434379|DRUG|Atezolizumab|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
219132146|NCT06606613|PROCEDURE|Intraurethral injection|"Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer"
219132147|NCT06606613|PROCEDURE|Mid-urethral sling|"Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision ."
219132148|NCT06628882|PROCEDURE|Infraclavicular Block|types of anesthesia used in upper extremity surgeries
219132149|NCT06628882|PROCEDURE|Wide-Awake Local Anesthesia with No Tourniquet|types of anesthesia used in upper extremity surgeries
219132150|NCT06630052|OTHER|adductor canal clinical examination|clinical examination of the adductor canal in patients with knee pain not matching the radiological changes
219132151|NCT06630351|BEHAVIORAL|Behavioral Counseling|Participate in MCP-C
219132152|NCT06630351|OTHER|Discussion|Participate in virtual group discussions
219132153|NCT06630351|OTHER|Health Promotion and Education|Receive reading exercises and workbook materials
219132154|NCT06630351|OTHER|Interview|Ancillary studies
219132155|NCT06630351|OTHER|Questionnaire Administration|Ancillary studies
219132156|NCT06697938|RADIATION|Preoperative SBRT for the Primary Lesion of Breast Cancer|SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
219132157|NCT06696339|DEVICE|PreemptiveAI SDK|Use the PreemptiveIAI SDK to measure heart rate.
219132158|NCT03867617|OTHER|Regulatory T cells|Single infusion of expanded regulatory T cells.
219132159|NCT03867617|DRUG|Tocilizumab|Treatment during first month post-transplant.
219713430|NCT05600920|DRUG|Recombinant human interleukin (IL) 7-hyFc|Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI \>=30 kg/m2, in which case adjusted body weight will be used.
219713431|NCT06229704|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
219713432|NCT06229704|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219713433|NCT06229704|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219713434|NCT06229704|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
219227126|NCT02268240|BEHAVIORAL|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
219132160|NCT03867617|OTHER|Bone marrow|Infusion of donor bone marrow cells.
219132161|NCT03867617|PROCEDURE|Kidney transplant|Living donor kidney transplantation.
219132162|NCT03867617|OTHER|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
219132163|NCT06698367|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
219132164|NCT06698367|OTHER|Unilateral high-intensity strength exercise|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.
219132165|NCT06698367|OTHER|Unilateral mobility exercises|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
219132166|NCT01867853|DEVICE|PLR|passive leg raising test was done before and at the end of SBT
219132167|NCT06697522|DRUG|Atropine Sulfate|low concentration atropine (0.01%)
219132168|NCT06697522|DRUG|Placebo|Blank comparator
219132169|NCT06696651|DEVICE|Electrical myostimulation|Electrical myostimulation in form of suit as in fig. Blue lines demonstrate areas of electrodes inside suit. twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks . 20 min = 1 min warm up, 6min upper body training, 6min lower body training, 6min core training, 1 min cooling down.
219132170|NCT06696651|DEVICE|Electronic cupping|Twenty females will undergo two weekly myofascial release sessions and a healthy diet for six weeks, using electronic cupping to ensure equal pressure on tender points.
219713435|NCT06229704|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
219713436|NCT03326336|COMBINATION_PRODUCT|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
219713437|NCT06005103|DEVICE|Treatment with MoodHeadBand (T-PEMF treatment)|The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
219713438|NCT06005103|DEVICE|Inactive treatment with MoodHeadBand (Placebo)|Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
219713439|NCT05728775|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
219713440|NCT05728775|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
219713441|NCT05551949|DRUG|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
219713442|NCT04443452|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
219713443|NCT04443452|RADIATION|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
219132171|NCT06696651|OTHER|healthy diet|The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
219132172|NCT06701838|DIAGNOSTIC_TEST|11C-Methionine PET/CT|After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.
219132173|NCT06703424|OTHER|Sit-cycling|Sit-cycling for 5 mins
219132174|NCT06703424|OTHER|Stand-twisting|Stand-twisting for 5 mins
219132175|NCT06711679|DRUG|Low-dose ropivacaine|0.5 ml/Kg ropivacaine
219360601|NCT03434379|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle
219132176|NCT06711679|DRUG|Medium-dose of ropivacaine|1ml/Kg ropivacaine
219132177|NCT06711679|DRUG|High-dose ropivacaine|1.5 ml/Kg ropivacaine
219132178|NCT06712654|DRUG|AP306 75mg TID|receiving orally AP306 75mg (one tablet), three times a day
219132179|NCT06712654|DRUG|AP306 100mg TID|receiving orally AP306 100 mg (one tablet), three times a day.
219132180|NCT06712654|DRUG|AP306 125mg TID|receiving orally AP306 125 mg (one tablet), three times a day
219713444|NCT04443452|PROCEDURE|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
219713445|NCT04443452|DIAGNOSTIC_TEST|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
219132181|NCT06712654|DRUG|AP306 125mg BID|receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet
219227127|NCT04675268|DIAGNOSTIC_TEST|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
219227128|NCT04029090|DRUG|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
219227129|NCT04029090|DRUG|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
219713446|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
219713447|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
219713448|NCT04443452|DIAGNOSTIC_TEST|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
219713449|NCT05464095|DEVICE|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
219713450|NCT05464095|DEVICE|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
219713451|NCT02993367|DRUG|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
219713452|NCT02993367|DRUG|Placebo Butylphthalide Soft Capsules|
219227130|NCT04029090|DRUG|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
219227131|NCT02581904|DEVICE|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
219713453|NCT04801329|DRUG|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
219132182|NCT06712654|DRUG|AP306 150mg BID|receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet
219227132|NCT02581904|DEVICE|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
219227133|NCT01065779|DRUG|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
219713454|NCT06229717|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
219132183|NCT06712654|DRUG|Placebo TID|receiving orally one placebo tablet of AP306, three times a day
219132184|NCT06707701|OTHER|acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
219132185|NCT06707675|OTHER|Assessment|The patients' demographic information, weight and height measurements, occupational activities and desk work time, daily screen usage time, pain intensity (with VAS), cervical joint range of motion examination, pain threshold (with pressure algometer), functional status (with Neck Pain Disability Scale), sleep quality (with Pittsburgh Sleep Quality Scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspects of pain (with Pain Catastrophizing Scale) will be evaluated. The patients' chronotype preferences will be evaluated with Morningness Eveningness Questionnaire.
219227134|NCT01065779|DRUG|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
219360602|NCT03434379|DRUG|Sorafenib|Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle
219360603|NCT00005783|DRUG|Recombinant-methionyl human stem cell factor|
219132186|NCT06711419|PROCEDURE|f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone|"Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed."
219132187|NCT06697457|OTHER|Craniocervical Flexion Exercise Group|"The patient will first be taught to contract the deep cervical flexors. Patients will be placed in a supine position (without a pillow) to ensure a neutral neck position. Patients will be asked to perform slow, controlled head and upper cervical flexion by bringing the chin closer to the chest (yes movement). The stabilizer will be inflated to 20 mmHg. Gradual training will be given to increase the pressure value by 2 mmHg between 20 and 30 mmHg. Each pressure value (22, 24, 26, 28 mmHg) will be held for 10 seconds and repeated 10 times. The exercise will be performed with 10 repetitions, 10 seconds of contraction and 5 seconds of relaxation. Exercise training will begin with 20 mmHg and once the patient can hold it for 10 seconds with 10 repetitions, the next level on the pressure stabilizer will be moved on.Treatments will be performed 3 days a week for 8 weeks."
219132188|NCT06697457|OTHER|Conventional Treatment Group|TENS will be applied with a TENS device at an intensity of 10-30 mA and a frequency of 80 Hz for 20 minutes. A pair of surface electrodes will be placed on the painful area of the neck. The intensity of TENS will be adjusted according to the patient's sensory thresholds so that the patient is not disturbed by a numb feeling. After TENS, continuous ultrasound will be applied to the cervical region to produce thermal effects. The intensity will be 1.5 W/cm² and the duration will be 5 minutes. Hotpack will be applied to the trapezius muscle for 10 minutes. Chin tuck exercise will be applied to the cervical region.Treatments will be performed 3 days a week for 8 weeks.
219132189|NCT06697457|OTHER|Dynamic Isometric Exercise Group|The exercises will be performed by the patient with an elastic band. The progression of the exercises will be performed using different colors of Thera-bands with different resistances. It will start with the red Thera-band with the lowest resistance and then move on to the green and then blue Thera-bands with increasing resistance. Cervical isometric exercises will be performed with elastic resistance bands, maintaining the chin tuck position, forward, backward, crosswise, right and left. There will be 10 repetitions for 10 seconds for each. Progression in Therabands will be according to the patient. When the patient does 10 repetitions for 10 seconds, the next Theraband will be used.Treatments will be performed 3 days a week for 8 weeks.
219227135|NCT06317623|DIAGNOSTIC_TEST|Prenatal and postnatal ultrasound examination|Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
219227136|NCT02157948|DRUG|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
219227137|NCT02157948|DRUG|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
219227138|NCT04069416|PROCEDURE|living donor liver transplantation|liver graft from a living donor
219227139|NCT05254392|DEVICE|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
219227140|NCT01012063|DRUG|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
219713455|NCT06229717|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219713456|NCT06229717|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
219713457|NCT06229717|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
219713458|NCT06229717|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
219713459|NCT02693067|DRUG|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
219713460|NCT06067711|DEVICE|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
219713461|NCT01124253|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
219713462|NCT06516211|DEVICE|Clara Pregnancy Test|Multi-Level Pregnancy Test
219713463|NCT06516211|DEVICE|Professional Marketed Pregnancy Test|Early Pregnancy Test
219713464|NCT02170714|OTHER|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
219132190|NCT06697457|OTHER|Static Isometric Exercise Group|The patient will perform isometric exercises with maximal effort against neck flexion, extension, lateral flexion and rotation with his/her hand in a sitting position. Each exercise will be performed for 10 seconds, with 15-second breaks in between, for 10 repetitions. Each patient will start with submaximal resistance to help them adapt to isometric exercises, and then progress will be checked until the patient reaches the maximum resistance that can be tolerated by each session. It will consist of cervical flexion, cervical extension, right lateral flexion, left lateral flexion, right rotation, left rotation exercises. Progress in the exercises will be according to the Rating of Perceived Exertion Borg (RPE) Scale according to the weeks.Treatments will be performed 3 days a week for 8 weeks.
219132191|NCT06714422|PROCEDURE|apple group|Doctors will bring apples during night shift
219132192|NCT06714422|PROCEDURE|no apple group|No apples during night shift
219132193|NCT06711094|DRUG|Dalpiciclib|"Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator"
219132194|NCT06711432|DRUG|Norepinephrine or phenylephrine|Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1ug/kg/min, or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on reaching the target MAP(\>=80mmHg).
219713465|NCT06188000|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|The patients was given extra virgin olive oil, an unrefined (not processed with chemicals or heat) for of olive oil
219713466|NCT06188000|DIETARY_SUPPLEMENT|Olive Oil|The patients was given olive oil.
219713467|NCT06188000|DIETARY_SUPPLEMENT|Placebo|The patients was given empty capsule
219713468|NCT05168904|DRUG|fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
219713469|NCT05234567|BIOLOGICAL|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
219132195|NCT06711081|DEVICE|low level laser device cryotherapy|using new device direct on the pulp tissue
219132196|NCT06711783|BEHAVIORAL|Family based therapy|Family based therapy following the Maudsley model
219713470|NCT05580562|DRUG|Dordaviprone (ONC201)|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
219713471|NCT05580562|DRUG|Dordaviprone (ONC201) + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
219713472|NCT05580562|OTHER|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
219713473|NCT02693535|DRUG|Palbociclib|drug
219132197|NCT06712381|DRUG|Fluorouracil|Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.
219132198|NCT06712381|PROCEDURE|Photodynamic therapy|Photodynamic therapy (PDT) is a procedure that uses a photosensitizing drug to apply light therapy selectively to target pre-skin cancer, acne and sun damage.
219132199|NCT06712381|PROCEDURE|Carac in combination with PDT|
219227141|NCT01012063|DRUG|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
219227142|NCT03559959|BEHAVIORAL|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
219713474|NCT02693535|DRUG|Sunitinib|drug
219713475|NCT02693535|DRUG|Temsirolimus|drug
219713476|NCT02693535|DRUG|Trastuzumab and Pertuzumab|drug
219713477|NCT02693535|DRUG|Vemurafenib and Cobimetinib|drug
219713478|NCT02693535|DRUG|Regorafenib|drug
219713479|NCT02693535|DRUG|Olaparib|drug
219713480|NCT02693535|DRUG|Pembrolizumab|drug
219713481|NCT02693535|DRUG|Nivolumab and Ipilimumab|drug
219713482|NCT02693535|DRUG|Abemaciclib|drug
219132200|NCT05798104|BEHAVIORAL|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
219132201|NCT00867347|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
219132202|NCT00867347|RADIATION|radiation therapy|Patients undergo radiotherapy
219132203|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care
219132204|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample at baseline.
219132205|NCT06628817|RADIATION|The Intensive Care Bundle with Mortality Reduction|a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
219132206|NCT05914558|DIAGNOSTIC_TEST|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
219132207|NCT02909439|DRUG|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
219132208|NCT02909439|DRUG|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
219132209|NCT03347045|COMBINATION_PRODUCT|Trimodal Prehab & ERP|"1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date."
219132210|NCT03347045|OTHER|No Prehab; ERP Alone|1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
219132211|NCT00472147|PROCEDURE|shock efficacy|
219132212|NCT05085184|DRUG|administration of UI018|Test
219132213|NCT05085184|DRUG|co-administration of UIC201806 and UIC201602|Reference
219132214|NCT01151254|DRUG|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
219132215|NCT01151254|OTHER|Propofol|Propofol for sedation in the CVICU
219132216|NCT00354094|DRUG|[S,S]-Reboxetine|
219132217|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
219132218|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
219132219|NCT05602857|OTHER|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
219132220|NCT05602857|OTHER|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
219132221|NCT05409404|OTHER|Aerobic exercise + hot water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
219132222|NCT05409404|OTHER|Aerobic exercise + thermoneutral water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
219132223|NCT03683472|BEHAVIORAL|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
219132224|NCT04565249|DRUG|PLN-74809|PLN-74809
219132225|NCT04565249|DRUG|Placebo|Placebo
219132226|NCT02337010|DEVICE|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
219132227|NCT02337010|DEVICE|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
219132228|NCT02337010|DRUG|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
219132229|NCT02337010|DRUG|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
219132230|NCT00738075|DEVICE|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
219132231|NCT05505929|DEVICE|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
219132232|NCT06630416|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219132233|NCT06630416|PROCEDURE|Computed Tomography|Undergo CT
219132234|NCT06630416|DRUG|Pemetrexed|Given IV
219132235|NCT04162509|OTHER|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
219132236|NCT03361592|PROCEDURE|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
219132237|NCT03361592|PROCEDURE|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
219132238|NCT04157712|DRUG|ALZ-801 or matching placebo|
219132239|NCT01369589|DRUG|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
219132240|NCT01369589|DRUG|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
219132241|NCT00984282|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
219227143|NCT01138384|DRUG|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
219227144|NCT01138384|DRUG|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
219227145|NCT05027633|DRUG|Pembrolizumab|given by IV
219227146|NCT05027633|DRUG|Docetaxel|given by IV
219227147|NCT05027633|DRUG|Cisplatin|given by IV
219227148|NCT05027633|DRUG|Carboplatin|given by IV
219227149|NCT00665392|DRUG|cisplatin|75 mg/m², day 1. 3 cycles
219227150|NCT00665392|DRUG|docetaxel|75 mg/m² Day 1. 3 cycles
219227151|NCT00665392|DRUG|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
219227152|NCT00665392|DRUG|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
219227153|NCT04712539|DRUG|Baloxavir Marboxil|Given PO
219227154|NCT04712539|DRUG|Oseltamivir|Given PO
219227155|NCT04250545|DRUG|Sapanisertib|Given PO
219227156|NCT04250545|DRUG|Telaglenastat Hydrochloride|Given PO
219227157|NCT02798341|OTHER|Biospecimen Collection|
219227158|NCT05643430|DEVICE|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
219227159|NCT03742414|COMBINATION_PRODUCT|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
219227160|NCT03742414|COMBINATION_PRODUCT|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
219713483|NCT02693535|DRUG|Talazoparib|drug
219713484|NCT02693535|DRUG|Atezolizumab and PHESGO|drug
219132242|NCT00984282|DRUG|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
219132243|NCT04553302|OTHER|This study does not contain any intervention.|This study does not contain any intervention.
219227161|NCT03742414|OTHER|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
219227162|NCT06335173|DRUG|sabirnetug|Intravenous sabirnetug
219227163|NCT06335173|DRUG|Placebo|Intravenous Placebo
219227164|NCT04810546|DIETARY_SUPPLEMENT|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
219227165|NCT05525455|DRUG|TT-816|TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
219132244|NCT04138771|DEVICE|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
219132245|NCT03013842|DEVICE|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
219132246|NCT04319796|OTHER|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~* Name of specialist center~* Pseudonym:~* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~* Sex~* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~* Age of onset~* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease\_Search.php?lng=DE~* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~* Agreement to be contacted for research purposes: Yes/No~* Biological samples (Yes / No)~* Link to a biobank (Link / No)~* Classification of disability (Disease group specific score)"
219132247|NCT00315055|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
219132248|NCT00315055|BIOLOGICAL|DTaP-IPV//PRP~T combined|0.5 mL, IM
219132249|NCT00315055|BIOLOGICAL|Hepatitis B vaccine|0.5 mL, IM
219132250|NCT02359435|DRUG|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
219132251|NCT02359435|DRUG|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
219713485|NCT02693535|DRUG|Atezolizumab and Talazoparib|drug
219713486|NCT02693535|DRUG|Entrectinib|drug
219713487|NCT02693535|DRUG|Larotrectinib|drug
219713488|NCT02693535|DRUG|Tucatinib plus Trastuzumab Subcutaneous (SC)|drug
219713489|NCT02693535|DRUG|Futibatinib|drug
219713490|NCT06770400|OTHER|Temperature Optimized for Sleep|Using the cloud-controlled thermostat, we will prescribed bedroom temperature based on the observed relationship between the individual's sleep quality and the temperature of their bedroom.
219713491|NCT06770400|OTHER|Participant's Preferred Temperature|Temperature is set by the individual based on their own habits and preference.
219132252|NCT05092906|OTHER|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
219132253|NCT05092906|OTHER|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide"
219132254|NCT00735800|BEHAVIORAL|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
219132255|NCT00735800|BEHAVIORAL|Telephone Support|Supportive telephone counseling about caregiving
219132256|NCT00496379|DRUG|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
219132257|NCT00719017|PROCEDURE|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
219132258|NCT00719017|RADIATION|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
219132259|NCT00719017|PROCEDURE|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
219132260|NCT01289119|DRUG|Alogliptin|Alogliptin tablets
219132261|NCT01289119|DRUG|Placebo to alogliptin|Alogliptin placebo-matching tablets.
219132262|NCT01289119|DRUG|Metformin|Stable metformin dose
219132263|NCT01289119|DRUG|Pioglitazone|Stable pioglitazone dose
219132264|NCT02414919|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
219132265|NCT02414919|DRUG|ParaGard|Copper T380A
219132266|NCT02414919|DRUG|Implanon/Nexplanon|Etonorgestrel contraceptive implant
219132267|NCT02389192|DRUG|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
219132268|NCT02074956|BIOLOGICAL|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
219132269|NCT02074956|BIOLOGICAL|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
219713492|NCT05291689|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
219713493|NCT03831724|DEVICE|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
219713494|NCT04248361|DIAGNOSTIC_TEST|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
219132270|NCT01407601|DIETARY_SUPPLEMENT|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
219132271|NCT02912195|DRUG|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
219132272|NCT02912195|DRUG|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
219132273|NCT01649791|DRUG|lenalidomide|Given orally
219227166|NCT05525455|DRUG|A PD-1 inhibitor|Programmed death receptor-1 (PD 1)-blocking antibody
219227167|NCT02422524|DRUG|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
219227168|NCT05507723|OTHER|Treat-to-target|Treatment to achieve urate target using supported self-management approach
219227169|NCT05507723|OTHER|Usual Care|Treatment escalation by GP based on usual clinical practice
219227170|NCT05594524|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
219227171|NCT05541965|OTHER|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
219227172|NCT00544115|DRUG|busulfan|
219227173|NCT00544115|DRUG|cyclophosphamide|
219227174|NCT00544115|DRUG|cyclosporine|
219227175|NCT00544115|DRUG|etoposide|
219132274|NCT01649791|OTHER|laboratory biomarker analysis|Correlative study
219132275|NCT01649791|PROCEDURE|lymph node biopsy|Correlative study
219227176|NCT00544115|DRUG|fludarabine phosphate|
219227177|NCT00544115|DRUG|melphalan|
219227178|NCT00544115|DRUG|methotrexate|
219227179|NCT00544115|DRUG|mycophenolate mofetil|
219227180|NCT00544115|DRUG|sirolimus|
219227181|NCT00544115|DRUG|tacrolimus|
219227182|NCT00544115|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219713495|NCT04248361|OTHER|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
219713496|NCT02612155|BIOLOGICAL|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
219132276|NCT01649791|PROCEDURE|bone marrow aspiration|Correlative study
219227183|NCT00544115|PROCEDURE|peripheral blood stem cell transplantation|
219227184|NCT00544115|RADIATION|total-body irradiation|
219227185|NCT06505122|BEHAVIORAL|Dyadic Life Review|DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.
219227186|NCT05206942|DIAGNOSTIC_TEST|Doppler ultrasound|Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
219713497|NCT02612155|BIOLOGICAL|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
219713498|NCT02876081|DRUG|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
219132277|NCT01649791|OTHER|pharmacological study|Correlative study
219132278|NCT01649791|OTHER|flow cytometry|Correlative study
219132279|NCT02687646|DRUG|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
219227187|NCT05206942|DIAGNOSTIC_TEST|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
219227188|NCT05206942|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
219227189|NCT01638000|DRUG|Mirabegron|oral tablet
219227190|NCT01638000|DRUG|Solifenacin succinate|oral tablet
219227191|NCT04220021|DRUG|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
219227192|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
219227193|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
219360604|NCT00817011|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
219360605|NCT00817011|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
219360606|NCT04798287|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
219360607|NCT04798287|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
219132280|NCT05482854|OTHER|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
219132281|NCT05475470|PROCEDURE|finger-blade technique|laparoscopic access technique for group a
219132282|NCT05475470|PROCEDURE|Hasson's technique|laparoscopic access technique for group b
219132283|NCT05475470|PROCEDURE|veress needle technique|laparoscopic access technique for group c
219132284|NCT02860923|DRUG|Exenatide|
219132285|NCT02860923|DRUG|Placebo|
219132286|NCT00004886|DRUG|docetaxel|
219227194|NCT06071468|DEVICE|UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
219713499|NCT06493747|DEVICE|Combined Low- and High-Frequency rTMS Intervention|This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.
219713500|NCT06493747|DEVICE|Combined High- and Low-Frequency rTMS Intervention|Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.
219713501|NCT06493747|DEVICE|rTMS|Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.
219132287|NCT00004886|DRUG|dofequidar fumarate|
219132288|NCT03079375|OTHER|basic intervention|medication review
219132289|NCT03079375|OTHER|extended intervention|medication review, medication interview before discharge and follow-up
219132290|NCT06413940|BEHAVIORAL|Myofunctional Therapy|Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
219132291|NCT06413940|BEHAVIORAL|Inspiratory Muscle Training|Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
219132292|NCT06413940|BEHAVIORAL|Aerobic Exercise|Exercise intensity :40%-60% HRmax , 3-5 days/week
219132293|NCT04045119|OTHER|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
219132294|NCT00991276|DRUG|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
219132295|NCT00991276|DRUG|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
219132296|NCT00991276|DRUG|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
219132297|NCT04619459|OTHER|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
219132298|NCT03474562|DRUG|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
219132299|NCT03474562|DRUG|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
219132300|NCT05701462|DIAGNOSTIC_TEST|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
219132301|NCT05381662|BIOLOGICAL|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
219132302|NCT03155490|BEHAVIORAL|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
219132303|NCT02138331|BIOLOGICAL|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
219713502|NCT06493747|DEVICE|rTMS + Acupuncture|"Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery."
219713503|NCT06493747|DEVICE|rTMS|Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.
219713504|NCT06493747|DEVICE|Acupuncture|"Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation."
219713505|NCT05484947|DIAGNOSTIC_TEST|Elisa HIV testing|HIV testing on a voluntary basis
219132304|NCT00551772|DRUG|SB-742457|
219132305|NCT02786771|DEVICE|Spire|
219132306|NCT02786771|DEVICE|Muse headband|
219132307|NCT04923139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
219132308|NCT00711646|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219132309|NCT00711646|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
219227195|NCT06071468|PROCEDURE|Endocscopic CTR|"Endoscopic CTR makes one or two short incisions to introduce instruments for visualizing. The key procedural steps involved in Endoscopic CTR are listed below.~1. Following the delivery of anesthesia, the surgeon makes a small wrist incision (usually less than 1.5 cm), with or without a small palmar incision (usually less than 1.5 cm, depending on whether they are using a single portal or double portal technique, respectively.~2. A series of dilators and raspers are used to create space in the carpal tunnel and clear synovial tissue from the undersurface fo the TCL.~3. A camera attached to a narrow tube (endoscope) is inserted into the carpal tunnel.~4. The transverse carpal ligament (which forms the roof of the carpal tunnel) is identified.~5. Using specialized cutting instruments and endoscopic guidance, the surgeon transects the TCL.~6. Endoscopic visualization and/or probing are used to confirm a complete release.~7. The wound(s) is/are typically closed with sutures."
219227196|NCT06071468|PROCEDURE|Open CTR|"OCTR is the most commonly used CTR technique in the United States.The key procedural steps involved in OCTR are listed below.~1. Following the delivery of anesthesia, an incision is made in the palm directly over the carpal tunnel.~2. The surgeon cuts through the palmar fascia to identify the TCL.~3. The surgeon transects the TCL with a scalpel and/or similar cutting instruments.~4. The surgeon inspects the carpal tunnel to ensure proper decompression.~5. The wound is closed with sutures."
219227197|NCT06025344|DRUG|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
219227198|NCT06025344|DRUG|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
219227199|NCT03901807|DEVICE|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
219713506|NCT06237881|DRUG|KSQ-001EX|Given by IV
219713507|NCT06237881|DRUG|Interleukin-2|Given by IV
219713508|NCT06237881|DRUG|Cyclophosphamide|Given by IV
219713509|NCT06237881|DRUG|Fludarabine|Given by IV
219713510|NCT05687110|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219713511|NCT05687110|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219713512|NCT05687110|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
219713513|NCT05687110|BIOLOGICAL|Novobiocin Sodium|Given PO
219132310|NCT04594330|DRUG|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
219132311|NCT04594330|OTHER|placebo|15 mL of placebo twice a day for 14 days
219132312|NCT00323752|PROCEDURE|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
219227200|NCT05465109|OTHER|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
219227201|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
219713514|NCT05710640|DEVICE|Active tcVNS or Sham tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
219713515|NCT05710640|DEVICE|Active tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
219713516|NCT01601977|DEVICE|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
219713517|NCT01601977|DEVICE|Usual care|Non-invasive ventilation with standard ventilator
219713518|NCT03590327|DEVICE|Transcranial Magnetic Stimulation|rTMS
219132313|NCT02485379|PROCEDURE|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
219713519|NCT03324113|DRUG|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219713520|NCT03324113|DRUG|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
219713521|NCT03324113|DRUG|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
219713522|NCT03324113|DRUG|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
219713523|NCT04055493|DRUG|Ribociclib 200Mg Oral Tablet|3 x 200 MG per os
219132314|NCT05982353|DEVICE|PTFE application|Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
219713524|NCT00261521|DRUG|epoetin alfa|
219132315|NCT05982353|DEVICE|Gelatin sponge|gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
219132316|NCT05237219|PROCEDURE|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
219132317|NCT05237219|PROCEDURE|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
219132318|NCT00198848|DRUG|Iron-folic acid supplement|
219132319|NCT03467724|DEVICE|Fractional Radiofrequency (FRF)|Fractional radiofrequency will be delivered to the area of the surgical scar.
219132320|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
219132321|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
219132322|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
219132323|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
219132324|NCT01644773|DRUG|Crizotinib|"Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
219132325|NCT01644773|DRUG|Dasatinib|"Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
219132326|NCT00677248|DRUG|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
219132327|NCT00677248|DRUG|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
219132328|NCT03721016|DRUG|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
219132329|NCT03721016|DRUG|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
219132330|NCT02488317|OTHER|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
219132331|NCT00921076|BEHAVIORAL|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
219132332|NCT04300816|BEHAVIORAL|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
219132333|NCT04300816|BEHAVIORAL|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
219132334|NCT03155152|OTHER|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
219132335|NCT03155152|OTHER|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
219227202|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
219227203|NCT03954782|DRUG|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
219227204|NCT03954782|DRUG|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
219227205|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
219713525|NCT03625128|DRUG|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
219713526|NCT05383378|DRUG|si-544|Subcutaneous injection in the abdomen
219713527|NCT05383378|DRUG|Placebo|Subcutaneous injection in the abdomen
219713528|NCT04767451|DIAGNOSTIC_TEST|ultrasound assessment|Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
219132336|NCT05285514|DIAGNOSTIC_TEST|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
219132337|NCT01680276|BEHAVIORAL|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
219132338|NCT01680276|OTHER|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
219132339|NCT02232178|DRUG|2 100mg Xaracoll implants|
219132340|NCT02232178|DRUG|3 100mg Xaracoll implants|
219132341|NCT02232178|DRUG|150mg Bupivacaine HCl injection|
219132342|NCT05097469|DEVICE|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
219132343|NCT05097469|DEVICE|Sham laser treatment|3 consecutive sessions of sham laser treatment
219132344|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets|
219132345|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
219713529|NCT00712504|DRUG|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
219713530|NCT00712504|DRUG|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
219713531|NCT05975645|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
219132346|NCT02184325|DRUG|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
219132347|NCT05001919|PROCEDURE|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
219227206|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
219227207|NCT04783038|OTHER|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
219713532|NCT05975645|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
219713533|NCT05975645|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219713534|NCT00992875|BEHAVIORAL|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
219132348|NCT05001919|PROCEDURE|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
219132349|NCT00957086|DRUG|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
219132350|NCT00957086|DRUG|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
219132351|NCT01225939|DRUG|AZD8329|tablet
219132352|NCT01225939|DRUG|AZD8329|Solution
219132353|NCT03015974|DRUG|Corticosteroid|
219227208|NCT04783038|OTHER|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
219713535|NCT06048224|DRUG|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
219713536|NCT06048224|DRUG|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
219132354|NCT03015974|DRUG|Cyclophosphamide|
219132355|NCT03015974|DRUG|Mycophenolate mofetil|
219132356|NCT03015974|DRUG|Dipyridamole|
219132357|NCT03015974|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|
219132358|NCT02454543|PROCEDURE|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
219132359|NCT02454543|DRUG|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
219132360|NCT00817635|DRUG|LCI699|LCI699 oral capsules
219132361|NCT00817635|DRUG|Eplerenone|Eplerenone oral capsules
219132362|NCT00817635|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
219132363|NCT00817635|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
219132364|NCT00913913|BIOLOGICAL|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
219132365|NCT00913913|DRUG|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
219713537|NCT06571305|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
219132366|NCT00913913|BIOLOGICAL|IL-2|IL-2 18 MiU/m2 CI 5 days
219132367|NCT00913913|BIOLOGICAL|IFN|IFN 6 MiU subc TIW
219132368|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
219132369|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
219132370|NCT02753413|BIOLOGICAL|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219132371|NCT02753413|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219132372|NCT05652530|DRUG|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
219132373|NCT06116162|DEVICE|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
219132374|NCT02853474|BEHAVIORAL|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
219227209|NCT03099356|DRUG|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
219132375|NCT02853474|OTHER|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
219132376|NCT02853474|OTHER|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
219132377|NCT02749045|RADIATION|SPECT imaging|myocardial perfusion imaging
219132378|NCT01020838|DRUG|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
219132379|NCT04340284|BIOLOGICAL|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
219132380|NCT02470936|BEHAVIORAL|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
219132381|NCT06554171|OTHER|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
219132382|NCT06554171|OTHER|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
219132383|NCT01930019|DRUG|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
219132384|NCT06348186|OTHER|Guidebook|Folder that will be given to the participant to carry out 5 minutes of intervention daily
219132385|NCT06348186|OTHER|Guidebook and Myofascial Reorganization® (RMF).|The intervention will be carried out once a week for 30 minutes for 6 weeks. It will include passive, active-assisted moments (with and without load). In addition to a folder that will be given to the participant to carry out 5 minutes of intervention daily.
219227210|NCT03099356|DRUG|Sirolimus|Sirolimus 4 mg, PO, days 1-28
219713538|NCT06571305|BEHAVIORAL|My Sleep Our Sleep (MSOS)|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
219713539|NCT04761250|DIETARY_SUPPLEMENT|Lifestyle|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
219713540|NCT00005047|DRUG|cisplatin|
219713541|NCT00005047|DRUG|doxorubicin hydrochloride|
219713542|NCT00005047|DRUG|methotrexate|
219713543|NCT00005047|DRUG|vinblastine|
219713544|NCT06502483|BEHAVIORAL|Promoting Resilience in Stress Management Program|Promoting Resilience in Stress Management (PRISM; Rosenberg et al., 2018; Rosenberg et al., 2021) is is an evidence-based skills-based resilience intervention. In the current study, PRISM sessions with be facilitated by a trained mental health provider to equip participants with skills for coping with anxiety, low mood, and adjustment to cancer diagnosis and to target four resilience resources (i.e., stress management, goal setting, cognitive reframing, and meaning-making). Sessions will be conducted by phone or Zoom, a HIPAA-compliant telemedicine platform. The optional mPRISM phone application includes 6 modules to practice PRISM skills and is available for iOS/Android.
219713545|NCT00104689|DRUG|capecitabine|
219713546|NCT00104689|DRUG|oxaliplatin|
219713547|NCT00232882|DRUG|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
219132386|NCT00518362|DRUG|TW|TW,120 mg/d
219132387|NCT00722215|DRUG|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
219132388|NCT00722215|DRUG|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
219132389|NCT00722215|DRUG|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
219132390|NCT01524536|DRUG|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
219132391|NCT01908634|DIETARY_SUPPLEMENT|Milk-based Strawberry Beverage without meal|
219132392|NCT01908634|DIETARY_SUPPLEMENT|Water-Based Strawberry Beverage without meal|
219132393|NCT01908634|DIETARY_SUPPLEMENT|Milk-based strawberry Beverage with meal|
219132394|NCT01908634|DIETARY_SUPPLEMENT|Water-Based strawberry Beverage with meal|
219713548|NCT00232882|DRUG|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
219132395|NCT02616861|DRUG|IW-1973|IW-1973 Tablet
219132396|NCT02616861|DRUG|Matching Placebo Tablet|Matching placebo tablet
219132397|NCT02638415|PROCEDURE|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
219132398|NCT02638415|OTHER|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
219713549|NCT00232882|DRUG|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
219713550|NCT02249325|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
219713551|NCT02789748|DEVICE|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
219713552|NCT04878900|OTHER|Survey|Survey
219713553|NCT01124240|DRUG|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
219713554|NCT06254339|PROCEDURE|OAGB|using OAGB procedure as metabolic bariatric surgery
219713555|NCT06254339|PROCEDURE|DJB-SG|using DJB-SG procedure as metabolic bariatric surgery
219713556|NCT06059599|OTHER|active informed consent|new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
219713557|NCT06189950|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
219713558|NCT03863912|OTHER|Disney movie|Disney movie on portable DVD Player.
219713559|NCT03863912|OTHER|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
219713560|NCT04866160|DRUG|BI 1291583|BI 1291583
219713561|NCT04866160|DRUG|Placebo|Placebo
219713562|NCT01500551|DRUG|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
219713563|NCT01500551|DRUG|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
219713564|NCT04614155|OTHER|Educational Intervention|Take part in health education session
219713565|NCT04614155|PROCEDURE|HPV Self-Collection|Receive HPV self-collection kit
219713566|NCT04614155|OTHER|Questionnaire Administration|Complete questionnaires
219713567|NCT05785611|DRUG|Filgotinib|Tablets administered orally once daily
219713568|NCT05785611|DRUG|Placebo|Tablets administered orally once daily
219713569|NCT03954535|BEHAVIORAL|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
219713570|NCT03954535|BEHAVIORAL|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
219713571|NCT06683378|PROCEDURE|Reparative Autologous peripheral nerve tissue|"At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed.~From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the nucleus basalis of Meynert (NBM) or substantia nigra (SN)."
219713572|NCT06348108|BIOLOGICAL|Talquetamab|Given subcutaneously (SQ)
219713573|NCT06348108|DRUG|Iberdomide|Given orally (PO)
219713574|NCT06348108|DRUG|Dexamethasone|Given PO
219713575|NCT06348108|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219713576|NCT04768972|DRUG|ION363|ION363 will be administered by IT bolus injection.
219713577|NCT04768972|DRUG|Placebo|Placebo will be administered by IT bolus injection.
219713578|NCT05255991|DRUG|Placebo|Placebo administered QID
219713579|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
219713580|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
219713581|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
219713582|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
219713583|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
219713584|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
219713585|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
219713586|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
219713587|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
219713588|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
219713589|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
219713590|NCT04388475|DRUG|OKN-007|Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
219713591|NCT04388475|DRUG|Temozolomide (TMZ)|Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
219713592|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
219713593|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
219713594|NCT00098475|DRUG|Dexamethasone|Given PO
218986988|NCT03890601|BIOLOGICAL|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
218986989|NCT04650711|DIAGNOSTIC_TEST|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
219132399|NCT02638415|DRUG|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
219132400|NCT00853424|PROCEDURE|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
219132401|NCT00853424|OTHER|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
219713595|NCT00098475|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219713596|NCT00098475|DRUG|Lenalidomide|Given PO
219713597|NCT00098475|DRUG|Thalidomide|Given PO
219713598|NCT05351580|DEVICE|DiSCERN|Smart watch Monitoring
219713599|NCT05667324|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
219713600|NCT05667324|DRUG|Dexamethasone|Plus 4 mg dexamethasone
219713601|NCT05667324|DRUG|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
219713602|NCT05393232|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
219713603|NCT05393232|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
218986990|NCT03935360|OTHER|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
218986991|NCT05950256|DEVICE|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
218986992|NCT04131426|DRUG|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
218986993|NCT04131426|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
218986994|NCT00636558|DRUG|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
218986995|NCT01750983|DRUG|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
218986996|NCT01750983|DRUG|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
218986997|NCT03742830|DEVICE|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
218986998|NCT03128411|DRUG|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
218986999|NCT00094705|BIOLOGICAL|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
218987000|NCT00094705|BIOLOGICAL|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
219713604|NCT03168672|DEVICE|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
219713605|NCT06413927|BEHAVIORAL|Online Vehicle and Driver Safety Education|This online video education program provides education in vehicle and driver safety (e.g. vehicle maintenance, adjusting car seats and seatbelts). This online training will take up to 2 hours to complete and will have a short quiz at the end to determine compliance with this online training.
219713606|NCT06413927|BEHAVIORAL|Online Driver Skills Training|The online driver training is the Accelerated Curriculum to Create Effective Learning (ACCEL) is designed to enhance the ability to anticipate, recognize and respond to hazards and to maintain attention to the road. The training is delivered online via a computer and can be done from home or at a school or other site that has a computer with internet access. It requires up to two hours to complete, and will be hosted on a platform that will track progress and completion through the training (such as accuracy, duration in modules, time to complete) and a short quiz will be provided at the end to assess learning.
219713607|NCT06413927|BEHAVIORAL|Behind-the-Wheel Driver Training|The professional behind-the-wheel training course will be conducted in-person, delivered by local driving school partner Coastline Academy. The curriculum consists of 6 hours of training with assigned practice between lessons, and meets Pennsylvania and national standards. Post-lesson forms completed by the instructors will record adherence and consistency (intervention fidelity).
219713608|NCT05514548|DRUG|INV-202|INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
219713609|NCT05514548|DRUG|Placebo|Placebo Matching size and number of tablets
219713610|NCT06136169|BEHAVIORAL|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
219713611|NCT04324619|OTHER|Online interactive learning activities|"1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
219713612|NCT03366246|DRUG|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
219713613|NCT03366246|DRUG|placebo|according randomized this side received placebo or active product
218987001|NCT04547712|DEVICE|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
218987002|NCT05276024|DEVICE|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
218987003|NCT04790929|DEVICE|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
218987004|NCT04790929|BEHAVIORAL|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
218987005|NCT05496400|RADIATION|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:"
218987006|NCT00993070|DRUG|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
218987007|NCT00993070|DRUG|placebo|vehicle gel, applied 4 times per day for 8 weeks
218987008|NCT04737382|DIAGNOSTIC_TEST|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
218987009|NCT04737382|DIAGNOSTIC_TEST|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
218987010|NCT00594659|BEHAVIORAL|Psychotherapy|Nine session treatment
218987011|NCT00594659|BEHAVIORAL|Computerized Psychotherapy|Nine session computer delivered treatment
218987012|NCT00594659|BEHAVIORAL|Motivational enhancement therapy|Two session treatment
218987013|NCT00065689|DEVICE|high-intensity light therapy|
218987014|NCT01937416|BIOLOGICAL|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
218987015|NCT03118713|DRUG|metformin|oral
219713614|NCT06208267|DRUG|Tranexamic acid|This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
219713615|NCT05836948|DRUG|SHR-9839|Weekly fixed dose injection of SHR-9839
219132402|NCT04176458|DEVICE|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
219132403|NCT04744779|BEHAVIORAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
219132404|NCT05060679|OTHER|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
219132405|NCT05060679|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
219132406|NCT05060679|OTHER|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
219132407|NCT03973424|BEHAVIORAL|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
219132408|NCT03973424|BEHAVIORAL|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
219132409|NCT01570751|DRUG|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
219132410|NCT01570751|DRUG|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
219132411|NCT05593952|OTHER|Dual task|exercise with dual task + usual treatment
219713616|NCT02807922|DRUG|Zopiclone|
219713617|NCT02807922|DRUG|Placebo|
219227211|NCT05352230|DEVICE|Free style libre-2|A cross-over design will allow estimation of feasibility and acceptability of patients using CGM vs patients using blood glucose meter monitoring (conventional therapy). The study will consist on two phases, the first will last three months, then it will be a two months of washout period followed by the crossover, then the second phase will last another three months. Patients in the conventional therapy group will also use masked CGM (CGM professional) during the first two and last two weeks of their study phase with the purpose of collecting CGM-parameters information. The cross over randomization will be stratified by donor type (live vs deceased) using a web-based randomization tool. During the washout period the patients will continue using blood glucose meter monitoring
219227212|NCT03991234|BEHAVIORAL|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, \& contextualized reading.
219713618|NCT02619201|DRUG|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
219713619|NCT02619201|DRUG|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
219713620|NCT00829153|DEVICE|U Clip|Interuppted nitional clips
219713621|NCT00829153|PROCEDURE|Conventional prolene anastomosis|Continuous prolene anastomosis
219132412|NCT05593952|OTHER|Single task|exercise without dual task + usual treatment.
219132413|NCT02808442|BIOLOGICAL|UCART19|
219132414|NCT00930813|DEVICE|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
219132415|NCT00930813|DEVICE|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
219713622|NCT03930433|DRUG|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
219713623|NCT03930433|DRUG|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
219713624|NCT03930433|DRUG|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
219713625|NCT02649699|OTHER|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
219713626|NCT06008002|PROCEDURE|M-TAPA block|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed
219713627|NCT06008002|PROCEDURE|EXORA block|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed
219713628|NCT06008002|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
219713629|NCT04520373|OTHER|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
219132416|NCT00882635|DRUG|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
219132417|NCT00882635|DRUG|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
219132418|NCT00452465|BEHAVIORAL|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
219132419|NCT00315120|PROCEDURE|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
219132420|NCT00315120|PROCEDURE|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
219132421|NCT00315120|PROCEDURE|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
219713630|NCT04520373|BIOLOGICAL|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
219713631|NCT04796857|DRUG|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
219713632|NCT04796857|DRUG|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
219713633|NCT05458128|DRUG|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
219713634|NCT00010998|PROCEDURE|Yoga|
219713635|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
219227213|NCT03991234|BEHAVIORAL|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge \& counting strategies to build arithmetic skill.
219713636|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
219713637|NCT02607072|DRUG|Placebo|
219713638|NCT02512419|BEHAVIORAL|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
219132422|NCT00315120|PROCEDURE|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
219227214|NCT03991234|BEHAVIORAL|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm \& similar objectives as the math intervention arm.
219713639|NCT02512419|BEHAVIORAL|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
219713640|NCT02512419|DEVICE|Actigraph GT3X|
219713641|NCT05436613|DEVICE|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
219713642|NCT03771716|BEHAVIORAL|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
219713643|NCT03771716|BEHAVIORAL|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
219713644|NCT05879718|DRUG|Placebo|Placebo (intravenous infusion)
219713645|NCT05879718|DRUG|PF-06823859|PF-06823859 (intravenous infusion)
219713646|NCT05679895|BIOLOGICAL|CD1a-CAR T|Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
218987016|NCT03118713|DRUG|ipragliflozin|oral
218987017|NCT03118713|DRUG|glimepiride|oral
218987018|NCT01941667|BEHAVIORAL|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
218987019|NCT01941667|OTHER|Usual Care|Usual care as defined by by the Cardiology Department.
218987020|NCT04941560|OTHER|No intervention|No intervention
218987021|NCT02318251|OTHER|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
219132423|NCT00604006|DRUG|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
219132424|NCT00604006|DRUG|Placebo|Placebo (lactose in capsules for blinding) once daily
219132425|NCT01603719|DIETARY_SUPPLEMENT|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
219132426|NCT00223119|DEVICE|Absorbable Sutures|
219132427|NCT01424332|DRUG|Darexaban|oral
219132428|NCT01424332|DRUG|Acetyl Salicylic Acid (ASA)|oral
219132429|NCT05923762|BEHAVIORAL|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
219132430|NCT01457560|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
219132431|NCT01457560|BIOLOGICAL|OPV|One dose administered orally
219132432|NCT03991949|OTHER|Experimental Infant Formula|Formula fed Ad libitum
219132433|NCT01942967|OTHER|Echocardiography|"Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow."
219713647|NCT04002362|DRUG|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) is administered deep in the gluteal muscle by a trained registered nurse.
219713648|NCT05344157|BIOLOGICAL|XSTEM-OA|XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
219132434|NCT01942967|OTHER|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
219132435|NCT05790408|DEVICE|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
219132436|NCT05790408|DEVICE|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
219132437|NCT05479539|BEHAVIORAL|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
219132438|NCT06060418|OTHER|aromtherapy|aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
219132439|NCT06173570|DRUG|AZD0780|AZD0780 administered orally, once daily for 12 weeks
219132440|NCT06173570|DRUG|Placebo|Placebo administered orally, once daily for 12 weeks
219132441|NCT06165185|OTHER|Water|Please see the associated arm description
219132442|NCT06165185|OTHER|Coffee|Please see the associated arm description
219132443|NCT06165185|OTHER|Control|Please see the associated arm description
219132444|NCT05061953|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219713649|NCT06263478|DRUG|INCA034176|IV infusion
219132445|NCT04726046|DRUG|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
219132446|NCT02161653|DRUG|Prednisone plus Metadoxine|
219132447|NCT02161653|DRUG|Pentoxifylline plus Metadoxine|
219132448|NCT00138606|DRUG|vildagliptin|
219132449|NCT05691660|DRUG|TAS3731 Dose1|Oral administration,1 day,QD
219132450|NCT05691660|DRUG|TAS3731 Dose2|Oral administration,7 days,QD
219132451|NCT05691660|DRUG|TAS3731 Dose3|Oral administration,7 days,BID
219713650|NCT06292741|DEVICE|Sudoscan|recording of sudomotor function and pupillary reactivity
219132452|NCT05691660|DRUG|Placebo|Oral administration, 1 day,QD
219132453|NCT05691660|DRUG|Placebo|Oral administration, 7 days,QD
219132454|NCT05691660|DRUG|Placebo|Oral administration, 7 days,BID
219132455|NCT00903019|BEHAVIORAL|Tele-Problem-Solving Therapy|Six sessions of tele-PST
219132456|NCT00903019|BEHAVIORAL|In-Person PST|Six sessions of in person PST
219132457|NCT00903019|BEHAVIORAL|Attention control|Six weekly telephone calls
219132458|NCT02480335|DRUG|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
219132459|NCT02485626|PROCEDURE|2D tissue doppler echocardiography|
219132460|NCT02809300|BIOLOGICAL|blood collection|
219132461|NCT00938535|BEHAVIORAL|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
219132462|NCT00221351|PROCEDURE|CRP point of care testing|
219132463|NCT00562913|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
219132464|NCT00201695|DRUG|Doxil®|40 mg/m2 IV day 1
219132465|NCT00201695|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
219132466|NCT00201695|DRUG|Dexamethasone|40 mg PO days 1-4
219132467|NCT00201695|DRUG|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
219713651|NCT05516498|DRUG|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
219713652|NCT05516498|DRUG|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
219713653|NCT05516498|DRUG|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
219713654|NCT05516498|DRUG|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
219713655|NCT05516498|DRUG|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
219713656|NCT05516498|DRUG|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
219713657|NCT05516498|DRUG|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
219713658|NCT05535244|DRUG|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
219713659|NCT05535244|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
219713660|NCT05350202|DRUG|Empagliflozin|Empagliflozin was administered according to the approved product information.
219713661|NCT06576869|PROCEDURE|Upper extremity orthopedic surgeries.|Upper extremity orthopedic surgeries that require the use of a tourniquet.
219713662|NCT06967129|DEVICE|Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent.|Test Lens
219713663|NCT06967129|DEVICE|ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.|Control Lens
219713664|NCT04635423|BIOLOGICAL|V503|9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
219132468|NCT01886014|DRUG|Oxytocin|
219713665|NCT04635423|OTHER|Placebo|0.9% sodium chloride (NaCL)
219713666|NCT06282861|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Product to be used according to specifications. 1 inhalation daily for 12 months
219713667|NCT06282861|DRUG|Brimica|As per product specifications
219713668|NCT06282861|DRUG|Duaklir|As per product specifications
219713669|NCT06282861|DRUG|Ultibro|As per product specifications
219713670|NCT06282861|DRUG|Ulunar|As per product specifications
219132469|NCT01886014|OTHER|placebo|
219132470|NCT06465680|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
219132471|NCT03768856|RADIATION|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
219713671|NCT06282861|DRUG|Xoterna|As per product specifications
219713672|NCT06282861|DRUG|Anoro|As per product specifications
219132472|NCT06327919|DIETARY_SUPPLEMENT|Probiotic supplement|multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks
219132473|NCT06327919|OTHER|Placebo supplement|The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
219713673|NCT06282861|DRUG|Laventair|As per product specifications
219713674|NCT06282861|DRUG|Spiolto Respimat|As per product specifications
219713675|NCT06282861|DRUG|Yanimo|As per product specifications
219713676|NCT06282861|DRUG|Foradil|As per product specifications
219713677|NCT06282861|DRUG|Broncoral|As per product specifications
219713678|NCT06282861|DRUG|Formoterol stada|As per product specifications
219713679|NCT06282861|DRUG|Oxis|As per product specifications
219713680|NCT06282861|DRUG|Formatris|As per product specifications
219713681|NCT06282861|DRUG|Formoterol Aldo|As per product specifications
219713682|NCT06282861|DRUG|Onbrez|As per product specifications
219713683|NCT06282861|DRUG|Oslif|As per product specifications
219713684|NCT06282861|DRUG|Hirobriz|As per product specifications
219713685|NCT06282861|DRUG|Striverdi|As per product specifications
219713686|NCT06282861|DRUG|Beglan|As per product specifications
219713687|NCT06282861|DRUG|Betamican|As per product specifications
219713688|NCT06282861|DRUG|Inaspir|As per product specifications
219713689|NCT06282861|DRUG|Serevent|As per product specifications
219713690|NCT06282861|DRUG|Soltel|As per product specifications
219713691|NCT06282861|DRUG|Eklira|As per product specifications
219713692|NCT06282861|DRUG|Bretaris|As per product specifications
219713693|NCT06282861|DRUG|Seebri|As per product specifications
219713694|NCT06282861|DRUG|Tovanor|As per product specifications
219713695|NCT06282861|DRUG|Enurev|As per product specifications
219713696|NCT06282861|DRUG|Spiriva|As per product specifications
219713697|NCT06282861|DRUG|Tavulus|As per product specifications
219713698|NCT06282861|DRUG|Sirkava|As per product specifications
219713699|NCT06282861|DRUG|Braltus|As per product specifications
219713700|NCT06282861|DRUG|Gregal|As per product specifications
219713701|NCT06282861|DRUG|Incruse|As per product specifications
219713702|NCT06282861|DRUG|Rolufta|As per product specifications
219713703|NCT06567678|DRUG|Colchicine 0.5 MG oral tablet twice daily|Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU and Aspirin reaction unit test assay, followed by a subsequent repeat test 2-week after a 2-week, colchicine 0.5mg oral tablet twice-daily
219132474|NCT02145182|DRUG|Eculizumab|Eculizumab is a complement component 5 inhibitor.
219132475|NCT02145182|DRUG|Placebo|0.9% sodium chloride
219132476|NCT01043471|OTHER|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
219132477|NCT01043471|OTHER|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
219132478|NCT03168191|DRUG|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
219713704|NCT06026709|BEHAVIORAL|EmoEase|"The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
219713705|NCT05928247|BEHAVIORAL|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
219713706|NCT05928247|BEHAVIORAL|Non-Contingent Reinforcement (NCR)|During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
219713707|NCT05928247|BEHAVIORAL|Competing Items and Response Blocking|The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
219713708|NCT05928247|BEHAVIORAL|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
219713709|NCT05278416|DEVICE|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
219713710|NCT03505281|BIOLOGICAL|Blood samples|"Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)"
219713711|NCT04325022|DEVICE|Primary Total Hip Arthroplasty|Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
219132479|NCT03168191|OTHER|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
219132480|NCT03168191|OTHER|Menthol Flavor|Menthol flavored e-cigarette for lab session
219132481|NCT04835038|DRUG|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
219132482|NCT04835038|DRUG|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
219132483|NCT02947568|OTHER|non-interventional study|
219132484|NCT00588419|BEHAVIORAL|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
219132485|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
219713712|NCT04325022|DEVICE|Revision Total Hip Arthroplasty|Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
219713713|NCT03628209|DRUG|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
219132486|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
219132487|NCT05996757|PROCEDURE|Wet clothing removal|The participants in the intervention group will have their clothing removed prior to insulation.
219132488|NCT03615248|DEVICE|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler."
219132489|NCT05416671|BEHAVIORAL|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
219132490|NCT03999554|BIOLOGICAL|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
219132491|NCT03999554|BIOLOGICAL|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
219132492|NCT03999554|BIOLOGICAL|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
219713714|NCT03628209|DRUG|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
219713715|NCT03628209|PROCEDURE|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
219713716|NCT06070649|DRUG|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
219713717|NCT06070649|DRUG|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
219713718|NCT06070649|DRUG|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
219713719|NCT04164979|DRUG|Cabozantinib|Given PO
219713720|NCT04164979|DRUG|Pembrolizumab|Given IV
219713721|NCT06965998|DRUG|Full dose rivaroxaban|The intervention group will receive full dose rivaroxaban for 90 days.
219713722|NCT06965998|DRUG|Low dose rivaroxaban|The comparator group will receive the standard treatment of low dose rivaroxaban.
219713723|NCT06965998|DRUG|Placebo|Since the treatment arm has an AM and PM dose of study drug from Day 1-21, the comparator group will take 1 placebo pill in the PM to keep the two arms blinded.
219132493|NCT03999554|BIOLOGICAL|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
219132494|NCT03999554|OTHER|Placebo|This group will receive saline placebo administered intranasally.
219132495|NCT03533036|DEVICE|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
219132496|NCT02465086|OTHER|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
219132497|NCT00699686|DRUG|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
219132498|NCT00699686|DRUG|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
219713724|NCT06600152|DEVICE|MAP Wound Matrix|The MAP Wound Matrix is indicated for the management of full thickness wounds, including surgical sites, donor skin graft sites, wound dehiscence, lacerations, and draining wounds. The application of MAP Wound Matrix will occur immediately after Mohs surgery once hemostasis has been achieved
219713725|NCT06600152|DEVICE|DuoDerm|DuoDerm is a hydrocolloid dressing will be topically applied to the wound immediately following Mohs surgery according to the manufacturer\&#39;s instructions.
219713726|NCT05325281|DRUG|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
219713727|NCT05325281|DRUG|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
219713728|NCT05325281|DRUG|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
219713729|NCT05325281|DRUG|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
219713730|NCT05325281|DRUG|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
219713731|NCT05325281|DRUG|Gemcitabine|Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
219713732|NCT05325281|RADIATION|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
219713733|NCT03133156|OTHER|Exercise Intervention|10-Week Aerobic Exercise Training
219713734|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
219713735|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
219713736|NCT05633654|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
219713737|NCT05633654|DRUG|Pembrolizumab|Administered intravenously
219713738|NCT05633654|DRUG|Capecitabine|Tablets administered orally
219713739|NCT05144503|DEVICE|SpherePVI™ Catheter|SpherePVI™ Catheter with the Affera Mapping and Ablation System
219713740|NCT05315700|DRUG|ORIC-114|ORIC-114 oral daily
219713741|NCT05315700|DRUG|Chemotherapy drug|21 days for up to 4 cycles
219713742|NCT05756530|OTHER|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
219713743|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
219713744|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
219713745|NCT06147778|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
219713746|NCT06025838|BEHAVIORAL|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
219713747|NCT06615258|BEHAVIORAL|Dynamic Neuromuscular Stabilization based breathing training and pelvic floor muscle training|"DNS-based breathing exercises will be taught to the women in this group using tactile biofeedback. To create tactile stimulation, one of the hard sponges placed within a belt will be positioned anteriorly in the inguinal region, and the other posteriorly in the Grynfeltt-Lesshaft triangle region. Breathing training will be provided in 3 different positions: sitting, crawling, and happy baby pose.~Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises.~Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position."
219713748|NCT06615258|BEHAVIORAL|Pelvic floor muscle training|Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises. Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position.
219713749|NCT04565054|DRUG|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
218987022|NCT02318251|OTHER|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
218987023|NCT02798874|DRUG|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
218987024|NCT02798874|DRUG|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
218987025|NCT00384501|DEVICE|Intacs|
218987026|NCT01906632|BIOLOGICAL|DC-CIK Immunotherapy|
218987027|NCT00228384|DEVICE|GORE VIABAHN Endoprosthesis|Implantation
218987028|NCT00228384|DEVICE|Bare Nitinol Stent|Implantation
218987029|NCT02836093|BEHAVIORAL|FACIT-Fatigue 52-point questionnaire|
218987030|NCT00002190|DRUG|Saquinavir|
218987031|NCT00002190|DRUG|Lamivudine|
218987032|NCT00002190|DRUG|Zidovudine|
218987033|NCT04498520|DRUG|Abexinostat Tosylate|Given PO
218987034|NCT04498520|DRUG|Fulvestrant|Given IM
218987035|NCT04498520|DRUG|Palbociclib|Given PO
218987036|NCT05746793|PROCEDURE|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
219713750|NCT04997902|DRUG|Tipifarnib|Oral administration
219713751|NCT04997902|DRUG|Alpelisib|Oral administration
219713752|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
219713753|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
219713754|NCT05307250|OTHER|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
219713755|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
219713756|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
219713757|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
219713758|NCT06358950|DRUG|ALKS 2680|Oral tablet of ALKS 2680 for once daily administration
219713759|NCT06358950|DRUG|Placebo|Oral tablet containing matching placebo for once daily administration
219713760|NCT05748990|DRUG|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
219713761|NCT05748990|DRUG|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
219713762|NCT06226051|DEVICE|PEAPOD Infant Body Composition measuring device|PEAPOD is a device to that collects body composition measurements.
219713763|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
219713764|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
219713765|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
219713766|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
218987037|NCT05746793|DIAGNOSTIC_TEST|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
218987038|NCT05746793|DIAGNOSTIC_TEST|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
218987039|NCT05746793|DIAGNOSTIC_TEST|Urine collection|Collection of urine in a plastic cup.
218987040|NCT05746793|OTHER|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
218987041|NCT05746793|DIAGNOSTIC_TEST|Baseline questionnaire|questionnaire the patient has to fill in
218987042|NCT05746793|OTHER|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
218987043|NCT05746793|DIAGNOSTIC_TEST|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
218987044|NCT05746793|DIAGNOSTIC_TEST|cardiac work-up|Using transthoracic ultrasound.
218987045|NCT05746793|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement
218987046|NCT01161459|DRUG|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
218987047|NCT01161459|DRUG|FK506|capsule
218987048|NCT03100500|DRUG|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
218987049|NCT00388596|DRUG|SB-751689|
218987050|NCT02352974|DRUG|GAD-Alum|
218987051|NCT02352974|DRUG|Vitamin D|
218987052|NCT04720469|DEVICE|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
218987053|NCT00227097|BEHAVIORAL|Education Notebook for anticoagulant treatment|
218987054|NCT01020175|PROCEDURE|Bone marrow transplantation|Patients received bone marrow transplantation
218987055|NCT01020175|PROCEDURE|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
219132499|NCT00335023|OTHER|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
219132500|NCT05571358|DEVICE|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
219132501|NCT01863004|DRUG|Bortezomib|
219132502|NCT03697733|PROCEDURE|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
219132503|NCT04405713|PROCEDURE|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
219132504|NCT04405713|PROCEDURE|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
219132505|NCT04405713|PROCEDURE|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
219132506|NCT02104648|OTHER|Placebo RO4602522|Daily oral doses
219132507|NCT02104648|DRUG|RO4602522|Daily oral doses
219132508|NCT02104648|DRUG|RO4602522|Single, oral dose
219713767|NCT05457985|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
219713768|NCT05457985|BEHAVIORAL|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
219713769|NCT05457985|BEHAVIORAL|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
219713773|NCT06620510|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
219713774|NCT06620510|BIOLOGICAL|No Interventions|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
219713775|NCT06523634|RADIATION|Stereotactic body radiotherapy (SBRT)|5 fractions of SBRT to the prostate bed with or without whole pelvic radiotherapy Treatment every other day.
219713776|NCT06523634|RADIATION|SOC RT|"Standard salvage radiotherapy to the prostate bed with or without whole pelvic radiotherapy. Each participating centre can specify upfront which RT schedule will be used in the control arm, with the choice between the following schedules:~* Hypofractionated: 20 fractions (Daily treatment (OTT 4-5 weeks))~* Normofractionated: 32-35 fractions (Daily treatment (OTT 7-8 weeks))"
219713777|NCT02990793|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
219713778|NCT02990793|DEVICE|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
219713779|NCT05986188|OTHER|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
219713780|NCT06974734|DRUG|PF-08046037|Given into the vein (IV; intravenous)
219713781|NCT06974734|DRUG|sasanlimab|Given under the skin (SQ; subcutaneous)
219713782|NCT06063486|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219713783|NCT06063486|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219713784|NCT06063486|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219132509|NCT02104648|DRUG|moxifloxacin|400 mg oral dose given on Day 1 or 11
219132510|NCT02104648|OTHER|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
219132511|NCT02274493|DEVICE|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
219132512|NCT02274493|PROCEDURE|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
219132513|NCT02274493|PROCEDURE|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
219132514|NCT02274493|BEHAVIORAL|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
219132515|NCT00558363|DRUG|Avodart|0.5 mg administered orally once daily
219132516|NCT00558363|OTHER|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
219713785|NCT06063486|DIETARY_SUPPLEMENT|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
219713786|NCT06063486|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
219713787|NCT06063486|DRUG|Placebo Administration|Given PO
219713788|NCT06063486|OTHER|Questionnaire Administration|Ancillary studies
219227215|NCT05403658|BEHAVIORAL|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
219132517|NCT05534633|OTHER|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
219132518|NCT03102710|DEVICE|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
219132519|NCT03102710|OTHER|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
219132520|NCT03102710|OTHER|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
219227216|NCT05403658|BEHAVIORAL|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
219227217|NCT06527755|DRUG|Eplontersen Solution for Injection|an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
219713789|NCT06975098|OTHER|Life balance intervention group program|Life balance intervention group program is a four-week group intervention program for individuals with depression, with sessions lasting two hours each week. The program will address life balance issues such as daily scheduling, time management, stress coping, emotional regulation, and social participation, and will be tailored to individual patient needs. Through group discussions and practical exercises, participants will learn to apply these skills in their daily lives. Telephone support will be provided during the intervention period to offer emotional support and enhance participation rates.
219713790|NCT06976229|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. XS228 in SAD and MAD following intrathecal injection through lumbar puncture in subacute spinal cord Injury participants.For SAD,the participants will single intrathecal injection with the dose level as 5×10\^7 cells 、1.5×10\^8 cells. For MAD, the participants will intrathecal injection of XS228 in Day 1, Day15, Day 29, Day 43 under the dose level of 5×10\^7 cells、1.5×10\^8 cells.Dose escalation followed a rule-based 3+3 design.~XS228 is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of subacute spinal cord injury and represents a novel approach in regenerative medicine."
219713791|NCT06976710|BEHAVIORAL|Preoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
219713792|NCT06976710|BEHAVIORAL|Postoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
219713793|NCT06976710|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
219132521|NCT03102710|OTHER|Control cream|A neutral cream will be applied on the arm as a control.
219132522|NCT06582563|DIAGNOSTIC_TEST|Whole Blood Clotting Time|Comparator
219132523|NCT05591079|DRUG|CS0159 (Linafexor)|Oral QD
219132524|NCT03780790|DRUG|Bupivacaine|% 0,25
219227218|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
219227219|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
219227220|NCT06965595|OTHER|Routine care|This group will be the control group. Routine care practices carried out in the hospital (vital sign monitoring, administration of analgesics, anti-inflammatory and antibiotics when necessary, and mobilization starting from the 6th hour) will be applied and the data will be recorded.
219227221|NCT06965595|OTHER|Routine care + Physiotherapy|"In addition to routine care practices, this group will receive physiotherapy and rehabilitation. During the postoperative period, the intervention will be applied twice a day.~Posture training: Information about posture will be provided in different positions and training will be conducted.~Breathing training (Diaphragmatic breathing, thoracic expansion exercises)~In-bed mobilization (Lower and upper extremity exercises, foot-ankle exercises (dorsiflexion-plantar flexion / inversion-eversion), hip and knee flexion-extension exercises, cervical region joint range of motion and stretching exercises, upper extremity exercises (shoulder elevation, circumduction, elbow and wrist flexion-extension exercises), pelvic floor training and exercises)~Out-of-bed mobilization (Sitting, standing, walking training after the 6th hour)"
219132525|NCT05074615|OTHER|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
219227222|NCT06965595|OTHER|Routine care + Vagal stimulation|In addition to routine care practices, this group will receive vagal stimulation. The stimulation will be applied to the cervical region at 10 Hz, 200 μs for 20 minutes, twice a day.
219227223|NCT06965595|OTHER|Routine care + Physiotherapy + Vagal stimulation|In addition to routine care practices, this group will receive physiotherapy and rehabilitation, along with vagal stimulation.
219227224|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
219227225|NCT06769685|DRUG|Basal therapy|Group A was treated with basal therapy including drugs such as interleukin-11, Ricocin, and Epsilon, and was administered until the PLT was ≥75×109/L.
219713794|NCT06976710|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
219713795|NCT06976710|BEHAVIORAL|Preoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
219713796|NCT06976710|BEHAVIORAL|Postoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
219713797|NCT06976710|OTHER|Preoperative Nursing|Risk management, Managing pain, Wound care, Bowel function, Surgical education
219227226|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group B)|In group B, they were treated with rhTPO and Heptabopa, and were medicated until their PLT was ≥75×109/L.
219227227|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group C)|Ctit patients with platelet counts \<50×109/L were included in group C. All were treated with rhTPO and hypertrombopa and medicated until PLT ≥75×109/L.
219227228|NCT06507189|OTHER|Combined endurance and resistance training|ET will consist of 3x/wk training (MWF) with MF being steady state cycling, treadmill, or elliptical at 70-75% HRR for 30 min and the W session being a 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) targeting 85-90% HRR. The treadmill and elliptical on M or F will be provided for variety but the mainstay will be cycle ergometry. On MF participants will complete 3 sets x 8-12 repetitions for leg press, knee extension, hamstring curl, chest press, seated row, overhead press, lat pulldown, triceps push-down, and biceps curl in superset fashion \[i.e., alternate between opposing muscle groups without rest (chest press followed by seated row)\] with a 60 s rest between supersets. Sets will be performed with load progression to ensure volitional fatigue in the 8-12 rep range. Core exercises (trunk flexion and extension) will also be included using bodyweight only for 3 sets.
219227229|NCT02224105|DRUG|BI 653048 BS|
219227230|NCT02224105|DRUG|Prednisolone low|
219227231|NCT02224105|DRUG|Prednisolone high|
219227232|NCT02224105|DRUG|Placebo|
219227233|NCT02224105|DRUG|sodium chloride infusion|
219713798|NCT06976710|OTHER|Postoperative Nursing|Risk management, Managing pain, Wound care, Bowel function/Stoma management, Education
219713799|NCT06976710|BEHAVIORAL|Preoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
219713800|NCT06976710|BEHAVIORAL|Postoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
219713801|NCT06976710|OTHER|Usual Care|All participants will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
219713802|NCT06028464|DRUG|BI 1810631|BI 1810631
219713803|NCT06028464|DRUG|Carbamazepine|Carbamazepine
219713804|NCT05291234|DRUG|ABBV-916|Intravenous administration
219713805|NCT05291234|DRUG|Placebo|Intravenous administration
219713806|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
219713807|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
219713808|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
219713809|NCT06619418|DEVICE|TENS device|will be using an FDA- cleared TENS device for electrical stimulation (TENS 7000, Compass Health Brands) in combination with commercially-available headphones for acoustic stimulation (AKG 845 BT).Will be shown how to use the device, trained on the multimodal stimulation procedure, and sent home with the device for 12 weeks.
219713810|NCT06619418|BEHAVIORAL|Integrative health modalities|will be instructed on the integrative health modalities for this study. They will be given a tablet that includes the videos for the visually guided deep breathing. They will also receive the reflective journal and be set up for health coaching visits. At the end of the 12 weeks, this group of participants will return to the U of M campus and complete an interview about satisfaction and usability of the IH modalities.
219132526|NCT05074615|OTHER|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
219132527|NCT00396058|DRUG|Methylphenidate|
219132528|NCT06582251|BEHAVIORAL|High-intensity functional training|Participants assigned to this group will undergo 8 weeks of high-intensity functional training.
219132529|NCT06582251|BEHAVIORAL|Traditional resistance training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training.
219132530|NCT06582251|BEHAVIORAL|Concurrent training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training followed by high-intensity interval aerobic training.
219132531|NCT01295918|DIETARY_SUPPLEMENT|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
219132532|NCT02862327|DRUG|intravenous dexamethasone|intravenous injection of dexamethasone
219132533|NCT02862327|DRUG|intravenous placebo|intravenous injection of placebo
219132534|NCT02862327|DRUG|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
219132535|NCT02862327|OTHER|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
219132536|NCT02118506|OTHER|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
219132537|NCT02118506|OTHER|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
219132538|NCT04012853|DEVICE|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
219132539|NCT00897637|OTHER|laboratory biomarker analysis|Correlative studies
219132540|NCT03530553|OTHER|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
219132541|NCT04962334|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
219132542|NCT04962334|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
219227234|NCT02224105|DRUG|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
219227235|NCT03340415|OTHER|Accelerated Rehabilitation plan|early weight bearing after surgery
219227236|NCT02983266|DEVICE|InTENsity MicroCombo|An electrotherapy device.
219713811|NCT04981093|DRUG|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
219713812|NCT04981093|DRUG|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
219713813|NCT06473207|OTHER|Remote ischemic post conditioning sessions|Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
219227237|NCT04493359|DRUG|Renin-angiotensin system inhibitors|switch anti-hypertensive class
219227238|NCT01683409|DRUG|Baricitinib|Administered orally
219227239|NCT01683409|DRUG|Placebo|Administered orally
219227240|NCT04728841|GENETIC|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses"
219227241|NCT00076674|DRUG|Intravenous Levodopa|
219227242|NCT03118206|DEVICE|lumbar traction|
219227243|NCT03118206|PROCEDURE|spinal manipulation|
219713814|NCT06473207|OTHER|Sham sessions|Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
219713815|NCT06838325|OTHER|Prostate Cancer Screening|"The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word).~Additionally, participant demographic information will be collected (such as your age)."
219227244|NCT03118206|PROCEDURE|surgery|
219227245|NCT05652868|DRUG|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days.
219227246|NCT06225570|DRUG|Isotretinoin|This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.
219227247|NCT06225570|DRUG|Tetracycline|This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
219713816|NCT05537116|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
219713817|NCT05537116|BEHAVIORAL|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
219713818|NCT05537116|BEHAVIORAL|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
219713819|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
219713820|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
219713821|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
219713822|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
219713823|NCT06443541|BEHAVIORAL|High-intensity implementation strategies (HIS)-Students|Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
219713824|NCT06443541|BEHAVIORAL|Low-intensity implementation strategies (LIS) for Students|Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
219713825|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Faculty|"* Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)"
219713826|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Faculty|Passive access to web-based educational materials
219227248|NCT04823468|DIETARY_SUPPLEMENT|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
219227249|NCT04823468|RADIATION|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
219227250|NCT04823468|DRUG|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
219227251|NCT06969833|OTHER|Constitution of a biological collection|"* Left-over tissue samples (tumor tissue of different nature) frozen and secured in paraffin, and derived from standard care, are collected at study entrance until the end of oncologic treatment.~* One blood sample of 28mL is collected at time of inclusion"
219227252|NCT06969833|OTHER|Assessment of Quality of Life and level of anxiety/depression|Questionnaires QLQ-C30, OV-28 and HADS are completed by the patients at inclusion, after 3 and 6 cycles of systemic treatment, and every 3 months up to 2 years after inclusion
219227253|NCT04218864|BEHAVIORAL|Strength for U in Relationship Empowerment (SURE)|A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.
219227254|NCT04218864|BEHAVIORAL|Attention, time, and information matched control|A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
219227255|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
219227256|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
219713827|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)"
219713828|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials"
219713829|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion"
219713830|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual"
219713831|NCT06617884|OTHER|Gait and balance training|The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
219713832|NCT05528419|DRUG|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
219713833|NCT05528419|DRUG|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
219713834|NCT04123535|DEVICE|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
219713835|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
219713836|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
219713837|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
219713838|NCT05626816|DEVICE|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
219713839|NCT05626816|DIAGNOSTIC_TEST|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
219713840|NCT05626816|DIAGNOSTIC_TEST|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
219227257|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
219227258|NCT01634789|DRUG|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
219227259|NCT06975410|DRUG|YH32364|"Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose.~Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment)"
219227260|NCT06981195|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the study drug. During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
219227261|NCT06981195|DRUG|Lemborexant 10 MG|During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
218987056|NCT02420340|BEHAVIORAL|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
219132543|NCT05555264|BEHAVIORAL|Self-Guided|Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.
219132544|NCT05555264|BEHAVIORAL|Therapist-Guided|Therapists will spend \~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
219132545|NCT02685280|DEVICE|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
218987057|NCT02151383|DRUG|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
218987058|NCT03501290|DIETARY_SUPPLEMENT|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
218987059|NCT03438929|DEVICE|Diode laser|Diolaze XL blended modes diode laser
218987060|NCT02099175|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
218987061|NCT02099175|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
218987062|NCT02099175|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
218987063|NCT02099175|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
218987064|NCT02099175|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
218987065|NCT02099175|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
218987066|NCT02099175|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
218987067|NCT02099175|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
218987068|NCT02099175|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
218987069|NCT02099175|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
218987070|NCT03424408|DRUG|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
218987071|NCT01785069|DEVICE|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
218987072|NCT03249883|DEVICE|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
218987073|NCT03372044|DRUG|PF-06865571 Immediate release suspension|Suspension
218987074|NCT03372044|DRUG|PF-06865571 Slow release MR tablets|Modified release tablets
218987075|NCT03372044|DRUG|PF-06865571 Fast release MR tablets|Modified release tablets
218987076|NCT03372044|DRUG|PF-06865571 Immediate release tablets|Immediate release tablets
218987077|NCT01421914|OTHER|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
218987078|NCT04378556|BEHAVIORAL|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
218987079|NCT05624281|DRUG|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
219227262|NCT03988101|DRUG|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
219713841|NCT05626816|DIAGNOSTIC_TEST|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
219713842|NCT05626816|DIAGNOSTIC_TEST|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
219713843|NCT05626816|DIAGNOSTIC_TEST|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
219713844|NCT05626816|DIAGNOSTIC_TEST|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
219713845|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
219713846|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
219713847|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
219713848|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
219713849|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
219713850|NCT06302543|PROCEDURE|autologous bone marrow cells injection|under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
219713851|NCT06389240|OTHER|6 weeks post-operatively early weight bearing|Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
219713852|NCT06389240|OTHER|10 weeks post-operatively weight bearing (standard of care)|Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
218987080|NCT05248061|OTHER|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~\- \*Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~\*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~\*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
219132546|NCT03883438|PROCEDURE|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
219132547|NCT04969822|DEVICE|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
219132548|NCT03284749|OTHER|Copper impregnated wound dressing|Copper impregnated wound dressing
219132549|NCT03284749|OTHER|Normal wound dressing|Normal wound dressing
219132550|NCT03284749|OTHER|Copper impregnated maternity pads|Copper impregnated maternity pads
219132551|NCT03284749|OTHER|Normal maternity pads|Normal maternity pads
219132552|NCT05693155|BEHAVIORAL|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
219132553|NCT05638230|DIAGNOSTIC_TEST|Left atrial reservoir strain|"LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase."
219132554|NCT00742274|DEVICE|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
219227263|NCT03988101|DRUG|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
219227264|NCT06602089|DEVICE|Arterial pressure monitoring|We will record intraarterial arterial pressure, finger-sensor arterial pressure and oscillometric arterial pressure in all included patients.
219132555|NCT00742274|OTHER|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
219132556|NCT00100984|DRUG|FUZEON [enfuvirtide]|
219132557|NCT00104611|DEVICE|Repetitive Transcranial Magnetic Stimulation|
219132558|NCT04638387|DIETARY_SUPPLEMENT|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
219132559|NCT04638387|DIETARY_SUPPLEMENT|Placebo|Placebo comparator to P125
219132560|NCT01101165|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
219132561|NCT01101165|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
219132562|NCT06549517|BEHAVIORAL|Cognitive training|MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
219132563|NCT05307991|DRUG|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
219132564|NCT05307991|DEVICE|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ \[FDA approved\]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA \[CE mark\]) if RPR is positive.
219132565|NCT05307991|BEHAVIORAL|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
219132566|NCT05307991|DIAGNOSTIC_TEST|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
219227265|NCT00281905|DRUG|carboplatin|
219227266|NCT00281905|DRUG|cisplatin|
219227267|NCT00281905|DRUG|cyclophosphamide|
219227268|NCT00281905|DRUG|methotrexate|
219227269|NCT00281905|DRUG|vincristine sulfate|
219227270|NCT00281905|RADIATION|radiation therapy|
219227271|NCT06595160|OTHER|Non-Interventional Study|Non-interventional study
219227272|NCT06586125|OTHER|Powered Mobility Training|The study procedure aims to observe the partecipants' behaviour while using the Virtual Reality - Power Mobility Program (VR-PMP) simulator applied during Power Mobility Training in clinical practice for 15 sessions. Participants use either semi-immersive mode (laptop screen with VR-PMP simulator) or immersive mode (head-mounted display with VR-PMP simulator). Five out of ten children unable to use conventional VR controllers or alternative access technologies available on the market, use brain-computer interface (BCI) developed specifically for these children to control the VR-PMP simulator.
219227273|NCT06141499|BEHAVIORAL|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
219227274|NCT06141499|BEHAVIORAL|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
219227275|NCT06980766|DEVICE|Non Invasive Blood Pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
219227276|NCT06982677|BEHAVIORAL|Nurse Navigator Intervention|The intervention will integrate education, decision support, patient activation strategies, and cognitive-behavioral menopause symptom management skills. Participants will receive video and audio-recorded materials and a written manual.
219227277|NCT06982677|OTHER|Education Control|"The control arm will receive the National Cancer Institute booklet, Facing Forward: Life After Cancer Treatment, which provides basic strategies for navigating cancer survivorship."
219227278|NCT06800989|BEHAVIORAL|sophrology sessions|Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
219132567|NCT00055432|DRUG|Gemzar and Alimta|
219132568|NCT00002111|DRUG|Saquinavir|
219132569|NCT03874455|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
219132570|NCT03655483|DRUG|GLS-010|Full-human anti-pd-1 monoclonal antibodies
219227279|NCT06800989|DEVICE|Morphee Device|Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.
219227280|NCT06978920|DRUG|Allogeneic dopaminergic neural precursor cell(NCR201)|Bilateral implantation
219227281|NCT06027268|DRUG|Trilaciclib|IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
219227282|NCT06027268|DRUG|Pembrolizumab|IV infusion Day 1 every 21 days, at dose of 200 mg
219227283|NCT06027268|DRUG|Gemcitabine|IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
219713853|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
219713854|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
219713855|NCT02972840|DRUG|Acalabrutinib|Administered orally (PO)
219713856|NCT02972840|DRUG|Bendamustine|Administered intravenously (IV)
219227284|NCT06027268|DRUG|Carboplatin|IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
219713857|NCT02972840|DRUG|Rituximab|Administered intravenously (IV)
219713858|NCT02972840|DRUG|Placebo|Placebo comparator
218987081|NCT05248061|OTHER|Group B|"The same exercises as in Group 1 will be suitable for the participants.~* PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~* Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
219713859|NCT04886284|DRUG|Ertapenem|Adjunctive ertapenem
218987082|NCT06039397|BEHAVIORAL|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
218987083|NCT01220050|DRUG|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
218987084|NCT01220050|DRUG|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
218987085|NCT02510196|BEHAVIORAL|reminder|
218987086|NCT00134238|DRUG|torcetrapib/atorvastatin|
219713860|NCT04886284|DRUG|Placebo|Saline placebo
219713861|NCT04657289|DRUG|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
219713862|NCT04657289|DEVICE|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
219713863|NCT05453630|BEHAVIORAL|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
219713864|NCT05453630|BEHAVIORAL|Usual Care Control|Educational brochure about colonoscopy
219713865|NCT05589519|DEVICE|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
218987087|NCT00134238|DRUG|atorvastatin|
219132571|NCT04517591|BEHAVIORAL|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
219132572|NCT00273676|PROCEDURE|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
219132573|NCT00800163|OTHER|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
219713866|NCT06303739|DRUG|psilocybin|25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
219713867|NCT06967415|OTHER|Pain, central sensitization,functional status and quality of life.|The patients' pain status, central sensitization functional status, and quality of life will be evaluated according to their stenosis grade.
219713868|NCT06967298|DEVICE|T30 Contact lenses|Individuals who have previously dropped out of Contact lenses (CL) due to discomfort will be refit into T30 contact lenses and their comfort with the product will be assessed.
219713869|NCT06505083|OTHER|modified stepping trainings|step-up on box texture difference
219713870|NCT06344325|DRUG|fospropofol|The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.
219713871|NCT05067491|BEHAVIORAL|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
219713872|NCT06326216|OTHER|Non-Interventional Study|Non-interventional study
219713873|NCT05184842|DRUG|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)
219713874|NCT05184842|DRUG|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
218987088|NCT05454098|DRUG|Clifutinib with fed state|40 mg Clifutinib with food
218987089|NCT05454098|DRUG|Clifutinib with fasted state|40 mg Clifutinib without food
219713875|NCT02025543|DEVICE|MRI|R2 MRI scan
219713876|NCT05707949|DRUG|Atogepant|Oral Tablet
219713877|NCT03893955|DRUG|ABBV-927|Intravenous (IV) Infusion
219713878|NCT03893955|DRUG|ABBV-368|Intravenous (IV) Infusion
219713879|NCT03893955|DRUG|ABBV-181|Intravenous (IV) Infusion
219713880|NCT03893955|DRUG|Carboplatin|Intravenous (IV) Infusion
219713881|NCT03893955|DRUG|Nab-paclitaxel|Intravenous (IV) Infusion
219713882|NCT03683030|DEVICE|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
218987090|NCT05504031|PROCEDURE|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
218987091|NCT05504031|PROCEDURE|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
218987092|NCT00004037|DRUG|docetaxel|
218987093|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
218987094|NCT04361318|COMBINATION_PRODUCT|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
218987095|NCT04361318|OTHER|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
218987096|NCT05176145|DEVICE|VisioCyt®|"* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test"
218987097|NCT00394147|DRUG|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
218987098|NCT00394147|DRUG|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
218987099|NCT04435132|DEVICE|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
219132574|NCT03460574|BEHAVIORAL|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
219132575|NCT03460574|BEHAVIORAL|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
219227285|NCT06986759|OTHER|Laser|The therapy system will be used the Thor DD Laser Therapy Unit. This will be a class 3B laser with an 810-nm, 100-mW infrared probe. Laser or placebo laser treatment protocols will be identical and will be delivered with the patients lying prone, with their foot over the end of the treatment plinth and the ankle plantar-grade. The contact method will be used to apply the laser treatment probe to 3 standardized points on both sides of the Achilles' tendon (6 in all: at the site of the lesion, 2cm proximal, and 2cm distal) for 30 seconds, giving a dose of 3J per point and 18J per session for the active probe(23). The treating physiotherapist, without any knowledge of which position on the switch will be the active laser, will select position 1 or 2 on the switch according to group allocation.
219227286|NCT06986759|OTHER|Extracorporeal shock wave therapy protocol|When treating Achilles tendinopathy, most researchers will be used 3 sessions of extracorporeal shock wave therapy (ESWT) with a one-week break in between. There will also be shorter breaks of 3 to 4 days or longer 2-week breaks. The number of pulses per session will range from 800 to 3000, and the pulse frequency will be between 4 and 50 Hz.
219132576|NCT03460574|BEHAVIORAL|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
219132577|NCT03460574|BEHAVIORAL|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
219132578|NCT04172844|DRUG|Azacitidine|75mg/m\^2 Days 1-7 given IV
219227287|NCT06269003|OTHER|Expert, one-sided|Participants will view a brief description of an expert source and see one-sided e-cigarette education messages.
219227288|NCT06269003|OTHER|Expert, two-sided|Participants will view a brief description of an expert source and see two-sided e-cigarette education messages.
219227289|NCT06269003|OTHER|Peer, one-sided|Participants will view a brief description of a peer source and see one-sided e-cigarette education messages.
219227290|NCT06269003|OTHER|Peer, two-sided|Participants will view a brief description of a peer source and see two-sided e-cigarette education messages.
219132579|NCT04172844|DRUG|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
219227291|NCT05563181|BEHAVIORAL|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
219227292|NCT05563181|BEHAVIORAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
219227293|NCT05563181|BEHAVIORAL|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
219227294|NCT06214923|DEVICE|RelieVRx|Participants will use RelieVRx daily for 20min/day for 3 weeks
219227295|NCT06214923|DEVICE|Sham-VR|"Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks"
219227296|NCT06214923|OTHER|No-VR (natural history control)|Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
219227297|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
219227298|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
219713883|NCT06101303|OTHER|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture."
219132580|NCT04172844|DRUG|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
219132581|NCT00015457|DRUG|Amlodipine plus Botulinum toxin|
219132582|NCT02775981|DRUG|RX0041-002|
219132583|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
219132584|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
219132585|NCT04397198|DIAGNOSTIC_TEST|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
219132586|NCT02799056|DEVICE|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
219227299|NCT07035548|OTHER|Educative: Peer-learning|Peer learning, also known as peer-to-peer learning, is a collaborative educational strategy where students actively learn from one another. It involves interaction among peers to share knowledge, solve problems, and develop skills. This methodology can take various forms, from peer tutoring, where a more advanced student assists a less experienced one, to study groups where everyone contributes equally. The process fosters critical thinking, effective communication, and the co-construction of knowledge. By explaining concepts to others or discussing ideas, students solidify their own understanding and discover new perspectives. Moreover, it promotes individual and collective responsibility, as each participant plays an active role in their own learning and that of their peers. This approach not only improves academic performance but also develops crucial social and emotional skills, such as empathy, patience, and the ability to collaborate, preparing students for more cooperative work
219713884|NCT06101303|BEHAVIORAL|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
219713885|NCT06101303|DIAGNOSTIC_TEST|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
219713886|NCT06101303|PROCEDURE|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (\>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
219132587|NCT03519321|DEVICE|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
219132588|NCT03047733|DEVICE|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
219132589|NCT03047733|DRUG|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
219132590|NCT04463264|DRUG|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
219132591|NCT04463264|DRUG|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
219132592|NCT00651885|DRUG|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
219132593|NCT00651885|DRUG|Placebo|Placebo
219132594|NCT02317705|DRUG|OTL38|
219132595|NCT02317705|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
219132596|NCT02317705|PROCEDURE|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
219132597|NCT05288101|DIETARY_SUPPLEMENT|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
219132598|NCT05288101|PROCEDURE|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
219132599|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
219132600|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
219132601|NCT02219490|DRUG|ABT-450/r/ABT-267|Tablet for oral use
219132602|NCT02219490|DRUG|ABT-333|Tablet for oral use
219132603|NCT02219490|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
219132604|NCT04551157|OTHER|Video Viewing|Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
219132605|NCT00955461|PROCEDURE|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
219132606|NCT00955461|PROCEDURE|Fractionated Laser treatment|
219132607|NCT00852228|DRUG|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
219132608|NCT00852228|DRUG|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
219227300|NCT07043257|BEHAVIORAL|Escape Room-Based Bladder Catheterization Training|This intervention involves an escape room-based educational strategy designed to teach bladder catheterization to nursing students. The method includes interactive puzzles, clinical problem-solving tasks, and scenario-based simulations. The training promotes engagement, teamwork, and application of theoretical knowledge in a gamified learning environment.
219227301|NCT07043257|BEHAVIORAL|Traditional Bladder Catheterization Training|This intervention includes standard bladder catheterization training based on traditional teaching methods. The students will receive theoretical instruction through lectures and demonstration-based simulation without interactive or gamified components.
219227302|NCT07042815|DEVICE|Epidural Stimulation Programs|Epidural stimulations will accompany stimulation programs that have been established during research visits in the prior study and have been recommended by the clinical research team for use in the home and community. Stimulation programs will be given for activities (such as standing or walking) and/or responses that were completed in the previous study. This will be continued until the device is removed or approved for commercial use.
219713887|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
219227303|NCT07042555|BEHAVIORAL|CBT-cp|The participants in CBT-cp arm will receive weekly sessions of Cognitive Behavior Therapy for Chronic Pain.
219713888|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
219713889|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
219713890|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
219713891|NCT06438562|OTHER|Unfortified bouillon plus vitamin A in oil|Participants consume unfortified bouillon with vitamin A oil
219713892|NCT06438562|OTHER|Bouillon fortified with vitamin A #1 plus unfortified oil|Participants consume vitamin A #1 fortified bouillon plus unfortified oil
219713893|NCT06438562|OTHER|Bouillon fortified with vitamin A #2 plus unfortified oil|Participants consume vitamin A #2 fortified bouillon plus unfortified oil
219227304|NCT07042555|OTHER|Pelvic Floor Therapy|The participants in PFT arm will receive weekly sessions of pelvic floor therapy.
219227305|NCT07042555|DRUG|Pharmacotherapy|The participants in Pharmacotherapy arm will receive prescription and non prescription pain medication.
219227306|NCT07042555|COMBINATION_PRODUCT|CBT-cp+PFT|The participants in integrated arm will receive weekly sessions of both CBT-cp and PFT.
219227307|NCT07042555|OTHER|Placebo|The participants in placebo arm will receive sham drug.
219227308|NCT07044050|BIOLOGICAL|allogenic natural killer cells|OT-C001 will be administered by IV infusion weekly for at least 3 doses.
219227309|NCT07042490|PROCEDURE|Plasma adsorption|Plasma adsorption was initiated after endovascular thrombectomy once daily for 3 days.
219713894|NCT06469385|BIOLOGICAL|ENS-002|"Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria.~Low Dose ENS-002 High Dose ENS-002"
219713895|NCT03229200|DRUG|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
219713896|NCT02390284|DRUG|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
219713897|NCT02390284|DRUG|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
219713898|NCT02390284|DRUG|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
219713899|NCT02390284|DRUG|Timolol|Lower intraocular pressure by decreasing production of fluid
219713900|NCT02390284|DRUG|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
219713901|NCT02390284|DRUG|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
219132609|NCT00852228|DRUG|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
219132610|NCT04669405|DEVICE|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
219132611|NCT04669405|OTHER|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
219132612|NCT01014338|DRUG|Fosinopril|10mg od
219132613|NCT01014338|OTHER|lactose|placebo
219132614|NCT06226974|OTHER|Static Stretching|"* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
219713902|NCT02390284|DRUG|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
219713903|NCT02390284|DRUG|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
219713904|NCT01242436|PROCEDURE|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
219713905|NCT03980223|DRUG|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
219713906|NCT05136599|BIOLOGICAL|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
219713907|NCT06239610|DEVICE|electromagnetic placement device|Daily use of an EMPD to verify FT position
219713908|NCT06516575|BEHAVIORAL|sentence manipulations|Auditory stimuli (sentences) are manipulated to have key words masked by noise, or to have prosody (pitch contour) manipulated to be consistent or inconsistent with a specific inferred meaning. Participants repeat the sentences while a camera tracks changes in their eye movements and changes in pupil dilation.
219713909|NCT01922934|BEHAVIORAL|Commercial weight loss program|vouchers for Weight Watchers
219713910|NCT01922934|BEHAVIORAL|Colorado Weigh|Group behavioral weight loss program
219713911|NCT01922934|DIETARY_SUPPLEMENT|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
219713912|NCT01922934|DRUG|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
219132615|NCT00620581|DRUG|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
219132616|NCT00986271|PROCEDURE|EVLI was determinated by PiCCO plus system.|
219132617|NCT04363762|BEHAVIORAL|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
219713913|NCT01922934|BEHAVIORAL|Recreation center passes|1 year pass to a Denver recreation center
219713914|NCT00120978|DRUG|Advair|
219713915|NCT00120978|DRUG|Flovent|
219713916|NCT00003308|RADIATION|stereotactic radiosurgery|
219713917|NCT02314013|DRUG|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
219713918|NCT03641157|OTHER|Easy Intubation|
219713919|NCT06280651|OTHER|dietary preferences and their implications for oral health in children with Autism Spectrum Disorder|This study design typically does not involve interventions. Instead, it observes and analyzes existing conditions or behaviors-in this case, dietary preferences and their implications for oral health in children with Autism Spectrum Disorder (ASD)-without the researchers applying any specific treatment or experimental condition to the participants. The aim is to identify correlations or patterns at a specific point in time, rather than to assess the effects of an intervention.
219713920|NCT02354118|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
219713921|NCT02354118|OTHER|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
219713922|NCT04103008|DIAGNOSTIC_TEST|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
219713923|NCT01583088|DEVICE|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
219132618|NCT04363762|DEVICE|Occlusal splint|Occlusal splint, standard
219132619|NCT03383211|OTHER|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
219132620|NCT05974943|OTHER|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
219132621|NCT04123002|OTHER|Miswak chewing sticks|Chewing stick are routinely used by this population
219132622|NCT02934035|DRUG|Antidepressant|
219132623|NCT01599325|DRUG|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
219132624|NCT03879642|BEHAVIORAL|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
219132625|NCT05406180|BIOLOGICAL|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
219227310|NCT07042490|PROCEDURE|Endovascular Thrombectomy|The patients will be treated with endovascular thrombectomy.
219227311|NCT07042958|PROCEDURE|zirconia membrane|Patients with atrophic maxilla will undergo a direct sinus lift procedure, utilizing a customized zirconia membrane for tenting, along with simultaneous implant placement.
219227312|NCT07042958|PROCEDURE|control group|Patients with atrophic maxilla will undergo a direct sinus lift procedure, using tenting with simultaneous implant placement.
219227313|NCT07043036|DEVICE|GutyCare|Device : GutyCare The participants will use GutyCare remote patient monitoring.
219713924|NCT01583088|DEVICE|sham phrenic nerve stimulation|sham phenic nerve stimulation
219132626|NCT00331214|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
219132627|NCT00331214|DRUG|placebo patch|placebo patch replaced every 3-4 days for 6 months
219132628|NCT02365298|DEVICE|etafilcon A|etafilcon A soft contact lens
219132629|NCT02365298|DEVICE|nelfilcon A|nelfilcon A
219132630|NCT01244100|DRUG|PL2200 fasted|Fasted state
219132631|NCT01244100|DRUG|PL2200 fed|Fed state
219132632|NCT05015972|BIOLOGICAL|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
219132633|NCT04054661|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
219132634|NCT04054661|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
219227314|NCT07042724|BEHAVIORAL|Physical exercise and nutrition intervention for the neoadjuvant setting|"* Physical exercise: 3 sessions/week. It will comprise high-intensity interval training consisting of 2 minutes of high-intensity intervals interspersed with 2 minutes of active recovery completed at mild intensity. The number of intervals will start with five and progress based on the patient's exercise response. Resistance training will include 3-4 exercises involving major muscle groups, performed with body weight or using elastic bands, at moderate to vigorous intensity.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly a high-calorie, high-protein nutritional blend containing arginine, nucleotides \[RNA\], and omega-3 fatty acids, will be proposed."
219227315|NCT07042724|BEHAVIORAL|Physical exercise and nutrition for the adjuvant setting|"* Physical exercise: 2-3 sessions/week. Each session will be composed of: i) resistance training, including 6-8 exercises for major muscle groups performed in 2-4 sets of 8-12 repetitions; ii) aerobic component, starting at 10-20 minutes, based on the patient's baseline assessments, with monthly progressions up to 40-45 minutes at the end of the program. The insentisy will be set from moderate to vigorous.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly whey protein, will be proposed."
219713925|NCT05166876|DRUG|Brequinar Sodium|50 mg, 100 mg, 150 mg, 200 mg x 5 days
219713926|NCT05166876|DRUG|Dipyridamole 75 MG|75 mg TID for 5 days
219713927|NCT05166876|DRUG|Placebo|50 mg, 100 mg, 150 mg, 200 mg x 5 days
219713928|NCT05790590|DIAGNOSTIC_TEST|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
219713929|NCT05790590|DIAGNOSTIC_TEST|Standard dose CT|CT with standard radiation dose and contrast media dose
219132635|NCT04054661|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
219132636|NCT00542022|DRUG|MK0812 / Duration of Treatment: 12 Weeks|
219132637|NCT00542022|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
219132638|NCT03767114|DIAGNOSTIC_TEST|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
219132639|NCT04816890|DRUG|M1 Pram P037|Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
219132640|NCT04816890|DRUG|Insulin lispro|Subcutaneous administration of insulin lispro in combination with a basal insulin.
219132641|NCT03985709|OTHER|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
219132642|NCT01588704|DRUG|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
219132643|NCT03971747|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
219132644|NCT00704756|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
219132645|NCT00704756|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
219132646|NCT01002443|DRUG|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
219132647|NCT01002443|DRUG|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
219132648|NCT05295082|PROCEDURE|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
219132649|NCT05295082|PROCEDURE|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
219132650|NCT02127476|DRUG|KHK6640|Single ascending dose and multiple ascending doses administration
219132651|NCT02127476|DRUG|Matching Placebo|Single ascending dose and multiple ascending doses administration
219227316|NCT07042724|BEHAVIORAL|Health educational material|Health educational materials, including the benefits of exercise and nutrition during cancer care, the current recommendations and information on how to pursue them, as well as strategies to achieve and maintain a healthy psychological status
219227317|NCT07043699|OTHER|Phonophoresis|Each woman in the first group received phonophoresis treatment. The procedure was performed using diclofenac sodium gel. Treatment was administered three times per week over a period of eight weeks. Ultrasound was applied at an intensity of 1 W/cm² for 8 minutes using a pulsed mode at a frequency of 1 MHz.
219713930|NCT01982864|DRUG|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
219713931|NCT00658528|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
219713932|NCT00658528|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
219713933|NCT01544231|BIOLOGICAL|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
219713934|NCT05919134|DIETARY_SUPPLEMENT|Dentoblis|dissolve the tablets in the mouth once a day for 4 weeks
219713935|NCT05919134|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
219132652|NCT03404843|DRUG|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
219132653|NCT03404843|OTHER|Saline|100 mL saline bag.
219132654|NCT00814281|OTHER|placebo|Placebo
219132655|NCT00814281|DRUG|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
219132656|NCT01715909|DRUG|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
219132657|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
219132658|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
219132659|NCT00567164|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
219132660|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
219132661|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
219132662|NCT02543216|DIETARY_SUPPLEMENT|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
219132663|NCT02302209|DRUG|Oxytocin|
219132664|NCT02302209|OTHER|Placebo Comparator|
219132665|NCT02648529|PROCEDURE|MRI|"Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)"
219132666|NCT02648529|PROCEDURE|functional MRI (fMRI)|"fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
219132667|NCT02648529|BEHAVIORAL|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
219132668|NCT00415558|DEVICE|Microwave Ablation System|
219132669|NCT00312312|BIOLOGICAL|Specific immunotherapy|
219132670|NCT00346593|DEVICE|Silicone hydrogel contact lens|
219132671|NCT00586014|PROCEDURE|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
219132672|NCT01750957|DRUG|Placebo|orally daily, 12 weeks
219132673|NCT01750957|DRUG|RO4917523|Dose A orally daily, 12 weeks
219132674|NCT01750957|DRUG|RO4917523|Dose B orally daily, 12 weeks
219132675|NCT04160689|BIOLOGICAL|implantology|placing of implant
219132676|NCT02952755|DRUG|Co-administration of DWC20155/DWC20156|
219132677|NCT02952755|DRUG|DWC20162|
219132678|NCT00710307|PROCEDURE|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
219132679|NCT00710307|GENETIC|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
219132680|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
219132681|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
219132682|NCT06200402|DRUG|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
219132683|NCT06200402|OTHER|Placebo|Placebo
219132684|NCT02577484|DEVICE|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
219132685|NCT02577484|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
219132686|NCT04056923|PROCEDURE|3D-printing guided|3D printed navigational template guided
219132687|NCT04056923|PROCEDURE|CT-guided|CT-guided
219132688|NCT04056923|DRUG|Indocyanine Green|The results are shown by comparison of different colors.
219132689|NCT04056923|DRUG|Methylene blue|The results are shown by comparison of different colors.
219132690|NCT04056923|PROCEDURE|Preoperative|Preoperative localization.
219132691|NCT04056923|PROCEDURE|Intraoperative|Intraoperative localization.
219132692|NCT00944801|DRUG|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
219132693|NCT05818800|DEVICE|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
219132694|NCT05818800|OTHER|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
219227318|NCT07043699|OTHER|Iontophoresis|Each woman in the second group received iontophoresis treatment using a diclofenac sodium solution (Voltaren ampoules). The solution was applied under the cathode (drug delivery electrode). The iontophoresis leads were connected, and the current intensity was adjusted based on individual tolerance, ranging between 1 and 4 mA, for a duration of 20 minutes. The negative electrode was placed on the medial side of the calcaneal tubercle (origin), while the positive electrode was positioned on the forefoot. Treatment was administered three times per week over a period of eight weeks.
219227319|NCT07043998|OTHER|Self-adhesive resin cement in SELF-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in SELF-CURED mode
219713936|NCT01918228|BEHAVIORAL|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
219227320|NCT07043998|OTHER|Self-adhesive resin cement in DUAL-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in DUAL-CURED mode
219713937|NCT03052621|PROCEDURE|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
219713938|NCT02402062|DRUG|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
219713939|NCT01577914|DRUG|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
219713940|NCT01577914|DRUG|Carvedilol|12.5mg tablet once a day
219713941|NCT01550926|DRUG|120 mg orlistat|2 X60 mg capsule
219713942|NCT01550926|DRUG|60 mg orlistat|60 mg orlistat
219713943|NCT01550926|DRUG|orlistat experimental dose|experimental
219713944|NCT00051597|DRUG|SGN-30 (monoclonal antibody)|
219713945|NCT05808959|BEHAVIORAL|Education group|After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
219713946|NCT03292302|DRUG|Placebo|Placebo comparator
219713947|NCT03292302|DRUG|ELX-02|Synthetic aminoglycoside
219713948|NCT04801212|OTHER|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
219713949|NCT04801212|OTHER|core stability exercises|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
219713950|NCT04017962|DRUG|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
219713951|NCT04017962|OTHER|blood draw|Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
219713952|NCT00056147|DRUG|denufosol tetrasodium (INS37217)|
219713953|NCT03183817|BEHAVIORAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform
219713954|NCT06381245|DIAGNOSTIC_TEST|PPG-based remote heart rhythm/rate monitoring|PPG-based remote heart rhythm/rate monitoring
219713955|NCT06381245|DIAGNOSTIC_TEST|ECG-based remote heart rhythm/rate monitoring|ECG-based remote heart rhythm/rate monitoring
219713956|NCT06381245|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography examination|Transthoracic and transesophageal echocardiography examination
219713957|NCT06381245|DIAGNOSTIC_TEST|Liver ultrasound examination|Liver ultrasound examination
219713958|NCT06381245|DIAGNOSTIC_TEST|Rotational angiography with three-dimensional reconstruction|Rotational angiography with three-dimensional reconstruction
219713959|NCT06381245|DIAGNOSTIC_TEST|Blood-derived biomarker analysis|Blood-derived biomarker analysis
219713960|NCT06381245|DIAGNOSTIC_TEST|Mobile health-based spirometry|Mobile health-based spirometry
219713961|NCT02071498|DEVICE|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
219713962|NCT02071498|OTHER|oral and written information|oral and written information about the most common errors of patients
219713963|NCT05590468|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
219713964|NCT05590468|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
219713965|NCT04311957|DRUG|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
219713966|NCT04311957|DRUG|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
219713967|NCT00101959|DRUG|Rebif|
219713968|NCT03517982|DRUG|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
219713969|NCT04165057|OTHER|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
219713970|NCT02695407|OTHER|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
219713971|NCT02695407|OTHER|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
219713972|NCT01428245|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
219713973|NCT01428245|DRUG|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
219713974|NCT01034553|DRUG|Aurora A kinase inhibitor MLN8237|Given orally
219713975|NCT01034553|DRUG|bortezomib|Given IV
219713976|NCT04552093|DRUG|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
219713977|NCT04552093|DEVICE|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
219132695|NCT03244176|DRUG|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
219227321|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with no subsequent laser Biostimulation|Sham laser application
219227322|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with subsequent laser Biostimulation|low lever biostimulation was performed on two consecutive sessions each of 100 s. First session was carried out immediately on surgery time after implant placement, using a diode laser Photo-biomodulation tip in a continuous wave and non-contact mode
219227323|NCT07047040|DRUG|Ketorolac Tromethamine 30 MG/ML Prefilled Syringe|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
219713978|NCT01067300|PROCEDURE|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
219713979|NCT03534219|DEVICE|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
219713980|NCT04151459|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
219713981|NCT05000762|DIETARY_SUPPLEMENT|Zinc|Zinc gluconate 30 mg/day orally
219713982|NCT04607031|DIAGNOSTIC_TEST|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
219713983|NCT00462462|DRUG|Ethanol 96% Gel|
219713984|NCT00462462|DRUG|Ethanol 98% Solution|
219713985|NCT03365245|DEVICE|Microperimetry|Microperimetry is performed at three different days
219713986|NCT03365245|DEVICE|automated visual field|Automated visual field ist performed at three different days
219713987|NCT05193487|OTHER|inferior alveolar nerve block|inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection
219713988|NCT05193487|OTHER|intra-osseous mandibular anaesthesia|intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
219713989|NCT00017160|DRUG|doxorubicin|
219713990|NCT00017160|DRUG|filgrastim|
219713991|NCT00017160|DRUG|ifosfamide|
219713992|NCT00017160|PROCEDURE|biological response modifier therapy|
219132696|NCT00787956|BEHAVIORAL|Internet Chronic Disease Self-Management Program (ICDSMP)|
219132697|NCT00420589|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
219132698|NCT00420589|DRUG|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
219132699|NCT03015831|DRUG|Colchicine|Colchicine will be given to open heart surgery patients
219227324|NCT07047040|DRUG|Gabapentin|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
219227325|NCT07047040|DRUG|Empty Medication Capsules|two empty capsules of gabapentin
219713993|NCT00017160|PROCEDURE|brachytherapy|
219713994|NCT00017160|PROCEDURE|chemotherapy|
219713995|NCT00017160|PROCEDURE|colony-stimulating factor therapy|
219713996|NCT00017160|PROCEDURE|conventional surgery|
219713997|NCT00017160|PROCEDURE|cytokine therapy|
219713998|NCT00017160|PROCEDURE|intraoperative radiotherapy|
219713999|NCT00017160|PROCEDURE|radiation therapy|
219714000|NCT00017160|PROCEDURE|surgery|
219714001|NCT03979404|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
219714002|NCT03024372|DEVICE|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
219714003|NCT03024372|DEVICE|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
219714004|NCT01163617|DEVICE|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
219714005|NCT01163617|DEVICE|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
219714006|NCT01163617|DEVICE|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
219714007|NCT01163617|DEVICE|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
219714008|NCT02394756|DEVICE|Marketed Soft Contact lens|Replacement schedule every 2 weeks
219714009|NCT02394756|DEVICE|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
219714010|NCT02394756|DEVICE|Biofinity®|Replacement schedule every 4 weeks
219714011|NCT03972540|BEHAVIORAL|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
219714012|NCT05188482|DEVICE|vibroacoustic therapy|Vibroacoustic respiratory therapy
219714013|NCT02907372|OTHER|neuropsychologic evaluation|
219714014|NCT02907372|OTHER|oncogeriatric evaluation|
219132700|NCT03015831|DRUG|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
219132701|NCT02096289|DRUG|Thioridazine|
219132702|NCT02537392|DIETARY_SUPPLEMENT|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
219132703|NCT02537392|DIETARY_SUPPLEMENT|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
219132704|NCT02537392|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid.
219714015|NCT02763618|OTHER|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
219132705|NCT00803426|PROCEDURE|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
219132706|NCT03441984|DRUG|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
219132707|NCT03441984|DRUG|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
219132708|NCT03441984|DRUG|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
219132709|NCT03441984|DRUG|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
219132710|NCT03441984|DRUG|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
219132711|NCT03441984|DRUG|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
219132712|NCT05566847|OTHER|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
219132713|NCT05566847|OTHER|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
219132714|NCT04164524|DRUG|Gentamycin|Gentamycin 160 mg spray applied over the mesh
219132715|NCT04138433|DEVICE|Real tDCS|Anodal tDCS 2 ma
219132716|NCT04138433|DEVICE|Sham tDCS|Sham tDCS 2 ma
219132717|NCT00927342|OTHER|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
219132718|NCT00927342|OTHER|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
219714016|NCT02763618|OTHER|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
219714017|NCT03120793|DEVICE|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
219714018|NCT02552940|DRUG|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
219714019|NCT05013801|OTHER|Cosmetic facial serum Q69|Cosmetic facial serum
219714020|NCT05013801|DRUG|2% Hydroquinone|2% Hydroquinone cream
219714021|NCT02335944|DRUG|Capmatinib|"In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
219714022|NCT02335944|DRUG|Nazartinib|"In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
219714023|NCT00398229|DRUG|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
219132719|NCT02430532|DRUG|dimethyl fumarate|capsule
219132720|NCT02430532|OTHER|Placebo|matched placebo capsule
219132721|NCT00271258|DRUG|SODIUM DIVALPROATE|
219132722|NCT00082719|BIOLOGICAL|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
219132723|NCT00000746|BIOLOGICAL|rgp120/HIV-1 SF-2|
219132724|NCT00000746|BIOLOGICAL|Env 2-3|
219132725|NCT00000746|BIOLOGICAL|HIVAC-1e|
219714024|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
219714025|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
219714026|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
219132726|NCT00000746|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219132727|NCT02962336|DRUG|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
219132728|NCT02962336|DRUG|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
219132729|NCT05464134|RADIATION|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
219132730|NCT03256344|BIOLOGICAL|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
219132731|NCT03256344|BIOLOGICAL|Atezolizumab|A monoclonal antibody given by intravenous injection.
219132732|NCT04954430|DIAGNOSTIC_TEST|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
219132733|NCT04490148|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
219132734|NCT04490148|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
219132735|NCT04490148|BEHAVIORAL|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
219132736|NCT04747106|BIOLOGICAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
219714027|NCT03535415|DRUG|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
219714028|NCT00576537|BIOLOGICAL|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
219714029|NCT06319833|BEHAVIORAL|Physical activity interacting with a video|This experimental condition will be implemented five times a week, once per day, over 8 weeks. It will follow a structured format, including seven consecutive 40-second blocks of physical activity. The total video duration will amount to 9 minutes (40 seconds of activity followed by 20 seconds of rest, maintaining a 2:1 work-to-rest ratio). Additionally, participants will engage in 5 minutes of warm-up exercises and 5 minutes of cool-down activities. The experimental condition will consist of 10 videos, each centered around one of five different themes (a different one will be administered every day).
219714030|NCT03687424|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
219132737|NCT05001906|BEHAVIORAL|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
219132738|NCT02885051|PROCEDURE|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
219132739|NCT03255772|DIAGNOSTIC_TEST|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
219132740|NCT01879371|DRUG|Ibuprofen+caffeine FDC|oral dose
219132741|NCT01879371|DRUG|Ibuprofen (Nurofen Immedia®)|oral dose
219132742|NCT01879371|DRUG|Ibuprofen (Brufen®)|oral dose
219132743|NCT01723670|DRUG|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
219132744|NCT01723670|DRUG|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
219132745|NCT01723670|DRUG|Placebo|oral tablet,once a day for 24 months
219714031|NCT03687424|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
219714032|NCT04685811|DRUG|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
219714033|NCT02650583|OTHER|Educational Intervention|Receive Enhancing Connections Program
219714034|NCT02650583|OTHER|Questionnaire Administration|Ancillary studies
219714035|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 100 mcg once
219714036|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 200 mcg once
219714037|NCT01270659|DRUG|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
219714038|NCT01270659|DRUG|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
219714039|NCT02873663|PROCEDURE|Plasma and head hair collection|Plasma and head hair collection
219714040|NCT03424642|BEHAVIORAL|Interactive 4D-ultrasound examination|Randomized controlled trial
219714041|NCT01680913|PROCEDURE|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
219714042|NCT01680913|PROCEDURE|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
219714043|NCT01680913|PROCEDURE|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
219714044|NCT04727008|BIOLOGICAL|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
219132746|NCT00624546|DRUG|Prevacid Solutabs|BID Prevacid Solutabs
219132747|NCT00624546|PROCEDURE|Antireflux surgery|Lap Nissen
219132748|NCT03014050|DEVICE|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
219132749|NCT04034758|PROCEDURE|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
219132750|NCT04034758|PROCEDURE|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
219132751|NCT03585361|BEHAVIORAL|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
219132752|NCT03585361|BEHAVIORAL|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
219132753|NCT03585361|BEHAVIORAL|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
219132754|NCT03585361|BEHAVIORAL|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
219132755|NCT03585361|BEHAVIORAL|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
219132756|NCT02945267|DRUG|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
219132757|NCT02945267|DRUG|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
219227326|NCT07043569|OTHER|Resistance Training with Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
219714045|NCT02530866|OTHER|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
219714046|NCT01762189|PROCEDURE|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
219714047|NCT01197066|DRUG|Certolizumab Pegol|Certolizumab Pegol 200mg
219714048|NCT02015156|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
219132758|NCT05045872|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
219714049|NCT02015156|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
219714050|NCT01706328|DRUG|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
219714051|NCT01706328|DRUG|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
219132759|NCT05450029|DRUG|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
219132760|NCT04035512|OTHER|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
219714052|NCT01706328|DRUG|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
219714053|NCT01706328|DRUG|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
219714054|NCT01706328|DRUG|Salbutamol as needed|Salbutamol inhalation powder
219714055|NCT00825240|BEHAVIORAL|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
219132761|NCT00946751|DRUG|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
219132762|NCT00946751|DRUG|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
219132763|NCT00540813|DEVICE|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
219714056|NCT03160170|DEVICE|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
219714057|NCT04651712|DIAGNOSTIC_TEST|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
219714058|NCT00576082|OTHER|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
219714059|NCT03018938|DRUG|Insulin Analog Mid Mixture|Administered SC
219714060|NCT03018938|DRUG|Basal Insulin Analog|Administered SC
219714061|NCT01769586|DRUG|Diphenhydramine|
219714062|NCT01769586|DRUG|Midazolam|
219714063|NCT02811159|DRUG|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
219714064|NCT00580086|OTHER|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
219714065|NCT00191100|DRUG|Gemcitabine|
219714066|NCT00191100|DRUG|Cisplatin|
219714067|NCT00191100|RADIATION|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
219714068|NCT00191100|RADIATION|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
219132764|NCT03875248|DEVICE|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
219132765|NCT04227990|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
219132766|NCT04227990|DRUG|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
219132767|NCT04227990|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
219132768|NCT01025206|BIOLOGICAL|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
219714069|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
219714070|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
219714071|NCT04428749|DIAGNOSTIC_TEST|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
219714072|NCT04428749|DIAGNOSTIC_TEST|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
219714073|NCT06646471|GENETIC|Bio-bank repository|Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
219132769|NCT05739929|DRUG|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
219132770|NCT05739929|DRUG|Placebo|Placebo tablets twice daily
219714074|NCT06646471|OTHER|Quality of Life (QoL)|"Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months."
219714075|NCT06646471|PROCEDURE|G-Code|G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
219714076|NCT01675726|OTHER|questionary on quality of life|
219714077|NCT05184816|DRUG|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
219714078|NCT06390904|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
219714079|NCT06390904|DRUG|Letrozole 2.5mg|2.5mg po qd.
219714080|NCT06385353|OTHER|Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome|"Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up."
219714081|NCT05360706|GENETIC|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
219714082|NCT03990974|DRUG|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
219714083|NCT03990974|OTHER|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
219132771|NCT05544578|BEHAVIORAL|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
219132772|NCT05054062|DIAGNOSTIC_TEST|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
219132773|NCT02866214|DRUG|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
219132774|NCT02866214|DRUG|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
219132775|NCT06279819|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|"The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks."
219132776|NCT01607619|DIETARY_SUPPLEMENT|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
219132777|NCT03586167|DEVICE|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
219132778|NCT03586167|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses
219132779|NCT02973243|DEVICE|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
219132780|NCT05289830|DRUG|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
219132781|NCT05289830|OTHER|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
219132782|NCT02580448|DRUG|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
219132783|NCT00500500|DRUG|EGb 761® (Tanakan®)|
219227327|NCT07043569|OTHER|Resistance Exercise with BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
219227328|NCT04412616|BIOLOGICAL|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
219227329|NCT07063914|BEHAVIORAL|Reframe-IT and CARIBOU|"Reframe-IT+ An individual intervention based on cognitive-behavioral therapy (CBT) focused on developing skills in behavioral activation, cognitive restructuring, emotion regulation, stress tolerance, and problem-solving. It is delivered in the school setting by a trained psychologist from the research team. The program consists of 13 weekly sessions of 45 minutes each: 5 face-to-face sessions and 8 combined digital/in-person sessions where students use a computer under the supervision of a psychologist facilitator.~CARIBOU An individual CBT-based intervention focused on behavioral activation, cognitive restructuring, problem-solving, and communication skills. It is conducted in the school setting by a trained psychologist and consists of 16 weekly sessions of 45 minutes each."
219227330|NCT06827080|DRUG|30 mCi NYMO32|The initial dose is set at 30 mCi.
219227331|NCT06827080|DRUG|50 mCi NYMO32|The dose will be escalated to 50 mCi.
219227332|NCT06827080|DRUG|80 mCi NYMO32|The dose will be escalated to 80 mCi.
219227333|NCT06827080|DRUG|130 mCi NYMO32|The dose will be escalated to 130 mCi.
219227334|NCT06827080|DRUG|200 mCi NYMO32|The maximum dose is set at 200 mCi.
219227335|NCT06864494|PROCEDURE|Endometrial ablation|Performed using a transfer catheter (used for embryo transfers) positioned at the level of the internal cervical orifice in the uterine cavity. Five ml of saline will be injected and collected in a dry tube
219227336|NCT04447027|DRUG|Romidepsin|Romidepsin (12mg/ m\^2) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
219227337|NCT04447027|DRUG|Lenalidomide|Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
219227338|NCT04447027|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
219227339|NCT04447027|DRUG|Dexamethasone|Dexamethasone, 40mg, by mouth (PO), will be given on days 1 and 10 of each cycle.
219227340|NCT04447027|DIAGNOSTIC_TEST|EKG|Screening
219227341|NCT04447027|PROCEDURE|Bone Marrow Aspiration/Biopsy|Baseline, end of treatment and disease progression, and Day 30 (+7).
219227342|NCT04447027|DIAGNOSTIC_TEST|MRI|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
219227343|NCT04447027|PROCEDURE|Lumbar Puncture|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
219714084|NCT06064149|BEHAVIORAL|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
219714085|NCT06532773|BEHAVIORAL|Nite2Day+|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
219714086|NCT03672162|PROCEDURE|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
219227344|NCT04447027|DIAGNOSTIC_TEST|TTE|Screening
219227345|NCT02227927|DRUG|Domperidone|10-30mg oral dose, four times daily.
219227346|NCT06850259|DEVICE|PureWick™ System|The PureWick™ System consists of the PureWick™ Urine Collection System used with the PureWick™ Male External Catheter (MEC), which is intended for non-invasive urine output management in male patients. The PureWick™ MEC is a single-use, non-sterile, commercially available device, which is Class I, 510(K) exempt.
219714087|NCT03619525|PROCEDURE|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
219227347|NCT06850259|DEVICE|UltraFlex™ Self-Adhering Male External Catheter|UltraFlex™ is a self-adhering male external catheter used for the drainage of urine. The catheter is applied by the patient or caregiver. The self-adhering male external catheter is designed for the management of adult male urinary incontinence.
219132784|NCT06555224|DEVICE|Systane Hydration MDPF eye drops|Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
219132785|NCT03068611|BEHAVIORAL|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
219132786|NCT03068611|BEHAVIORAL|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
219132787|NCT05252624|DRUG|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
219132788|NCT05252624|DRUG|Henagliflozin 5Mg Tab|Single oral tablet
219132789|NCT04163458|DRUG|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
219132790|NCT04163458|DRUG|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
219227348|NCT06809842|DRUG|Vastus lateralis nerve block|Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.
219227349|NCT06809842|DRUG|Lateral femoral cutaneous nerve block|Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.
219714088|NCT06010017|BEHAVIORAL|STEPP Intervention|Peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, via virtual platform. If participants do not have a smart device, one will be provided by the study team.
219714089|NCT05618301|DRUG|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
219714090|NCT05618301|DRUG|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
219714091|NCT05618301|PROCEDURE|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
219132791|NCT04163458|OTHER|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
219132792|NCT04163458|OTHER|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
219132793|NCT06552494|OTHER|L-mHealth program|The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
219132794|NCT02498158|DEVICE|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
219132795|NCT00812136|BEHAVIORAL|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
219132796|NCT01586299|DRUG|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
219132797|NCT01586299|DRUG|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
219132798|NCT01641172|PROCEDURE|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
219227350|NCT06394323|BEHAVIORAL|Behavioral: My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice), is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
219227351|NCT07097896|DEVICE|ESV|This study arm will undergo ESV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
219714092|NCT04323475|BIOLOGICAL|Bacteriophage cocktail spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10\^8 PFU/mL for an effective dosage of 2.5 x10\^5 PFU/cm\^2 of burned area. The study intervention will be applied in conjunction with standard of care.
219714093|NCT04323475|DRUG|Xeroform|Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
219132799|NCT01641172|PROCEDURE|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
219227352|NCT07097896|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
219227353|NCT07099235|DRUG|ketamine hydrochloride|Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.
219227354|NCT07099196|DEVICE|Headset-based Virtual Reality Simulation|The device used was a HEALTHY-MIND© PICO G2 Virtual Reality headset, which is medically graded and suited for distraction and relaxation in clinical settings.
219714094|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
219714095|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
219714096|NCT06468462|DRUG|WHO-recommended periodic presumptive treatment|400 mg po cefixime plus 1 gram azithromycin po under direct observation
219714097|NCT06468462|DRUG|Doxycycline post-exposure prophylaxis|200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
219714098|NCT02053116|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
219714099|NCT02053116|DRUG|Placebo|Tablet, 0 mg, twice daily, 2 weeks
219714100|NCT05604950|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
219714101|NCT05841875|OTHER|C reactive protein algorithm|"Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement.~Before discontinuing antibiotic therapy, physicians should confirm that the patient is clinically improving, with no signs of a persistent infectious focus. Additionally, they will be encouraged to verify that the Sequential Organ Failure Assessment (SOFA) score is stable or decreasing. These factors will assist in determining the appropriateness of stopping antibiotics."
219714102|NCT00637897|DRUG|docetaxel|
219714103|NCT00637897|DRUG|ixabepilone|
219714104|NCT00637897|DRUG|paclitaxel|
219714105|NCT00637897|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219714106|NCT00637897|DRUG|paricalcitol|
219714107|NCT02983656|BIOLOGICAL|live attenuated varicella vaccine|
219132800|NCT01641172|PROCEDURE|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
219227355|NCT07097935|DRUG|HS-10516 + Lenvatinib|Administered orally.
219227356|NCT07099586|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
219227357|NCT07098325|DEVICE|retainer with .5 mm thickness|direct 3d printed retainer with .5 mm thickness
219227358|NCT07098325|DEVICE|retainer with 1 mm thickness|direct 3d printed retainer with 1 mm thickness,
219714108|NCT03016637|DEVICE|SharkCore (TM) FNB Exchange System|
219714109|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
219714110|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
219714111|NCT01744821|DIETARY_SUPPLEMENT|Arm A: Vitamin D3 Group|
219714112|NCT01744821|DIETARY_SUPPLEMENT|Placebo|
219132801|NCT01641172|PROCEDURE|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
219132802|NCT01641172|DIETARY_SUPPLEMENT|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
219132803|NCT01641172|BEHAVIORAL|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
219132804|NCT01641172|BEHAVIORAL|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
219132805|NCT02144350|PROCEDURE|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
219132806|NCT02144350|PROCEDURE|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
219132807|NCT00542087|DRUG|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
219132808|NCT00542087|DRUG|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
219132809|NCT00624312|DRUG|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
219132810|NCT00624312|DRUG|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
219132811|NCT03967925|DRUG|Belimumab|Sub-cutaneous injection
219132812|NCT03967925|DRUG|Rituximab|IV infusion 1g x 2
219714113|NCT05593887|PROCEDURE|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
219714114|NCT05593887|PROCEDURE|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
219714115|NCT05593887|PROCEDURE|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
219132813|NCT03967925|DRUG|Prednisolone|20mg prednisolone tapering dose
219132814|NCT02129933|DRUG|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
219132815|NCT02129933|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
219132816|NCT01461213|DRUG|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
219714116|NCT03463239|BIOLOGICAL|Autologous tissue engineered corpora|penile tissue construct
219714117|NCT03590028|OTHER|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
219714118|NCT03590028|OTHER|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
219132817|NCT00100100|DRUG|Modafinil|
219714119|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
219714120|NCT03307356|OTHER|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
219714121|NCT00778180|DRUG|furosemide 80 mg tablets|
219132818|NCT00002932|DRUG|cisplatin|
219132819|NCT00002932|RADIATION|radiation therapy|
219132820|NCT00983164|DIETARY_SUPPLEMENT|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
219132821|NCT00570869|OTHER|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
219132822|NCT04243213|OTHER|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
219132823|NCT04243213|OTHER|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
219132824|NCT04243213|OTHER|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
219132825|NCT02558218|DRUG|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
219132826|NCT02558218|DRUG|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
219714122|NCT04573530|BEHAVIORAL|We Walk Plus Intervention|The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
219132827|NCT00807430|DEVICE|Grindcare (Active)|Active treatment
219132828|NCT00807430|DEVICE|Grindcare (Placebo - the device is not activated)|Placebo treatment
219132829|NCT05292599|OTHER|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
219132830|NCT05292599|OTHER|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
219132831|NCT01467700|DRUG|Ramelteon SL|Ramelteon SL tablets
219132832|NCT01467700|DRUG|Placebo|Ramelteon placebo-matching tablets
219132833|NCT03272113|BEHAVIORAL|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
219132834|NCT04136236|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|Suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI. After a washout period, nonexpert endoscopists take the second assessment with AI assistance.
219132835|NCT01293604|OTHER|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
219132836|NCT05372380|DRUG|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
219132837|NCT05372380|DRUG|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
219132838|NCT00384436|DRUG|escitalopram|
219132839|NCT05153135|DRUG|Ribociclib|Participants who initiated CDK4/6i therapy
219132840|NCT05153135|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
219132841|NCT05153135|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
219227359|NCT07099521|DEVICE|Active High-definition transcranial direct current stimulation|Participants completed 10 sessions of anodal HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the active HD-tDCS condition, current was ramped up to 2mA over 30 seconds, maintained for 20 minutes, then ramped down to 0mA at the end.
219714123|NCT02916771|DRUG|Ixazomib|Oral, proteasome inhibitor
219714124|NCT02916771|DRUG|Lenalidomide|Oral, immunomodulatory agent
219714125|NCT02916771|DRUG|Dexamethasone|Oral, steroid
219714126|NCT00116909|DRUG|OSI 7904L|
219714127|NCT05675085|DIAGNOSTIC_TEST|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
219714128|NCT05057637|DEVICE|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
219714129|NCT05899634|BEHAVIORAL|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
219714130|NCT06147271|DRUG|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
219714131|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
219714132|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
219714133|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
219714134|NCT04280952|DEVICE|CONVIVO|tumor tissue with the CONVIVO system
219132842|NCT05581160|DIAGNOSTIC_TEST|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
219132843|NCT04204408|DRUG|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
219714135|NCT03646617|RADIATION|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
219714136|NCT03646617|DRUG|Nivolumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
219132844|NCT04204408|DRUG|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
219132845|NCT03241888|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
219714137|NCT03646617|DRUG|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
219714138|NCT05556343|DRUG|MYK-224|Specified dose on specified days
219714139|NCT06166303|DIAGNOSTIC_TEST|sFlt-1/PGIF|Index of sFlt-1/PGIF
219714140|NCT06005220|OTHER|SBD121|Medical Food
219714141|NCT06005220|OTHER|Placebo|Placebo
219714142|NCT06547957|DRUG|EOS301984|Multiple doses of EOS301984
219714143|NCT06547957|DRUG|Anti-PD-1 monoclonal antibody|Multiple doses of EOS301984 in combination with Anti-PD-1
219714144|NCT06048445|DEVICE|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
219714145|NCT06054347|OTHER|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
219714146|NCT06409819|DRUG|phage therapy|phage therapy will consist of a combination of three lytic phages that are active against the participant's E. coli isolates and will be administered intravenously twice daily for 7 days.
219714147|NCT06409819|DRUG|control|Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
219714148|NCT04274179|OTHER|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
219227360|NCT07099521|DEVICE|Sham high-definition transcranial direct current stimulation|Participants completed 10 sessions of sham HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the sham condition, the current was ramped up to 2mA within the first and last 30 seconds to mimic the sensation of stimulation, but then ramped down, with no current maintained at other times.
219714149|NCT04274179|DRUG|Absence epilepsy medications|At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
219714150|NCT06804837|OTHER|Visual consent|Visual key information page
219132846|NCT03241888|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
219714151|NCT06804837|OTHER|Standard consent|Summary text only
219714152|NCT06032221|DEVICE|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
219714153|NCT05788029|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
219714154|NCT05788029|PROCEDURE|open pancreaticoduodenectomy|open pancreaticoduodenectomy
219714155|NCT05991713|BEHAVIORAL|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
219714156|NCT04628507|OTHER|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
219714157|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
219132847|NCT06631248|OTHER|Coordinative exercise protocol|During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.
219132848|NCT06629402|DRUG|PF614|Experimental oxycodone prodrug
219132849|NCT06629402|DRUG|Placebo|Inactive medication
219132850|NCT06630715|DRUG|Upadacitinib 15 MG [Rinvoq]|15 mg/ day
219132851|NCT06631885|PROCEDURE|regenerative endodontic procedure using blood clot according to AAE|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
219132852|NCT06631885|PROCEDURE|regenerative endodontic procedure using photo activated nanochitosan 2%|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
219132853|NCT06628973|BEHAVIORAL|Social prescribing|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
219132854|NCT06631625|DRUG|Lidocaine Intravenous Infusion|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
219227361|NCT07098429|DRUG|Bupivacain (Postoperative)|20ml of 0.25% bupivacaine instillation in gallbladder fossa after removal of gallbladder in laparoscopic cholecystectomy this study used less amount of drug
219227362|NCT07098429|DRUG|Normal (0.9%) saline|In 30 patients who underwent Laparoscopic Cholecystectomy , 20ml of 0.9% normal saline instillation in gallbladder fossa after removal of gallbladder.
219227363|NCT07098598|DEVICE|PET/CT|PET/CT with FAPI-74 tracer is performed.
219227364|NCT07098845|BEHAVIORAL|Learning to BREATHE|L2B is a group MBI designed for adolescents (Broderick \& Metz, 2009) and teaches three families of practices: focused attention (e.g., breath awareness), open awareness (i.e., awareness of sensations, thoughts, and feelings as they occur), and compassion. Each letter in BREATHE corresponds to a theme: Body, Reflections, Emotions, Attention, Tenderness, and Habits, building to the overall goal of Empowerment. Each session involves guided discussions, activities, and mindfulness practices.
219227365|NCT07098845|BEHAVIORAL|Learning to BREATHE Plus|"The in-person, group program portion of L2B PLUS and L2B are identical. But, L2B PLUS (Lucas-Thompson et al., 2020) builds on the standard L2B program with 3 additional supplements: 1) Extensive on-demand library designed by the team to be integrated with the group program and specifically to allow participants to independently practice skills that have already been introduced in the group program. 2) Intervention messages sent across the day. The team developed intervention messages to be sent 5 times a day to participants (Lucas-Thompson et al., 2020). Each week, participants receive intervention content tailored to what they have just learned in the group program. 3) JIT support. When participants indicate high stress via EMAs completed during the intervention period, tailored intervention content is delivered just-in-time during a moment of high need. These JIT messages were developed specifically to support applying or using mindfulness during periods of high stress."
219714158|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose|V-212 is a peptide antigen-based vaccine.
219714159|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose|V-212 is a peptide antigen-based vaccine.
219714160|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose|V-212 is a peptide antigen-based vaccine.
219714161|NCT06978530|DEVICE|3D custom plate|Custom 3D plate will be designed using preoperative CT and virtual surgical planning.
219714162|NCT06978530|DEVICE|Standard titanium fixation plates|The fixation will be performed according to established surgical principles for managing displaced mandibular sub-condylar fractures without patient-specific planning or customization.
219714163|NCT02738606|DRUG|Chemotherapy|
219714164|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
219714165|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
219714166|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
219714167|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
219714168|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
219714169|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
219714170|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
219714171|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
219714172|NCT05121337|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
219132855|NCT06631625|DRUG|Lidocaine and ketamine|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
219132856|NCT06631625|DRUG|lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
219227366|NCT07098845|BEHAVIORAL|HealthEd|Hey-Durham is a health education program that the team has extensive experience implementing (Lucas-Thompson et al., 2019; Shomaker, Berman, et al., 2019; Shomaker et al., 2016; Tanofsky-Kraff et al., 2014) and covers topics such as domestic violence, substance use, depression/signs of suicide, and conflict resolution. Mental health components focus only on prevalence and identification. There is no content overlap with L2B, but it is matched to L2B in format, time, frequency, in-person contact, and facilitator expertise. Inclusion of HealthEd in a future efficacy trial will allow us to test the extent to which the active ingredients of MBI (i.e,. a top-down and bottom-up focus on emotion and stress regulation(Zelazo \& Carlson, 2012)), with and without the between-session support L2B, improve mental health and stress responding, relative to an active control matched for critical characteristics but that does not include these active ingredients.
219227367|NCT03938792|DRUG|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
219227368|NCT07098819|DEVICE|Vibrational Shear wave elastography algorithm|An algorithm that detects the propogation of shear waves in the head and neck.
219714173|NCT05121337|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
219714174|NCT05643209|PROCEDURE|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
219714175|NCT06645015|DEVICE|AI augmented risk-stratification|A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
219714176|NCT06645015|OTHER|Expert-based Risk-stratification|Experienced colorectal surgeons assess patient risk based on clinical judgment and national guidelines.
219714177|NCT04748978|PROCEDURE|hysteroscopy|OPPIum and Myolysis
219714178|NCT01525589|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
219714179|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
219714180|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
219714181|NCT01331564|BEHAVIORAL|Control|Control women will receive non-weight related content during both time periods at the project website.
219714182|NCT00945737|DIETARY_SUPPLEMENT|Soy protein; 25 grams/day|Soy protein
219714183|NCT00945737|DIETARY_SUPPLEMENT|Control protein|Milk protein
219227369|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
219227370|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
219227371|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
219227372|NCT06827691|OTHER|Heat Therapy Intervention|Heat Therapy Intervention of shoulder depth submersion in a 40°C hot tub.
219227373|NCT04256031|OTHER|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
219714184|NCT03832478|DEVICE|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
219714185|NCT02383615|PROCEDURE|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
219714186|NCT05379556|DIAGNOSTIC_TEST|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
219714187|NCT05379556|DIAGNOSTIC_TEST|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
219132857|NCT03578731|DEVICE|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
219132858|NCT04713514|DRUG|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
219132859|NCT04713514|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
219132860|NCT06384430|DIAGNOSTIC_TEST|Shoulder functional tests and ultrasound|On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
219132861|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Inulin-fructan 15mg/day for 28days
219132862|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
219714188|NCT05379556|DIAGNOSTIC_TEST|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
219714189|NCT05379556|DIAGNOSTIC_TEST|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
219132863|NCT03137966|DRUG|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
219132864|NCT03137966|DRUG|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
219132865|NCT04005521|BEHAVIORAL|Preventive intervention|Preventive, structured exercise protocol
219132866|NCT04210024|OTHER|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
219132867|NCT00121199|BIOLOGICAL|rituximab|Given IV
219132868|NCT00121199|BIOLOGICAL|bevacizumab|Given IV
219132869|NCT00121199|DRUG|cyclophosphamide|Given IV
219132870|NCT00121199|DRUG|doxorubicin hydrochloride|Given IV
219132871|NCT00121199|DRUG|vincristine sulfate|Given IV
219132872|NCT00121199|DRUG|prednisone|Given PO
219132873|NCT00121199|OTHER|laboratory biomarker analysis|Correlative studies
219714190|NCT06815289|RADIATION|MR-informed stereotactic radiotherapy|MR-informed stereotactic radiotherapy for treatment of ultracentral lung tumours utilising a dedicated MR-simulator for daily adaptation followed by CBCT-guided treatment delivery.
219714191|NCT06982820|DEVICE|Prism Training|Participants will complete 20 Prism training sessions. The Prism training sessions take place twice a week over a 10-week period, with a minimum of one night of sleep between sessions. Participants will also receive two single booster sessions, 4 weeks and 8 weeks after their last NF session completed.
219132874|NCT05926505|DRUG|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
219132875|NCT05926505|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
219132876|NCT02518893|OTHER|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
219132877|NCT02518893|OTHER|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
219132878|NCT01250951|DRUG|Deferasirox|
219714192|NCT06811324|DRUG|Tirzepatide|Once weekly tirzepatide starting at 2.5 mg/weekly, with dose escalation monthly by 2.5 mg to a target dose of 10 mg/weekly or maximum tolerated
219132879|NCT04749433|DRUG|[11C]CPPC Injection|A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
219132880|NCT03999021|DRUG|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
219132881|NCT06631456|OTHER|PRP injection|A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
219132882|NCT06631456|OTHER|Ozone therapy|A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
219227374|NCT05440110|DEVICE|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
219227375|NCT05440110|DEVICE|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
219227376|NCT04779853|DIAGNOSTIC_TEST|Blood samples for pertussis antibody testing|Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
219227377|NCT06087406|DRUG|Imvotamab|Administered intravenously
219227378|NCT06087406|DRUG|Placebo|0.9% sodium chloride administered intravenously
219714194|NCT06311383|DRUG|First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
219714195|NCT06311383|DRUG|First-line endocrine therapy|As of physicians choice
219714196|NCT06311383|DRUG|First-line chemtherapy|As of physicians choice
219714197|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
219714198|NCT06649773|DRUG|Noiiglutide Injection|Experimental group
219714199|NCT06649773|DRUG|Noiiglutide Placebo|Placebo Comparator group
219714200|NCT04665206|DRUG|VT3989|25, 50, 100,150 or 200 mg capsules for oral administration.
219714201|NCT04665206|DRUG|Nivolumab & Ipilimumab|"Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion~Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion"
219132883|NCT02680093|OTHER|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
219227379|NCT06830252|BEHAVIORAL|Exercise|Exercise.
219227380|NCT05935085|DRUG|ANB032|BTLA agonist antibody
219227381|NCT05935085|DRUG|Placebo|Placebo
219227382|NCT06917352|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
219227383|NCT06910709|DRUG|AMG 378|Oral tablet
219714202|NCT04665206|DRUG|Osimertinib|40 or 80 mg tablets for oral administration
219714203|NCT06985888|DEVICE|SpeediCath® Standard male new coating|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP
219714204|NCT06985888|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP
219714205|NCT06986967|PROCEDURE|Antegrade Perfusion|Procedure in which the surgeon accesses one of two arteries that branch off from the aorta to provide blood to the brain.
219714206|NCT06986967|PROCEDURE|Retrograde Perfusion|Procedure in which the surgeon accesses the superior vena cava to supply blood to the brain.
219714207|NCT06821113|BEHAVIORAL|COVID-19 Group Problem Solving|"Participants will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a personal commitment called Mi Promesa to implement COVID mitigation practices. Navigation Component will consist of providing information and linking LDLs with social service providers and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support."
219714208|NCT06821113|BEHAVIORAL|Standard of Care|Participants will receive a COVID-19 prevention flyer and social resources list only
219132884|NCT04917432|PROCEDURE|intravascular ultrasound (IVUS)|Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
219227384|NCT06910709|DRUG|Placebo|Oral tablet
219227385|NCT04535414|DEVICE|Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes|Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
219132885|NCT04917432|PROCEDURE|Conventional CTO PCI (non-IVUS guided)|Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
219132886|NCT02232763|DRUG|Losartan|12 weeks of losartan or placebo with crossover to the other
219132887|NCT02232763|DRUG|Placebo|12 weeks of losartan or placebo with crossover to the other
219714209|NCT06821113|BEHAVIORAL|Booster session|"Participants in this group will also receive a booster phone call 10 to 15 days after the small group intervention to provide brief prompts to encourage participants to act on their personal commitments and encourage them to seek community resources."
219714210|NCT06305026|DIAGNOSTIC_TEST|Muscle- and skin biopsies|RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.
219714211|NCT03024008|BIOLOGICAL|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
219714212|NCT02924376|DRUG|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
219714213|NCT06389513|BIOLOGICAL|MCV4|4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
219714214|NCT04740307|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
219714215|NCT04740307|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
219714216|NCT04740307|BIOLOGICAL|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
219714217|NCT02899052|DRUG|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
219714218|NCT02899052|DRUG|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
219714219|NCT02899052|DRUG|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
219714220|NCT05912647|BEHAVIORAL|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
219714221|NCT05912647|BEHAVIORAL|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
219714222|NCT01471639|DRUG|intranasal ketorolac|15 mg
219714223|NCT00327093|DRUG|cetuximab|indication : second intention treatment
219714224|NCT00327093|DRUG|bevacizumab|Indication: first intention treatment
219714225|NCT06816004|DEVICE|Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity delivering a low-intensity electrical current.
219132888|NCT05258006|PROCEDURE|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
219132889|NCT05169255|DRUG|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
219227386|NCT04535414|DEVICE|Olympus Graphics Interchange Format (GIF) 190 endoscope|Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
219227387|NCT04535414|PROCEDURE|Gastric mucosal biopsy|As clinically indicated.
219227388|NCT06914297|DRUG|TQB2450 injection + oral progestin|TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)
219714226|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)|taVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through hydrogel electrodes to the left auricular branch of the vagus nerve.
219714227|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)|tcVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through cervical hydrogel electrodes to the left cervical branch of the vagus nerve.
219714228|NCT06587139|BEHAVIORAL|Teen Connection Project (TCP)|The Teen Connection Project (TCP) includes seven 90-minute sessions facilitated by transgender and/or gender minority (TGM) adults. Each transgender and/or gender minority youth (TGMY) will be paired with a TGM adult mentor based on TGMYs' rank-ordered preference for mentors. The research team seeks to match mentors \& mentees such that each TGMY is matched with one of their top 3 preferred mentors. Mentors and mentees participate together in each session along with other mentors \& mentees. Facilitators direct activities/discussion to promote TGMY social-emotional skills acquisition and facilitate mentor-mentee conversations. TCP sessions also include mentor-mentee breakout sessions where mentors share challenges they personally faced as TGMY and how they overcame them. Break-out discussions focus on self-acceptance, coming out, dating questions, hopes and goals for the future, \& how other marginalized social identities, such as race and ethnicity, intersect with identifying as TGMY.
219714229|NCT06588283|DRUG|Ixekizumab|Administered SC
219714230|NCT06588283|DRUG|Tirzepatide|Administered SC.
219227389|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
219227390|NCT03470597|OTHER|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
219714231|NCT06825897|OTHER|Conventional Triage for Mechanical Thrombectomy|Participants undergo the conventional standard-of-care triage process. Upon arrival at the thrombectomy-capable center, patients first undergo an initial evaluation in the emergency department (ED), which includes diagnostic imaging (CT or MRI) to confirm eligibility for mechanical thrombectomy (MT). If the patient is found to have a large vessel occlusion (LVO) suitable for thrombectomy, they are transferred to the neurointerventional suite for treatment.
219714232|NCT06825897|OTHER|Direct Transfer to Angiography Suite (DTAS|Patients who arrive at the thrombectomy-capable center (from home, mobile stroke units, or interfacility transfer) are immediately transferred to the neurointerventional suite, bypassing the emergency department (ED). Upon arrival in the neurointerventional suite, initial neuroimaging (typically using flat panel CT or other imaging modalities) is conducted to confirm the presence of a large vessel occlusion (LVO). If the patient is eligible for mechanical thrombectomy (MT), treatment is initiated directly in the angiography suite. This approach aims to reduce delays in care and improve clinical outcomes by providing faster access to thrombectomy treatment.
219132890|NCT02540044|BEHAVIORAL|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
219132891|NCT02540044|BEHAVIORAL|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
219132892|NCT01103973|BEHAVIORAL|Mind/Body Program|Ten week group mind/body program
219132893|NCT01103973|BEHAVIORAL|Control|Spa gift certificates
219132894|NCT05335681|BEHAVIORAL|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
219132895|NCT04109118|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
219132896|NCT04109118|DRUG|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
219132897|NCT01830842|DRUG|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
219132898|NCT01830842|DRUG|Placebo|nonsmokers will be measured following placebo administration
219132899|NCT01830842|OTHER|satiety|smokers will be measured in a smoking satiated condition
219132900|NCT01830842|OTHER|abstinence|smokers will be measured following 24-hours of smoking abstinence
219132901|NCT03235349|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
219227391|NCT00511316|DRUG|Montelukast/ Singulair|20 mg daily for six months
219227392|NCT00511316|DRUG|Placebo|Placebo 20 mg daily for 6 months
219227393|NCT04917185|OTHER|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
219227394|NCT01567852|DRUG|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
219714233|NCT06660732|DRUG|Rilonacept|320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
219227395|NCT01567852|DRUG|Methohexital|Methohexital (1.5mg/kg) will be given for induction
219227396|NCT05606185|PROCEDURE|retraction method|Three dimensional evaluation of root resorption using cone beam computed tomography
219714234|NCT06859866|OTHER|Standard oral hygiene|Standard protocol includes oral hygiene instructions (OHI), professional supragingival and subgingival instrumentation, and air polishing. A combination of manual tools (scalers/curettes) and electric tools (sonic/ultrasonic instruments) will be used to remove plaque and tartar, with particular attention to avoid damaging the implant surface. Both supragingival and subgingival surfaces will be treated with the air polishing device using glycine powder. A local antiseptic (1% chlorhexidine gel) will be prescribed twice daily for 7 days after TNC. OHI will be reinforced at each follow-up visit.
219132902|NCT04432974|DEVICE|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
219132903|NCT03553615|DRUG|Ivermectin Pill|oral anti-parasitic agent taken as a weekly dose for four weeks
219132904|NCT05601583|DEVICE|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
219132905|NCT06460363|DEVICE|Transcranial alternating current stimulation (TACS)|Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
219132906|NCT06460363|DEVICE|Sham TACS|Sham treatment with few seconds of actual electrical current and same electrode configuration
219132907|NCT06000969|DEVICE|Lung Recruitment Conventional|the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
219132908|NCT06000969|DEVICE|Lung Recruitment Ultrasound|the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
219132909|NCT05202080|OTHER|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
219132910|NCT05761509|DRUG|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
219132911|NCT06641778|OTHER|Fecal Microbiota Transplantation|Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
219132912|NCT03834844|BEHAVIORAL|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
219132913|NCT03834844|OTHER|AF Education|6 weekly education modules on topics related to AF
219132914|NCT03834844|OTHER|Phone Calls|Weekly phone call to discuss patient concerns or questions
219132915|NCT05735847|PROCEDURE|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
219132916|NCT05735847|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
219132917|NCT04114396|DRUG|Anti-IL5 Antibody|Asthma group: Anti-IL5 treatment Control group: No biologic.
219132918|NCT04114396|PROCEDURE|Bronchoscopy|Optional for both arms
219132919|NCT00057382|DRUG|T138067 intravenous|
219132920|NCT00057382|DRUG|doxorubicin intravenous|
219227397|NCT03792061|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
219227398|NCT04809623|DRUG|Edecesertib|Tablets administered orally
219132921|NCT04485741|DEVICE|RESP|The RESP device will be placed on the patient for periodic recording of auscultory sound.
219132922|NCT04811287|DEVICE|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
219132923|NCT04811287|PROCEDURE|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
219132924|NCT03396913|DEVICE|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
219132925|NCT03396913|DEVICE|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
219132926|NCT03396913|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
219132927|NCT00557843|DRUG|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
219132928|NCT00557843|DRUG|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
219132929|NCT01762371|OTHER|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
219132930|NCT02814825|OTHER|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
219132931|NCT02728986|DEVICE|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
219132932|NCT02728986|DEVICE|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
219132933|NCT01403675|PROCEDURE|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
219132934|NCT02611232|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
219132935|NCT02611232|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
219132936|NCT06494748|OTHER|Follow up Decision|"0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit"
219227399|NCT04809623|DRUG|Placebo|Placebo to match edecesertib tablets administered orally
219227400|NCT04809623|DRUG|Standard of Care|Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
219227401|NCT00217152|DRUG|CellCept|
219714235|NCT06859866|DEVICE|The addition of home-based dual-light photodynamic therapy (Lumorinse® + Lumoral®)|Lumorinse® is an effervescent tablet that provides a final concentration of indocyanine green (ICG) of 250 μg/mL when dissolved in 30 mL of water. After rinsing the mouth for 1 minute, the Lumoral® device is used to activate the ICG. The device consists of 48 LED lights in the shape of a mouthguard, which simultaneously provide antibacterial blue light (aBL) at 405 nm and near-infrared (NIR) LED light at 810 nm. In combination with the ICG photosensitizer, the device delivers simultaneous aBL and aPDT action on dental plaque. After 10 minutes of use (30 J/cm2 radiant exposure), the device automatically shuts off. After treatment, patients will follow regular home oral hygiene procedures according to the OHI provided.
219714236|NCT06988033|BEHAVIORAL|Whole Body Vibration Therapy|Participants receive whole-body vibration therapy in a static upright position on a vibration platform (Power Plate My5). The intervention is applied 3 times per week for 8 weeks, progressively increasing frequency from 8 Hz to 40 Hz and amplitude from 2 mm to 5 mm. Each session lasts up to 15 minutes. No exercise is performed during the vibration.
219714237|NCT06988033|BEHAVIORAL|Whole Body Vibration with Exercise|Participants perform lower extremity strengthening exercises on a vibration platform simultaneously with whole-body vibration. The protocol includes lunges, squats, heel raises, and ball squeezes. Vibration frequency ranges from 30 to 40 Hz and amplitude from 2 to 5 mm. Sessions are performed 3 times per week for 8 weeks, with duration progressing from 2 to 18 minutes depending on tolerance.
219714238|NCT06988033|BEHAVIORAL|Conventional Physiotherapy|Participants receive standard post-total knee arthroplasty physiotherapy 3 times per week for 12 weeks, lasting 40 to 70 minutes per session. In addition, a home-based exercise program is performed 3 times daily. The program includes range of motion, strengthening, and balance exercises. No vibration therapy is applied in this group.
219714239|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
219714240|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
219714241|NCT06481579|BIOLOGICAL|IVX-A12|IVX-A12 IM injection.
219714242|NCT06481579|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV Vaccine (AREXVY) IM injection.
219714243|NCT05492994|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
219714244|NCT05492994|DIAGNOSTIC_TEST|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
219714245|NCT05492994|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
219132937|NCT04145687|DRUG|Metformin|Metformin 500mg tid
219132938|NCT00006480|BIOLOGICAL|aldesleukin|
219132939|NCT00006480|BIOLOGICAL|therapeutic autologous lymphocytes|
219132940|NCT00006480|DRUG|chemotherapy|
219132941|NCT00006480|DRUG|ganciclovir|
219227402|NCT06499116|DRUG|Topiramate|Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
219227403|NCT06499116|DRUG|Flunarizine|Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
219714246|NCT05492994|DIAGNOSTIC_TEST|Chest Computer Tomography|Chest Computer Tomography
219714247|NCT05492994|DIAGNOSTIC_TEST|Blood biomarker analysis|Blood biomarker analysis
219714248|NCT06991257|DRUG|Placebo|ARM 1
219714249|NCT06991257|DRUG|Low Dose PF-07328948|ARM 2
219714250|NCT06991257|DRUG|Medium Dose PF-07328948|ARM 3
219714251|NCT06991257|DRUG|High Dose PF-07328948|ARM 4
219714252|NCT06989437|DRUG|ponsegromab|Double-Blind ponsegromab Treatment
219714253|NCT06989437|DRUG|placebo|Double-Blind placebo Treatment
219714254|NCT06174402|DRUG|Fenofibrate|Fenofibrate 200 mg/day
219714255|NCT06174402|DRUG|Placebo|1 tablet/ day
219714256|NCT06174402|DRUG|UDCA|UDCA 13-15mg/kg/day
219714257|NCT06992258|DRUG|Fruquintinib+ Lonsurf (trifluridine and tipiracil)|Experimental arm
219714258|NCT06992258|DRUG|Fruquintinib|Standard Of Care Arm
219132942|NCT03530280|DRUG|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
219132943|NCT03530280|DRUG|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
219132944|NCT03530280|DRUG|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
219227404|NCT06499116|DRUG|Amitriptyline|Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
219227405|NCT06499116|DRUG|Propranolol|Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
219714259|NCT06991842|PROCEDURE|Permanent dental restoration|In both study arms, permanent dental restorations are made with resin-based composite in permanent anterior teeth. Both study arms will use identical materials for the resin-based composite restoration (Tetric Plus Flow and Tetric Plus Fill) and universal adhesive (Adhese Universal), with the only difference being the duration of the phosphoric acid etching step. All other aspects of the restorative procedure, such as isolation of the operative field, application techniques, and final polishing, will remain consistent across both arms.
219714260|NCT06992778|DEVICE|Remote fine-tuning of hearing aids|"Remote Fine-Tuning of Hearing Aids allows patients to adjust their hearing aids remotely, without having to visit a clinic. Using a mobile app on the patient's device, real-time adjustments are made based on their feedback, with immediate changes during the session.~Unlike traditional face-to-face adjustments, this approach lets patients stay in their own familiar surroundings. This helps create a more accurate listening environment, as the adjustments are made based on the sounds they experience in their everyday life."
219714261|NCT06992778|DEVICE|Face-to-face fine-tuning of hearing aids|In the clinic, the standard procedure for fine-tuning hearing aids (HAs) involves a face-to-face consultation with an audiologist, typically lasting 30 minutes.
219714262|NCT05513560|DRUG|Ibudilast|10mg pills, 2 pills twice per day
219714263|NCT05513560|DRUG|Pentoxifylline|400mg pill 3 times per day
219714264|NCT05513560|OTHER|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
219714265|NCT03698162|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
219714266|NCT03698162|OTHER|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
219714267|NCT06597175|DEVICE|ORIGO|The device measurement is first performed on the breast area with the lesion, followed by the measurement of the corresponding area in the contralateral breast for comparison.
219714268|NCT03351348|DRUG|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
219714269|NCT03351348|BEHAVIORAL|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
219714270|NCT03351348|OTHER|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
219714271|NCT06992960|DEVICE|ChitoCare® medical Scar Healing Gel (Örsáragel)|ChitoCare® medical Scar Healing Gel is a topical gel indicated for the treatment of new and old scars. The Scar Healing Gel provides a soothing effect and support to the scar tissue to heal in an orderly manner. It protects against infections, stimulates cell proliferation in old and new scars, as well as correct tissue organization with proper collagen alignment for a better aesthetic appearance and skin flexibility. Ideal for treating scars after accidents, surgery, C-section and cosmetic surgery. For smoother and less visible scars. May be used by the whole population, also elderly and children.
219227406|NCT05013398|BEHAVIORAL|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
219227407|NCT04119947|DRUG|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
219227408|NCT01890278|RADIATION|Whole Brain IMRT|
219227409|NCT01890278|RADIATION|Conventional Whole Brain RT|
219227410|NCT00063089|DRUG|S. aureus Immune Globulin Intravenous (Human) 5%|
219227411|NCT01355445|DRUG|Vincristine, Irinotecan|"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
219227412|NCT01355445|DRUG|Vincristine, Irinotecan, Temozolomide|"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
219227413|NCT00407732|BEHAVIORAL|psychosocial intervention|motivational enhancing case management intervention
219132945|NCT00515138|DRUG|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
219132946|NCT00406289|PROCEDURE|18F-FDG-PET radiotherapy|
219227414|NCT02660086|BEHAVIORAL|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
219714272|NCT06992960|DEVICE|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch are silicon-based, single-patient, multi-use scar patches intended for use as scar reduction therapy in surgical breast scars. The silicone creates a moist environment on the scar, which prevents the scar from drying out. It keeps the scar soft and has a positive effect on scar tissue. The devices are specifically designed for breast scarring and are shaped to fit the normal surgical scars experienced after breast surgery.
219714273|NCT07000227|BEHAVIORAL|Low FODMAP diet|High FODMAP foods are swapped for low FODMAP alternatives, for two weeks (Elimination phase)
219714274|NCT07000227|BEHAVIORAL|Gentle FODMAP diet|Key High FODMAP foods will be identified from patients' food diaries and swapped with low FODMAP alternatives. (Elimination phase)
219714275|NCT07000227|BEHAVIORAL|Traditional Dietary Advice|Subjects are required to follow a set of healthy eating guidelines set by NICE guidelines for IBS for two weeks a. Have regular meals and take time to eat b. Avoid missing meals or leaving long gaps between eating c. Drink at least eight cups of fluid a day, especially water or other non-d. caffeinated drinks, such as herbal teas d. Restrict tea and coffee to three cups a day e. Reduce intake of alcohol and fizzy drinks . Limit intake of high-fibre food g. Reduce intake of resistant starch h. Limit fresh fruit to three portions a day
219714276|NCT06670937|OTHER|Induced sputum|Patients will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution
219714277|NCT06670937|OTHER|Blood sample|Patients will provide 2) a blood sample.
219714278|NCT07003425|DRUG|APG777|APG777 subcutaneous injection
219714279|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 12 weeks
219714280|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 24 weeks
219714281|NCT06260956|BEHAVIORAL|Consumption|Subjects consume peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
219714282|NCT06260956|BEHAVIORAL|Avoidance|Subjects avoid eating peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
219714283|NCT05583071|DRUG|Tafasitamab|IV
219714284|NCT05583071|DRUG|Lenalidomide|Oral
219714285|NCT05583071|DRUG|Rituximab|IV
219714286|NCT05583071|DRUG|Methotrexate|IV
219714287|NCT03922776|PROCEDURE|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
219714288|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
219714289|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
219132947|NCT05005169|DIAGNOSTIC_TEST|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
219227415|NCT01653509|DEVICE|Acyclovir patch|Patch containing acyclovir
219227416|NCT01653509|DEVICE|Placebo patch|Patch without acyclovir
219227417|NCT05338567|DIAGNOSTIC_TEST|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
219227418|NCT04089930|DIAGNOSTIC_TEST|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
219714290|NCT06871111|BIOLOGICAL|Commensal Bacteria Strains|7 doses containing 8 capsules will be administered over 7-10 days
219714291|NCT06138886|DEVICE|Pulsed electromagnetic therapy|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
219714292|NCT06138886|OTHER|calisthenics exercises|This group includes 30 burned patients who will perform calisthenics exercises program for 3 months (3times/week) in addition to their traditional physical therapy program and medical treatment.
219714293|NCT07009717|OTHER|No intervention (observational study)|No intervention; observational study
219227419|NCT00667017|BIOLOGICAL|RFT5-dgA immunotoxin|
219227420|NCT00667017|OTHER|fluorescence activated cell sorting|
219132948|NCT05005169|DIAGNOSTIC_TEST|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
219132949|NCT00836069|DRUG|No drug name provided by Sponsor; drug referenced as PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
219132950|NCT00836069|DRUG|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
219132951|NCT00836069|DRUG|Placebo|inactive substance, oral tablet, once per day, for 10 weeks.
219132952|NCT01066260|DIETARY_SUPPLEMENT|Probiotic formulation|Twice a day for 24 days
219227421|NCT00667017|OTHER|immunohistochemistry staining method|
219714294|NCT05112432|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
219714295|NCT05112432|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
219714296|NCT05112432|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
219714297|NCT06835751|BEHAVIORAL|Motivational Interviewing for PreP|Participants will receive MI-PrEP only will receive two 1-hour sessions with an intervention counselor. The first session will include information on PrEP and other HIV prevention and harm reduction strategies, and discussion on PrEP contemplation, importance, and confidence, and problem-solving around identified barriers to PrEP. The session will also include information on other available harm reduction strategies and services, including medications for opioid use disorder. The second session will focus on following up on any PrEP actions taken, challenges encountered, and problem-solving to address any challenges. Those ready to be linked to PrEP and/or harm reduction services will be offered an escort to a designated PrEP and/or opioid treatment clinic site or other harm reduction services.
219132953|NCT01066260|OTHER|Placebo|Twice a day for 24 days
219132954|NCT00819910|DRUG|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
219132955|NCT00819910|DRUG|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
219132956|NCT00819910|DRUG|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
219227422|NCT04012359|DIAGNOSTIC_TEST|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
219132957|NCT00819910|DRUG|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
219132958|NCT02537899|DRUG|NeuroAiD|
219132959|NCT03486340|PROCEDURE|Cardiologic assessment|Aggressive ischemic risk factor management
219132960|NCT00196170|PROCEDURE|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
219132961|NCT00196170|PROCEDURE|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
219132962|NCT00196170|PROCEDURE|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
219227423|NCT04012359|DIAGNOSTIC_TEST|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
219227424|NCT04012359|DIAGNOSTIC_TEST|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
219227425|NCT04012359|OTHER|Clinical examination|Standard clinical examination performed by investigating physician
219227426|NCT00505986|PROCEDURE|endometrial biopsy|
219227427|NCT00038636|DRUG|Lopinavir/ritonavir|
219714298|NCT06835751|BEHAVIORAL|Common Elements Treatment Approach (CETA) + MI-PrEP|Participants will receive CETA+MI-PrEP will receive 7 to 14 weekly one-hour sessions from an intervention counselor. Similar to the MI-PrEP group, women in this study arm will receive the two 1-hour MI-PrEP sessions with an intervention counselor with linkages to PrEP and/or harm reduction services. Women will then begin CETA sessions. The CETA intervention component is a modular and flexible approach comprised of nine elements that can be combined in various ways, including different sequences, to address clients' presenting symptoms and problem areas. CETA currently includes key engagement strategies, including MI, throughout the intervention. The intervention counselor will determine the specific intervention component sessions, sequence of sessions, and dose, or frequency of sessions, based on the primary problem area identified by the participant and intervention counselor as reported in the baseline assessment survey and initial discussions.
219132963|NCT00196170|PROCEDURE|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
219132964|NCT03528954|DRUG|Propofol|Those who received intravenous propofol
219132965|NCT05268198|DRUG|APR002|Active Investigational Product
219132966|NCT05268198|DRUG|Placebo|Placebo
219132967|NCT04393896|BEHAVIORAL|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
219132968|NCT01643291|PROCEDURE|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
219714299|NCT06122220|PROCEDURE|ONSD+AF|Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
219714300|NCT04945369|OTHER|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour"
219132969|NCT02841891|DEVICE|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
219132970|NCT02841891|PROCEDURE|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
219132971|NCT00001999|DRUG|Globulin, Immune|
219132972|NCT00001999|DRUG|Ganciclovir|
219132973|NCT00299702|DRUG|Abilify|10-30 mg once daily for 104 weeks
219132974|NCT00299702|DRUG|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
219132975|NCT00966199|DRUG|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
219132976|NCT00114933|DRUG|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
219714301|NCT00835718|DRUG|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
219714302|NCT00835718|DRUG|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
219132977|NCT00751036|DRUG|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
219132978|NCT00751036|DRUG|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
219132979|NCT05038969|DRUG|Stomopral|1 capsule contains 40 mg Esomeprazole
219132980|NCT05038969|DRUG|Nexium|1 capsule contains 40 mg Esomeprazole
219132981|NCT05460663|BEHAVIORAL|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
219132982|NCT03150368|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
219132983|NCT06654700|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
219132984|NCT06622148|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
219132985|NCT06622148|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
219132986|NCT06697002|OTHER|lower trapezius strenghtening excercise|32 participants will be in control group who will perform strenghtening excerise of lower trapezius
219132987|NCT06697002|OTHER|scapular mobility exercise|32 participants will be in experimental group who will perform scapular mobility exercise
219227428|NCT00038636|DRUG|Ritonavir|
219132988|NCT05592613|DEVICE|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
219227429|NCT03651934|DIETARY_SUPPLEMENT|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
219132989|NCT05592613|DRUG|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
219132990|NCT05592613|DRUG|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
219132991|NCT06711354|DRUG|Anti-CD20 Monoclonal Antibody|Injection of monoclonal anti-CD20 antibody as immunomodulatory treatment of multiple sclerosis
219227430|NCT03651934|DIETARY_SUPPLEMENT|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
219227431|NCT03651934|DIETARY_SUPPLEMENT|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
219227432|NCT03651934|DIETARY_SUPPLEMENT|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
219132992|NCT06712108|PROCEDURE|tranplant|double unit cord blood transplnat
219227433|NCT05353062|PROCEDURE|Hemostatic therapy|Bipolar hemostatic forceps
219227434|NCT05353062|PROCEDURE|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
219227435|NCT06436105|OTHER|FICB|FICB is applied to the patients after spinal anesthesia.
219227436|NCT06436105|OTHER|4 in 1 block|4 in 1 block is applied to the patients after spinal anesthesia.
219227437|NCT06436105|OTHER|Control|Peripheral nerve block will not be performed on Group Control patients.
219227438|NCT01303796|DRUG|Sapacitabine|Oral sapacitabine capsules
219227439|NCT01303796|DRUG|Decitabine|Decitabine intravenous
219227440|NCT03863587|BIOLOGICAL|HLX12|healthy volunters receive HLX12 (8mg/kg) once
219227441|NCT03863587|BIOLOGICAL|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
219227442|NCT02139241|DRUG|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
219227443|NCT02139241|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
219227444|NCT01711294|DEVICE|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
219227445|NCT01711294|DEVICE|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
219227446|NCT01711294|DEVICE|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
219227447|NCT02605174|DRUG|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
219132993|NCT06714227|GENETIC|Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample|The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.
219132994|NCT02620072|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
219132995|NCT02620072|OTHER|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
219132996|NCT05789472|BEHAVIORAL|Assessment|Executive functions and reaction times of all participants will be measured.
219132997|NCT02554240|DRUG|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
219132998|NCT02554240|DRUG|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
219132999|NCT02554240|DRUG|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
219133000|NCT01922570|DIETARY_SUPPLEMENT|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
219133001|NCT02339779|PROCEDURE|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
219133002|NCT02339779|PROCEDURE|breast implant|"Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
219133003|NCT05266352|OTHER|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
219133004|NCT05266352|DIAGNOSTIC_TEST|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
219714303|NCT00835718|DRUG|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
219714304|NCT00835718|DRUG|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
219714305|NCT00975923|BEHAVIORAL|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
219714306|NCT00975923|BEHAVIORAL|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
219714307|NCT06025110|BIOLOGICAL|TCD601|Investigational Product
219133005|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
219227448|NCT02605174|DRUG|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
219227449|NCT02605174|DRUG|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
219227450|NCT02605174|DRUG|Placebo|Two placebo tablets to match lasmiditan doses.
219227451|NCT06195449|OTHER|ALKASITE RESTORATIVE MATERIAL|Restorative material for primary teeth
219714308|NCT06025110|OTHER|Placebo|Comparator
219714309|NCT03941821|DRUG|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
219714310|NCT05492955|BEHAVIORAL|Community Health Worker Care Model|Participants will be given a digital BP Cuff and a standardized training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week and record them in a logbook. CHWs will return to participant homes every 2-4 weeks to collect BP measurements and enter them into a data collection system, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. BP readings will be brought by the CHW to their assigned nursing supervisors at their local clinic, who will initiate and tailor medications based on a standardized clinical decision support algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors. Participants will either obtain medication(s) at the pharmacy or, as possible, have them delivered by a CHW.
219133006|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
219133007|NCT03947086|BEHAVIORAL|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
219714311|NCT05492955|BEHAVIORAL|Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model|Participants in this arm will also be given a BP Cuff, (but with cellular network capability, such that BP data can be directly transmitted to trial server), given training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week, which will be automatically uploaded onto the server to be made available by the nurse supervisors. CHWs will return to participant homes every 2-4 weeks to ensure functionality of the devices and transmission, collect BP measurements if the system is not functional, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. Nursing supervisors at the clinic will use the remotely collected BP data to initiate and tailor medications based on the same standardized clinical decision support (CDS) algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors.
219714312|NCT05492955|BEHAVIORAL|Standard of Care Model|Participants in the SOC arm will be referred to their clinic for active care as per standard clinical protocols. All care will be provided at the clinic. Routine care consists of regular visits to the clinic until BP is under control (\<140/90 mmHg) and then at 6 monthly intervals. BP measurements to guide management decisions will be made at the clinic using standard clinic equipment. Symptoms related to hypertension and/or medications will be assessed at each visit. Medications available will include medications on the South African Essential Drug list and which are available in the pharmacy. Prescriptions are picked up at the clinic pharmacy by patients as per routine protocol at the clinics. CHWs may also conduct monitoring as guided by clinical guidelines and as advised by their clinical supervisors during the study period to assess for adherence and provide education.
219714313|NCT06023225|BEHAVIORAL|Pain|Postoperative pain levels
219714314|NCT06023225|BEHAVIORAL|Opioid use|Postoperative opioid use
219714315|NCT05179512|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference group.
219714316|NCT05179512|DRUG|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
219714317|NCT00562328|BIOLOGICAL|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
219714318|NCT00562328|BIOLOGICAL|Rituximab|"Weeks 2-5:~375 mg/m\^2 by IV once weekly"
219714319|NCT00562328|BIOLOGICAL|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
219714320|NCT05191186|DRUG|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
219714321|NCT03012243|PROCEDURE|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
219714322|NCT03012243|PROCEDURE|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
219714323|NCT00379041|BIOLOGICAL|bleomycin sulfate|
219714324|NCT00379041|DRUG|doxorubicin hydrochloride|
219714325|NCT00379041|DRUG|mechlorethamine hydrochloride|
219714326|NCT00379041|DRUG|prednisone|
219714327|NCT00379041|DRUG|procarbazine hydrochloride|
219714328|NCT00379041|DRUG|vinblastine sulfate|
219714329|NCT00379041|DRUG|vincristine sulfate|
219714330|NCT00379041|RADIATION|radiation therapy|
219714331|NCT05007925|DEVICE|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
219714332|NCT05558761|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
219133008|NCT01162655|BEHAVIORAL|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
219714333|NCT04543383|DRUG|Milvexian|Milvexian will be administered orally.
219714334|NCT04543383|BIOLOGICAL|4-Factor Prothrombin Complex Concentrate (4F-PCC)|4F-PCC will be administered intravenously.
219714335|NCT04543383|BIOLOGICAL|Recombinant Human Factor VIIa (rFVIIa)|rFVIIa will be administered intravenously.
219714336|NCT04543383|BIOLOGICAL|Placebo matching to 4F-PCC|Placebo matching to 4F-PCC will be administered intravenously.
219714337|NCT04543383|BIOLOGICAL|Placebo matching to rFVIIa|Placebo matching to rFVIIa will be administered intravenously.
219227452|NCT06195449|OTHER|Glass Ionomer Cement|Restorative material for primary teeth
219227453|NCT01010945|DRUG|erlotinib|administered orally
219227454|NCT01010945|DRUG|gemcitabine|administered intravenously
219227455|NCT01010945|DRUG|nab-paclitaxel|administered intravenously
219227456|NCT00005962|BIOLOGICAL|sargramostim|
219227457|NCT00005962|DRUG|cyclophosphamide|
219133009|NCT02552550|PROCEDURE|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
219133010|NCT02707224|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
219133011|NCT02707224|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
219133012|NCT02707224|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
219133013|NCT06100705|DRUG|Testosterone Cypionate|Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
219133014|NCT06100705|DRUG|Sipuleucel-T|Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
219714338|NCT01833182|OTHER|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
219714339|NCT01833182|OTHER|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
219227458|NCT00005962|DRUG|cytarabine|
219714340|NCT04031950|DEVICE|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
219714341|NCT02572167|DRUG|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
219714342|NCT02572167|DRUG|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
219133015|NCT04977856|BEHAVIORAL|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
219133016|NCT04977856|OTHER|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
219133017|NCT05779722|DEVICE|Vapor barrier|Vapor barrier
219227459|NCT00005962|DRUG|gemtuzumab ozogamicin|
219133018|NCT00686023|PROCEDURE|internal fixation (DHS - richard nail)|internal fixation
219133019|NCT00686023|PROCEDURE|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
219133020|NCT05526911|DRUG|TBAJ-876|"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
219227460|NCT00005962|DRUG|liposomal daunorubicin citrate|
219227461|NCT00005962|DRUG|topotecan hydrochloride|
219227462|NCT03081013|BEHAVIORAL|Social information|Social comparison information will be provided to the study participants weekly via SMS
219227463|NCT03081013|DEVICE|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
219227464|NCT00864006|DRUG|Divalproex Sodium|
219227465|NCT00864006|DRUG|Depakote DR Tablets|
219227466|NCT03585400|OTHER|Observational Study|Observational Study: Not Applicable for Observational Studies
219227467|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
219227468|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
219227469|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
219227470|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
219227471|NCT02522598|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
219227472|NCT02522598|DRUG|Placebo|water for injection
219227473|NCT00236652|DRUG|levofloxacin|
219227474|NCT05114993|DEVICE|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
219227475|NCT00681941|DRUG|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
219227476|NCT01888991|OTHER|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
219714343|NCT05722301|DRUG|Testosterone Therapy|The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
219714344|NCT05722301|OTHER|No Testosterone Therapy|For the sham procedure no pellets will be implanted.
219714345|NCT06437171|BIOLOGICAL|Omalizumab|Omalizumab dose and frequency based on baseline subject weight and total IgE
219714346|NCT05049694|DEVICE|zirconia crowns|esthetic crowns for capping permanent molars with caries
219133021|NCT05526911|DRUG|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
219133022|NCT05526911|DRUG|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
219133023|NCT05025449|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
219133024|NCT05025449|DRUG|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
219227477|NCT06234020|OTHER|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
219227478|NCT05922124|DRUG|Cefiderocol|Test drug regimen
219714347|NCT05049694|DEVICE|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
219714348|NCT06095388|DRUG|JR-441|IV infusion
219714349|NCT06095388|DRUG|JR-441|IV infusion
219714350|NCT06095388|DRUG|JR-441|IV infusion
219714351|NCT05135975|DRUG|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
219714352|NCT06345079|DRUG|Cessation of somatostatin analogues|Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
219227479|NCT05922124|DRUG|Ampicillin-sulbactam|Synergistic combination
219227480|NCT05922124|DRUG|Colistin|Historical comparator
219714353|NCT06345079|DRUG|Continuation of somatostatin analogues|Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
219714354|NCT05388643|DIAGNOSTIC_TEST|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
219714355|NCT05388643|DIAGNOSTIC_TEST|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
219714356|NCT04262856|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
219714357|NCT04262856|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
219714358|NCT04262856|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
219714359|NCT04016389|DRUG|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
219714360|NCT04016389|DRUG|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
219714361|NCT04016389|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
219227481|NCT05922124|DRUG|Meropenem|Historical comparator synergistic combination
219227482|NCT03398980|RADIATION|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
219227483|NCT05119699|DEVICE|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
219227484|NCT02976272|OTHER|bortezomib|
219133025|NCT03804411|DRUG|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
219133026|NCT03804411|DRUG|Standard treatment|"Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide"
219133027|NCT02518711|BEHAVIORAL|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
219227485|NCT00259116|DRUG|Relaxin|
219227486|NCT02964793|OTHER|intervention group|"The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
219227487|NCT01707303|OTHER|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
219227488|NCT01707303|OTHER|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
219227489|NCT06270732|BEHAVIORAL|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
219227490|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
219714362|NCT04016389|PROCEDURE|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
219714363|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
219714364|NCT00373672|DRUG|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
219714365|NCT00373672|DRUG|placebo|identical in appearance to active comparator
219714366|NCT06685133|DEVICE|Robotic assisted bronchoscopy|Subjects will undergo a robotic navigated bronchoscopy to biopsy peripheral pulmonary nodules.
219714367|NCT05612100|OTHER|Electronic Health Record Review|Ancillary studies
219714368|NCT05612100|OTHER|Questionnaire Administration|Complete alopecia questionnaires
219714369|NCT05612100|OTHER|Survey Administration|Complete alopecia surveys
219714370|NCT06666075|OTHER|Digital and Interactive Reminiscence|The intervention for the experimental group aims to enhance the psychological well-being of institutionalized seniors with Alzheimer's through a digital and interactive reminiscence therapy program. It begins with selecting participants based on specific inclusion and exclusion criteria, followed by developing personalized digital profiles that include photographs, music, videos, and life anecdotes to evoke emotional memories. Care staff receive training in using the digital software and reminiscence techniques. The core intervention consists of digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each, featuring multimedia content to encourage discussion and memory sharing. Interactive activities foster active participation, with facilitators promoting emotional expression and connection among participants, creating a supportive environment that stimulates cognitive function and reduces isolation.
219714371|NCT06322342|DRUG|RVP-001|MRI contrast agent
219714372|NCT06619249|DIETARY_SUPPLEMENT|CoQ10 supplementation|Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.
219714373|NCT06619249|DIETARY_SUPPLEMENT|Placebo supplementation|Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
219714374|NCT02108054|DEVICE|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
219714375|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
219714376|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
219714377|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
219714378|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
219714379|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
219714380|NCT03136146|DRUG|Bortezomib|Given SC
219714381|NCT03136146|DRUG|Clofarabine|Given IV
219133028|NCT02652234|DRUG|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
219133029|NCT02652234|DRUG|Chemotherapy|
219133030|NCT04903483|OTHER|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
219133031|NCT01353482|DRUG|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
219133032|NCT01353482|DRUG|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
219133033|NCT01353482|DRUG|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
219133034|NCT01353482|DRUG|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
219133035|NCT03612115|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
219133036|NCT00388011|DRUG|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
219133037|NCT00388011|DRUG|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
219714382|NCT03136146|DRUG|Cyclophosphamide|Given IV
219714383|NCT03136146|DRUG|Dexamethasone|Given IV or PO
219714384|NCT03136146|DRUG|Etoposide|Given IV
219714385|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
219714386|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
219714387|NCT03136146|BIOLOGICAL|Rituximab|Given IV
219714388|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
219714389|NCT04929002|OTHER|No intervention|No intervention
219714390|NCT04871074|DRUG|UCB-J|PET imaging with UCB-J
219714391|NCT04871074|DEVICE|MRI Scan|MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes
219714392|NCT04871074|DEVICE|PET Scan|PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer
219714393|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
219133038|NCT00388011|DRUG|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
219133039|NCT00388011|DRUG|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
219133040|NCT00388011|DRUG|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
219133041|NCT00388011|DRUG|Intranasal placebo|Intranasal placebo
219133042|NCT02345200|PROCEDURE|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
219714394|NCT06011798|DRUG|foselutoclax|Experimental drug
219714395|NCT06745297|DRUG|BI 3776528|BI 3776528
219714396|NCT06745297|DRUG|Placebo matching BI 3776528|Placebo matching BI 3776528
219714397|NCT06745297|DRUG|short-acting benzodiazepine|short-acting benzodiazepine
219714398|NCT05963516|OTHER|LIVEBORN: A Mobile Health Application (app) for Newborn Resuscitation|LIVEBORN is a mobile health application designed to help providers learn from their clinical practice during newborn resuscitation through real-time guidance and debriefing. Using LIVEBORN, an observer can document events during a resuscitation such as the actions of the provider and when the baby cries. A battery-operated heart rate meter, NeoBeat, measures and sends the newborn's heart rate to the LIVEBORN app via Bluetooth. LIVEBORN integrates data from the observer and NeoBeat to provide audio-visual real-time guidance to the provider during a resuscitation. Following the resuscitation, providers can also debrief using LIVEBORN. The app operates on the Android system and is functional off-line, except for the need for an internet connection to upload data to the cloud for research.
219714399|NCT05963516|DEVICE|NeoBeat: Heart Rate Meter for Newborn Resuscitation|NeoBeat is a low-cost device for the measurement of newborn heart rate (HR) that was developed by Laerdal Global Health for use in low-resource settings. It is applied by placing the device around the torso of the newborn. It detects HR accurately, quickly (\<5 sec), is reusable and can be easily disinfected. NeoBeat's dry electrodes detect HR which is digitally displayed and recorded. It uses an impedance system to sense skin contact and motion detection to validate signal quality. It does not require the use of buttons, adhesive, gel or cables and has no disposable parts. A single birth attendant can apply NeoBeat in 2-3 seconds.
219714400|NCT03837964|DRUG|BI 1291583|Tablet
219714401|NCT05007821|DRUG|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
219714402|NCT05007821|DRUG|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
219714403|NCT05007821|DRUG|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
219133043|NCT02345200|PROCEDURE|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
219133044|NCT05502211|DRUG|Fentanyl|induction of anaesthesia using fentanyl
219133045|NCT05502211|DRUG|Lidocaine IV|induction of anesthesia using lidocaine
219133046|NCT01839903|OTHER|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
219133047|NCT01839903|OTHER|Care as usual|Care as usual in the ED will be tracked
219133048|NCT05088226|DRUG|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
219133049|NCT03238729|BEHAVIORAL|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
219714404|NCT05007821|DRUG|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
219714405|NCT05007821|DRUG|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
219714406|NCT05007821|DRUG|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
219714407|NCT05007821|DRUG|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
219714408|NCT05007821|DRUG|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
219133050|NCT03238729|BEHAVIORAL|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
219133051|NCT05096806|OTHER|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
219133052|NCT05096806|DEVICE|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
219133053|NCT01953809|DRUG|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
219133054|NCT01953809|DRUG|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
219133055|NCT01953809|DRUG|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
219133056|NCT01953809|DRUG|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
219133057|NCT00301509|DRUG|peginterferon and ribavirin|
219133058|NCT03640455|DEVICE|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
219133059|NCT03640455|DEVICE|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
219133060|NCT03640455|DEVICE|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
219133061|NCT00569946|DRUG|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
219133062|NCT04276987|BIOLOGICAL|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
219133063|NCT01367561|DRUG|Naloxone|
219133064|NCT01367561|DRUG|IV Methylnaltrexone (MNTX)|
219133065|NCT01367561|DRUG|Placebo|
219714409|NCT06354257|DRUG|Microgynon|Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.
219714410|NCT06354257|DRUG|GSK3036656|Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.
219714411|NCT05108519|OTHER|Electronic Health Record Review|Medical records are reviewed
219714412|NCT06273852|DRUG|PBA-0405|Intratumoral microdose injection by the CIVO device.
219714413|NCT04132050|DRUG|R788|Oral administration
219714414|NCT04132050|DRUG|Placebo|Oral administration
219133066|NCT02165605|DRUG|HylaCare|cream
219133067|NCT02165605|DRUG|Placebo|placebo
219133068|NCT01549379|RADIATION|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
219133069|NCT02089243|PROCEDURE|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
219133070|NCT02089243|PROCEDURE|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
219133071|NCT02072005|OTHER|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
219133072|NCT01879904|PROCEDURE|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
219133073|NCT00192153|BIOLOGICAL|CAIV-T or TIV|
219133074|NCT03556605|OTHER|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
219133075|NCT03556605|OTHER|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
219133076|NCT00762463|DRUG|Celecoxib|capsule, 200 mg QD, 6-12 weeks
219133077|NCT00762463|DRUG|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
219133078|NCT00271765|DRUG|INO-1001|
219133079|NCT04413565|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
219133080|NCT04413565|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
219133081|NCT00876044|DRUG|aflibercept (AVE0005)|Intravenous route
219133082|NCT00876044|DRUG|placebo|Intravenous route
219133083|NCT01306331|DRUG|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
219133084|NCT01306331|DRUG|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
219133085|NCT03136276|OTHER|IPS Empress CAD|standard etchable glass ceramics
219133086|NCT03136276|OTHER|polished Celtra Duo|new glass ceramic material
219133087|NCT06165926|DRUG|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
219133088|NCT06165926|DRUG|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
219133089|NCT06165926|OTHER|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
219133090|NCT03766438|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
219133091|NCT03137914|BIOLOGICAL|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
219133092|NCT03137914|PROCEDURE|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
219360608|NCT03906500|BEHAVIORAL|High schools High on Life|"The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~* Online education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign competition~* Social norms campaign~Parent component~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website"
219360609|NCT03354182|PROCEDURE|Open flap surgery|Elevation of a flap in order to access the treated furcation
219714415|NCT06850701|BEHAVIORAL|mbsr|In order to evaluate the effect of MBSR programme on stress, anxiety, self-compassion and prenatal attachment of pregnant women with perinatal pregnancy loss, MBSR will be applied for four weeks (two sessions per week) for a total of eight sessions in the experimental group. The intervention protocol of this study includes the entire MBSR programme consisting of two sessions per week for 1 month and homework assignments given throughout the programme. In all sessions, mindfulness exercises such as 3-minute breathing, body and breathing exercises, body scanning meditation, sitting meditation, mountain meditation, compassion meditation will be applied to the participants under the guidance of the researcher (H.G.Ö) who is trained and certified in the field of MBSR. It will be done in sessions and individual practices in an environment where pregnant women will not be disturbed at any time of the day. The live online MBSR programme will be provided through mobile communication tools. Sess
219714416|NCT04487548|OTHER|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~1. A brief (\<5 minutes) advice~2. Preoperative smoking cessation video prepared by QuitNow~3. Patients will be provided brochures on smoking cessation~4. A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~5. All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
219133093|NCT05821322|OTHER|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
219133094|NCT00535067|BEHAVIORAL|Questionnaire|Questionnaires taking 60 minutes total to complete.
219133095|NCT00001129|DEVICE|Electronic Medication Reminder System|
219133096|NCT00001129|BEHAVIORAL|Medication Manager|
219133097|NCT01703923|DRUG|FP01|
219133098|NCT01703923|DRUG|placebo|
219133099|NCT01101685|DRUG|Escitalopram|7 days dosing of 10mg per day
219133100|NCT01101685|DRUG|Placebo|7 days dosing at 10mg daily
219133101|NCT04048135|DRUG|Pegozafermin|Subcutaneous injection
219133102|NCT04048135|OTHER|Placebo|Subcutaneous injection
219133103|NCT00172185|DRUG|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
219133104|NCT00172185|DRUG|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
219133105|NCT06364839|OTHER||
219133106|NCT02633423|PROCEDURE|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
219133107|NCT02633423|PROCEDURE|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
219133108|NCT02633423|PROCEDURE|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
219133109|NCT02633423|PROCEDURE|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
219714417|NCT06521242|OTHER|Patient Education|The intervention group was given 120 minutes of training.
219714418|NCT05873738|DRUG|Nicotine replacement|Nicotine patches
219714419|NCT01997580|DRUG|escitalopram|SSRI antidepressant
219714420|NCT01334099|BIOLOGICAL|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
219714421|NCT01334099|RADIATION|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
219714422|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
219714423|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
219714424|NCT00952913|DRUG|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
219714425|NCT00433537|DRUG|bortezomib|Given IV
219714426|NCT00433537|BIOLOGICAL|rituximab|Given IV
219714427|NCT00433537|DRUG|cyclophosphamide|Given IV
219714428|NCT00433537|DRUG|doxorubicin hydrochloride|Given IV
219714429|NCT00433537|DRUG|vincristine|Given IV
218987100|NCT06111820|BEHAVIORAL|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
218987101|NCT02547844|DRUG|efavirenz + emtricitabina + tenofovir|
218987102|NCT02547844|DRUG|rilpivirina + emtricitabina + tenofovir|
219133110|NCT06477926|DRUG|ABBV-668 IR|• Oral Capsule
219133111|NCT06477926|DRUG|ABBV-668 ER|• Oral Tablets
219714430|NCT00433537|DRUG|dexamethasone|Given IV
219714431|NCT00433537|BIOLOGICAL|filgrastim|Given SC
219714432|NCT00433537|BIOLOGICAL|pegfilgrastim|Given SC
219714433|NCT00433537|PROCEDURE|Autologous stem cell transplantation (ASCT)|
219714434|NCT02295449|DEVICE|biopsy sample performed after the SonoVue® injection|
219714435|NCT00555191|BEHAVIORAL|diet restriction|each meal should contain less than 2 gm fructose
219714436|NCT01725399|OTHER|Apple Juice|
219714437|NCT01725399|OTHER|Water|
219714438|NCT04328194|DIAGNOSTIC_TEST|Serum Autotaxin|Marker
218987103|NCT02015572|BEHAVIORAL|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
218987104|NCT02015572|OTHER|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
218987105|NCT01029834|BEHAVIORAL|family based lifestyle and behavioral counseling|16 group meetings
218987106|NCT01029834|BEHAVIORAL|counseling focused on the child|16 meetings
218987107|NCT02252783|DRUG|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
218987108|NCT00818480|DRUG|YM155|continuous infusion
219133112|NCT05039723|DRUG|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
219133113|NCT03071185|PROCEDURE|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
219133114|NCT05040750|OTHER|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
219714439|NCT04328194|RADIATION|chest x-ray|chest x- ray will be done for the study group
219714440|NCT04328194|DIAGNOSTIC_TEST|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
219714441|NCT04328194|DIAGNOSTIC_TEST|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
219714442|NCT04328194|RADIATION|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
219714443|NCT04328194|DIAGNOSTIC_TEST|Peripheral haemogram|blood sample will be taken from the patients
219714444|NCT04328194|DIAGNOSTIC_TEST|Renal and liver functions|to exclude any other morbidity
219714445|NCT04328194|DIAGNOSTIC_TEST|Prothrombin time and concentration|blood sample will be taken from the patients
219714446|NCT04328194|DIAGNOSTIC_TEST|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
219714447|NCT04328194|OTHER|Full medical history|full medical history will be taken from all patients
219714448|NCT04328194|OTHER|Full clinical examination|full clinical examination will be done for the patients
219714449|NCT05146765|DEVICE|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
219714450|NCT05146765|OTHER|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
219714451|NCT01757847|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
219133115|NCT04257851|DRUG|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
219133116|NCT04257851|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
219133117|NCT03879967|DEVICE|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
219133118|NCT03755440|DRUG|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
219133119|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
219133120|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
219133121|NCT05612243|OTHER|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
219133122|NCT04669249|BEHAVIORAL|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
219133123|NCT06631781|OTHER|GOLD-Cog+|6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
219133124|NCT06628596|DIETARY_SUPPLEMENT|Paraxanthine 200mg and 300mg|Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
219133125|NCT05120440|OTHER|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
219133126|NCT05120440|OTHER|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
219133127|NCT02915055|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
219714452|NCT01757847|BEHAVIORAL|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
219133128|NCT02915055|DRUG|standard oxycodone/acetaminophen|
219133129|NCT05070104|DRUG|CPI-613|250-1000mg/m2 -14 day cycle
219133130|NCT05070104|DRUG|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
219133131|NCT05070104|DRUG|Bevacizumab|5mg/kg IV
219133132|NCT04275817|OTHER|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
219133133|NCT06431035|DIETARY_SUPPLEMENT|caffeine|The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
219133134|NCT04338165|DRUG|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
219714453|NCT06166823|OTHER|EMR alert|EMR alert for medication optimization
219714454|NCT04175756|DEVICE|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
219133135|NCT04622527|OTHER|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
219133136|NCT03908047|OTHER|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
219133137|NCT04164628|OTHER|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
219133138|NCT05165290|DRUG|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
219714455|NCT05334836|DIAGNOSTIC_TEST|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
219714456|NCT03370276|DRUG|Nivolumab|Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
219714457|NCT03370276|DRUG|Cetuximab|Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
219714458|NCT03495388|DRUG|Oxycodone|Post-op pain management medication
219133139|NCT05165290|DRUG|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
219133140|NCT03491956|DEVICE|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
219133141|NCT00666120|OTHER|Enfamil LIPIL with iron|cow's milk based infant formula
219714459|NCT05239572|COMBINATION_PRODUCT|screening, prevention and counselling|Screening in Intergenerational solidarity clubs in Myanmar and Vietnam and in Posbindu programme in Indonesia
219714460|NCT05867121|DRUG|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
219714461|NCT05867121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
219714462|NCT05867121|DRUG|Capecitabine|Capecitabine will be administered as per the schedule specified in the respective arm.
219714463|NCT05867121|DRUG|S-1|S-1 will be administered as per the schedule specified in the respective arm.
219133142|NCT00666120|OTHER|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
219133143|NCT01861678|PROCEDURE|High tie of IMA|Conventional technique
219133144|NCT01861678|PROCEDURE|Low tie of IMA|Technique for preserving left colic arterial perfusion
219133145|NCT04311229|DEVICE|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
219133146|NCT04311229|OTHER|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
219360610|NCT03354182|DEVICE|Bio-oss collagen|Biomaterial for periodontal surgery
219714464|NCT05867121|DRUG|Nivolumab|Nivolumab will be administered as per the schedule specified in the respective arm.
219714465|NCT05867121|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
219714466|NCT05867121|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedule specified in the respective arm.
219714467|NCT05867121|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
219714468|NCT02337127|DRUG|Lamivudine|Lamivudine, 100mg/day, per os
219714469|NCT00297401|DRUG|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
219714470|NCT00297401|DRUG|placebo|QD, PO, up to 8 weeks
219714471|NCT00831844|BIOLOGICAL|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
219714472|NCT00831844|OTHER|laboratory biomarker analysis|Correlative studies
219133147|NCT00151996|DRUG|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
219133148|NCT00151996|DRUG|Amphetamine + SPD503|
219133149|NCT01544140|DRUG|Midazolam|Oral syrup 7.5 mg, single dose
219133150|NCT01544140|DRUG|vandetanib|Oral tablets, 800 mg, single dose
219133151|NCT05829174|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
219133152|NCT05829174|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
219360611|NCT03354182|DEVICE|Bio-gide|Biomaterial for periodontal surgery
219714473|NCT05031897|DRUG|Fludarabine|Given IV
219714474|NCT05031897|RADIATION|Total-Body Irradiation|Undergo TBI
219714475|NCT05031897|PROCEDURE|Donor Lymphocyte Infusion|Undergo DLI
219714476|NCT05031897|DRUG|Cyclophosphamide|Given IV
219714477|NCT05031897|DRUG|Tacrolimus|Given IV
219714478|NCT05031897|DRUG|Mycophenolate Mofetil|Given IV
219714479|NCT05031897|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
219714480|NCT05031897|DRUG|Melphalan|Given IV
219714481|NCT05031897|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/ biopsy
219714482|NCT05031897|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
219714483|NCT05031897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219714484|NCT06202183|BEHAVIORAL|Exercise Program|A 12 week, home-based, virtually supervised, aerobic and resistance exercise training program comprised of 36 sessions. Participants will be provided with a home stationary bike, resistance bands, and Fitbit. Virtually supervised sessions will be accessible via Zoom platform. For participants who do not have a device, a Wi-Fi-enabled tablet will also be provided.
219714485|NCT05948605|DEVICE|Empower Neuromodulation System|The Empower Neuromodulation System is designed to provide transcutaneous stimulation to the branches of a spinal nerve. The system comprised of three key components: (A) The Stimulator, (B) the Empower smartphone app, and (C) the Gel Patch. The smartphone application is used to coordinate treatment and record participant responses.
219714486|NCT00843882|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219714487|NCT00843882|BIOLOGICAL|Epoetin Alfa|Given SC
219714488|NCT00843882|OTHER|Laboratory Biomarker Analysis|Correlative studies
219714489|NCT00843882|DRUG|Lenalidomide|Given PO
219714490|NCT06833736|DEVICE|"The See Yourself Differently app"|As the app has not been evaluated before in terms of its impact on dietary change, the first intervention group will have the app as it stands. The overall aim of the syd is to improve general wellbeing across several health-related domains, which is achieved through engaging with its main features (the daily plan, journal, user profile, and chat function).
219714491|NCT06833736|DEVICE|"The See Yourself Differently app + messages"|The plant-forward recipes and information pages available on the app will be made more salient for app users in this group through sending them via targeted messages in the chat function at specific times. Each day, the information pages will be sent at 09:30 and the recipes will be sent at 13:00.
219714492|NCT06833736|BEHAVIORAL|General information|The (no app) control group will be sent general health and sustainability information via email immediately after randomisation is done. To incentivise participation in both baseline and follow-up assessments, the control group will be offered lifetime access to the app and a summary of their self-reported food intake at week 10. The control group will be sent one email reminder halfway through (week 5) to remind them that they are involved in the study, provide them with instructions on the follow-up assessment, and that they will receive the intervention and dietary feedback at week 10.
219714493|NCT04652141|DIAGNOSTIC_TEST|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
219714494|NCT06308562|DEVICE|Fuzzy Wale Compression Stockinet|EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
219714495|NCT04208919|BIOLOGICAL|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
219714496|NCT04926545|DRUG|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
219714497|NCT04926545|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
219714498|NCT04926545|DRUG|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
219714499|NCT03188198|DRUG|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
219714500|NCT02904343|DEVICE|domestic hemodialysis machine|WEGO, DBB-27C
219714501|NCT02904343|DEVICE|imported hemodialysis machine|Fresenius, 4008s
219714502|NCT05317546|DRUG|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
219714503|NCT03331250|DRUG|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
219714504|NCT04590963|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
219714505|NCT04590963|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
218987109|NCT00570570|PROCEDURE|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
218987110|NCT00570570|OTHER|conventional physiotherapy|trice a week during 6 weeks
218987111|NCT01228474|OTHER|Select the Number of embryos to transfer|Select the Number of embryos to transfer
218987112|NCT02508831|PROCEDURE|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
218987113|NCT06967935|OTHER|Cognitive memory task on a computer|"Encoding: (1) Participants will learn 60 associations between pairs of items (cue and target) that are presented sequentially at unique locations on a screen, in a given context. 30 pairs are presented once, and 30 pairs are presented repeatedly (4 times).~(2) After learning, the first recall phase begins after a short delay of 30 minutes: 50% of the pairs are tested in a similar way, this time with an assessment of contextual memory.~(3) The remaining 50% of pairs are tested after a 12-hour delay, involving either a day awake (condition 1) or a night asleep (condition 2)."
219133153|NCT05829174|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
219133154|NCT05829174|BEHAVIORAL|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
219133155|NCT02714127|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
219133156|NCT02714127|OTHER|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
219714506|NCT04590963|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
219714507|NCT05886894|DEVICE|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
219714508|NCT05886894|DEVICE|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
219133157|NCT02295475|DRUG|Apixaban|
219133158|NCT02295475|DRUG|Warfarin|
219714509|NCT06556121|PROCEDURE|Saddle block|The injected solution will be comprised of 5mg of heavy Bupivacaine 0.75% plus 100mcg of Morphine will be injected into the intrathecal space.
219714510|NCT06556121|PROCEDURE|pudendal nerve block|As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.
219714511|NCT05481151|DRUG|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
219714512|NCT05481151|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
219133159|NCT04257279|PROCEDURE|ExcelsiusGPS™|The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
219133160|NCT05798208|DIAGNOSTIC_TEST|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
219133161|NCT01801930|DRUG|OCV-103 and OCV-104|0.3 mg of each
219133162|NCT01801930|DRUG|OCV-103 and OCV-104|1 mg of each
219133163|NCT01801930|DRUG|OCV-103 and OCV-104|3 mg of each
219714513|NCT06371924|DEVICE|Machine Perfusion|The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.
219714514|NCT05920759|DIAGNOSTIC_TEST|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
219714515|NCT06557772|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
219714516|NCT06557772|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
219714517|NCT06557772|DIETARY_SUPPLEMENT|SIGE|Pharmaceutical form: Capsule Route of administration: Oral
219714518|NCT06557772|DIETARY_SUPPLEMENT|Gluten-free product (GFP)|Pharmaceutical form: Capsule Route of administration: Oral
219714519|NCT05473507|DIAGNOSTIC_TEST|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
219714520|NCT05473507|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
219714521|NCT05473507|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
219714522|NCT05473507|DIAGNOSTIC_TEST|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
219133164|NCT01801930|DRUG|OCV-103 and OCV-104|6 mg of each
219133165|NCT01654705|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
219133166|NCT01654705|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
219133167|NCT00004560|DEVICE|defibrillator|
219133168|NCT00266097|DRUG|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
219133169|NCT00266097|DRUG|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
219133170|NCT00266097|DRUG|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
219133171|NCT00266097|RADIATION|radiation therapy|5040 cGy, every week, up to 6 weeks
219133172|NCT00266097|DRUG|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
219133173|NCT00266097|DRUG|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
219133174|NCT03937687|DRUG|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
219133175|NCT03937687|DRUG|Placebo|Placebo
219133176|NCT03937687|DRUG|Caffeine|Caffeine
219133177|NCT03962192|OTHER|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
219714523|NCT05473507|DIAGNOSTIC_TEST|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
219714524|NCT04057365|DRUG|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
219714525|NCT04057365|DRUG|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
219714526|NCT02129543|PROCEDURE|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
219714527|NCT06499519|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
219714528|NCT04607421|DRUG|Encorafenib|75 mg capsules
219133178|NCT04209881|OTHER|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
219133179|NCT03380975|DRUG|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
219133180|NCT04311203|BEHAVIORAL|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
219133181|NCT01552018|DRUG|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
219133182|NCT01552018|DRUG|Placebo|Placebo, 1 tablet per day for 3 months.
219133183|NCT04672473|BIOLOGICAL|DC-CTL|DAC combined with Ag-CTL
219714529|NCT04607421|DRUG|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
219714530|NCT04607421|DRUG|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
219714531|NCT04607421|DRUG|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
219714532|NCT04607421|DRUG|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
219714533|NCT04607421|DRUG|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
219714534|NCT04607421|DRUG|Capecitabine|150 mg or 500 mg Tablet
218987114|NCT06967935|OTHER|Eye tracking|Eye-tracking will be carried out during the task to ensure that participants are focused on the task (quantification of the number and duration of eye fixations in the area of interest corresponding to the target presentation)
219714535|NCT04607421|DRUG|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
219714536|NCT06433037|DIETARY_SUPPLEMENT|Chicory inulin|Chicory inulin (12g/day) divided over two dosages (6g per dose)
219714537|NCT06433037|DIETARY_SUPPLEMENT|Resistant dextrin|Resistant dextrin (14g/day) divided over two dosages (7g per dose)
218987115|NCT06967935|OTHER|Questionnaires on task-related fatigue|Questionnaire on task-related fatigue (Likert-scale) will be completed by participants between blocks of items during the task
218987116|NCT06967935|OTHER|Questionnaire on task difficulty|Questionnaires on task difficulty (Likert-scale) will be completed by participants at the end of the task
218987117|NCT06967935|OTHER|Karolinska scale|Participants' state of sleepiness will be assessed at the beginning of each stage (encoding, immediate recall, delayed recall) using the Karolinska sleepiness scale
218987118|NCT05929131|OTHER|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
218987119|NCT05929131|OTHER|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
218987120|NCT05929131|OTHER|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
219227491|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
219227492|NCT04989842|BEHAVIORAL|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
219133184|NCT02509780|OTHER|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
219133185|NCT03425604|PROCEDURE|Intrauterine insemination|
219227493|NCT02290158|OTHER|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
219227494|NCT04460066|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
219714538|NCT06433037|DIETARY_SUPPLEMENT|Seaweed polysaccharide|Seaweed polysaccharide (1g/day) divided over two dosages (0.5g per dose). Additionally contains 7g/day of placebo as a volumetric and isocaloric filler.
219714539|NCT06433037|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (7g/day) will be provided in two divided doses (3.5g per dose)
219714540|NCT06565962|OTHER|Educaiton group|The experimental group will be made to watch training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles.
219714541|NCT06565962|OTHER|control group|The control group will receive standard care. The standard care programme will include brochures and guidance.
219714542|NCT05775289|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
219714543|NCT05775289|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
219714544|NCT05775289|DRUG|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
219714545|NCT05775289|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
219227495|NCT04460066|DRUG|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
219227496|NCT04460066|DRUG|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
219227497|NCT04460066|DRUG|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
219227498|NCT04460066|PROCEDURE|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
219227499|NCT06368999|DIAGNOSTIC_TEST|EEG|registration of 8 minutes of EEG
219227500|NCT00927706|DEVICE|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
219714546|NCT05775289|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
219714547|NCT04738487|BIOLOGICAL|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
219714548|NCT04738487|BIOLOGICAL|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
219714549|NCT03976375|BIOLOGICAL|Pembrolizumab|IV infusion of pembrolizumab at 200 mg
219714550|NCT03976375|DRUG|Lenvatinib|Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
219714551|NCT03976375|DRUG|Docetaxel|IV infusion of docetaxel at 75 mg/m\^2.
219714552|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
219714553|NCT06567847|OTHER|Neurocognitive Enriched Exercise|An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.
219714554|NCT06567847|OTHER|Multimodal Exercise|Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
219714555|NCT03873831|BEHAVIORAL|Animal-assisted intervention|The therapy dog is present during the session.
219714556|NCT03873831|BEHAVIORAL|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
219133186|NCT01976754|DRUG|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
219133187|NCT01487564|DRUG|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
219133188|NCT05251688|OTHER|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
219133189|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
219714557|NCT05406778|DEVICE|SPARK Test|Thirty (30) minutes of resting state EEG data collection.
219714558|NCT06965478|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
219714559|NCT05029999|DRUG|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
219714560|NCT05029999|DRUG|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
219714561|NCT05029999|DRUG|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
219714562|NCT06965530|DIETARY_SUPPLEMENT|Clinic-Based Medically Tailored Groceries (CB-MTG)|Patients have the opportunity to pick up medically tailored groceries every other week at the Food Is Medicine Clinic or Market associated with their provider.
219714563|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries (HD-MTG)|Patient receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery.
219133190|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
219714564|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries plus Education (HD-MTG_PLUS)|Patients receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery, plus also receives additional nutrition and culinary education and support throughout the trial.
219714565|NCT06494761|DRUG|zongertinib|zongertinib, Hernexeos®
219714566|NCT06494761|DRUG|midazolam|midazolam
219714567|NCT06494761|DRUG|omeprazole|omeprazole
219714568|NCT06494761|DRUG|repaglinide|repaglinide
219714569|NCT06965010|BEHAVIORAL|Measurement-based care|Patients will complete MBC measures with their treatment provider and follow-up surveys conducted at baseline and monthly intervals. Both providers and patients will use the Greenspace Mental Health tools to regularly assess patient-reported symptoms, review results together, and collaboratively design individualized treatment plans. Providers will implement MBC to guide treatment adjustments based on these assessments.
219714570|NCT06965010|BEHAVIORAL|Measurement As Usual|Patients will participate in Measurement As Usual (MAU) via the existing processes available within treatment sites. Currently, patients are assessed and participate in semi-structured interviews at 6-month increments to assess progress and appropriateness of level of care.
219714571|NCT06205030|DRUG|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
219714572|NCT06255392|DRUG|Fluzoparib|Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
219714573|NCT06255392|DRUG|Apatinib Mesylate|Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
219714574|NCT06255392|DRUG|Capecitabine tablets|Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
218987121|NCT05868395|DRUG|Polatuzumab, bendamustin und rituximab|"* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~* Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle~* Rituximab 375 mg/m2 i.v. on day 1 of each cycle~* Each cycle is 21 days long~* Up to 6 cycles per patients planned"
218987122|NCT05686031|OTHER|No interventions were done between groups|No interventions were done between groups
218987123|NCT06450262|DRUG|Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
218987124|NCT06450262|DRUG|Synjardy® 12.5mg/1000mg film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
218987125|NCT04370223|BIOLOGICAL|Ozone auto-hemotherapy|ozone auto-hemotherapy
218987126|NCT05232175|DRUG|ALT-BB4|Recombinant Hyaluronidase
218987127|NCT05232175|DRUG|0.9%NaCl|Normal Saline
218987128|NCT01067690|DRUG|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
218987129|NCT00875992|DEVICE|ETN with ASLS|Angle stable locking of ETN using ASLS
218987130|NCT00875992|DEVICE|ETN locked with conventional locking bolts|Conventional surgical procedure
218987131|NCT02041832|OTHER|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
218987132|NCT02041832|DEVICE|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
218987133|NCT00702195|DRUG|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
218987134|NCT00702195|DRUG|Placebo|single dose of placebo (administered under protocol 38805)
218987135|NCT00702195|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
218987136|NCT00660699|DRUG|Gemcitabine|
218987137|NCT00660699|DRUG|Docetaxel|
218987138|NCT00660699|RADIATION|Radiation|
219714575|NCT06255392|DRUG|Vinorelbine Tartrate Oral|For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
219714576|NCT06255392|DRUG|Eribulin mesylate injection|Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
219714577|NCT06255392|DRUG|Gemcitabine Hydrochloride|Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
219714578|NCT06255392|DRUG|Paclitaxel-albumin|Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
219714579|NCT05877846|DIETARY_SUPPLEMENT|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
219714580|NCT05877846|DIETARY_SUPPLEMENT|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
219714581|NCT05877846|DIETARY_SUPPLEMENT|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
219714582|NCT06269900|DRUG|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
219714583|NCT06269900|DRUG|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
219714584|NCT05378204|OTHER|Main study:|"For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment).~During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles).~At the time of progression: tumor biopsy and blood samples will be collected."
219714585|NCT05378204|OTHER|Sub-study:|For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
219714586|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (blinded)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
219133191|NCT00664846|DRUG|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
219133192|NCT00664846|DRUG|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
219714587|NCT06542198|DIAGNOSTIC_TEST|Placebo Infusion (blinded)|0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).
219714588|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (open label)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
219133193|NCT01301664|OTHER|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
219133194|NCT05140564|BEHAVIORAL|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
219714589|NCT06543316|PROCEDURE|Low Thermal Plasma (LTP) Treatment|For patients randomized to the LTP group, the first LTP treatment will be administered during the initial esophagogastroduodenoscopy (EGD) using a single-use 2.3 mm filtered argon plasma coagulation (FiAPC probe). The argon plasma will be applied at low power settings (\~1 W) to the ulcerated areas using pulsed APC effect 0.1.
219714590|NCT06543316|OTHER|Standard of Care Ulcer Treatment (typically PPI Administration)|Standard of care for treatment of ulcers is administration of a proton pump inhibitor (PPI). For patients in the SOC group whose ulcers have not healed completely by the second follow-up at 8 weeks, crossover to LTP treatment will be offered. This treatment will follow the same procedure as the initial LTP treatment.
219714591|NCT05411666|PROCEDURE|Saline solution maintenance of the CVC|"Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures."
219133195|NCT01188629|BEHAVIORAL|Safety Training|IT intervention focuses on safety in the home.
219133196|NCT01188629|BEHAVIORAL|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
219133197|NCT04069182|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
219133198|NCT06375824|DRUG|Bufei Recipe|Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
219133199|NCT06375824|DRUG|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
219133200|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program|The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
219133201|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support|The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
219133202|NCT03377855|OTHER|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
219133203|NCT01413113|DRUG|pazopanib hydrochloride|Given PO
219133204|NCT01413113|RADIATION|iodine I 131|Given IM
219133205|NCT02215044|DRUG|BI 2536, intravenous|
219133206|NCT02215044|DRUG|Gemcitabine, intravenous|
219133207|NCT04622826|BIOLOGICAL|immune plasma|immune covid 19 plasma infusion
219133208|NCT06454773|DIETARY_SUPPLEMENT|NCT/NFT|extract from black pepper and hemp hull
219133209|NCT04157257|DRUG|TDF tablet|TDF tablet 300mg QD
219133210|NCT04157257|DRUG|Entecavir Tablet|Entecavir tablet 0.5mg QD
219133211|NCT04157257|DRUG|QL-007|QL-007 tablets 200mg BID
219133212|NCT04371718|DRUG|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
219133213|NCT04371718|OTHER|Placebo|A capsule has same component but active drug
219133214|NCT04409210|BEHAVIORAL|Establishment of individual health records|Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
219133215|NCT04409210|BEHAVIORAL|Cardiovascular risk assessment|The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
219133216|NCT04409210|BEHAVIORAL|Popularization of medical knowledge|Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
219133217|NCT04409210|BEHAVIORAL|Personalized Reminders|"1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital."
219133218|NCT04409210|DRUG|Routine treatment|Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
219133219|NCT04371536|DRUG|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
219133220|NCT04371536|BEHAVIORAL|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content"
219227501|NCT03438409|OTHER|Robotic gait training|Robotic gait training
219227502|NCT06509204|DIETARY_SUPPLEMENT|Glucotrojan|"Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end"
219227503|NCT05376982|DIAGNOSTIC_TEST|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
219227504|NCT05376982|DIAGNOSTIC_TEST|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
219227505|NCT03031509|BIOLOGICAL|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
219227506|NCT03031509|PROCEDURE|debridement|debridement
219227507|NCT03737110|DRUG|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
219133221|NCT00908947|DEVICE|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
219133222|NCT00553215|PROCEDURE|quality-of-life assessment|
219133223|NCT00553215|PROCEDURE|questionnaire administration|
219227508|NCT03737110|DRUG|Placebo|Placebo SC injections once weekly
219133224|NCT04542369|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
219227509|NCT02409043|OTHER|Blood draw|Blood drawn for comparison with other groups
219227510|NCT02409043|OTHER|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
219227511|NCT05701579|PROCEDURE|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
219227512|NCT05407051|BEHAVIORAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
219227513|NCT05407051|BEHAVIORAL|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
219714592|NCT05411666|PROCEDURE|No maintenance of the CVC|"No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion."
219133225|NCT05578352|OTHER|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
219133226|NCT05578352|OTHER|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
219227514|NCT04696016|PROCEDURE|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
219227515|NCT04696016|PROCEDURE|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
219227516|NCT05697536|OTHER|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
219227517|NCT05697536|OTHER|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
219714593|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
219714594|NCT03346135|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
219714595|NCT03346135|BIOLOGICAL|Daratumumab|Given IV
219714596|NCT03346135|OTHER|Laboratory Biomarker Analysis|Correlative studies
219714597|NCT03346135|DRUG|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
219133227|NCT05578352|OTHER|Change insulin|Change premix insulin to long-acting insulin
219133228|NCT00504114|PROCEDURE|ACL Reconstruction Surgery|
219133229|NCT00504114|PROCEDURE|Cartilage Resurfacing Surgery|
219133230|NCT00504114|PROCEDURE|Total Knee Replacement|
219133231|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
219227518|NCT01619319|OTHER|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
219227519|NCT01619319|OTHER|computer games|computer games that that consist of word puzzles
219227520|NCT01235520|DRUG|Placebo|Oral doses, once a day for 52 weeks
219227521|NCT01235520|DRUG|RO4917838|Oral dose level 1, once a day for 52 weeks
219714598|NCT05785078|BEHAVIORAL|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
219714599|NCT06084234|DIAGNOSTIC_TEST|GALAD|GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
219714600|NCT06084234|DIAGNOSTIC_TEST|Liver Ultrasound with or without AFP|This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
218987139|NCT06404645|DEVICE|Near-infrared spectroscopy detection|Cranial CT confirm intracranial haematoma. Then the near-infrared spectroscopy device to collect date by red sensor probe in the corresponding position on the scalp and blue sensor probe on the opposite side of the hematoma. Collect data for 10 minutes.
218987140|NCT03569618|DEVICE|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
218987141|NCT04116970|PROCEDURE|Bronchoscopy|Undergo bronchoscopy with EBUS-TBNA
218987142|NCT04116970|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo bronchoscopy with EBUS-TBNA
218987143|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
218987144|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
218987145|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
218987146|NCT04560335|BEHAVIORAL|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
218987147|NCT04560335|BEHAVIORAL|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
218987148|NCT03432897|DRUG|Olaparib Pill|300 mg BID
218987149|NCT03432897|PROCEDURE|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
218987150|NCT03105479|DRUG|Cadazolid|Granules for oral suspension to be administered twice daily
218987151|NCT03105479|DRUG|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
218987152|NCT03105479|DRUG|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
218987153|NCT05439447|DIAGNOSTIC_TEST|Patients scheduled for VFSS testing group|Patients scheduled for VFSS testing, patient with voice.
218987154|NCT05292547|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
218987155|NCT02963649|DEVICE|DCB|Drug Coated Balloon
218987156|NCT02963649|DEVICE|PTA|Percutaneous Transluminal Angioplasty
218987157|NCT06144177|OTHER|Dark with star projector|When in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on.
218987158|NCT06144177|DRUG|Preoperative midazolam|Midazolam by mouth preoperatively.
218987159|NCT06144177|OTHER|Parental Presence|A parent or guardian will accompany the child into the OR and be present for the start of induction.
218987160|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
218987161|NCT05928026|BEHAVIORAL|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
218987162|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
218987163|NCT05358444|BEHAVIORAL|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
219133232|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
219133233|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
219227522|NCT01235520|DRUG|RO4917838|Oral dose level 2, once a day for 52 weeks
219133234|NCT01092806|DRUG|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
219133235|NCT05014555|BIOLOGICAL|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
219133236|NCT01282437|RADIATION|Prophylactic Cranial Irradiation|"* 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy"
219133237|NCT06138951|OTHER|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
219133238|NCT04861610|BEHAVIORAL|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
219133239|NCT04861610|BEHAVIORAL|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
219133240|NCT03441360|DRUG|Eribulin mesylate|Intravenous infusion
219133241|NCT00269399|DRUG|Rifaximin (Xifaxan)|
219133242|NCT00269399|DRUG|Vancomycin|
219133243|NCT03639324|DRUG|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
219133244|NCT03639324|DRUG|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
219133245|NCT03639324|DRUG|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
219133246|NCT03639324|DRUG|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
219714601|NCT05473598|BEHAVIORAL|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
219133247|NCT03639324|DRUG|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
219133248|NCT03639324|DRUG|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
219133249|NCT01760291|DEVICE|WATCHMAN LAA Closure Technology|
219227523|NCT03263117|DRUG|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
219360612|NCT03423498|OTHER|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
219133250|NCT02906878|PROCEDURE|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
219133251|NCT03396835|DEVICE|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
219133252|NCT02893228|PROCEDURE|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
219133253|NCT02893228|DRUG|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
219133254|NCT01239563|DRUG|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
219360613|NCT01431404|BIOLOGICAL|Etanercept (Enbrel)|prefilled syringe, SC
219714602|NCT05473598|BEHAVIORAL|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
219714603|NCT05473598|OTHER|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
219133255|NCT01239563|DRUG|Basiliximab|Intravenous 20mg, day 0\&4
219133256|NCT02052648|DRUG|Indoximod|
219133257|NCT02052648|DRUG|Temozolomide|
219133258|NCT02052648|DRUG|Bevacizumab|
219133259|NCT02052648|RADIATION|Stereotactic Radiation|
219133260|NCT05753852|DRUG|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
219133261|NCT00422019|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
219133262|NCT00422019|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
219133263|NCT01570660|DRUG|Pioglitazone|12 weeks of pioglitazone treatment
219133264|NCT04315454|DRUG|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
219133265|NCT00319943|PROCEDURE|Computer-based training for Mild Cognitive Impairment (MCI)|
219133266|NCT00583843|PROCEDURE|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
219714604|NCT05852054|BEHAVIORAL|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
219714605|NCT05852054|BEHAVIORAL|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
219714606|NCT05852054|BEHAVIORAL|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.
219714607|NCT05852054|BEHAVIORAL|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
219714608|NCT05852054|BEHAVIORAL|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
219714609|NCT05852054|BEHAVIORAL|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
219714610|NCT06370533|BEHAVIORAL|behavioral interventions|The investigators set diet, physical activity, and weight goals for each participant. During the lifestyle intervention period, the participants need to complete weekly self-monitoring of weight, weekly recording of diet behavioral goals, timely exercise logging, online health education course learning by using the WeChat public account. They will receive corresponding timely reminder and tailored feedback in the form of graphical illustration and text according to diet, physical activity, and weight data collected by WeChat public account and Huawei Wristband. They will receive individual face to face or telephone sessions every 2 weeks to complete health education, goal review, motivational interview as well as collecting adverse events.
219714611|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
219714612|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
219714613|NCT05661331|DEVICE|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
219133267|NCT03439124|DRUG|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
219360614|NCT01431404|BIOLOGICAL|HD203|HD203, prefilled syringe, SC injection
219360615|NCT00289107|DEVICE|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
219714614|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
219714615|NCT06113328|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
219714616|NCT06113328|DRUG|Placebo|Placebo comparator to MK-6194 administered SC
219714617|NCT02842619|BIOLOGICAL|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
219133268|NCT03439124|DRUG|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
219133269|NCT00162071|DRUG|apadenoson|
219714618|NCT06124196|DEVICE|wearable technology|Three wearable devices
219714619|NCT04720898|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.
219714620|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
219714621|NCT06965686|BEHAVIORAL|PERI-MIND|PERI-MIND will be informed by the focus group findings from phase one. However, the investigators anticipate including core components related to psychoeducation, psychological grounding, \& behavioral activation, which will be specifically adapted to the perimenopausal and menopausal population. Psychoeducation in this context will focus on menopausal symptoms like brain fog (e.g., how common they are, how long they typically last), information about dementia and its risk factors (e.g., most actionable risk factors in mid-life), and links between menopause and dementia (e.g., hormonal replacement therapy). Psychological grounding content will focus on practical training exercises in mindful monitoring of concerns about brain fog and other menopausal symptoms (e.g., meditation, deep breathing). Behavioral activation will focus on exercises to recognize and disrupt avoidant coping behaviors, and increase engagement in valued activities (e.g., social engagement, exercise, healthy eating).
219714622|NCT03848260|DEVICE|Magnetic device prototype|The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
219714623|NCT06967324|OTHER|Stepped care|Graduated palliative cross-sectoral care
219714624|NCT06967324|OTHER|Usual Care|Usual care at the outpatient respiratory clinic
219714625|NCT06972056|DRUG|Atogepant 60 mg|Atogepant at a dose up to 60 mg daily.
219714626|NCT06972056|DRUG|Propranolol 160 mg|Daily propranolol up to 80 mg twice daily.
219714627|NCT06972056|DRUG|Topiramate 100 mg|Daily topiramate, up to 50 mg twice daily
219714628|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
219714629|NCT04199026|DRUG|Doxorubicin|Given via microdevice
219714630|NCT04199026|DRUG|Doxorubicin Hydrochloride|Given via microdevice
219714631|NCT04199026|DEVICE|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
219360616|NCT00289107|DEVICE|Total knee replacement|Fixed Cruciate Substituting Knee System
219360617|NCT04556617|DRUG|PLX2853 20 mg|PLX2853 tablets
219360618|NCT04556617|DRUG|Olaparib|Olaparib tablets
219360619|NCT04556617|DRUG|Abiraterone acetate|Abiraterone acetate tablets
219360620|NCT04556617|DRUG|Prednisone|Prednisone (or equivalent) tablets
219714632|NCT04199026|DRUG|Everolimus|Given via microdevice
219714633|NCT04199026|BIOLOGICAL|Ganitumab|Given via microdevice
219714634|NCT04199026|DRUG|Ifosfamide|Given via microdevice
219714635|NCT04199026|DRUG|Irinotecan|Given via microdevice
219714636|NCT04199026|DRUG|Pazopanib|Given via microdevice
219714637|NCT04199026|DRUG|Polyethylene Glycol|Given via microdevice
219360621|NCT04556617|DRUG|PLX2853 40 mg|PLX2853 tablets
219360622|NCT04556617|DRUG|PLX2853 80 mg|PLX2853 tablets
219360623|NCT06194123|OTHER|Crest Daily Whitening Serum|one week's use of Crest Daily Whitening Serum as described on the label.
219360624|NCT05003388|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219714638|NCT04199026|DRUG|Temozolomide|Given via microdevice
219714639|NCT04199026|DRUG|Temsirolimus|Given via microdevice
219133270|NCT01385384|DEVICE|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
219133271|NCT06127888|OTHER|Interviews|Semi-structured interviews
219133272|NCT06127888|OTHER|Surveys|Estructured survey
219133273|NCT01325870|DEVICE|ACD-CPR|
219133274|NCT01325870|DEVICE|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
219133275|NCT01325870|PROCEDURE|S-CPR|standard manual CPR
219133276|NCT01325870|DEVICE|Impedance Threshold Device (ITD)|
219133277|NCT04124263|OTHER|Educational short message texts|Educational messages for patient engagement
219133278|NCT04124263|OTHER|Adherence short message texts|Reminder messages of medication use time
219133279|NCT04260750|BEHAVIORAL|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
219133280|NCT02236559|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
219133281|NCT02236559|DEVICE|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
219133282|NCT04106141|OTHER|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
219133283|NCT04106141|OTHER|4 weeks changing of archwire|changing the archwire every 4 weeks
219133284|NCT00343824|PROCEDURE|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
219133285|NCT01672840|DIETARY_SUPPLEMENT|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
219133286|NCT01672840|DIETARY_SUPPLEMENT|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
219133287|NCT02071979|DEVICE|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
219360625|NCT06539312|OTHER|APP assessment and management of asthma|APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
219360626|NCT05013255|DRUG|Pioglitazone 15mg|PIO 15mg orally once daily for 2 weeks
219714640|NCT04199026|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219714641|NCT04199026|DRUG|Vincristine|Given via microdevice
219360627|NCT05013255|DRUG|Pioglitazone 30 mg|PIO 30mg orally once daily for 2 weeks
219360628|NCT02811692|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
219360629|NCT04121247|OTHER|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
219714642|NCT05153239|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
219714643|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
219714644|NCT05153239|DRUG|Irinotecan|For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
219714645|NCT05153239|DRUG|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
219714646|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
219133288|NCT02071979|DEVICE|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
219133289|NCT02071979|DEVICE|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
219133290|NCT02071979|PROCEDURE|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
219133291|NCT01802229|PROCEDURE|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
219714647|NCT06646575|OTHER|Qualitative data, no intervention|This is a qualitative study
219714648|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
219714649|NCT02466971|RADIATION|Brachytherapy|Undergo brachytherapy
219714650|NCT02466971|DRUG|Cisplatin|Given IV
219714651|NCT02466971|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219714652|NCT02466971|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219714653|NCT02466971|OTHER|Laboratory Biomarker Analysis|Correlative studies
219714654|NCT02466971|RADIATION|Radiation Therapy|Undergo conventional RT
219714655|NCT02466971|DRUG|Triapine|Given IV
219714656|NCT03169673|DIAGNOSTIC_TEST|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
219714657|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
219714658|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
219714659|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
219714660|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
219714661|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
219714662|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
219714663|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
219714664|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
219714665|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
219714666|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
219714667|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
219714668|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
219714669|NCT03409367|OTHER|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
219714670|NCT06335797|DIETARY_SUPPLEMENT|Senna Tab|Senna 8.6mg two tablets per day post operative day 1 and and if needed, then continue on the same dose regiment until post operative day 5.
219714671|NCT06335797|DIETARY_SUPPLEMENT|Dulcolax Suppositories|Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post operative day 5.
219714672|NCT04649788|DEVICE|Ultrasound-guided axillary vein access|Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.
219714673|NCT04649788|DEVICE|Cephalic vein access|Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
219714674|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
219227524|NCT03263117|DRUG|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
219227525|NCT03263117|PROCEDURE|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
219133292|NCT01802229|PROCEDURE|Fascial suture|The port-site hole is closed with simple suture of the fascia
219133293|NCT06030908|PROCEDURE|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
219133294|NCT06336486|DEVICE|intermittent pneumatic compression +pregabalin group|The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
219133295|NCT06336486|OTHER|pregabalin group|only pregabalin treatment was continued.
219133296|NCT01835340|DEVICE|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
219133297|NCT02049866|DRUG|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
219133298|NCT04120051|DIETARY_SUPPLEMENT|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
219133299|NCT04120051|OTHER|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
219133300|NCT04820582|OTHER|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
219133301|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - GUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.
219133302|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - UNGUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
219133303|NCT02516644|BEHAVIORAL|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
219133304|NCT02516644|BEHAVIORAL|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
219133305|NCT04547348|DRUG|Denosumab Injection|Injections made subcutaneously per standard description
219227526|NCT02867579|BEHAVIORAL|"evaluation of the child quality attachment (Strange situation)"|
219227527|NCT05967130|BIOLOGICAL|Phage|Inserting specific specimen of phages in to the bladder
219227528|NCT06462781|DRUG|Lidocaine hydrochloride|Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
219227529|NCT06462781|DRUG|Methylprednisolone sodium succinate|Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
219227530|NCT04039646|COMBINATION_PRODUCT|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
219133306|NCT04208243|BEHAVIORAL|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
219133307|NCT02599844|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
219133308|NCT02599844|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
219133309|NCT02599844|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
219714675|NCT06480032|DEVICE|Blood Flow Restriction band|Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.
219133310|NCT02599844|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
219133311|NCT02599844|DRUG|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
219133312|NCT02321306|DRUG|LUM001|LUM001 administered orally once each day.
219133313|NCT05301400|DEVICE|Bti Unit|Comparison with or without the device
219133314|NCT02955069|DRUG|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
219133315|NCT02454205|DRUG|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
219133316|NCT02454205|DRUG|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
219133317|NCT02454205|DRUG|Levofloxacin|750mg (\<50kg) 1000mg (\>50kg)
219133318|NCT02454205|DRUG|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
219133319|NCT02454205|DRUG|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
219133320|NCT02454205|DRUG|Ethionamide|15mg/kg (max 900mg)
219133321|NCT02454205|DRUG|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
219133322|NCT02454205|DRUG|Moxifloxacin|400mg po daily.
219133323|NCT02454205|DRUG|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
219133324|NCT03178396|DIETARY_SUPPLEMENT|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
219133325|NCT00697814|DRUG|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
219133326|NCT03701230|OTHER|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
219133327|NCT03700658|DRUG|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
219133328|NCT03700658|DRUG|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
219133329|NCT03700658|DRUG|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
219133330|NCT05585567|BIOLOGICAL|V-01/V-01-B5|Contains 10μg of V-01 and 10μg of V-01-B5
219133331|NCT05585567|BIOLOGICAL|V-01-351/V-01-B5|Contains 10μg of V-01-351 and 10μg of V-01-B5
219133332|NCT05585567|BIOLOGICAL|V-01|Contains 10μg of V-01
219133333|NCT06502769|BEHAVIORAL|Therapeutic Exercise|A therapeutic exercise program will be carried out
219133334|NCT06502769|BEHAVIORAL|Pain Neurophysiology Education|A PNE program will be carried out
219133335|NCT01379287|DRUG|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
219133336|NCT02709616|BIOLOGICAL|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
219133337|NCT03076736|BEHAVIORAL|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
219133338|NCT03076736|BEHAVIORAL|Resource pack|Resource pack with information on living with aphasia and local community activities.
219714676|NCT04518748|DRUG|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
219714677|NCT04518748|DEVICE|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
219714678|NCT04518748|RADIATION|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
219714679|NCT04518748|DIAGNOSTIC_TEST|PET/CT|Within 3 hours of completing Y-90 SIRT
219714680|NCT04518748|DEVICE|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
219714681|NCT04903353|DRUG|Comparison of Risperidone and Aripiprazole|Comparing two FDA approved medications for treatment of irritability in autism
219714682|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
219714683|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
219714684|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
219714685|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
219714686|NCT05926765|OTHER|Placebo|Administration of diluent via Stensen's duct to each parotid gland
219714687|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 3|Administration of concentration 3 of AAV2-hAQP1 via Stensen's duct to each parotid gland
219714688|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 4|Administration of concentration 4 of AAV2-hAQP1 via Stensen's duct to each parotid gland
219714689|NCT04892953|DRUG|Carboplatin|Given IV
219714690|NCT04892953|BIOLOGICAL|Durvalumab|Given IV
219714691|NCT04892953|DRUG|Gemcitabine|Given IV
219714692|NCT04892953|PROCEDURE|Local Consolidation Therapy|Undergo LCT
219714693|NCT04892953|DRUG|Nab-paclitaxel|Given IV
219714694|NCT04892953|DRUG|Paclitaxel|Given IV
219714695|NCT04892953|DRUG|Pemetrexed|Given IV
219714696|NCT04892953|OTHER|Quality-of-Life Assessment|Complete questionnaire
219714697|NCT04892953|OTHER|Questionnaire Administration|Complete questionnaire
219714698|NCT06174038|DEVICE|Hearing Intervention|"The hearing intervention includes an auditory needs assessment, hearing aid fitting, establishing Bluetooth connectivity from hearing aids to devices such as smartphones and computers, systematic orientation and instruction in device use, and provision and discussion of hearing toolkit materials for self-management and communication strategies. The hearing intervention is person-centered, focusing on identification of individual needs, setting of specific goals, engagement in shared-informed decision-making, and development of self-management abilities. Intervention-centric outcomes (e.g., hearing aid data logging, real ear measures) to verify the best-practices intervention will be gathered at all 5 intervention sessions as well as weeks 16 and 52. Additional visits to troubleshoot hearing aids or address concerns will be scheduled as needed."
219714699|NCT06174038|BEHAVIORAL|Health Education Intervention|"The evidence-based interactive health education program is designed for older adults and addresses chronic disease and disability prevention. Session content will be individualized for each participant based on a key, depending on his/her goals/interests. The curriculum includes didactics, activities, and goal setting led by staff trained/certified to deliver the intervention."
219714700|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody|Drug: SHR-A1811 Drug: Pertuzumab
219714701|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.
219133339|NCT03794804|DEVICE|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
219133340|NCT03794804|DEVICE|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
219714702|NCT06740370|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
219714703|NCT06740370|DRUG|Lenvatinib|(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
219714704|NCT06740370|DRUG|PD-1 Inhibitors|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
219714705|NCT06187909|PROCEDURE|PECS II BLOCK|The patient laid supine with the ipsilateral arm abducted and externally rotated. The high-frequency linear probe was placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe was angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. After that, the block needle was inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine were administered. Then probe was moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs were detected. The needle targeted the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25% bupivacaine was done.
219133341|NCT04148937|DRUG|LY3475070|Administered orally
219133342|NCT04148937|DRUG|Pembrolizumab|Administered IV
219133343|NCT03807557|OTHER|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
219714706|NCT06187909|PROCEDURE|MTP BLOCK|The block was performed with the patient in a sitting position. A high-frequency linear probe was placed in a vertical orientation 3 cm lateral to the midline at the T2 level in the parasagittal plane. The distance between the parietal pleura and the transverse process was measured using ultrasound guidance. The block needle was inserted out of plane to the probe and advanced to a depth equivalent to half of the measured distance beyond the transverse process. Then, 10 mL of 0.25% bupivacaine was injected. A similar injection was performed at the T6 level, with sonographic identification and level determination achieved by counting from the second rib.
219360630|NCT06560164|OTHER|Red Blood Cell transfusion|When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
219714707|NCT06424275|DIAGNOSTIC_TEST|Risk-based screening algorithm|Risk-based screening algorithm
219714708|NCT05735327|DRUG|No intervention|As this is an observational study, no intervention will be administered.
219714709|NCT05997342|DRUG|TQB3912 tablets|TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.
219714710|NCT06067399|DIAGNOSTIC_TEST|Glycated hemoglobin (HbA1C)|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
219714711|NCT06067399|DIAGNOSTIC_TEST|RDW|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
219714712|NCT06067399|DIAGNOSTIC_TEST|Lipid profile|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
219714713|NCT06321068|DRUG|carboplatin|the usage and dosage should be determined by the investigator
219714714|NCT06321068|DRUG|Paclitaxel|the usage and dosage should be determined by the investigator
219714715|NCT06321068|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
219714716|NCT06798324|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation. Active tDCS involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
219714717|NCT06798324|DRUG|Varenicline 1mg BID|"Varenicline is the most effective approved treatment for quitting smoking. Varenicline as per standard prescribing for dose escalation (i.e. Days 1 to 3: 0.5 mg once daily; Days 4 to 7: 0.5 mg twice daily; Days 8 to end of treatment: 1 mg twice daily) will be given concurrently over the same 2 weeks as the tDCS protocol and continue for an additional 10 weeks as per standard treatment duration recommended on the product monograph for a total of 12 weeks of varenicline treatment. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).~The target quit date for smoking cessation will be on the last day of the two weeks of daily tDCS which corresponds to the recommended quit date after starting varenicline treatment."
219714718|NCT06798324|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS consists of 30s of 2 mA at the beginning and at the end of the 6 session (ramp up and down), then receiving 0 mA stimulation for the middle 19 min. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
219714719|NCT06142383|BIOLOGICAL|Placebo|S.C. Injection
219714720|NCT06142383|BIOLOGICAL|XXB750 Low dose|S.C. Injection
219714721|NCT06142383|BIOLOGICAL|XXB750 Medium Dose|S.C. Injection
219714722|NCT06142383|BIOLOGICAL|XXB750 High Dose|S.C. Injection
219714723|NCT06142383|DRUG|Sacubitril/valsartan|Tablet
219714724|NCT06648512|OTHER|No Interventions|No Intervention
219714725|NCT05077605|OTHER|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
219714726|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219714727|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
219714728|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
219714729|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
219714730|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
219133344|NCT03807557|OTHER|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
219133345|NCT00730002|PROCEDURE|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
219133346|NCT00730002|PROCEDURE|Magnetic resonance imaging|MR spectroscopy
219133347|NCT00730002|PROCEDURE|MRA|MRA of the brain
219133348|NCT00730002|PROCEDURE|MRA|
219133349|NCT00730002|PROCEDURE|diffusion Imaging|MRA of the Brain
219133350|NCT00730002|PROCEDURE|perfusion imaging.|MRA of the brain
219227531|NCT03851458|BEHAVIORAL|Initial in-person individual diet and exercise counseling (N vs. Y)|Individual counseling utilizing MI has been effective in promoting behavioral change.18 A SANOS interventionist (MRNY promotora) will deliver a 45-60 minute counseling session, utilizing MI techniques, on diet and exercise, and how to stretch one's food dollars (see description of 10 modules described above under COMIDA Pilot). The promotora will evaluate the participant's diet based on the 24-hour dietary recall132 conducted at intake (see below), will compare diet composition to the USDA's MyPlate guidelines, and will then personalize education to address identiﬁed knowledge gaps and unhealthy food choices. Promotoras will focus on goal-setting, problem solving, selfeﬃcacy enhancements, selfmonitoring skills (i.e., participants will be taught how to monitor their diet, weight, and physical activity (PA), with simple pencil-and-paper logs or with 'Self-monitoring tools' if randomized to also receive that component), and modeling of healthy behaviors.
219227532|NCT03851458|BEHAVIORAL|Thrice weekly diet and exercise text messages (N vs. Y)|Text message interventions have been demonstrated to be effective in increasing self-eﬃcacy, weight loss, and PA.65-67 Participants will receive thrice weekly healthy eating, PA, and health care access text message tips. Links to additional information and videos will also be sent via text (e.g. local farmers markets, healthy recipes, free exercise classes, workout videos, video demonstrations of how to prepare healthy meals, etc.). Texts were developed and piloted in the COMIDA Pilot, are designed to promote goal-setting, problem-solving, self-monitoring, modeling, and self-eﬃcacy, and will be further reﬁned during the formative research phase (see below). Texts will be sent via Mosio Text Messaging Solutions. Messages will be concise, as longer messages have shown no demonstrable impact. Based on each participant's status at intake, tailored text messages will also encourage regular follow-up with PCPs. Text messages will be interactive.
219714731|NCT05323149|OTHER|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
219714732|NCT05323149|DRUG|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
219714733|NCT05200442|DRUG|VS-6766/avutometinib|An oral anti-cancer medication.
219714734|NCT05200442|DRUG|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
219714735|NCT05200442|OTHER|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
219714736|NCT03135327|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
219714737|NCT06075264|DRUG|Artesunate ointment|topical ointment, as a non-surgical treatment
219714738|NCT06075264|DRUG|Placebo ointment|topical placebo ointment
219714739|NCT06624124|BEHAVIORAL|Gamified Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a video game-based training platform
219714740|NCT06624124|BEHAVIORAL|Traditional Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a traditional text-based training platform
219714741|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
219714742|NCT06976892|DRUG|Dose Level 2 (starting dose)|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 300 mg P.O. (days1-7, 15-21)
219714743|NCT06976892|DRUG|Dose Level 1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
219714744|NCT06976892|DRUG|Dose Level -1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 150 mg P.O. (days1-7, 15-21)
219714745|NCT06976892|DRUG|Dose Level 3|Idetrexed: 12 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
219714746|NCT06976892|DRUG|Maximum Tolerated Dose|MTD of Olaparib in combination with idetrexed established from Dose Escalation
219133351|NCT00365027|PROCEDURE|Delayed embryo transfer|
219133352|NCT02762318|OTHER|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
219133353|NCT03355495|PROCEDURE|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
219133354|NCT06364033|BIOLOGICAL|serologic response evaluation|Blood samples collection
219133355|NCT00968240|DRUG|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
219714747|NCT06974604|DRUG|Dexamethasone oral|Dexamethasone 10 mL daily for days 1-5 for each of the ﬁrst 3 cycles of therapy Datopotamab Deruxtecan 6.0 mg/kg IV on day 1 every 21 days
219133356|NCT03640273|DRUG|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
219133357|NCT03640273|DRUG|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
219227533|NCT03851458|BEHAVIORAL|Weekly telephone support (N vs. Y)|Several lifestyle interventions including Hispanics have successfully incorporated telephone support.134-138 Weekly telephone support (or more frequently if requested) will be delivered by the promotoras throughout the 6-month intervention. Frequent and prolonged contact in behavioral interventions is more effective than single sessions; most interventions leading to diet or PA changes persisting for \>12 months have follow-up contact sessions for at least 4 months.18 Greater numbers of follow-up sessions facilitate success of behavior change, and initial behavior change can decrease with decreased contact.18,139 Telephone sessions (10-15 minutes) will use MI principles, will focus on goal-setting, problem solving, reviewing/integrating new diet/PA knowledge/skills (including self-monitoring) into individuals' daily routines, self-eﬃcacy enhancements, encouraging participants to seek opportunities for modeling and encouraging regular follow-up with PCPs.
219227534|NCT03851458|BEHAVIORAL|Self-monitoring tools (N vs. Y) (for diet and weight)|Self-monitoring is an important component in achieving behavioral change.18 Participants will be given a SANOS food diary (adapted for and pilot-tested at the VDS in our pilot work) and a digital scale. As part of VDS Mobile usual care, all participants will receive a pedometer to assess exercise behavior (secondary outcome), so additional self-monitoring tools for PA will not be included in this component.
219227535|NCT00639418|BIOLOGICAL|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
219227536|NCT00444743|DRUG|MM-093|60 mg, administered subcutaneously, weekly
219227537|NCT00444743|OTHER|Placebo|Placebo
219227538|NCT00005826|DRUG|rubitecan|
219227539|NCT04541199|DEVICE|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
219227540|NCT04541199|DEVICE|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
219227541|NCT06509867|PROCEDURE|DGG+PRF|de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
219227542|NCT06509867|PROCEDURE|DGG|de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
219227543|NCT01453959|DRUG|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
219227544|NCT01453959|OTHER|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
219227545|NCT03028805|OTHER|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
219227546|NCT03028805|OTHER|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
219227547|NCT03438565|DEVICE|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
219227548|NCT02123953|DRUG|TAK-438|TAK-438 tablets
219227549|NCT02123953|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
219227550|NCT01738698|DRUG|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
219227551|NCT01738698|DRUG|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
219227552|NCT01738698|DRUG|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
219227553|NCT01738698|DRUG|Placebo|Oral administration once-daily for 12 weeks
219714748|NCT04907799|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
219714749|NCT04907799|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
219133358|NCT00757718|DEVICE|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
219133359|NCT00757718|DEVICE|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
219133360|NCT01817036|DIETARY_SUPPLEMENT|Placebo|placebo
219133361|NCT01817036|DIETARY_SUPPLEMENT|Vitamin D|400 IU vitamin D per pill
219714750|NCT06805461|DEVICE|RenovoCath®|Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.
219714751|NCT05848908|OTHER|Telehealth Visit|telemedicine visit and follow-up surveys
219714752|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
219133362|NCT04262414|DEVICE|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
219133363|NCT05826834|DEVICE|ball-rolling (Myostorm ball)|the intervention group
219133364|NCT03069781|DRUG|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
219714753|NCT03824158|BEHAVIORAL|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
219714754|NCT03824158|BEHAVIORAL|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
219133365|NCT03069781|DRUG|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
219133366|NCT02785744|OTHER|Gaucher disease DNA mutation analysis|
219714755|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
219714756|NCT03006068|DRUG|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
219714757|NCT03006068|DRUG|Placebo|Placebo will be administered orally.
219714758|NCT06395285|DRUG|DF-003|140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
219714759|NCT05007873|DRUG|Dasatinib|Given PO
219714760|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
219714761|NCT04046133|DRUG|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
219714762|NCT05092542|BEHAVIORAL|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
219714763|NCT00929006|DRUG|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
219133367|NCT00519129|DEVICE|3D-imager|3D-imager vs fluoroscopy during coloscopy
219133368|NCT02404064|DRUG|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
219133369|NCT02404064|DRUG|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
219133370|NCT02404064|DRUG|Placebo|No perioperative antibiotics
219133371|NCT04374708|DIAGNOSTIC_TEST|fMRI|fMRI: body morph test and neurocognitive testing
219133372|NCT01167426|DRUG|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
219133373|NCT01167426|DRUG|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
219714764|NCT00929006|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
219714765|NCT06084741|OTHER|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
219714766|NCT06084741|OTHER|Using intraabdominal drains|The investigators will put intraabdominal drains
219714767|NCT04865770|DRUG|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
219133374|NCT05086809|DEVICE|Device A|Participant wear Device A and evaluate the performance of the device.
219133375|NCT05086809|DEVICE|Device B|Participant wear Device B and evaluate the performance of the device.
219133376|NCT01363362|PROCEDURE|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
219133377|NCT05616559|COMBINATION_PRODUCT|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
219133378|NCT00504920|BEHAVIORAL|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
219714768|NCT04865770|DRUG|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
219714769|NCT04452526|OTHER|Best Practice|Receive usual care
219714770|NCT04452526|OTHER|Educational Intervention|Receive educational materials
219714771|NCT04452526|OTHER|Questionnaire Administration|Ancillary studies
219133379|NCT00077883|DRUG|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
219714772|NCT04452526|OTHER|Reminder|Receive reminder letter
219133380|NCT06398223|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
219133381|NCT06398223|PROCEDURE|Carotid artery stenting|Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
219133382|NCT01594502|DRUG|Dutasteride|0.5 mg daily
219133383|NCT01594502|DRUG|Placebo|Placebo Comparator
219133384|NCT00012987|BEHAVIORAL|Quality Improvement|
219133385|NCT05060185|DEVICE|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
219133386|NCT04590989|OTHER|Personalized Nutrition Plan|"* Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI"
219227554|NCT04233905|BEHAVIORAL|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
219227555|NCT04661774|OTHER|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
219227556|NCT04661774|OTHER|sham massage|traditional massage of the foot
219227557|NCT01170845|DRUG|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
219227558|NCT03863405|DRUG|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
219227559|NCT03863405|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
219227560|NCT03863405|DRUG|Placebo Oral Tablet|oral tablet
219227561|NCT04217252|DIAGNOSTIC_TEST|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
219227562|NCT03166605|DRUG|Simethicone|Giving simethicone before and after capsule ingestion.
219714773|NCT06975696|PROCEDURE|Standard endovascular thrombectomy with Fusion|Standard endovacular procedure with the addition of Fusion imaging according to the intended use of the ARTIS Icono Biplane.
219133387|NCT04590989|OTHER|Non-Personalized Nutrition Plan|"* Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
219133388|NCT02552277|BIOLOGICAL|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
219227563|NCT05005351|DEVICE|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
219227564|NCT05005351|DEVICE|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
219227565|NCT04689932|DRUG|Triferic AVNU|Ferric Pyrophosphate Citrate
219133389|NCT02552277|DRUG|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
219133390|NCT04312568|DRUG|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
219227566|NCT01698918|DRUG|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
219714774|NCT06975696|PROCEDURE|Standard EVT without Fusion|Standard endovacular procedure without the use of Fusion imaging on the ARTIS Icono Biplane.
219133391|NCT04312568|DRUG|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
219227567|NCT01698918|DRUG|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
219227568|NCT01698918|DRUG|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
219714775|NCT06119607|DEVICE|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
219714776|NCT06424509|OTHER|High degree of long (>5 days) and/or compulsory psychiatric inpatient care|High degree of long (\>5 days) and/or compulsory psychiatric inpatient care
219227569|NCT01698918|DRUG|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
219227570|NCT01698918|DRUG|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
219227571|NCT05851157|DRUG|VX-548|Tablets for oral administration.
219227572|NCT05785728|DRUG|DB-1202|Administered I.V.
219360631|NCT05083871|OTHER|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
219133392|NCT05138172|DEVICE|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
219133393|NCT00137605|BIOLOGICAL|Pneumovax|
219714777|NCT06340581|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
219714778|NCT06340581|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
219714779|NCT06340581|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
219714780|NCT06340581|DEVICE|AeroChamber Plus Flow-Vu Spacer|Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
219714781|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
219714782|NCT06460298|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
219714783|NCT06460298|DRUG|ProAgio Dose Expansion|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
219133394|NCT00137605|BIOLOGICAL|Prevnar|
219133395|NCT01989442|DEVICE|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
219133396|NCT01989442|DEVICE|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
219133397|NCT02197689|DEVICE|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
219714784|NCT04730921|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
219714785|NCT04730921|DEVICE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
219714786|NCT03488524|DRUG|AMX0035|Combination therapy of PB and TURSO
219714787|NCT05786664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219133398|NCT05114109|DRUG|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
219133399|NCT01611909|DRUG|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
219133400|NCT03877471|GENETIC|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
219133401|NCT03679962|BEHAVIORAL|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
219133402|NCT03679962|BEHAVIORAL|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
219133403|NCT05317962|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
219133404|NCT01468324|DRUG|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
219133405|NCT03653975|OTHER|no intervention|no intervention
219714788|NCT05786664|OTHER|Electronic Health Record Review|Review of records
219133406|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
219133407|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
219133408|NCT04762342|OTHER|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down"
219360632|NCT05702736|BEHAVIORAL|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
219360633|NCT01172652|DRUG|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
219714789|NCT05786664|OTHER|Quality-of-Life Assessment|Complete quality-of-life questionnaires
219714790|NCT05786664|OTHER|Survey Administration|Complete surveys
219714791|NCT04787679|PROCEDURE|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
219714792|NCT06177301|DRUG|Tislelizumab combined with GX|"Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
219714793|NCT06177301|DRUG|Tislelizumab combined with GP|"Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles."
219714794|NCT06379113|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
219714795|NCT06379113|DRUG|Letrozole 2.5mg|2.5mg po qd.
219714796|NCT05224726|OTHER|Platelet Rich Plasma|Injection of 5cc of PRP preparation at the myometrium around the uterine incision after it has been sutured.
219714797|NCT05224726|OTHER|Placebo|Injection of 5cc of 0.9% Normal Saline at the myometrium around the uterine incision after it has been sutured.
219714798|NCT06620406|DIETARY_SUPPLEMENT|Synbiotic IVS-1|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
219133409|NCT05730764|DIAGNOSTIC_TEST|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
219133410|NCT05730764|DIAGNOSTIC_TEST|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
219133411|NCT01899222|DEVICE|Handheld fundus photography|diagnostic imaging with two types of retina camera
219133412|NCT04469218|DEVICE|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
219227573|NCT00780793|DRUG|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop"
219714799|NCT06620406|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, a carbohydrate packaged similarly to the study intervention
219714800|NCT05614115|DRUG|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
219714801|NCT05614115|OTHER|Placebo|Placebo comparator
219714802|NCT02351141|OTHER|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
219714803|NCT03636438|OTHER|No Intervention|No Intervention
219714804|NCT04186832|DEVICE|FitBit|Wear FitBit
219714805|NCT04186832|DEVICE|Pedometer|Wear pedometer
219714806|NCT04186832|OTHER|Quality-of-Life Assessment|Ancillary studies
219714807|NCT04186832|OTHER|Questionnaire Administration|Ancillary studies
219714808|NCT05171647|DRUG|Mosunetuzumab|Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
219714809|NCT05171647|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
219714810|NCT05171647|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
219133413|NCT00832884|DRUG|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
219227574|NCT00780793|DRUG|DMARD maintenance|DMARD maintenance
219714811|NCT05171647|DRUG|Rituximab|Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
219714812|NCT05171647|DRUG|Gemcitabine|Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
219714813|NCT05171647|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
219714814|NCT01683526|PROCEDURE|Direct laryngoscopy|
219714815|NCT01683526|DEVICE|Video laryngoscopy (Glidescope)|
219714816|NCT01494558|OTHER|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
219714817|NCT04673734|DIAGNOSTIC_TEST|myelin sensitive MRI scan|"Acquisition of 3 myelin sensitive MRI scans as follows: 1. Two MRI during 1 day; the second after 30 min interval and a repositioning.~2\. One MRI within one week after the first one.~The total scan time will be \~ 1 hour. T1 maps will be calculated after magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE6) acquisition based on a product sequence. Magnetization Transfer (MT) sat maps will be calculated. Quantitative susceptibility mapping (QSM) maps will be reconstructed using an in-house implementation of the structural feature based collaborative reconstruction algorithm (SFCR). For the reconstruction of multi-shell diffusion data, AMICO10 Accelerated Microstructure Imaging via Convex Optimization (AMICO) from diffusion MRI data will be used. Myelin Water Fraction maps will be fitted voxel-wise using a Non-Negative Least Squares fitting."
219133414|NCT05098340|GENETIC|Quantitative Real-time polymerase chain reaction|Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
219714818|NCT04477863|OTHER|Follow-up Interview|Non Applicable
219714819|NCT05806970|OTHER|Email Nudge|An email to UCLA Health Cardiology clinic managers with a list of MRA-eligible HFrEF patients and a request to schedule or change cardiology appointments.
219714820|NCT03820232|DEVICE|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
219133415|NCT03735771|DRUG|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
219133416|NCT06057220|OTHER|No intervention sample collection only|No intervention
219133417|NCT02205931|OTHER|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
219133418|NCT02205931|DRUG|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
219133419|NCT00691951|DRUG|budesonide and budesonide/formoterol|
219133420|NCT00119899|PROCEDURE|FDG-PET scan|
219133421|NCT06135831|OTHER|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
219133422|NCT06135831|OTHER|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
219133423|NCT06135831|OTHER|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
219133424|NCT06135831|OTHER|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
219227575|NCT00310037|DRUG|bortezomib|Given IV
219714821|NCT00933153|DIETARY_SUPPLEMENT|Ensure Plus|Ensure plus supplement with meals
219714822|NCT00933153|DIETARY_SUPPLEMENT|Meals on Wheels|Two Meals on Wheels twice daily
219714823|NCT04243668|PROCEDURE|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
219714824|NCT04260113|DRUG|Apatinib Mesylate|Apatinib orally 500mg once daily half an hour after meal
219714825|NCT05645991|DIETARY_SUPPLEMENT|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
219714826|NCT05645991|DIETARY_SUPPLEMENT|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
219714827|NCT05507177|OTHER|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
219714828|NCT01937299|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
219714829|NCT01937299|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
219714830|NCT01937299|DRUG|Travoprost 0.004% ophthalmic solution|
219133425|NCT01859312|DRUG|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
219133426|NCT01859312|DEVICE|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
219133427|NCT01597518|DRUG|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
219133428|NCT01597518|DRUG|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
219133429|NCT03152149|DRUG|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
219133430|NCT03152149|DRUG|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
219227576|NCT04680598|DRUG|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
219227577|NCT04680598|DRUG|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
219133431|NCT06266650|OTHER|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
219133432|NCT04187157|DEVICE|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
219133433|NCT04187157|DEVICE|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
219714831|NCT05265572|BEHAVIORAL|Domestic Hygiene and household hygiene Intervention|A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
219714832|NCT06335199|PROCEDURE|Unilateral Left tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the left side after successful trials.
219714833|NCT06335199|PROCEDURE|Bilateral tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on both sides after successful trials.
219133434|NCT00851942|DRUG|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
219133435|NCT01492387|OTHER|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
219133436|NCT00680472|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
219133437|NCT00680472|OTHER|Placebo Patch|Treatment with Placebo Patch
219133438|NCT06166719|OTHER|No intervention|No intervention
219133439|NCT02121418|DRUG|Cytarabine|Given IV
219133440|NCT02121418|DRUG|Decitabine|Given IV
219133441|NCT02121418|OTHER|Laboratory Biomarker Analysis|Correlative studies
219133442|NCT06366594|BEHAVIORAL|Authentic leadership training program|37 first-line nurse managers received authentic leadership training program
219133443|NCT04087746|DRUG|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
219714834|NCT06335199|PROCEDURE|Unilateral Left Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the left side after successful trials.
219714835|NCT06335199|PROCEDURE|Bilateral Sham stimulation|Electrical stimulation to the earlobe of the outer ear on both sides after successful trials.
219714836|NCT06335199|PROCEDURE|Unilateral Right tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the right side after successful trials.
219133444|NCT04087746|DRUG|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
219133445|NCT04856228|DIAGNOSTIC_TEST|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
219133446|NCT03906630|DIAGNOSTIC_TEST|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
219133447|NCT03906630|DIAGNOSTIC_TEST|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
219714837|NCT06335199|PROCEDURE|Unilateral Right Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the right side after successful trials.
219714838|NCT01913353|BIOLOGICAL|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
219133448|NCT06582628|DRUG|Enzalutamide capsule|Enzalutamide capsules 160 mg orally daily
219133449|NCT06582628|DRUG|Enzalutamide capsule and Talazoparib capsule|Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
219133450|NCT00544440|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
219133451|NCT00544440|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
219133452|NCT01134419|OTHER|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
219133453|NCT01134419|OTHER|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
219133454|NCT01923948|DRUG|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
219133455|NCT01923948|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
219133456|NCT02971306|DRUG|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
219133457|NCT02971306|DRUG|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
219714839|NCT01913353|BIOLOGICAL|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
219714840|NCT02835066|OTHER|Integrated Fitness Assessment|Undergo function/fitness assessment
219227578|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
219360634|NCT01172652|DRUG|Placebo|Inactive control
219133458|NCT02971306|DRUG|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
219133459|NCT00004192|BIOLOGICAL|filgrastim|
219133460|NCT00004192|BIOLOGICAL|pegfilgrastim|
219133461|NCT00004192|DRUG|cisplatin|
219133462|NCT00004192|DRUG|cytarabine|
219133463|NCT00004192|DRUG|etoposide|
219133464|NCT00004192|DRUG|methylprednisolone|
219227579|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
219227580|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
219227581|NCT04856098|DRUG|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
219714841|NCT02835066|PROCEDURE|Psychosocial Assessment and Care|Undergo psychosocial health assessments
219227582|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
219227583|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
219714842|NCT02835066|PROCEDURE|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
219714843|NCT00163059|DRUG|NMDA Antagonist, CP-101,606 (traxoprodil)|
219714844|NCT01276834|DRUG|everolimus|comparison of everolimus-based and CNI-based immunosuppression
219714845|NCT01207960|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
219714846|NCT03793153|PROCEDURE|Uterine Cooling Technique|Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
219714847|NCT02061800|DEVICE|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
219714848|NCT02061800|DRUG|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
219133465|NCT05703204|DRUG|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
219133466|NCT03978533|BEHAVIORAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
219133467|NCT03526081|OTHER|Chamomile Tea|Chamomile Tea in 300mL hot water
219227584|NCT02198898|DEVICE|GUARDIX-SG|
219227585|NCT00643409|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
219227586|NCT00643409|OTHER|placebo|placebo
219227587|NCT00643409|DRUG|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
219227588|NCT00643409|OTHER|placebo|placebo
219227589|NCT06244914|DEVICE|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
219227590|NCT06244914|DEVICE|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
219227591|NCT06244914|DEVICE|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
219360635|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
219133468|NCT03526081|OTHER|Parsley based drink|3.2 g dried parsley in 300mL hot water
219133469|NCT03526081|OTHER|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
219133470|NCT03526081|OTHER|Apigenin|Apigenin capsule mixed with 300mL hot water
219133471|NCT03526081|OTHER|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
219360636|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
219133472|NCT05837468|BEHAVIORAL|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
219227592|NCT06244914|DEVICE|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
219227593|NCT05350670|BEHAVIORAL|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
219227594|NCT03773432|OTHER|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
219133473|NCT00002290|DRUG|Zidovudine|
219133474|NCT00002290|DRUG|Acyclovir|
219133475|NCT03533556|DIETARY_SUPPLEMENT|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
219133476|NCT03533556|DIETARY_SUPPLEMENT|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
219133477|NCT03533556|DIETARY_SUPPLEMENT|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
219133478|NCT03533556|OTHER|Placebo|Oral administration of 100 ml of water
219133479|NCT00683410|BIOLOGICAL|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
219227595|NCT04383392|DEVICE|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
219714849|NCT02061800|DRUG|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
219714850|NCT02061800|DRUG|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
219714851|NCT02061800|DRUG|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
219714852|NCT02061800|DRUG|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
219714853|NCT02061800|DRUG|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
219133480|NCT00591838|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
219133481|NCT04026191|DEVICE|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
219714854|NCT02061800|DRUG|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
219714855|NCT02061800|DRUG|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
219714856|NCT02013362|DRUG|Pralatrexate injection|
219714857|NCT02013362|DIETARY_SUPPLEMENT|Vitamin B12|
219133482|NCT05818306|DRUG|BL-001|Live biological product BL-001
219714858|NCT02013362|DIETARY_SUPPLEMENT|Folic Acid|
219714859|NCT03725553|DRUG|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
219714860|NCT03725553|DRUG|Placebo|the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
219714861|NCT06157476|OTHER|Stretch-shortening exercise|The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
219133483|NCT05818306|DRUG|Placebo|Placebo
219133484|NCT02774538|OTHER|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
219133485|NCT04980261|PROCEDURE|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
219133486|NCT04980261|PROCEDURE|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
219133487|NCT01814644|BEHAVIORAL|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
219133488|NCT01814644|BEHAVIORAL|Standard Care|Individual assessment, lifestyle counseling
219133489|NCT01126840|BEHAVIORAL|Telephone Interview|The phone interview should take 30-45 minutes to complete.
219133490|NCT01126840|BEHAVIORAL|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
219133491|NCT04682756|DIAGNOSTIC_TEST|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
219133492|NCT00885508|DRUG|Lenalidomide|"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
219133493|NCT01843465|OTHER|Maneuvers for documenting the disconnection|
219133494|NCT01711307|PROCEDURE|operative|
219133495|NCT01711307|PROCEDURE|non-operative|casting within 48 hrs
219133496|NCT05623995|DRUG|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
219133497|NCT05623995|DRUG|Statin|Guideline recommended statin therapy.
219714862|NCT06157476|OTHER|Standard exercise program|The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
219714863|NCT06418867|BEHAVIORAL|Mindfulness|Mindfulness Practice including 6 sessions with 1 hour for each
219714864|NCT00489580|DEVICE|SaeboFlex Dynamic Hand Orthosis|
219714865|NCT00489580|PROCEDURE|Saebo F.T.M. Arm Training Program|
219133498|NCT00881335|DEVICE|flutter mucus clearance device|five minutes every sessions, three sessions per day
219133499|NCT00967369|DRUG|Bortezomib|Given IV
219133500|NCT00967369|DRUG|Carboplatin|Given IV
219133501|NCT00967369|DRUG|Etoposide|Given IV
219133502|NCT00967369|DRUG|Ifosfamide|Given IV
219133503|NCT04989322|DRUG|Pembrolizumab|200 mg Q3W
219133504|NCT04989322|DRUG|Lenvatinib|8 mg daily
219133505|NCT04989322|DRUG|Pemetrexed|500 mg/m2 Q3W
219133506|NCT04989322|DRUG|Carboplatin|AUC5 Q3W
219133507|NCT01963026|OTHER|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
219133508|NCT01963026|OTHER|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
219133509|NCT02793427|BIOLOGICAL|blood sample collection|
219133510|NCT02023372|OTHER|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
219133511|NCT00296426|PROCEDURE|New technology - PAML|
219133512|NCT00005581|DRUG|cyclophosphamide|
219133513|NCT00005581|DRUG|epirubicin hydrochloride|
219133514|NCT00005581|DRUG|fluorouracil|
219133515|NCT00005581|DRUG|paclitaxel|
219133516|NCT02391662|DRUG|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
219133517|NCT02391662|DRUG|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
219714866|NCT01260948|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
219714867|NCT01260948|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
219714868|NCT05085145|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
219714869|NCT06417047|OTHER|Hand Holding|During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
219714870|NCT01250938|BEHAVIORAL|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
219714871|NCT04728256|BEHAVIORAL|Laughter therapy+Music listening+Keeping diary|"Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings."
219714872|NCT03236389|DEVICE|Q Collar|measuring changes in brain during MRI while wearing the Q collar
219714873|NCT05953467|OTHER|No intervention, observational.|None, observational study
219714874|NCT05174624|OTHER|No intervention|No intervention
219133518|NCT02796976|OTHER|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
219133519|NCT01300832|PROCEDURE|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
219714875|NCT05548374|DEVICE|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
219133520|NCT03183024|BIOLOGICAL|benralizumab|open-label treatment
219133521|NCT03183024|BIOLOGICAL|placebo|sterile water to mimic benralizumab
219133522|NCT05019781|OTHER|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
219133523|NCT05019781|OTHER|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
219133524|NCT06340126|OTHER|Active release techniques|Active release techniques are soft tissue systems or movement-based techniques. It is used to treat muscles, nerves, fascia, ligaments, and tendons.
219133525|NCT06340126|OTHER|Relaxation exercises|Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises. Exercises will be done in a sitting position
219133526|NCT03853733|RADIATION|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
219133527|NCT06390488|OTHER|Transcutaneous medial plantar nerve stimulation (T-MPNS)|T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.
219133528|NCT06390488|OTHER|Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)|Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
219133529|NCT05824351|DEVICE|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
219133530|NCT05824351|DEVICE|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
219133531|NCT05824351|DEVICE|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
219133532|NCT04913649|DRUG|Ferric Derisomaltose 100 MG/ML|Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
219133533|NCT04913649|DRUG|Sodium chloride|Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
219133534|NCT06466499|BEHAVIORAL|The intervention group|Is described in arm
219133535|NCT05390580|DEVICE|transcutaneous auricular vagal nerve stimulation|Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
219133536|NCT05390580|DEVICE|Sham transcutaneous vagal nerve stimulation|Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
219133537|NCT05953350|DRUG|600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
219360637|NCT02937350|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
219360638|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 5mg, with additional doses of 2.5mg as necessary
219133538|NCT05953350|DRUG|RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.|After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
219714876|NCT05548374|DEVICE|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
219714877|NCT00817791|DEVICE|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
219714878|NCT02717650|OTHER|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
219714879|NCT02717650|OTHER|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
219714880|NCT02717650|OTHER|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
219714881|NCT02406612|DEVICE|X-Seal 6F Vascular Closure Device|
219714882|NCT06059859|PROCEDURE|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
219714883|NCT06059859|DEVICE|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
219714884|NCT06059859|PROCEDURE|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
219714885|NCT05186155|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
219714886|NCT01060176|DRUG|Tranexamic Acid|
219714887|NCT01060176|DRUG|Saline Solution|
219714888|NCT06386042|OTHER|no intervention, observational study|no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
219714889|NCT02751905|DRUG|BIIB074|Administered orally as specified in treatment arm
219714890|NCT01143012|OTHER|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
219714891|NCT01143012|OTHER|Control group|The control group will not attend the group eczema education session.
219714892|NCT05660785|DRUG|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
219714893|NCT04249024|DEVICE|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
219714894|NCT04249024|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
219714895|NCT04249024|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
219714896|NCT05220345|DEVICE|colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)|All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
219714897|NCT05521958|PROCEDURE|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
219714898|NCT05521958|PROCEDURE|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
219133539|NCT05857293|DEVICE|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
219133540|NCT00828945|DEVICE|Lipid Self Test|Self test for lipid levels, twice during study period
219133541|NCT06434857|PROCEDURE|Strength training in older adults with mild or non existent cognitive impairment|Strength training program applied to strength training group
219133542|NCT06434857|PROCEDURE|Multimodal excercise in older adults with mild or non existent cognitive impairment|Multimodal exercise program applied to multimodal exercise group
219133543|NCT00012467|DRUG|Itraconazole|
219133544|NCT00012467|DRUG|Flucytosine|
219133545|NCT00012467|DRUG|Fluconazole|
219133546|NCT00012467|DRUG|Amphotericin B|
219133547|NCT00012467|DRUG|Interferon gamma-1b|
219133548|NCT01113515|DRUG|Esmolol hydrochloride|
219133549|NCT01113515|DRUG|Esmolol hydrochloride|
219133550|NCT01113515|DRUG|Esmolol hydrochloride|
219227596|NCT02803866|BEHAVIORAL|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
219227597|NCT02708498|BEHAVIORAL|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
219714899|NCT05521958|PROCEDURE|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
219714900|NCT07115108|DIETARY_SUPPLEMENT|High energy density enteral nutrition|High-energy-density enteral nutrition (100 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
219714901|NCT07115108|DIETARY_SUPPLEMENT|General energy density enteral nutrition|General energy density enteral nutrition (60-88 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
219714902|NCT07120906|DEVICE|MRI guided procedure software evaluation|For the use of the MRI-needle guidance system (LUMENA) developed by CLEAR GUIDE MEDICAL during clinical MRI-guided needle placement procedures for patients undergoing a liver biopsy/procedure.
219714903|NCT06651359|BEHAVIORAL|Surveys for Quality of Life|This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
219133551|NCT01113515|DRUG|Placebo gel|
219133552|NCT03319589|DIETARY_SUPPLEMENT|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
219133553|NCT03578523|OTHER|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
219133554|NCT03578523|OTHER|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
219133555|NCT03578523|BIOLOGICAL|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
219133556|NCT03578523|BIOLOGICAL|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
219133557|NCT03917329|OTHER|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
219133558|NCT02482233|BEHAVIORAL|ENDD (NJOY)|As described above.
219133559|NCT02482233|DRUG|NRT (NicoDerm CQ)|As described above.
219133560|NCT02482233|BEHAVIORAL|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
219227598|NCT06412432|OTHER|Exercise training (ET1+ET2)|Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.
219227599|NCT06412432|BEHAVIORAL|Optimal Medical Therapy (No-ET)|Patients will be handled according to optimal medical therapy
219714904|NCT06651359|BEHAVIORAL|Surveys and mHealth App access|"This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality."
219714905|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
219714906|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
219714907|NCT00809627|DRUG|saline|Normal saline
219714908|NCT06651788|OTHER|Ethyl Chloride|Topical anesthetic that rapidly cools the skin and underlying tissues
219714909|NCT06651788|OTHER|Cold Saline Spray|placebo application of cold saline spray
219714910|NCT06979388|DRUG|balcinrenone/ dapagliflozin|Participants will be receiving balcinrenone/ dapagliflozine in fasted or fed condition.
219714911|NCT06979388|DRUG|quinidine|Participants will be receiving quinidine orally in fasted condition.
219714912|NCT07131384|DIETARY_SUPPLEMENT|Dietary Supplement: Inorganic Nitrate (Beetroot juice)|Participants will be supplemented with inorganic nitrate in the form of beetroot juice for 4 days (12.9 mmol of NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
219714913|NCT07131384|DIETARY_SUPPLEMENT|Dietary supplement: Placebo (Nitrate-depleted beetroot juice)|Participants will be supplemented with nitrate-depleted beetroot juice for 4 days (\<0.01 mmol NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
219714914|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
219714915|NCT07130370|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-informed behavioral intervention that helps individuals accept difficult thoughts and feelings, clarify personal values, and commit to meaningful actions. It aims to improve psychological flexibility, enabling healthier coping with life's challenges.
219714916|NCT05501691|OTHER|Placebo|Laser Simulation
219714917|NCT05501691|RADIATION|445 nm Diode Laser Wavelength|Irradiated Using a 445 nm Diode Laser Wavelength
219714918|NCT05501691|RADIATION|660 nm Diode Laser Wavelength|Irradiated Using a 660 nm Diode Laser Wavelength
219133561|NCT02482233|BEHAVIORAL|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
219133562|NCT02482233|BEHAVIORAL|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure\_%20For%20Posting.pdf"
219133563|NCT06375356|BEHAVIORAL|Resistance Training|Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
219133564|NCT04345523|OTHER|Blood and derivatives.|Administration of fresh plasma from donor immunized against COVID-19
219133565|NCT04345523|DRUG|Standard of Care|Standard of care for the treatment of COVID-19 in hospitalized patients
219133566|NCT03116282|BEHAVIORAL|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
219133567|NCT03822351|DRUG|Durvalumab + Oleclumab|Durvalumab + Oleclumab
219133568|NCT03822351|DRUG|Durvalumab|Durvalumab
219714919|NCT05501691|RADIATION|970 nm Diode Laser Wavelength|Irradiated Using a 970 nm Diode Laser Wavelength
219714920|NCT05759338|DEVICE|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
219714921|NCT06597006|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \<16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
219714922|NCT06597006|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
219714923|NCT04918173|DRUG|Atenativ|Antithrombin concentrate
219133569|NCT03822351|DRUG|Durvalumab + Monalizumab|Durvalumab + Monalizumab
219133570|NCT05367674|BEHAVIORAL|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
219133571|NCT05367674|BEHAVIORAL|My Summer Plate (MSP)|My Summer Plate (MSP)
219360639|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 10mg, with additional doses of 2.5mg as necessary
219133572|NCT06228742|OTHER|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
219133573|NCT06228742|OTHER|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
219133574|NCT02851810|BEHAVIORAL|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
219133575|NCT02851810|BEHAVIORAL|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
219133576|NCT02851810|BEHAVIORAL|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
219227600|NCT04312425|PROCEDURE|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
219227601|NCT04312425|PROCEDURE|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
219227602|NCT05501340|DRUG|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
219227603|NCT05501340|DRUG|Molgramostim|200ug qd subcutaneous injection for 7 days
219227604|NCT05501340|RADIATION|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy\*3f
219227605|NCT01020097|DRUG|fluorine F18 EF5|Given IV
219227606|NCT01020097|PROCEDURE|immunohistochemistry staining method|Correlative study
219227607|NCT01020097|PROCEDURE|biopsy|Correlative study
219227608|NCT01020097|PROCEDURE|Positron Emission tomography|Undergo scan
219227609|NCT01218048|DRUG|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
219714924|NCT06979362|DRUG|CDR132L|CDR132L will be administered intravenously once every 4 weeks.
219714925|NCT06979362|DRUG|Placebo|Placebo will be administered intravenously once every 4 weeks.
219133577|NCT02851810|BEHAVIORAL|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
219133578|NCT02851810|BEHAVIORAL|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
219133579|NCT04272151|BIOLOGICAL|BCMA CAR-T cells|A single infusion of BCMA CAR-T cells will be administered intravenously.
219133580|NCT01227356|DRUG|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
219133581|NCT00369135|PROCEDURE|combined intervention|
219714926|NCT06982352|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
219714927|NCT06982352|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
219227610|NCT01218048|PROCEDURE|Surgery|Surgery for tumor
219227611|NCT01218048|RADIATION|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
219714928|NCT05481931|DRUG|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
219133582|NCT02157493|BEHAVIORAL|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
219133583|NCT02157493|BEHAVIORAL|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
219133584|NCT00462943|DRUG|Omacetaxine mepesuccinate|"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
219227612|NCT01218048|DRUG|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
219227613|NCT03683641|DEVICE|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
219227614|NCT03683641|DEVICE|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
219227615|NCT00505024|BEHAVIORAL|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
219227616|NCT00505024|OTHER|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
219227617|NCT00114452|BIOLOGICAL|Provacel|ex vivo cultured adult mesenchymal stem cells
219227618|NCT00114452|BIOLOGICAL|Placebo|Placebo
219227619|NCT02330900|OTHER|Study group|Exposure to cell phone interference of the ICD
219227620|NCT02743039|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
219360640|NCT00042380|DRUG|Novasoy|
219714929|NCT06812325|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
219714930|NCT06812325|DRUG|Placebo|Placebo injections that appear identical to VRDN-003 injections but have no active drug.
219133585|NCT03274102|BIOLOGICAL|Concomitant administration of EV71 vaccine with EPI vaccines|"1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
219227621|NCT04476524|OTHER|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
219227622|NCT05004909|DRUG|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
219227623|NCT03305705|DRUG|Iron Carboxymaltose|Single intravenous infusion within 20 min
219227624|NCT03305705|DRUG|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
219227625|NCT02718339|BEHAVIORAL|Intensive counseling|
219227626|NCT03279367|DIAGNOSTIC_TEST|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
219227627|NCT05160909|PROCEDURE|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
219227628|NCT05160909|PROCEDURE|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
219227629|NCT02039999|OTHER|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
219227630|NCT02039999|OTHER|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
219227631|NCT02039999|OTHER|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
219714931|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
219714932|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
219227632|NCT05200286|DRUG|Olorofim|Single oral dose
219133586|NCT03274102|BIOLOGICAL|Single injection of EPI vaccine|"1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
219133587|NCT03274102|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
219133588|NCT05186454|DRUG|Morphine Sulfate|analgesia
219133589|NCT05186454|DRUG|Bupivacaine|Analgesia
219227633|NCT00188812|DRUG|donepezil hcl|
219227634|NCT02730091|DRUG|Letrozole|Letrozole 2.5 mg daily
219227635|NCT02730091|DRUG|Anastrozole|anastrozole 1 mg daily
219227636|NCT02730091|DRUG|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
219227637|NCT01640288|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
219227638|NCT01640288|OTHER|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
219133590|NCT05186454|DRUG|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
219133591|NCT03166319|DIAGNOSTIC_TEST|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
219133592|NCT02929069|BEHAVIORAL|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
219133593|NCT02929069|BEHAVIORAL|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
219133594|NCT02929069|BEHAVIORAL|VCT|Voluntary Counselling and Testing (VCT).
219133595|NCT03042793|BIOLOGICAL|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
219714933|NCT02745470|DRUG|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
219133596|NCT04742855|DIETARY_SUPPLEMENT|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
219133597|NCT04977960|DRUG|Potassium Canrenoate|potassium canrenoate for 7 days in addition to maximal medical treatment
219227639|NCT03949478|DRUG|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
219227640|NCT03949478|DRUG|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
219227641|NCT03949478|DRUG|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
219227642|NCT04803734|DRUG|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
219714934|NCT02745470|OTHER|Placebo|Normal saline injection before performing fMRI
219714935|NCT00590473|DEVICE|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
219133598|NCT01845896|BEHAVIORAL|Training|
219133599|NCT01644162|DEVICE|iVAPS ventilation|3 months of ventilation on iVAPS mode
219133600|NCT04347499|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
219227643|NCT04803734|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
219227644|NCT04226118|DEVICE|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
219227645|NCT05570227|OTHER|[U-13C]Glucose Infusion|Peri-operative infusion of \[U-13C\]glucose
219227646|NCT04755907|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
219133601|NCT02631499|PROCEDURE|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
219133602|NCT02631499|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
219133603|NCT02631499|DRUG|lipiodol|lipiodol is a kind of embolization material used in TACE
219133604|NCT06182319|DRUG|Gastrografin|Administration of WSC (Gastrografin) 2 hours after placement of NGT.
219133605|NCT06182319|DRUG|Saline|Administration of Saline 2 hours after placement of NGT.
219133606|NCT06182319|PROCEDURE|SBO Treatment Without NG Tubes|Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
219133607|NCT04164563|DEVICE|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
219133608|NCT01025869|DEVICE|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
219227647|NCT04755907|OTHER|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
219133609|NCT05092412|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
219133610|NCT05092412|DRUG|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
219133611|NCT05092412|DRUG|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
219133612|NCT04757103|PROCEDURE|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
219227648|NCT04755907|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
219227649|NCT06506357|DIETARY_SUPPLEMENT|Good Girl Probiotics|Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
219227650|NCT04555057|PROCEDURE|Music therapy|Music selected according to the patient's individual preferences.
219227651|NCT05210985|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
219714936|NCT05317351|DEVICE|Standard Colonoscopy|Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
219714937|NCT05317351|DEVICE|Artificial Intelligence Aided Colonoscopy (GI Genius™)|Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
219714938|NCT05317351|DEVICE|Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
219714939|NCT03043781|OTHER|Continuous epidural infusion|Continuous infusion, 5 ml/h
219714940|NCT03043781|OTHER|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
219714941|NCT06815471|DRUG|COR-1167|28-day treatment
219714942|NCT06815471|DRUG|Placebo|28-day treatment
219714943|NCT05287503|DRUG|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
219714944|NCT05287503|DRUG|Placebo|Excipients
219714945|NCT00715611|PROCEDURE|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
219714946|NCT00715611|DRUG|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
219714947|NCT00715611|RADIATION|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
219714948|NCT04246879|OTHER|MRI|Subjects undergo one additional delayed MRI sequence
219714949|NCT06985121|OTHER|Placebo control|Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
219714950|NCT06985121|OTHER|Base formula only|Base formula consisting of active ingredients caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
219714951|NCT06985121|OTHER|Base formula plus IGF-1 and FGF-7|Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
219714952|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles|Base formula plus Centella asiatica extracellular vesicles. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
219714953|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7|Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
219714954|NCT06986083|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy
219714955|NCT06986083|DRUG|Local anesthesia|Local anesthesia in addition to IV sedation
219714956|NCT06982066|BEHAVIORAL|ReSPECT|ReSPECT is an interactive, web-based digital platform that integrates (1) an AYA-centered pre-visit questionnaire (PVQ) that will discretely alert clinicians to relevant SRH questions/concerns, (2) targeted patient education on PVQ selections, and (3) clinician-centered guidance for addressing SRH issues. At enrollment, all participants will complete a baseline survey (T1). AYAs will have access to the ReSPECT digital platform and will receive the first prompt to complete the PVQ 3-5 days before their next clinic appointment. Once completed, AYAs will receive an email/text with a link to tailored information based on their PVQ selections for review. Clinicians will receive an email with a link to the patient's PVQ results on the ReSPECT platform along with clinical management recommendations. All participants will complete a brief virtual survey (T2) and interview within 48 hours of the first postintervention clinic visit and a follow-up survey 2 months after study enrollment (T3).
219714957|NCT06605508|PROCEDURE|Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction|This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
219714958|NCT06605508|PROCEDURE|Stem cell-derived Exosomes Injection for Erectile Dysfunction|This intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
219714959|NCT06985043|DEVICE|Auricular vagus nerve stimulation (AVNS)|Auricular vagus nerve stimulation (AVNS) will be applied to both ears simultaneously, using a biphasic, asymmetric waveform with pulses of 300 microsecond duration and a frequency of 25 Hz, continuously for 20 minutes. The application will be performed in a single session and the follow-up time will be determined as 30 minutes.
219714960|NCT06605560|OTHER|Platelet Rich Plasma|PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
219133613|NCT02999581|DIETARY_SUPPLEMENT|C4 Extreme, C4 Extreme (without Advantra Z)|
219133614|NCT06650787|OTHER|Ultrasound was used to locate the end of the gastric tube|"1. Inform the family of the purpose and method of using bedside ultrasound to guide the placement of the gastric tube, and determine the position of the end of the tube.~2. The ultrasound machine was connected to the power supply and placed on the right side of the patient.~3. Select the appropriate type of gastric tube and measure the length of the indwelling gastric tube by nursing staff before inserting the tube.~4. Nurses who had been trained in ultrasound performed ultrasound judgment on the neck and abdomen of the children. Sonographers, intensive care physicians and nursing staff jointly judged the ultrasound images.~5. Conventional judgment method was used to determine the position of gastric tube~6. Bedside chest radiography, with results obtained by a radiologist.~7. Keep your child safe at all times."
219227652|NCT05210985|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
219133615|NCT06650787|OTHER|Conventional placing nasogastric tube group|"1. Choose the appropriate type of gastric tube, and measure the length of the indwelling gastric tube by the nursing staff before the tube insertion.~2. The gastric tube was inserted by the conventional blind insertion method.~3. The conventional judgment method was used to determine the position of the gastric tube.~4. Bedside chest radiography, with results obtained by a radiologist.~5. Keep your child safe at all times."
219133616|NCT05934773|DEVICE|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
219133617|NCT05767450|DIETARY_SUPPLEMENT|Probiotic Vivomixx®|The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
219133618|NCT05767450|DIETARY_SUPPLEMENT|Placebo|The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
219714961|NCT06984484|DEVICE|Afluxin®|Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
219133619|NCT06437002|BEHAVIORAL|Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body|"The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems."
219714962|NCT06984484|DRUG|Placebo|Inactive control stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
219714963|NCT06593314|BEHAVIORAL|Message with EchoGo|This alert will inform the provider that the patient has subclinical HFpEF
219714964|NCT06593314|BEHAVIORAL|Standard Message|This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
219714965|NCT06590961|DRUG|UBX-303061|UBX-303061 oral dosage
219714966|NCT06811896|BEHAVIORAL|Stress Management and Resiliency Training Program|The Stress Management and Resiliency Training Intervention is an evidence-based intervention to reduce physiologic responses to stress that may contribute to cardiovascular disease risk. The intervention is typically delivered over an 8-week period and works to decrease stress responses by improving psychological resiliency to structural and social stressors and decreasing sympathetic nervous system activation. Eliciting the relaxation response through meditation, mindfulness, and autogenic training are core components.
219714967|NCT06811896|OTHER|Usual Care|Usual social and clinical services provided to patients at the recruiting clinic
219714968|NCT06295406|OTHER|Neuropsychological assessment|Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
219133620|NCT00813488|DRUG|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
219714969|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
219133621|NCT00813488|DRUG|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
219133622|NCT04985383|DEVICE|AKST1210 S-15 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min
219133623|NCT04985383|DEVICE|AKST1210 S-15 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min
219714970|NCT06817720|DRUG|olverembatinib|GIven by PO
219714971|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
219133624|NCT04985383|DEVICE|AKST1210 S-25 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
219714972|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
219133625|NCT04985383|DEVICE|AKST1210 S-25 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
219714973|NCT06814496|DRUG|Tarlatamab|Tarlatamab will be administered at a step-up dose of 1mg on Cycle 1 Day 1 and then 10 mg on Cycle 1 Day 8 and Cycle 1 Day 15 and every 2 weeks thereafter. For cycle 2 onwards, tarlatamab infusion will occur every 2 weeks on days 1 and 15 of each cycle.
219714974|NCT06814496|RADIATION|Concurrent Radiation Therapy|Standard of care RT can begin as early as Cycle 1 Day 16 and as late as Cycle 2 Day 28, assuming there is no ongoing CRS (extracranial)/ICANS (cranial).
219714975|NCT06814496|RADIATION|Sequential Radiation therapy|Standard of care radiation therapy can occur prior to Cycle 1 Day 1 (if radiation treatment is completed \<7 days prior to the start of tarlatamab) or be interdigitated with tarlatamab with a 7-day washout between RT and infusion, with RT to begin as early as Cycle 1 Day 22 and as late as cycle 2 Day 28, assuming no ongoing CRS (extracranial)/ICANS (cranial).
219714976|NCT06821269|PROCEDURE|Robotic assisted total knee arthroplasty|Total knee arthroplasty with robotic assisatance
219133626|NCT04985383|DEVICE|AKST1210 S-35 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min
219714977|NCT06821269|PROCEDURE|Manual total knee arthroplasty|Total knee arthroplasty without robotic assistance
219714978|NCT06821269|PROCEDURE|Robotic assisted revision total knee arthroplasty|Revision total knee arthroplasty with robotic assistance
219714979|NCT06821269|PROCEDURE|Manual revision total knee arthroplasty|Revision total knee arthroplasty without robotic assistance
219714980|NCT06819111|DRUG|Potassium Citrate Extended Release Oral Tablet|In this crossover study, patients will serve as their own controls. Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets). The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate.
219133627|NCT04985383|DEVICE|AKST1210 S-35 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
219133628|NCT02207361|DRUG|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
219133629|NCT02207361|DRUG|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
219133630|NCT05601843|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
219133631|NCT04100356|OTHER|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
219133632|NCT04100356|OTHER|Normal Diet|Normal diet recommended by the health authorities
219133633|NCT04100356|OTHER|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
219133634|NCT01729871|DRUG|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
219133635|NCT01729871|DRUG|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
219133636|NCT01143077|DRUG|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
219133637|NCT04671628|BEHAVIORAL|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
219133638|NCT04228770|BEHAVIORAL|Meeting with pharmacist|Meeting with pharmacist to support drug management following their routine surgery.
219360641|NCT00561197|DRUG|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
219360642|NCT05866055|DRUG|VX-973|Suspension for oral administration.
219133639|NCT01671475|DEVICE|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
219133640|NCT00897767|OTHER|biologic sample preservation procedure|
219133641|NCT04094909|DRUG|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
219133642|NCT05750511|DIAGNOSTIC_TEST|molecular tissue analysis|
219133643|NCT04681417|DRUG|Melphalan or Melphalan + Topotecan|IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
219133644|NCT04681417|DRUG|etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy|2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
219133645|NCT04681417|DRUG|Carboplatin administered on Day 1|Chemothermotherapy : Intravenous injection by carboplatin
219133646|NCT04681417|DEVICE|Thermotherapy (local treatment)|Thermotherapy after carboplatin administered on Day 1
219133647|NCT04681417|DEVICE|Cryotherapy (local treatment)|Cryotherapy (local treatment)
219133648|NCT04681417|DEVICE|Iodine-125 plaques (local treatment)|Iodine-125 plaques (local treatment)
219133649|NCT04681417|DRUG|Intravitreal Melphalan chemotherapy injections (local treatment)|Intravitreal Melphalan chemotherapy injections (local treatment)
219133650|NCT03199716|OTHER|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
219133651|NCT03477682|OTHER|Early ambulation|Patients who are in the experimental arm will have a shorter duration of bedrest restriction following sartorius surgery (1 day) versus the standard group (5 days bedrest).
219133652|NCT02158065|OTHER|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
219133653|NCT03390556|OTHER|Nurse-delivered education|"The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care."
219360643|NCT05866055|DRUG|Placebo|Suspension for oral administration.
219360644|NCT05866055|DRUG|Midazolam|Syrup for oral administration.
219360645|NCT01897636|PROCEDURE|EUS-guided fine-needle injection of DCs vaccinations|
219714981|NCT06127732|DIETARY_SUPPLEMENT|Phytosterol supplements|Participants were randomized into two groups to receive diet plus phytosterols (DP) for 12 weeks, followed by a 7-day washout period with a second period of intervention, where treatments were switched, and participants received diet alone (D) and were followed for another 12 weeks.
219714982|NCT06401434|DIAGNOSTIC_TEST|On-site radiologist|All participants in this arm will be screened by CXR. All CXR images will be interpreted by only an on-site radiologist. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
219714983|NCT06401434|DIAGNOSTIC_TEST|CAD-based triage (with INSIGHT CXR software)|All participants in this arm will be screened by CXR. All CXR images will first be processed with the INSIGHT CXR CAD software (Lunit, South Korea) to identify the totally normal/clear CXR images; only those with the possibility of containing an abnormality (abnormality score ≥ 20) will be sent to the on-site radiologist for reading/interpretation. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
219714984|NCT06651593|DRUG|SAR444881|Given by IV
219360646|NCT04348409|DRUG|Nitazoxanide Tablets|Patients will receive nitazoxanide 600 mg BID for 7 days
219360647|NCT04348409|DRUG|Placebo|Patients will receive placebo BID for 7 days
219714985|NCT06651593|DRUG|Cemiplimab|Given by Iv
219714986|NCT06983392|BEHAVIORAL|Abstain from smoking/vaping|They may be asked to stop smoking cigarettes or vaping during the study for 21 days. If they are asked to abstain from their product use they will be given nicotine patches and/or lozenges to help with abstinence during the study.
219714987|NCT06610968|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|5000 IU Vitamin D (as cholecalciferol) capsules (Vitamin D3 125 mcg \[5,000 IU\], Pure Encapsulation, LLC) daily
219714988|NCT06610968|DIETARY_SUPPLEMENT|Placebo Group|One placebo capsule (Zeebo Imagine, Zeebo) daily.
219714989|NCT05589532|DEVICE|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
219714990|NCT05360186|DEVICE|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
219714991|NCT04611126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
219714992|NCT04611126|DRUG|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
219714993|NCT04611126|DRUG|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
219714994|NCT04611126|BIOLOGICAL|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
219133654|NCT03882515|OTHER|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
219714995|NCT04611126|DRUG|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
219714996|NCT04611126|DRUG|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
219714997|NCT03884374|BEHAVIORAL|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
219714998|NCT03884374|BEHAVIORAL|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
219714999|NCT03884374|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
219360648|NCT01568814|DRUG|Low volume PEG|low volume polyethylene glycol 2 liter one time
219360649|NCT01568814|DRUG|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
219715000|NCT03884374|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
219715001|NCT03240211|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV
219715002|NCT03240211|DRUG|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
219715003|NCT03240211|DRUG|Decitabine|Decitabine 10 mg/m2
219715004|NCT03561376|DRUG|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
219715005|NCT04172779|DRUG|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
219715006|NCT05482971|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
219715007|NCT06948695|OTHER|Warm-up|5-minute warm-up run on treadmill at a freely chosen speed
219715008|NCT06948695|OTHER|Random blade test|4-minute run on a treadmill with a flat incline.
219715009|NCT06948695|OTHER|Random blade test|4-minute run on treadmill with a 10% gradient
219715010|NCT06948695|OTHER|Comfort speed test|1 min running test on an instrumented treadmill (Gaitway, H/P/Cosmos, Nußdorf, Germany) at comfort speed.
219715011|NCT06948695|OTHER|Outdoor random blade test|100-metre outdoor run at a comfort speed
219715012|NCT06860035|OTHER|Dementia Caregivers' Link to Assistance and Resources (DECLARE)|The intervention for treatment branches includes two parallel processes: (1) calling eligible caregivers to field a self-assessment instrument and upload caregiver responses to the patient record, and (2) identifying and flagging cases for expedited social work access with dementia-trained social workers.
219715013|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 2 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 2 weeks."
219715014|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 4 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 4 weeks."
219715015|NCT03414008|DRUG|BI 1291583|Single dose
219715016|NCT03414008|DRUG|Matching placebo: Tartaric acid|Single dose
219715017|NCT06602258|DRUG|E2814|E2814 IV infusion.
219715018|NCT06602258|DRUG|Lecanemab|Lecanemab SC injection.
219715019|NCT06602258|DRUG|Placebo|Placebo IV infusion.
219715020|NCT03459846|DRUG|Durvalumab|Durvalumab 1500 mg IV q4w
219133655|NCT03882515|OTHER|Continuous Surface Slip Technique|"1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
219133656|NCT03882515|OTHER|Without intervention|Evaluation and re-evaluation without intervention
219715021|NCT03459846|DRUG|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
219715022|NCT03459846|DRUG|Placebo|Matching placebo for oral tablet BID
219715023|NCT05423756|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
219715024|NCT05423756|OTHER|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
219715025|NCT07126938|DRUG|Alcoholic beverage|Participants in the experimental group consumed self-selected amounts of alcohol, monitored by study staff to ensure safety and compliance with protocol guidelines. Participants then filled out the remainder of the general health questionnaire, including how many drinks they consumed, and whether or not they feel too impaired to drive a vehicle or go to work.
219715026|NCT04488224|DEVICE|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
219715027|NCT04488224|RADIATION|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
219715028|NCT04488224|OTHER|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
219715029|NCT06680778|DEVICE|Proactive Monitoring|Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
219715030|NCT07005206|BEHAVIORAL|Six Hats Thinking|A total of 6 sessions of thinking training were given once a week for 6 weeks.
219715031|NCT07005206|DEVICE|No Intervention (Control)|No intervention was made to this group.
219133657|NCT00635817|DRUG|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
219133658|NCT00635817|DRUG|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
219133659|NCT05926791|OTHER|Cosmetic product|The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
219133660|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
219133661|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done
219133662|NCT00809874|DIETARY_SUPPLEMENT|Casein|
219133663|NCT00809874|DIETARY_SUPPLEMENT|Whey Isolate|
219133664|NCT00809874|DIETARY_SUPPLEMENT|Whey Hydrolysate|
219133665|NCT00809874|DIETARY_SUPPLEMENT|Alphalact-Albumin|
219133666|NCT01452490|DEVICE|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
219715032|NCT06797687|DIAGNOSTIC_TEST|Cardiac computed tomography|Mitral valve annulus measurements in the enrolled patients obtained will be obtained from: coronary CT scan, intraoperative transesophageal echocardiography and the ring surgically implanted during surgery.
219715033|NCT06869148|OTHER|Prioritized assessment for older patients living with frailty|In the beginning of 2025, the Emergency department of University hospital of Linköping launched a clinical guideline which stated that patients aged 65 years or older should be assessed with CFS as early as possible, preferably in connection to triage. If the patients were assessed as living with frailty, the frailty score should be stated in the electronical overview of ED patients. The patient's needs of care should be met according to frailty level and the responsible clinical team should aim to decrease the ED length of stay for older patients living with frailty.
219133667|NCT00903721|DRUG|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
219133668|NCT00003891|DRUG|lurtotecan liposome|
219133669|NCT04401722|PROCEDURE|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
219133670|NCT04449744|OTHER|MySafeRx Inspire Plus|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
219133671|NCT04449744|OTHER|MySafeRx Inspire Flex|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
219133672|NCT03229798|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
219133673|NCT03229798|COMBINATION_PRODUCT|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
219227653|NCT05210985|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
219227654|NCT03790098|BEHAVIORAL|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
219227655|NCT02174978|BIOLOGICAL|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
219715034|NCT07011264|BEHAVIORAL|The BAJJAJJA intervention|"The BAJJAJJA intervention is composed of:~The IGA COMPONENT which is intended to promote economic empowerment by improving household income based on available resources. The component will consist of a series of 1-hour sessions with 3 separate GMC participant groups (8 GMCs per group). Two IGA experts will lead these sessions, weekly for the first two months and later monthly for the remaining 10 months of the 12-month intervention period.~The HEALTH COACHING COMPONENT will be informed by theChronic Disease Self-Management Education (CDSME) framework.54 This community-based, person-centered care model will be used to empower GMCs to manage their health through goal-setting, problem-solving, and chronic disease self-monitoring. I (PI) will leverage the community networks that I developed during my preliminary work to (1) recruit interventionists (two nurses) and (2) ensure their adequate training and adherence to the intervention manuals and procedures."
219715035|NCT07013643|DRUG|AZD6234|AZD6234 will be administered as a subcutaneous injection in the abdomen.
219715036|NCT07013643|DRUG|Ethinyl estradiol/Levonorgestrel (EE/LEVO)|EE/LEVO will be administered as combined oral tablets.
219133674|NCT04179240|OTHER|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
219227656|NCT02174978|OTHER|P falciparum Controlled Human Malaria Infection (CHMI)|
219227657|NCT01124552|DRUG|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
219227658|NCT01124552|DRUG|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
219227659|NCT01124552|OTHER|Vehicle|Vehicle Control
219227660|NCT01124552|DRUG|Placebo|Placebo Comparator
219227661|NCT06437158|DRUG|Bleomycin|To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
219227662|NCT00338325|BEHAVIORAL|Reading program|Reading of children's story/picture books preoperatively
219227663|NCT03883724|BEHAVIORAL|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
219715037|NCT07013643|DRUG|Acetaminophen (APAP)|APAP will be administered orally as a solution.
219715038|NCT07013643|DRUG|AZD9550|AZD9550 will be administered as a subcutaneous injection in the abdomen.
219715039|NCT07010835|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 and CD3.
219715040|NCT07013110|DRUG|dnaJP1|The study drug is dnaJP1 peptide. It is a manmade short protein that can be taken easily as a pill. dnaJP1 works to restore the body's immune tolerance by improving its ability to self-adjust - helps to restore the immune system and improve controls on inflammation that has been lost.
219715041|NCT07013110|DRUG|Placebo|This is the control.
219715042|NCT02141113|DRUG|Guanfacine Hydrochloride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
219715043|NCT02141113|OTHER|Placebo|Placebo of matching mg
219715044|NCT07013968|BEHAVIORAL|culturally tailored, trauma-informed mindfulness smoking cessation intervention|"Eight weekly in-person group sessions, each 90 minutes long. From the second half of PY01 to PY04, sessions will be performed in closed in groups of 7-10 participants (with a total of 6 groups). The curriculum is grounded in Lakota values and trauma-informed care. Each of the eight sessions will begin and end with a Lakota serenity prayer and wazílya (smudging of sage), and the meaning and relevance of one of the Lakota values will be discussed. Through a storytelling approach, which is central to Lakota culture, the participants will learn about their value as a Lakota woman, the role of caŋṡaṡa, the association between unresolved trauma and smoking, and the importance of Lakota mind-based and mindfulness strategies in their lives."
219715045|NCT07013578|BEHAVIORAL|Healing Circuits™ sessions|Treatment of the Study group will involve 12-weekly 50-minute sessions with a social worker who has been trained in the Healing Circuits™ Methodology - a structured mental health support delivered by a therapist in a one-on-one model.
219715046|NCT07013578|BEHAVIORAL|self-directed Healing Circuits™ curriculum|Treatment of the Control group will involve 12 weekly online modules of a self-directed Healing Circuits™ curriculum - structured mental health support being delivered in an web-based video instruction model.
219133675|NCT05548530|PROCEDURE|Stereotactic intracranial hematoma puncture|Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
219133676|NCT05548530|PROCEDURE|decompressive craniectomy|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
219133677|NCT05548530|PROCEDURE|Neuroendoscopic|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
219227664|NCT03883724|BEHAVIORAL|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
219715047|NCT05536739|DEVICE|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in a powered state providing assistance to the user that has been previously developed by the team. It is used to improve walking gait performance.
219715048|NCT05536739|OTHER|No hip exoskeleton|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing a hip exoskeleton.
219133678|NCT00871429|OTHER|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
219133679|NCT01912495|DRUG|Boceprevir|
219133680|NCT00898274|OTHER|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
219227665|NCT05076825|OTHER|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
219227666|NCT05076825|OTHER|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
219227667|NCT03810300|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
219715049|NCT05536739|DEVICE|Unpowered hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in an unpowered state that has been previously developed by the team. It is used to improve walking gait performance.
219715050|NCT07014618|OTHER|Pre & Post Surveys|As part of this intervention, patients will complete a pre-treatment questionnaire at the time of consent, which can be administered in person, over the phone, or through the mHealth mobile app, based on their preference. One month after treatment, patients will complete a post-treatment questionnaire using their chosen method. At the six-month mark, patients will complete an additional post-treatment questionnaire along with the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) survey.
219133681|NCT00898274|OTHER|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
219715051|NCT07014618|OTHER|Opt Out of Questionnaire|As part of this intervention, patients declined to participate in the optional questionnaire. However, their data will still be collected through chart review and will be compared to the data of patients who accepted both the questionnaire and navigation services.
219715052|NCT07016178|BEHAVIORAL|Acceptability and Feasibility of Twistle messaging for PDM+ patients|PC patients identified by the PDM as high risk for developing or having undetected MCI or ADRD will receive the patient-informed message developed in Aim 2. The patient-informed message will include instructions for completing validated questions about subjective memory concerns. In addition, interested patients will have the option to schedule a visit with the BHN, or enroll in research opportunities.
219133682|NCT02304653|OTHER|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
219133683|NCT06285175|OTHER|Tele-REINVENT|Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
219133684|NCT03323840|OTHER|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
219715053|NCT04878263|OTHER|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
219133685|NCT05380232|BEHAVIORAL|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
219133686|NCT03722433|DRUG|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
219133687|NCT03722433|DRUG|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
219133688|NCT02109393|OTHER|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
219133689|NCT02109393|OTHER|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
219133690|NCT00150566|DRUG|Lanthanum carbonate|
219133691|NCT02676297|DRUG|tiotropium|four inhalations
219227668|NCT03810300|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
219133692|NCT04717882|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
219133693|NCT06556212|OTHER|Real-time feedback using smart swim goggles|Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
219227669|NCT03810300|OTHER|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
219227670|NCT03810300|BEHAVIORAL|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
219227671|NCT03810300|OTHER|Control|No transfer, no behavior change communication
219715054|NCT04878263|OTHER|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
219133694|NCT03076450|DEVICE|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
219133695|NCT03076450|DIAGNOSTIC_TEST|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
219227672|NCT00195819|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
219227673|NCT00195819|BIOLOGICAL|placebo|Placebo every other week (eow)
219227674|NCT02124304|DEVICE|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
219227675|NCT04781322|DRUG|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
219133696|NCT06082076|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
219133697|NCT06082076|DRUG|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
219133698|NCT06082076|DRUG|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
219715055|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
219133699|NCT00817050|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
219133700|NCT00817050|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
219715056|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
219715057|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
219715058|NCT07018960|PROCEDURE|Chest wall reconstruction with 3D printed titan custom prothesis|"Dynamic Chest Wall Reconstruction with Patient-Specific 3D-Printed Titanium Prostheses~1\. Intervention Overview~A custom-designed, 3D-printed titanium prosthesis is surgically implanted to reconstruct chest wall defects following oncologic resection or traumatic injury. The prosthesis is engineered to:~Restore structural integrity of the thoracic cavity Preserve physiological chest wall dynamics during respiration Provide long-term biomechanical stability"
219715059|NCT07020559|DRUG|allogeneic platelet plasma|Al-PRP derived from healthy blood donors
219133701|NCT05320913|PROCEDURE|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
219133702|NCT05320913|PROCEDURE|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
219133703|NCT01391013|DRUG|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
219133704|NCT01391013|DRUG|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
219715060|NCT07020559|DRUG|autologous platelet plasma|Autologous platelet-rich plasma from the patient themselves
219133705|NCT01391013|DRUG|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
219133706|NCT01772719|DRUG|Simvastatin and zoledronic acid|"1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
219133707|NCT00477412|DRUG|Bortezomib|Given IV
219133708|NCT00477412|DRUG|Cyclophosphamide|Given IV
219133709|NCT00477412|DRUG|Cytarabine|Given IV
219133710|NCT00477412|DRUG|Dexamethasone|Given PO or IV
219133711|NCT00477412|DRUG|Doxorubicin|Given IV
219133712|NCT00477412|DRUG|Methotrexate|Given IV
219133713|NCT00477412|BIOLOGICAL|Rituximab|Given IV
219133714|NCT00477412|DRUG|Vincristine|Given IV
219133715|NCT02315885|OTHER|Alcohol administration; Placebo administration|consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
219133716|NCT03146351|OTHER|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
219133717|NCT02248454|DRUG|Lispro|Increasing insulin doses
219133718|NCT00731211|DRUG|Pazopanib|800 mg of pazopanib orally each day continuously
219133719|NCT01221337|OTHER|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
219133720|NCT04729244|DRUG|CBD|Hemp Oil
219133721|NCT00089258|BIOLOGICAL|beta-glucan|
219133722|NCT00089258|BIOLOGICAL|monoclonal antibody 3F8|
219133723|NCT00089258|BIOLOGICAL|sargramostim|
219133724|NCT00089258|DRUG|isotretinoin|
219133725|NCT00237341|DRUG|fentanyl|
219133726|NCT00618319|DRUG|BIIB021|Dose, schedule, and duration specified in protocol
219133727|NCT06092931|DRUG|DC-806|Oral tablets
219133728|NCT06092931|DRUG|Midazolam|Oral syrup
219133729|NCT06092931|DRUG|Repaglinide|Oral tablets
219133730|NCT06092931|DRUG|Digoxin|Oral tablets
219133731|NCT06092931|DRUG|Rosuvastatin|Oral tablets
219227676|NCT04781322|OTHER|Placebo|Heavy drinking healthy volunteers
219133732|NCT02741167|PROCEDURE|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
219133733|NCT01130064|BIOLOGICAL|QAX576|every 3 weeks via intravenous infusion
219133734|NCT01130064|DRUG|Placebo|every 3 weeks via intravenous infusion
219133735|NCT02279342|DRUG|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
219133736|NCT01985399|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing
219133737|NCT03702543|BEHAVIORAL|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
219133738|NCT01066741|DRUG|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
219133739|NCT01066741|DRUG|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
219133740|NCT00237107|PROCEDURE|Curretage|
219715061|NCT05341284|OTHER|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
219715062|NCT07017010|BEHAVIORAL|phonemic awareness intervention (PA)|All 12 weeks of lessons will exclusively focus on instruction at the phoneme level (i.e., the individual sounds in words), with activities addressing the blending of sounds to form short words. Other activities may include counting the number of sounds heard in a word, matching letter tiles to the sounds heard in the word, and separating short words into their component sounds.
219715063|NCT07017010|BEHAVIORAL|phonological sensitivity + phonemic awareness intervention (PSPA)|The first six weeks of intervention will include a focus on being able to manipulate (separate and blend) parts of words larger than the individual sounds. This will include manipulating compound word components, syllables, and initial sounds and rhyming components of words. Activities may include matching pictures of words, assembling/disassembling puzzle pieces that represent words, and sorting pictures (words) by their first or ending sounds. The second six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as what the children in the DPA intervention condition experience.
219715064|NCT07017010|BEHAVIORAL|delayed onset phonemic awareness intervention (DPA)|The six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as the second six weeks of lessons that the children in the PSPA intervention condition experience.
219715065|NCT07011797|DRUG|CX11|CX11 tablets administered orally once daily (QD) with meals
219715066|NCT07011797|OTHER|Placebo|Matching placebo tablets administered orally once daily (QD) with meals
219715067|NCT04430699|DRUG|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
219715068|NCT04430699|DRUG|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
219715069|NCT04430699|RADIATION|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
219227677|NCT05990933|DRUG|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
219227678|NCT04905004|PROCEDURE|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
219715070|NCT06704932|DRUG|SAR446959|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
219715071|NCT06704932|DRUG|Placebo|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
219715072|NCT06714279|DRUG|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
219715073|NCT06714279|DRUG|Intraperitoneal infiltration to liver|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
219133741|NCT03231436|DRUG|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
219133742|NCT03231436|DRUG|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
219133743|NCT01844544|OTHER|inspection of medical records|
219133744|NCT03121963|DRUG|Oxycodone|oxycodone tablet
219133745|NCT03121963|DRUG|Acetaminophen|acetaminophen tablet
219133746|NCT03121963|DRUG|Gabapentin|gabapentin tablet
219133747|NCT03121963|DRUG|Celecoxib|celecoxib tablet
219133748|NCT03121963|DRUG|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
219133749|NCT00042588|DRUG|Recombinant Chimeric Monoclonal Antibody|
219133750|NCT03545386|OTHER|Fecal microbiota transplantation|Stool from healthy donor administered via enema
219133751|NCT03545386|OTHER|Placebos|Saline with food coloring administered via enema
219133752|NCT02470104|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
219133753|NCT02549443|DIETARY_SUPPLEMENT|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
219133754|NCT06091436|DRUG|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
219133755|NCT06091436|DRUG|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
219133756|NCT06091436|BIOLOGICAL|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
219133757|NCT06091436|DRUG|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
219715074|NCT07044908|DRUG|TQB2922 injection ± TAS-102 tablets|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
219715075|NCT07044908|DRUG|TQB2922 injection+TAS-102 tablets ± Bevacizumab|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
219715076|NCT06886165|BEHAVIORAL|My Avenue to HelP|"The MAP intervention is based on AMBIT principles. A MAP team, consisting of designated employees from CAMHS and two municipalities, will be trained in AMBIT. A Key-Worker and a Mentalizing Case Manager will be assigned to each participant and step into the existing network, taking responsibility for integrating AMBIT principles into all aspects of the work with and around the young person. The Key-worker from the MAP team is responsible for reaching out to the young person at least once a week during the intervention. The Mentalizing Case Manager ensures that mentalization is upheld in the professional network. CAMHS will offer treatment as usual in accordance with the existing evidence-based clinical guidelines and best practice for any specific mental health disorder.~The MAP team members will meet once a week to work as a team and collaborate closely with family members and other potential informal caregivers. The network of helpers will meet and coordinate monthly."
219133758|NCT06091436|BIOLOGICAL|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
219133759|NCT06091436|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
219133760|NCT06091436|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
219133761|NCT06091436|DRUG|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
219133762|NCT03820986|BIOLOGICAL|Pembrolizumab|IV infusion
219133763|NCT03820986|DRUG|Lenvatinib|Oral capsule
219133764|NCT03820986|DRUG|Placebo for lenvatinib|Oral capsule
219133765|NCT02999217|DRUG|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
219133766|NCT02999217|DRUG|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
219133767|NCT05993403|OTHER|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
219133768|NCT02516774|DRUG|Adalimumab|
219133769|NCT02370732|OTHER|Alcohol|A weight based dose of alcohol will be administered during each study day.
219133770|NCT05279963|PROCEDURE|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
219133771|NCT05279963|DRUG|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
219133772|NCT05279963|PROCEDURE|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
219133773|NCT06614621|DRUG|Adebrelimab +Etoposide+Platinum-based drugs|Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W
219133774|NCT06614621|DRUG|Maintenance treatment period:|Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod
219133775|NCT06614023|PROCEDURE|coronary artery bypass grafting|surgical coronary revascularization
219133776|NCT06614972|DEVICE|Balloon-expandable drug-eluting stent|Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
219133777|NCT06613932|PROCEDURE|pulpotomy|removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure
219133778|NCT05760755|BEHAVIORAL|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
219715077|NCT06886165|BEHAVIORAL|Management as Usual|"Participants in the control group will receive non-manualized, standard treatment in CAMHS in collaboration with their municipality of residence, following local practice and guidelines. The MAU will be slightly enhanced compared to standard treatment: a) the young people will have an open case file during one year of participation in the MAP project (and longer if indicated), and b) the standard care services will receive feedback from the research assessment at baseline (after approval of the specific content from parents and the young person) in order to help the young person's caseworker to coordinate the support. These enhancements are made to improve the cohesion of care for the young person, yet without applying the mentalization-based AMBIT principles and MAP teams of the MAP treatment condition.~principles applied in the MAP treatment condition."
219715078|NCT07051993|DRUG|ZN-A-1041|Participants will be administered either a ZN-A-1041 capsule or a tablet orally.
219133779|NCT06697392|OTHER|ultrasound examination|The investigators intend to perform ultrasound examinations for the participants with CTS.
219133780|NCT06697054|DIAGNOSTIC_TEST|Sentinel node biopsy with either ICG or carbon dye injection to cervix|Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.
219133781|NCT05974839|OTHER|Ocrelizumab|Non-interventional
219133782|NCT06696703|DRUG|Human urinary kininogenase(HUK)|Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
219133783|NCT06696703|OTHER|Placebo|Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.
219133784|NCT06702839|OTHER|BETY (Cognitive Exercise Therapy Approach )|"Individuals with rheumatism were included in BETY sessions after the first session, which included functional gain with function-focused trunk stabilization exercises for their complaints and chronic pain management training based on neuroscience. BETY sessions included function-focused trunk stabilization exercises, chronic pain management, mood information management (dance therapy - authentic movement) as innovative. Individuals were included in a separate session of sexual information management and sleep education.~3 days a week for 3 months"
219133785|NCT06702839|OTHER|Home exercise program|Exercises have been shown and a brochure has been given The individuals in this group were mostly individuals from out of town who were given home exercise recommendations directed by a rheumatologist.
219133786|NCT06712524|PROCEDURE|Breast-conserving plastic surgery|The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.
219133787|NCT06712524|PROCEDURE|Traditional breast surgery|Traditional breast surgery
219133788|NCT06714500|DEVICE|LuxValve PLlus|The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies (11-13). However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein.
219715079|NCT07051993|DRUG|Rabeprazole|Participants will be administered rabeprazole BID.
219133789|NCT06713512|OTHER|No intervention|No Intervention
219715080|NCT07053618|DEVICE|Implantation of the VADLINK Percutaneous Left Ventricular Assist Device|To implant VADLINK percutaneous left ventricular assist device during percutaneous coronary intervention (PCI).
219133790|NCT06714175|BEHAVIORAL|Lower Limb Strength Training Program with Visual Feedback|This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
219227679|NCT02282254|OTHER|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
219133791|NCT06714084|DRUG|Neoadjuvant Chemotherapy (NACT)|Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer
219227680|NCT03781375|DRUG|Etanercept|Administered by subcutaneous injection twice a week
219227681|NCT03781375|DRUG|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
219227682|NCT03781375|DRUG|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
219227683|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
219227684|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
219227685|NCT03973515|DRUG|glucokinase activator|PB-201 is a kind of dual and partial GKA
219715081|NCT07053618|DEVICE|VA-ECMO|Received venous arterial extracorporeal membrane oxygenation (VA-ECMO) during PCI.
219715082|NCT07055555|BEHAVIORAL|Acute Stress|Participants randomized to the acute stress condition will complete the Trier Social Stress Test (TSST), a validated experimental method for inducing acute psychosocial stress. The TSST consists of a brief anticipation period followed by a 5-minute mock job interview and a 5-minute surprise mental arithmetic task, performed in front of a neutral panel of judges in professional attire.
219715083|NCT07055555|BEHAVIORAL|Non-Stress Control Task|Participants randomized to the control condition will complete a non-stressful task designed to parallel the structure of the Trier Social Stress Test without eliciting acute stress. They will have a brief anticipation period followed by a 5-minute description of their typical day or favorite hobby. This task is conducted without an evaluative panel, minimizing the potential for stress or anxiety.
219715084|NCT05285904|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
219133792|NCT06714084|DRUG|maintenance therapy|one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
219227686|NCT03973515|DRUG|Placebo|Placebo oral tablet
219227687|NCT01303510|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
219227688|NCT01218841|DIETARY_SUPPLEMENT|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
219227689|NCT01218841|DIETARY_SUPPLEMENT|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
219227690|NCT03770520|PROCEDURE|QFR-guided CABG|CABG surgery based on CAG and QFR
219227691|NCT03770520|PROCEDURE|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
219227692|NCT06161259|DRUG|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
219227693|NCT03877354|OTHER|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
219227694|NCT03877354|OTHER|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
219227695|NCT00891631|BEHAVIORAL|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
219227696|NCT00891631|BEHAVIORAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
219227697|NCT02797587|DRUG|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
219133793|NCT06713850|DEVICE|Shockwave balloons|To evaluate the effectiveness and safety of the Shockwave intraperipheral shockwave catheter system in peripheral arterial angioplasty.
219133794|NCT06713473|OTHER|Rehumanized Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of feeling less than human and mechanisms for reclaiming human identity. The summary will reveal general themes of humanness based on participant responses including body and soul awareness, agency, connection, and creativity.~1. write a 30-minute reflective essay on how did the rehumanization efforts described in the survey make people feel more human? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We would like to record you reading your essay on camera. We believe it would be especially impactful for clinicians developing these interventions to hear directly from someone who has recently navigated similar experiences."
219133795|NCT06713473|OTHER|Control Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of political attitudes and routes to political sophistication. The summary will reveal general themes of political sophistication based on participant responses including gathering information through diverse news outlets, analyzing policy and legislation, and participation in civic engagement~1. write a 30-minute reflective essay on how did the political efforts described in the survey refine political attitudes? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We plan to take excerpts of what you write here and share it with future voters to aid in developing political attitudes."
219133796|NCT06713473|DIAGNOSTIC_TEST|Clinical Interview|Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
219133797|NCT06713473|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
219133798|NCT06713473|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
219227698|NCT02797587|DRUG|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
219227699|NCT02797587|DRUG|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
219227700|NCT02797587|DRUG|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
219227701|NCT02797587|DRUG|Cytisine Placebo|Multi-daily dosing for 25 days.
219715085|NCT06742346|BEHAVIORAL|Non Tailored Messages|Generic messages promoting a plant-based diet were developed, with each message addressing one of the three most commonly mentioned motives for plant-based eating (Miki et al., 2019; Miki et al., 2020): health motives, environmental motives, and animal welfare motives. All messages were designed to be factual (including science-based statistics), concise (4-5 sentences), relevant to teens (e.g., addressing health concerns like acne), and autonomy-supportive (offering suggestions and tips rather than directives) (Hingle et al., 2013). The messages were intentionally crafted in a neutral linguistic style, avoiding highly emotive language, non-standard syntax, or emojis. These messages are delivered from Monday to Friday for two weeks.
219227702|NCT02797587|DRUG|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
219227703|NCT00822900|DRUG|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
219715086|NCT06742346|BEHAVIORAL|Linguistically tailored health messages|Linguistically tailored messages are generated using a Large Language Model. Generic messages promoting a plant-based diet were customized to align with participants' linguistic style, including their preferred choice of words, expressed valence, syntax, and emoji use. These messages are delivered from Monday to Friday for two weeks.
219133799|NCT06712953|OTHER|the peer assessment group|Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
219133800|NCT06713109|BEHAVIORAL|Motivational interview techniques|Motivational interviews will be conducted 4 times. As a result of these interviews, the breastfeeding problem or anxiety in the mother will be evaluated and the effectiveness of the interview will be solved.
219133801|NCT06711822|DEVICE|Shockplus-10|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
219133802|NCT00639366|BIOLOGICAL|trastuzumab|
219133803|NCT00639366|DRUG|chemotherapy|
219133804|NCT00639366|RADIATION|radiation therapy|
219133805|NCT01677936|OTHER|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
219133806|NCT01677936|OTHER|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
219133807|NCT02059044|OTHER|ISTOP-ADE|Interactive Voice Response System + Pharmacist
219133808|NCT02496975|DRUG|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
219133809|NCT02496975|OTHER|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
219133810|NCT05582616|DEVICE|Transcranial Direct Current Stimulation|See treatment arm description
219133811|NCT05582616|DEVICE|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
219133812|NCT06629727|OTHER|VR Group|the experimental group was shown a video through VRG during the lithotripsy procedure.
219133813|NCT06629727|OTHER|Control group|Patients received standard care during the procedure
219133814|NCT06480123|DRUG|Skin drug prepared with exome originated from stem cell|Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
219133815|NCT06629922|OTHER|No intervention|This is a observational study and the participants will not receive any intervention
219133816|NCT00356317|BEHAVIORAL|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
219133817|NCT00356317|BEHAVIORAL|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
219133818|NCT04844957|DRUG|Vitamin D|Clinical Study
219133819|NCT04844957|DEVICE|Full automatic chemiluminescence measuring instrument|Chemiluminescence immunoassay
219133820|NCT04358549|DRUG|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
219133821|NCT04358549|OTHER|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
219133822|NCT05661162|DEVICE|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
219715087|NCT06749912|DEVICE|Low back pain wrap|The low back pain wrap device includes heat, vibration, and red light to assist with reducing pain sensation, improving function.
219133823|NCT03479034|OTHER|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
219227704|NCT00822900|DRUG|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
219227705|NCT04874649|OTHER|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
219715088|NCT06004882|OTHER|PNS therapy|PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
219715089|NCT06004882|DRUG|Triamcinolone|Given by Injection
219133824|NCT01926002|DRUG|Low-Dose MK-8351|Single administration of low-dose MK-8351.
219133825|NCT01926002|DRUG|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
219133826|NCT01926002|DRUG|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
219133827|NCT05206890|DRUG|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
219133828|NCT01118377|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
219133829|NCT01118377|RADIATION|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
219133830|NCT03923946|BEHAVIORAL|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
219133831|NCT04296513|DIAGNOSTIC_TEST|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
219133832|NCT04296513|DIAGNOSTIC_TEST|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
219133833|NCT02032719|BEHAVIORAL|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
219133834|NCT02032719|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
219133835|NCT02780245|DRUG|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
219133836|NCT02780245|PROCEDURE|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
219133837|NCT04867902|BEHAVIORAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
219133838|NCT02787161|DEVICE|Hemodiafiltration|High volume online HDF
219227706|NCT04874649|OTHER|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
219227707|NCT03254472|DIAGNOSTIC_TEST|Measured concentrations of biomarkers|
219227708|NCT06177561|PROCEDURE|Lymphoplasma exchange|The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.
219227709|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
219715090|NCT06004882|DRUG|Bupivacaine|Given by Injection
219715091|NCT06004882|OTHER|Placebo|Given by Injection
219133839|NCT02787161|DEVICE|Hemodialysis|High-flux HD
219133840|NCT04244604|OTHER|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
219133841|NCT00568659|PROCEDURE|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
219133842|NCT03903081|DRUG|HEC110114 tablet|administered orally once daily
219133843|NCT03903081|DRUG|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
219227710|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
219227711|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
219227712|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
219227713|NCT03764020|DRUG|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
219227714|NCT03764020|DRUG|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
219715092|NCT07059767|DRUG|ETH47|single intranasal dose of ETH47
219715093|NCT07059767|DRUG|Placebo|single intranasal dose of placebo
219715094|NCT05888857|DRUG|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
219715095|NCT07060768|OTHER|Mandala Coloring|Mandala coloring at least 20 minutes each day. Totally 10 days intervention
219715096|NCT07056842|DRUG|Rifampin + VCT220|Participants will receive a single oral dose of VCT220 160 mg on Day 1. Rifampin 600 mg will be administered once daily from Day 4 to Day 10 and from Day 12 to Day 14. On Day 11, rifampin 600 mg will be administered followed 30 minutes later by VCT220 160 mg. All doses are administered under fed or fasting conditions with standardized restrictions on fluid and food intake.
219715097|NCT07056842|DRUG|Itraconazole + VCT220|Participants will receive a single oral dose of VCT220 40 mg on Day 1. Itraconazole 200 mg will be administered once daily from Day 4 to Day 11 and from Day 13 to Day 14. On Day 12, VCT220 40 mg will be co-administered with itraconazole 200 mg after breakfast. All doses are administered under fed conditions with standardized fluid and fasting controls.
219227715|NCT03569774|PROCEDURE|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
219227716|NCT03569774|PROCEDURE|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
219715098|NCT05164978|DRUG|DEP combine with PD-1 antibody|Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
219715099|NCT05113381|DEVICE|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
219715100|NCT01466868|DRUG|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
219715101|NCT06789510|OTHER|Autologous Platelet Rich Plasma|10 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
219133844|NCT05051449|DRUG|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
219133845|NCT06165731|BEHAVIORAL|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
219133846|NCT06165731|BEHAVIORAL|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
219133847|NCT06221332|OTHER|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
219133848|NCT06221332|OTHER|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
219133849|NCT02491736|DRUG|Ketoprofen|2.5% ketoprofen gel
219133850|NCT02491736|OTHER|Placebo|Placebo gel
219133851|NCT02931656|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
219133852|NCT02305485|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
219133853|NCT02305485|DEVICE|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
219133854|NCT04886180|DEVICE|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
219133855|NCT04886180|DEVICE|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
219133856|NCT04886180|BIOLOGICAL|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
219133857|NCT01144949|DRUG|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
219133858|NCT01144949|DRUG|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
219133859|NCT04213222|DRUG|Bevacizumab|bevacizumab combined with chemotherapy
219133860|NCT04166682|BEHAVIORAL|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
219133861|NCT04166682|BEHAVIORAL|Routine care|Routine care and followup
219133862|NCT06421948|DRUG|Linperlisib and chidamide|A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
219133863|NCT06421948|DRUG|cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone|A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
219133864|NCT00831597|DRUG|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
219133865|NCT00831597|DRUG|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
219133866|NCT03580967|DRUG|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
219133867|NCT01619943|OTHER|no intervention|clinical follow up
219133868|NCT01619943|OTHER|no intervention|no intervention
219133869|NCT00234143|BEHAVIORAL|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
219133870|NCT00234143|DRUG|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
219133871|NCT00602589|DRUG|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
219133872|NCT03552770|DRUG|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
219133873|NCT02167646|PROCEDURE|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
219133874|NCT04411446|DRUG|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
219133875|NCT04411446|DRUG|Placebo|5 capsules of containing placebo orally given all at once. One dose.
219133876|NCT02716909|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
219133877|NCT02943655|DRUG|combined contraceptive pills (microcept)|oral combined contraceptive once daily
219715102|NCT06789510|OTHER|Saline solution|10 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
219715103|NCT06795165|DRUG|Moxidectin 2 MG Oral Tablet|active medication
219715104|NCT06795165|DRUG|Placebo|placebo pills
219715105|NCT00578526|DRUG|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
219133878|NCT02943655|DRUG|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
219715106|NCT00578526|DRUG|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
219133879|NCT02943655|DRUG|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
219133880|NCT00470626|DEVICE|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
219133881|NCT01499108|DRUG|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
219133882|NCT02891629|DEVICE|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
219133883|NCT00633412|DRUG|Esomeprazole|20mg oral daily
219133884|NCT00633412|DRUG|Ranitidine|150mg oral twice daily
219133885|NCT00633412|DRUG|Esomeprazole|40mg oral tablet daily
219133886|NCT01749787|DRUG|PRTX-100 at 1.5 mcg/kg|
219133887|NCT01749787|DRUG|PRTX-100 at 3.0 mcg/kg|
219133888|NCT01749787|DRUG|PRTX-100 at 6.0 mcg/kg|
219133889|NCT01749787|DRUG|PRTX-100 at 12.0 mcg/kg|
219133890|NCT01749787|DRUG|PRTX-100 at 240 mcg|
219133891|NCT01749787|DRUG|Placebo|Placebo administered via infusion once per week for 5 weeks
219133892|NCT01749787|DRUG|PRTX-100 at 420 mcg|
219133893|NCT01061229|DRUG|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
219133894|NCT01061229|OTHER|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
219133895|NCT01194778|DIETARY_SUPPLEMENT|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
219133896|NCT01194778|DIETARY_SUPPLEMENT|vitamin K1|15 µg vitamin K1 per day during 12 weeks
219133897|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|15 µg vitamin K2 per day during 12 weeks
219133898|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|30 µg vitamin K2 per day during 12 weeks
219133899|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|45 µg vitamin K2 per day during 12 weeks
219133900|NCT04417270|DEVICE|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
219227717|NCT01802424|BEHAVIORAL|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
219715107|NCT05569681|DRUG|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
219715108|NCT05569681|DRUG|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
219133901|NCT04417270|DEVICE|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
219133902|NCT01729819|DRUG|Tolterodine tartrate extended release capsules|
219133903|NCT01729819|DRUG|Desmopressin orally disintegrating tablets|
219133904|NCT01729819|DRUG|Placebo orally disintegrating tablets|
219133905|NCT02966743|DRUG|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
219133906|NCT02966743|DRUG|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
219133907|NCT00471640|DRUG|dexamethasone|4 days 5 mg
219133908|NCT01426945|GENETIC|protein expression analysis|
219133909|NCT01426945|OTHER|immunohistochemistry staining method|
219133910|NCT01426945|OTHER|laboratory biomarker analysis|
219133911|NCT04936217|OTHER|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
219133912|NCT04936217|OTHER|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
219133913|NCT00101725|DRUG|crofelemer|
219133914|NCT02678624|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
219227718|NCT02095678|PROCEDURE|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
219133915|NCT04312776|OTHER|none intervention|
219133916|NCT03523910|DEVICE|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
219133917|NCT05857436|OTHER|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
219715109|NCT04761588|DIETARY_SUPPLEMENT|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
219715110|NCT07071766|BEHAVIORAL|Proud of Baby and Me|The original Baby \& Me curricula was adapted to be delivered in outpatient substance use treatment settings to newly postpartum women receiving medications for opioid use disorder (MOUD) for this study.
219133918|NCT01402271|DRUG|carboplatin|
219133919|NCT01402271|DRUG|paclitaxel|
219133920|NCT01402271|DRUG|pazopanib hydrochloride|
219133921|NCT01402271|OTHER|laboratory biomarker analysis|
219133922|NCT01402271|OTHER|pharmacological study|
219715111|NCT06614192|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219133923|NCT06216730|PROCEDURE|Endoscopic papillectomy|"patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding."
219133924|NCT02165891|DRUG|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
219133925|NCT02165891|PROCEDURE|primary video-assisted thorascopic surgery|
219133926|NCT04228055|BEHAVIORAL|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
219133927|NCT03923725|DRUG|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
219133928|NCT03923725|DRUG|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
219715112|NCT06614192|DRUG|Trifluridine/Tipiracil|Oral Tablet
219133929|NCT03923725|DRUG|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
219133930|NCT03923725|DRUG|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
219133931|NCT00608673|DRUG|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
219133932|NCT00608673|DRUG|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
219133933|NCT00009984|DRUG|fludarabine phosphate|Given IV
219133934|NCT00009984|DRUG|thalidomide|Given orally
219133935|NCT05582317|DRUG|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
219715113|NCT06614192|DRUG|Bevacizumab|IV Infusion
219715114|NCT06898125|OTHER|Extracorporeal Shockwave Therapy|Shock wave therapy is a new modality for the improvement of cellulite and lipedema; it is an easy, noninvasive, local therapy, without side effects, with short periods of application. Its original idea was the stimulation of lipid mobilization and improved lipolysis in areas with edema.
219715115|NCT06898125|OTHER|Complex Decongestive Therapy|Complex decongestive therapy (CDT) is one of the most important treatment modalities of choice for patients with this clinical condition. CDT has two phases: treatment and maintenance. The first stage consists of skin care, manual lymph drainage, kinesiotherapy and bandaging of the limb. Drainage can facilitate the return of lymphatic flow by stimulating the cisterna chyli. Next, kinesiotherapy is applied, which aims to activate the lymph. Finally, the limb is moistened and then a compressive bandage is applied aimed at creating a pressure gradient towards the areas where lymph absorption is greater. The second phase continues skin care, physical exercises and external compression applications using bandages with varying degrees of elasticity.
219715116|NCT06781307|OTHER|skin to skin|Intervention measures include 1 hour of skin-to-skin contact between mother and baby every day from day 1 to day 30 postpartum.
219715117|NCT06822517|DRUG|VENT-02|Orally administered capsules
219133936|NCT05582317|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
219133937|NCT00943605|DEVICE|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
219133938|NCT00943605|DEVICE|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
219133939|NCT00036933|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
219133940|NCT00036933|BIOLOGICAL|QS21|
219133941|NCT03686813|DRUG|Sildenafil Citrate|Oral sildenafil, 50 mg
219133942|NCT03686813|DRUG|Placebo Oral Tablet|Placebo
219133943|NCT05150613|OTHER|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
219133944|NCT05150613|OTHER|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
219133945|NCT05150613|OTHER|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
219133946|NCT03171896|OTHER|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
219133947|NCT03171896|OTHER|Sham|No clown will be present in the room during labor
219715118|NCT06822517|DRUG|Placebo|Orally administered capsules
219715119|NCT06733363|BEHAVIORAL|Behavioral Dietary Intervention|Participate in POW-R Health Only/Core program
219715120|NCT06733363|BEHAVIORAL|Telephone- Based Intervention|Receive live phone calls
219715121|NCT04643002|DRUG|Isatuximab|Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
219715122|NCT04643002|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
219715123|NCT04643002|DRUG|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
219133948|NCT04232592|BIOLOGICAL|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
219133949|NCT04232592|BIOLOGICAL|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
219133950|NCT05926050|DIETARY_SUPPLEMENT|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
219715124|NCT04643002|DRUG|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219715125|NCT04643002|DRUG|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219715126|NCT04643002|DRUG|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
219715127|NCT04643002|DRUG|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
219715128|NCT04643002|DRUG|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219715129|NCT02905591|DRUG|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
219715130|NCT02905591|DRUG|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used"
219715131|NCT02905591|DRUG|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used"
219715132|NCT02905591|DRUG|Ascorbic Acid|"Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts"
219133951|NCT05926050|OTHER|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
219133952|NCT02033096|DRUG|Stannsoporfin|No intervention was administered during this observational study
219133953|NCT02033096|DRUG|Placebo Control|No intervention was administered during this observational study
219133954|NCT02033096|OTHER|Phototherapy (as needed)|No intervention was administered during this observational study
219715133|NCT07075835|PROCEDURE|Enhanced external counterpulsation|20 (5 days a week for 4 weeks) one-hour procedures (compression pressure 220-280 mmHg) of enhanced external counterpulsation (device: LUMENAIR EECP, Vasomedical Inc., USA, registration certificate №2018/6915 dated 15.03.2018). The systolic deflation/diastolic inflation sequence of enhanced external counterpulsation leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
219715134|NCT06077201|OTHER|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
219133955|NCT06345612|BEHAVIORAL|hypoxia|eccentric training program conducted within normobaric hypoxic chamber
219715135|NCT06077201|OTHER|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
219715136|NCT06162377|DRUG|Methylnaltrexone|Given by SC (injection)
219715137|NCT07075679|DIAGNOSTIC_TEST|Group with AI iCAD version 3|Reading mammograms by one radiologist with AI support
219715138|NCT07075679|DIAGNOSTIC_TEST|Group without AI|Standard double reading by two radiologists without AI.
219715139|NCT07078786|DRUG|Betamethason Sodium Phosphate|Intramuscular injection of Betamethasone 12mg will be administered on 2 consecutive days
219715140|NCT07078786|DRUG|Dexamethasone|two doses of 12mg of IM Dexamethasone given 24 hours apart
219715141|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
219715142|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
219715143|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
219715144|NCT07080567|DRUG|Maraviroc|Maraviroc (300mg) twice daily for 90 days
219715145|NCT07080567|DRUG|Mannitol|Placebo intervention
219715146|NCT06406010|DRUG|Ropivacaine 5mg/ml 20ml|administered in a pericapsular nerve group (PENG) block
219715147|NCT06406010|DRUG|Saline 0.9%|administered in a pericapsular nerve group (PENG) block
219715148|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
219715149|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
219715150|NCT06795451|DEVICE|transcutaneous spinal direct current stimulation|transcutaneous spinal direct current stimulation
219715151|NCT06705478|DRUG|Pramipexole ER|Tablets self-administered orally
219715152|NCT06705478|DRUG|Escitalopram|Tablets self-administered orally
219715153|NCT06682364|BEHAVIORAL|Trauma-informed case management for women who use drugs|This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
219133956|NCT06345612|BEHAVIORAL|normoxia|eccentric training program conducted within normoxic conditions
219715154|NCT06682364|BEHAVIORAL|CRS Only Intervention|This intervention assesses the adequacy in which components of the gender-specific case management by certified peer recovery specialists function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
219133957|NCT06345612|DIETARY_SUPPLEMENT|creatine supplementation|5g of creatine per day
219715155|NCT03408353|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219715156|NCT03408353|PROCEDURE|Mammography|Undergo standard of care mammography
219715157|NCT03408353|OTHER|Questionnaire Administration|Complete questionnaires
219715158|NCT07084350|DRUG|lactulose|"1. Two days before the colonoscopy: The patients should respectively take 30mL of lactulose orally on an empty stomach in the morning and at 8:00 PM of the same day, respectively.~2. One Day Before the Colonoscopy: The patients should take 30mL of lactulose orally at 7:00 PM.~3. On the Day of the Colonoscopy:~For Morning Appointments:The patients should take 30mL of lactulose orally at 2:00 AM.~For Afternoon Appointments:The patients should take 30mL of lactulose orally at 7:00 AM."
219715159|NCT07084350|DRUG|PEG (solution given 4 L)|"1. One Day Before the Colonoscopy: The patients should take 2000mL of PEG solution at 8:00 PM, and drink the entire solution within 2 hours.~2. On the Day of the Colonoscopy:~For Morning Appointments: The patients should take 2000mL of PEG solution at 3:00 AM and drink the entire solution within 2 hours.~For Afternoon Appointments: The patients should take 2000mL of PEG solution at 7:00 AM and drink the entire solution within 2 hours."
219715160|NCT01125228|DRUG|Ziodovudine and Alpha Interferon|
219715161|NCT06646406|BEHAVIORAL|Patient letter and clinician communication|Single mailing to patients from practice with a reminder that the influenza and COVID-19 vaccines are due, and monthly emailing to the patients' clinicians with information about how to make a strong recommendation for those vaccines
219715162|NCT07084285|DRUG|Dexamethasone|A single 4mg (1mL) dexamethasone injection via the posterior intra-articular route, under CT guidance
219133958|NCT06345612|DIETARY_SUPPLEMENT|no creatine supplementation|no creatine supplementation
219133959|NCT02931123|DRUG|lattulose and rifaximine|
219133960|NCT04330950|OTHER|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
219715163|NCT07084285|OTHER|Isotonic saline solution|1 mL isotonic saline solution, injectable, for a single posterior intra-articular injection, under CT guidance.
219715164|NCT07121439|DRUG|a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES|Subjects were randomized to receive a combination serum The combination serum contained Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES. applied twice daily, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
219715165|NCT07121439|DRUG|2% hydroquinone cream|Subjects were randomized to received 2% hydroquinone cream, applied once daily at night, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
219133961|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
219133962|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
219133963|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
219133964|NCT00929591|DRUG|cyclophosphamide|
219133965|NCT00929591|DRUG|doxorubicin hydrochloride|
219133966|NCT00929591|DRUG|endocrine therapy|
219133967|NCT00929591|DRUG|endocrine-modulating drug therapy|
219133968|NCT00929591|DRUG|fluorouracil|
219133969|NCT00929591|DRUG|tamoxifen citrate|
219133970|NCT00929591|RADIATION|brachytherapy|
219133971|NCT00929591|RADIATION|low-LET electron therapy|
219133972|NCT00929591|RADIATION|low-LET photon therapy|
219133973|NCT00929591|RADIATION|radiation therapy|
219133974|NCT02467491|DEVICE|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
219133975|NCT01735240|DRUG|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
219133976|NCT01735240|DRUG|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
219133977|NCT03416465|BEHAVIORAL|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
219133978|NCT02419261|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
219133979|NCT02419261|PROCEDURE|Arthroscopic surgical repair of the anterior cruciate ligament|
219133980|NCT05395949|DRUG|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
219133981|NCT00145002|DRUG|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
219133982|NCT00145002|DRUG|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
219133983|NCT04117451|OTHER|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
219133984|NCT05880316|BEHAVIORAL|Intermittent Fasting|3:4 regime
219715166|NCT07120464|OTHER|Observation Only|All participants will receive post-exposure rabies vaccination using either the Zagreb or Essen regimen, in accordance with national immunization guidelines.
219715167|NCT07119996|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3|"1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.~4. Vitamin B3 tablet(also known as nicotinic acid tablet) supplementation daily(300mg QD or 500mg QD) after antibiotic treatment."
219715168|NCT07121335|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).
219715169|NCT07116733|DRUG|Desﬂurane group|"After routine induction, maintain anesthesia with inhaled desflurane , adjusting concentration as needed to sustain 0.5-2 MAC . To maximize the cardioprotective effects of inhaled anesthetics, adhere to this intraoperative strategy:~Maintain ≥1 MAC continuous desflurane for ≥30 minutes ; For on-pump CABG , discontinue desflurane 15 minutes before initiating cardiopulmonary bypass (CPB) ;~If intraoperative desflurane cessation is required, implement a wash-in/wash-out strategy (recommended but non-mandatory):~Perform 3 alternating cycles of:~Wash-in : ≥10 minutes of desflurane at ≥0.5 MAC, Wash-out : ≥10 minutes of complete cessation of inhaled anesthetics. Propofol is strictly prohibited for anesthesia maintenance throughout the procedure , except during CPB."
219715170|NCT07116733|DRUG|Propofol group|Administer total intravenous anesthesia (TIVA) using propofol infusion at 3-8 mg/kg/h . No inhaled anesthetics are permitted for maintenance. This may be delivered via:target-controlled infusion (TCI) systems, or manual adjustment of intravenous infusion rates.
219715171|NCT07120022|OTHER|Self-efficacy training|The primary goal of this study is to determine whether self-efficacy training can increase the probability of taking cold showers regularly over a three-month period.
219715172|NCT07124741|DIAGNOSTIC_TEST|Serial VEXUS Ultrasound Evaluation|Ultrasound assessments will be performed by an experienced anesthesiologist at three time points (0-4 hours, 12-24 hours, and 72 hours)to determine the degree of venous congestion using the VEXUS Score. No treatment changes will be made based on the VEXUS findings. The scores will solely be used for prognostic correlation with mortality outcomes.
219715173|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
219715174|NCT07081516|PROCEDURE|temperature|Adjusting the temperature of the local anesthetic drugs injected intrathecally
219715175|NCT07085403|OTHER|Cognitive Orientation to daily Occupational Performance (CO-OP) is a cognitive problem-solving approach|Cognitive Orientation to daily Occupational Performance (CO-OP; CO-OP approach) is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need, to or are expected to perform. CO-OP is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the CO-OP approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the CO-OP Approach, are situated within a structured intervention format, and may involve the parent/significant other as appropriate.
219715176|NCT04253626|DRUG|Ferumoxytol Injection [Feraheme]|510mg intravenous ferumoxytol
219715177|NCT04253626|DRUG|Ferrous Sulfate|325mg oral ferrous sulfate
219715178|NCT06904404|PROCEDURE|Cataract surgery at high IOP|Cataract surgery at high IOP (conventional)
219715179|NCT06904404|PROCEDURE|Cataract surgery at low IOP|Cataract surgery at low IOP
219715180|NCT05448365|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
219715181|NCT05448365|DIETARY_SUPPLEMENT|Placebo|Maltodextrines
219715182|NCT06812533|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
219715183|NCT06812533|OTHER|Sham-Control|Cardiac imaging
219133985|NCT04492631|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
219715184|NCT06818968|DRUG|MK-6916|Oral administration
219133986|NCT04492631|OTHER|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
219133987|NCT01842971|PROCEDURE|two stage hepatectomy|
219133988|NCT01272648|BEHAVIORAL|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
219133989|NCT01137799|DRUG|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
219133990|NCT01137799|DRUG|placebo|Once daily (single dose)
219715185|NCT06818968|DRUG|Diltiazem|Oral administration
219715186|NCT06771206|DEVICE|Owlet pulse oximeter neonatal accuracy validation|This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
219715187|NCT05701917|DEVICE|ClotTriever System|Mechanical thrombectomy
219133991|NCT01137799|DRUG|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
219133992|NCT01137799|DRUG|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
219133993|NCT01137799|DRUG|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
219133994|NCT01137799|DRUG|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
219133995|NCT05903963|DRUG|Midazolam|midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
219715188|NCT05701917|DRUG|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
219715189|NCT06821048|BIOLOGICAL|Intraperitoneal infusion of FAST CEA-targeted CAR-T|Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.
219715190|NCT05763875|DRUG|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
219715191|NCT05763875|DRUG|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
219715192|NCT05763875|DRUG|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
219715193|NCT05763875|DRUG|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
219715194|NCT07079332|OTHER|New Scale to evaluate ataxia motor symptoms|The Ataxia Trunk, Lower And upper extremity Scale (ATLAS) is a new scale. It differs from other Ataxia Scale by focusing on the assessment of coordination abilities of specific body segments: the trunk, lower limbs, and upper limbs.
219715195|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 125mg|Two capsules per day (125 mg/day) before sleep, with or without food, for 8 weeks.
219715196|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 250mg|Two capsules per day (250 mg/day) before sleep, with or without food, for 8 weeks.
219715197|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 500mg|Two capsules per day (500 mg/day) before sleep, with or without food, for 8 weeks
219715198|NCT07085819|DIETARY_SUPPLEMENT|Pacebo|Two capsules per day before sleep, with or without food, for 8 weeks.
219715199|NCT07087795|DRUG|NNC0194-0499|Participants will receive subcutaneous NNC0194-0499 once weekly.
219715200|NCT07087795|DRUG|Placebo|Participants will receive placebo matched to NNC0194-0499 subcutaneously.
219715201|NCT07087795|DRUG|Semaglutide|Participants will receive subcutaneous semaglutide once weekly.
219715202|NCT06043427|DRUG|Paclitaxel|80 mg/m²
219715203|NCT06043427|DRUG|Ramucirumab|8 mg/kg
219715204|NCT06043427|DRUG|Zanidatamab|Dose and schedule to be assigned at enrollment
218987164|NCT05358444|BEHAVIORAL|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
219715205|NCT04426214|DEVICE|tDCS|We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
219715206|NCT04426214|BEHAVIORAL|Cognitive Training|cognitive training on computer
219715207|NCT06821321|BEHAVIORAL|Plyometric Training|Participants will receive a total of twenty-four 45-minutes in-person resistance-training sessions, twice per week, using three sets of eight repetitions per set on five upper body exercises. During resistance-training participants will be allowed 1-minute rests between sets. Participants will also perform two jump training exercises on a horizontal Pilates reformer, the leg plyometric and ankle plantar plyometric jumps.
219715208|NCT06821321|BEHAVIORAL|Power Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include five upper-body exercises and two lower-body exercises.
219715209|NCT07094789|DEVICE|Next Generation Dome Helmet (NGDH)|Participants will receive two sessions of Magnetic Resonance-guided focused ultrasound neuromodulation, spaced four weeks apart, using the Next Generation Dome Helmet device. Treatments will target regions within the CSTC circuit identified by advanced MRI scans. Each session will include pre-treatment assessments, precise sonications of deep brain structures, real-time safety monitoring, and post-treatment imaging.
219715210|NCT06880276|DRUG|1.5% QLM3003 ointment|QLM3003 topical cream; 1.5% cream applied twice daily (BID)
219715211|NCT06880276|DRUG|2% QLM3003 ointment|QLM3003 topical cream; 2% cream applied twice daily (BID)
219715212|NCT06880276|DRUG|QLM3003 Placebo|vehicle; vehicle applied twice daily (BID)
219715213|NCT07094256|DEVICE|Peritorq|Novel torque device specifically designed for electrophysiology and ablation catheters
219715214|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
219715215|NCT06908967|DEVICE|EyeMirage device|This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
219715216|NCT07095101|BEHAVIORAL|Mobistudy Application|Treatment with mobile application
219715217|NCT07095101|DEVICE|Occlusal splint|Treatment with an occlusal splint
219715218|NCT07097506|DRUG|bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester)|25 g C8 ketone di-ester taken daily for approximately 6-weeks
219715219|NCT07097506|OTHER|Placebo|25 g Placebo taken daily for approximately 6-weeks
218987165|NCT06116578|DRUG|Pembrolizumab|cf Arm A
219715220|NCT05828212|DRUG|CAR-T cells injection|CAR-T cells in the treatment of R/R neuromyelitis optica
219715221|NCT06906497|DRUG|lebrikizumab|"Patients will receive lebrikizumab with a 500 mg loading dose administered subcutaneously at baseline and Week 2 followed by 250 mg every 2 weeks until Week 24.~At week 24, patients with ≥ Eczema Area and Severity Index (EASI) 50 will continue in the study and begin receiving lebrikizumab 250mg every 4 weeks (Q4W), while patients with \<EASI 50 will be discontinued from the study.~At week 36, patients with EASI ≥50 to \<90 will remain on Q4W through W60 (do not enter withdrawal arm), while patients with sustained low disease activity (IGA 0/1 or EASI≥90 response for at least 3 months assessed at W24 and W36) will withdraw from lebrikizumab treatment"
219715222|NCT07099443|OTHER|Non-Interventional Sample Collection and Analysis|This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.
218987166|NCT06116578|DRUG|Pembrolizumab and Olaparib|cf Arm B
218987167|NCT06116578|DRUG|Pembrolizumab adjuvant|After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
218987168|NCT05300737|OTHER|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
218987169|NCT02833064|RADIATION|Non-contrast magnetic resonance imaging|
218987170|NCT02833064|OTHER|Biological sampling|Blood, urine, stool and breath sampling and analysis
218987171|NCT05134935|DEVICE|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
218987172|NCT05134935|DEVICE|Orthokerathology lenses (OKL)|18 months of therapy.
218987173|NCT03802227|DRUG|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
218987174|NCT03802227|DRUG|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
218987175|NCT05602870|DIAGNOSTIC_TEST|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
218987176|NCT04203329|DEVICE|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
218987177|NCT06652984|OTHER|Exercise 1|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
218987178|NCT06652984|OTHER|Exercise 2|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
218987179|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
218987180|NCT04533165|BEHAVIORAL|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
218987181|NCT06980454|DRUG|HLX05|A single dose of 250 mg/m2 HLX05 will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
218987182|NCT06980454|DRUG|EU-Erbitux®|A single dose of 250 mg/m2 EU-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
218987183|NCT06980454|DRUG|US-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
219133996|NCT05903963|DRUG|dexmedetomidine|dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
219133997|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
219133998|NCT03107611|DRUG|Placebo Cream|
219133999|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
219134000|NCT02612584|DEVICE|Pinhole Soft Contact Lens apply for presbyopia|
219134001|NCT01720446|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
219134002|NCT01720446|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
219134003|NCT01720446|DRUG|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
219134004|NCT02496793|BEHAVIORAL|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
219134005|NCT06390891|OTHER|Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
219715223|NCT07098390|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"When patients are admitted to the Orthopedics and Traumatology Clinic for arthroplasty and agree to participate in the study, they will be informed about the research process and written informed consent will be obtained. The Descriptive Information Form, Numeric Rating Scale (NRS), The Fear of Falling Scale, and the State-Trait Anxiety Inventory (STAI) will be administered through face-to-face interviews by the researcher. After the pre-tests are completed, patients will be randomly assigned to the intervention and control groups.~In the preoperative period, upon admission to the clinic, patients in the intervention group will receive progressive muscle relaxation exercises (PMRE). To enhance concentration and minimize the impact of ambient noise, patients will listen to the exercises using headphones.~On the first postoperative day, the patient will be revisited by the researcher. After the physician explains that the patient will be mobilized, the State-Trait Anxiety Inventory will"
219715224|NCT07131969|OTHER|blood draw|Venous blood sampling into Tempus tube for RNA-sequencing
219134006|NCT06390891|OTHER|Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
219134007|NCT00361517|BEHAVIORAL|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
219715225|NCT06859307|PROCEDURE|intra-abdominal instillation of corticosteroids|after adhesiolysis, peritoneal lavage with diluted corticosteroids will be instillated intra-abdominally
219715226|NCT06859307|PROCEDURE|intra-abdominal instillation of fresh frozen plasma|after adhesiolysis, peritoneal lavage with diluted FFP will be instillated intra-abdominally
219715227|NCT07103564|OTHER|Immediately placed implant in maxillary premolars with local melatonin application|Patients will receive immediately placed implants with local melatonin powder (3mg) application.
219715228|NCT07103564|OTHER|Immediately placed implant in maxillary premolars without local melatonin application|Patients will receive immediately placed implants without local melatonin application.
219715229|NCT07103174|BIOLOGICAL|MG-K10 placebo|Administer the drug once every 4 weeks for a total of 6 times
219715230|NCT07103577|PROCEDURE|Island osteoperiosteal flap|Crestal incision using no. 15 blade on a bard parker no. 3. Two blind lateral vertical ostotomies at about 1.5 to 2 mm from the adjacent tooth roots to preserve subpapillary and root bone coverage. These cuts are to ensure the complete fracture of buccal plate while being attached to the overlying periosteum.
219715231|NCT07103577|PROCEDURE|Conventional ridge splitting|Crestal incision and 2 vertical releasing incisions will be made using a no.15 blade mounted on a Bard Parker no.3. Then, a full mucoperiosteal flap reflection to expose bone.
219715232|NCT07103291|OTHER|Respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks.
219715233|NCT07103291|OTHER|Sham respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks following a sham training procedure that is meant to elicit no physiologic changes.
219715234|NCT07102680|OTHER|L Max|L Max proprietary formulation
219715235|NCT07102680|OTHER|Placebo|Lactohale 300
219134008|NCT00361517|OTHER|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
219134009|NCT00361517|OTHER|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
219134010|NCT00361517|DRUG|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
219134011|NCT00361517|OTHER|blood test|Blood will be tested twice a week for the presence of Galactomannan.
219134012|NCT00361517|OTHER|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
219134013|NCT02529696|DEVICE|Accelerometer|Measures patient movement
219134014|NCT03862833|DRUG|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
219134015|NCT03862833|DRUG|Zoledronic Acid|4 mg at day +15 post graft
219134016|NCT05339971|OTHER|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
219134017|NCT02925052|DEVICE|Gastric Tube Guide|
219134018|NCT02925052|DEVICE|Conventional placement|
219134019|NCT04464421|BEHAVIORAL|Contingency Management (CM)|Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
219134020|NCT04464421|BEHAVIORAL|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
219134021|NCT03674190|PROCEDURE|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
219134022|NCT03674190|PROCEDURE|Total Disc Replacement|Total Disc Replacement
219134023|NCT02245854|DEVICE|Exacto™|Cold snare polypectomy
219134024|NCT01393353|OTHER|Cognitive Training|
219134025|NCT01393353|OTHER|computer game|
219134026|NCT00076986|DRUG|IL13-PE38QQR|
219134027|NCT00076986|PROCEDURE|surgery and catheter placement (2 procedures)|
219134028|NCT00076986|DRUG|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
219134029|NCT00076986|PROCEDURE|surgery and wafer placement (1 procedure)|
219134030|NCT04922658|DRUG|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
219134031|NCT04922658|DRUG|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
219134032|NCT06450977|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
219134033|NCT06450977|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
219134034|NCT02175212|DRUG|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"
219134035|NCT02175212|DRUG|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
219134036|NCT02175212|RADIATION|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
219134037|NCT02175212|RADIATION|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
219134038|NCT02874118|BEHAVIORAL|Fried scale for frailty assessement|
219134039|NCT03931044|PROCEDURE|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
219715236|NCT07104006|BEHAVIORAL|Multi-Theory Model (MTM)-Based Smoking Cessation Program|"Multi-Theory Model (MTM)-Based Smoking Cessation Program: A four-week online smoking cessation program based on the Multi-Theory Model (MTM). It uses behavior change strategies including participatory dialogue, building confidence, emotional transformation, practice for change, and changes in physical and social environment. Activities include storytelling, role-playing high-risk situations, emotional regulation, social support, stress management, reflection, and commitment exercises. The goal is to help young adults initiate and maintain quitting smoking.~Knowledge-Based Smoking Risk Education and Quit Strategies Program: A four-week, online educational program providing information on smoking risks, benefits of quitting, barriers, and practical quit strategies. This control arm focuses on increasing knowledge and awareness but does not include MTM-based behavior change techniques."
219715237|NCT00217737|BIOLOGICAL|Bevacizumab|Given IV
219715238|NCT00217737|DRUG|Fluorouracil|Given IV
219715239|NCT00217737|DRUG|Leucovorin|Given IV
219715240|NCT00217737|DRUG|Oxaliplatin|Given IV
219715241|NCT07108894|BIOLOGICAL|ABCL575|Participants will receive SC injection of ABCL575
219715242|NCT07108894|BIOLOGICAL|Placebo (Normal Saline 0.9%)|Participants will receive SC injection of placebo (Normal Saline 0.9%)
219715243|NCT06240754|DRUG|Enasidenib|Provided by BMS.
219715244|NCT07105904|DIAGNOSTIC_TEST|Viscoelastometric hemostatic assay|As part of usual care, when weaning the patient from CPB during cardiac surgery, blood samples are withdrawn from the patient to assess hemostasis: we test both Quantra viscoelastometric assay and biological hemostasis including QT, ACT, fibrinogen and platelet count
219715245|NCT07107529|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
219715246|NCT07107529|DRUG|Talquetamab|Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
219715247|NCT07107529|DRUG|Daratumumab|Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
219715248|NCT07104591|BIOLOGICAL|HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)|Banked, partially HLA-matched virus-specific T cells (VSTs) directed against EBV, CMV, adenovirus, and BK virus.
219715249|NCT06979466|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
219715250|NCT07103499|BEHAVIORAL|Pilates-Based Core and Breathing Exercise Program|An 8-week supervised Pilates-based exercise program for overweight and obese women, focusing on abdominal endurance and core stabilization. Sessions (3/week) include diaphragmatic breathing, use of reformer and cadillac equipment, and structured warm-up, main, and cool-down phases.
219134040|NCT02508896|BIOLOGICAL|AFFITOPE® AT04A+adjuvant|subcutaneous injection
219134041|NCT02508896|BIOLOGICAL|AFFITOPE® AT06A+adjuvant|subcutaneous injection
219134042|NCT02508896|BIOLOGICAL|Adjuvant without active component|subcutaneous injection
219134043|NCT01072357|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
219134044|NCT01072357|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
219134045|NCT02390258|DRUG|10mg XEN-D0103|
219134046|NCT02390258|DRUG|Placebo|
219134047|NCT02390258|DRUG|30mg XEN-D0103|
219134048|NCT02390258|DRUG|60mg XEN-D0103|
219134049|NCT02390258|DRUG|120mg XEN-D0103|
219134050|NCT02390258|DRUG|200mg XEN-D0103|
219134051|NCT02390258|DRUG|150mg XEN-D0103|
219134052|NCT05126719|DRUG|MRG003|Administered intravenously
219715251|NCT07103655|DRUG|mavacamten|Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.
219715252|NCT07103655|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Administer an appropriate dose of beta-blockers according to the patient's tolerance.
219715253|NCT07103655|DRUG|diltiazem|Administer an appropriate dose of diltiazem according to the patient's tolerance.
219715254|NCT06919757|DIAGNOSTIC_TEST|fetal ultrasound to assess lungs, heart and diaphragm|The potential association between fetal ultrasound parameters (estimation of lung volumes, diaphragmatic thickness and contractility, cardiac thickness and kinetics), perinatal complications and respiratory function in the first years of life will be studied. Variables include: neonatal complications, non-invasive markers of respiratory status during neonatal admission (e.g. peripheral oxygen saturation/rfaction of inspired oxygen ratio among others), lung function tests in the first two years of life.
219715255|NCT07142200|DRUG|Disitamab Vedotin|Each patient will receive Disitamab Vedotin injection \[2.0 mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
219227719|NCT02095678|DEVICE|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
219134053|NCT05126719|DRUG|Capecitabine tablets|Administered peros
219134054|NCT05126719|DRUG|Docetaxel injection|Administered intravenously
219134055|NCT04286165|OTHER|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
219134056|NCT02248025|OTHER|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
219134057|NCT06553222|BIOLOGICAL|Putty bone - Tricalcium phosphate with Collagen gel|Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone
219134058|NCT05039606|DRUG|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
219134059|NCT05039606|DRUG|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
219134060|NCT04753099|BEHAVIORAL|occupation-based coaching|"Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2)."
219134061|NCT00891618|OTHER|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
219134062|NCT00844571|OTHER|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
219134063|NCT05655442|PROCEDURE|early APM|early APM within 3 and 6 month knee pain symptoms
219134064|NCT05655442|PROCEDURE|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
219134065|NCT03812354|OTHER|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
219134066|NCT03812354|OTHER|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
219134067|NCT00328055|BEHAVIORAL|AD-Easy (Advance Directive-Easy)|
219134068|NCT00328055|BEHAVIORAL|AD-Standard (Advance Directive-Standard)|
219134069|NCT00530517|DEVICE|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
219134070|NCT05036746|OTHER|No intervention|No intervention
219134071|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
219134072|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
219227720|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
219227721|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
219227722|NCT01663454|BEHAVIORAL|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
219227723|NCT00000418|PROCEDURE|Psychosocial intervention|
219227724|NCT05467566|DEVICE|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
219227725|NCT05467566|DEVICE|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
219227726|NCT04377191|OTHER|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
219227727|NCT04377191|OTHER|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
219715256|NCT07142200|DRUG|PD-1 inhibitor|Each patient will receive Triprolizumab injection \[3mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
219715257|NCT07142200|RADIATION|radiotherapy|"1. Whole bladder treatment, recommended scope of application: T2 Suggestion: The total bladder radiotherapy dose is 2Gy/day, five times a week, up to a dose of 50Gy/25 times, to cover at least 95% of the planned target volume (PTV full bladder).~   The radiation dose for shrinking the field to bladder tumors is 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target dose (PTV bladder tumors).~2. Whole pelvic radiotherapy (whole bladder+selective pelvic lymph node radiotherapy), applicable range: T3-T4a Suggestion: Whole pelvic radiotherapy at 2Gy/day, five times a week, up to a dose of 46Gy/23 times, to cover at least 95% of the planned target dose.~Reduce the dosage to 2Gy/day for the entire bladder and up to 4Gy/twice. Bladder tumor (PTV bladder tumor) 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target volume.~The above radiotherapy plan is a suggestion, and the specific plan will"
219715258|NCT07142408|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine 4% solution will be applied from the neck down (avoiding the face, penis, and vagina), allowed to sit on the skin for one minute, then rinsed off in the shower every day for 5 days prior to surgery.
219715259|NCT07142408|DRUG|Mupirocin 2% Ointment|Mupirocin 2% ointment will be applied to the inside of the nostrils twice daily, in the morning and evening, for 5 days prior to surgery. A small amount of the ointment will be placed on the tip of a cotton swab to facilitate application to each nostril.
219715260|NCT07140835|DEVICE|SurgiStep Platform|The Surgistep (pedal-controlled, adjustable platform) allows real-time height adjustment during surgery. The surgeons can adjust the height of the platform.
218987184|NCT06980454|DRUG|CN-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
218987185|NCT06807216|BEHAVIORAL|YATAC|Age-specific rehabilitation for young adult cancer survivors
218987186|NCT06474221|BEHAVIORAL|Electronic Based Psychosocial Intervention (EBPSI)|Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
218987187|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
218987188|NCT06655142|DEVICE|ONCObind (Onco-Seraph) 100 Filter|The ONCObind Microbind® Affinity Blood Filter ( ONCObind) manufactured by ExThera Medical Corporation in Martinez, CA. The ONCObind filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. Literature search yielded over 60 publications and 500 treated patients with Seraph platform technology for pathogen removals without and significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of ONCObind consistent with the intended use. ExThera Medical concludes that the known and potential benefits of ONCObind, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
218987189|NCT06655142|OTHER|Matched Controls|Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
218987190|NCT01840306|OTHER|Biomarker Analysis|
218987191|NCT06607900|DRUG|hUC-MSC-sEV-001 nasal drops|hUC-MSC-sEV-001 nasal drops
218987192|NCT01330680|DIETARY_SUPPLEMENT|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
218987193|NCT01330680|DIETARY_SUPPLEMENT|Decaffeinated coffee|40 mL dose of decaffeinated coffee
218987194|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 5 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
218987195|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 10 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
218987196|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
218987197|NCT06619197|OTHER|Global reflexology|The EMC method is a global reflexology technique inspired by the work of the American naturopath Stanley Burrough (Vitaflex, 1976). It is a method of reflexology on the whole body, of acupressure massages (rhythmic and targeted movements) on so-called \&#34;reflex\&#34; zones which is practiced on different areas of the body (feet, hands, arms, legs, collarbone, ear) and allows the stimulation of all systems.
219715261|NCT07140835|DEVICE|Standard Foot stool|Foot stool is considered as the standard of care during surgery.
219715262|NCT07140822|DEVICE|Coronary Cutting Balloon Catheter|This product uses a pressure device to pressurize the balloon to expand it. The blades designed on the surface of the balloon produce a cutting effect on the vascular lesions, allowing it to better embed into the plaque.
219134073|NCT04846491|DRUG|TDF|Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
219134074|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
219134075|NCT06354738|PROCEDURE|total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging|"Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted."
219134076|NCT03988504|DIAGNOSTIC_TEST|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
219134077|NCT03010553|PROCEDURE|Detection and resection of sentinel lymph node|
219134078|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
219134079|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
219227728|NCT04377191|OTHER|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
219134080|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
219134081|NCT03256812|DEVICE|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
219134082|NCT03256812|DEVICE|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
219134083|NCT01313182|DRUG|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
219134084|NCT01313182|DRUG|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
219134085|NCT01695317|DRUG|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
219134086|NCT00641472|DRUG|Budesonide inhalation suspension|0.5mg
219134087|NCT00641472|DRUG|Montelukast Sodium|4mg or 5mg
219134088|NCT03101436|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
219134089|NCT02515682|DIETARY_SUPPLEMENT|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
219134090|NCT02515682|DIETARY_SUPPLEMENT|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
219134091|NCT02515682|DIETARY_SUPPLEMENT|Placebo|Participants will be give placebo for 24 weeks.
219134092|NCT03584646|DEVICE|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
219134093|NCT03584646|OTHER|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
219134094|NCT03584646|OTHER|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
219134095|NCT01927835|BIOLOGICAL|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
219134096|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
219134097|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
219134098|NCT01927835|BIOLOGICAL|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
219134099|NCT01927835|BIOLOGICAL|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
219134100|NCT01063023|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
219715263|NCT07140822|DEVICE|VesscideTM Cutting Balloon System|This product utilizes a pressure mechanism to inflate the balloon, causing it to expand. The blades on the balloon's surface create a cutting action on the vascular lesions, enabling the device to penetrate the plaque more effectively.
219134101|NCT01063023|DRUG|BMS-650032|Tablets, Oral, 600 mg, BID
219715264|NCT07140744|DIAGNOSTIC_TEST|P-tau217|Blood biomarker testing
219227729|NCT01758549|OTHER|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
219715265|NCT07140744|OTHER|Standard of Care|Standard of care
219715266|NCT07141979|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in left DLPFC
219715267|NCT07141979|DEVICE|Sham tDCS|20 min, left DLPFC Sham tDCS
219715268|NCT07142434|DEVICE|neonatal Umbilical Catheter Pathway Simulator|evaluate the quality of simulator
219715269|NCT07141186|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Enrolled patients will receive intravenous infusion of QL1706 once every 3 weeks at a dose of 5.0 mg/kg until disease progression, death, intolerable treatment toxicity, or withdrawal from the clinical trial for any reason.
219715270|NCT07141810|DRUG|Antifibrotic drugs (nidanib or pirfenidone)|One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy.
219715271|NCT07142330|PROCEDURE|Atherectomy|Two different techniques : rotational atherectomy or thromboendarterectomy
219715272|NCT05578872|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
219715273|NCT02799524|OTHER|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
219715274|NCT03421561|DEVICE|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
219715275|NCT03421561|DEVICE|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
219715276|NCT05592197|DRUG|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)
219715277|NCT05592197|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
219715278|NCT05592197|RADIATION|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
219715279|NCT05112120|DRUG|Olumiant|Olumiant (4mg) will be administered in line with standard of care guidance.
219715280|NCT00524498|DRUG|OPC-18|OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
219134102|NCT03875690|DRUG|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
219134103|NCT03875690|DRUG|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
219134104|NCT03875690|BIOLOGICAL|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
219134105|NCT00825435|PROCEDURE|Coronary CT Angiogram|Coronary CT Angiogram
219134106|NCT01854437|DRUG|Mg Oxide|250 mg orally for 4 weeks
219134107|NCT00618540|BIOLOGICAL|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
219134108|NCT00618540|DRUG|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
219134109|NCT00618540|DRUG|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
219134110|NCT00618540|PROCEDURE|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
219134111|NCT00957229|DRUG|GDC-0449|capsule, 150 mg, one pill daily, 18 months
219134112|NCT00727584|RADIATION|radiation therapy|Patients undergo external beam radiotherapy
219134113|NCT01161719|BEHAVIORAL|parent training|Behavioral management skill training
219715281|NCT00524498|DRUG|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
219715282|NCT04316715|BEHAVIORAL|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
219134114|NCT00606580|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
219715283|NCT04316715|BEHAVIORAL|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
219715284|NCT04949451|DIETARY_SUPPLEMENT|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
219715285|NCT04949451|DIETARY_SUPPLEMENT|Ketogenic aid|Participants consume ketogenic aid upon waking.
219715286|NCT04949451|OTHER|Control group - time restricted feeding only|Time restricted feeding.
219715287|NCT00001073|DRUG|Isotretinoin|
219715288|NCT00119704|DRUG|Botulinum toxin A injection or normal saline|
219715289|NCT05008770|OTHER|No intervention|No intervention
219134115|NCT00606580|DRUG|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
219715290|NCT03506477|DRUG|Enstilar® foam|for 4 weeks
219715291|NCT03506477|DRUG|Vehicle foam|for 4 weeks
219134116|NCT00606580|DRUG|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
219134117|NCT03326479|DIAGNOSTIC_TEST|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
219715292|NCT05974332|DIAGNOSTIC_TEST|Oncostatin M|Test to diagnosis of Ulcerative colitis
219715293|NCT01940848|DRUG|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
219715294|NCT01940848|DRUG|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
219715295|NCT05833815|DRUG|Everolimus 10 mg|Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
219715296|NCT05833815|DRUG|Standard of care|GemOx or CapOx
219715297|NCT02588287|OTHER|Blood draws for tenofovir PK, renal function|
219134118|NCT05037032|DRUG|Naltrexone Pill|50 mg PO one-time only
219134119|NCT05037032|DRUG|Placebo|Matching placebo for naltrexone
219134120|NCT05416450|DEVICE|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
219134121|NCT00028132|DRUG|Tenofovir|
219134122|NCT06463171|DRUG|Almonertinib|"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."
219134123|NCT03901729|DRUG|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
219134124|NCT03901729|OTHER|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
219134125|NCT03901729|DRUG|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
219134126|NCT03901729|OTHER|Placebo Furosemide|Tablet; Once daily in the morning; Oral
219715298|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
219715299|NCT05065996|DIAGNOSTIC_TEST|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
219715300|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
219715301|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
219715302|NCT03678129|DRUG|AZD7325_10|Single oral dose (10mg)
219715303|NCT03678129|DRUG|AZD7325_20|Single oral dose (20mg)
219715304|NCT03678129|DRUG|Placebo|Single oral dose placebo (capsule)
219715305|NCT03678129|DRUG|Clobazam|Single dose (5mg)
219715306|NCT06348225|BEHAVIORAL|Exercise|Participants will walk on a treadmill for 30 minutes at 55-60% of heart rate reserve. The treadmill will be set at 2mph and 2% grade, then be adjusted in the first 5 minutes to achieve target heart rate.
219715307|NCT06348225|OTHER|Heat Therapy|Participants will place their legs in a deep leg bath (mid-calf) set to 42C for 45 minutes.
219715308|NCT06348225|OTHER|Sham leg bath|Participants will place their legs in a deep leg bath (mid-calf) set to 36C for 45 minutes.
219715309|NCT02717611|DRUG|ACP-196 (acalabrutinib)|ACP-196 100 mg to be administered orally (PO) twice a day BID.
219134127|NCT05037344|BEHAVIORAL|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
219134128|NCT04974489|BEHAVIORAL|Emotion-based messages about the harm of VLNC|Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
219134129|NCT04974489|BEHAVIORAL|Continued-harm-framed messages about the harm of VLNC|Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
219134130|NCT04974489|BEHAVIORAL|Myth-refuting messages about the harm of VLNC|Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
219227730|NCT01758549|OTHER|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
219715310|NCT04310826|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary magnesium intervention
219715311|NCT04310826|OTHER|Media Intervention|Undergo video interviews
219715312|NCT04310826|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
219715313|NCT05777681|PROCEDURE|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
219715314|NCT06974058|DIETARY_SUPPLEMENT|Nasafytol® (Quercetin/Curcumin Supplement)|Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.
219715315|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.
219715316|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants initiating a CDK 4/6 i after progression on ET.
219715317|NCT03896737|DRUG|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
219134131|NCT04974489|BEHAVIORAL|Control messages about littering|Participants in this arm will receive 3 control messages about littering during the survey data collection.
219134132|NCT01735929|PROCEDURE|Neck Liposuction and Ultrasound Treatment|
219134133|NCT01735929|PROCEDURE|Sham Treatment|
219134134|NCT04301388|PROCEDURE|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
219134135|NCT01396109|PROCEDURE|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
219134136|NCT01396109|PROCEDURE|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
219134137|NCT03744117|OTHER|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
219134138|NCT03148054|DEVICE|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
219227731|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
219227732|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
219227733|NCT05995691|DRUG|ABP 501|SC injection
219227734|NCT05995691|DRUG|Adalimumab|SC injection
219227735|NCT03592407|DRUG|Epacadostat|Given PO
219227736|NCT03592407|OTHER|Laboratory Biomarker Analysis|Correlative studies
219227737|NCT03592407|BIOLOGICAL|Pembrolizumab|Given IV
219227738|NCT03592407|OTHER|Pharmacodynamic Study|Correlative studies
219715318|NCT03896737|DRUG|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
219715319|NCT05544929|DRUG|KFA115|Immunomodulatory agent
219715320|NCT05544929|DRUG|pembrolizumab|Anti-PD-1 antibody
219715321|NCT05600907|BIOLOGICAL|JSP191|A monoclonal antibody that targets human CD117
219715322|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
219715323|NCT05960773|DRUG|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
219715324|NCT02364713|BIOLOGICAL|Bevacizumab|Given IV
219715325|NCT02364713|DRUG|Gemcitabine Hydrochloride|Given IV
219134139|NCT00623246|BEHAVIORAL|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
219715326|NCT02364713|OTHER|Laboratory Biomarker Analysis|Correlative studies
219134140|NCT00623246|BEHAVIORAL|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
219715327|NCT02364713|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
219715328|NCT02364713|DRUG|Paclitaxel|Given IV
219134141|NCT01794377|BEHAVIORAL|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~* 30 sec at 120% of Vo2max,~* 1 min at 50% of Vo2max,~* 15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~* 1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
219134142|NCT01794377|BEHAVIORAL|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
219134143|NCT03389581|BEHAVIORAL|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
219227739|NCT04256395|OTHER|mobile internet survey on self-test|1\. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
219715329|NCT02364713|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219715330|NCT02364713|OTHER|Quality-of-Life Assessment|Ancillary studies
219715331|NCT02364713|DRUG|Topotecan Hydrochloride|Given IV
219715332|NCT06136403|DRUG|deucravacitinib|treatment by deucravacitinib in two phases of challenge
219715333|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
219715334|NCT06300138|DRUG|Itraconazole|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months
219715335|NCT06300138|DEVICE|Infrared thermotherapy apparatus|infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
219715336|NCT06300138|OTHER|Itraconazole and Infrared thermotherapy apparatus|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
219715337|NCT05546814|PROCEDURE|Sodium algorithm|Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
219134144|NCT02028130|PROCEDURE|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
219134145|NCT01250002|DRUG|Placebo|Placebo will receive the same volume of saline infusion.
219134146|NCT01250002|DRUG|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
219134147|NCT00466791|DRUG|Methylphenidate Transdermal System|Placebo
219134148|NCT01319435|PROCEDURE|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
219134149|NCT00029380|DRUG|Sangstat|
219134150|NCT00029380|DRUG|Cyclophosphamide|
219134151|NCT00029380|DRUG|Busulfan|
219134152|NCT00029380|DRUG|Mycophenolate Mofetil|
219134153|NCT00029380|DRUG|Cyclosporine|
219134154|NCT00029380|PROCEDURE|Cord Blood Transplantation|
219134155|NCT01297972|BIOLOGICAL|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
219134156|NCT05290740|DRUG|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
219134157|NCT05290740|DRUG|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
219134158|NCT02665130|OTHER|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
219134159|NCT02665130|OTHER|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
219134160|NCT04776486|DRUG|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
219715338|NCT05013138|BEHAVIORAL|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
219134161|NCT02430181|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
219715339|NCT05013138|BEHAVIORAL|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
219715340|NCT05611970|DEVICE|Vaginal pessary|A reusable vaginal pessary for stress urinary incontinence
219715341|NCT06462976|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
219715342|NCT05185440|BEHAVIORAL|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
219715343|NCT05185440|BEHAVIORAL|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
219715344|NCT05185440|BEHAVIORAL|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
219715345|NCT00325416|DRUG|melphalan|(Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
219715346|NCT00325416|DRUG|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)"
219715347|NCT00325416|PROCEDURE|Autologous Stem Cell Rescue|Day 0
219715348|NCT05847790|DEVICE|Invu monitoring belt|INVU monitoring belt used for remote NSTs
219715349|NCT05847790|OTHER|Standard of care|In-clinic NSTs - standard of care
219715350|NCT04608552|BEHAVIORAL|OMT Exercises|Oral and oropharyngeal exercises
219715351|NCT04608552|BEHAVIORAL|Nasal Breathing Exercises|Nasal breathing exercises each week
219715352|NCT04608552|OTHER|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
219715353|NCT06429241|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
219134162|NCT02430181|DRUG|peginterferon alfa-2a|immunomodulator
219134163|NCT02430181|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
219134164|NCT04127539|BEHAVIORAL|Strong & Steady exercise program|The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
219227740|NCT00043589|DRUG|donepezil|
219715354|NCT05368649|OTHER|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
219715355|NCT04589650|DRUG|Alpelisib|Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily.
219715356|NCT04589650|DRUG|Placebo|Participants will receive matching placebo once daily up to week 16.
219715357|NCT04993261|PROCEDURE|Dual-Energy Computed Tomography|Undergo dual energy CT scan
219715358|NCT02404571|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
219715359|NCT00639184|OTHER|Early intervention counseling|Bi-monthly home visits by counselor
219715360|NCT00639184|OTHER|Health education counseling|World Health Education health education counseling program at home visits,twice per month
219715361|NCT04156698|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
219715362|NCT04156698|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
219715363|NCT04156698|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
219134165|NCT03014687|DRUG|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
219227741|NCT00043589|PROCEDURE|Memory-training class|
219227742|NCT04262115|BEHAVIORAL|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
219227743|NCT04262115|BEHAVIORAL|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
219227744|NCT00134186|DRUG|motexafin gadolinium|
219715364|NCT04156698|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
219715365|NCT01267578|BIOLOGICAL|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
219715366|NCT02324153|DRUG|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
219715367|NCT02324153|DRUG|Microcrystalline Cellulose|Placebo Comparator
219715368|NCT02324153|DRUG|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
219715369|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
219715370|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
219227745|NCT02858115|OTHER|Fluid challenge|100 ml of crystalloid was infused over 1-min
219227746|NCT02858115|OTHER|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
219227747|NCT05850624|OTHER|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
219227748|NCT05850624|OTHER|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
219227749|NCT00774059|DEVICE|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
219227750|NCT02446275|OTHER|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
219715371|NCT01814540|DIETARY_SUPPLEMENT|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
219715372|NCT01814540|DIETARY_SUPPLEMENT|Placebo Glucose Polymer|
219715373|NCT03122106|BIOLOGICAL|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
219715374|NCT03122106|DEVICE|TDS-IM Electrode Array System|-Ichor Medical Systems
219715375|NCT03122106|PROCEDURE|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
219715376|NCT05237375|OTHER|The MIDWIZE model|"So-called MIDWIZE ambassadors are planned to be appointed to lead the clinical implementation of the quality improvement components.~Initial training workshops will be held with the ambassadors on practical aspects of the chosen components and how to explain their benefits to the units' staff. Training will also be provided on how to enhance interdisciplinary teamwork and coordinate quality improvements. The workshops will be held onsite at Naguru hospital and online via the project's MIDWIZE virtual platform. The ambassadors will themselves hold training workshops to support midwives and other healthcare providers at the clinics during the implementation of the quality improvements components. The virtual MIDWIZE platform will contain videos, posters, presentations, and other training material that the ambassadors can utilise to enhance the units' capacity and engage their colleagues."
219715377|NCT01214278|DRUG|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
219715378|NCT01214278|DRUG|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
219715379|NCT01214278|DRUG|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
219715380|NCT01214278|DRUG|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
219715381|NCT06310863|DEVICE|LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers|"Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box"
219134166|NCT03014687|DRUG|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
219715382|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219715383|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
219134167|NCT01188486|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
219134168|NCT01188486|RADIATION|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
219134169|NCT01188486|DEVICE|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
219715384|NCT03279458|DEVICE|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
219715385|NCT05413421|DRUG|ORIC-944|Oral, once daily, continuous
219715386|NCT05413421|DRUG|Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets|Oral, 1000 mg once daily, continuous
219715387|NCT05413421|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|Oral, 240 mg once daily, continuous
219715388|NCT05413421|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|Oral, 600 mg twice daily, continuous
219134170|NCT01188486|DEVICE|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
219134171|NCT01188486|DEVICE|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
219134172|NCT01188486|DRUG|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
219134173|NCT01188486|DRUG|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
219134174|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
219134175|NCT01316978|DRUG|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
219134176|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
219134177|NCT05203055|DRUG|Peginterferon alpha-2b|180μg/w
219134178|NCT05203055|DRUG|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
219227751|NCT02446275|OTHER|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
219227752|NCT03616015|BIOLOGICAL|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
219227753|NCT03616015|BIOLOGICAL|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
219227754|NCT03616015|BEHAVIORAL|Anxiety test|Test of Spielberger
219715389|NCT05413421|DRUG|Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets|Oral, 160 mg once daily, continuous
219715390|NCT02352194|OTHER|Rehabilitation|Physiotherapy and physical activity
219715391|NCT06387017|DIAGNOSTIC_TEST|blood sampling|blood collection
219715392|NCT06387017|DIAGNOSTIC_TEST|stool collection|stool collection
219715393|NCT06387017|RADIATION|low dose CT scan|low dose CT scan evaluation
219715394|NCT02871102|PROCEDURE|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
219134179|NCT05203055|DRUG|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
219134180|NCT00923676|DRUG|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
219134181|NCT00923676|DRUG|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
219227755|NCT03616015|BEHAVIORAL|Stress test|Test of Cohen
219227756|NCT01737749|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
219134182|NCT00923676|DRUG|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
219134183|NCT04322656|DEVICE|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
219134184|NCT06293547|DRUG|Silver Diamine Fluoride|Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
219134185|NCT01972139|DEVICE|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
219134186|NCT01972139|OTHER|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
219134187|NCT01972139|DEVICE|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
219134188|NCT00578214|DRUG|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
219134189|NCT00578214|OTHER|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
219134190|NCT00578214|DRUG|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
219227757|NCT02106884|DRUG|Nab-paclitaxel|
219715395|NCT03834090|DEVICE|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
219715396|NCT03834090|OTHER|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
219715397|NCT03167918|DRUG|Calcium Dobesilate|gave each patient 0.5 g bid，
219134191|NCT00578214|DRUG|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
219715398|NCT03167918|DRUG|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
219715399|NCT03167918|DRUG|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
219715400|NCT03167918|DRUG|metformin|gave each patient 1000 mg, bid, PO
219134192|NCT02162238|DEVICE|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
219134193|NCT00238316|DRUG|letrozole|2.5 mg PO daily for 1 year
219227758|NCT02106884|DRUG|Gemcitabine|
219227759|NCT00898521|DRUG|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
219715401|NCT03167918|DRUG|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
219715402|NCT04343144|DRUG|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
219715403|NCT03290768|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
219715404|NCT03290768|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
219134194|NCT00238316|OTHER|Placebo|2.5 mg PO daily for one 1 year
219134195|NCT02615522|DEVICE|BPK-S Integration|
219134196|NCT00589732|DRUG|Valsartan|Valsartan 160mg per day
219134197|NCT00667693|DEVICE|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
219134198|NCT00667693|DEVICE|Pentax AWS|Intubation with Pentax AWS
219134199|NCT02020018|DEVICE|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
219134200|NCT02020018|OTHER|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
219134201|NCT03492632|OTHER|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
219134202|NCT04002128|OTHER|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
219134203|NCT03976609|PROCEDURE|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
219134204|NCT04044664|DRUG|Placebo oral capsule|Matching placebo capsules.
219134205|NCT04044664|DRUG|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
219134206|NCT02518243|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
219134207|NCT00454662|DRUG|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
219134208|NCT00454662|DRUG|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
219134209|NCT06140849|DIAGNOSTIC_TEST|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
219134210|NCT03369587|BEHAVIORAL|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
219134211|NCT00392418|DRUG|Multiple micronutrient supplement (iron)|
219134212|NCT02709343|DRUG|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
219134213|NCT02709343|DRUG|Placebo|Placebo product visually very similar to mesenchymal stromal cells
219134214|NCT00045916|PROCEDURE|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
219134215|NCT00045916|DRUG|Nortriptyline|Participants will receive nortriptyline.
219134216|NCT00045916|DRUG|Venlafaxine|Participants will receive venlafaxine.
219134217|NCT00045916|DRUG|Lithium|Participants will receive lithium.
219134218|NCT00045916|PROCEDURE|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
219134219|NCT03658941|PROCEDURE|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
219134220|NCT03658941|PROCEDURE|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
219134221|NCT01982643|DRUG|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
219134222|NCT01106729|DIETARY_SUPPLEMENT|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
219134223|NCT03736785|DRUG|LY3209590|Administered SC
219134224|NCT03736785|DRUG|Insulin Degludec|Administered SC
219134225|NCT02605434|DRUG|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
219227760|NCT03315065|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
219227761|NCT02376309|BEHAVIORAL|Inactivity|Inactivity
219134226|NCT02605434|DRUG|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
219134227|NCT02605434|DRUG|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
219134228|NCT02605434|DRUG|Placebo- Sinemet|Placebo for Sinemet tables
219134229|NCT01236989|PROCEDURE|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
219134230|NCT01236989|PROCEDURE|Non-anatomical liver resection|non-anatomical liver resection
219134231|NCT06161064|DRUG|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
219134232|NCT01539603|DEVICE|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
219134233|NCT01539603|DEVICE|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
219134234|NCT01744691|DRUG|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
219134235|NCT03046290|PROCEDURE|circumcision|
219134236|NCT03046290|DRUG|Lidocaine|
219134237|NCT03046290|DRUG|Ropivacaine|
219134238|NCT01895257|DEVICE|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan"
219134239|NCT01895257|DRUG|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
219134240|NCT00000456|DRUG|naltrexone (Revia)|
219134241|NCT00000456|BEHAVIORAL|cognitive behavior therapy|
219134242|NCT00000456|BEHAVIORAL|motivational enhancement therapy|
219134243|NCT01700790|DRUG|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
219134244|NCT00198172|DRUG|Cisplatin plus Epirubicin|
219134245|NCT01034943|PROCEDURE|External fixation|Operation with external fixation and optional addition of k-wire
219227762|NCT02376309|DRUG|ND|1 nandrolone decanoate injection
219227763|NCT02376309|DIETARY_SUPPLEMENT|Leu|Leucine supplements
219227764|NCT03192709|DRUG|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
219227765|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
219227766|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
219134246|NCT01034943|PROCEDURE|Volar plate|Operation with a Synthes volar two column plate (TCP)
219134247|NCT03327155|DRUG|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
219134248|NCT05513690|PROCEDURE|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion and intrauterine temperature probe sensor
219134249|NCT04588480|BIOLOGICAL|BNT162b2|BNT162b2 (intramuscular injection)
219134250|NCT04588480|OTHER|Placebo|Placebo (intramuscular injection)
219134251|NCT03828162|DRUG|Anticoagulants|
219134252|NCT06213051|DEVICE|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
219134253|NCT04406168|PROCEDURE|urinary diversion|follow up outcomes of urinary diversion
219134254|NCT02814305|BEHAVIORAL|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
219134255|NCT02814305|BEHAVIORAL|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
219134256|NCT00921830|DRUG|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
219715405|NCT03290768|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
219715406|NCT00065871|BEHAVIORAL|Contraceptive Screening by Pharmacist|
219134257|NCT02578212|OTHER|Placebo|
219134258|NCT05523258|BEHAVIORAL|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
219134259|NCT05523258|BEHAVIORAL|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
219134260|NCT03762330|BEHAVIORAL|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
219134261|NCT03691961|OTHER|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
219134262|NCT03691961|DIAGNOSTIC_TEST|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
219134263|NCT01913119|DRUG|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
219134264|NCT04966572|DEVICE|Presurgical vacuum formed nasoalveolar molding aligners|at first visit, the infants will receive this appliance which is a maxillary vacuum plate incorporated with palatal screw, the infant's parents will be instructed to activate the screw and apply horizontal tap which will be placed at the base of nose in order to approximate lip segments and to change tape daily. After that, The infants will be recalled one week after the first visit to add the nasal stents into the appliance.
219134265|NCT04966572|DEVICE|Conventional Grayson acrylic formed nasoalveolar molding appliances|"at first visit, the infants will receive this appliance which is a maxillary acrylic plate without adding taping, the infants will be recalled bi weekly for activating the appliance.~When the cleft alveolar gap is reduced to 6mm or less, a pair of nasal stents will be added to mold the nasal cartilage. the infants will be followed up for 4-6 months."
219134266|NCT03354169|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
219134267|NCT00513734|OTHER|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
219134268|NCT00513734|OTHER|Lacrilube ointment|lubricant put into eye (inferior formix)
219134269|NCT03651531|DRUG|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
219134270|NCT03651531|DRUG|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
219134271|NCT01549652|DRUG|Ondansetron|Ondansetron 8 mg oral tablet
219134272|NCT01549652|DRUG|Placebo|Placebo to Match Ondansetron
219134273|NCT01549652|DRUG|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
219134274|NCT01549652|DRUG|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
219134275|NCT01549652|DRUG|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
219134276|NCT05936892|OTHER|upper extremity aerobic training|upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
219134277|NCT05936892|OTHER|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
219715407|NCT00065871|BEHAVIORAL|Contraceptive Prescribing by Pharmacist|
219715408|NCT03907345|BEHAVIORAL|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
219134278|NCT02932358|OTHER|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
219134279|NCT02932358|OTHER|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
219134280|NCT00546520|DRUG|Ciclesonide|
219134281|NCT00789919|PROCEDURE|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
219715409|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
219715410|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
219227767|NCT03120026|DIETARY_SUPPLEMENT|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
219715411|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
219715412|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
219715413|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
219715414|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
219715415|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
219715416|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
219715417|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
219715418|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
219715419|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
219715420|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
219715421|NCT04055870|PROCEDURE|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
219715422|NCT02603900|DRUG|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
219715423|NCT02603900|DRUG|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
219134282|NCT05853224|DEVICE|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine|The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
219134283|NCT00560014|DIETARY_SUPPLEMENT|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
219134284|NCT00560014|DIETARY_SUPPLEMENT|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
219134285|NCT03707678|DRUG|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
219134286|NCT03707678|DRUG|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
219227768|NCT03120026|DIETARY_SUPPLEMENT|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
219134287|NCT03707678|DRUG|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
219134288|NCT03707678|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
219134289|NCT03707678|OTHER|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
219134290|NCT03707678|OTHER|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
219134291|NCT02512042|DRUG|Test-Brinzolamide 1% Ophthalmic suspension|
219715424|NCT02603900|DEVICE|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
219134292|NCT02512042|DRUG|Reference-Brinzolamide 1% Ophthalmic suspension|
219134293|NCT04299230|DEVICE|Cortium C3|
219134294|NCT05147506|DEVICE|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
219134295|NCT05147506|OTHER|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
219134296|NCT00065052|BEHAVIORAL|Behavior modification|
219134297|NCT05653037|DRUG|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
219227769|NCT05815420|DEVICE|Non invasive ventilation|Treatment by non invasive ventilation
219227770|NCT03567278|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
219715425|NCT02603900|DEVICE|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
219715426|NCT03550209|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
219715427|NCT03550209|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
219715428|NCT05718596|OTHER|sweeps laser to use irrigation activation|The SWEEPS fiber tip (25 µs ultra-short dual pulse mode-Auto SWEEPS mode) was inserted into the Er:YAG laser source (2,940 nm, 20 mJ per pulse, 15 Hz, 0.3 W power, and 50 µs pulse frequency). 3% NaOCl solution was activated in three periods of 20 s. Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
219134298|NCT05653037|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
219134299|NCT04881136|DEVICE|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
219134300|NCT04617353|PROCEDURE|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
219134301|NCT04617353|PROCEDURE|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
219715429|NCT05718596|OTHER|PUI to use irrigation activation|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 2 mm behind the working length without touching the canal walls.
219715430|NCT03829384|BIOLOGICAL|mRNA-1944|mRNA encoding Chikungunya antibody
219715431|NCT03829384|OTHER|Placebo|Saline
219715432|NCT00143572|DRUG|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
219715433|NCT06319118|DRUG|Placebo|placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
219715434|NCT06319118|DRUG|dihydroergotine mesylate sustained-release tablets|Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
219715435|NCT04254757|PROCEDURE|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
219715436|NCT02555878|DRUG|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
219715437|NCT02555878|DRUG|Placebo|Placebo tablet will be administered orally once daily for 180 days.
219715438|NCT00765076|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
219715439|NCT00765076|BIOLOGICAL|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
219715440|NCT05234671|OTHER|Exercise programme|12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
219715441|NCT05948488|OTHER|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
219715442|NCT06251947|DRUG|Efbemalenograstim Alfa|Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
219715443|NCT00594139|BIOLOGICAL|Autologous neobladder construct|provision of an autologous neo-bladder construct
219715444|NCT00632294|PROCEDURE|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
219715445|NCT02875080|DRUG|OPC-34712|
219227771|NCT02161458|DRUG|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
219715446|NCT02701491|DIETARY_SUPPLEMENT|Ginger|ginger
219715447|NCT02701491|OTHER|Placebo|Placebo
219715448|NCT06439680|OTHER|"HASCV-R Health Programme"|"HASCV-R program Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
219715449|NCT05042297|PROCEDURE|Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention|Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
219715450|NCT01812915|DEVICE|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
219715451|NCT01812915|DEVICE|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
219715452|NCT06069089|RADIATION|Dexa scan|No intervention
219715453|NCT00768053|DRUG|Etanercept|Etanercept 50 mg once a week
219134302|NCT03376399|OTHER|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
219715454|NCT02066116|PROCEDURE|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
219715455|NCT02066116|OTHER|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
219134303|NCT05312866|PROCEDURE|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
219134304|NCT05312866|PROCEDURE|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
219134305|NCT04067960|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
219134306|NCT04067960|OTHER|Genetic Testing|Undergo pharmacogenomics testing
219134307|NCT04067960|OTHER|Quality-of-Life Assessment|Ancillary studies
219134308|NCT04067960|OTHER|Questionnaire Administration|Ancillary studies
219134309|NCT04643405|DRUG|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
219715456|NCT00304577|PROCEDURE|Bilateral recession|
219134310|NCT04643405|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
219134311|NCT04643405|DRUG|Nab paclitaxel|Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
219134312|NCT04178954|DIAGNOSTIC_TEST|semen fluid analysis|semen fluid analysis
219134313|NCT02179281|DEVICE|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
219134314|NCT01129778|DRUG|Zegerid (proton pump inhibitor)|
219134315|NCT01129778|PROCEDURE|Bravo pH monitoring|
219134316|NCT02971930|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
219134317|NCT03523962|DRUG|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
219134318|NCT03523962|DRUG|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
219134319|NCT05975788|DRUG|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
219134320|NCT03651713|BEHAVIORAL|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
219134321|NCT03651713|DIETARY_SUPPLEMENT|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
219134322|NCT04321642|DRUG|Entonox|Entonox gas with mouth piece
219134323|NCT04321642|DRUG|Not receive Entonox|Not receive any gas
219134324|NCT03168646|PROCEDURE|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
219715457|NCT00304577|PROCEDURE|Unilateral recession and resection|
219134325|NCT03168646|PROCEDURE|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
219134326|NCT06644430|PROCEDURE|Ablation|Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
219134327|NCT06644430|DRUG|system therapy|Paticipants received systemic therapy according the instructions.
219134328|NCT02606409|DRUG|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
219134329|NCT02606409|DRUG|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
219715458|NCT02756897|DRUG|Ibrutinib|Given PO
219715459|NCT02756897|OTHER|Laboratory Biomarker Analysis|Correlative studies
219715460|NCT02756897|DRUG|Venetoclax|Given PO
219715461|NCT01164475|DRUG|Granulocyte-colony stimulating factor (G-CSF)|
219715462|NCT01164475|DRUG|Fixed Dose Plerixafor|
219715463|NCT01164475|DRUG|Weight-Based Plerixafor|
219715464|NCT05991817|PROCEDURE|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
219715465|NCT02349880|BEHAVIORAL|shared decision making training|
219715466|NCT02959268|DEVICE|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
219715467|NCT02574091|DRUG|1% icotinib hydrochloride cream|Topical administration for twice daily
219715468|NCT02574091|DRUG|2% icotinib hydrochloride cream|Topical administration for twice daily.
219715469|NCT02574091|DRUG|Placebo|Topical administration for twice daily.
219715470|NCT01634594|DRUG|Group R|
219715471|NCT01634594|DRUG|Group N|
219715472|NCT01634594|DRUG|Group D|
219715473|NCT05267457|OTHER|Plasma vanadium concentration|Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
219715474|NCT04733885|DEVICE|Experimental|Current application will be made in the frequency range of 20-50 Hz. The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh.ES applications will be performed in the supine position with head and knee pillow supported.
219715475|NCT04733885|DEVICE|Control|The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh. The same device used in ES application to the sham group will be attached to the patients, however, active ES will not be issued from the device and only vacuum will turn on. ES applications will be performed in the supine position with head and knee pillow supported.
219715476|NCT00437762|DRUG|Botulinum Toxin A Injection|Botulinum Toxin A Injection
219715477|NCT00437762|DRUG|Placebo injection|Placebo Injection
219715478|NCT04235855|DEVICE|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
219715479|NCT04235855|DEVICE|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
219134330|NCT05933122|OTHER|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
219715480|NCT01719328|BEHAVIORAL|Vinyasa yoga|
219715481|NCT02205021|OTHER|No intervention|
219715482|NCT02247544|DRUG|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
219134331|NCT05933122|OTHER|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
219134332|NCT06041893|DRUG|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
219134333|NCT03727854|DIETARY_SUPPLEMENT|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
219134334|NCT03727854|BEHAVIORAL|Dietary modification|Subjects in this group will follow diabetes diet education.
219134335|NCT05005065|DRUG|IN-C005 X mg|Oral capsule
219134336|NCT05005065|DRUG|IN-A001 Y mg|Oral tablet
219134337|NCT05005065|DRUG|IN-C005 Y mg|Oral capsule
219715483|NCT04455932|DIAGNOSTIC_TEST|Abbreviated non-contrast MRI of the liver|every 6 months
219715484|NCT04455932|DIAGNOSTIC_TEST|Ultrasound surveillance|every 6 months
219715485|NCT04455932|DIAGNOSTIC_TEST|Multiphase contrast-enhanced liver MRI|screening
219715486|NCT01859091|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219715487|NCT06645847|OTHER|Ketone ester|"Ketone ester (KE) (Chemical name: Bis-octanoyl-(R)-1,3-butanediol, Common name: C8 ketone di-ester) formulated as a dietary supplement.~KE 12.5 g per day for 1 week; followed by KE 25 g per day for 1 week; followed by KE 37.5 g per day split into two doses for 1 week; followed by KE 50 g per day split into two doses for 17 weeks"
219715488|NCT06645847|OTHER|Placebo Comparator: Non-ketone placebo|Placebo oil (non-ketogenic canola oil) formulated as a dietary supplement. Placebo oil 12.5 g per day for 1 week; followed by Placebo oil 25 g per day for 1 week; followed by Placebo oil 37.5 g per day split into two doses for 1 week; followed by Placebo oil 50 g per day split into two doses for 17 weeks
219715489|NCT05306353|DRUG|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
219715490|NCT05306353|DRUG|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
219715491|NCT05306353|DRUG|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
219715492|NCT04603066|DRUG|Ondansetron 16 mg with Tariquidar|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
219715493|NCT04603066|DRUG|Ondansetron 16 mg with Placebo|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
219134338|NCT05005065|DRUG|IN-C005 Z mg|Oral capsule
219134339|NCT00889694|DRUG|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
219134340|NCT00889694|DRUG|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
219134341|NCT00889694|DRUG|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
219134342|NCT01640821|BEHAVIORAL|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
219715494|NCT04020172|DRUG|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
219715495|NCT02363660|BIOLOGICAL|GINI|
219715496|NCT00649948|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
219715497|NCT00649948|DRUG|Glucophage XR 500 mg|500mg, single dose fed
219715498|NCT04608630|DRUG|Denosumab 60 MG/ML|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
219715499|NCT04608630|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
219715500|NCT04608630|DRUG|Sodium Chloride 0.9% or 5% Dextrose Intravenous|Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
219134343|NCT06442254|OTHER|Virtual Reality|In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
219134344|NCT06513234|DRUG|Orelabrutinib and obinutuzumab|Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
219715501|NCT04608630|DRUG|Sodium Chloride 0.9% Injection|Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
219715502|NCT06078540|OTHER|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;"
219715503|NCT06666452|BEHAVIORAL|COMFI - a COMbined Fatigue Intervention|The COMFI intervention is a 24-week group-based outpatient fatigue intervention consisting of 1) Six group sessions based on CBA covering topics such as fatigue and related factors, PA, trying out PA, energy management, and enhancing peer support 2) a seventh group session intended as a booster session in week 24, 3) one optional individual session in week 6-9 of the intervention, and 4) a support line in week 13-23 of COMFI.
219715504|NCT05761249|OTHER|HeartInsight activation|HeartInsight is activated at enrollment. The attending physicians are free on how to integrate HeartInsight in the patient care. Any treatment is based on routine care according to guidleines. Only documentation occurs on how the physicians use HeartInsight and actions taken in response to HeartInsight alerts
219715505|NCT04939597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219134345|NCT04696250|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
219134346|NCT03699293|DRUG|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
219134347|NCT03699293|DRUG|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
219134348|NCT03699293|DRUG|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
219134349|NCT05481411|DRUG|Olpasiran|Subcutaneous injection
219134350|NCT00292383|PROCEDURE|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
219134351|NCT04951518|OTHER|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
219134352|NCT01081145|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
219715506|NCT04939597|PROCEDURE|Cognitive Assessment|Complete cognitive testing
219715507|NCT04939597|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219715508|NCT04939597|DRUG|Memantine Hydrochloride|Given PO
219715509|NCT04939597|DRUG|Placebo Administration|Given PO
219134353|NCT01081145|OTHER|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
219134354|NCT01253226|DRUG|LY2127399 (Tabalumab)|Administered subcutaneously
219134355|NCT01253226|DRUG|Placebo|Administered subcutaneously
219134356|NCT02036931|DEVICE|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
219134357|NCT02036931|DRUG|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
219134358|NCT02036931|DEVICE|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
219134359|NCT00046995|DRUG|carboplatin|
219134360|NCT00046995|DRUG|fluorouracil|
219134361|NCT00046995|DRUG|leucovorin calcium|
219134362|NCT00046995|PROCEDURE|adjuvant therapy|
219134363|NCT04609618|DEVICE|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
219134364|NCT00561743|DRUG|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
219134365|NCT01425983|DIETARY_SUPPLEMENT|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
219134366|NCT01425983|OTHER|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
219134367|NCT00988637|DRUG|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
219134368|NCT00988637|DRUG|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
219134369|NCT00745446|PROCEDURE|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
219134370|NCT06453356|DRUG|Zavegepant 10mg|intransal spray 10mg
219134371|NCT01205620|DEVICE|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
219715510|NCT04939597|OTHER|Questionnaire Administration|Ancillary studies
219715511|NCT05609864|OTHER|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
219715512|NCT06386029|BEHAVIORAL|Power Down bedtime manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
219715513|NCT05197426|DRUG|Oral Azacitidine|Specified dose on specified days
219134372|NCT01205620|OTHER|No intervention|No intervention will be performed in the control group
219134373|NCT03593070|BEHAVIORAL|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
219134374|NCT04813952|DRUG|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
219134375|NCT06630312|DIETARY_SUPPLEMENT|Alpha galactosidase|Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
219134376|NCT06630312|DIETARY_SUPPLEMENT|Placebo|Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
219134377|NCT06630468|OTHER|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
219134378|NCT06630468|OTHER|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
219134379|NCT06630988|OTHER|Failure rates|Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
219134380|NCT06630754|OTHER|No Intervention: Observational Cohort|No intervention; observation cohort study
219134381|NCT06631651|PROCEDURE|Brachioradialis release|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
219134382|NCT06631651|PROCEDURE|Brachioradialis not released|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
219134383|NCT06631703|OTHER|Group receiving Oral Colostrum Administiration|Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
219134384|NCT06631690|OTHER|Isokinetic and functional balance tests|Isokinetic and functional balance tests
219134385|NCT06629935|PROCEDURE|orthognathic surgery|Le Fort I surgery
219134386|NCT06631742|OTHER|Exergaming on Dividat Senso|"The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli."
219134387|NCT06631742|OTHER|Usual Care|Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
219134388|NCT04674449|DIAGNOSTIC_TEST|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
219715514|NCT05197426|OTHER|Placebo|Specified dose of specified days
219715515|NCT06254274|DRUG|RAY1225|Administered SC
219715516|NCT06254274|DRUG|Placebo|Administered SC
219134389|NCT04674449|OTHER|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
219134390|NCT04936789|DEVICE|IMES|Surgical implantation of IMES
219715517|NCT06665633|DRUG|Oxygen 100 % Gas for Inhalation|Oxygen 100% Gas for Inhalation in Hyperbaric Oxygen Therapy Chamber at 1.5 ATA
219715518|NCT06665633|DEVICE|Hyperbaric Oxygen Therapy Chamber|Hyperbaric Oxygen Therapy, 40 treatments, at 1.5 ATA and 100% Oxygen
219134391|NCT00574886|BIOLOGICAL|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
219134392|NCT01019616|DRUG|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
219134393|NCT02647749|DEVICE|Cardioinsight® mapping system|
219134394|NCT02647749|OTHER|Conventional method without non-invasive mapping|
219134395|NCT00816829|DRUG|Placebo|Fenofibrate-matching placebo tablet
219134396|NCT00816829|DRUG|Fenofibrate|145 mg NanoCrystal tablet
219134397|NCT03394027|DRUG|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
219134398|NCT06583590|DRUG|Botulinum toxin A|Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.
219134399|NCT06583590|DRUG|Tadalafil 5mg|Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
219134400|NCT05766098|GENETIC|Genotyping|Characterization of genetic profile of tumor tissues
219134401|NCT05557721|PROCEDURE|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
219715521|NCT06668090|BEHAVIORAL|Moderate intensity bike exercise|Participants will do moderate intensity bike exercise for up to one hour thrice weekly for 12 weeks.
219715522|NCT06809582|PROCEDURE|The T-Tilt position|"The T-Tilt position is a modified lithotomy position used during retrograde intrarenal surgery (RIRS). In this position:~The patient is placed in a 30-degree Trendelenburg position, meaning the head is slightly lower than the feet.~The surgical side is elevated at a 30-degree angle to improve access to the kidney.~This modified positioning is designed to enhance stone clearance, particularly by facilitating the movement of stone fragments away from the lower kidney calyces, where residual stones often remain. Researchers will compare this position to the standard lithotomy position to determine its impact on stone-free rates and surgical outcomes."
219715523|NCT05973045|PROCEDURE|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
219227772|NCT02161458|DRUG|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
219227773|NCT02161458|DRUG|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
219227774|NCT02161458|DRUG|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
219715524|NCT05973045|PROCEDURE|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
219134402|NCT05557721|PROCEDURE|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
219134403|NCT06156007|BEHAVIORAL|progressive muscle relaxation exercises|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
219134404|NCT05199025|DIAGNOSTIC_TEST|Biomarker|Perioperative biomarker analyses
219134405|NCT03879447|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
219134406|NCT03879447|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219134407|NCT03879447|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219134408|NCT03879447|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
219134409|NCT03879447|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219134410|NCT03879447|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219134411|NCT03879447|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219134412|NCT03879447|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
219134413|NCT05749029|BEHAVIORAL|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life."
219227775|NCT01078272|OTHER|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
219227776|NCT01078272|OTHER|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
219227777|NCT04547660|BIOLOGICAL|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
219715528|NCT06810583|DRUG|Dalbavancin|3 doses of q28 days dalbavancin (12 weeks).
219715529|NCT06810583|DRUG|Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)|28 days dalbavancin plus fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for up to 3 doses (12 weeks).
219715530|NCT07113587|DRUG|Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis|
219134414|NCT04559724|DEVICE|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
219134415|NCT01766856|OTHER|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
219134416|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
219134417|NCT02197234|DRUG|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
219134418|NCT02197234|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
219134419|NCT02197234|PROCEDURE|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
219134420|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
219134421|NCT05391126|DRUG|Irinotecan|Usual dosing per package insert.
219134422|NCT06555965|OTHER|Non-interventional study|There is no planned intervention in this study
219134423|NCT04427098|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
219227778|NCT04547660|OTHER|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
219227779|NCT04047407|DEVICE|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
219715531|NCT07113587|DRUG|Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis|
219715532|NCT07113587|DRUG|Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis|
219227780|NCT03046706|BEHAVIORAL|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
219227781|NCT03046706|BEHAVIORAL|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
219227782|NCT02476929|DEVICE|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
219227783|NCT02476929|DEVICE|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
219227784|NCT00213278|DRUG|vinblastine sulphate injection|Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
219715533|NCT07113587|DRUG|Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis|
219715534|NCT07114887|BEHAVIORAL|Virtual reality for vocational recovery|Intervention is an immersive virtual reality (VR) intervention, delivered through a VR headset, supported by a trained vocational specialist. Intervention content was co-designed with young people with mental health and vocational challenges, and vocational specialists with experiencing supporting this population. Content was guided by goals of vocational programs, including Individual Placement and Support.
219715535|NCT06827054|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219715536|NCT06827054|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
219715537|NCT06827054|OTHER|Interview|Ancillary studies
219715538|NCT06827054|DRUG|Psilocybine|Given PO
219134424|NCT04427098|DRUG|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
219134425|NCT06314594|PROCEDURE|Conventional treatment|Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines
219134426|NCT06314594|BEHAVIORAL|intervention treatment|"Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy"
219134427|NCT06111508|DEVICE|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
219134428|NCT06310993|OTHER|Exercise|Exercise programme is the intervention for this study
219134429|NCT06141057|BIOLOGICAL|Matrix M with RH5.1|50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.
219227785|NCT02436070|BEHAVIORAL|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
219715539|NCT06827054|BEHAVIORAL|Psychotherapy|Attend psychotherapy sessions
219715540|NCT06827054|OTHER|Questionnaire Administration|Ancillary studies
219715541|NCT07121530|PROCEDURE|HPV infection in infertile males|To investigate the status of HPV infection in infertile males in Qena government, and to Analyse the effects of HPV infection on semen parameters.
219715542|NCT07121244|DRUG|68Ga-R11228|68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions
219715543|NCT07121244|DRUG|177Lu-R11228|177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions
219715544|NCT07119567|OTHER|Multimodal Sleep and Biomarker Assessment|Participants will undergo non-invasive sleep assessments including polysomnography recordings (using the Somfit® device), actigraphy, self-reported questionnaires (on sleep, substance use), and urinary biomarker collection (for cortisol and melatonin levels) at three distinct stages of their substance use/withdrawal timeline.
219715545|NCT07120841|BEHAVIORAL|Telephone Education|Participants in this group will receive telephone follow-up education by a nurse during the two weeks after discharge
219134430|NCT05887323|DEVICE|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
219134431|NCT05893121|OTHER|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
219227786|NCT02436070|BEHAVIORAL|General text messages|Subjects received text messages generalized to children with asthma
219227787|NCT02253966|DRUG|Methylprednisoloneacetate|
219715546|NCT07120841|BEHAVIORAL|Standard Care (in control arm)|Participants in this group will receive standard post-discharge care without any follow-up telephone education
219227788|NCT02253966|DRUG|Lidocaine|
219715547|NCT04597008|DRUG|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed, which is placed right before wound closure at the final stafe of definitive fracture fixation.
219715548|NCT04597008|DRUG|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed, which is placed right before wound closure at the final stage of definitive fracture fixation.
219715549|NCT07125820|OTHER|Experimental Group|There are two groups: a study group and a control group. Both groups will continue taking their doctor-prescribed medications for migraine attacks. After the initial assessment, both groups will receive a 30-minute education and brochure containing lifestyle recommendations to address migraine triggers. The brochure will include recommendations for nutrition, environment, sleep, physical activity, and stress. Additionally, a Chattanooga Cefar® TENS device will be used. The frequency will be set at 100 Hz and the transition time will be set at 100 µs. The session will last 20 minutes. Individuals in the study group will be assigned an exercise program. Patients in this group will exercise in-person three days a week for eight weeks under the supervision of a physical therapist. The program will include cervical stabilization exercises, stretching, and balance exercises. The program is planned with a progression from easy to more difficult every two weeks.
219715550|NCT07125820|OTHER|control group|Individuals in the control group will receive a single session of placebo Chattanooga Cefar® TENS application and home exercise program in addition to drug treatment and patient education.Patients in this group will receive a single session of placebo TENS. Electrodes will be placed as in the study group. The physiotherapist will turn on the device but will not increase the current. Thus, the stimulation light of the device will be on but no current will be delivered. Patients will be told that they will not feel anything during the treatment and that this is a feature of the application. The application will be performed for 20 minutes.Home Exercise Program After the initial evaluation and patient education, patients will be offered an exercise program to be performed at home. This program will only consist of stretching exercises for the trapezius and levator scapula muscles. The exercises will be recommended to be performed once a day, 3 days a week, for 8 weeks with 10 repetitions.
219134432|NCT05893121|OTHER|Information note about MRI|explanatory note about MRI examination
219134433|NCT01018511|DRUG|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
219227789|NCT02253966|OTHER|sodium chloride|
219227790|NCT01560429|PROCEDURE|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
219227791|NCT01560429|PROCEDURE|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
219227792|NCT03837015|DRUG|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
219227793|NCT03837015|OTHER|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
219134434|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
219134435|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
219134436|NCT01018511|DRUG|tamsulosin hydrochloride OCAS 0.4 mg|tablet
219134437|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
219134438|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
219134439|NCT01021930|DEVICE|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
219134440|NCT05048355|DEVICE|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
219134441|NCT05048355|DEVICE|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
219134442|NCT03918577|OTHER|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
219134443|NCT06277817|OTHER|expiratory rib cage compression|Expiratory rib cage compression: The hands are placed on the lower third of the rib cage. During expiration, the end and sides of the patients' rib cage are gradually compressed with the hands.At the end of expiration, compression is released from the thorax to allow patients to take a free inspiration. After each compression, the patient is allowed to perform 3 breathing cycles.Expiratory rib cage compression is applied for 5 minutes.
219227794|NCT05705245|OTHER|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
219715551|NCT06653218|OTHER|No interventions|It is a observational study
219134444|NCT06277817|OTHER|percussion vibration|Percussion :Percussion is performed 3-5 times on each area from a height of approximately 10 cm with the domed hand. . It starts from the right and left lower lobes and goes up.Vibration:The hand is firmly/strongly placed on the application area. The arm and shoulder are stretched and the fingers are gently vibrated or shaken gently. While the patient is exhaling, vibration is performed 3-5 times in each area, starting from the right and left lower lobes.
219134445|NCT02900027|DRUG|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
219134446|NCT02900027|DRUG|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
219134447|NCT06199401|PROCEDURE|Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)|A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
219715552|NCT06653218|OTHER|Not have interventions|It is a observational study
219227795|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
219227796|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
219227797|NCT04028518|DRUG|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
219227798|NCT05586243|OTHER|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
219715553|NCT06977555|BEHAVIORAL|Communication Course and skills training|"A multi module intervention where the nurses will learn about communication with mechanically ventilated patients will be developed. The investigators hypothesize that this intervention will:~1. make it easier for mechanically ventilated ICU patients to communicate their needs and symptoms during mechanical ventilation and to improve their symptom burden.~2. improve ICU nurses' skills in communicating with ICU patients who are unable to speak. This will potentially contribute to better communication with critically ill patients, including those being delirious.~3. improve ICU nurses´ satisfaction with their communication."
219715554|NCT06976476|DRUG|IgPro20|Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump
219134448|NCT04523181|DRUG|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
219134449|NCT04523181|OTHER|Placebo|Capsule without active compound
219134450|NCT01688544|DRUG|Ilaprazole|Ilaprazole 10 mg for 7 days
219134451|NCT00919438|DEVICE|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
219134452|NCT01986374|DRUG|HCG is introduced|must have good blastocysts
219134453|NCT01102361|PROCEDURE|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
219227799|NCT04539015|DEVICE|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
219227800|NCT04810975|DEVICE|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
219227801|NCT02892591|DRUG|Cannabis|vaporized plant material
219227802|NCT02892591|DRUG|Oxycodone|oral capsule
219227803|NCT02892591|DRUG|Placebo for Cannabis|vaporized placebo plant material
219227804|NCT02892591|DRUG|Placebo for Oxycodone|oral placebo capsule
219227805|NCT02025504|DEVICE|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
219227806|NCT00158483|DRUG|Acyclovir (ACV)|
219227807|NCT04924296|DRUG|SHR-1314|SHR-1314 s.c. + Steroids
219227808|NCT04924296|DRUG|Placebo|Placebo s.c. + Steroids
219227809|NCT02285218|OTHER|serum blood sampling|
219227810|NCT05032716|OTHER|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
219227811|NCT05032716|OTHER|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
219227812|NCT04125901|OTHER|Pain Neuroscience Education and Exercise|The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes). The 1st session will be only PNE and will last approximately 45 minutes. In the 2nd session, there will be 30 minutes of PNE and the remaining 15 minutes of exercise. In the following 4th and 6th sessions, 15 minutes of each session will be used to clarify doubts and emphasize PNE concepts and strategies. The 8th session will include exercises only. In WhatsApp sessions, in addition to the video with the exercises, participants will receive activities about the PNE.
219134454|NCT01751997|DRUG|Transplants from 8/8-matched Unrelated donors|"* Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
219227813|NCT04125901|OTHER|Exercise|The exercise group will perform exercises in all sessions (45 minutes of exercise in face-to-face sessions). In WhatsApp sessions, participants will receive a video with exercises to perform at home.
219134455|NCT01751997|DRUG|Transplants from family-mismatched/haploidentical donors|"* Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
219715555|NCT03124355|DRUG|placebo sugar pill|placebo single oral dose
219715556|NCT03124355|DRUG|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
219715557|NCT03124355|DRUG|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
219134456|NCT05684003|OTHER|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
219134457|NCT02755922|BIOLOGICAL|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
219227814|NCT00705159|DRUG|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
219227815|NCT00705159|DRUG|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
219227816|NCT00705159|DRUG|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
219715558|NCT03124355|DEVICE|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
219227817|NCT00705159|DRUG|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
219227818|NCT02564536|DRUG|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
219227819|NCT02564536|DRUG|Decitabine|-From commercial stock
219227820|NCT00188305|BEHAVIORAL|General health counselling and risk information|General health counselling and risk information
219227821|NCT03942575|DEVICE|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
219715559|NCT03124355|DEVICE|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
219715560|NCT07125248|PROCEDURE|Bilateral chest tube placement|Bilateral chest tubes will be passed in this intervention group through intercostal spaces
219715561|NCT07125248|PROCEDURE|Single drain placement|A single transhiatal drain will be placed in mediastinum in this group
219715562|NCT06979128|PROCEDURE|PICC placement|Patient scheduled for PICC placement
219715563|NCT06084247|DEVICE|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
219715564|NCT06084247|DEVICE|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
219134458|NCT01686295|DEVICE|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
219134459|NCT01686295|DEVICE|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
219134460|NCT01462019|DEVICE|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
219134461|NCT06176144|DRUG|Desflurane|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
219134462|NCT06176144|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
219134463|NCT01580943|DRUG|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
219134464|NCT01580943|DRUG|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
219134465|NCT04550039|DEVICE|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
219134466|NCT04550039|DEVICE|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
219134467|NCT04391309|BIOLOGICAL|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
219134468|NCT04391309|OTHER|Placebo|Placebo administered intravenously on Days 1-4
219134469|NCT04391309|DRUG|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
219134470|NCT03514199|OTHER|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
219134471|NCT03514199|OTHER|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
219134472|NCT00322699|PROCEDURE|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
219134473|NCT00322699|DRUG|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
219134474|NCT03459183|DEVICE|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
219134475|NCT03459183|DEVICE|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
219227822|NCT04440800|DEVICE|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
219227823|NCT03736980|DRUG|Placebo|100% lactose
219227824|NCT03736980|DRUG|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
219227825|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
219227826|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
219715565|NCT05583877|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
219715566|NCT05583877|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
219715567|NCT06980480|BIOLOGICAL|IGI, 10%|IGI, 10% IV infusion.
219134476|NCT03459183|DEVICE|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
219227827|NCT03606551|DEVICE|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
219134477|NCT03459183|DEVICE|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
219134478|NCT02292394|BEHAVIORAL|Multicomponent Cognitive Behavioral Telephone Intervention|
219134479|NCT02292394|BEHAVIORAL|Telephone Intervention Pleasant Activities|
219134480|NCT04548622|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
219227828|NCT03385759|PROCEDURE|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
219227829|NCT03385759|PROCEDURE|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
219227830|NCT00349206|DRUG|sorafenib tosylate|Given orally
219227831|NCT00349206|DRUG|temsirolimus|Given IV
219134481|NCT02908620|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
219134482|NCT02908620|DRUG|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
219227832|NCT04275960|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
219227833|NCT02399241|DEVICE|Bluetooth enabled nebuliser device (I-neb)|
219227834|NCT03196869|DEVICE|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
219227835|NCT03196869|DEVICE|Routine intravenous drip|Routine intravenous drip-chemotherap
219227836|NCT03196869|DRUG|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
219227837|NCT03196869|DRUG|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
219227838|NCT03196869|DRUG|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
219227839|NCT03196869|DRUG|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
219227840|NCT03196869|RADIATION|intensity-modulated radiation therapy|control group is similar to Experimental group
219227841|NCT00794300|DEVICE|second magnetic resonance imaging scan|
219227842|NCT03897699|DEVICE|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
219227843|NCT03897699|BEHAVIORAL|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
219227844|NCT03897699|OTHER|Sham|Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
219227845|NCT03026166|DRUG|Ipilimumab|Administered by intravenous infusion
219227846|NCT03026166|DRUG|Nivolumab|Administered by intravenous infusion
219227847|NCT03026166|DRUG|Rovalpituzumab tesirine|Administered by intravenous infusion
219715568|NCT06980012|PROCEDURE|Pharmaceutical consultation|The pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment.
219715569|NCT06980012|PROCEDURE|Pharmaceutical consultation and follow-up|After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.
219715570|NCT05744479|DRUG|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
219134483|NCT02908620|COMBINATION_PRODUCT|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
219227848|NCT06082115|OTHER|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
219715571|NCT05744479|DRUG|Placebo|Oral placebo for 24 weeks
219715572|NCT05744479|BEHAVIORAL|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
219715573|NCT05879146|DRUG|Nirogacestat|Given by PO
219715574|NCT06815627|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
219715575|NCT06841562|BEHAVIORAL|TRAINERa intensive exercise training|Remotely-delivered exercise training intervention
219715576|NCT06815367|DEVICE|Pneumatic Compression|Following downhill running protocol, participants will complete 20 minutes of pneumatic compression at 100 mmHg.
219715577|NCT06815367|DEVICE|Blood Flow Restriction|Following the downhill running protocol, participants will complete 4 rounds of treatment: 3 minutes at 100% resting limb occlusion pressure, 2 minutes of 0% resting limb occlusion pressure.
219715578|NCT06814977|PROCEDURE|Acupuncture|Acupuncture is a non-pharmacological intervention that does not involve the use of any therapeutic agents or devices. Participants will receive 10 weekly treatments over 10 weeks.
219715579|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
219715580|NCT06587113|OTHER|Visual tasks|In the experiments, participants sit in front of a computer screen with their head in a chinrest to control for distance from the monitor and eye-tracking equipment. For the visual search task, participants will search for a visual target among distractors and make a response regarding its orientation. For the stop-signal task, participants will make an eye movement to a target that appears on the screen, except on trials where a visual signal appears indicating they should cancel this behavior. In the useful field of view task, participants will report the location of a briefly-presented and masked target, while also responding to the identify of a central target in some blocks.
219715581|NCT01371981|DRUG|Asparaginase|Given IM
219134484|NCT02908620|DRUG|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
219134485|NCT03025464|DEVICE|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
219134486|NCT02131740|OTHER|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
219227849|NCT06082115|OTHER|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
219227850|NCT06082115|OTHER|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
219715582|NCT01371981|DRUG|Bortezomib|Given IV
219715583|NCT01371981|DRUG|Cytarabine|Given IT or IV
219715584|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
219134487|NCT02131740|OTHER|No eye rubbing|This eye will not be rubbed
219134488|NCT00207129|DRUG|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
219134489|NCT00207129|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
219134490|NCT05921409|DIETARY_SUPPLEMENT|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
219715585|NCT01371981|DRUG|Etoposide|Given IV
219715586|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
219715587|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
219715588|NCT01371981|OTHER|Pharmacological Study|Correlative studies
219715589|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
219715590|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
219715591|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
219715592|NCT06593886|DEVICE|BabyG|This involves wearing a harness connected to the overhead device while in a 10 X 10 play area filled with toys and equipment commonly used for infants to promote mobility skills (e.g. crawling and walking). Families can choose to come for 3 30-minute or 2 45-minute sessions per week. Half of the children will participate in the training immediately after enrollment in the study, the others will wait for 12 weeks before starting training. All will receive a comprehensive assessment at 0, 12 and 24 weeks, with additional developmental assessments at 6 and 18 weeks
219715593|NCT06590727|OTHER|Distress Thermometer|Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.
219715594|NCT06502860|OTHER|skin to skin with sling|In the intervention group, skin-to-skin contact will be facilitated using a specially designed sling. This approach aims to enhance the quality and duration of skin-to-skin contact between the mother and the newborn.
219715595|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
219715596|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
219134491|NCT05921409|DIETARY_SUPPLEMENT|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
219134492|NCT06488599|RADIATION|Peri-apical radiographs on the implants|Peri-apical radiographs on the implants supporting the prosthesis
219134493|NCT05584020|PROCEDURE|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
219134494|NCT05584020|PROCEDURE|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
219715597|NCT06785129|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time
219715598|NCT06785129|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
219715599|NCT06785129|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
219715600|NCT06785129|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
219715601|NCT06785129|BIOLOGICAL|Hormonal assessment|Blood samples (approximately 2 tablespoons) and/or saliva and/or urine will be collected for analyses of sex hormone levels (e.g., prolactin, testosterone, estradiol).
219715602|NCT05447806|DEVICE|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
219715603|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
219715604|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
219715605|NCT03472092|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
219715606|NCT03472092|DRUG|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
219134495|NCT01756287|OTHER|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
219134496|NCT02983214|DRUG|Clopidogrel|
219134497|NCT02983214|DRUG|Cilostazol|
219134498|NCT01201187|DRUG|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
219134499|NCT01201187|DRUG|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
219134500|NCT00639613|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
219134501|NCT00639613|OTHER|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
219134502|NCT00953485|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
219134503|NCT06007144|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only~Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
219134504|NCT02466295|OTHER|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
219134505|NCT02466295|OTHER|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
219134506|NCT00303849|DRUG|Carboplatin|Given IA
219134507|NCT00303849|DRUG|Etoposide|Given IV
219134508|NCT00303849|DRUG|Etoposide Phosphate|Given IV
219134509|NCT00303849|OTHER|Laboratory Biomarker Analysis|Correlative studies
219715607|NCT03472092|DRUG|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
219715608|NCT03472092|BEHAVIORAL|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
219134510|NCT00303849|DRUG|Mannitol|Given IA
219134511|NCT00303849|DRUG|Melphalan|Given IA
219134512|NCT00303849|OTHER|Quality-of-Life Assessment|Ancillary studies
219134513|NCT00303849|DRUG|Sodium Thiosulfate|Given IV
219715609|NCT03472092|BEHAVIORAL|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
219134514|NCT01007708|DRUG|IDP-108|Topical application once a day for 48 weeks
219134515|NCT01007708|DRUG|Vehicle|Topical application once a day for 48 weeks
219134516|NCT03719209|OTHER|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
219134517|NCT03719209|OTHER|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
219134518|NCT03342924|OTHER|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
219134519|NCT05909943|DRUG|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
219134520|NCT04846101|OTHER|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
219134521|NCT04846101|OTHER|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
219134522|NCT04846101|DIAGNOSTIC_TEST|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
219134523|NCT04846101|OTHER|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
219134524|NCT04846101|OTHER|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
219134525|NCT06298188|DRUG|Risankizumab|Risankizumab
219134526|NCT02375516|BEHAVIORAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
219134527|NCT00215306|DEVICE|CHARITÉ Artificial Disc|
219134528|NCT00215306|DEVICE|Anterior Interbody Fusion with BAK Cage|
219134529|NCT03357549|OTHER|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
219134530|NCT03357549|OTHER|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
219134531|NCT04771273|DRUG|Survodutide|Survodutide
219715610|NCT06483737|DRUG|Human albumin infusion at a modified dosage|Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
219715611|NCT06483737|DRUG|Human albumin infusion at a routine dosage|Participants receive intravenous infusion of human albumin according to the current clinical practice.
219715612|NCT06483737|DRUG|Lactulose|All participants will receive standard treatment of overt HE according to the current practice guideline.
219715613|NCT06483737|DRUG|Rifaximin|All participants will receive standard treatment of overt HE according to the current practice guideline.
219715614|NCT06483737|DRUG|Ornithine Aspartate|All participants will receive standard treatment of overt HE according to the current practice guideline.
219134532|NCT04771273|DRUG|Placebo|Placebo
219134533|NCT05974605|BEHAVIORAL|MM+HighC|In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
219134534|NCT02582411|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
219134535|NCT02582411|DEVICE|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
219134536|NCT05751200|OTHER|No Intervention.|No Intervention.
219134537|NCT06155253|PROCEDURE|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 \& L1 in 2ESP group)"
219134538|NCT00164489|BEHAVIORAL|Weight control and physical activity promotion|
219134539|NCT02681276|PROCEDURE|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
219134540|NCT02681276|PROCEDURE|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
219134541|NCT02321358|BEHAVIORAL|Two-time implementation intention|Will be given intervention and booster at six weeks
219134542|NCT02321358|BEHAVIORAL|One-time implementation intention|Will only be given the intervention once
219134543|NCT02321358|BEHAVIORAL|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
219134544|NCT02321358|BEHAVIORAL|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
219134545|NCT03739411|RADIATION|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219134546|NCT03739411|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219134547|NCT03739411|RADIATION|Radiation Therapy|Undergo radiation therapy for cancer outside of this study.
219715615|NCT06483737|DRUG|Branched-Chain Amino Acids|All participants will receive standard treatment of overt HE according to the current practice guideline.
219715616|NCT06483737|DRUG|Arginine|All participants will receive standard treatment of overt HE according to the current practice guideline.
219134548|NCT03739411|DRUG|Chemotherapy|Undergo chemotherapy for cancer outside of this study.
219134549|NCT05542680|DEVICE|cushion|In the intervention group, the special cushion for semi recumbent position was used
219134550|NCT04277689|PROCEDURE|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
219134551|NCT04486729|OTHER|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
219134552|NCT04486729|OTHER|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
219134553|NCT04486729|OTHER|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
219134554|NCT04486729|OTHER|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
219134555|NCT02524444|DRUG|Mefloquine|Tabs Mefloquine 250mg
219134556|NCT02524444|DRUG|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
219134557|NCT02967237|DRUG|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
219134558|NCT01871818|BEHAVIORAL|Combined program|Combined program with physiotherapy, endurance training and resistance training
219134559|NCT01871818|BEHAVIORAL|Physiotherapy in private practice|Physiotherapy in private practice
219134560|NCT00555867|DRUG|Anastrozole|oral
219134561|NCT04541641|PROCEDURE|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
219134562|NCT04541641|PROCEDURE|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
219134563|NCT01943162|BEHAVIORAL|CPT|
219134564|NCT02377206|OTHER|ADAS-Cog evaluation|\[18F\]DPA-714 PET imaging
219134565|NCT04678934|PROCEDURE|TAVR|Transcatheter aortic valve replacement
219134566|NCT03429855|OTHER|trunk training|Bobath based trunk training
219134567|NCT03429855|OTHER|physiotherapy|conventional physiotherapy
219134568|NCT03438487|BIOLOGICAL|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
219134569|NCT03438487|BIOLOGICAL|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
219134570|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
219134571|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
219134572|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
219134573|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
219715617|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
219715618|NCT06662539|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
219715619|NCT06662539|DRUG|Placebo|Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
219715620|NCT05996835|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Immunotherapy Recombinant human CD39 enzyme
219715621|NCT05996835|OTHER|Placebo|0.9% sterile saline solution
219134574|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
219134575|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
219715622|NCT06530576|DRUG|Thalidomide and methotrexate|Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
219715623|NCT06361420|PROCEDURE|Driving pressure-guided positive end expiratory pressure|The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
219715624|NCT06361420|PROCEDURE|Optimal oxygenation-guided positive end expiratory pressure|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
219134576|NCT01372163|DRUG|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
219134577|NCT02712866|DRUG|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
219134578|NCT02063607|BIOLOGICAL|Peginterferon lambda|
219134579|NCT03728036|BEHAVIORAL|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
219134580|NCT06191406|DIAGNOSTIC_TEST|6 minute walk test|Test for physical functions and cognitive functions
219134581|NCT04043611|OTHER|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
219134582|NCT04043611|OTHER|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
219134583|NCT06713733|DRUG|Dexamethasone|local infiltration
219134584|NCT06713733|DRUG|Chymotrypsin|orally given
219134585|NCT03074851|DIETARY_SUPPLEMENT|low sodium salt|To give free low sodium salt intervention for 2 months
219134586|NCT03074851|OTHER|informational intervention|to give reporter informational intervention.
219134587|NCT03059992|DRUG|Ibrexafungerp|Experimental Study Drug
219134588|NCT06659289|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of cardiopulmonary bypass during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time ofcardiopulmonary bypass."
219134589|NCT02465359|DRUG|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
219134590|NCT00705991|PROCEDURE|ROTEM|
219134591|NCT06611176|DRUG|Local levobupivacaine|submucosal injection of levobupivacaine during esophageal esad
219227851|NCT05522023|PROCEDURE|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
219227852|NCT05522023|PROCEDURE|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
219227853|NCT01911559|DEVICE|standing-frame|
219227854|NCT05387863|OTHER|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
219227855|NCT05387863|OTHER|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
219227856|NCT01595867|DRUG|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
219134592|NCT06609863|PROCEDURE|dTACE-HAIC|dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
219134593|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
219134594|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
219134595|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
219134596|NCT06613464|DIAGNOSTIC_TEST|diagnosis confirmation|The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
219134597|NCT06615089|OTHER|balance training|the elderly patients will receive balance training in the form of proprioceptive and vestibular training components. proprioceptive training include Standing static balance, lateral weight transfer, Lateral weight transfer near to chair, tandem closed eyes, walking on toes, Postural control using ball. Vestibular training in the form of Balance with head movement, seated lateral step in addition to Insoles inside the subjects' own regular shoes
219134598|NCT06615089|OTHER|orthotic prescription|the elderly patients will receive Insoles inside the subjects' own regular shoes
219134599|NCT06613425|COMBINATION_PRODUCT|Combined platelets|1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
219134600|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight adjusted anti-TB therapy for six months
219134601|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight-adjusted anti-TB therapy for nine months
219134602|NCT06614413|OTHER|Neurodevelopment and behaviour assesment 2 years old|Mothers: Monthly visits guided or not by nutritionist (intervention vs control group) will consist in food questionnaires and 3-day food diary collection during pregnancy. Every three months during lactation. Children: From one year of age onwards, the KIDMED questionnaire will be administered quarterly Neurodevelopment and behavior assessment 18-24 months of age
219134603|NCT06615453|DEVICE|Thermo-mechanical action based peri-orbital fractional skin treatment|Participants will receive three Tixel® treatments at 2-weeks intervals
219134604|NCT06615453|DEVICE|Sham treatment|Participants will receive three sham treatments at 2-weeks intervals
219134605|NCT00708097|DRUG|NaF|Fluoride
219134606|NCT00708097|DRUG|Placebo|Placebo
219134607|NCT00708097|DRUG|NaMFP|Fluoride
219134608|NCT06615492|DEVICE|Routine ECMO|Routine intraoperative venoarterial ECMO during lung transplant
219134609|NCT06615492|DEVICE|On-demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative venoarterial ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion despite volume resuscitation and vasopressor administration and in the absence of readily correctable cause~2. Inability to tolerate pulmonary artery clamping~3. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~4. Inadequate exposure to the surgical field~5. The transplant team is concerned about the ability to maintain organ perfusion or ventilate with a lung protective strategy, even if the aforementioned criteria are unmet.~6. Concerns about donor lung quality and a desire to protect the implanted lung from single lung perfusion"
219134610|NCT06609850|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
219134611|NCT06609850|PROCEDURE|Ablation|Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.
219134612|NCT06609850|DRUG|Lenvatinb|Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
219134613|NCT06615310|OTHER|ultrasonograpic evaluotion|The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
219134614|NCT06309342|OTHER|PREVFUNKTION|Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
219134615|NCT06309342|OTHER|Control|Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
219134616|NCT06613945|PROCEDURE|ERCP biliary drainage|bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
219134617|NCT06613945|PROCEDURE|Combined ERCP and EUS-HGS biliary drainage|unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
219134618|NCT01960803|RADIATION|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
219134619|NCT05846165|DEVICE|Field-Cycling Imaging (FCI)|FCI scan
219134620|NCT06629909|DRUG|Secretome|3 ml Injection of secretome for 8 times two weeks apart
219134621|NCT06630559|BIOLOGICAL|CT-P55|CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
219134622|NCT06630559|BIOLOGICAL|EU-approved Cosentyx|European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
219134623|NCT06698094|BEHAVIORAL|Sustainable lifestyle|To encourage and nudge a sustainable lifestyle in an office context in order to improve public health and combat climate change.
219134624|NCT06698094|BEHAVIORAL|Healthy lifestyle|To encourage and nudge a healthy lifestyle in an office context, the participants in this arm will function as a control group receiving general recommendations based on NNR 2014 nutritional recommendations and WHO physical activity recommendations.
219134625|NCT06697262|DEVICE|Remote temperature monitoring device|"* Use of the Tucky® remote monitoring device for continuous temperature monitoring at home,~* In combination with education sessions on temperature monitoring and the device."
219134626|NCT06697262|DIAGNOSTIC_TEST|Home temperature monitoring by a nurse|"* Home temperature monitoring by a nyrse, twice a day,~* In association with education sessions on temperature monitoring."
219134627|NCT06696833|BIOLOGICAL|QH10304-BAL-01|dose escalation (3+3) : dose 1 (3 × 10\^8cells/kg) ,dose 2 (1 × 10\^9 cells/kg) ,dose 3 (3 × 10\^9cells/kg)
219134628|NCT06696833|DRUG|Fludarabine|Intravenous fludarabine 30mg/m2 on days-6 to -3,the infusion dose is adjusted according to the subject's condition
219134629|NCT06696833|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 1000mg/m2 on days -5 to -3, the infusion dose is adjusted according to the subject's condition
219134630|NCT06700993|BEHAVIORAL|Treatment as Usual in Collaborative Care or Integrated Behavioral Health|Treatment as Usual will be whatever primary care and behavioral health services are standardly implemented for adolescents or young adults experiencing suicidality
219134631|NCT06700993|BEHAVIORAL|Connections model|The Connections model applies the Aeschi Model of suicide care to Collaborative Care or other Integrated Behavioral Health by centering the patient's clinical narrative, focusing treatment on the patient's unique drivers of suicide, and maximizing collaboration while maintaining the standards of suicide assessment and management expected by accrediting bodies.
219134632|NCT05948098|BEHAVIORAL|Facilitated Tucking Position|a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands
219134633|NCT05948098|BEHAVIORAL|Gentle Human Touch|It is a form of healing touch
219134634|NCT06696378|DIETARY_SUPPLEMENT|Melatonin 6 mg|wo capsules per day; Each capsule includes 3mg Melatonin Nutrifoods® Laboratories, Barcelona, Spain) by the Magistral Formulation Laboratory of a Pharmacy (Soria, Spain), following the rules of the Royal Spanish Pharmacopoeia (Ministry of Health, Government of Spain). Melatonin has a technical data sheet that guarantees its composition and purity (Reference No.: DIE-134).
219134635|NCT06696378|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Melatonin tablets to ensure blinding.
219134636|NCT06705413|OTHER|Aerobic exercise|a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.
219134637|NCT06705413|OTHER|Microbiome diet|The participants will receive Microbiome diet for three consecutive menstrual cycles. A three-phase diet (21-day phase, 28-day phase and maintenance phase) will be followed by the experimental group which contains some food restrictions and addition for certain food types which may improve gut health.
219134638|NCT06705439|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
219227857|NCT01595867|DRUG|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
219134639|NCT06712212|PROCEDURE|Inguinal Hernias repair: Desarda|A splitting incision is made in this sutured medial leaf, partially separating a strip 1.5-2 cm wide. This splitting incision is extended medially up to the pubic symphysis and 1-2 cm beyond the abdominal ring laterally. The medial insertion and lateral continuation of this strip is kept intact. The upper free border of the strip is now sutured to the internal oblique with number 1 Monofilament Polydioxanone Violet continuous sutures all along its length. This will result in the strip of the EOA being placed behind the cord to form a new posterior wall of the inguinal canal. The spermatic cord is placed in the inguinal canal and the lateral leaf of the EOA is sutured to the newly formed medial leaf of the EOA in front of the cord. As before, number 1 Monofilament Polydioxanone Violet continuous sutures were used. Undermining of the newly formed medial leaf on both its surfaces and excision of the bulky cremasteric muscle facilitate its approximation to the lateral leaf
219134640|NCT06712212|PROCEDURE|Inguinal hernia repair: Darn|Skin and fascia are incised using a regular, oblique inguinal incision to expose the external oblique aponeurosis (EOA) the inguinal canal is opened into by dividing the external oblique aponeurosis through the external ring. After dealing with the hernia sac, a 0-size monofilament suture was used to reconstruct the inguinal bed with a tension-free darn starting with a good strong bite of the tough tendinous structures near the pubic tubercle and emerging out through the lateral edge of the internal oblique/rectus sheath from one side and through the inguinal ligament on the other side. The loosely interwoven bites continued laterally and the back-forming two rows of continuous stitches were placed in a staggered manner to spread the tension between the fibres of the inguinal ligament. Afterwards, the external oblique and other superficial layers with the skin are classically closed
219134641|NCT05267977|DRUG|Cephalosporin 1St Generation|
219134642|NCT05267977|DRUG|Aminoglycosides|
219227858|NCT01595867|DRUG|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
219227859|NCT04338451|OTHER|Music during the first part of ESWL|Music listening during first part of ESWL
219227860|NCT04338451|OTHER|Music during the second part of ESWL|Music listening during second part of ESWL
219227861|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
219227862|NCT01054859|OTHER|alcohol|0.5 g/kg alcohol
219227863|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD
219227864|NCT02231970|PROCEDURE|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
219227865|NCT05757674|OTHER|Sample examination|No intervention will be performed
219227866|NCT06497920|DEVICE|Active rTMS to the motor cortex|Active bilateral repetitive transcranial magnetic stimulation to the motor cortex
219227867|NCT06497920|DEVICE|Sham rTMS to the motor cortex|Sham bilateral repetitive transcranial magnetic stimulation to the motor cortex
219134643|NCT06353243|BEHAVIORAL|Bilateral alternating stimulation|positive touch intervention provided by parent to infant using alternating stimulation
219134644|NCT00557804|DEVICE|MUSE clinical system|non-invasive external monitoring device
219134645|NCT02162446|DRUG|satoreotide trizoxetan|
219134646|NCT05198089|OTHER|Internet-Based Intervention|Use MyInspiration website
219715625|NCT06361420|PROCEDURE|Ventilation strategy|A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value \> 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
219715626|NCT06361420|PROCEDURE|Management of hypoxemia|Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
219134647|NCT02772614|DRUG|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
219134648|NCT00394407|DRUG|sliding scale regular insulin|SSRI acqhs
219134649|NCT00394407|DRUG|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
219134650|NCT00982098|PROCEDURE|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
219134651|NCT03570957|DRUG|MT-2990|MT-2990 solution for injection in vial
219134652|NCT03570957|DRUG|Placebo|Placebo solution for injection in vial
219134653|NCT06630975|DEVICE|Hemiepiphysiodesis|8 plate
219134654|NCT06630975|PROCEDURE|Eight-Plates first described by Stevens are simple to use|fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded
219134655|NCT06630975|DEVICE|Hemiepiphysiodesis by eight Plate|Extraperiosteal eight plate insertion
219134656|NCT03895034|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
219134657|NCT03264742|OTHER|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
219134658|NCT01553513|OTHER|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
219227868|NCT03673605|DRUG|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
219227869|NCT03673605|DRUG|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
219227870|NCT02091752|DRUG|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
219134659|NCT01553513|PROCEDURE|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
219134660|NCT01553513|PROCEDURE|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
219134661|NCT01553513|OTHER|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
219134662|NCT01255033|DEVICE|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
219134663|NCT01505101|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
219134664|NCT01505101|BEHAVIORAL|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
219134665|NCT05289466|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
219134666|NCT05289466|PROCEDURE|Oncoplastic partial mastectomy|Breast Conserving Therapy
219134667|NCT05553613|DRUG|Ticagrelor 90 MG Oral Tablet|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
219134668|NCT05553613|DRUG|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
219134669|NCT03837028|OTHER|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
219134670|NCT04771793|BEHAVIORAL|new physical restraint protocols|new physical restraint protocols
219134671|NCT01496521|DRUG|Aspirin|100mg qd for 6 months.
219134672|NCT01496521|DIETARY_SUPPLEMENT|Tea Polyphenols|300mg bid for 6 months.
219134673|NCT04981015|DIAGNOSTIC_TEST|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
219134674|NCT03784963|DRUG|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
219134675|NCT03784963|OTHER|Placebo|Standard of care
219134676|NCT03680391|PROCEDURE|Cesarean section|"Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used"
219134677|NCT05307614|DRUG|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
219134678|NCT05307614|DRUG|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
219134679|NCT04619914|DRUG|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
219134680|NCT04619914|DRUG|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
219134681|NCT00157014|DRUG|Tacrolimus|Oral
219134682|NCT00157014|DRUG|Cyclosporine|Oral
219134683|NCT00157014|DRUG|Mycophenolate mofetil|Intravenous and Oral
219134684|NCT00157014|DRUG|Methylprednisolone|Intravenous
219134685|NCT00157014|DRUG|Prednisone|Oral
219134686|NCT05714735|RADIATION|Cerebral Venography|Cerebral Venography Observation by DSA examinations
219227871|NCT05406947|OTHER|Prospective observational study, no intervention|Prospective observational study, no intervention
219134687|NCT01362491|DRUG|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
219134688|NCT01362491|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
219134689|NCT01362491|DRUG|Placebo|Single-dose of placebo
219134690|NCT03181958|DEVICE|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
219134691|NCT03181958|DEVICE|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
219134692|NCT03181958|DEVICE|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
219227872|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
219227873|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
219227874|NCT03719352|PROCEDURE|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
219227875|NCT03719352|PROCEDURE|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
219227876|NCT03719352|PROCEDURE|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
219227877|NCT04703907|OTHER|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
219227878|NCT02180932|BIOLOGICAL|periodontal pocket samples|
219227879|NCT01420757|PROCEDURE|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
219227880|NCT02390778|BEHAVIORAL|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
219227881|NCT02390778|BEHAVIORAL|leisure activity (film showing)|
219134693|NCT00575523|DRUG|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
219134694|NCT00575523|DRUG|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
219134695|NCT02502396|OTHER|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
219134696|NCT04710017|DRUG|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
219134697|NCT04710017|DRUG|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
219134698|NCT02313090|OTHER|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
219134699|NCT01091233|PROCEDURE|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
219134700|NCT04358354|DRUG|Irinotecan|Irinotecan 150 mg/m2
219134701|NCT04358354|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
219134702|NCT04358354|DRUG|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
219134703|NCT03696771|DRUG|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
219134704|NCT00394069|DRUG|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
219134705|NCT02315391|DIETARY_SUPPLEMENT|isolated whey protein|isolated whey protein
219134706|NCT02315391|DIETARY_SUPPLEMENT|micellar whey protein|micellar whey protein
219134707|NCT02315391|DIETARY_SUPPLEMENT|glycine|glycine
219134708|NCT02315391|DIETARY_SUPPLEMENT|citrulline|citrulline
219134709|NCT02830152|DEVICE|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
219227882|NCT05344742|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
219227883|NCT05344742|DRUG|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
219227884|NCT05344742|DRUG|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
219227885|NCT05101317|DRUG|HMI-115|HMI-115 is human monoclonal antibody
219227886|NCT05101317|DRUG|Placebo|Placebo
219227887|NCT05647642|DRUG|Precedex and dormicum|Premedication
219227888|NCT06398210|OTHER|Cognitive Exercise Therapy Approach (BETY)|Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.
219134710|NCT02830152|DRUG|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
219134711|NCT01257503|DRUG|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
219134712|NCT01257503|DRUG|placebo|liquid made to look like the active homeopathic remedy
219134713|NCT01805414|OTHER|Modified Carbohydrate Breakfast|
219134714|NCT01805414|OTHER|Control Breakfast|
219227889|NCT00783952|DEVICE|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
219715627|NCT06449989|DIAGNOSTIC_TEST|Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI|"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."
219715628|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
219715629|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
219134715|NCT00219687|OTHER|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
219134716|NCT00219687|OTHER|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
219134717|NCT05942768|DRUG|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
219134718|NCT01343290|DRUG|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
219134719|NCT01384240|DRUG|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
219134720|NCT05583539|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
219134721|NCT05355116|DEVICE|Physiolab S1|A cryocompression device capable of circulating ice-water through a cuff at 6-12℃ with either a static pressure of 25mmHg or dynamic pressure of 25-50 mmHg or 25-75mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
219134722|NCT05355116|DEVICE|Breg Vpulse|A cryocompression device capable of circulating ice-water through a cuff at no lower than 5.5℃ with a dynamic peak pressure of 50 mmHg. The temperature of the ice-water, and the applied pressure, is not modifiable by the user.
219227890|NCT00783952|DEVICE|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
219227891|NCT01910194|DRUG|Luyxumia versus Lantus|
219715630|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
219715631|NCT00558545|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
219715632|NCT06597721|DRUG|ADCE-T02|Administered intravenously
219715633|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
219715634|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
219134723|NCT05355116|DEVICE|Aircast Cryo/Cuff|A cryocompression device capable of circulating ice-water through a cuff at an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
219134724|NCT05355116|DEVICE|GameReady|A cryocompression device capable of circulating ice-water through a cuff at 1-12℃ with a dynamic pressure of 5-15 mmHg, 5-50 mmHg, or 5-75 mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
219134725|NCT05355116|DEVICE|Physiolab Gel Therapy Wrap|A cryocompression cuff that applies an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
219134726|NCT01970358|BIOLOGICAL|Poly-ICLC|
219134727|NCT01970358|BIOLOGICAL|Peptides|
219134728|NCT03935308|RADIATION|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
219134729|NCT01090024|DRUG|BI 671800|BI 671800
219134730|NCT01090024|DRUG|Placebo|Placebo matching BI 671800
219134731|NCT03643029|DEVICE|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
219134732|NCT04800224|DRUG|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
219134733|NCT04800224|DRUG|Placebo|900mg/day of Placebo for 10 days.
219134734|NCT02008292|DRUG|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
219134735|NCT00003311|BIOLOGICAL|filgrastim|
219134736|NCT00003311|DRUG|cyclophosphamide|
219134737|NCT00003311|DRUG|cytarabine|
219134738|NCT00003311|DRUG|dexamethasone|
219134739|NCT00003311|DRUG|doxorubicin hydrochloride|
219134740|NCT00003311|DRUG|methotrexate|
219134741|NCT00003311|DRUG|vincristine sulfate|
219134742|NCT01371201|DRUG|Sunitinib|sunitinib 37.5 mg per day
219134743|NCT01371201|DRUG|Placebo|Placebo 37.5 mg per day
219134744|NCT03728725|DEVICE|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
219134745|NCT02118935|OTHER|Previously marketed cow's mlik-based infant formula|
219134746|NCT02118935|OTHER|Marketed cow's milk-based infant formula with prebiotics|
219134747|NCT04470102|PROCEDURE|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
219134748|NCT04470102|PROCEDURE|Septal myectomy|isolated extended septal myectomy
219134749|NCT02195557|DRUG|Synvisc®|
219134750|NCT00567879|DRUG|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
219134751|NCT00567879|DRUG|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
219134752|NCT04836793|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
219715635|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
219134753|NCT00501241|DRUG|ATI-7505|Tablet,placebo, BID
219134754|NCT00501241|DRUG|ATI-7505|ATI-7505 20 mg BID for 4 weeks
219134755|NCT00501241|DRUG|ATI-7505|tablet, 40 mg, BID, $ weeks
219227892|NCT03658603|PROCEDURE|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
219134756|NCT00501241|DRUG|ATI-7505|80 mg ATI-7505, BID for 4 weeks
219134757|NCT00501241|DRUG|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
219134758|NCT03359031|OTHER|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
219227893|NCT03658603|PROCEDURE|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
219134759|NCT04588285|DRUG|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
219134760|NCT04588285|DRUG|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
219134761|NCT03645850|DEVICE|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
219134762|NCT03645850|DEVICE|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
219134763|NCT05155371|OTHER|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
219134764|NCT00777556|DRUG|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
219227894|NCT03034278|OTHER|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
219227895|NCT02571868|DEVICE|Optimization CRT-D|
219134765|NCT03833102|OTHER|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
219715636|NCT06988176|DIAGNOSTIC_TEST|Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing|"Participants will undergo a structured frailty and muscle-strength assessment battery performed during their routine preoperative evaluation. These assessments serve as the primary exposure measures of interest and include:~Clinical Frailty Scale (CFS) evaluation (functional frailty assessment) Respiratory muscle strength assessment (Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) using a MicroRPM handheld respiratory pressure meter) Hand-grip strength measurement (using Jamar dynamometer) Physical performance evaluation (Timed Up-and-Go (TUG) test) Skeletal muscle mass estimation (Bioelectrical impedance analysis, InBody 120) Muscle thickness measurement (Rectus femoris muscle thickness using portable ultrasound) Cognitive function screening (Mini-Cog test) Nutritional risk screening (Perioperative Nutrition Screen \[PONS\]) No additional interventions beyond these observational assessments will be conducted."
219715637|NCT06980051|BEHAVIORAL|Virtual window|The virtual window, which displays 24h time-linked outdoor scene on a high-definition video monitor, will be on during working hours for three days each week.
219715638|NCT06859008|PROCEDURE|Biopsy|Undergo biopsy
219715639|NCT06859008|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
219715640|NCT06859008|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219715641|NCT06859008|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219715642|NCT06859008|PROCEDURE|Computed Tomography|Undergo CT
219715643|NCT06859008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219715644|NCT06859008|OTHER|Questionnaire Administration|Ancillary studies
219715645|NCT06859008|DRUG|Sonrotoclax|Given PO
219715646|NCT06859008|DRUG|Zanubrutinib|Given PO
219715647|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
219715648|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
219715649|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
219715650|NCT05415774|DEVICE|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219715651|NCT05415774|DEVICE|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219715652|NCT05415774|DEVICE|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219715653|NCT05415774|DEVICE|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219715654|NCT05415774|DEVICE|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219134766|NCT01517542|OTHER|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
219134767|NCT01768143|BEHAVIORAL|unexperienced endoscopy nurses|
219134768|NCT01768143|BEHAVIORAL|Experienced endoscopy nurses|
219227896|NCT03511144|DEVICE|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
219715655|NCT05415774|DEVICE|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
219715656|NCT05064631|DRUG|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
219715657|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) without Left Atrial Posterior Wall Isolation (PWI)|"A doctor inserts a thin, flexible tube (called a catheter) through a blood vessel, usually in the groin, and guides it to the heart.~Once the catheter is in place, the doctor uses pulsed field electroporation, heat (radiofrequency) or cold (cryoablation) to create small scars in the area where the pulmonary veins connect to the left atrium of the heart.~These scars block the faulty electrical signals that cause AF, helping the heart maintain a normal rhythm."
219715658|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) with Left Atrial Posterior Wall Isolation (PWI)|PVI with an additional step where the doctor also isolates the back wall (posterior wall) of the left atrium.
219715659|NCT06991114|DRUG|Allogeneic NK Cells|AlloNK, dosed after a conditioning regimen, combined with Rituximab.
219715660|NCT06170827|DRUG|AIO-001|AIO-001 Solution for SC injection.
219134769|NCT05550922|BEHAVIORAL|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
219134770|NCT02794948|OTHER|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
219134771|NCT02794948|DIETARY_SUPPLEMENT|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
219134772|NCT04137874|DIAGNOSTIC_TEST|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
219134773|NCT04137874|OTHER|Control|Conventional prehospital care
219134774|NCT02104609|DRUG|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
219134775|NCT04240730|PROCEDURE|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
219134776|NCT00373555|PROCEDURE|Bronchoscopy|
219134777|NCT00207844|DRUG|Selenium as sodium selenite|
219227897|NCT03511144|DEVICE|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
219227898|NCT00493688|OTHER|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
219134778|NCT05928364|PROCEDURE|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
219134779|NCT06630208|OTHER|Myofascial release|The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
219134780|NCT06630208|OTHER|Breathing exercises|Following the 3 phases of myofascial release, breathing exercises will be done for patients.
219227899|NCT02397707|DRUG|Voxilaprevir|100 mg tablet administered orally
219227900|NCT00142246|DRUG|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
219227901|NCT00142246|OTHER|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
219227902|NCT04942288|OTHER|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
219227903|NCT04123795|DRUG|Certolizumab pegol|"Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
219227904|NCT04123795|DRUG|Placebo|"Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
219227905|NCT06097260|DRUG|PLN-74809|PLN-74809
219715661|NCT05796089|RADIATION|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
219715662|NCT05796089|DRUG|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
219715663|NCT05796089|DRUG|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
219715664|NCT05253807|DRUG|Pemigatinib|13.5 mg tablet
219715665|NCT06081244|DRUG|Sacituzumab govitecan|10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
219715666|NCT06081244|DRUG|Pembrolizumab|200 mg every 3 weeks (q3w)
219715667|NCT06990724|OTHER|Videogame Intervention|No Baby No video game
219715668|NCT06990724|OTHER|Commercial game control|Commercial video game
219134781|NCT06630208|DRUG|Pharmacological treatment|Patients will take pharmacological treatment prescribed by the cardiologist.
219134782|NCT02787109|BIOLOGICAL|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
219134783|NCT02787109|BIOLOGICAL|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
219134784|NCT02787109|BIOLOGICAL|Placebo|Saline
219134785|NCT02380742|DRUG|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
219134786|NCT02380742|DRUG|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
219715669|NCT06989970|COMBINATION_PRODUCT|Active tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Active tDCS and cognitive training intervention. Participants will receive cognitive training paired with active tDCS for 3 weeks, followed by follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the active tDCS, stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to the left DLPFC at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes."
219715670|NCT06989970|COMBINATION_PRODUCT|Sham tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Sham tDCS and cognitive training intervention~Participants will receive cognitive training paired with sham tDCS for 3 weeks, followed follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the sham tDCS, electrodes will be placed in the same area as in the active tDCS condition, but current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds."
219715673|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
219134787|NCT06188962|BEHAVIORAL|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
219134788|NCT00802919|DRUG|Varenicline|Varenicline 1-2 mg/day
219134789|NCT00802919|DRUG|Placebo for varenicline|Placebo
219134790|NCT01714557|DRUG|Piperacillin|4.0g q8h 3-5 days
219134791|NCT01714557|DRUG|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
219227906|NCT06097260|DRUG|Placebo|Placebo
219715674|NCT03786081|DRUG|Bevacizumab|Given via IV
219715675|NCT03786081|DRUG|Pembrolizumab|Given via IV
219715676|NCT03786081|DRUG|Carboplatin|Given via IV
219715677|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC or IV injection.
219715678|NCT06585462|DRUG|Placebo|Placebo will be administered by SC or IV injection.
219715679|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC injection.
219715680|NCT06585462|DRUG|Placebo|Placebo will be administered by SC injection.
219715681|NCT04871321|DRUG|nab-paclitaxel plus gemcitabine-cisplatin|\- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
219715682|NCT04375631|DRUG|Cladribine|Given IV
219715683|NCT04375631|DRUG|Cyclophosphamide|Given IV
219715684|NCT04375631|DRUG|Cyclosporine|Given IV then PO
219715685|NCT04375631|DRUG|Cytarabine|Given IV
219715686|NCT04375631|BIOLOGICAL|Filgrastim|Given SC
219715687|NCT04375631|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
219715688|NCT04375631|DRUG|Mitoxantrone|Given IV
219715689|NCT04375631|DRUG|Mycophenolate Mofetil|Given IV or PO
219715690|NCT04375631|DRUG|Mycophenolate Sodium|Given PO
219134792|NCT00580073|DRUG|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
219134793|NCT00580073|DRUG|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
219134794|NCT03646370|DRUG|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
219134795|NCT02294929|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
219134796|NCT05358197|OTHER|yoga|laughter yoga
219134797|NCT04602936|DRUG|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
219134798|NCT04602936|DRUG|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
219134799|NCT04740359|OTHER|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
219134800|NCT04740359|OTHER|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
219134801|NCT00778739|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
219134802|NCT00424320|DRUG|Sodium bicarbonate|
219134803|NCT04408274|BEHAVIORAL|Emotional Processing Training|
219134804|NCT04408274|BEHAVIORAL|Placebo Control|
219134805|NCT00324506|DRUG|Mycophenolate Mofetil (CellCept)|
219134806|NCT01568749|DRUG|Paracetamol|Paracetamol
219134807|NCT01568749|DRUG|Paracetamol formulation 1|Paracetamol
219134808|NCT01568749|DRUG|Paracetamol Formulation 2|Paracetamol
219134809|NCT01568749|DRUG|Paracetamol formulation 3|Paracetamol
219715691|NCT04375631|RADIATION|Total-Body Irradiation|Undergo TBI
219715692|NCT04375631|DRUG|Idarubicin|Given IV
219134810|NCT01568749|DRUG|Paracetamol formulation 4|paracetamol
219134811|NCT04178109|DRUG|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
219134812|NCT04178109|DRUG|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
219134813|NCT04178109|DRUG|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
219134814|NCT04178109|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
219134815|NCT04178109|DRUG|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
219134816|NCT01434303|DRUG|Entinostat|Given PO
219134817|NCT01434303|OTHER|Laboratory Biomarker Analysis|Correlative studies
219715693|NCT04375631|DRUG|Fludarabine|Given IV
219715694|NCT04375631|DRUG|Cytarabine|Given IV
219715695|NCT04375631|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219134818|NCT01434303|DRUG|Lapatinib Ditosylate|Given PO
219134819|NCT01434303|BIOLOGICAL|Trastuzumab|Given IV
219134820|NCT01717794|PROCEDURE|Thunderbeat technology|
219134821|NCT01717794|PROCEDURE|Standard bipolar electrosurgery|
219134822|NCT03174054|PROCEDURE|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
219715696|NCT04375631|PROCEDURE|Echocardiography Test|Undergo ECHO
219134823|NCT04575493|DIETARY_SUPPLEMENT|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
219134824|NCT04575493|DRUG|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
219134825|NCT01725854|BEHAVIORAL|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
219134826|NCT02379546|DRUG|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
219134827|NCT02379546|DEVICE|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
219134828|NCT01941277|BEHAVIORAL|Current Recommendations Exercise Group|
219715697|NCT04375631|PROCEDURE|X-Ray Imaging|Undergo x-ray
219715698|NCT04375631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
219715699|NCT04375631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
219715700|NCT04375631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219134829|NCT01941277|BEHAVIORAL|Intensive Exercise Group|
219134830|NCT02548221|DEVICE|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
219134831|NCT00516503|DRUG|baclofen/amitriptyline/ketamine gel|Applied topically
219134832|NCT00516503|OTHER|placebo|Applied topically
219134833|NCT06412406|PROCEDURE|External Oblique Intercostal (EOI) block|EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
219134834|NCT06412406|PROCEDURE|Transversus abdominis plane (TAP) block|"TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
219227907|NCT05907720|BEHAVIORAL|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
219227908|NCT04803799|OTHER|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
219227909|NCT03707899|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
219227910|NCT03707899|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
219227911|NCT01604824|DRUG|Alirocumab|SC injection in the abdomen
219227912|NCT01604824|DRUG|Placebo|SC injection in the abdomen
219227913|NCT02795884|DRUG|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
219715701|NCT06860906|PROCEDURE|V-Y advancement flap|anal stenosis treated by removal of scarring tissue and cover the defect using V-Y advancement flap
219715702|NCT06859515|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
219715703|NCT06061341|DIAGNOSTIC_TEST|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
219227914|NCT02795884|DRUG|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
219227915|NCT04197791|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
219227916|NCT04197791|OTHER|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
219227917|NCT02073500|OTHER|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
219227918|NCT05173987|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
219227919|NCT05173987|DRUG|carboplatin|IV infusion
219227920|NCT05173987|DRUG|paclitaxel|IV infusion
219227921|NCT05173987|DRUG|docetaxel|IV infusion
219227922|NCT05173987|DRUG|cisplatin|IV infusion
219715704|NCT06613451|OTHER|Mobile Application|Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration
219715705|NCT06994065|DRUG|Ferric Carboxymaltose (FCM)|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
219227923|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
219134835|NCT06405867|PROCEDURE|delayed cord clamping (> 60 sec)|In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
219227924|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
219227925|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
219227926|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
219227927|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
219715706|NCT06994065|DRUG|Iron Sucrose injection|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
219227928|NCT03816839|DRUG|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
219715707|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
219715708|NCT06002282|BEHAVIORAL|Tailored messages|Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
219134836|NCT05478772|DRUG|CTP-543|12 mg on Day 1 and Day 7
219134837|NCT05478772|DRUG|Fluconazole|200 mg once daily on Days 3 through to Day 8
219134838|NCT00666939|DRUG|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
219134839|NCT00666939|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
219134840|NCT00666939|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
219227929|NCT05269394|DRUG|E2814|Administered intravenously in a blinded fashion
219227930|NCT05269394|DRUG|Lecanemab|Administered intravenously
219227931|NCT05269394|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
219227932|NCT06384573|DRUG|lecanemab|Administered intravenously
219227933|NCT05658497|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
219227934|NCT05658497|DRUG|Avonex|Administered as specified in the treatment arm.
219227935|NCT05658497|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
219227936|NCT05658497|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
219227937|NCT05283512|OTHER|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
219227938|NCT05283512|OTHER|Preventive treatment with oral hydration|Oral hydration with regular bottled water
219715709|NCT06002282|BEHAVIORAL|Standard messages|Generic reminder/recall HPV vaccination messages.
219134841|NCT00092599|DRUG|MK0653, ezetimibe|
219134842|NCT00092599|DRUG|Comparator: ezetimibe, placebo|
219134843|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
219134844|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
219227939|NCT03651973|OTHER|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
219227940|NCT03651973|OTHER|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
219227941|NCT06613087|OTHER|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
219227942|NCT05847998|DEVICE|Standardized measurement of capillary refill time by second generation DICART prototype|"Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax"
219134845|NCT03646669|BEHAVIORAL|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
219134846|NCT03646669|BEHAVIORAL|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
219227943|NCT05847998|DIAGNOSTIC_TEST|Clinical measurement of capillary refill time|"Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements."
219227944|NCT05835895|GENETIC|GNSC-001|intra-articular injection
219227945|NCT05835895|DRUG|transient immune-modulation|oral
219134847|NCT02292043|DRUG|HTEA|HTEA
219134848|NCT04866407|OTHER|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
219134849|NCT04866407|OTHER|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
219134850|NCT04809402|OTHER|remote monitoring after cataract surgery|remote monitoring after cataract surgery
219134851|NCT04127058|DRUG|Iloperidone|Oral Tablet
219134852|NCT05725889|DEVICE|recation time test|visual-finger tapping and auditory reaction time tests
219715710|NCT06865417|DRUG|Filgotinib|IP will be provided as commercially developed film-coated tablets (100 and 200 mg strength) or reduced-strength (65 mg) age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food).
219715711|NCT06863233|DRUG|Zirconium Zr 89 crefmirlimab berdoxam|Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.
219715712|NCT06863233|DIAGNOSTIC_TEST|PET/CT Scan|Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).
219715713|NCT06857955|OTHER|Saline|0.9% sodium chloride saline solution
219134853|NCT01265758|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
219715714|NCT06857955|DRUG|QCZ484|Solution of Injection
219134854|NCT03458780|DRUG|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
219134855|NCT01432158|BIOLOGICAL|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
219134856|NCT01432158|BIOLOGICAL|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
219134857|NCT04242758|DRUG|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
219134858|NCT04242758|DRUG|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
219227946|NCT05835895|DRUG|transient immune-modulation|intra-articular injection
219227947|NCT05835895|DRUG|Placebo|intra-articular injection
219227948|NCT04670640|DEVICE|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
219715715|NCT06863740|DRUG|Cannabis oil|5:1 CBD:THC oral formulation with a concentration of 25 mg/g CBD and 5 mg/g THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.
219715716|NCT06863740|DRUG|Cannabis placebo|Placebo oil
219715717|NCT06503614|DRUG|Durvalumab|Durvalumab 1500mg IV
219715718|NCT06503614|DRUG|Monalizumab|Monalizumab 1500mg IV
219134859|NCT00149279|PROCEDURE|Surgery: D2 dissection|
219134860|NCT00149279|PROCEDURE|Surgery: D2+paraaortic dissection|
219134861|NCT00590668|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
219134862|NCT02442466|DRUG|Endothelin Receptor B inhibitor BQ788|
219134863|NCT02442466|DRUG|PBS|
219134864|NCT04414878|DEVICE|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
219134865|NCT00541606|OTHER|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
219715719|NCT06994325|BEHAVIORAL|Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention|The Conversations Helpful for Awareness of illness Trajectory (CHAT) intervention will incorporate 4 health-coach sessions, supplemented by 7 educational videos. Each session will be up to 60 minutes long and will be conducted remotely. During the health coach sessions, a trained health coach will work with subjects, reviewing the content of each video and emphasizing key learning content.
219715720|NCT06994325|BEHAVIORAL|Standard of Care (SOC)|The Standard of Care Group will not have access to the Health Coach or video-based educational content. This group will have no study activities during Weeks 1-7 but will participate in follow-up assessments.
219134866|NCT00541606|OTHER|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
219134867|NCT02012166|DRUG|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
219134868|NCT02012166|DRUG|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
219134869|NCT02012166|DRUG|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
219134870|NCT02012166|DRUG|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
219134871|NCT02012166|DRUG|Placebo|Placebo administered orally in 240 mL of water
219715721|NCT07000110|DRUG|Anifrolumab|Anifrolumab prescribed per local practice
219715722|NCT07002528|BEHAVIORAL|sucrose solution|apply sucrose solution to evaluate pain among local anesthesia
219715723|NCT07002528|BEHAVIORAL|Cryotherapy|apply cryotheraby to evaluate pain among local anesthesia
219715724|NCT07002528|BEHAVIORAL|topical anesthesia|apply topical anesthesia to evaluate pain among local anesthesia
219134872|NCT02012166|BIOLOGICAL|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
219715725|NCT05984381|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
219715726|NCT05984381|DRUG|Dapsone|Dapsone 100 mg/day
219134873|NCT02012166|BIOLOGICAL|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
219134874|NCT02012166|BIOLOGICAL|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
219134875|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
219134876|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
219227949|NCT04670640|BEHAVIORAL|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
219715727|NCT05984381|DRUG|Methotrexate|Methotrexate 15 mg weekly
219715728|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
219715729|NCT05779930|BIOLOGICAL|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
219715730|NCT07003932|OTHER|Remote monitoring|The remote monitoring group will be more closely followed than the control group in order to detect any deterioration over time. This group will not be scheduled for a face-to-face consultation unless it is deemed necessary by a physiotherapist or if the patient contacts the hospital themselves.
219715731|NCT07003932|OTHER|Usual Care|The control group will follow usual care with face-to-face consultation with a physiotherapist at 2 and 12 months. They will also anwer questionnaires at 2, 6 and 12 months, but these will not be monitored.
219715732|NCT07003542|DRUG|Sitagliptin|"Sitagliptin will be self-administered orally by participants.~Dose level - sitagliptin~* 1 100 mg daily~* -1 50 mg daily~* -2 25 mg daily"
219715733|NCT07003685|DEVICE|GDD in posterior chamber|GDD in posterior chamber
219715734|NCT07003685|DEVICE|GDD in aterior chamber|GDD in anterior chamber
219715735|NCT05865886|DRUG|BI 1291583|BI 1291583
219134877|NCT04957654|OTHER|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
219134878|NCT04957654|OTHER|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
219134879|NCT04957654|OTHER|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
219134880|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
219134881|NCT05264467|BIOLOGICAL|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
219134882|NCT03874156|DRUG|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
219134883|NCT03874156|DRUG|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
219134884|NCT00753168|DRUG|OT-730 ophthalmic solution|one eye drop twice daily
219134885|NCT00753168|DRUG|timolol maleate ophthalmic solution|one eye drop twice daily
219134886|NCT00753168|DRUG|OT-730 placebo|one eye drop twice daily
219227950|NCT04670640|BEHAVIORAL|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
219227951|NCT06281496|BEHAVIORAL|AlloCare|Survivorship supportive care
219715736|NCT05865886|DRUG|Placebo to BI 1291583|Placebo matching BI 1291583
219134887|NCT01451814|BEHAVIORAL|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
219134888|NCT01451814|DRUG|Nicotine polacrilex|8 weeks of nicotine patch
219227952|NCT06849596|DEVICE|Ventilator derived positive pressure ventilation - V-PPV|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. Ventilator delivered positive pressure ventilation (V-PPV) using a nasal interface will be delivered to the infant in the resuscitation room.
219227953|NCT06849596|DEVICE|T-piece resuscitator (TPR)|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. PPV will be provided with a T-piece resuscitator (Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask.
219227954|NCT06853054|PROCEDURE|Personalized patch template|The personalized, sterilizable patch template will be used as the surgeon's guide in fashioning the precise size and shape of the surgical patch.
219227955|NCT05599191|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
219227956|NCT05599191|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
219715737|NCT05509218|BEHAVIORAL|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
219715738|NCT06867640|OTHER|Forgiveness-Based Group Psychoeducation|The effect of forgiveness-based group psychoeducation applied to cancer survivors on fear of cancer recurrence, forgiveness and psychiatric conditions.
219134889|NCT01451814|BEHAVIORAL|Relaxation training|Instructions in progressive muscle relaxation
219134890|NCT01451814|BEHAVIORAL|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
219134891|NCT04228536|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
219134892|NCT04228536|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
219134893|NCT04228536|PROCEDURE|Open anterior mesh repair (OAM)|
219134894|NCT04228536|PROCEDURE|Combined Anterior and Posterior technique (CAP)|
219134895|NCT04228536|PROCEDURE|Open PrePeritoneal Mesh technique (OPPM)|
219134896|NCT04228536|PROCEDURE|Sutured Repair|
219134897|NCT04635358|BEHAVIORAL|Hypnosis|Setting up hypnosis sessions
219134898|NCT04635358|BEHAVIORAL|Psychological support|Setting up psychological support
219134899|NCT04635358|BEHAVIORAL|Nutrional support|Setting up nutritional support
219134900|NCT02356549|BEHAVIORAL|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
219134901|NCT02356549|BEHAVIORAL|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
219134902|NCT02356549|BEHAVIORAL|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
219134903|NCT04619654|PROCEDURE|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
219134904|NCT06358066|DRUG|self assembling peptide p11-4 with fluoride|"Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment"
219134905|NCT06358066|DRUG|5% sodium fluoride varnish|Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
219134906|NCT04103671|PROCEDURE|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
219134907|NCT04103671|PROCEDURE|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
219134908|NCT05386446|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
219134909|NCT01672619|PROCEDURE|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
219715739|NCT06277258|OTHER|Patient Empowerment model|"Session I~* Knowledge about the disease, calories \& diet distribution, physical activities, symptoms of hypoglycemia, Blood Glucose target etc.~* Training on use of glucometer and record keeping Session II~* Evaluation and interpretation of sugar level based on the sugar chart.~* Tuning of diet and exercise if needed.~* Discussion about the challenges faced by the patient during maintenance of sugar level.~Session III \& ongoing~* Tuning of the diet based on calories, evaluation of the understanding~* Assessment of patient satisfaction~* Assessment of patients' knowledge and skill to designate her as Empowered~Assurance and counseling of patient and family will be rendered in each session."
219134910|NCT06231069|DIETARY_SUPPLEMENT|Multi-nutrient supplement|12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.
219134911|NCT06231069|OTHER|Exercise|12 weeks of short-duration mixed endurance and resistance exercise.
219227957|NCT05343741|OTHER|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
219715740|NCT05154513|OTHER|Cohort 1|No intervention provided in this study
219715741|NCT03579771|DRUG|Cisplatin|Given IV
219715742|NCT03579771|DRUG|Gemcitabine|Given IV
219134912|NCT03426683|OTHER|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
219227958|NCT06966401|DRUG|NBI-1065845|NBI-1065845 tablets
219227959|NCT05676346|GENETIC|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
219227960|NCT02502461|PROCEDURE|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
219715743|NCT03579771|DRUG|Nab-paclitaxel|Given IV
219715744|NCT05984537|DRUG|Bivalirudin|Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.
219715745|NCT05984537|DRUG|standard heparin|Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
219134913|NCT02298140|OTHER|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
219134914|NCT00950404|DRUG|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
219134915|NCT00950404|DRUG|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
219134916|NCT00950404|DRUG|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
219134917|NCT00950404|DRUG|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
219134918|NCT02989012|DRUG|GanMaoKangNing Granules|3 times a day, 2 bags each time.
219134919|NCT02989012|DRUG|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
219134920|NCT02989012|DRUG|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
219134921|NCT02989012|DRUG|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
219134922|NCT04206046|PROCEDURE|Spinal anaesthesia|Patients will receive a spinal anaesthetic
219134923|NCT04206046|PROCEDURE|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
219134924|NCT01921140|DRUG|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
219134925|NCT01921140|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
219134926|NCT01921140|OTHER|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
219134927|NCT01921140|OTHER|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
219134928|NCT05699213|DIAGNOSTIC_TEST|Lung MRI|MRI of the lung
219134929|NCT05699213|DIAGNOSTIC_TEST|Blood Draw|Blood Draw
219134930|NCT02492464|DIETARY_SUPPLEMENT|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
219134931|NCT02492464|DIETARY_SUPPLEMENT|Placebo|
219134932|NCT00338858|OTHER|walking and balance performance evaluation|
219227961|NCT04376775|OTHER|Transplant patient|Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
219715746|NCT04822766|PROCEDURE|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
219715747|NCT04822766|DRUG|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
219134933|NCT00338858|PROCEDURE|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
219134934|NCT00117871|DRUG|Resiquimod|
219227962|NCT03275961|BEHAVIORAL|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
219227963|NCT00892541|DRUG|ER OROS paliperidone|
219134935|NCT03093792|OTHER|Control|
219134936|NCT03093792|OTHER|American Heart Association plus exercise|
219134937|NCT03093792|OTHER|Curves Complete - I plus exercise|
219134938|NCT03093792|OTHER|Curves Complete - II plus exercise|
219134939|NCT03182036|DEVICE|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
219134940|NCT00835016|BEHAVIORAL|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
219134941|NCT00386204|DEVICE|Q-switched Ruby Laser|
219134942|NCT06411405|OTHER|Maternal medical history|See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
219134943|NCT05679830|DRUG|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
219134944|NCT01956669|DRUG|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
219134945|NCT06152484|OTHER|Pentacam, Corvis ST and CASIA2|morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
219227964|NCT02089295|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
219227965|NCT02089295|DRUG|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
219227966|NCT02089295|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
219134946|NCT00728637|BEHAVIORAL|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
219134947|NCT00728637|BEHAVIORAL|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
219134948|NCT02131324|DRUG|DFD06 Cream|
219134949|NCT02131324|DRUG|Clobetasol Propionate Cream 0.05%|
219134950|NCT02400151|DRUG|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
219134951|NCT02400151|DRUG|Placebo|Patients randomized to this group will receive placebo for 90 days.
219134952|NCT02400151|OTHER|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
219134953|NCT02400151|OTHER|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
219134954|NCT01693614|DRUG|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
219134955|NCT02650596|DRUG|GLP-1|Liraglutide were taken daily for 3 months
219134956|NCT02650596|DRUG|Placebo|Placebo were taken daily for 3 months
219134957|NCT05870241|OTHER|Ga-As Laser|Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
219134958|NCT05870241|OTHER|Microcurrent Electrical Stimulation|The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
219134959|NCT05870241|OTHER|traditional therapy|the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
219134960|NCT05609448|PROCEDURE|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
219134961|NCT02918786|DEVICE|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
219715748|NCT06819371|OTHER|Single Task Exercise|Patients will follow the exercises in a way to focus on only one task during the exercise sessions. In the creation of the exercise programme, the principles of the exercise prescription recommended by the American Sports Medicine Association for individuals with adult Type 2 diabetes will be taken into consideration. In this context, planning will be made by considering the progression of stretching, balance and walking exercises from simple to difficult.
219715749|NCT06819371|OTHER|Dual Task Exercise|Patients enrolled in the dual-task exercise group will perform a second task during the exercise sessions along with the exercises in the single-task exercise group. This second task will be determined individually according to the level and progress of the patient.
219134962|NCT02918786|DEVICE|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
219134963|NCT02272400|OTHER|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
219134964|NCT03774914|DRUG|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
219134965|NCT00090298|DRUG|MK0653A, ezetimibe (+) simvastatin|
219715750|NCT01462448|PROCEDURE|Blood Draw|Single blood draw of 30 ml
219715751|NCT05708924|DRUG|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
219715752|NCT05708924|BIOLOGICAL|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
219715753|NCT05743140|DIAGNOSTIC_TEST|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
219134966|NCT00090298|DRUG|Comparator: Rosuvastatin|
219134967|NCT01048788|DRUG|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
219134968|NCT06432842|OTHER|Laser Treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
219134969|NCT05677178|OTHER|observational|This study is an observational study without any intervention.
219134970|NCT00420316|BIOLOGICAL|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
219134971|NCT00420316|BIOLOGICAL|Placebo (primary vaccination study)|Two liquid oral doses of placebo
219134972|NCT00307450|DRUG|Levetiracetam|up to 200 mg per day in two dosages per day.
219134973|NCT05419557|BEHAVIORAL|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
219134974|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2321138A|intramuscular injections
219134975|NCT01196988|BIOLOGICAL|FluarixTM|intramuscular injections
219715754|NCT05374590|BIOLOGICAL|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
219715755|NCT06364956|DRUG|Tislelizumab combined with two predefined dose groups of palbociclib|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
219715756|NCT06364956|DRUG|RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.|After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
219715757|NCT02487134|DEVICE|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
219715758|NCT02487134|DEVICE|Control|Closure of the abdomen with conventional technique
219715759|NCT06868355|OTHER|No intervention (observational study)|This is an observational study
219715760|NCT06865534|OTHER|Local language model|Group will be given access to local language model first after using ChatGPT and then will get access to pdf file
219715761|NCT06865534|OTHER|Guideline pdf|Group will be given access to pdf file after ChatGPT and then to a local language model
219715762|NCT05628324|BEHAVIORAL|practice muscle activation patterns|practice upper limb muscle activation patterns using EMG-controlled games
219715763|NCT05628324|BEHAVIORAL|task practice|practice functional upper limb tasks
219715764|NCT06608277|PROCEDURE|Group A active comparator|Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion
219715765|NCT06608277|DRUG|Group B active comparator|Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
219715766|NCT06608277|COMBINATION_PRODUCT|Group C Experimental|Group C experimental Stellate Ganglion Block plus ketamine infusion
219715767|NCT06608277|OTHER|Group D Placebo Comparator|Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
219134976|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2604409A|intramuscular injections
219134977|NCT01337869|PROCEDURE|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
219227967|NCT03593785|DRUG|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
219227968|NCT05113134|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
219227969|NCT00293410|DRUG|clofarabine|
219227970|NCT00293410|DRUG|cyclophosphamide|
219715768|NCT07010497|DRUG|irpagratinib|Patients will receive oral administration of ABSK-011 capsules in a repetitive dosing regimen for a period of 21 consecutive days as a cycle, either once daily or twice daily, until the investigators make a comprehensive assessment of imaging examinations, laboratory data, and the clinical condition of the patients, and determine that there is intolerable toxicity or disease progression.
219715769|NCT05186272|BEHAVIORAL|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
219715770|NCT05186272|BEHAVIORAL|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
219715771|NCT06588088|OTHER|Dietary|The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week, and in the second week, 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the nighttime eating syndrome (NES) criteria, after 20.30 in the evening.
219134978|NCT01337869|PROCEDURE|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
219134979|NCT04950855|DIAGNOSTIC_TEST|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
219134980|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
219134981|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
219134982|NCT01807858|OTHER|Maltodextrin|Maltodextrin
219134983|NCT01807858|DIETARY_SUPPLEMENT|İnulin|900 mg inulin per day will be given
219134984|NCT03824262|DEVICE|HICO-VARIOTHERM 550|Warming during perioperative period.
219715772|NCT00357565|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
219715773|NCT00357565|DRUG|busulfan|Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
219715774|NCT00357565|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
219715775|NCT00357565|DRUG|fludarabine phosphate|Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
219715776|NCT00357565|DRUG|melphalan|Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
219715777|NCT00357565|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
219715778|NCT00357565|PROCEDURE|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
219715779|NCT06863012|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
219715780|NCT06863012|DIAGNOSTIC_TEST|Hepatic Venous Pressure Gradient (HVPG) Measurement|Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.
219134985|NCT03824262|DEVICE|Mistral-Air Plus forced air warming device|Warming during perioperative period.
219134986|NCT00601848|DRUG|chemotherapy|
219134987|NCT00601848|DRUG|porfimer sodium|
219134988|NCT00601848|OTHER|immunohistochemistry staining method|
219134989|NCT00601848|OTHER|laboratory biomarker analysis|
219134990|NCT00601848|PROCEDURE|spectroscopy|
219134991|NCT00601848|PROCEDURE|therapeutic conventional surgery|
219134992|NCT04502511|DIAGNOSTIC_TEST|Standard diagnosis test|Care as usual
219134993|NCT01703130|PROCEDURE|Dose of of ropivacaine 0.75% used in block procedure|
219134994|NCT03375255|DRUG|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
219134995|NCT04486222|DEVICE|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
219134996|NCT00035542|DRUG|Glucovance (metformin HCl/glyburide)|
219134997|NCT00035542|DRUG|metformin HCl|
219134998|NCT00035542|DRUG|glyburide|
219134999|NCT03126656|DRUG|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
219135000|NCT03945942|DEVICE|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
219135001|NCT03945942|DEVICE|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
219135002|NCT05189340|OTHER|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
219135003|NCT00920686|DRUG|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
219135004|NCT00920686|DRUG|placebo|administered as 3 placebo hard gelatin capsules
219135005|NCT00920686|DRUG|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
219135006|NCT02182414|DRUG|BI 207127 NA (TF-I)|200 mg tablet
219135007|NCT02182414|DRUG|BI 207127 NA (TF-II)|400 mg tablet
219135008|NCT02182414|DRUG|BI 207127 NA delayed release|400 mg tablet
219135009|NCT02182414|DRUG|BI 207127 NA extended release (10% HPMC)|400 mg tablet
219227971|NCT03775213|BEHAVIORAL|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
219227972|NCT03775213|BEHAVIORAL|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
219227973|NCT00912171|DRUG|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
219715781|NCT05880836|DEVICE|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
219227974|NCT00912171|DRUG|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
219227975|NCT00451711|DRUG|Liposomal amphotericin B|
219715782|NCT05880836|DEVICE|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
219715783|NCT06626256|BIOLOGICAL|Aldesleukin|Given SC
219135010|NCT02182414|DRUG|BI 207127 NA extended release (15% PEO)|400 mg tablet
219135011|NCT02182414|DRUG|BI 207127 NA extended release (20% HPMC)|400 mg tablet
219135012|NCT00868192|DRUG|Pemetrexed|
219135013|NCT00868192|DRUG|Bevacizumab|
219227976|NCT01963598|DRUG|REGN1033 (SAR391786)|
219227977|NCT01963598|DRUG|placebo|
219135014|NCT02434718|DRUG|Aducanumab|As described in the treatment arm
219135015|NCT02434718|DRUG|Placebo|IV administration of 0.9% sodium chloride
219135016|NCT03203018|BEHAVIORAL|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
219135017|NCT04304534|DRUG|BAY2433334|Tablet, taken orally once a day.
219135018|NCT04304534|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
219135019|NCT06225999|DRUG|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
219227978|NCT06968351|BEHAVIORAL|Animal-Assisted Intervention|A brief animal-assisted intervention is offered on a group basis across four sessions. Each session lasts approximately 60 minutes and covers the same themes but through different exercises. These themes include effective communication, behavioral principles, problem-solving, and teamwork. The first part of a session involves learning to give effective single-component commands to a rehabilitative dog under the guidance of a professional dog handler. The second part of a session involves the applications of two or more of these single-component commands to an interactive group activity. Project staff are present at each session to facilitate discussions among participants on any challenges encountered, learning, and intra- as well as inter-personal experiences during the session.
219227979|NCT06458036|DRUG|Selpercatinib Monotherapy|Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.
219715784|NCT06626256|PROCEDURE|Biopsy|Undergo biopsy
219135020|NCT06225999|DRUG|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
219135021|NCT06225999|DRUG|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
219135022|NCT06225999|DRUG|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
219135023|NCT04102449|DRUG|Apremilast|Single arm receiving Apremilast and ultrasound examinations
219135024|NCT06555471|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1
219135025|NCT06555471|DRUG|S-1|po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
219715785|NCT06626256|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219715786|NCT06626256|PROCEDURE|Computed Tomography|Undergo CT
219715787|NCT06626256|DRUG|Cyclophosphamide|Given IV
219715788|NCT06626256|PROCEDURE|Excisional Biopsy|Undergo excisional biopsy
219715789|NCT06626256|DRUG|Fludarabine|Given IV
219715790|NCT06626256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219715791|NCT06626256|PROCEDURE|Standard Treatment|Receive standard of care therapy
219715792|NCT06626256|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given STIL101 for injection IV
219715793|NCT06866132|DEVICE|Investigational Noninvasive Neuromodulation Device|The investigational noninvasive neuromodulation device will be setup by the patient at bedtime and will be used every night. The IRB has established that the investigational device is non-significant risk.
219715794|NCT06859320|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy is one of the popular bariatric surgeries known for weight reduction
219135026|NCT06555471|DRUG|Capecitabine|1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
219135027|NCT06555471|RADIATION|Extraperitoneal radiation therapy|once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
219135028|NCT03795740|DIAGNOSTIC_TEST|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
219135029|NCT05043987|DRUG|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
219135030|NCT02931435|PROCEDURE|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
219135031|NCT02931435|PROCEDURE|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
219135032|NCT00464672|BIOLOGICAL|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
219135033|NCT00464672|BIOLOGICAL|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
219135034|NCT01645917|DEVICE|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
219715795|NCT07022054|DEVICE|iCare IC1000 measurement|Measurement of intraocular pressure with iCare IC1000
219715796|NCT06632600|DRUG|LXE408|LXE408 administered by oral route
219715797|NCT06632600|DRUG|Placebo|Placebo administered by oral route
219135035|NCT04900142|PROCEDURE|Micropulsed laser trabeculoplasty|Trabeculoplasty
219135036|NCT05581654|PROCEDURE|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
219135037|NCT02970708|DEVICE|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
219135038|NCT02970708|DEVICE|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
219135039|NCT02253719|PROCEDURE|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
219135040|NCT06152198|DEVICE|Treatment|Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
219135041|NCT00462969|PROCEDURE|Sonohysterography|Sonohysterography
219135042|NCT03906734|PROCEDURE|Septal myectomy|Transaortic septal myectomy
219135043|NCT03906734|PROCEDURE|alfieri stich|Transaortic Mitral valve repair using alfieri technique
219135044|NCT03906734|PROCEDURE|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
219227980|NCT06458036|RADIATION|131I Therapy|Patients will receive 131I therapy after 6 months of selpercatinib.
219715798|NCT06632600|DRUG|Benznidazole|Benznidazole administered by oral route (administered as standard of care)
219715799|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS active|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.
219715800|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS sham|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
219715801|NCT06698796|DRUG|Dazukibart|anti-interferon beta therapy
219715802|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
219715803|NCT06160531|DRUG|Placebo|Matching placebo
219715804|NCT06141005|DIAGNOSTIC_TEST|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
219715805|NCT05856331|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
219715806|NCT05856331|DRUG|Zemaira|Alpha1-Proteinase Inhibitor (Human)
219135045|NCT04042519|DIAGNOSTIC_TEST|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
219135046|NCT04042519|DIAGNOSTIC_TEST|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
219135047|NCT04042519|DIAGNOSTIC_TEST|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
219135048|NCT05145517|DEVICE|Open repair|Open repair of the aorta and peripheral arteries
219135049|NCT02887261|DEVICE|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
219135050|NCT02887261|DEVICE|Conventional Port|not for power injection for contrast media.
219135051|NCT04470817|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil
219135052|NCT01282775|BEHAVIORAL|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
219135053|NCT01282775|BEHAVIORAL|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
219135054|NCT01006746|OTHER|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
219135055|NCT02876146|DRUG|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
219227981|NCT06305312|BEHAVIORAL|Community Service Navigation|Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.
219135056|NCT05608967|DEVICE|PREHapp|Prehabilitation programme through the PREHapp platform
219135057|NCT01382810|DRUG|Altaire Gel forming solution|Three times a day for two months
219135058|NCT01382810|DRUG|Refresh Tears|Three times a day for two months
219135059|NCT00774111|DRUG|GSK1349572|GSK1349572 50 mg in combination with Etravirine
219135060|NCT01168453|BEHAVIORAL|head position change|AL-US distance measure using the ultrasound in two different head position
219135061|NCT01105884|PROCEDURE|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
219135062|NCT01105884|PROCEDURE|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
219135063|NCT01105884|PROCEDURE|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
219135064|NCT01105884|PROCEDURE|Hydrogel|All the subjects in this group will be treated with Hydrogel
219227982|NCT06305312|OTHER|Usual Care|Standard referral to community resources.
219135065|NCT01105884|PROCEDURE|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
219135066|NCT00569738|PROCEDURE|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
219135067|NCT05800821|PROCEDURE|Carotid revascularization|Carotid revascularization
219135068|NCT02888158|OTHER|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
219135069|NCT02888158|OTHER|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
219135070|NCT06441656|PROCEDURE|Vitrectomy with ILM flap|In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
219135071|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135072|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135073|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135074|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135075|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135076|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135077|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135078|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135079|NCT01276990|DRUG|BI 224436|Oral drinking solution
219135080|NCT01276990|DRUG|Placebo|Oral drinking solution
219135081|NCT00382135|DRUG|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
219135082|NCT00382135|DRUG|placebo|Placebo tablet taken by mouth once a day for 40 weeks
219135083|NCT01398930|OTHER|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
219135084|NCT04675463|DRUG|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
219135085|NCT04675463|DRUG|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
219135086|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
219135087|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
219135088|NCT01320709|DRUG|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
219715807|NCT07030452|DEVICE|Laser Acupuncture|Laser acupuncture irradiation was performed using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW. The laser probe was positioned perpendicularly to the skin surface, using a continuous wave mode with a dose of 4 Joules. The acupuncture points targeted were EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. Each point received irradiation for 1 minute and 20 seconds. During the therapy session, subjects wore a headset playing music and protective glasses. The treatment was administered twice a week for a total of 8 sessions.
219135089|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
219135090|NCT02601703|DRUG|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
219135091|NCT02601703|DRUG|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
219135092|NCT02601703|DRUG|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
219135093|NCT00001575|BIOLOGICAL|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
219135094|NCT00001575|DRUG|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
219135095|NCT01700569|DRUG|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
219135096|NCT01700569|DRUG|folinic acid at pharmacological dose is the escalated drug|
219135097|NCT01700569|RADIATION|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
219135098|NCT01228851|OTHER|Balance Training|Group balance training sessions three times a week for 8 weeks
219135099|NCT05583240|DRUG|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
219135100|NCT00300456|DRUG|ABT-335|135 mg, daily, 12 weeks
219135101|NCT00300456|DRUG|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
219135102|NCT00300456|DRUG|Placebo|Daily, 12 weeks, see Arm Description for placebo information
219135103|NCT00728845|BIOLOGICAL|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
219135104|NCT00728845|DRUG|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
219135105|NCT00728845|DRUG|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
219135106|NCT00728845|DRUG|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
219227983|NCT00462475|DRUG|Recombinant Growth Hormone, Genotropin (Pfizer)|
219135107|NCT01801319|DEVICE|Libra Deep Brain Stimulation System|
219135108|NCT00247143|DRUG|Kaletra (drug)|
219135109|NCT04258774|OTHER|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
219135110|NCT02667730|DRUG|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
219135111|NCT02667730|DRUG|Naproxen|naproxen 500mg twice daily for 7 days
219135112|NCT02667730|DRUG|Celecoxib|celecoxib 100mg twice daily
219135113|NCT02667730|OTHER|physiotherapy only|physiotherapy only (no drug)
219135114|NCT02458534|OTHER|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
219135115|NCT02458534|OTHER|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
219135116|NCT02458534|OTHER|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
219135117|NCT02086708|DEVICE|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
219135118|NCT04874571|OTHER|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
219135119|NCT02805244|DRUG|JTZ-951, 14C-JTZ-951|
219135120|NCT00438555|BEHAVIORAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
219227984|NCT05962476|DEVICE|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
219227985|NCT03784469|OTHER|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
219227986|NCT04634682|DIETARY_SUPPLEMENT|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
219227987|NCT03936777|DRUG|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
219135121|NCT00438555|BEHAVIORAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
219135122|NCT01168011|DRUG|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
219135123|NCT04251351|DRUG|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
219135124|NCT04251351|PROCEDURE|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
219135125|NCT04912362|DEVICE|YAG iridotomy|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
219135126|NCT03278197|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
219135127|NCT03278197|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
219135128|NCT03278197|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
219135129|NCT03278197|OTHER|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
219135130|NCT01724788|DRUG|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
219135131|NCT01724788|DRUG|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
219135132|NCT02701361|BEHAVIORAL|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
219135133|NCT02701361|BEHAVIORAL|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
219227988|NCT04914702|DEVICE|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
219227989|NCT04914702|DEVICE|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
219227990|NCT05402566|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
219227991|NCT03507179|OTHER|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
219227992|NCT03507179|OTHER|conventional dentures|conventional dentures
219227993|NCT04821271|OTHER|Placebo|Participants received Placebo capsule orally once daily for three weeks.
219227994|NCT04821271|DRUG|TS-161|Participants received TS-161 50-100 mg capsule orally once daily for three weeks. TS-161 is a mGlu2/3 receptor antagonist prodrug.
219227995|NCT02414178|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219227996|NCT04076059|DRUG|Enzalutamide|Oral
219227997|NCT04076059|DRUG|Placebo|Oral
219227998|NCT04076059|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
219227999|NCT05640167|BEHAVIORAL|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
219228000|NCT06326996|DRUG|Thiamine|Participants will be given an infusion of thiamine.
219135134|NCT02701361|BEHAVIORAL|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
219135135|NCT04591301|DRUG|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
219135136|NCT04591301|DRUG|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
219135137|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
219228001|NCT06326996|DRUG|Placebo|Participants will be given an infusion of the placebo treatment.
219228002|NCT06626919|BIOLOGICAL|anito-cel|Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
219228003|NCT06626919|DRUG|Standard Lymphodepletion regimen|Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
219135138|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
219135139|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
219135140|NCT04898803|OTHER|conventional DGVS training|see above
219135141|NCT04898803|OTHER|extended simulator training|see above
219228004|NCT06772246|DRUG|Quizartinib|Participants will receive a single oral dose of 90 mg
219228005|NCT06772246|OTHER|Placebo|Participants will receive a single oral dose of 90 mg
219228006|NCT03830788|RADIATION|Radiation by brachytherapy|Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
219228007|NCT03830788|RADIATION|Radiation by SBRT|SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
219228008|NCT02678182|DRUG|Capecitabine|1250 mg/m2/day, 21 day cycle
219228009|NCT02678182|DRUG|MEDI4736 (Durvalumab)|IV treatment on days 1\&15 of 28 day cycle
219228010|NCT02678182|DRUG|Trastuzumab|6mg/kg on day 1 cycle every 21 days
219228011|NCT02678182|DRUG|Rucaparib|600mg PO twice daily
219228012|NCT02678182|DRUG|Ramucirumab|ramucirumab 8mg/kg IV day 1 and day 8
219135142|NCT02175537|BEHAVIORAL|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
219135143|NCT02426320|OTHER|Sedation Interruption Protocol|
219135144|NCT02426320|OTHER|Standard Sedation Protocol|
219135145|NCT04599582|DEVICE|Hip Arthroplasty|Patients are operated with hip replacement.
219135146|NCT05100329|DRUG|Mitoxantrone Hydrochloride Liposome injection|20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
219135147|NCT05129982|DEVICE|whole body vibration|whole body vibration is a modality of physical therapy
219135148|NCT04990791|DRUG|Aspirin 75mg|Aspirin 75mg OD for 14 days
219135149|NCT04990791|DRUG|Aspirin 20mg|Aspirin 20mg BD for 14 days
219135150|NCT04990791|DRUG|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
219135151|NCT06486818|PROCEDURE|Ablation of idiopathic monomorphic PVCs|3D carto ablation of idiopathic monomorphic PVCs
219135152|NCT04258410|DRUG|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
219135153|NCT04258410|DRUG|Quercetin|experimental drug contained in soft chew
219135154|NCT01174316|DEVICE|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
219135155|NCT01174316|DEVICE|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
219135156|NCT00996372|DRUG|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
219135157|NCT00996372|DRUG|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
219135158|NCT02280655|BIOLOGICAL|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
219135159|NCT02280655|BIOLOGICAL|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
219135160|NCT00317655|DRUG|Glucosamine sulphate|
219135161|NCT00317655|DRUG|Ginger|
219135162|NCT00317655|DRUG|Ginger-Avocado-Soya|
219228013|NCT03156816|DRUG|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
219715808|NCT07030452|DEVICE|Sham Laser Acupuncture|Sham laser acupuncture irradiation was conducted using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW at the acupuncture points EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. However, the laser device was not activated, and no radiation was delivered to the patient. The laser probe was positioned perpendicularly to the skin surface at the same acupuncture points, but without activating the laser. During the session, subjects wore a headset with music and protective glasses, similar to the active treatment group. The sham treatment was administered twice a week for a total of 8 sessions.
219135163|NCT00317655|DRUG|Ginger-ibuprofen|
219135164|NCT04940676|DRUG|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
219135165|NCT04940676|DRUG|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
219135166|NCT03995810|DIETARY_SUPPLEMENT|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
219135167|NCT01190150|DRUG|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
219135168|NCT02797405|RADIATION|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
219135169|NCT02576418|OTHER|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
219135170|NCT04675255|PROCEDURE|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
219135171|NCT04675255|PROCEDURE|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
219135172|NCT04675255|PROCEDURE|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
219135173|NCT04564313|DRUG|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
219135174|NCT01738555|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
219135175|NCT01738555|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
219135176|NCT02834182|BEHAVIORAL|IRMf|
219135177|NCT02834182|BEHAVIORAL|Mini International Neuropsychiatric Interview|
219135178|NCT02834182|BEHAVIORAL|Positive And Negative Syndrom Scale|
219135179|NCT02834182|BEHAVIORAL|Young Mania Rating Scale|
219135180|NCT02834182|BEHAVIORAL|Hamilton Depression Scale|
219135181|NCT04461106|OTHER|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
219135182|NCT04312191|OTHER|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
219715809|NCT07033689|DEVICE|Suizenji (an ultrasound-guided HIFU therapy system)|Suizenji (an ultrasound-guided HIFU therapy system)
219715810|NCT07033689|DRUG|Nal-IRI/FL|Standard of care
219715811|NCT07033689|DRUG|mFOLFIRINOX adjuvant chemotherapy|standard of care
219715812|NCT07033689|DRUG|Gem/nab-PTX|standard of care
219715813|NCT07028398|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post- appointment follow-up call.
219135183|NCT02628691|OTHER|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
219135184|NCT02041676|PROCEDURE|Chest physiotherapy|
219135185|NCT02041676|PROCEDURE|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
219135186|NCT00866996|DRUG|Methylphenidate extended-release; Atomoxetine|
219135187|NCT06317688|DIETARY_SUPPLEMENT|Extra-Virgin Coconut Oil|Active ingredients act as a destructor of bacteria, viruses and fungus
219228014|NCT03156816|DRUG|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
219228015|NCT05993754|OTHER|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
219228016|NCT05452681|OTHER|Educational Intervention|Receive Y-AMBIENT
219228017|NCT05452681|OTHER|Quality-of-Life Assessment|Ancillary studies
219135188|NCT01506362|DRUG|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
219135189|NCT05994092|BEHAVIORAL|Voluntary Isocapnic Hyperpnea|The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
219228018|NCT05452681|OTHER|Questionnaire Administration|Ancillary studies
219228019|NCT05452681|OTHER|Control Intervention|Receive cookbook and socialization calls
219228020|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219228021|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
219135190|NCT02900365|PROCEDURE|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
219135191|NCT02900365|PROCEDURE|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
219135192|NCT03917706|OTHER|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
219135193|NCT04140058|DRUG|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
219135194|NCT04140058|DRUG|Normal saline|Placebo of 10 mL normal saline was administered.
219135195|NCT01881919|DIETARY_SUPPLEMENT|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
219135196|NCT01881919|DIETARY_SUPPLEMENT|Control|Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
219135197|NCT00578617|DRUG|Rate Control|Metoprolol 50-100mg
219135198|NCT00578617|DEVICE|Ablation Therapy|
219135199|NCT00578617|DRUG|Rate Control|Atenolol 50-100mg,
219135200|NCT00578617|DRUG|Rate control|Propranolol 40-80mg
219135201|NCT00578617|DRUG|Rate control|Acebutolol 200mg
219135202|NCT00578617|DRUG|Rate control|Carvedilol 6.25mg
219135203|NCT00578617|DRUG|Rate Control|Diltiazem 180-240mg
219228022|NCT01690416|PROCEDURE|Traditional palpation technique|
219228023|NCT01690416|PROCEDURE|Ultrasound DNTP|
219228024|NCT00741546|PROCEDURE|Cardiac Surgery|Cardiac Surgery
219228025|NCT02831816|DRUG|ZuraPrep|Apply topically.
219228026|NCT02831816|DRUG|ChloraPrep|Apply topically.
219135204|NCT00578617|DRUG|Rate Control|Verapamil 180-240mg
219135205|NCT00578617|DRUG|Rate Control|Digoxin 0.125mg
219135206|NCT00578617|DRUG|Rhythm Control|Propafenone 450mg
219135207|NCT00578617|DRUG|Rhythm control|Flecainide 200mg
219135208|NCT00578617|DRUG|Rhythm control|Sotalol 240mg
219135209|NCT00578617|DRUG|Rhythm control|Dofetilide 500mcg
219135210|NCT00578617|DRUG|Rhythm control|Amiodarone 200mg
219135211|NCT00578617|DRUG|Rhythm control|Quinidine 600-900mg
219228027|NCT02831816|DRUG|ZP Vehicle|Apply topically.
219135212|NCT01624636|DRUG|Placebo|
219135213|NCT01624636|DRUG|LFG316|
219135214|NCT01624636|DRUG|LFG316|
219135215|NCT02905968|DEVICE|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
219135216|NCT04782999|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
219135217|NCT04782999|DIAGNOSTIC_TEST|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
219135218|NCT06278064|OTHER|Gastric Cancer|Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
219135219|NCT06278064|OTHER|Esophagus Cancer|Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
219135220|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
219135221|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
219228028|NCT06623669|BEHAVIORAL|MORPH|A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.
219228029|NCT06623669|BEHAVIORAL|Measurement Only|This intervention entails receipt of a body weight scale and wearable activity monitor.
219715814|NCT07115199|PROCEDURE|Remote Patient Monitoring|The patients randomized to this intervention will get set up with remote patient monitoring. For these patients, blood pressure management and medication adjustment will be based on remote blood pressure measurements.
219715815|NCT07114237|PROCEDURE|Opioid Free Anesthesia|patients will receive opioid free anesthesia and bilateral ultrasound guided transversus abdominus plane block.
219715816|NCT07114237|PROCEDURE|Control group (general anesthesia)|patients will receive conventional general anesthesia
219715817|NCT07035886|OTHER|No intervention|As this is an observational study, no intervention will be administered.
219715818|NCT04539041|DRUG|antisense oligonucleotide|solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
219715819|NCT04539041|DRUG|placebo|placebo for each dose level
219135222|NCT05629364|DRUG|KIO-101|Randomized, Controlled
219135223|NCT03244787|BEHAVIORAL|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
219135224|NCT00843193|DRUG|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
219135225|NCT00843193|DRUG|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
219135226|NCT00843193|DRUG|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
219135227|NCT00820118|DRUG|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day"
219135228|NCT00240916|BIOLOGICAL|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
219135229|NCT00240916|BIOLOGICAL|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
219135230|NCT00921739|RADIATION|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
219135231|NCT04511650|DRUG|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
219135232|NCT04511650|DRUG|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
219228030|NCT04587648|OTHER|NA, observational study|NA, observational study
219228031|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
219228032|NCT00527267|DRUG|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
219228033|NCT00527267|DRUG|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
219135233|NCT05272124|OTHER|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
219135234|NCT05272124|OTHER|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
219135235|NCT06022536|DRUG|SSS40|Subjects injected with SSS40
219135236|NCT06022536|DRUG|Placebo|Subjects injected with Placebo
219135237|NCT02561403|BEHAVIORAL|EVO multitask video game|Participants will play a multitasking game for 4 weeks
219135238|NCT02561403|BEHAVIORAL|EVO words video game|Participants will play a word puzzle game for 4 weeks
219135239|NCT02929511|PROCEDURE|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
219135240|NCT02929511|PROCEDURE|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
219715820|NCT06883097|BEHAVIORAL|Learn to Quit-HIV (LTQ-H) App|LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.
219715821|NCT06883097|BEHAVIORAL|QuitStart|This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.
219715822|NCT06892314|BIOLOGICAL|Exposure to hyperglycemia (type 2 diabetes)|Exposure to hyperglycemia, in the context of type 2 diabetes, as measured by continuous glucose monitoring
219715823|NCT06743074|OTHER|foot exercise|foot exercise
219715824|NCT06743074|OTHER|hip exercise|hip exercise
219715825|NCT06743074|OTHER|control|control
219715826|NCT06740721|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
219715827|NCT06840548|DRUG|[68Ga]Ga-OncoCAIX|Single intravenous bolus administration.
219715828|NCT07056244|DRUG|Dexmedetomidine|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
219715829|NCT07056244|DRUG|Dexamethasone|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
219715830|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
219135241|NCT02929511|PROCEDURE|Active comparator Protaper multi-file system|
219135242|NCT05027087|DIETARY_SUPPLEMENT|Blueberry gummy|Gummy bear containing blueberry powder
219135243|NCT05027087|DIETARY_SUPPLEMENT|Placebo gummy|Gummy bear with no active ingredients
219715831|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
219715832|NCT06346899|OTHER|No intervention|This is a non-interventional study.
219715833|NCT05295407|GENETIC|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
219715834|NCT06768320|DRUG|Lomaira 8Mg Tablet|8 mg tablet up to three times a day
219715835|NCT00632359|DRUG|Lenalidomide|10 mg daily given for 12 months
219715836|NCT06845553|DRUG|Vutiglabridin|Once-daily oral administration
219715837|NCT06845553|DRUG|Placebo|Once-daily oral administration
219715838|NCT06892847|PROCEDURE|Transcranial Magnetic Stimulation|Participants will receive TMS for treatment measures as determined by referral and presentation.
219715839|NCT07041151|OTHER|At-home Foley Catheter Self-Removal with Passive Void Trial|Participants will remove their foley catheter at home and perform a passive void trial. They will be instructed to drink fluids and attempt to void within a designated time frame. Instructions and support will be provided to ensure safety and follow-up, including clinic contact if voiding is unsuccessful.
219135244|NCT03682328|PROCEDURE|vertebroplasty|Cement augmentation of the vertebral body
219135245|NCT03682328|PROCEDURE|kyphoplaty|Cement augmentation of the vertebral body
219135246|NCT00454792|OTHER|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
219135247|NCT00454792|OTHER|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
219135248|NCT01007344|DIETARY_SUPPLEMENT|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
219135249|NCT01007344|DIETARY_SUPPLEMENT|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
219715840|NCT07041151|OTHER|In-Office Foley Catheter Removal and Backfill Void Trial|Participants will return to clinic for removal of their foley catheter and undergo a backfill void trial. Standard protocols for instillation and assessment of urinary retention will be followed.
219715841|NCT06772077|DEVICE|Rehabilitation treatment with ATLAS2030|10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.
219715842|NCT06717399|OTHER|Mindfulness meditation|Each mindfulness meditation session will be 30 minutes long, consisting of a 5-minute introduction, 15 minutes of guided mindfulness meditation, and 10 minutes of educational discussion.
219715843|NCT06751784|DRUG|Fampridine SR|Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
219715844|NCT06751784|OTHER|Placebo|no active substance
219715845|NCT07083232|DIETARY_SUPPLEMENT|standard normal diet|Group I: formed of normal animals. They were allowed standard normal diet and water. They received no drugs
219715846|NCT07083232|DRUG|low dose Streptozotocin|Non-treated diabetic rats; diabetes was induced by administration of 20% fructose solution in drinking water for 2 weeks, then intra peritoneal injection of a low dose STZ (40 mg/kg b.w.), was done
219715847|NCT07083232|DRUG|Sitagliptin (Novartis, USA)|Sitagliptin treated diabetic group sitagliptin was administered by gastric gavage in a dose 10mg/ kg /day for 4 weeks
219715848|NCT07083232|DRUG|Pioglitazone hydrochloride (Unipharma., Egypt)|Pioglitazone treated diabetic group (G4); Pioglitazone was administered by gastric gavage in a dose 10 mg/ kg /day for 4 weeks
219228034|NCT05328570|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
219228035|NCT04740580|DIETARY_SUPPLEMENT|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
219228036|NCT04740580|DIETARY_SUPPLEMENT|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
219228037|NCT04740580|DIETARY_SUPPLEMENT|Alanine|The placebo arm will supplement Alanine
219715849|NCT07083232|DRUG|Dapagliflozine hemihydrate (Janssen, USA)|Dapagliflozine treated diabetic group (G5); Dapagliflozine was administered by gastric gavage in a dose 1mg/ kg /day for 4 weeks
219715850|NCT07119658|BEHAVIORAL|Composite intervention to address MetS|"The composite intervention includes six components: 1. All patients will be provided a Fitbit Charge device at ED discharge with instructions to wear on their wrist for study duration. 2. Participants in the intervention group will first watch a brief (\~5 minute) educational video outlining the adverse effects of MetS and the benefit of walking, via iPad tablet. 3. Participants in the intervention group will also be given accompanying written exercise prescription encouraging them to walk 150 minutes per week. 4. Reminder texts encouraging continued walking behavior (i.e. Remember to get in your steps!) will be sent to the intervention group, at approximate 2-3x/week intervals for the 3-month follow-up period. 5. The intervention group will also be provided written resources for healthy eating practices upon ED discharge. 6. All intervention group participants will receive referrals into primary care clinic and the Eskenazi Health Healthy Me Program for follow-up."
219135250|NCT04744519|OTHER|Collect data|\- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
219135251|NCT00590850|PROCEDURE|ORIF with Plate and Screws|ORIF with plate and screws
219135252|NCT00590850|PROCEDURE|Pin Fixation|Clavicle fixation with clavicle pin
219135253|NCT02637908|BEHAVIORAL|Mindfulness training|6-weeks of group-based mindfulness training for parents
219135254|NCT01848548|PROCEDURE|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
219135255|NCT02982213|OTHER|Companion Present|A companion will be present during the epidural catheter placement.
219135256|NCT04878796|DIAGNOSTIC_TEST|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
219228038|NCT06980090|BEHAVIORAL|Session A: Positive Placebo + Active tTIS|Participants receive active tTIS, with two signals set at 2000 Hz and 2080 Hz, creating an 80 Hz interference beat targeting the anterior/mid-cingulate cortex (aMCC). Stimulation is delivered at 2 mA for 20 minutes. The stimulation is combined with a positive social placebo intervention delivered by the care provider. Participants complete three multimodal negative affect tasks (MNAT) before and after the stimulation.
219551093|NCT05920486|DEVICE|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
219551094|NCT03250117|DRUG|Ropinirole oral product|oral immediate-release ropinirole
219551095|NCT03250117|DRUG|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
219715851|NCT07115134|DEVICE|Bearables Gastrostomy Tube Dressing|"The gastrostomy tube dressing in its current design is composed of two parts, both of which are external to the patient: one part is rigid and holds the gastrostomy at a fixed position, this is a 3D printed design that is produced here. The second part is a 3 x 3 flexible, cushioned, biocompatible adhesive bandage designed to fit around the skin opening (Silicone Foam Dressing, NH NeuHeils, USA). The design is subject to minor changes including the number of parts and location with the structure of the padding and securement but will continue to be designed with comfort as a priority. After assembly, the device is packaged (sterilization pouches, Plastcareusa, USA), sealed, and sanitized using UV light prior to patient use."
219551096|NCT00108030|PROCEDURE|Partial Body-weight supported Treadmill Training|
219551097|NCT00108030|PROCEDURE|PBWST + Power training|
219551098|NCT00108030|PROCEDURE|"Usual physiotherapy care"|
219551099|NCT05295524|OTHER|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
219551100|NCT02247687|DRUG|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
219551101|NCT02247687|DRUG|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
219551102|NCT02247687|OTHER|Counseling arm|No change of antiretroviral treatment but only counseling
219551103|NCT02186353|BEHAVIORAL|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
219551104|NCT01731977|BEHAVIORAL|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
219551105|NCT00084097|DRUG|Omalizumab|
219551106|NCT02957578|DEVICE|Solo TTD|Placement of tympanostomy tube with Solo TTD
219551107|NCT01390051|DRUG|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
219551108|NCT01390051|DRUG|tinzaparin|Dose 4,500 IE daily
219551109|NCT05942976|OTHER|ULTRASOUND|10 enthesis areas will be evaluated in 20 minutes with ultrasound.
219135257|NCT06360016|BEHAVIORAL|Recreation Activity Program|Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
219715852|NCT06930040|OTHER|Action observation therapy protocol|The examined group got 30 minutes of a standard, selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter in front of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement. The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick.
219715853|NCT06930040|OTHER|Kenisiotaping|"Shoulder taping will done using two Kinesiotex tapes(2.5 · 7 cm), in the form of I shape. The tapes follow the line of pull of the anterior and posterior deltoid muscle fibers applied in order to assist the deltoid muscle action .~The tape was applied with the child in a sitting position by assistance from his care giver, while the therapist supported the child's arm. The first tape was initiated from the upper border of the lateral 1/3 of the clavicle to the deltoid prominence on the middle of the lateral side of the body of the humerus moving backward and lateralward while the arm was externally rotated and horizontally abducted. The second tape was initiated from the lower lip of the posterior border of the spine of the scapula towards also the humeral deltoid prominence moving forward and lateralward while the arm was horizontally adducted and internally rotated as if reaching to the outside of the contralateral hip."
219715854|NCT07087015|PROCEDURE|Cervical sympathetic nerve block|Patients will receive a CSB.
219715855|NCT07087015|PROCEDURE|Subcutaneous sham injection|Patients will receive a subcutaneous sham injection of saline.
219715856|NCT07087015|DRUG|Ropivacaine|The CSB group will receive ropivacaine 0.5% 10ml.
219715857|NCT07087015|DRUG|Normal Saline|The control group will receive 3 ml of normal saline in the sham injection.
219715858|NCT06930872|DRUG|Part 1|ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)
219715859|NCT06930872|DRUG|Part 2|ZYN002 (transdermal), VPA (oral)
219715860|NCT07078773|PROCEDURE|peng block|A convex ultrasound probe (frequency 2-5 MHz) was positioned at the patient's inguinal ligament, with one end directed toward the anterior inferior iliac spine (AIIS), clearly visualizing the bony prominences of the iliopubic eminence and the AIIS. The needle tip was directed medially toward the pectineus muscle. Upon reaching the space between the pectineus muscle and the pubic bone, and after confirming the absence of blood on aspiration, 30 ml of 0.375% ropivacaine was injected.
219135258|NCT02646670|DRUG|Ranibizumab|\- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
219135259|NCT02646670|DRUG|Aflibercept|\- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
219135260|NCT02646670|DRUG|Ranibizumab and Aflibercept|\- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
219228039|NCT06980090|BEHAVIORAL|Session B: Positive Placebo + Sham tTIS|Participants receive sham tTIS, using two identical 2000 Hz signals that produce no low-frequency interference. The device mimics active parameters (2 mA, 20 minutes) without delivering effective stimulation. The sham stimulation is paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
219551110|NCT03983135|OTHER|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
219715861|NCT07078773|PROCEDURE|obturator nerve block|An ultrasound probe was positioned at the inguinal ligament, with the needle inserted parallel to the long axis of the probe. After confirming no blood upon aspiration, 15 ml of 0.375% ropivacaine was injected into the fascial plane between the adductor brevis and adductor magnus, as well as into the midportion of the adductor longus and adductor brevis muscles.
219715862|NCT06905288|DRUG|Secukinumab|This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
219715863|NCT06879574|OTHER|Measuring dietary intake|During 5-week study, participants will monitor their usual dietary intake during two 3-day periods (on weeks 1 and 5). During week 3 (calibration week) participants will consume a test diet. Wearable camera technology, self-collected blood and urine samples, and online FFQ (eNutri) will be used to monitor food intake during study weeks. Study tools as well as foods/drinks for the test diet will be delivered to each participant and they will be asked to comply with the study procedures in their home or working environment. Participants will post study samples and the study equipment/logs at designated times using pre-paid envelopes or a courier collection, respectively.
219715864|NCT00453505|DEVICE|TMS|\<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
219715865|NCT00453505|DEVICE|tDCS|tDCS up to 2 mA for up to 60mins.
219715866|NCT00453505|DEVICE|tACS|tACS up to 1 mA for up to 10 minutes.
219715867|NCT00453505|DEVICE|CPNS|CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
219228040|NCT06980090|BEHAVIORAL|Session C: Negative Placebo + Active tTIS|Participants receive active tTIS (2000 Hz and 2080 Hz signals, 2 mA, 20 minutes) combined with a negative social placebo intervention (neutral or skeptical messaging about treatment efficacy). Participants complete three MNAT tasks before and after the stimulation.
219228041|NCT06980090|BEHAVIORAL|Session D: Negative Placebo + Sham tTIS|Participants receive sham tTIS (identical 2000 Hz signals, mimicking active stimulation) combined with a negative social placebo intervention. Participants complete three MNAT tasks before and after the session.
219135261|NCT02646670|DRUG|Aflibercept and ranibizumab|\- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
219135262|NCT02247258|DRUG|Azathioprine|See arm/group descriptions
219135263|NCT02247258|DRUG|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
219135264|NCT02247258|PROCEDURE|Ileocolonoscopy|See arm/group descriptions
219135265|NCT02247258|PROCEDURE|Small bowel follow trough|See arm/group descriptions
219135266|NCT03099824|DRUG|GC4711 Oral Capsule G-101|82 mg (1 capsule)
219135267|NCT03099824|DRUG|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
219715868|NCT07082777|BEHAVIORAL|Narrative therapy|The intervention is structured around 4 central tasks focusing on different aspects of narrative repair. Task 1: Introduction to life story exploration and building alliance. Task 2: Explore and process the impact of mental illness on identity, externalizing negative narratives, and making sense of emotional responses such as guilt, grief, or shame. Task 3: Identify positive identity conclusions (e.g., strengths, values, skills) from past or current life experiences, and support their integration into the personal narrative. Task 4: Support the imagining of a realistic and hopeful future narrative, grounded in insights of previous sessions. Tasks 1-4 are addressed in a total of 8-12 sessions, depending on the specific user needs. Sessions will have an app. duration of 45-60 mins and will be delivered by the PI who is a trained therapist and psychologist (MSc. Psych.), receiving ongoing supervision. The intervention manual will be made freely available in relation to study publication.
219135268|NCT03099824|DRUG|GC4711 Oral Capsule G-101|164 mg (2 capsules)
219135269|NCT03099824|DRUG|GC4711 Oral Capsule G-101|246 mg (3 capsules)
219135270|NCT03099824|DRUG|GC4711 Oral Capsule G-111|175 mg (1 capsule)
219551111|NCT03983135|OTHER|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
219715869|NCT07089901|DRUG|transdermal nicotine replacement therapy|All participants will receive transdermal nicotine replacement therapy (21 mg. patches)
219135271|NCT03099824|DRUG|GC4711 Oral Capsule G-112|145 mg (1 capsule)
219135272|NCT03099824|DRUG|GC4711 Oral Capsule G-119|233 mg (1 capsule)
219135273|NCT03099824|DRUG|GC4711 Oral Capsule G-125|233 mg (1 capsule)
219135274|NCT03099824|DRUG|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
219135275|NCT04619303|DRUG|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
219135276|NCT04619303|DRUG|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
219135277|NCT05826678|DEVICE|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
219135278|NCT05826678|BEHAVIORAL|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
219135279|NCT03610997|PROCEDURE|Photorefractive keratectomy|
219135280|NCT05939648|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
219135281|NCT05939648|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
219135282|NCT01972152|DRUG|G-Pen(TM) 1 mg|
219135283|NCT01972152|DRUG|Lilly Glucagon(TM) 1 mg|
219135284|NCT01972152|DRUG|G-Pen(TM) 0.5 mg|
219715870|NCT07092254|DRUG|No drug|No study drug will be administered in this non-interventional study.
219715871|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
219135285|NCT06479733|PROCEDURE|buccal pedicle flap|For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture
219135286|NCT06479733|PROCEDURE|connective tissue graft|For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.
219135287|NCT06479733|PROCEDURE|acellular dermal matrix|"* For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone."
219135288|NCT06479733|PROCEDURE|control group|only placement of dental implant without soft tissue augmentation
219715872|NCT03907046|DRUG|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
219135289|NCT03211637|COMBINATION_PRODUCT|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
219135290|NCT00001886|PROCEDURE|Real time 3-dimensional stress echocardiography|
219135291|NCT01967407|PROCEDURE|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
219135292|NCT00950144|OTHER|medical chart review|
219135293|NCT00950144|OTHER|questionnaire administration|
219135294|NCT00950144|OTHER|study of socioeconomic and demographic variables|
219135295|NCT00950144|PROCEDURE|quality-of-life assessment|
219135296|NCT03329742|OTHER|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
219135297|NCT03329742|OTHER|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
219135298|NCT02001714|BEHAVIORAL|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
219135299|NCT01194258|DRUG|Insulin lispro|
219715873|NCT03907046|DRUG|Aspirin|Aspirin is an oral antiplatelet drug.
219715874|NCT03997123|DRUG|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
219715875|NCT03997123|DRUG|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
219135300|NCT01194258|DRUG|Insulin aspart|
219135301|NCT01194258|DRUG|Recombinant human hyaluronidase PH20|
219135302|NCT01194258|DRUG|Insulin glulisine|
219135303|NCT01194258|DRUG|Insulin glargine|
219135304|NCT01559506|DEVICE|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
219135305|NCT05739513|DIAGNOSTIC_TEST|miRNA analysis in plasma|blood sample
219135306|NCT04184804|BEHAVIORAL|Behavioral Intervention|"The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents"
219135307|NCT02012543|DIETARY_SUPPLEMENT|Agar jelly|
219135308|NCT04241224|DEVICE|Atherectomy|Endovascular treatment of peripheral arterial disease
219135309|NCT01966055|DRUG|Solithromycin|
219135310|NCT06339918|OTHER|KegelExercise|Kegel exercises (also called pelvic floor exercises)will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
219135311|NCT06339918|OTHER|4-7-8 breathing technique|This can be performed in the following way: Participants taking part should locate a comfy spot to sit. Inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
219228042|NCT06980090|BEHAVIORAL|Session E: On-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation followed by no current) paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
219228043|NCT06980090|BEHAVIORAL|Session F: Off-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation, then no current) without any placebo intervention. Participants complete three MNAT tasks before and after the session.
219228044|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
219228045|NCT06116968|DRUG|Aficamten|5-20mg
219135312|NCT06630910|PROCEDURE|Pancreaticojejunostomy without stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall without stenting or omental patch.
219135313|NCT06630910|PROCEDURE|Pancreaticojejunostomy with stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall, a nelaton stent 6f was inserted into the pancreatic duct and jejunum of each patient receiving PJ. The larger omentum was separated longitudinally over an avascular zone, and one or two omental branches of the gastroepiploic arteries were preserved using pedicle omental flaps. The omental flap was pushed between the posterior surface of PJ and the portal vein, then wrapped over the anterior surface of PJ. The omentum was rolled up and secured with a few PDS sutures.
219135314|NCT06631300|DRUG|Prednisone|A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
219135315|NCT06631300|DRUG|Placebo|A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
219135316|NCT06631911|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format.~The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences."
219135317|NCT03614234|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
219135318|NCT06629571|OTHER|Education|Training for the patient before surgery
219715876|NCT03997123|DRUG|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
219715877|NCT06461143|DRUG|%4 articaine with 1:200 000 adrenaline|For intraosseous anesthesia SleeperOne5 device is going to be used.
219715878|NCT07094724|BIOLOGICAL|Plasma|administration of IV high-titer WNV-neutralizing plasma
219135319|NCT01582945|DRUG|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
219715879|NCT07092995|BEHAVIORAL|VR Freezing Task|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes
219715880|NCT07092995|BEHAVIORAL|Dual Task|Walking overground with and without concomitant performance of secondary cognitive or motor task
219715881|NCT07092995|BEHAVIORAL|External Cueing|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes with and without addition of visual and auditory cues.
219715882|NCT07095842|DRUG|Ketamine|Intramuscular ketamine 2 mg/kg (max 90 mg)
219135320|NCT00910702|DEVICE|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
219135321|NCT01855464|PROCEDURE|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
219715883|NCT07095842|DRUG|Midazolam|Intramuscular midazolam 0.2 mg/kg (max 10 mg)
219135322|NCT01855464|PROCEDURE|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
219135323|NCT06053931|BEHAVIORAL|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s)."
219135324|NCT06053931|BEHAVIORAL|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
219135325|NCT02920359|DRUG|LEUPRORELIN ACETATE|
219715884|NCT07095764|OTHER|Manual Lymphatic Drainage|Specific manual lymph drainage techniques including stationary circles, rotary circles, pumping, and scooping will be applied to both lower extremities using gentle, rhythmic skin movements in accordance with the direction of the lymphatic flow.
219715885|NCT07095764|OTHER|Cardiac Rehabilitation|An individualized program consists of progressive, low-intensity exercises including respiratory exercises, range of motion exercises for major joints, postural exercises, flexibility exercises, and gradual mobilization exercises such as sitting and walking will be applied.
219135326|NCT02560818|OTHER|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
219135327|NCT02560818|OTHER|use of a previous blood collection for patients|
219135328|NCT02710968|DEVICE|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
219135329|NCT03066596|BEHAVIORAL|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
219135330|NCT04798521|OTHER|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
219135331|NCT04798521|OTHER|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
219135332|NCT02443792|PROCEDURE|Unicirc with tissue adhesive|As above
219135333|NCT02443792|PROCEDURE|Open Surgical|As above
219135334|NCT02573740|DRUG|ABT-957|
219135335|NCT02573740|OTHER|Placebo|
219715886|NCT07096388|PROCEDURE|endovascular repair|at first the iliac pathology main endovascular treatment was the graft stenting extended along the common and the external iliac artery with the embolisation of the internal iliac artery, with an high risk of pelvic ischemic complications, bowel ischemia, spinal cord ischemia, buttock claudication, erectile dysfunction. Nowadays, off-the-shelf endografts with a special design, the Iliac Branch Endoprosthesis, are available. These grafts, which preserve the hypogastric artery, avoiding complications due to its occlusion; they ensure better distal sealing by reducing the rate of type Ib endoleaks. The patient can be treated under local anesthesia and sedation or general anesthesia. Ultrasound-guided percutaneous access to one or both femoral arteries and, if needed, to the axillary or brachial artery is gained.
219715887|NCT07096388|PROCEDURE|open surgical repair|in case of surgical repair of aorto-iliac aneurysms, general anesthesia is required. Access to the aorta can be achieved through a transperitoneal or retroperitoneal approach. A bifurcated graft is usually used for reconstruction as it is more similar to the native anatomical conformation, but it is not the only option. Although not mandatory, it may be necessary to revascularize one or both internal iliac arteries. This is a very complex surgical technique, challenging even for the most experienced operators due to the location of the iliac arteries. It is a procedure with a high risk of bleeding and mortality, and a high risk of damaging nearby structures such as the ureters and great veins. At the end of the procedure the patient is awake and is usually monitored in the recovery room and then translated to the ward, with fewer than 20% of patients needing Intensive Care Unit (ICU) admission.
219715888|NCT06911060|DIETARY_SUPPLEMENT|Flaxseed|30 g/day for 12 weeks
219135336|NCT01656304|BIOLOGICAL|bevacizumab|Given IV
219135337|NCT01656304|OTHER|laboratory biomarker analysis|Correlative studies
219135338|NCT05826431|DEVICE|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
219135339|NCT00475813|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
219135340|NCT00469118|DEVICE|DRX9000™|Nonsurgical spinal decompression
219135341|NCT01322958|DEVICE|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
219135342|NCT06631924|DEVICE|Implant|Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
219715889|NCT06911060|BEHAVIORAL|Diet|Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
219715890|NCT07098572|DEVICE|Cyclic single channel neuromuscular stimulation|Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions
219715891|NCT07098572|DEVICE|Electromyogram-triggered 4 channel neuromuscular stimulation|EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions
219715892|NCT06911346|DIETARY_SUPPLEMENT|Diet supplementation|Healthy plant-based diet (plus supplemental foods) as part of a hypocaloric diet.
219135343|NCT05838664|DRUG|No OAC|AF Patient who were not exposed to oral anticoagulation
219135344|NCT05838664|DRUG|VKA|AF patients who received VKA
219135345|NCT05838664|DRUG|apixaban|AF patients who received apixaban
219135346|NCT05838664|DRUG|rivaroxaban|AF patients who received rivaroxaban
219135347|NCT05838664|DRUG|dabigatran|AF patients who received dabigatran
219135348|NCT03519373|BIOLOGICAL|TDaP|Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
219135349|NCT04068545|DEVICE|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
219135350|NCT02163915|DRUG|TAK-137|TAK-137 tablets
219135351|NCT02163915|DRUG|TAK-137 Placebo|TAK-137 placebo-matching tablets
219135352|NCT06055712|DRUG|Cefazolin|Intravenous dose(s).
219135353|NCT06055712|DRUG|Cephalexin|Five days oral.
219135354|NCT04139694|DIETARY_SUPPLEMENT|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
219135355|NCT04139694|BEHAVIORAL|Food plan without cinnamon supplementation|Cardiometabolic diet only
219135356|NCT05956600|DRUG|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
219135357|NCT03981549|BIOLOGICAL|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
219135358|NCT03981549|BIOLOGICAL|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
219135359|NCT06599021|BEHAVIORAL|Muscular strengthening training|6 weeks daily muscular strengthening training.
219135360|NCT06599021|BEHAVIORAL|Skill-based training|15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
219135361|NCT00865956|BEHAVIORAL|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
219135362|NCT00865956|OTHER|Case management|Nurse case manager assigned to participant
219135363|NCT00689156|DRUG|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
219135364|NCT00689156|DRUG|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
219715893|NCT06911346|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Hypocaloric diet with polyphenol-rich supplement. Polyphenol-rich sachets containing ≈30g/day of a combination of plant extracts rich in polyphenol. Frequency: 2 sachets a day. Duration: 12 weeks
219715894|NCT06911346|OTHER|Placebo|Hypocaloric diet plus Placebo. The placebo is a sachet (≈30g/day) with similar appearance, taste, and texture but without active polyphenols. Frequency: 2 sachets a day. Duration: 12 weeks
219715895|NCT07095023|DRUG|Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab|"Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment.~Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w."
219715896|NCT07099690|PROCEDURE|Perineal massage|"Perineal massage will be performed during labor, either between or during contractions, regardless of the position chosen by the laboring woman.~The researcher, wearing gloves, will insert one or two fingers (index and middle) into the participant's vaginal canal and move them from side to side in a U-shaped motion, for approximately one second in each direction. Light downward pressure will be applied toward the rectum, according to the woman's tolerance, until relaxation of the massaged perineal muscles is observed.~A water-based lubricant will be used to facilitate the procedure. The massage will last no longer than 5 minutes."
219715897|NCT06755450|DRUG|AUR112|Once daily
219715898|NCT07097025|DEVICE|vagus nerve stimulation|VNS is a neuromodulatory treatment involving implantation of a subcutaneous device that delivers intermittent electrical stimulation to the vagus nerve, modulating central pathways associated with mood regulation.
219715899|NCT07097532|PROCEDURE|Radiofrequency|Under sterile conditions and fluoroscopic guidance, pulsed radiofrequency treatment was applied unilaterally to the dorsal root ganglia at the L4-L5 and L5-S1 spinal levels. Sensory and motor stimulation were performed to confirm appropriate electrode placement. Pulsed radiofrequency was delivered at 45 volts for 300 seconds at 42°C using standard radiofrequency equipment. Patients were monitored for three hours following the procedure, and cutaneous silent period (CSP) recordings were obtained on the same day and during follow-up assessments.
219715900|NCT07097532|PROCEDURE|Transforaminal Epidural Steroid Injection|Using a fluoroscopic C-arm device, transforaminal epidural steroid injection (TFESI) was performed at the L4-L5 and L5-S1 foraminal levels. At each level, a total of 4 mL of solution containing 16 mg of dexamethasone and sterile saline was administered following confirmation of appropriate contrast spread. Negative aspiration was verified prior to injection. Cutaneous silent period (CSP) measurements were conducted on the same day and at designated follow-up intervals.
219715901|NCT07093359|PROCEDURE|Laparoscopic or robotic LINX procedure|Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
219715902|NCT07093359|PROCEDURE|Laparoscopic or robotic fundoplication|Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
219715903|NCT07100912|OTHER|Mitopure Topical Formula 5|Topical skin cream containing Mitopure
219715904|NCT07100912|OTHER|Mitopure Topical Formula 6|Topical skin cream containing Mitopure
219715905|NCT07100912|OTHER|Mitopure Topical Formula 7|Topical skin cream containing Mitopure
219715906|NCT07100912|OTHER|Mitopure Topical Formula 8|Topical skin serum containing Mitopure
219715907|NCT07100912|OTHER|Mitopure Topical Formula 9|Topical skin exfoliator containing Mitopure
219135365|NCT06610799|DRUG|IBI363|IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
219135366|NCT06613399|PROCEDURE|MTI-TME|Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME
219715908|NCT07100912|OTHER|Mitopure Topical Formula 10|Topical skin cleanser containing Mitopure
219135367|NCT06613399|PROCEDURE|C-TME|Conventional Total Mesorectal Excision，C-TME
219135368|NCT06614426|PROCEDURE|Test group 1 (T1)|Test group 1 (T1): Open flap debridement using electrolysis decontamination
219135369|NCT06614426|PROCEDURE|Test group 2 (T2)|Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
219135370|NCT06614426|PROCEDURE|Control group (C)|Conventional open flap debridement
219135371|NCT03484182|BEHAVIORAL|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
219135372|NCT03484182|BEHAVIORAL|Standard Home Exercise Program|Standard paper-based home exercise program
219135373|NCT05397470|DRUG|Losmapimod|Losmapimod 15 mg will be administered BID by mouth along with food.
219135374|NCT05397470|DRUG|Placebo oral tablet|Placebo will be administered BID by mouth along with food.
219135375|NCT06607731|OTHER|Collecting data from medical records|Data collected: clinical data (particularly pain), biological data, imaging.
219135376|NCT06668740|BEHAVIORAL|The use of Virtual Reality Glasses in Elderly|The group first completed a pretest, after which they watched 360-degree VR videos, such as nature walks and trips, for 10 minutes once a week over four weeks. Following this, a posttest was conducted. The outcomes will be used to measure changes in Quality of Life.
219135377|NCT05621655|BIOLOGICAL|Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
219135378|NCT05621655|BIOLOGICAL|High dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
219135379|NCT05621655|BIOLOGICAL|Placebo|0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
219135380|NCT05518110|DRUG|Trametinib|2mg of Trametinib (orally) daily.
219135381|NCT05518110|DRUG|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
219135382|NCT05799222|DIETARY_SUPPLEMENT|Bariatrix Meal Replacement Products|Meal replacement products offered through the Massachusetts General Hospital Weight Center.
219135383|NCT03808922|DRUG|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
219551112|NCT03983135|OTHER|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
219715909|NCT07103265|DEVICE|Transcranial focused ultrasound stimulation|Parameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 \* Thermal index (TI) 0.8oC \*\*
219715910|NCT07103265|DEVICE|Sham stimulation|Same set-up as for real stimulation but with without delivering any ultrasound stimulation
219715911|NCT07102992|DEVICE|High intensity laser therapy|"High intensity Laser Therapy :A standard handpiece endowed with fixed spacers will used to provide the same distance to the skin and perpendicularly to the zone to be treated with a laser beam diameter of 5 mm. Three phases of treatment will be performed for every session. The total energy that will be delivered to the patient during one session will be 1275 J through three phases of treatment.~Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
219715912|NCT07102992|DEVICE|Shock Wave therapy|"radial extracorporeal shock wave therapy (2,000 shots, 4 Bar, 5 Hz) (once a week) will be administered to the ulnar nerve at the proximal cubital tunnel region.~Frequency of treatment: Treatment will be given 1 time / week for 4 sessions"
219715913|NCT07102992|OTHER|Ulnar nerve gliding exercises.|"While keeping patients head in a neutral position, will teach the patient to:~1. Begin with your arm out, palm side of the hand facing up.~2. Bend the elbow toward you, palm side facing you.~3. Rotate the palm of your hand outward and bend your wrist so that the fingers are pointing towards you.~4. Twist your wrist so that the palm of your hand is now facing upward.~5. While your wrist remains bent, stretch out your arm into a straight position, with your fingers bent towards the floor.~Hold each position for 5 seconds, repeat series 3-5 times. Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
219715914|NCT07104877|DRUG|SYS6010|Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg
219715915|NCT07104877|DRUG|SYH2051|Administered via oral at the dose of 40-80 mg
219715916|NCT07100600|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan：4.8mg/kg Q3W
219715917|NCT07100600|RADIATION|FSRT or WBRT|FSRT （8Gy/3-5 fx）or WBRT（30Gy/10fx）
219715918|NCT07103590|PROCEDURE|single Sagittal Split plate|patients will be treated using a single Sagittal Split plate at the neutral zone of mandible
219715919|NCT07103590|PROCEDURE|two conventional miniplates|patients will be treated using two conventional miniplates according to Champy's osteosynthesis lines.
219135384|NCT03808922|DRUG|Placebo|Placebo nebulized qd x 7 OR 10 days
219135385|NCT03808922|DRUG|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
219135386|NCT03808922|DRUG|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
219135387|NCT04968574|DRUG|taladegib|hedgehog pathway inhibitor dosed once daily
219135388|NCT04968574|DRUG|placebo|identical tablets to the experimental arm with no active ingredient
219135389|NCT02952261|DEVICE|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
219135390|NCT02952261|OTHER|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
219135391|NCT06613958|BEHAVIORAL|Physical activity timing|The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
219551113|NCT04499664|DEVICE|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
219715920|NCT07103031|BEHAVIORAL|Behavioral therapy|Patients in PedMIDAS stage 1-2 (score ≤ 30) received behavioral therapy including lifestyle counseling, stress management techniques, sleep hygiene education, and individualized headache triggers review. Additionally, each patient was provided with a headache report card to self-monitor symptoms, triggers, and medication use over a 3-month period.
219715921|NCT07103031|DRUG|Propranolol|Patients in PedMIDAS stage 3-4 (score \> 30) received oral propranolol treatment at a dose of 1-3 mg/kg/day, adjusted by weight and tolerance, for a total of 3 months. The medication was prescribed and monitored by a pediatric neurologist. Patients were followed with routine check-ups and adverse effects were recorded.
219135392|NCT06615063|OTHER|Hasi's Splint|A splint made up of cotton and gauze piece rolled over a hard cardboard piece and covered by adhesive tape was applied to the limb immediately after fixing the cannula, as per the standardised method, to prevent movement at the underlying joint. Dimensions of the splints used were standardised as length extending two and a half inches on either side of the joint and width equal to the width of the limb just proximal to the joint.
219135393|NCT06614257|DRUG|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
219135394|NCT06614257|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
219135395|NCT06614257|DRUG|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
219135396|NCT06614231|DRUG|Tislelizumab Combined With Chemotherapy|Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
219135397|NCT02165059|PROCEDURE|Surgical Full Thickness Biopsy|Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
219135398|NCT03193567|BIOLOGICAL|HEKT cell|3 cycles of HEKT cell treatment
219135399|NCT05233085|DRUG|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
219135400|NCT05233085|OTHER|Placebo|Participants will receive oral solution of placebo as stated in arm description.
219135401|NCT06693739|PROCEDURE|Platelet rich fibrin|PRF membrane is placed as a scaffold inside the canal with no hyaluronic acid
219135402|NCT06693739|PROCEDURE|hyaluronic acid|hyaluronic acid gel is placed as a scaffold inside the canal with no PRF
219135403|NCT06693739|PROCEDURE|no scaffold|initiate bleeding using hand files size beyond apex with sharp strokes with no PRF or hyaluronic acid placed
219135404|NCT00798265|BIOLOGICAL|Gardasil|.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months
219135405|NCT00798265|BEHAVIORAL|Survey|Administration of online risk behavior and knowledge survey done at week 0.
219551114|NCT05320146|OTHER|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
219551115|NCT04962945|PROCEDURE|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
219551116|NCT04962945|PROCEDURE|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
219551117|NCT03147768|DEVICE|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
219551118|NCT03750448|OTHER|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
219551119|NCT03750448|OTHER|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
219551120|NCT03750448|OTHER|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
219551121|NCT03332732|DRUG|VNRX-5133|β-lactamase inhibitor
219551122|NCT03332732|DRUG|VNRX-5022|Approved β-lactam antibiotic
219551123|NCT03332732|DRUG|Metronidazole|Approved antibiotic and antiprotozoal medication
219551124|NCT03332732|DRUG|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
219551125|NCT05025163|DRUG|1.23% fluoride foam application|topical application of fluoride foam every 6 months
219551126|NCT05025163|DRUG|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
219135406|NCT05177341|OTHER|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
219135407|NCT06631118|PROCEDURE|pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B|Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
219135408|NCT06696547|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
219135409|NCT06696547|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
219135410|NCT02482493|DEVICE|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
219135411|NCT06706518|PROCEDURE|Single-shot ablation technologies|"Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.~* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.~* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.~* 28 mm diameter PolarX balloon catheter\*."
219135412|NCT06711120|PROCEDURE|Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively|During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.
219551127|NCT02291796|DRUG|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
219551128|NCT02068651|BEHAVIORAL|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
219551129|NCT01582464|BEHAVIORAL|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
219551130|NCT00169364|DEVICE|positron emission tomography|
219551131|NCT01739647|DRUG|AZD3293|Oral solution
219551132|NCT01739647|DRUG|Placebo|Oral solution
219551133|NCT03817151|PROCEDURE|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
219551134|NCT02840669|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|
219551135|NCT02840669|PROCEDURE|Exercise-stress test|
219551136|NCT02840669|PROCEDURE|Echocardiography (ECHO)|
219551137|NCT02840669|PROCEDURE|Cardiac-related blood studies|
219551138|NCT00285961|DEVICE|Cork splint materials (instead of plaster splint)|
219551139|NCT01989884|DRUG|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
219551140|NCT00229944|DRUG|Azithromycin|
219551141|NCT05895435|DEVICE|radiofrequancy|"* Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance."
219135413|NCT06708325|OTHER|Resistance Training Program|The 12-week resistance training program consisted of three supervised sessions per week, each lasting approximately 55-60 minutes. Sessions were structured as follows: 5-7 minute dynamic warm-up, 35-40 minutes of resistance training, and 4-5 minutes of stretching for active recovery.Participants were paired based on similar strength fitness levels and progressed according to the principle of periodized progressive overload. Training was delivered using a circuit protocol with 2-3 sets per exercise. The initial 4-week phase included 2 sets per exercise, with 8-20 repetitions and 1-2 minutes rest between sets. .The program incorporated functional exercises targeting the lower extremities, core, and upper extremities, utilizing equipment such as resistance bands, medicine balls, jump ropes, dumbbells, bars, and stability balls. Participants performed exercises in a circuit sequence, with the intensity, number of sets, and repetitions
219135414|NCT06711848|BEHAVIORAL|A web-based educational intervention on oral cancer|This intervention will involve administering education, via a website, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
219715922|NCT05467527|BEHAVIORAL|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
219715923|NCT05467527|BEHAVIORAL|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
219715924|NCT06913595|DRUG|Direct Oral Anticoagulant.|Direct Oral Anticoagulant AFTER BARIATRIC SURGERY
219715925|NCT06913595|DRUG|Low Molecular Weight Heparine|Low molecular weight heparin after bariatric surgery
219715926|NCT07105657|OTHER|Rehabilitation|Three weeks intensive rehabilitation where patients undergo group-based and individualised rehabilitation focusing at improving pain, function and quality of life for the patient
219715927|NCT07103226|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the plantar fascia.
219715928|NCT07103226|OTHER|Physical Exercise|The therapeutic physical exercise focused on the flexor muscles of the foot will consist of 3 periods of isometric contraction of 15 seconds, with a rest period of 30 seconds, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
219135415|NCT06711848|BEHAVIORAL|A mobile health app-based educational intervention on oral cancer|This intervention will involve administering education, via a mhealth application prototype, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
219135416|NCT06712225|BEHAVIORAL|Anomia therapy: semantic feature analysis and phonological components analysis;|After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
219135417|NCT06712225|BEHAVIORAL|Executive function training: computerized equipment|Executive function training will be conducted by means of a computerized material specifically designed for the study, consisting of verbal and nonverbal exercises targeting, always in the same order, inhibition, shifting, working memory and planning functions, with a gradient of difficulty. Training will always be done at the beginning of the session, during 20 minutes, before anomia therapy.
219135418|NCT06711185|DRUG|Dapagliflozin 10 mg|Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
219135419|NCT06711185|OTHER|Placebo|Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment
219135420|NCT06709677|BEHAVIORAL|Arabic version of The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace|"The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace. It is commonly used in occupational health and ergonomic assessments to gather information about the prevalence and severity of musculoskeletal issues such as pain, discomfort, and limitations in movement. The NMQ typically includes questions about specific body regions (e.g. neck, shoulders, back, wrists) and asks individuals to report any symptoms they may be experiencing in those areas. This information can help identify potential risk factors for musculoskeletal disorders and guide interventions to prevent or manage these conditions in the workplace (Namnik et al., 2016).~• Section 1: a general questionnaire of 40 forced-choice items identifying areas of the body causing musculoskeletal problems. Completion is aided by a body map to indicate nine symptom sites being neck, shoulders, upper back, elbows, low back, wrist/hands, hips/thi"
219135421|NCT06696482|DRUG|Escitalopram 10mg|Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
219135422|NCT06696482|DRUG|Placebo 10 mg|Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
219715929|NCT07103226|OTHER|Stretching|The plantar fascia stretch will be performed with the patient in the supine position. Maximum dorsiflexion will be achieved, and the lower limb will be elevated with the knee extended as tolerated. This procedure will be performed three times in a row for 30 seconds, with a 1-minute rest between each stretch.
219715930|NCT07103226|OTHER|Orthopedic insole|Imposition of an orthopedic insole
219135423|NCT06696560|OTHER|Minimal Invasive Approaches in Aortic surgeries.|Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries
219135424|NCT06713122|BEHAVIORAL|İntervention Group- Group receiving Symptom Management Training with Mobile Application|"The application to be developed in the research will be both Android and IOS supported.~Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.~The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.~Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time."
219135425|NCT06705491|BEHAVIORAL|TIPPI-R|The TIPPI-R intervention protocol consists of a one session, during which time the interventionist offers psychoeducation related to the following content areas: procedural pain related to oncology treatment, factors that may affect the perception of pain, evidenced-based tools for assessing and monitoring pain, cognitive and behavioral pain management interventions, and resources to facilitate family to advocacy for pain management in a medical setting. During this session, the interventionist discusses opportunities for families to utilize skills throughout treatment, and addresses family questions as needed. A follow-up session 4 weeks after the initial intervention session will assess family knowledge and skills and offer a referral for a mental health provider, if further pain management support is needed. TIPPI-R is designed to be delivered by a psychologist, psychology trainee, or social worker working in the oncology context.
219135426|NCT06712771|DRUG|VSA003|subcutaneous injections
219135427|NCT06712771|DRUG|Placebo|subcutaneous injections
219135428|NCT06711575|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
219135429|NCT06711250|PROCEDURE|khoury technique|autogenous bone augmentation
219135430|NCT06711250|PROCEDURE|khoury technique with i-PRF injections|autogenous bone augmentation with repeated i-PRF injections
219135431|NCT06713980|OTHER|sham acupuncture|In the sham acupuncture group, sham acupuncture was applied at 14 specific non-acupuncture points on the back.
219135432|NCT06713980|OTHER|acupuncture|acupuncture:the choice of acupoints was based on the theory of traditional Chinese medicine (TCM). All needles were manually manipulated to achieve the deqi sensation
219135433|NCT06713057|DRUG|Cyclophosphamide+Pemetrexed+5-Fluorouracil|IV or PO
219135434|NCT06713057|DRUG|Cyclophosphamide+Doxorubicin+5-Fluorouracil|IV or PO
219135435|NCT06713057|DRUG|Vindesine + Cisplatin|IV or PO
219135436|NCT06713057|DRUG|Doxorubicin + Cisplatin|IV or PO
219135437|NCT06713057|DRUG|Doxorubicin + Cyclophosphamide + Cisplatin|IV or PO
219135438|NCT06713057|DRUG|Docetaxel + Doxorubicin|IV or PO
219135439|NCT06713057|DRUG|Paclitaxel + Carboplatin|IV or PO
219135440|NCT06713057|DRUG|Paclitaxel + Doxorubicin|IV or PO
219135441|NCT06713057|DRUG|Paclitaxel + Cisplatin|IV or PO
219135442|NCT06713057|DRUG|Gemcitabine alone|IV or PO
219135443|NCT06713252|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
219135444|NCT06713252|BEHAVIORAL|Regular therapy|Standard treatment
219135445|NCT06714669|DRUG|propofol|"Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam."
219135446|NCT06714669|DRUG|Remimazolam|"Experimental Group (Remimazolam Anesthesia Arm):~Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy."
219135447|NCT06714331|DIETARY_SUPPLEMENT|Supplements|Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
219135448|NCT06713564|DRUG|LS301-IT|LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.
219135449|NCT06714474|OTHER|Virtual Simulation Game|The Virtual Simulation Game (VSG) is an interactive, scenario-based digital training tool designed to enhance venous blood sampling (VBS) skills. Participants engage with the VSG platform to complete modules that simulate real-life clinical scenarios, allowing them to refine decision-making and procedural skills in a safe, controlled environment. This intervention is used in addition to traditional training to reinforce learning through repetition and feedback.
219715931|NCT07104708|PROCEDURE|The Child-Parent- Trainer exercise program|The Child-Parent-Trainer exercise program is a 12-week exercise training program, which is based on the sensory and cognitive needs of children with ASD, multiple game forms are integrated to form a multi-sensory intervention model. The exercise program is developed according to the types of exercise recommended in the Exercise Guidelines for Preschool Children of China, including the development of basic motor skills, such as physical movement, posture control, object control; development of important physical qualities, such as agility, balance, coordination. The training program for different age group consists of physical movement items, object control items and limb coordination items. The exercise intensity is moderate.
219715932|NCT07104708|PROCEDURE|The regular physical training|The regular physical training courses will last for 12 weeks. It is training in motor skills and fine motor skills. The items include passing the ball, lifting small dumbbells, running, handicrafts, etc. There is no requirement for the intensity of the exercise.
219715933|NCT07103421|DIAGNOSTIC_TEST|Non-Surgical Periodontal Therapy|Non-surgical periodontal therapy involves the removal of bacterial plaque and calculus from tooth surfaces and root surfaces beneath the gum line using manual or ultrasonic instruments. This treatment is performed for patients with periodontitis to improve gum health and reduce inflammation. Serum cystatin C levels will be compared before and after treatment between healthy patients and those with renal impairment.
219135450|NCT06714474|OTHER|Traditional Training|Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
219135451|NCT06713174|DIAGNOSTIC_TEST|Assessment of Interleukin 8 and 10 Level Changes Before and During Root Canal Treatment for Necrotic Pulp with Apical Periodontitis|This study will be performed to investigate interleukin-8 (IL-8) and interleukin-10 (IL-10) level changes in gingival crevicular fluid (GCF) and periapical fluid before and during root canal treatment (RCT) in patients with necrotic pulp and apical periodontitis. The null hypothesis tested will be There is no significant difference in (IL-8) and (IL-10) levels in gingival crevicular fluid (GCF) and periapical before and during root canal treatment (RCT) for necrotic pulp with apical periodontitis.
219135452|NCT06714097|DEVICE|AI|STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase
219135453|NCT06714097|OTHER|healthy dialogue|Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA
219135454|NCT06711913|DRUG|Dexmedetomidine|intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
219135455|NCT06711913|OTHER|Normal Saline (Placebo)|control group receive normal saline as placebo
219135456|NCT06712277|OTHER|Video training|After the procedure, caregivers will be trained on tube care and patient feeding by demonstrating and performing the procedure on an iPad.
219135457|NCT06698068|OTHER|Equine-assisted therapy|15 equine therapy sessions, twice a week, over 7 to 8 weeks. Each session will last 60 minutes, including various activities such as emotional expression, contact with the horse, grooming, activities on foot or on horseback, and a debriefing time.
219135458|NCT06712368|DEVICE|virtual reality glasses|Designed cardiac physical therapy program applied through virtual reality glasses for study group
219135459|NCT06712368|OTHER|Designed cardiac physical therapy program|Designed cardiac physical therapy program without virtual reality glasses
219135460|NCT06712394|PROCEDURE|IPACK|The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.
219135461|NCT06711016|OTHER|fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc|ECMO flow, IABP , ventilator support parameters, temperature management level and time
219135462|NCT06714266|DRUG|Trilaciclib|"Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib"
219135463|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|4 months if treatment
219135464|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|6 months of treatment
219135465|NCT06712030|DRUG|Sacubitril / Valsartan|Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)
219135466|NCT06711328|DEVICE|New oropharyngeal airway|This product is produced and sold by Shanghai Elifu Medical Technology Co., LTD., and has been officially put into clinical use in March 2023.The product is named oropharyngeal airway for disposable endoscope, which is composed of nasal plug, bite, oropharyngeal channel, oxygen supply tube, lanyard and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.The model used in this study is JK (Oropharyngeal airway for endoscope with end-expiratory carbon dioxide Collection) with L/M/S three specifications, which is used to prevent airway obstruction caused by backward tongue fall during endoscopic surgery/examination, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time
219135467|NCT06711029|OTHER|Conventional needle irrigation|Conventional needle irrigation method was applied. As a final irrigation, 6 ml NaOCl was applied with 60 seconds of needle irrigation followed by 60 seconds of rest.
219715934|NCT07104526|DRUG|Propranolol + Bleomycin|Oral propranolol at 1 mg/kg/day for 6 months plus intralesional bleomycin (1 mg/mL solution) injected once monthly. The bleomycin dose was 0.2-0.5 mg per injection site, not exceeding a total of 1 mg/kg per session or a cumulative dose of 10 mg.
219715935|NCT07104526|DRUG|Propranolol|Oral propranolol hydrochloride solution administered at a dose of 1 mg/kg/day for 6 months.
219715936|NCT07104890|BEHAVIORAL|Enhanced Recovery After Surgery (ERAS) Protocol, which includes early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early urinary catheter removal, an|The Enhanced Recovery After Surgery (ERAS) Protocol for elective cesarean section includes a multimodal perioperative care approach aimed at accelerating postoperative recovery. Key components are early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early removal of the urinary catheter, and gum chewing to stimulate bowel function. This protocol is compared with Standard Perioperative Cesarean Care, which involves overnight fasting, delayed oral intake until bowel function returns, conventional analgesia, later mobilization, and routine catheter removal.
219715937|NCT07105150|BEHAVIORAL|video-based education program|"The video-based education program will include 4 workshops of 20 minutes each, at a rate of 1 video per week:~Video 1: Anatomy and physiology of the pelvic floor; Video 2: Physiology of the urinary tract; Video 3: Physiology of the digestive tract; Video 4: Pathophysiology of urinary incontinence and other pelvic floor disorders (genital prolapse and anal incontinence) and preventive measures in daily activities."
219715938|NCT07105150|OTHER|written information|The control group will receive a paper information document (containing the same information as the intervention group) during the 4-week period
219715939|NCT07104396|OTHER|Cogito digital therapeutics development platform|Cogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.
219715940|NCT07103694|DRUG|anti-CGRP monoclonal antibodies|erenumab, fremanezumab, galcanezumab, eptinezumab
219715941|NCT07103694|DRUG|gepants|atogepant, rimegepant
219715942|NCT07103694|DRUG|combination of sumatriptan and naproxen|combination of sumatriptan and naproxen
219135468|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 3*20 sn|In the final irrigation, 6 ml (3×2 ml) NaOCl was activated by PUI for 20 seconds in 3 cycles (60 seconds total). Before each cycle, 2 ml of NaOCl solution was refreshment.
219715943|NCT07103694|DRUG|ditan|lasmiditan
219715944|NCT07103434|BEHAVIORAL|VR Mindfulness intervention|Parallel randomized controlled trial
219135469|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 6*10 sn|For the final irrigation, 6 ml (6×1 ml) NaOCl was activated with PUI for 10 seconds in 6 cycles (60 seconds total). Before each cycle, 1 ml of NaOCl solution was refreshment.
219135470|NCT05708261|BEHAVIORAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
219135471|NCT05708261|OTHER|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
219135472|NCT02494830|DRUG|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
219135473|NCT06711549|PROCEDURE|Serratus Posterior Superior Plane Intercostal Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus posterior superior plane and the ribs
219135474|NCT06711549|PROCEDURE|Serratus Anterior Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus anterior and the external intercostal muscles and ribs
219135475|NCT06713434|BIOLOGICAL|ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)|ELK-003 eye drops are a standardized amniotic fluid secretome formulation. It contains essential extracellular matrix proteins, such as collagen type VII and laminin-332, which are critical for maintaining corneal integrity in EB patients. In addition, ELK-003 also includes growth factors that stimulate corneal healing and tissue regeneration. This combination of matrix proteins and growth factors aims to enhance corneal surface stability.
219135476|NCT06714110|DEVICE|Intramedullary Limb Lengthening Device|The Precice IMLL System is composed of the Precice nail, screws, and uses an external remote controller (ERC) for rod distraction. The Precice IMLL System is designed to fit the anatomy of long bones and is intended to be placed internally in an intramedullary manner. It achieves limb correction through gradual lengthening or compression and providing intramedullary fixation for fractures of long bones.
219135477|NCT06714110|DEVICE|External Fixator Limb Lengthening Device|External fixator devices consist of an external frame (ring, half-ring, monolateral, and rail); bone fixation is accomplished by the transcutaneous bone fixations implants (pins, wires, cables, screws), and the lengthening is accomplished by the vertical components (struts). Generally, femoral lengthening devices are monolateral and tibial lengthening devices have ring or half-ring frames. The external fixators are made of a variety of materials, including stainless steel, titanium, carbon fiber, and aluminum.
219135478|NCT05971225|OTHER|remote monitoring only|remote monitoring only can replace in-office device monitoring
219135479|NCT06421597|DRUG|Prednisolone|prednisoline 25 mg/day for seven days
219135480|NCT06421597|DRUG|Placebo|Placebo treatment for seven days
219228046|NCT04961762|OTHER|Navigator Program|The main role of the Homeless Outreach Counsellor is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. The Homeless Outreach Counsellor also helps address specific needs of participants, develop comprehensive care plans with members of patient's multidisciplinary circle of care, and facilitate the transition of clients to long-term community-based health and social services.
219135481|NCT01838200|BIOLOGICAL|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
219135482|NCT01838200|DRUG|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
219135483|NCT01838200|DRUG|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
219228047|NCT06825715|OTHER|Multilevel intervention|3 components: patient education video, provider audit/feedback, and EMR ordering change
219551142|NCT05895435|OTHER|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
219551143|NCT03997799|PROCEDURE|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
219551144|NCT05740098|BEHAVIORAL|Best Practices|Five As plus referral to a quit line
219551145|NCT05740098|BEHAVIORAL|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
219551146|NCT05740098|DRUG|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
219551147|NCT02452463|BIOLOGICAL|Durvalumab|Given IV
219551148|NCT02452463|DRUG|Nintedanib|Given PO
219551149|NCT02452463|OTHER|Placebo|Given PO
219551150|NCT02452463|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219551151|NCT00794794|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
219551152|NCT00794794|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
219551153|NCT01942616|OTHER|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
219551154|NCT01942616|OTHER|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
219551155|NCT01942616|OTHER|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
219135484|NCT06398626|DRUG|Etrasimod|As provided in real world practice
219135485|NCT02777983|BEHAVIORAL|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
219228048|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
219135486|NCT05438732|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
219135487|NCT01801449|DRUG|Rilonacept|
219135488|NCT01327469|DRUG|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
219135489|NCT01327469|DRUG|Albendazole 400mg|Albendazole 400mg
219715945|NCT07103434|BEHAVIORAL|Audio-based MBI|Parallel randomized controlled trial
219135490|NCT01327469|DRUG|Mebendazole 500mg|Mebendazole 500mg
219228049|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
219715946|NCT07103434|BEHAVIORAL|Waitlist control|Parallel randomized controlled trial
219715947|NCT07102758|PROCEDURE|L-PRF with dental implant and customized healing abutment|L-PRF with dental implant and customized healing abutment
219228050|NCT04984213|DEVICE|Karma Posterior Fixation Device|Posterior Fixation
219715948|NCT07102758|PROCEDURE|Connective tissue with dental implant and customized healing abutment|Connective tissue with dental implant and customized healing abutment
219715949|NCT07103447|DRUG|AK112, Carboplatin, Paxlitaxel|The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.
219135491|NCT01327469|DRUG|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
219135492|NCT01327469|DRUG|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
219135493|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
219135494|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
219135495|NCT00181909|BEHAVIORAL|Smoking cessation counseling delivered by telephone|
219135496|NCT02391246|OTHER|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
219135497|NCT05605743|BEHAVIORAL|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
219228051|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
219715950|NCT07104045|OTHER|Reduced light color temperature|reduced light color temperature on postpartum mothers' well-being, breastfeeding motivation, and psychological well-being after a cesarean section
219715951|NCT07103915|DRUG|Lidocaine 10% Spray|This study evaluates whether intranasal 10% lidocaine spray reduces pain and improves first-pass success during nasogastric tube (NGT) insertion compared to placebo.
219715952|NCT07103915|OTHER|Placebo|Drug: Placebo Spray (Ethanol-matched solution without lidocaine)
219228052|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
219228053|NCT07006181|DRUG|cyproheptadine hydrochloride|Giving Cyproheptadine hydrochloride 0.25 mg/kg/day divided by 2 dose every 12 hours for 4 weeks.
219228054|NCT07006181|OTHER|Giving placebo divided by 2 dose every 12 hours for 4 weeks.|Giving placebo divided by 2 dose every 12 hours for 4 weeks.
219715953|NCT07105267|DRUG|FMT Protocol|FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale
219715954|NCT07103460|COMBINATION_PRODUCT|Essential Oil Diffusion Combined with Respiratory Training|three commonly used essential oils (wintergreen, peppermint, and eucalyptus) will be integrated into IS respiratory training
219715955|NCT07104994|DEVICE|Dental implant|insertion of dental implants after surgical tranlocation of the inferior alveolar nerve.
219135498|NCT04010643|BEHAVIORAL|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
219135499|NCT04010643|BEHAVIORAL|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
219360650|NCT01849861|DRUG|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity"
219715956|NCT07102667|BEHAVIORAL|Protein intake 1.2 g/kg/day and resistance exercise|Protein intake of 1.2 g/kg/day in combination with resistance exercise using resistance bands
219715957|NCT07102667|BEHAVIORAL|Protein intake 1.0 g/kg/day and resistance exercise|Protein intake 1.0 g/kg/day in combination with resistance exercise using resistance bands
219715958|NCT07104734|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)
219715959|NCT07104734|OTHER|Hesperetin (Hesperetin trial)|The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).
219715960|NCT07103837|OTHER|Reactive Skill Test|The Reactive Skill Test will be conducted using a setup consisting of four pods, white cones, and balls that match the colors of the light signals During the test, a ReactionX device configured with four distinct light colors (red, green, blue, and yellow) will be used. The test protocol is programmed via the ReactionX mobile application to control the sequence and display of lights. Each LED light is illuminated in a randomized order with zero delay time. Upon illumination, the participant is required to select the ball corresponding to the color of the light, place it on the matching cone, and then deactivate the LED light of the same color as the last placed ball. The test concludes once this sequence is completed for all four lights. Performance is evaluated based on parameters such as reaction time, accuracy, and total completion time. This protocol is specifically designed to assess cognitive skills such as color recognition, reaction time, motor coordination, and attention.
219715961|NCT07103213|BEHAVIORAL|IMPACTREEL programme|The IMPACTREEL programme is a school-based intervention designed to promote positive body image in adolescents. It combines social media literacy education with third-wave strategies, including mindfulness, self-compassion, and psychological flexibility. The intervention consists of 7 weekly group sessions lasting 55 minutes each, delivered by trained psychologists facilitators during school hours. The content targets appearance ideal internalisation, critical thinking about social media, and healthier body image attitudes.
219715962|NCT07104656|PROCEDURE|Inferior Osteotomy made by border saw|Inferior border saw used to make the inferior border osteotomy
219715963|NCT07104656|PROCEDURE|Inferior Osteotomy made with reciprocating saw|reciprocating saw used to make the inferior osteotomy
219715964|NCT07102888|DRUG|RSS0393 Ointment|RSS0393 ointment.
219715965|NCT07103798|OTHER|College Park ICON|Subjects will be fitted and trained on the College Park ICON MPK. An accommodation period of 2 months will be provided prior to evaluation with the knee joint.
219715966|NCT07103798|OTHER|Conventional NMPK|Subjects will be tested walking with their conventional, mechanical prosthetic knee prior to being fitted with the MPK.
219715967|NCT07104305|BEHAVIORAL|High-contact communication strategy|Patients will have contact with their clinician more frequently. The communication strategy may utilize text, email, portal, phone, video or other options as agreed on. The frequency will be at least once a week. All patients will complete a set of questionnaires at the end of the visit.
219715968|NCT07104019|PROCEDURE|Biofiller Injection|Biofiller will be prepared by heating the platelet-poor plasma (PPP) component obtained from peripheral blood, which is then mixed with concentrated PRF (c-PRF). After creating a surgical tunnel in the mandibular anterior region (canine to canine), 0.5 mL of the prepared biofiller will be injected into each tooth region under the gingiva. The procedure is performed under local anesthesia and aims to increase gingival thickness in patients with a thin periodontal phenotype.
219135500|NCT00676533|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
219135501|NCT03758339|DRUG|tucatinib|Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
219135502|NCT06232226|OTHER|Patients suffering from the co-occurrence of ADHD and addiction(s)|All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
219135503|NCT01064843|DEVICE|Imtec MDI|4 Imtec MDI
219135504|NCT03811587|OTHER|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
219135505|NCT01796093|DRUG|Digoxin and ivabradine|No more details
219135506|NCT03712930|DRUG|Pamiparib|60 mg orally twice daily (BID)
219135507|NCT03297346|OTHER|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
219135508|NCT03465488|DRUG|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
219715969|NCT07104019|PROCEDURE|connective tissue graft|A connective tissue graft will be harvested from the palatal donor site and placed under the gingiva using a minimally invasive tunneling technique in the mandibular anterior region (canine to canine). The procedure will be performed under local anesthesia and aims to increase gingival thickness. No biomaterials or adjunctive agents will be used.
219135509|NCT02085356|BEHAVIORAL|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
219135510|NCT02833155|DRUG|Entinostat|Given PO
219715970|NCT04132440|OTHER|Interview|Complete interview
219715971|NCT04132440|OTHER|Questionnaire Administration|Complete questionnaire
219715972|NCT05164172|DRUG|Eptinezumab|Concentrate for solution for infusion
219135511|NCT02833155|DRUG|Exemestane|Given PO
219135512|NCT01250548|BIOLOGICAL|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
219135513|NCT01250548|OTHER|Placebo|
219715976|NCT05019885|DRUG|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
219715977|NCT01237093|OTHER|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
219135514|NCT00914823|DRUG|kisspeptin 112-121|One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
219135515|NCT00914823|DRUG|GnRH|One or more IV doses of GnRH, and/or SC administration of GnRH
219135516|NCT04095403|OTHER|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
219135517|NCT04095403|OTHER|passive cooling|Supine rest.
219360651|NCT02037659|PROCEDURE|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
219135518|NCT03126084|DRUG|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
219135519|NCT03126084|DRUG|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
219135520|NCT03126084|DRUG|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
219135521|NCT03126084|DRUG|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
219135522|NCT03126084|PROCEDURE|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
219135523|NCT03126084|DRUG|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
219135524|NCT03583021|DRUG|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
219135525|NCT03583021|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
219135526|NCT03221569|DRUG|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
219135527|NCT03221569|DRUG|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
219135528|NCT03221569|DRUG|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
219715978|NCT01237093|OTHER|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
219715979|NCT01237093|OTHER|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
219715980|NCT01237093|OTHER|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
219715981|NCT01237093|OTHER|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
219715982|NCT01237093|OTHER|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
219715983|NCT01237093|OTHER|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
219715984|NCT01237093|OTHER|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
219135529|NCT03221569|DRUG|Normal saline|1ml intravenous push as placebo for double-blinding purposes
219135530|NCT05599399|DIETARY_SUPPLEMENT|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
219135531|NCT06221618|OTHER|High-frequency carotid arteries ultrasound, CCTA, Cranial MRA|CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
219228055|NCT06831994|OTHER|gp-multitool.de|"The intervention is based on the digital tool gp-multitool.de. The GPs can send questionnaires by email to patients and patients can fill out questionnaires at their home or in the waiting room of the practice using any digital device with browser and access to the internet. The digital tool also includes instructions for conducting a medication review. Results will be available from the computers of attending GPs. Decisions from talks between GPs and patients can be documented in the tool. The tool includes ten questionnaires:~1. patient preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. social life (including a. activities and participation, and b. social support);~3. treatment situation (including a. problems with medication, and b. treatment burden);~4. health complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~5. resilience and protective behavior against heat."
219228056|NCT07013344|DIAGNOSTIC_TEST|BNP|Measurement of plasma NT-proBNP level.
219228057|NCT07012239|DRUG|Azathioprine (AZA)|"Patient fulfilled indication of AZA Maintenance of remission of lupus nephritis, Neuro-psychiatric lupus, vasculitis, intolerance to steroid, associate with Defuse Parenchymal Lung Disease (DPLD) Starting AZA at a dose of 1 mg/kg/ body weight~First follow-up at 2nd week and change dose of AZA 2 mg /kg/ BW/day~Then Follow-up 4 weekly for total 12 week~Not adverse effect of Azathioprine"
219228058|NCT07012239|DRUG|TPMT|Adverse effect of azathioprine in SLE
219228059|NCT07012278|OTHER|Caesarean section scar dressing with St. John's wort oil|Dressing the incision site with St. John's wort oil once a day every day
219228060|NCT06699472|DRUG|Chemotherapy|Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
219228061|NCT06699472|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
219228062|NCT06698653|DEVICE|SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
219228063|NCT06698653|DEVICE|Over bed pole hoist (control device)|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
219228064|NCT06632691|DEVICE|Virtual reality headset|Use of a virtual reality headset during rectosigmoidoscopy
219228065|NCT07025850|DRUG|Digoxin|p.o. 0.5mg q.d.
219228066|NCT07025850|DRUG|Fuquinitinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
219228067|NCT07025850|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
219228068|NCT06692608|OTHER|strength training|Comparison between isometric and dynamic strength training in soccer players
219228069|NCT06698991|BIOLOGICAL|Plasma Exchange|"• Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours"
219228070|NCT06698991|OTHER|Standard Medical Treatment|Standard Medical Treatment
219228071|NCT06691776|DEVICE|online CBCT-guided adaptive radiation therapy using a new software|Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
219228072|NCT06706310|DRUG|Placebo|Placebo contains no active substance.
219135532|NCT00739102|DEVICE|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
219228073|NCT06706310|DRUG|TQA3334 Tablet|Inhibit viral replication.
219228074|NCT06706310|DRUG|Nucleoside (acid) analogs (NAs)|Inhibit viral replication.
219228075|NCT07038694|OTHER|Qualitative semi structured interview|60 minute, virtually performed via Microsoft Teams, semi-structured interview
219228076|NCT06704009|DRUG|NT-101 0.05 mM|Low concentration of NT-101 (0.05 mM)
219228077|NCT06704009|DRUG|NT-101 0.2 mM|High concentration of NT-101 (0.2 mM)
219715985|NCT07108660|BEHAVIORAL|Infection Preventionist Led Best Practices Reminders|Infection preventionists at each study hospital review a dashboard on a daily basis that contains predictions for the infection preventionist's hospital. If a patient is predicted to have a possible CLABSI by the ML model, the infection preventionist reviews the case and recommends next steps to the care team based on Providence's CLABSI prevention best-practices bundle, which include reviewing the line for necessity and recommending alternate IV access when appropriate. If line-removal isn't possible, the infection preventionist collaborates with the direct care team to ensure that the line maintenance best practices are observed, including maintaining a clean, dry and intact dressing and using daily chlorhexidine baths.
219135533|NCT03244696|BEHAVIORAL|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
219135534|NCT03244696|BEHAVIORAL|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
219715986|NCT06828328|BIOLOGICAL|GC203 TIL|the candidates will be assigned to GC203 TIL(gene-edited TIL) group
219715987|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
219135535|NCT01391442|BIOLOGICAL|blood and urine samples|58 ml of blood 120 ml of urine
219135536|NCT01391442|GENETIC|blood sample|11 ml of blood
219135537|NCT01391442|OTHER|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
219135538|NCT01391442|OTHER|Stanislas ancillary study : MRI examination with GRICS technique|
219135539|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
219135540|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
219135541|NCT03285685|DEVICE|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
219135542|NCT03617653|DIAGNOSTIC_TEST|Group A|Refer to detailed study Description
219228078|NCT06883032|OTHER|AR Eyeglasses first, SR Eyeglasses second|First Eyeglasses based on Automated Refraction, Second Eyeglasses based on Subjective Refraction
219228079|NCT06883032|OTHER|SR Eyeglasses first, AR Eyeglasses second|First Eyeglasses based on Subjective Refraction, Second Eyeglasses based on Automated Refraction
219135543|NCT00868595|BIOLOGICAL|BPX-101|Vaccine
219135544|NCT00868595|DRUG|AP1903|Activating agent, infusion
219135545|NCT03196167|DRUG|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
219228080|NCT07038382|DRUG|HLX79 10mg/kg/Placebo+HLX01|Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2
219715988|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
219715989|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
219715990|NCT06448754|DRUG|Ramucirumab|Participants will receive ramucirumab via IV infusion.
219715991|NCT06448754|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion.
219715992|NCT07110142|OTHER|Tongueometer|The Tongueometer device features an air-filled bulb that is placed against the roof of the mouth by the tongue for resistance training. This setup allows for an initial measurement of the patient's maximum tongue strength and endurance, which helps establish goals that are specific to each patient. The device connects to a mobile application that provides visual biofeedback, ensuring consistent monitoring as the patient completes exercises using the tongue bulb for resistance. Once the patient's goals are set based on their initial measurements, the app offers two exercise modules designed to improve both tongue strength and endurance.
219715993|NCT07101302|BEHAVIORAL|App-Based Cognitive Behavioural Therapy for Insomnia|The iCANSleep app is based on an established CBT-I protocol. The core features of the iCANSleep app include 1) a modified CBT-I protocol for cancer survivors and 2) daily sleep diaries. Core components of CBT-I treatment to be implemented include sleep restriction, stimulus control, cognitive restructuring, and psychoeducation. These components will be modified into 7-weekly modules.
219715994|NCT07099326|OTHER|Educational Method Using Interactive Video|"Phase 1 - Interactive Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform via the website https://spotplayer.ir/ and watch a comprehensive interactive video related to end-stage renal disease (ESRD) and its replacement therapies. This video consists of ten 30-minute sessions, uploaded at the rate of one session per day. During the viewing, pop-up questions will appear, which patients are required to answer. Different response options will lead to the presentation of different educational scenarios. In addition, multiple-choice questions related to the content will be included throughout the video, and patients must record their answers in the system. The instructor will be able to review these responses through a management dashboard. It is worth noting that all patients will have previously received the necessary training to use the interactive videos, including Q\&A sessions designed to ensure sufficient skill acquisition in utilizing the interact"
219715995|NCT07099326|OTHER|Educational Method Using Conventional Video|"This educational intervention will be carried out in two phases with a total duration of six hours. A total of 55 patients will participate in this study, organized into groups of five and guided by an experienced instructor familiar with the interactive video-based educational system.~Phase 1 - Conventional Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform through the website https://spotplayer.ir/ and watch in-depth educational videos related to end-stage renal disease (ESRD) and its replacement therapies. The video content consists of ten 30-minute sessions, which will be uploaded for the patients at the rate of one session per day.~Phase 2 - Consolidation and Reinforcement Session (1 hour):~After completing the ten video sessions, patients will participate in group discussions to analyze the scenarios, topics, and questions presented in the videos. The instructor will facilitate the discussions, summarize the outcomes, and assess the over"
219715996|NCT07104201|DRUG|Fenofibrate|Fenofibrate 200mg
219715997|NCT07102914|BEHAVIORAL|Screening, Brief Intervention and Referral for Treatment (SBIRT)|A single-arm, open pilot design maximizes the ability of the investigators to work collaboratively with NHAEC staff and administration to tailor the implementation strategy, establish the feasibility and acceptability of study methods and interventions (e.g., recruiting students, training SRSs to deliver SBIRT with integrity, response rates to assessment measures, student receipt of SBIRT, retention of SRSs and students), address the structural barriers within the AEC setting, identify the needs of the populations of interest, and gather data that points to best approaches to ensuring the study's success.
219715998|NCT07104448|BEHAVIORAL|Standardized Perioperative Care Protocol|A multi-component protocol involving preoperative patient education, nutritional screening, standardized anesthesia, goal-directed fluid therapy, multimodal opioid-sparing analgesia, and a structured physiotherapy-led mobilization schedule starting on postoperative day 1.
219715999|NCT07104448|OTHER|Conventional care|Standard, non-protocolized institutional perioperative care, with management decisions based on the discretion of the attending surgeon and care team.
219716000|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
219716001|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
219716002|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
219716003|NCT07103148|BIOLOGICAL|Measles, combinations with mumps and rubella, live attenuated|Powder, lyophilized, for suspension for reconstitution Subcutaneous or intermuscular
219716004|NCT07108465|DRUG|Bupivacaine 0,5%|Injection of bupivacaine 0,5% in group A
219716005|NCT07108465|DRUG|Ropivacaine 0,75%|Injection of ropivacaine 0,75% in group B
219135546|NCT03196167|OTHER|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
219135547|NCT04455399|DEVICE|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
219135548|NCT04455399|DEVICE|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
219135549|NCT01091454|DRUG|brostallicin|Given IV
219135550|NCT01091454|DRUG|cisplatin|Given IV
219135551|NCT04043767|PROCEDURE|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
219135552|NCT00271167|DRUG|INO-1001|
219135553|NCT02772315|OTHER|omics|diagnostic procedures applying omics results
219135554|NCT01204528|DRUG|Zemplar|Vitamin D receptor activator (VDRA)
219228081|NCT07038382|DRUG|HLX79 20mg/kg/Placebo + HLX01|Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2
219228082|NCT07038382|DRUG|HLX79 30mg/kg/placebo+HLX01|Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2
219228083|NCT07033156|DIAGNOSTIC_TEST|This study does not require intervention trials|This study does not require intervention trials
219228084|NCT07039786|DIETARY_SUPPLEMENT|Placebo Control|Participants will use their Radicle Health Control Study Product as directed for a period of 6 weeks.
219228085|NCT07039786|DIETARY_SUPPLEMENT|Active Product|Participants will use their Radicle Health Active Study Product as directed for a period of 6 weeks.
219228086|NCT06887348|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
219716006|NCT07104851|BEHAVIORAL|Resilience-Satir Hybrid Intervention|A structured, 12-week, group-based psychological intervention integrating principles from Resilience Theory and the Satir Model to enhance coping skills, self-esteem, communication, and family dynamics.
219716007|NCT07104851|OTHER|Treatment as Usual (TAU)|Standard care for adolescent depression, including pharmacotherapy and routine nursing support, without structured psychotherapy.
219716008|NCT07108335|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
219716009|NCT07112482|BEHAVIORAL|Standard Oncological Care + Tailored Dietary Counseling + Nutritional Monitoring|"Participants in this group will receive:~Standard oncological care (e.g., chemotherapy and routine cancer treatments)~Individualized dietary counseling: Nutrition plans tailored by a clinical dietitian to meet energy needs (25-30 kcal/kg/day) and protein needs (1.2-1.5 g/kg/day), adapted to clinical status, dietary tolerance, and treatment side effects.~Regular nutritional monitoring: Counseling sessions every 15-21 days over a period of six months.~Dietary adherence tracking: Through structured food records and goal adherence checklists.~Light physical activity guidance: Encouragement to engage in low-intensity activity suited to patient capacity.~Psychosocial support: Sessions with a certified clinical psychologist addressing emotional distress, fatigue, and anorexia.~Adherence criteria: Defined as attending ≥75% of sessions and meeting ≥80% of dietary goals."
219716010|NCT06910397|DRUG|Probiotic Arm|one tablet daily for 28 days
219716011|NCT06910397|OTHER|Placebo|placebo tablet once daily for 28 days
219716012|NCT07112118|OTHER|data collection|Collect the facial expressions, audio, text and postural behavior data of the respondents using electronic devices.
219716013|NCT02145390|PROCEDURE|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
219716014|NCT02145390|RADIATION|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
219716015|NCT02145390|BEHAVIORAL|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
219716016|NCT02145390|BEHAVIORAL|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
219716017|NCT07104149|DRUG|Cadonilimab combined with cisplatin|Neoadjuvant chemotherapy plus cadonilimab for locally advanced cervical cancer
219716018|NCT07105241|OTHER|VR therapy|Patients in the VR intervention group receive a VR 'relax and distract' intervention in addition to standard care. This type of VR utilizes video's, relaxation exercises and cognitive games to immerse patients in a novel, calming and distracting environment, enhancing the patient's ability to manage anxiety, stress and pain. The VR set is introduced to the patient in the cardiology day care unit prior to the procedure allowing for familiarization with the device. After moving the patient to the catheterization laboratory, the VR set is re-offered to the patient and the VR intervention is started. The intervention ends with the conclusion of the procedure, or when the patient indicates that they would like to discontinue the therapy earlier.
219228087|NCT07043140|OTHER|mobile application|mobile application for lymphedema information and exercise
219228088|NCT07042984|DIAGNOSTIC_TEST|AI-Ultrasound RET Prediction|Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.
219228089|NCT06736769|DRUG|Ketamine infusion|Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
219228090|NCT06829303|DEVICE|Emotional Facial Expression Paradigm (EFP)|The experimental intervention is a social cognition gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on EEG signal. The training consists of a visual stimulation model, specifically an emotional facial paradigm, where the subject is asked to observe the movements of a facial expression (referred to as cue image) expressing either happiness or sadness and to adapt the visual gaze according the cue image.
219228091|NCT06829303|DEVICE|Speller task|The control intervention is a executive function gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on the P300 EEG signal. The task consists of a speller, in which the participant is asked to write a word, by sequentially focusing the attention on the necessary letters.
219228092|NCT06754644|DRUG|QL2107|200mg on day 1 of each 21-day cycle of the study
219228093|NCT06754644|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
219716019|NCT07105241|OTHER|360 degree education videos|Prior to the procedure, patients in the VR intervention group are additionally offered an educational video consisting of a virtual tour of the EP laboratory with a visual explanation of the upcoming procedure. These videos will be recorded as 360ͦ videos to support an optimal immersive experience when viewed on the VR set. In this way, the videos will serve simultaneously as additional educational measures for the procedure, as well as a way to familiarize patients with the VR set. Use of the educational videos is not obligatory, but is offered optionally according to patients' preference.
219716020|NCT07102706|DRUG|GR1803 injection|weekly dose up to week 24 , biweekly dose from week 24 to week 36, and triweekly dose from week 36 to week 52
219135555|NCT04542148|DRUG|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
219135556|NCT04542148|DRUG|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
219135557|NCT04542148|DRUG|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
219135558|NCT04542148|DEVICE|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
219135559|NCT02139748|PROCEDURE|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
219135560|NCT02139748|PROCEDURE|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
219135561|NCT03284905|DIETARY_SUPPLEMENT|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
219135562|NCT03284905|DIETARY_SUPPLEMENT|Placebo supplement|Capsule containing maize starch
219135563|NCT03849495|DRUG|CKD-370|Test drug
219135564|NCT03849495|DRUG|D745|Reference drug
219135565|NCT01158196|DEVICE|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
219135566|NCT01510912|DRUG|Diclofenac|35 mg bid or tid Capsules
219135567|NCT03745118|DEVICE|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
219135568|NCT03745118|DEVICE|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
219135569|NCT03745118|DEVICE|Empatica E4|wearable seizure detection wristband
219135570|NCT03745118|DEVICE|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
219135571|NCT03745118|DEVICE|GeneActiv|wearable seizure detection watch
219135572|NCT05990517|BIOLOGICAL|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
219135573|NCT03179787|DRUG|Aripiprazole oral product|oral administration of aripiprazole
219135574|NCT01958541|BEHAVIORAL|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
219135575|NCT01958541|BEHAVIORAL|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
219135576|NCT05883475|OTHER|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
219135577|NCT05883475|OTHER|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
219135578|NCT05883475|OTHER|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
219135579|NCT05883475|OTHER|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
219135580|NCT05883475|OTHER|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
219228094|NCT06754644|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
219716021|NCT07101458|BEHAVIORAL|Promoting Resilience in Stress Management intervention|PRISM is a manualized, skills-based training program comprised of three 60-minute, one-on-one sessions designed to build resilience resources (stress management, goal-setting, cognitive-reframing, and meaning-making) in adolescents and young adults (AYAs). The sessions are scheduled every 1-2 weeks based on participant preference. In this study, the PRISM sessions will be facilitated by trained nurses who hold bachelor's degrees in Nursing Science with a specialisation in mental health.
219135581|NCT05377151|OTHER|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
219135582|NCT04778124|PROCEDURE|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
219135583|NCT04778124|PROCEDURE|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
219135584|NCT05216692|PROCEDURE|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
219135585|NCT05216692|PROCEDURE|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
219135586|NCT02318381|PROCEDURE|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
219135587|NCT04143919|DIAGNOSTIC_TEST|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
219135588|NCT04143919|PROCEDURE|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
219135589|NCT04143919|DIAGNOSTIC_TEST|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
219135590|NCT05823350|OTHER|Abdominal massage|Abdominal massage after colonoscopy
219135591|NCT02030028|DRUG|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
219135592|NCT05184361|BEHAVIORAL|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
219135593|NCT05184361|BEHAVIORAL|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
219716022|NCT07103252|OTHER|Blood Flow Restriction Therapy|Personalized Blood Flow Restriction Therapy uses an an inflatable cuff (Delfi PTS system) around the upper thigh which partially restricts arterial inflow during exercise. BFR allows for similar improvements of muscular strength and muscle mass as traditional heavy load strength training while using significantly lower loads. The reduced stress on supporting tissues ( tendons, joints, bones and ligaments) allows people who normally couldn't tolerate high loads to enhance their strength and muscle mass.
219716023|NCT07103759|BEHAVIORAL|Refrain from caffeine techniques|Participants will be asked to refrain from drinking caffeinated beverages in the late afternoon and evening.
219716024|NCT07103759|BEHAVIORAL|Project REST Platform|Participants will use the Project REST platform
219716025|NCT07110051|DRUG|Nalbuphine|this group will a single dose of nalbuphine (0.2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)
219716026|NCT07110051|DRUG|Tramadol|this group will receive a single dose of tramadol (2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).
219135594|NCT04491032|PROCEDURE|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
219135595|NCT02122848|DEVICE|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
219228095|NCT06754644|DRUG|Keytruda®|200mg on day 1 of each 21-day cycle of the study
219228096|NCT06808048|BEHAVIORAL|Cognitive testing|Participants will complete a cognitive testing battery that includes measures of attention, learning, memory, problem-solving and executive function.
219135596|NCT06353958|DRUG|MiSaver|"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."
219228097|NCT06808048|BEHAVIORAL|Task-based fMRI measure of inhibitory control|All participants will complete a task-based fMRI measure of inhibitory control. This Go/No-Go task provides a contrast of BOLD signals when response conflict is low (execution of motor responses on frequent Go trials) vs high (inhibiting the prepotent response on infrequent NoGo trials). It will provide an assessment of the effects of cannabis use on the frontostriatal implicit motor learning and cognitive control systems. Participants view shapes and press a button quickly (Go trials) to every shape except circles and squares (NoGo Trials). To increase response prepotency, Go trials are frequent (75%). Button presses must be rapid to be considered correct. The task uses an event-related design with each stimulus presented for 600 ms, followed by a 1.0-4.5 second jittered ISI during which a white fixation crosshair is displayed. Trial type is pseudo-randomized with the constraint of equal frequencies of consecutive Go trials (2, 3, or 4) between NoGo trials.
219228098|NCT06808048|BEHAVIORAL|Task-based fMRI measure of face-name learning|"This task is ideally suited to assess cannabis effects on explicit associative learning and memory as mediated by frontohippocampal networks. Participants memorize names corresponding to faces (encoding phase), and then recall the names after a short delay. The first encoding block begins with a 2-second cue (MEMORIZE) followed by 5 face-name pairs, each shown for 4 seconds; participants press a button when they encode each face-name pair. A distractor block follows. Next, a retrieval block begins with a cue to RECALL followed by presentations of each of the same 5 faces, now paired with ??? (i.e., prompting recall of previously paired names), with a 4 second stimulus duration and no ISI. On recall trials, participants press a button to indicate that they have recalled the name for the displayed face. Participants engage in silent uncued recall of face-name pairs. Immediately following the scan, participants are tested for accuracy of name retrieval."
219228099|NCT06897046|DRUG|QL1706|PD-1/CTLA-4
219228100|NCT06897046|DRUG|QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed|PD-1/CTLA4 combined chemotherapy drugs
219228101|NCT05735496|DRUG|TQB2102 injection|TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
219716027|NCT07104253|DEVICE|Ex vivo cryo-ablation|With informed consent obtained prior to transplantation, explanted lungs from patients undergoing lung transplantation will be obtained. The organs will be placed in an acrylic box and will be perfused at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 7 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon. The cryocatheter will be inserted in the lungs and cryoablation will be performed with varying freeze-thaw cycles to confirm design and operating specifications of the device.
219135597|NCT03970811|PROCEDURE|Immediate Implants|dental implants are immediately placed after tooth extraction
219135598|NCT03970811|PROCEDURE|temporary restoration|temporary restoration will be placed immediately after implant placement
219135599|NCT03970811|PROCEDURE|final restoration|final restoration (loading) will be placed 3 months postsurgical
219228102|NCT06776146|DIAGNOSTIC_TEST|proteomic profiling|proteomic profiling
219228103|NCT05831605|PROCEDURE|venipuncture with near-infrared light|with near-infrared light to locate the veins
219228104|NCT07064226|OTHER|RICORDO|"During the RICORDO intervention, participants will engage in a multidomain cognitive telerehabilitation program using a digital platform (\[http://www.ricordo-dtx.com/\]), which allows for personalized interventions through an adaptive algorithm allowing an increment in task difficulties according to patients' needs. The treatment can be self-administered by the patient at home. The program lasts five weeks, with three treatment sessions per week, each lasting approximately 45 minutes.~The active control group (TAU) will undergo the same type of treatment with the following differences: the digital platform will not be used, as the treatment will consist solely of paper-and-pencil exercises; and there will be no personalization of the exercises, since automatic adaptation is not possible."
219228105|NCT07064226|OTHER|Treatment as Usual (TAU)|As described above, this type of intervention will consist in a multidomain cognitive rehabilitation treatment to be self administered by the participants at home with pencil paper excercises. Treatment will last 5 weeks, 3 sessions per week, each lasting approximately 45 minutes. The treatment will follow a predefined incremental difficulty structure since no personalization is available.
219360652|NCT05562154|PROCEDURE|Total Ankle Replacement|Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
219716028|NCT07111637|DEVICE|AI software|icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
219135600|NCT01025583|DIETARY_SUPPLEMENT|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
219135601|NCT01025583|DIETARY_SUPPLEMENT|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
219135602|NCT00087269|DRUG|erlotinib hydrochloride|Given orally
219716029|NCT07105293|OTHER|PEEP 5 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:5 cmH2o
219135603|NCT00087269|PROCEDURE|therapeutic endoscopic surgery|Undergo surgical resection
219135604|NCT00087269|OTHER|laboratory biomarker analysis|Correlative studies
219135605|NCT02904707|OTHER|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
219135606|NCT02869620|OTHER|Data collection|
219716030|NCT07105293|OTHER|PEEP 10 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:10 cmH2o
219716031|NCT07103707|PROCEDURE|open cholecystectomy|standard open cholecystectomy performed under general anesthesia
219716032|NCT07103707|PROCEDURE|Laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy using minimally invasive technique
219716033|NCT07106593|BEHAVIORAL|Cognitive Processing Therapy|CPT (Resick, Monson, \& Chard, 2024) consists of 12 50-minute sessions conducted over a 6- to 12-week period (Resick, Monson, \& Chard, 2008). The three phases of CPT include psychoeducation, processing, and challenging beliefs and assumptions related to the trauma, oneself, and the world.
219716034|NCT07106593|BEHAVIORAL|CBT-t|The standard CBT-t protocol is gathered from the Progressive Tinnitus Management (PTM) program, and includes psychoeducation about how tinnitus can develop. CBT-t includes using behavioral principles to help manage tinnitus reactions, including the use of sounds: soothing sounds, background sound, and interesting sound. CBT-t teaches relaxation exercises, scheduling pleasant activities, and learn how to modify thoughts related to tinnitus. Therapists will also provide basic education on how to protect hearing health among participants in order to prevent worsening of tinnitus and to prevent exacerbation of any hearing loss.
219716035|NCT07103746|DRUG|Ublituximab|Initial dose includes 150 mg dose followed by 450 mg two weeks later; maintenance dose is 450 mg
219716036|NCT07103746|DRUG|Placebo for Ublituximab|0.9% sodium chloride injection
219716037|NCT07105072|PROCEDURE|Vitrectomy|vtrectomy is a surgical procedure to remove vitreous humor and can be used in case of viritis and as a debulking procedure for ciliary body granuloma.
219716038|NCT07104955|OTHER|MDT referral and review software|Use of the multi-disciplinary team (MDT) meeting software to submit, review and discuss referrals
219716039|NCT06914726|OTHER|Patient Centered Clinical Decision Support (PC-CDS)|The intervention provides patient specific recommendations on managing cancer risk due to hereditary cancer gene variants that is integrated into an existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and all subsequent primary care encounters using the most up to date available clinical information.
219716040|NCT07105969|OTHER|Strontium Incorporated Hydroxyapatite [Sr-HA] coated mini-screws purchased from Dentarum company|Maxillary canine retraction by mini-screw loaded with 150g Niti coil spring
219716041|NCT07111390|DEVICE|60Hz Intermittent Light Therapy|Intermittent 60 Hz flickering white light delivered via a wearable headset.
219716042|NCT07111390|DEVICE|Sham Light Therapy|Constant white light delivered via a wearable headset.
219716043|NCT07115693|BEHAVIORAL|Telerehabilitation-Based Resistance Exercise Program|Participants received synchronous telerehabilitation sessions three times per week for six weeks. Each session lasted 45 minutes and included supervised resistance exercises for upper extremity muscle groups. Exercise bands were chosen based on baseline strength. Pulse oximeters were used to monitor heart rate and oxygen saturation.
219716044|NCT07115693|BEHAVIORAL|Home Exercise Program|Participants were given a home-based, unsupervised exercise program to follow three times per week for six weeks. The exercises were taught at the beginning, and adherence was monitored using a physical activity diary. No tele-supervision was provided.
219716045|NCT07116161|OTHER|Exercise Therapy Arm (ET)|Consists of a self-supervised individualized exercise prescription by the rehabilitation professional consisting of aerobic (e.g. brisk walking / cycling) and resistance training exercises, customized by patient preference.
219716046|NCT07116161|OTHER|Experimental: Exercise Therapy (ET) plus Cognitive Behavioural Therapy (CBT)|Consists of four major components adapted from previous studies,13,15,16 and delivered by qualified and trained study psychologists. First, the ABC model of cognitive behavioural therapy (A: activating events, B: beliefs, C: consequences) will be taught and applied to identify negative, unhelpful beliefs and the emotional, behavioural and physical consequences of those beliefs. Second, patients were taught behavioural strategies to manage fatigue (e.g. sleep hygiene, activity scheduling). Lastly, participants will be guided to reformulate dysfunctional cognitions regarding fatigue, improve coping strategies in relation to significant others (e.g. family, friends) and set goals.
219716047|NCT07115082|DRUG|Climen 21 Tablets|Climen is commonly used clinically as a hormone replacement therapy and was administered to all patients in both the control and experimental groups in this project.
219716048|NCT07115082|BIOLOGICAL|hA-MSCs|The patients who were part of the experimental group were administered oral Clomid medication in conjunction with a combined intravenous injection of human amniotic MSCs.
219135607|NCT03563391|OTHER|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
219135608|NCT00203580|DRUG|Tinzaparin sodium|
219135609|NCT03814395|OTHER|No intervention|This is an observational study without any intervention
219135610|NCT04752735|OTHER|endovascular treatment|all enrolled patients must receive endovascular treatment.
219135611|NCT03887546|DEVICE|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
219135612|NCT03887546|PROCEDURE|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
219135613|NCT02930343|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
219716049|NCT07115797|OTHER|arthrocentesis - PRP injection -ARS|oarthrocentesis then PRP injection and then ARS
219135614|NCT02930343|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
219716050|NCT07115797|OTHER|ARS|Insertion Of ARS Only
219716051|NCT07115004|DRUG|VGA039|VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
219716052|NCT06912633|BIOLOGICAL|human retinal progenitor cells|Single intravitreal injection of 8.8 million retinal progenitor cells (RPCs)
219716053|NCT06912633|OTHER|Mock injection|Pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection. Subjects randomized to the sham control group will undergo identical preparation as the active treatment group immediately prior to treatment, including application of anesthetics.
219716054|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
219716055|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
219716056|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
219716057|NCT07115992|PROCEDURE|RARP±SRT|Participants will undergo robot-assisted radical prostatectomy (RARP). Upon biochemical recurrence, they will receive salvage radiotherapy: 52.5-62.5 Gy in 20-25 fractions/2.5-3.0 Gy per fraction, per 2025 AUA/ASTRO/SUO guidelines.
219716058|NCT07115992|PROCEDURE|RARP+ePLND|Participants will undergo robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND), encompassing bilateral removal of obturator, external iliac, internal iliac, and common iliac lymph nodes. The dissection field extends laterally to the genitofemoral nerve, medially to the bladder wall, proximally to the ureter crossing the common iliac vessels, and distally to the deep circumflex iliac vein and femoral canal.
219135615|NCT02930343|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
219135616|NCT02930343|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
219135617|NCT02930343|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
219135618|NCT02930343|DRUG|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
219135619|NCT05356923|RADIATION|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
219135620|NCT04473638|PROCEDURE|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
219135621|NCT00043264|DRUG|Rifampin|
219716059|NCT07116187|OTHER|Train-Your-Brain (TYB) Stroke Recovery Programme|The intervention involves a structured brain health programme delivered by clinical neuropsychologists in three phases: an initial needs assessment, a multi-session intervention, and follow-up support. Participants will receive assessments, attend group sessions covering topics such as lifestyle, mood, cognition, and return-to-work strategies, and be supported with workbooks and referrals to community services. The programme combines in-person and online formats.
219716060|NCT07124260|DIAGNOSTIC_TEST|gut microbiota|Fresh fecal samples were collected from patients during the non-menstrual period and subjected to 16S rDNA sequencing.
219716061|NCT07124260|DIAGNOSTIC_TEST|tongue coating microbiota|Tongue coating samples were collected under fasting conditions between 6:00-9:00 AM on the same day as fecal specimen collection and subjected to 16S rDNA sequencing.
219716062|NCT07124260|DIAGNOSTIC_TEST|tongue picture|Tongue images were captured under fasting conditions between 6:00-9:00 AM on the same morning as fecal specimen collection.
219716063|NCT07130591|OTHER|Cogniplat game platform|The Cogniplat gaming platform is designed to improve cognitive function in geriatric individuals, with or without mild cognitive impairment. Participants played the Cogniplat games face-to-face with a physiotherapist twice a week on non-consecutive days for 10 weeks, sessions lasting about 30-45 minutes. Scores from the platform were recorded to evaluate progress.
219716064|NCT07130591|OTHER|Control group|Individuals in this group did not participate in any regular play program. Demographic data were recorded. For evaluation purposes, a single session of Cogniplat game platform was applied in the first interview and in the second interview 10 weeks later. Initial and final evaluations were recorded.
219716065|NCT07138768|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be performed to all patients
219716066|NCT07141823|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid) regularly has been taken|
219716067|NCT07141212|DEVICE|Virtual reality glass|"Virtual reality (VR), with its immersion and interactivity, offers the possibility to amplify the effectiveness of breathing techniques in promoting mental health by creation of relaxing scenarios and has been successfully employed in promoting relaxation and stress reduction. Virtual reality can turn breathing exercises into an interactive experience that feels more like a fun activity than a tedious task. It consists of VR headset, two touch controllers, glasses spacer with adjustable straps for good vision as follows:~1. Colour Breathing VR program (Box Breathing) :~   Patient sit in comfortable position with relaxed both shoulders. Breath in for 4 second, Hold breath for 4 sec, Breath out for 4 sec, Hold for 4 sec, Inhalations and exhalations move a 3D cloud shaped object closer and farther away from the user.~2. LAMINAL VR (Calm): Inhalations and exhalations grow and shrink a 2D circle with bubbles in between, changing in color."
219716068|NCT07141212|PROCEDURE|Buteyko Breathing|"1. The ''Control pause (CP)'' breathing test: Hold his nose on the out breath, with empty lungs but not too empty and count how many seconds that he can comfortably last before the need to breathe in again.~2. Shallow breathing Sit up straight: breathe air slightly into the tip of the nostrils. Concentrate on calming his breath to reduce the amount of warm air he feel on his finger, try to maintain the need for air for about 4 min.~3. Putting it together Take Control pause:~Reduced breathing for 4 min. Wait 2 min and take Control pause. Reduced breathing for 4 min. Wait 2 min and take Control pause."
219716069|NCT07141030|DRUG|GZR18 injection|GZR18 injection:3mg
219716070|NCT07142174|DEVICE|cervical facet implant will be introduced into the cervical levels that were mobile on flexion-extension x-ray and exhibited foramen stenosis or spondylolisthesis|"The patients will be managed according to the current practice for posterior cervical spine surgical approaches regarding patient positioning, surgical exposure, and neural decompression. The patients will be positioned prone with the head in a Mayfield headrest, All patients will be monitored using intraoperative motor evoked potentials (MEP) and somatosensory evoked potentials (SSEP). Intra-operative X-rays (antero-posterior and lateral) will be used to identify the index cervical level and to guide facet preparation and CeLFI insertion. Exposure of the posterior surface of the lateral mass at the index level of the cervical spine will be done either through a midline open technique or para-midline; inter-muscular approach (MIS). The facet joint-space (FJS) will be opened using a monopolar cautery with careful attention to preserve the joint's capsule on the lateral and medial boundaries.~The FJS will be prepared using sequential dilators; designed for this purpose. Each dilator me"
219135622|NCT00043264|DRUG|Azithromycin|
219135623|NCT01603784|BEHAVIORAL|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
219135624|NCT01603784|BEHAVIORAL|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
219228106|NCT05197998|BEHAVIORAL|ColorBRAVE|The intervention is a multi-module program delivered via a mobile app for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
219228107|NCT06841640|DRUG|AERO-001|Open-label
219228108|NCT06841640|DRUG|AERO-002|Open-label
219135625|NCT01603784|BEHAVIORAL|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
219135626|NCT01603784|BEHAVIORAL|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
219135627|NCT04738565|DIETARY_SUPPLEMENT|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
219135628|NCT04738565|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
219716071|NCT07141069|OTHER|Art therapy combined with Exercise|one hour of expressive art intervention followed by one hour of exercise training. The art therapy will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and inviting them to share their current status. This is followed by a 10-minute brief mindfulness exercise to help center participants and promote relaxation, setting the stage for the creative activities that follow. The core of each session consists of a 20-minute art-making process centered around specific themes that guide participants in exploring their pain and personal narratives.
219716072|NCT07141069|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
219716073|NCT07141706|DRUG|DB-1317|Administered I.V.
219716074|NCT07141407|OTHER|Supportive Care|Attend TAC telephone-based coaching sessions
219716075|NCT07141407|BEHAVIORAL|Telephone-Based Intervention|Attend TAC telephone-based coaching sessions
219716076|NCT07141407|OTHER|Survey Administration|Ancillary studies
219716077|NCT07141407|OTHER|Educational Intervention|Receive an ACP brochure/handout
219135629|NCT01750554|OTHER|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
219135630|NCT00678158|RADIATION|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
219228109|NCT06841640|DRUG|AERO-007|Double-blind
219228110|NCT03173950|DRUG|Nivolumab|Individuals will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
219228111|NCT05656248|DRUG|CPX-351|Given Intraveneously (IV)
219228112|NCT05656248|DRUG|MHA|Given Intrathecal (IT)
219228113|NCT05656248|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219228114|NCT06416436|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1680 mg IV route every 4 weeks (1680 mg on Day 1 of each 28-day cycle), which is an approved dosage for atezolizumab, as outlined in the prescribing information.
219716078|NCT07142629|PROCEDURE|Selective caries removal|Selective carious removal to firm dentine. Subsequently, 2 mm of Biodentine will be placed as a liner over the pulpal wall leaving the peripheries of the cavity available for bonding of the subsequent restoration.
219716079|NCT07142629|PROCEDURE|Non-Selective caries removal|Complete caries excavation will be done to hard scratchy dentine, with the aid of caries detector dye.If no pulp exposure is evident 2 mm of Biodentine will be placed and the cavity will be restored. If pulp exposure occurred, and it is bleeding normally and uniformly red with no zones of degeneration or necrosis then direct pulp capping will be attempted with Biodentine as a capping material. If no hemostasis is achieved, then the procedure will be modified to either partial pulpotomy, full pulpotomy or RCT depending on the clinical assessment.
219716080|NCT07141095|DRUG|maribavir|Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.
219716081|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via fenestration of the lesser omentum) and the celiac branch (via skeletonization of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor, preserving \>50% of the residual stomach. Double-tract reconstruction was then performed: an end-to-side esophagojejunostomy was created first, followed by a side-to-side gastrojejunostomy between the residual stomach and jejunum, and finally a side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This approach achieves oncological resection while maximizing preservation of digestive physiology (gallbladder contraction, reduced dumping syndrome, and partial gastric reservoir function).
219135631|NCT02657629|OTHER|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
219228115|NCT06416436|RADIATION|Stereotactic Ablative Radiotherapy (SBRT)|"Ultra-High Doses of Ablative Radiosurgery~SBRT is delivered to metastases over 3-5 fractions within 1-2 weeks"
219228116|NCT07094230|DIAGNOSTIC_TEST|biomarkers analyses|blood analyses
219228117|NCT07099144|DRUG|Inhaled nitric oxide (NO)|"The starting dose of INOmax is 20 ppm, which is controlled by the INOmax DSIR Plus delivery system in the respiratory circuit during mechanical ventilation. The dose will be maintained at 20 ppm for 4 hours after the start of administration, then the dose can be weaned to 5 ppm provided that the arterial oxygenation is adequate, as determined by the investigator within 4-24 hours of therapy, and the therapy should be maintained at 5 ppm until the fraction of inspired oxygen (FiO2) \< 0.60.~The treatment will be maintained until the potential hypoxia is resolved, or the investigator determines that the neonate no longer needs to use this drug. The maintenance treatment time is usually less than 4 days (96 hours). If the oxygenation level has not improved significantly after 4 days of maintenance treatment, the suitability of the treatment plan should be reassessed."
219228118|NCT07099014|DRUG|Inahled Isoflurane|treatment administration
219228119|NCT07099014|DRUG|Propofol, midazolam|treatment administration
219716082|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via lesser omentum fenestration adjacent to the liver edge), while deliberately not preserving the celiac branch (by direct transection at the root of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor with preservation of \>50% gastric remnant. Double-tract reconstruction was then executed: end-to-side esophagojejunostomy (circular stapler) → side-to-side gastrojejunostomy (linear cutter) → side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This technique achieves oncological resection while utilizing the residual stomach and dual-pathway design to minimize postoperative dumping syndrome and preserve partial gastric function.
219716083|NCT07141264|DRUG|Adebrelimab combined with Etoposide Capsules|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Adebrelimab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Etoposide Capsules is given orally at a dosage of 50mg or 25mg daily, every 3 weeks. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
219135632|NCT02657629|OTHER|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
219135633|NCT00004367|PROCEDURE|Clinical vestibular tests|
219135634|NCT03787706|OTHER|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
219135635|NCT03787706|OTHER|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
219135636|NCT02987543|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
219135637|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
219135638|NCT02987543|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
219228120|NCT07098923|BEHAVIORAL|combination of aerobic and resistance exercise|"Aerobic exercise: The main form is walking(gait), which includes three parts: warm-up, walking, and relaxation. Exercise time and frequency: 30-60 minutes of exercise per day, 3-5 times per week.~Resistance exercise: Mainly uses elastic bands to enhance resistance exercise, since the risks of increased intra-abdominal pressure and fluid leakage in peritoneal dialysis patients is high, Investigator considered selective resistance exercise especially for limb and shoulder joint exercises. Patients can choose 3-5 muscle groups based on individual conditions, with each action 10-15 times and maintained for 10 seconds. Start with 2 sets of resistance exercise and then gradually increase to 3-5 sets, with 2-3 minutes of rest between each sets. Exercise frequency and duration: 2 times a week (non-consecutive days), 20 minutes each time."
219228121|NCT07098780|DRUG|Tranexamic Acid|At the time of incision, 1000mg of the drug would be given intravenous, followed by two postoperative doses of 1000mg eight hours apart.
219228122|NCT07098780|OTHER|Normal Saline (Placebo)|At the time of incision, 10ml of the drug would be given intravenous, followed by two postoperative doses of 10ml eight hours apart.
219228123|NCT07098806|DRUG|186RNL|Multiple Doses of 186RNL
219228124|NCT07099599|DIAGNOSTIC_TEST|CT Perfusion|CT perfusion within 90 minutes of complete angiographic reperfusion
219228125|NCT07098117|DRUG|SHR0302 Base Gel|Part I: once daily. Part 2:, twice daily.
219228126|NCT07098117|DRUG|SHR0302 Base Gel Placebo|Part I: once daily. Part II: twice daily.
219228127|NCT07100041|OTHER|Breathing Exercise Group|Before the dressing procedure, patients who volunteer to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and their pain level before dressing will be recorded using the GAS. After their vital signs are checked, they will be given a practical demonstration of breathing exercises. The breathing exercise will first be explained verbally by the project coordinator in the burn centre's training room, followed by a practical demonstration. The patient will then be asked to perform the exercise. Once the project coordinator is confident that the patient has learned how to perform the breathing exercise, the patient will be taken to the dressing room. During the standard dressing procedure, the patient will be instructed to continue performing the breathing exercise. Immediately before the dressing change, the patient will be positioned comfortably, and they will be instructed to use the breathing
219135639|NCT02987543|DRUG|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
219135640|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg tablets) once daily
219135641|NCT03145337|BIOLOGICAL|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
219135642|NCT03145337|BIOLOGICAL|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
219228128|NCT07100041|OTHER|Stress Ball Group|The stress ball is made of a medium-hard plastic material that can be easily held in the hand. Before the dressing procedure, patients who volunteer to participate in the study will be given information about the use of the stress ball after the patient information form, the burn-specific pain and anxiety scale, and the pain level before dressing have been recorded using the GAS, and their vital signs have been checked. During the standard dressing procedure, patients will be instructed to squeeze and release the stress ball periodically until the dressing procedure is complete, focusing solely on the stress ball during this time (Ozen et al., 2023) (Kasar et al., 2020). A separate stress ball will be used for each patient in the stress ball group to ensure that the effectiveness of the stress ball remains consistent. To support patients' relaxation during the dressing procedure, a stress ball usage guide prepared by the project team will be provided
219135643|NCT04630457|DEVICE|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
219135644|NCT04630457|DEVICE|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
219135645|NCT04630457|DEVICE|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
219135646|NCT01990937|DRUG|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
219228129|NCT07100041|OTHER|Control (Standard Treatment) Group|The standard dressing procedure in the control group is as follows: The protective covering over the wound is removed, and the wound is washed with an irrigation solution. Appropriate medications (decontamination and moisturising gel, debridement gel, alginate, antibiotics, and medications that promote cell regeneration) are applied based on the condition of the wound. A non-adhesive wound care dressing is then placed over the wound, and gauze is applied on top to cover it. Analgesia is not routinely administered in standard wound care. The dressing procedure takes an average of 5 minutes, depending on the size of the burn wound. In the control group, before the dressing procedure, the patient who volunteered to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and the pain level before dressing will be recorded using the Visual Analogue Scale (VAS) and vital signs will be checked,
219228130|NCT07099391|DRUG|Dara-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
219228131|NCT07099391|DRUG|Tec-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
219716084|NCT07142616|OTHER|03 - Summaries of and clinical notes from several providers|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care, like in arm 02. In addition, access to information management features, such as summaries of patient's priorities, and clinical summaries of key health problems, including links to source documents.
219716085|NCT07142616|OTHER|01 - Clinical notes from one provider|Access to all clinical notes available to the provider in the patient's case. The provider is General practice in two patient cases, and hospital in one patient case.
219716086|NCT07142616|OTHER|02 - Access to notes from primary and secondary care|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care.
219228132|NCT07098494|DIETARY_SUPPLEMENT|Saccharomyces Boulardii Probiotic Supplement|• Saccharomyces boulardii (strain CNCM I-745): 250 mg per day (5 billion colony-forming units (CFU)
219228133|NCT07099794|DRUG|Liposomal irinotecan+5-FU/LV+Lenvatinib|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w Renvastinib: ≥60kg, 12mg; \<60kg, 8mg, PO, once daily 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
219716087|NCT07141797|OTHER|Executive functions assessment|"Inhibition: Emotional (hot) and logical (cold) inhibition using Emotional and Classic Stroop tests. Participants identify the color of words or emotion in photos while inhibiting automatic responses. Inhibition scores are based on the difference in response times between congruent and interference conditions.~Working Memory: Participants recall a sequence of points on a grid, first in the original order, then in reverse. The working memory score is the difference between the two tasks.~Cognitive Flexibility: A task requiring alternation between identifying numbers as greater/less than 5 or even/odd based on color cues. Flexibility is scored by comparing response times for alternating and non-alternating tasks.~Visuospatial abilities are assessed with a global-local task. Raven's Progressive Matrices will assess general intelligence, and socio-economic data will be collected."
219135647|NCT02899286|BIOLOGICAL|PEG-BCT-100|PEGylated recombinant human arginase
219135648|NCT06532760|OTHER|Blood sampling|Blood sampling to study sodium fragment kinetics
219135649|NCT04156724|DEVICE|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
219135650|NCT04965467|DIAGNOSTIC_TEST|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
219135651|NCT04928872|COMBINATION_PRODUCT|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
219135652|NCT00370448|BEHAVIORAL|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
219135653|NCT06249633|DRUG|Nitric Oxide|Inhaled nitric oxide
219135654|NCT04582344|BIOLOGICAL|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
219135655|NCT04582344|BIOLOGICAL|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
219135656|NCT01906060|DEVICE|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
219135657|NCT04776993|DRUG|Methimazole|Methimazole for 72 weeks
219135658|NCT04776993|PROCEDURE|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
219228134|NCT07099794|DRUG|NALIRI|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
219716088|NCT07140978|DIETARY_SUPPLEMENT|Green Chef Meal Delivery Program|Participants will receive Green Chef meals for lunch and dinner, delivered weekly for 16 weeks. Meals include organic produce, responsibly sourced protein, and nutritionist-approved recipes. Participants will also receive guidelines for preparing healthy breakfasts and will use smart devices to record biomarker data.
219716089|NCT07141927|OTHER|Measurements|First, the demographic characteristics of all participants were recorded. For those who met the inclusion criteria, primary and secondary outcome measurements were performed by the same physical therapist in a single session
219716090|NCT07141329|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
219135659|NCT00105794|PROCEDURE|Psychiatric Advance Directives intervention|
219135660|NCT04588337|DRUG|rhTNK-tPA|Thrombolysis
219135661|NCT05376930|DRUG|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
219135662|NCT04323995|OTHER|Sprint Interval Training|Sprint interval training of 2 weeks and more.
219135663|NCT05351372|RADIATION|Ultra-low dose protocol|
219135664|NCT05351372|RADIATION|Standard dose protocol|
219135665|NCT05574530|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
219135666|NCT05574530|DIETARY_SUPPLEMENT|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
219135667|NCT02485041|DRUG|Dapoxetine 30mg|Tablet, Orally administered
219135668|NCT02485041|DRUG|Mirodenafil 100mg|Table, Orally administered
219135669|NCT01315899|DRUG|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
219135670|NCT01315899|DRUG|ORM-12471|Given as a single dose once during the study as per Williams crossover design
219135671|NCT01315899|DRUG|placebo|Given once as a single dose during the study as per Williams crossover design
219135672|NCT04009070|DEVICE|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
219135673|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|40 mg, QD
219135674|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|80 mg, QD
219135675|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|160 mg, QD
219135676|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|240 mg, QD
219135677|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|320 mg, QD
219135678|NCT01977612|DEVICE|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
219135679|NCT01977612|DEVICE|Stainless steel staples|Skin closure using stainless steel staples.
219135680|NCT00079664|BEHAVIORAL|Tai Chi|
219135681|NCT02188758|OTHER|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
219135682|NCT06320119|OTHER|PDO Group|Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
219135683|NCT01280591|DRUG|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
219135684|NCT01280591|DRUG|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
219135685|NCT01280591|DRUG|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
219135686|NCT01280591|DRUG|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
219135687|NCT03943719|DIAGNOSTIC_TEST|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
219135688|NCT02504619|BIOLOGICAL|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
219135689|NCT01886430|OTHER|Functional electrical stimulation|Functional electrical stimulation for 10 days
219135690|NCT01886430|OTHER|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
219135691|NCT02396979|DRUG|Methadone|
219135692|NCT02396979|BEHAVIORAL|Holistic Health Recovery Program|
219135693|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
219135694|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
219135695|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
219135696|NCT05323682|OTHER|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
219135697|NCT05323682|OTHER|NO Individualized physical exercise program|Usual medication
219135698|NCT05178758|DEVICE|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
219135699|NCT06260696|OTHER|No treatment is given|No treatment is given
219135700|NCT01606553|DEVICE|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
219135701|NCT01606553|DEVICE|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
219135702|NCT03284411|DEVICE|Spinal Cord Stimulation|Programming
219135703|NCT04074148|BEHAVIORAL|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
219135704|NCT04074148|BEHAVIORAL|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
219135705|NCT04667988|DIAGNOSTIC_TEST|JAK expression|JAK2 assessment in blood by PCR
219135706|NCT01883492|DEVICE|Femoral Stem|JMDN classification/Class III device
219135707|NCT01883492|DEVICE|Acetabular Cup|JMDN classification: Class III device
219135708|NCT01883492|DEVICE|Acetabular Liner|JMDN classification: Class III device
219135709|NCT03721432|DRUG|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
219135710|NCT03721432|DRUG|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
219135711|NCT05181579|OTHER|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
219228135|NCT07099703|OTHER|Experimental|At Kırşehir Ahi Evran University, which is part of the Intervention Group, Ahilik education is a compulsory course within the current curriculum and will be taught over a period of 14 weeks. Ahilik education covers topics such as morality, etiquette, ethics, values, and professional ethics.
219228136|NCT07099703|OTHER|Routine education|They will continue with their current curriculum and will not receive any Ahilik training.
219228137|NCT07100002|DEVICE|Control Group|Patients in this group did not receive any treatment to improve pain and sleep quality during the study period. Routine postoperative care was applied in the clinic.
219228138|NCT07100002|DEVICE|Earplug Group|Patients who met the inclusion criteria were fitted with standard earplug of the same brand by the researcher at night. The researcher applied the earplug from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
219228139|NCT07100002|DEVICE|Eye mask Group|Patients who met the inclusion criteria were fitted with standard eye masks of the same brand by the researcher at night. The researcher applied the eye mask from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
219228140|NCT07098208|BEHAVIORAL|Twin Heart Meditation|"Participants in this group receive the Twin Heart Meditation intervention, a guided meditative technique based on the principles of loving-kindness and spiritual energy. The intervention is designed to reduce exam-related anxiety by promoting inner peace and emotional regulation. The meditation protocol follows the steps conceptualized by Master Choa Kok Sui and includes the following components:~* Physical warm-up exercises~* Activation of the heart chakra~* Activation of the crown chakra~* Blessing the Earth with loving-kindness~* Silent meditation using the phrase Amen~* Expression of gratitude~* Closing exercises~Participants practice the meditation in three guided sessions over one week, each lasting 30 minutes, under the supervision of a trained instructor. Sessions are conducted in a quiet room with audio guidance and follow-up support."
219228141|NCT07099859|DRUG|Losartan 50 mg|Losartan 50 mg per day
219135712|NCT05181579|OTHER|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
219135713|NCT05042791|COMBINATION_PRODUCT|radiation combined with pyrotinib and capecitabine|This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
219135714|NCT01101152|DRUG|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
219135715|NCT01259102|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
219135716|NCT04436055|OTHER|No Intervention will be used|Since this is an observational study, there are no interventions.
219135717|NCT06492889|DRUG|Levonorgestrel|Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
219135718|NCT06492889|DRUG|Mifepristone|Participants in both groups will receive one tablet of 200 mg mifepristone
219135719|NCT01615835|OTHER|EnSite NavX System|EnSite NavX system is a 3D Mapping system
219135720|NCT00888108|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
219135721|NCT00888108|DRUG|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
219228142|NCT07099859|DRUG|Placebo|Placebo 1 pill per day
219228143|NCT07098442|BEHAVIORAL|Control Group|On the first clinical day, students had a 30-45 minute meeting with the patient they were responsible for, which included the instructor.
219228144|NCT07098442|BEHAVIORAL|Online Interview Group|"Before the Interview~* Preliminary briefings were given by providing a scenario for the standard patient to be interviewed.~* Students were given the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a pre-determined standard patient.~After the Interview~* The instructor, who monitored the interview, debriefed the students.~* On the first clinical day after the intervention, students conducted a 30-45 minute interview with the patient they were responsible for, which included the instructor."
219135722|NCT01541358|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
219135723|NCT01541358|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
219135724|NCT01876511|DRUG|MK-3475|MK-3475 10 mg/kg every 14 days
219135725|NCT00480012|DEVICE|rTMS|repetitive transcranial meagnetic stimulation of the brain
219135726|NCT05657041|DRUG|Clopidogrel|Body weight adjusted clopidogrel dosing
219135727|NCT02156687|DEVICE|Y mesh|Y mesh
219135728|NCT02156687|DEVICE|Dual flat mesh|Dual flat mesh
219135729|NCT06461637|BEHAVIORAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
219135730|NCT01233050|DRUG|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
219135731|NCT01233050|DRUG|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
219135732|NCT02854761|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
219135733|NCT02533908|DRUG|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
219135734|NCT02533908|DRUG|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
219135735|NCT01590836|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
219135736|NCT01590836|DRUG|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
219135737|NCT00241930|BEHAVIORAL|Integrating drug treatment into HIV services|
219135738|NCT04187664|BEHAVIORAL|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
219135739|NCT04187664|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
219135740|NCT02708069|OTHER|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
219135741|NCT02708069|OTHER|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
219135742|NCT02411942|DRUG|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
219135743|NCT02411942|DRUG|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
219135744|NCT02411942|DRUG|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
219135745|NCT01611831|BEHAVIORAL|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
219135746|NCT01611831|BEHAVIORAL|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
219135747|NCT01064817|DRUG|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
219135748|NCT01064817|DRUG|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
219135749|NCT00257283|DRUG|Omega-3-acid ethyl esters 90|
219135750|NCT00334594|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
219135751|NCT00334594|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
219135752|NCT00334594|PROCEDURE|Therapeutic conventional surgery|Extrapleural pneumonectomy
219135753|NCT00334594|RADIATION|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
219135754|NCT02267967|DRUG|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
219135755|NCT04375449|DIETARY_SUPPLEMENT|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
219135756|NCT04375449|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
219135757|NCT03347942|BEHAVIORAL|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
219135758|NCT03347942|OTHER|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
219716091|NCT07140926|DEVICE|Recovery Connect|"Recovery Connect is a white-labeled version of the Recovery Path platform, rebranded to maintain partner organizations' brand identity while leveraging its established digital infrastructure. Recovery Path is a HIPAA-compliant remote patient monitoring system that supports a blended model of care for medication for opioid use disorder (MOUD), integrating in-person treatment with continuous digital engagement.~The app provides patients with daily check-ins, access to evidence-based resources and coping strategies, and secure messaging with their care teams. Clinicians receive real-time data on patient progress, risks, and setbacks. Between visits, clinicians can recommend tailored coping tools and psychoeducational content, reinforcing accountability and enhancing continuity of care.~RC is also integrated into the clinic's electronic medical record system to streamline workflows, reduce administrative burden, and improve documentation accuracy through auto-generated case notes."
219716092|NCT07141017|OTHER|Initial standardized global review|"The intervention under study will be the initial standardized global review, which will be performed as soon as axial spondyloarthritis is diagnosed (less than 12 months from diagnosis is mandatory) and only at the baseline visit.~This review includes both the assessment of different domains of the disease, but also the education and information on such different domains of the disease and its management~The domains assessed during the intervention will be: diagnosis of spondyloarthritis, spondyloarthritis phenotype, disease activity, disease severity and function, treatment adherence and comorbidities.~At the end of the intervention, a detailed medical report on this initial standardized global review will be produced and sent to the patient, their rheumatologist, their general practitioner, and their dispensing pharmacist."
219716093|NCT07142187|OTHER|electro-thumbtack needle|The treatment acupoints include bilateral ovarian acupoints, Guan Yuan (CV4), bilateral Shen Shu (BL23), bilateral waist and eye acupoints (EX-B7), bilateral San Yin Jiao (SP6), and bilateral Zu San Li (ST36), totaling 11 acupoints. Among them, the bilateral ovarian acupoints and bilateral waist eye acupoints (EX-B7) were treated with electro-thumbtack needle. Other acupoints were treated with thumbtack needle.Choose a sparse and dense waveform, adjust the intensity to the maximum patient can tolerate, and stimulate for 30 minutes each time. After the stimulation is completed, remove the electrode patch and electroacupuncture device, and keep the electric needle at the acupoint for another 3 days.During the needle retention period, the electric needles at the bilateral ovarian acupoints and bilateral waist and eye acupoints were alternately stimulated once every other day using an electroacupuncture device for 30 minutes each time.
219716094|NCT07142187|OTHER|placebo electro-thumbtack needle|The control group selected acupoints that were the same as the treatment group. Bilateral ovarian acupoints and bilateral waist and eye acupoints are treated with placebo electro-thumbtack needle, while other acupoints are treated with placebo electro-thumbtack needle. The treatment methods for placebo electro-thumbtack needle and placebo thumbtack needle are the same as those for the treatment group.
219716095|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
219716096|NCT06932315|DRUG|HRS-9190 for Injection|Subject will receive the HRS-9190 injection at different dose levels.
219716097|NCT06943443|DEVICE|Miniscrew-Assisted Rapid Palatal Expansion (MARPE) Treatment|"Vitamin D Supplementation: Vitamin D plays a crucial role in calcium absorption, bone health, immune system function, and cellular growth. It is primarily obtained through sunlight exposure, certain foods, and supplements. In the context of your study, Vitamin D supplementation will be used to improve the Vitamin D levels in patients undergoing Miniscrew-Assisted Rapid Palatal Expansion (MARPE) treatment.~Key Points:~Purpose: To correct Vitamin D deficiency, which may affect bone metabolism and orthodontic treatment outcomes.~Administration: Vitamin D supplementation is typically provided in the form of oral tablets or soft gels, with a usual dosage of 800-2000 IU per day, depending on the individual's baseline levels.~Measurement: Vitamin D levels will be measured at the beginning and end of treatment using 25-hydroxyvitamin D (25(OH)D tests to assess the effectiveness of supplementation.~Effect on MARPE: Adequate Vitamin D levels may support better bone remodeling and healing, pote"
219716098|NCT06938685|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
219135759|NCT01213706|DEVICE|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
219135760|NCT01213706|DEVICE|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
219135761|NCT05714358|BEHAVIORAL|Education|"* The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~* After the training, the biochemical parameters of the patients were followed for 6 months.~* In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
219135762|NCT03899818|DEVICE|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
219135763|NCT03899818|DEVICE|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
219135764|NCT03258619|BIOLOGICAL|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
219135765|NCT03258619|BIOLOGICAL|Natriuresis|natriuresis levels
219135766|NCT04538248|OTHER|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
219135767|NCT03014830|DRUG|Alirocumab|150 mg SQ every 2 weeks
219135768|NCT03014830|DRUG|Placebos|Placebo injections SQ every 2 weeks
219135769|NCT03551132|OTHER|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
219135770|NCT02309567|OTHER|Blood Collection|
219135771|NCT05218408|BIOLOGICAL|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
219135772|NCT04910919|DIETARY_SUPPLEMENT|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
219135773|NCT04910919|OTHER|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
219228145|NCT07098442|BEHAVIORAL|Clinical Real Patient Group|"Before the Interview~* Patients who were willing to be interviewed in the clinic, stable, and physically and psychologically competent were selected, and the faculty member who would monitor the interview provided preliminary information about the interview.~* Students were provided with the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a real patient in the pre-determined clinic.~After the Interview~* The faculty member who monitored the interview debriefed the students.~* On the first clinical day after the intervention, students had a 30-45 minute interview with the patient for whom they were responsible, which included the faculty member."
219716099|NCT06938685|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219228146|NCT07098949|OTHER|Acupuncture|The patient takes a sitting or lateral position. The following acupoints are selected Baihui (GV20), Yintang (EX-HN3), Zhongwan (CV12), Bilateral Neiguan (PC6), Bilateral Zusanli (ST36), Bilateral Sanyinjiao (SP6), Bilateral Gongsun (SP4), Bilateral Pishu (BL20). Electroacupuncture is applied at bilateral Sanyinjiao (SP6) and bilateral Zusanli (ST36) by connecting them to an electroacupuncture device. The needles are retained for 30 minutes.
219228147|NCT07098949|OTHER|Sham Acupuncture|sham acupuncture procedure that mirrors the acupuncture treatment in terms of acupoint selection and treatment schedule. However, instead of actual needle insertion, a blunt-tipped sham needle will be used to apply superficial pressure at the designated acupoints. The design of the sham needle includes a base that allows for simulated insertion, providing patients with a mild sensation of pressure and a visual cue as the needle appears to move toward the skin. This innovative approach ensures that while participants experience a similar tactile sensation, there is no penetration of the skin, distinguishing it clearly from the actual acupuncture treatment.
219716100|NCT07141771|DRUG|Serplulimab|Serplulimab: 4.5mg/kg, ivgtt, 21 days/cycle
219716101|NCT07141771|DRUG|Fluzoparib|100mg BID oral
219716102|NCT07141771|DRUG|Topotecan/Irinotecan/Paclitaxel/Temozolomide|second-line chemotherapy options: Topotecan/Irinotecan/Paclitaxel/Temozolomide etc.
219716103|NCT07141771|DRUG|Etoposide/Carboplatin/Cisplatin|First-line chemotherapy: the original first-line chemotherapy regimen, recommended Etoposide 100mg / m2 d1-3, Carboplatin AUC = 5 d1 / Cisplatin 75mg / m2 d1 q21d
219716104|NCT07141771|DRUG|Lurbinectedin|2.6mg/m2 (3 patients, if safe, in the 3.2mg / m2 dose group) or 3.2 mg / m2, ivgttd,21d / cycle .
219716105|NCT07141771|DRUG|Temozolomide|150mg/m2, oral, on days 1-5,28d / cycle
219716106|NCT07141316|DEVICE|Blood flow restriction combined with electrostimulation.|Participants will perform 30 minutes of blood flow restriction once a day during electrostimulation of the quadriceps of the operated limb.
219716107|NCT07141693|PROCEDURE|NIRS-guided management|NIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ increase)
219716108|NCT07141693|PROCEDURE|Standard anesthesia management|Standard anesthesia management
219716109|NCT07142057|BIOLOGICAL|23-valent pneumococcal vaccine|Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
219716110|NCT07140965|PROCEDURE|Pegulicianine Fluorescence-Guided Surgery|Given by Surgery
219716111|NCT07140965|PROCEDURE|Digital Breast Tomosynthesis|Given by Procedure
219716112|NCT07140965|PROCEDURE|Breast Conserving Therapy|Given by Procedure
219716113|NCT07141173|BEHAVIORAL|Individual lifestyle management|Manage the diet, exercise, weight and healthy lifestyle of pregnant women
219135774|NCT04172948|DEVICE|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
219135775|NCT04172948|BEHAVIORAL|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
219135776|NCT01559480|DRUG|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
219135777|NCT01559480|DRUG|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
219135778|NCT05388344|OTHER|Booklet reading|Submission of the questionnaire before and after booklet reading
219135779|NCT05639023|OTHER|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
219135780|NCT05639023|OTHER|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
219135781|NCT00810550|OTHER|Carotid ultrasound|Measurement of intima-media thickness
219135782|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
219135783|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
219135784|NCT05824338|DRUG|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
219135785|NCT06140680|BEHAVIORAL|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
219135786|NCT06140680|BEHAVIORAL|Physical education|The control group received 12-week traditional physical education lesson as usual.
219135787|NCT03087539|BIOLOGICAL|Abciximab|
219135788|NCT03087539|BIOLOGICAL|Placebo|
219135789|NCT02064569|GENETIC|GS010|
219135790|NCT06230874|BEHAVIORAL|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
219135791|NCT06230874|BEHAVIORAL|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
219135792|NCT06337110|DRUG|Lu AF28996|Oral solution containing radiolabelled \[14C\]-Lu AF28996.
219135793|NCT06409637|DRUG|FOLFOX4 regimen|FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
219135794|NCT06409637|DRUG|lenvatinib|Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
219135795|NCT01466881|DRUG|Alisertib|Given PO
219135796|NCT01466881|OTHER|Laboratory Biomarker Analysis|Correlative studies
219135797|NCT01466881|OTHER|Pharmacological Study|Correlative studies
219135798|NCT00130741|DRUG|CHT - herbal therapy|
219135799|NCT01228448|PROCEDURE|PET scan|In-Room PET scan
219135800|NCT03496649|DRUG|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
219135801|NCT00130780|DRUG|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
219135802|NCT00130780|DRUG|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
219135803|NCT02817217|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
219135804|NCT02817217|DRUG|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
219135805|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
219135806|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
219135807|NCT00662324|BEHAVIORAL|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
219135808|NCT04590924|PROCEDURE|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
219135809|NCT05453955|DRUG|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
219135810|NCT05453955|DRUG|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
219135811|NCT03835572|OTHER|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
219135812|NCT03835572|OTHER|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
219135813|NCT03015454|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
219135814|NCT03015454|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
219135815|NCT03812003|DRUG|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
219135816|NCT06181318|DIAGNOSTIC_TEST|Multiparametric MRI scan of the liver|MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
219135817|NCT02960139|DEVICE|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
219135818|NCT02981186|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
219135819|NCT02981186|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
219135820|NCT01065636|BEHAVIORAL|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
219135821|NCT01065636|BEHAVIORAL|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
219135822|NCT01065636|BEHAVIORAL|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
219135823|NCT04580303|DRUG|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
219135824|NCT00000646|DRUG|Pentoxifylline|
219135825|NCT01444287|DEVICE|narafilcon B|test product
219135826|NCT01444287|DEVICE|Polymacon|marketed product
219135827|NCT01444287|DEVICE|Lotrafilcon A|marketed product
219228148|NCT07098949|DRUG|Chemotherapy|Adjuvant chemotherapy with either the XELOX (capecitabine + oxaliplatin) or SOX (S-1 + oxaliplatin) regimen
219135828|NCT01444287|OTHER|Spectacles|None - subject used own spectacles
219135829|NCT05451199|DRUG|ICP-488|ICP-488 will be administered as tablet
219135830|NCT05451199|DRUG|Placebo|Matching placebo will be administered as tablet
219716114|NCT07141667|PROCEDURE|Erector spinae plane block with liposomal bupivacaine|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 1.33% liposomal bupivacaine.
219135831|NCT02773017|DRUG|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
219135832|NCT02773017|DRUG|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
219135833|NCT02773017|DRUG|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
219135834|NCT00434278|DRUG|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
219716115|NCT07141667|PROCEDURE|Erector spinae plane block with bupivacaine HCL|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 0.5% bupivacaine HCL.
219716116|NCT07142460|BEHAVIORAL|Intervention|The students in the experimental group were shared the digital stories prepared for drug applications from the WhatsApp group and were asked to watch them for two weeks. Students were able to watch the stories on their mobile phones at the time and frequency they wanted. During 2 weeks, the researchers met with the students twice in the classroom environment and received feedback on the digital stories. Feedbacks about the real meaning of the stories and their contribution to education were obtained by using discussion and question-answer methods. Each student explained their opinions about the stories and had the opportunity to think deeply about them by receiving feedback from their classmates.
219716117|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
219716118|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
219716119|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
219716120|NCT07138781|DRUG|Ketamine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg).
219716121|NCT07138781|DRUG|29 ml bupivacaine 0.25% + 1 ml saline|Patients will receive 29 ml of bupivacaine 0.25% + 1 ml of saline.
219716122|NCT07142538|OTHER|exercises|Exercise training was provided to both groups.
219716123|NCT07141680|PROCEDURE|Replantation|Root canal treatment Tooth extraction and replacement Splinting
219716124|NCT07141680|PROCEDURE|Splint|Root canal treatment Splinting
219716125|NCT07141615|COMBINATION_PRODUCT|Qingwei Huazhuo Decoction: Mulberry leaf powder, lotus leaf powder, malt powder, hawthorn powder, Poria cocos powder, gardenia powder, dried tangerine peel powder, licorice powder, momordica grosvenor|"On the basis of receiving dietary and exercise education, the pediatric patients were given the Qingwei Huazhuo Decoction orally.~Composition:Mulberry Leaf Powder, Lotus Leaf Powder, Germinated Barley Powder, Hawthorn Powder, Poria Mushroom Powder, Cape Jasmine Fruit Powder, Tangerine Peel Powder, Licorice Root Powder, Monk Fruit Powder.~Administration Method:Take one sachet each time, add 150ml of warm boiled water, stir well, and drink.~Treatment Course:The first-stage course lasts for 12 weeks.For participants in the experimental group who have completed the first 12-week stage, they may continue to take the Qingwei Huazhuo Decoction orally for another 12 weeks"
219135835|NCT00434278|DRUG|placebo|2.5 mg inhalation dose twice daily for 14±2 days
219135836|NCT00665379|OTHER|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
219135837|NCT00665379|OTHER|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
219135838|NCT02372019|BEHAVIORAL|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
219228149|NCT07098975|DRUG|Pravastatin 40 mg|This study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and/or fetal growth restriction.
219228150|NCT07098975|OTHER|Placebo|A visually identical but inactive pill (a placebo),
219135839|NCT02372019|BEHAVIORAL|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
219135840|NCT02372019|BEHAVIORAL|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
219135841|NCT02964429|DEVICE|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
219135842|NCT01536730|BEHAVIORAL|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
219135843|NCT00439933|BEHAVIORAL|low fat and polysaccharide rich diet|
219135844|NCT00439933|BEHAVIORAL|specific physical training program for obese children|
219135845|NCT01424579|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
219135846|NCT01424579|OTHER|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
219135847|NCT01424579|OTHER|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
219135848|NCT04837313|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
219135849|NCT02565056|OTHER|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
219135850|NCT02299635|DRUG|PF-03084014|Tablet, 10 mg, twice a day.
219360653|NCT03598387|OTHER|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~* The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~* The minimal target weekly Kt/V is 2.1-3.5/W."
219360654|NCT03598387|OTHER|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
219360655|NCT01332539|OTHER|no intervention|non-interventional study
219135851|NCT02299635|DRUG|PF-03084014|Tablet, 50 mg, twice a day
219135852|NCT02299635|DRUG|PF-03084014|Tablet, 100 mg, twice a day
219135853|NCT00234377|DRUG|Seroquel SR|
219135854|NCT00927823|DRUG|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
219135855|NCT05104905|DRUG|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
219135856|NCT00190216|DEVICE|Magnetic stimulator|
219135857|NCT02943382|OTHER|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
219135858|NCT06474806|DRUG|64Cu-DOTA-AE105|AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
219135859|NCT04128839|DIETARY_SUPPLEMENT|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
219135860|NCT04128839|OTHER|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
219135861|NCT00828672|DRUG|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
219135862|NCT00828672|DRUG|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
219135863|NCT00828672|DRUG|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
219135864|NCT00828672|RADIATION|radiotherapy|Total dose 45Gy
219135865|NCT02239796|DEVICE|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
219135866|NCT02239796|DEVICE|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
219716126|NCT07141615|BEHAVIORAL|diet and exercise education|"① Dietary Education With reference to the Balanced Diet Pagoda for School-Age Children Aged 6-10 Years in the Chinese Dietary Guidelines for School-Age Children (2022), the children were required to record their daily diet and complete a dietary diary.~② Exercise Education~Children were advised to accumulate at least 60 minutes of moderate-to-vigorous physical activity (MVPA) daily, mainly consisting of aerobic exercise. The specific requirements were as follows:~1.3-5 sessions of aerobic exercise per week; 2.2-3 sessions of resistance exercise per week; 3.Daily screen time limited to less than 2 hours. The parents were asked to record their children's daily completion of the above requirements."
219716127|NCT07141368|OTHER|Curcumin Dispersome formulation|75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule
219716128|NCT07141368|OTHER|Non-formulated Curcumin|dose: 90 mg, 1 capsule
219716129|NCT07141368|OTHER|Benchmark Formulation 1 - Turmipure Gold™|recommended daily dose: 300 mg, 1 capsule
219135867|NCT04596579|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
219135868|NCT04596579|DIAGNOSTIC_TEST|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
219360656|NCT01877083|DRUG|Lenvatinib|Starting dose of 24 mg orally, once per day
219360657|NCT06549959|DRUG|Telitacicept Pre-filled Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
219716130|NCT07141368|OTHER|Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength|recommended daily dose: 1000 mg, 2 capsules of 500 mg each
219135869|NCT04596579|BEHAVIORAL|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
219135870|NCT04714450|BEHAVIORAL|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
219135871|NCT05784155|DRUG|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
219135872|NCT00288964|DEVICE|Hattler Respiratory Assist Catheter|
219135873|NCT06314256|BIOLOGICAL|Injection|İnterdental papilla will be injected by i-PRF.
219135874|NCT06314256|DRUG|Injection|Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
219360658|NCT06549959|DRUG|Telitacicept Freeze-dried powder Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
219360659|NCT05949229|DRUG|Duloxetine 60 MG|Patients will recieve 2-hour preoperative duloxetine
219228151|NCT06668428|DEVICE|Virtual Reality Glasses|Pharmacological and non-pharmacological methods are applied in the management of pain and anxiety after cesarean section (Tetik \& Tekinemre, 2017). In addition to medical treatment during the post-cesarean care process, complementary and supportive non-pharmacological approaches can be used to address the woman holistically and provide multi-faceted contributions to the health of the mother and baby (Ali, 2022; Bayraktar, 2023). One of the non-pharmacological approaches, virtual reality glasses, is a device that provides two or three-dimensional environments to stimulate our senses by creating illusions of images (Appel et al., 2021). SGG creates a therapeutic effect by diverting attention, provides relaxation, and can thus be used in the management of pain and anxiety (Ayed et al., 2019). It has been determined that virtual reality glasses are an effective method in the management of pain and anxiety in the field of nursing (Akıncı \& Aydın Özkan, 2024).
219228152|NCT07097987|DIETARY_SUPPLEMENT|WM formula Group|Participants in the intervention group will consume a single dose of WM formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
219228153|NCT07097987|OTHER|Control group|Participants in the control group will consume 50 mL water
219228154|NCT07098754|OTHER|Dry Needling|"will use dry needles of different recommended sizes to intercept the trigger points~will add on myofascial release technique manually."
219228155|NCT07098754|OTHER|Trigger point therapy|"will release trigger points by manual pressure using trigger point therapy technique protocols~will ad on stretching techniques"
219228156|NCT07098754|OTHER|Maitlands' Mobilizations|"Maitlands' Mobilizations Grade-1\& Grade-2 will be applied to upper thoracic and cervical regions~dry cupping therapy will be applied as ad on therapy"
219228157|NCT07098754|OTHER|Tens and ultrasound|TENS and ultrasound will be applied according to recommended dosages followed by stretching and Range of motion activities
219228158|NCT07100028|OTHER|SSC crown with Hall technique|SSC crown placement using Hall technique
219228159|NCT07100028|OTHER|SSC with conventional technique|SSC placement using conventional technique
219228160|NCT07099807|BEHAVIORAL|Carbohydrate Mouth Rinse|A 6.4% maltodextrin solution (64 g/L) was prepared using Nutricost Maltodextrin Powder. Participants performed five mouth rinses per trial, each using 25 mL of the solution for 10 seconds before expectorating. Each rinse was followed by a 30-second rest. Participants were instructed not to swallow the solution. Rinsing procedure was standardized across all sessions.
219228161|NCT07099807|BEHAVIORAL|Placebo Mouth Rinse|A placebo solution containing 0.05 g/L of non-caloric sucralose in distilled water was used to match sweetness and viscosity of the CHO-MR. Participants performed five rinses of 25 mL for 10 seconds each, spitting out the solution after each rinse. 30-second rest intervals followed each rinse. Swallowing was not allowed. Rinse frequency, volume, and duration were standardized.
219228162|NCT07099807|BEHAVIORAL|Music Listening|"Participants listened to high-tempo music (120 bpm) for 15 minutes before exercise using standardized earbuds. Music was selected from a public YouTube playlist titled 120 BPM Best Dance Music for Running and Working Out. Volume was calibrated at 65 dB (50% of max device volume). Auditory conditions were standardized across all participants."
219716131|NCT07142213|PROCEDURE|ALPPS|In recent years, Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) provides new hope for the solution of large/unresectable hepatobiliary malignancies. This technique promotes the rapid proliferation and regeneration of the remaining liver by separating the liver and ligation of the portal vein, so that the patients whose original liver function is not enough to tolerate large-scale liver resection can complete liver regeneration in a short time, so as to perform secondary resection. Compared with traditional two-stage hepatectomy, ALPPS significantly speeds up the rate of liver regeneration, shortens the waiting time for a second surgery, and provides a safer radical treatment for tumors in high-risk patients.
219716132|NCT07141420|BEHAVIORAL|Routine Care|Participants receive standard post-ICU follow-up care according to hospital protocols . This includes routine health assessments and general rehabilitation guidance at designated intervals (discharge, 1/3/6 months post-discharge). No structured PICS management program or AI technology is provided.
219228163|NCT07098078|DRUG|Domperidone (drug)|The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.
219228164|NCT07099261|OTHER|Crowns|"1. Tooth Preparation: Prepare the teeth to receive a zirconia crown.~2. Impression Taking: Obtain impressions using silicone.~3. Digital Conversion: Convert impressions into a digital model using a laboratory scanner.~4. Design Submission: Send the digital model to selected crown design program.~5. Crown Fabrication: crowns designed will be produced from PMMA using a milling unit.~6. Clinical Evaluation: Conduct a clinical assessment of the crowns~7. the best crown design will be milled from zirconia and delivered~Evaluation of Crowns designed by following metrics:~1. Marginal fit~2. proximal contact~3. Occlusion"
219360660|NCT00326365|DRUG|Kali bichromicum 10-60 (C30)|
219360661|NCT04345445|DRUG|Tocilizumab|IV infusion
219360662|NCT04345445|DRUG|Methylprednisolone|IV infusion
219135875|NCT01134575|DRUG|CMC-544 (Inotuzumab Ozogamycin)|"First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
219135876|NCT01134575|DRUG|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
219135877|NCT01970943|OTHER|Placebo|Placebo will be compared to No Intervention.
219135878|NCT05415930|OTHER|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
219135879|NCT05415930|OTHER|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
219135880|NCT05415930|OTHER|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
219135881|NCT05415930|OTHER|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
219551156|NCT02421627|DEVICE|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
219135882|NCT03078920|DEVICE|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
219135883|NCT05760690|PROCEDURE|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
219135884|NCT05760690|PROCEDURE|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
219135885|NCT05760690|PROCEDURE|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
219135886|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
219135887|NCT06378372|BEHAVIORAL|Music therapy based on piano learning|The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
219135888|NCT01948960|DRUG|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
219135889|NCT04440943|DRUG|CDX-527|CDX-527 is administered by infusion every 2 weeks
219716133|NCT07141420|BEHAVIORAL|Health Promotion Model-Based Optimized Program|"An evidence-based, multidisciplinary rehabilitation protocol for Post-Intensive Care Syndrome (PICS) management, developed using the Health Promotion Model (HPM). It includes:~Personalized rehabilitation plans addressing physical, cognitive, and psychological recovery.~Structured follow-up at discharge, 1/3/6 months post-discharge. Components: Physical function training, cognitive exercises, anxiety/depression coping strategies, and sleep hygiene education.~Delivery: Clinician-guided (no AI/technology involved). Developed via literature review and validated by ICU physicians and nursing experts ."
219716134|NCT07141420|BEHAVIORAL|LLM-Enhanced Optimized Program|"Combines the HPM-Based Optimized Program with Large Language Model (LLM) technology for dynamic personalization:~AI-generated rehabilitation plans: ChatGPT-4 synthesizes patient data (baseline + follow-ups) to create/update monthly plans, reviewed by a multidisciplinary expert team.~Patient-facing LLM tool: Kimi Smart Assistant installed for daily health queries under strict safety protocols (all outputs validated by nurses via WeChat).~Phased implementation:~Pre-discharge: LLM training + baseline plan generation. 1/3/6 months: Plan updates + outcome tracking. 3/6 months: Semi-structured interviews on LLM experience. Includes LLM usage guidelines and expert validation safeguards ."
219135890|NCT01249040|PROCEDURE|Physical therapy|
219716135|NCT07141524|OTHER|Physiology measurements|Measurement of lung perfusion (via EIT) and transpulmonary pressure (via esophageal manometry) during decremental PEEP trial
219716136|NCT07141290|DEVICE|Silent fish and bunny game|Participants play two levels of a computer game. In one level they need to squat at different levels to make a bunny jump and catch some carrots. In the other level they need to catch fiches by adjusting the extension of their leg.
219716137|NCT07141290|DEVICE|Sound supported fish and bunny game|In the auditory feedback group sound is used to transfer the Knowledge of Results. The sound is linked to the joint position.
219716138|NCT07142096|DIETARY_SUPPLEMENT|MitoQ (mitoquinol mesylate)|Dietary supplement course before surgery or chemo/radio-therapy
219716139|NCT07142226|GENETIC|Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS))|Peripheral blood will be collected from patients with advanced biliary tract cancer for circulating tumor DNA (ctDNA) testing. Next-generation sequencing (NGS) will be performed to detect clinically relevant genomic alterations, including IDH1 mutations, FGFR2 fusions, ERBB2 amplifications, and MSI-H/dMMR. The ctDNA results will be compared with tissue-based genomic profiling to evaluate concordance and clinical utility.
219716140|NCT07142070|OTHER|Saliva, serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, serum were then stored at -80 °C until analysis.
219716141|NCT07142070|DRUG|oral isotretinoin|oral isotretinoin
219135891|NCT01249040|PROCEDURE|steroid intraarticular injection|
219135892|NCT02377531|OTHER|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
219716142|NCT07141394|DRUG|Medication for Addiction Treatment (MAT)|MAT includes medications for alcohol use disorder (MAUD) and medications for opioid use disorder (MAUD). It reduces substance use, increases SUD treatment engagement, enhances quality of life, and reduces overdoses.
219716143|NCT07141394|BEHAVIORAL|Cognitive Behavioral Therapy for Substance Use Disorders (CBT-SUD)|An evidence-based psychotherapy that uses cognitive behavioral therapy to further recovery goals across SUD diagnoses.
219716144|NCT07140887|OTHER|Bone Ring|"Patients in this group will be treated with the bone ring technique. An implant drill will be used next to prepare central osteotomies corresponding to the final implant diameter to be placed in the center of the disc converting it to a bone ring."
219135893|NCT02377531|OTHER|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
219135894|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
219135895|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
219135896|NCT01271270|DRUG|Palomid 529|
219135897|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
219135898|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
219135899|NCT05711498|OTHER|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
219135900|NCT03092440|OTHER|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
219135901|NCT02274402|BIOLOGICAL|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
219135902|NCT03569683|PROCEDURE|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
219135903|NCT03569683|DEVICE|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
219716145|NCT07140887|OTHER|Split Bone block|Patients of this group will be treated with split bone block with simultaneous implant technique. The bone shell will be split into two bone shells each 1 \~ 2 mm in thickness using a disc.
219716146|NCT04903795|DRUG|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
219716147|NCT04523961|DRUG|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
219716148|NCT04523961|DRUG|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
219716149|NCT06187077|BEHAVIORAL|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
219135904|NCT03569683|OTHER|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
219135905|NCT03569683|OTHER|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
219135906|NCT02588482|DEVICE|high-density electroencephalography|Auditory stimulations during electroencephalography recording
219135907|NCT02588482|DEVICE|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
219135908|NCT05403307|BIOLOGICAL|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
219135909|NCT05403307|BIOLOGICAL|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
219551157|NCT02421627|DEVICE|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
219135910|NCT00459264|DRUG|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
219135911|NCT00459264|DRUG|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
219135912|NCT05653089|PROCEDURE|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~* Choice and adjustments of the wheelchair~* Choice and adjustments of the wheelchair/patient interface"
219551158|NCT04656938|BEHAVIORAL|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
219551159|NCT05695417|DRUG|OTX-TKI|Injection of OTX-TKI
219551160|NCT05695417|DRUG|Sham|Sham Injection of OTX-TKI
219551161|NCT05814068|DRUG|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
219551162|NCT03316222|DRUG|GNS561|Escalating doses to be administered 3 times a week.
219551163|NCT04573309|DRUG|ALXN1840|Administered orally as tablets.
219551164|NCT05269563|OTHER|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
219551165|NCT00260793|DRUG|Ropinirole Hydrochloride|
219551166|NCT00070239|DRUG|alvocidib|Given IV
219551167|NCT00070239|OTHER|pharmacological study|Correlative studies
219551168|NCT00070239|RADIATION|fludeoxyglucose F 18|Correlative studies
219551169|NCT00070239|OTHER|fluorine F 18 fluorothymidine|Correlative studies
219551170|NCT00070239|PROCEDURE|positron emission tomography|Correlative studies
219551171|NCT04815460|BEHAVIORAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
219551172|NCT04815460|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
219551173|NCT02172469|DRUG|Tiotropium inhalation powder capsule|
219551174|NCT02172469|DRUG|Placebo Metered Dose Inhaler|
219551175|NCT02172469|DRUG|Ipratropium Bromide Metered Dose Inhaler|
219551176|NCT02172469|DRUG|Placebo inhalation powder capsule|
219551177|NCT02071368|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
219551178|NCT02071368|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
219551179|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
219551180|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
219551181|NCT02980172|OTHER|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
219551182|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
219228165|NCT07094542|DRUG|Temporo-masseteric Nerve Block Injection|The TMNB injection/placebo will be administered by the Principal Investigator. The injection will only be delivered on Day 2 on the side/s of significant jaw muscle pain. Following disinfection of skin overlying the suprazygomatic injection site, a single carpule of 1.8 ml 2% lidocaine with 1:100,000 epinephrine will be delivered using a 25- or 27- gauge 30 mm needle). The injection site will be approximately a centimeter above the zygomatic arch, and a centimeter behind the palpable posterior border of the frontal process of the zygomatic bone. The needle will be directed at a 45-degree downward angle, directed medially along the coronal plane. At the depth of insertion of the needle, the local anesthetic/placebo will be delivered.
219135913|NCT04223362|OTHER|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
219228166|NCT07094542|DRUG|Oral Pain Medications only|For participants with jaw muscle pain to palpation \<5 NRS score, no additional injection will be given. The participant will take the recommended pain medications as described.
219228167|NCT07099924|DRUG|Ropivacaine 0.2%|2x30ml (bilateral) ropivacaine 0.2% every 8 hours via rectus sheath catheter
219135914|NCT04223362|OTHER|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
219135915|NCT01766167|DRUG|MP-424|Low
219135916|NCT01766167|DRUG|MP-424|Middle
219135917|NCT01766167|DRUG|MP-424|High
219135918|NCT01766167|DRUG|MP-424|Multiple
219135919|NCT02828605|DEVICE|Virtual Interactive Platform (VIP) Transplant|
219135920|NCT03035656|DRUG|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
219135921|NCT03035656|OTHER|Saline|Administration of saline via epidural injection intra-operatively
219135922|NCT03047590|BEHAVIORAL|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
219135923|NCT03047590|BEHAVIORAL|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
219135924|NCT03047590|BEHAVIORAL|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
219135925|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
219135926|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
219135927|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
219135928|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
219135929|NCT02325050|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline.
219135930|NCT02780947|PROCEDURE|Ventricular tachycardia substrate ablation|"Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
219135931|NCT02951117|DRUG|Venetoclax|Tablet
219135932|NCT02951117|DRUG|ABBV-838|Intravenous infusion
219135933|NCT02951117|DRUG|Dexamethasone|Tablet or intravenous infusion
219135934|NCT03368378|PROCEDURE|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
219135935|NCT04975243|DEVICE|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
219228168|NCT07099924|DRUG|Saline 0.9%|2x30ml saline 0.9% every 8 hours via rectus sheath catheter
219551183|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
219551184|NCT01894230|GENETIC|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele
219551185|NCT02178124|DRUG|Donepezil|
219551186|NCT02178124|DRUG|placebo|
219551187|NCT04646824|DRUG|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
219551188|NCT05659238|BEHAVIORAL|the effect on language development & attention|Tv \& other electronic devices effects onn children's language development \& attention
219551189|NCT00225849|DRUG|Aspirin|
219551190|NCT01109849|BEHAVIORAL|behavior therapy|combination of individual and group parent training plus school consultation
219551191|NCT01109849|DRUG|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
219551192|NCT01109849|OTHER|monitoring|monthly weight, height and BMI checks
219551193|NCT01109849|OTHER|drug holiday|switch from seven day a week dosing to medication only on school days
219135936|NCT02005666|DRUG|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
219135937|NCT02005666|DRUG|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
219135938|NCT02005666|DRUG|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
219135939|NCT03163862|PROCEDURE|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
219135940|NCT03163862|DRUG|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
219135941|NCT03163862|DRUG|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
219135942|NCT00831792|DRUG|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
219135943|NCT05097573|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
219135944|NCT03208101|BIOLOGICAL|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
219135945|NCT03208101|BIOLOGICAL|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
219135946|NCT01909232|DEVICE|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
219135947|NCT01909232|DEVICE|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
219135948|NCT01142713|RADIATION|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
219135949|NCT03370055|DEVICE|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
219135950|NCT03370055|OTHER|Control,|Usual wound care in a specialized clinic
219228169|NCT07098533|BEHAVIORAL|Cognicise Training|The Cognicise program included 16 sessions over 8 weeks (twice weekly, 60 minutes each). This dual-task training combined motor activities with cognitive exercises. During basic gymnastic movements, participants responded to real-time changes in live music and visual stimuli while also solving simple verbal and math tasks. Sessions were divided into 15 minutes of warm-up, 30 minutes of dual-task activity, and 15 minutes of breathing and relaxation exercises.
219228170|NCT07098533|BEHAVIORAL|Yoga Training|The yoga intervention consisted of 16 instructor-led sessions over 8 weeks (twice weekly, 60 minutes each). Each session included a warm-up (15 minutes), a main phase (30 minutes) focused on exercises targeting the spine, pelvis, and hips, and a relaxation period (15 minutes), including 10 minutes of deep relaxation techniques.
219228171|NCT07098936|DRUG|Momelotinib treatment|Patients included will receive momelotinib continuously until disease progression or loss of response, at physician's discretion.
219228172|NCT07098871|DIAGNOSTIC_TEST|Ultrasonography (Rectus and diaphragma muscle thickness measurement)|Rectus and diaphragma muscle thickness will be measured by ultrasonography preoperatively.
219228173|NCT07098520|OTHER|No intervention, just observation|no intervention, study investigates biomarkers associated with a disease
219228174|NCT07099833|OTHER|Azita Sadeghzade|Azita Sadeghzade
219716150|NCT06187077|BEHAVIORAL|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
219716151|NCT06219005|BEHAVIORAL|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
219716152|NCT03772873|PROCEDURE|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
219716153|NCT05853068|DEVICE|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
219716154|NCT04706338|DEVICE|TMS treatment|Using TMS to stimulate (5 Hz, 90%\~110% resting motor threshold) patients' primary motor area and SMA.
219716155|NCT00000142|DRUG|Cidofovir|"Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
219716156|NCT02199587|BEHAVIORAL|Presence of medical clown during endocrine test|
219716157|NCT02805491|OTHER|meconium|to evaluate internal exposure to pesticide
219716158|NCT02805491|OTHER|self questionnaires to parents|to evaluate external exposure to pesticide
219716159|NCT05319470|DIAGNOSTIC_TEST|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
219716160|NCT05319470|DIAGNOSTIC_TEST|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
219228175|NCT07099547|DRUG|ZG005|ZG005 20 mg/kg IV Q3W
219716161|NCT05319470|DIAGNOSTIC_TEST|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
219716162|NCT05319470|DIAGNOSTIC_TEST|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
219135951|NCT05465811|OTHER|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
219135952|NCT01003015|DRUG|BAY73-4506|160 mg BAY73-4506
219135953|NCT00065390|DRUG|Pyrimethamine|
219135954|NCT02410291|OTHER|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
219135955|NCT02637271|OTHER|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
219135956|NCT02637271|OTHER|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
219135957|NCT04181632|DEVICE|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
219135958|NCT04181632|DEVICE|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
219135959|NCT04181632|DEVICE|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
219135960|NCT01638624|DRUG|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
219135961|NCT01638624|DRUG|Placebo|
219135962|NCT02469064|OTHER|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
219135963|NCT02469064|OTHER|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
219135964|NCT02155829|DRUG|Riluzole|
219135965|NCT02155829|DRUG|Placebo (for Riluzole)|
219228176|NCT07099547|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
219228177|NCT07099547|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 Q3W. Gemcitabine will be administered on D1/D8 in every three weeks cycle.
219228178|NCT07099547|DRUG|Cisplatin|Cisplatin 25mg/m\^2 Q3W. Cisplatin will be administered on D1/D8 in every three weeks cycle.
219716163|NCT05319470|DIAGNOSTIC_TEST|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
219716164|NCT03119311|DIAGNOSTIC_TEST|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
219716165|NCT03119311|DIAGNOSTIC_TEST|APCT|alternative prism cover test
219716166|NCT03260400|DEVICE|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
219716167|NCT00077194|DRUG|romidepsin|
219716168|NCT02653820|OTHER|Reflexology|
219716169|NCT01732783|OTHER|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
219716170|NCT05954871|DRUG|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
219716171|NCT05954871|DRUG|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
219716172|NCT05954871|DRUG|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
219135966|NCT00866762|DRUG|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
219135967|NCT01407900|DRUG|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
219135968|NCT01407900|DRUG|5% Dextrose in Water|four hour infusion IV
219135969|NCT04272073|OTHER|High-Protein Mediterranean Diet|As in arm/group descriptions
219135970|NCT04272073|OTHER|Resistance Exercise|As in arm/group descriptions
219135971|NCT04272073|OTHER|Standard Dietary Advice|As in arm/group descriptions
219135972|NCT04272073|OTHER|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
219135973|NCT05971355|DEVICE|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
219135974|NCT05971355|OTHER|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
219716173|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
219716174|NCT06567691|PROCEDURE|EUS Gastrojejunostomy|Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
219716175|NCT06567691|PROCEDURE|Surgical Gastrojejunostomy|Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
219716176|NCT06567691|OTHER|Gastric Outlet Obstruction Scoring System (GOOSS)|A previously validated instrument for assessing tolerance of oral intake.
219135975|NCT05971355|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
219135976|NCT02303444|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
219135977|NCT02303444|DRUG|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
219135978|NCT04656236|BIOLOGICAL|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
219135979|NCT01549496|DRUG|Amlodipine|amlodipine 2.5 mg QD
219135980|NCT01549496|DRUG|Diltiazem|diltiazem 120 mg qd
219135981|NCT00678795|DRUG|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
219135982|NCT00678795|DRUG|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
219135983|NCT02392156|BIOLOGICAL|rFVIIIFc|As described in the treatment arm
219135984|NCT02392156|BIOLOGICAL|rFIXFc|As described in the treatment arm
219135985|NCT02392156|DRUG|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
219135986|NCT02392156|DRUG|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
219135987|NCT02870270|OTHER|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
219716177|NCT06310239|OTHER|Collection of biologic samples and data|"* collection of skin flora samples via swabs~* data collection regarding subject's medications See Detailed Description in Study Description section above for more details"
219716178|NCT05419518|BIOLOGICAL|EXTERNAL BEAM RADIATION|A minimum of three daily radiation therapy treatments are required in any given week. Any missed radiation treatments will be made up at the end of the treatment schedule, such that the total number of delivered 5 Gy fractions remains ten.
219716179|NCT01808742|DEVICE|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
219716180|NCT03890432|DEVICE|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
219135988|NCT03960983|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
219135989|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
219135990|NCT03960983|RADIATION|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
219135991|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
219135992|NCT02750709|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
219716181|NCT03890432|DEVICE|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
219716182|NCT03890432|DEVICE|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
219135993|NCT02750709|DRUG|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
219716183|NCT06547255|DRUG|Bupivacaine liposome injectable suspension|At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
219135994|NCT02750709|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
219135995|NCT00966966|DRUG|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
219716184|NCT04115098|DRUG|Celecoxib|Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
219716185|NCT04115098|DRUG|Naproxen|Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
219716186|NCT04115098|DRUG|Meloxicam|Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
219135996|NCT05095675|BEHAVIORAL|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
219135997|NCT04238234|DEVICE|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
219228179|NCT07099287|BEHAVIORAL|TRANSform your health|A culturally adapted smoking cessation intervention for transgender and gender diverse individuals living in Argentina
219551194|NCT01109849|DIETARY_SUPPLEMENT|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
219551195|NCT04042649|BEHAVIORAL|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
219551196|NCT01096602|BIOLOGICAL|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
219551197|NCT00137202|DRUG|Ondansetron (Zofran)|
219551198|NCT00137202|DRUG|Diphenhydramine (Benadryl)|
219551199|NCT02583308|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
219551200|NCT02583308|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
219551201|NCT02300987|DRUG|LEE011|
219551202|NCT02300987|DRUG|LEE011 Placebo|
219551203|NCT02488109|OTHER|Higher Calorie Refeeding|
219551204|NCT02488109|OTHER|Lower Calorie Refeeding|
219551205|NCT00110851|DRUG|rosiglitazone|
219551206|NCT00110851|DRUG|metformin|
219551207|NCT00110851|DRUG|PN2034|
219551208|NCT00785876|OTHER|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
219551209|NCT01954901|DEVICE|Hyperbaric oxygen therapy|
219551210|NCT01954901|DEVICE|Hyperbaric room air|
219551211|NCT05080140|DRUG|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
219551212|NCT05141786|DRUG|MRG002|Administrated intravenously
219551213|NCT03969641|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
219551214|NCT03969641|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
219551215|NCT02754128|BEHAVIORAL|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
219716187|NCT06236932|DIETARY_SUPPLEMENT|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
219716188|NCT06236932|DIETARY_SUPPLEMENT|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
219135998|NCT04238234|DEVICE|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100"
219135999|NCT02864238|OTHER|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
219136000|NCT05159141|BEHAVIORAL|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
219551216|NCT02754128|BEHAVIORAL|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
219551217|NCT02206009|DEVICE|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
219551218|NCT01541215|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
219551219|NCT01541215|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
219551220|NCT01541215|DRUG|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
219551221|NCT05314062|DIETARY_SUPPLEMENT|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
219551222|NCT05314062|DIETARY_SUPPLEMENT|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
219551223|NCT00693589|DRUG|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
219551224|NCT01104948|DRUG|DA-8031|
219551225|NCT01104948|DRUG|Placebo|
219551226|NCT02735330|PROCEDURE|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
219551227|NCT02735330|PROCEDURE|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
219551228|NCT02735330|PROCEDURE|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
219551229|NCT03008538|OTHER|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
219551230|NCT03008538|OTHER|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
219228180|NCT07099573|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the bursa.
219228181|NCT07099573|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
219716189|NCT05273190|DEVICE|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
219716190|NCT06172907|BEHAVIORAL|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
219716191|NCT05725421|PROCEDURE|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
219716192|NCT05725421|PROCEDURE|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
219716193|NCT05725421|PROCEDURE|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
219136001|NCT05333887|BEHAVIORAL|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
219136002|NCT01693965|OTHER|sputum samples|
219136003|NCT01317134|DEVICE|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
219136004|NCT01317134|BIOLOGICAL|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
219136005|NCT00404079|DRUG|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
219136006|NCT00404079|DRUG|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
219228182|NCT07099573|OTHER|Stretching|Stretching of the involved muscles will involve 3 periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
219716194|NCT06408857|DRUG|MAM01 300 mg SC|MAM01 300 mg will be administered SC
219716195|NCT06408857|DRUG|MAM01 300 mg IM|MAM01 300 mg will be administered IM route
219716196|NCT06408857|DRUG|MAM01 2000 mg IV|MAM01 2000 mg will be administered IV
219716197|NCT06408857|DRUG|MAM01 190 mg SC|MAM01 190 mg will be administered SC
219136007|NCT03034252|PROCEDURE|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
219136008|NCT01120275|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
219716198|NCT06408857|DRUG|MAM01 225 mg SC|MAM01 225 mg will be administered SC
219716199|NCT06408857|DRUG|MAM01 150 mg SC|MAM01 150 mg will be administered SC
219716200|NCT06408857|DRUG|MAM01 150 mg IM|MAM01 150 mg will be administered IM
219716201|NCT06408857|DRUG|MAM01 150 mg IV|MAM01 150 mg will be administered IV
219716202|NCT06408857|DRUG|Placebo SC|Placebo will be administered SC
219136009|NCT01120275|OTHER|laboratory biomarker analysis|Correlative studies
219136010|NCT03425890|BEHAVIORAL|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
219136011|NCT05771090|DEVICE|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
219228183|NCT07098104|DRUG|Immunotherapy|The nICT group received PD-1 inhibitors (sintilimab 200mg, tislelizumab 200mg, or nivolumab 240mg, all iv q3w) combined with two-drug chemotherapy (SOX: oxaliplatin 130mg/m² d1 + S-1 40-60mg bid d1-14; or XELOX: oxaliplatin 130mg/m² d1 + capecitabine 1000mg/m² bid d1-14, both q3w). The nCT group included two subgroups: nCT2 (SOX/XELOX) and nCT3 (FLOT: docetaxel 50mg/m² + oxaliplatin 85mg/m² + leucovorin 200mg/m² d1 + fluorouracil 2600mg/m² 48h CIV q2w; or DCF: docetaxel 75mg/m² + cisplatin 75mg/m² d1 + fluorouracil 750mg/m² d1-5 q3w).
219228184|NCT07098507|PROCEDURE|sentinel lymph node biopsy|As sentinel lymph node biopsy is still a standard of care in early-stage breast cancer surgery, it represents the intervention in the standard of care arm
219228185|NCT07098507|PROCEDURE|omission of sentinel lymph node biopsy|omission of sentinel lymph node biopsy is the intervention in the experimental arm
219716203|NCT06408857|DRUG|Placebo IV|Placebo will be administered IV.
219716204|NCT06408857|DRUG|Placebo IM|Placebo will be administered IM
219136012|NCT03736005|OTHER|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
219716205|NCT02379416|DRUG|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
219716206|NCT04941300|OTHER|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
219716207|NCT04941300|OTHER|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)"
219136013|NCT04103736|DIETARY_SUPPLEMENT|Beet It Sport Shot|Source of naturally occurring dietary nitrates
219136014|NCT04103736|DIETARY_SUPPLEMENT|Nitrate-depleted placebo|Placebo
219136015|NCT02181348|DRUG|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
219136016|NCT02181348|DRUG|placebo (edible oil)|
219136017|NCT03445130|OTHER|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
219136018|NCT03445130|OTHER|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
219136019|NCT03445130|OTHER|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
219136020|NCT03445130|OTHER|Water|two drops on the inside of an oxygen face mask for 15 minutes.
219136021|NCT01208467|OTHER|Laboratory Biomarker Analysis|Correlative studies
219136022|NCT00290732|DRUG|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
219136023|NCT00290732|DRUG|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
219136024|NCT04408287|OTHER|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
219716208|NCT05619614|DEVICE|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
219716209|NCT05438199|DEVICE|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
219716210|NCT06978088|DRUG|LP-168|Patients will receive LP-168 200 mg daily beginning day 1 of therapy for 12 cycles.
219716211|NCT06978088|DRUG|Obinutuzumab|Patients will with LP-168 and then receive obinutuzumab for a total of 6 cycles, beginning cycle 7, days 1, 2, 8 and 15, and then day 1 of cycles 8-12. A minimum of 12 cycles of therapy will be administered.
219716212|NCT07124702|BEHAVIORAL|Simultaneous cessation intervention|This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
219716213|NCT07124702|BEHAVIORAL|Stepwise cessation intervention|This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
219136025|NCT02887313|DRUG|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
219136026|NCT02887313|RADIATION|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
219136027|NCT02306343|DEVICE|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
219136028|NCT01087177|OTHER|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
219136029|NCT02595398|DRUG|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
219136030|NCT02595398|DRUG|Sham Procedure|Sham procedure administered at 2 timepoints
219136031|NCT02909699|OTHER|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
219136032|NCT04509713|BEHAVIORAL|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
219716214|NCT07124702|BEHAVIORAL|Behavior counseling only|Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.
219716215|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
219716216|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
219716217|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
219716218|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219716219|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219716220|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219716221|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219716222|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219716223|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
219136033|NCT04175886|DRUG|Tofacitinib|Patients will be treated with tofacitinib
219136034|NCT00542386|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
219136035|NCT00542386|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
219136036|NCT01573858|OTHER|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
219228186|NCT06831695|PROCEDURE|Craniotomy|Intervention: Bone flap replaced after dural closure Additional Information: This procedure involves creating a single free bone flap using high-speed drills. The bone is repositioned and secured using mini plates or sutures after the surgical intervention is completed. Post-operative monitoring will include assessment for CSF leakage, wound healing, and neurological recovery.
219716224|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
219716225|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
219136037|NCT01573858|OTHER|Acupuncture treatment 2|Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
219228187|NCT06831695|PROCEDURE|Craniectomy|Intervention: Bone permanently removed Additional Information: In this approach, the bone is removed in pieces using rongeurs, leaving an open dural surface without replacement of the bone. The dura is closed with sutures, and dural augmentation may be performed as needed. Post-operative assessment will focus on complications such as pseudomeningocele, CSF leakage, and extended hospital stays.
219228188|NCT06830161|DIAGNOSTIC_TEST|Gingival Thermal Images|The degree of inflammation was evaluated using the Gingival Index
219716226|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
219716227|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
219716228|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
219716229|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
219716230|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
219716231|NCT06258447|DEVICE|Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system|the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
219716232|NCT05584059|BEHAVIORAL|Focused Acceptance and Commitment Therapy|This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
219716233|NCT06979583|DEVICE|4.8 Fr Ureteral stents|After surgery, patients will have the Boston Scientific 4.8 Fr ureteral stent placed.
219716234|NCT06979583|DEVICE|7 Fr Ureteral stents|After surgery, patients will have the Bard 7 Fr ureteral stent placed.
219716235|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
219716236|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
219716237|NCT06210919|BIOLOGICAL|TRTP-101|Intradermal injection of the each of four sites
219716238|NCT06557356|DRUG|LY3532226|Administered SC
219136038|NCT01573858|OTHER|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
219136039|NCT01573858|OTHER|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
219136040|NCT04564391|DIETARY_SUPPLEMENT|protein supplement|protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
219136041|NCT04564391|DIETARY_SUPPLEMENT|placebo supplement|Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
219136042|NCT00197015|BIOLOGICAL|Havrix®|2 doses administered intramuscularly
219136043|NCT00197015|BIOLOGICAL|M-M-R®II|1 dose administered subcutaneously
219136044|NCT00197015|BIOLOGICAL|VARIVAX®|1 dose administered subcutaneously
219136045|NCT00614406|DRUG|Celebrex|One 400mg tablet daily.
219136046|NCT00614406|DRUG|Placebo|One tablet daily.
219136047|NCT00003435|BIOLOGICAL|anti-thymocyte globulin|
219136048|NCT00003435|DRUG|melphalan|
219136049|NCT00003435|PROCEDURE|antiviral therapy|
219136050|NCT00003435|PROCEDURE|bone marrow ablation with stem cell support|
219136051|NCT00003435|PROCEDURE|peripheral blood stem cell transplantation|
219716239|NCT06557356|DRUG|Placebo|Administered SC
219716240|NCT04396808|DEVICE|Decipher|The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
219716241|NCT04396808|DEVICE|Prolaris|The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
219716242|NCT04396808|DEVICE|Oncotype Dx Genomic Prostate Score (GPS)|The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
219716243|NCT04396808|OTHER|Standard of care (askMUSIC score)|AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
219716244|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
219716245|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
219136052|NCT00003435|PROCEDURE|umbilical cord blood transplantation|
219136053|NCT00003435|RADIATION|radiation therapy|
219136054|NCT01191463|OTHER|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
219136055|NCT01191463|OTHER|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
219136056|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
219136057|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
219136058|NCT03525041|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
219136059|NCT03525041|PROCEDURE|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
219136060|NCT00880906|PROCEDURE|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
219136061|NCT00880906|DRUG|Steroid and Proton Pump Inhibitor Therapy|
219716246|NCT06649032|OTHER|No intervention|no difference: both cohorts are followed in the same way
219136062|NCT03097237|OTHER|Wholegrain rye|Cereal products based on wholegrain rye
219716247|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
219716248|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
219716249|NCT06595290|OTHER|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
219716250|NCT06595290|OTHER|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist\&#39;s instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
219136063|NCT03097237|OTHER|Refined wheat|Cereal products based on refined wheat
219136064|NCT00221078|DEVICE|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
219136065|NCT03985917|OTHER|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
219136066|NCT03985917|OTHER|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
219136067|NCT02622230|DRUG|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
219136068|NCT02622230|DRUG|Placebo|Placebo to match with experimental groups
219136069|NCT04163224|DEVICE|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
219136070|NCT04806113|BIOLOGICAL|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
219136071|NCT04998799|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
219716251|NCT06590857|DRUG|RYZ101|Ac-225
219716252|NCT06587061|DRUG|HRS-4642+AG|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.
219716253|NCT06997094|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219716254|NCT06997094|DRUG|Chemotherapy|Given concurrent chemotherapy
219716255|NCT06997094|DRUG|Decitabine|Given IV
219716256|NCT06997094|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219716257|NCT06997094|OTHER|Questionnaire Administration|Ancillary studies
219716258|NCT06997094|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
219716259|NCT05330442|BEHAVIORAL|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
219716260|NCT04972760|DRUG|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
219716261|NCT04972760|DRUG|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
219716262|NCT06864689|BEHAVIORAL|Video-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers|This intervention is a video-log (vlog) series based health communication intervention that will be disseminated through community health centers (CHCs) and social media to increase willingness for and use of PrEP among cisgender Black women and to increase willingness to prescribe and refer PrEP among healthcare providers.
219716263|NCT06611813|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
219716264|NCT06611813|DRUG|HR+ HER2 breast cancer|During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
219716265|NCT06675864|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
219716266|NCT06857435|PROCEDURE|Full Thickness Skin Graft (FTSG)|Full thickness skin in FTSGs are harvested by different means by surgeon preference and standard of care. Typically an area of skin with matching color and texture to the site which needs reconstruction is identified from a hidden and/or non-cosmetic area and collected via excision. After excision the donor site is closed and the graft is thinned by using a scalpel or scissors to remove excess fat or other soft tissues from the deep surface before being placed in the donor site.
219136072|NCT03269019|DIAGNOSTIC_TEST|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
219136073|NCT01534910|DRUG|aged garlic extract|2400 mg a day
219136074|NCT01534910|DRUG|placebo|placebo
219136075|NCT00564967|BEHAVIORAL|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
219136076|NCT00564967|BEHAVIORAL|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
219136077|NCT00432029|PROCEDURE|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
219136078|NCT00432029|DEVICE|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
219136079|NCT03581968|DEVICE|Artificial Pancreas|"The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
219136080|NCT02047851|OTHER|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
219136081|NCT05527236|OTHER|Breathing Exercise|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
219136082|NCT05527236|OTHER|Virtual Reality|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
219136083|NCT01080599|PROCEDURE|obturator nerve block|
219716267|NCT06857435|PROCEDURE|Base of wound fat graft with Split Thickness Skin Graft (STSG) Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
219716268|NCT06861543|BIOLOGICAL|TMT101 Injection|Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. The initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. TMT101 will be injected intramuscularly, Once a week,a total of 9 times
219136084|NCT03045900|OTHER|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
219136085|NCT03203356|DRUG|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
219136086|NCT03469154|OTHER|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
219136087|NCT03469154|OTHER|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
219136088|NCT02883088|PROCEDURE|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
219136089|NCT05337657|DRUG|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
219136090|NCT00559949|OTHER|Laboratory Biomarker Analysis|Correlative studies
219136091|NCT00559949|DRUG|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
219136092|NCT00132717|DRUG|MK0653A (ezetimibe [+] simvastatin)|
219136093|NCT00132717|DRUG|Comparator: atorvastatin|
219136094|NCT00132717|DRUG|Comparator: fluvastatin|
219136095|NCT00132717|DRUG|Comparator: lovastatin|
219136096|NCT00132717|DRUG|Comparator: pravastatin|
219136097|NCT00132717|DRUG|Comparator: rosuvastatin|
219136098|NCT00132717|DRUG|Comparator: simvastatin|
219136099|NCT01830010|DRUG|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
219716269|NCT06042283|BEHAVIORAL|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
219716270|NCT06860321|DEVICE|Adjunct antibacterial home-use dual-light medical device|Crossover active intervention.
219716271|NCT06860321|OTHER|Regular oral self care|Crossover regular intervention.
219716272|NCT07000006|BEHAVIORAL|Home-based Core Stability Exercise|The online exercise program aims to improve trunk stability and reduce low back pain. A clinical exercise physiologist will deliver real-time exercise sessions, with each session lasting 40-45 minutes, three days a week for 12 weeks. Participants will join private group sessions using a free video platform.
219716273|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Placebo Control|Participants will use their Relaxation Placebo Control as directed for a period of 6 weeks.
219716274|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 1|Participants will use their Relaxation Active Product 1 as directed for a period of 6 weeks.
219716275|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 2|Participants will use their Relaxation Active Product 2 as directed for a period of 6 weeks.
219716276|NCT07002125|OTHER|Whole Body Vibration|Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)
219716277|NCT07002125|OTHER|Aerobic Exercise|From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.
219716278|NCT07002112|BIOLOGICAL|LVIVO-TaVec100 product|Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.
219136100|NCT01830010|DRUG|Study Part 2: KRP203 lower dose|
219136101|NCT01830010|DRUG|Study Part 2: KRP203 higher dose|
219716279|NCT07001241|BEHAVIORAL|Telehealth Exercise Program|BfitBwell-TP is a 12-week telehealth exercise intervention. Exercise prescriptions are created, personalized, and delivered by Cancer Exercise Specialists. Exercise content is delivered using a combination of videoconference sessions and a commercial personal training application (accessible via smartphone or internet browser). Patient-reported symptoms (specifically cancer-related fatigue) are assessed every two weeks via emailed surveys. Survey scores are compared to a reference chart of predicted improvements during the program, developed from an established clinical exercise oncology program. Additional videoconference sessions are initiated for participants demonstrating lower than expected symptom improvement, with the goal of adapting the current exercise prescription to improve symptom response.
219716280|NCT04193891|OTHER|Modified Atkins Diet|The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
219716281|NCT03194893|DRUG|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
219716282|NCT03194893|DRUG|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
219716283|NCT07011849|DRUG|Pembrolizumab|Given by IV
219716284|NCT07011849|DRUG|Lenvatinib|Given by mouth
219716285|NCT07018570|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered via intravenous infusion over 30 minutes, twice at 21-day intervals.
219136102|NCT00414648|DRUG|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
219136103|NCT00414648|DRUG|Placebo|A placebo dose of 2 tablets per day for 1 year.
219136104|NCT04366882|PROCEDURE|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
219136105|NCT02428088|DRUG|Dasotraline|Dasotraline 2 mg once daily
219136106|NCT02428088|DRUG|Dasotraline|Dasotraline 4 mg once daily
219136107|NCT02428088|DRUG|Placebo Comparator|Placebo once daily
219136108|NCT01105143|BEHAVIORAL|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
219136109|NCT01105143|BEHAVIORAL|placebo|no intervention, only follow up
219136110|NCT05037851|DRUG|Opelconazole|Nebulizer suspension
219716286|NCT07018570|DRUG|Docetaxel|Docetaxel 50 mg/m2 will be administered over 60 minutes.
219716287|NCT07018570|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 will be administered over 2 hours.
219716288|NCT07018570|DRUG|Levofolinate|Leucovorin 200 mg/m2 will be administered over 2 hours.
219716289|NCT07018570|DRUG|Fluorouracil (5-FU)|5-FU 2600 mg/m2 will be administered over 24 hours.
219136111|NCT05037851|DRUG|Standard of Care|Standard of Care
219136112|NCT01094041|OTHER|Gluten free diet|A 4-week gluten free diet provided
219136113|NCT01094041|OTHER|Gluten rich diet|A 4-week gluten rich diet is provided
219136114|NCT00484575|DRUG|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
219136115|NCT00484575|DRUG|propofol|propofol given intravenously for sedation in control group
219136116|NCT01220336|BEHAVIORAL|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
219136117|NCT05246956|OTHER|Intradialytic exercise|Intradialytic exercise group
219136118|NCT04479254|DIETARY_SUPPLEMENT|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
219136119|NCT04352452|PROCEDURE|laparoscopic surgery|differences in musculoskeletal and cognitive stress
219716290|NCT07018570|RADIATION|Radiation Therapy|25Gy (5Gy×5fr)
219716291|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
219716292|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
219716293|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
219716294|NCT07019909|BIOLOGICAL|20vPnC|20 valent pneumococcal conjugate vaccine
219716295|NCT07019909|BIOLOGICAL|13vPnC|13 valent pneumococcal conjugate vaccine
219716296|NCT07016971|DRUG|CBG/CBD Oil|Participants will receive a commercially available high CBG/CBD hemp extract oil that also contains small amounts of cannabichromene (CBC). The product is formulated as a sublingual oil and administered twice daily. Participants will take 0.5 mL of the oil sublingually twice daily during the first week, followed by 1 mL sublingually twice daily for the remaining 11 weeks. The oil has a defined and independently verified cannabinoid and terpene profile and is marketed as a dietary supplement.
219136120|NCT03502278|BEHAVIORAL|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
219136121|NCT05300451|BIOLOGICAL|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
219136122|NCT04789850|DRUG|Itacitinib|200 mg oral for 360 days
219136123|NCT04789850|DRUG|Placebo|200 mg oral for 360 days
219136124|NCT04858425|DRUG|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
219136125|NCT04858425|DRUG|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
219136126|NCT04163484|OTHER|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
219136127|NCT02687243|DEVICE|Interactive Virtual Application|Online application via tablet
219136128|NCT05995782|DRUG|FB418|Oral dose
219136129|NCT05917717|PROCEDURE|Neuroprotective 'bundle of care'|"This includes the 3 devices:~* Head up cardiopulmonary resuscitation (HUP-CPR)~* Active compression decompression CPR~* Impedance threshold device (ITD)"
219716297|NCT07018362|OTHER|restricted fetal growth|The fetus is of abnormal size and has not reached its genetic growth potential in utero. Fetal birth weight is less than two standard deviations from the average weight for the same gestational age, or less than the 10th percentile of normal weight for the same age.
219716298|NCT06875180|OTHER|Tele-rehabilitation exercise|For this group, McKenzie extension exercises were applied to 50 patients online via the zoom platform.
219136130|NCT05228860|BEHAVIORAL|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
219136131|NCT05228860|BEHAVIORAL|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
219136132|NCT03356483|DRUG|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
219136133|NCT03356483|DRUG|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
219716299|NCT06875180|OTHER|Face-to-face exercise|For this group, 50 patients face-to-face in the clinical environment under the supervision of a physiotherapist in charge.
219136134|NCT00362843|DRUG|[15-O]water|
219228189|NCT06914492|BEHAVIORAL|AWARD advice|AWARD advice include Ask about smoking history, Warn about the high risk, Advise to quit, Refer smokers to smoking cessation services (with a referral card), and Do it again.
219716300|NCT06612294|BEHAVIORAL|PEF Interventional Session|3 sessions over 6 weeks for asthma management
219716301|NCT06612294|BEHAVIORAL|Control Sessions|3 sessions over 6 weeks for asthma management
219716302|NCT06612294|BEHAVIORAL|Control Booster|A single booster session after the 6-months assessments are completed.
219716303|NCT06612294|BEHAVIORAL|Active booster|A single booster session after the 6-months assessments are completed.
219716304|NCT06693661|OTHER|Kidney Health Coaching|"The intervention entails support from a KHC that includes:~* An initial rapport-building call~* Ongoing telephone support at least twice a month for six months~* Meeting the patient at all in-person clinic appointments~* Documenting interactions in the EMR using a customized platform~Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session."
219716305|NCT06693661|OTHER|Usual Care|"ER Discharge (d/c): Patients may receive consultations and support from Care Management in the ER such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.~Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.~Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.~Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care."
219716306|NCT04278898|DRUG|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
219716307|NCT06683352|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
219716308|NCT06683352|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
219716309|NCT06683352|COMBINATION_PRODUCT|Influenza and COVID Combination Vaccine|Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine
219716310|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
219716311|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
219716312|NCT06683352|OTHER|Placebo|Saline
219716313|NCT07023302|DRUG|Upadacitinib|Oral Tablets
219716314|NCT07023302|DRUG|Upadacitinib Placebo|Oral Tablets
219716315|NCT06696053|OTHER|Transversal therapeutic education|Additional patient consultation for therapeutic education with nurses.
219716316|NCT04950686|BEHAVIORAL|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
219716317|NCT04950686|BEHAVIORAL|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
219136135|NCT00870350|BIOLOGICAL|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
219136136|NCT00870350|BIOLOGICAL|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
219136137|NCT01560143|DRUG|Tigecycline|100 mg IV as a single infusion over 30 minutes
219136138|NCT02783183|DRUG|YHD1119|2 by 2
219136139|NCT02783183|DRUG|Lyrica|2 by 2
219136140|NCT04415112|BEHAVIORAL|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
219716318|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
219716319|NCT06827509|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging (based on blood speckle tracking) of the carotid artery will be acquired at 6-8 weeks after surgery.
219716320|NCT05849740|DRUG|Daratumumab and corticosteroid treatment|Daratumumab and corticosteroid treatment
219716321|NCT07021443|OTHER|non-interventional|non-interventional
219716322|NCT07024563|DRUG|Ravulizumab|Participants will receive Ravulizumab via intravenous (IV) infusion.
219716323|NCT02184013|PROCEDURE|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
219716324|NCT05931380|DRUG|Orforglipron|Administered orally
219716325|NCT05931380|DRUG|Placebo|Administered orally
219716326|NCT07024082|OTHER|Land-based Liuzijue exercise|This group includes 40 patients.Will be Performed twice a week from 9:00 to 10:00 a.m. in the rehabilitation department of Shanghai Yue-Yang Hospital under the guidance of an experienced instructor. The LG exercise program consisted of three parts: (1) Warm ups: 5-10 min of stretching and joint activity covering the limbs, neck, and trunk; (2) Land-based Liuzijue exercise: Liuzijue exercise consist of six distinct sounds (xu, he, hu, si, chui, and xi) and corresponding movements was performed with the knees in a semi-flexed position for 45 min; and the time to complete an intact Liuzijue exercise lasts 12-15 min; (3) Cool down: regulate breathing and relax muscles including flap and stretch muscles for 5-10 min.
219551231|NCT02633241|DRUG|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
219716327|NCT07024082|OTHER|Water-based Liuzijue exercise|"This group includes 40 patients. Water-based Liuzijue exercise will be performed twice a week, from 1:00-2:00 p.m., between June and September 2016, in the thermostatic swimming pool located at Shanghai University of Sport (Shanghai, China). The temperature of swimming pool was between 26°C and 30°C, while the temperature of air was between 30°C and 34°C, and the relative humidity was between 60% and 80%. Circulating water purification and disinfection equipment coordinated with chlorine disinfectant was used to sterilize the pool water. The participants were immersed in water to a level between their xiphisternum (lowest part of the sternum) and clavicles. Water-based Liuzijue exercise requires that participants remain awake and have eaten no sooner than 1 h prior to entering the pool to exercise. The WG exercise program consisted of three parts similar with LG:~(1) Warm ups; (2) Water-based Liuzijue exercise; and (3) Cool down."
219716328|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
219716329|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
219716330|NCT06004830|DRUG|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
219716331|NCT05935410|BEHAVIORAL|DM Social Needs|6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.
219716332|NCT05935410|BEHAVIORAL|Usual Care|Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
219716333|NCT07030959|DRUG|AUBE00|AUBE00 as an oral administration
219716334|NCT06877624|DRUG|QRL-101|This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.
219716335|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
219716336|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
219716337|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
219716338|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
219716339|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
219136141|NCT04415112|BEHAVIORAL|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
219551232|NCT02633241|DRUG|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
219551233|NCT02633241|DRUG|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
219551234|NCT00007787|BIOLOGICAL|Cyclosporine|
219716340|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
219716341|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
219716342|NCT07032077|DRUG|HRS-7058|HRS-7058 combimed with antitumor drugs
219716343|NCT06877533|DRUG|EOS006215|Multiple doses of EOS006215
219716344|NCT06877533|DRUG|Anticancer agent|Multiple doses of EOS006215 in combination with other anticancer agents
219136142|NCT01155869|DRUG|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
219136143|NCT01155869|DRUG|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
219136144|NCT01888406|BEHAVIORAL|Guided Self-Help|
219136145|NCT01888406|BEHAVIORAL|Pure Self-Help|
219136146|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
219136147|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
219716345|NCT06701006|OTHER|Integrated skills and safety planning app|This is a digital app that includes supported safety planning resources in clinic as well as coping skills and lived experience videos for adolescents, young adults and parents/caregivers that can be accessed in clinic or at home.
219716346|NCT06703983|OTHER|Low Glycemic index therapy|In intervention arm, patients will receive a low glycemic index diet(LGIT). The LGIT is a modified form of the ketogenic diet that restricts carbohydrate intake to sources with a glycemic index of less than 50. This diet provides approximately 60% of total calories from fat, 30% from protein, and 10% from carbohydrates.In the LGIT arm, there will be 20 participants who will follow a LGIT diet under the care of a Registered Dietitian and a Pediatric Neurologist. After three months, seizure outcomes will be categorized into the following groups: At the end of the study period, seizure outcomes will be analyzed and categorized into four groups: Seizure-free participants. Participants with \>90% seizure reduction. Participants with \>50% seizure reduction. Participants with \<50% seizure reduction (non-responders). Results will be analyzed and compared with Classic Ketogenic diet which serves as the standard dietary therapy for epilepsy.
219716347|NCT06703983|OTHER|Classic Ketogenic Diet|"This study includes two interventions: Low Glycemic Index Therapy(LGIT) and Classic Ketogenic diet(CKD) with the CKD used as a comparison.~There will have a total of 40 participants, randomly divided into two groups and each group would have 20 participants.~The randomization process will use the block randomization technique and will be conducted via a website.~Participants will first have a session with a pediatric neurologist and then meet with a Dietitian who will explain the ketogenic diet in detail for them.~The participants in the CKD group will follow a Classic Ketogenic diet where 90% of calories come from fats, 6% from proteins, and 4% from carbohydrates.~Patients receive the diet, and investigators will remain in online contact throughout the 3-month study, with monthly in-person visits for assessment and to ensure proper adherence to the diet.~The primary outcome will be the reduction in seizures, as reported by the participants' parents."
219716348|NCT06703398|BIOLOGICAL|GC101 TIL|Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for resection
219716349|NCT06703398|DRUG|dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin|monotherapy or combination of dacarbazine, temozolomide, paclitaxel, platinum or cisplatun, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator
219716350|NCT06878430|OTHER|Functional and Cognitive scores|We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).
219716351|NCT07032649|DRUG|Benzoyl Peroxide 10% Bar|Active ingredient for drug included. Blind identification by package number
219716352|NCT07032649|OTHER|Placebo|Placebo that looks like active treatment, blinded but available to ID via package number
219716353|NCT07034677|DRUG|Indapamide 1.5 MG SR|14 days treatment with indapamide 1.5 mg/day compared to placebo
219716354|NCT07034677|DRUG|Placebo|14 days treatment with placebo
219716355|NCT07033897|BEHAVIORAL|Adapted HARP|The adapted HARP intervention includes two to three in-home visits conducted by an OT practitioner over approximately 5 weeks in the homes of PwD. At the end of the first home visit, solutions to remove the identified fall hazards will be determined collaboratively with the participant, using motivational interviewing to establish hazards and shared-decision making and tailoring to help the participant brainstorm solutions to remove the hazards. Participants will then receive one to two additional visits from the OT, and a contractor if needed, to implement solutions using a self-management approach, identifying any additional hazards and subsequent modifications if necessary. All adaptive equipment and modifications will be provided at no cost to the participant. Booster visit(s) will be completed 3-6 months after the initial treatment sessions to ensure the home modifications are still appropriate, troubleshoot any equipment issues and review the self-management process.
219716356|NCT06709053|DIAGNOSTIC_TEST|standing hight-based|The model equation for predicting double-lumen tube insertion depth using standing hight -based: Depth = 1.083 + 0.166×standing hight (cm)
219716357|NCT06709053|DIAGNOSTIC_TEST|sitting height-based|The model equation for predicting double-lumen tube insertion depth using sitting height ( depth = 0.32 × sitting height)
219716358|NCT06709053|DIAGNOSTIC_TEST|CT-based|The model equation for predicting double-lumen tube insertion depth using CT depth = 1.543 + 0.155\*standing hight,cm + 0.202\*Ds-c,cm
219716359|NCT06710886|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
219716360|NCT06710886|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
219716361|NCT07119203|PROCEDURE|Robotic cholecystectomy|Robotic multiport cholecystectomy
219716362|NCT07119203|PROCEDURE|Laparoscopic cholecystectomy|Conventional multiport laparoscopic cholecystectomy
219716363|NCT07120880|PROCEDURE|AD + SHR + active LT and extended-release melatonin 2mg|Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
219716364|NCT07120880|PROCEDURE|AD + SHR + active LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
219716365|NCT07120880|PROCEDURE|AD + SHR + placebo LT and extended-release melatonin 2mg|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
219716366|NCT07120880|PROCEDURE|AD + SHR + placebo LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
219716367|NCT07123818|DEVICE|AI software|AI software that will verify brain NECT scans on the presence of unruptured intracranial aneurysms (UIA). Brain NECT scans will be send to the AI software which will detect possible unruptured intracranial aneurysms (UIA). NECT scans on which a possibe UIA has been detected will be send to a platform on which involved radiologist can verify the AI result(s).
219716368|NCT07035197|DRUG|Eptinezumab|"Eptinezumab 100 mg IV q 3 months~* Baseline visit: Within 24 hours of receiving eptinezumab (duration of IDI \~30 - 45 minutes)~  * Semi-structured In-depth interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 3-month follow-up visits (duration of interview: \~10 minutes):~  * Semi-structured brief interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 6-month follow-up visit:~  * no interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)"
219716369|NCT07035197|OTHER|Sham (No Treatment)|"\*\* No intervention, neither eptinezumab nor placebo, was given~* Baseline visits: Within 24 hours of giving eptinezumab administration (duration of IDI \~30 - 45 minutes) - Semi-structured in-depth interview"
219716370|NCT07038785|DIAGNOSTIC_TEST|Breath test|Breath sample collection using a sample collection kit
219716371|NCT06720636|DEVICE|EndoSign|"The EndoSign cell collection device is a non-endoscopic capsule sponge device used to collect pan-esophageal samples.~The Endosign procedure consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Seven minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter is retrieved by pulling on the string. Upon retrieval the capsule-sponge scrapes against the surface of the top of the stomach and esophagus and collects epithelial cells. The capsule-sponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests."
219716372|NCT06721793|DIETARY_SUPPLEMENT|carbohydrate electrolyte drink|2% carbohydrate solution with 1,020 mg/L of Sodium
219716373|NCT06721793|DIETARY_SUPPLEMENT|no-sugar electrolyte drink|1% carbohydrate solution with 1,060 mg/L of Sodium
219716374|NCT06721793|DIETARY_SUPPLEMENT|Caffeinated Carbohydrate and electrolyte drink|2% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L caffeine
219716375|NCT06721793|DIETARY_SUPPLEMENT|Water (Placebo)|flavored water with non-caloric, non-sodium-containing sweetner
219716376|NCT07040592|DRUG|semaglutide|All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support
219716377|NCT03421808|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS
219716378|NCT07037134|OTHER|Natural soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated natural soundscapes via high-fidelity open-back reference headphones powered by a DAC/amplifier and corrected for frequency response using calibration software. Participants are randomly assigned one of 22 recordings. Each includes 10-second fade-in/out effects and are calibrated to 45-55 dB. The stereo recordings (320-kbps MP3, 48 kHz/24-bit) feature biophony (e.g., bird vocalizations) and geophony (e.g., rainfall), free of urban sounds and selected for ecological validity based on predefined criteria: (i) recognizable/context-specific sounds; (ii) culturally neutral; (iii) foreground presence and depth; (iv) no prolonged silence; (v) no technical artifacts. During exposure, they lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active, causal listening under continuous researcher supervision.
219716379|NCT07037134|OTHER|Urban soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated urban soundscapes, using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned one of 22 recordings, calibrated to 45-55 dB (Leq,20min). The recordings feature anthropophony (e.g., unintelligible background speech) and technophony (e.g., transportation-related sounds), free of natural sounds and selected for ecological validity based on the same predefined criteria as the natural soundscapes. To prevent semantic processing, participants are pre-screened and post-session reconfirmed to ensure they do not understand the languages used. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
219136148|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
219136149|NCT02824432|DRUG|TAK-085|TAK-085 capsules
219136150|NCT01615809|DRUG|AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
219136151|NCT05511454|OTHER|Salivary and crevicular samples|The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.
219136152|NCT04654936|BEHAVIORAL|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
219136153|NCT04654936|BEHAVIORAL|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
219136154|NCT04658615|PROCEDURE|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
219136155|NCT00127647|DRUG|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
219136156|NCT00127647|DRUG|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
219136157|NCT01624168|BEHAVIORAL|Anxiety Management Education|written materials on management of anxiety for self-study
219136158|NCT01624168|BEHAVIORAL|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
219551235|NCT00007787|BIOLOGICAL|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
219551236|NCT00007787|DRUG|Tacrolimus|
219551237|NCT04485507|OTHER|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
219551238|NCT04485507|OTHER|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
219551239|NCT05453409|OTHER|No intervention|No intervention
219551240|NCT06126328|DEVICE|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
219551241|NCT06428851|OTHER|Laser therapy|Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.
219551242|NCT06428851|OTHER|Neuromuscular electrical nerve stimulation|Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.
219551243|NCT06428851|OTHER|Control|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
219551244|NCT03237117|BIOLOGICAL|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
219551245|NCT00003700|BIOLOGICAL|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
219551246|NCT00003700|DRUG|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
219551247|NCT00003700|DRUG|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
219551248|NCT00003700|DRUG|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
219551249|NCT00003700|DRUG|daunorubicin hydrochloride|80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
219551250|NCT00003700|DRUG|leucovorin calcium|"Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose"
219551251|NCT00003700|DRUG|mercaptopurine|60mg/sq m/d PO every day Course VII
219551252|NCT00003700|DRUG|methotrexate|15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
219551253|NCT00003700|DRUG|prednisone|60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
219551254|NCT00003700|DRUG|vincristine sulfate|2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
219551255|NCT00003700|DRUG|Allopurinol|300mg PO q day Days 1-14 Course I
219551256|NCT05306600|DIAGNOSTIC_TEST|whole exome and whole genome sequencing analysis|"Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer"
219551257|NCT00001842|DRUG|Granulocyte colony-stimulating factor|
219551258|NCT00001842|DRUG|Dexamethasone|
219551259|NCT00818220|PROCEDURE|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
219551260|NCT00818220|OTHER|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
219551261|NCT01023776|BIOLOGICAL|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
219551262|NCT04043819|DRUG|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
219551263|NCT05124496|DEVICE|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
219551264|NCT05735418|DIETARY_SUPPLEMENT|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
219551265|NCT05735418|DIETARY_SUPPLEMENT|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
219551266|NCT00464113|DRUG|XL228|1-hour IV infusion
219551267|NCT02906813|DRUG|TAK-935 Tablets|Tablets
219551268|NCT02906813|DRUG|TAK-935 Oral Solution|Oral solution
219551269|NCT03878264|DRUG|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
219551270|NCT03878264|DRUG|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
219551271|NCT03878264|DRUG|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
219136159|NCT01624168|BEHAVIORAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
219136160|NCT04436120|PROCEDURE|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
219136161|NCT04436120|PROCEDURE|Research blood draws|Blood biospecimens collected following disease progression
219136162|NCT05744128|BIOLOGICAL|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
219136163|NCT02357784|DEVICE|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
219136164|NCT00282776|BEHAVIORAL|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
219136165|NCT00282776|BEHAVIORAL|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
219136166|NCT04797533|DEVICE|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~* Micro-changes in weight distribution~* Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~* Movement and sleep~* Heart rate"
219136167|NCT01151033|DEVICE|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
219136168|NCT06037135|DRUG|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
219136169|NCT06037135|DRUG|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
219136170|NCT01874184|OTHER|counseling intervention|Take part in weekly group counseling sessions
219551272|NCT01135264|BEHAVIORAL|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
219551273|NCT01135264|BEHAVIORAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
219551274|NCT04386408|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
219551275|NCT04386408|COMBINATION_PRODUCT|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
219551276|NCT06200584|DRUG|Risperidone|Antipsychotic Agent
219551277|NCT06200584|DRUG|Olanzapine|Antipsychotic Agent
219551278|NCT06200584|DRUG|Quetiapine|Antipsychotic Agent
219551279|NCT06200584|DRUG|Risperidone and Vitamin D and Vitamin E|vitamin
219551280|NCT06200584|DRUG|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
219551281|NCT06200584|DRUG|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
219551282|NCT00498199|PROCEDURE|visual tests|
219136171|NCT01874184|BEHAVIORAL|behavioral dietary intervention|Set goals for changing dietary habits
219136172|NCT01874184|BEHAVIORAL|exercise intervention|Attend group exercise activities
219136173|NCT01874184|OTHER|questionnaire administration|Ancillary studies
219136174|NCT01874184|OTHER|laboratory biomarker analysis|Correlative studies
219136175|NCT02814266|OTHER|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
219136176|NCT02814266|OTHER|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
219136177|NCT04480814|DIAGNOSTIC_TEST|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
219136178|NCT01543685|DRUG|Indomethacin|40 mg TID capsules
219136179|NCT01543685|DRUG|Indomethacin|40 mg BID capsules
219136180|NCT01543685|DRUG|Indomethacin|20 mg TID capsules
219136181|NCT01543685|DRUG|Celecoxib|200 mg capsules
219136182|NCT01543685|DRUG|Placebo|Capsules
219136183|NCT04776213|DRUG|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants were followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants were not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
219551283|NCT03102879|PROCEDURE|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
219551284|NCT03102879|PROCEDURE|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
219716380|NCT07037134|OTHER|Broadband sound exposure|Participants receive a standardized 20-minute auditory exposure to broadband sounds (i.e., white or pink noise), using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned to one of the two noise types, with equal distribution across conditions. The stimuli are generated using professional audio software and calibrated to 50 dB (Leq,20min). During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
219136184|NCT00051974|DRUG|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
219136185|NCT06123585|OTHER|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
219136186|NCT06123585|OTHER|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
219136187|NCT05754463|OTHER|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
219136188|NCT04735354|DRUG|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
219136189|NCT02931396|DEVICE|FES|
219136190|NCT00961142|DRUG|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
219136191|NCT05264337|OTHER|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
219136192|NCT05264337|OTHER|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
219136193|NCT05264337|OTHER|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
219136194|NCT00123799|PROCEDURE|Positron Emission Tomography Imaging|
219136195|NCT01394809|BEHAVIORAL|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
219136196|NCT02013037|DRUG|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
219136197|NCT05201768|OTHER|balance tests,questionnaire|Individuals will be tested and recorded.
219136198|NCT01304147|DRUG|Ketamine|A single dose of intranasal ketamine up to 50 mg
219136199|NCT01304147|DRUG|placebo|Single dose of saline intranasal
219136200|NCT01425762|OTHER|Drug Dose|100 versus 200 mcg IT morphine
219551285|NCT00387608|DRUG|veliparib|
219551286|NCT00387608|OTHER|pharmacological study|
219551287|NCT00387608|PROCEDURE|biopsy|
219551288|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
219551289|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
219136201|NCT03537573|BEHAVIORAL|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
219228190|NCT06914492|BEHAVIORAL|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking.
219136202|NCT03537573|BEHAVIORAL|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
219136203|NCT03537573|BEHAVIORAL|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
219136204|NCT06609876|PROCEDURE|Thermal ablation|Thermal ablation of tumors
219551290|NCT00754052|DRUG|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
219136205|NCT06609876|DRUG|Donafenib|Donafenib ( 100 mg，bid)
219136206|NCT04092985|DEVICE|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
219136207|NCT02525705|BIOLOGICAL|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
219136208|NCT06615297|DIAGNOSTIC_TEST|ultrasonographic evaluation|facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
219136209|NCT06613815|OTHER|radiofrequency of the geniculate nerves|radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
219136210|NCT06614387|DRUG|Infliximab|Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
219136211|NCT00759200|DRUG|alb-interferon alfa 2b|900 mcg every 4 weeks
219136212|NCT00759200|DRUG|alb-interferon alfa 2b|1200 mcg every 4 weeks
219136213|NCT00759200|DRUG|alb-interferon alfa 2b|1500 mcg every 4 weeks
219136214|NCT00759200|DRUG|alb-interferon alfa 2b|1800 mcg every 4 weeks
219136215|NCT00759200|DRUG|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
219551291|NCT00508833|BIOLOGICAL|287615 containing HBsAg with adjuvants|
219551292|NCT01426087|DRUG|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
219716381|NCT07037134|OTHER|Blank tape attention placebo control|Participants receive a standardized 20-minute exposure to blank audio (silence), using the same equipment and technical specifications as all other intervention conditions. At study onset, participants are informed they will hear a range of environmental sounds, including some that may be inaudible (i.e., present but beyond the range of human hearing). During the placebo condition, a blank recording is played, producing silence, while participants remain unaware of whether they are receiving an active or placebo stimulus. This attention-control condition ensures procedural consistency while delivering no auditory stimulation. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
219551293|NCT01426087|PROCEDURE|endoscopic therapy|gastroscope plus EIS/EVL/HI
219551294|NCT03981978|BEHAVIORAL|Physical Activity|Self-report questionnaires assessing physical activity level.
219551295|NCT00909571|DRUG|FK506E (modified release tacrolimus)|oral
219716382|NCT06723743|OTHER|Transcutaneous vagus nerve stimulation for attention in veterans with TBI|taVNS does not require surgery or medication, offering a safe and accessible treatment option. Each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden.
219136216|NCT05218915|DRUG|Dulaglutide|Dulaglutide once weekly subcutaneous
219136217|NCT05218915|DRUG|Insulin Degludec|Insulin degludec once daily
219136218|NCT05218915|DEVICE|Continuous glucose monitor|Dexcom G6 CGM system
219136219|NCT04332276|DRUG|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
219136220|NCT04332276|DRUG|optimized oral treatment|The patient will received his usual dopaminergic treatment.
219551296|NCT00909571|DRUG|Prograf (tacrolimus)|injection
219136221|NCT06615128|DIAGNOSTIC_TEST|blood sampling|blood sample to detect sCD25 from systemic sclerosis and Healthy control.
219136222|NCT01244828|DRUG|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
219136223|NCT06615024|DIAGNOSTIC_TEST|G6pd enzyme sickling test|Measuring the enzyme level of G6PD and presence of Hbs
219136224|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and sickling test|Measuring enzyme level of G6PD and level of HbS
219136225|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and HPLC|Measuring G6PD enzyme level in neonates and measuring level of HbS
219136226|NCT06527768|BEHAVIORAL|Theory-based health behaviour change interventio|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
219136227|NCT06616688|OTHER|Organoid-guided treatment|After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures
219136228|NCT06614634|OTHER|Remotely supervised exercise at home or outdoors|Aerobic and strengthening exercise program at home/outdoors at least three days a week for four weeks using a Polar H9 heart rate monitor and elastic band.
219136229|NCT06614634|OTHER|Hospital-based exercise program|The aerobic and strengthening exercise program three days a week for four weeks under supervision in our cardiopulmonary rehabilitation unit.
219136230|NCT06614634|BEHAVIORAL|Cardiovascular risk modification|Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
219136231|NCT06614634|OTHER|Phone calls with reinforcement feedback|Calls once a week that include symptom inquiries and encouraging feedback on exercise logs.
219136232|NCT01278862|DEVICE|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
219551297|NCT01086228|DEVICE|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
219136233|NCT01278862|DEVICE|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
219136234|NCT06622408|OTHER|HypnoVR© virtual reality headset|Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
219136235|NCT05870930|OTHER|Carob beverage|Volunteers will consume 2 tablespoons of carob powder in 200mL drinking water.
219136236|NCT05210894|BIOLOGICAL|Anti-IL8|
219228191|NCT06914492|BEHAVIORAL|Referral card|The contents consist of brief information and a highlight of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.
219551298|NCT00316940|DRUG|bortezomib|
219551299|NCT00316940|RADIATION|samarium Sm 153 lexidronam pentasodium|
219551300|NCT04201795|OTHER|Laser|laser with no emision will applied
219551301|NCT04201795|OTHER|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
219551302|NCT02658019|DRUG|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
219551303|NCT04802213|OTHER|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
219551304|NCT04802213|DEVICE|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
219551305|NCT04802213|DEVICE|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
219551306|NCT02751216|OTHER|EEG recording + pain protocol|
219551307|NCT03494686|PROCEDURE|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
219551308|NCT03494686|PROCEDURE|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
219551309|NCT00006434|BIOLOGICAL|tumor-pulsed dendritic cells|
219551310|NCT03145324|OTHER|Collection of vaccine histories|
219136237|NCT00603447|DRUG|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
219136238|NCT00603447|DRUG|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
219136239|NCT00603447|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
219136240|NCT05416749|DRUG|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
219136241|NCT06630520|COMBINATION_PRODUCT|Periarticular injection|"A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery."
219136242|NCT06629636|DIETARY_SUPPLEMENT|NMN capsule|Total of 900mg/day for 8 weeks
219228192|NCT06914492|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
219716383|NCT06723743|DEVICE|Soterix Medical Vagus Nerve Stimulation mini-CT|Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.
219551311|NCT06285006|DRUG|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
219716384|NCT06184152|DIAGNOSTIC_TEST|CEUS imaging|Contrast-enhanced ultrasound (CEUS)
219716385|NCT06184152|DIAGNOSTIC_TEST|aMRI imaging|contrast enhanced abbreviated MRI (AMRI)
219136243|NCT06629636|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
219136244|NCT06698198|BIOLOGICAL|Pneumococcal Conjugate Vaccine|Suspension for Intramuscular injection
219136245|NCT06698198|BIOLOGICAL|Prevnar 13®|Suspension for Intramuscular injection
219136246|NCT06712056|BEHAVIORAL|Mindfulness|study of focusing attention
219360663|NCT03834532|OTHER|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
219360664|NCT03834532|OTHER|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
219551312|NCT01461291|DEVICE|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
219551313|NCT01461291|PROCEDURE|Cataract surgery|Cataract surgery alone
219551314|NCT00697801|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
219136247|NCT06713135|DRUG|vamorolone 40 mg/mL oral suspension|Vamorolone is administered at a dose range between 2 mg/kg/day and 6 mg/kg/day for boys weighing \<40 kg. For boys weighing 40 kg or above, the dose range will be 80 mg to 240 mg once daily. Doses can be adjusted within the dose range as determined by the Investigator based on tolerability. The highest tolerated dose should be used.
219136248|NCT06711341|DEVICE|Whole-body Vibration (WBV) Training|"Participants use the Compex Winplate, designed specifically for vibration training. The device is set with a frequency of 30 Hz and an amplitude of 4 mm. Participants perform a total of 5 exercises consisting of static and dynamic squat exercises, with a 30-second rest period between sets and between different exercises. The exercises and progression over the weeks are as follows:~Week 1:~* Static squat with knees flexed at 30° - 2 sets of 30 seconds each~* Dynamic squat with knees flexed between 0-60° - 2 sets of 30 seconds each~* Fingertip-to-sole partial dynamic squat with knees flexed at 30° - 2 sets of 30 seconds each~* Consecutive weight transfer with knees flexed at 45° - 2 sets of 30 seconds each~* Single leg static squat with knees flexed at 30° - 30 seconds per leg~Subsequent Weeks: The duration of each set increases by 10 seconds each week. Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
219360665|NCT03781648|DIAGNOSTIC_TEST|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
219551315|NCT00697801|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
219551316|NCT00697801|DRUG|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
219551317|NCT00271557|DRUG|nesiritide|
219136249|NCT06711341|BEHAVIORAL|Progressive Resistance Exercise (PRE)|"Training Duration: Participants undergo approximately 15-20 minute training sessions, 3 days per week for 3 weeks.~Exercise Regimen: The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle:~* At the beginning of each week, the 10-repetition maximum (10RM) is measured.~* During that week, participants perform their training sets as follows:~  * First set: 50% of 10RM~ * Second set: 75% of 10RM~ * Final set: 100% of 10RM Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
219228193|NCT06914492|BEHAVIORAL|Personalized active referral|Smokers will be introduced to various SC services in Hong Kong (using the referral card) and be motivated to use these services. Well-trained SC ambassadors will assist smoker to choose favourite/most convenient or preferred type of services. Research staff will assist participants in booking or re-booking the SC services at the 1- and 2-month follow-ups (after very brief questionnaire surveys). Participants' contact information will be forwarded to SC services providers within seven days, and providers are expected to contact the participants within 1-2 weeks. Research staff will also monitor SC services use of the participants at each follow-up (1-, 2-, 3- and 6- month) and assist participants to book or re-book the appointments if necessary at 1- and 2- month follow-up. We shall liaise with the existing service providers and seek their assistance in helping our smokers in helping our smokers in a timely manner.
219228194|NCT06914492|BEHAVIORAL|12 weeks of chatbot-based instant messaging support|Participants in the intervention group will receive 12 weeks of instant messaging support delivered by the LLM-based chatbot accessible via WhatsApp platform. The chatbot, powered by GPT-4o model (or more advanced model available) using prompt-engineering and agent-based techniques, will deliver brief theory-based, structured SC intervention alongside freeform, on-demand support. The structured intervention session deploys the 5As model (Ask, Advise, Assess, Assist, and Arrange follow-up) and 5Rs model (Relevance, Risks, Rewards, Roadblocks, Repetition), as used in our previous telephone-counselling trials and recommended by WHO for brief SC intervention.
219228195|NCT06914492|BEHAVIORAL|Reminder messages|WhatsApp messages on follow-up survey reminders.
219228196|NCT06934265|BEHAVIORAL|exuberant voice therapy|exuberant voice therapy validated for patients with age-related voice changes (i.e., vocal fold atrophy, presbyphonia)
219716386|NCT07043452|DRUG|Blinded Study Medication - Condition 1|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
219228197|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
219228198|NCT06943638|OTHER|Mild Exercise and stretches|For 15 minutes the patient received an individualized mild workout program intending to relax and relieve some of his stress. The workout includes deep breaths, easy-to-do exercises, and stretches from lying on the bed, sitting in a chair, or standing. I always followed the patient's tempo and provided him with as many breaks as he needed.
219228199|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
219228200|NCT06955286|DIAGNOSTIC_TEST|complete ACTH stimulation test the day after surgery|patients complete ACTH stimulation test on the one day after surgery
219228201|NCT06952023|PROCEDURE|Modified Maze ablation with PFA|Modified Maze ablation with PFA
219228202|NCT06952023|PROCEDURE|PVI only with PFA|PVI only with PFA
219228203|NCT06951984|DIAGNOSTIC_TEST|11C/18F-HED|Each subject receive a single intravenous injection of 11C/18F-HED and undergo PET/CT or MRI imaging within the specificed time.
219360666|NCT07177703|DRUG|Treprostinil|Treprostinil is initiated at a dose of 1.25 ng/kg/min. The dose is then titrated upwards based on individual patient tolerability and clinical response. The planned titration schedule is an increase of 1.25 ng/kg/min weekly for the first four weeks of treatment, followed by weekly increases of 2.5 ng/kg/min thereafter, as tolerated.
219360667|NCT07178457|DRUG|Brentuximab Vedotin (Bv)|1.8 mg/kg in 100 mlof NaCl 0.9%, Q3W with a maximum of 16 cycles
219360668|NCT07178457|DRUG|Placebo|NaCl 0.9% 100 ml IV Q3W with a maximum of 16 cycles
219360669|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
219360670|NCT03576417|DRUG|Cisplatin|Intravenous
219360671|NCT03576417|DRUG|Nivolumab|Intravenous
219360672|NCT03576417|RADIATION|RT|IMRT 66 Gy / 6.5 weeks
219360673|NCT05246332|DEVICE|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
219360674|NCT02262494|PROCEDURE|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
219360675|NCT02262494|PROCEDURE|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
219360676|NCT02262494|PROCEDURE|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
219360677|NCT00003267|PROCEDURE|infection prophylaxis and management|
219136250|NCT06711341|BEHAVIORAL|Home-Based Exercise|"Protocol: Participants receive a printed document with instructions for home exercises and are instructed on how to perform the exercises.~Training Duration: Sessions are conducted three days per week for 3 weeks.~Exercise Regimen: The exercises include:~* Bilateral Quadriceps Isometric Exercise: Participants lie on their backs with a roll below each knee, pressing for 10-second holds, totaling 20 repetitions.~* Knee Extensions: Participants performed knee extensions while seated, holding each extension for 5 seconds, completing 10 repetitions per leg.~* Knee Range of Motion (ROM) Exercises: Participants lie face down and alternately bend their knees, completing 10 repetitions.~Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises"
219136251|NCT06714383|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.
219136252|NCT06714383|DRUG|Pirarubicin|Pirarubicin: 60 mg/m2，IV，d1-2
219136253|NCT06714383|DRUG|Lobaplatin|LobaplLatin: 40 mg/m2,，IV，d1
219136254|NCT06714409|DIAGNOSTIC_TEST|VExUS guided decongestion|Treatment team will be provided information about venous organ congestion status.
219136255|NCT06714487|OTHER|cognitive stimulation through games|cognitive stimulation through games
219136256|NCT06713681|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times
219360678|NCT00003267|PROCEDURE|management of therapy complications|
219360679|NCT00003267|PROCEDURE|surgical procedure|
219360680|NCT05197231|PROCEDURE|Resisted knee extension exercise|Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
219360681|NCT05197231|DRUG|IV amino acids|IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
219360682|NCT01138956|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
219360683|NCT01138956|DRUG|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
219360684|NCT01504282|DRUG|mitomycin-C|
219360685|NCT01504282|DRUG|Placebo|balanced salt solution (BSS)
219360686|NCT00939198|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
219360687|NCT03050983|DEVICE|IPI|Enable the IPI algorithm and IPI alarm algorithm
219360688|NCT05006014|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
219360689|NCT04864873|DIAGNOSTIC_TEST|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
219360690|NCT04864873|DIAGNOSTIC_TEST|Standard microbiological diagnostic pathway|See previous.
219360691|NCT02363478|DRUG|buspirone|buspirone 10 mg X2 for 4 weeks
219360692|NCT05620355|DRUG|BG2109|BG2109 100mg film coated tablet for oral administration once daily.
219360693|NCT05620355|DRUG|Placebo for BG2109|Placebo for BG2109 100mg tablet for oral administration once daily.
219360694|NCT05620355|DRUG|Placebo for add-back therapy|Placebo for add-back therapy tablet for oral administration once daily.
219360695|NCT05620355|DRUG|Add-back therapy|Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.
219360696|NCT06103747|DRUG|Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of test drug
219360697|NCT06103747|DRUG|Galvumet® Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of reference drug
219360698|NCT00953693|PROCEDURE|Biopsy|Skin biopsy
219360699|NCT00768898|OTHER|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
219360700|NCT00008112|DRUG|cisplatin|
219360701|NCT00008112|PROCEDURE|hyperthermia treatment|
219360702|NCT00008112|RADIATION|brachytherapy|
219360703|NCT00008112|RADIATION|radiation therapy|
219360704|NCT03262363|COMBINATION_PRODUCT|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
219360705|NCT03262363|COMBINATION_PRODUCT|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
219360706|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
219360707|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
219360708|NCT00576238|DRUG|urea|Topical application twice daily for up to 6 months
219360709|NCT05087615|DRUG|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
219360710|NCT05087615|DRUG|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
219360711|NCT05087615|DRUG|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
219360712|NCT05087615|DRUG|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
219360713|NCT03599700|DIAGNOSTIC_TEST|myeloproliferative neoplasms|BLOOD SAMPLING
219360714|NCT03160560|DRUG|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
219136257|NCT06710574|DRUG|PD-RBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs
219136258|NCT06710574|DRUG|iRBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time.
219136259|NCT04341298|OTHER|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
219136260|NCT04341298|OTHER|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
219136261|NCT04341298|DEVICE|Avulux®|Avulux® device
219136262|NCT04341298|DEVICE|Sham Avulux®|Sham Avulux®
219136263|NCT05974072|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
219136264|NCT05974072|OTHER|PAINDOC Program|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
219136265|NCT06714643|DEVICE|Active tDCS|The active tDCS protocol consist of 15 excitatory tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC at an intensity of 2 mA. The electrodes are positioned according to the 10-20 electroencephalography system (Anode on F3 and Cathode on F4).
219136266|NCT06714643|DEVICE|Sham treatment|The sham-tDCS intervention consist of a placebo 15 tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC. During the sessions only a 15-second initiation current is applied, providing the patient with the sensation of receiving an electric current on the scalp. Participants will also experience sounds and stimuli similar to those produced by active tDCS.
219228204|NCT06951568|OTHER|Physical Exercise Program|The physiotherapy protocol has been developed using the GMFCS scale as a reference. Based on this assessment, each patient's level is determined according to their functional motor abilities, limitations, and use of assistive or mobility devices. Each protocol consists of a total of five exercises: two general exercises and three specific exercises focused on the phases of the corresponding transfer and on skills common to all transfers. Rest periods of 2 minutes and 30 seconds are provided between exercises to ensure adequate recovery and a safe progression. The somatosensory stimulation will consist of intermittent mechanical pressure applied to the skin over the neuromuscular motor points of the quadriceps and gastrocnemius muscles. T
219228205|NCT05552066|OTHER|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
219228206|NCT05552066|OTHER|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
219228207|NCT03895658|DEVICE|MRI|Structural and functional neuroimaging pre and post ECT treatment
219228208|NCT03895658|DEVICE|MagPro TMS stimulator and coil|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
219228209|NCT03895658|DEVICE|Thymatron (R) System IV paired with 4X1 HDECT|Multi-Channel Stimulation Interface (Model 4X1 HDECT)
219228210|NCT04313114|BEHAVIORAL|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
219136267|NCT06711445|OTHER|Tele-assessment|"The participants were evaluated in two settings on different days (24-48 h apart): (i) in clinical settings (face-to-face) and (ii) at home via 'WhatsApp' phone application (both asynchronized and synchronized tele-assessment).~The evaluations steps were as follows:~1. Face-to-face/ Clinic assessment: Rater 1 completed all clinical assessments.~2. Synchronized tele-assessment: Rater 1 repeated the same evaluations via video calls to the patients (these were recorded to be used in step 3).~3. Asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 2).~4. Retest of synchronized tele-assessment: Rater 1 evaluated patients via video calls (these were recorded to be used in step 5).~5. Retest of asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 4)."
219136268|NCT06457607|DEVICE|LinearZ|High Intensity Focues Ultrasound
219136269|NCT06406101|OTHER|Floor|Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
219136270|NCT06406101|OTHER|Bed|Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
219136271|NCT01764451|DRUG|Simvastatin|
219716387|NCT07043452|DRUG|Blinded Study Medication - Condition 2|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
219136272|NCT04423588|DIAGNOSTIC_TEST|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
219136273|NCT04423588|DIAGNOSTIC_TEST|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
219136274|NCT03208270|DRUG|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
219360715|NCT03160560|DRUG|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
219716388|NCT07043452|DRUG|Blinded Study Medication - Condition 3|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
219716389|NCT07043452|DRUG|Blinded Study Medication - Condition 4|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
219136275|NCT03208270|DRUG|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
219136276|NCT03426280|DEVICE|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
219136277|NCT02117401|DRUG|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
219136278|NCT02117401|DRUG|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
219360716|NCT03160560|OTHER|Placebo|Subjects in Placebo group will receive Placebo Rinse.
219136279|NCT02117401|DRUG|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
219716390|NCT07043452|DRUG|Blinded Study Medication - Condition 5|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
219716391|NCT07043452|DRUG|Placebo|Double blind administration of placebo.
219551318|NCT05534048|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
219551319|NCT05534048|BIOLOGICAL|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
219551320|NCT05945810|DRUG|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
219551321|NCT05945810|DRUG|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
219551322|NCT04234555|DIAGNOSTIC_TEST|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
219551323|NCT04234555|DIAGNOSTIC_TEST|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
219551324|NCT04234555|DIAGNOSTIC_TEST|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
219716392|NCT07038668|PROCEDURE|Using of viscoelastic during the operation|Using of viscoelastic during the operation
219716393|NCT07038668|PROCEDURE|No using of viscoelastic during the operation|No using of viscoelastic during the operation
219716394|NCT07042945|DRUG|MK-4646|MK-4646 in capsular form administered orally
219136280|NCT02117401|DRUG|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
219136281|NCT02117401|DRUG|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
219136282|NCT03297112|DRUG|Perflutren Lipid Microspheres|Given IV
219136283|NCT03297112|PROCEDURE|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
219136284|NCT02738840|PROCEDURE|MRI scan|MRI scan
219136285|NCT06499584|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered."
219136286|NCT01356069|OTHER|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
219551325|NCT04234555|DIAGNOSTIC_TEST|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
219551326|NCT04234555|DIAGNOSTIC_TEST|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
219136287|NCT01356069|OTHER|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
219136288|NCT01716858|DIETARY_SUPPLEMENT|Sulforaphane-rich Broccoli Sprout Extract|
219551327|NCT05521022|DRUG|AT-02|AT-02 via IV infusion
219551328|NCT05521022|OTHER|AT-02 (Placebo)|Normal saline solution via IV infusion
219551329|NCT01212549|PROCEDURE|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
219551330|NCT01212549|PROCEDURE|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
219136289|NCT05780788|DEVICE|Monitoring Tooth Movement|Monitoring Canine Retraction
219136290|NCT04476472|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
219136291|NCT03806907|RADIATION|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
219136292|NCT01326039|DRUG|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
219716395|NCT07039305|BEHAVIORAL|Physical capacity training for chronic stroke - building aerobic capacity and muscle strength|The general format of each exercise session includes assessment of resting heart rate (HR), blood pressure (BP), and rating of perceived exertion (RPE) followed by a 5-minute warm-up, a minimum of 30 minutes of aerobic exercise followed by 25 minutes of resistance exercise. Aerobic exercise will always include a minimum of 10 minutes of walking (overground or treadmill) at the prescribed intensity followed by cycle, arm or rowing ergometry. Sessions will begin at a target intensity of \~60% heart rate reserve (HRR) determined from the exercise tolerance test performed at baseline and calculated using Karvonen's formula. The goal will be to increase training intensity by \~5% HRR every \~3 weeks and progressed as tolerated. Resistance exercise will target all major muscle groups and include multiple sets dosed at the 10-repetition to fatigue level (\~75% of the 1-repetition maximum). Resistance exercises will be progressed with improvements in strength or as tolerated.
219136293|NCT01326039|DRUG|saline|perineural isotonic saline 20 ml
219136294|NCT01082289|DRUG|Lurasidone|
219136295|NCT01357044|DIETARY_SUPPLEMENT|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
219136296|NCT01357044|DIETARY_SUPPLEMENT|Placebo|Tablets, two in the morning and two in the evening
219136297|NCT01645111|DRUG|Clevidipine|
219136298|NCT04755530|DIETARY_SUPPLEMENT|Regular whole milk|400 g/day of regular whole milk
219136299|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
219136300|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
219136301|NCT04755530|DIETARY_SUPPLEMENT|Acidified whole milk|400 g/day of yogurt with acidified whole milk
219716396|NCT07043946|DRUG|Budoprutug|Single IV dose of study product on Day 1 and Day 15
219228211|NCT04313114|BEHAVIORAL|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
219136302|NCT00407082|DRUG|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
219136303|NCT00407082|DRUG|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
219136304|NCT04810260|BEHAVIORAL|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
219136305|NCT04036162|BEHAVIORAL|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
219136306|NCT02211898|DRUG|BNS003|
219136307|NCT02695381|DRUG|Etodolac-lidocaine topical patch|Once daily
219136308|NCT02695381|DRUG|Placebo|Once daily
219136309|NCT02550067|DRUG|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
219136310|NCT02550067|DRUG|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
219136311|NCT02550067|DRUG|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
219136312|NCT02210806|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
219136313|NCT02210806|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
219136314|NCT02210806|OTHER|Placebo DPI|Placebo, 1 inhalation
219136315|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
219360717|NCT02594644|DEVICE|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
219360718|NCT02594644|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
219360719|NCT02594644|RADIATION|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
219360720|NCT01608425|PROCEDURE|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
219360721|NCT03972631|BEHAVIORAL|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
219360722|NCT03972631|BEHAVIORAL|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
219360723|NCT03972631|BEHAVIORAL|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
219360724|NCT02077790|DEVICE|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
219360725|NCT02913248|PROCEDURE|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
219360726|NCT01769937|DRUG|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
219360727|NCT05205590|OTHER|Non|Non
219136316|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
219136317|NCT02703714|DRUG|Pembrolizumab|200 mg given intravenously (IV)
219136318|NCT02703714|DRUG|Sargramostim|250 µg given subcutaneously (SC)
219136319|NCT05991999|OTHER|Stretching|"Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week."
219136320|NCT05991999|OTHER|Training|Participants continued their swimming training 2 days a week.
219136321|NCT03872362|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
219136322|NCT06120699|OTHER|Pelvic floor muscle training with 360 degree expanded diaphragm exercises|Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
219136323|NCT06120699|OTHER|Pelvic floor muscle training with standard diaphragm exercises|"Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied."
219228212|NCT04313114|BEHAVIORAL|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 \& 3 - follow-up will follow same procedure as year 1."
219228213|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
219228214|NCT05133700|OTHER|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
219228215|NCT05133700|OTHER|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
219228216|NCT01458015|DRUG|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
219228217|NCT05972837|DEVICE|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
219228218|NCT05972837|OTHER|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
219228219|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
219228220|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
219228221|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
219360728|NCT00667576|DRUG|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
219716397|NCT07043322|PROCEDURE|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
219136324|NCT02388139|PROCEDURE|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
219136325|NCT02388139|PROCEDURE|coronarography|
219136326|NCT02388139|PROCEDURE|coronary angioplasty|
219136327|NCT02388139|PROCEDURE|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
219136328|NCT02388139|PROCEDURE|body composition monitoring|using Fresenius device
219136329|NCT02888535|OTHER|Internal Medicine consultation|
219136330|NCT04057196|BEHAVIORAL|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
219136331|NCT02555449|DRUG|[¹⁴C]-LY3202626|Administered as solution by mouth
219136332|NCT02466516|DRUG|SEL|SEL tablet administered orally once daily
219136333|NCT02466516|BIOLOGICAL|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
219136334|NCT02986906|DRUG|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
219136335|NCT02986906|DRUG|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
219136336|NCT02986906|DEVICE|Ultrasound|The ultrasound was used for injection guidance
219136337|NCT03573999|DRUG|Mannitol|4.6 ml/kg will be administered before dura opening
219136338|NCT03573999|DRUG|NaCl 7.5%|2 ml/kg will be administered before dura opening
219228222|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
219228223|NCT01818063|DRUG|Paclitaxel|Given IV
219716398|NCT07043322|DRUG|Cabergoline|Cabergoline is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems, fertility problems in men and women, and pituitary prolactinomas
219228224|NCT01818063|DRUG|Carboplatin|Given IV
219228225|NCT01818063|DRUG|Doxorubicin|Given IV
219228226|NCT01818063|DRUG|Cyclophosphamide|Given IV
219716399|NCT06382480|OTHER|Diet with specific macronutrient composition.|The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.
219716400|NCT07038915|DRUG|Tiragolumab|Given by IV
219716401|NCT07038915|DRUG|Ivonescimab|Given by IV
219228227|NCT01818063|DRUG|Veliparib|Given PO
219228228|NCT04353778|DRUG|Pyridostigmine|Eight weeks of low-dose pyridostigmine
219716402|NCT06727253|DIETARY_SUPPLEMENT|Glycan|The post-operative CD patients will receive an orally administered glycan.
219716403|NCT03084757|DIAGNOSTIC_TEST|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
219716404|NCT06883695|DRUG|SHR-3045 Injection|SHR-3045 injection.
219716405|NCT06883695|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
219136339|NCT01332058|BEHAVIORAL|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
219136340|NCT01414231|DRUG|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
219136341|NCT02178020|DEVICE|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
219136342|NCT02178020|DEVICE|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
219136343|NCT05396976|BEHAVIORAL|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
219136344|NCT02452294|DRUG|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
219136345|NCT00695006|OTHER|Sham Traction|Traction \<5lbs
219136346|NCT00695006|OTHER|Traction|Standard supine intermittent traction
219136347|NCT03018119|OTHER|Survey|
219136348|NCT04490252|DIETARY_SUPPLEMENT|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
219136349|NCT04870060|DRUG|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
219136350|NCT03147456|DIETARY_SUPPLEMENT|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
219136351|NCT03147456|DIETARY_SUPPLEMENT|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
219228229|NCT04353778|DRUG|Placebos|matching placebo x 8 weeks
219228230|NCT04353778|PROCEDURE|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
219228231|NCT03411421|DRUG|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
219228232|NCT03411421|DRUG|Placebo|Matching placebo tablets will be administered.
219716406|NCT06729463|DRUG|Humira|Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy
219716407|NCT07050433|DIAGNOSTIC_TEST|CXCR2 as a biomarker|CXCR2 biomarker expression will be measured in tumor and immune cell samples
219716408|NCT07044440|OTHER|digital outpatient follow-up|In addition to routine outpatient follow-up visits on day 14 and 28 post-operative, digital follow-up by questionnaire on their health status and general well-being are provided. Possibility to request an interaction with a doctor from our department at any time during the 28 days following discharge
219716409|NCT07044440|OTHER|standard follow-up|routine outpatient follow-up visits on day 14 and 28 post-operative
219716410|NCT06734364|DEVICE|buddy tape|Buddy-taping a finger dynamically splints one finger to an adjacent, uninjured finger.
219136352|NCT02959957|DRUG|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
219136353|NCT02959957|DRUG|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
219136354|NCT02108743|DRUG|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
219136355|NCT02108743|DRUG|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
219136356|NCT02457702|OTHER|Orally administered labeled glycerol|Oral administration of labeled glycerol
219136357|NCT01331824|DRUG|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
219136358|NCT05318885|OTHER|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
219136359|NCT00646451|DRUG|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
219136360|NCT00646451|DRUG|placebo|up to 4 capsules bid as tolerated
219136361|NCT03353467|PROCEDURE|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
219136362|NCT03353467|RADIATION|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
219228233|NCT02589106|DEVICE|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
219228234|NCT05509569|DRUG|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
219136363|NCT05904535|OTHER|Cerbrospinal fluid sampling.|Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
219716411|NCT06734364|DEVICE|splint|Short arm splint immobilize and maintain stability of the injured finger, the hand is immobilized in the intrinsic plus position with syndactyly of the injured finger and adjacent finger
219716412|NCT06736405|OTHER|Pericapsular nerve group block|Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain
219136364|NCT05003570|DRUG|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
219228235|NCT06463860|DEVICE|DermDx|DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
219228236|NCT04180904|OTHER|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
219228237|NCT04180904|OTHER|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
219716413|NCT06736405|OTHER|No Pericapsular nerve group block|Patients will be given standard treatment to prevent postoperative pain
219716414|NCT01688492|DRUG|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
219716415|NCT07049341|DEVICE|MemorEM|The MemorEM device delivers 915MHz electromagnetic waves to the head via 8 emitters in a cap worn on the head and powered by a control box and battery worn on the arm.
219716416|NCT02769273|DEVICE|Percutaneous Transluminal Angioplasty|
219716417|NCT02790515|DRUG|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
219136365|NCT05003570|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
219716418|NCT02790515|DRUG|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
219716419|NCT02790515|DRUG|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
219716420|NCT02790515|DRUG|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
219716421|NCT02790515|DRUG|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
219716422|NCT02790515|DRUG|Melphalan|Given IV prior to transplant on Days -2 and -1.
219716423|NCT02790515|DRUG|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
219716424|NCT02790515|DRUG|Rituximab|Given IV prior to transplant on Day -1.
219716425|NCT02790515|DRUG|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
219716426|NCT02790515|DRUG|Thiotepa|Given IV prior to transplant on Day -3.
219716427|NCT02790515|BIOLOGICAL|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
219136366|NCT00005113|DRUG|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
219136367|NCT00005113|DRUG|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
219716428|NCT02790515|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219136368|NCT00005113|DRUG|Tacrolimus|dosage is in oral form titrated to target trough level
219136369|NCT05999864|OTHER|Rehabilitation|Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
219136370|NCT01304849|DRUG|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
219228238|NCT05230784|OTHER|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
219716429|NCT02790515|DRUG|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
219716430|NCT05934838|DRUG|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
219716431|NCT06732154|DRUG|HRS-5632|HRS-5632 Injection
219716432|NCT06732154|DRUG|Placebo|Sodium chloride injection
219716433|NCT06886464|DRUG|Cilastatin Sodium|Intravenous cilastatin reconstituted in normal saline solution
219716434|NCT06886464|DRUG|Placebo-Saline|Identical looking normal saline solution
219716435|NCT07048496|OTHER|BCG delivery at home|The BCG at home project will be a single-arm prospective pilot, to evaluate the feasibility, scalability and effectiveness of home treatment, and utilize the BB-Bot (chatbot) for PRO and adverse event measurement.
219716436|NCT06892340|DEVICE|Transcutaneous Auricular Neurostimulation device|The Sparrow Ascent device will be programmed to the preset stimulation parameters. Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region 1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set to 250 #s for all participants. The stimulation intensities (mA) will be set to 1.0 and 1.4 (for Region 1 and 2, respectively) based on the median values observed in the previous data set. If the participant states that the stimulation intensity is discomforting, the research coordinator will gradually decrease/increase until a comfortable stimulation intensity is achieved
219716437|NCT06892184|BEHAVIORAL|hypnotic communication|During local anaesthesia, the operator will not remain silent, nor will he describe to his patient the anaesthesia he is performing, nor warn his patient of possible future pain. When performing anesthesia, the operator will use a dissociative, hypnotic language, standardized across all patients.
219228239|NCT05230784|OTHER|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
219228240|NCT06021457|DRUG|RBT-1|Intravenous administration
219228241|NCT06021457|DRUG|Placebo|Intravenous administration
219716438|NCT06892184|BEHAVIORAL|conventional communication|suggestions typically uttered by the practitioner, who describes what he is doing and warns of possible pain.
219228242|NCT00768716|DRUG|Acetaminophen|2 x 500 mg by mouth once
219228243|NCT04560049|DRUG|Silver Nitrate|application of silver nitrate to sinus tract
219716439|NCT07044414|DEVICE|Manual Acupuncture|Manual acupuncture is administered at bilateral ST36 Zusanli, SP6 Sanyinjiao, and midline points CV4 Guanyuan and CV6 Qihai using sterile, single-use 0.25 × 25 mm acupuncture needles. The insertion depth follows standard clinical practice and safety guidelines, with twirling stimulation performed at minutes 0 and 10. Each session lasts approximately 20 minutes and is conducted three times per week for a total of 21 sessions. Participants continue to receive their standard chemoradiotherapy for head and neck cancer.
219716440|NCT07044414|DEVICE|Sham Manual Acupuncture|Sham Manual acupuncture uses Park sham needles with telescopic tips that do not penetrate the skin, applied at the same acupoints (ST36, SP6, CV4, CV6) with identical procedure and appearance to mimic real acupuncture. Adhesive bases are used to fix the sham needles. Stimulation is mimicked at minutes 0 and 10. Sessions last the same duration and frequency as the intervention group. Participants also continue their standard chemoradiotherapy.
219716441|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment|Traditional exposure therapy (ET) includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), and (d) relapse prevention strategies and further treatment planning (session 10).
219716442|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment with addition of Augmented Reality (AR) Component|Traditional exposure therapy (ET) with addition of Augmented Reality component includes the following: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), (d) relapse prevention strategies and further treatment planning (session 10), and (e) 30 minutes of each 90 minute session dedicated to augmented reality exposure therapy (ARET). During ARET, the clinician guides participant, who is wearing augmented reality (AR) goggles, through preset scenarios during which characters mingle with each other (e.g., grocery store, social gathering), as well as custom scenarios where participant can interact with the character.
219716443|NCT06670534|DRUG|JMKX003142 tablets|JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.
219551331|NCT01518335|PROCEDURE|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
219551332|NCT01518335|PROCEDURE|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
219551333|NCT00428818|DRUG|trimethoprim-sulfamethoxazole or doxycycline|
219551334|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 3 weeks|3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
219551335|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 4.5 weeks|4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
219551336|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 6 weeks|6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
219716444|NCT06670534|DRUG|Torasemide tablets|Torasemide tablets for active comparator group.Take the torasemide tablets once daily for seven days.
219136371|NCT05911256|BEHAVIORAL|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
219136372|NCT05911256|DEVICE|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
219136373|NCT05911256|BEHAVIORAL|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
219551337|NCT04364854|OTHER|No Therapy 6 Weeks|Participants will not be getting any SET for 6 weeks
219136374|NCT00253240|PROCEDURE|Screening|
219136375|NCT00253240|PROCEDURE|Management|
219136376|NCT03778593|DRUG|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
219136377|NCT03778593|DRUG|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
219551338|NCT01422928|PROCEDURE|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
219136378|NCT03778593|DRUG|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
219716445|NCT06739447|OTHER|Consumer Wearable Device Vital Sign Measurement|Consumer Wearable Devices such as the Fitbit, are durable devices that can provide vital sign data.
219716446|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
219716447|NCT05666245|BEHAVIORAL|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
219716448|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
219716449|NCT05666245|BEHAVIORAL|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
219716450|NCT07051668|OTHER|Pediatric Sepsis Diagnostic Toolkit|The toolkit consists of the following items: 1) a recommendation to request and report vital signs in all pediatric hospital/ED transfers, 2) dissemination of evidence based pediatric sepsis diagnostic criteria to accepting and referring providers and transfer nurses, and 3) accepting physician education in conversational strategies to promote improved diagnostic accuracy during pediatric transfer conversations.
219716451|NCT02996773|DRUG|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
219716452|NCT02996773|DRUG|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
219716453|NCT04042844|BIOLOGICAL|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
219716454|NCT04042844|DRUG|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
219136379|NCT03778593|DRUG|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
219136380|NCT03778593|DRUG|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
219136381|NCT01921543|DEVICE|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
219136382|NCT01921543|DEVICE|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
219136383|NCT01921543|DEVICE|No stimulation|
219136384|NCT04687553|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
219136385|NCT03720990|DRUG|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
219136386|NCT03838796|DRUG|lenvatinib|for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
219136387|NCT03838796|PROCEDURE|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
219136388|NCT02721225|DIETARY_SUPPLEMENT|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
219136389|NCT02721225|DIETARY_SUPPLEMENT|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
219136390|NCT02540551|PROCEDURE|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
219136391|NCT05280964|BEHAVIORAL|Better Together Physician Coaching|6 month, online group coaching program
219136392|NCT00462410|OTHER|counseling intervention|
219136393|NCT00462410|PROCEDURE|psychosocial assessment and care|
219136394|NCT01249092|DRUG|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
219716455|NCT07054281|DEVICE|UNITY Vitreoretinal Cataract System (VCS)|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. In this study, the UNITY VCS posterior segment functionalities will be used to perform posterior segment (i.e., vitreoretinal) ophthalmic surgery.
219716456|NCT07054281|DEVICE|CONSTELLATION Vision System|CONSTELLATION is a commercially approved, multifunctional surgical instrument used during ophthalmic surgery to cut vitreous and tissues, emulsify the lens, illuminate the posterior segment of the eye, and apply diathermy to stop bleeding.
219716457|NCT07054281|PROCEDURE|Vitreoretinal ophthalmic surgery|Ophthalmic surgery performed in the posterior segment of the eye
219716458|NCT07055113|BEHAVIORAL|Individual-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes one-on-one visits with a physiotherapist.~Multi-modal Self-management program comprises:~* Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~* Personalized Goal Setting in partnership with therapist to promote patient activation.~* Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~* Physical activity goals using FitBit step count, to increase daily activity as tolerated."
219716459|NCT07055113|BEHAVIORAL|Group-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes group classes (4-5 participants) with two physiotherapists. In each session, each participant will also have a 10-12 min one-on-one interaction with one of the physiotherapists.~Multi-modal Self-management program comprises:~Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~Personalized Goal Setting in partnership with therapist to promote patient activation.~Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~Physical activity goals using FitBit step count, to increase daily activity as tolerated."
219136395|NCT00751491|DRUG|Adenosin|Intracoronary Adenosin 50 microg;
219551339|NCT05389670|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
219551340|NCT05389670|DEVICE|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
219551341|NCT03993535|DRUG|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
219551342|NCT05565690|DEVICE|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
219551343|NCT01472432|DRUG|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
219551344|NCT01472432|DRUG|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
219551345|NCT04168307|DEVICE|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
219136396|NCT00751491|OTHER|placebo|no intervention
219136397|NCT00751491|DRUG|Clopidogrel|Clopidogrel 300/600 mg
219136398|NCT00449813|DRUG|Pantoprazole|40 mg Pantoprazole
219136399|NCT04621682|OTHER|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
219551346|NCT04168307|OTHER|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
219136400|NCT04621682|OTHER|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
219136401|NCT02824939|OTHER|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
219136402|NCT02824939|OTHER|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
219136403|NCT00424216|PROCEDURE|DC Polarization|
219136404|NCT06438406|DEVICE|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
219136405|NCT06438406|DEVICE|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
219136406|NCT03980964|DEVICE|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
219228244|NCT04560049|DRUG|Phenol|phenolisation of sinus tract
219228245|NCT06237465|DRUG|Normal saline|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
219716460|NCT06896201|DIAGNOSTIC_TEST|Neuropsychological Assessments and Other Questionnaires|A brief assessment of the cognitive status will be performed by the means of Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR-SB), Activities of the Daily Living (ADL) and Instrumental Activities of the Daily Living (IADL) scales. Moreover, extended neuropsychological assessments assessing memory, language, executive functions, attention and visuospatial perception will be conducted by trained neuropsychologists, as per clinical practice. Concerning depression and behavioural / neuropsychiatric symptoms, which are known to be relevant in cognitive decline and ageing, data will be collected by the means of Neuropsychiatric Inventory (NPI). Additional questionnaires about subjective cognitive decline, quality of sleep (Pittsburgh scale) and cognitive reserve (CRIq) will be conducted on some subgroups of subjects.
219716461|NCT06896201|BIOLOGICAL|Blood Exams, Fluid Biomarkers, Genetics|All patients will undergo a blood samples collection at T0 and T4, as per clinical practice. Additional blood samples will be collected stored and processed according to literature recommendation-based standardized operating procedures.. Blood will be collected into EDTA tubes and will be immediately refrigerated and centrifugated at 2000x g for 10 minutes. Plasma will then be aliquoted in 0.5 ml polypropylene vials and frozen at -80°C. Levels of blood biomarkers of amyloidopathy, tauopathy, neurodegeneration and neuroinflammation will be measured using the Lumipulse G assays (Fujirebio) and the Multiplex assays for Ella (Biotechne). Whole blood samples will be used for genetic analysis, which will include the determination of APOE genotype
219716462|NCT06896201|OTHER|Connectivity Analysis|"Functional Magnetic Resonance Imaging (fMRI) and/or high-density electroencephalography (EEG) will be used to assess connectivity in selected group of subjects. EEG data will be collected during four 5-minute runs of alternating eyes-open and eyes-closed conditions using a 128-electrode high-density EEG system.~The EEG spectral coherence analysis will evaluate the functional coupling between the brain areas under study. Brain connectivity measures will be computed for each frequency band and for each subject, to be used as measure of weight of the graph in a graph analyses.~A subsample of subjects will be also investigated with connectivity measures of MRI by applying FA e DTI technique. All the data will be collected both at baseline and after a 2-years-period during which the prevention and intervention strategies will be performed."
219716463|NCT06896201|DEVICE|Physical Activity|Participants will be proposed an unsupervised, monitored exercise program consisting of three 60-minute sessions of moderate-intensity aerobic exercise (40%-85% of their maximum heart rate) each week. To track exercise intensity. The activity will be personalized according to specific attitude of each subjects including walking session, bike sessions or swim sessions. The type, frequency and intensity of the activity will be recorded by means of a commercially available wearables (Garmin Vivosmart 4, Garmin Vivosmart 5) and the Healthentia application. Those non using the wearables will keep a diary of the activity. Study investigators will ensure both protocol adherence and participant safety through regular follow-up telephone contacts.
219136407|NCT05864482|OTHER|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
219136408|NCT03669562|DRUG|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
219136409|NCT03669562|DRUG|Placebo|intravenous infusion liposome control
219136410|NCT05963308|BEHAVIORAL|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
219136411|NCT00796068|DRUG|Cyclosporine|Given IV or PO
219136412|NCT00796068|DRUG|Fludarabine Phosphate|Given IV
219136413|NCT00796068|OTHER|Laboratory Biomarker Analysis|Correlative studies
219136414|NCT00796068|DRUG|Mycophenolate Mofetil|Given IV
219136415|NCT00796068|RADIATION|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
219136416|NCT00796068|DRUG|Treosulfan|Given IV
219136417|NCT00796068|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
219136418|NCT03357341|DEVICE|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
219136419|NCT03357341|DEVICE|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
219136420|NCT03357341|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
219136421|NCT03357341|DEVICE|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
219228246|NCT06237465|DRUG|Botulinum toxin type A|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
219228247|NCT03753256|DEVICE|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
219716464|NCT06896201|DEVICE|Healthentia|Healthentia, developed by Innovation Sprint, is a Software as a Medical Device (SaMD) designed for remote patient monitoring, virtual coaching, and automatic alerts using real-world data. It has been successfully used in over 20 studies and integrates features like teleconsultations, activity tracking, medication management, and support for wearable devices. It provides a patient companion app, offering remote patient monitoring and self-reporting, personalized advice or content in the form of dialogues. It is designed to optimize and improve patient engagement and ensure data integrity. The software facilitates daily self-reporting, providing information to patients and collecting other current data through self-reported questionnaires (health status, physical activity, quality of life, etc.), which will be crucial in order to control the adherence of patients to the program
219228248|NCT03753256|DEVICE|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
219228249|NCT03753256|DEVICE|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
219136422|NCT03357341|OTHER|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
219136423|NCT03357341|OTHER|CAT|Subjects will be required to complete CAT monthly.
219136424|NCT03357341|OTHER|ACT|Subjects will be required to complete ACT monthly.
219136425|NCT00010946|PROCEDURE|Acupuncture|
219136426|NCT03709628|DRUG|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
219136427|NCT05737238|BEHAVIORAL|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
219136428|NCT06076434|OTHER|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
219228250|NCT03753256|DEVICE|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
219228251|NCT01267188|DRUG|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
219228252|NCT06720272|OTHER|School nurse program|The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
219228253|NCT06359574|OTHER|Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training|The Core Competency Model (CCM; Cramer et al., 2013, 2019) is an evidence-based educational training program for BHCs in suicide prevention core suicide prevention skills. The ten core competencies are: (1) Manage personal attitudes and reactions to suicide; (2) Maintain a collaborative stance toward the client; (3) Elicit evidence-based risk and protective factors; (4) Focus on current suicide plan and intent of suicidal ideation; (5) Determine risk level; (6) Enact a collaborative evidence-based treatment plan; (7) Notify and involve other persons; (8) Document risk, plan, and reasoning for clinical decisions; (9) Know the law concerning suicide, and; (10) Engage in debriefing and self-care. The CCM will be adapted for this pilot trial. In light of the SDV problem in carceral settings, the CCM for Corrections (CCM-C; Cramer, Kaniuka, \& Peiper, 2022) was adapted to address both suicide and self-injury assessment, treatment, and prevention.
219228254|NCT05586178|BEHAVIORAL|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
219136429|NCT00878618|DRUG|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
219136430|NCT00878618|DRUG|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
219136431|NCT01060137|DRUG|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
219136432|NCT05896319|DEVICE|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
219136433|NCT02932709|BEHAVIORAL|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
219136434|NCT05193188|DRUG|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
219136435|NCT05193188|DRUG|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
219136436|NCT02882048|PROCEDURE|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
219136437|NCT02882048|OTHER|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
219136438|NCT02410538|OTHER|"list of FAQ"|
219136439|NCT04765163|DEVICE|Intelligent Operating Handle|Intelligent Operating Handle
219136440|NCT06202599|DRUG|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
219136441|NCT02925000|DRUG|TLC178|TLC178
219136442|NCT03360552|OTHER|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
219136443|NCT03360552|OTHER|Usual care|Usual clinical evaluation
219136444|NCT01284907|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
219136445|NCT01284907|DIETARY_SUPPLEMENT|Placebo Drops|
219136446|NCT04538755|DRUG|Placebo oral capsule|Placebo before sleep
219136447|NCT04538755|DRUG|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
219228255|NCT05586178|BEHAVIORAL|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
219136448|NCT05672446|OTHER|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
219136449|NCT04674332|DRUG|Long acting insulin|long acting insulin analogue once daily at bed time
219136450|NCT04674332|DRUG|multiple dose regimen|intermediate and short acting insulin
219136451|NCT00887835|DEVICE|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
219136452|NCT01771666|DEVICE|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
219136453|NCT01771666|DRUG|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
219136454|NCT01771666|DRUG|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
219136455|NCT01771666|DRUG|99technetium-sulfur colloid radiolabel|
219136456|NCT01130467|DRUG|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
219228256|NCT05586178|BEHAVIORAL|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
219228257|NCT05586178|BEHAVIORAL|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
219551347|NCT06283888|DRUG|CYP2C19 Genotype Guided DAPT|Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
219551348|NCT06283888|DRUG|Conventional DAPT|Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
219551349|NCT01634685|RADIATION|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
219551350|NCT01634685|DRUG|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
219551351|NCT01634685|DRUG|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
219551352|NCT04837456|DIETARY_SUPPLEMENT|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
219136457|NCT01130467|DRUG|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
219136458|NCT01130467|BEHAVIORAL|behavioral modification|Parenting and teaching skill education
219136459|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
219136460|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
219228258|NCT05586178|BEHAVIORAL|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
219228259|NCT05460910|OTHER|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
219228260|NCT05460910|OTHER|core stability exercise without treadmill|technique used to improve stability
219228261|NCT04596488|DRUG|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
219228262|NCT05750719|GENETIC|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
219228263|NCT05277454|DRUG|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
219136461|NCT04517331|PROCEDURE|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
219136462|NCT04517331|PROCEDURE|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
219136463|NCT02047461|DRUG|ORGN001 (formerly ALXN1101)|IV infusion
219136464|NCT04735939|RADIATION|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
219228264|NCT04304378|BEHAVIORAL|Stabilization Techniques (ST)|The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
219136465|NCT00092560|DRUG|MK0653, ezetimibe|
219136466|NCT00092560|DRUG|Comparator: fenofibrate monotherapy|
219136467|NCT00000251|DRUG|30% N2O|
219136468|NCT00000251|DRUG|0.2% isoflurane|
219360729|NCT00667576|DRUG|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
219360730|NCT01151683|DIETARY_SUPPLEMENT|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
219360731|NCT01151683|DIETARY_SUPPLEMENT|placebo|Two capsules of placebo per oral twice a day
219360732|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
219360733|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
219360734|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
219360735|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
219360736|NCT01390389|DRUG|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
219360737|NCT03179085|BEHAVIORAL|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
219360738|NCT04110041|BEHAVIORAL|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
219360739|NCT02002975|DRUG|Pioglitazone|Pioglitazone tablets
219360740|NCT06108362|DRUG|Terlipressin|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
219360741|NCT06108362|DRUG|normal saline|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
219360742|NCT01350856|DRUG|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
219360743|NCT01350856|DRUG|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
219360744|NCT06036589|DRUG|CA and BAM8-22|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
219716465|NCT06896201|DEVICE|Eligence|Based Platform exercising the brain and the cognitive skills through 35+ games and activities designed by specialized health experts. It offers over 30 games focusing on cognitive skills such as memory, reasoning, attention, orientation, executive functions, construction skills, and language. It allows healthcare professionals to create personalized training sessions, monitor performance in real-time, and generate detailed evaluation reports. Accessible from any device, it is aimed at individuals in early stages of dementia or rehabilitation phases. In our clinical study, subjects will be trained on seven cognitive programs, which can be executed at home with or without assistance and supervision of a Health Professional (who can easily create personalized sessions to follow-up at distance) and/or an informal carer
219716466|NCT06896201|OTHER|Nutrition|Participants will follow a personalized nutrition plan, as per clinical practice, receiving dietary advice derived by the same scheme already used in the FINGER project on prevention. The plan focuses on balanced, nutrient-rich meals, based on the reduction of carbohydrate assumption and stable inclusion of seeds, vegetables, fish and omega 3 aliments in the diet that may protect the brain through anti-inflammatory and antioxidant properties. A diary of the meals will be recorded in a diary included in the Healthentia application. No integrated meals or nutraceutical product will be used.
219716467|NCT04251416|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
219136469|NCT00000251|DRUG|0.4% isoflurane|
219136470|NCT00000251|OTHER|100% oxygen|Placebo
219136471|NCT05566405|PROCEDURE|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
219136472|NCT05566405|PROCEDURE|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
219716468|NCT06739655|RADIATION|Preoperative radiotherapy|"In this study the patients assigned to the experimental treatment arm will receive preoperative radiotherapy instead of postoperative radiotherapy.~This preoperative radiotherapy will follow the standard of care (SoC) principles as they are defined for postoperative radiotherapy in breast cancer, as defined by international guidelines."
219716469|NCT06739655|RADIATION|Postoperative radiotherapy|Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
219136473|NCT05566405|PROCEDURE|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
219136474|NCT02860260|BIOLOGICAL|Blood samples|
219136475|NCT02860260|OTHER|Cerebral MRI|
219136476|NCT01049620|DRUG|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
219136477|NCT06501079|PROCEDURE|ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%|"ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively."
219360745|NCT06036589|DRUG|Vehicle and BAM8-22 application|Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
219360746|NCT06036589|DRUG|CA|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
219360747|NCT06036589|DRUG|vehicle|Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
219716470|NCT06739655|PROCEDURE|Immediate breast reconstruction|In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
219716471|NCT06739655|PROCEDURE|Immediate or delayed breast reconstruction|In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
219716472|NCT03157635|DRUG|Crovalimab|Crovalimab will be administered as per schedule described in individual arm.
219136478|NCT01813903|BEHAVIORAL|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
219228265|NCT04304378|BEHAVIORAL|Stabilization Techniques with Behavioral Activation (ST+BA)|The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
219228266|NCT04304378|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
219228267|NCT01372475|DEVICE|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
219228268|NCT01372475|PROCEDURE|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
219716473|NCT03157635|DRUG|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
219716474|NCT07056400|PROCEDURE|First Ejaculate for ICSI|Intervention 1: First Ejaculate for ICSI In this intervention, sperm collected from the first ejaculate will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used in fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the first ejaculate
219716475|NCT07056400|PROCEDURE|Second Ejaculate for ICSI|In this intervention, sperm collected from the second ejaculate (obtained within 1-2 hours after the first ejaculate) will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used for fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the second ejaculate and its impact on fertilization rates and embryo development
219716476|NCT07057115|PROCEDURE|vNOTES Salpingectomy Group.|Participants will undergo salpingectomy using the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique. This minimally invasive procedure is performed transvaginally without abdominal incisions, offering potential benefits such as less postoperative pain, faster recovery, and better cosmetic outcomes.
219716477|NCT07057115|PROCEDURE|Laparoscopic Salpingectomy|Participants will undergo conventional laparoscopic salpingectomy, a minimally invasive surgical technique performed through small abdominal incisions using a laparoscope. This method is the current standard approach for managing ectopic pregnancies.
219716478|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
219716479|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
219716480|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
219716481|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219716482|NCT06786533|DRUG|Anti-FLT3 CAR-T cells|Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
219228269|NCT00949117|DIETARY_SUPPLEMENT|Ensure|Given orally
219228270|NCT00949117|DIETARY_SUPPLEMENT|PediaSure|Given orally
219228271|NCT00949117|DRUG|cyproheptadine hydrochloride|Given orally
219716483|NCT04404283|DRUG|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
219716484|NCT04404283|DRUG|Rituximab|375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
219228272|NCT05867992|OTHER|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
219228273|NCT03926806|OTHER|Plain yoghurt|cups of 200 g yoghurt
219228274|NCT03926806|OTHER|Vitamin B yoghurt|cups of 200 g yoghurt
219716485|NCT04404283|DRUG|Lenalidomide|20 mg given by mouth (orally) daily
219716486|NCT04404283|OTHER|Placebo|Administered via intravenous infusion every 3 weeks
219716487|NCT05979935|DIAGNOSTIC_TEST|tongue diagnosis|The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.
219716488|NCT01786265|DRUG|Abiraterone Acetate|Given PO
219716489|NCT01786265|DRUG|Bicalutamide|Given PO
219716490|NCT01786265|DRUG|Degarelix|Given via injection
219716491|NCT01786265|DRUG|Flutamide|Given PO
219716492|NCT01786265|DRUG|Goserelin Acetate|Given via injection
219716493|NCT01786265|DRUG|Leuprolide Acetate|Given via injection
219716494|NCT01786265|DRUG|Nilutamide|Given PO
219716495|NCT01786265|DRUG|Prednisone|
219716496|NCT06213831|DRUG|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
219136479|NCT01813903|BEHAVIORAL|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
219716497|NCT03324646|DRUG|[11C]PS13|A novel PET ligand to selectively image COX-1
219716498|NCT07061340|BEHAVIORAL|Therapeutic Touch|no Therapeutic Touch
219716499|NCT07057089|DRUG|Capecitabine|Capecitabine: 825mg/m2, bid;
219716500|NCT07057089|DRUG|Camrelizumab|Camrelizumab: 200mg
219716501|NCT07057089|DRUG|CAPOX|CAPOX
219716502|NCT07057089|RADIATION|Involve-field irradiation|Involve-field irradiation: Primary rectal tumor + metastatic or suspicious pelvic lymph nodes, mesorectal region, and presacral region
219716503|NCT07057089|RADIATION|Elective nodal irradiation|Elective nodal irradiation: Large pelvic field
219716504|NCT07057089|PROCEDURE|TME surgery|TME surgery
219716505|NCT01838538|DRUG|Bevacizumab|
219716506|NCT01838538|DRUG|TC:paclitaxel + carboplatin|
219716507|NCT06757205|DIAGNOSTIC_TEST|Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions. The Italian version of the Mentalization Questionnaire (MZQ) was develop|"Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions.~* The Italian version of the Mentalization Questionnaire (MZQ) was developed as a self-rated instrument to assess mentalization. It consists of 15 items with responses ranging from 1 = 'no agreement at all' to 5 = 'total agreement' on a 5-point Likert scale. Calculated sum scores for the total scale range from 15 to 75 with higher scores indicating lower mentalization capacities.~* The Toronto Alexithymia Scale (TAS) is a measure of deficiency in understanding, processing, or describing emotions (alexithymia). It has twenty statements rated on a five-point Likert scale. The total score ranges from 40 to 200 and the higher score indicates a greater level of alexithymia."
219716508|NCT05387642|DRUG|10 mg PRAX-114, 20 mg PRAX-114, and Placebo|Single dose with a washout period between doses
219716509|NCT05387642|DRUG|10 mg PRAX-114 or 20 mg PRAX-114|Once daily oral treatment for 28 days
219716510|NCT07053787|BEHAVIORAL|Standard Yoga|Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos.
219716511|NCT07053787|BEHAVIORAL|Enhanced Yoga|"Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos ...~plus six weekly 50-minute 1-on-1 coaching sessions starting week 10 of the standard yoga intervention and ending week 15 (3 wks after end of standard yoga). During this transition, participants are supported with development and execution of their plan for continuing their yoga practice. Participants will be offered 1 additional ad-hoc coaching session to help them re-start yoga if they get off track and/or experience major life events such as moving, job change, medical issues, etc."
219716512|NCT06603779|DEVICE|Ultasound Therapy|a device that transmit ultrasound waves to the participant through direct contact
219716513|NCT06603779|OTHER|Integrated Neuromuscular technique|Integrated Neuromuscular technique is a kind of Manual therapy which include Ischemic Compression, Strain counter-strain and muscle energy technique
219716514|NCT06603779|OTHER|Cervical and Scapular Stabilization exercises|Cervical and Scapular Stabilization exercises are a group of therapeutic exercises.
219136480|NCT03942822|DIETARY_SUPPLEMENT|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
219136481|NCT03646331|DRUG|Imeglimin Reference product|Reference product
219228275|NCT04024982|OTHER|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
219136482|NCT03646331|DRUG|Imeglimin|Test product (new formulation tablet)
219136483|NCT05674370|DEVICE|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
219136484|NCT05674370|DIAGNOSTIC_TEST|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
219136485|NCT01710514|DRUG|FE 999913 vaginal tablet|
219228276|NCT04024982|OTHER|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
219136486|NCT05166174|PROCEDURE|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
219228277|NCT02393976|DIETARY_SUPPLEMENT|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
219716515|NCT06864832|OTHER|Mirror image postural exercises|Patients will recieve mirror image postural exercise on the 3D postural analysis
219716516|NCT06864832|OTHER|Back exercises|Exercises in the form of back muscles stretching exercises and abdominal muscles strengthening exercises.
219716517|NCT06842017|DEVICE|Passive Exoskeleton.|The passive exoskeleton is used to assist patients with shoulder musculoskeletal disorders during the performance of activities of daily living (ADLs), such as overhead reaching and lifting. The device helps reduce biomechanical load and muscle strain, providing support for the shoulder joint.
219716518|NCT06842017|PROCEDURE|Shoulder Rehabilitation with Passive Exoskeleton.|The rehabilitation protocol involves the use of a passive exoskeleton during physical tasks to improve shoulder function and reduce pain. Patients perform specific exercises while wearing the exoskeleton, which is tailored to their individual needs.
219136487|NCT03634189|DRUG|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
219136488|NCT02393898|DRUG|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
219136489|NCT02393898|DRUG|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
219136490|NCT02393898|DRUG|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
219136491|NCT02846415|BEHAVIORAL|Play Intervention for Dementia|"1. 8 weekly session, 45-75 minutes each~2. Play with toys~3. Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
219136492|NCT02265731|DRUG|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
219136493|NCT02265731|DRUG|venetoclax|Step-up doses of venetoclax to the designated cohort dose
219136494|NCT02265731|DRUG|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
219136495|NCT02265731|DRUG|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
219228278|NCT02393976|DIETARY_SUPPLEMENT|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
219228279|NCT00749827|DRUG|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
219228280|NCT00749827|DRUG|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
219716519|NCT06842017|OTHER|Usability Assessment and Patient Satisfaction.|The usability of the passive exoskeleton is evaluated using validated scales, such as the System Usability Scale (SUS), to assess its comfort, effectiveness, and overall satisfaction. The assessment also includes patient feedback on the ease of use and perceived benefits of the device during rehabilitation sessions.
219716520|NCT06551402|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
219716521|NCT06551402|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
219716522|NCT06740760|BEHAVIORAL|Genetic counselling|Behavioral: genetic counselling
219716523|NCT06740760|BEHAVIORAL|Leaflet|Genetic information as a form of a leaflet
219716524|NCT06767059|OTHER|Walking Group|Patients will be asked to walk for 30 minutes at least 3 times for 8 weeks. In order to ensure regular follow-up, patients will be asked to write on the walking tracking form when they walk and the number of steps before they start walking and the number of steps after walking using the application.
219136496|NCT05933720|DRUG|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
219136497|NCT05933720|DEVICE|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
219136498|NCT05933720|OTHER|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
219136499|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
219136500|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
219136501|NCT02934958|BEHAVIORAL|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
219136502|NCT02934958|BEHAVIORAL|Standard of Care|Patients will be tracked to compare how effective are usual care methods
219136503|NCT05230875|BEHAVIORAL|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
219136504|NCT03383887|DRUG|Placebo oral capsule|Placebo before sleep
219136505|NCT03383887|DRUG|DAW1033D oral capsule|DAW1033D before sleep
219136506|NCT06554132|OTHER|Scleroderma Group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
219136507|NCT06554132|OTHER|Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
219136508|NCT02837380|DRUG|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
219136509|NCT02837380|DRUG|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
219716525|NCT06767059|OTHER|Grounding Group|Patients will be asked to walk with a grounding stick for 30 minutes at least 3 times for 8 weeks. Patients will be asked to fill in the walking follow-up form and grounding follow-up form for regular follow-up.
219716526|NCT04628624|DIETARY_SUPPLEMENT|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
219716527|NCT04628624|DIETARY_SUPPLEMENT|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
219136510|NCT04991259|PROCEDURE|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
219136511|NCT04991259|OTHER|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
219136512|NCT03742713|DRUG|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
219716528|NCT04628624|DIETARY_SUPPLEMENT|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
219136513|NCT02703129|OTHER|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
219136514|NCT00742573|DRUG|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
219136515|NCT00742573|BEHAVIORAL|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
219136516|NCT00647205|DEVICE|QuantiFERON TB Gold In-Tube|
219136517|NCT00647205|DEVICE|T-SPOT.TB®|
219136518|NCT02509390|PROCEDURE|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
219136519|NCT00697229|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 or 3 doses
219136520|NCT00697229|BIOLOGICAL|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
219136521|NCT03775447|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
219136522|NCT00640666|BEHAVIORAL|Exercise Behavior Change|Multidisciplinary
219136523|NCT02860091|DRUG|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
219136524|NCT03511885|OTHER|There is no intervention|
219716529|NCT06631417|DRUG|BI 1291583|formulation 1
219716530|NCT06631417|DRUG|BI 1291583|formulation 2
219716531|NCT06631417|DRUG|BI 1291583|formulation 3
219716532|NCT06796738|DIAGNOSTIC_TEST|HPV testing|This study will use the Roche Cobas® 8800 system for HPV testing. The Roche Cobas HPV test is a PCR test that detects 14 hrHPV types and specifically identifies types 16 and 18.
219716533|NCT06840600|BEHAVIORAL|Public safety rationale|Rationale provided for policy is to increase community safety.
219716534|NCT06840600|BEHAVIORAL|Right-to-health rationale|Rationale provided for policy is to support humans' right to healthy food.
219716535|NCT06840600|BEHAVIORAL|Cost-saving rationale|Rationale provided for policy is to save the government money.
219716536|NCT06840600|BEHAVIORAL|No rationale (Control)|In this arm, no rationale is provided for the policy.
219716537|NCT04994132|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219716538|NCT04994132|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219136525|NCT01242085|PROCEDURE|trumatch group|these patient will have CT based customized knee instruments used for surgery
219136526|NCT01242085|PROCEDURE|control group|these patients will have standard instrumentation used for for knee replacement
219136527|NCT01819038|PROCEDURE|continuous renal replacement therapy|
219136528|NCT03489265|DRUG|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
219136529|NCT03489265|OTHER|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
219136530|NCT02422121|DRUG|RNS60|
219136531|NCT02422121|DRUG|Placebo|
219136532|NCT02916719|DEVICE|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
219136533|NCT05905406|OTHER|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
219136534|NCT03678116|DRUG|Sugar Pill (placebo)|Taken orally in capsule form
219136535|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
219136536|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine)|Taken orally in capsule form
219136537|NCT04269850|BIOLOGICAL|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
219136538|NCT04269850|DRUG|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
219716539|NCT04994132|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219716540|NCT04994132|PROCEDURE|Bone Scan|Undergo bone scan
219716541|NCT04994132|PROCEDURE|Computed Tomography|Undergo CT
219716542|NCT04994132|DRUG|Cyclophosphamide|Given IV or PO
219716543|NCT04994132|BIOLOGICAL|Dactinomycin|Given IV
219716544|NCT04994132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219716545|NCT04994132|PROCEDURE|Positron Emission Tomography|Undergo PET
219716546|NCT04994132|RADIATION|Radiation Therapy|Undergo radiation therapy
219716547|NCT04994132|DRUG|Vincristine Sulfate|Given IV
219716548|NCT04994132|DRUG|Vinorelbine Tartrate|Given IV
219716549|NCT04994132|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219716550|NCT05016596|DIETARY_SUPPLEMENT|turmeric|Turmeric supplement
219716551|NCT05016596|DIETARY_SUPPLEMENT|placebo|Placebo
219716552|NCT06586957|DRUG|NKT3964|Oral CDK2 Degrader
219136539|NCT04269850|DRUG|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
219136540|NCT04767035|DRUG|midazolam / ketamine sublingual tablet|sublingual tablet
219136541|NCT02886793|DRUG|fludeoxyglucose|
219136542|NCT04898192|OTHER|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
219716553|NCT02643277|BEHAVIORAL|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
219716554|NCT02643277|OTHER|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
219716555|NCT02206347|BEHAVIORAL|attention focus|
219136543|NCT00404794|DRUG|prednisolone and mycophenolate mofetil|
219136544|NCT00404794|DRUG|prednisolone and tacrolimus|
219136545|NCT06121310|OTHER|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
219136546|NCT00431808|BIOLOGICAL|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
219136547|NCT00431808|BIOLOGICAL|AMA1|50 micrograms of AMA1
219136548|NCT06204796|DRUG|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
219716556|NCT06763952|OTHER|AI-BRIDGE|AI-based eye screening program
219716557|NCT07058558|BEHAVIORAL|Nutrition Education and Community Gardening|Participants will be presented with 16 nutrition education modules based on the Portfolio Diet, through group-based virtual sessions delivered by the investigators for one year. In addition, participants will take part in two community gardening sessions during growing season, and will grow Portfolio Diet foods such as eggplant, okra, and temperate climate fruit.
219716558|NCT07059819|DEVICE|Local hyperthermia device|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18.
219716559|NCT06758388|OTHER|home exercise program|The prepared home exercise program is a program that includes gradual strengthening exercises that participants will do once a day, 5 days a week, for 8 weeks. The exercises will be performed as 1 set for the first 2 weeks, 2 sets in the 3rd and 4th weeks, and 3 sets in the last 4 weeks.
219716560|NCT06758388|BEHAVIORAL|home exercise program + brisk walking exercise|In addition to the home exercise program applied by the control group, a brisk walk will be performed. The brisk walking exercise will be done for 30 minutes, 5 days a week for 8 weeks. The intensity of the exercise will be adjusted according to the Borg CR-10 scale and the Speech test. Moderate intensity exercise is recommended for participants. The participant will walk rhythmically for 30 minutes at a speed where he/she will give 4-6 points on the Borg CR-10 Scale, and can speak a few sentences without getting out of breath according to the Speech test, but cannot sing. Before and after the brisk walk, he/she will be asked to walk at a slow speed for 5 minutes (warm-up-cool down).
219716561|NCT06752213|DEVICE|Vagus nerve Stimulation|Vagus nerve Stimulation
219716562|NCT06752213|OTHER|Manual therapy|Manual therapy
219716563|NCT06769022|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
219136549|NCT06204796|DRUG|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
219136550|NCT02909049|DRUG|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
219136551|NCT02909049|DRUG|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
219136552|NCT02909049|DRUG|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
219136553|NCT02909049|DRUG|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
219136554|NCT00434018|BEHAVIORAL|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
219136555|NCT00434018|BEHAVIORAL|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
219136556|NCT05334758|DEVICE|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
219136557|NCT05334758|DEVICE|Standard of Care COVID-19 Test|Standard of care
219716564|NCT03630991|DRUG|Edetate Calcium Disodium|Given IV
219716565|NCT03630991|DIETARY_SUPPLEMENT|Multivitamin|Given PO
219716566|NCT03630991|DRUG|Succimer|Given PO
219716567|NCT06827002|DRUG|Dichrostachys glomerata|DGE were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
219136558|NCT05334758|DIAGNOSTIC_TEST|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
219716568|NCT06827002|DRUG|Cissus quadrangularia|CQR-300® were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
219136559|NCT03930823|OTHER|Interview|One to one interview
219136560|NCT00937846|DRUG|GSK1034702|Single oral 5 mg dose in liquid formulation
219136561|NCT05359224|DRUG|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
219136562|NCT05359224|DRUG|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
219716569|NCT06827002|DRUG|Dextrin|Placebo capsules containing 400 mg of dextrin, looking identical to DGE and CQE were also procured from Gateway Health Alliances, Fairfield, California, USA.
219716570|NCT06827002|DRUG|Semaglutide (Rybelsus®)|Oral semaglutide (Rybelsus®) was purchased and then repackaged into capsules looking identical to DGE, CQE and placebo capsules.
219716571|NCT07064616|DEVICE|Catheter ablation using pulsed field ablation|"PulseSelect™ Pulsed Field Ablation System:~This intervention uses the PulseSelect™ system to perform pulsed field ablation (PFA) for pulmonary vein isolation in patients with persistent atrial fibrillation. PFA delivers short, high-voltage electrical pulses that selectively affect myocardial cells while minimizing damage to surrounding tissues such as the esophagus or phrenic nerve. This technique is designed to reduce procedural complications and improve safety compared to traditional thermal ablation methods."
219136563|NCT05844748|OTHER|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
219716572|NCT07064616|DEVICE|Catheter ablation using cryoballoon ablation|"Cryoballoon Ablation:~This intervention uses a cryoballoon catheter to perform pulmonary vein isolation by freezing tissue around the pulmonary veins. The balloon delivers extreme cold temperatures to create transmural lesions that block abnormal electrical signals responsible for atrial fibrillation. Cryoballoon ablation is widely used and considered effective for atrial fibrillation treatment but may carry risks related to collateral tissue injury."
219716573|NCT07066891|DRUG|CSII in the prediction model group|"1. Everyday insulin dosage decided by AI prediction model.~2. CSII treatment continues for 1 to 2 weeks based on whehter or not the patient is newly diagnosed or with different disease duration."
219716574|NCT07066891|DRUG|CSII in the empirical group|"1. Everyday insulin dosage decided by clinicans' experience.~2. CSII treatment continues for 1 to 2 weeks based on whether or not the patient is newly diagnosed or with different disease duration."
219716575|NCT07065058|DRUG|Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin|Single dose of Repaglinide at Day 2, Rosuvastatin and Digoxin at Day 3 Orally VCT220 once daily from Day 9 to Day 78, titrated from 20mg to 160mg. Co-administrated Repaglinide at Day 72, co-administrated Rosuvastatin and Digoxin at Day 73
219716576|NCT07064005|DRUG|Gamma- glutamylcysteine|400 mg (two times) per day
219136564|NCT06345534|DEVICE|Questionnaire|"Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years."
219136565|NCT06435338|BEHAVIORAL|Patient decision aid|The patient decision aid for HPV vaccination among mid-adults, named HPV Decide. It is delivered online on a website.
219136566|NCT06435338|BEHAVIORAL|Control|Vaccine information sheet on HPV vaccination. Attention control condition.
219136567|NCT06360042|DRUG|Adebrelimab plus Apatinib|Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
219136568|NCT06360042|DRUG|Adebrelimab plus Bevacizumab|Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
219716577|NCT07066202|OTHER|No intervention is planned in this study. Only the assessment of a specific condition.|No intervention is planned in this study. Only the assessment of a specific condition.
219136569|NCT06360042|DRUG|Camrelizumab plus Apatinib|camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
219136570|NCT00635895|OTHER|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
219136571|NCT02559258|DRUG|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
219136572|NCT02559258|DRUG|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
219136573|NCT02559258|DRUG|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
219136574|NCT02559258|DRUG|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
219136575|NCT02559258|DRUG|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
219716578|NCT06776341|OTHER|GEMIN5-Related Neurodevelopmental Disorder|This is an observational study. The investigators will collect data from participants' medical records regarding neurodevelopmental outcomes (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), Time to event (Acquistion and loss of developmental milestones), and, if available, data regarding MRIs (presence of cerebellar atrophy), survival, visiion, hearing, and biomarkers of disease.
219716579|NCT06461754|OTHER|Sonographic evaluation of diaphragm and lung|While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
219716580|NCT06769490|DRUG|Ziftomenib|Participants will receive treatment in tablet form
219716581|NCT06769490|DRUG|Quizartinib|Participants will receive treatment in tablet form
219716582|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
219716583|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
219716584|NCT07068932|DRUG|SHR-4506 Injection|SHR-4506 injection.
219716585|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
219716586|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth continuously.
219136576|NCT01456819|BIOLOGICAL|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
219136577|NCT01456819|BIOLOGICAL|Mononuclear cells|Intramuscular administration into the ischemic limb
219136578|NCT02668263|PROCEDURE|Surgery alone|Surgery
219136579|NCT02668263|PROCEDURE|Surgery and Drain(s)|Drains inserted as per standard practice
219136580|NCT02668263|PROCEDURE|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
219136581|NCT06010888|DRUG|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
219136582|NCT01606163|BIOLOGICAL|GC1102|"1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
219136583|NCT01606163|OTHER|JW normal saline|"1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
219136584|NCT05379881|BEHAVIORAL|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
219136585|NCT00607503|DRUG|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
219136586|NCT02596035|DRUG|Nivolumab|
219136587|NCT02066441|DIETARY_SUPPLEMENT|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
219136588|NCT02066441|OTHER|Placebo|
219228281|NCT02930265|DRUG|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
219551353|NCT04837456|PROCEDURE|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
219551354|NCT04837456|PROCEDURE|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
219551355|NCT04837456|PROCEDURE|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
219551356|NCT06383130|DIAGNOSTIC_TEST|Oscillometry with reversibility testing|Oscillometry is a test that uses sound waves to measure the mechanical properties in the lungs during tidal breathing
219551357|NCT06383130|DIAGNOSTIC_TEST|Breath volatile testing|We will be optimising and evaluating the sensitivity and specificity of a novel breath volatile organic compound test of a combination of reactive aldehydes using a gas chromatography-ion mobility spectrometry device
219551358|NCT06383130|DIAGNOSTIC_TEST|Nasal eosinophil peroxidase|We will be evaluating the sensitivity and specificity of a novel nasal swab test for eosinophil peroxidase
219716587|NCT06475547|OTHER|Descriptive|This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.
219716588|NCT07062965|DRUG|PF-07248144|KAT6 inhibitor
219716589|NCT07062965|DRUG|Fulvestrant|Endocrine therapy
219716590|NCT07062965|DRUG|Everolimus|mTOR inhibitor
219716591|NCT07062965|DRUG|Exemestane|Endocrine therapy
219716592|NCT07068607|DRUG|Vonoprazan|Vonoprazan - amoxicillin dual therapy: Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days; Vonoprazan-minocycline dual therapy:Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
219716593|NCT07068607|DRUG|Tetracycline 500mg tid|Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days
219716594|NCT07068607|DRUG|Minocycline|Vonoprazan-minocycline dual therapy Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days
219716595|NCT07068607|DRUG|Bismuth|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
219716596|NCT07068607|DRUG|Clarithromycin 500 mg|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
219716597|NCT07068607|DRUG|Amoxicillin|Vonoprazan - amoxicillin dual therapy:Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
219551359|NCT06383130|DIAGNOSTIC_TEST|Handheld capnometry|We will be evaluating handheld capnometry (carbon dioxide breath testing) to diagnose adult asthma
219716598|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
219716599|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
219136589|NCT00929721|PROCEDURE|Blood draw|culture for Streptococcus pneumoniae Frequency-1
219716600|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
219716601|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
219716602|NCT06392126|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
219716603|NCT06788509|DRUG|JNJ-75348780|Participants from the parent study (75348780LYM1001 \[NCT04540796\]) who are deriving benefit from study treatment will continue to receive subcutaneous JNJ-75348780.
219551360|NCT03755596|DRUG|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
219551361|NCT04619862|DRUG|Gabapentin|See arm descriptions
219551362|NCT04619862|DRUG|Placebo|See arm descriptions
219551363|NCT00006262|DRUG|becatecarin|
219551364|NCT03064867|DRUG|Venetoclax|"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
219551365|NCT03064867|DRUG|Rituximab|"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
219551366|NCT03064867|DRUG|Ifosfamide|"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
219551367|NCT03064867|DRUG|Carboplatin|"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
219551368|NCT03064867|DRUG|Etoposide|"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
219136590|NCT00929721|PROCEDURE|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
219136591|NCT00929721|PROCEDURE|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
219136592|NCT00929721|PROCEDURE|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
219136593|NCT00929721|PROCEDURE|sputum|culture for Streptococcus pneumoniae Frequency-1
219136594|NCT00855153|OTHER|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
219716604|NCT06788509|DRUG|JNJ-67856633|Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.
219136595|NCT00855153|DRUG|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
219136596|NCT01513135|BIOLOGICAL|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
219136597|NCT01513135|BIOLOGICAL|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
219136598|NCT00956306|DRUG|Udenafil|100mg Single Oral Dose of Udenafil
219716605|NCT06788509|DRUG|JNJ-54179060|Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.
219136599|NCT05696977|DRUG|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
219716606|NCT06788509|DRUG|JNJ-64264681|Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.
219136600|NCT03163953|BEHAVIORAL|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
219136601|NCT03163953|BEHAVIORAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
219136602|NCT03163953|OTHER|Control|No intervention
219136603|NCT03552913|PROCEDURE|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
219136604|NCT03552913|PROCEDURE|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
219136605|NCT03552913|PROCEDURE|No specific program toward improving practices|No specific program toward improving practices
219136606|NCT04361253|BIOLOGICAL|High-Titer COVID-19 Convalescent Plasma (HT-CCP)|250mL HT-CCP x2 doses given sequentially.
219136607|NCT04361253|BIOLOGICAL|Standard Plasma (FFP)|250mL FFP or FP24 x2 doses given sequentially.
219136608|NCT02839369|OTHER|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
219136609|NCT02839369|OTHER|walking under varies conditions|walking on electronic walkway under different conditions
219136610|NCT01604447|PROCEDURE|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
219136611|NCT01604447|PROCEDURE|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
219136612|NCT01335932|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
219136613|NCT01335932|DRUG|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
219716607|NCT06788509|DRUG|JNJ-74856665|Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.
219136614|NCT02035735|PROCEDURE|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
219136615|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on breast cancer tissues|Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
219136616|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on plasma samples|miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
219136617|NCT06555354|DIAGNOSTIC_TEST|miRNA profiling of breast cancer tissues|Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
219136618|NCT05490654|PROCEDURE|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
219136619|NCT01169363|GENETIC|proteomic profiling|
219136620|NCT01169363|OTHER|flow cytometry|
219136621|NCT01169363|OTHER|laboratory biomarker analysis|
219136622|NCT00952718|OTHER|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
219136623|NCT04531137|DIETARY_SUPPLEMENT|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
219136624|NCT04531137|OTHER|Placebo|Placebo milk powder one a day for 12 weeks
219136625|NCT04531137|OTHER|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
219136626|NCT01998555|OTHER|CBT|
219136627|NCT02171663|DRUG|BIBW 2992|
219136628|NCT06233812|PROCEDURE|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
219136629|NCT06233812|PROCEDURE|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
219136630|NCT05158361|OTHER|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
219136631|NCT05158361|OTHER|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
219136632|NCT00161018|DRUG|Quetiapine, Risperidone, Fluphenazine|
219136633|NCT02560519|DRUG|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
219716608|NCT06788509|DRUG|JNJ-70218902|Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.
219716609|NCT06788509|DRUG|JNJ-64619178|Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.
219716610|NCT07071402|PROCEDURE|Ultrasound-guided vacuum-assisted excision combined with surgical treatment|Patients undergoing VAE surgery （EnCor® vacuum-assisted minimally invasive rotary system）are placed in an appropriate position, undergo routine disinfection and blanching, and the tumor location is located by ultrasound. After local anesthesia, a vacuum-assisted rotary cutting needle is percutaneous punctured beneath the tumor. Under ultrasound guidance, the tumor tissue is gradually resected until the ultrasound shows complete tumor resection. The resected tissue is sent for pathological examination. After the patient is confirmed to have breast cancer through VAE resection biopsy, depending on the patient's specific condition, they are hospitalized for radical mastectomy. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, sentinel lymph node biopsy is performed, and the resected tissue is sent for pathological examination. The surgical process follows the surgical treatment norms for breast cancer.
219716611|NCT07071779|OTHER|Alcohol-specific inhibition training|Twelve sessions of alcohol-specific inhibition training
219716612|NCT07071779|OTHER|Control training|Twelve sessions of unspecific inhibition training
219228282|NCT04531007|DIAGNOSTIC_TEST|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
219228283|NCT01246635|DEVICE|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
219228284|NCT01246635|PROCEDURE|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
219228285|NCT02980432|OTHER|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
219551369|NCT05545228|BEHAVIORAL|Link work intervention|Intervention from a link worker to support participants to access dental services.
219551370|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
219551371|NCT02093728|DRUG|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
219551372|NCT02093728|DRUG|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
219551373|NCT02093728|DRUG|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
219551374|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
219551375|NCT02093728|DRUG|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
219136634|NCT02560519|DRUG|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
219136635|NCT04589130|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
219716613|NCT07070700|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 will be administered by IV, 5 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219136636|NCT04589130|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
219136637|NCT05056753|DEVICE|HWBV chair|vibration-actuated, saddle-seat type stool
219136638|NCT04308746|BEHAVIORAL|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
219136639|NCT04308746|BEHAVIORAL|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
219136640|NCT06269536|OTHER|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
219136641|NCT05230641|OTHER|No intervention|This is a prospective observational study
219136642|NCT05906225|PROCEDURE|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
219136643|NCT05906225|PROCEDURE|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
219136644|NCT01235949|BIOLOGICAL|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
219136645|NCT01235949|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
219716614|NCT07070700|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219716615|NCT07070700|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus QL1706 will be administered 1-3 days after cryoablation.
219136646|NCT01235949|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
219136647|NCT01235949|DRUG|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
219136648|NCT01235949|DRUG|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
219136649|NCT02466048|PROCEDURE|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
219136650|NCT02466048|DEVICE|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
219136651|NCT04173572|BEHAVIORAL|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
219136652|NCT04173572|BEHAVIORAL|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
219136653|NCT00383188|DRUG|placebo|Capsule, once daily (QD) for 12 weeks
219136654|NCT00383188|DRUG|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
219136655|NCT00383188|DRUG|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
219136656|NCT00383188|DRUG|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
219136657|NCT00383188|DRUG|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
219136658|NCT01847651|PROCEDURE|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136659|NCT01847651|DRUG|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
219136660|NCT01847651|OTHER|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136661|NCT01847651|OTHER|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136662|NCT01847651|OTHER|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136663|NCT01847651|OTHER|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136664|NCT01847651|OTHER|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
219136665|NCT01847651|OTHER|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
219228286|NCT04711291|COMBINATION_PRODUCT|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
219228287|NCT04711291|DRUG|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
219228288|NCT00799409|DRUG|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
219228289|NCT00799409|DRUG|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
219716616|NCT07071337|DRUG|SKB264|5mg/kg, IV on Day 1 and Day 15 of each 28 day cycle
219716617|NCT07071337|DRUG|Nab-paclitaxel|100 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks
219716618|NCT07071337|DRUG|Paclitaxel|90 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks; or 80 mg/m\^2, IV, weekly, every 3 weeks
219716619|NCT07071337|DRUG|Capecitabine|1000-1250 mg/m\^2, orally, Days 1-14, twice daily, every 3 weeks
219716620|NCT07071259|OTHER|TMS Stimulation|For the TMS session, participants will be positioned on a chair, in a seated position. They will be equipped with an EEG cap 64 active electrodes, using gel to ensure good measurements of brain activation, and a sensor on the forehead to measure the location of the head in space for the neuronavigation system. They will also wear headphones generating white noise to mask the TMS coil noise. Preparation time for the EEG acquisitions is estimated at 30 min. The TMS coil will be shaped in 8 for good spatial resolution. It will be positioned on the participant's head using a robot (approved medical CE) allowing good targeting accuracy and stability during the experiment. The stimulation target will be defined beforehand on the participant's MRI, and the robot will read this information to position itself.
219716621|NCT06383611|COMBINATION_PRODUCT|VT-X7 Treatment System|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
219716622|NCT06774625|DRUG|LTG-001 High Dose|LTG-001 High Dose
219716623|NCT06774625|DRUG|LTG-001 Mid Dose|LTG-001 Mid Dose
219136666|NCT01847651|OTHER|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
219228290|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
219228291|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
219228292|NCT05488990|DRUG|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
219228293|NCT05488990|DRUG|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
219716624|NCT06774625|DRUG|LTG-001 Low Dose|LTG-001 Low Dose
219716625|NCT06774625|OTHER|Placebo|Placebo
219716626|NCT06774625|DRUG|Suzetrigine|Active comparator - Nav1.8 inhibitor
219136667|NCT03660917|DRUG|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
219136668|NCT03660917|DRUG|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
219136669|NCT03206736|OTHER|Loop DS surgery|these patients will receive a loop DS bariatric procedure
219228294|NCT05488990|DRUG|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
219228295|NCT05488990|DRUG|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
219228296|NCT05825105|BIOLOGICAL|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
219228297|NCT05979766|OTHER|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
219716627|NCT06214507|OTHER|No intervention|No intervention
219716628|NCT07073274|DIAGNOSTIC_TEST|EEG analysis|All patients will have a continous recording of their EEG during anesthesia
219716629|NCT07070349|DRUG|HRS-6213|HRS-6213 IV administered as imaging agent for PET scan.
219136670|NCT04033042|DEVICE|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
219136671|NCT04964479|DRUG|TQB2450 injection|1200mg injection once every 3 week
219136672|NCT04964479|DRUG|Anlotinib Hydrochloride Capsules|12mg capsule once daily
219716630|NCT03973229|DRUG|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
219716631|NCT03973229|OTHER|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
219716632|NCT07068581|PROCEDURE|Maternal voice|"Mothers of the infants in the intervention group will be asked to read aloud the lyrics of a designated in a calm tone of voice in a quiet environment, and their voices will be recorded. The recorded maternal voice will then be played to the infants in the NICU using the same Bluetooth-enabled device with built-in speakers. The audio device will be placed inside the incubator or open warmer, approximately 20-30 cm from the infant.~Each infant will be assigned an individual audio device, which will be used exclusively for that infant. Maternal voice playback will begin 20 minutes before morning and evening oral feedings and will continue throughout the feeding session, twice daily, for a maximum of 5 days. If the infant is discharged earlier, the intervention will be discontinued.. During the playback of the maternal voice, monitor sounds in the NICU will be minimized, and the staff will be instructed to speak quietly to maintain a calm environment."
219716633|NCT07068581|OTHER|Control Group (standard feeding )|The control group will not be exposed to maternal voice, and standard feeding procedures will be applied.
219716634|NCT06898151|PROCEDURE|CEA/CAS plus best medical treatment|Timing of CEA/CAS plus best medical treatment
219136673|NCT04964479|DRUG|Pembrolizumab injection|200mg injection once every 3 week
219136674|NCT04964479|DRUG|Placebo|Placebo capsule once daily
219716635|NCT06632951|DRUG|Livmoniplimab|Intravenous (IV) Infusion
219716636|NCT06632951|DRUG|Budigalimab|IV Infusion
219716637|NCT06632951|DRUG|Docetaxel|IV Infusion
219136675|NCT02469337|DRUG|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
219136676|NCT02469337|DIETARY_SUPPLEMENT|Carbohydrate drinks|preoperative carbohydrate drinks
219136677|NCT02469337|BEHAVIORAL|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
219136678|NCT03936348|DEVICE|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
219136679|NCT02491749|PROCEDURE|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
219136680|NCT02476890|DRUG|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
219136681|NCT02476890|DRUG|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
219136682|NCT04908982|DRUG|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
219136683|NCT00835380|BIOLOGICAL|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
219136684|NCT05735444|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
219716638|NCT06632951|DRUG|Paclitaxel|IV Injection
219716639|NCT06632951|DRUG|Docetaxel|IV Injection
219716640|NCT06632951|DRUG|Paclitaxel|IV Infusion
219716641|NCT06632951|DRUG|Gemcitabine|IV Infusion
219716642|NCT05063162|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab."
219716643|NCT05063162|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo."
219716644|NCT05046080|OTHER|Electronic Health Record Review|Medical records reviewed
219716645|NCT05046080|OTHER|Laboratory Biomarker Analysis|Correlative studies
219716646|NCT07073170|DRUG|LY3549492|Administered orally
219716647|NCT07073170|DRUG|Placebo|Administered orally
219716648|NCT07069244|DIAGNOSTIC_TEST|Complete Blood Count Test|Complete blood count test provides data on total white blood cell count, neutrophil count, neutrophil percentage, lymphocyte count, lymphocyte percentage, monocyte count, monocyte percentage, eosinophil count, eosinophil percentage, basophil count, basophil percentage, platelet count, platelet distribution width (PDW), mean platelet volume (MPV), plateletcrit (PCT), erythrocyte count, hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell distribution width (RDW). In addition, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-leukocyte ratio (PLR), Pan-Immune-Inflammation Value (PIV), Systemic Immune-Inflammation Index (SII), Hemoglobin-to-Red Cell Distribution Width Ratio (HRR) values are also formulated from these parameters.
219716649|NCT07069244|DIAGNOSTIC_TEST|Periodontal examinations|With periodontal evaluation, plaque percentage, probing pocket depth, percentage of bleeding on probing, clinical attachment level, number of teeth, periodontal inflammatory surface area (PISA) parameters are recorded.
219136685|NCT03614546|RADIATION|SBRT|Stereotactic Body Radiation Therapy (SBRT)
219136686|NCT03614546|RADIATION|IMRT|Intensity-modulated Radiation Therapy (IMRT)
219136687|NCT03614546|PROCEDURE|Hepatectomy|Hepatectomy
219136688|NCT03614546|PROCEDURE|TACE|transarterial chemoembolization (TACE)
219136689|NCT04610008|OTHER|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
219136690|NCT02892968|PROCEDURE|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
219136691|NCT02892968|PROCEDURE|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
219136692|NCT02779608|DRUG|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
219136693|NCT02779608|DRUG|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
219136694|NCT04883762|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
219136695|NCT03247543|DRUG|Placebo|Placebo was administered once daily
219136696|NCT03247543|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
219136697|NCT03247543|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
219136698|NCT01377259|OTHER|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
219136699|NCT00491517|DRUG|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
219136700|NCT00491517|DRUG|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
219136701|NCT01097343|DRUG|clopidogrel 75 mg|75 mg once daily
219136702|NCT01097343|DRUG|Clopidogrel 150 mg|clopidogrel 150 mg
219136703|NCT02243813|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
219136704|NCT02332369|DEVICE|Capsular Tension Ring|
219136705|NCT06000072|OTHER|Core Exercise Program|Core exercises
219136706|NCT02059980|BEHAVIORAL|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
219136707|NCT02059980|BEHAVIORAL|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
219136708|NCT04462107|OTHER|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
219136709|NCT01104415|DRUG|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
219136710|NCT06351787|BEHAVIORAL|Resting and movement-based focused awareness meditations|Resting and movement-based focused awareness meditations
219136711|NCT01537003|DEVICE|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
219136712|NCT01537003|DEVICE|Coban 2 layer|Compression bandage
219136713|NCT00155363|DEVICE|conventional artificial kidney (AK) vs. high flux AK|
219136714|NCT06511817|OTHER|No intervention will be performed|No intervention will be performed
219136715|NCT04286529|DRUG|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
219136716|NCT04286529|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
219136717|NCT04392713|DRUG|Ivermectin 6 MG Oral Tablet (2 tablets)|12 mg single dose of Ivermectin will be given to intervention arm
219716650|NCT07069244|DIAGNOSTIC_TEST|Clinical Dementia Rating scale|Stage I: mild Alzheimer's disease, Stage II: moderate Alzheimer's disease, Stage III: severe Alzheimer's disease
219136718|NCT03501173|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
219136719|NCT05368025|DEVICE|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
219136720|NCT02341625|DRUG|BMS-986148|
219136721|NCT02341625|BIOLOGICAL|Nivolumab|
219136722|NCT02026778|DRUG|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
219136723|NCT02026778|DRUG|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
219136724|NCT02748265|DRUG|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
219136725|NCT02748265|DRUG|Sevoflurane|Volatile maintenance anesthesia
219716651|NCT07069244|DIAGNOSTIC_TEST|Standardized Mini-Mental Test|Cognitive status is assessed with the Standardized Mini-Mental Test.
219136726|NCT02748265|DRUG|Propofol|Intravenous maintenance anesthesia
219136727|NCT00165451|DRUG|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
219136728|NCT00165451|DRUG|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
219136729|NCT00165451|DRUG|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
219136730|NCT00165451|DRUG|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
219136731|NCT02616835|DEVICE|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
219136732|NCT02616835|DEVICE|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
219136733|NCT02275325|OTHER|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
219136734|NCT00319566|DRUG|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
219136735|NCT03551067|DRUG|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
219716652|NCT07066189|BEHAVIORAL|Exercise and Medical Nutrition|10, 30-minute sessions spread out over the course of their neoadjuvant therapy and in the weeks leading up to surgery. On weeks counseling is not scheduled an exercise session will be observed.
219716653|NCT07073235|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the contralesional cerebellum, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
219716654|NCT07073235|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation.
219716655|NCT07071883|BEHAVIORAL|Holotropic breathwork|HB is the practice of self-directed hyperventilation while lying down with the support of a selected music set and trained facilitators. Participants may experience an expanded state of consciousness with altered cognition, perception, and emotions.
219716656|NCT07071883|BEHAVIORAL|Multiple modality|Multiple Modality (MM) intervention (yoga, meditation, and a film/discussion)
219716657|NCT04610866|DRUG|Mitapivat|Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
219716658|NCT06797713|PROCEDURE|Esophageal doppler|Fluid/inotrope decisions will be made with parameters such as stroke volume (SV), stroke volume variation (SVV), pulse pressure variation (PVV), systemic vascular resistance (SVR), and cardiac output (CO) on the Doppler monitor screen.
219716659|NCT06797713|PROCEDURE|Conventional method|Fluid therapy is performed by monitoring parameters such as blood pressure, urine output, lactate...
219136736|NCT03551067|COMBINATION_PRODUCT|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
219716660|NCT06794866|DRUG|OnabotulinumtoxinA|Intramuscular Injections
219716661|NCT06794866|DRUG|Placebo|Intramuscular Injections
219136737|NCT06364150|BIOLOGICAL|Autologous Peripheral Blood Stem Cell injection|For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
219136738|NCT06393244|BEHAVIORAL|a theory-based home-based multi-component exercise training|The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
219136739|NCT04055766|DEVICE|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
219136740|NCT05633368|OTHER|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology"
219136741|NCT04307407|BEHAVIORAL|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
219136742|NCT02168751|DRUG|propofol|
219136743|NCT02168751|DRUG|Sevoflurane|
219136744|NCT04418323|PROCEDURE|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
219136745|NCT00917865|DRUG|anti [18F]FACBC|Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
219228298|NCT03072745|DIAGNOSTIC_TEST|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
219136746|NCT04628715|DEVICE|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
219228299|NCT05861232|BEHAVIORAL|Behavioral|fear and anxiety during inhalation therapy
219136747|NCT02040935|DRUG|Trastuzumab|600 mg SC Q3W by SID
219716662|NCT06874361|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
219716663|NCT06771323|DRUG|Valbenazine|To assess if valbenazine 80mg daily improves motor symptoms in idiopathic CD patients with persistent symptoms despite current treated with botulinum toxin injections.
219136748|NCT06512649|BEHAVIORAL|Early intervention|90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.
219136749|NCT06512649|BEHAVIORAL|Active monitoring|90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
219136750|NCT01777893|BEHAVIORAL|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
219136751|NCT01777893|BEHAVIORAL|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
219136752|NCT01777893|BEHAVIORAL|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
219716664|NCT06771323|DRUG|Placebo|Placebo
219716665|NCT06419608|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 6 weeks
219716666|NCT06419608|DRUG|Placebo|Matching placebo taken once daily for 6 weeks
219716667|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
219716668|NCT04890834|OTHER|Best Practice|Receive standard care
219716669|NCT04890834|OTHER|Exercise Intervention|Participate in yoga sessions
219716670|NCT04890834|OTHER|Questionnaire Administration|Ancillary studies
219716671|NCT05521373|DEVICE|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
219716672|NCT05521373|DEVICE|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
219716673|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
219716674|NCT05495464|DRUG|Acalabrutinib|Given by PO
219716675|NCT05495464|DRUG|Rituximab|Given by IV (vein)
219136753|NCT01777893|BEHAVIORAL|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
219136754|NCT03907098|DRUG|Endostar|an anti-angiogenesis drug
219136755|NCT03907098|DRUG|Chemotherapy|Physician's choice
219716676|NCT05495464|OTHER|Brexucabtagene Autoleucel|Given by IV (vein)
219716677|NCT05495464|DRUG|Cyclophosphamide|Given by IV (vein)
219716678|NCT05495464|DRUG|Fludarabine Phosphate|Given by IV (vein)
219716679|NCT06891547|DIETARY_SUPPLEMENT|Spark Placebo Control 5.1|Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks.
219716680|NCT06891547|DIETARY_SUPPLEMENT|Spark Active Study Product 5.1 Usage|Participants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks.
219716681|NCT06764927|BIOLOGICAL|Cryoprecipitate Intercept Fibrinogen Complex (IFC)|INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.
219136756|NCT03816124|PROCEDURE|radiofrequency ablation|radiofrequency ablation of the genicular nerves
219228300|NCT04427124|OTHER|Multidisciplinary Team Based Care Model|All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
219716682|NCT06764927|BIOLOGICAL|Cryoprecipitate Antihemophilic Factor (AHF)|Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
219716683|NCT06760182|DRUG|TQH2722 injection|TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
219716684|NCT06760182|DRUG|TQH2722 Placebo|Placebo without drug substance.
219716685|NCT06901310|DEVICE|Hyberbaric Oxygen Therapy|Treating participants with 100% Oxygen at 2.4 Atmospheres for 90 minutes at 10 treatments.
219716686|NCT06692322|DRUG|Zongertinib (BI 1810631)|Film-coated tablet
219716687|NCT03858322|DRUG|Paclitaxel|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
219716688|NCT03858322|DRUG|Cyclophosphamide|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
219716689|NCT03858322|DRUG|Carboplatin|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
219136757|NCT01263730|BEHAVIORAL|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
219136758|NCT06040333|OTHER|Exercise|Dynamic Neuromuscular Stabilisation Exercise
219136759|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
219228301|NCT02776124|DIETARY_SUPPLEMENT|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
219228302|NCT05233904|DIAGNOSTIC_TEST|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
219228303|NCT05233904|DIAGNOSTIC_TEST|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
219228304|NCT03964974|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
219228305|NCT03964974|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
219228306|NCT01702103|DRUG|Mometasone furoate|
219228307|NCT06236204|PROCEDURE|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
219228308|NCT01729793|DIETARY_SUPPLEMENT|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
219716690|NCT07073001|OTHER|Telephone interview|A structured telephone interview at three months will assess the degree of implementation, explore associated barriers (administrative, cognitive, organizational, ...), and investigate any potential link with hospital readmissions or changes in patients' living situations.
219716691|NCT07074327|DRUG|VX-407|Suspension for oral administration.
219716692|NCT07074327|DRUG|LNG/EE|Combination Tablets for Oral Administration.
219136760|NCT05325853|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
219136761|NCT05325853|DRUG|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
219716693|NCT07074327|DRUG|NGM/EE|Combination Tablets for Oral Administration.
219716694|NCT07074327|DRUG|NET/EE|Combination Tablets for Oral Administration.
219136762|NCT01669382|DEVICE|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
219136763|NCT01598636|PROCEDURE|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
219136764|NCT01839877|DRUG|HIA DEBIRI + systemic FOLFOX|
219136765|NCT04678128|BEHAVIORAL|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
219136766|NCT04678128|BEHAVIORAL|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
219228309|NCT01729793|OTHER|Placebo|Capsule containing microcrystalline cellulose
219228310|NCT01698567|DRUG|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
219716695|NCT07074327|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
219716696|NCT07073469|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
219716697|NCT07073469|OTHER|Standard medical treatment|Standard medical treatment according to local guidelines
219228311|NCT01698567|DRUG|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
219136767|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
219136768|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
219136769|NCT03072355|OTHER|Elastic Band|Localized muscle resistance test for shoulder
219136770|NCT03072355|OTHER|Isokinetic dynamometer|Localized muscle resistance test for shoulder
219136771|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made
219136772|NCT00684034|OTHER|Sampling of blood|A sampling of bood will be made before the dialysis
219136773|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made.
219136774|NCT03897309|BIOLOGICAL|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
219136775|NCT03897309|BIOLOGICAL|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
219136776|NCT03897309|BIOLOGICAL|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
219136777|NCT04285762|OTHER|LVEEA|lymphaticovenous end-to-end
219136778|NCT04285762|OTHER|LVESA|lymphaticovenous end-to-side
219136779|NCT04285762|OTHER|LVSEA|lymphaticovenous side-to-end
219136780|NCT02286765|DEVICE|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
219136781|NCT01805349|RADIATION|Hand X-rays|Hand X-rays to assess the digital arthrosis
219228312|NCT05148949|BIOLOGICAL|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
219136782|NCT03098030|BIOLOGICAL|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
219136783|NCT03098030|DRUG|Irinotecan|Irinotecan injection, IV infusion
219136784|NCT03098030|DRUG|Topotecan|Topotecan for injection
219136785|NCT01726023|DRUG|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
219136786|NCT01726023|DRUG|metronidazole|Metronidazole 500mg/100ml solution for infusion
219136787|NCT01726023|DRUG|Meropenem|Meropenem powder for solution for infusion 1000mg
219136788|NCT00414206|DRUG|Mecamylamine|
219136789|NCT00414206|DRUG|Placebo|
219551376|NCT02093728|DRUG|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
219551377|NCT02093728|DRUG|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
219551378|NCT02651987|DRUG|Lanreotide autogel 120 mg|
219551379|NCT00616993|DRUG|Difluprednate|Difluprednate
219551380|NCT00616993|OTHER|Placebo|Vehicle
219551381|NCT04406545|OTHER|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
219551382|NCT00163124|PROCEDURE|spinal manipulation & patient education/nutrition|
219551383|NCT03685617|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
219551384|NCT03685617|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
219551385|NCT04731324|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
219551386|NCT00759616|DEVICE|Oxford Partial Knee|Oxford Partial Knee
219551387|NCT00522041|DRUG|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
219551388|NCT00522041|DRUG|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
219551389|NCT00486434|DRUG|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
219551390|NCT00486434|DRUG|SMC021 Placebo|Placebo orally, twice daily
219551391|NCT02786433|OTHER|conventional physiotherapy|
219551392|NCT02786433|OTHER|Virtual Reality with X- Box Kinect®|
219551393|NCT00279045|DRUG|Rosiglitazone|
219551394|NCT00279045|DRUG|glyburide|
219551395|NCT00279045|DRUG|metformin|
219551396|NCT01311596|OTHER|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
219551397|NCT01610050|DRUG|LFA102|
219551398|NCT05092035|DIAGNOSTIC_TEST|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
219551399|NCT06204939|PROCEDURE|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
219136790|NCT02008253|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
219136791|NCT05211063|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
219136792|NCT05211063|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 42 days.
219136793|NCT02158481|DIETARY_SUPPLEMENT|A capsule containing both polyphenols and carotenoids|
219136794|NCT02158481|DIETARY_SUPPLEMENT|Placebo intervention|Placebo intervention
219136795|NCT05903066|PROCEDURE|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
219136796|NCT04756401|DRUG|Carfilzomib|Given IV
219136797|NCT04756401|BIOLOGICAL|Daratumumab|Given IV
219136798|NCT04756401|DRUG|Dexamethasone|Given PO
219136799|NCT04756401|OTHER|Quality-of-Life Assessment|Ancillary studies
219136800|NCT04756401|DRUG|Selinexor|Given PO
219136801|NCT05515770|DRUG|Cabotegravir Injection|Long action cabotegravir injection
219136802|NCT06316674|BEHAVIORAL|sixth finger illusion|Participants will undertake the sixth finger illusion that is a body illusion which elicits the presence of an extra numerary finger due to visuo-tactile stimulation.
219136803|NCT04968132|OTHER|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
219136804|NCT04968132|OTHER|Standard care|Standard perioperative care, surgical treatment, and pain medications.
219136805|NCT05457491|BIOLOGICAL|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
219136806|NCT05457491|OTHER|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
219136807|NCT05457491|OTHER|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
219136808|NCT05457491|OTHER|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
219136809|NCT05457491|OTHER|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
219136810|NCT04536077|DRUG|CDX-301|The drug will be supplied free of charge by Celldex
219136811|NCT04536077|DRUG|CDX-1140|The drug will be supplied free of charge by Celldex
219136812|NCT04536077|PROCEDURE|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
219136813|NCT03368001|BEHAVIORAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
219136814|NCT03368001|BEHAVIORAL|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
219136815|NCT06549309|DRUG|JMKX003801|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
219136816|NCT06549309|DRUG|Placebo|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
219136817|NCT05161403|DRUG|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
219228313|NCT05148949|BIOLOGICAL|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
219136818|NCT05161403|DIETARY_SUPPLEMENT|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
219136819|NCT01243801|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
219136820|NCT06037616|OTHER|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
219136821|NCT06037616|OTHER|video skill|Video showing skill to perform a skin suture
219136822|NCT06037616|OTHER|video errors|Video showing errors of skin suture
219136823|NCT01077245|DRUG|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
219228314|NCT05942664|BEHAVIORAL|Sleep|Sleep will be restricted to 60% normal sleep duration
219228315|NCT00513123|PROCEDURE|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
219228316|NCT00620230|DRUG|NVP-VAK694|
219228317|NCT00620230|DRUG|NVP-VAK694|
219136824|NCT01077245|DRUG|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
219136825|NCT00554801|PROCEDURE|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
219136826|NCT04005313|DEVICE|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
219136827|NCT02884583|OTHER|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
219136828|NCT01521585|DRUG|SEN0014196|50 mg oral once daily tablet
219136829|NCT01521585|DRUG|SEN0014196|200 mg oral once daily tablet
219136830|NCT01521585|DRUG|Placebo|oral once daily tablet
219136831|NCT03896828|DIETARY_SUPPLEMENT|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
219136832|NCT02785978|DRUG|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
219136833|NCT02785978|OTHER|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
219136834|NCT02785978|OTHER|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
219136835|NCT02785978|DEVICE|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
219136836|NCT02785978|OTHER|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
219136837|NCT00284973|BIOLOGICAL|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
219136838|NCT00782639|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
219136839|NCT00782639|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
219136840|NCT01890889|DIETARY_SUPPLEMENT|Ad-Chol-Pre|
219136841|NCT01890889|DIETARY_SUPPLEMENT|Half-dose Ad-Chol-Pre|
219136842|NCT01890889|OTHER|Defatted egg yolk without the active ingredient of the other two interventions|
219136843|NCT06457568|DIAGNOSTIC_TEST|Blood pressure measurement|The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
219136844|NCT04705857|COMBINATION_PRODUCT|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
219136845|NCT05724173|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
219136846|NCT04313452|OTHER|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
219136847|NCT05203913|DRUG|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
219136848|NCT05203913|DRUG|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
219136849|NCT05203913|DRUG|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
219136850|NCT05203913|RADIATION|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
219136851|NCT04003428|DEVICE|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
219136852|NCT03211325|PROCEDURE|Biopsy|
219136853|NCT02942056|DRUG|Cinnamon|Cinnamon tablets to treat type 2 DM
219136854|NCT02942056|DRUG|placebo|placebo
219136855|NCT04700007|DRUG|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
219136856|NCT04700007|DRUG|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
219136857|NCT04700007|DRUG|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
219136858|NCT04700007|DRUG|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
219136859|NCT04700007|DRUG|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
219136860|NCT00126009|DRUG|Amisulpride|
219136861|NCT06359054|DIAGNOSTIC_TEST|18F FDG PET/CT|"18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position)."
219136862|NCT06359054|DIAGNOSTIC_TEST|68Ga DOTATATE PET/CT|"68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression."
219136863|NCT01285258|PROCEDURE|hysterectomy|excluding the uterus with saving ovaries
219136864|NCT03328949|DEVICE|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
219136865|NCT06165549|OTHER|Light therapy|The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
219136866|NCT06165549|OTHER|Light placebo therapy|The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
219136867|NCT06165549|OTHER|Emotion Bias Modification Training|The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
219136868|NCT01876654|DEVICE|TruMatch® patient specific cutting guide|
219136869|NCT02048709|DRUG|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
219136870|NCT01712113|DRUG|Irbesartan|
219136871|NCT01712113|DRUG|Avapro|
219136872|NCT00380627|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
219136873|NCT05388565|BEHAVIORAL|Domestic Violence Enhanced Perinatal Care Program|Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
219136874|NCT05388565|BEHAVIORAL|Standard of Care|Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
219136875|NCT00572000|BIOLOGICAL|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
219551400|NCT06204939|PROCEDURE|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
219551401|NCT00968916|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
219551402|NCT00080613|DRUG|exemestane|
219551403|NCT00080613|PROCEDURE|adjuvant therapy|
219551404|NCT00080613|PROCEDURE|aromatase inhibition|
219551405|NCT00080613|PROCEDURE|conventional surgery|
219551406|NCT00080613|PROCEDURE|endocrine therapy|
219551407|NCT00080613|PROCEDURE|hormone therapy|
219551408|NCT00080613|PROCEDURE|neoadjuvant therapy|
219551409|NCT00080613|PROCEDURE|surgery|
219551410|NCT02752334|DRUG|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
219551411|NCT06260982|RADIATION|18-FDG-PET|18-FDG-PET and neuropsychological tests (language, memory, visuo-spatial tests, etc.).
219551412|NCT00746460|BEHAVIORAL|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
219551413|NCT00686062|OTHER|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
219551414|NCT00686062|OTHER|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
219136876|NCT02698241|DEVICE|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
219136877|NCT04511806|OTHER|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
219136878|NCT06628414|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation
219136879|NCT05761080|DRUG|Amoxicillin clavulanic acid IV during hospitalization|Amoxicillin clavulanic acid IV 5 days during hospitalization. Application of discharge criteria at 5 postoperative days, according to guidelines current clinic.
219136880|NCT05761080|DRUG|Amoxicillin clavulanic acid IV 3 days and PO until day 5|"Amoxicillin clavulanic acid IV 3 days during hospitalization and at discharge Amoxicillin clavulanic acid PO until day 5.~Application of discharge criteria at 72 postoperative hours, administering oral antibiotic therapy with a spectrum similar to that of the control group total of 5 days and sending the patient home with oral analgesia."
219136881|NCT02819193|OTHER|raw mother's own milk|Infants receive mother's own milk before day 7.
219136882|NCT05414929|DIAGNOSTIC_TEST|HPV self-sampling|HPV self-sampling (Cobas Uniswab)
219136883|NCT00604721|DRUG|selumetinib|Given orally
219136884|NCT00604721|OTHER|pharmacological study|
219136885|NCT04288193|DRUG|Recommendation to Deprescribe|Recommendation to Deprescribe
219136886|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
219136887|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
219136888|NCT04217785|DRUG|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
219136889|NCT04217785|BIOLOGICAL|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
219136890|NCT04217785|DRUG|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
219136891|NCT03286205|DRUG|IV iron|IV iron infusion based on weekly or every 3 week dosage.
219136892|NCT02993497|DEVICE|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
219136893|NCT02993497|DEVICE|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
219136894|NCT00556543|DEVICE|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
219136895|NCT04796285|DEVICE|Lab Clasp|Finger-based interstitial fluid assessment device
219136896|NCT01139697|OTHER|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
219136897|NCT05052411|OTHER|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
219136898|NCT02704481|DRUG|Mifepristone|200mg oral mifepristone
219136899|NCT02704481|DRUG|Misoprostol|800mcg buccal misoprostol
219136900|NCT02704481|DRUG|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
219136901|NCT02704481|DRUG|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
219136902|NCT00708279|PROCEDURE|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
219136903|NCT04006860|DRUG|SHC014748M Capsules|SHC014748M Capsules: 200mg
219136904|NCT01838551|DRUG|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
219136905|NCT00124826|DRUG|Insulin|
219136906|NCT00508690|DRUG|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
219136907|NCT00508690|DRUG|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
219136908|NCT00906282|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
219136909|NCT00906282|DRUG|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
219136910|NCT01930279|OTHER|Blood withdrawal|Blood withdrawal
219136911|NCT01026662|PROCEDURE|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
219136912|NCT01026662|DEVICE|eMatrixCO2|
219136913|NCT01792609|PROCEDURE|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
219136914|NCT01792609|PROCEDURE|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
219136915|NCT00071643|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
219136916|NCT00071643|DRUG|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
219716698|NCT07071428|PROCEDURE|Regular acupuncture|Primary acupoints: Baihui (GV20), Hegu (LI4, bilateral), Fengchi (GB20, bilateral), Taichong (LV3, bilateral), Jinsuo (GV8), and Ganshu (BL18, bilateral). Operational procedures: Preoperative preparation identical to the treatment group; for Baihui (GV20), perform subcutaneous insertion backward (0.5 cun); for Fengchi (GB20), apply oblique insertion toward the nasal tip (0.8 cun); for Hegu (LI4) and Taichong (LV3), use perpendicular insertion (0.5 cun); for back-shu points (Ganshu BL18), rapid needling is applied due to low safety and inconvenience of retaining needles. Needle manipulation for qi activation, cycle, and frequency align with the treatment group. Treatment protocol: 3 sessions per week, 10 sessions constituting one course, totaling 20 sessions.
219716699|NCT07071428|PROCEDURE|the Nourishing the vital energyand Regulating the spirit needle technique|Primary points: Zhongwan (RN12), Xiawan (RN10), Qihai (RN6), Guanyuan (RN4), Taixi (KI3/bilat.), Baihui (GV20), Sishencong (EX-HN1), Shenting (GV24), Benshen (GB13/bilat.). Supplemental points: Blinking: Zanzhu (BL2) + Taiyang (EX-HN5/affected); Mouth twitch: Dicang (ST4) + Jiache (ST6/affected); Neck twitch: Fengchi (GB20) + Shangqu (KI17/affected); Limb twitch: UL-Waiguan (SJ5) + Quchi (LI11/affected), LL-Futu (ST32) + Yanglingquan (GB34/affected); Vocal tics: Tongue Three Needles (HN23). Post-disinfection: Calm child pre-needling. Sequence: Scalp → abdomen → limbs. Techniques: Scalp points-subcutaneous backward 0.5in; Taixi (KI3)-perpendicular 0.5in, mild lift-thrust/twirl to deqi; Abdomen-abdominal acupuncture (linea alba ref.), adipose/fascial layer insertion (no muscle/deqi), 30min retention no manipulation; Rapid withdrawal with pressure. Protocol: 3 sessions/week, 10-session course, 20 sessions total.
219716700|NCT06750276|DRUG|AZD2389|Doses of AZD2389 or placebo will be administered orally.
219716701|NCT07073950|DRUG|Budesonide/Glycopyrronium/Formoterol Fumarate|BGF will be administered as 2 inhalations via oral route of administration
219716702|NCT07073950|DRUG|Placebo|Matching placebo will be administered as 2 inhalations via oral route of administration
219716703|NCT07073950|DEVICE|Metered dose inhaler|Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.
219716704|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
219716705|NCT06345339|DRUG|Armour Thyroid|Oral Capsule or Tablet
219716706|NCT06345339|DRUG|Levothyroxine|Oral Capsule
219716707|NCT07129187|DRUG|SHR-A1811|Drug: SHR-A1811 4.8mg/kg
219716708|NCT06927245|DEVICE|PTeye Device|Near infrared stimulation of parathyroid tissue using light at a wavelength of approximately 690 - 770 nm results in autofluorescence of parathyroid tissue. Near infrared autofluorescence detection devices, such as PTEye have been developed with probe-based methods, displaying quantitative real-time information to aid surgeons in detection of parathyroid tissue relative to surrounding tissue.
219716709|NCT05486182|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
219716710|NCT06382272|DEVICE|Bionic Breast implant|A small medical device will be temporarily implanted in one of the breasts at the time of the mastectomy. This device is capable of sending very small electrical currents to the nerves that can deliver sensory stimulation in response to touch and pressure applied to the breast
219716711|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
219716712|NCT07072091|OTHER|Total body physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed in upper limb, trunk, and lower limb muscles, in a whole-body approach.
219716713|NCT07072091|OTHER|Focus shoulder physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed only in the shoulder district, focusing on the trunk-arm muscles.
219716714|NCT07072091|OTHER|Education|Single education session providing information about posture hygiene and proper warm-up
219716715|NCT07073924|BEHAVIORAL|Implementation strategy bundle|The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.
219136917|NCT00071643|OTHER|Placebo|Participants will receive a placebo pill.
219136918|NCT04266561|OTHER|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
219136919|NCT00395811|PROCEDURE|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
219136920|NCT05497869|OTHER|active release group|Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
219228318|NCT03188978|DRUG|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
219136921|NCT05497869|OTHER|active control group|Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
219136922|NCT02661646|DEVICE|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
219136923|NCT04210856|OTHER|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
219136924|NCT06085950|DEVICE|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
219136925|NCT03515720|PROCEDURE|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
219136926|NCT01771900|BEHAVIORAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
219136927|NCT01771900|BEHAVIORAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
219136928|NCT04822129|BEHAVIORAL|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
219136929|NCT04822129|BEHAVIORAL|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
219136930|NCT03553446|DRUG|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
219136931|NCT03949322|BEHAVIORAL|Adapted Physical Activity Program|The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
219136932|NCT01019577|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
219136933|NCT04310059|DIETARY_SUPPLEMENT|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
219136934|NCT04310059|DIETARY_SUPPLEMENT|Materna|Materna
219136935|NCT00991744|DRUG|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
219136936|NCT00991744|DRUG|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
219136937|NCT05541237|DIETARY_SUPPLEMENT|Food|Food
219136938|NCT00573703|PROCEDURE|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
219136939|NCT00573703|PROCEDURE|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
219136940|NCT02289560|DEVICE|Transcranial ExAblate|Transcranial ExAblate
219136941|NCT01037933|OTHER|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
219136942|NCT01037933|OTHER|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
219136943|NCT02540213|DEVICE|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
219136944|NCT02350595|OTHER|Lean fish|
219136945|NCT02350595|OTHER|Fatty fish|
219136946|NCT01506843|BIOLOGICAL|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
219228319|NCT03188978|OTHER|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
219228320|NCT04004520|BEHAVIORAL|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
219228321|NCT04004520|BEHAVIORAL|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
219228322|NCT04004520|BEHAVIORAL|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
219716716|NCT07076069|DRUG|Multimodal Pain Regimen|"Preoperatively: One dose of Pregabalin 100mg and Celecoxib 400mg along with interscalene block~Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml~Postoperatively (Discharge): Acetaminophen 975mg every 4 hours, Meloxicam 7.5mg once per day, Pregabalin 50mg twice per day, Magnesium 400mg once per day, along with rescue Oxycodone 5mg every 4 hours, as needed"
219716717|NCT07076069|DRUG|Standard of Care Pain Regimen|No preoperative medications. Interscalene block in the preoperative holding area. Alternating Acetaminophen 975mg and Ibuprofen 600mg every 4 hours, with rescue Oxycodone 5mg every 4 hours, as needed
219716718|NCT04725539|PROCEDURE|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m"
219716719|NCT03986034|DRUG|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
219716720|NCT02157324|DRUG|acalabrutinib|
219716721|NCT02157324|DRUG|ACP-319|
219136947|NCT05236543|DRUG|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
219136948|NCT05236543|DRUG|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
219136949|NCT04465578|PROCEDURE|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
219136950|NCT04465578|PROCEDURE|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
219136951|NCT04651361|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
219136952|NCT04651361|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
219136953|NCT03265873|OTHER|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
219136954|NCT01247558|OTHER|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for \>120 days
219136955|NCT01247558|OTHER|Not treated with Metanx®|Non-treated comparative cohort
219136956|NCT02214251|DEVICE|PK-16CH EXG system|
219136957|NCT00035230|DRUG|Topiramate|
219136958|NCT03254329|OTHER|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
219136959|NCT02696629|PROCEDURE|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
219136960|NCT02696629|DEVICE|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
219136961|NCT02696629|BEHAVIORAL|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
219136962|NCT01286402|DRUG|Bupropion SR|"* 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
219136963|NCT01286402|OTHER|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
219136964|NCT03650322|BEHAVIORAL|Yoga|12 weeks, total of 150 minutes of exercise per week.
219136965|NCT03650322|BEHAVIORAL|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
219136966|NCT03650322|BEHAVIORAL|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
219136967|NCT02987335|DRUG|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
219716722|NCT06882057|DRUG|Blinatumomab|All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+ (historically given in LR-B-AL with MRD19\>0.1% in the 2020 protocol). Additionally, second 14 days of blinatumomab will be given after completion of HDMTX consolidation treatment.
219716723|NCT06882057|DRUG|Reinduction-2 omission|Reinduction-2 will be omitted for patients with NGS-MRD46\<10\^-6 who have receive the two courses of Blina-14.
219716724|NCT06882057|DRUG|Chemo-light Maintenance 2|Patients with FCM-MRD19\<0.01% and IgH rearrangement NGS MRD 46\<10\^-6 will receive chemo-light maintenance-2 with 4 cyles of 8-week course of MTX + 6MP (totally 32 weeks).
219716725|NCT07080528|DRUG|Sevofluorane|Investigation of the effect of Sevoflurane on muscle relaxation
219228323|NCT03306329|DRUG|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
219716726|NCT07080528|DRUG|Propofol|Investigation of the effect of Propofol on muscle relaxation
219716727|NCT06878846|OTHER|Correlation Study|Assessment of correlation
219716728|NCT05061888|OTHER|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
219716729|NCT05061888|OTHER|Smart Intervention for Stress Management|Will receive a Smart Intervention on stress management practices and strategies.
219136968|NCT02784327|DRUG|PRF110|
219136969|NCT00684970|DRUG|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
219136970|NCT03842150|DIAGNOSTIC_TEST|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
219136971|NCT02759029|DRUG|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
219136972|NCT02780362|DRUG|Prodactariv|1 tablet contains 60 mg Daclatasvir
219136973|NCT02780362|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
219136974|NCT00431509|PROCEDURE|conventional vs. navigated total knee arthroplasty|
219136975|NCT00822913|DRUG|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
219136976|NCT02989961|OTHER|Resticutis|Autologous, Activated-Platelets type of Preparation
219136977|NCT02989961|OTHER|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
219136978|NCT04247711|BEHAVIORAL|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
219136979|NCT04247711|BEHAVIORAL|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
219136980|NCT03165149|DRUG|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
219136981|NCT03165149|DRUG|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
219716730|NCT06828432|DEVICE|CRUISE CTICU CareTaker Vitalstream Device|The CareTaker Vitalstream device is a patented PDA technology and artificial intelligence algorithms derive continuous hemodynamic parameters by analyzing reflective pulse wave analyzes the pulse pressure waveform at 500 times per second, isolates the individual central aortic pulses that give rise to the observed pulse shape, reads central aortic measurements therefore eliminating the effects of hydrostatic pressure, and tracks vascular tone.
219716731|NCT06828432|DEVICE|CRUISE CTICU CNAP Device|The CNAP Monitor provides advanced hemodynamic information from the non-invasive reusable CNAP finger sensor. It supports your Goal Directed Therapy whenever an arterial line is not indicated. Patient-friendly, easy-to-use, cost-efficient. CNAP Monitor offers a unique set of parameters to support your daily routine - all non-invasive \& continuous allowing for perioperative fluid management even in low and moderate-risk surgeries and patients.
219136982|NCT03165149|DRUG|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
219136983|NCT01981356|BEHAVIORAL|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
219136984|NCT01981356|OTHER|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
219228324|NCT03306329|DRUG|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
219551415|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
219551416|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
219551417|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
219136985|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
219136986|NCT02317016|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
219136987|NCT02317016|DRUG|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
219136988|NCT02317016|PROCEDURE|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
219136989|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
219136990|NCT00778804|BEHAVIORAL|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
219136991|NCT00536380|DRUG|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
219136992|NCT00536380|DRUG|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
219136993|NCT00536380|DRUG|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
219136994|NCT01670110|DRUG|Pasireotide LAR|Injectible, 60mg per month
219136995|NCT01670110|DRUG|Placebo|To be injected once per month
219136996|NCT06523855|PROCEDURE|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
219136997|NCT02555631|BEHAVIORAL|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
219136998|NCT00290706|DRUG|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
219136999|NCT00290706|DRUG|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
219551418|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
219551419|NCT05553496|DRUG|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
219551420|NCT05553496|DRUG|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
219551421|NCT01969864|BEHAVIORAL|HRSA Video Intervention|
219137000|NCT04884737|OTHER|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
219137001|NCT05708066|OTHER|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
219137002|NCT05708066|OTHER|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
219551422|NCT01969864|BEHAVIORAL|PI Video Intervention|
219551423|NCT01969864|BEHAVIORAL|CDC Health Website Intervention|
219551424|NCT05824949|PROCEDURE|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
219551425|NCT05824949|PROCEDURE|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
219551426|NCT00623558|DRUG|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
219137003|NCT02633189|DRUG|Erlotinib|given orally 150 mg daily
219137004|NCT02633189|DRUG|Bevacizumab|15 mg/kg intravenously every 21 days.
219137005|NCT01768676|DRUG|avanafil|100 mg
219137006|NCT01768676|DRUG|Placebo|
219137007|NCT04066738|DIAGNOSTIC_TEST|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
219228325|NCT03306329|DRUG|Placebo|Placebo tablets administered once daily
219228326|NCT02976363|RADIATION|Radiotherapy breast cancer|
219551427|NCT00623558|DRUG|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
219551428|NCT00623558|DRUG|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
219551429|NCT02707887|BEHAVIORAL|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
219551430|NCT02707887|BEHAVIORAL|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
219551431|NCT02707887|BEHAVIORAL|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
219551432|NCT00037752|DRUG|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
219716732|NCT06828432|DEVICE|CRUISE CTICU Edwards Clearsight Device|The Edwards ClearSight system provides continuous blood pressure and advanced hemodynamic parameters from a noninvasive finger cuff. Continuous data offered by the ClearSight system enables you to proactively optimize perfusion through hemodynamic management.
219716733|NCT03842007|DIAGNOSTIC_TEST|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
219716734|NCT03842007|DIAGNOSTIC_TEST|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
219716735|NCT06773975|DIETARY_SUPPLEMENT|Oral nutritional supplementation|The oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly
219716736|NCT07080957|PROCEDURE|Mesh-free laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy without synthetic mesh was performed by utilizing native tissue fixation techniques. The uterus was suspended to the iliopectineal ligaments using permanent sutures without mesh implantation. The procedure aimed to provide apical support and avoid mesh-related complications. Postoperative follow-up included assessments of anatomical correction, functional recovery, and patient satisfaction.
219137008|NCT04066738|DIAGNOSTIC_TEST|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
219137009|NCT04066738|DIAGNOSTIC_TEST|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
219137010|NCT00770978|DRUG|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
219137011|NCT00770978|DRUG|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
219137012|NCT06141980|DRUG|DWP16001 0.3 mg|DWP16001 0.3mg, Tablets, Orally, Once daily
219137013|NCT01396291|DRUG|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
219137014|NCT01396291|DRUG|placebo|asenapine-matched placebo, sublingual tablets, BID
219137015|NCT03395353|DRUG|Duloxetine Hydrochloride|Administered orally
219137016|NCT00195078|DRUG|ZD1839 (IRESSA)|
219137017|NCT00195078|DRUG|Cisplatin|
219137018|NCT00195078|PROCEDURE|Radiation Therapy|
219137019|NCT02493933|DRUG|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
219716737|NCT07080957|PROCEDURE|Mesh-based laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy was performed using a synthetic mesh to provide apical support while preserving the uterus. The mesh was bilaterally fixed to the iliopectineal (Cooper's) ligaments, and the uterus was suspended in a tension-free manner. This technique is designed to restore pelvic anatomy and improve symptoms of prolapse. Patients were followed postoperatively to assess anatomical success, complications, and functional outcomes.
219137020|NCT01196429|DRUG|Carboplatin|Given IV
219137021|NCT01196429|DRUG|Docetaxel|Given IV
219137022|NCT01196429|OTHER|Laboratory Biomarker Analysis|Correlative studies
219137023|NCT01196429|DRUG|Paclitaxel|Given IV
219137024|NCT01196429|DRUG|Temsirolimus|Given IV
219137025|NCT05851768|DRUG|Bupivacaine|Bupivacaine 0.25%
219137026|NCT05851768|DRUG|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
219137027|NCT05851768|DRUG|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
219137028|NCT01260298|DEVICE|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
219137029|NCT02486588|OTHER|Messaging|See detailed study description for overview of the different messaging interventions in this study
219137030|NCT02486588|OTHER|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
219137031|NCT05591001|DRUG|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
219137032|NCT05591001|DRUG|Propofol|propofol (100 ug /kg/min) infusion
219137033|NCT04218669|PROCEDURE|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
219137034|NCT04218669|PROCEDURE|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
219137035|NCT03693742|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
219137036|NCT03693742|OTHER|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
219228327|NCT02976363|OTHER|Evaluation Maximal Respiratory Pressures|
219228328|NCT01505699|GENETIC|RNA analysis|
219551433|NCT00037752|BEHAVIORAL|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
219716738|NCT07084142|OTHER|Online, patient-facing decision-making aid (app) with personalized risk information.|"The online, patient-facing decision-making aid will have the following features:~1. Clinical Data Input,~2. Introduction via Animated Video,~3. Common Questions,~4. Check-In Quiz,~5. Risk and Values Exploration based on patient specific information,~6. Wrap-Up,~7. Patient-Physician Worksheet,~These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue."
219716739|NCT07084142|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Some participants, in their course of medical care unrelated to the study intervention, will undergo implantation of an ICD.
219716740|NCT07084142|OTHER|Online, patient-facing decision-making app without personalized risk information.|The online, patient-facing decision-making aid will have the following features: 1) Clinical Data Input, 2) Introduction via Animated Video, 3) Common Questions, 4) Check-In Quiz, 5) Generic Risk and Values Exploration without patient specific information, 6) Wrap-Up, 7) Patient-Physician Worksheet, These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue.
219716741|NCT06372145|DRUG|Tolebrutinib|Pharmaceutical form:Tablet-Route of administration:oral
219716742|NCT06372145|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:oral
219716743|NCT06372145|DRUG|Teriflunomide|Pharmaceutical form:Tablet-Route of administration:oral
219137037|NCT03693742|OTHER|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
219137038|NCT02589210|OTHER|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
219137039|NCT03910517|OTHER|No intervention|No intervention
219137040|NCT04167891|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
219137041|NCT04248829|DRUG|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
219137042|NCT04248829|DRUG|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
219137043|NCT04248829|DRUG|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
219137044|NCT04248829|DRUG|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
219137045|NCT05799560|OTHER|THERAPEUTIC TOUCH|Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.
219137046|NCT05799560|OTHER|REİKİ|It will be applied twice a week for two weeks, each application for 20 minutes.
219137047|NCT00776711|DRUG|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
219137048|NCT00776711|DRUG|VRC-AViDNA036-00-VP|
219137049|NCT02685033|DRUG|Dalbavancin|
219716744|NCT07116863|DRUG|KDF1901-R0|Fixed-dose combination tablet containing valsartan 80 mg and amlodipine 5 mg. Orally administered once daily for 4 weeks during the run-in period, and for 2 weeks during Treatment Period 1(Dual Therapy group).
219137050|NCT02685033|DRUG|Comparator|
219137051|NCT02132702|DEVICE|Ekso|
219137052|NCT04375644|OTHER|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
219137053|NCT01477619|DRUG|Tasimelteon|20mg single dose on Day 1
219137054|NCT06652763|OTHER|Minnesota Living with Heart Failure Questionnaire|Self-administered, validated questionnaire to assess symptoms of heart failure
219137055|NCT06652763|DIAGNOSTIC_TEST|Echocardiogram|Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
219137056|NCT06652763|DIAGNOSTIC_TEST|Six-minute walk test|Standardised, objective assessment of exercise capacity
219137057|NCT06652763|DIAGNOSTIC_TEST|Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy|Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
219137058|NCT06652763|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan|Scan including adenosine stress perfusion
219137059|NCT06652763|DIAGNOSTIC_TEST|Blood tests|Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
219228329|NCT01505699|GENETIC|cytogenetic analysis|
219228330|NCT01505699|GENETIC|microarray analysis|
219228331|NCT01505699|OTHER|laboratory biomarker analysis|
219228332|NCT02211508|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
219228333|NCT05010499|DRUG|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
219551434|NCT04846439|BIOLOGICAL|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
219716745|NCT07116863|DRUG|KDF1901-L|"Fixed-dose combination tablet containing valsartan 80 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg.~Orally administered once daily for 2 weeks during Treatment Period 1."
219716746|NCT07116863|DRUG|KDF1901|"Fixed-dose combination tablet containing valsartan 160 mg, amlodipine 10 mg, and chlorthalidone 25 mg.~Orally administered once daily for 6 weeks during Treatment Period 2."
219716747|NCT07116863|DRUG|KDF1901-R1|Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.
219716748|NCT07113808|DEVICE|contrast-enhanced ultrasound examination|to evaluate the the application of contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses aged from 29 days to 18 years old
219716749|NCT07113808|DRUG|SonoVue®|perform contrast enhanced ultrasound (CEUS) using Sonovue as the contrast agent
219137060|NCT06374056|DEVICE|Kintsugi Voice Device|"The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs."
219137061|NCT00968331|DRUG|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
219137062|NCT04573374|PROCEDURE|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
219137063|NCT06214221|DEVICE|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
219137064|NCT06214221|OTHER|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
219137065|NCT04774224|DRUG|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
219137066|NCT04774224|DRUG|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
219137067|NCT06614010|DRUG|Dexmedetomidine Injection|Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
219137068|NCT06614010|DRUG|Ropivacaine and Dexmedetomidine|Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
219137069|NCT06614010|DRUG|Sodium Chloride Injection|Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
219137070|NCT05565521|RADIATION|Dose escalation + Reduced Margin Adaptive Radiotherapy|Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.
219137071|NCT06692556|RADIATION|Adjuvant radiotherapy|"Patients will receive an adjuvant radiotherapy corresponding to an equivalent dose of 45 to 50 Gy (Equivalent Dose in 2 Gy Fractions \[EQD2\] with a tumor alpha/beta ratio of 10 Gy) delivered on the operating bed.~Patients will be treated by :~* either external radiation therapy using high-energy electrons or photons:~  * 45 Gy in 15 fractions of 3 Gy~ * 50 Gy in 25 fractions of 2 Gy~* or interstitial brachytherapy or brachytherapy via skin applicators:~  * 36 Gy in 8 fractions of 4.5 Gy~ * 36 Gy in 9 fractions of 4 Gy~ * 40 Gy in 8 fractions of 5 Gy~Radiation therapy should be started within 8 weeks after surgery (or 10 if delayed healing).~Patients will be monitored regularly until the date of the first relapse (local, regional or metastatic), or until the date of death (if no relapse).~Regardless of the type of relapse, remedial treatments will be left to the the investigator's discretion up to the first metastatic relapse."
219137072|NCT06629545|OTHER|irrigation activation with PUI|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.
219137073|NCT06629545|OTHER|irrigation with sonic activation|A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
219137074|NCT06628726|DIAGNOSTIC_TEST|Liver biopsy|surgical biopsy from liver
219137075|NCT06698172|OTHER|Virtual Reality rehabilitation|"The study includes 12 weekly 45-minute visual rehabilitation sessions using a Virtual Reality device with Visionary Sport software. Originally designed for sports visual training, this software features gamified exercises to improve visual response times under professional supervision. Activities include games to enhance fixation, ocular motility, peripheral vision, and vergence.~The Peripheral Attention activity trains reaction times to static stimuli perceived in the peripheral retina, adjustable to the patient's visual field defect. Stimuli can be placed at 10, 20, or 30 degrees in the peripheral field. The VR headset (Vive Focus 3) includes an eye tracker to monitor and adapt stimuli based on patient performance.~Patients also perform 30 minutes of daily exercises at home, using proprietary software and Tobii 4C and 5C eye-tracking devices for ocular monitoring."
219228334|NCT05010499|DRUG|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
219228335|NCT03462771|DRUG|Fish oil|4g of fish oil daily for 14 weeks
219228336|NCT03462771|DRUG|sunflower oil|4g of sunflower oil daily for 14 weeks
219228337|NCT00705172|DRUG|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
219137076|NCT06696898|PROCEDURE|Somatosensory Motor Control Exercises|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
219137077|NCT06696898|PROCEDURE|Myofascial Release Technique|Manual therapy technique that applies sustained pressure to myofascial tissues around the lumbar spine and pelvis to release tension and improve mobility.Myofascial Release Technique MFR is given with the ulnar border from proximal to distal direction with a light gentle pressure over the hamstring muscle until the slack in the skin is loosened. (2) Every strike is to be held for 30 seconds, 5 repetitions per session
219137078|NCT06696898|PROCEDURE|Sensorymotor training|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
219137079|NCT06696911|PROCEDURE|Core stability Exercises|"The exercises have been divided into three difficulty categories based on the level of difficulty.~Level I: When the patients were unable to sit independently, level I core stability therapy was administered. First-level exercises were done in a supine position on a plinth. The workout program mostly included side bridging movements, leg crosses, one-leg curl-ups, and straight and diagonal reaching activities. Patients can move to level once they can sit on a plinth edge unsupported for one minute while flexing their knees and hips to 90 degrees.~Level II: Exercises included straight-arm curl-ups, diagonal-arm curl-ups, and arm curl-ups with the arms crossed. The patient will go to stage three once they can sit on an unstable surface for thirty seconds.~Level III: Using a physio ball, the exercises were done while seated. The exercises performed with the ball consisted push-ups, bird dog, side Bridge, abdominal curl-ups, and bridge movements"
219228338|NCT04421534|DRUG|Lactoferrin|adding lactoferrin to standard of care treatment regimens
219228339|NCT04870905|DRUG|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
219716750|NCT06183476|BEHAVIORAL|Amplify-RHYTHM|Amplify-RHYTHM will have two main components: 1) timed light exposure (increase light in the morning, blue light reduction in the evening and eye masks at night), 2) weekly remote coaching session by psychologist to optimize circadian and sleep behaviors
219716751|NCT07121374|DRUG|Neoadjuvant chemo-immunotherapy|Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1 cycle of Yervoy for inoperable T2-T3 TNM 9 patients with PM
219716752|NCT07121374|PROCEDURE|Extended pleurectomy/decortication in case of reaching operability|After the systemic treatment the surgery will follow if patient is operable.
219716753|NCT07122583|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
219716754|NCT07122609|DRUG|Pirtobrutinib|Dose:200mg，d1-21
219716755|NCT07122609|DRUG|R-GemOx|Dose: Rituximab: 375mg/m2, d1; Gemcitabine: 1000mg/m2, d2; Oxaliplatin:100mg/m2, d2
219716756|NCT07122609|DRUG|Polatuzumab Vedotin|Dose: 1.8mg/kg，iv，d1 (For patient who is CD79b positive and has not previously received polatuzumab Vedotin)
219716757|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice|The alliance-focused DBT training plus deliberate practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. This training intervention involves a didactic component, video analysis, and case-based learning. Deliberate practice methods (e.g., setting individualized training goals, skills coaching, feedback, and opportunities for repeated practice) will be integrated both within and between training sessions.
219716758|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Reflective Practice|The alliance-focused DBT training plus reflective practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. Trainings will involve a didactic component, video analysis, and case-based learning. Reflective practice methods (i.e., thinking about past experiences to gain insight for future actions) will be integrated both within and between training sessions.
219716759|NCT07122037|DEVICE|DosMedical Smell Training Set|Olfactory training with four different odorants (e.g., rose, eucalyptus, lemon, and cloves) for approximately 10 seconds each, twice a day, in the morning and in the evening
219716760|NCT07122037|BEHAVIORAL|Nasal Airflow Inducing Maneuver|"Repeated generation of an underpressure in the oral cavity by simultaneously lowering the jaw, the floor of the mouth the tongue, the base of the tongue and soft palate with securely closed lips. This negative pressure created in the oral cavity generates an airflow through the nose."
219716761|NCT07124728|BEHAVIORAL|Technology-enabled Telehealth Care Plan|Participants receive a 6 month personalized telehealth intervention via a multidisciplinary care team, delivering care via a secure digital platform, including education, risk assessment, lifestyle coaching, medical history review, and stroke risk reduction planning. The Healthie EHR is used for communication, documentation, and data integration. Syntrillo Navigators and neurology providers conduct onboarding, telemedicine visits, and coordination with patient's primary care providers and care team.
219716762|NCT07124728|DEVICE|Blood Pressure Monitoring Device|Participants will receive a cellular-enabled, FDA-cleared blood pressure monitor supplied by Tenovi. Blood pressure is measured twice daily during baseline and at least once daily throughout the 6-month intervention. Data is transmitted via a secure gateway to the Healthie EHR for real-time monitoring and analysis.
219137080|NCT06696911|PROCEDURE|Motor Imagery|"The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity."
219137081|NCT06711497|OTHER|global postural reeducation exercises|Subjects will be trained on global postural reeducation exercises (GPR) and active neck exercises. At each session, they will maintain two different lying postures to stretch anterior and posterior muscle chain and one standing posture to integrate the postural correction into activity of daily living (ADL.Initially, without gravity load, a lying posture was applied to the anterior muscle chain for approximately 15 min, then another lying posture to the posterior muscle chain for other 15 min, and finally the patients worked in a standing posture for postural integration under a gravity load for 5 min.
219137082|NCT06711497|OTHER|deep neck flexor activation exercise|"Subjects will be trained on deep neck flexor activation using pressure biofeedback and active neck exercises . The pressure sensor will be put under the neck and will be asked to de gentle nod as if saying yes so that the pressure sensor measures 2mmHg above baseline (20mmHg), then 4mmHg, followed by 6mmHg,8mmHg, and 10 mmHg without rests in between. the pressure sensor should read 30mmHg at the end of the movement sequence. Patient will hold each increment for 2 seconds, 10 seconds total after all 5 increments. Highest level achieved will be repeated with the correct form until a total of 10 reps with 10-second holds will be achieved in three series with 30 seconds of interval between the series plus active neck flexor exercise"
219137083|NCT06709209|PROCEDURE|Colonoscopy after bowel cleansing|Colonoscopy will be performed using HD-WLE; TXI; RDI and NBI.
219137084|NCT06709209|PROCEDURE|Intestinal biopsies|During colonoscopy, at least 2 biopsies from each segment will be taken as standard of care to assess inflammation in UC
219137085|NCT06709209|DIAGNOSTIC_TEST|blood sampling|Blood samples will be taken for standard of care by appropriately trained members of the clinical research team. The results of the standard of care blood will be used in the research.
219137086|NCT06709209|DIAGNOSTIC_TEST|Stool|The stool sample will be sent to the laboratory for Faecal Calprotectin (FCP) as a marker of disease activity.
219137087|NCT06709209|OTHER|Clinical follow-up|Patients will be followed-up at 6 and 12 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. Partial Mayo Score (PMS) and occurrence of clinical outcomes will be evaluated.
219551435|NCT02045355|OTHER|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
219137088|NCT06712173|DRUG|linperlisib and SHR2554|Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
219137089|NCT06708429|DIAGNOSTIC_TEST|LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)|"A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)"
219137090|NCT06711003|DEVICE|enhanced external counterpulsation|Enhanced External Counterpulsation (EECP) is a non-invasive treatment primarily used for patients with angina or heart failure. It involves the application of pressure cuffs to the legs, which inflate and deflate in sync with the cardiac cycle. This enhances blood flow to the heart during diastole, the phase when the heart is resting between beats. The increased pressure promotes coronary artery perfusion, helping to improve oxygen delivery to the heart muscle, reduce angina symptoms, and enhance cardiovascular function. EECP is typically recommended for patients who are not good candidates for invasive procedures like angioplasty or bypass surgery, or for those seeking supplementary treatment for angina. Over time, it may promote the development of new blood vessels (collateral circulation), further improving heart health. The treatment is generally administered over several weeks in outpatient settings, with each session lasting around one hour.
219137091|NCT06711003|PROCEDURE|post acute care|Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
219137092|NCT06714032|DRUG|TCM plus conventional drug|All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
219137093|NCT06714032|DRUG|TCM placebo plus conventional drug|All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
219137094|NCT06713915|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Only patients in the prospective cohort will undergo CEM in addition to breast ultrasound.
219137095|NCT06711172|OTHER|Health coaching intervention|The health coaching intervention will consist of seventeen, 30 to 60-minute telehealth sessions that were dispersed over six months. Participants will work closely with a health coach to create a plan for making appropriate lifestyle changes and for accomplishing the clinical recommendations that were received from their comprehensive evaluation at the War Related Illness and Injury Study Center.
219228340|NCT02713594|BEHAVIORAL|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
219551436|NCT00510419|DRUG|"InvestigationalAuto-injector (sumatriptan succinate)"|
219551437|NCT02998541|DRUG|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
219137096|NCT06706882|BEHAVIORAL|Experimental Training: VIRTRAEL/LUCCIDY|"Cognitive stimulation of the different cognitive functions to be addressed will be conducted in the following sessions:~* Session 1: Shopping lists. Balls. Gift shopping. Long-term memory of the Shopping List.~* Session 2: Disordered objects. Whats different? Semantic series. Logical series. Puzzle pieces. Semantic analogies.~* Session 3: Classifiable objects. Gift shopping. Bag of objects.~* Session 4: Shopping lists. Balls. Disordered objects. Long-term memory of the Shopping List.~* Session 5: Semantic series. Logical series. Puzzle pieces. Semantic analogies. Gift shopping.~* Session 6: Classifiable objects. Bag of objects. Disordered objects.~* Session 7: Shopping lists. Semantic series. Logical series. Puzzle pieces. What\&amp;#39;s different? Semantic analogies. Long-term memory of the Shopping List.~* Session 8: Disordered objects. Gift shopping. Balls.~* Session 9: Bag of objects. Semantic series. Logical series. Whats different? Semantic analogies. Classifiable objects."
219137097|NCT06706882|BEHAVIORAL|Active Comparator: Standard Training: Reflection Group (TAU) (Andalusian Institute of Women, 2010)|This 9-session program explores how societal norms shape women\&amp;#39;s roles and identities. In Session 1, it discusses how women are socially positioned as caretakers in relationships and introduces the concept of the self in relation. Session 2 delves into gender conflicts, focusing on the tension between societal demands and personal desires. Session 3 explores guilt when women fail to meet expected roles, and the fear of being selfish when prioritizing their own needs. Session 4 examines how dependence is fostered by seeking external validation for self-worth. Session 5 critiques romantic love as a cultural tool to prioritize men desires over women. Session 6 analyzes how intimate partner violence (IPV) emerges as a means to maintain power imbalances in relationships. Session 7 looks at the family role in socializing women, while Session 8 explores fears of abandonment. Finally, Session 9 focuses on building life skills and concludes the program.
219137098|NCT06707324|PROCEDURE|drug injected between the rectus abdominis muscle and the transversus abdominis muscle|20 ml of 0.25% bupivacaine + 8 mg dexamethasone between the rectus abdominis muscle and the transversus abdominis muscle on both sides
219137099|NCT06707324|PROCEDURE|drug injected in the external oblique intercostal plane on both sides|20 ml of 0.25% bupivacaine+ 8 mg dexamethasone into the external oblique intercostal plane on both sides
219137100|NCT06711263|OTHER|Mouthwash Product|"* In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores."
219137101|NCT04893421|DEVICE|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
219137102|NCT06009419|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
219137103|NCT02101905|OTHER|Laboratory Biomarker Analysis|Correlative studies
219137104|NCT02101905|DRUG|Lapatinib|Given PO
219137105|NCT02101905|DRUG|Lapatinib Ditosylate|Given PO
219137106|NCT02101905|OTHER|Pharmacological Study|Correlative studies
219137107|NCT02101905|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
219137108|NCT03203525|BIOLOGICAL|Bevacizumab|Given IV
219137109|NCT03203525|DRUG|Fluorouracil|Given via pump
219137110|NCT03203525|DRUG|Leucovorin|Given via pump
219137111|NCT03203525|DRUG|Oxaliplatin|Given via pump
219551438|NCT02998541|DRUG|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
219551439|NCT02998541|OTHER|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
219551440|NCT03391050|DRUG|APR-246|Intravenous infusion
219551441|NCT03391050|DRUG|Dabrafenib|Oral administration
219551442|NCT01134549|DRUG|Etelcalcetide|Administered as a single intravenous (IV) injection
219551443|NCT01134549|DRUG|Placebo|Administered as a single intravenous (IV) injection
219551444|NCT01929486|BIOLOGICAL|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
219551445|NCT00396162|DRUG|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
219551446|NCT00396162|OTHER|Placebo|Placebo pill
219551447|NCT01677338|DRUG|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
219551448|NCT01677338|DRUG|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
219551449|NCT03734354|DRUG|Brexpiprazole|Brexpiprazole , single/oral/with fasting
219551450|NCT03086941|DEVICE|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
219551451|NCT03852745|BEHAVIORAL|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
219551452|NCT03276767|OTHER|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
219551453|NCT01931449|PROCEDURE|Modified method of digestive tract reconstruction|
219551454|NCT01931449|PROCEDURE|Routine digestive tract reconstruction|
219716763|NCT07124728|DEVICE|Tenovi Smart Pillbox|Participants receive a connected 7-day smart pillbox that detects compartment openings and refills. Medication adherence data is uploaded in real time to a secure dashboard and integrated into the EHR.
219137112|NCT03203525|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219137113|NCT03203525|DRUG|Temsirolimus|Given IV
219137114|NCT03203525|PROCEDURE|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
219137115|NCT05394779|DEVICE|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
219137116|NCT05394779|DEVICE|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
219137117|NCT05904340|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) uses machines to generate electric current, flows through the skin and conducts to the nerves, triggers a chain reaction of nerves through a new stimulus source, and achieves the effect of pain relief. Using different frequencies and intensities will Produce different effects and trigger different physiological mechanisms.
219137118|NCT02960659|DRUG|Liraglutide|Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
219137119|NCT02960659|DRUG|Metformin|Metformin 500mg oral tablet
219137120|NCT03640403|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
219137121|NCT03640403|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
219137122|NCT05601830|DRUG|QN-030a|NK cell therapy
219137123|NCT05601830|DRUG|Cyclophosphamid|Lympho-conditioning Agent
219137124|NCT05601830|DRUG|Fludarabine|Lympho-conditioning Agent
219137125|NCT05601830|DRUG|Cytarabine|Lympho-conditioning Agent
219137126|NCT04655118|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
219137127|NCT04655118|DRUG|Placebo|Placebo to match TL-895
219137128|NCT05604885|DRUG|AP1189, 60 mg|AP1189 tablets for oral use
219137129|NCT05604885|DRUG|AP1189, 80 mg|AP1189 tablets for oral use
219137130|NCT05604885|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
219551455|NCT02920476|DRUG|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
219137131|NCT05604885|DRUG|Placebo|Matching placebo tablets for oral use
219137132|NCT03482804|OTHER|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
219137133|NCT01013012|DRUG|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
219137134|NCT01013012|DRUG|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
219137135|NCT06315777|GENETIC|cumulus cell oocytes complex (COC) among women with poor ovarian reserve|level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
219137136|NCT02749968|DRUG|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
219137137|NCT02749968|DRUG|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
219137138|NCT03068468|DRUG|BIIB092|BIIB092 intravenous infusion on specified days
219137139|NCT03068468|DRUG|Placebo|Placebo intravenous infusion on specified days
219137140|NCT00129948|DRUG|Troxatyl™ (troxacitabine)|
219137141|NCT05800041|DRUG|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
219137142|NCT05068037|OTHER|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
219137143|NCT05068037|OTHER|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
219137144|NCT05068037|OTHER|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
219137145|NCT05826444|DIAGNOSTIC_TEST|Echocardiography|Echocardiography with afterload change
219137146|NCT05826444|DIAGNOSTIC_TEST|Magnetic resonance imaging|Stress-MRI
219137147|NCT05826444|DIAGNOSTIC_TEST|Magnetocardiography|Magnetocardiography
219137148|NCT05826444|DIAGNOSTIC_TEST|Histology|Histological analysis
219137149|NCT05826444|DIAGNOSTIC_TEST|Genetics|miRNA sequencing
219137150|NCT05826444|DIAGNOSTIC_TEST|calcium signaling|cardiomyocyte calcium signaling
219137151|NCT05826444|DIAGNOSTIC_TEST|IMR|Index of microvascular resistance measurement
219137152|NCT05826444|DIAGNOSTIC_TEST|Angio-IMR|Angiography derived post-processing index if microvascular resistance
219137153|NCT04565522|OTHER|Prospective observation|Prospective observation until one year follow-up
219137154|NCT03619616|DRUG|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
219551456|NCT04179396|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
219716764|NCT07124728|DEVICE|Wearable Activity Trackers (Fitbit or Apple Watch)|Participants will utilize a commercially available wearable activity tracker to monitor step counts, resting heart rate, and heart rate variability. This data is integrated into the EHR. Devices will be provided if participants do not already own one.
219137155|NCT03619616|DRUG|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
219137156|NCT03619616|DRUG|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
219137157|NCT03619616|DRUG|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
219137158|NCT03619616|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
219137159|NCT03619616|DRUG|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
219137160|NCT03619616|DRUG|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
219137161|NCT00773435|BIOLOGICAL|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
219137162|NCT00773435|OTHER|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
219716765|NCT07124728|OTHER|Healthie EHR|HIPAA-compliant electronic medical record system used for participant management, secure communication, clinical documentation, and device data integration, consisting of custom workflows used for risk tracking and care planning.
219716766|NCT07124728|OTHER|Secure Messaging Platforms (TigerConnect, Weave, AirCall)|Participants and providers may communicate using secure messaging platforms for appointment reminders, assessments, and care support, to enhance participation engagement and care coordination.
219551457|NCT04179396|DRUG|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
219551458|NCT04179396|DRUG|Abiraterone|Abiraterone will be administered once daily with prednisone
219137163|NCT03282526|DIAGNOSTIC_TEST|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
219137164|NCT01462058|DIETARY_SUPPLEMENT|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
219137165|NCT01462058|DRUG|Placebo|Placebo, daily, 12 weeks
219716767|NCT07124728|DRUG|Antihypertensive Medication Management|Participants may be prescribed or have existing antihypertensive regimens adjusted (ACE inhibitors, beta blockers, calcium channel blockers, diuretics, etc) by neurologists or nurse practitioners based on individual risk assessments and clinical findings during the study. Changed will be recorded in EHR.
219551459|NCT03196817|DRUG|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
219716768|NCT07124728|DRUG|Statin Medication Management|Lipid-lowering medications, including statins, may be initiated or adjusted as part of participants' care plans. Medication use is guided by cardiovascular risk and AHA guidelines. Changed will be recorded in EHR.
219716769|NCT07124728|DRUG|Antiplatelet or Anticoagulant Therapy|Participants with atrial fibrillation or elevated cardiovascular risk may be started on or have changes to antiplatelet or anticoagulant therapy. Medication decisions are made by neurologist or nurse practitioners during telemedicine visits. Changed will be recorded in EHR.
219716770|NCT07124728|PROCEDURE|Laboratory Blood Test Collection|Blood samples may be collected at baseline and at 6 months to assess inflammation through high-sensitivity C-reactive protein.
219716771|NCT07123571|BEHAVIORAL|Contagious Laughter|Contagious laughter videos
219716772|NCT07123675|DEVICE|Device: AI Clinical Decision Support System|An AI-based software system that provides real-time, on-screen recommendations to the anesthesiologist regarding drug administration and adjustments to maintain optimal patient physiological parameter
219137166|NCT02669524|DRUG|LY2409021|
219137167|NCT02669524|DRUG|LY2409021 placebo|
219137168|NCT02669524|PROCEDURE|OGTT|
219137169|NCT02669524|PROCEDURE|IIGI|
219137170|NCT02669524|PROCEDURE|Standardised liquid meal|
219716773|NCT07123675|PROCEDURE|Procedure: Standard of Care Anesthesia|Standard anesthesia management according to institutional guidelines. The attending anesthesiologist makes all clinical decisions based on their expertise and judgment without input from the investigational AI system.
219137171|NCT02338739|BEHAVIORAL|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
219137172|NCT02338739|BEHAVIORAL|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
219137173|NCT02338739|BEHAVIORAL|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
219137174|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
219137175|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
219137176|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
219551460|NCT03196817|DEVICE|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
219551461|NCT00890864|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
219551462|NCT00218322|DRUG|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
219551463|NCT00218322|DRUG|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
219551464|NCT01080820|DRUG|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
219137177|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
219137178|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
219137179|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
219137180|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
219137181|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
219716774|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 1
219716775|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 2
219716776|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor, tissue, and blood sample collection
219716777|NCT05504291|DRUG|Carboplatin|Given IV
219716778|NCT05504291|DRUG|Etoposide|Given IV
219716779|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
219716780|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219716781|NCT05504291|DRUG|Melphalan|Given I-VITRE
219716782|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
219716783|NCT05504291|DRUG|Vincristine|Given IV
219716784|NCT06908590|BEHAVIORAL|Education, Providing and Engaging Social Support and Assistance with Health System Navigation|"1. Introduction to Program and Cardiac Rehab Needs Assessment Education about Cardiac Rehab~2. Education about CVD and how Cardiac Rehab can help in the participants recovery~3. Social Support Module~4. Health System Navigation Module"
219716785|NCT07096076|OTHER|Thoracolumbar fascia inhibition|Soft tissue mobilization: Participants will be asked to lie on their backs without a pillow in a hook-lying position, placing a foam roller under the inferior part of the scapula and clasping their hands behind the cervical region. Then, they will be instructed to lift their hips off the ground and roll the foam roller in a cranial and caudal direction from the inferior scapular region to the sacral area for 30 seconds, performing flexion and extension movements with their knees. This application will be performed in a total of 4 sets.
219137182|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
219137183|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
219716786|NCT07096076|OTHER|Suboccipital inhibition group|Soft tissue mobilization: Participants will be asked to lie in a supine position on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and by dorsiflexing the ankle, they will pull the extended leg toward themselves. This position should be maintained for 30 seconds (8). It is important that the opposite knee does not flex during the exercise. The application will be performed bilaterally.
219716787|NCT07096076|OTHER|hamstring stretching|Participants performed passive hamstring stretching using a sheet for self-assistance. Participants will be asked to lie supine on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and performing ankle dorsiflexion, they will pull the leg-kept in knee extension-toward themselves. This position should be held for 30 seconds (8). It is important that the opposite knee does not move into flexion during the exercise. The application will be performed bilaterally.
219716788|NCT07093034|DEVICE|Extended nocturnal use of auricular vagus nerve stimulator device|Patients will wear the ParasymTM device with an ear clip on the tragus that provides stimulation at sub-detection threshold.
219716789|NCT07087951|DEVICE|Gamma auditory stimulation device (active setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
219716790|NCT07087951|DEVICE|Gamma auditory stimulation device (sham setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
219716791|NCT07096427|BEHAVIORAL|Virtual Reality-Based Prenatal Education|This intervention involves prenatal education based on Pender's Health Promotion Model delivered using immersive 360-degree virtual reality (VR) videos. The content focuses on healthy lifestyle behaviors during pregnancy, including nutrition, physical activity, stress management, and health responsibility. Participants view the videos via VR headsets in three weekly sessions, each lasting approximately 20 minutes. Motivational follow-up calls are conducted after the sessions.
219716792|NCT07096427|BEHAVIORAL|Booklet-Based Prenatal Education|This intervention includes prenatal education based on Pender's Health Promotion Model delivered through printed booklets. The educational content is identical to that of the VR group and covers healthy behaviors in pregnancy. The booklets are discussed in three face-to-face sessions, held once per week for three weeks. Each session lasts about 20 minutes. Participants receive motivational follow-up phone calls after the sessions.
219716793|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
219716794|NCT05629091|DEVICE|Epicite hydro|Wound dressing
219716795|NCT05629091|DEVICE|Epiprotect|Wound dressing
219716796|NCT07098858|DEVICE|The Wise System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
219137184|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
219137185|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
219137186|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
219137187|NCT06140745|DRUG|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
219137188|NCT06140745|DRUG|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
219137189|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
219137190|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
219137191|NCT00143689|DRUG|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
219137192|NCT01711710|DEVICE|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
219137193|NCT05185921|BEHAVIORAL|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
219137194|NCT04307199|PROCEDURE|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
219228341|NCT02713594|OTHER|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
219228342|NCT02125409|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
219228343|NCT02125409|PROCEDURE|Screening colonoscopy|
219228344|NCT05459974|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
219228345|NCT05459974|DRUG|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
219228346|NCT03337022|DRUG|CC-90006|CC-90006
219228347|NCT03337022|OTHER|Placebo|Placebo
219551465|NCT01080820|DRUG|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
219551466|NCT01080820|DRUG|Viread|One single oral dose of 300mg Viread.
219551467|NCT01944722|DEVICE|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
219551468|NCT01944722|PROCEDURE|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
219551469|NCT03539926|DEVICE|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
219551470|NCT03539926|DIAGNOSTIC_TEST|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
219551471|NCT06048848|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
219551472|NCT06048848|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
219551473|NCT06048848|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
219551474|NCT04929821|DEVICE|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
219551475|NCT04153825|DEVICE|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
219551476|NCT04153825|DEVICE|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
219551477|NCT04153825|OTHER|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
219551478|NCT04153825|DEVICE|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
219137195|NCT02313441|OTHER|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
219716797|NCT06910540|OTHER|Acu-TENS|This protocol makes use of the acu-TENS treatment on the acupoints Hegu (LI4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LR3). After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTR+ Myolito Multifunctional Stimulator MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 3-5 mA, and pulse width of 300µS will be delivered continually during TUGOR.
219716798|NCT06910540|OTHER|Sham acu-TENS|In the sham acu-TENS, within the same time interval, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.
219716799|NCT07099222|DRUG|Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks|Low, non-weight based dose of Dexamethasone and Dexmedetomidine adjunct with Ropivacaine (local anesthetic) for use in peripheral nerve blocks to look for synergistic effects of the combination in extending the duration of the block while limiting any potential side effects of each additive.
219716800|NCT07099222|DRUG|Ropivacaine with low, non weight based Dexamethasone additive|Very accepted, standard peripheral nerve block with steroid adjunct solution used to increase the duration of local anesthetic by 4-6hrs.
219716801|NCT07094035|DIETARY_SUPPLEMENT|food supplement based on a mixture of green tea extract and a pool of probiotics.|two capsules of food supplement (verum) or placebo, daily for 56 consecutive days. The daily consumption of the food supplement provides: green tea extract (Camellia sinensis (L.) Kuntze - folium) 300 mg, as a green capsule, and a pool of probiotics (Lactobacillus rhamnosus LRH020 2x10\^9 UFC, Bifidobacterium lactis BL050 2x10\^9 UFC, Lactobacillus plantarum PBS067 2x10\^9 UFC), as a white capsule.
219716802|NCT07094035|DIETARY_SUPPLEMENT|Placebo|1 capsule/day of maltodextrin (500 mg) with a green shell, and 1 capsule/day of maltodextrin (500 mg) with a white shell for 56 days. The two colours are applied to maintain the binding.
219716803|NCT07097961|BEHAVIORAL|Pulmonary Rehabilitation|The intervention includes twice-weekly walking and wall sit exercises, guided by a physiotherapy assessment. Participants use a pedometer, receive written instructions, and are monitored weekly by phone or home visit. Caregivers supervise the exercises and sessions are logged in a participant workbook.
219716804|NCT05279300|DRUG|CS5001|The dose and dosing schedule is decided by the Safety Monitoring Committee.
219716805|NCT05279300|BIOLOGICAL|Rituximab|IV infusion
219716806|NCT05279300|DRUG|Gemcitabine|IV infusion
219716807|NCT05279300|DRUG|Oxaliplatin|IV infusion
219716808|NCT05279300|DRUG|Lenalidomide|PO
219716809|NCT05279300|DRUG|Cyclophosphamide|IV infusion
219716810|NCT05279300|DRUG|Doxorubicin|IV infusion
219716811|NCT05279300|DRUG|Vincristine|IV infusion
219716812|NCT05279300|DRUG|Prednisone|PO
219551479|NCT04153825|DEVICE|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
219716813|NCT06862115|DRUG|ACE-I and/or ARB antihypertensive treatment|When the ACE-I and/or ARB duration of action is ≥24 hours, the drug will be stopped 48 hours prior to surgery. All other ACE-I and/or ARB will be stopped 24 hours before surgery.
219137196|NCT03407131|PROCEDURE|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
219137197|NCT03407131|PROCEDURE|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
219551480|NCT04386122|DRUG|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
219716814|NCT06795126|OTHER|Little NIRVANA|Augmented reality (AR) digital solution where children interact with the game using a magic wand
219716815|NCT07095725|DIAGNOSTIC_TEST|Record EMG maximum amplitude from rectus abdominis, erector spinae L3 level|"EMG Electrode Placement and Muscle Assessment:~Electrodes for the rectus abdominis were placed longitudinally at the umbilical level. For the erector spinae, L3 was located using a line between the posterior superior iliac crests, and electrodes were placed \~3 cm lateral to the L3 spinous process.~Assessment:~Rectus Abdominis: In the crook-lying position, participants performed a slow curl-up (\~35-40°), holding for 10 seconds.~Erector Spinae: In the prone position with a 10-cm pad under the abdomen, participants lifted the upper body with neutral cervical alignment for 10 seconds.~Each test was repeated three times with 2-minute rest intervals."
219716816|NCT07096674|DRUG|ORX750|Oral ORX750
219716817|NCT07096674|DRUG|ORX750|Oral ORX750
219716818|NCT07096674|DRUG|ORX750|Oral ORX750
219716819|NCT07095868|BIOLOGICAL|EVM14|Cancer Vaccine
219716820|NCT07095868|COMBINATION_PRODUCT|Pembrolizumab|Anti-PD1 antibody
219716821|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
219716822|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
219716823|NCT06910774|OTHER|Dosage of serotonin and tryptophan metabolites levels in serum|These measurements will be performed on residual blood samples in the laboratory, after blood collection carried out as part of routine care. Patients will not need to undergo an additional blood draw.
219716824|NCT06908629|OTHER|Implementation of social determinants of health screening and referral|Participants will be referred to community-based resources in response to their answers on the screening tool.
219716825|NCT03105102|DRUG|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
219716826|NCT03105102|DRUG|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
219137198|NCT03392558|OTHER|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
219716827|NCT03105102|DRUG|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
219716828|NCT03105102|DRUG|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
219716829|NCT03105102|DRUG|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
219716830|NCT07102524|DRUG|TSHA-105|AAV9/SLC13A5
219716831|NCT07101575|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography with bubble test, by intravenous infusion of agitate saline solution
219716832|NCT06744322|PROCEDURE|Fast discharge strategy|Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
219716833|NCT02180867|DRUG|Doxorubicin|Given IV
219716834|NCT02180867|DRUG|Doxorubicin Hydrochloride|Given IV
219137199|NCT03392558|OTHER|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
219137200|NCT06321913|DRUG|IBI343 combined with IBI308|IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
219137201|NCT01936753|BEHAVIORAL|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
219137202|NCT01830166|RADIATION|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
219137203|NCT04648436|OTHER|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
219137204|NCT04648436|OTHER|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
219137205|NCT00486759|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
219137206|NCT00486759|DRUG|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
219137207|NCT00486759|DRUG|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
219137208|NCT00486759|DRUG|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
219137209|NCT04096144|DRUG|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
219137210|NCT01181180|DIETARY_SUPPLEMENT|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
219137211|NCT01552304|OTHER|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
219137212|NCT01552304|OTHER|Control group|
219137213|NCT03823534|DRUG|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
219137214|NCT03823534|DRUG|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
219137215|NCT03823534|DRUG|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
219716835|NCT02180867|DRUG|Ifosfamide|Given IV
219137216|NCT03823534|DRUG|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
219137217|NCT03823534|DRUG|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
219137218|NCT03823534|DRUG|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
219137219|NCT03823534|DRUG|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
219137220|NCT05518201|BIOLOGICAL|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
219716836|NCT02180867|DRUG|Pazopanib|Given PO
219716837|NCT02180867|DRUG|Pazopanib Hydrochloride|Given PO
219716838|NCT02180867|RADIATION|Radiation Therapy|Undergo radiation therapy
219716839|NCT02180867|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219716840|NCT07104266|DRUG|Celecoxib (Celebrex)|The participants will take one capsule celecoxib (100 mg) or placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
219716841|NCT07104266|DRUG|Placebo|Participants will take one capsule of placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
219716842|NCT07103902|BEHAVIORAL|Moderate-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 70% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
219716843|NCT07103902|BEHAVIORAL|Low-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 40-50% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
219716844|NCT07104864|DIAGNOSTIC_TEST|histopathological confirmation|histopathological confirmation
219716845|NCT07105202|DRUG|levosimendan|Participants randomized to to the intervention will receive levosimendan. The infusion is administered over 24 hours, starting at a dose of 0.1 µg/kg/min. After 4 hours, the dose may be increased to 0.2 µg/kg/min if tolerated, based on clinical judgment. A maximum of four treatment cycles may be given if the patient is not successfully weaned from mechanical ventilation within 7 days.
219137221|NCT05518201|BIOLOGICAL|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
219137222|NCT02305082|OTHER|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
219137223|NCT05139264|OTHER|Observational|Observation of diet, physical activity, sleep and interstitial glucose
219137224|NCT02469467|DIETARY_SUPPLEMENT|VS-505|VS-505 is orally administered with meal for 8 weeks
219137225|NCT01299974|OTHER|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
219137226|NCT02535624|PROCEDURE|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
219137227|NCT02535624|PROCEDURE|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
219137228|NCT02541643|DRUG|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)"
219137229|NCT05167253|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
219137230|NCT00024531|DRUG|Atorvastatin calcium|
219137231|NCT00917358|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
219137232|NCT04881318|OTHER|Waist-High Compression Tights|Waist-high compression tights providing 15-40 mmHg of pressure.
219137233|NCT04881318|OTHER|Abdominal Compression Garments|Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.
219137234|NCT04881318|DRUG|Medications that modulate heart rate and blood pressure|Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
219137235|NCT06002360|BEHAVIORAL|Reach Out and Read|Families will be provided with a book and ROR programming from trained study team members (either the principal investigator or a research assistant, both of whom are ROR trained). ROR programming will include discussion of current reading practices, anticipatory guidance on the importance and benefits of reading, modeling of active reading, discussion of how to incorporate reading into a daily routine and answering any questions parents/caregivers may have.
219137236|NCT03738137|DEVICE|Narotrend|Narcotrend motoring
219137237|NCT03738137|DEVICE|BIS|Bispectral index monitoring
219137238|NCT03738137|DRUG|Sufentanil|sufentanil is applied.
219137239|NCT03738137|DRUG|Lidocaine|Topical Anesthesia
219137240|NCT03738137|DRUG|Midazolam|midazolam is applied.
219137241|NCT02794064|DEVICE|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
219137242|NCT05112146|DIETARY_SUPPLEMENT|Whey protein isolate|Oral administration
219137243|NCT05112146|DIETARY_SUPPLEMENT|Whey protein microgel|Oral administration
219551481|NCT04386122|DRUG|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
219551482|NCT05788250|PROCEDURE|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
219137244|NCT05112146|DIETARY_SUPPLEMENT|Water|Oral administration
219137245|NCT00174317|DRUG|Celecoxib|
219137246|NCT00174317|DRUG|Diclofenac|
219137247|NCT00109967|BIOLOGICAL|rituximab|375 mg/m\^2 Given IV
219137248|NCT00109967|DRUG|temsirolimus|25 mg given IV
219137249|NCT04313543|DIETARY_SUPPLEMENT|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
219137250|NCT05745376|BEHAVIORAL|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
219137251|NCT00105820|PROCEDURE|System level depression care quality improvement|
219137252|NCT02076919|DRUG|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
219137253|NCT02076919|DRUG|LHA510 Vehicle|Inactive ingredients used for masking purposes
219551483|NCT05788250|PROCEDURE|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
219551484|NCT02906917|DRUG|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
219551485|NCT02906917|DRUG|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
219137254|NCT00169780|RADIATION|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
219137255|NCT02857491|DRUG|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
219137256|NCT02857491|DRUG|sham|sham intravitreal injection before vitrectomy
219137257|NCT02857491|PROCEDURE|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
219137258|NCT02590042|BIOLOGICAL|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)"
219137259|NCT03427255|BEHAVIORAL|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
219137260|NCT03427255|OTHER|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
219137261|NCT01819493|BEHAVIORAL|Lifestyle Intervention|Family-based group lifestyle intervention
219137262|NCT01819493|BEHAVIORAL|Standard Family-Based intervention|Comparison intervention
219137263|NCT04779892|DRUG|Infliximab|100mg/vial
219137264|NCT01809964|BIOLOGICAL|ANT-1401|
219716846|NCT07105202|DRUG|Soluvit|Participants randomized to this arm will receive a placebo consisting of Soluvit diluted in glucose 5%, administered as an intravenous infusion over 24 hours. The infusion will mimic the Levosimendan administration protocol, starting at 0.1 µg/kg/min and potentially increasing to 0.2 µg/kg/min after 4 hours, to maintain blinding. A maximum of four placebo treatment cycles may be administered if the patient is not successfully weaned from mechanical ventilation within 7 days.
219137265|NCT01809964|BIOLOGICAL|Vehicle|
219137266|NCT00130819|BEHAVIORAL|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
219137267|NCT00130819|BEHAVIORAL|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
219137268|NCT00740415|BIOLOGICAL|rituximab|Rituximab, 375 mg/m2 Intraveinous
219716847|NCT07105202|OTHER|Standard care|All patients in this arm will receive standard ICU care, including daily assessments for readiness to wean from invasive ventilation.
219716848|NCT07104136|BEHAVIORAL|COPD-care seminar|"A two day seminar which will include:~Lecture: Understanding COPD and Current Guidelines Overview of COPD pathophysiology. Review of the latest GOLD guidelines and treatment strategies Hands-on Session: Inhaler Technique and Device Selection Practical demonstration of different inhaler devices. Evaluating patient inspiratory effort and selecting suitable devices. Understanding advantages of each device and molecule. Motivational interview seminar- On line pre-course lectures about the theory behind motivational interview. Two workshops for simulation and practice of the technic through clinical cases with relevance to COPD patients including smoking cessation counseling techniques.~Panel Discussion: Multidisciplinary Approach to COPD Management Involving respiratory specialists, physiotherapists, and primary care physicians.~Discussion on referral practices and collaborative care."
219137269|NCT00740415|DRUG|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
219137270|NCT00740415|DRUG|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
219137271|NCT00740415|DRUG|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
219137272|NCT00918957|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
219137273|NCT00918957|DRUG|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
219137274|NCT03313206|DRUG|Pembrolizumab|"Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
219551486|NCT02906917|DRUG|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
219551487|NCT02995187|DRUG|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
219551488|NCT02232945|DRUG|placebo of oseltamivir phosphate|
219551489|NCT02232945|DRUG|oseltamivir phosphate|
219551490|NCT02232945|DRUG|Banlangen (Radix Isatidis) granules|
219551491|NCT02232945|DRUG|placebo of Banlangen(Radix Isatidis) granules|
219551492|NCT04457115|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
219551493|NCT04457115|PROCEDURE|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
219551494|NCT02926170|DRUG|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
219551495|NCT02926170|DRUG|acenocumarol|Doses will be adjusted according to INR
219551496|NCT02393560|PROCEDURE|DECT scan|
219551497|NCT02865148|BEHAVIORAL|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
219551498|NCT01437735|DRUG|QAW039|QAW039 po
219551499|NCT01437735|DRUG|Montelukast|Montelukast 10 mg po
219551500|NCT01437735|DRUG|Placebo|Placebo
219716849|NCT07105410|OTHER|Aim #1: The effect of post-exercise circulatory occlusion on H-reflex and V-wave|Aim #1 follows a randomized and crossover design in which 16 young and healthy males are evaluated during thigh circulatory occlusion performed after a submaximal isometric plantar flexion contraction (PECO day). In the other session, participants are evaluated during free-flow conditions and without previous fatiguing contraction (no-PECO day). In PECO day, participants complete a 3-min contraction at 40% of maximal force. Then, for testing, blood flow from lower-leg is blocked during 4 min, by an inflatable cuff around the ipsilateral thigh before task termination, during which H- reflex is tested. At the end of recordings, the cuff is deflated. Participants ware allowed to rest for 5-10 min. Then, they are requested to perform a new 3 min contraction with the cuff being inflated before task termination. The cuff remains inflated for \~ 2 min during which V-wave recordings are obtained. In both days, leg pain intensity is reported by participants and brachial AP is measured.
219716850|NCT07105410|OTHER|Aim #2: The hypoalgesic effects of acute exercise of different modalities|Aim #2 follows a randomized and crossover-controlled design, consisting on two experimental sessions. 24 healthy male (all diferent from Experiment 1) are randomly allocated to one of the following exercising regimens: aerobic, anaerobic or dynamic resistance (8 participants for each exercise group). In one of the experimental days, participants are evaluated for pain sensitivity and neuromuscular responses both before and after a lower-limb acute exercise protocol (exercise day) and in the other day before and after 15 min of quiet rest (non-exercise day). In both sessions, participants are evaluated for rectus femoris, upper trapezius and biceps brachiis muscles pressure pain threshold, followed by the application of a cold pain tolerance test on the foot. The intensity of pain is reported by a 0-100mm VAS and AP and HRV continously measured. Then, participants are tested for H-reflex and V-wave excitability during PECO, with leg pain intensity (0-10) and brachial AP recorded.
219137275|NCT03313206|PROCEDURE|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
219551501|NCT05863845|DRUG|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
219551502|NCT05863845|DRUG|Carmustine|300mg/m2 day -7, Given IV
219137276|NCT03313206|RADIATION|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
219137277|NCT03313206|DRUG|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
219228348|NCT02734784|PROCEDURE|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
219228349|NCT02734784|PROCEDURE|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
219228350|NCT00670449|DRUG|Fingolimod|Fingolimod was supplied in capsules.
219228351|NCT01452867|DEVICE|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
219551503|NCT05863845|DRUG|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
219551504|NCT05863845|DRUG|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
219551505|NCT05863845|DRUG|Melphalan|140mg/m2, day -2, Given IV
219551506|NCT05863845|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
219551507|NCT04352062|DRUG|Melatonin|
219551508|NCT04352062|OTHER|placebo|
219137278|NCT05153551|OTHER|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
219228352|NCT01452867|DEVICE|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
219228353|NCT01452867|DEVICE|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
219551509|NCT04352062|DRUG|Pantoprazole 40mg|pantoprazole 2 x 40mg
219551510|NCT04352062|DRUG|Amoxicillin|Amoxicillin 2 x 1000mg
219551511|NCT04352062|DRUG|Levofloxacin 500mg|Levofloxacin 2 x 500mg
219551512|NCT00210639|DRUG|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
219551513|NCT01242124|PROCEDURE|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
219137279|NCT02162667|DRUG|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
219137280|NCT01803646|DRUG|AM-101|AM-101 gel for intratympanic injection
219137281|NCT01803646|DRUG|Placebo|Placebo gel for intratympanic injection
219137282|NCT00652119|DRUG|Paclitaxel|Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.
219137283|NCT00652119|DRUG|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
219137284|NCT00652119|DRUG|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
219137285|NCT03282786|OTHER|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
219137286|NCT00572078|DRUG|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
219137287|NCT00773708|DRUG|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
219716851|NCT07105410|OTHER|Aim #3: The hypoalgesic effects of chronic training of different modalities|Aim #3 follows a randomized-controlled design. 32 healthy male (all the 24 participants from Experimental 2 plus 8 new subjects) are randomly allocated to one of the following groups: aerobic, anaerobic, dynamic resistance training and no-training (control) (8 participants for each group). Each intervention group perform 6 weeks of exercise training (3x week). Participants allocated to each training group are evaluated before and after training (2 assessment days in each time-point). On one day participants are tested for pressure pain threshold and cold pain tolerance with concomitant measures of pain ratings (0-100mm VAS), AP and HRV. The influence of metaboreflex activation on H-reflex and V-wave is also measured (during PECO). In addition, during PECO ischemic pain rating and AP are obtained. On another day, participants are evaluated for motor performance (maximal oxygen uptake, maximal voluntary contraction and peak power) and neuromuscular adaptations (i.e. H-reflex and V-wave)
219137288|NCT02864095|DRUG|Tranexamic acid (TXA)|IV and topical administration
219137289|NCT02864095|DRUG|Epinephrine|
219137290|NCT02092077|DRUG|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
219137291|NCT02092077|DRUG|somatropin|Dose may be adjusted as required
219551514|NCT01242124|PROCEDURE|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
219551515|NCT04144998|DIAGNOSTIC_TEST|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
219551516|NCT05281120|DEVICE|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
219551517|NCT05281120|DEVICE|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
219228354|NCT00201045|OTHER|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
219228355|NCT00709605|DRUG|VRC-HIVADV014-00-VP|
219228356|NCT04728191|OTHER|Physiotherapy|physiotherapeutical instructions and training as described.
219228357|NCT04728191|OTHER|standard care|Standard care as described.
219228358|NCT01058694|BEHAVIORAL|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
219551518|NCT02622867|OTHER|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
219551519|NCT02622867|DIETARY_SUPPLEMENT|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
219137292|NCT02675920|DRUG|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
219137293|NCT06225882|DRUG|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
219137294|NCT02260310|OTHER|Weizhong and Huantiao|
219137295|NCT02260310|OTHER|A-shi point|
219137296|NCT01188252|DRUG|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
219137297|NCT02615912|OTHER|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
219137298|NCT02615912|OTHER|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
219137299|NCT02615912|OTHER|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
219137300|NCT02615912|OTHER|Silwet* DA-63 (Momentive) 1.5%|
219137301|NCT02615912|OTHER|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
219137302|NCT02615912|OTHER|Water (control)|
219137303|NCT05983484|DEVICE|Skiin Underwear|All participants enrolled will wear simultaneously the PocketECG (Standard Holter) and the Skiin Underwear Chestband (wearable textile). Each participant will wear both systems for the duration prescribed by their physician (1 to 14 days).
219137304|NCT03996746|DIAGNOSTIC_TEST|No intervention|No intervention
219137305|NCT03008499|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219137306|NCT03921450|DEVICE|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
219137307|NCT03921450|DEVICE|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
219228359|NCT05770115|PROCEDURE|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
219228360|NCT05770115|PROCEDURE|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
219137308|NCT03921450|DRUG|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
219137309|NCT03106142|PROCEDURE|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
219137310|NCT04104698|DIAGNOSTIC_TEST|Quantitative EEG|"1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
219137311|NCT04416971|PROCEDURE|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
219137312|NCT01131494|OTHER|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
219137313|NCT01691963|DEVICE|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
219137314|NCT05860140|OTHER|Education video|Six minutes long education video focusing on protein and energy meals
219137315|NCT04584489|OTHER|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
219137316|NCT05227066|OTHER|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
219137317|NCT05227066|OTHER|traditional physical therapy group|traditional physical therapy group
219137318|NCT04440124|OTHER|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
219137319|NCT06553014|OTHER|Endovascular Plug Embolization|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
219137320|NCT02890368|DRUG|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
219137321|NCT02890368|DRUG|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
219137322|NCT02890368|DRUG|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
219137323|NCT02890368|OTHER|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
219137324|NCT02890368|OTHER|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
219137325|NCT04797416|DEVICE|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
219137326|NCT04797416|DEVICE|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
219137327|NCT04797416|DEVICE|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
219137328|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
219137329|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
219228361|NCT00495066|DRUG|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
219360748|NCT06040983|DEVICE|FR-101 Chest Dressing|"Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent Build-up effect. If the application time is longer than the recommendation, discomfort may happen depending on subject's condition."
219551520|NCT01977521|DEVICE|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
219137330|NCT02704819|OTHER|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
219137331|NCT02704819|OTHER|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
219137332|NCT02704819|OTHER|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
219716852|NCT07103681|PROCEDURE|Ventriculoperitoneal Shunt (VP)|VP Shunt surgery involves surgical insertion of a catheter (tube) to divert brain fluid from the cerebral ventricles to the abdominal peritoneum. This will be performed in Group 1 patients as clinically indicated.
219716853|NCT07103681|PROCEDURE|Brain and Skin Biopsy|Brain and skin biopsy's may be taken during the VP shunt to assist in histological analysis for neurodegenerative changes.
219716854|NCT07103681|DIAGNOSTIC_TEST|MRI Brain|MRI brain with diffusion imagining will be performed before and after shunt surgery.
219716855|NCT07105059|DRUG|Teclistamab|After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
219716856|NCT07105059|DRUG|Mezigdomide|Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
219716857|NCT07105124|DRUG|Sibeprenlimab|Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.
219716858|NCT07103824|OTHER|Upper Extremity Neurocognitive Tests|The validity and test-retest reliability of the Reactive Neurocognitive Upper Extremity Tests (Reactive CKCUEST and Reactive 90/90 Wall Throws Test) will be analyzed through this protocol. Participants will undergo three assessment sessions spaced one week apart: measurements will be conducted using the Catchpad device during the first and third weeks, and the BlazePod™ device during the second week. To ensure blinding, the personnel responsible for conducting the assessments, recording the data, and performing the statistical analyses will be distinct individuals. Participants will be familiarized with the devices one week prior to testing, and a standardized 5-minute free walking warm-up will be administered at each session. All assessments will be performed under similar environmental conditions and at consistent times of day.
219551521|NCT01977521|DEVICE|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
219551522|NCT02805764|DEVICE|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
219137333|NCT02704819|OTHER|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
219360749|NCT00101257|BIOLOGICAL|therapeutic autologous lymphocytes|
219360750|NCT01935050|BEHAVIORAL|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
219360751|NCT05666713|DEVICE|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
219551523|NCT01202253|DRUG|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
219360752|NCT01430442|DRUG|Rimegepant|Rimegepant capsules
219551524|NCT06731491|OTHER|Concurrent Training|Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes
219551525|NCT06731491|OTHER|Massage therapy and Aromatherapy|Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
219137334|NCT02704819|OTHER|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
219137335|NCT01013441|BIOLOGICAL|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
219137336|NCT00257348|DRUG|Capecitabine|
219137337|NCT00257348|DRUG|Docetaxel|
219137338|NCT06360744|BIOLOGICAL|Johnson & Johnson|Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
219137339|NCT05712941|DRUG|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
219137340|NCT05712941|DRUG|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
219137341|NCT05712941|DRUG|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
219137342|NCT03597841|DRUG|Combination therapy|Patients who are given combination therapy will be allocated to this group.
219716859|NCT07104435|OTHER|Artmaking and exergaming|Weekly visual artmaking and exergaming
219716860|NCT07103616|DRUG|Randomization of Propofol or Dexmedetomidine|This intervention is a randomization of Propofol or Dexmedetomidine. Each group will receive three minutes of research images, followed by induction of anesthesia and immediately followed by three minutes of imaging. The subject will receive standard care clinical magnetic resonance imaging for 45 minutes and three minutes of research images at the end of the scan.
219716861|NCT07104331|DRUG|nab-Sirolimus|nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.
219551526|NCT05591729|OTHER|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
219360753|NCT01430442|DRUG|Placebo|Rimegepant placebo-matching capsules
219716862|NCT07104071|OTHER|reduced light brightness|reduced light brightness
219551527|NCT05591729|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
219551528|NCT00550329|DRUG|Glipizide GITS|
219360754|NCT01430442|DRUG|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
219360755|NCT01641939|DRUG|Taxane|Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.
219360756|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
219360757|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
219551529|NCT06405815|OTHER|tumor and peritumor radiomic feature|extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
219551530|NCT05939102|COMBINATION_PRODUCT|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
219137343|NCT04178291|DEVICE|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
219360758|NCT02897895|BIOLOGICAL|levels of CNI in whole blood|
219360759|NCT02897895|BIOLOGICAL|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
219360760|NCT05665270|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
219360761|NCT05665270|DRUG|Prednisolone Acetate 1%|"Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen."
219360762|NCT01231997|DRUG|Udenafil|100mg Single Oral Dose of
219360763|NCT02545725|OTHER|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
219137344|NCT04178291|DEVICE|Air polishing with erythritol powder|Air flow PLUS
219137345|NCT03334019|OTHER|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
219137346|NCT00086892|BIOLOGICAL|cetuximab|
219137347|NCT00086892|DRUG|carboplatin|
219137348|NCT06000618|DEVICE|Intrapulmonary Percussive ventilator|The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
219137349|NCT01368406|BEHAVIORAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
219137350|NCT01539655|DRUG|vandetanib|Oral tablets, 300 mg, single dose
219137351|NCT01539655|DRUG|omeprazole|Oral capsules, 40 mg, multiple doses
219137352|NCT01539655|DRUG|ranitidine|Oral tables, 150 mg, multiple doses
219137353|NCT04691778|PROCEDURE|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
219137354|NCT04691778|PROCEDURE|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
219137355|NCT02850055|OTHER|Conventional Physiotherapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home."
219137356|NCT02850055|OTHER|Specific Manual Therapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
219137357|NCT02521844|DRUG|ETC-1922159|Oral administration
219551531|NCT05939102|COMBINATION_PRODUCT|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
219551532|NCT00794053|PROCEDURE|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
219551533|NCT06676618|OTHER|Multimodal Exercise Training|"The exercise training consisting of aerobic, strengthening and balance exercises will be applied for 12 weeks/3days for 1hour. One day of the exercise training will be performed in a clinical environment with a physiotherapist, and the other 2 days of the week, participants will be asked to apply asynchronous video-based telerehabilitation over the internet in their own homes. The asynchronous video-based telerehabilitation application will be performed through an account created specifically for the participant on the www.telenororehab.com website. The exercise program will be created according to the individual's condition and progression will be provided every 3 weeks. Patients who do not attend 3 consecutive sessions will be excluded from the study."
219137358|NCT02521844|DRUG|Pembrolizumab|IV administration
219137359|NCT04386733|OTHER|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
219137360|NCT00112983|BIOLOGICAL|eculizumab|
219137361|NCT00610688|DRUG|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
219137362|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
219137363|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
219137364|NCT02228408|DRUG|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
219137365|NCT02228408|DRUG|Placebo|Placebo titration will mimic titration of active study arm
219137366|NCT03728595|DIAGNOSTIC_TEST|Venepuncture|A blood sample will be taken for serum bicarbonate
219137367|NCT03728595|DIAGNOSTIC_TEST|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
219137368|NCT03728595|DIAGNOSTIC_TEST|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
219137369|NCT00000878|DRUG|Lamivudine|
219137370|NCT00000878|DRUG|Stavudine|
219137371|NCT00000878|DRUG|Zidovudine|
219137372|NCT04566042|BEHAVIORAL|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
219137373|NCT01230619|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
219137374|NCT01230619|DRUG|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
219137375|NCT02742896|OTHER|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
219137376|NCT02173444|OTHER|Blood test|
219137377|NCT03425630|DIETARY_SUPPLEMENT|Argicolina|8 weeks
219137378|NCT03425630|DIETARY_SUPPLEMENT|Normolip|8 weeks
219137379|NCT05257733|OTHER|None, pure observationnal study|pure observationnal study
219137380|NCT04911049|DIAGNOSTIC_TEST|Blood Pressure measurement|Blood Pressure measurement
219137381|NCT01240941|DRUG|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
219137382|NCT01240941|DRUG|Exemestane|25 mg orally daily
219137383|NCT01240941|DRUG|Goserelin|3.6 mg orally monthly
219137384|NCT03896841|OTHER|Observation|Ocular Findings Observations
219137385|NCT05463354|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
219137386|NCT05463354|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
219137387|NCT01428895|PROCEDURE|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
219137388|NCT01428895|OTHER|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
219137389|NCT00906620|OTHER|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
219137390|NCT00199108|DRUG|Depocyt|
219137391|NCT00199108|DRUG|Dexamethasone|
219137392|NCT02490176|DRUG|liraglutide|Liraglutide were taken daily for 7 days
219716863|NCT07103109|OTHER|Proximal stabilization exercises|Patients will receive Scapular mobilization in five manners, superior glide, inferior glide, up-ward rotation, down-ward rotation, and distraction. Each mobilization will be done ten times. A thirty second break will be given between each set. Also scapular strengthening exercises composed of diagonal two (D2) flexion pattern to augment the upper, middle, lower, and serratus anterior muscles' activity level. To activate upper trapezius muscle, shoulder shrug exercise will be used. To activate serratus anterior muscle, Wall slide exercise will be used. Scapular retraction exercise for rhomboids and middle trapezius activation will be done. Strengthening exercises will be performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5 kg and progressed to 0.75, and1kg, it will be applied 5 days per week for 6 weeks
219716864|NCT07103109|OTHER|Conventional physical therapy|Patients will receive shoulder joint mobilization, posterior capsular stretching, and ROM exercises in form of Codman/pendulum exercise. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide will be performed to the patients in a supine lying position at a frequency of two to three oscillations/second for one to two minutes. Every direction was repeated three to four times. At the resting position rhythmic oscillations grade I and II will be applied. In posterior capsule stretching each stretch will be repeated ten times for 20 seconds, between each stretching a 30-second break will be given. Pendulum exercise will be demonstrated to the patient at first, then they will performed it in the forward-backward direction, side-to-side direction, and circular pattern, for two to three minutes in each direction, it will be applied 5 days per week for 6 weeks
219716865|NCT07105033|BEHAVIORAL|FACT Session|Participants will participate in 4 weekly, 35-45 minute sessions
219716866|NCT07105033|BEHAVIORAL|Enhanced Usual Care and Assessments|Participants will complete a symptoms questionnaire
219716867|NCT07105345|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
219716868|NCT07105345|OTHER|Treatment as Usual (TAU)|Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.
219716869|NCT07103005|PROCEDURE|Intensive behavioral change with physical activity and diet. A single-group pre-post design|"The group of 43 participants recieved a lifestyle intervention, and was measurred before and after the intervention.~The intervention was intensive physical activity with focus om muscle strength and dietary advice from dietition, with focus on more fruits, vegetables, proteins and fiber.~Body composition was measurred using Bioelectrical impedance, DEXA and WRIC. Health related quality of life was measured using the questionnaire RAND-36, and diet was registered with the questionnaire DIGIKOST."
219137393|NCT02490176|DRUG|placebo|Placebo were taken daily for 7 days
219137394|NCT00001934|DRUG|Zenapax|
219137395|NCT04114383|OTHER|D3-Creatine|30mg D3-Creatine to measure muscle mass
219137396|NCT04114383|OTHER|Deuterium Oxide|D2O provided to measure muscle protein synthesis
219137397|NCT04114383|OTHER|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
219137398|NCT03336450|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
219137399|NCT03336450|DRUG|MHOS/SHP615|MHOS/SHP615
219137400|NCT02278848|OTHER|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
219137401|NCT02735486|DIETARY_SUPPLEMENT|Ginger drink|300 ml ginger drink
219137402|NCT02735486|DIETARY_SUPPLEMENT|Placebo: Super pure water|Placebo: Super pure water
219137403|NCT04241653|PROCEDURE|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
219137404|NCT04241653|PROCEDURE|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
219137405|NCT04241653|PROCEDURE|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
219137406|NCT04241653|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
219137407|NCT04241653|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
219137408|NCT01955694|DRUG|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
219137409|NCT01955694|DRUG|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
219137410|NCT01955694|DRUG|Placebo|matching placebo
219137411|NCT04293783|DIETARY_SUPPLEMENT|L.Reuteri|daily supplementation with two tablet for six months
219137412|NCT04293783|DIETARY_SUPPLEMENT|Placebo|daily supplementation with two tablet for six months
219137413|NCT05997654|DEVICE|MEDGEL ANTIAGE|The MEDGEL ANTIAGE is a medical grade silicone plate, biocompatible.
219137414|NCT01928511|DRUG|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
219137415|NCT01928511|DRUG|Nucleos(t)ide analogue therapy|
219137416|NCT02473120|BIOLOGICAL|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
219137417|NCT04292093|BEHAVIORAL|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
219137418|NCT04292093|BEHAVIORAL|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
219137419|NCT00242853|PROCEDURE|Power doppler ultrasonography|
219137420|NCT00242853|PROCEDURE|High frequency ultrasonography|
219137421|NCT00242853|PROCEDURE|Exhaled nitric oxide assessment|
219137422|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
219137423|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
219137424|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
219137425|NCT06290544|OTHER|Standard of care plus additional examinations|The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
219137426|NCT03923387|DEVICE|MynxGrip|Vascular Closure
219137427|NCT03923387|OTHER|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
219137428|NCT03794180|DRUG|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
219137429|NCT03794180|DRUG|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
219137430|NCT00574743|DRUG|Enteric-coated Mycophenolate Sodium|
219137431|NCT00762099|DRUG|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
219137432|NCT00762099|DRUG|Placebo|Placebo/sugar tabs will look identical to active drug.
219137433|NCT05478902|PROCEDURE|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
219137434|NCT05478902|PROCEDURE|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
219137435|NCT05478902|PROCEDURE|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
219137436|NCT03670602|BEHAVIORAL|Episodic Future Thinking|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
219360764|NCT04886934|DEVICE|CS1 System|Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
219360765|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219360766|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219360767|NCT02167178|OTHER|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
219360768|NCT02167178|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
219137437|NCT03670602|BEHAVIORAL|Daily Check in|Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
219137438|NCT01772056|DRUG|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
219137439|NCT01772056|DRUG|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
219137440|NCT02396056|OTHER|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
219137441|NCT02396056|OTHER|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
219137442|NCT02544282|DRUG|Levobupivacaine|Pecs II Block
219137443|NCT02544282|DRUG|NaCl 0.9%|Placebo Pecs II block
219137444|NCT02544282|DRUG|Sevoflurane|General Anesthesia
219137445|NCT02544282|DRUG|Propofol|General Anesthesia
219137446|NCT02544282|DRUG|Sufentanil|General Anesthesia
219137447|NCT02544282|DRUG|Atracurium|General Anesthesia
219137448|NCT02544282|DRUG|Paracetamol|Pain Relief
219137449|NCT02544282|DRUG|Tramadol|Pain Relief
219137450|NCT02544282|DRUG|Piritramide|Pain Relief
219137451|NCT01456936|DRUG|Placebo|Triple dummy placebo for each treatment arm
219137452|NCT01456936|DRUG|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
219137453|NCT01456936|DRUG|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
219137454|NCT01456936|DRUG|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
219228362|NCT05213182|BEHAVIORAL|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
219228363|NCT01181115|DRUG|Avonex|Interferon treatment for MS
219551534|NCT06676618|OTHER|Control Group|Participants in the control group will be placed on the waiting list after all evaluation methods have been applied and will be re-evaluated at the end of 12 weeks. After the evaluations, individuals in the control group will also be given multimodal exercise training.
219551535|NCT04141878|BEHAVIORAL|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
219137455|NCT05990569|OTHER|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
219228364|NCT05082688|BIOLOGICAL|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
219551536|NCT04141878|BEHAVIORAL|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
219137456|NCT00543725|DRUG|TMC278|25 mg tablet once daily for 96 weeks
219137457|NCT00543725|DRUG|efavirenz|600 mg tablet once daily for 96 weeks
219137458|NCT00003790|GENETIC|polymerase chain reaction|
219137459|NCT00003790|OTHER|flow cytometry|
219137460|NCT04301674|DEVICE|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
219137461|NCT04109690|DRUG|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
219137462|NCT01571778|BEHAVIORAL|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
219137463|NCT04483843|OTHER|No intervention|No intervention will be performed while it is retrospective observational study.
219137464|NCT01526603|DRUG|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
219137465|NCT01526603|BIOLOGICAL|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
219137466|NCT01526603|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) \> 2000/μL for 3 consecutive days.
219716870|NCT07103161|DEVICE|Uresta bladder support device|The Uresta bladder support device is an intravaginal device indicated for adult women over 18 years of age who experience stress urinary incontinence, including urine leakage during exercise and non-exercise activities such as coughing and laughing. The device is FDA-cleared and licensed by Health Canada. Participants receive the entire kit that includes the three most common sizes which fit 90% of women. Two additional sizes are available in the lab if needed. Participants will be instructed to self-insert the Uresta prior to running, following the manufacturer instructions with researcher guidance as needed. The device aims to provide mechanical support to the urethra and bladder neck to prevent urine leakage during activities that provoke leakage.
219137467|NCT01526603|RADIATION|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring \>1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
219137468|NCT01526603|DRUG|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
219137469|NCT01526603|DRUG|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
219137470|NCT01526603|DRUG|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
219137471|NCT00906698|DRUG|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
219716871|NCT07103161|DEVICE|Sportex regular tampon|Participants will use a regular absorbency Sportex tampon as a conservative intravaginal support to potentially reduce stress urinary incontinence (SUI) symptoms during running. Participants will be instructed to insert the tampon prior to running into the mid-to-upper vaginal canal while standing or sitting.
219716872|NCT07105306|OTHER|Buteyko Breathing Technique Training|Buteyko Breathing Technique (BBT), developed in the 1950s, which focuses on reducing dysfunctional hyperventilation patterns through breath control and extended breath-holding phases called control pauses
219716873|NCT07105007|BEHAVIORAL|Exercise Intervention|After completing the education sessions, the participants will start 8 weeks of a hybrid exercise intervention, three days/week, being one supervised session in the exercise center and two unsupervised sessions at home. Sessions at the exercise center will be supervised by experienced exercise trainers in a 1:1 ratio. The intervention is designed to meet the recommendation of at least 150 minutes of MVPA per week and the recommendations on exercise intensity and volume from the ACSM. Each exercise session will be composed of aerobic and resistance exercises at moderate intensity (i.e., combined exercise training), which is the best exercise model for the needs of PLWH. Additionally, poor muscle strength has been associated with lower VO2peak among PLWH, suggesting that appropriate muscle-strengthening exercises can improve the aerobic performance of these patients. The aerobic exercise will be performed in a continuous manner and prescribed using the heart rate reserve.
219551537|NCT04505163|PROCEDURE|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
219551538|NCT04505163|DEVICE|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
219137472|NCT00906698|DRUG|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
219137473|NCT00906698|DRUG|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
219551539|NCT02586350|DRUG|Anlotinib|
219137474|NCT00906698|DRUG|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
219137475|NCT00906698|DRUG|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
219137476|NCT00906698|DRUG|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
219137477|NCT02892799|OTHER|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
219137478|NCT02892799|OTHER|Standard of Care|
219137479|NCT03095508|DRUG|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
219551540|NCT02586350|DRUG|Placebo|Placebo p.o. qd
219551541|NCT00343681|BIOLOGICAL|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
219551542|NCT04888039|OTHER|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~* At diagnosis (before starting 1st line of treatment),~* after the induction phase (before autologous transplantation for patients who will be transplanted),~* after the consolidation phase,~* after the maintenance phase : 1 year and 2 years after the start of the maintenance."
219137480|NCT03095508|DRUG|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
219228365|NCT05082688|BIOLOGICAL|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
219228366|NCT05082688|BIOLOGICAL|Placebo|0.9% NaCl
219228367|NCT05559697|DEVICE|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
219228368|NCT05559697|DEVICE|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
219228369|NCT03482102|DRUG|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
219228370|NCT03482102|DRUG|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
219228371|NCT03482102|RADIATION|Radiation|Radiation therapy is used to shrink cancer cells.
219228372|NCT01503450|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
219228373|NCT04518397|BEHAVIORAL|Theatre|6-week participatory arts culturally-informed theatre program
219228374|NCT02771366|DRUG|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
219228375|NCT02771366|OTHER|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
219228376|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
219228377|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
219228378|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
219137481|NCT05460936|OTHER|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
219228379|NCT02443909|DEVICE|Holmium laser device|
219228380|NCT02144883|BEHAVIORAL|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
219228381|NCT02144883|BEHAVIORAL|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
219228382|NCT02068157|OTHER|Laboratory Biomarker Analysis|Correlative studies
219228383|NCT02068157|DRUG|Photodynamic Therapy|Undergo image-guided I-PDT
219228384|NCT02068157|DRUG|Porfimer Sodium|Given IV
219228385|NCT01363128|DRUG|Cyclophosphamide|Given IV
219228386|NCT01363128|DRUG|Cytarabine|Given IV
219228387|NCT01363128|DRUG|Dexamethasone|Given IV or PO
219228388|NCT01363128|DRUG|Doxorubicin Hydrochloride|Given IV
219228389|NCT01363128|OTHER|Laboratory Biomarker Analysis|Correlative studies
219228390|NCT01363128|DRUG|Methotrexate|Given IV
219228391|NCT01363128|BIOLOGICAL|Ofatumumab|Given IV
219137482|NCT05460936|OTHER|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
219137483|NCT00637676|PROCEDURE|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
219137484|NCT00637676|PROCEDURE|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
219137485|NCT04215341|BEHAVIORAL|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
219228392|NCT01363128|DRUG|Vincristine Sulfate|Given IV
219228393|NCT02155868|OTHER|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
219228394|NCT02155868|OTHER|Standard treatment|Standard treatment
219137486|NCT02830750|PROCEDURE|Ablation|
219228395|NCT00778609|DRUG|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
219228396|NCT00778609|DRUG|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
219137487|NCT02886741|OTHER|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
219137488|NCT01231113|DRUG|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
219137489|NCT01231113|DRUG|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
219137490|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
219137491|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
219137492|NCT00361621|DRUG|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
219137493|NCT00361621|DRUG|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
219137494|NCT00361621|DRUG|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
219137495|NCT00361621|DRUG|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
219137496|NCT00361621|DRUG|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
219137497|NCT00361621|DRUG|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
219137498|NCT00361621|RADIATION|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
219137499|NCT03767764|DIAGNOSTIC_TEST|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
219137500|NCT03921684|DRUG|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
219137501|NCT03921684|RADIATION|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
219228397|NCT03917732|BEHAVIORAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
219360769|NCT02167178|OTHER|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
219360770|NCT02167178|OTHER|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
219360771|NCT00416338|DEVICE|film dressing by adhesive|
219716874|NCT07105007|BEHAVIORAL|Education sessions|At the beginning of the program, the participants will receive two face-to-face group education sessions, consisting of 90 minutes of exercise and cardiovascular health education. The material for the education sessions will be developed by the study team (a diverse team including exercise scientists, nurse, cardiologist, and infectious disease specialist). The focus of the sessions will be to increase the participants' knowledge and self-efficacy. The education sessions will occur prior to the start of the exercise intervention, to teach the participants how to safely perform the home-based exercises. An interventionist, who will possess a degree in a health profession, will present the content following the completion of standard training using material and guidance developed for this purpose. The content of the sessions will include a self-assessment on exercise and physical activity, and incorporate the ACSM recommendations for quantity and quality of exercise
219137502|NCT03921684|DRUG|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
219137503|NCT03921684|DRUG|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
219137504|NCT01429779|DRUG|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
219137505|NCT03983889|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
219137506|NCT03983889|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
219137507|NCT03983889|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
219137508|NCT03983889|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
219137509|NCT03983889|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
219137510|NCT02476773|BIOLOGICAL|Na-GST-1/Alhydrogel plus GLA-AF|
219137511|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
219137512|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
219137513|NCT02476773|BIOLOGICAL|Sterile Saline Placebo|
219137514|NCT03308487|DIETARY_SUPPLEMENT|vitamin D3 (1000 IU)|
219137515|NCT03308487|DIETARY_SUPPLEMENT|Vitamin D3 (2000 IU)|
219137516|NCT02690103|DRUG|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
219137517|NCT02690103|DIETARY_SUPPLEMENT|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
219137518|NCT02690103|DRUG|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
219137519|NCT00013143|BEHAVIORAL|Patient risk profiling (potential ADEs) w/provider feedback|
219137520|NCT03201809|DEVICE|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
219137521|NCT03201809|DRUG|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
219228398|NCT03917732|BEHAVIORAL|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
219228399|NCT01868555|DRUG|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
219228400|NCT01868555|DRUG|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
219228401|NCT01868555|DRUG|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
219228402|NCT01868555|DRUG|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
219716875|NCT07105007|BEHAVIORAL|Behavioral coaching|At the end of their weekly in-person exercise sessions, the participants will receive a 20 minute coaching session to address their attitudes, self-efficacy, and behavioral self-management skills towards exercise. During the sessions, the trainers will be taught to use motivational interviewing, an evidence-based communication strategy that identifies and enhances patients' own motivations and reasons for health behavior change. Motivational interviewing is an approach to assessment and intervention based on the Stages of Motivational Readiness for Change model, which has been shown to increase physical activity in people with chronic health conditions. According to the Stages of Motivational Readiness for Change Model, individuals move through a series of stages (i.e., Precontemplation, Contemplation, Preparation, Action, and Maintenance) as they adopt and maintain a new habit. The coaching session will also address barriers from the home-based sessions, discuss HIV-specific barriers
219137522|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
219137523|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
219137524|NCT01816113|BIOLOGICAL|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
219137525|NCT01816113|BIOLOGICAL|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
219137526|NCT04138862|BEHAVIORAL|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
219137527|NCT04373187|DRUG|CC-93538|one injection of 2mL
219137528|NCT04373187|DRUG|CC-93538|two injections of 1.2mL
219137529|NCT02824003|DRUG|ISIS-GCGRRx|once weekly dosing for 13 weeks
219137530|NCT02824003|DRUG|Placebo|once weekly dosing for 13 weeks
219137531|NCT03557333|COMBINATION_PRODUCT|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
219137532|NCT04601311|BEHAVIORAL|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
219137533|NCT04601311|BEHAVIORAL|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
219137534|NCT02272517|DRUG|Vortioxetine 10-20 mg|
219137535|NCT02272517|DRUG|Escitalopram 10-20 mg|
219137536|NCT01793740|BEHAVIORAL|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
219228403|NCT06500546|PROCEDURE|Treatment of cervical lesions|"Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,"
219228404|NCT00016042|BIOLOGICAL|lymphokine-activated killer cells|
219228405|NCT00016042|BIOLOGICAL|recombinant interferon alfa|
219228406|NCT00016042|BIOLOGICAL|sargramostim|
219228407|NCT00016042|DRUG|fluorouracil|
219228408|NCT00644501|DRUG|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
219228409|NCT01214200|DEVICE|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
219228410|NCT01256242|DEVICE|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
219228411|NCT01256242|PROCEDURE|Standard Suture Repair|standard suture repair
219228412|NCT00721097|OTHER|spirometry, and blood taken|each month during one year
219228413|NCT01719172|DEVICE|Veriset™ Hemostatic Patch|Topical Hemostat
219228414|NCT00907933|DRUG|SB-705498|0.5mg intranasal SB-705498
219228415|NCT00907933|DRUG|SB-705498|1.5mg intranasal SB-705498
219228416|NCT00907933|DRUG|SB-705498|3mg intranasal SB-705498
219137537|NCT04178395|DEVICE|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
219137538|NCT02293421|OTHER|Obstructive sleep apnea|
219228417|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498
219228418|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498
219228419|NCT00907933|DRUG|Placebo|Placebo '498
219228420|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498 for 14 days bid
219228421|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498 14 days bid
219228422|NCT00907933|DRUG|Placebo|Placebo
219228423|NCT05944666|PROCEDURE|Multimodal technology (MT)|"Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
219228424|NCT05944666|PROCEDURE|Conventional rehabilitation|It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
219228425|NCT01752816|BEHAVIORAL|exercise training|
219228426|NCT02027259|BEHAVIORAL|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
219228427|NCT01605448|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
219137539|NCT06089629|PROCEDURE|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
219137540|NCT00078533|BIOLOGICAL|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
219137541|NCT04045743|DRUG|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
219137542|NCT04045743|DRUG|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
219228428|NCT00678925|DIETARY_SUPPLEMENT|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
219228429|NCT00678925|DIETARY_SUPPLEMENT|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
219228430|NCT03100188|OTHER|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
219228431|NCT05292066|DRUG|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
219228432|NCT05292066|DRUG|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
219228433|NCT05825274|DEVICE|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
219228434|NCT00770874|DRUG|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
219228435|NCT00770874|DRUG|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
219228436|NCT04250636|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
219228437|NCT04250636|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
219228438|NCT04062396|DEVICE|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
219228439|NCT04062396|DEVICE|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
219228440|NCT00539812|BEHAVIORAL|Standard Care|Standard 40 hour state mandated batterer intervention program
219228441|NCT00539812|BEHAVIORAL|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
219228442|NCT02433587|DRUG|Aspirin|Patients will take Aspirin 81 mg
219228443|NCT02433587|DRUG|Clopidogrel|Patients will take Clopidogrel 75 mg
219228444|NCT04598594|DRUG|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
219228445|NCT04598594|DRUG|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
219228446|NCT04024176|OTHER|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
219228447|NCT00937014|OTHER|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
219228448|NCT00937014|OTHER|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
219228449|NCT01874964|BEHAVIORAL|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
219228450|NCT01874964|BEHAVIORAL|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
219228451|NCT00002801|DRUG|leucovorin calcium|
219228452|NCT00002801|DRUG|tegafur-uracil|
219228453|NCT00002801|RADIATION|radiation therapy|
219228454|NCT02326506|DEVICE|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
219228455|NCT00666419|OTHER|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
219228456|NCT02199626|DEVICE|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
219228457|NCT03963466|DRUG|tranexamic acid|Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
219228458|NCT03963466|RADIATION|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
219228459|NCT03963466|RADIATION|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
219228460|NCT01292213|PROCEDURE|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
219228461|NCT01292213|PROCEDURE|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
219228462|NCT01292213|PROCEDURE|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
219228463|NCT01292213|PROCEDURE|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
219228464|NCT01292213|PROCEDURE|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
219228465|NCT01292213|OTHER|Data collection|Questionnaire completion.
219228466|NCT01730456|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
219228467|NCT05582824|OTHER|Blood and urine test|Daily blood and urine samples
219228468|NCT03185936|PROCEDURE|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
219228469|NCT03041090|DEVICE|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
219228470|NCT04012242|DIAGNOSTIC_TEST|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
219228471|NCT02117310|DRUG|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
219228472|NCT01782105|BEHAVIORAL|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
219228473|NCT01782105|BEHAVIORAL|Control group|Evaluation of nutritional and physcial activity habits
219228474|NCT01087437|DIETARY_SUPPLEMENT|gastrolith calcium|
219137543|NCT00246012|DRUG|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
219137544|NCT00246012|DRUG|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
219137545|NCT00246012|DRUG|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
219137546|NCT04708743|DIAGNOSTIC_TEST|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
219137547|NCT05424159|RADIATION|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
219137548|NCT01178762|DRUG|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
219137549|NCT02301221|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
219137550|NCT02301221|DRUG|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
219137551|NCT03787875|PROCEDURE|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
219137552|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
219228475|NCT02202317|DEVICE|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
219228476|NCT02718196|BEHAVIORAL|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
219228477|NCT05374694|DIAGNOSTIC_TEST|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
219228478|NCT05820763|DRUG|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
219228479|NCT05820763|DRUG|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
219228480|NCT05820763|DRUG|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
219228481|NCT05868304|DEVICE|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
219228482|NCT05868304|OTHER|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
219137553|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
219137554|NCT02322216|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
219137555|NCT04246697|DRUG|Tylenol|Used for both arms, scheduled
219228483|NCT04886466|PROCEDURE|core stability in a sitting position and while walking in one place|The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
219228484|NCT00764166|DRUG|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
219137556|NCT04246697|DRUG|Oxycodone|Used for both arms PRN
219137557|NCT04246697|DRUG|Morphine|Used for both arms PRN
219137558|NCT04246697|DRUG|Gabapentin|Used for Arm B
219228485|NCT00764166|DRUG|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
219228486|NCT01580436|PROCEDURE|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
219137559|NCT04246697|DRUG|toradol|Used for Arm B
219137560|NCT04246697|DRUG|Bupivacaine|Used for Arm B - anesthesia block
219716876|NCT07105007|BEHAVIORAL|Mobile health support|At the beginning of the program the participants will receive a fitness activity tracker (e.g., Fitbit or similar) to help in achieving their PA goals. Contemporary activity trackers provide reliable information on heart rate, steps count, and amount of PA performed, that will help the participants to monitor the intensity and amount during the home-base sessions. Heart rate monitoring will also be used to assess compliance with the home-based exercise prescription. Trackers also include gamification, awarding badges and trophies when goals are attained, that is demonstrated to be motivating.
219716877|NCT07104747|PROCEDURE|Static Exercise Intervention|Static exercises generally involve maintaining a fixed position without movement-such as standing on one leg or holding a specific posture-emphasizing isometric muscle control and stability.
219716878|NCT07104747|PROCEDURE|(Dynamic Exercises Group|Dynamic exercises were structured across three progressive stages-basic, moderate, and advanced-each increasing in complexity and difficulty. These exercises were performed in various positions, including sitting, standing, and walking.
219716879|NCT05765500|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
219716880|NCT05765500|DRUG|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
219716881|NCT07105826|OTHER|Prebiotic Soda 1|A single dose of 12 ounces of Olipop will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
219716882|NCT07105826|OTHER|Prebiotic Soda 2|A single dose of 12 ounces of Poppi will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
219716883|NCT07105826|OTHER|Diet Soda|A single dose of 12 ounces of Diet Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
219716884|NCT07105826|OTHER|Regular Coke|A single dose of 12 ounces of Regular Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
219716885|NCT06911541|DEVICE|Wireless respiratory rate monitor|This sensor is being fasten on the chest of the patients and measures respiratory rate with the help of an accelerometer. Data is being sent wireless to a backend monitor.
219716886|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
219716887|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
219716888|NCT07106138|DEVICE|Conventional syringe injection|Manual injection using a conventional dental syringe and needle to deliver local anesthetic.
219716889|NCT07106138|DEVICE|Star Pen|A computer-controlled local anesthetic delivery system designed to provide slow, controlled injection with improved comfort.
219716890|NCT07106138|DEVICE|Comfort-In|A needle-free injection system that delivers anesthetic through high-pressure jet injection, reducing injection-related discomfort.
219716891|NCT07106138|DEVICE|Vibraject|A vibrating attachment for dental syringes that provides vibrotactile stimulation during injection to distract from pain perception
219716892|NCT07106775|BEHAVIORAL|Family Intervention Program (PIF)|Home psychoeducational intervention in an individual format driven by a practitioner where caregivers learn parenting competences and children learn autonomy and emotional regulation skills
219716893|NCT07106385|DEVICE|rtms|Participants will undergo a treatment protocol involving six sessions of rTMS using the EXOMIND™ device, administered once or twice a week. Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds. The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in our research centre with medical staff supported.
219716894|NCT06630091|DRUG|Golidocitinib|150 mg once per day by PO
219137561|NCT00904527|BEHAVIORAL|relaxation (Schultz)|Patients have relaxation consultations during 2 months
219137562|NCT03149406|OTHER|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
219137563|NCT00440284|DRUG|conventional vs. flexible, intensive insulin therapy|
219716895|NCT06630091|DRUG|Cyclophosphamide|750 mg/m2 by IV
219716896|NCT06630091|DRUG|Doxorubicin|50 mg/m2 by IV
219716897|NCT06630091|DRUG|Vincristine|1.4 mg/m2 (max: 2 mg) by IV
219716898|NCT06630091|DRUG|Prednisone|100 mg by PO
219137564|NCT01651949|BIOLOGICAL|9vHPV Vaccine|9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
219137565|NCT02997618|BEHAVIORAL|Community based exercise programme|20 week community (home or gym based) exercise programme
219137566|NCT02997618|OTHER|Control|Usual care consisting of advice.
219137567|NCT02186405|DRUG|LEVOTHYROXINE|administration of levothyroxine
219137568|NCT00000433|DRUG|Anti-Tumor Necrosis Factor|
219137569|NCT00346931|PROCEDURE|Phacoemulsification, implantation of intraocular lens|
219137570|NCT00346931|PROCEDURE|Phacoemulsification, Implantation of IOL, trabeculotomy|
219137571|NCT01806714|OTHER|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
219137572|NCT01806714|OTHER|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
219137573|NCT02867046|DRUG|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
219228487|NCT05372224|DRUG|Cholecalciferol|4000 IU were administrated once a day for 3 months.
219137574|NCT02520570|DRUG|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
219137575|NCT04570644|DRUG|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
219137576|NCT06421688|DRUG|Ascorbic acid|After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
219716899|NCT07104903|OTHER|Data collection from medical records|Data are collected from the information system and medical records, including demographic characteristics, presence of surgical site infection, comorbidities, data regarding neoadjuvant oncological therapy, preoperative laboratory findings, type and duration of surgical intervention, perioperative complications, and SENIC and NNIS scores are calculated.
219716900|NCT05145595|DEVICE|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
219716901|NCT05145595|DEVICE|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
219716902|NCT05145595|DEVICE|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
219716903|NCT05145595|BEHAVIORAL|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
219716904|NCT05145595|BEHAVIORAL|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined \[22; 55\]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
219716905|NCT05145595|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
219716906|NCT05145595|BEHAVIORAL|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
219716907|NCT05145595|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM\<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
219137577|NCT06421688|DRUG|Saline|After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
219137578|NCT05701592|PROCEDURE|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
219228488|NCT02459860|BEHAVIORAL|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
219228489|NCT02459860|BEHAVIORAL|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
219228490|NCT05563571|DRUG|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
219228491|NCT05563571|OTHER|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
219137579|NCT06228807|COMBINATION_PRODUCT|The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.|Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
219137580|NCT00470743|DRUG|Ibuprofen|
219137581|NCT00470743|DRUG|Indomethacin|
219137582|NCT02834689|BEHAVIORAL|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
219137583|NCT02834689|BEHAVIORAL|Seated Control|Sitting for 50 minutes
219137584|NCT01982019|BEHAVIORAL|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
219137585|NCT00001421|DRUG|methimazole|
219137586|NCT00768781|BEHAVIORAL|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
219137587|NCT00768781|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
219137588|NCT00768781|BEHAVIORAL|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
219137589|NCT06394791|DRUG|Tislelizumab + IL-2 Combined with Capox|Tislelizumab + IL-2 Combined with Capox
219716908|NCT05145595|BEHAVIORAL|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms \[41\]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA\<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
219716909|NCT05145595|BEHAVIORAL|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
219716910|NCT07103980|DRUG|Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule|"Mesenchymal stem cell derived exosome nebulization (FITCELL 5ml nebulization QD) was combined with compound methoxyphenamine capsule ( Asmei 2 capsules oral TID) for cough treatment."
219716911|NCT07103980|DRUG|Normal saline nebulization combined with the compound methoxyphenamine capsule|"Normal saline nebulization (0.9% sodium chloride 5ml nebulization QD) was combined with the compound methoxyphenamine capsule (Asmei 2 capsules oral TID) for cough treatment."
219716912|NCT07104552|DRUG|Course of amoxicillin|Oral amoxicillin per os at 50 mg/kg/day
219716913|NCT07103473|DEVICE|Interactive Binocular Treatment|Patients in the intervention group will be asked to play the games which will be designed based on the Interactive Binocular Treatment System and the patients in the placebo group will be asked to play games without the Interactive Binocular Treatment System.
219716914|NCT07105332|DEVICE|OMI and Photometer|A glucose sensitive ocular mini insert (OMI) is placed sub-conjunctivaly. When exited by photometer the glucose concentration is measured.
219137590|NCT00368719|DRUG|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
219137591|NCT04061408|RADIATION|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
219137592|NCT00232011|DRUG|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
219137593|NCT02057354|BEHAVIORAL|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
219137594|NCT02057354|BEHAVIORAL|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
219137595|NCT00759837|DRUG|Bosutinib|
219137596|NCT01884389|OTHER|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
219716915|NCT07102745|BEHAVIORAL|HomeLink|HomeLink is a structured post-discharge home-based care program for people living with HIV, designed to improve health outcomes after hospital discharge. Starting one week after discharge, trained nurse-clinician and counselor teams conduct regular home visits every two weeks for up to six visits. During these visits, the team will provide clinical assessments, medication adherence support, psychosocial counseling, specimen collection, and home safety evaluations. The intervention aims to offer personalized, continuous care that addresses medical, psychological, and social needs in the participant's home environment, enhancing recovery and reducing post-hospital mortality.
219716916|NCT07102745|BEHAVIORAL|HomeLink Plus Nutritional Support|This intervention combines the HomeLink home-based care program with the provision of nutritional support through food parcels. Participants receive food parcels designed to address nutritional needs and support overall health and recovery. The combined approach aims to improve post-discharge outcomes by addressing both medical and nutritional factors contributing to patient well-being.
219716917|NCT07103928|BEHAVIORAL|Impart Assisted Partner Notification|Participants randomized to the Impart arm may choose per partner either a) sell-tell notification or b) having an Impart-trained APN notifier team locate, notify, and offer HIV testing to their partners without revealing the identity of who had named them. Impart notifiers initially contact named partners by telephone and identify themselves as health service providers with important information about the partner's health that needs to be shared in person. Partners who agree to meet are asked to choose a location. Notification by telephone is only delivered as a last resort when circumstances prevent in-person notification or a partner insists on learning the reason for the telephone call. Once contact is made at a private location, partners will be advised of their possible shared exposure to HIV. APN notifiers never reveal participant names or identifying information during this meeting. All notified partners are offered immediate HIV testing and treatment referral, if HIV-positive.
219716918|NCT07103928|BEHAVIORAL|Self-Tell Notification|"Participants who wish to self-notify one or more partners are coached to do so either in person or by telephone. APN counselors confirm the names of partners for whom participants provide contact information before giving the phone to the participant to explain the reason for the call: I want to speak with you because I was diagnosed with HIV and I believe we shared an exposure. Alternately, participants who wish to notify partners in person are coached to inform partners that they have a serious health matter that they wish to discuss, and ask the partner to visit them in jail/prison. Either way, the APN counselor is present to record the names of partners whom participants self-notify, and offers to speak with the partner immediately afterwards to answer their questions about HIV and to provide information about HIV testing and contact information should the partner wish to contact an HIV provider on their own to learn more about HIV testing or to schedule an HIV test."
219716919|NCT07103785|OTHER|Mobile game app|The mobile game designed to modify attentional bias toward alcohol-related cues was developed by integrating game elements into a modified version of the dot-probe task. This gamified intervention was installed on the smartphones of participants assigned to the experimental group, and each participant was provided with a unique username and password for access. Participants were instructed to engage with the mobile game every other day over one month.
219716920|NCT07103785|DRUG|Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson)|Medicines prescribed by a doctor for the treatment of Alcohol Use Disorder (Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson))
219716921|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
219716922|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
219716923|NCT02337686|OTHER|Laboratory Biomarker Analysis|Correlative studies
219716924|NCT02337686|BIOLOGICAL|Pembrolizumab|Given IV
219716925|NCT02337686|OTHER|Pharmacological Study|Correlative studies
219716926|NCT02337686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219716927|NCT06762808|DRUG|Atezolizumab|Given by IV infusion
219716928|NCT06762808|DRUG|Talazoparib|Given by IV infusion
219716929|NCT06082037|DRUG|Belumosudil|Tablet, Oral
219716930|NCT06082037|DRUG|Azithromycin|Depends on pharmaceutical presentation, Oral
219716931|NCT06082037|DRUG|Placebo|Tablet, Oral
219137597|NCT03096184|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
219137598|NCT03096184|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
219137599|NCT00680537|PROCEDURE|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
219716932|NCT06448637|DEVICE|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
219716933|NCT06448637|DEVICE|Drug Eluting Stent (DES)|Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
219716934|NCT07108296|OTHER|cardiopulmonary exercise testing (CPET)|In this study, the cardiopulmonary exercise testing (CPET) system used breath-by-breath continuous analysis for gas exchange and ventilation variables. The protocol included spirometry with an 8-breath data collection method. The cycle ergometer workload ranged from 10 to 40 W/min using a RAMP protocol. The standard CPET protocol comprised a 3-min rest, 3-min warm-up, 8 - 12 min incremental exercise phase, and 3-min each of active and passive recovery.
219137600|NCT02534441|OTHER|Skin patch test|
219137601|NCT01585038|DRUG|Efavirenz|600mg orally every evening
219137602|NCT01585038|DRUG|Rilpivirine|25mg orally once daily
219137603|NCT03724370|BEHAVIORAL|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
219137604|NCT03724370|OTHER|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
219137605|NCT00272935|DRUG|Cenestin 0.3 mg Tablets|1 tablet daily
219716935|NCT07108387|DRUG|Tocilizumab|"Participants will continue Tocilizumab (TCZ) at a lower dose of either 4 mg/kg IV monthly or 162 mg SC every 2 weeks~Participants randomized to the stepped-down treatment arm will receive TCZ on their current route of administration. The route of administration may change if needed during study participation at the discretion of the investigator"
219137606|NCT00272935|OTHER|Placebo|1 tablet daily
219228492|NCT01052974|DRUG|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
219228493|NCT01318850|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
219228494|NCT01318850|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
219228495|NCT01318850|OTHER|Healthy controls|No intervention
219716936|NCT07108387|DRUG|Discontinue Tocilizumab|"Participants will discontinue Tocilizumab and will have visits at Week 2, Month 1 and 2, and then every 2 months during the TCZ Withdrawal Phase until the Month 18 Visit.~Participants who remain in remission will enter the Follow-Up Phase for an additional 12 months at Month 18 and will continue withdrawal at that time."
219716937|NCT07110285|OTHER|Artificial intelligence-based algorithm|Trigger day timing decision by an artificial intelligence-based algorithm
219716938|NCT07104643|DRUG|TYK-00540|Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
219716939|NCT07104643|DRUG|Enzalutamide|Take orally, 160mg each time, once a day. Take orally with or without meals.
219716940|NCT07109557|OTHER|Baduanjin|Baduanjin exercise
219716941|NCT07109895|OTHER|Standard Care Only|Standard care includes routine wound debridement, moist wound dressings infection control, glycemic management, vascular assessment, and patient education in line with international DFU management guidelines.
219716942|NCT07109895|OTHER|TENS plus Standard Care|This experimental group will receive the same intervention plus Transcutaneous Electrical Nerve Stimulation (TENS) in burst mode (1-4 Hz at 100 Hz) applied around the wound site for 30 minutes, along with standard care.
219716943|NCT07109895|OTHER|Custom Insole + Standard Care|The experimental group will receive customised polyethene foam insoles with a Poron top layer along with standard care.
219716944|NCT07109895|OTHER|TENS + Custom Insole + Standard Care|Participants in this group will receive a combination of transcutaneous electrical nerve stimulation (TENS), custom-made insole therapy, and standard care for diabetic foot ulcers (DFUs).
219716945|NCT05948761|OTHER|Hypoxia through modified hypoxic generator|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants.
219716946|NCT05948761|OTHER|Normoxia through hypoxic generator without active elements|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants, without active elements.
219716947|NCT07111494|DRUG|GLP-1 agonists|GLP-1, any assigned drug
219716948|NCT07111494|OTHER|Nutrition Counseling|Nutrition Counseling in PsA
219716949|NCT07102836|DRUG|Zinc sulfate|Oral zinc sulfate syrup in a dose providing 5mg elemental zinc daily as adjuvant to phototherapy.
219137607|NCT02952053|DEVICE|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
219137608|NCT02952053|DEVICE|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
219137609|NCT04007302|OTHER|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
219137610|NCT04007302|OTHER|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
219137611|NCT04007302|OTHER|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
219228496|NCT05927259|DRUG|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
219228497|NCT05927259|DRUG|standard treatment|stabilization and antidotes
219228498|NCT01115036|DRUG|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
219228499|NCT02177825|DRUG|Imatinib Mesylate|oral administration
219137612|NCT02678104|PROCEDURE|Tooth extraction|Tooth removal
219137613|NCT02678104|DRUG|Chlorhexidine mouth wash|Chlorhexidine mouth wash
219137614|NCT02678104|DRUG|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
219137615|NCT01947179|BEHAVIORAL|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
219228500|NCT01481974|DRUG|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
219716950|NCT07102836|DRUG|Probiotic lactobacillus rhamnosus GG|Oral Probiotic Lactobacillus rhamnosus GG drops daily as adjuvant to phototherapy.
219716951|NCT00080626|BIOLOGICAL|pegfilgrastim|6 mg injection on day 1 of each cycle
219716952|NCT00080626|DRUG|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
219716953|NCT00080626|PROCEDURE|conventional surgery|lumpectomy or mastectomy at end of treatment
219551543|NCT02854800|DRUG|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
219551544|NCT00973388|DRUG|Telaprevir; Moxifloxacin; Placebo|
219137616|NCT01760044|DEVICE|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
219137617|NCT04107805|DRUG|BI 1323495|Tablet
219137618|NCT04107805|DRUG|Placebo|Tablet
219137619|NCT04107805|DRUG|Midazolam|Oral administration
219716954|NCT00080626|PROCEDURE|neoadjuvant therapy|treatment prior to definitive breast surgery
219716955|NCT07106879|OTHER|Blood Work|Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
219716956|NCT07103954|OTHER|McKenzie Exercises plus Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~For McKenzie exercises, the participant will be in a comfortable sitting posture with proper back support. He will be asked to perform the following exercises:~1. Retraction in supine and sitting positions~2. Retraction with patient and therapist overpressure~3. Retraction with extension and rotation~4. Rotation with patient and therapist overpressure~5. Lateral flexion~6. Lateral flexion with patient and therapist overpressure • All these exercises will be done with a hold of one or two seconds and the movement is then repeated for five to six times."
219716957|NCT07103954|OTHER|Mulligan Mobilization with Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~The Mulligan mobilization, the patient will be seated in a comfortable position on a chair and the therapist stood behind to perform the mulligan mobilization. A gliding force will be applied by the therapist on the patient's spinous process or on the facet joint of the superior vertebra of the target segment for treatment. This gliding force will be maintained by the therapist. Then the patient will move his head towards the painful side (flexion, extension, rotation, and lateral flexion), and more pressure will be applied by the patient at the end of active movement. The Mulligan mobilization will be repeated 10 times for 3 sets."
219716958|NCT07112781|RADIATION|Single Dose Radiotherapy|Procedure: external-beam radiotherapy (EBRT) on a linear accelerator with a dose 24 Gy in one session using technique of image-guided volumetric intensity modulation arc therapy (VMAT-IGRT) and a set of dedicated devices that ensure target immobilization and reproducibility of prostate anatomical localization during treatment. A special air-filled endorectal balloon will be used for immobilization of the prostate and anatomical reproducibility of organs at risk during treatment. A Foley catheter will be used to ensure reproducibility of the urethral position and online tracking of the prostate gland position during treatment. A special external immobilization system, including patient positioning on a patient transfer trolley, which allows for patient transfer without removing the endorectal balloon and urinary catheter from the table at all stages of pre-radiation preparation (MR, CT, Positron emission tomography (PET) / CT simulation) and during the treatment.
219137620|NCT01919697|DRUG|Plecanatide|
219228501|NCT00315848|DRUG|Buprenorphine transdermal delivery system|
219551545|NCT00000245|DRUG|Desipramine|
219137621|NCT04590651|PROCEDURE|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
219137622|NCT04590651|PROCEDURE|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
219137623|NCT01304394|DRUG|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
219137624|NCT00768131|DRUG|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
219137625|NCT00768131|DRUG|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
219137626|NCT00768131|DRUG|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
219137627|NCT04820101|DRUG|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
219137628|NCT01450124|DRUG|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
219228502|NCT01130298|DRUG|Testosterone Gel 1.62%|5 grams
219228503|NCT04714346|OTHER|no interventions|there is no intervention
219228504|NCT00130182|DRUG|denufosol tetrasodium (INS37217)|
219228505|NCT02808403|OTHER|No intervention|No intervention; observation of routine medical care
219551546|NCT01916239|DIETARY_SUPPLEMENT|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
219551547|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-1|New pomegranate extract formulation-1
219551548|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-2|New pomegranate extract formulation-2
219551549|NCT04546282|OTHER|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
219551550|NCT03639181|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
219551551|NCT05971056|OTHER|Care transition|Cancer care is transitioned to a satellite site.
219551552|NCT05971056|OTHER|No care transition|Cancer care is not transitioned to a satellite site.
219137629|NCT02869958|OTHER|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
219137630|NCT02869958|OTHER|Written action plan|
219137631|NCT06206473|OTHER|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
219137632|NCT02286999|DRUG|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
219137633|NCT02286999|DRUG|Placebo|
219137634|NCT06055114|DIAGNOSTIC_TEST|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
219137635|NCT02563704|DRUG|Artesunate|
219137636|NCT02563704|DRUG|Quinine|
219137637|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
219137638|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
219137639|NCT02261688|DIETARY_SUPPLEMENT|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
219137640|NCT05196438|OTHER|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
219137641|NCT03558204|PROCEDURE|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
219137642|NCT03558204|PROCEDURE|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
219137643|NCT02777632|PROCEDURE|Living donor liver transplantation|
219137644|NCT01934829|DRUG|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
219137645|NCT03098290|PROCEDURE|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
219137646|NCT03098290|PROCEDURE|Bypass-Surgery|Venous or alloplastic or comparable Bypass
219137647|NCT03098290|PROCEDURE|Endarterectomy|Endarterectomy, Patchplasty
219137648|NCT05787730|DEVICE|Transobturator tape|
219137649|NCT05623384|PROCEDURE|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
219137650|NCT05623384|PROCEDURE|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
219137651|NCT05623384|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
219137652|NCT06256211|DRUG|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
219551553|NCT01538459|DRUG|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
219551554|NCT01538459|DRUG|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
219551555|NCT04125186|DIAGNOSTIC_TEST|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
219716959|NCT07111533|PROCEDURE|Open Flap Debridement (OFD)|Under Local Anesthesia , intrasulcular incisions using surgical blade #15c Then, a full thickness mucoperiosteal flap will be raised . Then, the granulation tissue in the intrabony defect will be debrided and the root will be planned using manual and ultrasonic instruments followed by saline and chlorohexidine irrigation till obtaining a healthy sound bone surface.
219716960|NCT07111533|PROCEDURE|Bone Graft|Bovine Xenograft material packed into the debrided defect.
219716961|NCT07111533|PROCEDURE|Autogenous Periosteal Pedicle Graft (PPG)|"* Vertical releasing incisions will be used if necessary for better access.~* The periosteal membrane will be separated from this flap and released with one vertical incision mesially and one horizontal incision apically . Posteriorly, the periosteum remained attached to the mucoperiosteal flap for adequate blood supply.~* periosteal membrane will be turned over to cover this defect completely and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture. \*The soft tissue flap will be sutured with 5-0 nonabsorbable prolene suture material and a periodontal dressing was given."
219716962|NCT07111533|PROCEDURE|Pericardium Membrane|A pericardium membrane was adapted for defect coverage and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture.
219716963|NCT04391556|DRUG|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
219716964|NCT06736821|DIETARY_SUPPLEMENT|Open sinus augmentation with melatonin gel mixed with xenograft|"All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors"
219716965|NCT06736821|PROCEDURE|Open sinus augmentation with xenograft|All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
219716966|NCT07104188|DIETARY_SUPPLEMENT|A non-active placebo supplement.|Placebo powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
219137653|NCT05753644|PROCEDURE|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
219137654|NCT05753644|DRUG|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
219137655|NCT05753644|DRUG|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
219137656|NCT00588965|DRUG|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
219137657|NCT00588965|DRUG|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
219137658|NCT06064032|BEHAVIORAL|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
219228506|NCT03087318|BEHAVIORAL|Physical activity|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months."
219228507|NCT03372252|DEVICE|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
219228508|NCT03739606|BIOLOGICAL|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
219228509|NCT01005615|DEVICE|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
219716967|NCT07104188|DIETARY_SUPPLEMENT|Caffeine|220 mg caffeine powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
219716968|NCT07104188|DIETARY_SUPPLEMENT|Energy Drink|A supplement containing 220 mg caffeine, 1800 mg anserine extract, and 400 mg elderberry extract, mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
219137659|NCT06064032|BEHAVIORAL|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
219137660|NCT00422201|DRUG|Mifepristone|Singe dose
219137661|NCT04354610|PROCEDURE|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
219137662|NCT04354610|PROCEDURE|Clinical examination|Clinical examination
219137663|NCT04354610|PROCEDURE|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
219137664|NCT02000505|DEVICE|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
219137665|NCT02000505|DEVICE|Metronome|5 minutes chest-compression-only CPR, using a metronome
219137666|NCT02000505|DEVICE|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
219716969|NCT07103525|BEHAVIORAL|INSPIRE Initiative|Culturally relevant, multi-level intervention designed to increase HIV testing through reducing intersectional stigma. Intervention includes series of four one-on-one conversations (45 minutes each over a six-week period) via mobile phone between the Hunter peer advocates and FSWs, which are reinforced through weekly text messages from the peer advocates and through role-model stories shared online.
219716970|NCT07103525|BEHAVIORAL|Standard of Care|Standard HIV prevention information with no tailored components via one mobile phone verbal conversation with peer advocates.
219137667|NCT03718793|DIAGNOSTIC_TEST|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
219137668|NCT01234532|DRUG|entinostat|orally
219137669|NCT01234532|DRUG|anastrozole|Given PO
219137670|NCT01234532|OTHER|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
219137671|NCT01234532|PROCEDURE|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
219716971|NCT07104344|BIOLOGICAL|CM355|CM355 injection
219716972|NCT07103330|DEVICE|Metallic fixation hardware|Control
219137672|NCT02716649|OTHER|No intervention|
219137673|NCT03168204|BEHAVIORAL|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
219137674|NCT05460806|OTHER|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
219137675|NCT05097924|OTHER|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
219137676|NCT00853827|DRUG|Placebo|Placebo
219716973|NCT07103330|DEVICE|Cranial flap placement and fixation using only Montage Flowable Settable Bone Paste|Experimental
219137677|NCT00853827|DRUG|Aliskiren|300 mg
219137678|NCT02377505|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
219137679|NCT02377505|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
219137680|NCT01636206|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
219137681|NCT01636206|DRUG|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
219137682|NCT03939572|BEHAVIORAL|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
219137683|NCT03939572|BEHAVIORAL|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
219228510|NCT01005615|DEVICE|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
219137684|NCT03939572|BEHAVIORAL|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
219228511|NCT01014299|OTHER|Recruitment maneuver|"Assigned interventions:~* No intervention after tracheal intubation (control group)~* Alveolar recruitment maneuver (RM group) immediately after intubation"
219228512|NCT02151084|DRUG|Selumetinib|
219228513|NCT02151084|DRUG|Cisplatin|
219228514|NCT02151084|DRUG|Gemcitabine|
219228515|NCT04224415|DRUG|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
219716974|NCT07105046|OTHER|Interviews|A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.
219716975|NCT07105046|OTHER|Focus Groups|45 to 60 minutes video conference
219716976|NCT07108283|DRUG|Zasocitinib|Zasocitinib capsules.
219716977|NCT07108283|OTHER|Placebo|Zasocitinib matching placebo capsules.
219716978|NCT07107243|DIAGNOSTIC_TEST|Speaking valve combined with airway pressure|All patients wore speaking valves for 30 minutes, during which the transtracheal end-expiratory pressure was measured to assess the patency of the upper airway.
219716979|NCT07107243|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
219716980|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
219137685|NCT03939572|BEHAVIORAL|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
219228516|NCT02085512|PROCEDURE|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
219228517|NCT02085512|OTHER|Control, web-based tasks|No training modules
219360772|NCT04704479|DEVICE|Russian current|For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration
219137686|NCT02087306|DRUG|Brincidofovir|BCV administered twice weekly, dose depending on weight.
219137687|NCT00685893|BEHAVIORAL|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
219137688|NCT00685893|BEHAVIORAL|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
219137689|NCT00685893|BEHAVIORAL|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
219137690|NCT00685893|BEHAVIORAL|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
219137691|NCT00685893|BEHAVIORAL|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
219137692|NCT01156116|DEVICE|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
219137693|NCT01156116|DRUG|Placebo|oral placebo tablet
219137694|NCT03857334|BIOLOGICAL|Injection of autologous platelet rich plasma|
219137695|NCT03857334|DRUG|Injection of cortivazol : Altim®|Corticosteroids
219137696|NCT01952795|BEHAVIORAL|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
219137697|NCT01563991|PROCEDURE|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
219137698|NCT01563991|PROCEDURE|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
219137699|NCT02703155|DEVICE|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
219137700|NCT00651378|DRUG|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
219137701|NCT00651378|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
219137702|NCT00651378|DRUG|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
219137703|NCT00209443|DRUG|Gadodiamide Injection|
219137704|NCT01254591|OTHER|18F-fluoromisonidazole|
219137705|NCT01254591|OTHER|fluorescence angiography|
219137706|NCT01254591|OTHER|laboratory biomarker analysis|
219228518|NCT05781932|PROCEDURE|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
219716981|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
219716982|NCT07114328|OTHER|hand massage|The hand massage was applied to both hands for 5-6 minutes, for a total of 10-12 minutes
219716983|NCT07113899|OTHER|Approach to spirituality through hope and acceptance|"This study is a prospective longitudinal research study. The sample consisted of two groups: the Intervention Group, which included patients from the community palliative care support team (ECSCP-BM), and the Control Group, with primary health care selected patients from the family health units Nautilus and Coimbra Centro (CSP), with serious illness, comorbidities, and a poor prognosis. The patients chosen from ECSCP-BM were made up only of new patients referred to the team without any prior home consultations. The first questionnaire application took place during the first visit, and the second one was administered fourteen days later. The Primary Health Care patients were selected by invitation, and the questionnaire was administered. It included sociodemographic data, clinical data, the Herth Hope Index and open questions.~During the palliative care team's home visit, spirituality was addressed in in the clinical history through the assessment of hope and acceptance."
219716984|NCT07113574|DRUG|Meropenem 1000 mg|Administration of meropenem after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
219716985|NCT07113574|DRUG|Aztreonam 2000 mg|Administration of aztreonam after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
219716986|NCT07113574|OTHER|automated peritoneal dialysis with following long time dwell|The cycler therapy, followed by a prolonged dwell, will be performed as outlined in the study protocol.
219716987|NCT07113574|DIAGNOSTIC_TEST|Sampling|The sampling of blood, dialysate, and urine will be performed as outlined in the study protocol.
219716988|NCT07114172|DIAGNOSTIC_TEST|68Ga-ACC-DE/68Ga-FASN-DE/68Ga-ACLY-DE PET/CT|Recruit 15 healthy adult volunteers, divided into three groups, to undergo dynamic PET/CT (1 hour) and static PET/CT (2 hours and 3 hours) imaging with 68Ga-ACC-DE, 68Ga-FASN-DE, or 68Ga-ACLY-DE, respectively, to assess safety, biodistribution, and radiation dosimetry, laying the foundation for subsequent studies.
219716989|NCT07116304|DRUG|Lidocaine, a local anaesthetic.|it will be given as a pretreatment prior to injection of propofol, with a tourniquet applied.
219137707|NCT01254591|PROCEDURE|infrared thermography|
219137708|NCT01254591|PROCEDURE|magnetic resonance imaging|
219137709|NCT01254591|PROCEDURE|therapeutic conventional surgery|
219137710|NCT01254591|RADIATION|[18F]-ML-10|
219137711|NCT01254591|RADIATION|fludeoxyglucose F 18|
219137712|NCT01254591|RADIATION|rubidium Rb-82|
219137713|NCT02931851|OTHER|ICU Families Website|Professionally developed website for relatives of ICU patients
219137714|NCT02931851|OTHER|Placebo|Standard Information provided online
219137715|NCT06341491|BEHAVIORAL|Pé-de-Meia Program|"The Pé-de-Meia Program was established by the Brazilian Federal Government with the aim of encouraging the retention of low-income students in high school by providing maintenance scholarships and savings opportunities. To be eligible for the program, a young person must: Be properly enrolled in a regular public high school course, be between 14 to 24 years old, come from a low-income family, and be registered in the Bolsa Família Program. The Program offers four types of incentives:~An enrollment grant registered at the beginning of the academic year, paid once a year in the amount of 200 BRL.~A minimum school attendance of 80% of the total class hours, paid in nine installments throughout the year at 200 BRL each.~Proven participation in the National High School Exam (ENEM), paid once to the student enrolled in the third year of high school, in the amount of 200 BRL.~Completion of the high school academic years, paid in a single installment of 1,000 BRL."
219716990|NCT07116304|DRUG|Parecoxib 40mg|atients in this group will receive IV parecoxib 40 mg (the standard full dose for an adult) diluted to a total volume of 5 mL with normal saline.
219716991|NCT07114367|DRUG|NB02 (Poseltinib)|Dose Level 1, Dose Level 2, Dose Level 3
219716992|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab + Pertuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously and Pertuzumab (initial dose 840 mg, subsequent doses 420 mg) intravenously. This regimen was repeated every 21 days for 6 cycles.
219716993|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously. This regimen was repeated every 21 days for 6 cycles.
219137716|NCT00048828|DRUG|Olanzapine|Participants will receive olanzapine for 12 weeks.
219137717|NCT00048828|DRUG|Clozapine|Participants will receive 12 weeks of clozapine.
219137718|NCT00481234|DEVICE|Heart Rate Variability analysis|
219137719|NCT00540202|DRUG|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
219137720|NCT00540202|DRUG|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
219137721|NCT01191788|BEHAVIORAL|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
219137722|NCT01191788|BEHAVIORAL|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
219137723|NCT04081506|OTHER|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
219137724|NCT01245439|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
219137725|NCT06238154|DRUG|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
219137726|NCT01082809|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
219137727|NCT06319664|PROCEDURE|retrosigmoid approach (RSA)|The skull base approach choice was fundamentally followed by the modified classification.
219716994|NCT07118397|OTHER|dry needling|Dry needling involved the insertion of fine needles into identified myofascial trigger points within the plantar fascia and associated muscles. The technique aimed to release muscle tightness and alleviated pain by stimulating the trigger points. Needles were inserted perpendicularly to the skin at the identified trigger points, with the depth of insertion typically ranged from 35 to 70 mm, with 0.30mm diameter.
219716995|NCT07118397|OTHER|kinesiology taping|Kinesiology Taping was applied using an I-shape technique. The taping began from the metatarsal head, extending through the plantar fascia and along the Achilles' tendon to the calf muscle. The application involved specific tension levels to support the plantar fascia and improve functional movement. The taping was applied with the foot in a slightly dorsiflexed position to ensure proper adherence and function.
219716996|NCT06923605|DRUG|Epoetin 4000|Erythropoietin hormone
219716997|NCT06923605|OTHER|Placebo|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl) 4 times daily
219716998|NCT07121049|BEHAVIORAL|Strength training|Through systematic muscle training and promotion of outdoor activities, the program integrates early childhood education college students with kindergartens to promote the all-round development of children and establish habits to prevent myopia.
219137728|NCT06319664|PROCEDURE|subtemporal transtentorial transpetrosal approach (STTA)|The skull base approach choice was fundamentally followed by the modified classification.
219137729|NCT06319664|PROCEDURE|extended pterional transtentorial approach (EPTA)|The skull base approach choice was fundamentally followed by the modified classification.
219137730|NCT06319664|PROCEDURE|pretemporal trancavernous anterior transpetrosal approach (PTCA)|The skull base approach choice was fundamentally followed by the modified classification.
219137731|NCT06319664|PROCEDURE|presigmoid combined supra-infratentorial approach (PCA)|The skull base approach choice was fundamentally followed by the modified classification.
219137732|NCT06319664|PROCEDURE|inoperable|The skull base approach choice was fundamentally followed by the modified classification.
219137733|NCT02276508|DRUG|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
219137734|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
219716999|NCT07120009|PROCEDURE|selective caries removal|The caries is not completely removed but covered with a remineralizing material. Its purpose is to maintain pulp vitality.
219717000|NCT07120009|PROCEDURE|partial pulpotpmy|Complete cleaning of the caries resulting in pulp expose. pulp tissue is surgically removed by 1-3 mm.The aim is to remove the inflamed superficial pulp tissue to allow healing from the underlying healthy tissue.
219717001|NCT07118800|DRUG|FOLFOX4s|"6 cycles of FOLFOX4s intravenously: Oxaliplatin 85mg/m² over 2h, folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h, Fluorouracil bolus 400mg/m², Fluorouracil: 2400mg/m² over 46h, every 14 days for 12 weeks (max: 6 cycles). FOLFOX4 regimen will be started 2-4 weeks after completion of radiotherapy"
219717002|NCT07118800|RADIATION|Short Course Radiotherapy|25Gy in 5 fractions of 5Gy delivered in one week (short-course radiotherapy)
219717003|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation A)|One dose of Flu mRNA (Formulation A) received intramuscularly.
219717004|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation B)|One dose of Flu mRNA (Formulation B) received intramuscularly.
219137735|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
219717005|NCT07121192|COMBINATION_PRODUCT|Comparator 1|One dose of Comparator 1 received intramuscularly.
219717006|NCT07121192|COMBINATION_PRODUCT|Comparator 2|One dose of Comparator 2 received intramuscularly.
219137736|NCT04327882|DIAGNOSTIC_TEST|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
219137737|NCT01130818|DRUG|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
219137738|NCT01130818|DRUG|placebo|single dose, oral solution
219137739|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
219137740|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
219137741|NCT05147389|DIAGNOSTIC_TEST|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
219228519|NCT04053699|DRUG|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
219228520|NCT05704192|PROCEDURE|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
219137742|NCT05147389|DIAGNOSTIC_TEST|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
219137743|NCT04806256|BEHAVIORAL|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
219137744|NCT04806256|OTHER|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
219137745|NCT00702806|DRUG|Org 36286|Intra-abdominal injection of Org 36286
219137746|NCT00702806|DRUG|Puregon®|Subcutaneous Puregon® 150 IU
219137747|NCT00702806|DRUG|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
219137748|NCT00702806|DRUG|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
219137749|NCT04652817|DEVICE|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
219137750|NCT02209740|OTHER|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
219137751|NCT02717299|DEVICE|Verasense|Verasense will collect balancing data on all patients in this trial.
219137752|NCT00374699|DRUG|Velcade|
219137753|NCT00509769|DRUG|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
219137754|NCT04956224|BIOLOGICAL|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
219137755|NCT05407142|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
219137756|NCT05407142|OTHER|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
219137757|NCT03101618|OTHER|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
219717007|NCT07121192|COMBINATION_PRODUCT|Comparator 3|One dose of Comparator 3 received intramuscularly.
219717008|NCT07119372|BIOLOGICAL|BCD-131 (pegdarbepoetin beta)|BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
219717009|NCT07119372|BIOLOGICAL|Mircera (methoxypolyethylene glycol-epoetin beta)|Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
219717010|NCT07120204|DRUG|Corticosteroid Injection|The symptomatic foot will be prepared with povidone-iodine and draped in a sterile manner. A sterile-covered ultrasound probe will be placed over the heel to visualize the calcaneus, plantar fascia, and any calcaneal spur. Subsequently, 1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.
219137758|NCT03101618|OTHER|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
219137759|NCT01191619|PROCEDURE|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
219137760|NCT04009356|PROCEDURE|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
219137761|NCT00754936|DRUG|Escitalopram|20 mg by mouth daily
219137762|NCT02370563|DRUG|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
219137763|NCT01992354|DEVICE|PET MR Device|GE PET/MRI system
219137764|NCT04963049|OTHER|Protocol with Mask|Look at differences in group with facemask and no mask
219137765|NCT01387113|OTHER|Computed tomography perfusion imaging|As per standard of care at CPMC
219228521|NCT06390449|OTHER|Kahoot intervention|Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
219137766|NCT03665090|BEHAVIORAL|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
219137767|NCT04480593|DRUG|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
219717011|NCT07120204|PROCEDURE|Radiofrequency thermocoagulation|The patient will be in the lateral decubitus position with the symptomatic foot below. The foot was prepared with povidone-iodine and draped under sterile conditions. A sterilized ultrasound probe was placed over the heel to visualize the calcaneus, plantar fascia, and calcaneal spur. A 10 cm long radiofrequency (RF) needle with a 5 mm active tip was advanced in-plane under ultrasound guidance toward the tip of the calcaneal spur. Sensory stimulation at 50 Hz elicited paresthesia in the medial calcaneus, while motor stimulation at 2 Hz did not produce any muscle contractions. The RF generator (Beijing Neo Science Co., RFE 4b) was set to 80 °C for 90 seconds, and the RFA procedure was initiated.
219717012|NCT07121140|PROCEDURE|Home Blood Transfusion|Participants will be provided with transfusion of blood products, specifically red blood cells and platelets, in the home setting.
219717013|NCT07121504|DEVICE|Hybrid closed-loop insulin delivery system|Perioperative patients with T2D receiving parenteral nutrition will receive hybrid closed-loop insulin delivery system for glycemic management.
219717014|NCT07121504|DEVICE|conventional insulin pumps combined with CGM|Perioperative patients with T2D receiving parenteral nutrition will receive conventional insulin pumps combined with CGM for glycemic management.
219717015|NCT06921980|OTHER|Brain function and psychological assessment|Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.
219717016|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
219717017|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
219717018|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
219717019|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
219717020|NCT06915844|BEHAVIORAL|SHARP Tanzania|Building on existing adolescent health services, including HPV+, this intervention adds desired services for adolescent health education, screening, counseling, and referrals. In addition, this intervention has strategic community engagement to identify out of school girls with limited access to existing integrated health services available in schools, community sensitization activities, and training for healthcare workers.
219717021|NCT06919198|DRUG|Ketamine|ketamine 2.5 mg/kg
219717022|NCT07122323|PROCEDURE|robotic arm-assisted total hip replacement|using robotic total hip replacement in patients with Legg-Calvé-Perthes disease
219717023|NCT07122323|PROCEDURE|conventional total hip replacement|applying conventional total hip replacement in patients with Legg-Calvé-Perthes disease
219717024|NCT06923293|DEVICE|Utilization of motorized orthosis|While part of this study, participants will be fitted for the motorized orthosis and will complete walking tests with and without the AFO.
219717025|NCT07119294|DIAGNOSTIC_TEST|FAPI PET/MR|FAPI PET/MR prior surgery or during recurrence suspiscion
219717026|NCT07121803|OTHER|specialized food based on ice cream, order 1|Order of intervention: 1. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose; 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin; 3: standard ice cream (12% fat)
219717027|NCT07121803|OTHER|specialized food based on ice cream, order 2|"1. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin;~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose;~3. standard ice cream (12% fat)"
219717028|NCT07121803|OTHER|specialized food based on ice cream, order 3|"1. standard ice cream (12% fat)~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose~3. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin"
219137768|NCT04480593|OTHER|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
219137769|NCT00005786|DRUG|arsenic trioxide|Given IV
219137770|NCT00005786|OTHER|laboratory biomarker analysis|Correlative studies
219137771|NCT03773861|OTHER|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
219717029|NCT07123168|BEHAVIORAL|Triangle Hierarchical Management|A nurse-led, risk-stratified management model where patients are categorized into high-, medium-, or low-risk tiers. High-risk patients receive intensive professional care (90%) and minimal self-management education (10%); medium-risk patients receive a balanced approach (50% each); and low-risk patients focus on self-management education (90%) with minimal professional care (10%). The intervention is delivered by trained nurses over 24 weeks.
219717030|NCT07123168|BEHAVIORAL|routine care|Standard nursing management for hemodialysis patients, including monthly monitoring, routine assessments, and general health education sessions. This care does not involve risk stratification or tailored interventions.
219137772|NCT02460484|BIOLOGICAL|Autologous Cord Blood Infusion|Intravenous infusion
219137773|NCT04302519|BIOLOGICAL|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
219137774|NCT04807725|GENETIC|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
219137775|NCT04807725|OTHER|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
219137776|NCT06631040|BIOLOGICAL|anti CD19 CAR NK cells|Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
219137777|NCT04979988|DRUG|Lortlatinib|as provided in real world practice
219137778|NCT05585775|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
219137779|NCT05585775|BEHAVIORAL|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
219137780|NCT00683735|DRUG|Sitagliptin|100 mg once daily in the morning
219137781|NCT00683735|DRUG|Metformin|up to 2000 mg/day
219137782|NCT00683735|DRUG|Placebo|500mg 1-0-0-0
219137783|NCT00683735|DRUG|Placebo|100mg 1-0-0-0
219137784|NCT01545674|PROCEDURE|Blood Draw|Blood will be drawn from the mother and father
219137785|NCT04791124|OTHER|Electroencephalography|"EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential"
219137786|NCT01228513|DRUG|ZK245186|Daily topical application
219137787|NCT01228513|DRUG|Placebo (vehicle without active ingredient)|Daily topical application
219137788|NCT01749761|OTHER|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
219137789|NCT01749761|OTHER|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
219137790|NCT04329663|DEVICE|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
219137791|NCT01227707|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
219137792|NCT01227707|DRUG|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
219137793|NCT01227707|RADIATION|Radiation therapy|Total dose of 45 Gy over 38 days
219137794|NCT01227707|PROCEDURE|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
219137795|NCT01227707|DRUG|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
219137796|NCT01227707|DRUG|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
219137797|NCT01227707|DRUG|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
219137798|NCT02900326|OTHER|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
219137799|NCT02900326|OTHER|Mindfulness-based-stress-reduction|
219137800|NCT02900326|OTHER|Both interventions together|
219137801|NCT02900326|OTHER|Vo2max measurements|
219137802|NCT02900326|GENETIC|Telomerase activity on a blood sample|
219137803|NCT02900326|OTHER|Quality of life (questionnaires)|
219137804|NCT02900326|OTHER|Cerebral IRMf|
219137805|NCT03073499|PROCEDURE|Oncological Home Hospitalization|
219137806|NCT04830722|DEVICE|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
219228522|NCT05206058|PROCEDURE|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
219228523|NCT03292406|DRUG|Placebo|Non active ingredients of CD11301
219228524|NCT03292406|DRUG|CD11301 0.03%|Topical Gel
219228525|NCT03292406|DRUG|CD11301 0.06%|Topical Gel
219228526|NCT00647075|DIETARY_SUPPLEMENT|Yunzhi extract|3.5 g/day
219228527|NCT00647075|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
219137807|NCT05663619|DEVICE|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
219137808|NCT05663619|OTHER|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
219137809|NCT06553573|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
219137810|NCT06553573|OTHER|Parasternal Block and Erector Spinae Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
219137811|NCT01115049|DRUG|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
219137812|NCT01115049|DRUG|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
219717031|NCT07122258|DEVICE|CAROL NSCLC treatment Device|"Participants in this single-arm study will undergo treatment with the CAROL device for localized lung tumors (NSCLC ≤ 2 cm, cT1b). All participants will receive a single CAROL procedure using a conformable electrode, followed by surgical resection of the tumor.~The first 3 sentinel participants will receive a maximum dose of 0.3 mL of the conformable electrode. The next 4 participants will receive up to 2.0 mL. Safety and preliminary efficacy will be assessed through scheduled follow-up visits, including imaging, pulmonary function testing, laboratory assessments and pain monitoring.~Adverse events will be monitored throughout the study, with grading based on CTCAE v5.0, specifically focusing on Respiratory, thoracic, and mediastinal disorders. The study includes visits at screening, pre-procedure, post-procedure (24-36 hours), pre- and post-resection, and follow-up at approximately one and three months."
219717032|NCT07123155|DRUG|S-606001|S-606001 administered orally
219717033|NCT07123155|DRUG|Placebo|S-606001 matching placebo administered orally
219717034|NCT07122765|OTHER|Mixed Meal Feeding Challenge|Liquid flavored Ensure Plus Shake of varying caloric content based on individual daily estimated caloric need
219717035|NCT07122466|DIAGNOSTIC_TEST|Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)|ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
219717036|NCT07123922|DIETARY_SUPPLEMENT|Silymarin|Participants received Silymarin 140 mg capsule orally thrice daily for 12 weeks
219717037|NCT07123922|DIETARY_SUPPLEMENT|Placebo|Participants received Silymarin placebo capsule thrice daily for 12 weeks
219717038|NCT07123961|OTHER|High Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Dräger, Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 25 cmH2O (rate of pressure delivery). The Children's Hospital of Philadelphia (CHOP) PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 Electrical Impedance Tomography (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
219717039|NCT07123961|OTHER|Low Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 15 cmH2O (rate of pressure delivery). CHOP PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
219717040|NCT07122999|DEVICE|Eustachi|A handheld device that delivers pulsed air through the nasal passage to facilitate opening of the eustachian tube. Participants in this group use the device twice daily for 5 weeks after tympanostomy tube extrusion.
219137813|NCT00780663|DRUG|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
219137814|NCT05556356|DRUG|Acetaminophen|pre-operative acetaminophen (1000mg)
219137815|NCT05556356|OTHER|Placebo: Multivitamin|pre-operative Multivitamin
219717041|NCT07123441|DRUG|Bevacizumab,Irinotecan liposome (II),5-FU/LV|Bevacizumab: 5 mg/kg, intravenous infusion, Day 1; Irinotecan liposome (II): 60 mg/m² (based on free base), intravenous infusion for at least 90 minutes, Day 1; 5-FU: 400 mg/m², intravenous bolus injection, Day 1; followed by 1200 mg/(m²·day) × 2 days of continuous intravenous infusion (total dose 2400 mg/m², infused over 46-48 hours); LV: 400 mg/m², intravenous infusion over 2 hours, Day 1; Q2w, continued until an event meeting the treatment discontinuation criteria occurs or the subject withdraws from the study.
219717042|NCT07124195|DRUG|Medroxyprogesterone acetate oral suspension|Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)
219137816|NCT01224678|DIETARY_SUPPLEMENT|vitamin D|Given orally
219137817|NCT01224678|OTHER|placebo|Given orally
219137818|NCT05108896|DIAGNOSTIC_TEST|3-Screenings Protocol|The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
219717043|NCT07124195|COMBINATION_PRODUCT|high antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily), Fosaprepitant (administered on Day 1, 150 mg, once daily)
219717044|NCT07124195|COMBINATION_PRODUCT|moderate antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily)
219717045|NCT07125469|OTHER|The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses|"All patients with severe aortic stenosis (AS) who are scheduled for Surgical Aortic Valve Replacement (SAVR) with a bioprosthetic valve will undergo a pre-operative Computed Tomography (CT) scan. This CT scan will follow the pre-Transcatheter Aortic Valve Replacement (pre-TAVR) protocol and will focus only on imaging the aortic root, using a method called retrospective electrocardiogram (ECG) gating to capture detailed heart motion.~The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses:"
219717046|NCT07120776|DRUG|Camzyos (Mavacamten)|Camzyos (Mavacamten), a selective cardiac myosin inhibitor prescribed as part of routine care in patients with symptomatic HOCM. The study evaluates its effect on myocardial perfusion over a 12-month period using PET-CT imaging.
219717047|NCT07125768|OTHER|Thermal Radiofrequency Neurolysis|Patients received C-arm guided neurolysis of superior medial \[SM\], superior lateral \[SL\], and inferior medial \[IM\] genicular nerves by thermal radiofrequency.
219717048|NCT07125768|OTHER|Alcoholic Neurolysis|Patients received C-arm guided injection of each of the three genicular nerves with 1 ml of a solution containing 70% alcohol in 0.25% lidocaine.
219717049|NCT07125118|BEHAVIORAL|The OurRelationship Program|A guided self-help program for couples delivered online over 10 weeks. Participants complete structured learning modules and engage in planned couple conversations focused on improving communication, problem-solving, and emotional connection. Each couple receives support from a trained coach through five scheduled telephone or video calls. The program is designed to be flexible and completed at the couple's own pace within the 10-week period.
219717050|NCT07125118|BEHAVIORAL|Bibliotherapy|"An unguided self-help program for couples using the Danish book Take Care of Your Relationship \[Pas på Parforholdet\] and an accompanying reading guide. Couples are encouraged to read assigned sections, engage in planned couple conversations, and apply strategies for improving relationship functioning. The intervention is self-paced and completed over 10 weeks without guidance from a coach or therapist."
219717051|NCT07125937|DRUG|38% Silver Diamine Fluoride|A topical ammonia solution containing silver and fluoride ions applied directly to enamel caries lesions. Application will follow the UCSF protocol: lesions will be cleaned, isolated, and treated with SDF for 2 minutes using a microbrush applicator.
219137819|NCT05108896|DIAGNOSTIC_TEST|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
219137820|NCT05108896|DIAGNOSTIC_TEST|Tracheal Ultrasound|Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
219137821|NCT05117450|DEVICE|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
219228528|NCT02605850|OTHER|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
219228529|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
219228530|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
219137822|NCT05671198|DIAGNOSTIC_TEST|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~* Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~* Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~* Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
219137823|NCT04074499|OTHER|No intervention|There is no intervention.
219137824|NCT05484726|OTHER|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
219137825|NCT05866510|DRUG|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
219137826|NCT00133588|BIOLOGICAL|Trivalent split Inf|
219137827|NCT02744079|BEHAVIORAL|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
219137828|NCT02744079|BEHAVIORAL|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
219137829|NCT02283255|OTHER|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
219137830|NCT02283255|OTHER|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
219137831|NCT02283255|OTHER|No Exercise Training|Usual care
219137832|NCT03210727|BEHAVIORAL|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
219137833|NCT03468920|DRUG|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
219137834|NCT03468920|DRUG|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
219137835|NCT03468920|DRUG|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
219137836|NCT03468920|DRUG|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
219137837|NCT03955419|DIETARY_SUPPLEMENT|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
219228531|NCT03720249|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
219228532|NCT03720249|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
219228533|NCT01058018|DRUG|RVX000222|RVX000222 twice a day for 12 weeks
219228534|NCT01058018|DRUG|Placebo|Placebo twice a day for 12 weeks
219137838|NCT04589611|DRUG|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
219137839|NCT04589611|DRUG|Placebo (single dose)|One dose of placebo during the initial surgical intervention
219228535|NCT04951791|DRUG|SMOFlipid|will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
219228536|NCT04951791|OTHER|Normal saline 0.9%|will receive intravenous infusion of 2ml\\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
219228537|NCT05818852|DRUG|VX-548|Tablets for oral administration.
219228538|NCT05818852|DRUG|Moxifloxacin|Capsules for oral administration.
219228539|NCT05818852|DRUG|Moxifloxacin Placebo|Capsules for oral administration.
219228540|NCT05818852|DRUG|VX-548 Placebo|Tablets for oral administration.
219228541|NCT01293292|DRUG|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
219228542|NCT02746107|OTHER|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
219228543|NCT02056847|DRUG|Pitavastatin calcium 4mg|taking once a day
219228544|NCT02056847|DRUG|Pitavastatin calcium 2mg|Taking once a day
219228545|NCT01992965|OTHER|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
219228546|NCT00022672|DRUG|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
219228547|NCT00022672|DRUG|anastrazole (Arimidex®)|1 mg tablet taken orally daily
219137840|NCT04589611|DRUG|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
219137841|NCT04589611|DRUG|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
219228548|NCT06050941|DRUG|idarubicin|Idarubicin 6mg/m2 d5-7
219228549|NCT06050941|DRUG|Cytarabine|Cytarabine 60mg/m2 d5-9
219228550|NCT00403494|OTHER|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
219228551|NCT00403494|DRUG|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
219228552|NCT02434276|BIOLOGICAL|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
219228553|NCT02434276|BIOLOGICAL|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
219717052|NCT07124806|COMBINATION_PRODUCT|Botulinum toxin guided by ultrasonography and anatomical references|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in four places: two of them into the medial gastrocnemius and the other two into the lateral gastrocnemius. For medial gastrocnemius muscle, ¼ of the dose will be injected into the muscle belly at the 25% of the distance between the popliteal fossa and the intermalleolar line. Another ¼ will be injected into the muscle belly at the 35% of the previously mentioned distance. For lateral gastrocnemius, ¼ of the dose will be injected into the muscle belly at the 20% of the distance between the popliteal fossa and the intermalleolar line. The remaining ¼ of the dose will be injected into the muscle belly at the 30% of the previously described distance. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
219228554|NCT04171674|DRUG|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
219228555|NCT02614157|PROCEDURE|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
219228556|NCT02614157|DEVICE|labeled line|
219228557|NCT02693288|PROCEDURE|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
219137842|NCT02050594|DRUG|Ipilimumab|
219137843|NCT04239339|DRUG|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
219137844|NCT04239339|DRUG|Placebo|Placebo daily for approximately 3 weeks.
219137845|NCT03684733|DIAGNOSTIC_TEST|MRI|Clinical MRI breast screening examination
219228558|NCT00269815|DRUG|methylphenidate HCl|
219228559|NCT04648215|OTHER|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
219228560|NCT04648215|OTHER|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
219228561|NCT02731066|OTHER|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
219228562|NCT02731066|OTHER|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
219228563|NCT02731066|OTHER|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
219228564|NCT02731066|OTHER|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
219551556|NCT04125186|DIAGNOSTIC_TEST|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
219551557|NCT04125186|DIAGNOSTIC_TEST|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
219551558|NCT04125186|OTHER|No other intervention|No other intervention
219551559|NCT05508490|DIAGNOSTIC_TEST|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
219551560|NCT00827463|BIOLOGICAL|dosage of the NFS and iron|a blood test will be made.
219551561|NCT03648580|DIETARY_SUPPLEMENT|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
219551562|NCT03648580|OTHER|verbal nutrition education|give the verbal nutrition education
219551563|NCT05014438|DRUG|BMS-986166|Specified dose on specified days
219551564|NCT05014438|DRUG|Branebrutinib|Specified dose on specified days
219551565|NCT05014438|OTHER|Placebo|Specified dose on specified days
219551566|NCT02509143|PROCEDURE|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
219137846|NCT04467463|PROCEDURE|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
219137847|NCT05702710|OTHER|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1\) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
219137848|NCT04810455|OTHER|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
219137849|NCT04810455|OTHER|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
219137850|NCT00501020|DRUG|Rosiglitazone|
219137851|NCT04188028|DRUG|Dextromethorphan 5 MG|dextromethorphan 5 mg po
219137852|NCT04188028|DRUG|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
219137853|NCT04188028|DRUG|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
219137854|NCT04966208|PROCEDURE|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
219137855|NCT05425836|DEVICE|Standard oxygen therapy|nasal cannula
219137856|NCT05425836|DEVICE|HFNC|High flow nasal cannula
219137857|NCT06409195|DRUG|SM-020 1% Gel|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
219137858|NCT04303182|PROCEDURE|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
219137859|NCT04303182|PROCEDURE|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
219137860|NCT05042271|DRUG|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
219137861|NCT04461756|DRUG|PPP001|inhalation (vape)
219137862|NCT00155610|DEVICE|intravesical current perception test|
219137863|NCT01512966|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
219551567|NCT02509143|DEVICE|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
219137864|NCT01532232|DRUG|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
219551568|NCT02509143|DRUG|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
219551569|NCT04492930|BEHAVIORAL|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
219137865|NCT01532232|DRUG|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
219137866|NCT02501772|DEVICE|acupressure by ankle band|
219137867|NCT01712594|DEVICE|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
219137868|NCT03143192|COMBINATION_PRODUCT|Micropulse Laser|Aflibercept injection with Micropulse laser.
219137869|NCT03143192|DEVICE|Sham Laser|Aflibercept injection with Sham Laser
219137870|NCT02373228|OTHER|Audio signal processing (applied offline before playback)|
219137871|NCT05649098|DRUG|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
219137872|NCT01093534|DRUG|Placebo|Matching solifenacin placebo tablet
219137873|NCT01093534|DRUG|solifenacin|Tablet for oral administration
219137874|NCT00143650|BEHAVIORAL|House dust|
219137875|NCT05506098|OTHER|no intervention|no intervention
219137876|NCT03028363|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
219551570|NCT04492930|BEHAVIORAL|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
219137877|NCT03028363|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
219137878|NCT04729296|DRUG|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
219137879|NCT04729296|DRUG|Placebo|Inactive Drug
219137880|NCT00207532|DRUG|folic acid|
219137881|NCT01792648|OTHER|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
219137882|NCT01792648|OTHER|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
219137883|NCT01792648|OTHER|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
219137884|NCT04204330|DEVICE|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
219137885|NCT03185663|OTHER|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
219137886|NCT03185663|OTHER|a pillow between the legs|setting up a pillow between the legs before the care
219137887|NCT00608933|OTHER|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
219137888|NCT00608933|OTHER|questionnaire administration|Patients complete questionnaires
219137889|NCT00281918|DRUG|Rituximab|Intravenous repeating dose
219137890|NCT00281918|DRUG|Cyclophosphamide|Intravenous repeating dose
219137891|NCT00281918|DRUG|Fludarabine Phosphate|Intravenous repeating dose
219137892|NCT03593291|DIAGNOSTIC_TEST|Anti Xa|Levels of Anti Xa measure
219137893|NCT03321955|DRUG|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
219551571|NCT01827696|DIETARY_SUPPLEMENT|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
219551572|NCT00418158|BEHAVIORAL|use of Airlife (therapy)|
219551573|NCT02792816|DRUG|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
219551574|NCT01576458|DRUG|ursodeoxycholic acid|450 mg/day for 14 days
219551575|NCT01576458|DRUG|Placebo|placebo
219551576|NCT02424435|DRUG|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
219137894|NCT03321955|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
219137895|NCT03321955|DIAGNOSTIC_TEST|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
219137896|NCT01199237|DRUG|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
219137897|NCT01199237|DRUG|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
219137898|NCT01199237|DRUG|Rocuronium|
219137899|NCT01199237|DRUG|Neostigmine|
219137900|NCT01199237|DRUG|Glycopyrrolate|
219137901|NCT01421654|DEVICE|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
219137902|NCT01421654|DEVICE|S9 Elite|S9 Elite Flow Generator
219717053|NCT07124806|COMBINATION_PRODUCT|Botulinum neurotoxin guided by ultrasonography and in vivo location of innervation zones guided by high-density electromyography|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in eight places: four will be located in vivo for gastrocnemius medialis and four for gastrocnemius lateralis. These places will correspond to innervation zones located by high-density electromyography in different zones of each muscle. Thus, each of the eight located innervation zones will receive 1/8 of the calculated dose for the gastrocnemius muscle. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
219717054|NCT07124715|DEVICE|Rough Surface Zygomatic Implant|Surgical placement of a zygomatic implant with a fully roughened surface from apex to collar. Used for the control arm.
219551577|NCT02627963|DRUG|Tivozanib hydrochloride|Tivozanib hydrochloride
219717055|NCT07124715|DEVICE|Partially Machined Surface Zygomatic Implant|Surgical placement of a modified zygomatic implant with a smooth machined coronal portion, a non-threaded machined middle section, and a rough apical portion. Used for the test arm.
219137903|NCT00023218|DRUG|Lopinavir/Ritonavir|
219137904|NCT00023218|DRUG|Efavirenz|
219137905|NCT06409949|DIAGNOSTIC_TEST|Walking assessment|"Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)"
219137906|NCT06409949|OTHER|QOL Survey|Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
219137907|NCT06409949|DIAGNOSTIC_TEST|Ankle pressure at rest and after stress|Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
219137908|NCT06409949|DIAGNOSTIC_TEST|Muscle Oxygen|Evaluation of calf muscle heme oxygen saturation
219137909|NCT06409949|DIAGNOSTIC_TEST|Serum MitoQ Level|Evaluation of serum concentrations of MitoQ
219137910|NCT06409949|PROCEDURE|Needle Biopsy|Needle biopsy of the calf muscle
219137911|NCT05620303|OTHER|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
219137912|NCT01837641|BIOLOGICAL|LY3002813-IV|Administered IV
219137913|NCT01837641|BIOLOGICAL|LY3002813-SC|Administered SC
219137914|NCT01837641|DRUG|Placebo-IV|Administered IV
219137915|NCT04026620|BEHAVIORAL|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
219137916|NCT04026620|BEHAVIORAL|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
219137917|NCT04318444|DRUG|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
219551578|NCT02627963|DRUG|Sorafenib|Sorafenib
219137918|NCT04318444|DRUG|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
219137919|NCT04217421|DRUG|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
219137920|NCT04217421|DRUG|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
219137921|NCT06365554|DEVICE|Remedy Robot|A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
219551579|NCT01515163|BEHAVIORAL|Exercise training|Aerobic exercise training, two times a week
219551580|NCT02315963|OTHER|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
219137922|NCT03118752|BEHAVIORAL|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
219228565|NCT01784809|BEHAVIORAL|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
219228566|NCT01784809|BEHAVIORAL|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
219137923|NCT03770624|DRUG|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
219137924|NCT03770624|DRUG|TDF|TDF will be administered orally daily over the 28 days e.
219228567|NCT01784809|BEHAVIORAL|Wellness Promotion|
219228568|NCT05159271|DEVICE|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
219228569|NCT05159271|DEVICE|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
219228570|NCT00047385|DEVICE|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
219137925|NCT03717987|DRUG|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
219137926|NCT03717987|DIETARY_SUPPLEMENT|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
219137927|NCT02181699|DRUG|KHK2823|single agent KHK2823
219137928|NCT06081855|DIAGNOSTIC_TEST|CT|Measuring aortic root diameter by CT
219228571|NCT00047385|DEVICE|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
219228572|NCT00057499|BIOLOGICAL|IBC-VS01|IBC-VS01
219228573|NCT00057499|BIOLOGICAL|IBC-VS01 placebo|IBC-VS01 placebo
219228574|NCT03490032|DRUG|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
219228575|NCT05593107|DRUG|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
219228576|NCT01459952|DIETARY_SUPPLEMENT|Rose hip Liquid|Rose hip Liquid, 20 ml BID
219228577|NCT02343666|BIOLOGICAL|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
219228578|NCT02343666|DRUG|Carmustine|Given IV
219551581|NCT02379624|DRUG|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
219551582|NCT01787695|PROCEDURE|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
219551583|NCT01904513|DIETARY_SUPPLEMENT|Pasteurized Whole Milk|
219551584|NCT01904513|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1|
219551585|NCT01508065|DEVICE|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
219551586|NCT05971394|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
219551587|NCT04990648|DEVICE|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
219137929|NCT04173962|DRUG|Ketamine|administered 1 week prior to a laboratory-induced stress
219137930|NCT04173962|DRUG|Midazolam|administered 1 week prior to a laboratory-induced stress
219717056|NCT07124637|BEHAVIORAL|Multicomponent Social Cognitive Theory-Based Educational Program to Increase Fruit and Vegetable consumption in Students|"This multilevel blended educational intervention applies Social Cognitive Theory (SCT) to increase fruit/vegetable (F/V) intake among female middle school students. The 8-week program includes:~A) Student Components:~* Seven 60-minute sessions (4 in-person, 3 WhatsApp-delivered)~* Interactive activities: cooking demonstrations, goal-setting workshops, and educational games~* SCT-focused content: self-efficacy building, outcome expectation modification~B) Parental Engagement:~* Weekly SMS nutrition tips~* Two virtual workshops on creating F/V-supportive home environments~* School Environment Modifications:~* Cafeteria redesign to promote F/V accessibility~* Peer-led 'Healthy Eating Ambassador' program~Unique aspects distinguishing this intervention:~* First SCT-based program specifically adapted for Iranian adolescent females~* Dual delivery (in-person + digital) optimized for school settings~* Simultaneously targets individual, social, and environmental determinants."
219717057|NCT07124988|PROCEDURE|regional flap|regional flap reconstruction for palatomaxillary defects
219717058|NCT07124988|PROCEDURE|distant flap|Distant flap reconstruction for palatomaxillary defects
219717059|NCT07125833|DEVICE|Cryoneurolysis|Cryoneurolysis of the suprascapular nerve
219717060|NCT07125833|OTHER|No cryoneurolysis|Control Group
219717061|NCT07124663|OTHER|Breastfeeding education|Women will receive education on breast milk and breastfeeding during pregnancy.The education program consists of two sessions, with a total duration of 60 minutes.
219717062|NCT07123311|BEHAVIORAL|Online Stress Management Program|"This is an online pilot stress management program tailored for health students, combining cognitive-behavioral therapy and guided mindfulness meditation. Over eight sessions, participants engage with interactive psychoeducation modules, videos, and practical exercises to understand stress and develop coping strategies.~The sessions cover stress awareness, mindfulness meditation (basic and advanced), breathing techniques, time management using the Eisenhower matrix, and cognitive-behavioral methods to foster positive thinking and problem-solving.~The final session helps participants create a personalized action plan to integrate learned skills into daily life. Throughout the program, a support group encourages interaction and provides ongoing guidance to enhance well-being and stress management."
219717063|NCT07138794|OTHER|Subtransverse process interligamentary|Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.
219717064|NCT07138794|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.
219717065|NCT07141628|DIAGNOSTIC_TEST|lipoprotein A level dosing|Plasma levels measured in mmol/l
219137931|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
219137932|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
219137933|NCT04699669|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
219137934|NCT00605033|DRUG|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
219137935|NCT00605033|DRUG|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
219137936|NCT01719536|DRUG|Icotinib|Icotinib: 125 mg is administered orally three times per day.
219137937|NCT01719536|DRUG|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
219137938|NCT00111020|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
219137939|NCT05722951|DRUG|Levetiracetam &/or sodium valproate|levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
219137940|NCT05722951|DRUG|Metformin|metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
219137941|NCT03245164|OTHER|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
219137942|NCT03245164|OTHER|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
219137943|NCT03824899|DIAGNOSTIC_TEST|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
219228579|NCT02343666|BIOLOGICAL|Filgrastim|Given SC
219717066|NCT07142304|DEVICE|The Lilac Device|The Lilac Glove and Boot devices are wearable, non-sterile device for patients undergoing cancer treatment who wish to reduce the risk of peripheral neuropathy. Treatment with the Lilac Glove and Boot devices is administered by the healthcare professional in the healthcare environment. The Lilac Glove and Boot devices are designed for continual use; the devices must be fitted and turned on before infusion begins; the devices must be used without interruption during infusion, and for up to two (2) hours after infusion is complete.
219717067|NCT07142304|DEVICE|Sham device|The sham device will look, appear to function and worn for the same duration as the Lilac Device. The only difference between the devices is the level of compression applied.
219717068|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
219228580|NCT02343666|OTHER|Laboratory Biomarker Analysis|Correlative studies
219137944|NCT03932617|DEVICE|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
219137945|NCT02082366|DEVICE|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
219137946|NCT06485596|DEVICE|XVIVO Heart Assist Transport System|Direct procurement of donor hearts from DCD donation
219228581|NCT02343666|DRUG|O6-Benzylguanine|Given IV
219137947|NCT06598852|OTHER|TPVB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
219137948|NCT06598852|OTHER|ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
219228582|NCT02343666|DRUG|Plerixafor|Given SC
219228583|NCT01040312|DRUG|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
219228584|NCT01040312|DRUG|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
219551588|NCT02638922|DRUG|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
219551589|NCT06398522|DIETARY_SUPPLEMENT|Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
219551590|NCT06398522|OTHER|Placebo|Placebo
219551591|NCT01608646|DRUG|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
219551592|NCT02244190|DRUG|Tipranavir|New oral solution (back up) formulation
219551593|NCT02244190|DRUG|Tipranavir|
219551594|NCT02244190|DRUG|Ritonavir|
219551595|NCT03007563|DEVICE|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
219551596|NCT03007563|PROCEDURE|bilirubin concentration measured in standard blood samples|
219551597|NCT03007563|DEVICE|bilirubin concentration measured by transcutaneous device|
219551598|NCT05278858|COMBINATION_PRODUCT|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
219551599|NCT00362635|DRUG|Clevudine|
219551600|NCT04320563|PROCEDURE|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
219551601|NCT00354419|RADIATION|total-body irradiation|Undergo radiotherapy
219551602|NCT00354419|DRUG|cyclophosphamide|Given IV
219551603|NCT00354419|BIOLOGICAL|anti-thymocyte globulin|Given IV
219551604|NCT00354419|DRUG|cyclosporine|Given IV
219551605|NCT00354419|PROCEDURE|umbilical cord blood transplantation|Undergo transplantation
219551606|NCT00354419|DRUG|mycophenolate mofetil|Given IV or orally
219551607|NCT00354419|PROCEDURE|bone marrow aspiration|Correlative study
219551608|NCT00354419|GENETIC|DNA analysis|Correlative study
219551609|NCT00354419|BIOLOGICAL|filgrastim|Given IV or SC
219551610|NCT02265679|DRUG|BIIL 284 BS, low dose, pediatric patients|
219551611|NCT02265679|DRUG|BIIL 284 BS, medium dose, pediatric patients|
219551612|NCT02265679|DRUG|BIIL 284 BS, high dose, pediatric patients|
219551613|NCT02265679|DRUG|BIIL 284 BS, low dose, adult patients|
219551614|NCT02265679|DRUG|BIIL 284 BS, medium dose, adult patients|
219551615|NCT02265679|DRUG|BIIL 284 BS, high dose, adult patients|
219551616|NCT02265679|DRUG|Placebo|
219551617|NCT03315533|DRUG|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
219551618|NCT03315533|DRUG|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
219551619|NCT03315533|DRUG|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
219551620|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
219551621|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
219551622|NCT05392959|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
219551623|NCT05392959|DRUG|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
219551624|NCT03610542|BEHAVIORAL|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
219137949|NCT06598852|OTHER|TPVB combined ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
219717069|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
219717070|NCT07141056|OTHER|Psychological stress status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
219137950|NCT06598852|OTHER|ICNB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.
219551625|NCT03610542|BEHAVIORAL|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
219551626|NCT03610542|BEHAVIORAL|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
219551627|NCT03610542|BEHAVIORAL|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
219551628|NCT03610542|BEHAVIORAL|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
219551629|NCT00983099|DRUG|Neramexane|single and multiple dose, tablets, oral
219551630|NCT05759715|OTHER|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
219551631|NCT02022306|DRUG|TD-6450|
219551632|NCT02022306|DRUG|Placebo|
219551633|NCT00019487|BIOLOGICAL|aldesleukin|
219551634|NCT00019487|BIOLOGICAL|gp209-2M antigen|
219551635|NCT00019487|BIOLOGICAL|incomplete Freund's adjuvant|
219551636|NCT05862805|PROCEDURE|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
219551637|NCT02985060|DEVICE|Arctic Sun|"1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)"
219551638|NCT02985060|OTHER|Standard treatment|"1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
219551639|NCT02985060|DRUG|Saline|
219551640|NCT03821974|PROCEDURE|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
219551641|NCT03821974|PROCEDURE|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
219551642|NCT05109104|DRUG|CAP UnScented|Sunscreen lip balm.
219551643|NCT05109104|DRUG|CAP Herbal Mint|Sunscreen lip balm.
219551644|NCT05109104|DRUG|CAP Mountain Berry|Sunscreen lip balm.
219551645|NCT05109104|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
219551646|NCT00503867|DEVICE|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
219551647|NCT00897676|DRUG|Exendin-(9-39)|100-500pmol/kg/min
219551648|NCT00897676|DRUG|placebo|placebo (0.9% NaCl)
219551649|NCT01979146|OTHER|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
219551650|NCT05863026|BEHAVIORAL|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
219137951|NCT06614335|OTHER|After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation|All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.
219137952|NCT06711380|OTHER|Peer Ambassador|Patient mentor (patient with history of gynecologic cancer who has experience with clinical trials) one on one discussion with patient mentee (patient receiving standard of care treatment for gynecologic cancers).
219137953|NCT06712238|PROCEDURE|NB-UVB|Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
219137954|NCT06706505|BEHAVIORAL|Mindfulness-based art therapy|"MBAT combines art therapy and mindfulness to promote self-awareness and emotional well-being. It uses art to express thoughts and feelings, while cultivating mindfulness skills. MBAT addresses stress, anxiety, and emotional regulation. Grounded in research, it's an effective therapeutic approach.~The mindfulness-based art therapy sessions were designed based on the literature, drawing on the researches. By integrating art therapy techniques and mindfulness practices, the sessions were developed. Expert opinions were sought from specialists in the field to ensure the content validity of the sessions, and necessary adjustments were made accordingly. The MBAT application consists of five sessions in total. Each session has a specific theme and is designed to last 90-120 minutes."
219717071|NCT07142499|BEHAVIORAL|Memory Support System|Participants and study partners in the MSS treatment group will work with a study trainer to learn the MSS and eventually adapt the skills to support functioning in their daily life. The MSS trainer will follow a 10-session MSS Training Workbook as the standardized protocol for training. Additional sessions beyond the standard 10 sessions can be added if needed to support mastery of the MSS (up to a maximum of 15 total sessions). Participants and study partners will also receive a copy of the brain health education workbook that contains the same educational information for the control group at the 8-week follow up.
219717072|NCT07142499|BEHAVIORAL|Brain Health Education|Participants and study partners in the control group will be provided with the MSS guidebook and day planner for self-study of the MSS system. They will also meet with a study trainer to complete 10 sessions of a brain health education course that is tailored for individuals with MCI. The trainer will use a HABIT-based brain health education workbook to provide the content. Additional sessions beyond the standard 10 sessions can be added up to a maximum of 15 total sessions. Participants and study partners will receive a copy of the brain health education workbook at the 8-week follow up.
219717073|NCT07141875|OTHER|No intervention|This is an observational study without any interventions.
219717074|NCT07141433|OTHER|LLM-Assisted Public Health Emergency Training Program|"A hybrid training program integrating the hospital's standard public health emergency (PHE) curriculum with Large Language Model (LLM) technology as an auxiliary learning tool. Participants receive:~* Standardized PHE training (online lectures + offline simulations) covering professional knowledge, skills, and emergency drills (e.g., infectious disease response, trauma management).~* LLM-enabled interactive support: Structured guidance to use LLMs for:~Reviewing session content Resolving knowledge uncertainties via Exploring unfamiliar PHE concepts~• Duration: 1 month, with 20-minute sessions. Distinguishing feature: Uses LLMs to dynamically adapt to individual learning needs, enabling on-demand knowledge reinforcement and overcoming spatiotemporal limitations of traditional training."
219717075|NCT07141433|OTHER|Standard Public Health Emergency Training Program|"The hospital's existing public health emergency (PHE) training program without AI augmentation. Participants receive:~* Identical core content as the experimental group: Professional knowledge, skills training, and emergency drills for PHE response (e.g., disaster protocols, infection control).~* Explicit restriction: Prohibited from using LLMs or any AI tools for learning support.~* Delivery: Hybrid format (online + offline), 1-month duration, 20-minute sessions.~Distinguishing feature: Represents traditional training methods reliant on instructor-led content without personalized, on-demand AI-driven reinforcement."
219717076|NCT07141784|DEVICE|C-Mill® Treadmill Training Combined with Conventional Physiotherapy|Participants received a 4-week integrated rehabilitation program consisting of 10 C-Mill® treadmill training sessions in addition to individualized conventional physiotherapy. C-Mill® sessions incorporated virtual reality and gamified tasks to improve static and dynamic balance, gait speed, stride regulation, and safe obstacle negotiation. Conventional physiotherapy targeted mobility, muscle strength, and functional skills to enhance walking performance and independence.
219717077|NCT07141550|OTHER|Clinical Pilates Group|Participants will be introduced to the principles of Pilates, the workout program, and its five key elements: neutral spine, lumbopelvic and scapular stabilization, focus, and breathing. Clinical Pilates sessions will be held twice weekly for 8 weeks, 60 minutes each, via synchronous telerehabilitation (Zoom/WhatsApp). Each session includes a 10-minute warm-up, 40 minutes of Pilates exercises, and a 10-minute cool-down. The physiotherapist will provide visual and verbal guidance to ensure correct posture and breathing. Exercises start with 6-8 repetitions in the first week, increasing progressively according to participant ability and advancing to higher-level positions.
219717078|NCT07141550|OTHER|Kinesthetic Brain Exercises Group|16 sessions, approximately 40 minutes each, will be administered twice a week for eight weeks by a physical therapist via video chat programs such as Zoom or WhatsApp. Kinesthetic brain exercises consist of three phases: a warm-up phase, an exercise phase, and a cool-down phase. The warm-up and cool-down phases consist of hand-eye coordination and relaxation exercises. The exercise phase consists of independent and dependent movements, as well as a combination of both.
219137955|NCT03354390|BIOLOGICAL|cell infusion|This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
219137956|NCT01066923|DRUG|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
219137957|NCT01066923|OTHER|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
219137958|NCT01066923|DRUG|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
219137959|NCT01066923|OTHER|Passive cooling|Removing protective garments for passive cooling following exercise
219717079|NCT07141160|OTHER|Combined: Mobile app + 6WELLS|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training. Together with onsite 6 WELLS Group-Based Activity is a structured, group-based, cognitive health promotion programme that aims to build communities of practice, stimulate goal attainment, and drive behavioural change towards cognitive health and wellbeing. The curriculum is delivered via a 10-week onsite programme comprising weekly facilitated small-group activities centred on six key components.
219717080|NCT07141160|OTHER|Remote mobile based app|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training.
219717081|NCT07141355|DIAGNOSTIC_TEST|microcirculation using the video microscopy tool.|"The study intervention is the assessment of microcirculation using the video microscopy tool.~This study's primary purpose is to perform this specific diagnostic procedure-measuring microcirculatory parameters with the CytoCam-IDF device-at two distinct time points: at inclusion (H0) and again 48 hours later (H48).~The administration of empagliflozin (or not), which is pa and 48 hours after initiating empagliflozin treatment, microcirculatory data will be collected using a videomicroscope. A camera, roughly the size of a large pen, is placed under the patient's tongue for a few seconds to acquire images of the sublingual microcirculation. The entire image acquisition process takes less than 5 minutes and is unaffected by whether the patient is intubated.~Images are then analyzed in real-time by the MicroTools software, which calculates key microcirculatory parameters.~All anonymized images are stored on a dedicated, password-protected computer accessible only to the investigators."
219717082|NCT07140952|BEHAVIORAL|Strong SC|The Strong SC intervention combines the StrongPeople StrongHearts program with a supplemental medically tailored grocery program. The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. The supplemental MTG program will utilize a grocery delivery platform(s) to deliver a weekly medically tailored grocery box of produce worth approximately $30 (costs covered by grant funds). Box contents will be tailored by the PI, who is a registered dietitian licensed in South Carolina, to participants' nutrition needs and functional abilities (e.g., pre-cut vegetables for participants with limited hand functionality). Participants will receive an allotment of produce each week, as well as a recipe(s) and virtual cooking demonstration providing practical strategies on incorporating each week's produce.
219717083|NCT07140952|BEHAVIORAL|StrongPeople StrongHearts|The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. Participants of this intervention will receive a systematically adapted version of this program tailored to the physical capacities of the target population (chronic stroke survivors). The systematically adapted version of StrongPeople StrongHearts will be used across both experimental arms in this study.
219717084|NCT07141953|BEHAVIORAL|Yoga|Participants in the intervention group will take part in an 8-week yoga program designed for women who have entered surgical menopause after gynecological cancer surgery. The program will consist of two 60-minute sessions per week, one delivered online and one delivered face-to-face, conducted in small groups (5-6 participants) or individually, depending on participant availability. The sessions will include physical postures, breathing exercises, and relaxation/meditation techniques. The program will be delivered by a certified yoga instructor.
219717085|NCT07142343|DRUG|Pozelimab|Administered per the protocol
219717086|NCT07141758|DIAGNOSTIC_TEST|ELISA|Unstimulated saliva samples will be non-invasively collected from participants in this study to measure the concentrations of E-cadherin, Calprotectin, and MMP-9. These protein concentrations will be quantified using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits.
219717087|NCT07141511|DRUG|BG-71332|Administered orally
219717088|NCT07141511|DRUG|Zanubrutinib|Administered orally
219717089|NCT07141511|DRUG|Sonrotoclax|Administered orally
219137960|NCT01066923|DRUG|Daily placebo|Placebo comparator for daily aspirin therapy
219137961|NCT01066923|DRUG|Acute placebo|Placebo comparator for acute aspirin therapy
219137962|NCT02817282|OTHER|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
219137963|NCT05486312|DEVICE|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
219137964|NCT06195891|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219137965|NCT06195891|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219137966|NCT06195891|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219137967|NCT06195891|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT/MRI scan
219137968|NCT06195891|PROCEDURE|Echocardiography|Undergo echocardiography
219228585|NCT00416975|OTHER|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
219717090|NCT07140848|BEHAVIORAL|CGM-DPP|Participants in the DPP who receive personalized CGM coaching.
219717091|NCT07140848|BEHAVIORAL|Control|Participants in control group will be referred to DPP.
219717092|NCT07141602|DIAGNOSTIC_TEST|lateral cephalometric x- ray and dental panoramic tomogram|lateral cephalometric x- ray and dental panoramic tomogram
219717093|NCT07142161|DRUG|RD13-02 cell infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphami
219717094|NCT07142421|DRUG|Combination therapy (COMB)|Trifluridine/tipiracil combined with Anlotinib in treatment
219717095|NCT07142239|DIAGNOSTIC_TEST|• Complete blood count , MPV|CBC report
219717096|NCT07142239|DIAGNOSTIC_TEST|Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:|CBC report
219717097|NCT07142239|DIAGNOSTIC_TEST|Antiphospholipid antibody profile|Patient record
219717098|NCT05922085|OTHER|Ultrasound|performed within 3 hours prior to extubation
219717099|NCT05922085|OTHER|nasofibroscopie|performed within 24 to 36 hours after extubation
219717100|NCT05892198|PROCEDURE|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
219717101|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
219717102|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
219137969|NCT06195891|DRUG|Fludarabine|Given IV
219137970|NCT06195891|PROCEDURE|Magnetic Resonance Imaging|Undergo DECT/MRI scan
219137971|NCT06195891|DRUG|Melphalan|Given IV
219137972|NCT06195891|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219137973|NCT06195891|BIOLOGICAL|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Given IV
219137974|NCT06195891|DRUG|Tacrolimus|Given tacrolimus
219137975|NCT06195891|DRUG|Thiotepa|Given IV
219717103|NCT00128388|OTHER|PFPP|Psychoanalytic Psychotherapy for panic disorder
219717104|NCT00128388|OTHER|ART|Applied Relaxation Training
219717105|NCT00376844|RADIATION|External Beam Radiation Therapy|
219137976|NCT06195891|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
219137977|NCT05348096|DRUG|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
219137978|NCT03167034|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
219137979|NCT03167034|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
219137980|NCT02556034|OTHER|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
219137981|NCT03140176|DRUG|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
219137982|NCT02242929|DRUG|Imiquimod 5% cream with prior curettage|
219137983|NCT02242929|PROCEDURE|Standard surgical excision|
219137984|NCT00718848|PROCEDURE|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
219717106|NCT00376844|RADIATION|Vaginal Brachytherapy|
219717107|NCT04709887|PROCEDURE|Wound treatment|According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
219717108|NCT04709887|PROCEDURE|Vascular intervention surgery|Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
219717109|NCT04709887|PROCEDURE|Tibial transverse transport surgery|In the anteromedial area of the proximal tibia of the affected limb, the external fixation frame was compared with the area along the midline of the medial longitudinal axis of the proximal tibia. Subsequently, two 3.0 Steinmann pins were inserted through the single layer of cortical bone. The skin was cut along the long axis with the 3.0 Steinmann pin as the centre, and the subcutaneous tissue was separate bluntly to expose the periosteum. The Steinmann pins were used as the centre point for the drilling on four sides with a 2.0 drill bit and use of a rapid osteotomy device; the length of each side was 2.5 cm. Subperiosteal osteotomy was performed with a 5-mm narrow bone knife at an angle of 15°-30° to the bone surface. The surgeons should pay attention to protect the blood supply of the periosteum during this procedure. The external fixators were fixed with 4.0 Steinmann pins at the distal and proximal ends. The subcutaneous tissue and skin were sutured.
219137985|NCT00718848|PROCEDURE|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
219137986|NCT00505323|DEVICE|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
219137987|NCT02695290|DRUG|Afatinib|
219137988|NCT05365633|BEHAVIORAL|Empowerment activity-enhanced tobacco cessation assistance|Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and skills. Examples are compiling publicly-available information about school board meetings to support community members in participating in their school districts and making follow-up phone calls with a script to Freedom OK's name change clinic participants.
219137989|NCT00318019|DIETARY_SUPPLEMENT|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
219137990|NCT00318019|OTHER|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
219137991|NCT05819450|PROCEDURE|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
219137992|NCT00666094|BEHAVIORAL|Endurance training|supervised endurance training. Three sessions per week in three months.
219137993|NCT00666094|BEHAVIORAL|strength training|Supervised strength training. Three sessions per week in three months.
219137994|NCT06242041|DRUG|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
219228586|NCT00416975|OTHER|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
219228587|NCT00416975|PROCEDURE|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
219228588|NCT03950726|PROCEDURE|ileocolic resection|Ileocolic resection through McBurney incision
219228589|NCT05583656|PROCEDURE|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
219717110|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
219717111|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
219137995|NCT03751891|DEVICE|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
219137996|NCT03751891|DEVICE|HearingAid_A|HearingAid\_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_A which will be fitted to the participants individual Hearing loss.
219137997|NCT03751891|DEVICE|HearingAid_B|HearingAid\_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_B which will be fitted to the participants individual Hearing loss.
219137998|NCT04722094|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
219137999|NCT04722094|OTHER|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
219138000|NCT06211907|DEVICE|Postoperative intraocular tamponade|Flushing the eye cavity with a tamponade at the end of surgery
219138001|NCT05371288|DRUG|NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
219138002|NCT00427557|DRUG|Fludarabine|30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
219138003|NCT00427557|DRUG|Melphalan|140 mg/m\^2 by vein for 1 Day (Day -7).
219138004|NCT00427557|PROCEDURE|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
219138005|NCT00427557|DRUG|Rituximab|375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
219138006|NCT00427557|OTHER|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
219228590|NCT05371951|DEVICE|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
219717112|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
219717113|NCT00084253|DRUG|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
219138007|NCT04090320|DEVICE|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
219138008|NCT04689321|OTHER|No intervention|This is not an interventional study.
219717114|NCT00084253|DRUG|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
219717115|NCT03606824|DRUG|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
219551651|NCT03648931|BEHAVIORAL|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
219228591|NCT04336709|DRUG|Calcipex II|Water based intracanal medicament
219228592|NCT04336709|DRUG|Metapex|Oil based intracanal medicament
219228593|NCT04648670|BEHAVIORAL|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
219228594|NCT03028285|DRUG|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
219228595|NCT03160976|OTHER|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
219228596|NCT02404844|DRUG|BKM120|daily oral
219228597|NCT02404844|DRUG|Tamoxifen|daily oral
219228598|NCT01852045|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
219228599|NCT04220983|RADIATION|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
219228600|NCT02584426|DEVICE|Ultrasonic Distribution of Cefazolin|
219228601|NCT03274648|DIETARY_SUPPLEMENT|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
219228602|NCT03274648|DIETARY_SUPPLEMENT|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
219228603|NCT03274648|DIETARY_SUPPLEMENT|Habitual diet|Patients follow the habitual diet
219228604|NCT00012688|DRUG|Doxycycline HCI 10mg po for 2 weeks|
219717116|NCT03606824|DRUG|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
219138009|NCT02932293|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
219228605|NCT00012688|PROCEDURE|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
219228606|NCT02799537|OTHER|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
219228607|NCT02007070|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219228608|NCT02028390|DEVICE|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
219228609|NCT02028390|DEVICE|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
219228610|NCT02028390|DEVICE|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
219717117|NCT01614418|DEVICE|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
219138010|NCT00154648|PROCEDURE|CE-MRA|
219138011|NCT03683862|OTHER|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
219138012|NCT00470795|OTHER|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
219138013|NCT00470795|PROCEDURE|placebo/sham acupuncture|acupuncture at sham points without skin penetration
219138014|NCT02491931|DIETARY_SUPPLEMENT|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
219228611|NCT02028390|DEVICE|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
219551652|NCT03648931|BEHAVIORAL|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
219138015|NCT03223883|DRUG|Curcumin|Oral supplement for 12 months
219551653|NCT03028792|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
219551654|NCT03028792|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
219551655|NCT04207229|DEVICE|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
219717118|NCT06231121|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
219138016|NCT03223883|OTHER|Placebo|Oral placebo for 12 months
219138017|NCT04769609|DEVICE|bioresorbable membrane|reconstructive surgical treatment of peri-implant bone defects
219138018|NCT06063356|PROCEDURE|Intra-articular and extra-articular Dextrose Prolotherapy injection|In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.
219138019|NCT06063356|PROCEDURE|Intra-articular and extra-articular Saline injection|In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.
219138020|NCT03668327|OTHER||
219228612|NCT02028390|DEVICE|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
219138021|NCT00837499|BEHAVIORAL|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
219138022|NCT01087684|PROCEDURE|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
219138023|NCT01087684|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
219138024|NCT04405063|DEVICE|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
219138025|NCT04612894|DRUG|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
219228613|NCT00693836|GENETIC|genetic linkage analysis|
219138026|NCT04612894|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
219138027|NCT04612894|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
219138028|NCT04665661|BEHAVIORAL|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
219138029|NCT04665661|BEHAVIORAL|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
219138030|NCT02899000|DRUG|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
219138031|NCT02899000|DRUG|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
219228614|NCT00693836|GENETIC|loss of heterozygosity analysis|
219228615|NCT00693836|GENETIC|mutation analysis|
219228616|NCT00693836|GENETIC|polymerase chain reaction|
219138032|NCT02319122|OTHER|High Intensity Interval Training|See arm description
219138033|NCT02319122|OTHER|Progressive Resistance Training|See arm description
219138034|NCT04275193|DRUG|Zishenqing|Zishenqing Granule
219138035|NCT04275193|DRUG|Placebo|Granule manufactured to mimic Zishenqing(containing 10% composition)
219138036|NCT03712306|OTHER|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
219138037|NCT03712306|OTHER|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
219138038|NCT06420713|PROCEDURE|Horizontal Bone Augmentation of Alveolar Ridge|Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
219138039|NCT06420713|PROCEDURE|Groups|"The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen."
219138040|NCT06420713|PROCEDURE|Dental Implants|"After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation."
219138041|NCT05824377|OTHER|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
219138042|NCT05824377|OTHER|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
219138043|NCT00954707|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
219138044|NCT00954707|DRUG|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
219138045|NCT05218837|OTHER|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
219138046|NCT06126536|PROCEDURE|Crestal Maxillary Sinus Floor Elevation using Osseodensification|Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
219228617|NCT00693836|GENETIC|polymorphism analysis|
219717119|NCT02807090|OTHER|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
219717120|NCT02807090|OTHER|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
219717121|NCT00687518|DRUG|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
219228618|NCT00693836|OTHER|biologic sample preservation procedure|
219228619|NCT00693836|OTHER|medical chart review|
219228620|NCT00693836|OTHER|questionnaire administration|
219228621|NCT00693836|PROCEDURE|evaluation of cancer risk factors|
219228622|NCT01473069|DRUG|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
219228623|NCT01473069|DRUG|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
219138047|NCT06126536|PROCEDURE|Lateral Maxillary Sinus Floor Elevation|A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
219138048|NCT01103219|DIETARY_SUPPLEMENT|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
219138049|NCT03967886|DRUG|YYD601 20mg|Patients should take drugs an hour before breakfast.
219138050|NCT03967886|DRUG|Nexium 20mg|Patients should take drugs an hour before breakfast.
219138051|NCT03967886|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
219138052|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
219138053|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
219138054|NCT03003988|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
219551656|NCT04560725|DRUG|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
219138055|NCT03003988|DIETARY_SUPPLEMENT|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
219138056|NCT03003988|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
219138057|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
219138058|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
219138059|NCT04182087|BEHAVIORAL|Cognitive tasks|Attention, language, memory, decision-making or executive functions
219138060|NCT02860884|PROCEDURE|liver biopsy|
219551657|NCT05208892|PROCEDURE|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
219551658|NCT05208892|PROCEDURE|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
219551659|NCT03905967|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
219551660|NCT03905967|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
219551661|NCT04584073|PROCEDURE|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
219551662|NCT00448825|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
219551663|NCT00448825|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
219551664|NCT06089330|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
219551665|NCT06089330|DRUG|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
219551666|NCT06089330|DRUG|Irinotecan|180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
219551667|NCT06089330|DRUG|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
219551668|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
219138061|NCT02860884|OTHER|infrared spectroscopy|
219138062|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
219138063|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
219138064|NCT05534100|DEVICE|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
219138065|NCT02001623|DRUG|Tisotumab Vedotin (HuMax-TF-ADC)|
219138066|NCT04481386|DEVICE|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
219551669|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
219551670|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
219551671|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
219551672|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
219551673|NCT01140672|DRUG|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
219138067|NCT03042520|OTHER|Observation only|
219138068|NCT00596648|DRUG|XL184|Capsules administered orally daily
219138069|NCT00596648|DRUG|erlotinib|Tablets administered orally daily.
219138070|NCT00309452|BEHAVIORAL|Cognitive Behavioral Group Therapy|once per week
219138071|NCT00309452|BEHAVIORAL|Cognitive remediation|as needed
219138072|NCT00309452|DRUG|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
219138073|NCT00309452|BEHAVIORAL|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
219138074|NCT00309452|BEHAVIORAL|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
219138075|NCT00309452|OTHER|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
219138076|NCT01036113|DRUG|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
219138077|NCT04815057|BEHAVIORAL|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
219138078|NCT05722106|BEHAVIORAL|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
219717122|NCT00687518|DRUG|Placebo|Intravenous injection of equivalent volume of saline serum
219717123|NCT00358514|DEVICE|Continuous Compartment Pressure Monitoring|See Detailed Description.
219717124|NCT05372770|DEVICE|Flourish Vaginal Care system|Flourish includes Restore® vaginal moisturizing gel, a Class II medical device cleared by the FDA, in addition to two other kit components
219717125|NCT05992727|DIAGNOSTIC_TEST|Galectin 3 measurement in serum and saliva by ELIZA|Galectin 3 measurement in serum and saliva by ELISA in the two groups
219717126|NCT01177176|OTHER|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
219138079|NCT02452242|DRUG|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
219138080|NCT02452242|OTHER|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
219138081|NCT06392451|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV, & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 real-time (RT) PCR assay is a Point of Care (POC) system that enables the extraction, amplification, detection and differentiation of influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 viral RNA from dry nasal swabs (NS). The system consists of the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, the LIAISON® NES system (with LIAISON® NES Software), and associated accessories. In the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, extraction reagents and lyophilized fluorescent probes are used together with corresponding forward and reverse primers to extract and amplify influenza A, influenza B, RSV, SARS-CoV-2 and internal control RNA targets.
219138082|NCT06392451|DIAGNOSTIC_TEST|LIAISON PLEX Respiratory Flex Assay|"The LIAISON PLEX® (also known as VERIGENE® II) RSP Flex Assay is an automated test for the detection and identification of common viruses and bacteria, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, from upper respiratory specimens. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is performed on the VERIGENE® II System. The VERIGENE® II System is an automated platform that performs sample preparation and is capable of polymerase chain reaction (PCR) for the detection of target-specific nucleic acids. The VERIGENE® II System is a fully automated, bench-top sample-to-answer device. The test reagents are supplied in a single, disposable test cartridge."
219138083|NCT00771667|DRUG|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
219138084|NCT00771667|DRUG|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
219138085|NCT00771667|DRUG|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
219138086|NCT00771667|DRUG|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
219717127|NCT01177176|OTHER|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
219717128|NCT00177671|DRUG|Escitalopram|Escitalopram, 10mg to 20mg daily.
219717129|NCT00177671|DRUG|Donepezil|Donepezil, 5mg to 10mg daily.
219717130|NCT00177671|DRUG|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
219717131|NCT00177671|DRUG|Placebo|
219717132|NCT00177671|DRUG|Duloxetine|
219717133|NCT04410822|OTHER|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
219717134|NCT01644929|PROCEDURE|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
219138087|NCT00771667|DRUG|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
219138088|NCT00771667|DRUG|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
219138089|NCT00771667|DRUG|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
219551674|NCT05782439|OTHER|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
219228624|NCT06452121|OTHER|triglyceride glucose index|"The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG"
219228625|NCT03556852|DRUG|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
219228626|NCT03556852|DRUG|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
219228627|NCT03945084|DRUG|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
219717135|NCT01644929|PROCEDURE|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
219138090|NCT00771667|DRUG|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
219138091|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
219138092|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
219138093|NCT01557998|BEHAVIORAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
219138094|NCT01557998|DRUG|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
219138095|NCT01557998|BEHAVIORAL|Control - No intervention|
219138096|NCT06133452|PROCEDURE|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
219228628|NCT03945084|OTHER|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
219717136|NCT01644929|PROCEDURE|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
219228629|NCT01890954|DEVICE|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
219228630|NCT05549466|DRUG|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
219228631|NCT05549466|DRUG|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
219228632|NCT05549466|DRUG|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
219551675|NCT00323258|BEHAVIORAL|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
219717137|NCT01723059|DRUG|Standard Triple Therapy|for 10 days
219717138|NCT01723059|DRUG|Sequential Therapy|total 10 days
219717139|NCT00475046|BEHAVIORAL|Motivational Interviewing|
219717140|NCT05389696|DRUG|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
219717141|NCT05389696|DRUG|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
219717142|NCT05389696|DRUG|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
219717143|NCT03947034|DRUG|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
219138097|NCT00573339|OTHER|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
219138098|NCT02049697|DRUG|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
219138099|NCT03586596|BEHAVIORAL|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
219138100|NCT03586596|BEHAVIORAL|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
219138101|NCT03899480|BIOLOGICAL|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
219138102|NCT00628862|DRUG|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
219138103|NCT00628862|DRUG|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
219138104|NCT00628862|DRUG|Turbuhaler® placebo|placebo inhaled twice daily
219138105|NCT01063036|DRUG|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
219138106|NCT01063036|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
219138107|NCT02491554|DEVICE|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
219138108|NCT02491554|DEVICE|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
219228633|NCT05549466|DRUG|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
219228634|NCT03052517|DRUG|QAW039 150 mg|One tablet of QAW039 150 mg once daily
219228635|NCT03052517|DRUG|QAW039 450 mg|One tablet of QAW039 450 mg once daily
219228636|NCT03052517|DRUG|Placebo|One tablet of Placebo once daily
219138109|NCT04459988|DRUG|Ocrelizumab|Description Needed
219138110|NCT01740570|DRUG|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
219138111|NCT02834871|DEVICE|Electromyogram|
219138112|NCT04235283|DEVICE|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
219138113|NCT04235283|PROCEDURE|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
219138114|NCT05295134|DIETARY_SUPPLEMENT|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
219228637|NCT02102698|DRUG|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
219228638|NCT02605876|DEVICE|Whole body vibration|
219228639|NCT02605876|DEVICE|Local muscle vibration|
219551676|NCT00323258|DEVICE|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
219551677|NCT00323258|DEVICE|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
219551678|NCT00323258|BEHAVIORAL|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
219551679|NCT00323258|BEHAVIORAL|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
219551680|NCT00323258|BEHAVIORAL|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
219551681|NCT00323258|BEHAVIORAL|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
219551682|NCT00323258|OTHER|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
219717144|NCT02293499|BEHAVIORAL|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
219138115|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
219138116|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
219138117|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
219138118|NCT02715258|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
219138119|NCT02715258|DRUG|Placebo|tablets matching the appearance of bexagliflozin tablets
219138120|NCT03443037|DRUG|amantadine sulphate|
219138121|NCT03002246|OTHER|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
219138122|NCT05113355|DRUG|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
219138123|NCT05113355|DRUG|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
219138124|NCT04215198|DIETARY_SUPPLEMENT|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
219138125|NCT04215198|DIETARY_SUPPLEMENT|Placebo|Placebo
219138126|NCT02814643|DRUG|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
219138127|NCT02814643|DRUG|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
219138128|NCT02814643|DRUG|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
219138129|NCT01944410|BIOLOGICAL|PRP injection|injection of PRP to traumatic bone cyst defect
219138130|NCT02263508|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
219138131|NCT02263508|DRUG|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
219138132|NCT02263508|DRUG|Placebo|Administered by intratumoral injection
219138133|NCT05857358|PROCEDURE|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
219138134|NCT05857358|DRUG|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
219138135|NCT05573854|DIETARY_SUPPLEMENT|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
219138136|NCT05573854|DIETARY_SUPPLEMENT|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
219138137|NCT02008019|DRUG|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
219138138|NCT02008019|DRUG|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
219138139|NCT03483519|OTHER|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
219138140|NCT03483519|OTHER|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
219138141|NCT02241668|PROCEDURE|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
219138142|NCT02241668|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
219138143|NCT00531518|DRUG|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
219717145|NCT05732545|BEHAVIORAL|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
219138144|NCT00531518|BEHAVIORAL|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
219138145|NCT00531518|BEHAVIORAL|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
219138146|NCT02783235|OTHER|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
219138147|NCT00873691|DEVICE|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
219138148|NCT06302491|DRUG|AND017 capsules|Administer AND017 capsules once per day (QD)
219138149|NCT06302491|DRUG|AND017 Placebo|Administer AND017 matching placebo capsules once per day (QD)
219228640|NCT03180476|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
219717146|NCT03483753|DRUG|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
219717147|NCT03483753|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
219717148|NCT06398288|OTHER|Dermal matrix (Oracell, LifeNet, USA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
219717149|NCT06398288|OTHER|No dermal matrix|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
219717150|NCT01360476|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
219717151|NCT01360476|DIETARY_SUPPLEMENT|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
219138150|NCT00440973|DRUG|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
219228641|NCT00996242|DRUG|L-lysine|6 g/day for four weeks
219717152|NCT03527602|PROCEDURE|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
219717153|NCT05285449|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|30 mg CBD in the form of 300 mg of 10% CBD isolate
219717154|NCT05285449|DIETARY_SUPPLEMENT|Matching Placebo Cannabidiol (CBD) powder formulation|Matching Placebo
219717155|NCT00417222|DRUG|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
219717156|NCT05259215|OTHER|physiotherapy|Standard usual care physiotherapy after stroke
219717157|NCT03118882|BEHAVIORAL|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
219138151|NCT00440973|DRUG|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
219138152|NCT00992238|DRUG|Flavoxate Hydrochloride Tablets, 100mg|
219138153|NCT00992238|DRUG|Urispas® Tablets, 100mg|
219138154|NCT01833507|BEHAVIORAL|Self-Exercise|Behavioral Goal Setting
219138155|NCT01833507|BEHAVIORAL|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
219138156|NCT03265210|BEHAVIORAL|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
219138157|NCT00182845|DRUG|Donepezil|
219138158|NCT05756140|OTHER|No intervention|No Control
219138159|NCT00411996|DRUG|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
219138160|NCT00598208|DRUG|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
219138161|NCT00598208|DRUG|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
219138162|NCT06125106|DRUG|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
219138163|NCT00686517|BIOLOGICAL|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
219138164|NCT00686517|DRUG|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
219138165|NCT02169102|OTHER|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
219138166|NCT02169102|RADIATION|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
219138167|NCT02169102|RADIATION|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
219138168|NCT02169102|RADIATION|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
219138169|NCT04289610|DEVICE|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
219138170|NCT03861741|GENETIC|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
219138171|NCT03861741|DIAGNOSTIC_TEST|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
219138172|NCT03861741|DIAGNOSTIC_TEST|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
219138173|NCT03861741|OTHER|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
219138174|NCT01153451|OTHER|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
219138175|NCT01567683|DRUG|Imiquimod (topical use)|
219138176|NCT00140088|DRUG|ALGRX 3268|
219138177|NCT05936671|PROCEDURE|EEG-and-ANI-guided anesthesia|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
219138178|NCT05936671|PROCEDURE|standard anesthesia|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
219138179|NCT05936671|DRUG|Sevoflurane and remifentanil|For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
219138180|NCT05936671|DEVICE|EEG and ANI|EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
219138181|NCT03302546|PROCEDURE|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
219138182|NCT03302546|PROCEDURE|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
219717158|NCT03118882|BEHAVIORAL|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
219138183|NCT06422650|DRUG|Nigella Sativa capsule 500mg|Nigella Sativa capsule 500mg twice daily for 8 weeks
219138184|NCT06422650|DRUG|Placebo|Oral placebo identical to astaxanthin
219138185|NCT01698255|BEHAVIORAL|ENGAGE|
219138186|NCT01698255|BEHAVIORAL|Standard of Care Psychotherapy|
219138187|NCT02281318|BIOLOGICAL|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
219138188|NCT02281318|DRUG|Placebo|Sterile 0.9% sodium chloride solution
219138189|NCT02281318|DRUG|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
219138190|NCT05876130|RADIATION|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
219138191|NCT02804516|BEHAVIORAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
219138192|NCT02804516|BEHAVIORAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
219228642|NCT02580227|DRUG|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
219228643|NCT02580227|OTHER|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
219138193|NCT05344014|PROCEDURE|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
219138194|NCT05344014|PROCEDURE|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
219138195|NCT06400446|OTHER|Standard care|The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
219138196|NCT06400446|OTHER|Kangaroo care|Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
219138197|NCT04379349|BEHAVIORAL|SMS text messaging - interactive check-in|Interactive SMS text message check-ins delivered once weekly to participants.
219228644|NCT00911391|DEVICE|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
219228645|NCT00911391|PROCEDURE|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
219228646|NCT02404441|BIOLOGICAL|PDR001|anti-PD1 antibody
219228647|NCT00177619|DRUG|Alendronate|
219717159|NCT03118882|BEHAVIORAL|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
219717160|NCT05370326|OTHER|Enhanced Opioid Stewardship Program|The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
219717161|NCT06461884|OTHER|Percussions|Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
219138198|NCT04379349|BEHAVIORAL|SMS text messaging - inactive control|Minimally interactive SMS text message delivered once weekly to participants.
219138199|NCT00812877|DRUG|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
219228648|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
219228649|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
219228650|NCT04864834|BIOLOGICAL|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
219228651|NCT04864834|BIOLOGICAL|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
219228652|NCT02764970|DRUG|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
219228653|NCT00944359|DIETARY_SUPPLEMENT|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
219717162|NCT06461884|OTHER|, Diaphragmatic breathing exercise|Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
219717163|NCT03138681|DRUG|Placebo|placebo is given intravenously twice a day for 14 days
219717164|NCT03138681|DRUG|ATP|ATP (100mg) is given intravenously twice a day for 14 days
219228654|NCT00944359|DIETARY_SUPPLEMENT|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
219228655|NCT00944359|DIETARY_SUPPLEMENT|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
219717165|NCT03138681|DRUG|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
219717166|NCT03877809|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
219228656|NCT00944359|OTHER|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
219228657|NCT01849523|BEHAVIORAL|Web-based information and support|
219228658|NCT00946972|DRUG|JNJ-38431055; Placebo|
219228659|NCT02067689|DEVICE|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
219228660|NCT04597931|DRUG|Romosozumab|SC Romosozumab 210 mg/monthly
219717167|NCT05181722|OTHER|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
219717168|NCT01847209|PROCEDURE|Video-Assisted Thoracic Surgery (VATS) wedge resection|
219228661|NCT04597931|DRUG|Zoledronic Acid|IV Zoledronic acid 5 mg
219228662|NCT04317430|DRUG|Niclosamide|Niclosamide tablets 1 gram once daily
219228663|NCT04317430|DRUG|Placebo oral tablet|lactose tablets
219228664|NCT00105846|PROCEDURE|Home care telemedicine|
219717169|NCT03956706|RADIATION|Stereotactic Radiosurgery|Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
219138200|NCT00812877|DRUG|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
219138201|NCT04809090|BEHAVIORAL|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
219138202|NCT04809090|DEVICE|App CA|An APP together a CA (Conversational Agent).
219138203|NCT05948358|OTHER|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
219228665|NCT01593644|DRUG|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
219717170|NCT05403918|OTHER|conventional physiotherapy|Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
219138204|NCT00130013|DRUG|Oral Amoxicillin|
219138205|NCT01000129|OTHER|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
219228666|NCT02427191|OTHER|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
219717171|NCT05403918|OTHER|scapular stabilization exercises along with conventional physiotherapy|Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
219717172|NCT02606305|DRUG|Mirvetuximab soravtansine|
219138206|NCT01000129|OTHER|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
219138207|NCT02614560|DRUG|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
219138208|NCT02614560|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
219138209|NCT02614560|DRUG|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
219138210|NCT02614560|DRUG|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
219138211|NCT00565110|BEHAVIORAL|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
219138212|NCT00432588|DRUG|misoprostol|
219138213|NCT00432588|DRUG|dinoprostone|
219138214|NCT00703911|DRUG|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
219138215|NCT03173105|DEVICE|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
219228667|NCT02427191|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
219228668|NCT01868230|BEHAVIORAL|Lifestyle Intervention|
219228669|NCT02733731|DRUG|Chinese Herbal Compound Ointment|
219228670|NCT02733731|DRUG|Estriol|
219717173|NCT02606305|DRUG|Bevacizumab|
219717174|NCT02606305|DRUG|Carboplatin|
219717175|NCT02606305|DRUG|Pegylated Liposomal Doxorubicin|
219717176|NCT02606305|DRUG|Pembrolizumab|
219717177|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
219717178|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
219717179|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
219717180|NCT00984945|BIOLOGICAL|Placebo|0.5 mL, IM, two injections 21 days apart
219717181|NCT00865605|DRUG|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
219717182|NCT00865605|DRUG|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
219717183|NCT01610193|PROCEDURE|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
219717184|NCT03233750|BEHAVIORAL|Stress Inoculation Training|see description in arm/group descriptions
219717185|NCT03233750|BEHAVIORAL|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
219717186|NCT03735576|BEHAVIORAL|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
219228671|NCT05178706|OTHER|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
219228672|NCT05178706|DIAGNOSTIC_TEST|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
219551683|NCT06449534|BEHAVIORAL|Patient Education|It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
219551684|NCT06449534|BEHAVIORAL|Exercise Therapy|Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
219717187|NCT03735576|DIAGNOSTIC_TEST|Questionnaires|There will be a total of four assessments (see primary \& secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
219717188|NCT03735576|OTHER|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
219717189|NCT03735576|OTHER|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
219717190|NCT04462146|BEHAVIORAL|Internet-based Self Applied Treatment Program|"It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
219717191|NCT04462146|BEHAVIORAL|Videoconference treatment with a therapist|"It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention."
218987198|NCT05334914|BEHAVIORAL|Acceptance Commitment Therapy|"ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc."
218987199|NCT02439190|DRUG|BMS-986120|
218987200|NCT02439190|DRUG|Aspirin|
218987201|NCT02439190|DRUG|Clopidogrel|
218987202|NCT01913678|OTHER|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
219717192|NCT00601627|BIOLOGICAL|panitumumab|
219717193|NCT00601627|DRUG|capecitabine|
219717194|NCT00601627|DRUG|fluorouracil|
219717195|NCT00601627|DRUG|gemcitabine hydrochloride|
219717196|NCT00601627|RADIATION|radiation therapy|
218987203|NCT01913678|OTHER|Complete diet|The participants will be given all dietary items in their diet with no additional products.
219551685|NCT06449534|BEHAVIORAL|Cold Application|Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
219551686|NCT02518139|DRUG|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
219551687|NCT02518139|DRUG|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
219717197|NCT02479490|DRUG|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
219717198|NCT02749734|PROCEDURE|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
219717199|NCT01858948|DRUG|Omega|Omega-3 supplements
219717200|NCT01858948|DRUG|Placebo|Similar in shape and color to Omega supplements
219717201|NCT01858948|DRUG|Quetiapine fumarate|Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
219717202|NCT02737618|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
219717203|NCT05690516|BEHAVIORAL|Wearing face masks|Participants are asked to wear face masks in public spaces.
219717204|NCT01684605|DRUG|NESP 60μg|Administrated NESP 60μg once intravenously
219717205|NCT01684605|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
219717206|NCT00620607|DRUG|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
219717207|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
219717208|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
219717209|NCT01503801|DRUG|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
219717210|NCT01503801|DEVICE|respiratory support|Routine respiratory support.
219717211|NCT02716285|DRUG|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
218987204|NCT01913678|OTHER|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
218987205|NCT02900976|BIOLOGICAL|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
218987206|NCT02900976|BIOLOGICAL|Rituximab|Given IV
218987207|NCT06673147|OTHER|Prenatal Nordic Walking|Traditional Nordic walking poles will be modified according to International Nordic Walking Federation guidelines, which meant that the elbows were bent at a 90°angle when holding the poles in a vertical position. Nordic Walking will be conducted in two phases consisting of a 4-week learning phase followed by an 8-week main phase of intervention.
218987208|NCT06517212|DRUG|Tirzepatide|Patients will receive tirzepatide once weekly for up to 2 years.
218987209|NCT06989489|BEHAVIORAL|Multilevel Adherence Intervention|Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent based on their risk-stratified monitoring category. Participants will be followed longitudinally and will receive tailored support.
218987210|NCT00876421|DRUG|Placebo|Placebo / 12 weeks
218987211|NCT00876421|DRUG|Tolterodine|4mg / 12 weeks
218987212|NCT00876421|DRUG|ONO-8539|low dose / 12 weeks
218987213|NCT00876421|DRUG|ONO-8539|medium dose / 12 weeks
219138216|NCT03173105|DEVICE|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
219717212|NCT02716285|DRUG|Placebo|Placebo capsule, containing microcrystalline cellulose
218987214|NCT00876421|DRUG|ONO-8539|higher dose / 12 weeks
218987215|NCT06677567|OTHER|Air-Q Intubating Airway|Patients will be inserted Air-Q Intubating Airway under general anesthesia
218987216|NCT06677567|OTHER|proseal laryngeal mask|Patients will be inserted proseal laryngeal mask under general anesthesia.
219138217|NCT03173105|OTHER|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
219717213|NCT02716285|DRUG|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
219717214|NCT00038415|BIOLOGICAL|CLL vaccine using DNA plasmid vector|
219717215|NCT00989027|DRUG|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
219717216|NCT00989027|DRUG|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
219717217|NCT00989027|DRUG|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
219717218|NCT00989027|DRUG|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
219551688|NCT05201235|DEVICE|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
219551689|NCT05201235|DEVICE|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
219551690|NCT01586039|DEVICE|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
219717219|NCT00989027|DRUG|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
219717220|NCT03907423|DRUG|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
219717221|NCT03907423|DRUG|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
219717222|NCT04650620|DEVICE|Plenhyage® thin|0.75%
219717223|NCT04650620|DEVICE|Plenhyage® medium|2%
219717224|NCT04650620|DEVICE|Plenhyage® strong|2.5%
218987217|NCT06676670|OTHER|real acupuncture|Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.
219138218|NCT03173105|OTHER|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
219138219|NCT00596310|OTHER|CT|Screening CT
219138220|NCT05495477|DEVICE|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
219138221|NCT00919685|BIOLOGICAL|blood sample|from rest of blood sample collected for other measurements
219138222|NCT06375291|OTHER|splint /steroid injection/both|pregnant women treated in pain department by splint /steroid injection/both
219551691|NCT04436198|DEVICE|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
219717225|NCT04324320|DIAGNOSTIC_TEST|medical assessment|"medical assessment includes the collection of~* sociodemographic data~* anthropometric data (weight, height, body mass index)~* medical data~* psycho-oncologic basis assessment (PO-BADO questionnaire)~* pain assessment (VAS: visual analogue scale)~* 3 functional tests:~  * handgrip strength~ * 6 Minute Walking Test~ * Timed Get up and Go Test"
219717226|NCT04324320|DIAGNOSTIC_TEST|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~* quality of life: SF-36~* anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~* subjective stress perception: Perceived Stress Scale (PSS-10)~* resilience: resilience scale (RS-13)~* fatigue: Brief Fatigue Inventory (BFI)~* disability related to pain: Pain Disability Index (PDI)~* workability: Work Ability Index - short version (WAI-K)~* psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
219717227|NCT01879852|BEHAVIORAL|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
219717228|NCT01879852|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
219717229|NCT05124678|DRUG|Isoniazid Tablets|High dose of isoniazid
219717230|NCT05217264|OTHER|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
219717231|NCT02696616|DRUG|BI 655088|
219138223|NCT05287282|OTHER|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
219138224|NCT01551056|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
219138225|NCT01551056|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
219138226|NCT06404710|BEHAVIORAL|Exercise|Participants in this group will be given a gradual muscle relaxation exercise.
219138227|NCT00337545|DRUG|RAD001|
219138228|NCT00613782|DRUG|Reandron 1000|1000mg at 0,6,18,30 weeks
219138229|NCT00613782|DRUG|placebo|placebo injection 0,6.18.30 weeks
219138230|NCT05975749|DRUG|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
219138231|NCT05975749|DRUG|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
219138232|NCT05975749|DRUG|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
219138233|NCT00579189|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219138234|NCT00579189|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
219138235|NCT00579189|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
219138236|NCT05857306|DIETARY_SUPPLEMENT|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
219138237|NCT05857306|DIETARY_SUPPLEMENT|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
219138238|NCT02174562|BEHAVIORAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
219138239|NCT02174562|BEHAVIORAL|Enhanced Usual Care|Usual care enhanced with education and attention
219228673|NCT03760653|OTHER|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
219717232|NCT02696616|DRUG|Placebo|
219717233|NCT00884065|OTHER|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
219138240|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
219138241|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
219138242|NCT00545376|OTHER|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
219138243|NCT04533464|BIOLOGICAL|MultiStem|Intravenous Infusion
219138244|NCT04533464|BIOLOGICAL|Placebo|Intravenous Infusion
219228674|NCT03760653|DIETARY_SUPPLEMENT|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
219717234|NCT00884065|OTHER|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
219138245|NCT00633854|PROCEDURE|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
219138246|NCT06554067|DEVICE|Active transcranial direct current stimulation|Ten minutes of active transcranial direct current stimulation
219228675|NCT03760653|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
219138247|NCT06554067|DEVICE|Active vagus nerve stimulation|Ten minutes of active vagus nerve stimulation
219138248|NCT06554067|OTHER|Sham transcranial direct current stimulation|Ten minutes of sham tDCS
219138249|NCT06554067|OTHER|Sham vagus nerve stimulation|Ten minutes of sham VNS
219138250|NCT05193318|DRUG|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
219138251|NCT00798096|DRUG|Fostamatinib Disodium|200 mg PO BID
219138252|NCT01291004|DRUG|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
219138253|NCT01291004|DRUG|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
219138254|NCT01291004|DRUG|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
219138255|NCT02054299|DRUG|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
219138256|NCT02054299|DRUG|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
219138257|NCT02054299|DRUG|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
219138258|NCT02054299|DRUG|Drug application Proguanil|Proguanil: 200mg, single oral application
219717235|NCT06208332|BEHAVIORAL|Photo-Narrative|Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
219717236|NCT04553315|PROCEDURE|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
219717237|NCT04959513|PROCEDURE|LPRF bone block|Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
219138259|NCT02054299|DRUG|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
219138260|NCT02054299|DRUG|Drug application Thiamine|Thiamine: 200mg, single oral application
219138261|NCT05154942|DEVICE|DOXO+electroacupuncture|DOXO+electroacupuncture
219138262|NCT01833065|DRUG|Elobixibat 10 mg/day|Elobixibat 10 mg/day
219138263|NCT01833065|DRUG|Elobixibat 5 mg/day|Elobixibat 5 mg/day
219138264|NCT01833065|DRUG|Placebo|Placebo
219138265|NCT01772420|DRUG|Eltrombopag Olamine|Given PO
219138266|NCT01772420|OTHER|Laboratory Biomarker Analysis|Correlative studies
219138267|NCT01772420|DRUG|Lenalidomide|Given PO
219138268|NCT05541757|DRUG|In vitro heparin|In vitro heparin and in vitro LMWH
219138269|NCT04584021|DEVICE|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
219138270|NCT04584021|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
219138271|NCT04584021|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
219138272|NCT04584021|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
219138273|NCT04584021|OTHER|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
219717238|NCT01500083|DRUG|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
219138274|NCT04584021|OTHER|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
219138275|NCT04584021|OTHER|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
219138276|NCT05787444|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
219138277|NCT06494124|DEVICE|transcranial Alternating current stimulation (tACS)|It is a non-invasive brain stimulation technique that uses small, pulsed alternating current (1mA) to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
219138278|NCT06494124|DEVICE|transcranial Direct current stimulation (tDCS)|It is a non-invasive brain stimulation technique that uses constant, low direct current to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
219138279|NCT06494124|DEVICE|Sham controlled|1mA current will be applied for the first 30 seconds to provide the initial sensation of real stimulation, and then the current will be stopped, thus minimizing the stimulatory effects. It is known to have no effect on psychopathology/neuro-cognition and means to mimic the tDCS/tACS (in order to help blinding of the participants).
219138280|NCT02970461|OTHER|Gamified Group|See Gamified Group in Arms description.
219138281|NCT02970461|OTHER|Control Group|See Control Group in Arms description.
219138282|NCT03038503|DRUG|Methylene Blue|after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
219551692|NCT04436198|DEVICE|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
219138283|NCT03038503|DRUG|Terlipressin|after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
219138284|NCT01588015|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given SC
219138285|NCT01588015|OTHER|laboratory biomarker analysis|Correlative studies
219138286|NCT00565708|OTHER|placebo|Placebo Comparator
219138287|NCT00565708|DRUG|Acetylsalicylic acid|Adjuvant Therapy
219138288|NCT00657280|DRUG|Sitagliptin|No one is blinded to the treatments.
219138289|NCT00094809|DRUG|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
219138290|NCT00094809|DRUG|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
219138291|NCT04333069|PROCEDURE|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
219138292|NCT01723436|OTHER|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
219138293|NCT03172208|BIOLOGICAL|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
219138294|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
219138295|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
219138296|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
219138297|NCT03172208|OTHER|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
219138298|NCT03172208|OTHER|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
219138299|NCT03172208|OTHER|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
219138300|NCT03693443|BEHAVIORAL|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
219138301|NCT00990678|DRUG|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
219138302|NCT00990678|DRUG|Vitamin D|tablets, vitamin D3, 30 microgram daily
219138303|NCT00990678|DRUG|Calcium|tablets, 400 mg calcium, 3 times daily
219138304|NCT02888431|DEVICE|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
219138305|NCT03665701|PROCEDURE|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
219138306|NCT02219906|DIETARY_SUPPLEMENT|Resveratrol|1000mg tid
219138307|NCT02219906|DIETARY_SUPPLEMENT|Placebo|1000mg tid placebo
219138308|NCT02117843|DEVICE|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
219138309|NCT00457990|DRUG|Oral administration of ferrous sulphate|
219138310|NCT04889664|DRUG|Ketamine|Repeated intravenous Ketamine infusions.
219228676|NCT06466616|OTHER|Real stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.
219228677|NCT06466616|OTHER|Placebo stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
219717239|NCT01500083|DRUG|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
219138311|NCT04889664|BEHAVIORAL|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
219138312|NCT04581837|DIAGNOSTIC_TEST|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
219138313|NCT02205086|OTHER|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
219138314|NCT04653714|PROCEDURE|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
219138315|NCT04653714|DEVICE|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
219717240|NCT03035539|OTHER|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
219717241|NCT03035539|OTHER|Standard treatment|Standard treatment
219138316|NCT05328076|DRUG|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
219138317|NCT05328076|DEVICE|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
219138318|NCT00698802|DRUG|EX1000|Treat-to-target titration scheme, s.c. injection
219138319|NCT00698802|DRUG|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
219138320|NCT02313844|BIOLOGICAL|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
219138321|NCT06175923|BIOLOGICAL|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
219717242|NCT00176332|DRUG|rosuvastatin|
219138322|NCT00461799|DRUG|orlistat|
219138323|NCT03608670|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
219138324|NCT02950779|OTHER|Handgrip Strength Measurement|
219138325|NCT04991233|PROCEDURE|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
219138326|NCT04991233|PROCEDURE|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
219138327|NCT03636451|DRUG|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
219138328|NCT03636451|DRUG|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
219138329|NCT02438800|BEHAVIORAL|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
219138330|NCT01043406|DEVICE|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
219138331|NCT01784146|OTHER|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
219717243|NCT00429247|DRUG|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
219138332|NCT01784146|OTHER|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
219138333|NCT01784146|OTHER|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
219138334|NCT03012919|OTHER|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
219228678|NCT03177226|DEVICE|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
219717244|NCT02744768|DRUG|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
219717245|NCT02744768|DRUG|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
219717246|NCT01555931|DRUG|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
219717247|NCT02499315|DRUG|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
219717248|NCT02499315|DRUG|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
219717249|NCT01063907|DRUG|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
219717250|NCT01063907|DRUG|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
219138335|NCT02755363|OTHER|osteopathic manual therapy|"* suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
219551693|NCT00873990|OTHER|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
219138336|NCT02755363|OTHER|control group|"* manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
219138337|NCT02834143|OTHER|No intervention|The is no intervention. This study is a descriptive one
219138338|NCT01356225|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
219138339|NCT01356225|DRUG|Placebo|IN placebo
219138340|NCT05318950|BEHAVIORAL|E-learning|8 lessons about nutrition and lifestyle
219138341|NCT05318950|DIETARY_SUPPLEMENT|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
219138342|NCT03408860|OTHER|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
219138343|NCT01645852|DIETARY_SUPPLEMENT|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
219228679|NCT03177226|DEVICE|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
219228680|NCT04129099|BIOLOGICAL|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
219717251|NCT04831658|DRUG|the dose-escalation phase|"The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times."
219138344|NCT00744250|DRUG|Pancrelipase|PANCRECARB MS-16
219138345|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
219138346|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
219138347|NCT01596751|DRUG|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
219138348|NCT01596751|DRUG|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
219138349|NCT01191086|DRUG|USL255|
219138350|NCT02205151|DRUG|Fimasartan|
219228681|NCT05307952|DIAGNOSTIC_TEST|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
219228682|NCT05307952|DIAGNOSTIC_TEST|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
219228683|NCT05307952|DIAGNOSTIC_TEST|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
219228684|NCT05307952|DIAGNOSTIC_TEST|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
219228685|NCT05307952|OTHER|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
219228686|NCT05307952|BEHAVIORAL|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
219228687|NCT02879942|OTHER|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
219138351|NCT02205151|DRUG|Amlodipine|
219138352|NCT02205151|DRUG|Fimasartan/Amlodipine combination|
219138353|NCT01014858|DRUG|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
219138354|NCT03248011|OTHER|Stretching|Lower extremity flexibility exercises will be performed
219138355|NCT03248011|OTHER|Strengthening|Eccentric hamstring strengthening exercises will be performed
219138356|NCT03248011|OTHER|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
219138357|NCT03817736|PROCEDURE|TACE|Procedure of TACE will be standardized.
219138358|NCT03817736|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
219138359|NCT03817736|DRUG|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
219138360|NCT00771849|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219551694|NCT00873990|OTHER|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
219551695|NCT00558402|BEHAVIORAL|Meditation|meditation class 1/week for 8 weeks
219138361|NCT00771849|BIOLOGICAL|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
219138362|NCT01762072|DIETARY_SUPPLEMENT|Fish oil|
219138363|NCT01762072|DIETARY_SUPPLEMENT|vitaminB12|
219138364|NCT02167243|BEHAVIORAL|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
219138365|NCT02167243|OTHER|Standard of care|Subjects receive standard of care
219138366|NCT06234865|OTHER|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
219138367|NCT06234865|OTHER|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
219138368|NCT03748433|DEVICE|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
219138369|NCT03748433|DEVICE|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
219138370|NCT04216823|DEVICE|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
219138371|NCT00893373|DRUG|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
219138372|NCT00893373|DRUG|placebo|Standard AML chemotherapy plus placebo
219138373|NCT04376385|BEHAVIORAL|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
219138374|NCT00913328|DRUG|Montelukast (Singulair)|10 mg tablet once daily
219138375|NCT00913328|DRUG|Placebo|Oral placebo once daily
219717252|NCT02299167|DRUG|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
219717253|NCT02333032|OTHER|Inclined treadmill training|
219717254|NCT03956875|OTHER|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
219717255|NCT06135259|DRUG|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
219717256|NCT06135259|DRUG|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
219717257|NCT01540734|DRUG|Marketed paracetamol|Marketed formulation
219551696|NCT00558402|BEHAVIORAL|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
219717258|NCT01540734|DRUG|Experimental paracetamol formulation|Experimental formulation
219138376|NCT02754011|DRUG|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
219138377|NCT06326866|DIAGNOSTIC_TEST|Otoacoustic emissions (non-invasive)|There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
219138378|NCT00061672|DRUG|ABT-510 - Thrombospondin-1 Mimetic|
219138379|NCT02592837|DEVICE|Flexible 19G EBUS-TBNA needle|
219138380|NCT02592837|DEVICE|21G EBUS-TBNA needle|
219551697|NCT00558402|BEHAVIORAL|Respite only|Respite care 90 mins per week for 8 weeks
219717259|NCT06056609|OTHER|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
219138381|NCT05468606|BIOLOGICAL|GA2|GA2 sporozoites administered by 50 mosquito bites
219138382|NCT05468606|BIOLOGICAL|BCG|0.1 mL BCG vaccine intradermally
219551698|NCT00945490|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
219138383|NCT05468606|BIOLOGICAL|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
219138384|NCT05468606|DRUG|Imiquimod|250mg imiquimod 5% cream topical
219138385|NCT05468606|OTHER|Mock immunization|50 bites by uninfected mosquitoes
219228688|NCT02879942|OTHER|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
219228689|NCT05804825|BEHAVIORAL|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
219717260|NCT03960827|OTHER|EE Training|Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
219717261|NCT03960827|OTHER|RE Training|Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
219551699|NCT00945490|DRUG|Placebo|Single intraprostatic injection of placebo
219551700|NCT02372006|DRUG|afatinib|
219551701|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 50 mg QD
219717262|NCT01806792|DRUG|risedronate combine|
219717263|NCT01806792|DRUG|Risedronate|
219138386|NCT02046616|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
219138387|NCT02046616|DRUG|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
219228690|NCT05804825|BEHAVIORAL|Simple forewarning message|Participants will be presented with a simple forewarning message.
219228691|NCT01005693|OTHER|questionnaire administration|
219228692|NCT01005693|PROCEDURE|cognitive assessment|
219228693|NCT01005693|PROCEDURE|examination|
219551702|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD
219551703|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD
219551704|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
219551705|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
219551706|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
219138388|NCT02046616|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
219138389|NCT03591809|OTHER|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
219138390|NCT05420168|OTHER|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
219138391|NCT04983745|DRUG|Combination drug|niraparib and dostarlimab combination
219138392|NCT02736799|DEVICE|Sham vibrating capsule|Sham device without vibration
219138393|NCT02736799|DEVICE|Vibrant Capsule (1 vibration)|1 vibration/min
219138394|NCT02736799|DEVICE|Vibrant Capsule (3 vibration)|3 vibration/min
219138395|NCT02736799|DEVICE|Vibrant Capsule (5 vibration)|5 vibration/min
219138396|NCT05640596|DRUG|Betamethasone|
219138397|NCT03316794|DRUG|SC-005|intravenous
219228694|NCT01005693|PROCEDURE|management of therapy complications|
219228695|NCT01061580|DEVICE|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
219551707|NCT01316237|DRUG|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
219551708|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900mg , BID
219551709|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900 mg
219551710|NCT04848688|DRUG|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
219551711|NCT04848688|DRUG|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
219551712|NCT04848688|DRUG|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
219551713|NCT01614288|PROCEDURE|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
219551714|NCT01614288|OTHER|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
219138398|NCT01183533|DRUG|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
219138399|NCT03684096|DIETARY_SUPPLEMENT|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
219138400|NCT03684096|OTHER|placebo|placebo -non-estrogenic pollen extract PCC-100
219138401|NCT02034149|BEHAVIORAL|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
219138402|NCT02034149|BEHAVIORAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
219138403|NCT02034149|BEHAVIORAL|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
219138404|NCT03036735|DEVICE|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
219138405|NCT05576051|OTHER|patterns of use of combination therapy and monotherapy|
219138406|NCT00344019|DRUG|Placebo Oral Tablet|placebo pre-PCI for ACS
219138407|NCT00344019|DRUG|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
219138408|NCT00344019|OTHER|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
219228696|NCT01562964|BEHAVIORAL|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
219228697|NCT01562964|BEHAVIORAL|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
219228698|NCT03056378|BIOLOGICAL|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
219717264|NCT01806792|DRUG|Placebo(for Risedronate)|
219138409|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
219138410|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
219138411|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
219138412|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
219138413|NCT00684528|DRUG|Metformin 1500 mg daily|500 mg thrice daily
219138414|NCT00684528|DRUG|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
219138415|NCT02057718|DRUG|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
219138416|NCT01367548|DRUG|IV Methylnaltrexone (MNTX)|
219228699|NCT03491566|OTHER|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
219717265|NCT01806792|DRUG|Placebo(for risedronate combine)|
219717266|NCT00189384|DRUG|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
219138417|NCT01367548|DRUG|Placebo|
219138418|NCT03031756|DEVICE|glycine powder air-polishing (Air-Flows)Perio Powder|
219138419|NCT03031756|DEVICE|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
219138420|NCT05095558|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
219138421|NCT04008394|GENETIC|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
219138422|NCT00864812|DRUG|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
219138423|NCT00864812|DRUG|tiotropium|COPD patients treated with tiotropium
219138424|NCT00508963|DRUG|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
219138425|NCT04089618|BEHAVIORAL|MBLM|Complex 8 week Mind-Body program.
219138426|NCT03183232|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
219138427|NCT03183232|BIOLOGICAL|γδ T cell|γδ T cells will be used against Lung Cancer
219138428|NCT03183232|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
219138429|NCT03187782|DIAGNOSTIC_TEST|ANSWatch|
219138430|NCT02343744|DRUG|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
219138431|NCT00320502|DRUG|BXT-51072|
219138432|NCT02503202|BIOLOGICAL|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
219138433|NCT02503202|BIOLOGICAL|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
219138434|NCT02503202|BIOLOGICAL|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
219138435|NCT02503202|BIOLOGICAL|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
219138436|NCT02503202|BIOLOGICAL|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
219138437|NCT03114020|DRUG|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
219138438|NCT03114020|DRUG|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
219138439|NCT05689268|DIAGNOSTIC_TEST|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
219138440|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
219138441|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
219138442|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
219138443|NCT00339469|DIETARY_SUPPLEMENT|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
219138444|NCT03965702|DEVICE|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
219138445|NCT03965702|OTHER|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
219138446|NCT01738802|DIETARY_SUPPLEMENT|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
219138447|NCT01738802|DRUG|Placebo|This group will take a placebo.
219138448|NCT00920296|DRUG|GSK1265744|GSK drug
219228700|NCT03491566|OTHER|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
219228701|NCT02446106|DIETARY_SUPPLEMENT|Soup with MSG|0.5% MSG + 0.48% salt
219228702|NCT02446106|DIETARY_SUPPLEMENT|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
219228703|NCT01933997|DRUG|Metadoxine (MG01CI )|
219138449|NCT05187767|DIAGNOSTIC_TEST|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
219138450|NCT04577170|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
219138451|NCT04454892|OTHER|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
219138452|NCT00235040|BEHAVIORAL|Smart Form|Computer Decision Support System
219228704|NCT04249440|PROCEDURE|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
219228705|NCT04865744|DRUG|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
219228706|NCT04865744|DRUG|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
219228707|NCT04865744|DRUG|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
219228708|NCT01220999|DRUG|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
219228709|NCT01302106|DRUG|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
219228710|NCT04058847|OTHER|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
219228711|NCT03861234|DRUG|BI 836880|Solution for Intravitreal (IVT) injection
219228712|NCT05914896|DRUG|HighOsmo|This group received a priming solution with high osmolality
219551715|NCT04987645|PROCEDURE|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
219138453|NCT05444179|BEHAVIORAL|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
219138454|NCT02521116|OTHER|Dynamic Vessel Analyzer|
219138455|NCT02521116|OTHER|Oxymap T1|
219138456|NCT04897737|BEHAVIORAL|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
219138457|NCT04897737|DIAGNOSTIC_TEST|Orasure/UrSure test|See above
219138458|NCT00250562|DRUG|valsartan plus hydrochlorothiazide|
219138459|NCT04554823|BEHAVIORAL|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
219138460|NCT04554823|BEHAVIORAL|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
219138461|NCT00477100|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and stool
219138462|NCT00477100|OTHER|Interview|Participate in interview
219138463|NCT00477100|OTHER|Medical Chart Review|Undergo collection of medical data
219138464|NCT00477100|OTHER|Questionnaire Administration|Ancillary Studies
219138465|NCT00405951|DRUG|Obatoclax mesylate 250 ml|
219138466|NCT00405951|DRUG|Docetaxel|
219138467|NCT04059237|BEHAVIORAL|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
219138468|NCT01887041|PROCEDURE|Stent|Endoscopically inserted biliary tract drainage
219138469|NCT01887041|PROCEDURE|Biliodigestive anastomosis|Biliodigestive anastomosis
219717267|NCT00908778|DRUG|Vitreosolve|intravitreal injection
219717268|NCT00908778|DRUG|Vitreosolve|intravitreal injection
219138470|NCT04921423|BEHAVIORAL|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
219138471|NCT03869918|OTHER|Exercise Program|Exercise at home or through a class as chosen by the subject.
219228713|NCT03883217|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
219228714|NCT02345603|PROCEDURE|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
219717269|NCT02995889|DEVICE|FLT-PET|
219717270|NCT04939584|DEVICE|MultiPulse Therapy|Electrical Stimulation
219717271|NCT00370708|PROCEDURE|Oral Intake following admittance to the postpartum ward|
219138472|NCT04875858|DRUG|ProDiax-23 (PPSV23)|diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
219138473|NCT00135135|DRUG|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
219717272|NCT03358953|DEVICE|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
219717273|NCT03358953|DEVICE|Nicotine Replacement Patch|NiQuitin 21mg
219138474|NCT00135135|PROCEDURE|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
219228715|NCT01053793|OTHER|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
219228716|NCT02798016|PROCEDURE|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
219228717|NCT02798016|PROCEDURE|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
219228718|NCT02066636|DRUG|Nivolumab|
219717274|NCT04056026|BIOLOGICAL|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
219717275|NCT02802475|BIOLOGICAL|vena punction|
219717276|NCT00473499|DEVICE|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
219717277|NCT04474821|OTHER|Educational Intervention|Receive educational materials on HPV
219717278|NCT04474821|OTHER|Survey Administration|Ancillary studies
219717279|NCT05057013|DRUG|HMBD-001|Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.
219138475|NCT02050308|OTHER|Internet-All Nations Breath of Life (I-ANBL)|"* Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session"
219138476|NCT02050308|OTHER|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
219138477|NCT02050308|DRUG|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
219138478|NCT00906035|DRUG|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
219138479|NCT00906035|DRUG|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
219138480|NCT00906035|DRUG|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
219228719|NCT06021613|BEHAVIORAL|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
219228720|NCT02878616|DRUG|LFG316|LFG316 single dose
219228721|NCT02878616|DRUG|IVIG|IVIG single dose
219228722|NCT01849536|DEVICE|SENSIMED Triggerfish®|
219228723|NCT00849485|DRUG|Levetiracetam|750 mg Tablet
219228724|NCT00849485|DRUG|Keppra®|750 mg Tablet
219228725|NCT00528216|DRUG|Capsaicin Dermal Liquid|
219717280|NCT05057013|DRUG|HMBD-001 and enzalutamide|Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
219717281|NCT05085873|DRUG|Sodium Oxybate injection|"* Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
219717282|NCT05085873|DRUG|Midazolam injection|"* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
219717283|NCT05799352|DEVICE|Endoscopic lung volume reduction|a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.
219717284|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt and Suspenders|Endoscopic sleeve gastroplasty using belt and suspender plications.
219717285|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt|Endoscopic sleeve gastroplasty using belt only plications.
219717286|NCT04083183|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
219717287|NCT04083183|DRUG|Fludarabine|Given IV
219717288|NCT04083183|DRUG|Cyclophosphamide|Given IV
219717289|NCT04083183|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
219717290|NCT04083183|RADIATION|Total-Body Irradiation|Undergo TBI
219717291|NCT04083183|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
219717292|NCT04083183|DRUG|Mycophenolate Mofetil|Given PO or IV
219717293|NCT04083183|DRUG|Sirolimus|Given PO
219717294|NCT04083183|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219717295|NCT04083183|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219717296|NCT06971887|OTHER|Clear Communication of Lab Test Result letter|The Clear Communication of Lab Test Result letter (CCLR) was designed using clear communication and health literacy best practices to explain test done, meaning of results, and any future action recommended.
219717297|NCT05115214|DEVICE|SpherePVI™ Catheter|Affera SpherePVI™ Multi-Ablation System
219138481|NCT03109704|PROCEDURE|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
219138482|NCT03109704|PROCEDURE|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
219138483|NCT03109704|PROCEDURE|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
219138484|NCT06051500|BEHAVIORAL|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
219551716|NCT04987645|PROCEDURE|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
219551717|NCT05432687|DIAGNOSTIC_TEST|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
219551718|NCT04819009|OTHER|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~1. Creating a therapeutic alliance (communication skills and reassurance)~2. Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~3. Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~4. Postcard with reminder messages on how to self manage the back."
219551719|NCT03306758|DRUG|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
219551720|NCT00603967|PROCEDURE|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
219551721|NCT00603967|PROCEDURE|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
219551722|NCT00603967|BEHAVIORAL|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
219138485|NCT06051500|BEHAVIORAL|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
219138486|NCT03058991|BEHAVIORAL|Distress Tolerance Intervention|See arm/group description.
219138487|NCT03058991|BEHAVIORAL|Working Memory Intervention|See arm/group description.
219138488|NCT03058991|BEHAVIORAL|Control Informational Intervention|See arm/group description.
219138489|NCT02533206|PROCEDURE|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
219228726|NCT06157554|OTHER|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
219551723|NCT05311072|PROCEDURE|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
219551724|NCT04416750|DRUG|Imatinib Mesylate|Treatment with Imatinib
219551725|NCT05612958|DEVICE|DKM-410|Injection up to 2.0ml
219717298|NCT06286982|OTHER|Oral Symptom Assessment Scale|The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
219717299|NCT04598828|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
219138490|NCT02533206|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
219138491|NCT00057850|DRUG|cisplatin|
219138492|NCT00057850|DRUG|ixabepilone|
219138493|NCT00999843|DRUG|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
219551726|NCT05612958|DEVICE|Juvederm ULTRA PLUS XC 1.0ml|Injection up to 2.0ml
219551727|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
219551728|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
219138494|NCT00518557|PROCEDURE|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
219138495|NCT03724838|DRUG|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
219138496|NCT03724838|DRUG|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
219138497|NCT03724838|DRUG|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
219138498|NCT03724838|DRUG|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
219138499|NCT00130637|DRUG|Daclizumab|
219138500|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
219138501|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
219138502|NCT00444613|DRUG|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
219138503|NCT05731648|DEVICE|Intrathecal balofen pump|Management of spasticity
219138504|NCT06187480|PROCEDURE|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
219138505|NCT02787941|BEHAVIORAL|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
219138506|NCT02081898|DIETARY_SUPPLEMENT|LCD|approximate 100 kcal/d caloric deficit
219138507|NCT03122704|PROCEDURE|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
219138508|NCT05831917|RADIATION|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
219138509|NCT02881749|RADIATION|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
219138510|NCT02881749|DRUG|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
219138511|NCT02114749|DEVICE|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
219138512|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
219138513|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
219138514|NCT00740155|BIOLOGICAL|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
219551729|NCT00686764|OTHER|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
219551730|NCT02169323|OTHER|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
219551731|NCT00130949|DRUG|ALGRX 4975|
219551732|NCT00320307|DRUG|abacavir|
219551733|NCT02911909|DEVICE|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
219551734|NCT02911909|OTHER|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
219551735|NCT04947761|DRUG|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
219551736|NCT04947761|OTHER|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
219551737|NCT00189553|DRUG|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
219551738|NCT00189553|DRUG|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
219138515|NCT00740155|BIOLOGICAL|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
219138516|NCT00740155|BIOLOGICAL|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
219138517|NCT02999048|DRUG|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
219138518|NCT00942149|DRUG|Daptomycin|single dose of 6 mg/kg of daptomycin
219138519|NCT02438124|BEHAVIORAL|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
219138520|NCT06164249|OTHER|strength training|Strength training, three times a week, during nine weeks.
219138521|NCT01701713|DEVICE|DKI ED2011|
219138522|NCT01701713|DEVICE|Sham-TDCS|
219138523|NCT01460342|DRUG|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
219138524|NCT01460342|DRUG|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
219138525|NCT02170636|DRUG|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
219138526|NCT02170636|DRUG|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
219138527|NCT02170636|DRUG|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
219138528|NCT02170636|DRUG|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
219138529|NCT02170636|DRUG|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
219138530|NCT02170636|DRUG|Pantoprazole|40 mg Pantoprazole
219138531|NCT01689519|DRUG|Placebo|Placebo supplied as tablets
219138532|NCT01689519|DRUG|Vemurafenib|Vemurafenib supplied as tablets
219138533|NCT01689519|DRUG|Cobimetinib|Cobimetinib supplied as tablets
219138534|NCT04555954|OTHER|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
219138535|NCT03082430|BIOLOGICAL|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
219138536|NCT03285191|OTHER|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
219138537|NCT03285191|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
219138538|NCT05252871|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
219138539|NCT02488174|OTHER|PROOFcheck|
219138540|NCT02488174|OTHER|Standard Care|
219138541|NCT03140579|OTHER|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
219138542|NCT04353830|DRUG|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
219551739|NCT00189553|DRUG|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
219551740|NCT04872777|BEHAVIORAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
219551741|NCT00804011|OTHER|ATC|Automatic tube compensation
219138543|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
219551742|NCT00804011|OTHER|PSV|Pressure support ventilation
219551743|NCT03762954|OTHER|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
219551744|NCT02832921|BEHAVIORAL|cognitive training by virtual reality|
219551745|NCT02832921|BEHAVIORAL|watching a scientific TV documentary|
219138544|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
219138545|NCT00116623|DRUG|Indomethacin|
219138546|NCT00116623|DRUG|Magnesium sulfate|
219138547|NCT00098280|DRUG|Eculizumab|
219138548|NCT03673943|DRUG|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
219138549|NCT01713530|DRUG|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
219138550|NCT01713530|DRUG|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
219138551|NCT01713530|DRUG|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
219138552|NCT05422716|DEVICE|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
219138553|NCT01507948|BEHAVIORAL|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
219138554|NCT04249388|OTHER|No Intervention, just observation|No Intervention, just observation
219138555|NCT01955668|DRUG|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
219138556|NCT03956641|OTHER|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
219138557|NCT05042193|OTHER|SARS-CoV-2|Observational
219138558|NCT05046132|DRUG|Setmelanotide|Administered once daily via SC injection.
219138559|NCT05046132|DRUG|Moxifloxacin|Moxifloxacin capsules via oral administration.
219717300|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
219138560|NCT05046132|DRUG|Oral Placebo|Placebo capsules via oral administration.
219138561|NCT05046132|DRUG|SC Placebo|Placebo via SC injection.
219138562|NCT02425254|DRUG|Intravenous paracetamol|1000mg intravenous solution for infusion
219138563|NCT02425254|DRUG|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
219138564|NCT01638949|BEHAVIORAL|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
219138565|NCT01638949|BIOLOGICAL|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
219138566|NCT01638949|GENETIC|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
219138567|NCT01638949|OTHER|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
219138568|NCT01959412|DRUG|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
219138569|NCT01959412|DRUG|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
219138570|NCT01959412|DRUG|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
219138571|NCT01959412|DRUG|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
219138572|NCT01959412|DRUG|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
219138573|NCT01959412|DRUG|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
219138574|NCT05004272|PROCEDURE|Massage|20-minute manual full-body massage
219138575|NCT05004272|PROCEDURE|Gymnastics|20-minute moderate body workout
219138576|NCT05004272|OTHER|Lecture|20-minute lecture on medicinal herbs
219138577|NCT00365638|DRUG|simvastatin|
219138578|NCT04159636|OTHER|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
219138579|NCT00545324|DRUG|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
219138580|NCT00545324|DRUG|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
219138581|NCT01669148|DEVICE|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
219138582|NCT01669148|DEVICE|Conventional|conventional (2D) imaging (standard mammography)
219138583|NCT01081340|BEHAVIORAL|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
219138584|NCT01081340|BEHAVIORAL|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
219138585|NCT00931593|DEVICE|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
219138586|NCT06121830|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
219138587|NCT06121830|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
219138588|NCT06121830|DRUG|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
219138589|NCT00619645|DRUG|busulfan|
219138590|NCT00619645|DRUG|cyclosporine|
219138591|NCT00619645|DRUG|fludarabine phosphate|
219138592|NCT00619645|DRUG|mycophenolate mofetil|
219138593|NCT00619645|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219138594|NCT00619645|PROCEDURE|peripheral blood stem cell transplantation|
219138595|NCT01671241|DEVICE|Polyethylene wrap|
219138596|NCT01671241|DEVICE|Polyethylene wrap|
219138597|NCT04364269|DRUG|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
219138598|NCT04364269|DRUG|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
219138599|NCT04364269|DRUG|Placebo|Participants will receive hard capsules of Placebo, twice a day.
219138600|NCT00005840|DRUG|Paclitaxel|Given IV
219138601|NCT00005840|DRUG|Cisplatin|Given IV
219138602|NCT00005840|RADIATION|Radiation Therapy|Undergo whole abdominal radiation therapy
219138603|NCT06116812|OTHER|the laughter yoga group|"They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
219138604|NCT06116812|OTHER|the mindfulness based stress reduction group|"Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
219138605|NCT01598948|DRUG|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
219138606|NCT04155151|OTHER|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
219138607|NCT00234442|DRUG|Iressa (Gefitinib)|
219138608|NCT00140972|DRUG|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
219138609|NCT00140972|DRUG|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
219138610|NCT04742842|BIOLOGICAL|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
219138611|NCT04742842|BIOLOGICAL|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
219138612|NCT04742842|BIOLOGICAL|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
219551746|NCT02832921|DEVICE|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
219138613|NCT04742842|BIOLOGICAL|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
219138614|NCT04246762|DRUG|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
219138615|NCT04246762|DRUG|Omeprazole|Tablets, 20 mg, oral
219138616|NCT04246762|DRUG|Caffeine|Tablets, 100 mg, oral
219138617|NCT04246762|DRUG|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
219138618|NCT04246762|DRUG|Midazolam|Syrup, 2 mg/mL, oral
219228727|NCT06157554|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
219228728|NCT00186446|DRUG|bupropion and smoking cessation behavioral intervention|
219228729|NCT01576796|RADIATION|Radiotherapy|"No additional dose (patients negative F-miso)~* Radiation therapy is conducted under standard conditions of conformal radiotherapy:~* The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
219551747|NCT00001698|DRUG|Ketorolac Rinse|
219138619|NCT00597519|DRUG|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
219138620|NCT00597519|PROCEDURE|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
219138621|NCT05679713|DIAGNOSTIC_TEST|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
219138622|NCT00212784|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
219138623|NCT00212784|DRUG|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
219138624|NCT01006551|DRUG|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
219138625|NCT03908424|OTHER|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
219138626|NCT00765492|DRUG|AZD8529|oral
219138627|NCT00765492|DRUG|Placebo|oral
219138628|NCT02953080|OTHER|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
219138629|NCT01345838|PROCEDURE|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
219138630|NCT01662180|DRUG|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
219717301|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
219717302|NCT06069479|PROCEDURE|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
219717303|NCT06598462|DRUG|Solrikitug Low Dose|Solrikitug low dose subcutaneous injection
219138631|NCT05404893|DIAGNOSTIC_TEST|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
219138632|NCT02206386|OTHER|MHTraining-Net|See Arm Description for more details.
219138633|NCT02206386|OTHER|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
219138634|NCT04848441|OTHER|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
219717304|NCT06598462|DRUG|Solrikitug Mid Dose|Solrikitug mid dose subcutaneous injection
219717305|NCT06598462|DRUG|Solrikitug High Dose|Solrikitug high dose subcutaneous injection
219717306|NCT06598462|OTHER|Placebo|Placebo subcutaneous injection
219717307|NCT02676973|PROCEDURE|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
219717308|NCT02676973|PROCEDURE|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
219717309|NCT02676973|PROCEDURE|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
219228730|NCT05215249|PROCEDURE|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
219228731|NCT02170532|DRUG|levalbuterol|0.5 ml. levalbuterol
219228732|NCT02170532|DRUG|saline|0.5ml saline
219228733|NCT02170532|OTHER|levalbuterol MDI|
219228734|NCT02170532|DEVICE|breath actuated nebulizer|
219228735|NCT02170532|DEVICE|aerochamber max|
219228736|NCT02170532|DRUG|ipratroprium|
219228737|NCT03064906|DEVICE|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
219228738|NCT01381341|DRUG|linifanib|QD on Day 1 of Periods 1 and 2
219228739|NCT02833948|DRUG|Acetylsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
219228740|NCT02833948|DRUG|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
219138635|NCT02572024|DEVICE|BAT|Baroreflex activation therapy device ON
219138636|NCT02572024|OTHER|Placebo|Baroreflex activation therapy device OFF
219138637|NCT05353517|DEVICE|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
219228741|NCT02833948|DRUG|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
219228742|NCT05071677|PROCEDURE|Discussion|Participate in treatment planning meeting
219138638|NCT04911933|BEHAVIORAL|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
219138639|NCT02979899|BIOLOGICAL|TRC105|TRC105 antibody
219138640|NCT02979899|DRUG|Votrient|pazopanib
219138641|NCT01816958|OTHER|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
219138642|NCT06468657|OTHER|mortality rates|mortality rates
219228743|NCT05071677|OTHER|Interview|Participate in interview
219228744|NCT05071677|OTHER|Survey Administration|Complete survey
219228745|NCT04393571|OTHER|Mobile application|telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
219228746|NCT00249405|DRUG|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
219228747|NCT00249405|BEHAVIORAL|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
219228748|NCT02789488|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|Furocyst one caps BID
219228749|NCT05816317|BEHAVIORAL|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
219228750|NCT05816317|BEHAVIORAL|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
219228751|NCT04810832|OTHER|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery."
219228752|NCT04373772|OTHER|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
219228753|NCT05967845|PROCEDURE|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
219228754|NCT05967845|PROCEDURE|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
219551748|NCT02994147|DRUG|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
219551749|NCT02994147|DRUG|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
219551750|NCT00171145|DRUG|Darifenacin|Darifenacin 15 mg tablets once daily
219551751|NCT00171145|DRUG|Placebo|Placebo tablets once daily
219551752|NCT05609617|DEVICE|injection|Intradermal injection on the face and neck/or décolleté by the NCTF135 HA
219551753|NCT05609617|OTHER|Cream application|Application of hydra filler cream on the face and neck/or décolleté
219551754|NCT03053245|BEHAVIORAL|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
219551755|NCT03053245|BEHAVIORAL|Attention Control|Patients in this group will receive regular wellness calls from the research team.
219717310|NCT06144606|DRUG|Tecartus|Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
219228755|NCT00365885|OTHER|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
219228756|NCT02852824|DRUG|BI 655130 (spesolimab)|
219228757|NCT02852824|DRUG|Placebo|
219228758|NCT02611869|PROCEDURE|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
219717311|NCT06524349|DEVICE|3D printed knee extender device|Participants will receive a 3D printed knee extender device with sealed water bottles and an at-home rehabilitation program designed to be used with the 3D printed knee extender device.
219717312|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
219138643|NCT06629012|PROCEDURE|Breast reconstruction with neurotization|Patients received breast reconstruction with neurotization procedure
219138644|NCT06629012|PROCEDURE|Breast reconstruction without neurotization|Patients received breast reconstruction without neurotization
219138645|NCT02403024|BEHAVIORAL|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
219138646|NCT02403024|BEHAVIORAL|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
219138647|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
219228759|NCT02611869|PROCEDURE|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
219228760|NCT05369000|BIOLOGICAL|LAVA-1207|"In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion."
219228761|NCT05369000|BIOLOGICAL|LAVA-1207 plus Pembrolizumab|Pembrolizumab will be administered via intravenous infusion
219228762|NCT02102113|DRUG|Placebo|placebo
219228763|NCT02102113|DRUG|Very Low Dose THC|Subjects will receive 0.010mg/kg.
219228764|NCT02102113|DRUG|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
219138648|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
219138649|NCT03692520|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
219228765|NCT04556773|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
219228766|NCT04556773|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
219228767|NCT04556773|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
219228768|NCT04556773|DRUG|Capivasertib|Capivasertib: administered orally
219228769|NCT04556773|DRUG|Anastrozole|Anastrozole: administered orally
219228770|NCT04556773|DRUG|Fulvestrant|Fulvestrant: administered as an IM injection
219228771|NCT04556773|DRUG|Capecitabine|Capecitabine: administered orally
219228772|NCT04402073|DRUG|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
219228773|NCT04402073|DRUG|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
219228774|NCT04402073|DRUG|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
219228775|NCT04402073|DRUG|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
219228776|NCT04402073|RADIATION|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
219228777|NCT06542562|PROCEDURE|guided implant placement|The key difference is that in Group 1, the guide is only used for the drilling sequence, while in Group 2 the guide is used for both the drilling and the actual implant placement.
219228778|NCT06416397|DIAGNOSTIC_TEST|Proteomic profile|"Proteomic analysis of bile samples will be performed every 5 bile samples. Bile samples will be taken during endoscopy with retrograde papillary catheterization or radiological procedures in selected patients. In clinical practice, bile samples are taken for bacteriological purposes. An average of 10 mL is taken.~Five mL are required for bacteriological analysis. The remaining millilitres, which are usually discarded, will be kept for storage and to form the bile bank at the Biological Resources Centre before to be analyzed in proteomics."
219717313|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
219717314|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
219138650|NCT04495634|DEVICE|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
219138651|NCT03030950|DRUG|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
219138652|NCT03030950|DRUG|Normal saline|to give normal saline to the other group as a placebo
219138653|NCT02417311|OTHER|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
219138654|NCT02431143|DRUG|Miltefosine|
219138655|NCT04388488|DEVICE|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
219138656|NCT04388488|DEVICE|Any conventional handmade socket|Subjects current socket
219138657|NCT01413594|BEHAVIORAL|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
219138658|NCT00741988|DRUG|Ixabepilone|ixabepilone 30 mg/m2
219138659|NCT00741988|DRUG|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
219138660|NCT00741988|DRUG|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
219138661|NCT00193518|DRUG|Arsenic Trioxide|
219138662|NCT02104765|DRUG|LY2951742|Administered subcutaneously.
219138663|NCT02104765|DRUG|Placebo|Administered subcutaneously.
219138664|NCT06113406|BEHAVIORAL|Classroom Training|Active Comparator
219138665|NCT06113406|BEHAVIORAL|Virtual Reality Training|Experimental
219138666|NCT01970618|DRUG|RV1162 single dose|Safety and tolerability of single escalating doses
219138667|NCT01970618|DRUG|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
219138668|NCT01970618|DRUG|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
219138669|NCT01970618|DRUG|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
219138670|NCT01970618|DRUG|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
219138671|NCT01970618|DRUG|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
219138672|NCT04204564|DEVICE|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
219138673|NCT03990038|DRUG|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
219138674|NCT03990038|DRUG|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
219138675|NCT05453682|RADIATION|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
219717315|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
219138676|NCT00281762|DRUG|NSAID|
219138677|NCT06554197|DIAGNOSTIC_TEST|CMV/EBV-CMI|The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
219138678|NCT01024179|DEVICE|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
219138679|NCT02124460|BEHAVIORAL|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
219228779|NCT01401790|DEVICE|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program"
219138680|NCT04168814|OTHER|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
219228780|NCT01401790|OTHER|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
219138681|NCT05880238|BEHAVIORAL|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
219138682|NCT05880238|OTHER|Control group|The control group will continue their education according to the preschool education curriculum.
219138683|NCT05976854|OTHER|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
219138684|NCT05976854|OTHER|Prenatal education|The standard prenatal education is based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.
219138685|NCT06560840|OTHER|dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
219138686|NCT06107517|OTHER|DREAMS-OT|"Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach."
219138687|NCT01657318|OTHER|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
219138688|NCT00926939|BEHAVIORAL|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
219138689|NCT00926939|BEHAVIORAL|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
219138690|NCT04840862|DRUG|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
219138691|NCT04840862|DRUG|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
219138692|NCT03256682|BEHAVIORAL|Stress management counseling|stress management counseling based on CBT and relaxation
219138693|NCT00995709|DRUG|AIN457|
219138694|NCT00995709|DRUG|AIN457|
219138695|NCT00995709|DRUG|Placebo|
219138696|NCT05123638|DEVICE|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
219138697|NCT05123638|BEHAVIORAL|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
219138698|NCT00421902|PROCEDURE|Acupuncture|Patients will be have acupuncture (with electro stimulation)
219138699|NCT01137903|PROCEDURE|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
219138700|NCT01137903|DRUG|Ciprofloxacin|500 mg/ 12 hours during 90 days
219138701|NCT01137903|DRUG|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
219138702|NCT01137903|DRUG|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
219138703|NCT04758897|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
219138704|NCT05998096|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
219138705|NCT05998096|DIETARY_SUPPLEMENT|Placebo|Placebo void of all active ingredients
219138706|NCT03317639|BEHAVIORAL|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
219138707|NCT03904199|DRUG|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
219138708|NCT04204837|DRUG|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
219138709|NCT04204837|DRUG|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
219138710|NCT02178917|OTHER|Neurofeedback therapy|
219138711|NCT02178917|OTHER|No neurofeedback therapy|
219228781|NCT05913791|DIETARY_SUPPLEMENT|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
219138712|NCT00846313|OTHER|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
219138713|NCT01111903|DRUG|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
219138714|NCT01697319|DRUG|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
219138715|NCT05391724|DRUG|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
219138716|NCT02984319|DIETARY_SUPPLEMENT|Cherry versus placebo concentrate|Acute cherry concentrate
219138717|NCT04222959|BEHAVIORAL|Girls Invest Intervention|"App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings."
219138718|NCT03872869|OTHER|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
219138719|NCT01516788|OTHER|Phototesting|Single MED dose on Day 2
219138720|NCT02183246|DRUG|Porfiromycin|
219138721|NCT02183246|DRUG|Placebo|
219138722|NCT02183246|RADIATION|Radiotherapy|
219138723|NCT01549730|PROCEDURE|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
219138724|NCT02401919|BEHAVIORAL|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
219138725|NCT01109095|BIOLOGICAL|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2"
219138726|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
219717316|NCT05958381|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
219138727|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be added to the particulate demineralized dentin graft forming sticky demineralized tooth graft then inserted in the extraction socket and covered then suturing
219138728|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
219138729|NCT04710225|PROCEDURE|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
219138730|NCT02039713|DEVICE|DeSyne drug eluting stent group|
219138731|NCT06206330|OTHER|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
219138732|NCT01322919|PROCEDURE|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
219138733|NCT01623349|DRUG|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
219138734|NCT01623349|DRUG|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
219228782|NCT05913791|OTHER|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
219138735|NCT06555146|DRUG|Semaglutide, 0.5 mg/mL|1 subcutaneous injection on baseline day
219138736|NCT06555146|DRUG|Placebo, Saline|1 subcutaneous injection on baseline day
219138737|NCT02083991|DRUG|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
219138738|NCT05262803|GENETIC|CYP2C19*2/*3|"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
219138739|NCT05262803|OTHER|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
219138740|NCT00640029|PROCEDURE|Arthrodesis|"* posterior,~* anterior,~* circumference approach"
219138741|NCT00640029|DEVICE|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"* SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®"
219138742|NCT02519699|DRUG|norepinephrine|Increase in mean arterial pressure using norepinephrine
219138743|NCT03008915|DRUG|Aspirin|81mg aspirin taken once per day in the morning
219138744|NCT03008915|DRUG|Placebo|placebo taken once per day in the morning
219138745|NCT03008915|OTHER|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
219138746|NCT04411836|DRUG|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
219138747|NCT04411836|DRUG|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
219138748|NCT06554769|PROCEDURE|non rigid indirect anchorage connection|a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.
219138749|NCT06554769|PROCEDURE|rigid indirect anchorage connection|a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.
219138750|NCT06395311|OTHER|COPD psychological well-being assessment|Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
219138751|NCT06628635|BEHAVIORAL|Exercise|Exercise involving aerobics, isometrics, and stretching
219138752|NCT06628635|BEHAVIORAL|Resting|Resting
219138753|NCT05972694|DIETARY_SUPPLEMENT|Freeze dried grape powder|46g/d freeze-dried grape powder
219138754|NCT00712166|DRUG|AZLI 75 mg three times daily (TID)|
219138755|NCT00712166|DRUG|Placebo three times daily (TID)|
219138756|NCT04995887|DEVICE|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
219138757|NCT03944343|OTHER|Cereal based products|The cereal products are made from common Swedish cereals.
219138758|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
219138759|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
219138760|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
219138761|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
219138762|NCT02889822|DRUG|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
219138763|NCT05949203|DRUG|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
219138764|NCT06414980|BEHAVIORAL|Experimental|The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
219228783|NCT06133075|DRUG|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
219138765|NCT01769391|DRUG|Necitumumab|Administered IV
219138766|NCT01769391|DRUG|Paclitaxel|Administered IV
219138767|NCT01769391|DRUG|Carboplatin|Administered IV
219138768|NCT04243343|DEVICE|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
219138769|NCT04243343|OTHER|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
219138770|NCT00006391|DRUG|oxaliplatin|
219138771|NCT00006391|DRUG|topotecan hydrochloride|
219138772|NCT00345202|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
219138773|NCT00000106|DEVICE|Whole body hyperthermia unit|
219138774|NCT04671108|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
219228784|NCT06133075|DRUG|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
219228785|NCT06970249|BEHAVIORAL|Music intervention|Patient-preferred music (e.g., classical, jazz, ambient) will be selected preoperatively from a standardized list and delivered via headphones at 40-60 dB, verified by a sound meter.
219228786|NCT06452576|DEVICE|Vibration|Watch vibrates.
219228787|NCT06452576|BEHAVIORAL|constraint-induced movement therapy|A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.
219228788|NCT03950427|BEHAVIORAL|Videogame-based physical activity|videogame-based physical activity
219228789|NCT03950427|BEHAVIORAL|Sedentary videogame|sedentary videogame
219228790|NCT03950427|DRUG|Bupropion|Bupropion
219228791|NCT03950427|BEHAVIORAL|Counseling|Counseling for smoking cessation
219228792|NCT02790281|PROCEDURE|Blood sampling|Blood sample collected at a single visit
219138775|NCT00345852|PROCEDURE|Fetoscopic Selective Laser Photocoagulation|
219138776|NCT06524700|PROCEDURE|pectopexy mesh|pectopexy with mesh
219138777|NCT06524700|PROCEDURE|pectopexy autologous|pectopexy using autologous graft
219138778|NCT03227757|DEVICE|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
219138779|NCT05409664|BEHAVIORAL|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
219138780|NCT05409664|BEHAVIORAL|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
219138781|NCT03047083|OTHER|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
219138782|NCT03047083|OTHER|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
219138783|NCT06461624|BIOLOGICAL|anti-GPC3 CAR-T|All subjects were intravenous administrated with CBG166.
219138784|NCT01866969|OTHER|questionnaire administration|Ancillary studies
219138785|NCT01866969|PROCEDURE|quality-of-life assessment|Ancillary studies
219138786|NCT00121329|DRUG|Intrauterine lidocaine infusion 4%|
219138787|NCT00821184|DRUG|Vesicare (solifenacin)|5mg po qd
219138788|NCT00821184|BEHAVIORAL|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
219138789|NCT04820621|DRUG|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release \[MR\] tablet
219138790|NCT01366898|DRUG|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
219138791|NCT02995460|BEHAVIORAL|interval training|4x4 high intensity interval training
219138792|NCT02414906|OTHER|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
219138793|NCT02342210|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
219138794|NCT04618224|DIAGNOSTIC_TEST|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
219228793|NCT05123144|BEHAVIORAL|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
219228794|NCT03787628|DRUG|Cannabidiol (CBD) 600 mg|CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc. (California, USA) under cGMP conditions.
219228795|NCT03787628|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc. under cGMP conditions. The amount (number of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
219228796|NCT05288959|DEVICE|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
219228797|NCT05288959|DEVICE|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
219228798|NCT06510088|PROCEDURE|3-week multimodal prehabilitation program|"This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care."
219228799|NCT02124356|OTHER|Evaluation of functional performance|
219228800|NCT02521493|DRUG|Asparaginase|Given IM or IV
219228801|NCT02521493|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
219138795|NCT04618224|DIAGNOSTIC_TEST|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
219138796|NCT02571816|DRUG|ASP2215|oral
219138797|NCT03286244|DRUG|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
219138798|NCT04681079|DRUG|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
219138799|NCT04681079|DRUG|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
219228802|NCT02521493|DRUG|Cytarabine|Given IT and IV
219228803|NCT02521493|DRUG|Daunorubicin Hydrochloride|Given IV
219228804|NCT02521493|DRUG|Etoposide|Given IV
219138800|NCT04944446|OTHER|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
219138801|NCT06188611|DRUG|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
219138802|NCT01875250|BIOLOGICAL|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
219138803|NCT01875250|BIOLOGICAL|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
219138804|NCT01875250|DRUG|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
219138805|NCT00502229|DRUG|Clomiphene citrate, metformin, highly purified urinary FSH|
219138806|NCT03547791|DRUG|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
219138807|NCT03547791|DRUG|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
219138808|NCT02273986|DRUG|Digoxin|
219138809|NCT02273986|DRUG|K-877|
219138810|NCT04689061|DEVICE|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
219138811|NCT03861221|DEVICE|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
219228805|NCT02521493|OTHER|Laboratory Biomarker Analysis|Correlative studies
219228806|NCT02521493|DRUG|Mitoxantrone Hydrochloride|Given IV
219228807|NCT02521493|DRUG|Thioguanine|Given PO
219228808|NCT06060353|BEHAVIORAL|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
219551756|NCT05535998|PROCEDURE|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
219551757|NCT05535998|PROCEDURE|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
219551758|NCT05535998|DRUG|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
219138812|NCT06478992|PROCEDURE|A:hysteroscopic suture fixation of Mirena|A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
219717317|NCT05958381|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
219138813|NCT06478992|PROCEDURE|A: simple Mirena placement under hysteroscopy|A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
219717318|NCT04558619|BEHAVIORAL|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
219138814|NCT06478992|PROCEDURE|B: hysteroscopic suture fixation of Mirena|B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
219138815|NCT06478992|PROCEDURE|B：simple Mirena placement under hysteroscopy|B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
219138816|NCT02675088|RADIATION|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
219138817|NCT02675088|RADIATION|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
219138818|NCT00538213|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
219138819|NCT00538213|BIOLOGICAL|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
219138820|NCT03181464|DRUG|Lidocaine 4%|lidocaine solution
219551759|NCT05535998|DRUG|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
219551760|NCT02802852|DEVICE|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
219717319|NCT05357612|DRUG|Pimavanserin|PD related Psychosis
219717320|NCT02580604|DRUG|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
219717321|NCT02580604|DRUG|Half-Normal Saline|This is the placebo comparative infusion. Half-normal saline will be infused at the second collection visit following the identical infusion schedule determined during the calcium infusion visit.
219717322|NCT05840484|OTHER|Active Surveillance|Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
219138821|NCT03181464|DRUG|Placebo|saline .9% injection
219138822|NCT05709873|BEHAVIORAL|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
219138823|NCT05709873|BEHAVIORAL|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
219138824|NCT01645423|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
219138825|NCT04611360|OTHER|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
219138826|NCT04611360|OTHER|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
219138827|NCT03379740|OTHER|E-cigarette|Subject's own e-cigarette
219138828|NCT03379740|OTHER|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
219138829|NCT03379740|OTHER|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
219138830|NCT03379740|OTHER|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
219551761|NCT02802852|DRUG|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
219551762|NCT04877145|OTHER|drill|single 3.25 mm stainless steel drill
219551763|NCT01347749|BEHAVIORAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
219138831|NCT03379740|OTHER|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
219551764|NCT01347749|BEHAVIORAL|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
219551765|NCT04303221|OTHER|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
219138832|NCT04815616|RADIATION|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
219138833|NCT04075357|OTHER|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
219138834|NCT05734924|DEVICE|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
219138835|NCT01824030|DEVICE|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
219138836|NCT01824030|DEVICE|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
219138837|NCT02234778|DEVICE|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
219138838|NCT02312336|OTHER|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
219138839|NCT02312336|OTHER|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
219138840|NCT03988036|DRUG|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
219138841|NCT03988036|DRUG|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
219138842|NCT03988036|DRUG|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
219138843|NCT02764645|DEVICE|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
219138844|NCT02764645|DEVICE|22Fr curved Cannula|arterial cannula for use in cardiac surgery
219138845|NCT02086370|PROCEDURE|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
219138846|NCT02086370|PROCEDURE|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
219138847|NCT05573191|DRUG|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
219138848|NCT05573191|DRUG|Normal saline|Normal saline
219138849|NCT06101992|DRUG|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
219138850|NCT06101992|OTHER|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
219138851|NCT00003880|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
219138852|NCT00003880|DRUG|carboplatin|
219138853|NCT00003880|DRUG|paclitaxel|
219138854|NCT00652301|DRUG|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
219138855|NCT00652301|DRUG|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
219138856|NCT00652301|DRUG|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
219138857|NCT05571436|BEHAVIORAL|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q\&A and Discussion, Goal setting, and Testing Healthy Snacks."
219551766|NCT03369535|OTHER|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
219551767|NCT03369535|OTHER|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
219138858|NCT01748318|DRUG|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
219138859|NCT01748318|DRUG|Bactrim DS|Bactrim DS
219551768|NCT03369535|OTHER|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
219551769|NCT04211935|DEVICE|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
219138860|NCT01841437|DEVICE|iStent|
219138861|NCT00616733|DRUG|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
219138862|NCT00616733|DRUG|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
219138863|NCT00616733|DRUG|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
219228809|NCT06060353|BEHAVIORAL|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
219228810|NCT06439329|BEHAVIORAL|Standard PN|Standard of care
219138864|NCT02892903|DEVICE|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
219138865|NCT04265378|DEVICE|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
219138866|NCT04265378|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
219138867|NCT00221208|BEHAVIORAL|Resistance Training|
219138868|NCT00149630|DRUG|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
219138869|NCT00149630|DRUG|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
219138870|NCT00149630|BEHAVIORAL|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
219228811|NCT06439329|BEHAVIORAL|Patient Choice|Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.
219138871|NCT00149630|OTHER|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
219138872|NCT01174329|DEVICE|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
219138873|NCT01174329|DEVICE|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
219138874|NCT03667547|DRUG|Raltegravir|Raltegravir 600 mg tablet
219228812|NCT01470300|OTHER|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
219228813|NCT05527613|OTHER|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
219551770|NCT04211935|DEVICE|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
219551771|NCT04211935|DEVICE|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
219551772|NCT02172781|DRUG|Ipratropium - unit dose vial|
219551773|NCT02172781|DRUG|Tiotropium - inhalation capsule|
219551774|NCT02172781|DRUG|Placebo matching tiotropium|
219551775|NCT02172781|DRUG|Placebo matching ipratropium|
219551776|NCT02666807|DIETARY_SUPPLEMENT|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
219551777|NCT02666807|DIETARY_SUPPLEMENT|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
219551778|NCT00156182|DRUG|Asoprisnil|10mg Tablet, oral Daily for 6 months
219551779|NCT03032536|DRUG|AL-3778|AL-3778 tablets or capsules
219551780|NCT03032536|DRUG|Entecavir|Entecavir once daily for 14 days
219551781|NCT03032536|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
219551782|NCT04184167|OTHER|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
219551783|NCT01728636|DRUG|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
219551784|NCT05515458|DRUG|Chiglitazar|Oral single dose 48 mg
219551785|NCT03255980|DEVICE|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
219551786|NCT03255980|OTHER|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
219551787|NCT02017873|DRUG|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
219551788|NCT00867919|BEHAVIORAL|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary"
219551789|NCT00867919|OTHER|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
219551790|NCT02533466|OTHER|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
219551791|NCT02533466|OTHER|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
219551792|NCT02480634|DRUG|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
219551793|NCT02480634|RADIATION|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
219551794|NCT00901719|DRUG|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
219551795|NCT00901719|DRUG|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
219138875|NCT05283460|BEHAVIORAL|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
219138876|NCT05298111|OTHER|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
219138877|NCT05298111|OTHER|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
219138878|NCT04538820|DRUG|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
219138879|NCT04538820|DRUG|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
219138880|NCT04538820|DRUG|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
219138881|NCT04895007|BIOLOGICAL|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
219138882|NCT00218556|BEHAVIORAL|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
219138883|NCT02689349|DEVICE|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
219138884|NCT03518112|BIOLOGICAL|Blinatumomab|Given IV
219138885|NCT03518112|DRUG|Cyclophosphamide|Given IV
219138886|NCT03518112|DRUG|Cytarabine|Given IT or IV
219228814|NCT00951691|BEHAVIORAL|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
219228815|NCT00951691|BEHAVIORAL|Treatment as usual|Standard treatment with physical and occupational therapies
219228816|NCT01194011|BEHAVIORAL|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
219717323|NCT05936437|DEVICE|Subjects treated with Newest medical device|"Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks."
219717324|NCT00870506|BEHAVIORAL|video|5-minute video compared (intervention) to no video and no other intervention (control)
219717325|NCT06023953|DEVICE|Nerivio device|REN treatment with Nerivio device
219717326|NCT04549636|OTHER|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
219717327|NCT04549636|OTHER|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
219717328|NCT04549636|OTHER|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
219138887|NCT03518112|DRUG|Dexamethasone|PO or IV
219138888|NCT03518112|BIOLOGICAL|Filgrastim|Given SC
219138889|NCT03518112|OTHER|Laboratory Biomarker Analysis|Correlative studies
219138890|NCT03518112|DRUG|Leucovorin Calcium|Given IV
219138891|NCT03518112|DRUG|Mercaptopurine|Given PO
219138892|NCT03518112|DRUG|Methotrexate|Given IT or IV
219138893|NCT03518112|BIOLOGICAL|Pegfilgrastim|Given SC
219138894|NCT03518112|BIOLOGICAL|Rituximab|Given IV
219138895|NCT03518112|DRUG|Vincristine Sulfate|Given IV
219138896|NCT03723512|DEVICE|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
219138897|NCT06055595|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
219138898|NCT01546155|RADIATION|PET imaging|Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
219138899|NCT00752817|OTHER|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
219138900|NCT00752817|OTHER|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
219138901|NCT01182116|PROCEDURE|J Pouch|Comparing J pouch, side to end coloanal surgery
219138902|NCT03094104|OTHER|News items with spin|Interpretation of news items with spin
219138903|NCT03094104|OTHER|News items without spin|Interpretation of news items without spin
219138904|NCT02034916|DRUG|talazoparib|
219138905|NCT04748575|DIETARY_SUPPLEMENT|Acai smoothie|Smoothie containing 150g acai pulp
219228817|NCT00352599|DRUG|Lovastatin|
219717329|NCT04549636|OTHER|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
219717330|NCT04549636|OTHER|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
219138906|NCT04748575|DIETARY_SUPPLEMENT|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
219138907|NCT03131206|DRUG|Alectinib|"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
219138908|NCT06297135|BEHAVIORAL|Behavioral Parent Training|Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
219138909|NCT04019509|DIAGNOSTIC_TEST|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
219138910|NCT04019509|OTHER|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
219228818|NCT00352599|DRUG|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
219717331|NCT04549636|OTHER|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
219717332|NCT04549636|OTHER|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
219717333|NCT01078662|DRUG|olaparib|Tablets Oral BID
219717334|NCT05695313|DRUG|OnLife®|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
219717335|NCT05695313|OTHER|Placebo|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
219551796|NCT00901719|DRUG|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
219551797|NCT00901719|DRUG|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
219551798|NCT03273751|PROCEDURE|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
219228819|NCT00352599|DRUG|placebo pill|
219228820|NCT02727205|DRUG|Rotigotine Transdermal System|
219551799|NCT03273751|PROCEDURE|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
219717336|NCT01502891|OTHER|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
219717337|NCT04412421|PROCEDURE|Gastric Bypass, Sleeve Gastrectomy|Lifelong vitamin and Mineral supplementation
219138911|NCT05906940|DEVICE|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
219138912|NCT00189969|BIOLOGICAL|Elstree-BN|
219138913|NCT04946487|PROCEDURE|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
219138914|NCT03753152|DEVICE|experimental|Neuramis® Deep Lidocaine
219138915|NCT03753152|DEVICE|comparator|YVOIRE® Volume Plus
219138916|NCT02520856|OTHER|blood sample|
219138917|NCT01616654|DRUG|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
219138918|NCT01616654|DRUG|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
219551800|NCT01885897|BIOLOGICAL|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
219551801|NCT03141151|BEHAVIORAL|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
219551802|NCT03141151|BEHAVIORAL|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
219138919|NCT01616654|DRUG|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
219138920|NCT01616654|DRUG|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
219138921|NCT01616654|DRUG|Vehicle cream|Vehicle cream applied once daily
219138922|NCT04008836|DEVICE|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
219138923|NCT04750850|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
219138924|NCT04750850|OTHER|Usual care|Usual routine as walking and activities of daily living.
219138925|NCT00286741|OTHER|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
219228821|NCT04334005|DIETARY_SUPPLEMENT|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
219717338|NCT01294813|DEVICE|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
219717339|NCT00058591|BIOLOGICAL|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
219717340|NCT01813175|OTHER|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
219717341|NCT01813175|OTHER|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
219717342|NCT01813175|OTHER|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
219138926|NCT04369807|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
219138927|NCT04038229|OTHER|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
219138928|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
219138929|NCT02093533|DRUG|Eculizumab|
219138930|NCT02057692|DRUG|LUM001|LUM001 administered orally
219551803|NCT00929019|BIOLOGICAL|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
219551804|NCT03811977|DIETARY_SUPPLEMENT|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
219551805|NCT03811977|DIETARY_SUPPLEMENT|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
219551806|NCT00235963|DRUG|Simvastatin|
219551807|NCT04506918|OTHER|IVR survey|Participants will receive an IVR survey
219551808|NCT04506918|OTHER|SMS survey|Participants will receive a SMS survey
219551809|NCT01087567|DRUG|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
219551810|NCT01087567|DRUG|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
219551811|NCT05778890|OTHER|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
219551812|NCT05778890|OTHER|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
219551813|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
219551814|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
219551815|NCT03116776|PROCEDURE|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
219551816|NCT03116776|DRUG|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
219551817|NCT04498676|OTHER|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
219138931|NCT02057692|DRUG|Placebo|Placebo administered orally
219138932|NCT00860353|DRUG|AZD2551|Single dose of oral solution.
219138933|NCT00860353|DRUG|Placebo|Single dose of oral solution
219138934|NCT06306378|DIAGNOSTIC_TEST|social memory levels and spindle levels|Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
219551818|NCT03864458|DRUG|KHK7791|oral administration
219551819|NCT03864458|DRUG|Placebo|oral administration
219551820|NCT05575245|DEVICE|Drug-eluting Stent|Drug-eluting Stent angioplasty
219551821|NCT05575245|DEVICE|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
219551822|NCT05339191|BEHAVIORAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
219717343|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
219717344|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
219717345|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
219717346|NCT00942851|DRUG|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
219717347|NCT00942851|DRUG|placebo|topical treatment NOT containing AH-8
219717348|NCT02157090|OTHER|Herpes Patch SOS (Hansaplast®)|
219717349|NCT02157090|OTHER|Herpes vesicle patch of Compeed®|
219717350|NCT00229801|RADIATION|MRI|
219717351|NCT02627716|PROCEDURE|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
219717352|NCT05319704|OTHER|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
219717353|NCT05319704|OTHER|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
219717354|NCT02100787|OTHER|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
219717355|NCT04937387|DRUG|FF/VI|FF/VI will be administered.
219717356|NCT04937387|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
219717357|NCT04937387|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
219138935|NCT00839046|BEHAVIORAL|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
219138936|NCT00839046|OTHER|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
219717358|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
219717359|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
219717360|NCT02708836|PROCEDURE|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
219717361|NCT02708836|DEVICE|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
219717362|NCT02708836|DEVICE|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
219717363|NCT02708836|PROCEDURE|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
219717364|NCT02708836|PROCEDURE|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
219717365|NCT02708836|PROCEDURE|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
219717366|NCT02708836|PROCEDURE|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
219717367|NCT02708836|PROCEDURE|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
219717368|NCT07119333|DEVICE|Air purifiers|Air purifiers
219717369|NCT07119333|DEVICE|Sham air purifiers|Sham air purifiers
219717370|NCT07115420|DEVICE|Fully covered self expanding metal stent (FCSEMS) within LAMS|In those randomised to FCSEMS, size will depend on the size of the LAMS with a 6mm LAMS to be stented with 8mm diameter FCSEMS and an 8mm LAMS to be stented with a 10mm FCSEMS, 4cm or 6cm length. The aim is to have at least 3cm of FCSEMS in the duodenal lumen If unable to place FCSEM through LAMS, crossover to DPS is allowed with plan for both intention to treat and per protocol analysis to be undertaken after completion of the study
219717371|NCT07115420|DEVICE|Double pigtail stent (DPS) within LAMS|In those randomised to DPS, a double pigtail will be placed through the LAMS. The size of the stents will be left to the discretion of the proceduralist though 7Fr calibre with 7cm length is the recommended size
219717372|NCT07120230|PROCEDURE|Tubeless Lung Transplantation Surgery|Patients undergoing this surgery receive lung transplantation surgery without standard tracheal intubation. Instead, they will breathe on their own using a special airway device called a laryngeal mask airway (LMA), combined with a bronchial blocker to separate lung ventilation during surgery. Sedation is maintained with intravenous medications (propofol, remifentanil, and dexmedetomidine), and participants will remain spontaneously breathing or receive minimal breathing assistance as needed. The surgical incision will be numbed using local anesthesia with lidocaine and ropivacaine injections. After surgery, the LMA will be removed in the operating room, and participants will transition directly to non-invasive breathing support before being monitored in the ICU.
219138937|NCT00839046|OTHER|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
219138938|NCT05025267|OTHER|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
219138939|NCT05753917|DEVICE|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy)
219138940|NCT04911842|DEVICE|HydroMID|Hydrophilic biomaterial
219551823|NCT02711527|OTHER|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
219551824|NCT02711527|OTHER|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
219551825|NCT02582944|DEVICE|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
219138941|NCT04911842|DEVICE|TPU|Thermoplastic polyurethane
219138942|NCT04460573|DEVICE|Boot|Smart boot in one of three configurations provided to participants
219138943|NCT04362215|DIAGNOSTIC_TEST|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
219551826|NCT02582944|DEVICE|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
219551827|NCT02582944|DEVICE|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
219551828|NCT02582944|PROCEDURE|Biopsy|
219551829|NCT01874535|DRUG|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
219551830|NCT01215721|DRUG|Vesicare|5 mg daily
219551831|NCT03949296|BEHAVIORAL|Mindfulness Intervention|"10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends"
219551832|NCT03949296|BEHAVIORAL|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine"
219551833|NCT00096655|DRUG|Infliximab|
219551834|NCT00193323|DRUG|Docetaxel|
219551835|NCT00193323|DRUG|Gemcitabine|
219551836|NCT02835755|OTHER|Educational Intervention|Receive standard HPV and HPV vaccine information
219551837|NCT02835755|OTHER|Educational Intervention|Receive mHealth HPV vaccine intervention
219551838|NCT02835755|OTHER|Survey Administration|Ancillary studies
219551839|NCT06293352|DEVICE|All-cement articulating spacer|Two-stage intervention
219551840|NCT06293352|DEVICE|Durable, real-component articulating spacer|Single stage intervention
219551841|NCT06293352|DEVICE|Rigid Spacer|Observation intervention
219551842|NCT06618638|BEHAVIORAL|Shared decision making model|Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
219551843|NCT06618638|BEHAVIORAL|Usual Care|Usual care for ADPKD patients
219551844|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
219138944|NCT04023916|DRUG|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
219138945|NCT02536430|DRUG|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
219138946|NCT02536430|DRUG|Placebo|buccal infiltration of Normal Saline.
219138947|NCT00192400|BIOLOGICAL|CAIV-T|
219138948|NCT04761237|DRUG|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
219138949|NCT04009642|OTHER|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
219717373|NCT07121686|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
219717374|NCT07121686|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care.
219717375|NCT07121322|DRUG|dornase alfa i.v. and cisplatin|Cisplatin 100mg/m2 day 1, every 3 weeks, Dornase alfa 125 microgram/kg day 1-5 i.v. push over 30 seconds±5 seconds
219717376|NCT07121634|DRUG|Misoprostol 25 µg Vaginal|The Misoprostol group (n=40) were Misoprostol cases, a synthetic PGE1 in the form of vaginal tablets of 25 µg (Vagiprost; ADWIA Co/Egypt) applied locally to the posterior fornix every 4 hours for cervical ripening before induction of labor is started (up to 3-doses).
219717377|NCT07121634|DRUG|Isosorbide Mononitrate|"The Isosorbide Mononitrate group (n=40) were nitric acid donor cases applied to the posterior fornix prior to induction of labor. Isosorbide mononitrate (IMN) (Monomack; Mack Pharmaceutics; Jordan) in a vaginal dose of 40 mg was used every 4 hours (up to 3 doses).~Women who scored a BS of \> 6 from the assigned time were labelled as (1), after the passage of 40 hours, while those women whose BS was less than 6 were labelled (0) for construction of the Kaplan Meier curve for both groups."
219717378|NCT07119216|BEHAVIORAL|Peer Mentorship|The iPeer2Peer intervention is a peer support mentorship program that will provide modelling and reinforcement by pre-screened and trained peer mentors to the mentees. The mentorship program will encourage mentees to develop and engage in self-management and transition skills and support the participants; practice of these skills. The mentors will provide information and support to mentee participants via 5-10 calls (using WhatsApp) of 20-30 minute durations and text messaging (using WhatsApp) for 12 weeks to encourage participation in self-management skill building tailored to their needs.
219717379|NCT07120334|BEHAVIORAL|PortionSize Ed + MedDiet Support|Full PortionSize Ed app access with personalized dietary feedback, educational videos, 3 virtual sessions with a registered dietitian (RDN), standard of care (for post-stroke with pre-diabetes or T2D) over 12 weeks.
219228822|NCT05070559|OTHER|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
219228823|NCT05070559|OTHER|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
219717380|NCT07120334|BEHAVIORAL|Standard of care for Stroke and Prediabetes or T2D|Uses a basic version of the PortionSize Ed app without feedback or RDN support and receives usual care for stroke recovery and prediabetes or T2D for 12 weeks.
219138950|NCT00774436|PROCEDURE|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
219138951|NCT03020108|OTHER|Blood sample|2 cc blood samples will be drawn from antecubital vein
219138952|NCT01326715|DRUG|Mangafodipir (Teslascan)|gadolinium enhancement on contrast enhanced brain MRI.
219138953|NCT03441763|DEVICE|Emed foot device|foot pressure will be measure by using emed foot pressure system
219138954|NCT04722276|OTHER|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
219228824|NCT03449771|OTHER|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
219228825|NCT05734690|DRUG|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
219228826|NCT05734690|BEHAVIORAL|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
219228827|NCT00140400|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
219228828|NCT04142255|BIOLOGICAL|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
219228829|NCT00973999|DRUG|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
219228830|NCT00968903|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
219228831|NCT02337114|BEHAVIORAL|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
219228832|NCT02337114|BEHAVIORAL|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
219228833|NCT02101138|DRUG|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
219228834|NCT00968695|DRUG|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
219228835|NCT01670474|DRUG|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
219228836|NCT01670474|DRUG|rt-PA|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
219228837|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
219228838|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
219228839|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
219228840|NCT00446368|DRUG|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
219228841|NCT01218594|DRUG|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
219228842|NCT03932214|DEVICE|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
219138955|NCT04722276|OTHER|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
219138956|NCT04399525|DRUG|Desloratadine Single Dose|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
219138957|NCT04399525|DRUG|Levocetirizine Single Dose|Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
219138958|NCT04399525|DRUG|Desloratadine Fourfold Dose|Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
219138959|NCT04399525|DRUG|Levocetirizine Fourfold Dose|Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
219138960|NCT06343584|OTHER|Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale.|Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours (Appendix B) and Group 2 will receive a work-issued smartphone with instructions for use (Appendix C). Both groups will use a pre-post test format designed to compare the outcomes between the two groups. Post-study analysis will compare pre- and post-tests within each group and will compare Group 1 and Group 2 post-intervention outcomes.
219138961|NCT05242926|DRUG|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
219138962|NCT02228811|DRUG|DCC-2701 tablet|
219138963|NCT04527614|DIAGNOSTIC_TEST|qRT-PCR and serology|qRT-PCR and serology
219138964|NCT02303769|DRUG|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
219138965|NCT02303769|DRUG|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
219138966|NCT05532813|DRUG|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
219138967|NCT00864682|DRUG|Saline|3.3 mL normal saline
219138968|NCT00864682|DRUG|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
219138969|NCT00864682|DRUG|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
219138970|NCT00545844|DRUG|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
219717381|NCT07121673|BEHAVIORAL|Dental appointment message|Patients receive a WhatsApp message offering a preventive dental check-up for $19,990.
219717382|NCT07121673|BEHAVIORAL|Dental appointment message with price discount|Patients receive a WhatsApp message offering a preventive dental check-up for $990.
219717383|NCT07121673|BEHAVIORAL|Bundling frame|The message includes language indicating they can schedule the dental appointment on the same day as their upcoming medical appointment to save time.
219717384|NCT07122960|OTHER|Visual ICF|This visual ICF fully represents all the content of the standard, text-only ICF using cartoon characters, graphics and easy text.
219717385|NCT07122960|OTHER|Text-only ICF|Text-only ICF
219717386|NCT07120711|PROCEDURE|EGR2/NLRP3 pathway activity|"Peripheral blood collection \& PBMC isolation:~Children: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG.~Collected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14/CD16, HLA-DR, CD11b, CD80/CD86, CD163/CD206.~RNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum/plasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays~Saliva sampling \& processing:~2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C."
219717387|NCT07120711|PROCEDURE|fatty tissue|"Subcutaneous fat biopsy (adults undergoing surgery):~100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers"
219717388|NCT07119528|OTHER|AF application enhancing AF education|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
219717389|NCT07119528|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
219717390|NCT07122089|DEVICE|Selective Internal Radiotherapy|SIRT will use Yttrium-90 glass-microspheres (TheraSphereTM). SIRT needs two steps: the treatment simulation (diagnostic angiography and scintigraphy of hepatic perfusion with 99mTc-MAA) and the administration (during a therapeutic angiography).
219717391|NCT07122089|DRUG|Tremelimumab|Tremelimumab should be done 1 to 3 weeks after SIRT and is administrated according to the Summary of Product Characteristic (SPC).
219717392|NCT07122089|DRUG|Durvalumab|After the end of the tremelimumab infusion, patient receive durvalumab then one injection every 4 weeks until further progression upon investigator decision. Also administrated according to the Summary of Product Characteristic (SPC).
219138971|NCT00957658|DEVICE|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
219138972|NCT04146818|BEHAVIORAL|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
219138973|NCT04146818|BEHAVIORAL|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
219138974|NCT03662048|BEHAVIORAL|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
219138975|NCT00714558|DRUG|Fentanyl citrate; Naltrexone; Naloxone|
219138976|NCT03321539|DRUG|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
219228843|NCT02955966|DEVICE|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
219138977|NCT03321539|DRUG|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
219138978|NCT04455009|DIETARY_SUPPLEMENT|Fitness Drink Formula|Single drink provided following baseline assessments
219138979|NCT06118229|DEVICE|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
219138980|NCT00975806|DRUG|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
219138981|NCT00975806|DRUG|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
219717393|NCT07113600|OTHER|Nerve Block|"Ilioinguinal/ Iliohypogastric nerve block:~In the supine position, the ultrasound probe probe is positioned in a transverse manner, superior to the anterior superior iliac spine. The three anterior abdominal muscle layers are identified, and the two nerves are identified in the abdominal neurovascular plane.~A echogenicneedle is inserted in a medial-to-lateral direction. After negative aspiration, 5 ml saline is injected to ensure correct needle tip position then 20 ml of bupivacaine 0.25% is injected gradually close to the nerves.~Erector spinae plane block:~In a lateral position, the erector spinae is visualized about 3 cm lateral to T7-T9 spinous processes on the target side. A echogenic needle (50 mm/22 gauge) is advanced in a cephalad to caudad direction until the tip reaches the plane deep to the erector spinae muscle immediately lateral to the transverse process. A 20 ml bupivacaine 0.25% is injected gradually into this plane."
219228844|NCT02955966|BIOLOGICAL|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
219228845|NCT01597674|DRUG|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
219717394|NCT06653842|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% Rapamycin Anhydrous Gel
219717395|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
219717396|NCT06977711|DRUG|Loncastuximab|Intravenous (IV) administration 0.15 mg/kg day 1 cycles 1-2, and 0.075mg/kg day 1, cycles 3-5
219717397|NCT06977711|DRUG|Roflumilast|Oral administration of 500mcg days 1-21, cycles 1-8
219717398|NCT06977711|DRUG|Rituximab|IV administration of 375mg/m2 day 1, cycles 1-8
219717399|NCT06977711|DRUG|Cyclophosphamide|IV administration of 750mg/m2 day 1, cycles 3-8
219138982|NCT02377362|DRUG|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
219228846|NCT02562274|DIETARY_SUPPLEMENT|Placebo|Subjects are received placebo treatments once daily for 8 weeks
219228847|NCT02562274|DIETARY_SUPPLEMENT|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
219228848|NCT02562274|DIETARY_SUPPLEMENT|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
219228849|NCT06151340|OTHER|Data collection|Data collection
219228850|NCT02516709|RADIATION|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
219717400|NCT06977711|DRUG|Vincristine|IV administration 1.4mg/m2 (max 2mg) day 1, cycles 3-8
219717401|NCT06977711|DRUG|Doxorubicin|IV administration 50mg/m2 day 1, cycles 3-8
219717402|NCT06977711|DRUG|Prednisone|Oral administration 100mg/days 1-5, cycles 3-8
219717403|NCT07125963|PROCEDURE|Custom-made positioning appliance-assisted mandibular segment repositioning|A patient-specific surgical guide designed using STL-based digital planning in Blender and produced via 3D printing with biocompatible surgical resin (Formlabs SLA printer). Used to guide and stabilize the proximal mandibular segment during sagittal split ramus osteotomy.
219138983|NCT02377362|DRUG|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
219138984|NCT02377362|DRUG|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
219138985|NCT02377362|DRUG|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
219138986|NCT02377362|DRUG|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
219138987|NCT02377362|DRUG|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
219138988|NCT00409058|BEHAVIORAL|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
219138989|NCT05171998|PROCEDURE|venous blood sample|Phlebotomy procedure for a venous blood draw.
219228851|NCT05594732|BEHAVIORAL|Weak outdoor light|Stay and stare far on the balcony or under the tree
219228852|NCT05594732|BEHAVIORAL|Strong outdoor light|Stay and stare far in the sunlight
219228853|NCT01959958|OTHER|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
219228854|NCT06287957|PROCEDURE|Labrida BioClean|Debriding the tissue around the implant with Labrida Bioclean
219228855|NCT06287957|PROCEDURE|EMS Handy 3.0 Perio Premium|Debriding the tissue around the implant with Air-Flow Device
219717404|NCT07125963|PROCEDURE|Conventional Manual Positioning|The proximal mandibular segment is positioned manually by the surgeon based on visual and tactile feedback without the use of a positioning guide. This technique represents the standard method in sagittal split ramus osteotomy.
219717405|NCT07124364|BEHAVIORAL|Benson Relaxation Technique|The Benson Relaxation Technique is a structured relaxation method involving the repetition of a word, sound, or phrase while sitting quietly in a comfortable position with eyes closed, combined with passive muscle relaxation. In this study, it will be delivered in weekly 30-minute group sessions for 8 weeks by a trained instructor. Participants will be instructed to practice the technique daily at home for 10-15 minutes.
219717406|NCT07124364|BEHAVIORAL|Mindfulness-Based Stress Reduction Meditation|Mindfulness-Based Stress Reduction meditation is a practice focusing on cultivating awareness of the present moment through seated meditation and mindful breathing. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, guided by an experienced instructor. They will also be encouraged to perform daily mindfulness meditation at home for 10-15 minutes.
219717407|NCT07124364|BEHAVIORAL|Breathing Therapy|Breathing therapy consists of guided breathing exercises designed to promote relaxation, reduce stress, and improve psychological well-being by regulating breathing patterns. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, led by a trained facilitator. Daily home practice of slow deep breathing techniques for 10-15 minutes will be encouraged.
219138990|NCT04604054|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
219138991|NCT04604054|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
219717408|NCT07124208|DEVICE|Biophoton Generators|Biophoton Generators will be placed around the subject's bed and used during the night sleep during the entire study period.
219717409|NCT07125456|OTHER|Postmortem Care Teaching Simulation|"The participants in the experimental group will be administered the Informed Consent Form, Demographic Characteristics Form, Postmortem Care Knowledge Test for Nursing Students (PCKTNS), and End-of-Life and Postmortem Care Self-Efficacy Scale for Nursing Students (ELPMCSESN) prior to the theoretical education. Following the pre-tests, it is planned to provide theoretical education for approximately 4 class hours (with each class hour lasting 45 minutes). The first 2 hours of the theoretical education will cover topics related to Death and General Aspects of Death, while the remaining 2 class hours will be delivered as a PowerPoint presentation focusing on postmortem care application content.~Following the theoretical education, the experimental and control groups will be shown the Postmortem Care Skills Video. Additionally, prior to the teaching simulation for postmortem care, the experimental group will be shown the Scenario Case Video, after which the scenario prepared fo"
219717410|NCT07124936|DRUG|HDM2005|HDM2005 will be administered as an intravenous injection.
219717411|NCT07124936|DRUG|Rituximab or Rituximab biosimilar|Rituximab or Rituximab biosimilar will be administered as an intravenous injection.
219717412|NCT07124936|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous injection.
219717413|NCT07124936|DRUG|Oxaliplatin|Oxaliplatin will be administered as an intravenous injection.
219717414|NCT07124936|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous injection.
219717415|NCT07124936|DRUG|Doxorubicin|Doxorubicin will be administered as an intravenous injection.
219717416|NCT07124936|DRUG|Prednisone|Prednisone will be administered orally.
219138992|NCT04602052|PROCEDURE|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
219138993|NCT05069935|DRUG|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
219138994|NCT05069935|DRUG|Cyclophosphamide|Lympho-conditioning agent
219228856|NCT04748341|OTHER|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
219228857|NCT04748341|OTHER|Traditional Method|"The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins"
219228858|NCT00258609|DRUG|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
219228859|NCT00684242|DRUG|Lenalidomide|10 mg by mouth daily
219228860|NCT03085407|PROCEDURE|early cholecystectomy|cholecystectomy was done within 48 after admission
219138995|NCT05069935|DRUG|Fludarabine|Lympho-conditioning agent
219138996|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
219138997|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
219138998|NCT01805362|OTHER|Randomization that determine the time of treatment|
219138999|NCT01558921|OTHER|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
219139000|NCT01558921|OTHER|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
219139001|NCT01833832|DRUG|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
219139002|NCT01833832|PROCEDURE|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
219139003|NCT01833832|DRUG|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
219139004|NCT00533013|OTHER|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
219139005|NCT00533013|OTHER|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
219139006|NCT05879588|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
219139007|NCT05879588|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
219139008|NCT02139449|PROCEDURE|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
219139009|NCT02777099|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
219139010|NCT02777099|PROCEDURE|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
219139011|NCT00744393|DRUG|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
219139012|NCT00744393|DRUG|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
219139013|NCT01050569|DRUG|Nicotine Patch|21 mg
219139014|NCT01050569|OTHER|VLNC Cigarette|Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
219717417|NCT06106477|BEHAVIORAL|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
219139015|NCT01050569|OTHER|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
219139016|NCT00869037|DRUG|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
219139017|NCT00869037|DRUG|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
219139018|NCT05356312|BIOLOGICAL|Vaccination|Personalized neoantigen vaccination
219139019|NCT03525119|BIOLOGICAL|TDV|TDV SC injection
219228861|NCT03085407|PROCEDURE|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
219139020|NCT03525119|BIOLOGICAL|HAV Vaccine|HAV Vaccine IM injection.
219228862|NCT04823754|OTHER|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
219228863|NCT00692185|DRUG|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
219228864|NCT00692185|DRUG|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
219228865|NCT03510169|DEVICE|NeoVest|Negative pressure ventilation with NeoVest
219139021|NCT03525119|BIOLOGICAL|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
219139022|NCT03525119|BIOLOGICAL|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
219228866|NCT05407272|OTHER|Health Education Manual|A health education manual based on a shared model
219228867|NCT05407272|OTHER|manual|routine care
219228868|NCT05895578|DIETARY_SUPPLEMENT|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
219717418|NCT06590974|DRUG|Freeze-dried Human Protein C Concentrate|Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
219717419|NCT06986512|PROCEDURE|bronchoscopy|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF)
219717420|NCT06857344|PROCEDURE|AI Controlled General Anesthesia|During gastrointestinal endoscopy, anesthesia will be induced using ciprofol, and controlled by an AI model.
219139023|NCT03178994|DRUG|2% ketoconazole cream|2% ketoconazole cream applies twice daily
219139024|NCT03178994|DRUG|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
219139025|NCT02795650|DRUG|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
219139026|NCT02795650|DRUG|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
219139027|NCT04857346|DRUG|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
219139028|NCT00199589|DRUG|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
219139029|NCT04456348|OTHER|there is no intervention|There is no intervention
219139030|NCT01186848|DEVICE|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
219139031|NCT01186848|DEVICE|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
219717421|NCT06857344|PROCEDURE|General Anesthesia (GA)|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
219717422|NCT06855810|DRUG|Venetoclax|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in induction therapy. CAT will replace CAT+ during early intensification. Venetoclax will replace daunorubicin in interim therapy 2 and 4. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
219717423|NCT06855810|DRUG|Dasatinib|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD \<0.01% on day 46, CAT will replace CAT+ during early intensification, and patients will be continuously subjected to dasatinib combined with chemotherapy during early intensification, interim tharapy, reinduction therapy and maintenance therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
219717424|NCT06855810|DRUG|homoharringtonine|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD ≥0.01% on day 46，CAT+ will be replaced with randomized doses of homoharringtonine (HHT) during early intensification, and HHT will be administrated during reinduction therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
219717425|NCT06979921|DEVICE|Blood test|Blood test
219717426|NCT06618040|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for Caregivers (BTS-C)|The BTS-C includes 6 educational modules on different topics related to sleep health: principles of healthy sleep practices include sleep routines, the sleep environment, considerations for screen time, timing of sleep and activities surrounding sleep, expectations for healthy sleep and sleep duration. Caregivers will also receive a combination of tailored messages or prompts to explore progress, identify strategies for change, and goal setting.
219717427|NCT06123338|DRUG|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
219717428|NCT06123338|DRUG|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
219717429|NCT06123338|DRUG|Oxaliplatin|Oxaliplatin every 3 weeks, +/-7 days
219139032|NCT04551794|BEHAVIORAL|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
219139033|NCT04551794|BEHAVIORAL|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
219139034|NCT02508844|DIETARY_SUPPLEMENT|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
219139035|NCT02508844|DIETARY_SUPPLEMENT|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
219228869|NCT05895578|DIETARY_SUPPLEMENT|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
219228870|NCT05895578|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo every 12 hours for 6-months.
219139036|NCT00711919|DRUG|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
219139037|NCT00711919|DRUG|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
219139038|NCT01852019|DRUG|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
219228871|NCT00708266|DEVICE|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
219717430|NCT06123338|DRUG|Capecitabine|Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
219717431|NCT06123338|DRUG|5-Fluorouracil|5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks
219717432|NCT06123338|DRUG|Docetaxel|Docetaxel administered intravenously once every 2 weeks.
219717433|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
219717434|NCT05732818|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
219717435|NCT06603285|DRUG|Treprostinil|sc/iv continuously
219717436|NCT06998875|DRUG|Tofacitinib and Acitretin Capsules.|The same with Arms.
219717437|NCT06998875|DRUG|Acitretin Capsules.|The same with Arms.
219717438|NCT06162403|OTHER|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
219717439|NCT06364865|DEVICE|laparoscopic procedure|Not applicable, subject requiring procedure will have a laparoscopic procedure performed according to the institutions standard of care procedures. There are no clinical procedures performed on the subject as part of this registry study. Surgeon will answer questionnaires regarding use of the device upon completion of the laparoscopic procedure.
219717440|NCT06869967|PROCEDURE|Auricularis Magnus Nerve Block|Auricularis Magnus Nerve block will be performed using 5 mL of %0.5 bupivacaine
219717441|NCT06869967|PROCEDURE|Control Group|Intravenous analgesics 1 gram paracetamol, 20 mg tenoxicam, 8 mg ondansetron will be administered.
219717442|NCT06672016|DRUG|Transdermal system containing progestin|MR-130A-01 transdermal system, patch to be used for female contraception
219717443|NCT06867094|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
219717444|NCT06867094|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
219139039|NCT01852019|DRUG|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
219228872|NCT00708266|DIETARY_SUPPLEMENT|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
219228873|NCT00708266|OTHER|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
219717445|NCT05300139|OTHER|Color Doppler Ultrasound|Comparison between D90±5 and baseline CDUS
219717446|NCT06436209|BEHAVIORAL|Multitask Practice Intervention (MPI)|Multitask practice intervention (MPI) includes multiple behavioral testing sessions during which participants receive practice with multitasking two tasks using the psychological refractory period procedure.
219717447|NCT06436209|BEHAVIORAL|Single-task Practice Intervention (SPI)|Single task practice intervention (SPI) includes multiple behavioral testing sessions during which participants receive separate practice on two tasks.
219717448|NCT05419024|OTHER|Acute Treatment Interruption|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
219717449|NCT03485794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219717450|NCT03485794|OTHER|Laboratory Biomarker Analysis|Correlative studies
219717451|NCT06874933|DRUG|Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart|"Group A: Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by nab-paclitaxel + Benmelstobart administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is simultaneously combined. It is taken orally once a day, before breakfast. Take the medicine continuously for two weeks, then stop taking it for one week. One cycle is 21 days, and there are a total of 3 cycles.~Group B: Nab-paclitaxel + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by Epirubicin + cyclophosphamide + Benmelstobart, which are administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is also used in combination. It should be taken orally once a day before breakfast, continuously for two weeks, then stop taking it for one week."
219717452|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
219717453|NCT07021027|DRUG|Whole Egg - 4|Participants will be asked to consume 4 medium Eggland's Best eggs per day for 5 months.
219717454|NCT07021027|DRUG|Whole Egg - 2|Participants will be asked to consume 2 medium Eggland's Best eggs per day for 5 months.
219717455|NCT07014826|DRUG|HRS-5965|HRS-5965
219717456|NCT07014826|DRUG|Placebo|Placebo
219139040|NCT03966794|DEVICE|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
219139041|NCT03966794|COMBINATION_PRODUCT|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
219228874|NCT00452114|DEVICE|In-Exsufflator Cough Assist Device|
219228875|NCT00452114|DEVICE|Active Comparator: Flutter Valve Device|Active Comparator
219228876|NCT06156176|OTHER|COVIDEx|The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
219139042|NCT04283825|BEHAVIORAL|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
219139043|NCT05322824|DRUG|standard medical treatment|standard medical treatment
219139044|NCT05322824|PROCEDURE|Interventional stenting|Interventional stenting
219139045|NCT04061902|OTHER|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
219139046|NCT00208507|DEVICE|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
219139047|NCT00208507|DEVICE|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
219139048|NCT04935749|DEVICE|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
219139049|NCT02903836|DRUG|Nafithromycin 800 mg 3 days|
219139050|NCT02903836|DRUG|Nafithromycin 800 mg 5 days|
219139051|NCT02903836|DRUG|Moxifloxacin 400 mg|
219139052|NCT00756743|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
219139053|NCT00756743|DRUG|Placebo|Placebo capsules q12 hours for 10 days
219139054|NCT03465345|DRUG|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
219139055|NCT03465345|DRUG|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
219139056|NCT05329454|DRUG|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
219228877|NCT00848289|BEHAVIORAL|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
219717457|NCT07021794|DRUG|Placebo|A single dose of placebo (saline) indistinguishable from the active drug in appearance
219139057|NCT04593719|OTHER|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
219139058|NCT02786602|GENETIC|pyrosequencing|
219139059|NCT01183780|BIOLOGICAL|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
219139060|NCT01183780|BIOLOGICAL|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
219139061|NCT01183780|DRUG|Irinotecan|180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
219717458|NCT07021794|BIOLOGICAL|Sipavibart|A single intramuscular dose of Sipavibart, 300 mg
219139062|NCT01183780|DRUG|Folinic Acid|400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
219717459|NCT07023081|BIOLOGICAL|20vPnC|20vPnC vaccine
219717460|NCT06686121|BEHAVIORAL|Home Based Exercise|This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention
219717461|NCT06686121|DRUG|Nitrate Rich Beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.
219717462|NCT06686121|BEHAVIORAL|Attention Control|"Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D."
219717463|NCT06686121|DRUG|Placebo Beetroot Juice Without Nitrate|Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
219139063|NCT01183780|DRUG|5-Fluorouracil|400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
219139064|NCT00002995|BIOLOGICAL|dactinomycin|
219139065|NCT00002995|BIOLOGICAL|filgrastim|
219139066|NCT00002995|BIOLOGICAL|sargramostim|
219139067|NCT00002995|DRUG|cyclophosphamide|
219139068|NCT00002995|DRUG|vincristine sulfate|
219139069|NCT00002995|RADIATION|radiation therapy|
219139070|NCT00092716|DRUG|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
219139071|NCT00092716|DRUG|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
219139072|NCT00982033|DRUG|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
219139073|NCT00982033|DRUG|placebo|placebo qd for 24 weeks
219139074|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
219139075|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
219139076|NCT04875130|DIAGNOSTIC_TEST|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
219139077|NCT04760119|PROCEDURE|Vein bypass surgery first strategy|Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
219139078|NCT04760119|PROCEDURE|Endovascular treatment first (drug coated balloon angioplasty) strategy|Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
219139079|NCT01872819|OTHER|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
219139080|NCT01872819|DRUG|chemotherapy|Patients receive 1 of 160 possible interventions
219139081|NCT01872819|BIOLOGICAL|biological therapy|Patients receive 1 of 160 possible interventions
219228878|NCT06988774|PROCEDURE|chromopertubation|Pre- and post-myomectomy chromopertubation procedure using dilute methylene blue dye solution for evaluation of tubal occlusion
219139082|NCT05112861|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
219139083|NCT03335969|DEVICE|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
219139084|NCT02148133|DRUG|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
219228879|NCT06992076|DRUG|Marstacimab|the first visit (V1) is scheduled on the day of the first administration of marstacimab. The recommended dosing frequency for the patient should follow the instructions provided, which are as follows: On Day 1, administer 300 mg subcutaneously (divided into two injections, each 150 mg) (loading dose); starting from Day 8, administer 150 mg subcutaneously once a week. Record the patient's prescription recommendations, actual treatment records (administration time, dosage, frequency), and adherence rates. Visit 2 (V2) and visit 3 (V3) are defined as 30 days (±7 days) and 180 days (±30 days) after the initiation of marstacimab treatment, respectively.
219139085|NCT02148133|DRUG|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
219139086|NCT05241119|PROCEDURE|SLNB|undergo fluorescence SLNB.
219139087|NCT05241119|PROCEDURE|pALND|undergo low axillary lymph node dissection with ICBN as the boundary
219139088|NCT05241119|PROCEDURE|ALND|undergo ALND
219139089|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
219139090|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
219139091|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
219139092|NCT01595854|DRUG|dabigatran etexilate|low dose dabigatran
219139093|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
219139094|NCT03337568|PROCEDURE|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
219139095|NCT01505946|OTHER|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
219139096|NCT03829267|BEHAVIORAL|eFIT Intervention|eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
219139097|NCT03829267|BEHAVIORAL|eJournal Intervention|1-hour online each week engaged in an active journaling activity
219139098|NCT03829267|BEHAVIORAL|Treatment as usual|Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
219139099|NCT00079183|DRUG|sirolimus|Given PO
219139100|NCT06226636|OTHER|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
219139101|NCT00325923|BEHAVIORAL|Decision aid|
219139102|NCT05977933|DEVICE|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
219139103|NCT00202969|DRUG|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
219139104|NCT00202969|DRUG|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
219139105|NCT00202969|DRUG|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
219139106|NCT04352582|OTHER|Survey|Survey
219139107|NCT01597154|BEHAVIORAL|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
219139108|NCT02959658|DRUG|Dimethyl fumarate|
219139109|NCT02959658|DRUG|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
219717464|NCT06686784|BEHAVIORAL|After School Plus|"The afterschool program as usual runs M-H and consists of a variety of clubs from which middle school students chose to enroll for a semester (\~4 months). Clubs are offered on either a M/W or T/H schedule. Students receive a snack in the cafeteria each day before attending their class.~Afterschool plus is the same as Afterschool as Usual with the addition of young adult mentors. Following snack, mentors will lead students in a short emotion regulation exercise including physical activity and breathing exercises. Mentors will prompt students to identify how they are feeling and make connections between the activities they are doing and their mood and then do activities with students in each class. On T/H, \~4 mentors will lead a new DiscoverU  club which is based on behavioral activation principles and spends more time helping students identify and do more activities that improve their mood. The class promotes physical activity as an important strategy for mental health."
219717465|NCT06631144|BEHAVIORAL|Spanish-language Caregiver-Enabled Care Program (CECP)|CECP is a nonmedical digital population health intervention to support and engage family caregivers of persons with dementia. CECP consists of digital content, including health education videos and tutorials, that is delivered to caregivers on a dedicated tablet based on their specific needs. Caregivers are supported by a proactive human coach who provides support, access to resources, and performs risk mitigation measures as necessary. Alerts are shared with providers and/or care management teams via a data hub that makes it easy to track, manage and resolve alerts. CECP is delivered over a 6-month period via a dedicated tablet that is shipped to the caregiver's home at no cost to the caregiver or person with dementia. This study's CECP is in Spanish.
219139110|NCT06544382|OTHER|The Long COVID Rehabilitation Intervention|The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
219139111|NCT06544382|OTHER|Usual care|A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
219139112|NCT00480766|DRUG|MK0217/Duration of Treatment : 12 Months|
219139113|NCT04701294|DEVICE|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
219717466|NCT06690346|OTHER|Systematic oral health education|Provide systematic oral health education to patients in experimental group, including oral hygiene instruction and dietary instruction
219717467|NCT06690346|OTHER|Routine oral health education|Provide routine oral health education to patients in control group, including routine oral self-care instruction
219139114|NCT04701294|DEVICE|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
219139115|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
219139116|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
219139117|NCT05001750|DRUG|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
219139118|NCT01412034|DRUG|CER-001|Biweekly infusion
219139119|NCT01569919|BIOLOGICAL|TroVax®|Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
219717468|NCT06690970|DIAGNOSTIC_TEST|68Ga/18F-PSMA/PSFA|Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.
219139120|NCT01569919|DRUG|Pemetrexed|500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
219139121|NCT01569919|DRUG|Cisplatin|75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
219139122|NCT01569919|DIETARY_SUPPLEMENT|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
219139123|NCT01569919|DIETARY_SUPPLEMENT|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
219139124|NCT01569919|DRUG|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
219139125|NCT01826695|OTHER|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
219139126|NCT01826695|OTHER|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
219139127|NCT05183906|DIAGNOSTIC_TEST|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
219139128|NCT02276820|BIOLOGICAL|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
219139129|NCT01687452|BIOLOGICAL|Blood samples|
219139130|NCT03312335|DRUG|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
219139131|NCT02573818|DEVICE|SEDASYS System|propofol sedation with the SEDASYS System
219139132|NCT02613364|BEHAVIORAL|Behavioral Intervention|Undergo yoga intervention
219139133|NCT02613364|OTHER|Cognitive Intervention|Undergo CBT-I intervention
219139134|NCT02613364|OTHER|Educational Intervention|Receive health education
219139135|NCT02613364|OTHER|Laboratory Biomarker Analysis|Correlative studies
219139136|NCT02613364|DEVICE|Monitoring Device|Correlative studies
219139137|NCT02613364|OTHER|Quality-of-Life Assessment|Ancillary studies
219228880|NCT06538090|BEHAVIORAL|Early Movers|The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
219717469|NCT01290835|RADIATION|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
219717470|NCT01290835|RADIATION|stereotactic radiotherapy|
219717471|NCT07023354|DRUG|BI 1291583|BI 1291583
219717472|NCT07023731|DRUG|ARV-806|Intravenous infusion at assigned dose and dosing schedule
219717473|NCT07023640|DIAGNOSTIC_TEST|68Ga-DOTA-mPNE|PET/CT examination was performed after intravenous injection of 68GA-DOTA-mPNE tracer
219717474|NCT07023393|DEVICE|Intraoperative spinal measurement system|The design is a prospective study to evaluate the effectiveness of a novel intraoperative spinal measurement tool to assist the surgeon with achieving preoperatively planned alignment-related parameters during surgery.
219139138|NCT00001384|DRUG|Adriamycin|
219139139|NCT00001384|DRUG|cyclophosphamide|
219139140|NCT00001384|DRUG|G-CSF|
219139141|NCT00001384|DRUG|paclitaxel|
219139142|NCT02967588|BEHAVIORAL|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
219139143|NCT05539248|DRUG|CAN106 20 mg/kg|"Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;"
219139144|NCT05539248|DRUG|CAN106 40 mg/kg|"Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；"
219139145|NCT05539248|DRUG|CAN106 80 mg/kg|"Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter."
219139146|NCT04189107|DRUG|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
219139147|NCT04189107|DRUG|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
219139148|NCT03719391|OTHER|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
219139149|NCT03719391|OTHER|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
219139150|NCT03719391|OTHER|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
219717475|NCT02244073|DRUG|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
219717476|NCT07026266|OTHER|Water|"Calcium-bicarbonate mineral water Lete"
219717477|NCT07026266|OTHER|Water|"Oligomineral water Sorgesana"
219228881|NCT06860295|DIAGNOSTIC_TEST|Single Cell RNA Sequencing|"Reprocessing~Data normalization, dimensionality reduction, and clustering will be performed using the Seurat package (based on R).~Cell types will be identified based on canonical marker gene expression. Cell Subpopulation Identification~Clusters will be annotated based on signatures of known cell types (e.g., endothelial cells, smooth muscle cells, macrophages, etc.).~Differential gene expression analysis will be conducted to identify disease-associated genes.~Pathway and Function Enrichment~Gene Set Enrichment Analysis (GSEA) and pathway analyses (e.g., KEGG, Reactome) will be carried out to investigate the biological processes and pathways driving atherosclerosis.~Quality Control~Sequencing reads will be assessed for quality using FASTQC, and low-quality reads will be filtered out.~The Cell Ranger software (10x Genomics) will be used to align reads to the human genome and quantify gene expression at the single-cell level."
219228882|NCT06616779|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal insulin algorithm is to maintain blood glucose (BG) within acceptable targets according to the predefined health status. For a limited time period after therapy start, three BG measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status. Nurses and nursing assistants will be trained in the use of the GlucoTab system.
219228883|NCT06616779|OTHER|Diabetes Treatment|Diabetes Standard Care
219228884|NCT06993155|DRUG|Leflutrozole, Dose 1|Leflutrozole, Dose 1 once weekly for 16 weeks
219228885|NCT06993155|DRUG|Leflutrozole, Dose 2|Leflutrozole, Dose 2 once weekly for 16 weeks
219228886|NCT06993155|DRUG|Leflutrozole, Dose 3|Leflutrozole, Dose 3 once weekly for 16 weeks
219228887|NCT06993155|DRUG|Placebo|Placebo once weekly for 16 weeks
219139151|NCT03719391|OTHER|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
219139152|NCT03719391|OTHER|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
219139153|NCT03719391|OTHER|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
219139154|NCT03719391|OTHER|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
219139155|NCT01846169|BEHAVIORAL|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
219139156|NCT03844854|OTHER|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
219139157|NCT04615299|DEVICE|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
219228888|NCT06861660|BEHAVIORAL|Digitally Prompted Parenting|Parents will receive an email invitation to sign up for Digitally Prompted Parenting, a text message-delivered PBI. Parents set up an account and input information about themselves and their student, which will customize the text messages they receive. Parents will receive at least two text prompts per week for the first 10 weeks of their student's first semester in college. These texts will (1) prompt parents to call their student to discuss the past week and week ahead, and (2) prompt parents to send an alcohol-specific risk reducing text to their student.
219717478|NCT06696781|PROCEDURE|Pacemaker stimulation|We deactivate the pacemaker to establish baseline measurements of NOL, bispectral index (BIS), mean arterial pressure (MAP), and heart rate (HR), recorded every minute for 5 minutes. We then adjust the pacemaker to 90 bpm and 110 bpm in subsequent 5-minute phases to assess the physiological responses. After deactivating the pacemaker to analyze washout effects, we reactivate it at 110 bpm to observe any changes. A temporary disconnection of the NOL monitor for 1 minute tests system reliability, followed by continued monitoring at the same rate for an additional 5 minutes. Each measurement phase averages data from the last 10 seconds each minute to ensure accuracy and reduce artifacts.
219717479|NCT07027488|DRUG|AB821|AB821 will be administered via IV infusion using weight-based dosing. Patients will receive the drug at a dose escalation every two weeks for up to 52 cycles.
219139158|NCT01056835|DRUG|prostaglandin I2 analogue|
219139159|NCT00371566|DRUG|Lapatinib oral tablets|
219139160|NCT00371566|DRUG|Placebo|
219139161|NCT02029664|DEVICE|Visual distortion increment based on the gait pattern|
219139162|NCT02009735|DEVICE|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
219139163|NCT02961127|OTHER|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
219717480|NCT06700070|DRUG|PBA-0111|Intratumoral microdose injection by the CIVO device.
219717481|NCT07026331|PROCEDURE|balloon angioplasty|Balloon angioplasty treatment followed by standard medical therapy post-procedure.
219139164|NCT06444386|DEVICE|MPP + SyncAV|Cardiac resynchronization therapy (CRT) features of MultiPoint Pacing (MPP) and SyncAV (dynamic atrioventricular delay programming) enabled.
219139165|NCT02375048|RADIATION|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
219139166|NCT02375048|RADIATION|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
219139167|NCT03662399|DEVICE|Insoles|Orthotic Insoles
219139168|NCT03662399|OTHER|Standard shoe|Standard shoe
219717482|NCT07026331|PROCEDURE|Stent|Patients will receive either balloon-assisted stenting or direct stenting, followed by standard medical therapy after the endovascular treatment.
219139169|NCT04534712|DIAGNOSTIC_TEST|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
219139170|NCT04630912|OTHER|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
219139171|NCT04083833|DRUG|Tetrodotoxin|A single TTX dose in a dose ascending study
219139172|NCT04083833|DRUG|Placebos|matching placebo comparator
219717483|NCT07026344|PROCEDURE|Stent placement|For patients who fail thrombectomy, perform stent placement.
219717484|NCT07026344|PROCEDURE|Continued Thrombectomy|For patients with failed thrombectomy, perform at least one additional thrombectomy attempt
219717485|NCT07026344|PROCEDURE|balloon angioplasty|For patients who fail thrombectomy, perform balloon angioplasty.
219139173|NCT04302155|OTHER|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
219139174|NCT04302155|OTHER|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
219139175|NCT04635488|PROCEDURE|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
219139176|NCT02404337|DRUG|Betaine|
219139177|NCT02457507|DIETARY_SUPPLEMENT|Vitamin B12|2 tablets
219139178|NCT02457507|DIETARY_SUPPLEMENT|Placebo|2 tablets
219139179|NCT00568542|DRUG|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
219139180|NCT00568542|DRUG|placebo|35 I.E. kg body weight placebo to erythropoetin beta
219139181|NCT05452980|PROCEDURE|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
219139182|NCT05452980|PROCEDURE|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
219139183|NCT00576888|OTHER|no intervention|no intervention - observational only
219139184|NCT00309088|DRUG|tacrolimus|oral
219139185|NCT00309088|DRUG|placebo|oral
219139186|NCT02873754|BEHAVIORAL|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
219139187|NCT02873754|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
219139188|NCT02873754|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
219139189|NCT02873754|DRUG|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
219139190|NCT02873754|DRUG|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
219139191|NCT02873754|DRUG|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
219139192|NCT03547752|OTHER|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
219139193|NCT00585455|DRUG|sertraline|open label 25-50 mg daily as tolerated
219139194|NCT02578108|PROCEDURE|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
219139195|NCT02578108|PROCEDURE|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
219139196|NCT00506181|DRUG|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
219139197|NCT00506181|DRUG|Placebo|
219139198|NCT00197886|DRUG|Changing dose of norepinephrine and blood pressure|
219139199|NCT00972504|DRUG|GSK835726 10mg|GSK835726 10mg tablet
219139200|NCT00972504|DRUG|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
219139201|NCT00972504|DRUG|Cetirizine 10mg|Cetirizine 10mg active comparator
219139202|NCT00972504|DRUG|placebo|placebo to match actives
219139203|NCT04094155|DIAGNOSTIC_TEST|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
219717486|NCT07032597|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or Deep Dermal or Supraperiosteal Injection
219717487|NCT07032597|DEVICE|Restylane® Perlane® Lidocaine|Subcutaneous to Supraperiosteal Implantation Injection
219139204|NCT00732368|DRUG|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
219139205|NCT06252727|DRUG|Aminolevulinic Acid|Given PO
219139206|NCT05112718|BIOLOGICAL|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
219139207|NCT05112718|OTHER|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
219139208|NCT00410124|DRUG|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
219717488|NCT07033663|DRUG|Monoclonal antibody|non-intervention. Drug used in clinical practice as per practitioner decision
219717489|NCT06711991|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor
219717490|NCT06711991|DRUG|TQC3927 powder for inhalation placebo|A placebo without drug substance.
219717491|NCT06712641|DRUG|Gentamicin + narrow spectrum betalactam|Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
219717492|NCT06712641|DRUG|Cefotaxime|Empirical therapy for suspected community-acquired sepsis with cefotaxime
219717493|NCT06712641|DRUG|Piperacillin-tazobactam|Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
219139209|NCT00410124|DRUG|Placebo|
219139210|NCT01184235|DRUG|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
219139211|NCT02955524|DRUG|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
219139212|NCT02955524|DRUG|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
219139213|NCT01800513|PROCEDURE|Endometrial Biopsy|
219139214|NCT01800513|PROCEDURE|Sham Procedure|
219139215|NCT04473586|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
219139216|NCT01377129|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
219139217|NCT01377129|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
219139218|NCT05998005|BEHAVIORAL|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
219139219|NCT04580199|PROCEDURE|thyroidectomy|to excise the thyroid gland
219139220|NCT04467788|OTHER|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
219139221|NCT04467788|OTHER|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
219139222|NCT01787773|DEVICE|Veniti Inferior Vena Cava Filter|
219139223|NCT04275778|DRUG|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
219139224|NCT04275778|DRUG|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
219139225|NCT04382365|OTHER|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
219139226|NCT03636867|OTHER|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
219139227|NCT00362726|DRUG|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
219139228|NCT00362726|DRUG|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
219139229|NCT00362726|DRUG|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
219139230|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
219139231|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
219717494|NCT06710509|BEHAVIORAL|Three Messaging Nudges|Patients in the Experimental Condition will receive a set of up to three email and text messages over the course of five days, while also receiving usual care which could include messaging from their practice or the electronic health record.
219717495|NCT07114133|OTHER|Environmental Probiotic Spray Intervention|The probiotic strains include Bacillus subtilis YHX001J, Bacillus amyloliquefaciens YHX002J, and Bacillus velezensis YHX003J
219139232|NCT01527253|OTHER|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
219228889|NCT06861660|BEHAVIORAL|Active Control|Parents will receive an email that explains the Parent Handbook intervention and includes a link to a website where the Handbook is embedded. They will also receive three booster emails summarizing the key points of the intervention. Parents can review both the Parent Handbook and the booster emails at their own pace.
219139233|NCT03951207|DRUG|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
219139234|NCT03951207|DRUG|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
219139235|NCT03951207|DRUG|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
219139236|NCT02533713|DEVICE|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
219228890|NCT07004179|BEHAVIORAL|Implementation strategy developed using the Implementation Mapping model to enhance the effective integration of the Protocol for Assistance to People with Diabetic Foot|"The intervention will be based on the Implementation Mapping methodology (IM). This model is based on the Intervention Mapping. IM consists of several specific tasks:~1. Conduct an assessment of needs and identification of programme adopters and implementers through a review of qualitative or mixed studies assessing the perceptions of both patients and professionals regarding DF prevention as well as individual semi-structured interviews with patients, health professionals and management staff~2. Indicate adoption and implementation outcomes and action objectives, identifying determinants and create matrices of change; this process will allow for the identification of determinants, which are those factors that influence the actions will be implemented~3. Select theoretical methods and select or design implementation strategies using the ERIC model (Expert Recommendations for Implementing Change)~4. Produce implementation protocols and materials~5. Evaluate implementation results"
219228891|NCT07004179|OTHER|Sham Comparator|Usual care: No systematic implementation of the protocol based on the prevention of foot at risk, ulcer treatment and screening of the risk of diabetic foot ulcer for referral to hospital care.
219228892|NCT07008014|OTHER|Magnetic Resonance Imaging|Participants will receive an additional MRI image in addition to standard of care to investigate if it was a useful imaging modality for their condition
219228893|NCT06067763|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
219228894|NCT06067763|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
219228895|NCT06067763|OTHER|The Weight of the Nation|This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
219717496|NCT07114133|OTHER|Purified water spray (containing no active ingredients) as the placebo control|Purified water spray
219717497|NCT07119164|OTHER|Laughter yoga|Laughter yoga is a mind-body practice that combines unconditional laughter with yogic breathing techniques (known as pranayama). Developed by Dr. Madan Kataria in 1995, the practice is based on the principle that voluntary laughter can provide similar physiological and psychological benefits as spontaneous laughter. It is typically conducted in group sessions involving eye contact, playful behavior, and laughter exercises, which aim to reduce stress, enhance mood, and promote overall well-being.
219717498|NCT07120867|DIAGNOSTIC_TEST|Pleural manometry|Pleural manometry will be performed during the first thoracentesis using a water column connected to the pleural drainage system. Pleural pressure will be measured at baseline and at intervals during fluid removal to evaluate lung expandability. The water column manometer allows estimation of pressure changes in real time. Based on the pressure curve and indicators of non-expandable lung (such as early pressure drop, plateauing, or sustained negative pressures), the treatment plan will be adapted. If adequate lung re-expansion is observed, pleurodesis will be considered. If the pressure pattern suggests a non-expandable lung, pleurodesis will be avoided due to the high risk of failure, and a tunneled pleural catheter will be recommended instead.
219717499|NCT07124039|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the EHR data from the Tianjin Healthcare and Medical Big Data Platform (China) database.
219717500|NCT07125729|PROCEDURE|Biospecimen Collection|Undergo archival tissue and/or blood sample collection
219228896|NCT07012980|DRUG|Glofitamab|Glofitamab will be administered i.v. on a step-up dosing schedule starting on Day 8 of Cycle 1 (2.5 mg), Day 15 of Cycle 1 (10 mg), followed by 30 mg on Day 1 of Cycles 2-6, with each cycle being 21 days. A single dose of obinutuzumab 1000 mg will be administered intravenously on Day 1 of Cycle 1.
219717501|NCT07125729|OTHER|cfDNA or ctDNA Measurement|Undergo Haystack MRD and Signatera ctDNA/cfDNA testing
219717502|NCT07125729|OTHER|Electronic Health Record Review|Ancillary studies
219717503|NCT07125404|RADIATION|Low-level laser auriculotherapy (LLLT-AT)|Low-Level Laser Auriculotherapy (LLLT-AT) is a non-invasive, painless treatment that applies infrared laser (class IIIb, 905 nm) to specific auricular acupuncture points. It aims to reduce musculoskeletal pain and anxiety by stimulating mitochondrial cytochrome c oxidase, increasing ATP production, promoting tissue repair, and modulating inflammation. LLLT also reduces nerve excitability and triggers β-endorphin release, aiding in pain control. Auricular stimulation may influence autonomic nervous system activity, impacting both physical and emotional symptoms. The intervention consists of two sessions per week over three weeks, following standard laser safety procedures.
219717504|NCT07125404|OTHER|Sham Low-level laser auriculotherapy (sham LLLT-AT)|Sham LLLT-AT replicates the active procedure using the same laser device and parameters, but without light emission. The probe will be deactivated and applied to the same auricular points twice weekly for three weeks. As LLLT is painless and athermal, participants are unlikely to distinguish the sham condition. Standard safety protocols will be maintained.
219139237|NCT04719377|DEVICE|catheter placement|catheter placement
219139238|NCT06521892|BEHAVIORAL|social surveillance and health education interventions|"Social surveillance: In the intervention group retail pharmacies posted or hung signs antibiotics need to be purchased by prescription, if found without prescription sales, welcome to call 12315 hotline to report, to form social supervision intervention.~Health education: On-site training for retail pharmacy staff, inviting respiratory physicians and pediatricians to give health education lectures on disease diagnosis, treatment and medication."
219139239|NCT00812526|PROCEDURE|Suction cup application|
219139240|NCT00812526|PROCEDURE|Squatting|
219139241|NCT00188604|DRUG|sodium selenite|
219139242|NCT01245452|DRUG|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
219139243|NCT01245452|DRUG|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
219139244|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
219139245|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
219717505|NCT07125404|OTHER|Myofascial release|Myofascial release is a manual therapy applied bilaterally to the masseter and temporalis muscles as a baseline intervention. Each session includes 1 minute of ischemic pressure, 1 minute of myofascial release, 30 seconds of positional release, and 30 seconds of general mobilization per muscle. The protocol consists of two sessions per week for three weeks (six sessions total), aiming to reduce muscle tension and improve mandibular function.
219717506|NCT06712914|DEVICE|MagPro X100 by MagVenture|Participants will receive 5 session per day of TBS for 6 days (30 sessions total). Six treatment days have to occur within a 2 week period. Each session will be comprised of 1800 pulses, using a MagVenture MagPro X100.
219139246|NCT02807493|DEVICE|Occlusal Support Device|Bite plate
219139247|NCT02807493|OTHER|Control|Control group
219139248|NCT02590913|DIETARY_SUPPLEMENT|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
219139249|NCT02590913|DIETARY_SUPPLEMENT|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
219139250|NCT05437783|DRUG|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
219139251|NCT03441048|BIOLOGICAL|Lintuzumab-Ac-225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
219139252|NCT03441048|DRUG|Cladribine|Cladribine is a purine antimetabolite.
219139253|NCT03441048|DRUG|Cytarabine|Cytarabine is an antineoplastic anti-metabolite.
219139254|NCT03441048|DRUG|Mitoxantrone|Mitoxantrone is an anthracenedione antineoplastic agent.
219139255|NCT03441048|DRUG|G-CSF|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
219139256|NCT01720719|DRUG|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
219139257|NCT01720719|DRUG|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
219139258|NCT03417843|DEVICE|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
219139259|NCT03526120|OTHER|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
219139260|NCT01203553|PROCEDURE|Abdominal surgery|Intraoperative mesh implantation
219139261|NCT00541697|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
219139262|NCT00541697|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
219139263|NCT03103412|DRUG|TD-3504|TD-3504
219139264|NCT03103412|DRUG|15N2-tofacitinib|15N2-tofacitinib
219139265|NCT03103412|DRUG|Placebo|Placebo
219139266|NCT02250716|PROCEDURE|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
219139267|NCT02621593|DEVICE|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
219139268|NCT04397172|PROCEDURE|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial function testing~* Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial functions testing~* Neurophysiological examination (MVRC recording)~* Day 10 only: Extended neurophysiological examination according to diagnostic criteria~* Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~* Clinical examination~* Grading of muscle strength (MRC)~* Modified Rankin Scale (mRS)~* Barthel Scale~* Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
219139269|NCT05172154|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
219139270|NCT03611530|DEVICE|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
219139271|NCT03611530|OTHER|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
219139272|NCT04990219|DRUG|Lu AG06466|Lu AG06466 - capsule
219228897|NCT07012980|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin (1.8 mg/kg) will be administered intravenously on Day 2 of Cycle 1 and on Day 1 of the subsequent Cycle 2-6 (each Q3W).
219139273|NCT04990219|DRUG|Placebo|Placebo - capsule
219139274|NCT05602909|DEVICE|Guided biaxial alveolar distraction device|A crestal incision will be done, a surgical guide will be placed to assist the correct position of osteotomy, an Extraosseous alveolar distractor will be placed on the ridge to mark screw sites and then will be removed, A distractor will be stabilized to the basal segment with a monocortical screw.
219139275|NCT05365529|BEHAVIORAL|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
219228898|NCT07012980|DRUG|Zanubrutinib|Zanubrutinib (160mg bid p.o.) will be administered for 7 days as pretreatment and from D1 to D21 through all 12 cycles Q3W.
219228899|NCT07012460|DEVICE|CTI ablation|CTI ablation will be performed with PFA. Before ablation, The RA geometry will be created with a multipolar catheter. Coronary angiogram will be performed at baseline in LAO 45 degree before and after each set of ablations. After ablation, a 15-minute waiting period will be mandated. The CTI block will be rechecked with 3D mapping system and multipolar catheter. If there is persistent CTI conduction, ablation will be repeated until CTI block is achieved. This will be followed by another 15 minutes of waiting period before rechecking the block across CTI, and so on. TNG will be prepared. It will be given via intracoronary route in 100-200mcg bolus if severe spasm is observed. If CTI block cannot be achieved with repeated PFA ablation, ablation with radiofrequency will be allowed to achieve block. Patient will come back for follow up at 3 months for a remapping procedure. During the remapping procedure, a RCA coronary angiogram will be performed to exclude late coronary damage.
219228900|NCT07012304|DRUG|Gecacitinib Hydrochloride Tablets|Gecacitinib hydrochloride tablets are taken orally on an empty stomach. The starting dose is 50 mg once daily (QD). The maximum dose is 100 mg twice daily (BID), and the minimum dose is 50 mg every other day (QOD). Dose adjustments should be made in 50-mg increments or decrements.
219228901|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
219228902|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
219228903|NCT07013955|DRUG|Saline|Group I (Group C): (control group) Patients in this group will receive only 5 ml of intranasal saline.
219228904|NCT07013955|DRUG|Dexmedetomidine|Group II (Group D): Patients in this group will receive only intranasal Dexmedetomidine (1 mcg/kg) made up to 5 ml in normal saline.
219139276|NCT05365529|BEHAVIORAL|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
219139277|NCT00819442|PROCEDURE|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
219139278|NCT04463524|DEVICE|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
219139279|NCT00811057|DRUG|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
219139280|NCT00811057|DRUG|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
219228905|NCT07013955|DRUG|Midazolam|Group III (Group M): Patients in this group will receive only intranasal midazolam (0.2 mg/kg) made up to 5 ml in normal saline.
219228906|NCT07013955|DRUG|Bupivacaine|Group IV (Group B): Patients in this group will receive only intranasal bupivacaine (0.5% solution) 5 ml.
219228907|NCT07012837|DRUG|Placebo|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
219228908|NCT07012837|DRUG|Desmopresin|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
219228909|NCT07013370|BIOLOGICAL|Anti-CMV immunoglobulins [Megalotect (R)]|Children received an anti-CMV immunoglobulin to prevent viral infections
219717507|NCT07036666|DIETARY_SUPPLEMENT|Active Product|Women's (vaginal) Health Active Product
219139281|NCT00811057|DRUG|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
219139282|NCT05061524|DRUG|YH35324|Subcutaneous injection of YH35324
219139283|NCT05061524|DRUG|Placebo|Subcutaneous injection of None of active ingredient
219139284|NCT05061524|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
219139285|NCT06409988|OTHER|Safe discharge|There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
219139286|NCT04263545|BEHAVIORAL|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
219139287|NCT04263545|BEHAVIORAL|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
219139288|NCT03699488|BEHAVIORAL|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
219139289|NCT02885311|BEHAVIORAL|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
219717508|NCT07036406|BEHAVIORAL|Semantic Feature Analysis (traditional)|This treatment involves naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc.), and creating sentences using the objects' names. It does not include direct metacognitive strategy training.
219717509|NCT07036406|BEHAVIORAL|Semantic Feature Analysis + Metacognitive Strategy Training|This treatment involves metacognitive teaching and practice, naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc), creating sentences using the objects' names, debriefing on overall performance, and discussing recent and future opportunities for strategy implementation in real life.
219717510|NCT07122440|OTHER|acute mastoiditis|retrospective data collection from clinical charts
219139290|NCT02885311|BEHAVIORAL|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
219139291|NCT02885311|DRUG|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
219139292|NCT02885311|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
219139293|NCT02885311|OTHER|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
219139294|NCT00768651|DRUG|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
219139295|NCT00768651|DRUG|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
219139296|NCT02444013|DRUG|Folic acid|
219139297|NCT02444013|DRUG|Placebo|
219139298|NCT00515450|BIOLOGICAL|GB-0998 (Intravenous immunoglobulin)|
219139299|NCT00515450|PROCEDURE|Plasmapheresis|
219139300|NCT03799380|DIETARY_SUPPLEMENT|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
219139301|NCT03799380|DIETARY_SUPPLEMENT|Standard of care nutritional support|Standard of care nutritional support
219139302|NCT03766711|OTHER|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
219139303|NCT06272162|RADIATION|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
219139304|NCT05134025|OTHER|Pump settings|Alteration in the pump setting prior to exercise commencement
219139305|NCT04367376|OTHER|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
219139306|NCT04367376|OTHER|manual therapy|manual therapy
219228910|NCT06866678|PROCEDURE|Observational Data Collection|No intervention will be performed as part of this study. This is an observational study; all patients will receive standard perioperative care according to current clinical practice. The study will only observe and record data related to frailty status and postoperative outcomes in patients undergoing elective colorectal cancer surgery. No experimental procedures, drugs, or additional interventions will be administered.
219139307|NCT04367376|OTHER|instrumental manual therapy|instrumental manual therapy
219139308|NCT02156609|DEVICE|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
219139309|NCT05027178|OTHER|Chiropractic Care|Chiropractic care on stroke participants
219228911|NCT07012681|OTHER|discharge training (oral and written brochure)|The group that received oral and written brochure training during discharge training
219228912|NCT07012681|OTHER|discharge education (oral education)|group receiving oral training in discharge training
219228913|NCT07025018|DRUG|HMPL-306|IDH small molecule inhibitor
219228914|NCT06699992|DIAGNOSTIC_TEST|Blood biomarkers quantification|Blood biomarkers quantification
219228915|NCT06698419|DEVICE|RADA16 gel application into mastoid cavity|A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.
219717511|NCT07114575|OTHER|Gait Analysis|All participants will undergo gait analysis at three different walking speeds.
219717512|NCT07122336|PROCEDURE|PVI|PVI
219717513|NCT07122336|PROCEDURE|PWI|PWI
219717514|NCT07122336|PROCEDURE|EGM|EGM
219717515|NCT07123636|DIETARY_SUPPLEMENT|Hair Care Products|"Daily oral intake of 2 tablets (Not Today, Grey). Twice-daily application of 3-4 pumps of To The Root serum. Wash and Smooth used according to hair type (daily or every other day)."
219717516|NCT07124689|OTHER|Treatment outcome|Patients will be evaluated for their central sensitization scores before the injection, the pain they experienced during the injection 1 hour after the injection, their daytime and nighttime pain intensity before and 1 month after the injection, their pain thresholds for tactile sensation around the shoulder, and their pain and disability levels.
219228916|NCT06688539|DRUG|Varenicline Pill|In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
219139310|NCT03201224|DEVICE|"After Group"|
219139311|NCT06189105|OTHER|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
219139312|NCT06189105|OTHER|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
219139313|NCT04332757|OTHER|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
219139314|NCT03338218|DRUG|Volulyte 6%|Solution for infusion
219139315|NCT03338218|DRUG|Ionolyte|Solution for infusion
219139316|NCT00331162|DRUG|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
219139317|NCT00331162|DRUG|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
219139318|NCT02703740|DEVICE|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
219139319|NCT02098382|DEVICE|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
219139320|NCT01944319|DRUG|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
219139321|NCT01944319|DRUG|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
219139322|NCT01139398|DIETARY_SUPPLEMENT|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
219139323|NCT02994017|OTHER|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
219228917|NCT06688539|BEHAVIORAL|Contingency management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
219228918|NCT06688539|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
219228919|NCT06698523|BEHAVIORAL|Breathing exercise|bubble blower used as play toys to facilitate the breathing exercise
219717517|NCT07122050|DEVICE|Prizvalve® system Transcatheter valve-in-valve replacement|Transcatheter valve-in-valve replacement procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted.
219717518|NCT07123090|DRUG|Sasanlimab|Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol
219139324|NCT05450302|OTHER|PURE EP (Observational Study)|This is an observational study. No interventions involved in this study.
219139325|NCT03667248|DEVICE|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
219228920|NCT06698523|BEHAVIORAL|Deep breathing|pin wheel used as a play toy for achievement of breathing exercise
219228921|NCT06699160|DEVICE|Revision arthroplasty|Hip or knee revision surgery resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains.
219717519|NCT07123090|DRUG|Palbociclib|Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol
219717520|NCT07123090|DRUG|Axitinib|Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care
219139326|NCT05448755|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
219139327|NCT04457141|COMBINATION_PRODUCT|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
219139328|NCT00694811|BEHAVIORAL|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
219139329|NCT04374318|DRUG|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
219139330|NCT01773122|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
219717521|NCT07124481|BEHAVIORAL|Mindfulness based stress reduction|8 weekly sessions of 2.5 hour per session, face-to-face in a group consisting of maximum 15 participants, supervised by a certified mindfulness trainer
219717522|NCT07122063|DRUG|SYS6045|SYS6045, IV Q3W
219139331|NCT01773122|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
219139332|NCT01773122|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
219139333|NCT01773122|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
219139334|NCT00378677|DRUG|Cyclosporine A dry powder inhalation (Drug)|
219139335|NCT02712619|DRUG|Metformin|
219139336|NCT01264718|BEHAVIORAL|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
219139337|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
219139338|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
219139339|NCT03317535|PROCEDURE|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
219139340|NCT03317535|PROCEDURE|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
219139341|NCT03317535|PROCEDURE|Spontaneous breath|Patients will be kept spontaneous breath.
219139342|NCT03317535|PROCEDURE|Controlled ventilation|Patient will be kept with controlled ventilation.
219139343|NCT05543811|DIETARY_SUPPLEMENT|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
219139344|NCT02646592|DRUG|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
219139345|NCT02646592|DRUG|sevoflurane or propofol|
219139346|NCT02664376|OTHER|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
219551845|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
219551846|NCT05357287|DEVICE|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
219551847|NCT03790137|DRUG|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
219551848|NCT06248645|DRUG|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
219551849|NCT06248645|DRUG|Placebo|High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
219551850|NCT00570128|DRUG|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
219551851|NCT00570128|DRUG|Placebo|Liquid formulation matched to active treatment for oral administration.
219228922|NCT06698952|OTHER|Intervention Group|The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
219228923|NCT06698952|OTHER|control group|Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
219228924|NCT06698341|PROCEDURE|Blood Draw|3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
219717523|NCT07123038|OTHER|Long Term Safety Monitoring Procedures|In accordance with the schedule of assessments, participants will complete the long term safety and health questionnaire and will undergo routine physical examinations. A review will be conducted on selected adverse events, medical history, and concomitant medication use. Collection of biospecimens (blood and tissue) will be taken as appropriate at scheduled visits to monitor for delayed adverse events related to prior cell therapy.
219717524|NCT07122115|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting Education|"The intervention was an 8-week mindfulness-based childbirth and parenting education program specifically adapted for pregnant women experiencing prenatal distress. The program included weekly 120-minute online sessions combining formal mindfulness practices (such as mindful breathing, body scan, and sitting meditation), informal exercises (e.g., mindful eating, mindful walking), psychoeducation, group sharing, and guided reflections.~Participants were also asked to complete daily home practice assignments using audio recordings. The content was adapted from the Mindfulness-Based Childbirth and Parenting (MBCP) curriculum and integrated with prenatal education. The intervention was delivered by a trained instructor and tailored to meet the emotional and cognitive needs of expectant mothers."
219717525|NCT07125716|DEVICE|1 inch|1 inch suture length
219717526|NCT07125716|DEVICE|0.5 inch|0.5 inch suture length
219717527|NCT07125417|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.
219717528|NCT07125417|OTHER|Non-Antithrombotic Therapy|Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.
219717529|NCT06876909|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
219717530|NCT06704022|DIETARY_SUPPLEMENT|Oral nutritional supplement|Consumption of the oral nutritional supplement
219717531|NCT07031687|DEVICE|Active TIBS|Participants receive active TIBS targeted at the bilateral hippocampus. Stimulation parameters include a 5 Hz (Theta band) low-frequency modulation envelope, generated by two high-frequency current pairs (e.g., f1=2000 Hz, f2=2005 Hz). Peak-to-peak current intensity for each pair will be 2 mA (or 1 mA per electrode). Stimulation is delivered daily for 40 minutes, 6 days/week, for a total of 2 weeks. Individualized targeting and initial intensity optimization are guided by baseline sMRI and DTI. Real-time high-density EEG monitoring during each daily session (D2-D11) provides feedback on brain activity
219139347|NCT00598897|DRUG|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
219139348|NCT04621708|DEVICE|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
219228925|NCT07032350|OTHER|Web-based pain management support tool|The Pain Control Enhancement App (PACE-app) is a web-based tool designed to help family caregivers manage pain in persons with dementia. The app provides a brief screening to identify caregiver challenges and delivers tailored strategies, communication prompts for providers, and an educational resource library. It includes a digital pain diary for tracking daily pain, treatments, and urgent care use, with weekly reports that can be shared with healthcare providers. The app is accessible on any internet-connected device and designed for caregivers with varying levels of digital literacy.
219228926|NCT07032350|BEHAVIORAL|Usual Pain Management Care|Caregivers receive no new intervention; they manage their care recipient's pain according to standard practices. No access to the PACE-app is given during the study period.
219717532|NCT07031687|DEVICE|Sham TIBS|Participants receive sham stimulation designed to mimic the sensation of active TIBS without therapeutic output. This involves using a sham coil or a device mode with extremely low current intensity (e.g., 0.1-0.2 mA) or brief ramp-up/ramp-down sensations at the beginning and end of sessions, with no effective current delivery during the main stimulation period. The stimulation position and apparent parameters are identical to the active TIBS group to maintain blinding.
219139349|NCT04178343|RADIATION|tomotherapy|"1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
219139350|NCT04893135|OTHER|pratice physical activity|treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
219139351|NCT04910347|DRUG|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
219139352|NCT02328820|OTHER|Percutaneous coronary intervention (PCI)|For lesions with both FFR\<=0.8 and CFR\<2.0
219139353|NCT02328820|OTHER|Optimal medical therapy (OMT)|For lesions with FFR\>0.8 or CFR\>=2.0 or both
219139354|NCT00999492|DEVICE|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
219139355|NCT06049108|DRUG|[14C]-LY3871801|Administered orally
219139356|NCT05273281|PROCEDURE|Transabdominal plane block|Peripheral nerve block
219228927|NCT07039071|DEVICE|Laceback|"Lacebacks are a kind of orthodontic auxilliaries used during the initial phase of orthodontic fixed appliance treatment, especially in premolar extraction cases. They are 0.010 stainless steel ligatures tied in figure-of-8 fashion beneath the main archwires, from the canine bracket till the first molar hook of one quadrant. For this study, on the side that is randomly allocated to receive laceback, laceback will be put on both upper and lower arches (from canine bracket to 1st molar hook)."
219717533|NCT07037121|BEHAVIORAL|Whole Food Plant Based Diet Jumpstart|"Participants receive personally-tailored support by a research nutritionist during five total visits: (1)baseline visit to collect surveys on health status, current home kitchen-based habits, kitchen inventory, food preferences, and clinical measures, followed by assessing health goals, obstacles, and opportunities. At least two breakfast, three lunch, and five dinner WFPB recipes will be selected. (2) A kitchen-centered visit will target the fridge, pantries, and cabinets to assist participants in cleaning out ultra-processed junk foods. These foods will be stored in a large tote during the study. (3) The day before the intervention starts will be a grocery shopping trip to purchase the WFPB heart-healthy groceries together. (4) Intervention day 1 will focus on jumpstarting meal prep. After day 1, weekly 30-min telehealth nutrition consultations will provide additional support. (5) Clinical measures and postintervention surveys will be collected on day 29."
219717534|NCT06705933|OTHER|Core stability exercise|Lumbo-pelvic stabilizing exercises (posterior pelvic tilt, bilateral hip abduction, bilateral knee raise, bridging, hip shrugging) will be performed three times per week for eight weeks.
219139357|NCT05273281|PROCEDURE|Quadratus lumborum block|Peripheral nerve block
219139358|NCT04376814|DRUG|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
219139359|NCT04376814|DRUG|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
219139360|NCT04376814|DRUG|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
219717535|NCT06705933|OTHER|Myofascial release|The participants will receive myofascial release technique for 20 min for 3 times per week for 8 weeks.
219717536|NCT06705933|OTHER|Kinesiotaping|The participants will receive Kinesio-Taping over the sacroiliac joint and the hip region. Following a test trial of a small patch for 24 hours, they will be instructed to keep the tape on for 48 hours (it will be replaced after 48 hours) . It will be applied for 8 weeks.
219139361|NCT01895517|OTHER|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
219139362|NCT01895517|OTHER|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
219139363|NCT04349384|PROCEDURE|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
219139364|NCT03812159|DEVICE|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
219139365|NCT03476109|DRUG|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
219717537|NCT06704867|OTHER|High flow nasal cannula|Subjects undergoing endoscopic ultrasound will receive high flow nasal cannula during the procedure
219139366|NCT03476109|DRUG|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
219228928|NCT06712719|OTHER|LP then HP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP"
219228929|NCT06712719|OTHER|HP then LP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP"
219228930|NCT07043153|DIAGNOSTIC_TEST|Albumin to globulin ratio and prognostic nutritional index model|Measurement of albumin to globulin ratio and prognostic nutritional index in participants to assess disease activity in systemic lupus erythematosus patients
219717538|NCT06712355|DRUG|BNT327|Solution for intravenous infusion
219717539|NCT06712355|DRUG|Atezolizumab|Concentrate for solution for intravenous infusion
219717540|NCT06712355|DRUG|Etoposide|Solution for infusion
219717541|NCT06712355|DRUG|Carboplatin|Solution for infusion
219717542|NCT07042022|DEVICE|Development of digital defocus vision training (DDVT)|During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted VR display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.
219139367|NCT01045317|DRUG|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
219228931|NCT07042867|BIOLOGICAL|biobanking|blood draw at each time point
219228932|NCT07042867|RADIATION|low dose scan|low dose lung scan will be performed at each timepoint
219717543|NCT07041177|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219717544|NCT06882889|DEVICE|Domestic hearing aids|The domestic hearing aids used in this study are from the Bigsound brand. Using domestic hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Subsequently, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
219717545|NCT06882889|DEVICE|Imported hearing aids|The imported hearing aids used in this study are from the Phonak brand. Using imported hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Then, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
219717546|NCT06702462|DRUG|HFA-152A propellant|HFA-152A propellant is administered via oral inhalation
219717547|NCT06702462|DRUG|HFA-134A propellant|HFA-134A propellant is administered via oral inhalation
219717548|NCT06878703|DRUG|Midazolam|Continuous intravenous administration with a loading dose of 10 µg/kg over 30 min, followed by a maintenance dose (from 10 to 40 µg/kg/h)
219717549|NCT06878703|DRUG|Dexmedetomidine|Continuous intravenous administration with a loading dose of 0.05 μg/kg over 30 minutes followed by a maintenance dose (from 0.05 to 0.2 μg/kg/h)
219717550|NCT06883175|DIAGNOSTIC_TEST|FLIP|Functional Lumen Impedance Planimetry
219717551|NCT06883175|DIAGNOSTIC_TEST|HRM|HIgh Resolution Manometry
219717552|NCT06883175|OTHER|Prucalopride|Medication
219717553|NCT06717451|DEVICE|Control-IQ Technology v1.5|"Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5.~Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months."
219717554|NCT06714526|GENETIC|Point-of-Care CYP2C19 Testing|Genetic testing with the Genomadix cube to determine P2Y12 inhibitor
219717555|NCT06714526|DRUG|ticagrelor + aspirin|If patients are poor or intermediate metabolizers of clopidogrel, they will receive ticagrelor (90 mg PO BID) + aspirin (81 mg PO daily)
219717556|NCT06714526|DRUG|clopidogrel + aspirin|Normal, rapid, and ultra-rapid metabolizers of clopidogrel will receive 75 mg PO daily of clopidogrel and 81 mg PO daily of aspirin.
219717557|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
219717558|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
219717559|NCT06550882|DRUG|OBIZUR|OBIZUR injection.
219717560|NCT06886204|BEHAVIORAL|YEAH: Youth Empowered Advocating for Health|"The Youth Empowered Advocating for Health (YEAH) program is a Youth Participatory Action Research (YPAR) intervention aimed at addressing community violence by fostering youth and community healing. It combines photovoice and theater arts performances.~In photovoice sessions, Black youth explore structural determinants of community violence through a participatory research process. Guided by trained facilitators, youth learn the method after obtaining parental consent and youth assent. Using the structured SHOWED framework, they analyze and discuss images, generating ideas for social action. During the photovoice sessions, photo assignments will be completed, with discussions recorded, analyzed for themes, and shared for validation.~The final four sessions will integrate these themes into theater arts performances, allowing youth to creatively express insights and experiences, fostering empowerment and social change."
219717561|NCT06704126|OTHER|Passive movement|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes.
219717562|NCT06704126|OTHER|Passive movement with blood flow restriction|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes. During the 60 seconds on of passive movement training, blood flow restriction cuffs which will be applied to the legs, will be inflated to cause 80% arterial blood flow occlusion.
219717563|NCT05420207|OTHER|No intervention|No intervention included
219717564|NCT06719713|BEHAVIORAL|Store Safely|"The Store Safely intervention occurs online and is self-administered. Once directed to the Store Safely website, participants are welcomed and instructed to complete each step of the online program. Upon clicking Start, participants are taken to Step 1 of the intervention and instructed to review a brief video. Step 2 involves a review of a data infographics. Participants are then directed to the Decision Aid in Step 3. In Step 4, participants are instructed to complete the Family Firearm Storage Action Plan. In Step 5, participants will review another brief video. There will also be an optional step, consisting of a resource page that details local options for obtaining safe storage devices. At the end of each step, participants mark a checkbox to indicate they have completed the intervention activity which facilitates website analytics of participant engagement. Lastly, participants are thanked and provided with details about the final steps of the trial."
219717565|NCT07044674|DEVICE|UNITY Vitreoretinal Cataract System|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. It consists of a console, remote control, foot controller, video overlay, and compatible anterior segment devices. In this study, it will be used for the removal of cataracts.
219717566|NCT07044674|DEVICE|CENTURION Vision System with Active Sentry|CAS is a commercially approved surgical system for use during anterior segment ophthalmic surgery. It consists of a console, foot controller, remote control, video overlay, and compatible anterior segment devices. The Active Sentry handpiece will be used.
219228933|NCT07043712|DIETARY_SUPPLEMENT|High pulse consumption|Subjects are provided a high pulse diet for 4 weeks.collection, and anthropometrics measured.
219228934|NCT06716606|DRUG|Belimumab|Belimumab will be administered.
219228935|NCT07042828|DRUG|Bilastine oral dispersible tablets|Bilastine 20 mg oral dispersible tablets
219228936|NCT07042828|DRUG|Bilaxten oral dispersible tablets|Bilaxten 20 mg oral dispersible tablets
219228937|NCT07044141|DRUG|Azathioprine|azathioprine 50mg twice daily will be given
219228938|NCT07044141|DRUG|Tofacitinib|It is a janus kinase inhibitor
219139368|NCT04945694|OTHER|Ultrasound-guided bilateral pecto-intercostal fascial block|\- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
219139369|NCT04945694|DRUG|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
219139370|NCT04945694|DRUG|Propofol|Propofol anesthesia
219139371|NCT04945694|DRUG|Sevoflurane|Sevoflurane anesthesia
219139372|NCT04945694|DRUG|Atracurium|Intravenous atracurium
219139373|NCT04945694|DEVICE|ultrasound|ultrasound-guided block
219139374|NCT01673113|DEVICE|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
219139375|NCT06479018|BIOLOGICAL|Blood sampling|Venous blood sampling will be carried out for each patient included in the study.
219139376|NCT06479018|BIOLOGICAL|Liquid bubble sampling|Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
219139377|NCT06479018|PROCEDURE|Cutaneous biopsy|At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
219228939|NCT06410846|DEVICE|TopSpin360|Neck strength and conditioning device used during neck strengthening program.
219228940|NCT06410846|OTHER|Neck Strengthening Exercise Plan|Physical therapist designed neck strengthening program.
219228941|NCT06500988|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement a comprehensive digital atrial fibrilation guideline-recommended toolkit
219228942|NCT06547515|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
219228943|NCT07052760|DRUG|111In-ABD147|Given intravenously (IV) prior to imaging
219717567|NCT07044674|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
219139378|NCT02058914|DIETARY_SUPPLEMENT|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
219139379|NCT02058914|DIETARY_SUPPLEMENT|High Glucose sweetened beverage|HG-sweetened beverage
219139380|NCT03261661|BEHAVIORAL|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
219139381|NCT03261661|BEHAVIORAL|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
219139382|NCT03261661|BEHAVIORAL|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
219228944|NCT07052760|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Undergo imaging
219228945|NCT07052773|DEVICE|Lung Cancer Detection System (LCDS)|An AI-based decision support software designed to detect solid pulmonary nodules on LDCT chest scans. In this study, the LCDS is applied retrospectively to 100 previously acquired LDCT scans, and its performance is compared to a ground truth established by double-read radiologist reports with arbitration.
219228946|NCT07052370|DRUG|Thymoglobulin|IV
219228947|NCT07052370|DRUG|Cyclophosphamide|IV
219228948|NCT07052370|DRUG|Fludarabine|IV
219228949|NCT07052370|DRUG|Thiotepa|IV
219228950|NCT07052370|DRUG|Melphalan|IV
219228951|NCT07052370|DRUG|Mesna|IV
219228952|NCT07052370|DRUG|Filgrastim|IV
219228953|NCT07052370|DRUG|Blinatumomab|IV
219228954|NCT07052370|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
219228955|NCT07052812|BEHAVIORAL|MCT|Metacognitive Therapy (MCT) is a 12-week manualized treatment for OCD targeting maladaptive thought patterns. Clinicians deliver structured sessions including: (1) Attention Training to modify focus, (2) Detached Mindfulness to change responses to intrusive thoughts, and (3) behavioral experiments to reduce compulsions. Treatment progresses through psychoeducation, challenging perfectionism, addressing thought control, and relapse prevention. Primary outcome: Y-BOCS; secondary: MCQ-30 and TFI. Based on the evidence-based myMCT protocol.
219228956|NCT06897683|DRUG|PF-07220060|Single dose PF-07220060 tablet administered with a moderate-fat standard calorie meal
219228957|NCT06897683|DRUG|Carbamazepine ER Tablet|Carbamazepine dosing titration regimen in Period 2 from Day 1 to 18
219228958|NCT06842134|DRUG|Numeta G16%E|Numeta G16%E (1000mL) will be given intravenously via peripherally inserted central catheter and will provide an equimolar IV phosphate dose of 8.7 mmol over 9 h.
219228959|NCT06842134|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted 1000mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 8.7 mmol over 9 h.
219139383|NCT03261661|BEHAVIORAL|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
219139384|NCT06413303|BEHAVIORAL|Experiential Classroom|Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
219139385|NCT03425162|DRUG|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
219139386|NCT03425162|PROCEDURE|Group P|Group P:patient-controlled analgesia (PCA) morphine
219139387|NCT03425162|PROCEDURE|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
219139388|NCT02837237|DRUG|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
219717568|NCT07045493|DRUG|A single dose of Albendazole 400mg + Ivermectin (200 µg/ kg) combination therapy|Children will receive the medication after being randomly assigned to either treatment arm. Albendazole will be administered as a syrup and ivermectin tablets as powdered tablets because ivermectin suspension is not available in Bangladesh. The commercially available 6 mg unscored Ivermectin tablets will be crushed, the tablet fragments ground into a powder, and stored in an airtight plastic container in a dry, cool environment after all aseptic procedures. According to the weight of the children, the investigators will provide the needed amount (weighted by microgram scale) of the drug mixed with 5 ml of water. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children.
219717569|NCT07045493|DRUG|A single dose of 400 mg Oral Albendazole monotherapy|Albendazole will be given in syrup form. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children. Both drugs will be given using direct observation at the field clinic. Parents will be advised to report any adverse effects, including vomiting, after taking the medication. If vomiting occurs within one hour of medication, a redosing will be provided.
219717570|NCT06723457|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219717571|NCT06723457|PROCEDURE|Computed Tomography|Undergo PET/CT
219551852|NCT03442192|OTHER|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
219551853|NCT00032240|DEVICE|Shoe Insert|
219717572|NCT06723457|BIOLOGICAL|Epcoritamab|Given SC
219717573|NCT06723457|DRUG|Lenalidomide|Given PO
219139389|NCT01338727|BEHAVIORAL|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
219139390|NCT04181931|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
219139391|NCT04181931|PROCEDURE|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
219139392|NCT03100162|DIETARY_SUPPLEMENT|Probiotic|
219139393|NCT03100162|DIETARY_SUPPLEMENT|Placebo|
219551854|NCT01929681|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
219717574|NCT06723457|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219717575|NCT06723457|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219139394|NCT04994743|DRUG|CORT113176|CORT113176 lipid capsule formulation for oral administration
219139395|NCT04994743|DRUG|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
219139396|NCT01144182|BEHAVIORAL|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
219139397|NCT03332134|BEHAVIORAL|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
219551855|NCT06066671|OTHER|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
219139398|NCT00394381|PROCEDURE|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
219139399|NCT00841958|PROCEDURE|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
219139400|NCT02575391|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
219139401|NCT00006204|DRUG|naltrexone (Revia)|
219139402|NCT00006204|DRUG|fluoxetine (Prozac)|
219228960|NCT06762769|DRUG|Isatuximab|Subcutaneous isatuximab will be delivered using an unlicensed medical device (On Body Delivery System)
219717576|NCT07043478|OTHER|Bragg ACV Liquid|Apple Cider Vinegar
219139403|NCT00436137|BEHAVIORAL|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
219139404|NCT04274751|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
219139405|NCT06015594|DRUG|Metformin|Patients treated with metformin
219139406|NCT01624558|DEVICE|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
219139407|NCT00308958|DEVICE|High frequency chest wall oscillator|
219139408|NCT03772964|DRUG|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
219139409|NCT03772964|DRUG|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
219139410|NCT00662636|DRUG|dasatinib|Given orally
219139411|NCT00662636|DRUG|lapatinib ditosylate|Given orally
219139412|NCT00662636|OTHER|pharmacological study|Correlative study (cohort II only)
219228961|NCT06762769|DRUG|Iberdomide|Oral iberdomide
219717577|NCT07043478|OTHER|Placebo|Water
219139413|NCT00662636|OTHER|laboratory biomarker analysis|Correlative study (cohort II only)
219139414|NCT03538054|DRUG|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
219139415|NCT03538054|DRUG|Placebo|1 capsule, by mouth, twice daily every 12 hours.
219139416|NCT05547191|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
219139417|NCT03264456|DIAGNOSTIC_TEST|[18F] Fluciclovine PET/MRI|\[18F\] fluciclovine PET/MRI
219139418|NCT03264456|DRUG|[18F] fluciclovine|\[18F\] fluciclovine
219139419|NCT05128305|DRUG|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
219139420|NCT01701609|BEHAVIORAL|Cognitive Remediation Therapy|
219139421|NCT00941356|DIETARY_SUPPLEMENT|Bio-K+ CL1285|2 capsules per day before breakfast
219139422|NCT00941356|DIETARY_SUPPLEMENT|Placebo|2 capsules per day before breakfast
219139423|NCT05527483|DRUG|[68Ga]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
219139424|NCT05527483|DRUG|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
219139425|NCT05527483|DIAGNOSTIC_TEST|PET/CT|Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
219139426|NCT00798772|DIETARY_SUPPLEMENT|Micronutrients and antioxidants|8 capsules twice daily for two years
219139427|NCT00798772|DIETARY_SUPPLEMENT|Multivitamins and minerals|8 capsules twice daily for two years
219139428|NCT02078934|PROCEDURE|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
219139429|NCT05835115|DIAGNOSTIC_TEST|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
219228962|NCT06762769|DRUG|Dexamethasone|Oral dexamethasone
219228963|NCT03407079|OTHER|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
219228964|NCT03407079|OTHER|Placebo|Placebo capsules will be taken orally for 28 days
219228965|NCT05004662|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
219228966|NCT05004662|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
219228967|NCT05004662|BEHAVIORAL|Counceling|Phone counseling with the Florida Quitline
219228968|NCT05004662|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
219228969|NCT07063056|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|1 capsule per day at a usual curcumin dose for this particular product (80 mg curcumin)
219228970|NCT07063056|DIETARY_SUPPLEMENT|Half Dose Curcumin (Longvida™)|1 capsule per day at half the usual curcumin dose for this particular product (40 mg curcumin as the half dose)
219228971|NCT07063056|DIETARY_SUPPLEMENT|Astaxanthin|1 capsule per day at a usual astaxanthin dose (12 mg)
219717578|NCT06717477|PROCEDURE|Changes to the care pathway for carpal tunnel syndrome (The Carpal Tunnel Plus Pathway)|Changes to the care pathway for carpal tunnel syndrome. Features of the CTS+ pathway include new referral form, care map for mild, moderate and severe CTS established, point or care ultrasound with steroid injection introduced, and expedited referral to surgeons.
219139430|NCT02200952|DRUG|recombinant LH|recombinant LH twice/day for 10 days from pick up
219139431|NCT03132324|DRUG|INCB059872|INCB059872 tablets
219139432|NCT04991974|BEHAVIORAL|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
219139433|NCT04991974|DRUG|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
219139434|NCT03279666|OTHER|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
219139435|NCT05602155|PROCEDURE|Group 1|Even numbered patients will partial weight bearing after treatment,
219139436|NCT05602155|PROCEDURE|Group 2|patients with odd numbers will walk with full weight bearing after treatment
219139437|NCT05341518|PROCEDURE|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
219139438|NCT02672813|PROCEDURE|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
219139439|NCT03360396|DEVICE|Endobronchial Coils|Endobronchial Coil implants
219139440|NCT01991912|PROCEDURE|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
219139441|NCT06069986|PROCEDURE|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
219139442|NCT03254394|DRUG|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
219139443|NCT03254394|DRUG|Placebo|Dextrose 5% in water will be administered as active comparator.
219139444|NCT03254394|DRUG|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
219139445|NCT00076180|BIOLOGICAL|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
219139446|NCT03543839|BIOLOGICAL|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
219551856|NCT02860325|DEVICE|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
219551857|NCT02860325|DEVICE|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
219551858|NCT03111381|DRUG|Toradol|IV toradol
219139447|NCT03543839|BIOLOGICAL|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
219139448|NCT03543839|OTHER|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
219139449|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
219139450|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
219139451|NCT00350831|DRUG|XL820|
219139452|NCT05102266|DRUG|BR1016C|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
219139453|NCT05102266|DRUG|BR1016D|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
219139454|NCT02351180|DRUG|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
219139455|NCT02351180|DRUG|Placebo|Placebo will serve as a control treatment
219139456|NCT05447013|BIOLOGICAL|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
219139457|NCT05447013|OTHER|standard of care (SOC)|standard of care (SOC)
219228972|NCT07063056|OTHER|Placebo Control|Subject will get 1 capsule per day of a small amount of cellulose
219228973|NCT06758804|DEVICE|Winterized Pistacia Lentiscus Oil Nasal Drops (Bactorinol®)|Participants will receive winterized Pistacia lentiscus oil nasal drops (Bactorinol®), administered as 3 drops per nostril, three times daily for six consecutive days.
219228974|NCT06758804|DEVICE|Saline Solution (0.9% NaCl)|Participants will receive a saline solution (0.9% NaCl) administered as 3 drops per nostril, three times daily for six consecutive days.
219228975|NCT05501054|DRUG|Ipilimumab|Given by IV (vein)
219228976|NCT05501054|DRUG|Nivolumab|Given by IV (vein)
219228977|NCT05501054|DRUG|Ciforadenant|Given by PO
219551859|NCT05316636|DEVICE|Vibrational forces|
219551860|NCT05316636|PROCEDURE|Orthodontic treatment with clear aligners|
219551861|NCT04949386|DRUG|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
219551862|NCT04949386|OTHER|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
219551863|NCT01073631|DRUG|voriconazole tablet|200 mg PO bid (orally, twice a day)
219551864|NCT02171988|DRUG|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
219551865|NCT02171988|DRUG|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
219228978|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2)|"1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)"
219139458|NCT04666337|PROCEDURE|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
219228979|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)|"1\. 12 years or older~\- Single booster dose, 15/15 μg, administered after ≥3 months after primary series"
219228980|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)|"1\. 12 years or older~\- Single booster dose, 15/15 μg administered after ≥3 months after primary series"
219139459|NCT05288517|BEHAVIORAL|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
219139460|NCT02116855|OTHER|according to the efficacy of AJBRs|
219139461|NCT02930590|OTHER|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
219139462|NCT02930590|OTHER|Gel mattress|IsoGel, Stryker, USA
219139463|NCT02930590|OTHER|Basic foam|Standard hospital mattress
219139464|NCT02686554|OTHER|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
219139465|NCT04872829|DEVICE|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
219139466|NCT01071967|OTHER|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
219139467|NCT03545217|BEHAVIORAL|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
219139468|NCT03764943|DIETARY_SUPPLEMENT|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
219139469|NCT01300858|DRUG|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
219139470|NCT00001994|DRUG|Atovaquone|
219139471|NCT01556256|OTHER|Caregiver-Related Intervention or Procedure|Undergo TMV+P
219139472|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV
219139473|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV+P
219551866|NCT02171988|DRUG|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
219551867|NCT02171988|DRUG|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
219551868|NCT01260623|DRUG|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
219228981|NCT07098767|DIAGNOSTIC_TEST|ultrasound evaluation|Use high-frequency ultrasonography to assess the swallowing function in patients with dysphagia. The ultrasound examination focuses on visualization of the pharyngeal region to measure vocal cord movement, swallowing reflex, pharyngeal contraction, and the presence and location of pharyngeal residue.
219551869|NCT02278302|DRUG|Aggrenox®|
219551870|NCT02278302|DRUG|Placebo|
219551871|NCT02278302|OTHER|Ethanol|
219551872|NCT04437303|DRUG|Continuation of oral anticoagulants|Oral anticoagulant treatment will not be interrupted before the procedure.
219551873|NCT04437303|DRUG|Interruption of oral anticoagulants|"Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician."
219139474|NCT01556256|OTHER|Quality-of-Life Assessment|Ancillary studies
219139475|NCT01556256|OTHER|Questionnaire Administration|Ancillary studies
219551874|NCT04363359|BIOLOGICAL|0.5ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
219139476|NCT02095704|DRUG|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
219139477|NCT02095704|DRUG|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
219139478|NCT00673296|DRUG|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
219139479|NCT01393912|DRUG|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
219139480|NCT01123083|BIOLOGICAL|Otelixizumab|infusion
219139481|NCT01123083|BIOLOGICAL|Placebo|Infusion
219228982|NCT07098767|DIAGNOSTIC_TEST|Fiberoptic endoscopic evaluation of swallowing (FEES)|FEES involves the use of a flexible endoscope inserted through the nasal passage to observe the pharyngeal phase of swallowing directly. This procedure allows for the real-time assessment of key aspects of swallowing, including vocal cord function, swallowing reflex, pharyngeal contraction, and the detection of aspiration or penetration.
219551875|NCT04363359|BIOLOGICAL|0.25ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
219139482|NCT01117441|DRUG|PEG-L-asparaginase|see detailed protocol description
219139483|NCT01117441|DRUG|cyclophosphamide|see detailed protocol description
219139484|NCT01117441|DRUG|cytarabine|see detailed protocol description
219139485|NCT01117441|DRUG|daunorubicin hydrochloride|see detailed protocol description
219139486|NCT01117441|DRUG|dexamethasone|see detailed protocol description
219551876|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/V)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
219551877|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/Y)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
219139487|NCT01117441|DRUG|doxorubicin hydrochloride|see detailed protocol description
219139488|NCT01117441|DRUG|etoposide|see detailed protocol description
219139489|NCT01117441|DRUG|ifosfamide|see detailed protocol description
219139490|NCT01117441|DRUG|mercaptopurine|see detailed protocol description
219139491|NCT01117441|DRUG|methotrexate|see detailed protocol description
219139492|NCT01117441|DRUG|prednisone|see detailed protocol description
219139493|NCT01117441|DRUG|thioguanine|see detailed protocol description
219139494|NCT01117441|DRUG|vincristine sulfate|see detailed protocol description
219139495|NCT01117441|DRUG|vindesine|see detailed protocol description
219139496|NCT01117441|DRUG|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
219139497|NCT01117441|DRUG|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
219139498|NCT01117441|RADIATION|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
219139499|NCT02061332|BIOLOGICAL|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
219139500|NCT03418324|DRUG|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
219139501|NCT03418324|DRUG|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
219139502|NCT03418324|DRUG|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
219139503|NCT00159796|DRUG|Asenapine|Asenapine, 3 weeks
219139504|NCT00159796|DRUG|Olanzapine|Olanzapine, 3 weeks
219139505|NCT00159796|DRUG|Placebo|placebo, 3 weeks
219139506|NCT05679037|OTHER|Placebo|Inactive capsules
219139507|NCT05679037|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
219139508|NCT01751724|DRUG|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
219228983|NCT07098741|OTHER|Core stability exercises with electrotherapy|electrotherapy modalities for pain control will be used and exercises strengthening abdominal core muscles will be applied in two phases.
219228984|NCT07098741|OTHER|Soft tissue release with manual therapy and stretching|Manual soft tissue release will be performed and then stretching of back muscles and thigh muscles will be added to treatemnet.
219228985|NCT07098741|OTHER|Postural correction exercises with contrast therapy|Hot and cold packs will be used one after other for 10-15mins and specific exercises which are designed to improve posture will be taught and performed
219551878|NCT02105220|OTHER|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
219551879|NCT01528735|DRUG|BI 207127 NA|one fix dose
219551880|NCT01528735|DRUG|peginterferon|per package insert
219551881|NCT01528735|DRUG|Ribavirin|per weight BID
219551882|NCT01528735|DRUG|Ribavirin|per weight BID
219551883|NCT01528735|DRUG|BI 207127 NA|one fix dose
219551884|NCT01528735|DRUG|BI 201335 NA|high dose
219551885|NCT01528735|DRUG|BI 201335 NA|low dose
219551886|NCT01528735|DRUG|peginterferon|per package insert
219551887|NCT03354780|OTHER|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
219139509|NCT01751724|OTHER|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
219228986|NCT07098741|OTHER|combination of electrotherapy with stretching and flexibility exercises|some pain reducing electrotherapy modality like TENS will be used and general stretching and flexibility exercises will be performed
219228987|NCT07090447|BEHAVIORAL|Nutrition in Cirrhosis guide|"Patients in the intervention group received a paper copy of the Nutrition in Cirrhosis guide and were instructed to read and use it over the 6 months study period. The Nutrition in Cirrhosis guide consists 7 chapters, namely:~Chapter 1: Malnutrition - What is it and why is it so important?; Chapter 2: What should patients eat and what to avoid?; Chapter 3: Tips for when patients do not feel like eating; Chapter 4: Recipe list; Chapter 5: Using meal supplements; Chapter 6: Managing weight loss and cirrhosis; Chapter 7: What to expect in the hospital."
219228988|NCT07098221|DIETARY_SUPPLEMENT|Molecular Hydrogen|Participants in this arm will consume a single 250 mL dose of hydrogen-rich water containing approximately 1.6-2.0 ppm of dissolved molecular hydrogen (H₂), The HRW will be ingested following an overnight fast, and resting metabolism will be measured approximately 30-60 minutes post-consumption using indirect calorimetry.
219228989|NCT07098221|DIETARY_SUPPLEMENT|Placebo Comparator|Non-hydrogen-producing tablets, identical in appearance and taste to the active supplement
219551888|NCT03354780|OTHER|Survey on first pregnancy|rate of miscarriage was noted
219139510|NCT00627874|DEVICE|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
219551889|NCT03709953|DRUG|Apatinib|500 mg，po，QD； 28 days every cycle
219551890|NCT03112031|DRUG|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
219551891|NCT03112031|DRUG|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
219551892|NCT03112031|DRUG|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
219551893|NCT02161705|DRUG|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
219551894|NCT02161705|DRUG|Saline|Up to 0.8 mL/kg of normal saline administered
219551895|NCT02469480|DRUG|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
219551896|NCT02469480|DRUG|Ferro sanol|200 mg ferro sanol per day over 12 weeks
219551897|NCT01971554|DRUG|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
219551898|NCT01971554|DRUG|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
219551899|NCT01426854|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
219551900|NCT01426854|OTHER|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
219551901|NCT03803267|OTHER|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38\_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
219551902|NCT03803267|OTHER|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
219551903|NCT03803267|DRUG|Propofol|Propofol (2 mg/kg)
219551904|NCT03803267|DRUG|Fentanyl NCS|Fentanyl (1µg/Kg)
219551905|NCT03803267|DRUG|Atracurium Injectable Product|atracurium (0.5mg/kg)
219551906|NCT03803267|OTHER|Endotracheal intubation|endotracheal intubation
219551907|NCT03803267|DRUG|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
219551908|NCT03803267|DRUG|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
219139511|NCT02584153|DRUG|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
219139512|NCT02584153|DRUG|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
219228990|NCT07098364|BIOLOGICAL|Vevoctadekin|Given SC
219228991|NCT07098364|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219228992|NCT07098364|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219228993|NCT07098364|PROCEDURE|Computed Tomography|Undergo CT
219228994|NCT07098364|PROCEDURE|Echocardiography Test|Undergo ECHO
219228995|NCT07098364|PROCEDURE|Leukapheresis|Undergo leukapheresis
219228996|NCT07098364|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219228997|NCT07098364|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219228998|NCT07098364|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy
219228999|NCT07098364|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219229000|NCT07098364|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219229001|NCT07098364|PROCEDURE|X-Ray Imaging|Undergo x-ray
219229002|NCT07098364|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219229003|NCT07098299|DRUG|Metformin|Metformin will be given for 14 days alone as a run in and then added to any standard of care chemotherapy or immunotherapy for solid tumors.
219229004|NCT07098793|DEVICE|Cough monitoring|continuous recording of cough in patients sleeping area for 90-180 days
219229005|NCT07100054|GENETIC|Whole gene sequencing|Whole gene sequencing of CYP3A4 and PXR
219229006|NCT07100054|OTHER|Drug-drug interaction analysis|Evaluating potential drug interactions with CYP3A4 inhibitors and inducers
219229007|NCT07100054|OTHER|Biomarker analysis|Determination of circulating CYP3A4 mRNA, and 4b-hydroxycholesterol
219229008|NCT06247553|OTHER|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
219229009|NCT06247553|OTHER|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
219229010|NCT07100015|DEVICE|Control Group|in which patients did not receive any treatment and received routine postoperative care in the clinic
219139513|NCT06315400|DRUG|Ingavirin®|60 mg/day for 5 days
219139514|NCT06315400|DRUG|Placebo|1 capsule/day for 5 days
219229011|NCT07100015|DEVICE|therapeutic touch|Therapeutic touch applications
219229012|NCT07100015|DEVICE|Shoulder massage|shoulder massage was applied
219229013|NCT07098585|DRUG|Lisdexamfetamine capsule|Lisdexamfetamine 70 mg capsule
219229014|NCT07098585|DRUG|Elvanse® (Lisdexamfetamine dimesylate capsules, hard)|Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)
219229015|NCT07099781|DEVICE|handheld dynamometer and hand grip dynamometer|using handheld dynamometer and hand grip dynamometer to test the strength of the hand grip and lateral rotators of the shoulder
219139515|NCT03488056|OTHER|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
219229016|NCT07099976|DIAGNOSTIC_TEST|The novel care pathway intervention|The pathway uses already-ascertained data, bioMérieux Spotfire testing, and POC CRP testing to stratify patients into risk categories. The first step in the pathway will be POC CRP testing; children with CRP \> 60 mg/L will be deemed 'appreciable risk', whereas those with CRP \< 20 mg/L will be deemed 'low risk'. The CRP cut-offs of 20mg/L (more sensitive) and 60mg/L (more specific) were selected after reviewing the literature, with particular emphasis on meta-analyses; other large recent studies have also used 60mg/L as an upper cut-off for bacterial infection. Participants with CRP between 20-60mg/L will be categorized further to identify children either more likely to have bacterial pneumonia or more intolerant of misclassification. 'If they have O2 saturation \<95% AND tachypnoea as per age-specific norms, they will be 'appreciable risk' (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y).
219551909|NCT00438750|OTHER|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
219551910|NCT00438750|OTHER|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
219551911|NCT04627857|DEVICE|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
219551912|NCT04627857|DEVICE|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|\- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
219139516|NCT03488056|OTHER|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
219229017|NCT07099976|OTHER|Usual Care Alone|Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management.
219229018|NCT07099612|DEVICE|MEMS® Mobile smartphone application|The MEMS® Mobile app is a smartphone application that connects to the Cere®Pak smart blister pack via near-field communication (NFC). It allows participants to view their medication intake history, receive optional reminders, and manually edit or confirm recorded dosing events. The app is installed on the participant's own smartphone (iOS or Android) and used throughout the 8-week study period. Participants are encouraged to scan their blister at least once daily to synchronize data. This intervention is for the Arm 1 group only.
219139517|NCT00612391|PROCEDURE|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
219139518|NCT00612391|PROCEDURE|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
219139519|NCT05097781|DRUG|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
219139520|NCT01025999|OTHER|No intervention|
219229019|NCT07099612|DEVICE|Cere®Pak smart blister pack|The Cere®Pak is an electronic blister pack with 28 cavities containing placebo tablets. It automatically records the date and time when each cavity is opened, using embedded electronics. Participants are instructed to simulate a twice-daily medication schedule (morning and evening) for 8 weeks by pushing out tablets without ingesting them. The device functions independently in the control group and connects with the MEMS® Mobile app in the intervention group. Both arms work with this intervention.
219229020|NCT07097974|DIETARY_SUPPLEMENT|WM formula liquid drink|One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
219229021|NCT07097974|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
219139521|NCT05969236|DRUG|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228\_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
219139522|NCT05969236|DRUG|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228\_mesylate is absent.
219139523|NCT00095004|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
219139524|NCT00095004|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
219139525|NCT02060019|DRUG|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
219139526|NCT02197299|DIETARY_SUPPLEMENT|L-carnitine|
219139527|NCT02197299|DIETARY_SUPPLEMENT|Placebo|
219229022|NCT07099248|OTHER|Cervico-vestibular Home Exercise Program|Patients who consent to participate in this study will be given an informational handout by clinical athletic trainers that provides information about the study, the exercises in their cervico-vestibular home exercise program, and a detailed progression to higher HEP levels/intensities based on their symptoms. The handout will also provide the purpose of the program, definitions of unfamiliar terms, a planning section for frequency and success, how to monitor symptoms through program completion, and how to properly access their exercises, log their completion, and track their progression in the Medbridge Go app.
219551913|NCT04627857|DEVICE|Sonic toothbrush|\- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
219551914|NCT04627857|DEVICE|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|\- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
219551915|NCT03505151|DRUG|BI 409306 (C-13/N-15)|i.v solution
219551916|NCT03505151|DRUG|BI 409306|Film-coated tablet
219551917|NCT02610647|DRUG|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
219551918|NCT02610647|OTHER|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
219551919|NCT02610647|OTHER|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
219551920|NCT02610647|OTHER|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
219551921|NCT01942135|DRUG|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
219551922|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
219551923|NCT01942135|DRUG|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
219551924|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
219551925|NCT06563063|DRUG|Flumazenil|The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.
219717579|NCT03496129|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
219717580|NCT03496129|BEHAVIORAL|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
219717581|NCT03496129|BEHAVIORAL|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
219717582|NCT06728358|DIAGNOSTIC_TEST|Molecular analyses|Search for molecular alterations that correlate with patient prognosis
219717583|NCT06734858|DEVICE|SAT014|SAT-014 in Combination with Baseline Conventional Treatment Participants in this arm will use the SAT-014 application for 6 weeks in combination with their baseline conventional treatment, which may include pharmacological therapy or simple counseling (excluding cognitive behavioral therapy and psychoanalytic counseling therapy). The aim of this study is to assess the efficacy and safety of SAT-014 for alleviating symptoms of trauma and stressor-related disorders, such as PTSD and adjustment disorder.
219717584|NCT06734858|OTHER|Control|Baseline Conventional Treatment Participants in this arm will receive only conventional treatment, which includes the medication they were taking at baseline for the indication or the basic counseling therapy they were receiving at baseline.
219551926|NCT02272335|BEHAVIORAL|Group Sessions|"10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
219551927|NCT00950300|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
219139528|NCT03906968|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
219139529|NCT04841733|OTHER|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
219139530|NCT04841733|OTHER|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
219139531|NCT04841733|OTHER|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
219551928|NCT00950300|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
219551929|NCT00950300|DRUG|Docetaxel|Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
219551930|NCT00950300|DRUG|Epirubicin|Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
219551931|NCT00950300|DRUG|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
219717585|NCT06726096|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|"The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control"
219717586|NCT05371613|DRUG|tividenofusp alfa|Intravenous repeating dose
219717587|NCT05371613|DRUG|idursulfase|Intravenous repeating dose
219717588|NCT06891066|DRUG|ISL|ISL 1mg oral capsule will be administered as 2mg orally (each capsule 1mg) as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
219139532|NCT00908336|DRUG|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
219551932|NCT00950300|DRUG|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
219551933|NCT05008380|PROCEDURE|prone positioning|3-6 hours of prone-positioning twice a day
219551934|NCT01897324|DRUG|Growth hormone (Norditropin, Novo nordisk)|
219717589|NCT06891066|DRUG|ULO|ULO 100mg oral tablet will be administered as 200mg (2 tablets) orally as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
219139533|NCT00908336|DRUG|Erlotinib|150 mg/day po daily
219139534|NCT03121950|OTHER|Dance|The primary intervention is a dance class
219139535|NCT03121950|OTHER|Music|the secondary intervention is listening to live music
219139536|NCT04803630|OTHER|Quality-of-Life Assessment|Ancillary studies
219717590|NCT06891066|DRUG|BIC/FTC/TAF|BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally to group 2 participants for 48 weeks in part 1 of the study.
219717591|NCT06892002|DRUG|Teplizumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
219717592|NCT07047638|DEVICE|Restylane Skinboosters Vital Lidocaine|Restylane Skinboosters Vital Lidocaine is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Skinboosters Vital Lidocaine has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.
219717593|NCT06889831|BEHAVIORAL|WORTH Paths Digital Intervention|Participants in this arm will receive the WORTH Paths digital intervention, a culturally tailored program designed for women involved in the criminal legal system with substance use disorders and unmet contraceptive needs. The intervention consists of three facilitated group sessions over videoconference with digital interactive activities to support behavior change.
219717594|NCT06889831|BEHAVIORAL|WORTH Paths Wellness Group|A wellness-focused intervention consisting of three facilitated group sessions over videoconference with digital interactive activities. Sessions cover general health, stress reduction, and navigating health services, including education about substance use and sexual/reproductive health risks, guided meditation, stress management techniques, and an overview of available health services. Participants also receive digital wellness resources, including recorded mindfulness exercises and links to online health service platforms.
219717595|NCT04968496|OTHER|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
219139537|NCT04803630|OTHER|Questionnaire Administration|Ancillary studies
219139538|NCT04803630|PROCEDURE|Thermotherapy|Undergo thermal therapy
219139539|NCT04117724|OTHER|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
219139540|NCT03902236|OTHER|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
219139541|NCT03902236|OTHER|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
219139542|NCT03902236|OTHER|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
219139543|NCT03902236|OTHER|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
219139544|NCT00861510|DRUG|ON01910 Na|
219717596|NCT00230516|DRUG|Nexium|
219717597|NCT00230516|DRUG|Prevacid|
219717598|NCT05628350|OTHER|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
219717599|NCT05628350|OTHER|High UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet with high UPF intake (81% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
219717600|NCT05465408|BEHAVIORAL|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|One-to-One virtual (videoconference) behavioral intervention.
219717601|NCT06884033|BEHAVIORAL|Cinematherapy|Cinematherapy, also known as cinema therapy and movie therapy, involves therapist-directed viewing of movies for specific therapeutic purposes.
219717602|NCT02279953|DRUG|Vortioxetine 10-20 mg|
219717603|NCT02279953|DRUG|Placebo|
219717604|NCT02279953|DRUG|SSRI|escitalopram, citalopram or sertraline
219139545|NCT00639015|DRUG|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
219717605|NCT04611087|BEHAVIORAL|Discussion|Attend focus groups
219717606|NCT04611087|OTHER|Interview|Attend interviews
219717607|NCT04611087|OTHER|Survey Administration|Ancillary studies
219717608|NCT04753515|DRUG|dexmedetomidine combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
219717609|NCT04753515|DRUG|propofol combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
219717610|NCT01434316|DRUG|Dinaciclib|Given IV
219717611|NCT01434316|DRUG|Veliparib|Given PO
219717612|NCT04905901|DRUG|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
219717613|NCT04905901|OTHER|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
219717614|NCT07070973|DEVICE|Assisted Fluid Management|Intraoperative fluid infusion will be regulated according to the Assisted Fluid Management (AFM) software and on Hypotension Prediction Index (HPI) will be used to titrate vasopressors and inotropes.
219139546|NCT00639015|DRUG|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
219139547|NCT02043717|DIETARY_SUPPLEMENT|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
219139548|NCT04231474|DEVICE|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
219139549|NCT01646775|DRUG|epidural fentanyl|withold epidural fentanyl
219139550|NCT01867580|DEVICE|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
219229023|NCT07098689|OTHER|The BEM (Body Emotional Maps) program|"The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The intervention is organized into three sessions.~The first session consists of an introduction and group formation. The second session involves sharing the onset of diabetes, identifying the most critical daily challenges, and the primary change the participants wish to implement. The third session features the BEM pathway, which includes guided visualization and the creation of a map with spatial anchors."
219229024|NCT07098689|OTHER|Control group|The control group will receive the same diabetes management information, accompanied by parent discussion sessions and recreational activities guided by the diabetes team staff. As with the BEM group, activities will take place over three days in an off-hospital location, in contact with nature.
219229025|NCT06812975|OTHER|No intervention|This is an observational study
219229026|NCT07098013|BEHAVIORAL|Relaxation Self-Coach|This intervention is a fully automated, unguided internet-based relaxation program in English. Unlike many digital mental health programs, it required no therapist involvement or incentives and was structured for real-world use. It combined evidence-based techniques-mindfulness, deep breathing, progressive muscle relaxation, guided imagery, and acceptance practices-delivered via audio modules. The program was tested in two formats: a 4-week daily format (28 sessions) and a revised 3-week modular format (21 sessions) with enhanced usability and adherence features, such as a simplified multimedia interface, reminder emails, and optional reflection prompts.
219229027|NCT07099066|OTHER|sampling blood|3 types of sampling : urine, skin and blood.
219229028|NCT07098156|OTHER|Single Research Visit 3T MRI Research Scan|Single research visit scan performed with a 3T magnetic resonance imaging scanner.
219229029|NCT07098156|OTHER|Demographic and Behavioural Questionnaires|A series of demographic and behavioural questionnaires to be completed by participants, either online or during the single study visit. Questionnaires include the Eating Disorder Examination Questionnaire, Autism Spectrum Quotient, Monotropism Questionnaire, Camouflaging Autistic Traits Questionnaire, Hospital Anxiety and Depression Scale, Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, Work and Social Adjustment Scale, International Trauma Questionnaire and Leibowitz Social Anxiety Scale. These questionnaires will also include a demographic questionnaire to acquire measures such as age, BMI, co-occurring conditions, etc.
219229030|NCT07099118|DRUG|HEC169584 capsule|Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
219229031|NCT07099118|DRUG|placebo|The placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
219229032|NCT07099417|DIAGNOSTIC_TEST|No intervention (observational study)|No intervention (observational study)
219229033|NCT07099027|DIAGNOSTIC_TEST|Low dose CT|In this arm, participants will undergo a respiratory assessment, smoking cessation, low-dose CT and biospecimen for translational research.
219551935|NCT01427036|PROCEDURE|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
219717615|NCT07070973|OTHER|Goal Directed Fluid Therapy (GDT)|Institutional goal directed therapy protocol used to optimize SVI and reduce intraoperative hypotension
219717616|NCT07070830|DEVICE|Active Comparator: Omnipod M System with lower starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
219717617|NCT07070830|DEVICE|Active Comparator: Omnipod M System with higher starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
219139551|NCT01867580|DEVICE|V.A.C.Ulta without instillation|NPWT only
219139552|NCT05852366|DRUG|Toothpaste Preparation|Dentifrice for management of dentinal hypersensitivity
219139553|NCT06614985|DRUG|Telitacicept|Subcutaneous injection of 160 mg is administered once a week.
219139554|NCT06614985|DRUG|Prednisone|Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.
219139555|NCT06614985|DRUG|Cyclophosphamide|An intravenous injection of 0.4 g is administered twice a month.
219139556|NCT03397914|DRUG|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
219229034|NCT07099495|DEVICE|Low Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 10 Hz, duration of 10 seconds (ON time: 10s), interspersed with a 20-second rest period (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
219551936|NCT01427036|PROCEDURE|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
219717618|NCT06854328|DEVICE|Prism|Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
219139557|NCT06614348|DRUG|Prednisolone acetate eye drop group|Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
219139558|NCT06614348|DRUG|Sodium hyaluronate eye drops|Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
219139559|NCT06628583|OTHER|Magnetic Resonance Imaging with Contrast|The study was retrospective and did not set interventions
219139560|NCT05423587|PROCEDURE|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
219139561|NCT05423587|PROCEDURE|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
219139562|NCT03141788|DEVICE|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
219139563|NCT04419181|DRUG|Docetaxel|Dose: 75 mg/m2 q3w
219139564|NCT04419181|DRUG|Carboplatin|Dose: area under the concentration-time curve \[AUC\] 6 q3w
219139565|NCT04419181|DRUG|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
219139566|NCT04419181|DRUG|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
219139567|NCT04419181|DRUG|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
219139568|NCT00697411|OTHER|Syndrome cause identification|
219139569|NCT00644709|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
219139570|NCT03523702|DRUG|PembroRT|"Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial."
219139571|NCT05877638|DEVICE|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
219551937|NCT00765635|DRUG|drops intilation (Taponoto ® )|four drops, unique doses
219551938|NCT00765635|DRUG|drops intilation (Otocerum®)|four drops, unique doses
219551939|NCT00765635|DRUG|drops intilation (Placebo)|Placebo
219139572|NCT05877638|DRUG|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
219139573|NCT04439747|OTHER|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
219139574|NCT01984086|DRUG|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
219139575|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
219139576|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
219139577|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
219139578|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
219139579|NCT01984086|DRUG|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
219139580|NCT01984086|DRUG|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
219551940|NCT01717040|DRUG|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
219229035|NCT07099495|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 50 Hz, duration of 10 seconds (ON time: 10s), interspersed by a period of 20 seconds of rest (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
219229036|NCT07099495|DEVICE|Neuromuscular Electrical Stimulation without generating contractility|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. No muscle contractions will be generated. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
219229037|NCT07097948|DRUG|Etoposide|Specified dose on specified days.
219229038|NCT07097948|DRUG|Platinum|Specified dose on specified days.
219229039|NCT07097948|DRUG|Toripalimab|Specified dose on specified days.
219229040|NCT07099131|DRUG|Anesthetic spray|will be applied to back of the throat for 10 seconds; their chin will also be concealed from the GSI examiner using a small cup and masking tape.
219229041|NCT07099131|DEVICE|Acupuncture|"A 6C file (endodontic instrumentation file) will be placed on the patient's mentolabial fold (CV24). This file will be concealed by a small paper cup; A clean alcohol wipe will be used to clean the mentolabial area prior to placing the acupuncture needle (6 C-File)."
219229042|NCT07099131|GENETIC|Masking Tape|A piece of commercially available masking tape will be adhered to the patient's mentolabial fold and concealed by the small paper cup
219229043|NCT07098702|OTHER|educational sessions and booklet|educational sessions and booklet about ergonomic practices during breastfeeding which include appropriate body mechanics , breastfeeding positions, and use of breastfeeding pillows.
219229044|NCT07098702|OTHER|No Interventions|In this group, the mothers will breastfeed their newborns according to the routine hospital postpartum instructions only.
219229045|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
219139581|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
219139582|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
219139583|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
219139584|NCT01984086|DRUG|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
219139585|NCT01984086|DRUG|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
219139586|NCT05178225|DIETARY_SUPPLEMENT|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
219139587|NCT05178225|OTHER|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
219139588|NCT05178225|DIAGNOSTIC_TEST|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
219139589|NCT00846326|DRUG|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
219139590|NCT00846326|DRUG|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
219139591|NCT00319306|DRUG|Budesonide/formoterol|
219139592|NCT00319306|DEVICE|Symbicort® Turbohaler®|
219139593|NCT03084744|BEHAVIORAL|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
219139594|NCT03084744|BEHAVIORAL|Active monitoring|Active tele-monitoring by clinical psychologists.
219229046|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
219229047|NCT05318027|DEVICE|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
219229048|NCT07099872|OTHER|Control|Wear normal attire (shorts/t-shirt) during exercise sessions in a gym-like environment.
219229049|NCT07099872|OTHER|Overdressing|Wear standardized overdressing ensemble during exercise sessions in a gym-like environment.
219229050|NCT06130553|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
219139595|NCT04036877|OTHER|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
219139596|NCT03357640|DRUG|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
219139597|NCT02734056|OTHER|Music|Listening to music that the patient likes
219139598|NCT02734056|OTHER|Control|Control
219139599|NCT05068167|DIAGNOSTIC_TEST|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
219229051|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
219229052|NCT04576689|DRUG|IBE-814 70ug|At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.
219229053|NCT04576689|DRUG|IBE-814 140ug|Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.
219229054|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
219229055|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
219229056|NCT03649724|DRUG|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
219229057|NCT03649724|DRUG|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
219717619|NCT07073404|DRUG|Omalizumab Injection|Treatment with omalizumab in monotherapy for 16 weeks in patients allergic to vegetables due to sensitization to lipid transfer proteins (LTPs) and profilin.
219717620|NCT05813873|OTHER|Triflow|Triflow
219717621|NCT05813873|OTHER|Control|Exercise
219139600|NCT03119363|DEVICE|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
219139601|NCT03119363|DEVICE|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
219139602|NCT01234610|BEHAVIORAL|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
219139603|NCT01576133|BEHAVIORAL|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
219139604|NCT01576133|BEHAVIORAL|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
219139605|NCT02220478|DEVICE|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
219229058|NCT06941337|BEHAVIORAL|HealthySteps (HS)|Evidence-based program that focuses on addressing Adverse Childhood Experiences (ACEs) and family stressors. The program provides parenting guidance, mental health support, and care coordination. The program is delivered during well-child visits by an HS specialist.
219551941|NCT01717040|DRUG|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
219551942|NCT05642949|DRUG|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
219551943|NCT00494013|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
219551944|NCT00494013|DRUG|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
219551945|NCT04174053|DEVICE|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
219551946|NCT06677684|DIETARY_SUPPLEMENT|Vitamin A|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation (25,000 IU daily for two days)
219551947|NCT04544033|DIAGNOSTIC_TEST|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
219551948|NCT04544033|DIAGNOSTIC_TEST|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
219551949|NCT05235022|OTHER|Questionnaires|"The participants included in the study will have to answer:~1. a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~2. the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
219551950|NCT01682421|DRUG|Weak steroid (Flurolon, Allergan)|
219551951|NCT01682421|DRUG|Potent steroid (Maxidex, Alcon)|
219551952|NCT05913115|DRUG|FPA144|FPA144 will be administered intravenously Q2W.
219551953|NCT04237220|DIAGNOSTIC_TEST|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
219551954|NCT01394094|BEHAVIORAL|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
219229059|NCT06941337|BEHAVIORAL|PlayReadVIP|Evidence-based program that promotes Positive Childhood Experiences (PCEs) and strengthens parent-child interactions. The program involves recording and reviewing videos of parents engaging with their child to provide feedback and encourage positive practices. Families receive toys, books, and guides to extend activities at home.
219139606|NCT03789955|PROCEDURE|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
219139607|NCT00067691|PROCEDURE|Acupuncture|
219139608|NCT00042198|BEHAVIORAL|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
219139609|NCT00042198|BEHAVIORAL|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
219139610|NCT00189813|DRUG|YM060|
219139611|NCT06087549|DRUG|Pericapsular nerve group block using 0.2% ropivacaine|Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
219139612|NCT06087549|DRUG|Erector Spinae Plane Block using 0.2% ropivacaine|Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
219229060|NCT06945796|OTHER|ACT based eating disorder prevention program|"This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques.~Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action."
219229061|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Active|"This intervention involves non-invasive brain stimulation using transcranial direct current stimulation (tDCS) delivered via saline-soaked sponge electrodes. The anode is placed at F3 (left dorsolateral prefrontal cortex) and the cathode at Fp2 (right frontopolar cortex), according to the international 10-20 EEG system. A 2 mA current is applied for 20 minutes per session, administered once daily on 10 consecutive workdays.~During stimulation, participants engage in cognitive training using the NeuronUP platform, which provides structured, interactive tasks designed to train executive function, attention, and working memory. This combination aims to enhance neural plasticity by pairing neuromodulation with cognitive engagement."
219229062|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Sham|The sham condition mimics the active setup but delivers only brief ramp-up/down stimulation, producing the initial sensation without sustained current.
219717622|NCT06241287|BEHAVIORAL|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
219717623|NCT06241287|OTHER|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
219139613|NCT06087549|OTHER|Standard care|No erector spinae block and no pericapsular nerve group block
219139614|NCT05099575|DRUG|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
219139615|NCT00382161|DRUG|Fluvastatin-sodium|
219139616|NCT01025843|DRUG|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
219139617|NCT01025843|DRUG|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
219139618|NCT01025843|DRUG|Comparator: Pbo|Placebo
219139619|NCT03224299|DRUG|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
219139620|NCT03224299|DRUG|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
219139621|NCT03224299|OTHER|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
219139622|NCT03224299|OTHER|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
219139623|NCT00444990|DEVICE|Magnetic Flex Pad|
219139624|NCT00479206|DRUG|Artesunate|
219139625|NCT02882230|DRUG|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
219229063|NCT06946433|BEHAVIORAL|Cognitive Training|The cognitive training intervention in this study is delivered through NeuronUP, a digital platform offering evidence-based cognitive stimulation activities. This intervention targets core cognitive domains such as working memory, attention, and executive function through personalized, interactive tasks. What distinguishes this approach is NeuronUP's extensive library of over 10,000 activities, its ability to tailor difficulty levels in real time based on individual performance, and the inclusion of functional tasks that mirror real-life scenarios. Unlike other interventions, NeuronUP also enables therapist-guided customization, allowing for individualized treatment plans that evolve with participant progress, ensuring both relevance and ecological validity.
219229064|NCT05454124|BEHAVIORAL|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
219229065|NCT05454124|BEHAVIORAL|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
219229066|NCT06123143|OTHER|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
219139626|NCT03109886|DRUG|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
219139627|NCT04928053|GENETIC|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
219139628|NCT01679262|DEVICE|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
219139629|NCT03702400|DRUG|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
219139630|NCT03702400|DRUG|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
219139631|NCT00377455|DRUG|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
219139632|NCT00377455|DRUG|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
219139633|NCT03200587|DRUG|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
219139634|NCT03200587|DRUG|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
219139635|NCT02846194|BEHAVIORAL|brief guided imagery|
219139636|NCT00959920|PROCEDURE|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
219139637|NCT00959920|PROCEDURE|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
219139638|NCT03391908|DIAGNOSTIC_TEST|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
219229067|NCT02421679|DRUG|TNX-102 SL|1x 2.8mg TNX-102 SL Sublingual tablet
219717624|NCT07073248|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the ipsilesional motor cortex, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
219717625|NCT07073248|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation
219717626|NCT05993884|DRUG|iEPCs|Patients receive iEPCs IV with the single dose
219717627|NCT05993884|DRUG|Placebo|Patients receive placebo IV with a single dose
219139639|NCT02289625|OTHER|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
219717628|NCT06594991|DRUG|Fianlimab|Fianlimab IV given every three weeks
219139640|NCT05453864|BEHAVIORAL|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
219139641|NCT05804604|PROCEDURE|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
219717629|NCT06594991|DRUG|Cemiplimab|Cemiplimab IV given every three weeks
219717630|NCT06594991|DRUG|Ipilimumab|Ipilimumab will be give every 6 weeks continuously
219139642|NCT05804604|PROCEDURE|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
219139643|NCT04484480|PROCEDURE|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
219229068|NCT04476199|COMBINATION_PRODUCT|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
219229069|NCT03616886|DRUG|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
219229070|NCT03616886|DRUG|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
219229071|NCT03616886|DRUG|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
219551955|NCT01301937|DRUG|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
219551956|NCT03226613|PROCEDURE|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
219551957|NCT03226613|PROCEDURE|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
219551958|NCT03226613|PROCEDURE|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
219551959|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
219551960|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
219551961|NCT00582244|BEHAVIORAL|CBT and relaxation|Group A: CBT and relaxation.
219551962|NCT00582244|BEHAVIORAL|Physical activity|Group B: Physical exercise program.
219551963|NCT00582244|BEHAVIORAL|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
219551964|NCT00582244|OTHER|Control group|Waiting list control group
219551965|NCT02818751|DRUG|Escitalopram|Patients being randomized to receive escitalopram.
219551966|NCT02818751|OTHER|Placebo|Patients being randomized to receive placebo.
219551967|NCT04599751|DEVICE|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
219551968|NCT01806272|DRUG|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
219551969|NCT01806272|DRUG|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
219551970|NCT02937259|OTHER|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
219551971|NCT05064917|DIAGNOSTIC_TEST|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
219551972|NCT02043522|DRUG|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
219139644|NCT02242162|PROCEDURE|phrenic nerves magnetic stimulations|
219139645|NCT01897233|DRUG|Lumacaftor|
219139646|NCT01897233|DRUG|Ivacaftor|
219139647|NCT02220491|RADIATION|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
219139648|NCT02220491|RADIATION|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
219139649|NCT06555276|DEVICE|Disposable endoscope linear cutting stapler and components|to use the study device for excision, transection and anastomosis of lung, bronchial tissue, stomach and intestine in open or endoscopic surgery.
219139650|NCT02065050|OTHER|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
219551973|NCT05497986|DEVICE|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
219551974|NCT05497986|DEVICE|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
219551975|NCT02281253|DIETARY_SUPPLEMENT|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
219717631|NCT06680128|BIOLOGICAL|GBP560-A|"injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
219229072|NCT03616886|DRUG|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
219229073|NCT05643534|DRUG|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
219229074|NCT05643534|DRUG|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
219139651|NCT04962282|OTHER|Follow-up by telephone|Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
219139652|NCT06081231|DEVICE|open-source APS;|a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
219139653|NCT04989725|OTHER|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
219229075|NCT05643534|DRUG|Placebo|Participants will be randomized to receive matching placebo
219229076|NCT06434246|BEHAVIORAL|pulley system exercise regimen|The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.
219229077|NCT06434246|BIOLOGICAL|physical therapy program for CP|Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
219139654|NCT04989725|RADIATION|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
219139655|NCT01975311|OTHER|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
219139656|NCT01975311|OTHER|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
219139657|NCT00332644|DRUG|nicotine patch|used according to FDA package label
219551976|NCT02281253|DIETARY_SUPPLEMENT|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
219139658|NCT00332644|DRUG|nicotine lozenge|used according to FDA-approved package directions
219139659|NCT00332644|DRUG|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
219551977|NCT05014958|OTHER|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
219551978|NCT02280707|OTHER|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
219139660|NCT00332644|DRUG|bupropion|dosage according to FDA-approved instructions
219139661|NCT00332644|DRUG|bupropion + lozenge|dosage according to FDA approved standard instructions
219139662|NCT00332644|DRUG|placebo|dosage same as active drug conditions
219139663|NCT01281813|DRUG|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
219139664|NCT01281813|DRUG|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
219139665|NCT03546907|DRUG|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
219139666|NCT03546907|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
219139667|NCT03546907|DRUG|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
219229078|NCT02553616|BEHAVIORAL|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
219229079|NCT03559452|PROCEDURE|Eccentric exercise|300 eccentric contractions of the knee extensors
219229080|NCT04528147|BEHAVIORAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
219551979|NCT04750239|DRUG|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
219551980|NCT02031250|DRUG|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
219551981|NCT02031250|DRUG|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
219229081|NCT04528147|BEHAVIORAL|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
219229082|NCT06001593|DEVICE|YPS-201b|electrical stimulation device.
219229083|NCT06001593|DRUG|betahistine|Relieve symptoms of balance disorders or dizziness
219229084|NCT06001593|DEVICE|YPS-201b|sham electrical stimulation device.
219551982|NCT02031250|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
219551983|NCT02031250|RADIATION|Boost Radiation to Hypoperfused Volumes|
219139668|NCT03546907|DRUG|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
219717632|NCT06680128|BIOLOGICAL|GBP560-B|"injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
219717633|NCT06680128|BIOLOGICAL|IXIARO|injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2
219717634|NCT06680128|BIOLOGICAL|IMOJEV|injection volume of 0.5mL on V5 (29day) in stage1 and stage2
219717635|NCT06680128|BIOLOGICAL|Normal Saline (Placebo)|injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
219717636|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
219717637|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
219717638|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
219717639|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219717640|NCT06494657|OTHER|Corticosteroid injection|Corticosteroid injection for frozen shoulder
219717641|NCT07076355|DRUG|Botulinum Toxin type a (Botox)|A single dose of 25 units of botulinum toxin type A (BTX-A) was injected into the lateral pterygoid muscle using ultrasonography-guided technique. The injection was performed under local anesthesia with patient monitoring.
219717642|NCT07079189|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
219717643|NCT06455189|OTHER|Control Group - Standard of care neurosurgical resection|The control group will include only standard of care tools. - Standard of care neurosurgical resection will include the use of all standard neurosurgical instruments and techniques (eg, microscope, intraoperative ultrasound, 5-ALA fluorescence guided surgery and neuronavigation system).
219717644|NCT06455189|PROCEDURE|MRF/MRI infiltration guidance for extended resection|Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body
219139669|NCT03546907|DRUG|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
219717645|NCT07066098|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
219551984|NCT00903877|DRUG|T3|Patients receive T3 in a dose of 25mcg and 50mcg
219551985|NCT00919711|DRUG|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
219139670|NCT03546907|DRUG|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
219139671|NCT04560855|DEVICE|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
219229085|NCT04614688|BEHAVIORAL|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
219551986|NCT00919711|DRUG|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
219551987|NCT02965261|DRUG|Torrent's Fluoxetine Tablets|
219551988|NCT02965261|DRUG|Warner Chilcott LLC Sarafem Tablets|
219551989|NCT00163345|DRUG|Ciclesonide|
219551990|NCT02409797|OTHER|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
219551991|NCT00107263|DRUG|letrozole|
219717646|NCT07066098|DRUG|Placebo|Subjects in the control arm will receive placebo 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
219717647|NCT07076472|DRUG|Aminolevulinic Acid Intravenous Formulation SONALA-001|Given IV
219717648|NCT07076472|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219717649|NCT07076472|PROCEDURE|Computed Tomography|Undergo CT
219717650|NCT07076472|OTHER|Electronic Health Record Review|Ancillary studies
219717651|NCT07076472|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219717652|NCT07076472|PROCEDURE|MRI-Guided Focused Ultrasound Ablation|Undergo transcranial MRgFUS
219717653|NCT06846008|BEHAVIORAL|Ahead of the Game|"Evidence-based injury prevention training programs and exercises will be send weekly to participants in the intervention arm.~Additionally, participants in the intervention arm will be encouraged to access a study specific online platform containing information, inspiration, pep-talks and posters on injury prevention training."
219717654|NCT06846008|OTHER|Usual Practice|Usual training
219717655|NCT06843070|PROCEDURE|PENILE BLOCK ARM|P arm: Patients who underwent Dorsal Penile Block after circumcision surgery
219717656|NCT06843070|PROCEDURE|SACRAL ESP BLOCK ARM|S arm: Patients who underwent Sacral Erector Spinae Plane Block after circumcision surgery
219717657|NCT01294332|OTHER|Aerobic Exercise Training|supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
219717658|NCT06813053|OTHER|Decision Aid (DA)|Tools designed to foster shared decision-making by contextualizing the risks and benefits of treatment options around the patient's personal values, thereby allowing them to weigh personal preferences when making treatment decisions. The study team has developed a prototype DA incorporating longitudinal institutional QoL data among patients who have undergone breast cancer surgery .
219717659|NCT06813053|OTHER|Standard of Care (SOC)|Electronic copy of an alternative educational pamphlet discussing surgical options for breast cancer.
219139672|NCT01980069|DRUG|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
219139673|NCT01980069|DRUG|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
219139674|NCT01189006|DRUG|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
219139675|NCT02810080|DEVICE|Closed Loop Control Ventilation|Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
219229086|NCT05676541|OTHER|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
219229087|NCT01867879|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219229088|NCT01867879|DRUG|Placebo|Placebo tablets, orally, single dose.
219717660|NCT07120243|PROCEDURE|Toothpaste Product|Administration ofa toothpaste
219717661|NCT07120243|PROCEDURE|Varnishes, Fluoride|The tooth will be dried, and cotton roll isolated. According to manufacturer instructions, thin coat of the varnish will be applied on the teeth for 10 - 20 s using a microbrush in a horizontal sweeping motion , then drying with air will be done.
219717662|NCT07121114|OTHER|No treatment given|No treatment given
219229089|NCT05052151|OTHER|Low dialysate temperature|35°C
219229090|NCT05052151|OTHER|High dialysate temperature|37°C
219229091|NCT05052151|OTHER|Low dialysate bicarbonate concentration|30 mmol/L
219139676|NCT02810080|DEVICE|Manual Control Ventilation|Manual control ventilation using ZOLL 731 ventilator
219139677|NCT05432934|DRUG|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
219139678|NCT03510949|DEVICE|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
219229092|NCT05052151|OTHER|High dialysate bicarbonate concentration|38 mmol/L
219229093|NCT01064778|OTHER|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
219551992|NCT00107263|DRUG|zoledronic acid|
219551993|NCT00087529|DRUG|placebo|Intravenous repeating dose
219551994|NCT00087529|DRUG|rituximab|Intravenous repeating dose
219551995|NCT00163319|DRUG|Ciclesonide|
219551996|NCT02665780|PROCEDURE|Periodontal debridement|teeth cleaning
219551997|NCT02665780|OTHER|Cetylpyridium chloride|mouthrinse
219551998|NCT05389813|DRUG|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
219551999|NCT05389813|DRUG|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
219552000|NCT05389813|DRUG|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
219717663|NCT07118995|OTHER|Analysis of preoperative CTA|A review of preoperative contrast-enhanced CTA from patients with thoracoabdominal aneurysms, included in Braile's database, who were indicated for endovascular treatment with Braile's custom-made multi-branched endograft between 2022 and 2024
219717664|NCT07124897|BEHAVIORAL|VR-Supported Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, supported by VR technology. It is applied to women experiencing perinatal loss, aiming to reduce grief, anxiety, depression, and stress, postpartum depression, and to enhance psychosocial well-being. The care is delivered face-to-face during hospitalization and includes emotional support, active listening, presence, and empathy, aligned with the core concepts of Swanson's theory. The VR component consists of immersive, calming 360-degree visual environments that are integrated into the care sessions to promote emotional regulation. The intervention continues with structured psychosocial support via telephone on day 7 and day 30 after discharge.
219717665|NCT07124897|BEHAVIORAL|Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, without the use of VR. It is delivered to women who have experienced perinatal loss, aiming to support emotional healing and reduce psychological symptoms such as grief, anxiety, depression, stress, and postpartum depression. The intervention is provided face-to-face during hospitalization and focuses on presence, listening, empathy, and emotional support in alignment with Swanson's caring processes. Follow-up support is also provided via telephone calls on day 7 and day 30 after discharge, continuing the psychosocial care process without any technological enhancement.
219139679|NCT03973944|DEVICE|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
219139680|NCT00588302|DRUG|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
219139681|NCT01446068|DIETARY_SUPPLEMENT|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
219139682|NCT06379711|DEVICE|Transcutaneous Spinal Cord Stimulation (tSCS)|Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
219139683|NCT05308381|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
219139684|NCT05308381|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
219139685|NCT05308381|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
219139686|NCT01790529|PROCEDURE|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
219139687|NCT01790529|PROCEDURE|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
219552001|NCT03747107|BEHAVIORAL|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
219139688|NCT01365208|DRUG|Chemotherapy|platinum-based chemotherapy
219139689|NCT03248271|DRUG|Insulin Lispro|Insulin
219139690|NCT02599142|DEVICE|Group A: Closed-face shell|As for arm description
219139691|NCT02599142|DEVICE|Group B: Open-face shell|As for arm description
219139692|NCT02620761|DRUG|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
219139693|NCT02620761|DRUG|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
219139694|NCT03737097|OTHER|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
219139695|NCT03737097|OTHER|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
219139696|NCT05110391|DRUG|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
219139697|NCT00044148|DRUG|LY333531|
219552002|NCT05651958|OTHER|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
219139698|NCT06242899|OTHER|Exercise|"Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
219139699|NCT05054764|DEVICE|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
219139700|NCT04693130|BEHAVIORAL|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
219139701|NCT04693130|BEHAVIORAL|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
219139702|NCT04033432|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
219139703|NCT02965248|DRUG|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
219139704|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
219139705|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
219139706|NCT02886221|PROCEDURE|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
219139707|NCT02598596|BIOLOGICAL|Pegloticase|Pegloticase, IV
219139708|NCT02598596|DRUG|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
219139709|NCT04790604|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
219139710|NCT06070324|PROCEDURE|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
219139711|NCT06070324|DEVICE|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
219552003|NCT05651958|OTHER|Breathing Technique|15 repeatations of Breathing in morning and evening
219552004|NCT03516058|OTHER|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
219139712|NCT05617586|OTHER|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
219139713|NCT05617586|OTHER|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
219139714|NCT00393848|DRUG|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
219139715|NCT00393848|DRUG|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
219139716|NCT00393848|DRUG|Placebo|Placebo for Ketoconazole
219139717|NCT04226703|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
219139718|NCT04581317|OTHER|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
219139719|NCT04581317|OTHER|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
219139720|NCT04581317|OTHER|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
219139721|NCT05939063|PROCEDURE|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
219139722|NCT05939063|PROCEDURE|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
219139723|NCT05417893|DEVICE|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
219139724|NCT00637936|DRUG|Oxygen|Inspiratory fraction during anaesthesia
219139725|NCT01443416|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
219139726|NCT01443416|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
219139727|NCT05559281|OTHER|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
219552005|NCT01170741|BEHAVIORAL|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
219552006|NCT01628887|OTHER|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
219552007|NCT00106886|DRUG|Folic acid, vitamin B6 and B12 or placebo|
219552008|NCT02282722|OTHER|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
219552009|NCT02282722|OTHER|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
219552010|NCT01853722|DRUG|DCN01|Three serial applications per periocular region.
219552011|NCT01853722|DRUG|Unisol|Three serial applications per periocular region.
219552012|NCT00213122|DRUG|miglitol|
219552013|NCT06363799|OTHER|4th ventricle compression technique|"For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards."
219552014|NCT06363799|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
219552015|NCT06363799|OTHER|Diaphragmatic breathing technique|For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
219552016|NCT01664650|DIETARY_SUPPLEMENT|Genistein|
219552017|NCT01664650|DIETARY_SUPPLEMENT|Placebo|
219552018|NCT01473173|DRUG|CJ-12420|
219552019|NCT01473173|DRUG|Esomeprazole 40mg|
219229094|NCT01064778|OTHER|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
219229095|NCT03385291|DEVICE|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
219229096|NCT03795688|OTHER|Pregnancy|Peripartum transition from pregnant to postpartum state
219229097|NCT03560271|DRUG|Cyclo-Z|Cyclo (His-Pro) and zinc
219552020|NCT04935905|DEVICE|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
219552021|NCT01698736|DEVICE|Membrane filtration|Membrane filtration (Polysulfone)
219552022|NCT01698736|DEVICE|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
219717666|NCT07124871|BIOLOGICAL|PRP-derived exosomes injection|"All subjects will receive three sessions of PRP-derived exosomes injection with 21± 3 days treatment interval.The patient will be positioned supine.~A ¼-inch Penrose drain will be used as a tourniquet by placing it at the base of the penis and maintaining it in place under tension by a sterile clamp. We will obtain 10 mL of PRP per patient, but one of them will be used for platelet cell count analysis. A total 9 mL of the PRP-derived exosomes will be infused steadily over a 2 minutes period - 4.5 mL each into the right and left corpus cavernosum. The infusion will be performed at this slow speed - each side over 2 minutes of infusion - to minimize injury to the exosomes and cells. Following administration, compression of the penis will be achieved with a clenched fist for 20 minutes. At 20 minutes, the tourniquet will be removed, and a compressive dressing will be placed around the penile shaft. The patient will be instructed to remove the compression bandage in 4 hours"
219717667|NCT07123493|BIOLOGICAL|Anti ALPP CAR-T cells treatment|Biological: anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide
219717668|NCT07124793|DRUG|IBI363+IBI305|Each treatment cycle lasts for 21 days (the first treatment cycle is 28 days). Subjects will receive IBI363 Q3W in combination with bevacizumab Q3W until 2 years of treatment, PD, intolerable toxicity, start of new anti-tumor treatment, withdrawal of informed consent, death, or study termination (whichever occurs first).
219717669|NCT07124286|OTHER|Abdominal Bracing Training|The group underwent an abdominal bracing maneuver training. Following the training, they performed the Closed Kinetic Chain Upper Extremity Stability Test and the Seated Medicine Ball Throw Test in 2 conditions: with abdominal bracing and without abdominal bracing.
219717670|NCT07124546|BEHAVIORAL|Acceptance and Commitment Therapy|Attend ACT-HBC telehealth group sessions
219139728|NCT05559281|PROCEDURE|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
219139729|NCT04566458|OTHER|No intervention|retrospective chart review study
219139730|NCT02212522|OTHER|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
219717671|NCT07124546|OTHER|Questionnaire Administration|Ancillary studies
219717672|NCT07124546|OTHER|Telemedicine|Attend ACT-HBC telehealth group sessions
219717673|NCT07122635|DRUG|Diquafosol Sodium 3%|Diquafosol Sodium 3% ophthalmic solution, 1 drop each time, 6 times daily, from baseline (1 week after the surgery) to 12 weeks
219717674|NCT07123506|DRUG|Beta-blocker treatment group|After PFO closure, the beta-blocker treatment group will receive an extended-release beta-blocker, either bisoprolol or nebivolol, at a dose of 1.25 mg QD for 30 days.
219717675|NCT07123506|DRUG|Non-treatment group|After PFO closure, the non-treatment group will not receive a beta-blocker.
219139731|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
219139732|NCT02212522|OTHER|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
219139733|NCT02212522|OTHER|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
219139734|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
219139735|NCT00947817|OTHER|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
219139736|NCT02589002|OTHER|Sucralose|
219139737|NCT01793441|DRUG|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
219139738|NCT01793441|DRUG|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
219139739|NCT03201549|DIETARY_SUPPLEMENT|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
219229098|NCT03560271|OTHER|Placebo|Matching placebo
219229099|NCT06358599|DRUG|Cisplatin|Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
219229100|NCT04751097|OTHER|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
219229101|NCT00006200|DRUG|thalidomide|
219229102|NCT00006200|DRUG|dacarbazine|
219229103|NCT01160159|OTHER|Tests|Arterial parameters
219229104|NCT01160159|OTHER|Healthy volunteers|Arterial parameters and blood test
219139740|NCT03110458|DRUG|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
219139741|NCT03110458|DRUG|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
219139742|NCT03110458|DRUG|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
219139743|NCT02192606|DEVICE|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
219139744|NCT02192606|DEVICE|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
219139745|NCT01736098|OTHER|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
219139746|NCT02351648|OTHER|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
219139747|NCT02351648|OTHER|Control|Patients receive usual standard of care from the internal medicine team
219139748|NCT00239434|DRUG|tiotropium inhalation powder capsule|
219139749|NCT00239434|DRUG|ipratropium bromide Metered Dose Inhaler|
219139750|NCT04306705|DRUG|Tocilizumab|Administered as an intravenous infusion.
219229105|NCT00671853|DRUG|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
219229106|NCT00671853|DRUG|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
219229107|NCT05726097|DRUG|polyethylene glycol|colonic preparation
219229108|NCT05726097|DRUG|sodium phosphate|colonic preparation
219229109|NCT05726097|DRUG|polyethylene glycol + ascorbic acid|colonic preparation
219229110|NCT05726097|DRUG|gastrografin|colonic preparation
219229111|NCT05726097|DRUG|magnesiumoxid + sodium picosulfate|colonic preparation
219229112|NCT05726097|DRUG|prucalopride|colonic preparation
219229113|NCT01000935|OTHER|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
219139751|NCT04306705|OTHER|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
219139752|NCT04306705|PROCEDURE|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
219139753|NCT05030077|DRUG|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
219139754|NCT05030077|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
219229114|NCT02008214|DRUG|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
219229115|NCT02008214|DRUG|Placebo|Placebo matching pentoxifylline dosage
219229116|NCT03266432|OTHER|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
219229117|NCT00470756|OTHER|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
219229118|NCT00785798|DRUG|Vorinostat|200mg to 400 mg twice daily on days 1-7
219229119|NCT00785798|DRUG|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
219229120|NCT05516745|DEVICE|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
219229121|NCT05516745|OTHER|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
219229122|NCT04809701|PROCEDURE|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
219139755|NCT05030077|DRUG|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
219139756|NCT05030077|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
219139757|NCT03278769|PROCEDURE|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
219139758|NCT03903900|BEHAVIORAL|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
219229123|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
219229124|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
219229125|NCT04809701|PROCEDURE|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
219229126|NCT03252210|PROCEDURE|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
219229127|NCT01648049|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).
219139759|NCT00497991|DRUG|AZD1152|
219229128|NCT01648049|BEHAVIORAL|Treatment as usual|Standard Care - Treatment as usual
219229129|NCT05168345|OTHER|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
219229130|NCT04617145|OTHER|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
219139760|NCT03179722|BEHAVIORAL|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
219139761|NCT03179722|BEHAVIORAL|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
219139762|NCT05201261|DEVICE|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
219139763|NCT04302246|GENETIC|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
219139764|NCT03185780|OTHER|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
219139765|NCT04792554|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
219229131|NCT04122820|DIAGNOSTIC_TEST|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
219229132|NCT02876653|OTHER|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
219552023|NCT01954212|OTHER|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
219552024|NCT05046340|OTHER|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
219552025|NCT02747680|OTHER|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
219552026|NCT05319054|DEVICE|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
219552027|NCT05319054|DEVICE|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
219552028|NCT05319054|OTHER|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
219552029|NCT06366555|PROCEDURE|Manual Acupuncture Twirling,|Manual Acupuncture twirling : using 0.14x 25 mm needle, punctured and penetrated the skin and then a twirling manipulation is carried out, 180 degrees, 3 rad/second, for 30 second each at LU5 and PC2. The needles retained for 20 minutes and manipulated at 0 minutes and 10 minutes.
219552030|NCT06366555|PROCEDURE|Manual Acupuncture Sham|Manual Acupuncture Sham : Using 0.14x25mm needles on plesterin without being penetrated into skin and no manipulation given, retained for 20 minutes
219552031|NCT00873587|PROCEDURE|Chest tube pull on inspiration|Pull chest tube on Inspiration
219552032|NCT00873587|PROCEDURE|Expiration|Pull chest tube on Expiration
219552033|NCT03699930|DEVICE|tDCS|Anodal or sham tDCS will be applied to the scalp.
219552034|NCT03699930|BEHAVIORAL|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
219552035|NCT00475410|DRUG|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
219552036|NCT00475410|DRUG|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
219552037|NCT00685334|DRUG|Olanzapine|Participants will take olanzapine daily for 12 weeks.
219552038|NCT00685334|DRUG|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
219552039|NCT00095537|DRUG|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
219552040|NCT06255145|DEVICE|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
219552041|NCT00964054|OTHER|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
219552042|NCT00964054|OTHER|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
219552043|NCT02288923|PROCEDURE|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
219229133|NCT03937089|OTHER|Data collection|Data collection from medical file
219229134|NCT03723902|OTHER|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
219229135|NCT03723902|DIETARY_SUPPLEMENT|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
219229136|NCT06173622|BEHAVIORAL|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
219229137|NCT05390515|DRUG|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
219717676|NCT07125300|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Colonoscopy|"The intervention involves the use of an artificial intelligence tool during screening colonoscopy. This system includes two integrated functions:~* CADe (Computer-Aided Detection): Highlights suspected lesions in real time on the endoscopic video to assist in identifying polyps.~* CADx (Computer-Aided Diagnosis): Provides real-time optical histology predictions to help distinguish between hyperplastic and adenomatous polyps.~The AI system operates autonomously during the procedure and displays visual cues on the monitor to support the endoscopist in detecting and characterizing colorectal lesions."
219717677|NCT07122206|PROCEDURE|Blood Draws|Research-related blood draws will be used to ascertain FGF19 levels.
219717678|NCT07123545|BIOLOGICAL|iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine|Administered subcutaneously at 0.3 mg/peptide on Days 1, 4, 8, 15, 22, 52, and 82, followed by booster immunizations every 2-3 months.
219717679|NCT07123545|BIOLOGICAL|iNeo-Vac-T01 Personalized T Cell Injection|Administered via intravenous infusion: Dose Level 1: 5×10⁹ to 10×10⁹ cells; Dose Level 2: 1×10¹⁰ to 5×10¹⁰ cells.
219717680|NCT07121998|PROCEDURE|Core needle biopsy|Core needle biopsy of metastatic lesions
219717681|NCT07121998|PROCEDURE|Phlebotomy|Phlebotomy of peripheral vein
219717682|NCT06901544|DIAGNOSTIC_TEST|Serum C Reactive Protein|values for serum albumin is 35 to 55 g/l and for CRP is less than 6 mg/dl CLI will be calculated as CRP divided by serum albumin and multiplied by 100
219717683|NCT06902961|OTHER|Game-based exercise group|Game-based exercise group
219139766|NCT03195426|PROCEDURE|distal nerves blocks group|"* ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
219139767|NCT03195426|PROCEDURE|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
219139768|NCT01184664|DRUG|Nicotine Patch|Varenicline + nicotine patch
219139769|NCT01184664|DRUG|Placebo|Varenicline + placebo patch
219139770|NCT01184664|DRUG|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
219139771|NCT00711126|DRUG|GW642444|2.5mcg IV
219139772|NCT00711126|DRUG|GW642444|5mcg IV
219139773|NCT00711126|DRUG|GW642444|10mcg IV
219139774|NCT00711126|DRUG|GW642444|100mcg inhaled
219139775|NCT00711126|DRUG|GW642444|20mcg IV
219139776|NCT00711126|DRUG|GW642444|500mcg oral
219229138|NCT02122484|DRUG|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
219229139|NCT04566276|BIOLOGICAL|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
219229140|NCT04566276|OTHER|Placebo|Saline
219717684|NCT06902961|OTHER|control group|control group
219717685|NCT04919824|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
219139777|NCT00557206|DRUG|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
219139778|NCT01458210|DRUG|Ortho-Cyclen|Administered orally
219229141|NCT03015753|BEHAVIORAL|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
219139779|NCT01458210|BIOLOGICAL|Dulaglutide|Administered subcutaneously
219139780|NCT01551407|DRUG|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
219139781|NCT01562925|DIETARY_SUPPLEMENT|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
219139782|NCT01562925|DIETARY_SUPPLEMENT|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
219139783|NCT01562925|DIETARY_SUPPLEMENT|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
219717686|NCT04919824|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
219717687|NCT06905171|OTHER|Auditory Stimulation|A tone at a 1000 Hz frequency, delivered through speakers at a comfortable volume
219717688|NCT06905171|OTHER|Visual Stimulation|A checkerboard pattern displayed on a monitor, with colors alternating every 25 ms
219717689|NCT06905171|OTHER|Somatosensory Stimulation|A train of three electrical stimuli, each lasting 1 ms, separated by 8 ms, at an intensity that clearly elicits a pricking sensation
219717690|NCT06905171|OTHER|Auditory-Visual Stimulation|Stimulation using auditory and visual stimuli concomitantly
219139784|NCT01021865|DRUG|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
219139785|NCT01900834|OTHER|No treatment given|The participants will not receive any treatment
219139786|NCT02937792|DRUG|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
219139787|NCT02921399|OTHER|eradication timing|patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
219139788|NCT04126239|OTHER|Online survey - questionnaire|Online survey - questionnaire
219139789|NCT05136092|DIETARY_SUPPLEMENT|Cohort 1: HFCS (fructose) fed|"Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
219139790|NCT05136092|DIETARY_SUPPLEMENT|Cohort 2: D-Xylose (xylose-fed)|"Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
219139791|NCT01810250|DEVICE|Endurant Stent Graft|
219139792|NCT05347199|DRUG|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
219139793|NCT05347199|DRUG|Placebo|two doses, orally
219717691|NCT06905171|OTHER|Visual-Somatosensory Stimulation|Stimulation using visual and somatosensory stimuli concomitantly
219717692|NCT06905171|OTHER|Auditory-Somatonsensory Stimulation|Stimulation using auditory and somatosensory stimuli concomitantly
219717693|NCT06905171|OTHER|Auditory-Visual-Somatosensory Stimulation|Stimulation using auditory, visual and somatosensory stimuli concomitantly
219717694|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
219717695|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
219717696|NCT04455698|BEHAVIORAL|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
219552044|NCT02288923|PROCEDURE|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
219139794|NCT04747392|BIOLOGICAL|SAL001|administrated once by subcutaneous injection
219139795|NCT04747392|BIOLOGICAL|FORSTEO|administrated once by subcutaneous injection
219552045|NCT02288923|PROCEDURE|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
219717697|NCT05105841|DRUG|Venetoclax|Oral Tablet
219717698|NCT05105841|DRUG|Ibrutinib|Oral Capsule
219717699|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
219717700|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219717701|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
219717702|NCT04851119|DRUG|Tegavivint|Given IV
219717703|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219717704|NCT07093541|DRUG|ecopipam HCl ~2mg/kg/day|Saily oral tablet taken every evening before bedtime.
219717705|NCT07093476|DRUG|Metformin|tablets, QD, oral administration
219717706|NCT07093476|DRUG|Alogliptin|tablets, QD, oral administration
219717707|NCT07093476|DRUG|empagliflozin|tablets, QD, oral administration
219229142|NCT03015753|OTHER|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
219229143|NCT04125342|DEVICE|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
219229144|NCT04125342|DEVICE|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
219717708|NCT06903702|DRUG|Azacitidine (AZA)|given daily for 7 days starting on Day 1 of each Cycle
219717709|NCT06903702|DRUG|Venetoclax|orally daily for 28 days
219717710|NCT06903702|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|After the conditioning treatment, the HSCT procedure is part of standard care on Day 0.
219717711|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg|Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks
219717712|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg placebo|Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks
219717713|NCT07092384|DRUG|Remifentanil|Observe the incidence of pruritus and paresthesia after different doses of remifentanil and fospropofol disodium
219139796|NCT06264648|OTHER|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
219139797|NCT03923491|BEHAVIORAL|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
219139798|NCT03923491|BEHAVIORAL|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
219229145|NCT05940805|PROCEDURE|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"1. Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~2. Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~3. Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~4. Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
219229146|NCT05940805|PROCEDURE|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
219229147|NCT00587171|DEVICE|Patching|2 hours daily patching
219552046|NCT02288923|PROCEDURE|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
219717714|NCT07092384|DRUG|Sufentanil|Observe the incidence of pruritus and paresthesia after sufentanil and fospropofol disodium
219717715|NCT06911931|OTHER|EEG measure of visual processing|Non-invasive scalp EEG measure of early cortical visual processing.
219717716|NCT07092826|OTHER|Psychopathological assessment and non-invasive multisensory stimulation|This intervention consists of a non-invasive, cross-sectional assessment involving standardized psychopathological interviews and multisensory stimulation tasks (auditory, tactile, and combined). It is designed to explore formal and content-related features of obsessive-compulsive symptoms, insight levels, and trauma-related correlates in patients with OCD and schizophrenia spectrum disorders. No pharmacological treatment or experimental therapy is administered as part of this study.
219717717|NCT07099885|DIAGNOSTIC_TEST|Standard of Care (SOC)|Diuretic treatment per attending physician.
219717718|NCT07099885|DIAGNOSTIC_TEST|Algorithhm-based decongestion|Patient will receive standarized furosemide dosing based on the result of the algorithm-estimated 6h urine output (profiles of diuretic response).
219717719|NCT00980460|DRUG|Cisplatin|Given IV
219717720|NCT00980460|DRUG|Dexrazoxane|Given IV
219139799|NCT01091831|DRUG|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
219717721|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
219552047|NCT02288923|DRUG|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
219717722|NCT00980460|DRUG|Fluorouracil|Given IV
219717723|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
219139800|NCT01091831|DRUG|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
219139801|NCT01091831|DRUG|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
219139802|NCT01091831|DRUG|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
219717724|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
219717725|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
219717726|NCT00980460|DRUG|Temsirolimus|Given IV
219717727|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219717728|NCT00980460|DRUG|Vincristine Sulfate|Given IV
219717729|NCT06908538|DEVICE|cryoablation|Cryoanalgesia, also known as Cryoablation, Cryoneurolysis, or Cryonerve Block, has been used for decades to treat chronic pain and has recently been employed for the management of Phantom Limb Pain. Cryoanalgesia involves the use of a probe to apply extreme cold (approximately -70◦C) to induce reversible axonal injury and Wallerian degeneration to produce a temporary conduction block that is sustained until regeneration of the axon and sensation is restored, typically weeks to months later.
219717730|NCT06911294|BEHAVIORAL|Polygenic Risk Score|genetic test for the evaluation of cardiovascular risk
219717731|NCT06911294|BEHAVIORAL|Digital app and wearable device|a wearable device connected with its app
219717732|NCT07098377|DIAGNOSTIC_TEST|nasopharyngeal swab for biological sample analysis|nasopharyngeal swab for biological sample analysis
219717733|NCT07099534|DRUG|IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder|Participants receive two intravenous (IV) infusions of ketamine at a dose of 0.5 mg/kg over 40 minutes. The first infusion is administered at Hour 0 (H0) and the second at Hour 24 (H24). Vital signs and potential adverse effects are closely monitored before, during, and after each infusion. This intervention aims to assess the short-term efficacy and safety of ketamine in reducing symptoms of severe borderline personality disorder.
219717734|NCT07111052|BEHAVIORAL|Lock and Protect is a self-administered, web-based decision aid for caregivers of adolescents at risk for suicide.|Lock and Protect is a user-friendly web-based decision aid that identifies preferences and explores options for removing or storing lethal means safety through: (a) education on home means of suicide, such as firearms, medications, and other potentially dangerous home and external items/situations (e.g., poisons, methods/ligatures used in suffocation/hanging), and community hazards (e.g., subways, heights); (b) safe storage options; and (c) protective monitoring and supervision as a means of increasing adolescent safety during a time of elevated risk.
219717735|NCT07105761|BEHAVIORAL|Body-Mind-Spirit|The experimental group participated in a 10-week BMS group intervention, with weekly 130-minute sessions. The intervention combined Eastern philosophy and Western psychotherapy to enhance emotional balance and psychological resilience. Core components included observing merits (recognizing strengths), cultivating gratitude, and practicing forgiveness. Physical activities such as finger dexterity training, diaphragmatic breathing, and stretching supported autonomic regulation and flexibility. Psychological strategies involved positive thinking, emotional expression, and life story sharing. All materials were adapted with audio descriptions for accessibility. Participants with visual impairment received orientation training and volunteer support for transportation and on-site assistance.
219717736|NCT07111403|PROCEDURE|SAP fluoride plus|The agent was applied by removing the safety clip, activating the applicator and squeezing out the sponge above the lesion and the solution was left to diffuse for 5 min.the patients were instructed to eat only soft foods and avoid hot liquids for two hours. Also, they were educated and motivated about the importance of oral hygiene.
219717737|NCT07111403|PROCEDURE|10% n-HAp.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks.they instructed to adhere to oral hygiene measures.
219717738|NCT07111403|PROCEDURE|10% n-BAG.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks. patients instructed to adhere to oral hygiene measures.
219717739|NCT07111403|PROCEDURE|Flour Protector S|After application of varnish, the patient was instructed to avoid abrasive diet for the rest of the day and not brush or floss until the next morning. The treatment was done at baseline and after 6 months.
219717740|NCT07111702|DRUG|Cefazolin|A single 2g intravenous dose administered once before surgery.
219717741|NCT07113496|BIOLOGICAL|Allogeneic CAR-T|Patients will receive lymphodepletion chemotherapy followed by a single intravenous infusion of Allogeneic CAR-T cells. In select cases, CAR-T infusion may be administered post-autologous hematopoietic stem cell transplantation (auto-HSCT)
219552048|NCT02288923|DRUG|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
219717742|NCT06480539|DRUG|Placebo|The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
219717743|NCT06480539|DRUG|Dexmedetomidine|Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
219717744|NCT07104409|OTHER|virtual reality hypnosis device|VRH group, in which patients will receive conventional sedation (remifentanil 0.1 mcg/kg/min and propofol 0.5 mg/kg if necessary) and a Virtual Reality headset with an environment chosen by the patient and hypnosis support with suggestions to reduce their anxiety.
219717745|NCT07105397|OTHER|Conversational AI system|The conversational AI intervention utilizes interactive dialogue to collect patient medical histories. Powered by advanced Large Language Models (LLMs), the system engages participants in open-ended, natural language conversations. A Dialogue Manager coordinates the dialogue, ensuring conversations remain medically relevant, personalized, and safe. Clinicians monitor the interactions in real-time, validating and ensuring accuracy of antidepressant recommendations informed by an evidence-based Antidepressant Knowledgebase.
219552049|NCT02288923|DRUG|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
219139803|NCT02327104|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
219139804|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
219139805|NCT02433795|DRUG|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
219139806|NCT02376517|BEHAVIORAL|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
219139807|NCT02454244|BEHAVIORAL|ART with Mindfulness|"1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice"
219139808|NCT02454244|BEHAVIORAL|Mindfulness Compassion|"1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations"
219139809|NCT02454244|BEHAVIORAL|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
219139810|NCT00223548|DRUG|sodium 2-mercaptoethane sulfonate|
219139811|NCT05162144|PROCEDURE|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
219229148|NCT00587171|PROCEDURE|Near activities|30 minutes daily near activities at home
219139812|NCT00426036|DRUG|Licarbazepine|
219139813|NCT00038714|DRUG|SGN-00101|
219229149|NCT00587171|PROCEDURE|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
219229150|NCT00587171|PROCEDURE|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
219229151|NCT04246905|DRUG|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
219229152|NCT04246905|OTHER|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
219229153|NCT04246905|DRUG|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
219552050|NCT02288923|DRUG|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
219552051|NCT02288923|DRUG|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
219552052|NCT01891357|PROCEDURE|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
219552053|NCT01891357|DRUG|paclitaxel|
219552054|NCT01891357|DRUG|lapatinib|
219552055|NCT01891357|DRUG|trastuzumab|
219552056|NCT06227741|OTHER|Concept Mapping: as a Tool for Problem Based Learning|Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
219552057|NCT04823091|DRUG|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
219552058|NCT00002158|DRUG|Nitazoxanide|
219552059|NCT02431949|OTHER|Admission to BCPP|There is no intervention associated with this study.
219552060|NCT01763554|DRUG|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
219552061|NCT02552082|DEVICE|Scorpio NRG posterior stabilized (PS)|
219139814|NCT04970810|BEHAVIORAL|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
219139815|NCT04970810|BEHAVIORAL|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
219717746|NCT07105397|OTHER|Structured Survey Questionnaire|"The structured questionnaire intake utilizes a predefined, multiple-choice survey that systematically collects patient medical history without conversational interaction. Questions are algorithmically selected based on the patient's earlier responses to maximize information efficiency, typically requiring fewer than 13 items. Patients select from standardized responses (including options like I do not know or I do not want to say). Contextual help messages are provided as needed. Upon completion, the system generates antidepressant recommendations using the same Antidepressant Knowledgebase as the Conversational AI system, clearly explaining its rationale. A prototype version is available at http://MeAgainMeds.com, with ongoing development to enhance features and usability."
219717747|NCT07104097|PROCEDURE|spinal anesthesia|spinal anesthesia at L3-L4 plain bupivacaine 0.5% 2.2 ml
219139816|NCT05359913|BEHAVIORAL|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
219229154|NCT06102538|BEHAVIORAL|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|\# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
219717748|NCT07104097|PROCEDURE|superficial erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 on top of L3 transverse process, between bone and erector spinae muscle
219229155|NCT04389554|OTHER|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
219229156|NCT00865033|DRUG|Metformin HCL Tablets, 1000 mg Sandoz|
219717749|NCT07104097|PROCEDURE|deep (inter laminar) erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 between L3 and L4 transverse process, between erector spinae muscle and deep muscles
219717750|NCT07104097|DRUG|Dexamethasone|8 mg iv preoperatively
219717751|NCT07104097|DRUG|Ibuprofen 400 mg|preoperatively and postoperatively (every 8 hours)
219717752|NCT07104097|DRUG|Paracetamol|1000 mg preoperatively and postoperatively (every 8 hours)
219717753|NCT07104097|DRUG|Morphine|Patient Controlled Analgesia
219717754|NCT06395519|DRUG|ETX-19477|Oral medication taken daily
219717755|NCT07113964|DRUG|QL1706 + olaparib|"QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies.~Other Names: Iparomlimab and Tuvonralimab Injection Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor with biologic activity in ovarian cancer as well as other solid tumors..~Other Names: NA"
219717756|NCT07115290|DEVICE|Glass ionomer-based fissure sealant|A high-viscosity, self-curing glass ionomer sealant used for the occlusal surfaces of newly erupted permanent molars. This material releases fluoride and is moisture-tolerant during application. The product used in this study was Fuji Triage™ Capsule (GC Corporation, Japan).
219717757|NCT07115290|DEVICE|Resin-based fissure sealant|A moisture-tolerant, light-cured resin-based fissure sealant designed for application to occlusal surfaces in partially erupted permanent molars. The material exhibits strong adhesion in moist conditions and forms a durable barrier against caries. The product used in this study was UltraSeal XT® Hydro (Ultradent Products Inc., USA).
219229157|NCT00865033|DRUG|Glucophage 1000 mg|
219229158|NCT01599078|DRUG|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
219229159|NCT01599078|DRUG|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
219229160|NCT01848483|BEHAVIORAL|AIDS EPC Package plus MI|"1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care."
219717758|NCT07116564|DRUG|Enhanced Recovery After Surgery|Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.
219717759|NCT07116564|DRUG|Control|Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg
219717760|NCT07114523|PROCEDURE|collagen membrane|collagen membrane apply to distal surface of second molar after third molar surgery
219717761|NCT07114523|PROCEDURE|third molar surgery|standard third molar surgery without any additional application
219139817|NCT04983537|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
219139818|NCT04041999|BEHAVIORAL|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
219229161|NCT01848483|OTHER|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
219229162|NCT01148017|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
219229163|NCT02813954|DEVICE|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
219717762|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention A|Study intervention A: one tablet of dose strength 1 one tablet of dose strength 1 = two tablets of dose strength 2
219717763|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention B|Study intervention B: two tablets of dose strength 2 two tablets of dose strength 2 = one tablet of dose strength 1
219717764|NCT07114250|PROCEDURE|spinal anesthesia|Spinal Anesthesia group: Patients included in this group will undergo supine Percutaneous nephrolithotomy under spinal anesthesia
219552062|NCT06628297|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
219552063|NCT03944057|DRUG|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
219552064|NCT00310297|DRUG|Insulin Glulisine|
219552065|NCT02634736|DEVICE|Exergame plus usual treatment|An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
219552066|NCT01465932|OTHER|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
219552067|NCT01465932|OTHER|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
219552068|NCT05587023|PROCEDURE|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
219552069|NCT00656539|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
219552070|NCT06491979|DIETARY_SUPPLEMENT|Vitamin A treatment|Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks
219552071|NCT06491979|DIETARY_SUPPLEMENT|Monounsaturated fatty acid mixture|Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks
219552072|NCT06491979|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid mixture|Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
219552073|NCT06491979|DIETARY_SUPPLEMENT|Fatty acid mixture|Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
219552074|NCT00000708|DRUG|Flucytosine|
219552075|NCT00000708|DRUG|Fluconazole|
219552076|NCT00000708|DRUG|Amphotericin B|
219552077|NCT06356987|PROCEDURE|Herniotomy|In Group A Laparoscopic assisted needle herniotomy was done
219552078|NCT02217709|DRUG|phenelzine sulfate|Given by mouth
219552079|NCT02217709|OTHER|laboratory biomarker analysis|Correlative studies
219552080|NCT02217709|OTHER|questionnaire administration|Ancillary studies
219552081|NCT02647515|DRUG|ranibizumab|
219552082|NCT01495715|DRUG|Idebenone|
219552083|NCT01495715|DRUG|Placebo|
219552084|NCT01245842|OTHER|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
219717765|NCT07114250|PROCEDURE|General Anesthesia|General Anesthesia : Patients included in this group will undergo supine Percutaneous nephrolithotomy under general anesthesia
219139819|NCT03300037|DEVICE|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
219139820|NCT05776680|OTHER|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
219139821|NCT05277831|OTHER|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
219139822|NCT05277831|OTHER|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
219139823|NCT06961110|DIETARY_SUPPLEMENT|Hydrogen-rich water|Hydrogen-rich water with molecular hydrogen concentration 1.2-1.6 ppm. No added sugar or preservatives.
219229164|NCT06304051|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219139824|NCT06961110|DIETARY_SUPPLEMENT|Placebo|Drinking water with molecular hydrogen concentration 0.0 ppm. No added sugar or preservatives.
219139825|NCT05774587|BEHAVIORAL|mHealth control group|Cardiac rehab control group
219139826|NCT05774587|BEHAVIORAL|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
219139827|NCT03107403|BEHAVIORAL|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
219139828|NCT01615432|DEVICE|V-PAP III ventilator|
219139829|NCT01615432|DEVICE|Stellar 150 ventilator|
219229165|NCT06304051|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, the investigators made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219717766|NCT07115550|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib
219139830|NCT01615432|DEVICE|BiPAP vision ventilator|
219139831|NCT01615432|DEVICE|V60 ventilator|
219139832|NCT01406262|BIOLOGICAL|Albiglutide|once weekly subcutaneous injection
219139833|NCT01406262|DRUG|Moxifloxacin|oral tablet
219139834|NCT00692562|PROCEDURE|simultaneous islet-kidney transplantation|
219139835|NCT02175043|PROCEDURE|atrial electrogram and liner ablation|"1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
219139836|NCT03484585|DRUG|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
219139837|NCT06251193|BEHAVIORAL|E-CBSST|E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
219139838|NCT03005249|PROCEDURE|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
219139839|NCT03005249|OTHER|the control group|The patients will be assigned to the control group for cerebral palsy.
219139840|NCT00819884|DRUG|AZD1656|Oral suspension
219139841|NCT03236064|DRUG|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
219139842|NCT03252106|PROCEDURE|Contour augmentation with implant placement|Contour augmentation with implant placement
219139843|NCT05829096|OTHER|The COMBINED approach|"1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
219139844|NCT02633358|DEVICE|Therapeutic hypothermia group|Therapeutic hypothermia
219717767|NCT07113938|DEVICE|Ambient AI Scribe|Software that records audio of a clinical interaction and generates a clinical note.
219139845|NCT04589000|OTHER|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
219139846|NCT04559243|DIAGNOSTIC_TEST|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
219139847|NCT02378116|PROCEDURE|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
219139848|NCT05303155|DIAGNOSTIC_TEST|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
219139849|NCT02545062|OTHER|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
219139850|NCT01870479|OTHER|Live music|
219139851|NCT01870479|OTHER|Taped music|
219139852|NCT05283616|DRUG|Pegfilgrastim|Pegfilgrastim 3mg per chemotherapy cycle
219139853|NCT06545994|OTHER|Observation|It's a observational cohort study and no interventions are performed.
219139854|NCT02401633|PROCEDURE|CO-CPR|CPR provided by bystander with chest-compressions only
219139855|NCT02401633|PROCEDURE|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
219139856|NCT02935218|BEHAVIORAL|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
219139857|NCT05675956|DEVICE|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
219139858|NCT05675956|DEVICE|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
219139859|NCT06281704|BIOLOGICAL|AK101 IV|AK101 will be administered intravenously.
219139860|NCT06281704|BIOLOGICAL|AK101 SC|AK101 will be administered subcutaneously.
219139861|NCT06281704|BIOLOGICAL|Placebo|Placebo will be administered subcutaneously or intravenously.
219139862|NCT06281704|BIOLOGICAL|AK101 IV/AK101 SC|AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
219139863|NCT01169311|DEVICE|Hemorrhoidopexy|
219139864|NCT02306577|DRUG|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
219139865|NCT04879082|OTHER|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
219139866|NCT02798718|DIETARY_SUPPLEMENT|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
219139867|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
219139868|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
219139869|NCT02559518|DEVICE|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
219139870|NCT02559518|DEVICE|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
219139871|NCT02559518|DEVICE|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
219139872|NCT02559518|DEVICE|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
219139873|NCT02559518|DEVICE|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
219139874|NCT01209546|OTHER|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
219229166|NCT03758391|OTHER|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
219139875|NCT01209546|OTHER|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
219139876|NCT01209546|OTHER|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
219139877|NCT01209546|OTHER|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
219139878|NCT02899585|OTHER|Questionnaires|
219139879|NCT02899585|OTHER|Score|
219139880|NCT05394896|DEVICE|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
219139881|NCT05394896|DEVICE|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
219139882|NCT01564875|DRUG|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
219139883|NCT01564875|DRUG|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
219139884|NCT00845611|BIOLOGICAL|peptide vaccine|peptides emulsified with Montanide ISA51
219139885|NCT04683718|DEVICE|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
219229167|NCT00143806|DRUG|Transitioning patients from cyclosporine to alefacept|
219229168|NCT00239512|DRUG|Indomethacin and Ibuprofen|
219717768|NCT07116343|DRUG|Ropivacaine|The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.
219717769|NCT07116343|DRUG|0.9 % NaCl|The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.
219717770|NCT07115446|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219717771|NCT07115446|DRUG|HRS-5041|HRS-5041 was given oral administration, QD, at a 21-day cycle.
219139886|NCT00241644|BIOLOGICAL|Rotarix™|Two or Three doses, oral administration
219139887|NCT00241644|BIOLOGICAL|Placebo|One or three doses, oral administration.
219139888|NCT00012506|DRUG|TNFR:Fc|
219229169|NCT04910204|OTHER|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
219229170|NCT00163501|DRUG|Ciclesonide|
219229171|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 200mg
219229172|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 300mg
219229173|NCT00082966|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
219229174|NCT04880018|DEVICE|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
219229175|NCT01792401|DRUG|Probiotics|
219139889|NCT05246553|PROCEDURE|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
219229176|NCT01792401|DRUG|Placebo|
219229177|NCT01855165|BEHAVIORAL|Advice on DDIs|
219229178|NCT00853528|OTHER|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
219229179|NCT00853528|PROCEDURE|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
219229180|NCT00853528|PROCEDURE|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
219229181|NCT00853528|RADIATION|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
219229182|NCT00853528|RADIATION|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
219229183|NCT04338919|PROCEDURE|Percutaneous coronary intervention|PCI with stent implantation
219717772|NCT07115433|BEHAVIORAL|School-Based Oral Health Promotion Program|Arm Description: The oral health promotion intervention will be implemented through weekly interactive sessions lasting 30-40 minutes over a period of six months. These sessions, conducted by trained dental educators and teachers, will use animations, storytelling, demonstrations, and role-plays to teach proper toothbrushing, the importance of fluoride toothpaste, healthy eating habits, and the need for regular dental visits. Children will participate in supervised toothbrushing once a week, supported by peer ambassadors who reinforce daily practices. Educational leaflets and videos will engage parents, while posters in classrooms serve as reminders. Follow-up assessments, including questionnaires and clinical indices, will be conducted at six months.
219139890|NCT05246553|PROCEDURE|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
219139891|NCT05246553|DIAGNOSTIC_TEST|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
219139892|NCT05246553|DIAGNOSTIC_TEST|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
219139893|NCT00261547|DRUG|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
219139894|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
219139895|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo R-LESS RP
219139896|NCT02079155|OTHER|laboratory biomarker analysis|Correlative studies
219139897|NCT02079155|OTHER|quality-of-life assessment|Ancillary studies
219139898|NCT02079155|OTHER|questionnaire administration|Ancillary studies
219139899|NCT02949570|DRUG|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
219139900|NCT03751150|OTHER|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
219139901|NCT01027286|DEVICE|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
219139902|NCT02890693|BEHAVIORAL|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
219139903|NCT04132024|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
219139904|NCT04189900|DRUG|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
219229184|NCT04338919|DRUG|Ticagrelor plus aspirin|Ticagrelor plus aspirin
219139905|NCT03333655|PROCEDURE|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
219139906|NCT03495284|DIETARY_SUPPLEMENT|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
219139907|NCT03495284|DIETARY_SUPPLEMENT|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
219139908|NCT00199641|DEVICE|enteral nutrition|
219139909|NCT02918916|OTHER|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
219139910|NCT02918916|OTHER|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
219139911|NCT06062706|PROCEDURE|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
219139912|NCT06116019|RADIATION|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
219139913|NCT05381701|PROCEDURE|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
219139914|NCT03080792|BEHAVIORAL|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
219229185|NCT01779050|DRUG|Doxorubicin|
219139915|NCT04194502|DIAGNOSTIC_TEST|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
219139916|NCT01253499|DRUG|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
219139917|NCT00522756|DRUG|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
219139918|NCT00522756|DRUG|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
219229186|NCT01779050|BIOLOGICAL|Trastuzumab|
219229187|NCT01779050|DRUG|Cyclophosphamide|
219229188|NCT01779050|DRUG|Paclitaxel|
219139919|NCT04437056|PROCEDURE|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
219139920|NCT01085279|DEVICE|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
219139921|NCT01085279|DRUG|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
219139922|NCT05610696|OTHER|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
219139923|NCT05610696|OTHER|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
219139924|NCT05610696|OTHER|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
219139925|NCT02562352|OTHER|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
219139926|NCT06288152|DRUG|Sodium Thiosulfate|0.15 mL administered
219139927|NCT01563354|DRUG|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
219139928|NCT01563354|DRUG|Everolimus|10 mg tables administered orally once a day
219139929|NCT01563354|DRUG|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
219139930|NCT01565928|DRUG|MDV3100|4 x 40 mg capsules, orally, once per day
219139931|NCT05823181|DEVICE|laparoscopy|laparoscopic exploration of common bile duct
219139932|NCT02684565|DIETARY_SUPPLEMENT|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
219139933|NCT02684565|DIETARY_SUPPLEMENT|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
219139934|NCT00478335|DRUG|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
219139935|NCT00478335|DRUG|calcitonin|one nasal spray daily for 4 days
219139936|NCT00478335|DRUG|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
219717773|NCT07116538|OTHER|Nishauri mHealth Intervention|The Nishauri mHealth intervention, developed by Palladium with Kenya's Ministry of Health and funded by PEPFAR/CDC, is a client-centered digital platform designed to enhance HIV care in Kenya. It supports appointment scheduling, ART referrals, and patient engagement through features such as automated medication and appointment reminders, tailored health education, two-way communication, and behavior-change strategies. Interoperable with national health systems like KenyaEMR and Ushauri, it enables real-time data exchange and continuity of care. Despite national scale-up, uptake remains low and varies across facilities, providers, and patients, particularly among men, who face unique sociocultural barriers. Addressing gender norms and contextual factors is key to improving implementation and achieving sustained engagement and better outcomes.
219139937|NCT00478335|DRUG|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
219139938|NCT00478335|DRUG|Placebo for sildenafil|one tablet daily for 4 days
219139939|NCT00478335|DRUG|placebo for calcitonin|one nasal spray daily
219229189|NCT01779050|DRUG|Epirubicin|
219229190|NCT01779050|DRUG|Docetaxel|
219139940|NCT00608907|DRUG|bortezomib|1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
219139941|NCT00608907|DRUG|bortezomib, rifampicin|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
219229191|NCT01779050|DRUG|Carboplatin|
219139942|NCT00608907|DRUG|bortezomib, dexamethasone|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
219139943|NCT05483335|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
219229192|NCT01779050|DRUG|Fluorouracil|
219139944|NCT02458599|DIETARY_SUPPLEMENT|Test product|Whey protein hydrolysate (20 g)
219139945|NCT02458599|DIETARY_SUPPLEMENT|Reference product 1|Iso-energetic carbohydrate (20 g)
219139946|NCT02458599|DIETARY_SUPPLEMENT|Reference product 2|Negligible energy placebo (20 g)
219139947|NCT04943380|DIAGNOSTIC_TEST|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
219139948|NCT02710149|BIOLOGICAL|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
219139949|NCT01986686|PROCEDURE|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
219229193|NCT00977249|BEHAVIORAL|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
219139950|NCT02667249|OTHER|clinical pathway|implementation of a standardized clinical pathway
219139951|NCT01988233|BEHAVIORAL|BAILAMOS© Dance Program|
219139952|NCT01988233|BEHAVIORAL|Health Education Control Group|
219139953|NCT04369534|DRUG|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
219139954|NCT04369534|DRUG|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
219139955|NCT01844141|DRUG|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
219139956|NCT01844141|DRUG|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
219139957|NCT00470106|BEHAVIORAL|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
219139958|NCT00470106|BEHAVIORAL|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
219139959|NCT00470106|BEHAVIORAL|hybrid intervention|A combination of the two groups listed above.
219717774|NCT07116655|BEHAVIORAL|Single-session solution focused consultation|"In the SSC, the interventionist first sets expectations, explaining that the session is a means of providing short-term support. The interventionist will then praise the participant for agreeing to receive support and introduce the Action Plan, which will guide the session's structure. The interventionist will then work with the participant to (1) identify a specific, modifiable issue they are facing; (2) use the miracle question to envision their ideal outcome where the problem is resolved, and rates their current proximity to that; (3) determine the smallest possible step they can take towards this outcome through a scaling exercise; and (4) develop a personalized action plan that leverage on their current resources to begin addressing the problem. Upon ending the SSC, the interventionist writes a personalized note to the participant, highlighting their strengths and expressing confidence in their ability to follow through."
219717775|NCT07116655|BEHAVIORAL|Single-session supportive intervention|In the supportive consultation session, the interventionist will allow the participant to decide what they wish to discuss during the session and listen empathetically, validate their feelings and offer reassurance to the patient. The exact wording or questions will vary depending on the client's needs and sharing.
219139960|NCT00470106|BEHAVIORAL|skills training|Skills training in how to identify symptoms of illness and medication side effects.
219139961|NCT03621761|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
219139962|NCT03621761|DRUG|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
219139963|NCT04914936|DRUG|ACP-196|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
219139964|NCT04914936|DRUG|Calcium carbonate|Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
219139965|NCT04914936|DRUG|Omeprazole|Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
219139966|NCT04914936|DRUG|Rifampin|Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
219139967|NCT03939819|DEVICE|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
219139968|NCT03939819|DEVICE|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
219139969|NCT00006413|PROCEDURE|Stem cell transplantation|
219139970|NCT05921526|DIAGNOSTIC_TEST|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
219229194|NCT00977249|DRUG|varenicline|
219229195|NCT00977249|DRUG|placebo|
219229196|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
219229197|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
219229198|NCT04185818|OTHER|Reading a book|"Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed"
219229199|NCT01353274|DRUG|Micamlo|Telmisartan plus Amlodipine T40/A5
219229200|NCT04514562|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
219229201|NCT00386685|DRUG|larotaxel (XRP9881)|intravenous administration
219229202|NCT00386685|DRUG|trastuzumab|intravenous administration
219139971|NCT05921526|DIAGNOSTIC_TEST|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
219139972|NCT00182936|BEHAVIORAL|Delirium Abatement Program|
219139973|NCT04033237|OTHER|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
219139974|NCT03522519|BEHAVIORAL|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
219139975|NCT05156450|DRUG|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
219139976|NCT01229839|OTHER|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
219139977|NCT01229839|OTHER|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
219139978|NCT01229839|OTHER|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
219229203|NCT01603108|DRUG|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
219139979|NCT02770196|BEHAVIORAL|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
219139980|NCT06242964|BEHAVIORAL|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
219139981|NCT05292638|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
219139982|NCT05292638|DRUG|Botox®|Intramuscular injection Botox®
219139983|NCT05042024|PROCEDURE|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
219139984|NCT05042024|DRUG|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
219139985|NCT05042024|DRUG|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
219139986|NCT00444769|DRUG|GW842166|
219139987|NCT00423254|BIOLOGICAL|PSMA/PRAME|Low dose
219139988|NCT00423254|BIOLOGICAL|PSMA/PRAME|high dose
219229204|NCT01603108|DRUG|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
219717776|NCT07114211|DIAGNOSTIC_TEST|99mTc-HYNIC-FAPI-04 SPECT-CT|Perform quantitative SPECT/CT with 99mTc-HYNIC-FAPI-04 on selected patients. Acquire whole-body images in a planar format and SPECT/CT images of two or more sites in a tomographic format.
219717777|NCT07114432|DRUG|BCMA/CD19-targeted allogeneic CAR-T|Lymphodepletion chemotherapy followed by allogeneic CAR-T cell (RN1201) infusion
219139989|NCT06112717|OTHER|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
219139990|NCT03413319|DRUG|ABBV-8E12|Solution for infusion
219139991|NCT00270426|DRUG|Benazepril|
219139992|NCT03259919|DRUG|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
219139993|NCT03259919|DRUG|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
219229205|NCT05075499|BIOLOGICAL|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
219229206|NCT06031818|OTHER|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
219229207|NCT06031818|OTHER|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
219229208|NCT06031818|OTHER|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
219717778|NCT07115511|PROCEDURE|Surgery|Recombined recanalization surgery
219139994|NCT01492218|DRUG|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
219139995|NCT04379713|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
219139996|NCT04379713|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
219139997|NCT04089488|OTHER|Medical Chart Review|Correlative studies
219139998|NCT04089488|OTHER|Survey Administration|Respond to surveys
219139999|NCT00258037|BEHAVIORAL|Pelvic Floor Muscle training|
219140000|NCT02762006|DRUG|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
219140001|NCT02762006|DRUG|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
219140002|NCT04709796|DRUG|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
219140003|NCT04709796|DRUG|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
219140004|NCT02399696|BEHAVIORAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
219140005|NCT02399696|BEHAVIORAL|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
219140006|NCT06054867|DEVICE|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
219140007|NCT03808883|BEHAVIORAL|TGNC Directed Advocacy Meetings|Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
219140008|NCT03808883|BEHAVIORAL|Facilitated Dialogues between TGNC Cohort and Healthcare Participants|Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
219140009|NCT04680260|OTHER|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
219140010|NCT04680260|OTHER|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
219140011|NCT04628572|DRUG|Ceftazidime-avibactam|Non-Interventional Study
219140012|NCT00243399|DRUG|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
219140013|NCT05236491|BIOLOGICAL|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
219140014|NCT00158054|BEHAVIORAL|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
219140015|NCT00158054|BEHAVIORAL|Referred depression care|Physician notified of depression symptoms, usual care followed.
219140016|NCT00855465|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
219229209|NCT02431767|BIOLOGICAL|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
219140017|NCT00855465|DRUG|Placebo|Matching Placebo tid orally for 16 weeks
219229210|NCT02431767|BIOLOGICAL|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
219140018|NCT02470949|BEHAVIORAL|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
219140019|NCT02470949|BEHAVIORAL|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
219140020|NCT01219699|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
219229211|NCT02431767|BIOLOGICAL|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
219229212|NCT00944541|DRUG|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
219552085|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
219552086|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
219552087|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
219552088|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
219552089|NCT06678425|DEVICE|Peripheral magnetic stimulator|a non-invasive method of delivering a rapidly pulsed, high-intensity magnetic field to peripheral muscles
219552090|NCT06678425|DEVICE|Peripheral magnetic stimulator|The same coil as real rPMS, but in a position perpendicular to the skin
219717779|NCT07114107|DEVICE|VPAT (Vibratory Positive Pressure Therapeutic Apparatus）|"VPAT (Vibratory Positive Pressure Therapeutic Apparatus）is a physical solution which can relieve nasal congestion and discomforts by applying acoustic vibration and oscillatory positive expiratory pressure. Clinical research has shown that low-frequency vibration at approximately 130 Hz promotes the production of the highest concentration of Nitric Oxide (NO) in the paranal sinuses, which helps to regulate the nasal mucosal blood, restoring the mucous membrance-cilia mechanism, clean up the bacteria, viruses and allergenic particles in the respiratory tract.~Combined with Oscillatory Positive Expiratory Pressure and Transnasal Breathing, it can help to cultivate the habit of nasal breathing and slow breathing, as well as to restore the function of lungs."
219140021|NCT01219699|DRUG|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
219140022|NCT05434611|DIAGNOSTIC_TEST|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
219140023|NCT04630080|DEVICE|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
219140024|NCT02674646|RADIATION|Radiotherapy|Radiation as indicated by the cancer diagnosis
219140025|NCT02674646|DEVICE|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
219140026|NCT04825652|DRUG|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
219140027|NCT04825652|DRUG|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
219140028|NCT04676568|PROCEDURE|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
219140029|NCT04460612|DEVICE|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
219140030|NCT04460612|OTHER|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
219229213|NCT03649191|OTHER|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
219229214|NCT03649191|OTHER|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
219229215|NCT05501652|DEVICE|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
219229216|NCT02808234|PROCEDURE|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
219229217|NCT02808234|OTHER|Nucel|Allograft derived from human amnion and amniotic fluid
219229218|NCT00978159|DRUG|esomeprazole|esomeprazole 20 mg po for 4 weeks
219229219|NCT00978159|DRUG|Famotidine|Famotidine 40 mg po for 4 weeks
219140031|NCT02727764|GENETIC|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
219140032|NCT03045419|PROCEDURE|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
219140033|NCT03977116|DRUG|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
219140034|NCT03977116|DRUG|Placebo|These patients will receive placebo therapy after catheter ablation.
219140035|NCT03646006|DRUG|Bupivacaine|10 mL (5mg/mL)
219140036|NCT03646006|DRUG|Placebo|10 mL normal saline
219140037|NCT03038399|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
219140038|NCT03038399|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
219140039|NCT03038399|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
219140040|NCT03038399|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
219140041|NCT02219919|OTHER|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
219140042|NCT02219919|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
219229220|NCT00237120|DRUG|Imatinib|
219140043|NCT05026034|DEVICE|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
219140044|NCT06335836|BEHAVIORAL|social isolation|social isolation (0≤LSNS-6≤12)
219140045|NCT03298919|BEHAVIORAL|Exercise Video Games|12 weeks laboratory based exercise videogames
219140046|NCT03298919|BEHAVIORAL|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
219140047|NCT03298919|BEHAVIORAL|Home exercise videogames|videogame console and active videogames
219717780|NCT07114107|DRUG|basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA|"All participants need basic control drugs contains antihistamines(Ebastine 10 mg once daily for 2 weeks), mometasone furoate nasal spray(Spray 2 puffs into each nostril, each puff contains 50 μg of mometasone furoate, i.e., 100 μg per administration, once daily for 2 weeks).~Asthma participants should added Inhaled corticosteroids-long-acting beta-agonists (ICS-LABA) therapy. For mild to moderate asthma: budesonide/formoterol (160μg/4.5μg) , with 1 inhalation each time, twice daily, or salmeterol/fluticasone propionate (50μg/100μg) with 1 inhalation each time, twice daily. For moderate to severe asthma: Budesonide/Formoterol (320μg/4.5μg), with 1 inhalation each time, twice daily; or salmeterol/fluticasone propionate (50μg/250μg or 50μg/500μg) with 1 inhalation each time, twice daily. Dosage adjustments should be evaluated and determined by the physician based on the patient's disease control status."
219140048|NCT03298919|BEHAVIORAL|Home Standard Exercise|Personalized physical activity promotion materials
219140049|NCT00155558|DRUG|5-Fluorouracil, Leucovorin|
219140050|NCT03861169|DEVICE|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
219140051|NCT04126109|OTHER|questionaire|A questionaire will be offered to every parents
219140052|NCT00366171|DRUG|Bifeprunox|
219140053|NCT04848649|OTHER|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
219717781|NCT07114107|DEVICE|OPEP（Oscillating Positive Expiratory Pressure device）|Oscillating Positive Expiratory Pressure (OPEP) device contain a inner ball that creates a resistance and oscillates when the patient blows through the device. This resistance helps splint the airways open during exhalation whilst the oscillation loosens the mucous within the airways. This makes it easier for some patients to clear their sputum.
219229221|NCT00856687|DRUG|PF-03893787|Oral, two doses 12 hours apart
219229222|NCT00856687|DRUG|Placebo|Oral, two doses 12 hours apart
219229223|NCT00856687|DRUG|Montelukast|Oral, two doses 12 hours apart
219229224|NCT01409837|DRUG|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
219229225|NCT03960645|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
219717782|NCT07114809|DEVICE|Experimental group (EG) performing Anodal-tDCS (A-tDCS) and VR|"Patients in the EG group will undergo a simultaneous A-tDCS over the left DLFPC. The tDCS will be delivered by a battery-driven, constant current simulator, two holding bags of plant cellulose (7x5 cm) and two electrodes of conductive silicone. The active (anodal) electrode will be placed by means of a cap on the scalp overlying the left DLPFC (46 Brodmann Area). The reference electrode will be located over the right shoulder. The choice of the left DLPFC as the site of stimulation relies upon the evidence that this region has a critical role in the top-down control of the task-relevant stimuli processing (Miller 2001).The DLPFC contributes to increase cognitive control through its connections with the anterior cingulate cortex and has been shown to enhance working memory and executive function. During the cognitive training (on-line procedure), A-tDCS (current of 1,5 mA) will be delivered for 20 minutes, while maintaining the current density (0.06 mA/cm2) below the safety limits."
219717783|NCT07114809|DEVICE|Sham Comparator: Control group (CG) performing sham-tDCS (S-tCDS) and VR|CG will receive a S-tDCS over the DLPFC. In the S-tDCS session, the current will be turned off 30 sec after the beginning of the stimulation and turned on for the last 30 sec. By doing this, the patient feels an itching sensation below the electrodes at the beginning and at the end of stimulation, making this condition indistinguishable from the real A-tDCS stimulation. Doing this, all the subjects will be blinded on the type of stimulation. As well as in the EG, CG performs cognitive training including motor and cognitive exergames that incorporate enjoyment, technology, and health care.
219717784|NCT07115771|OTHER|Postoperative analgesia management|After determining the L5-S1 level with ultrasound guidance, an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany) will be advanced in a cranio-caudal direction. Following hydrodissection, 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered.
219229226|NCT02638506|DRUG|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
219229227|NCT02638506|OTHER|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
219229228|NCT05610566|DEVICE|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
219140054|NCT04365400|DRUG|DS102|DS102 Epeleuton capsules
219140055|NCT04365400|DRUG|Placebo|Placebo capsules
219229229|NCT05474950|DRUG|minocycline|minocycline capsule (100mg) per day orally
219229230|NCT05545800|DRUG|metformin+empagliflozin+insulin glargine|Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.
219229231|NCT05545800|DRUG|IDegLira|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
219717785|NCT07115771|OTHER|Postoperative analgesia management|After identifying the adductor canal with a high-frequency linear US probe (GE ML6-15-D Matrix Linear), 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered into the adductor canal using an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany).
219717786|NCT07115251|BEHAVIORAL|Plans4Care|Caregivers assigned to treatment condition will receive: 1) access to the web-app; 2) an orientation to the web-app involving initial set up; and 3) a brief video explaining use of the web-app. Caregivers will be guided through accessing the platform, creating an account and completing a brief set of background questions.
219140056|NCT03938428|OTHER|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
219140057|NCT03489317|DRUG|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
219140058|NCT03489317|BEHAVIORAL|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
219140059|NCT03489317|DRUG|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
219140060|NCT03489317|DRUG|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
219140061|NCT05377346|OTHER|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
219229232|NCT05545800|DRUG|premixed insulin analogues|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
219229233|NCT01450007|DRUG|Ropivacaine|25 ml ropivacaine 0.5%
219229234|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (perineural)
219229235|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
219229236|NCT01450007|DRUG|Normal saline|5 ml normal saline (intravenous)
219229237|NCT01450007|DRUG|Normal saline|0.8 ml normal saline (perineural)
219229238|NCT05020028|DRUG|Cannabidiol (CBD)|Patients will be dispensed enough 25mg cannabidiol (CBD) Orally Disintegrating Tablets (ODT) to take a standard dose of 50mg three times daily for 84 days.
219229239|NCT05020028|DRUG|Placebo|25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
219229240|NCT00204399|BEHAVIORAL|Telephone counseling support|
219229241|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
219229242|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
219229243|NCT03744026|DEVICE|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
219229244|NCT03744026|DRUG|Carboplatin|Dose of carboplatin infusion is AUC4-6
219229245|NCT02501369|BEHAVIORAL|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
219229246|NCT00357019|DRUG|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
219717787|NCT07115160|OTHER|Training following a predefined protocol.|Training following a predefined protocol.
219717788|NCT07115901|OTHER|Guaranteed Income|Participants will receive guaranteed income (GI) to the amount of $6,750 over the study period. While all participants will receive the GI intervention, there will be variation in the method of disbursement. Some participants will receive the GI as a one-time lump sum payment whereas other participants will receive the same GI amount split into 9-monthly installments.
219717789|NCT07114029|PROCEDURE|Mesh-free Sacrocolpopexy via VNOTES|Mesh-free sacrocolpopexy is performed via the VNOTES technique to treat pelvic organ prolapse. Outcomes will be evaluated before and 6 months after surgery.
219717790|NCT07114289|PROCEDURE|Spontaneous breathing trial using pressure support ventilation|Patients will receive low level pressure support ventilation for 1 hour before extubation
219717791|NCT07114289|PROCEDURE|Spontaneous breathing trial using T-Piece|Patients will receive a T-piece with oxygen for 1 hour before extubation
219229247|NCT03851094|BEHAVIORAL|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
219229248|NCT02542332|OTHER|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
219229249|NCT00712413|DRUG|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
219229250|NCT06020300|DRUG|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
219140062|NCT04941924|PROCEDURE|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
219140063|NCT04941924|DEVICE|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
219140064|NCT04524832|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
219229251|NCT06020300|DRUG|Oral Pyridoxine 10 mg|Colchicine look alike placebo
219229252|NCT01332266|DRUG|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
219717792|NCT07114731|OTHER|Synchronous Action Observation Therapy|Real-time observation and execution of motor tasks through structured video modules designed based on participants' GMFCS level and extremity involvement.
219717793|NCT07114731|OTHER|Asynchronous Action Observation Therapy|Observation of structured motor task videos followed by delayed execution, adapted to individual GMFCS levels and extremity involvement patterns.
219717794|NCT07114627|DRUG|Blood sampling for pharmacokinetics|Extra blood samples are collected for assement of the pharmacokinetics of capecitabine.
219717795|NCT07115654|DRUG|CM336 (BCMA/CD3 bispecific antibody)|CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.
219717796|NCT07114497|DIAGNOSTIC_TEST|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
219552091|NCT05740696|PROCEDURE|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
219552092|NCT05740696|PROCEDURE|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
219552093|NCT05740696|PROCEDURE|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
219552094|NCT03670719|OTHER|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
219552095|NCT03670719|OTHER|Exercise|Exercises for the cervical spine
219717797|NCT07114497|DIAGNOSTIC_TEST|excised|Intervertebral disc tissues that are not degenerated will be collected during surgery and stored in the same manner as in the IVDD group. These samples will be used for comparative analysis of miRNA expression via rt-PCR to serve as the control baseline.
219717798|NCT07114497|DIAGNOSTIC_TEST|Diagnostic work up|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
219717799|NCT07114705|DIAGNOSTIC_TEST|Transvaginal ultrasound|This is the only method
219717800|NCT07114783|DEVICE|Dual-function semi-rigid thoracoscopy|Patients received pleural biopsy via dual-function semi-rigid thoracoscopy.
219717801|NCT07114783|DEVICE|Rigid thoracoscopy|Patients received pleural biopsy via rigid thoracoscopy.
219140065|NCT04107129|PROCEDURE|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
219140066|NCT04107129|OTHER|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
219229253|NCT01332266|DRUG|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
219229254|NCT02196610|OTHER|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
219229255|NCT02022293|DRUG|Atorvastatin|Patients in this group will take 20mg per night.
219229256|NCT02022293|OTHER|Placebo|
219229257|NCT02734706|DIETARY_SUPPLEMENT|LRC™ capsule|Twice per day (BID), 9 weeks
219229258|NCT02734706|OTHER|Placebo capsule|Twice per day (BID), 9 weeks
219552096|NCT06076941|OTHER|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
219140067|NCT04107129|DIAGNOSTIC_TEST|Blood sample|Estradiol and Progesterone levels in the blood will be checked
219140068|NCT06281431|PROCEDURE|Echogenic nerve block needle|A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
219140069|NCT06281431|PROCEDURE|Non-echogenic nerve block needle|A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
219140070|NCT06278025|DIAGNOSTIC_TEST|assessment|"DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle."
219140071|NCT00993850|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
219140072|NCT00993850|OTHER|Bipolar education|Psychoeducation
219229259|NCT03306498|DRUG|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
219229260|NCT03302091|DRUG|BI 1467335|28 day treatment period
219229261|NCT02086461|DEVICE|Pneumatic pyloric dilatation|
219229262|NCT02086461|OTHER|15 mm pyloric balloon dilatation|
219229263|NCT01536704|DRUG|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
219229264|NCT01536704|DRUG|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
219229265|NCT02792855|DEVICE|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
219229266|NCT02792855|DEVICE|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
219229267|NCT02680015|BEHAVIORAL|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
219552097|NCT02971813|BEHAVIORAL|Facebook|"1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
219552098|NCT01245491|OTHER|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
219552099|NCT02822482|DRUG|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
219552100|NCT02822482|DRUG|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
219552101|NCT00203320|DRUG|etanercept given by perispinal administration|
219552102|NCT04445701|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
219552103|NCT04445701|DRUG|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
219552104|NCT04445701|DRUG|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
219552105|NCT06099990|DRUG|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
219552106|NCT06099990|DRUG|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
219552107|NCT00504179|PROCEDURE|Osteopathic Manipulative Treatment|
219552108|NCT01897987|BIOLOGICAL|Pneumostem®|
219552109|NCT01897987|BIOLOGICAL|normal saline|
219552110|NCT05344287|OTHER|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
219140073|NCT04643236|BEHAVIORAL|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
219140074|NCT04643236|BEHAVIORAL|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
219140075|NCT00273949|DRUG|lactulose|
219140076|NCT04567888|BEHAVIORAL|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
219229268|NCT04301999|PROCEDURE|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
219229269|NCT04301999|PROCEDURE|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
219229270|NCT03139526|OTHER|observational study so no intervention|observational study, so no intervention
219229271|NCT00994851|DRUG|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
219229272|NCT00994851|DRUG|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
219229273|NCT03233152|DRUG|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
219229274|NCT03233152|DRUG|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
219552111|NCT05344287|OTHER|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
219552112|NCT05418985|BEHAVIORAL|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
219229275|NCT00986752|DEVICE|Stenting (Smart Stent)|Nitinol stent
219229276|NCT00986752|DEVICE|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
219229277|NCT00986752|PROCEDURE|Atherectomy (SilverHawk device)|Atherectomy
219229278|NCT02124044|DRUG|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
219552113|NCT03103828|BEHAVIORAL|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
219552114|NCT03103828|BEHAVIORAL|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
219552115|NCT03103828|BEHAVIORAL|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
219229279|NCT02124044|DRUG|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
219229280|NCT02487680|DIETARY_SUPPLEMENT|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
219229281|NCT02487680|DIETARY_SUPPLEMENT|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
219140077|NCT02817724|DEVICE|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
219140078|NCT02817724|OTHER|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
219140079|NCT03874650|BEHAVIORAL|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
219140080|NCT03874650|BEHAVIORAL|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
219140081|NCT03874650|BEHAVIORAL|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
219140082|NCT01052233|PROCEDURE|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
219140083|NCT01052233|PROCEDURE|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
219140084|NCT05128019|BEHAVIORAL|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
219140085|NCT01137266|DEVICE|TENS|TENS
219140086|NCT06367517|DRUG|Tocilizumab|Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
219140087|NCT03414736|DRUG|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
219140088|NCT02376036|DRUG|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
219140089|NCT02376036|DRUG|Placebo|Placebo comparator.
219140090|NCT02376036|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
219140091|NCT05981534|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
219140092|NCT05981534|DRUG|Placebo|Placebo will be used for 6 months
219140093|NCT00803933|DRUG|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
219140094|NCT00803933|DRUG|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
219140095|NCT04028635|BEHAVIORAL|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
219552116|NCT02361957|DIETARY_SUPPLEMENT|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
219140096|NCT04028635|BEHAVIORAL|Cognitive behavioral therapy|Usual CBT
219140097|NCT04671719|BIOLOGICAL|blood sample|blood sample for circulating autotaxin measurement (5ml).
219140098|NCT06440824|DRUG|Romiplostim N01|2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication
219140099|NCT06440824|DRUG|Recombinant Human Thrombopoietin|30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication
219140100|NCT00630188|OTHER|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
219140101|NCT00630188|OTHER|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
219552117|NCT02361957|DIETARY_SUPPLEMENT|Placebo|Placebo
219140102|NCT05300399|DEVICE|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
219140103|NCT00199342|DRUG|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
219140104|NCT03870854|PROCEDURE|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
219140105|NCT03145935|DIAGNOSTIC_TEST|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
219140106|NCT03145935|DIAGNOSTIC_TEST|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
219140107|NCT03320096|DEVICE|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
219552118|NCT05743634|BIOLOGICAL|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219552119|NCT05743634|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219552120|NCT05743634|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219552121|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
219552122|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
219552123|NCT02998606|DRUG|Naloxegol|MOVANTIK™ 25 mg, daily
219552124|NCT02998606|DRUG|Placebo Oral Capsule|Placebo 25 mg, daily
219552125|NCT02466087|DRUG|Mg Cl|Four supplements a day for 6 weeks.
219552126|NCT03915977|BEHAVIORAL|Post ICU recovery program|Standardized follow up program
219552127|NCT00878787|DEVICE|Transcranial magnetic stimulation|
219140108|NCT01002768|DRUG|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
219140109|NCT01002768|DRUG|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
219140110|NCT04136496|DEVICE|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
219140111|NCT05456386|BEHAVIORAL|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
219229282|NCT04081532|PROCEDURE|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
219140112|NCT04485156|DRUG|High-dose rifampicin|30mg/kg
219140113|NCT04485156|DRUG|Isoniazid|300mg
219140114|NCT04485156|DRUG|Pyrazinamide|20-30mg/kg
219140115|NCT04485156|DRUG|Ethambutol|15-20mg/kg
219140116|NCT04485156|DRUG|Rifampicin|10mg/kg
219140117|NCT02772653|OTHER|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140118|NCT02772653|OTHER|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140119|NCT02772653|OTHER|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140120|NCT02772653|OTHER|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140121|NCT02772653|OTHER|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140122|NCT02772653|OTHER|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
219140123|NCT04577625|DIETARY_SUPPLEMENT|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
219552128|NCT05392569|OTHER|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
219552129|NCT03209024|OTHER|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
219552130|NCT03209024|DEVICE|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
219552131|NCT02930135|PROCEDURE|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
219552132|NCT04633616|OTHER|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
219552133|NCT04633616|OTHER|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
219140124|NCT00750750|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
219140125|NCT00750750|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
219140126|NCT00750750|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
219140127|NCT00750750|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
219229283|NCT02815865|DEVICE|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
219229284|NCT02815865|DEVICE|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
219140128|NCT06552390|PROCEDURE|Cardiac Rehabilitation|"HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5."
219140129|NCT00595205|OTHER|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
219140130|NCT05818904|OTHER|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
219140131|NCT03582618|DRUG|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
219140132|NCT03582618|DRUG|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
219140133|NCT02939469|OTHER|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
219140134|NCT01899872|BEHAVIORAL|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
219140135|NCT01899872|BEHAVIORAL|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
219140136|NCT00755781|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
219140137|NCT04946045|OTHER|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
219140138|NCT00215345|DRUG|Taxotere|
219140139|NCT00215345|DRUG|Celecoxib|
219140140|NCT05274334|OTHER|Assessment of de novo lipogenesis non-invasively in exhaled breath|"1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
219140141|NCT02309580|DRUG|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
219140142|NCT05541393|BEHAVIORAL|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
219140143|NCT00709644|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid.|
219140144|NCT00261053|DRUG|i.v. recombinant human C1 inhibitor|
219140145|NCT00436644|DRUG|Lapatinib|1250 mg orally days 1 -28.
219140146|NCT00436644|DRUG|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
219140147|NCT05843136|OTHER|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
219140148|NCT04994054|DIETARY_SUPPLEMENT|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
219140149|NCT04994054|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,400 mg/day for 12 weeks
219140150|NCT03229707|DEVICE|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness."
219140151|NCT03229707|DEVICE|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
219552134|NCT01623804|DEVICE|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
219552135|NCT01623804|DEVICE|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
219140152|NCT01114945|DEVICE|McGrath|Intubation with the McGrath device
219140153|NCT01114945|DEVICE|GlideScope|Intubation with the GlideScope device
219140154|NCT01114945|DEVICE|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
219140155|NCT01114945|DEVICE|Video-Mac|Intubation with the Video-Mac device
219140156|NCT04629118|DEVICE|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
219552136|NCT05452434|DRUG|mirabegron|mirabegron 50mg QD for 12 weeks.
219552137|NCT01891058|DEVICE|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
219552138|NCT06678958|PROCEDURE|Reconstruction of acetabular defect by trabecular metal augment|The augments were used in the flying buttress position
219140157|NCT05481333|DRUG|REGN7999|Ascending IV or SC dose administered per protocol
219140158|NCT05481333|DRUG|Placebo|Ascending IV or SC dose administered per protocol
219140159|NCT04683159|DRUG|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
219140160|NCT04683159|DRUG|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
219140161|NCT01064804|DRUG|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
219140162|NCT04276402|PROCEDURE|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
219140163|NCT03326648|OTHER|Strength training|Heavy load strength training performed twice a week for 10 weeks.
219140164|NCT03326648|DIETARY_SUPPLEMENT|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
219140165|NCT00908817|DRUG|triamcinolone acetonide|paste applied over tracheal tube for lubrication
219140166|NCT00908817|DRUG|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
219140167|NCT04347135|DRUG|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
219140168|NCT05309980|OTHER|standard of care|retrospective study : standard of care
219140169|NCT01490580|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
219140170|NCT01490580|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
219229285|NCT02815865|DRUG|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
219552139|NCT03065699|DEVICE|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
219552140|NCT00997477|DRUG|Foradil Combi (Formoterol-budesonide)|
219140171|NCT03437642|BEHAVIORAL|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
219140172|NCT06024369|DEVICE|CPM Device|Wearable monitor used for 5 minutes per day.
219140173|NCT05356572|DEVICE|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
219140174|NCT05356572|DEVICE|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
219140175|NCT05356572|DEVICE|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
219140176|NCT01802866|DRUG|ACU-4429|Take orally once daily for 24 months
219140177|NCT01802866|DRUG|Placebo|Take orally once daily for 24 months
219140178|NCT00413595|OTHER|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
219140179|NCT04300426|DRUG|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
219140180|NCT02200159|DRUG|Sedation with dexmedetomidine|
219140181|NCT01130558|OTHER|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
219140182|NCT04381273|OTHER|No intervention|questionnaire-based assessment
219140183|NCT03572023|OTHER|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
219140184|NCT03572023|OTHER|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
219140185|NCT03329066|BEHAVIORAL|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
219140186|NCT03329066|BEHAVIORAL|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
219140187|NCT03329066|BEHAVIORAL|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
219140188|NCT03330418|BIOLOGICAL|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
219552141|NCT01999088|OTHER|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
219552142|NCT01999088|OTHER|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
219229286|NCT03019432|BEHAVIORAL|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
219229287|NCT01772199|DRUG|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
219229288|NCT01772199|DRUG|Placebo|White to almost white, round tablets. Once daily orally.
219552143|NCT05053724|OTHER|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
219140189|NCT03330418|BIOLOGICAL|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
219140190|NCT00756730|DRUG|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
219229289|NCT02822599|DRUG|RiaStAP|To decrease post-operative bleeding volume.
219140191|NCT00756730|DRUG|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
219140192|NCT01872403|DRUG|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
219140193|NCT04320186|BEHAVIORAL|Entertainment education|
219140194|NCT04320186|OTHER|video|video
219229290|NCT02822599|DRUG|Saline|Placebo consisting of normal saline 0.9%
219229291|NCT00851513|DRUG|Lidocaine|local anesthetics
219229292|NCT00851513|DRUG|Depmedrol|local steroids
219229293|NCT00851513|OTHER|physiological serum|important volumes of physiological serum
219229294|NCT05352737|DIAGNOSTIC_TEST|methylmalonic acid testing|
219229295|NCT02128269|BIOLOGICAL|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
219229296|NCT06026943|DEVICE|DaRT seeds insertion|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
219229297|NCT00878189|DRUG|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
219229298|NCT04753450|OTHER|No intervention|No intervention
219552144|NCT06793592|BEHAVIORAL|Behaviorally informed recruitment message|Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.
219552145|NCT06793592|BEHAVIORAL|Simplified direct message with no employer value proposition|Study participants will receive a simplified message that does not highlight any specific employer value proposition.
219552146|NCT06793592|BEHAVIORAL|No message|Study participants will not receive a recruitment message.
219552147|NCT06094842|DRUG|Bendamustine|Given IV
219552148|NCT06094842|PROCEDURE|Biopsy|Undergo tissue biopsy
219552149|NCT06094842|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219552150|NCT06094842|PROCEDURE|Bone Scan|Undergo bone scan
219552151|NCT06094842|PROCEDURE|Bridge Therapy|Undergo bridging therapy
219552152|NCT06094842|PROCEDURE|Computed Tomography|Undergo CT
219552153|NCT06094842|DRUG|Cyclophosphamide|Given IV
219552154|NCT06094842|PROCEDURE|Echocardiography|Undergo ECHO
219552155|NCT06094842|DRUG|Fludarabine|Given IV
219552156|NCT06094842|PROCEDURE|Leukapheresis|Undergo leukapheresis
219552157|NCT06094842|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219552158|NCT06094842|BIOLOGICAL|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
219552159|NCT06094842|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
219552160|NCT01206803|DRUG|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
219552161|NCT02160613|PROCEDURE|Open flap debridement|an access flap
219552162|NCT03522649|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
219552163|NCT03522649|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
219552164|NCT03522649|DRUG|Leucovorin|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
219552165|NCT03522649|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
219552166|NCT03192813|DEVICE|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
219552167|NCT03192813|DEVICE|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
219552168|NCT04182555|DEVICE|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
219140195|NCT02323529|DRUG|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
219140196|NCT00064714|DRUG|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
219140197|NCT00064714|DRUG|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
219140198|NCT01161498|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection
219140199|NCT01161498|RADIATION|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
219140200|NCT01161498|DRUG|Cisplatin|Administered by intravenous infusion
219140201|NCT04677322|DRUG|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
219140202|NCT06271304|DEVICE|Blue blocking eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
219140203|NCT06271304|DEVICE|Low filtration eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
219140204|NCT05095246|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
219140205|NCT04476745|DIETARY_SUPPLEMENT|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
219140206|NCT00967512|DRUG|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
219140207|NCT00967512|DRUG|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
219140208|NCT00967512|DRUG|idarubicin, cytarabine|idarubicin, cytarabine
219140209|NCT01544062|DRUG|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
219140210|NCT01544062|DRUG|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
219140211|NCT01548846|RADIATION|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
219140212|NCT00873899|DEVICE|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
219140213|NCT05928819|PROCEDURE|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
219140214|NCT00212056|DRUG|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
219140215|NCT00212056|DRUG|Control|placebo
219140216|NCT04222270|BEHAVIORAL|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
219140217|NCT06538558|DRUG|Tezampanel|Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
219140218|NCT06538558|DRUG|Placebo|Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
219140219|NCT01312337|DRUG|salvage iressa|Iressa 250mg per day until progression
219140220|NCT03873324|DRUG|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
219552169|NCT04182555|DIAGNOSTIC_TEST|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
219552170|NCT04182555|DEVICE|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
219552171|NCT04182555|OTHER|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
219552172|NCT06173960|DEVICE|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
219552173|NCT05462080|DIAGNOSTIC_TEST|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
219552174|NCT02231957|OTHER|educational text message reminders|
219552175|NCT02231957|OTHER|conventional text message reminders|
219552176|NCT03318133|PROCEDURE|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
219229299|NCT01623011|PROCEDURE|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
219717802|NCT07115498|BEHAVIORAL|iTAG|Participants in this intervention start by receiving a brief (15 minute) in-person standard-of-care counseling session focused on increasing their knowledge of HIV treatment adherence and strategies to improve adherence. Following this session, they will then receive daily or less frequent text messages (SMS) over the course of three months. Messages are primary two-way, automated, and have preprogrammed response options. Message content includes HIV medication reminders, motivational messages, information on topics relevant to HIV treatment (e.g., HIV disclosure) in the form of quizzes, opportunities to reach out for support from clinic staff or peer mentors, and game-based messages including story messages, a weekly scoreboard, point system progress, and peer interactions.
219717803|NCT07116551|DEVICE|Abbott BE TAVI System|Abbott BE TAVI System
219717804|NCT07115056|DRUG|Tranexamic Acid (TXA)|Oral tranexamic acid (TXA) is administered at a dose of 1.95 grams per day, divided into three 650 mg capsules taken once daily, starting on postoperative day (POD) 1 through POD 10 (10 total doses; 30 capsules) to the treatment group.
219140221|NCT03873324|DRUG|Placebo|matching placebo capsules
219140222|NCT00005813|BIOLOGICAL|bispecific antibody MDX447|
219140223|NCT00005813|BIOLOGICAL|lymphokine-activated killer cells|
219140224|NCT00005813|PROCEDURE|conventional surgery|
219140225|NCT01343654|BEHAVIORAL|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
219140226|NCT01343654|BEHAVIORAL|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
219140227|NCT03782558|PROCEDURE|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
219140228|NCT04842669|OTHER|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
219140229|NCT04842669|OTHER|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
219140230|NCT06477302|BEHAVIORAL|Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)|Patients will be given a measurement instrument to determine the level of therapeutic adherence.
219140231|NCT03103971|BIOLOGICAL|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
219140232|NCT03103971|DRUG|Cyclophosphamide|Given IV
219140233|NCT03103971|DRUG|Fludarabine|Given IV
219140234|NCT03103971|OTHER|Laboratory Biomarker Analysis|Correlative studies
219140235|NCT03103971|PROCEDURE|Leukapheresis|Undergo leukapheresis
219229300|NCT01623011|PROCEDURE|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
219717805|NCT07115056|DRUG|Placebo|Participants in this arm will receive oral placebo capsules (microcrystalline cellulose), 3 capsules daily from postoperative day (POD) 1 to POD 10, for a total of 10 doses (30 capsules).
219717806|NCT07114588|DIETARY_SUPPLEMENT|ETHANWELL BALANCED|A nutritional powder providing 250 kcal, 13.5 g protein (including 6.75 g whey protein and 2740 mg BCAAs), and 166.953 mg POLYCAN® (β-glucan) per serving. Administered 3 times daily for 8 weeks.
219717807|NCT07114588|BEHAVIORAL|Elastic Band Training|Participants perform 5 specific resistance exercises (push up \& press down, straight arm lift, seated rowing, squat, seated leg raise). Each exercise is done in 3 sets of 10 reps, 3 times per week, for 8 weeks.
219140236|NCT03103971|OTHER|Pharmacological Study|Correlative studies
219140237|NCT00180102|DRUG|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
219140238|NCT00180102|PROCEDURE|early allogeneic PBSCT within induction therapy|
219140239|NCT00180102|PROCEDURE|autologous PBSCT|
219140240|NCT00163085|DRUG|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
219140241|NCT00241423|DRUG|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
219140242|NCT00241423|DRUG|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
219140243|NCT00392678|DRUG|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
219140244|NCT00392678|DRUG|Placebo|Placebo to Salsalate
219140245|NCT01694628|BEHAVIORAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
219140246|NCT02294643|DRUG|Sarpogrelate|
219140247|NCT02294643|DRUG|Aspirin|
219140248|NCT02294643|DRUG|Clopidogrel|
219140249|NCT02294643|DRUG|Placebo (for Sarpogrelate)|
219140250|NCT04117191|DIETARY_SUPPLEMENT|Doctor's Best L-Tryptophan|2g tryptophan loading once
219140251|NCT01979354|DRUG|Spinal morphine|0.15 mg spinal morphine
219140252|NCT03775369|OTHER|endurance training|physical activity and exercising (PAE)
219140253|NCT03775369|OTHER|social support and counseling|social support and counseling
219140254|NCT03775369|OTHER|resistance training|physical activity and exercising (PAE)
219140255|NCT01970748|DRUG|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
219140256|NCT01970748|PROCEDURE|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
219140257|NCT02981706|PROCEDURE|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
219140258|NCT02981706|PROCEDURE|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
219140259|NCT02328352|PROCEDURE|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
219717808|NCT07116356|DIAGNOSTIC_TEST|Antibiotic administration|different samples were collected from patients admitted at oncology center at sohag
219717809|NCT07116356|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|"Molecular detection of carbapenem resistant genes:~* Extraction of nucleic acid from isolated organisms by boiling.~* Primers will be used for detection of carbaenem resistant genes"
219717810|NCT07115316|OTHER|Exercises|"1. Nordic hamstring curls~2. Seated leg curls~3. Prone leg curls~4. Knee Straightening (Extension)~5. Knee Bend (Flexion)~6. Inner Range Quads~7. Straight Leg Raise~8. Lunge to Split Lunge~9. Single Leg Sit to Stand~10. Standing Hamstring Curls~11. Double/Single Leg Bridge~12. Side Lie Hip Abductions~13. Crab Walks~14. Forward Step Ups~15. Calf Raises~16. Single Leg Balance~17. Clock Face Mini Squat~18. Arabesque Clock~19. Two-Legged Jump / Single-Legged Hop"
219717811|NCT07114315|DRUG|AK112|Following a predefined dose and date.
219717812|NCT07114315|DRUG|AK130|Following a predefined dose and date.
219717813|NCT07113756|DRUG|topical metformin 30% cream|"each patient will use topical metformin 30% cream twice daily for 12 weeks.~o Preparation of metformin 30% cream: Weighing 30 gm standard metformin ( E. Merck ) supplied by chemtech. Using digital balance then Grinding the powder by pestle \& Morter then Adding 30 ml propylene glycol and alcohol to reach a total 100 gm weight then adding parabens mix as preservative with 0.5 gm then mix thoroughly followed by Levegating \& mixing then divide to smaller well tighten closure with labels"
219717814|NCT07113756|DRUG|betamethasone valerate.1% cream|"each patient (age, sex and BMI matched) will use topical betamethasone valerate 0.1% cream twice daily for 12 weeks.~o Manufactured by Egyptian international pharmaceutical industries co. E.I.P.I.C.O. and will be purchased from local pharmacy, Sohag, Egypt."
219717815|NCT07114978|DEVICE|Echocardiography|simple, bedsided, non-invasive
219717816|NCT07115485|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
219717817|NCT07115485|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.5mg/kg
219717818|NCT07115485|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 3.0mg/kg
219717819|NCT07111546|DRUG|LBL-024 for Injection|Intravenous infusion.
219140260|NCT02328352|PROCEDURE|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
219140261|NCT02328352|PROCEDURE|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
219140262|NCT02328352|PROCEDURE|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
219717820|NCT07111546|DRUG|Durvalumab Injection|Intravenous infusion.
219140263|NCT05923008|DRUG|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
219140264|NCT04533139|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
219140265|NCT03958513|DRUG|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
219140266|NCT03958513|DRUG|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
219717821|NCT07111546|DRUG|Cisplatin Injection|Intravenous infusion.
219717822|NCT07111546|DRUG|Gemcitabine Hydrochloride for Injection|Intravenous infusion.
219140267|NCT05638204|BEHAVIORAL|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
219140268|NCT00005890|DRUG|corticotropin|
219140269|NCT03922243|OTHER|retrospective|Retrospective study to assess treatment done by dental students
219140270|NCT03795077|OTHER|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
219140271|NCT00028301|DRUG|Atazanavir|
219140272|NCT00028301|DRUG|Lopinavir/Ritonavir|
219140273|NCT00964184|DRUG|Metformin|
219140274|NCT00964184|BEHAVIORAL|Lifestyle modification|
219717823|NCT07111546|DRUG|Bevacizumab Injection|Intravenous infusion.
219140275|NCT06650930|DRUG|Oral calcium carbonate|All participants receive a single, open-label dose of oral calcium carbonate 3000mg
219140276|NCT04783181|BIOLOGICAL|AAV BBP-631|intravenous
219140277|NCT05012644|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
219140278|NCT05012644|DRUG|Aromatase inhibitor|Aromatase inhibitor
219717824|NCT07113548|BEHAVIORAL|Personalized iCBT for depression|"Participants receive 12 sessions of personalized treatment in an online iCBT program. The treatment includes the option for weekly written feedback from a psychologist, or video-based interventions depending on the participant's current status. The content of the 12-week program is tailored to the participant's individual symptom profile.~The treatment incorporates elements from standard Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Compassion-Focused Therapy (CFT), and Positive Activity Interventions (PAT).~The program consists of nine modules, each targeting a specific area:~Rumination,~Anhedonia,~Tearfulness and emotional regulation,~Sleep problems,~Difficulty concentrating,~Eating issues,~Low energy,~Social withdrawal,~Self-critical thinking,~The treatment concludes with support aimed at preventing relapse."
219717825|NCT07113548|BEHAVIORAL|Standard iCBT|"Standard iCBT consisting of a one size fits all progression of cognitive behavioral therapy over 12 weeks. This includes:~Introduction to Online Cognitive Behavioral Therapy~Start of Treatment~Rumination~Activity Monitoring~Activity Planning~Cognitive Restructuring~Behavioral Experiment I~Behavioral Experiment II~Core Beliefs I~Core Beliefs II~Relapse Prevention"
219717826|NCT06914713|DRUG|Jin-shui Huan-xian granule|"Jin-shui Huan-xian Granules: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks."
219717827|NCT06914713|DRUG|Jin-shui Huan-xian granule placebo|"Jin-shui Huan-xian granule placebo: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell."
219717828|NCT07111507|DRUG|Tarlatamab|Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.
219140279|NCT06070415|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
219140280|NCT06070415|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
219140281|NCT06070415|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
219717829|NCT07113691|DRUG|Iadademstat|Iadademstat is administered orally (PO) on an empty stomach (two hours after eating or one hour prior to food ingestion). After drinking the entire solution, the participant will be asked to refill the bottle with water and drink it again. Then they will drink another glass of water to wash their mouth and esophagus. Time of administration of the drug should be the same every day, preferentially in the mornings, and the time should be registered using the Dosing Instructions and Participant Drug Diary. If a dose is missed, the dose should be administered as soon as possible within 24 hours of the missed dose time. If more than 24 hours have passed, or a dose is vomited, the participant should call their medical team for instructions.
219140282|NCT02251613|DRUG|Olopatadine HCl ophthalmic solution, 0.1%|
219140283|NCT02251613|DRUG|Epinastine HCl ophthalmic solution, 0.05%|
219140284|NCT02600442|OTHER|non interventional study|
219140285|NCT02008734|DRUG|PD0332991|
219140286|NCT00255437|DRUG|ferumoxytol or oral iron|
219140287|NCT01303835|DRUG|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
219140288|NCT01303835|DRUG|Placebo|Randomized patients received placebo to be taken every night before bed.
219140289|NCT05298384|OTHER|Compression stockings|Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
219717830|NCT07113691|DRUG|Atezolizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1680mg on Day 1 (+/-3 days) of each 28-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the treating investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.~Administration of atezolizumab will be performed in a monitored setting where there is immediate access to trained personnel and adequate equipment and medicine to manage potentially serious reactions."
219717831|NCT07113691|RADIATION|SBRT|The first fraction of SBRT should be delivered after the initiation of iadademstat and atezolizumab, ideally between Cycle 1, Day 8, and Cycle 1, Day 15. Initiation of SBRT may be delayed up to 14 days beyond Cycle 1, Day 15 if iadademstat dose adjustment is required for toxicity
219140290|NCT02517411|OTHER|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
219140291|NCT02517411|OTHER|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
219140292|NCT00423007|DRUG|Bromfenac|
219140293|NCT00423007|DRUG|Placebo|
219140294|NCT04283409|OTHER|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
219140295|NCT04283409|OTHER|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
219140296|NCT06619639|BEHAVIORAL|Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
219140297|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks|
219140298|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks, telephone counselling|
219229301|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
219229302|NCT01750788|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
219717832|NCT06921603|OTHER|Furosemide (Standard Diuretic) Treatment|Participants in this group will receive intravenous furosemide as part of their routine care, based on clinical assessments including symptoms, physical examination. Daily POCUS imaging will be performed for research purposes; however, the findings will not be shared with the treating clinical team. Fluid management decisions and discharge planning will follow usual care protocols, without additional imaging-based guidance.
219229303|NCT05413993|RADIATION|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
219229304|NCT04017364|DEVICE|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
219229305|NCT04017364|DEVICE|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
219140299|NCT06631560|DIAGNOSTIC_TEST|ELISA testing|Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
219140300|NCT06629116|DRUG|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).|Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
219140301|NCT06629805|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
219229306|NCT02560155|DRUG|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
219140302|NCT06629805|DIETARY_SUPPLEMENT|Placebo|Placebo 1,000 mg/day for 12 weeks
219229307|NCT02560155|DRUG|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
219140303|NCT06714539|DEVICE|Patient Specific Virtual Reality Stimulation|A novel virtual reality (VR) simulator for spine procedures that will take patient specific medical imaging (3D scans) and create a virtual patient that surgical procedures can be performed on.
219140304|NCT06713941|OTHER|Study of the treatment|Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
219140305|NCT06713096|BEHAVIORAL|Tempos Certos protocol|Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.
219229308|NCT05391867|DRUG|Lenvatinib|Tyrosine kinase inhibitor
219229309|NCT05774262|PROCEDURE|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
219229310|NCT05774262|PROCEDURE|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate \> 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
219140306|NCT06709911|BEHAVIORAL|Basic Manipulation Stretching|This group received standard hand tenosynovitis stretching therapy, which focused on the flexor and extensor muscle groups of the wrist and hand for release. Muscle tension and tendon adhesions were relieved by basic stretching maneuvers, with each intervention lasting 20-30 minutes, twice a week, over a 4- to 8-week period.
219140307|NCT06709911|BEHAVIORAL|Massage and Tui Na Manipulation|The group received Tui Na manipulation interventions, including pointing, pressing and rolling techniques for the tendon sheath and thumb region, focusing on the stimulation of acupoints such as Hegu, Yangchi and Waiguan. The aim of Tui Na manipulation was to relieve the inflammatory reaction around the tendon sheath, promote blood circulation and improve local function. Each intervention lasts 20-30 minutes, twice a week for 4-8 weeks.
219140308|NCT06709911|BEHAVIORAL|Blood flow restriction training|This group used pressurized blood flow restriction training, in which the proximal part of the temporal joint was pressurized by a pressurized device to restrict blood flow. The training consisted of low-load wrist flexion and extension, fist clenching and unclenching, and wrist rotation. The training intensity was set at 20%-50% 1RM, and the frequency was 2 times per week for 4 to 8 weeks. Pressurization was performed before training and the pressure was set in the range of 20-50 mmHg, and the training period was supervised by a professional.
219140309|NCT06709911|BEHAVIORAL|Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention|This group received the combined intervention of magnetic bead pressure stimulation and Tui Na manipulation. Before treatment, the magnetic beads were applied to specific acupoints on the hand (e.g., Hegu, Ahshi, Waiguan, etc.), fixed by breathable patches, and combined with Tui Na manipulation. During Tui Na, the magnetic beads are pressed and kneaded to further enhance the stimulation effect of the acupoints. After Tui Na, the magnetic beads remain in the affected area and can be pressed and kneaded 2-3 times a day for 3 minutes each time to produce a slight sensation of soreness and distension. The aim of the massage is to relieve the inflammatory reaction around the tendon, loosen muscle tension and tendon sheath adhesions and promote blood circulation and joint mobility. The cycle of intervention is 4 to 8 weeks.
219140310|NCT06712043|BEHAVIORAL|Personalised Exercise|An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
219140311|NCT06712043|BEHAVIORAL|Historical control group|Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
219140312|NCT04687085|OTHER|10 minute mindful meditation recording|10 minute mindful meditation recording
219140313|NCT06712160|DIAGNOSTIC_TEST|Artificial Intelligence|The number of canals detected by AI
219140314|NCT05052983|DRUG|Nemolizumab|Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
219140315|NCT05052983|DRUG|Placebo|Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
219140316|NCT06713395|OTHER|The control group received standard postoperative care|standard postoperative care
219229311|NCT06374407|BEHAVIORAL|Dietary intervention based on the MIND diet|A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
219229312|NCT03165305|OTHER|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
219229313|NCT00703092|DRUG|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
219229314|NCT05255744|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
219229315|NCT05396365|DIAGNOSTIC_TEST|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
219229316|NCT04155372|PROCEDURE|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
219229317|NCT05173766|OTHER|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
219229318|NCT03748056|BEHAVIORAL|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
219229319|NCT03748056|BEHAVIORAL|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
219229320|NCT00539955|BEHAVIORAL|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
219229321|NCT00539955|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
219229322|NCT01558726|BEHAVIORAL|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
219229323|NCT01558726|BEHAVIORAL|Usual Treatment|The usual treatment used for regular patients of CAPSad
219229324|NCT06215326|BEHAVIORAL|moderate-intensity continuous training|Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
219140317|NCT06713395|OTHER|PERMA|"1. Establishment of the Integrated Psychological Intervention Team:~   The team consisted of 2 primary nurses, 4 specialist nurses, 1 psychologist, 2 physicians at the attending level or higher, and 2 researchers.~   Team Responsibilities: The primary and specialist nurses were responsible for implementing the intervention protocol. The physicians handled any adverse reactions experienced by the patients. The researchers were in charge of developing the intervention protocol and collecting data. All team members were required to undergo specialized training from the psychologist and pass an assessment before initiating the intervention.~2. Protocol Development:~   The intervention protocol, including specific content, team responsibilities, implementation process, and responses to adverse events, was carefully developed in written form by the researchers. The protocol was discussed and approved by all team members before implementation.~3. Protocol Implementation:~Emotional Support Intervention:"
219717833|NCT06921603|OTHER|POCUS-Assessed Diuretic Management|POCUS will be used to provide objective, non-invasive assessments of fluid status by measuring right internal jugular vein (RIJV) cross-sectional area (CSA) and calculating the Distensibility Index (DI). This information will be shared with the treating clinical team as an additional tool for fluid management. However, all final decisions regarding diuretic therapy will be made at the discretion of the treating physicians.
219717837|NCT07116239|DRUG|Edoxaban 60 mg|film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH
219717838|NCT07116239|DRUG|Enoxaparin 40 mg|enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE
219140318|NCT06713486|PROCEDURE|Fixed pressure obtained in the polysomnography for 28 days|home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days
219140319|NCT06713486|PROCEDURE|Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode|dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode (program B) for 28 days, using the apnea threshold obtained in the titration as the maximum EPAP pressure and adjusting the support pressure for inferred Vt to 8 ml/kg of ideal body weight. After the first 28 days, a polysomnography will be performed under therapy with the device, and the next morning, cycle ergometry will be conducted.
219140320|NCT03425643|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
219140321|NCT03425643|DRUG|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
219140322|NCT03425643|DRUG|Cisplatin|75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
219229325|NCT06215326|BEHAVIORAL|high-intensity interval training|Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
219717839|NCT07114822|BEHAVIORAL|Harnessing Online Peer Education|This group will have peer leaders that will engage participants in the groups. These peer leaders are those with type II diabetes that have over the recommended amount of exercise each week.
219717840|NCT07113886|PROCEDURE|Mixture of Autogenous and Xenograft Particulates|This group will receive guided bone regeneration using a 1:1 mixture of autogenous bone harvested from the mandibular ramus and xenograft bone substitute (e.g., Bio-Oss). The graft material will be covered with a titanium meshes. Standard flap design, fixation, and suturing techniques will be used
219140323|NCT03425643|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
219229326|NCT02520336|BEHAVIORAL|Reminder|
219229327|NCT02382172|BEHAVIORAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
219229328|NCT02382172|OTHER|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
219229329|NCT04347005|DRUG|Cohort 1: AR882|Single dose of AR882 or matching placebo
219229330|NCT04347005|DRUG|Cohort 2: AR882|Single dose of AR882 or matching placebo
219140324|NCT03425643|DRUG|Pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
219140325|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
219140326|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
219140327|NCT04133363|PROCEDURE|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
219140328|NCT05144217|DRUG|Placebo|1 capsule per day of placebo
219140329|NCT05144217|DRUG|2x 140 mg per day|2 capsule per day of silimarit
219140330|NCT05144217|DRUG|3x 280 mg per day|3 capsule per day of silimarit
219140331|NCT05144217|DRUG|1x 1120 mg|8 capsule per day of silimarit
219229331|NCT04347005|DRUG|Cohort 3: AR882|Single dose of AR882 or matching placebo
219229332|NCT04347005|DRUG|Cohort 4: AR882|Single dose of AR882 or matching placebo
219229333|NCT04347005|DRUG|Cohort 5: AR882|Single dose of AR882 or matching placebo
219229334|NCT04347005|DRUG|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
219229335|NCT04347005|DRUG|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
219229336|NCT04347005|DRUG|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
219140332|NCT05866016|BEHAVIORAL|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
219140333|NCT01254981|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
219140334|NCT03315507|DRUG|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
219140335|NCT00238446|DRUG|EC-MPS|
219140336|NCT04415333|DRUG|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
219140337|NCT04415333|DRUG|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
219140338|NCT04637750|BEHAVIORAL|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
219229337|NCT04347005|DRUG|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
219229338|NCT05121285|OTHER|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
219229339|NCT05121285|OTHER|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
219229340|NCT05015842|OTHER|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
219229341|NCT05015842|OTHER|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
219229342|NCT01273298|DRUG|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
219229343|NCT01273298|DRUG|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
219140339|NCT00849147|BIOLOGICAL|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
219140340|NCT00849147|BIOLOGICAL|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days"
219717841|NCT07113886|PROCEDURE|Patient-Specific Sticky Bone|This group will receive guided bone regeneration using patient-specific sticky bone, created by mixing autogenous bone and xenograft with autologous fibrin glue (PRF). The sticky bone graft will be molded and applied directly to the defect site, covered with a titanium meshes, and stabilized using standard surgical protocol.
219140341|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version B|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
219140342|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
219140343|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
219140344|NCT06174220|DRUG|Tideglusib|Tideglusib 1g po daily
219140345|NCT06174220|DRUG|Placebo|Matching placebo 1g po daily
219717842|NCT07115810|OTHER|No additional drugs(control Group)|No intervention
219717843|NCT07114939|DRUG|[18F]FluorThanatrace|Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.
219717844|NCT07114926|DIETARY_SUPPLEMENT|Taiwanese green propolis|"Intervention Details:~Experimental Group: Take two capsules of Taiwan Green Propolis (each containing 500 mg/mL of propolis) before breakfast and dinner daily, totaling four capsules/day for 12 consecutive weeks.~During the intervention period, both groups will maintain their usual diet and activity levels and receive the same health education on nutrition and exercise."
219717845|NCT07114926|DIETARY_SUPPLEMENT|placebo|Take placebo capsules identical in appearance, smell, and content, with the same dosage and frequency.
219717846|NCT07115186|BEHAVIORAL|Psychoeducation|Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
219717847|NCT07115186|BEHAVIORAL|guided written therapy|In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
219717848|NCT07115186|BEHAVIORAL|wait-list condition|Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.
219140346|NCT05138601|OTHER|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
219140347|NCT01210820|DEVICE|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
219140348|NCT04633980|DRUG|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
219229344|NCT06509594|OTHER|Protocol of Scapular Stabilization Exercises;|"Exercise for the middle trapezius and rhomboid muscles: Participants were instructed to stand with their arms hanging beside their bodies. Then, they were instructed to flex their elbows 90◦ holding an elastic band and performing an external rotation of the shoulder, pulling both scapula together. Subsequently, they returned to a neutral shoulder position with elbow flexion.~Exercise for the lower trapezius muscle: Participants were instructed to lie down in a prone position while holding an elastic band attached at one end under a mattress. They were then instructed to raise their shoulder 140◦.~Exercise for the serratus anterior muscle: Participants were instructed to stand and flex their elbows 90◦ while holding an elastic band fixed behind the participants. Next, they were instructed to move the arm forward with a protracted scapula."
219717849|NCT06920745|DEVICE|The TriClip System|The TriClip System
219717850|NCT07116603|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Participants completed the International Continence Questionnaire-Short Form (ICIQ-SF) and the Incontinence Impact Questionnaire (IIQ-7) form were completed
219717851|NCT07114263|DRUG|Group F (fentanyl group)|Group F (fentanyl group):will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 0.5 ml (25 mcg) Fentanyl and 1 ml glucose 5% with total volume of 3ml.
219717852|NCT07114263|DRUG|Group D :Dexmedetomidine group|Group D :Dexmedetomidine group: will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 1 ml (4 mcg) Dexmedetomidine and 0.5 ml glucose 5% with total volume of 3ml.
219717853|NCT07114263|DRUG|Group DF :Fentanyl and Dexmedetomidine group|Fentanyl and Dexmedetomidine group:will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5%, 0.5 ml (25 mcg) Fentanyl and 1 ml (4 mcg) Dexmedetomidine with total volume of 3ml.
219140349|NCT03980873|BEHAVIORAL|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
219140350|NCT02064660|DEVICE|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
219140351|NCT00019669|BIOLOGICAL|aldesleukin|
219140352|NCT00019669|BIOLOGICAL|fowlpox virus vaccine vector|
219140353|NCT00019669|BIOLOGICAL|gp100 antigen|
219140354|NCT04246619|DRUG|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
219140355|NCT04246619|DRUG|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
219140356|NCT00075972|BEHAVIORAL|Mood Tolearance|
219140357|NCT00075972|BEHAVIORAL|Mood Management|
219717854|NCT07114354|OTHER|PDCogniCare platform|Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease
219717855|NCT07113704|PROCEDURE|Conventional Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy technique starting at Calot's triangle. Used as the comparator group in this study.
219717856|NCT07113704|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy technique initiated at the gallbladder fundus and carried out retrogradely toward Calot's triangle. This method was applied to difficult gallbladders (Nassar Grade 3-4) to improve operative safety and avoid conversion to open surgery.
219717857|NCT07116226|OTHER|Medical Keto Education Program|4 hour asynchronous educational class
219140358|NCT00075972|DRUG|Nicotine Replacement therapy|
219140359|NCT02421081|PROCEDURE|vessel microsurgery|That is a surgery ro repair artery laceration.
219717858|NCT07115225|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
219717859|NCT07115225|OTHER|Analytical test - Shoulder Strength|Shoulder external rotation and internal rotation measured with a hand held dynanometer in supine lying
219140360|NCT02421081|PROCEDURE|tendon repair|That is a surgery ro repair tendon cut.
219140361|NCT02421081|PROCEDURE|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
219140362|NCT03635294|OTHER|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
219140363|NCT03692013|DRUG|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
219140364|NCT04456543|PROCEDURE|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
219140365|NCT02628093|DEVICE|THUNDERBEAT|Tissue dissection and vessels ligation
219140366|NCT02628093|DEVICE|LIGASURE|Tissue dissection and vessels ligation
219140367|NCT02768272|DEVICE|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
219140368|NCT02768272|PROCEDURE|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
219140369|NCT04628286|OTHER|Sham Laser|Sham Laser in plantar fascia
219140370|NCT04628286|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
219140371|NCT03865758|DEVICE|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
219140372|NCT00748150|BIOLOGICAL|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
219140373|NCT04672772|DRUG|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
219717860|NCT07115225|OTHER|Modified-Athletic Shoulder Test (M-AST)|Shoulder strength in the antero-posterior plane measured with a hand held dynanometer in prone lying
219140374|NCT04672772|DRUG|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
219140375|NCT03311568|DEVICE|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
219140376|NCT04505813|BIOLOGICAL|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
219717861|NCT07115225|OTHER|Physical performance test - Unilateral Seated Shot-Put Test (USSPT)|Set up requires that the subject is placed in a seated position (knees bent at 90° degrees) with their back against the wall, and a 3 kg medicine ball held at height of the shoulder. When ready, the subject will perform a shot put motion to push the medicine ball as far as possible in a horizontal direction. The average of three trials is recorded for each arm.
219717862|NCT07115225|OTHER|Physical performance test - modified-Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a push-up position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
219140377|NCT06416202|DEVICE|Advanced hybrid closed loop insulin pump|All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
219140378|NCT06416202|OTHER|Open Loop Insulin Delivery system|the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
219140379|NCT02631148|DRUG|Melatonin|2mg controlled release melatonin tablet
219140380|NCT02631148|DRUG|Placebo|placebo tablet identical to circadin
219140381|NCT04431934|DIETARY_SUPPLEMENT|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
219140382|NCT04431934|DIETARY_SUPPLEMENT|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
219140383|NCT04157855|PROCEDURE|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
219140384|NCT05752136|BIOLOGICAL|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
219140385|NCT01256736|DRUG|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
219140386|NCT01256736|DRUG|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
219140387|NCT03657017|DIAGNOSTIC_TEST|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
219140388|NCT02391207|PROCEDURE|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
219140389|NCT06533878|DRUG|HY-209|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
219140390|NCT06533878|DRUG|HY-209 placebo|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
219140391|NCT03919864|BEHAVIORAL|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
219140392|NCT03919864|BEHAVIORAL|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
219140393|NCT01191892|DRUG|carboplatin|
219140394|NCT01191892|DRUG|gemcitabine hydrochloride|
219140395|NCT01191892|DRUG|vandetanib|
219140396|NCT01191892|DRUG|Placebo|Placebo of vandetanib tablet
219140397|NCT04002973|DEVICE|INVSENSOR00037|Noninvasive regional oximeter.
219140398|NCT04745663|DRUG|Povidone-Iodine 0.3%|Low concentration iodine
219140399|NCT04745663|DRUG|Povidone-Iodine 5%|Standard concentration iodine
219140400|NCT03233919|DEVICE|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
219140401|NCT02378714|DRUG|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
219140402|NCT02378714|BEHAVIORAL|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
219140403|NCT02378714|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
219140404|NCT04775290|BEHAVIORAL|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
219140405|NCT02525796|DRUG|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
219140406|NCT02525796|DRUG|amiloride|amiloride, titrated up to a maximum of 10mg BID
219140407|NCT02525796|DRUG|Placebo|
219140408|NCT02525796|DRUG|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
219140409|NCT00001318|DRUG|interferon gamma|
219140410|NCT02488980|DRUG|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
219140411|NCT02488980|DRUG|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
219140412|NCT02488980|DRUG|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
219140413|NCT01820195|DRUG|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
219140414|NCT01820195|DRUG|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
219140415|NCT01820195|DRUG|Placebo group|The patients in this group will be received both oral placebo and IV placebo
219140416|NCT04147910|DRUG|KW-6356|Single oral dose of KW-6356
219229345|NCT06509594|OTHER|Protocol of Muscle Energy technique;|"During upper trapezius stretching, the participants were in seated position by holding the chair with one arm, and laterally tilted the head to the opposite side with the other hand pushing the head to increase lateral stretch.~For pectoralis muscle stretch, participants were asked to stand in front of the Doorframe with elbow bent at 90 degree and was asked to lean forward without Taking a step forward. The stretch is felt across the anterior chest, which is held for 15-30 seconds with 2-3 repetitions. For levator scapulae stretch, the subjects were asked to take the seated position while holding the chair with one hand in order to maintain shoulder depression, then To flex and rotate neck to the opposite side by placing the other hand at the back of their head and to slowly pull it down toward the armpit."
219229346|NCT00958048|DEVICE|non-invasive ventilation|CPAP, BiPAP
219140417|NCT03107962|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
219140418|NCT02618018|PROCEDURE|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
219140419|NCT01162876|DRUG|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
219140420|NCT03624413|BEHAVIORAL|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
219140421|NCT03624413|OTHER|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
219229347|NCT05020067|RADIATION|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
219229348|NCT01021748|DRUG|MK-2206|Oral tablets
219229349|NCT01021748|DRUG|AZD6244|Oral capsules
219229350|NCT01260883|DRUG|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
219229351|NCT01260883|DRUG|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
219229352|NCT01260883|DRUG|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
219229353|NCT02027350|DEVICE|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
219229354|NCT03070548|DRUG|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
219229355|NCT04907383|OTHER|quality of life|QoL assessment
219229356|NCT01566383|PROCEDURE|24-hr pH monitoring|"Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device"
219229357|NCT02319707|DRUG|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
219229358|NCT02319707|DRUG|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
219229359|NCT01829711|DRUG|Moxetumomab pasudotox|
219229360|NCT01829711|DRUG|IV Bag Protectant for Moxetumomab pasudotox|
219140422|NCT03329144|BEHAVIORAL|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
219140423|NCT04020718|BEHAVIORAL|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
219140424|NCT04020718|DRUG|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
219140425|NCT04020718|BEHAVIORAL|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
219140426|NCT00566514|DIETARY_SUPPLEMENT|D-ribose|5 grams administered orally TID
219140427|NCT00566514|OTHER|dextrose|5 grams orally TID
219140428|NCT01885845|DEVICE|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
219140429|NCT01885845|OTHER|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
219140430|NCT02835768|OTHER|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
219140431|NCT01261234|DRUG|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
219140432|NCT02385669|DRUG|Ipilimumab|Checkpoint blockade inhibitor
219140433|NCT02385669|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219140434|NCT05433935|OTHER|Observation|This is an observational study.
219140435|NCT04077151|BEHAVIORAL|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
219140436|NCT00970307|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
219140437|NCT00970307|BIOLOGICAL|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
219140438|NCT00970307|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
219140439|NCT00970307|BIOLOGICAL|Menjugate®|Intramuscular, two doses
219140440|NCT05061641|DRUG|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
219140441|NCT03597100|DEVICE|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
219140442|NCT02464293|OTHER|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
219140443|NCT03005197|DEVICE|Laser Doppler Flowmetry|
219140444|NCT01456715|BIOLOGICAL|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
219229361|NCT01214070|OTHER|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
219140445|NCT01456715|BIOLOGICAL|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
219140446|NCT00989937|DRUG|Oxytocin|20 IU BID or 40 IU BID
219140447|NCT00989937|DRUG|Placebo|20 IU BID or 40 IU BID
219229362|NCT01214070|BEHAVIORAL|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
219229363|NCT01214070|BEHAVIORAL|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
219229364|NCT01214070|BEHAVIORAL|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
219140448|NCT06467279|DEVICE|Target Controlled İnfusion|TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
219140449|NCT06467279|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
219140450|NCT04476095|DEVICE|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
219140451|NCT04476095|DEVICE|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
219140452|NCT00355914|PROCEDURE|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
219140453|NCT01740063|DRUG|DAS181-F02 formulation|
219229365|NCT01482091|DRUG|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
219229366|NCT01482091|DRUG|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
219229367|NCT01480258|BIOLOGICAL|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
219229368|NCT01480258|BIOLOGICAL|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
219229369|NCT01480258|BIOLOGICAL|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
219229370|NCT01480258|BIOLOGICAL|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
219229371|NCT01000207|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
219229372|NCT03477084|BIOLOGICAL|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
219229373|NCT01315977|DIETARY_SUPPLEMENT|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
219229374|NCT03799809|DRUG|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
219229375|NCT02953756|RADIATION|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
219229376|NCT04089202|OTHER|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
219229377|NCT04089202|OTHER|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
219229378|NCT06092177|PROCEDURE|Periodontal surgery with virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
219229379|NCT06092177|PROCEDURE|Periodontal surgery without virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
219229380|NCT03316170|BEHAVIORAL|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
219229381|NCT03316170|DRUG|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
219229382|NCT02636114|PROCEDURE|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
219229383|NCT02169414|DRUG|BIA 9-1067 5 mg|OPC, Opicapone
219140454|NCT01740063|DRUG|DAS181-F04 formulation|
219140455|NCT01740063|DRUG|Placebo|
219229384|NCT02169414|DRUG|BIA 9-1067 25 mg|OPC, Opicapone
219229385|NCT02169414|DRUG|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
219229386|NCT02169414|DRUG|Placebo|PLC, Placebo
219229387|NCT02169414|DRUG|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
219229388|NCT00368602|DRUG|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
219229389|NCT00368602|OTHER|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
219140456|NCT00480662|DRUG|alendronate|Duration of Treatment : 6 Months
219140457|NCT05390736|BEHAVIORAL|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
219140458|NCT05390736|BEHAVIORAL|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
219140459|NCT05390736|BEHAVIORAL|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
219140460|NCT05390736|BEHAVIORAL|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
219140461|NCT05390736|BEHAVIORAL|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
219140462|NCT05390736|BEHAVIORAL|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
219140463|NCT05390736|BEHAVIORAL|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
219140464|NCT05390736|BEHAVIORAL|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
219140465|NCT00354640|DRUG|anastrozole|1 milligram tablet PO QD for 14 days
219140466|NCT00354640|DRUG|simvastatin|40 milligram tablet PO QD for 14 days
219140467|NCT00354640|OTHER|pharmacological study|laboratory analysis
219140468|NCT00354640|PROCEDURE|adjuvant therapy|laboratory analysis
219140469|NCT01418118|DRUG|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
219140470|NCT01418118|DRUG|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
219140471|NCT01418118|DRUG|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
219140472|NCT01418118|DRUG|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
219140473|NCT02894151|DRUG|Depot medroxyprogesterone acetate|
219140474|NCT02894151|DEVICE|LNG-IUS|
219140475|NCT00753012|DRUG|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
219140476|NCT02116543|DRUG|TD-6450|
219140477|NCT02116543|DRUG|Placebo|
219140478|NCT00590707|DEVICE|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
219140479|NCT00590707|DEVICE|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
219140480|NCT06373744|DRUG|cyclophosphamide , methotrexate , vinorelbine ,capecitabine|The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
219140481|NCT01982136|PROCEDURE|end-to-end urethroplasty|
219229390|NCT03874949|DEVICE|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
219140482|NCT01982136|PROCEDURE|substitution urethroplasty (buccal mucosa)|
219140483|NCT01982136|PROCEDURE|substitution urethroplasty (pedicled skin flap)|
219140484|NCT05647980|OTHER|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
219140485|NCT01367483|DRUG|IV methylnaltrexone (MNTX)|
219140486|NCT04616053|BEHAVIORAL|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
219140487|NCT00366353|OTHER|Sedation during SBT|
219140488|NCT00366353|OTHER|No sedation|
219140489|NCT00793286|PROCEDURE|Mesh fixation by staples|Mesh fixation by staples
219140490|NCT00793286|PROCEDURE|Mesh fixation by glue|Mesh fixation by glue
219717863|NCT07115225|OTHER|Supine moving apprehension test (SMAT)|The beginning position of the participant is lying in a supine position while holding the weight just over their chest. Participants move their shoulder to 135° of abduction with the elbow extended, then returning to the starting position, and immediately move their shoulder to 180° of abduction with the elbow fully extended and finally return to the starting position. This cycle is repeated as much as possible for 1 minute.
219717864|NCT07115225|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm in 90° of horizontal abduction, the point at which the participant is to hold the arm as long as possible until fatigue. The participant holds a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg).
219552177|NCT00860145|PROCEDURE|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
219552178|NCT00860145|PROCEDURE|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
219140491|NCT05662891|OTHER|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
219140492|NCT00943735|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
219140493|NCT00943735|BEHAVIORAL|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
219140494|NCT00221637|DRUG|Sodium Valproate|
219552179|NCT01083797|DRUG|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
219140495|NCT03060642|DEVICE|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
219140496|NCT03060642|DEVICE|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
219552180|NCT01083797|DRUG|Chloral Hydrate|Initial dose=50 mg/kg
219140497|NCT02329613|OTHER|Standard evening meals.|Patients will receive usual evening meals.
219140498|NCT02329613|OTHER|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
219140499|NCT05603520|OTHER|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
219140500|NCT00521937|OTHER|Dermagen®|Weekly topical applications
219140501|NCT05502458|DRUG|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
219140502|NCT05502458|DRUG|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
219140503|NCT00367692|DRUG|PSI-697|
219229391|NCT03874949|DEVICE|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
219229392|NCT03374254|BIOLOGICAL|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
219140504|NCT04136639|OTHER|Miswak|sticks
219140505|NCT04136639|OTHER|Grape Seed Extract Mouthwash|Mouthwash
219140506|NCT04136639|OTHER|fluoride|mouthwash
219140507|NCT02383108|DRUG|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
219140508|NCT02383108|DRUG|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
219140509|NCT00003429|PROCEDURE|biopsy|
219140510|NCT00003429|PROCEDURE|computed tomography|
219140511|NCT00003429|PROCEDURE|positron emission tomography|
219140512|NCT00003429|RADIATION|fludeoxyglucose F 18|
219140513|NCT06476925|PROCEDURE|sonar guided stellate ganglion injection|using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
219229393|NCT03374254|DRUG|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
219717865|NCT07115225|OTHER|Patient-reported outcome measure - The Shoulder Instability-Return to Sport after Injury (SIRSI)|Psycho-social questionnaire assessing the psychological readiness of athletes to return to sport following traumatic shoulder instability and conservative or surgical management. The SIRSI includes 12 questions with an 11-point Likert scale in the form of blocks to be ticked from 0 to 10. The total score is equal to the sum of the values of the 12 responses then determined in relation to 100 to obtain a percentage. High scores correspond to a positive psychological response.
219717866|NCT07115225|OTHER|Patient-reported outcome measure - Numeric Pain Rating Scale (NPRS)|"Patient's shoulder pain will be measured using an 11-point NRS, with a minimum value of zero (no pain) and a maximum score of 10 (the worst pain possible)"
219140514|NCT06476925|PROCEDURE|sonar guided stellate ganglion block|using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
219140515|NCT02587130|DRUG|Ketamine|ketamine administered in bolus by subcutaneous injection
219140516|NCT03804918|OTHER|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
219140517|NCT00206258|DRUG|Pramlintide and glucagon|
219140518|NCT05575869|OTHER|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
219140519|NCT05575869|OTHER|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
219140520|NCT05719038|DIAGNOSTIC_TEST|observational study|observational study
219140521|NCT06131047|OTHER|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
219140522|NCT06131047|OTHER|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
219140523|NCT00242190|DRUG|oxaliplatin|
219140524|NCT00242190|DRUG|gemcitabine|
219140525|NCT00242190|PROCEDURE|radiation therapy|
219140526|NCT04277299|DEVICE|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
219140527|NCT01329328|DEVICE|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
219140528|NCT00002555|DRUG|cisplatin|
219140529|NCT00002555|RADIATION|low-LET cobalt-60 gamma ray therapy|
219140530|NCT00002555|RADIATION|low-LET electron therapy|
219140531|NCT00002555|RADIATION|low-LET photon therapy|
219140532|NCT02896894|OTHER|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
219229394|NCT03374254|DRUG|Oxaliplatin|85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
219229395|NCT03374254|DRUG|Leucovorin|400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
219229396|NCT03374254|DRUG|5-Fluorouracil [5-FU]|2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
219229397|NCT03374254|DRUG|Irinotecan|180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
219717867|NCT07115225|OTHER|Modified Tampa-Scale of Kinesiophobia for Anterior Shoulder Instability (TSK-SI)|"modified Tampa Scale of Kinesiophobia (TSK) to make it suitable for application in patients with anterior shoulder instability. The TSK-SI contains 18 items and the total score can range from 18 to 72, with 18 being the best score (no fear of movement/kinesiophobia) and 72 being the worst score (severe fear of movement/kinesiophobia)"
219140533|NCT03767257|DRUG|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
219140534|NCT02973919|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
219140535|NCT02973919|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
219140536|NCT00298649|BEHAVIORAL|Lay Health Advisor|
219140537|NCT02507336|DRUG|Thalidomide|100-300 mg capsule taken by mouth once daily.
219140538|NCT04035291|OTHER|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
219140539|NCT04768361|BEHAVIORAL|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
219140540|NCT04768361|BEHAVIORAL|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
219140541|NCT00727038|DRUG|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
219140542|NCT02760381|DEVICE|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
219140543|NCT01040741|OTHER|Non-intervention observational study|Non-intervention observational study
219140544|NCT04960176|PROCEDURE|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
219140545|NCT04960176|PROCEDURE|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
219229398|NCT06012409|DEVICE|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
219552181|NCT05167149|PROCEDURE|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
219552182|NCT05167149|PROCEDURE|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
219552183|NCT00055549|DRUG|Dextromethorphan|
219140546|NCT04201327|BEHAVIORAL|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
219140547|NCT02331043|DIETARY_SUPPLEMENT|Plant stanol ester|
219140548|NCT02331043|DIETARY_SUPPLEMENT|Placebo|
219140549|NCT00227682|DIETARY_SUPPLEMENT|ascorbic acid|
219140550|NCT00227682|DRUG|arsenic trioxide|
219140551|NCT00227682|DRUG|dexamethasone|
219140552|NCT00227682|DRUG|thalidomide|
219140553|NCT00455754|DRUG|Esomeprazole|
219140554|NCT01535989|DRUG|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
219140555|NCT01535989|DRUG|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
219717868|NCT07116005|BEHAVIORAL|Mandala Coloring|"Participants in this group receive the Mandala Art Therapy intervention, a creative, mindfulness-based activity rooted in complementary and alternative medicine. The intervention is designed to reduce exam-related anxiety by fostering visual focus, emotional calm, and self-expression. The Mandala protocol includes the following components:~* Distribution of printed Mandala outlines on A4 paper~* Provision of six colored pencils (red, orange, yellow, green, blue, and purple)~* A 20-minute individual coloring session in a quiet and relaxed setting~* No prescribed patterns-participants color freely to encourage self-directed engagement The Mandala coloring session is conducted exactly one hour before the Objective Structured Clinical Examination (OSCE). The activity is supervised by the researcher to ensure a supportive and distraction-free environment. Participants are encouraged to concentrate on the process of coloring to promote psychological grounding and reduce pre-exam stress."
219717869|NCT07113834|DRUG|Adalimumab|A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.
219717870|NCT07113834|DRUG|Systemic corticosteroids|Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.
219717871|NCT07116135|DEVICE|hearing instruments|Participants will be fit with three different models of hearing instruments.
219552184|NCT00055549|DRUG|Lorazepam|
219552185|NCT03957096|DRUG|SGN-CD47M|SGN-CD47M administered intravenously
219140556|NCT04689568|BEHAVIORAL|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
219140557|NCT04689568|BEHAVIORAL|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
219140558|NCT04689568|BEHAVIORAL|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
219140559|NCT03022903|PROCEDURE|Aminolevulinic Acid (ALA)|Photosensitizing
219140560|NCT04993963|OTHER|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
219140561|NCT04993963|OTHER|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
219140562|NCT05719818|DRUG|biphosphonates|Initiation of bisphosphonate therapy
219140563|NCT05719818|PROCEDURE|Dental care|Surgical dental care
219140564|NCT04920617|DRUG|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
219140565|NCT04920617|DRUG|Pembrolizumab|IV infusion every 3 weeks
219140566|NCT04920617|DRUG|CPA|50 mg twice daily, week on then week off
219140567|NCT04179227|OTHER|Questionnaire Administration|Ancillary studies
219140568|NCT04179227|OTHER|Survey Administration|Ancillary studies
219140569|NCT06555380|BEHAVIORAL|The one-year intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
219140570|NCT06555380|BEHAVIORAL|The three-year intervention|A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
219552186|NCT01981044|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
219140571|NCT01027299|DEVICE|Biventricular pacing|Optimised temporary biventricular pacing.
219140572|NCT06373549|PROCEDURE|Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
219140573|NCT06373549|PROCEDURE|Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
219140574|NCT00141830|DRUG|Methotrexate plus ERB-041 for 12 weeks|
219552187|NCT02832466|OTHER|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
219552188|NCT04013750|OTHER|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
219552189|NCT05765617|DRUG|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
219552190|NCT05765617|OTHER|Placebo|Placebo give 2x1 per day for five day
219552191|NCT02191124|DRUG|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
219552192|NCT02191124|DRUG|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
219552193|NCT05995990|DEVICE|Raman Spectrometry|Laboratory technique of Raman Spectrometry
219552194|NCT05883397|OTHER|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
219552195|NCT05883397|OTHER|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
219552196|NCT04478708|BIOLOGICAL|maridebart cafraglutide|Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
219140575|NCT00141830|DRUG|Placebo for 12 weeks|
219140576|NCT04855513|DRUG|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
219717872|NCT07113652|DEVICE|TI stimulation device (nerviox-1000）|"The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment phase lasting 7 consecutive days.~Sham stimulation uses identical electrode placement and setup as active stimulation. A brief 30-second ramp-up is applied to mimic real stimulation, followed by rapid reduction to 0 mA or minimal current. A 1 mA tail current is delivered in the final 30 seconds to simulate the tapering effect of active stimulation."
219552197|NCT04478708|DRUG|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
219140577|NCT05372094|DEVICE|Phonak Hearing Aid|Commercially available hearing aid with various noise reduction strengths
219717873|NCT07114159|DEVICE|Sacral nerve stimulation|Device: G132 system, Beijing PINS Medical Co., China Neuromodulation was performed according to the usual protocol
219717874|NCT07116447|BEHAVIORAL|Health messages - existing Swedish legislation|Textual health warning messages currently mandated for use in printed alcohol advertisements under the Swedish Alcohol Ordinance, focusing on communicated various alcohol harms
219717875|NCT07116447|BEHAVIORAL|Health messages - pictograms|Pictograms indicating no alcohol use during pregnancy and while driving
219552198|NCT03609749|BEHAVIORAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
219717876|NCT07116577|RADIATION|Palliative radiotherapy|Conventional fractionation, low-dose hypofractionated radiotherapy, or high-dose hypofractionated radiotherapy may be employed.
219140578|NCT02116829|OTHER|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
219140579|NCT02116829|OTHER|Olive oil|
219140580|NCT01420718|DRUG|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
219140581|NCT01420718|DRUG|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
219140582|NCT01762241|BEHAVIORAL|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
219140583|NCT01801293|DRUG|GS-5806|
219140584|NCT01348191|PROCEDURE|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
219552199|NCT00159172|DEVICE|Motor cortex stimulation|
219140585|NCT02897622|OTHER|Case management|Case management by Eira unit
219140586|NCT05165849|DRUG|GFS101A|GFS101A will be administrated intravenously Q3W.
219140587|NCT05165849|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
219140588|NCT04503356|PROCEDURE|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
219552200|NCT05120791|DIETARY_SUPPLEMENT|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
219552201|NCT05120791|DIETARY_SUPPLEMENT|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
219140589|NCT04503356|PROCEDURE|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
219140590|NCT04154137|OTHER|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
219140591|NCT03889678|DIAGNOSTIC_TEST|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
219140592|NCT02153606|DRUG|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
219140593|NCT02153606|OTHER|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
219140594|NCT04420195|DRUG|Extended-Release Tacrolimus|Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
219140595|NCT04420195|DRUG|Immediate-Release Tacrolimus|Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
219140596|NCT03775551|BEHAVIORAL|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
219140597|NCT00596167|DRUG|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
219140598|NCT04270604|OTHER|Biological sample collection|Biological sample collection for biobanking and research
219140599|NCT01187576|BEHAVIORAL|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
219140600|NCT01187576|BEHAVIORAL|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
219140601|NCT04835987|DIAGNOSTIC_TEST|Holter ECG|Measurement of the modification of the sympathomimetic balance
219140602|NCT04835987|BEHAVIORAL|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
219140603|NCT04835987|DIAGNOSTIC_TEST|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
219140604|NCT02242773|DEVICE|Multi-Parametric MRI|Multi-Parametric MRI
219140605|NCT02242773|DEVICE|MRI-Guided Biopsy|MRI-Guided Biopsy
219140606|NCT04842604|DRUG|Glasdegib|25 mg or 100 mg tablet
219140607|NCT04842604|DRUG|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
219140608|NCT03683628|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
219140609|NCT03683628|DRUG|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
219140610|NCT03126409|PROCEDURE|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
219140611|NCT03126409|PROCEDURE|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
219140612|NCT02773160|OTHER|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
219140613|NCT02773160|OTHER|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
219552202|NCT05120791|DIETARY_SUPPLEMENT|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
219552203|NCT05120791|DIETARY_SUPPLEMENT|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
219552204|NCT00147693|BEHAVIORAL|Diagnosis of caregivers' problems|
219552205|NCT00147693|BEHAVIORAL|Professional service: treatment of problems by counseling or practical support|
219552206|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
219552207|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
219552208|NCT05953506|DRUG|HS-10506|HS-10506 will be administered orally once on Day 1.
219552209|NCT05953506|DRUG|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
219717877|NCT07116577|DRUG|Iparomlimab and tuvonralimab|5 mg/kg, intravenously infused on Day 1 of each cycle, administered every 3 weeks (with each cycle defined as 21 days).
219717878|NCT07116577|DRUG|TAS-102|35 mg/m², orally twice daily on Days 1 to 5 and Days 8 to 12 of each cycle, with each cycle spanning 28 days (4 weeks).
219552210|NCT01406639|DRUG|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
219229399|NCT04288869|OTHER|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
219717879|NCT07116577|DRUG|Bevacizumab|7.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
219140614|NCT02773160|OTHER|Control group|Subjects will receive no feedback during the learning phase of a motor control task
219552211|NCT04559841|OTHER|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
219717880|NCT07115628|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique
219717881|NCT07118267|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|containing 60 billion CFU (administered as two capsules per day)
219717882|NCT07117760|DRUG|225Ac-LNC1011|administered intravenously once every 8-10 weeks (1 cycle) for 4 cycles
219717883|NCT07117760|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 MBq at screening and at time of centrally confirmed radiographic progressive disease
219717884|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, once, 6 months
219140615|NCT03601351|OTHER|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
219140616|NCT03094767|OTHER|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
219140617|NCT03094767|OTHER|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
219140618|NCT01821586|OTHER|Modified ORS-1|
219140619|NCT01821586|OTHER|Modified ORS-2 (ReSoMal)|
219140620|NCT01821586|OTHER|Modified ORS-3 (Benefibre)|
219140621|NCT01377519|PROCEDURE|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
219140622|NCT01377519|PROCEDURE|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
219229400|NCT04288869|OTHER|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
219229401|NCT04288869|OTHER|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
219717885|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, every two weeks for four doses, 6 months
219717886|NCT07116954|PROCEDURE|Twenty-Two adult Patients who indicated for bilateral maxillary first premolar extraction will be randomly assigned into two equal group.|Group1: Elastomeric chains will be used on the right side, and NiTi closed-coil springs will be used on the left side. Group2: NiTi closed-coil springs will be used on the right side, Elastomeric chains will be used on the left side.
219717887|NCT07116954|PROCEDURE|Canin retraction with NiTi Closed-Coil Springs and elastomeric chains|Comparison between canine retraction using NiTi closed-coil springs versus elastomeric chains
219717888|NCT07118761|BEHAVIORAL|Home-based walking training|Patients enrolled in the experimental group will undergo an exercise-based intervention at home guided by a smartphone application. Each exercise session will encompass 8 walking minutes at home at a fixed slow speed to be repeated twice per day. Every week the speed will be slightly increased to maintain an adequate training stimulus.
219717889|NCT07117461|BEHAVIORAL|NCCN Distress Thermometer|A tool used to determine on a number scale the amount of distress for the past week
219140623|NCT01392872|OTHER|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
219140624|NCT02618317|DRUG|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
219140625|NCT02618317|DRUG|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
219140626|NCT02618317|DRUG|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
219229402|NCT04288869|OTHER|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
219140627|NCT04586036|OTHER|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
219140628|NCT04586036|OTHER|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
219229403|NCT05637944|PROCEDURE|oro tracheal intubation|chest trauma requiring oro tracheal intubation
219229404|NCT01164176|DRUG|everolimus|
219229405|NCT01164176|OTHER|laboratory biomarker analysis|
219229406|NCT03040453|DEVICE|Microwave ablation|
219140629|NCT04586036|OTHER|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
219229407|NCT03040453|DEVICE|Irreversible electroporation|
219229408|NCT04502459|PROCEDURE|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
219140630|NCT04586036|OTHER|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
219140631|NCT04586036|OTHER|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
219140632|NCT05079061|DRUG|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
219229409|NCT05409170|PROCEDURE|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
219229410|NCT02176694|BEHAVIORAL|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
219229411|NCT02309515|OTHER|Laboratory Biomarker Analysis|Correlative studies
219229412|NCT02309515|DRUG|Lenalidomide|Given PO
219229413|NCT02309515|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
219229414|NCT02369328|DEVICE|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
219229415|NCT03481153|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
219229416|NCT06321094|DRUG|Vericiguat|Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
219229417|NCT02205255|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
219229418|NCT02205255|DRUG|Placebo|
219229419|NCT05205083|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
219552212|NCT03824834|DRUG|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
219552213|NCT03824834|OTHER|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
219552214|NCT06417632|OTHER|Graded Zirconia Crown|monolithic implant supported crown
219552215|NCT06417632|OTHER|Conventional Zirconia Crown|monolithic implant supported crown
219552216|NCT00158535|PROCEDURE|liver transplantation|
219552217|NCT03768817|OTHER|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
219552218|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
219552219|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
219552220|NCT00757991|GENETIC|polymorphism analysis|
219552221|NCT00757991|OTHER|laboratory biomarker analysis|
219552222|NCT00757991|OTHER|questionnaire administration|
219552223|NCT02941588|PROCEDURE|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
219717890|NCT07117045|DIAGNOSTIC_TEST|Diagnostic Evaluation for Positive AI Findings|MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).
219229420|NCT04717687|PROCEDURE|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
219140633|NCT01455051|DRUG|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
219140634|NCT04213560|DEVICE|weighted waist-hooping|weighted waist-hooping
219140635|NCT02706067|DRUG|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
219140636|NCT01193153|DRUG|Placebo|monthly by i.m. injection for 15 months
219140637|NCT01193153|DRUG|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
219229421|NCT03794388|DRUG|Capsaicin|Application of capsaicin patches at 8% on painful area
219229422|NCT03794388|DRUG|Pregabalin|Taking Pregabalin tablets
219229423|NCT05689177|BIOLOGICAL|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
219229424|NCT01903954|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
219717891|NCT07117370|BEHAVIORAL|Coach Mpilo|Peer support for treatment navigation. Peer supporters (coaches) with TB and HIV treatment experiences are trained in listening, support, and action planning to assist men in navigating and staying on treatment.
219717892|NCT07118163|OTHER|Other|No intervention was applied in this study.
219717893|NCT07118163|OTHER|No intervention; Observational study|No intervention
219717894|NCT07114419|DRUG|Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
219717895|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg QW|Efsubaglutide Alfa 40 mg QW
219717896|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg Q2W|Efsubaglutide Alfa 40 mg Q2W
219717897|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg QW|Efsubaglutide Alfa 80 mg QW
219717898|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg Q4W|Efsubaglutide Alfa 80 mg Q4W
219140638|NCT01648140|DRUG|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
219140639|NCT01648140|DRUG|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
219140640|NCT01648140|DRUG|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
219229425|NCT01903954|DRUG|placebo|Orally b.i.d.
219229426|NCT01903954|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
219229427|NCT01903954|DRUG|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
219229428|NCT02399956|OTHER|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
219229429|NCT04191863|OTHER|Clinical, EEG and laboratory assessment at presentation|"* The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG."
219229430|NCT04191863|DRUG|Valproate|valproate monotherapy
219229431|NCT04026256|DRUG|Teriparatide|teriparatide daily subcutaneous injection
219229432|NCT04026256|DRUG|Denosumab|denosumab subcutaneous injection
219140641|NCT01648140|DRUG|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
219140642|NCT01648140|DRUG|Telaprevir|375 mg film-coated tablet
219229433|NCT02820506|PROCEDURE|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
219229434|NCT00162409|DRUG|Folic acid|
219229435|NCT01864590|DEVICE|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
219717899|NCT07114419|OTHER|Placebo|Placebo
219717900|NCT07114393|BEHAVIORAL|Liberal use of intracoronary imaging during complex PCI|A new protocol regarding use of intracoronary imaging will be implemented in multiple PCI centers in the Netherlands. Main goal of this protocol will be to increase the use of imaging in complex PCI in the Netherlands. Moreover operators will be trained according to the new protocol and on site training will be organized to improve the skills in using imaging during complex PCI.Operators are requested to use of intracoronary imaging preferentially in all complex coronary lesions, but at least increase their use with at least 50% and minimum of 25% of the cases. Throughout the second phase, individual participating operators will receive personalized feedback on their use of intracoronary imaging at multiple intervals. Based on this result, the implementation process will be refined as necessary. These intermediate measurements will also be shared with all participating centres anonymous.
219717901|NCT07115147|DEVICE|Blue diode laser|All procedures would be performed under spinal or general anaesthesia. Blue diode laser vaporization would be performed according to the standard approach for the obstructing prostate
219717902|NCT07114094|OTHER|Deprescribing Tool|"Deprescribing Tool will be used for medication review during patient consultation. The prescriber will be encouraged to refer to the tool for medication review of elderly patients aged ≥ 60 years and take deprescribing decision if indicated.~Deprescribing may take place in any of the following ways-~1. Immediate discontinuation of a drug, e.g., a duplicate drug~2. Initiation of gradual tapering of a drug e.g., an anxiolytic, which is no longer indicated~3. Reduction in dose of a drug, e.g., lower dose of an NSAID for relief of symptoms of rheumatoid arthritis Only 1-3 medicines will be deprescribed at a time. Medicines with overlapping indications will not be deprescribed at the same time so it is clear which medicine is responsible if withdrawal effects occur."
219717903|NCT07113873|OTHER|ultra-translucent monolithic multi layered zirconia|laminate veneer
219717904|NCT07113873|OTHER|lithium disilcate ceramics|laminate veneer
219717905|NCT07116460|DEVICE|Austin Air Cleaner|The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.
219140643|NCT05566418|OTHER|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
219140644|NCT05566418|OTHER|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
219140645|NCT03746418|DRUG|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
219140646|NCT03275077|DEVICE|Thromboelastography|A viscoelastic test of coagulation
219140647|NCT05715151|OTHER|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
219140648|NCT05715151|OTHER|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
219140649|NCT03522558|BEHAVIORAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
219140650|NCT03522558|BEHAVIORAL|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
219140651|NCT00485940|DRUG|Prucalopride|2 mg o.d.
219140652|NCT00485940|OTHER|Placebo|Placebo o.d.
219140653|NCT00485940|DRUG|Prucalopride|4 mg o.d.
219140654|NCT04390958|DRUG|nab-paclitaxel|125mg/m2 ivgtt d1、d8
219140655|NCT04390958|DRUG|Cisplatin|60mg/m2 ivgtt d1 or d1-2
219140656|NCT04390958|DRUG|Capecitabine|1750mg/m2 po bid d1-14
219140657|NCT02061930|PROCEDURE|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
219140658|NCT00316316|BEHAVIORAL|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
219140659|NCT00316316|BEHAVIORAL|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
219140660|NCT03319017|PROCEDURE|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
219140661|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
219140662|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
219140663|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
219140664|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
219140665|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
219140666|NCT01596725|BIOLOGICAL|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
219140667|NCT03097016|DRUG|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
219140668|NCT01119950|DRUG|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
219717906|NCT07114718|DEVICE|Ductus Arteriosus Stent|The eligible subjects will proceed to implantation of the Lifeline Ductus Arteriosus Stent to maintain patency of the PDA.
219717907|NCT07115381|BEHAVIORAL|Therapeutic Horticulture|Therapeutic Horticulture uses plant cultivation and related gardening activities as the medium of action, allowing patients to participate in gardening activities such as planting, maintenance, and harvesting of plants.
219140669|NCT01119950|DRUG|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
219140670|NCT01119950|DRUG|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
219140671|NCT01119950|DRUG|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
219140672|NCT01119950|DRUG|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
219140673|NCT01119950|DRUG|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
219140674|NCT01119950|DRUG|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
219140675|NCT01119950|DRUG|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
219140676|NCT04256876|DEVICE|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
219140677|NCT04256876|DEVICE|TTNS Sham|See section 'arms'
219140678|NCT00048529|DRUG|T900607-sodium intravenous|
219140679|NCT05399394|DRUG|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
219140680|NCT05399394|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
219140681|NCT04353674|DEVICE|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
219140682|NCT04353674|DEVICE|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
219140683|NCT05218733|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
219140684|NCT05218733|DRUG|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
219140685|NCT05218733|DRUG|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
219140686|NCT02562911|PROCEDURE|Data collection|"* Clinical examination~* Complete pelvic ultrasound abdominal ultrasound~* Bone age: X-ray~* biological examination~* Lung function assessed by the Maximum Volume Expired~* Brasfield radiological score (if available)"
219140687|NCT00319085|PROCEDURE|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
219140688|NCT03801551|DIAGNOSTIC_TEST|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
219140689|NCT00927667|PROCEDURE|No Drug|Patients have received primary FVIII prophylaxis (started \< 2 years of age)
219140690|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
219140691|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
219140692|NCT00927667|PROCEDURE|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
219140693|NCT00927667|PROCEDURE|No Drug|Patients have received on-demand therapy
219140694|NCT03175913|DEVICE|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
219140695|NCT03175913|DRUG|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
219140696|NCT05966779|OTHER|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
219140697|NCT02667535|DRUG|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
219140698|NCT03009006|DRUG|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
219140699|NCT03009006|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
219140700|NCT03990220|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
219140701|NCT01345604|PROCEDURE|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
219140702|NCT01345604|PROCEDURE|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
219140703|NCT04767828|DRUG|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
219140704|NCT04767828|RADIATION|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
219140705|NCT03900819|OTHER|dexterity measurement|4 non-invasive tests will be performed
219140706|NCT06167265|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
219140707|NCT06167265|DRUG|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
219140708|NCT00034463|DRUG|ALIMTA|
219140709|NCT00034463|DRUG|folic acid|
219140710|NCT00034463|DRUG|multi-vitamins|
219140711|NCT01689272|PROCEDURE|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
219140712|NCT03895788|DRUG|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
219140713|NCT03895788|DRUG|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
219140714|NCT02572219|DIETARY_SUPPLEMENT|Nutraceutical compound|
219552224|NCT01480895|BEHAVIORAL|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
219552225|NCT03320863|DEVICE|Enso device|An active Enso device that delivers neuromodulation therapy.
219552226|NCT02856594|DRUG|Dexmedetomidine|Dexmedetomidine
219552227|NCT02856594|DRUG|Placebo|Placebo
219552228|NCT03044873|DRUG|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
219552229|NCT03044873|DRUG|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
219552230|NCT04709757|DEVICE|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
219552231|NCT04709757|DEVICE|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
219552232|NCT02133638|DRUG|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
219717908|NCT07115381|OTHER|Routine treatment and nursing|The conventional treatment mainly involves the use of antidepressant drugs, supplemented by physical therapy, psychological therapy, and rehabilitation training, etc. The routine care includes admission introduction, health education (manifestations, hazards, treatment methods of depression and non-suicidal self-harm, as well as the importance of following medical advice for treatment), medication guidance, discharge guidance, and psychological care, etc.
219552233|NCT02133638|DRUG|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
219552234|NCT03387462|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
219552235|NCT03387462|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
219140715|NCT02572219|DIETARY_SUPPLEMENT|Placebo|
219140716|NCT02925195|DIETARY_SUPPLEMENT|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
219140717|NCT02925195|DRUG|Placebo|
219140718|NCT03618849|DEVICE|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
219140719|NCT03264248|DEVICE|E-Scale|Daily bodyweight system used under legs of bed
219140720|NCT02435199|DRUG|EMA401 600mg|
219140721|NCT02435199|DRUG|Placebo|
219140722|NCT04915599|DEVICE|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
219140723|NCT00711542|BIOLOGICAL|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
219140724|NCT00711542|BIOLOGICAL|placebo medium|intracoronary infusion of placebo medium
219140725|NCT00159354|DRUG|predisolone|
219140726|NCT04977128|DRUG|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
219140727|NCT05603767|OTHER|RMT+ VR|(RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
219140728|NCT00183638|BEHAVIORAL|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
219140729|NCT00183638|BEHAVIORAL|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
219140730|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
219140731|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
219140732|NCT00444431|PROCEDURE|Pyeloplasty|
219140733|NCT00217672|BIOLOGICAL|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
219140734|NCT00217672|DRUG|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
219140735|NCT02178540|DRUG|Placebo|one dose (4 capsules) of placebo
219140736|NCT02178540|DEVICE|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
219140737|NCT01409512|PROCEDURE|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
219140738|NCT04650048|DEVICE|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
219140739|NCT04650048|DEVICE|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
219140740|NCT01296425|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
219140741|NCT01787240|DRUG|Escitalopram 10mg|
219140742|NCT01787240|DRUG|Placebo|
219140743|NCT01640678|PROCEDURE|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
219140744|NCT01640678|PROCEDURE|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
219140745|NCT03951649|DRUG|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
219140746|NCT01161563|DRUG|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
219140747|NCT01161563|DRUG|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
219229436|NCT01864590|DEVICE|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
219717909|NCT07117721|PROCEDURE|Endoscopic Band Ligation (ENDOBAND-DM)|Endoscopic band ligation of the second through fourth parts of the duodenum, from just distal to the ampulla of Vater to the ligament of Treitz. The aim is to induce localized mucosal remodeling that may enhance enteroendocrine signaling (GLP-1, GIP) and improve glycemic control in patients with type 2 diabetes mellitus.
219229437|NCT06092905|OTHER|Endoscopic clearance of common bile duct stones|Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
219229438|NCT05575687|OTHER|Water (reference)|Ingestion of 500 ml mineral water
219229439|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
219140748|NCT04836624|DEVICE|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
219140749|NCT04731051|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
219717910|NCT07121127|COMBINATION_PRODUCT|FSN+Vitamin supplement|Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements
219140750|NCT04731051|DRUG|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
219140751|NCT02852863|OTHER|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
219140752|NCT03437746|DRUG|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
219140753|NCT03437746|BIOLOGICAL|Blood samples|Blood samples (D0, D1, D2, D3, D4)
219140754|NCT02246816|DRUG|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
219140755|NCT01591616|DRUG|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
219140756|NCT03278288|DEVICE|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
219717911|NCT07121127|DRUG|Vitamin Supplements|oral Vitamin C and vitamin E supplements
219717912|NCT07121257|DEVICE|VENTIJET system|The Ventijet system is an investigational ventilation device delivering continuous high-velocity gas flow through a proximal nozzle. The system is designed to maintain alveolar recruitment with low driving pressures, acting as an expiratory brake. Patients received continuous flow ventilation using Ventijet for 1 to 24 hours after baseline assessment with conventional mechanical ventilation.
219140757|NCT05796440|DRUG|LUM-201|Administered orally once daily
219140758|NCT03013348|DEVICE|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
219140759|NCT00819819|DIETARY_SUPPLEMENT|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
219140760|NCT00819819|DIETARY_SUPPLEMENT|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
219140761|NCT02865733|DRUG|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
219140762|NCT02865733|DRUG|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
219140763|NCT00758602|DRUG|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
219140764|NCT00758602|DRUG|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
219140765|NCT00758602|DRUG|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
219140766|NCT00758602|DRUG|corticosteroids|According to center's practice
219140767|NCT03259932|OTHER|no physical activity|no physical activity
219140768|NCT03259932|OTHER|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
219229440|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
219717913|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Blood Clot as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points. Bleeding was induced by instrumentation with a K-type file, at 2 mm past the apical foramen, thus creating a blood clot within the canal. MTA was applied on the scaffold as capping material.
219717914|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Chitosan as a Scaffold|"During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material. The patient has been scheduled for a follow-up appointment within one to four weeks.~During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Chitosan in gel form was placed into the root canal space with the help of an injector.MTA was applied on the scaffold as capping material."
219717915|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Platelet Rich Fibrin as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Ten milliliters of venous blood was collected from the patient and immediately placed in a centrifuge at 3000 rpm for 10 minutes. The prepared PRF was placed in the canal space. MTA was applied on the scaffold as capping material.
219717916|NCT07119671|OTHER|HOPAIR Intervention: Meeting between Peer Helper and Concerned Individual in Psychiatric Crisis Unit|This intervention begins with an initial discussion focused on the individual's lived experience, followed by an explanation of the Hope Box's principle, utility, and use. After each intervention, the peer supporter will complete a satisfaction self-questionnaire to provide feedback.
219552236|NCT05651698|DEVICE|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
219140769|NCT03961152|BEHAVIORAL|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
219140770|NCT04258358|OTHER|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
219140771|NCT00571818|PROCEDURE|Oral glucose tolerance test|test done over 2 hours
219140772|NCT00571818|PROCEDURE|IV Glucose Tolerance Test|Done over 4 hours
219140773|NCT05421988|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
219140774|NCT04213599|DIAGNOSTIC_TEST|Coronary intervention|Patients with STEMI undergo coronary intervention
219140775|NCT00001304|DRUG|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
219140776|NCT00001304|DRUG|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
219140777|NCT01726530|DRUG|transdermal fentanyl patch (50 mcg/hour)|
219140778|NCT01726530|DRUG|Placebo|
219552237|NCT01884844|DRUG|Vitamin D3, Cholecalciferol|
219229441|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
219140779|NCT02187900|DRUG|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
219140780|NCT02187900|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
219140781|NCT01125319|OTHER|blood sample|
219140782|NCT01610479|DRUG|TAS-114 + S-1|
219229442|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
219229443|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
219229444|NCT04293718|OTHER|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
219229445|NCT02892318|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
219229446|NCT02892318|DRUG|Guadecitabine|Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
219229447|NCT04236297|DEVICE|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
219552238|NCT01884844|DRUG|Placebo|
219140783|NCT03068637|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
219140784|NCT01544569|GENETIC|DNA analysis|
219140785|NCT01544569|GENETIC|fluorescence in situ hybridization|
219140786|NCT01544569|GENETIC|gene expression analysis|
219140787|NCT01544569|GENETIC|gene mapping|
219140788|NCT01544569|GENETIC|microarray analysis|
219717917|NCT07117656|BEHAVIORAL|Project Vuselela|A four session intervention with people who inject drugs and family members. Delivered three group sessions and one dyad session. Session content designed to improve coping and communication skills that will in turn improve treatment outcomes.
219140789|NCT01544569|GENETIC|polymerase chain reaction|
219140790|NCT01544569|GENETIC|protein expression analysis|
219140791|NCT01544569|OTHER|laboratory biomarker analysis|
219552239|NCT01460628|DRUG|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
219552240|NCT03170739|DRUG|Dexmedetomidine|Dexmedetomidine given during surgery.
219552241|NCT03170739|DRUG|Dopamine|Dopamine given during surgery.
219552242|NCT04785053|DEVICE|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
219552243|NCT01887158|DRUG|Polyethylene glycol|
219140792|NCT01544569|OTHER|medical chart review|
219140793|NCT02371746|DRUG|ENV515-3 Travoprost XR|
219140794|NCT02371746|DRUG|ENV515-1 Travoprost XR|
219140795|NCT02371746|DRUG|ENV515-3-2 Travoprost XR|
219140796|NCT05516654|DIAGNOSTIC_TEST|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
219552244|NCT01887158|DRUG|Bisacodyl|
219552245|NCT02371837|OTHER|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
219552246|NCT03004157|PROCEDURE|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
219552247|NCT05638035|DIAGNOSTIC_TEST|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
219552248|NCT06338410|BEHAVIORAL|Kangaroo Mother Care|KMC is a care system for LBW and preterm infants at birth, based on skin-to-skin contact between the infant and the mother and exclusive breast feeding. The mother carries her Preterm infant for at least one hour per day. Urine collected before and after skin-to-skin contact.
219140797|NCT05516654|DIAGNOSTIC_TEST|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
219140798|NCT05516654|DIAGNOSTIC_TEST|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
219140799|NCT05516654|DIAGNOSTIC_TEST|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
219140800|NCT02045719|DRUG|uncaria tomentosa (cat´s claw)|
219140801|NCT00435799|PROCEDURE|corneal cross-linking (CCL)|
219140802|NCT00435799|DRUG|Riboflavin/dextran eyedrops|
219140803|NCT00435799|DEVICE|UV-X system|
219140804|NCT00153309|BEHAVIORAL|People with Arthritis Can Exercise|
219229448|NCT00000250|DRUG|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
219229449|NCT00000250|DRUG|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
219229450|NCT03046394|DEVICE|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
219229451|NCT03046394|DEVICE|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
219229452|NCT03046394|DEVICE|A-DER|Triton by Otto Bock, advertised for activity category 3-4
219552249|NCT05809180|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt d1;
219552250|NCT05809180|DRUG|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
219552251|NCT05809180|DRUG|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
219552252|NCT05809180|DRUG|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
219552253|NCT05809180|DRUG|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
219552254|NCT02926040|PROCEDURE|Irreversible electroporation|
219229453|NCT03775915|OTHER|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
219229454|NCT03775915|OTHER|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
219229455|NCT05667909|DRUG|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
219140805|NCT03342872|BEHAVIORAL|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
219229456|NCT02400645|PROCEDURE|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
219229457|NCT02400645|PROCEDURE|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
219140806|NCT03342872|BEHAVIORAL|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
219140807|NCT01667354|BEHAVIORAL|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
219229458|NCT02400645|DRUG|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
219229459|NCT02400645|DRUG|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
219229460|NCT02400645|DRUG|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
219229461|NCT05064566|DEVICE|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
219717918|NCT07118865|OTHER|Online Pilates exercise|Participants will be asked to do their Pilates practice while watching the videos (not from memory) to ensure that they are performing techniques optimally. Each module lasts 25 minutes, but includes some resting activities so modules are not vigorous or fatiguing for most people. Nonetheless, subjects will be instructed to omit activities that they feel they cannot do safely. Participants can pause a session to add more rest breaks, if needed, or stop and complete a session later. Participants will attempt to do 3 Pilates modules per week, for a total of 75-90 minutes/week (depending on the exact length of the modules they do).
219717919|NCT07117851|DRUG|Disitamab Vedotin combined with Bicalutamide|Single Group Assignment
219140808|NCT03219645|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
219140809|NCT03219645|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
219140810|NCT05125133|OTHER|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
219229462|NCT00624377|DRUG|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
219229463|NCT03958266|DEVICE|MyIBD Care|Novel mobile phone application
219229464|NCT02979678|OTHER|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
219229465|NCT03779945|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
219229466|NCT03779945|PROCEDURE|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
219229467|NCT03966456|DRUG|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
219229468|NCT05260437|BIOLOGICAL|CV2CoV (2 µg)|Study vaccine was administered as a single intramuscular injection.
219229469|NCT05260437|BIOLOGICAL|CV2CoV (4 µg)|Study vaccine was administered as a single intramuscular injection.
219229470|NCT05260437|BIOLOGICAL|CV2CoV (8 µg)|Study vaccine was administered as a single intramuscular injection.
219229471|NCT05260437|BIOLOGICAL|CV2CoV (12 µg)|Study vaccine was administered as a single intramuscular injection.
219229472|NCT05260437|BIOLOGICAL|CV2CoV (16 µg)|Study vaccine was administered as a single intramuscular injection.
219229473|NCT05260437|BIOLOGICAL|CV2CoV (20 µg)|Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
219140811|NCT02297880|OTHER|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
219140812|NCT02297880|OTHER|Still water|Still water (no flavour)
219140813|NCT02886754|BEHAVIORAL|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
219140814|NCT02886754|BEHAVIORAL|National e-learning programme only|National e-learning programme (COMPASS)
219140815|NCT02886754|BEHAVIORAL|Standard simulation|Paper based simulation cases
219140816|NCT01795144|DRUG|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
219140817|NCT01795144|DRUG|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
219140818|NCT02485236|DEVICE|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
219140819|NCT02485236|DEVICE|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
219140820|NCT04852146|PROCEDURE|Electronic feedback|Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
219140821|NCT00001524|DRUG|Thalidomide|
219140822|NCT02749318|GENETIC|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
219140823|NCT02845856|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
219140824|NCT02845856|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
219717920|NCT05911269|OTHER|TiMBRe|"1 \& 2 Music Listening~* Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~  3 \& 4 Music Facilitated Breathing~* The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~  5 \& 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~* Using music as a structured auditory cue for tensing and releasing of muscles.~  7 Body Percussion~* The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body.~  8 Participants Choice~* will be selected by the participant."
219717921|NCT05911269|OTHER|Control|Standard of care study staff calls and cancer survivorship resources
219552255|NCT02233374|OTHER|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
219717922|NCT07121881|DEVICE|Bar Attachment|A bar attachment supported by three mandibular implants (placed in the midline and canine regions) is used to retain a mandibular overdenture. The bar provides rigid splinting across the implants and allows retention using friction or clips, without additional attachment components. This serves as the control group.
219140825|NCT03163186|PROCEDURE|Transarterial embolization|Transarterial hepatic embolization of liver cancer
219140826|NCT01157182|DRUG|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
219140827|NCT01157182|DRUG|Activella®|1/0.5 mg Tablets
219140828|NCT00525850|OTHER|high fat diet|high saturated fat no starch diet
219140829|NCT00525850|OTHER|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
219140830|NCT00002819|DRUG|carboplatin|
219140831|NCT00002819|DRUG|cyclophosphamide|
219140832|NCT00002819|DRUG|mitoxantrone hydrochloride|
219140833|NCT00002819|DRUG|paclitaxel|
219140834|NCT00002819|PROCEDURE|autologous bone marrow transplantation|
219140835|NCT00002819|PROCEDURE|peripheral blood stem cell transplantation|
219140836|NCT04505943|DRUG|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
219140837|NCT04505943|DRUG|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
219140838|NCT04505943|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
219140839|NCT03743246|DRUG|JCAR017|JCAR017
219140840|NCT03743246|DRUG|Lymphodepleting|Lymphodepleting
219140841|NCT03743246|DRUG|Fludarabine|Fludarabine
219140842|NCT03743246|DRUG|Cyclophosphamide|Cyclophosphamide
219140843|NCT02526680|DEVICE|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
219140844|NCT03321344|DEVICE|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
219140845|NCT00878722|DRUG|PXD101|
219140846|NCT00878722|DRUG|idarubicin|
219140847|NCT03400488|DRUG|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
219717923|NCT07121881|DEVICE|Bar with OT Equator Attachment|A bar attachment supported by three mandibular implants is combined with two OT Equator attachments to enhance denture retention and allow slight vertical and rotational resilience. The OT Equator system includes metal housings and retentive nylon caps, intended to reduce cap wear and improve patient comfort. This is the experimental arm.
219717924|NCT07120178|OTHER|slit lamp examination|data collected: tumor size, pigmentation, vascularization, cells
219717925|NCT07120178|OTHER|dermatoscopy examination x20 and x400|data collected: tumor size, pigmentation, vascularization, cells
219717926|NCT07120178|OTHER|confocal microscopy examination|data collected: tumor size, pigmentation, vascularization, cells
219717927|NCT07120698|DRUG|Sintilimab|"Patients who met the inclusion criteria were treated with adaptive adjuvant sintilimab therapy guided by MRD.~Patients should test twice at postoperative days 3 to 7 and again at postoperative day 28 (±3 days). The results of these two tests will be used to determine the subsequent treatment pathway. Participants with two consecutive positive MRD tests or a single positive MRD test will be enrolled in the MRD+ treatment cycle：they will receive adjuvant treatment with sintilimab (200 mg, intravenous infusion, every 3 weeks). Follow-up visits will be conducted every 3 months, during which chest CT scans and MRD testing will be performed. If MRD becomes negative, treatment will be discontinued and the participant will be monitored. If MRD remains positive, treatment with sintilimab will continue.~Participants with two consecutive negative MRD tests will be enrolled in the MRD- treatment cycle：they will undergo follow-up observation only. Follow-up visits will be conducted every 3 months"
219717928|NCT06142682|DEVICE|Cochlear Implant|cochlear implantation with dexamethasone eluting electrode
219717929|NCT07140757|OTHER|Questionnaire|This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.
219717930|NCT07142564|OTHER|Carrier Care (CC)|Carrier care uses an infant carrier to secure the infant to the caregiver, while SSC does not have a securing device. The caregiver holds the infant with their arms.
219717931|NCT07141576|OTHER|Erbium laser (2940 nm): Infrared light energy|The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA. Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
219717932|NCT07141576|OTHER|Diode laser (650 nm): Visible red light energy|Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
219717933|NCT07141576|DRUG|Fluoride varnish|Biological Intervention
219717934|NCT07141563|DRUG|Nivolumab + platinum-based chemotherapy|According to the product label
219717935|NCT07141108|DEVICE|Paindrainer Care system|Self management digital tool for chronic pain
219717936|NCT07141940|OTHER|Indonesian-language application-based auditory guided imagery therapy|This study used a mobile application developed by researchers using Indonesian language to deliver an auditory guided imagery therapy
219717937|NCT07141940|OTHER|Psychoeducation|Psychoeducation consists of sleep hygiene and relaxation therapy (breathing exercise, progressive muscle relaxation, and guided imagery)
219717938|NCT07142447|BEHAVIORAL|Multi-Component Behavioral intervention|"A multicomponent behavioral intervention during pregnancy and up to the first 18 months after delivery, composed by:~1. Digital tool called App Hypiend Digital Tool aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations~2. Telephone monitoring~3. Workshop about environmental health education"
219717939|NCT07142447|BEHAVIORAL|Control group|Minimal behavioral intervention. Usual care
219717940|NCT06299761|DRUG|BBI-825|Oral RNR inhibitor
219140848|NCT03400488|OTHER|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
219140849|NCT01159704|BEHAVIORAL|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
219140850|NCT01159704|BEHAVIORAL|HIV Counseling and Education Model|"The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
219140851|NCT04658212|PROCEDURE|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
219140852|NCT04658212|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
219140853|NCT01813825|OTHER|Registry|
219717941|NCT03850106|DIETARY_SUPPLEMENT|Placebo|Placebo
219717942|NCT03850106|DIETARY_SUPPLEMENT|Indus810|Active product
219717943|NCT05845593|OTHER|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
219717944|NCT06213974|OTHER|No Intervention|This is non-interventional study.
219717945|NCT02749955|BEHAVIORAL|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
219717946|NCT02749955|BEHAVIORAL|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
219717947|NCT05020912|DRUG|ALA|At first visit, ALA applied to one BCC lesion
219717948|NCT05020912|PROCEDURE|PDT|PDT with blue light (for 30 min (\~20 mJ/cm2))
219140854|NCT01465243|DRUG|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
219717949|NCT05944549|BEHAVIORAL|Financial coaching using TrustPlus|Participants will be assigned a financial coach, who will, prepare a budget, conduct a soft pull of their credit report and score to analyze the credit score. Based on the participant's goals and financial limitations as highlighted by the, the participant and financial coach will create a personalized financial action plan comprising of strategies, follow-up actions, and resources, which includes unlimited access to one-on-one sessions with the financial coach. After the intensive financial coaching, participants will maintain access to the TrustPlus Portal and can continue to connect with their financial coach as needed throughout the 6-month intervention period. Participants will also have ongoing access to educational webinars and Trust+Ed, an interactive resource that provides self-guided content on many financial topics of interest, such as credit building and debt management.
219140855|NCT04955119|DIAGNOSTIC_TEST|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
219140856|NCT04302844|BEHAVIORAL|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
219140857|NCT04302844|BEHAVIORAL|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
219140858|NCT00949975|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
219140859|NCT00949975|DRUG|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
219140860|NCT00949975|DRUG|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
219140861|NCT00949975|DRUG|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
219140862|NCT04664049|DIETARY_SUPPLEMENT|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
219717950|NCT05944549|BEHAVIORAL|Brighter Bites|Families receive a weekly distribution of fresh fruits and vegetables for 24 weeks, there will be Nutrition education in school throughout the school year using the evidence-based CATCH (Coordinated Approach to Child Health) program and weekly healthy recipe tastings and cooking skill demos for families during produce pick-up time.Fruit and vegetable access is complemented by CATCH, an evidence based, Texas Education Agency-approved, coordinated school health program designed to promote healthy nutrition, physical activity, and prevent obesity in schoolchildren. In addition, the Brighter Bites website and mobile app are freely available in English and Spanish.
219717951|NCT05944549|BEHAVIORAL|Noom|Participants will get access to Noom which is a mobile app for weight loss that shifts the paradigm from dieting to a digitally supported and artificial intelligence (AI)-driven cognitive behavioral therapy approach to support personalized behavior changes towards eating, physical activity and stress management. The Noom Healthy Weight curriculum covers foundations in weight loss, nutrition, physical activity, sleep and stress management.Daily tasks (e.g., weight and food logs, readings) are organized vertically in simple cards on the phone screen, allowing users to easily scroll through what needs to be done. It will pull physical activity data (e.g., steps) directly from the health app on smartphones or apps associated with external devices such as Fitbit. Furthermore, Noom stands out from other app-based programs by assigning a personal coach to each user, helping users navigate the emotional and physiological experiences of the Noom weight loss experience.
219140863|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
219140864|NCT00128193|OTHER|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
219140865|NCT00128193|OTHER|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
219140866|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
219140867|NCT00128193|OTHER|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
219140868|NCT02010619|BEHAVIORAL|Cognitive behavior therapy|
219140869|NCT02010619|BEHAVIORAL|Supportive therapy|
219140870|NCT05626504|DEVICE|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
219140871|NCT05505279|DEVICE|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
219140872|NCT00716144|DRUG|Talarozole|Oral Capsule Once Daily
219140873|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 500|Experimental arm
219140874|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 1000|Experimental arm
219140875|NCT03574844|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm
219140876|NCT00866554|DRUG|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
219140877|NCT00866554|DRUG|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
219717952|NCT04445415|DIAGNOSTIC_TEST|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
219717953|NCT01435941|DRUG|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
219717954|NCT01435941|DRUG|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
219140878|NCT04801836|DRUG|Estetrol monohydrate 15 mg|One Estetrol monohydrate (E4) 15 mg tablet once per day
219140879|NCT04801836|DRUG|Placebo|One placebo tablet once per day
219140880|NCT05214235|DRUG|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
219140881|NCT00909363|DRUG|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
219717955|NCT00676884|DRUG|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
219717956|NCT00676884|DRUG|placebo|1.5 mL s.c. b.i.d.
219717957|NCT04392804|PROCEDURE|scaling and root planing|one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution
219717958|NCT02124174|DRUG|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
219140882|NCT00909363|DIAGNOSTIC_TEST|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
219717959|NCT01292902|OTHER|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.
219717960|NCT01292902|OTHER|inspiratory muscle exercise|Equal to the group with chronic heart failure.
219717961|NCT04926415|DEVICE|taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
219717962|NCT04926415|DEVICE|Sham taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
219717963|NCT02742688|DIETARY_SUPPLEMENT|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
219717964|NCT02742688|DIETARY_SUPPLEMENT|Placebo|Placebo(4g/day)
219140883|NCT00909363|DIAGNOSTIC_TEST|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
219140884|NCT05641311|DRUG|ALXN1840|Tablet for oral use.
219140885|NCT06076382|PROCEDURE|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
219140886|NCT06076382|PROCEDURE|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
219140887|NCT00166192|PROCEDURE|Jessner's solution chemical peel|
219140888|NCT00166192|PROCEDURE|Trichloroacetic acid chemical peel|
219717965|NCT01089595|DRUG|Nilotinib|Nilotinib 400 mg po bid
219717966|NCT01089595|DRUG|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
219717967|NCT01816607|PROCEDURE|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
219717968|NCT02159638|DEVICE|Guardian Enlite sensor|Sensor insertion
219717969|NCT02159638|DEVICE|Dexcom G4 platinum sensor|Sensor insertion
219717970|NCT06515730|DRUG|Apixaban|5 mg tablet twice a daily with dose reduction according to label
219717971|NCT06515730|DRUG|Warfarin|2.5 mg tablet once daily, with individual dosing according to coagulation tests
219717972|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
219717973|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
219717974|NCT02210754|OTHER|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
219717975|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
219717976|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
219717977|NCT02210754|OTHER|Marlboro Cigarette|cigarettes
219140889|NCT01949740|OTHER|questionnaire administration|Ancillary studies
219140890|NCT01949740|PROCEDURE|quality-of-life assessment|Ancillary studies
219140891|NCT00809120|DEVICE|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
219140892|NCT02674451|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
219140893|NCT01555684|PROCEDURE|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
219140894|NCT03448757|OTHER|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
219717978|NCT01692015|OTHER|Questionnaire on dietary history|
219717979|NCT01692015|OTHER|Questionnaire on nosebleed severity|
219717980|NCT01692015|OTHER|One week food diary generated by weighing foods|
219717981|NCT01692015|PROCEDURE|Blood tests for full blood count, albumin, and indices of nutritional status|
219717982|NCT05002751|OTHER|UCSD Vaginal Dilator Questionnaire|14 question survey
219717983|NCT05002751|OTHER|EORTC Sexual Health Questionnaire|22 question survey
219717984|NCT01415076|PROCEDURE|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
219717985|NCT01626716|OTHER|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
219717986|NCT01680172|DRUG|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
219717987|NCT01680172|DRUG|Placebo|Single dose of liquid placebo solution taken by mouth
219717988|NCT00992888|DEVICE|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
219717989|NCT06403059|DIAGNOSTIC_TEST|Cervical Length|trans vaginal ultrasound
219140895|NCT03705299|DEVICE|Non-Invasive CVP vs Standard CVP|
219140896|NCT03390569|BEHAVIORAL|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
219140897|NCT06345417|OTHER|Patient Blood Management (PBM)|PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
219140898|NCT06345417|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
219140899|NCT00082810|DRUG|fulvestrant|Given intramuscularly
219140900|NCT00082810|DRUG|tipifarnib|Given IV
219140901|NCT00354406|DRUG|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
219140902|NCT05053009|DRUG|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
219140903|NCT02950558|DRUG|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
219717990|NCT06403059|DIAGNOSTIC_TEST|Uterocervical Angle|by trans vaginal ultrasound
219717991|NCT02981589|DEVICE|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
219717992|NCT02109224|DRUG|Ibrutinib|Given PO
219717993|NCT02109224|OTHER|Laboratory Biomarker Analysis|Correlative studies
219717994|NCT02109224|OTHER|Pharmacological Study|Correlative studies
219717995|NCT02408822|DEVICE|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
219717996|NCT02408822|DEVICE|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
219717997|NCT04168489|DEVICE|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
219140904|NCT02950558|PROCEDURE|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
219140905|NCT06017167|DRUG|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
219717998|NCT04168489|DEVICE|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
219717999|NCT04519775|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
219718000|NCT02826473|OTHER|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
219718001|NCT00083278|DRUG|MDX-010|
219718002|NCT00742677|PROCEDURE|nutritional support|Given orally
219718003|NCT02886663|OTHER|stimulation of the blind visual field|
219140906|NCT06017167|DRUG|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
219140907|NCT05078424|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
219140908|NCT06342063|DEVICE|Blood Flow Restriction Therapy|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
219140909|NCT06342063|DEVICE|Blood Flow Restriction Therapy Sham|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
219140910|NCT00319436|BEHAVIORAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
219140911|NCT00319436|BEHAVIORAL|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
219140912|NCT05577611|COMBINATION_PRODUCT|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
219140913|NCT00004878|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219140914|NCT00004878|DRUG|cytarabine|
219140915|NCT00004878|DRUG|fludarabine phosphate|
219140916|NCT00004878|DRUG|idarubicin|
219140917|NCT00004878|DRUG|methotrexate|
219140918|NCT00004878|DRUG|tacrolimus|
219229474|NCT03936725|OTHER|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
219718004|NCT04462679|OTHER|COMMIT mHealth application|We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
219140919|NCT00004878|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219140920|NCT00004878|PROCEDURE|peripheral blood stem cell transplantation|
219140921|NCT01147380|BIOLOGICAL|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
219140922|NCT01321606|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
219718005|NCT02852083|DRUG|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
219140923|NCT01321606|DIETARY_SUPPLEMENT|sugar pill (placebo)|Placebo identical to the active product will be given
219140924|NCT06318104|DRUG|Tegoprazan|Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
219140925|NCT06318104|DRUG|Esomeprazole 40mg|Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
219718006|NCT02852083|DRUG|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
219229475|NCT00910962|DRUG|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
219718007|NCT02852083|DRUG|Treosulfan|Treosulfan 250 mg twice daily, p.o.
219718008|NCT02852083|DRUG|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
219718009|NCT05861271|DRUG|Capecitabine，Pyrotinib|Pyrotinib and Capecitabine for half a year
219140926|NCT04747756|OTHER|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
219140927|NCT05739903|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
219140928|NCT05739903|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
219140929|NCT03745001|DRUG|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
219140930|NCT03745001|DRUG|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
219140931|NCT03745001|DRUG|Matching placebo|Oral liquid administration daily
219140932|NCT05496816|DIAGNOSTIC_TEST|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
219140933|NCT00021008|DRUG|picoplatin|
219140934|NCT00637234|DRUG|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
219140935|NCT00637234|DRUG|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
219140936|NCT02387099|DRUG|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
219140937|NCT02387099|DRUG|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
219140938|NCT02387099|DRUG|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
219140939|NCT02387099|DRUG|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
219140940|NCT04876573|DRUG|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
219140941|NCT04039984|DEVICE|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
219140942|NCT02613676|DEVICE|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
219140943|NCT02613676|OTHER|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
219140944|NCT03311113|OTHER|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
219140945|NCT00537563|DRUG|Telithromycin|
219140946|NCT00933088|OTHER|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
219140947|NCT01464736|OTHER|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
219140948|NCT02271971|DIETARY_SUPPLEMENT|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
219140949|NCT02271971|DIETARY_SUPPLEMENT|Placebo|A daily placebo capsule during 6 weeks.
219718010|NCT01323218|DRUG|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
219718011|NCT00690898|DRUG|Lanreotide autogel 120 mg|12 months
219140950|NCT02889237|DIETARY_SUPPLEMENT|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
219229476|NCT00910962|DRUG|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
219229477|NCT00910962|DRUG|Placebo|Placebo
219140951|NCT02889237|DIETARY_SUPPLEMENT|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
219140952|NCT02889237|DIETARY_SUPPLEMENT|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
219140953|NCT02914522|DRUG|Filgotinib|Tablet(s) administered orally once daily
219140954|NCT02914522|DRUG|PTM filgotinib|Tablet(s) administered orally once daily
219140955|NCT01629186|OTHER|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
219140956|NCT03276104|PROCEDURE|IOL repositioning|Intraocular lens repositioning by scleral suturing
219140957|NCT03276104|PROCEDURE|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
219140958|NCT04838158|DIAGNOSTIC_TEST|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
219140959|NCT06064357|OTHER|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
219140960|NCT01482013|DRUG|HPP854|Oral, once a day for 28 days.
219140961|NCT01482013|DRUG|Placebo|Oral, once a day for 28 days.
219140962|NCT04825184|BEHAVIORAL|Body image chatbot|See arm/group description.
219140963|NCT03949348|PROCEDURE|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
219140964|NCT03949348|PROCEDURE|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
219140965|NCT04043364|BEHAVIORAL|LIVE|Learning, Innovation, Volunteers and Empowerment
219140966|NCT02662530|DRUG|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
219140967|NCT00375453|DRUG|SH U04722|
219140968|NCT00345761|DRUG|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
219140969|NCT00345761|DRUG|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
219140970|NCT00345761|DRUG|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
219140971|NCT01426178|DEVICE|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
219140972|NCT05619016|DIAGNOSTIC_TEST|[68Ga]Ga-ABY-025 PET|\[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
219718012|NCT05783973|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
219140973|NCT05619016|DIAGNOSTIC_TEST|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
219140974|NCT03857971|DEVICE|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
219140975|NCT03093467|BEHAVIORAL|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
219140976|NCT03093467|DRUG|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
219140977|NCT03093467|BEHAVIORAL|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
219140978|NCT02849535|BEHAVIORAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
219229478|NCT03043339|OTHER|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
219718013|NCT00782093|DRUG|volociximab|volociximab intravitreal injection
219140979|NCT05271188|PROCEDURE|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function \[8\]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity \[9, 10\]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) \[11\]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
219140980|NCT01622075|DEVICE|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
219718014|NCT05139147|DEVICE|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
219140981|NCT01622075|DEVICE|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
219140982|NCT04349150|DEVICE|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
219140983|NCT05698069|DIAGNOSTIC_TEST|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
219140984|NCT05698069|OTHER|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
219140985|NCT05698069|OTHER|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
219140986|NCT03293056|OTHER|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
219140987|NCT03293056|OTHER|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
219718015|NCT04320537|OTHER|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
219140988|NCT02542852|DRUG|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
219140989|NCT03684213|DRUG|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
219140990|NCT03684213|DRUG|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
219140991|NCT03684213|DRUG|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
219140992|NCT03684213|DRUG|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
219140993|NCT00319397|BEHAVIORAL|Exercise-Training Program|
219718016|NCT01369303|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
219718017|NCT06005376|OTHER|Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive|The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
219718018|NCT05447832|DEVICE|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
219718019|NCT05447832|DEVICE|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
219140994|NCT02499471|OTHER|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
219140995|NCT05382104|DRUG|Maribavir|Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
219140996|NCT00639002|DRUG|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
219140997|NCT00639002|DRUG|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
219140998|NCT05907473|OTHER|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
219140999|NCT05907473|OTHER|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
219718020|NCT05447832|DIAGNOSTIC_TEST|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
219718021|NCT00025142|DRUG|FOLFOX regimen|
219718022|NCT00025142|DRUG|fluorouracil|
219141000|NCT03506880|BEHAVIORAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
219141001|NCT03506880|BEHAVIORAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
219141002|NCT00000217|DRUG|Carbamazepine|
219141003|NCT05074836|DIETARY_SUPPLEMENT|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
219141004|NCT05074836|DIETARY_SUPPLEMENT|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
219141005|NCT05074836|OTHER|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months"
219141006|NCT03462589|DRUG|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
219141007|NCT03950869|BEHAVIORAL|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
219141008|NCT03950869|BEHAVIORAL|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
219141009|NCT00298597|DRUG|granulocyte - colony stimulating factor (G-CSF)|
219141010|NCT00298597|DRUG|erythropoetin (EPO)|
219141011|NCT02354885|DRUG|Tranexamic Acid|Coagulation Management / Efficiency
219141012|NCT06231277|DRUG|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
219141013|NCT02052375|DRUG|ASP2408|subcutaneous injection
219718023|NCT00025142|DRUG|gefitinib|
219718024|NCT00025142|DRUG|leucovorin calcium|
219718025|NCT00025142|DRUG|oxaliplatin|
219718026|NCT03307850|OTHER|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
219718027|NCT02880176|OTHER|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
219141014|NCT02052375|DRUG|Placebo|subcutaneous injection
219141015|NCT05261997|PROCEDURE|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
219141016|NCT05261997|DRUG|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
219141017|NCT02509585|DRUG|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
219141018|NCT00102258|DRUG|Growth Hormone Therapy|
219141019|NCT00848627|OTHER|Specimen and questionnaires only|Specimen and questionnaires only
219141020|NCT02010372|OTHER|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
219141021|NCT02010372|OTHER|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
219141022|NCT01052246|DRUG|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
219718028|NCT01330927|DRUG|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
219718029|NCT04355273|DRUG|Heparin|heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
219718030|NCT04355273|DRUG|Heparin|heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
219718031|NCT04355273|DRUG|normal saline|normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
219141023|NCT01052246|DEVICE|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm"
219141024|NCT01148719|OTHER|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
219141025|NCT04010318|PROCEDURE|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
219141026|NCT02867566|DRUG|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
219141027|NCT02867566|DRUG|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
219141028|NCT00739765|BEHAVIORAL|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
219141029|NCT00739765|BEHAVIORAL|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
219141030|NCT00739765|BEHAVIORAL|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
219141031|NCT06630377|DIETARY_SUPPLEMENT|GOS|During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219141032|NCT06630377|DIETARY_SUPPLEMENT|Placebo|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
219141033|NCT06628518|BEHAVIORAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
219141034|NCT06632132|OTHER|Antimicrobial resistance Training in Hemodialysis Units|"The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos."
219141035|NCT05838495|OTHER|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
219141036|NCT05469802|BIOLOGICAL|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
219141037|NCT05469802|OTHER|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
219141038|NCT01304342|DRUG|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
219141039|NCT01304342|DRUG|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
219141040|NCT01304342|DRUG|Normal saline|Normal saline intravenously and intranasally
219718032|NCT06339840|DIETARY_SUPPLEMENT|Low-carbohydrate diet group|During the initial 8-week weight loss phase, participants will adopt a low-carbohydrate dietary pattern (with carbohydrate energy ratio of 20-30%, protein energy ratio of 30-40%, and fat energy ratio of 40-45%), with a caloric intake approximately 75% of their usual daily intake, but not less than 1200 kcal. Throughout the intervention period, participants will receive a daily nutritionally balanced meal replacement for 8 weeks to substitute for staple foods and control carbohydrate intake. Nutritionists will reinforce interventions by setting health goals, providing health education, implementing dietary and exercise interventions, and monitoring through a combined approach using a mobile platform. During the subsequent 4-week transition phase, participants' diets will gradually transition to a balanced dietary pattern (with carbohydrate energy ratio of 45-60%, protein energy ratio of 20-30%, and fat energy ratio of 20-25%) under the guidance of nutritionists.
219141041|NCT05686421|DEVICE|OCT Imaging Using Device N|Standard conventional OCT imaging device equipped with extendable and comfortable chin and forehead rest.
219141042|NCT05686421|DEVICE|OCT Imaging Using Device C|Standard conventional OCT imaging device.
219141043|NCT02812459|OTHER|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
219141044|NCT02812459|OTHER|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
219141045|NCT03752385|BEHAVIORAL|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
219141046|NCT02196818|DEVICE|Mpact Acetabular Shell|Total Hip Replacement
219141047|NCT00718406|DRUG|Metoprolol|
219141048|NCT00718406|DRUG|metoprolol plus morphine|
219141049|NCT03312439|BEHAVIORAL|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
219141050|NCT00367055|DRUG|rosiglitazone-metformin|
219141051|NCT00367055|DRUG|Metformin|
219141052|NCT00367055|DRUG|metformin+ gliclazide|
219141053|NCT05712018|DRUG|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219141054|NCT05712018|DRUG|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219141055|NCT05712018|DRUG|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
219141056|NCT02729272|PROCEDURE|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
219141057|NCT02729272|PROCEDURE|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
219141058|NCT02729272|DEVICE|Monopolar ESD|
219141059|NCT02729272|DEVICE|Ultrasonic ESD|
219141060|NCT06112119|DEVICE|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
219141061|NCT03612804|BEHAVIORAL|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
219141062|NCT03612804|BEHAVIORAL|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
219141063|NCT06498453|DEVICE|Trak-Physio knee condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
219141064|NCT06498453|DEVICE|Trak-Physio in shoulder condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
219141065|NCT06498453|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
219141066|NCT06498453|OTHER|Shoulder conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
219141067|NCT03316456|DIAGNOSTIC_TEST|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
219141068|NCT03316456|DIAGNOSTIC_TEST|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
219141069|NCT03316456|DIAGNOSTIC_TEST|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
219141070|NCT04716803|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
219141071|NCT04716803|DEVICE|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
219141072|NCT03105128|DRUG|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
219141073|NCT03105128|DRUG|risankizumab IV|Risankizumab administered by intravenous infusion
219229479|NCT03043339|OTHER|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
219141074|NCT03105128|DRUG|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
219141075|NCT00869570|DRUG|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
219141076|NCT00869570|DRUG|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
219141077|NCT00869570|RADIATION|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
219141078|NCT00629200|DRUG|Sodium Stibogluconate|400 mg/m\^2 IV daily on days 1-5.
219141079|NCT00629200|DRUG|Interferon Alpha-2b|3x10\^6 units subcutaneously three times weekly
219229480|NCT03043339|OTHER|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
219718033|NCT06339840|BEHAVIORAL|Health Education Group|Upon enrollment, nutritionists will provide lifestyle guidance to patients, including personalized adjustments such as limiting total energy intake to \<1600 kcal/day, adjusting macronutrient distribution to 45-55% for carbohydrates, 20-30% for fats, and 20-30% for protein. Participants are advised to accumulate at least 150 minutes of moderate-intensity aerobic exercise per week (achieving 50%-70% of maximum heart rate). At enrollment, nutritionists will educate participants on healthy lifestyle principles, train them on nutritional intervention tools, and assist in food selection for weight management planning. Throughout the intervention, nutritionists will conduct follow-ups with patients via phone or mobile platforms to monitor weekly dietary and exercise habits, weight changes, and address any participant concerns promptly.
219229481|NCT03043339|OTHER|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
219229482|NCT04434872|PROCEDURE|Colonoscopy|Fecal microbiota transplantation through colonoscopy
219229483|NCT04434872|PROCEDURE|Gastroscopy|Fecal microbiota transplantation through gastroscopy
219141080|NCT05776706|DIAGNOSTIC_TEST|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
219141081|NCT04878341|OTHER|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
219141082|NCT04598529|OTHER|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
219141083|NCT04598529|OTHER|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
219141084|NCT00387361|PROCEDURE|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
219718034|NCT02008370|DRUG|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
219552256|NCT02233374|OTHER|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
219141085|NCT04083651|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
219229484|NCT04434872|DRUG|Fecal Microbiota|
219229485|NCT04434872|PROCEDURE|Enema|Fecal microbiota transplantation through enema
219229486|NCT00637559|DRUG|Esomeprazole Magnesium|
219141086|NCT04083651|DRUG|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
219141087|NCT04135378|DRUG|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
219141088|NCT04135378|OTHER|placebo|:- included 30 students given placebo for one week before presentation.
219141089|NCT05895760|OTHER|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
219141090|NCT01928004|DEVICE|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
219141091|NCT01928004|PROCEDURE|Conventional reline|conventional reline of the existing mandibular complete denture
219141092|NCT01393470|PROCEDURE|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
219229487|NCT03788707|OTHER|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
219229488|NCT01950689|DRUG|Nimorazole|
219229489|NCT01950689|RADIATION|Radiotherapy|
219229490|NCT01333449|DRUG|Decitabine|20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
219229491|NCT03222232|BEHAVIORAL|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
219229492|NCT06019715|BEHAVIORAL|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
219229493|NCT01858688|DEVICE|Multiparametric MRI|an MRI of the prostate will be performed
219229494|NCT01858688|PROCEDURE|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
219141093|NCT04066751|DRUG|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
219141094|NCT03955640|DRUG|Olaparib|Given PO
219141095|NCT03955640|PROCEDURE|Hyperthermia Treatment|Undergo hyperthermia treatment
219229495|NCT01964586|DRUG|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
219229496|NCT01964586|DRUG|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
219229497|NCT01964586|DRUG|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
219141096|NCT03955640|OTHER|Questionnaire Administration|Ancillary studies
219141097|NCT03955640|OTHER|Quality-of-Life Assessment|Ancillary studies
219141098|NCT06430125|DRUG|Nicorandil 10 MG Oral Tablet|Nicorandil 10 MG oral tablet twice daily
219141099|NCT02875665|DEVICE|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
219141100|NCT06258980|DRUG|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
219141101|NCT04008420|OTHER|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
219141102|NCT04025606|DRUG|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
219141103|NCT04025606|DRUG|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
219141104|NCT01267409|OTHER|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
219141105|NCT03161691|PROCEDURE|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
219141106|NCT01774994|OTHER|stable isotope infusion for measurement of metabolism|
219141107|NCT00413179|DRUG|Metformin|
219141108|NCT00413179|DRUG|Clomiphene citrate|
219141109|NCT00413179|DRUG|Placebo|
219141110|NCT04973852|DEVICE|Ekso|Exoskeleton walking
219141111|NCT05255718|DIETARY_SUPPLEMENT|Aronia juice|Once daily dose of 100 mL of aronia juice
219141112|NCT05255718|OTHER|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
219141113|NCT03986424|DRUG|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
219229498|NCT04123119|BIOLOGICAL|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
219141114|NCT03986424|DRUG|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
219141115|NCT01400750|DRUG|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
219141116|NCT01400750|DRUG|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
219141117|NCT03232684|DIAGNOSTIC_TEST|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
219141118|NCT00329979|BEHAVIORAL|vascular access site|Randomized vascular access site
219141119|NCT00371020|DRUG|low molecular weight heparin, 5-FU|
219141120|NCT03386929|DRUG|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
219141121|NCT03386929|DRUG|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
219141122|NCT03386929|DRUG|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
219141123|NCT05310929|DRUG|Labetalol and Glyceril trinitrate|for control of blood pressure
219141124|NCT06388447|BIOLOGICAL|Umbilical cord-mesenchymal stem cells|One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
219141125|NCT05872321|OTHER|Complication|whether or not complications occur
219141126|NCT00258518|PROCEDURE|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
219141127|NCT01975467|DEVICE|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
219141128|NCT02765373|DRUG|Exemestane|
219141129|NCT02765373|DRUG|Letrozole|
219229499|NCT05612009|COMBINATION_PRODUCT|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
219229500|NCT00001998|DRUG|Nystatin|
219141130|NCT02765373|DRUG|Anastrozole|
219141131|NCT05193630|DIETARY_SUPPLEMENT|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
219141132|NCT03503630|DRUG|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
219141133|NCT03503630|RADIATION|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
219141134|NCT03503630|DRUG|mFOLFOX|Given every 2 weeks for 6 cycles
219141135|NCT03503630|PROCEDURE|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
219141136|NCT01805921|BIOLOGICAL|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10\^10 vp
219229501|NCT02973932|BEHAVIORAL|Cognitive-bahavioral psychotherapy|
219229502|NCT02593552|DEVICE|DriveCam|Video event monitoring device
219718035|NCT04999787|DRUG|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
219718036|NCT04999787|DRUG|Placebo|Placebo
219141137|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10\^8 pfu
219141138|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10\^10 vp
219141139|NCT01805921|BIOLOGICAL|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10\^9 vp
219229503|NCT00833599|DRUG|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
219229504|NCT01999335|DRUG|Oprozomib|Extended release (ER) tablets administered orally
219229505|NCT01999335|DRUG|Pomalidomide|Capsules for oral administration
219229506|NCT01999335|DRUG|Dexamethasone|Tablets for oral administration
219229507|NCT02013804|DRUG|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
219229508|NCT00787176|DRUG|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
219229509|NCT00787176|DRUG|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
219229510|NCT00787176|DRUG|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
219229511|NCT00787176|DRUG|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
219229512|NCT03732456|PROCEDURE|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
219229513|NCT03037736|DRUG|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
219718037|NCT04884568|DEVICE|Exufiber|Wound dressed with Exufiber for up to 21 days.
219718038|NCT03317496|DRUG|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
219718039|NCT03317496|DRUG|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
219141140|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10\^7 pfu
219141141|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10\^9 vp
219229514|NCT03037736|DRUG|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
219718040|NCT03317496|DRUG|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
219718041|NCT03317496|DRUG|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
219718042|NCT00977418|BEHAVIORAL|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
219718043|NCT00977418|OTHER|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
219141142|NCT03860220|DRUG|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
219141143|NCT03860220|DRUG|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
219141144|NCT00387465|DRUG|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
219141145|NCT00387465|DRUG|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
219229515|NCT03037736|DRUG|Normal saline|Normal saline will be used as the placebo.
219229516|NCT04463654|DEVICE|Zero Self-Harm app|Safety plan app for smartphones
219229517|NCT01775657|DEVICE|Thopaz (Digital drainage)|
219229518|NCT01775657|DEVICE|Pleur Evac (Analogue drainage)|
219229519|NCT04518865|DEVICE|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
219229520|NCT01274156|DEVICE|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
219229521|NCT01274156|DEVICE|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
219229522|NCT01274156|DEVICE|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
219229523|NCT01274156|DEVICE|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
219229524|NCT00992745|DRUG|123-I-MIP-1072|Single 10 mCi intravenous injection
219229525|NCT00992745|DRUG|111-In capromab pendetide|Single 5 mCi intravenous injection
219229526|NCT00992745|DRUG|123-I-MIP-1072|Single 5 mCi intravenous injection
219229527|NCT02556697|DEVICE|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
219718044|NCT03568903|OTHER|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
219718045|NCT00049829|DRUG|Zoledronic Acid|
219141146|NCT00387465|DRUG|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
219141147|NCT05678296|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
219141148|NCT05678296|DRUG|Analgesic|Analgesics are prescribed for the patients for all groups.
219141149|NCT05678296|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
219141150|NCT05678296|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
219141151|NCT05678296|DRUG|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
219141152|NCT00907218|DRUG|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
219141153|NCT02347163|DRUG|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
219141154|NCT00006450|DRUG|Phenylbutyrate|
219141155|NCT02511639|DRUG|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
219141156|NCT02511639|DRUG|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
219141157|NCT04296032|BEHAVIORAL|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
219141158|NCT04296032|BEHAVIORAL|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
219141159|NCT04251143|PROCEDURE|corneal cross-linking|UV-A Irradiation and riboflavin
219141160|NCT04251143|DIAGNOSTIC_TEST|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
219141161|NCT04514419|DRUG|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
219552257|NCT02924649|PROCEDURE|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
219552258|NCT04292548|DIAGNOSTIC_TEST|taking saliva samples to determine TAS, TOS and LL-37|
219552259|NCT01591720|BEHAVIORAL|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
219141162|NCT04514419|DRUG|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
219141163|NCT00600457|DEVICE|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
219141164|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
219141165|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
219141166|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
219141167|NCT03007589|DRUG|otc sunscreens|Sunscreens of various SPF levels and ingredients
219141168|NCT03007589|OTHER|sun protection fabrics|fabrics
219141169|NCT03007589|OTHER|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
219141170|NCT06362759|DRUG|TOUR006 - 50 MG|TOUR006 50 MG
219141171|NCT06362759|DRUG|TOUR006 - 25 MG|TOUR006 25 MG
219141172|NCT06362759|DRUG|TOUR006 - 15 MG|TOUR006 15 MG
219141173|NCT06362759|OTHER|Placebo|Placebo
219141174|NCT04482894|OTHER|Palliative Care Visits|Regular visits with a palliative (supportive) care specialist
219141175|NCT04167969|DRUG|(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, or (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
219141176|NCT04167969|DIAGNOSTIC_TEST|PET/MRI/fluorescence imaging|Imaging will be performed using the GE Signa PET/MRI.
219141177|NCT04167969|OTHER|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
219552260|NCT01067950|PROCEDURE|Isolated Pancreas Transplant|
219552261|NCT01067950|DRUG|Intensive Insulin Therapy|
219552262|NCT05445180|BEHAVIORAL|Contingency management|Contingency management will be used to encourage abstinence
219552263|NCT05136001|DEVICE|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
219552264|NCT04462198|DRUG|PIPE-505|Intratympanic injection
219552265|NCT04462198|DRUG|Placebo|Intratympanic injection
219552266|NCT05284877|OTHER|No intervention|The study is an observational study without intervention.
219552267|NCT01006954|DRUG|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
219141178|NCT04167969|PROCEDURE|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
219141179|NCT03729011|DRUG|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
219141180|NCT03729011|DRUG|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
219141181|NCT06487806|BEHAVIORAL|SmokefreeSGM|Participants will be asked to set a quit date within the next 15 days before being enrolled in the SmokefreeSGM Español text messaging program. They will be mailed a 6-week supply of nicotine patches. The participants will get daily text messages for 6 weeks that will encourage them to quit smoking.
219141182|NCT06479889|BEHAVIORAL|Guardians receiving counseling + lock|Guardians of patients admitted to the Pediatric Hospital Medicine behavioral health team will be provided a brief lethal means educational session and offered up to 3 secure storage devices of their choosing (lock box and or cable locks)
219141183|NCT05507749|PROCEDURE|cryoballoon ablation|Cryoballoon ablation for the treatment of atrial fibrillation
219141184|NCT05507749|DEVICE|implantable loop recorder insertion|The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
219141185|NCT04822753|PROCEDURE|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
219141186|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
219141187|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
219141188|NCT06788717|DEVICE|Comprehensive Primary Revision Stems|Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.
219141189|NCT03645031|OTHER|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
219141190|NCT03645031|OTHER|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
219141191|NCT05204446|BEHAVIORAL|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
219141192|NCT05204446|BEHAVIORAL|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
219141193|NCT06831669|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
219141194|NCT03608202|BEHAVIORAL|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
219141195|NCT03608202|OTHER|Control group|Routine protocol of the treating team is followed
219141196|NCT05900791|PROCEDURE|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
219141197|NCT04922606|DIAGNOSTIC_TEST|US ot the GSV|Ultrasound of the Great Saphenous Vein
219141198|NCT04199728|DRUG|Liraglutide Pen Injector|Liraglutide will be provided using an injection pen provided by the manufacturer
219141199|NCT04199728|DRUG|Placebo|Placebo injection pen
219141200|NCT05543057|RADIATION|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
219141201|NCT06070207|PROCEDURE|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
219141202|NCT06070207|PROCEDURE|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
219141203|NCT02328963|DRUG|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
219552268|NCT01006954|DRUG|Flare up|Flare up protocol in poor responders for IVF/ICSI
219552269|NCT02156453|PROCEDURE|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
219552270|NCT05755854|BIOLOGICAL|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
219229528|NCT01190995|DRUG|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
219229529|NCT01190995|DRUG|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
219229530|NCT01817894|DRUG|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
219141204|NCT02328963|DRUG|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
219141205|NCT02976532|OTHER|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
219141206|NCT00482729|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
219229531|NCT00059527|BEHAVIORAL|Healthy Youth Places: a behavior change model|
219229532|NCT02486939|DRUG|CHS-0214|Open label
219229533|NCT02649725|BEHAVIORAL|patient's satisfaction|Questionnaire based measurement.
219141207|NCT00482729|DRUG|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
219229534|NCT01291810|BIOLOGICAL|TNF Kinoid|TNF Kinoid
219141208|NCT04487600|OTHER|Active voiding trial|
219141209|NCT01416558|DRUG|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
219141210|NCT05721924|PROCEDURE|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
219229535|NCT01291810|BIOLOGICAL|WFI|WFI
219229536|NCT05723666|OTHER|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
219229537|NCT01837602|BIOLOGICAL|cMet RNA CAR T cells|
219229538|NCT01141972|DIETARY_SUPPLEMENT|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
219229539|NCT01141972|OTHER|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
219229540|NCT01769716|PROCEDURE|Umbilical cord blood transplantation|
219229541|NCT02336958|DRUG|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
219229542|NCT02336958|DRUG|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
219229543|NCT02336958|DRUG|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
219229544|NCT02336958|DRUG|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
219141211|NCT05721924|PROCEDURE|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
219141212|NCT01675895|DRUG|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
219141213|NCT01675895|DRUG|levobupivacaine Spinal anesthesia|spinal anesthesia
219141214|NCT03357289|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
219141215|NCT01606124|DRUG|defined green tea catechin extract|Given PO
219141216|NCT01606124|OTHER|placebo|Given PO
219141217|NCT01606124|OTHER|questionnaire administration|Ancillary studies
219141218|NCT01606124|OTHER|laboratory biomarker analysis|Correlative studies
219141219|NCT02948114|OTHER|Control: Cow milk-based infant formula|
219141220|NCT02948114|OTHER|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
219141221|NCT02948114|OTHER|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
219141222|NCT02948114|OTHER|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
219141223|NCT02234128|DEVICE|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
219141224|NCT06093386|OTHER|Intensive Transition Support|Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
219141225|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 1|
219141226|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 2|
219141227|NCT00092014|DRUG|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
219141228|NCT00092014|DRUG|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
219141229|NCT00092014|DIETARY_SUPPLEMENT|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
219141230|NCT00092014|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
219141231|NCT00092014|DRUG|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
219141232|NCT00092014|DRUG|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
219141233|NCT05618236|DRUG|Group N; neostigmine+atropine|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
219141234|NCT05618236|DRUG|GROUP S; decurarized with sugammadex.|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
219141235|NCT01708499|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219141236|NCT02126878|DRUG|Kenalog|
219141237|NCT05242653|PROCEDURE|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
219141238|NCT05242653|PROCEDURE|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
219141239|NCT05215925|DRUG|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
219141240|NCT05215925|DRUG|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
219141241|NCT05215925|DRUG|HLX07|HLX07 1500mg q3w
219141242|NCT00661778|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
219141243|NCT00661778|DRUG|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
219141244|NCT00661778|DRUG|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
219141245|NCT00766298|BEHAVIORAL|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
219141246|NCT00766298|BEHAVIORAL|Weight Loss|The reduction of kcal/day through implementation of low fat diet
219229545|NCT02374736|DRUG|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
219229546|NCT01753167|DRUG|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
219141247|NCT00766298|BEHAVIORAL|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
219141248|NCT02468388|OTHER|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
219141249|NCT02468388|OTHER|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
219141250|NCT02468388|OTHER|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
219229547|NCT01753167|DRUG|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
219718046|NCT01035788|BEHAVIORAL|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
219141251|NCT03156595|BEHAVIORAL|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
219141252|NCT03156595|BEHAVIORAL|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
219141253|NCT01573598|DRUG|Placebo|Matching placebo given orally, once per day
219718047|NCT01035788|BEHAVIORAL|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
219141254|NCT01573598|DRUG|Vilazodone|Vilazodone, 20 mg per day, oral administration
219141255|NCT01573598|DRUG|Vilazodone|Vilazodone, 40 mg once per day, oral administration
219141256|NCT00455494|DRUG|AQ-13|
219141257|NCT03710057|DRUG|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
219141258|NCT01601041|OTHER|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
219141259|NCT05408559|DRUG|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
219141260|NCT04831385|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
219141261|NCT06442969|OTHER|Education and resources provided by community health workers|The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
219141262|NCT00002436|DRUG|Lamivudine|
219141263|NCT00002436|DRUG|Zidovudine|
219141264|NCT00002436|DRUG|Zalcitabine|
219141265|NCT02750072|PROCEDURE|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
219141266|NCT02750072|PROCEDURE|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
219141267|NCT03430414|DIAGNOSTIC_TEST|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
219141268|NCT04961749|OTHER|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
219141269|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
219141270|NCT04271449|BEHAVIORAL|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
219141271|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
219141272|NCT02515838|DRUG|Sevuparin|The Drug Product sevuparin solution for IV infusion
219141273|NCT02515838|OTHER|Placebo|Placebo for IV infusion
219141274|NCT06174337|BEHAVIORAL|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
219141275|NCT04378062|PROCEDURE|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
219229548|NCT01753167|DRUG|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
219552271|NCT05755854|DRUG|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
219552272|NCT05755854|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
219552273|NCT05755854|DRUG|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
219552274|NCT04809662|DRUG|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for \~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
219552275|NCT05252988|DRUG|Neratinib|Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
219552276|NCT05252988|DRUG|Loperamide|Loperamide orally.
219552277|NCT05252988|DRUG|Colesevelam|Colesevelam capsules orally, 2 times a day for the first month (28 days).
219229549|NCT03372694|BEHAVIORAL|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
219229550|NCT03372694|DRUG|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
219229551|NCT03372694|OTHER|Rehabilitation Education|General health education
219229552|NCT03372694|DRUG|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
219229553|NCT05127967|OTHER|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
219229554|NCT02322424|PROCEDURE|pancreaticoduodenectomy|
219229555|NCT00328666|BEHAVIORAL|Iyengar yoga|
219229556|NCT00328666|BEHAVIORAL|Enhanced nutritional care classes|
219229557|NCT02909205|OTHER|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
219229558|NCT02909205|OTHER|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
219229559|NCT05671445|BIOLOGICAL|CM326|CM326 injection
219229560|NCT02234141|DRUG|Placebo|Tablet administered orally once daily
219229561|NCT02234141|DRUG|Selonsertib|Tablets administered orally once daily
219229562|NCT05746741|BEHAVIORAL|Telehealth solution|Video conferencing
219229563|NCT04694066|BEHAVIORAL|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
219229564|NCT04694066|BEHAVIORAL|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
219229565|NCT01496339|BIOLOGICAL|MenSCs transplantation|1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
219229566|NCT01496339|DRUG|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
219229567|NCT01217866|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
219229568|NCT01092715|PROCEDURE|Spinal mobilization|Non thrust mobilization to the cervical spine
219229569|NCT01092715|PROCEDURE|Massage|Sedative massage to cervical paraspinal muscles
219141276|NCT01037530|DRUG|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
219141277|NCT01070888|DRUG|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
219141278|NCT01070888|DRUG|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
219229570|NCT01092715|PROCEDURE|Neck exercises|Range of motion exercises to include foraminal opening
219229571|NCT03042767|BIOLOGICAL|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
219229572|NCT03042767|OTHER|Placebo|Matched Placebo
219229573|NCT01385800|BIOLOGICAL|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
219229574|NCT01385800|BIOLOGICAL|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
219229575|NCT04641715|PROCEDURE|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
219229576|NCT05963802|OTHER|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
219229577|NCT02216084|DRUG|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
219229578|NCT03020433|DEVICE|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
219229579|NCT03020433|DEVICE|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
219229580|NCT03020433|DEVICE|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
219229581|NCT03020433|DEVICE|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
219229582|NCT00412178|DEVICE|telecommunication based glucose monitoring system|
219229583|NCT01501721|BEHAVIORAL|Exercise|Home-based exercise program
219229584|NCT01501721|BEHAVIORAL|Diet|Nutritional counseling aiming to reduce suggar intake
219229585|NCT01854866|OTHER|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
219229586|NCT03326856|BIOLOGICAL|botulinum toxin, Type A|topical liniment
219718048|NCT04691934|PROCEDURE|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
219229587|NCT03326856|BIOLOGICAL|Vehicle|Vehicle Formulation
219229588|NCT04243772|OTHER|Data extraction|Data extraction from medical files
219229589|NCT02037568|BEHAVIORAL|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
219229590|NCT05064072|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure."
219229591|NCT05064072|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure"
219229592|NCT05064072|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure"
219229593|NCT04001582|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
219229594|NCT02967822|GENETIC|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
219229595|NCT02967822|GENETIC|Biological samples for healthy relatives|Blood samples.
219718049|NCT02590315|OTHER|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
219718050|NCT02590315|DEVICE|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
218987218|NCT06676670|OTHER|sham acupuncture|"Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo"
218987219|NCT06604065|DRUG|AMS2434 (amino acids)|The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.
218987220|NCT06604065|DRUG|Placebo|Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
218987221|NCT06866080|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
218987222|NCT07008235|DRUG|Tablet Amitriptyline 10 milligrams|Tablet Amitriptyline 10 milligrams at night will be given to patients along with standard first line treatment of functional dyspepsia
218987223|NCT07008235|DRUG|Tablet Trifluoperazine 1 milligrams twice daily|Tablet Trifluoperazine 1 milligrams twice daily will be given to patients along with standard first line treatment of functional dyspepsia
218987224|NCT06681610|DEVICE|Transcranial Pulse Stimulation|low intensity shock-waves stimulation of the motor cortex, bilateral
219141279|NCT04152616|OTHER|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
219141280|NCT05047341|DRUG|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
219141281|NCT00024466|BIOLOGICAL|GVAX|
219141282|NCT00024466|PROCEDURE|Autologous transplant|
219141283|NCT00460785|DRUG|Opioid|
219141284|NCT04074902|DEVICE|Ultrasonography|Mindray dp1100 plus.
219229596|NCT00621842|DRUG|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
219718051|NCT02590315|DEVICE|Conventional digital mammography.|Conventional digital mammography.
219718052|NCT05304325|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
219718053|NCT05304325|OTHER|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
219718054|NCT05304325|OTHER|Blood pressure|Systolic and diastolic blood pressure will be measured.
219718055|NCT05304325|OTHER|Anthropometric measurements|Body weight, height and waist circumference will be measured.
218987225|NCT06681493|DRUG|YZJ-4729 Tartrate injection|Infusion, QD
218987226|NCT06681493|DRUG|YZJ-4729 simulated injection|Infusion, QD
218987227|NCT06680219|DIETARY_SUPPLEMENT|Placebo|Crystal Light Raspberry Lemonade: Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water).
218987228|NCT06680219|DIETARY_SUPPLEMENT|Active comparator|"ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931): Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily.~(8-12 oz of water is approximately 236-354 mL of water)."
218987229|NCT06680024|PROCEDURE|Intercostal tube|Intercostal tube drainage as a first management of second stage empyema
218987230|NCT06680024|PROCEDURE|Video assisted thoracoscope|Video assisted thoracoscopic surgery as a first management for second stage empyema
218987231|NCT05240599|OTHER|Exercise Training|Exercise training will be applied 3 times a day for 8 weeks.
218987232|NCT06873113|DEVICE|Active BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains 50% of participants limb occlusion pressure for the duration of each strengthening exercise.
218987233|NCT06873113|DEVICE|Sham BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains a pressure of 20mmHg for the duration of each strengthening exercise.
218987234|NCT06873113|BEHAVIORAL|Strengthening Exercises with BFRT|Participants perform 4 strengthening exercises while using the BFR device: seated scapular plane elevation, prone horizontal abduction, side-lying external rotation, and prone scapular plane elevation. Each exercise is performed unilaterally. Participants perform 1 set of 30 repetitions followed by 3 sets of 15 repetitions (4 total sets, 75 total repetitions). Participants are given 30 seconds rest between sets and 2 minutes of rest between strengthening exercises. Selected resistance for each strengthening exercise is equal to 20% of the participant's maximal force production as measured by handheld dynamometry. Resistance is adjusted weekly.
218987235|NCT06873113|BEHAVIORAL|Skilled Physical Therapy Care|Participants perform non-strengthening interventions as part of skilled physical therapy care. Non-strengthening interventions include an upper arm ergometer for warm-up, active assisted range of motion of the shoulder, shoulder stretching, shoulder joint mobilizations, and cryotherapy. Non-strengthening interventions are prescribed at the discretion of the treating physical therapist. Participants are enrolled in physical therapy for a minimum of 4 weeks. After 4 weeks, the treating physical therapist can discharge a participant based on their progress in meeting their rehabilitation goals. Participants discharged from skilled physical therapy care will continue to complete strengthening exercises with BFRT until the end of the trial period (8 weeks).
218987236|NCT06681298|DRUG|The experimental group received Nivolumab|Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
218987237|NCT05215886|BEHAVIORAL|Surgery|Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
218987238|NCT06623682|BEHAVIORAL|Transdiagnostic cognitive behavioural therapy|Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
218987239|NCT05000723|OTHER|Standard of care|"Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
218987240|NCT06875102|DEVICE|Acupuncture (ACU)|acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention.
218987241|NCT06875102|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|"Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation.~Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020)."
219141285|NCT00669461|DRUG|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
219141286|NCT06553287|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% for topical application
219141287|NCT06553287|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% for topical application
219141288|NCT06553287|DRUG|LNK01004 ointment 1.5%|LNK01004 ointment 1.5% for topical application
219229597|NCT00621842|DRUG|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
218987242|NCT06875102|OTHER|APA (adapted physical activity )|The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks
219141289|NCT06553287|DRUG|Vehicle BID|Inactive vehicle matched to LNK01004 ointment for topical application.
219141290|NCT00091624|DRUG|CC-5013|
219141291|NCT06134466|DIETARY_SUPPLEMENT|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
219552278|NCT06849869|BEHAVIORAL|COMPASS+|COMPASS+ is centered around the integration of a care manager (a licensed mental health clinician) who provides mental health supports (e.g. short-term therapy) and symptom monitoring to perinatal patients. The care manager works closely with the patient and obstetric clinician to create a treatment plan based on the patient's preferences and needs. The care manager also utilizes a care registry to send monthly mental health screeners to patients and track their symptoms. The care manger meets weekly with the obstetric clinician and a consulting psychiatrist to review and modify treatment plans as needed. The care manager services are available throughout pregnancy and up to one year postpartum.
219552279|NCT01046097|BIOLOGICAL|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
219552280|NCT04710823|PROCEDURE|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
219552281|NCT04710823|PROCEDURE|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
219552282|NCT04703933|OTHER|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
219552283|NCT03736577|OTHER|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
219552284|NCT04411251|BEHAVIORAL|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
219552285|NCT04411251|BEHAVIORAL|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
219552286|NCT05429463|BIOLOGICAL|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
219552287|NCT05429463|DRUG|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
219552288|NCT05429463|DRUG|Albumin-Bound Paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
219552289|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
219552290|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
219552291|NCT02582554|BEHAVIORAL|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
219552292|NCT03232450|DRUG|Aspirin|Subjects will receive 81 mg enteric coated aspirin
218987243|NCT06875102|DEVICE|Acupuncture (sham_ACU)|Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention.
218987244|NCT06875102|DEVICE|Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS)|"Simulated Transcutaneous Vagus Nerve Stimulation (sim\_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in simulated mode."
218987245|NCT05656118|DEVICE|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
218987246|NCT06631755|DEVICE|Xience Skypoint stent over calcified coronary lesions|Patients with Xience Skypoint stent implanted after OCT assesment of calcification
218987247|NCT06685809|DRUG|FZ008-145 solution|Dose formulation- Oral solution
218987248|NCT06685809|DRUG|FZ008-145 Tablet|Dose formulation- Oral tablet
218987249|NCT06685809|DRUG|Placebo|Dose formulation- Matching doses
219141292|NCT02712411|DRUG|HCP1303|
219141293|NCT02712411|DRUG|HGP1201|
219141294|NCT02712411|DRUG|HIP1402|
219141295|NCT03749590|DRUG|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
219141296|NCT03749590|DRUG|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
219141297|NCT00626418|DRUG|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
219141298|NCT00626418|DRUG|Placebo|Placebo tablets
219552293|NCT03232450|DEVICE|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
219552294|NCT03232450|DEVICE|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
219552295|NCT00362505|DRUG|Clevudine|
219552296|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
219552297|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
218987250|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
218987251|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
218987252|NCT03424863|OTHER|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
218987253|NCT06706674|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
218987254|NCT06706674|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
218987255|NCT06706674|DRUG|Placebo|Matching Placebo administered orally once daily
218987256|NCT06704373|OTHER|thoracal manipulation|Thoracal manipulation will be applied only one session.
218987257|NCT06704373|OTHER|Exercise|Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.
218987258|NCT07033936|OTHER|Questionnaire|An online Questionnaire will be shared via social media such as WhatsApp, Facebook or X for Egyptian medical students and intern to fill
218987259|NCT07028619|DEVICE|Bimodal Streaming Configuration|Participants' devices are configured for bimodal streaming. Participants complete a survey following a trial with the new bimodal streaming feature.
218987260|NCT07039838|DIAGNOSTIC_TEST|3D print of coronary arteries|Based on a pre-surgical cardiac CT the optimal graft insertions points on the target coronary arteries wil be marked and a patient-specific model of the coronary arteries will be 3D-printed and sterialized to be available during CABG to guide the placement of the distal graft anastomosis.
218987263|NCT06702930|OTHER|Morning high-intensity interval exercise|High-intensity interval exercise was performed between 8-10 am
218987264|NCT06702930|OTHER|Evening high-intensity interval exercise|High-intensity interval exercise was performed between 5-7 pm
218987265|NCT07033832|BEHAVIORAL|ACT-based intervention|"Parents in this group will receive two-hour weekly session with the question-and-answer session at the end. The contents of each session are as follows: (1) the first session consist of introductions of ACT, discussion on stress and struggles, and setting homework, (2) the second section includes role play, and the meaning of value, (3) the third session involves introducing mindfulness of the breath exercise, debrief and homework on practicing mindfulness and (4) the last session includes introduction of thoughts, and putting values into feasible actions."
218987266|NCT07048002|OTHER|Managements for NeuroFirst target bundle|"In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg or within 10% preoperative baseline values, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% or within 10% preoperative baseline values, and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB.~To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments."
218987267|NCT07048002|OTHER|Managements for institutional routine|MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.
218987268|NCT07053371|OTHER|Peanut birth ball|The 45 x 80 cm peanut birth ball was positioned between the woman's legs during the first stage's active phase, starting at 4 cm cervical dilatation for the intervention group
218987269|NCT07055009|DIAGNOSTIC_TEST|Targeted long-read HLA sequencing|Genetic study
218987270|NCT07055009|OTHER|RNA extraction|Nanostring technology, Seattle
218987271|NCT07055009|OTHER|Full Skin examination|Skin and mucosa examination
218987272|NCT07054593|DEVICE|CapScan|Gut sampling capsule
218987273|NCT07053462|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney|The donor kidney is treated outside the body with CRISPR-Cas9 ribonucleoprotein complexes targeting the genes HLA-A, HLA-B, and CIITA. This genetic intervention knocks out HLA-A/B on donor cells and disables expression of HLA-DR, -DQ, -DP by disrupting CIITA (essential for class II antigen presentation). The goal is to create a transplanted organ with greatly reduced immunogenic surface proteins. (This is a one-time genetic manipulation applied to the donor organ prior to transplantation; no direct gene therapy is given to the patient's own cells.)
218987274|NCT07053462|PROCEDURE|Kidney Transplantation with Standard Care|After gene editing, the donor kidney is implanted into the recipient in a surgical transplant procedure. Standard peri-operative care is provided. All patients will receive standard immunosuppressive therapy post-transplant (such as tacrolimus, mycophenolate, and prednisone, per center protocol) to prevent rejection, though the regimen may be tailored based on the edited graft's expected lower immunogenicity. Patients will be hospitalized for transplant and monitored closely during the immediate post-op period, then followed in clinic frequently for transplant aftercare.
219229598|NCT04580433|BEHAVIORAL|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
219141299|NCT05875285|OTHER|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
219141300|NCT05875285|OTHER|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
219229599|NCT02136641|DRUG|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
219141301|NCT00190008|DRUG|piracetam|
219141302|NCT04368858|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
219141303|NCT06552702|OTHER|There is no intervention|There is no intervention.
219141304|NCT02740686|OTHER|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
219141305|NCT03556137|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
219229600|NCT02136641|DRUG|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
219229601|NCT02136641|DRUG|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
219141306|NCT00003339|BIOLOGICAL|gp100 antigen|
219229602|NCT02506270|DEVICE|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
219141307|NCT00003339|BIOLOGICAL|incomplete Freund's adjuvant|
219141308|NCT00003339|BIOLOGICAL|recombinant interleukin-12|
219229603|NCT02506270|DEVICE|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
219229604|NCT03901781|COMBINATION_PRODUCT|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
219229605|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet and exercise advice
219229606|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
219229607|NCT02926118|DIETARY_SUPPLEMENT|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
219229608|NCT02926118|DIETARY_SUPPLEMENT|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
219229609|NCT00857077|DRUG|Sulfadoxine-pyrimethamine|
219552298|NCT05588063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
219552299|NCT05588063|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
219552300|NCT04022122|PROCEDURE|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
219552301|NCT03492138|DRUG|ONC201|625mg
219552302|NCT03492138|DRUG|Ixazomib|Dose to be determined in Phase 1 of study
219552303|NCT03492138|DRUG|Dexamethasone|40mg
219552304|NCT03431961|DRUG|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
219552305|NCT03431961|DRUG|Placebo|twice daily for 14 days
219552306|NCT05833425|DEVICE|Respiratory Pressure Meter (MicroRPM)|Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
219552307|NCT04879927|OTHER|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
219552308|NCT04879927|OTHER|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
219552309|NCT04509648|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
219552310|NCT03611335|BEHAVIORAL|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
219141309|NCT00003339|BIOLOGICAL|tyrosinase peptide|
219229610|NCT00857077|DRUG|Placebo|
219229611|NCT03139331|DRUG|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
219141310|NCT02195713|DEVICE|Accuryn|Accuryn is a novel electronic urine output monitor
219229612|NCT03139331|DRUG|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
219229613|NCT03139331|DRUG|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
219552311|NCT04392999|DRUG|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
219552312|NCT04392999|DRUG|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
219552313|NCT05280288|DEVICE|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
219552314|NCT04173611|DRUG|EXPAREL|Injection into the Intrathecal space.
219552315|NCT04173611|DRUG|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
219552316|NCT04173611|OTHER|Placebo|Injection into the Intrathecal space.
218987275|NCT07055204|OTHER|"Diapason & Metronome musical learning"|Participants will make music with the two instruments we all have in common: the voice and the body. The method is three-dimensional built on: rhythm, simple sound and harmony. The music sessions will take place in the same place and on the same day of the week, at a fixed time to establish a regularity that is suitable to this population. The courses will be taught in a cultural location, both to give meaning to the approach on a contextual level and to allow patients to be in the city and not in the hospital. A training of the music teachers will be planned before the beginning of the study. This training combined with regular debriefings during the music sessions, should ensure that the teachers' practices are consistent across the different groups.
219552317|NCT03204851|DEVICE|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
219552318|NCT01121601|PROCEDURE|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
219141311|NCT00942058|OTHER|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
219141312|NCT03521037|DRUG|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
219141313|NCT05918159|OTHER|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
219141314|NCT04128436|OTHER|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
219229614|NCT00405184|DRUG|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
219552319|NCT01121601|PROCEDURE|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
219552320|NCT03090282|PROCEDURE|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
219552321|NCT00627731|DRUG|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
219552322|NCT00627731|DRUG|prednisolone (PSL)|PSL 40 mg per day for 10 days
219552323|NCT00001191|DRUG|Pantoprazole|
219552324|NCT00001191|DRUG|Omeprazole|
219552325|NCT03426657|COMBINATION_PRODUCT|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
219552326|NCT03797248|COMBINATION_PRODUCT|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
219552327|NCT03056144|DEVICE|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
219552328|NCT05722496|OTHER|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
219552329|NCT00486239|BEHAVIORAL|TLE Arm 1|Behavioral/cognitive testing
219552330|NCT00486239|BEHAVIORAL|Emotion Memory Test|Behavioral/cognitive Measure
219552331|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
219552332|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
219229615|NCT00405184|DRUG|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
219229616|NCT06032689|COMBINATION_PRODUCT|Xtra-fill|the material was placed in bulk.
219229617|NCT06032689|COMBINATION_PRODUCT|x-base|The x-base liner was placed and then veneered with Xtra-fill.
219718056|NCT05304325|OTHER|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
219718057|NCT05304325|OTHER|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
219718058|NCT05304325|OTHER|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
219718059|NCT05304325|PROCEDURE|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
219718060|NCT06049342|BIOLOGICAL|NCR100 injection|Subjects will receive a one-dose intra-articular NCR100 injection.
219718061|NCT00704353|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
219718062|NCT00704353|DRUG|Standard Medical Care (SMC)|Per product label
219718063|NCT02748031|PROCEDURE|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
218987276|NCT04997304|COMBINATION_PRODUCT|AirDuo Digihaler|"Participants will receive the AirDuo® Digihaler™ at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis."
218987277|NCT04997304|COMBINATION_PRODUCT|ProAir Digihaler|Participants will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
219718064|NCT06552195|OTHER|learning with augmented reality|"Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience."
218987278|NCT07053839|BEHAVIORAL|Daily Text Reminder|"The intervention, titled AdhasText, involved sending a daily SMS reminder to caregivers, specifically mothers of children with asthma. The message, If you want to stay healthy, you must use your inhaler, was sent at 7:00 p.m. over a 90 days period."
218987279|NCT07053020|DRUG|Cytarabine|Given by intravenous adminstration
218987280|NCT07053020|DRUG|Oral Cladribine|Given Orally
218987281|NCT06734975|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
218987282|NCT06734975|DRUG|Superior laryngeal nerve block - Placebo (saline)|Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
219229618|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
219229619|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
218987283|NCT03196726|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
218987284|NCT03196726|BEHAVIORAL|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
218987285|NCT06321523|DRUG|Tafamidis 61 milligrams|Tafamidis 61mg as provided in real-world practice
218987286|NCT01752985|DRUG|BMS-813160|
218987287|NCT01752985|DRUG|Placebo matching with BMS-813160|
218987288|NCT06906276|OTHER|Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.|Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)
218987289|NCT06902129|DEVICE|EDDIS Platform - Portable Inhalation Delivery Systems (VMT, Atomizer, Ultrasonic)|A set of three single-use, disposable, closely matched and uniform in size, breath-actuated, digitally monitored portable inhalation devices designed for precision aerosol delivery. Devices include a vibrating mesh (VMT), an atomizer-based unit (ATM), and an ultrasonic micro-vibration unit (ULT). Each system records inhalation parameters and connects via Bluetooth to a mobile application for real-time feedback and logging. Used to assess technical performance, gas dynamics, and digital control functions using a non-active NaCl-based aerosol with chitosan nanoparticles.
218987290|NCT06775327|DRUG|INCB000631|Oral; Tablet
218987291|NCT06775327|DRUG|Placebo|Oral; Tablet
219229620|NCT01825720|DRUG|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
219229621|NCT01825720|DRUG|normal saline group|same rate of normal saline
219229622|NCT03805243|DEVICE|test of sensors for somnonaute device|test of sensors
219229623|NCT03805243|DEVICE|test of sensors for uronaute device|test of sensors
219229624|NCT03805243|DEVICE|test of sensors for toconaute device|test of sensors
219229625|NCT03805243|DEVICE|test of sensors for neuronaute device|test of sensors
219229626|NCT03805243|DEVICE|test of sensors for cardioskin device|test of sensors
219229627|NCT06009666|DIAGNOSTIC_TEST|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
219229628|NCT06009666|DIAGNOSTIC_TEST|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
219229629|NCT06009666|DIAGNOSTIC_TEST|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
219229630|NCT06009666|DIAGNOSTIC_TEST|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
219229631|NCT06009666|OTHER|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
219718065|NCT06552195|OTHER|learning with traditional methods|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience"
219718066|NCT03819127|DRUG|Vildagliptin 50 MG Oral Tablet|
219718067|NCT03819127|DRUG|Metformin Pill|
219229632|NCT04707820|DIAGNOSTIC_TEST|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
219229633|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
219718068|NCT03380741|DIAGNOSTIC_TEST|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
219718069|NCT01001104|DRUG|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
219718070|NCT01001104|DRUG|Placebo|Administered by SC injection, QW for 12 weeks.
219718071|NCT01007877|OTHER|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
218987292|NCT01995825|DRUG|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
218987293|NCT01995825|DRUG|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
218987294|NCT01050868|DEVICE|Accu-Chek Combo Kit mg DE/de|
218987295|NCT00605111|DRUG|biphasic insulin aspart|
218987296|NCT04099628|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
218987297|NCT03510754|PROCEDURE|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
219718072|NCT00087412|DRUG|erlotinib hydrochloride|Given orally
219718073|NCT00087412|OTHER|laboratory biomarker analysis|Correlative studies
219718074|NCT02092428|OTHER|Image Quality|"The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
219718075|NCT02092428|OTHER|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
219718076|NCT02560766|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
219718077|NCT02560766|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
219718078|NCT02560766|DRUG|Placebo|Placebo once daily
219718079|NCT02397837|DRUG|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
219718080|NCT02397837|DRUG|Placebo|placebo match study drug
219718081|NCT03235414|DEVICE|MRI|Will receive a one time research MRI (MR elastography)
219718082|NCT03235414|DIAGNOSTIC_TEST|Blood draw|Will receive a one time blood draw to confirm healthy liver status
219718083|NCT05592691|PROCEDURE|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
219718084|NCT05016336|OTHER|Social interaction combined with cognitive training based on mnemonic strategies.|In the first six sessions, participants in the experimental group learned and practiced six different mnemonic strategies: Story-Formation strategy, Face-Name strategy, Peg-Word strategy, Chunking strategy, Key-Word strategy and the Method of Loci. In the following six sessions, in order to assimilate the strategies they learned, participants practiced the same tasks.
218987298|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
218987299|NCT01866774|OTHER|Fecal calprotectin level|
218987300|NCT00002210|DRUG|Delavirdine mesylate|
218987301|NCT01603004|OTHER|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
218987302|NCT03959358|DRUG|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
218987303|NCT03959358|DRUG|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
218987304|NCT06050278|OTHER|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
218987305|NCT01130142|DRUG|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
218987306|NCT01130142|DRUG|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
218987307|NCT03809143|DRUG|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
218987308|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
218987309|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
218987310|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
218987311|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
218987312|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
218987313|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
218987314|NCT01385566|BIOLOGICAL|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
218987315|NCT01385566|BIOLOGICAL|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
218987316|NCT02974166|OTHER|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
218987317|NCT02974166|OTHER|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
219718085|NCT05016336|OTHER|Social interaction group|In the control group, each session also began with a conversation between the participants. The sessions then dealt with the content of interpersonal communication and the acquisition of tools for creating interpersonal relationships. Participants were asked to share the way they used the tools they acquired between sessions and received feedback from the other participants
219718086|NCT00599313|DRUG|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
219718087|NCT00078494|DRUG|EBV-LMP-2|
219718088|NCT00258661|PROCEDURE|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
219718089|NCT00258661|PROCEDURE|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
219229634|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
219229635|NCT04466137|DRUG|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
219229636|NCT03482999|DEVICE|TissuGlu Surgical Adhesive|
219229637|NCT03062072|DRUG|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
219718090|NCT02536794|BIOLOGICAL|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
219718091|NCT02536794|OTHER|Laboratory Biomarker Analysis|Correlative studies
219718092|NCT02536794|OTHER|Pharmacological Study|Correlative studies
219718093|NCT02536794|BIOLOGICAL|Tremelimumab|Given IV
219718094|NCT03745781|DRUG|Placebos|placebo pills
219718095|NCT04033913|OTHER|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
219718096|NCT01011296|DRUG|PF-04427429|Single 0.2mg dose of intravenous infusion
218987318|NCT02974166|DRUG|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
218987319|NCT02974166|DRUG|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
218987320|NCT04127864|PROCEDURE|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
218987321|NCT01539694|DEVICE|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
218987322|NCT01539694|DEVICE|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
218987323|NCT04944069|DRUG|Almonertinib|110 mg oral once daily
218987324|NCT04944069|DRUG|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
218987325|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
218987326|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
218987327|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
218987328|NCT00403234|DRUG|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
218987329|NCT02362217|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
218987330|NCT02362217|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
218987331|NCT02362217|BIOLOGICAL|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
218987332|NCT02362217|BIOLOGICAL|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
218987333|NCT02139111|DRUG|Placebo|Oral placebo capsule
218987334|NCT02139111|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
218987335|NCT02139111|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
218987336|NCT02139111|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
218987337|NCT02139111|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
218987338|NCT02606448|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
218987339|NCT02606448|PROCEDURE|Femoral nerve block|Pre-operative femoral nerve block
218987340|NCT02606448|DRUG|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
218987341|NCT04694781|DRUG|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
218987342|NCT04694781|DRUG|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
218987343|NCT01880502|DRUG|Belviq 10mg|Belviq 10mg single dose administration
218987344|NCT01880502|DRUG|Belviq 20mg|Belviq 20mg single dose administration
218987345|NCT01880502|DRUG|Placebo|Placebo single dose administration
218987346|NCT00691860|DEVICE|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
218987347|NCT00691860|PROCEDURE|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
218987348|NCT00702039|OTHER|No Music|No music will be played in patients in arm 2 of the study.
218987349|NCT00702039|OTHER|Music Therapy|Classical music being played during intravitreal injection.
218987350|NCT01958333|PROCEDURE|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
218987351|NCT01958333|PROCEDURE|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
218987352|NCT01958333|PROCEDURE|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
218987353|NCT04092582|DRUG|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
218987354|NCT04092582|DRUG|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
219141315|NCT02971176|RADIATION|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
219141316|NCT02971176|RADIATION|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
219141317|NCT02574026|BEHAVIORAL|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
219141318|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
219229638|NCT04604652|DRUG|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
219229639|NCT06510413|DRUG|Loxoprofen Sodium Patches(reference product)|Single dose of one patch in each period; Apply for 24 hours each time
219141319|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
219141320|NCT00269516|DRUG|pardoprunox|fixed dose 6 mg
219141321|NCT00269516|DRUG|Pardoprunox|fixed dose 12 mg
219141322|NCT00269516|DRUG|Pardoprunox|12-42mg
219141323|NCT00269516|DRUG|Placebo|Placebo
219141324|NCT06339489|DIAGNOSTIC_TEST|Testing the serum levels of bone metabolic markers|Testing serum levels of TRACP-5b and BALP, BMD values of lumbar spine L1-L4, left and right hip, left and right femoral neck et.al.
219141325|NCT01305733|DRUG|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
219141326|NCT01305733|OTHER|saline injection|saline
219141327|NCT04065932|DRUG|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
219141328|NCT04065932|DRUG|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
219141329|NCT04065932|DRUG|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
219229640|NCT06510413|DRUG|Loxoprofen Sodium Patches(test product )|Single dose of one patch in each period; Apply for 24 hours each time
219552333|NCT06150196|BEHAVIORAL|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
219552334|NCT06150196|BEHAVIORAL|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
219552335|NCT00377117|PROCEDURE|Management|
219552336|NCT00377117|PROCEDURE|Screening|
219552337|NCT03108235|BEHAVIORAL|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
219552338|NCT03108235|BEHAVIORAL|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
219552339|NCT03108235|BEHAVIORAL|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
219552340|NCT05072535|DRUG|HA121-28 tablet B|HA121-28 tablet B 200 mg
219552341|NCT05072535|DRUG|HA121-28 tablet A|HA121-28 tablet A 200 mg
219552342|NCT05954663|OTHER|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
219552343|NCT01269658|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
219552344|NCT01269658|DRUG|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
219552345|NCT00838838|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
219552346|NCT00408018|DRUG|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
219552347|NCT01537718|DEVICE|REPLY 200|REPLY 200 pacemaker
219552348|NCT05191238|OTHER|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
219552349|NCT01291095|DRUG|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
219552350|NCT01291095|RADIATION|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
219718097|NCT01011296|DRUG|PF-04427429|Single 1mg dose of intravenous infusion
219718098|NCT01011296|DRUG|PF-04427429|Single 3 mg dose of intravenous infusion
219718099|NCT00926120|DIETARY_SUPPLEMENT|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
219229641|NCT03929198|OTHER|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
219229642|NCT04888052|DEVICE|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
219229643|NCT05544305|OTHER|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
219229644|NCT02906137|OTHER|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
219229645|NCT05118100|DRUG|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
219229646|NCT05118100|DRUG|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
219229647|NCT02500082|DRUG|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
219229648|NCT01110096|BEHAVIORAL|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
219229649|NCT01110096|BEHAVIORAL|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
219229650|NCT01110096|BEHAVIORAL|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
219229651|NCT01469585|DRUG|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
219141330|NCT05133063|BEHAVIORAL|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
219141331|NCT05133063|BEHAVIORAL|Control intervention|"Participants receive the following instructions:~Think of the room you are in…. In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
219141332|NCT02845063|BEHAVIORAL|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
219141333|NCT02845063|BEHAVIORAL|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
219141334|NCT02845063|GENETIC|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
219141335|NCT01773980|OTHER|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
219141336|NCT01773980|OTHER|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
219141337|NCT00490685|DRUG|Sorafenib (BAY-43-9006)|
219229652|NCT03692871|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
219229653|NCT03692871|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
219229654|NCT05923788|DIAGNOSTIC_TEST|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
219229655|NCT01042132|PROCEDURE|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
219229656|NCT01042132|PROCEDURE|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
219229657|NCT02644122|DRUG|SF1126|
219229658|NCT00162253|DRUG|BMS 587101|
219229659|NCT06178380|OTHER|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
219229660|NCT00399685|DRUG|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
219229661|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
219229662|NCT00399685|DRUG|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
219229663|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
219229664|NCT03182244|DRUG|Gilteritinib|Tablet administered orally once daily.
219141338|NCT00696280|BEHAVIORAL|Functional Living Index - Emesis|
219141339|NCT03503084|BEHAVIORAL|Classical Yang's TCC exercise|
219718100|NCT01926639|BIOLOGICAL|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
219718101|NCT05220735|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
219718102|NCT01191385|DRUG|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
219718103|NCT01406912|OTHER|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
219718104|NCT01406912|OTHER|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
219718105|NCT00169260|BEHAVIORAL|motivational counseling|behavioral motivational counselling
219718106|NCT00169260|BEHAVIORAL|placebo|
219718107|NCT00458835|DRUG|Ciclesonide|
219229665|NCT03182244|DRUG|Cytarabine|Once/twice daily Intravenously (IV)/subcutaneously (SC).
219229666|NCT03182244|DRUG|Mitoxantrone|Once daily IV injection.
219229667|NCT03182244|DRUG|Etoposide|Once daily IV injection.
219229668|NCT03182244|DRUG|G-CSF|Once daily IV/SC injection.
219229669|NCT03182244|DRUG|Fludarabine|Once daily IV injection.
219229670|NCT02135315|DRUG|Isosorbide Dinitrate|administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
219229671|NCT02266927|DRUG|Flovent HFA|
219229672|NCT02266927|DRUG|OPTINOSE™ FLUTICASONE|
219229673|NCT06553027|DRUG|CVN424 75 mg|Participants will receive 75 mg CVN424 tablet once daily.
219229674|NCT06553027|DRUG|CVN424 150 mg|Participants will receive 150 mg CVN424 tablet once daily.
219229675|NCT06553027|DRUG|Placebo|Participants will receive matching placebo tablet once daily.
219229676|NCT06204653|DEVICE|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
219718108|NCT04424602|DRUG|cyclo phosphamide|500mg vial
219718109|NCT04424602|DRUG|mycophenolate|500mg film-coated tablets.
219718110|NCT02887599|PROCEDURE|Blood collection|1ml of blood specimen collection
219718111|NCT00005795|DRUG|arsenic trioxide|
218987355|NCT04087265|DIAGNOSTIC_TEST|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
218987356|NCT03210246|DRUG|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
218987357|NCT03210246|DRUG|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
218987358|NCT03210246|DRUG|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
218987359|NCT03210246|DRUG|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
218987360|NCT03133169|DIAGNOSTIC_TEST|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
218987361|NCT03133169|DIAGNOSTIC_TEST|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
218987362|NCT05865262|DIAGNOSTIC_TEST|ECG|"A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula."
218987363|NCT05865262|DIAGNOSTIC_TEST|blood test (assessing ionic and hormonal circulating levels)|Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
218987364|NCT00690274|DRUG|BF2.649|up to 20mg per day
218987365|NCT00690274|DRUG|Placebo|up to 20mg per day
218987366|NCT05214495|DRUG|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
218987367|NCT05214495|DRUG|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
218987368|NCT05638178|OTHER|No intervention|No intervention, cohort study.
218987369|NCT00896246|DRUG|Klean-Prep®|Four litres of solution administered orally as a divided dose.
218987370|NCT00896246|DRUG|Moviprep®|Two litres of solution administered orally as a divided dose
219141340|NCT02828423|PROCEDURE|EMD|Regenerative surgery with EMD
219141341|NCT02828423|PROCEDURE|BC|Regenerative surgery with BC
219141342|NCT02787694|OTHER|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
219141343|NCT02787694|DEVICE|treadmill|
219141344|NCT00168662|BIOLOGICAL|Measles and inactivated polio vaccine|
219141345|NCT04860258|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
219141346|NCT02607384|BEHAVIORAL|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
219141347|NCT02607384|BEHAVIORAL|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
219141348|NCT02607384|OTHER|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
219141349|NCT00001637|PROCEDURE|Blood cell transplantation|
219141350|NCT02130128|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
219141351|NCT04045977|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
219141352|NCT04045977|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
219141353|NCT04045977|BEHAVIORAL|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
219141354|NCT06555510|OTHER|InBody|Bioelectrical impedance analysis
219141355|NCT05731466|DEVICE|CardioMems HF System|"1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
219141356|NCT02576821|OTHER|Neurological examinations|
219141357|NCT02576821|OTHER|Neuropsychological examinations|
219141358|NCT02576821|OTHER|Clinical examinations|
219141359|NCT02576821|RADIATION|MRI 3T|
219141360|NCT02576821|RADIATION|MRI 7T|
219229677|NCT06204653|DEVICE|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
219229678|NCT01652014|DRUG|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
219229679|NCT01652014|DRUG|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
219229680|NCT01652014|DRUG|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
219141361|NCT01465724|PROCEDURE|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
219141362|NCT03336424|DIAGNOSTIC_TEST|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
219141363|NCT03336424|DIAGNOSTIC_TEST|Invasive investigations|Cystomanometry, pressure flow study, EMG
219141364|NCT04383730|DRUG|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
219229681|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
219229682|NCT01652014|PROCEDURE|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
219141365|NCT04383730|DRUG|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
219141366|NCT01271517|DRUG|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
219229683|NCT01652014|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
219552351|NCT06628011|OTHER|Intervention group/training group|We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
219552352|NCT06245928|DEVICE|Individualized Respiratory Exercise Device|The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.
219552353|NCT06245928|DEVICE|Threshold® IMT + Threshold™ PEP|The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
219552354|NCT00259896|DRUG|exenatide|
219552355|NCT00006153|BIOLOGICAL|HIV-1 Immunogen|
219718112|NCT05397418|BEHAVIORAL|Supervised resistance exercise program|12 week supervised low impact resistance training program
219718113|NCT05397418|BEHAVIORAL|Unsupervised resistance exercise program|12 week unsupervised low impact resistance training program
219141367|NCT01271517|DRUG|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
219229684|NCT01652014|RADIATION|total-body irradiation|Undergo TBI
219141368|NCT01271517|DRUG|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
219141369|NCT00487578|DRUG|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
219141370|NCT03458546|DRUG|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
219141371|NCT04663464|COMBINATION_PRODUCT|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
219141372|NCT04663464|COMBINATION_PRODUCT|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
219141373|NCT00552097|DRUG|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
219141374|NCT00552097|DRUG|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
219141375|NCT03185156|DRUG|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
219141376|NCT03185156|DRUG|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
219141377|NCT05538455|DEVICE|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
219141378|NCT03565939|BIOLOGICAL|Trichuris suis ova|Eggs from the pig whipworm
219141379|NCT03565939|BIOLOGICAL|Placebo|Solution without TSO
219141380|NCT01517347|DRUG|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
219141381|NCT03802032|DRUG|Lidocaine Gel|topical lidocaine gel
219141382|NCT03802032|DRUG|KY jelly|topical KY jelly
219141383|NCT02001818|DRUG|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
219141384|NCT01199783|DRUG|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
219229685|NCT01652014|DRUG|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
219718114|NCT06096948|DEVICE|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
219718115|NCT05470998|DRUG|L-Arginine|L-Arginine 1000 mg free form, rapid release capsules
219718116|NCT00152230|DRUG|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
219141385|NCT01199783|DRUG|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
219141386|NCT00785863|OTHER|Placebo|Placebo IV before placebo infusion
219141387|NCT00785863|DRUG|Remifentanil|placebo IV and remifentanil infusion
219141388|NCT00785863|DRUG|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
219718117|NCT00152230|PROCEDURE|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
219718118|NCT00817063|DRUG|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
219718119|NCT00817063|DRUG|Placebo|Patients receive matching placebo for up to 24 weeks
219718120|NCT01773369|BEHAVIORAL|Early leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
219718121|NCT01773369|BEHAVIORAL|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.
219141389|NCT00785863|DRUG|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
219141390|NCT00726999|DRUG|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
219141391|NCT00726999|DRUG|Placebo|
219141392|NCT00726999|DRUG|Morphine|Administered as needed
219141393|NCT05111483|OTHER|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
219229686|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
219229687|NCT01652014|PROCEDURE|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
219229688|NCT00257894|DRUG|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
219229689|NCT00257894|DRUG|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
219141394|NCT05111483|OTHER|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
219141395|NCT02227771|DEVICE|Percutaneous coronary intervention|
219718122|NCT01773369|BEHAVIORAL|Parent leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
219718123|NCT01496456|DEVICE|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
219718124|NCT01496456|BEHAVIORAL|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
219718125|NCT01374737|DRUG|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
219718126|NCT01800760|DIETARY_SUPPLEMENT|Probiotics|Probiotics once a day for three weeks.
219718127|NCT00795574|DRUG|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
219718128|NCT00795574|DRUG|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
219718129|NCT04444869|DRUG|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
219718130|NCT00513448|OTHER|Group wellness intervention|
219718131|NCT00513448|OTHER|Individualized physical rehabilitation|
219141396|NCT00955825|DRUG|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
219141397|NCT00955825|DRUG|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
219141398|NCT01499134|DRUG|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
219718132|NCT06091514|DEVICE|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
219718133|NCT06091514|OTHER|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
219718134|NCT04919161|DEVICE|Body weight support system control group|The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
219718135|NCT04919161|DEVICE|Body weight support system with balance perturbations|"The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress."
219718136|NCT03808857|BIOLOGICAL|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
219718137|NCT00712920|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
219141399|NCT01499134|DRUG|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
219229690|NCT01276275|DRUG|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
219229691|NCT06452173|DIAGNOSTIC_TEST|Plasma|Plasma levels of metabolites and some proteins will be further determined
219229692|NCT06452173|DIAGNOSTIC_TEST|carotid high-resolution magnetic resonance imaging|Define plaque composition and morphological characteristics
219718138|NCT00712920|DRUG|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
219718139|NCT00712920|DRUG|Placebo|Placebo
219718140|NCT03686111|DIAGNOSTIC_TEST|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
219718141|NCT06348043|DEVICE|Jarvik 2015 LVAD|Medical device used to treat children awaiting heart transplant who fail optimal medical therapy.
219718142|NCT02199496|BIOLOGICAL|Stelara (ustekinumab)|"* In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~* In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40"
219718143|NCT02826096|BEHAVIORAL|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
219718144|NCT06413407|BEHAVIORAL|Tai Chi Exercise|Tai Chi Exercise will be applied to this group.
219718145|NCT06413407|BEHAVIORAL|Receptive Music Therapy|Receptive Music Therapy will be applied to this group.
219718146|NCT06413407|BEHAVIORAL|Experimental|Tai Chi Exercise and Receptive Music Therapy techniques will be applied together to this group.
219718147|NCT04863534|DEVICE|Ultrasound|Muscular grayscale ultrasound
219718148|NCT02004171|OTHER|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
219141400|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
219141401|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
219141402|NCT00542113|BEHAVIORAL|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
219141403|NCT03003637|DRUG|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
219141404|NCT03003637|DRUG|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
219141405|NCT01755897|PROCEDURE|radical hysterectomy + pelvic lymph node dissection|
219141406|NCT01755897|DRUG|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
219141407|NCT01755897|DRUG|Cisplatin|75 mg/m(2) IV on day 2 and 3
219552356|NCT06475651|GENETIC|Methylation analysis|Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
219552357|NCT06561269|PROCEDURE|Multifidus plane block|"Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine."
219552358|NCT06561269|PROCEDURE|caudal block|"The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique."
219552359|NCT03673267|BEHAVIORAL|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
219552360|NCT04281472|BIOLOGICAL|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
219552361|NCT04281472|OTHER|placebo in stage B|Stage A: N/A, stage B: placebo
219552362|NCT02025660|DRUG|Mw, 0.3ml x three days sc|
219552363|NCT02025660|DRUG|Placebo|
219552364|NCT04488380|OTHER|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
219552365|NCT01746550|DEVICE|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
219552366|NCT02344550|DRUG|Everolimus(afinitor)|Everolimus 10mg p.o. daily
219552367|NCT02344550|DRUG|Letrozole|Letrozole 2.5 mg p.o. daily
219552368|NCT02344550|DRUG|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
219552369|NCT05649904|DEVICE|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
219552370|NCT05649904|DEVICE|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
219552371|NCT03680001|BEHAVIORAL|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
219552372|NCT01884701|DEVICE|ENABLER-P Catheter System|
219141408|NCT01755897|DRUG|Cisplatin|35 mg/m(2) IV once a week
219141409|NCT01755897|RADIATION|Pelvic RT|IMRT
219141410|NCT02546219|OTHER|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
219552373|NCT04122950|BEHAVIORAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
219552374|NCT00731458|DEVICE|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
219552375|NCT03811158|DEVICE|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
219552376|NCT03811158|DEVICE|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
219552377|NCT03508596|OTHER|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
219552378|NCT04589286|BEHAVIORAL|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
219552379|NCT04589286|OTHER|Electronic Handouts|Generic wellness-related electronic handouts
219552380|NCT05010135|DEVICE|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
219552381|NCT05493163|DRUG|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
219552382|NCT05493163|DRUG|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
219718149|NCT02004171|DRUG|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
219718150|NCT02971904|OTHER|human milk collection|
219141411|NCT01091298|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
219141412|NCT01091298|OTHER|Placebo|Single dose (0.5 mL) of the placebo administered orally
219141413|NCT01701453|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
219141414|NCT01495936|PROCEDURE|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
219141415|NCT01495936|PROCEDURE|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
219141416|NCT05967338|DEVICE|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
219552383|NCT05308186|BEHAVIORAL|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
219552384|NCT05308186|BEHAVIORAL|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
219141417|NCT04529278|DRUG|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
219141418|NCT01198275|DRUG|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
219141419|NCT01198275|DRUG|Placebo|1.0 g of olive oil,one capsule twice a day
219141420|NCT01198275|DRUG|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
219141421|NCT01198275|DRUG|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
219141422|NCT00649935|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fed
219141423|NCT00649935|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fed
219141424|NCT00391846|DRUG|Captopril|
219141425|NCT00391846|DRUG|Enalapril|
219141426|NCT00391846|DRUG|Lisinopril|
219141427|NCT00391846|DRUG|Ramipril|
219229693|NCT04564365|DRUG|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
219229694|NCT03791736|PROCEDURE|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
219229695|NCT04343898|OTHER|No intervention|Observational
219229696|NCT01316913|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
219552385|NCT03558295|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
219552386|NCT04883996|DRUG|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
219552387|NCT04883996|OTHER|Saline control|Saline
219552388|NCT01932021|PROCEDURE|adipose tissue grafting|
219552389|NCT03850938|DEVICE|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
219552390|NCT03850938|DEVICE|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
219552391|NCT02095613|OTHER|traditional food|
219552392|NCT02095613|OTHER|food that is nutrient dense|
219552393|NCT00042835|DRUG|cisplatin|Given IV
219141428|NCT00391846|DRUG|Trandolapril|
219141429|NCT00391846|DRUG|Bisoprolol|
219141430|NCT00391846|DRUG|Carvedilol|
219141431|NCT00391846|DRUG|Metoprolol succinate|
219141432|NCT00391846|DRUG|Candesartan|
219141433|NCT00391846|DRUG|Valsartan|
219141434|NCT00391846|DRUG|Eplerenone|
219141435|NCT00391846|DRUG|Spironolactone|
219141436|NCT00391846|DRUG|Diuretics|
219141437|NCT00391846|DRUG|HF treatment according to Swedish guidelines|
219141438|NCT00391846|PROCEDURE|Blood samples|
219141439|NCT00391846|PROCEDURE|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
219229697|NCT01316913|DRUG|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
219229698|NCT01316913|DRUG|GSK573719|125 mcg once-daily
219552394|NCT00042835|DRUG|etoposide|Given IV
219552395|NCT00042835|DRUG|erlotinib hydrochloride|Given orally
219552396|NCT00042835|RADIATION|radiation therapy|Undergo radiotherapy
219552397|NCT00042835|DRUG|docetaxel|Given IV
219552398|NCT00042835|DRUG|paclitaxel|Given IV
219552399|NCT00042835|DRUG|carboplatin|Given IV
219552400|NCT00042835|OTHER|laboratory biomarker analysis|Correlative studies
219552401|NCT05120388|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
219552402|NCT05137093|DEVICE|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
219552403|NCT02267707|DRUG|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
219552404|NCT02267707|DRUG|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
219718151|NCT02362451|BIOLOGICAL|Autologus elutriated monocyte placebo vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
219141440|NCT04040530|PROCEDURE|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
219141441|NCT04040530|PROCEDURE|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
219141442|NCT02217644|DRUG|BI 653048 H3PO4 solution|
219141443|NCT02217644|DRUG|BI 653048 H3PO4 low dose capsule|
219141444|NCT02217644|DRUG|BI 653048 H3PO4 high dose capsule|
219141445|NCT02217644|DRUG|Placebo|
219141446|NCT04091425|DRUG|TAK-925|TAK-925 IV infusion
219141447|NCT04091425|DRUG|Placebo|TAK-925 placebo-matching IV infusion
219141448|NCT05019417|DRUG|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
219141449|NCT00041548|DRUG|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
219141450|NCT00041548|DRUG|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
219141451|NCT05598580|DRUG|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
219141452|NCT05598580|DRUG|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
219141453|NCT00150176|DRUG|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
219141454|NCT00150176|DRUG|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
219141455|NCT00150176|DRUG|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
219141456|NCT01126112|BIOLOGICAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W
219229699|NCT01316913|DRUG|tiotropium bromide|18 mcg once-daily
219552405|NCT01545193|OTHER|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
219552406|NCT00313937|DRUG|Insulin glargine|
219552407|NCT04579653|DEVICE|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
219552408|NCT03574051|DRUG|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
219552409|NCT03862547|DIAGNOSTIC_TEST|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
219552410|NCT06001463|DRUG|CSMed Dressing|Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
219552411|NCT00152451|DRUG|Seletracetam (ucb 44212)|"* Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration"
219552412|NCT03056547|OTHER|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
219552413|NCT05456451|DEVICE|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
219552414|NCT03766360|BEHAVIORAL|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
219552415|NCT05053360|BEHAVIORAL|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
219552416|NCT05053360|OTHER|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
219552417|NCT05645120|OTHER|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
219141457|NCT02468297|DEVICE|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
219141458|NCT02468297|DRUG|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
219229700|NCT03267797|OTHER|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
219229701|NCT03267797|OTHER|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
219141459|NCT02494999|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
219141460|NCT02494999|BIOLOGICAL|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
219141461|NCT03915340|DRUG|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
219141462|NCT03915340|DRUG|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
219229702|NCT00872248|PROCEDURE|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
219229703|NCT00872248|PROCEDURE|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
219141463|NCT00366873|PROCEDURE|Calcium absorption|formula with or without prebiotics
219141464|NCT04442919|DRUG|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
219229704|NCT03564106|DRUG|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
219229705|NCT03564106|DRUG|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
219229706|NCT03973021|BIOLOGICAL|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
219141465|NCT04442919|DRUG|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
219141466|NCT04442919|DRUG|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
219141467|NCT02729701|DRUG|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
219229707|NCT05729126|OTHER|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
219229708|NCT05716438|RADIATION|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
219229709|NCT00541996|DRUG|vabicaserin|
219229710|NCT00236509|DRUG|topiramate|
219229711|NCT06510985|DEVICE|transcutaneous vagus nerve stimulation|The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
219552418|NCT00155220|DEVICE|Low Stretch Bandage and Kinesio Tape|
219552419|NCT05995769|DRUG|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
219552420|NCT05705869|DIAGNOSTIC_TEST|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
219552421|NCT04468880|OTHER|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
219552422|NCT04468880|OTHER|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
219552423|NCT00254280|PROCEDURE|Intense Pulsed Light + paring versus paring alone|
219552424|NCT00620880|BEHAVIORAL|Blood sample|
219141468|NCT04753580|GENETIC|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
219141469|NCT02854319|DEVICE|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
219141470|NCT02888249|OTHER|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
219141471|NCT02825225|OTHER|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
219229712|NCT06510985|BEHAVIORAL|Monitoring|Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
219229713|NCT06510985|DEVICE|cardiowatch bracelet|The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
219229714|NCT06052722|OTHER|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
219229715|NCT04896567|DIAGNOSTIC_TEST|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
219229716|NCT05440760|DEVICE|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
219229717|NCT01668719|DRUG|Bortezomib|Given SC or IV
219229718|NCT01668719|DRUG|Dexamethasone|Given PO or IV
219229719|NCT01668719|BIOLOGICAL|Elotuzumab|Given IV
219718152|NCT02362451|BIOLOGICAL|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
219229720|NCT01668719|OTHER|Laboratory Biomarker Analysis|Correlative studies
219229721|NCT01668719|DRUG|Lenalidomide|Given PO
219229722|NCT03539055|DRUG|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
219229723|NCT05148988|DIAGNOSTIC_TEST|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
219229724|NCT05148988|DIAGNOSTIC_TEST|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
219229725|NCT03237780|DRUG|Atezolizumab|Given IV
219229726|NCT03237780|PROCEDURE|Biopsy Procedure|Undergo biopsy
219229727|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219229728|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
219229729|NCT03237780|DRUG|Eribulin Mesylate|Given IV
219229730|NCT02646774|DRUG|Micafungin|Injection
219229731|NCT02278627|OTHER|manual lymphatic drainage|
219718153|NCT03425370|PROCEDURE|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
219718154|NCT04926493|BIOLOGICAL|microbiological characterization|microbiological characterization of endotracheal tube biofilm
219718155|NCT05259293|OTHER|No intervention - retrospective study|This is a retrospective study. No intervention.
219718156|NCT05920265|PROCEDURE|Quadratus Lumborum plain Block|ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
219718157|NCT05920265|PROCEDURE|fascia iliaca block|ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
219718158|NCT05920265|DIAGNOSTIC_TEST|control group|no intervention
219229732|NCT00552253|DRUG|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
219718159|NCT00817102|PROCEDURE|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
219718160|NCT05017636|DEVICE|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
219718161|NCT00308776|PROCEDURE|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
219141472|NCT02825225|PROCEDURE|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
219718162|NCT00308776|PROCEDURE|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
219718163|NCT02078037|DEVICE|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
219718164|NCT02078037|OTHER|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
219718165|NCT04501575|OTHER|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
219718166|NCT04501575|OTHER|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
219718167|NCT03139201|DEVICE|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
219718168|NCT03139201|DEVICE|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
219718169|NCT06018168|OTHER|Skincare Routine|"Morning:~1\. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
219718170|NCT06018168|DIETARY_SUPPLEMENT|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
219718171|NCT05144282|PROCEDURE|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
219718172|NCT05144282|PROCEDURE|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
219718173|NCT02887586|OTHER|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
219718174|NCT01010620|BEHAVIORAL|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
219718175|NCT00215956|DRUG|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
219718176|NCT00215956|PROCEDURE|radiation|Preoperative radiation
219718177|NCT00215956|PROCEDURE|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
219718178|NCT00169312|BEHAVIORAL|behavioral dietary intervention|
219718179|NCT00169312|DIETARY_SUPPLEMENT|dietary intervention|
219718180|NCT00169312|OTHER|educational intervention|
219141473|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
219141474|NCT01623336|DRUG|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
219718181|NCT00169312|OTHER|internet-based intervention|
219718182|NCT00169312|OTHER|preventative dietary intervention|
219718183|NCT00169312|PROCEDURE|evaluation of cancer risk factors|
219141475|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
219141476|NCT02875938|BEHAVIORAL|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
219141477|NCT02875938|BEHAVIORAL|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
219141478|NCT02875938|BEHAVIORAL|Control|control condition using reading materials without music.
219141479|NCT01808495|DRUG|Mitomycin C|
219141480|NCT06376513|OTHER|Evaluation|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
219141481|NCT04330768|PROCEDURE|PRF pulp capping|PRF is injected in the site of exposure
219141482|NCT04330768|PROCEDURE|MTA pulp capping|conventional pulp capping procedure
219141483|NCT02667743|DRUG|Paclitaxel Micelles for Injection|
219141484|NCT02667743|DRUG|Paclitaxel Injection|
219141485|NCT02667743|DRUG|Cisplatin|
219141486|NCT04080258|OTHER|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
219141487|NCT04080258|OTHER|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
219141488|NCT00369733|DRUG|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
219141489|NCT05964231|DIETARY_SUPPLEMENT|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated, 2caps daily use
219141490|NCT05964231|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, 2caps daily use
219141491|NCT04298788|OTHER|Blue dishware|blue dishware is used for plates and bowls
219552425|NCT03711591|DEVICE|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
219141492|NCT00118768|DRUG|valopicitabine|
219141493|NCT00118768|DRUG|Pegylated Interferon Alfa|
219141494|NCT00360386|DRUG|Clopidogrel|
219141495|NCT02180763|BIOLOGICAL|Gammanorm|Sub-Q IgG
219141496|NCT05257798|DRUG|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
219141497|NCT05257798|OTHER|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
219141498|NCT01685528|BEHAVIORAL|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
219141499|NCT00816751|PROCEDURE|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
219141500|NCT00816751|PROCEDURE|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
219141501|NCT00816751|DRUG|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
219552426|NCT02604680|DRUG|BLI1100-1|BLI1100-1 Topical gel
219552427|NCT02604680|DRUG|BLI1100-2|BLI1100-2 Topical gel
219552428|NCT02604680|DRUG|BLI1100-3|BLI1100-3 Topical gel
219552429|NCT02604680|DRUG|BLI1100-4|BLI1100-4 Topical gel
219552430|NCT02604680|DRUG|Placebo|Placebo - Topical gel
219552431|NCT04697173|OTHER|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
219552432|NCT03807440|DRUG|Empagliflozin|Empagliflozin
219552433|NCT03807440|DRUG|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
219552434|NCT03807440|DRUG|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
219552435|NCT03807440|DRUG|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
219552436|NCT05649358|DEVICE|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
219552437|NCT04821232|OTHER|yoga|"Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
219552438|NCT04821232|OTHER|Routin control|Students will be checked on a routine basis
219552439|NCT03947905|PROCEDURE|Virtual visit|Type of visit
219552440|NCT03161197|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
219552441|NCT05643105|PROCEDURE|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
219552442|NCT00582205|DRUG|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
219552443|NCT02107469|DRUG|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
219141502|NCT04707729|DIAGNOSTIC_TEST|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
219141503|NCT04519671|DRUG|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
219141504|NCT04519671|OTHER|Placebo|Normal saline
219141505|NCT00281996|DRUG|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
219141506|NCT00281996|DRUG|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
219141507|NCT03184623|OTHER|muscle mass measurement|measurement of muscle mass by echocardiography
219141508|NCT03485859|DEVICE|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
219141509|NCT03485859|DEVICE|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
219141510|NCT00920257|DRUG|GSK2141795|GSK2141795 is an oral AKT inhibitor.
219141511|NCT00075491|DRUG|fenretinide|Given orally
219141512|NCT00075491|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219141513|NCT00075491|OTHER|pharmacological study|Correlative studies
219141514|NCT00075491|OTHER|laboratory biomarker analysis|Correlative studies
219141515|NCT03087084|DEVICE|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
219141516|NCT05485402|DIETARY_SUPPLEMENT|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
219141517|NCT05485402|DIETARY_SUPPLEMENT|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
219141518|NCT05485402|DIETARY_SUPPLEMENT|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
219141519|NCT05485402|DIETARY_SUPPLEMENT|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
219141520|NCT05485402|OTHER|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
219141521|NCT05751499|DIAGNOSTIC_TEST|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"* Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale"
219141522|NCT02107339|DRUG|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
219141523|NCT02107339|DRUG|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
219141524|NCT03655626|OTHER|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
219141525|NCT00002018|DRUG|Interferon alfa-n3|
219552444|NCT02107469|DRUG|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
219552445|NCT02107469|DRUG|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
219552446|NCT02107469|DRUG|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
219552447|NCT02107469|OTHER|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
219552448|NCT02107469|OTHER|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
219552449|NCT00981344|OTHER|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
219718184|NCT04493177|BEHAVIORAL|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
219141526|NCT06448598|OTHER|Exercise|The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
219141527|NCT02105064|DEVICE|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
219718185|NCT04493177|OTHER|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
219718186|NCT02648906|DRUG|Choline alfoscerate|
219718187|NCT02648906|DRUG|Placebo|
219718188|NCT02111980|DEVICE|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
219718189|NCT00138970|DRUG|Zenapax®, CellCept® and prednisolone|
219718190|NCT00138970|DRUG|Sandimmun Neoral®, CellCept® and prednisolone|
219141528|NCT02105064|DEVICE|SHAM rTMS|Sham rTMS, without brain stimulation
219141529|NCT00834951|RADIATION|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
219141530|NCT04723706|DIAGNOSTIC_TEST|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
219141531|NCT02082158|OTHER|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
219141532|NCT04781881|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
219141533|NCT06112899|BEHAVIORAL|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
219229733|NCT06152900|DEVICE|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
219718191|NCT03415256|OTHER|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
219718192|NCT03415256|OTHER|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
219718193|NCT01346553|DEVICE|ESVV device|wearing the ESVV device for 6 hours
219718194|NCT02200081|DRUG|MGN1703|
219718195|NCT02200081|OTHER|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
219718196|NCT04791826|BEHAVIORAL|On-screen electronic alert|On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
219718197|NCT01922011|DRUG|Daptomycin|IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
219718198|NCT01922011|DRUG|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
219718199|NCT01922011|DRUG|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
219718200|NCT05256264|DRUG|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
219718201|NCT04575012|PROCEDURE|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
219718202|NCT04575012|PROCEDURE|Early invasive strategy|Primary PCI
219718203|NCT00918307|DRUG|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
219718204|NCT00918307|DRUG|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
219141534|NCT00738699|DRUG|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
219141535|NCT00738699|DRUG|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
219718205|NCT05404659|OTHER|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
219718206|NCT05404659|OTHER|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
219718207|NCT01287247|BIOLOGICAL|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
219718208|NCT04171076|PROCEDURE|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
219718209|NCT01056575|DRUG|OC000459|OC000459 100mg tablet, twice daily
219718210|NCT03802110|DEVICE|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
219718211|NCT04925323|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
219718212|NCT04925323|BIOLOGICAL|surgical tissue samples|unused surgical tissue removed during plastic surgeries
219718213|NCT06268119|OTHER|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
219718214|NCT04135651|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
219141536|NCT00738699|DRUG|Paclitaxel|
219141537|NCT05414786|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine (100µg)|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
219141538|NCT02067026|DIETARY_SUPPLEMENT|Aleurone|
219229734|NCT01828671|OTHER|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
219718215|NCT04135651|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
219718216|NCT02565472|OTHER|White grape juice|
219718217|NCT02565472|OTHER|Apple juice|
219718218|NCT01442636|DEVICE|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
219141539|NCT02067026|DIETARY_SUPPLEMENT|Placebo|
219141540|NCT04807322|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
219141541|NCT02073123|DRUG|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
219718219|NCT04601285|DRUG|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
219718220|NCT04548128|DEVICE|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
219141542|NCT02073123|DRUG|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
219229735|NCT01828671|OTHER|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
219229736|NCT01828671|OTHER|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
219229737|NCT01828671|OTHER|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
219229738|NCT01828671|OTHER|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
219229739|NCT02958566|DRUG|Acetaminophen|
219229740|NCT02958566|DRUG|Gabapentin|
219229741|NCT02958566|DRUG|Orphenadrine|
219229742|NCT02958566|DRUG|Lidocaine|
219718221|NCT04002271|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
219141543|NCT02073123|DRUG|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
219141544|NCT02073123|DRUG|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
219141545|NCT04571606|PROCEDURE|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
219141546|NCT04571606|PROCEDURE|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
219141547|NCT00539799|DRUG|prednisolone|5 - 7.5 mg/day
219141548|NCT00539799|DRUG|Placebo|Matched placebo to prednisolone
219141549|NCT00160004|BEHAVIORAL|Intensive Controlled Exercise|
219141550|NCT00131144|DRUG|Octreotide Acetate in Microspheres 20 mg|
219141551|NCT00131144|DRUG|Octreotide Acetate in Microspheres|
219141552|NCT00131144|DRUG|Placebo|
219141553|NCT02550197|BIOLOGICAL|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
219141554|NCT02550197|BIOLOGICAL|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
219141555|NCT03182959|DRUG|Avmacol®|Avmacol® tablets
219141556|NCT02218502|OTHER|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
219229743|NCT02958566|DRUG|Marcaine|
219229744|NCT02958566|DRUG|Ketamine|
219229745|NCT02958566|DRUG|Methadone|
219229746|NCT02958566|DRUG|Tramadol|
219141557|NCT02218502|OTHER|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
219141558|NCT02218502|OTHER|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
219141559|NCT02218502|OTHER|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
219141560|NCT00554736|BIOLOGICAL|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
219229747|NCT02958566|DRUG|Ketorolac|
219229748|NCT02958566|DRUG|Morphine Sulfate|
219229749|NCT02958566|DRUG|Fentanyl|
219229750|NCT02958566|DRUG|Dilaudid|
219229751|NCT02958566|DRUG|Hydrocodone-Acetaminophen Tab 5-325 MG|
219229752|NCT02958566|DRUG|Morphine Sulfate|PCA
219229753|NCT02958566|DRUG|Fentanyl|PCA
219229754|NCT02958566|DRUG|Dilaudid|PCA
219229755|NCT02958566|DRUG|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
219229756|NCT01719874|BIOLOGICAL|TCN-032|
219229757|NCT01719874|BIOLOGICAL|Placebo (saline)|
219229758|NCT01567007|BEHAVIORAL|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
219141561|NCT02345018|PROCEDURE|Mechano-chemical ablation|Treatment with mechano-chemical ablation
219141562|NCT03426033|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
219141563|NCT03426033|DRUG|Warfarin|25mg tablet administered orally
219141564|NCT01763086|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
219141565|NCT03854253|PROCEDURE|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
219141566|NCT03854253|PROCEDURE|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
219141567|NCT00549848|DRUG|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
219141568|NCT00549848|DRUG|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
219141569|NCT03262935|DRUG|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
219141570|NCT03262935|DRUG|Physician's choice|See drug label
219141571|NCT02389777|BIOLOGICAL|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
219141572|NCT02389777|BIOLOGICAL|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
219141573|NCT00419094|DRUG|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
219141574|NCT00419094|DRUG|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
219141575|NCT06427486|OTHER|Parents Telecoaching Intervention|\- Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
219141576|NCT02504086|BEHAVIORAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
219141577|NCT00307463|PROCEDURE|strict volume control policy|strict volume control by UF and dietary salt restriction
219141578|NCT00307463|PROCEDURE|antihypertensive drugs administration|continue antihypertensive medications
219141579|NCT01547546|DRUG|GDC-0084|Multiple doses
219141580|NCT02830906|DRUG|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
219141581|NCT02830906|DRUG|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
219141582|NCT04030767|DRUG|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
219141583|NCT01811706|DRUG|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
219141584|NCT01811706|DRUG|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
219141585|NCT01060514|DRUG|Pazopanib|dose escalation, administered orally, daily
219141586|NCT01060514|DRUG|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
219141587|NCT06068439|DRUG|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
219141588|NCT06068439|DRUG|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
219141589|NCT02224924|OTHER|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
219141590|NCT02224924|DEVICE|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
219141591|NCT05819099|DIAGNOSTIC_TEST|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
219141592|NCT04674436|BEHAVIORAL|Walking|6 minute casual walk
219141593|NCT01352533|PROCEDURE|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
219141594|NCT01352533|PROCEDURE|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
219141595|NCT01352533|PROCEDURE|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
219141596|NCT03623997|OTHER|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
219141597|NCT03020745|DRUG|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
219141598|NCT03020745|DRUG|Placebo|Placebo is available as a Clear colorless solution.
219141599|NCT03901937|DRUG|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
219718222|NCT04002271|DRUG|Sevoflurane|Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
219718223|NCT04002271|PROCEDURE|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
219718224|NCT00153920|DRUG|bortezomib|
219718225|NCT05667129|DRUG|XEN-101|Capsule formulation
219718226|NCT05667129|DRUG|Placebo|capsule formulation
219718227|NCT03637829|OTHER|Control|Water
219718228|NCT03637829|OTHER|White chocolate|Experimental snack treatment
219718229|NCT03637829|OTHER|Dark chocolate 1|Experimental snack treatment
219718230|NCT03637829|OTHER|Dark chocolate 2|Experimental snack treatment
219718231|NCT01029821|DRUG|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
219718232|NCT03517215|BEHAVIORAL|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
219141600|NCT03901937|PROCEDURE|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
219141601|NCT04825028|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
219141602|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive BBT-CI
219718233|NCT03517215|BEHAVIORAL|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
219718234|NCT02957825|DEVICE|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
219718235|NCT04797728|DRUG|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
219718236|NCT00538538|DRUG|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
219718237|NCT00538538|DRUG|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
219141603|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive HEAL
219141604|NCT04829539|OTHER|Quality-of-Life Assessment|Ancillary studies
219141605|NCT04829539|OTHER|Questionnaire Administration|Ancillary studies
219141606|NCT06332040|DRUG|Gentamicin|random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
219141607|NCT05231408|OTHER|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
219141608|NCT05231408|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
219718238|NCT03807635|DEVICE|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
219718239|NCT03807635|DEVICE|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
219718240|NCT00063622|DRUG|Pioglitazone|30 mg daily
219718241|NCT00063622|DIETARY_SUPPLEMENT|Vitamin E|800 IU daily
219718242|NCT00063622|DRUG|Matching placebo|Daily
219718243|NCT01878266|RADIATION|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
219718244|NCT01878266|RADIATION|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
219718245|NCT01878266|RADIATION|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
219718246|NCT00248053|DRUG|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
219718247|NCT02551146|DEVICE|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
219141609|NCT06131359|DIAGNOSTIC_TEST|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
219141610|NCT03754218|DRUG|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
219141611|NCT03754218|PROCEDURE|SOC Wound Covering|Institutional standard of care wound covering.
219141612|NCT03145649|OTHER|Dietary therapy or insulin injection|
219141613|NCT01244113|DRUG|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
219141614|NCT06222918|PROCEDURE|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
219141615|NCT00617331|BIOLOGICAL|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
219141616|NCT03196310|DRUG|Platelet Concentrate|Platelet Rich plasma
219141617|NCT03196310|DRUG|Corticosteroid injection|Kenalog
219141618|NCT03196310|OTHER|Normal Saline|Control Group - Placebo
219141619|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; low temperature)|
219141620|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; low temperature)|
219141621|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; high temperature)|
219141622|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; high temperature)|
219141623|NCT03036644|OTHER|tobacco cigarette|
219141624|NCT06522880|DIAGNOSTIC_TEST|CMV PCR on saliva|Observational study to measure prevalence of CMV shedding by saliva PCR
219141625|NCT01965119|DRUG|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
219141626|NCT00801658|DEVICE|selective Laser Trabeculoplasty (SLT)|
219141627|NCT00203216|DRUG|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
219141628|NCT00203216|PROCEDURE|Transcranial Magnetic Stimulation|
219141629|NCT05717218|DEVICE|Ultra-protective mechanical ventilation monitored by electrical impedance tomography|"A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored."
219141630|NCT06070688|DIAGNOSTIC_TEST|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
219141631|NCT06070688|DIAGNOSTIC_TEST|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
219141632|NCT06316206|DRUG|Ethinylestradiol/Dienogest 0.03mg/2mg|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
219141633|NCT03629730|BEHAVIORAL|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
219141634|NCT04957485|DRUG|Tecovirimat|oral antiviral
219141635|NCT04957485|DRUG|Smallpox and Mpox Vaccine|vaccine
219141636|NCT04957485|OTHER|Placebo|TPOXX Placebo
219141637|NCT01192542|DEVICE|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
219141638|NCT01192542|DEVICE|enfilcon A lens|Marketed silicone hydrogel contact lens
219229759|NCT01567007|BEHAVIORAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
219718248|NCT02551146|DEVICE|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
219141639|NCT05142137|DIETARY_SUPPLEMENT|Drinkable solution|The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
219141640|NCT02797249|DRUG|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
219141641|NCT02797249|OTHER|Blank|Routine examination during pregnancy.
219141642|NCT05761834|OTHER|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
219141643|NCT01886625|PROCEDURE|unilateral single-port VATS sympathicotomy|
219141644|NCT02497092|OTHER|Technique of injection|
219141645|NCT00316641|DRUG|Lipid-lowing Tea|
219141646|NCT00208078|DEVICE|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
219229760|NCT01567007|BEHAVIORAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
219718249|NCT00259636|DRUG|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
219229761|NCT05383989|BEHAVIORAL|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
219141647|NCT06043128|OTHER|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
219141648|NCT01033058|DRUG|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
219141649|NCT01033058|DRUG|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
219141650|NCT03573258|DIETARY_SUPPLEMENT|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
219141651|NCT03359460|DRUG|Ibrutinib|Given PO
219229762|NCT05383989|BEHAVIORAL|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
219718250|NCT00006180|DRUG|Alendronate|
219718251|NCT03170310|DRUG|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
219718252|NCT00738088|DRUG|gliclazide|Gliclazide 80mg bd for 6 weeks
219718253|NCT02153281|OTHER|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
219141652|NCT03359460|DRUG|Lenalidomide|Given PO
219229763|NCT05383989|BEHAVIORAL|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
219229764|NCT05383989|BEHAVIORAL|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
219718254|NCT04373070|COMBINATION_PRODUCT|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
219718255|NCT01792466|PROCEDURE|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
219718256|NCT04529460|DIAGNOSTIC_TEST|COVID-19 antibody point of care test kit|A disponible point of care test that identifies the presence of antibodies to COVID-19
219718257|NCT05316987|RADIATION|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
219718258|NCT03184272|PROCEDURE|baseline alert 1|measurement in supine position
219718259|NCT03184272|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
219718260|NCT03184272|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
219718261|NCT03184272|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
219718262|NCT03184272|PROCEDURE|passive leg raising|measurement under passive leg raising
219718263|NCT03184272|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
219718264|NCT03184272|PROCEDURE|baseline in narcosis 2|measurement in supine position
219718265|NCT03184272|PROCEDURE|start capnoperitoneum|measurement in supine position
219718266|NCT03184272|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
219229765|NCT05383989|BEHAVIORAL|Service as usual provided by the University|It is the regular university-provided well-being services.
219229766|NCT00258115|DRUG|salsalate|
219229767|NCT00786188|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
219229768|NCT00786188|DRUG|Sugar pill|Subjects will receive a sugar pill.
219229769|NCT00655785|BIOLOGICAL|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
219229770|NCT00655785|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
219229771|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
219229772|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
219229773|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
219229774|NCT01537497|DRUG|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
219229775|NCT02848105|DRUG|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
219141653|NCT00520208|DRUG|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
219141654|NCT00325858|DRUG|Tramadol HCl ER|
219229776|NCT03483649|DRUG|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
219229777|NCT03483649|DRUG|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
219229778|NCT03483649|DRUG|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
219229779|NCT03483649|DRUG|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
219552450|NCT05104996|BEHAVIORAL|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
219552451|NCT04170335|PROCEDURE|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
219552452|NCT00198835|BEHAVIORAL|Maternal nutrition and infant feeding advice|
219718267|NCT03184272|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
219718268|NCT03184272|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
219718269|NCT03184272|PROCEDURE|baseline|measurement in supine position
219718270|NCT03184272|PROCEDURE|baseline alert 2|measurement in supine position
219718271|NCT03184272|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
219718272|NCT03184272|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
219141655|NCT02023554|DRUG|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
219718273|NCT01695746|DRUG|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
219141656|NCT02023554|DRUG|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
219718274|NCT06520059|COMBINATION_PRODUCT|Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration|"Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week."
219141657|NCT04617717|PROCEDURE|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
219141658|NCT04617717|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Standard ergometer bicycle test
219229780|NCT05912049|DRUG|9MW3811 Injection|Single dose intravenously infused on day 1
219229781|NCT05912049|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
219718275|NCT02145858|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
219718276|NCT05569941|DRUG|ABI-4334 Tablet|ABI-4334 Tablet
219718277|NCT05569941|DRUG|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
219718278|NCT03175939|RADIATION|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
219718279|NCT03175939|DRUG|Cisplatin|cisplatin IV injection over 3 hours
219718280|NCT03175939|DRUG|5-FU|5-FU IV 24 hours continuous infusion
219718281|NCT04615507|DEVICE|JJVC Investigational Multifocal Contact Lens|TEST Lens
219718282|NCT04615507|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
219229782|NCT01412606|PROCEDURE|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
219229783|NCT05605132|OTHER|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination"
219718283|NCT01144806|BEHAVIORAL|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
219718284|NCT01144806|DIETARY_SUPPLEMENT|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
219141659|NCT04617717|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
219141660|NCT04617717|DIAGNOSTIC_TEST|Holter monitoring|24h 5 lead or 12 lead ECG recording
219229784|NCT05605132|OTHER|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
219229785|NCT05605132|OTHER|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
219229786|NCT03295409|BEHAVIORAL|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
219229787|NCT06152718|OTHER|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
219229788|NCT03576092|DIAGNOSTIC_TEST|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
219229789|NCT02305498|OTHER|Vigorous yoga practice|
219229790|NCT02305498|OTHER|Restorative (gentle) yoga practice|
219229791|NCT02959385|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
219229792|NCT02959385|PROCEDURE|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
219229793|NCT01324076|DRUG|doxorubicin-eluting beads|
219718285|NCT00837460|OTHER|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
219141661|NCT04617717|DIAGNOSTIC_TEST|Transthoracic echocardiography|2D echocardiography
219141662|NCT04617717|DIAGNOSTIC_TEST|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
219141663|NCT05349097|DRUG|SAD IMG-004 30mg|Each participant will be randomized to receive a single oral dose of 30mg IMG-004
219141664|NCT05349097|DRUG|SAD IMG-004 100mg|Each participant will be randomized to receive a single oral dose of 100mg IMG-004
219141665|NCT05349097|DRUG|SAD IMG-004 200mg|Each participant will be randomized to receive a single oral dose of 200mg IMG-004
219141666|NCT05349097|DRUG|SAD IMG-004 400mg|Each participant will be randomized to receive a single oral dose of 400mg IMG-004
219552453|NCT01055834|DRUG|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
219552454|NCT01055834|DRUG|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
219552455|NCT03333863|OTHER|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
219552456|NCT03528486|BEHAVIORAL|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
219552457|NCT03259841|OTHER|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
219229794|NCT01324076|DRUG|sorafenib tosylate|
219229795|NCT01324076|OTHER|laboratory biomarker analysis|
219229796|NCT01324076|OTHER|pharmacogenomic studies|
219229797|NCT01324076|OTHER|pharmacological study|
219229798|NCT01324076|PROCEDURE|quality-of-life assessment|
219229799|NCT05088200|PROCEDURE|surgery|Our study is observational and we use secondary data
219229800|NCT00640588|DRUG|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
219229801|NCT00640588|DRUG|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
219229802|NCT04063124|DRUG|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
219229803|NCT00524797|DIETARY_SUPPLEMENT|Profonycia|
219552458|NCT02754219|DRUG|Evogliptin|DPP4-inhibitor, Evogliptin
219718286|NCT05044988|DRUG|HS-10342|HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
219552459|NCT01717313|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
219141667|NCT05349097|DRUG|SAD IMG-004 600mg|Each participant will be randomized to receive a single oral dose of 600mg IMG-004
219229804|NCT02950961|BEHAVIORAL|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
219229805|NCT02709200|DRUG|Dexmedetomidine|
219141668|NCT05349097|DRUG|SAD Placebo 30mg|Each participant will be randomized to receive a single oral dose of 30mg matching placebo
219229806|NCT04158206|OTHER|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
219141669|NCT05349097|DRUG|SAD Placebo 100mg|Each participant will be randomized to receive a single oral dose of 100mg matching placebo
219141670|NCT05349097|DRUG|SAD Placebo 200mg|Each participant will be randomized to receive a single oral dose of 200mg matching placebo
219141671|NCT05349097|DRUG|SAD Placebo 400mg|Each participant will be randomized to receive a single oral dose of 400mg matching placebo
219141672|NCT05349097|DRUG|SAD Placebo 600mg|Each participant will be randomized to receive a single oral dose of 600mg matching placebo
219141673|NCT05349097|DRUG|MAD IMG-004 50mg|Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
219141674|NCT05349097|DRUG|MAD Placebo 50mg|Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
219141675|NCT05349097|DRUG|MAD IMG-004 150mg|Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
219141676|NCT05349097|DRUG|MAD Placebo 150mg|Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
219141677|NCT05349097|DRUG|MAD IMG-004 300mg|Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
219229807|NCT02241785|DRUG|natalizumab|Administered as specified in the treatment arm
219229808|NCT01640340|DRUG|aprepitant|Given by mouth
219229809|NCT01640340|DRUG|palonosetron hydrochloride|Given IV(intervenous infusion)
219229810|NCT01640340|DRUG|ondansetron|Given PO
219229811|NCT01640340|DRUG|dexamethasone|Given PO
219229812|NCT03055988|DRUG|Tiotropium|Fixed Dose Combination
219229813|NCT03055988|DRUG|Olodaterol|Fixed Dose Combination
219229814|NCT03055988|DRUG|Fluticasone propionate|Fixed Dose Combination
219229815|NCT03055988|DRUG|Salmeterol|Fixed Dose Combination
219229816|NCT06131957|COMBINATION_PRODUCT|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
219229817|NCT06131957|DRUG|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
219229818|NCT05591937|BEHAVIORAL|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
219141678|NCT05349097|DRUG|MAD Placebo 300mg|Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
219141679|NCT05349097|DRUG|FE IMG-004 150mg|A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
219141680|NCT00964366|DRUG|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
219552460|NCT01717313|DRUG|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
219552461|NCT01717313|DRUG|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
219141681|NCT00964366|DRUG|Dapsone gel|Twice-daily applications of dapsone gel
219141682|NCT03009513|DRUG|Teneligliptin+Glimepiride|
219141683|NCT04286256|BEHAVIORAL|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
219141684|NCT01370694|DRUG|MK-8808|
219552462|NCT01717313|DRUG|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
219552463|NCT01717313|DRUG|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
219552464|NCT02134821|PROCEDURE|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
219552465|NCT00276536|BIOLOGICAL|recombinant interferon alpha-1b|interferon
219141685|NCT01370694|DRUG|cyclophosphamide|
219141686|NCT01370694|DRUG|vincristine|
219141687|NCT01370694|DRUG|prednisolone|
219141688|NCT00497562|DRUG|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
219141689|NCT00497562|DRUG|amitriptyline, fluoxetine and tramadol alone (control group)|
219141690|NCT02009358|OTHER|mental health promotion|
219141691|NCT00127829|DRUG|Gefitinib|Oral tablet
219141692|NCT02393716|DEVICE|Endurant Evo AAA Stent Graft System|
219141693|NCT02393716|PROCEDURE|Endovascular aneurysm repair (EVAR)|
219141694|NCT03107286|DRUG|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
219141695|NCT03107286|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
219141696|NCT00000634|DRUG|Nevirapine|
219141697|NCT01494246|OTHER|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
219141698|NCT05633199|OTHER|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
219141699|NCT04806919|DRUG|Progesteron TID|increasing the dose
219141700|NCT03014596|OTHER|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
219141701|NCT00872417|DRUG|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
219141702|NCT00872417|DRUG|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
219141703|NCT00978237|DRUG|EFV|one pill QD VO.
219141704|NCT00978237|DRUG|LPV/r|2 pills QD VO
219141705|NCT02319785|BEHAVIORAL|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
219141706|NCT02319785|BEHAVIORAL|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
219141707|NCT02319785|BEHAVIORAL|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
219141708|NCT02319785|BEHAVIORAL|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
219141709|NCT02319785|BEHAVIORAL|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
219141710|NCT02319785|BEHAVIORAL|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
219141711|NCT02957539|BEHAVIORAL|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
219552466|NCT00276536|DRUG|IFN|IFN daily
219552467|NCT03504085|OTHER|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
219552468|NCT03504085|OTHER|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
219552469|NCT04133311|DRUG|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
219552470|NCT04133311|DRUG|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
219552471|NCT04133311|DRUG|DE-130A/DE-130A|After Week 12, received DE-130A continuously.
219552472|NCT04133311|DRUG|Xalatan®/DE-130A|From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
219552473|NCT03935815|DRUG|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
219552474|NCT03935815|PROCEDURE|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
219141712|NCT02957539|BEHAVIORAL|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
219141713|NCT05752513|PROCEDURE|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
219141714|NCT05752513|PROCEDURE|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
219141715|NCT00947596|DRUG|atropine sulfate|dry powder for inhalation
219141716|NCT00947596|DRUG|atropine sulfate|intramuscular injection
219141717|NCT02931383|DRUG|Liraglutide 3 mg (Saxenda)|
219141718|NCT02931383|DRUG|Liraglutide 3 mg placebo|
219141719|NCT05471726|BEHAVIORAL|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
219141720|NCT05493124|DRUG|Manpixiao|A traditional Chinese medicine composition
219141721|NCT05493124|DRUG|Active comparator|Other drugs that may have therapeutic effects
219141722|NCT00391833|DRUG|Panax Ginseng|
219141723|NCT04826055|OTHER|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
219141724|NCT04826055|OTHER|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
219141725|NCT00939042|PROCEDURE|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
219141726|NCT00939042|PROCEDURE|BMNC therapy|Injection of BMNC after common PCI
219141727|NCT01256034|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
219141728|NCT02655367|OTHER|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
219141729|NCT02655367|OTHER|Milled oats|Test meal consisting of 264g porridge made with milled oats
219552475|NCT00091377|DRUG|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
219552476|NCT00091377|DRUG|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
219552477|NCT00091377|DRUG|phenoxodiol|IV 3 mg/kg
219552478|NCT06069037|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
219552479|NCT03522532|PROCEDURE|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552480|NCT03522532|PROCEDURE|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552481|NCT03522532|PROCEDURE|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552482|NCT03522532|PROCEDURE|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552483|NCT03522532|PROCEDURE|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552484|NCT03522532|PROCEDURE|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
219552485|NCT06249451|OTHER|Checklist-based phone calls|"The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines."
219552486|NCT00252161|PROCEDURE|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
219552487|NCT00252161|DRUG|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
219552488|NCT00728754|DEVICE|Dental implant Osseotite Prevail|Root form titanium dental implant
219552489|NCT00728754|DEVICE|Dental implant Osseotite|root form titanium dental implant
219552490|NCT00668577|DRUG|Lactic acid (Dermacid)|
219552491|NCT00623077|BIOLOGICAL|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
219552492|NCT00623077|DRUG|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
219552493|NCT00623077|DRUG|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
219552494|NCT00623077|DRUG|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
219552495|NCT00623077|DRUG|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
219552496|NCT00623077|DRUG|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
219229819|NCT05591937|BEHAVIORAL|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
219229820|NCT05591937|BEHAVIORAL|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
219229821|NCT01733862|OTHER|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
219229822|NCT06085989|BEHAVIORAL|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
219229823|NCT06085989|BEHAVIORAL|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
219229824|NCT03307694|DIAGNOSTIC_TEST|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
219552497|NCT00623077|PROCEDURE|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
219552498|NCT00623077|RADIATION|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
219552499|NCT00623077|RADIATION|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
219141730|NCT05257785|BEHAVIORAL|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
219141731|NCT05257785|BEHAVIORAL|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
219141732|NCT03781336|BEHAVIORAL|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
219141733|NCT00878462|DRUG|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
219141734|NCT00878462|DRUG|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
219141735|NCT00878462|DRUG|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
219141736|NCT01596504|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
219141737|NCT01596504|DRUG|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
219141738|NCT01596504|DRUG|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
219141739|NCT01596504|DRUG|Metformin|If previously taken metformin to be continued at stable dose throughout the study
219141740|NCT01901276|DRUG|Omeprazole 40 mg bid|As above.
219141741|NCT04666818|DEVICE|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
219141742|NCT04000269|DEVICE|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
219141743|NCT04000269|DEVICE|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
219141744|NCT02015741|DEVICE|EEG monitoring with Bispectral Index and NeuroSENSE|
219141745|NCT02015741|BEHAVIORAL|Clinical observation|Patients will be observed during awake periods and during natural sleep.
219141746|NCT05045703|DIETARY_SUPPLEMENT|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
219141747|NCT00000313|DRUG|Fenfluramine|
219718287|NCT06224257|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
219718288|NCT06968403|BEHAVIORAL|Community emotional intelligence network|This intervention focuses on developing emotional intelligence (EI) to tackle climate change-induced mental health challenges like eco-anxiety, solastalgia, and stress from displacement and natural disasters. It is community-centered, utilizing local resources and volunteers for EI training and mental health support, unlike traditional clinical interventions that depend on centralized healthcare systems. A mobile app is integrated to facilitate communication, learning resources, and participant connections, offering remote support and continuous engagement, even during climate events like floods or cyclones. Targeting coastal communities in Bangladesh, this program addresses the mental health impacts of frequent natural disasters, saltwater intrusion, and displacement. Unlike other mental health programs, it not only treats symptoms but also builds resilience against environmental stressors, empowering communities to cope with climate-induced mental health challenges.
219141748|NCT00703625|DRUG|Temsirolimus|
219141749|NCT00703625|DRUG|Docetaxel|
219718289|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
219718290|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
219718291|NCT06127563|OTHER|creation of a clinical pathway to increase vaccination coverage in frail patients|creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
219229825|NCT03307694|DIAGNOSTIC_TEST|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
219229826|NCT03307694|DIAGNOSTIC_TEST|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
219718292|NCT05836870|OTHER|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
219229827|NCT05695469|DEVICE|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
219718293|NCT05836870|BEHAVIORAL|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
219718294|NCT02920658|DRUG|NAVS Naphthalan|
219552500|NCT00623077|DRUG|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
219552501|NCT00623077|RADIATION|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
219552502|NCT00002253|DRUG|Octreotide|
219552503|NCT01926119|DEVICE|Transcranial Magnetic Stimulation|
219552504|NCT03948854|OTHER|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
219552505|NCT03948854|OTHER|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
219552506|NCT03948854|OTHER|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
219718295|NCT02920658|DRUG|0.05% Betamethasone dipropionate|
219141750|NCT00294905|BEHAVIORAL|Implementation of a combined smoking cessation strategy|
219141751|NCT03890640|PROCEDURE|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
219141752|NCT02894749|RADIATION|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
219229828|NCT05695469|OTHER|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
219229829|NCT03389919|BIOLOGICAL|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
219229830|NCT05089487|PROCEDURE|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
219552507|NCT03948854|OTHER|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
219141753|NCT03629119|DIETARY_SUPPLEMENT|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
219141754|NCT03502317|BEHAVIORAL|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
219141755|NCT03502317|BEHAVIORAL|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
219141756|NCT00492791|DEVICE|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
219141757|NCT04459819|OTHER|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~* early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~* patients positioning~* non-invasive mechanical ventilation / CPAP~* tracheostomy management~* invasive mechanical ventilation weaning~* airway clearance~* oxygen titration"
219141758|NCT04090762|BEHAVIORAL|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
219141759|NCT04090762|BEHAVIORAL|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
219141760|NCT05061342|OTHER|No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.|Any anticancer or palliative care
219229831|NCT00845520|DEVICE|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
219718296|NCT02198638|BIOLOGICAL|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
219718297|NCT03212937|DRUG|Selinexor|Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
219718298|NCT03212937|DRUG|ICE Chemotherapy|"IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle"
219718299|NCT01021189|DRUG|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
219718300|NCT01021189|DRUG|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
219718301|NCT05731765|DIAGNOSTIC_TEST|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
219718302|NCT06036095|DRUG|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
219718303|NCT06036095|DRUG|Propofol|Intravenous maintenance of anesthesia group using propofol
219718304|NCT00990886|DRUG|Placebo|Once daily for 12 weeks
219718305|NCT00990886|DRUG|Oxybutynin chloride|15 mg once daily for 12 weeks
219718306|NCT05130437|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
219718307|NCT02239289|OTHER|Biofeedback|Idem as described in the arm section (above)
219141761|NCT04620018|DRUG|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
219229832|NCT00845520|DEVICE|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
219229833|NCT00845520|DEVICE|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
219718308|NCT05869474|PROCEDURE|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
219718309|NCT05869474|DRUG|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
219718310|NCT01453231|PROCEDURE|thighplasty|Plastic surgery of thigh
219718311|NCT05632991|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
219718312|NCT05632991|OTHER|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
219718313|NCT05172570|DRUG|Gabapentin|Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
219141762|NCT06315049|OTHER|Music therapy|Music therapy sessions to reduce anxiety
219141763|NCT05967819|BEHAVIORAL|Exercise Stress|Increased exercise volume
219141764|NCT05967819|BEHAVIORAL|Psychosocial Stress|cognitive tasks
219141765|NCT05590273|BEHAVIORAL|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
219141766|NCT03835390|BEHAVIORAL|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
219141767|NCT06184854|OTHER|3D-Enhanced Training Models|3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2
219141768|NCT06184854|OTHER|Standard 3D LapPass Training Models|Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
219141769|NCT03016455|OTHER|Presence of DSA w/ cAMR|
219141770|NCT03016455|OTHER|Presence of DSA w/o cAMR|
219141771|NCT03016455|OTHER|No DSA No cAMR|
219141772|NCT03617406|DIAGNOSTIC_TEST|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
219141773|NCT04347954|DRUG|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
219141774|NCT04347954|DRUG|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
219141775|NCT04347954|DRUG|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
219141776|NCT05988307|DEVICE|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
219141777|NCT03906942|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
219141778|NCT04108754|OTHER|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
219141779|NCT05781555|DEVICE|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
219141780|NCT00761930|DRUG|Fluoride|Brush twice daily
219141781|NCT00761930|DRUG|Triclosan and fluoride|Brush twice daily
219141782|NCT00761930|DRUG|Herbal Ingredient and fluoride|Brush twice daily
219141783|NCT03257813|DRUG|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
219141784|NCT03257813|DRUG|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
219141785|NCT02878330|DRUG|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
219141786|NCT02878330|DRUG|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
219141787|NCT02274896|DEVICE|PD Catheter group|PD catheter
219141788|NCT00092833|DRUG|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
219141789|NCT00578656|DIETARY_SUPPLEMENT|Baked Milk|Extensively heated milk
219141790|NCT02683811|BEHAVIORAL|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
219141791|NCT02698007|DEVICE|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
219141792|NCT06466564|DEVICE|Nufairy® Coil embolization system for intracranial aneurysm|Nufairy® Coil embolization system for intracranial aneurysm
219141793|NCT02511197|DRUG|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
219141794|NCT02511197|DEVICE|PET/CT|
219141795|NCT00349583|DRUG|Topical Cyclosporine, Tears|
219141796|NCT00107835|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
219229834|NCT02507869|BEHAVIORAL|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
219229835|NCT02507869|BEHAVIORAL|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
219229836|NCT01357694|BEHAVIORAL|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
219229837|NCT00860236|OTHER|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
219229838|NCT00860236|BEHAVIORAL|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
219718314|NCT03796663|BEHAVIORAL|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
219718315|NCT03796663|BEHAVIORAL|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
219718316|NCT06530810|DRUG|HS-10382+Flumatinib|Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily
219141797|NCT04203264|DIAGNOSTIC_TEST|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
219141798|NCT02732678|DRUG|PROPRANOLOL|
219141799|NCT01424540|DRUG|GSK2336805 150mg|Single Dose
219141800|NCT01424540|OTHER|Placebo|Single Dose
219141801|NCT01315886|DRUG|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
219141802|NCT02215278|DIETARY_SUPPLEMENT|10 x 55 g/ bean per arm|
219141803|NCT03725371|OTHER|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
219229839|NCT01181232|DRUG|Zolpidem MR|oral
219718317|NCT06480630|DRUG|Basiliximab|Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
219718318|NCT00886457|DRUG|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
219141804|NCT02805439|DRUG|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
219141805|NCT02805439|DRUG|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
219229840|NCT01181232|DRUG|Zolpidem IR|oral
219229841|NCT01736475|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
219229842|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
219229843|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
219229844|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|On-demand treatment
219229845|NCT00127582|PROCEDURE|Electrophysiological study|
219229846|NCT00127582|DEVICE|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
219229847|NCT02807857|PROCEDURE|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
219229848|NCT01876966|DRUG|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
219229849|NCT01876966|DRUG|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
219229850|NCT01876966|DRUG|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
219229851|NCT03632876|DIETARY_SUPPLEMENT|retinyl palmitate|The intervention is a daily vitamin A supplement.
219229852|NCT02509858|DRUG|thyroxine|treatment with 50μg of thyroxine once daily for two months.
219229853|NCT02509858|DRUG|Placebo|treatment with 50μg of placebo, once daily, for two months.
219229854|NCT02509858|OTHER|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
219229855|NCT00482742|DEVICE|CiTop(TM) Guidewire|
219229856|NCT05001126|BEHAVIORAL|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
219718319|NCT05699681|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
219718320|NCT03785821|DIETARY_SUPPLEMENT|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
219718321|NCT03785821|DIETARY_SUPPLEMENT|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
219718322|NCT01202591|DRUG|AZD4547|Tablet oral twice daily
219718323|NCT01202591|DRUG|Exemestane|Tablet oral once daily
219718324|NCT01202591|DRUG|Placebo|Tablet oral twice daily
219718325|NCT01202591|DRUG|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
219718326|NCT04298853|DRUG|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
219718327|NCT04298853|DRUG|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
219141806|NCT02805439|DRUG|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
219141807|NCT05146817|OTHER|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
219141808|NCT04557488|OTHER|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
219141809|NCT04557488|BEHAVIORAL|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
219141810|NCT03070938|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
219141811|NCT06354283|BEHAVIORAL|Progressive Muscle Relaxation Exercises|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
219141812|NCT00388661|DRUG|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
219141813|NCT00388661|DRUG|Placebo comparator|Placebo comparator
219141814|NCT00033163|DRUG|Adefovir dipivoxil|
219141815|NCT00033163|DRUG|Tenofovir disoproxil fumarate|
219141816|NCT05483374|OTHER|observation|Not applicable, it is an observational registry
219141817|NCT05966389|OTHER|No interventions|No interventions
219141818|NCT06292182|DEVICE|Near-infrared light|daily application of near-infrared light
219229857|NCT05001126|BEHAVIORAL|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
219718328|NCT02830087|PROCEDURE|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
219718329|NCT07103018|DRUG|KTX-2001|Participants will receive escalating doses of KTX-2001 monotherapy
219718330|NCT07103018|DRUG|KTX-2001 + Darolutamide (NUBEQA®)|Participants will receive escalating doses of KTX-2001, in combination with the oral androgen receptor (AR) pathway inhibitor (ARPI), darolutamide (NUBEQA®)
219141819|NCT01737008|DRUG|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
219229858|NCT05001126|BEHAVIORAL|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
219229859|NCT02515123|DEVICE|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
219141820|NCT01737008|RADIATION|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
219141821|NCT01737008|DRUG|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
219141822|NCT02533167|OTHER|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
219141823|NCT05028712|BEHAVIORAL|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
219141824|NCT05028712|BEHAVIORAL|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
219141825|NCT03649165|DRUG|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
219141826|NCT03649165|DRUG|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
219141827|NCT03649165|DRUG|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
219141828|NCT03649165|DRUG|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
219141829|NCT03649165|DRUG|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
219141830|NCT01586780|DIETARY_SUPPLEMENT|Protein drink|Test drink providing 9g protein
219141831|NCT01586780|DIETARY_SUPPLEMENT|Reference meal|Control meal
219229860|NCT02515123|DEVICE|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
219229861|NCT01137916|DRUG|Imatinib|800 mg
219141832|NCT02459899|DRUG|Placebo|Placebo, once daily, before the first meal of the day
219552508|NCT04464005|DRUG|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
219552509|NCT04464005|OTHER|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
219552510|NCT02155153|OTHER|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
219552511|NCT00009945|DRUG|clodronate|1600 mg PO daily
219552512|NCT00009945|DRUG|placebo|2 pills PO daily
219552513|NCT01800838|DRUG|silicon phthalocyanine 4|Given topically
219552514|NCT01800838|DRUG|photodynamic therapy|Undergo PDT
219552515|NCT01800838|OTHER|pharmacological study|Correlative studies
219552516|NCT01800838|OTHER|laboratory biomarker analysis|Correlative studies
219552517|NCT01769898|DRUG|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
219552518|NCT01769898|DRUG|Theophylline|Theophylline 0.1 Q12H
219552519|NCT01769898|DRUG|Placebo|Placebo for theophylline 0.1 Q12H
219552520|NCT00955838|OTHER|Rehabilitation technique|12 therapy session
219552521|NCT03304223|DIAGNOSTIC_TEST|[18F]FB-IL2 PET scan|\[18F\]FB-IL2 PET scan procedure
219552522|NCT02569138|DEVICE|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
219552523|NCT02569138|DEVICE|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
219552524|NCT03344120|OTHER|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
219552525|NCT06360887|PROCEDURE|Conservative|Conservative treatment
219552526|NCT06360887|PROCEDURE|ORIF|Open surgery
219552527|NCT06360887|PROCEDURE|CRPP|Minimal invasive surgery
219552528|NCT05140759|DEVICE|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
219229862|NCT04237909|BIOLOGICAL|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
219229863|NCT06143007|DRUG|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
219718331|NCT07104617|DRUG|TY-302|Take the specified dose (75mg or 100mg) orally once a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
219718332|NCT07104617|DRUG|Abiraptor|Take orally, 1000mg each time, once a day. Take it on an empty stomach in the morning with warm water, or take it orally at least two hours after fasting.
219141833|NCT02459899|DRUG|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
219718333|NCT07104058|DIAGNOSTIC_TEST|68Ga-FAPI PET / CT|IgG4-RD patients with clinical complete remission after hormone and immunosuppressive therapy and 18F-FDG PET / CT negative were included. After enrollment, 68Ga-FAPI PET / CT screening was performed.
219718334|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with application of clips for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by application of clips
219718335|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with ligature for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by ligation
219141834|NCT01118338|DEVICE|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
219229864|NCT00056654|DRUG|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
219229865|NCT00746759|DEVICE|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
219229866|NCT05554549|OTHER|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
219718336|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT A|A 3 km solo hike at a leisurely walking pace on a path that is easy to walk and has very little elevation gain. Located in Pontevedra Province.
219718337|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT B|A 3 km solo hike at a leisurely pace on an easy walking trail with very little elevation gain. Located in the province of Pontevedra.
219718338|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT C|3 km solo hike at a leisurely pace on an easy trail with little elevation gain. Located in the province of Pontevedra.
219718339|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT D|Individual 3 km treadmill walk in a closed room facing a wall without pictures or windows at a leisurely walking pace with no gradient. This room will be located on the Pontevedra University Campus.
219718340|NCT07113717|OTHER|virtual Hospital at Home|telemedicine set-up, virtual Hospital at Home
219718341|NCT07117123|DEVICE|Transcutaneous electrical acupoint stimulation|The doctor will stick special electrodes on your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect the electrical stimulation device (Han's Pain Treatment Device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and provided by this project team). The current intensity will gradually increase from a small amount to the maximum level you can tolerate (starting from 1mA, not exceeding the maximum safety range of 10mA). The entire transcutaneous acupoint electrical stimulation lasts for 30 minutes. This electrical stimulation is non-traumatic and painless. Most people only feel slight numbness, swelling, and heat.
219718342|NCT07117123|OTHER|No electrical stimulation|The doctor will attach special electrodes to your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect them to an electrical stimulation device (Han's pain treatment device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and is provided by this project team). No electricity (i.e. no stimulation)
219141835|NCT01118338|DEVICE|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
219141836|NCT04143555|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
219718343|NCT07118644|DRUG|MEOPA|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. MEOPA will be used for nebulization. MEOPA is a gas with analgesic, amnesic and anxiolytic properties.
219718344|NCT07118644|OTHER|Standard induced sputum|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. Oxygen will be used for nebulization.
219141837|NCT02847117|OTHER|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
219229867|NCT04205799|DRUG|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
219229868|NCT03530631|DRUG|Adderall|Participants will be administered Adderall
219229869|NCT03530631|DRUG|Placebo|Participants will be administered placebo
219141838|NCT01026636|DRUG|Ceftobiprole|
219141839|NCT01866566|BIOLOGICAL|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
219141840|NCT01866566|BIOLOGICAL|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
219718345|NCT07116720|OTHER|Unloading maneuvers|Participants will perform unloading maneuvers four times with 15 min of spinal flexion protocol in between. The intervention will include self traction on a box (5 s) and sustained standing trunk extension (8 s). Both maneuvers will be repeated twice at each timepoint.
219718346|NCT07118618|DRUG|Probenecid Oral Tablet|2gr daily
219718347|NCT07118618|DRUG|Placebo Oral Tablet|Inactive compound
219718348|NCT07120802|BEHAVIORAL|BETTER4U Mobile App and Wearable Use (End-User Group)|"Participants from the general population (end-users) will use a smartwatch and the BETTER4U mobile app for 21 days. The app passively collects data (physical activity, sleep, eating behaviors, environment), while participants may self-report certain behaviors. The goal is to assess the usability, feasibility, and acceptability of the tools and to collect real-world behavioral data for refining AI models."
219718349|NCT07120802|BEHAVIORAL|BETTER4U Intervention Platform Testing (Implementer Group)|Healthcare professionals and other potential implementers will test the BETTER4U Intervention Platform and mobile app for 7 days. They will assess system usability, complete synthetic case simulations, and provide daily feedback via Google Forms. They also wear the smartwatch and use the app for data validation purposes. The goal is to evaluate platform usability and collect ground-truth data for validating AI algorithm outputs.
219552529|NCT05553444|BEHAVIORAL|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
219552530|NCT04143607|DRUG|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
219552531|NCT04143607|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
219141841|NCT01866566|BIOLOGICAL|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
219552532|NCT04143607|DRUG|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
219141842|NCT01866566|BIOLOGICAL|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
219141843|NCT00940992|DRUG|DER 45 EV|Topical application to face for 12 weeks
219552533|NCT04143607|DRUG|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
219552534|NCT02606032|DRUG|Metronidazole|active comparator
219552535|NCT02606032|DRUG|Doxycycline|active comparator
219718350|NCT07121348|PROCEDURE|Platelet rich fibrin|platelet rich fibrin is obtained by removing the middle layer from a centrifuged blood sample and is rich with platelets that plays an important role in tissue regeneration mesoporous silica nanoparticles are high surface area and excellent biocompatibility and enhance the outcome hyalurnic acid nanoparticles are high water capacity and involved in cell proliferation and adhesion and help in tissue regeneration pomegranate nanoparticles has anti-inflammatory and antibacterial effect and also help in tissue proliferation and regeneration
219229870|NCT01827982|DRUG|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
219141844|NCT00940992|DRUG|Vehicle|Topical application to face for 12 weeks
219141845|NCT01918644|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219141846|NCT01918644|DRUG|capecitabine|Given PO
219141847|NCT01918644|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
219141848|NCT01918644|PROCEDURE|magnetic resonance imaging|Optional correlative studies
219141849|NCT01918644|OTHER|laboratory biomarker analysis|Optional correlative studies
219141850|NCT04426045|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
219229871|NCT01827982|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
219229872|NCT01827982|DRUG|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
219229873|NCT01827982|DRUG|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
219229874|NCT01827982|DRUG|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
219718351|NCT07120113|OTHER|cupping massage|This group will receive cupping massage three sessions per week for four weeks
219718352|NCT07120113|OTHER|Myofascial release technique|This group will receive the myofascial release technique three sessions per week for four weeks
219718353|NCT07120113|OTHER|Traditional exercises|This group will receive traditional exercises three sessions per week for four weeks
219718354|NCT07122362|DEVICE|Elastic Lower Extremity Orthosis|Participants in the intervention group receive conventional neurodevelopmental therapy combined with an elastic lower extremity orthosis designed to correct internal rotation deformities and improve gait and balance in children with spastic cerebral palsy. The orthosis applies elastic tension around the femoral region and tibia to target rotational problems.
219718355|NCT07122362|BEHAVIORAL|Neurodevelopmental Therapy|Participants receive conventional neurodevelopmental therapy only.
219718356|NCT07123844|DIETARY_SUPPLEMENT|low cholesterol diet|low cholesterol diet
219718357|NCT07124065|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy|Spectral data collection with diffuse reflectance spectroscopy
219718358|NCT07126002|BEHAVIORAL|Yoga|: Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, bodybalance training, and coordination of breath with movement), and meditation and relaxation (e.g.supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
219718359|NCT07125690|OTHER|local heat application|The newborns included in this group received local dry heat application 5 minutes before the heel prick procedure, with the newborn in the supine position. Local dry heat was applied using a thermometer heated with water between 40 and 45˚C. The temperature of the water inside the thermometer was measured before application. The thermometer was applied to the sole of the newborn's right foot. Contact with bare skin was prevented, and the thermometer was used in a protective cover.
219718360|NCT07125690|OTHER|oral sucrose|In accordance with the Neonatal Pain and Treatment Guidelines, a total of 1 ml of sucrose at a 24% concentration recommended for full-term infants was prepared in a syringe. It was administered to the anterior tongue 2 minutes before the heel prick
219718361|NCT07125690|OTHER|mixed group|Newborns included in the combined intervention group received local dry heat with a thermometer heated with water at 40-45˚C 5 minutes before blood collection, with the infant in the supine position. At the third minute of the local heating, 1 ml of 24% sucrose was applied to the anterior tongue over 1 minute. A stopwatch was used to monitor the procedure times.
219718362|NCT07124143|OTHER|PRP|venous blood will be drawn postoperatively and sent to Erciyes University Medical Faculty laboratories for PRP preparation. PRP will be centrifuged according to the manufacturer's specifications, transferred to sterile eye drop bottles, and given to the patients for application. Since PRP maintains its efficacy for seven days, a second blood draw and PRP preparation will be conducted during the first-week follow-up.
219718363|NCT07124143|OTHER|Placebo|Patients will be provided with sterile eye drop bottles containing physiological saline and instructed to apply 3-4 drops to the wound site four times a day for 14 days.
219718364|NCT07125287|BEHAVIORAL|Exposure based CBT|This intervention is an exposure-based CBT program developed for children with blood-injection-injury (BII) phobia and a co-occurring somatic illness. The treatment includes a structured home training kit with medical materials (e.g., syringes, swabs) related to the child's fear, enabling frequent and realistic exposure exercises at home between sessions, guided by parents. This allows for higher treatment intensity and continuity. The intervention is tailored to children who require regular medical procedures and whose phobia interferes with essential care. Unlike previous studies, this model integrates both clinical sessions and structured home practice to increase adherence and reduce fear in medical settings.
219718365|NCT07125170|DEVICE|Kinesix XR on Meta Quest 3|Participants receive cognitive rehabilitation using immersive virtual reality through the Meta Quest 3 headset and the Kinesix XR application. Each session lasts one hour, with the first 30 minutes involving VR-based tasks guided by an occupational therapist. The intervention consists of a total of ten sessions, delivered two to three times per week. The VR component is integrated into the standard outpatient cognitive rehabilitation program. The study aims to evaluate the feasibility, safety, and acceptability of using this device during therapy.
219718366|NCT07124000|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan monotherapy
219718367|NCT07125352|OTHER|neutrophil lymphocyte ratio in COPD patients|Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients
219141851|NCT04426045|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
219141852|NCT06147245|BEHAVIORAL|Person-centred culturally sensitive course of treatment|12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
219141853|NCT06023186|DRUG|mavacamten|Study participants will receive mavacamten under the standard of care
219229875|NCT01827982|DRUG|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
219552536|NCT02606032|DRUG|Terbinafine|active comparator
219552537|NCT02606032|DRUG|Placebo|identical placebos to all antibiotics
219552538|NCT00835588|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
219552539|NCT00835588|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
219718368|NCT07124156|BIOLOGICAL|SUM-101|Once randomised to either the SUM-101 or the rabies control vaccine, the participant will always receive the same dose of the same compound (150 µg MSP1 protein dissolved in 0.9% NaCl with 250 µl (5µg) of adjuvant GLA-SE and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
219718369|NCT07124156|OTHER|CHMI|"Experimental intervention: The participants will receive a target dose of 2,800 viable intraerythrocytic P. falciparum 3D7 parasites, in a volume of 2 mL injectable saline. The erythrocytes will be thawed, resuspended and viability will be calculated. The total erythrocyte number will be between \~3.9×106 and \~5.2×108 (average: \~4.55×108) per dose with ≥80% (\~3.64×108) P. falciparum ring-stage parasites and around 34% (\~1.24×108) viability. This number of viable P. falciparum ring-stage parasites will be diluted to establish 2800 per syringe that will be administered. Challenge dose will be administered to all volunteers as an intravenous injection at the clinical site following instructions in an established SOP. The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis.~The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis. No dose adjustments are foreseen. As described in the protocol"
219141854|NCT05384132|OTHER|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
219141855|NCT05384132|OTHER|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
219141856|NCT01343342|DIETARY_SUPPLEMENT|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
219141857|NCT05062577|DRUG|ASP8062|oral
219141858|NCT05062577|DRUG|Placebo ASP8062|oral
219141859|NCT05062577|DRUG|buprenorphine/naloxone|sublingual
219141860|NCT05638945|BEHAVIORAL|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
219141861|NCT05175248|BEHAVIORAL|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
219141862|NCT00391755|DRUG|ramelteon|"1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary"
219141863|NCT00732953|DEVICE|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
219141864|NCT00732953|DEVICE|Genous stent implantation|Genous stent implantation
219141865|NCT03356132|DEVICE|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
219141866|NCT03356132|DEVICE|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
219229876|NCT01827982|DRUG|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
219552540|NCT02382224|BEHAVIORAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
219552541|NCT02382224|BEHAVIORAL|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
219141867|NCT04470193|OTHER|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
219141868|NCT04663802|BEHAVIORAL|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
219141869|NCT04663802|BEHAVIORAL|Physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
219141870|NCT04663802|BEHAVIORAL|Respiratory therapist (RT)-targeted accountable justification|If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
219141871|NCT05829681|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
219141872|NCT04443153|DEVICE|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
219141873|NCT04443153|DEVICE|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
219141874|NCT04443153|DEVICE|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
219141875|NCT04518930|OTHER|Peanuts or plain Greek yogurt|Two different types of dietary snacks
219141876|NCT04004000|DRUG|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
219141877|NCT03035045|DRUG|Paracetamol|
219141878|NCT03035045|DRUG|Placebo Oral Tablet|
219141879|NCT02781584|DRUG|SEL|Administered orally once daily
219141880|NCT02781584|DRUG|FIR|Administered orally once daily
219141881|NCT02781584|DRUG|CILO|Administered orally once daily
219141882|NCT02781584|DRUG|FENO|Administered orally once daily
219141883|NCT02781584|DRUG|VAS|Administered orally two times daily
219229877|NCT01827982|DRUG|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
219141884|NCT06414382|OTHER|Tape-stripping|22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
219141885|NCT04743128|BEHAVIORAL|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
219141886|NCT02767219|DRUG|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
219141887|NCT02767219|DRUG|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
219141888|NCT02767219|DRUG|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
219141889|NCT02200341|BEHAVIORAL|MBCT|
219141890|NCT02200341|BEHAVIORAL|PRT-PsyEd|
219229878|NCT01827982|DRUG|Placebo|Matching placebo will be given as a single oral dose.
219229879|NCT05137600|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
219229880|NCT05137600|DRUG|Midazolam|Midazolam is a sensitive CYP3A index substrate
219229881|NCT05137600|DRUG|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
219229882|NCT01042184|DRUG|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
219229883|NCT01042184|DRUG|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
219229884|NCT01042184|DRUG|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
219229885|NCT01472406|DEVICE|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
219229886|NCT01472406|DEVICE|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
219229887|NCT01472406|DEVICE|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
219229888|NCT01472406|DEVICE|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
219229889|NCT01472406|DEVICE|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
219718370|NCT07124156|BIOLOGICAL|Verorab®|Once randomised the participant will receive the or Verorab® and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
219718371|NCT01253486|BEHAVIORAL|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
219718372|NCT01253486|BEHAVIORAL|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
219141891|NCT03776890|BEHAVIORAL|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
219141892|NCT02006017|OTHER|Evidence summary alone plus a recommendation|
219141893|NCT02006017|OTHER|Evidence summary alone|
219141894|NCT04441242|OTHER|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
219141895|NCT04441242|OTHER|Low lighting|Use of low lighting (\<75 lux) in endoscopy room.
219229890|NCT02457806|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
219229891|NCT02457806|DRUG|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
219229892|NCT05913349|BEHAVIORAL|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
219229893|NCT06272032|PROCEDURE|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
219229894|NCT06272032|DRUG|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
219141896|NCT03517579|DEVICE|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
219141897|NCT00191035|DRUG|Atomoxetine|
219229895|NCT03186248|PROCEDURE|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
219229896|NCT04851665|OTHER|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
219718373|NCT01253486|BEHAVIORAL|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
219718374|NCT01267032|BEHAVIORAL|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
219141898|NCT01761396|BEHAVIORAL|CBT|
219141899|NCT01761396|BEHAVIORAL|UC|
219718375|NCT01267032|BEHAVIORAL|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
219718376|NCT01267032|BEHAVIORAL|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
219718377|NCT02583269|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis|Correlative studies
219718378|NCT02583269|DRUG|Muscadine Grape Skin Extract|Given PO
219718379|NCT02583269|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219718380|NCT04503005|OTHER|Time Restricted Eating|Effect of 16, 14 or 12 hours of daily fasting
219718381|NCT02402751|PROCEDURE|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
219141900|NCT06306365|BEHAVIORAL|Modern board game-based learning|Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
219141901|NCT04561037|DEVICE|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
219141902|NCT04561037|OTHER|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
219141903|NCT01778712|BEHAVIORAL|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
219718382|NCT02402751|DEVICE|MRI|
219718383|NCT02172547|DRUG|Spiriva|
219718384|NCT02812043|DEVICE|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
219141904|NCT05019729|DRUG|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
219141905|NCT05019729|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
219141906|NCT00612001|BIOLOGICAL|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
219141907|NCT03313128|OTHER|Sanitation|Improved sanitation facility
219141908|NCT06028451|OTHER|Record the information data|Record the information data
219141909|NCT00185016|BEHAVIORAL|a training to improve recognition of partner abuse.|
219141910|NCT02824094|DRUG|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
219141911|NCT00839540|DRUG|micafungin|100 mg qd by slow IV infusion for 24 h
219141912|NCT00839540|DRUG|Micafungin|200 mg qd by slow IV infusion for 24 h
219229897|NCT03681366|DEVICE|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
219718385|NCT02812043|DRUG|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
219718386|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
219718387|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
219718388|NCT02677389|OTHER|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
219718389|NCT02677389|OTHER|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
219718390|NCT02677389|DEVICE|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
219141913|NCT00839540|DRUG|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
219141914|NCT00032799|DRUG|natalizumab|
219229898|NCT02334215|DRUG|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
219229899|NCT02334215|BEHAVIORAL|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
219718391|NCT02677389|OTHER|Quality-of-Life Assessment|Ancillary studies
219718392|NCT02677389|OTHER|Questionnaire Administration|Ancillary studies
219718393|NCT04910464|DRUG|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
219718394|NCT04910464|OTHER|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
219718395|NCT06982508|DRUG|Obicetrapib 10mg|Active Drug
219718396|NCT06982508|DRUG|Placebo|Placebo Control
219141915|NCT04402320|DRUG|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
219141916|NCT04402320|DEVICE|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
219141917|NCT00299741|DRUG|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
219141918|NCT05311319|DRUG|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
219141919|NCT06369090|DEVICE|Electrical impedance tomography (EIT)|Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
219141920|NCT01326988|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
219141921|NCT06031350|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
219141922|NCT02885350|DRUG|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
219141923|NCT02885350|DRUG|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
219141924|NCT05632731|PROCEDURE|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
219141925|NCT05016713|COMBINATION_PRODUCT|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
219141926|NCT05016713|DEVICE|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
219141927|NCT05016713|OTHER|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
219141928|NCT04279171|DIAGNOSTIC_TEST|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 7/32
219141929|NCT04279171|DIAGNOSTIC_TEST|DES dissociation scale|Screening for dissociative symptoms
219229900|NCT02334215|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
219229901|NCT05324085|BEHAVIORAL|High-intensity interval training|Supervised exercise intervention, three times a week for eight weeks.
219141930|NCT04279171|DIAGNOSTIC_TEST|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
219141931|NCT04279171|DIAGNOSTIC_TEST|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
219141932|NCT01638884|BEHAVIORAL|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
219141933|NCT01638884|OTHER|Structural MRI|to compare differences between each populations
219141934|NCT01638884|OTHER|Functional MRI|to compare differences between each populations
219229902|NCT05324085|BEHAVIORAL|Treatment as usual|The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
219552542|NCT04563481|OTHER|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
219552543|NCT04563481|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
219552544|NCT00295490|DRUG|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
219552545|NCT00295490|DRUG|Placebo|Placebo has same dosing freq as for active intervention and for same time period
219552546|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
219718398|NCT06396416|DRUG|Semaglutide|Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
219718399|NCT06396416|BEHAVIORAL|Virtual Weight Management Coaching|Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
219141935|NCT01638884|OTHER|Virtual reality / Memory assessment|to compare differences between each populations
219141936|NCT05969665|DEVICE|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
219718400|NCT06989814|DIAGNOSTIC_TEST|Blood Product|An (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.
219718401|NCT00514254|OTHER|questionnaire administration|
219718402|NCT00514254|OTHER|study of socioeconomic and demographic variables|
219718403|NCT00514254|PROCEDURE|evaluation of cancer risk factors|
219718404|NCT06993363|OTHER|Quadriceps Strengthening|"Static Quad Pull the toes up towards your shin, push your knee into the bed to tighten the quad muscles. This should cause your heel to slightly lift off the bed. Hold for 7 seconds. Repeat on affected leg.~Straight leg raising~* Lie on back with hips square and legs laid out comfortably on the floor~* Bend the knee of non-injured leg at a 90-degree angle, planting the foot flatly on the floor.~* Stabilize the muscles on your straight leg by contracting your quadriceps (the group of muscles on the front of your thigh).~* Inhaling slowly, lift the straight leg six inches off the ground.~* Hold for three seconds.~* Exhaling slowly, lower the leg to the floor with control~* Relax and repeat 10 times more."
219718405|NCT06993363|OTHER|Hamstring and calf stretching exercise|"Hamstring stretching exercise will be done in the long sitting position. The patient will be instructed to keep his affected knee always extended while folding the other leg to the side then he will bend his trunk forward as much as he could in order to touch his toes by his fingers.~Calf muscle stretching: The patient will be positioned in the long-sitting with the knees extended. The patient will be instructed to pull his foot into dorsiflexion as much as he could with the assistance of a rolled towel holding this position for 30 seconds (Fig14). The patient will then be instructed to go back to starting position and relax for 30 seconds. This exercise will be done 5 times per session."
219141937|NCT05969665|DEVICE|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
219141938|NCT03773120|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
219141939|NCT02770430|BIOLOGICAL|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
219141940|NCT02770430|DRUG|conventional treatment|"1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
219141941|NCT04304859|DIAGNOSTIC_TEST|BASIC|Validation
219141942|NCT01551433|DEVICE|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
219141943|NCT02398565|OTHER|No intervention|
219141944|NCT01972763|DRUG|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
219718406|NCT06993363|OTHER|Kinesotaping application|"1 full 25cm strip of KT Tape cut in half. Apply one hour before beginning activity. Clean dirt, oils and lotions from area. After application rub tape vigorously to activate adhesive. Bend the knee at a 90 degree angle Anchor the middle of a half strip of tape diagonally over the point of pain with 80% stretch. Apply ends of tape without stretch.~Anchor the middle of a second half strip across the first strip to form an X pattern over the point of pain with 80% stretch."
219718407|NCT04960566|OTHER|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
219718408|NCT04960566|OTHER|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
219229903|NCT03182816|BIOLOGICAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
219229904|NCT07011862|BEHAVIORAL|Cancer, Older adults, Balance and Resistance Activities|The COBRA intervention is delivered as a web-based application through an iPad configured to allow access only to the study application and Zoom videoconferencing icons during the trial.
219141945|NCT00361283|DRUG|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
219141946|NCT03399968|DEVICE|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
219141947|NCT03399968|DEVICE|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
219141948|NCT00459758|DEVICE|Hans unit|
219141949|NCT03356444|DRUG|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
219141950|NCT03356444|DRUG|Docetaxel|"Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
219141951|NCT04446689|BEHAVIORAL|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
219141952|NCT03201614|DEVICE|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
219141953|NCT03201614|DEVICE|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
219141954|NCT03201614|DRUG|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
219141955|NCT05931107|OTHER|Stress ball practice group (Stress ball squeezing)|The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
219229905|NCT07013448|OTHER|Foot scan|This does not constitute a intervention but all participants will undergo image scans of their ulcer
219229906|NCT07014189|DRUG|Neviparine (NVP)/ Lamivudine (3TC)|Treatment with nevirapine (400mg retard) and lamivudine (300mg) once daily
219229907|NCT07013695|DEVICE|Virtual reality headset|Patients in the intervention group receive a virtual reality session with a hypnotic purpose during surgery under regional anesthesia. The device consists of a virtual reality headset providing visual and auditory immersion in a calming environment, freely chosen by the patient. The session begins before the regional anesthesia is administered and may continue throughout the entire surgical procedure
219229908|NCT07013695|OTHER|Standard Care (in control arm)|Participants in this group receive standard anesthetic and surgical care without the use of virtual reality
219229909|NCT07012720|DIAGNOSTIC_TEST|Single-cell sequencing and spatial transcriptome|Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.
219229910|NCT02359565|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219229911|NCT02359565|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo standard MRI
219229912|NCT02359565|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
219229913|NCT02359565|PROCEDURE|Diffusion Weighted Imaging|Undergo MR diffusion imaging
219229914|NCT02359565|PROCEDURE|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
219141956|NCT03031444|DRUG|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
219552547|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
219552548|NCT01662050|DRUG|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
219552549|NCT04254315|BEHAVIORAL|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
219718409|NCT06672185|DRUG|ARC101|ARC101 will be administered according to an assigned dose schedule.
219141957|NCT03031444|DRUG|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
219141958|NCT00038103|DRUG|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
219141959|NCT00038103|DRUG|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
219141960|NCT06426303|DRUG|Naltrexone|12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
219141961|NCT06041087|BEHAVIORAL|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
219141962|NCT06041087|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
219141963|NCT06041087|DIETARY_SUPPLEMENT|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
219141964|NCT06041087|DIETARY_SUPPLEMENT|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
219141965|NCT06041087|DIETARY_SUPPLEMENT|Water|500ml consumed immediately after exercise and 1h after exercise.
219141966|NCT01569906|RADIATION|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
219141967|NCT00117364|DRUG|SACCHACHITIN patch|
219141968|NCT00719823|DRUG|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
219141969|NCT06266858|OTHER|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
219141970|NCT06266858|DIAGNOSTIC_TEST|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
219141971|NCT06266858|DIAGNOSTIC_TEST|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
219141972|NCT06266858|OTHER|fasting|At the beginning of the study, the patients need to fast when receive UCG.
219141973|NCT04593797|DIAGNOSTIC_TEST|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
219141974|NCT03658499|BEHAVIORAL|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
219141975|NCT03658499|BEHAVIORAL|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
219141976|NCT01159249|DRUG|Vildagliptin|
219141977|NCT03849716|OTHER|Blood sample|Blood samples obtained for biomarker analyses
219141978|NCT03849716|OTHER|Cheek swab|Cheek swab obtained for genetic analysis
219141979|NCT06159127|BEHAVIORAL|SMART@Home|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
219141980|NCT05208359|BEHAVIORAL|Supporting Transition Resilience Of Newcomer Groups (STRONG)|10 group sessions that offer skills, strengths, support, and affirmation for newcomer youth
219141981|NCT05147233|DRUG|OCS-01|Dexamethasone ophthalmic suspension, 1.5%
219141982|NCT05147233|DRUG|Vehicle|Vehicle
219141983|NCT05828550|DIAGNOSTIC_TEST|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
219141984|NCT06964282|PROCEDURE|PENG Block|Also performed under ultrasound guidance with an 80 mm B-Braun X360 needle and a 3-5 MHz curved probe. The femoral nerve, femoral artery, iliopsoas muscle, and pubic ramus are identified. The needle is inserted in-plane, and 14 ml of ropivacaine 3.75 mg/ml is injected between the psoas tendon and pubic ramus.
219141985|NCT06964282|PROCEDURE|Iliopsoas nerve block|Performed under ultrasound guidance with a curvilinear probe (5-2 MHz). The transducer is positioned transversely below the anterior superior iliac spine (ASIS), then pivoted medially. After identifying the femoral head and acetabular rim, a 22G 80 mm needle is inserted in-plane to reach the iliopsoas plane, lateral to the iliopsoas tendon. 7 ml of ropivacaine 7.5 mg/ml is then injected.
219718410|NCT06280677|OTHER|AURORA-Donor|Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.
219141986|NCT04670822|BEHAVIORAL|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
219141987|NCT04670822|BEHAVIORAL|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
219141988|NCT06154265|DEVICE|TEE probe|Transesophageal echocardiography, ultrasound probe
219141989|NCT04225403|BEHAVIORAL|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
219141990|NCT06953180|OTHER|Genetic: DNA analysis|Investigation of telomere length (TL) and DNA methylation level analysis
219141991|NCT06434389|DIAGNOSTIC_TEST|the Electrochemical-based device|Electrochemical-based device for rapid detection of fibrinogen is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.
219141992|NCT04517864|DRUG|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
219141993|NCT04517864|DRUG|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
219141994|NCT04662710|BIOLOGICAL|Pembrolizumab|400 mg Q6W by IV infusion
219141995|NCT04662710|BIOLOGICAL|Lenvatinib|Administered PO QD, 8 mg induction/20 mg consolidation.
219141996|NCT04662710|DRUG|Oxaliplatin|130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
219141997|NCT04662710|DRUG|Capecitabine|1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
219141998|NCT04662710|DRUG|Leucovorin (or Levoleucovorin)|Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
219141999|NCT04662710|DRUG|5-FU|400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
219142000|NCT02201043|DRUG|Thalidomide 150mg|
219142001|NCT02201043|DRUG|Thalidomide 100mg|
219142002|NCT02201043|DRUG|Placebo|
219142003|NCT04323202|DRUG|Pembrolizumab|Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)
219142004|NCT04323202|OTHER|Tissue collection|Non-marginal tissue as well as pre-op biopsy tissue to be stored
219142005|NCT06013514|DEVICE|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
219142006|NCT05260359|DRUG|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
219142007|NCT05260359|DRUG|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
219718411|NCT06673979|DIAGNOSTIC_TEST|Numeric Rating Scale|The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).
219718412|NCT06669351|DRUG|ZX-7101A|On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
219718413|NCT06669351|OTHER|Placebo for ZX-7101A tablet|"Placebo for ZX-7101A tablet:~The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water."
219142008|NCT05260359|OTHER|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
219142009|NCT05260359|OTHER|Petrolatum vehicle|SU-E-101413-83
219142010|NCT05260359|OTHER|0.9% Saline|low irritancy control
219142011|NCT05260359|OTHER|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
219142012|NCT05260359|OTHER|Undosed patch|negative control
219142013|NCT04722003|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
219142014|NCT04722003|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
219142015|NCT03255928|DIAGNOSTIC_TEST|PAS assay, TGT|Evaluation of platelet function
219142016|NCT02703623|DRUG|Abiraterone Acetate|Given PO
219142017|NCT02703623|DRUG|Apalutamide|Given PO
219718414|NCT06669351|DRUG|Oseltamivir phosphate dry suspension|"Drug: Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
219718415|NCT06669351|OTHER|Placebo for Oseltamivir phosphate dry suspension:|"Drug: Placebo for Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
219142018|NCT02703623|DRUG|Cabazitaxel|Given IV
219142019|NCT02703623|DRUG|Carboplatin|Given IV
219142020|NCT02703623|BIOLOGICAL|Ipilimumab|Given IV
219142021|NCT02703623|OTHER|Laboratory Biomarker Analysis|Correlative studies
219142022|NCT02703623|DRUG|Prednisone|Given PO
219229915|NCT02359565|PROCEDURE|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
219229916|NCT02359565|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
219229917|NCT02359565|BIOLOGICAL|Pembrolizumab|Given IV
219142023|NCT04246177|DRUG|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
219142024|NCT04246177|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
219142025|NCT04246177|DRUG|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
219142026|NCT04246177|DRUG|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
219142027|NCT04246177|PROCEDURE|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
219142028|NCT05520658|DRUG|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
219142029|NCT05520658|DRUG|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
219142030|NCT06139315|DRUG|BI 765845|BI 765845
219142031|NCT06139315|DRUG|Placebo|Placebo
219142032|NCT03883542|GENETIC|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
219142033|NCT06795763|DEVICE|CTO-PCI Procedure with Acolyte Catheter System|Acolyte Catheter System is used to facilitate placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions with persistent symptoms following medical therapy. The device provides real-time visualization of a coronary chronic total occlusion allowing for guidewire placement in the true lumen of the target vessel and subsequent revascularization.
219142034|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
219142035|NCT02301559|BEHAVIORAL|Pilates exercises|Pilates exercises with emphasis on pelvic region
219142036|NCT01049503|OTHER|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
219142037|NCT00726596|DRUG|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
219142038|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
219142039|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
219142040|NCT05966350|OTHER|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
219142041|NCT05966350|OTHER|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
219142042|NCT05966350|OTHER|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
219229918|NCT07014124|BEHAVIORAL|Nicotine Replacement Therapy (NRT) Sampling|Participants will be advised to choose the NRT according to their preferences and daily cigarette consumption. Cigarette consumption of ≤20 daily will receive the 14mg patch or 2mg gum and participants consume \>20 cigarettes daily will receive the 21mg patch. An NRT use card (Appendix 6 draft) containing the instructions and potential side effects were given with a brief oral explanation. Full course of pharmacological treatment for 12-week are available in smoking cessation services. Participants requesting for additional or full course of NRT will be actively refer to the respective services as part of the Referral step in the AWARD model (Ask, Warn, Advise, Refer, and Do-it-again).
219552550|NCT01167439|PROCEDURE|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
219552551|NCT05054777|PROCEDURE|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
219552552|NCT05054777|PROCEDURE|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
219552553|NCT06301386|DRUG|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
219552554|NCT06301386|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
219552555|NCT06422286|DEVICE|low-level laser|children will be allocated to the device then the gag reflex will be re-evaluated
219142043|NCT02952209|DEVICE|Xenograft|
219142044|NCT02370758|DRUG|Valganciclovir or Ganciclovir|
219142045|NCT02036307|DIETARY_SUPPLEMENT|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
219142046|NCT02036307|DIETARY_SUPPLEMENT|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
219142047|NCT04591067|OTHER|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)"
219142048|NCT04191954|DRUG|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
219142049|NCT04191954|DRUG|receive artificial tears drop|receive artificial tears drop with the same frequency
219142050|NCT05747313|DRUG|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
219142051|NCT06203197|OTHER|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
219142052|NCT02974634|OTHER|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
219142053|NCT00881842|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
219142054|NCT05603013|DRUG|Vinorelbine|Vinorelbine Tartrate Oral
219142055|NCT05603013|RADIATION|Radiotherapy|hypofractionated radiotherapy
219142056|NCT05603013|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
219142057|NCT05603013|DRUG|GM-CSF|GM-CSF subcutaneous injection
219142058|NCT05603013|DRUG|IL-2|IL-2 subcutaneous injection
219142059|NCT02645006|BEHAVIORAL|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
219142060|NCT02645006|BEHAVIORAL|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
219142061|NCT02067949|DRUG|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
219142062|NCT01263002|DRUG|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~4. During treatment period, composite virological response : stop the medication and F/U for 2 years~5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.~   * complete virological response: HBV DNA \< 60 IU/ml~  * virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
219142063|NCT02743078|DRUG|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
219142064|NCT02743078|DEVICE|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
219142065|NCT04233632|DEVICE|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
219142066|NCT04233632|DEVICE|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
219142067|NCT04233632|DEVICE|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
219142068|NCT01399671|OTHER|vestibular stimulation|vestibular stimulation
219552556|NCT06422286|BIOLOGICAL|microcurrent stimulation|children will be allocated to the device then the gag reflex will be re-evaluated
219142069|NCT01985269|OTHER|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
219142070|NCT02002052|DRUG|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
219142071|NCT02002052|RADIATION|Standard Radiotherapy, 60 Gy in 30 fractions.|
219142072|NCT02002052|RADIATION|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
219142073|NCT02444130|DEVICE|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
219142074|NCT04308330|DRUG|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
219142075|NCT05791448|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219142076|NCT05791448|PROCEDURE|Computed Tomography|Undergo CT scan
219229919|NCT07014124|BEHAVIORAL|mHealth-based motivational counselling|The mHealth intervention will be delivered via the most popular instant messaging app in Hong Kong (WhatsApp). A total of 24 messages with contents including the harms of smoking and smoke exposure for children, encouragement, benefits of quitting for children, methods of quitting, dealing with craving, and measures to reduce cigarette smoke exposure at home will be provided. The messages will be scheduled in a tapering schedule that participants will receive 5 messages in the first week, then cut down to 3 messages/week for the next 4 weeks and 1 message/week for the last 7 weeks. Using a more personalized approach, the messages will be tailored to the participants' motivation, intention to quit and other quitting patterns collected at baseline. Real-time conversations could be initiated by participants themselves, triggered by regular messages, or through prompt inquires (e.g., asking about the quitting progress).
219552557|NCT06422286|DEVICE|placebo|children will be allocated to a deactivated meridian pen
219552558|NCT03181386|DRUG|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
219142077|NCT05791448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219142078|NCT05791448|DRUG|RNA Transcription Modulator AU-409|Given PO
219142079|NCT04123132|OTHER|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
219142080|NCT05304663|DRUG|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
219142081|NCT05304663|DRUG|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
219552559|NCT03181386|DRUG|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
219552560|NCT03181386|DRUG|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
219552561|NCT03472196|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
219552562|NCT01307358|OTHER|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
219552563|NCT01617096|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
219552564|NCT01617096|COMBINATION_PRODUCT|Placebo Ring|Vaginal ring containing no drug substance
219552565|NCT06347627|BEHAVIORAL|Group 1 (I x S x S x F)|Experimental message: Individual x Safety x Storytelling x Factual
219552566|NCT06347627|BEHAVIORAL|Group 2 (O x S x S x F)|Experimental message: Organization x Safety x Storytelling x Factual
219552567|NCT06347627|BEHAVIORAL|Group 3 (I x E x S x F)|Experimental message: Individual x Effectiveness x Storytelling x Factual
219552568|NCT06347627|BEHAVIORAL|Group 4 (O x E x S x F)|Experimental message: Organization x Effectiveness x Storytelling x Factual
219552569|NCT06347627|BEHAVIORAL|Group 5 (I x S x S x M)|Experimental message: Individual x Safety x Storytelling x Misinformation
219552570|NCT06347627|BEHAVIORAL|Group 6 (O x S x S x M)|Experimental message: Organization x Safety x Storytelling x Misinformation
219552571|NCT06347627|BEHAVIORAL|Group 7 (I x E x S x M)|Experimental message: Individual x Effectiveness x Storytelling x Misinformation
219552572|NCT06347627|BEHAVIORAL|Group 8 (O x E x S x M)|Experimental message: Organization x Effectiveness x Storytelling x Misinformation
219552573|NCT06347627|BEHAVIORAL|Group 9 (I x S x D x F)|Experimental message: Individual x Safety x Scientific data x Factual
219552574|NCT06347627|BEHAVIORAL|Group 10 (O x S x D x F)|Experimental message: Organization x Safety x Scientific data x Factual
219552575|NCT06347627|BEHAVIORAL|Group 11 (I x E x D x F)|Experimental message: Individual x Effectiveness x Scientific data x Factual
219552576|NCT06347627|BEHAVIORAL|Group 12 (O x E x D x F)|Experimental message: Organization x Effectiveness x Scientific data x Factual
219142082|NCT02425449|DRUG|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
219142083|NCT02947217|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
219142084|NCT02947217|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
219142085|NCT04455516|PROCEDURE|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
219142086|NCT02962674|DEVICE|prostaFix System|
219142087|NCT05013606|DIETARY_SUPPLEMENT|Hydrogen water|This is an over the counter pill supplement that is dissolved in water.
219142088|NCT02091336|DRUG|Metformin|patients treatment
219142089|NCT02091336|DRUG|Glyburide|patients treatment
219142090|NCT04438668|DEVICE|Centaflow and Standard Care|The intervention is screening methods
219142091|NCT04438668|DIAGNOSTIC_TEST|Standard Care|The intervention is screening methods
219142092|NCT05250336|OTHER|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
219142093|NCT01299753|DRUG|placebo|identically packed placebo
219142094|NCT01299753|DRUG|propranolol|20-40 mg q6-8h
219142095|NCT00092781|DRUG|MK0663, etoricoxib|
219142096|NCT00092781|DRUG|Comparator: celecoxib|
219142097|NCT00364286|DRUG|Dasatinib (BMS-354825)|50mg Orally twice daily
219142098|NCT03780816|OTHER|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
219718416|NCT04620915|BEHAVIORAL|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
219718417|NCT04620915|BEHAVIORAL|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
219142099|NCT06030713|DRUG|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
219142100|NCT01061424|BEHAVIORAL|community health worker|community health worker provides home visits for education
219142101|NCT01061424|BEHAVIORAL|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
219142102|NCT04668742|DEVICE|DYNAtraq|Tracheostomy alignment with DYNAtraq
219142103|NCT01566708|BEHAVIORAL|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
219142104|NCT01566708|BEHAVIORAL|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
219142105|NCT01566708|BEHAVIORAL|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
219142106|NCT02577419|OTHER|Target Fortification|
219142107|NCT02577419|OTHER|Higher Initial Concentration|
219142108|NCT02577419|OTHER|Portagen Formula|
219142109|NCT04847219|DEVICE|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
219142110|NCT04847219|DEVICE|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
219142111|NCT05339763|RADIATION|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
219142112|NCT02716220|DEVICE|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
219142113|NCT03703219|OTHER|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
219142114|NCT04292054|DRUG|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
219229920|NCT07014124|BEHAVIORAL|Brief cessation advice and self-help material|At baseline, participants will receive brief face-to-face advice on quitting smoking for the health of the children using the validated AWARD model (Ask, Warn, Advise, Refer, Do-it-again) with a print-based self-help material providing detailed information on health hazards of SHS exposure on children, methods to deal with craving and withdrawal symptoms, and measures on preventing SHS exposure for children at home.
219229921|NCT07013552|DRUG|Administration of a single or repeated dose of a long half-life antibiotic - oritavancin|"Intravenous administration of a single or repeated dose of lipoglycopeptide antibiotic - oritavancin.~In superficial ABSSSI or PI: Single dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution.~In LRIE: First dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution, subsequent doses of 800 mg (2 vials) administered as a 2-3 hour intravenous infusion at 7-day intervals, to achieve the required duration of drug therapy of 2-6 weeks (counted from the day of transvenous lead extraction)."
219229922|NCT07013552|DRUG|Administration of a repeated dose of a short half-life antibiotic - vancomycin|"Intravenous administration of repeated doses of glycopeptide antibiotic - vancomycin.~Repeated doses of 15-20 mg/kg body weight every 8-12 hours administered as an hourly intravenous infusion in 0.9% sodium chloride solution, under monitoring the drug concentration in serum, for 7-10 days in ABSSSI, for 10-14 days in PI, and for 2-6 weeks in LRIE (counted from the day of transvenous lead extraction)."
219229923|NCT06869915|DIAGNOSTIC_TEST|Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).|This study is an observational prospective multi-centric non interventional study. The focus of the study is a homeless population sheltered in accommodation and social rehabilitation centres. The prevalence of neurodevelopmental disorders in this population will be studied.
219229924|NCT06874504|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
219229925|NCT03731221|DRUG|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
219229926|NCT03731221|DRUG|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
219229927|NCT03778554|DRUG|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
219229928|NCT03778554|DRUG|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
219229929|NCT03778554|DRUG|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
219142115|NCT04292054|OTHER|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
219142116|NCT04707430|OTHER|blood progesterone test|progesterone levels on blood sample
219142117|NCT06156319|OTHER|No intervention|No intervention
219142118|NCT03737682|DIAGNOSTIC_TEST|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
219142119|NCT02108106|DRUG|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
219142120|NCT02108106|DRUG|Placebo|
219142121|NCT05570188|BIOLOGICAL|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
219142122|NCT06376357|OTHER|Foot Massage with roller|The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
219142123|NCT01624844|OTHER|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
219142124|NCT05635604|DRUG|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
219142125|NCT05635604|DRUG|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
219142126|NCT06076980|DRUG|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
219142127|NCT06076980|DRUG|Normal saline|as placebo
219142128|NCT00014248|DRUG|adenosine triphosphate|
219142129|NCT00014248|PROCEDURE|quality-of-life assessment|
219142130|NCT02416076|DEVICE|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
219142131|NCT02416076|DEVICE|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
219142132|NCT03746665|BIOLOGICAL|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
219229930|NCT03778554|DRUG|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
219142133|NCT01124188|DRUG|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
219142134|NCT01124188|BEHAVIORAL|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
219229931|NCT07014306|DIAGNOSTIC_TEST|MRI|Cohort 2
219229932|NCT07014306|DIAGNOSTIC_TEST|Computed tomography|Quantitative computed tomography
219142135|NCT01124188|BEHAVIORAL|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
219142136|NCT02120599|DIETARY_SUPPLEMENT|ready-to-use supplementary food|
219142137|NCT02120599|DIETARY_SUPPLEMENT|corn-soy blend|
219142138|NCT02120599|DIETARY_SUPPLEMENT|iron|
219229933|NCT03905642|DRUG|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
219718418|NCT04620915|BEHAVIORAL|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
219142139|NCT02120599|DIETARY_SUPPLEMENT|folic acid|
219142140|NCT02120599|DIETARY_SUPPLEMENT|UNIMMAP|
219142141|NCT05640869|BEHAVIORAL|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
219142142|NCT03579368|DEVICE|Symfony implantation|Bilateral Symfony IOL Implantation
219142143|NCT01976936|DRUG|Low Dose Lovastatin|80 mg daily for 3 days
219142144|NCT01976936|OTHER|Placebo|Placebo for 3 days
219142145|NCT01976936|DRUG|High Dose Lovastatin|640 mg daily for 3 days
219142146|NCT01796782|DRUG|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
219142147|NCT01796782|DRUG|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
219229934|NCT07013097|DRUG|PG-033|Oral tablets (2mg， 10mg)
219142148|NCT00028769|DRUG|bicalutamide|
219142149|NCT00028769|DRUG|estramustine|
219142150|NCT00028769|DRUG|etoposide|
219142151|NCT00028769|DRUG|flutamide|
219142152|NCT00028769|DRUG|goserelin|
219142153|NCT00028769|DRUG|leuprolide|
219142154|NCT00028769|DRUG|nilutamide|
219142155|NCT00028769|DRUG|paclitaxel|
219142156|NCT05922215|OTHER|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
219229935|NCT07013097|DRUG|PG-033 placebo comparator|Oral tablets (2 mg, 10 mg) (matching corresponding study medication)
219229936|NCT07012551|PROCEDURE|Common iliac artery stenting|Stenting of common iliac artery by balloon mounted stent
219229937|NCT06223633|DEVICE|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
219229938|NCT06164743|DRUG|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
219229939|NCT06164743|DRUG|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
219229940|NCT06164743|DRUG|Vehicle|Topical ocular drug
219552577|NCT06347627|BEHAVIORAL|Group 13 (I x S x D x M)|Experimental message: Individual x Safety x Scientific data x Misinformation
219552578|NCT06347627|BEHAVIORAL|Group 14 (O x S x D x M)|Experimental message: Organization x Safety x Scientific data x Misinformation
219552579|NCT06347627|BEHAVIORAL|Group 15 (I x E x D x M)|Experimental message: Individual x Effectiveness x Scientific data x Misinformation
219552580|NCT06347627|BEHAVIORAL|Group 16 (O x E x D x M)|Experimental message: Organization x Effectiveness x Scientific data x Misinformation
219552581|NCT03612973|DIAGNOSTIC_TEST|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
219552582|NCT03612973|DIAGNOSTIC_TEST|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
219552583|NCT03612973|DIAGNOSTIC_TEST|fibro scan|liver stiffness by fibro scan before and after treatment
219552584|NCT01753362|DRUG|liraglutide|
219552585|NCT01753362|DRUG|placebo|
219718419|NCT04882709|DEVICE|Recording with hearing aid|Each participant will listen to sound samples via headphones. Sound samples have been recorded with a hearing aid that was set to each participant's individual hearing loss and different amplification strategies, and an unaided reference. Participants will be asked to rate different aspects of sound quality while listening to the different sound samples.
219142157|NCT05922215|OTHER|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
219142158|NCT01134562|DRUG|Placebo|Single IV injection.
219142159|NCT01134562|DRUG|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
219142160|NCT00357396|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
219142161|NCT00357396|DRUG|busulfan|
219142162|NCT00357396|DRUG|melphalan|
219718420|NCT07001384|DRUG|Alectinib|All patients will receive a lead-in cycle (28 days) of alectinib.
219718421|NCT07001384|DRUG|Duvelisib|After the lead-in cycle of alectinib, in the absence of progressive disease as assessed by PET/CT scan, all patients will then receive two 28-day cycles of alectinib plus duvelisib.
219142163|NCT00357396|DRUG|thiotepa|
219142164|NCT00357396|PROCEDURE|allogeneic bone marrow transplantation|
219142165|NCT00357396|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219142166|NCT00357396|PROCEDURE|peripheral blood stem cell transplantation|
219142167|NCT02496702|DEVICE|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
219142168|NCT02152813|BEHAVIORAL|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
219142169|NCT01291290|PROCEDURE|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
219229941|NCT06698354|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.
219229942|NCT06698354|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
219552586|NCT03921762|PROCEDURE|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
219718422|NCT07009288|OTHER|Children's Oncology Group Heart Health Link|Educational materials on healthy lifestyle behaviors.
219718423|NCT07009288|OTHER|Monthly weights|Weight (kg): measured remotely via Withings Body + scale, Height, weight, waist circumference, BP, and % body fat
219718424|NCT07009288|OTHER|Fasting|(14-hour fast x 2 weeks; 15-hour fast x- 1 week; 16-hour fast for the remainder of the active intervention)
219142170|NCT01086917|BIOLOGICAL|PfSPZ Challenge|each volunteer to receive a single dose
219142171|NCT01227278|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
219142172|NCT01227278|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
219142173|NCT00184041|DRUG|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
219142174|NCT03636919|OTHER|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
219142175|NCT04184336|OTHER|surveillance|
219142176|NCT05813899|DIETARY_SUPPLEMENT|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
219142177|NCT04035668|DRUG|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
219142178|NCT04035668|DRUG|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
219142179|NCT06552676|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
219552587|NCT03921762|PROCEDURE|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
219552588|NCT03892343|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
219552589|NCT03202927|DRUG|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
219552590|NCT03040895|OTHER|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
219552591|NCT03040895|OTHER|Treatment as usual|Treatment as usual through the data collection period (6 months)
219552592|NCT01826760|OTHER|Using training and testing groups to construct ANN based on laboratory tests|
219229943|NCT06699368|PROCEDURE|The ultra-high-power ablation group|The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
219229944|NCT06699368|PROCEDURE|The high-power ablation group|The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
219229945|NCT06699108|DRUG|VGR-R01|Subretinal injection of VGR-R01 (0.1 mL)
219229946|NCT07034365|OTHER|No intervention|No intervention
219229947|NCT06711640|DRUG|LUCEMYRA (lofexidine) tablets|Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.
219229948|NCT06716632|DEVICE|Using Ligasure for heamostasis|Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm.
219229949|NCT06716632|PROCEDURE|Use of conventional knot tying technique for heamostasis|Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers. While these techniques effectively control bleeding from vessels, they are time-consuming and carry the risk of harming adjacent structures like the recurrent and superior laryngeal nerves.
219229950|NCT06699173|OTHER|Heat ped|The hot ped was used during ricig cystoscopy
219229951|NCT06717165|COMBINATION_PRODUCT|ERP combined with high-definition active tACS|The active tACS +ERP referred to a period of tACS applied in the first 20 minutes of the ERP treatment (the tACS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tACS+ERP treatment. Based on the EEG parameters, individualized modeling was conducted to determine specific stimulation parameter schemes (stimulation frequency). Anode electrode will be localized in front of the mPFC on the Fz point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AFz, Fcz, F1, F2).
219229952|NCT06717165|COMBINATION_PRODUCT|ERP combined with sham tACS|Patients will get the same CBT setting as the active tACS group and they were applied the sham tACS cocurrently with ERP. The sham tACS device is the same as the active comparator's except that the sham tACS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tACS.
219229953|NCT07043244|BEHAVIORAL|virtual reality simulation|no description, work attempt completed
219229954|NCT06737809|DEVICE|IP Plasmafit® Revision cup (and stem) system|Revision total hip arthroplasty (THA) due to periprosthetic joint infection
219229955|NCT07098195|DEVICE|Coronary Stent|RisoR Crest Everolimus Eluting Coronary Stent System
219229956|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
219229957|NCT06952231|DRUG|Sitagliptin + Metformin|Self administration of Sitagliptin (as phosphate monohydrate) 50 mg twice daily plus metformin HCl 1000 mg twice daily
219229958|NCT06952231|DRUG|Empagliflozin + Metformin|Self administration of Empagliflozin 12.5 mg twice daily plus metformin HCl 1000 mg twice daily.
219718425|NCT07009288|OTHER|Calls|Month 1-3: Bi-weekly call using motivational interviewing Months 4-6: Monthly call using motivational interviewing Support via SMS text
219229959|NCT04596358|OTHER|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
219229960|NCT00000111|PROCEDURE|Oral mucosal graft|
219229961|NCT03477266|DRUG|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
219229962|NCT03477266|DRUG|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
219229963|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
219229964|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
219229965|NCT03769090|DRUG|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
219229966|NCT03030365|DEVICE|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
219229967|NCT00837291|DRUG|CF101|CF101 tablets 1 mg BID
219718426|NCT07009288|OTHER|Participant Questionnaires|Questions on worry, perceived self-efficacy, health beliefs and knowledge of late effects (adapted from EQUAL study), Behavioral Risk Factor Surveillance System, Physical Activity Questionnaire, Link to Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool with accompanying sleep module
219718427|NCT07009288|OTHER|Dried blood spot|Glucose, insulin, hemoglobin A1c, lipids. Measured remotely in the fasting state via dried blood spots in the participant's home.
219718428|NCT06615570|DRUG|VX-973|Suspension for oral administration.
219718429|NCT06615570|DRUG|Placebo|Suspension for oral administration.
219718430|NCT06072183|DRUG|Ritlecitinib|100mg Capsule
219718431|NCT06072183|DRUG|Ritlecitinib|50mg Capsule
219718432|NCT06072183|DRUG|Placebo|Matching capsule
219718433|NCT06622109|BIOLOGICAL|20-valent Pneumococcal Conjugate Vaccine|Injection in the muscle or subcutaneous , 1 dose 0.5mL
219142180|NCT05686434|DRUG|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
219142181|NCT05516004|DEVICE|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
219142182|NCT05673252|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
219142183|NCT05673252|PROCEDURE|biopsy|histopathology findings
219142184|NCT04675944|DRUG|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
219142185|NCT04675944|DRUG|treprostinil|1 mg (1 extended-release tablet), oral route
219142186|NCT01437358|OTHER|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
219142187|NCT04828642|DIETARY_SUPPLEMENT|Vitamin C and vitamin E|1000 mg 235 mg
219142188|NCT04828642|DIETARY_SUPPLEMENT|Placebo|Placebo
219142189|NCT01521013|BEHAVIORAL|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
219142190|NCT01521013|BEHAVIORAL|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
219142191|NCT00018226|BEHAVIORAL|Case Management|
219142192|NCT03396848|OTHER|SHAReClinic|Online clinic with educational modules
219142193|NCT00228007|DRUG|Antidepressant Medication|
219142194|NCT05222399|DRUG|LY3871801|Administered orally.
219142195|NCT00457769|DRUG|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
219142196|NCT00457769|DRUG|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
219142197|NCT00502736|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
219142198|NCT04700930|OTHER|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
219142199|NCT03696862|PROCEDURE|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
219142200|NCT03426228|DIAGNOSTIC_TEST|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~1. At baseline (second day of the menstrual period)~2. Triggering phase (post-egg retrieval procedure)~3. Embryo transfer phase (post-transfer procedure)~4. Week 4 (positive bHCG)~4\. Week 8 of pregnancy"
219142201|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
219229968|NCT00837291|DRUG|Placebo|Placebo tablets BID
219142202|NCT00516386|DRUG|RhIGF-1|35-40 mcg/k/dose twice daily SC
219142203|NCT05018325|PROCEDURE|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
219142204|NCT05018325|PROCEDURE|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
219142205|NCT05018325|PROCEDURE|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
219142206|NCT00006035|BIOLOGICAL|bleomycin sulfate|
219142207|NCT00006035|DRUG|electroporation therapy|
219142208|NCT06237751|DRUG|Sildenafil 100 MG|Sildenafil 100mg orally half an hour before surgery
219142209|NCT03231722|DRUG|Panitumumab|6 mg/kg iv over 60 minutes, day 1
219229969|NCT02806752|DRUG|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
219552593|NCT01485068|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
219552594|NCT04473326|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
219142210|NCT03231722|DRUG|Irinotecan|150 mg/sqm iv over 60 minutes day 1
219142211|NCT03231722|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
219142212|NCT03231722|DRUG|l-leucovorin|200 mg/sqm iv over 2 hours
219142213|NCT03231722|DRUG|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
219142214|NCT00553683|DRUG|cyclophosphamide|
219142215|NCT00553683|DRUG|poly ICLC|
219142216|NCT00553683|PROCEDURE|hepatic artery embolization|
219142217|NCT00553683|RADIATION|3-dimensional conformal radiation therapy|
219229970|NCT02806752|DRUG|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
219229971|NCT03054766|PROCEDURE|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
219229972|NCT03054766|DRUG|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
219229973|NCT00329914|DRUG|Progesterone|Vaginal pessaries, 200 mg/day
219229974|NCT00329914|DRUG|Placebo|Placebo pessaries containing peanut oil
219718434|NCT07008482|OTHER|Music intervention|patient enrolment, administration of the APAIS and NRS scales (T0), administration of the standard music therapy/assistance intervention (20 minutes duration), re-evaluation with re-administration of the APAIS and NRS scales (T1) and completion of the CRF. The administration will take place at the patient's bedside, respecting the privacy and confidentiality of the subjects involved, guaranteeing absolute tranquillity, also with the help of dividers to avoid distractions and interruptions.
219229975|NCT01921985|DRUG|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
219142218|NCT03789786|DIAGNOSTIC_TEST|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
219142219|NCT03789786|DIAGNOSTIC_TEST|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
219142220|NCT03789786|BEHAVIORAL|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
219142221|NCT00795054|OTHER|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
219142222|NCT00596609|DRUG|Intrathecal Morphine|"* In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
219142223|NCT04940117|DIETARY_SUPPLEMENT|Eefooton oral solution|Check eGFR value, liver and kidney function every month
219142224|NCT03411278|DEVICE|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
219142225|NCT00191412|DRUG|Pemetrexed|
219142226|NCT01149395|DRUG|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
219142227|NCT01376089|DRUG|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
219142228|NCT01376089|DRUG|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
219142229|NCT04827654|DIETARY_SUPPLEMENT|Weekly produce box and gift card|Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
219142230|NCT01354795|PROCEDURE|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
219142231|NCT01354795|PROCEDURE|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
219142232|NCT04484753|OTHER|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
219142233|NCT04484753|OTHER|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
219718435|NCT06987318|BIOLOGICAL|VRC07-523LS|Administered by Intravenous (IV) infusion at Week 0 and 12 weeks later
219718436|NCT06987318|BIOLOGICAL|PGT121.414.LS|Administered by IV infusion at Week 0
219142234|NCT04484753|BEHAVIORAL|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
219142235|NCT04484753|BEHAVIORAL|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
219142236|NCT00404417|DRUG|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
219142237|NCT00404417|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
219142238|NCT00404417|DRUG|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
219142239|NCT00404417|DRUG|Placebo / Placebo|Placebo at first injection / Placebo at second injection
219229976|NCT01921985|DRUG|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
219229977|NCT05636306|DRUG|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
219718437|NCT06880445|PROCEDURE|Povidone-Iodine (PVP-I)|The experimental group will use povidone-iodine for disinfection.
219142240|NCT03621826|OTHER|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
219142241|NCT00328731|PROCEDURE|Procedure|
219229978|NCT05636306|DRUG|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
219229979|NCT04808024|PROCEDURE|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
219718438|NCT06880445|PROCEDURE|Water|The control group will undergo perineal preparation using clean water
219229980|NCT03878394|OTHER|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
219229981|NCT03878394|OTHER|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
219229982|NCT05057819|DRUG|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
219229983|NCT05057819|DRUG|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
219229984|NCT01643122|OTHER|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
219229985|NCT01643122|OTHER|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
219229986|NCT00864188|DIETARY_SUPPLEMENT|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
219229987|NCT00864188|DIETARY_SUPPLEMENT|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
219229988|NCT00864188|DIETARY_SUPPLEMENT|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
219229989|NCT00864188|DIETARY_SUPPLEMENT|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
219229990|NCT00539604|PROCEDURE|MDCT and Coronary Angiography|
219229991|NCT04214093|DRUG|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
219229992|NCT01838707|DRUG|0.125% Bupivacaine HCL @ 4-5 ml/h|
219229993|NCT01838707|DRUG|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
219229994|NCT01838707|DRUG|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
219718439|NCT06674824|DEVICE|massimo|measure plethysmography variability index in patients on spontaneous trial planning for extubation and evaluate its sensitivity in relation to transthoracic echocardiographic velocity time integral in early detecting weaning induced pulmonary edema
219718440|NCT07009847|OTHER|Case control study of clinical malaria|Case control study of clinical malaria
219718441|NCT07009847|OTHER|Case control study of severe malaria|Case control study of severe malaria
219229995|NCT04845542|BEHAVIORAL|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
219229996|NCT04737993|DRUG|licocain|pulsed radiofrequency stimulation
219229997|NCT04737993|OTHER|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
219229998|NCT05201625|DIAGNOSTIC_TEST|real time PCR|real time PCR
219552595|NCT05535920|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
219552596|NCT00005873|DRUG|rubitecan|
219552597|NCT04233060|DRUG|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
219552598|NCT02840162|DRUG|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
219552599|NCT02840162|DRUG|Placebo|
219552600|NCT02611362|BEHAVIORAL|IMB Gaming Intervention|
219718442|NCT07009847|OTHER|Case control study of death (all cause)|Case control study of death (all cause)
219718443|NCT05635370|DRUG|Pentoxifylline|Pentoxifylline claim is used as the exposure group.
219718444|NCT05635370|DRUG|Cilostazol|Cilostazol claim is used as the reference group.
219718445|NCT06678022|DEVICE|No Drone delivery|Usual ART delivery to landing sites
219718446|NCT06678022|DEVICE|Fixed Wing drones|Last Mile fixed wing drone delivery
219718447|NCT06426498|DEVICE|Brainsonix Bx Pulsar machine tFUS|This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
219229999|NCT06306937|DIAGNOSTIC_TEST|Evalution of serum levels of vitamin D and IL8|"Group 1 (Periodontitis Group): The intervention involves observing and analyzing individuals diagnosed with periodontitis based on established clinical criteria. The focus is on assessing vitamin D and IL8 levels in the serum and correlating these levels with the severity of periodontitis, determined by clinical indices such as probing depth, clinical attachment loss, and bleeding on probing.~Group 2 (Control Group): The intervention involves observing and analyzing individuals without any signs or history of periodontal disease. The focus is on assessing vitamin D and IL8 levels in the serum for comparison with the periodontitis group. This group serves as the healthy control for the study."
219230000|NCT00001895|DRUG|FDG|
219230001|NCT00001895|DRUG|NH(3)|
219230002|NCT00055068|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219230003|NCT00055068|BEHAVIORAL|Relaxation Training|
219230004|NCT04634994|DRUG|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
219230005|NCT03062488|DRUG|IV acetaminophen|multi-modal analgesia with IV acetaminophen
219230006|NCT03062488|DRUG|Fentanyl|single modal analgesia
219552601|NCT01274143|BEHAVIORAL|TeleCARE|Personalized telephone-delivered cancer risk assessment.
219552602|NCT01274143|BEHAVIORAL|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
219142242|NCT03204968|DEVICE|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
219142243|NCT05489536|BEHAVIORAL|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
219142244|NCT05312021|DRUG|IMR-687|150 mg and 200 mg tablets
219142245|NCT05312021|OTHER|IMR-687 Placebo|Matching placebo to IMR-687
219142246|NCT02731885|DRUG|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
219142247|NCT02731885|DRUG|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
219142248|NCT00168519|DRUG|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
219142249|NCT00016250|DRUG|MKC-1|
219142250|NCT06522711|DEVICE|Virtual reality headset|A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.
219142251|NCT06522711|OTHER|Standard of care|Standard of care in anesthesia with patient-controlled sedation.
219142252|NCT01709266|DIETARY_SUPPLEMENT|Probiotics|
219142253|NCT01709266|DIETARY_SUPPLEMENT|Placebo|
219142254|NCT01924975|PROCEDURE|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
219142255|NCT01924975|DEVICE|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
219142256|NCT01924975|DEVICE|A 22 or 24 G intravenous catheter|
219142257|NCT04874415|BEHAVIORAL|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
219142258|NCT04874415|BEHAVIORAL|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
219142259|NCT04874415|BEHAVIORAL|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
219142260|NCT04874415|BEHAVIORAL|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
219142261|NCT04874415|BEHAVIORAL|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
219142262|NCT04874415|BEHAVIORAL|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
219142263|NCT04874415|BEHAVIORAL|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
219142264|NCT04874415|BEHAVIORAL|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
219142265|NCT04874415|BEHAVIORAL|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
219142266|NCT04874415|BEHAVIORAL|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
219142267|NCT04874415|BEHAVIORAL|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
219142268|NCT04874415|BEHAVIORAL|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
219142269|NCT04874415|BEHAVIORAL|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
219142270|NCT04874415|BEHAVIORAL|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
219142271|NCT04874415|BEHAVIORAL|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
219142272|NCT04874415|BEHAVIORAL|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
219230007|NCT03062488|DRUG|PO acetaminophen|multi-modal analgesia with PO acetaminophen
219230008|NCT02014402|BIOLOGICAL|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
219230009|NCT02014402|BIOLOGICAL|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
219552603|NCT05972590|OTHER|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
219142273|NCT06567119|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection
219142274|NCT06567119|OTHER|Placebo|Sterile isotonic solution, subcutaneous injection
219142275|NCT03590288|PROCEDURE|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
219142276|NCT05845710|DEVICE|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
219230010|NCT03463291|DEVICE|MRI|"* T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
219230011|NCT02297464|OTHER|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
219230012|NCT02297464|OTHER|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
219230013|NCT03105024|OTHER|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
219142277|NCT03457246|OTHER|D-Pigment rich texture|
219142278|NCT03457246|OTHER|Hydrance optimale riche|
219230014|NCT03105024|OTHER|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
219718448|NCT06685640|OTHER|prefabricated stainless steel crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
219142279|NCT03823300|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
219142280|NCT03823300|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
219142281|NCT03823300|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
219142282|NCT02571387|BEHAVIORAL|Mindfulness-based intervention|
219142283|NCT02571387|BEHAVIORAL|Sham meditation|
219230015|NCT05024396|DIAGNOSTIC_TEST|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
219142284|NCT03703037|DIAGNOSTIC_TEST|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
219142285|NCT04017169|OTHER|No intervention as observational study|
219142286|NCT00003717|DRUG|estramustine phosphate sodium|
219230016|NCT01985945|OTHER|Yoga|
219552604|NCT00948480|BIOLOGICAL|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
219552605|NCT00948480|DRUG|GM-CSF|500 mcg
219552606|NCT03146143|PROCEDURE|ultrafiltration|ultrafiltration after cardiopulmonary bypass
219552607|NCT02325180|DRUG|Dihydroartemisinin-Piperaquine|
219552608|NCT02325180|DRUG|Artemether-lumefantrine|
219142287|NCT00003717|DRUG|paclitaxel|
219142288|NCT04190342|OTHER|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
219230017|NCT03650972|OTHER|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
219230018|NCT03684772|DRUG|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
219552609|NCT00854126|DRUG|GDC-0980|Escalating repeating dose
219230019|NCT03684772|DRUG|Furosemide Topical Gel|Furosemide (0.125%)
219230020|NCT03684772|DRUG|Digoxin Topical Gel|Digoxin (0.125%)
219552610|NCT01155531|DRUG|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
219552611|NCT03357380|DRUG|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
219552612|NCT03357380|DRUG|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
219552613|NCT00464594|BEHAVIORAL|Standard lifestyle guidance|
219718449|NCT06685640|OTHER|prefabricated zirconia crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
219718450|NCT07016295|BEHAVIORAL|Biomechanical analysis of arm movement|Marker based kinematic analysis
219718451|NCT07016295|BEHAVIORAL|Pose estimation of arm movement|Marker free kinematic analysis
219142289|NCT04190342|BEHAVIORAL|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
219142290|NCT03477110|DRUG|Temozolomide|Given PO
219142291|NCT03477110|RADIATION|Radiation Therapy|Undergo radiation therapy
219142292|NCT03477110|DEVICE|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
219142293|NCT03477110|PROCEDURE|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
219142294|NCT04352803|BIOLOGICAL|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
219142295|NCT06369922|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
219142296|NCT06369922|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
219142297|NCT03368833|DIAGNOSTIC_TEST|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
219142298|NCT05058469|DEVICE|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
219142299|NCT05565859|BEHAVIORAL|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
219142300|NCT04859595|OTHER|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
219142301|NCT01678196|BEHAVIORAL|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
219142302|NCT01678196|OTHER|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
219142303|NCT01377623|DRUG|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
219142304|NCT01377623|DRUG|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
219230021|NCT03684772|DRUG|Vehicle Topical Gel|Vehicle Gel
219230022|NCT05228964|DEVICE|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
219230023|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
219230024|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 48 weeks
219230025|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
219230026|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 24 weeks
219230027|NCT04156256|BIOLOGICAL|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
219230028|NCT04785261|DRUG|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
219230029|NCT04785261|DRUG|Carbomer|1 drip each time, at bedtime, for 12 weeks.
219230030|NCT04785261|DRUG|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
219230031|NCT04633200|OTHER|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
219230032|NCT05313477|DRUG|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
219230033|NCT05313477|DRUG|Calcium carbonate|1000mg of Calcium carbonate daily
219142305|NCT00401323|DRUG|docetaxel (XRP6976)|
219142306|NCT00401323|DRUG|cisplatin|
219142307|NCT00401323|DRUG|5-fluorouracil (5-FU)|
219142308|NCT01320280|DRUG|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
219230034|NCT04768556|OTHER|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
219230035|NCT04768556|OTHER|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
219230036|NCT02312544|DRUG|OTX-TP|OTX-TP and placebo drops
219230037|NCT02312544|DRUG|Timolol|Timolol drops and placebo punctum plug
219230038|NCT04582994|BEHAVIORAL|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
219230039|NCT04582994|BEHAVIORAL|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
219142309|NCT06186739|BEHAVIORAL|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
219142310|NCT06186739|BEHAVIORAL|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
219142311|NCT05340244|DEVICE|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
219142312|NCT00139737|DRUG|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
219142313|NCT05857319|BEHAVIORAL|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
219142314|NCT00653341|DRUG|insulin glargine|
219142315|NCT00653341|DRUG|NPH human insulin|
219142316|NCT02346006|BEHAVIORAL|More physical activity.|Subjects receiving more physical activity in school.
219142317|NCT00773019|DEVICE|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
219142318|NCT00151606|PROCEDURE|Reinforced isolation + Muciprocine|
219142319|NCT03165071|DRUG|ACT-132577|Capsule
219142320|NCT03460756|DRUG|Ganaxolone|Oral
219142321|NCT03460756|DRUG|Placebo|Oral
219142322|NCT02950948|DRUG|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
219142323|NCT02950948|DRUG|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
219142324|NCT05622786|OTHER|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
219142325|NCT05622786|OTHER|Low intensity physical therapy|Low Intensity Gait Activities
219142326|NCT03987451|DRUG|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
219142327|NCT03987451|DRUG|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
219142328|NCT04372394|DRUG|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
219142329|NCT01491399|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
219142330|NCT01491399|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
219142331|NCT02441036|DEVICE|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
219142332|NCT03284086|DIAGNOSTIC_TEST|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
219142333|NCT03284086|DIAGNOSTIC_TEST|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
219230040|NCT04582994|BEHAVIORAL|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
219142334|NCT00325013|DRUG|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
219718452|NCT07014345|PROCEDURE|DLT placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, Double lumen tube placement was performed while the patient remained in the lateral position.
219142335|NCT04838886|OTHER|Telerehabilitation-based Pilates Exercise|The group that will receive telerehabilitation-based pilates training via telerehabilitation
219142336|NCT01434134|DRUG|Metoprolol|Tablet, target dose 100 mg once daily
219142337|NCT01434134|DRUG|Placebo|Tablet, target dose 100 mg once daily
219142338|NCT01434134|DRUG|Candesartan|Tablet, target dose 32 mg once daily
219142339|NCT01434134|DRUG|Placebo|Tablet, 32 mg once daily
219142340|NCT03279718|PROCEDURE|Periodontal Treatment|Scaling and root planing
219142341|NCT01282944|BEHAVIORAL|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
219142342|NCT01282944|BEHAVIORAL|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
219142343|NCT01194154|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
219142344|NCT01194154|DRUG|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
219142345|NCT03884244|OTHER|chewing gum|The group who take chewing gum after operation
219142346|NCT00979056|DRUG|Rifaximin|400 mg per day, oral use, maximum duration 28 days
219142347|NCT00979056|DRUG|Lactose|Coated Tablet, Oral Use
219142348|NCT02785718|OTHER|Global Haemostasis assays|
219142349|NCT05570019|PROCEDURE|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
219142350|NCT02026258|PROCEDURE|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
219142351|NCT02026258|DEVICE|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
219142352|NCT04440046|OTHER|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
219142353|NCT04440046|OTHER|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
219718453|NCT07015515|OTHER|Sham blood flow restriction exercise|"a BFR cuff will be placed on the upper extremity in the same location as in the real BFR group. During the application, the participant will be led to believe that the cuff is being inflated, although no actual pressure will be applied. The participant will see the cuff being wrapped and apparently inflated, but there will be no physical pressure restricting circulation during the exercise. This aims to control the psychological effects (e.g., the belief that something is being applied) on performance"
219718454|NCT07015515|OTHER|Control group|Participants perform push-up exercises without any cuff application. The same repetition and rest protocol is followed
219230041|NCT06152497|DRUG|Placebo|Oral placebo
219142354|NCT04440046|OTHER|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
219142355|NCT04440046|OTHER|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
219142356|NCT04440046|OTHER|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
219142357|NCT03753594|DEVICE|tissue oxygenation saturation|tissue oxygenation saturation
219142358|NCT00027820|DRUG|Fludarabine Phosphate|Given IV
219142359|NCT00027820|RADIATION|Total-Body Irradiation|Undergo TBI
219142360|NCT00027820|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
219142361|NCT00027820|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
219142362|NCT00027820|DRUG|Cyclosporine|Given PO
219230042|NCT06152497|DRUG|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
219230043|NCT06152497|BEHAVIORAL|Resistance training|Resistance training: lower body exercise
219230044|NCT06113393|PROCEDURE|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
219142363|NCT00027820|DRUG|Mycophenolate Mofetil|Given PO
219142364|NCT05573711|OTHER|assessments|Assessments, no specific intervention
219142365|NCT03653013|BEHAVIORAL|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
219142366|NCT03653013|BEHAVIORAL|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
219142367|NCT04925739|OTHER|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
219718455|NCT07015515|OTHER|Blood flow restriction exercise group|Participants will perform push-up exercises with 50% arterial occlusion pressure applied to their dominant arm. The cuff is inflated before the exercise and maintained throughout 3 sets of 5 repetitions. There is a 2-minute rest between sets.
219718456|NCT03890887|DRUG|BI 1291583|Tablet
219718457|NCT03890887|DRUG|Itraconazole|Oral solution
219718458|NCT04836546|DEVICE|Blood glucose meter|First phase: SMBG for 6 months
219718459|NCT04836546|DEVICE|Eversense CGM System|Second phase: CGM for 6 months
219718460|NCT06688734|PROCEDURE|Inital water seal|After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.
219718461|NCT06688734|PROCEDURE|Initial suction|After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.
219718462|NCT05823727|DIETARY_SUPPLEMENT|SOLUGEL|Bovine collagen peptide supplement
219142368|NCT04925739|OTHER|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
219142369|NCT04925739|OTHER|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
219142370|NCT04925739|OTHER|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
219142371|NCT04925739|OTHER|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
219142372|NCT04925739|OTHER|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
219142373|NCT04925739|OTHER|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
219142374|NCT04925739|OTHER|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
219142375|NCT02534350|DRUG|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
219142376|NCT02534350|DRUG|Placebo|Tablets administered orally or via NG tube once daily
219142377|NCT01510041|OTHER|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
219142378|NCT01510041|OTHER|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
219142379|NCT04330469|PROCEDURE|Periodontal therapy|"Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth."
219142380|NCT04330469|PROCEDURE|Oral hygiene advice|Oral hygiene advised by Periodontist
219142381|NCT04673851|DEVICE|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
219142382|NCT00003900|DRUG|docetaxel|
219142383|NCT00003900|DRUG|irinotecan hydrochloride|
219142384|NCT06234644|OTHER|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
219142385|NCT06234644|OTHER|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
219718463|NCT05823727|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219718464|NCT05308654|DRUG|ABBV-453|Oral; Tablet
219718465|NCT05308654|DRUG|Dexamethasone|Oral Tablet
219718466|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
219718467|NCT05308654|DRUG|Lenalidomide|Oral Capsule
219718468|NCT07011992|DRUG|Rosuvastatin|Oral tablet
219718469|NCT07011992|DRUG|BPN14770|Oral capsule
219718470|NCT06682559|OTHER|Prefabricated healing abutment with scan peg|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of prefabricated healing abutment with scan peg having convex emergence profile
219142386|NCT02939378|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
219142387|NCT02939378|DIETARY_SUPPLEMENT|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
219142388|NCT02618239|DIETARY_SUPPLEMENT|Bimuno Galacto-oligo-saccharide|
219230045|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
219230046|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
219230047|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
219718471|NCT06682559|OTHER|Customized healing abutment|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of custom healing abutment having concave emergence profile
219718472|NCT07024134|OTHER|Shoulder flossing application|Select a floss band, typically made of latex, which is about 1-2 inches wide. Ensure the area to be wrapped is clean and dry to prevent slipping. Begin wrapping the floss band around the upper arm, just below the shoulder joint. Start at the deltoid's base. Leave about 2 inches of the band free at the start to tuck in the end when you finish wrapping. Wrap the band tightly but not to the point of causing discomfort or cutting off circulation, the band should be snug but not so tight that it causes numbness or tingling. Aim for about a 50% stretch of the band as you wrap. Continue wrapping down the arm, covering the entire upper arm and ending just above the elbow Overlap each layer by about 50% to ensure even coverage and compression. Once you reach the desired coverage area, tuck the end of the band under the last loop to secure it. Check the tightness to ensure it is snug but not overly constrictive.
219552614|NCT00464594|DRUG|Lifestyle guidance and monotherapy with acarbose|
219142389|NCT01767259|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
219142390|NCT01767259|DRUG|Valsartan|Valsartan alone
219142391|NCT01767259|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
219142392|NCT01026233|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
219552615|NCT00464594|DRUG|Lifestyle guidance and monotherapy with metformin|
219142393|NCT03899675|DIETARY_SUPPLEMENT|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
219142394|NCT03899675|OTHER|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
219230048|NCT02643368|BIOLOGICAL|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
219230049|NCT06093451|DRUG|Dexmedetomidine|Moderate agitation: 120 mcg Severe agitation: 180 mcg
219230050|NCT06093451|DRUG|Lorazepam 2 MG/ML|2 mg
219230051|NCT02642640|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
219552616|NCT00464594|DRUG|Lifestyle guidance and monotherapy with gliclazide|
219230052|NCT02642640|DRUG|placebo|
219230053|NCT04674605|DEVICE|biomarkers|biomarkers
219230054|NCT03493282|DRUG|Active Treatment- CT1812 100 mg|CT1812
219230055|NCT03493282|DRUG|Active Treatment- CT1812 300 mg|CT1812
219552617|NCT03103594|DRUG|DMSO|DMSO will be instilled intravesically.
219552618|NCT03103594|DRUG|Botox|Botox will be instilled intravesically with DMSO.
219552619|NCT05343273|DIAGNOSTIC_TEST|taking a blood sample|blood collection for routine biochemical analysis
219552620|NCT00354159|DEVICE|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
219552621|NCT05907694|PROCEDURE|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
219230056|NCT03493282|DRUG|Placebo|Matching Placebo
219230057|NCT04580732|DEVICE|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
219230058|NCT02333747|DEVICE|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
219142395|NCT03179969|OTHER|paravalvular leak|Observational study on patients with paravalvular leak
219142396|NCT00676234|DRUG|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
219142397|NCT01566513|BEHAVIORAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
219142398|NCT01566513|BEHAVIORAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
219230059|NCT00070707|DRUG|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
219142399|NCT01566513|BEHAVIORAL|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
219142400|NCT01132794|DRUG|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
219142401|NCT01132794|DRUG|Placebo|Intranasal nasal saline
219142402|NCT01273844|DRUG|Bortezomib|Bortezomib
219142403|NCT02886897|BIOLOGICAL|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
219142404|NCT01311180|DRUG|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
219142405|NCT01311180|DRUG|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
219142406|NCT05826951|DRUG|Alcohol|Alcohol (0.8g/kg)
219142407|NCT05826951|DRUG|Placebo|Placebo
219142408|NCT03498170|DRUG|BCT197|Single dose of BCT197
219142409|NCT03498170|DRUG|Itraconazole 200 mg|Single dose of itraconazole
219142410|NCT01989910|DRUG|Raltegravir|Raltegravir 400mg oral twice daily
219142411|NCT01989910|DRUG|Efavirenz|Efavirenz 600mg oral at bedtime
219142412|NCT02983370|PROCEDURE|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
219142413|NCT02467296|OTHER|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
219142414|NCT03747354|DIAGNOSTIC_TEST|blood samples|blood samples
219142415|NCT04060537|OTHER|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
219142416|NCT04060537|OTHER|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
219142417|NCT00974025|DIETARY_SUPPLEMENT|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
219142418|NCT00974025|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered twice daily for four weeks
219142419|NCT01760837|OTHER|Baked milk products to cow's milk allergic patients|
219142420|NCT02747732|DRUG|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
219142421|NCT02528591|DEVICE|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
219142422|NCT04948151|DRUG|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
219142423|NCT04948151|DRUG|Placebo|Patients will apply 2-gram applications up to 9 times per month
219142424|NCT04097210|DIAGNOSTIC_TEST|POC|
219142425|NCT00688948|DRUG|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
219142426|NCT03145246|PROCEDURE|regeneration treated teeth loss|number of regeneration treated teeth loss
219142427|NCT03145246|PROCEDURE|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
219142428|NCT03429062|OTHER|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
219142429|NCT02526641|PROCEDURE|Functional Hepatic Nitrogen Clearance (FHNC)|
219142430|NCT02526641|PROCEDURE|Galactose Elimination Capacity (GEC)|
219142431|NCT02526641|PROCEDURE|Liver vein catheterization|
219142432|NCT01099891|DRUG|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
219142433|NCT01099891|DRUG|Placebo|Placebo, Spray type, Twice a day
219142434|NCT04988048|BIOLOGICAL|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
219142435|NCT05171218|BEHAVIORAL|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
219142436|NCT05171218|BEHAVIORAL|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
219230060|NCT00070707|DRUG|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
219230061|NCT00070707|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
219230062|NCT04859465|DRUG|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
219230063|NCT01765699|DEVICE|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
219230064|NCT03185143|DRUG|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
219718473|NCT07024134|OTHER|Nerve glide application|With the band in place, perform slow and controlled arm movements. Start with shoulder abduction (lifting the arm sideways) and progress to external rotation (turning the arm outward) this is for axillary nerve glide, (extending your arm and fingers while tilting your head away from the affected side) this for median nerve glide and (Extend your arm out to the side at shoulder height-Rotate the arm so the palm faces upwards-Flex the wrist and fingers back gently-Tilt your head away from the extended arm to increase the stretch) this for radial nerve glide. Ensure movements are within a pain-free range. Stop if any discomfort occurs. Keep the floss band in place for 1-2 minutes while performing nerve glides. Remove the band after the exercise, allowing the skin to recover from compression.
219718474|NCT07024134|OTHER|Shoulder flossing with Nerve Glide|Procedures of Shoulder flossing application adding to Procedures of Nerve glide application.
219718475|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
219718476|NCT03611946|BIOLOGICAL|Single dose of placebo via subcutaneous injection (0.5ml).|Administered by subcutaneous injection.
219718477|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
219718478|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Full)|Participants in the ActiveGirls Full Intensity intervention group will receive a series of 6 health coaching visits delivered via telemedicine. These visits will address physical activity goal setting within the family. Participants will also receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 1-6 of their study participation).
219718479|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Delayed Lower Intensity)|Participants in this group will only receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 7-12 of their study participation)
219718480|NCT07114770|DEVICE|Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)|Participants will receive a single session of either iTBS or cTBS (600 pulses) targeting the right cerebellar Crus I/II. One week after the initial TBS, they will receive another single session of iTBS or cTBS (600 pulses) at the same site.
219718481|NCT07116252|PROCEDURE|EDTA|17% EDTA as a final rinse after instrumentaion (sequential chelation)
219718482|NCT07116252|PROCEDURE|Etidronate|9% HEBP as a final rinse after instrumentation (sequential chelation)
219718483|NCT07116252|PROCEDURE|clodronate|0.26 M (7.6%) clodronate as a final rinse after instrumentation (sequential chelation)
219718484|NCT07116252|PROCEDURE|Etidronic acid /sodium hypochlorite|(2.5% NaOCl + 9% HEBP) during instrumentation and as a final rinse after instrumentation (continous chelation)
219718485|NCT07116252|PROCEDURE|clodronate + sodium hypochlorite|2.5% NaOCl + 0.26 M (7.6%) clodronate during instrumentation and as a final rinse after instrumentation (continuous chelation)
219718486|NCT07113795|PROCEDURE|TCM dummy therapy combined with mesenchymal stem cell injection therapy|Combines TCM dummy therapy with mesenchymal stem cell injection, integrating traditional local stimulation and modern stem cell regenerative mechanisms.
219718487|NCT07113795|PROCEDURE|Dummy Line Therapy Group|Utilizes traditional thread-embedding techniques, placing specialized threads at specific sites to effectively drain inflammatory exudates and necrotic materials.
219142437|NCT05171218|BEHAVIORAL|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
219142438|NCT05171218|BEHAVIORAL|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
219142439|NCT05705700|DRUG|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
219142440|NCT05705700|DRUG|Abiraterone|1000 mg PO daily
219142441|NCT04126330|DIETARY_SUPPLEMENT|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
219142442|NCT04126330|DIETARY_SUPPLEMENT|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
219142443|NCT02954848|DRUG|Placebo|TAK-438 placebo-matching tablets
219142444|NCT02954848|DRUG|TAK-438 10 mg|TAK-438 tablets
219142445|NCT04224181|RADIATION|Cardiac PET|A scan examining blood flow to the heart
219142446|NCT04224181|RADIATION|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
219142447|NCT04224181|RADIATION|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
219142448|NCT00025987|DEVICE|Head and Neck Cooling System|
219142449|NCT00025987|DEVICE|Thermometer Pill|
219142450|NCT00968448|BEHAVIORAL|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
219142451|NCT00968448|BEHAVIORAL|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
219142452|NCT00226148|PROCEDURE|Use of a membrane to cover bonedefects around implant|
219142453|NCT00226148|DEVICE|Use of bonechips to fill up defects around implant|
219142454|NCT00226148|PROCEDURE|Use of membrane and bonechips to manage defects|
219718488|NCT07113795|PROCEDURE|MSC Group|Administers mesenchymal stem cell injections directly to target areas, leveraging their differentiation and anti-inflammatory properties to enhance tissue repair.
219230065|NCT03185143|DRUG|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
219718489|NCT07114952|BEHAVIORAL|alternative nasal breathing|The alternate nasal breathing exercise involves breathing in and out through both nostrils in a certain pattern and for a certain period of time. For example, an individual who breathes in through the right nostril for 5 seconds with the left nostril closed, then closes the right nostril and exhales through the left nostril for 5 seconds. Then he/she inhales through the left nostril for 5 seconds and exhales through the right nostril. A total of 6 breaths are taken per minute. The application is applied for 5 minutes, the patient rests in a calm environment for two minutes and the application is performed for another 5 minutes. In order to increase the compliance of individuals with the application, a sample video was watched and application instructions were given by the researcher. The application was performed while the patients were in an upright sitting position.
219718490|NCT07116070|OTHER|Clinical Assessments|"Participants will undergo the following assessments:~* Muscle strength: Handgrip strength test (using a digital dynamometer),~* Muscle mass: Bioelectrical impedance analysis (BIA) or DXA,~* Physical performance: 6-minute walk test, 5-repetition sit-to-stand test,~* Fatigue: Modified Fatigue Impact Scale (MFIS),~* Disability: EDSS,~* Nutritional status: Mini Nutritional Assessment (MNA),~* Physical activity: Godin Leisure-Time Exercise Questionnaire,~* Quality of life: MSQoL-54."
219718491|NCT07121010|DIETARY_SUPPLEMENT|Animal-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from high-quality animal-based protein, such as whey protein isolate or pasteurized egg whites. It is designed to evaluate the postprandial metabolic and immune response to animal-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
219718492|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, such as pea or rice protein isolate. It is designed to evaluate the postprandial metabolic and immune response to plant-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
219718493|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie with Leucine|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, using sources such as pea or rice protein isolate. In addition, it is supplemented with pharmaceutical-grade leucine to match the leucine content typically found in animal-based protein sources. The smoothie is designed to assess whether leucine supplementation can modulate the postprandial metabolic and immune response to plant-derived protein. It is prepared in a food-safe certified kitchen and consumed after an overnight fast to maintain consistency across study conditions.
219718494|NCT07121062|OTHER|Online parent administered questionnaire|Unsettled Infant Questionaire (UnIQue)
219718495|NCT07120529|OTHER|CT scan|CT chest, abdominal, pelvis during follow-up
219718496|NCT07120529|PROCEDURE|Ultrasound scan (Transvaginal or Transabdominal)|Transvaginal and transabdominal ultrasound scan during follow-up
219718497|NCT07120529|PROCEDURE|Gynecological examination|Gynecological standard examination during follow-up
219718498|NCT07119346|PROCEDURE|EOI block|EOI block with 0.25% ropivacaine 1 mL/kg (max 40 mL) bilaterally under ultrasound guidance
219718499|NCT07119346|PROCEDURE|sham block|Sham block with equal volume of normal saline bilaterally under ultrasound guidance
219718500|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times
219718501|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
219718502|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
219718503|NCT07121101|DRUG|placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
219718504|NCT07120750|DRUG|Intervention for Group 1|Participants will receive standard NAs therapy, which may include entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF). NAs are antiviral medications used to suppress HBV replication and manage chronic hepatitis B infection.
219142455|NCT01069341|DRUG|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
219142456|NCT00269880|DRUG|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
219142457|NCT00269880|DRUG|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
219142458|NCT00269880|DRUG|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
219142459|NCT01802632|DRUG|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
219142460|NCT02342119|OTHER|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
219230066|NCT03185143|DRUG|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
219230067|NCT05673616|OTHER|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
219142461|NCT02342119|OTHER|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
219142462|NCT02326649|DEVICE|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
219142463|NCT03890016|DIAGNOSTIC_TEST|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
219142464|NCT03890016|DIAGNOSTIC_TEST|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
219718505|NCT07120750|DRUG|Intervention for Group 2|Participants will receive Peg-IFNα-2b in addition to NAs therapy. Peg-IFNα-2b is an antiviral medication that works by boosting the immune system and has additional antiviral, antifibrotic, and anti-tumor effects. It is used to treat chronic hepatitis B and may help reduce the recurrence of liver cancer.
219142465|NCT05702996|DRUG|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
219230068|NCT06086067|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
219718506|NCT07122375|DIAGNOSTIC_TEST|Angle Specific Torque Profile Analysis|All assessment data will be obtained from the archival records of young healthy adults, and no new assessments will be conducted. Raw data from wrist flexion and extension evaluations performed using an isokinetic dynamometer will be utilized.
219718507|NCT07123454|DRUG|AZD4512|AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
219718508|NCT06877962|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in hemodialysis (HD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private, and the professional will send the link for each training session and will control the access of the participants.
219142466|NCT03404154|DIAGNOSTIC_TEST|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
219142467|NCT03404154|PROCEDURE|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
219230069|NCT01281436|OTHER|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
219230070|NCT01281436|OTHER|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
219230071|NCT01052935|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
219230072|NCT03928743|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219230073|NCT03928743|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
219230074|NCT05658094|DEVICE|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
219230075|NCT03999788|PROCEDURE|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
219718509|NCT06718218|BEHAVIORAL|Mindfulness Pain Management|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice.
219230076|NCT03999788|PROCEDURE|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
219230077|NCT05085418|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
219230078|NCT00808496|OTHER|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
219142468|NCT03781206|DEVICE|PICO™ 7|PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
219142469|NCT03814668|DIETARY_SUPPLEMENT|Probiotic|Intake of probiotic
219142470|NCT03814668|DIETARY_SUPPLEMENT|Lactase|Intake of lactase
219230079|NCT00808496|OTHER|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
219230080|NCT00808496|OTHER|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
219718510|NCT06718218|BEHAVIORAL|Mindfulness Recording With Sustained Tone|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice, that is accompanied by a sustained low C tone at 65.41 Hertz.
219718511|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear.
219142471|NCT03814668|OTHER|Placebo|Intake of placebo
219142472|NCT05402735|DIAGNOSTIC_TEST|Serum uric acid level|Serum uric acid level
219142473|NCT06333132|BEHAVIORAL|Weight loss-induced Diabetes Remission|Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
219142474|NCT01052454|BEHAVIORAL|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
219142475|NCT02578615|OTHER|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
219142476|NCT02418806|BEHAVIORAL|Psychotherapy groups|
219230081|NCT02666404|OTHER|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
219230082|NCT04390516|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
219230083|NCT02430454|BEHAVIORAL|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
219230084|NCT05569343|OTHER|No intervention|This is an observational study without any intervention
219230085|NCT05904652|DEVICE|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
219230086|NCT05904652|DEVICE|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
219230087|NCT05581251|BEHAVIORAL|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
219142477|NCT02418806|BEHAVIORAL|Self-help groups|
219142478|NCT01628237|DEVICE|comparison of spinal cord stimulation|
219142479|NCT00109785|PROCEDURE|positron emission tomography|
219230088|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
219142480|NCT00109785|RADIATION|fludeoxyglucose F 18|
219142481|NCT00109785|RADIATION|iodine I 124 iododeoxyuridine|
219142482|NCT06554548|DRUG|HS-10518|Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
219142483|NCT02770599|OTHER|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
219142484|NCT01953757|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
219142485|NCT01953757|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
219142486|NCT04558424|DIETARY_SUPPLEMENT|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
219142487|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|5mg/day
219230089|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
219230090|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
219230091|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
219230092|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
219230093|NCT01208506|DRUG|placebo|A single dose of NNC0114-0000-0005 placebo.
219230094|NCT03765385|OTHER|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
219230095|NCT03765385|OTHER|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
219230096|NCT01539252|PROCEDURE|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
219230097|NCT01539252|PROCEDURE|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
219230098|NCT05556200|DRUG|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
219230099|NCT05556200|DRUG|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
219230100|NCT03105960|DRUG|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
219230101|NCT03105960|DRUG|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
219230102|NCT02941744|DRUG|nivolumab|low fixed dose ipilimumab in combination with nivolumab
219230103|NCT02941744|DRUG|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
219230104|NCT00286039|PROCEDURE|Blood sampling|Blood sampling is used.
219230105|NCT02392507|DRUG|Necitumumab|Administered IV
219230106|NCT02392507|DRUG|Nab-Paclitaxel|Administered IV
219142488|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|10mg/day
219142489|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|25mg/day
219230107|NCT02392507|DRUG|Carboplatin|Administered IV
219230108|NCT02224755|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
219230109|NCT02224755|DEVICE|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
219230110|NCT06323369|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219142490|NCT00288691|DRUG|Placebo|Placebo
219142491|NCT01230840|DIETARY_SUPPLEMENT|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
219230111|NCT06323369|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230112|NCT06323369|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230113|NCT06323369|PROCEDURE|Surgical resection|Standard of care
219230114|NCT06323369|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230115|NCT06323369|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230116|NCT06323369|RADIATION|Radiation|Recommended, standard of care
219230117|NCT06323369|DRUG|Carboplatin（neoadjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230118|NCT06323369|DRUG|Carboplatin（adjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
219230119|NCT06269068|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
218987371|NCT05236049|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
218987372|NCT02959320|PROCEDURE|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
218987373|NCT01696084|DRUG|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
219142492|NCT01230840|DIETARY_SUPPLEMENT|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
219142493|NCT02892162|PROCEDURE|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
219142494|NCT02061228|DEVICE|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
219142495|NCT03385967|DRUG|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
219142496|NCT03385967|DRUG|ropivacaine|Standard of care 0.5%ropivacaine
219142497|NCT03630224|DRUG|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
219142498|NCT03630224|DRUG|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
219142499|NCT01392313|DIETARY_SUPPLEMENT|Carnitine|Carnitine Ingestion
219142500|NCT01392313|DIETARY_SUPPLEMENT|Placebo|Carnitine placebo
219142501|NCT03969472|DRUG|probiotics|apply probiotic after operation
219142502|NCT03969472|DEVICE|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
219142503|NCT05769517|DIAGNOSTIC_TEST|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
219142504|NCT04424836|DEVICE|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
219142505|NCT03058965|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
219142506|NCT03058965|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
219142507|NCT03058965|DRUG|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
219142508|NCT00751075|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
219142509|NCT00751075|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
219142510|NCT00751075|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
219142511|NCT00751075|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
219142512|NCT03698708|BEHAVIORAL|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
219142513|NCT03922412|PROCEDURE|PLANTAR BLOCK|"1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
219142514|NCT03922412|PROCEDURE|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
219142515|NCT00476255|BEHAVIORAL|Enhanced Standard Care (ESC)|Reading material
219142516|NCT00476255|BEHAVIORAL|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
219142517|NCT04635267|OTHER|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
219142518|NCT02806869|DRUG|Single dose of ibuprofen (800 mg tablet)|
219142519|NCT02806869|DIETARY_SUPPLEMENT|Pulmocare, two 8.0 oz (236.6 mL) cans|
219142520|NCT02652936|DRUG|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
219142521|NCT02652936|DRUG|Placebo comparator|AF-130 matching placebo capsule
219142522|NCT00360451|BEHAVIORAL|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
219142523|NCT00360451|BEHAVIORAL|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
219142524|NCT03495713|DRUG|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
219142525|NCT05081310|DEVICE|superior vena cava isolation|SVC isolation by the means of cryoballoon
219142526|NCT05081310|DEVICE|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
219142527|NCT04001517|DRUG|Neflamapimod|Double-Blind, Placebo-Controlled
219142528|NCT06356116|OTHER|Usual care|"During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital."
219718512|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats and Theta Music|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear as well as instrumental theta wave music.
219142529|NCT06356116|OTHER|Accelerated rehabilitation|"Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation"
219142530|NCT02880241|DRUG|MMV390048|Tablets of 20mg each
219718513|NCT06703606|DRUG|MARSTACIMAB|Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
219142531|NCT05516641|DIETARY_SUPPLEMENT|Soluble Corn Fiber|once daily additive to diet
219142532|NCT05516641|DIETARY_SUPPLEMENT|Maltodextrin|once daily additive to diet
219142533|NCT04250285|OTHER|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
219142534|NCT01131624|DRUG|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
219718514|NCT07047209|DRUG|Digoxin|Digoxin tablets will be administered orally in a once daily dosage. Each tablet is scored and is of 125 mcg strength. Participants will take 1 tablet, two tablets or half a tablet depending on the dosing tier they are in during study participation.
219718515|NCT02207608|DRUG|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
219718516|NCT02207608|DRUG|BCG (Immucist®)|Usual BCG treatment
219142535|NCT01131624|DRUG|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
219142536|NCT03253913|DRUG|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
219142537|NCT03253913|DRUG|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
219142538|NCT05983107|DRUG|Everolimus|Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
219142539|NCT05983107|DRUG|Chidamide|Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
219142540|NCT05983107|DRUG|Endocrine therapy|Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
219142541|NCT05983107|DRUG|Ovarian function suppression(OFS)|Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
219142542|NCT02110056|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
219142543|NCT02110056|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
219142544|NCT04812951|DRUG|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
219142545|NCT04812951|DEVICE|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
219142546|NCT03332992|BEHAVIORAL|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
219142547|NCT03332992|BEHAVIORAL|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
219142548|NCT03332992|BEHAVIORAL|General intentions|Question language asking about general interest in getting influenza vaccination
219142549|NCT03332992|BEHAVIORAL|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
219142550|NCT03332992|BEHAVIORAL|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
219142551|NCT02018224|PROCEDURE|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
219142552|NCT02018224|PROCEDURE|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
219142553|NCT04014803|DRUG|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm"
219142554|NCT03189316|OTHER|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
219230120|NCT06269068|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
219718517|NCT04743466|OTHER|Electronic Health Record Review|Biobank records are reviewed
219718518|NCT05805501|DRUG|Tobemstomig|Participants will receive IV tobemstomig Q3W.
219230121|NCT06269068|OTHER|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
219718519|NCT05805501|DRUG|Tiragolumab|Participants will receive IV tiragolumab Q3W.
219142555|NCT06467253|DEVICE|1. rTMS + CS|"In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
219142556|NCT06467253|DEVICE|2. rTMS Sham + CS|"In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
219142557|NCT06467253|DEVICE|3. tDCS + CS|"In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS."
219142558|NCT06467253|DEVICE|4. tDCS Sham + CS|"In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS."
219142559|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
219142560|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
219142561|NCT02705586|BEHAVIORAL|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
219142562|NCT04713371|DRUG|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
219142563|NCT04713371|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
219142564|NCT04713371|DRUG|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
219142565|NCT04713371|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
219142566|NCT04713371|DRUG|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
219142567|NCT02068430|DRUG|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
219230122|NCT06269068|OTHER|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
219230123|NCT06269068|OTHER|Visual analogue scale|global pain score on a 0 to 10
219552622|NCT05907694|DRUG|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
219552623|NCT02364531|OTHER|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
219718520|NCT05805501|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
219718521|NCT05805501|DRUG|Axitinib|Participants will receive axitinib PO BID.
219718522|NCT07114874|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
219718523|NCT07117214|DRUG|[68Ga]Ga-DWJ155|Radioligand imaging agent
219718524|NCT07118137|DEVICE|7T MRI|Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.
219718525|NCT07118137|DEVICE|EEG|Resting-state EEG
219718526|NCT07118137|BIOLOGICAL|Blood samples|Blood samples taken for analysis of central blood biomarkers.
219718527|NCT07118137|BIOLOGICAL|Stool samples|Stool samples collected to identify distinct gut-microbiota compositions between the groups.
219142568|NCT02068430|OTHER|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
219552624|NCT00870129|PROCEDURE|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
219230124|NCT04686617|DIAGNOSTIC_TEST|Mechanical Vibration|Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
219230125|NCT01404637|DRUG|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
219142569|NCT01785004|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
219142570|NCT01785004|DRUG|omega-3 fatty acids (fish oil)|
219142571|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 1 month|temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
219142572|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 2 months|temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
219142573|NCT05515042|DRUG|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
219142574|NCT05237921|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
219142575|NCT05237921|BEHAVIORAL|Standard Care|Standard Care
219142576|NCT04209049|DRUG|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
219142577|NCT02194933|DRUG|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
219142578|NCT03053388|DRUG|Nitric Oxide|Nitric Oxide given via inhalation in cycles
219142579|NCT03053388|OTHER|Supportive treatment|Supportive treatment (including oxygen)
219142580|NCT02789917|OTHER|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
219142581|NCT02789917|OTHER|Triple Therapy|"HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
219230126|NCT01404637|DRUG|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
219230127|NCT05582226|PROCEDURE|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
219142582|NCT05254171|DRUG|SBP-101|small molecule polyamine metabolic inhibitor for subcutaneous injection
219142583|NCT05254171|DRUG|Nab-paclitaxel|paclitaxel protein-bound particles for injectable suspension
219142584|NCT05254171|DRUG|Gemcitabine|gemcitabine for injection
219230128|NCT05582226|PROCEDURE|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
219230129|NCT02504411|DEVICE|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
219142585|NCT05254171|OTHER|Placebo|Normal Saline
219142586|NCT03400462|DRUG|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
219230130|NCT02504411|DEVICE|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
219552625|NCT01627639|DRUG|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
219718528|NCT07118137|DIAGNOSTIC_TEST|Neuropsychologic test (MoCA)|Map cognition with clinically well-established neuropsychology test
219718529|NCT07125924|DEVICE|Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.)|Bladder instillation of Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.) will be administered aseptically once weekly for a total of five times following each session of radiotherapy.
219718530|NCT07125924|OTHER|Normal Saline (NS)|Normal saline will be instilled into the bladder following the same schedule as the intervention group, i.e., five times after each radiotherapy session.
219552626|NCT01627639|DRUG|Placebo|Placebo
219142587|NCT03400462|DEVICE|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
219142588|NCT03400462|OTHER|dry needling|Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
219142589|NCT01454661|DIETARY_SUPPLEMENT|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
219142590|NCT01454661|DIETARY_SUPPLEMENT|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
219142591|NCT01454661|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is used as placebo.
219142592|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
219142593|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
219142594|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
219142595|NCT02747563|OTHER|Blood test (PSA)|Measurement of blood PSA levels
219142596|NCT02447263|PROCEDURE|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
219142597|NCT01312441|DRUG|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
219142598|NCT01312441|DRUG|Placebo|Placebo by mouth once weekly for 6 months
219142599|NCT02045836|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219142600|NCT02045836|BIOLOGICAL|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219142601|NCT06513442|OTHER|Trabecular bone score software|To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
219142602|NCT05561036|DRUG|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
219142603|NCT05561036|DRUG|Saline Solution|saline solution
219142604|NCT02053363|DRUG|Tranexamic Acid (Cyklokapron)|
219142605|NCT02582710|DIETARY_SUPPLEMENT|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
219142606|NCT02582710|DIETARY_SUPPLEMENT|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
219142607|NCT04930393|PROCEDURE|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
219142608|NCT05033509|OTHER|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
219142609|NCT06240663|BEHAVIORAL|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
219142610|NCT05676190|COMBINATION_PRODUCT|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
219142611|NCT05676190|COMBINATION_PRODUCT|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
219142612|NCT05676190|COMBINATION_PRODUCT|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
219142613|NCT05676190|COMBINATION_PRODUCT|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
219142614|NCT04878198|BEHAVIORAL|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
219142615|NCT04878198|DRUG|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
219142616|NCT04273412|BEHAVIORAL|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
219142617|NCT01550666|BEHAVIORAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
219142618|NCT03305003|OTHER|Spiral notebook|
219142619|NCT03305003|OTHER|Mobile application|
219552627|NCT00048139|DRUG|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
219552628|NCT00048139|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
219142620|NCT01794936|DEVICE|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
219142621|NCT03920215|DRUG|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
219142622|NCT03920215|DRUG|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
219142623|NCT03920215|DRUG|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
219142624|NCT03920215|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
219142625|NCT02000817|BIOLOGICAL|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
219142626|NCT02000817|BIOLOGICAL|Placebo|Placebo is available 0.9% w/v sodium chloride
219142627|NCT03094013|OTHER|Assessment|Assessment
219142628|NCT01063686|DEVICE|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
219142629|NCT03731312|OTHER|No intervention|This is an observational study and no interventions will be administered.
219142630|NCT01038648|DRUG|Sitagliptin|100mg/day
219142631|NCT01038648|OTHER|life style modification at base line|Advice on physical activity, diet and drug adherence.
219142632|NCT02785380|PROCEDURE|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
219142633|NCT02785380|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
219142634|NCT01752465|BEHAVIORAL|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
219142635|NCT01752465|BEHAVIORAL|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
219552629|NCT01667822|BEHAVIORAL|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
219142636|NCT01405872|OTHER|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
219142637|NCT00097188|DRUG|rituximab|
219142638|NCT02886637|OTHER|None intervention|
219142639|NCT03812978|OTHER|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
219142640|NCT00177216|DRUG|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
219142641|NCT00177216|DRUG|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
219552630|NCT01667822|BEHAVIORAL|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
219552631|NCT02544139|OTHER|Chagas Detect Plus|
219552632|NCT02046122|DRUG|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
219552633|NCT02046122|DRUG|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
219142642|NCT00177216|DRUG|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
219142643|NCT00113971|DRUG|epratuzumab|
219552634|NCT02046122|BIOLOGICAL|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
219142644|NCT05475405|OTHER|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
219142645|NCT05475405|OTHER|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
219142646|NCT03310112|BEHAVIORAL|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
219230131|NCT04613284|DRUG|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
219230132|NCT04613284|RADIATION|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
219230133|NCT04630119|OTHER|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
219230134|NCT02736188|DRUG|Aceneuramic Acid Extended-Release Tablets|
219230135|NCT00240994|DRUG|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
219718531|NCT07125586|DIAGNOSTIC_TEST|High-Sensitivity Spectroscopy with Autofluorescence for eCRSwNP Diagnosis|This intervention employs a non-invasive diagnostic procedure using a high-sensitivity spectroscopy system with autofluorescence to identify eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP). A specialized thin probe, guided by an endoscopic light source, contacts nasal polyp tissue to emit a proprietary wavelength laser light, exciting fluorescent substances (primarily flavin adenine dinucleotide, FAD). The probe captures autofluorescence signals at a specific emission wavelength, and signal intensity analysis distinguishes eosinophilic from non-eosinophilic polyps in real-time. Unlike invasive histopathological diagnosis via biopsy or surgery, this method enables rapid preoperative typing. Conducted once at the initial visit, results are validated against post-biopsy/surgical histopathology (gold standard) to assess diagnostic accuracy (sensitivity ≥90%, specificity ≥85%). Safety is monitored for adverse events like mucosal irritation or bleeding within 24 hours.
219552635|NCT05419739|OTHER|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
219552636|NCT05719467|DRUG|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
219552637|NCT05719467|DRUG|Sodium bicarbonate|4 g orally
219552638|NCT05719467|DRUG|Placebo|4g orally
219552639|NCT05719467|DRUG|Nacl 0.9%|1 mL intravenously
219552640|NCT03795441|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
219552641|NCT01653704|BEHAVIORAL|observational role|observational role in crisis scenario
219552642|NCT01653704|BEHAVIORAL|active role|active role in managing crisis scenario
219552643|NCT00795158|DRUG|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
219230136|NCT00240994|DRUG|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
219230137|NCT00240994|DRUG|Mycophenolate mofetil|Per recommendation
219230138|NCT00240994|DRUG|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
219230139|NCT01375790|DEVICE|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
219230140|NCT01375790|OTHER|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
219230141|NCT03738592|OTHER|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
219230142|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
219230143|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
219230144|NCT01835652|OTHER|Active Exercise|
219230145|NCT01835652|OTHER|Passive Exercise|
219230146|NCT05448222|DIAGNOSTIC_TEST|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
219142647|NCT03310112|BEHAVIORAL|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
219142648|NCT03383146|DRUG|Placebo|Placebo injected subcutaneously twice daily.
219552644|NCT00397657|DRUG|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
219142649|NCT03383146|DRUG|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
219142650|NCT00636064|DRUG|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
219552645|NCT00397657|DRUG|ezetimibe|Ezetimibe 10mg once daily
219552646|NCT00694044|DRUG|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
219552647|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
219552648|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
219552649|NCT00694044|DRUG|Placebo|Placebo for 21 days
219552650|NCT02928744|OTHER|COPD|Plethysmography
219552651|NCT02928744|OTHER|COPD|Forced oscillations
219552652|NCT06287216|BEHAVIORAL|Mental Hygiene|Mental hygiene are daily evidence based practices that support mental wellbeing.
219552653|NCT06287216|BEHAVIORAL|Self-Care|Instructed to do 10 minutes of self-care daily.
219552654|NCT05428696|DRUG|ALXN2080|Powder-in-capsule
219552655|NCT05428696|DRUG|Placebo|Powder-in-capsule
219552656|NCT05128058|DRUG|Ritlecitinib 50 mg|50 mg single dose
219552657|NCT05128058|DRUG|Ritlecitinib 200 mg|200 mg single dose
219552658|NCT01728116|DEVICE|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
219552659|NCT01728116|PROCEDURE|Sham Procedure|Endoscopic evaluation but no device placement
219552660|NCT06256224|DRUG|Toripalimab|Toripalimab combined with CCRT
219552661|NCT06256224|RADIATION|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
219552662|NCT04132063|DRUG|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
219552663|NCT03727763|DRUG|Vemurafenib|960mg po bid
219552664|NCT03727763|DRUG|Cetuximab|500mg/m2 iv gtt (14 days per course)
219552665|NCT00646984|DRUG|Standard continuous antiretroviral therapy|
219552666|NCT00646984|DRUG|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
219552667|NCT00646984|DRUG|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
219142651|NCT00636064|DRUG|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
219142652|NCT00636064|OTHER|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
219142653|NCT03399370|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
219142654|NCT03399370|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
219142655|NCT03665298|BEHAVIORAL|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
219718532|NCT07122596|DRUG|Meropenem Infusion|"Inclusion Criteria:~* 1 month to 16 years old~* Bacterial Infection (suspected or known) Admitted to PICU with suspected or known bacterial infection~* Prescribed intravenous meropenem~* Informed consent obtained from parent/guardian~Exclusion Criteria:~* Known allergy to carbapenems~* Severe renal impairment (eGFR \< 30 mL/min/1.73 m²)~* Use of other investigational antibiotics at the same time~* Prematurely Terminating the Treatment or Early Discharge Against Medical Advice Age Range: 1 month to 16 years old Gender: BOTH Sample Size (Number of participants): 150"
219718533|NCT04524611|DRUG|Risankizumab|Intravenous (IV) Infusion
219230147|NCT03688087|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
219230148|NCT03688087|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
219718534|NCT04524611|DRUG|Risankizumab|Subcutaneous (SC) Injection
219718535|NCT04524611|DRUG|Ustekinumab|Intravenous (IV) infusion
219718536|NCT04524611|DRUG|Ustekinumab|Subcutaneous (SC) injection
219718537|NCT06901739|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic supplement contains both tannins (350mg) and probiotic strains (Lactobacillus acidophilus, Lactobacillus casei, y Bifidobacterium lactis 2×10 9 UFC/g each) that have already demonstrated a positive health effect in obesity. Besides, participants will follow a dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
219718538|NCT06901739|DIETARY_SUPPLEMENT|Placebo|Subjects will recieve a placebo supplement, contained in an identical capsule form as the synbiotic, along with the same dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
219718539|NCT07092267|DEVICE|ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.|ArtiFix® is a synthetic surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. ArtiFix® adheres to the dura, so that sutures are not required to prevent cerebrospinal fluid (CSF) leakage.
219718540|NCT06907953|OTHER|Observational - no intervention|Pilot, observational study - no intervention
219718541|NCT07091747|OTHER|Cannabis 50 mg of CBD and 5 mg of THC|Cannabis 50 mg of CBD and 5 mg of THC
219718542|NCT07103122|OTHER|Experimental Group|A Personalized Adaptive Mirror Therapy for Upper-Limb Post-Stroke Rehabilitation using Virtual Reality and Myoelectric Control for 24 sesion in 8 weeks in add on to standard therapy.
219718543|NCT07103122|OTHER|Control Group|Conventional Therapy
219142656|NCT04193215|BIOLOGICAL|V114|IM injection
219142657|NCT04193215|OTHER|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
219142658|NCT05342766|DIETARY_SUPPLEMENT|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
219142659|NCT06628856|OTHER|Quality of life|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
219142660|NCT02498769|DRUG|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
219142661|NCT02498769|DRUG|Placebo|
219230149|NCT04070105|DEVICE|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
219230150|NCT04070105|DEVICE|AllPro|Participants will be fit with a high activity foot designed to be used for walking and running
219230151|NCT01942525|OTHER|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
219230152|NCT05164926|OTHER|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
219230153|NCT03665714|OTHER|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
219230154|NCT03665714|OTHER|Enteral Nutrition Emulsion(TPF-T)|TPF-T
219718544|NCT07103603|DRUG|Menopausal hormone therapy|Menopausal hormone therapy including oral or transdermal estrogen, with or without progestin, administered based on clinical indications.
219718545|NCT06589934|DIAGNOSTIC_TEST|Precise Image|Image reconstruction software
219718546|NCT07109492|OTHER|Mandala|Mandala Painting
219230155|NCT03237026|OTHER|No intervention required|No intervention required
219718547|NCT07108361|PROCEDURE|Osseodensification|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. Implant site preparation starts with a pilot drill, in clockwise motion, in the center of the septum, until 1 mm deeper than the planned implant length. Densah® Burs (Versah, LLC, Jackson, MI, USA) were then sequentially used in OD mode (counterclockwise, drilling speed 800-1500 rpm, with copious irrigation) in small increments to gradually expand the osteotomy, until reaching the desired width for the planned implant diameter, Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket, insertion torque will be measured using the torque wrench and ISQ values
219142662|NCT05639699|OTHER|motivational interview|Quitting smoking with motivational interviewing
219552668|NCT05689541|OTHER|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
219142663|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
219230156|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
219718548|NCT07108361|PROCEDURE|conventional drilling|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. The initial (pointed) drill will be used to make a hole (starting point) in the interradicular bone to avoid slippage of the subsequent the drills in the socket of the remaining roots. The drills of increasing diameters will be used to complete the implant osteotomy according to manufacturer instructions. In case of limited interradicular bone volume, drilling will be made at the socket of mesial or distal roots. Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket insertion torque will be measured using the torque wrench and ISQ values
219718549|NCT07102771|PROCEDURE|Ultrasound guided erector spinae plane block|ESP block is most often performed using an in-plane ultrasound-guided technique. It is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves
219718550|NCT07104812|DRUG|Osilodrostat 1 MG|Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks
219718551|NCT07109713|DIETARY_SUPPLEMENT|Active|Cranberry Beverage
219718552|NCT07109713|DIETARY_SUPPLEMENT|Placebo|Placebo Beverage
219718553|NCT07110896|DIETARY_SUPPLEMENT|Humiome Post LB (Postbiotic)|Heat-inactivated lactobacilli with fermented medium (a postbiotic) in 340mg powder format
219718554|NCT07110896|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose, 340mg powder format
219718555|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 8 mL normal saline (10 mL total)
219718556|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 1 mL normal saline (3 mL total)
219718557|NCT07115914|RADIATION|PSMA PET/CT scan|A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate.
219718558|NCT07116473|DRUG|Acoramidis (AG10)|TTR stabilizer administered orally twice daily (BID)
219142664|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
219142665|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
219142666|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
219142667|NCT04465071|DRUG|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
219552669|NCT05828290|BEHAVIORAL|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
219718559|NCT07115563|DIETARY_SUPPLEMENT|Targeted Amino Acid Supplement|Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
219718560|NCT07115563|DIETARY_SUPPLEMENT|Control (placebo)|The inert amino acid (alanine) will serve as an isonitrogenous control.
219718561|NCT07114744|OTHER|Take home tests|"These tests will test the discriminability of sounds that vary systematically along the frequency and temporal dimensions of sound. Over the course of the 3 months post-activation, subjects will self-complete take-home tests at location of their choosing. Each test session will include the entire test-battery will be repeated frequency as often as every day and then reducing frequency of testing corresponding to the rate of speech perception improvement."
219718562|NCT07116057|BIOLOGICAL|MOv19-BBz CAR T cells|Autologous T cells engineered to express an extracellular single chain variable fragment (scFv) with FRa specificity.
219718563|NCT07116057|DRUG|Cyclophosphamide/Fludarabine|Cytotoxic chemotherapy agents used for lymphodepletion prior to MOv19-BBz CAR T cell administration.
219142668|NCT03557788|DRUG|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
219142669|NCT00300040|DRUG|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
219142670|NCT00300040|DRUG|6% Hydroxyethylstarch|250ml for intravenous infusion
219230157|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
219230158|NCT05964309|OTHER|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
219230159|NCT05964309|OTHER|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
219230160|NCT05576779|OTHER|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
219230161|NCT00854594|BEHAVIORAL|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
219230162|NCT04221165|DRUG|Opioids|Opioids will be prescribed as per institutional standards.
219230163|NCT04221165|DRUG|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
219230164|NCT01039909|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
219230165|NCT01039909|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
219230166|NCT02395692|OTHER|Treatment|Correlative studies
219230167|NCT02395692|DRUG|Methoxyamine|Given PO
219552670|NCT06449703|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
219718564|NCT07116057|DEVICE|FRa Expression Testing|Laboratory Developed Test used to determine subject eligibility
219718565|NCT07114666|BIOLOGICAL|XH001|mRNA neoantigen cancer vaccine
219718566|NCT07114666|DRUG|Chemotherapy|Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU
219718567|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Oral suspension -Route of administration:Oral or nasogastric tube
219718568|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Tablet formulation-Route of administration:Oral
219718569|NCT07115836|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
219718570|NCT07115836|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
219142671|NCT03265717|BIOLOGICAL|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
219142672|NCT00307307|DRUG|Niacin/simvastatin compared to simvastatin alone at 2 doses|
219142673|NCT06554080|PROCEDURE|Platform-switched implant placement|NobelParallel or NobelActive implants placed
219718571|NCT07114406|DRUG|PBK_M2502 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
219718572|NCT07114406|DRUG|PBK_M2502 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
219718573|NCT07115342|DRUG|Standard Allergic Rhinitis Treatment|Participants will receive standard-of-care treatment for allergic rhinitis, including oral antihistamines and/or intranasal corticosteroids, according to current clinical guidelines. No additional supplementation will be provided in the control group. This arm serves as the comparator for evaluating the effects of probiotic and vitamin D supplementation
219142674|NCT06554080|PROCEDURE|Platform-matched implant placement|Nobel Brånemark, NobelSpeedy Groovy implants placed
219142675|NCT02739035|DRUG|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
219142676|NCT02739035|DRUG|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
219230168|NCT02395692|DRUG|Temozolomide|Given PO
219230169|NCT01941576|DRUG|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
219552671|NCT06449703|DRUG|Xultophy®|Xultophy®
219552672|NCT01196390|DRUG|Carboplatin|Given IV
219552673|NCT01196390|OTHER|Laboratory Biomarker Analysis|Correlative studies
219552674|NCT01196390|DRUG|Paclitaxel|Given IV
219552675|NCT01196390|OTHER|Quality-of-Life Assessment|Ancillary studies
219552676|NCT01196390|RADIATION|Radiation Therapy|Undergo radiation therapy
219552677|NCT01196390|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219552678|NCT01196390|BIOLOGICAL|Trastuzumab|Given IV
219552679|NCT01532908|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
219552680|NCT01532908|DRUG|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
219142677|NCT03384069|BEHAVIORAL|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
219142678|NCT03384069|BEHAVIORAL|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
219142679|NCT00293865|PROCEDURE|sentinel node|detection of the sentinel node in breast cancer
219142680|NCT00293865|PROCEDURE|GAS|
219142681|NCT00552942|PROCEDURE|laparoscopic gastric bypass plus omentectomy|
219142682|NCT01352611|DRUG|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
219142683|NCT06258031|DRUG|Psilocybin (COMP360)|Up to 10mg on two occasions
219142684|NCT03210402|DEVICE|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
219142685|NCT03210402|DEVICE|Elevated night pacing off|Device will be programmed to normal lower rates
219142686|NCT05819190|DEVICE|Healsea Rescue*|Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
219142687|NCT05819190|DEVICE|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
219142688|NCT05131919|DRUG|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
219142689|NCT00193297|DRUG|Topotecan|
219142690|NCT00193297|DRUG|Paclitaxel|
219142691|NCT00193297|DRUG|Carboplatin|
219142692|NCT02517307|DRUG|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
219142693|NCT02517307|DRUG|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
219142694|NCT02517307|DRUG|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
219142695|NCT04499131|DRUG|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
219142696|NCT04499131|OTHER|Artificial Cycle (no intervention)|Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
219142697|NCT05960162|DIAGNOSTIC_TEST|90K|Blood test
219142698|NCT02051439|PROCEDURE|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
219142699|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
219142700|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
219142701|NCT02939690|DEVICE|Ultrasound|
219142702|NCT00823979|DRUG|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
219142703|NCT00823979|DRUG|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
219142704|NCT00823979|DRUG|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
219142705|NCT03771885|DRUG|BI 705564|Film-coated Tablet
219142706|NCT03771885|DRUG|Placebo|Film-coated Tablet
219142707|NCT04895566|BIOLOGICAL|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
219552681|NCT01532908|DRUG|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
219552682|NCT04646603|DRUG|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
219552683|NCT04646603|DRUG|Placebo|Subjects will receive subcutaneous placebo injections.
219552684|NCT05702255|OTHER|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
219230170|NCT01941576|DRUG|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
219552685|NCT05702255|OTHER|Sham acuptressure|The same protocol as the active acupressure group.
219552686|NCT06348979|PROCEDURE|Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns|restoration of endodontically treated teeth by endocrowns
219552687|NCT06348979|PROCEDURE|all ceramic Endocrowns (emax)|restoration of endodontically treated teeth by endocrowns
219552688|NCT03312894|DRUG|TAK-653|TAK-653 tablets
219552689|NCT03312894|DRUG|Placebo|Placebo-matching tablets
219552690|NCT03336788|DEVICE|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
219552691|NCT03336788|DEVICE|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
219230171|NCT00534677|DRUG|Terlipressin|2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
219230172|NCT00534677|DRUG|Octreotide|Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
219230173|NCT06021002|DRUG|R848|Nasal R848 administration
219718574|NCT07115342|DIETARY_SUPPLEMENT|Combined Vitamin D and Probiotics Supplementation|Participants in this group will receive a combination therapy of Vitamin D3 plus a daily oral probiotic capsule containing a standardized blend of Lactobacillus and Bifidobacterium species. Both supplements will be administered once daily for 12 weeks. This intervention aims to assess the synergistic effect of vitamin D and probiotics on immune response and symptom relief in allergic rhinitis.
219230174|NCT06021002|DRUG|Saline|Nasal saline administration
219718575|NCT07113847|BIOLOGICAL|Resin-Based Desensitizer|resin desensitizing agent
219718576|NCT07113847|DEVICE|Laser Desensitizer|Low-power Diode laser
219718577|NCT07113847|BIOLOGICAL|Fluoride-Based Desensitizer|Fluoride-based varnish
219718578|NCT07115277|DRUG|Flotufolastat F-18 Injection|All patients will receive one injection of Flotufolastat F-18 Injection, a PET radiopharmaceutical selective for PSMA. For the injection, subjects will receive a target dose of 8 mCi (296 MBq) ± 20% IV as a bolus injection. Flotufolastat F-18 Injection will be followed by a 10 ml saline flush.
219718579|NCT07119060|PROCEDURE|Cystectomy|Surgical removal of the endometrioma by gently pulling the cyst wall away from the ovarian tissue (divergent traction technique)
219142708|NCT03586544|DRUG|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
219142709|NCT03586544|BEHAVIORAL|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
219142710|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
219142711|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
219142712|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
219142713|NCT03490851|OTHER|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
219142714|NCT03523091|DRUG|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
219230175|NCT06038747|OTHER|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
219142715|NCT01070251|BEHAVIORAL|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
219230176|NCT06038747|OTHER|Individual Psychotherapy|Individual psychotherapy sessions
219230177|NCT03162835|OTHER|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
219142716|NCT01070251|BEHAVIORAL|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
219142717|NCT03451435|DRUG|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
219142718|NCT00984087|DEVICE|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
219230178|NCT05918549|DEVICE|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
219230179|NCT03471442|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
219230180|NCT03471442|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
219230181|NCT03471442|DRUG|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
219552692|NCT04051307|DRUG|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
219552693|NCT04051307|DRUG|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
219552694|NCT06232837|DEVICE|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
219552695|NCT02588911|PROCEDURE|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
219552696|NCT02588911|PROCEDURE|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
219552697|NCT01894009|PROCEDURE|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
219552698|NCT01894009|PROCEDURE|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
219230182|NCT03471442|DRUG|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
219142719|NCT01242150|DEVICE|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow \>40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
219142720|NCT01242150|DEVICE|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
219142721|NCT04639349|BEHAVIORAL|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
219230183|NCT03471442|DRUG|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
219142722|NCT04639349|OTHER|control group|the control group will not be trained
219230184|NCT00749944|DRUG|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
219230185|NCT00749944|DRUG|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
219230186|NCT00913445|PROCEDURE|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
219230187|NCT00201656|PROCEDURE|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
219230188|NCT00201656|PROCEDURE|Removal of Cerclage|Immediate removal of Cerclage following randomization
219718580|NCT07119060|PROCEDURE|plasma vaporization|It consists of destroying the cyst wall (vaporization) using plasma energy
219718581|NCT07119060|PROCEDURE|Sclerotherapy|Ethanol sclerotherapy destroys the endometriotic tissue lining the inner wall of the cyst through prolonged contact with 96% alcohol
219142723|NCT05790941|COMBINATION_PRODUCT|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
219142724|NCT04242732|DIAGNOSTIC_TEST|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
219142725|NCT04242732|DIAGNOSTIC_TEST|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
219142726|NCT00471029|DRUG|esomeprazole|
219142727|NCT02888002|BEHAVIORAL|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
219142728|NCT00820079|DRUG|ADX10059|oral administration
219142729|NCT00820079|DRUG|ADX10059 Matching Placebo|oral administration
219142730|NCT01832506|DRUG|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
219142731|NCT00670020|PROCEDURE|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
219230189|NCT00201656|PROCEDURE|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
219230190|NCT00006214|DRUG|flutamide|
219230191|NCT00006214|OTHER|placebo|
219230192|NCT04235920|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
219230193|NCT01995734|DRUG|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
219230194|NCT00000617|DRUG|azithromycin|
219230195|NCT02629575|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
219552699|NCT00513253|DRUG|lapatinib|
219552700|NCT01720953|OTHER|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
219552701|NCT02519153|DRUG|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
219142732|NCT02563613|BEHAVIORAL|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
219142733|NCT02563613|BEHAVIORAL|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
219142734|NCT02563613|OTHER|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
219718582|NCT07117019|OTHER|Self-care and lifestyle intervention advice|All females in both groups will follow self-care and lifestyle advice for 4 weeks.
219230196|NCT03556267|DEVICE|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
219230197|NCT03152214|OTHER|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
219142735|NCT01001078|DEVICE|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
219142736|NCT01001078|DEVICE|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
219142737|NCT01001078|DEVICE|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
219142738|NCT00270803|DRUG|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
219142739|NCT03629444|RADIATION|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
219142740|NCT03863834|DEVICE|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
219142741|NCT02685488|DEVICE|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
219142742|NCT02685488|DEVICE|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
219230198|NCT03152214|OTHER|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
219230199|NCT02400528|BEHAVIORAL|quality of life questionnaires|
219230200|NCT06500195|PROCEDURE|implantation of the hybrid instrumentation system|Surgery corrections were performed using the hybrid instrumentation system (screws and bands).
219230201|NCT06022653|OTHER|Treatment|EVAR,TEVAR,PTA
219230202|NCT04669119|DIETARY_SUPPLEMENT|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
219142743|NCT04118374|OTHER|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
219230203|NCT04669119|DIETARY_SUPPLEMENT|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
219230204|NCT04669119|DIETARY_SUPPLEMENT|Placebo|Placebo
219230205|NCT01622049|DEVICE|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
219142744|NCT04118374|OTHER|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
219142745|NCT05216120|DRUG|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
219142746|NCT01126307|DRUG|Verapamil|80 mg tid
219142747|NCT01126307|DRUG|placebo|placebo tid
219142748|NCT02964780|PROCEDURE|Gastric bypass surgery|
219142749|NCT02964780|BEHAVIORAL|Conservative weight loss program|
219142750|NCT04481906|PROCEDURE|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
219142751|NCT01177852|DRUG|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~\- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
219142752|NCT01177852|DRUG|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
219142753|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
219142754|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
219142755|NCT00043082|DRUG|carboplatin|intravenous q 4 weeks
219142756|NCT00043082|DRUG|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
219142757|NCT03409263|OTHER|Observational study|Not applicable (observational registry study)
219142758|NCT04479540|RADIATION|Angiography scanner|systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
219142759|NCT01597128|DEVICE|Flex HD|Flex HD mesh for hernia repair
219142760|NCT01597128|DEVICE|Strattice|Strattice mesh for hernia repair
219142761|NCT03234816|DRUG|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
219142762|NCT03234816|DRUG|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
219142763|NCT03234816|DRUG|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
219142764|NCT03234816|DRUG|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
219142765|NCT02473562|DRUG|Varenicline|Tablet 1 mg BID
219142766|NCT02473562|DRUG|Placebo (for varenicline)|Tablet 1 mg BID
219142767|NCT00208767|DRUG|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
219142768|NCT00208767|DRUG|Placebo|A matched placebo pill will be given orally daily.
219142769|NCT01735474|OTHER|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
219142770|NCT01735474|OTHER|Placebo|Usual care
219142771|NCT03342651|OTHER|Vitamin D|Vitamin D, general anesthesia, respiratory complications
219142772|NCT03545984|OTHER|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
219142773|NCT03545984|OTHER|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
219142774|NCT00156117|DRUG|asenapine|5 mg BID or 10mg BID
219142775|NCT00156117|DRUG|Placebo|Placebo
219142776|NCT00156117|DRUG|olanzapine|olanzapine 15 mg QD
219142777|NCT06345560|DRUG|Drospirenone|4 mg tablet once daily
219142778|NCT03800667|DRUG|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
219142779|NCT02308137|DRUG|Domperidone|Simon-2-stage design for domperidone futility
219142780|NCT01843491|BIOLOGICAL|Ad-PfCA|Vaccine
219142781|NCT04548011|OTHER|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
219142782|NCT00597350|DIETARY_SUPPLEMENT|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
219142783|NCT03644537|PROCEDURE|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
219142784|NCT03119636|BIOLOGICAL|NPC transplantation|The cells are stereotactically implanted in the striatum.
219142785|NCT03119636|DRUG|Levodopa|Levodopa is used depending on the patient's condition
219142786|NCT02545751|RADIATION|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
219142787|NCT02545751|DRUG|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
219142788|NCT06676423|BIOLOGICAL|Lenzumestrocel|1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
219142789|NCT06676423|DRUG|Riluzole|In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
219142790|NCT06676462|DEVICE|Video laryngoscopy with visionPRO|Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.
219230206|NCT02525185|OTHER|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
219230207|NCT03979937|PROCEDURE|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
219230208|NCT02677688|BIOLOGICAL|Autologous EBV specific CTL infusion|
219230209|NCT03054506|DEVICE|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
219230210|NCT03054506|DEVICE|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
219230211|NCT03054506|DEVICE|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
219230212|NCT00923078|BEHAVIORAL|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
219230213|NCT00923078|BEHAVIORAL|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
219230214|NCT06300294|OTHER|acupressure|After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
219230215|NCT04372706|DRUG|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
219718583|NCT07117019|OTHER|Myofascial release|Females in the experimental group will receive intravaginal myofascial release in lithotomic position. After ensuring empty bladder/bowel, therapist uses sterile gloves and lubricant to insert fingers 2-3cm into vagina, pressing vaginal walls bilaterally for 2 minutes. Perineal massage follows, targeting scar tissue and tender points with friction at right angles. Treatment duration starts at 5 minutes (due to pain tolerance) and gradually increases to 20 minutes. Hot pack or ultrasound may be used pre-treatment for pain relief. Therapist performs gentle U-shaped reciprocating massage movements up and down towards rectum for 20 minutes total. Sterile technique maintained throughout with hand washing and glove changes between procedures.
219718584|NCT07117019|OTHER|Acupressure|"Each female in the experimental group will receive acupressure on BL 23 as follows: Acupressure is also another branch of acupuncture. In this method, fingers press the key points on the skin to stimulate and induce the body's natural self-healing capabilities. In the present study, the BL23 point located 1.5 cm lateral to the lower border of the spinous process of the second lumbar vertebra was employed.~The therapist will apply pressure on BL 23 points with the thumb for 5 minutes in the counterclockwise direction. In the second 5 minutes, pressure was applied in the opposite direction for 5 minutes. Similarly, the pressure was continued for 20 minutes."
219142791|NCT06676462|DEVICE|Video laryngoscopy with Glidescope|Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
219142792|NCT01070056|BEHAVIORAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
219142793|NCT01070056|BEHAVIORAL|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
219142794|NCT06631404|DIAGNOSTIC_TEST|renal doppler|doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
219142795|NCT06629324|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cell Transfusion|Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
219230216|NCT04372706|DRUG|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
219230217|NCT04883515|DIETARY_SUPPLEMENT|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
219142796|NCT06629324|OTHER|Rehabilitation|Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
219142797|NCT06629051|DRUG|Berberine Hydrochloride|post-intervention of berberine
219142798|NCT06629051|DRUG|Placebo|Looks the same as berberine
219230218|NCT04883515|DIETARY_SUPPLEMENT|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
219230219|NCT04883515|PROCEDURE|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
219230220|NCT04883515|PROCEDURE|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
219230221|NCT05220813|DRUG|Lidocaine|local infiltration by lidocaine in the surgical site
219230222|NCT05220813|DRUG|Bupivacain|44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
219230223|NCT02028650|BIOLOGICAL|the first donor's stem cell|HLA-matched stem cell infusion
219230224|NCT02028650|BIOLOGICAL|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
219230225|NCT05228834|DRUG|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
219230226|NCT05228834|DRUG|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
219230227|NCT00884806|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
219230228|NCT00884806|DEVICE|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
219230229|NCT00884806|DEVICE|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
219230230|NCT00884806|DEVICE|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
219230231|NCT00884806|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
219230232|NCT00559572|BEHAVIORAL|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
219230233|NCT00559572|OTHER|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
219230234|NCT06469931|OTHER|range of motion exercises|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
219230235|NCT06469931|DEVICE|Extracorporeal shock wave therapy|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
219230236|NCT06469931|OTHER|ozone therapy|ozone therapy
219230237|NCT04044885|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
219230238|NCT02936401|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
219230239|NCT03431649|DRUG|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
219230240|NCT03431649|DRUG|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
219230241|NCT00006084|BIOLOGICAL|lintuzumab|
219230242|NCT00825318|PROCEDURE|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
219230243|NCT01948557|BEHAVIORAL|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
219230244|NCT01631409|OTHER|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
219230245|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
219230246|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
219230247|NCT01631409|PROCEDURE|PCA|Percutaneous coronary angioplasty
219142799|NCT06711523|DRUG|PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
219142800|NCT06711523|DRUG|PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
219142801|NCT01212757|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
219230248|NCT01631409|PROCEDURE|CABG|Coronary artery bypass grafting
219230249|NCT01631409|DEVICE|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
219230250|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
219230251|NCT00564447|DRUG|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
219230252|NCT00564447|DRUG|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
219142802|NCT01212757|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
219142803|NCT01212757|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
219142804|NCT01212757|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
219142805|NCT06712199|DRUG|oxalidine|"Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:"
219142806|NCT03714750|PROCEDURE|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
219142807|NCT03714750|PROCEDURE|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
219142808|NCT00284401|PROCEDURE|Evaluation of the placement of the Delta prosthesis|
219230253|NCT01762397|DRUG|PMK-S005|
219230254|NCT00502359|DEVICE|capillary blood glucose measurement|
219230255|NCT00988845|DIETARY_SUPPLEMENT|Indole-3-carbinol|200 mg bid po X 8 weeks
219230256|NCT06495463|DRUG|Trifluridine/tipiracil|"Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
219142809|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
219142810|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
219230257|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 1|SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
219230258|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 2|SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
219230259|NCT06962969|DRUG|Ibrance|Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer
219230260|NCT04719026|OTHER|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
219230261|NCT04241952|OTHER|Exercise|Bedcycling
219230262|NCT04751799|DEVICE|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
219230263|NCT04751799|DEVICE|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
219230264|NCT05380089|OTHER|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
219230265|NCT03807596|PROCEDURE|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
219230266|NCT03807596|PROCEDURE|Scaling & root planning alone|Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
219142811|NCT02280161|OTHER|cytology specimen collection procedure|Correlative studies
219142812|NCT00647530|BIOLOGICAL|panitumumab|
219142813|NCT00647530|DRUG|capecitabine|
219142814|NCT00647530|DRUG|fluorouracil|
219142815|NCT00647530|DRUG|oxaliplatin|
219142816|NCT01029093|OTHER|no intervention, MRI and motor skill test|Two MR Investigations at two different times
219142817|NCT02611427|BEHAVIORAL|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
219142818|NCT02611427|BEHAVIORAL|Education|The education group will receive information about safe physical activity.
219230267|NCT03597087|PROCEDURE|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
219230268|NCT03597087|DRUG|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
219718585|NCT07118657|OTHER|Vegan Diet|"Vegan diet would be defined as a diet based solely of plant products with exclusion of all animal products including meat, fish, dairy, honey and eggs.• Additional supplementation of vitamin B12 (500 µg/day) in the vegan diet group along with calcium (50-75 mg/kg/day), vitamin D (800-1600 IU/day) and iron supplementation (3-6 mg/kg/day) as per requirement.~o Monitoring- Based on vitamin B12 levels, 25(OH) vitamin D3 levels, serum calcium, and serum iron studies (complete hemogram, ferritin, iron, transferrin saturation, total iron binding capacity)."
219552702|NCT04055233|DRUG|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
219142819|NCT02812966|DEVICE|Lutonix|Drug Coated Balloons
219142820|NCT02812966|DEVICE|IN.PACT|Drug Coated Balloons
219142821|NCT06220045|COMBINATION_PRODUCT|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
219142822|NCT06220045|COMBINATION_PRODUCT|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
219142823|NCT03244436|PROCEDURE|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
219142824|NCT05571722|DRUG|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
219142825|NCT05571722|DRUG|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
219142826|NCT06789367|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
219142827|NCT06789367|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
219142828|NCT05583526|DRUG|Ritlecitinib|50 mg capsule
219230269|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
219230270|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
219142829|NCT05583526|DRUG|Placebo|Matching capsule
219142830|NCT00867867|DRUG|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
219142831|NCT00867867|DRUG|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
219142832|NCT00867867|DRUG|Placebo|9.3 mg once per day, 6 days per week, for 9 months
219142833|NCT06242782|PROCEDURE|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
219142834|NCT06242782|PROCEDURE|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
219230271|NCT01835639|DIETARY_SUPPLEMENT|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
219230272|NCT03109080|DRUG|Olaparib|five levels of dose, per os administration, twice daily each day
219230273|NCT03109080|RADIATION|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
219718586|NCT07118657|OTHER|Standard Diet|Standard Diet
219142835|NCT06242782|PROCEDURE|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
219142836|NCT06242782|PROCEDURE|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
219142837|NCT01566916|PROCEDURE|Total Hip Arthroplasty|
219142838|NCT06185738|OTHER|WCM app|WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
219718587|NCT07118787|OTHER|Active Release Technique|A manual therapy technique applied to release soft tissue tension in the hamstrings.
219718588|NCT07118787|OTHER|Proprioceptive Neuromuscular Facilitation|A stretching technique involving passive stretching and isometric contractions of the hamstrings.
219142839|NCT04901312|BEHAVIORAL|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
219142840|NCT04901312|BEHAVIORAL|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
219142841|NCT04901312|BEHAVIORAL|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
219142842|NCT04901312|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
219142843|NCT04901312|OTHER|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
219142844|NCT02549313|PROCEDURE|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
219142845|NCT04459169|PROCEDURE|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
219142846|NCT05653583|DEVICE|Wrist Device|peripheral nerve stimulation via wrist-worn device
219142847|NCT05653583|DEVICE|Ear Device|peripheral nerve stimulation via ear-worn device
219142848|NCT05653583|DEVICE|Sham Device|Wrist-worn device that does not actually deliver stimulation
219142849|NCT06411834|BEHAVIORAL|Decision navigation tool|An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
219142850|NCT06235294|DIETARY_SUPPLEMENT|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
219142851|NCT06235294|DIETARY_SUPPLEMENT|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
219230274|NCT03547154|BIOLOGICAL|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
219230275|NCT03547154|BIOLOGICAL|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
219230276|NCT04679675|OTHER|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
219230277|NCT04679675|BEHAVIORAL|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
219230278|NCT04679675|BEHAVIORAL|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
219718589|NCT07117331|BEHAVIORAL|Technology-Enhanced Continuous Nursing System|A multi-faceted behavioral and educational intervention lasting 6 months post-discharge. It utilized a smartphone app, WeChat, tele-monitoring (phone/video calls), and community health partnerships to provide structured education, personalized rehabilitation plans, and continuous professional nursing support.
219718590|NCT07117331|BEHAVIORAL|Routine Postoperative Care|Standard institutional care including standard discharge instructions and routine outpatient follow-up appointments.
219230279|NCT04679675|BEHAVIORAL|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
219230280|NCT05584748|DEVICE|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
219230281|NCT05049941|DIAGNOSTIC_TEST|lactat and blood gases|observational
219230282|NCT03421249|OTHER|Exercises|Muscle strengthening exercises of the hip and knee muscles
219230283|NCT03421249|OTHER|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
219718591|NCT07117357|BEHAVIORAL|Neuroathletic Training Protocol|This intervention involves a 20-minute neuroathletic training session using the Z-Health® kit. It includes visual reset exercises (eye massage, palming), star chart eye muscle training, saccade training with letter cards, convergence-divergence drills using Brock string, vestibular activation through lunges, spinal and hip extension exercises, slap tap coordination drills, and use of pinhole glasses. The aim is to stimulate sensory pathways and enhance neuromotor readiness acutely.
219142852|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
219142853|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
219718592|NCT07117357|BEHAVIORAL|Standard Warm-Up Protocol|This 20-minute warm-up consists of two components: 10 minutes of light walking at a moderate pace and 10 minutes of dynamic stretching (leg swings, hip flexor stretches, knee hugs, high knees, butt kicks, arm circles, and trunk rotations). It is intended to mimic standard pre-activity routines and serves as the comparator condition.
219718593|NCT07117487|BIOLOGICAL|mRNA-1345|Suspension for injection
219718594|NCT07118969|OTHER|Breast Cancer Awareness Training|A structured breast cancer education program consisting of five sessions, each lasting 90 minutes. The program covers breast cancer risk factors, early detection methods including breast self-examination (BSE), clinical breast examination, mammography, and health-promoting behaviors. The sessions are conducted in group settings within university faculties. The education aims to increase participants' knowledge and awareness of breast cancer and encourage early detection practices.
219718595|NCT07119125|DRUG|MRT-8102|Oral capsules
219718596|NCT07119125|DRUG|Placebo|Oral capsules
219718597|NCT07116746|DRUG|AR882 75 mg|Solid Oral Capsule
219718598|NCT07116746|DRUG|XOI Low Dose|Solid Oral Tablet
219718599|NCT07116746|DRUG|XOI High Dose|Solid Oral Tablet
219718600|NCT07117916|BEHAVIORAL|Supervised nutritional guidance, physical exercise, cognitive training, social engagement, and management of vascular and metabolic risk factors.|In addition to health advice, participants in the intervention group will receive a structured, multidomain lifestyle program comprising nutritional guidance, physical exercise, cognitive training and social engagement, and monitoring and management of vascular and metabolic risk factors. The STRONGER 60+ intervention is based on the FINGER protocol and has been specifically adapted for primary care to enhance feasibility and scalability. Key adaptations include 1) delivering physical exercise sessions at external gym facilities rather than at primary care centers, and 2) shortening the intervention duration from two years to six months.
219718601|NCT07117812|PROCEDURE|Laparoscopic purse-string forceps and multifunctional sealing ring|Performing totally laparoscopic radical total gastrectomy with R0 resection, completing esophagojejunostomy using purse-string forceps and multifunctional sealing ring.
219142854|NCT03143842|DEVICE|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
219142855|NCT03090776|DRUG|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
219142856|NCT03090776|OTHER|Placebo saline|bolus and infusion saline, administered under general anesthesia
219142857|NCT05646004|DEVICE|Cataract surgery|Implantation of 621 lens
219142858|NCT01275287|DRUG|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
219142859|NCT01275287|DRUG|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
219142860|NCT05162391|BEHAVIORAL|Contingency Management|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
219718602|NCT07118930|DRUG|Sivelestat Sodium injection 2 h after OPCABG for 72 h|Sivelestat Sodium injection 2 h after OPCABG for 72 h
219718603|NCT07118930|DRUG|Saline (0.9% NaCl)|Saline (0.9% NaCl) instead of Sivelestat
219718604|NCT07117630|DRUG|L-Ornithine L-Aspartate|3g orally three times daily
219718605|NCT07117630|DRUG|Dalpiciclib|150mg orally once daily (3 weeks on/1 week off per 28-day cycle)
219718606|NCT07117630|DRUG|Fulvestrant|500mg IM on Days 1 \& 15 of Cycle 1, then Day 1 of subsequent cycles
219718607|NCT07118293|BEHAVIORAL|MSE-PEACE|"The MSE-PEACE (Multi-Sensory Environment-Parent Empowerment and Child Engagement) intervention is a family-centered, therapist-guided sensory integration program specifically developed for children with developmental disabilities and their caregivers. Unlike traditional child-only sensory therapies, this intervention actively involves parents in all stages-assessment, goal setting, activity participation, and follow-up.~Each participant dyad (parent and child) attends 10 biweekly sessions (60 minutes each) in a structured sensory therapy space equipped with adjustable lighting, tactile materials, auditory inputs, and other multisensory tools. The intervention is tailored to each child's sensory processing profile and emotional regulation needs, while promoting parent-child co-regulation, bonding, and collaborative engagement.~Occupational therapists facilitate the sessions using individualized strategies to support child-led participation and empower parents with real-time coaching,"
219142861|NCT03406936|DRUG|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
219718608|NCT07117383|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
219718609|NCT07117383|DRUG|ASP-001|Oral liquid suspension of sildenafil
219718610|NCT07117383|DRUG|Commercial Sildenafil and Sildenafil/Tadalafil Products|A selection of marketed sildenafil or sildenafil + tadalafil products used as comparators. Includes tablets and chewables such as Viagra®, Galotam, BlueChew, Aristo Sildaristo, Lemonaid Viagra, Ro Sparks, Hims Hard Mints, and Hello Cake ED Cake Meds.
219718611|NCT07119034|DIAGNOSTIC_TEST|Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)|Blood samples were collected from the antecubital vein and processed at the TrueLab medical laboratory. The whole blood was initially collected in plain tubes, and subsequently centrifuged to obtain serum samples. Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) Thioredoxin and 4-Hydroxynonenal quantification, malondialdehyde levels
219142862|NCT00550394|DRUG|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
219142863|NCT00550394|DRUG|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
219142864|NCT06208397|DIAGNOSTIC_TEST|Magnetic Resonance Elastography and routine MRI|Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.
219142865|NCT06333990|DRUG|Quetiapine Fumarate|Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
219142866|NCT06333990|DRUG|TAU|Standard of care psychotropic medications for treatment of patients with mTBI.
219142867|NCT06399679|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
219142868|NCT06399679|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
219142869|NCT04947072|PROCEDURE|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
219142870|NCT04947072|PROCEDURE|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
219142871|NCT01750307|DIETARY_SUPPLEMENT|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
219142872|NCT01750307|DIETARY_SUPPLEMENT|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
219142873|NCT00719459|DRUG|Iron Sucrose|Venofer 20 mg/mL
219142874|NCT00719459|DRUG|Iron Sucrose|Iron sucrose 20 mg/mL
219142875|NCT02170324|DRUG|Exenatide|
219142876|NCT02170324|DRUG|Placebo|
219142877|NCT01645098|DRUG|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
219142878|NCT01645098|DRUG|Dexmedetomidine|0.5 mcg/kg/hr IV
219142879|NCT05499039|DEVICE|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
219142880|NCT05499039|DEVICE|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
219142881|NCT01522092|DRUG|escitalopram|5mg-20mg, tablet, od, 12 months
219142882|NCT01664871|DEVICE|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
219142883|NCT01340261|BEHAVIORAL|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
219142884|NCT00939419|OTHER|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
219230284|NCT02470169|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
219142885|NCT00939419|OTHER|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
219142886|NCT00939419|OTHER|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
219142887|NCT03656094|DRUG|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
219142888|NCT03656094|DRUG|Placebo plus chemotherapy|Placebo plus chemotherapy
219142889|NCT01324453|PROCEDURE|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
219142890|NCT01324453|PROCEDURE|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
219142891|NCT02042898|OTHER|Restrictive Transfusion Strategy|
219142892|NCT02042898|OTHER|Liberal transfusion strategy|
219142893|NCT04730999|DRUG|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
219142894|NCT04730999|DRUG|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
219142895|NCT04730999|DRUG|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
219142896|NCT04730999|DRUG|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
219142897|NCT05505071|DEVICE|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
219142898|NCT05790096|BIOLOGICAL|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
219230285|NCT02470169|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
219230286|NCT02470169|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
219230287|NCT02470169|DEVICE|shepherd catheter|
219230288|NCT02470169|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
219230289|NCT03849482|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
219230290|NCT03849482|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
219142899|NCT05790096|BIOLOGICAL|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
219142900|NCT00708032|DEVICE|spectacles|habitual spectacles
219142901|NCT00708032|DEVICE|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
219142902|NCT01400776|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
219142903|NCT01400776|DRUG|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
219142904|NCT01807546|DRUG|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
219142905|NCT05783726|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
219230291|NCT03849482|DIAGNOSTIC_TEST|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
219230292|NCT03849482|DIAGNOSTIC_TEST|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
219230293|NCT02861456|OTHER|Standard Model of Care|
219230294|NCT02861456|OTHER|Alternative Model of Care|
219230295|NCT02725138|DIETARY_SUPPLEMENT|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
219142906|NCT05783726|BEHAVIORAL|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
219230296|NCT02725138|OTHER|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
219230297|NCT01788605|DRUG|ramosetron|
219142907|NCT05783726|BEHAVIORAL|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
219142908|NCT05783726|BEHAVIORAL|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
219142909|NCT00837746|DRUG|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
219142910|NCT02174393|DRUG|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
219142911|NCT02174393|PROCEDURE|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
219230298|NCT04471441|DRUG|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
219718612|NCT07117149|BEHAVIORAL|multicomponent, tiered intervention|"Kindergarten: Train teachers and integrate healthy weight management into kindergarten health policies; deliver health education sessions for children; monitor extra dietary intake and physical activity; conduct monthly height and weight measurements.~Family: Provide multi-format health education (lectures, short videos, articles) to communicate core intervention messages; set health behavior goals and deliver personalized feedback; conduct motivational interviewing in offline parent meetings or by phone.~Hospital: Offer professional health guidance and medical services. PKU-SMART online platform: Health Education Module; Growth Monitoring Module; Health Behavior Module; Home-Kindergarden Partnership Module."
219718613|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 1 in a single dose of tablet fasted Period 2: Participants received Form 5 in a single dose of tablet fasted
219142912|NCT02174393|DRUG|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
219142913|NCT02174393|DRUG|Post-Universal Peel Skin Care|"* Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening"
219142914|NCT02797717|RADIATION|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
219142915|NCT02797717|DRUG|Vincristine|ARM A and ARM B
219142916|NCT02797717|DRUG|Etoposide|ARM B , 100mg/m2/day
219142917|NCT02797717|DRUG|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
219142918|NCT02797717|DRUG|Doxorubicin|ARM B , 25mg/m2
219142919|NCT02797717|DRUG|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
219142920|NCT02797717|DRUG|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
219142921|NCT00212745|BEHAVIORAL|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
219230299|NCT04471441|DRUG|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
219230300|NCT01488084|PROCEDURE|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
219230301|NCT01488084|PROCEDURE|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
219230302|NCT00895245|DRUG|fosaprepitant dimeglumine|Given IV
219230303|NCT00895245|DRUG|cisplatin|Given IV
219230304|NCT00895245|DRUG|palonosetron hydrochloride|Given IV
219230305|NCT00895245|DRUG|dexamethasone|Given IV and orally
219230306|NCT00895245|OTHER|Functional Living Index-Emesis Questionnaire|Ancillary studies
219230307|NCT00895245|BEHAVIORAL|Emesis Diary|Ancillary studies
219230308|NCT00895245|RADIATION|Radiotherapy|Undergo radiotherapy
219230309|NCT01717066|DRUG|the ginsenoside Rg3|
219230310|NCT01717066|DRUG|Placebo|
219230311|NCT04653688|DEVICE|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
219230312|NCT04653688|DEVICE|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
219718614|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 5 in a single dose of tablet fasted Period 2: Participants received Form 1 in a single dose of tablet fasted
219718615|NCT07117799|DRUG|PF-07248144|Period 1: Fasted participants received a single dose of tablet of Form 1 orally Period 2: Participants received a single dose of tablet orally of Form 5 in a fed state
219230313|NCT04653688|RADIATION|MRI|"* an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis"
219230314|NCT04653688|RADIATION|DaTSCAN|"* quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease."
219230315|NCT02764905|BEHAVIORAL|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
219230316|NCT00989755|OTHER|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
219230317|NCT05028465|PROCEDURE|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
219230318|NCT05028465|PROCEDURE|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
219230319|NCT04976556|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
219230320|NCT02706483|DRUG|Plecanatide|
219142922|NCT03315884|PROCEDURE|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
219230321|NCT05657821|DIETARY_SUPPLEMENT|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
219230322|NCT02587052|DRUG|Generic tacrolimus|Generic tacrolimus
219230323|NCT02587052|DRUG|Prograf|Prograf, the original tacrolimus
219230324|NCT01972776|DRUG|QBM076|Supplied in 25 mg and 75 mg capsules
219230325|NCT01972776|DRUG|Placebo|Matching placebo capsules
219230326|NCT00655109|DRUG|Olopatadine|Ophthalmic solution
219230327|NCT00655109|DRUG|Fluticasone|Nasal spray
219230328|NCT00655109|DRUG|Saline|Nasal spray
219230329|NCT00655109|DRUG|Artificial tears|Ophthalmic Solution
219230330|NCT05928754|DIAGNOSTIC_TEST|care strategy|"Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
219230331|NCT03328637|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
219230332|NCT02969200|DRUG|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
219230333|NCT01388413|DRUG|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
219230334|NCT01594606|BEHAVIORAL|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
219230335|NCT03763968|OTHER|treatment and outcome|
219230336|NCT03032757|DIETARY_SUPPLEMENT|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
219230337|NCT00330785|DRUG|Amlodipine/Atorvastatin|
219230338|NCT05565898|DEVICE|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
219230339|NCT02782260|DRUG|Dipyridamole|
219230340|NCT02782260|DRUG|Placebo|
219230341|NCT01774240|OTHER|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
219230342|NCT01984099|DRUG|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
219230343|NCT01984099|DRUG|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
219230344|NCT00995683|DRUG|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
219230345|NCT00995683|DRUG|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
219230346|NCT01543204|DRUG|Etanercept|Administered by subcutaneous injection
219230347|NCT00458185|DRUG|etanercept|
219142923|NCT03315884|PROCEDURE|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
219142924|NCT04651881|DRUG|Reference drug|1 Cap., single oral administration under fed condition
219142925|NCT04651881|DRUG|Test drug 1|1 Tab., single oral administration under fed condition
219142926|NCT04651881|DRUG|Test drug 2|1 Tab., single oral administration under fed condition
219142927|NCT00014794|DRUG|15-O labeled water|
219142928|NCT01012388|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
219142929|NCT04528706|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
219142930|NCT06552884|BEHAVIORAL|(Maternity Identity Development Training)|Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
219142931|NCT04618757|BEHAVIORAL|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
219142932|NCT04618757|BEHAVIORAL|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
219142933|NCT04618757|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
219142934|NCT00168467|DRUG|Ramipril|
219142935|NCT04544761|OTHER|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
219142936|NCT02320123|BEHAVIORAL|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
219142937|NCT04666506|OTHER|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
219142938|NCT00422617|DRUG|Alefacept (Amevive)|
219230348|NCT00603018|DRUG|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
219230349|NCT05713136|DEVICE|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
219142939|NCT00432523|BIOLOGICAL|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
219230350|NCT01470209|DRUG|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
219230351|NCT01470209|DRUG|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
219230352|NCT05052398|DRUG|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
219230353|NCT05052398|DRUG|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
219230354|NCT04749329|DEVICE|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
219230355|NCT02333565|DRUG|Everolimus|
219230356|NCT02333565|DRUG|Octreotide|
219142940|NCT05457127|DEVICE|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
219718616|NCT07118345|PROCEDURE|Early prophylactic decompressive hemicraniectomy|Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).
219718617|NCT07118670|DRUG|Aflibercept 8mg|Solution in Vial, intravitreal (IVT) injection
219718618|NCT07117006|DEVICE|miniscrew- supported maxillary posterior segments' intrusion using clear aligners|maxillary posterior segments will be intruded with the aid of miniscrews and clear aligners
219718619|NCT07116018|BEHAVIORAL|Psychoeducation|The intervention comprises 8 individual psychoeducational sessions over 12 weeks, as an adaptation of the Psychoeducation, Paced Respiration, and Relaxation (PEPRR) (Laudenslager et al., 2015). The adaptation in the current study involves delivery by a trained nurse and omission of the biofeedback component.
219718620|NCT07115849|BEHAVIORAL|Physical training|Aerobic and resistance training three times per week. Two supervised training sessions.
219718621|NCT07115719|OTHER|No Intervention: Observational Cohort|NO INTERVENTION
219142941|NCT06552663|DEVICE|CCTA|Coronary CT angiography
219718622|NCT06918704|BEHAVIORAL|Coherence|Coherence is a music-based rhythm training app.
219718623|NCT06918704|BEHAVIORAL|Worder|Worder is a word search app.
219718624|NCT07116213|RADIATION|Moderately Hypofractionated Adaptive Radiotherapy|Moderately Hypofractionated Adaptive Postoperative Radiotherapy
219718625|NCT07115641|DRUG|Huoluo Pills|Huoluo Pills: Orally take 1 pill once, twice a day (swallow with warm water)
219142942|NCT01767714|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
219142943|NCT01767714|DRUG|Plerixafor|0.24 mg/kg/day subcutaneous injection
219142944|NCT01767714|DRUG|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
219142945|NCT06261372|BEHAVIORAL|The mindfulness meditation combined with progressive muscle relaxation training .|The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
219142946|NCT06552325|BEHAVIORAL|Single Session Narrative Therapy|The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
219142947|NCT05756335|BEHAVIORAL|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
219552703|NCT04055233|DRUG|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
219552704|NCT05303441|PROCEDURE|percutaneous coronary intervention|conventional coronary angiography
219552705|NCT01457092|DEVICE|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
219552706|NCT03787017|DRUG|FDC(MP-513 20mg/Metformin XR 1000mg)|
219552707|NCT03787017|DRUG|MP-513 20mg|
219552708|NCT03787017|DRUG|Metformin XR 1000mg|
219718626|NCT07115641|DRUG|Iguratimod Tablets|Iguratimod Tablets: Orally take 1 tablet once, twice a day (one tablet in the morning and one in the evening, after meals)
219718627|NCT07114991|BEHAVIORAL|E-Bike Commuting|Participants in the intervention group will receive a pedal-assist electric bicycle (e-bike), a helmet, safety training, and a cycling computer. They will be asked to use the e-bike for commuting or personal travel at least four times per week for 12 weeks. E-bike usage will be monitored using a Garmin Edge device. Participants will also complete baseline, 12-week, and 24-week assessments including fitness testing, blood tests, body composition, surveys, and wearable activity monitoring.
219718628|NCT07116330|OTHER|Vascuar risk factor screening (blood pressure, medical history, BMI, laboratory tests)|"The vascular risk assessment is outlined below, there may be slight variations according to local routines. Overall, the screening should include:~Family history of vascular disease~Tests/examinations (order or obtain from medical records \[past 3 months\]) Weight Height Waist circumference 12-lead ECG Resting and standing blood pressure Total cholesterol HDL cholesterol LDL cholesterol HbA1c High sensitivity CRP Serum creatinine Urine albumin-to-creatinine ratio~Medical history Atherosclerotic cardiovascular disease Atrial fibrillation Congestive heart failure Diabetes mellitus Hypertension Kidney disease Life-style risk factors (smoking, exercis"
219142948|NCT01500395|PROCEDURE|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
219142949|NCT01533870|DRUG|NKTR-118|Oral 25 mg
219142950|NCT01533870|DRUG|Rifampin|Oral 600 mg
219142951|NCT00680342|DRUG|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
219142952|NCT00680342|DRUG|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
219142953|NCT00680342|OTHER|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
219142954|NCT06357910|DRUG|HCP2303|Take 1 tablet once per period
219142955|NCT06357910|DRUG|RLD2302|Take 1 tablet once per period
219142956|NCT06357910|DRUG|RLD2102|Take 1 tablet once per period
219142957|NCT00078572|DRUG|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
219142958|NCT00078572|DRUG|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
219142959|NCT04583046|DRUG|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
219142960|NCT04583046|DRUG|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
219142961|NCT00609908|PROCEDURE|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
219552709|NCT03770793|PROCEDURE|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
219142962|NCT00609908|PROCEDURE|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
219142963|NCT00609908|PROCEDURE|serial excision|as much scar as possible is excised, whereafter the wound is closed
219142964|NCT00609908|PROCEDURE|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
219142965|NCT00005137|OTHER|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
219142966|NCT02064959|DEVICE|Temperature management Zoll Intravascular Temperature Management device|
219142967|NCT02694835|DEVICE|Delefilcon A contact lenses with UV Absorber|
219142968|NCT02694835|DEVICE|Delefilcon A contact lenses|
219142969|NCT00897546|OTHER|laboratory biomarker analysis|
219142970|NCT04369495|OTHER|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
219142971|NCT02208258|DEVICE|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
219142972|NCT02278393|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
219142973|NCT02278393|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
219142974|NCT02712658|DRUG|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
219142975|NCT02712658|DRUG|Placebo|
219142976|NCT05315336|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
219142977|NCT01328418|PROCEDURE|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
219142978|NCT02552186|OTHER|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
219142979|NCT04162119|BIOLOGICAL|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
219142980|NCT04931446|PROCEDURE|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
219142981|NCT00622531|DEVICE|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
219142982|NCT00622531|OTHER|hidden BNP value|no intervention
219142983|NCT03192319|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection
219142984|NCT02711839|DIETARY_SUPPLEMENT|Commercial diabetic formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
219142985|NCT02711839|DIETARY_SUPPLEMENT|White sweet potato formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
219142986|NCT02704741|DEVICE|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
219142987|NCT00561886|DRUG|Formoterol|One inhalation of 24µg Formoterol
219142988|NCT04307316|OTHER|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
219142989|NCT04307316|OTHER|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
219142990|NCT02477670|DRUG|AVP-786|
219142991|NCT02477670|DRUG|Placebo|
219142992|NCT01815008|DRUG|Clopidogrel|Clopidogrel 75 mg daily
219142993|NCT01815008|DRUG|Aspirin|Aspirin 81 mg daily
219142994|NCT03493269|DRUG|BAY1834845|Orally administered.
219142995|NCT03493269|OTHER|Matching Placebo|Orally administered.
219142996|NCT03493269|DRUG|Midazolam|Part 1: Orally administered 1mg as a single dose.
219142997|NCT04168619|DRUG|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
219142998|NCT04168619|OTHER|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
219142999|NCT02026076|OTHER|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
219143000|NCT00787033|DRUG|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
219143001|NCT05319457|OTHER|The radon app|Participants will be asked to use the radon app.
219143002|NCT05319457|OTHER|Print brochure|Participants will receive print brochures.
219143003|NCT00446550|DRUG|afegostat tartrate|
219143004|NCT02937831|BIOLOGICAL|RIXUBIS|
219143005|NCT04407325|DEVICE|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
219143006|NCT04407325|DEVICE|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
219143007|NCT02379299|DEVICE|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
219143008|NCT02379299|DEVICE|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
219143009|NCT05254769|DEVICE|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
219143010|NCT05000944|OTHER|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
219143011|NCT05000944|OTHER|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
219143012|NCT05000944|OTHER|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
219143013|NCT01301716|DRUG|GDC-0980|Oral escalating dose
219143014|NCT01301716|DRUG|bevacizumab|Intravenous repeating dose
219360964|NCT06528470|DEVICE|Sham Stimulation|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when no stimulation is delivered. No stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
219360965|NCT00001387|DRUG|paclitaxel|
219143015|NCT01301716|DRUG|carboplatin|Intravenous repeating dose
219143016|NCT01301716|DRUG|cisplatin|intravenous repeating dose
219143017|NCT01301716|DRUG|paclitaxel|Intravenous repeating dose
219143018|NCT01301716|DRUG|pemetrexed|intravenous repeating dose
219143019|NCT04573803|DRUG|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
219143020|NCT04573803|DRUG|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
219143021|NCT04133740|DRUG|Oxygen|Liberal versus conservative oxygen therapy.
219143022|NCT03997682|OTHER|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
219143023|NCT06463054|BEHAVIORAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
219143024|NCT06463054|BEHAVIORAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
219230357|NCT01820702|OTHER|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
219143025|NCT05344326|OTHER|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
219143026|NCT04310072|DEVICE|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
219143027|NCT02983617|DRUG|Tirabrutinib|Administered orally once daily
219230358|NCT02527694|DEVICE|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
219230359|NCT02527694|DEVICE|mechanical CPR|
219230360|NCT05197088|DRUG|Tamsulosin|1 week of tamsulosin
219230361|NCT03742297|DRUG|Lenalidomide.|Lenalidomide
219230362|NCT03742297|DRUG|Carfilzomib|Carfilzomib
219230363|NCT03742297|DRUG|Bortezomib|Bortezomib
219143028|NCT02983617|DRUG|Entospletinib|Administered orally once daily
219143029|NCT02983617|DRUG|Obinutuzumab|Administered intravenously
219143030|NCT03646136|PROCEDURE|Retained fluid|Retained fluid
219143031|NCT03646136|PROCEDURE|Emptied fluid|Emptied fluid
219143032|NCT03791905|DRUG|Paclitaxel|chemotherapy drug
219143033|NCT03791905|DRUG|Cisplatin|chemotherapy drug
219230364|NCT03742297|DRUG|Daratumumab|Daratumumab
219230365|NCT03742297|DRUG|Dexamethasone|Dexamethasone
219230366|NCT03742297|DRUG|Prednisone|Prednisone
219230367|NCT03742297|DRUG|Melphalan|Melphalan
219230368|NCT05856409|DIAGNOSTIC_TEST|68Ga-FAPI|\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
219230369|NCT01896609|BIOLOGICAL|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
219230370|NCT01896609|DRUG|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
219230371|NCT01896609|DRUG|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
219230372|NCT01896609|DRUG|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
219230373|NCT06451107|OTHER|specific strength training with static neck stretching|The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
219360966|NCT05370573|OTHER|No intervention|Observational - no interventions
219360967|NCT05210504|DRUG|L-Lysine|5g L-lysine in 50ml water, administered orally
219360968|NCT05210504|DRUG|Normal Saline|Normal (0.9%) Saline
219360969|NCT01471665|DRUG|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
219552710|NCT01787929|PROCEDURE|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
219552711|NCT05193734|DRUG|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
219360970|NCT01471665|DRUG|Placebo|Placebo will be administered once daily for up to 16 days.
219360971|NCT00127751|BEHAVIORAL|Enhance health lifestyle changes and medication compliance|
219360972|NCT04026984|DRUG|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
219143034|NCT03791905|DRUG|Oxaliplatin|chemotherapy drug
219143035|NCT03791905|DRUG|5-FU|chemotherapy drug
219143036|NCT03791905|DRUG|Leucovorin|chemotherapy drug
219143037|NCT03791905|RADIATION|Intensity-modulated radiotherapy|radiotherapy technique
219143038|NCT03791905|DEVICE|PET|Using PET to evaluate response to induction chemotherapy
219360973|NCT04026984|DRUG|Placebo|Matching Placebo tablets
219143039|NCT00831272|DRUG|naltrexone|50mg/day
219143040|NCT00831272|DRUG|Placebo|Placebo
219360974|NCT02504788|RADIATION|hippocampal-sparing WBRT|
219360975|NCT03015467|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
219360976|NCT03015467|OTHER|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
219143041|NCT05380791|OTHER|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
219143042|NCT03720210|DEVICE|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
219230374|NCT06451107|OTHER|Specific Strength Training|The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
219230375|NCT01688388|PROCEDURE|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
219230376|NCT02322645|DRUG|Eszopiclone Tablets 3 mg|
219230377|NCT01697826|DRUG|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
219230378|NCT01697826|DRUG|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
219718629|NCT07116122|DEVICE|Tracking/finding system|Persons living with Alzheimer's Disease or Related dementias will wear the Care Companion smartwatch for approximately one month (stage I) or 6 months (stage 2). The Caretakers will utilize the smart phone application (app) to monitor the person wearing the watch and be alerted to elopements. The system will notify a caregiver if the person with dementia leaves a defined area (e.g., the home) via the application. In the tether mode (e.g., outside of the home), the system monitors the distance between the smartwatch and the caregiver's smartphone. When a separation distance exceeds a set threshold, the application will alert the caregiver and start tracking the location of the person with dementia by displaying the person's position on the caregiver's smartphone.
219230379|NCT02203656|DRUG|Placebo|placebo supplement
219230380|NCT02203656|DIETARY_SUPPLEMENT|Nutritional Supplement|protein supplement
219230381|NCT02203656|BEHAVIORAL|In-home exercise|In-home exercise program
219230382|NCT02203656|DRUG|Testosterone|Testosterone injection
219230383|NCT02449902|DRUG|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
219230384|NCT02449902|DRUG|placebo|1 placebo capsule inserted vaginally for 14 days.
219230385|NCT04515550|DIAGNOSTIC_TEST|lumbar puncture|Some participants will have an optional lumbar puncture
219143043|NCT05245825|OTHER|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
219143044|NCT05245825|OTHER|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
219143045|NCT00114244|DRUG|sorafenib tosylate|Given PO
219143046|NCT00114244|DRUG|gemcitabine hydrochloride|Given IV
219143047|NCT00114244|OTHER|laboratory biomarker analysis|Correlative studies
219143048|NCT02698891|DRUG|Paclitaxel|
219143049|NCT02698891|DRUG|Neulasta|
219230386|NCT00465114|PROCEDURE|Hemodynamic Monitoring|
219230387|NCT02362789|BIOLOGICAL|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
219230388|NCT02362789|BIOLOGICAL|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
219230389|NCT01289834|DEVICE|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
219230390|NCT01289834|DEVICE|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
219230391|NCT05234489|BIOLOGICAL|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
219230392|NCT03033056|BEHAVIORAL|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
219230393|NCT01498614|BEHAVIORAL|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
219230394|NCT06455072|DRUG|Nituzumab|EGFR monoclonal antibody
219230395|NCT06455072|DRUG|Serplulimab|PD-1 (programmed death receptor 1) monoclonal antibody
219230396|NCT02589613|DIETARY_SUPPLEMENT|tap water|300ml tap water via nasogastric tube
219230397|NCT02589613|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g Glucose via nasogastric tube
219230398|NCT02589613|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g Fructose via nasogastric tube
219230399|NCT06418919|PROCEDURE|Radiofrequency ablation treatment|RFA is used to ablate the entire thyroid gland
219230400|NCT02594267|DRUG|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"
219230401|NCT00407485|BIOLOGICAL|ziv-aflibercept|Given IV
219143050|NCT05539755|PROCEDURE|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
219143051|NCT02817334|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
219230402|NCT00407485|OTHER|pharmacological study|Correlative studies
219230403|NCT02684136|DRUG|suvorexant|suvorexant 20 mg taken before sleep
219230404|NCT02684136|DRUG|placebo|placebo taken before sleep
219230405|NCT00721734|DRUG|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
219230406|NCT04037592|DEVICE|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
219552712|NCT05193734|DRUG|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
219230407|NCT04037592|DEVICE|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
219230408|NCT04037592|DEVICE|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
219230409|NCT01274000|DRUG|YM060|oral
219718630|NCT07115017|DRUG|[18F] FZTA|Participants will receive a single intravenous bolus injection of 7 ± 20% milliCurie (mCi) of the investigational radiotracer \[18F\]-FZTA. Participants will then undergo a brain \[18F\]-FZTA PET scan
219718631|NCT07114913|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
219718632|NCT07114913|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
219718633|NCT07114913|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold is used to measure deep muscular tissue pain sensitivity.
219718634|NCT07114757|PROCEDURE|Renal denervation after stroke|Renal sympathetic denervation (RDN) is a minimally invasive catheter-based procedure targeting renal sympathetic nerve fibers to achieve sustained reductions in blood pressure.
219143052|NCT01908296|DRUG|FK949E|Oral
219143053|NCT01908296|DRUG|fluvoxamine|Oral
219552713|NCT01204138|DRUG|Apremilast|Apremilast 30mg BID
219143054|NCT00711958|DRUG|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
219552714|NCT01204138|DRUG|Placebo|Placebo BID
219552715|NCT01198392|DRUG|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
219230410|NCT01274000|DRUG|placebo|oral
219230411|NCT03655704|DRUG|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
219552716|NCT01198392|DRUG|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
219143055|NCT00711958|DRUG|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
219230412|NCT05786768|DRUG|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
219230413|NCT05786768|DRUG|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
219230414|NCT02762786|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
219230415|NCT05196958|OTHER|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
219230416|NCT00432445|RADIATION|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
219552717|NCT00785603|DRUG|Paroxetine|tablets of 20 mg paroxetine
219552718|NCT00785603|DRUG|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
219552719|NCT00785603|DRUG|Tramadol|Capsules of 50 mg tramadol
219552720|NCT01949532|DRUG|Carfilzomib|Carfilzomib was administered by IV injection.
219143056|NCT00003728|DRUG|asparaginase|
219143057|NCT00003728|DRUG|cyclophosphamide|
219143058|NCT00003728|DRUG|cytarabine|
219143059|NCT00003728|DRUG|daunorubicin hydrochloride|
219230417|NCT00432445|PROCEDURE|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
219230418|NCT00296686|DRUG|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
219230419|NCT00296686|DRUG|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
219230420|NCT00296686|DRUG|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
219552721|NCT04995354|DRUG|EGF loaded Hydrogel|Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
219552722|NCT04995354|DRUG|Hydrogel|Non-medicated self-healing hydrogel to be applied three times a day for 1 week
219552723|NCT02037854|OTHER|Nutrient formulation|
219143060|NCT00003728|DRUG|dexamethasone|
219143061|NCT00003728|DRUG|doxorubicin hydrochloride|
219143062|NCT00003728|DRUG|etoposide|
219143063|NCT00003728|DRUG|leucovorin calcium|
219143064|NCT00003728|DRUG|mercaptopurine|
219143065|NCT00003728|DRUG|methotrexate|
219143066|NCT00003728|DRUG|methylprednisolone|
219552724|NCT00003795|PROCEDURE|quality-of-life assessment|
219552725|NCT02298387|DRUG|OMP-305B83|intravenous (in the vein) infusions
219143067|NCT00003728|DRUG|mitoxantrone hydrochloride|
219552726|NCT02498938|GENETIC|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
219552727|NCT03141580|DIAGNOSTIC_TEST|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
219552728|NCT00236886|DRUG|topiramate|
219552729|NCT02943096|DIETARY_SUPPLEMENT|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
219552730|NCT02943096|OTHER|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
219552731|NCT03258996|PROCEDURE|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
219552732|NCT03258996|PROCEDURE|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
219552733|NCT00709514|DRUG|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
219552734|NCT00709514|DRUG|Placebo|Placebo
219552735|NCT05921812|DIAGNOSTIC_TEST|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
219552736|NCT02707016|OTHER|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
219552737|NCT02707016|OTHER|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
219143068|NCT00003728|DRUG|prednisolone|
219143069|NCT00003728|DRUG|therapeutic hydrocortisone|
219143070|NCT00003728|DRUG|thioguanine|
219143071|NCT00003728|DRUG|vincristine sulfate|
219143072|NCT00003728|DRUG|vindesine|
219143073|NCT00003728|PROCEDURE|allogeneic bone marrow transplantation|
219143074|NCT00003728|PROCEDURE|peripheral blood stem cell transplantation|
219230421|NCT06301867|DIAGNOSTIC_TEST|Plateau Pressure|Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
219230422|NCT06311266|DEVICE|Robotic endoscopic neurosurgical intervention|Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
219230423|NCT00004831|DRUG|cysteine hydrochloride|
219230424|NCT03620474|DRUG|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
219230425|NCT04813224|BEHAVIORAL|TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT|Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
219230426|NCT01989689|DRUG|Etanercept|Etanercept 50mg twice weekly
219230427|NCT01989689|DRUG|Placebo|
219230428|NCT03795532|PROCEDURE|SWL|Shock wave lithotripsy
219230429|NCT00491101|OTHER|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
219230430|NCT00491101|OTHER|spirometry|spirometry
219552738|NCT04387617|DRUG|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
219552739|NCT04387617|DRUG|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
219552740|NCT02413008|DRUG|estriol|0.005% estriol vaginal gel
219143075|NCT03881449|COMBINATION_PRODUCT|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
219230431|NCT03154775|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
219143076|NCT04627493|BEHAVIORAL|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
219552741|NCT02413008|DRUG|Placebo|placebo vaginal gel
219143077|NCT01609517|DRUG|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
219143078|NCT00012935|BEHAVIORAL|Help with decision making on prostate cancer treatment|
219143079|NCT02200523|DEVICE|SARA electrode|
219143080|NCT02200523|DEVICE|Gold cup|
219143081|NCT06007118|RADIATION|APBI|accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
219143082|NCT06007118|RADIATION|WBI|accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
219143083|NCT02176538|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days
219143084|NCT02176538|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
219143085|NCT02319434|DEVICE|Ostom-i Alert Sensor|Sensor on ostomy bag.
219143086|NCT05177601|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
219143087|NCT05177601|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
219143088|NCT05177601|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
219143089|NCT05177601|DRUG|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
219143090|NCT00781378|DRUG|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
219143091|NCT00781378|DRUG|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
219143092|NCT05597280|DRUG|BE-PEP Bedaquiline|bedaquiline
219143093|NCT05597280|DRUG|SDR-PEP Rifampicin|SDR-PEP: rifampicin
219143094|NCT05597280|DRUG|BE-PEP Rifampicin|BE-PEP rifampicin
219143095|NCT02363192|BEHAVIORAL|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
219143096|NCT01180088|PROCEDURE|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
219143097|NCT04562636|OTHER|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
219143098|NCT04562636|OTHER|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
219143099|NCT04562636|OTHER|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
219143100|NCT05632471|BEHAVIORAL|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
219143101|NCT05632471|OTHER|The control group was not trained|The control group was not trained
219143102|NCT02694978|DRUG|Ferumoxytol|
219143103|NCT02694978|DRUG|FCM|
219552742|NCT06361355|BIOLOGICAL|Post-change CMAB807|for subcutaneous injection only
219552743|NCT06361355|BIOLOGICAL|Prolia|for subcutaneous injection only
219143104|NCT04997746|BEHAVIORAL|Multiprofessional educational interventions|Preventive educational interventions
219230432|NCT02570100|PROCEDURE|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles"
219230433|NCT02148575|BEHAVIORAL|Self-Management Group|
219230434|NCT02148575|BEHAVIORAL|Symptom Management Group|
219230435|NCT04913506|OTHER|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
219552744|NCT03483350|DRUG|Granisetron|Ampoule
219552745|NCT03483350|DRUG|Midazolam|Ampoule
219552746|NCT00939523|DRUG|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
219552747|NCT05074706|BIOLOGICAL|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
219143105|NCT04997746|OTHER|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
219143106|NCT03270124|BEHAVIORAL|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
219143107|NCT03270124|BEHAVIORAL|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
219230436|NCT04913506|DEVICE|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
219230437|NCT04913506|OTHER|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
219230438|NCT01051869|PROCEDURE|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
219230439|NCT01051869|PROCEDURE|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
219718635|NCT07113925|DRUG|TQB2101 for Injection|TQB2101 for Injection is an ROR1 ADC, an antibody-drug conjugate. It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
219718636|NCT07118202|DEVICE|TheraBionic P1|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening
219230440|NCT00526994|OTHER|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
219230441|NCT00526994|BEHAVIORAL|universal education|receives referral information
219230442|NCT04698694|DEVICE|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
219230443|NCT04698694|DEVICE|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
219552748|NCT05074706|BIOLOGICAL|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
219552749|NCT04733313|PROCEDURE|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
219552750|NCT00870935|PROCEDURE|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
219143108|NCT03270124|BEHAVIORAL|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
219143109|NCT02560649|DRUG|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
219143110|NCT02560649|DRUG|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
219143111|NCT02560649|DRUG|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
219143112|NCT02560649|DRUG|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
219143113|NCT02560649|DRUG|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
219143114|NCT02560649|DRUG|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
219143115|NCT02560649|DRUG|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
219143116|NCT02560649|DRUG|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
219143117|NCT01580319|OTHER|physical exercise|150 minutes per week
219143118|NCT03489915|DEVICE|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
219143119|NCT01613716|DRUG|Ozurdex|Ozurdex .7 mg injected into the treated eye
219143120|NCT00818454|DRUG|Combivent CFC MDI|
219143121|NCT00818454|DRUG|Albuterol HFA MDI|
219230444|NCT01034488|BIOLOGICAL|Suine|5000UI /mL
219230445|NCT01034488|BIOLOGICAL|Suine|5000UI/mL
219552751|NCT00870935|PROCEDURE|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
219552752|NCT00201136|BEHAVIORAL|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
219718637|NCT07114068|OTHER|Self mobilization of Obturator Internus Muscle using wand|Participants will be randomly assigned to the internal or external Obturator Internus mobilization groups. The internal mobilization group will access the Obturator Internus muscle via the vagina, which is common practice in Pelvic Health Physical Therapy. The external mobilization group will be accessing the Obturator Internus muscle with the same pelvic wand, but externally. Pelvic wands will be provided for each participant at no cost and will be used for only that participant. Prior to intervention with a pelvic wand, each participant will be provided education regarding the anatomy of the pelvic floor and hip and a protocol review of the intervention.
219143122|NCT00818454|DRUG|Respimat Combivent|
219143123|NCT00904852|DRUG|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
219143124|NCT00255281|DRUG|AZD7009, no generic name available|
219143125|NCT03848910|DEVICE|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
219143126|NCT01171625|DEVICE|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
219143127|NCT04763044|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219143128|NCT04763044|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219143129|NCT04763044|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219143130|NCT04763044|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
219143131|NCT04763044|DRUG|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
219143132|NCT03417869|DEVICE|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
219143133|NCT01689090|OTHER|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
219143134|NCT01689090|OTHER|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
219230446|NCT01331772|OTHER|Control arm|Dietetic follow-up only
219718638|NCT07113665|DEVICE|ExAblate Neuro 4000|The ExAblate Neuro 4000 is an MRI-guided focused ultrasound (MRgFUS) system designed to perform noninvasive thermal ablation of targeted brain tissue. In this study, the ExAblate Neuro 4000 will be used to perform a bilateral capsulotomy by ablating the anterior limb of the internal capsule (ALIC) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD). The procedure will be conducted under real-time MRI guidance and thermometry to ensure accurate targeting and controlled thermal delivery. This study aims to evaluate the safety, feasibility, and preliminary clinical benefit of MRgFUS in improving psychiatric symptoms and quality of life in this patient population.
219718639|NCT07118579|DRUG|Remimazolam|remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)
219552753|NCT00201136|BEHAVIORAL|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
219552754|NCT00024258|DRUG|arsenic trioxide|
219552755|NCT01625390|DRUG|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
219143135|NCT01689090|OTHER|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
219143136|NCT02759588|BIOLOGICAL|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
219143137|NCT01377428|DRUG|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
219230447|NCT01331772|OTHER|Intervention arm|Dietetic follow up + adapted physical activity
219718640|NCT07118579|DRUG|Propofol|Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)
219143138|NCT01377428|DRUG|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
219143139|NCT02817984|BIOLOGICAL|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
219230448|NCT04402476|DEVICE|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
219230449|NCT02673866|DRUG|DS-1971a|
219230450|NCT02673866|DRUG|placebo|
219230451|NCT02673866|DRUG|pregabalin|pregabalin
219552756|NCT01625390|DRUG|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
219552757|NCT01625390|DRUG|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
219552758|NCT05418790|DEVICE|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
219552759|NCT02026479|DRUG|Dexamethasone Phosphate|5mg; postauricular injection
219552760|NCT02026479|DRUG|Dexamethasone Phosphate|10mg; postauricular injection
219552761|NCT02026479|DRUG|Ginaton|40mg/pill, 3times/day,oral
219143140|NCT05471635|BIOLOGICAL|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
219143141|NCT03168048|OTHER|mobile application|Oncologic therapy support by means of a mobile application
219143142|NCT04583306|OTHER|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
219230452|NCT03251456|OTHER|Tertiary care|"1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
219718641|NCT07118579|DRUG|Ciprofol|Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)
219718642|NCT07116395|DRUG|Tranexamic Acid (TXA)|orthopedic trauma patients who are on anticoagulation
219718643|NCT07117825|OTHER|AORTIC DISSECTION CT SCAN ANALYSIS|Patients with type A or type B acute aortic dissection, treated either with medical therapy or with endovascular/open surgery in the study period and who underwent subsequent radiological follow-up.
219718644|NCT07118605|PROCEDURE|Minimally Invasive Sagittal Split Ramus Osteotomy|This procedure involves a limited mucosal incision and tunnel dissection technique combined with low and short osteotomy and minimal soft tissue manipulation. The goal is to reduce surgical trauma, edema, blood loss, and operative time while maintaining clinical effectiveness.
219718645|NCT07118605|PROCEDURE|Conventional Sagittal Split Ramus Osteotomy|This procedure follows the traditional wide exposure technique with full-thickness mucoperiosteal flap elevation. This method is widely accepted and serves as the control for comparison.
219718646|NCT07118475|BIOLOGICAL|Autologous islet transplantation|"1. EUS-FNB or surgical procurement of pancreatic tissue~2. In vitro culture of adult pancreatic progenitor~3. In vitroinduction of islets~4. islet transplantation beneath the anterior rectus sheath~5. Post-transplant follow-up"
219718647|NCT07118709|DRUG|KC1086|"Part 1: Dose-escalation phase , five dose groups are included: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg.~Part 2: Dose-expansion phase, 2 to 3 dose levels will be selected for expansion based on the results of the dose escalation phase."
219718648|NCT07104110|DRUG|QLH12016|oral AR PROTAC
219718649|NCT07104110|DRUG|abiraterone acetate|oral CYP17 inhibitor
219718650|NCT07104110|DRUG|enzalutamide|oral androgen receptor inhibitor
219718651|NCT07121231|OTHER|Motor Support Program|The MSP was implemented over 12 weeks, two days a week, 50 minutes per session. Based on pre-test results, 30% (15 minutes) of each session was devoted to individualized activities, and 70% (35 minutes) to group activities supporting peer interaction. This structure allowed for both personalized support and social engagement. The program was carried out by the research team and eight special education teachers at the children's rehabilitation centers. Each child received one-on-one support from at least one teacher. Activities were aligned with preschool motor development goals and followed a four-phase structure: (1) Warm-up (5 min): rhythmic movements (e.g., walking, running, jumping); (2) Preparation (5 min): functional exercises for flexibility and joint mobility; (3) Main activity (35 min): individual and group exercises to enhance motor, social, and pre-academic skills; (4) Cool-down (5 min): group games reinforcing learned skills and social interaction.
219718652|NCT07121738|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL): Gyn Cancer Program|Evidence-based lifestyle medicine program for cancer survivors
219552762|NCT01050764|DRUG|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg"
219143143|NCT02794194|OTHER|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
219552763|NCT01050764|DRUG|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
219552764|NCT01050764|DRUG|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
219718653|NCT07117929|DEVICE|Active PEMF|PEMF: 1.5mT, 10Hz, 10 minutes
219230453|NCT03251456|OTHER|Usual Care|"1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
219718654|NCT07117929|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
219718655|NCT07117929|OTHER|Exercise|Standardised home exercise protocol
219143144|NCT02794194|OTHER|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
219143145|NCT03002805|DRUG|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
219718656|NCT07117682|DEVICE|Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection|Under general anesthesia, patients undergo lower abdominal liposuction (aspirate: 100-360 mL). ADRCs are immediately prepared bedside using the Celution® system (Cytori Therapeutics): Lipoaspirate is processed in a sterile container with automated separation, centrifugation, and resuspension (90-120 min). From the 5mL ADRCs suspension obtained, 0.5mL is reserved for QC (cell count/viability/surface markers); 4.5mL is injected bilaterally into ovarian stroma (2-2.5mL/ovary). Post-procedure, patients are monitored supine for 30 min for local/systemic reactions before discharge if stable.
219230454|NCT06142838|BEHAVIORAL|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
219552765|NCT01050764|DRUG|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
219718657|NCT07119411|OTHER|ICU Beacon|Availability of a proprietary clinician awareness for potential organ deterioration software to treating clinicians (ICU Beacon) in addition to the standard of care.
219552766|NCT01050764|DEVICE|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
219552767|NCT01050764|DRUG|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
219143146|NCT01495663|DRUG|I-131-CLR1404|"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
219143147|NCT00317577|DRUG|brimonidine, timolol|
219143148|NCT05948644|DRUG|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
219143149|NCT00617812|BIOLOGICAL|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
219143150|NCT02680457|DRUG|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
219143151|NCT02680457|DRUG|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
219143152|NCT02349503|DRUG|NBI-77860|
219143153|NCT02349503|DRUG|NBI-77860|
219143154|NCT02349503|DRUG|NBI-77860|
219143155|NCT04056039|DRUG|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
219143156|NCT04056039|DRUG|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
219143157|NCT04525170|DEVICE|HPT treatment|
219143158|NCT04525170|DEVICE|untreated|
219143159|NCT02273544|DRUG|Asasantin ER (new formulation - low)|
219143160|NCT02273544|DRUG|Asasantin ER (new formulation - medium)|
219143161|NCT02273544|DRUG|Asasantin ER (new formulation - high)|
219143162|NCT02273544|DRUG|Asasantin ER - commercial formulation|
219143163|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
219143164|NCT05174013|DRUG|Placebo|Placebo will be administered
219143165|NCT06516809|DEVICE|DormoTech Vlab SpO2 sensor|The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
219143166|NCT03287622|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
219143167|NCT03287622|BEHAVIORAL|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
219143168|NCT02889341|DIETARY_SUPPLEMENT|DHA|
219143169|NCT02889341|OTHER|Placebo|
219143170|NCT00919594|BEHAVIORAL|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
219143171|NCT00919594|BEHAVIORAL|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
219143172|NCT01418794|DEVICE|High dose rapamycin stent|Concentration of rapamycin is 2.5%
219718658|NCT07120282|DRUG|Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group|Tislelizumab 400 mg iv, q6w, for up to 1 year; patients are permitted to receive concurrent adjuvant platinum-based doublet chemotherapy (q3w, up to 4 cycles) starting from the first dose of tislelizumab; during concurrent chemotherapy, a tislelizumab dosage of 200 mg iv, q3w is allowed.
219143173|NCT01418794|DEVICE|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
219143174|NCT03568799|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
219143175|NCT05688761|DRUG|Proton pump inhibitor|Long-term use of medications, particularly proton pump inhibitors
219143176|NCT00271700|BEHAVIORAL|Order Set, Education, Feedback|
219230455|NCT03938272|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
219143177|NCT06037824|OTHER|cryotherapy|"cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
219143178|NCT04726813|BEHAVIORAL|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
219143179|NCT04726813|BEHAVIORAL|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
219143180|NCT01727128|DRUG|BKM120|
219143181|NCT05951218|OTHER|inhibition technique|Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator
219143182|NCT05951218|OTHER|placebo|"The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors."
219143183|NCT05193994|DRUG|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
219143184|NCT05193994|DRUG|Placebo|Matching placebo.
219143185|NCT04131166|BEHAVIORAL|Mediterranean diet|A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
219143186|NCT04131166|BEHAVIORAL|Low-carbohydrate, ketogenic diet|A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
219143187|NCT04131166|BEHAVIORAL|Low-fat diet|A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
219143188|NCT04131166|OTHER|Annual follow-up testing for 5 years|Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
219143189|NCT03520673|DIAGNOSTIC_TEST|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
219143190|NCT02028637|OTHER|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
219143191|NCT01976910|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
219143192|NCT05266599|OTHER|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
219143193|NCT05266599|OTHER|AH Plus root canal sealer|Root canal treatments were performed with AH plus
219143194|NCT04536441|BEHAVIORAL|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
219143195|NCT04536441|BEHAVIORAL|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
219143196|NCT03612882|OTHER|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
219143197|NCT00660478|DEVICE|Endeavor|Comparison of two different drug eluting coronary stents
219552768|NCT01050764|DRUG|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
219552769|NCT02697708|DIETARY_SUPPLEMENT|Potassium control diet|No additional potassium.
219552770|NCT02697708|DIETARY_SUPPLEMENT|Potassium gluconate diet|1000 mg K from potassium gluconate.
219552771|NCT02697708|DIETARY_SUPPLEMENT|Potato Diet|1000 mg K from potatoes.
219552772|NCT02697708|DIETARY_SUPPLEMENT|French Fries Diet|1000 mg K from French Fries.
219552773|NCT04520243|DIAGNOSTIC_TEST|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
219552774|NCT02312037|BIOLOGICAL|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles~2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
219552775|NCT06324305|PROCEDURE|Pars plana vitrectomy (PPV) and drainage of subretinal fluid|Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
219552776|NCT04552405|DIETARY_SUPPLEMENT|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
219143198|NCT00660478|DEVICE|Cypher Select|Comparison of two different drug eluting coronary stents
219230456|NCT04201314|DIETARY_SUPPLEMENT|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
219230457|NCT04201314|DIETARY_SUPPLEMENT|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
219230458|NCT05935839|DEVICE|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
219230459|NCT05935839|DIAGNOSTIC_TEST|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
219230460|NCT05935839|DIAGNOSTIC_TEST|Neuropathy Disability Score|Single measurement of the NSS
219143199|NCT02402920|DRUG|Carboplatin|Given IV
219230461|NCT02875704|OTHER|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
219143200|NCT02402920|DRUG|Cisplatin|Given IV
219143201|NCT02402920|DRUG|Etoposide|Given IV
219143202|NCT02402920|OTHER|Laboratory Biomarker Analysis|Correlative studies
219230462|NCT00069706|DRUG|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219230463|NCT00069706|OTHER|AL-12182 Ophthalmic Solution Vehicle|Placebo
219230464|NCT00069706|DRUG|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219143203|NCT02402920|BIOLOGICAL|Pembrolizumab|Given IV
219230465|NCT00069706|DRUG|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219230466|NCT00069706|DRUG|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219230467|NCT04085952|PROCEDURE|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
219230468|NCT04085952|PROCEDURE|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
219552777|NCT00351117|DRUG|St. John's Wort|SJW in capsule form 300 mg PO TID
219143204|NCT02402920|PROCEDURE|Radiation Therapy|Undergo radiation therapy
219143205|NCT04429230|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
219143206|NCT04429230|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
219143207|NCT05650268|DRUG|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
219143208|NCT05650268|OTHER|95% MCT|95% MCT supplement 3-7 day before surgery
219143209|NCT00326924|BIOLOGICAL|Transfusion|PRBC blood transfusions.
219552778|NCT00351117|DRUG|Lactose|lactose in gelatin capsule that same as St. John's wort
219552779|NCT03414073|DEVICE|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
219552780|NCT03414073|DEVICE|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
219552781|NCT03414073|DEVICE|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
219552782|NCT03109327|DIAGNOSTIC_TEST|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
219552783|NCT03045627|DRUG|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
219552784|NCT03045627|DRUG|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
219143210|NCT01373398|DRUG|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
219143211|NCT02891278|DRUG|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
219230469|NCT02053506|DIETARY_SUPPLEMENT|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
219230470|NCT02053506|DIETARY_SUPPLEMENT|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
219230471|NCT02053506|DIETARY_SUPPLEMENT|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
219230472|NCT03052998|DRUG|Ivermectin|Effect of Ivermectin on frequency of seizures
219230473|NCT01874366|DRUG|P11187|"* Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
219143212|NCT02891278|DRUG|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
219143213|NCT02891278|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
219143214|NCT02662855|OTHER|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
219143215|NCT02662855|DRUG|Favipiravir|oral administration of Favipiravir tablets
219143216|NCT00507689|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
219718659|NCT07120191|DEVICE|post op communication software|MyConnect Post Op is a communication tool that utilizes Technology Assisted Conversation to aid in the recovery of total knee and hip replacement patients
219143217|NCT00507689|DRUG|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
219143218|NCT05383313|DRUG|Psilocybin|Effect of psilocybin on treatment-resistant depression
219143219|NCT05383313|DRUG|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
219143220|NCT05383313|DRUG|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
219143221|NCT01927965|DRUG|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
219143222|NCT00486330|DRUG|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
219143223|NCT03244579|BEHAVIORAL|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
219143224|NCT04215406|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
219143225|NCT05817630|OTHER|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
219143226|NCT05501249|BEHAVIORAL|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
219143227|NCT02083029|PROCEDURE|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
219143228|NCT04878991|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
219143229|NCT00023725|DRUG|semaxanib|
219143230|NCT00023725|PROCEDURE|conventional surgery|
219143231|NCT00023725|RADIATION|radiation therapy|
219143232|NCT00541749|DRUG|rhuMAb IFNalpha|Intravenous repeating dose
219143233|NCT04606251|OTHER|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
219143234|NCT03184558|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
219143235|NCT03081949|DRUG|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
219143236|NCT03123172|DIAGNOSTIC_TEST|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
219143237|NCT02506257|DRUG|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
219143238|NCT02506257|DRUG|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
219143239|NCT02506257|DRUG|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
219143240|NCT02506257|DRUG|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
219143241|NCT00148291|DRUG|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
219143242|NCT03760419|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
219143243|NCT04360057|OTHER|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
219143244|NCT04360057|OTHER|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
219143245|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
219143246|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
219143247|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
219230474|NCT01874366|DRUG|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
219143248|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
219143249|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
219143250|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
219143251|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
219143252|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
219143253|NCT03514251|PROCEDURE|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
219230475|NCT04396210|OTHER|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
219143254|NCT00877435|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
219143255|NCT03829917|DRUG|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
219143256|NCT03829917|DRUG|miltefosine|28 days of miltefosine
219143257|NCT03829917|DRUG|paromomycin|28 days of paromomycin creaam
219143258|NCT03052946|PROCEDURE|Bulking agent|Filling bulking agent in the anal canal
219143259|NCT03052946|PROCEDURE|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
219143260|NCT03827512|OTHER|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
219143261|NCT02355535|DRUG|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
219143262|NCT04247204|BIOLOGICAL|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
219143263|NCT01122420|OTHER|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
219143264|NCT01122420|OTHER|Health Web Sites|Access to publicly available health-related web sites
219143265|NCT05979324|DEVICE|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
219143266|NCT04018508|OTHER|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
219143267|NCT01740817|DRUG|Intralipid 20%|30 ml/h for 48 h
219143268|NCT01740817|DRUG|Saline|30 ml/h for 48 h
219230476|NCT03936699|DEVICE|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet."
219230477|NCT03936699|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
219552785|NCT03045627|DRUG|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
219143269|NCT00786448|DRUG|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
219552786|NCT03045627|DRUG|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
219143270|NCT00932022|DRUG|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
219143271|NCT00932022|OTHER|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
219143272|NCT03888755|DRUG|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
219143273|NCT05695833|DEVICE|Radiofrequency|Device emitting electric waves generating heat
219552787|NCT05523960|PROCEDURE|No MBP|No mechanical bowel preparation before operation
219552788|NCT03757468|DEVICE|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
219552789|NCT00943865|BEHAVIORAL|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
219552790|NCT00943865|BEHAVIORAL|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
219230478|NCT01494766|DIETARY_SUPPLEMENT|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
219230479|NCT05143125|BIOLOGICAL|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
219230480|NCT03269500|OTHER|use of nutrition education tools|"Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
219230481|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
219230482|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
219143274|NCT04314830|DEVICE|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
219143275|NCT04314830|DEVICE|Gait training without perturbation|Walking on a treadmill with steady belt speed
219230483|NCT06216704|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
219230484|NCT06216704|DIAGNOSTIC_TEST|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
219230485|NCT06216704|DIAGNOSTIC_TEST|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
219230486|NCT03393390|DIAGNOSTIC_TEST|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
219230487|NCT03393390|OTHER|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
219230488|NCT03021616|OTHER|energy drink|32oz of commercially available energy drink
219230489|NCT03021616|OTHER|Moxifloxacin 400mg|400mg moxifloxacin active control drink
219230490|NCT03021616|OTHER|Placebo|Placebo drink
219230491|NCT00068107|DRUG|Replagal|enzyme replacement therapy
219230492|NCT02025712|DRUG|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
219230493|NCT02025712|DRUG|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
219230494|NCT03673618|DRUG|Soluble Corn Fiber|Fiber or placebo
219230495|NCT02602691|OTHER|AlloMap®|
219230496|NCT02602691|PROCEDURE|Endomyocardial biopsies|
219230497|NCT02321956|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound to determine the size of endotracheal tube
219230498|NCT01838603|OTHER|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
219143276|NCT00764413|DRUG|methylprednisolone|1 gram intravenous a day for 3 days
219143277|NCT00764413|DRUG|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
219143278|NCT00723450|DRUG|lamictal|Flexible Dosing
219143279|NCT02033018|DRUG|Aflibercept Injection|Aflibercept intravitreal injection
219143280|NCT02120313|OTHER|inpatient rehabilitation|
219143281|NCT02120313|OTHER|outpatient rehabilitation|
219143282|NCT00001182|PROCEDURE|current standard of care treatments|
219143283|NCT02523391|DRUG|TA-8995|Capsule
219143284|NCT02523391|DRUG|TA-8995|Tablet
219143285|NCT00532220|DRUG|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
219143286|NCT00532220|DRUG|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
219143287|NCT01738308|PROCEDURE|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
219718660|NCT07121920|DEVICE|Confocal Laser Endomicroscopy|"Patients will undergo Esophagogastroduodenoscopy (EGD) and/or Ileocolonoscopy (IC) EGD with CLE as per standard of care. Each participant will have 3-4 mucosal biopsies taken from the terminal ileum, rectosigmoid and cecum, ideally from the most affected areas of accessible segment.~Ex vivo staining of biopsied tissue will be expanded to include FITC-labeled antibodies to cytokines IL12 and IL12/IL23 and to cytokine receptors IL12R and IL23R and possibly other cytokines, receptors and adhesion molecules. All biopsies tested for membrane bound antibodies will be done using CLE technology with artificial intelligence (AI). The cellular landscape will be characterized by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD.~We will develop algorithm using AI to predict responders versus non-responders and to further subclassify IBD patients using phenotype data."
219718661|NCT07122492|BEHAVIORAL|FoRtitude 2.0|A website and an interactive text-messaging feature
219718662|NCT07122492|BEHAVIORAL|Attention Control|Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
219718663|NCT07123974|BEHAVIORAL|Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)|DBT-PTSD is 45-week individual psychotherapy (DBT-PTSD) designed to treat adults presenting with both borderline personality disorder (BPD) and complex post-traumatic stress disorder (C-PTSD). The intervention integrates dialectical behavior therapy (DBT) skills, trauma-focused exposure-based interventions, and strategies from compassion-focused therapy and acceptance and commitment therapy. All participants will receive the full sequence of the therapy in outpatient settings, following the structured treatment protocol.
219143288|NCT01738308|PROCEDURE|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
219143289|NCT03920371|OTHER|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
219143290|NCT01102049|DIETARY_SUPPLEMENT|fish, beef, fruit|
219143291|NCT00765934|DRUG|Rapydan|lidocaine / tetracaine 70/70 mg patch
219143292|NCT04915885|OTHER|Routine care|Routine contraceptive counseling and routine method availability
219143293|NCT04915885|OTHER|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
219143294|NCT04915885|OTHER|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
219143295|NCT01957319|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
219143296|NCT01957319|DRUG|sugar pill|
219143297|NCT06223529|BEHAVIORAL|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
219230499|NCT03543904|PROCEDURE|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
219718664|NCT07122544|BEHAVIORAL|Therapeutic stay in subterranean sanatorium chambers (microclimate therapy)|"Characteristics of the underground environment in the Wieliczka sanatorium chambers:~Stable climatic conditions: relative humidity ranging from 60-75%, temperature between 12.9-14.5°C; High chemical and biological air purity; Mineral content in the air: 2.7-8.1 mg/m³, consisting mainly of chloride, sodium, potassium, calcium, and fluoride ions; Air ionization: 1,200-4,700 aeroions/cm³ of air. Elevated atmospheric pressure: increased by approximately 16-20 mmHg compared to surface conditions."
219143298|NCT03565796|BEHAVIORAL|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
219143299|NCT03565796|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
219143300|NCT03565796|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
219230500|NCT03543904|PROCEDURE|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
219230501|NCT00661206|DRUG|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
219143301|NCT03565796|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
219143302|NCT03565796|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
219143303|NCT05038072|DRUG|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
219143304|NCT00612586|DRUG|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
219143305|NCT00612586|DRUG|Placebo|oral, daily (up to 1 yr or until progressive disease)
219143306|NCT00612586|DRUG|Leucovorin (LV)|400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
219143307|NCT00612586|DRUG|5-fluorouracil (5-FU)|400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
219143308|NCT00612586|DRUG|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
219143309|NCT05379491|DRUG|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
219143310|NCT05379491|DRUG|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
219143311|NCT02631343|BEHAVIORAL|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
219230502|NCT00661206|DRUG|Placebo|Patients randomized in this group will receive placebo for 6 months.
219230503|NCT05749237|OTHER|respiratory exercises|respiratory exercises
219230504|NCT05749237|OTHER|relaxation exercises|relaxation exercises
219230505|NCT03288506|BEHAVIORAL|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
219230506|NCT00695188|DRUG|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
219718665|NCT07122544|BEHAVIORAL|Breathing exercises|30 minutes daily. Breathing exercises will include active respiratory exercises, drainage and effective coughing techniques, resistance training of the respiratory muscles, chest mobilization and relaxation exercises, breathing through pursed lips, as well as short and prolonged exhalation exercises.
219718666|NCT07122544|BEHAVIORAL|General fitness exercises|30 minutes daily. General conditioning exercises will incorporate components aimed at improving overall aerobic capacity (e.g., walking-based activities, dance routines, step exercises), flexibility and coordination (e.g., stretching and balance exercises), and strength (e.g., exercises using resistance bands or dumbbells). The training will be conducted in interval, circuit, and free-form formats. Resistance levels will be individually adjusted to the patient's capacity.
219718667|NCT07122544|BEHAVIORAL|Relaxation training|30 minutes, once during the entire cycle. Relaxation training will include rest in a seated position, with dimmed lighting and calming music.
219718668|NCT07122544|BEHAVIORAL|Health education|"Educational materials in printed form for distribution covering the following topics:~COPD - information about the disease;~Breathing exercises and bronchial hygiene;~Benefits of physical activity, including examples of exercises that can be performed at home."
219718669|NCT07123714|PROCEDURE|Nebulization of magnesium sulfate|patient will be nebulized with 5 mg magnesium sulfate (5 ml) 15 minutes before induction of anesthesia
219718670|NCT07123376|DRUG|HRS-9231|HRS-9231 was administered intravenously;
219718671|NCT07123376|DRUG|Placebo|Placebo was administered intravenously.
219143312|NCT02631343|OTHER|Essential newborn care|
219143313|NCT03516604|DRUG|PF-04995274|PF-04995274 tablets
219143314|NCT03516604|DRUG|Citalopram|Citalopram capsule
219143315|NCT03516604|DRUG|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
219143316|NCT03516604|DRUG|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
219143317|NCT01151839|PROCEDURE|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
219143318|NCT01151839|PROCEDURE|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
219143319|NCT01909336|DRUG|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
219230507|NCT00695188|DRUG|methotrexate|25 mg oral administration
219230508|NCT00164996|PROCEDURE|Local pharyngeal anaesthesia|
219230509|NCT00164996|DEVICE|Ultrathin endoscope|
219718672|NCT07123935|DEVICE|RenalGuard® Therapy|RenalGuard Therapy®
219718673|NCT07123935|OTHER|Standard of Care (SOC)|Standard of care
219718674|NCT07123233|BEHAVIORAL|Pain Reprocessing Therapy|"One cohort of 30 patients (PRT+TAU group) will receive eight sessions of Pain Reprocessing Therapy (PRT) in addition to Treatment-as-Usual (TAU). PRT is a cognitive-behavioral-inspired approach aimed at helping patients reinterpret chronic pain as brain-generated rather than structurally caused.~A second cohort of 30 patients (TAU group) will undergo the same assessment phases but will receive only Treatment-as-Usual without PRT.~Use this module to add a description of each group or cohort in the study and to list any interventions of interest."
219718675|NCT07123233|BEHAVIORAL|Usual Therapy|Patients undergo yhe usual pharmacological tretment as prescrived by neurologist
219230510|NCT05914532|OTHER|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
219230511|NCT00487045|DEVICE|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
219230512|NCT06075030|DRUG|AND017|Oral administration of AND017 capsules three times per week
219230513|NCT01419184|DRUG|Daptomycin|
219230514|NCT01419184|DRUG|Vancomycin|
219230515|NCT05751733|DRUG|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
219230516|NCT05751733|DRUG|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
219230517|NCT03794232|DIETARY_SUPPLEMENT|NIUCHANG|
219230518|NCT03794232|DIETARY_SUPPLEMENT|Placebo|
219230519|NCT04242797|DEVICE|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.
219230520|NCT04242797|DEVICE|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
219143320|NCT01909336|DRUG|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
219143321|NCT01909336|DRUG|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
219143322|NCT02314117|DRUG|Ramucirumab|Administered IV
219143323|NCT02314117|DRUG|Capecitabine|Administered orally
219143324|NCT02314117|DRUG|Cisplatin|Administered IV
219143325|NCT02314117|DRUG|Placebo|Administered IV
219143326|NCT02314117|DRUG|Fluorouracil|Administered IV
219143327|NCT03988569|OTHER|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
219143328|NCT04679519|OTHER|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
219230521|NCT00821288|BEHAVIORAL|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
219552791|NCT00943865|BEHAVIORAL|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
219552792|NCT00943865|BEHAVIORAL|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
219552793|NCT00943865|BEHAVIORAL|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
219143329|NCT06020131|PROCEDURE|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
219143330|NCT06020131|PROCEDURE|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
219143331|NCT06020131|PROCEDURE|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
219143332|NCT00099619|DRUG|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
219552794|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
219552795|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
219552796|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
219552797|NCT06212674|PROCEDURE|PVI + LAAO|Treatment with a complex procedure of PVI + LAAO
219143333|NCT00099619|DRUG|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
219143334|NCT04962906|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.
219143335|NCT00530842|DRUG|Tiotropium plus Salmeterol|
219143336|NCT00530842|DRUG|Fluticasone/Salmeterol|
219143337|NCT05270551|PROCEDURE|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
219143338|NCT01714193|DRUG|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
219143339|NCT01714193|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
219143340|NCT00355940|DEVICE|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
219143341|NCT00355940|DEVICE|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
219552798|NCT06212674|PROCEDURE|LAAO|Tratment with LAAO procedure
219552799|NCT06212674|DRUG|NOAC|NOAC treatment
219718676|NCT07122947|DEVICE|Apple Watch: AFib History|The Apple Watch AFib History feature uses PPG pulse rhythm data to detect and quantify the burden of atrial fibrillation.
219718677|NCT07122947|DEVICE|Zio Patch|The 14-day Zio Patch monitoring device (iRhythm Technologies, Inc., San Francisco, CA) uses continuous ambulatory ECG monitoring to quantify the burden of atrial fibrillation.
219230522|NCT00821288|BEHAVIORAL|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
219143342|NCT00431431|DRUG|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
219143343|NCT00431431|DRUG|raloxifen|2 years treatment with raloxifene (60 mg)
219143344|NCT02713048|OTHER|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
219143345|NCT01215019|DRUG|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
219143346|NCT01215019|DRUG|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
219143347|NCT03471611|DRUG|Autologous CD34+ Cells|The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
219143348|NCT03471611|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
219143349|NCT03631537|OTHER|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
219143350|NCT00922207|DRUG|Adefovir|From week -4 to week 2
219143351|NCT00922207|DRUG|Entecavir|From week -4 to week 2
219143352|NCT00922207|DRUG|Placebo|From week -4 to week 2
219143353|NCT00922207|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
219143354|NCT05381571|OTHER|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
219143355|NCT00176813|DRUG|Gemcitabine|
219143356|NCT00176813|DRUG|Cisplatin|
219143357|NCT00176813|DRUG|Celecoxib|
219143358|NCT01765686|DEVICE|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
219143359|NCT01765686|DEVICE|Ligasure Small Jaw (Covidien, USA)|
219143360|NCT00427752|PROCEDURE|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
219143361|NCT00541125|BIOLOGICAL|bevacizumab|
219143362|NCT00541125|BIOLOGICAL|filgrastim|
219143363|NCT00541125|DRUG|fluorouracil|
219143364|NCT00541125|DRUG|irinotecan hydrochloride|
219143365|NCT00541125|DRUG|leucovorin calcium|
219143366|NCT02423135|BIOLOGICAL|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
219143367|NCT01983306|DRUG|SP-333 1 mg|Tablet
219143368|NCT01983306|DRUG|SP-333 3 mg|Tablet
219143369|NCT01983306|DRUG|SP-333 6 mg|Tablet
219143370|NCT01983306|DRUG|Placebo|Tablet
219143371|NCT02135172|BEHAVIORAL|Sitting|
219143372|NCT02135172|BEHAVIORAL|Standing|
219143373|NCT02135172|BEHAVIORAL|Walking|
219143374|NCT00243854|DRUG|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
219230523|NCT04417075|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
219143375|NCT00920725|DRUG|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
219143376|NCT03343938|OTHER|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
219143377|NCT00980135|DEVICE|Sinecort cream|Application over 29 days
219143378|NCT00980135|DRUG|Hydrocortison cream|Application over 29 days
219143379|NCT00980135|OTHER|Untreated skin|
219143380|NCT04810793|DRUG|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
219143381|NCT04810793|DRUG|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
219143382|NCT04810793|DRUG|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
219143383|NCT04810793|DRUG|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
219143384|NCT04810793|DRUG|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
219143385|NCT04810793|DRUG|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
219143386|NCT02955498|DRUG|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
219143387|NCT02955498|DRUG|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
219143388|NCT01490112|DRUG|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
219143389|NCT01518478|DRUG|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
219143390|NCT04505982|OTHER|Data extraction from medical files|Data extraction from medical files
219143391|NCT05263115|OTHER|Resistance Exercise intervention|12-week progressive resistance exercise intervention
219143392|NCT05263115|OTHER|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
219143393|NCT02841150|DRUG|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
219143394|NCT02841150|DRUG|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1\*560 mg, tablet.
219143395|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
219143396|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
219143397|NCT01420393|PROCEDURE|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
219143398|NCT01420393|OTHER|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
219143399|NCT01301469|DRUG|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
219143400|NCT01301469|DRUG|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
219143401|NCT05817968|DEVICE|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
219143402|NCT01783977|BIOLOGICAL|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
219143403|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
219143404|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
219143405|NCT01783977|BIOLOGICAL|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
219143406|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
219143407|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
219552800|NCT01352052|OTHER|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
219552801|NCT02119936|BEHAVIORAL|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
219552802|NCT05191745|DRUG|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
219552803|NCT05191745|DRUG|Standard of care|All standard management of postoperative pain, as per local protocols
219143408|NCT03391635|DEVICE|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
219143409|NCT03391635|DEVICE|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
219143410|NCT02874326|DRUG|Octreotide LAR|
219143411|NCT05727202|DIAGNOSTIC_TEST|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
219143412|NCT04866069|BIOLOGICAL|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
219143413|NCT04866069|BIOLOGICAL|Placebo|0.9% NaCl
219143414|NCT05159297|OTHER|Reference values|Normative reference values of coordination tests will be obtained
219143415|NCT03255096|DRUG|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
219143416|NCT03255096|DRUG|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
219143417|NCT03255096|DRUG|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
219143418|NCT01141322|DRUG|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
219143419|NCT01141322|DRUG|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
219552804|NCT05886127|DEVICE|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
219718678|NCT07125326|PROCEDURE|Intermittent catheterization|intermittent bladder catheterization every four hours, or shorter intervals if volume exceeds 500mL per expert recommendation
219143420|NCT03292315|DRUG|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
219143421|NCT03292315|OTHER|No Intervention|No injection will be administered
219143422|NCT02644174|PROCEDURE|Bariatric Surgery|
219143423|NCT00166166|DRUG|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
219143424|NCT00166166|DRUG|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
219143425|NCT00166166|DRUG|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
219143426|NCT00166166|DRUG|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
219143427|NCT00166166|DRUG|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
219143428|NCT00166166|DRUG|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
219143429|NCT00166166|DRUG|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
219143430|NCT05989646|DEVICE|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
219143431|NCT04042545|DRUG|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
219143432|NCT04042545|DRUG|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
219143433|NCT04943770|PROCEDURE|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
219143434|NCT04943770|DIAGNOSTIC_TEST|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
219143435|NCT04943770|DEVICE|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
219143436|NCT03320434|DRUG|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
219552805|NCT05894031|BEHAVIORAL|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
219143437|NCT03320434|DRUG|PRT-2761 1%|Six drops in each eye over a 17 day period.
219552806|NCT01436448|DRUG|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
219143438|NCT03320434|DRUG|Patanol|Six drops in each eye over a 17 day period.
219143439|NCT03320434|DRUG|Pred-forte|Four drops in each eye over a 3 day period.
219143440|NCT03320434|DRUG|PRT-2761 0%|Six drops in each eye over a 17 day period.
219143441|NCT05767294|OTHER|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
219143442|NCT00984737|DRUG|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
219230524|NCT04417075|BEHAVIORAL|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
219230525|NCT03989232|DRUG|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
219552807|NCT01620281|DEVICE|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
219143443|NCT02534311|DRUG|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
219143444|NCT06461871|OTHER|BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training
219143445|NCT06461871|OTHER|Moderate intensity resistance exercises in combination with balance training|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
219143446|NCT00099086|DRUG|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
219143447|NCT00099086|DRUG|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
219143448|NCT00099086|DRUG|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
219143449|NCT00099086|RADIATION|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
219143450|NCT03834792|OTHER|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
219230526|NCT03989232|DRUG|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
219230527|NCT04658888|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
219143451|NCT03900637|DRUG|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
219143452|NCT03900637|DRUG|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
219143453|NCT03900637|GENETIC|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
219143454|NCT05404906|DRUG|Azacitidine|Given SC
219143455|NCT05404906|DRUG|Venetoclax|Given PO
219143456|NCT05404906|OTHER|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
219143457|NCT03082846|RADIATION|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
219143458|NCT03082846|DRUG|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
219143459|NCT04558112|DRUG|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
219143460|NCT04558112|DRUG|Placebo|two gel capsules of placebo
219143461|NCT00003375|DRUG|lomustine|
219143462|NCT00003375|DRUG|procarbazine hydrochloride|
219143463|NCT00003375|DRUG|vincristine sulfate|
219143464|NCT00003375|RADIATION|radiation therapy|
219143465|NCT01015404|DRUG|Trafermin|Administered to the bone defect during flap operation
219143466|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
219552808|NCT03711396|BEHAVIORAL|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
219143467|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
219143468|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
219143469|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
219143470|NCT03385681|OTHER|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
219143471|NCT03573063|OTHER|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
219143472|NCT06359327|DIETARY_SUPPLEMENT|Placebo|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
219143473|NCT06359327|DIETARY_SUPPLEMENT|Pep19 2 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
219143474|NCT06359327|DIETARY_SUPPLEMENT|Pep19 5 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
219143475|NCT04716855|OTHER|Quality of life and daily living activities assessment tests|
219143476|NCT04707313|DRUG|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
219143477|NCT04707313|DRUG|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
219143478|NCT04707313|DRUG|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
219552809|NCT04912063|DRUG|Lemzoparlimab|Intravenous (IV) Infusion
219552810|NCT04912063|DRUG|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
219552811|NCT04912063|DRUG|Venetoclax|Oral Tablet
219552812|NCT03092414|PROCEDURE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
219552813|NCT03092414|PROCEDURE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
219718679|NCT07125326|PROCEDURE|Continuous catheterization|One catheter is placed in the bladder until pushing
219143479|NCT04707313|DRUG|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
219143480|NCT03165175|BEHAVIORAL|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
219143481|NCT03525951|BEHAVIORAL|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
219143482|NCT03525951|OTHER|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
219143483|NCT02709174|PROCEDURE|blood draw|blood draw
219143484|NCT04761562|DRUG|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
219143485|NCT04761562|PROCEDURE|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
219143486|NCT02491723|DRUG|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
219143487|NCT05885126|OTHER|MANDALA TECHNIQUE|The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
219143488|NCT05839938|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
219143489|NCT05839938|OTHER|Placebo|Placebo
219143490|NCT03770507|OTHER|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
219718680|NCT07125508|DRUG|Tranexamic Acid (TXA) treatment|Patients randomized to the interventional arm will take oral tranexamic acid 650 mg three times per day for 3 months. They will have blood work drawn every month for the 3 month trial period.
219143491|NCT00383513|BIOLOGICAL|Epratuzumab|360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
219143492|NCT02156635|DEVICE|Transcranial direct current stimulation|
219143493|NCT02156635|BEHAVIORAL|Constraint-Induced Movement Therapy|
219143494|NCT02156635|OTHER|Placebo|
219143495|NCT02176096|DIETARY_SUPPLEMENT|Glycosade|
219143496|NCT03433950|OTHER|No Intervention|Observational
219143497|NCT00145041|DRUG|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
219143498|NCT00253058|DRUG|Cetirizine Dry Syrup|
219143499|NCT05899335|DEVICE|SmartCP (mobile phone app)|As described
219552814|NCT04194008|DEVICE|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
219552815|NCT01144845|PROCEDURE|Thoracic surgery|Thoracoscopy or anterior thoracotomy
219552816|NCT02725060|DRUG|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
219552817|NCT02725060|DRUG|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
219552818|NCT02725060|RADIATION|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
219552819|NCT02725060|PROCEDURE|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
219552820|NCT02725060|PROCEDURE|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
219552821|NCT02725060|PROCEDURE|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
219718681|NCT07125508|DRUG|Placebo|Placebo intervention
219718682|NCT07125755|DRUG|Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
219143500|NCT01550978|DEVICE|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
219143501|NCT03128658|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
219143502|NCT03128658|DIAGNOSTIC_TEST|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
219143503|NCT02618278|OTHER|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
219143504|NCT04076202|DEVICE|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
219143505|NCT00595218|BEHAVIORAL|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
219143506|NCT00595218|OTHER|Patient Preference Results|Knowledge of Patient Preference Results
219143507|NCT04584450|OTHER|Questionnaire|data collection using questionnaire
219143508|NCT04052919|OTHER|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
219143509|NCT04298086|OTHER|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
219143510|NCT04298086|OTHER|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
219143511|NCT04298086|OTHER|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
219143512|NCT04298086|OTHER|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
219143513|NCT04298086|OTHER|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
219230528|NCT03400579|DEVICE|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
219143514|NCT03398837|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
219143515|NCT03398837|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
219143516|NCT03398837|OTHER|Placebo oral capsule|Subjects will receive placebo twice daily.
219143517|NCT02709863|DRUG|Sevoflurane|1-1.5 MAC, inhalation route, during operation
219143518|NCT02709863|DRUG|Desflurane|1-1.5 MAC, inhalation route, during operation
219143519|NCT02709863|DRUG|Propofol|6-10 mg/kg/h, iv infusion, during operation
219552822|NCT02725060|PROCEDURE|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
219552823|NCT02725060|OTHER|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
219552824|NCT02725060|OTHER|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
219552825|NCT02725060|PROCEDURE|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
219552826|NCT00652002|DRUG|budesonide/formoterol|
219552827|NCT00652002|DRUG|budesonide|
219552828|NCT00652002|DRUG|formoterol|
219552829|NCT02411149|DRUG|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
219552830|NCT02411149|DRUG|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
219552831|NCT02411149|DRUG|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
219230529|NCT04901416|BIOLOGICAL|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
219143520|NCT00132119|DRUG|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
219143521|NCT00132119|OTHER|Placebo|Placebo tablet
219143522|NCT01671124|OTHER|Soline capsule|
219143523|NCT05060562|OTHER|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
219143524|NCT05060562|OTHER|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
219143525|NCT00324038|DRUG|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
219143526|NCT00324038|DRUG|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
219143527|NCT04575285|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
219143528|NCT03070483|DRUG|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
219143529|NCT00628719|DRUG|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
219143530|NCT00628719|DRUG|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
219143531|NCT01514903|DRUG|HIP0908|SINGLE DOSE , CROSS OVER
219552832|NCT04427033|DEVICE|Bone Conduction Implant|Bonebridge system BCI 602
219552833|NCT05999734|DRUG|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
219552834|NCT02218216|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
219552835|NCT00147134|PROCEDURE|open colectomy|Procedure/Surgery: open colectomy
219143532|NCT01514903|DRUG|viagra|single dose, cross over
219143533|NCT00920244|PROCEDURE|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
219143534|NCT00920244|DRUG|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
219143535|NCT00920244|DRUG|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.
219143536|NCT00920244|DRUG|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
219143537|NCT00920244|DEVICE|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
219143538|NCT04913779|DRUG|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
219143539|NCT04913779|DRUG|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
219552836|NCT00147134|PROCEDURE|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
219552837|NCT00980941|DIETARY_SUPPLEMENT|soup with or without starch|
219552838|NCT05608239|DEVICE|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
219552839|NCT03363555|DRUG|SHR-1210|A humanized monoclonal immunoglobulin.
219552840|NCT03193021|DEVICE|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
219552841|NCT03193021|OTHER|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
219552842|NCT03680144|PROCEDURE|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
219552843|NCT03680144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
219552844|NCT00461435|PROCEDURE|hyperbaric oxygen therapy|
219552845|NCT01139762|DRUG|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
219552846|NCT01139762|DRUG|Placebo|Administered orally, once daily for 26 weeks
219552847|NCT01139762|DRUG|Finasteride|5mg administered orally, once daily for 26 weeks
219552848|NCT03911635|PROCEDURE|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
219143540|NCT02770248|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
219143541|NCT02770248|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
219143542|NCT01215695|DEVICE|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
219143543|NCT01215695|DEVICE|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
219143544|NCT02296619|PROCEDURE|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
219143545|NCT02296619|PROCEDURE|Control|A sham band-aid will be applied to the abdomen of subjects
219143546|NCT04935489|DEVICE|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
219143547|NCT01940003|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
219143548|NCT00924534|DRUG|Placebo|Placebo
219143549|NCT00924534|DRUG|SLV337|SLV337 400 mg/day
219143550|NCT00924534|DRUG|SLV337|SLV337 800 mg/day
219143551|NCT00924534|DRUG|SLV337|SLV337 1400 mg/day
219143552|NCT05937919|DRUG|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
219552849|NCT01226953|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
219552850|NCT00621660|PROCEDURE|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
219552851|NCT00621660|PROCEDURE|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
219552852|NCT05546060|DRUG|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
219143553|NCT04483063|DRUG|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
219143554|NCT00092755|DRUG|MK0663, etoricoxib|
219143555|NCT00092755|DRUG|Comparators: ibuprofen and placebo|
219143556|NCT06553521|OTHER|MyHEARTSMAP Youth Self-assessment Tool (At Admission)|MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
219143557|NCT05132686|BEHAVIORAL|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
219143558|NCT05132686|BEHAVIORAL|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
219143559|NCT01326130|BEHAVIORAL|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
219143560|NCT00509535|DRUG|vitreoscilla filiformis cream|
219143561|NCT02701855|BEHAVIORAL|Cognitive tests|"Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)"
219143562|NCT02701855|BIOLOGICAL|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
219143563|NCT02701855|RADIATION|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
219143564|NCT02701855|OTHER|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
219230530|NCT03868878|OTHER|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
219230531|NCT03690557|BEHAVIORAL|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
219230532|NCT00539084|DEVICE|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
219718683|NCT07124390|DEVICE|Name: Electroacupuncture (EA) Type: Device-based acupuncture therapy|Description: Insertion of acupuncture needles at specific points with electrical stimulation (2 Hz) for 30 minutes per session.
219718684|NCT07124390|DEVICE|Neuromodulation therapy|"Type: Neuromodulation therapy~Description: Insertion of a needle electrode near the medial malleolus with low-voltage electrical stimulation (20 Hz) applied for 30 minutes per session."
219718685|NCT07124390|DEVICE|Sham Acupuncture|"Type: Placebo~Description: Non-invasive, non-penetrating placebo needles placed at the same points as in the EA group, without electrical stimulation, for 30 minutes per session."
219718686|NCT07125547|DRUG|PD-1 inhibitior|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
219718687|NCT07125547|DRUG|Nab-paclitaxel|Nab-Paclitaxel 125mg/m2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
219718688|NCT07125547|PROCEDURE|distal ureterectomy|Distal ureterectomy (Distal ureterectomy + Partial cystectomy +Psoas hitch procedure + Ureteral reimplantation into the bladder + Ipsilateral pelvic lymph node dissection) will be conducted after neoadjuvant treatment.
219718689|NCT07125846|DEVICE|Bioactive Glass Bone Graft (UNIGRAFT)|A bioactive glass bone graft material (UNIGRAFT, Biomed Inc., USA) used for maxillary sinus floor augmentation via open sinus lift technique.
219718690|NCT07125846|DEVICE|Xenograft Bone Graft (Bio-Oss)|A commercially available bovine-derived xenograft material (Bio-Oss, Geistlich Pharma) used for maxillary sinus floor augmentation via open sinus lift technique.
219718691|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
219718692|NCT07102953|BEHAVIORAL|Focused-attention meditation|This is a type of mindfulenss meditation, which instructes participants to keep focusing on own breathing with a sitting and rest posture.
219718693|NCT07102953|BEHAVIORAL|Open-monitoring meditation|This is a type of mindfulenss meditation, which instructs participants to stay aware of their vision with a sitting and rest posture.
219718694|NCT07102953|BEHAVIORAL|Audio-listening control|Participants listen to stories about creativity with a sitting and rest posture.
219718695|NCT07105085|PROCEDURE|living donor liver transplantation|other intervention cannot be applied.
219718696|NCT07116616|DRUG|mRNA-2808|intravenous
219718697|NCT07121205|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
219718698|NCT07120828|DRUG|Empagliflozin (oral)|Empagliflozin 10 mg oral tablet administered once daily for 6 months.
219718699|NCT07120828|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg oral tablet administered once daily for 6 months
219718700|NCT07120828|DRUG|Metfomin|metformin 500-1000 mg/day administered as part of standard care, based on clinical indication.
219718701|NCT06925542|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
219718702|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
219718703|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
219718704|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
219718705|NCT06937476|DRUG|Escitalopram|Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
219718706|NCT06937476|DRUG|Aripiprazole 5mg|Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, after which aripiprazole will be tapered and discontinued. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms.
219143565|NCT06318624|OTHER|Mobilisation with Movement and Taping|For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
219143566|NCT06318624|OTHER|Sham|During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
219143567|NCT04776265|OTHER|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
219143568|NCT00476060|PROCEDURE|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
219143569|NCT03644329|OTHER|Control group|The volunteers will not performed the interventions.
219230533|NCT02053714|BEHAVIORAL|Diabetes self-management and education|
219718707|NCT06939283|DRUG|WTX-330|Investigational Product
219718708|NCT06936891|COMBINATION_PRODUCT|Virtual Ward|Hospital-level care at home using remote vital sign monitoring, digital anamnesis via the Digizorg app, and integration with the Electronic Medical Record (HiX), managed by Virtual Ward staff following predefined care pathways.
219718709|NCT06945276|DRUG|ALG-097558|A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro with pan-coronavirus activity
219718710|NCT06945276|DRUG|Dabigatran|A direct thrombin inhibitor approved for the treatment and prevention of blood clots to reduce the risk of stroke
219718711|NCT06945276|DRUG|Itraconazole|A substrate and strong dual inhibitor of CYP3A4/P-glycoprotein (P-gp)
219718712|NCT06945276|OTHER|Placebo|Placebo
219718713|NCT06943066|OTHER|Reformer Pilates|Reformer Pilates
219718714|NCT06943066|OTHER|Pilates control|Pilates control
219718715|NCT06943066|OTHER|online pilates|online pilates
219718716|NCT06955871|OTHER|Toothpaste containing 1.05% Chitosan|Toothpaste containing 1.05% Chitosan
219718717|NCT06955871|OTHER|Silica-based NaF Toothpaste|Silica-based NaF Toothpaste
219718718|NCT06955871|OTHER|Toothpaste with 67% bicarbonate|Toothpaste containing 67% Bicarbonate
219718719|NCT02850406|DRUG|Voxelotor|"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
219718720|NCT07117890|DRUG|Sunvozertinib|sunvozertinib 300mg QD
219718721|NCT06545695|DRUG|Erlotinib|Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
219718722|NCT07119710|BEHAVIORAL|Cognitive Behavioral Therapy|Individual tele-therapy 12-16 weeks
219230534|NCT02450084|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
219718723|NCT07119710|BEHAVIORAL|Cognitive Behavioral therapy with 2 check in calls|Cognitive Behavioral therapy with 2 calls a week
219718724|NCT06105437|OTHER|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
219230535|NCT02450084|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
219230536|NCT02450084|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
219718725|NCT01892852|PROCEDURE|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
219718726|NCT03869437|DRUG|Cefiderocol|2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
219718727|NCT03869437|OTHER|Best Available Therapy|Standard of care was determined by the investigator
219718728|NCT05983406|DEVICE|Doppler investigation|Doppler investigation
219718729|NCT06002113|OTHER|GOCD Tool|Web-based tool with 4 components; pre-admission health status; current illness prognosis for hospital survival; in-hospital cardiorespiratory arrest prognosis; values and goals of care
219718730|NCT06002113|OTHER|Usual care|Attending physicians responsible for GOCD during hospitalization using their usual approaches
219718731|NCT01092923|DRUG|sevoflurane on air/O2|sevoflurane on air/O2
219718732|NCT01092923|DRUG|sevoflurane in N2O/O2|sevoflurane in N2O/O2
219230537|NCT02450084|DRUG|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
219230538|NCT05851014|DRUG|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
219143570|NCT03644329|OTHER|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
219143571|NCT03644329|OTHER|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
219143572|NCT03644329|OTHER|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
219143573|NCT00694681|BEHAVIORAL|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
219143574|NCT06972563|OTHER|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder
219143575|NCT06972563|OTHER|The initiative was not implemented.|The initiative was not implemented.
219143576|NCT06974409|DEVICE|foam roller|foam rollers with grids, knobs, and spikes
219143577|NCT01376336|DEVICE|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
219143578|NCT04415086|BIOLOGICAL|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
219143579|NCT04183959|DEVICE|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
219143580|NCT04183959|DEVICE|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
219143581|NCT01036412|DRUG|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
219230539|NCT05851014|DRUG|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
219230540|NCT04738214|OTHER|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
219143582|NCT01036412|BEHAVIORAL|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
219143583|NCT02380209|OTHER|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
219143584|NCT01585558|DRUG|Ospemifene (Dose 1)|
219143585|NCT01585558|DRUG|Ospemifene (Dose 2)|
219143586|NCT01585558|DRUG|Placebo|
219143587|NCT01378065|DEVICE|Restorelle Direct Fix A&P|Restorelle Direct Fix A\&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
219143588|NCT04561544|BEHAVIORAL|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
219143589|NCT00476333|DEVICE|APOS biomechanical gait system|
219143590|NCT00566124|DRUG|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
219143591|NCT00566124|DRUG|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
219143592|NCT00566124|DRUG|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
219230541|NCT04269044|DIAGNOSTIC_TEST|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
219230542|NCT05253092|OTHER|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
219230543|NCT02383797|BIOLOGICAL|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
219230544|NCT00223769|DRUG|Oxandrolone|
219230545|NCT02721407|DRUG|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
219552853|NCT05546060|DRUG|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
219552854|NCT05546060|DRUG|Etoposide|Etoposide 75mg/m2 qw d1-56
219552855|NCT03510260|OTHER|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
219552856|NCT03510260|OTHER|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
219552857|NCT03510260|OTHER|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
219143593|NCT00891176|BIOLOGICAL|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
219143594|NCT00891176|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
219143595|NCT00891176|BIOLOGICAL|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
219143596|NCT00891176|BIOLOGICAL|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
219143597|NCT00891176|BIOLOGICAL|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
219143598|NCT00891176|BIOLOGICAL|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
219143599|NCT00891176|BIOLOGICAL|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
219143600|NCT00891176|BIOLOGICAL|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
219143601|NCT00891176|BIOLOGICAL|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
219143602|NCT00111709|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
219143603|NCT00111709|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
219143604|NCT04709744|DRUG|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
219143605|NCT04709744|DIAGNOSTIC_TEST|ELISA|Measure vitamin D level
219718733|NCT06112145|OTHER|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
219143606|NCT00667745|DRUG|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
219143607|NCT00667745|DRUG|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
219143608|NCT05301556|OTHER|Experimental Product|"* Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
219143609|NCT05301556|OTHER|Control Product|"* Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
219143610|NCT04850482|OTHER|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
219143611|NCT04546997|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
219143612|NCT02160106|DRUG|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
219143613|NCT01606995|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
219143614|NCT01523249|DEVICE|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
219143615|NCT03768206|BEHAVIORAL|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
219143616|NCT03768206|BEHAVIORAL|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
219718734|NCT00876395|DRUG|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
219718735|NCT00876395|DRUG|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
219718736|NCT00876395|DRUG|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
219718737|NCT00876395|DRUG|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
219718738|NCT03168724|BEHAVIORAL|GMT intervention|
219718739|NCT06031129|DRUG|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
219143617|NCT03768206|BEHAVIORAL|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
219143618|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
219143619|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
219143620|NCT04814043|DRUG|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
219143621|NCT06553248|DRUG|GZR4|Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
219143622|NCT06553248|DRUG|Insulin Degludec|Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
219718740|NCT06031129|DRUG|normal saline|normal saline contain 0.9% NaCl sodium.
219143623|NCT03037502|BEHAVIORAL|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
219143624|NCT03655938|PROCEDURE|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
219143625|NCT01941563|DRUG|Condoliase|1.25U, intradiscal injection, one time
219143626|NCT01941563|DRUG|placebo|
219143627|NCT00002527|DRUG|aspirin|
219143628|NCT00002527|OTHER|placebo|
219143629|NCT03799536|DRUG|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
219143630|NCT03799536|DRUG|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
219143631|NCT04063410|PROCEDURE|Angiography|Undergo standard of care CTA
219143632|NCT04063410|PROCEDURE|MRI-Based Angiogram|Undergo pPCA
219143633|NCT04063410|OTHER|Quality-of-Life Assessment|Ancillary studies
219143634|NCT01713946|DRUG|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
219143635|NCT01713946|DRUG|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
219143636|NCT01713946|DRUG|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
219143637|NCT01713946|DRUG|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
219143638|NCT03183518|OTHER|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
219143639|NCT03183518|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
219143640|NCT02827617|DRUG|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
219143641|NCT05265559|PROCEDURE|Partial Indirect Restoration|Dental restorative treatment
219143642|NCT03446482|OTHER|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
219143643|NCT00681252|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
219143644|NCT01910636|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
219718741|NCT01405573|OTHER|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
219718742|NCT01405573|DRUG|sorafenib|400 mg twice a day
219718743|NCT06505148|DRUG|Acetaminophen|administered alternatively with other drug
219718744|NCT06505148|DRUG|Ibuprofen|administered alternatively with other drug
219718745|NCT01850329|OTHER|computed-assisted information program|
219718746|NCT02666599|RADIATION|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
219718747|NCT00482144|PROCEDURE|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
219143645|NCT01910636|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
219143646|NCT00283374|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
219143647|NCT04851561|DIAGNOSTIC_TEST|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
219143648|NCT06269874|DIAGNOSTIC_TEST|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
219143649|NCT01946035|DRUG|Doxazosin XL|
219230546|NCT04243915|OTHER|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
219230547|NCT04243915|OTHER|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
219552858|NCT04190160|DRUG|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
219552859|NCT02614196|DRUG|Galcanezumab|Administered SC
219143650|NCT01946035|OTHER|Placebo|
219143651|NCT05358730|OTHER|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
219143652|NCT05358730|OTHER|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
219143653|NCT05358730|OTHER|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
219143654|NCT06673602|DRUG|FCYC+Conventional treatment|Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
219143655|NCT06673602|DRUG|conventional treatment|The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
219552860|NCT02614196|DRUG|Placebo|Administered SC
219552861|NCT03790163|DRUG|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
219552862|NCT05965908|DRUG|liraglutide|glucagon-like peptide 1 receptor agonist
219552863|NCT05965908|DRUG|Metformin|biguanide antihyperglycemic
219552864|NCT01539239|DEVICE|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
219552865|NCT01539239|PROCEDURE|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
219552866|NCT05597631|DEVICE|G-IVF PLUS|Experimental
219552867|NCT05437068|OTHER|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
219552868|NCT02179788|BEHAVIORAL|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
219552869|NCT02179788|DRUG|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
219552870|NCT02179788|DRUG|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
219552871|NCT01750827|DRUG|SB659032|single dose
219552872|NCT03302598|DIAGNOSTIC_TEST|serum C-reactive protein|
219552873|NCT00789776|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
219552874|NCT00789776|DRUG|Cyclophosphamide|Given IV
219552875|NCT00789776|DRUG|Fludarabine Phosphate|Given IV
219552876|NCT00789776|OTHER|Laboratory Biomarker Analysis|Correlative studies
219552877|NCT00789776|DRUG|Mycophenolate Mofetil|Given PO
219718748|NCT00482144|PROCEDURE|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
219143656|NCT06675994|DRUG|PCSK9 Antibody, PCSK9 Enzyme|In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
219143657|NCT06676956|PROCEDURE|Order of bronchoscopy procedures for peripheral nodule biopsy|Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
219143658|NCT06677333|OTHER|Whey Protein|This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
219143659|NCT06677333|OTHER|Pea protein|This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
219143660|NCT06620614|COMBINATION_PRODUCT|0.5% Heavy Bupivacaine|There are two groups.
219143661|NCT06631716|DEVICE|CVT|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is CVT.
219718749|NCT03588520|DIAGNOSTIC_TEST|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
219718750|NCT03807843|BIOLOGICAL|V184|Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.
219143662|NCT06631716|DEVICE|HFCWO|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is HFCWO.
219143663|NCT06631716|DEVICE|MetaNeb|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is MetaNeb.
219143664|NCT06632067|DRUG|sugammadex|sugammadex used for neuromuscular reversal
219718751|NCT03807843|OTHER|Placebo|Sterile physiological saline for IM injection
219718752|NCT02961725|BIOLOGICAL|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
219718753|NCT01312129|DRUG|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
219718754|NCT01312129|DRUG|Placebo|Placebo capsule x 3 doses 12 hours apart
219718755|NCT00386698|BIOLOGICAL|Fluarix|
219718756|NCT00386698|BIOLOGICAL|adjuvanted influenza vaccine|
219718757|NCT05053828|DRUG|Antiplatelet Drug|Antiplatelet drugs and agents
219230548|NCT04243915|OTHER|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
219143665|NCT06632067|DRUG|Neostigmine + Atropine|Neostigmine and Atropine used for neuromuscular reversal
219143666|NCT06628661|PROCEDURE|Surgery for HCC larger than 6.5 cm|Surgery for HCC larger than 6.5 cm without mVI
219143667|NCT06628661|PROCEDURE|Surgery for HCC larger than 2 cm|Surgery for HCC larger than 2 cm with mVI
219143668|NCT06713200|PROCEDURE|High intensity percutaneous electrolysis|A sterile, disposable stainless steel needle of different lengths depending on the area to be treated will be connected to the EP device; the gauge of these needles will be 0.25 mm. A current of 3 mA will be applied for 3 times with a duration of 3 seconds each. In order to avoid biases, the technique will be performed for 90 seconds as in the low intensity treatment group and in the last 20 seconds the current will be applied with the parameters previously described. Three sessions divided in three consecutive weeks will be applied.
219230549|NCT04243915|OTHER|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
219230550|NCT00002086|DRUG|Zidovudine|
219718758|NCT03685513|OTHER|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
219718759|NCT03685513|OTHER|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
219718760|NCT03975634|DEVICE|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
219718761|NCT00496457|DRUG|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
219718762|NCT00496457|DRUG|Placebo comparator|4 Capsules of PBO per day before noon meal
219143669|NCT06713200|PROCEDURE|Low intensity Percutaneous Electrolysis|This technique will be performed with the same instrument as the high intensity technique. It differs from the previous treatment group in that the current intensity in this case will be of an amperage of 0.3mA during 90 seconds. In the same way, 3 sessions divided in 21 consecutive days will be applied.
219143670|NCT06713200|PROCEDURE|Simulated Percutaneous Electrolysis|The needle and PD device will be connected in the same way as for the other treatment groups. The needle will be inserted without reaching the lesion area and the characteristic sound of turning on the PD machine will be made. It will last 90 seconds and at no time the galvanic current will be applied. The same aseptic precautions will be applied, in addition to performing the same final hemostasis guidelines and providing the same post-treatment guidelines as for all the other subjects in the study.
219143671|NCT06711393|OTHER|Exercise|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week. In addition, game-based exercises 15 minutes at the time and three times over the week.
219143672|NCT06711393|OTHER|Exercise as usual|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week without exergaming.
219143673|NCT06713876|DEVICE|VA-ECMO-assisted PCI|A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.
219143674|NCT06711900|DRUG|SKB264|IV Infusion
219143675|NCT06711900|DRUG|Pembrolizumab|IV Infusion
219143676|NCT06711900|DRUG|pemetrexed|IV Infusion
219143677|NCT06711900|DRUG|carboplatin or cisplatin|IV Infusion
219143678|NCT06711237|OTHER|self-adhesive resin cement (RC)|Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
219718763|NCT00104234|DRUG|N-acetylgalactosamine 4-sulfatase|
219143679|NCT06711237|OTHER|resin-modified glass-ionomer cement (RMGIC)|Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
219143680|NCT04493242|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219143681|NCT04493242|OTHER|Intravenous normal saline|Placebo
219143682|NCT05632068|DRUG|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
219143683|NCT01125761|DRUG|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
219143684|NCT01125761|DRUG|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
219143685|NCT01942707|PROCEDURE|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
219143686|NCT01942707|PROCEDURE|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
219143687|NCT04045470|DEVICE|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
219143688|NCT04045470|OTHER|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
219143689|NCT04045470|OTHER|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
219143690|NCT01473719|BEHAVIORAL|motivational intervention|7-session individual motivationally-based intervention
219143691|NCT01473719|BEHAVIORAL|health education|7 individual sessions focusing on health education
219143692|NCT01230047|BEHAVIORAL|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
219143693|NCT04857944|BEHAVIORAL|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
219143694|NCT04857944|DEVICE|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
219143695|NCT03180905|DEVICE|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
219143696|NCT03180905|DEVICE|ImPACT Online|ImPACT Online will be administered at 2 time points.
219143697|NCT05903027|DRUG|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
219143698|NCT00590382|DEVICE|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
219143699|NCT05709899|OTHER|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
219718764|NCT00104234|DRUG|Placebo/rhASB|
219718765|NCT04674527|DRUG|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
219718766|NCT04674527|DRUG|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
219718767|NCT02315820|PROCEDURE|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
219718768|NCT01233830|DRUG|AZD2423|oral solution
219718769|NCT01233830|DRUG|Placebo|oral solution
219143700|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
219143701|NCT04513522|BIOLOGICAL|Nivolumab|Specified dose on specified days
219230551|NCT00002086|DRUG|Zalcitabine|
219230552|NCT00002086|DRUG|Interferon alfa-n1|
219230553|NCT00911638|BEHAVIORAL|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
219230554|NCT00911638|BEHAVIORAL|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
219230555|NCT04565717|DRUG|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
219230556|NCT04565717|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
219230557|NCT05149963|OTHER|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
219230558|NCT03942094|DRUG|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
219230559|NCT05141409|DEVICE|Artificial Intelligence|Artificial Intelligence
219230560|NCT02567591|OTHER|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
219718770|NCT00236431|DRUG|Galantamine hydrobromide|
219143702|NCT04513522|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219143703|NCT05218044|PROCEDURE|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
219230561|NCT02691702|DRUG|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
219230562|NCT02691702|DRUG|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
219230563|NCT01694147|DEVICE|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
219230564|NCT04876846|DEVICE|GEN 3 Monitoring of Fetus|"Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity"
219230565|NCT06389877|DRUG|BEAM-302|BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
219230566|NCT05169684|BIOLOGICAL|BMS-986218|Specified dose on specified days
219230567|NCT05169684|DRUG|Docetaxel|Specified dose on specified days
219230568|NCT05169684|BIOLOGICAL|Nivolumab|Specified dose on specified days
219230569|NCT06352619|OTHER|Conservative SBP Control|No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg
219230570|NCT06352619|OTHER|Moderate SBP Control|If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated
219230571|NCT06352619|OTHER|Intensive SBP Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
219230572|NCT05147675|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219552878|NCT00789776|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
219552879|NCT00789776|DRUG|Tacrolimus|Given IV or PO
219552880|NCT00789776|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
219552881|NCT02627001|DEVICE|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
219552882|NCT02627001|DEVICE|Bag Valve Mask|Conventional bag valve mask
219552883|NCT06374654|OTHER|Home-based Exercise Protocol|The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.
219143704|NCT04599764|OTHER|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. During anodal DLPFC stimulation, participants received stimulation at 2 mA for 30 minutes, including a 30-second ramp-up period at the start and a 30-second ramp-down period at the end.
219143705|NCT04599764|OTHER|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. This trial will employ a computerized multi-domain adaptive training program. This program and training model have been demonstrated to be effective and beneficial in patients with vascular cognitive impairment. In the CCT intervention group, participants will undergo 2 weeks of computerized, multi-domain, adaptive training. The training domains include processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Task rigor varies across domains and determines task grouping. Participants are required to complete 30 minutes of daily training(one session each of six 5-minute tasks).
219143706|NCT04599764|OTHER|Sham tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. For sham stimulation, participants received only the initial 30-second ramp-up to 2 mA, after which stimulation was immediately terminated.
219143707|NCT06337526|DEVICE|Apple Watch v8|Apple Watch used for data collection only
219143708|NCT04541303|DRUG|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
219143709|NCT04541303|DRUG|normal saline|0.9% sodium chloride
219143710|NCT00589667|DRUG|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
219143711|NCT05967637|OTHER|Whole body vibration|The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.
219143712|NCT05967637|OTHER|Sham-Whole body vibration|The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
219143713|NCT03538041|DRUG|Parsaclisib|Parsaclisib administered orally.
219143714|NCT01850836|PROCEDURE|repetitive transcranial magnetic stimulation|
219143715|NCT03759743|DIETARY_SUPPLEMENT|LMT1-48|capsules containing Probiotics
219143716|NCT03759743|DIETARY_SUPPLEMENT|Placebo|capsules that did not contain any probiotics
219143717|NCT03922880|DRUG|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
219143718|NCT03922880|DRUG|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
219143719|NCT03922880|DRUG|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
219143720|NCT03827369|DIAGNOSTIC_TEST|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
219143721|NCT00131066|OTHER|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
219143722|NCT03310645|DRUG|BAY1817080|4 different doses over the course of study
219143723|NCT03310645|DRUG|Matching Placebo|Matching placebo for BAY1817080
219143724|NCT02990754|BEHAVIORAL|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
219718771|NCT02113566|DRUG|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
219718772|NCT00924651|BEHAVIORAL|exercise|home based walking and progressive resistance training exercise
219718773|NCT05885958|OTHER|Time|Patients will be given up to 30 minutes to void.
219718774|NCT05885958|OTHER|Time|Patients will be given up to 60 minutes to void.
219718775|NCT03318419|DRUG|Cladribine|5mg/㎡ d1-5
219718776|NCT03318419|DRUG|G-CSF|300ug d0-14
219718777|NCT03318419|DRUG|Cytarabine|10mg/㎡ q12h SC d1-14
219718778|NCT03318419|DRUG|Pegaspargase|2500U/m2 im d1
219718779|NCT02080130|DIETARY_SUPPLEMENT|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
219230573|NCT04922242|BEHAVIORAL|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
219143725|NCT04737681|OTHER|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
219143726|NCT00071253|DRUG|Divalproex Sodium (Delayed-Release Tablets)|
219143727|NCT00071253|DRUG|Divalproex Sodium (Extended-Release Tablets)|
219143728|NCT00071253|DRUG|Olanzapine|
219143729|NCT03868397|DIAGNOSTIC_TEST|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
219230574|NCT04922242|OTHER|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
219230575|NCT04489355|PROCEDURE|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
219230576|NCT06186960|DEVICE|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
219230577|NCT02732171|OTHER|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
219230578|NCT06533722|DRUG|Gemcitabine, Vinorelbine, or Eribulin|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
219143730|NCT06572163|DEVICE|Eximis CS (Contained Segmentation) System|The Eximis CS System is an integrated system consisting of a 900 mL Capture Bag, Inflation Mechanism, two Eximis Segmenters, and the Eximis RF Generator.
219143731|NCT06140303|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
219143732|NCT06140303|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot"
219143733|NCT06415448|DRUG|Donidalorsen|Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
219143734|NCT06324201|DEVICE|Ablation Procedure|Ablation Procedure for paroxysmal atrial fibrillation
219143735|NCT01266265|DRUG|inhaled prostacyclin|Tyvaso
219143736|NCT01266265|DRUG|inhaled prostacyclin|As prescribed by the physician
219143737|NCT01266265|DRUG|prostacyclin|As prescribed by the physician
219143738|NCT01266265|DRUG|subcutaneous and intravenous prostacyclin|As prescribed by physician
219143739|NCT01266265|DRUG|oral ERA|As prescribed by physician
219143740|NCT01266265|DRUG|oral PDE5 inhibitors|As prescribed by physician
219143741|NCT01580293|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
219143742|NCT03816228|DRUG|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219143743|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Hita, Oita, Japan)|
219143744|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Aso-gun, Kumamoto, Japan)|
219143745|NCT00479648|BIOLOGICAL|CSL412|
219143746|NCT00479648|BIOLOGICAL|Inactivated trivalent influenza vaccine|
219143747|NCT04949607|DIETARY_SUPPLEMENT|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
219143748|NCT00009217|DRUG|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
219143749|NCT00009217|DRUG|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
219143750|NCT06513117|BEHAVIORAL|Behaviour change|healthy conversations to support behaviour change
219143751|NCT06513117|BEHAVIORAL|Dietary support|Guidance on healthy eating
219143752|NCT06513117|BEHAVIORAL|Breathing pattern retraining|guidance on breathing pattern in exercise
219143753|NCT06513117|BEHAVIORAL|Exercise training|Exercise intervention prescribed to participant fitness level
219143754|NCT03814265|BEHAVIORAL|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
219143755|NCT03932188|BEHAVIORAL|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
219143756|NCT03932188|DEVICE|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
219143757|NCT01967186|PROCEDURE|Intraportal islet transplantation|
219143758|NCT01967186|PROCEDURE|Intramuscular islet transplantation|
219143759|NCT01967186|PROCEDURE|Intramuscular transpl with stemcells|
219143760|NCT01967186|PROCEDURE|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
219143761|NCT02048592|DIETARY_SUPPLEMENT|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks."
219143762|NCT02048592|DIETARY_SUPPLEMENT|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
219143763|NCT02806518|PROCEDURE|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
219143764|NCT00768664|DRUG|PF-00299804|45 mg by continuous oral dosing
219143765|NCT02561871|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
219143766|NCT02561871|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
219143767|NCT02561871|DRUG|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
219143768|NCT03926884|DIETARY_SUPPLEMENT|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
219143769|NCT03926884|DIETARY_SUPPLEMENT|Control|warm water with negligible amount of the three-seeds mixture
219143770|NCT00484614|PROCEDURE|Positron Emission Mammography|Molecular Imaging Device
219143771|NCT00484614|PROCEDURE|Magnetic Resonance Imaging|Imaging Device
219143772|NCT00096967|DRUG|Avastin (bevacizumab)|
219230579|NCT04923256|BEHAVIORAL|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
219230580|NCT04923256|BEHAVIORAL|Sham training control|Complete an AAT on a weekly basis for four weeks
219718780|NCT02080130|DIETARY_SUPPLEMENT|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
219718781|NCT02080130|OTHER|Placebo|Placebo
219718782|NCT05301699|OTHER|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
219718783|NCT05686941|OTHER|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
219143773|NCT02675309|DRUG|MT-8554|
219143774|NCT02675309|DRUG|rosuvastatin|
219143775|NCT02675309|DRUG|simvastatin|
219143776|NCT00015990|DRUG|thalidomide|Given orally
219143777|NCT00015990|OTHER|laboratory biomarker analysis|Correlative studies
219143778|NCT06239948|OTHER|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
219143779|NCT06239948|OTHER|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
219143780|NCT01012453|BEHAVIORAL|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
219143781|NCT05263609|DRUG|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
219143782|NCT05263609|DRUG|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
219143783|NCT02624219|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
219143784|NCT02624219|DRUG|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
219143785|NCT02624219|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
219143786|NCT00002450|DRUG|Tenofovir disoproxil fumarate|
219143787|NCT03648346|DRUG|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
219143788|NCT03648346|DRUG|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
219143789|NCT03648346|DRUG|Placebo|Placebo eye drops
219143790|NCT05223205|PROCEDURE|Air|Test if air is sufficient for macular hole closure.
219718784|NCT05686941|OTHER|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
219143791|NCT05223205|PROCEDURE|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
219143792|NCT01314352|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
219143793|NCT04399148|DRUG|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
219143794|NCT04399148|DRUG|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
219143795|NCT04399148|DRUG|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
219143796|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
219143797|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
219143798|NCT03109223|OTHER|sole source nutrition|Infant formula
219143799|NCT00423098|DRUG|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
219143800|NCT00423098|DRUG|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
219143801|NCT00423098|DRUG|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
219143802|NCT04891835|OTHER|Data extraction from medical files|Data extraction from medical files
219143803|NCT06020963|PROCEDURE|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
219143804|NCT06020963|DRUG|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
219143805|NCT05747495|OTHER|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
219143806|NCT01639638|DRUG|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
219143807|NCT00309595|DEVICE|stent|Cordis SMART™ Nitinol Stent System
219143808|NCT00309595|DEVICE|balloon|balloon angioplasty
219143809|NCT06210334|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
219143810|NCT06210334|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
219143811|NCT00211913|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
219143812|NCT00211913|BIOLOGICAL|placebo|single IM dose
219718785|NCT02663986|BEHAVIORAL|Organizational Skills Training (OST) Intervention|
219718786|NCT02078466|OTHER|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
219143813|NCT00006505|DRUG|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
219143814|NCT02284555|DRUG|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
219143815|NCT01129232|DRUG|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
219143816|NCT01129232|OTHER|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
219230581|NCT03497052|OTHER|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
219143817|NCT00465816|BIOLOGICAL|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
219143818|NCT00465816|BIOLOGICAL|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
219143819|NCT04480827|DRUG|Aramchol free acid tablet 600mg, single dose|Aramchol free acid tablet 600mg, single dose
219143820|NCT04480827|DRUG|Aramchol free acid tablet 300mg, bid|Aramchol acid tablet 300mg, bid for 12 days
219143821|NCT05572801|DIAGNOSTIC_TEST|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
219143822|NCT06048991|DIAGNOSTIC_TEST|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
219143823|NCT00703950|PROCEDURE|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
219718787|NCT06224049|BIOLOGICAL|hNeo-T|After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning, and the investigators will decide whether to use it. Chemotherapy preconditioning will be performed before hNeo-T transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is \<0.8×10\^9/L and the subject meets the criteria for cell transfusion, the chemotherapy preconditioning will not be performed and subsequent cell transfusion can be performed directly.
219718788|NCT06224049|DRUG|Cyclophosphamide|Chemotherapy preconditioning will be performed before hNeo-T transfusion.
219143824|NCT00703950|PROCEDURE|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
219143825|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
219143826|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
219718789|NCT06224049|DRUG|Fludarabine|Chemotherapy preconditioning will be performed before hNeo-T transfusion
219718790|NCT00214435|DRUG|once daily minimum 3-drug regimen of anti-retroviral medications|
219718791|NCT01865851|DEVICE|Classic Face Mask and NuMask|
219718792|NCT05709080|OTHER|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
219718793|NCT06532942|DRUG|(Part A) MKND-201|Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1
219143827|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
219143828|NCT04781595|DIETARY_SUPPLEMENT|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
219143829|NCT04781595|DIETARY_SUPPLEMENT|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
219143830|NCT04781595|DIETARY_SUPPLEMENT|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
219143831|NCT04781595|DIETARY_SUPPLEMENT|Placebo|A single dose of maltodextrin
219143832|NCT05118581|DEVICE|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
219143833|NCT02384577|DRUG|Budesonide, Formoterol Fumarate Dihydrate|
219718794|NCT06532942|DRUG|Placebo|Participants will receive matching placebo across Part A and Part B of the study.
219143834|NCT06219642|BEHAVIORAL|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
219143835|NCT04305574|BEHAVIORAL|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
219230582|NCT03497052|OTHER|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
219230583|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
219230584|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
219143836|NCT02531568|DRUG|Warfarin|
219143837|NCT02531568|DRUG|MT-3995|
219143838|NCT03690037|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
219143839|NCT03690037|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
219143840|NCT03450278|PROCEDURE|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
219143841|NCT00941655|DRUG|Oxaliplatin|"Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,"
219230585|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
219143842|NCT00941655|DRUG|Irinotecan|Irinotecan 165 mg/m\^2 IV over 90 minutes
219230586|NCT06498609|BIOLOGICAL|iprf|i-PRF with leveling and alignment
219230587|NCT06498609|PROCEDURE|MOPs with leveling and alignment|mop
219230588|NCT03307044|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
219143843|NCT00941655|DRUG|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours."
219143844|NCT00941655|DRUG|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes."
219143845|NCT00941655|PROCEDURE|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
219143846|NCT04563156|DIAGNOSTIC_TEST|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
219143847|NCT02541916|OTHER|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
219143848|NCT02731339|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
219143849|NCT02731339|BEHAVIORAL|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
219143850|NCT02731339|BEHAVIORAL|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
219230589|NCT03307044|OTHER|Questionnaire Administration|Ancillary studies
219230590|NCT05484661|DIETARY_SUPPLEMENT|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
219230591|NCT03670121|DEVICE|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
219230592|NCT04786275|DRUG|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
219230593|NCT04786275|OTHER|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
219230594|NCT01286636|OTHER|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
219143851|NCT02731339|BEHAVIORAL|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
219143852|NCT04683263|OTHER|Placebo|topical cream with same composition as Intervention but without active ingredients
219143853|NCT04683263|OTHER|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
219143854|NCT02482519|OTHER|High calorie diet|High calorie diet for 10 days
219230595|NCT01286636|OTHER|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
219230596|NCT00152672|DEVICE|nCPAP vs oral appliance|
219230597|NCT00875706|BEHAVIORAL|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
219230598|NCT03789357|DIAGNOSTIC_TEST|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
219230599|NCT02804256|OTHER|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
219230600|NCT04037033|BEHAVIORAL|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
219230601|NCT03615833|DRUG|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
219230602|NCT01904097|DRUG|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
219230603|NCT01904097|OTHER|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
219230604|NCT01904097|OTHER|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
219230605|NCT04872296|DEVICE|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
219230606|NCT04872296|PROCEDURE|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
219143855|NCT02482519|OTHER|Fasting|10 day fast
219143856|NCT06456970|DEVICE|fibroscan|"Fibroscan examination with controlled attenuation parameterCAP (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)"
219143857|NCT03273348|PROCEDURE|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
219143858|NCT03802708|DIAGNOSTIC_TEST|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
219143859|NCT03290248|BIOLOGICAL|B244 suspension|B244 suspension in 30ml/bottle
219143860|NCT03290248|BIOLOGICAL|Vehicle|Vehicle, 30ml/bottle
219143861|NCT04848233|DIETARY_SUPPLEMENT|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
219143862|NCT00004124|DRUG|bicalutamide|
219143863|NCT00004124|DRUG|goserelin|
219143864|NCT00004124|DRUG|mitoxantrone hydrochloride|
219143865|NCT00004124|DRUG|prednisone|
219143866|NCT00983593|BEHAVIORAL|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
219143867|NCT05486260|DIETARY_SUPPLEMENT|DMB lowest dose|Intake of 150 mg of DMB
219143868|NCT05486260|DIETARY_SUPPLEMENT|DMB highest dose|Intake of 300 mg of DMB
219143869|NCT05486260|DIETARY_SUPPLEMENT|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
219718795|NCT06532942|DRUG|(Part B) MKND-201|Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7
219718796|NCT04134871|BEHAVIORAL|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
219718797|NCT00563173|DRUG|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
219718798|NCT03445429|OTHER|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
219718799|NCT03445429|OTHER|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
219718800|NCT00209482|DRUG|glucophage XR|
219718801|NCT05502172|DIETARY_SUPPLEMENT|fish oil|healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
219143870|NCT06241989|OTHER|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
219143871|NCT00851240|DRUG|BTT-1023|intravenous
219143872|NCT00851240|DRUG|Placebo|Intravenous
219143873|NCT00018668|DRUG|Risperidone|
219143874|NCT00018668|DRUG|Olanzapine|
219143875|NCT00018668|DRUG|Quetiapine|
219143876|NCT03825133|PROCEDURE|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
219143877|NCT03825133|PROCEDURE|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
219143878|NCT03825133|DRUG|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
219143879|NCT05859542|DEVICE|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
219143880|NCT05859542|DEVICE|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
219143881|NCT03356665|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
219143882|NCT03356665|DIAGNOSTIC_TEST|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
219143883|NCT02630719|DRUG|Timolol eye drops|eye drops
219143884|NCT02630719|DRUG|Artificial tears|Placebo drop
219143885|NCT01552980|DRUG|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
219143886|NCT02888457|OTHER|Nasopharyngeal sampling with a swab|
219143887|NCT04761146|RADIATION|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
219143888|NCT00651105|DRUG|Vildagliptin|
219143889|NCT00651105|DRUG|Placebo|
219143890|NCT03733522|PROCEDURE|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
219143891|NCT03733522|PROCEDURE|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
219230607|NCT02525822|DRUG|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
219718802|NCT01609972|DEVICE|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
219143892|NCT02640781|PROCEDURE|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
219143893|NCT02640781|PROCEDURE|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
219143894|NCT05591040|DEVICE|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
219143895|NCT05591040|OTHER|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
219718803|NCT04621084|BEHAVIORAL|Eating habits|Questionnary online
219718804|NCT03382093|BEHAVIORAL|Personalized Feedback Intervention|Personalized Feedback Intervention for smoking and anxiety.
219143896|NCT01751958|RADIATION|Epidural steroid injection|Epidural steroid injection
219143897|NCT05209230|PROCEDURE|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
219143898|NCT05209230|OTHER|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
219143899|NCT02894463|OTHER|questionnaire|
219143900|NCT02296463|BIOLOGICAL|RSV F Vaccine with adjuvant (0.5mL injection)|
219143901|NCT02296463|BIOLOGICAL|RSV F Vaccine (0.5mL injection)|
219143902|NCT02296463|BIOLOGICAL|Hepatitis A Vaccine (0.5mL injection)|
219230608|NCT02525822|DRUG|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
219230609|NCT02525822|DRUG|Vehicle Cream|Comparator Product: Vehicle Cream
219718805|NCT03382093|BEHAVIORAL|Smoking Information Control|Smoking Information with no personalized feedback.
219718806|NCT00974870|PROCEDURE|needling treatment|Needling treatment applied to half of the face at each study visit
219718807|NCT04464772|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
219718808|NCT02126332|OTHER|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
219718809|NCT02126332|OTHER|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
219718810|NCT03201107|OTHER|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
219718811|NCT01949987|OTHER|two hours|
219718812|NCT01949987|OTHER|one hour|
219143903|NCT02296463|BIOLOGICAL|Placebo (0.5mL injection)|
219230610|NCT02525822|DRUG|Vehicle Lotion|Comparator Product: Vehicle Lotion
219230611|NCT03516032|BEHAVIORAL|exercises|
219230612|NCT06439992|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
219718813|NCT06324591|OTHER|Collection biological sample and analysis|collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
219718814|NCT00662259|DRUG|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
219718815|NCT00662259|DRUG|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
219230613|NCT04290741|PROCEDURE|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
219143904|NCT01689844|BEHAVIORAL|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
219143905|NCT01689844|BEHAVIORAL|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
219143906|NCT03022123|DRUG|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
219143907|NCT01525446|RADIATION|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
219143908|NCT00807144|DRUG|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
219143909|NCT00807144|DRUG|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
219143910|NCT05520294|OTHER|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
219143911|NCT05774119|OTHER|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
219230614|NCT04290741|PROCEDURE|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
219230615|NCT03515369|DRUG|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
219718816|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
219718817|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
219143912|NCT05774119|OTHER|breakfast with water|breakfast with 250 mL of water
219143913|NCT03352596|OTHER|low frutose diet|
219143914|NCT06118827|DRUG|HS-10518|QD, orally for 7 days
219143915|NCT06118827|DRUG|Placebo|QD, orally for 7 days
219143916|NCT03567941|DRUG|Placebo|Tablet orally administered under fasting
219143917|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
219143918|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
219143919|NCT03567941|DRUG|Reference|Tablet orally administered under fasted conditions
219143920|NCT02135042|DRUG|Cisplatin|Given IV
219143921|NCT02135042|OTHER|Clinical Observation|Undergo clinical observation
219143922|NCT02135042|DRUG|Fluorouracil|Given IV
219143923|NCT02135042|DRUG|Gemcitabine Hydrochloride|Given IV
219143924|NCT02135042|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219143925|NCT02135042|OTHER|Laboratory Biomarker Analysis|Correlative studies
219143926|NCT02135042|DRUG|Paclitaxel|Given IV
219143927|NCT02135042|OTHER|Quality-of-Life Assessment|Ancillary studies
219143928|NCT01956552|OTHER|biopsy or cytopuncture|
219143929|NCT05728008|DRUG|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
219143930|NCT05728008|DRUG|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
219143931|NCT06033287|DRUG|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
219143932|NCT01134237|DRUG|urokinase|intrapleural urokinase injection
219143933|NCT01134237|DRUG|placebo|Normal saline as a placebo for control arm
219143934|NCT02568644|DIETARY_SUPPLEMENT|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
219143935|NCT02568644|OTHER|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
219143936|NCT02568644|DRUG|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
219143937|NCT00432458|DRUG|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
219143938|NCT00432458|DRUG|zoledronic acid|4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
219143939|NCT05345119|DRUG|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
219143940|NCT05345119|DRUG|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
219143941|NCT04368403|DRUG|KHK4827|210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
219718818|NCT02323438|OTHER|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
219143942|NCT00604019|DRUG|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
219552884|NCT06374654|OTHER|Formal Physical Therapy|Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
219552885|NCT00685854|DRUG|Ranibizumab|
219718819|NCT02323438|OTHER|Electronic Cigarette #1|Electronic cigarette
219718820|NCT02323438|OTHER|Electronic Cigarette #2|Electronic cigarette
219718821|NCT02323438|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
219718822|NCT01750346|DRUG|Topical acetyl hexapeptide-8|
219718823|NCT01750346|DRUG|Placebo|
219143943|NCT00604019|DRUG|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
219143944|NCT02749578|DRUG|Atorvastatin|
219143945|NCT02749578|DRUG|MGL-3196|
219143946|NCT01290224|OTHER|scrambler therapy|Undergo MC5-A therapy
219143947|NCT01290224|PROCEDURE|sham intervention|Undergo sham procedure
219143948|NCT01290224|OTHER|questionnaire administration|Ancillary studies
219143949|NCT04271410|BIOLOGICAL|CD19 CAR-T cells|CD19 CAR-T cell therapy
219143950|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
219143951|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
219143952|NCT00346333|DRUG|Lutein|12mg/d
219143953|NCT00346333|DIETARY_SUPPLEMENT|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
219143954|NCT03023280|PROCEDURE|Radiofrequency ablation|
219143955|NCT03763721|DEVICE|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
219143956|NCT05949749|DIAGNOSTIC_TEST|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
219143957|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
219143958|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
219143959|NCT02401646|DIETARY_SUPPLEMENT|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
219552886|NCT04637139|DRUG|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi \[14C\]VBR.
219552887|NCT01758406|BIOLOGICAL|Intracoronary injection|stem cell transplantation
219552888|NCT01758406|BIOLOGICAL|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
219552889|NCT00660387|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
219552890|NCT00660387|DRUG|Placebo Gel|
219552891|NCT00660387|DRUG|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
219552892|NCT00660387|DRUG|Placebo (PBO) oral capsules|
219552893|NCT00660387|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219552894|NCT00660387|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
219552895|NCT00660387|DEVICE|J-tube|jejunal tube
219552896|NCT03538925|BEHAVIORAL|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
219552897|NCT03538925|BEHAVIORAL|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
219552898|NCT03164187|DRUG|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
219552899|NCT03710707|DRUG|DNL201|Oral repeating dose
219552900|NCT03710707|DRUG|Placebo|Oral repeating dose
219552901|NCT00536588|GENETIC|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
219552902|NCT01616199|DRUG|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
219552903|NCT01616199|DRUG|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
219552904|NCT05164835|OTHER|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
219230616|NCT03515369|DRUG|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
219143960|NCT02401646|DIETARY_SUPPLEMENT|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
219143961|NCT03652207|OTHER|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
219143962|NCT03652207|OTHER|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
219143963|NCT00391547|DRUG|Frio Oral Rinse|
219143964|NCT04965987|DRUG|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
219143965|NCT04965987|DRUG|Placebo|Placebo
219143966|NCT01405924|DRUG|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
219143967|NCT01405924|DRUG|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
219143968|NCT01405924|DRUG|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
219143969|NCT01405924|DRUG|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
219143970|NCT00154791|DRUG|oxaliplatin|
219143971|NCT00154791|DRUG|gemcitabine|
219143972|NCT00154791|DRUG|5-FU/LV|
219230617|NCT01856569|OTHER|no intervention|in real life of drug,dosage,frequency and duration
219230618|NCT05077475|DRUG|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
219230619|NCT05077475|DRUG|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
219230620|NCT04841096|DRUG|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
219143973|NCT05513300|OTHER|Exercise intervention|12 weeks of exercise training, 3 times per week, \~1h long
219143974|NCT06194734|DRUG|KC1036|KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
219143975|NCT06194734|DRUG|Irinotecan|Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
219143976|NCT06194734|DRUG|Docetaxel|Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
219143977|NCT06194734|DRUG|S-1|S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
219552905|NCT06467851|DRUG|Suanzaoren Decoction and Huanglian Wenda Decoction|Twice daily. Chinese herbal medicine includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
219552906|NCT05950217|OTHER|Education|Nurse-led patient education
219230621|NCT04841096|DRUG|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
219230622|NCT04841096|DRUG|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
219552907|NCT01858350|OTHER|Active Music Therapy|
219552908|NCT01858350|OTHER|Passive Music Therapy|
219552909|NCT01858350|OTHER|Distraction Therapy|
219552910|NCT06147414|BIOLOGICAL|Blood sample|"A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing."
219552911|NCT04509050|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
219143978|NCT04709055|OTHER|Co-management|Personalized and intensive geriatric peri-operative care
219143979|NCT04709055|OTHER|Usual care|Pre-operative and post-operative geriatric care as per usual practice
219143980|NCT05314400|DIAGNOSTIC_TEST|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
219143981|NCT05314400|DIAGNOSTIC_TEST|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
219143982|NCT01028118|OTHER|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
219143983|NCT04364789|DRUG|TT-00920|Tablets
219143984|NCT04364789|DRUG|Placebos|Tablets
219143985|NCT03148990|BIOLOGICAL|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
219143986|NCT03148990|BIOLOGICAL|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
219143987|NCT01051583|PROCEDURE|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
219143988|NCT00620217|GENETIC|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
219143989|NCT03914170|DRUG|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
219143990|NCT03387319|BEHAVIORAL|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
219143991|NCT03387319|BEHAVIORAL|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
219143992|NCT02212054|BEHAVIORAL|conservative|anal dilatation; colonic lavage; oral probiotic
219143993|NCT02212054|PROCEDURE|operative|one stage pull through radical colectomy
219143994|NCT02020824|BEHAVIORAL|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
219143995|NCT02020824|OTHER|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
219143996|NCT02020824|OTHER|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
219143997|NCT02020824|OTHER|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
219143998|NCT02020824|OTHER|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
219143999|NCT04010955|DRUG|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
219144000|NCT02863900|OTHER|cohort of BC of each subtypes|
219144001|NCT03396692|PROCEDURE|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
219230623|NCT04841096|DRUG|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
219718824|NCT03248895|DEVICE|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
219718825|NCT00598403|DRUG|cefditoren pivoxil|400 mg, oral, single dose during 3 days
219230624|NCT03315338|DRUG|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
219230625|NCT03315338|DRUG|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
219718826|NCT00598403|DRUG|Ciprofloxacin|250 mg, oral, twice a day for 3 days
219718827|NCT00109369|OTHER|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
219718828|NCT02034591|DRUG|Apixaban|
219718829|NCT02034591|DIETARY_SUPPLEMENT|Boost Plus|
219718830|NCT00597675|BIOLOGICAL|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
219718831|NCT00597675|BIOLOGICAL|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
219718832|NCT04697706|DIETARY_SUPPLEMENT|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
219718833|NCT04697706|OTHER|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
219144002|NCT03396692|PROCEDURE|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
219144003|NCT03396692|PROCEDURE|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
219144004|NCT01128530|DRUG|JNJ-32729463|250 mg tablet twice daily
219144005|NCT01128530|DRUG|linezolid|600 mg tablet twice daily
219144006|NCT01128530|DRUG|JNJ-32729463 placebo|1 placebo tablet twice daily
219144007|NCT01128530|DRUG|linezolid placebo|1 placebo tablet, twice daily
219144008|NCT06389071|DEVICE|Fractional 2940 nm Laser|Fractional 2940 nm Laser
219144009|NCT01899027|DRUG|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
219144010|NCT01899027|DRUG|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
219144011|NCT01387334|BEHAVIORAL|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
219144012|NCT01140113|PROCEDURE|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
219144013|NCT04501276|DRUG|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
219144014|NCT04501276|DRUG|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
219552912|NCT05767216|OTHER|Biological sampling|Blood, skin and stool samples for laboratory analysis
219144015|NCT04501276|DRUG|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
219144016|NCT01700400|DRUG|Everolimus|
219144017|NCT01700400|DRUG|Pemetrexed|
219552913|NCT01632163|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
219144018|NCT01700400|DRUG|Carboplatin|
219144019|NCT01700400|DRUG|Bevacizumab|
219144020|NCT00079482|DRUG|CEP-701|
219144021|NCT00079482|DRUG|high-dose cytarabine|Chemotherapy
219144022|NCT00079482|DRUG|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
219144023|NCT05983068|DRUG|dupilumab|solution for injection; by subcutaneous (SC) injection
219144024|NCT05586113|DRUG|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
219230626|NCT03315338|DRUG|Glucose|75 g in 300 mL solution, orally administered
219552914|NCT01632163|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
219552915|NCT04433494|DRUG|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
219552916|NCT03191838|OTHER|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
219552917|NCT03498924|DIAGNOSTIC_TEST|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
219552918|NCT00402519|RADIATION|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
219718834|NCT00229528|DRUG|Paxil-CR|
219230627|NCT03315338|DRUG|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
219144025|NCT01305434|DIETARY_SUPPLEMENT|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
219144026|NCT01170299|DIETARY_SUPPLEMENT|dietary intervention|
219144027|NCT01170299|OTHER|laboratory biomarker analysis|
219144028|NCT01170299|PROCEDURE|gastrointestinal complications management/prevention|
219230628|NCT03315338|DRUG|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
219230629|NCT03315338|DRUG|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
219144029|NCT01170299|PROCEDURE|management of therapy complications|
219144030|NCT01170299|RADIATION|selective external radiation therapy|
219144031|NCT04645069|BIOLOGICAL|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
219144032|NCT04645069|BIOLOGICAL|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
219144033|NCT04645069|BIOLOGICAL|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
219144034|NCT03851549|DEVICE|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
219230630|NCT03315338|DRUG|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
219230631|NCT03315338|DRUG|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
219230632|NCT03315338|DRUG|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
219230633|NCT03315338|DRUG|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
219144035|NCT01611467|DRUG|CC-223|20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
219144036|NCT01611467|DRUG|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
219144037|NCT02158754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
219230634|NCT03315338|DRUG|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
219144038|NCT00770965|BIOLOGICAL|AIN457|
219230635|NCT03315338|DRUG|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
219230636|NCT03315338|DRUG|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
219230637|NCT03315338|DRUG|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
219552919|NCT00402519|RADIATION|External beam whole breast irradiation|Standard Whole breast irradiation
219552920|NCT02827396|BEHAVIORAL|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
219552921|NCT06214637|DRUG|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
219552922|NCT06214637|DRUG|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
219552923|NCT01120899|DRUG|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
219552924|NCT01989299|DEVICE|ILR implantation|
219144039|NCT00770965|BIOLOGICAL|Placebo|
219144040|NCT04208802|OTHER|Use of fluoridated toothpaste|Use of fluoridated toothpaste
219144041|NCT04208802|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
219230638|NCT03315338|DRUG|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
219230639|NCT03315338|DRUG|Placebo oral capsule|Placebo capsules, orally administered
219230640|NCT03315338|DRUG|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
219230641|NCT05611385|OTHER|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
219230642|NCT04693169|DRUG|11C-Choline|1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
219230643|NCT06122025|DEVICE|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
219230644|NCT02590094|DRUG|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
219230645|NCT00434694|PROCEDURE|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
219230646|NCT01436214|DRUG|APC-100|Daily oral, dose escalation, 28-day cycle(s)
219144042|NCT04208802|OTHER|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
219144043|NCT00487305|BIOLOGICAL|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
219144044|NCT00473811|BEHAVIORAL|Low GI|low-GI education
219144045|NCT00473811|BEHAVIORAL|ADA diet|ADA dietary education
219144046|NCT01696578|BEHAVIORAL|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
219230647|NCT03742622|BEHAVIORAL|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219144047|NCT03193619|DEVICE|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
219144048|NCT03309488|DIAGNOSTIC_TEST|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
219230648|NCT03742622|BEHAVIORAL|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
219230649|NCT03742622|BEHAVIORAL|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219230650|NCT02279732|BIOLOGICAL|Paclitaxel|
219552925|NCT06083987|BEHAVIORAL|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
219552926|NCT06083987|BEHAVIORAL|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
219552927|NCT06083987|BEHAVIORAL|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
219552928|NCT06083987|BEHAVIORAL|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
219552929|NCT06083987|BEHAVIORAL|Control Group - No Interventions|Control Group - Will be given no interventions
219552930|NCT04810533|DRUG|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
219552931|NCT00820599|DEVICE|Sapien XT™ transcatheter heart valve and delivery system|
219552932|NCT02377388|DRUG|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
219552933|NCT02377388|DRUG|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
219144049|NCT02770495|OTHER|blood sample|
219144050|NCT00559286|DRUG|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
219144051|NCT03353116|PROCEDURE|the mandible first|the mandible osteotomy is going to be done and fixed first
219144052|NCT03353116|PROCEDURE|the maxilla first|the maxilla osteotomy is going to be done and fixed first
219230651|NCT02279732|BIOLOGICAL|Carboplatin|
219230652|NCT02279732|BIOLOGICAL|Ipilimumab|
219230653|NCT02279732|OTHER|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
219144053|NCT03608618|BIOLOGICAL|MCY-M11|Intraperitoneal administration
219144054|NCT03608618|DRUG|Cyclophosphamide|Intravenous administration for preconditioning
219144055|NCT05380869|DIAGNOSTIC_TEST|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
219144056|NCT06068699|OTHER|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
219144057|NCT00318253|PROCEDURE|cranberry juice|
219230654|NCT05116098|COMBINATION_PRODUCT|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
219144058|NCT05569837|OTHER|Regular meal pattern|6 meals every day
219144059|NCT05569837|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
219144060|NCT06410963|BEHAVIORAL|Reactivate|The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
219144061|NCT03192046|DEVICE|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
219144062|NCT03192046|OTHER|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
219230655|NCT05966480|DRUG|ESK-001|Oral tablet
219144063|NCT04412018|DRUG|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
219144064|NCT03922867|BEHAVIORAL|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
219230656|NCT05966480|DRUG|Placebo|Oral tablet
219230657|NCT05167318|OTHER|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
219230658|NCT00002840|DRUG|lomustine|
219230659|NCT00002840|DRUG|procarbazine hydrochloride|
219230660|NCT00002840|DRUG|vincristine sulfate|
219230661|NCT00002840|RADIATION|radiation therapy|
219552934|NCT04374188|DRUG|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
219230662|NCT04711200|DRUG|Adipose derived stromal cells intravenously injected|2×10\^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
219230663|NCT06580275|DEVICE|CLAAS|All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
219552935|NCT04374188|DRUG|Levofloxacin|levofloxacin pill
219552936|NCT01717937|PROCEDURE|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
219552937|NCT03686215|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
219552938|NCT00387205|DRUG|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
219552939|NCT02806609|OTHER|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
219552940|NCT02806609|OTHER|immersion in water at room temperature|immersion in water at room temperature
219552941|NCT02806609|OTHER|active recovery - running|active recovery
219552942|NCT02806609|OTHER|rest in the chair|rest in the chair
219552943|NCT02653729|BEHAVIORAL|cognitive behaviour therapy|
219552944|NCT02653729|DRUG|Espidone|
219552945|NCT02653729|DRUG|Olepra|
219552946|NCT02653729|DRUG|Donu|
219552947|NCT01273857|PROCEDURE|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
219552948|NCT01273857|PROCEDURE|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
219230664|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
219230665|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
219230666|NCT00824408|DRUG|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
219552949|NCT02396290|PROCEDURE|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
219552950|NCT02396290|PROCEDURE|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
219552951|NCT06002178|DIAGNOSTIC_TEST|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
219144065|NCT00762606|PROCEDURE|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
219144066|NCT00762606|PROCEDURE|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
219144067|NCT01045655|BEHAVIORAL|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
219144068|NCT02500654|DEVICE|Emdogain®|Surgery and Emdogain®
219230667|NCT01088841|DIETARY_SUPPLEMENT|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
219230668|NCT03292692|BEHAVIORAL|OurRelationship|Online intervention with coach support
219230669|NCT02110381|DEVICE|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
219230670|NCT02110381|DEVICE|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
219230671|NCT01915888|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
219552952|NCT04125615|BEHAVIORAL|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
219144069|NCT02500654|DEVICE|Surgery alone|Surgery alone
219144070|NCT04421391|DIETARY_SUPPLEMENT|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
219144071|NCT00781196|DRUG|folic acid|capsule 0.5 mg once a day
219144072|NCT00781196|DRUG|placebo|capsule, once a day
219144073|NCT00731523|DRUG|fingolimod (FTY720)|
219144074|NCT05697081|OTHER|Medical doctors infected with COVID-19|web-based survey
219144075|NCT01335165|DRUG|ALXN1102|Single Ascending Dose IV
219230672|NCT06584734|OTHER|Not exercise|Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
219230673|NCT06584734|OTHER|Exercise during hemodiafiltration session|Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
219552953|NCT06519760|DRUG|68Ga-C1|68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
219552954|NCT00962494|BEHAVIORAL|Cancer: Thriving and Surviving Online Workshop|
219552955|NCT05416099|PROCEDURE|laser|grid vs micropulse laser
219552956|NCT06298565|BIOLOGICAL|efgartigimod|efgartigimod
219552957|NCT03244605|OTHER|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
219552958|NCT03244605|OTHER|Rehabilitation Education|General health education
219552959|NCT03244605|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
219552960|NCT03244605|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
219552961|NCT01275976|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
219552962|NCT01275976|OTHER|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
219552963|NCT03514186|BEHAVIORAL|Speech and Language Therapy|"Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication"
219552964|NCT01863186|DRUG|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
219144076|NCT01335165|DRUG|ALXN1103|Single Ascending Dose IV or SC
219144077|NCT05206266|OTHER|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
219144078|NCT05206266|OTHER|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
219144079|NCT03450096|OTHER|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
219144080|NCT03197246|DEVICE|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
219144081|NCT03197246|DEVICE|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
219144082|NCT01080872|DEVICE|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
219552965|NCT01863186|DRUG|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
219144083|NCT01418391|PROCEDURE|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose"
219144084|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
219552966|NCT01863186|DRUG|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
219552967|NCT04239495|OTHER|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
219552968|NCT00069030|BIOLOGICAL|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
219144085|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
219144086|NCT01505881|DRUG|dabigatran etexilate low dose|active treatment (low)
219144087|NCT01505881|DRUG|warfarin 5mg|comparator warfarin
219144088|NCT01505881|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
219144089|NCT01505881|DRUG|warfarin 1mg|comparator warfarin
219552969|NCT05353036|OTHER|Survey|Survey assessing incidence, frequency, and type of illicit substance use
219552970|NCT05659329|DEVICE|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
219552971|NCT01242618|BIOLOGICAL|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
219552972|NCT04768634|DIAGNOSTIC_TEST|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
219552973|NCT01813435|DRUG|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
219552974|NCT01813435|DRUG|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
219552975|NCT01813435|DRUG|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
219552976|NCT06081361|DRUG|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
219552977|NCT06081361|DRUG|Delamanid|Oral, 100mg bid
219552978|NCT06081361|DRUG|Contezolid|Oral, 800mg bid
219552979|NCT06081361|DRUG|Levofloxacin|Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg
219552980|NCT06081361|DRUG|Moxifloxacin|Oral, 400mg qd
219552981|NCT06081361|DRUG|Clofazimine|Oral, 100mg qd
219552982|NCT06081361|DRUG|Linezolid|Oral, 600mg qd
219552983|NCT06081361|DRUG|Cycloserine|Oral, 250mg bid
219552984|NCT06081361|DRUG|Prothionamide|Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg
219552985|NCT06081361|DRUG|Pyrazinamide|Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg
219552986|NCT06081361|DRUG|Para-Aminosalicylic Acid|8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg
219552987|NCT06081361|DRUG|Ethambutol|750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
219552988|NCT00399724|DRUG|Insulin glargine|
219552989|NCT05940987|BEHAVIORAL|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
219552990|NCT04394390|DIETARY_SUPPLEMENT|vitamin d|vitamin D levels
219552991|NCT04375943|DRUG|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
219552992|NCT06298877|OTHER|Frailty and Quality of Life evaluation|Frailty and Quality of Life evaluation after surgery
219552993|NCT06187701|BEHAVIORAL|Co-Active Therapeutic Theatre (Co-ATT)|There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
219552994|NCT00989053|DRUG|escitalopram|10 mg/d for a duration of 8 weeks
219552995|NCT00989053|DRUG|placebo|1 pill per day for 8 weeks
219552996|NCT00496990|BEHAVIORAL|Enhanced care|this group received counseling, contingency management and methadone or detoxification
219552997|NCT00496990|BEHAVIORAL|control|this group receives the opportunity to participate in a support group
219144090|NCT01505881|DRUG|dabigatran etexilate high dose|active treatment (high)
219144091|NCT01505881|DRUG|warfarin 3mg|comparator warfarin
219144092|NCT05056051|DEVICE|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
219144093|NCT05056051|DEVICE|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
219144094|NCT00842257|DRUG|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
219230674|NCT01189929|DRUG|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
219230675|NCT01189929|DRUG|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
219230676|NCT01189929|DRUG|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
219230677|NCT03347851|OTHER|MRI|Enrolled patients will complete a non-contrast cardiac MRI
219230678|NCT03347851|OTHER|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
219230679|NCT04114019|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
219230680|NCT04802681|DEVICE|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
219230681|NCT01943669|DEVICE|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
219230682|NCT05063006|OTHER|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
219552998|NCT00452348|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
219552999|NCT00452348|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
219553000|NCT05073523|OTHER|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
219553001|NCT06278090|DRUG|Ursodeoxycholic Acid Only Product|Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
219553002|NCT00275249|DRUG|levorphanol|
219553003|NCT02275403|PROCEDURE|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
219553004|NCT02275403|OTHER|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
219553005|NCT01490190|DRUG|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
219553006|NCT02560051|DRUG|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
219553007|NCT02560051|DRUG|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
219553008|NCT02560051|DRUG|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
219553009|NCT02560051|DRUG|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
219553010|NCT02560051|DRUG|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
219144095|NCT04956146|DRUG|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
219144096|NCT03768843|PROCEDURE|Harms technique|Atlantoaxial fusion
219144097|NCT00395018|DRUG|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
219144098|NCT01306513|BIOLOGICAL|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
219144099|NCT02245334|DRUG|Povidone-Iodine|1 pill per biopsy
219144100|NCT03795428|DRUG|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
219144101|NCT01985906|PROCEDURE|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
219144102|NCT01985906|DEVICE|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
219144103|NCT00015236|BEHAVIORAL|Amantadine|
219144104|NCT06556186|PROCEDURE|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
219144105|NCT06556186|DRUG|Bromocriptin 2.5mg, 2-3 times a day|Bromocriptin 2.5mg, 2-3 times a day
219144106|NCT05603338|PROCEDURE|LSG with omental band|LSG with omental band
219144107|NCT05603338|PROCEDURE|LSG|just to do sleeve gastrectomy
219230683|NCT05063006|OTHER|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
219144108|NCT04439799|DRUG|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
219144109|NCT04439799|DRUG|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
219144110|NCT05565391|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219144111|NCT05565391|DRUG|Standard of care|Standard of care
219144112|NCT05925686|DRUG|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
219230684|NCT01406106|DIETARY_SUPPLEMENT|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
219230685|NCT03704519|DRUG|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
219144113|NCT03175432|DRUG|Atezolizumab|Given IV
219144114|NCT03175432|BIOLOGICAL|Bevacizumab|Given IV
219144115|NCT03175432|DRUG|Cobimetinib|Given PO
219144116|NCT03175432|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219144117|NCT05339256|DRUG|Buprenorphine SL|Up to 24 mg per day
219144118|NCT05339256|OTHER|Telehealth|Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
219144119|NCT05339256|OTHER|In-person treatment as usual|in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
219144120|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
219144121|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
219144122|NCT00362206|DRUG|Pravastatin|Pravastatin 40 mg
219144123|NCT02228356|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
219144124|NCT04296227|DEVICE|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
219144125|NCT02716324|BEHAVIORAL|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
219230686|NCT03704519|DRUG|Enzalutamide|4 x 40 mg capsules, once orally
219230687|NCT03704519|OTHER|Placebo|4 placebo tablets, once orally
219230688|NCT05932303|DRUG|BMS-986278|Specified dose on specified days
219230689|NCT05932303|DRUG|Itraconazole|Specified dose on specified days
219144126|NCT02716324|OTHER|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
219144127|NCT01426750|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
219144128|NCT06373107|BEHAVIORAL|High intensity gait training|Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
219144129|NCT00888979|DRUG|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
219144130|NCT04558437|OTHER|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
219144131|NCT00662480|PROCEDURE|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
219144132|NCT01391130|DRUG|LY2510924|Administered subcutaneously
219144133|NCT01391130|DRUG|Sunitinib|Administered orally
219144134|NCT00510601|DEVICE|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
219144135|NCT05827393|PROCEDURE|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
219144136|NCT01113333|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
219144137|NCT01113333|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
219144138|NCT03961633|BEHAVIORAL|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
219144139|NCT02533635|DIETARY_SUPPLEMENT|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
219718835|NCT05074147|DRUG|Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks|"Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day"
219718836|NCT00440024|DRUG|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
219144140|NCT03215251|OTHER|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
219230690|NCT05932303|DRUG|Gemfibrozil|Specified dose on specified days
219144141|NCT03758950|DRUG|Placebo|Once daily inhaled placebo for 48 weeks
219144142|NCT03758950|DRUG|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
219230691|NCT05932303|DRUG|Carbamazepine|Specified dose on specified days
219230692|NCT03701906|DIETARY_SUPPLEMENT|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
219230693|NCT03701906|DIETARY_SUPPLEMENT|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
219230694|NCT06145191|DRUG|Tranexamic acid|Prophylactic topical application (1x) of tranexamic acid (100mg, 2ml, room temperature) before sampling
219718837|NCT00440024|DRUG|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
219230695|NCT06145191|DRUG|Adrenaline|Prophylactic topical application (1x) of adrenaline (1:10.000, 2ml, room temperature) before sampling
219718838|NCT00440024|DRUG|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
219718839|NCT04298385|OTHER|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
219144143|NCT00549536|DIETARY_SUPPLEMENT|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
219144144|NCT06391619|OTHER|No intervention|Study is observational
219144145|NCT00653276|DRUG|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
219144146|NCT00653276|DRUG|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
219144147|NCT03491696|DRUG|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
219144148|NCT01771588|DIETARY_SUPPLEMENT|Human milk fortifier|
219144149|NCT03068858|DIAGNOSTIC_TEST|real-time feedback of SYNTAX score category|
219144150|NCT05692947|DEVICE|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
219144151|NCT05127551|DEVICE|iStent Infinite|Implantation of the iStent Infinite
219144152|NCT05127551|DEVICE|Competitor Device|Implantation of competitor device
219718840|NCT02375503|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
219718841|NCT02375503|DIETARY_SUPPLEMENT|Placebo|
219144153|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions)|
219144154|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
219144155|NCT02612818|DEVICE|Coelioscopy|
219144156|NCT05800639|PROCEDURE|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
219144157|NCT05800639|PROCEDURE|General anesthesia|General anesthesia will be performed as standard practice of our institution.
219144158|NCT04484415|COMBINATION_PRODUCT|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
219144159|NCT04484415|COMBINATION_PRODUCT|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
219144160|NCT04642794|OTHER|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
219144161|NCT00420654|DRUG|Growth Hormone|1.25 mg, 6 months
219144162|NCT00420654|DRUG|Placebo|Equivalent to 1.25 mg, 6 months
219144163|NCT00420654|OTHER|Healthy controls|Healthy controls
219144164|NCT02602743|DRUG|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
219144165|NCT02602743|DRUG|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
219144166|NCT02602743|DRUG|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
219144167|NCT04788433|DIAGNOSTIC_TEST|glycomic analysis|Analysis of glycans on plasma samples
219144168|NCT04788433|OTHER|Phone interview|patients are followed up by phone up to 1 year
219144169|NCT03280836|BEHAVIORAL|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
219144170|NCT04176367|DRUG|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
219144171|NCT04176367|DRUG|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
219230696|NCT06145191|DRUG|Placebo|Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
219718842|NCT03847077|BEHAVIORAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
219718843|NCT03847077|BEHAVIORAL|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
219718844|NCT02254824|DRUG|Xuezhikang|Xuezhikang
219718845|NCT02254824|DRUG|Atorvastatin|Atorvastatin
219144172|NCT01891968|DRUG|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
219144173|NCT03778099|DRUG|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
219144174|NCT03778099|DRUG|Placebo|450 mg of starch and 50 mg of cinnamon powder
219144175|NCT04233931|BEHAVIORAL|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
219144176|NCT03731936|OTHER|No intervention|No intervention
219718846|NCT02254824|BEHAVIORAL|Lifestyle modification|Lifestyle modification
219718847|NCT01175720|PROCEDURE|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
219718848|NCT05619419|BEHAVIORAL|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
219718849|NCT05619419|BEHAVIORAL|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
219718850|NCT03942731|OTHER|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
219718851|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
219230697|NCT01141257|DRUG|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
219144177|NCT00880048|DRUG|orvepitant|neurokinin-1 antagonist
219144178|NCT00880048|OTHER|Placebo|Placebo to match orvepitant 30 mg and 60 mg
219144179|NCT04141917|COMBINATION_PRODUCT|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
219144180|NCT04021615|OTHER|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
219230698|NCT02915783|DRUG|lenvatinib|4 mg and 10 mg capsules
219230699|NCT02915783|DRUG|everolimus|5 mg tablets
219144181|NCT04021615|OTHER|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
219144182|NCT00964197|DEVICE|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
219144183|NCT03444506|DRUG|Molo 1 (also referred as GSP 301-2 NS)|
219144184|NCT03444506|DRUG|Molo 2 (also referred as GSP 301-1 NS)|
219144185|NCT03444506|DRUG|Placebo nasal spray|
219144186|NCT03444506|DRUG|DYMISTA nasal spray|
219144187|NCT03444506|DRUG|PATANASE nasal spray|
219144188|NCT04554628|DIAGNOSTIC_TEST|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
219144189|NCT03354039|DRUG|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
219144190|NCT03354039|DRUG|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
219144191|NCT01184508|DRUG|Placebo|Administered orally, once daily, for 12 weeks
219144192|NCT01184508|DRUG|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
219144193|NCT02887768|DEVICE|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
219144194|NCT02887768|PROCEDURE|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
219144195|NCT01414842|DEVICE|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
219230700|NCT06360224|DEVICE|MiraQ systems with Transit Time Flow Measurement (TTFM) and High Frequency Ultrasound (HFUS) probes|The objective of this study is to harvest a wide dataset of high quality to allow exploratory analysis and training of machine learning
219144196|NCT01414842|DEVICE|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
219144197|NCT02032329|DEVICE|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
219144198|NCT05790616|PROCEDURE|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
219144199|NCT05790616|OTHER|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
219144200|NCT04014933|DIAGNOSTIC_TEST|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
219144201|NCT05685095|BEHAVIORAL|Physical training|Supervised gait training program 3 times a week, 12 weeks
219144202|NCT02861937|PROCEDURE|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
219144203|NCT00002810|BIOLOGICAL|filgrastim|
219144204|NCT00002810|DRUG|melphalan|
219144205|NCT00002810|PROCEDURE|bone marrow ablation with stem cell support|
219144206|NCT00002810|PROCEDURE|peripheral blood stem cell transplantation|
219144207|NCT05131386|DRUG|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
219144208|NCT03684265|DRUG|Meloxicam Capsule (Test)|single dose
219144209|NCT03684265|DRUG|Meloxicam Tablet (Reference)|single dose
219144210|NCT02724085|DRUG|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
219144211|NCT05723510|DRUG|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
219144212|NCT05723510|DRUG|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
219144213|NCT05723510|DRUG|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
219144214|NCT05723510|DRUG|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
219144215|NCT02009839|BEHAVIORAL|Meeky Mouse program|
219144216|NCT02009839|OTHER|Computer Games|
219144217|NCT05692908|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
219144218|NCT03870607|DIETARY_SUPPLEMENT|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
219144219|NCT02570295|OTHER|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
219144220|NCT00790790|DRUG|Placebo|LY545694 placebo BID po for 5 weeks
219144221|NCT00790790|DRUG|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
219144222|NCT00790790|DRUG|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
219144223|NCT03441204|DRUG|LTOT 24 h/day|LTOT prescribed for 24 h/day.
219230701|NCT04958837|OTHER|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
219230702|NCT04958837|OTHER|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
219230703|NCT05058157|DIETARY_SUPPLEMENT|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
219230704|NCT00454922|BEHAVIORAL|standard of care|no intervention
219718852|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
219718853|NCT00679198|BEHAVIORAL|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
219718854|NCT05834153|DEVICE|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
219718855|NCT05834153|DEVICE|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
219718856|NCT04964232|DEVICE|Infrared Camera|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
219718857|NCT04964232|DEVICE|Esophageal Temperature Probe|In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.
219718858|NCT04964232|DEVICE|Skin temperature probe|In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
219718859|NCT00416949|DEVICE|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
219144224|NCT03441204|DRUG|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
219718860|NCT02782468|DRUG|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m\^2 intravenous infusion.
219718861|NCT02782468|DRUG|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m\^2 intravenous infusion.
219718862|NCT02782468|DRUG|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m\^2 intravenous infusion.
219718863|NCT02782468|DRUG|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m\^2 intravenous infusion.
219718864|NCT02782468|DRUG|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
219718865|NCT01722799|DEVICE|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
219718866|NCT01722799|DEVICE|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
219718867|NCT06091384|OTHER|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
219718868|NCT04114370|DRUG|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
219718869|NCT03342859|DRUG|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
219718870|NCT03342859|DRUG|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
219718871|NCT00074191|DRUG|cytarabine|
219144225|NCT02566707|DRUG|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
219144226|NCT02566707|DRUG|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
219144227|NCT02566707|DRUG|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
219144228|NCT01112644|DRUG|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
219144229|NCT01112644|OTHER|Placebo (PLA)|Different daily doses; intake every 12 hours
219718872|NCT00074191|DRUG|dexamethasone|
219718873|NCT00074191|DRUG|lomustine|
219718874|NCT00074191|DRUG|methotrexate|
219144230|NCT01356758|DRUG|biological treatment|patients treated with anti-psoriatic biological agents
219144231|NCT06282744|OTHER|Outpatient physical therapy improvement in movement assessment log|The Outpatient Physical Therapy Improvement in Movement Assessment Log (OPTIMAL) is an instrument that measures difficulty and self-confidence in performing 22 movements that a patient needs to accomplish in order to do various functional activities.
219144232|NCT06469684|BEHAVIORAL|Health education session|1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
219144233|NCT03141333|BEHAVIORAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
219144234|NCT01895218|DRUG|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
219144235|NCT01895218|OTHER|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
219230705|NCT00454922|OTHER|education|meet with trained glaucoma educator 6 times over life of study
219230706|NCT03450811|PROCEDURE|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
219718875|NCT00074191|DRUG|procarbazine hydrochloride|
219718876|NCT00607594|DRUG|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
219718877|NCT02591303|OTHER|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
219718878|NCT04003571|BEHAVIORAL|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
219718879|NCT04003571|BEHAVIORAL|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
219718880|NCT01410604|DRUG|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
219718881|NCT01410604|DRUG|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
219718882|NCT04784975|OTHER|No intervention|No intervention
219718883|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
219718884|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
219718885|NCT04856566|DRUG|Placebo|Placebo drug with no THC
219718886|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
219718887|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
219718888|NCT05753475|OTHER|renal transplantation|patients undergoing renal transplantation
219718889|NCT05189002|DRUG|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
219718890|NCT05189002|DRUG|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
219718891|NCT05189002|DRUG|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
219718892|NCT00356590|BIOLOGICAL|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
219718893|NCT00744835|PROCEDURE|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
219718894|NCT02979288|DRUG|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
219718895|NCT02979288|OTHER|NO Intervention|NO Intervention
219718896|NCT05678114|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol (4g/die)
219718897|NCT05505890|OTHER|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
219718898|NCT06283030|DEVICE|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
219718899|NCT01149785|DRUG|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
219718900|NCT01149785|DRUG|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
219718901|NCT01149785|DRUG|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
219718902|NCT01201863|DRUG|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
219718903|NCT01201863|OTHER|Placebo gel|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
219718904|NCT01264471|PROCEDURE|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
219718905|NCT01264471|PROCEDURE|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
219718906|NCT02199574|DRUG|EXPAREL|133 mg EXPAREL in 10 mL.
219718907|NCT02124226|DRUG|Methotrexate|7.5 mg/week + folic acid the day after
219718908|NCT02124226|DRUG|Placebo|matched placebo
219718909|NCT03605056|DRUG|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
219718910|NCT03605056|DRUG|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
219718911|NCT03605056|DRUG|dexamethasone|40mg weekly, will be administered orally or intravenously
219718912|NCT00448357|BIOLOGICAL|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
219718913|NCT00448357|BIOLOGICAL|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
219718914|NCT00448357|DRUG|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
219718915|NCT00448357|DRUG|fludarabine phosphate|30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
219718916|NCT00448357|DRUG|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
219718917|NCT00448357|PROCEDURE|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
219718918|NCT00448357|PROCEDURE|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
219718919|NCT00448357|DRUG|methotrexate|5 mg/m\^2 on days +1, +3 and +6
219718920|NCT00828256|PROCEDURE|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
219718921|NCT04221971|DRUG|chemotherapy combined with NK cells infusion|chemotherapy combined with NK cells infusion
219718922|NCT02714738|PROCEDURE|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
219718923|NCT03470766|DEVICE|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
219718924|NCT01491516|DEVICE|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
219718925|NCT01464762|DRUG|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
219718926|NCT04215770|DRUG|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
219718927|NCT02413762|OTHER|No intervention|No intervention
219718928|NCT02500355|PROCEDURE|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
219718929|NCT02500355|PROCEDURE|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
219718930|NCT02500355|PROCEDURE|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
219718931|NCT02500355|DEVICE|endoscope or an arthroscopic device|
219718932|NCT00898807|DRUG|citalopram|target dose 30mg daily for 9 weeks
219718933|NCT00898807|DRUG|placebo|daily for 9 weeks
219718934|NCT03469973|PROCEDURE|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
219144236|NCT01183871|PROCEDURE|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
219144237|NCT02940704|PROCEDURE|Reciproc|"* Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used."
219144238|NCT02940704|PROCEDURE|One Shape|"* Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
219144239|NCT05496907|BEHAVIORAL|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
219144240|NCT06081686|DRUG|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
219144241|NCT06081686|DRUG|Phase II:[177Lu]Lu-XT033 Injection|Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
219144242|NCT03385824|BEHAVIORAL|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
219144243|NCT02570711|DRUG|ACP-196|ACP-196 capsule
219144244|NCT02570711|DRUG|Nab-paclitaxel|Nab-paclitaxel infusion
219144245|NCT02570711|DRUG|Gemcitabine|Gemcitabine infusion
219144246|NCT02905812|OTHER|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
219144247|NCT03646435|DEVICE|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
219144248|NCT03916835|DEVICE|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
219230707|NCT03869970|BEHAVIORAL|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
219718935|NCT04804488|PROCEDURE|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
219718936|NCT02885675|OTHER|blood sampling|sample no more than 3ml
219144249|NCT04178226|OTHER|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
219144250|NCT04178226|DEVICE|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
219144251|NCT02798835|DRUG|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
219230708|NCT03869970|BEHAVIORAL|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
219718937|NCT02103842|DRUG|Omega-3 fatty acids|
219718938|NCT00942643|DEVICE|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
219718939|NCT00105378|BEHAVIORAL|Dutch EASYcare Study Geriatric Intermediate Care Programme|
219718940|NCT00005769|DRUG|Hormone Replacement Therapy|
219718941|NCT04428489|OTHER|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
219718942|NCT05323851|BEHAVIORAL|COVID-surg-SPIGC questionnaire|The questionnaire aimed to evaluate how the COVID-19 pandemic determined a shift in daily practice through a multidimensional assessment of surgical clinical care in three different time frames.
219144252|NCT02798835|DRUG|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
219144253|NCT02798835|DRUG|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
219144254|NCT02798835|DRUG|Bupivacaine|Used in spinal anesthetic
219144255|NCT02798835|DRUG|Fentanyl|May or may not be used in spinal anesthetic
219144256|NCT02798835|DRUG|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
219144257|NCT02798835|DRUG|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
219144258|NCT01315314|DRUG|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
219144259|NCT00168922|DRUG|Bendamustin/Ribomustin|
219144260|NCT00128596|DRUG|arsenic trioxide|
219144261|NCT01291563|DRUG|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
219144262|NCT01291563|DRUG|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
219144263|NCT01291563|DRUG|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
219144264|NCT01291563|DRUG|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
219144265|NCT00841035|DRUG|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
219144266|NCT02315469|OTHER|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
219144267|NCT02315469|OTHER|Questionnaire Administration|Ancillary studies
219230709|NCT03869970|BEHAVIORAL|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
219230710|NCT00703391|DRUG|AZD9668|30mg oral tablets twice daily (bid) for 14 days
219230711|NCT00703391|DRUG|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
219144268|NCT06047522|DEVICE|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
219144269|NCT06164327|DRUG|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
219144270|NCT06164327|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
219144271|NCT06164327|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
219144272|NCT06164327|DRUG|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
219144273|NCT06164327|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
219144274|NCT06164327|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
219230712|NCT02994004|OTHER|no intervention|
219230713|NCT01583959|DRUG|Folic Acid|Folic acid tablets 5 mg
219230714|NCT01583959|DRUG|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
219230715|NCT03700034|OTHER|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
219718943|NCT01098695|OTHER|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
219144275|NCT06164327|DRUG|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
219144276|NCT04364594|DIAGNOSTIC_TEST|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
219144277|NCT00501618|DRUG|Fazaclo|single-arm
219144278|NCT05824546|PROCEDURE|Intervention Arm (uSINE-PAMS-technique)|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
219144279|NCT01270633|DEVICE|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
219144280|NCT01270633|OTHER|Standard of Care|Following sharp debridement, moist wound therapy
219144281|NCT04704739|DRUG|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
219144282|NCT04704739|DRUG|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of \[14C\]-GLPG1205
219230716|NCT01075152|DRUG|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
219144283|NCT04704739|DRUG|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
219230717|NCT01075152|BIOLOGICAL|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
219230718|NCT04263740|PROCEDURE|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
219230719|NCT04263740|PROCEDURE|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
219230720|NCT05696405|PROCEDURE|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
219230721|NCT03846037|OTHER|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
219144284|NCT03829813|OTHER|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
219718944|NCT05523739|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
219718945|NCT00002940|DRUG|hydroxyurea|
219230722|NCT03846037|OTHER|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
219230723|NCT03080350|DRUG|Fentanyl sublingual|Fentanyl sublingual
219230724|NCT03080350|DRUG|Fentanyl ev|Fentanyl ev
219230725|NCT03080350|DRUG|Placebo sublingual|Placebo sublingual
219230726|NCT03080350|DRUG|Placebo ev|Placebo - NaCL 0,9% ev
219230727|NCT00035048|DRUG|aprepitant|
219718946|NCT04822909|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
219144285|NCT03749044|OTHER|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
219230728|NCT00035048|DRUG|Comparator: placebo (unspecified)|
219718947|NCT02115386|DRUG|Nilotinib|supplied in 150 mg capsules to be taken orally
219718948|NCT00530166|DRUG|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
219718949|NCT00530166|DRUG|sham comparator|3(100 mg) tablets once daily for 12 weeks
219718950|NCT05496010|OTHER|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
219718951|NCT02493855|DRUG|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
219230729|NCT02339519|DEVICE|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
219230730|NCT02339519|DEVICE|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
219230731|NCT02339519|DEVICE|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
219718952|NCT02493855|DRUG|Dasabuvir|Dasabuvir tablets
219718953|NCT02493855|DRUG|Ribavirin (RBV)|Ribavirin tablets
219718954|NCT00620919|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
219718955|NCT05104346|PROCEDURE|appendectomy|open or laparoscopic appendectomy
219718956|NCT01484002|DEVICE|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
219718957|NCT02453048|BIOLOGICAL|BPZE1|Intranasal live, attenuated vaccine
219144286|NCT05656846|DEVICE|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
219144287|NCT05656846|DEVICE|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
219144288|NCT01852526|DEVICE|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
219144289|NCT01852526|DEVICE|Active Comparator: Plif|monosegmental PLIF
219144290|NCT05834946|OTHER|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
219144291|NCT05834946|OTHER|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
219144292|NCT00094575|PROCEDURE|Endovascular Repair|Endovascular Repair
219144293|NCT00094575|PROCEDURE|Standard Open Repair|Standard Open Repair
219144294|NCT06460688|OTHER|Mother Rehabilitative Aid Education Program|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
219144295|NCT06460688|OTHER|Neuro physical Therapy|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
219144296|NCT03199781|DEVICE|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
219144297|NCT03105505|DRUG|Permethrin 5%|Facial skin application once a night for 3 months.
219144298|NCT03105505|DRUG|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
219230732|NCT06604481|BEHAVIORAL|eCoaching for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. This program is designed to operate individually on an e-platform. It consists of 6 weekly sessions, each lasting for less than 90 minutes. The content of the sessions focuses on teaching caregivers CBT techniques, lifestyle modifications to improve caregiving experiences, and effective communication strategies. In between each session, participants are assigned home practices to reinforce the skills learned further. All content will be included.
219718958|NCT02453048|OTHER|Placebo|Diluent
219553011|NCT04152356|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
219144299|NCT03105505|DRUG|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
219144300|NCT04970342|DRUG|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
219144301|NCT04970342|DRUG|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
219144302|NCT04970342|DRUG|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
219144303|NCT04970342|DRUG|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
219144304|NCT00188136|DRUG|Melphalan, ATG, Fludarabine|allo Tx during aplasia
219718959|NCT00656526|DRUG|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
219718960|NCT00656526|DRUG|Lidocaine|0.5 cc %2 lidocaine,single injection
219144305|NCT05625334|DRUG|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
219553012|NCT04152356|DRUG|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
219553013|NCT03469960|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
219553014|NCT03469960|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
219553015|NCT02545530|DRUG|transdermal clonidine|2.5mg/patch per week
219553016|NCT04345822|PROCEDURE|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
219718961|NCT06193629|DRUG|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
219144306|NCT05625334|DRUG|non-enteric-coated chewable aspirin|Orally administered
219718962|NCT06193629|DRUG|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
219718963|NCT03268863|DEVICE|Virtual Reality|Google Cardboard virtual reality headset
219718964|NCT03268863|OTHER|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
219718965|NCT02136589|DRUG|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
219144307|NCT04077632|DEVICE|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
219144308|NCT03958734|OTHER|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
219144309|NCT01625013|DEVICE|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
219144310|NCT01398124|BIOLOGICAL|Cyclin B1 Peptide|vaccine
219144311|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
219144312|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
219144313|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
219144314|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
219144315|NCT03830736|COMBINATION_PRODUCT|Control product|Glucose based beverage without added test components is used as control product
219144316|NCT02869022|DRUG|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
219144317|NCT02869022|DRUG|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
219144318|NCT02869022|PROCEDURE|organ perfusion for heart transplantation|
219144319|NCT05035004|DEVICE|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
219144320|NCT05035004|DEVICE|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
219144321|NCT05035004|DEVICE|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
219144322|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
219144323|NCT04189744|DRUG|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
219144324|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
219144325|NCT05516927|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
219144326|NCT05220215|OTHER|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
219144327|NCT05220215|OTHER|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
219144328|NCT03809299|OTHER|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
219144329|NCT03809299|OTHER|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
219144330|NCT00922675|PROCEDURE|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
219553017|NCT04467619|DEVICE|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
219553018|NCT04883164|OTHER|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
219144331|NCT00922675|PROCEDURE|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
219144332|NCT03855709|DIAGNOSTIC_TEST|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
219144333|NCT04133974|BEHAVIORAL|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
219144334|NCT06208696|OTHER|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
219144335|NCT01632930|OTHER|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
219144336|NCT06141577|DRUG|UI059|take UI059 1cap/day for 7 days
219144337|NCT06141577|DRUG|UIC202201|take UIC202201 1cap/day for 7 days
219144338|NCT05161507|PROCEDURE|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
219144339|NCT05161507|PROCEDURE|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
219144340|NCT05161507|PROCEDURE|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
219144341|NCT03985150|OTHER|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
219230733|NCT06604481|BEHAVIORAL|eCoaching (need specific) for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills as in eCoaching I. However, eCoaching II will include content specified to carer's specific need.
219230734|NCT06604481|BEHAVIORAL|Control Intervention for Caregivers of Older Adults|The control group attends 6 weekly online sessions that primarily provide educational information about lifestyle factors and communication. These sessions aim to enhance the control group's knowledge and understanding of the factors that impact caregiving. Each session in the control group also lasts for 90 minutes. The focus of these activities will be on building practical caregiving skills and promoting overall well-being, rather than targeting any particular psychological or mental health-related factors directly.
219230735|NCT04557176|DEVICE|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
219230736|NCT07006493|DEVICE|Transcatheter Intramyocardial Septal Radiofrequency Ablation System|The device system includes a single-use RF ablation catheter, sheath, RF generator, and irrigation pump. Ablation is guided by intracardiac echocardiography (ICE).
219230737|NCT07013994|PROCEDURE|peripheral venous cannulation with ultrasound-guided technique|Peripheral venous cannulation with short peripheral vascular access device, performed by ultrasound technique.
219230738|NCT07013994|PROCEDURE|Arterial gas puncture using ultrasound-guided technique|Arterial puncture using a needle and heparinised syringe to extract a sample for arterial blood gas analysis, using the ultrasound-guided technique.
219553019|NCT02752854|OTHER|pain threshold measurement|pressure algometer
219553020|NCT04459754|DRUG|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
219553021|NCT00250354|DRUG|Risperidone oral solution|
219553022|NCT05174754|BEHAVIORAL|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
219553023|NCT05174754|DRUG|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
219553024|NCT02532192|DRUG|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
219553025|NCT02532192|DRUG|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
219553026|NCT02532192|DRUG|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
219553027|NCT02532192|DRUG|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
219553028|NCT02532192|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
219553029|NCT02532192|DRUG|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
219718966|NCT03512886|OTHER|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
219718967|NCT03512886|OTHER|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
219718968|NCT04600037|DRUG|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
219718969|NCT01482221|DRUG|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
219718970|NCT01482221|DRUG|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
219718971|NCT01482221|DRUG|Placebo|0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
219718972|NCT01574404|PROCEDURE|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
219718973|NCT06373510|BIOLOGICAL|Blood collection|Collection of blood before and after a non mandatory vaccination
219718974|NCT00589368|BEHAVIORAL|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
219144342|NCT03985150|RADIATION|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
219144343|NCT01927952|PROCEDURE|Kirschner wire|Surgical fixation utiliziing Kirschner wire
219144344|NCT01927952|PROCEDURE|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
219144345|NCT01927952|PROCEDURE|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
219144346|NCT05356819|DEVICE|Smart Capnography™, Microstream®|patients monitored by capnograph
219144347|NCT00762619|DRUG|Fluoride|Brush twice daily
219144348|NCT00762619|DRUG|Triclosan, fluoride|Brush twice daily
219144349|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
219144350|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
219144351|NCT00961636|DRUG|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
219144352|NCT00961636|DRUG|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
219144353|NCT00890786|DRUG|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
219144354|NCT00890786|DRUG|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
219144355|NCT00890786|DRUG|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
219144356|NCT03854006|PROCEDURE|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
219144357|NCT04297982|OTHER|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
219144358|NCT04297982|OTHER|Routine nursing care|Interventions routinely implemented by nurses in the clinic
219144359|NCT05073718|DRUG|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
219144360|NCT05073718|DRUG|Placebo|Placebo
219144361|NCT04891887|BEHAVIORAL|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
219144362|NCT02310295|DEVICE|Laser|focal macular laser therapy
219144363|NCT02310295|DRUG|Bevacizumab|Intravitreal injection of Bevacizumab
219144364|NCT02310295|DRUG|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
219144365|NCT01138215|BIOLOGICAL|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
219144366|NCT02341924|OTHER|Portfolio of functional foods|
219144367|NCT02341924|OTHER|Control foods|
219144368|NCT04158999|DEVICE|milk analyzer|Human Milk Sample
219144369|NCT04158999|BEHAVIORAL|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
219144370|NCT01705249|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
219144371|NCT00227032|DRUG|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
219144372|NCT00202748|BEHAVIORAL|Increase in activity to control weight|
219144373|NCT00202748|BEHAVIORAL|Increase in activity to control weight.|
219144374|NCT01370707|DRUG|Metformin|1000\~1500mg/day, 24weeks
219144375|NCT01370707|DRUG|CJ-30001/CJ-30002|0.6/1500mg\~0.9/1500mg/day, 24weeks
219144376|NCT02813252|GENETIC|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219144377|NCT06027372|DEVICE|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
219144378|NCT05032937|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
219230739|NCT07013994|PROCEDURE|Peripheral venous cannulation with traditional technique|Cannulation of a short peripheral vascular access device using the traditional visualisation and palpation technique.
219230740|NCT07013994|PROCEDURE|Arterial puncture by traditional technique|Arterial puncture using a needle and heparinised syringe to extract an arterial blood sample for arterial gamosetry analysis, performed using the traditional arterial pulse palpation technique.
219553030|NCT02532192|DRUG|Fluconazole|100 mg by mouth daily for 10 days.
219553031|NCT00307541|BIOLOGICAL|Pneumococcal (vaccine)|
219553032|NCT04632641|DEVICE|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
219553033|NCT04632641|OTHER|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
219553034|NCT02559843|DIETARY_SUPPLEMENT|pomegranate juice|
219144379|NCT01964469|BEHAVIORAL|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
219144380|NCT00622830|DRUG|SB-480848 (Darapladib)|
219144381|NCT05593042|BIOLOGICAL|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
219144382|NCT05593042|BIOLOGICAL|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
219144383|NCT05593042|BIOLOGICAL|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
219144384|NCT00862680|PROCEDURE|4-Dimensional Computed Tomography|Undergo 4D PET/CT
219144385|NCT00862680|PROCEDURE|4D PET Scan|Undergo 4D PET/CT scan
219144386|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
219144387|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
219144388|NCT05647967|DIAGNOSTIC_TEST|Ultrasound|Each patient underwent ultrasound after admission of ICU.
219144389|NCT03598972|OTHER|intervention|elementary analysis
219144390|NCT01390402|DRUG|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
219144391|NCT01390402|DRUG|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
219144392|NCT01390402|PROCEDURE|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
219144393|NCT01390402|DRUG|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
219230741|NCT06683209|DIAGNOSTIC_TEST|Schocket scleral depressor|Use of this instrument to examine one eye
219230742|NCT06683209|DIAGNOSTIC_TEST|Josephberg-Besser|Use of this instrument to examine one eye
219553035|NCT02559843|BEHAVIORAL|lifestyle modification|
219553036|NCT04068818|DEVICE|ANTERION|Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
219553037|NCT04438044|DRUG|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
219553038|NCT06200376|DRUG|T3011|T3011 will be administered intraperitoneally twice a week.
219144394|NCT01390402|DRUG|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
219144395|NCT01390402|PROCEDURE|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
219144396|NCT01390402|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
219144397|NCT01390402|DRUG|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
219144398|NCT01390402|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
219144399|NCT00332436|DRUG|brimonidine/timolol fixed combination|
219144400|NCT04954040|DRUG|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
219144401|NCT04954040|DRUG|SOC|Acetaminophen or Metamizole. Antitussives if needed.
219144402|NCT00329732|DRUG|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
219144403|NCT00329732|DRUG|Saline placebo|matching volume of saline (placebo)
219144404|NCT05658198|BEHAVIORAL|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
219144405|NCT04812938|DIAGNOSTIC_TEST|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
219144406|NCT00664911|OTHER|chemotherapy|
219144407|NCT06073158|PROCEDURE|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
219144408|NCT02864628|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
219144409|NCT02864628|OTHER|Placebo|Tris Buffered Saline
219144410|NCT00411099|DRUG|agomelatine|
219718975|NCT03646578|OTHER|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
219144411|NCT00411099|DRUG|placebo|
219718976|NCT05827744|OTHER|Isokinetic evaluations|Peak torque and total amount of work of hip flexors and extensors will be determined by the Cybex 6000 model computer-aided isokinetic system.
219144412|NCT01125306|DEVICE|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
219144413|NCT00466414|DEVICE|Polycaprolactone Scaffold|
219144414|NCT01038349|OTHER|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
219144415|NCT01884636|DRUG|isavuconazole|oral
219144416|NCT01884636|DRUG|methotrexate|oral
219144417|NCT01948804|DRUG|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
219144418|NCT01948804|DRUG|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
219144419|NCT01948804|DRUG|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
219144420|NCT01948804|DRUG|GnRH antagonist protocol (Cetrotide, Serono)|
219144421|NCT00127179|DRUG|MK0906, finasteride / Duration of Treatment: 48 weeks|
219144422|NCT00127179|DRUG|Comparator: placebo / Duration of Treatment: 48 weeks|
219144423|NCT00000635|DRUG|Trifluridine|
219144424|NCT00000635|DRUG|Bacitracin zinc/Polymyxin B sulfate|
219144425|NCT00220350|DRUG|leuprolide acetate|
219144426|NCT05393336|OTHER|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
219230743|NCT06683209|DIAGNOSTIC_TEST|Cotton tip applicator|Use of this instrument to examine one eye
219553039|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing native palm olein|
219144427|NCT05393336|OTHER|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
219144428|NCT02551055|DRUG|MLN1117|MLN1117 Tablets
219144429|NCT02551055|DRUG|TAK-659|TAK-659 Tablets
219144430|NCT02551055|DRUG|Alisertib|Alisertib Tablets
219144431|NCT02551055|DRUG|Paclitaxel|Paclitaxel intravenous infusion
219144432|NCT02551055|DRUG|Docetaxel|Docetaxel intravenous infusion
219144433|NCT05861388|PROCEDURE|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
219144434|NCT05213715|OTHER|assessment|assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
219144435|NCT02023125|DRUG|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
219144436|NCT02023125|DRUG|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
219144437|NCT02023125|OTHER|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
219144438|NCT02023125|OTHER|Standard Meal|Standard meal served prior to alectinib administration
219144439|NCT05826704|DIETARY_SUPPLEMENT|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
219553040|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing interesterified palm olein|
219553041|NCT05280080|OTHER|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
219144440|NCT02969954|OTHER|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
219144441|NCT00430300|DRUG|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
219144442|NCT00430300|DRUG|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
219144443|NCT01597752|BIOLOGICAL|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
219144444|NCT02044588|BIOLOGICAL|HBsAg positive kidney allograft donor|
219144445|NCT03463135|DRUG|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
219144446|NCT03463135|DRUG|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
219144447|NCT03463135|DRUG|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
219144448|NCT03463135|DRUG|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
219144449|NCT02754479|DEVICE|Nd:YAG laser|Treatment of lower extremity spider veins
219144450|NCT00402155|BEHAVIORAL|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
219144451|NCT03911479|PROCEDURE|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
219144452|NCT04408937|DRUG|triopifexor|Tropifexor as a dry blend in hard gelatin capsules for oral administration
219144453|NCT04408937|DRUG|Placebo|Placebo capsules for oral administration
219144454|NCT03012230|OTHER|Laboratory Biomarker Analysis|Correlative studies
219144455|NCT03012230|BIOLOGICAL|Pembrolizumab|Given IV
219144456|NCT03012230|DRUG|Ruxolitinib Phosphate|Given PO
219144457|NCT02666742|DRUG|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
219144458|NCT02666742|DRUG|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
219144459|NCT01535144|DEVICE|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
219144460|NCT01535144|DEVICE|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
219144461|NCT05559346|OTHER|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
219144462|NCT05559346|OTHER|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
219144463|NCT00002972|DRUG|paclitaxel|
219144464|NCT04128423|BIOLOGICAL|AMV564|AMV564 will be administered daily
219144465|NCT04028336|OTHER|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
219144466|NCT04656886|DRUG|Intravenous Infusion|
219144467|NCT01277796|DEVICE|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
219144468|NCT03026036|RADIATION|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
219144469|NCT02205307|DEVICE|PINPOINT|
219144470|NCT02205307|DEVICE|SPY Elite|
219144471|NCT05338996|BEHAVIORAL|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
219144472|NCT04878081|BEHAVIORAL|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
219144473|NCT02041104|DIETARY_SUPPLEMENT|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
219144474|NCT02041104|DIETARY_SUPPLEMENT|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
219144475|NCT04013646|DRUG|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
219144476|NCT04013646|DRUG|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
219144477|NCT04013646|DRUG|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
219718977|NCT05827744|OTHER|Ultrasonographic evaluations|Ultrasonographic evaluations will be performed with a 5-12 MHz linear probe (Logic e portable; GE Healthcare, China). The thicknesses of the hip flexor (psoas major) and extensor (gluteus maximus) muscles will be measured while the patient is in the prone position, in accordance with the literature.
219718978|NCT04399005|OTHER|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
219718979|NCT04399005|OTHER|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
219718980|NCT03086343|DRUG|Abatacept|IV infusion
219718981|NCT03086343|DRUG|Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)|IV infusion
219718982|NCT03086343|DRUG|Upadacitinib|15 mg extended release tablet
219718983|NCT03086343|DRUG|Placebo for upadacitinib|Film-coated tablet
219718984|NCT04549441|PROCEDURE|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
219718985|NCT01667614|DRUG|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
219718986|NCT03723824|DRUG|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
219718987|NCT04857710|DEVICE|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
219718988|NCT04857710|DEVICE|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
219144478|NCT04013646|DRUG|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
219144479|NCT04013646|PROCEDURE|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
219718989|NCT04857710|DEVICE|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
219718990|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
219718991|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
219718992|NCT01047501|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks
219718993|NCT00741611|DEVICE|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
219718994|NCT00741611|DRUG|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
219718995|NCT04558827|OTHER|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
219718996|NCT04558827|OTHER|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
219718997|NCT00731198|DRUG|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
219718998|NCT00731198|DRUG|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
219718999|NCT02242344|DRUG|Telmisartan|
219144480|NCT01063517|DRUG|olaparib|100mg BID oral tablet continuous
219144481|NCT01063517|DRUG|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
219719000|NCT02242344|DRUG|Placebo|
219144482|NCT01063517|DRUG|Placebo|100mg BID oral tablet to match olaparib tablet
219144483|NCT03824080|DRUG|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
219144484|NCT06512714|OTHER|A diagnosis of mycetoma in a medical, radiologic, or laboratory record.|For each patient, data will be extracted for each clinical, laboratory or radiologic visit related to the condition that may meet this study's case definition.
219144485|NCT03984617|OTHER|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
219144486|NCT04423328|BEHAVIORAL|acupressure|self-acupressure
219144487|NCT04181307|BEHAVIORAL|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
219144488|NCT00184925|PROCEDURE|Tracheostomy|trachesotomy with subglottic drainage
219144489|NCT00184925|DEVICE|cannula with subglottic drainage|
219144490|NCT00617201|DRUG|atomoxetine|Once daily oral dosing
219144491|NCT00617201|DRUG|placebo|Once daily oral dosing - matched placebo
219144492|NCT00333658|BEHAVIORAL|Goal setting and work feedback group|Goal setting and feedback using WBI
219144493|NCT01257074|DRUG|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
219144494|NCT01257074|DRUG|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
219144495|NCT01382030|DRUG|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
219144496|NCT01682200|DRUG|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
219144497|NCT03943459|DRUG|Quercetin|Quercetin 250 mg BID
219144498|NCT00003292|DRUG|ifosfamide|
219144499|NCT05619107|DEVICE|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
219144500|NCT05619107|DEVICE|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
219144501|NCT04680871|DEVICE|In-Ear Sensor|The device will passively monitor participants' biometrics
219144502|NCT04220359|DEVICE|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
219144503|NCT00396851|DRUG|Gurmar|
219144504|NCT00396851|DRUG|Metformin|
219144505|NCT06060002|PROCEDURE|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
219144506|NCT06060002|DIAGNOSTIC_TEST|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
219144507|NCT00546871|DRUG|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
219230744|NCT07012733|OTHER|Thoracic mobilization|Participants in this group will receive thoracic mobilization techniques in addition to conventional respiratory therapy. Thoracic mobilization will be delivered by a licensed physical therapist using passive manual techniques targeting the thoracic spine and rib cage to improve chest wall mobility and respiratory function.
219719001|NCT04942873|OTHER|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
219719002|NCT06403722|DIAGNOSTIC_TEST|Standard of care|No intervention. Clinical evolution was recorded, looking for perinatal complications.
219719003|NCT00536835|DRUG|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
219144508|NCT06382649|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
219144509|NCT06382649|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
219144510|NCT04516135|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
219144511|NCT04516135|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219144512|NCT04516135|OTHER|Quality-of-Life Assessment|Ancillary studies
219144513|NCT04516135|OTHER|Questionnaire Administration|Ancillary studies
219144514|NCT04516135|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
219144515|NCT06814717|DRUG|cP12|cP12 is a novel fibronectin derived, 14-mer peptide
219144516|NCT05300308|OTHER|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
219230745|NCT07012733|OTHER|conventional therapy|Participants in this group will receive conventional respiratory therapy, including diaphragmatic breathing, pursed-lip breathing, and chest expansion exercises. The therapy will be administered by a licensed physical therapist following standard pulmonary rehabilitation protocols.
219230746|NCT07012109|DRUG|BEBT-507 Injection|The initial dose of BEBT-507 injection is 1.25mg/kg, administered subcutaneously at 1.25mg/kg, 2.5mg/kg, 5mg/kg, 10mg/kg or 15mg/kg every 12 weeks for two doses in total.
219230747|NCT07012642|DRUG|GLP-1 Receptor Agonists|GLP-1 RAs in lymphedema
219230748|NCT07013942|PROCEDURE|Dry Needling Group|Group A, which will be considered the interventional group. This group will be receiving the dry needling along with the PNF techniques for spasticity and functional performance.
219230749|NCT07013942|PROCEDURE|Sham Needling Group|Group B, which will be considered the control group. This group will be receiving sham needling in addition to the PNF techniques for spasticity and the functional performance
219144517|NCT05909683|DIAGNOSTIC_TEST|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
219144518|NCT05909683|OTHER|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
219144519|NCT04411082|DRUG|IMR-687|Oral administration of once daily IMR-687
219144520|NCT04411082|DRUG|Placebo|Oral administration of once daily Placebo
219144521|NCT04710771|OTHER|Prone Lying Position|patient lies on his/ her stomach facing floor.
219144522|NCT04710771|OTHER|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
219230750|NCT07012473|BEHAVIORAL|Nutrition education on green leafy vegetables and legumes|The nutrition education intervention will be based on the Theory of Reasoned Action, Social Cognitive Theory, and the Health Belief Model to influence key behaviour change factors such as knowledge, attitudes, practices, and beliefs. Educational materials will include stickers featuring indigenous green leafy vegetables, legumes, and vitamin C-rich fruits, with information on their benefits, storage, preparation, and the importance of combining them for enhanced iron absorption. Other materials include videos, messages, and affirmative words on iron deficiency and its prevention. The intervention will be delivered to selected households in the intervention community through biweekly meetings and phone calls over six months. The control community will not receive any intervention from the researcher.
219230751|NCT07013773|DRUG|Y-4 tablet|The enrolled subjects will be randomly divided into group AB and group BA, with a total of 10 subjects in each group, all subjects will take one Y-4 tablet (pregabalin 112.5 mg, riluzole 28.125 mg) at each period. Subjects of group AB will take Y-4 tablet under fasted condition in period 1, and take Y-4 tablet under fed condition in period 2. In contrast, subjects of group BA will take Y-4 tablet under fed condition in period 1, and take Y-4 tablet under fasted condition in period 2. There will be 7 days of wash-out between the two periods.
219230752|NCT07011693|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
219230753|NCT07011693|DRUG|Agomelatine|Commonly used oral antipsychotics intervention therapy.
219144523|NCT02804594|DRUG|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
219144524|NCT02804594|DRUG|Placebo|placebo taken three times daily
219230754|NCT07011693|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
219144525|NCT00343486|DRUG|Solabegron|
219144526|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
219144527|NCT03877159|OTHER|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
219144528|NCT04620902|OTHER|Tear sampling|Tear sampling using Schirmer's strips
219144529|NCT02077426|OTHER|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
219144530|NCT04435236|PROCEDURE|Cervical ESP block|Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
219144531|NCT03720236|PROCEDURE|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
219144532|NCT03720236|PROCEDURE|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
219144533|NCT04498624|PROCEDURE|inverted flap|full thickness macular hole surgery
219144534|NCT04498624|PROCEDURE|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
219144535|NCT06108375|OTHER|music therapy|music played live by a music therapist
219144536|NCT06108375|OTHER|recording|a recording of the same music played by the music therapist
219719004|NCT02940379|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219144537|NCT03432403|DEVICE|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
219719005|NCT02940379|DRUG|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
219719006|NCT02940379|DRUG|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
219144538|NCT03432403|DEVICE|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
219144539|NCT03762668|DEVICE|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
219144540|NCT03762668|DEVICE|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
219144541|NCT03886116|OTHER|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
219144542|NCT04658030|DEVICE|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
219144543|NCT04658030|OTHER|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
219144544|NCT00470899|PROCEDURE|drainage of placenta of fetal blood|
219144545|NCT03118804|DIAGNOSTIC_TEST|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
219144546|NCT01489982|DEVICE|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
219144547|NCT01489982|BEHAVIORAL|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
219144548|NCT01489982|DRUG|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
219144549|NCT01489982|DEVICE|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
219144550|NCT04306354|DRUG|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
219144551|NCT04306354|DRUG|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
219144552|NCT02329457|BIOLOGICAL|Zostavax|varicella zoster vaccine
219144553|NCT02329457|BIOLOGICAL|Normal Saline|normal saline placebo vaccine
219144554|NCT02027558|BEHAVIORAL|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
219144555|NCT02027558|BEHAVIORAL|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
219144556|NCT04783454|OTHER|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
219144557|NCT00459446|DRUG|MS-325 Injection (Gadofosveset Trisodium)|
219144558|NCT03778645|PROCEDURE|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
219144559|NCT06399029|DRUG|Ruxolitinib Topical Cream|Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
219144560|NCT05319626|OTHER|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
219144561|NCT05319626|OTHER|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
219144562|NCT05319626|OTHER|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
219144563|NCT05319626|OTHER|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
219144564|NCT00203372|DRUG|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
219144565|NCT00203372|DRUG|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
219144566|NCT00203372|DRUG|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
219144567|NCT00203372|DRUG|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
219719007|NCT01385644|OTHER|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
219719008|NCT05876494|DIAGNOSTIC_TEST|serum lactate|assessment of serum lactate and mean platelets volume
219719009|NCT00675350|DRUG|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
219719010|NCT00078520|BIOLOGICAL|Dose Level 1|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0
219719011|NCT00078520|BIOLOGICAL|Dose Level 2|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6
219719012|NCT00078520|BIOLOGICAL|Dose Level 2- Fixed Dose|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7
219144568|NCT01574859|OTHER|levothyroxine|titration of T4 according to biochemical values
219144569|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
219144570|NCT02719600|BEHAVIORAL|Virtual reality|Evaluation of observational motor learning using virtual reality
219144571|NCT02383472|DEVICE|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
219144572|NCT02383472|DEVICE|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
219144573|NCT02013830|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
219144574|NCT02013830|DRUG|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
219144575|NCT01111526|DRUG|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
219144576|NCT03981042|DEVICE|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~\- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
219144577|NCT04436393|DIAGNOSTIC_TEST|Guardant360 test|tumor cfDNA testing
219144578|NCT04424641|BIOLOGICAL|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
219144579|NCT01438086|DRUG|mecasermin|Intracoronary bolus
219144580|NCT01438086|DRUG|mecasermin|Intracoronary bolus
219144581|NCT01438086|DRUG|0.9% sodium chloride injection|Intracoronary bolus
219144582|NCT00597038|DRUG|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."
219144583|NCT04238429|DRUG|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
219144584|NCT04238429|DRUG|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
219144585|NCT04094532|DRUG|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
219144586|NCT04094532|DRUG|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
219144587|NCT03446859|OTHER|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
219719013|NCT04687722|OTHER|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
219144588|NCT01087255|DEVICE|Electronic Pillbox Monitoring System|Daily exposure for six months
219144589|NCT04014114|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
219144590|NCT06313125|OTHER|3-dimensional foot-ankle extension exercises|In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
219230755|NCT07014228|PROCEDURE|single visit re-endo|In this group, a single visit re-endodontic treatment will be performed and completed in the same visit, including all the steps.
219144591|NCT06313125|OTHER|Clam exercise|In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
219144592|NCT06313125|OTHER|Short-foot exercise|In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
219144593|NCT06480942|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
219144594|NCT03245580|DIAGNOSTIC_TEST|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
219144595|NCT00304135|DRUG|cisplatin|
219144596|NCT00304135|DRUG|gemcitabine hydrochloride|
219144597|NCT00304135|DRUG|oxaliplatin|
219144598|NCT02769468|OTHER|The Back|
219719014|NCT04687722|OTHER|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
219719015|NCT03578913|OTHER|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
219144599|NCT02769468|OTHER|Chest|
219144600|NCT02769468|OTHER|Left Axilla|
219144601|NCT01876602|BEHAVIORAL|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
219144602|NCT04128358|DIAGNOSTIC_TEST|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
219144603|NCT04128358|DIAGNOSTIC_TEST|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
219144604|NCT02807467|DRUG|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
219144605|NCT02807467|DRUG|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
219144606|NCT02014142|DRUG|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
219144607|NCT01374893|BEHAVIORAL|Exercise|The intervention group will perform the multi-session per day training program
219144608|NCT01374893|BEHAVIORAL|Control|Usual care
219144609|NCT02296424|DRUG|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
219144610|NCT00084045|PROCEDURE|Intrapartum HIV counseling/testing|
219144611|NCT00084045|PROCEDURE|Postpartum HIV counseling/testing|
219144612|NCT00000152|DRUG|Aspirin|
219144613|NCT00000152|DRUG|Beta-Carotene|
219144614|NCT05317572|DRUG|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
219144615|NCT05317572|DRUG|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
219230756|NCT07014228|PROCEDURE|multi visit re-endo|In this group, a multi-visit re-endodontic treatment will be performed and completed over different visits, including all the steps.
219230757|NCT06875362|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
219144616|NCT05317572|DRUG|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
219144617|NCT00743444|DRUG|AZD3355|65 mg capsules, oral, 3 single doses
219144618|NCT00743444|DRUG|Placebo|capsules, oral, 3 single doses
219144619|NCT05723133|DEVICE|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
219144620|NCT05723133|BEHAVIORAL|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
219144621|NCT06367816|PROCEDURE|INTELLiVENT|Closed-loop mode of ventilation
219144622|NCT06367816|PROCEDURE|Conventional ventilation|Mode of ventilation
219144623|NCT05910918|BEHAVIORAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
219144624|NCT02452918|DRUG|Oritavancin|Administered intravenously
219144625|NCT02452918|DRUG|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
219144626|NCT00016471|PROCEDURE|Audiogram|
219144627|NCT00016471|PROCEDURE|Electroretinogram|
219144628|NCT05496777|PROCEDURE|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
219144629|NCT02784132|OTHER|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
219144630|NCT06131385|DRUG|intravenous thrombolysis|Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
219144631|NCT02735291|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
219144632|NCT05972915|DIAGNOSTIC_TEST|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
219144633|NCT00900211|GENETIC|microarray analysis|
219144634|NCT00900211|GENETIC|molecular diagnostic method|
219230758|NCT06875362|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
219144635|NCT00900211|OTHER|biologic sample preservation procedure|
219144636|NCT00394615|PROCEDURE|Metabolic Imaging|
219144637|NCT04523922|DRUG|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
219230759|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
219144638|NCT04523922|DRUG|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
219230760|NCT07012538|DRUG|Renin-angiotensin system inhibitors (RASi)|Using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or inappropriate use of RASi.
219230761|NCT07012538|DRUG|No renin-angiotensin system inhibitors (No RASi)|Not using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or needing RASi.
219144639|NCT04523922|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
219144640|NCT06290297|DEVICE|Telerehabilitation VRRS|Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
219144641|NCT01337635|DRUG|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
219144642|NCT05977179|OTHER|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|As it was described in the arm/group descriptions.
219144643|NCT05977179|OTHER|Attention Control|As it was described in the arm/group descriptions.
219144644|NCT01536834|DEVICE|Medical Device|
219230762|NCT07012499|DEVICE|Automated peritoneal dialysis with Sharesource device|Patients receive APD with an FMC device that contains sharesource software which can communicate with the medical team.
219230763|NCT07012499|DEVICE|APD without sharesource|Patients received APD with Same machine but this patients dose not using sharesource software
219230764|NCT07013123|DRUG|Tezepelumab|"Patients will take Tezepelumab for 3 to 6 months (M-3/-6) to control asthma symptoms.~Once asthma symptoms are controlled (D0), patients will take an additionnal of 18 months of Tezepelumab"
219230765|NCT07013123|DRUG|Acarizax|Once asthma symptoms are controlled (D0), patients will take 18 months of Acarizax.
219230766|NCT07013123|DRUG|Placebo|Once asthma symptoms are controlled (D0), patients will take 18 months of Placebo.
219144645|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
219144646|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
219144647|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
219719016|NCT03578913|OTHER|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
219719017|NCT01805050|PROCEDURE|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
219144648|NCT05704920|OTHER|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
219144649|NCT05704920|OTHER|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
219144650|NCT02759913|PROCEDURE|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
219144651|NCT01307267|DRUG|PF-05082566|Intravenous, Dose escalation, once per month
219144652|NCT01307267|DRUG|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
219144653|NCT01307267|DRUG|PF-05082566|IV, Dose escalation, once per month
219144654|NCT03804580|DRUG|osimertinib|Non-randomized trial, all patients receive therapy
219144655|NCT06242379|BIOLOGICAL|GMP compliant-BM-MSC derived sEVs|The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
219144656|NCT03667911|OTHER|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
219144657|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, single dose
219144658|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
219144659|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, single dose
219144660|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
219144661|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
219144662|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, single dose
219230767|NCT05430841|DIAGNOSTIC_TEST|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
219719018|NCT02715557|BEHAVIORAL|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
219144663|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, single dose
219144664|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, single dose
219144665|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, single-dose
219144666|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
219144667|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
219144668|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
219144669|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
219144670|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
219144671|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
219144672|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
219144673|NCT02887898|DEVICE|Automated bolus calculator|
219144674|NCT02887898|OTHER|Education|
219144675|NCT06520137|PROCEDURE|Tooth extraction|Extraction of maxillary third molars
219144676|NCT00252278|DRUG|atomoxetine|
219144677|NCT04956575|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219144678|NCT04956575|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
219144679|NCT04956575|BIOLOGICAL|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
219144680|NCT04536519|OTHER|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
219230768|NCT06699082|OTHER|KinesioTaping and Keltonborn Mobilization|Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
219719019|NCT00378859|BEHAVIORAL|Skim milk|
219719020|NCT00378859|BEHAVIORAL|Lean meat|
219230769|NCT06699238|OTHER|Home Exercise|Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
219144681|NCT03593876|BEHAVIORAL|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
219144682|NCT00258635|BIOLOGICAL|RagweedMATAMPL|
219144683|NCT04456218|DEVICE|NCKU-scope-01 (a custom-made biliary endoscope system)|The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
219144684|NCT00281424|DEVICE|pedometer|gave pedometer and info
219144685|NCT05882812|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
219144686|NCT05882812|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
219144687|NCT05882812|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
219144688|NCT03195075|PROCEDURE|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
219144689|NCT03195075|PROCEDURE|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
219144690|NCT02682446|DRUG|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
219144691|NCT00289835|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
219144692|NCT01204346|OTHER|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
219144693|NCT01204346|OTHER|treatment as usual|less intensive and structured psychotherapeutic program
219144694|NCT05136807|OTHER|Quality-of-Life Assessment|Complete questionnaires
219144695|NCT05136807|OTHER|Questionnaire Administration|Complete questionnaires
219230770|NCT06699238|OTHER|Aerobic exercise|The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
219230771|NCT06883110|DRUG|Z11020076|Beijing Tongrentang Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
219230772|NCT06883110|DRUG|Z20063878|Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
219230773|NCT07044193|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
219230774|NCT07044193|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
219144696|NCT03409913|RADIATION|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
219144697|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
219144698|NCT03725059|BIOLOGICAL|Pembrolizumab (K)|IV infusion Q3W
219144699|NCT03725059|DRUG|Placebo (P)|Normal saline or dextrose IV infusion Q3W
219144700|NCT03725059|DRUG|Paclitaxel (X)|IV infusion QW
219144701|NCT03725059|DRUG|Doxorubicin (A)|IV infusion either in Q2W or Q3W
219144702|NCT03725059|DRUG|Epirubicin (E)|IV infusion either in Q2W or Q3W
219144703|NCT03725059|DRUG|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
219144704|NCT03725059|DRUG|Endocrine therapy|Variable endocrine therapy for up 10 years
219144705|NCT03725059|RADIATION|Radiation therapy|Variable radiation therapy per local standard of care
219144706|NCT03725059|PROCEDURE|Surgery|Surgery for breast cancer
219230775|NCT06728982|DRUG|Metformin|1000mg of metformin twice daily by mouth
219230776|NCT07045909|DRUG|Daratumumab|Daratumumab will be administered by subcutaneous (SC) injection.
219230777|NCT07045909|DRUG|Isatuximab|Isatuximab will be administered IV.
219230778|NCT07045909|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area at baseline and will be administered by SC injection.
219230779|NCT07045909|DRUG|Lenalidomide|Lenalidomide will be administered by oral route (all cohorts at induction, and cohorts A and B at maintenance).
219230780|NCT07045909|DRUG|Cyclophosphamide|As part of lymphodepleting therapy before CAR-T manufacture, administered IV.
219230781|NCT07045909|DRUG|Fludarabine|As part of lymphodepleting therapy before CAR-T manufacture, administered IV
219230782|NCT07045909|DRUG|Anitocabtagene Autoleucel|Single infusion IV
219144707|NCT06129149|BEHAVIORAL|Trauma-Informed Care-adapted and Checklist-guided ACP intervention|The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
219144708|NCT06025019|BEHAVIORAL|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
219144709|NCT06352541|DRUG|PRO-232|Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
219144710|NCT06352541|OTHER|Placebo|Vehicle Control, ophthalmic solution
219144711|NCT05955898|BEHAVIORAL|Parents THRIVE|Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.
219144712|NCT05955898|BEHAVIORAL|Sharing Feelings Project|Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
219144713|NCT04151472|DRUG|Placebo|Placebo oral tablet, three times a day
219144714|NCT04151472|DRUG|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
219144715|NCT04151472|DRUG|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
219144716|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
219230783|NCT07050732|BIOLOGICAL|Arexvy (2 doses total)|Arexvy at enrollment, Arexvy at Day 365
219230784|NCT07050732|BIOLOGICAL|Arexvy (3 doses total)|Arexvy at enrollment, Day 60, and Day 365
219230785|NCT07050732|BIOLOGICAL|Arexvy (1 dose total)|Arexvy at enrollment
219230786|NCT07050732|OTHER|Placebo|Placebo vaccine at day 60
219230787|NCT05675059|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
219230788|NCT05675059|BEHAVIORAL|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
219230789|NCT05675059|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
219144717|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
219230790|NCT07052799|DRUG|Aspirin 80mg|8-day (-5, +3) supply of aspirin 80mg before and after colonoscopy
219230791|NCT07052799|DRUG|Placebo Oral Tablet|8-day (-5, +3) supply of placebo before and after colonoscopy
219144718|NCT02960269|OTHER|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
219719021|NCT04757584|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
219230792|NCT07052838|DRUG|HSK39297 tablets|200mg QD
219144719|NCT00657943|DRUG|metformin|metformin tablets 2 g x 2
219144720|NCT00657943|DRUG|insulin detemir|insulin as requested
219144721|NCT00657943|DRUG|insulin aspart + insulin aspart protamin|insulin as requested
219230793|NCT06782178|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
219230794|NCT06782178|PROCEDURE|Arthrocentesis/Saline|Arthrocentesis refers to a blind irrigation of the temproromandibular joint with saline solution
219230795|NCT07052721|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants will adjust the amplitude, as needed.
219230796|NCT07052721|DEVICE|Sham Comparator|SHAM percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants can adjust the amplitude, as needed; but no electrical current will ever reach the patient's body.
219144722|NCT00657943|DRUG|Insulin aspart|insulin as requested
219144723|NCT00813449|DRUG|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
219144724|NCT00813449|DRUG|dacarbazine plus placebo (control group)|dacarbazine plus placebo
219230797|NCT07099950|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, administered as a single dose (1-epoch), or in multiple doses (3-epoch).
219230798|NCT07099664|DIAGNOSTIC_TEST|Measurement of aortic Vmax and VTI with suprasternal doppler.|Measurement of aortic Vmax and VTI with suprasternal doppler. Measurement of VTI variation and cardiac output after general anaesthesia. After preoperative fasting compensation, measurement of cardiac output (CO). Search of a difference in the suprasternale VTI variability between the patients who have increased their CO after fasting compensation and the patient who haven't.
219230799|NCT07098728|DRUG|Levetiracetam IV|Leveget injection 500mg/5ml
219230800|NCT07098728|DRUG|Phenobarbital|Phenobarbital injection 200mg/ml (BPI Insein)
219230801|NCT07099378|OTHER|Saliva and Serum|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
219230802|NCT07099378|OTHER|Saliva and Serum|ELISA method will be used to measure TNF-α values in collected saliva and serum samples.RT-qPCR based miRNA gene expression analyses will be performed with 2-step qRT-PCR Kits (Thermofisher Scientific, MA, USA).
219230803|NCT05523505|DEVICE|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
219230804|NCT05523505|DEVICE|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus using transcranial alternating current stimulation (tACS).
219230805|NCT05523505|DEVICE|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
219230806|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
219719022|NCT02992379|DEVICE|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
219144725|NCT00783133|DRUG|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
219230807|NCT06941792|DRUG|inclisiran sodium injection|After randomization, patients in the inclisiran group will receive inclisiran sodium injection
219230808|NCT06941792|COMBINATION_PRODUCT|Standard of Care|After randomization switching to or adding on another/other lipid-lowering therapies
219230809|NCT04742894|BEHAVIORAL|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
219230810|NCT04475874|OTHER|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
219719023|NCT02992379|DEVICE|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
219719024|NCT01510756|DRUG|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
219719025|NCT05181384|OTHER|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
219719026|NCT05181384|OTHER|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
219719027|NCT05181384|OTHER|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
219719028|NCT04613869|DRUG|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
219144726|NCT00783133|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
219144727|NCT02178111|OTHER|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
219144728|NCT02178111|PROCEDURE|episiotomy|
219144729|NCT01721434|DRUG|Levosimendan|
219719029|NCT04613869|DRUG|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
219144730|NCT01721434|DRUG|Placebo|Similar coloured placebo
219144731|NCT06340646|OTHER|Return of Genetic Results: Biomarker information from cancer cells|Participants will receive a novel return of results report that is tailored to their choices.
219144732|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to cancer|Participants will receive a novel return of results report that is tailored to their choices.
219144733|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to other medical issues|Participants will receive a novel return of results report that is tailored to their choices.
219144734|NCT00006369|DRUG|ERA-923|
219719030|NCT04613869|DRUG|Hydromorphone|No esketamine added
219144735|NCT05319041|DRUG|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
219719031|NCT04705571|DEVICE|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
219719032|NCT04187521|OTHER|Meal A|A breakfast meal with a specific macronutrient proportions.
219719033|NCT04187521|OTHER|Meal B|A breakfast meal with a specific macronutrient proportions.
219719034|NCT02038842|BIOLOGICAL|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
219719035|NCT02038842|BIOLOGICAL|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
219719036|NCT02038842|BIOLOGICAL|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
219719037|NCT02197637|DRUG|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
219719038|NCT04693728|BEHAVIORAL|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
219719039|NCT02413268|DRUG|Nitroglycerin|
219144736|NCT05319041|DRUG|Placebo|0.5g maltodextrin without any herbs medicine
219144737|NCT06568536|OTHER|Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG|The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
219144738|NCT05502900|DRUG|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
219144739|NCT05837806|DRUG|tislelizumab+disitamab-vedotin|Patients enrolled will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin (RC48) 2.0mg/kg intravenously.
219144740|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
219144741|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
219144742|NCT05978037|BIOLOGICAL|RH5.1 and/or RH5.2-VLP with Matrix-M|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
219144743|NCT05390099|DRUG|Moringa oleifera leaf|Moringa toothpaste
219144744|NCT05767099|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
219144745|NCT06960590|OTHER|Training - static streching|The intervention group performed one training session per week. Each training session consisted of 2 series of static stretching of the back band. The rest time between series was 45 s. The intervention lasted 6 weeks.
219144746|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
219144747|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
219144748|NCT06504368|DRUG|DCR-PDL1|Solution for IV Infusion
219144749|NCT04063826|DEVICE|PET MRI|All participants will have a liver scan
219144750|NCT00502372|DIETARY_SUPPLEMENT|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
219719040|NCT01721239|OTHER|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
219719041|NCT00000678|DRUG|Zidovudine|
219144751|NCT00502372|DIETARY_SUPPLEMENT|Juven|comparison of Juven with arginine only product in wound healing
219144752|NCT00814346|DRUG|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
219144753|NCT00814346|DRUG|Placebo|Placebo 1 tablet BID
219719042|NCT00000678|DRUG|Zalcitabine|
219719043|NCT02585167|PROCEDURE|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
219719044|NCT02585167|DEVICE|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
219719045|NCT05340595|OTHER|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
219719046|NCT06190119|OTHER|none intervention|This study has no intervention
219719047|NCT01723943|OTHER|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
219230811|NCT04475874|OTHER|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
219230812|NCT06584955|OTHER|Weighted Blanket|Participants will be given a weighted blanket
219230813|NCT02572986|DRUG|Permethrin|
219230814|NCT01523392|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
219230815|NCT01523392|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
219144754|NCT02713334|BEHAVIORAL|survey|
219230816|NCT00893100|DRUG|Diltiazem|2%,3 times daily
219230817|NCT01415206|BEHAVIORAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
219719048|NCT01723943|OTHER|counseling intervention|Undergo Helping Her Heal educational counseling program
219719049|NCT01723943|OTHER|educational intervention|Undergo Helping Her Heal educational counseling program
219230818|NCT01415206|BEHAVIORAL|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
219719050|NCT01723943|OTHER|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
219719051|NCT04167800|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
219719052|NCT04764253|BEHAVIORAL|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
219719053|NCT04764253|BEHAVIORAL|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
219230819|NCT01685476|DEVICE|Echodia® hand-held equipment|
219230820|NCT05995730|OTHER|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
219230821|NCT05995730|OTHER|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
219230822|NCT03462966|DRUG|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
219230823|NCT01331278|PROCEDURE|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
219230824|NCT01331278|PROCEDURE|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
219719054|NCT02243826|DRUG|50:50 mixture of nitrous oxide/oxygen|
219144755|NCT02713334|BEHAVIORAL|semi-structured interview|
219144756|NCT04800016|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
219144757|NCT04800016|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
219144758|NCT04551781|DRUG|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
219144759|NCT04551781|DRUG|control|symptomatic ttt
219144760|NCT03382080|OTHER|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
219144761|NCT03382080|OTHER|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
219144762|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
219144763|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
219144764|NCT03941912|DEVICE|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
219144765|NCT06395870|BIOLOGICAL|LUCAR-G39D cells product|Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
219144766|NCT02692742|DRUG|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
219144767|NCT02692742|DRUG|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
219144768|NCT01443117|BIOLOGICAL|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
219144769|NCT01443117|BIOLOGICAL|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
219144770|NCT01443117|BIOLOGICAL|Placebo Vaccine|Administered as a 0.5 mL IM dose
219144771|NCT03419156|OTHER|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
219144772|NCT04143126|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
219144773|NCT04143126|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
219144774|NCT04483856|DEVICE|DermoRelizema cream|Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment
219144775|NCT04483856|DEVICE|Dexeryl|FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
219144776|NCT02513238|DRUG|Mesenchymal stem cell|Stemcells injected into submandibularis
219144777|NCT02513238|DRUG|Isotonic NaCl|
219144778|NCT03622580|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
219144779|NCT03622580|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
219144780|NCT03622580|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
219144781|NCT03105219|DRUG|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
219144782|NCT03105219|OTHER|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
219144783|NCT01441453|PROCEDURE|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
219144784|NCT05599256|DRUG|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
219144785|NCT05136443|DRUG|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
219719055|NCT03562507|DRUG|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
219144786|NCT03097744|DEVICE|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
219144787|NCT01486550|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
219144788|NCT01486550|DRUG|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
219144789|NCT00587925|OTHER|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
219144790|NCT04181255|DRUG|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
219144791|NCT04181255|DRUG|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
219144792|NCT02279017|BEHAVIORAL|mHealth Texting for Weight Loss|
219144793|NCT06000748|DRUG|MAP-Target Algorithm|This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
219144794|NCT00910754|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
219144795|NCT00910754|DRUG|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
219230825|NCT05190224|OTHER|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
219144796|NCT01806454|DRUG|calcium|
219553042|NCT02277262|DEVICE|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
219144797|NCT03575819|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
219144798|NCT03071848|OTHER|No Intervention|This was an observational study.
219144799|NCT02221219|DRUG|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
219144800|NCT02221219|PROCEDURE|delay in umbilical cord clamp at birth|provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
219144801|NCT02221219|DRUG|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
219230826|NCT01212822|BIOLOGICAL|bevacizumab|Given IV
219553043|NCT02277262|PROCEDURE|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
219553044|NCT03673592|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
219553045|NCT00960154|DEVICE|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
219230827|NCT01212822|DRUG|oxaliplatin|Given IV
219230828|NCT01212822|DRUG|leucovorin calcium|Given IV
219553046|NCT00960154|PROCEDURE|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
219719056|NCT03562507|DRUG|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
219719057|NCT05702151|PROCEDURE|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
219719058|NCT05702151|DRUG|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
219144802|NCT02221219|PROCEDURE|immediate cord clamp at birth|no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
219144803|NCT03007836|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219144804|NCT02613871|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219144805|NCT04559555|DRUG|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
219230829|NCT01212822|DRUG|fluorouracil|Given IV
219230830|NCT01212822|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219230831|NCT01212822|OTHER|laboratory biomarker analysis|Correlative studies
219719059|NCT01484366|PROCEDURE|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
219719060|NCT01484366|PROCEDURE|plating|Surgical plating of both bonforearm fractures
219719061|NCT03459651|BEHAVIORAL|ANS training|In-home computer-based ANS training
219719062|NCT00792480|BEHAVIORAL|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
219719063|NCT02132468|DRUG|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
219719064|NCT03600428|BIOLOGICAL|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
219719065|NCT03600428|BIOLOGICAL|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
219719066|NCT04985656|DRUG|Pevonedistat|Pevonedistat IV infusion
219719067|NCT04985656|DRUG|Decitabine|Decitabine tablets
219719068|NCT04985656|DRUG|Cedazuridine|Cedazuridine tablets
219719069|NCT01133106|BEHAVIORAL|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
219719070|NCT01133106|OTHER|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
219553047|NCT04793633|COMBINATION_PRODUCT|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
219553048|NCT04238962|DRUG|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
219144806|NCT06155071|OTHER|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
219144807|NCT06155071|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
219144808|NCT01203618|DRUG|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
219144809|NCT05300061|BEHAVIORAL|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
219144810|NCT05300061|BEHAVIORAL|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
219144811|NCT02873312|DEVICE|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
219144812|NCT01240837|OTHER|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
219144813|NCT01240837|OTHER|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
219553049|NCT04238962|DRUG|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
219553050|NCT02931630|OTHER|Whey protein powder|60 g of whey protein powder
219553051|NCT02931630|OTHER|Maltodextrin powder|60 g of Maltodextrin powder
219553052|NCT02931630|OTHER|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
219719071|NCT05188794|PROCEDURE|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
219719072|NCT05188794|PROCEDURE|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
219719073|NCT01295892|DRUG|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
219719074|NCT00446784|DRUG|CE-224,535|
219553053|NCT02931630|OTHER|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
219144814|NCT01240837|OTHER|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
219553054|NCT04654429|DRUG|IV Ondansetron 4mg|IV ondansetron 4mg
219719075|NCT00446784|DRUG|Methotrexate|
219719076|NCT02368236|BEHAVIORAL|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
219144815|NCT06555653|OTHER|Video based multimedia information|The intervention group was shown a 5 minute informational video before amniocentesis including definition of amniocentesis, its indications, the setup of amniocentesis room, the purpose and steps of the procedure, potential complications and how to manage them
219144816|NCT02876471|OTHER|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
219144817|NCT03954015|DIAGNOSTIC_TEST|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
219144818|NCT03954015|DRUG|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
219144819|NCT02783755|BEHAVIORAL|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
219144820|NCT03794193|PROCEDURE|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
219144821|NCT06849778|DRUG|TS-172|oral administration of TS-172 20 mg
219144822|NCT03600935|OTHER|Vancouver Clinical Pathway|Vancouver Clinical Pathway
219144823|NCT02169154|DRUG|1% Diclofenac Sodium|1% diclofenac sodium
219144824|NCT02169154|DRUG|3% Menthol|3% Menthol
219144825|NCT02169154|DRUG|0.09% Menthol|0.09% Menthol
219144826|NCT02169154|DRUG|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
219144827|NCT02169154|DRUG|0.9% Saline|0.9% Saline
219144828|NCT01483248|BIOLOGICAL|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks."
219144829|NCT01483248|DRUG|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
219144830|NCT00437346|PROCEDURE|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
219553055|NCT04654429|OTHER|Higher OT temperature range|OT temperature set to 19-22 degree celsius
219553056|NCT04654429|DRUG|Placebo|IV Normal Saline 2cc will be given
219553057|NCT04654429|OTHER|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
219553058|NCT02817828|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
219553059|NCT01470898|DEVICE|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
219553060|NCT04092595|DRUG|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
219553061|NCT04092595|DRUG|Rosuvastatin|10 mg oral tablet
219553062|NCT00072514|DRUG|gemcitabine hydrochloride|Given IV
219553063|NCT00072514|DRUG|carboplatin|Given IV
219553064|NCT00072514|DRUG|dexamethasone|Given PO
219553065|NCT00072514|BIOLOGICAL|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
219553066|NCT01380613|BEHAVIORAL|Workshop|10 session intervention
219553067|NCT01380613|BEHAVIORAL|Workshop control|1 session intervention on standard HIV/STD information
219553068|NCT02207764|BEHAVIORAL|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
219553069|NCT01528293|DEVICE|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
219553070|NCT01528293|OTHER|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
219144831|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
219144832|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
219144833|NCT01930045|DRUG|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
219144834|NCT01930045|DRUG|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
219144835|NCT01018524|PROCEDURE|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
219144836|NCT01197807|PROCEDURE|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
219144837|NCT01197807|PROCEDURE|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
219144838|NCT04971447|DRUG|gender affirming hormonal treatment in transgender men|testosterone enanthate
219144839|NCT04971447|DRUG|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
219144840|NCT01845428|DRUG|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
219144841|NCT04824443|OTHER|Aerobic Exercise Therapy|Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).
219144842|NCT03558893|BEHAVIORAL|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
219144843|NCT02616237|BEHAVIORAL|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
219230832|NCT04195789|OTHER|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
219230833|NCT01493882|DRUG|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
219144844|NCT06479668|BEHAVIORAL|Trier Social Stress Task|Specify details not covered in associated Arm Description.
219144845|NCT02997917|BEHAVIORAL|Education|
219144846|NCT02997917|BEHAVIORAL|Sham|
219144847|NCT00232895|DRUG|lipuro propofol|
219230834|NCT01493882|DRUG|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
219230835|NCT01493882|DRUG|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
219230836|NCT01493882|DRUG|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
219230837|NCT02236611|DRUG|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
219230838|NCT02236611|DRUG|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
219144848|NCT00232895|DRUG|standard formulation propofol|
219144849|NCT05590650|DRUG|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
219144850|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219144851|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219144852|NCT04163081|BEHAVIORAL|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
219144853|NCT00831415|DRUG|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
219144854|NCT03895268|DEVICE|ALiA Analyser|NPS specimens shall be tested with the investigational device
219144855|NCT03895268|DEVICE|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
219553071|NCT06447753|PROCEDURE|Direct pulp capping|after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
219719077|NCT02617290|DRUG|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
219719078|NCT02617290|DRUG|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
219719079|NCT03611127|OTHER|pulmonary rehabilitation|pulmonary rehabilitation standardized program
219719080|NCT04482790|PROCEDURE|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
219719081|NCT04482790|PROCEDURE|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
219230839|NCT04131257|BEHAVIORAL|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
219230840|NCT01056159|DRUG|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
219230841|NCT01056159|DRUG|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
219230842|NCT00004474|DRUG|Anti-thymocyte globulin|Given via IV over 4 hours
219230843|NCT00004474|DRUG|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
219230844|NCT00004474|PROCEDURE|Bone marrow transplantation|Given on Day 0
219230845|NCT02311062|OTHER|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
219230846|NCT02311062|OTHER|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
219230847|NCT02311062|OTHER|Control|Only soccer training
219230848|NCT05193799|DEVICE|Investigational devices must be used 8 hours per day|During 3 consecutive days
219230849|NCT03175406|DIAGNOSTIC_TEST|Manipal cervical scoring system|
219230850|NCT00002235|DRUG|Indinavir sulfate|
219230851|NCT00002235|DRUG|Nelfinavir mesylate|
219230852|NCT00002235|DRUG|Efavirenz|
219230853|NCT04349319|DEVICE|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
219230854|NCT00815100|DRUG|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
219230855|NCT00815100|DRUG|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
219230856|NCT03830320|DRUG|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
219553072|NCT06447753|PROCEDURE|Complete Pulpotomy|exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
219553073|NCT00377156|RADIATION|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
219553074|NCT00377156|RADIATION|stereotactic radiosurgery|
219553075|NCT03283748|DEVICE|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
219553076|NCT02407496|OTHER|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
219553077|NCT02156219|OTHER|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop."
219553078|NCT00125541|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
219553079|NCT00544167|DRUG|Doxorubicin|
219553080|NCT00544167|DRUG|Cyclophosphamide|
219553081|NCT00544167|DRUG|Paclitaxel|
219230857|NCT03830320|DEVICE|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
219553082|NCT00544167|DRUG|Sorafenib|
219553083|NCT01937806|DRUG|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
219553084|NCT01937806|DRUG|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
219553085|NCT04323215|DEVICE|Support system|A support system named Provement will be used to provide behavioral treatment.
219719082|NCT04398134|DRUG|ABI-H2158|3 X 100 mg tablets for oral administration
219719083|NCT04398134|DRUG|Placebo|Sugar pill manufactured to mimic the ABI-H2158 tablets
219719084|NCT04398134|DRUG|Entecavir (ETV)|0.5 mg tablet for oral administration
219230858|NCT03830320|PROCEDURE|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
219230859|NCT03830320|PROCEDURE|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
219230860|NCT01128959|DRUG|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
219230861|NCT02338999|RADIATION|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
219144856|NCT05347108|PROCEDURE|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
219144857|NCT03852836|OTHER|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
219144858|NCT06449300|OTHER|Resistance exercise-LVT|(low volume training - 3 sessions of 12 exercises per week)
219144859|NCT06449300|OTHER|Resistance exercise-MVT|(moderate volume training - 4 sessions of 12 exercises per week)
219144860|NCT06449300|OTHER|Resistance exercise-HVT|(high volume training - 5 sessions of 12 exercises per week)
219144861|NCT04299360|DEVICE|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
219144862|NCT00779545|DRUG|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
219144863|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
219144864|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
219144865|NCT00779545|DRUG|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
219230862|NCT02338999|DRUG|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
219230863|NCT02338999|DRUG|Placebo|
219230864|NCT05077670|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
219230865|NCT05077670|DEVICE|Atrial substrate mapping|Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
219230866|NCT05483166|BEHAVIORAL|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~1. Becoming aware of the child's core strengths and difficulties~2. Helping the child to be optimally responsive to the guidance of the parent(s), and~3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
219230867|NCT03142867|OTHER|non-applicable|non-applicable
219230868|NCT02701296|DRUG|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
219144866|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
219144867|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
219230869|NCT02701296|DRUG|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
219230870|NCT01683669|OTHER|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
219230871|NCT01683669|OTHER|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
219553086|NCT00856349|BEHAVIORAL|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
219144868|NCT05222087|RADIATION|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
219230872|NCT05044416|DEVICE|VieScope|intubation with VieScope laryngoscope
219230873|NCT05044416|DEVICE|Videolaryngoscopy|intubation with videolaryngoscope
219230874|NCT01044446|DRUG|Icodextrin|one exchange daily
219230875|NCT01044446|DRUG|glucose-based peritoneal dialysate|original exchange frequency
219230876|NCT02441374|DEVICE|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
219230877|NCT02441374|OTHER|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
219230878|NCT04334252|OTHER|Questionnaire|Questionnaire
219553087|NCT02725515|BIOLOGICAL|XmAb5871|
219230879|NCT01844401|DRUG|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
219553088|NCT02725515|BIOLOGICAL|Placebo to match XmAb5871|
219553089|NCT00353535|PROCEDURE|Total Lymphoid irradiation|
219553090|NCT00056433|DRUG|Hydroxyurea|
219553091|NCT00056433|DRUG|L-Arginine|
219230880|NCT01844401|DRUG|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
219144869|NCT05222087|DRUG|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
219230881|NCT02082990|BEHAVIORAL|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
219144870|NCT06259058|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
219144871|NCT06259058|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
219144872|NCT06259058|DRUG|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
219144873|NCT06259058|DRUG|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
219144874|NCT06259058|RADIATION|SBRT|30Gy/5Fx
219144875|NCT05018754|DEVICE|TREATMENT OF ORAL MUCOSITIS USING PLATELET-RICH-FIBRIN (PRF)|All patients were affected by oral mucositis (9 RIOM, 6 chemotherapy-related oral mucositis). They were treated with almost 2 different systemic therapies before and during platelets gel applications. Median of time before the lesions were treated with platelets gel were 7 days. Lesions affected buccal mucosa, tongue, labial commissure and lower lip. Preliminar parameters were the microbiological contamination of lesions and presence of pain. Patients refer spontaneous widespread pain worsened by swallowing and feeding. Response to treatment has been evaluated in relation to the reduction of lesions dimensions, to the involution of pain and presence of granulation tissue after every application of platelet gel.
219144876|NCT04668391|PROCEDURE|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
219144877|NCT04668391|PROCEDURE|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
219144878|NCT02128607|DEVICE|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
219144879|NCT02128607|DEVICE|Sham|
219144880|NCT03145480|DRUG|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
219144881|NCT03145480|DRUG|Ibrutinib|560mg po daily
219144882|NCT03145480|OTHER|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
219144883|NCT02076958|BEHAVIORAL|Community Health Advisor education|
219230882|NCT02082990|BEHAVIORAL|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
219144884|NCT03416842|DEVICE|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
219144885|NCT04800302|PROCEDURE|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
219144886|NCT04800302|PROCEDURE|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
219144887|NCT04800302|PROCEDURE|Intra-venous Morphine|Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
219144888|NCT05758727|OTHER|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
219144889|NCT03531853|DEVICE|hand-held swept source optical coherence tomography|images the eye
219144890|NCT03949686|DRUG|Saline Solution|0.5 ml/kg saline
219230883|NCT05103891|DRUG|Binimetinib Oral Tablet|two-period, crossover study
219230884|NCT03360617|DEVICE|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
219230885|NCT03360617|DEVICE|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
219144891|NCT03949686|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
219230886|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
219230887|NCT06169566|DIETARY_SUPPLEMENT|synbiotics|synbiotics
219230888|NCT06169566|COMBINATION_PRODUCT|placebo|placebo
219553092|NCT00056433|DRUG|Sildenafil|
219553093|NCT01085981|DRUG|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
219553094|NCT01085981|DRUG|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
219144892|NCT03034915|DRUG|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
219144893|NCT03034915|DRUG|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
219144894|NCT03034915|DRUG|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
219144895|NCT03034915|DRUG|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
219144896|NCT03034915|DRUG|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
219144897|NCT05890521|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
219144898|NCT05493462|DRUG|Human FGF-1|Intranasal administration of human FGF-1
219144899|NCT04255888|PROCEDURE|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
219144900|NCT04255888|PROCEDURE|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
219144901|NCT04986683|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
219144902|NCT04986683|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
219144903|NCT06117683|DEVICE|ADULT Sotair Device|Sotair® device employs a flow limiting and pressure control valve mechanism.
219144904|NCT00447733|BEHAVIORAL|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
219144905|NCT00447733|BEHAVIORAL|Treatment as usual|Non-standardized psychiatric outpatient treatment
219144906|NCT00629941|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
219144907|NCT02138006|DRUG|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
219144908|NCT02138006|DRUG|Standard insulin treatment|Insulin Mixtard
219144909|NCT05935319|OTHER|Vivifrail|Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
219144910|NCT03624140|DEVICE|blood measurement|Hemoglobin measurement
219144911|NCT03624140|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
219144912|NCT03624140|DEVICE|hemoCue|non invasive method of hemoglobin measurement
219144913|NCT00162331|DRUG|Technetium Tc99m Sestamibi|
219144914|NCT00243256|DRUG|Cholecalciferol|
219144915|NCT03861767|DRUG|Metformin ER|tablet
219144916|NCT03861767|DRUG|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
219144917|NCT04893980|DRUG|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
219144918|NCT04893980|DRUG|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
219144919|NCT01436838|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
219553095|NCT01085981|DRUG|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
219553096|NCT00874549|BIOLOGICAL|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
219553097|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219553098|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
219553099|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219553100|NCT02898740|BEHAVIORAL|Structural exercise|Exercise instruction and encouragement
219553101|NCT02898740|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
219553102|NCT01415596|DRUG|salbutamol|
219553103|NCT01415596|DRUG|Placebo|
219719085|NCT02112591|PROCEDURE|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
219230889|NCT04778813|DRUG|Artemether-lumefantrine|In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
219230890|NCT02748200|RADIATION|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
219230891|NCT06200090|OTHER|No intervention|No intervention
219230892|NCT04082598|DRUG|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
219230893|NCT04082598|DIETARY_SUPPLEMENT|Bifidobacterium longum and Lactoferrin|
219144920|NCT06400394|DEVICE|Hydrocyn Aqua®|The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure
219144921|NCT06400394|DEVICE|Normal Saline|aqueous solution of electrolytes and other hydrophilic molecules
219144922|NCT01087762|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
219230894|NCT01535898|OTHER|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
219230895|NCT00644306|DRUG|Thalidomide|100 mg/day continuously for 18 months
219230896|NCT00644306|DRUG|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
219230897|NCT00644306|DRUG|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
219230898|NCT04865718|DIAGNOSTIC_TEST|ICGA imaging|subjects undergoing intraoperative ICGA imaging
219230899|NCT06510959|OTHER|Digital course|The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
219230900|NCT03451461|OTHER|No intervention|Observational study. Clinical data recorded
219230901|NCT01596686|DRUG|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
219230902|NCT01337752|DRUG|BHQ880|
219230903|NCT01337752|DRUG|BHQ880 Placebo|Intravenous infusion
219230904|NCT01337752|DRUG|bortezomib|intravenous injection
219230905|NCT01337752|DRUG|dexamethasone|Oral
219230906|NCT03014791|OTHER|Brief lifestyle/medical history questionnaire|Core Measurement
219230907|NCT03014791|OTHER|Anthropometric measures|Core Measurement
219230908|NCT03014791|OTHER|Blood pressure and arterial stiffness|Core Measurement
219230909|NCT03014791|OTHER|Cardiac output and lung function|Core Measurement
219719086|NCT02112591|PROCEDURE|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
219719087|NCT00205166|PROCEDURE|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
219144923|NCT01087762|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
219144924|NCT01087762|OTHER|Placebo|Matching Placebo to CZP injection.
219144925|NCT00813904|BIOLOGICAL|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
219144926|NCT01829386|OTHER|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
219144927|NCT01188499|DRUG|Birinapant|
219230910|NCT03014791|OTHER|Heart rate variability|Core Measurement
219230911|NCT03014791|OTHER|Blood sample & spot urine sample|Core Measurement
219230912|NCT03014791|OTHER|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
219230913|NCT03014791|OTHER|24 hour urine collection|Detailed Measurement (Optional for participants).
219230914|NCT03014791|OTHER|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
219230915|NCT03014791|OTHER|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
219230916|NCT03014791|OTHER|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
219230917|NCT03014791|OTHER|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
219230918|NCT03014791|OTHER|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
219230919|NCT03014791|OTHER|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
219230920|NCT03014791|OTHER|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
219230921|NCT03014791|OTHER|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
219230922|NCT03014791|OTHER|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
219719088|NCT00205166|DRUG|Caffeine|Caffeine 400 mg po
219719089|NCT00205166|DRUG|Caffeine|Caffeine 200 mg po
219144928|NCT00971711|BIOLOGICAL|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
219144929|NCT06554262|OTHER|No intervention|No intervention was involved in this study
219144930|NCT05302713|DIETARY_SUPPLEMENT|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
219144931|NCT05302713|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
219230923|NCT03014791|OTHER|Small artery dilatory function: Forearm blood flow|Detailed Measurement (Optional for participants).
219230924|NCT03111368|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
219230925|NCT01247077|OTHER|selenium|200 ug selenium once daily
219230926|NCT01247077|OTHER|placebo|
219230927|NCT03004989|BEHAVIORAL|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
219230928|NCT00308308|DRUG|Technosphere Insulin|Inhalation, 15U/30U
219230929|NCT00308308|DRUG|Active comparator|sc injectable insulin
219230930|NCT04009772|DRUG|Cefepime|Antibiotic prophylaxis
219230931|NCT04009772|DRUG|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
219230932|NCT00120549|PROCEDURE|Assisted embryo hatching|
219230933|NCT03090698|DRUG|Hylan G-F 20|intra-articular administration
219144932|NCT00424762|DRUG|rosiglitazone|6 months of treatment of blinded study drug
219144933|NCT00424762|DRUG|placebo|blinded treatment with matching placebo
219144934|NCT02311972|DEVICE|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
219144935|NCT02311972|DEVICE|Standard of care feeding tube|
219144936|NCT02054455|DIETARY_SUPPLEMENT|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
219144937|NCT02054455|DIETARY_SUPPLEMENT|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
219144938|NCT02087644|BIOLOGICAL|CYT003|Injections
219144939|NCT02087644|BIOLOGICAL|Placebo|Injections
219144940|NCT06184308|BEHAVIORAL|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
219144941|NCT06184308|BEHAVIORAL|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
219144942|NCT04686942|DIAGNOSTIC_TEST|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
219144943|NCT01596946|BEHAVIORAL|Contact tracing mode test at clinic|
219144944|NCT01596946|BEHAVIORAL|Self-sampling at home - Sent Test Kit|
219230934|NCT03090698|DRUG|Triamcinolone|Intra-articular administration
219230935|NCT01319032|OTHER|Extraction of whole blood|Extraction of DNA from whole blood
219230936|NCT05659394|OTHER|Standard Wound Care Alone|gold standard compression therapy
219230937|NCT05659394|DEVICE|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
219230938|NCT04784988|DRUG|EHL-FVIII|prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
219144945|NCT02847312|OTHER|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
219144946|NCT02847312|OTHER|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
219144947|NCT02847312|OTHER|Control|Control are matched with energy and insoluable fibre.
219144948|NCT00877422|DIETARY_SUPPLEMENT|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
219144949|NCT02655380|DRUG|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
219144950|NCT02655380|DRUG|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
219230939|NCT04784988|DRUG|FVIII concentrate|standard prophylaxis with FVIII concentrate according to current guidelines
219230940|NCT05093894|DEVICE|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
219230941|NCT00332852|DRUG|Letrozole|2.5 mg/day - oraly
219230942|NCT01095848|BIOLOGICAL|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
219230943|NCT01802333|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
219230944|NCT01802333|DRUG|Cytarabine|Given IV
219230945|NCT01802333|DRUG|Daunorubicin Hydrochloride|Given IV
219230946|NCT01802333|DRUG|Idarubicin|Given IV
219230947|NCT01802333|OTHER|Laboratory Biomarker Analysis|Correlative studies
219230948|NCT01802333|DRUG|Vorinostat|Given PO
219230949|NCT03709797|PROCEDURE|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
219230950|NCT01755559|DRUG|Artesunate-amodiaquine|antimalarial ACT
219230951|NCT01755559|DRUG|Dihydroartemisinin-piperaquine|antimalarial ACT
219230952|NCT01755559|DRUG|Artemether-lumefantrine|antimalarial ACT
219230953|NCT00861874|DRUG|Decitabine|20 mg/m2 IV, Days 1-5
219719090|NCT05224323|OTHER|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
219553104|NCT06175741|PROCEDURE|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
219553105|NCT02383706|DEVICE|ApneaLink Air|Overnight, home polysomnography device
219144951|NCT02655380|DRUG|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
219144952|NCT02272959|BEHAVIORAL|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
219144953|NCT02272959|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
219144954|NCT04148417|DEVICE|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
219144955|NCT03308461|DRUG|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
219144956|NCT03692117|DEVICE|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
219144957|NCT01122901|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
219144958|NCT01122901|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219144959|NCT01122901|OTHER|pharmacological study|Correlative studies
219144960|NCT01122901|OTHER|laboratory biomarker analysis|Correlative studies
219144961|NCT03197337|PROCEDURE|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
219144962|NCT02488252|DRUG|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
219144963|NCT02488252|DRUG|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
219144964|NCT03030248|DRUG|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
219230954|NCT00861874|DRUG|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
219719091|NCT02246894|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
219719092|NCT05735470|DEVICE|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
219144965|NCT03030248|DRUG|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
219230955|NCT01947491|DRUG|DFD01 Spray|
219719093|NCT04229901|DRUG|HepaStem|HepaStem will be administered as an intravenous (IV) infusion
219719094|NCT04229901|DRUG|Placebo|Placebo will be administered as an intravenous (IV) infusion
219719095|NCT01706627|DRUG|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
219230956|NCT01947491|DRUG|Comp01 Lotion|
219553106|NCT02383706|BEHAVIORAL|Berlin Quesionnaire|OSA screening questionnaire
219553107|NCT02383706|BEHAVIORAL|Epworth Sleepiness Scale|OSA screening questionnaire
219553108|NCT02383706|BEHAVIORAL|STOP-BANG questionnaire|OSA screening questionnaire
219553109|NCT02383706|OTHER|Physical exam|Physical exam of neck, mouth and upper airway
219719096|NCT01706627|DRUG|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
219230957|NCT01947491|DRUG|Vehicle Lotion|
219230958|NCT01947491|DRUG|Vehicle Spray|
219230959|NCT02488798|PROCEDURE|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
219230960|NCT02488798|PROCEDURE|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
219553110|NCT02036749|PROCEDURE|nerve block|quadratus lumborum block
219553111|NCT05981716|OTHER|No intervention|This is an observational study. There is no intervention.
219553112|NCT00432705|PROCEDURE|Checking stability of ankle|Flexing and walking
219230961|NCT02488798|PROCEDURE|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
219230962|NCT04598646|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
219230963|NCT04598646|BEHAVIORAL|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
219230964|NCT00606788|DEVICE|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
219230965|NCT00606788|PROCEDURE|Conventional weaning|Patients received physician-directed non-protocolized weaning
219230966|NCT03879265|DIAGNOSTIC_TEST|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
219230967|NCT05158426|DRUG|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
219230968|NCT02067663|DEVICE|Paragard|The IUD will be placed as part of standard clinical care.
219230969|NCT02067663|DRUG|Mirena|The IUD will be placed as part of standard clinical care.
219230970|NCT04103164|DEVICE|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
219719097|NCT01706627|DRUG|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
219719098|NCT02747160|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
219144966|NCT04333758|DEVICE|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
219144967|NCT00188461|DEVICE|CT Thorax|
219144968|NCT00002472|DRUG|cisplatin|
219144969|NCT00002472|DRUG|etoposide|
219144970|NCT00002472|PROCEDURE|conventional surgery|
219144971|NCT00002472|PROCEDURE|neoadjuvant therapy|
219144972|NCT00002472|RADIATION|radiation therapy|
219144973|NCT01564199|DRUG|salmeterol / fluticasone propionate|100/1000 μg oral capsule
219144974|NCT02458911|DEVICE|Paclitaxel-eluting balloon|
219144975|NCT05023512|BEHAVIORAL|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
219144976|NCT01842724|PROCEDURE|Motec total wrist arthroplasty|
219144977|NCT01842724|PROCEDURE|Remotion total wrist arthroplasty|
219144978|NCT05987969|OTHER|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
219144979|NCT01807663|DEVICE|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
219144980|NCT01807663|DEVICE|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
219230971|NCT04130932|OTHER|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
219230972|NCT01154504|OTHER|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
219230973|NCT01154504|PROCEDURE|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
219230974|NCT01154504|PROCEDURE|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
219230975|NCT03124472|PROCEDURE|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
219230976|NCT03124472|PROCEDURE|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~\- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers"
219230977|NCT00163358|DRUG|Ciclesonide|
219230978|NCT05814809|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet
219719099|NCT02038426|BIOLOGICAL|BLOOD SAMPLES|
219144981|NCT02537769|DEVICE|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
219144982|NCT02537769|PROCEDURE|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
219144983|NCT05247749|DEVICE|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
219144984|NCT02968472|GENETIC|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
219144985|NCT02678091|DEVICE|Ultrasound exam with Doppler|Ultrasound exam of the orbit
219144986|NCT05168553|OTHER|Revascualrization|Regain pulp vascularity for mature permenant teeth
219144987|NCT05168553|OTHER|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
219144988|NCT04891458|DRUG|Patients received lighter sedation with propofol after spinal anesthesia.|MOAA/S 0-2.
219144989|NCT04891458|DRUG|Patients received heavier sedation with propofol after spinal anesthesia|MOAA/S 3-5.
219144990|NCT04891458|DRUG|Patients received lighter sedation with dexmedetomidine after spinal anesthesia|MOAA/S 0-2.
219144991|NCT04891458|DRUG|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|MOAA/S 3-5.
219144992|NCT05646745|PROCEDURE|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
219144993|NCT03504072|DRUG|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
219144994|NCT03504072|DRUG|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
219719100|NCT02038426|DEVICE|Radiographs of the sacroiliac joints|
219719101|NCT02038426|DEVICE|Radiographs of heels|
219719102|NCT02038426|DEVICE|SCAN|
219719103|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (New website)|Complete the new website smoking cessation program
219719104|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (Standard of care website)|Complete the standard of care website smoking cessation intervention
219719105|NCT04502524|BEHAVIORAL|Health Education|Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
219144995|NCT02952768|BEHAVIORAL|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
219144996|NCT04563559|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
219144997|NCT04563559|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
219144998|NCT00232635|DRUG|A-60444|
219144999|NCT02916836|OTHER|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
219145000|NCT02916836|OTHER|No Use of therapeutic drug conciliation sheet (TDC)|
219145001|NCT02230358|PROCEDURE|Regional anesthesia|Regional anesthesia
219145002|NCT02230358|PROCEDURE|General anesthesia|General anesthesia
219719106|NCT04502524|OTHER|Health Promotion and Education|Receive motivational and reminder text messages
219719107|NCT04502524|OTHER|Questionnaire Administration|Ancillary studies
219719108|NCT02060162|OTHER|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
219145003|NCT02230358|DEVICE|Transcranial Doppler ultrasonography|6x for 4 hours
219145004|NCT02230358|PROCEDURE|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
219145005|NCT02230358|PROCEDURE|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
219145006|NCT02230358|PROCEDURE|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
219145007|NCT02230358|BEHAVIORAL|Neurological Control|perioperative, 2-3 days, as done in clinical routine
219145008|NCT02230358|BEHAVIORAL|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
219145009|NCT02230358|DEVICE|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
219145010|NCT05998525|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months
219145011|NCT05998525|DRUG|Placebo|patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
219145012|NCT00031512|OTHER|Placebo|Placebo.
219145013|NCT00031512|DRUG|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
219719109|NCT01523197|DEVICE|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
219145014|NCT04738903|PROCEDURE|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
219145015|NCT03557658|DRUG|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
219145016|NCT02361437|DIETARY_SUPPLEMENT|Vasculera|Vasculera 630 mg b.i.d.
219230979|NCT05814809|DRUG|JP-1366 20mg capsule|R : JP-1366 20mg capsule
219230980|NCT05999448|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
219145017|NCT05261568|BEHAVIORAL|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
219145018|NCT04267744|OTHER|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
219145019|NCT01147341|DRUG|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
219145020|NCT01147341|DRUG|Placebo|prefilled saline syringe
219145021|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
219145022|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
219145023|NCT04164680|DIAGNOSTIC_TEST|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
219145024|NCT04771234|BEHAVIORAL|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
219145025|NCT00398606|DRUG|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
219145026|NCT00398606|DRUG|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
219145027|NCT05676736|OTHER|No intervention|No intervention to be done for the group
219145028|NCT06269822|DIAGNOSTIC_TEST|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
219145029|NCT03694288|PROCEDURE|Implant removal|Surgical Implant removal
219145030|NCT03126812|DRUG|Carboplatin|Carboplatin AUC=6
219145031|NCT03126812|DRUG|Paclitaxel|paclitaxel 80 mg/m2
219145032|NCT03126812|DRUG|Pembrolizumab|200 mg flat dose, starting cycle 2
219145033|NCT00958386|DRUG|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
219145034|NCT03769233|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
219145035|NCT04832542|OTHER|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
219230981|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual|CICBT-Individual will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
219553113|NCT03887598|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
219553114|NCT01388998|OTHER|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
219553115|NCT03857724|PROCEDURE|prolapse surgery|prolapse surgery
219553116|NCT02413034|DRUG|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
219553117|NCT02413034|OTHER|Control group|no antibiotic prophylaxis
219553118|NCT06677736|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
219553119|NCT06677736|RADIATION|Diode laser as adjunctive to conventional scaling and debridement|Diode laser as adjunctive to conventional scaling and debridement
219553120|NCT02370836|OTHER|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
219553121|NCT01812629|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
219553122|NCT04922294|OTHER|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
219553123|NCT00859040|DRUG|SOM230C|Injection in the buttocks every 28 days
219553124|NCT03264716|DEVICE|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
219553125|NCT04212819|OTHER|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
219145036|NCT04696341|PROCEDURE|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
219230982|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Group|CICBT-Group will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
219145037|NCT04696341|PROCEDURE|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
219145038|NCT04707417|OTHER|Home care|Advanced home care
219145039|NCT03709719|DRUG|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
219145040|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
219145041|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
219145042|NCT03478696|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
219145043|NCT03478696|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
219145044|NCT03478696|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
219145045|NCT03478696|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
219145046|NCT03478696|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
219145047|NCT03478696|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
219553126|NCT04212819|OTHER|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
219145048|NCT03478696|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
219145049|NCT03478696|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
219145050|NCT03478696|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
219145051|NCT03478696|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
219145052|NCT03615924|DRUG|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
219145053|NCT03615924|DRUG|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
219145054|NCT03782350|DRUG|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
219230983|NCT05999448|BEHAVIORAL|Dialectical Behavioral Therapy (DBT)|DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
219553127|NCT02279784|DEVICE|Freeway PTA|angioplasty with Freeway drug-eluting balloon
219553128|NCT02279784|DEVICE|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
219145055|NCT03782350|DRUG|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
219145056|NCT00783354|DRUG|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
219230984|NCT05999448|BEHAVIORAL|Durand Sleep Intervention|Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
219230985|NCT05999448|BEHAVIORAL|RUBI Intervention|RUBI will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
219230986|NCT05999448|BEHAVIORAL|Naturalistic Communication Intervention (NCI)|NCI will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
219230987|NCT05999448|BEHAVIORAL|Self-Guided Resources|Participants will be provided a self-guided resource notebook that includes 12 weeks of content that parallels the topics examined in other support programs (child behavior management, child sleep, child communication, caregiver mental health, caregiver health behaviors, community connection)
219553129|NCT05546242|DRUG|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
219553130|NCT05546242|DRUG|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
219553131|NCT03008941|BIOLOGICAL|FMT|Capsules with fecal microbiota from healthy donors
219553132|NCT03008941|OTHER|Placebo|Placebo capsules
219719110|NCT01600859|DRUG|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
219719111|NCT01600859|DRUG|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
219719112|NCT06196359|PROCEDURE|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
219719113|NCT06473818|DEVICE|Non-invasive monitoring|Non-invasive cardiac output monitoring
219145057|NCT00783354|DRUG|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
219145058|NCT01685788|OTHER|No intervention|
219145059|NCT01305291|OTHER|placebo|
219145060|NCT01305291|DIETARY_SUPPLEMENT|digestion-resistant maltodextrin|
219145061|NCT05103748|BEHAVIORAL|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
219145062|NCT05103748|BEHAVIORAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
219145063|NCT02794350|DEVICE|Cochlear implant|
219145064|NCT02828254|DRUG|PRI-724|
219145065|NCT03580798|PROCEDURE|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
219145066|NCT03580798|PROCEDURE|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
219145067|NCT05076318|OTHER|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
219145068|NCT05790928|DEVICE|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
219145069|NCT03958500|PROCEDURE|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
219145070|NCT01568918|DRUG|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
219145071|NCT01568918|OTHER|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
219145072|NCT01285830|DIETARY_SUPPLEMENT|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
219145073|NCT01285830|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
219145074|NCT01198340|PROCEDURE|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
219145075|NCT01198340|PROCEDURE|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
219145076|NCT00877513|BEHAVIORAL|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
219145077|NCT02639013|PROCEDURE|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
219145078|NCT04301986|DEVICE|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
219230988|NCT05999448|BEHAVIORAL|Participation Enhancement Intervention (PEI)|"A standardized PEI intervention will be conducted by trained peer coaches who are also rare disorder caregivers. Each peer coach will work with their clients to complete a Change Plan Worksheet and will complete two booster sessions at midpoint and end of treatment. Coaches will also meet with their clients after follow-up data are complete to support connection back to community resources and patient-specific rare disorder communities."
219719114|NCT06473818|DEVICE|Invasive monitoring|Invasive cardiac output monitoring
219719115|NCT00832806|BEHAVIORAL|Extended IVR (integrated voice response technology)|See detailed description
219719116|NCT00832806|DRUG|Varenicline (Champix)|See detailed description
219719117|NCT00832806|BEHAVIORAL|IVR treatment|See detailed description
219719118|NCT02800252|DRUG|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
219719119|NCT02800252|DRUG|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
219145079|NCT04301986|DEVICE|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
219145080|NCT04301986|DEVICE|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
219145081|NCT01679951|DRUG|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
219145082|NCT01679951|DRUG|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
219145083|NCT01679951|DRUG|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
219145084|NCT01679951|DRUG|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
219145085|NCT01679951|DRUG|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
219145086|NCT01799148|OTHER|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
219145087|NCT00306449|BEHAVIORAL|Small group seminar-based educational intervention|
219145088|NCT03522467|DRUG|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
219145089|NCT06111937|OTHER|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
219145090|NCT03432780|DRUG|Docetaxel|
219145091|NCT03432780|BIOLOGICAL|Hormone and radiation therapy|
219145092|NCT03432780|RADIATION|Radiation therapy|
219145093|NCT04481373|BEHAVIORAL|THRIVE|"The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes."
219719120|NCT02800252|DRUG|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
219719121|NCT02896023|DRUG|human menopausal gonadotropin|Induction of ovulation followed by ICSI
219719122|NCT03947723|DEVICE|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
219719123|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|Anthocyans
219719124|NCT00634387|OTHER|placebo|
219719125|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|
219719126|NCT01586182|RADIATION|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
219719127|NCT04185727|OTHER|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
219719128|NCT02151201|BEHAVIORAL|Influenza vaccination video education|Influenza vaccination video education
219719129|NCT02151201|BEHAVIORAL|Hand washing video education|Hand washing video education
219719130|NCT04700605|BEHAVIORAL|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
219145094|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
219145095|NCT00480519|PROCEDURE|Meatotomy|
219145096|NCT04048018|DIAGNOSTIC_TEST|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
219145097|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
219719131|NCT03804307|RADIATION|standard treatment|3000 cGy in 10 daily fractions
219719132|NCT03804307|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
219719133|NCT02703025|DIETARY_SUPPLEMENT|GCB-70|green coffee bean extract
219719134|NCT02632214|OTHER|fMRI measure|
219145098|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
219145099|NCT04045106|OTHER|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
219145100|NCT04735341|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
219145101|NCT06233591|DRUG|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
219145102|NCT03368937|DEVICE|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
219145103|NCT02485444|DRUG|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
219719135|NCT06956547|DRUG|nogapendekin-alfa inbakicept|1.0mg nogapendekin-alfa inbakicept (NAI) administered by subcutaneous injection no less than every 3 weeks and no more frequently than every 2 weeks between doses in combination with the standard of care schedule of chemotherapy, immunotherapy, and/or radiation therapy. Patients who are known HIV+ will be dosed with NAI at 0.5 mg
219719136|NCT06831565|DIAGNOSTIC_TEST|ROTEM|ROTEM Tests
219145104|NCT03411239|DEVICE|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
219145105|NCT01681251|OTHER|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
219145106|NCT01681251|OTHER|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
219145107|NCT01018836|DRUG|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
219145108|NCT01018836|RADIATION|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
219145109|NCT06212167|BEHAVIORAL|Nursing Interventions for Stroke Patient Care|In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
219719137|NCT01756703|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
219145110|NCT03686891|OTHER|Skin prick tests with four native legumes|Skin prick tests with four native legumes
219145111|NCT04893213|OTHER|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
219145112|NCT02462551|DEVICE|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
219553133|NCT06579417|DIAGNOSTIC_TEST|RSI MRI|In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.
219553134|NCT05592483|OTHER|None (Observational Study)|Not Applicable since observational study
219145113|NCT01269736|BEHAVIORAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
219553135|NCT01712568|DRUG|Test Product (Ropinirole)|"one Tablet at 0 hour"
219553136|NCT01712568|DRUG|Reference Product (REQUIP )|"one Tablet at 0 hour"
219719138|NCT01756703|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
219719139|NCT01756703|DRUG|Placebo|Placebo for 8 weeks
219230989|NCT03137784|DRUG|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
219230990|NCT03137784|DRUG|Placebo|In each treatment arm, patient will receive placebo
219719140|NCT04858711|DRUG|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
219719141|NCT04858711|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
219719142|NCT03053011|OTHER|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
219719143|NCT03791372|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
219145114|NCT01229358|OTHER|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
219145115|NCT05566080|PROCEDURE|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
219145116|NCT03178110|BEHAVIORAL|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
219145117|NCT04820439|DRUG|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
219145118|NCT04820439|DRUG|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
219145119|NCT05942963|DRUG|Empagliflozin 10 MG|10-25 mg/day
219145120|NCT05942963|DRUG|Pioglitazone 15mg|15-45 mg/day
219145121|NCT05942963|DRUG|Metformin|1000mg-2850mg/ day
219145122|NCT02808338|DEVICE|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
219145123|NCT02808338|DEVICE|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
219145124|NCT02808338|DEVICE|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
219145125|NCT02808338|DEVICE|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
219145126|NCT00903266|BEHAVIORAL|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
219145127|NCT00903266|BEHAVIORAL|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
219553137|NCT06031337|DIAGNOSTIC_TEST|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
219553138|NCT04386213|DEVICE|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
219553139|NCT05799235|DEVICE|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
219553140|NCT05799235|OTHER|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
219553141|NCT02310841|DEVICE|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
219553142|NCT04566549|COMBINATION_PRODUCT|Test group Probiotic Shampoo|Probiotic Shampoo
219553143|NCT04566549|COMBINATION_PRODUCT|Placebo group|Shampoo base
219553144|NCT00970788|BEHAVIORAL|Video intervention|Video of goals of care
219553145|NCT02591849|DIETARY_SUPPLEMENT|Glucagon-like peptide-1 (GLP-1)|
219553146|NCT02591849|OTHER|Isotonic saline|
219145128|NCT00969371|DEVICE|posterior chamber IOL implantation|
219145129|NCT00969371|DEVICE|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
219145130|NCT00057837|BIOLOGICAL|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.
219145131|NCT00057837|DRUG|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
219553147|NCT02591849|OTHER|Hyperglycemic clamp|
219553148|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
219553149|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
219719144|NCT03791372|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
219719145|NCT02472093|OTHER|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
219145132|NCT00057837|DRUG|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
219145133|NCT00057837|DRUG|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
219145134|NCT00057837|DRUG|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
219145135|NCT02537522|DEVICE|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
219145136|NCT02537522|DEVICE|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
219145137|NCT01379014|BEHAVIORAL|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
219145138|NCT01379014|OTHER|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
219145139|NCT01382342|DRUG|Rasagiline|1 mg daily
219719146|NCT02472093|OTHER|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
219719147|NCT02472093|OTHER|Control group|The control group did brief educational sessions.
219719148|NCT01666652|BIOLOGICAL|4 µg TDENV-PIV with Alum adjuvant|
219719149|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS03B1 adjuvant|
219719150|NCT01666652|OTHER|Phosphate buffered saline|
219719151|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
219719152|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS01E1 adjuvant|
219719153|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Dalap Duo®|
219719154|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Epiduo®|
219719155|NCT01018979|DRUG|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
219145140|NCT01382342|DRUG|Placebo|1 mg daily
219145141|NCT04393246|DRUG|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
219230991|NCT00410748|DRUG|OROS hydromorphone HCI CR|
219553150|NCT05385900|DRUG|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
219553151|NCT05766956|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
219553152|NCT05766956|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
219553153|NCT03538795|COMBINATION_PRODUCT|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
219553154|NCT02753465|PROCEDURE|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
219553155|NCT02753465|PROCEDURE|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
219553156|NCT01112891|DRUG|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
219553157|NCT01112891|DRUG|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
219553158|NCT01112891|DRUG|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
219553159|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
219553160|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
219719156|NCT01018979|DRUG|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
219719157|NCT04841265|DIETARY_SUPPLEMENT|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
219719158|NCT00113139|BEHAVIORAL|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
219719159|NCT00113139|OTHER|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
219719160|NCT04770974|OTHER|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
219719161|NCT02909426|DEVICE|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
219145142|NCT04393246|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
219145143|NCT04393246|DRUG|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
219145144|NCT04393246|OTHER|Standard of care|Regular standard of care for COVID-19 patients
219145145|NCT00192491|BIOLOGICAL|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
219145146|NCT00192491|BIOLOGICAL|FluMist|Nasal sprayer of FluMist
219145147|NCT00192491|OTHER|Placebo|Nasal Sprayer of Placebo
219145148|NCT02655835|BEHAVIORAL|Internet Mindfulness Meditation|
219145149|NCT02655835|BEHAVIORAL|Access|
219230992|NCT05578807|PROCEDURE|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
219230993|NCT01157195|BEHAVIORAL|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
219230994|NCT01157195|BEHAVIORAL|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
219230995|NCT04210830|DIAGNOSTIC_TEST|Quantra-Device|Point of Care Coagulation Monitoring System
219553161|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
219553162|NCT02697617|DRUG|Pioglitazone|Pioglitazone
219553163|NCT02697617|DRUG|Placebo|Placebo
219553164|NCT03865225|OTHER|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
219553165|NCT03865225|OTHER|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
219553166|NCT04580186|PROCEDURE|bladder exstrophy repair|primary complete bladder exstrophy repair
219553167|NCT01058122|PROCEDURE|Collection of adverse drug events|
219553168|NCT02460835|RADIATION|Adaptive Radiation Therapy|
219553169|NCT06535763|OTHER|professional caregiver|"Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist."
219553170|NCT06222658|DEVICE|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
219553171|NCT03141216|DEVICE|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
219553172|NCT03141216|DEVICE|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
219553173|NCT01157234|DRUG|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.
219553174|NCT01157234|DRUG|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
219553175|NCT02531490|DRUG|Labetalol|
219553176|NCT02531490|DRUG|Nifedipine|
219553177|NCT02531490|DRUG|Methyldopa|
219553178|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
219553179|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
219553180|NCT00999284|DRUG|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
219553181|NCT02212106|BIOLOGICAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
219553182|NCT02212106|BIOLOGICAL|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
219719162|NCT02909426|DEVICE|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
219553183|NCT04924699|DRUG|MRG002|Administrated intravenously
219553184|NCT04924699|DRUG|Trastuzumab Emtansine for Injection|Administrated intravenously
219553185|NCT05544656|DRUG|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
219553186|NCT05544656|DRUG|Placebo|matching placebo administered three times a day
219553187|NCT06113913|DRUG|Infliximab|Weekly administration of subcutaneous infliximab.
219553188|NCT06113913|DRUG|Infliximab|Bi-weekly administration of subcutaneous infliximab.
219553189|NCT06113913|DRUG|Infliximab|Optimized dosing schedule of intravenous infliximab.
219553190|NCT01151449|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
219553191|NCT01151449|OTHER|laboratory biomarker analysis|Correlative studies
219553192|NCT01027767|DEVICE|Molecular Breast Imaging|Molecular Breast Imaging
219553193|NCT03304782|OTHER|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
219145150|NCT02995096|PROCEDURE|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
219145151|NCT02995096|DRUG|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
219145152|NCT02337569|DRUG|NPC-02|
219145153|NCT02337569|DRUG|Placebos|
219145154|NCT00952263|BIOLOGICAL|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
219145155|NCT00588809|DRUG|selumetinib|Given PO
219145156|NCT00106054|DRUG|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
219145157|NCT03328715|DEVICE|intraoperative OCT|before and after surgery intraoperative OCT is performed
219145158|NCT03328715|DEVICE|stand-alone OCT|before and after surgery stand-alone OCT is performed
219145159|NCT01444235|DRUG|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
219145160|NCT01444235|DRUG|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
219230996|NCT02265107|OTHER|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
219230997|NCT01869465|OTHER|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
219230998|NCT01869465|BEHAVIORAL|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
219230999|NCT00714207|BEHAVIORAL|NOT program|Students in this arm of the study received the reformatted NOT intervention
219719163|NCT04790383|OTHER|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
219719164|NCT04790383|OTHER|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
219719165|NCT04093999|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
219719166|NCT03570424|DIETARY_SUPPLEMENT|Nutrient support to HIIT|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
219145161|NCT04034745|DRUG|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
219145162|NCT01435395|DRUG|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
219145163|NCT02129049|OTHER|educational intervention|Participate in the Enhancing Connections Telephone Program
219145164|NCT02129049|BEHAVIORAL|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
219145165|NCT02129049|OTHER|questionnaire administration|Ancillary studies
219145166|NCT03408925|OTHER|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
219145167|NCT05116839|DEVICE|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
219145168|NCT05116839|DEVICE|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
219145169|NCT05116839|DEVICE|i gel air way|supraglottic air way device
219145170|NCT05733936|OTHER|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
219145171|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
219145172|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
219231000|NCT00714207|BEHAVIORAL|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
219231001|NCT00714207|BEHAVIORAL|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
219145173|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
219145174|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
219231002|NCT00714207|BEHAVIORAL|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
219231003|NCT02832128|DRUG|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
219231004|NCT02832128|DRUG|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
219231005|NCT01020266|PROCEDURE|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
219231006|NCT01020266|PROCEDURE|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
219553194|NCT04918992|DIAGNOSTIC_TEST|Artificial Intelligence|investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy
219553195|NCT01324544|DRUG|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
219553196|NCT00517192|DRUG|Tipranavir|
219553197|NCT00517192|DRUG|Darunavir|
219553198|NCT00517192|DRUG|Ritonavir|
219553199|NCT04583150|PROCEDURE|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
219553200|NCT03992651|DEVICE|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
219553201|NCT01486108|PROCEDURE|dorsal column stimulator|test different settings of stimulation
219553202|NCT06274424|BEHAVIORAL|The Friends Program|A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
219553203|NCT02318550|OTHER|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~* Normal operating mode~* SAR ≤ 2.0 W/kg per patient."
219553204|NCT05341856|DRUG|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
219553205|NCT05341856|DRUG|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
219553206|NCT06198647|PROCEDURE|Tui-na massage|Using Tui-na massage for the back muscles
219553207|NCT06198647|PROCEDURE|positional release technique|using positional release manual technique to relax the back muscles
219553208|NCT00476437|DRUG|biphasic insulin aspart|
219553209|NCT00476437|DRUG|biphasic human insulin|
219553210|NCT00804245|PROCEDURE|needle biopsy|Biopsy of positive findings found on CT scan
219553211|NCT00804245|DRUG|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
219553212|NCT00230594|DRUG|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
219553213|NCT00230594|DRUG|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
219553214|NCT05770557|BEHAVIORAL|survey|administration of a survey among healthcare workers
219553215|NCT02007668|OTHER|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
219553216|NCT02965872|OTHER|No intervention|
219145175|NCT01331863|PROCEDURE|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
219553217|NCT05190432|DIETARY_SUPPLEMENT|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
219553218|NCT05190432|DIETARY_SUPPLEMENT|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
219553219|NCT05190432|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose.
219553220|NCT05069233|OTHER|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
219553221|NCT02733627|DRUG|BI 1467335|
219553222|NCT02733627|DRUG|Placebo|
219553223|NCT00183196|DRUG|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
219553224|NCT00183196|DRUG|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
219553225|NCT00183196|OTHER|Inactive Placebo|Placebo
219553226|NCT06548243|BEHAVIORAL|Act with Nature Programme|The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
219145176|NCT00346684|DRUG|Rituximab|
219145177|NCT03630939|DRUG|ESR-114|ESR-114 Topical Gel
219145178|NCT03630939|OTHER|Placebo|Placebo Topical Gel
219145179|NCT05132348|DIAGNOSTIC_TEST|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
219145180|NCT02878772|DRUG|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
219145181|NCT02878772|DRUG|Aspirin|100mg, once daily, oral medication
219145182|NCT00281008|DRUG|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219145183|NCT00281008|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219145184|NCT00281008|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219145185|NCT00281008|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
219145186|NCT00957411|BIOLOGICAL|cetuximab|Given IV
219145187|NCT00957411|DRUG|cisplatin|Given IV
219145188|NCT05319288|DEVICE|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
219145189|NCT04425408|DEVICE|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
219145190|NCT05709431|OTHER|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
219145191|NCT01059877|DEVICE|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
219145192|NCT01059877|DEVICE|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
219145193|NCT05142202|RADIATION|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
219145194|NCT05858073|OTHER|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
219145195|NCT05858073|OTHER|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
219145196|NCT02903615|OTHER|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
219145197|NCT02903615|OTHER|Standard diet|Standard diabetes diet recommendations
219145198|NCT06103630|OTHER|Oropharyngeal Exercises|Oropharyngeal Exercises
219719167|NCT03570424|DIETARY_SUPPLEMENT|Placebo|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
219145199|NCT06103630|OTHER|Mandibular advancement device|Mandibular advancement device
219145200|NCT00502424|DEVICE|Splint|
219145201|NCT04949035|DIAGNOSTIC_TEST|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
219145202|NCT00695071|DRUG|Itraconazole|Oral
219145203|NCT00448721|DRUG|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
219145204|NCT00656721|DEVICE|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
219719168|NCT02287519|BEHAVIORAL|Group Session|
219719169|NCT02287519|BEHAVIORAL|Telephone Coaching Session|
219719170|NCT02287519|BEHAVIORAL|Webinar|
219719171|NCT02317549|DRUG|LB1148|
219719172|NCT02317549|DRUG|Placebo|
219719173|NCT05841576|OTHER|COMET monitoring device|Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
219145205|NCT04559659|OTHER|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
219231007|NCT05137366|DIAGNOSTIC_TEST|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~1. Suprasternal window~2. Parasternal long axis window~3. Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
219231008|NCT03443206|OTHER|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
219145206|NCT04195516|OTHER|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
219145207|NCT04444258|OTHER|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
219231009|NCT03443206|OTHER|psychoeducation|educational materials related to mental health
219231010|NCT03443206|OTHER|online resources|links to online mental health resources
219145208|NCT04444258|OTHER|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
219231011|NCT04083209|BEHAVIORAL|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
219231012|NCT03142932|DEVICE|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
219553227|NCT05910294|OTHER|questionnaires|Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast Clinical Care and Symptom Survey (BCCSS) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
219231013|NCT03142932|OTHER|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
219231014|NCT03142932|BEHAVIORAL|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
219231015|NCT01934322|OTHER|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
219231016|NCT00091728|DRUG|Depo Medroxyprogesterone acetate|
219231017|NCT00091728|DRUG|Combined oral contraceptives|
219231018|NCT03880981|DRUG|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
219231019|NCT03880981|DRUG|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
219553228|NCT05910294|OTHER|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
219553229|NCT05910294|OTHER|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
219553230|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
219553231|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
219553232|NCT06093893|DRUG|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
219553233|NCT06093893|DRUG|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
219553234|NCT06093893|DRUG|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
219553235|NCT06537869|BEHAVIORAL|iCBT for depression|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
219553236|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
219553237|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
219553238|NCT06314490|DRUG|nL-SCN2A-002|Personalized antisense oligonucleotide
219553239|NCT03957928|OTHER|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
219553240|NCT03957928|OTHER|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
219553241|NCT06743269|BEHAVIORAL|High-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 55% maximal inspiratory pressure (PIMAX) during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3-6.
219553242|NCT06743269|BEHAVIORAL|Low-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 15% maximal inspiratory pressure (PIMAX) for all 6 weeks.
219553243|NCT06743269|DEVICE|POWERbreathe K3 device|Inspiratory muscle training device
219553244|NCT06130956|DIETARY_SUPPLEMENT|Vegan diet|Vegan diet for 2 weeks before surgery
219553245|NCT06130956|DIETARY_SUPPLEMENT|Omnivorous diet|Omnivorous diet for 2 weeks before surgery
219553246|NCT05696392|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
219553247|NCT06794229|DRUG|Zanzalintinib|Zanzalintinib 100mg orally (PO) once daily for 12 weeks up (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1)
219553248|NCT06794229|DRUG|Nivolumab|Nivolumab will be administered at either 240mg IV every 2 weeks or 480mg IV 4 every weeks for 12 weeks (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1).
219553249|NCT05639036|DEVICE|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
219553250|NCT05639036|PROCEDURE|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
219553251|NCT06406725|DIAGNOSTIC_TEST|Point-of-Care Ultrasound of the Airway|Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
219553252|NCT02153203|BEHAVIORAL|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
219553253|NCT02153203|OTHER|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
219553254|NCT06624735|DIAGNOSTIC_TEST|psychometry|ADHD test and measurement of IQ level
219553255|NCT01961817|OTHER|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
219553256|NCT01961817|OTHER|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
219553257|NCT01513239|BIOLOGICAL|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
219553258|NCT01513239|BIOLOGICAL|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
219553259|NCT01513239|BIOLOGICAL|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
219553260|NCT01513239|DRUG|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
219553261|NCT04005222|DRUG|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
219553262|NCT04005222|DRUG|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
219145209|NCT02249988|DRUG|ABX203 therapeutic Hepatitis B vaccine treatment arm|
219145210|NCT01667796|DIETARY_SUPPLEMENT|Vitamin D3|
219719174|NCT04354571|PROCEDURE|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
219719175|NCT04354571|PROCEDURE|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
219719176|NCT01371682|DRUG|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
219719177|NCT02279251|BEHAVIORAL|VÅG|Low-intensity CBT intervention
219553263|NCT02873260|BIOLOGICAL|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
219145211|NCT00880477|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
219145212|NCT00880477|BIOLOGICAL|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
219145213|NCT00880477|BIOLOGICAL|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
219145214|NCT03023800|PROCEDURE|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
219145215|NCT03023800|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
219145216|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
219145217|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
219553264|NCT02873260|BIOLOGICAL|rDEN3Δ30|Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
219145218|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
219145219|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
219145220|NCT06288932|DRUG|Mycophenolate Mofetil (MMF) Treatment|The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
219145221|NCT06500377|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
219145222|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing only meditation
219145223|NCT06500377|PROCEDURE|Meditation Therapy|Learn focused attention only meditation
219145224|NCT06500377|PROCEDURE|Meditation Therapy|Learn mindfulness only meditation
219145225|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing, focused attention, and mindfulness combined meditation
219145226|NCT06500377|OTHER|Questionnaire Administration|Ancillary studies
219553265|NCT02873260|BIOLOGICAL|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
219553266|NCT00842062|DEVICE|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
219719178|NCT02279251|BEHAVIORAL|CHILLED|Standard length CBT intervention
219719179|NCT01802671|OTHER|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
219553267|NCT01327976|DEVICE|vBloc (Active Device)|Active device will deliver vBloc Therapy
219145227|NCT03729453|DEVICE|SpyGlass|Visualization of main pancreatic duct with SpyGlass catheter.
219553268|NCT01327976|DEVICE|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
219719180|NCT01802671|BEHAVIORAL|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
219145228|NCT06192394|OTHER|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
219145229|NCT06192394|OTHER|Walking Exercise|Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.
219145230|NCT06192394|OTHER|Control|Patients will undergo standard bowel preparation determined by the hospital.
219145231|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
219145232|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
219145233|NCT06581939|PROCEDURE|Rehabilitation group|In the rehabilitation group, patients will follow an individualized rehabilitation program started early in the ICU and continued in the post-ICU ward then at home for 12 weeks, combining goal-directed nutrition and physical activity, tailored to gains made over time by each patient, with the involvement of dieticians, physiotherapists, and adapted-physical-activity instructors.
219145234|NCT06581939|PROCEDURE|Control group|In the control group, patients will receive usual care from day-0 to day-180.
219553269|NCT03582423|OTHER|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
219553270|NCT03390790|DRUG|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
219145235|NCT05574192|BEHAVIORAL|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~1. arts-based activities.~2. physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
219145236|NCT06649097|DEVICE|IRRAflow® CNS (Active Fluid Exchange) System|The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
219145237|NCT04408898|GENETIC|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
219145238|NCT06097000|DEVICE|powered exoskeletons|Whether to use powered exoskeletons for exercise rehabilitation
219553271|NCT03390790|OTHER|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
219553272|NCT06423014|BEHAVIORAL|Wearable devices only|self-monitoring
219553273|NCT06423014|BEHAVIORAL|Wearable devices with the 1st behavior change technique|reminder
219553274|NCT06423014|BEHAVIORAL|Wearable devices with the 2nd behavior change technique|social support
219553275|NCT06423014|BEHAVIORAL|Wearable devices with the 3rd behavior change technique|Competition
219553276|NCT06423014|BEHAVIORAL|Wearable devices with the 4th behavior change technique|Goal-setting
219553277|NCT06423014|BEHAVIORAL|Wearable devices with the 5th behavior change technique|health coach
219553278|NCT06423014|BEHAVIORAL|Wearable devices with all behavior change techniques|Self-monitoring, health coach, goal-setting, competition, social support, and reminder
219145239|NCT06369623|OTHER|Monetary Incentive Delay Task|The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
219145240|NCT06488625|DRUG|Low-Dose CICR-NAM|2 g/d CICR-NAM (blinded)
219231020|NCT04277494|OTHER|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
219231021|NCT04188457|OTHER|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
219231022|NCT04188457|OTHER|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
219231023|NCT04131036|OTHER|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
219231024|NCT00259363|DRUG|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
219231025|NCT00973414|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
219231026|NCT00973414|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
219231027|NCT00244452|DRUG|Cetrorelix|
219231028|NCT02547974|BIOLOGICAL|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
219231029|NCT02547974|BIOLOGICAL|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
219231030|NCT02547974|BIOLOGICAL|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
219145241|NCT06488625|DRUG|High-Dose CICR-NAM|3 g/d CICR-NAM (blinded)
219145242|NCT06488625|DRUG|0 g/d CICR-NAM (blinded)|Placebo (blinded)
219145243|NCT06488625|DRUG|Open-Label|3 g/d CICR-NAM (open label)
219145244|NCT06448364|BIOLOGICAL|PF-07329640|an anti-lymphotoxin beta receptor agonist
219145245|NCT06448364|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
219145246|NCT06448364|BIOLOGICAL|bevacizumab|a monoclonal antibody that blocks VEGF
219145247|NCT03858205|OTHER|Quality-of-Life Assessment|Ancillary studies
219145248|NCT03858205|OTHER|Questionnaire Administration|Ancillary studies
219145249|NCT03858205|RADIATION|Radiation Therapy|Receive low-dose radiation therapy
219231031|NCT02547974|DRUG|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
219231032|NCT02290353|DEVICE|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
219231033|NCT01721694|DRUG|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
219231034|NCT01721694|DRUG|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
219553279|NCT03167606|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
219553280|NCT03483818|PROCEDURE|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
219553281|NCT00059332|DRUG|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
219553282|NCT00059332|DRUG|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
219553283|NCT01239303|DIETARY_SUPPLEMENT|Citrulline|single dose
219553284|NCT01239303|DIETARY_SUPPLEMENT|alanine|single dose
219553285|NCT04142996|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
219553286|NCT01476358|DIETARY_SUPPLEMENT|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
219553287|NCT01404351|DEVICE|PEAK PlasmaBlade|
219553288|NCT01404351|PROCEDURE|Scalpel and Traditional Electrosurgery|
219553289|NCT05214677|DRUG|DW1809|pelubiprofen 30mg
219553290|NCT05214677|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
219553291|NCT04097041|PROCEDURE|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
219145250|NCT03467555|DEVICE|Class II correction using miniplates in zygomatic region|
219145251|NCT03301454|DRUG|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
219145252|NCT01350804|BIOLOGICAL|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
219145253|NCT01350804|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
219231035|NCT01648114|OTHER|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
219145254|NCT01350804|BIOLOGICAL|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
219145255|NCT03688659|DRUG|Vancomycin and gentamycin|intravenous
219145256|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
219145257|NCT04134143|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
219145258|NCT04049435|DEVICE|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
219231036|NCT02212626|DEVICE|Rotarex S|
219231037|NCT06340984|DRUG|Montelukast 10 Mg Oral Tablet|group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
219231038|NCT03308500|BEHAVIORAL|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
219145259|NCT04225780|DRUG|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
219145260|NCT03349736|OTHER|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
219145261|NCT05574452|DEVICE|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
219145262|NCT03143309|BEHAVIORAL|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
219145263|NCT03143309|OTHER|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
219145264|NCT03328117|DRUG|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
219145265|NCT03328117|DRUG|Placebo oral capsule|Matching placebo oral capsule
219145266|NCT00158639|BEHAVIORAL|Home BP;secure messaging;pharmaceutical care;|
219145267|NCT02464852|BEHAVIORAL|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
219145268|NCT02464852|BEHAVIORAL|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
219145269|NCT02464852|DEVICE|Sheffield Support Snood|
219145270|NCT02464852|DEVICE|sEMG|
219145271|NCT02299336|DRUG|Aflibercept|pro re nata (PRN)
219145272|NCT02299336|PROCEDURE|Focal Laser|Focal laser administered based on pre-specified criteria
219145273|NCT02940561|DRUG|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
219145274|NCT02940561|DRUG|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
219145275|NCT01359371|BEHAVIORAL|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
219145276|NCT03203798|PROCEDURE|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
219145277|NCT03203798|PROCEDURE|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
219145278|NCT04948593|PROCEDURE|Native kidney biopsy|
219145279|NCT04204720|DEVICE|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
219145280|NCT04204720|DEVICE|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
219145281|NCT01897298|BEHAVIORAL|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
219145282|NCT05035199|BEHAVIORAL|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
219145283|NCT02106442|DRUG|Sodium risedronate|Sodium risedronate tablets
219145284|NCT06600685|OTHER|Functionally oriented music therapy (FMT)|There are different methods of music therapy and one of these is FMT. It is a body-based and music therapeutic treatment method that is used for health-promoting purposes. With the help of i.e. drums, cymbals, various custom-made drumsticks, flutes, chairs, balance balls and balance cushions. FMT strives to support, strengthen and develop the person's physical, mental and social abilities. FMT-sessions (20 minuets/1 time a week) are performed individuelly (a patient with a educated music therapist).
219145285|NCT05402891|DRUG|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
219145286|NCT01181089|BIOLOGICAL|Placebo|
219145287|NCT01181089|BIOLOGICAL|Baminercept|
219145288|NCT06990984|DRUG|TTI-0102: cysteamine-pantetheine disulfide|TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration
219145289|NCT06990984|DRUG|D-Mannitol|D-Mannitol
219145290|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
219145291|NCT03134235|OTHER|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
219145292|NCT00634452|BIOLOGICAL|MDX-1401|IV weekly for 4 weeks
219145293|NCT06628427|DIAGNOSTIC_TEST|MoCA Test|MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.
219145294|NCT06628427|DEVICE|Random Dot Motion (RDM) task|Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.
219719181|NCT01802671|BEHAVIORAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
219145295|NCT06628427|DEVICE|P300-BCI task without feedback|Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.
219145296|NCT06631664|OTHER|Traditional physical therapy|Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
219145297|NCT06631664|DEVICE|A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)|"The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction."
219145298|NCT06631014|DIAGNOSTIC_TEST|Early Rehab|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
219145299|NCT06631014|COMBINATION_PRODUCT|Delayed Rehab|The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
219145300|NCT06630065|BEHAVIORAL|fMRI with emotional task and pupillometry|"Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences."
219145301|NCT06630065|BEHAVIORAL|Behavioral task with emotional facial expressions|Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)
219145302|NCT06630065|GENETIC|Biological investigation|Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
219145303|NCT06632106|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
219145304|NCT06632106|DRUG|Tyrosine kinase inhibitor (TKIs)|TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
219145305|NCT06632106|DRUG|Immune Checkpoint Inhibitors|ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
219145306|NCT05535491|OTHER|Educational and Research Hospital|breathing exercise
219145307|NCT03911245|OTHER|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
219719182|NCT04087590|DRUG|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
219719183|NCT04005339|DRUG|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
219145308|NCT06697873|OTHER|Experimental Group: A|21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes
219145309|NCT06697873|OTHER|Experimental: Group B|21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
219145310|NCT06714162|DIETARY_SUPPLEMENT|Longevity pill|vitamins and herbs
219145311|NCT03043638|PROCEDURE|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
219145312|NCT03043638|PROCEDURE|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
219145313|NCT05756504|DRUG|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
219145314|NCT05756504|DRUG|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
219145315|NCT06473506|DIAGNOSTIC_TEST|Saliva collection|Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
219145316|NCT06834633|OTHER|Standard-of-care|Management according to current ICU practices
219145317|NCT06834633|OTHER|Systematic nephroprotection bundle-of-care|"The nephroprotection bundle-of-care includes 5 components:~1. Prevention of drugs' nephrotoxicity~2. Hemodynamic optimization, for 24h~3. Blood glucose control and avoidance of hyperglycemia~4. Early detection of rhabdomyolysis~5. Monitoring of renal function"
219719184|NCT04005339|DRUG|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
219145318|NCT05328297|DRUG|JNJ-55308942|JNJ-55308942 capsules will be administered orally.
219145319|NCT05328297|DRUG|Placebo|Matching placebo capsules will be administered orally.
219145320|NCT06104514|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219145321|NCT04019327|DRUG|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
219145322|NCT04019327|DRUG|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8"
219145323|NCT05208372|DIAGNOSTIC_TEST|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
219145324|NCT05208372|DIAGNOSTIC_TEST|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
219145325|NCT04921293|BEHAVIORAL|Ketogenic diet|A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
219145326|NCT04921293|DIETARY_SUPPLEMENT|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
219145327|NCT04921293|BEHAVIORAL|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
219145328|NCT01450228|DRUG|KI1001|Prolonged release melatonin 2mg
219145329|NCT01450228|DRUG|Placebo KI1001|Placebo KI1001 tablets
219145330|NCT02788604|OTHER|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
219553292|NCT04097041|PROCEDURE|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
219145331|NCT02788604|OTHER|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
219145332|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
219145333|NCT05425199|OTHER|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
219145334|NCT05425199|OTHER|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
219145335|NCT05425199|OTHER|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
219145336|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
219145337|NCT02986178|BIOLOGICAL|lerapolturev|A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant
219145338|NCT02986178|DRUG|Lomustine|one cycle of oral lomustine
219553293|NCT04484090|DEVICE|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
219145339|NCT05537038|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
219145340|NCT05537038|BIOLOGICAL|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
219145341|NCT05537038|OTHER|Placebo|Placebo
219145342|NCT03023631|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219145343|NCT02016352|BIOLOGICAL|patient CSF extraction with hydrocephalus|CSF extraction
219145344|NCT02016352|BIOLOGICAL|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
219145345|NCT02957812|DEVICE|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
219145346|NCT05685030|DIETARY_SUPPLEMENT|Placebo|product vehicle (sunflower oil)
219145347|NCT05685030|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
219145348|NCT05685030|DIETARY_SUPPLEMENT|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
219145349|NCT02206763|DRUG|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
219145350|NCT02206763|DRUG|Erlotinib|Tablet(s) administered orally once daily.
219145351|NCT05936333|PROCEDURE|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
219145352|NCT01393119|DRUG|GTx-758|3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
219145353|NCT06246435|OTHER|moderate aerobic exercise|
219145354|NCT02544152|DRUG|Lubiprostone|8 mcg administered orally twice daily (BID)
219145355|NCT02544152|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
219145356|NCT06638112|PROCEDURE|Brachial Plexus Block|Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam or propofol.
219145357|NCT06638112|PROCEDURE|General Anesthesia (control group)|General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
219231039|NCT03308500|BEHAVIORAL|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
219231040|NCT00251147|PROCEDURE|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
219145358|NCT03571191|DRUG|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
219553294|NCT01812603|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
219145359|NCT04157426|OTHER|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
219145360|NCT04157426|OTHER|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
219145361|NCT00646035|DRUG|paricalcitol capsules|baseline iPTH/60
219145362|NCT06266780|BEHAVIORAL|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
219145363|NCT06412341|BEHAVIORAL|Accepting your Body after Cancer|See 'Arm Description'
219145364|NCT06412341|BEHAVIORAL|Macmillan body image booklet|See 'Arm Description'
219145365|NCT00534937|PROCEDURE|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
219145366|NCT00534937|PROCEDURE|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
219145367|NCT06490159|DRUG|Paclitaxel|Gastric cancer second-line chemotherapy
219145368|NCT04432688|DRUG|Lurasidone HCl|This is a non-interventional, observational study
219553295|NCT04808908|BIOLOGICAL|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
219145369|NCT04114149|DEVICE|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
219145370|NCT04114149|DRUG|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
219145371|NCT05185830|OTHER|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
219145372|NCT02488200|OTHER|No intervention|No intervention
219145373|NCT03700853|DIAGNOSTIC_TEST|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
219553296|NCT00413049|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
219553297|NCT00413049|DRUG|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
219553298|NCT04546412|DEVICE|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
219553299|NCT02587143|DRUG|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
219553300|NCT02587143|DRUG|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
219553301|NCT04038866|OTHER|rehabilitation gait with dual task|
219553302|NCT04038866|OTHER|rehabilitation gait without dual task|
219553303|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 1)|"* 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
219553304|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 2 and 3)|"* 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
219553305|NCT02128516|OTHER|oral powder in sachet|
219553306|NCT03670758|DIAGNOSTIC_TEST|Protein S activity|Intravenous blood sample
219553307|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Rockwood Clinical Frailty Scale
219553308|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
219553309|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Clinician's subjective 'end-of-bed' test
219553310|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
219553311|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|11-item modified Frailty Index (mFI-11)
219553312|NCT01675739|BEHAVIORAL|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
219553313|NCT01675739|DRUG|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
219553314|NCT02837913|DEVICE|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
219553315|NCT03373630|DEVICE|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
219553316|NCT00165919|OTHER|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
219553317|NCT05024487|DIAGNOSTIC_TEST|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
219553318|NCT02557464|BEHAVIORAL|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
219553319|NCT02557464|BEHAVIORAL|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
219553320|NCT06378320|OTHER|App access and Text message|Access to App and Text messages with app related breastfeeding related question
219553321|NCT06378320|OTHER|App access only|Access to App without Text messages with app related breastfeeding related question
219553322|NCT03314857|DEVICE|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
219553323|NCT02230930|DRUG|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
219553324|NCT02230930|DEVICE|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
219553325|NCT02230930|DRUG|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
219553326|NCT02230930|DRUG|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
219553327|NCT06331650|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
219719185|NCT04005339|DRUG|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
219719186|NCT06405581|OTHER|Edmonton frailty scale calculation|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
219719187|NCT01772862|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
219231041|NCT00251147|PROCEDURE|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
219231042|NCT03677271|BEHAVIORAL|Physical Activity|
219231043|NCT03555656|BEHAVIORAL|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
219231044|NCT03555656|BEHAVIORAL|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
219231045|NCT01623609|DRUG|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
219231046|NCT01623609|DRUG|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
219231047|NCT01765023|DRUG|Period I : atorvastatin, Period II : atorvastatin and metformin|
219231048|NCT01765023|DRUG|Period I : metformin, Period II : atorvastatin and metformin|
219231049|NCT00312949|BEHAVIORAL|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
219231050|NCT00312949|BEHAVIORAL|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
219231051|NCT04766996|BEHAVIORAL|Guided mindfulness exercises|Guided Meditation twice daily
219231052|NCT04766996|OTHER|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
219231053|NCT04766996|DRUG|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
219231054|NCT04766996|DRUG|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
219231055|NCT04766996|DRUG|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
219231056|NCT04766996|DRUG|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
219719188|NCT02229604|OTHER|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
219719189|NCT02229604|DRUG|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
219719190|NCT05694585|DRUG|Esmolol|Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
219719191|NCT05694585|DRUG|saline|Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
219719192|NCT01470534|DIETARY_SUPPLEMENT|carbohydrate drink|carbohydrate drink
219719193|NCT01470534|PROCEDURE|Muscle biopsy|Open muscle biopsy
219719194|NCT01470534|PROCEDURE|Blood sampling|Venopuncture
219231057|NCT04766996|DRUG|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
219719195|NCT01470534|DIETARY_SUPPLEMENT|Placebo|
219719196|NCT05743972|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
219719197|NCT05743972|DIAGNOSTIC_TEST|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
219719198|NCT02259322|BEHAVIORAL|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
219719199|NCT02259322|BEHAVIORAL|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
219719200|NCT02259322|BEHAVIORAL|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
219719201|NCT00120718|DRUG|fasudil|
219719202|NCT01320566|DEVICE|AeriSeal System|Not applicable. Follow-Up study only.
219231058|NCT04766996|DRUG|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
219231059|NCT04766996|DRUG|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
219231060|NCT04766996|DRUG|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
219231061|NCT04766996|DRUG|Zofran|Zofran 4 mg pre-operative
219231062|NCT04766996|DRUG|Pepcid|Pepcid 20 mg pre-operative
219231063|NCT04766996|DRUG|Reglan|Reglan 10 mg pre-operative
219231064|NCT04766996|DRUG|Versed|Versed 2 mg pre-operative
219231065|NCT04766996|DRUG|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
219231066|NCT04766996|DRUG|Propofol|Propofol 10-125 mcg/kg/min intraoperative
219231067|NCT04766996|DRUG|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
219231068|NCT04766996|DRUG|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
219231069|NCT04766996|DRUG|Decadron|Decadron 10 mg intraoperative
219231070|NCT04766996|DRUG|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
219719203|NCT02439619|OTHER|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
219719204|NCT00852878|BEHAVIORAL|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
219719205|NCT00852878|BEHAVIORAL|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
219719206|NCT05600959|DIAGNOSTIC_TEST|cytokine|Peripheral blood samples were collected at diagnosis, 2 weeks after the first cycle of chemotherapy and 2 weeks after the second cycle of chemotherapy to monitor cytokine level changes.
219719207|NCT05758454|BEHAVIORAL|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
219719208|NCT02629458|PROCEDURE|Treatment by Surgical resection|
219719209|NCT02629458|PROCEDURE|Stereotactic Ablative Radiotherapy (SABR)|
219719210|NCT03251417|DRUG|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
219231071|NCT04766996|DRUG|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
219231072|NCT05624814|DEVICE|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
219231073|NCT05624814|OTHER|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
219231074|NCT00508183|PROCEDURE|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
219231075|NCT00508183|PROCEDURE|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
219231076|NCT01613456|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
219231077|NCT01613456|DIETARY_SUPPLEMENT|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
219719211|NCT03251417|DRUG|Apatinib|Apatinib 500 mg oral take, daily
219719212|NCT06518226|RADIATION|Ultrahypofractionated MRgRT in 2 fractions|2x12 Gy with boost to GTV up to 13.5 Gy
219231078|NCT01554332|DEVICE|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
219231079|NCT06122818|OTHER|Immobile patients receiving home health care|Demographic characteristics, duration of immobility, sarcopenia presence, thigh circumference , Hand grip strength , bioelectrical impedance analysis
219231080|NCT01113736|BIOLOGICAL|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
219231081|NCT05454059|PROCEDURE|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
219231082|NCT05454059|DIAGNOSTIC_TEST|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
219231083|NCT05454059|OTHER|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
219231084|NCT05454059|OTHER|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
219231085|NCT05454059|DIAGNOSTIC_TEST|HbA1c Level|Measurement of HbA1c levels from blood tests
219231086|NCT02988713|DEVICE|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
219719213|NCT06518226|RADIATION|Standard of care: MRgRT in 5 fractions|5x7.25 Gy
219719214|NCT06287229|DRUG|Blinatumomab|Given by Infusion
219719215|NCT06287229|DRUG|Inotuzumab Ozogamicin|Given by IV
219719216|NCT06287229|DRUG|Hyper-CVAD|Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
219719217|NCT06287229|DRUG|Mini-hyper-CVD|Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
219719218|NCT04487236|DRUG|ZN-A-1041 50mg BID|Orally 21days for one cycle
219719219|NCT04487236|DRUG|ZN-A-1041 100mg BID|Orally 21days for one cycle
219145374|NCT06515951|DIAGNOSTIC_TEST|STANDING algorithm|The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
219145375|NCT05674136|DEVICE|INVSENSOR00061|Noninvasive pulse oximeter sensor
219145376|NCT00583817|DEVICE|Endovascular stent-graft implantation|Endovascular repair of aorta
219145377|NCT00136058|PROCEDURE|bone densitometry (DEXA)|
219145378|NCT00136058|DRUG|alendronate or risedronate|
219231087|NCT04852471|BEHAVIORAL|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
219231088|NCT04852471|BEHAVIORAL|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
219231089|NCT06172036|DRUG|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
219231090|NCT06172036|DRUG|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
219231091|NCT02424968|BIOLOGICAL|Anti-Thymocyte Globulin|Given per standard institutional practice
219719220|NCT04487236|DRUG|ZN-A-1041 200mg BID|Orally 21days for one cycle
219719221|NCT04487236|DRUG|ZN-A-1041 400mg BID|Orally 21days for one cycle
219719222|NCT04487236|DRUG|ZN-A-1041 600mg BID|Orally 21days for one cycle
219719223|NCT04487236|DRUG|ZN-A-1041 800mg BID|Orally 21days for one cycle
219719224|NCT04487236|DRUG|ZN-A-1041 1000mg BID|Orally 21days for one cycle
219145379|NCT02015546|DRUG|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
219145380|NCT06426823|OTHER|Saline / placebo|NaCl (9 mg/ml)
219145381|NCT06426823|OTHER|GIPR antagonist / study tool|GIP(3-30)NH2
219231092|NCT02424968|DRUG|Cyclosporine|Given PO
219231093|NCT02424968|DRUG|Mycophenolate Mofetil|Given PO
219231094|NCT02424968|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
219231095|NCT02424968|BIOLOGICAL|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
219231096|NCT02424968|RADIATION|Total Nodal Irradiation|Undergo TLI
219231097|NCT06144437|DIAGNOSTIC_TEST|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
219231098|NCT03610620|PROCEDURE|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
219231099|NCT02065609|DRUG|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
219231100|NCT02065609|DRUG|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
219231101|NCT04947709|BEHAVIORAL|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
219719225|NCT04487236|DRUG|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
219719226|NCT04487236|DRUG|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
219719227|NCT04487236|DRUG|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
219719228|NCT04487236|DRUG|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
219719229|NCT04341090|DRUG|Apatinib Mesylate|Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
219719230|NCT04560842|DEVICE|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
219145382|NCT05554185|DIETARY_SUPPLEMENT|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
219145383|NCT04988568|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
219145384|NCT01426269|DRUG|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
219145385|NCT01426269|DRUG|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
219145386|NCT01426269|DRUG|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
219145387|NCT04739280|DEVICE|CardioFlux Magnetocardiography|Magnetocardiography
219145388|NCT05857371|PROCEDURE|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
219145389|NCT05857371|PROCEDURE|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
219145390|NCT05857371|DRUG|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
219145391|NCT01909258|OTHER|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
219145392|NCT01909258|OTHER|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
219145393|NCT01909258|OTHER|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
219145394|NCT04580160|DEVICE|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
219145395|NCT06322797|DEVICE|rTMS|"Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min."
219145396|NCT06322797|DEVICE|rTMS|Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
219145397|NCT06322797|DEVICE|Sham|In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
219145398|NCT05906875|OTHER|Lateral Stepping Exercise 1|1\. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
219145399|NCT05906875|OTHER|Active Control Group Exercise 1|1\. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
219145400|NCT05906875|OTHER|Active Control Group Exercise 2|2\. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
219145401|NCT05906875|OTHER|Active Control Group Exercise 3|3\. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
219145402|NCT05906875|OTHER|Active Control Group Exercise 4|4\. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
219145403|NCT05906875|OTHER|Lateral Stepping Exercise 2|2\. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
219145404|NCT05906875|OTHER|Lateral Stepping Exercise 3|3\. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
219145405|NCT05906875|OTHER|Lateral Stepping Exercise 4|4\. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
219231102|NCT05958966|OTHER|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
219231103|NCT01861015|DRUG|Epinephrine|
219719231|NCT04560842|DEVICE|Conventional oxygen therapy|Conventional oxygen device
219231104|NCT01861015|DRUG|Vasopressin|
219719232|NCT03010501|OTHER|Food Energy Density|Food Energy density manipulated
219719233|NCT06068959|DEVICE|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
219719234|NCT06068959|DEVICE|Placebo|Photobiomodulation Placebo
219719235|NCT00640289|DRUG|Fibrogammin P|Prophylaxis treatment
219719236|NCT00864318|DRUG|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
219719237|NCT00864318|DRUG|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
219719238|NCT00864318|DRUG|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
219719239|NCT00864318|DRUG|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
219719240|NCT00864318|PROCEDURE|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
219719241|NCT02103075|DEVICE|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
219719242|NCT00306488|DRUG|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
219719243|NCT02257151|DRUG|BMS-986142|
219719244|NCT02257151|DRUG|Placebo|
219719245|NCT04050605|DEVICE|somofilcon A toric contact lens|Contact Lens
219719246|NCT04050605|DEVICE|fanfilcon A toric contact lens|Contact Lens
219719247|NCT04546698|OTHER|blood sampling|Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
219719248|NCT00544882|DRUG|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
219719249|NCT00544882|DRUG|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
219719250|NCT00544882|DRUG|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
219719251|NCT07102719|DRUG|HD-P023|Single dose administration of HD-P023
219719252|NCT07102719|DRUG|Teneligliptin and Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
219719253|NCT07115238|DRUG|XTR006|all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.
219719254|NCT07116044|DIAGNOSTIC_TEST|virological tests diagnostic tests|"The parameters collected will include blood sugar, HbA1c, complete blood count, lipid profile (total cholesterol, LDL, HDL, triglycerides), liver profile (ALT, AST, total and fractionated bilirubin, alkaline phosphatase, GGT) and renal profile (creatinine, azotemia), electrophoretic protein picture. Additionally, specific data for HDV and HBV infection will be collected, including HBsAg, anti-HBs, anti-HBc, HBV-DNA, and HDV-RNA. The glomerular filtration rate shall be calculated using the formula CKD-EPI.~• Instrumental Tests: Results of abdominal ultrasounds, Fibroscan®/CAP for the evaluation of liver fibrosis"
219719255|NCT07117955|OTHER|Autologous Platelet Rich Plasma|6 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
219231105|NCT04248868|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
219719256|NCT07117955|OTHER|Saline solution|6 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
219719257|NCT07117318|DRUG|NSAIDs|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure
219719258|NCT07117318|DEVICE|NSAIDs plus PDS|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure. When eligibility is met, PDS placement will be performed by ERCP colonoscopists.
219719259|NCT07118150|OTHER|Assessment of Pre-Hospital Neglect and Abuse in Elderly Trauma Surgery Patients|"This study is an observational research that does not involve any direct intervention (treatment, application, etc.). After obtaining informed consent from the patients or their legal representatives, data will be collected through hospital records, face-to-face interviews with the patients and/or their relatives, and standardized questionnaires.~Pre-hospital living conditions, care status, and signs of neglect and abuse will be assessed.~The relationship between clinical data, trauma severity, and the presence of neglect or abuse will be examined."
219231106|NCT04248868|DRUG|r-tPA|Pulse spray and infusion
219231107|NCT02418689|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
219145406|NCT05906875|OTHER|Lateral Stepping Exercise 5|5\. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
219145407|NCT00155415|BEHAVIORAL|Different timing of taking polyethylene glycol(PEG)|
219145408|NCT05260086|DEVICE|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
219145409|NCT00051272|DRUG|Extended-release Bupropion Hydrochloride|
219145410|NCT02722070|DEVICE|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
219145411|NCT02764944|PROCEDURE|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
219145412|NCT00701896|DRUG|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
219145413|NCT00701896|DRUG|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
219145414|NCT00701896|OTHER|Biological Control|No treatment intervention only information and procedures.
219145415|NCT00701896|BEHAVIORAL|Motivational Interview|60 minute one-on-one Interview
219145416|NCT00959582|PROCEDURE|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
219145417|NCT01098344|DRUG|Notch signaling pathway inhibitor MK0752|
219231108|NCT04347941|PROCEDURE|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
219231109|NCT04347941|PROCEDURE|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
219231110|NCT03131713|DRUG|Acetaminophen|Acetaminophen 1000mg
219231111|NCT01504984|DRUG|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
219231112|NCT01504984|DRUG|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
219231113|NCT00916409|DEVICE|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
219231114|NCT00916409|DRUG|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
219719260|NCT07121621|DRUG|PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.|"The pharmacological intervention, which will be the same for all patients in the study, will consist in administering MPH at CIC 1415 (URHC of Tours) in the form of Prolonged Release at the patient's usual dosage, in the early morning.~Pharmacokinetic study with repeated measurements at T0 (just before MPH administration) then T30 minutes, T1 hour, T2h, T3h, T4h, T6h, T8h (8 measurements) after MPH administration, in 15 patients with ADHD and obesity (BMI≥30 kg/m2) and in 15 patients with ADHD but without obesity (BMI\<30 kg/m2)."
219719261|NCT07120321|DRUG|Mineral Trioxide Aggregate (MTA)|Used as the capping agent after coronal pulp removal in primary molars.
219719262|NCT07120321|DRUG|Biodentine|Used as a bioactive pulpotomy agent following coronal pulp amputation.
219145418|NCT01098344|DRUG|gemcitabine hydrochloride|
219145419|NCT01098344|OTHER|imaging biomarker analysis|
219145420|NCT01098344|OTHER|laboratory biomarker analysis|
219145421|NCT01098344|OTHER|pharmacological study|
219145422|NCT00006327|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
219231115|NCT01976507|DRUG|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
219231116|NCT02208843|DRUG|Afatinib|Afatinib tablet once daily until progression
219145423|NCT03473522|DEVICE|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
219145424|NCT03473522|BEHAVIORAL|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
219145425|NCT00141349|DRUG|UK-369,003|
219145426|NCT05157022|DEVICE|ESWT|Extracorporeal Shock-wave Therapy
219145427|NCT00186186|DRUG|Depakote ER|Depakote ER
219145428|NCT02327611|DRUG|Custodiol|
219145429|NCT02327611|DRUG|Enriched Ringer's lactate solution|
219231117|NCT04996654|BEHAVIORAL|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
219231118|NCT04996654|BEHAVIORAL|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
219231119|NCT01676298|DEVICE|Spartan FRX CYP2C19 Test System|
219145430|NCT04670159|BEHAVIORAL|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
219145431|NCT04670159|BEHAVIORAL|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
219145432|NCT04830501|DRUG|TT-00434|Once daily \[QD\], 28 days/cycle.
219145433|NCT06176482|DEVICE|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
219145434|NCT03203538|DEVICE|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
219145435|NCT03203538|DEVICE|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
219145436|NCT03203538|DEVICE|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
219145437|NCT03203538|DEVICE|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
219231120|NCT01762982|DRUG|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
219231121|NCT01762982|DRUG|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
219231122|NCT01762982|DRUG|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
219231123|NCT01762982|OTHER|Empty Finn Chamber|Empty Finn Chamber
219231124|NCT03003104|DRUG|DMT210 Topical Gel 5%|
219231125|NCT03003104|OTHER|Vehicle Control|
219553328|NCT00753350|DEVICE|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
219553329|NCT01119625|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
219553330|NCT01119625|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, one dose
219553331|NCT06353724|DEVICE|conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning|"Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment."
219553332|NCT06353724|DEVICE|Digital positioning stent|Digital positioning stent
219553333|NCT03237156|DRUG|TAK-906|TAK-906 capsules.
219553334|NCT03237156|DRUG|TAK-906 Placebo|Placebo capsules.
219553335|NCT04499209|DRUG|XG005|XG005 Capsule
219553336|NCT04499209|DRUG|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
219553337|NCT04499209|DRUG|Placebos|Placebo Capsule
219553338|NCT01706809|OTHER|blood sampels from vena rectalis superior and vena cubiti|
219553339|NCT01286805|PROCEDURE|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
219553340|NCT01286805|PROCEDURE|Control|The control group will receive only a combined spinal-epidural.
219553341|NCT01721772|BIOLOGICAL|BMS-936558 (Nivolumab)|
219553342|NCT01721772|BIOLOGICAL|Placebo matching BMS-936558 (Nivolumab)|
219553343|NCT01721772|DRUG|Dacarbazine|
219553344|NCT01721772|DRUG|Placebo matching Dacarbazine|
219145438|NCT03203538|DEVICE|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
219145439|NCT03203538|DEVICE|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
219231126|NCT02912247|DRUG|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
219719263|NCT07120321|DRUG|Ferric Sulfate|15.5% Ferric Sulfate applied to pulp stumps for 15 seconds during pulpotomy procedure.
219719264|NCT07120321|DRUG|Sodium hypochlorite gel application|5% NaOCl gel applied to pulp tissue during pulpotomy for its hemostatic and disinfectant effects.
219553345|NCT03447691|DRUG|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
219553346|NCT03447691|DRUG|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
219553347|NCT02213887|DRUG|Pantoprazole|40 mg PO QAM
219553348|NCT02213887|DRUG|Pantoprazole|0 mg PO QAM
219145440|NCT02301442|BEHAVIORAL|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
219145441|NCT02301442|BEHAVIORAL|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
219145442|NCT05377567|BEHAVIORAL|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
219145443|NCT05377567|BEHAVIORAL|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
219231127|NCT02912247|DRUG|adalimumab|adalimumab, 40mg,subcutaneous injection,once
219231128|NCT02799849|OTHER|Sleep and metabolism assessment|
219231129|NCT00569439|DRUG|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
219231130|NCT00569439|DRUG|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
219231131|NCT00569439|DRUG|NS|Normal Saline solution at 125 cc/hr
219231132|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
219719265|NCT07121764|DRUG|Bupivacaine %0.25 (isobaric)|1 ml/kg of 0.25% Bupivacaine will be used for caudal block.
219145444|NCT05377567|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
219553349|NCT00422253|BEHAVIORAL|dietary intervention|
219719266|NCT07121764|DRUG|Dexmedetomidine & Bupivacaine.|1 ml/kg of 0.25% Bupivacaine PLUS 1 μg/kg Dexmedetomidine in 1 ml Normal Saline will be used for caudal block.
219145445|NCT00427323|PROCEDURE|light exposure|
219145446|NCT00003540|DRUG|gemcitabine hydrochloride|
219231133|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
219231134|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
219231135|NCT02160301|DRUG|Gabapentin|PO
219231136|NCT02160301|DRUG|Acetaminophen|PO
219719267|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm A)
219719268|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm B)
219719269|NCT07121413|DRUG|SV001|SV001 ： Multiple-dose
219145447|NCT00142558|DRUG|MK0663; etoricoxib / Duration of Treatment: 5 Days|
219231137|NCT02160301|DRUG|Acetaminophen|IV
219231138|NCT02160301|DRUG|Celecoxib|PO
219231139|NCT02160301|DRUG|Dexamethasone|IV
219231140|NCT02160301|DRUG|Oxycodone|PO
219231141|NCT02684032|DRUG|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
219231142|NCT02684032|DRUG|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
219145448|NCT00142558|DRUG|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
219145449|NCT02522468|PROCEDURE|Radioactive Seed Localization|
219145450|NCT02522468|PROCEDURE|Wire Localization|
219145451|NCT01673516|PROCEDURE|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
219145452|NCT01673516|DEVICE|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
219145453|NCT02405559|DRUG|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
219145454|NCT04413838|DRUG|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
219145455|NCT04413838|OTHER|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
219145456|NCT01742169|BEHAVIORAL|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
219145457|NCT05492409|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection.
219145458|NCT06336473|PROCEDURE|skin biopsy|Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
219145459|NCT03176654|PROCEDURE|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
219145460|NCT03176654|PROCEDURE|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
219145461|NCT01113931|DRUG|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
219145462|NCT01113931|DRUG|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
219145463|NCT02250118|DRUG|Bevacizumab|Intrapleural Bevacizumab
219145464|NCT02567656|DRUG|RP6530|Tablet starting at 200 mg
219145465|NCT06116708|DEVICE|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
219553350|NCT01095887|DRUG|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
219145466|NCT06116708|DEVICE|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
219145467|NCT01402531|DRUG|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
219145468|NCT04134793|PROCEDURE|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
219145469|NCT00002893|DRUG|fluorouracil|
219145470|NCT00002893|DRUG|leucovorin calcium|
219145471|NCT00002893|DRUG|raltitrexed|
219145472|NCT04559126|DRUG|EDP-297|EDP-297 Oral solution
219145473|NCT04559126|DRUG|Placebo|placebo to match EDP-297
219145474|NCT02459782|PROCEDURE|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
219145475|NCT00839371|DRUG|Propofol|i.v. propofol titration until adequate depth of sedation
219145476|NCT00839371|DRUG|Midazolam|i.v. midazolam titration until adequate depth of sedation
219145477|NCT03990272|DRUG|AIT drops|once a day
219145478|NCT03990272|DRUG|placebo drops|once a day
219145479|NCT00161733|DRUG|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
219145480|NCT00161733|DRUG|TISSEEL VH fibrin sealant|
219145481|NCT00816049|DRUG|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
219145482|NCT00816049|DRUG|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
219145483|NCT04735315|OTHER|Preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
219145484|NCT06096142|DEVICE|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
219145485|NCT06096142|DEVICE|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
219145486|NCT00111722|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
219231143|NCT02684032|DRUG|Letrozole|Letrozole at 2.5 mg daily
219719270|NCT07121413|DRUG|Placebo|Placebo ： Multiple-dose
219719271|NCT07121088|DRUG|(Intensive treatment) Chuanzhi Tongluo Capsules|4 capsules each time, orally, 3 times a day; administration from day 1 to day 14 of the disease.
219145487|NCT00111722|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
219145488|NCT04608955|DRUG|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
219145489|NCT04608955|DRUG|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
219145490|NCT04608955|DRUG|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
219145491|NCT04608955|DRUG|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
219145492|NCT04561219|DRUG|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
219145493|NCT04561219|DRUG|Placebo|Placebo three times a day for 5 days
219145494|NCT01241435|DRUG|LY2216684|Administered orally
219145495|NCT03444649|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
219145496|NCT03444649|DRUG|Idarubicin|Standard chemotherapy d1-d3 cycle 1
219145497|NCT03444649|DRUG|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
219145498|NCT03444649|DRUG|Daunorubicin|Standard chemotherapy d1-3 cycle 2
219145499|NCT04873336|DEVICE|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
219145500|NCT02418013|OTHER|Fresh cord blood(experimental group A)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
219145501|NCT02418013|OTHER|Frozen cord blood(experimental group B)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
219145502|NCT02418013|OTHER|Frozen plasma(experimental group C)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
219145503|NCT02418013|OTHER|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
219145504|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
219145505|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
219145506|NCT03959241|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
219145507|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
219231144|NCT02684032|DRUG|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
219553351|NCT06581120|DRUG|Glucagon-Like Peptide-1 receptor agonists|GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
219553352|NCT06581120|DIAGNOSTIC_TEST|Point of Care Gastric Ultrasound|A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
219553353|NCT00796874|OTHER|active surveillance|Correlative Study
219553354|NCT00796874|OTHER|imaging biomarker analysis|Correlative Study
219553355|NCT00796874|PROCEDURE|biopsy|Tissue Removal
219553356|NCT00796874|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
219553357|NCT00796874|PROCEDURE|magnetic resonance imaging|Radiolical Medical Imaging
219553358|NCT00796874|PROCEDURE|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
219553359|NCT05530291|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
219553360|NCT00973050|DRUG|Bicalutamide|50 mg Tablet
219553361|NCT00973050|DRUG|Casodex®|50 mg Tabelt
219553362|NCT00005668|DRUG|Itraconazole oral solution|
219553363|NCT04620941|DIAGNOSTIC_TEST|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
219553364|NCT02465684|PROCEDURE|unicondylar knee arthroplasty|
219553365|NCT02146690|OTHER|osteopathic manipulative treatment|
219553366|NCT02146690|OTHER|sham therapy|
219553367|NCT02146690|OTHER|usual care|
219719272|NCT07121088|OTHER|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
219719273|NCT07121088|DRUG|(Sequential treatment) Chuanzhi Tongluo Capsules|2 capsules each time, orally, 3 times a day; administration from day 15 to day 365.
219719274|NCT07121088|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
219719275|NCT07121829|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
219719276|NCT07121829|DRUG|Tovorafenib Drug: Pimasertib|Tovorafenib tablet for oral use. Pimasertib capsule for oral use
219719277|NCT07123766|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
219719278|NCT06927076|DRUG|N,N-Dimethyltryptamine|administration of a 2mg/min DMT perfusion over 20 min
219719279|NCT06927076|DRUG|Placebo|administration of a placebo perfusion over 20 min
219719280|NCT06927076|PROCEDURE|Propofol|30 min propofol sedation
219719281|NCT06927076|PROCEDURE|no sedation|no sedation
219553368|NCT06440278|BEHAVIORAL|Behavioral Activation for Health and Depression (BA-HD)|BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
219553369|NCT06440278|OTHER|Enhanced Usual Care|Patients will receive depression and heart disease education, as well as a list of local mental health resources.
219145508|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
219145509|NCT03959241|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
219145510|NCT03959241|DRUG|Cyclophosphamide|Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
219231145|NCT04514081|DRUG|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
219553370|NCT06106152|DRUG|WTX212A injection|The WTX212A infusion is given every 21 days
219553371|NCT06106152|DRUG|PD -1/PD-L1 monoclonal antibody|The PD -1/PD-L1 monoclonal antibody is given every 21 days
219719282|NCT07124520|DEVICE|Iowa Oral Performance Instrument (IOPI)|The Iowa Oral Performance Instrument/IOPI is an instrument that objectively measures tongue strength using a standard-sized air-filled bulb. An individual presses the bulb against the roof of the mouth with the tongue to generate a pressure measurement in kilopascals (kPa). Maximum tongue strength can be determined using a measure of pressure.
219231146|NCT04514081|DRUG|Decitabine+Camrelizumab|Decitabine+Camrelizumab
219553372|NCT00352807|DRUG|Brimonidine Purite|
219553373|NCT00287053|DRUG|divalproex sodium|Divalproex sodium vs. placebo
219553374|NCT05156086|DRUG|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
219553375|NCT00234780|PROCEDURE|pediatric nursing used in home to avoid hospitalization|
219719283|NCT07124169|OTHER|Kinesiotape + home exercise|Kinesiotaping will be applied to the knee once weekly for 6 weeks. In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
219719284|NCT07124169|OTHER|Home exercise|In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
219719285|NCT05872126|PROCEDURE|VATS-Surgical pleurodesis|VATS drainage and surgical abrasion.
219719286|NCT05872126|PROCEDURE|Tube Drainage|Tube drainage for malignant pleural effusion
219719287|NCT07124884|DRUG|Administration of experimental treatment association (sotorasib, panitumumab 5FU)|Panitumumab is administered at a dose of 6 mg/kg via intravenous infusion over one hour during the first cycle, and over 30 minutes from the second cycle onward. The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion, followed by a 5-FU bolus (400 mg/m² over 10 minutes), and a continuous 5-FU infusion (2400 mg/m² over 46 hours). Sotorasib is given orally at a dose of 960 mg once daily on a continuous basis.
219719288|NCT07124533|DRUG|Toothpaste Tablet|Denttabs toothpaste tablets
219719289|NCT07124533|DRUG|Conventional Toothpaste|Colgate Cavity Protection toothpaste
219719290|NCT00851487|DRUG|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
219145511|NCT04555265|DEVICE|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
219145512|NCT03183999|DIETARY_SUPPLEMENT|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
219145513|NCT03183999|DIETARY_SUPPLEMENT|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
219145514|NCT01026064|OTHER|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
219145515|NCT01026064|DRUG|Azithromycin|Zithromax (250 mg oral capsule).
219145516|NCT01026064|DRUG|Placebo|Matching placebo
219145517|NCT04925648|DRUG|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
219145518|NCT04925648|DRUG|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
219145519|NCT04323358|DIAGNOSTIC_TEST|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
219145520|NCT04323358|DIAGNOSTIC_TEST|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
219145521|NCT01234844|BEHAVIORAL|care of guinea pigs|twice weekly sessions of care with guinea pigs
219145522|NCT01234844|BEHAVIORAL|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
219145523|NCT01511471|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
219145524|NCT01174199|DRUG|vorinostat|Given orally
219145525|NCT01174199|DRUG|temsirolimus|Given IV
219145526|NCT01174199|OTHER|laboratory biomarker analysis|Correlative study
219145527|NCT01174199|PROCEDURE|positron emission tomography/computed tomography|PET scan
219145528|NCT06109831|DRUG|SHR-1918|SHR-1918
219145529|NCT06109831|DRUG|SHR-1918 placebo|SHR-1918 placebo
219145530|NCT03671525|DRUG|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
219145531|NCT03671525|DRUG|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
219145532|NCT06257693|DRUG|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
219719291|NCT00851487|DRUG|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
219145533|NCT01301196|BEHAVIORAL|Educational workshop|3h attendance at educational workshop plus self-monitoring
219145534|NCT00861458|DRUG|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
219145535|NCT03993613|BIOLOGICAL|human apotransferrin|Intravenous infusions
219145536|NCT06530264|OTHER|DCR|6\. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
219145537|NCT06002542|BEHAVIORAL|Information provided|get information at every stage of care in emergency room
219145538|NCT06002542|BEHAVIORAL|Control|Information is only provided when participants request it.
219145539|NCT00367991|DRUG|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
219145540|NCT00367991|DRUG|Placebo|Normal saline to match active drug (rHuEpo)
219145541|NCT06640387|DIAGNOSTIC_TEST|Daily Influenza, RSV or SARS-CoV-2 PCR testing for 10 days|Each participant will undergo daily PCR testing for Influenza, RSV or SARS-CoV-2 to assess viral dynamics
219145542|NCT06089694|DEVICE|Enabling Sensor Research Holter Mode feature|The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
219145543|NCT05214287|DRUG|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
219145544|NCT00867191|DRUG|Placebo|Placebo, 1 tablet daily, per os., 15 days
219145545|NCT00867191|DRUG|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
219719292|NCT07124572|OTHER|Imaging and ocular examinations|"2D and 3D Facial photography, blinking videos, orbital CT and MRI images, fundus images and images of nine gaze positions are taken.~Clinical information is recorded. Quality of life is assessed. Ocular examinations, such as visual acuity, levator function, exophthalmos measurement, strabismus test, visual field examination, axial length measurement, OCT, OCTA are made."
219145546|NCT06556160|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered."
219145547|NCT00777244|DRUG|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
219145548|NCT06639282|DRUG|Siponimod|Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
219145549|NCT06639282|DRUG|Placebo|A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
219145550|NCT05289349|DRUG|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
219145551|NCT05289349|DRUG|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
219719293|NCT07123857|DIAGNOSTIC_TEST|re-triage|Patients in the test group will be re-triaged into the orange MTS category.
219719294|NCT07081139|OTHER|observational study, no interventional|no interventions
219719295|NCT03043573|BEHAVIORAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
219553376|NCT04604210|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
219719296|NCT03043573|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
219719297|NCT07084233|BEHAVIORAL|Mindfulness based, trauma informed, self-regulation skills training|"The study intervention, MMFT, consists of 7.5 hours of live, online courses, in three sessions, over three weeks. The entire intervention group (n=100) will participate in each session simultaneously, with four trainers and two translators.~Session 1 (3 hours): This session will introduce three mind fitness exercises. Session 2 (3 hours): This session will begin with mind fitness practice and discussion about participants' experience with the exercises during the previous two weeks.~Session 3 (1.5 hours): This session is for participants to integrate course content at an experiential level-no new content will be offered. The session will include some guided practice, but mostly focus on answering questions from participants and/or providing guidance to participants for how to navigate challenges with practice.~During the three weeks participants are in the course, they will be asked to practice the MMFT techniques for 5-60 minutes per day."
219719298|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
219719299|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
219231147|NCT01794299|BIOLOGICAL|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
219719300|NCT06387667|DIAGNOSTIC_TEST|Complete blood count|blood sample
219553377|NCT03547414|OTHER|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2\*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
219145552|NCT00509639|DRUG|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
219719301|NCT06387667|DIAGNOSTIC_TEST|C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)|serum sample
219553378|NCT04646356|DRUG|Tacrolimus capsule (low-dose)|low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
219553379|NCT03960801|DRUG|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
219553380|NCT03960801|DRUG|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
219719302|NCT06387667|RADIATION|CT chest|Computed tomography of the chest
219145553|NCT00346151|DRUG|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
219145554|NCT00346151|DRUG|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
219231148|NCT03630549|OTHER|Standard of Care|Clinic-based HIV care
219145555|NCT00346151|DRUG|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
219231149|NCT03630549|OTHER|Village-based ART refill|Option to get ART refill and care by the village health worker
219231150|NCT03575507|DEVICE|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
219231151|NCT05474326|DEVICE|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
219231152|NCT04453488|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
219145556|NCT00346151|DRUG|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
219231153|NCT04453488|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
219231154|NCT02105571|BEHAVIORAL|Intervention|
219719303|NCT06387667|DIAGNOSTIC_TEST|Microscopic examination|sputum and bronchoalveolar lavage (BAL)
219719304|NCT06387667|DIAGNOSTIC_TEST|culture and sensitivity|for bacterial and fungal
219719305|NCT05751668|DRUG|Paclitaxel|Given IV
219719306|NCT05751668|DRUG|Monosialotetrahexosylganglioside|Given IV
219145557|NCT02203630|DRUG|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
219553381|NCT02542462|DRUG|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
219553382|NCT02542462|DRUG|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
219145558|NCT02203630|DRUG|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
219145559|NCT02537704|BEHAVIORAL|Group Lifestyle Balance Program|
219145560|NCT00477776|DRUG|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
219145561|NCT00477776|DRUG|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
219145562|NCT01422616|DRUG|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
219145563|NCT01422616|DRUG|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
219145564|NCT01422616|OTHER|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
219145565|NCT01422616|OTHER|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
219553383|NCT02542462|DRUG|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
219145566|NCT04962074|DEVICE|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
219231155|NCT02144597|DIETARY_SUPPLEMENT|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
219553384|NCT02542462|DRUG|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
219553385|NCT05823662|PROCEDURE|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
219231156|NCT02144597|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
219231157|NCT02144597|OTHER|Control diet|
219553386|NCT05823662|DRUG|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
219553387|NCT06244420|OTHER|Clinical data review|review the medical records, radiological imaging, and histological data of these patients
219553388|NCT04096586|OTHER|Red juice|To determine the effects of red juice on satiety and gut health
219553389|NCT04096586|OTHER|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
219719307|NCT05751668|OTHER|Questionnaire Administration|Ancillary Studies
219719308|NCT05751668|OTHER|Quality-of-life assessment|Ancillary Studies
219719309|NCT05751668|DRUG|Placebo Administration|Given IV
219719310|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube one size smaller than the traditional method|During tracheal intubation，choose a Left Double-lumen Endobronchial Tubethat is one size smaller than the traditional method.In this study, all patients planned to be enrolled are female. In experimental group the relationship between height and size is roughly as follows: For patients with a height between 152 - 165 cm, a 32Fr (French) tube is often selected. For patients with a height between 165 - 177 cm, a 35Fr tube is often selected. For patients with a height of more than 177 cm, a 37Fr tube is often selected.
219145567|NCT04962074|DEVICE|Density gradient|Density gradient centrifugation
219145568|NCT04177017|BEHAVIORAL|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
219145569|NCT00281489|DEVICE|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
219553390|NCT01146080|DEVICE|Promus Element|Promus Element implanted to treat coronary artery lesions.
219553391|NCT01146080|DEVICE|Promus|Promus stent implanted to treat coronary artery lesions
219553392|NCT01899833|DIAGNOSTIC_TEST|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
219553393|NCT02779933|OTHER|Epidemiology od HAP|no intervention
219553394|NCT00397254|DRUG|rizatriptan|10mg ODT 27 tablets
219553395|NCT00397254|DRUG|rizatriptan|10mg ODT 9 tablets
219553396|NCT00493883|DEVICE|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
219553397|NCT01531816|DEVICE|Early Rehabilitation intervention|"1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
219553398|NCT02374216|PROCEDURE|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
219553399|NCT05266287|DIETARY_SUPPLEMENT|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
219553400|NCT05266287|DIETARY_SUPPLEMENT|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
219553401|NCT05904639|GENETIC|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
219553402|NCT05214144|OTHER|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~* PRO-CTCAE (approximately 11 questions plus free text)~* Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~* PRO ECOG question (1 question)~* EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~* Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~* The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
219553403|NCT05214144|OTHER|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
219553404|NCT05214144|DEVICE|Fitbit|wearable device
219553405|NCT05214144|OTHER|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
219553406|NCT05214144|OTHER|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
219553407|NCT04153318|DEVICE|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
219553408|NCT01632449|DRUG|Test product|Dimethyl Fumarate (BG00012)
219553409|NCT01632449|DRUG|Reference product|Dimethyl Fumarate (BG00012)
219553410|NCT02212236|OTHER|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
219553411|NCT04881188|DIAGNOSTIC_TEST|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
219553412|NCT02102815|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
219553413|NCT02102815|DRUG|Normal saline|NSS 50 mL IV slowly push over 5 minutes
219553414|NCT02340780|DRUG|Buparlisib|
219553415|NCT05857345|OTHER|Collection of breastmilk|Collection of breastmilk and other information about the participant
219553416|NCT00310492|BIOLOGICAL|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
219553417|NCT01733576|DEVICE|HD-tDCS|
219145570|NCT00281489|BEHAVIORAL|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
219145571|NCT04852432|DEVICE|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
219145572|NCT04852432|DEVICE|nasal prong|Oxygen is administered via nasal prong
219719311|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube according to traditional methods|"During tracheal intubation，choose the regular Left Double-lumen endobronchial tube according to the traditional method. The selection of double-lumen tube sizes using traditional methods relies on two factors: height and gender. In this study, all patients planned to be enrolled are female, so the traditional corresponding relationship is roughly as follows:~For patients with a height of less than 152 cm, a 32Fr (French) tube is often selected.~For patients with a height between 152 - 165 cm, a 35Fr tube is often selected. For patients with a height between 165 - 177 cm, a 37Fr tube is often selected. For patients with a height of more than 177 cm, a 39Fr tube is often selected."
219719312|NCT07090759|DRUG|GST-HG141|GST-HG141 50 mg BID
219145573|NCT01471392|DEVICE|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
219145574|NCT03897413|DRUG|S-888711|Administered orally as three 0.25 mg tablets
219145575|NCT03897413|DIETARY_SUPPLEMENT|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
219145576|NCT06176924|DEVICE|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
219145577|NCT06176924|OTHER|Relaxation technique|Relaxation technique
219145578|NCT00566904|DRUG|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
219145579|NCT00566904|DRUG|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
219145580|NCT00566904|OTHER|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
219145581|NCT04778917|DRUG|Low-Molecular-Weight Heparins Calcium Injection|We use different dose of low-molecular-weight heparins calcium injection to different interventions
219145582|NCT01764815|DEVICE|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
219145583|NCT04353102|DRUG|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
219145584|NCT03151590|BEHAVIORAL|exercise training|
219719313|NCT07090759|DRUG|GST-HG141 Placebo|GST-HG141 Placebo BID
219145585|NCT03573284|DIAGNOSTIC_TEST|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
219145586|NCT03573284|DIAGNOSTIC_TEST|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
219145587|NCT06170593|DRUG|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
219145588|NCT03774459|DRUG|High dose ANAVEX2-73|Active oral capsule
219145589|NCT03774459|DRUG|Mid dose ANAVEX2-73|Active oral capsule
219145590|NCT03774459|DRUG|Placebo oral capsule|Placebo oral capsule
219145591|NCT03146065|BIOLOGICAL|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
219145592|NCT03146065|DRUG|Placebo|Comparison of Placebo to different doses of PF-06730512
219145593|NCT02886858|DEVICE|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
219231158|NCT02364856|DEVICE|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
219719314|NCT07096830|DRUG|Topical Tetrachlorodecaoxide (TCDO/Oxoferin)|Topical Tetrachlorodecaoxide (TCDO), a solution with antimicrobial and oxygen-releasing properties, will be applied once daily to the wound bed for 21 consecutive days or until satisfactory healing.
219719315|NCT07096830|OTHER|Standard Wound Care|Standard wound care includes saline irrigation, wound debridement, antibiotic administration as necessary, and sterile dressing. Provided to all participants.
219145594|NCT02886858|DEVICE|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
219145595|NCT02539212|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
219145596|NCT02539212|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
219145597|NCT05987878|PROCEDURE|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
219231159|NCT05640505|BEHAVIORAL|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
219231160|NCT01029704|DRUG|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
219231161|NCT01029704|DRUG|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
219231162|NCT00383383|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
219231163|NCT00383383|BIOLOGICAL|Engerix-B|
219231164|NCT01246804|DRUG|raltegravir single dose|single dose 400mg raltegravir
219719316|NCT07093008|DRUG|AQ280 Capsule|AQ280 administered orally in capsule formulation.
219719317|NCT07093008|DRUG|AQ280 Tablet for Oral Suspension|AQ280 administered orally in tablet for oral suspension formulation.
219719318|NCT07093008|DRUG|Placebo Capsule|Placebo administered orally in capsule formulation.
219719319|NCT07093008|DRUG|Placebo Tablet for Oral Suspension|Placebo administered orally in tablet for oral suspension formulation.
219719320|NCT07094425|DIAGNOSTIC_TEST|transthoracic echocardiography|"Transthoracic echocardiography (TTE) is a non-invasive method for assessing cardiac morphology and function. As part of the study protocol, TTE will be performed at the time of study inclusion (within the first 24 hours after ICU admission), on day 3, day 7, and day 14, followed by weekly assessments (until discharge from the ICU), as well as on the day of planned ICU or hospital discharge.~To verify skeletal muscle mass in relation to myocardial mass and its changes over the course of the ICU stay, bioelectrical impedance analysis (BIA) will be performed at the time points mentioned above."
219719321|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
219145598|NCT03264235|DEVICE|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
219145599|NCT03264235|OTHER|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
219145600|NCT05375188|DRUG|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
219231165|NCT01246804|DRUG|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
219231166|NCT04166084|OTHER|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
219231167|NCT04166084|OTHER|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
219231168|NCT00765544|DEVICE|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
219231169|NCT00765544|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
219231170|NCT02163148|BEHAVIORAL|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
219231171|NCT00077558|DRUG|fludarabine phosphate|
219231172|NCT00077558|DRUG|triapine|
219719322|NCT07095452|DRUG|Etentamig|Intravenous (IV) Infusion
219719323|NCT07095452|DRUG|Lenalidomide|Oral Capsule
219719324|NCT07095452|DRUG|Daratumumab|Subcutaneous Injection
219719325|NCT07095452|DRUG|Dexamethasone|Oral Tablet
219719326|NCT07095452|DRUG|Dexamethasone|IV Injection
219719327|NCT07103200|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
219145601|NCT05375188|DRUG|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
219145602|NCT05520086|DRUG|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
219231173|NCT04999072|PROCEDURE|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
219145603|NCT05520086|DRUG|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
219145604|NCT01501188|OTHER|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
219145605|NCT01501188|OTHER|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
219145606|NCT04957225|BEHAVIORAL|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
219145607|NCT06300489|DRUG|irinotecan liposomes+capecitabine|"Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD)."
219145608|NCT01688089|DRUG|ODM103|
219145609|NCT01688089|DRUG|Placebo|
219145610|NCT01688089|DRUG|Entacapone|
219145611|NCT01688089|DRUG|Levodopa/carbidopa|
219145612|NCT00239083|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219145613|NCT04906278|DEVICE|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
219145614|NCT04906278|PROCEDURE|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
219145615|NCT04906278|DRUG|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
219145616|NCT01599897|BIOLOGICAL|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
219145617|NCT01599897|BIOLOGICAL|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
219145618|NCT00506298|DRUG|bezafibrate + diflunisal|bezafibrate + diflunisal
219145619|NCT00506298|DRUG|bezafibrate + placebo|bezafibrate + placebo
219145620|NCT00977223|DRUG|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
219145621|NCT01257932|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
219145622|NCT00463788|DRUG|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
219145623|NCT00463788|DRUG|cisplatin|"Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
219145624|NCT03178292|DRUG|Levofloxacin|Levofloxacin 500Mg daily for 5 days
219145625|NCT03178292|DRUG|Placebo|Placebo Oral Tablet daily for 5 days
219145626|NCT05943171|DEVICE|Cognitive Behavioral Therapy|All participants will receive Cognitive Behavioral Therapy. They will be randomized to either Digital RITch®CBT or Standard CBT
219145627|NCT00360698|DRUG|Insulin Glargine|One daily injection at bedtime
219145628|NCT00360698|DRUG|Glimepiride|At same dosage as during the run-in period
219145629|NCT00360698|DRUG|Insulin Glulisine|One bolus given before the main meal
219145630|NCT00360698|DRUG|Metformin|At same dosage as during the run-in period
219145631|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
219145632|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
219231174|NCT01968824|PROCEDURE|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
219231175|NCT04226456|DRUG|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
219231176|NCT00089791|DRUG|placebo|Placebo administered by subcutaneous injection
219231177|NCT00089791|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection
219145633|NCT04088032|DRUG|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
219145634|NCT01042639|BEHAVIORAL|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
219145635|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
219145636|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
219145637|NCT05789771|DRUG|Abemaciclib|Abemaciclib 200 mg orally every 12 hours
219145638|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status"
219145639|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
219231178|NCT06080087|BEHAVIORAL|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
219231179|NCT04176952|DRUG|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
219231180|NCT04176952|DRUG|AG|"* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
219553418|NCT03109041|DEVICE|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
219553419|NCT02593019|DRUG|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
219553420|NCT05311150|DEVICE|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
219553421|NCT05311150|DEVICE|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
219553422|NCT02798406|BIOLOGICAL|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
219553423|NCT02798406|BIOLOGICAL|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
219553424|NCT02671877|PROCEDURE|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
219553425|NCT03212378|OTHER|percutaneous coronary interventions|Percutaneous coronary intervention.
219553426|NCT04273438|DEVICE|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
219553427|NCT04273438|DEVICE|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
219553428|NCT01516762|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
219553429|NCT00066391|DRUG|cisplatin|
219553430|NCT00066391|DRUG|irinotecan hydrochloride|
219553431|NCT00066391|PROCEDURE|neoadjuvant therapy|
219553432|NCT02181140|DEVICE|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
219553433|NCT04251091|OTHER|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
219553434|NCT04251091|OTHER|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
219553435|NCT05753995|DIAGNOSTIC_TEST|PET imaging|The evaluation of PET imaging using PET ligand \[18F\]JNJ-64413739 or a \[18F\] labeled equivalent in vivo in patients.
219231181|NCT00148122|DRUG|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
219231182|NCT00148122|DRUG|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
219719328|NCT07103200|BEHAVIORAL|Restless Bandit|"Participants are presented with three targets (decks of cards) on the screen, which they select with a mouse movement. Each of the three targets is associated with a hidden probability of reward, which drifts unpredictably and independently across trials. This encourages participants to exploit good options when they are available, but also occasionally to explore other targets, which could become better at any time. Eye Tracking is done at each visit while the participant completes the Restless Bandit tasks."
219145640|NCT04414098|DRUG|INC424 / Ruxolitinib|"1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
219145641|NCT02277288|OTHER|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
219145642|NCT05816486|DIAGNOSTIC_TEST|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
219145643|NCT02147535|DRUG|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
219145644|NCT05165082|DRUG|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
219145645|NCT05165082|PROCEDURE|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
219145646|NCT04062760|DRUG|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
219145647|NCT04062760|DRUG|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
219145648|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
219145649|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
219231183|NCT04179565|BEHAVIORAL|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
219231184|NCT00904085|DRUG|Oxymorphone IR|5 mg
219719329|NCT07104227|BEHAVIORAL|body mechanics training|"Randomization: The Demographic and Health Data Form will be applied to the participants by the researcher responsible for randomization, and the information obtained will be kept in consecutively numbered, closed, opaque envelopes. The block randomization method will be used when dividing the participants into intervention and control groups. In order to ensure balance in important demographic and health-related variables, the participants will be randomized by stratifying them according to age. The person responsible for collecting the study data will be unaware of the randomization process until the researcher responsible for randomization reports the results. Intervention group: After the initial data collection, the breastfeeding behaviors of the mothers in the intervention group will be observed. Then, the mothers will be given training on ergonomic breastfeeding, correct breastfeeding positions and body mechanics to strengthen the musculoskeletal system during the breas"
219719330|NCT07104227|OTHER|to inform|Kontrol grubundaki anneler, hastanenin rutin bakım hizmetleri kapsamında emzirme danışmanı ebe tarafından verilen bilgilendirme ve destek hizmetlerinden yararlanacaklardır. Ayrıca bu anneler için emzirme döneminde doğru duruş ve emzirme pozisyonlarında dikkat edilmesi gereken durumlar konusunda bir broşür hazırlanacak ve kendilerine verilecektir. Kontrol grubunun izlem verilerinin telefon görüşmesi yöntemi ile toplanacağı belirtilerek bir görüşme-izlem planı anne ile birlikte oluşturulacaktır. Kontrol grubundaki anneler müdahale grubu ile eşzamanlı olarak doğum sonu 6. Hafta ve 3.aylarda aranarak sırt ve boyun ağrıları değerlendirilecektir.
219231185|NCT04738149|DRUG|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
219231186|NCT04738149|DEVICE|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
219145650|NCT02975310|PROCEDURE|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
219145651|NCT02975310|PROCEDURE|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
219145652|NCT02975310|OTHER|General Anesthesia|ESS will be performed under general anesthesia in the operating room
219145653|NCT02975310|OTHER|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
219145654|NCT03024606|BEHAVIORAL|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
219145655|NCT02838342|DRUG|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
219145656|NCT02838342|DRUG|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
219145657|NCT04598321|DRUG|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
219231187|NCT04738149|DEVICE|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
219719331|NCT07104487|DRUG|[18F]AlF-OC|Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.
219719332|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFOX|Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W
219719333|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFIRI|Ongericimab, Toripalimab, Bevacizumab, Irinotecan, Calcium folinate, 5-FU, Q2W
219719334|NCT07105917|DRUG|SGLT-2 inhibitors|"Any of the following SGLT2 inhibitors (SGLT2i) can be selected for treatment:~Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD) If the patient has concurrent diabetes, the use of other antidiabetic drugs is not restricted.~The treatment should last for at least 14 days."
219145658|NCT03339024|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
219145659|NCT03339024|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
219145660|NCT04068207|DRUG|Minocycline|Tab. Minocycline 100mg po per day for 12 months
219145661|NCT06478680|BEHAVIORAL|Exoskeleton mediated gait training|"1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training"
219145662|NCT06478680|BEHAVIORAL|High intensity gait training|"2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement"
219145663|NCT02244060|OTHER|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
219145664|NCT01211093|PROCEDURE|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
219719335|NCT07105917|OTHER|Standard medical treatment|According to the guideline-recommended standard treatment, if the patient has diabetes, there is no restriction on the use of other antidiabetic drugs (except SGLT-2 inhibitors).
219145665|NCT01211093|PROCEDURE|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
219145666|NCT01211093|PROCEDURE|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
219145667|NCT03626558|OTHER|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
219231188|NCT00276679|DRUG|temozolomide|
219231189|NCT05247307|BIOLOGICAL|convalescent plasma infusion covid 19|"Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts."
219719336|NCT07100821|DIAGNOSTIC_TEST|Hemodynamic parameters was measured by using electric cardiometry (ICON)|Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.
219719337|NCT07114445|OTHER|Diabetes Treatment|Training with virtual reality glasses
219719338|NCT07115758|PROCEDURE|control GBR|will have a full thickness papilla preservation FLAP, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
219231190|NCT05508477|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
219231191|NCT05508477|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
219145668|NCT03996863|DEVICE|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
219145669|NCT03996863|DEVICE|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
219719339|NCT07115758|PROCEDURE|VST|"Pre extraction procedure:~Prior to tooth extraction, cone beam computed tomography (CBCT) images will be taken to inspect the overall socket condition.~All patients will be scanned pre-operatively using an intra-oral scanner (IOS).~Extraction protocol:~incisal extraction technique, where atraumatic tooth extraction to the hopeless tooth will be performed using periotomes followed by conventional forceps."
219145670|NCT01407393|DEVICE|Glucosanol|2 tablets 3x daily for 12 weeks
219145671|NCT01407393|DEVICE|Placebo|2 tablets 3x daily for 12 weeks
219145672|NCT03601910|DRUG|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
219145673|NCT03601910|DRUG|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
219145674|NCT02364349|DRUG|Bee Venom (BV)|Raw Bee Venom
219145675|NCT02364349|DRUG|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
219145676|NCT00761436|BIOLOGICAL|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
219145677|NCT02547922|BIOLOGICAL|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
219145678|NCT02547922|DRUG|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
219145679|NCT04836806|DRUG|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
219145680|NCT04836806|DRUG|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
219145681|NCT02167906|OTHER|arterial stiffness measurement|
219145682|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
219145683|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
219145684|NCT02747381|DIETARY_SUPPLEMENT|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
219145685|NCT00710515|DRUG|AZD6244|75mg
219145686|NCT04614675|PROCEDURE|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
219145687|NCT04614675|PROCEDURE|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
219145688|NCT00432718|PROCEDURE|Saline Instillation before Tracheal Suctioning|
219231192|NCT00519207|DRUG|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
219231193|NCT00519207|DRUG|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
219231194|NCT01785056|BIOLOGICAL|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
219231195|NCT04514978|PROCEDURE|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
219145689|NCT04843306|BEHAVIORAL|Biofeedback|Relaxation coaching will be used in this study.
219145690|NCT04843306|BEHAVIORAL|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
219145691|NCT05429034|BEHAVIORAL|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
219145692|NCT05429034|BEHAVIORAL|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
219145693|NCT05727241|DIAGNOSTIC_TEST|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
219145694|NCT04970979|OTHER|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
219145695|NCT03107767|PROCEDURE|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
219145696|NCT01528306|BIOLOGICAL|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
219145697|NCT01528306|OTHER|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
219145698|NCT02282085|DRUG|Aripiprazole Once-Monthly|
219145699|NCT02282085|DRUG|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
219145700|NCT03221777|DIAGNOSTIC_TEST|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
219145701|NCT06307223|DRUG|30% supramolecular salicylic acid|The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
219145702|NCT06307223|DRUG|supramolecular active zinc|The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
219231196|NCT02016365|DRUG|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
219231197|NCT02016365|DRUG|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
219231198|NCT06092736|DRUG|Compound Danshen Dropping Pills|Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
219145703|NCT01867632|DEVICE|Acellular Dermal Matrix|
219145704|NCT03772457|DRUG|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
219231199|NCT06092736|DRUG|Placebo|placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
219231200|NCT04697615|DEVICE|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
219719340|NCT07113977|BIOLOGICAL|CAR-T(CD70)|In this clinical study, participants with advanced renal cell carcinoma will receive a novel humanized CD70-targeted CAR-T-cell product that incorporates the TLR2 co-stimulatory domain. Peripheral blood mononuclear cells will be collected from each subject, genetically modified to express the CAR construct, and expanded ex vivo; after passing multiple quality-control assays, the CAR-T cells will be administered intratumorally under CT guidance at the pre-specified dose. Following treatment, the efficacy and safety of CD70-directed CAR-T-cell therapy will be comprehensively assessed through clinical symptom evaluations, quality-of-life questionnaires, biomarker analyses, laboratory tests, imaging studies, adverse-event monitoring, and long-term follow-up.
219719341|NCT07117292|DEVICE|Xsens DOT|Wearable inertial sensor used to capture cervical range of motion in three planes.
219719342|NCT07117292|DEVICE|Trigno Avanti Sensors|Wearable inertial sensor used to capture cervical range of motion in three planes.
219719343|NCT07117292|DEVICE|Universal Goniometer|Standard clinical tool used to measure cervical spine motion angles manually.
219719344|NCT07117604|OTHER|Virtual Reality|Standard virtual reality applications rely on computer-generated animation environments and avatars; however, in the present study, the content created by actors/actresses with theater training by using cameras and audio recording devices suitable for creating virtual reality content included images of real environments and people.
219719345|NCT07117604|OTHER|Control group|While the participants in the intervention group received training on virtual reality, those in the control group took the standard curriculum course. Students in the control group received no training. The students in the control group were told that the program would be implemented to those who volunteered after the study was completed.
219719346|NCT07116941|BEHAVIORAL|Cognitive Exercises|Participants perform a 30-minute session of cognitive tasks during the sitting phase of early ICU mobilization. Activities include word games, attention exercises, and simple problem-solving tasks designed to engage memory and executive function.
219719347|NCT07116941|BEHAVIORAL|Auditory Stimulation|Participants listen to calming music or nature sounds through headphones for 30 minutes during early mobilization in the ICU. The auditory content is selected to reduce anxiety and promote relaxation.
219231201|NCT06505096|PROCEDURE|cataract surgery|Phaco+IOL implention
219231202|NCT02817360|DRUG|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
219231203|NCT02817360|OTHER|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
219719348|NCT07116941|BEHAVIORAL|Multisensory Stimulation|Participants receive 30 minutes of combined sensory stimulation during the sitting phase in the ICU. This includes tactile stimulation using hand therapy balls and olfactory stimulation with lavender or mint-scented materials to enhance relaxation and sensory engagement.
219719349|NCT07117526|DEVICE|Aneurysm occlusion with an intrasaccular device|Intervention with HARBOR Occlusion Device
219145705|NCT00739141|DRUG|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
219145706|NCT02336438|DIETARY_SUPPLEMENT|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
219145707|NCT02607670|DRUG|TAT4 Gel|
219145708|NCT02607670|DRUG|Matching placebo|
219145709|NCT06484504|DIETARY_SUPPLEMENT|Kombucha beverage|After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
219145710|NCT01317420|DRUG|BI 836845|Intravenous infusion
219145711|NCT02993588|DRUG|Melatonin|Melatonin 6 mg tablet once daily
219145712|NCT02993588|OTHER|Placebo|one tablet once daily
219145713|NCT04210505|DRUG|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
219145714|NCT04210505|OTHER|Standard Care|Control group will receive standard care as provided by the dialysis center
219145715|NCT04003805|DRUG|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
219145716|NCT04003805|DRUG|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
219145717|NCT03194958|BEHAVIORAL|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
219145718|NCT03194958|BEHAVIORAL|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
219145719|NCT04828148|BEHAVIORAL|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
219145720|NCT00317226|DRUG|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
219145721|NCT02511613|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
219145722|NCT02511613|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
219145723|NCT02511613|DRUG|ranibizumab|ranibizumab intravitreal injection
219145724|NCT01968226|DRUG|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
219145725|NCT05757388|DRUG|Parecoxib + paracetamol|Administers after induction of anesthesia.
219145726|NCT05757388|DRUG|Normal saline|Administers after induction of anesthesia.
219553436|NCT04711824|DRUG|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
219553437|NCT04711824|RADIATION|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
219553438|NCT04711824|DRUG|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
219553439|NCT04711824|DRUG|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
219719350|NCT07116434|BEHAVIORAL|Discovery Prgoram|"The Discovery Program is a novel, hybrid intervention specifically designed to address the psychosocial barriers faced by adolescents and young adults with T1D. This intervention integrates three key components:~1. Patient-Reported Measures~2. In-Clinic Collaborative Goal Setting~3. Personalized Mobile Health Communications~The Discovery Program will be delivered over a 3-month intervention period, followed by a 6-month follow-up to assess outcomes. This approach not only aims to improve glycemic control but also seeks to enhance diabetes self-management behaviors, reduce diabetes distress, and build problem-solving skills among participants. The integration of clinical informatics, personalized support, and mobile health technology distinguishes this intervention from traditional diabetes care practices, which often overlook psychosocial factors affecting health outcomes."
219719351|NCT07115173|DRUG|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
219719352|NCT07115030|BEHAVIORAL|PCT+2HOPE|"Each PCT+ group follows the same structure and starts with the group setting an agenda. Clients identify issues to work on using these steps: 1) Identify an issue and if/how it relates to their PTSD or substance use, 2) Brainstorm ideas that may help, 3) Evaluate how useful each idea is, and 4) Choose a plan. Clients are encouraged to implement and evaluate the effectiveness of the plan and share the outcome at their next group. At the end of the group, clients process their experiences of the discussion.~HOPE is a flexible, module-based individual treatment where the ordering and emphasis of each module are determined by client priorities. HOPE is trauma-focused; clients relate their current symptoms to their experience of IPV, but do not process traumatic memories. Modules focus on 1) Establishing safety, providing information and skills that enhance empowerment, 2) Cognitive behavioral therapy skills, and 3) Improving relationships and establishing healthy boundaries."
219719353|NCT07114848|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily for 14 days
219553440|NCT03449680|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
219719354|NCT07114848|DRUG|solifenacin|Solifenacin 5 mg once daily for 14 day
219719355|NCT07119008|DEVICE|Virtual reality|Patients will perform 12 virtual reality sessions at a rate of 2 sessions per week for 6 weeks. The patient will be offered to properly store food groceries by differentiating perishable or non-perishable foods from non-food items, or to prepare cooking recipes.
219719356|NCT07116174|BIOLOGICAL|Xcell Amnio Matrix|A lyophilized amniotic membrane allograft
219145727|NCT00886145|DEVICE|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
219145728|NCT00259961|PROCEDURE|open fundoplication|
219145729|NCT00259961|PROCEDURE|laparoscopic fundopliaction|
219553441|NCT03449680|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
219145730|NCT06331611|DEVICE|TOF monitoring|Reversal with Sugammadex will be based on TOF monitoring
219553442|NCT01221051|PROCEDURE|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
219145731|NCT02971488|OTHER|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
219145732|NCT00903227|DRUG|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
219145733|NCT00903227|DRUG|Placebo|1 puff of inhaled Placebo twice a day
219145734|NCT00903227|DRUG|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
219145735|NCT00903227|DRUG|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
219145736|NCT00903227|DRUG|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
219231204|NCT02990494|BEHAVIORAL|STANDARD|Standard Internet-delivered behavioral weight loss
219553443|NCT01221051|PROCEDURE|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
219553444|NCT05626023|DRUG|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
219553445|NCT05887687|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
219553446|NCT02902133|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
219145737|NCT05932082|PROCEDURE|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
219145738|NCT02010138|PROCEDURE|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
219145739|NCT02010138|PROCEDURE|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
219145740|NCT02456506|RADIATION|Hyperfractionated IMRT|
219145741|NCT02456506|RADIATION|Conventional Fraction IMRT|
219231205|NCT02990494|BEHAVIORAL|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
219231206|NCT02990494|BEHAVIORAL|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
219231207|NCT00038597|DRUG|SCH66336|
219145742|NCT05786898|OTHER|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
219145743|NCT01368198|OTHER|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
219145744|NCT01368198|OTHER|OPTIVE™|One instillation of the eye drop in each eye
219145745|NCT01323777|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219145746|NCT02202824|OTHER|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
219145747|NCT00237770|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
219145748|NCT00237770|PROCEDURE|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
219145749|NCT01827345|DIETARY_SUPPLEMENT|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
219145750|NCT05704751|DEVICE|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
219145751|NCT01845259|DRUG|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
219145752|NCT01845259|DRUG|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
219145753|NCT00392054|PROCEDURE|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
219231208|NCT01365546|BIOLOGICAL|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
219231209|NCT04217798|DRUG|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
219231210|NCT05394636|OTHER|None, pure observational study|None, pure observational study
219231211|NCT01235936|DRUG|AKB-6548|Different dose levels
219231212|NCT04454476|DRUG|Trametinib treatment|1 mg taken by mouth once a day for 14 days
219553447|NCT06385548|DRUG|Lurbinectedin|participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
219145754|NCT00392054|DRUG|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
219145755|NCT02176772|OTHER|Stable iron isotopes, non-drug intervention|
219145756|NCT04975308|DRUG|Imlunestrant|Administered orally.
219145757|NCT04975308|DRUG|Exemestane|Administered orally.
219145758|NCT04975308|DRUG|Fulvestrant|Administered IM.
219145759|NCT04975308|DRUG|Abemaciclib|Administered orally.
219145760|NCT04333355|BIOLOGICAL|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
219231213|NCT04454476|PROCEDURE|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
219231214|NCT03398798|DEVICE|".014"|".014 CuNiTi orthodontic arch wire"
219231215|NCT03398798|DEVICE|".016"|".016 CuNiTi orthodontic arch wire"
219231216|NCT03398798|DEVICE|Twin brackets|Ormco Insignia Metal Twin brackets
219231217|NCT03398798|DEVICE|Self-ligating brackets|Ormco Insignia SL brackets
219231218|NCT01847859|PROCEDURE|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
219145761|NCT02709655|DRUG|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
219145762|NCT02709655|DRUG|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
219145763|NCT02709655|DRUG|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
219145764|NCT02709655|OTHER|Placebo|Encapsulated tablet, orally
219145765|NCT00102063|DRUG|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
219231219|NCT03200574|DIAGNOSTIC_TEST|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
219231220|NCT03200574|DEVICE|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
219231221|NCT00364988|DRUG|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
219231222|NCT00364988|DRUG|losartan|losartan (100 mg daily)
219231223|NCT01758068|PROCEDURE|Coconut Oil Application|Coconut oil - 4 ml
219231224|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
219231225|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
219231226|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
219231227|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
219553448|NCT06385548|DRUG|Dostarlimab|participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
219553449|NCT05426200|BEHAVIORAL|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
219553450|NCT05139238|DRUG|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
219553451|NCT05139238|DRUG|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
219145766|NCT00102063|DRUG|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
219145767|NCT00102063|DRUG|Placebo tablet|Placebo tablet po qd x 42 days
219145768|NCT02771171|RADIATION|CT Scan|CT imaging
219145769|NCT03461575|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
219145770|NCT03461575|DRUG|Restasis|cyclosporine 0.05%
219231228|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
219231229|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
219231230|NCT04183491|BIOLOGICAL|Placebo|Placebo (administered either IM or SC)
219231231|NCT04602949|DIAGNOSTIC_TEST|Breath Biopsy Analysis|Analysis of a single breath Biopsy
219231232|NCT00972920|PROCEDURE|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
219231233|NCT02221778|RADIATION|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
219231234|NCT04003792|DRUG|oxaliplatin|intra-arterial oxaliplatin administration
219231235|NCT04003792|DRUG|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
219231236|NCT04003792|DRUG|Bevacizumab|systemic bevacuzimab therapy
219231237|NCT05156606|DRUG|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
219231238|NCT02538094|DEVICE|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
219719357|NCT07118384|DRUG|Cefoperazone-sulbactam injection|Two grams of Cefoperazone/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a maximum final concentration of 250 mg/ml
219145771|NCT03461575|DRUG|Moisview|trehalose 3%
219145772|NCT01493778|DRUG|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
219145773|NCT03957213|DEVICE|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
219231239|NCT02538094|DEVICE|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
219231240|NCT04027452|BEHAVIORAL|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
219553452|NCT00620958|BEHAVIORAL|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
219553453|NCT00620958|BEHAVIORAL|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
219553454|NCT00620958|BEHAVIORAL|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
219719358|NCT07118384|DRUG|Ampicillin - Sulbactam Injection|Two grams of Ampicillin/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a final concentration not exceeding 45mg/ml.
219145774|NCT03957213|BEHAVIORAL|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
219145775|NCT05082077|DEVICE|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
219145776|NCT00224601|PROCEDURE|Colonoscopy with chromoscopy|
219145777|NCT03695536|BEHAVIORAL|ultrasound use during resuscitation|ultrasound use during resuscitation
219145778|NCT03309579|OTHER|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
219145779|NCT03309579|OTHER|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
219145780|NCT06335654|DIAGNOSTIC_TEST|artificial intelligence system|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
219553455|NCT04301258|OTHER|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
219145781|NCT05150054|DEVICE|CardioFlux|Not an intervention
219145782|NCT05082025|DRUG|Copanlisib|Given by IV
219145783|NCT05082025|DRUG|fulvestrant|Given by IM
219145784|NCT04210180|DRUG|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
219145785|NCT04210180|OTHER|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
219145786|NCT02220816|BEHAVIORAL|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
219145787|NCT02220816|BEHAVIORAL|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
219145788|NCT01179334|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
219145789|NCT01179334|DRUG|Placebo|Placebo for 12 weeks
219145790|NCT01179334|DRUG|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
219145791|NCT00857649|DRUG|Memantine|20 mg Oral Tablets Once Daily
219145792|NCT00857649|DRUG|Placebo|Oral Tablets Once Daily
219145793|NCT01325558|BIOLOGICAL|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
219145794|NCT01912131|BEHAVIORAL|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
219145795|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
219145796|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
219553456|NCT03956758|OTHER|Semi-directed interview|Semi-directed interview on ChemSex practice
219145797|NCT01912131|BEHAVIORAL|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
219145798|NCT01912131|BEHAVIORAL|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
219145799|NCT00092898|DRUG|MK0653, ezetimibe|
219145800|NCT00092898|DRUG|Comparator: placebo|
219145801|NCT05893459|BEHAVIORAL|Debrief|Post-Stressor Discussion with a Friend
219145802|NCT04329793|DEVICE|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
219145803|NCT04329793|OTHER|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
219145804|NCT00043654|DRUG|Mifepristone|
219145805|NCT05357365|OTHER|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
219145806|NCT00316953|DRUG|dasatinib|Given orally
219145807|NCT00316953|OTHER|pharmacological study|Correlative studies
219145808|NCT00316953|OTHER|laboratory biomarker analysis|Correlative studies
219145809|NCT06289348|BEHAVIORAL|socio-psychological questionnaire|ton collecte socio-demographic variable
219145810|NCT06289348|BEHAVIORAL|revised event impact scale (IER-S)|22 items assessed on a scale of frequency from 0 (not at all) to 4 (extremely)
219145811|NCT06289348|OTHER|Non directive interview|composed of a very broad opening sentence to encourage the parents' discourse
219145812|NCT06289348|OTHER|Stern interview|54 questions to investigate the impact of the announcement and the parenthood construction
219553457|NCT01897077|DRUG|Peanut Dissolving Film|
219553458|NCT06560866|BEHAVIORAL|Just Care for Families|Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
219145813|NCT06289348|OTHER|semi-directive interview|to propose ideas for improving and harmonizing practices
219145814|NCT05787964|PROCEDURE|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
219145815|NCT04537065|OTHER|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
219145816|NCT05190419|DRUG|Orismilast modified release tablets|Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
219145817|NCT05190419|DRUG|Placebo|Matching placebo tablets
219145818|NCT04643340|OTHER|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
219553459|NCT05597228|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
219553460|NCT01264523|OTHER|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
219553461|NCT01852721|BEHAVIORAL|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
219553462|NCT01852721|BEHAVIORAL|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
219553463|NCT02671630|OTHER|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
219553464|NCT03768635|OTHER|necrotizing external otitis|description of necrotizing external otitis
219553465|NCT06626906|DIAGNOSTIC_TEST|Echocardiography, Blood sampling for biomarker assays|
219553466|NCT04261374|DIAGNOSTIC_TEST|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
219553467|NCT03586622|DIETARY_SUPPLEMENT|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
219553468|NCT03586622|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
219553469|NCT00774540|DRUG|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
219553470|NCT00774540|DRUG|Placebo|Saline
219553471|NCT01732562|OTHER|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
219553472|NCT00014469|DRUG|busulfan|
219553473|NCT00014469|DRUG|melphalan|
219553474|NCT00014469|DRUG|methotrexate|
219553475|NCT00014469|DRUG|tacrolimus|
219553476|NCT00014469|PROCEDURE|allogeneic bone marrow transplantation|
219553477|NCT05031455|DRUG|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization."
219553478|NCT06348888|DRUG|BAY2927088|Oral
219553479|NCT06348888|DRUG|Itraconazole|Capsule, 100 mg, oral.
219553480|NCT06348888|DRUG|Carbamazepine|Tablet, 100 mg, 200mg and 300mg, oral.
219553481|NCT04268797|DEVICE|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
219145819|NCT03426072|OTHER|modified IHI breakthrough series|"There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5\. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
219145820|NCT00114699|DRUG|CCR5mAb004|
219145821|NCT00919763|DRUG|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
219145822|NCT00919763|DRUG|Vehicle Ointment, twice daily|Topical Ointment
219145823|NCT01094405|BIOLOGICAL|Recombinant Epstein-Barr Virus (EBV) Vaccine|
219145824|NCT04705922|DRUG|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
219145825|NCT04705922|DRUG|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
219145826|NCT00036036|DRUG|CP-461|
219145827|NCT00833365|DRUG|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
219231241|NCT04027452|BEHAVIORAL|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
219145828|NCT00833365|DRUG|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
219231242|NCT00053118|BIOLOGICAL|filgrastim|IV
219231243|NCT00053118|DRUG|carboplatin|IV
219231244|NCT00053118|DRUG|etoposide|IV
219231245|NCT00053118|PROCEDURE|bone marrow ablation with stem cell support|IV
219231246|NCT00053118|PROCEDURE|peripheral blood stem cell transplantation|IV
219231247|NCT05983861|DIAGNOSTIC_TEST|Identification o Multi Drug Resistant Bacteria|Identification o Multi Drug Resistant Bacteria
219231248|NCT00524069|BIOLOGICAL|bevacizumab|
219231249|NCT00524069|DRUG|capecitabine|
219231250|NCT00524069|DRUG|gemcitabine hydrochloride|
219231251|NCT00524069|OTHER|flow cytometry|
219231252|NCT00524069|OTHER|laboratory biomarker analysis|
219231253|NCT00524069|PROCEDURE|adjuvant therapy|
219719359|NCT07113730|OTHER|immune reconstitution|Detection of immune reconstitution in peripheral blood of patients by flow cytometry at 30-day intervals for 180 days post-transplantation.
219145829|NCT01591733|DRUG|FOLFIRINOX|Up to Eight-14 day cycles
219145830|NCT01591733|DRUG|Capecitabine|Orally, for 10 days
219145831|NCT01591733|RADIATION|Short Course Radiation|Five or ten days
219145832|NCT01591733|PROCEDURE|Surgery|1-4 weeks after completion of capecitabine therapy
219145833|NCT04036630|DEVICE|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
219145834|NCT04036630|DEVICE|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
219231254|NCT00524069|PROCEDURE|computed tomography|
219231255|NCT00524069|PROCEDURE|neoadjuvant therapy|
219231256|NCT03189303|DEVICE|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
219231257|NCT05198219|DEVICE|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
219231258|NCT05198219|DEVICE|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
219231259|NCT02676726|PROCEDURE|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
219231260|NCT02676726|PROCEDURE|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
219231261|NCT03788226|DRUG|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
219553482|NCT04268797|DEVICE|sham|SHAM HF rTMS coil once daily x 20 days
219553483|NCT01756716|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
219553484|NCT01756716|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
219553485|NCT01756716|DRUG|Placebo|Placebo for 8 weeks
219553486|NCT02016235|DRUG|Phosphorus Supplement|250 mg po qid
219553487|NCT02016235|OTHER|Observation|Baseline blood and urine measurements only
219145835|NCT03516435|DEVICE|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
219719360|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
219719361|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
219231262|NCT03788226|DRUG|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
219231263|NCT03885544|OTHER|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
219231264|NCT03885544|OTHER|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
219719362|NCT07118696|DRUG|Extra 600mg of Rifampicin|Intervention group participants will receive standard treatment (RHZE), plus an optimised regimen consisting of RIfampicin at 20 mg/kg (additional 600mg rifampicin in each weight band) during a shortened treatment period of 16 weeks.
219719363|NCT07118696|DRUG|Placebo|The standard treatment regimen for DS-TB (rifampicin at 10 mg/kg and isoniazid for 6 months, plus pyrazinamide and ethambutol for the first 2 months; 2RHZE/4RH), with additional placebo for the first 4 months (16 weeks).
219719364|NCT07116993|DEVICE|theraputic ultrasound|Ultrasound is a mechanical sound wave with frequencies above human hearing, requiring a medium like air or tissue to travel, commonly used in imaging.
219719365|NCT07116993|DEVICE|infrared radiation|Infrared, in contrast, is electromagnetic radiation associated with heat, doesn't need a medium, and is used in applications like thermal imaging and remote controls.
219719366|NCT07117435|DRUG|paclitaxel cationic liposome for injection|Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2
219719367|NCT07117435|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 i.v. on D1
219719368|NCT07117435|DRUG|Capecitabine|Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14
219719369|NCT07117435|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg i.v. on D1
219719370|NCT07116707|BEHAVIORAL|Short Mental Health Literacy Program (SMHLP)|A single 45-minute behavioral health education lesson delivered by homeroom teachers. The session included a slide-based introduction to mental health, a 10-minute animated video about a student experiencing psychological stress, and a worksheet-based reflection activity. Teachers prepared using self-guided materials.
219719371|NCT07118059|DIETARY_SUPPLEMENT|Omega-3 (EPA+DHA)|In this study omega-3 will be the real thing mega omega supreme capsule, it will be used as an adjunct therapy with TB treatment in the intensive phase of treatment. Participant will receive x3, 1g capsules which will provide approximately 2g of EPA and DHA
219719372|NCT07118059|DIETARY_SUPPLEMENT|Placebo|This group will receive the placebo, which will be 3 x 1g capsules of high linoleic sunflower oil, the sunflower capsules have been encapsulated to match the dimension of the omega 3 supplement. The capsules will also be given as and adjunct to TB treatment of the intensive phase of TB treatment
219719373|NCT07117175|DRUG|Anti-human CD7 CAR-NK cell injection|Administer anti-human CD7 CAR-NK cell injection on D0
219719374|NCT06923423|BEHAVIORAL|Group Cognitive Processing Therapy (CPT)|Participants in CPT group therapy will learn about trauma and how to change upsetting thoughts related to it. Participants will attend up to a total of 12 sessions held 1-2x/week for 90 minutes. No more than 10 participants will be in a group. In this study, CPT provided is a version that was adapted for prisons.
219719375|NCT06923423|BEHAVIORAL|Control Group Individual trauma focused self-help via workbook|The self-help therapy is a therapy that people do on their own using a workbook. By reading and doing practice assignments in the workbook, people can learn skills to recover from trauma.
219719376|NCT07103668|DRUG|CAR T cells|better PFS/OS data comparing to the other studies.
219719377|NCT07103668|DRUG|Control|Chemo therapy by PI options.
219145836|NCT03516435|DEVICE|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
219719378|NCT06231511|DEVICE|Hip flexion soft exosuit|Participants will utilize a Wyss designed hip flexion soft exosuit. This device has a small rope winch at the front of the hip connected to a functional textile waistband and thigh band. It applies an assistive torque in response to wearable sensor measurements.
219719379|NCT06231511|DEVICE|ReWalk ReStore soft exosuit|Participants will utilize the ReWalk ReStore ankle soft exosuit. This device provides dynamic plantarflexion and dorsiflexion during walking intended to restore paretic limb function resulting in improved gait symmetry, reduced energy cost of walking and improved stability. The exosuits consists of a body-worn actuation unit containing motors, gears, and pulleys that when powered generate forces that are transmitted via Bowden cables to functional textiles anchored proximal and distal to a joint. This actuation occurs in response to signals from embedded wearable sensors.
219719380|NCT06231511|OTHER|Conventional physical therapy|Participants will complete conventional physical therapy without use of exosuits during the course of their inpatient rehabilitation stay.
219719381|NCT07120126|DEVICE|EDDY Sonic Activation|Sonic activation was performed using the EDDY device with 2.5% NaOCl and 17% EDTA solutions during final irrigation, following root canal preparation.
219719382|NCT07120126|PROCEDURE|Conventional Syringe Irrigation|Final irrigation was performed using syringe irrigation with 2.5% NaOCl and 17% EDTA solutions, without any activation.
219719383|NCT07119866|OTHER|OXYGEN RESERVE INDEX|Noted for each patient.
219719384|NCT07119918|DRUG|Recaticimab|Recaticimab 300mg subcutaneous Q8W for 1 year.
219145837|NCT05682183|BEHAVIORAL|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
219145838|NCT05682183|OTHER|Treatment as usual|Care management from assigned care manager
219719385|NCT07119918|DRUG|Placebo|Matched placebo subcutaneous Q8W for 1 year.
219719386|NCT07119814|DEVICE|Conventional Separators placement|Safe T separators and conventional elastomeric separators will be placed in patients of fixed orthodontic treatment.
219719387|NCT07119814|DEVICE|Safe T separator|Safe T separators will be placed in patients of fixed orthodontic treatment
219719388|NCT07120646|OTHER|Questionnaire, actigraphy measurement and sleep diary|Baseline questionnaires (measuring socio-demographic and health-related information, as well as most outcome measures), followed by 2 weeks of actigraphy measurement and daily sleep diary.
219719389|NCT07120308|DRUG|ZKY001 eye drops|Administer to eyes
219231265|NCT03885544|OTHER|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
219231266|NCT05918107|DRUG|PM8002|IV infusion
219231267|NCT05918107|DRUG|Pemetrexed|IV infusion
219553488|NCT03458741|OTHER|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
219719390|NCT07120308|DRUG|Vehicle (placebo)|Administer to eyes
219719391|NCT07119450|DRUG|GZR18 injection、[14C]GZR18 injection|Participants will get a single dose of \[14C\]GZR18 injection
219719392|NCT07121699|DRUG|Inotrope|Hypotensive attacks with MAP below 55 mmHg or prolonged duration (2 minutes or more) will be treated with ephedrine 0.1 mg/kg.
219719393|NCT07120659|OTHER|soft touch massage|Soft superficial massage which follows the anatomy of the body without penetrating into the deeper tissues
219719394|NCT07120659|OTHER|vacuum massage|Intense stimulation through suction of the skin and deeper layers
219719395|NCT07119749|OTHER|Stable isotope tracer consumption|Daily consumption of oral deuterium oxide (0.3 ml per kg of lean body mass) to equilibrate in body water and become slowly incorporated into muscle protein, enabling measurement of muscle protein synthesis rates
219145839|NCT01336283|OTHER|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
219145840|NCT01336283|OTHER|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
219145841|NCT01336283|OTHER|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
219145842|NCT03133117|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
219145843|NCT00624026|DRUG|Memantine-HCl|20 mg per day (once daily)
219231268|NCT05918107|DRUG|Cisplatin|IV infusion
219231269|NCT05918107|DRUG|Carboplatin|IV infusion
219231270|NCT01542983|BEHAVIORAL|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
219231271|NCT01542983|BEHAVIORAL|treatment as usual|Standard treatment for fatigue and insomnia
219231272|NCT02486107|PROCEDURE|surgical procedure|
219719396|NCT07119749|RADIATION|DXA scan|Whole body DXA scan to assess lean body mass for prescription of deuterium oxide tracer
219719397|NCT07119749|BEHAVIORAL|Controlled diet|Participant will be asked to consume a provided 6-day diet package that will be prepared by the research team. This package will include 3 meals per day plus snacks
219719398|NCT07119749|OTHER|Saliva sample|Obtained from participants by asking them to spit into a tube each day during the study, for 11 days in total.
219719399|NCT07119749|OTHER|Blood sample|Resting venous blood sample from a forearm vein on 6 separate occasions
219719400|NCT07119749|PROCEDURE|Muscle biopsy|A highly experienced researcher will sample a small section of muscle (\~200 mg) from the vastus lateralis muscle under local anaesthetic (5 ml, 1% Lidocaine)
219145844|NCT00147485|DRUG|AG-024322|
219145845|NCT03697538|PROCEDURE|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
219145846|NCT03666403|PROCEDURE|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
219231273|NCT00734682|DRUG|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
219231274|NCT00515242|BEHAVIORAL|massage|therapeutic massage
219231275|NCT00515242|BEHAVIORAL|thermotherapy|heat therapy
219231276|NCT00515242|BEHAVIORAL|relaxing environment|time in a relaxing environment
219231277|NCT00898313|GENETIC|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
219231278|NCT00898313|GENETIC|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
219231279|NCT00898313|GENETIC|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
219553489|NCT04303208|PROCEDURE|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
219553490|NCT05004649|BEHAVIORAL|Psychophysical task|A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
219553491|NCT05526703|DRUG|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
219553492|NCT05526703|DRUG|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
219553493|NCT02063815|PROCEDURE|Fissure sealant application|
219553494|NCT01698645|DRUG|PecFent® (fentanyl) nasal spray|
219553495|NCT02987153|RADIATION|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
219553496|NCT02654145|DRUG|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
219553497|NCT02654145|DRUG|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
219553498|NCT02654145|DRUG|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
219553499|NCT01905605|DRUG|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
219553500|NCT01905605|DRUG|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
219553501|NCT02637141|BIOLOGICAL|AMG 714|AMG 714 administered by subcutaneous injection
219553502|NCT02637141|BIOLOGICAL|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
219553503|NCT02637141|OTHER|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
219553504|NCT02637141|OTHER|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
219553505|NCT04605211|BEHAVIORAL|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
219553506|NCT04605211|OTHER|Internet-Based Webinars|Attend webinars
219553507|NCT01991548|DEVICE|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
219553508|NCT01943435|DRUG|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
219553509|NCT01943435|PROCEDURE|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
219553510|NCT01943435|OTHER|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
219553511|NCT01943435|OTHER|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
219719401|NCT07119749|BEHAVIORAL|Resistance exercise|participants will complete 8 sets of 10 repetitions of unilateral eccentric knee extensions on an isokinetic dynamometer.
219231280|NCT00898313|OTHER|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
219231281|NCT00898313|PROCEDURE|nasal brushing|Using a brush, superficial cells are removed from the nose.
219553512|NCT01943435|OTHER|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
219231282|NCT00898313|PROCEDURE|Blood draw|Venous blood will be collected
219553513|NCT01282736|BEHAVIORAL|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
219553514|NCT01282736|BEHAVIORAL|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
219553515|NCT00097734|DRUG|ertapenem|
219553516|NCT03885934|BIOLOGICAL|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
219553517|NCT03885934|BIOLOGICAL|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
219553518|NCT06563193|DIAGNOSTIC_TEST|NERVE GROWTH FACTOR|urinary neurotrophins
219231283|NCT00898313|PROCEDURE|Urine collection|Subjects will be asked to provide a urine specimen.
219553519|NCT00370851|DRUG|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
219231284|NCT00898313|PROCEDURE|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
219553520|NCT03849547|OTHER|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
219719402|NCT07119749|OTHER|Isometric strength test|Bilateral isometric strength will be measured using a well-established protocol on an isokinetic dynamometer.
219719403|NCT07119749|DIETARY_SUPPLEMENT|Supplement|Consumption of 3 supplements a day for 3 days following resistance exercise. All supplements are commercially available.
219719404|NCT07116408|DRUG|Lidocaine (drug)|Tx 360/lidocaine
219719405|NCT07116408|DEVICE|Tx 360|Tx 360 device
219719406|NCT07117071|OTHER|collection of medical data|collection of medical data : Age, Sex, Previous cataract surgery, Cellularity, Dermatological pathology, results of screening of Fuchs endothelial corneal dystrophy by Specular microscopy
219719407|NCT07117747|OTHER|Healthy volunteers|All subject belong to the same arm and ther is no intervention
219719408|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
219719409|NCT07119827|DIAGNOSTIC_TEST|Motor, cognitive and psychological assessment|Participants evaluated at T0 (Initial assessment upon admission to the rehabilitation facility), T1 (at discharge from the inpatient rehabilitation program, as long as at least 30 days have passed since the initial assessment (T0), T2 (at 12 months from the event for patients with stroke, and at 18 months from the event for patients with sABI).
219719410|NCT07123701|DRUG|Tanshinone capsules|Tanshinone capsules were used in this intervention for COVID-19 patients
219719411|NCT07123779|BIOLOGICAL|HS235|Subcutaneous Injection
219719412|NCT07123779|OTHER|Placebo|Subcutaneous Injection
219553521|NCT03849547|OTHER|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
219553522|NCT03921801|OTHER|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
219553523|NCT03921801|OTHER|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
219553524|NCT00662272|BIOLOGICAL|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
219719413|NCT07122674|DRUG|18F-Pentixafor|Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
219719414|NCT07122557|DRUG|Biktarvy|this study applies secondary use of data collected from medical health records
219231285|NCT00898313|PROCEDURE|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
219719415|NCT07122024|DRUG|Keverprazan 10 days|"Keverprazan dual therapy for 10 days (K10 group):~Keverprazan 20 mg per dose, twice daily (bid) + Amoxicillin 1 g per dose, three times (tid) daily, for 10 days."
219719416|NCT07122024|DRUG|Keverprazan 14 days|Keverprazan dual therapy for 14 days (K14 group): Keverprazan 20 mg, bid + Amoxicillin 1 g, tid, for 14 days.
219719417|NCT07122024|DRUG|Rabeprazole|Rabeprazole quadruple therapy for 14 days (R14 group): Rabeprazole sodium 10 mg + Amoxicillin 1 g + Clarithromycin 500 mg + Colloidal pectin bismuth 200 mg, bid, for 14 days.
219231286|NCT00898313|PROCEDURE|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
219231287|NCT00898313|PROCEDURE|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
219719418|NCT07125573|DRUG|Saline Solution (NaCl 0,9%)|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery,Administer saline solution one minute after induction of anesthesia and continue until 30 minutes before the end of surgery.
219719419|NCT07125573|DRUG|Low-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, administer esketamine 0.2 mg/kg 1 minute after induction of anesthesia, maintain at 2 μg/kg/min after intubation until 30 minutes before the end of surgery.
219719420|NCT07125573|DRUG|High-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, Administer 0.2 mg/kg of esketamine 1 minute after induction of anesthesia, and maintain at 4 μg/kg/min after intubation until 30 minutes before the end of surgery.
219719421|NCT07124338|OTHER|Exercise, supervised|nital nutrition plan by a trained dietician, based on Nutritional risk, identifying of nutrion impact symtomes, daily nutritional intake regristration and adjustments to the nutrion plan
219719422|NCT07124299|DRUG|Experimental: Alpha-blocker group|Participants in the experimental arm will receive an oral alpha-blocker (tamsulosin 0.4 mg) once daily for 7 consecutive days before undergoing flexible ureterorenolithotripsy. The medication is intended to relax ureteral smooth muscle fibers, potentially facilitating the insertion of the ureteral access sheath and reducing the need for a secondary procedure. The dose, route, and timing are standardized for all participants in this arm.
219719423|NCT07124299|DRUG|No intervention (observational study)|Participants in this arm will undergo flexible ureterorenolithotripsy without receiving any alpha-blocker prior to surgery. All other perioperative care and surgical procedures will follow the same protocol as the experimental group.
219719424|NCT07125092|DEVICE|compression group|"All patients enrolled in the study will be instructed to wear the compression garment for 8 weeks, as long as possible during the day. In parallel, all patients will receive the same advice about routine care: physical exercises, nutrition aspect that are part of the centre's current practice.~3 study visits are planned: the inclusion visit (V0) includes patient information and consent signature, measurements for custom-made compression stockings. The initial visit (V1) includes devices collection and fitting, patient questionnaires, physician assessment (medical and lipedema history, BMI, WHtR, blood sample collection, pain description, lipedema associated symptoms, leg perimeter measurements, Moisture Meter, pressure under the garment). The follow-up visit (V2) after 8 weeks includes: patient questionnaires and physician assessment.~After 8 weeks, another compression garment will be given to the patient with a new satisfaction e-questionnaire at 10 weeks of follow-up."
219719425|NCT07125040|OTHER|Cardiac MRI|On a subset of adult patients
219719426|NCT07124091|BEHAVIORAL|Positive Event Writing Intervention|Mothers in the intervention group will be asked to write down three positive events each day for four weeks as part of a positive psychology journaling activity..
219719427|NCT07124858|DRUG|Fruquintinib|Fruquintinib will be administered according to the summary of product characteristics (SmPC) : 5 mg, 21 days of treatment followed by a 7-day break until progression, unacceptable toxicity, death, or patient refusal.
219719428|NCT07124767|OTHER|6 weeks of diet with low insulin index diet|6 weeks diet period for the low insulin index group. this group has a diet programme assigned by the conductor dietitian.
219719429|NCT07124767|OTHER|6 weeks of dieting according to TÜBER nutrition recommendations|6 weeks of diet according to the TÜBER recomendations were applied to this group. Diets were assigned by the conductor dietitian.
219553525|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
219553526|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
219553527|NCT00893919|DRUG|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
219553528|NCT01291862|DEVICE|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
219719430|NCT07120087|BEHAVIORAL|Intervention|Virual Webinar and online personalised clinical visit
219145847|NCT03666403|PROCEDURE|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
219145848|NCT03666403|PROCEDURE|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
219231288|NCT01872104|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
219231289|NCT06003244|OTHER|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
219231290|NCT06003244|OTHER|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
219231291|NCT01187888|DRUG|Rasagiline|tablet once daily 1 mg 1 year
219719431|NCT07120451|DRUG|Senaparib|100mg qd
219719432|NCT07120451|DRUG|Bevacizumab|7.5mg/kg q3w
219719433|NCT07117617|BEHAVIORAL|Dynamic Stability Training with Inertial load of water|A 10-week training program using AquaBag to enhance lower limb joint stability and neuromuscular coordination. Exercises included dynamic stepping, lunging, and landing tasks under water load-induced perturbations.
219719434|NCT07119788|DIETARY_SUPPLEMENT|Placebo|6g serving of a calorie-matched powder, artificially coloured and flavoured to resemble berry powder
219719435|NCT07119788|DIETARY_SUPPLEMENT|Pure haskap berry powder|6g serving of a pure, freeze-dried haskap berry powder
219719436|NCT07119788|DIETARY_SUPPLEMENT|Vitamin-and mineral-enhanced haskap berry powder|6g serving of a vitamin- and mineral-enhanced haskap berry powder (fortified with potassium iodide, zinc bisglycinate, vitamin B5, and vitamin B12
219719437|NCT07123584|DIETARY_SUPPLEMENT|Eye Empower|A multi-ingredient oral supplement formulated to support eye health. Daily dose (3 capsules).
219145849|NCT04520490|BEHAVIORAL|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
219145850|NCT04520490|DRUG|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
219145851|NCT04520490|DRUG|Placebo|Weekly placebo injections
219145852|NCT03681652|DRUG|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
219145853|NCT03681652|DRUG|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
219145854|NCT06221046|DRUG|Control (Standard treatment)|Patients in the control arm will be treated with a standard zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
219145855|NCT06221046|OTHER|Novel Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
219553529|NCT01936662|DEVICE|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
219145856|NCT05927935|OTHER|Supervised strength exercise intervention|A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.
219145857|NCT05927935|OTHER|Minimal educational intervention (usual care)|Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, patients will receive a referral for physiotherapy and supplementary a minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like.
219145858|NCT03992417|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219145859|NCT05722535|BEHAVIORAL|Family Media Check-In (FMC)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
219145860|NCT05286632|DEVICE|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
219145861|NCT06086925|DRUG|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
219231292|NCT01187888|DRUG|Sugar pill|tablet once daily one year
219231293|NCT03192189|OTHER|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
219231294|NCT04976946|OTHER|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
219231295|NCT00209885|DRUG|Gabapentin|
219231296|NCT00209885|DRUG|S-ketamine|
219231297|NCT00209885|DRUG|Lidocaine|
219231298|NCT00209885|DRUG|Droperidol|
219231299|NCT00297297|OTHER|No intervention. Applying gene profiling on needle aspirates|
219553530|NCT01936662|DEVICE|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
219553531|NCT03029364|BEHAVIORAL|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
219553532|NCT03825562|BEHAVIORAL|acceptance and commitment therapy, ACT|
219553533|NCT00400634|DRUG|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10\^11 vg
219553534|NCT00400634|PROCEDURE|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
219719438|NCT07123584|DIETARY_SUPPLEMENT|Placebo|Identical gelatin capsules filled with inert rice flour, administered in the same dosage (3 capsules daily).
219145862|NCT05019144|PROCEDURE|Face-to-face burn care|If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.
219719439|NCT07119905|GENETIC|genotyping assay by polymerase chain reaction|"Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.~Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction"
219145863|NCT05019144|PROCEDURE|Telemedicine enhanced burn care|Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
219719440|NCT06934252|DRUG|TRB-061|Single subcutaneous injection of TRB-061 at escalating doses
219719441|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses
219719442|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for 3 doses
219719443|NCT06934252|DRUG|Placebo|Single and multiple Subcutaneous doses of placebo matching TRB-061 in patients.
219553535|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
219553536|NCT01559116|DRUG|tiotropium|low dose
219553537|NCT01559116|DRUG|olodaterol|one dose only
219145864|NCT05868122|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
219145865|NCT05868122|DRUG|Placebo|Placebo will be administered orally.
219145866|NCT03618654|DRUG|Metformin|Given PO
219145867|NCT03618654|BIOLOGICAL|Durvalumab|Given IV
219145868|NCT00710892|BIOLOGICAL|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
219145869|NCT05389644|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
219145870|NCT05931887|DEVICE|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|A foley catheter is assigned and used according to regular standard of care
219145871|NCT02024542|OTHER|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
219145872|NCT05839873|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
219719444|NCT03327467|BIOLOGICAL|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling, autologous, or unrelated donor)
219553538|NCT01559116|DRUG|tiotropium|high dose
219553539|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
219553540|NCT01559116|DRUG|Placebo|placebo matching tiotropium+olodaterol FDC
219719445|NCT05630794|PROCEDURE|Biopsy Procedure|Undergo biopsy
219553541|NCT01559116|DEVICE|Respimat|Respimat inhaler
219553542|NCT04728750|PROCEDURE|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
219553543|NCT03526484|BEHAVIORAL|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
219553544|NCT03526484|BEHAVIORAL|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
219553545|NCT00857779|BIOLOGICAL|subcutaneous immunotherapy|7 injections
219553546|NCT06074328|DEVICE|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
219719446|NCT05630794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219719447|NCT05630794|PROCEDURE|Colonoscopy|Undergo colonoscopy
219719448|NCT05630794|DRUG|Dordaviprone|Given PO
219719449|NCT05630794|OTHER|Questionnaire Administration|Ancillary studies
219719450|NCT05630794|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
219719451|NCT05623488|DRUG|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
219719452|NCT05623488|DEVICE|Mesothelin Expression Testing|Laboratory Developed Test
219145873|NCT05754814|OTHER|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
219145874|NCT04137536|DRUG|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~\- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
219145875|NCT06132854|OTHER|VR|The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.
219145876|NCT06132854|OTHER|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
219145877|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
219145878|NCT04580901|BEHAVIORAL|Group Interpersonal Psychotherapy|Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
219145879|NCT05245786|BIOLOGICAL|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
219145880|NCT05245786|PROCEDURE|Imaging Technique|Undergo imaging
219145881|NCT04785989|OTHER|[U-13C]glucose|\[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
219145882|NCT04785989|OTHER|[13C5]glutamine|6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
219145883|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
219719453|NCT06937346|DEVICE|The Rehand Robotic Glove|"The exoskeleton hand system provides recovery and training for paralyzed fingers using an innovative method that mirrors the movements of a healthy hand. The system uses a sensor glove to read movements and transfer them to a rehabilitation glove. This forces the injured hand to repeat the same movements as the healthy hand, helping to restore motor skills.~The system combines flexible robotics with neuroscience to help patients retrain their muscles. It reduces muscle tension and swelling, relieves stiffness, improves blood circulation, and restores muscle performance after atrophy. It also reduces hypertension and joint pain, and activates neuroplasticity through passive and active techniques.~All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020."
219719454|NCT06937346|OTHER|Standard Rehabilitation|All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020.
219719455|NCT06766292|PROCEDURE|primary intervention|In the study group: 2.0 mm screws were fixed to the lateral wall of the sinus above the superior osteotomy and placed buccopalatally where the schneiderian membrane was elevated and maintained. this technique will suspends the membrane in position to allow the blood clot to organized and formation of bone.
219719456|NCT06766292|PROCEDURE|open sinus lifting with xenograft only|ll Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
219719457|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
219719458|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
219719459|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
219719460|NCT06939426|BEHAVIORAL|Music therapy intervention|"The intervention protocol is based on four main themes, which are addressed over the course of eight sessions:~* Self-care~* Self-recognition and expression of emotions~* Empathy~* Teamwork~Each theme is related to factors from the HUMAS (affection, self-efficacy, emotional understanding, dispositional optimism, and sociability) and/or ProQOL (compassion satisfaction, burnout, and compassion fatigue). A variety of techniques related to the four main methods of music therapy will be used in the sessions: receptive, re-creative, composition, and improvisation."
219145884|NCT05732207|PROCEDURE|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
219231300|NCT03778788|OTHER|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
219231301|NCT03778788|OTHER|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
219553547|NCT01876758|BEHAVIORAL|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
219145885|NCT05968573|OTHER|Video Format with Captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
219145886|NCT05968573|OTHER|Video Format without Captions|A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
219145887|NCT05968573|OTHER|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
219719461|NCT06936930|OTHER|Sex hormone monitoring|Sex hormone monitoring includes the concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), prolactin (PRL), and testosterone (T).
219719462|NCT03452787|OTHER|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
219719463|NCT06380569|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 10 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
219719464|NCT07103083|DIETARY_SUPPLEMENT|Beverage 1|Fruit juice with zero sugar
219145888|NCT05854017|DIETARY_SUPPLEMENT|Theanine for stress relief formulation|Theanine for stress relief formulation tablet
219145889|NCT05854017|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
219719465|NCT07103083|DIETARY_SUPPLEMENT|Beverage 2|Fruit juice with low sugar - formulation 1
219719466|NCT07103083|DIETARY_SUPPLEMENT|Beverage 3|Fruit juice with low sugar - formulation 2
219719467|NCT07103083|DIETARY_SUPPLEMENT|Beverage 4|Fruit juice with full sugar
219553548|NCT01876758|BEHAVIORAL|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
219553549|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
219145890|NCT06425042|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program
219231302|NCT03778788|OTHER|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
219231303|NCT01552083|OTHER|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
219231304|NCT02074384|DEVICE|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
219553550|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
219719468|NCT07103083|DIETARY_SUPPLEMENT|Beverage 5|Fruit juice with full sugar
219719469|NCT07103083|DIETARY_SUPPLEMENT|Beverage 6|Glucose control beverage
219719470|NCT06943014|DEVICE|Actimetry Protocol|Our goal is to develop an actimetry protocol using both accelerometers and pressure insoles to quantify physical activity, involving the upper and/or lower limbs, as well as sedentary behavior in post-stroke individuals. Recent studies have explored the use of validated accelerometer configurations designed for healthy individuals, applied to the post-stroke population to monitor their physical activity and sedentary behavior. However, although these protocols have been validated for healthy individuals, they need to be adapted for post-stroke patients, who exhibit slower, asymmetric, and lower-amplitude movements compared to healthy subjects. This protocol could be valuable in both clinical practice and research, helping to optimize stroke rehabilitation and promote a healthy, active lifestyle.
219719471|NCT06945237|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of GERD
219719472|NCT06945237|DRUG|Lansoprazole and placebo|Placebo and Lansoprazole for GERD
219719473|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
219231305|NCT02074384|DEVICE|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
219231306|NCT02074384|OTHER|Clinician|Survey of clinicians after study visits
219719474|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
219719475|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
219719476|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
219719477|NCT06834906|DIAGNOSTIC_TEST|EasyEyeFM-AutoML-AI-platform test|AI platforms using
219719478|NCT06834906|DIAGNOSTIC_TEST|AutoML-EasyEyeFM-AI-platform test|AI-platform using
219145891|NCT06425042|DIETARY_SUPPLEMENT|Placebo|Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
219145892|NCT06223152|OTHER|parental support|parental support
219145893|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
219145894|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
219145895|NCT04602598|DRUG|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
219145896|NCT05677633|DRUG|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
219145897|NCT04704830|BIOLOGICAL|R21/Matrix-M|Adjuvanted malaria vaccine
219145898|NCT04704830|BIOLOGICAL|Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine|Placebo Comparator
219145899|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
219553551|NCT04766905|PROCEDURE|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
219145903|NCT06261398|BEHAVIORAL|BETTER: motivational interviewing and text messaging|Motivational interviewing to encourage individuals to address their social needs and engage with text messages that allow individuals to connect to their care team, a local organization that can help them address their social needs, and/or a resource that enables them to find help to address their needs based on their zip code.
219145904|NCT06261398|BEHAVIORAL|Standard of care|No motivational interviewing or text messages will be provided.
219231307|NCT00869609|BEHAVIORAL|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
219553552|NCT00273013|DRUG|GW274150|GW274150 will be available as 30 mg white oval tablets.
219553553|NCT00273013|DRUG|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
219553554|NCT00273013|DRUG|Placebo|Matching placebo for Singulair and GW274150 will be available.
219553555|NCT02218398|DRUG|Albuterol|
219553556|NCT04651335|DEVICE|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
219553557|NCT04651335|DEVICE|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
219553558|NCT04610580|DRUG|ALXN1840|ALXN1840 will be administered orally.
219553559|NCT04122027|OTHER|Cerebral oximeter|Near infra-red spectroscopy, NIRS
219553560|NCT05586386|OTHER|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
219553561|NCT05586386|OTHER|Placebo group|200 mL of placebo juice twice/day
219553562|NCT03067935|DRUG|glembatumumab vedotin|
219553563|NCT01097694|DRUG|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
219553564|NCT01097694|DRUG|Placebo|Placebo
219553565|NCT02377349|BIOLOGICAL|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
219553566|NCT02377349|DRUG|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
219553567|NCT06288217|DEVICE|NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)|Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
219145905|NCT04187131|BEHAVIORAL|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
219145906|NCT04860336|OTHER|Observational|Observational
219145907|NCT04834414|BIOLOGICAL|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
219145908|NCT04834414|BIOLOGICAL|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
219145909|NCT06476067|PROCEDURE|Surgery|Esophagectomy
219145910|NCT03893487|DRUG|Fimepinostat|Fimepinostat capsules
219145911|NCT03893487|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219145912|NCT06229392|BIOLOGICAL|Fluzone Quadrivalent|Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu
219145913|NCT04482400|BEHAVIORAL|NEAT!2|8 week sedentary reduction program
219145914|NCT04482400|BEHAVIORAL|MyKneeGuide|8 week surgery recovery education program
219145915|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter
219145916|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
219145917|NCT06342778|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study under fed conditions
219145918|NCT06342778|DRUG|Diclectin|A single dose of R or T drug in each of 2 periods of the study under fed conditions
219145919|NCT05216510|BIOLOGICAL|TNX-2110|TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
219145920|NCT05216510|BIOLOGICAL|TNX-2120|TNX-2120 represents the spike protein and is administered intradermally.
219145921|NCT05216510|BIOLOGICAL|TNX-2130|TNX-2130 represents non-spike proteins and is administered intradermally.
219145922|NCT05216510|BIOLOGICAL|CANDIN|Candida albicans antigens to be administered intradermally as a positive control.
219231308|NCT00869609|BEHAVIORAL|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
219553568|NCT06288217|OTHER|Upper Limb Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
219553569|NCT06288217|OTHER|Sham Stimulation|Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
219553570|NCT04986098|DEVICE|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
219553571|NCT04986098|DRUG|Paclitaxel|Paclitaxel
219553572|NCT00001763|DRUG|Interleukin-12|
219553573|NCT03621046|DRUG|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
219553574|NCT03621046|OTHER|Placebo|Placebo
219553575|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
219553576|NCT04238195|DRUG|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
219553577|NCT04238195|OTHER|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
219553578|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
219553579|NCT00096850|DRUG|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
219553580|NCT00096850|DRUG|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
219553581|NCT00096850|DRUG|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
219553582|NCT05450549|DRUG|DNL919|Single doses
219553583|NCT05450549|DRUG|Placebo|Single doses
219553584|NCT00314288|DRUG|Sarizotan HCl|
219553585|NCT03650751|OTHER|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
219553586|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal Plus (SC+)|
219553587|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal (SC), fortified oil, sugar|
219553588|NCT02077907|DIETARY_SUPPLEMENT|Plumpy Sup|
219553589|NCT02077907|DIETARY_SUPPLEMENT|Corn Soy Blend 14 (CSB14) and fortified oil|
219553590|NCT00441961|DRUG|methotrexate|methotrexate
219553591|NCT05536960|OTHER|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
219553592|NCT05016427|BIOLOGICAL|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
219553593|NCT00629057|BIOLOGICAL|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
219553594|NCT00629057|BIOLOGICAL|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
219553595|NCT00629057|BIOLOGICAL|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
219553596|NCT05414162|DIAGNOSTIC_TEST|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
219553597|NCT00405262|DRUG|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
219553598|NCT00405262|DRUG|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
219145923|NCT05216510|BIOLOGICAL|Diluent|Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
219145924|NCT05323734|DRUG|Ganaxolone|GNX will be administered
219145925|NCT05323734|DRUG|Placebo|Placebo will be administered
219145926|NCT02281838|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
219145927|NCT04975048|DIETARY_SUPPLEMENT|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
219145928|NCT04975048|DIETARY_SUPPLEMENT|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
219145929|NCT04541914|DIAGNOSTIC_TEST|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
219145930|NCT05452720|DEVICE|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
219145931|NCT04652076|DRUG|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
219145932|NCT04652076|DRUG|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
219145933|NCT04652076|DRUG|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
219145934|NCT04652076|DRUG|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
219145935|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
219145936|NCT05930041|PROCEDURE|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
219145937|NCT05930041|PROCEDURE|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
219145938|NCT05431192|BEHAVIORAL|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
219145939|NCT05431192|OTHER|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
219145940|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
219145941|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
219145942|NCT05548621|OTHER|Decision aid|Online interactive decision aid for RCC
219145943|NCT05562271|RADIATION|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
219145944|NCT05562271|RADIATION|sham radiation therapy|sham radiation therapy to involved knee joint
219145945|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by local anesthesia during treatments|Patients were divided according to the randomization procedure. infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
219145946|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by topical anesthesia during treatments|Patients were divided i according to the randomization procedure. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
219719479|NCT05800145|BEHAVIORAL|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
219719480|NCT05800145|BEHAVIORAL|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
219719481|NCT05800145|BEHAVIORAL|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
219719482|NCT07115472|DRUG|Fluoxetine|Refractory SMAS patients with SSD received oral fluoxetine treatment, initiated at 20 mg/day and increased to a maximum of 60 mg/day based on therapeutic response.
219719483|NCT07103044|BEHAVIORAL|Early Achievements - Shaping Early Language and Literacy Skills|EA-SHELLS is a professional development program that includes a 6-hour workshop and about 14 in-person coaching sessions using Practice-Based Coaching. Teachers will implement the EA-SHELLS instructional approach in their classrooms during whole-group book sharing activities to target vocabulary, syntax, story grammar, and listening comprehension. Teachers will also lead story retelling activities using pictures cards and 3D props to further target all four skills. Teachers will be provided with commercially available children's books augmented with supplemental text to explicitly define vocabulary and cue teachers' elicitation of children's verbal engagement for targeted vocabulary, syntactically elaborated sentences, and story grammar elements. Instructional strategies include naturalistic developmental behavioral intervention and language facilitating (e.g., focused stimulation) strategies. Teachers will read each provided book about four times over one to two weeks.
219719484|NCT06947304|DRUG|Miricorilant|100 mg administered orally, once daily
219719485|NCT06952478|BIOLOGICAL|CT-P44(Daratumumab)|CT-P44 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 26, whichever occurs first.
219719486|NCT06952478|BIOLOGICAL|Darzalex Faspro(Daratumumab)|Darzalex Faspro 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 13, whichever occurs first.
219719487|NCT07123649|BEHAVIORAL|Shared Decision-Making Toolkit|The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.
219719488|NCT07124611|OTHER|Interview|Ancillary studies
219719489|NCT07124611|PROCEDURE|Nutritional Therapy|Attend nutritional appointments
219719490|NCT07124611|PROCEDURE|Physical Therapy|Attend physical therapy appointments
219231309|NCT01297088|DRUG|BAY86-9596|One single dose administration of a diagnostic agent
219553599|NCT00405262|DRUG|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
219553600|NCT06241157|OTHER|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
219145947|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by the application of rubber dam during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
219231310|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
219719491|NCT07124611|BEHAVIORAL|Psychosocial Care|Receive psychosocial care
219231311|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
219231312|NCT00299507|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
219719492|NCT07124611|OTHER|Questionnaire Administration|Ancillary studies
219719493|NCT07119554|BEHAVIORAL|HBM-Based Postpartum Contraceptive Counselling|This intervention involves providing a structured, individual contraceptive counseling session based on the Health Belief Model (HBM) to women in the postpartum period.The session is delivered face-to-face, lasts approximately 30 to 45 minutes, and is structured around the core components of the HBM: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action. The aim of the intervention is to improve attitudes toward family planning and increase the intention to use contraceptive methods.
219719494|NCT07120061|DIAGNOSTIC_TEST|First MWT|MWT during the first visit of the protocol
219719495|NCT07120061|DIAGNOSTIC_TEST|second MWT|MWT during the second visit of the protocol
219719496|NCT07120061|DEVICE|actimetry|In order to monitor compliance with the guidelines prior to each MWT, namely good sleep hygiene in the 14 days preceding the MWT, and in accordance with the recommendations of the AASM, an actimeter will be worn by the participant.
219719497|NCT07120997|DIETARY_SUPPLEMENT|Prunes|Participants randomized to the 50g prune group will consume 6 prunes per day for the duration of the 18-month intervention.
219145948|NCT06779448|OTHER|Evaluation of the objective and subjective stress parameters caused by the application of cotton rolls during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
219145949|NCT04426786|OTHER|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
219145950|NCT04426786|OTHER|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
219145951|NCT06779188|DEVICE|Transcranial Magnetic Stimulation|TMS (in the form of theta burst stimulations) will be delivered over Supplementary Motor Area while the subject is seated in the Treatment group. TMS is capable to induce neuroplastic facilitatory changes in the brain that last beyond the duration of stimulation. TMS will be delivered once daily, 5 days per week, for 4 weeks.
219145952|NCT06779188|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS will be delivered in the sham group using a sham coil once daily, 5 days per week, for 4 weeks.
219145953|NCT04811053|DRUG|HR021618|Treatment group A: HR021618 injection
219145954|NCT04811053|DRUG|Placebo|Treatment group B: Saline injection
219231313|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
219719498|NCT07120997|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements daily for a baseline period and for the duration of the 18-month intervention.
219719499|NCT07120997|DIETARY_SUPPLEMENT|Vitamin D Supplement|All participants will consume Vitamin D supplements daily for a baseline period and for the duration of the 18-month intervention.
219145955|NCT06237842|DIAGNOSTIC_TEST|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
219145956|NCT05697497|BEHAVIORAL|Daily exercise intervention|Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
219145957|NCT02486718|DRUG|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
219145958|NCT02486718|DRUG|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
219145959|NCT02486718|DRUG|Vinorelbine|Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
219145960|NCT02486718|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
219145961|NCT02486718|DRUG|Gemcitabine|Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
219145962|NCT02486718|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
219145963|NCT05065736|DRUG|18F-Clofarabine|The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
219145964|NCT04795128|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
219719500|NCT07113782|DRUG|1. Magnesium Sulphate 2. Tramadol|"Magnesium Sulphate (Group M): 50 mg magnesium sulphate added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally.~Tramadol (Group T): 25 mg tramadol added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally."
219145965|NCT05489211|DRUG|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
219145966|NCT05489211|DRUG|Capecitabine|Administered orally
219231314|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
219231315|NCT01861041|DRUG|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
219231316|NCT01861041|DRUG|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
219719501|NCT07121777|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis|A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）
219719502|NCT07121751|DRUG|use of combination of recombinant FSH and recombinant LH|in this arm the patients will use the combination of recFSH:recLH in the same dose as in her prior cycle
219719503|NCT07121751|DRUG|higher dose recFSH|in this arm the patient will use an additional 75 IU/day recFSH compared to her previous drug dose
219145967|NCT05489211|DRUG|5-Fluorouracil|Administered as an IV
219145968|NCT05489211|DRUG|Volrustomig|Administered as an IV
219145969|NCT05489211|DRUG|Carboplatin|Administered as an IV
219145970|NCT05489211|DRUG|Leucovorin LV|Administered as an IV
219145971|NCT05489211|DRUG|Bevacizumab|Administered as an IV
219145972|NCT05489211|DRUG|Rilvegostomig|Administered as an IV
219145973|NCT05489211|DRUG|Prednisone/ prednisolone|Administered orally
219145974|NCT05489211|DRUG|Cisplatin|Administered as an IV
219145975|NCT05959356|DRUG|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
219231317|NCT03528304|BEHAVIORAL|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
219231318|NCT05081726|DIAGNOSTIC_TEST|Functional MRI|Series of MRI scans of the brain
219231319|NCT00004085|BIOLOGICAL|filgrastim|as prescribed by physician
219231320|NCT00004085|PROCEDURE|autologous bone marrow transplantation|1-2 weeks prior to treatment
219231321|NCT00004085|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
219231322|NCT00004085|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
219231323|NCT02461979|OTHER|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
219231324|NCT02516085|DRUG|Metformin|
219719504|NCT07121751|DRUG|unchanged dose|in this groups the patient will receive the same recFSH dose as in her prior cycle
219145976|NCT05959356|DRUG|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
219145977|NCT05848583|OTHER|Compleat 1.5|EN Formula
219145978|NCT06849401|BIOLOGICAL|VGO-Cs01p|Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)
219145979|NCT05746247|BEHAVIORAL|Testing centralized referral mechanism for PCPs|"For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed."
219145980|NCT05746247|BEHAVIORAL|Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation|All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
219145981|NCT01047735|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
219231325|NCT02516085|DRUG|L-Arginine|
219231326|NCT03212638|DRUG|Baricitinib suspension|Administered orally
219231327|NCT03212638|DRUG|Baricitinib tablet|Administered orally
219231328|NCT02950883|DRUG|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
219231329|NCT02950883|DRUG|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
219231330|NCT06466759|DEVICE|Mc Grath Videolaryngoscope|Use of Videolaryngoscope with Mc Grath versus direct laryngoscopy
219231331|NCT03096132|BEHAVIORAL|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
219231332|NCT03096132|BEHAVIORAL|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
219231333|NCT00110669|DRUG|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
219231334|NCT02186106|DRUG|Cholecalciferol|
219231335|NCT04431128|BEHAVIORAL|infant feeding position|correlation with allergy, GER or feeding position
219719505|NCT07120035|DIETARY_SUPPLEMENT|Lycopene-rich juice|We sought to deliver 8400 µg of lycopene per day, and so participants were asked to drink approximately 4 fluid ounces per day of the tomato-based, lycopene-rich juice.
219145982|NCT01047735|PROCEDURE|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
219145983|NCT01047735|BEHAVIORAL|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
219145984|NCT05924412|DRUG|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
219145985|NCT05924412|OTHER|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
219145986|NCT05437588|GENETIC|Genetic testing|Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
219231336|NCT00090415|BEHAVIORAL|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
219231337|NCT03652610|BIOLOGICAL|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
219231338|NCT03652610|BIOLOGICAL|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
219231339|NCT05244967|OTHER|vaginal swab|self-sampling, vaginal swab
219231340|NCT06148636|DRUG|[212Pb] VMT-α-NET|Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
219553601|NCT03259165|DRUG|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
219553602|NCT03259165|DRUG|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
219553603|NCT02822716|PROCEDURE|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
219553604|NCT02822716|DEVICE|Ultrasound|
219553605|NCT05203692|DRUG|DS-7011a|Intravenous or subcutaneous administration, single dose
219553606|NCT05203692|DRUG|Placebo|Intravenous or subcutaneous administration, single dose
219553607|NCT03039816|DEVICE|Nasaleze|Nasaleze cellulose powder
219553608|NCT03039816|DEVICE|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
219553609|NCT04483895|PROCEDURE|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
219553610|NCT01609270|DEVICE|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
219553611|NCT01127776|DEVICE|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
219553612|NCT01127776|OTHER|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
219553613|NCT00021541|DRUG|tipifarnib|Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
219553614|NCT00021541|OTHER|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
219553615|NCT04003441|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
219553616|NCT04003441|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
219553617|NCT02392858|OTHER|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
219553618|NCT01927016|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
219145987|NCT04143646|BEHAVIORAL|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
219145988|NCT05748067|PROCEDURE|SDF|Silver diamine fluoride
219145989|NCT05748067|PROCEDURE|HVGIC restoration|High viscosity glass ionomer restoration
219145990|NCT05748067|PROCEDURE|SSC|Stainless steel crown
219145991|NCT03845114|OTHER|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
219145992|NCT03845114|OTHER|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
219145993|NCT03845114|OTHER|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
219145994|NCT03845114|OTHER|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
219145995|NCT05674825|DRUG|Targeted agent|"The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment."
219145996|NCT05674825|DRUG|Standard of care agent|Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
219145997|NCT05514717|DRUG|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
219145998|NCT03096262|DEVICE|Citizen Science intervention using kinect|Users are asked to tag objects on a screen
219145999|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
219231341|NCT06148636|DIAGNOSTIC_TEST|[203Pb] VMT-α-NET SPECT/CT|The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.
219553619|NCT02032316|DEVICE|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
219146000|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
219146001|NCT05133362|DEVICE|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
219146002|NCT05133362|PROCEDURE|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
219146003|NCT03752840|OTHER|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
219146004|NCT03752840|OTHER|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
219146005|NCT03752840|OTHER|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
219146006|NCT03752840|OTHER|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
219146007|NCT03752840|OTHER|Fundus Photography|Fundus cameras will be used to image the macula and optic nerve. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
219553620|NCT05440305|PROCEDURE|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
219553621|NCT03234127|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
219553622|NCT01547728|DRUG|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
219553623|NCT04960761|OTHER|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
219553624|NCT05397444|OTHER|No intervention|This is an observational study with no intervention.
219553625|NCT02570854|BIOLOGICAL|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
219553626|NCT02570854|DRUG|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
219553627|NCT03828539|BIOLOGICAL|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
219553628|NCT03828539|DRUG|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
219146008|NCT02819336|DEVICE|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
219231342|NCT03744052|OTHER|Motivational Messages|Messages regarding physical activity will be texted to participants.
219146009|NCT02819336|DEVICE|Sham electroacupuncture|"1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
219146010|NCT04414683|PROCEDURE|staging surgery|laparoscopic or laparotomic staging surgery
219146011|NCT02343211|DRUG|Immunoglobulin|
219146012|NCT04510454|DIAGNOSTIC_TEST|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
219231343|NCT01860079|PROCEDURE|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
219231344|NCT05596006|DRUG|ASIMOMMY®|ASIMOMMY 500 mg
219231345|NCT05596006|DRUG|Domperidon|Domperidone capsule 10 mg
219231346|NCT05596006|DRUG|Placebo|Capsules of placebo 500mg.
219231347|NCT01579071|PROCEDURE|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
219231348|NCT04377542|PROCEDURE|LIFT|Ligation of the fistula tract in the intersphincteric plane
219553629|NCT03828539|BIOLOGICAL|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
219553630|NCT03828539|DRUG|Topiramate matching placebo|Topiramate matching placebo administered daily
219553631|NCT01341405|DRUG|CG100649|once daily for 28 days
219553632|NCT01341405|DRUG|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
219553633|NCT04211480|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
219719506|NCT07116811|DRUG|Steroids therapy|Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by 20 mg of prednisone acetate (oral intake, once daily) from day 4 to day 10.
219719507|NCT07116811|DRUG|Placebo|Methylprednisolone sodium succinate placebo powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by prednisone acetate placebo (oral intake, once daily) from day 4 to day 10.
219719508|NCT07121296|BEHAVIORAL|Contingency management for substance use|Participants receive escalating incentives for each consecutive negative weekly urine drug screen.
219719509|NCT07121296|BEHAVIORAL|Contingency management for attendance|Participants receive escalating incentives for each consecutive counseling session they attended.
219146013|NCT05997836|OTHER|Implementation Facilitation|Implementation Facilitation involves and External Facilitator (from outside of the participating medical center) and an Internal Facilitator (from inside the participating medical center) working together to help BHIP teams within the site adopt care practices that are more consistent with the CCM
219146014|NCT05997836|OTHER|Centralized Technical Assistance|Centralized Technical Assistance involves having external experts available for ad hoc consultation related to collaborative BHIP care practices.
219146015|NCT06368089|OTHER|Inspiratory muscle training (IMT) group|The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
219231349|NCT04377542|PROCEDURE|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
219553634|NCT06127186|DIAGNOSTIC_TEST|Swab test for viral antigens|No intervention except for a routine examination and viral testing is planned.
219553635|NCT01173536|DRUG|GDC-0449|Oral repeating dose
219231350|NCT04377542|PROCEDURE|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
219231351|NCT04498780|DRUG|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
219231352|NCT00785499|BEHAVIORAL|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
219231353|NCT04923022|OTHER|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
219231354|NCT04923022|OTHER|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
219231355|NCT00326183|BIOLOGICAL|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
219231356|NCT00326183|BIOLOGICAL|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
219231357|NCT00748891|DRUG|Recentin (Cediranib)|30mg once daily, oral dose
219553636|NCT01173536|DRUG|moxifloxacin|Oral single dose
219553637|NCT01173536|DRUG|placebo|Oral repeating dose
219553638|NCT00826241|DRUG|Temozolomide|Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.
219553639|NCT00826241|DRUG|Lapatinib|Starting dose 1250 mg daily by mouth.
219553640|NCT04443049|DRUG|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
219553641|NCT04443049|DRUG|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
219553642|NCT04443049|OTHER|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
219719510|NCT07121296|BEHAVIORAL|Group-based Matrix counseling|Group-based Matrix counseling
219719511|NCT07121296|BEHAVIORAL|Individual-based Matrix counseling|Individual-based Matrix counseling
219146016|NCT06368089|OTHER|Early mobilization (EM) group|The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
219146017|NCT05800977|BIOLOGICAL|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
219146018|NCT00256243|DRUG|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
219146019|NCT00256243|DRUG|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
219146020|NCT00256243|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
219146021|NCT00256243|DRUG|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
219146022|NCT00256243|DRUG|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
219146023|NCT00256243|DRUG|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
219146024|NCT03969823|DRUG|Tagrisso|Osimertinib 80mg once daily until disease progression
219146025|NCT01603810|OTHER|OCT|Optical coherence tomography of periocular basal cell carcinoma
219146026|NCT02813486|BIOLOGICAL|Biological: GC3111 vaccine|0.5mL, Intramuscular
219146027|NCT02813486|BIOLOGICAL|Biological: Boostrix® vaccine|0.5mL, Intramuscular
219146028|NCT02490982|DRUG|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
219146029|NCT03310996|OTHER|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
219146030|NCT01267838|PROCEDURE|PCI|PCI of bifurcation lesions with double stenting
219146031|NCT03207854|PROCEDURE|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
219146032|NCT03207854|OTHER|Laboratory Biomarker Analysis|Correlative studies
219146033|NCT03207854|OTHER|Questionnaire Administration|Ancillary studies
219146034|NCT04894318|BEHAVIORAL|Low-fat and low-cholesterol diet|Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
219146035|NCT05061693|DRUG|INCB054707|Oral; Tablet
219146036|NCT05061693|DRUG|Placebo|Oral; Tablet
219146037|NCT05707052|OTHER|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
219146038|NCT05707052|OTHER|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
219146039|NCT06153641|OTHER|N/A-Observational Study|N/A-Observational Study
219146040|NCT06129370|DEVICE|Standard practice|Lexicomp and manual calculator
219146041|NCT06129370|DEVICE|Medication dosing software|Medication dosing software
219146042|NCT05561803|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.
219146043|NCT01219218|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
219231358|NCT00336882|DRUG|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
219231359|NCT00336882|DRUG|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
219231360|NCT04329585|DRUG|flumazenil|EEG is observed in both groups to compare the difference between two groups.
219231361|NCT04329585|DRUG|Placebos|Placebo is the normal saline, which is given in the controlled group.
219231362|NCT04890626|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
219553643|NCT06017427|OTHER|Questionnaires|Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
219553644|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
219553645|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
219553646|NCT00002367|DRUG|Saquinavir|
219553647|NCT00002367|DRUG|Lamivudine|
219553648|NCT00002367|DRUG|Zidovudine|
219553649|NCT03252990|DIAGNOSTIC_TEST|PET-MRI|Additional 18F-choline PET-MRI examination
219553650|NCT03252990|PROCEDURE|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
219553651|NCT04142658|DRUG|Apixaban 5 MG|"For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
219553652|NCT04142658|DRUG|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
219553653|NCT04142658|DRUG|Warfarin|Active Control Intervention
219553654|NCT04142658|DEVICE|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
219553655|NCT05772858|OTHER|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
219146044|NCT06966076|PROCEDURE|calisthenic training|"COMMAND AND TARGET MUSCLE GROUP~1. LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND IN FRONT. LOWER THEM BACK DOWN WITHOUT TOUCHING THE FLOOR.~   TARGETS HIP FLEXOR~2. SIDE LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND AND TAKE IT TO SIDE MAXIMALL WITHOUT TOUCHING THE FLOOR.~   TARGETS LOWER ABS AND HIP ABDUCTORS~3. GLUTE BRIDGES ( BACK STRENGTH) LIE ON YOUR BACK WITH YOUR KNEES BENT. LIFT YOUR HIPS OFF THE GROUND, SQUEEZING YOUR GLUTES. LOWER AND REPEAT. TARGETS GLUTES AND HAMSTRINGS.~4. QUADRUPTED POSITION:~   ASK THE PATIENT TO RIDE YOUR KNEES PLAY 'HORSY' AND SLOWLY MOVE YOUR KNEES TO AND FRO AND SIDEWAYS SO THAT TO SHIFT WEIGHT FROM SIDE TO SIDE.~5. WALL LEG LIFTS IN STANDING STAND WITH YOUR SIDE FACING A WALL. LIFT YOUR LEG OUT TO THE SIDE AS HIGH AS POSSIBLE.~   LOWER AND REPEAT WITH THE OTHER LEG. TARGETS HIP ABDUCTERS~6. KNEELING~7. VERTICLE LIFT~8. Squats"
219231363|NCT04890626|DRUG|Baricitinib + dexamethasone|Rescue randomization
219231364|NCT04890626|DRUG|Dexamethasone|Rescue randomization
219231365|NCT01960972|OTHER|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
219231366|NCT04910711|DRUG|Dolutegravir|Dolutegravir-based antiretroviral therapy
219231367|NCT04910711|DRUG|Levonorgestrel implant|Women initiating the levonorgestrel implant
219231368|NCT04910711|DRUG|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
219231369|NCT04014452|PROCEDURE|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
219231370|NCT04014452|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
219231371|NCT03230981|DEVICE|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
219231372|NCT01578629|OTHER|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
219231373|NCT01578629|OTHER|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
219231374|NCT05254067|DEVICE|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
219231375|NCT02970318|DRUG|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
219231376|NCT02970318|DRUG|Rituximab|Rituximab in combination with idelalisib or bendamustine
219146045|NCT06966076|PROCEDURE|Conventional physical therapy group|CONVENTIONAL PHYSICAL THERAPY CONVENTIONAL PHYSICAL THERAPY Week 1 Orientation of exercises Week 2-3 UPPER LIMB (20 MINS) Lifting a glass of water with elbow extended Moving objects from the table to a box Combing Hairs LOWER LIMB (20 MINS) Lifting the lower extremity and lowering in o nto a footstool sit to stand Standing up with loaded trey in hand corner hamstring stretch butterfly stretch Week 4-5 UPPER LIMB (20 MINS) Grasping and releasing objects lifting a glass of water to a level of 90° shoul der flexion with an extended elbow Moving objects from the table to a box LOWER LIMB (20 MINS) Reciprocal leg flexion and extension single leg stance Kicking a ball Week 5-8 UPPER LIMB (20 MINS) Opening Jars Throwing Balls Same As previous weeks LOWER LIMB (20 MINS) Squatting
219146046|NCT03823911|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
219146047|NCT03823911|PROCEDURE|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
219146048|NCT01152190|DRUG|Tadalafil|Administered orally, once daily for 8 weeks
219146049|NCT01152190|DRUG|Placebo|Administered orally, once daily for 8 weeks
219231377|NCT02970318|DRUG|Idelalisib|Idelalisib in combination with rituximab
219231378|NCT02970318|DRUG|Bendamustine|Bendamustine in combination with rituximab
219231379|NCT05498155|DRUG|Neoadjuvant Olaparib monotherapy group|Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
219231380|NCT05498155|COMBINATION_PRODUCT|Neoadjuvant combination therapy with olaparib plus durvalumab|Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
219231381|NCT00221559|PROCEDURE|Blood sampling for determination of serum Zn|
219231382|NCT02563119|PROCEDURE|Gastric Bypass or Sleeve gastrectomy|
219231383|NCT00982917|BEHAVIORAL|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
219231384|NCT00982917|BEHAVIORAL|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
219231385|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
219231386|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
219231387|NCT01658241|DRUG|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
219231388|NCT05470231|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
219231389|NCT03476772|DRUG|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
219231390|NCT02589457|DRUG|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
219553656|NCT05772858|OTHER|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
219719512|NCT07114120|DRUG|Bailing Capsules in combination Guben Kechuan Granules|Bailing Capsules (four capsules each time, three times a day) in combination Guben Kechuan Granules (1 bag each time，three times a day,)
219146050|NCT01469949|OTHER|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
219146051|NCT03439904|OTHER|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
219146052|NCT03261596|DRUG|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
219146053|NCT02266641|BEHAVIORAL|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
219146054|NCT02266641|DIETARY_SUPPLEMENT|multivitamin supplement|
219146055|NCT03052361|DRUG|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
219146056|NCT03052361|DRUG|Placebos|similar looking and tasting liquid placebo
219553657|NCT05772858|OTHER|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
219553658|NCT05772858|OTHER|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
219553659|NCT05772858|OTHER|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
219553660|NCT06202534|OTHER||radiotherapy
219553661|NCT05940259|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
219553662|NCT04409379|DIAGNOSTIC_TEST|Relative telomere length|Relative telomere length in peripheral blood cell
219553663|NCT01216254|DEVICE|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
219553664|NCT05543551|OTHER|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
219553665|NCT05543551|OTHER|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
219553666|NCT00924053|DRUG|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
219553667|NCT00924053|DRUG|Placebo|Placebo capsules to match EGT0001474
219553668|NCT04833205|DRUG|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
219553669|NCT04651816|BEHAVIORAL|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
219553670|NCT04651816|BEHAVIORAL|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
219553671|NCT04651816|BEHAVIORAL|DPP Program|All Participants will be enrolled in the DPP program.
219553672|NCT02946255|BEHAVIORAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
219553673|NCT02946255|BEHAVIORAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
219146057|NCT01677104|DRUG|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
219146058|NCT01677104|DRUG|Placebo|
219146059|NCT04539951|DRUG|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
219146060|NCT04539951|DRUG|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
219146061|NCT04539951|DRUG|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
219146062|NCT04539951|DRUG|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
219231391|NCT02589457|DRUG|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
219231392|NCT03584074|DRUG|Pregabalin 75mg|Orally taken twice daily for 8 weeks
219231393|NCT03584074|DRUG|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
219231394|NCT01179802|OTHER|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
219231395|NCT00718120|BIOLOGICAL|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
219231396|NCT00125905|BEHAVIORAL|Advice|
219231397|NCT00125905|BEHAVIORAL|Motivational Interviewing|
219231398|NCT00125905|DRUG|Nicotine Gum and Patch|
219231399|NCT00125905|DRUG|Bupropion|
219231400|NCT00040105|DRUG|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
219146063|NCT04539951|DRUG|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
219146064|NCT04539951|DRUG|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
219146065|NCT03709693|DEVICE|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
219231401|NCT00040105|DRUG|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
219231402|NCT02971215|DEVICE|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~\+ Physical Therapy protocol."
219231403|NCT02971215|DEVICE|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
219231404|NCT02695004|DRUG|DKF-310|
219146066|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
219146067|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
219146068|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
219146069|NCT02318771|RADIATION|Radiation Therapy (RT)|Undergo RT
219231405|NCT02695004|DRUG|Placebo|
219146070|NCT02318771|DRUG|MK-3475|Given IV
219146071|NCT00547118|DRUG|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
219146072|NCT00547118|DRUG|Placebo|One placebo tablet given 1 time per day for 112 days.
219146073|NCT05101148|DRUG|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
219146074|NCT04267250|DRUG|PF-06700841|60 mg by mouth (PO) once daily (QD).
219146075|NCT04267250|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
219231406|NCT03241810|DRUG|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
219231407|NCT03241810|DRUG|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
219231408|NCT03241810|DRUG|Placebo|Placebo
219231409|NCT04566263|DEVICE|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
219231410|NCT04255251|DRUG|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
219231411|NCT04255251|DRUG|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
219553674|NCT02946255|BEHAVIORAL|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
219553675|NCT03201003|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
219553676|NCT03201003|OTHER|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
219553677|NCT00843089|OTHER|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
219553678|NCT01715077|DRUG|Ipilimumab at 3 mg/kg dose|
219553679|NCT00834613|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
219553680|NCT00834613|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
219553681|NCT04112199|DRUG|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
219146076|NCT01335542|PROCEDURE|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
219146077|NCT01335542|PROCEDURE|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
219146078|NCT00518726|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
219719513|NCT07115589|OTHER|Muscle Your Heart home-based program|2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses
219146079|NCT02404233|DRUG|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
219146080|NCT02404233|DRUG|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
219719514|NCT07118488|PROCEDURE|Multitarget PFA Ablation|"* Informed consent gave by the patient.~* Implantable loop recorder procedure~* Clinical procedure starts~* Electrophysiologycal study~* Non-invasive map is obtained.~* Electroanatomical map of both atria is generated.~* Intracavitary electrogram (EGM) driver assessment~* Pulmonary vein isolation~* Extra pulmonary drivers ablation based on EGM findings (rotational and high frequency sites).~* Non-invasive map is obtained to assess ablation impact on driver distribution.~* Remap and extra pulmonary lesions are carried out until activity. At drivers sites disappears or decreases in at least 2 hertz or up to physician criteria.~* Patient follow up"
219719515|NCT07121361|DEVICE|Mouthwash Product|DNA mouthwash
219719516|NCT07121361|DEVICE|Control|Placebo mouthwash
219719517|NCT07120581|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy at increasing pressure to 2.8 ATA for 2 hours sessions. Breaks of 5 every 20 minutes from the oxygen to air to avoid hyperoxia. Continued for the duration of the hospitalization in the ICU on a daily basis.
219719518|NCT07113613|RADIATION|Exemption from additional radiotherapy on the tumor bed after surgery|For patients who met the inclusion criteria and were enrolled, postoperative tumor bed boost radiotherapy was waived, and only whole breast and/or regional lymph node irradiation was administered.
219719519|NCT07120074|OTHER|Exercise|A low-activity exercise group, and highly active dual-task exercise group determined based on physical performance level, was subjected to 6 weeks of dual-task exercises aimed at improving balance and cognitive function. Dual-task refers to performing two different tasks simultaneously. In the first week, tasks included generating 3- and 4-letter words while standing in a tandem position, reciting the months and seasons in order while shifting weight forward and backward on a balance board, and performing addition and subtraction tasks while walking. The difficulty level of the tasks was increased each week.
219719520|NCT07120490|OTHER|FMT (fecal microbiota transplantation)|This intervention consists of a two-phase treatment for Clostridioides difficile infection in high-risk adults. First, participants receive a short-course (5 days) of oral vancomycin to reduce C. difficile bacterial load. Following antibiotic pretreatment, fecal microbiota transplantation (FMT) is administered to restore healthy gut microbiota. FMT is delivered primarily via encapsulated microbiota capsules, with alternative routes including colonoscopy, gastroscopy, nasojejunal tube, or rectal enema if capsules are contraindicated. A second FMT dose is given 7 days after the first, either as daily capsules over six days or as a single endoscopic administration. This approach aims to reduce CDI recurrence by combining targeted antibiotic reduction of pathogens with microbiome restoration.
219719521|NCT07120490|DRUG|Fidaxomicin|Participants receive a 10-day course of fidaxomicin administered orally at a dose of 200 mg twice daily. Fidaxomicin is a narrow-spectrum macrocyclic antibiotic specifically targeting Clostridioides difficile with minimal impact on the normal gut microbiota. This monotherapy aims to eradicate C. difficile infection while preserving the intestinal microbiome, thereby reducing the risk of recurrence. No additional interventions are provided during the treatment period. Biological samples are collected before and after treatment to evaluate clinical response, safety, and microbiome changes.
219719522|NCT07120490|DRUG|Vancomycin (VAN) treatment|Participants receive a 10-day course of oral vancomycin at a dose of 125 mg four times daily. Vancomycin is a broad-spectrum glycopeptide antibiotic commonly used as standard-of-care therapy for Clostridioides difficile infection. This monotherapy aims to eradicate C. difficile by reducing bacterial load in the colon. No additional interventions are applied during the treatment period. Biological samples are collected before and after treatment to monitor clinical outcomes, safety, and changes in the gut microbiome.
219719523|NCT07120256|OTHER|locator attachment|mandibular single implant overdenture retained by locator attachment
219719524|NCT07120256|OTHER|ball and socket attachment|mandibular single implant overdenture retained by ball and socket attachment
219719525|NCT03817398|PROCEDURE|Biospecimen Collection|Undergo blood collection
219719526|NCT03817398|OTHER|Drug Withdrawn|Stop taking TKI medication
219719527|NCT03817398|OTHER|Quality-of-Life Assessment|Ancillary studies
219719528|NCT03817398|OTHER|Questionnaire Administration|Ancillary studies
219146081|NCT04288219|DEVICE|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
219146082|NCT04288219|DRUG|Nifedipine|Nifedipine 30mg, Pharmacotherapy
219146083|NCT04288219|OTHER|supplemental oxygen|supplemental oxygen
219146084|NCT00920881|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
219146085|NCT04789798|DEVICE|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
219146086|NCT04789798|OTHER|Usual care|Usual diabetes care, as provided by primary care providers
219146087|NCT03213249|OTHER|Normal saline|Intraoperative pocket irrigation with normal saline
219719529|NCT03817398|DRUG|Tyrosine Kinase Inhibitor|Re-start TKI medication
219719530|NCT07119775|DRUG|Tideglusib|
219719531|NCT05339126|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
219719532|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
219719533|NCT06480357|PROCEDURE|laparoscopic adrenalectomy|laparoscopic transabdominal approach.
219719534|NCT03477981|OTHER|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
219719535|NCT01379209|DRUG|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
219719536|NCT01379209|DRUG|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
219719537|NCT01379209|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
219719538|NCT01379209|DRUG|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
219719539|NCT01379209|PROCEDURE|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
219719540|NCT01379209|DRUG|Methotrexate|
219719541|NCT01379209|DRUG|Mofetil Mycophenolate|
219719542|NCT01379209|DRUG|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
219719543|NCT05011435|DEVICE|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
219719544|NCT06451744|OTHER|Blood samples collection|50 mL blood sample
219146088|NCT03213249|DRUG|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
219146089|NCT03213249|PROCEDURE|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
219146090|NCT03213249|PROCEDURE|Bilateral skin- or nipple-sparing mastectomies|Standard of care
219146091|NCT03213249|DEVICE|Tissue expander|Standard of care
219719545|NCT06451744|OTHER|Skin or mucous membrane brushing|brushing on skin or mucous membrane lesions
219719546|NCT06451744|OTHER|Skin or mucous membrane biopsy|6 mm biopsy
219719547|NCT06393452|DRUG|PP405 0.05% Topical Gel|PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)
219719548|NCT06393452|DRUG|PP405 Topical Vehicle Gel|PP405 Vehicle = placebo
219719549|NCT04604782|DRUG|Regadenoson|Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
219719550|NCT05937568|DRUG|Imetelstat|Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
219719551|NCT06148883|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously
219719552|NCT06478095|BEHAVIORAL|Visual aids|Diagrams, models, and videos
219146092|NCT03213249|DEVICE|Breast implant|"* Standard of care~* Either breast implant or autologous flap"
219146093|NCT03213249|PROCEDURE|Autologous flap|"* Standard of care~* Either breast implant or autologous flap"
219146094|NCT03213249|OTHER|Acellular dermal matrix sling|Standard of care
219146095|NCT03213249|DRUG|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
219146096|NCT03213249|DRUG|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
219146097|NCT01233713|PROCEDURE|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
219146098|NCT01233713|PROCEDURE|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
219146099|NCT01641913|OTHER|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
219719553|NCT01373229|DRUG|Lenalidomide + Plerixafor (+ Rituximab)|"1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression."
219719554|NCT02906618|DRUG|LY3039478|Administered orally
219719555|NCT02906618|DRUG|13C 15N 2H-LY3039478 IV|Administered IV
219719556|NCT05855759|OTHER|Acellular Dermal Matrix|Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
219146100|NCT00982618|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
219146101|NCT00982618|PROCEDURE|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
219146102|NCT00982618|DRUG|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
219146103|NCT00567515|DEVICE|AtriCure LAA Exclusion System|Placement of clip of LAA.
219146104|NCT02602106|BEHAVIORAL|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
219146105|NCT02927132|BEHAVIORAL|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
219719557|NCT05855759|OTHER|Acellular Dermal Matrix with autologous orthobiologics|Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
219719558|NCT02467816|BEHAVIORAL|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
219719559|NCT02467816|BEHAVIORAL|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
219719560|NCT02467816|BEHAVIORAL|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
219146106|NCT02927132|BEHAVIORAL|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
219146107|NCT02950896|OTHER|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
219146108|NCT03083119|DRUG|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
219719561|NCT04254211|OTHER|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
219146109|NCT03083119|DRUG|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
219146110|NCT04504916|DRUG|Zilovertamab vedotin|Intravenous infusion
219146111|NCT05510544|DRUG|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
219146112|NCT02331004|OTHER|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
219719562|NCT01730196|BEHAVIORAL|Fit Body and Soul|
219719563|NCT01730196|BEHAVIORAL|Wellness Education|
219719564|NCT02874898|BEHAVIORAL|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
219719565|NCT04213131|OTHER|Stem cell transplantation|The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
219719566|NCT00143507|DRUG|Ivabradine|
219146113|NCT02331004|OTHER|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
219146114|NCT04010448|BIOLOGICAL|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
219146115|NCT04010448|BIOLOGICAL|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
219146116|NCT01918163|DIETARY_SUPPLEMENT|Pomegranate pills|
219146117|NCT03750942|DEVICE|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
219146118|NCT00834834|DRUG|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
219146119|NCT00834834|BEHAVIORAL|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
219146120|NCT00834834|DRUG|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
219719567|NCT00143507|DRUG|Placebo|
219719568|NCT04095013|DRUG|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
219719569|NCT04095013|DRUG|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
219719570|NCT00330096|DRUG|Hesperidin|
219719571|NCT00330096|OTHER|Placebo|
219719572|NCT01388426|DEVICE|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
219719573|NCT06256276|DIETARY_SUPPLEMENT|Whey protein powder and L-carnitine|Dietary supplement intervention for 16 weeks
219719574|NCT06256276|DIETARY_SUPPLEMENT|Maltodextrin placebo powder and Psyllium Husk capsules|Maltodextrin placebo powder and Psyllium Husk capsules
219719575|NCT04136678|OTHER|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
219719576|NCT00587457|DRUG|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
219146121|NCT03400124|PROCEDURE|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
219146122|NCT03400124|PROCEDURE|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
219146123|NCT00001992|BIOLOGICAL|rgp120/HIV-1IIIB|
219146124|NCT00947986|OTHER|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
219146125|NCT06355388|DEVICE|Active tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
219146126|NCT06355388|DEVICE|Sham tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
219146127|NCT03034681|OTHER|Physiotherapy technique: TENS|
219146128|NCT03034681|OTHER|Physiotherapy technique: Vojta Therapy|
219146129|NCT00442117|DRUG|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
219146130|NCT00442117|DRUG|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
219146131|NCT04016025|BEHAVIORAL|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
219146132|NCT02008084|DRUG|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
219146133|NCT02008084|DRUG|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
219146134|NCT04796337|BIOLOGICAL|Sotatercept|Sotatercept SC injection at a dose of 0.3 to 0.7 mg/kg.
219146135|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours
219146136|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
219146137|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
219553682|NCT00748137|DEVICE|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
219553683|NCT00748137|OTHER|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
219553684|NCT01368354|BEHAVIORAL|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
219553685|NCT01693809|DRUG|Caffeine|
219553686|NCT00079287|DRUG|carboplatin|
219553687|NCT00079287|DRUG|docetaxel|
219553688|NCT00079287|DRUG|gemcitabine hydrochloride|
219553689|NCT00079287|DRUG|paclitaxel|
219553690|NCT00079287|DRUG|vinorelbine tartrate|
219553691|NCT06375915|RADIATION|radioembolization with Y-90|Radioembolization with Y-90 will be performed in nominal day 0
219553692|NCT06375915|DRUG|Durvalumab|Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
219553693|NCT06375915|DRUG|Cisplatin|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
219553694|NCT06375915|DRUG|Gemcitabine|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
219553695|NCT02293928|PROCEDURE|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
219553696|NCT01751087|OTHER|Mifepristone|oral mifepristone 200 mg on Day 1.
219553697|NCT01751087|DRUG|misoprostol|buccal misoprostol 400 mcg on Day 2
219553698|NCT01751087|DEVICE|Osmotic dilators|osmotic dilators on Day 1
219553699|NCT01751087|OTHER|placebo|placebo for mifepristone, on day 1
219553700|NCT01751087|OTHER|placebo|placebo for misoprostol, on day 2
219553701|NCT02379533|OTHER|Aerobic exercise|
219553702|NCT00681486|DRUG|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
219553703|NCT00681486|DRUG|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
219146138|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
219146139|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
219146140|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
219146141|NCT05905913|DRUG|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
219146142|NCT05905913|DRUG|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
219146143|NCT05541458|OTHER|Food as medicine|"* Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~* Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~* Increase nutrition literacy.~* Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
219146144|NCT06666608|DEVICE|Bone Stimulator|Subjects will be asked to wear their device (if applicable) for a minimum of 30 minutes a day for 12 weeks with no maximum usage time. The device will track compliance. Bone stimulator should be worn at rest.
219146145|NCT06666608|OTHER|Standard of Care Spondylolysis Treatment|Participants will follow the standard of care regimen for spondylolysis treatment at Houston Methodist which will involve physical therapy and wearing a back brace.
219146146|NCT04390529|OTHER|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
219146147|NCT04925674|DRUG|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
219146148|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
219146149|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
219146150|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
219146151|NCT06295614|DEVICE|ARC-IM System implantation|Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
219146152|NCT03290937|BIOLOGICAL|Cetuximab|Given IV
219146153|NCT03290937|DRUG|Irinotecan Hydrochloride|Given IV
219146154|NCT03290937|OTHER|Pharmacodynamic Study|Correlative studies
219719577|NCT00587457|DRUG|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
219146155|NCT03290937|BIOLOGICAL|Utomilumab|Given IV
219146156|NCT04632901|DIAGNOSTIC_TEST|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
219146157|NCT04632901|DIAGNOSTIC_TEST|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
219146158|NCT03063944|DRUG|STAT Inhibitor OPB-111077|Given PO
219146159|NCT03063944|DRUG|Decitabine|Given IV
219146160|NCT03063944|DRUG|Venetoclax|Given PO
219146161|NCT03063944|OTHER|Laboratory Biomarker Analysis|Correlative studies
219231412|NCT04290533|DEVICE|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
219719578|NCT00587457|DRUG|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
219719579|NCT00446875|OTHER|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
219146162|NCT06023329|DRUG|ropivacaine|will receive SCPB with ropivacaine via regional anesthesia team
219146163|NCT06023329|DRUG|Saline|will receive SCPB with saline via regional anesthesia team
219146164|NCT06381570|DRUG|Tovorafenib|"Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)"
219146165|NCT06381570|DRUG|Vinblastine|vinblastine in combination with tovorafenib
219146166|NCT06792188|DEVICE|Galaxy Watch 4, Samsung Electronics Co., Ltd., South Korea|Use of the Galaxy Watch 4 during sleep for approximately two weeks prior to the polysomnography test, including the night of the test.
219146167|NCT06791525|DRUG|Tirbanibulin ointment 1%|Topical application
219146168|NCT05798117|DRUG|YTB323|Single infusion of YTB323
219146169|NCT03882671|DEVICE|EpiTel Epilog|EEG recording device
219146170|NCT03882671|DEVICE|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
219146171|NCT03882671|DEVICE|GENEActiv|Temperature, light level and accelerometry recording device
219146172|NCT04029194|BEHAVIORAL|Assistance with old age pension application|The intervention will offer elderly assistance in applying for the old age pension.
219146173|NCT05952934|BIOLOGICAL|0.5 mL Candin®/injection|Candin or placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
219146174|NCT05952934|OTHER|Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)|Placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
219146175|NCT06453798|OTHER|cervical spine exercises|Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.
219146176|NCT06453798|OTHER|Neuromobilization|Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
219146177|NCT05317390|DIAGNOSTIC_TEST|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
219146178|NCT01494103|BIOLOGICAL|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
219146179|NCT01494103|DRUG|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
219146180|NCT05217628|DRUG|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
219146181|NCT05217628|OTHER|Placebo|Participant randomized to receive matching placebo once daily.
219146182|NCT03967704|PROCEDURE|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
219146183|NCT02139696|RADIATION|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
219146184|NCT06795152|OTHER|No intervention|Observational. Natural history study.
219146185|NCT06545604|OTHER|Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation|Two visits per week with a yoga therapist while receiving neoadjuvant chemotherapy to cover dietary counseling, yoga-based movement practices, breathwork practices, mind practices, and behavioral support for the purpose of preparing patients' mind and body for a planned surgery.
219146186|NCT06545604|OTHER|Usual care supportive services including nutrition counseling per usual care|Usual care supportive services while receiving neoadjuvant chemotherapy.
219146187|NCT01522898|PROCEDURE|AV nodal ablation|Percutaneous catheter ablation of the AV node.
219146188|NCT01522898|DRUG|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
219146189|NCT03344588|PROCEDURE|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
219146190|NCT03344588|PROCEDURE|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
219146191|NCT02496377|DRUG|ferrous glycine sulfate Tardyferon|
219146192|NCT02496377|DRUG|Epoetin Alfa|
219146193|NCT02496377|DRUG|ferric carboxymaltose Ferinject|
219146194|NCT04993898|OTHER|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
219146195|NCT04993898|OTHER|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
219146196|NCT02755181|BEHAVIORAL|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
219146197|NCT05437094|DRUG|CRD-740|CRD-740
219146198|NCT05437094|DRUG|Itraconazole|Itraconazole
219146199|NCT03332758|PROCEDURE|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
219146200|NCT03332758|PROCEDURE|External drainage|Standard of care treatment for retinal detachment.
219146201|NCT06630884|BIOLOGICAL|Typhoid VI Polysaccharide Vaccine Injectable Solution|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
219146202|NCT06630884|OTHER|Saline Placebo (0.5mL injection)|The placebo injection will consist of 0.5mL of saline.
219146203|NCT02968225|BEHAVIORAL|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
219553704|NCT04872231|DRUG|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
219553705|NCT04872231|DRUG|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
219719580|NCT00446875|OTHER|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
219146204|NCT06081049|DRUG|Colchicine|0.5 mg once daily
219231413|NCT04290533|DEVICE|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
219231414|NCT06454929|PROCEDURE|operative|open reduction : fixation by k-wires or screws
219231415|NCT06454929|PROCEDURE|non-operative|close reduction : by cast Immobilization
219719581|NCT03881787|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
219553706|NCT04682327|OTHER|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
219553707|NCT04682327|OTHER|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
219719582|NCT03881787|DRUG|Cetuximab injection|Cetuximab injection
219719583|NCT04569344|OTHER|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
219719584|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
219719585|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed."
219719586|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
219146205|NCT06081049|DRUG|Placebo|Once daily
219146206|NCT00117130|DRUG|Aranesp®|
219146207|NCT05583253|PROCEDURE|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
219146208|NCT05961462|BEHAVIORAL|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
219146209|NCT03584152|DRUG|Norco 5Mg-325Mg Tablet|Opioid Analgesics
219146210|NCT03584152|DRUG|Tylenol 325Mg Caplet|Non opioid analgesics
219146211|NCT03584152|DRUG|Ibuprofen 200 mg|Non opioid analgesics
219146212|NCT05929105|PROCEDURE|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
219231416|NCT03445364|OTHER|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
219231417|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
219231418|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
219231419|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
219146213|NCT05929105|OTHER|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
219146214|NCT02810184|RADIATION|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
219146215|NCT02889718|DEVICE|CONCERT-CL® station|"During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare"
219146216|NCT02889718|OTHER|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
219146217|NCT01662336|DRUG|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
219146218|NCT01662336|BEHAVIORAL|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
219146219|NCT06248229|DRUG|Dyanavel XR|"Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
219231420|NCT02252822|BEHAVIORAL|Overcoming Bulimia Online Programme|
219553708|NCT04042415|OTHER|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
219553709|NCT04042415|OTHER|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
219553710|NCT05628311|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
219553711|NCT05628311|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219553712|NCT00697619|DRUG|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
219553713|NCT03711448|DRUG|prednisone treatment|tapering prednisone regimen
219553714|NCT03711448|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
219553715|NCT03711448|OTHER|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
219553716|NCT03711448|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
219553717|NCT00471510|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
219553718|NCT03093025|DRUG|TS-121 10 mg|Orally taken once daily
219553719|NCT03093025|DRUG|TS-121 50 mg|Orally taken once daily
219553720|NCT03093025|DRUG|Placebo|Orally taken once daily
219553721|NCT01664169|OTHER|laboratory biomarker analysis|
219553722|NCT05462548|DRUG|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
219553723|NCT05770011|DEVICE|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
219553724|NCT05770011|DEVICE|impression material|conventional recording
219553725|NCT05770011|DEVICE|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
219553726|NCT05534243|OTHER|Standard neuromuscular blocker practices|Usual care neuromuscular blocker in the ED
219553727|NCT05534243|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
219553728|NCT06543394|BEHAVIORAL|Primer postcard|Mailed primer postcard
219553729|NCT06543394|BEHAVIORAL|Control recruitment letter|Mailed recruitment letter with usual care message framing
219553730|NCT06543394|BEHAVIORAL|Behavioral theory-informed recruitment letter|Mailed recruitment letter with prospect-theory informed message framing
219553731|NCT06543394|BEHAVIORAL|2 phone calls|Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
219553732|NCT06543394|BEHAVIORAL|4 phone calls|Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
219553733|NCT04317664|COMBINATION_PRODUCT|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
219719587|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (RMT-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
219719588|NCT02971826|DEVICE|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
219146220|NCT06248229|DRUG|Placebo|"Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
219146221|NCT00105313|DRUG|MEDI-507|
219146222|NCT05133154|BIOLOGICAL|Blood samples|In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
219146223|NCT06005051|OTHER|Dietary intervention|Using different combination of foods to see if the glucose response to a load of carbohydrates can be mitigated.
219146224|NCT06345027|BIOLOGICAL|Treatment Arm A|"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."
219146225|NCT02840149|DRUG|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
219146226|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
219146227|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
219146228|NCT04425733|DRUG|Frespaciguat|Frespaciguat administered at a dose of 180 µg or ≤360 µg QD via inhalation
219146229|NCT04425733|DRUG|Placebo|Frespaciguat-matching placebo administered QD via inhalation
219146230|NCT06419231|DIETARY_SUPPLEMENT|Butyrate Formulation|Butyrate Formulation capsule: Take daily
219146231|NCT06419231|DIETARY_SUPPLEMENT|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation capsule: Take daily
219146232|NCT06419231|DIETARY_SUPPLEMENT|Placebo|Placebo: Take daily
219146233|NCT05318105|DEVICE|Aquadex Smartflow® System|ultrafiltration
219146234|NCT05318105|DRUG|IV Loop Diuretics|diuretics
219146235|NCT06104397|OTHER|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
219146236|NCT06104397|OTHER|Physical therapy|A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
219146237|NCT04947189|DRUG|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
219719589|NCT01051284|RADIATION|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
219719590|NCT02194075|DRUG|Fluvoxamine+Methylphenidate hydrochloride|
219719591|NCT02194075|DRUG|Fluvoxamine+sugar pill|
219146238|NCT04947189|DRUG|Docetaxel|Use of docetaxel chemotherapy for solid tumours
219146239|NCT02206841|PROCEDURE|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
219146240|NCT02206841|DEVICE|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
219146241|NCT02206841|DEVICE|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
219146242|NCT02206841|DEVICE|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
219146243|NCT05575024|DEVICE|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
219146244|NCT05575024|DEVICE|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
219146245|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
219146246|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
219146247|NCT03061552|DIAGNOSTIC_TEST|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
219719592|NCT03219580|DRUG|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
219719593|NCT03219580|DRUG|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
219719594|NCT00432432|DRUG|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
219146248|NCT00178399|PROCEDURE|Stereotactic Body Radiation Therapy|
219146249|NCT04992156|DRUG|Palbociclib|Palbociclib 125mg/d
219719595|NCT03234881|BEHAVIORAL|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
219719596|NCT03234881|BEHAVIORAL|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
219719597|NCT05057208|BIOLOGICAL|COVID|COVID vaccination
219719598|NCT03392857|OTHER|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
219146250|NCT05543837|DRUG|Capsaicin|Patients will receive a fixed dose of capsaicin
219146251|NCT01723410|BEHAVIORAL|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
219146252|NCT01723410|OTHER|Writing about places, objects|
219146253|NCT00415272|BEHAVIORAL|Pulmonary Rehabilitation|
219146254|NCT00506727|DRUG|Mixed amphetamine salts (ADDERALL XR)|
219146255|NCT00506727|DRUG|Atomoxetine hydrochloride|
219146256|NCT04409912|DEVICE|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
219146257|NCT04409912|DEVICE|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
219146258|NCT00844636|DEVICE|Sharp needle|
219146259|NCT00844636|DEVICE|Blunt needles|
219146260|NCT03601780|DRUG|local wound infiltration plus usual care|local wound infiltration plus usual care
219146261|NCT03601780|DRUG|usual care only|usual care only
219146262|NCT03784768|OTHER|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
219146263|NCT03784768|OTHER|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
219146264|NCT01474707|BEHAVIORAL|Group one|Group 1 will view the knowledge-based video only
219146265|NCT01474707|BEHAVIORAL|Group two|Group two will view the motivational video only
219146266|NCT01474707|BEHAVIORAL|Group three|Group three will view both knowledge-based and motivational videos
219146267|NCT01474707|BEHAVIORAL|Group four|Group four will view the printed educational pamphlet and will not view either video
219146268|NCT05965388|DRUG|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
219146269|NCT00516321|DRUG|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
219146270|NCT00516321|DRUG|placebo|matched placebo taken once daily orally
219146271|NCT01959126|BEHAVIORAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
219146272|NCT04738058|DRUG|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
219146273|NCT04738058|DRUG|placebo|placebo
219146274|NCT00164333|BEHAVIORAL|TAP: Treatment Advocacy Program|
219146275|NCT04133298|PROCEDURE|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
219231421|NCT04434651|PROCEDURE|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
219719599|NCT02520973|OTHER|Sputum sample|
219719600|NCT02071160|DRUG|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
219146276|NCT04133298|PROCEDURE|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
219146277|NCT05701397|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
219146278|NCT02207972|DEVICE|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
219146279|NCT02207972|PROCEDURE|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
219146280|NCT03431922|DEVICE|endovascular denervation|multi-electrode catheter-based endovascular denervation
219146281|NCT03381820|OTHER|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
219146282|NCT03335748|OTHER|Cognitive training Cogmed program|Cognitive training Cogmed program
219146283|NCT00300131|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
219146284|NCT04149548|DIAGNOSTIC_TEST|ultrasound|Obstetric ultrasound to pregnant women
219146285|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 3)|
219231422|NCT03592524|BEHAVIORAL|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
219719601|NCT03011853|PROCEDURE|Non-invasive and/or invasive mechanical ventilation|Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
219719602|NCT02329288|DRUG|Triamcinolone Acetonide|
219146286|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5)|
219146287|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5D)|
219146288|NCT01123408|DRUG|Clozapine|500 mg/day
219146289|NCT01123408|DRUG|Olanzapine|20 mg/day
219146290|NCT01123408|DRUG|Haloperidol|20 mg/day
219146291|NCT04898140|DIAGNOSTIC_TEST|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
219231423|NCT06047535|DRUG|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
219231424|NCT04365205|PROCEDURE|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
219231425|NCT03602950|BIOLOGICAL|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
219146292|NCT04898140|DIAGNOSTIC_TEST|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
219146293|NCT04898140|DIAGNOSTIC_TEST|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
219146294|NCT00004423|DRUG|-aminosalicylic acid|
219146295|NCT00232349|DRUG|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
219146296|NCT01765543|DRUG|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
219719603|NCT02329288|DRUG|placebo|
219719604|NCT05804903|DEVICE|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
219719605|NCT02314884|DRUG|Cafusertib Hydrochloride|
219719606|NCT01181882|DIETARY_SUPPLEMENT|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
219719607|NCT03991767|OTHER|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
219719608|NCT03991767|DIAGNOSTIC_TEST|Serology HIV|Realization of HIV serology for included patients.
219719609|NCT04200924|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
219719610|NCT04200924|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
219719611|NCT01178931|DRUG|Oral dydrogesterone|oral-2x10mg
219146297|NCT01765543|DRUG|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
219146298|NCT06537167|DEVICE|Transcutaneous electrical acupoint stimulation|Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
219146299|NCT06537167|DEVICE|Sham stimulation|Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
219146300|NCT04243304|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
219146301|NCT04243304|OTHER|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
219146302|NCT03329391|BEHAVIORAL|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
219146303|NCT02144584|DRUG|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
219146304|NCT02144584|DRUG|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
219146305|NCT02667808|OTHER|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
219146306|NCT02667808|OTHER|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
219146307|NCT00488410|DEVICE|Doppler echocardiography|
219146308|NCT03702673|DRUG|K-877 CR Tablet A|K-877 Controlled Release Tablet A
219146309|NCT03702673|DRUG|K-877 CR Tablet B|K-877 Controlled Release Tablet B
219146310|NCT03702673|DRUG|K-877 CR Tablet E|K-877 Controlled Release Tablet E
219146311|NCT03702673|DRUG|K-877 IR Tablet|K-877 Immediate Release Tablet
219146312|NCT05800405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219146313|NCT05800405|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
219146314|NCT05800405|PROCEDURE|Computed Tomography|Undergo PET/CT
219146315|NCT05800405|RADIATION|External Beam Radiation Therapy|Undergo radiation therapy
219146316|NCT05800405|PROCEDURE|Leukapheresis|Receive leukapheresis
219146317|NCT05800405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219231426|NCT02954289|BEHAVIORAL|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
219146318|NCT05800405|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219146319|NCT04116515|BEHAVIORAL|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
219146320|NCT04116515|BEHAVIORAL|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
219146321|NCT04116515|BEHAVIORAL|Standard clinical care|Each clinic will provide standard clinical care to the participants.
219146322|NCT00482378|DRUG|Pamidronate|90 mg by IV monthly.
219146323|NCT00482378|DRUG|Zoledronic acid|4 mg by IV monthly.
219146324|NCT00482378|RADIATION|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
219146325|NCT02651233|OTHER|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
219146326|NCT04911439|OTHER|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
219146327|NCT04911439|OTHER|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
219146328|NCT04911439|OTHER|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
219146329|NCT05700513|COMBINATION_PRODUCT|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
219146330|NCT05700513|DRUG|Placebo capsules|Placebo capsules containing maltodextrin
219146331|NCT00084903|PROCEDURE|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
219146332|NCT00084903|PROCEDURE|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
219146333|NCT00148369|DRUG|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
219146334|NCT04109534|DIAGNOSTIC_TEST|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
219146335|NCT04109534|DIAGNOSTIC_TEST|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
219146336|NCT04109534|DIAGNOSTIC_TEST|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
219231427|NCT00514306|DRUG|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
219231428|NCT01323790|DRUG|NKTR-118|12.5 mg oral tablet once daily
219146337|NCT04109534|DIAGNOSTIC_TEST|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
219146338|NCT00004266|DRUG|Lisinopril|
219146339|NCT00004266|DRUG|Nifedipine|
219146340|NCT00004266|DRUG|Simvastatin|
219146341|NCT03234088|BEHAVIORAL|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
219146342|NCT00004004|DRUG|procarbazine hydrochloride|
219146343|NCT01926678|OTHER|Swedish massage therapy|
219146344|NCT01926678|OTHER|Light touch therapy|
219146345|NCT02399865|OTHER|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
219146346|NCT00846066|OTHER|Hands on training|Hands on training by a pediatric dentist on preventive oral health
219146347|NCT00846066|OTHER|Web based training|Web based training alone
219146348|NCT01574807|DRUG|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
219146349|NCT01574807|DRUG|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
219146350|NCT05500664|DRUG|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
219146351|NCT05126004|DRUG|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
219146352|NCT05126004|DRUG|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
219231429|NCT01323790|DRUG|NKTR-118|25 mg oral tablet once daily
219231430|NCT01323790|DRUG|Placebo|Placebo to NKTR-118
219231431|NCT01351259|DEVICE|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
219719612|NCT01178931|DRUG|Crinone 8% gel|vaginal-1x90mg
219719613|NCT05246748|OTHER|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
219719614|NCT05246748|OTHER|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
219719615|NCT00729586|OTHER|Laboratory Biomarker Analysis|Correlative studies
219231432|NCT03352726|DRUG|DBV712 IHRP|DBV712 Solution for Skin Prick Test
219719616|NCT00729586|DRUG|Megestrol Acetate|Given PO
219146353|NCT06319586|PROCEDURE|Radial Forearm Flap|"* Elevate the flap from ulnar to radial side toward the FCR~* Elevate flap from radial to ulnar side to the brachioradialis tendon. Ligate and divide the radial artery and venae comitantes distally.~* incise the skin over the cephalic vein proximally to the cubital fossa. Identify the venous branching pattern and perforating vein.~* Elevate the skin and subcutaneous paddles proximally off of the FCR and brachioradialis.~* Define the venous anatomy at the cubital fossa. In most cases, the median basilic vein and continuation of the median vein contribution to the cephalic vein can be harvested proximal to the perforating vein. This anatomy allows two large veins to be harvested that drain both the deep and superficial systems. Occasionally, one large vein will be identified.~* Closure is performed by harvesting a 0.018-inch skin graft to cover the donor defect. The radial skin edge should be advanced to cover the exposed radial nerve."
219231433|NCT02676011|DRUG|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
219231434|NCT02676011|DRUG|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
219231435|NCT02676011|DRUG|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
219231436|NCT02676011|DRUG|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
219231437|NCT02676011|DRUG|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
219231438|NCT02676011|DRUG|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
219719617|NCT00729586|DRUG|Tamoxifen Citrate|Given PO
219719618|NCT00729586|DRUG|Temsirolimus|Given IV
219719619|NCT03090906|PROCEDURE|Soft tissue augmentation palate|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
219719620|NCT03090906|PROCEDURE|Soft tissue augmentation tuberosity|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
219146354|NCT03133039|PROCEDURE|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
219146355|NCT04303156|DRUG|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
219146356|NCT05233007|PROCEDURE|Minor endoscopic biopsy|As per standard of care
219146357|NCT05072171|PROCEDURE|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
219146358|NCT06092697|OTHER|3D printed PEEK restorations|Indirect dental restoration
219146359|NCT05746273|DRUG|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
219146360|NCT05746273|DRUG|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
219146361|NCT04367415|DIAGNOSTIC_TEST|Darwish test for a free endometrial cavity|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
219146362|NCT04367415|DIAGNOSTIC_TEST|Darwish test for an endometrial cavity with endometrial polyps|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
219146363|NCT01663519|OTHER|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
219146364|NCT01663519|OTHER|Prefabricated insoles|Prefabricated insoles
219146365|NCT01663519|OTHER|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
219146366|NCT04385355|DEVICE|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
219146367|NCT04385355|DEVICE|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
219146368|NCT06142851|OTHER|Data collection|data collection
219146369|NCT04593914|DEVICE|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
219146370|NCT03127995|RADIATION|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
219146371|NCT03127995|RADIATION|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
219146372|NCT06386237|OTHER|Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
219146373|NCT03379935|PROCEDURE|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
219146374|NCT01465516|DRUG|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
219146375|NCT06306313|DEVICE|ReoGo|ReoGo is a fixed arm rehabilitation exoskeleton that comes on a small and compact wheeled platform. The end-effector extension is capable of producing a wide range or repeatable movements in 3D space. ReoGo can be used by both adults and children. It is an arm rehabilitation exoskeleton with a fixed base. Its design allows limited controlled movements of the shoulder as well as the elbow and wrist.
219719621|NCT03090906|DEVICE|Intraoral optical scan|Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
219719622|NCT01665027|PROCEDURE|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
219719623|NCT01665027|PROCEDURE|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
219719624|NCT01991314|DRUG|Ferrous sulphate|200mg tablets.
219146376|NCT06306313|OTHER|Conventional Physiotherapy|Physiotherapy protocols will be created with traditional physiotherapy practices such as neurodevelopmental techniques based on muscle strengthening and task-oriented exercises. Protocols in general terms; It will include passive and active joint range of motion exercises, stretching exercises, stimulation and facilitation techniques, strengthening exercises, fine motor skills and functional task training for daily living activities. Protocols will be tailored to each patient's level of motor impairment and functional needs.
219231439|NCT06359548|PROCEDURE|Peeled ILM Reposition|"The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required."
219231440|NCT06359548|PROCEDURE|ILM Peeling|The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
219231441|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
219231442|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
219231443|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
219231444|NCT01263496|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
219719625|NCT02190058|DRUG|DS-1971a|suspension
219719626|NCT02190058|DRUG|placebo|placebo matching DS-1971a
219231445|NCT01263496|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
219231446|NCT01263496|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
219231447|NCT01263496|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
219231448|NCT01263496|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
219719627|NCT03834012|DRUG|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
219719628|NCT03834012|DRUG|Placebo|Intervention: Drug: placebo
219719629|NCT03834012|DRUG|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
219719630|NCT03834012|DRUG|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
219719631|NCT06215495|RADIATION|reduced target volume|"Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV\_6000.~The clinical target volume\_6000 cGy (CTV\_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included.~If CTV\_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy"
219719632|NCT06215495|RADIATION|EORTC (European organisation for research and treatment of cancer) target volume|delineate according to EORTC guideline
219719633|NCT05311865|OTHER|Club event|Participate in a club event without a mask, indoors, with vaccinated people.
219719634|NCT05408988|DIAGNOSTIC_TEST|hs-TnT (high-sensitive cardiac troponin T) plasma concentration|hs-TnT plasma concentration measured once every 12 hours
219719635|NCT05408988|DIAGNOSTIC_TEST|CK-MB (creatine kinase myocardial band) plasma concentration|CK-MB plasma concentration measured every 12 hours
219146377|NCT01812148|PROCEDURE|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
219146378|NCT03123198|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
219146379|NCT04358939|OTHER|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
219146380|NCT04956679|DIAGNOSTIC_TEST|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
219719636|NCT05408988|DIAGNOSTIC_TEST|CPK (creatine phosphokinase) plasma concentration|CPK plasma concentration measured every 12 hours
219146381|NCT01219205|PROCEDURE|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
219146382|NCT02092519|DEVICE|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
219146383|NCT02092519|DEVICE|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
219146384|NCT00478478|PROCEDURE|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
219146385|NCT04129619|DRUG|ORP-101|Oral tablet
219146386|NCT04129619|DRUG|Placebo|Oral tablet
219146387|NCT02872753|BIOLOGICAL|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
219146388|NCT02872753|OTHER|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
219146389|NCT03161990|PROCEDURE|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
219146390|NCT03161990|PROCEDURE|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
219146391|NCT00548574|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
219146392|NCT00548574|DRUG|Mesalazine|
219146393|NCT00126646|DRUG|BL22 immunotoxin|
219146394|NCT00126646|PROCEDURE|antibody-drug conjugate therapy|
219146395|NCT00126646|PROCEDURE|immunotoxin therapy|
219146396|NCT05420090|BEHAVIORAL|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
219146397|NCT05420090|BEHAVIORAL|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
219146398|NCT05420090|BEHAVIORAL|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
219146399|NCT01708798|DRUG|Eplerenone|
219146400|NCT01708798|DRUG|Placebo|
219146401|NCT03189329|DRUG|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
219146402|NCT03189329|DRUG|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
219146403|NCT06552819|OTHER|No intervention|No intervention
219146404|NCT00405535|DRUG|glycine|
219146405|NCT00405535|OTHER|placebo|
219719637|NCT05408988|DIAGNOSTIC_TEST|NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration|NT-proBNP plasma concentration measured every 12 hours
219719638|NCT05408988|DIAGNOSTIC_TEST|Metanephrine concentration in urine|Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
219146406|NCT00478738|DRUG|GSK961081|
219146407|NCT02423291|DRUG|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
219146408|NCT01653834|PROCEDURE|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
219231449|NCT02842957|BEHAVIORAL|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
219231450|NCT00780806|BIOLOGICAL|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
219231451|NCT00780806|PROCEDURE|Blood draw|Blood draw
219231452|NCT00046475|DRUG|Midodrine Hydrochloride|
219719639|NCT01718496|DRUG|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
219719640|NCT01718496|DRUG|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
219719641|NCT02650752|DRUG|Lapatinib in Tandem With Capecitabine|
219719642|NCT01936155|DEVICE|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
219146409|NCT04925765|OTHER|Virtual Reality Biofeedback Session|"The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression."
219146410|NCT06161844|DRUG|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
219146411|NCT06161844|DRUG|Ozempic®|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
219146412|NCT04297306|BEHAVIORAL|Exercise Prescription|Standardised Exercise Prescription.
219146413|NCT04297306|DEVICE|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
219146414|NCT04246307|DIAGNOSTIC_TEST|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~* before the surgery (S1)~* during the hepatectomy, 10 minutes before the anhepatic phase (S2)~* in the anhepatic phase, before starting portal vein anastomosis: (S3)~* in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~* in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~* haemodynamic measurements by PiCCO~* arterial blood gas analysis from radial artery catheter~* central venous blood gas analysis from subclavian vein catheter~* blood temperature measurement in the femoral artery by PiCCO catheter~* hourly urinary output"
219146415|NCT01683149|DRUG|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
219146416|NCT01683149|DRUG|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
219146417|NCT03094182|DRUG|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
219146418|NCT03094182|DRUG|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
219146419|NCT01680250|DRUG|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
219146420|NCT05339893|DEVICE|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
219719643|NCT00879359|DRUG|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
219719644|NCT05314725|DRUG|SGLT2 inhibitor|10 days of SGLT2 inhibitor after surgery
219719645|NCT05314725|DRUG|Placebo|10 days of placebo after surgery
219719646|NCT00864071|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
219719647|NCT00864071|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
219719648|NCT01539200|DIETARY_SUPPLEMENT|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
219146421|NCT05283395|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
219146422|NCT01531075|BIOLOGICAL|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
219146423|NCT01531075|BIOLOGICAL|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
219146424|NCT01068756|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
219146425|NCT01068756|DRUG|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
219146426|NCT03697655|DRUG|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
219146427|NCT04452539|PROCEDURE|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
219146428|NCT01587053|OTHER|therapeutic education program|
219719649|NCT01539200|DIETARY_SUPPLEMENT|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
219146429|NCT05579106|DEVICE|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
219146430|NCT05579106|DEVICE|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
219231453|NCT03908164|BIOLOGICAL|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
219719650|NCT00576615|DRUG|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
219719651|NCT00576615|DRUG|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
219146431|NCT05579106|OTHER|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
219146432|NCT03875963|OTHER|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
219146433|NCT01224015|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
219146434|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
219231454|NCT03375424|BIOLOGICAL|vedolizumab|duration of disease and kind of therapy
219231455|NCT00198185|PROCEDURE|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
219231456|NCT02070809|PROCEDURE|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
219231457|NCT02070809|PROCEDURE|split-thickness skin graft method|This method is traditional split-thickness skin graft
219231458|NCT01668394|BEHAVIORAL|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
219231459|NCT01668394|OTHER|Control arm|Usual care. Teaching style: deductive.
219719652|NCT00970944|DRUG|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
219719653|NCT00970944|DRUG|Placebo|Placebo administered twice daily.
219719654|NCT06306703|OTHER|group1, group2, group 3|to teaching with verbal instruction to teaching with digital vaginal palpation to teaching with perineometer
219231460|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
219231461|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
219719655|NCT03022175|DRUG|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
219719656|NCT03022175|DRUG|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
219719657|NCT05415657|DRUG|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
219719658|NCT05415657|DRUG|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
219719659|NCT05913947|DRUG|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
219146435|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
219231462|NCT06413888|PROCEDURE|pancreaticoduodenectomy|Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
219231463|NCT00006045|BIOLOGICAL|lintuzumab|
219231464|NCT00006045|DRUG|cytarabine|
219146436|NCT04877067|BIOLOGICAL|Wharton jelly derived mesenchymal stem cell|WJ-MSC
219146437|NCT04877067|DEVICE|Repetitive electromagnetic stimulation|rEMS
219146438|NCT02646358|DRUG|Vepoloxamer|
219231465|NCT00006045|DRUG|etoposide|
219231466|NCT00006045|DRUG|mitoxantrone hydrochloride|
219231467|NCT02441569|BEHAVIORAL|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
219231468|NCT02441569|BEHAVIORAL|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
219231469|NCT00266656|DRUG|Humatrope|According to investigator's clinical practice and guided by the approved package insert
219719660|NCT05913947|DRUG|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
219719661|NCT00972738|DRUG|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
219146439|NCT03436277|DRUG|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
219146440|NCT03436277|DIETARY_SUPPLEMENT|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
219146441|NCT03738111|DRUG|TG02 Citrate|TG02 citrate capsules
219146442|NCT01996917|DEVICE|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
219146443|NCT00712335|DRUG|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
219146444|NCT00712335|DRUG|Montelukast|PO 10 mg QHS for 3 weeks
219146445|NCT00712335|DRUG|Salmeterol|DPI 50mg BID for 3 weeks
219146446|NCT03401112|DRUG|IMR-687|Oral administration of IMR-687 once daily with or without HU.
219146447|NCT03401112|DRUG|Placebo|Oral administration of placebo once daily with or without HU.
219146448|NCT05777317|DEVICE|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
219146449|NCT05777317|OTHER|CMM alone|Conventional medical management alone
219146450|NCT03675256|BIOLOGICAL|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
219146451|NCT03675256|BIOLOGICAL|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
219146452|NCT03675256|BIOLOGICAL|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
219146453|NCT04206215|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
219146454|NCT04206215|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
219146455|NCT04431388|DEVICE|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
219146456|NCT04431388|DRUG|Levobupivacaine|using the same AL
219146457|NCT04777968|DRUG|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
219146458|NCT04324333|BEHAVIORAL|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
219146459|NCT01202955|DRUG|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
219146460|NCT01202955|DRUG|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
219146461|NCT00223535|BEHAVIORAL|Cognitive Remediation|
219146462|NCT00223535|BEHAVIORAL|Social Skills Training|
219719662|NCT00972738|DRUG|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
219719663|NCT00972738|DRUG|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
219719664|NCT03366753|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
219719665|NCT03366753|PROCEDURE|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
219719666|NCT03499132|PROCEDURE|anesthesia|Different anesthetic procedures
219719667|NCT00697164|DRUG|Placebo|Saline Admission, day 1, day 2 3 days
219719668|NCT00697164|DRUG|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
219719669|NCT00033644|BIOLOGICAL|sargramostim|
219719670|NCT00033644|DRUG|cisplatin|
219146463|NCT04782635|DEVICE|mobile based application|Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
219146464|NCT04782635|BEHAVIORAL|Pamphlet|A pamphlet which will be provide knowledge to the patients
219146465|NCT04592393|DIAGNOSTIC_TEST|Abbreviated PB MRI|Annual non-contrast PB MRI.
219146466|NCT04592393|GENETIC|Gene mutation test|K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
219146467|NCT04592393|DIAGNOSTIC_TEST|Conventional follow-up|Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
219146468|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
219146469|NCT05675150|BEHAVIORAL|Expressive Arts-Based Intervention|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflection and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in intervention may seek meaning, clarity, insight and healing.
219146470|NCT00988975|PROCEDURE|Insertion of pelvicol graft|Pelvicol graft
219146471|NCT00813059|DRUG|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
219146472|NCT01860820|DEVICE|Geko device|
219146473|NCT06405880|OTHER|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
219146474|NCT01993160|DRUG|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
219146475|NCT01993160|RADIATION|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
219146476|NCT01993160|RADIATION|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
219146477|NCT05028673|DRUG|Lu AG06466 Capsule|Hard capsule
219146478|NCT05028673|DRUG|Lu AG06466 Tablet|Film-coated tablet
219146479|NCT05028673|DRUG|Antacid|Oral suspension
219146480|NCT02115139|DRUG|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
219146481|NCT03982303|DRUG|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
219146482|NCT04783168|OTHER|Best Practice|Receive usual care
219231470|NCT01720706|DEVICE|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
219146483|NCT04783168|OTHER|Health Promotion and Education|Install and use Fitbit app
219146484|NCT04783168|OTHER|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
219231471|NCT01990625|DEVICE|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
219231472|NCT00018512|PROCEDURE|Implant-supported denture|
219146485|NCT04783168|OTHER|Quality-of-Life Assessment|Ancillary studies
219146486|NCT04783168|OTHER|Questionnaire Administration|Ancillary studies
219146487|NCT01736891|DRUG|Rasagiline|Tablets, qd
219146488|NCT01736891|DRUG|Placebo|Tablets, qd
219553734|NCT04317664|BEHAVIORAL|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
219553735|NCT00640341|DEVICE|PureVision Contact Lens|contact lens for daily wear
219553736|NCT00640341|DEVICE|Acuvue Oasys Contact Lens|contact lens for daily wear
219553737|NCT00640341|DEVICE|O2Optix Contact lens|contact lens for daily wear
219553738|NCT00000564|PROCEDURE|oxygen inhalation therapy|
219553739|NCT02761720|OTHER|No Intervention|
219553740|NCT03673514|PROCEDURE|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
219553741|NCT02973269|BIOLOGICAL|daxibotulinumtoxin type A|Intramuscular injection
219553742|NCT02973269|BIOLOGICAL|Placebo|Intramuscular injection
219553743|NCT05829239|BIOLOGICAL|ADI-PEG20|Intramuscular injection weekly for 8 weeks
219553744|NCT05829239|OTHER|Placebo|Intramuscular injection weekly for 8 weeks
219553745|NCT00466479|DRUG|brimonidine|
219553746|NCT00466479|PROCEDURE|laser trabeculoplasty|
219553747|NCT01085890|BEHAVIORAL|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
219553748|NCT02190318|DRUG|Losartan|
219553749|NCT02190318|DRUG|spirolactone|
219553750|NCT02190318|OTHER|blank control|
219553751|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
219146489|NCT00841633|DRUG|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
219146490|NCT01909778|DRUG|BI 201335|single oral doses
219146491|NCT06513455|DRUG|Irinotecan liposome（40mg/m2）|irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
219146492|NCT06513455|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
219146493|NCT06513455|DRUG|Gemcitabine|gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
219146494|NCT06513455|DRUG|Irinotecan Liposome（60mg/m2）|irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
219146495|NCT05261815|OTHER|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
219146496|NCT05261815|OTHER|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
219146497|NCT04088123|DRUG|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
219231473|NCT01836159|OTHER|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test"
219146498|NCT06456255|DRUG|Sensorcaine with Epinephrine|The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.
219146499|NCT06456255|OTHER|Sham injection|Punctures without any medication injected onto the septum
219146500|NCT06480812|DIETARY_SUPPLEMENT|Synbiotic|"The proposed protocol will provide a simple but robust intervention study using a synbiotic (pre and probiotic combination) in order to improve our understanding of the mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.~This pilot study will comprise a controlled randomised intervention in which participants will be grouped into the active synbiotic arm or the control arm. The ratios will be 10g of the prebiotic supplement and 170ml of kefir. Randomisation will control for equal distribution of age and biological sex; characteristics that may confound between group comparisons and will be assessed by analysis of baseline data."
219146501|NCT04231721|DEVICE|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
219146502|NCT05750823|DRUG|Ruxolitinib Cream|Ruxolitinib cream will be applied twice daily for upto 48 weeks
219146503|NCT06357143|OTHER|REMOVE|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
219231474|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
219231475|NCT00532766|DRUG|Jusline|
219231476|NCT02203032|DRUG|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
219719671|NCT00033644|DRUG|dacarbazine|
219719672|NCT00033644|DRUG|doxorubicin hydrochloride|
219719673|NCT00033644|DRUG|mitomycin C|
219231477|NCT02203032|DRUG|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
219231478|NCT02203032|DRUG|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
219553752|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
219553753|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
219553754|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
219553755|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
219146504|NCT06357143|OTHER|CONTROL|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
219146505|NCT03687892|DEVICE|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
219146506|NCT03687892|DEVICE|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
219146507|NCT02471755|DEVICE|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
219146508|NCT02471755|DEVICE|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
219146509|NCT04783610|OTHER|Ethanol|Ethanol will be administered via oral route.
219146510|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
219719674|NCT05578547|OTHER|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1\) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
219146511|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
219719675|NCT05578547|OTHER|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
219719676|NCT02661724|BEHAVIORAL|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
219719677|NCT05855187|DRUG|Bravamax 200 mg (Modafinil)|Test drug
219719678|NCT05855187|DRUG|Vigil 200 mg (Modafinil)|Reference drug
219719679|NCT03915067|DRUG|BOTOX® purified neurotoxin complex|BOTOX® superficial intramuscular injections.
219719680|NCT03915067|DRUG|Placebo|Placebo injections.
219719681|NCT01033942|DRUG|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
219719682|NCT01033942|DRUG|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
219719683|NCT01033942|BEHAVIORAL|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
219719684|NCT04011072|RADIATION|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
219719685|NCT02693418|DRUG|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
219719686|NCT02693418|DRUG|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
219719687|NCT02693418|DRUG|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
219719688|NCT02693418|DRUG|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
219719689|NCT00934882|DRUG|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
219719690|NCT03558724|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
219719691|NCT03558724|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
219719692|NCT03071744|DRUG|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
219146512|NCT04177394|DEVICE|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
219146513|NCT01491698|PROCEDURE|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
219146514|NCT01491698|PROCEDURE|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
219146515|NCT05947045|OTHER|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
219146516|NCT05947045|OTHER|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
219146517|NCT04472806|DRUG|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
219146518|NCT04472806|DRUG|chemotherapy in combination with Endostar|chemotherapy+ Endostar
219146519|NCT06966297|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography|Measurement of calf muscle Perfusion via Multispectral optoacoustic Tomography
219146520|NCT06423742|DEVICE|Transcranial direct current stimulation|The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
219146521|NCT01789489|DEVICE|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
219146522|NCT03080038|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
219146523|NCT02608528|RADIATION|[18F]fluoroglucose(FDG)|
219231479|NCT02203032|DRUG|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
219231480|NCT03507244|DRUG|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
219231481|NCT03507244|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
219231482|NCT03507244|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
219231483|NCT02258178|BIOLOGICAL|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
219553756|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
219231484|NCT06269497|PROCEDURE|Scaffold placement|The scaffold is placed in the alveola following extraction
219553757|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
219553758|NCT00591071|OTHER|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
219553759|NCT00591071|OTHER|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
219719693|NCT01199614|DRUG|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
219146524|NCT03806751|DRUG|[O-15]Water|All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
219146525|NCT03806751|DRUG|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
219146526|NCT02248480|DRUG|Duloxetine|Administered orally
219146527|NCT02248480|DRUG|Placebo|Administered orally
219146528|NCT01595321|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
219146529|NCT01595321|BIOLOGICAL|GVAX Pancreas Vaccine|GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
219146530|NCT01595321|RADIATION|Stereotactic Body Radiation|"Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX."
219146531|NCT01595321|DRUG|FOLFIRINOX|"FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus."
219231485|NCT06269497|RADIATION|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
219231486|NCT03371316|BIOLOGICAL|ViaShield|Anti-adhesion scores using amnion patch
219231487|NCT01192555|BIOLOGICAL|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
219553760|NCT06090708|DIETARY_SUPPLEMENT|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
219553761|NCT05590390|DIAGNOSTIC_TEST|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
219553762|NCT05590390|DIAGNOSTIC_TEST|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
219553763|NCT05590390|DIAGNOSTIC_TEST|PROs|questionnaires to investigate patients reported outcome on quality of life
219553764|NCT03436316|DRUG|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
219553765|NCT06186219|DRUG|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
219553766|NCT01573819|DRUG|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
219553767|NCT01573819|DRUG|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
219553768|NCT04598958|OTHER|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
219553769|NCT03900884|DRUG|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
219553770|NCT03900884|DRUG|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
219553771|NCT03900884|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
219719694|NCT02811107|OTHER|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
219146532|NCT04978935|OTHER|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
219146533|NCT01638611|DRUG|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
219231488|NCT01192555|DRUG|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
219553772|NCT05610007|DRUG|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
219146534|NCT01638611|DRUG|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
219146535|NCT01533519|DRUG|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
219146536|NCT03561610|DIETARY_SUPPLEMENT|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
219146537|NCT03561610|DIETARY_SUPPLEMENT|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
219146538|NCT01334320|PROCEDURE|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
219146539|NCT05026086|OTHER|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
219146540|NCT05026086|OTHER|isometric exercises|10 patients will be treated with isometric exercises
219146541|NCT03371966|DIETARY_SUPPLEMENT|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
219146542|NCT03371966|DIETARY_SUPPLEMENT|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
219146543|NCT00234091|DRUG|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
219146544|NCT00234091|DRUG|Efavirenz|200 to 600 mg taken orally once daily
219146545|NCT00234091|DRUG|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
219146546|NCT00234091|DRUG|Lopinavir/Ritonavir|230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
219146547|NCT00234091|DRUG|Nelfinavir|45-55 mg/kg taken orally twice daily with food
219146548|NCT00234091|DRUG|Nevirapine|120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
219146549|NCT00234091|DRUG|Zidovudine|180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
219146550|NCT00687388|DRUG|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
219146551|NCT00687388|DRUG|celecoxib|200mg daily for 8 weeks
219146552|NCT00687388|DRUG|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
219146553|NCT03726268|DRUG|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
219146554|NCT03726268|DRUG|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
219553773|NCT03157349|OTHER|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
219553774|NCT03157349|OTHER|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
219553775|NCT00250315|DRUG|Dobutamine|
219553776|NCT02251509|DRUG|Carvedilol|
219553777|NCT02251509|DRUG|Metoprolol tartrate|
219553778|NCT00000449|DRUG|naltrexone (Revia)|
219553779|NCT00000449|BEHAVIORAL|cognitive behavioral therapy|
219553780|NCT00000449|BEHAVIORAL|cue exposure treatment|
219553781|NCT02301533|BEHAVIORAL|Shikamana Intervention|See arm description
219553782|NCT02301533|BEHAVIORAL|Standard Care|See arm description
219553783|NCT04902911|DEVICE|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
219553784|NCT03756701|BEHAVIORAL|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual"
219553785|NCT01691430|DIETARY_SUPPLEMENT|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
219553786|NCT01691430|DIETARY_SUPPLEMENT|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
219553787|NCT04129255|DRUG|Octreotide Acetate|administration every 28 days
219553788|NCT01763255|BIOLOGICAL|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
219553789|NCT02480608|DRUG|Imatinib|
219553790|NCT02480608|DRUG|Hydroxyurea|
219231489|NCT01915914|DRUG|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
219231490|NCT04700202|OTHER|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
219231491|NCT05038202|DRUG|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
219231492|NCT05038202|DRUG|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
219231493|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
219231494|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
219231495|NCT03278977|BIOLOGICAL|Blood sample for specific analyzes|"Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
219231496|NCT02541292|OTHER|No intervention, observational|
219231497|NCT00519935|BEHAVIORAL|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
219231498|NCT01528605|DIETARY_SUPPLEMENT|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
219231499|NCT01528605|DIETARY_SUPPLEMENT|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
219231500|NCT01528605|DIETARY_SUPPLEMENT|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
219231501|NCT01528605|DIETARY_SUPPLEMENT|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
219231502|NCT01528605|DIETARY_SUPPLEMENT|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
219231503|NCT01528605|DIETARY_SUPPLEMENT|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
219719695|NCT04256408|DEVICE|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
219719696|NCT06553469|DEVICE|sacral neuromodulation|After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
219719697|NCT01143792|BEHAVIORAL|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
219553791|NCT05659758|PROCEDURE|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
219719698|NCT01143792|BEHAVIORAL|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
219719699|NCT01143792|BEHAVIORAL|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
219231504|NCT01404338|DRUG|Halobetasol 0.05% ointment|
219553792|NCT02805413|OTHER|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
219553793|NCT02756949|OTHER|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
219231505|NCT01404338|DRUG|Placebo Ointment|
219553794|NCT02756949|DEVICE|Smartphone|
219719700|NCT06045260|DRUG|177Lu-DOTATOC|Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
219719701|NCT02548182|DEVICE|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
219719702|NCT02548182|OTHER|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
219719703|NCT02260986|DRUG|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
219146555|NCT03726268|DRUG|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
219146556|NCT03726268|DRUG|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
219146557|NCT03726268|DRUG|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
219146558|NCT02238210|DRUG|Atrovent®|
219146559|NCT02884544|DRUG|HLD100|Treatment
219146560|NCT02430740|DRUG|recFSH|
219146561|NCT00381173|DRUG|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
219146562|NCT00373529|DRUG|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
219146563|NCT01714882|BEHAVIORAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
219231506|NCT05664776|DEVICE|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
219231507|NCT02918045|DEVICE|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
219719704|NCT02260986|DRUG|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
219719705|NCT02260986|OTHER|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
219146564|NCT01714882|BEHAVIORAL|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
219146565|NCT05672797|OTHER|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
219146566|NCT05672797|BEHAVIORAL|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
219146567|NCT05088629|DIAGNOSTIC_TEST|Clinical Tests|Clinical Tests
219231508|NCT02918045|DEVICE|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
219231509|NCT04890457|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
219231510|NCT04890457|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
219719706|NCT02194491|OTHER|[11C]AS2471907|intravenous radiotracer
219231511|NCT01615770|BEHAVIORAL|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
219553795|NCT03930849|BEHAVIORAL|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
219553796|NCT03930849|BEHAVIORAL|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
219553797|NCT02573285|PROCEDURE|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
219553798|NCT02573285|PROCEDURE|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
219553799|NCT05454085|DIETARY_SUPPLEMENT|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
219553800|NCT02700971|PROCEDURE|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
219553801|NCT02219009|DEVICE|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
219553802|NCT01510509|DEVICE|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
219553803|NCT01510509|DEVICE|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
219553804|NCT01463709|DEVICE|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
219553805|NCT03866928|DRUG|Stiripentol|1500 mg of stiripentol b.i.d.
219553806|NCT01944553|DEVICE|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
219719707|NCT02194491|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
219719708|NCT02194491|DRUG|ASP3662|oral
219719709|NCT03137368|DRUG|Exemestane Tablets|drug therapy
219719710|NCT03137368|OTHER|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
219719711|NCT03137368|GENETIC|CYP2D6*10 gene test|CYP2D6\*10 gene test
219719712|NCT03137368|DRUG|Tamoxifen|drug therapy
219146568|NCT04528264|DEVICE|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
219146569|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction technique
219146570|NCT01568073|DRUG|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
219146571|NCT01568073|DRUG|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
219146572|NCT01568073|DRUG|Placebo|200 mg
219146573|NCT01568073|DRUG|Levodopa|
219146574|NCT01568073|DRUG|Carbidopa|DOPA decarboxylase inhibitor
219146575|NCT01568073|DRUG|Benserazide|DOPA decarboxylase inhibitor
219146576|NCT01477879|OTHER|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
219146577|NCT01477879|OTHER|placebo (versabase gel only)|versabase gel only
219146578|NCT03207568|DEVICE|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
219146579|NCT02140138|BIOLOGICAL|CV9104|
219146580|NCT02140138|DEVICE|needle free injection device (Tropis®)|
219146581|NCT04042129|OTHER|gynecologic operations with urological complications|
219146582|NCT00539292|PROCEDURE|Primary placement of a spring-loaded silo|
219553807|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
219146583|NCT00539292|PROCEDURE|Primary Closure|primary closure of abdomen
219146584|NCT05717114|PROCEDURE|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
219146585|NCT04151407|DRUG|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
219146586|NCT00305591|DRUG|l-ornithine l-aspartate|
219553808|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
219553809|NCT01251393|DRUG|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
219553810|NCT01251393|DRUG|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
219553811|NCT06226259|DIETARY_SUPPLEMENT|GABA supplement|Oral administration of GABA supplement once daily before sleep for 14 days.
219553812|NCT06226259|DIETARY_SUPPLEMENT|placebo|Oral administration of placebo once daily before sleep for 14 days.
219553813|NCT04413461|OTHER|TENS|Transcutaneous Electro Neuro Stimulation
219553814|NCT04413461|OTHER|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
219553815|NCT00249717|BEHAVIORAL|Contingency management|Receive rewards (prizes) abstinence and attendance
219553816|NCT01948401|DRUG|LABA|long-acting beta-agonist treatment
219146587|NCT00707135|DRUG|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
219146588|NCT00486005|DRUG|Olanzapine Hydrochloride|
219146589|NCT00486005|DRUG|Nizatidine|
219146590|NCT00486005|DRUG|Placebo|
219146591|NCT02801071|DRUG|15g L-citrulline daily p.o.|
219146592|NCT02801071|DRUG|Placebo|
219146593|NCT00630786|DRUG|Panitumumab|Administered by intravenous infusion
219146594|NCT00630786|DRUG|Conatumumab|Administered by intravenous infusion
219146595|NCT02412774|BEHAVIORAL|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
219146596|NCT02412774|BEHAVIORAL|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
219146597|NCT04009577|DRUG|LEM 5 mg|LEM tablet.
219146598|NCT04009577|DRUG|LEM 10 mg|LEM tablet.
219146599|NCT00488657|DEVICE|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
219146600|NCT00866866|DRUG|N-Acetyl Cysteine|600 mg PO BID
219146601|NCT00866866|DRUG|Placebo|1 tab PO BID
219146602|NCT02613806|DRUG|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
219146603|NCT02613806|DRUG|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
219146604|NCT03690596|OTHER|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
219146605|NCT03690596|OTHER|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
219146606|NCT03690596|OTHER|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
219146607|NCT03393078|DEVICE|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
219146608|NCT03393078|DEVICE|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
219146609|NCT02234739|DRUG|Voriconazole|2-week long intravenous instillation of voriconazole
219146610|NCT02165761|DEVICE|GORE® Hybrid Vascular Graft|
219146611|NCT02165761|DEVICE|Non-heparin bonded synthetic graft|
219146612|NCT00238836|BEHAVIORAL|Self-management of chronic illness|
219146613|NCT00176839|PROCEDURE|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
219146614|NCT00176839|DRUG|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
219146615|NCT00176839|DRUG|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
219146616|NCT00176839|DRUG|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
219146617|NCT00176839|DRUG|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
219146618|NCT00176839|DRUG|ATG|ATG will be administered to umbilical cord blood recipients.
219146619|NCT00788853|OTHER|No treatment given|No treatment is given
219146620|NCT01600729|DRUG|No Intervention|No intervention.
219146621|NCT01227876|DRUG|Ster|prednisolone 1% ophthalmic suspension
219146622|NCT01227876|DRUG|Pred Fort|prednisolone 1% ophthalmic suspension
219146623|NCT02951013|OTHER|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
219146624|NCT02951013|OTHER|liberal transfusion|
219146625|NCT06522295|DEVICE|ultrasonography|Ultrasonographic Measurement of Optic Nerve Sheath Diameter
219146626|NCT05004935|DIETARY_SUPPLEMENT|beetroot juice|single intake of beetroot juice containing 800mg nitrates
219146627|NCT05004935|OTHER|nitrate|single intake of 800mg nitrates
219146628|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
219146629|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
219146630|NCT04605016|DEVICE|Hydrophilic surface implants|A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
219146631|NCT04605016|DEVICE|Hydrophobic surface implants|A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
219146632|NCT04826575|OTHER|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
219146633|NCT00202865|BIOLOGICAL|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
219146634|NCT00202865|BIOLOGICAL|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
219146635|NCT02020616|DRUG|LY3053102|Administered SC
219146636|NCT02020616|DRUG|Exenatide ER|Administered SC
219146637|NCT02020616|DRUG|Placebo|Administered SC
219146638|NCT02020616|DRUG|Metformin|Administered orally (PO)
219146639|NCT02881944|BEHAVIORAL|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
219146640|NCT02881944|BEHAVIORAL|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
219146641|NCT05503212|OTHER|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
219146642|NCT05503212|OTHER|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
219146643|NCT05503212|OTHER|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
219146644|NCT05323838|BEHAVIORAL|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
219146645|NCT05323838|PROCEDURE|Blood extraction|Blood collection by qualified personnel.
219146646|NCT05323838|BEHAVIORAL|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
219553817|NCT01948401|DRUG|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
219553818|NCT01948401|DRUG|prednisolone|additional 0.5 mg/kg orally for 7 days
219553819|NCT04311346|DIAGNOSTIC_TEST|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
219553820|NCT03037424|DRUG|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
219553821|NCT03037424|DRUG|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
219146647|NCT05323838|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
219146648|NCT03199235|DEVICE|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
219146649|NCT03199235|OTHER|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
219146650|NCT06334549|DRUG|Ephedrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
219146651|NCT06334549|DRUG|Phenylephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
219146652|NCT06334549|DRUG|Norepinephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
219146653|NCT06334549|DRUG|Ephedrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
219146654|NCT06334549|DRUG|Phenylephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
219146655|NCT06334549|DRUG|Norepinephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
219146656|NCT00786942|PROCEDURE|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
219146657|NCT00786942|PROCEDURE|higi tibial osteotomy|the gap of the tibia is unfilled
219146658|NCT00006276|DRUG|Micellar Paclitaxel|
219146659|NCT02771938|OTHER|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
219146660|NCT05235789|OTHER|Rational-Emotive-Behavioral Therapy|"The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history."
219146661|NCT05235789|OTHER|Control Group usual care|In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
219146662|NCT04576858|DIAGNOSTIC_TEST|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
219146663|NCT00748410|DRUG|SB-656933|7 days repeat dose
219146664|NCT02523651|GENETIC|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
219146665|NCT02523651|OTHER|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
219146666|NCT02980718|BEHAVIORAL|intensive olfactory training|
219146667|NCT02980718|BEHAVIORAL|ordinary olfactory training|
219146668|NCT04215471|DRUG|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
219146669|NCT01595906|PROCEDURE|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
219146670|NCT02620618|DRUG|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
219146671|NCT05632432|PROCEDURE|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs-patch with epicardial transplantation onto the epicardium of the scarred myocardium at the end of CABG surgery
219146672|NCT05632432|DIAGNOSTIC_TEST|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
219146673|NCT05632432|DIAGNOSTIC_TEST|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
219146674|NCT05632432|DIAGNOSTIC_TEST|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both hospital discharge and 3-month follow-up)
219146675|NCT05632432|DIAGNOSTIC_TEST|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
219146676|NCT05632432|OTHER|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
219146677|NCT05632432|OTHER|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
219146678|NCT05632432|DIAGNOSTIC_TEST|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
219146679|NCT05632432|DIAGNOSTIC_TEST|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
219231512|NCT02432274|DRUG|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
219231513|NCT02432274|DRUG|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
219231514|NCT02432274|DRUG|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
219231515|NCT02432274|DRUG|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
219146680|NCT05632432|PROCEDURE|Epicardial collagen-based patch transplantation|Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
219146681|NCT00412321|DRUG|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
219146682|NCT00327665|BIOLOGICAL|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
219146683|NCT00327665|BIOLOGICAL|Pneumo 23™|Single-dose intramuscular injection.
219146684|NCT00327665|BIOLOGICAL|Placebo|1 intramuscular injection.
219146685|NCT00327665|BIOLOGICAL|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
219146686|NCT00028678|DRUG|dalteparin|
219146687|NCT00028678|RADIATION|radiation therapy|
219146688|NCT04905225|PROCEDURE|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
219146689|NCT03978468|OTHER|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
219146690|NCT03978468|OTHER|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
219146691|NCT06974292|DRUG|[14C]VC005|Take a suspension of 50 mg VC005 ,containing about 120 μCi \[14C\]VC005, in fasting within 5 minutes
219146692|NCT06969534|DRUG|Pucotenlimab combined with GP regimen|A total of 33 cases are planned to be enrolled. All the subjects will receive Pucotenlimab (3mg/kg, on day 1, with a maximum dose not exceeding 200mg), administered once every 3 weeks (Q3W), and combined with the GP regimen. The chemotherapy is a fixed regimen, with Gemcitabine at a dose of 1g/m² on day 1 and day 8, and cisplatin at a dose of 80mg/m² on day 1. The chemotherapy will be given for 3 to 6 cycles, once every 3 weeks (Q3W).
219146693|NCT01071993|DRUG|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
219146694|NCT01071993|DRUG|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
219146695|NCT00296907|BEHAVIORAL|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
219146696|NCT06266455|DIETARY_SUPPLEMENT|Standardized Fortification|Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
219146697|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
219146698|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
219146699|NCT04382963|OTHER|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
219146700|NCT04382963|OTHER|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
219146701|NCT04382963|OTHER|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
219146702|NCT01967654|OTHER|Technical Assistance, training and clinical reminders|
219146703|NCT01967654|OTHER|Referral to Community Health Worker|
219146704|NCT00305695|OTHER|Laboratory Biomarker Analysis|Correlative studies
219146705|NCT00305695|DRUG|Zoledronic Acid|Given IV
219146706|NCT05127499|OTHER|progressive relaxation exercises|progressive relaxation exercises will do
219146707|NCT00147277|DEVICE|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
219146708|NCT02496806|DIETARY_SUPPLEMENT|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
219146709|NCT06372912|PROCEDURE|Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.|Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
219146710|NCT03092713|BEHAVIORAL|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
219146711|NCT03092713|BEHAVIORAL|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
219146712|NCT04324242|OTHER|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
219146713|NCT05817409|DRUG|Intrathecal Baclofen Pump|intrathecal baclofen treatment
219146714|NCT04157530|DEVICE|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
219146715|NCT04157530|DEVICE|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
219146716|NCT04157530|DEVICE|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
219146717|NCT02031471|DRUG|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
219719713|NCT05390554|BEHAVIORAL|Buteyko Breathing Technique|"* The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~* Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~* The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~* The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~* The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP."
219719714|NCT01860508|DRUG|pemetrexed /carboplatin|
219146718|NCT03960619|BEHAVIORAL|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
219146719|NCT04050631|BEHAVIORAL|maternal arrest simulation on L&D floor|AFE on L\&D
219146720|NCT05112354|DRUG|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
219146721|NCT00002415|DRUG|Tenofovir disoproxil fumarate|
219146722|NCT03505619|BEHAVIORAL|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
219146723|NCT05059730|OTHER|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
219146724|NCT05059730|OTHER|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
219146725|NCT05059730|OTHER|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
219146726|NCT05059730|OTHER|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
219146727|NCT01649180|DRUG|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
219146728|NCT02657200|OTHER|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
219146729|NCT02538263|DEVICE|Volume-targeted noninvasive ventilation|
219719715|NCT02841735|DEVICE|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
219146730|NCT00233519|DRUG|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
219146731|NCT00868569|PROCEDURE|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
219146732|NCT00868569|PROCEDURE|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
219146733|NCT01987154|OTHER|Marketed cow milk-based premature infant formula|
219146734|NCT01987154|OTHER|Marketed extensively hydrolyzed casein infant formula|
219146735|NCT03795558|DRUG|Etelcalcetide|Up-Titration
219146736|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Sport|Vitamin -supplemented chewing gum
219146737|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Immunity|Vitamin -supplemented chewing gum
219146738|NCT03230396|DIETARY_SUPPLEMENT|Placebo|Control chewing gum. No vitamin content.
219146739|NCT04704778|COMBINATION_PRODUCT|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
219146740|NCT04704778|COMBINATION_PRODUCT|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
219146741|NCT04704778|DIAGNOSTIC_TEST|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
219146742|NCT03289611|BIOLOGICAL|sFlt-1 / PlGF ratio|"* Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued"
219146743|NCT02891525|DIETARY_SUPPLEMENT|50g glucose|
219146744|NCT02891525|DIETARY_SUPPLEMENT|25g fructose|
219146745|NCT02891525|DIETARY_SUPPLEMENT|220mg acesulfame-K|
219146746|NCT02891525|DIETARY_SUPPLEMENT|250mL tap water|
219146747|NCT05857969|DEVICE|Functional Precision Medicine|Ex Vivo Drug Sensitivity Testing + Genomic Tumor Profiling
219146748|NCT01235884|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
219146749|NCT01235884|DIETARY_SUPPLEMENT|Placebo|5 drops daily for 28 days
219719716|NCT02841735|DEVICE|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
219146750|NCT02425917|DEVICE|geko|neuromuscular electrostimulator
219146751|NCT02425917|DEVICE|IPC-Calf|IPC used on calf with or without geko
219146752|NCT00000760|DRUG|Ro 24-7429|
219146753|NCT00000760|DRUG|Zidovudine|
219146754|NCT00000760|DRUG|Didanosine|
219146755|NCT04279548|DEVICE|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
219146756|NCT05619861|BIOLOGICAL|CAR-T|Patients will receive CAR-T treatment
219146757|NCT01980641|BEHAVIORAL|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
219146758|NCT01980641|DEVICE|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
219146759|NCT03122574|OTHER|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
219146760|NCT03122574|OTHER|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
219146761|NCT04074577|DIAGNOSTIC_TEST|Standard technique First|colonoscopy without automated polyp detection software
219146762|NCT04074577|DIAGNOSTIC_TEST|combination technique First|automated polyp detection software
219146763|NCT00005772|DEVICE|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
219146764|NCT00005772|DEVICE|Control|Control group: standard care
219146765|NCT00092885|DRUG|MK0476, montelukast sodium|
219146766|NCT00092885|DRUG|Comparator: placebo|
219146767|NCT02705937|OTHER|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
219146768|NCT02705937|DEVICE|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
219146769|NCT06261996|DRUG|Fospropofol|Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
219719717|NCT02841735|DEVICE|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
219719718|NCT03657953|OTHER|surgical approach|
219719719|NCT00202150|BEHAVIORAL|Application of a management action plan|
219719720|NCT06430060|DRUG|zinc containing toothpaste|Toothpaste
219719721|NCT06430060|DRUG|MFP Fluoride toothpaste|toothpaste
219146770|NCT00997386|DRUG|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
219146771|NCT03072953|DRUG|APD334|APD334 active treatment
219146772|NCT03932981|DRUG|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
219146773|NCT06174636|PROCEDURE|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
219719722|NCT04764604|DEVICE|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
219146774|NCT03956004|OTHER|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
219146775|NCT03956004|OTHER|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
219146776|NCT06575413|OTHER|Direct Electrical Stimulation|The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.
219146777|NCT01579916|BIOLOGICAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
219146778|NCT01579916|OTHER|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
219146779|NCT03950609|DRUG|Everolimus|Given PO
219146780|NCT03950609|DRUG|Lenvatinib|Given PO
219146781|NCT06974305|RADIATION|FDG-PET/fMRI/EEG imaging|Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
219231516|NCT02432274|DRUG|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
219231517|NCT02432274|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
219231518|NCT02432274|DRUG|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
219231519|NCT02432274|DRUG|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
219719723|NCT04764604|DEVICE|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
219719724|NCT00574652|DRUG|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
219719725|NCT03888690|DEVICE|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
219146782|NCT04658771|DEVICE|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
219146783|NCT06778642|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Posterior Superior Intercostal Plane Block (SPSIPB) with bupivacaine after induction and before the surgical procedure begins.
219146784|NCT06778642|PROCEDURE|Serratus Anterior Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Anterior Plane Block (SAPB) with bupivacaine after induction and before the surgical procedure begins.
219146785|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
219146786|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a.|3 months of treatment
219146787|NCT02570542|PROCEDURE|leukapheresis|
219146788|NCT02570542|DRUG|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
219231520|NCT02432274|DRUG|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
219231521|NCT06238934|BIOLOGICAL|Bone marrow aspirate matrix|Bone marrow aspirate \* Hyaluronic acid
219231522|NCT06238934|BIOLOGICAL|Bone marrow aspirate|Bone marrow aspirate
219231523|NCT06238934|DEVICE|Hyaluronic acid|Hyaluronic acid
219719726|NCT04893031|DRUG|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
219719727|NCT02310308|DIETARY_SUPPLEMENT|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
219719728|NCT02866448|DRUG|Vehicle control|Described in arm
219719729|NCT02866448|DRUG|Isoquercetin|Described in arm
219719730|NCT02866448|DRUG|Aspirin|Described in arm
219719731|NCT02866448|DRUG|Isoquercetin plus Aspirin|Described in arm
219719732|NCT02274428|DRUG|pneumostem|human umbilical cord blood derived mesenchymal stem cells
219719733|NCT05752409|DRUG|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
219719734|NCT05752409|DRUG|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
219719735|NCT05752409|DRUG|Propofol|2mg•kg-1propofol for general anesthesia induction.
219553822|NCT06678308|DEVICE|Embolisation with Magic Glue®|Magic Glue® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
219553823|NCT06678308|DEVICE|Embolisation with Embosphere®|Embosphere® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
219553824|NCT03086135|DEVICE|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
219553825|NCT00033436|DIETARY_SUPPLEMENT|niacinamide|
219553826|NCT00033436|DRUG|carbogen|
219553827|NCT00033436|RADIATION|radiation therapy|
219553828|NCT02889302|DRUG|KPS-0373|24 weeks
219719736|NCT01453647|OTHER|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
219719737|NCT02087592|BEHAVIORAL|Structured exercise training plus mediterranean diet|
219719738|NCT01793935|DRUG|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
219553829|NCT02889302|DRUG|Placebo|24 weeks
219553830|NCT03888521|BEHAVIORAL|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
219553831|NCT01639664|DEVICE|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
219553832|NCT00601406|GENETIC|gene expression analysis|
219553833|NCT00601406|GENETIC|gene rearrangement analysis|
219553834|NCT00601406|GENETIC|polymorphism analysis|
219553835|NCT00601406|OTHER|laboratory biomarker analysis|
219553836|NCT00601406|RADIATION|radiation therapy|
219553837|NCT00762411|DRUG|LY450139|Administered orally once daily.
219553838|NCT00762411|DRUG|Placebo|Administered orally once daily.
219553839|NCT01023061|DRUG|abiraterone acetate|Given PO
219553840|NCT01023061|DRUG|prednisone|Given PO
219553841|NCT01023061|DRUG|leuprolide acetate|Given via injection
219146789|NCT02570542|DRUG|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
219146790|NCT02570542|PROCEDURE|Autologous Stem Cell Transplantation|
219146791|NCT06369350|DRUG|Vitamin B6 25 MG|Vitamin B6 25 mg/day will be given for up to 31 days.
219146792|NCT06369350|DRUG|Vitamin B6 50 MG|Vitamin B6 50 mg/day will be given for up to 31 days.
219146793|NCT06369350|DRUG|Vitamin B6 100 MG|Vitamin B6 100 mg/day will be given for up to 31 days.
219146794|NCT06369350|DRUG|Placebo|Placebo capsule will be given for up to 31 days.
219146795|NCT06459817|DEVICE|BB-02 therapy|Biophysical stimulation with magnetic fields
219146796|NCT05076656|DIETARY_SUPPLEMENT|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
219146797|NCT05076656|BIOLOGICAL|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
219146798|NCT05076656|DRUG|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
219146799|NCT02763124|PROCEDURE|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
219146800|NCT02994654|DEVICE|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
219146801|NCT02207075|DRUG|[C11]PK-1195 PET scan|PET scan with tracer \[C11\]PK-1195
219553842|NCT01023061|OTHER|laboratory biomarker analysis|Correlative study
219553843|NCT01023061|RADIATION|external beam radiation therapy|Undergo radiotherapy
219553844|NCT01023061|DRUG|goserelin acetate|Given via injection
219553845|NCT01119586|GENETIC|DNA analysis|
219553846|NCT01119586|GENETIC|genetic linkage analysis|
219553847|NCT01119586|GENETIC|microarray analysis|
219553848|NCT01119586|GENETIC|nucleic acid sequencing|
219553849|NCT01119586|GENETIC|polymerase chain reaction|
219553850|NCT01119586|GENETIC|polymorphism analysis|
219553851|NCT01119586|OTHER|laboratory biomarker analysis|
219553852|NCT04650750|DRUG|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
219553853|NCT04650750|DRUG|Placebo|Similar placebo 4g twice a day for two months
219553854|NCT02966340|DRUG|Prazosin|2mg Prazosin
219553855|NCT02966340|DRUG|Placebo|Placebo
219553856|NCT05157048|OTHER|Charcoal-filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
219553857|NCT05157048|OTHER|Non-charcoal filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
219553858|NCT01853540|DRUG|Sildenafil|
219553859|NCT02259348|DRUG|Cyclophosphamide|Given intravenously (IV)
219553860|NCT02259348|DRUG|Fludarabine|Given IV
219553861|NCT02259348|BIOLOGICAL|G-CSF|Given IV or subcutaneously (SQ)
219553862|NCT02259348|BIOLOGICAL|Interleukin-2|Given SQ
219553863|NCT02259348|DRUG|Melphalan|Given IV
219553864|NCT02259348|DRUG|Thiotepa|Given IV
219553865|NCT02259348|DRUG|Rituximab|Given IV
219553866|NCT02259348|BIOLOGICAL|Natural killer cell therapy|Given IV
219553867|NCT02259348|BIOLOGICAL|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
219553868|NCT02259348|BIOLOGICAL|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
219553869|NCT00187265|DEVICE|Cardiac Resynchronization Therapy|
219553870|NCT01094262|DRUG|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
219553871|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
219553872|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
219553873|NCT01094262|DRUG|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
219553874|NCT01622660|DRUG|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
219553875|NCT01622660|DRUG|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
219719739|NCT01793935|DRUG|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
219719740|NCT04656119|OTHER|there is no intervention in our study|there is no intervention in our study
219553876|NCT01663467|DRUG|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
219553877|NCT01663467|BEHAVIORAL|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
219719741|NCT01111370|DEVICE|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
219553878|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
219719742|NCT04038125|DRUG|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
219719743|NCT01149252|OTHER|Psoralait|Cream to be used as instructed.
219719744|NCT01149252|OTHER|Placebo cream.|Cream to be used as instructed
219719745|NCT04136301|OTHER|Informative Video group|Informative Video group before labor in nulliparous women
219719746|NCT00313170|DRUG|Fulvestrant|intramuscular injection 250 mg \& 500 mg
219719747|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
219719748|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
219719749|NCT05302232|OTHER|painDETECT questionnaire|painDETECT questionnaire
219719750|NCT05680701|OTHER|real tACS|The participant will receive one session of 10 Hz tACS for 20-minutes
219231524|NCT00116649|DRUG|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
219231525|NCT05758584|OTHER|Intervention|Vibrating tourniquet
219553879|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
219553880|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
219553881|NCT06677801|BIOLOGICAL|Telitacicept 160mg|Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
219553882|NCT04211766|DIETARY_SUPPLEMENT|Dietary Fiber|Given fiber supplement
219553883|NCT04211766|DIETARY_SUPPLEMENT|Fish Oil|Given fish oil supplement
219719751|NCT05680701|OTHER|sham tACS|The participant will receive one session of active-sham tACS for 20-minutes
219719752|NCT05531097|DRUG|HSK31679|Single or multiple oral doses of HSK31679
219719753|NCT05531097|DRUG|Placebo|Matching placebo
219719754|NCT00529035|DRUG|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
219719755|NCT05470803|BIOLOGICAL|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
219719756|NCT05470803|BIOLOGICAL|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
219719757|NCT05470803|BIOLOGICAL|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
219719758|NCT05400330|BIOLOGICAL|LX1001|Gene therapy
219146802|NCT05917249|DEVICE|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
219146803|NCT03367494|DIAGNOSTIC_TEST|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
219146804|NCT01981330|BIOLOGICAL|aMSC|aMSC injected into the vocal fold of the patient
219146805|NCT01981330|BIOLOGICAL|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
219146806|NCT03276039|DIAGNOSTIC_TEST|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
219231526|NCT05758584|OTHER|Distraction card|Distraction card
219231527|NCT04696900|PROCEDURE|Exercise training|exercise training in an approved rehabilitation program
219146807|NCT01611376|DEVICE|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
219146808|NCT04346888|DRUG|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
219146809|NCT04346888|DRUG|Placebos|Placebo, HBM9161 Injection (340mg)
219146810|NCT04346888|DRUG|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
219146811|NCT03414710|BEHAVIORAL|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
219146812|NCT03414710|BEHAVIORAL|Health education booklet only|Participants in the intervention group will only receive a health education booklet
219146813|NCT00385801|DRUG|Risperidone|
219146814|NCT00385801|DRUG|Placebo|
219146815|NCT03659201|DRUG|Neosil complete|Oral, during 24 weeks.
219146816|NCT03659201|DRUG|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
219146817|NCT03659201|DRUG|Neosil|Oral, during only 12 weeks.
219146818|NCT05535530|DEVICE|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
219146819|NCT03870191|OTHER|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
219146820|NCT04747457|DEVICE|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
219146821|NCT02050724|DRUG|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
219231528|NCT02176577|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
219231529|NCT04057261|DRUG|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
219231530|NCT04057261|DRUG|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
219231531|NCT05794659|BIOLOGICAL|AST-201|i.d. (3-week interval, 3 cycles in total)
219231532|NCT05794659|DRUG|Paclitaxel|3-week interval, 6 cycles in total
219231533|NCT05794659|DRUG|Carboplatin|3-week interval, 6 cycles in total
219231534|NCT05794659|DRUG|Placebo|i.d. (3-week interval, 3 cycles in total)
219553884|NCT04211766|OTHER|Comparator|Given fiber supplement placebo
219553885|NCT04211766|OTHER|Comparator|Given fish oil supplement placebo (corn oil)
219553886|NCT00545116|OTHER|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
219553887|NCT00929981|DRUG|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
219553888|NCT05648539|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
219553889|NCT02769650|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
219553890|NCT02769650|DRUG|Optimal medicamentous treatment|
219553891|NCT02769650|PROCEDURE|Stress-MRI|A standard stress-MRI test with adenosine
219553892|NCT06353750|OTHER|Magnesium supplement|Intravenous magnesium supplement (10mmol).
219553893|NCT03791541|BEHAVIORAL|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
219553894|NCT05581134|DEVICE|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
219146822|NCT02050724|DEVICE|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
219146823|NCT02050724|DEVICE|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
219146824|NCT02247063|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
219146825|NCT00003604|BIOLOGICAL|aldesleukin|
219719759|NCT05619341|DIETARY_SUPPLEMENT|psyllium|psyllium 20g
219719760|NCT05619341|DIETARY_SUPPLEMENT|inulin|long chain fructan
219719761|NCT04966429|DRUG|Maraviroc|Tablets
219719762|NCT05129202|DRUG|immune therapy|The patient receives immunotherapy
219146826|NCT04552886|BIOLOGICAL|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
219719763|NCT01026597|DRUG|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
219719764|NCT01026597|DRUG|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
219719765|NCT02175758|DRUG|SOF|SOF administered orally once daily
219146827|NCT06116058|OTHER|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
219146828|NCT06116058|OTHER|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
219146829|NCT06116058|OTHER|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
219146830|NCT03324152|OTHER|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
219146831|NCT03324152|OTHER|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
219146832|NCT03324152|OTHER|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
219146833|NCT01123928|BEHAVIORAL|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
219146834|NCT03603717|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
219146835|NCT03603717|BEHAVIORAL|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
219146836|NCT00732381|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
219146837|NCT00732381|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
219146838|NCT04073914|BEHAVIORAL|Type 1 Teamwork Program|Psychoeducational web program
219146839|NCT00755118|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219146840|NCT00755118|DRUG|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219146841|NCT00755118|DRUG|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219146842|NCT00755118|DRUG|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219231535|NCT05794659|DRUG|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
219231536|NCT03428438|OTHER|Rehabilitation at home via SMS|Cardiac rehabilitation
219231537|NCT05305508|DRUG|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
219719766|NCT02175758|DRUG|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
219719767|NCT04213911|RADIATION|low-dose chest CT scan|The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.
219719768|NCT04213911|DEVICE|insertion of esophageal balloon|The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
219719769|NCT05080270|BIOLOGICAL|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
219719770|NCT00652652|DRUG|nesiritide, furosemide|
219719771|NCT04791852|DIAGNOSTIC_TEST|Donor-derived Cell Free DNA|We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
219719772|NCT06355921|PROCEDURE|radiofrequency ablation|"Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure."
219719773|NCT02409901|BEHAVIORAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
219146843|NCT00755118|DRUG|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219146844|NCT00755118|DRUG|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
219146845|NCT00390728|DRUG|Insulin Glargine|
219719774|NCT03372421|OTHER|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
219719775|NCT03372421|OTHER|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
219719776|NCT05880030|DRUG|Cholecalciferol|cholecalciferol 10000 UI
219719777|NCT05880030|OTHER|placebo|sunflower oil
219719778|NCT00226213|PROCEDURE|Peripherally Inserted Central Catheter Placement|
219719779|NCT01804907|BEHAVIORAL|Cognitive Behavioral Therapy|
219146846|NCT02614118|DRUG|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
219146847|NCT02614118|DRUG|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
219719780|NCT01804907|BEHAVIORAL|Behavioral Modification|
219719781|NCT01716195|RADIATION|Induction Chemotherapy followed by Response Adapted Chemoradiation|All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
219719782|NCT01975441|DRUG|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
219719783|NCT01975441|DRUG|Albendazole|Albendazole 400mg
219146848|NCT02614118|DRUG|Placebo|placebo 45 minutes before root canal treatment
219719784|NCT01975441|DRUG|Ivermectin|Ivermectin 200 mcg/kg
219719785|NCT01852903|DIETARY_SUPPLEMENT|calcium ascorbate|
219719786|NCT01852903|DIETARY_SUPPLEMENT|ascorbic acid|
219719787|NCT01852903|OTHER|placebo|
219719788|NCT05457543|DIAGNOSTIC_TEST|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
219719789|NCT01159847|DRUG|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
219719790|NCT01159847|DRUG|Insulin|
219719791|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
219146849|NCT02204618|DEVICE|cochlear implantation|
219146850|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
219146851|NCT04280913|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
219146852|NCT02707913|DRUG|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
219146853|NCT02707913|DRUG|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
219146854|NCT01252316|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
219146855|NCT01252316|OTHER|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
219146856|NCT02026219|DRUG|Clopidogrel|Clopidogrel 600mg loading
219146857|NCT02026219|DRUG|Ticagrelor|Ticagrelor 180mg loading
219146858|NCT04727424|DIETARY_SUPPLEMENT|Spirulin Platensis|Two tablets every 12 hours since randomization through day 09 following randomization
219719792|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
219719793|NCT03962816|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
219719794|NCT04051801|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
219719795|NCT04051801|DRUG|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
219719796|NCT03607084|BEHAVIORAL|School Health Worker Program|The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
219719797|NCT05720247|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
219719798|NCT05720247|BEHAVIORAL|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
219719799|NCT00406380|DRUG|Bevacizumab|
219719800|NCT00406380|PROCEDURE|Intravitreal injection of Bevacizumab|
219719801|NCT01458977|DRUG|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
219146859|NCT04727424|DRUG|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
219146860|NCT04727424|DRUG|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
219146861|NCT04727424|DRUG|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
219146862|NCT00939991|DRUG|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
219146863|NCT03398811|DRUG|Depot medroxy-progesterone acetate|Injection every 3 months
219146864|NCT03398811|DRUG|Etonogestrel|68 mg implant
219146865|NCT03398811|DRUG|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
219146866|NCT05907551|OTHER|Questionnaires|25-items questionnaire
219146867|NCT06199648|OTHER|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
219146868|NCT02754999|DRUG|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
219146869|NCT01018212|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
219146870|NCT03210129|BEHAVIORAL|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
219553895|NCT05581134|BEHAVIORAL|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
219553896|NCT05184803|DRUG|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
219553897|NCT02299687|DRUG|Omeprazole|
219146871|NCT02403219|DRUG|Botulinum toxin type A injection|Injection of botulinum toxin type A
219146872|NCT02403219|OTHER|Saline solution injection|Injection of saline solution
219146873|NCT06656689|PROCEDURE|Rezum (water vapor thermal therapy)|Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
219146874|NCT02355158|DRUG|clonidine hydrochloride topical gel, 0.1%|
219231538|NCT05305508|DRUG|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
219231539|NCT06140550|DEVICE|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
219231540|NCT06140550|DEVICE|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
219231541|NCT01728298|BIOLOGICAL|SLITone ULTRA HDM immunotherapy|
219231542|NCT00781118|DEVICE|Guardian System|There is no intervention in this study. The device is a diagnostic only.
219553898|NCT03854409|DRUG|Aripiprazole|Injection.
219553899|NCT06407999|DEVICE|Expiratory Pressure Relief|EPR is a function used in CPAP intended to improve comfort by reducing delivered pressure during the expiratory phase. When EPR is not used, the patient receives true CPAP.
219553900|NCT01136928|DRUG|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
219553901|NCT00396955|DRUG|PLA-695|
219553902|NCT04556734|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
219553903|NCT04556734|DRUG|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
219146875|NCT00003516|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
219146876|NCT06677411|OTHER|Observention of vitamin D|It is an observational study
219146877|NCT07002073|DRUG|ketamine-dexmedetomidine admixture induction of Anesthesia|To compare incidence of hypotension following ketodex versus ketofol during induction of general anesthesia in elderly patients
219553904|NCT04556734|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily
219146881|NCT06631976|DRUG|1ml of Depo-Medrol® injection|1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
219553905|NCT03869424|OTHER|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
219553906|NCT00067717|BEHAVIORAL|Distance healing|
219553907|NCT01015924|PROCEDURE|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
219553908|NCT01015924|PROCEDURE|ESIN|Elastiv stable intramedullary nailing
219553909|NCT02342041|DRUG|SUVN-G3031|
219553910|NCT02342041|DRUG|Placebo|
219553911|NCT00526435|BEHAVIORAL|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
219553912|NCT00526435|BEHAVIORAL|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
219553913|NCT00164918|DEVICE|nasogastric tube|
219553914|NCT00519506|OTHER|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
219553915|NCT05287087|BEHAVIORAL|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
219553916|NCT05287087|BEHAVIORAL|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
219553917|NCT05034185|DEVICE|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
219553918|NCT00063609|DRUG|zoledronic acid|
219553919|NCT01433887|DRUG|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
219553920|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
219553921|NCT01433887|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
219146882|NCT06631976|OTHER|Rehabilitation|Rehabilitation
219146883|NCT06631976|DRUG|Nerve block with 4ml of 2% lidocaine|Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
219146884|NCT06631976|DRUG|Tropocells® PRP injection|Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
219146885|NCT07023965|DRUG|NL003|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
219146886|NCT07023965|DRUG|Placebo|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
219146887|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
219146888|NCT03719092|OTHER|Best Practice|Receive usual care
219146889|NCT07033585|DRUG|Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
219146890|NCT07033585|DRUG|China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
219146891|NCT06712615|BIOLOGICAL|PG-102|"* Participants will receive PG-102 by subcutaneous (SC) injection.~* Other Names: MG12"
219553922|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
219553923|NCT00359671|DRUG|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
219553924|NCT00359671|DRUG|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
219553925|NCT05437406|BEHAVIORAL|Parent-based treatment- All caregivers (PBT-AC)|PBT-AC provides all the elements of FBT, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
219553926|NCT05437406|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
219553927|NCT01680016|BIOLOGICAL|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
219146892|NCT06712615|OTHER|Placebo|Participants will receive placebo by SC injection
219146893|NCT00573833|OTHER|questionnaire administration|
219146894|NCT00573833|PROCEDURE|quality-of-life assessment|
219146895|NCT00573833|RADIATION|brachytherapy|
219146896|NCT07047274|BEHAVIORAL|Education group (DBM/BMP)|A structured web-based training program, consisting of ten one-hour sessions, was delivered to students in the intervention group. To foster active engagement and reinforce learning outcomes, each session incorporated interactive, game-based activities through the Kahoot platform. The content of the training was developed in collaboration with a panel of 12 subject-matter experts, including specialists in emergency care, public health, internal medicine, surgery, and education. Additionally, the structure and thematic scope of the program were aligned with the emergency action guidelines of AFAD, Türkiye's official disaster management authority. The curriculum encompassed a comprehensive range of topics, including the classification of disasters, disaster awareness, risk assessment, use of personal protective equipment, triage procedures, post-disaster management, basic first aid practices, and the psychosocial dimensions of disaster response.
219146897|NCT07046351|BEHAVIORAL|weSIPsmarter|weSIPsmarter is grounded by the Theory of Planned Behavior as well as Satter's Feeding Dynamic Model. weSIPsmarter will also integrate relevant behavior change techniques and target concepts from health literacy, health numerary, media literacy, and eHealth literacy.
219146898|NCT07046351|BEHAVIORAL|weLearn2Read|weLearn2Read participants will have access to a website with resources to improve reading readiness, including 6 structured parent lessons, setting reading goals, and 6 children's books (one mailed home each week), and options to receive weekly reminders (e.g., email or text) to encourage reading readiness.
219146899|NCT07041684|DIETARY_SUPPLEMENT|Very Low Energy Ketogenic Therapy with vegan meal replacements|Metagenomics analysis of gut microbiota at baseline and after 45 days
219146900|NCT07049861|OTHER|Comprehensive Multidisciplinary Obesity Care|CMOC is an innovative approach to obesity care delivery that leverages policy, clinical and community linkages, and digital technology for scalability. CMOC involves training providers (medical providers, registered dietitians, and behavioral health providers) to deliver guideline-based obesity care for youth and adults with obesity who receive Medicaid. Guidelines-based care involves screening, identification, weight counseling, and referral to intensive behavioral treatment by medical providers, and delivery of multicomponent intensive behavioral treatment by behavioral health providers and registered dietitians.
219146901|NCT07049861|OTHER|Implementation as Usual Control|The standard of care implemented in FQHCs in the absence of CMOC training.
219146902|NCT07052916|OTHER|Music Therapy/MT|Therapeutic music lessons are the core component of the Music Therapy/MT intervention. Other components include guided music listening to help participants use music as a tool for regulating mood, energy, and attention, as well as music-centered discussions to help participants discover songs with personal meaning that they will enjoy learning to play.
219231543|NCT05086874|OTHER|butylphthalide|Observational only and no predesigned interventions in this study
219231544|NCT01486459|DRUG|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
219231545|NCT00005943|BIOLOGICAL|aldesleukin|
219231546|NCT00005943|BIOLOGICAL|staphylococcal enterotoxin B|
219231547|NCT00779194|DRUG|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
219231548|NCT00513071|DRUG|saracatinib|Given orally
219231549|NCT00513071|OTHER|laboratory biomarker analysis|Correlative studies
219231550|NCT03526406|DIETARY_SUPPLEMENT|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
219231551|NCT03526406|DIETARY_SUPPLEMENT|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
219231552|NCT05842382|DRUG|Active Ingredient|IV Vitamin C (12g/day)
219146903|NCT07052916|OTHER|Therapist-Attention Music Education/TAME Control|Participants will receive 12, weekly 60-minute TAME sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts and serve as transitions to subsequent sessions. The TAME control group will involve board-certified music therapists guiding participants through music listening exercises.
219231553|NCT05842382|DRUG|Placebo|IV dextrose 5%
219231554|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
219231555|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
219231556|NCT02089529|DRUG|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
219231557|NCT02089529|DRUG|Placebo|Placebo with no information, positive information and neutral information
219231558|NCT00354237|OTHER|Conventional antidiabetic treatment|No intensive treatment
219231559|NCT00354237|OTHER|Intensive insulin treatment|Intensive insulin treatment
219553928|NCT01680016|BIOLOGICAL|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
219553929|NCT04130217|PROCEDURE|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
219553930|NCT04130217|PROCEDURE|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
219553931|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
219719802|NCT01458977|DRUG|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
219146904|NCT06896162|OTHER|Expert Review|Expert reflexive review of next-generation sequencing (NGS) results will be visible in electronic health records (EPIC) for provider review at the University of North Carolina Health System. Expert review will include recommendations for Genome-informed therapy (GIT), identification of available clinical trials, recommendations for additional testing, and/or referrals for genetic counseling.
219553932|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
219553933|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
219553934|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
219553935|NCT05192096|BEHAVIORAL|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
219146905|NCT06896162|OTHER|Blood or tissue samples collection.|Blood or tissue samples will be collected for next-generation sequencing (NGS) per standard of care.
219146906|NCT06896162|OTHER|The Precision Oncology Navigation|The precision oncology navigator will coordinate the collection of blood and /or tissue for next-generation sequencing (NGS), as well as order the NGS if not already ordered. Precision oncology navigator will also assist in NGS financial aid applications, if applicable.
219146907|NCT02216500|DIETARY_SUPPLEMENT|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
219553936|NCT03512249|BIOLOGICAL|H56:IC31|5ug H56/500 nmol IC31
219146908|NCT03995069|BEHAVIORAL|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
219146909|NCT03995069|BEHAVIORAL|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
219146910|NCT07061639|DRUG|QLS5133|antibody drug conjugate (ADC)
219553937|NCT03512249|BIOLOGICAL|Placebo|Sterile saline for injection
219553938|NCT00089167|BIOLOGICAL|filgrastim|
219553939|NCT00089167|DRUG|dexamethasone|
219553940|NCT00089167|DRUG|melphalan|
219553941|NCT00089167|DRUG|thalidomide|
219553942|NCT02335372|PROCEDURE|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
219553943|NCT02335372|DRUG|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
219553944|NCT02335372|DRUG|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
219553945|NCT02335372|PROCEDURE|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
219553946|NCT06210204|OTHER|Telehealth follow-up|Patients to follow-up via phone after surgery
219553947|NCT05518227|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
219719803|NCT00063037|BEHAVIORAL|Behavioral modification - nutrition education|
219719804|NCT04163380|BEHAVIORAL|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
219719805|NCT04491487|OTHER|pre-operative counselling|pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
219146911|NCT07060625|BEHAVIORAL|Semi-reclining position|During anesthesia recovery, the patient's position should be in a semi-recumbent position
219146912|NCT07060430|PROCEDURE|Kaltenborn Mobilization|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Kaltenborn mobilizations with each mobilization technique performed for 10 repetitions, and each repetition maintained for 2 to 3 seconds. Mobilizations included palmar (volar) glide, dorsal glide, radial glide, and ulnar glide. In addition to wrist mobilizations, anterior and posterior glides were applied to the distal radioulnar joint.
219231560|NCT02368652|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
219553948|NCT01883791|BEHAVIORAL|SBIRT|See above Arm description.
219553949|NCT01883791|BEHAVIORAL|Health Education|See Arm Description.
219553950|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
219553951|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
219553952|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
219553953|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
219719806|NCT04061629|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
219719807|NCT04172272|DRUG|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
219146913|NCT07060430|PROCEDURE|Mulligan Mobilization with Movement|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Mulligan's Mobilization with Movement (MWM) technique, which involved 10 repetitions of each mobilization, with each repetition held for 2 to 3 seconds. First, a lateral glide or rotational movement of the carpal bones on the radius was applied, accompanied by the patient actively performing the intended wrist movement, such as flexion, extension, or deviation. Second, an ulnar-directed mobilization of the radius was provided simultaneously with active patient movement.
219146914|NCT07061886|DRUG|LSD|The serotonin 2A receptor agonist LSD
219146915|NCT07061886|DRUG|Placebo|Distilled water (0.26 mL)
219553954|NCT02485158|DRUG|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
219553955|NCT02485158|DRUG|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
219553956|NCT02485158|DRUG|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
219553957|NCT02485158|DRUG|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
219553958|NCT02485158|DRUG|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
219553959|NCT04282239|PROCEDURE|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
219553960|NCT04282239|DRUG|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
219553961|NCT04282239|DRUG|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
219553962|NCT04282239|DRUG|Dexmedetomidine 0.004 MG/ML|10 mL
219553963|NCT04086524|OTHER|Binocular cartoon treatment at home|see arm description.
219553964|NCT04086524|OTHER|Patching|see arm description
219553965|NCT04086524|OTHER|Binocular cartoon treatment in office|see arm description.
219553966|NCT03001024|BEHAVIORAL|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
219553967|NCT03001024|BEHAVIORAL|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
219553968|NCT04986124|OTHER|treatment as usual|No inervention. Treatment regime remains unchanged.
219553969|NCT01133236|DIETARY_SUPPLEMENT|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
219553970|NCT00565513|PROCEDURE|blood test|cord blood and maternal milk test
219553971|NCT02793713|PROCEDURE|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
219553972|NCT04618484|OTHER|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
219553973|NCT06617663|BEHAVIORAL|EMDR|Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.
219553974|NCT06617663|BEHAVIORAL|ACT|Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
219553975|NCT03710096|DEVICE|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
219553976|NCT03710096|DEVICE|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
219553977|NCT01034852|PROCEDURE|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
219553978|NCT05987085|OTHER|Diet and exercise|Routine intervention included diet control and exercise
219553979|NCT00559598|GENETIC|proteomic profiling|
219146916|NCT07059676|DRUG|Zejula (Niraparib)|PARPi inhibitors have been incorporated into managing first-line advanced ovarian cancer with different approvals depending on homologous recombination (HR) status. Niraparib has received approval independent from HR status. Although the benefit is more remarkable in HR-deficient patients, there is no biomarker to predict sustained response to niraparib at the start of treatment helping the clinician to make decisions among the different treatment options.
219146917|NCT07061444|OTHER|Inspiratory Muscle Training|Inspiratory muscle training will be performed at 40% of MIP workload, 1 set of 8-10 diaphragmatic respirations for 15 minutes, with 5-10 seconds rest intervals between sets. 5 days a week, 2 sessions per day.
219146918|NCT07061444|OTHER|Functional Inspiratory Muscle Training|This study investigates the integration of functional inspiratory muscle training (IMT) with conventional physiotherapy. Patients will perform inspiratory muscle training using the threshold loading technique with the POWERbreathe IMT device, combined with functional exercises. The functional IMT protocol will be administered face-to-face, 3 days a week, for 30 minutes per session over a 6-week period. Resistance on the IMT device will be set to 40% of the patient's maximal inspiratory pressure (MIP) and adjusted weekly based on measured MIP values. Exercises will be categorized into three progressive difficulty levels (easy, medium, and hard), with each stage lasting 2 weeks. Patients will inhale through the POWERbreathe IMT device during exercise movements and exhale during the return phase, ensuring simultaneous respiratory muscle activation and functional training.
219146919|NCT07061444|OTHER|Sham Inspiratory Muscle Training|Control group will be performed at 10% of the MIP workload, 1 set of 8-10 diaphragmatic breaths for 15 minutes, with 5-10 seconds rest intervals between sets. 2 sessions per day, 5 days a week.
219146920|NCT07060066|DEVICE|Active rTMS stimulation|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
219146921|NCT07060066|DEVICE|Sham rTMS stimulation|Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
219146922|NCT07060872|DIETARY_SUPPLEMENT|Spirulina Syrup|A natural dietary supplement derived from Spirulina algae, administered orally as a syrup formulation. Used as an adjunct therapy to assess its potential effect on reducing anxiety symptoms in children with non-idiopathic autism. Dosage and duration are standardized according to study protocol.
219146923|NCT07060872|DIETARY_SUPPLEMENT|Placebo Syrup|Placebo Syrup
219146924|NCT07060872|DRUG|Risperidone|Risperidone
219146925|NCT07061665|BEHAVIORAL|Multi-level, Multi-component Intervention Package|The CBH COPI intervention applies multi-level strategies to improve children's environments and foster healthy behaviors. In schools, activities include schoolyard enhancements (e.g., hopscotch), inter-school sports events, nutrition lectures, healthy snacks, and educational materials linking health and academics. In parks and roads, improvements include cycling/walking promotions, signage, healthier vending machines, and community events. Supermarkets support healthy choices through menu information, loyalty incentives, cooking classes, product placement, and healthy food sales. At home and in communities, the Min-Challe app supports habit formation, with athletes, mascots, and ambassadors promoting healthy living. The coordinated program aims to naturally promote healthy eating, physical activity, and sustained lifestyle change among children aged 6-12 in Chiba City.
219146926|NCT07060196|DIAGNOSTIC_TEST|Distant Visual Acuity|Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.
219146927|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical Coherence Tomography of the macula will be performed to all patients.
219146928|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography of the macula will be performed to all patients.
219146929|NCT07060196|DIAGNOSTIC_TEST|Autofluorescence imaging|Autofluorescence imaging using fundus camera for AMD staging.
219231561|NCT02368652|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
219553980|NCT00559598|OTHER|medical chart review|
219553981|NCT01134198|DRUG|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
219553982|NCT01134198|DRUG|placebo|placebo
219553983|NCT03436953|DRUG|CX-8998|T-type calcium channel blocker
219553984|NCT03436953|DRUG|Placebo|Placebo comparator
219553985|NCT01417351|DIETARY_SUPPLEMENT|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
219553986|NCT01417351|DIETARY_SUPPLEMENT|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
219553987|NCT06136416|OTHER|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
219553988|NCT06678126|RADIATION|Prostate and Pelvic Nodes Radiotherapy|60 Gy prostate and 44 Gy pelvic nodes with 20 fractions
219553989|NCT05093881|BIOLOGICAL|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
219553990|NCT01636817|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
219553991|NCT01636817|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
219553992|NCT06679335|OTHER|Lateralization Imagery Training|"Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training."
219719808|NCT04172272|PROCEDURE|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
219146930|NCT07060313|PROCEDURE|Ganglion Impar Block|The ganglion impar was accessed with a Quincke spinal needle, transsacrococcygeally (from between the first and second coccygeal vertebrae if sacrococcygeal access could not be achieved). Then, 1 mL of non-ionic contrast medium was administered, and fluoroscopic anterior-posterior and lateral imaging was performed to confirm the appropriate spread of contrast (Figure 1). After this confirmation, 2 mL of 0.5% bupivacaine, 2 mL of saline, and 40 mg of methylprednisolone acetate were injected.
219146931|NCT07060313|PROCEDURE|Ganglion Impar Block and Pericoccygeal Injection|In the combination therapy group who underwent pericoccygeal injection in addition to impar block, following the same procedure, 5 mL of 0.25% bupivacaine and 20 mg of methylprednisolone were injected into the posterior pericoccygeal region while the needle was withdrawn, thus also targeting blockade of the anococcygeal nerve.
219146932|NCT05508737|DRUG|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
219146933|NCT02290834|OTHER|Cognitive, functional and subjective assessments|Cognitive and functional assessments
219146934|NCT02290834|DEVICE|MRI|Magnetic Resonance Imaging (MRI) Scan
219719809|NCT04172272|OTHER|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
219719810|NCT04623151|BEHAVIORAL|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
219146935|NCT02290834|RADIATION|PET Scan|Positron Emission Tomography (PET) Scan
219146936|NCT05399329|DRUG|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
219719811|NCT03940534|DEVICE|TAD|TAD is a device used to aid medication adherence.
219146937|NCT05399329|DRUG|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
219146938|NCT06909838|DEVICE|radial Extracorporeal shockwave therapy (rESWT)|4 rESWT interventions, with a one week interval, are added to the conventional treatment plan
219146939|NCT06909838|OTHER|Conventional treatment|Usual conventional therapy, including physiotherapy, ergotherapy, hippotherapy,..
219146940|NCT06325696|DRUG|hymecromone|400 mg
219146941|NCT06905626|DRUG|Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule|Qsymia
219146942|NCT06905626|DRUG|Placebo|Placebo
219146943|NCT03996083|OTHER|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
219146944|NCT03996083|OTHER|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
219146945|NCT03815396|DRUG|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
219146946|NCT06937879|OTHER|Hand Grip Strength|The grip strength of the participants will be performed with a hydraulic hand dynamometer on a chair with back and arm support. The participant will be asked to squeeze the dynamometer with maximum force. The measurement will be performed 3 times and the average value will be recorded.
219146947|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
219719812|NCT03027934|DRUG|Ticagrelor|Ticagrelor, 90mg twice daily
219719813|NCT03027934|DRUG|Prasugrel|Prasurgrel, 10mg once daily
219719814|NCT00219271|DRUG|Zoledronic acid|
219719815|NCT01785316|PROCEDURE|IHP|
219719816|NCT05607043|DEVICE|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
219719817|NCT02049762|DRUG|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
219719818|NCT03061643|DRUG|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
219719819|NCT03061643|OTHER|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
219719820|NCT02811978|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
219719821|NCT02811978|DRUG|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
219146948|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
219146949|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
219146950|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
219146951|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (2X)|The (1) control group (2X) will receive an exercise screening checklist and 24 group training sessions, 2 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults.
219146952|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (3X)|The (3) experimental group (3X) will receive an exercise screening checklist and 36 group training sessions, 3 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults. This additional session will increase weekly exercise volume compared to the control group, also being closer to complying to the WHO International Guidelines of weekly physical activity (Bull et al., 2020)
219146953|NCT07060989|DRUG|NTS071|Oral administration
219146954|NCT03047239|DEVICE|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
219146955|NCT06019299|BEHAVIORAL|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
219146956|NCT03882554|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
219146957|NCT06105333|PROCEDURE|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
219146958|NCT01366677|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
219146959|NCT06837142|DRUG|Triazolam and TS-172|Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
219146960|NCT06837142|DRUG|TS-172 and itraconazole|Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase
219146961|NCT01613118|DRUG|RE-021 (Sparsentan)|Oral, once-daily
219146962|NCT01613118|DRUG|Irbesartan|Oral, once-daily
219719822|NCT04903977|DIAGNOSTIC_TEST|Laboratory tests: blood and faeces tests|To be performed at V2
219719823|NCT04903977|DIAGNOSTIC_TEST|Gynaecological and proctological examinations|To be performed at V1 (Examination with a gynaecological speculum, Bimanual examination, Rectal examination, and Anoscopy)
219146963|NCT00038506|DRUG|abacavir/lamivudine/zidovudine|
219146964|NCT00038506|DRUG|tenofovir|
219146965|NCT03656406|BEHAVIORAL|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
219146966|NCT03656406|DEVICE|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
219146967|NCT00443001|DEVICE|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
219146968|NCT02861846|BIOLOGICAL|profile of CSF biomarkers of AD|dosage of biomarker of AD
219719824|NCT04903977|DIAGNOSTIC_TEST|3-D Endoanal Ultrasound|To be performed at V1 (as a reference and for group assignment)
219719825|NCT04903977|DEVICE|ONIRY measurement|To be performed at V2 (the electrical impedance of anal sphincter muscles will be measured)
219719826|NCT04903977|DIAGNOSTIC_TEST|High-resolution anorectal manometry|To be performed at V3
219719827|NCT04903977|DIAGNOSTIC_TEST|ECG|To be performed at V1 and V2 (for safety reasons)
219719828|NCT02353741|DRUG|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
219719829|NCT02353741|RADIATION|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
219719830|NCT00505583|DRUG|MOA-728|
219719831|NCT03613870|DEVICE|PermeaDerm|Wound treatment with PermeaDerm
219719832|NCT03613870|DEVICE|Mepilex Ag|Wound treatment with Mepilex Ag
219719833|NCT04648176|DEVICE|Moses technology|Using Holmium laser with Moses technology or conventional one
219719834|NCT00478036|DRUG|Acular LS|Details covered in arm description
219719835|NCT00478036|DRUG|Pred Forte|Details covered in arm description
219719836|NCT00478036|OTHER|Refresh Tears|Placebo
219719837|NCT04407520|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
219719838|NCT03355027|DRUG|Alirocumab 150 MG/ML|Dosing to be performed by subcutaneous injection in clinic
219146969|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
219146970|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
219231562|NCT05679479|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
219231563|NCT05679479|OTHER|Normal saline|0.9% normal saline
219231564|NCT03977805|DRUG|Hetrombopag Olamine|a single oral taking
219231565|NCT01660659|DEVICE|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
219231566|NCT01479010|DRUG|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
219719839|NCT03355027|DRUG|Ezetimibe 10Mg Tablet|Patients will be instructed to take once daily at night.
219719840|NCT03355027|DRUG|Atorvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
219719841|NCT03355027|DRUG|Atorvastatin 80Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
219146971|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
219146972|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
219146973|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
219146974|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
219719842|NCT03355027|DRUG|Rosuvastatin 20Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
219719843|NCT03355027|DRUG|Rosuvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
219719844|NCT03355027|DRUG|Simvastatin 80mg|Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
219719845|NCT03669679|PROCEDURE|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
219719846|NCT05924932|DEVICE|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
219719847|NCT05924932|DEVICE|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
219719848|NCT02004795|RADIATION|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
219146975|NCT02297061|BIOLOGICAL|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
219231567|NCT01409772|DRUG|Ethanol Lock|Ethanol Lock
219231568|NCT02481804|OTHER|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
219719849|NCT00762905|DEVICE|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
219231569|NCT02481804|OTHER|Standard treatment|Standard treatment will be continued
219231570|NCT00297466|DRUG|transdermal nicotine patches|
219231571|NCT00297466|BEHAVIORAL|Motivational interview|
219231572|NCT01573338|DRUG|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
219231573|NCT01573338|DRUG|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
219231574|NCT01573338|DRUG|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
219146976|NCT06667557|DEVICE|Superpulse Thulium Fiber Laser (sTFL) Treatment|The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
219146977|NCT06667557|DEVICE|Holmium:YAG Laser (Ho:YAG) Treatment|The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
219719850|NCT00762905|DEVICE|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
219146978|NCT00457275|DRUG|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
219146979|NCT03544515|DEVICE|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
219146980|NCT03544515|PROCEDURE|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
219146981|NCT03544515|DEVICE|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
219719851|NCT00756301|OTHER|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
219719852|NCT03917888|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
219719853|NCT03787407|BEHAVIORAL|stress management and meditation|mindfulness training using mobile application
219719854|NCT01116531|DRUG|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
219719855|NCT01116531|DRUG|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
219719856|NCT01116531|DRUG|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
219719857|NCT03787160|DIAGNOSTIC_TEST|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
219719858|NCT03787160|DIAGNOSTIC_TEST|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
219146982|NCT03175172|BIOLOGICAL|CRS-207|Administered by IV infusion over approximately 1 hour.
219146983|NCT03175172|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
219146984|NCT03169244|DRUG|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
219146985|NCT03169244|DRUG|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
219146986|NCT05887063|OTHER|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
219719859|NCT03787160|DIAGNOSTIC_TEST|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
219719860|NCT03787160|DIAGNOSTIC_TEST|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
219719861|NCT03787160|DIAGNOSTIC_TEST|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
219146987|NCT01725464|DEVICE|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
219231575|NCT01573338|DRUG|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
219231576|NCT05348603|OTHER|Traditional Letter|Patients receive a traditional letter.
219231577|NCT05348603|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
219146988|NCT04373590|BEHAVIORAL|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
219719862|NCT03787160|DIETARY_SUPPLEMENT|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
219719863|NCT03787160|DIAGNOSTIC_TEST|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
219719864|NCT03787160|DIAGNOSTIC_TEST|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
219719865|NCT03787160|DIAGNOSTIC_TEST|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
219719866|NCT06115980|DEVICE|lead extraction (Xtrac O.S. system)|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications"
219719867|NCT03357055|DRUG|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
219719868|NCT03357055|DRUG|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
219719869|NCT05084326|PROCEDURE|Engagement of fetal head as a predictor of a successful vaginal delivery|"In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section."
219719870|NCT03647007|OTHER|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
219146989|NCT02343029|OTHER|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
219146990|NCT02343029|OTHER|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
219146991|NCT00962234|OTHER|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
219146992|NCT00962234|BIOLOGICAL|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
219231578|NCT05348603|OTHER|Chatbot|Patients are contacted by a chatbot via the portal.
219231579|NCT05348603|OTHER|Banner|Patients are exposed to a banner ad via the portal.
219231580|NCT03056066|DEVICE|Plethysmograph|A full Body Plethysmography examination
219231581|NCT01177449|PROCEDURE|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
219553993|NCT01784016|RADIATION|[11C]-PHNO|\[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
219553994|NCT02432118|PROCEDURE|Lumpectomy|Undergo lumpectomy
219553995|NCT02432118|OTHER|Questionnaire Administration|Ancillary studies
219553996|NCT02432118|PROCEDURE|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
219553997|NCT03003364|DRUG|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
219553998|NCT03003364|DRUG|Placebo|Placebo in a blinded syringe
219553999|NCT01065116|DRUG|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
219554000|NCT01065116|DRUG|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
219554001|NCT00006228|BIOLOGICAL|trastuzumab|Given IV
219554002|NCT00006228|BIOLOGICAL|aldesleukin|Given SC
219554003|NCT00006228|OTHER|laboratory biomarker analysis|Correlative studies
219554004|NCT00006228|OTHER|pharmacological study|Correlative studies
219719871|NCT03823625|DRUG|Nivolumab plus Ipilimumab|Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
219146993|NCT00962234|PROCEDURE|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
219719872|NCT03823625|DRUG|Platinum-based chemotherapy plus Nivolumab|"Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days."
219719873|NCT04695678|DIAGNOSTIC_TEST|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
219719874|NCT00420836|DRUG|Tobramycin|
219146994|NCT06258668|DRUG|Deucravacitinib|As per product label
219146995|NCT05714332|OTHER|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
219146996|NCT05714332|OTHER|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
219146997|NCT04532658|BEHAVIORAL|Coaching program|"* Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement"
219146998|NCT06123195|OTHER|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
219146999|NCT04668339|BIOLOGICAL|ARCT-021 single dose priming|ARCT-021 higher dose (one dose) + placebo (one dose)
219147000|NCT04668339|BIOLOGICAL|ARCT-021 two lower dose priming|ARCT-021 lower dose (two doses, Day 0 and Day 28)
219147001|NCT04668339|BIOLOGICAL|ARCT-021 two higher dose priming|ARCT-021 higher dose (two doses, Day 0 and Day 28)
219147002|NCT04668339|BIOLOGICAL|Placebo (two doses), priming|Placebo (two doses, Day 0 and Day 28)
219147003|NCT04668339|BIOLOGICAL|Randomized booster|ARCT-021 (single dose) OR placebo, booster
219147004|NCT04668339|BIOLOGICAL|Placebo booster|Placebo (single dose)
219147005|NCT04872478|DRUG|MRX-2843|MRX-2843 capsules
219147006|NCT03472573|DRUG|Palbociclib|Given PO
219147007|NCT03472573|DRUG|Dexamethasone|Given PO
219147008|NCT01627093|OTHER|Medical Chart Review|Review of medical records
219147009|NCT01627093|OTHER|Questionnaire Administration|Complete questionnaires
219554005|NCT00442351|DRUG|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
219147010|NCT03622593|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
219147011|NCT03622593|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
219147012|NCT03622593|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
219147013|NCT06325111|OTHER|Determinants of T1D glycaemic control|DNA genotyping, microbiome, DNA methylation and microRNAs analysis
219147014|NCT04219930|DIAGNOSTIC_TEST|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
219147015|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
219147016|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
219147017|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
219554006|NCT00442351|OTHER|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
219554007|NCT04119557|DRUG|Placebo|Administered SC
219554008|NCT04119557|DRUG|LY3471851|Administered SC
219554009|NCT04647734|BEHAVIORAL|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
219554010|NCT04647734|BEHAVIORAL|Standard care|standard care after discharge from hospital (control group)
219554011|NCT06368024|OTHER|This is a retrospective analysis study of data collected with a diagnostic medical device|Transcranial Magnetic stimulation and Electroencephalogram
219554012|NCT05583097|DIAGNOSTIC_TEST|Non-selective cytology|All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
219554013|NCT06530745|PROCEDURE|Hyaluronic acid (HA) injection|2% hyaluronic acid Synocrom Forte (Croma-Pharma GmbH, Leobendorf, Austria) injection
219554014|NCT06530745|PROCEDURE|Platelet-rich plasma (PRP) injection|PRP from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with iFuge D06 (Neuation Technologies Pvt. Ltd, Gujarat, India) injection
219719875|NCT03457597|DRUG|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
219719876|NCT03457597|DRUG|Metoprolol tartrate|Metoprolol tartrate 100 mg
219719877|NCT03457597|DRUG|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
219719878|NCT03457597|DRUG|Tolbutamide|Tolbutamide 500 mg
219719879|NCT03457597|DRUG|Omeprazole|Omeprazole 20 mg
219719880|NCT03457597|DRUG|Relacorilant|Relacorilant 350mg
219719881|NCT00429299|DRUG|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
219719882|NCT00429299|BIOLOGICAL|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
219719883|NCT00429299|DRUG|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
219719884|NCT00429299|DRUG|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
219719885|NCT00429299|DRUG|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
219719886|NCT00429299|DRUG|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
219719887|NCT05125497|PROCEDURE|In Vitro Fertilisation (IVF)|Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
219719888|NCT00306072|DRUG|nutritional herbal extract from Salacia oblonga|
219147018|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
219147019|NCT01750463|OTHER|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
219147020|NCT01750463|OTHER|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
219147021|NCT02894242|DEVICE|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
219719889|NCT05141994|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
219147022|NCT06475508|BIOLOGICAL|Complarate®|The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
219147023|NCT06475508|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
219147024|NCT03830658|BEHAVIORAL|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
219147025|NCT00842049|DEVICE|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
219147026|NCT00842049|OTHER|No lumbar drain|No lumbar drain
219147027|NCT00001730|DRUG|Thyrogen|
219147028|NCT00238212|DRUG|sorafenib tosylate|Given orally
219147029|NCT00238212|OTHER|laboratory biomarker analysis|Correlative studies
219147030|NCT02338245|DRUG|ASLAN001|ASLAN001 400mg BID
219147031|NCT02338245|DRUG|Lapatinib|Lapatinib 1250mg QD
219147032|NCT02338245|DRUG|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
219147033|NCT06565208|DRUG|SAT-3247|SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
219147034|NCT06565208|DRUG|matched placebo|matched placebo
219147035|NCT06480552|DRUG|TEV-56278|Administered intravenously
219147036|NCT06480552|DRUG|Pembrolizumab|Administered intravenously
219231582|NCT03146026|BEHAVIORAL|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
219231583|NCT02659540|DRUG|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
219554015|NCT03035890|RADIATION|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
219554016|NCT03035890|DRUG|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
219554017|NCT04582799|DEVICE|ECCO2R|Extracorporeal CO2 Removal
219554018|NCT04582799|DEVICE|NIV|Non-invasive ventilation
219554019|NCT02012335|DRUG|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
219554020|NCT05720663|OTHER|Standard of care|Participants will receive the standard of care for their condition
219554021|NCT00343720|DRUG|VELCADE|
219554022|NCT00343720|DRUG|Alimta|
219719890|NCT05141994|DRUG|4mg of BAT5906|Specification: 4mg of BAT5906
219719891|NCT03261258|OTHER|Questionnaire|
219719892|NCT00850577|DRUG|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
219147037|NCT06123871|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
219147038|NCT01287286|DIETARY_SUPPLEMENT|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
219147039|NCT01287286|DIETARY_SUPPLEMENT|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
219719893|NCT00850577|DRUG|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
219719894|NCT00850577|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
219719895|NCT00850577|DRUG|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
219147040|NCT01681381|DEVICE|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
219719896|NCT00850577|DRUG|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
219719897|NCT04874779|OTHER|non|follow up investigations
219719898|NCT00118794|DRUG|Chlorproguanil-dapsone (Lapdap)|
219719899|NCT00118794|DRUG|Lumefantrine-artemether (Coartemether )|
219147041|NCT01681381|DEVICE|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
219147042|NCT06255795|DRUG|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
219147043|NCT06255795|DRUG|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
219147044|NCT04906369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219147045|NCT02329132|DRUG|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
219147046|NCT02139046|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
219147047|NCT02139046|DRUG|Febuxostat XR|Febuxostat XR over-encapsulated capsules
219147048|NCT02139046|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
219147049|NCT02139046|DRUG|Colchicine|Colchicine tablets
219147050|NCT02139046|DRUG|Naproxen|Naproxen tablets
219147051|NCT02139046|DRUG|Lansoprazole|Lansoprazole capsules
219147052|NCT00540748|DRUG|oxytocin|5 U i.v. during surgical abortion
219147053|NCT05672888|DRUG|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
219147054|NCT05672888|DRUG|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
219147055|NCT04978051|DRUG|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
219147056|NCT04978051|OTHER|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
219554023|NCT02161263|OTHER|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
219554024|NCT01494090|DRUG|Rosuvastatin|5 or 20 mg per day during 6 months
219147057|NCT03801967|DRUG|AZD9977|Randomized participants will receive oral dose of AZD9977.
219147058|NCT03801967|DRUG|Placebo|Randomized participants will receive oral dose of matching placebo.
219147059|NCT03675581|DRUG|Microgynon|fixed sequence trial
219147060|NCT03675581|DRUG|Nintedanib|fixed sequence trial
219231584|NCT02659540|DRUG|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
219231585|NCT02659540|RADIATION|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
219231586|NCT01240590|DRUG|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
219554025|NCT01494090|DRUG|Placebo|5 or 20 mg per day during 6 months
219554026|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
219554027|NCT00288704|DRUG|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
219554028|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
219554029|NCT01579006|DRUG|Tocilizumab|
219554030|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
219554031|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
219554032|NCT03971734|DRUG|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
219554033|NCT03971734|DRUG|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
219554034|NCT03971734|DRUG|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
219554035|NCT03971734|DRUG|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
219719900|NCT03315364|DRUG|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
219719901|NCT03315364|DRUG|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
219719902|NCT04871113|BIOLOGICAL|GSK3810109A|GSK3810109A available as sterile aqueous solution.
219147061|NCT03557008|BIOLOGICAL|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
219147062|NCT03557008|DRUG|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
219147063|NCT03557008|DRUG|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
219147064|NCT03557008|DRUG|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
219147065|NCT00853918|OTHER|$20 cash|$20 cash incentive mailed with survey
219147066|NCT00853918|OTHER|$50 cash|$50 cash incentive mailed with survey
219147067|NCT00853918|OTHER|$50 check|$50 check incentive mailed with survey
219147068|NCT00853918|OTHER|$100 check|$100 check incentive mailed with survey
219147069|NCT02833506|OTHER|Laboratory Biomarker Analysis|Correlative studies
219147070|NCT02833506|BIOLOGICAL|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
219147071|NCT02833506|DRUG|Sirolimus|Given PO
219147072|NCT06224946|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
219147073|NCT05918614|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
219147074|NCT05918614|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
219147075|NCT02355197|DRUG|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
219147076|NCT00003005|DRUG|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
219147077|NCT00003005|DRUG|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
219147078|NCT03402633|OTHER|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
219147079|NCT00767754|DRUG|Paxil CR|12 week treatment of Paxil(20-40mg)
219231587|NCT01240590|DRUG|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
219231588|NCT02123940|DEVICE|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
219231589|NCT02106325|DRUG|Ketamine|IV of Ketamine (.25mg/kg)
219231590|NCT02106325|DRUG|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
219719903|NCT04871113|BIOLOGICAL|Dolutegravir+lamivudine SOC regimen|Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
219719904|NCT00933127|GENETIC|DNA analysis|
219147080|NCT01426295|DEVICE|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0."
219147081|NCT01426295|DRUG|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
219147082|NCT05452759|DEVICE|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
219147083|NCT05452759|DEVICE|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
219147084|NCT05658406|DRUG|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
219147085|NCT05658406|DRUG|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
219231591|NCT00147667|DRUG|Erythromycin|
219231592|NCT03167008|DIAGNOSTIC_TEST|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
219231593|NCT03167008|DIAGNOSTIC_TEST|blood sample|blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
219719905|NCT00933127|GENETIC|polymerase chain reaction|
219719906|NCT00933127|GENETIC|polymorphism analysis|
219719907|NCT00933127|OTHER|laboratory biomarker analysis|
219719908|NCT01522547|DRUG|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
219231594|NCT00738959|DRUG|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
219231595|NCT05290090|DRUG|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
219231596|NCT04396938|DRUG|Lamotrigine|Active Drug Capsule
219231597|NCT04396938|DRUG|Placebos|Placebo Capsule
219231598|NCT02120807|DRUG|Certolizumab|
219554036|NCT03971734|DRUG|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
219554037|NCT03971734|DRUG|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
219554038|NCT03971734|DRUG|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
219554039|NCT01960608|OTHER|24_hours_urine_sodium|
219554040|NCT02853916|DIETARY_SUPPLEMENT|500 mg InSea2®|
219554041|NCT02853916|DIETARY_SUPPLEMENT|250 mg InSea2®|
219147086|NCT05658406|DRUG|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
219147087|NCT05658406|DRUG|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
219147088|NCT05511766|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
219147089|NCT05511766|DRUG|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
219147090|NCT05511766|DRUG|Placebo|not containing drugs
219147091|NCT00048217|DRUG|T-1249|
219147092|NCT00002964|DRUG|porfimer sodium|
219147093|NCT00002964|OTHER|fluorophotometry|
219147094|NCT03197090|DEVICE|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
219147095|NCT04413812|BEHAVIORAL|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
219147096|NCT00069901|DRUG|CT-2103 (poly(L)glutamate-paclitaxel)|
219147097|NCT00069901|DRUG|carboplatin|
219147098|NCT04866238|DEVICE|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
219147099|NCT04866238|DEVICE|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
219147100|NCT00921154|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
219147101|NCT04630600|OTHER|No intervention|Normal waiting room without an aquarium
219147102|NCT04630600|OTHER|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
219147103|NCT04630600|OTHER|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
219147104|NCT03658460|OTHER|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
219147105|NCT06347172|BEHAVIORAL|Nudge Intervention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
219147106|NCT02086097|DRUG|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
219147107|NCT02086097|DRUG|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
219147108|NCT02086097|DRUG|PLACEBO|INACTIVE SUGAR PILLS
219147109|NCT00134069|DRUG|sorafenib tosylate|Given orally
219147110|NCT00134069|DRUG|cetuximab|Given IV
219147111|NCT00134069|DRUG|irinotecan hydrochloride|Given IV
219147112|NCT00525486|DRUG|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
219147113|NCT06041373|DEVICE|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
219147114|NCT06041373|DEVICE|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
219147115|NCT06041373|DEVICE|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
219231599|NCT02120807|DRUG|cisplatin|
219231600|NCT02120807|DRUG|pemetrexed|
219231601|NCT00470483|DRUG|Placebo treatment during 8 weeks|comparator
219231602|NCT00470483|DRUG|Paroxetine treatment during 8 weeks|treatment drug
219554042|NCT02853916|DIETARY_SUPPLEMENT|Placebo|
219147116|NCT03632811|OTHER|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
219147117|NCT01340859|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
219147118|NCT01718041|DRUG|Experimental: VRS-317|Active treatment arm
219147119|NCT03097679|DEVICE|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
219147120|NCT03097679|DEVICE|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
219147121|NCT02263573|OTHER|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
219147122|NCT02263573|OTHER|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
219147123|NCT04572945|DIAGNOSTIC_TEST|kidney function test|laboratory and imaging
219147124|NCT03753308|BIOLOGICAL|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
219147125|NCT03753308|BIOLOGICAL|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
219147126|NCT05279157|PROCEDURE|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
219147127|NCT05279157|PROCEDURE|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
219147128|NCT01074788|BEHAVIORAL|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
219147129|NCT00813657|BEHAVIORAL|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
219147130|NCT05082636|OTHER|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
219147131|NCT02437006|OTHER|exercise|cycle ergometry
219147132|NCT04833179|BIOLOGICAL|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
219147133|NCT04833179|OTHER|placebo|placebo
219231603|NCT03824340|DRUG|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
219719909|NCT01257542|DRUG|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
219719910|NCT01257542|DRUG|Placebo|A single 10 mL dose of matching placebo syrup
219719911|NCT04332120|PROCEDURE|tubal sterilization|
219719912|NCT01566162|DRUG|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
219231604|NCT02118922|PROCEDURE|Brillouin imaging|
219231605|NCT04987801|OTHER|Drug Toxicity|Patients who took over dose of Drugs
219231606|NCT03695757|BIOLOGICAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
219719913|NCT00712049|DRUG|simvastatin|simvastatin 40 mg
219147134|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
219147135|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
219147136|NCT00746655|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
219147137|NCT00746655|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
219147138|NCT03644849|DEVICE|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
219147139|NCT03644849|OTHER|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
219147140|NCT03305536|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
219231607|NCT03695757|BIOLOGICAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
219231608|NCT00105963|BEHAVIORAL|Education about infant crying|
219231609|NCT04820491|DIAGNOSTIC_TEST|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
219231610|NCT04820491|DIAGNOSTIC_TEST|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
219719914|NCT00712049|DRUG|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
219147141|NCT01346254|DRUG|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
219147142|NCT01346254|DRUG|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
219147143|NCT01346254|BEHAVIORAL|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
219147144|NCT00483093|DRUG|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
219147145|NCT00483093|DRUG|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
219231611|NCT03280511|DRUG|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
219231612|NCT04033250|DRUG|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
219719915|NCT01108159|PROCEDURE|Blood Draw|
219719916|NCT01108159|PROCEDURE|Skin Biopsy|
219147146|NCT04048668|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
219147147|NCT01988649|DRUG|Intranasal Oxytocin|Administration of intranasal Oxytocin
219147148|NCT01988649|DRUG|Placebo (saline)|Administration of normal saline intranasally.
219147149|NCT05728684|BIOLOGICAL|CM310|CM310 Injection
219147150|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
219231613|NCT00937287|OTHER|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
219231614|NCT00366470|DRUG|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
219231615|NCT00366470|OTHER|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
219231616|NCT00563134|DRUG|GR270774|
219719917|NCT00693303|BEHAVIORAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
219719918|NCT03251599|DRUG|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
219147151|NCT02393001|OTHER|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
219147152|NCT02393001|OTHER|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
219719919|NCT03251599|DRUG|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
219719920|NCT03664258|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
219719921|NCT02792634|PROCEDURE|Sleeve-Gastrectomy, Roux en Y gastric bypass|
219147153|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
219147154|NCT05094050|DRUG|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
219147155|NCT02623868|DRUG|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
219147156|NCT02623868|DRUG|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
219147157|NCT02623868|DRUG|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
219147158|NCT00002919|BIOLOGICAL|filgrastim|
219147159|NCT00002919|DRUG|cisplatin|
219147160|NCT00002919|DRUG|doxorubicin hydrochloride|
219147161|NCT00002919|DRUG|methotrexate|
219147162|NCT00002919|DRUG|vinblastine sulfate|
219147163|NCT00002919|PROCEDURE|conventional surgery|
219147164|NCT06107959|OTHER|Pre-surgical nutrition, hydration, RMR, and body composition assessments|Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.
219147165|NCT06107959|OTHER|Post-surgical nutrition, hydration, RMR and body composition assessments|Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.
219147166|NCT04032353|OTHER|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
219147167|NCT05048251|DEVICE|cTBS|continuous theta burst stimulation
219147168|NCT05048251|DEVICE|iTBS|intermittent theta burst stimulation
219147169|NCT05048251|DEVICE|sham|sham stimulation
219147170|NCT01057758|DRUG|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
219147171|NCT01057758|DRUG|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
219147172|NCT05230680|DRUG|ACHOP|"1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
219554043|NCT05061992|DRUG|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
219554044|NCT02473393|DRUG|OPS-2071 tablet|
219147173|NCT01269749|RADIATION|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
219147174|NCT01269749|DRUG|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
219719922|NCT00523380|DRUG|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
219147175|NCT02919176|DRUG|Mirabegron|Mirabegron 50 mg/day
219147176|NCT02919176|DRUG|Pioglitazone|Pioglitazone 30 mg/day
219147177|NCT02919176|DRUG|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
219147178|NCT01145885|DRUG|BI 6727|PLK-1 inhibitor
219147179|NCT01023490|DRUG|Vitamin D|34,5000 IU vitamin D per week
219147180|NCT01023490|DRUG|Placebo|Placebo
219147181|NCT02673788|OTHER|observation without intervention in this follow up study|observation without intervention in this follow up study
219147182|NCT02100371|DRUG|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
219147183|NCT03547479|BEHAVIORAL|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
219147184|NCT03547479|BEHAVIORAL|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
219147185|NCT03691428|BEHAVIORAL|Wish Outcome Obstacle Plan|"1\. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan."
219554045|NCT04274829|PROCEDURE|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
219554046|NCT01751633|PROCEDURE|Surgical|
219554047|NCT01751633|PROCEDURE|Conservative treatment|
219554048|NCT01713166|DRUG|plasmalyte solution|plasmalyte solution
219554049|NCT01713166|DRUG|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
219554050|NCT00458159|DRUG|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
219719923|NCT00523380|DRUG|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
219719924|NCT06426407|DRUG|Vasopressin|Fixed dosage vasopressin ordered as an adjunctive vasopressor to norepinephrine
219147186|NCT02527148|DEVICE|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
219147187|NCT02527148|DEVICE|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
219147188|NCT02527148|PROCEDURE|Total Knee Replacement|
219147189|NCT02527148|DEVICE|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
219147190|NCT06357819|DEVICE|INSTI HCV Self Test|Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
219147191|NCT06554860|OTHER|scapular Blackburn stabilization plus exercise|scapular Blackburn stabilization
219147192|NCT06554860|OTHER|PNF plus Exercise|PNF plus Exercise
219147193|NCT06554860|OTHER|exercise only|Exercise only
219231617|NCT04885166|OTHER|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
219231618|NCT04885166|BEHAVIORAL|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
219231619|NCT03263572|BIOLOGICAL|Blinatumomab|Given IV
219231620|NCT03263572|DRUG|Cytarabine|Given intrathecally via spinal tap
219231621|NCT03263572|DRUG|Methotrexate|Given intrathecally via spinal tap
219231622|NCT03263572|DRUG|Ponatinib|Given PO
219231623|NCT06999577|DRUG|Omeprazole 40 MG|8 week double dose therapy of proton pump inhibitor or placebo.
219231624|NCT06999577|BEHAVIORAL|Laryngeal Recalibration Therapy|LRT utilizes therapies that SLPs standardly utilize (mechanical and cognitive guidance) in combination specifically designed to treat laryngeal symptoms. Each session with the SLP will guide subjects through these therapies. The existing script-based LRT protocol consists of the following: 1) mechanical guidance (laryngeal suppression, voice production, breath coordination), 2) cognitive guidance (identification of thinking patterns, recalibration of thoughts about laryngeal sensations).
219231625|NCT06999577|BEHAVIORAL|GERD Lifestyle Recommendations|This is the typical lifestyle recommendations for GERD used clinically.
219231626|NCT06820177|DRUG|Tranexamic Acid|1g tranexamic acid
219231627|NCT06820177|DRUG|Placebo|10 mL 0.9% normal saline
219231628|NCT07013591|DRUG|MIB-626|An orally-administered stable crystalline tablet formulation of NMN
219231629|NCT07013591|OTHER|Placebo|matching placebo tablets
219231630|NCT07013786|DIAGNOSTIC_TEST|Pressure biofeedback assessment|Participants will be assessed for lumbar motor control using a pressure biofeedback unit (PBU) during the Abdominal Draw-In Maneuver (ADIM) in both crock lying and prone positions. This is a non-invasive test to evaluate deep core muscle function (TrA and MF) in patients with NSCLBP. No therapeutic intervention will be administered.
219231631|NCT07013188|OTHER|Neuromuscular function|Assessing their neuromuscular abilities using some functional and electromyography assessments
219147194|NCT06405555|DRUG|Midodrine Oral Tablet|Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
219147195|NCT03091010|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
219231632|NCT05628363|DEVICE|Ethos Varian treatment system|Device that will be used to administer radiotherapy
219231633|NCT05628363|RADIATION|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
219231634|NCT05628363|DRUG|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
219147196|NCT03091010|DRUG|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
219147197|NCT04973735|DRUG|LY-CovMab|single IV infusion
219147198|NCT04097418|BEHAVIORAL|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
219147199|NCT05489406|DRUG|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
219147200|NCT05489406|DRUG|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
219147201|NCT05888584|OTHER|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
219147202|NCT01292681|OTHER|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
219147203|NCT04908371|PROCEDURE|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
219147204|NCT04908371|PROCEDURE|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
219147205|NCT04864925|DRUG|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
219147206|NCT04864925|DRUG|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
219147207|NCT06176716|DRUG|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
219147208|NCT02871999|DEVICE|Acupuncture therapy|
219147209|NCT02871999|PROCEDURE|Laparoscopic Surgery|
219147210|NCT06961630|DRUG|Rivaroxaban|Rivaroxaban 2.5mg will be orally administered twice daily for 6 months.
219147211|NCT06961630|DRUG|Atorvastatin|Atorvastatin 80mg will be orally administered daily for 6 months.
219147212|NCT01581736|DRUG|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
219147213|NCT01581736|OTHER|Exercise|Single episode of exercise riding a stationary bike.
219147214|NCT03802266|DEVICE|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
219147215|NCT03802266|DEVICE|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
219719925|NCT03697356|DRUG|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~* Rituximab 375 mg/m2 intravenous on day 1~* Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~* Lenalidomide 15mg p.o on day 1-21~* Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
219719926|NCT02202616|DRUG|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
219147216|NCT03160781|BIOLOGICAL|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
219147217|NCT00810680|DRUG|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
219147218|NCT01282346|DEVICE|SOLX Gold Shunt|Single use implant
219147219|NCT00206024|DRUG|Esomeprazole magnesium (Nexium)|
219147220|NCT01831791|DRUG|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
219147221|NCT03587168|OTHER|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
219147222|NCT03587168|OTHER|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
219147223|NCT03587168|OTHER|Four Square Step Test|The Four Square Step Test measures dynamic balance.
219147224|NCT03587168|OTHER|Functional Reach Test|The Functional Reach Test assesses limits of stability.
219147225|NCT03587168|OTHER|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
219147226|NCT03587168|OTHER|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
219147227|NCT03587168|OTHER|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
219147228|NCT03587168|OTHER|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
219147229|NCT04932707|OTHER|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
219147230|NCT04932707|OTHER|Neurodynamic mobilization|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
219147231|NCT04932707|OTHER|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
219719927|NCT05026918|OTHER|MCPT|Postural Drainagewith percussion and vibration
219719928|NCT05026918|OTHER|ACBT|ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
219719929|NCT00993889|BEHAVIORAL|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
219719930|NCT00993889|BEHAVIORAL|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
219147232|NCT00494780|DRUG|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
219147233|NCT00494780|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
219147234|NCT00494780|DRUG|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
219147235|NCT00494780|DRUG|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
219147236|NCT00494780|DRUG|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
219147237|NCT01948999|PROCEDURE|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
219147238|NCT01948999|PROCEDURE|SHAM ECT|Anesthesia and concomitant muscular paralysis
219147239|NCT01948999|DRUG|Anesthesia|Temporary induced state of analgesia
219147240|NCT03078634|OTHER|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
219719931|NCT00993889|BEHAVIORAL|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
219719932|NCT03687697|BIOLOGICAL|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
219719933|NCT01334515|BIOLOGICAL|hu14.18-IL2 fusion protein|Given IV
219719934|NCT01334515|DRUG|isotretinoin|Given PO
219719935|NCT01334515|BIOLOGICAL|sargramostim|Given SC
219147241|NCT03078634|OTHER|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
219147242|NCT05315180|DRUG|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
219147243|NCT01254019|DRUG|GSK2402968 6mg/kg/week|subcutaneous
219147244|NCT03061474|DRUG|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
219147245|NCT03061474|DRUG|Placebo Comparator|Oral Tablet
219147246|NCT03156712|DIETARY_SUPPLEMENT|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
219147247|NCT00980330|DRUG|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
219147248|NCT00980330|DRUG|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
219147249|NCT00980330|DRUG|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
219147250|NCT00980330|DRUG|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
219147251|NCT06204055|OTHER|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
219147252|NCT05117372|OTHER|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
219231635|NCT07052747|OTHER|Clinical periodontal assessment|Comprehensive site-level and full-mouth evaluations of periodontal parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), recession depth (RD), bleeding on probing (BOP), keratinized tissue width (KTW), mucosal phenotype, mucosal redness (MR), mucosal discomfort (MD), and torque gauge (TG) measurements.
219719936|NCT01334515|OTHER|laboratory biomarker analysis|Correlative studies
219719937|NCT04327271|BEHAVIORAL|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
219719938|NCT01251679|BEHAVIORAL|Hand washing|hand washing education and material
219719939|NCT01251679|DEVICE|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
219719940|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
219719941|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
219147253|NCT05117372|OTHER|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
219147254|NCT03860532|DRUG|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
219147255|NCT03860532|DRUG|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
219147256|NCT03103295|BIOLOGICAL|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
219147257|NCT02129582|RADIATION|total marrow irradiation|Undergo TMI
219147258|NCT02129582|DRUG|fludarabine phosphate|Given IV
219147259|NCT02129582|DRUG|busulfan|Given IV or PO
219147260|NCT02129582|PROCEDURE|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
219147261|NCT02129582|BIOLOGICAL|anti-thymocyte globulin|Given IV
219147262|NCT02129582|DRUG|tacrolimus|Given IV or PO
219147263|NCT02129582|DRUG|methotrexate|Given IV
219147264|NCT02129582|OTHER|laboratory biomarker analysis|Correlative studies
219719942|NCT01554813|BIOLOGICAL|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
219147265|NCT03697616|DEVICE|Ridge augmentation with sticky bone and GBR|"* Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
219147266|NCT05360043|DEVICE|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
219147267|NCT00103025|DRUG|Sodium Nitrite|
219147268|NCT00103025|DRUG|Sodium Nitrite Injection|
219147269|NCT00190931|DRUG|Atomoxetine Hydrochloride|
219147270|NCT00190931|DRUG|placebo|
219147271|NCT01630564|BIOLOGICAL|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
219147272|NCT01630564|PROCEDURE|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
219147273|NCT01630564|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
219147274|NCT04749017|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
219147275|NCT04749017|OTHER|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
219147276|NCT00666276|DRUG|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
219147277|NCT03853655|RADIATION|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
219147278|NCT04617652|DRUG|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
219147279|NCT04617652|DRUG|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
219147280|NCT00007956|BIOLOGICAL|monoclonal antibody mono-dgA-RFB4|
219147281|NCT00389246|BEHAVIORAL|Consultation without genetic information|
219147282|NCT00389246|BEHAVIORAL|Consultation with genetic information|
219147283|NCT02765438|DEVICE|BOBO|"Each subject will play four games with the BOBO system."
219147284|NCT02778958|DRUG|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
219147285|NCT02778958|DRUG|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
219147286|NCT05480358|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
219147287|NCT02582437|OTHER|History for opioid use|
219231636|NCT07052851|DEVICE|CCoat, Liposphere Ltd|a single IA injection of 4 ml CCoat
219231637|NCT07052851|DEVICE|Synvisc-One® (hylan G-F 20)|Group 2 (Active Comparator): a single IA Synvisc-One® (hylan G-F 20) of 6 mL, Genzyme Corporation
219147288|NCT05824442|BIOLOGICAL|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
219147289|NCT01065220|DRUG|Testolactone undecanoate|4ml i.m.
219554051|NCT05880888|BIOLOGICAL|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
219554052|NCT03316157|DIETARY_SUPPLEMENT|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
219147290|NCT01065220|DRUG|Lynestrenol|2/day
219147291|NCT01065220|DRUG|Cyproterone Acetate|50mg per day
219147292|NCT01065220|DRUG|Estradiol|100 microgram TTS twice a week
219147293|NCT01065220|DRUG|5-alpha reductase inhibitor|1mg daily
219147294|NCT04153435|DRUG|Calcium Chloride|Calcium chloride 5 mmol
219147295|NCT04153435|DRUG|Sodium chloride 0.9%|Placebo
219147296|NCT06436144|DRUG|Osimertinib|Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
219147297|NCT04091152|OTHER|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
219554053|NCT03316157|BEHAVIORAL|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
219719943|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
219719944|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
219147298|NCT04102462|DRUG|BI 764198|Capsules
219147299|NCT04102462|DRUG|Matching placebo|Capsules
219147300|NCT01511172|DRUG|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
219147301|NCT01511172|DRUG|metformin|1000 mg daily, administered orally
219147302|NCT01511172|DRUG|placebo|Metformin placebo administered orally. 1000 mg daily
219147303|NCT01511172|DRUG|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
219147304|NCT01511172|DRUG|glimepiride|Individually adjusted dose, administered orally
219147305|NCT00915330|PROCEDURE|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
219147306|NCT00915330|PROCEDURE|TBNA|transbronchial needle aspiration
219147307|NCT05238194|OTHER|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
219147308|NCT06490991|DRUG|HRS-5965 tablets；HRS-5965 capsules|Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
219147309|NCT01317719|PROCEDURE|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
219147310|NCT03264755|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
219147311|NCT00665444|DRUG|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
219147312|NCT03299816|BEHAVIORAL|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
219147313|NCT03299816|BEHAVIORAL|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
219147314|NCT00194623|DRUG|Botulinum Toxin A (Botox)|
219147315|NCT03520413|OTHER|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
219147316|NCT03520413|OTHER|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
219147317|NCT02311907|DRUG|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
219147318|NCT02311907|DRUG|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
219147319|NCT02311907|OTHER|Laboratory Biomarker Analysis|Correlative studies
219147320|NCT02311907|DRUG|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
219719945|NCT03759184|BIOLOGICAL|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
219719946|NCT00708669|DEVICE|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
219719947|NCT00708669|DEVICE|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
219719948|NCT03469804|DRUG|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
219719949|NCT01479530|DRUG|Placebo|Once daily; tablet; orally; 16 weeks
219147321|NCT02311907|OTHER|Placebo|Given IV
219231638|NCT06890767|DEVICE|Wearable mobile device|Patients admitted due to an acute COPD exacerbation will be asked to wear the wearable mobile device for a period of 3 months. An app linked to the device will be installed on their phone, and be used to send vital parameter data to the investigators.
219147322|NCT02311907|OTHER|Quality-of-Life Assessment|Ancillary studies
219147323|NCT02600052|OTHER|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
219147324|NCT02600052|DEVICE|treadmill|AEROBIC TRAINING
219147325|NCT00092105|DRUG|MK0476, montelukast sodium|
219147326|NCT00092105|DRUG|Comparator: placebo|
219231639|NCT06890767|OTHER|CAT Questionnaire|During the time of hospital admission and at the end of study, a COPD Assessment Test questionnaire will be taken.
219231640|NCT06890767|OTHER|DHRQ Questionnaire|During the time of hospital admission, the patient will be asked to fill in the Digital Health Readiness Questionnaire
219719950|NCT01479530|DRUG|Azilect®|1 mg daily; tablet; orally; 16 weeks
219719951|NCT02504203|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
219719952|NCT00312611|DEVICE|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
219719953|NCT01995435|DEVICE|Telemedicine refraction|
219719954|NCT01995435|DEVICE|Traditional refraction|
219719955|NCT04986969|BEHAVIORAL|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
219147327|NCT01385891|DRUG|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
219147328|NCT00338299|DRUG|Epoetin alfa|
219147329|NCT00625937|DRUG|cisplatin|
219147330|NCT00625937|DRUG|docetaxel|
219231641|NCT07097922|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
219147331|NCT00625937|DRUG|tegafur-gimeracil-oteracil potassium|
219147332|NCT00625937|RADIATION|radiation therapy|
219147333|NCT06326632|OTHER|Constant-load Aerobic Exercise|The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
219147334|NCT06326632|OTHER|Graded Aerobic exercise|The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.
219147335|NCT06326632|OTHER|Respiratory Re-training|The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
219147336|NCT01637662|DRUG|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
219147337|NCT06174662|DEVICE|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
219147338|NCT02120911|DRUG|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
219719956|NCT04918628|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
219147339|NCT02846480|OTHER|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
219231642|NCT07097922|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
219231643|NCT07098481|DRUG|ACCESS+ strategy Epclusa 400/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg once daily for 12 weeks), (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
219719957|NCT00608738|OTHER|informational intervention|
219719958|NCT00608738|OTHER|medical chart review|
219719959|NCT00608738|OTHER|questionnaire administration|
219719960|NCT00608738|PROCEDURE|assessment of therapy complications|
219719961|NCT00608738|PROCEDURE|management of therapy complications|
219147340|NCT02846480|OTHER|surgical treatment|Surgical correction of POP.
219147341|NCT02846480|OTHER|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
219147342|NCT03855891|DIAGNOSTIC_TEST|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
219147343|NCT01271452|BIOLOGICAL|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
219147344|NCT01271452|BIOLOGICAL|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
219147345|NCT03616639|DRUG|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
219147346|NCT03616639|DRUG|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
219147347|NCT03590080|DRUG|Methylprednisolone|
219147348|NCT05022251|PROCEDURE|Lumbar discectomy|surgically removing a hernia
219231644|NCT07098481|DRUG|ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
219554054|NCT03730740|DRUG|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
219554055|NCT02809768|DRUG|Avatrombopag|
219554056|NCT02809768|DRUG|Fluconazole|
219554057|NCT02809768|DRUG|Itraconazole|
219554058|NCT02809768|DRUG|Rifampin|
219554059|NCT03635268|OTHER|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
219554060|NCT02849236|DRUG|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
219554061|NCT02849236|DRUG|Placebo|20 mL saline 0.9%
219147349|NCT04051255|DRUG|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
219147350|NCT05677438|DRUG|CKD-498 dose#1|oral, once daily, 24 weeks
219147351|NCT05677438|DRUG|CKD-498 dose#2|oral, once daily, 24 weeks
219147352|NCT05677438|DRUG|CKD-498 dose#3|oral, once daily, 24 weeks
219147353|NCT05677438|DRUG|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
219147354|NCT05677438|DRUG|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
219147355|NCT05677438|DRUG|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
219147356|NCT03089840|DEVICE|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
219147357|NCT00910767|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
219147358|NCT00910767|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
219231645|NCT07098481|DRUG|Standard Strategy Vosevi 400/100/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
219231646|NCT07098481|DRUG|Standard Strategy Epclusa 400/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
219231647|NCT07098026|DRUG|Shenqi Fuwei Mixture|Shenqi Fuwei Mixture
219231648|NCT07098026|DRUG|Shenqi Fuwei Mixture Placebo|Shenqi Fuwei Mixture Placebo
219231649|NCT06936280|BEHAVIORAL|ACTnow|"The group-based psychological intervention consists of six bi-weekly sessions, each lasting two hours, with 6-10 participants per group, led by a psychologist and nurse.~The intervention is based on Acceptance and Commitment Therapy (ACT), an evidence-based approach shown to be effective for chronic diseases, with additional elements from cognitive behavioral therapy and health education. It is manual-based, developed by experienced clinicians at SDCO, and includes tools from an existing diabetes distress intervention (REDUCE).~Each session includes a mindfulness exercise, a review of the previous session, a new topic, individual homework assignments, and a conclusion. Participants complete an online questionnaire to track diabetes distress after each session. The group process lasts about 3 months. Preliminary results from a feasibility study showed positive outcomes in recruitment, patient satisfaction, and reduction of diabetes distress (publication in progress)."
219231650|NCT03976323|BIOLOGICAL|Pembrolizumab|IV infusion
219231651|NCT03976323|DRUG|Pemetrexed|IV infusion
219231652|NCT03976323|DRUG|Carboplatin|IV infusion
219231653|NCT03976323|DRUG|Cisplatin|IV infusion
219147359|NCT00246714|DRUG|repeated injections of endotoxin during 5 days|
219147360|NCT03842488|DRUG|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
219147361|NCT03842488|DRUG|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
219147362|NCT00814047|DRUG|Yohimbine hydrochloride|
219147363|NCT01948648|DRUG|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
219147364|NCT01948648|DIETARY_SUPPLEMENT|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
219147365|NCT01948648|DRUG|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
219147366|NCT00929617|BEHAVIORAL|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
219147367|NCT00929617|OTHER|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
219231654|NCT03976323|DRUG|Olaparib|Oral Tablet
219147368|NCT01043263|DRUG|EN3324 (axomadol)|twice daily dosing
219147369|NCT01043263|DRUG|Placebo|twice daily dosing
219147370|NCT03883529|OTHER|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
219147371|NCT02219178|DRUG|lenalidomide|25mg days 1 - 14 of 21 day schedule
219147372|NCT02219178|DRUG|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
219147373|NCT02219178|DRUG|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
219147374|NCT05881577|OTHER|Observational|Impact of AR on educational outcomes
219147375|NCT04825366|DEVICE|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
219231655|NCT06944821|PROCEDURE|In-situ simulation|Each simulation session takes place over one day, with 4 scenarios recreating life-threatening emergency situations (cardiorespiratory arrest, hemorrhagic shock, etc.). Each scenario is designed to meet specific pedagogical objectives, which will be debriefed by simulation trainers: crisis resource management (communication, alerting, etc.) or organization of multi-professional teamwork
219231656|NCT06944821|OTHER|Role-playing using a simulation scenario|Team performance in critical situations, assessed during a simulation scenario for all participants. The assessment will be carried out blind by 1 examiner, trained in CRM (Crisis Resource Management) analysis in simulation and debriefing.
219231657|NCT06944821|OTHER|Questionnaires|Quality of lige questionnaire Pro-QOL, Karasek questionnaire, Satisfaction questionnaire at work : WRQoL, Work Life Balance scale, Mayo Hight Team Performance scale will be completed at baseline and at 6 months
219554062|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
219719962|NCT01457027|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
219719963|NCT00231192|DRUG|Repaglinide and Insulin|
219719964|NCT00303628|DRUG|oxaliplatin|Given IV
219719965|NCT00303628|DRUG|fluorouracil|Given IV
219719966|NCT00303628|DRUG|leucovorin calcium|Given IV
219719967|NCT00303628|DRUG|bevacizumab|Given IV
219719968|NCT02040064|DRUG|Gefitinib|Oral tablet
219719969|NCT02040064|DRUG|Tremelimumab|IV
219719970|NCT00032760|BEHAVIORAL|Meditation|
219719971|NCT04516200|DEVICE|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
219719972|NCT04516200|OTHER|designed physical therapy program|sensory training and balance training
219719973|NCT02211742|DRUG|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
219719974|NCT05196139|OTHER|retrospective study|vitrectomy performed in case of submacular bleeding
219719975|NCT00002390|DRUG|Abacavir sulfate|
219719976|NCT00776997|DEVICE|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
219719977|NCT03803696|BEHAVIORAL|Enhanced Standard Care|"* Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material"
219719978|NCT03803696|BEHAVIORAL|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~\- 3 Monthly visits with trained study nurse practitioners~* Referral to specialist if~* Psychological etiology~* Sexual Trauma~* Relationship Discord~* Concern for Malignancy or anatomic scarring requiring surgery"
219719979|NCT02292225|DRUG|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
219719980|NCT02292225|DRUG|Obinutuzumab|1000mg/40mL single-use vials
219147376|NCT04825366|OTHER|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
219147377|NCT04825366|OTHER|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
219147378|NCT04825366|OTHER|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
219147379|NCT04825366|OTHER|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
219147380|NCT04825366|OTHER|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
219719981|NCT02193893|OTHER|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
219719982|NCT02193893|OTHER|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
219719983|NCT01193985|DEVICE|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
219719984|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
219719985|NCT05650697|BIOLOGICAL|Group 1 cannabidiol (CBD) with silicone ointment|"Vantage Hemp CBD Isolate + Silicone patch The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
219147381|NCT04825366|OTHER|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
219147382|NCT04825366|OTHER|Well-being|The WHO-5 well-being index will be used to assess well-being.
219554063|NCT06377683|DRUG|177Lu-Dansyl-PSMA radioligand therapy|Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
219719986|NCT05650697|BIOLOGICAL|Group 2 silicone patch|"Silicone patch Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
219719987|NCT06959888|DRUG|ALG-055009|"Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 1)~Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 2)"
219719988|NCT03487445|DRUG|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
219554064|NCT06221670|DRUG|Toripalimab|This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
219719989|NCT03487445|DRUG|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
219719990|NCT00474513|DRUG|GSK239512|
219719991|NCT05821478|DRUG|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
219554065|NCT06559202|DIAGNOSTIC_TEST|chest and abdominoplevic CT|chest and abdominopelvic computed tomography on the same day for health screening purposes
219554066|NCT03690063|OTHER|Follow up|Follow up of treatment, behavior, co-morbidity
219554067|NCT01635582|OTHER|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
219554068|NCT01635582|OTHER|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
219554069|NCT00033150|BEHAVIORAL|Fast ForWord|
219147383|NCT04825366|OTHER|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
219147384|NCT04825366|OTHER|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
219147385|NCT04825366|DEVICE|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
219147386|NCT04825366|DEVICE|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
219719992|NCT05821478|DRUG|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
219719993|NCT06415331|PROCEDURE|Pulsed radiofrequency|Individualized dose of pulsed radiofrequency is given for 6 minutes.
219719994|NCT06415331|OTHER|Conventional therapy|"Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise"
219719995|NCT05191784|DRUG|GX-I7|Administered by intramuscular (IM) injection
219719996|NCT05191784|DRUG|Bevacizumab|Administered by intravenous (IV) injection
219719997|NCT00733798|DRUG|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
219719998|NCT05803317|OTHER|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
219147387|NCT04825366|OTHER|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
219147388|NCT05284812|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
219147389|NCT05284812|BIOLOGICAL|High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
219554070|NCT00033150|BEHAVIORAL|Computer Assisted Language Intervention|
219554071|NCT00033150|BEHAVIORAL|Individual Language Intervention|
219554072|NCT00033150|BEHAVIORAL|Academic enrichment|
219554073|NCT04831138|PROCEDURE|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
219147390|NCT05284812|BIOLOGICAL|High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
219147391|NCT05284812|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
219231658|NCT06948604|BEHAVIORAL|Exercise|this exercise used to improve urine complication post TURP
219231659|NCT06951997|DRUG|QL1706|5mg/kg, q3w
219231660|NCT06951997|DRUG|Chidamide|20mg, biw, q3w
219231661|NCT06951997|DRUG|Gemcitabine|1000mg/m2 Q3W
219231662|NCT06951997|DRUG|Nab-paclitaxel|125mg/m2 Q3W
219231663|NCT06951945|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
219231664|NCT06951945|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
219231665|NCT05447286|DRUG|NYX-783|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
219231666|NCT05447286|DRUG|Placebo|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
219231667|NCT05447286|DRUG|Oxycodone|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
219231668|NCT00682318|DRUG|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
219231669|NCT00682318|DIETARY_SUPPLEMENT|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
219231670|NCT00682318|DIETARY_SUPPLEMENT|Ethanol|"Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
219147392|NCT00869323|BIOLOGICAL|rituximab|375 mg/m\^2 intravenously on Days 1,8, 15 and 22
219147393|NCT00869323|DRUG|bortezomib|1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
219231671|NCT00682318|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
219231672|NCT00682318|DIETARY_SUPPLEMENT|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)"
219231673|NCT05561244|DEVICE|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
219231674|NCT03425461|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
219231675|NCT03425461|BIOLOGICAL|Ipilimumab|Given IV
219231676|NCT03425461|OTHER|Laboratory Biomarker Analysis|Correlative studies
219231677|NCT03425461|BIOLOGICAL|Nivolumab|Given IV
219231678|NCT03425461|OTHER|Pharmacological Study|Correlative studies
219231679|NCT03596697|DRUG|CRV431|Single or multiple dose(s) of CRV431
219231680|NCT03596697|DRUG|Placebo|Single Placebo dose
219231681|NCT03596697|DRUG|TDF|Single or multiple dose(s) of TDF
219231682|NCT04832724|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
219231683|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
219231684|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
219231685|NCT03644082|BEHAVIORAL|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
219231686|NCT03644082|BEHAVIORAL|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
219231687|NCT03644082|BEHAVIORAL|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
219231688|NCT03644082|BEHAVIORAL|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
219231689|NCT03644082|BEHAVIORAL|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
219231690|NCT03644082|BEHAVIORAL|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
219719999|NCT05969691|DIAGNOSTIC_TEST|Validation of IDH1 mutations from the radiomics model|During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.
219720000|NCT03918200|OTHER|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
219720001|NCT05011032|DIAGNOSTIC_TEST|Homocysteine|It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
219720002|NCT03301714|BEHAVIORAL|Oral Health Education|Group-based oral health education vs Individual-based oral health education using motivational interviewing
219720003|NCT06322498|DIAGNOSTIC_TEST|Uterine lavage|Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
219720004|NCT01194310|PROCEDURE|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
219720005|NCT01194310|PROCEDURE|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
219720006|NCT01194310|PROCEDURE|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
219720007|NCT01709344|BEHAVIORAL|PS-OT|
219720008|NCT01709344|OTHER|Usual care|Supportive and rehabilitation services available at DHMC
219720009|NCT04055519|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
219720010|NCT04055519|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
219720011|NCT04055519|DEVICE|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
219720012|NCT01418898|OTHER|Dietary Intervention|Nutrient fortified oat beverage
219720013|NCT05733299|DEVICE|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
219720014|NCT05733299|OTHER|Standard care|Health service standard care will be continued
219720015|NCT01669850|DEVICE|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
219720016|NCT01669850|PROCEDURE|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
219720017|NCT01326221|DRUG|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
219147394|NCT02744521|OTHER|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
219147395|NCT00717626|DRUG|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
219147396|NCT04688801|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
219147397|NCT04688801|DRUG|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
219554074|NCT00497250|DRUG|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
219554075|NCT00497250|DEVICE|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
219720018|NCT04984408|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"* The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
219720019|NCT04984408|BIOLOGICAL|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"* The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
219231691|NCT03644082|BEHAVIORAL|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
219554076|NCT06236100|BEHAVIORAL|Strengthening Families Program + Family Advocate|This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.
219554077|NCT06236100|BEHAVIORAL|Strengthening Families Program|This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
219554078|NCT03782493|BEHAVIORAL|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
219554079|NCT04195828|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
219554080|NCT04195828|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
219554081|NCT04195828|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
219720020|NCT02635035|DRUG|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
219720021|NCT02635035|DRUG|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
219720022|NCT01403584|DEVICE|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
219720023|NCT01403584|DEVICE|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
219720024|NCT04913636|DEVICE|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
219720025|NCT04913636|OTHER|Sham Control|Subjects will perform their regular denture cleaning routine.
219720026|NCT02763995|BEHAVIORAL|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
219720027|NCT04464447|BEHAVIORAL|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
219720028|NCT03543774|DRUG|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
219720029|NCT03543774|DRUG|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
219720030|NCT03543774|DRUG|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
219720031|NCT01460771|DEVICE|TDCS (Transcranial Direct-current Stimulation)|active TDCS
219720032|NCT01460771|DEVICE|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
219720033|NCT02247856|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
219720034|NCT02247856|DEVICE|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
219720035|NCT02247856|DEVICE|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
219720036|NCT04627584|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
219720037|NCT04627584|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
219720038|NCT03412890|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
219231692|NCT03644082|BEHAVIORAL|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
219231693|NCT03644082|BEHAVIORAL|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
219231694|NCT03909074|BIOLOGICAL|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
219231695|NCT03909074|BIOLOGICAL|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
219231696|NCT03909074|BIOLOGICAL|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
219231697|NCT04173000|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
219231698|NCT04173000|OTHER|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
219231699|NCT01578304|DRUG|Imidafenacin|Tablet, 12 weeks twice daily
219554082|NCT04195828|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
219554083|NCT04851067|OTHER|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
219554084|NCT04851067|OTHER|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
219554085|NCT04435249|OTHER|BPF-001|Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold
219720039|NCT03412890|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
219720040|NCT04419259|DRUG|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
219720041|NCT04131192|DRUG|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
219720042|NCT04131192|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
219720043|NCT00515593|DRUG|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
219720044|NCT04450875|DIETARY_SUPPLEMENT|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
219720045|NCT05138757|DRUG|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
219720046|NCT05138757|DRUG|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
219720047|NCT05822466|BEHAVIORAL|Virtual tai ji quan: moving for better balance intervention (V-TJQMBB)|This intervention involves a tai ji quan exercise program, named tai ji quan: moving for better balance
219720048|NCT05822466|BEHAVIORAL|Virtual multimodal exercise intervention (V-Multimodal)|This intervention involves a multimodal exercise program that consists of balance, strength, light walking, and stretching exercises
219554086|NCT06641037|DRUG|LY3866288|Administered orally
219554087|NCT00820885|DRUG|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
219554088|NCT00820885|DRUG|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
219554089|NCT00820885|DRUG|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
219554090|NCT01341951|DRUG|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
219554091|NCT01698554|DRUG|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
219554092|NCT01698554|DRUG|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
219720049|NCT05271487|OTHER|Multi-Step Botanical Skin Care Regimen|"The intervention includes 7 different topical products:~1. Cleanser~2. Toner~3. Oil Control Cream~4. Exfoliating Facial Scrub~5. Clay Mask~6. Acne Spot Treatment~7. Body Scrub"
219720050|NCT04840719|DEVICE|RECO|
219720051|NCT05838599|DRUG|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
219720052|NCT05838599|RADIATION|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
219720053|NCT01060371|GENETIC|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
219720054|NCT01166334|BEHAVIORAL|WebQuit study group|Description withheld to protect integrity of study
219720055|NCT01166334|BEHAVIORAL|WebQuit control group|Identity and description withheld to protect integrity of study
219231700|NCT01578304|DRUG|Fesoterodine|Tablet, 12 weeks once daily
219231701|NCT06012799|DIAGNOSTIC_TEST|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
219231702|NCT00003599|DIETARY_SUPPLEMENT|Vitamin E (AT)|Orally daily
219231703|NCT00003599|DRUG|Isotretinoin|Orally daily
219231704|NCT00535626|DEVICE|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
219231705|NCT03814226|OTHER|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
219720056|NCT05331924|PROCEDURE|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
219720057|NCT05331924|PROCEDURE|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
219720058|NCT02338830|DRUG|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
219720059|NCT02949934|DRUG|Tolcapone|
219720060|NCT02949934|DRUG|Placebo|
219720061|NCT02546141|OTHER|skimmed milk (UHT)|
219720062|NCT02546141|OTHER|skimmed milk (pasteurized)|
219720063|NCT02546141|OTHER|skimmed yoghurt|
219720064|NCT02546141|OTHER|full-fat milk (UHT)|
219720065|NCT02546141|OTHER|non-homogenized full-fat milk (pasteurized)|
219720066|NCT02546141|OTHER|full-fat cheese (semi-matured)|
219720067|NCT02546141|OTHER|whey protein|
219720068|NCT02546141|OTHER|micellar casein|
219720069|NCT01052415|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
219231706|NCT01386632|DRUG|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
219231707|NCT01386632|DRUG|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
219231708|NCT02710669|DRUG|(R)-propafenone|
219231709|NCT02710669|DRUG|(S)-Propafenone|
219231710|NCT02710669|DRUG|Placebo|
219231711|NCT06470347|DRUG|A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy|During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
219720070|NCT02615353|BEHAVIORAL|Intensive Lifestyle Intervention|6-months of lifestyle education
219720071|NCT02615353|OTHER|Usual Care Control|Medical visit and dietary counseling
219720072|NCT01770964|DRUG|Pregabalin|
219720073|NCT01770964|DRUG|placebo|
219720074|NCT01770964|BEHAVIORAL|Training Type A|
219720075|NCT01770964|BEHAVIORAL|Training Type B|
219720076|NCT06027437|DRUG|Danicamtiv|Specified dose on specified days.
219720077|NCT02883556|DRUG|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
219720078|NCT00923312|BIOLOGICAL|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
219720079|NCT03205631|OTHER|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
219720080|NCT02453022|DRUG|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
219720081|NCT02453022|DRUG|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
219147398|NCT01740310|BEHAVIORAL|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
219720082|NCT02453022|DRUG|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
219720083|NCT02013427|DRUG|Naproxen|Take one 500mg naproxen capsule twice a day.
219720084|NCT02013427|DRUG|Placebo|Take one placebo capsule twice a day.
219147399|NCT00145743|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
219147400|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
219147401|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
219720085|NCT02013427|DRUG|Omeprazole|Take one 20mg omeprazole capsule twice a day.
219147402|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
219147403|NCT01135511|DRUG|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
219147404|NCT01135511|DRUG|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
219147405|NCT03897348|DRUG|Placebo|Oral medication
219147406|NCT03897348|DRUG|Lacosamide 100 mg|Oral medication
219147407|NCT03897348|DRUG|Lacosamide 200 mg|Oral medication
219147408|NCT01340079|BEHAVIORAL|virtual world|health education using virtual world Second Life
219147409|NCT01340079|BEHAVIORAL|face to face|health education delivered in face to face groups
219720086|NCT03906994|OTHER|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
219720087|NCT00430365|DRUG|lenalidomide|oral drug
219720088|NCT00430365|DRUG|placebo|oral placebo
219720089|NCT00008177|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
219720090|NCT00008177|RADIATION|total-body irradiation|Undergo total-body irradiation
219720091|NCT00008177|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219720092|NCT00008177|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219147410|NCT01990924|RADIATION|15 FPS|X-ray pictures
219147411|NCT01990924|RADIATION|7.5 FPS|X-ray pictures
219147412|NCT03312309|PROCEDURE|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
219147413|NCT01901510|DRUG|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
219147414|NCT01901510|OTHER|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
219147415|NCT05971680|DRUG|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
219147416|NCT05971680|DEVICE|intra-uterine contraceptive device|intra-uterine contraceptive device
219231712|NCT04738370|OTHER|Sample collection|Bloods +/- urine +/- vaginal swabs taken
219720093|NCT00008177|DRUG|fludarabine phosphate|Given IV
219720094|NCT00008177|DRUG|cyclosporine|Given orally or IV
219720095|NCT00008177|DRUG|mycophenolate mofetil|Given orally or IV
219720096|NCT00008177|OTHER|laboratory biomarker analysis|Correlative studies
219720097|NCT04801082|DRUG|Alcohol injection|Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
219720098|NCT04801082|DEVICE|Radiofrequency Ablation|coeliac plexus is identified and punctured with 19G EUSRA RFA needle with 10W-30W of energy for 10-50s bilaterally or unilaterally depends on individual anatomical characteristics.
219720099|NCT03411551|PROCEDURE|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
219720100|NCT02797730|BEHAVIORAL|art-therapy sessions|
219720101|NCT01653886|OTHER|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
219720102|NCT01653886|OTHER|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
219720103|NCT01653886|OTHER|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
219720104|NCT07115355|PROCEDURE|Removable Uterine Compression Suture (RUCS)|Removable Uterine Compression Suture (RUCS) is a uterus-preserving surgical technique used to control postpartum hemorrhage (PPH) when medical management fails. The suture is placed in a way that allows for its removal after hemostasis is achieved, potentially reducing the risk of complications such as intrauterine synechiae. In this study, RUCS was applied to 11 patients following delivery-related hemorrhage.
219720105|NCT07115784|DRUG|Chlorhexidine Varnish|A 40% chlorhexidine varnish formulation (40% chlorhexidine, 36% sandarac, 24% ethanol) applied topically to the buccal surfaces of teeth in the selected upper quadrant. The varnish is applied using a blunt needle syringe before bonding and at monthly follow-up visits for three months. Teeth are dried before application, and patients are instructed not to eat or drink for 3 hours and to avoid brushing until the next day.
219720106|NCT07115784|DRUG|Placebo Varnish|A placebo varnish composed of 60% sandarac and 40% ethanol applied topically in the same manner and frequency as the chlorhexidine varnish. Used on the opposite quadrant of the same patient in a split-mouth design. Participants are blinded to whether chlorhexidine or placebo was applied.
219720107|NCT07116421|DRUG|2-phenylethanol rose scent|"Name: 2-phenylethanol (rose scent). Dose: 3 drops, diffused into room air over 24 hours. Frequency: Once over 24 hours. Route of administration: Essential oil diffuser. Manufactured by: The Essential Oil Company in Portland, OR. Manufacturing details: The rose scent is purified by hydrodistillation, shelf-stable, and in terms of verification of quality has been previously used in a peer-reviewed and IRB-approved study by Woo et al (2023) published in Frontiers in Neuroscience. Preparation: The Key Personnel listed in the study's IRB will prepare the rose essential oil scent by squeezing 3 drops of the product from the manufactured bottle into the essential oil compartment of the Aroma Ace™ MINI Diffuser essential oil diffuser, corresponding with both the rose essential oil and diffuser manufacturers' instructions for each product respectively."
219720108|NCT07114302|BEHAVIORAL|Interactive E-book BBTI Group|Researchers will guide you on how to use the interactive e-book and help install it on your smartphone. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the e-book to perform sleep stimulus control, sleep restriction, and relaxation techniques to promote better sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
219720109|NCT07114302|BEHAVIORAL|BBTI-APP Group|Researchers will assist you in creating an account for the mobile application and will explain the interface and how to operate it. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the mobile app to carry out sleep stimulus control, sleep restriction, and relaxation techniques to improve sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
219720110|NCT07114640|DRUG|Mirabegron 25mg|Taking 25 mg mirabegron in the nighttime
219720111|NCT07114640|DRUG|Solifenacin 5 mg|Taking 5 mg solifenacin in the nighttime
219720112|NCT07114640|DRUG|Tolterodine 4 mg|Taking 5 mg tolterodine in the nighttime
219720113|NCT07114640|DRUG|Oxybutynin ER 5 mg|Taking 5 mg oxybutynin ER in the nighttime
219720114|NCT07116980|DEVICE|'Transcranial Direct Current Stimulation - tDCS|"Participants will receive by trained personnel, transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC). According to the international 10-20 EEG system, the anodal electrode will be placed over the left F3 position and the cathodal electrode over the right F4 position. Active stimulation will be delivered using a constant current of 2 milliamperes (mA) for 20 minutes per session. The intervention will consist of twelve consecutive daily sessions (Monday to Friday), totaling four week of treatment. A certified tDCS device will be used, programmed to deliver a ramp-up and ramp-down period of 30 seconds.~In the sham condition, the same electrode montage will be used; however, the device will automatically ramp down the current after 30 seconds, mimicking the initial tingling sensation without producing lasting neuromodulatory effects. This sham protocol is commonly used to ensure participant blinding in tDCS studies."
219720115|NCT07116850|DEVICE|Intermittent Theta-Burst Stimulation (iTBS)|Stimulation delivered using a Magstim RAPID2 stimulator. The target was the left DLPFC (F3 position). The protocol consisted of 20 sessions (5 days/week for 4 weeks) at 100% of the individual's motor threshold (MT), with each session delivering 2400 pulses.
219720116|NCT07116850|DRUG|Risperidone|Oral risperidone (Jiangsu Enhua Pharmaceutical Co., Ltd.) initiated at 1 mg/day and flexibly titrated based on efficacy and tolerability to a maximum of 6 mg/day.
219720117|NCT07116850|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Manualized CBT administered twice weekly for 12 weeks. The therapy comprised an initial individual phase (4 weeks) focusing on psychoeducation and a subsequent group phase (8 weeks) targeting social and emotional skills.
219720118|NCT07117565|DRUG|Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine|"Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine~Detailed Description:~This intervention consists of a single intrathecal injection of 10 micrograms of dexmedetomidine combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anaesthesia for lower limb surgery. The total volume administered is 3.5 mL. Dexmedetomidine is an alpha-2 non-opioid adjuvant used as a spinal adjuvant for enhancing analgesia"
219720119|NCT07117565|DRUG|Intervention 2: Intrathecal Fentanyl with Bupivacaine|This intervention consists of a single intrathecal injection of 25 micrograms of fentanyl combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anesthesia for lower limb surgery. The total volume administered is 3.5 mL. Fentanyl is a lipophilic opioid commonly used as a spinal adjuvant for enhancing analgesia. This arm is being compared with dexmedetomidine to evaluate differences in POUR incidence, analgesic effectiveness, and side effect profiles.
219720120|NCT07118826|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
219720121|NCT07118826|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
219720122|NCT07118423|OTHER|Exercise|The intervention group performed twice per week, nonconsecutive, resistance training over 12 weeks. The sessions consisted of 1-3 sets of eight exercises at 50-70% of the estimated one-repetition maximum.
219720123|NCT07116902|DEVICE|phone application|Participants in the digital twin arm will receive information on their disease progression which will be based on projected change in HbA1C in alternative realities and specific recommendations on medication dosing and lifestyle changes based on this data. The digital twin information will be presented on an iPad in a game- like manner. The alternate realities will include scenarios of change in medication adherence, physical activity metrics, dietary changes etc.
219720124|NCT07116902|OTHER|Standard of Care (SOC)|Participants in the control arm will receive standard of care which is medication change recommendations based on HbA1C and blood glucose values every 3 months and standard lifestyle education.
219720125|NCT07118735|DIETARY_SUPPLEMENT|A standardized extract of cultured Lentinula edodes mycelia (AHCC®)|3 grams of AHCC® taken orally once daily for 6 months or until disease progression or intolerance
219720126|NCT07118735|DIETARY_SUPPLEMENT|Placebo|3 grams of dextrin (placebo) taken orally once daily for 6 months or until disease progression or intolerance
219231713|NCT05646602|DRUG|Collagenase Clostridium Histolyticum|Intralesional injection
219231714|NCT05646602|DEVICE|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
219231715|NCT01404702|DRUG|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
219231716|NCT01404702|BIOLOGICAL|Aldesleukin|"Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
219231717|NCT00731692|DRUG|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
219231718|NCT00731692|DRUG|Placebo|Matching placebo capsules were administered orally once daily
219231719|NCT00972686|DRUG|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
219554093|NCT01698554|DRUG|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
219554094|NCT01698554|DRUG|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
219554095|NCT03453554|OTHER|Digital Notebook app|Training in use of Digital Memory Notebook app
219554096|NCT03453554|OTHER|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
219554097|NCT02694653|DRUG|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
219554098|NCT02694653|DRUG|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
219554099|NCT02042547|OTHER|Tissue samples from the right atrium|
219554100|NCT02042547|OTHER|Blood samples|
219554101|NCT00004105|DRUG|estramustine phosphate sodium|
219554102|NCT00004105|DRUG|paclitaxel|
219554103|NCT00004105|DRUG|vinorelbine ditartrate|
219554104|NCT03026153|BEHAVIORAL|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
219554105|NCT03026153|BEHAVIORAL|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
219554106|NCT03192397|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
219554107|NCT03192397|DRUG|Cyclophosphamide|Given IV
219554108|NCT03192397|DRUG|Fludarabine Phosphate|Given IV
219231720|NCT05293691|BEHAVIORAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
219554109|NCT03192397|OTHER|Laboratory Biomarker Analysis|Correlative studies
219554110|NCT03192397|DRUG|Melphalan Hydrochloride|Given IV
219554111|NCT03192397|DRUG|Mycophenolate Mofetil|Given IV
219554112|NCT03192397|DRUG|Sirolimus|Given IV and PO
219554113|NCT03192397|RADIATION|Total-Body Irradiation|Undergo TBI
219554114|NCT03715751|OTHER|ASV|Adaptive Support Ventilation
219554115|NCT03715751|OTHER|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
219554116|NCT06626854|DEVICE|RF-PNS|Noninvasive peripheral nerve stimulator using interferential multi source radio frequency
219554117|NCT06159647|BEHAVIORAL|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
219554118|NCT06159647|BEHAVIORAL|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
219554119|NCT06159647|BEHAVIORAL|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
219554120|NCT06159647|BEHAVIORAL|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
219554121|NCT06159647|BEHAVIORAL|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
219554122|NCT06159647|BEHAVIORAL|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
219554123|NCT06159647|BEHAVIORAL|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
219554124|NCT06159647|BEHAVIORAL|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
219554125|NCT06159647|BEHAVIORAL|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
219554126|NCT06159647|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
219554127|NCT06159647|BEHAVIORAL|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
219720127|NCT07119502|OTHER|Minimal-equipment progressive resistance training|The intervention consists of resistance training exercises that target major upper and lower body muscle groups with the use of portable equipment such as resistance bands and wrist/ankle weights. The exercise dosage will be progressively increased across the 16 weeks to achieve training adaptations. The exercise programme will be conducted three times per week, with each session lasting approximately 30 to 45 minutes.
219720128|NCT07114042|DIAGNOSTIC_TEST|Upper endoscopy|Prediction of upper gastrointestinal r\_bleeding and mortality
219720129|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is delivered via 6 weekly 60-min sessions via telemedicine. CBT-I is a multisession treatment approach that focuses on sleep-specific behaviors and thoughts through various methods.
218987374|NCT01696084|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
218987375|NCT01881347|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
218987376|NCT01881347|DIETARY_SUPPLEMENT|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
218987377|NCT03811028|DRUG|SOBI003|weekly i.v. infusion
218987378|NCT01244269|DRUG|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
219720130|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia and Nightmares|Cognitive Behavioral Therapy for Insomnia and Nightmares (CBT-I\&N) is a combination of CBT for Insomnia (CBT-I) and Exposure, Relaxation, and Rescripting Therapy used for the treatment of nightmares (ERRT). CBT-I\&N is delivered via 6 weekly 60-min sessions via telemedicine and includes the modification of sleep habits, exposure, and progressive muscle relaxation.
219720131|NCT07121270|BEHAVIORAL|Sleep Education|Sleep education is delivered via telemedicine via 6 weekly 60-min sessions. These sessions will be focused on psychoeducation on sleep after trauma, including common sleep disturbances that may emerge and sleep hygiene guidelines to minimize these disruptions (e.g., wind-down routine, avoid caffeine).
219720132|NCT07121270|BEHAVIORAL|Sleep Education enhanced with Nightmare Education|Sleep education enhanced with nightmare education will include all the components of normal sleep education, as described above, in addition to normalizing the experience of nightmares after trauma and providing psychoeducation on nightmares. The treatment is provided over 6 weekly 60-min sessions via telemedicine.
219720133|NCT07121075|DEVICE|Dynamic arm support|The participant will receive a new dynamic arm support.
219720134|NCT07118566|PROCEDURE|Hyperthermia|Each session of hyperthermia should be spaced at least 24 hours apart, with at least one session administered prior to ICI (immune checkpoint inhibitor) treatment. Five times q3w.
219720135|NCT07118566|DRUG|Immunotherapy|iv，d1，q3w
219720136|NCT07119463|DRUG|Human Serum Albumin Infusion for LAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 25 g/L. The infusion is goal-oriented, with the aim of maintaining albumin levels above 25 g/L during the postoperative period. The dose is calculated based on the albumin deficit and patient weight to ensure optimal therapeutic effect.
219720137|NCT07119463|DRUG|Human Serum Albumin Infusion for HAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 30 g/L. The intervention aims to maintain albumin levels above 30 g/L during the postoperative period. The dose is similarly calculated based on the albumin deficit and patient weight.
219720138|NCT07120763|DRUG|Ketamine + Lidocaine|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
219720139|NCT07120763|DRUG|Ketamine group|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
219720140|NCT07120763|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
219720141|NCT07120139|PROCEDURE|episodic use of the desensitizing toothpaste|subjects assigned to episodic treatment will use the assigned toothpaste with the same previous instructions for two 8-week treatment periods, followed by an 8-week phase in which they will use the conventional fluoride dentifrice (Signal Complete 8 Original, Unilever, Egypt), which has no documented desensitizing efficacy
219720142|NCT07120139|PROCEDURE|continuous use of the conventional desensitizing toothpaste|The patients will be instructed to use 1 inch amount of the assigned desensitizing toothpaste and soft bristle toothbrushes with the same brushing technique they will be taught in the intervention visit for 2 minutes twice a day (morning and last thing at night ) without further rinsing, only spitting of the excess material every day along the whole study period for the continuous treatment group.
219720143|NCT07123792|DRUG|Calcium Hydroxide (20%)|A 20% calcium hydroxide paste will be placed as an intracanal medicament following root canal instrumentation. Applied using a Lentulo spiral, excess is removed, and the tooth is sealed with a glass ionomer temporary restoration.
219147417|NCT05249036|PROCEDURE|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
219147418|NCT05249036|PROCEDURE|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
219147419|NCT04562259|RADIATION|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
219147420|NCT04054635|DEVICE|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
219147421|NCT05084612|DEVICE|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
219147422|NCT05084612|DEVICE|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
219147423|NCT03783754|DRUG|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
219147424|NCT03783754|DRUG|Placebo oral capsule|matched placebo
219147425|NCT03768869|DRUG|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
219147426|NCT03768869|DRUG|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
219147427|NCT03768869|DRUG|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
219147428|NCT02457117|RADIATION|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
219147429|NCT01573130|BEHAVIORAL|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
219147430|NCT05491031|OTHER|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
219147431|NCT05919017|DRUG|Naltrexone implant|Naltrexone implant
219147432|NCT05919017|DRUG|Placebo|Placebo
219147433|NCT03567369|DRUG|Dexamethasone|Dexamethasone 4,0 mg/mL
219147434|NCT03567369|DRUG|Traumeel S|Traummel S 2,2 mg/mL
219147435|NCT05296811|PROCEDURE|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
219147436|NCT05204615|OTHER|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
219147437|NCT04660214|DEVICE|septotomy|endoscopic diverticulotomy
219147438|NCT02576613|OTHER|MPP-S|\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
219147439|NCT02576613|OTHER|TAU|standard medical treatment without structured psychotherapeutic intervention
219147440|NCT02700191|DEVICE|uCor|
219147441|NCT04450199|DRUG|Vitamin D2|Vitamin D tablets
219147442|NCT04450199|OTHER|Placebo|Over encapsulated sugar pills
219720144|NCT07123792|DRUG|Chlorhexidine Gel (2%)|A 2% chlorhexidine gel will be used as an intracanal medicament following canal preparation. It will be delivered with a Lentulo spiral, cleaned from the chamber, and the tooth sealed.
219720145|NCT07123792|DRUG|Modified Triple Antibiotic Paste|A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral. The excess paste will be removed, and the cavity will be sealed with temporary restorative material.
219147443|NCT01013246|OTHER|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
219147444|NCT00891930|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
219147445|NCT00891930|BIOLOGICAL|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
219147446|NCT00891930|DRUG|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
219147447|NCT00638963|DRUG|temozolomide|Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
219147448|NCT02038868|DRUG|ASP4901|oral
219147449|NCT02038868|DRUG|Tamsulosin|oral
219147450|NCT02038868|DRUG|Placebo|oral
219147451|NCT05398965|DRUG|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
219147452|NCT05398965|DRUG|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
219147453|NCT02403596|DRUG|Exacyl®|
219147454|NCT02403596|OTHER|Placebo of Exacyl®|
219147455|NCT04688268|DRUG|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
219147456|NCT03040661|PROCEDURE|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
219147457|NCT03999866|DEVICE|airtraq|airtraq videolaryngoscope
219147458|NCT03999866|DEVICE|mcgrath mac x-blade|mcgarth mac videolaryngoscope
219147459|NCT03999866|DEVICE|storz c-mac|storz c-mac videolaryngoscope
219147460|NCT03999866|DEVICE|storz d-blade|storz d-blade video laryngoscope
219147461|NCT00889499|DRUG|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
219147462|NCT00889499|DRUG|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
219147463|NCT00889499|DRUG|Placebo|NHCL 0,9%
219147464|NCT01778283|BIOLOGICAL|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
219147465|NCT01556971|DRUG|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
219147466|NCT01556971|DRUG|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
219147467|NCT00210509|DRUG|almotriptan malate|
219147468|NCT00187941|DRUG|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
219147469|NCT00761709|DRUG|AL-39256 Ophthalmic Suspension, 1%|
219147470|NCT00761709|DRUG|Latanoprost Ophthalmic Solution, 0.005%|
219147471|NCT00761709|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
219147472|NCT05262478|DEVICE|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
219147473|NCT06363357|DEVICE|Shoulder orthosis|muscle-mimicking, fabric-type shoulder orthosis
219147474|NCT04679571|BIOLOGICAL|Albumin|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
219147475|NCT04679571|DRUG|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
219147476|NCT04191265|DIAGNOSTIC_TEST|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
219147477|NCT05007665|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
219147478|NCT01499771|DRUG|Atorvastatin|80 Mg tablets
219147479|NCT02245581|PROCEDURE|SVV-guided fluid management|
219147480|NCT02245581|PROCEDURE|CVP-guided fluid management|
219147481|NCT00860717|PROCEDURE|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
219147482|NCT00860717|RADIATION|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
219147483|NCT04154241|DIAGNOSTIC_TEST|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
219147484|NCT00823225|PROCEDURE|standard therapy|wound debridement, moist wound dressing
219147485|NCT00823225|DRUG|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU"
219147486|NCT03393377|DRUG|fluvastatin 10 mg and valsartan 20 mg|
219147487|NCT03393377|DRUG|placebo|
219147488|NCT02014766|PROCEDURE|Interscalene block|Ultrasound-guided interscalene block is performed.
219147489|NCT02014766|PROCEDURE|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
219147490|NCT06491888|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|Photoelectric detection was carried out on the subjects of the experimental group.
219147491|NCT00362869|DRUG|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
219147492|NCT00362869|DRUG|Placebo|Sodium bicarbonate solution
219147493|NCT00362869|BIOLOGICAL|Enteroaggregative E. coli (EAEC)|Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
219720146|NCT07125482|OTHER|bed exercise group|"In the first interview, demographic data and other patient information will be collected from the patient record file between 07-08 in the morning before starting bed exercise and nutrition, and the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Face Pain Scale, 'Enteral Nutrition Monitoring Form' will be filled in by the researcher before the intervention and nutrition (1st Interview).~* In the first interview, bed exercises will be applied by the researcher for approximately 15 minutes before nutrition between 07-08 in the morning (1st Interview).~* In the second interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in the morning (2nd Interview).~* In the third interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in"
219147494|NCT06108271|DEVICE|Triglotix®|The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
219147495|NCT06108271|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube that is currently used worldwide
219147496|NCT01833364|PROCEDURE|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
219147497|NCT05001945|DRUG|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
219147498|NCT05001945|OTHER|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
219147499|NCT05001945|OTHER|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
219147500|NCT05001945|DRUG|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
219147501|NCT02448446|DRUG|ranibizumab 0.3mg|intravitreally administered
219147502|NCT02201173|BEHAVIORAL|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
219147503|NCT02055794|PROCEDURE|Suturing of the perineal skin|
219147504|NCT02055794|PROCEDURE|Closing perineal skin with surgical glue|
219147505|NCT02055794|PROCEDURE|No suturing of the perineal skin|
219147506|NCT00661648|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
219147507|NCT00365157|DRUG|Eribulin Mesylate|Given IV
219147508|NCT00365157|OTHER|Laboratory Biomarker Analysis|Correlative studies
219147509|NCT00365157|OTHER|Pharmacological Study|Correlative studies
219147510|NCT02425111|DRUG|Vedolizumab|Vedolizumab intravenous injection
219147511|NCT01801410|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
219147512|NCT01801410|DRUG|Misoprostol|25mcg every 2 hours for maximum of 12 doses
219147513|NCT04332666|DRUG|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
219147514|NCT04332666|DRUG|Placebos|infusion of NaCl 0.9% without diluted peptide in it
219147515|NCT00162292|DRUG|BMS-582949 and Methotrexate|
219147516|NCT00411138|RADIATION|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
219147517|NCT00411138|DRUG|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
219147518|NCT00411138|DRUG|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
219147519|NCT00411138|DRUG|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
219147520|NCT06178978|DEVICE|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
219147521|NCT03598478|BEHAVIORAL|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
219147522|NCT03598478|BEHAVIORAL|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
219147523|NCT03598478|BEHAVIORAL|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
219554128|NCT06159647|BEHAVIORAL|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
219554129|NCT06159647|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
219554130|NCT06159647|BEHAVIORAL|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
219554131|NCT06159647|BEHAVIORAL|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
219554132|NCT06159647|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
219554133|NCT06159647|BEHAVIORAL|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
219554134|NCT02923336|DRUG|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
219554135|NCT02229084|BIOLOGICAL|P10s-PADRE/ MONTANIDE™ ISA 51 VG|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions concurrent with chemotherapy.
219554136|NCT02229084|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
219554137|NCT02229084|DRUG|Cyclophosphamide|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
219147524|NCT03009305|OTHER|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
219147525|NCT03009305|DEVICE|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
219147526|NCT03009305|DEVICE|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
219147527|NCT04283552|DEVICE|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
219147528|NCT02033148|DRUG|icotinib hydrochloride|Given PO
219147529|NCT02033148|OTHER|laboratory biomarker analysis|Correlative studies
219147530|NCT02033148|OTHER|pharmacological study|Correlative studies
219147531|NCT02756377|DRUG|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
219147532|NCT02756377|DRUG|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
219147533|NCT00545077|DRUG|Letrozole|
219147534|NCT00545077|DRUG|Bevacizumab|
219147535|NCT00545077|DRUG|Fulvestrant|
219147536|NCT04201041|PROCEDURE|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
219147537|NCT04554082|PROCEDURE|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
219147538|NCT04136470|BIOLOGICAL|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
219147539|NCT06196177|DRUG|Levosimontane injection|Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
219147540|NCT02202499|DRUG|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
219147541|NCT02202499|OTHER|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
219147542|NCT02202499|OTHER|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
219147543|NCT01240330|DEVICE|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
219147544|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
219147545|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
219147546|NCT01288326|DRUG|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
219147547|NCT02976116|DRUG|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
219147548|NCT02976116|DRUG|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
219147549|NCT00535145|DRUG|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
219147550|NCT00177086|OTHER|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
219147551|NCT03267966|DIAGNOSTIC_TEST|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
219147552|NCT03260140|BEHAVIORAL|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
219147553|NCT02304952|PROCEDURE|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
219147554|NCT02304952|OTHER|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
219147555|NCT02304952|DEVICE|Arthrocare Topaz MicroDebrider|
219147556|NCT01043458|DRUG|ABT-126|ABT-126 Low Dose \& ABT-126 High Dose
219147557|NCT01043458|DRUG|Placebo for ABT-126|Matching Placebo for Arms 1 \& 2
219147558|NCT03961906|BEHAVIORAL|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
219147559|NCT02622672|DIETARY_SUPPLEMENT|water-soluble ubiquinol|100 mg/d
219147560|NCT02622672|DIETARY_SUPPLEMENT|Placebo|glycerin.soy-lecithin, and water
219147561|NCT05372588|DRUG|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
219147562|NCT05372588|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
219147563|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
219147564|NCT05372588|DRUG|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
219147565|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
219147566|NCT04461197|DEVICE|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
219147567|NCT04461197|DEVICE|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
219147568|NCT01906788|DRUG|Artemether Lumefantrine|
219147569|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
219147570|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
219147571|NCT02929485|DRUG|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
219147572|NCT02929485|DRUG|Placebo|Placebo (200mg) administered at study visit
219147573|NCT02929485|DRUG|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
219147574|NCT03127280|OTHER|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
219147575|NCT01372761|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
219147576|NCT01372761|DRUG|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
219147577|NCT00024141|DRUG|fluorouracil|
219147578|NCT00024141|DRUG|irinotecan hydrochloride|
219147579|NCT06215053|OTHER|erector spine plane block|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
219147580|NCT02060669|DRUG|Xeloda|Xeloda
219147581|NCT00640250|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
219147582|NCT03132922|GENETIC|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
219147583|NCT03132922|RADIATION|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
219231721|NCT05293691|BEHAVIORAL|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
219231722|NCT02709265|DRUG|amikacin/fosfomycin|single aerosolized dose
219147584|NCT05133375|PROCEDURE|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
219147585|NCT06552624|DRUG|Magaldrate|A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
219231723|NCT02596178|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
219231724|NCT03332589|DRUG|E6201|E6201 formulated in cyclodextrin for IV administration.
219231725|NCT03332589|DRUG|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
219231726|NCT03990376|OTHER|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
219231727|NCT04823078|OTHER|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
219231728|NCT04823078|OTHER|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
219231729|NCT00279409|DRUG|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
219231730|NCT00279409|DRUG|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
219231731|NCT02542202|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
219231732|NCT05653609|DEVICE|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
219231733|NCT03161509|DRUG|Paracetamol|single dose of 1 gr paracetamol
219231734|NCT03161509|DRUG|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
219231735|NCT03957759|DIAGNOSTIC_TEST|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
219231736|NCT04745455|OTHER|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
219231737|NCT03627299|DRUG|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
219231738|NCT00108355|DRUG|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
219231739|NCT00108355|DRUG|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
219231740|NCT00108355|DRUG|Midodrine|Midodrine oral tablet at 10 mg three times a day.
219231741|NCT00108355|DRUG|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
219231742|NCT00108355|DRUG|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
219231743|NCT00108355|DRUG|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
219231744|NCT00108355|PROCEDURE|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
219554138|NCT02229084|DRUG|Docetaxel|"Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.~If docetaxel is not tolerated, paclitaxel (175mg/m2) may be used in its place."
219554139|NCT00414479|DRUG|praziquantl, iron, ACT|
219554140|NCT05290519|OTHER|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
219554141|NCT02774018|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) program|
219554142|NCT02809196|BEHAVIORAL|1: Tailored SMS program implicating friend and mother|
219554143|NCT02809196|BEHAVIORAL|2: Standardized SMS program implicating friend and mother|
219231745|NCT00674037|OTHER|monetary incentive|75 euros for each patient included
219231746|NCT04529824|DEVICE|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
219554144|NCT02809196|BEHAVIORAL|3: Tailored SMS program implicating friend, not mother|
219554145|NCT02809196|BEHAVIORAL|4: Standardized SMS program implicating friend, not mother|
219554146|NCT02809196|BEHAVIORAL|5: Tailored SMS program implicating mother, not friend|
219554147|NCT02809196|BEHAVIORAL|6: Standardized SMS program implicating mother, not friend|
219554148|NCT02809196|BEHAVIORAL|7: Tailored SMS program not implicating mother or friend|
219554149|NCT02809196|BEHAVIORAL|8: Standardized SMS program not implicating mother or friend|
219554150|NCT02809196|BEHAVIORAL|9: No SMS program|
219147586|NCT06552624|DRUG|Magaldrate|A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
219147587|NCT04949581|OTHER|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
219147588|NCT04949581|OTHER|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
219147589|NCT04957069|PROCEDURE|fixation|double row fixation with 3-4 wire anchors
219147590|NCT04957069|PROCEDURE|primary repair|end-to-end repair
219147591|NCT00176371|BEHAVIORAL|physical exercise|
219147592|NCT02324010|DRUG|Sitagliptin|100mg mane for 2 days
219147593|NCT02324010|DRUG|Placebo|Inactive drug (Placebo)
219147594|NCT00678912|DEVICE|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
219147595|NCT06554041|DEVICE|Dental Crown with Titanium-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
219147596|NCT06554041|DEVICE|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
219147597|NCT06554041|DEVICE|Dental Crown with Zirconia-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
219231747|NCT06046807|OTHER|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
219231748|NCT02915003|BEHAVIORAL|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
219231749|NCT06060847|PROCEDURE|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
219231750|NCT06060847|PROCEDURE|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
219147598|NCT06554041|DEVICE|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
219231751|NCT06102278|OTHER|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
219231752|NCT03833765|PROCEDURE|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
219231753|NCT03833765|PROCEDURE|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
219231754|NCT02757456|BEHAVIORAL|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
219231755|NCT02757456|OTHER|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
219554151|NCT04244643|OTHER|data collection|"Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
219554152|NCT01096641|BEHAVIORAL|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
219554153|NCT01096641|BEHAVIORAL|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
219147599|NCT01480505|PROCEDURE|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
219231756|NCT01718223|DRUG|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
219231757|NCT01718223|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219147600|NCT00107796|DRUG|Modafinil|
219231758|NCT01718223|OTHER|laboratory biomarker analysis|Correlative studies
219231759|NCT01718223|DRUG|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
219231760|NCT04669366|DRUG|sunitinib|As provided in real world
219231761|NCT04669366|DRUG|axitinib|As provided in real world
219231762|NCT02239991|PROCEDURE|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
219231763|NCT02474004|PROCEDURE|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
219231764|NCT00680134|DRUG|AN2690|AN2690 1% Solution, once daily for 180 days
219231765|NCT00680134|DRUG|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
219231766|NCT02301507|BEHAVIORAL|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
219720147|NCT07125482|OTHER|abdominal massage|"* In the first interview, between 07-08 in the morning, demographic data and other information about the patients will be collected from the patient record file before the intervention and feeding by the researcher using the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form' (Interview 1).~* In the first interview, between 07-08 in the morning, abdominal massage will be applied to the patient by the researcher for approximately 15 minutes before feeding (Interview 1).~* In the second interview, between 07-08 in the morning, abdominal massage will be repeated for approximately 15 minutes by filling out the 'Enteral Feeding Monitoring Form' before feeding and abdominal massage will be repeated (Interview 2).~* In the third interview, between 07-08 in the morning, the 'Enteral Nutrition Monitoring Form' will be filled out before abdominal massage and feeding, and the abdominal massage will be repeated for approxim"
219720148|NCT07125482|OTHER|control group|"In the first interview, between 07-08 am, demographic data and other patient information will be collected from the patient record file before feeding, using the Patient Information Form and the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form', before the intervention and feeding (Interview 1).~* In the second interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 2).~* In the third interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 3).~* In the fourth interview, between 07-08 in the morning, data will be collected with the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale and 'Enteral Feeding Monitoring Form' before feeding (Interview 4)."
219720149|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
219720150|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
219147601|NCT04206098|OTHER|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
219231767|NCT00488605|DRUG|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
219231768|NCT00488605|DRUG|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
219231769|NCT02002689|DRUG|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
219147602|NCT00002380|DRUG|Nelfinavir mesylate|
219147603|NCT00002380|DRUG|Saquinavir|
219720151|NCT07125313|BEHAVIORAL|YOGA|The participants randomized to the yoga group will perform 16 weeks of yoga training, three times/week for 60 minutes.
219720152|NCT07125313|BEHAVIORAL|Control|Usual care
219720153|NCT07124819|DRUG|Sodium enoxaparin|"Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
219720154|NCT07124819|DRUG|Dimolegin|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 1B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days."
219720155|NCT07124819|DRUG|Dimolegin placebo|Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days. Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days.
219720156|NCT07124819|DRUG|Sodium enoxaparine placebo|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive palcebo Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
219720157|NCT06748547|PROCEDURE|scalp nerve block|scalp nerve block is performed bilaterally by an anesthesiologist after induction of anesthesia and 5 minutes before head immobilization, according to the technique described by Pinosky et al. Prepare a syringe (20 mL) for scalp blocks. It is performed using 0.35% bupivacaine and 5 mcg epinephrine (1:2,000,000) using a 23-gauge needle inserted at a 45° angle to the skin and penetrating deeply into the outer edge of the scalp.
219720158|NCT04377295|DRUG|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
219720159|NCT06514131|PROCEDURE|Pre-moistened wipes|Patients receiving the experimental treatment will have perineal hygiene performed with the pre-moistened wipes without water
219720160|NCT07115615|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
219720161|NCT07115615|DEVICE|Sham tDCS|To demonstrate the same stimulation sensation as under real conditions, only 40 seconds of real stimulation (2mA) are given at the beginning of the treatment. In the remaining 20 minutes, only about 15ms of short current pulses of 110uA occur every 550ms.
219720162|NCT07125196|OTHER|Data collection and self-administered questionnaire|Exhaustive collection of data in a health data warehouse: collection of clinical, radiological examinations (standard of care), and self-administered questionnaire: a questionnaire concerning the psychological state of the patients (questionnaire according to DSM V) and a questionnaire on nutritional status.
219720163|NCT07085702|BIOLOGICAL|Low dose Strep A Alum|Low dose Strep A Alum vaccine will be administered intramuscularly (IM)
219720164|NCT07085702|BIOLOGICAL|Medium dose Strep A Alum|Medium dose Strep A Alum vaccine will be administered IM
219720165|NCT07085702|BIOLOGICAL|High dose Strep A Alum|High dose Strep A Alum vaccine will be administered IM
219720166|NCT07085702|BIOLOGICAL|Low dose Strep A AS37|Low dose Strep A AS37 vaccine will be administered IM
219720167|NCT07085702|BIOLOGICAL|Medium dose Strep A AS37|Medium dose Strep A AS37 vaccine will be administered IM
219720168|NCT07085702|BIOLOGICAL|High dose Strep A AS37|High dose Strep A AS37 vaccine will be administered IM
219720169|NCT07085702|DRUG|Strep A Alum Placebo|Strep A Alum Placebo will be administered IM
219720170|NCT06905067|OTHER|questionnaire and dental clinical examination|Assessment of the DMFT index
219720171|NCT07091578|BEHAVIORAL|Supervised toothbrushing|In supervised toothbrushing intervention, dental hygienists trained school staff, obtained consent forms, distributed the oral hygiene kits, and provided support and advice if needed. Teachers' training included guidelines for infection prevention and control, and toothbrushing in dry areas adapted from the Public Health England (PHD) toothbrushing programme toolkit. A dry toothbrushing model was employed. Toothbrushing sessions took place daily during regular school hours for one academic year. Each session lasted for approximately 10 minutes and occured after break time at 9:20 am. Oral hygiene kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were disseminated every three months. Teachers and dental hygienists provided monthly oral health educational sessions to students during regular school time.
219720172|NCT07091578|BEHAVIORAL|Oral Health Education|In oral health education intervention, dental hygienists and school staff collaborated to educate students about oral health. Dental hygienists trained school staff to deliver this programme effectively and offer continued support and guidance to school staff during the programme implementation. An oral health education toolkit partly adapted from the PHE toothbrushing programme toolkit was provided to the school before the start of the programme. Educational materials including lectures, leaflets, and activities were dispensed monthly. Oral health education was conducted once a month during regular school hours in the classroom, and each session lasted for one hour. Students were provided with comprehensive knowledge about oral health, such as proper toothbrushing techniques, the importance of routine dental check-ups, and healthy nutrition. Moreover, toothbrushing kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were distributed every three months.
219720173|NCT07090863|DEVICE|AM manufacturing method|additively manufactured implant-supported prostheses
219720174|NCT07090863|DEVICE|SM manufacturing method|subtractively manufactured implant-supported prostheses
219720175|NCT06909110|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
219720176|NCT06909110|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
219720177|NCT06909110|BIOLOGICAL|Epstein-Barr Virus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
219720178|NCT06901687|DEVICE|Active tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
219720179|NCT06901687|DEVICE|Sham tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Sham tDCS (or placebo) the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30-s) and down (for 30-s) at the end.
219720180|NCT06332560|BEHAVIORAL|Anti-inflammatory diet (DI)|12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
219147604|NCT05167877|OTHER|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
219720181|NCT06332560|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
219720182|NCT07090811|DEVICE|Aortic valve repair/replacement|TAVR or valvuloplasty using the Fusion System for delivery of the treatment system and for temporary rapid pacing
219720183|NCT06864273|BEHAVIORAL|Pharmacy Technician Educational Training|Pharmacy Technicians will participate in a stepped-wedge educational training program. The first step will be a control condition where they will receive no training, the second step will include viewing online modules, the third step will include online discussions, and the fourth step will include practical experiences with adults with bilateral hearing loss. Pre-training quizzes and surveys will be completed before and after each step.
219147605|NCT00002072|DRUG|Epoetin alfa|
219720184|NCT06825702|DRUG|KIO-104|KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
219720185|NCT06909565|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
219720186|NCT06909565|DRUG|Normal Saline (Placebo)|Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
219720187|NCT07100366|BEHAVIORAL|ChatGPT|Phase 3:In Experimental Group 1, participants will be invited to use the ICT app, which they are encouraged to engage with for at least 15 minutes daily. This app is designed to actively monitor the users' emotional status and automatically notify both the research team and family members if any negative mood is detected.
219720188|NCT07100366|BEHAVIORAL|community social|Phase 3:In Experimental Group 2, participants will be encouraged to increase their social participation through community-based activities, while the Control Group will continue with their routine lifestyle.
219147606|NCT05458817|OTHER|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
219231770|NCT02169609|DRUG|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
219720189|NCT07104240|OTHER|Best Practice|Offer standard of care adolescent vaccination promotion practices
219720190|NCT07104240|OTHER|Educational Intervention|Receive vaccination information
219720191|NCT07104240|OTHER|Health Promotion and Education|Receive all TweenVax components and trainings for the practice, providers and staff, parents and adolescents
219720192|NCT07104240|OTHER|Health Promotion and Education|Receive components and trainings for the practice and provider levels
219231771|NCT04524676|PROCEDURE|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
219554154|NCT00106106|PROCEDURE|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
219554155|NCT00106106|DRUG|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
219554156|NCT04417348|DRUG|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
219554157|NCT01874041|OTHER|Massage|
219554158|NCT01874041|OTHER|Occlusal splint|
219554159|NCT00746486|DRUG|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
219554160|NCT00746486|DRUG|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
219554161|NCT00630253|BIOLOGICAL|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
219720193|NCT07104240|OTHER|Internet-Based Intervention|Receive access to TweenVax application
219720194|NCT07104084|DEVICE|lavage chlorhexidine|Patient will receive a chlorhexidine lavage for 3 minutes following total hip component placement followed by saline lavage.
219720195|NCT07104084|DEVICE|lavage povidone-iodine|Patient will receive povidone-iodine lavage for 3 minutes following total hip component placement followed by saline lavage.
219720196|NCT07104981|PROCEDURE|Mesenchymal Stem Cell Transplantation|intraoperative infiltration of micronized adipose tissue obtained using the Matrigen system.
219720197|NCT07105189|DEVICE|Wireless monitoring|"Patients included in the study will be continuous monitored by CPC12S is a wearable sensor that is worn on the chest using electrodes measuring electrocardiography single lead (ECG), Heart rate, respiratory rate, SpO2, blood pressure and temperature.~The system calculates the heart rate by analysing R-peaks of QRS-complexes in the raw ECG data.~Respiratory rate is recorded using impedance pneumography. SpO2 is determined by analysing the photoplethysmogram (PPG) wave. Blood pressure is derived by calculating the pulse transit time (PTT) using R-peaks from the QRS complexes, peaks in the photoplethysmogram (PPG) pulse waves, and timing of the second heart-tone corresponding to the dicrotic notch, measured by a stethoscope in the device.~Temperature is measured by a thermistor placed in the axilla. Vital signs are updated every 20 seconds and measurements are transmitted via Bluetooth to an Android cell phone that is uploading the data via WIFI to a secured server."
219231772|NCT04330612|OTHER|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
219554162|NCT00630253|DRUG|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
219147607|NCT01595802|DEVICE|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
219147608|NCT01595802|DEVICE|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
219554163|NCT00630253|DRUG|Fludarabine|35 mg/m\^2 intravenously (IV) on days -6 through -2.
219147609|NCT04906161|DIAGNOSTIC_TEST|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
219231773|NCT01169402|DRUG|Fluconazole|25mg/kg intravenously once weekly while on ECMO
219554164|NCT00630253|PROCEDURE|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
219147610|NCT00322920|DRUG|Topotecan|
219147611|NCT00322920|DRUG|Cisplatin|
219231774|NCT01626833|DRUG|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
219554165|NCT00630253|DRUG|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
219554166|NCT00630253|DRUG|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
219554167|NCT00630253|DRUG|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
219554168|NCT00630253|DRUG|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
219554169|NCT01328782|DRUG|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
219147612|NCT02436213|OTHER|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
219147613|NCT02436213|PROCEDURE|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
219147614|NCT02367924|DRUG|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
219147615|NCT04212195|GENETIC|Next generation sequencing|Saliva samples
219147616|NCT04212195|DIAGNOSTIC_TEST|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
219147617|NCT00592813|BEHAVIORAL|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
219147618|NCT00592813|BEHAVIORAL|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
219231775|NCT01626833|BIOLOGICAL|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
219231776|NCT01377844|DRUG|EGT0001442|
219554170|NCT01328782|DRUG|Bupivacaine 0.25%|"* Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
219554171|NCT01328782|DRUG|Ropivacaine 0.20%|"* Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
219554172|NCT02135991|BEHAVIORAL|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
219554173|NCT02135991|BEHAVIORAL|Project CHOICE|Sites will receive standard training for Project CHOICE.
219554174|NCT04535986|DRUG|Ensifentrine|Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
219554175|NCT04535986|DRUG|Placebo|Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
219554176|NCT02964663|DEVICE|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
219554177|NCT03210363|OTHER|Human Biological samples|Blood sample
219554178|NCT00905541|DRUG|simvastatin|40 mg/day
219554179|NCT00905541|DRUG|simvastatin|80 mg simvastatin acute-on-chronic
219554180|NCT04174118|DRUG|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
219554181|NCT04174118|DRUG|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
219554182|NCT03066479|DEVICE|Fitbit|Wearable activity \& sleep tracker.
219554183|NCT03066479|OTHER|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
219554184|NCT03066479|DIAGNOSTIC_TEST|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
219554185|NCT03347019|OTHER|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
219554186|NCT03347019|OTHER|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
219554187|NCT02004769|DRUG|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
219554188|NCT02004769|DRUG|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
219554189|NCT02004769|DRUG|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
219554190|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
219554191|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
219231777|NCT01377844|DRUG|Placebo|
219554192|NCT05303649|BEHAVIORAL|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
219720198|NCT07098273|DEVICE|TMS and FES- based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the hand area of the primary motor cortex will be stimulated using active rTMS. The rTMS protocol will use intermittent theta burst stimulation (iTBS), which delivers bursts of 3 pulses at 50 Hz every 200 ms (5 Hz) for 2 seconds, followed by 8 seconds of rest, totaling 600 pulses in \~3 minutes. The hand area will be identified as the optimal site for eliciting a motor evoked potential (MEP) in the abductor digiti minimi (ADM) muscle, contralateral to the dominant limb, with the lowest possible stimulation intensity.~Subsequently, FES will be applied to assist the subject's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
219720199|NCT07098273|DEVICE|FES-based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the TMS coil will be positioned over the hand areas of the primary motor cortex, but tilted away from the scalp so as to produce a sound similar to the real intervention, but at a low intensity, without inducing current in the cortex.~FES will then be applied to assist the patient's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
219720200|NCT07104565|DRUG|INCA000585|Tafasitamab will be administered intravenously at protocol defined timepoints.
219720201|NCT07104786|DRUG|Obeticholic Acid 10 MG|10mg OCA was given once daily for 6 months
219720202|NCT07104786|DIETARY_SUPPLEMENT|Vitamin E 400mg|Vitamin E 400mg was given twice daily for 6 months
219554193|NCT05303649|DEVICE|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
219554194|NCT01223755|DRUG|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
218987379|NCT01244269|DRUG|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
218987380|NCT01244269|DRUG|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
218987381|NCT01244269|DRUG|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
218987382|NCT00560105|DEVICE|Lung Flute|8 weeks home use, twice daily
218987383|NCT00560105|DEVICE|Acapella|8 weeks home use, twice daily
218987384|NCT01581788|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
218987385|NCT04407364|DEVICE|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
218987386|NCT01810874|PROCEDURE|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
218987387|NCT01810874|PROCEDURE|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
218987388|NCT01542125|DRUG|Liposomal Lidocaine|4% Liposomal Lidocaine
218987389|NCT01542125|DRUG|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
218987390|NCT02927665|DEVICE|Reshape Integrated Dual Balloon|
218987391|NCT00071097|DRUG|TMC114/rtv|800mg TMC114/100mg rtv once daily
218987392|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
218987393|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv once daily
218987394|NCT00071097|DRUG|TMC114/rtv|600mg TMC114/100mg rtv twice daily
218987395|NCT05860478|DEVICE|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
219231778|NCT01928732|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
219720204|NCT07106398|DEVICE|repetitive transcranial magnetic stimulation|"Six sessions of rTMS using the EXOMIND™ device, administered once or twice a week.~Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds.~The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in the research centre with medical staff supported."
219720205|NCT06826599|DEVICE|Investigational Biometer|Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and measurement of anterior segment and biometric parameters
219720206|NCT06826599|DEVICE|IOLMaster 700 Biometer|Commercially available non-contact instrument used to capture optical biometry measurements
219720207|NCT07107802|DRUG|ATX101|Single intravenous dose
219720208|NCT07107802|DRUG|Placebo|Single intravenous dose
219720209|NCT06911177|DIETARY_SUPPLEMENT|Yeast mannan|Yeast cell wall fraction of manno-oligosaccharides and mannoproteins supplemented at 12 g/day.
219720210|NCT06911177|DIETARY_SUPPLEMENT|Control (placebo)|A supplement containing yeast protein, yeast extract, and maltodextrin, provided at 12 g/day.
219720211|NCT07105137|BEHAVIORAL|AI-GNW|This is a three-day writing intervention. Each session lasts 20 minutes. On the first day, participants in both GNW conditions will recount a negative experience and reflect on their thoughts and feelings; on the second day, they will focus exclusively on the negative aspects of that experience; and on the third day, they will explore its positive dimensions. AI-GNW participants would receive AI-generated feedback.
219720212|NCT07105137|BEHAVIORAL|NF-GNW|guided narrative writing without feedbacks
219720213|NCT07105137|BEHAVIORAL|NWG|In contrast, NWG participants will objectively document their previous day's daily routine.
218987396|NCT00957970|DEVICE|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
218987397|NCT00957970|DEVICE|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
218987398|NCT04511546|DEVICE|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
218987399|NCT04250220|DIAGNOSTIC_TEST|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
218987400|NCT01012271|OTHER|MRI|MR arthrography is used to evaluate wrist abnormalities
218987401|NCT00261144|DRUG|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
218987402|NCT00261144|BIOLOGICAL|Biological|Collagenase injection
218987403|NCT00304291|DRUG|Mitoxantrone|
218987404|NCT03090802|BEHAVIORAL|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
218987405|NCT05338593|OTHER|Outcome|Mortality rate of prolonged therapy.
218987406|NCT00948701|BEHAVIORAL|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
218987407|NCT01152710|DRUG|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
218987408|NCT01661621|DRUG|Detrusitol 4 mg QD|Group 1
218987409|NCT01661621|DRUG|Doxazosin 4 mg QD|Group 2
218987410|NCT03663816|DEVICE|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
218987411|NCT01155232|DRUG|Teriparatide|Forteo (teriparatide)pen daily for 24 months
218987412|NCT00027261|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
218987413|NCT00763568|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
218987414|NCT00763568|BIOLOGICAL|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
218987415|NCT05504564|GENETIC|The experiment does not required any intervention|The experiment does not required any intervention
218987416|NCT04157439|OTHER|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
219147619|NCT05654467|BIOLOGICAL|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
219147620|NCT05654467|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
219147621|NCT01854229|DEVICE|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
219147622|NCT03423277|DEVICE|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
219147623|NCT04676321|OTHER|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
219147624|NCT00424645|DRUG|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
219147625|NCT00424645|DRUG|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
219147626|NCT01622413|PROCEDURE|joimax TESSYS|Transforaminal Endoscopic Surgery System
219147627|NCT01622413|PROCEDURE|Microdiscectomy|Standard procedure for disc surgery
219147628|NCT03148600|BEHAVIORAL|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
219147629|NCT03148600|OTHER|Standard arm|Standard medical and nursing care
219147630|NCT03806348|PROCEDURE|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
219147631|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
219147632|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
219147633|NCT06190522|DIAGNOSTIC_TEST|Emergency physician clinical ultrasound|Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
219147634|NCT00368186|BIOLOGICAL|Pneumo 23|
219147635|NCT04476810|DEVICE|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
219231779|NCT01928732|BEHAVIORAL|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
219231780|NCT01185340|DRUG|LY2216684|
219231781|NCT01185340|DRUG|Placebo|
219554195|NCT01223755|DRUG|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
219554196|NCT05625607|PROCEDURE|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
219554197|NCT00456898|DRUG|desvenlafaxine sustained release (DVS SR)|
219554198|NCT00456898|DRUG|Paroxetine|
219554199|NCT00456898|DRUG|Codeine|
219554200|NCT02284139|DRUG|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
219554201|NCT02284139|DRUG|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
219554202|NCT02284139|DRUG|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
219554203|NCT06083623|BIOLOGICAL|TNM001|single dose intramuscular injection
219231782|NCT01185340|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
219231783|NCT00009763|BIOLOGICAL|filgrastim|
219554204|NCT06083623|BIOLOGICAL|placebo|single dose intramuscular injection
219554205|NCT03256149|DRUG|Dexamethasone|
219554206|NCT03256149|DRUG|Placebo|Normal saline (IV placebo)
219554207|NCT05086653|PROCEDURE|Surgery|Sutured by Prolene 3-0 with two layers of pledge
219554208|NCT01257451|DRUG|Vildagliptin|vildagliptin 50mg bid
219554209|NCT01257451|DRUG|Placebo|Placebo 50mg bid
219554210|NCT02725996|BIOLOGICAL|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
219554211|NCT02725996|OTHER|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
219554212|NCT04566497|OTHER|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
219554213|NCT04566497|PROCEDURE|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
219554214|NCT00939380|BEHAVIORAL|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
219554215|NCT00939380|OTHER|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
219554216|NCT00939380|OTHER|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
219554217|NCT00939380|OTHER|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
219554218|NCT01861990|DRUG|Valproic Acid|All participants enrolled on valproic acid arm.
219554219|NCT05901116|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
219554220|NCT00522223|BEHAVIORAL|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
219554221|NCT02179190|DEVICE|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
219554222|NCT05757609|DEVICE|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
219554223|NCT05757609|DEVICE|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
219554224|NCT00004906|BIOLOGICAL|filgrastim|
219554225|NCT00004906|DRUG|anastrozole|
219554226|NCT00004906|DRUG|carboplatin|
219554227|NCT00004906|DRUG|cisplatin|
219554228|NCT00004906|DRUG|cyclophosphamide|
219554229|NCT00004906|DRUG|docetaxel|
219554230|NCT00004906|DRUG|doxorubicin hydrochloride|
219554231|NCT00004906|DRUG|etoposide|
219554232|NCT00004906|DRUG|pamidronate disodium|
219554233|NCT00004906|DRUG|thiotepa|
219554234|NCT00004906|PROCEDURE|peripheral blood stem cell transplantation|
219554235|NCT01552330|DRUG|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
219554236|NCT01552330|DRUG|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
219554237|NCT03213548|PROCEDURE|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
219554238|NCT03213548|PROCEDURE|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
219231784|NCT00009763|BIOLOGICAL|monoclonal antibody m170|
219231785|NCT00009763|DRUG|cyclosporine|
219231786|NCT00009763|DRUG|paclitaxel|
219554239|NCT03937206|DIETARY_SUPPLEMENT|NutriterraTM|Nutriterra 1000mg
219554240|NCT03937206|DIETARY_SUPPLEMENT|Placebo|Corn Oil 1000mg
219554241|NCT06220526|DEVICE|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Transbronchial biopsy with Menghini-type or Franseen type Needle
219554242|NCT04809844|OTHER|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
219720214|NCT07104682|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, a myc sequence for product identification, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. After infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance
219720215|NCT07113327|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Staging and Grading for Diagnosis of Periodontitis|A deep learning diagnostic model (using DenseNet and VGG16 architectures) was applied to panoramic radiographs of 47 patients to classify the stage and grade of periodontitis. The model was trained on an external dataset and validated against expert-labeled outcomes. The purpose was to assess the accuracy of AI in replicating clinician-level diagnosis based on the 2017 classification system of periodontitis.
219720216|NCT07103187|PROCEDURE|Zygomatico-Orbital reconstruction|Zygomatico-Orbital reconstruction was done by ORIF for the zygomatic complex fractures at multiple suture lines by mini plates and screws. Orbital floor reconstruction was done mainly by using a prebent titanium mesh on a 3D printed model.
219720217|NCT07114562|DEVICE|Epicare|All participants will receive treatment with the Epicare fractional nano-thulium (Tm:YAP, 1938 nm) laser device for the reduction of periorbital wrinkles.
219720218|NCT07116668|DEVICE|Colovac Anastomosis Protection Device placement following low anterior resection of colon cancer|Subjects in the Investigational cohort (SAFE-3CV) will undergo an LAR procedure followed by Colovac placement. Colovac retrieval will then occur at \~10 days post LAR procedure.
219720219|NCT07114224|DIAGNOSTIC_TEST|AV45/AV-1、AV1451 PET|"Use PET equipment to collect multimodal imaging data. Sixty to ninety minutes after intravenous injection of 3.7 MBq/kg of 18F-AV45 or 18F-AV1, perform PET imaging in list mode to simultaneously collect structural and functional information under the same pathophysiological conditions.~The next day, perform 18F-AV1451 PET imaging to obtain tau protein distribution information."
219720220|NCT07118501|DEVICE|Total Ankle Replacement|Incompass™ Total Ankle System
219720221|NCT07118410|DEVICE|Application of a vascular restriction device during resistance training|"In the BFR-RT group, sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases.~In the control group (RT group) it will be the same intervention with same intensities but without using BFR."
219720222|NCT07117305|DRUG|CD7 CAR-T combined with autologous hematopoietic stem cell transplantation|"Phase I adopts a standard 3+3 dose-escalation design (with exploratory doses of 1×10⁶, 2×10⁶, and 2.5×10⁶ CAR⁺ cells/kg) to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase II expands at the RP2D to further assess efficacy.~During screening, eligible patients will be identified and consented. In the collection phase, patients undergo two separate apheresis procedures: G-CSF-mobilized peripheral blood stem cell collection for ASCT and PBMC collection for CAR-T manufacturing. Bridging therapy and gut preparation may be performed. The pretreatment phase(recommended: BEAM therapy) starts from Day -8. Investigators may adjust the pretreatment regimen based on the patient's performance. On Day 0, autologous stem cells are infused. CD7 CAR-T cells are infused on Days 2-7 post-transplant. Follow-up visits occur on Days 10, 14, 21, 28, and Months 2, 3, 6, and 12."
219720223|NCT07116824|DRUG|HB1801|HB1801 is administered by intravenous infusion.
219720224|NCT07116824|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.
219720225|NCT07116824|DRUG|Pertuzumab|Pertuzumab is administered by intravenous infusion, 840mg loading dose and then 420mg per cycle, Q3W.
219720226|NCT07116824|DRUG|Docetaxel|Docetaxel is administered by intravenous infusion, 75mg/m\^2, Q3W.
219720227|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
219147636|NCT04236973|DEVICE|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
219147637|NCT04236973|OTHER|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
219147638|NCT02697201|DRUG|Intralipid|0.55 ml/kg/h
219231787|NCT00009763|PROCEDURE|peripheral blood stem cell transplantation|
219147639|NCT02697201|DRUG|Saline|0.55 ml/kg/h for
219147640|NCT04082611|BEHAVIORAL|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
219231788|NCT00009763|RADIATION|yttrium Y 90 monoclonal antibody m170|
219231789|NCT00087516|DRUG|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
219231790|NCT00087516|DRUG|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
219231791|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
219231792|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
219231793|NCT00087516|DRUG|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
219147641|NCT04082611|BEHAVIORAL|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
219147642|NCT01820182|DEVICE|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
219720228|NCT07104669|OTHER|diet|diet adherence
219147643|NCT06175572|DEVICE|coronary physiological indices|coronary physiological indices
219147644|NCT00857545|OTHER|Laboratory Biomarker Analysis|Correlative studies
219147645|NCT00857545|BIOLOGICAL|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
219147646|NCT00857545|BIOLOGICAL|Saponin-based Immunoadjuvant OBI-821|Given SC
219147647|NCT00959946|DRUG|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
219147648|NCT00959946|DRUG|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
219147649|NCT05288868|OTHER|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
219147650|NCT02348658|DRUG|TAK-536TCH|TAK-536TCH tablets
219147651|NCT02308618|OTHER|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
219147652|NCT02308618|OTHER|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
219147653|NCT01320215|PROCEDURE|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
219147654|NCT01320215|PROCEDURE|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
219147655|NCT06554353|DEVICE|Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
219147656|NCT06178588|PROCEDURE|Biopsy|Undergo tumor biopsy
219231794|NCT00612521|DRUG|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
219231795|NCT00972036|DEVICE|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
219720229|NCT07104669|OTHER|Physical activity|Physical activity level
219720230|NCT07104669|OTHER|body composition|body composition assessment
219720231|NCT07104669|OTHER|hydration status|hydration status assessment
219147657|NCT06178588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219147658|NCT06178588|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219147659|NCT06178588|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219147660|NCT06178588|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219720232|NCT07104669|OTHER|health status|perception of health status
219147661|NCT06178588|BIOLOGICAL|Sacituzumab Govitecan|Given IV
219147662|NCT02284412|DRUG|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
219147663|NCT02284412|DRUG|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
219720233|NCT07120984|BIOLOGICAL|L19TNF|1 cycle of TNF before resection and 6 cycles after surgery
219720234|NCT07120984|BIOLOGICAL|L19TNF and TMZ|6 cycles of 28 days with L19TNF and TMZ
219720235|NCT07120984|BIOLOGICAL|L19TNF and CCNU|6 cycles of 6 weeks of L19TNF and CCNU every 6 weeks
219720236|NCT07120984|BIOLOGICAL|L19TNF monotherapy|6 cycles of 6 weeks with L19TNF
219720237|NCT07120984|BIOLOGICAL|L19TNF and TMZ in recurrent astrocytoma|6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).
219720238|NCT07120984|BIOLOGICAL|L19TNF and CCNU in recurrent astrocytoma|6 cycles of 6 weeks of L19TNF (D1, D3, D5, D22, D24 and D26) and CCNU (D1) every 6 weeks
219147664|NCT02284412|DRUG|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
219147665|NCT05855291|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
219147666|NCT05990894|DRUG|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
219147667|NCT03614611|DEVICE|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
219147668|NCT05232630|DRUG|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
219147669|NCT06969495|OTHER|xLr oral gel|25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative.
219147670|NCT06969495|OTHER|Placebo|oral gel base formulation without the Lignosus rhinocerus extract
219147671|NCT06969495|DRUG|Kanolone|Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%)
219147672|NCT05482399|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
219147673|NCT00658996|DEVICE|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
219554243|NCT05414695|DEVICE|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
219147674|NCT00658996|DEVICE|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
219147675|NCT00206375|DRUG|Growth hormone|Growth hormone + Synthroid + Lupron
219147676|NCT00206375|DRUG|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
219147677|NCT04145492|DRUG|Vitamin K2|Patients will take 90 ug of vitamin K2
219147678|NCT04145492|DRUG|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
219147679|NCT04145492|DRUG|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
219147680|NCT04988451|BEHAVIORAL|ASL Services|ASL specialist meets with participants and provides ASL instruction
219147681|NCT05503251|OTHER|Best Practice|Receive usual care
219147682|NCT05503251|BEHAVIORAL|Neuropsychological Assessment|Undergo neuropsychological evaluation
219147683|NCT05503251|OTHER|Quality-of-Life Assessment|Ancillary studies
219147684|NCT05503251|OTHER|Questionnaire Administration|Ancillary studies
219147685|NCT06238063|BEHAVIORAL|Nurse-led Advance Care Planning (ACP) Intervention|An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
219147686|NCT01547741|DRUG|Doxorubicin|
219147687|NCT01547741|DRUG|Cyclophosphamide|
219147688|NCT01547741|DRUG|Docetaxel|
219554244|NCT05414695|DEVICE|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
219147689|NCT01547741|DRUG|Paclitaxel|
219147690|NCT00466076|DRUG|Copaxone (Glatiramer acetate)|
219147691|NCT00605904|DRUG|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
219147692|NCT00605904|DRUG|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
219147693|NCT00605904|DRUG|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
219147694|NCT00605904|DRUG|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
219147695|NCT02619266|OTHER|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
219554245|NCT05983523|DRUG|PEP07|PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
219554246|NCT03506841|DRUG|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
219554247|NCT00384592|DRUG|Esomeprazole|
219147696|NCT02619266|OTHER|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
219147697|NCT02619266|DRUG|Megestrol Acetate|Megestrol Acetate 160mg tablet
219147698|NCT02619266|DRUG|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
219147699|NCT03505099|BIOLOGICAL|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
219554248|NCT00384592|PROCEDURE|Physical exam|
219554249|NCT00384592|PROCEDURE|Pregnancy test if applicable|
219231796|NCT05304221|OTHER|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
219231797|NCT02638558|OTHER|written + oral explanation|
219147700|NCT00290849|DRUG|Bivalirudin|
219147701|NCT04178941|BEHAVIORAL|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
219231798|NCT02638558|OTHER|written explanation|
219231799|NCT02065895|DEVICE|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
219231800|NCT02065895|DEVICE|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
219231801|NCT02065895|DEVICE|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
219231802|NCT01093690|DRUG|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
219231803|NCT01093690|DRUG|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
219231804|NCT01959776|PROCEDURE|Vitrectomy|
219231805|NCT03811665|PROCEDURE|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
219231806|NCT03811665|RADIATION|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
219231807|NCT01229904|BEHAVIORAL|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
219231808|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
219147702|NCT04178941|BEHAVIORAL|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
219231809|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
219147703|NCT03161392|DIAGNOSTIC_TEST|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
219231810|NCT01049516|BEHAVIORAL|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
219231811|NCT01049516|BEHAVIORAL|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
219554250|NCT03504020|DEVICE|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
219554251|NCT01323062|DRUG|Bavituximab|Administered 3 mg/kg weekly
219554252|NCT04288076|OTHER|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
219554253|NCT04338334|OTHER|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
219554254|NCT04338334|OTHER|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
219554255|NCT00881569|DRUG|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
219554256|NCT04714060|BIOLOGICAL|UB-621|mAb by SC administration
219554257|NCT02948426|BIOLOGICAL|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
219554258|NCT05517096|OTHER|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
219554259|NCT04863131|BIOLOGICAL|EXG-5003|COVID-19 self-replicating mRNA vaccine
219554260|NCT04863131|BIOLOGICAL|Placebo|placebo solution
219720239|NCT07120984|BIOLOGICAL|L19TNF monothery in recurrent oligodendroglioma|6 cycles of 6 weeks with L19TNF
219720240|NCT07119736|DEVICE|VR relaxation|Relaxation with a VR glass and 360° video's of nature
219231812|NCT04870775|BEHAVIORAL|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
219231813|NCT02399605|OTHER|Stimulation|Subcutaneous abdominal electrical stimulation
219231814|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
219147704|NCT03161392|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
219147705|NCT01979913|DRUG|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
219147706|NCT01810263|DIETARY_SUPPLEMENT|high protein supplement|Dietary Supplement: high protein supplement
219231815|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
219231816|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
219231817|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
219231818|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
219147707|NCT04910932|OTHER|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
219147708|NCT04910932|OTHER|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
219147709|NCT04391283|DRUG|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
219554261|NCT04391829|DIAGNOSTIC_TEST|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
219554262|NCT00180401|BEHAVIORAL|CRT-P and CRT-D devices|
219147710|NCT05593146|BEHAVIORAL|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
219231819|NCT02132520|DEVICE|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
219231820|NCT02132520|BEHAVIORAL|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
219231821|NCT00156845|PROCEDURE|AI-700 contrast-enhanced echocardiography|
219231822|NCT00113308|DRUG|GW406381|
219231823|NCT03403036|DRUG|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
219231824|NCT01411657|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
219231825|NCT03862898|OTHER|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
219231826|NCT01630304|BEHAVIORAL|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
219231827|NCT00568087|DRUG|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
219231828|NCT00568087|DRUG|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
219231829|NCT02751710|OTHER|Whole-body FDG PET-CT alone|FDG PET-CT imaging
219231830|NCT01682928|DRUG|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
219554263|NCT03515044|DRUG|40 mg Rifaximin SSD once daily|SSD once daily (QD)
219554264|NCT03515044|DRUG|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
219554265|NCT03515044|DRUG|80 mg Rifaximin SSD once daily|SSD once daily (QD)
219554266|NCT03515044|DRUG|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
219554267|NCT03515044|DRUG|Placebo|Administered twice daily (BID)
219554268|NCT05305586|DEVICE|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
219554269|NCT05305586|DEVICE|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
219554270|NCT01993940|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
219554271|NCT01993940|DRUG|Placebo|Placebo tablet taken orally once a day
219554272|NCT04225065|OTHER|Chlorhexidine|Chlorhexidine prep prior to surgery
219554273|NCT04225065|OTHER|Betadine|Betadine prep prior to surgery
219554274|NCT01599689|OTHER|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
219554275|NCT04817995|BEHAVIORAL|FOREST|Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
219554276|NCT04693221|OTHER|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
219147711|NCT05593146|BEHAVIORAL|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
219720241|NCT07119736|OTHER|Standard relaxation|Relaxation with music, reading a book, playing computer game
219147712|NCT06020651|DIAGNOSTIC_TEST|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
219720242|NCT07120555|DEVICE|atherectomy|Conventional balloon angioplasty remains a first-line endovascular treatment but is limited by high restenosis and vessel recoil rates. Atherectomy, a plaque debulking technique, aims to improve luminal gain and vessel compliance prior to angioplasty, potentially enhancing outcomes in heavily calcified lesions. The combination of atherectomy and balloon angioplasty has shown promise in reducing dissection rates and improving technical success, yet its superiority over conventional angioplasty alone remains controversial.
219720243|NCT07120555|DEVICE|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long
219231831|NCT01682928|OTHER|Hydrotherapy|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
219720244|NCT07120503|DRUG|WIN378|WIN378 is a fully human, long-acting monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving asthma control over an extended dosing interval.
219554277|NCT04693221|OTHER|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
219231832|NCT01008917|DRUG|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
219231833|NCT05019859|BEHAVIORAL|low carb diet|low carb diet
219231834|NCT06509321|PROCEDURE|subinguinal loupe-assisted varicocelectomy (LV)|to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
219231835|NCT06509321|PROCEDURE|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
219231836|NCT05848856|BEHAVIORAL|Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
219231837|NCT03605420|OTHER|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
219231838|NCT05498051|PROCEDURE|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
219231839|NCT03682003|DIAGNOSTIC_TEST|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
219554278|NCT05123885|OTHER|Study on Data|Study on Data
219554279|NCT00486993|BEHAVIORAL|Dietary and nutritional modification|
219554280|NCT00486993|BEHAVIORAL|Stop smoking|
219147713|NCT02168335|OTHER|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
219147714|NCT02168335|OTHER|Sea salt|Unmedicated sea salt
219554281|NCT00486993|BEHAVIORAL|Regular physical activities|
219720245|NCT07120503|DRUG|Placebo|A sham injection consisting of placebo to mask WIN378.
219720246|NCT07121543|RADIATION|Brachytherapy|Brachytherapy is a cancer treatment where radioactive sources are placed inside or near the tumor.
219554282|NCT00486993|BEHAVIORAL|Weight reduction to normal ranges|
219554283|NCT00486993|BEHAVIORAL|Regular intake of polyphenols, esp. from Ilex paraguayensis|
219554284|NCT02096484|BEHAVIORAL|Group Metacognitive Therapy|
219554285|NCT02096484|BEHAVIORAL|Mindfulness Meditation Therapy|
219554286|NCT00695045|DRUG|intra thecal morphine|100 mcg intrathecal morphine given once .
219554287|NCT00695045|DRUG|intra thecal morphine|200 mcg intrathecal morphine given once
219554288|NCT00695045|DRUG|intra thecal morphine|300 mcg intrathecal morphine given once
219147715|NCT05344300|OTHER|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
219147716|NCT00688519|DRUG|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
219554289|NCT01415245|DEVICE|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
219554290|NCT00095160|DRUG|852A|
219554291|NCT01567527|DRUG|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
219554292|NCT01567527|DRUG|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
219554293|NCT00521573|OTHER|Dark chocolate|
219554294|NCT06368076|BEHAVIORAL|Exercise|High intensity interval training on a bike or pedaltrainer from the wheelchair.
219147717|NCT00688519|DRUG|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
219147718|NCT02163954|DRUG|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
219720247|NCT07121595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219720248|NCT07121595|DRUG|Carboplatin|Given IV
219720249|NCT07121595|DRUG|Cisplatin|Given IV
219720250|NCT07121595|PROCEDURE|Computed Tomography|Undergo CT and/or SPECT-CT
219720251|NCT07121595|PROCEDURE|Modified Barium Swallow|Undergo video fluoroscopic swallow study
219720252|NCT07121595|DRUG|Paclitaxel|Given IV
219720253|NCT07121595|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219720254|NCT07121595|OTHER|Questionnaire Administration|Ancillary studies
219720255|NCT07121595|RADIATION|Radiation Therapy|Undergo RT
219720256|NCT07121595|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
219720257|NCT07121595|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
219720258|NCT07121595|RADIATION|Technetium Tc 99m-labeled Tilmanocept|Given via injection
219720259|NCT07121595|OTHER|Technetium Tc-99m Sulfur Colloid|Given via injection
219720260|NCT06865391|BEHAVIORAL|Delayed cord clamping|
219231840|NCT05519306|BEHAVIORAL|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
219231841|NCT04224597|DIAGNOSTIC_TEST|ultrasonography|all participants will be determined by ultrasonography.
219720261|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times.
219147719|NCT02163954|DRUG|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
219147720|NCT01838824|BEHAVIORAL|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
219147721|NCT04670419|OTHER|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
219720262|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
219720263|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
219720264|NCT07121023|DRUG|Placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
219720265|NCT07119359|OTHER|Home-based HIV self-testing|Integration of HIV self-testing into TB household contact investigation
219720266|NCT07119359|OTHER|Home-based initiation of PrEP|Integration of PrEP initation into TB household contact investigation
219720267|NCT07120815|DRUG|Metformin 1500 mg daily|metformin 500mg tablets, 3 times per day
219720268|NCT07120815|DRUG|Metformin 2250 mg daily|Metformin 750mg, 3 times daily
219720269|NCT07119242|DRUG|68Ga-DOTATATE Injection|The eligible subjects who participate in 68Ga study will be intravenously injected with 68Ga-DOTATATE Injection on Day1，and undergo PET/CT examination within 60 minutes after injection. Corresponding safety examination is performed before administration of 68Ga-DOTATATE Injection, 3h±1.0h after administration, and Day2. Telephone safety visit is conducted at Day7 after administration.
219720270|NCT07119385|OTHER|Multicomponent non-pharmacological interventions|Multicomponent non-pharmacological interventions to prevent delirium in frail patients
219720271|NCT07119385|OTHER|Usual care|Usual care
219720272|NCT07119632|OTHER|RFE therapy|
219720273|NCT07121452|BEHAVIORAL|Sleep Navigator|Sleep Navigator will provide education, troubleshooting, motivation, and support pertaining to any additional questions or concerns regarding OSA. They will consult closely with the board-certified sleep medicine physician to ensure that participant care needs are met.
219720274|NCT07120542|DEVICE|Dermoscopy|dermoscopic assessment of skin aging signs
219720275|NCT07121036|DRUG|high - dose vitamin C|Different dose of high - dose vitamin C in arm1, 2 and 3
219147722|NCT01803516|BEHAVIORAL|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
219147723|NCT05429424|OTHER|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
219147724|NCT05429424|OTHER|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
219147725|NCT05429424|OTHER|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
219147726|NCT01348880|DRUG|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
219147727|NCT01348880|DRUG|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
219147728|NCT04628650|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
219147729|NCT03546634|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
219147730|NCT05944822|OTHER|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
219147731|NCT00138138|DRUG|Ritalin|
219147732|NCT01180153|DRUG|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
219147733|NCT01353963|DRUG|desvenlafaxine succinate|50 mg tablet once daily
219147734|NCT03967717|OTHER|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
219147735|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
219147736|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
219147737|NCT03654235|OTHER|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
219147738|NCT03654235|OTHER|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
219147739|NCT03654235|OTHER|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
219147740|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)"
219147741|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
219147742|NCT03861949|OTHER|5 cmH2O CPAP|
219147743|NCT03861949|OTHER|head-up position|
219147744|NCT06401174|BEHAVIORAL|Delivery of patient navigation|Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
219147745|NCT03055416|OTHER|Mobile Men App Prototype|Testing of app functionality
219147746|NCT01694823|DRUG|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
219147747|NCT06974318|OTHER|ABCDEF Bundle to Prevent Delirium|The ABCDEF Care Bundle-comprising components focused on pain management (A), spontaneous awakening and breathing trials (B), choice of sedation and analgesia (C), delirium assessment and management (D), early mobility (E), and family engagement (F)-was developed to promote patient-centered care in the ICU and improve clinical outcomes. Nurses play a central role in the effective implementation of this bundle, given their continuous patient interaction and responsibility for early detection and response to delirium symptoms.
219231842|NCT03656198|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
219231843|NCT03656198|DRUG|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
219231844|NCT03940339|OTHER|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
219231845|NCT03940339|OTHER|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
219147748|NCT06974318|OTHER|Standard Care to Prevent Delirium|Standard care inclued pain management, Glasgow Coma Scale evaluation, Richmond Agitation-Sedation Scale evaluation and control of the stimulations.
219147749|NCT06546605|DEVICE|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training is a novel training modality that involves the simultaneous electrical stimulation of multiple muscle groups while performing dynamic exercises. Participants in the WB-EMS Training Group will use the miha bodytec device (Augsburg, Germany), which consists of a special suit with integrated electrodes covering major muscle groups. The device generates electrical impulses (85 Hz, 350 μs) that cause involuntary muscle contractions during exercises like squats, lunges, and trunk rotations.Each 20-25-minute WB-EMS session will be conducted twice a week during the two 8-week intervention periods. Sessions will include a warm-up followed by 4-6 WB-EMS exercises performed for 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the stimulation and exercises will be progressively increased based on individual adaptation and tolerance, with the stimulation intensity set at 70-85% of the maximal tolerable level.
219720276|NCT07120854|OTHER|Decision aid with decision analysis model|Women will use the web version of the decision aid tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by their central research team via e-mail. Each woman is expected to use the web tool and select her preferences (utilities) regarding different health conditions (e.g. hip fracture). The results of the exercises will be received automatically at the central level (by institutional e-mail to the researcher responsible for the data a PDF file will be sent from the web). The research team at the central level will apply the decision analysis model, using information on the baseline fracture risk and preferences of each participant entered into the tool. The results of the decision analysis model will be delivered to the women directly by e-mail in plain language, so that they can make the final decision together with their general practitioner in a second visit.
219720277|NCT07120854|OTHER|Decision aid alone|Participants will use the web tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by the central research team via e-mail. Each woman is expected to navigate through the different functions of the web tool, at home or at a time other than the medical visit, and select her preferences (utilities) with respect to different health conditions (e.g. hip fracture). The women in this group would decide whether or not to take the pharmacological treatment based on the information provided by the tool but without the results of the decision analysis model described for the intervention group. Subsequently, those who wished to do so would make a final decision together with their physician at a second visit.
219147750|NCT06546605|BEHAVIORAL|Plyometric Training|"Plyometric Training is a high-intensity, explosive strength training modality that involves quick, powerful movements designed to increase muscle power, speed, and agility. Participants in the Plyometric Training Group will engage in a progressive plyometric training program that emphasizes eccentric muscle loading followed by rapid concentric contractions.~The plyometric exercises will include various types of jumps, hops, and bounds, such as box jumps, depth jumps, split squat jumps, and single-leg hops. Each training session will begin with a dynamic warm-up, followed by 4-6 plyometric drills performed for 3-5 sets of 8-12 repetitions, with 60-90 seconds of rest between sets. The intensity and volume of the exercises will be gradually increased over the two 8-week intervention periods."
219147751|NCT06546605|BEHAVIORAL|Functional Training|"Functional Training is a training approach that focuses on exercises that simulate the demands of specific sports or daily activities, targeting multiple muscle groups and movement patterns simultaneously. Participants in the Functional Training Group will engage in a tailored functional training program designed to enhance their performance in basketball or volleyball.~The functional training exercises will incorporate multi-joint, multi-planar movements that mimic game-specific actions, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills. Each session will start with a dynamic warm-up, followed by 6-8 functional exercises performed for 3-4 sets of 8-12 repetitions, with 60 seconds of rest between sets. The program will also include core stability and injury prevention exercises."
219147752|NCT06813976|DRUG|mFOLFORINOX|"mFOLFIRINOX every 2 weeks during 12 cycles (24 weeks):~* Oxaliplatin 85 mg/m²~* Irinotecan 150 mg/m²~* Leucovorin 400 mg/m²~* Fluorouracil 2400 mg/m² during 46 hours"
219147753|NCT06813976|DRUG|Capecitabine or gemcitabine|"investigator's choice:~* Capecitabine 1250 mg/m² BID, 2 weeks on, 1 week off during 8 cycles (24 weeks) OR~* Gemcitabine 1000 mg/m² in 30 min; 3 weeks on, 1 week of, during 6 cycles ((24 weeks)"
219147754|NCT06813976|OTHER|Quality of life questionnaires: QLQ-C30 and PAN26|Before treatment, during treatment (every 12 weeks in any treatment arm Until disease progression or end of follow-up) and after treatment discontinuation (30 days after the end of treatment)
219147755|NCT06813976|BIOLOGICAL|Biological assessment|Before each course of treatment and between courses of treatment if necessary
219147756|NCT06813976|DIAGNOSTIC_TEST|Paraclinical examinations|Every 3 months
219231846|NCT04276506|OTHER|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
219231847|NCT04276506|OTHER|information group|A visual information booklet which is prepared by the researchers will be used
219231848|NCT00569166|BEHAVIORAL|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
219231849|NCT00569166|BEHAVIORAL|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
219231850|NCT00569166|BEHAVIORAL|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
219231851|NCT06027970|DRUG|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
219720278|NCT07120854|OTHER|Usual Care|Women in this group will receive standard clinical practice, without the use of the shared decision support tool or the decision analysis model or any other support. At the end of the visit, their physician will provide them with a link to access the assessment questionnaires.
219720279|NCT07120932|BEHAVIORAL|Effects of Emotional Freedom Techniques (EFT)|Effects of Emotional Freedom Techniques (EFT)
219720280|NCT07118462|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
219147757|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
219147758|NCT04592211|DRUG|olaparib+pembrolizumab+paclitaxel|olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly
219147759|NCT01228916|BEHAVIORAL|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
219147760|NCT03957681|DRUG|KHK4827|210 mg Q2W, SC
219147761|NCT03957681|DRUG|Placebo|Q2W, SC
219147762|NCT02578589|PROCEDURE|Plica resection vs conservative treatment|Plica resection vs conservative treatment
219147763|NCT06657976|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
219147764|NCT06657976|BEHAVIORAL|Attention Control|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
219147765|NCT06657976|COMBINATION_PRODUCT|Nitrate-Rich Beetroot Juice + supervised exercise therapy|Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
219147766|NCT06657976|COMBINATION_PRODUCT|Placebo + supervised exercise therapy|Participants randomized to this group will drink placebo while engaged in supervised exercise.
219147767|NCT04036058|OTHER|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
219147768|NCT06671717|OTHER|Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation|"Drug: Pralatrexate, Chidamide~1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)~2. After the 6-week therapy, the patients should receive PET/CT evaluation.~3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.~4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies."
219147769|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 800 IU/day|Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
219720281|NCT07118462|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
219720282|NCT07114679|DEVICE|Molecular Breast Imaging|MBI is a molecular imaging (nuclear medicine) technique using a low dose i.v. radiopharmaceutical injection and solid-state gamma cameras to image the breast, where cancer mitochondria avidly take up the radiopharmaceutical.
219554295|NCT05324891|DRUG|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
219147770|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 400 IU/day|Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
219147771|NCT06862908|OTHER|placebo|placebo administered subcutaneously(SC), once a week
219554296|NCT05324891|DRUG|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
219720283|NCT07114679|DEVICE|MBI-guided biopsy|Two stereotactic MBI views of the breast produce a precise 3D location for each lesion targeted for biopsy. A vacuum-assisted core biopsy needle is guided to the lesion position.
219720284|NCT07121647|PROCEDURE|renal replacement therapy.|veno-venous hemodiafiltration for emergency indications (CVVHDF).
219147772|NCT06862908|DRUG|IBI362|IBI362 administered subcutaneously(SC), once a week
219147773|NCT06240715|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
219147774|NCT06423781|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
219231852|NCT06027970|OTHER|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
219554297|NCT02004691|DRUG|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
219720285|NCT07121647|PROCEDURE|early isolated CVVHDF.|early isolated CVVHDF.
219147775|NCT06711315|BEHAVIORAL|Oral Mucosit Care Protocol|"The children in the intervention group were subjected to a four-stage intervention carried out by the nurse researcher. The practices in each stage were as follows.~Stage 1: Oral care protocol training to prevent oral mucositis Stage 2: Introduction and application of training material (brochure) Stage 3: Introduction and implementation of oral care calendar Stage 4: Implementation of oral care protocol"
219147776|NCT07041099|DRUG|CLN-978|Specified dose on specified days
219147777|NCT01128790|OTHER|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
219147778|NCT01128790|OTHER|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
219147779|NCT02186197|OTHER|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
219147780|NCT07059780|DEVICE|Virtual Reality Glasses|Participants in the intervention group wore virtual reality (VR) glasses during the gynecological examination. The VR content included immersive nature-themed scenes accompanied by calming background music. The intervention aimed to provide a multisensory distraction to reduce perceived anxiety and pain levels during the procedure.
219147781|NCT02677974|DEVICE|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
219147782|NCT06943599|OTHER|Text Message Reminder|Participants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit.
219147783|NCT06943599|OTHER|Health Worker Visit|Participants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit.
219147784|NCT06940414|OTHER|No Intervention|This is an observational study with no interventions. POCT devices, provided by Eaglenos Sciences, Inc., are used to measure blood glucose, creatinine, uric acid, hemoglobin, and potassium levels in non-dialysis CKD patients for data collection purposes only.
219231853|NCT03840096|DEVICE|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
219231854|NCT00653185|DRUG|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
219554298|NCT02004691|DRUG|Olipudase alfa|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
219554299|NCT00625339|DRUG|Entecavir|entecavir 0.5 mg QD
219554300|NCT00625339|DRUG|Lamivudine|lamivudine 100 mg QD
219554301|NCT00509301|DRUG|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
219147785|NCT02315157|DRUG|Bendamustine|Given IV
219231855|NCT00653185|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
219231856|NCT00653185|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
219554302|NCT01391650|PROCEDURE|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
219554303|NCT02623218|DEVICE|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
219554304|NCT02623218|DEVICE|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
219554305|NCT01726803|OTHER|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
219554306|NCT01726803|OTHER|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
219554307|NCT02816684|BEHAVIORAL|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
219554308|NCT02816684|BEHAVIORAL|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
219554309|NCT04334837|DIAGNOSTIC_TEST|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
219554310|NCT01449409|OTHER|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
219554311|NCT00759707|DRUG|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
219147788|NCT05972720|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
219147789|NCT05972720|DRUG|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
219147790|NCT05972720|DRUG|firi-cel (Experimental drug)|Investigational agent
219147791|NCT04848909|RADIATION|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
219147792|NCT01284920|DRUG|MDV3100|oral
219147793|NCT02594813|PROCEDURE|Biopsy, cold or hot snare polypectomy, or EMR|
219147794|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
219147795|NCT06634030|DRUG|Saline|Normal saline
219147796|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
219147797|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
219147798|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
219147799|NCT04925661|DRUG|HEC53856|Either dose of HEC53856 will be administered after fasting .
219147800|NCT04925661|DRUG|Roxadustat|Roxadustat will be administered after fasting .
219147801|NCT04925661|DRUG|Placebo|Either dose of placebo will be administered after fasting .
219147802|NCT01420250|DRUG|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
219147803|NCT01420250|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
219147804|NCT01420250|DRUG|Anti-Androgen Therapy: Bicalutamide|"* Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT"
219147805|NCT01420250|GENETIC|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"* First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form"
219147806|NCT06513572|DEVICE|FlowSense|This study collects data using non-invasive devices for assessing CSF shunt flow using thermal anisotropy measurements in a prospective study setting. The study will collect data to compare measurements from flowing shunts, non-flowing shunts, and off-shunt locations.
219147807|NCT05073159|BIOLOGICAL|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
219147808|NCT04995627|DIETARY_SUPPLEMENT|Salt (NaCl)|12 grams of salt (NaCl) per day
219147809|NCT04995627|OTHER|Placebo|Placebo
219147810|NCT04816799|BEHAVIORAL|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
219147811|NCT06205303|OTHER|Patient Decision Aid (Video)|Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
219147812|NCT04257409|OTHER|Physical intervention by exercise|12 week lasting exercise intervention
219147813|NCT03204565|PROCEDURE|coronally advanced flap|coronally advanced flap alone (CAF- control)
219147814|NCT03204565|DEVICE|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
219147815|NCT03351075|OTHER|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
219147816|NCT03351075|OTHER|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
219147817|NCT03351075|OTHER|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
219231857|NCT00653185|DRUG|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
219231858|NCT00653185|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
219231859|NCT01582321|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
219231860|NCT01582321|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
219554312|NCT03084562|OTHER|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
219147818|NCT00493649|DRUG|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
219147819|NCT00493649|DRUG|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
219147820|NCT00493649|DRUG|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
219147821|NCT04143204|OTHER|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
219147822|NCT05053321|DRUG|Valbenazine|All participants will be treated with Valbenazine for 6 weeks.
219147823|NCT05664204|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
219147824|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
219147825|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
219147826|NCT03086369|DRUG|Olaratumab|Administered IV
219147827|NCT03086369|DRUG|Nab-paclitaxel|Administered IV
219147828|NCT03086369|DRUG|Gemcitabine|Administered IV
219147829|NCT03086369|DRUG|Placebo|Administered IV
219147830|NCT05341869|PROCEDURE|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
219147831|NCT02639286|DRUG|ISIS 304801|300 mg of ISIS 304801 administered as SC
219147832|NCT02639286|DRUG|Placebo|Placebo administered via SC
219147833|NCT06394284|DRUG|MDMA-AT|As described above in arm description
219147834|NCT06394284|BEHAVIORAL|SEA-IT|As described in arm description
219147835|NCT06459063|DRUG|Allocetra - Safety run-in phase|Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
219147836|NCT06459063|OTHER|Placebo|Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
219147837|NCT06459063|DRUG|Allocetra - Randomization phase|Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
219147838|NCT00425152|DRUG|fluorouracil|
219147839|NCT00425152|DRUG|leucovorin calcium|
219554313|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
219147840|NCT00425152|DRUG|levamisole hydrochloride|
219147841|NCT03160599|OTHER|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
219554314|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
219554315|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
219554316|NCT00005967|DRUG|tipifarnib|
219554317|NCT03369496|OTHER|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
219554318|NCT00691470|DRUG|ATI-5923|Dose Adjusted based on INR.
219554319|NCT00691470|DRUG|Coumadin (warfarin)|Dose adjusted based on INR.
219554320|NCT05881733|DEVICE|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
219554321|NCT00204451|DRUG|0.75 levonorgestrel|
219554322|NCT00204451|DRUG|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
219554323|NCT05219734|DIAGNOSTIC_TEST|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
219554324|NCT05078827|DRUG|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
219554325|NCT05078827|DRUG|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
219554326|NCT05078827|DRUG|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
219554327|NCT05869162|DRUG|SY-3505|A Third-generation ALK TKI
219554328|NCT03138044|PROCEDURE|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
219147842|NCT03475524|DRUG|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
219147843|NCT03475524|DRUG|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
219147844|NCT03475524|DRUG|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
219147845|NCT03475524|DRUG|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
219147846|NCT01947088|BEHAVIORAL|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
219147847|NCT06846684|DRUG|SB17170|PO, QD
219147848|NCT06846684|DRUG|SB_MDZ|IV
219147849|NCT06162897|BEHAVIORAL|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
219147850|NCT04185571|DEVICE|PEPA|
219147851|NCT04663698|OTHER|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
219147852|NCT04663698|OTHER|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
219147853|NCT04663698|OTHER|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
219231861|NCT03950206|OTHER|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
219554329|NCT00592579|DRUG|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
219554330|NCT03757520|DIAGNOSTIC_TEST|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
219147854|NCT04663698|OTHER|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
219147855|NCT04663698|OTHER|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
219147856|NCT01946854|BEHAVIORAL|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
219147857|NCT05049382|PROCEDURE|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
219231862|NCT06509685|OTHER|Ladder Training|9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).
219231863|NCT06509685|OTHER|balance training|9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
219231864|NCT04546451|BEHAVIORAL|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
219231865|NCT04546451|BEHAVIORAL|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
219231866|NCT03555812|OTHER|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
219147858|NCT05398861|DRUG|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
219147859|NCT04679662|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
219231867|NCT03803150|PROCEDURE|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
219554331|NCT03757520|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
219554332|NCT02373839|OTHER|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
219554333|NCT01320722|DRUG|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
219554334|NCT01320722|DRUG|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
219147860|NCT06522724|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.
219147861|NCT06522724|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
219147862|NCT05212675|OTHER|Short daily dialysis|7 days 2hours dialysis
219147863|NCT04229368|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
219147864|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
219147865|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
219147866|NCT03808558|DRUG|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
219147867|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
219147868|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
219147869|NCT05856084|BIOLOGICAL|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
219147870|NCT05856084|BIOLOGICAL|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
219147871|NCT05856084|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
219147872|NCT05856084|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
219147873|NCT04779333|BEHAVIORAL|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
219147874|NCT04779333|BEHAVIORAL|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
219147875|NCT03594500|OTHER|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
219147876|NCT03594500|OTHER|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
219147877|NCT04297371|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
219147878|NCT05390749|DRUG|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
219147879|NCT05390749|DRUG|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
219147880|NCT05390749|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
219147881|NCT05390749|DRUG|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
219147882|NCT02823106|DRUG|Verapamil and Citicoline|Single dosing strategy will be used.
219147883|NCT02823106|OTHER|Placebo|Single matching dosing strategy will be used.
219147884|NCT00964730|DRUG|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
219147885|NCT00964730|DRUG|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
219147886|NCT00964730|DRUG|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
219147887|NCT05011734|OTHER|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
219554335|NCT01320722|DRUG|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
219147888|NCT01180192|DRUG|oxygen|either 8 L/minute O2 via face mask for 2 hours
219147889|NCT00003868|DRUG|cyclophosphamide|
219147890|NCT00003868|DRUG|methotrexate|
219147891|NCT00003868|PROCEDURE|allogeneic bone marrow transplantation|
219147892|NCT00003868|PROCEDURE|peripheral blood stem cell transplantation|
219147893|NCT00003868|RADIATION|iodine I 131 monoclonal antibody BC8|
219147894|NCT00003868|RADIATION|radiation therapy|
219147895|NCT01890811|DIETARY_SUPPLEMENT|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
219147896|NCT06335576|OTHER|This study is a single-arm and observational study with no intervention.|This study is a single-arm and observational study with no intervention.
219147897|NCT01904071|PROCEDURE|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
219554336|NCT01320722|DRUG|Placebo|Placebo soft gel once per week for 8 weeks
219554337|NCT01320722|DRUG|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
219147898|NCT01904071|PROCEDURE|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
219147899|NCT01904071|DRUG|IVMS (IV Morphine)|Intravenous Morphine
219147900|NCT06355492|DEVICE|Virtual reality goggles (VR )|Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
219147901|NCT06355492|DEVICE|regular screen|Patients will take buccal infiltration anaethesia using (regular screen ).
219231868|NCT03803150|PROCEDURE|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
219720286|NCT07121647|PROCEDURE|combined extracorporeal blood purification therapy|Patients received early combined extracorporeal blood purification therapy (EBPT) (SPF and CVVHDF).
219720287|NCT07117084|DIAGNOSTIC_TEST|CCTA-derived Plaque Quantification|Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.
219147902|NCT05834842|BEHAVIORAL|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
219147903|NCT03230786|DRUG|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
219147904|NCT02860286|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
219147905|NCT00598377|DRUG|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
219147906|NCT04625257|OTHER|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
219147907|NCT04625257|OTHER|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
219231869|NCT05005247|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
219147908|NCT04625257|OTHER|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
219147909|NCT04625257|OTHER|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
219147910|NCT05816902|OTHER|The location of the patient's treatment|The location of the patient's treatment
219147911|NCT04529382|DIAGNOSTIC_TEST|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
219147912|NCT01354769|DEVICE|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
219147913|NCT03939195|OTHER|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
219147914|NCT00523146|DRUG|Kanion Capsule|
219147915|NCT04064866|DEVICE|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
219231870|NCT04437004|DRUG|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
219231871|NCT01883063|DEVICE|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
219231872|NCT01883063|DEVICE|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
219554338|NCT01603667|DRUG|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
219554339|NCT01603667|DRUG|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
219554340|NCT02330016|DEVICE|Voluma XC|Voluma XC
219554341|NCT01182792|DIETARY_SUPPLEMENT|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
219554342|NCT01182792|DIETARY_SUPPLEMENT|Placebo|1 month Placebo
219554343|NCT01268839|DRUG|TMC278|25mg tablet once daily for 28 days
219554344|NCT01268839|DRUG|TMC278|25mg tablet once daily for 14 days
219231873|NCT04213768|PROCEDURE|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
219231874|NCT04213768|PROCEDURE|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
219231875|NCT05731206|OTHER|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
219147916|NCT04064866|OTHER|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
219231876|NCT05731206|OTHER|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
219231877|NCT02958553|DEVICE|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
219231878|NCT02958553|DEVICE|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
219231879|NCT00407498|DRUG|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
219231880|NCT03682614|DRUG|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
219231881|NCT03682614|OTHER|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
219231882|NCT01116609|DRUG|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
219147917|NCT04064866|DEVICE|ProPlaz PPC|Trademarked name of an FDA-cleared product
219147918|NCT00034528|DRUG|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
219147919|NCT00034528|DRUG|Fludarabine|30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
219147920|NCT00034528|DRUG|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
219147921|NCT00034528|DRUG|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
219147922|NCT00354653|DRUG|LAMIVUDINE|
219147923|NCT03454646|DRUG|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
219147924|NCT05622123|DRUG|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
219147925|NCT01424397|DRUG|SB-705498|12mg intranasal
219147926|NCT01424397|DRUG|FP|200ug intranasal
219231883|NCT01686152|DRUG|Imiquimod Cream, 3.75%|
219231884|NCT01686152|DRUG|Zyclara®|
219231885|NCT01686152|OTHER|Vehicle of Test Product|
219231886|NCT02194907|BEHAVIORAL|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
219231887|NCT02194907|BEHAVIORAL|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
219231888|NCT00154609|DRUG|Gu-Sui-Bu (Davallia Divaricata)|
219231889|NCT00724009|DRUG|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
219147927|NCT01424397|DRUG|placebo|placebo intranasal
219147928|NCT05898191|OTHER|vaginal laser treatment|non-ablative vaginal laser application
219231890|NCT03077256|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
219231891|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
219554345|NCT01268839|DRUG|Efavirenz|600mg tablet once daily for 14 days
219147929|NCT06333717|DIETARY_SUPPLEMENT|Whole grain bread|Consumption of high-fibre bread as a dietary supplementation
219147930|NCT06333717|DIETARY_SUPPLEMENT|Control bread|Consumption of control bread as a dietary supplementation
219147931|NCT04395235|OTHER|Survey|A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
219147932|NCT04010006|PROCEDURE|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
219147933|NCT04010006|PROCEDURE|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
219231892|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
219231893|NCT01061658|OTHER|Placebo|Placebo
219231894|NCT00704340|DEVICE|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
219231895|NCT00704340|OTHER|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
219231896|NCT02586467|BEHAVIORAL|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
219231897|NCT02586467|BEHAVIORAL|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
219231898|NCT02586467|BEHAVIORAL|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
219231899|NCT02586467|BEHAVIORAL|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
219554346|NCT02586324|BIOLOGICAL|global medium|
219554347|NCT02586324|BIOLOGICAL|SSM|
219554348|NCT03687619|OTHER|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
219554349|NCT03687619|OTHER|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
219554350|NCT06369935|DRUG|Equecabtagene Autoleucel|Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
219554351|NCT03595241|DEVICE|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
219554352|NCT02398734|DEVICE|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
219554353|NCT01377441|DRUG|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
219554354|NCT01377441|DRUG|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
219554355|NCT02806063|PROCEDURE|intraoperative samples|
219554356|NCT02473055|OTHER|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
219554357|NCT01875055|DEVICE|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
219554358|NCT01875055|DEVICE|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
219554359|NCT04642781|DIAGNOSTIC_TEST|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
219554360|NCT00784095|OTHER|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
219554361|NCT00784095|OTHER|Attention Control|Subjects will listen to a non-guided relaxation CD.
219554362|NCT01816230|DRUG|NiCord®|
219147934|NCT02070666|BEHAVIORAL|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O"
219231900|NCT02586467|BEHAVIORAL|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
219231901|NCT00905294|OTHER|Blood draws|Observational: blood draws only
219231902|NCT02074228|DRUG|Methylphenidate (Concerta)|
219720288|NCT07117500|BEHAVIORAL|Routine|"Inpatient Care: Continuously monitor vital signs (BP, HR, SpO₂), neurological status, and limb function; administer prescribed antihypertensives with thorough medication education and efficacy tracking. Strictly prohibit Valsalva maneuvers . Assess pain levels, wounds, and psychological state; deliver scheduled analgesics and emotional counseling to maintain stable mood. Implement lifestyle optimization: 7+hr sleep/night, portion-controlled nutrition, and gradual postoperative mobilization.~Discharge \& Follow-up: Enforce BP control through medication adherence. Ban vigorous activities (mountaineering/swimming/competitive sports); allow low-stress aerobics . Distribute Exercise Diaries (Appx 6) mandating daily logs with critical warnings: STOP immediately if nausea, chest pressure, dizziness, dyspnea, or arrhythmia occur and urgent revisit. Require complete tobacco cessation and secondhand smoke avoidance."
219720289|NCT07117500|BEHAVIORAL|BCW|"1.1 Assessment of physical fitness and formulation of individualized exercise rehabilitation plans 1.2 Inpatient Phase (Postoperative Day 1 - Week 1): Monitor via ICU Mobility Scale (IMS) before each session:▪ Score 0 : Passive range of motion (PROM) exercises▪ Scores 1-3 : Active bed-based joint mobility training▪ Scores 4-6 : Standing balance training▪ Scores 7-10 : Ambulatory walking training 1.3 Early Outpatient Phase (Weeks 2-4): Initiate when IMS=10:▪ Perform 6-Minute Walk Test (6MWT) ▪ If distance \>450m: Prescribe low-intensity aerobic walking  Speed: 3 km/h Progression: Start at 10 min/day (≈500 steps), increase by 10 min every other day up to 40 min/day 1.4 Intermediate Rehabilitation (Weeks 5-12): Moderate-intensity aerobic walking + Resistance training :▪ Walking: 4-6 km/h, 30 min/session, 3 sessions/week▪ Resistance training: Seated elastic band exercises, 20 min/session, 2 sessions/week"
219231903|NCT05484336|OTHER|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219231904|NCT05484336|OTHER|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219231905|NCT05484336|OTHER|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219554363|NCT04817514|OTHER|Shoulder rehabilitation exercises and aerobic exercises|"SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines."
219554364|NCT03610555|OTHER|new patient centered website|
219554365|NCT01689155|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219231906|NCT05484336|OTHER|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
219554366|NCT06625255|BEHAVIORAL|Parent Education - Promoting Playfulness|Parents will participate in 2, 45 minute parent education sessions promoting playfulness through information about child development, parent stressors, and parent advocacy.
219554367|NCT01497743|DRUG|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
219147935|NCT02070666|BEHAVIORAL|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O."
219147936|NCT02070666|OTHER|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
219231907|NCT01437540|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
219231908|NCT01437540|DRUG|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
219231909|NCT04417309|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
219231910|NCT04417309|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
219231911|NCT00130091|DRUG|clonidine|2 mcg clonidine added to local anesthetic
219231912|NCT01299285|DRUG|LY3009104|Administered orally
219231913|NCT03709225|BEHAVIORAL|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
219231914|NCT00197444|DRUG|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
219231915|NCT00197444|RADIATION|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
219231916|NCT04059575|OTHER|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
219231917|NCT04059575|OTHER|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
219231918|NCT05691400|DRUG|Palbociclib 125Mg Tab|125 mg single dose
219231919|NCT05691400|DRUG|Ribociclib 200Mg Oral Tablet|200 mg single dose
219231920|NCT05691400|DRUG|Abemaciclib 150 MG Oral Tablet|150 mg single dose
219231921|NCT06169345|OTHER|Echocardiographic evaluation|Echocardiographic follow-up
219231922|NCT02445404|DRUG|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
219231923|NCT02445404|DRUG|fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
219231924|NCT01967394|OTHER|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
219231925|NCT01967394|OTHER|No use of social media|No social media ads will be available in these counties.
219231926|NCT04986371|DRUG|Niraparib|Usage following drug insert is recommended
219231927|NCT06430606|PROCEDURE|Tint Time|Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
219231928|NCT06430606|PROCEDURE|T0 Time|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
219231929|NCT06430606|PROCEDURE|T1|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
219231930|NCT02359071|OTHER|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
219231931|NCT03559777|OTHER|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
219554368|NCT06390813|BEHAVIORAL|Otago Exercise Training|A total of 18 sessions of Otago Training were conducted 3 days a week for 6 weeks, each session lasting 60 minutes in total, including 5 minutes of warm-up and cool-down periods.
219554369|NCT06390813|BEHAVIORAL|Square Stepping Exercise Training|A total of 18 sessions of SSE were performed 3 days a week for 6 weeks, each session lasting 40 minutes.
219147937|NCT04674371|OTHER|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
219147938|NCT00477035|DRUG|CIK cells|2x10e8 cells/kg
219147939|NCT00477035|DRUG|etoposide|60 mg/kg
219147940|NCT00477035|DRUG|bcnu|15 mg/kg
219720290|NCT07118956|OTHER|Active RAVANS|Real RAVANS was performed on the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation.
219720291|NCT07118956|OTHER|Sham RAVANS|Sham RAVANS was performed on on the cymba conchae of left ear according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation and the interval between stimulus is 29 seconds.
219147941|NCT00477035|DRUG|cyclophosphamide|100 mg/kg
219554370|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
219554371|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
219554372|NCT04475315|DEVICE|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
219554373|NCT04475315|PROCEDURE|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
219554374|NCT02731781|OTHER|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
219554375|NCT04123587|DRUG|discontinuation of Sulfonylureas|"1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
219554376|NCT00070759|DRUG|Daclizumab|
219554377|NCT02177552|DRUG|Carboplatin|
219720292|NCT07118449|DRUG|XC001|22 injections will be administered at the end of the CABG procedure as a one time treatment.
219720293|NCT07118449|DRUG|A195/placebo|22 injections of A195/placebo will be administered at the end of the CABG procedure.
219147942|NCT00477035|DRUG|gemcitabine|1250 mg/m2
219147943|NCT00477035|DRUG|vinorelbine|30 mg/m2
219147944|NCT00477035|DRUG|melphalan|200 mg/m2
219147945|NCT01613274|OTHER|gum chewing|gum chewing three times a day for up to 20 minutes
219147946|NCT01613274|OTHER|no gum chewing|no gum chewing
219147947|NCT01493310|DRUG|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
219147948|NCT01493310|DRUG|placebo|Given orally
219147949|NCT01493310|DRUG|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
219147950|NCT02561039|DRUG|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
219147951|NCT04457752|BIOLOGICAL|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
219147952|NCT03434652|DEVICE|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
219147953|NCT01084031|DRUG|propofol|intravenous propofol with sevoflurane inhalation induction
219147954|NCT00547469|DRUG|DDP733|
219147955|NCT04456751|OTHER|Redo op|Patients with a redo operation
219147956|NCT00648726|DRUG|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
219147957|NCT00648726|DRUG|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
219147958|NCT00648726|DRUG|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
219147959|NCT00824135|DRUG|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
219147960|NCT00824135|PROCEDURE|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
219147961|NCT00824135|OTHER|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
219147962|NCT00824135|DRUG|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
219147963|NCT00824135|DRUG|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
219554378|NCT02177552|DRUG|Docetaxel|
219554379|NCT02177552|DRUG|Capecitabine|
219554380|NCT02177552|DRUG|Epirubicin|
219554381|NCT02177552|DRUG|Oxaliplatin|
219554382|NCT00003906|DRUG|Raloxifene|60 mg/day plus placebo for 5 years
219554383|NCT00003906|DRUG|Tamoxifen|20 mg/day plus placebo for 5 years
219147964|NCT00824135|DRUG|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
219147965|NCT00824135|DRUG|Rituximab|375 mg/m2 intravenous for 1 dose total
219147966|NCT00824135|OTHER|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
219554384|NCT06627985|DIAGNOSTIC_TEST|GPT-4o|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
219554385|NCT06627985|DIAGNOSTIC_TEST|GPT-4o mini|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
219147967|NCT05692778|OTHER|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
219147968|NCT05692778|OTHER|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
219147969|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
219147970|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
219147971|NCT00591708|DIETARY_SUPPLEMENT|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
219147972|NCT00591708|DIETARY_SUPPLEMENT|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
219147973|NCT04630535|PROCEDURE|aorto-bifemoral bypass surgery|aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
219147974|NCT00119951|BEHAVIORAL|Participation on the ACOR Listserv|
219147975|NCT02359188|DEVICE|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
219147976|NCT00742300|PROCEDURE|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
219554386|NCT06627985|DIAGNOSTIC_TEST|MedicalGPT|Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
219554387|NCT06627985|DIAGNOSTIC_TEST|Claude-3.5 Sonnet|Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
219554388|NCT06627985|DIAGNOSTIC_TEST|Claude 3 Haiku|Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
219554389|NCT06627985|DIAGNOSTIC_TEST|Real Doctors|Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
219554390|NCT05365698|BEHAVIORAL|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
219554391|NCT04598607|DRUG|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
219554392|NCT04598607|DRUG|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
219554393|NCT00245882|BEHAVIORAL|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
219554394|NCT00245882|BEHAVIORAL|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
219554395|NCT03955276|OTHER|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
219554396|NCT04485806|OTHER|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
219554397|NCT04485806|OTHER|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
219554398|NCT04485806|OTHER|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
219554399|NCT04485806|OTHER|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
219554400|NCT03290807|DEVICE|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
219147977|NCT06328023|OTHER|SCOAT 6 to find association|we will use SCOAT 6 to find the association between concussion , sleep and physical performance
219720294|NCT07119021|DRUG|Intravenous thrombolysis + edaravone|The patient underwent intravenous t-PA thrombolysis and sublingual administration of edaravone tablets in the prehospital ambulance. Intravenous t-PA thrombolysis was performed in accordance with international guidelines: t-PA dose was calculated according to 0.9mg/kg; 10% of the total dose was injected intravenously, and the remaining 90% was administered intravenously at a uniform rate within one hour.
219720295|NCT07119021|DRUG|IV thrombolysis + placebo (control group)|Patients underwent intravenous t-PA thrombolysis + placebo sublingual administration. The method of intravenous t-PA thrombolysis is in accordance with the international guideline standards: t-PA dose is calculated according to 0.9mg/kg; 10% of the total dose is injected intravenously, and the remaining 90% is administered intravenously at a constant rate within 1 hour.
219554401|NCT04568707|OTHER|blood sample|blood sample for serum (serology, biomarkers) and DNA
219554402|NCT04919785|DEVICE|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
219554403|NCT02667951|OTHER|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
219554404|NCT06678451|DRUG|Sugammadex|When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
219554405|NCT06678451|DRUG|Neostigmine|When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
219720296|NCT07118176|PROCEDURE|Computed Tomography|Undergo PET/CT
219147978|NCT01686906|PROCEDURE|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
219147979|NCT01444417|DRUG|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
219147980|NCT01444417|DRUG|Placebo|Matching placebo administered by subcutaneous injection
219147981|NCT03370796|OTHER|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
219147982|NCT00010738|PROCEDURE|Meditation|
219147983|NCT00362778|DRUG|Insulin|intravenous continuous insulin infusion for 48 hours
219231932|NCT03559777|OTHER|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
219231933|NCT00585793|DRUG|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
219231934|NCT01229332|DRUG|Saline|Continuous 24 h administration
219231935|NCT01229332|DRUG|Carbidopa|Continuous 24 h administration
219720297|NCT07118176|OTHER|Fludeoxyglucose F-18|Given IV
219147984|NCT01909167|BEHAVIORAL|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
219147985|NCT01909167|OTHER|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
219147986|NCT04018924|DEVICE|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
219720298|NCT07118176|RADIATION|Gallium Ga 68 FAPi-46|Given IV
219231936|NCT06305910|DRUG|Treatment with CD200AR-L|Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
219147987|NCT00291824|BEHAVIORAL|Cardiovascular risk factors and willingness to change|
219147988|NCT01760564|DRUG|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
219147989|NCT06519253|OTHER|Virtual reality (VR) music intervention|The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
219147990|NCT06519253|OTHER|Music only control|The control group consists of the same musical performances, with the audio only
219147991|NCT01214824|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
219147992|NCT03924882|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219147993|NCT03899324|DRUG|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
219147994|NCT03899324|DRUG|Placebo white, oblong, scored tablet|placebo intake identically to group 1
219147995|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
219147996|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
219147997|NCT03433690|BEHAVIORAL|HIIT|High Intensity Interval Training for twelve weeks
219147998|NCT03433690|BEHAVIORAL|Moderate training|Moderate training for twelve weeks
219147999|NCT02648503|DRUG|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
219148000|NCT02648503|DRUG|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
219148001|NCT01747070|OTHER|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
219148002|NCT01747070|OTHER|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
219148003|NCT01747070|OTHER|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
219148004|NCT01747070|OTHER|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
219148005|NCT02981888|RADIATION|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
219148006|NCT03475316|BEHAVIORAL|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
219148007|NCT03475316|BEHAVIORAL|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
219148008|NCT04608305|BIOLOGICAL|IIBR-100, low dose (prime)|Single administration of IIBR-100 1\*10E5 pfu/ml
219554406|NCT04522245|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
219554407|NCT04522245|OTHER|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
219554408|NCT06678711|PROCEDURE|minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion|Make a 4.5 cm incision along the median line and then dissect the trapezius, splenius capitis, and semispinalis capitis muscle laterally 1.5 cm off the median line. Retract the obliquus capitis inferior muscle to expose the C1-C2 intra-articular space. Remove the articular cartilage, insert allogenic granular bone and 3D-printed cage. Place the screws and rod in the same positions as conventional surgery, and the operation is completed.
219554409|NCT06678711|PROCEDURE|Open atlantoaxial fixation and fusion|The Goel-Harms procedure will be used in the control group. Screws and rods are placed in the same position as in the experimental group, and a negative-pressure drain was placed until daily drainage was \<50 mL.
219554410|NCT00936351|BEHAVIORAL|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
219554411|NCT00936351|BEHAVIORAL|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
219554412|NCT00966628|DRUG|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
219554413|NCT00966628|DRUG|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
219554414|NCT05471687|DEVICE|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
219554415|NCT05471687|DRUG|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
219554416|NCT03893617|DRUG|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
219720299|NCT07118176|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219720300|NCT07119086|BIOLOGICAL|Biological samples|Blood and urine samples
219720301|NCT07119086|OTHER|Questionnaires|Quality of life questionnaires
219720302|NCT07117474|DRUG|HRS-9563, placebo|A single subcutaneous injection of HRS-9563 injection or placebo was administered
219231937|NCT04776122|DEVICE|Therapy|Device-assisted breathing for relaxation
219231938|NCT04776122|OTHER|No device|Breathing platform without device
219720303|NCT07118085|DRUG|experimental Arm IMC-003|"Part 1: Single Dose Dose Escalation (SAD):~Dose and frequency: 0.03mg/kg, 0.1mg/kg, 0.3mg/kg, 0.7mg/kg, 1.0mg/kg for single administration, with the test drug or placebo administered respectively.~Part 2: Multiple Dose Dose Escalation (MAD):~Dose and frequency: Tentatively set at 0.3mg/kg, 0.5mg/kg, 0.7mg/kg. Administer once every 3 weeks for 5 consecutive times (unless the subject cannot tolerate, withdraw prematurely, or is lost to follow-up, etc.), with the test drug or placebo administered respectively."
219720304|NCT07118085|DRUG|The placebo Arm: The placebo of IMC-003|Part 1(SAD) subject will receive IMC-003 once ; Part 2 (MAD) subject will receive the placebo of IMC-003 for 5 times, with an interval of 21 days between each administration.
219720305|NCT07116785|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|Rotational field TMS (rfTMS) is a novel technology where two orthogonal coils are operated with a 90 phase shift between them. The combined electric field vector of rfTMS from both coils rotates up to a complete cycle during the TMS pulse. This method overcomes the inherent limitation of conventional unidirectional TMS by influencing neurons in various orientations (Roth et al., 2020b). This unique advance bears enormous potential for therapeutic applications in various neuropsychiatric disorders. The coil Array includes the H7 coil as the lower coil, and an upper coil perpendicular to it. Hence, the HAC/H7 coil Array induces similar electric field distribution and affects the same brain structures as the H7 coil, but stimulates neurons in various orientations within these regions.
219720306|NCT07116785|DEVICE|BrainsWay Deep TMS Sham Coil|Participants assigned to this intervention will receive sham stimulation using a BrainsWay Deep TMS sham coil that mimics the sensation and acoustic properties of active stimulation but does not deliver effective magnetic pulses to the brain. This condition is used as a placebo control to blind participants and investigators.
219720307|NCT07118774|BEHAVIORAL|Behavioral: mindfulness and compassion training|Parallel randomized controlled trial
219720308|NCT07118774|BEHAVIORAL|Behavioral: caregiver skills training|Parallel randomized controlled trial
219720309|NCT07118774|BEHAVIORAL|Behavioral: Communication skills training|Parallel randomized controlled trial
219720310|NCT07116876|OTHER|Graft Application|Place the graft on the debrided DFU and secure. Follow with conventional care wound management (dressings and off-loading). Product may be applied weekly.
219554417|NCT03893617|DRUG|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
219554418|NCT03893617|BEHAVIORAL|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
219720311|NCT07116876|OTHER|Wound Dressing Material|The wound will be debrided and undergo a moist-wound therapy and will be covered with a gauze that is appropriate for the type of wound (moist or dry). Dressings will cover each wound wound for at least 5 days, but no more than 9 days, (7 days +/- 2 days) until the next study visit. Off-loading of the wound is required.
219148009|NCT04608305|BIOLOGICAL|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1\*10E6 pfu/ml
219720312|NCT07117422|DRUG|VEN + DEC|"Induction regimen~Venetoclax (VEN): Day1-10~Decitabine (DEC):20mg/m²/day, Day 2-4~20mg/m² every 8 hours, Day 5-6~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14~Post-Remission Treatment~Venetoclax (VEN): 400 mg/day, Day 1-7~Decitabine (DEC): 20 mg/m² every 8 hours, Day 2-3 (Regimen repeated every 4-6 weeks)~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14"
219720313|NCT07117786|OTHER|CT Contrast|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
219148010|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1\*10E7 pfu/ml
219148011|NCT04608305|BIOLOGICAL|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
219148012|NCT04608305|OTHER|Saline Placebo (single)|Single administration of saline placebo
219231939|NCT01061307|DIETARY_SUPPLEMENT|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
219231940|NCT00929526|PROCEDURE|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
219148013|NCT04608305|OTHER|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
219148014|NCT04608305|BIOLOGICAL|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
219148015|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
219148016|NCT04608305|BIOLOGICAL|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
219720314|NCT07117786|OTHER|Computed Tomography|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
219720315|NCT07118553|OTHER|classic facial massage|Powder was used as an intermediate product in facial massage application. Before the application, the participants were made to lie in the supine position on the patient's bed. The researchers performed the facial massage by standing at the participants' bedside. During the massage application, three stroking movements were applied to the chin, mouth, nose, eyes and forehead areas, respectively. Kneading motion was then applied to the same areas three times each. Then, stroking was applied to these five areas again and the facial massage application was terminated at the end of approximately 20-30 minutes. Friction movement was applied to the temporal region in each stroking and kneading application
219720316|NCT07119047|BEHAVIORAL|"A Brazilian adaptation of the Irish intervention iHELP Stroke"|The intervention comprises a set of interactive experiential learning activities. A physiotherapist will serve as the coordinator, and other healthcare professionals will be invited to participate as guest speakers. The educational session aims to provide knowledge about stroke (what stroke and recurrent stroke are, their signs and symptoms, and lifestyle-related risk factors). The individual session aims: (1) to identify the current self-reported health status after stroke; (2) to recognize and raise awareness of risk factors associated with lifestyle-related behaviors, including the setting of behavior change goals, which are structured using the SMART Goals method; and (3) to identify the individual's preferences and ability to participate in the intervention program. Each group session comprises six components covered across the six sessions: education, goal setting, physical activity participation, emotional self-regulation, skill training, and peer learning.
219720317|NCT07119957|OTHER|Blood, urine and stool biocollection|Collection of blood, urine and stool sampling in order to build up a biocollection
219554419|NCT03893617|BEHAVIORAL|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
219554420|NCT04416854|PROCEDURE|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
219148017|NCT03131037|BIOLOGICAL|CAN-2409 + valacyclovir|CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
219148018|NCT03352024|OTHER|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
219148019|NCT03352024|OTHER|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
219148020|NCT05235698|PROCEDURE|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
219148021|NCT05235698|PROCEDURE|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
219148022|NCT03946046|PROCEDURE|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
219148023|NCT03946046|PROCEDURE|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
219148024|NCT05298020|DRUG|Envafolimab|400mg,sc,d1,Q4W
219148025|NCT05298020|DRUG|Endostar|210mg，CIV72h，d1-3，Q4W
219231941|NCT00929526|PROCEDURE|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
219148026|NCT05298020|DRUG|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
219148027|NCT05298020|DRUG|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
219148028|NCT05035303|PROCEDURE|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
219148029|NCT02799134|DRUG|Dexamethasone|
219148030|NCT02799134|DRUG|Vitamin C|
219148031|NCT04532450|DEVICE|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
219148032|NCT02555215|DRUG|dimethyl fumarate|administered orally
219148033|NCT05407571|BEHAVIORAL|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
219554421|NCT04416854|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
219554422|NCT04416854|DRUG|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
219554423|NCT05183282|DEVICE|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
219554424|NCT03202251|OTHER|It's is a cohort|It is a prospective, observational, cohort study
219148034|NCT00468052|DRUG|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
219148035|NCT00468052|DRUG|fentanyl|1 microgram/kilogram as a bolus
219231942|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
219231943|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
219720318|NCT07120685|OTHER|maintaining mechanical load|"The method for maintaining mechanical load (artificially reproducing the stabilization of initial body weight) will involve the use of a weighted vest.~Participants will be asked to wear the weighted vest for at least eight hours a day over a four-week period without changing their lifestyle. Patients will also be contacted by phone every week after surgery to confirm that they are using the vest in accordance with the protocol and to collect information on any potential adverse events. During these calls, weight adjustments-based on body weight changes-will be discussed with the patient and regularly recorded to stay as close as possible to the initial body weight, with a tolerance of ±1 kg. However, the maximum weight of the vest will not exceed 15% of the patient's initial weight (weight at the time of surgery).~Between the 4th and 12th week, patients will be asked to wear the weighted vest loaded with the weight lost calculated at week 4 for at least four hours per day."
219554425|NCT06340698|BEHAVIORAL|Resilience intervention|"Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing."
219148036|NCT03702647|DRUG|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
219148037|NCT03702647|DRUG|Normal saline|30mL of normal saline placed in the POEM tunnel
219148038|NCT05865145|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
219148039|NCT04892290|OTHER|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
219148040|NCT05221736|PROCEDURE|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
219148041|NCT03189589|DRUG|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
219148042|NCT03189589|DRUG|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
219148043|NCT03212079|BEHAVIORAL|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
219148044|NCT03212079|BEHAVIORAL|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
219148045|NCT00709423|DRUG|Moxaverine|
219148046|NCT00709423|DRUG|Moxaverin 150mg|intravenous administration
219148047|NCT00709423|DRUG|NaCl|intravenous administration
219554426|NCT06340698|BEHAVIORAL|Adherence intervention|"Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems."
219554427|NCT03025451|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
219554428|NCT04664751|OTHER|Nil-per-Oral|NPO details
219554429|NCT06677697|DRUG|Ropivacaine 0,5%|Group B 30 patients recive 0.5% ropivacine
219554430|NCT03637127|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
219148048|NCT00092274|DRUG|HuMax-CD20|
219148049|NCT00003432|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
219148050|NCT02025257|OTHER|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
219148051|NCT01204359|RADIATION|Iodine 131|iodine 131，185、370、555mBq，6 months
219148052|NCT03389191|DRUG|Acyclovir|
219148053|NCT00718939|DEVICE|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
219148054|NCT05605535|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
219148055|NCT05605535|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
219148056|NCT05605535|DRUG|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
219148057|NCT05605535|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
219148058|NCT02492048|DEVICE|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
219720319|NCT07120893|BEHAVIORAL|brief culturally adapted behavioral activation|The brief culturally adapted behavioral intervention in this study is a three individual-session intervention, delivered in primary health care center by primary care psychologist. Each session will last 30-45 minutes in face-to-face. During each session, participants will learn about behavioral techniques to reduce depression and enhance well-being, and practice it in their daily life through homework activities.
219720320|NCT07121400|PROCEDURE|Interactive e-learning-group|The Interactive-E-learning group had full access to a pedagogical internet platform with online documents; national experts' recommendations on the management of diabetic patients in anesthesia, slide presentation lectures on the topic by local university teachers, and, the possibility to contact a virtual mentor (anaesthesiologist of our department) by email for interactive discussion or questions about the topic.
219720321|NCT07122908|DEVICE|repetitive transcranial magnetic stimulation|10Hz stimulation group will receive 1600 pulses of stimulation in a single session
219720322|NCT07122310|DEVICE|1064-nm Fractional Picosecond Laser (PicoWay)|Intervention Name: 1064-nm Fractional Picosecond Laser (PicoWay) Participants in this group received full-face treatments using a PicoWay® laser system (Candela, Wayland, MA, USA) equipped with a 1064-nm RESOLVE fractional handpiece. Treatment parameters included a 6 mm spot size, 6 Hz repetition rate, 450 ps pulse duration, and energy settings ranging from 1.5 to 2.3 mJ per microbeam. Each session consisted of 2-3 passes (approximately 2000-4000 pulses), adjusted based on individual response. Three sessions were delivered at 4-6-week intervals. Cold compresses were applied for 20 minutes immediately post-treatment.
219720323|NCT07122310|DEVICE|Intense Pulsed Light Therapy (M22 IPL System)|"Intervention Name: Intense Pulsed Light Therapy (M22 IPL System)~Intervention Description:~Participants in this group underwent full-face treatments using an M22® IPL system (Lumenis, Yokneam, Israel) with a 560 nm cutoff filter. Treatment parameters included a pulse duration of 3.5-4 ms, pulse delay of 25-30 ms, and fluence of 12-18 J/cm², adjusted based on individual response. Each treatment involved approximately 40-60 pulses. Three sessions were performed at 4-6-week intervals. A layer of medical ultrasound gel was applied before treatment and maintained for 15-20 minutes post-treatment."
219148059|NCT02492048|PROCEDURE|Split Thickness Skin Graft|Split Thickness Skin Graft
219148060|NCT05992701|DEVICE|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
219148061|NCT00457743|DRUG|Sunitinib malate (SU011248)|SU011248
219148062|NCT00566527|BIOLOGICAL|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
219148063|NCT05395546|OTHER|dCBT-I|"1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
219148064|NCT00739739|DRUG|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
219148065|NCT00739739|DRUG|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
219148066|NCT00739739|DRUG|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
219148067|NCT02866435|DRUG|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
219148068|NCT02866435|DRUG|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
219554431|NCT03637127|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
219148069|NCT02866435|DRUG|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
219148070|NCT06114615|DEVICE|LiveCare|Patient use LiveCare device to monitor their blood pressure and data is transmitted to dashboard.
219148071|NCT06114615|BEHAVIORAL|Text Messages|Patients also receive text messages after their PCI procedure for follow up appointment reminders, enrollment in cardiac rehab, and diet and exercise counseling.
219554432|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|9-cis Rich Powder
219554433|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawill|9-cis Rich Powder
219554434|NCT01256697|OTHER|Sugar pill|Sugar pill
219554435|NCT00619853|BEHAVIORAL|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
219554436|NCT00619853|BEHAVIORAL|treatment approach - HABIT|HABIT-2 months, 2Hr per day
219554437|NCT06103760|DRUG|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
219554438|NCT04912206|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
219554439|NCT02092701|DRUG|Cholecalciferol|
219720324|NCT07119931|DRUG|lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab|Iparomlimab and Tuvonralimab Injection（Q1706）: 7.5 mg/kg, q3w, given on Day 1 (±7 days) of each 21-day cycle; Bevacizumab: 7.5 mg/kg, q3w, administered on Day 1 (±7 days) of each 21-day cycle; HAIC:Oxaliplatin 85 mg/m² via arterial infusion over 2-3 hours, Levoleucovorin 200 mg/m² via arterial infusion over 1-2 hours, 5-Fluorouracil 400 mg/m² via arterial bolus injection, followed by continuous arterial infusion of 2400 mg/m² over 23 hours, q3w, with the treatment interval not exceeding 4 weeks.
219554440|NCT00057941|DRUG|anastrozole|Given orally
219554441|NCT00057941|DRUG|gefitinib|Given orally
219148072|NCT06114615|OTHER|Conventional Care|No digital monitoring with LiveCare device and no text messages.
219148073|NCT05290168|DIAGNOSTIC_TEST|abdominal Doppler|"1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler"
219720325|NCT07120594|DRUG|Unbuffered lidocaine 2% with epinephrine 1:80,000|Standard local anesthetic solution without pH modification. Used for maxillary extraction of infected primary molars in pediatric patients.
219720326|NCT07120594|DRUG|Buffered lidocaine 2% with epinephrine 1:80,000|Local anesthetic solution mixed with sodium bicarbonate to increase pH before injection. Used for maxillary extraction of infected primary molars in pediatric patients.
219554442|NCT00057941|DRUG|fulvestrant|Given intramuscularly
219554443|NCT00057941|OTHER|laboratory biomarker analysis|Correlative studies
219554444|NCT01591824|OTHER|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation."
219554445|NCT01591824|OTHER|column exercise group|"* paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises"
219148074|NCT01784653|BEHAVIORAL|iMET|Self-completed, computerized motivational enhancement therapy
219148075|NCT01784653|BEHAVIORAL|MET|Clinician-delivered Motivational Enhancement Therapy
219148076|NCT00356265|DRUG|Procedure: Regional phenylephrine arterial infusion|
219148077|NCT03071653|PROCEDURE|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
219231944|NCT00519844|DRUG|somatropin|
219231945|NCT01583855|PROCEDURE|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
219231946|NCT01583855|DEVICE|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
219554446|NCT04956848|DEVICE|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
219554447|NCT02103101|OTHER|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
219554448|NCT02103101|GENETIC|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
219554449|NCT05028140|DRUG|PIEMONTE|Piemonte association 1 coated tablet once a day
219554450|NCT05028140|OTHER|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
219554451|NCT05028140|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
219554452|NCT05028140|OTHER|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
219148078|NCT03071653|OTHER|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
219148079|NCT03929770|PROCEDURE|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
219148080|NCT03929770|PROCEDURE|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
219148081|NCT05874830|OTHER|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
219148082|NCT04479969|BEHAVIORAL|Video Chat|Video chat with health coach using a computer tablet.
219231947|NCT02723799|BEHAVIORAL|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
219231948|NCT02723799|OTHER|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
219231949|NCT02807285|DRUG|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
219148083|NCT02154217|DRUG|Bimatoprost|
219148084|NCT02154217|DRUG|Latanoprost/Timolol|
219148085|NCT01512810|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
219148086|NCT00981643|BEHAVIORAL|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
219148087|NCT06199323|BEHAVIORAL|Routine rehabilitation training|"1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
219148088|NCT06199323|BEHAVIORAL|Swallowing rehabilitation training|"1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week."
219231950|NCT06121765|OTHER|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
219231951|NCT00753155|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
219231952|NCT04062383|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
219231953|NCT01428609|PROCEDURE|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
219231954|NCT01984216|PROCEDURE|Roux-en-Y for the gastrojejunostomy reconstruction|
219231955|NCT01984216|PROCEDURE|Billroth II for the gastrojejunostomy reconstruction|
219554453|NCT05028140|DRUG|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
219554454|NCT05028140|OTHER|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
219554455|NCT03407729|OTHER|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
219554456|NCT03407729|OTHER|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
219554457|NCT01145157|DEVICE|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
219554458|NCT01145157|DEVICE|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
219554459|NCT01145157|DEVICE|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
219554460|NCT02775058|DEVICE|synergoss Pxx|dental grafting
219720327|NCT07122791|OTHER|Home Exercise Group|In addition to the exercise program, Group 2 will receive motor imagery training. This will be carried out using the telerehabilitation method, under the supervision of a physiotherapist, and will be delivered twice a week for six weeks. A text containing posture exercises will be prepared by the physiotherapist for motor imagery training. The motor imagery text will be updated as the home exercise program is completed. The content of the motor imagery program will consist of 5 minutes of relaxation and 15 minutes of imagery training. Relaxation training will include relaxation and breathing exercises. After relaxation training, the patient will be asked to stand up with his eyes closed in a safe environment where he feels comfortable, and then a text containing posture exercises prepared by the physiotherapist for motor imagery will be read. The patient will be asked to perform the exercise by imagining it in his mind without moving his body.
219720328|NCT07123831|OTHER|virtual reality supported privacy education|The experimental group was shown a video with virtual reality application for 15 minutes in an empty classroom environment determined in the primary school at a time and in a way that would not disrupt the lessons. Then, verbal expression, question-answer and feedback were given for 10 minutes. After this training session, the experimental group was repeated twice with virtual reality goggles at two-week intervals and their questions were answered. No intervention was made to the students in the control group. At the end of the sixth week, the researcher administered post-tests to each student in the experimental and control groups.
219720329|NCT07122414|DRUG|FL115|FL115 single agent dose escalation,
219720330|NCT07122414|DRUG|FL115+BCG|FL115 in combination with BCG
219148089|NCT06199323|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
219720331|NCT07121790|DEVICE|Implant Mg-based RemeOs™ drillpins|"This is a first-in-human clinical feasibility study of a novel absorbable magnesium-zinc-calcium alloy DrillPin (RemeOs™) for internal fixation during surgical correction of hammertoe deformities in adult patients. The implant is investigational, not CE-marked, and represents an alternative to conventional stainless steel or titanium K-wires commonly used in toe correction surgery.~The RemeOs™ DrillPin is designed to provide mechanical stability during osteotomy healing and gradually resorbs over 2-3 years, potentially eliminating the need for secondary implant removal.~The study focuses on evaluating safety, performance, and implant resorption using standardized clinical and radiographic assessments. The DrillPin is made from the same magnesium alloy (ZX00) as the CE-marked RemeOs™ Screw, which has demonstrated clinical safety and performance in prior applications."
219720332|NCT07123181|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
219720333|NCT07123181|OTHER|Higher polyphenol intake by consumption of oregano and basil|Patients consume 4-5 grams of dried oregano and 4-5 grams of dried basil leaves daily for two months in addition to their usual medical treatment.
219720334|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor|Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
219720335|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes|Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions
219720336|NCT07122648|BIOLOGICAL|placebo|Participants will receive a single IV dose of 300 µg of placebo
219720337|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 300 µg of PN-101
219720338|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 600 µg of PN-101.
219148090|NCT03216538|DRUG|AS101 1% oral solution|0.4 ml daily p.o.
219148091|NCT03216538|DRUG|Placebo|0.4 ml daily p.o.
219148092|NCT00851708|DRUG|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
219148093|NCT06327386|DIAGNOSTIC_TEST|18F-FAPI#18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
219148094|NCT02779998|OTHER|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
219148095|NCT02779998|OTHER|Standard oxygen therapy with facial mask|
219148096|NCT05364632|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
219148097|NCT05364632|OTHER|Aerobic Training|The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
219148098|NCT02074488|OTHER|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
219231956|NCT01282645|DEVICE|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
219554461|NCT03434145|OTHER|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
219720339|NCT07122518|DEVICE|PALMAZ MULLINS XD™ Pulmonary Stent|The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.
219720340|NCT07122830|OTHER|Family Education and Parental Involvement|Parents will be oriented to the programme, tools provided for their own learning (pamphlets, information handouts, audio-visual resources), and a checklist of infant care topics to be completed. The primary caregiver will be asked to commit to spending one to two hours per day to attend education sessions on the topic(s) of their choice. Parents will be encouraged to provide progressively more daily care for their infants as they complete more education sessions. After each education session, parents will check off for each completed topic on their skills checklist.
219554462|NCT05821608|OTHER|Message variation 1|Message before call letting member know they will be called (variation 1)
219720341|NCT07123415|DRUG|APX-343A|Oral administration twice daily
219720342|NCT07123415|DRUG|Pembrolizumab|intravenous \[IV\]
219720343|NCT07123688|DEVICE|Tc-99mMDP bone scan|5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging.
219720344|NCT07122128|DIAGNOSTIC_TEST|saliva a a diagnostic tool for early detection of oral cancer|Three groups will be compared on the basis of cytology, genes and biochemical analysis
219720345|NCT07122245|BEHAVIORAL|Demographics and risk factors of lung cancer|A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU).
219148099|NCT02074488|OTHER|Informational Brochure|Informational Brochure on falls prevention
219148100|NCT01837966|OTHER|Lavender oil|2 drops for aromatherapy
219148101|NCT01837966|OTHER|Placebo|2 drops unscented mineral oil for aromatherapy
219554463|NCT05821608|OTHER|Message variation 2|Message before call letting member know they will be called (variation 2)
219720346|NCT07125222|DRUG|Gocovri (extended-release amantidine)|Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is no dose-limited event after 28 days, the dose will be increased to 274mg daily which will become the new standard dose for the remaining 20 weeks of the patient's participation in the study.
219720347|NCT07125950|DRUG|SHR2554|SHR2554
219148102|NCT04421261|DEVICE|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
219148103|NCT04421261|DEVICE|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
219148104|NCT06168149|DIAGNOSTIC_TEST|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
219148105|NCT03910491|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
219148106|NCT03293498|BIOLOGICAL|NanoFlu|Vaccine
219148107|NCT03293498|BIOLOGICAL|Fluzone HD - Day 0|Vaccine
219148108|NCT03293498|BIOLOGICAL|Fluzone HD - Day 21|Vaccine
219148109|NCT03293498|OTHER|Saline - Day 21|Placebo
219148110|NCT02178423|PROCEDURE|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
219554464|NCT03950674|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
219554465|NCT03950674|DRUG|Cisplatin|IV infusion
219554466|NCT03950674|DRUG|Carboplatin|IV infusion
219720348|NCT07125950|DRUG|HRS-8080|HRS-8080
219720349|NCT07125950|DRUG|HRS-1358|HRS-1358
219720350|NCT07125807|OTHER|upper extremity plyometric exercises|upper extremity plyometric exercises in neuro rehabilitation
219148111|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
219148112|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
219148113|NCT01917097|DRUG|Dexmedetomidine|
219148114|NCT01885793|DEVICE|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
219148115|NCT02983669|DIETARY_SUPPLEMENT|Thyme|Thyme capsule 350 mg twice daily
219148116|NCT02983669|OTHER|Placebo|Placebo capsule 350 mg twice daily
219148117|NCT00159783|DRUG|asenapine|Asenapine, 40 weeks
219148118|NCT00159783|DRUG|Olanzapine|Olanzapine, 40 weeks
219148119|NCT00592410|DRUG|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
219554467|NCT03950674|DRUG|Pemetrexed|IV infusion
219554468|NCT03950674|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
219148120|NCT03104387|OTHER|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
219148121|NCT03104387|OTHER|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
219148122|NCT05536037|DRUG|Metformin|Given PO
219148123|NCT05536037|PROCEDURE|Biopsy|Undergo biopsy
219148124|NCT03995082|OTHER|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
219148125|NCT04046575|RADIATION|Intensity Modulated Radiation Therapy|-15 fractions of treatment
219148126|NCT04046575|DRUG|Carboplatin|Begins on day 1 of radiotherapy
219148127|NCT04046575|OTHER|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
219148128|NCT04046575|OTHER|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
219148129|NCT04046575|OTHER|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
219148130|NCT04046575|OTHER|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
219148131|NCT04046575|OTHER|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
219231957|NCT01729767|DRUG|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
219554469|NCT03950674|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
219554470|NCT03950674|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
219148132|NCT04046575|PROCEDURE|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
219148133|NCT04046575|PROCEDURE|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
219148134|NCT04046575|DRUG|Paclitaxel|Begins on day 1 of radiotherapy
219148135|NCT01006824|OTHER|Capsule endoscopy|Capsule endoscopy
219148136|NCT01006824|OTHER|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
219148137|NCT02928224|DRUG|Encorafenib|Orally, once daily.
219148138|NCT02928224|DRUG|Binimetinib|Orally, twice daily.
219148139|NCT02928224|DRUG|Cetuximab|Standard of care.
219148140|NCT02928224|DRUG|Irinotecan|Standard of care.
219148141|NCT02928224|DRUG|Folinic Acid|Standard of care.
219148142|NCT02928224|DRUG|5-Fluorouracil|Standard of care.
219148143|NCT04993807|OTHER|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
219148144|NCT00818805|DRUG|Olopatadine 0.1%|one drop in one eye
219148145|NCT00818805|DRUG|Tranilast 0.5%|one drop in one eye
219554471|NCT03950674|DRUG|Saline solution|IV infusion
219554472|NCT06120660|OTHER|Music Therapy|Music Therapy
219148146|NCT00818805|DRUG|Placebo (Olopatadine)|one drop in contralateral eye
219148147|NCT00818805|DRUG|Placebo (Tranilast)|one drop in contralateral eye
219148148|NCT01278394|DRUG|AN2690 Solution, 5.0%|Once daily application for 360 days
219148149|NCT02961010|BEHAVIORAL|Keeping Safe|A whole school Preventative Education programme
219554473|NCT01346644|OTHER|Infant formula|Powder infant formula
219554474|NCT01346644|OTHER|Infant formula|Powder infant formula
219554475|NCT04394130|DRUG|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
219554476|NCT05361057|DRUG|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
219554477|NCT05361057|DRUG|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
219554478|NCT04804839|OTHER|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
219554479|NCT04804839|OTHER|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
219554480|NCT04804839|OTHER|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
219554481|NCT00193492|DRUG|Bevacizumab|
219554482|NCT00193492|DRUG|Rituximab|
219554483|NCT00830167|DRUG|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
219554484|NCT00830167|DRUG|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
219554485|NCT02176616|PROCEDURE|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
219148150|NCT02232295|DEVICE|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
219148151|NCT02232295|DEVICE|Mirror Box|A resource used for many pain and disability states of the hands and feet.
219148152|NCT04565418|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
219148153|NCT01236560|BIOLOGICAL|Bevacizumab|Given IV
219148154|NCT01236560|DRUG|Temozolomide|Given PO
219148155|NCT01236560|DRUG|Vorinostat|Given PO
219148156|NCT02472275|DRUG|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
219148157|NCT02472275|OTHER|Laboratory Biomarker Analysis|Correlative studies
219231958|NCT01729767|DRUG|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
219231959|NCT05513729|DRUG|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
219231960|NCT05513729|DRUG|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
219231961|NCT01271894|DRUG|Efavirenz|600 mg once daily; given as 3 x 200 mg once
219231962|NCT01271894|DRUG|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
219231963|NCT01049698|BEHAVIORAL|Resistance Training|3 d/wk resistance training
219231964|NCT01049698|BEHAVIORAL|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
219231965|NCT02064686|OTHER|Exhaled breath temperature|
219231966|NCT04728035|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection
219231967|NCT03332316|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone injection
219231968|NCT03332316|DRUG|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
219231969|NCT03332316|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
219148158|NCT02472275|DRUG|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
219231970|NCT01236898|DRUG|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
219148159|NCT02472275|RADIATION|Radiation Therapy|Undergo radiation therapy
219148160|NCT02197975|DRUG|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
219148161|NCT02197975|DRUG|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
219148162|NCT02197975|DRUG|Placebo MDI|Placebo MDI. Administered as 2 inhalations
219148163|NCT06028503|BEHAVIORAL|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
219231971|NCT03914586|DEVICE|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
219720351|NCT07125807|OTHER|upper extremity resistance exercises|upper extremity resistance exercises in neuro rehabilitation
219148164|NCT06028503|DEVICE|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
219148165|NCT06028503|OTHER|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
219231972|NCT05832970|OTHER|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
219231973|NCT04169802|DIAGNOSTIC_TEST|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
219231974|NCT04169802|DIAGNOSTIC_TEST|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
219231975|NCT00321971|BEHAVIORAL|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
219231976|NCT00321971|BEHAVIORAL|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
219231977|NCT02414594|DRUG|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
219231978|NCT02414594|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219231979|NCT05308888|DIAGNOSTIC_TEST|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG (\[18F\]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
219231980|NCT05928494|OTHER|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
219231981|NCT01753440|PROCEDURE|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
219231982|NCT00988130|OTHER|laboratory biomarker analysis|
219231983|NCT00988130|OTHER|questionnaire administration|
219231984|NCT00988130|PROCEDURE|assessment of therapy complications|
219148166|NCT06034028|DEVICE|J-Valve TF System|The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
219148167|NCT00378222|PROCEDURE|Autologous Stem Cell Transplantation|
219148168|NCT04327167|BEHAVIORAL|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
219148169|NCT04525651|DEVICE|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
219148170|NCT04525651|OTHER|Manual Acupuncture|Manual acupuncture to acheive de qi.
219148171|NCT04525651|OTHER|Sham Acupuncture|Sham acupuncture to avoid de qi.
219148172|NCT00125645|DRUG|Irbesartan Oral Tablet|
219148173|NCT01813773|DRUG|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
219148174|NCT01337622|PROCEDURE|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
219231985|NCT00988130|PROCEDURE|high-intensity focused ultrasound ablation|
219231986|NCT00988130|PROCEDURE|quality-of-life assessment|
219231987|NCT06080945|OTHER|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
219231988|NCT01333709|DRUG|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
219231989|NCT01333709|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
219231990|NCT01333709|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
219231991|NCT01333709|RADIATION|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
219720352|NCT07125144|BEHAVIORAL|Black Youth Suicide Prevention in Chicago|The Culturally Adapted intervention uses intervention video content that specifically addresses topics that shape Black youth's psychological wellbeing and development. The goal of this intervention is to share suicide prevention information in ways that are culturally responsive and attentive to the specific needs of Black adolescents.
219720353|NCT07125144|BEHAVIORAL|Signs of Suicide: Standard/Existing|Students attending schools assigned to the Standard/Existing Intervention condition will receive the Signs of Suicide curriculum.
219148175|NCT01337622|PROCEDURE|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
219148176|NCT01079065|DRUG|Famotidine|Tablets
219148177|NCT05467319|DRUG|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
219148178|NCT05467319|DRUG|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
219148179|NCT05981157|DRUG|Anrotinib plus Tirelizumab|Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
219231992|NCT01333709|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
219231993|NCT01382706|DRUG|docetaxel|Given IV
219231994|NCT01382706|DRUG|lapatinib ditosylate|Given PO
219231995|NCT01382706|OTHER|immunohistochemistry staining method|Correlative studies
219231996|NCT01382706|GENETIC|fluorescence in situ hybridization|Correlative studies
219231997|NCT01382706|OTHER|laboratory biomarker analysis|Correlative studies
219148180|NCT03107806|DEVICE|OptiScanner®|"1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®"
219148181|NCT03688360|BEHAVIORAL|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
219148182|NCT03281382|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
219148183|NCT03516240|OTHER|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
219148184|NCT03516240|OTHER|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
219148185|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 14 days
219148186|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
219148187|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 28 days
219148188|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
219148189|NCT02034773|DRUG|Placebo|Placebo will be administered once daily for up to 28 days
219148190|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
219148191|NCT02034773|DRUG|CC-220|CC-220 1mg (once every 7 days for 28 days)
219148192|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
219554486|NCT02176616|PROCEDURE|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
219554487|NCT02738216|BEHAVIORAL|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
219554488|NCT02738216|BEHAVIORAL|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
219554489|NCT00379158|DRUG|Micronutrient supplements|
219554490|NCT01985724|DRUG|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
219554491|NCT01985724|DRUG|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
219554492|NCT01985724|DRUG|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
219554493|NCT01985724|DRUG|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
219554494|NCT01985724|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
219554495|NCT03168035|DRUG|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
219554496|NCT04315779|PROCEDURE|Salpingectomy|Patients will undergo removal of the affected tube
219554497|NCT04287608|DRUG|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
219554498|NCT03096067|OTHER|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
219554499|NCT03096067|OTHER|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
219554500|NCT02828631|DEVICE|Macintosh laryngoscope|
219554501|NCT02828631|DEVICE|McGrath videolaryngoscope|
219554502|NCT02828631|DEVICE|Pentax videolaryngoscope|
219554503|NCT04789330|DRUG|Norepinephrine|Norepinephrine administered during anesthesia
219554504|NCT04789330|DRUG|Phenylephrine|Phenylephrine administered during anesthesia
219554505|NCT00279760|DRUG|Belatacept|
219554506|NCT00279760|DRUG|Abatacept|
219554507|NCT02589067|DRUG|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
219554508|NCT02589067|DRUG|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
219554509|NCT02962180|DEVICE|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
219554510|NCT00860262|DRUG|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
219148193|NCT03114410|BEHAVIORAL|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
219148194|NCT05600335|PROCEDURE|ERAS protocol|Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
219231998|NCT04577391|OTHER|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
219231999|NCT04577391|OTHER|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
219232000|NCT04271865|OTHER|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
219232001|NCT04271865|OTHER|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
219232002|NCT04271865|OTHER|recipe book|3\) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
219554511|NCT00860262|DRUG|telmisartan|telmisartan 80mg for the 8w, no titration required
219148195|NCT04415528|OTHER|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
219554512|NCT00860262|DRUG|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
219554513|NCT05702762|DRUG|Gentamicin|5 mg/kg intramuscular injection
219554514|NCT05702762|DRUG|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
219148196|NCT05915533|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
219148197|NCT06630442|OTHER|Educational Intervention|Attend a food safety educational training program
219148198|NCT06630442|OTHER|Questionnaire Administration|Ancillary studies
219148199|NCT04593251|BIOLOGICAL|CALY-002|1-hour intravenous infusion
219148200|NCT04593251|BIOLOGICAL|Placebo|1-hour intravenous infusion
219148201|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
219148202|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
219148203|NCT05166889|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
219148204|NCT06063733|OTHER|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
219148205|NCT01618643|PROCEDURE|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
219148206|NCT01497704|DRUG|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
219148207|NCT03665779|DRUG|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
219148208|NCT03665779|DRUG|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
219232003|NCT04271865|OTHER|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
219148209|NCT04356820|OTHER|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
219232004|NCT05730192|DEVICE|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
219232005|NCT01780272|OTHER|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
219232006|NCT00211042|OTHER|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
219232007|NCT03264222|OTHER|Security screening procedure|Screening procedure with security device (model QPS 100)
219720354|NCT07124780|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support is an evidence-based model of supported employment for individuals with mental illness. In IPS, participants will meet with an IPS specialist weekly who will help the study participant create resumes, conduct job searches online or in the community, complete job applications, role-play interviews, and, if requested, accompany them when visiting prospective employers.
219720355|NCT07124780|BEHAVIORAL|Standard Vocational Services|In Standard Vocational Services, participants will meet with a representative from the American Jobs Center (AJC) who will help them find a job by identifying their interests, assess their skills and abilities, and advise them on in-demand jobs and potential training opportunities.
219720356|NCT07123805|DEVICE|Acupuncture group|In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side.
219720357|NCT07122505|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
219720358|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 5mg/kg/day in two divided doses will be given for three days to two subjects
219720359|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in two divided doses will be given for three days to two subjects.
219720360|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 20mg/kg/day in two divided doses will be given for seven days to three subjects.
219720361|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in two divided doses will be given for 14 days to three subjects.
219720362|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 15mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, the next Cohort will increase to 25mg/kg/day (Cohort 2) or decrease to 10mg/kg/day (Cohort 3)
219232008|NCT04181385|DRUG|Olanzapine 10 milligram|Oral olanzapine capsule
219232009|NCT04181385|DRUG|Bromocriptine 5 milligram|Oral bromocriptine capsule
219232010|NCT04181385|DRUG|Placebo oral tablet|oral placebo capsules
219232011|NCT00579839|PROCEDURE|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
219148210|NCT00468910|DRUG|acetylsalicylic acid|Given orally
219148211|NCT00468910|DRUG|placebo|Given orally
219148212|NCT00468910|OTHER|laboratory biomarker analysis|Correlative study
219148213|NCT00963625|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
219148214|NCT00963625|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
219148215|NCT04531592|DRUG|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
219148216|NCT04531592|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
219148217|NCT05028959|OTHER|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
219232012|NCT00579839|PROCEDURE|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
219554515|NCT00348517|OTHER|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
219148218|NCT06198114|OTHER|Multi Sensory Therapy|This group will be treated with activity based training by place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box. 5 days in a week
219232013|NCT01662232|DIETARY_SUPPLEMENT|Green tea beverage|
219232014|NCT01662232|DIETARY_SUPPLEMENT|Green tea extract|
219232015|NCT01662232|DIETARY_SUPPLEMENT|EGCG|
219232016|NCT01662232|OTHER|Placebo|
219232017|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
219554516|NCT00348517|OTHER|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
219554517|NCT04980105|BIOLOGICAL|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
219554518|NCT04980105|DRUG|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
219554519|NCT04980105|DRUG|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
219554520|NCT02117141|DRUG|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
219554521|NCT02117141|DRUG|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
219554522|NCT00124618|BIOLOGICAL|cetuximab|
219554523|NCT00124618|RADIATION|radiation therapy|
219554524|NCT05736250|DIAGNOSTIC_TEST|biopsie|gingival biopsie
219554525|NCT04349696|DRUG|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
219554526|NCT05589636|DIETARY_SUPPLEMENT|Bergamot Juice|Bergamot Juice (35% in water)
219554527|NCT01401296|BEHAVIORAL|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
219554528|NCT01401296|BEHAVIORAL|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
219554529|NCT00899951|DRUG|fentanyl citrate|
219554530|NCT00899951|OTHER|pharmacological study|
219554531|NCT01116505|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-containing cereals removed from diet
219554532|NCT04384289|PROCEDURE|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
219554533|NCT05033145|DRUG|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
219554534|NCT05033145|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
219554535|NCT00882245|OTHER|Vehicle ointment|Topical vehicle cream
219554536|NCT00882245|DRUG|Ointment|SRD441 Ointment
219554537|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
219554538|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
219554539|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
219554540|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
219554541|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
219554542|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
219554543|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
219554544|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
219554545|NCT03001934|OTHER|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
219554546|NCT03161236|OTHER|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
219554547|NCT03161236|OTHER|non exercise program|continue usual lifestyle
219554548|NCT02977416|OTHER|anti-TNFα|
219554549|NCT06276153|OTHER|no interventions|retrospective registry cohort with no other specific interventions
219554550|NCT02691676|DRUG|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
219148219|NCT06198114|OTHER|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).5 days a week for an hour/daily.
219148220|NCT05066958|BIOLOGICAL|boost anti-viral immunity after T-cell depleted HSCT|"* Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening"
219148221|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
219148222|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
219148223|NCT05158387|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
219148224|NCT01290185|DEVICE|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
219148225|NCT03123809|DEVICE|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
219148226|NCT06113146|OTHER|ultra-processed slow eating rate diet|Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
219148227|NCT06113146|OTHER|Ultra-processed fast eating rate diet|Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
219148228|NCT06240351|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a Janus kinase (JAK) inhibitor
219148229|NCT06029023|COMBINATION_PRODUCT|MTA Cement, propolis nano particle, curcumin nanoparticles|MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.
219148230|NCT02044523|DEVICE|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
219148231|NCT02530073|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
219554551|NCT02691676|DRUG|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
219554552|NCT03149900|DRUG|Secukinumab|See Arm Description
219554553|NCT03721718|BIOLOGICAL|GLS-5300|\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
219554554|NCT03721718|DEVICE|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
219554555|NCT02542254|DRUG|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
219554556|NCT02542254|DRUG|Ipratropium|40 micrograms ipratropium administered using a pMDI
219554557|NCT02542254|DRUG|RPL554|6 mg RPL554 administered using a nebuliser
219554558|NCT02542254|DRUG|Salbutamol matched placebo|Placebo pMDI
219554559|NCT02542254|DRUG|Ipratropium matched placebo|Placebo pMDI
219554560|NCT02542254|DRUG|RPL554 matched placebo|Nebulised placebo
219554561|NCT04816396|BEHAVIORAL|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
219554562|NCT03069963|DRUG|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
219554563|NCT03069963|DRUG|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
219554564|NCT03275363|DIAGNOSTIC_TEST|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span."
219554565|NCT03275363|DIAGNOSTIC_TEST|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
219554566|NCT03275363|BIOLOGICAL|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
219554567|NCT03275363|DIAGNOSTIC_TEST|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
219148232|NCT06406816|COMBINATION_PRODUCT|Neoantigen Vaccine plus Capecitabine|"1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination."
219148233|NCT01168154|DIETARY_SUPPLEMENT|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
219148234|NCT01168154|DIETARY_SUPPLEMENT|placebo|placebo
219148235|NCT00521833|PROCEDURE|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
219148236|NCT04396730|DRUG|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
219148237|NCT04396730|DRUG|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
219148238|NCT04396730|DRUG|Combined oral contraceptive pill|All participants will receive oral contraceptives
219148239|NCT02748590|DEVICE|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
219148240|NCT03538912|OTHER|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
219148241|NCT03538912|OTHER|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
219148242|NCT06201819|DRUG|Liraglutide injection|Liraglutide (GLP-1 analog) injection during 3 months
219148243|NCT00664430|DRUG|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
219148244|NCT00664430|DRUG|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
219148245|NCT03404583|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
219554568|NCT03275363|DIAGNOSTIC_TEST|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
219554569|NCT02279277|BEHAVIORAL|Supervised physical therapy program prior to total knee replacement surgery|
219554570|NCT00989716|DRUG|Transdermal glyceryl trinitrate patch|5mg per day
219554571|NCT00989716|DRUG|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
219554572|NCT04196296|BEHAVIORAL|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
219554573|NCT04196296|BEHAVIORAL|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
219554574|NCT05511662|OTHER|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
219554575|NCT01360216|BEHAVIORAL|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
219554576|NCT01282450|RADIATION|Radiotherapy|Radiotherapy
219554577|NCT01223027|DRUG|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
219554578|NCT01223027|DRUG|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
219554579|NCT00704249|DRUG|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
219554580|NCT00704249|DRUG|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
219554581|NCT01656876|BEHAVIORAL|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
219554582|NCT01656876|OTHER|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
219148246|NCT02035969|BEHAVIORAL|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
219148247|NCT06088225|DEVICE|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
219148248|NCT05286710|DEVICE|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was \>50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was \>50% after PTA treatment.
219148249|NCT00018785|PROCEDURE|donor bone marrow infusion|
219148250|NCT01217905|DRUG|AZD7687|Oral suspension
219148251|NCT03340714|DEVICE|Monitoring Device|Wear ADAMM
219148252|NCT05096663|DIETARY_SUPPLEMENT|Cobalamin|Given intramuscularly
219148253|NCT05096663|DRUG|Dexamethasone|Given orally (PO)
219148254|NCT05096663|DRUG|Docetaxel|Given IV
219148255|NCT05096663|DIETARY_SUPPLEMENT|Folic Acid|Given PO
219148256|NCT05096663|DRUG|Gemcitabine|Given IV
219148257|NCT05096663|DRUG|Nogapendekin Alfa|Given SC
219148258|NCT05096663|BIOLOGICAL|Pembrolizumab|Given IV
219148259|NCT05096663|DRUG|Pemetrexed|Given IV
219720363|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 25mg/kg/day or 15mg/kg/day will be dose selected for the next Cohort (Cohort 4)
219148260|NCT05096663|BIOLOGICAL|Ramucirumab|Given IV
219148261|NCT04589208|DRUG|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
219720364|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 10mg/kg/day dose selected for the next Cohort (Cohort 4) or the study will be stopped due to excessive toxicity.
219148262|NCT03180502|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219720365|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be selected from either Cohort 2 or 3 based on tolerance. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for seven days to 6 subjects.
219148263|NCT03180502|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219148264|NCT03180502|OTHER|Laboratory Biomarker Analysis|Correlative studies
219148265|NCT03180502|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219148266|NCT03180502|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219148267|NCT03180502|OTHER|Quality-of-Life Assessment|Ancillary studies
219148268|NCT03180502|OTHER|Questionnaire Administration|Ancillary studies
219148269|NCT03180502|DRUG|Temozolomide|Drug
219148270|NCT06804096|DRUG|Faropenem|Tab. Faropenem 200mg three times daily
219148271|NCT06804096|DRUG|Co-amoxiclav|Tab. Co-Amoxiclav 625mg three times daily
219148272|NCT06804096|DRUG|Clarithromycin 500 mg|Tab. Clarithromycin 500mg two times daily
219148273|NCT03217305|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
219148274|NCT05001477|DEVICE|TULSA Procedure|Transurethral ultrasound ablation procedure
219148275|NCT01824485|DRUG|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
219148276|NCT01824485|DRUG|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
219148277|NCT06969404|BIOLOGICAL|capillary blood sampling|capillary blood sampling during the hospital transfert
219148278|NCT06121349|DRUG|ocrelizumab|infusion therapy administered every six months
219148279|NCT06121349|DRUG|ofatumumab|self-injectable every month
219148280|NCT05979870|PROCEDURE|Valvuloplasty,|Choice of type of intervention decided on a multidisciplinary conference
219148281|NCT04287478|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
219148282|NCT03302741|DRUG|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
219148283|NCT03302741|OTHER|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
219148284|NCT03302741|DEVICE|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
219720366|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be the same as Cohort 4. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for 14 days to 6 subjects.
219720367|NCT07119697|OTHER|Shacklock Neural Mobilization|In the SNM group, participants lay supine with hips neutral and knees flexed to 45 degrees. Therapists applied the remote slider technique by extending the knee near end-range and dorsiflexing the ankle to 15 degrees, performed in 3 sets of 15 reps with 30-second rests. Each session lasted 20 minutes including setup. Progression was made by increasing hip flexion in 5 degrees increments when a VAS pain reduction of ≥2 cm was observed. This technique, based on neurodynamic principles, was designed to reduce neural mechanosensitivity and improve mobility in patients with lumbar radiculopathy.
219720368|NCT07119697|OTHER|McKenzie Extension Principle|MEP group was treated with MEP in a prone position, starting with 10 repetitions of active trunk extension, holding end-range for 3 seconds. If no symptom centralization occurred, therapists progressed from patient-applied overpressure (EIL-POP) to clinician-applied grade III mobilizations (3 oscillations/second), following McKenzie's force progression model. Each session included 3 sets of 10 repetitions with 1-minute rest between sets, totaling 15 minutes of active intervention. For unilateral symptoms, the approach advanced to hips-off-center techniques involving a 15 degree lateral shift. This graded sequence aimed to reduce nerve root compression and promote symptom centralization.
219148285|NCT03302741|DEVICE|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
219720369|NCT07119697|OTHER|Hydrocollator hot packs|Both groups received standardized thermotherapy using hydrocollator-heated moist hot packs (40 degrees centigrade, wrapped in 6-8 towel layers) applied to the lumbar region for 15-20 minutes to improve tissue compliance and reduce pain. Participants were positioned prone or side-lying based on comfort and symptom severity; semi-prone positions with pillow support were used for those with heightened sensitivity to maintain spinal neutrality. Thermotherapy was administered five times in week 1 and three times weekly during weeks 2-3. Skin condition and comfort were monitored. This pre-treatment method promoted transient pain relief and muscle relaxation, enhancing tolerance to subsequent therapeutic interventions.
219720370|NCT03599713|DRUG|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
219720371|NCT06805656|DRUG|Maraviroc|antiretroviral intensification
219720372|NCT06805656|DRUG|Dolutegravir|antiretroviral intensification
219720373|NCT06805656|BIOLOGICAL|Dendritic Cell Vaccine|therapeutic vaccination
219720374|NCT06805656|DRUG|Auranofin|purging
219720375|NCT06805656|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
219720376|NCT06942247|DEVICE|Active Comparator: Fracture Fixation (Inion Freedom Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
219720377|NCT06942247|DEVICE|Experimental: Fracture Fixation (Biological Hollow Bone Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
219554583|NCT01656876|BEHAVIORAL|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
219554584|NCT05748938|BIOLOGICAL|RD14-01|ROR1 Targeted CAR-T cells
219148286|NCT06164756|OTHER|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
219554585|NCT00540358|DRUG|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
219554586|NCT00540358|DRUG|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
219554587|NCT04618172|OTHER|Exercise|30 minute long exercises twice a week
219554588|NCT01581164|BIOLOGICAL|Influenza vaccine|Influenza vaccine: Injection, post transplant
219554589|NCT01581164|BIOLOGICAL|Varicella vaccine|Varicella vaccine: Injection, post transplant
219554590|NCT04169815|DIAGNOSTIC_TEST|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
219554591|NCT02812381|PROCEDURE|KT|to aplicate neuromuscular bandage technique(KT)
219554592|NCT02812381|PROCEDURE|SCS|To aplicate strain-counterstrain above trigger point
219554593|NCT03643731|DEVICE|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
219554594|NCT03572582|DRUG|Nivolumab|Nivolumab therapy combined with standard TACE treatment
219554595|NCT03572582|DRUG|TACE|TACE is performed by using drug eluting beads
219554596|NCT02575651|DRUG|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
219554597|NCT00333450|BIOLOGICAL|Pneumococcal vaccine|
219554598|NCT02722421|DRUG|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
219720378|NCT07114081|DIAGNOSTIC_TEST|Diagnostic laparoscopy|Minimal access surgery to determine the presence of characteristic endometriosis lesions on visual inspection of the pelvis
219720379|NCT06950593|OTHER|Task Specific Training (TST)|Task specific training activities are types of activities that may be used in standard of care for stroke rehabilitation. Tasks will be completed in sitting or standing. As is usual in studies for upper limb hemiparesis, study participants will be picking up objects with their affected hands. They will work on grasp, grasp-lift of objects, release of objects, reaching and grasping, and reaching without grasping.
219148287|NCT06164756|OTHER|Treatment As Usual (TAU)|Participants will receive standard of care treatment
219148288|NCT05390567|BEHAVIORAL|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
219148289|NCT05390567|BEHAVIORAL|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
219148290|NCT05390567|BEHAVIORAL|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
219148291|NCT06603090|BEHAVIORAL|Text message influenza vaccine reminders|Text message influenza vaccine reminders
219148292|NCT06603090|BEHAVIORAL|Text message COVID-19 vaccine reminders|Text message COVID-19 vaccine reminders
219148293|NCT06603090|BEHAVIORAL|Text message influenza and COVID-19 vaccine reminders|Text message influenza and COVID-19 vaccine reminders
219148294|NCT06532435|DIETARY_SUPPLEMENT|DHA & ARA Candy|Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
219148295|NCT05764187|OTHER|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
219148296|NCT06972524|DIETARY_SUPPLEMENT|a special probiotics from Mengniu Group, supplemented with milk powder|Sorbitol 、Xylitol 、Paracaseobacterium LC19 、Bifidobacterium lactis subsp. animalis MN-Gup 、Mulberry Leaf Extract 、Bitter Melon Powder 、Resistant Dextrin 、White Kidney Bean Extract 、Stachyose 、Galactooligosaccharides 、Food Flavoring、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide
219148297|NCT06972524|DIETARY_SUPPLEMENT|regular milk powder does not contain any additional supplementation, and the color, flavor, shape, taste, and weight are same with the probiotic milk powder|Sorbitol、Xylitol 、Food Flavoring 、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide、Maltodextrin
219148298|NCT06973733|BEHAVIORAL|Clinical data and biospecimen collection|"Clinical Data Collection: Case report forms were utilized to systematically capture multimodal clinical data, including: demographic characteristics, clinical symptoms and physical signs, laboratory test results, chest imaging data, organ support parameters, pharmacological interventions , complications and clinical outcomes.~Biospecimen Collection: ARDS patients underwent biospecimen collection at days 1, 4, and 7 post-diagnosis. High-risk ARDS cohorts provided specimens within 24 hours of ICU admission. Specimens included: peripheral blood, Sputum/BALF, stool and urine."
219148299|NCT06973954|OTHER|Text Message Intervention|This intervention was prepared by the researcher with the support of artificial intelligence to increase the activation of diabetic individuals in the experimental group. It consists of short messages with the themes of gain, loss and motivation related to diabetes and self-management.
219148300|NCT06974227|DEVICE|Assistive Pulse Data Collection (APDC) Device|An Assistive Pulse Data Collection Device prototype has been designed and manufactured by the Logistics and Supply Chain MultiTech R\&D Centre, Hong Kong. The device comprises a pulse sensor to record the patient's pulse and digitalize the pulse feature into waveform data. The digitalized waveform data is then converted the electronic signal into mechanical vibration that responds to the patient's pulse.
219554599|NCT02722421|DRUG|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
219554600|NCT01131091|DRUG|SK-0403|SK-0403 400 mg
219554601|NCT03641222|DEVICE|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
219554602|NCT06082505|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
219554603|NCT06082505|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
219554604|NCT00724958|BIOLOGICAL|Infliximab|Not specified in the protocol.
219554605|NCT06028477|DEVICE|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
219554606|NCT06622239|DRUG|Naltrexone|naltrexone 50mg for 6 weeks
219554607|NCT06622239|DRUG|Placebo|placebo for 6 weeks
219148301|NCT06973980|OTHER|Exercise|The exercises will be applied only to the intervention group for 12 weeks and will be progressively intensified every 4 weeks.
219148302|NCT06972329|OTHER|Cerebral Near infrared spectroscopy (NIRSc).|Continuous cerebral near-infrared spectroscopy (NIRSc) during resuscitation in a patient treated for out-of-hospital cardiac arrest (OHCA).
219148303|NCT06972862|OTHER|Osteogenic Index Optimized Exercise Training Program|The OI- Optimized Training is 6 months of planned, non-linear periodized training on a leg press machine called the PPM (Athletic Republic, Salt Lake City, UT) with a maintenance program during the semester breaks, as necessary.
219148304|NCT06974266|DIETARY_SUPPLEMENT|Probiotic|Subjects receive AKM Lab-01 Enteric-coated once daily by oral, 34B TFU/day , within half an hour after breakfast for 3 months.
219148305|NCT06974266|DIETARY_SUPPLEMENT|Placebo|Subjects receive placebo once daily by oral, one capsule/day, within half an hour after breakfast for 3 months.
219554608|NCT01869556|DRUG|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
219554609|NCT01869556|DRUG|Ergot|Ergot 0.25mg IV
219554610|NCT01869556|DRUG|Carboprost|Carboprost 0.25mg IM
219148306|NCT06974136|DEVICE|transcranial electrical stimulation|Transcranial electrical stimulation (tES) is a non-invasive neuromodulation technique that applies low-intensity electrical currents to the scalp to modulate brain activity. It targets specific brain regions to influence neuronal excitability, connectivity, and plasticity, offering potential therapeutic benefits for neurological and psychiatric conditions. tES is portable, cost-effective, and generally well-tolerated, with minimal side effects such as mild tingling or itching at the stimulation site.
219148307|NCT06973200|COMBINATION_PRODUCT|Dihydroartemisin-piperaquine|All children with S. mansoni and/or S. haematobium infections at enrolment will then be treated with dihydroartemisinin-piperaquine (DP) and followed up on days 1, 2, 3, 4, 28, and 42 to assess the efficacy and safety of DP.
219148308|NCT05103527|DEVICE|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
219148309|NCT03144674|DRUG|Parsaclisib|Parsaclisib at the protocol-defined dose.
219148310|NCT04100109|DIETARY_SUPPLEMENT|Polylactose|Polylactose 15 g/day
219148311|NCT04100109|OTHER|Placebo|Cellulose 15 g/day
219554611|NCT01591915|OTHER|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
219554612|NCT03908307|DRUG|OZURDEX|Implant 700 μg
219554613|NCT00150683|DEVICE|vibration and passive standing versus passive standing alone|
219554614|NCT05191511|RADIATION|Far- infrared|safety of far- infrared
219554615|NCT05194202|BEHAVIORAL|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
219554616|NCT02559219|OTHER|Questionniares|
219554617|NCT03017352|DRUG|Exenatide|
219554618|NCT03017352|DRUG|Placebos|
219554619|NCT01520987|DRUG|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
219554620|NCT01520987|DRUG|Placebo|once-daily
219554621|NCT05735028|DRUG|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
219554622|NCT05735028|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
219554623|NCT05109520|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
219554624|NCT03567460|BEHAVIORAL|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
219554625|NCT02919020|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
219554626|NCT02919020|OTHER|Resistance exercise|resistance exercise to strengthen lower limbs
219554627|NCT04997720|OTHER|Training|"Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation."
219554628|NCT02005562|DRUG|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
219554629|NCT02005562|DRUG|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
219554630|NCT02005562|DRUG|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
219554631|NCT02005562|DRUG|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
219554632|NCT02005562|DRUG|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
219232018|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
219148312|NCT03008018|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
219720380|NCT06950593|OTHER|Transcutaneous electrical spinal cord stimulation (TESS)|The Digitimer DS8R Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation. The stimulus intensity used during the intervention will be determined based on individual maximum tolerance. We expect this current amplitude to be between 10mA and 100mA. Stimulation time will be standardized to a 30min duration during which the participant will perform task specific training tasks.
219720381|NCT06950593|OTHER|Sham transcutaneous electrical spinal cord stimulation (Sham TESS)|The Sham TESS intervention will utilize the same device and setup as the true TESS intervention. However, after turning on the stimulation and reaching the appropriate intensity, the stimulation will be ramped down and turned off for the remainder of the treatment session. The participant will be told that the stimulation was brought down to a sub-threshold level in order to maintain treatment group blinding.
219720382|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
219720383|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
219720384|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
219720385|NCT01420744|DRUG|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
219720386|NCT01420744|DRUG|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
219720387|NCT06551558|OTHER|global warming|A systematic pre- and post-operative warming associated with the optimization of per-operative warming.
219720388|NCT06551558|OTHER|per operative warming|"per-operative warming only thanks to the Optimized Forced air blanket with a prewarming of 10 minutes performed in the operating room."
219720389|NCT04652310|DEVICE|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
219148313|NCT04169399|DRUG|Toripalimab|240mg intravenously every 3 weeks
219148314|NCT04169399|RADIATION|Stereotactic body radiotherapy|Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
219148315|NCT05788146|OTHER|Cognitive Behavioural Therapy|A psychological intervention used to target depression
219720390|NCT04652310|DEVICE|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
219720391|NCT00347490|DRUG|Enoxaparine|
219720392|NCT03537430|PROCEDURE|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
219720393|NCT03537430|PROCEDURE|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
219720394|NCT06037915|DEVICE|low flow oxygen with nasopharyngeal tube|low flow oxygen with nasopharyngeal tube
219720395|NCT06037915|DEVICE|high flow oxygen with OptiflowTM Nasal High Flow|high flow oxygen with OptiflowTM Nasal High Flow
219232019|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
219232020|NCT04323514|DIETARY_SUPPLEMENT|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
219554633|NCT01479062|BEHAVIORAL|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
219148316|NCT05968833|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
219232021|NCT04570488|OTHER|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
219554634|NCT01479062|BEHAVIORAL|Usual Care|Placebo Control
219554635|NCT05721469|BEHAVIORAL|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
219554636|NCT04171401|OTHER|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
219720396|NCT04167670|DRUG|Vonoprazan|Over-encapsulated tablets administered orally.
219720397|NCT04167670|DRUG|Amoxicillin|Capsules administered orally.
219720398|NCT04167670|DRUG|Clarithromycin|Tablets administered orally.
219720399|NCT04167670|DRUG|Lansoprazole|Over-encapsulated capsules administered orally.
219148317|NCT05582694|BIOLOGICAL|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
219148318|NCT06973447|PROCEDURE|Anterior suprascapular nerve block (ASSNB)|10 mL of 0.25% bupivacaine
219148319|NCT06973447|PROCEDURE|Infraclavicular Brachial Plexus Block (ICBPB)|15 mL of 0.25% bupivacaine
219148320|NCT06973447|PROCEDURE|Costoclavicular brachial plexus block (CCBPB)|15 mL of 0.25% bupivacaine
219148321|NCT00922649|DEVICE|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
219148322|NCT05576181|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
219148323|NCT05576181|DRUG|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
219148324|NCT05576181|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219148325|NCT05576181|DRUG|VP-16|VP-16 is used for lymphodepletion.
219148326|NCT05576181|PROCEDURE|HSCT|Hematological stem cell transplantation
219148327|NCT06225388|OTHER|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
219148328|NCT06225388|OTHER|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
219148329|NCT03611205|PROCEDURE|Computed Tomography|Undergo dPET/CT
219148330|NCT03611205|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
219148331|NCT03209037|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
219148332|NCT05592925|DIAGNOSTIC_TEST|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
219148333|NCT06491212|DIAGNOSTIC_TEST|Determination of Foot Deformity Level|One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.
219148334|NCT06491212|DIAGNOSTIC_TEST|Foot Function Index|Evaluation of Foot Function
219148335|NCT06491212|DIAGNOSTIC_TEST|UFAA-International Physical Activity Questionnaire|To determination of physical activity level.
219148336|NCT06491212|DIAGNOSTIC_TEST|Diaphragm ultrasound measurements|Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.
219148337|NCT06491212|DIAGNOSTIC_TEST|NeuruCom Balance Master Balnce and Performans Test|Balance master will be used for postural stability, static and dynamic balance measurements.
219148338|NCT06491212|DIAGNOSTIC_TEST|Plantar Pressure Assessment|When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
219148339|NCT04488783|DIETARY_SUPPLEMENT|zinc and ascorbate|oral zinc and ascorbate
219148340|NCT00223587|OTHER|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
219232022|NCT00783185|BEHAVIORAL|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
219232023|NCT00783185|BEHAVIORAL|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
219554637|NCT00636324|DEVICE|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
219554638|NCT00636324|DEVICE|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
219554639|NCT04729101|DRUG|Vonoprazan|Oral tablet
219554640|NCT04729101|DRUG|Lansoprazole|Oral capsule
219554641|NCT03241186|DRUG|Ipilimumab|1mg/kg
219554642|NCT03241186|DRUG|Nivolumab|3mg/kg
219554643|NCT03241186|DRUG|Nivolumab|480mg
219554644|NCT00274625|DEVICE|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
219554645|NCT00274625|PROCEDURE|Control|Incision is closed without the placement of a graft material (standard of care control)
219554646|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
219554647|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
219554648|NCT03845816|BEHAVIORAL|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
219554649|NCT06677723|BEHAVIORAL|physical activity|moderate-intensity running
219554650|NCT05060458|OTHER|No intervention|No intervention
219554651|NCT00388219|DRUG|Transtec (R) PRO (buprenorphine)|
219554652|NCT02959840|DEVICE|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
219554653|NCT02959840|DRUG|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
219554654|NCT02959840|DRUG|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
219554655|NCT02802462|BEHAVIORAL|HIT|3-minute intervals at 40% and 80%VO 2max
219554656|NCT02802462|BEHAVIORAL|MCT|sustained 60%VO 2max
219148341|NCT06465979|BEHAVIORAL|Speech Manipulation|"The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition."
219148342|NCT04845685|DEVICE|Continuous Glucose Monitor (CGM)|A device that measures blood sugar levels every 1-5 minutes
219148343|NCT03368664|DRUG|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
219148344|NCT03368664|DRUG|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
219148345|NCT03368664|DRUG|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
219148346|NCT03368664|DRUG|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
219148347|NCT03368664|DRUG|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
219148348|NCT03368664|DRUG|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
219148349|NCT03368664|DRUG|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
219148350|NCT03368664|DRUG|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
219148351|NCT03368664|DRUG|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
219148352|NCT03368664|DRUG|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
219148353|NCT03368664|DRUG|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
219148354|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
219148355|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
219148356|NCT00837616|DRUG|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
219148357|NCT00837616|DRUG|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
219148358|NCT00562679|OTHER|There is no intervention|
219148359|NCT04090190|DRUG|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
219148360|NCT00956982|DRUG|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing \< 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
219148361|NCT04448418|OTHER|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
219554657|NCT00003387|DRUG|carboplatin|
219554658|NCT00003387|DRUG|chemotherapy|
219554659|NCT00003387|DRUG|paclitaxel|
219554660|NCT00003387|RADIATION|radiation therapy|
219554661|NCT04022031|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
219554662|NCT05746507|BEHAVIORAL|Night Respite Care|(see description above)
219554663|NCT02795026|PROCEDURE|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
219554664|NCT02795026|PROCEDURE|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
219554665|NCT00497679|DRUG|AZD1152|7-day continuous intravenous infusion
219554666|NCT06375187|BIOLOGICAL|Engineering Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
219554667|NCT01762228|DEVICE|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
219148362|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
219232024|NCT02254902|BEHAVIORAL|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
219232025|NCT01924117|OTHER|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
219232026|NCT01393600|DRUG|NBI-98854|12.5 mg powder in bottle once daily for 14 days
219232027|NCT01393600|DRUG|NBI-98854|50 mg powder in bottle once daily for 14 days
219232028|NCT01393600|DRUG|Placebo|Solution containing no active substance
219232029|NCT02374372|DEVICE|conventional hemodialysis|
219232030|NCT02374372|DEVICE|hemodiafiltration On-line|
219232031|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
219232032|NCT00603798|DRUG|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
219232033|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
219232034|NCT03848741|BEHAVIORAL|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
219232035|NCT03848741|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
219232036|NCT03848741|DIETARY_SUPPLEMENT|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
219232037|NCT03848741|DIETARY_SUPPLEMENT|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
219554668|NCT01762228|DIETARY_SUPPLEMENT|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
219720400|NCT01127061|BEHAVIORAL|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
219148363|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
219232038|NCT02687841|DRUG|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
219554669|NCT03348488|PROCEDURE|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
219232039|NCT02687841|DRUG|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
219232040|NCT04996186|OTHER|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
219232041|NCT04326894|DRUG|25 mg/week oral methotrexate tablets|
219554670|NCT06677983|OTHER|Bioflex Crowns|A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.
219554671|NCT06677983|OTHER|Stainless steel crown|An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
219554672|NCT06628609|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
219554673|NCT06628609|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
219148364|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
219148365|NCT00457691|DRUG|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
219148366|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
219148367|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
219148368|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
219232042|NCT04326894|DRUG|25mg/week oral placebo tablets|
219232043|NCT05116306|DRUG|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
219232044|NCT05116306|DRUG|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
219232045|NCT04006015|OTHER|No intervention being delivered.|No interventions are being delivered.
219232046|NCT03153566|BIOLOGICAL|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
219232047|NCT03153566|DEVICE|cryotherapy|10 sec 1 cycle into all genital warts
219232048|NCT04366895|OTHER|conventional single implant overdenture|conventional manufactured implant overdenture
219232049|NCT04366895|OTHER|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
219232050|NCT03039322|DIAGNOSTIC_TEST|Serum Golgi Protein 73|Serum test
219232051|NCT02327806|DEVICE|pulsed electromagnetic field therapy|
219232052|NCT02264847|DRUG|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
219232053|NCT02264847|DRUG|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
219148369|NCT00457691|DRUG|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
219148370|NCT02644239|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet with high fat (90%)
219148371|NCT00042224|PROCEDURE|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
219148372|NCT00042224|DRUG|Clozapine|Patients with psychotic symptoms will receive clozapine
219148373|NCT04316234|OTHER|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
219148374|NCT01818401|DEVICE|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
219148375|NCT01818401|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
219148376|NCT00009646|DRUG|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
219148377|NCT00009646|DRUG|Indomethacin|0.1 mg per kilogram of body weight
219148378|NCT00009646|DRUG|Placebo|0.1 mg per kilogram of body weight
219148379|NCT05744206|OTHER|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
219148380|NCT01456078|DRUG|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
219148381|NCT03915613|DRUG|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
219148382|NCT03915613|DRUG|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
219148383|NCT01165658|RADIATION|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
219148384|NCT01559519|DRUG|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
219148385|NCT01656096|DEVICE|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
219148386|NCT01656096|OTHER|Sham procedure|
219148387|NCT04114968|OTHER|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
219148388|NCT03772379|DEVICE|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
219148389|NCT03772379|PROCEDURE|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
219148390|NCT01121549|DRUG|Aromasin|25 mg daily continuously
219148391|NCT00001063|DRUG|Stavudine|
219148392|NCT00001063|DRUG|Zidovudine|
219148393|NCT00001063|DRUG|Didanosine|
219554674|NCT06628609|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
219148394|NCT04789408|DRUG|Cyclophosphamide|Administered intravenously
219148395|NCT04789408|DRUG|Fludarabine|Administered intravenously
219148396|NCT04789408|BIOLOGICAL|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
219148397|NCT01278888|PROCEDURE|Anterolateral thoracotomy|Standard anterolateral thoracotomy
219148398|NCT01278888|PROCEDURE|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
219148399|NCT01278888|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
219148400|NCT01278888|PROCEDURE|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
219148401|NCT04021667|OTHER|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
219148402|NCT02808039|OTHER|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
219554675|NCT06628609|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
219554676|NCT01355328|PROCEDURE|laser and radiofrequency|different laser and radiofrequency with different fluences
219148403|NCT00687011|DRUG|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
219148404|NCT03547804|DRUG|Apatinib|500 mg qd/250mg
219720401|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
219720402|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
219720403|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
219720404|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
219720405|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
219720406|NCT00962598|DRUG|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
219720407|NCT00962598|DIETARY_SUPPLEMENT|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
219720408|NCT03719547|PROCEDURE|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
219148405|NCT03547804|DRUG|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
219148406|NCT00012740|BEHAVIORAL|Casefinding and Referral System|
219148407|NCT00211731|BEHAVIORAL|Chronic Disease Self Management Course|
219148408|NCT02079844|DRUG|Roflumilast|Roflumilast tablets
219720409|NCT03719547|PROCEDURE|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
219720410|NCT03719547|DIAGNOSTIC_TEST|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
219720411|NCT06532916|OTHER|Experimental: Group1: Estelite Sigma Quick|Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).
219720412|NCT06532916|OTHER|Experimental: Group 2: Estelite Flow Quick|Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
219720413|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
219720414|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
219720415|NCT05310552|OTHER|No interventions - observational study|No interventions - observational study
219720416|NCT02955394|DRUG|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
219720417|NCT02955394|DRUG|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
219720418|NCT02729168|BIOLOGICAL|Human rabies vaccine|
219720419|NCT05846581|DEVICE|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
219148409|NCT02079844|DRUG|Placebo|Roflumilast placebo-matching tablets
219148410|NCT02079844|DRUG|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
219148411|NCT04771351|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
219148412|NCT04771351|DRUG|Placebo|Diluent solution
219720420|NCT05957107|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|The drug was administered once every 4 weeks.
219720421|NCT03850587|DRUG|Celecoxib 200mg|comparator medication
219720422|NCT03850587|DRUG|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
219720423|NCT03850587|DRUG|Tramadol 75mg+ Celecoxib 200mg|experimental medication
219720424|NCT03850587|DRUG|Tramadol 150mg+ Celecoxib 200mg|experimental medication
219720425|NCT06367114|BIOLOGICAL|ssCART-19|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
219720426|NCT06367114|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
219148413|NCT01420549|DRUG|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
219148414|NCT01420549|DRUG|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
219148415|NCT06011525|OTHER|standard cold cap|"Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device."
219148416|NCT06011525|OTHER|scalp-cooling technique|Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
219720427|NCT06367114|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
219720428|NCT05872399|OTHER|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
219720429|NCT03172000|DIAGNOSTIC_TEST|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
219720430|NCT01168180|OTHER|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
219720431|NCT01168180|OTHER|Ultrasound therapy and hot pack|
219148417|NCT02021760|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
219148418|NCT02791750|OTHER|questionnary of quality of life|
219720432|NCT00133211|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation
219720433|NCT04373057|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
219720434|NCT04373057|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
219720435|NCT01576965|DRUG|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
219720436|NCT01610388|DRUG|500mg IV GSK1322322/placebo|500mg IV
219720437|NCT01610388|DRUG|1000mg oral GSK1322322/placebo|1000mg oral
219720438|NCT01610388|DRUG|1000mg IV GSK1322322/placebo|1000mg IV
219720439|NCT01610388|DRUG|1500mg oral GSK1322322/placebo dose|1500mg oral
219720440|NCT01610388|DRUG|1500mg IV GSK1322322/placebo|1500mg IV
219720441|NCT01610388|DRUG|2000mg IV GSK1322322J/placebo|2000mg IV
219720442|NCT01610388|DRUG|3000mg IV GSK1322322J/placebo|3000mg IV
219720443|NCT01610388|DRUG|1000mg IV GSK1322322J/placebo|1000mg IV
219720444|NCT04375215|PROCEDURE|Selective caries removal|After caries removal restoration of tooth will be performed
219148419|NCT04414904|OTHER|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
219148420|NCT06184451|OTHER|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
219554677|NCT05122351|DRUG|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
219554678|NCT04414137|OTHER|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
219554679|NCT05550831|PROCEDURE|Radiofrequency|Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
219554680|NCT04397640|DIAGNOSTIC_TEST|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
219554681|NCT04931160|OTHER|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
219554682|NCT01754376|DRUG|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
219720445|NCT04375215|PROCEDURE|Stepwise caries removal|After caries removal restoration of tooth will be performed
219720446|NCT00003456|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219720447|NCT06078293|BEHAVIORAL|Home-based Exercise Program|12-week home-based exercise program that involves individualized exercise prescription and motivational health coaching calls.
219720448|NCT05136664|DRUG|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
219720449|NCT05136664|DRUG|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
219720450|NCT05136664|DRUG|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
219720451|NCT06957223|DRUG|Dextromethorphan-Bupropion|Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.
219720452|NCT06957223|DRUG|SSRIs|Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.
219720453|NCT06955845|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|Patients in this arm will receive weekly EMDR sessions for 6 weeks
219554683|NCT01754376|DRUG|Vemurafenib|Tablets given twice daily.
219554684|NCT03091868|DRUG|Placebo oral capsule|Matching placebo capsules. Oral administration.
219554685|NCT03091868|DRUG|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
219554686|NCT03091868|DRUG|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
219148421|NCT06184451|DEVICE|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
219148422|NCT06184451|DEVICE|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
219148423|NCT01403168|OTHER|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
219148424|NCT01403168|OTHER|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
219148425|NCT06972992|DRUG|ASC47 +Semaglutide|ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
219148426|NCT06972992|DRUG|Placebo+Semaglutide|Placebo single subcutaneous injection + Semaglutide QW for 4 weeks
219148427|NCT06429852|BEHAVIORAL|The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program|The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
219148428|NCT05857813|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
219148429|NCT04861532|DIAGNOSTIC_TEST|Imaging|MRI scanning using new protocols
219148430|NCT06820879|DEVICE|Viscoelastic Tests (ROTEM)|Viscoelastic Tests (2-6 tests for the study over the first 24 hours)
219148431|NCT06463470|BEHAVIORAL|Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
219148432|NCT00541333|DRUG|Copaxone Injection|
219148433|NCT05485129|DEVICE|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
219148434|NCT01048931|PROCEDURE|single-port LAVH|single-port LAVH
219148435|NCT05604937|OTHER|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
219148436|NCT05604937|DRUG|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
219148437|NCT06994806|DRUG|KQB168|Oral KQB168
219148438|NCT06994806|DRUG|Pembrolizumab|Intravenous pembrolizumab
219148439|NCT06993870|DRUG|HBT-708|bispecific antibody
219148440|NCT06677515|OTHER|VR training|The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
219148441|NCT06677099|PROCEDURE|chest physiotherapy|Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique , positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
219554687|NCT03091868|DRUG|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
219554688|NCT03091868|DRUG|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
219554689|NCT01735786|DEVICE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
219554690|NCT02502968|DRUG|Cytarabine|
219554691|NCT02502968|DRUG|BL-8040|
219554692|NCT02502968|DRUG|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
219554693|NCT01056926|BEHAVIORAL|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
219554694|NCT01056926|DRUG|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
219554695|NCT01056926|DRUG|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
219148442|NCT06677099|PROCEDURE|EIT-guided chest physiotherapy|EIT-guided modified postural drainage combined with vibrations and chest percussion: tidal variation images in EIT reveals heterogeneously ventilated regions. Physiotherapist identified such regions at the bedside and instructed the patient to take the appropriate drainage position, so that the poorly ventilated regions became gravity non-dependent regions. Subsequently, the physiotherapist put her hands on the poorly ventilated area with a vibratory force. A compressive pressure was produced by the therapist's arms.
219148443|NCT06861894|DRUG|Adebrelimab and nab-paclitaxel and carboplatin|Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy
219148444|NCT06861894|RADIATION|Radiation|concurrent chemoradiotherapy
219148445|NCT06861894|PROCEDURE|standard oesophagectomy|standard oesophagectomy
219148446|NCT06861894|OTHER|active surveillance|active surveillance
219148447|NCT06377345|DEVICE|AeviceMD device|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
219148448|NCT06377345|BEHAVIORAL|Standard care|All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
219148449|NCT06677528|OTHER|Questionnaire|Questionnaire on Aortic Valve Disease, HADS-D, SCL-27, MLHFQ
219232054|NCT04389086|DRUG|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
219232055|NCT04389086|RADIATION|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
219232056|NCT04389086|PROCEDURE|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
219232057|NCT00623649|DRUG|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
219232058|NCT00623649|DRUG|Placebo|Dose escalation study with a full review of all safety data following each cohort.
219232059|NCT05310292|BIOLOGICAL|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
219232060|NCT05310292|BIOLOGICAL|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
219232061|NCT00811239|DRUG|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
219720454|NCT06955845|DRUG|Selective serotonin reuptake inhibitors|The patients will receive an SSRI medication daily for 6 weeks. The dose will be titrated by the clinician.
219720455|NCT04239664|OTHER|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
219720456|NCT04270955|PROCEDURE|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
219720457|NCT04270955|PROCEDURE|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
219720458|NCT00297934|DEVICE|Pro-adjuster mechanical spinal manipulative device|
219720459|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
219720460|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
219720461|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
219720462|NCT00479232|DRUG|vorinostat|
219720463|NCT00479232|DRUG|decitabine|
219720464|NCT02689622|OTHER|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
219720465|NCT02689622|OTHER|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
219720466|NCT02689622|OTHER|physical performance|Activities of Daily Living and physical performance
219148450|NCT06676202|BEHAVIORAL|Progressive Relaxation Exercises|It combines the contraction and relaxation of large muscle groups such as the face, arms, legs, neck and back with deep breathing exercises. Before applying progressive relaxation exercises, the environment should be quiet, dimly lit, a comfortable chair or armchair should be sat or lying down, and clothing should be loose and comfortable, and it is recommended to apply it one hour after eating. In the application of progressive relaxation exercises, it is first asked to breathe regularly. After our breathing rhythm is regulated, the hands, arm muscles, shoulder and neck muscles, chest, abdominal and hip muscles, legs, feet and facial muscles are contracted with a 5-7 second breathing exercise and relaxed during exhalation. This is repeated with 4-5 breathing exercises for each muscle and the exercise is ended when the eyelids are opened.
219148451|NCT02163876|DRUG|HuCNS-SC cells|surgery arm
219232062|NCT00811239|OTHER|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
219232063|NCT00005635|BIOLOGICAL|trastuzumab|
219554696|NCT03098186|BEHAVIORAL|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
219554697|NCT03098186|BEHAVIORAL|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
219554698|NCT04590781|BIOLOGICAL|XmAb18087|Monoclonal bispecific antibody
219148452|NCT04313868|DRUG|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
219148453|NCT06611982|OTHER|Unconditional cash transfer|$1000/month for 12 months
219148454|NCT06611982|OTHER|Contact information for social worker and financial counselor|Information on financial toxicity and contact information for social worker and financial counselor
219148455|NCT06109129|DEVICE|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
219232064|NCT00005635|DRUG|paclitaxel|
219232065|NCT04891497|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
219232066|NCT04891497|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
219232067|NCT02899533|DRUG|[18F] FES|\[18F\] FES PET/CT scan, imaging tracer
219232068|NCT03358485|DRUG|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
219232069|NCT03358485|OTHER|Placebo|Placebo
219232070|NCT02407288|DEVICE|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
219232071|NCT02407288|DEVICE|Sham tDCS|
219554699|NCT04590781|DRUG|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
219554700|NCT01737255|OTHER|Whole body MRI|Individuals will undergo whole body and brain MRI
219554701|NCT01737255|OTHER|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
219554702|NCT00071539|DRUG|TP-38|Recombinant chimeric protein
219554703|NCT00071539|DRUG|TP38|recombinant chimeric protein
219554704|NCT01386034|DRUG|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
219554705|NCT00006034|BIOLOGICAL|keyhole limpet hemocyanin|Given intradermally and IV
219554706|NCT00006034|DRUG|doxorubicin hydrochloride|Given IV
219554707|NCT04449458|BEHAVIORAL|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
219554708|NCT04449458|BEHAVIORAL|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
219554709|NCT01291641|DRUG|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
219554710|NCT01291641|DRUG|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
219554711|NCT01291641|DRUG|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
219554712|NCT04313296|DEVICE|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
219720467|NCT03945136|BEHAVIORAL|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
219148456|NCT07022340|BEHAVIORAL|Resistance Training Intervention|Participants will complete a brief aerobic warm-up and dynamic stretching prior to each strength training session. Participants will complete 9 exercises for all major muscle groups. Strength testing at the baseline study visit will be used to determine initial load. Participants will complete 1 set of moderate-intensity loads (\~50% maximum and \~12 repetitions) in week 1, 2 sets in week 2, and 3 sets in week 3. By week 4, participants will be completing 3 sets at 60% of maximum. Weight loads will be progressively increased so volitional fatigue is reached by 8-12 repetitions/set.
219148457|NCT06631222|BEHAVIORAL|cognitive behavioral therapy|The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.
219148458|NCT06631222|OTHER|sub-occipital inhibitory pressure|The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.
219148459|NCT06631222|OTHER|deep friction massage|Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
219232072|NCT00002977|BIOLOGICAL|filgrastim|
219232073|NCT00002977|DRUG|melphalan|
219232074|NCT00002977|DRUG|thiotepa|
219232075|NCT00002977|PROCEDURE|peripheral blood stem cell transplantation|
219232076|NCT02491645|OTHER|Sensory interventions|"1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done."
219232077|NCT06315465|DIETARY_SUPPLEMENT|Modified Atkin's Diet with standard of care|children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
219232078|NCT06315465|OTHER|Standard of Care|Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
219232079|NCT00889863|DRUG|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
219232080|NCT00889863|DRUG|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
219232081|NCT04211194|PROCEDURE|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
219232082|NCT00475969|DRUG|duloxetine|
219232083|NCT00475969|DRUG|placebo|
219232084|NCT01118156|OTHER|Education|75-minute training teaching utilization of new standardized suicide nomenclature
219232085|NCT01532609|BEHAVIORAL|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
219148460|NCT06631222|OTHER|Spinal manipulation|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateral flexion will be used. Application will be bilateral. First, cephalic decompression will be performed lightly, followed by small circumductions. Selective tension will be applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique will be applied with the aim of increasing occiput, atlas, and axis joint mobility.
219232086|NCT02405000|OTHER|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
219232087|NCT03161665|OTHER|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
219232088|NCT05121376|GENETIC|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
219232089|NCT05121376|GENETIC|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
219232090|NCT05121376|GENETIC|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
219232091|NCT05121376|GENETIC|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
219232092|NCT05121376|GENETIC|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
219232093|NCT05121376|GENETIC|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
219148461|NCT06631222|OTHER|Exercises for forward head posture|"Scapular stabilization exercises:~1. In quadruped position, the patient lift¬ up his arms alternatively with shoulder abduction and 120 ° flexion.~2. In sitting position, with 90° knee flexion on a stool or bed without backrest, patient hold a pair of dumb¬bells (2 kg) in each hand and lift them up laterally while maintaining scapulae's height below 80°. The patient was instructed to hold each stage for 10 seconds and then re-turn to the starting position and three sets of 10 repetitions with 30-second pause in between were completed.~3. As for the progression of scapular stability exercise, T to Y the patient was instructed to lie in prone lying position on Swiss ball with arms abducted to 90° (the letter T); then she asked to flex elbows to 90°, retract scapulae and externally ro¬tate arms while keeping arm in 90° abductions. While maintaining the retraction of scapula, the patient is asked to raise his arms above head and extend the elbow while his arm flexed and abducted to 120°"
219720468|NCT00470613|GENETIC|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
219720469|NCT05879913|DEVICE|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
219720470|NCT05399771|DEVICE|Laser Doppler|Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
219720471|NCT05399771|DEVICE|Radiofrequency Heating System|The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
219720472|NCT05399771|DEVICE|Thermal Imaging|Study team will take thermal imaging photographs of the treatment area following each treatment.
219720473|NCT05399771|OTHER|Healthcare Questionnaire & Measurement|"A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape."
219720474|NCT05253508|DRUG|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
219720475|NCT03112252|OTHER|no specifications. Depending on the patients|patients with allergic rhinitis
219720476|NCT02562885|DEVICE|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
219720477|NCT00520000|DRUG|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
219554713|NCT04264819|DRUG|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
219554714|NCT02247518|DRUG|Cialis Tab. 5mg|
219554715|NCT02247518|DRUG|Harnal-D Cap. 0.2mg|
219554716|NCT06535490|PROCEDURE|EUS-FNA|Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
219554717|NCT06535490|DRUG|ATBp|Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
219148462|NCT07023094|DRUG|Ropivacaine 0.2% for PENG Block|U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
219148463|NCT07023094|DRUG|Ropivacaine 0.2% for LFCB|LFCB (0.1 mL/kg) with 0.2% ropivacaine
219148464|NCT07023094|DRUG|Ropivacaine 0.2% for L-ESPB|Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
219148465|NCT07023094|DRUG|Ropivacaine 0.2% for S-ESPB|Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
219720478|NCT00520000|DRUG|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
219720479|NCT00520000|DRUG|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
219720480|NCT00520000|DRUG|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
219148466|NCT07025304|DEVICE|REFLEX ULTRA 45|One time use for surgery
219148467|NCT05669014|DRUG|Daxdilimab|Participants will be administered daxdilimab by subcutaneous (SC) injection.
219148468|NCT05669014|DRUG|Placebo|Participants will be administered identically matching placebo by SC injection.
219232094|NCT05121376|GENETIC|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
219232095|NCT01070199|BEHAVIORAL|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
219554718|NCT00459823|DRUG|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
219554719|NCT03336879|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
219720481|NCT06962579|BEHAVIORAL|Exercise intervention|"* 30-minute face-to-face session with physiotherapist outlining the state of the science on the importance and benefits of physical activity during and after cancer treatment and advising patients to engage in regular physical activity according to the general guidelines~* 12-week individually tailored exercise program~  * Home-based aerobic exercise, 3 times per week at moderate intensity~ * Supervised resistance and sensorimotor exercises, 2 times per week"
219720482|NCT03542799|BIOLOGICAL|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
219148469|NCT06689501|COMBINATION_PRODUCT|SPICE BLEND CAPSULE|The study product is a powder mix of L-carnitine tartrate yeast protein hydrolysate and dihydrocapsiate.in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
219720483|NCT05579340|OTHER|Exercise|6 months of combined aerobic and resistance exercise
219554720|NCT04502706|DRUG|GS-0189|GS-0189 will be administered intravenously.
219554721|NCT04502706|DRUG|Rituximab|Rituximab will be administered intravenously.
219148470|NCT06689501|OTHER|Placebo|The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
219148471|NCT06720987|DRUG|KQB365|Intravenous KQB365
219148472|NCT06720987|DRUG|Cetuximab|Intravenous cetuximab
219148473|NCT07039539|BEHAVIORAL|Harm Reduction intervention|Care intervention guided by the harm reduction paradigm. Based on the acceptance of participants' needs as a starting point for constructing care responses. Guidance will be provided in collective meetings with information based on reliable scientific evidence and will support the construction of new knowledge and practices of mutual support.
219232096|NCT01070199|BEHAVIORAL|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
219554722|NCT02136706|PROCEDURE|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
219554723|NCT05302479|OTHER|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
219148474|NCT06705517|BEHAVIORAL|Mediterranean Diet|The MD emphasizes a plant-based approach, with a high consumption of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate amounts of fish, seafood, and dairy, while limiting meat, particularly red and processed varieties. Olive oil serves as the main fat source in the diet. In the case of this study participants will also be instructed to limit dairy intake, that although traditionally part of the MD, might exacerbate disease symptomatology in PD patients, likely due to the urate lowering effect of dairy.
219554724|NCT01159106|OTHER|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
219554725|NCT01159106|OTHER|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
219554726|NCT02400463|DRUG|Ruxolitinib|
219554727|NCT05393349|BEHAVIORAL|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
219554728|NCT00602615|DRUG|Torsemide|
219554729|NCT02400515|OTHER|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
219554730|NCT03205501|DRUG|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
219554731|NCT03205501|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
219720484|NCT03284099|DRUG|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
219720485|NCT01713517|OTHER|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
219720486|NCT01713517|DEVICE|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
219148475|NCT06728644|DRUG|L-arginine intervention|L-arginine intervention for 3 months, 3 g per day.
219720487|NCT02849886|DRUG|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
219720488|NCT02849886|DRUG|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC."
219148476|NCT07052188|PROCEDURE|without any preoperative stenting|Patients will have RIRS without any preoperative stenting.
219148477|NCT07052188|PROCEDURE|(DJ) stent placed with sedation and undergo RIRS within 2-4 weeks|Patients will have a double-J (DJ) stent placed with sedation and undergo RIRS within 2-4 weeks.
219148478|NCT07052188|PROCEDURE|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks.|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks
219148479|NCT07053163|DRUG|Crystalloid and blood as resuscitation|Patients receive crystalloid and blood as resuscitation
219720489|NCT05751863|OTHER|Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects|"The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects."
219720490|NCT05751863|OTHER|Protocol Directed Sedation and Daily Sedation Interruption|The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
219720491|NCT00957710|BEHAVIORAL|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
219720492|NCT02787291|DEVICE|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
219720493|NCT04320667|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
219720494|NCT01268735|DRUG|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
219720495|NCT00484159|PROCEDURE|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
219720496|NCT00484159|DRUG|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
219232097|NCT01070199|BEHAVIORAL|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
219554732|NCT05402917|PROCEDURE|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
219720497|NCT00484159|DRUG|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
219720498|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
219720499|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
219720500|NCT00484159|PROCEDURE|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
219720501|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
219720502|NCT05206539|DRUG|Self-assembling peptide (P11-4)|"Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions."
219554733|NCT03481855|DEVICE|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
219148480|NCT07053163|DRUG|crystalloid, blood and low dose of norepinephrine|Group 2: receive crystalloid, blood and low dose of norepinephrine
219148481|NCT07053410|DEVICE|Direct 3D-Printed Retainer|Orthodontic retainers fabricated using direct 3D printing technology from digital STL models. The retainers are printed with biocompatible clear resin using an additive manufacturing process.
219148482|NCT07053410|DEVICE|Single-Layer Thermoformed Retainer|Clear orthodontic retainers fabricated by thermoforming a single-layer thermoplastic sheet over a 3D printed dental model using a vacuum forming machine.
219554734|NCT04556916|DIAGNOSTIC_TEST|Blood sample|"Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
219720503|NCT05206539|DRUG|CPP-ACFP|"Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions"
219148483|NCT07053410|DEVICE|Multi-Layer Thermoformed Retainer|Orthodontic retainers fabricated using a multi-layer thermoforming technique combining different thermoplastic materials to enhance durability and fit accuracy.
219148484|NCT07052877|DIAGNOSTIC_TEST|PSMA PET/CT scan|PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
219148485|NCT05844826|DEVICE|SIMBA Capsule|Participants will swallow capsule
219720504|NCT05206539|DRUG|Resin infiltration|The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
219720505|NCT05206539|OTHER|Control Group, No Treatment|Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
219720506|NCT00171288|DRUG|fluvastatin, ezetimibe|
219720507|NCT05668247|OTHER|FOOT BATH|In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
219720508|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
219720509|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
219720510|NCT03530228|DRUG|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
219720511|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
219720512|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
219148486|NCT07054138|DRUG|Dexmedetomidine|Patients will be nebulized with dexmedetomidine 1 mcg/kg in 3 ml of 0.9 % saline 15 minutes before shifting the patients to the operating room with a face mask 6 L/min in a sitting position.
219148487|NCT07054138|DRUG|Normal Saline|Patients will be nebulized with 3 ml of 0.9% normal saline 15 minutes before shifting the patients to the operating room with a face mask, 6 L/min in a sitting position.
219148488|NCT07055529|DRUG|Group A recieving PUVA therapy|This group A will recieve PUVA therapy twice weekly for 6 months
219148489|NCT07055529|DRUG|Group B receiving Tablet Tofacitinib|This group will be given tablet Tofacitinib 5mg twice daily for 6 months
219148490|NCT07056179|BEHAVIORAL|Brief behavioural intervention|Participants will receive a brief behavioural intervention comprising a regularity-focused sleep diary, 10 tips for maintaining sleep regularity, and a sleep education information sheet. The regularity-focused sleep diary is designed to emphasize in-bed and out-of-bed times, drawing participants' attention to their sleep regularity. Participants will be provided with a yellow marker to highlight their sleep periods. The 10 tips for maintaining sleep regularity include establishing a consistent out-of-bed time, using natural light to regulate the circadian clock, adjusting mealtimes, etc. The sleep education sheet contains information on reducing caffeine intake in the afternoon, limiting screen time before bed, etc.
219148491|NCT07056179|BEHAVIORAL|Health education|Participants will receive general health information without specific emphasis on sleep, such as weight control, smoking cessation, etc.
219148492|NCT06299657|BEHAVIORAL|IMPROVE|"IMPROVE is an individual manualized intervention.~Session1 includes:~* psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations~* guided discussion of maladaptive thoughts about bodily sensations related to anxiety~* how to challenge bodily sensations cognitively~* generating three takeaways about the benign nature of anxiety~Session 2 includes:~* review of homework~* psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty.~* when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty.~Session 3 includes:~* review interoceptive exposure (IE) and behavioral exercises (BE) for progress~* revisit beliefs related to cognitive biases~* discuss areas where skills can be used moving forward"
219554735|NCT00856622|DRUG|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
219554736|NCT00856622|DRUG|timolol 0.5% ophthalmic solution|one drop in the morning and evening
219148493|NCT06299657|BEHAVIORAL|PHET|"Clinicians will administer PHET using a Powerpoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. PHET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
219148494|NCT07060157|DRUG|resveratrol 1 % gel|left side of face the patient will be given resveratrol 1 % gel once daily at night (Home use ).
219148495|NCT07060157|DRUG|TCA20%|left side of face the patient will be given resveratrol 1 % gel once daily at night (homThee use ).
219554737|NCT00856622|DRUG|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
219554738|NCT00549341|DRUG|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
219720513|NCT03530228|DRUG|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
219554739|NCT00549341|OTHER|Physiologic saline|Single injection.
219554740|NCT00817141|OTHER|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
219720514|NCT03530228|DRUG|Tegoprazan (C3)|Tegoprazan QD, oral administration
219148496|NCT07060040|DIETARY_SUPPLEMENT|BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g|Oral nutritional supplementation: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g
219148497|NCT07060040|DIETARY_SUPPLEMENT|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g
219148498|NCT07059689|DEVICE|High Flow Nasal Cannula (HFNC)|Participants in this arm will receive High Flow Nasal Cannula therapy using the Airvo™3 Nasal High Flow System immediately after planned extubation following cardiac surgery
219148499|NCT07059689|DEVICE|Non-Invasive Ventilation (NIV)|Participants in this arm will receive Non-Invasive Ventilation (NIV) immediately after planned extubation following cardiac surgery. NIV will be delivered using standard ICU ventilator settings, with parameters tailored to each patient's clinical condition
219148500|NCT07061106|OTHER|Otago exercise program|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group A received Otago Exercise Program and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). The Otago Exercise Program is a fall prevention well designed program for older adults. It includes 17 strength and balance exercises and a walking program, which are typically performed three times a week and helps to prevent falls in older adults by strengthening muscles and improving balance. In this study, modified form of Otago would be used that focuses on balance and strengthening exercises.
219148501|NCT07061106|OTHER|Kitchen Sink Balance Exercises|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group B received Kitchen Sink Balance Exercises and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). Kitchen sink balance exercises are beneficial for improving overall Individual's stability, strength, and coordination. These exercises can be easily integrated into daily routine and it also providing a practical way to enhance balance and overall fitness.
219148502|NCT07061743|BEHAVIORAL|activity management training|In activity management training, first week awareness training, second week ergonomics training, third week activity stepping training, fourth week joint-energy conservation training, and fifth week relaxation training will be given.
219148503|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Cetuximab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
219148504|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Bevacizumab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
219148505|NCT07061236|OTHER|Elastomeric Pump Education|This intervention involves a 15-20 minute face-to-face training session about the use of the elastomeric pump with 5-FU, supported by visual materials and an educational booklet developed by the researchers based on current literature and expert opinion
219148506|NCT07060599|OTHER|INvasion Screening with Intelligent Guidance for Histopathology Triage (INSIGHT) Workflow|An AI-generated segmentation model are refined through a post-processing pipeline: retaining only invasive carcinoma (IC) regions, filtering detections \<500 µm², grouping adjacent IC areas, and generating per-cluster bounding boxes (red boxes). This converted raw segmentations into clinically actionable ROI proposals, balancing sensitivity and specificity for pathologist review in external testing and clinical validation. The INSIGHT workflow addresses key diagnostic challenges in EIC cases by pre-screening whole-slide images (WSIs) and intelligently marking potential IC regions. This guides pathologists to prioritize diagnostically critical areas across multiple slides or within extensive DCIS - a task particularly valuable when IC is multifocal or presents as subtle micro-invasive foci easily overlooked during routine manual examination.
219148507|NCT07060443|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Indocyanine Green (ICG) is used to guide the extent of D3 lymph node dissection during right hemicolectomy. After informed consent, participants randomized to the experimental group undergo bowel preparation and receive an endoscopic submucosal injection of ICG (0.25 mg/ml in saline) at two sites adjacent to the tumor one day prior to surgery. During surgery, near-infrared laparoscopic or robotic imaging systems detect the fluorescence emitted by ICG, guiding targeted D3 lymph node dissection at the origins of the ileocolic artery (ICA) and middle colic artery (MCA).
219148508|NCT07060443|OTHER|Standard Right Hemicolectomy (Non-ICG)|Participants in the control group undergo standard right hemicolectomy with D3 lymph node dissection without the use of Indocyanine Green (ICG) or fluorescence imaging. The extent of dissection is determined by conventional anatomical landmarks and the surgeon's clinical judgment.
219148509|NCT07060144|BEHAVIORAL|Regular CPT|Standard-model Cognitive Processing Therapy (CPT) - one 60-min session per week for 12 weeks total
219554741|NCT01267916|DEVICE|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
219554742|NCT01267916|DEVICE|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
219554743|NCT01267916|DEVICE|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
219554744|NCT01267916|DEVICE|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
219554745|NCT01267916|DEVICE|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
219554746|NCT01267916|DEVICE|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
219554747|NCT06504303|DEVICE|3D-printed socket|During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
219148510|NCT07060144|BEHAVIORAL|Massed CPT|Massed CPT - two 60-min sessions each day for 5 consecutive days (10 sessions total)
219232098|NCT01070199|BEHAVIORAL|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
219232099|NCT05187520|DEVICE|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
219232100|NCT05187520|DRUG|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
219232101|NCT04300764|BEHAVIORAL|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
219232102|NCT04214808|DRUG|AD-208|Dutasteride 0.2mg
219232103|NCT04214808|DRUG|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
219232104|NCT03199495|OTHER|electroacupuncture|acupuncture needle with TENS device
219232105|NCT03082313|BEHAVIORAL|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
219232106|NCT05996315|OTHER|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
219232107|NCT05996315|OTHER|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
219232108|NCT05765331|DEVICE|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
219554748|NCT01200017|BIOLOGICAL|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
219554749|NCT01866176|DEVICE|Stabilizing Knee Brace|Brace with no valgus action
219554750|NCT01866176|DEVICE|Valgus Knee Brace|Valgus brace with traditional three point bending system
219554751|NCT01866176|DEVICE|New Knee Brace|Brace with new mechanism to decrease the knee loading.
219554752|NCT04564404|OTHER|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
219554753|NCT00919334|DEVICE|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
219148511|NCT07061795|BEHAVIORAL|healthy living behaviors|Effect of prenatal care with home visits on healthy lifestyle behaviors during pregnancy
219148512|NCT07061808|DIAGNOSTIC_TEST|Lipedema Screening Questionnaire|The Lipoedema screening questionnaire (LSQ) is a practical tool that can be applied quickly and easily and is used to identify patients with lipoedema during history taking and physical examination.
219148513|NCT07060404|DRUG|Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water|Women will receive daily doses of PQ (0.5 mg/kg per day) for 14 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
219554754|NCT02111434|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
219554755|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
219148514|NCT07060404|DRUG|Daily primaquine 1 mg/kg per day for 7 days given with food and water|Women will receive daily doses of PQ (1 mg/kg per day) for 7 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
219720515|NCT04641637|PROCEDURE|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
219720516|NCT00410488|DRUG|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
219720517|NCT00410488|DRUG|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
219720518|NCT00410488|DRUG|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
219720519|NCT00410488|DRUG|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
219148515|NCT07060404|DRUG|Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort|Women will receive a single dose of 300mg tafenoquine. Treatment will be given with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
219148516|NCT07061223|PROCEDURE|SFIB|The block technique is based on administration of a local anesthetic under the iliac fascia to block the femoral, lateral femoral cutaneous, and obturator nerves. It is assumed that further leakage of local anesthetic through the interfascial space leads to blocking of the branches of the lumbar plexus in the small pelvis.
219148517|NCT07061223|PROCEDURE|PENG block|The hip capsule is the main source of pain because the innervation of the joint capsule is a developed network of articular branches of the femoral, sciatic and obturator nerves. The main idea of this technique is to block these branches at the point of common passage between the tendon of the lumbar muscle and the crest of the pubic bone. The block technique is based on administration of a local anesthetic under the ileo-lumbar tendon. Anesthetic spreads through the hip joint capsule and blocks small sensitive branches of the femoral and obturator nerves.
219148518|NCT07061223|PROCEDURE|Patient control analgesia|In the postoperative period, if pain occurs, the patient will be offered the opportunity to use 20 ug Fentanyl solution bolus according to the patient control analgesia (PCA) without a basic infusion.
219148519|NCT07061223|PROCEDURE|General inhalation anaesthesia|General inhalation anesthesia will be performed in all groups, Desflurane with a minimal alveolar concentration (MAC) of 0.6-0.8 will be used for maintenance
219148520|NCT07061314|DEVICE|Elastic Barbell|A flexible plastic barbell that creates top-down perturbations during movement. Participants perform single-leg deadlifts using this elastic bar at three different speeds: normal (2 sec), fast (1 sec), and power (as fast as possible). The bar is loaded to 30% of the participant's estimated 1RM.
219148521|NCT07061314|DEVICE|Inelastic Barbell|A standard rigid steel barbell with no elasticity. Participants perform single-leg deadlifts using this barbell under the same speed conditions and loading parameters as the elastic barbell.
219720520|NCT00410488|DRUG|Zinecard|750 mg/m2 as an IV bolus.
219720521|NCT00410488|DRUG|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
219148522|NCT07060703|DIAGNOSTIC_TEST|Osteodensitometry|"exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology.~comparison of ultrasound parameters (cortical thickness and porosity, among others) with BMD values (spine, right and left femoral necks) obtained by DXA.~\[Time Frame: 20 MIN\]"
219148523|NCT07061210|DRUG|HRS-2189|HRS-2189
219148524|NCT07061210|DRUG|Adebrelimab|Adebrelimab
219148525|NCT07061210|DRUG|BP102|BP102
219148526|NCT07061652|BEHAVIORAL|Survey|Participants will receive up to eight coaching sessions with a caregiver coach and resource materials and access to an online tool designed to help caregivers find resources.
219148527|NCT07061652|OTHER|the resource booklet from the American Cancer Society|The caregiver will receive the resource booklet from the American Cancer Society.
219720522|NCT00410488|DRUG|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
219720523|NCT00410488|DRUG|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
219720524|NCT00296595|BEHAVIORAL|Nutrition|
219720525|NCT02513199|RADIATION|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
219720526|NCT02513199|DRUG|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
219720527|NCT00095966|DRUG|sorafenib tosylate|Given orally
219720528|NCT00095966|DRUG|gemcitabine hydrochloride|Given IV
219720529|NCT03247244|DRUG|Cannabis|THC 10%, CBD \<0.5%
219720530|NCT03247244|DRUG|Cannabis|THC 8.6%, CBD 8.6%
219720531|NCT03247244|DRUG|Cannabis|THC 0.6%, CBD 14%
219720532|NCT06334900|OTHER|GAD patients|Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
219720533|NCT05875480|PROCEDURE|synchronized telerehabilitation|In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.
219720534|NCT05875480|PROCEDURE|asynchronized telerehabilitation|The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
219720535|NCT05875480|PROCEDURE|supervised (face to face) rehabilitation|In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
219720536|NCT03639389|DRUG|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
219720537|NCT03639389|DRUG|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
219720538|NCT02216409|DRUG|Hu5F9-G4|
219720539|NCT00223431|DEVICE|all-ceramic fixed partial denture|
219720540|NCT04808453|DRUG|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
219720541|NCT02204462|DRUG|FBnTP|A PET imaging radiotracer
219720542|NCT03545841|OTHER|HIT|Participants completed 6 weeks of HIT
219720543|NCT03545841|OTHER|MICT|Participants completed 6 weeks of MICT
219720544|NCT04527250|DRUG|ASC41|ASC41,1mg/table;5mg/table
219720545|NCT04527250|DRUG|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
219720546|NCT01381510|DRUG|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
219720547|NCT02321904|PROCEDURE|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
219720548|NCT02321904|PROCEDURE|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
219720549|NCT02321904|PROCEDURE|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
219720550|NCT02321904|PROCEDURE|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
219720551|NCT02321904|PROCEDURE|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
219720552|NCT00009893|DRUG|fluorouracil|
219720553|NCT00009893|DRUG|gemcitabine hydrochloride|
219720554|NCT00009893|DRUG|leucovorin calcium|
219720555|NCT03223194|GENETIC|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
219720556|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level -1|(1 x 10\^3 T cells/Kg)
219720557|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 1|(1 x 10\^4 T cells/Kg)
219720558|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 2|(1 x 10\^5 T cells/Kg)
219720559|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 3|(1 x 10\^6 T cells/Kg)
219720560|NCT00586547|BIOLOGICAL|T-Cell Infusion- Dose Level 4|(5 x 10\^6 T cells/Kg)
219720561|NCT05143775|PROCEDURE|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
219720562|NCT02756520|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
219148528|NCT07059559|OTHER|Rhythmic walking|Patients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group.
219148529|NCT07060170|DEVICE|Augmented Reality Glasses|The child will wear the augmented reality glass, and a cartoon movie will be displayed during the injection of local anesthesia
219148530|NCT07060170|DEVICE|Virtual Reality Glasses|The child will wear the glass, and a cartoon movie will be displayed during the injection of local anesthesia.
219148531|NCT07061600|BEHAVIORAL|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in youth as well as its Social Media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e. short videos with overlays of text and music). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
219148532|NCT07061600|BEHAVIORAL|Instagram profile that provides educational content|The participants of the control group asked to follow an Instagram profile that provides educational content produced by a public broadcaster (https://www.instagram.com/terrax/) and is not dedicated to the topic of mental health. This channel also posts several times a week and provides educational or informational content.
219554756|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
219554757|NCT04768296|DRUG|Topotecan|Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
219554758|NCT04999696|PROCEDURE|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
219554759|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate|1.2 g/kg/h
219554760|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
219554761|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
219554762|NCT06675890|DIAGNOSTIC_TEST|serum homocysteine|serum homocysteine is associated with atherosclerosis and vascular diseases.
219554763|NCT00646503|DRUG|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
219554764|NCT01910337|DEVICE|Use the Polar Cardiac rate meter|
219554765|NCT03274037|DIAGNOSTIC_TEST|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
219554766|NCT05333315|DIETARY_SUPPLEMENT|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
219554767|NCT05333315|DIETARY_SUPPLEMENT|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
219554768|NCT05333315|DIETARY_SUPPLEMENT|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
219554769|NCT05333315|DIETARY_SUPPLEMENT|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
219554770|NCT05333315|DIETARY_SUPPLEMENT|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
219554771|NCT06677788|DRUG|Roflumilast 500 Mcg Oral Tablet|Patients in this group received roflumilast 500 μg once daily for three months.
219554772|NCT06677788|DRUG|Vitamin E capsule|vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily
219554773|NCT00658957|DRUG|gentamicin-collagen sponge|5 × 5 cm sponge
219554774|NCT00658957|DRUG|placebo collagen sponge|5 × 5 cm sponge
219554775|NCT04934020|OTHER|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
219554776|NCT04934020|OTHER|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
219554777|NCT04066920|DRUG|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
219554778|NCT03825367|DRUG|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
219148533|NCT07060352|DIAGNOSTIC_TEST|Ankle Dorsiflexion Index (ADI) measurement|Ankle Dorsiflexion Index (ADI) measurement at D0 and W8
219148534|NCT07061587|BEHAVIORAL|Gout action plan|Gout action plan (that we aim to develop and refine during the study based on traffic light color system which will be categorized into zone system- green zone (well controlled), yellow zone (mild symptoms), red zone (severe symptoms). It will outline how to manage gout, identifying triggers, recognizing symptoms, appropriate medication usage, and when to seek medical attention)
219148535|NCT07059871|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
219148536|NCT07059871|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
219148537|NCT07061171|DEVICE|Continuous Positive Airway Pressure|Using a ResMed S9 AutoSet-S device with a pressure range of 4-20 cmH2O. Used for 5-7 hours per night, at least 5 nights per week, for 3 months.
219148538|NCT07061171|DRUG|Herbal Decoction|A daily dose of a decoction containing Ban Xia, Ju Hong, Shi Chang Pu, Yu Jin, Lai Fu Zi, Fu Ling, Bai Zhi, Cang Er Zi, and Gan Cao, administered orally in two divided doses.
219148539|NCT07061171|PROCEDURE|Acupuncture|Daily sessions with needle retention for 30 minutes, 5 times per week. Acupoints included Anmian (EX-HN22), Lianquan (CV23), Shanzhong (CV17), Zhongwan (CV12), Kongzui (LU6), Pishu (BL20), Fenglong (ST40), Zusanli (ST36), Yinlingquan (SP9), and Zhaohai (KI6).
219148540|NCT07061171|PROCEDURE|Tuina Massage|Includes massage techniques applied to the head and occipital region to relax muscles and improve local circulation.
219148541|NCT07061756|PROCEDURE|SRP|Full-mouth scaling and root planing (SRP) was performed using an ultrasonic scaler (EMS AIR-FLOW MASTER PIEZON®) supplemented by Gracey curettes for subgingival instrumentation. All procedures were conducted under local anesthesia by a calibrated periodontist, with each quadrant treated for a minimum of 30 minutes. Patients received standardized oral hygiene instructions and were scheduled for a 3-month postoperative follow-up.
219148542|NCT07061756|PROCEDURE|ND|"In addition to the identical SRP protocol described above, adjunctive Nd:YAG laser therapy (Wiser Waterlase MD, Vista Dental) was applied immediately post-SRP. Laser parameters were set at 150 mJ/pulse, 20 Hz frequency with water (level 1) and air (level 3) coolant. The fiber optic tip (300 μm diameter) was moved in a continuous Zig-zag pattern along the root surface and pocket epithelium, maintaining 2-second irradiation per site at a 30° angle to the tooth axis. Standardized oral hygiene instructions and 3-month follow-up were similarly provided."
219148543|NCT07060885|BIOLOGICAL|HDM SLIT-tablet (12 SQ-HDM)|"For daily administration (1 tablet per day)~Other Names: Acarizax, Odactra"
219148544|NCT07060885|OTHER|Placebo|For daily administration (1 tablet per day)
219148545|NCT07061093|DRUG|Ethynyl estradiol and Drospirenone|Oral ethynyl estradiol (20 mcg) and 3 mg drospirenone for 24 days and 4 days free of hormones
219148546|NCT07061093|DRUG|Drospirenone|A drospirenone (4mg) only pill
219148547|NCT07061093|DRUG|Estetrol and Drospirenone|Oral estetrol (15 mg) and drospirenone (3 mg) for 24 days and 4 days of interval free of hormone
219148548|NCT07061015|PROCEDURE|osseodenification with osseodensifying burs|different osseodensification techniques to be studied
219148549|NCT07061015|PROCEDURE|reverse drilling|using the conventional drills in reverse mode
219148550|NCT07061015|PROCEDURE|rotary expanders|expanders in clockwise direction
219148551|NCT07059832|DRUG|68Ga-NODAGA-SNA006|68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
219148552|NCT07060027|PROCEDURE|horizontal bone augmentation using single tenting screw|Patients in this group will undergo guided bone regeneration (GBR) using a single titanium bone screw placed in the crestal position to stabilize the graft material. The surgical procedure includes sulcular and vertical releasing incisions, elevation of full-thickness buccal and palatal/lingual flaps, and multiple cortical perforations to enhance angiogenesis. The defect will be filled with particulate allograft extended 10-12 mm apicocoronally and covered with a bovine pericardium membrane. A tension-free primary closure will be achieved using 5-0 polypropylene sutures. Bone screw removal and implant placement will occur 6 months postoperatively. This group is distinguished by the use of a single crestal screw for graft stabilization compared to dual-screw fixation in the control group.
219554779|NCT03825367|DRUG|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
219554780|NCT01911104|BEHAVIORAL|Exercise|10 weeks of aerobic exercise
219554781|NCT03798340|OTHER|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
219554782|NCT03798340|OTHER|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
219554783|NCT03798340|OTHER|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
219554784|NCT06679166|OTHER|No intervention|No intervention
219554785|NCT00491257|BIOLOGICAL|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
219554786|NCT05229055|DRUG|Ketamine|giving ketamine intranasal
219554787|NCT03966950|DIETARY_SUPPLEMENT|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
219554788|NCT03966950|DRUG|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
219554789|NCT03818295|DRUG|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
219232109|NCT02680262|BEHAVIORAL|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
219232110|NCT02680262|BEHAVIORAL|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
219232111|NCT02680262|BEHAVIORAL|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
219232112|NCT01918033|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
219232113|NCT01918033|DRUG|Placebo|Matching placebo to desloratadine 5 mg tablets
219232114|NCT05279066|DEVICE|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
219554790|NCT06679023|DIAGNOSTIC_TEST|MolecuLight i:X and Wound blotting and Alcian blue biofilm detection kit|we will enroll patients with chronic wounds and quantify the biofilm severity by staining color of Wound blotting and Alcian blue biofilm detection kit, and by non-touched flourescent intensity of MolecuLight i:X.
219554791|NCT00003850|DRUG|thalidomide|
219554792|NCT06236412|BEHAVIORAL|Health education|Health education about the contents listed under each arm will be provided for the participants.
219554793|NCT05867524|OTHER|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
219554794|NCT05867524|OTHER|Cycling test|2 hours of moderate activity level cycling
219554795|NCT01477424|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
219554796|NCT01477424|DRUG|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
219554797|NCT06616103|DIAGNOSTIC_TEST|computerized tomography|noncontrast abdominal CT
219554798|NCT04492397|DEVICE|Test Contact Lens|Subjects will be randomized to wear test lenses.
219554799|NCT04492397|DEVICE|Control Contact Lens|Subjects will be randomized to wear control lenses.
219554800|NCT06355830|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
219554801|NCT03087786|DRUG|Nicotine Bitartrate Lozenge 4mg|Test Product
219554802|NCT03087786|DRUG|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
219554803|NCT06787716|DEVICE|The whole body vibration|Patients in the study group will receive the traditional physical therapy program first (passive and active ROM exercises, stretching and strengthening exercises) for 60 minutes, 3 days/ week for 12 weeks.This will be followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program will be three sessions a week for 12 weeks. WBV duration started with 10 min at the 1st week up to 35 min at the 12th week, with a regular increase of five minutes every two successive weeks.
219554804|NCT06787716|OTHER|The traditional physical therapy program|The traditional physical therapy program will be three days a week for 12 weeks. The program will include 60 minutes of a supervised and individualized exercise program including passive and active exercises of the hip, knee, and ankle joints, stretching exercises for the Calf and hamstring muscles followed by strengthening exercises of the hip, knee, ankle, and foot muscles. To improve the strength, free weights will be used for all exercises. During the first week, 50 to 60% of the repetitions maximum test will be set as the starting weight. Then, from the second week to the sixth, the weight will be increased to 70%-75% of three repetitions maximum (3 sets, 4-10 repetitions). The training amplitude then will be raised to 80%-85% of the three-repetition maximum (3 sets, 8-12 repetitions) that will be continued through weeks 7 to 12, holding 5 seconds at the end of the range.
219554805|NCT02145624|DRUG|Repevax|vaccine
219554806|NCT02145624|DRUG|Boostrix-IPV|vaccine
219554807|NCT04383717|DRUG|Levamisole and isoprinosine|oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
219554808|NCT04383717|DRUG|Azithromycin and hydroxychloroquine|oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
219554809|NCT06616883|DRUG|DA-5221_01|single dose administration (DA-5221\_01 one tablet once a day)
219554810|NCT06616883|DRUG|DA-5221_01-R1 + DA-5221_01-R2|single dose administration (DA-5221\_01-R1 one tablet once a day + DA-5221\_01-R2 one tablet once a day)
219554811|NCT06433193|DEVICE|PAK HD Sorbent Therapy|"Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful."
219554812|NCT04386109|OTHER|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
219554813|NCT00122447|DRUG|Aspirin|325 mg PO QD
219720563|NCT01764581|PROCEDURE|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
219720564|NCT04338997|DRUG|IZD174|Small molecule inhibitor of NLRP3
219720565|NCT06457932|BEHAVIORAL|Heart rate variability biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
219720566|NCT06457932|BEHAVIORAL|Guided meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
219232115|NCT00529204|DRUG|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
219232116|NCT00427440|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
219232117|NCT00427440|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
219720567|NCT05442931|DRUG|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
219720568|NCT05442931|DRUG|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
219720569|NCT05442931|DRUG|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
219720570|NCT05442931|OTHER|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
219148553|NCT07060027|PROCEDURE|horizontal bone augmentation using Double tenting screw|Participants in this group will receive guided bone regeneration (GBR) with two titanium bone screws for enhanced graft stabilization. One screw will be placed at the crestal level, while a second screw will be inserted 5 mm apical to the first, providing vertical stabilization of the graft material. The procedure involves sulcular and vertical releasing incisions, full-thickness flap elevation on both buccal and palatal/lingual aspects, and multiple cortical perforations to stimulate vascularization. The defect will be filled with particulate allograft extending 10-12 mm apicocoronally and covered with a bovine pericardium membrane. Tension-free primary closure will be performed using 5-0 polypropylene sutures. At 6 months, screws will be removed and dental implants placed. This intervention is distinguished by the dual-screw fixation technique, designed to provide greater mechanical stability compared to the single-screw approach used in the comparator group.
219720571|NCT02341469|OTHER|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
219720572|NCT06154473|PROCEDURE|Open heart surgery group.|Patients undergoing open heart surgery.
219720573|NCT06154473|PROCEDURE|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
219720574|NCT06104293|OTHER|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
219148554|NCT07060794|DRUG|Tafenoquine|Tafenoquine in combination with DHA-piperaquine
219148555|NCT07060391|PROCEDURE|Deep cervical lymphatic-venous anastomosis|Lymph node reconstruction was carried out using microsurgical techniques,improve cerebral lymphatic circulation and return, accelerate the excretion of pathological proteins, the metabolic products of the brain, from the brain. This is to delay the degenerative changes of the brain and the progression of Alzheimer's disease.
219232118|NCT03810170|BEHAVIORAL|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
219232119|NCT03810170|OTHER|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
219232120|NCT03072303|OTHER|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
219720575|NCT02174172|DRUG|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
219720576|NCT02174172|DRUG|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
219720577|NCT02174172|DRUG|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
219720578|NCT02174172|DRUG|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
219720579|NCT02174172|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
219720580|NCT02174172|DRUG|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
219720581|NCT00330018|DRUG|Valganciclovir|Valganciclovir
219720582|NCT00330018|DRUG|Acyclovir|Acyclovir
219720583|NCT00580398|BEHAVIORAL|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
219720584|NCT00580398|DRUG|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
219720585|NCT01635647|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
219720586|NCT01635647|BIOLOGICAL|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
219720587|NCT03291015|DEVICE|radiographic|using plain x ray to determind the treatment plan
219720588|NCT03291015|DEVICE|arthroscopy|using wrist arthroscopy to determind the treatment plan
219720589|NCT02503930|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
219720590|NCT02503930|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
219232121|NCT02695199|PROCEDURE|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
219720591|NCT05452512|OTHER|Self monitoring|Self monitoring using smart clinical trial application
219720592|NCT05452512|OTHER|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
219720593|NCT05452512|DRUG|Vitamin D|Vitamin D self-administration for 3 months
219720594|NCT04772547|DRUG|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
219720595|NCT01771913|GENETIC|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
219720596|NCT01771913|GENETIC|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
219148556|NCT07060391|DRUG|Donepezil drug treatment|All patients stopped taking cognitive-enhancing drugs after enrollment, and marketed therapeutic drugs include ginkgo biloba, high-dose vitamin E, lecithin, estrogen, non-steroidal anti-inflammatory drugs, memegan, etc.
219148557|NCT07061561|DEVICE|Peak Expiratory Flow Measurement Using Peak Flow Meter and Lorio Device|This intervention involves the use of two respiratory measurement devices to assess cough strength in tracheotomized patients: the traditional Peak Flow meter, which measures peak expiratory flow (PEF), and the Lorio device, a novel tool designed for respiratory rehabilitation with customizable training exercises. Measurements are taken at multiple time points before and after decannulation to compare accuracy, reproducibility, and patient usability.
219148558|NCT07061028|BEHAVIORAL|Progressive Muscle Relaxation|This intervention involves five weekly 30-minute sessions of Progressive Muscle Relaxation (PMR) based on the ABC relaxation theory. The PMR protocol developed by Smith (2005) involve tense-and-release exercises for 11 different muscle groups, including hands, arms, sides, back, shoulders, face, neck, stomach, chest, legs, and feet. For five to ten seconds, each muscle group is contracted, and for twenty to thirty seconds, it is relaxed. The sensations of stress and relaxation were the participants' main concern. To release any residual tension, they looked at each muscle group after the workout. With the exception of the time needed for measurements and instructions, the entire operation took roughly thirty minutes.
219148559|NCT07061028|OTHER|Control Group|The control group received no intervention from the researcher during the study. However, following the intervention, the control group participants were given the audio recordings of the intervention protocol along with an explanation of them.
219148560|NCT07060274|PROCEDURE|Doppler Ultrasound|Doppler ultrasound of temporal arteries at D0, D3 and D7 (+ D15 if halo detected at D7) after initiation of corticosteroid therapy.
219720597|NCT03464838|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
219720598|NCT03464838|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
219720599|NCT03909503|DEVICE|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
219720600|NCT04307394|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
219720601|NCT00447681|DRUG|ILV-094|
219720602|NCT06161090|BIOLOGICAL|CM310|CM310 injection
219720603|NCT06161090|DRUG|Placebo|subcutaneous injection
219720604|NCT04403282|DRUG|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
219720605|NCT04403282|DRUG|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
219720606|NCT04119336|DRUG|Nivolumab|Given intravenously once per cycle
219720607|NCT04119336|DRUG|Ixazomib|Given orally on days 1, 8, 15.
219720608|NCT04119336|DRUG|Dexamethasone|Given orally on days 1, 8, 15, 22
219720609|NCT04119336|DRUG|Cyclophosphamide|Given intravenously on days 1, 8, 15.
219720610|NCT03243890|DIETARY_SUPPLEMENT|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
219720611|NCT03243890|DIETARY_SUPPLEMENT|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
219720612|NCT00164866|DRUG|Omeprazole|
219720613|NCT04949295|DEVICE|ocular surface analyzer|Using ocular surface analyzer for Inspection
219720614|NCT05419440|PROCEDURE|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
219720615|NCT01784185|PROCEDURE|virtual bronchoscopy guided transbronchial needle aspiration|
219720616|NCT01784185|PROCEDURE|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
219720617|NCT05390606|COMBINATION_PRODUCT|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
219720618|NCT05467137|DEVICE|MSOT|MSOT imaging (after ICG injection)
219720619|NCT01733888|DEVICE|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
219720620|NCT01733888|DEVICE|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
219720621|NCT01733888|DEVICE|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
219720622|NCT01733888|DEVICE|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
219720623|NCT03281720|PROCEDURE|TAD|the same intervention as listed in the arm description
219720624|NCT05376306|BEHAVIORAL|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
219720625|NCT05376306|BEHAVIORAL|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
219554814|NCT00122447|DRUG|Alpha lipoic acid|600 mg PO BID
219720626|NCT03715647|OTHER|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
219720627|NCT03715647|OTHER|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
219720628|NCT03715647|OTHER|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
219720629|NCT05403073|PROCEDURE|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
219720630|NCT03928327|DRUG|TAK-788|TAK-788 Capsules
219720631|NCT03928327|DRUG|Itraconazole|Itraconazole Oral solution
219720632|NCT03928327|DRUG|Rifampin|Rifampin Capsules
219554815|NCT00122447|DRUG|Olmesartan|40 mg PO QD
219720633|NCT00174395|DRUG|eletriptan|
219720634|NCT00407511|DRUG|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
219720635|NCT03439514|DRUG|ARRY-371797 (PF-07265803)|400 mg twice daily (BID)
219554816|NCT00122447|DRUG|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
219554817|NCT02574715|DRUG|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
219720636|NCT03439514|OTHER|Placebo|BID
219720637|NCT04987970|DRUG|CKD-386(2)|QD, PO
219720638|NCT04987970|DRUG|D013, D326, D337|QD, PO
219554818|NCT03885869|OTHER|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
219720639|NCT03454958|OTHER|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
219720640|NCT03974490|OTHER|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
219148561|NCT07060534|BEHAVIORAL|Building Healthy Eating and Self-Esteem Together for University Students|Building Healthy Eating and Self-Esteem Together for University Students (BEST-U) is an mHealth program that includes modules based on second- and third-wave behavior therapy deployed through a smart phone app paired with 20-30-minute coaching sessions. BEST-U incorporates a range of evidence-based skills, and the electronic format allows coaches immediate and easy access to participant reports. BEST-U provides a comprehensive all-in-one assessment and intervention package, is easy-to-implement, brief, and has been tested across genders and in diverse ages and ethnic groups. BEST-U, therefore, has the potential to deliver effective, time-limited, interventions applicable to all university students in routine student healthcare settings.
219148562|NCT07060534|BEHAVIORAL|Present-Centered Therapy|"Present-Centered Therapy (PCT) is a brief intervention that focuses on building adaptive responses to current life stressors that are directly or indirectly related to psychopathology. PCT focuses on resolving interpersonal disconnection through the development of a positive therapeutic relationship, encouraging connection with others, and addressing interpersonal concerns. PCT was originally developed as a placebo intervention for post-traumatic stress disorder but is significantly more efficacious than wait-list in reducing psychiatric symptoms."
219720641|NCT04153656|OTHER|Reading and studying Spiritual Flow|The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
219232122|NCT02695199|PROCEDURE|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
219232123|NCT03878966|DEVICE|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
219720642|NCT00198120|DRUG|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
219720643|NCT00198120|DRUG|Placebo|Placebo: same dosing schedule and capsule strength
219720644|NCT04900272|BEHAVIORAL|VIPA and companion booklet|Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
219720645|NCT03940092|OTHER|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
219720646|NCT03940092|OTHER|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
219720647|NCT00580281|OTHER|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
219720648|NCT02903654|OTHER|observational|
219148563|NCT07059611|BIOLOGICAL|RP2|Upper endoscopy with RP2 intra-tumoral injection of 1 x 10(6) plaque forming units (PFU)/mL for first intra-tumoral injection, up to 10mL of 1x107 PFU/mL of RP2 for subsequent intra-tumoral injections. Injection will occur within 4 days prior of each cycle FLOT.
219148564|NCT07059611|COMBINATION_PRODUCT|5-Fluorouracil|5-Fluorouracil as part of the FLOT regimen 2,600mg/m2 intravenous infusion over 24 hours on day 1 of each 14-day cycle for 4 cycles.
219232124|NCT01857999|DRUG|Losartan|
219232125|NCT01857999|DRUG|Placebo|
219232126|NCT01402518|PROCEDURE|Per-oral enodscopic myotomy|
219232127|NCT01702259|DEVICE|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
219148565|NCT07059611|COMBINATION_PRODUCT|Leucovorin|Leucovorin as part of the FLOT regimen 200mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
219232128|NCT01702259|DEVICE|Placebo device|Inactive Erchonia GLS.
219232129|NCT05012462|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value.
219232130|NCT05012462|DEVICE|CM-1600|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors Bioelectrical Impedance, Photoplethysmography (PPG) Amplitude, ECG Amplitude and Skin Temperature. A combination of these parameters is represented by a single number known as the Relative Index value.
219232131|NCT04666181|BEHAVIORAL|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
219232132|NCT06510244|DEVICE|EEG EMOTIV|The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
219232133|NCT00644566|OTHER|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
219232134|NCT06499142|DEVICE|Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.|"The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line."
219232135|NCT06088576|OTHER|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
219232136|NCT01846715|BIOLOGICAL|Implantation of SRC|
219232137|NCT03195803|BEHAVIORAL|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
219232138|NCT05760950|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
219720649|NCT06109688|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
219720650|NCT06109688|DIETARY_SUPPLEMENT|placebo|Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
219720651|NCT01576393|BEHAVIORAL|Home-based Family Therapy|12 home-based family therapy sessions
219720652|NCT01576393|BEHAVIORAL|office-based family therapy|12 office-based family therapy sessions
219720653|NCT01576393|BEHAVIORAL|WHE|12 Women's Health Education Sessions
219720654|NCT06125418|PROCEDURE|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
219720655|NCT06125418|PROCEDURE|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
219720656|NCT03295448|OTHER|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
219720657|NCT03295448|OTHER|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
219720658|NCT03295448|OTHER|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
219720659|NCT02184117|DRUG|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
219720660|NCT02184117|DRUG|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
219720661|NCT02184117|DRUG|Resting conditions|Baseline measurement of aortic and coronary pressures
219720662|NCT02875600|OTHER|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
219720663|NCT00265278|DRUG|Modafinil|
219720664|NCT00800540|DRUG|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
219148566|NCT07059611|COMBINATION_PRODUCT|Oxaliplatin|Oxaliplatin as part of the FLOT regimen 85mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
219148567|NCT07059611|COMBINATION_PRODUCT|Docetaxel|Docetaxel as part of the FLOT regimen 50mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
219148568|NCT07059611|DRUG|Pegfilgrastim|Pegfilgrastim or Filgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
219148569|NCT07059611|DRUG|Filgrastim|Filgrastim or Pegfilgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
219720665|NCT00800540|DRUG|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
219720666|NCT01537796|BEHAVIORAL|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
219148570|NCT07059611|PROCEDURE|Surgical Resection of Primary Tumor|Following 4 cycles of preoperative FLOT with RP2 injections, surgical resection of esophageal, GEJ, or gastric primary tumor per standard of care practice.
219148571|NCT07061574|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
219148572|NCT07061574|DRUG|verapamil extended-release capsule|Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
219148573|NCT07061574|DRUG|Adalimumab|40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.
219148574|NCT07061353|BEHAVIORAL|Therapeutic touch|Therapeutic touch will be performed
219148575|NCT07061184|DRUG|FLCWK|FLCWK and matching placebo to be taken in a randomised order for 9 months
219148576|NCT07061184|DRUG|Placebo|FLCWK and matching placebo to be taken in a randomised order for 9 months
219148577|NCT07060664|PROCEDURE|open reduction internal fixation|treatment with open reduction and plates/screws
219148578|NCT07060664|PROCEDURE|intramedullary nail|open reduction and intramedullary nail
219148579|NCT07060664|PROCEDURE|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
219148580|NCT07060833|DEVICE|External pressure transducer|The delivered CPAP pressure will be measured using an ultra-thin, multi-use catheter pressure transducer inserted into a port in the expiratory limb of the bubble CPAP circuit.
219148581|NCT07060833|DEVICE|Standard microphone|The bubble sound of the water tank will be collected with a standard condenser microphone directly affixed to the pole holding the water tank, with a secure clip.
219148582|NCT07060833|DEVICE|Wireless acoustic sensor|The wireless acoustic sensor contains a dual microphone capable of capturing target sounds as well as ambient noise. The frequencies associated with ambient noise will be subtracted to maximize the signal-to-noise ratio of the bubble sound waveform. The wireless sensor will be placed on the suprasternal notch of the infant for monitoring the bubble sounds transmitted to the lungs and secured using a silicone-based tape approved for use in neonates. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller and stored for future analysis.
219148583|NCT07060833|DEVICE|Internal pressure transducer|The transmitted CPAP pressure will be measured using an ultra-thin, single-use catheter pressure transducer inserted through the mouth to the level of the infant's nasopharynx. The data will be acquired with a sampling rate of 10kHz and stored for later analysis.
219148584|NCT07060651|OTHER|Present odors to participants while recording and stimulating brain activity|Present odors to participants while recording brain activity
219148585|NCT07061002|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. In this group, just before extubation, the patients in this group will be given 6 breaths with a tidal volume of 2 times the vital capacity, an inspiratory/expiratory ratio of 1/1 and a lung plateau pressure of \< 35 cmH2O, and a recruitment maneuver will be performed at the end of the surgery.
219148586|NCT07061002|OTHER|Positional Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens the length of hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. Patients in this group will be placed in the right and then left lateral decubitus position before extubation at the end of surgery and a recruitment maneuver will be performed by giving 6 breaths in each position, with a tidal volume twice the vital capacity, a 1/1 inspiratory/expiratory ratio, and a lung plateau pressure \< 35 cmH2O.
219148587|NCT07061158|BEHAVIORAL|Structured Yoga Course Intervention|Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, body balance training, and coordination of breath with movement), and meditation and relaxation (e.g., supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
219148588|NCT04080427|DRUG|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
219148589|NCT04080427|DRUG|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
219232139|NCT02417285|DRUG|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
219232140|NCT02417285|DRUG|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
219232141|NCT04775537|DEVICE|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
219232142|NCT03259568|DEVICE|Repetitive TMS|1-10 Hertz rTMS will be administered
219232143|NCT01784107|DRUG|Belotecan and Ifosfamide|
219232144|NCT00234000|DRUG|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
219554819|NCT03885869|OTHER|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
219720667|NCT01537796|BEHAVIORAL|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
219720668|NCT01537796|BEHAVIORAL|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
219720669|NCT01244282|PROCEDURE|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
219720670|NCT05909423|DRUG|Influenza vaccine|Intratumoral influenza vaccine treatment, administered via endoscopic procedure
219720671|NCT05909423|DRUG|Pembrolizumab|Single dose pembrolizumab treatment
219720672|NCT02142543|DRUG|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
219720673|NCT02142543|DRUG|Placebo Comparator|
219720674|NCT04604860|BEHAVIORAL|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
219148590|NCT07061249|BEHAVIORAL|Waltz Dance|Participants in this arm will receive a structured Waltz dance intervention as moderate-intensity aerobic exercise. The program consists of 3 supervised sessions per week for 12 weeks, each lasting 105 minutes. Each session includes a 5-minute warm-up, 50 minutes of solo and partner Waltz practice, a 5-minute rest, 40 minutes of choreographed combinations, and a 5-minute cool-down. The dance routines are progressive and designed to improve cardiovascular fitness, coordination, and balance. Exercise intensity is maintained at 50-70% of estimated maximum heart rate, with music tempo and movement complexity adjusted as needed. Physical activity is monitored using accelerometers to ensure target intensity is achieved.
219720675|NCT02643784|DRUG|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
219720676|NCT02643784|OTHER|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
219720677|NCT05371704|DIETARY_SUPPLEMENT|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
219720678|NCT05371704|OTHER|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
219148591|NCT07061418|OTHER|Dental Implant|Dental implants were placed to volunteers in need of implantation in mandible, maxilla or both
219148592|NCT07060183|PROCEDURE|Ross procedure|aortic valve replacement
219148593|NCT07061626|DRUG|Rhenium-186 Nanoliposome|Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL), BMEDA-chelated-186rhenium encapsulated within liposomes, allows the 186Re to be directly delivered to the site of the tumor through CED and maintain localization at the site of infusion.
219720679|NCT04781465|DEVICE|Immersive Virtual Reality|"Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
219720680|NCT00860925|DRUG|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
219148594|NCT07060937|OTHER|Physiotherapy Protocol|Each participant consenting to the study will be given a physiotherapy session on post-op day 1 and day 2 by a physiotherapist. The session will include bed mobility exercises including active ROM exercises of all extremities, breathing exercises, nebulization and chest physical therapy, incentive spirometer. Progressing to supported sitting at the edge of bed, sitting on a chair under supervision, supported walk inside the room , sitting independently in chair and lastly before discharge climbing 2 flights of stair.
219720681|NCT00860925|DRUG|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
219720682|NCT00860925|DRUG|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
219720683|NCT00860925|DRUG|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
219720684|NCT02140827|OTHER|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
219720685|NCT01594268|DRUG|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
219720686|NCT01830686|OTHER|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
219720687|NCT01830686|OTHER|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
219720688|NCT01830686|OTHER|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
219720689|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
219720690|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
219720691|NCT04954144|DEVICE|Leap Motion Sensor|As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
219720692|NCT04954144|OTHER|Neurodevelopmental Treatment Approach|It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
219148595|NCT07059741|OTHER|integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized low dose RT: 1-1.5Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
219720693|NCT05249751|DIAGNOSTIC_TEST|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
219720694|NCT06054425|DRUG|Risankizumab|Infusion; intravenous
219720695|NCT04082520|RADIATION|Gallium Ga 68-DOTATATE|Given IV
219720696|NCT04082520|DRUG|Lutetium Lu 177 Dotatate|Given IV
219720697|NCT04082520|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219720698|NCT04082520|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219720699|NCT04082520|OTHER|Questionnaire Administration|Ancillary studies
219720700|NCT04082520|PROCEDURE|Computed Tomography|Undergo PET/CT and/or SPECT/CT
219720701|NCT04082520|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219720702|NCT04082520|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219720703|NCT05341245|PROCEDURE|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
219720704|NCT05341245|PROCEDURE|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
219720705|NCT04472741|DEVICE|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
219720706|NCT03848078|DEVICE|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
219720707|NCT02447029|DRUG|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
219720708|NCT02447029|DRUG|standard lidocaine paracervical block|1% lidocaine paracervical injection
219720709|NCT06506955|DRUG|futibatinib|TAS-120 futibatinib monotherapy
219720710|NCT06506955|DRUG|futibatinib, fulvestrant|TAS-120 futibatinib combination therapy with fulvestrant
219720711|NCT01239745|DRUG|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
219720712|NCT00726557|BIOLOGICAL|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
219720713|NCT00726557|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
219720714|NCT02011334|DRUG|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
219720715|NCT02253498|DEVICE|deep brain stimulation (DBS)|
219720716|NCT00075374|DRUG|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
219720717|NCT00315822|OTHER|80% oxygen|Supplemental oxygen will be administered during surgery
219720718|NCT00315822|OTHER|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
219720719|NCT01601795|DRUG|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
219720720|NCT01601795|DRUG|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
219720721|NCT00159809|DRUG|Viagra (Sildenafil citrate)|
219720722|NCT00396669|DRUG|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
219720723|NCT00396669|DRUG|Bupropion|Brain imaging after treatment with Bupropion
219554820|NCT03885869|OTHER|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
219554821|NCT03885869|OTHER|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
219720724|NCT01229553|DRUG|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
219720725|NCT02912377|BIOLOGICAL|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
219720726|NCT00000599|DRUG|colestipol|
219720727|NCT00000599|DRUG|niacin|
219720728|NCT00000599|BEHAVIORAL|diet, fat-restricted|
219148596|NCT07059741|OTHER|integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized high dose RT: 3-6Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
219148597|NCT05242744|DRUG|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
219148598|NCT04580485|DRUG|INCB106385|INCB106385 will be administered orally QD
219148599|NCT04580485|DRUG|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
219720729|NCT01328119|OTHER|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
219148600|NCT06835400|DRUG|Paclitaxel Capsule|Paclitaxel Capsule
219720730|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
219720731|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
219720732|NCT00081458|DRUG|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
219720733|NCT00081458|DRUG|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
219720734|NCT00081458|DRUG|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
219720735|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
219720736|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
219148601|NCT06835400|DRUG|IV Paclitaxel|IV Paclitaxel
219148602|NCT06835400|DRUG|Encequidar tablet|Encequidar tablet
219232145|NCT00234000|DRUG|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
219148603|NCT07061535|DRUG|Tafolecimab|Patients will receive Tafolecimab 300 mg every 3 weeks.
219232146|NCT06177821|DEVICE|Rezum®|Rezum® Water vaporization device
219232147|NCT01230970|DRUG|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
219720737|NCT03177850|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
219720738|NCT03177850|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
219232148|NCT03006393|DRUG|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
219720739|NCT00915187|DRUG|CCS/C|Adjuvant to influenza vaccine
219148604|NCT07061535|DRUG|Sintilimab (approved)|Patients will receive Sintilimab 200 mg every 3 weeks.
219148605|NCT07061535|DRUG|Etoposide|Patients will recieve Etoposide (100 mg/m2) intravenously on days 1, 2, and 3 of each 3-week cycle.
219148606|NCT07061535|DRUG|Carboplatin / Cisplatin|Patients will receive carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2) intravenously on day 1 of each 3-week cycle for up to 4 to 6 cycles.
219148607|NCT07056335|BEHAVIORAL|Self-monitoring|Self-monitoring as a behavior change technique to support pain self-care behaviors
219232149|NCT03006393|OTHER|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
219232150|NCT00831948|GENETIC|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
219232151|NCT01485809|DRUG|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
219232152|NCT00605137|DRUG|insulin detemir|
219232153|NCT00605137|DRUG|insulin NPH|
219232154|NCT01474382|DRUG|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
219148608|NCT07056335|BEHAVIORAL|Physical activity and percussive massage therapy education|Participants will receive education on why physical activity and massage are important for pain self-care. They will also receive daily physical activity and massage goals.
219148609|NCT07056335|DEVICE|Percussive massage therapy|Participants will receive a massage gun to support daily pain self-care.
219232155|NCT01474382|OTHER|Sham injection|No drug administered, simulation of injection used in same manner as drug
219232156|NCT04885673|DEVICE|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
219720740|NCT00915187|BIOLOGICAL|Influenza Vaccine|Influenza vaccine
219720741|NCT02471742|PROCEDURE|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
219720742|NCT02471742|PROCEDURE|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
219720743|NCT00005790|OTHER|laboratory biomarker analysis|
219232157|NCT04885673|DEVICE|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
219232158|NCT01596465|OTHER|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
219232159|NCT01596465|OTHER|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
219232160|NCT00017355|BIOLOGICAL|filgrastim|
219148610|NCT07061730|BEHAVIORAL|Traditional Therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP.
219148611|NCT07061730|BEHAVIORAL|Hybrid therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP. In addition to these weekly sessions, the child will practice using the AI-based speech therapy tool, Jessica, at home between sessions for 60 minutes per week. The tool will provide real-time feedback on the child's articulation and track their progress. The child will be asked to practice specific speech exercises, such as producing target sounds (e.g., /r/, /s/) in words, phrases, or sentences.
219148612|NCT07061782|PROCEDURE|Group A|"Treatment protocol given to the both groups will be carried out for 7 sessions for 2 weeks on alternative days.~It will consist of a 10 minute hot pack.~Neuromuscular reeducation for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors Neuromuscular reeducation It will break adhesion result in loosen the scar tissue will increase the temperature and cause in increase of blood flow . Muscles contract when myosin pulls actin filaments together using energy from ATP shortening the muscle fiber and causing contraction. They relax when calcium is removed, allowing the filaments to slide apart muscle will return to its resting state. The continuously muscle contraction and relaxation help to loosen up and become more flexible .~Strengthening exercises"
219232161|NCT00017355|BIOLOGICAL|therapeutic autologous dendritic cells|
219232162|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 supplement|
219232163|NCT01662193|DIETARY_SUPPLEMENT|calcium supplement|
219232164|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 and calcium supplement|
219232165|NCT01662193|DIETARY_SUPPLEMENT|placebo|
219232166|NCT01827748|DEVICE|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
219232167|NCT01827748|DEVICE|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
219232168|NCT01738997|DEVICE|Dilation 10 sec|
219232169|NCT01738997|DEVICE|Dilation 2 min|
219232170|NCT03191448|PROCEDURE|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
219232171|NCT03191448|DEVICE|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
219720744|NCT00005790|PROCEDURE|biopsy|
219720745|NCT00005790|PROCEDURE|magnetic resonance imaging|
219720746|NCT00005790|RADIATION|gadopentetate dimeglumine|
219720747|NCT00549328|DRUG|Pazopanib (GW786034)|Pazopanib monotherapy
219720748|NCT05455866|DEVICE|central venous catheter|collection and descriptionof central venous catheter-related complications
219720749|NCT00770484|DRUG|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
219720750|NCT00770484|DRUG|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
219720751|NCT00535834|PROCEDURE|diagnostic procedure|
219720752|NCT00535834|PROCEDURE|molecular diagnostic method|
219720753|NCT00535834|PROCEDURE|protein expression analysis|
219720754|NCT02196545|BEHAVIORAL|Exercise|
219720755|NCT03687255|DRUG|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
219720756|NCT03687255|DRUG|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
219148613|NCT07061782|PROCEDURE|Group B|"Treatment protocol was given to both groups for 7 session sessions for 2 weeks on alternative days.~It was comprises of HOT PACK for 10 minutes . Post facilitation stretch for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors~Post facilitation stretch :~Post Facilitation Stretch is an isometric Contraction in which he participants were instructed to contract the muscles to the maximum voluntary capacity that involves first putting the target muscle through a high-intensity isometric contraction (roughly 75-100% of maximal effort) for 5-10 seconds, and then quickly and continuously passively stretching the same muscle for at least 10 seconds.~Strengthening exercises"
219232172|NCT03191448|DEVICE|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
219720757|NCT03963830|BEHAVIORAL|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
219720758|NCT02162433|DRUG|Normal Saline|to arms 2,4. Serves as the placebo.
219720759|NCT02162433|DRUG|Dexmedetomidine|to arms 1,3
219720760|NCT05616897|BEHAVIORAL|Physiological responses during sustained CPR|
219148614|NCT07060482|DIAGNOSTIC_TEST|Panel of biomarkers including Gastrin 17, pepsinogen 1 and 2, and anti-helicobacter pylori antibodies.|This study will be assessing the diagnostic accuracy of this panel of biomarkers for diagnosing gastric atrophy in the Irish population for the first time. This reflects the assessment of these biomarkers in diagnosing gastric atrophy in a low-risk Western population.
219720761|NCT02189447|PROCEDURE|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
219720762|NCT05183620|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
219720763|NCT05463770|DRUG|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
219720764|NCT04680143|DRUG|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
219720765|NCT01946802|DEVICE|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
219720766|NCT03097315|DRUG|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
219720767|NCT01332201|DRUG|Advagraf|oral
219720768|NCT01332201|DRUG|Prograf|oral
219148615|NCT07061873|PROCEDURE|Aerobic excersise|20 aerobic exercise sessions, with a duration of 45 to 60 minutes, for 10 weeks.
219148616|NCT07061873|PROCEDURE|Muscle strength limbs, inspiratory muscle strength|20 sessions of exercise Muscle strength limbs, inspiratory muscle strength, with a duration of 60 minutes, for 10 weeks
219720769|NCT03890939|DEVICE|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
219720770|NCT03890939|DEVICE|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
219720771|NCT03890939|DEVICE|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
219720772|NCT00811109|DEVICE|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
219148617|NCT07059806|BEHAVIORAL|T1CARE|The intervention includes navigation by a Community Health Navigator (CHN), who will assess and help address patients' SDOH-related needs, coordinate care, and provide social support.
219232173|NCT03608111|OTHER|single task balance training|single task balance training
219232174|NCT03608111|OTHER|dual task balance training|dual task balance training
219232175|NCT05185973|DIETARY_SUPPLEMENT|"For Baby supplements provided as powder"|One sachet daily
219720773|NCT00811109|DEVICE|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
219148618|NCT06816979|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219148619|NCT06816979|PROCEDURE|Lumbar Puncture|Undergo LP
219232176|NCT05185973|DIETARY_SUPPLEMENT|Micronutrient powder provided as powder|One sachet daily
219232177|NCT03136861|BIOLOGICAL|AIN457|anti IL-17a monoclonal antibody
219232178|NCT03136861|DRUG|AIN457 Placebo|Placebo matching AIN457
219720774|NCT00811109|DEVICE|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
219720775|NCT00422435|DEVICE|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
219554822|NCT03885869|OTHER|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
219148620|NCT06816979|DEVICE|Magnetic Resonance Imaging|Undergo MRI
219148621|NCT06655675|DEVICE|Ultrasound|Ultrasound scan of the umbilical artery
219232179|NCT02689011|PROCEDURE|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
219148622|NCT06835569|DRUG|ALTA3263|Oral ALTA3263 tablets will be administered at a protocol-defined dose
219148623|NCT02479698|BIOLOGICAL|Allogeneic BK-specific Cytotoxic T-lymphocytes|Given IV
219148624|NCT02479698|OTHER|Laboratory Biomarker Analysis|Correlative studies
219148625|NCT06773026|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
219148626|NCT03971253|DRUG|Peficitinib|Oral
219232180|NCT02689011|PROCEDURE|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
219232181|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
219232182|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
219232183|NCT02936544|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
219232184|NCT03661398|DEVICE|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
219232185|NCT00982527|DRUG|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
219232186|NCT00982527|DRUG|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
219554823|NCT03885869|OTHER|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
219554824|NCT02775578|PROCEDURE|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
219148627|NCT06906029|DRUG|Catheter Sclerotherapy|Place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.
219148628|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
219148629|NCT04120454|BIOLOGICAL|Pembrolizumab|Given IV
219148630|NCT04120454|BIOLOGICAL|Ramucirumab|Given IV
219232187|NCT00920985|DRUG|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
219232188|NCT00920985|DRUG|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
219554825|NCT02775578|PROCEDURE|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
219554826|NCT02775578|PROCEDURE|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
219554827|NCT05103709|OTHER|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
219554828|NCT05103709|OTHER|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
219554829|NCT06461793|RADIATION|Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients|this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
219554830|NCT00458107|DRUG|SCA-136|
219720776|NCT02999321|OTHER|aspartame|will be given 5mg aspartame or 15 mg aspartame
219720777|NCT02999321|OTHER|water|control group
219720778|NCT01805336|OTHER|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
219720779|NCT01805336|OTHER|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
219720780|NCT01805336|OTHER|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
219720781|NCT01805336|OTHER|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
219720782|NCT01805336|OTHER|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
219720783|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
219720784|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
219720785|NCT04881721|PROCEDURE|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
219720786|NCT05309889|OTHER|no intervention|no intervention
219720787|NCT00247793|DRUG|Oral Impact (preoperative enteral nutritional supplement)|
219720788|NCT00277563|DEVICE|reduction of pain scores by magnetic energy|
219720789|NCT04328285|DRUG|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
219720790|NCT04328285|DRUG|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
219720791|NCT04328285|DRUG|Lopinavir and ritonavir|LPV/r Oral Tablets
219148631|NCT05114980|PROCEDURE|Parathyroid Allotransplant|Patients that meet inclusion criteria and are enrolled in the trial will undergo parathyroid allotransplantation
219148632|NCT06923670|DIAGNOSTIC_TEST|NGS testing|The investigators will test in NGS the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
219148633|NCT06923670|DIAGNOSTIC_TEST|NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies|The investigators will evaluate the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
219148634|NCT07060547|DEVICE|HepQuant DuO Test|HepQuant DuO is commercially available in the U.S. as a Laboratory Developed Test (LDT), but it will be used in this study as a nonsignificant risk investigational device to measure change in liver function over time.
219148635|NCT04584099|DEVICE|Radiofrequency device treatment|TempSure firm
219148636|NCT05607186|RADIATION|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
219148637|NCT05551065|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
219148638|NCT03265886|DRUG|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
219148639|NCT03265886|DRUG|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
219232189|NCT06395207|BEHAVIORAL|Proactive community case management|Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
219232190|NCT06395207|BEHAVIORAL|Strengthened SBCC and stock out mitigation|Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
219232191|NCT04723979|DRUG|Eptacog alfa|Recombinant coagulation factor VII activated
219232192|NCT04723979|OTHER|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
219232193|NCT00161122|BIOLOGICAL|trivalent inactivated influenza vaccine|
219720792|NCT04328285|DRUG|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
219720793|NCT06468917|BEHAVIORAL|1st day removal of abdominal drain|once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
219720794|NCT04772430|RADIATION|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
219720795|NCT03166176|DRUG|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
219720796|NCT03880409|DRUG|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
219720797|NCT03880409|DRUG|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
219720798|NCT05842707|DRUG|dualCAR-NK19/70 cell|Given by IV (vein)
219720799|NCT04279678|PROCEDURE|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
219720800|NCT03996460|DRUG|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
219720801|NCT03996460|DRUG|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
219148640|NCT04934904|DRUG|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
219232194|NCT00161122|BIOLOGICAL|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
219554831|NCT03983798|OTHER|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
219554832|NCT00030524|DRUG|gefitinib|
219554833|NCT01453153|DRUG|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
219554834|NCT01453153|DRUG|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
219554835|NCT01453153|DRUG|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
219554836|NCT01497119|DRUG|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
219554837|NCT01497119|DRUG|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
219554838|NCT01497119|DRUG|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
219554839|NCT03662724|DRUG|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
219554840|NCT06073899|OTHER|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
219554841|NCT02711033|PROCEDURE|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
219554842|NCT02711033|PROCEDURE|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
219720802|NCT03996460|DRUG|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
219148641|NCT01731041|DRUG|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
219148642|NCT01731041|DRUG|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
219148643|NCT00166283|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
219148644|NCT00166283|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
219232195|NCT01989845|DRUG|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
219554843|NCT03474809|DEVICE|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
219554844|NCT04735107|PROCEDURE|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
219554845|NCT06013930|BEHAVIORAL|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
219554846|NCT06013930|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
219554847|NCT06013930|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
219554848|NCT05113563|DEVICE|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
219554849|NCT03055871|BEHAVIORAL|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
219554850|NCT03055871|BEHAVIORAL|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
219554851|NCT00361049|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
219720803|NCT00726427|DRUG|AZD1656|Dose escalation to achieve maximum tolerated dose
219720804|NCT00726427|DRUG|AZD1656|Oral single dose
219554852|NCT00361049|GENETIC|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
219554853|NCT00361049|OTHER|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
219720805|NCT00559715|DRUG|bevacizumab|1.25 mg intravitreally monthly/on demand
219554854|NCT00361049|OTHER|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
219554855|NCT00361049|OTHER|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
219554856|NCT00361049|PROCEDURE|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
219554857|NCT00361049|PROCEDURE|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
219554858|NCT04657315|DRUG|MSC11FCD|"Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration"
219554859|NCT02751866|DIETARY_SUPPLEMENT|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
219554860|NCT02751866|DIETARY_SUPPLEMENT|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
219554861|NCT04750590|PROCEDURE|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
219554862|NCT04750590|PROCEDURE|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
219554863|NCT05856799|DEVICE|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
219554864|NCT05856799|DEVICE|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
219554865|NCT01072162|DRUG|Eltrombopag|25 mg tablet
219554866|NCT01072162|DRUG|Eltrombopag|25 mg powder for oral suspension
219554867|NCT00324896|DRUG|eszopiclone|eszopiclone
219554868|NCT00324896|OTHER|placebo|matching placebo administered at night
219554869|NCT03379636|DEVICE|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
219554870|NCT03379636|DEVICE|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
219554871|NCT01802216|PROCEDURE|Scaling and root planing|non-surgical periodontal disease treatment
219554872|NCT01802216|DRUG|Minocycline|antibiotic microspheres
219554873|NCT04402606|OTHER|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
219554874|NCT00799708|DRUG|Comparator: placebo|placebo capsule once daily for 7 days.
219554875|NCT00799708|DRUG|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
219554876|NCT00880334|DRUG|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
219554877|NCT00880334|DRUG|vandetanib|taken orally once a day, every day
219554878|NCT00880334|DRUG|Placebo|Taken orally once a day every day
219720806|NCT00559715|DRUG|ranibizumab|0.5 mg intravitreally monthly/on demand
219148645|NCT05103423|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
219148646|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
219554879|NCT03343639|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
219554880|NCT03343639|DRUG|Matching Placebo Tablets|Placebo Tablets
219554881|NCT04346563|OTHER|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
219148647|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
219148648|NCT02986412|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
219720807|NCT06328231|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
219720808|NCT00351104|DRUG|Ketoprofen Topical Patch 20%|
219720809|NCT04900857|OTHER|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
219720810|NCT04900857|DEVICE|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
219720811|NCT03573765|PROCEDURE|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
219720812|NCT03573765|PROCEDURE|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
219720813|NCT03573765|PROCEDURE|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
219720814|NCT03573765|PROCEDURE|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
219720815|NCT03573765|PROCEDURE|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
219148649|NCT02819414|DRUG|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
219148650|NCT02819414|OTHER|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
219148651|NCT00002842|DRUG|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
219554882|NCT04346563|OTHER|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1\) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
219554883|NCT03523546|OTHER|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
219554884|NCT04408534|OTHER|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
219554885|NCT00076245|BEHAVIORAL|Light Therapy|Light therapy will involve exposure to bright light twice a day.
219554886|NCT00076245|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
219720816|NCT03573765|PROCEDURE|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
219148652|NCT00002842|DRUG|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
219148653|NCT00002842|DRUG|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
219148654|NCT00002842|PROCEDURE|adjuvant therapy|Chemotherapy given after hepatic resection
219148655|NCT00002842|PROCEDURE|conventional surgery|Hepatic resection
219148656|NCT05661994|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
219148657|NCT03572257|DRUG|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
219148658|NCT03572257|OTHER|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
219148659|NCT00002900|PROCEDURE|management of therapy complications|
219148660|NCT04781790|OTHER|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
219148661|NCT00491959|PROCEDURE|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
219720817|NCT03573765|PROCEDURE|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
219720818|NCT03573765|PROCEDURE|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
219148662|NCT00508924|DRUG|Argatroban|
219148663|NCT00508924|DRUG|Argatroban|
219720819|NCT03573765|PROCEDURE|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
219720820|NCT03573765|PROCEDURE|Intra-articular injection|Any intra-articular injection
219148664|NCT00508924|DRUG|Argatroban|
219148665|NCT00508924|DRUG|Heparin|
219148666|NCT04695483|DRUG|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
219148667|NCT04695483|DRUG|Follitropin Beta|Daily controlled ovarian stimulation protocol
219148668|NCT02460549|BEHAVIORAL|therapeutic education program|
219148669|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
219148670|NCT01109498|DRUG|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
219148671|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
219148672|NCT01109498|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
219148673|NCT02755805|BEHAVIORAL|CO-OP|
219148674|NCT02755805|BEHAVIORAL|Attention Control|
219148675|NCT01355549|BIOLOGICAL|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
219148676|NCT02369484|DRUG|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
219148677|NCT04067219|PROCEDURE|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
219148678|NCT03466931|OTHER|Milk|Meals containing Milk and Milk
219148679|NCT02178241|DRUG|Eribulin Mesylate|Given IV
219148680|NCT02178241|DRUG|Gemcitabine Hydrochloride|Given IV
219148681|NCT00039000|DRUG|HSPPC-96 or Oncophage|
219148682|NCT05641506|DRUG|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
219148683|NCT05641506|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
219148684|NCT06160518|BEHAVIORAL|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
219148685|NCT00329264|DRUG|Quetiapine fumarate|
219148686|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
219720821|NCT01300520|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
219148687|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
219148688|NCT04816175|BEHAVIORAL|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
219148689|NCT02520349|DEVICE|MarkTen and e-Go e-cigarettes|
219148690|NCT01125254|DRUG|Amlodipine|5mg po for 12 months
219148691|NCT06510881|PROCEDURE|Rhinoplasty with or without cleft alveolus repair|"* Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years ."
219148692|NCT03590275|DRUG|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
219148693|NCT04043169|DIAGNOSTIC_TEST|Clearblue pregnancy test|Urine pregnancy test
219148694|NCT02334436|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
219148695|NCT02334436|OTHER|0.9% sterile, unpreserved saline|Placebo Comparator Arm
219148696|NCT03754036|BEHAVIORAL|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
219148697|NCT01091649|DRUG|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
219148698|NCT01091649|DRUG|ritonavir|ritonavir see Arm Description for more information
219554887|NCT06358027|DIAGNOSTIC_TEST|lung ultrasound|The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
219554888|NCT03368027|BEHAVIORAL|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
219554889|NCT03368027|OTHER|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
219554890|NCT01738217|PROCEDURE|Fluobeam|
219554891|NCT05253430|PROCEDURE|Lymphadenectomy type|D1 vs D2 lymph node dissection
219554892|NCT06616181|DEVICE|Anodal tDCS over M1|The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
219554893|NCT06616181|DEVICE|Anodal tDCS over DLPFC|The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
219554894|NCT06616181|BEHAVIORAL|Exercise telerehabilitation|Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.
219554895|NCT04838379|DRUG|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB\&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block \& tap block was performed
219554896|NCT06459960|GENETIC|Hydrotherapy|Heated pool (32°C); Convention rehabilitation + Hydrotherapy
219554897|NCT06459960|GENETIC|Convention|Convention rehabilitation only
219554898|NCT00040794|DRUG|paclitaxel|Given IV
219554899|NCT00040794|DRUG|carboplatin|Given IV
219554900|NCT00040794|DRUG|gefitinib|Given PO
219148699|NCT01091649|DRUG|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
219148700|NCT00756405|BEHAVIORAL|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
219148701|NCT00756405|DIETARY_SUPPLEMENT|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
219148702|NCT00756405|DIETARY_SUPPLEMENT|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
219148703|NCT03819166|DEVICE|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
219148704|NCT03819166|DEVICE|without deep touch pressure application|The deep touch pressure will not be applied.
219148705|NCT03149302|OTHER|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
219554901|NCT00040794|RADIATION|radiation therapy|Undergo radiotherapy
219554902|NCT00040794|OTHER|laboratory biomarker analysis|Optional correlative studies
219554903|NCT00616096|PROCEDURE|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
219554904|NCT04262739|DRUG|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
219554905|NCT04262739|DRUG|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
219148706|NCT03149302|OTHER|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
219148707|NCT03149302|OTHER|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
219148708|NCT03149302|OTHER|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
219554906|NCT04262739|DRUG|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
219554907|NCT02077881|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
219148709|NCT06145932|DEVICE|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
219148710|NCT06145932|DEVICE|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
219148711|NCT01238874|DEVICE|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
219148712|NCT04669028|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
219148713|NCT04669028|DRUG|Placebo|capsules that do not contain NE3107
219148714|NCT03045354|OTHER|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
219148715|NCT03045354|OTHER|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
219148716|NCT03045354|OTHER|Breakfast skipping|No breakfast
219148717|NCT03045354|OTHER|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
219148718|NCT03045354|OTHER|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
219148719|NCT02021006|DRUG|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
219148720|NCT02021006|OTHER|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
219554908|NCT02077881|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
219554909|NCT02077881|DRUG|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
219554910|NCT02658435|DRUG|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
219554911|NCT02658435|DRUG|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
219554912|NCT00297141|DRUG|Capecitabine|chemotherapy oral use
219554913|NCT00297141|DRUG|Oxaliplatin|chemotherapy intravenous use
219554914|NCT00891098|BEHAVIORAL|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
219554915|NCT00891098|BEHAVIORAL|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
219554916|NCT02874950|OTHER|office exercise training|The exercise group, did 6 months office exercise training.
219554917|NCT02874950|OTHER|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
219554918|NCT02874950|OTHER|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
219554919|NCT02874950|OTHER|Control|Control group did not do any exercise and did not follow any ergonomic modification.
219554920|NCT04224948|DEVICE|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
219554921|NCT00481026|DEVICE|transcranial direct current stimulation (tDCS)|tDCS
219554922|NCT00481026|DEVICE|active tDCS|Active tDCS
219554923|NCT02899312|DRUG|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
219554924|NCT02153723|DRUG|Glatiramer Acetate|
219554925|NCT01677650|DRUG|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
219554926|NCT02684539|DEVICE|tilt table Erigo®|tilting table with onset of syncope
219554927|NCT01149434|DRUG|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
219554928|NCT01149434|DRUG|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
219554929|NCT06004934|DRUG|Avacopan|Administered orally.
219554930|NCT05296941|PROCEDURE|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
219554931|NCT00556699|DRUG|rituximab|Escalating intravenous repeating dose
219554932|NCT00556699|DRUG|SGN-40|Escalating intravenous repeating dose
219720822|NCT00701194|BEHAVIORAL|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
219148721|NCT02021006|DRUG|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
219148722|NCT02021006|DRUG|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
219232196|NCT04803045|OTHER|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
219232197|NCT00439686|DRUG|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
219232198|NCT05320133|DRUG|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
219720823|NCT04508413|OTHER|KB295|KB295 is a novel glycan
219720824|NCT01289535|PROCEDURE|Blood sample|Blood sample of 7 ml
219720825|NCT02403037|DEVICE|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
219720826|NCT02403037|DEVICE|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
219720827|NCT02403037|DRUG|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
219720828|NCT04796467|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
219720829|NCT04796467|DRUG|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
219554933|NCT03537911|BEHAVIORAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
219554934|NCT00117182|DRUG|Dry powder mannitol|
219232199|NCT05320133|DRUG|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
219232200|NCT02346357|PROCEDURE|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
219554935|NCT00117182|DRUG|Budesonide 400mcg administered via turbuhaler|
219554936|NCT00117182|DRUG|Ipratropium bromide 80mcg|
219554937|NCT00117182|DRUG|Salbutamol 400mcg|
219232201|NCT02346357|DRUG|Ropivacaine|
219554938|NCT04559750|BEHAVIORAL|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
219554939|NCT06674135|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
219554940|NCT03278158|DRUG|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
219554941|NCT03278158|DRUG|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
219554942|NCT03278158|DRUG|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
219554943|NCT03278158|DRUG|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
219720830|NCT00909974|DIETARY_SUPPLEMENT|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
219720831|NCT00909974|DIETARY_SUPPLEMENT|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
219720832|NCT03862885|DRUG|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
219720833|NCT02407015|OTHER|Nintendo 3DS gameplay|
219720834|NCT03313193|OTHER|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
219232202|NCT02346357|DRUG|Placebo Saline|
219554944|NCT03278158|DRUG|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
219554945|NCT03994536|BEHAVIORAL|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
219554946|NCT03994536|OTHER|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
219554947|NCT03085368|DRUG|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
219554948|NCT06628999|OTHER|Visual Training|16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness
219554949|NCT06628999|OTHER|Control Group|16-week of active lifestyle based on healthy habits
219554950|NCT06628999|OTHER|Visual Training-detraining|8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
219554951|NCT05393271|DRUG|VH4011499|VH4011499 will be administered.
219554952|NCT05393271|DRUG|Placebo|Placebo will be administered.
219554953|NCT05393271|DRUG|Midazolam|Midazolam will be administered
219554954|NCT06323070|OTHER|Low-fat cookies|To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
219232203|NCT01584648|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily
219554955|NCT06323070|OTHER|Watermelon|To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
219554956|NCT03759236|BEHAVIORAL|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
219554957|NCT03759236|BEHAVIORAL|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
219554958|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
219554959|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
219554960|NCT06321276|DEVICE|extracorporeal shockwave therapy|Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
219554961|NCT03946995|OTHER|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
219554962|NCT03946995|OTHER|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
219554963|NCT02075645|OTHER|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
219720835|NCT05103592|DIAGNOSTIC_TEST|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
219232204|NCT01584648|DRUG|Trametinib|Trametinib 2 mg once daily
219232205|NCT01584648|DRUG|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
219232206|NCT04970602|DRUG|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
219232207|NCT03698383|DRUG|Trastuzumab biosimilars(Herzuma), Gedatolisib|"* Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
219232208|NCT03730038|DRUG|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
219720836|NCT05099406|DEVICE|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
219148723|NCT02021006|DRUG|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
219720837|NCT04273789|DEVICE|Far infrared reflecting sleepwear|100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
219720838|NCT04273789|DEVICE|Placebo sleepwear|100% microlyocell sleepwear (shorts + shirt)
219720839|NCT06380608|PROCEDURE|Local anesthesia|Patients who will undergo a dental surgery under local anesthesia
219720840|NCT06380608|PROCEDURE|General anesthesia|Patients who will undergo a dental surgery under general anesthesia
219720841|NCT00417729|DRUG|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
219232209|NCT03730038|BEHAVIORAL|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
219148724|NCT04380155|OTHER|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
219148725|NCT02426996|PROCEDURE|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
219148726|NCT02291094|DRUG|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
219554964|NCT04175158|BIOLOGICAL|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
219554965|NCT04175158|BIOLOGICAL|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
219148727|NCT02291094|DRUG|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
219554966|NCT04968925|DEVICE|ACUVUE Oasys 1-Day|TEST
219554967|NCT04968925|DEVICE|Precision 1|CONTROL
219232210|NCT01319058|PROCEDURE|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
219148728|NCT03050957|DIETARY_SUPPLEMENT|menthol|Alimentary bolus supplemented with menthol
219148729|NCT05254912|DRUG|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
219148730|NCT05254912|DRUG|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
219554968|NCT02829684|OTHER|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
219148731|NCT05254912|OTHER|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
219148732|NCT02252042|BIOLOGICAL|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
219554969|NCT03408730|BIOLOGICAL|Hepatitis B Vaccination|Hepatitis B Vaccination
219720842|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
219720843|NCT03384966|DRUG|Placebo|Matching placebo for subcutaneous administration.
219720844|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
219720845|NCT06330376|OTHER|Usual care of traditional treatment|Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated
219720846|NCT06330376|OTHER|Specific DB program/Diaphragmatic manipulation program|12 weeks of 2 sessions/week: one session will be remote and one in-person
219720847|NCT01567514|PROCEDURE|Glass ionomer cement lining|Resin-modified glass ionomer lining
219720848|NCT06303817|OTHER|Double knots facia closure method during cesarean section|In Group I (double knots group), the edge of the fascia was identified with a Kocher clamp. A synthetic absorbable multifilament suture was used to close the fascia in a continuous fashion, starting from the opposite side up to the Kocher clamp. The knots were tied with the same single suture. I
219720849|NCT06303817|OTHER|Triple knots facia closure method during cesarean section|n Group II (triple knots group), the edge of the fascia was fixed with the same suture material instead of the Kocher clamp. The fascia was closed similarly, starting from the opposite corner via the second loop. The loops from the first suture were tied to the second suture.
219720850|NCT04658589|PROCEDURE|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
219720851|NCT03841292|DRUG|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
219720852|NCT03841292|DEVICE|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
219720853|NCT03841292|DEVICE|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
219720854|NCT04649983|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
219720855|NCT01972828|DRUG|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
219148733|NCT02252042|DRUG|Methotrexate|40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
219148734|NCT02252042|DRUG|Docetaxel|75 mg/m\^2 IV on Day 1 of each 3- week cycle
219148735|NCT02252042|BIOLOGICAL|Cetuximab|400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
219148736|NCT05456334|DEVICE|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
219148737|NCT05456334|DEVICE|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
219148738|NCT05456334|DRUG|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
219148739|NCT04820049|DRUG|F573|F573 for injection
219148740|NCT04820049|OTHER|Placebo|Water for injection
219554970|NCT06209034|OTHER|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
219554971|NCT05682963|OTHER|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
219554972|NCT05682963|OTHER|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
219148741|NCT04124185|DIAGNOSTIC_TEST|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
219148742|NCT02189772|DRUG|Metadoxine extended release|MG01CI
219148743|NCT02189772|DRUG|Placebo|Inactive drug
219148744|NCT00604955|DRUG|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
219148745|NCT02273999|DEVICE|RecoveryRx™|Appliance of the device after surgery
219554973|NCT02930876|BEHAVIORAL|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
219554974|NCT00504634|DRUG|Bortezomib|1 mg/m\^2 IV On Days 1, 4, 8, and 11.
219554975|NCT04517526|DRUG|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
219554976|NCT00876265|DEVICE|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
219554977|NCT00876265|DEVICE|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
219554978|NCT02625311|PROCEDURE|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
219720856|NCT01972828|DRUG|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
219720857|NCT03976700|DRUG|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
219720858|NCT03976700|DRUG|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
219720859|NCT04007900|BEHAVIORAL|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
219720860|NCT02158598|DRUG|Vitamin D chewable tablet supplementation|
219232211|NCT04827849|OTHER|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
219554979|NCT06010823|DEVICE|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
219554980|NCT05077501|DRUG|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
219554981|NCT05077501|DRUG|Placebo|Placebo oral solution
219554982|NCT01566994|BEHAVIORAL|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
219554983|NCT01566994|BEHAVIORAL|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
219554984|NCT01566994|BEHAVIORAL|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
219554985|NCT02458391|OTHER|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
219554986|NCT03160079|DRUG|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
219554987|NCT03160079|DRUG|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
219554988|NCT02360007|DRUG|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"
219554989|NCT04284007|DRUG|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
219554990|NCT04284007|DRUG|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
219554991|NCT04284007|DRUG|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
219554992|NCT00487695|DEVICE|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
219554993|NCT00487695|DEVICE|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
219554994|NCT03677219|OTHER|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
219720861|NCT02158598|DRUG|Vitamin D pill supplementation|
219720862|NCT01248975|DRUG|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
219720863|NCT01248975|DRUG|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
219720864|NCT01248975|DRUG|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
219720865|NCT01248975|DRUG|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
219720866|NCT01248975|DRUG|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
219720867|NCT01248975|DRUG|Placebo capsule (PM)|Placebo capsule (PM)
219148746|NCT04942184|BEHAVIORAL|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
219148747|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
219148748|NCT04942184|OTHER|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
219148749|NCT04942184|BEHAVIORAL|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
219148750|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
219554995|NCT06677619|DEVICE|intrusion by reverse curve wire in cervical position of twin slot bracket|intrusion of anterior teeth by putting reverse curve wire in incisal slot of twin slot bracket
219554996|NCT06075849|DRUG|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
219554997|NCT03433703|DRUG|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
219554998|NCT06033313|BEHAVIORAL|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
219554999|NCT06033313|BEHAVIORAL|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
219555000|NCT01957150|DRUG|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
219555001|NCT01957150|DRUG|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
219555002|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
219555003|NCT00000136|DRUG|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
219555004|NCT00000136|DRUG|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
219555005|NCT06476106|DEVICE|Venoconstrictive Thigh Cuff (VTC)|The VTC is an adjustable fabric cuff that is worn on the upper thighs to retain some fluid in the legs. It consists of wide straps and a buckle which allow it to be tightened, then velcro to secure the strap in the tightened position. There is also lacing that can be tightened for micro adjustments. Imbedded within the fabric strap is a bladder that is not used for increasing tightness but allows the pressure of the cuff to be measured and tracked.
219555006|NCT01207752|DRUG|Systane Balance|Artificial tear emulsion drop
219555007|NCT01207752|DRUG|Optive Lubricant Eye Drops|Artificial tear eye drop
219555008|NCT05746377|DRUG|Metoclopramide 10mg|IV Metoclopramide
219555009|NCT05746377|DRUG|Saline|Placebo
219555010|NCT04425031|DRUG|Low oxygenation target|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
219555011|NCT04425031|DRUG|High oxygenation target|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
219555012|NCT00680498|DRUG|Ranibizumab|Ranibizumab 0.5 mg
219555013|NCT00680498|DRUG|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
219555014|NCT01632215|DRUG|Gabapentine|Gabapentine 600 mg 01 dose
219555015|NCT01632215|OTHER|Sugar pill|Sugar pill 01 dose
219555016|NCT03997253|OTHER|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
219555017|NCT02637180|DRUG|anti-osteoporotic medication|check previous information
219555018|NCT00041860|PROCEDURE|Controlled Exposure to Environmental Contaminant|
219555019|NCT06380387|DIETARY_SUPPLEMENT|Meal|Liquid meal
219555020|NCT00212654|DRUG|ONO-1101|
219555021|NCT02528019|DRUG|DPP-4 inhibiotors|
219555022|NCT02528019|DRUG|SGLT2 inhibitors|
219555023|NCT02528019|DRUG|Glimepiride|
219555024|NCT02720549|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
219555025|NCT02720549|PROCEDURE|valvular surgery with bypass|valvular surgery with bypass
219555026|NCT03153605|OTHER|Common toothpaste|different toothpaste
219555027|NCT03786705|OTHER|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
219555028|NCT03786705|OTHER|Non-Massive Transfusion|Trauma patients who had received blood transfusion\<10 U
219148751|NCT04942184|OTHER|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
219148752|NCT02593149|DEVICE|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
219148753|NCT05247437|BEHAVIORAL|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
219148754|NCT05247437|BEHAVIORAL|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
219148755|NCT04620421|OTHER|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
219148756|NCT05122468|PROCEDURE|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
219232212|NCT05684809|OTHER|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
219232213|NCT05684809|OTHER|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
219555029|NCT01745094|DRUG|mirabegron|oral
219555030|NCT01745094|DRUG|solifenacin|oral
219555031|NCT05795296|DRUG|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
219555032|NCT05795296|DRUG|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
219555033|NCT03936894|DRUG|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
219555034|NCT05585489|OTHER|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
219555035|NCT05951751|OTHER|TRI-MOM intervention|"The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections"
219555036|NCT03095950|OTHER|News items with spin|Interpretation of news items with spin
219555037|NCT03095950|OTHER|News items without spin|Interpretation of news items without spin
219555038|NCT03414034|DRUG|Onvansertib|Onvansertib orally
219555039|NCT03414034|DRUG|Abiraterone|Abiraterone orally
219555040|NCT03414034|DRUG|Prednisone|Prednisone orally
219555041|NCT02725645|OTHER|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
219555042|NCT03368391|DRUG|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
219555043|NCT03368391|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
219555044|NCT03368391|DRUG|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
219555045|NCT03368391|DRUG|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
219555046|NCT03368391|DRUG|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
219555047|NCT00162968|DRUG|escitalopram|
219555048|NCT05029427|OTHER|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
219555049|NCT05029427|OTHER|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
219555050|NCT04010227|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
219720868|NCT03156140|OTHER|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
219148757|NCT05122468|PROCEDURE|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
219720869|NCT01365611|DRUG|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
219720870|NCT01365611|DRUG|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
219232214|NCT05684809|OTHER|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
219232215|NCT01672242|DEVICE|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
219720871|NCT01356810|OTHER|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
219720872|NCT01356810|OTHER|Standard Care|Delirium management by the attending physician's preferences.
219148758|NCT00989469|DRUG|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
219148759|NCT00043966|DRUG|Lopinavir/ritonavir|
219148760|NCT00043966|DRUG|Tenofovir DF|
219148761|NCT00043966|DRUG|Emtricitabine|
219148762|NCT00071799|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
219148763|NCT00071799|OTHER|Physician Choice|"Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
219148764|NCT02345174|DRUG|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
219148765|NCT02345174|DRUG|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
219148766|NCT02474238|DEVICE|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
219148767|NCT02474238|DEVICE|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
219148768|NCT01571557|DRUG|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
219148769|NCT02379715|DRUG|Remifentanil|
219148770|NCT02379715|DRUG|Desflurane|
219148771|NCT04072328|DRUG|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
219148772|NCT04072328|DRUG|Midazolam|midazolam with propofol
219148773|NCT00979992|OTHER|Laboratory Biomarker Analysis|Correlative studies
219148774|NCT00979992|DRUG|Sunitinib Malate|Given PO
219232216|NCT01672242|DEVICE|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
219232217|NCT02613767|OTHER|Protein meal|Ingestion of protein
219232218|NCT02613767|OTHER|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
219232219|NCT04709185|DRUG|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
219232220|NCT04709185|DRUG|Placebo|oral placebo at 23:00-24:00 the night before AVS
219232221|NCT04834830|DIAGNOSTIC_TEST|Pleural effusion will be examined for various cytokines and PD1-lymphocytes.|Examination of pleural effusion
219720873|NCT02662920|OTHER|No Intervention|
219720874|NCT03459586|OTHER|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
219720875|NCT04632719|DEVICE|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
219720876|NCT06397638|PROCEDURE|Rescue carotid stenting|Rescue carotid stenting in tandem occlusions
219720877|NCT04416542|DIAGNOSTIC_TEST|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
219232222|NCT05671549|PROCEDURE|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
219232223|NCT02079259|PROCEDURE|Ultrafiltration|
219720878|NCT02271802|DIETARY_SUPPLEMENT|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
219720879|NCT02271802|DIETARY_SUPPLEMENT|NaCl|
219148775|NCT06267131|DEVICE|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
219148776|NCT05919368|DIETARY_SUPPLEMENT|Yam pill|It consists of sweet potato, white art and ginseng
219148777|NCT06227637|OTHER|Local Muscle Vibration compared to Muscle energy technique in SIJD|Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
219148778|NCT03913715|OTHER|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
219148779|NCT04807556|OTHER|Alusti Test|Physical and psychological functional conditions are key factors in the elderly population
219720880|NCT02836769|BEHAVIORAL|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
219148780|NCT02740595|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
219148781|NCT02740595|OTHER|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
219232224|NCT05376397|BEHAVIORAL|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
219232225|NCT02757378|PROCEDURE|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
219232226|NCT02757378|PROCEDURE|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
219232227|NCT01328756|DRUG|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
219232228|NCT00652600|DRUG|Propranolol|ER Capsules, 160 mg, single-dose
219232229|NCT00652600|DRUG|Inderal-LA|ER Capsules, 160 mg, single-dose
219232230|NCT05575349|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
219232231|NCT00237705|DRUG|metoclopramide|
219232232|NCT01266837|DRUG|Everolimus|10 mg p.o once daily
219148782|NCT02740595|OTHER|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
219148783|NCT02350842|DEVICE|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
219148784|NCT02350842|DEVICE|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
219148785|NCT04468698|OTHER|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
219148786|NCT00947453|DRUG|montelukast|montelukast 10 mg once daily for 8 weeks
219148787|NCT04722237|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
219232233|NCT02970578|PROCEDURE|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
219232234|NCT03999294|OTHER|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
219232235|NCT00838045|DEVICE|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
219720881|NCT06447896|DEVICE|Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)|"Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers."
219720882|NCT06447896|DIAGNOSTIC_TEST|Conventional method of CARTs|Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
219720883|NCT06447896|DEVICE|Ambulatory holter station Model i12 plus|Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
219720884|NCT02580071|DIETARY_SUPPLEMENT|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
219720885|NCT01119222|DRUG|Gabapentin|Capsule, single 1200mg dose
219720886|NCT01119222|DRUG|Diphenhydramine|Tablet, single 50mg dose
219720887|NCT01119222|DRUG|Morphine|IV, single 10mg dose
219555051|NCT04010227|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
219555052|NCT04752527|DRUG|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
219555053|NCT00590694|DRUG|ranibizumab|0.5mg injection monthly according to protocol for one year
219148788|NCT02663297|DRUG|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"
219232236|NCT02070276|PROCEDURE|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
219232237|NCT02070276|PROCEDURE|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
219555054|NCT01093560|DIETARY_SUPPLEMENT|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
219720888|NCT01119222|DRUG|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
219555055|NCT05429944|OTHER|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
219555056|NCT05429944|OTHER|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
219555057|NCT05429944|OTHER|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
219720889|NCT04626336|PROCEDURE|Cystectomy|Cystectomy
219720890|NCT01223677|BEHAVIORAL|Rumination Focused CBT|see arms
219720891|NCT05658991|DIAGNOSTIC_TEST|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
219720892|NCT02861976|OTHER|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
219148789|NCT04532528|DRUG|Dabigatran|Dabigatran
219555058|NCT00460850|DRUG|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
219720893|NCT00292994|BEHAVIORAL|Exercise|
219720894|NCT00292994|BEHAVIORAL|Weight Loss|
219148790|NCT06181916|BEHAVIORAL|Amp|Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
219148791|NCT06065332|OTHER|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
219148792|NCT01636687|DRUG|Placebo|2 injections of placebo to secukinumab 150mg per dose
219148793|NCT01636687|DRUG|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
219148794|NCT01636687|DRUG|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
219148795|NCT03924037|BEHAVIORAL|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
219148796|NCT03924037|BEHAVIORAL|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
219148797|NCT01824056|DRUG|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
219148798|NCT00648349|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
219148799|NCT00648349|DRUG|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
219148800|NCT04425551|PROCEDURE|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
219720895|NCT01573377|DRUG|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
219720896|NCT01573377|DRUG|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
219720897|NCT03786575|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
219720898|NCT01354535|PROCEDURE|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
219720899|NCT01354535|PROCEDURE|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
219720900|NCT02372084|DRUG|osilodrostat|
219720901|NCT01899703|DRUG|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
219720902|NCT01899703|DRUG|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
219720903|NCT01899703|DRUG|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
219720904|NCT06217146|DRUG|Medical Cannabis|MediCane's medical cannabis oil
219720905|NCT06217146|DRUG|Placebo Oil|Placebo Oil
219720906|NCT00376506|DEVICE|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
219720907|NCT00376506|DEVICE|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
219720908|NCT02962466|OTHER|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
219720909|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
219720910|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
219720911|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
219720912|NCT05007509|BIOLOGICAL|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
219148801|NCT00769353|BEHAVIORAL|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
219148802|NCT00769353|BEHAVIORAL|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
219148803|NCT02255877|DEVICE|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
219148804|NCT02255877|DEVICE|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
219148805|NCT03001362|RADIATION|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
219148806|NCT03809936|DEVICE|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
219232238|NCT06284356|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
219148807|NCT03809936|DEVICE|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
219148808|NCT01203306|DRUG|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
219148809|NCT00567333|OTHER|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
219148810|NCT00567333|OTHER|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
219148811|NCT00829348|OTHER|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
219148812|NCT00829348|BEHAVIORAL|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
219148813|NCT04302805|DRUG|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
219148814|NCT04302805|DRUG|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
219148815|NCT04302805|OTHER|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
219148816|NCT03522454|DIETARY_SUPPLEMENT|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
219148817|NCT03522454|BEHAVIORAL|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
219148818|NCT02771899|DEVICE|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
219148819|NCT02771899|DEVICE|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
219148820|NCT02949206|DRUG|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
219148821|NCT02949206|DRUG|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
219148822|NCT02949206|DRUG|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
219148823|NCT05342818|DRUG|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
219148824|NCT05342818|DRUG|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
219148825|NCT05342818|DRUG|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
219555059|NCT03051776|OTHER|Kinesio Taping|
219555060|NCT03051776|OTHER|Compression Garment|
219555061|NCT03232762|DIETARY_SUPPLEMENT|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
219555062|NCT03232762|DIETARY_SUPPLEMENT|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
219555063|NCT04784169|DEVICE|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
219555064|NCT04784169|DEVICE|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
219555065|NCT06053840|DRUG|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
219555066|NCT03655860|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
219555067|NCT01333917|DRUG|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
219555068|NCT03565562|OTHER|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
219555069|NCT03565562|OTHER|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
219555070|NCT05155293|DRUG|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
219555071|NCT05155293|DRUG|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
219555072|NCT04636450|PROCEDURE|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
219555073|NCT04636450|PROCEDURE|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
219555074|NCT05139394|PROCEDURE|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
219555075|NCT04811729|BEHAVIORAL|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
219555076|NCT04811729|BEHAVIORAL|Medical advice|Usual care
219555077|NCT03078257|DRUG|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
219555078|NCT03078257|DRUG|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
219555079|NCT03078257|DRUG|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
219555080|NCT03078257|DRUG|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
219555081|NCT03078257|DRUG|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
219148826|NCT05342818|OTHER|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
219148827|NCT05342818|OTHER|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
219720913|NCT00689988|BEHAVIORAL|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
219148828|NCT00994097|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
219148829|NCT00994097|DRUG|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
219148830|NCT00994097|DRUG|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
219148831|NCT00994097|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
219148832|NCT05089097|OTHER|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
219148833|NCT04706078|DIAGNOSTIC_TEST|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
219148834|NCT03835819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
219555082|NCT03078257|DRUG|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
219720914|NCT02819388|BEHAVIORAL|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
219720915|NCT04626778|DRUG|Peroxyl Mouthwash|Mouthwash
219720916|NCT04626778|DRUG|Placebo Mouthwash|Mouthwash
219148835|NCT03835819|DRUG|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
219148836|NCT01189513|DRUG|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
219148837|NCT00681525|DRUG|ABT-335|One ABT-335 135 mg capsule QD for 10 days
219148838|NCT00681525|DRUG|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
219555083|NCT03078257|DRUG|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
219555084|NCT01968369|DIETARY_SUPPLEMENT|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
219720917|NCT04311580|COMBINATION_PRODUCT|intravesical electromotive administration of mitomycin|
219720918|NCT03073057|DRUG|Budesonide/formoterol|2 inhalations as a single dose
219720919|NCT03073057|OTHER|Charcoal|
219720920|NCT03073057|DRUG|Symbicort Turbuhaler|2 inhalations as a single dose
219720921|NCT00001857|DRUG|BG9588|
219720922|NCT03144635|DRUG|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
219720923|NCT05916287|BIOLOGICAL|Blood and urine samples|Blood and urine samples
219148839|NCT00681525|DRUG|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
219148840|NCT02229019|BEHAVIORAL|Volunteer mealtime assistance|
219148841|NCT03318484|DRUG|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
219148842|NCT03318484|COMBINATION_PRODUCT|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
219148843|NCT01865253|DEVICE|Renal Denervation|Renal Denervation
219720924|NCT05916287|GENETIC|Blood samples|Blood samples
219720925|NCT05916287|OTHER|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
219148844|NCT04333589|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
219148845|NCT01231568|DRUG|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
219148846|NCT01231568|DRUG|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
219148847|NCT01231568|DRUG|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
219148848|NCT01231568|DRUG|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
219148849|NCT00470938|DEVICE|SpineForce Reactive Neuromuscular Trainer|
219148850|NCT03784378|DRUG|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
219148851|NCT03593213|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
219148852|NCT03593213|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
219148853|NCT03703518|OTHER|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
219148854|NCT03703518|OTHER|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
219148855|NCT01321411|OTHER|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
219148856|NCT01321411|OTHER|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
219148857|NCT00115713|BEHAVIORAL|Aerobic Exercise Training|
219148858|NCT00115713|BEHAVIORAL|Resistance Exercise Training|
219148859|NCT02671344|OTHER|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
219148860|NCT00944372|DRUG|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
219232239|NCT00861315|DRUG|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
219232240|NCT00861315|DRUG|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
219232241|NCT00861315|DRUG|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
219232242|NCT00861315|DRUG|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
219555085|NCT02149394|OTHER|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
219555086|NCT02149394|OTHER|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
219555087|NCT05735626|COMBINATION_PRODUCT|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
219555088|NCT05735626|COMBINATION_PRODUCT|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
219555089|NCT05735626|COMBINATION_PRODUCT|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
219555090|NCT00163969|DRUG|ketamine|
219555091|NCT06207669|OTHER|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
219555092|NCT02101073|BIOLOGICAL|ALX-0061|single dose, intravenous
219555093|NCT02101073|BIOLOGICAL|ALX-0061|single dose, subcutaneous
219555094|NCT05072119|DEVICE|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
219555095|NCT04186286|DRUG|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
219555096|NCT04186286|DRUG|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
219555097|NCT04186286|DRUG|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
219555098|NCT00197834|DRUG|Depakote|
219555099|NCT02052817|DEVICE|Optimal Medical Therapy Debridement + Toad Brace|
219148861|NCT02353988|DRUG|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
219148862|NCT02353988|OTHER|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
219148863|NCT04889131|BEHAVIORAL|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
219148864|NCT04889131|BEHAVIORAL|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
219148865|NCT04889131|OTHER|Activity Monitor|Garmin VivoSmart activity monitor throughout study
219148866|NCT02462369|DRUG|Saxagliptin|
219232243|NCT00472082|DRUG|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
219148867|NCT02462369|DRUG|glimepiride|
219232244|NCT06186063|OTHER|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
219232245|NCT06186063|OTHER|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
219232246|NCT04252794|PROCEDURE|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
219232247|NCT04252794|OTHER|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
219232248|NCT05634161|OTHER|Cognitive improvement software|Cognitive improvement software
219232249|NCT02714244|OTHER|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
219232250|NCT02222649|DIETARY_SUPPLEMENT|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
219555100|NCT02052817|OTHER|Optimal Medical Therapy - Debridement|
219555101|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
219555102|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
219555103|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
219555104|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
219555105|NCT01841073|DIETARY_SUPPLEMENT|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
219555106|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
219555107|NCT05447416|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
219555108|NCT05447416|DEVICE|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
219555109|NCT01799850|DRUG|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
219555110|NCT01799850|DRUG|placebo|placebo assigned randomly, double blind
219555111|NCT03313713|DIETARY_SUPPLEMENT|Beta-glucans|Placebo consumption at breakfast (3 g per day)
219555112|NCT03313713|DIETARY_SUPPLEMENT|Placebo|Placebo consumption at breakfast (3 g per day)
219555113|NCT01189656|BIOLOGICAL|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
219555114|NCT04808388|OTHER|MRI|Using MRI for fat fraction and Biodex for isometric strength
219555115|NCT01670097|DRUG|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
219555116|NCT01670097|DRUG|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
219555117|NCT01670097|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
219555118|NCT01670097|DEVICE|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
219555119|NCT01670097|OTHER|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
219555120|NCT04759989|PROCEDURE|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
219555121|NCT04759989|PROCEDURE|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
219555122|NCT04759989|PROCEDURE|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
219555123|NCT01812239|DRUG|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
219555124|NCT01812239|PROCEDURE|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
219720926|NCT05916287|BEHAVIORAL|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
219720927|NCT05916287|OTHER|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
219720928|NCT05916287|OTHER|Hemodynamic parameters|Systolic pressure index measurement
219555125|NCT01812239|DRUG|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
219555126|NCT00768352|OTHER|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
219555127|NCT05248399|BEHAVIORAL|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
219148868|NCT06450730|BEHAVIORAL|Cognitive-Behavioral Therapy: face-to-face + app|"This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos)."
219148869|NCT02658240|DRUG|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
219148870|NCT02658240|DRUG|Epinephrine|0.5 mg epinephrine
219148871|NCT01460290|DRUG|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
219148872|NCT04805996|BEHAVIORAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
219148873|NCT01881386|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
219148874|NCT00771160|DRUG|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
219148875|NCT02561949|BEHAVIORAL|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
219555128|NCT05248399|BEHAVIORAL|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
219720929|NCT05916287|OTHER|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
219720930|NCT05916287|OTHER|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
219720931|NCT05916287|OTHER|Hemodynamic parameters|Electrocardiogram
219720932|NCT05916287|BEHAVIORAL|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
219720933|NCT05916287|OTHER|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
219720934|NCT05916287|BIOLOGICAL|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
219720935|NCT05916287|OTHER|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
219720936|NCT05916287|OTHER|Women specific questionnaire|Women specific questionnaire
219720937|NCT05916287|BEHAVIORAL|Women specific questionnaire|Women specific questionnaire
219720938|NCT05916287|DIAGNOSTIC_TEST|NYHA dyspnea questionnaire|Determination of NYHA class.
219720939|NCT05916287|BEHAVIORAL|Anxiety questionnaire|Assessment of anxiety
219720940|NCT05916287|BEHAVIORAL|Epworth Sleepiness Scale|sleep quality assessment
219232251|NCT02222649|DIETARY_SUPPLEMENT|Placebo|Capsules of starch, no therapeutic action
219232252|NCT05094947|PROCEDURE|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
219232253|NCT05094947|PROCEDURE|trial without catheter|catheter Foley
219148876|NCT02561949|OTHER|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
219232254|NCT05094947|DRUG|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
219232255|NCT06248021|BEHAVIORAL|Ecological Footprint Awareness Program|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
219555129|NCT03910049|DRUG|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
219555130|NCT06628349|DIETARY_SUPPLEMENT|Whey Protein Isolate 90%|Commercially available animal based protein powders
219555131|NCT06628349|DIETARY_SUPPLEMENT|Soy Protein Isolate (90% Protein)|Commercially available plant based protein powders
219555132|NCT06628349|DIETARY_SUPPLEMENT|Organic Pea Protein Isolate|Commercially available plant based protein powders
219555133|NCT06628349|DIETARY_SUPPLEMENT|Placebo (Water)|Normal drinking water
219720941|NCT05916287|OTHER|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
219720942|NCT05916287|BEHAVIORAL|A questionnaire on eating behaviors|Assessment of eating behaviors
219555134|NCT03994952|DEVICE|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
219555135|NCT03994952|DEVICE|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
219720943|NCT05916287|BEHAVIORAL|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
219720944|NCT05916287|DIETARY_SUPPLEMENT|A questionnaire on food supplements use|Evaluation od food supplements intake
219720945|NCT05916287|OTHER|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
219720946|NCT05916287|OTHER|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
219148877|NCT03663842|OTHER|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
219720947|NCT05916287|BIOLOGICAL|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
219148878|NCT03553212|RADIATION|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
219148879|NCT01071408|OTHER|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
219148880|NCT03166449|DIETARY_SUPPLEMENT|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
219148881|NCT03166449|DIETARY_SUPPLEMENT|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
219148882|NCT06386627|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
219148883|NCT06386627|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation to assess the integrity of corticospinal connections
219148884|NCT05717751|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
219148885|NCT01442935|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
219148886|NCT01442935|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
219148887|NCT01442935|DRUG|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
219148888|NCT01442935|DRUG|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
219148889|NCT01442935|DRUG|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
219148890|NCT01442935|DRUG|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
219148891|NCT01442935|DRUG|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
219555136|NCT02247037|OTHER|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
219555137|NCT00550147|DRUG|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM."
219555138|NCT00550147|DRUG|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
219555139|NCT04320745|DRUG|Androderm®|Androderm® transdermal dose.
219555140|NCT01824498|OTHER|Low Fat diet|Low fat diet = 20% fat
219555141|NCT01824498|OTHER|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
219555142|NCT01824498|OTHER|High Fat Diet|High Fat Diet = 40% fat
219555143|NCT04358627|DRUG|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
219148892|NCT06371196|DRUG|Babaodan Capsule|Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
219148893|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
219720948|NCT04787458|DEVICE|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
219720949|NCT02843607|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
219148894|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
219555144|NCT01021501|DRUG|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
219555145|NCT02759380|OTHER|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
219555146|NCT03965065|DEVICE|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
219555147|NCT03965065|DEVICE|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
219148895|NCT05033301|DEVICE|Nurse Ned Clinic|Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
219148896|NCT06241235|DRUG|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
219555148|NCT00496067|DEVICE|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
219555149|NCT02118324|BEHAVIORAL|Exergaming Program|Participants will exercise through exergaming play.
219555150|NCT04609397|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
219555151|NCT04609397|DRUG|Hemay005|Hemay005 tables 45mg bid p.o
219555152|NCT04609397|OTHER|Placebo|placebo to Hemay005 tables bid p.o
219555153|NCT00382083|DRUG|1000 mg acetaminophen|
219555154|NCT00382083|DRUG|800 mg ibuprofen|
219555155|NCT00382083|DRUG|1 oz 4% lidocaine gel|
219555156|NCT04702789|DRUG|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
219555157|NCT04702789|DRUG|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
219555158|NCT04989244|BEHAVIORAL|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
219555159|NCT02382601|RADIATION|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
219555160|NCT02382601|RADIATION|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
219555161|NCT02382601|PROCEDURE|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
219720950|NCT02843607|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
219720951|NCT01430884|OTHER|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
219720952|NCT06005155|DRUG|Lithium|Sustained long-term exposure
219720953|NCT05842980|OTHER|sepsis|collect 5ml blood from patient
219720954|NCT02306785|DRUG|TP05 Coating D|One radio-labelled tablet given to subjects
219555162|NCT02382601|BEHAVIORAL|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
219555163|NCT02382601|PROCEDURE|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
219720955|NCT02306785|DRUG|TP05 Coating E|One radio-labelled tablet given to subjects
219720956|NCT02306785|DRUG|TP05 Coating H|One radio-labelled tablet given to subjects
219148897|NCT06241235|DRUG|Paclitaxel|IV infusion
219148898|NCT06241235|BIOLOGICAL|Bevacizumab|IV infusion
219148899|NCT06241235|DRUG|Cisplatin|IV infusion
219720957|NCT04887038|DRUG|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
219720958|NCT04887038|OTHER|Matching Placebo for SRT-015|Matching Placebo
219720959|NCT03780387|BIOLOGICAL|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
219720960|NCT04675281|OTHER|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
219720961|NCT05753969|DEVICE|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
219720962|NCT00006457|DRUG|oltipraz|
219720963|NCT05076786|DRUG|Chidamide|20mg, administered orally. Week 1/2: twice a week (d0, d4, d7, d11); Week 3: stop. Repeat every 3 weeks for 4-6 cycles.
219720964|NCT05076786|DRUG|Etoposide + Cisplatin/Carboplatin|"Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (75mg/m2; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (25mg/m2; intravenous infusion; d1-3). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Carboplatin (AUC=5; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles."
219148900|NCT06241235|DRUG|Carboplatin|IV infusion
219148901|NCT00495417|BIOLOGICAL|AFFITOPE AD01|s.c. injection
219720965|NCT04715035|OTHER|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
219720966|NCT02788227|BIOLOGICAL|rVSV-Zebov GP vaccine|primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
219232256|NCT06052943|BEHAVIORAL|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
219232257|NCT06052943|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
219232258|NCT06052943|BEHAVIORAL|Physical Activity|Combines aerobic and resistance training though game play.
219555164|NCT02382601|PROCEDURE|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
219555165|NCT02382601|RADIATION|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
219720967|NCT05266469|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
219720968|NCT05266469|OTHER|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
219720969|NCT05229913|DRUG|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
219720970|NCT05229913|DRUG|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
219720971|NCT05229913|DRUG|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
219720972|NCT05229913|DRUG|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
219148902|NCT00495417|BIOLOGICAL|AFFITOPE AD01 adjuvanted|s.c. injection
219148903|NCT05752006|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
219148904|NCT02455141|DRUG|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
219148905|NCT02455141|DRUG|Taxanes|Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
219148906|NCT02455141|DRUG|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
219720973|NCT05229913|DRUG|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
219720974|NCT02948400|BEHAVIORAL|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
219720975|NCT02403271|DRUG|Ibrutinib|BTK Inhibitor
219720976|NCT02403271|DRUG|Durvalumab|Anti PDL-1
219720977|NCT02450136|DRUG|pazopanib|
219148907|NCT01035658|DRUG|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
219148908|NCT01035658|DRUG|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
219148909|NCT00987961|BEHAVIORAL|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
219148910|NCT05756010|DEVICE|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
219148911|NCT02118077|BIOLOGICAL|G17DT|
219148912|NCT06311799|BEHAVIORAL|WIC Referral|Clinical team will refer study participants to WIC
219148913|NCT06311799|BEHAVIORAL|RDN Referral|Clinical team will refer study participants to a RDN
219148914|NCT00817830|DRUG|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
219555166|NCT02584166|BEHAVIORAL|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
219555167|NCT05626348|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219555168|NCT05626348|DRUG|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219555169|NCT05626348|DRUG|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219555170|NCT05626348|DRUG|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219555171|NCT05626348|DRUG|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219555172|NCT06213792|OTHER|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
219555173|NCT03057535|DRUG|Sodium Bicarbonate|
219555174|NCT03057535|DRUG|Sodium Chloride|
219555175|NCT02702635|PROCEDURE|DCE MRI of the brain|An MRI of the brain including a DCE sequence
219555176|NCT00421863|DRUG|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555177|NCT00421863|DRUG|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555178|NCT00421863|DRUG|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555179|NCT00421863|DRUG|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555180|NCT00421863|DRUG|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555181|NCT00421863|DRUG|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555182|NCT00421863|DRUG|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555183|NCT00421863|DRUG|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555184|NCT00421863|DRUG|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
219555185|NCT01740934|OTHER|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
219555186|NCT01740934|OTHER|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
219555187|NCT05260203|DEVICE|RITA (App)|"The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources."
219555188|NCT03941795|BIOLOGICAL|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
219555189|NCT03941795|DRUG|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
219148915|NCT04520880|DIAGNOSTIC_TEST|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
219720978|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
219148916|NCT04520880|DIAGNOSTIC_TEST|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
219148917|NCT02847702|DRUG|VM902A 200-mg Capsules|Taken orally with food twice daily
219148918|NCT02847702|DRUG|VM902A 400-mg Capsules|Taken orally with food twice daily
219720979|NCT05765734|DRUG|TAS3351 oral administration|TAS3351 will be administered orally
219148919|NCT02847702|DRUG|Naproxen 500-mg Capsules|Taken orally with food twice daily
219148920|NCT02847702|DRUG|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
219148921|NCT03908671|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
219148922|NCT03280017|DRUG|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
219148923|NCT03280017|DRUG|Normal saline|normal saline infusion
219148924|NCT05317910|OTHER|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
219148925|NCT02874430|DRUG|Metformin Hydrochloride|Given orally
219148926|NCT02874430|DRUG|Doxycycline|Given orally
219148927|NCT03238326|DRUG|Brexpiprazole|Once daily, oral tablets
219148928|NCT04589689|BEHAVIORAL|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
219148929|NCT05076435|DRUG|Isotonic crystalloids|"Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
219148930|NCT03637231|DIAGNOSTIC_TEST|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
219148931|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 6-min per time, with focus, until the completion of the study.
219232259|NCT06052943|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
219232260|NCT06052943|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
219232261|NCT06052943|BEHAVIORAL|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
219232262|NCT02189434|OTHER|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
219720980|NCT01140139|BIOLOGICAL|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
219720981|NCT05749185|DEVICE|radiofrequency high voltage|nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
219148932|NCT05462561|OTHER|Quality-of-Life Assessment|Ancillary studies
219720982|NCT05749185|PROCEDURE|standard RF|A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
219720983|NCT05783050|DEVICE|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
219148933|NCT05462561|PROCEDURE|Robotic Vascularized Composite Bladder Allograft Transplantation|Undergo robotic VCBA transplantation.
219148934|NCT04867291|DIETARY_SUPPLEMENT|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
219148935|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Sheets|Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
219148936|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
219148937|NCT04867291|DIETARY_SUPPLEMENT|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
219720984|NCT05783050|DEVICE|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
219720985|NCT04837521|BEHAVIORAL|Unified Protocol|Five session psychotherapy
219148938|NCT01587755|OTHER|TTOP|Patient is taken care of in an intensified, optimised manner
219148939|NCT01587755|OTHER|non-TTOP|Standard medical care
219148940|NCT00001354|DRUG|Interleukin-2/Zidovudine (AZT)|
219148941|NCT02888080|DRUG|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
219148942|NCT02888080|DRUG|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
219148943|NCT05201976|OTHER|Virtually administered Cardiac Rehab program|Virtual cardiac rehab program delivered through the CardaHealth platform.
219148944|NCT05201976|OTHER|Standard of Care in person Cardiac Rehab Program|Clinically ordered standard of care cardiac rehab program (in-person).
219148945|NCT02599818|BEHAVIORAL|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
219148946|NCT05625282|PROCEDURE|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
219148947|NCT05625282|PROCEDURE|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
219148948|NCT00845832|DRUG|Placebo|iv on days 1 and 15 (Parts 1 and 2)
219148949|NCT00845832|DRUG|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
219148950|NCT00845832|DRUG|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
219555190|NCT03941795|OTHER|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
219555191|NCT01277510|DRUG|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
219555192|NCT01277510|DRUG|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
219555193|NCT01277510|DRUG|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
219555194|NCT02768974|DRUG|OPRX-106|Oral delivery, once daily.
219555195|NCT05317806|DRUG|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
219148951|NCT00190619|DRUG|Duloxetine|
219148952|NCT00190619|DRUG|Placebo|
219148953|NCT01665092|DRUG|Levo-Carnitine|
219148954|NCT01665092|DRUG|placebo|
219148955|NCT00189202|DRUG|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
219148956|NCT03417492|DRUG|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
219148957|NCT03147391|DEVICE|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
219148958|NCT05657730|DIETARY_SUPPLEMENT|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
219148959|NCT02910388|DEVICE|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
219555196|NCT01151696|DRUG|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
219555197|NCT01151696|DRUG|Placebo|Placebo
219555198|NCT06110819|OTHER|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
219148960|NCT02910388|OTHER|LLETZ without colposcopy|Loop procedure without using a colposcope
219148961|NCT06466902|OTHER|Quality assessment of D2 lymphadenectomy using the PhotoNode Score|"During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers."
219148962|NCT01145170|RADIATION|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
219148963|NCT01145170|BIOLOGICAL|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
219148964|NCT05093218|DIETARY_SUPPLEMENT|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
219148965|NCT05093218|OTHER|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
219148966|NCT01291615|DRUG|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
219148967|NCT01291615|DRUG|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
219148968|NCT05211544|OTHER|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
219148969|NCT05211544|OTHER|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
219148970|NCT05211544|OTHER|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
219148971|NCT00568854|BIOLOGICAL|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
219148972|NCT02700958|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
219148973|NCT02700958|PROCEDURE|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
219148974|NCT00317902|DRUG|Epoetin alfa|
219148975|NCT04337307|BIOLOGICAL|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
219720986|NCT06397781|DRUG|Skin Cleanser Combination No.1|"1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily."
219720987|NCT06129760|DEVICE|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
219720988|NCT04092153|DEVICE|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
219720989|NCT06482996|OTHER|Intraocular pressure (IOP) was measured|The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
219720990|NCT02611024|DRUG|Lurbinectedin|lurbinectedin (PM01183) 4 mg vials
219720991|NCT02611024|DRUG|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
219720992|NCT06223516|DRUG|Subcutaneous (SC) ABBV-383|SC Injection
219720993|NCT06223516|DRUG|Intravenous (IV) ABBV-383|IV Infusion
219720994|NCT05955378|DEVICE|DSR Ankle|This is the experimental ankle component used in the overall prosthetic intervention.
219720995|NCT05955378|DEVICE|Predicate Ankle|This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
219720996|NCT02922036|DEVICE|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
219720997|NCT00221104|DRUG|Pravastatin|
219720998|NCT00766818|DRUG|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
219720999|NCT02989389|DRUG|LY3323795|Administered orally
219721000|NCT02989389|DRUG|Itraconazole|Administered orally
219721001|NCT02989389|DRUG|Placebo|Administered orally
219721002|NCT04857177|DRUG|CKD-701|CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
219148976|NCT03050788|DEVICE|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
219148977|NCT02466672|OTHER|none - observational only|
219721003|NCT04857177|DRUG|Lucentis®|Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
219721004|NCT04470427|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219721005|NCT04470427|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219721006|NCT00164723|PROCEDURE|Capsule endoscopy|Capsule endoscopy and colonoscopy
219721007|NCT03682640|DRUG|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
219721008|NCT03682640|DRUG|Insulin Lispro|Solution for intravenous or subcutaneous use
219721009|NCT03682640|BEHAVIORAL|Dietician support|Dietary advice
219721010|NCT01766284|DEVICE|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
219721011|NCT04490707|DRUG|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
219721012|NCT04490707|DRUG|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
219721013|NCT03415269|DRUG|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
219721014|NCT04041518|PROCEDURE|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
219721015|NCT01855906|PROCEDURE|Gap balanced surgical technique|Gap balanced surgical technique
219721016|NCT01855906|PROCEDURE|Measured resection|Measured resection surgical technique
219721017|NCT00745160|OTHER|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
219721018|NCT00872157|DRUG|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
219721019|NCT06165874|RADIATION|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
219721020|NCT00474565|PROCEDURE|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
219721021|NCT01526382|DEVICE|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
219555199|NCT06110819|OTHER|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
219721022|NCT01526382|PROCEDURE|central venous catheter|patients in this arm can receive central venous catheter
219721023|NCT03718260|DIAGNOSTIC_TEST|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
219148978|NCT05861063|DEVICE|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
219148979|NCT05861063|DRUG|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
219148980|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
219148981|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
219148982|NCT01039688|DRUG|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
219721024|NCT00318864|BEHAVIORAL|Cognitive behavioral therapy|
219721025|NCT04259489|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
219721026|NCT03408145|DEVICE|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
219721027|NCT03408145|DEVICE|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
219721028|NCT03408145|DRUG|Saline|Injection of Saline
219148983|NCT05400707|DIAGNOSTIC_TEST|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
219148984|NCT05400707|DIAGNOSTIC_TEST|Assessment of patient mobility at presentation|Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
219721029|NCT05320588|DRUG|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
219721030|NCT05320588|DRUG|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
219721031|NCT02342951|OTHER|Lung clearance index determination|Lung clearance index determination
219555200|NCT02143596|OTHER|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
219555201|NCT01685008|DRUG|MOR00208 (formerly Xmab 5574)|
219721032|NCT05389839|DEVICE|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
219721033|NCT05582603|BEHAVIORAL|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
219721034|NCT01642160|BEHAVIORAL|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
219721035|NCT01642160|BEHAVIORAL|Standard of care|participants will receive education from staff nurses as needed.
219721036|NCT02941952|DEVICE|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
219148985|NCT05400707|DIAGNOSTIC_TEST|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
219721037|NCT05756478|OTHER|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
219721038|NCT02450474|DEVICE|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
219721039|NCT02450474|DEVICE|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
219721040|NCT01356056|DEVICE|Kinesia HomeView|Quantifies motor symptom severity in the home
219721041|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
219721042|NCT05482191|BEHAVIORAL|Lifestyle intervention|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses~* Diet and exercise instruction by professional nutritionist using internet applet~* Take part in sports activities that are organized by the sports health teacher during school hours."
219721043|NCT02685930|BEHAVIORAL|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
219721044|NCT01053832|DEVICE|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
219721045|NCT06464159|BIOLOGICAL|Biological collection|A collection of maternal plasma, serum and urine
219721046|NCT03117270|DRUG|filgotinib|one filgotinib oral tablet q.d.
219721047|NCT03117270|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
219721048|NCT01522053|PROCEDURE|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
219721049|NCT01522053|PROCEDURE|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
219721050|NCT00247286|BEHAVIORAL|weighted vaginal cones|
219721051|NCT00247286|BEHAVIORAL|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
219148986|NCT05400707|DIAGNOSTIC_TEST|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
219148987|NCT05400707|DIAGNOSTIC_TEST|Assessment of what matters most in patients of 65 years and older|"Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?."
219721052|NCT04764890|OTHER|Electroacupuncture|Electroacupuncture in several point
219721053|NCT04764890|OTHER|Manual therapy|Manual therapy in the lower spine.
219721054|NCT00397241|DRUG|Drug: dorzolamide/timolol|
219148988|NCT05400707|DIAGNOSTIC_TEST|Assessment of Decision-making in senior physicians|Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
219721055|NCT00397241|DRUG|Drug: latanoprost/timolol|
219721056|NCT00397241|DRUG|dorzolamide/timolol and latanoprost|
219721057|NCT00397241|DRUG|placebo (artificial tears)|
219148989|NCT05400707|DIAGNOSTIC_TEST|Pain Numeric Rating Scale (NRS)|"The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))"
219148990|NCT05400707|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
219721058|NCT05460247|DIETARY_SUPPLEMENT|Protein|Participants will receive a diet supplemented by the above protein
219721059|NCT02649933|DEVICE|Watch PAT 200|screening of OSA with Watch PAT 200
219721060|NCT05643508|DRUG|(D) DWC202206|Drug of DWC202206 A mg
219721061|NCT05643508|DRUG|(D) DWC202207|Drug of DWC202207 B/C mg
219721062|NCT05643508|DRUG|(P) DWC202206|Placebo of DWC202206 A mg
219721063|NCT05643508|DRUG|(P) DWC202207|Placebo of DWC202207 B/C mg
219721064|NCT01777724|BEHAVIORAL|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
219721065|NCT05759910|DIETARY_SUPPLEMENT|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
219721066|NCT05759910|DIETARY_SUPPLEMENT|Placebo|Participants will take placebo capsules during 3 months
219721067|NCT02092935|DRUG|SMT19969|
219721068|NCT02092935|DRUG|Vancomycin|
219721069|NCT01415674|DRUG|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
219721070|NCT02612675|OTHER|ONS|
219721071|NCT03778372|DRUG|Methadone|see desc above
219721072|NCT03015701|DRUG|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
219721073|NCT03015701|OTHER|Placebo|placebo matching mifepristone
219721074|NCT00021255|DRUG|Doxorubicin|
219721075|NCT00021255|DRUG|Cyclophosphamide|
219721076|NCT00021255|DRUG|Docetaxel|
219721077|NCT00021255|DRUG|Herceptin|
219721078|NCT00021255|DRUG|Carboplatin|
219721079|NCT01651598|DRUG|Placebo to BI 144807|multiple dose (bid)
219721080|NCT01651598|DRUG|BI 144807|multiple dose (bid, low to high dose)
219721081|NCT01377506|BEHAVIORAL|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
219721082|NCT01377506|BEHAVIORAL|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
219721083|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
219721084|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
219721085|NCT01895998|DRUG|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
219721086|NCT01163656|DEVICE|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
219721087|NCT01163656|DEVICE|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
219555202|NCT03144479|PROCEDURE|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
219555203|NCT03454490|PROCEDURE|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
219555204|NCT05055687|DRUG|FL058|2500mg、3000mg
219721088|NCT00420264|DEVICE|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
219721089|NCT01132755|PROCEDURE|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
219721090|NCT02183974|PROCEDURE|Peptest|
219721091|NCT01801254|OTHER|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
219721092|NCT01801254|OTHER|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
219555205|NCT05055687|DRUG|Placebo|empty bottle
219555206|NCT05055687|DRUG|FL058|500mg、1000mg、2000mg
219555207|NCT05055687|DRUG|Placebo|empty bottle
219721093|NCT01182961|OTHER|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
219721094|NCT01182961|OTHER|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
219721095|NCT01182961|OTHER|exercise group|standard of care exercise group to improve strength and balance
219555208|NCT03492476|DEVICE|Circaid|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
219555209|NCT03492476|DEVICE|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
219555210|NCT00009776|BIOLOGICAL|monoclonal antibody Lym-1|
219148991|NCT04201249|DRUG|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
219148992|NCT04201249|DEVICE|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
219555211|NCT00009776|DRUG|cyclosporine|
219555212|NCT00009776|DRUG|paclitaxel|
219555213|NCT00009776|RADIATION|indium In 111 monoclonal antibody Lym-1|
219555214|NCT00009776|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
219721096|NCT02232698|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
219555215|NCT04541680|DRUG|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
219555216|NCT04541680|OTHER|Placebo|Placebo
219555217|NCT03750591|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
219232263|NCT00761267|DRUG|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
219232264|NCT00761267|DRUG|Fluconazole|Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
219721097|NCT02232698|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
219721098|NCT04490655|BEHAVIORAL|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
219721099|NCT04490655|BEHAVIORAL|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
219721100|NCT01997931|DEVICE|Bispectral Index Sedation monitor|
219721101|NCT04058301|OTHER|Text message information|Geographically proximate resources delivered by text message
219721102|NCT05381870|BEHAVIORAL|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
219721103|NCT05381870|BEHAVIORAL|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
219721104|NCT02393755|DRUG|Capecitabine|Given PO
219721105|NCT02393755|OTHER|Laboratory Biomarker Analysis|Correlative studies
219721106|NCT02393755|DRUG|Nintedanib|Given PO
219721107|NCT02393755|OTHER|Pharmacological Study|Correlative studies
219721108|NCT05954689|OTHER|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
219721109|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219721110|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
219721111|NCT06055179|DRUG|Xiao Chai Hu Tang (XCHT)|XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
219721112|NCT06055179|DRUG|Placebo|Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
219232265|NCT04492475|DRUG|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
219721113|NCT06055179|DRUG|Irinotecan regimen|"Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks."
219721114|NCT06055179|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
219721115|NCT02705157|PROCEDURE|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
219721116|NCT02705157|RADIATION|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
219148993|NCT00668863|DRUG|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219721117|NCT04225650|OTHER|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
219148994|NCT00668863|DRUG|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
219148995|NCT02995655|DRUG|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
219148996|NCT02995655|DRUG|Azacitidine|Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
219148997|NCT02995655|PROCEDURE|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
219148998|NCT02995655|PROCEDURE|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
219148999|NCT02768571|DRUG|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
219149000|NCT02768571|DRUG|Placebo|Placebo- saline 100 ml/day \* 21 days with rehabilitation
219149001|NCT01883908|DEVICE|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
219149002|NCT01883908|OTHER|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
219149003|NCT01296191|DRUG|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
219149004|NCT01296191|DRUG|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
219149005|NCT04959136|DEVICE|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
219149006|NCT01283750|BEHAVIORAL|care coordination|dementia-related care coordination
219149007|NCT03844269|DEVICE|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
219149008|NCT05652933|DIAGNOSTIC_TEST|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
219149009|NCT02540746|BEHAVIORAL|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
219555218|NCT03750591|PROCEDURE|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
219555219|NCT03750591|PROCEDURE|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
219555220|NCT03750591|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
219555221|NCT03750591|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219555222|NCT03750591|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219555223|NCT03750591|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219555224|NCT03750591|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
219555225|NCT00499473|DRUG|sunitinib malate|Given orally
219555226|NCT00499473|OTHER|pharmacological study|Correlative studies
219555227|NCT00642057|DRUG|tetrabenazine|25 mg titrated to optimal dose per patient
219555228|NCT03706508|PROCEDURE|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
219555229|NCT03335241|DRUG|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
219555230|NCT03335241|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
219555231|NCT02581917|OTHER|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
219555232|NCT02581917|OTHER|Laboratory Biomarker Analysis|Undergo metabolic analysis
219555233|NCT00112216|BIOLOGICAL|Melan-A analog peptide|
219555234|NCT00112216|BIOLOGICAL|FluMa peptide|
219555235|NCT00112216|BIOLOGICAL|Mage-A10 peptide|
219555236|NCT00112216|BIOLOGICAL|SB AS-2 adjuvant|
219555237|NCT00112216|BIOLOGICAL|Montanide adjuvant|
219721118|NCT05278091|OTHER|None, pure observationnal study|None, pure observationnal study
219721119|NCT00048659|DRUG|YM598|
219149010|NCT02540746|BEHAVIORAL|Motivational Enhancement|Three week Motivational Enhancement group
219721120|NCT04124796|OTHER|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
219721121|NCT00728923|DRUG|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
219721122|NCT05324371|DEVICE|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
219721123|NCT00731003|DRUG|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
219721124|NCT00731003|OTHER|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
219555238|NCT05654363|PROCEDURE|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
219149011|NCT02540746|BEHAVIORAL|Family Skills Training|12-week group-based family skills training using Family Connections model
219149012|NCT01932450|PROCEDURE|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
219721125|NCT00731003|OTHER|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
219721126|NCT00731003|DRUG|Placebo capsule|Placebo for 5-HTP
219721127|NCT05232721|DIAGNOSTIC_TEST|The new instrument and colonoscopy with pathological examination|Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
219721128|NCT03556306|PROCEDURE|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively \[17\] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
219149013|NCT01932450|DRUG|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
219149014|NCT00864786|DRUG|PF03635659|Inhaled doses of 200 mcgQD
219149015|NCT00864786|DRUG|PF03635659|Inhaled doses of 600 mcg QD
219149016|NCT00864786|DRUG|PF03635659|Inhaled doses of 1000 mcg QD
219149017|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
219149018|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
219149019|NCT01733238|DRUG|PNT2258|
219149020|NCT00101010|BIOLOGICAL|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
219149021|NCT00101010|BIOLOGICAL|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
219149022|NCT00101010|BIOLOGICAL|Rituximab|375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
219149023|NCT00101010|DRUG|Cyclophosphamide|750 mg/m\^2 IVPB on day 1
219149024|NCT00101010|DRUG|Pegylated liposomal doxorubicin hydrochloride|40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
219149025|NCT00101010|DRUG|Prednisone|40 mg/m\^2 oral days 1 - 5.
219149026|NCT00101010|DRUG|Vincristine Sulfate|2 mg IV, day 1
219149027|NCT04433429|DIETARY_SUPPLEMENT|Liposcudil Plus|
219149028|NCT06441539|DEVICE|Bingo® Paclitaxel coated balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
219149029|NCT06441539|DEVICE|Xience® Alpine Everolimus Eluting Coronary Stent System|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
219149030|NCT00230399|DRUG|Celecoxib|
219232266|NCT04492475|OTHER|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
219721129|NCT01949896|OTHER|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
219149031|NCT00230399|DRUG|Capecitabine|
219149032|NCT00230399|DRUG|Irinotecan|
219149033|NCT01809392|DRUG|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
219149034|NCT00992173|DRUG|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
219149035|NCT04705376|DEVICE|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
219149036|NCT04705376|DEVICE|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
219721130|NCT01949896|OTHER|Control group: continue feedings|Feedings will be continued in this group.
219721131|NCT03447795|PROCEDURE|Alveolar ridge preservation|grafting procedure using autogenous tooth.
219149037|NCT05486364|DIAGNOSTIC_TEST|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
219232267|NCT04492475|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
219232268|NCT02417350|OTHER|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
219721132|NCT04324840|DRUG|CC-90010|Specified dose on specified days
219721133|NCT04324840|DRUG|Temozolomide|Specified dose on specified days
219721134|NCT04324840|RADIATION|Radiotherapy|Specified dose on specified days
219721135|NCT04547751|OTHER|targeted high-resolution mass spectrometry|"difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry"
219149038|NCT05486364|DIAGNOSTIC_TEST|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
219149039|NCT03098810|DRUG|Zinc sulphate|Oral syrup zinc sulphate
219149040|NCT03098810|OTHER|Placebo|Oral syrup placebo
219149041|NCT05473260|OTHER|Control|In-patient care.
219149042|NCT05473260|OTHER|Experimental|Early discharge and outpatient follow-up.
219149043|NCT04813419|DEVICE|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
219149044|NCT04813419|DEVICE|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
219149045|NCT04181463|DRUG|Isopropyl Alcohol|Given via nasal inhalation
219149046|NCT04181463|OTHER|Placebo|Given via nasal inhalation
219149047|NCT04181463|OTHER|Questionnaire Administration|Ancillary studies
219149048|NCT05176964|RADIATION|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
219149049|NCT05176964|DRUG|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
219149050|NCT05176964|DRUG|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
219149051|NCT01814033|OTHER|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
219721136|NCT02691338|OTHER|EEG|EEG analysis
219149052|NCT01814033|OTHER|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
219232269|NCT02417350|OTHER|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
219721137|NCT02691338|OTHER|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
219721138|NCT02991521|PROCEDURE|Fast exam|Positional change before Fast exam
219232270|NCT03451695|DRUG|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
219232271|NCT03451695|DRUG|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
219232272|NCT05729386|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
219232273|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
219232274|NCT05729386|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
219232275|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
219232276|NCT05277285|DRUG|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
219232277|NCT02696200|DEVICE|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
219232278|NCT02359916|OTHER|Time delays on delivery of less healthy snacks|
219721139|NCT01474187|DRUG|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
219721140|NCT01474187|DRUG|Capecitabine|625mg/m2,bid,d1-5,qw
219721141|NCT01474187|RADIATION|Radiotherapy|50Gy for whole pelvis
219721142|NCT05112133|DIETARY_SUPPLEMENT|Mulberry leaf extract|Oral administration
219721143|NCT05112133|DIETARY_SUPPLEMENT|Water|Oral administration
219721144|NCT05927415|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
219721145|NCT04088253|PROCEDURE|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
219721146|NCT03734094|DEVICE|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
219721147|NCT03734094|DEVICE|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
219721148|NCT01122953|DRUG|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
219721149|NCT01122953|DRUG|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
219721150|NCT02448108|BEHAVIORAL|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
219721151|NCT02448108|OTHER|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
219721152|NCT00848432|DRUG|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
219721153|NCT03837275|PROCEDURE|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
219721154|NCT03837275|PROCEDURE|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
219721155|NCT05201417|OTHER|adapted physical activity|The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
219721156|NCT05411978|DRUG|Idebenone+ placebo|Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
219721157|NCT05411978|DRUG|Idebenone|Participants will receive Idebenone 90 mg for 12 weeks.
219721158|NCT05411978|DRUG|Placebo|Participants will receive Placebo 90 mg for 12 weeks
219721159|NCT02719795|DRUG|Ropivacaine|Local injection of local anesthetic into the fascial spaces
219721160|NCT02719795|DRUG|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
219721161|NCT03611660|BEHAVIORAL|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
219721162|NCT03611660|BEHAVIORAL|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
219721163|NCT06277375|BEHAVIORAL|Massage|The application starts from the neck with small circular strokes with the thumbs. Surface strokes are performed with the palm of the hand from the base of the skull towards the sacral region. Then rhythmic strokes are repeated from the sacrum along the entire spine towards the skull.The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
219721164|NCT06099483|OTHER|Action observation and motor imagery|EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.
219721165|NCT06099483|OTHER|Active breathing exercise|EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.
219721166|NCT06099483|OTHER|Control group|EEG recording was taken while resting with eyes closed for 10 minutes.
219721167|NCT02177357|DRUG|Pramipexole|
219721168|NCT02177357|DRUG|Placebo|
219721169|NCT05779644|DRUG|Liraglutide|Liraglutide is injected once a day.
219721170|NCT05779644|DRUG|Semaglutide|Semaglutide is injected once a week.
219721171|NCT05779644|DRUG|Metformin|Metformin is taken orally daily.
219721172|NCT00331487|DRUG|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
219149053|NCT06167525|DEVICE|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
219149054|NCT00971789|RADIATION|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
219232279|NCT02359916|OTHER|25%/$0.25 discount on healthy snacks|
219721173|NCT00331487|DRUG|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
219721174|NCT07114835|PROCEDURE|Cycling with Blood Flow Restriction (15 min at 40% VO₂max with 60-80% LOP)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed on an electronically braked Astrand cycle ergometer for 15 minutes per session. During each session, pneumatic cuffs (10 cm wide, manually adjustable) are applied to the upper thighs to restrict blood flow. Individualized limb occlusion pressure (LOP) is determined via Doppler ultrasound and set progressively at 60% (weeks 1-4), 70% (weeks 5-7), and 80% (weeks 8-9). Sessions are conducted three times per week over a 9-week period. The aim is to simulate the physiological effects of high-intensity training using a low-intensity protocol.
219721175|NCT07114835|PROCEDURE|Cycling Exercise (40 min at 40% VO₂max)|This intervention involves standard low-intensity cycling exercise at 40% of the participant's VO₂max, performed for 40 minutes per session on an electronically braked Astrand cycle ergometer. Sessions are conducted three times per week for a total duration of 9 weeks. This group does not receive any blood flow restriction or external loading. The aim is to observe the effects of traditional low-intensity, long-duration aerobic exercise on VO₂max, muscle strength, and muscle thickness.
219232280|NCT02359916|OTHER|25%/$0.25 tax on less healthy snacks|
219232281|NCT02160600|OTHER|Standard multiphase CT|
219232282|NCT02160600|OTHER|split bolus Dual energy CT|
219232283|NCT04266496|OTHER|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
219721176|NCT07114835|PROCEDURE|Short-Duration Cycling Control (15 min at 40% VO₂max)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed for 15 minutes per session, using an electronically braked Astrand cycle ergometer. Participants exercise three times per week for 9 weeks. No blood flow restriction is applied. The aim of this control condition is to match the duration of the BFR intervention while omitting the occlusion component, to isolate the effect of BFR.
219721177|NCT07119138|BEHAVIORAL|Emotional Freedom Technique|"Emotional Freedom Technique (EFT) is used as an effective method for managing various adverse conditions, including the reduction of exam anxiety. Although there are several studies in the literature on this topic, research conducted specifically with nursing students remains limited. In particular, the Surgical Nursing course is a fundamental subject offered in the second year of nursing education, encompassing both theoretical and clinical components. Academic success in this course is an important indicator of the quality of nursing education. Therefore, as a surgical nursing instructor, it is believed that reducing exam anxiety can positively influence student performance.~This study also aims to improve student success through anxiety management. To date, no studies addressing this issue with nursing students have been found in the literature."
219721178|NCT07124026|OTHER|No Intervention: Observational Cohort|No intervention
219721179|NCT07124416|OTHER|No intervention|No intervention: observational case-control study
219721180|NCT01173172|RADIATION|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
219721181|NCT01741870|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
219721182|NCT01741870|OTHER|Treatment as usual|routine care
219721183|NCT00112164|DRUG|Xigris|
219721184|NCT07117032|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and delivery.
219721185|NCT07117032|RADIATION|Celiac plexus SBRT|Participants will receive SBRT per standard of care. This treatment visit will take up to 1.5 hours.
219721186|NCT06928597|PROCEDURE|Global Postural Reeducation|"Global Postural Reeducation, better known as GPR, was developed by Philippe Souchard in the 1980s and involves a sequence of postures or treatment positions, including the main ones: frog on the ground with arms open; frog on the ground with arms closed; frog in the air with arms open; frog in the air with arms closed; standing against the wall; standing at the center; anterior tilt sitting; anterior tilt standing.~GPR is based on the concept of proprioception and inhibition. Souchard (2016) describes RPG as a proprioceptive method of inhibition, where proprioception refers to the body's ability to perceive its position in space, and inhibition refers to the muscle relaxation induced after intense contraction. This principle is applied through the postures and techniques used in treatment, aiming to correct postural deviations, promote one bigger conscious body, and relieve pain."
219149055|NCT00971789|DRUG|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
219149056|NCT00971789|OTHER|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
219149057|NCT04802369|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
219149058|NCT00471627|PROCEDURE|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
219149059|NCT03443453|DRUG|MIV-711|MIV-711 administered as tablets and capsules at four occasions
219149060|NCT06073860|DRUG|Luspatercept|According to the approved label
219149061|NCT02434107|PROCEDURE|Completion Lymphadenectomy|
219149062|NCT02434107|PROCEDURE|Clinical Monitoring (Palpation and node ultrasound)|
219149063|NCT04291729|DRUG|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
219149064|NCT03989986|BEHAVIORAL|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
219149065|NCT03561064|BEHAVIORAL|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
219149066|NCT01257555|DEVICE|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
219149067|NCT02384070|PROCEDURE|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
219149068|NCT02384070|DRUG|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
219149069|NCT02384070|DRUG|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
219149070|NCT02384070|DRUG|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
219149071|NCT06038916|DRUG|STSA-1002 Injection Placebo|Intravenous infusion
219149072|NCT06038916|DRUG|STSA-1002 Injection|Intravenous infusion
219721187|NCT06928597|PROCEDURE|Global Postural Reeducation Sham|Global Postural Reeducation Sham is the comparator group.
219721188|NCT07100158|OTHER|Ultrasonographic Measurement of Optic Nerve Sheath Diameter (ONSD)|Non-invasive ultrasonographic measurement of optic nerve sheath diameter (ONSD) using a 7.5 MHz linear probe at predefined time points: preoperative and postoperative 6, 12, 24, 36, and 48 hours.
219721189|NCT07102940|DRUG|Eftilagimod Alfa (Efti)|Eftilagimod Alfa (Efti) will be administered subcutaneously at a dose of 30 mg beginning of week 1 of the trial for a total of 3 doses (week 1, 2 and 3). After 3 weeks, efti will be administered starting with week 4, every 2 weeks and combined with either TC or AC
219721190|NCT07102940|DRUG|Docetaxel-cyclophosphamide (TC) intravenous (i.v)|"TC will be administered at docetaxel 75mg/m2 IV and cyclophosphamide 600mg/m2 IV every 3 weeks for a total of 4 administrations starting on week 4 of the trial (weeks 4, 7,10, and 13).~Docetaxel is administered over 60min (dilute in 250 mL NS or D5W to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes).~Cyclophosphamide is administered over 30-60min (dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes after docetaxel).~G-CSF support for TC is per institutional SOC guidelines. Efti is to be given always ≥ 30 minutes after TC is finished if both regimens are administered the same day."
219721191|NCT07102940|DRUG|Dose dense Adriamycin-cyclophosphamide (AC) i.v|"AC will be administered at doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 IV every 2 weeks for a total of 4 administrations starting week 4 of the trial (weeks 4, 6, 8 and 10):~Doxorubicin is administered over 5 min (Dilute with NS to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or D5W).~Cyclophosphamide is administered over 30-60min (Dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes).~G-CSF support is per SOC/institutional guidelines.~Paclitaxel is given weekly for a period of 12 weeks (weeks 12 to 23) at 80mg/m2 (Dilute with 250 to 500 mL NS or D5W (final concentration of 0.3 to 1.2 mg/mL) and administered per institutional guidelines). Alternatively nab-paclitaxel weekly can be used (if paclitaxel cannot be used due to allergic reaction).~Efti is to be given always ≥ 30 minutes after AC or paclitaxel is finished if both regimens are administered the same day."
219721192|NCT07105384|COMBINATION_PRODUCT|Radiotracer|Patients will receive a brain tau radiotracer
219721193|NCT07103408|DRUG|Immuno-chemotherapy|Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.
219721194|NCT07103408|RADIATION|Radiotherapy|"Definitive dose of thoracic radiotherapy was delivered no later than the three cycle of immuno-chemotherapy.~Prophylactic cranial irradiation (PCI) was delivered with a total dose of 25Gy in 10 fractions. PCI was recommended for patients who achieved complete response or partial response after thoracic chemoradiotherapy."
219721195|NCT07103408|DRUG|Consolidative therapy|Consolidation therapy regimen included iparomlimab and tuvonralimab, and thymosin alpha 1, with a duration of one year.
219149073|NCT05706168|DEVICE|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
219149074|NCT05706168|DEVICE|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
219149075|NCT04260906|DEVICE|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
219721196|NCT07103642|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
219149076|NCT04260906|OTHER|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
219149077|NCT06187246|BEHAVIORAL|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
219149078|NCT06187246|OTHER|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
219149079|NCT02806557|DEVICE|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
219555239|NCT05654363|PROCEDURE|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
219149080|NCT01981837|DRUG|ALN-TTRSC (revusiran) for subcutaneous administration|
219555240|NCT00160524|BIOLOGICAL|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
219149081|NCT02861066|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
219232284|NCT04266496|DIAGNOSTIC_TEST|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
219232285|NCT04266496|DIAGNOSTIC_TEST|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
219232286|NCT04266496|DIAGNOSTIC_TEST|Blood sample|Blood collection to measure plasma sodium and osmolality.
219232287|NCT04266496|DIAGNOSTIC_TEST|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
219232288|NCT00838994|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
219721197|NCT07102927|DEVICE|Virtual reality-based training for the treatment of neglect syndrom in stroke|"An occupational therapist provided 1:1 assistance with fitting and removing the virtual reality headset (HMD), operating the software and explaining the procedures, as well as offering physical support and movement assistance when necessary to enable participants to engage in the virtual reality-based training program for neglect syndrome.~Following measurement of each participant's interpupillary distance, the headset (HTC VIVE PRO) was adjusted and fitted while the participant was seated. The lens distance was fine-tuned using adjustment knobs to match the individual's eyes.~The training for neglect was performed with participants seated and wearing the headset. The NEGTREA program provided a virtual environment along with visual fixation training."
219721198|NCT07102927|BEHAVIORAL|Conventional occupational therapy|"An occupational therapist conducted conventional neglect therapy in a 1:1 setting for 30 minutes per session. The therapy comprised therapist-supervised, table-top tasks carefully designed to parallel the virtual reality exercises as closely as possible.~These table-top tasks primarily focused on promoting visual scanning and sustained attention toward the neglected hemifield through practical, goal-oriented activities such as object search and manipulation. The therapist utilized a variety of tools to facilitate and optimize patient engagement in these training."
219721199|NCT07105228|DRUG|aflibercept 2mg|No study-specific interventions administered in this observational study
219721200|NCT07104357|DEVICE|Inspiratory muscle training|Participants will perform 20 sessions of respiratory muscle strengthening (20 minutes at 30-60% of MIP), using the Threshold Inspiratory Muscle Training device
219721201|NCT01251861|DRUG|Akt Inhibitor MK2206|Given PO
219721202|NCT01251861|DRUG|Bicalutamide|Given PO
219149082|NCT03410446|DRUG|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
219149083|NCT03264443|BEHAVIORAL|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
219232289|NCT06405906|OTHER|Fat-free diet|The low-fat diet will consist of instructions to avoid fatty foods.
219232290|NCT06405906|OTHER|Balanced WHO diet|The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
219232291|NCT01122134|DRUG|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
219721203|NCT01251861|OTHER|Clinical Observation|Undergo clinical observation
219721204|NCT01251861|OTHER|Laboratory Biomarker Analysis|Correlative studies
219721205|NCT06780800|OTHER|The Back Belief Questionnaire Tr (BBQ) and Backs-tr|200 people will be administered The Back Belief Questionnaire Tr (BBQ) and Backs-tr.
219721206|NCT06780800|OTHER|Backs-tr retest|100 people will fill in the Backs-tr again after 1 week.
219149084|NCT03264443|BEHAVIORAL|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
219232292|NCT03964779|DIAGNOSTIC_TEST|Hormonal assay|Measurement of Thyroid stimulating hormone
219232293|NCT03964779|DIAGNOSTIC_TEST|Antibody assay|antithyroglobulin and antithyroid peroxidase
219232294|NCT04411771|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
219721207|NCT07118007|OTHER|adapted physical activity|adapted physical activity for 30 to 45 minutes twice per week
219721208|NCT06310629|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula
219721209|NCT06310629|DEVICE|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
219721210|NCT03720847|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
219721211|NCT03720847|DRUG|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
219721212|NCT03720847|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
219721213|NCT03720847|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
219721214|NCT00129896|DRUG|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
219149085|NCT01839981|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219149086|NCT00930098|DRUG|clofarabine|
219721215|NCT00129896|DRUG|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
219721216|NCT00129896|DRUG|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
219149087|NCT01373697|DRUG|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
219149088|NCT01373697|DRUG|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
219149089|NCT04275245|DRUG|Meplazumab for Injection|humanized MAb against CD147
219149090|NCT02773303|DEVICE|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
219149091|NCT02773303|DEVICE|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
219149092|NCT04691635|OTHER|evaluation of movements with sensors|evaluation of movements with sensors
219149093|NCT04896034|DEVICE|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
219721217|NCT00272090|DRUG|Insulin glargine|
219721218|NCT01710085|DEVICE|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
219721219|NCT04621201|OTHER|observation and biopsy|biopsy
219721220|NCT04257617|DRUG|ZL-1201|Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
219721221|NCT00653562|DRUG|zolpidem|Oral
219721222|NCT05222815|OTHER|CGM|Continuous glucose monitor (CGM)-based glucose monitoring
219721223|NCT05222815|OTHER|SMBG|Self-monitoring of blood glucose (SMBG)-based glucose monitoring
219721224|NCT01239680|DRUG|Glutamine|Intravenous 25 grams once over 6 hours
219721225|NCT01239680|DRUG|Ringer's Lactate|Intravenous 1 liter once over 6 hours
219721226|NCT01239680|DRUG|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
219149094|NCT04896034|DEVICE|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
219721227|NCT03033901|DEVICE|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
219721228|NCT03033901|DEVICE|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
219721229|NCT03033901|OTHER|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
219721230|NCT03096353|OTHER|Placebo|saline
219149095|NCT05985512|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
219721231|NCT03096353|DRUG|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
219721232|NCT05293470|OTHER|Piqray|There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
219721233|NCT03832452|DRUG|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
219721234|NCT03832452|OTHER|Placebo|hard capsules for oral administration
219721235|NCT03832452|DRUG|Moxifloxacin|400 mg; film-coated tablets for oral administration
219721236|NCT03832452|DRUG|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
219721237|NCT03832452|DRUG|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
219721238|NCT04716309|PROCEDURE|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
219721239|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
219721240|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
219149096|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
219149097|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
219149098|NCT03009864|DRUG|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
219149099|NCT03009864|DRUG|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
219149100|NCT00376363|DEVICE|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
219149101|NCT00376363|DEVICE|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
219149102|NCT04377698|BIOLOGICAL|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
219232295|NCT04411771|BEHAVIORAL|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
219721241|NCT06838013|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will be set at 2 mA for 30 minutes.
219721242|NCT06838013|DEVICE|Sham transcranial direct current stimulation (Sham-tDCS)|Sham tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will The stimulator will only be applied for the first and last 30 seconds.
219721243|NCT06838013|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
219721244|NCT06838013|DEVICE|Placebo transcutaneous electrical nerve stimulation (Placebo-TENS)|Placebo-TENS will be applied to identical-looking TENS devices, with the electrical circuit disconnected inside the devices. Placebo-TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes that set at 100 Hz, with 0.2 ms square pulses.
219721245|NCT06838013|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 5 exercises for 30 minutes, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, gait re-education and transition training.
219721246|NCT02748993|DRUG|PAC-14028 Cream 0.1%|Topical application
219721247|NCT02748993|DRUG|PAC-14028 Cream 0.3%|Topical application
219721248|NCT02748993|DRUG|PAC-14028 Cream 1.0%|Topical application
219721249|NCT02748993|DRUG|PAC-14028 Cream Vehicle|Topical application
219721250|NCT03300765|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
219721251|NCT03300765|RADIATION|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
219721252|NCT03885063|BEHAVIORAL|Benjamin Rose Institute Care Consultation (BRI-CC)|The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
219721253|NCT01464138|DRUG|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
219555241|NCT06403150|DRUG|Levetiracetam Injection|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
219555242|NCT06403150|DRUG|Fosphenytoin Injection|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
219555243|NCT00111696|BIOLOGICAL|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
219721254|NCT02734667|DEVICE|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
219721255|NCT01870596|DRUG|Cytarabine|Given IV
219721256|NCT01870596|DRUG|CHK1 Inhibitor SCH 900776|Given IV
219721257|NCT01870596|OTHER|Laboratory Biomarker Analysis|Correlative studies
219721258|NCT06355973|DEVICE|Using tablets and workbooks cognitive function.|Cognitive training programs corresponding to memory, attention, time and space, and orientation are conducted for 35 to 60 minutes.
219721259|NCT06355973|DEVICE|self-programming of physical function training.|The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.
219721260|NCT06387316|OTHER|No Oral Stimulation|No oral stimulation
219721261|NCT06387316|OTHER|Oral water stimulation|Oral water stimulation
219721262|NCT06387316|OTHER|Oral Salt Stimulation|Oral Salt Stimulation
219721263|NCT06387316|OTHER|Oral Sucralose Stimulation|Oral Sucralose Stimulation
219721264|NCT06387316|OTHER|Oral Sucrose stimulation|Oral Sucrose stimulation
219721265|NCT00499213|PROCEDURE|Home Care Assisted Peritoneal Dialysis|
219721266|NCT01996995|DEVICE|Nd:YAG laser pulse therapy|
219149103|NCT04377698|BIOLOGICAL|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
219149104|NCT05997966|OTHER|Progresive Resistance Exercises|At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).
219232296|NCT00005820|DRUG|nitrocamptothecin|
219232297|NCT01981746|PROCEDURE|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
219555244|NCT04542746|PROCEDURE|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
219555245|NCT04033484|PROCEDURE|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
219555246|NCT00892749|DRUG|ASP1585|oral
219555247|NCT04805385|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
219555248|NCT00869115|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
219555249|NCT00869115|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
219555250|NCT00869115|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
219555251|NCT00869115|DRUG|Istaroxime|Placebo continuous i.v. infusion for 24 hours
219555252|NCT06679387|DRUG|Memantine-HCl|Memantine hydrochloride 20 mg once daily for 12 weeks.
219555253|NCT06679387|DRUG|Placebo Oral Tablet|A once daily matched tablet of placebo for 12 weeks
219555254|NCT00609154|DRUG|glucagon like peptide-1|GLP-1 1 pmole/kg/min
219555255|NCT00609154|DIETARY_SUPPLEMENT|glucose control|glucose without GLP-1
219555256|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
219555257|NCT02224053|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
219555258|NCT02224053|DRUG|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
219555259|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
219555260|NCT01157598|DEVICE|bispectral index monitoring|parameter monitoring of bispectral index
219555261|NCT04720547|DRUG|Zolpidem|A nonbenzodiazepine hypnotic
219555262|NCT04720547|OTHER|No Treatment|The Control condition in which participants do not receive medication.
219555263|NCT01876745|DRUG|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
219555264|NCT01898598|DRUG|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
219555265|NCT01898598|DRUG|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
219555266|NCT03833427|DRUG|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.
219555267|NCT03833427|DRUG|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
219555268|NCT02650973|DRUG|CHS-1701|
219555269|NCT02650973|DRUG|Pegfilgrastim|
219555270|NCT04513327|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
219555271|NCT04513327|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
219555272|NCT02894827|BIOLOGICAL|Blood sample|
219555273|NCT02894827|OTHER|Flow cytometry|
219555274|NCT02894827|OTHER|western blot|
219555275|NCT05983627|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
219555276|NCT05008120|OTHER|No intervention|No intervention
219555277|NCT04320576|DEVICE|Bulk-fill|Bulk-fill resin composite (bulk technique)
219555278|NCT04320576|DEVICE|Nano-fill|Nano-fill resin composite (layering technique)
219555279|NCT03526562|BEHAVIORAL|Exercise|Exercise according to dose escalation
219555280|NCT03439995|OTHER|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
219555281|NCT03439995|OTHER|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
219555282|NCT02069262|OTHER|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
219555283|NCT00176891|PROCEDURE|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
219555284|NCT00176891|DRUG|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
219555285|NCT03930069|DRUG|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
219721267|NCT01996995|DEVICE|Sham procedure|Sham procedure
219149105|NCT05997966|OTHER|No intervation|After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
219721268|NCT02166879|BEHAVIORAL|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
219721269|NCT01988415|DEVICE|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
219721270|NCT03852576|DRUG|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
219721271|NCT02026349|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
219721272|NCT02026349|DRUG|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
219555286|NCT03930069|DRUG|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
219149106|NCT02455752|PROCEDURE|LE-TME|Retroperitoneal approach for total mesorectal excision
219149107|NCT05025995|BEHAVIORAL|Serious health game|Serious health game
219149108|NCT05815797|DRUG|SDD formula|SDD formula consists of 23 herbal medicines
219149109|NCT05815797|DRUG|Placebo|Placebo
219149110|NCT00906529|DRUG|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
219555287|NCT03059329|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
219149111|NCT01691690|DRUG|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
219149112|NCT01691690|DRUG|Normal Saline Flush|Saline placebo will be infused intraoperatively.
219149113|NCT01691690|DRUG|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
219149114|NCT01691690|DRUG|Sevoflurane|Sevoflurane for anesthesia induction.
219149115|NCT01691690|DRUG|Nitrous Oxide/Oxygen|Combination of NO2 \& O2 for anesthesia induction.
219721273|NCT05036460|PROCEDURE|Ultrasonography|"The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted."
219721274|NCT05036460|PROCEDURE|Direct visualization|While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
219721275|NCT04935515|DRUG|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
219721276|NCT04935515|DRUG|Oral low dose steroid|Low dose oral methyl prednisolone was added.
219721277|NCT04935515|DRUG|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
219232298|NCT03205488|DRUG|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
219555288|NCT01499160|DRUG|letrozole|Drug is are to be taken orally. 2.5 mg once daily
219721278|NCT04935515|DRUG|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
219721279|NCT05786300|DEVICE|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
219721280|NCT05786300|PROCEDURE|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
219721281|NCT00747513|BEHAVIORAL|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
219149116|NCT01691690|DRUG|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
219149117|NCT01691690|DRUG|Morphine|Morphine 0.1 mg/kg given prior to intubation.
219721282|NCT01776203|DRUG|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
219149118|NCT01691690|DRUG|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
219149119|NCT01691690|DRUG|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
219149120|NCT01869946|DRUG|Ropivacaine|
219149121|NCT04958343|PROCEDURE|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
219149122|NCT01755949|DRUG|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
219149123|NCT01755949|DRUG|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
219149124|NCT00436072|DRUG|ZD6474|Orally on a daily basis
219149125|NCT00436072|DRUG|Cetuximab|Infusion once weekly
219149126|NCT00436072|DRUG|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
219555289|NCT01499160|DRUG|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
219555290|NCT01499160|DRUG|everolimus|Drug is to be taken orally. 5 mg once daily.
219555291|NCT03212820|PROCEDURE|Drilling at low speed|
219555292|NCT03212820|PROCEDURE|Drilling at conventional or high speed|
219555293|NCT02319057|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
219555294|NCT02319057|DRUG|ORM-12741 IR|Immediate release formulation of ORM-12741
219555295|NCT02319057|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
219555296|NCT06581601|OTHER|physiotherapy, exercises|An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
219555297|NCT00222040|RADIATION|Ultrasound|2-MHz, low intensity transcranial ultrasound
219555298|NCT00222040|DRUG|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
219555299|NCT01763658|DRUG|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
219555300|NCT01763658|OTHER|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
219555301|NCT02339363|BEHAVIORAL|Sitting Meditation|4 weeks Sitting Meditation
219555302|NCT02339363|BEHAVIORAL|Hatha yoga|4 weeks of Hatha yoga
219555303|NCT00862212|BEHAVIORAL|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
219555304|NCT04436718|DIAGNOSTIC_TEST|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
219555305|NCT04554264|OTHER|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score \> 25 indicate complicated grief.
219555306|NCT03041532|PROCEDURE|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
219555307|NCT03041532|PROCEDURE|Frontal view|The investigator explore twice right colon with frontal viewing
219555308|NCT00730652|BIOLOGICAL|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
219555309|NCT03455036|OTHER|Whole body vibration training|10 x 1 min whole body vibration exposure
219555310|NCT05107739|BIOLOGICAL|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
219555311|NCT05746143|DRUG|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
219555312|NCT05746143|DRUG|Placebo|two days preoperatively and five days postoperatively
219555313|NCT05377294|OTHER|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
219555314|NCT03789630|DEVICE|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
219555315|NCT05533151|DEVICE|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
219555316|NCT02344849|DRUG|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
219555317|NCT01918813|DRUG|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
219555318|NCT04361838|BEHAVIORAL|prayer|receive prayers daily while in ICU
219555319|NCT06149962|PROCEDURE|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
219721283|NCT01521364|DRUG|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
219555320|NCT03951727|DEVICE|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
219149127|NCT01449422|DEVICE|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
219149128|NCT01449422|DEVICE|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
219721284|NCT00465868|PROCEDURE|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
219721285|NCT00508508|BEHAVIORAL|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
219721286|NCT00508508|BEHAVIORAL|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
219721287|NCT02636283|DRUG|Entresto|Oral pills
219721288|NCT02636283|DRUG|Placebo group|The placebo pills
219721289|NCT04408079|DRUG|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
219721290|NCT02307500|DRUG|Regorafenib|oral therapy
219555321|NCT03261843|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
219555322|NCT03261843|PROCEDURE|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
219555323|NCT00526136|DRUG|Placebo|
219555324|NCT00526136|DRUG|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
219149129|NCT06075069|DEVICE|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
219149130|NCT04454151|DRUG|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
219555325|NCT02050165|DIETARY_SUPPLEMENT|KIND Bars|Consumption of KIND Bars for 12 weeks
219555326|NCT02050165|DIETARY_SUPPLEMENT|Typical American Snack|Consumption of typical American snacks for 12 weeks
219555327|NCT00935805|DRUG|Metformin|850 mg TID
219555328|NCT00935805|DRUG|Glybenclamide|10 mg BID
219555329|NCT00935805|DRUG|NPH insulin|Variable SC dose
219555330|NCT00935805|DRUG|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
219555331|NCT00935805|DRUG|Propranolol|40 mg BID
219555332|NCT00935805|DRUG|Captopril|50 mg TID
219555333|NCT00935805|DRUG|Amlodipine|10 mg QD
219555334|NCT04099433|DIETARY_SUPPLEMENT|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
219555335|NCT04099433|OTHER|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
219555336|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
219555337|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
219555338|NCT05692115|DIAGNOSTIC_TEST|stress ECG|stress ECG to patients suspected to be ischemic patients .
219555339|NCT01118767|OTHER|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
219555340|NCT04876001|BEHAVIORAL|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
219555341|NCT01037231|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
219555342|NCT01037231|DRUG|Placebo|placebo
219555343|NCT01875887|PROCEDURE|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
219721291|NCT05804968|OTHER|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
219721292|NCT03055078|BIOLOGICAL|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
219721293|NCT03234452|DIETARY_SUPPLEMENT|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
219149131|NCT05164094|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
219149132|NCT05164094|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219149133|NCT05468411|OTHER|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
219149134|NCT05468411|OTHER|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
219149135|NCT03967626|DEVICE|external cooling with the xxxxx device|external cooling with the xxxxx device
219232299|NCT03205488|DRUG|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
219232300|NCT03205488|DRUG|Placebo|2 capsules taken once daily
219232301|NCT06041438|DRUG|BI 1584862|BI 1584862
219232302|NCT06041438|DRUG|itraconazole|itraconazole
219232303|NCT06459128|DEVICE|Limbic Care|"Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener."
219232304|NCT06459128|DEVICE|Digital Workbook|The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
219555344|NCT01596127|DRUG|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
219555345|NCT00141258|DRUG|pregabalin|
219555346|NCT05796843|PROCEDURE|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
219555347|NCT05796843|PROCEDURE|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
219555348|NCT05796843|PROCEDURE|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
219555349|NCT01573663|DRUG|Ambroxol and Levodropropizine|Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
219555350|NCT01573663|DRUG|Ambroxol|Ambroxol HCl 30mg, PO, single dose
219555351|NCT01573663|DRUG|Levodropropizine|Levodropropizine 60mg, PO, single dose
219555352|NCT05958433|BEHAVIORAL|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
219555353|NCT00637533|PROCEDURE|Lumbar sympathetic block with Botulinum Toxin type A|
219555354|NCT03748251|OTHER|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
219555355|NCT03748251|OTHER|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
219555356|NCT06623695|OTHER|Exercise|SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
219555357|NCT06623695|OTHER|Exercise|USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
219555358|NCT03311061|OTHER|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
219555359|NCT01675596|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
219555360|NCT02313545|DRUG|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
219721294|NCT03234452|DIETARY_SUPPLEMENT|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
219721295|NCT02565251|DEVICE|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
219721296|NCT02565251|DEVICE|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
219721297|NCT02565251|DEVICE|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
219721298|NCT00157625|BEHAVIORAL|Automatic stop order|
219721299|NCT00609505|OTHER|Telemedicine|Telemedicine genetic counseling
219555361|NCT04205539|DRUG|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
219149136|NCT05082935|BEHAVIORAL|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
219149137|NCT05082935|BEHAVIORAL|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
219149138|NCT02122445|DEVICE|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
219149139|NCT02589340|DRUG|Buspirone|
219149140|NCT02589340|DRUG|Placebo|Sugar Pill
219149141|NCT02957136|DEVICE|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
219149142|NCT02045459|BEHAVIORAL|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
219149143|NCT05179486|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, and blood
219149144|NCT05179486|OTHER|Questionnaire Administration|Complete questionnaire
219149145|NCT05689125|DEVICE|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
219555362|NCT06246591|OTHER|Extracorporeal Shockwave Therapy (Group A)|Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
219555363|NCT06246591|OTHER|Mesotherapy (Group B)|Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
219555364|NCT05290896|DEVICE|Phacoemulsification|Phacoemulsification for senile cataract.
219555365|NCT06467032|OTHER|superficial CO2 laser resurfacing|Application of the tested product and comparators on the laser treated side of the back
219721300|NCT00609505|OTHER|Face-to-Face|Face-to-face genetic counseling
219721301|NCT00361153|DRUG|Colesevelam hydrochloride|Welchol tablet 625mg
219232305|NCT00003259|DRUG|vinorelbine tartrate|
219721302|NCT00361153|DRUG|placebo|placebo
219721303|NCT05549245|DEVICE|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
219721304|NCT05549245|DEVICE|CPAP|Patients were treated with CPAP for three nights
219232306|NCT03116191|DRUG|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
219721305|NCT00093938|DRUG|Cranberry juice|
219721306|NCT03570593|PROCEDURE|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
219721307|NCT01794975|DRUG|Ketamine|
219721308|NCT01794975|DRUG|Atomoxetine|
219721309|NCT01794975|OTHER|Cold pressor test|
219721310|NCT01794975|DRUG|Placebo|
219721311|NCT02952677|BEHAVIORAL|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
219149146|NCT05689125|DEVICE|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
219149147|NCT05689125|DEVICE|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
219149148|NCT02710708|DRUG|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
219149149|NCT00345007|PROCEDURE|Scleral buckling|
219149150|NCT00439569|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
219149151|NCT02755116|DRUG|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
219149152|NCT02755116|DRUG|Placebo|placebo by mouth prior to anesthetic induction
219149153|NCT02200770|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
219149154|NCT02200770|OTHER|Placebo|Participants will receive IV placebo matched to inebilizumab.
219149155|NCT03957798|BEHAVIORAL|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
219721312|NCT02952677|BEHAVIORAL|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
219721313|NCT02952677|OTHER|Control|Participants received usual care
219721314|NCT01565551|OTHER|N/A (Observational Study)|No Interventions: Observational Study
219721315|NCT04987905|OTHER|Mindfulness|"In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice)."
219721316|NCT04379180|DRUG|Bosentan Tablets|2mg/kg, bid
219721317|NCT04379180|DRUG|Sildenafil Tablet|1mg/kg, q6h/q8h
219721318|NCT04379180|DRUG|Tadalafil Tablets|1mg/kg, qd
219149156|NCT04239586|DRUG|Sulfonylurea|Starting treatment with sulfonylurea class of drug
219232307|NCT03116191|DRUG|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
219232308|NCT05174026|OTHER|Fludeoxyglucose F-18|Given IV
219232309|NCT05174026|PROCEDURE|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
219232310|NCT05174026|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
219721319|NCT01620346|PROCEDURE|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
219721320|NCT01620346|PROCEDURE|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
219721321|NCT05679310|DIETARY_SUPPLEMENT|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
219721322|NCT02821559|DRUG|TOMOX|
219721323|NCT02821559|DRUG|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
219721324|NCT01837303|PROCEDURE|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
219721325|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
219721326|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
219721327|NCT00226733|BEHAVIORAL|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
219721328|NCT00226733|BEHAVIORAL|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
219721329|NCT02874131|BEHAVIORAL|Behavioral Activation|Behavioral activation
219721330|NCT02874131|BEHAVIORAL|Cognitive Processing Therapy|Cognitive processing therapy
219721331|NCT06478628|BEHAVIORAL|Inpatient rehabilitation|Inpatient multimodal rehabilitation in specialist health care
219721332|NCT06478628|BEHAVIORAL|Outpatient day rehabilitation|Multimodal rehabilitation in specialist health care with program lasting whole work days
219721333|NCT02785705|BIOLOGICAL|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
219721334|NCT00756834|DEVICE|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
219721335|NCT02985281|DRUG|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
219721336|NCT02985281|DRUG|Ribavirin|antiviral drug for HCV infection
219721337|NCT05985551|OTHER|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
219721338|NCT06252337|OTHER|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
219721339|NCT03308643|DRUG|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
219232311|NCT01341769|OTHER|Dietary Intervention|
219232312|NCT01341769|OTHER|Dietary Intervention|
219555366|NCT06467032|OTHER|Laser untreated side|Application of the tested product and comparators on the laser untreated (control) side of the back
219232313|NCT01341769|OTHER|Dietary Intervention|
219555367|NCT00266487|DRUG|Folic acid|
219555368|NCT00266487|DRUG|Vitamin B12|
219555369|NCT00266487|DRUG|Vitamin B6|
219232314|NCT01341769|OTHER|Dietary Intervention|
219555370|NCT02786784|OTHER|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
219555371|NCT02246348|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
219555372|NCT01235260|OTHER|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
219555373|NCT01235260|DRUG|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
219555374|NCT05878899|DRUG|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
219555375|NCT04895553|OTHER|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
219555376|NCT00633022|DRUG|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
219555377|NCT00633022|DRUG|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
219721340|NCT03308643|OTHER|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
219721341|NCT05804500|BEHAVIORAL|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
219721342|NCT04389138|OTHER|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
219721343|NCT03873688|OTHER|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
219721344|NCT04190095|DEVICE|Motion Tracking in VR|Participant will wear motion sensors and VR devices
219721345|NCT04190095|BEHAVIORAL|VR Interaction|Participant will perform VR interaction task
219721346|NCT04834115|DRUG|Ivermectin Tablets|Oral ivermectin at a one time dose
219721347|NCT04834115|OTHER|Placebo|Oral placebo at a one time dose
219149157|NCT01647438|BEHAVIORAL|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
219149158|NCT01647438|OTHER|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
219232315|NCT03069209|BIOLOGICAL|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
219555378|NCT04483596|DRUG|melatonin effect on the Abbreviated Mental Test|"Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1"
219555379|NCT00987480|DRUG|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
219555380|NCT00987480|DEVICE|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
219555381|NCT04388787|DEVICE|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
219555382|NCT04327401|DRUG|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
219555383|NCT03698357|BEHAVIORAL|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
219555384|NCT03698357|BEHAVIORAL|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
219555385|NCT04541264|DIAGNOSTIC_TEST|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
219555386|NCT06447285|DIAGNOSTIC_TEST|SensoDetect BERA technology|"All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min."
219555387|NCT01855880|BIOLOGICAL|AbGn-168H|
219555388|NCT01855880|BIOLOGICAL|placebo|
219555389|NCT01232244|OTHER|GLP-1 infusion|1 pmol/kg/min
219555390|NCT01232244|OTHER|Glucagon infusion|3ng/kg/min
219555391|NCT01232244|OTHER|Oxyntomodulin infusion|3 pmol/kg/min
219555392|NCT01232244|OTHER|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
219555393|NCT01232244|OTHER|Placebo|NaCl 9 g/L infusion
219555394|NCT03045198|DRUG|Azithromycin|
219555395|NCT00688844|DRUG|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
219555396|NCT01287351|DRUG|extra-fine hydrofluoroalkane beclometasone dipropionate|
219555397|NCT01287351|DRUG|Fluticasone propionate|
219555398|NCT00174980|DRUG|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
219555399|NCT02803879|DEVICE|Cardiogoniometry|
219555400|NCT01721551|OTHER|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
219555401|NCT01721551|OTHER|Usual Treatment|The CON group received no intervention but the usual treatment
219555402|NCT00259194|BEHAVIORAL|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
219555403|NCT00259194|BEHAVIORAL|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
219555404|NCT04876716|DRUG|Azole|Dosing according to the SPC
219555405|NCT04876716|DRUG|Anidulafungin|200mg loading dose on day 1 and 100mg QD thereafter
219555406|NCT01374451|DRUG|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
219555407|NCT01374451|DRUG|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
219555408|NCT06249113|DRUG|NaCl 0.9%|NaCl 0.9% continous intravenous on tumor craniotomy surgery
219555409|NCT06249113|DRUG|Adjuvant lidocaine continous|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
219721348|NCT04135001|BEHAVIORAL|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
219721349|NCT04135001|OTHER|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
219721350|NCT04034680|OTHER|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
219721351|NCT04034680|OTHER|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
219721352|NCT05665842|OTHER|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
219721353|NCT05665842|OTHER|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
219721354|NCT00823888|DEVICE|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
219721355|NCT00195429|DRUG|Tacrolimus|
219721356|NCT00195429|DRUG|Sirolimus|
219721357|NCT00195429|DRUG|prednisone|
219721358|NCT03713788|OTHER|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
219721359|NCT01535066|PROCEDURE|acupuncture therapy|Receive acupuncture
219721360|NCT01535066|PROCEDURE|sham acupuncture|Receive sham acupuncture
219721361|NCT05016050|DEVICE|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
219721362|NCT00477217|DRUG|Zoledronic acid|
219721363|NCT00373711|DRUG|Iodine-124|2 mCi, oral
219721364|NCT00373711|DRUG|Iodine-123|2 mCi, oral
219555410|NCT05013619|OTHER|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
219721365|NCT00373711|DRUG|F-18 FDG|10-15 mCi, iv
219721366|NCT03313765|BEHAVIORAL|Motivational interviewing (MI)|Brief MI intervention
219721367|NCT03313765|OTHER|Standard-of-care|Standard-of-care education and counseling
219149159|NCT05086159|BEHAVIORAL|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
219232316|NCT00006079|DRUG|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
219232317|NCT00006079|OTHER|Placebo|Patients receive oral placebo daily for 28 days.
219721368|NCT01495728|PROCEDURE|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
219721369|NCT01495728|PROCEDURE|Sham Manipulation|Mid and Upper Thoracic Spine
219721370|NCT04775134|DIAGNOSTIC_TEST|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
219721371|NCT00156130|RADIATION|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
219721372|NCT00156130|RADIATION|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
219721373|NCT05219344|PROCEDURE|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
219721374|NCT02965131|PROCEDURE|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
219721375|NCT02352142|OTHER|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
219149160|NCT05086159|BEHAVIORAL|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
219721376|NCT02352142|BEHAVIORAL|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
219721377|NCT02892708|PROCEDURE|Surgery|partial or complete resection followed by radiotherapy
219721378|NCT02892708|RADIATION|radiotherapy|radiotherapy after a brain biopsy
219721379|NCT04956965|RADIATION|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
219721380|NCT05372939|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
219721381|NCT05372939|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
219721382|NCT05372939|COMBINATION_PRODUCT|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
219149161|NCT05086159|BEHAVIORAL|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
219149162|NCT00120367|DRUG|Enfuvirtide|
219149163|NCT00120367|DRUG|Tenofovir-Emtricitabine|
219149164|NCT01832467|DRUG|cetuximab-containing chemotherapy|
219149165|NCT04363996|OTHER|New Bioactive Restorative Material|Filling material
219149166|NCT03963336|DRUG|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
219721383|NCT05811975|DRUG|KSX01-TCRT injection|individualization TCR-T cell injection
219721384|NCT03868566|DRUG|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
219721385|NCT03868566|DRUG|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
219721386|NCT02541903|DRUG|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
219721387|NCT02019251|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
219721388|NCT02019251|DEVICE|MRI|
219721389|NCT04067245|DEVICE|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
219721390|NCT02080078|DRUG|Theophylline|
219721391|NCT02080078|DRUG|Erlotinib|
219149167|NCT03963336|DRUG|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
219149168|NCT04665440|OTHER|Voice alone|mother's voice without tactile stimuli
219149169|NCT04665440|OTHER|Voice + tactile stimuli|mother's voice with tactile stimuli
219149170|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
219721392|NCT00696566|DRUG|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
219721393|NCT06407440|OTHER|control|There will be no interference ergonomics training
219721394|NCT06407440|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
219721395|NCT05925634|BEHAVIORAL|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
219721396|NCT05925634|BEHAVIORAL|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
219721397|NCT06404528|OTHER|Blood glucose stress combined with low-dose chemotherapy|By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
219721398|NCT04645706|OTHER|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
219721399|NCT03637374|DEVICE|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
219721400|NCT03637374|DEVICE|Unitary Manifold|Endovascular stent graft system
219721401|NCT03637374|DEVICE|TAAA Debranching Stent Graft System|Endovascular stent graft system
219721402|NCT02029547|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
219721403|NCT04517539|DRUG|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
219721404|NCT00363168|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
219149171|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
219149172|NCT02710851|BIOLOGICAL|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
219149173|NCT02710851|BIOLOGICAL|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
219149174|NCT06449170|OTHER|Mango Ataulfo|In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
219149175|NCT06449170|OTHER|Avocado Hass|In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
219149176|NCT06449170|OTHER|Nopal|In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
219149177|NCT06449170|OTHER|3 corn tortilla|In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
219721405|NCT00363168|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
219721406|NCT05303285|DRUG|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
219149178|NCT06449170|OTHER|Guava|In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
219149179|NCT06449170|OTHER|Amaranth|In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
219721407|NCT05303285|DRUG|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
219721408|NCT04795323|DEVICE|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
219149180|NCT06449170|DIETARY_SUPPLEMENT|Control Beverage (Supportan Drink ® Capuccino)|In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
219149181|NCT04277221|BIOLOGICAL|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
219721409|NCT04795323|DEVICE|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
219721410|NCT05807503|DRUG|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
219721411|NCT04256499|PROCEDURE|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
219721412|NCT03039725|OTHER|Observational|Retrospective chart review on vaccine compliance
219721413|NCT04783948|OTHER|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
219721414|NCT03003689|PROCEDURE|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
219721415|NCT03003689|DEVICE|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
219721416|NCT02285972|DRUG|saline|before the anesthesia induction, 2mL saline iv injection
219721417|NCT02285972|DRUG|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
219555411|NCT05013619|OTHER|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
219555412|NCT05013619|OTHER|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
219555413|NCT05013619|OTHER|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
219555414|NCT02643407|DRUG|Docetaxel|60mg/m2
219721418|NCT02285972|DRUG|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
219721419|NCT00514527|DRUG|oritavancin|Oritavancin as a single, infrequent or daily dose.
219721420|NCT04288791|OTHER|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
219721421|NCT04288791|OTHER|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
219555415|NCT02643407|DRUG|Nedaplatin|80mg/m2
219555416|NCT02643407|DRUG|Cisplatin|75mg/m2
219555417|NCT00382187|BIOLOGICAL|MF59 adjuvanted H5N1 influenza vaccine|"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"
219555418|NCT01121744|DEVICE|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
219555419|NCT02061280|DRUG|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
219555420|NCT02061280|DRUG|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
219555421|NCT02061280|DRUG|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
219721422|NCT02079870|DRUG|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
219721423|NCT02079870|DRUG|placebo|Solution for subcutaneous (s.c. - under the skin) injection
219149182|NCT02287441|OTHER|Tomato|Tomato Products (tomato)
219149183|NCT02287441|OTHER|Raw|Vegetables Prepared Raw (raw).
219149184|NCT01711905|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
219149185|NCT00435578|DRUG|Glufosfamide|
219149186|NCT01860612|DEVICE|Artificial Iris (CustomFlex)|
219149187|NCT02034903|OTHER|Feedings warmed with commercial warmer|
219149188|NCT00946582|BEHAVIORAL|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
219149189|NCT00667056|DRUG|tacrolimus ointment|topical
219149190|NCT00667056|DRUG|placebo ointment|topical
219721424|NCT00380523|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
219721425|NCT01815619|OTHER|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
219555422|NCT04247841|OTHER|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
219555423|NCT04247841|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
219555424|NCT05215496|DIAGNOSTIC_TEST|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
219555425|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
219555426|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
219721426|NCT01815619|OTHER|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
219721427|NCT01186406|DRUG|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
219721428|NCT01186406|RADIATION|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
219149191|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
219149192|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
219721429|NCT01186406|DRUG|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
219721430|NCT01186406|DRUG|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
219232318|NCT02181179|BEHAVIORAL|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
219232319|NCT01987518|OTHER|Procedure surgery behavioral and genetic diagnosis|Observational Study
219232320|NCT01987518|PROCEDURE|quality of life after different type of surgery|
219555427|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
219721431|NCT04452006|DRUG|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
219555428|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
219555429|NCT06111534|BEHAVIORAL|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
219555430|NCT04162197|DEVICE|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
219721432|NCT04452006|DRUG|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
219721433|NCT04452006|DRUG|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
219721434|NCT04452006|DRUG|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
219721435|NCT04452006|DRUG|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
219721436|NCT04452006|DRUG|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
219555431|NCT04162197|DEVICE|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
219555432|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
219555433|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
219555434|NCT05595616|DEVICE|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
219555435|NCT06679426|DRUG|Conestat Alfa|See arm/group descriptions
219555436|NCT02710214|DRUG|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
219149193|NCT01353001|BEHAVIORAL|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
219149194|NCT01353001|BEHAVIORAL|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
219721437|NCT04452006|DRUG|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
219721438|NCT04452006|DRUG|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
219721439|NCT04077606|OTHER|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
219149195|NCT01353001|BEHAVIORAL|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
219721440|NCT04077606|OTHER|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
219721441|NCT04116047|DRUG|Cisplatin|
219555437|NCT02710214|DRUG|Placebo|Once-daily dosing of placebo for 8 weeks
219149196|NCT05976295|DRUG|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
219555438|NCT04273087|OTHER|Observation|Clinical signs and symptoms
219555439|NCT04544852|BEHAVIORAL|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
219555440|NCT04544852|BEHAVIORAL|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
219555441|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
219721442|NCT04116047|DRUG|Durvalumab|
219721443|NCT04116047|PROCEDURE|Radiotherapy|
219721444|NCT02905864|DRUG|Liraglutide 3 mg (Saxenda)|
219721445|NCT02905864|DRUG|Liraglutide 3 mg placebo|
219721446|NCT02357433|DEVICE|High Doses CPFA|
219555442|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
219721447|NCT02723422|PROCEDURE|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
219721448|NCT02723422|PROCEDURE|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
219555443|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
219149197|NCT05976295|DRUG|Placebo|The control group will receive a placebo treatment.
219149198|NCT00917202|DRUG|Methylenblue|
219149199|NCT02214160|DRUG|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
219149200|NCT03380611|DIETARY_SUPPLEMENT|Wakame|Consumption of 4.8 grams wakame per day for 17 days
219149201|NCT03380611|DIETARY_SUPPLEMENT|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
219149202|NCT03380611|DIETARY_SUPPLEMENT|Control|Consumption of microcrystalline cellulose for 17 days
219149203|NCT00181753|DRUG|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.
219149204|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant infusion
219149205|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
219149206|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
219149207|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
219555444|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
219721449|NCT00585650|BIOLOGICAL|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
219721450|NCT00585650|OTHER|Placebo injections|Placebo injections twice weekly for 12 weeks.
219555445|NCT00131482|DRUG|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
219555446|NCT05373667|PROCEDURE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
219721451|NCT02451319|PROCEDURE|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
219721452|NCT05967559|OTHER|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
219721453|NCT05967559|OTHER|Traditional learning Group|The control group is the group that received traditional learning training.
219721454|NCT01275027|DIETARY_SUPPLEMENT|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
219721455|NCT01344200|DRUG|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
219721456|NCT01344200|DRUG|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
219149208|NCT04882553|PROCEDURE|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
219149209|NCT04882553|PROCEDURE|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
219149210|NCT04882553|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
219149211|NCT02423798|DEVICE|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
219232321|NCT03631966|DRUG|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
219555447|NCT05722249|BEHAVIORAL|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
219555448|NCT05722249|BEHAVIORAL|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
219721457|NCT01197898|BIOLOGICAL|Collagenase Santyl Ointment|Topical daily application
219721458|NCT01197898|OTHER|Placebo Comparator|Topical daily application
219721459|NCT01687933|DEVICE|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
219149212|NCT03596853|OTHER|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
219149213|NCT03596853|OTHER|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
219721460|NCT01687933|OTHER|usual care|Women in Control group did not use the glasses.
219721461|NCT06007443|OTHER|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
219721462|NCT04558242|DEVICE|Genix|Low Level Light (LEDs)
219721463|NCT04558242|DEVICE|Sham|Incandescent Bulbs Colored Red
219721464|NCT03033836|DRUG|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
219721465|NCT05540275|DRUG|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
219721466|NCT06363500|OTHER|non applicable|Only blood sample collection
219721467|NCT03821532|OTHER|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
219721468|NCT00111332|BEHAVIORAL|Progressive resistance and aerobic training|
219721469|NCT02960685|PROCEDURE|Echocardiography|
219721470|NCT05886023|DIETARY_SUPPLEMENT|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
219721471|NCT05886023|DIETARY_SUPPLEMENT|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
219721472|NCT03142750|DEVICE|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
219721473|NCT00653757|DRUG|goserelin acetate|
219721474|NCT00653757|DRUG|leuprolide acetate|
219721475|NCT00653757|RADIATION|image-guided radiation therapy|
219149214|NCT04191486|DRUG|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
219149215|NCT04191486|DRUG|Placebo|Placebo once daily
219149216|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
219721476|NCT00653757|RADIATION|intensity-modulated radiation therapy|
219721477|NCT00983970|BEHAVIORAL|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
219721478|NCT00983970|BEHAVIORAL|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
219721479|NCT04925934|DRUG|VIB7734|VIB7734
219149217|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
219149218|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
219149219|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
219721480|NCT04925934|OTHER|Placebo|Placebo
219721481|NCT04094389|OTHER|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
219721482|NCT04094389|OTHER|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
219721483|NCT04094389|OTHER|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
219555449|NCT05954819|OTHER|Planned patient education|Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
219721484|NCT03158688|DRUG|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
219721485|NCT03158688|DRUG|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
219555450|NCT02503813|PROCEDURE|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
219555451|NCT00313508|BIOLOGICAL|Autologous Dendritic Cells (DC)|Given intranodally
219555452|NCT00313508|DRUG|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
219149220|NCT04113096|DRUG|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
219149221|NCT04113096|DRUG|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
219149222|NCT04113096|DRUG|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
219149223|NCT04113096|DRUG|Cancer of the Prostate Placebo|20 mg once daily for 6 months
219149224|NCT01063972|BEHAVIORAL|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
219149225|NCT01063972|BEHAVIORAL|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
219555453|NCT00313508|BIOLOGICAL|Autologous Lymphocyte Infusion (ALI)|Infusion
219555454|NCT00458445|DRUG|SPD465|
219149226|NCT02962817|OTHER|Educational intervention|
219149227|NCT02962817|OTHER|Video explaining the clinical practice guidelines on low back pain|
219149228|NCT04114786|DEVICE|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
219555455|NCT00458445|OTHER|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
219555456|NCT00374049|DRUG|MUC_1|Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
219555457|NCT04688372|OTHER|Surge Index|See study description above
219149229|NCT04114786|DEVICE|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
219149230|NCT04134273|DRUG|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
219149231|NCT04134273|DRUG|Clindamycin|Clindamycin Phosphate topical gel 1%
219149232|NCT04134273|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
219555458|NCT02937506|DRUG|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
219555459|NCT02937506|DRUG|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
219555460|NCT04522999|DEVICE|Photobiomodulation|The Valeda™ Light Delivery System
219149233|NCT04719858|BEHAVIORAL|#LIFEGOALS|"Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention."
219149234|NCT00634621|DRUG|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
219149235|NCT05920642|DRUG|Intrathecal morphine administration|Administration of morphine into the spinal canal.
219149236|NCT05920642|DRUG|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
219555461|NCT04602585|BEHAVIORAL|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
219555462|NCT02456987|DEVICE|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
219555463|NCT05962268|OTHER|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
219721486|NCT03158688|DRUG|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity."
219721487|NCT05635864|PROCEDURE|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
219721488|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
219721489|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
219721490|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
219721491|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
219721492|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
219721493|NCT05903443|DIAGNOSTIC_TEST|ancillary tests|electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
219721494|NCT01115010|DEVICE|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
219721495|NCT01115010|DEVICE|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
219721496|NCT01115010|DEVICE|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
219721497|NCT04928586|DRUG|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
219721498|NCT04928586|DRUG|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
219721499|NCT00565864|DRUG|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
219721500|NCT06055556|PROCEDURE|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
219721501|NCT06055556|OTHER|Freshly procured valve|Fresh donor graft semilunar heart valve.
219721502|NCT04865276|BEHAVIORAL|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
219149237|NCT02579031|DEVICE|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
219721503|NCT06266507|BEHAVIORAL|Ergotherapy Based Parent Coaching|Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.
219721504|NCT06266507|OTHER|Informative Brochure Distribution|No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
219721505|NCT06850727|DRUG|OD-07656|Experimental intervention
219721506|NCT06850727|DRUG|Vedolizumab|Active standard of care comparator
219721507|NCT06848400|DEVICE|AI-integrated Capsule Gastroscopy (ACG) examination|Product name: Gastric Capsule Endoscope System Specification model: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
219721508|NCT06848400|DEVICE|Electronic gastroduodenoscopy (EGD) examination|"EGD was the reference standard against which ACG was compared, and it was performed within 24 hours post-ACG ingestion time.~Product name: Electronic gastrointestinal endoscope (EGD) Specifications and models: GIF-290 series Manufacturer: Olympus, Tokyo, Japan"
219721509|NCT06077604|OTHER|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
219721510|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
219721511|NCT06847464|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
219721512|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 23
219721513|NCT06847464|DRUG|carbamazepine|Subjects will receive carbamazepine on Days 5 - 27
219721514|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 8
219721515|NCT06847464|DRUG|Quinidine|Subjects will receive quinidine on Days 5-12
219721516|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
219721517|NCT06847464|DRUG|fluconazole|Subjects will receive fluconazole on Days 5-18
219721518|NCT03022825|DRUG|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
219555464|NCT05962268|OTHER|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
219555465|NCT02978651|DRUG|Pitolisant (BF2.649)|
219555466|NCT02978651|DRUG|Placebo Oral Tablet|
219555467|NCT06424691|DIETARY_SUPPLEMENT|Tailored Recommendations|Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
219555468|NCT06424691|BEHAVIORAL|Consult Call|Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
219721519|NCT03022825|DRUG|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
219721520|NCT06390436|DIAGNOSTIC_TEST|Blood sample|A blood sample will be taken, in addition to blood samples taken for the usual follow-up, with 4 dry tubes for the determination of ADA and anti-ADA antibodies and for bio-collection.
219721521|NCT06390436|DRUG|Adalimumab Injection|Adalimumab Injection
219721522|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
219721523|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
219721524|NCT03204123|DRUG|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
219149238|NCT02579031|DEVICE|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
219149239|NCT02742571|OTHER|non applicable|
219149240|NCT04224792|OTHER|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
219555469|NCT06424691|BEHAVIORAL|Email Series|Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
219555470|NCT02749591|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
219149241|NCT04224792|OTHER|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
219149242|NCT03427216|DRUG|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
219149243|NCT03427216|DRUG|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
219149244|NCT05877352|RADIATION|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
219555471|NCT02749591|OTHER|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
219555472|NCT02749591|OTHER|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
219555473|NCT02749591|OTHER|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
219555474|NCT06237101|DRUG|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
219555475|NCT06237101|DRUG|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
219555476|NCT03393481|DRUG|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
219555477|NCT03393481|DRUG|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
219555478|NCT04360408|OTHER|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
219555479|NCT03480685|DEVICE|IVUS and OCT Imaging|Use of an imaging catheter
219555480|NCT06678815|OTHER|Emergency response|Those delivering or receiving emergency care from a CFR.
219555481|NCT03224078|OTHER|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
219555482|NCT05922488|PROCEDURE|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
219555483|NCT05922488|PROCEDURE|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
219555484|NCT02838940|PROCEDURE|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
219555485|NCT02838940|DRUG|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
219555486|NCT02853539|DRUG|Denosumab|Subcutaneous injection of Denosumab
219555487|NCT01188226|DEVICE|Denture teeth|Denture teeth made of nano hybrid composite material
219555488|NCT05916716|PROCEDURE|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
219555489|NCT05916716|PROCEDURE|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
219555490|NCT05916716|DEVICE|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
219555491|NCT05916716|DRUG|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
219555492|NCT05916716|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
219555493|NCT04977596|OTHER|No intervention|Retrospective study without intervention
219149245|NCT05877352|PROCEDURE|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
219149246|NCT03284567|BEHAVIORAL|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors"
219149247|NCT06445699|OTHER|Photodynamic therapy|A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
219149248|NCT06445699|OTHER|Hydrogel dressing|Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
219149249|NCT02191319|DRUG|Viramune®|
219149250|NCT04933890|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
219149251|NCT00521131|DRUG|Levocetirizine dihydrochloride|
219721525|NCT03204123|DIAGNOSTIC_TEST|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
219721526|NCT03204123|DIAGNOSTIC_TEST|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
219721527|NCT05431608|BIOLOGICAL|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
219721528|NCT05431608|BIOLOGICAL|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
219721529|NCT02252263|DRUG|Elotuzumab|
219721530|NCT02252263|DRUG|Lirilumab|
219721531|NCT02252263|DRUG|Urelumab|
219721532|NCT05074537|DIAGNOSTIC_TEST|MRI exam|Participants who are receiving standard of care or investigational MRI exams at the Wright Center will be eligible for enrollment in this data bank.
219721533|NCT05074537|DIAGNOSTIC_TEST|PET/CT imaging exam|Participants who are receiving standard of care or investigational PET/CT exams at the Wright Center will be eligible for enrollment in this data bank.
219721534|NCT05074537|DIAGNOSTIC_TEST|CT imaging exam|Participants who are receiving standard of care or investigational CT exams at the Wright Center will be eligible for enrollment in this data bank.
219721535|NCT01759914|DRUG|Potent topical steroid|
219555494|NCT05116137|BEHAVIORAL|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
219555495|NCT00002228|DRUG|Enfuvirtide|
219555496|NCT02371928|OTHER|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
219149252|NCT03668197|BIOLOGICAL|microbiological analysis|microbiological analysis of the peritoneal fluid
219721536|NCT01759914|DRUG|Superpotent topical steroid|
219721537|NCT00374868|DRUG|pemetrexed|"Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
219721538|NCT00374868|DRUG|cisplatin|"Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
219721539|NCT03188185|DRUG|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
219149253|NCT01635712|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
219149254|NCT02063425|DRUG|Fluoxetine|1 pill of 20mg / day, during 3 months
219149255|NCT02063425|DRUG|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
219149256|NCT04410510|DRUG|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
219149257|NCT04410510|OTHER|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
219149258|NCT00855686|DRUG|Memantine|20mg once daily oral dose
219149259|NCT00855686|DRUG|Placebo|Daily oral dose
219149260|NCT05973578|RADIATION|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
219149261|NCT04328155|PROCEDURE|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
219149262|NCT04328155|PROCEDURE|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
219721540|NCT03188185|DRUG|ALKS 5461 Placebo|Placebo tablet, administered sublingually
219721541|NCT03557944|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
219721542|NCT02281877|PROCEDURE|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
219721543|NCT02281877|BEHAVIORAL|Standard Rehabilitation Protocol|Standard physical therapy after TKA
219721544|NCT05862701|DRUG|Permethrin|5% permethrin cream
219721545|NCT05862701|DRUG|Sulphur|10% Sulfur ointment
219555497|NCT02371928|OTHER|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
219555498|NCT05120687|DRUG|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
219149263|NCT04328155|PROCEDURE|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
219149264|NCT04328155|PROCEDURE|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
219149265|NCT00065832|BEHAVIORAL|Reading Instruction|
219721546|NCT05219890|DIETARY_SUPPLEMENT|Fish oil|They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
219721547|NCT03869021|OTHER|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
219721548|NCT03869021|OTHER|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
219721549|NCT05546528|DEVICE|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
219721550|NCT05546528|DEVICE|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
219149266|NCT01510717|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
219149267|NCT01510717|DEVICE|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
219149268|NCT00042848|DRUG|modafinil|
219149269|NCT00826475|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
219149270|NCT00826475|BEHAVIORAL|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
219149271|NCT03873896|DIAGNOSTIC_TEST|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
219555499|NCT02846883|BIOLOGICAL|1 million MSCs/kg|Intravenous infusion of 1 million allogeneic MSCs/kg.
219555500|NCT02846883|BIOLOGICAL|3 million MSCs/kg|Intravenous infusion of 3 million allogeneic MSCs/kg
219555501|NCT02846883|DRUG|Placebo|Intravenous infusion of Plasmalyte A (placebo)
219555502|NCT01590251|OTHER|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
219555503|NCT01590251|BEHAVIORAL|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
219721551|NCT02661477|DRUG|pegylated interferon alfa 2|
219721552|NCT02661477|OTHER|Placebo|0,9% natrium chlorine solution
219721553|NCT04415905|DRUG|Propofol|The participants in the group P are anesthetized with propofol
219721554|NCT04415905|DRUG|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
219721555|NCT02522845|DEVICE|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
219721556|NCT02525978|BEHAVIORAL|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
219721557|NCT02525978|OTHER|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
219721558|NCT04285411|DEVICE|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
219721559|NCT00694746|DRUG|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
219721560|NCT00694746|DRUG|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
219721561|NCT02842021|DRUG|S2G6T-1|Twice a day topical cream
219721562|NCT02842021|DRUG|S2G6T-2|Twice a day topical cream
219721563|NCT02842021|DRUG|S2G6T-3|Twice a day topical cream
219721564|NCT02842021|DRUG|S2G6T-4|Twice a day topical cream
219721565|NCT04512872|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
219721566|NCT04512872|BIOLOGICAL|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
219721567|NCT05055596|BEHAVIORAL|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
219721568|NCT05055596|BEHAVIORAL|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
219721569|NCT02315625|DRUG|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
219721570|NCT02315625|DRUG|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
219721571|NCT06410131|DRUG|FTL008.16|IV infusion every 2 weeks
219721572|NCT06410183|OTHER|no intervention|no intervention
219721573|NCT03915457|OTHER|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
219721574|NCT03915457|OTHER|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
219721575|NCT01836822|PROCEDURE|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
219721576|NCT01836822|PROCEDURE|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
219721577|NCT01836822|PROCEDURE|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
219721578|NCT01836822|PROCEDURE|Bronchoalveolar lavage (BAL)|
219721579|NCT01836822|PROCEDURE|Endobronchial forceps biopsy|
219721580|NCT05639595|DEVICE|Web interface for health center staff and mobile application on smart phones for village health volunteers|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
219721581|NCT06023797|DRUG|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
219721582|NCT01684592|BEHAVIORAL|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
219721583|NCT01684592|BEHAVIORAL|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
219721584|NCT02395770|OTHER|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
219721585|NCT02980653|DRUG|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
219721586|NCT03896620|DEVICE|Preoperative RT|Radiation delivered before surgery.
219721587|NCT03896620|DEVICE|Postoperative RT|Radiation delivered after surgery.
219721588|NCT03896620|DRUG|Chemotherapy|Physician's choice of chemotherapy.
219721589|NCT03896620|OTHER|Surgery|Surgical excision of tumor.
219721590|NCT04288037|DIAGNOSTIC_TEST|fetal heart rate variability|observational study. no intervention
219721591|NCT00945620|DRUG|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
219721592|NCT00945620|DRUG|placebo|Placebo
219721593|NCT03678662|OTHER|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
219721594|NCT03678662|OTHER|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
219721595|NCT03678662|OTHER|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
219721596|NCT03634150|BIOLOGICAL|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
219721597|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
219721598|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
219721599|NCT05414773|OTHER|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
219721600|NCT04777903|OTHER|collect date about all participants|a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
219721601|NCT00857051|OTHER|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
219721602|NCT00857051|OTHER|Film|A DVD addressing common stressors in the early postpartum.
219721603|NCT00680173|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
219721604|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
219721605|NCT04573946|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219555504|NCT01520545|DRUG|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
219721606|NCT04573946|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219555505|NCT01520545|DEVICE|SynchroMed® II Programmable Pump|Intrathecal programmable pump
219555506|NCT03440333|DRUG|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
219555507|NCT00927251|DEVICE|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
219555508|NCT05531851|OTHER|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
219555509|NCT01618630|DIETARY_SUPPLEMENT|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
219555510|NCT01618630|DIETARY_SUPPLEMENT|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
219555511|NCT06226025|DRUG|Melatonin|Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
219555512|NCT06226025|OTHER|Placebo|Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
219555513|NCT06226025|BEHAVIORAL|Behavioral sleep intervention|An active intervention that is typically paired with melatonin to maximize treatment effects.
219555514|NCT06226025|BEHAVIORAL|Behavioral sleep control|A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.
219721607|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3|"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"
219721608|NCT01868451|DRUG|Brentuximab vedotin (SGN-35)|
219721609|NCT01868451|DRUG|Doxorubicin HCL|
219721610|NCT01868451|DRUG|Vinblastine Sulfate|
219721611|NCT01868451|DRUG|Dacarbazine|
219721612|NCT01868451|RADIATION|Involved-Site Radiation Therapy (ISRT)|
219721613|NCT01868451|PROCEDURE|Interim PET|
219721614|NCT01868451|RADIATION|consolidation volume RT (CVRT)|
219721615|NCT05705271|DRUG|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
219721616|NCT03485417|DRUG|Aripiprazole|for oral or depot preparation
219721617|NCT03485417|DRUG|Paliperidone|for oral or depot
219721618|NCT03485417|OTHER|Treatment as Usual|to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
219721619|NCT05621980|BEHAVIORAL|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
219721620|NCT05621980|BEHAVIORAL|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
219721621|NCT05919056|OTHER|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
219555515|NCT00706719|DRUG|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
219555516|NCT00706719|DRUG|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
219721622|NCT05919056|OTHER|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
219149272|NCT03873896|PROCEDURE|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
219149273|NCT01264679|DRUG|Ferumoxytol|IV Ferumoxytol
219721623|NCT05919056|OTHER|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
219149274|NCT04153747|OTHER|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
219149275|NCT04153747|OTHER|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
219149276|NCT04153747|OTHER|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
219555517|NCT05472896|PROCEDURE|cTACE|transcatheter arterial chemoembolization with
219555518|NCT05472896|DRUG|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
219555519|NCT05472896|DRUG|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
219555520|NCT04140929|OTHER|Oral Health Tool Box|Please see, description of the intervention group
219555521|NCT03749707|DIAGNOSTIC_TEST|HPV analysis|HPV analysis of SLNs with an in-house targeted Next Generation Sequencing assay
219149277|NCT04153747|DIAGNOSTIC_TEST|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
219149278|NCT04692909|DEVICE|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
219149279|NCT05146271|PROCEDURE|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
219149280|NCT02455297|DRUG|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
219149281|NCT00000223|DRUG|Buprenorphine|
219721624|NCT04822194|BEHAVIORAL|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
219721625|NCT04701996|BIOLOGICAL|serological surveillance|serological surveillance, detection of antibodies (Total Ig and IgM) developed against SARS-CoV-2 in a population living in a rural area (Kimpese, DRC)
219721626|NCT04057768|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
219721627|NCT04078308|BIOLOGICAL|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
219721628|NCT04078308|OTHER|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
219721629|NCT03060681|DRUG|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
219721630|NCT05574985|BIOLOGICAL|Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)|Injected one dose of research vaccine
219721631|NCT05574985|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero Cell)|Injected one dose of control vaccine
219721632|NCT03594552|DRUG|Arbaclofen_15|Single oral dose (15mg)
219721633|NCT03594552|DRUG|Arbaclofen_30|Single oral dose (30mg)
219149282|NCT05878470|BEHAVIORAL|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
219721634|NCT03594552|DRUG|Placebo|Single oral dose placebo (oral tablet)
219721635|NCT00130364|DRUG|Pimecrolimus|Pimecrolimus 1 % cream
219721636|NCT00130364|DRUG|Placebo|Pimecrolimus vehicle cream (placebo)
219721637|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
219721638|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
219721639|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
219149283|NCT02476409|DRUG|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
219721640|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
219149284|NCT02476409|OTHER|Placebo|Placebo for tolvaptan
219149285|NCT03017625|OTHER|Blood is drawn|Blood analyses
219149286|NCT00275392|BEHAVIORAL|Vestibular rehabilitation|vestibular adaptation and substitution exercises
219149287|NCT00275392|BEHAVIORAL|Placebo|placebo vestibular exercises
219149288|NCT01830738|PROCEDURE|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
219149289|NCT01830738|PROCEDURE|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
219555522|NCT05146024|BEHAVIORAL|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
219555523|NCT05048862|DIAGNOSTIC_TEST|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
219555524|NCT05048862|DIAGNOSTIC_TEST|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
219555525|NCT05048862|DIAGNOSTIC_TEST|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
219555526|NCT05048862|DIAGNOSTIC_TEST|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
219555527|NCT05048862|DIAGNOSTIC_TEST|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7\~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
219149290|NCT04498663|BEHAVIORAL|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
219721641|NCT03195556|DEVICE|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
219721642|NCT01947933|BIOLOGICAL|Mirikizumab- IV|Administered IV
219721643|NCT01947933|BIOLOGICAL|Mirikizumab - SC|Administered SC
219721644|NCT01947933|BIOLOGICAL|Placebo - IV|Administered IV
219721645|NCT03407456|OTHER|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
219721646|NCT04571034|PROCEDURE|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
219721647|NCT04571034|PROCEDURE|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
219721648|NCT04571034|PROCEDURE|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
219721649|NCT05309772|DIAGNOSTIC_TEST|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
219721650|NCT05309772|DIAGNOSTIC_TEST|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
219721651|NCT03509155|OTHER|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
219721652|NCT03509155|OTHER|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
219721653|NCT03588468|OTHER|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
219721654|NCT03588468|OTHER|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
219721655|NCT00350285|BEHAVIORAL|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
219721656|NCT00350285|BEHAVIORAL|Marijuana education|Information about health and behavioral effects of marijuana use.
219721657|NCT02700256|BEHAVIORAL|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
219721658|NCT04021797|DEVICE|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
219721659|NCT00294398|OTHER|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
219721660|NCT00294398|OTHER|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
219721661|NCT00248547|DRUG|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
219721662|NCT00248547|DRUG|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
219721663|NCT00248547|DRUG|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
219721664|NCT00248547|DRUG|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
219721665|NCT03620279|BEHAVIORAL|Magic camp intervention|Hand-arm bimanual motor skills training
219721666|NCT02965833|DEVICE|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
219721667|NCT02965833|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
219149291|NCT05865938|DEVICE|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
219149292|NCT00142285|DRUG|Zinc sulphate (20 mg)|
219149293|NCT03848572|DIAGNOSTIC_TEST|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
219149294|NCT05142878|DEVICE|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
219149295|NCT02779634|DRUG|ubiquinol|Ubiquinol three times daily
219555528|NCT05048862|DIAGNOSTIC_TEST|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
219149296|NCT02779634|DRUG|Placebo|Sugar pill three times daily
219149297|NCT04221828|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
219149298|NCT01983371|DRUG|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
219149299|NCT01983371|OTHER|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
219149300|NCT01595061|DRUG|Cisplatin|Given IV
219149301|NCT01595061|DRUG|Gemcitabine Hydrochloride|Given IV
219555529|NCT05048862|DIAGNOSTIC_TEST|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS \& Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics \& Protein Function Core Lab in National Taiwan University.
219555530|NCT05048862|DIAGNOSTIC_TEST|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
219555531|NCT05048862|DIAGNOSTIC_TEST|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18\~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1\~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
219555532|NCT05048862|DIAGNOSTIC_TEST|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at \>32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
219555533|NCT05048862|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
219555534|NCT05048862|DIAGNOSTIC_TEST|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
219555535|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
219721668|NCT02965833|DEVICE|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
219149302|NCT01595061|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219149303|NCT01595061|PROCEDURE|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
219149304|NCT00529789|DRUG|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
219149305|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
219149306|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
219149307|NCT02204982|DRUG|Duvelisib|PI3K Inhibitor
219149308|NCT02204982|DRUG|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
219555536|NCT03874026|DRUG|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
219555537|NCT00613041|PROCEDURE|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
219555538|NCT05361343|OTHER|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"1. Nutrition: intermittent fasting;~2. Physical activity: medium-intensity or high-intensity physical activity;~3. Hypoxic training (at least three per visit to the center);~4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~5. Individual motivational counseling."
219555539|NCT02274558|DRUG|NBI-98854|NBI-98854 40 mg capsules
219555540|NCT02274558|DRUG|Placebo|NBI-98854 placebo capsules
219555541|NCT03860025|OTHER|No intervention.|No intervention.
219555542|NCT06143462|DRUG|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
219555543|NCT06143462|OTHER|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
219555544|NCT06143462|BEHAVIORAL|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
219555545|NCT04479735|DEVICE|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
219555546|NCT02655224|DRUG|Relugolix|Relugolix Tablets
219555547|NCT02655224|DRUG|Relugolix placebo|Relugolix placebo-matching tablets
219555548|NCT04592419|DRUG|KSI-301|Intravitreal Injection
219555549|NCT04592419|DRUG|Aflibercept|Intravitreal Injection
219555550|NCT04592419|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
219555551|NCT03033134|DEVICE|BSJ003W|BSJ003W implant
219555552|NCT06678321|BEHAVIORAL|Mobil game|Participants in the intervention group will be asked to play the game and complete all parts.
219555553|NCT06148779|BEHAVIORAL|Digitally delivered first-line treatment for osteoarthritis|Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
219555554|NCT06148779|BEHAVIORAL|Face-to-face first-line treatment for osteoarthritis|First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
219555555|NCT02964390|PROCEDURE|Balloon Pulmonary Angioplasty|
219555556|NCT05603936|OTHER|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~* QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~* QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
219555557|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
219721669|NCT03860480|PROCEDURE|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
219721670|NCT03860480|PROCEDURE|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
219149309|NCT02204982|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
219149310|NCT01884441|DRUG|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
219149311|NCT01884441|DRUG|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
219149312|NCT01884441|DRUG|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
219149313|NCT06034886|DRUG|Troriluzole|BHV-4157 140mg, 200mg or 280mg once daily by mouth.
219149314|NCT05459259|OTHER|Interviews and Delphi Survey|no intervention delivered
219149315|NCT01247831|PROCEDURE|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
219149316|NCT03164408|PROCEDURE|Orthopaedic Implant Removal|
219149317|NCT00401206|DRUG|dexmedetomidine|
219149318|NCT05794568|DEVICE|OITcontrol app monitoring|App to monitor OIT patients
219149319|NCT03576833|DEVICE|Elipse Balloon system|intragastic balloon
219149320|NCT00960141|DRUG|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
219149321|NCT00960141|DRUG|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
219149322|NCT00960141|DRUG|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
219149323|NCT00185549|BEHAVIORAL|CF. DOC|
219149324|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
219149325|NCT04470258|DEVICE|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
219149326|NCT01323166|PROCEDURE|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
219149327|NCT05806476|DIETARY_SUPPLEMENT|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
219149328|NCT05806476|DIETARY_SUPPLEMENT|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
219149329|NCT03411291|DEVICE|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
219149330|NCT02444598|DEVICE|Vaccum Assisted Closure device|Negative-pressure wound therapy
219149331|NCT02444598|PROCEDURE|Conventional wound dressings|Conventional wound dressings
219149332|NCT02577198|OTHER|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
219149333|NCT02896699|BEHAVIORAL|PrEP Intervention Group|
219149334|NCT02896699|OTHER|Control Group|
219149335|NCT03009136|DRUG|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
219149336|NCT03009136|DRUG|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
219149337|NCT02730923|DRUG|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
219149338|NCT02730923|DRUG|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
219149339|NCT02191098|DRUG|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
219149340|NCT05320796|DIAGNOSTIC_TEST|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
219149341|NCT00581854|DRUG|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
219555558|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
219555559|NCT01264913|BEHAVIORAL|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
219721671|NCT01769365|DRUG|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
219721672|NCT01769365|DRUG|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
219149342|NCT03184038|PROCEDURE|Cognitive Assessment|Undergo assessment of neurocognitive function
219149343|NCT03184038|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219149344|NCT03184038|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219149345|NCT03184038|OTHER|Quality-of-Life Assessment|Ancillary studies
219149346|NCT05444244|OTHER|Relational Research Recruitment and Engagement Intervention|"* Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)"
219149347|NCT00296751|PROCEDURE|ECG recording|
219149348|NCT00296751|PROCEDURE|Epidural catheter insertion|
219149349|NCT00296751|DRUG|Intravenous meperidine injection|
219149350|NCT00296751|DRUG|Epidural Bupivacaine and fentanyl injection|
219149351|NCT06523374|PROCEDURE|Endoscopic brush cytology|A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.
219149352|NCT06073769|DRUG|Oral azacitidine|Maintenance therapy according to the approved label
219149353|NCT05689307|DEVICE|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
219149354|NCT06326320|PROCEDURE|Combined SAPB|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the supine position. 40 ml of 0.25% bupivacaine will be used in applications.
219555560|NCT05333653|OTHER|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
219555561|NCT05333653|OTHER|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
219555562|NCT02509260|DEVICE|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
219555563|NCT02509260|OTHER|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
219555564|NCT01853371|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
219555565|NCT01853371|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
219555566|NCT00808262|BIOLOGICAL|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
219555567|NCT01775722|DEVICE|Pulsed Dye Laser|port wine stain
219555568|NCT01775722|DEVICE|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
219555569|NCT04158778|DRUG|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
219555570|NCT04158778|OTHER|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
219555571|NCT03547830|DRUG|Plerixafor|Plerixafor for Conditioning before HSCT.
219555572|NCT03547830|DRUG|Gcsf|GCSF for Conditioning before HSCT.
219555573|NCT01876953|DRUG|cytarabine|Given IV
219555574|NCT01876953|DRUG|idarubicin|Given IV
219555575|NCT01876953|DRUG|dasatinib|Given PO
219555576|NCT01876953|OTHER|laboratory biomarker analysis|Correlative studies
219555577|NCT00964353|DRUG|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
219555578|NCT03389763|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
219555579|NCT03135340|PROCEDURE|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
219555580|NCT03135340|PROCEDURE|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
219555581|NCT03135340|DRUG|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
219721673|NCT01769365|DRUG|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
219721674|NCT05726136|DRUG|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
219149355|NCT04275102|OTHER|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
219721675|NCT05726136|DRUG|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
219149356|NCT05388110|BEHAVIORAL|SKY Breath Intervention|Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
219149357|NCT00793754|DRUG|Aspirin|100 mg / day for 8 weeks
219721676|NCT05726136|DRUG|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
219721677|NCT00408954|DRUG|UK-369,003|100 mg MR tablet once daily for 2 weeks
219721678|NCT00408954|DRUG|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
219721679|NCT05015023|BEHAVIORAL|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
219555582|NCT03135340|DRUG|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
219555583|NCT00099580|DRUG|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
219149358|NCT00793754|DRUG|Atorvastatin|40 mg / day for 8 weeks
219149359|NCT00793754|DRUG|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
219555584|NCT00099580|DRUG|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
219721680|NCT05708651|DEVICE|Investigational device [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].
219149360|NCT06534554|BEHAVIORAL|Patient Navigation|A lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
219149361|NCT06510348|DIETARY_SUPPLEMENT|Supplemental Parenteral Nutrition (SPN)|Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
219721681|NCT05708651|DEVICE|Comparator [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
219721682|NCT03017664|OTHER|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
219721683|NCT03017664|OTHER|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
219721684|NCT02606539|PROCEDURE|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
219721685|NCT02606539|DRUG|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
219721686|NCT06286943|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFAs).|Colon-delivery capsules of SCFAs.
219721687|NCT06286943|DIETARY_SUPPLEMENT|Placebo|Microcrystaline cellulose placebo capsules.
219721688|NCT06286943|OTHER|Maastricht Acute Stress Task|The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
219721689|NCT06286943|OTHER|No-stress control task|The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
219721690|NCT03478995|DRUG|GX-I7|GX-I7 25mg/ml/vial
219149362|NCT01792830|DRUG|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
219149363|NCT01792830|DRUG|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c \> 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
219232322|NCT04890899|PROCEDURE|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
219232323|NCT04103099|DIETARY_SUPPLEMENT|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
219232324|NCT02834559|DRUG|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
219555585|NCT02419573|DEVICE|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
219555586|NCT02419573|DEVICE|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
219555587|NCT01782755|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
219232325|NCT02834559|DRUG|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
219232326|NCT03279406|DEVICE|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
219721691|NCT02639533|DRUG|Pregabalin|Pregabalin 150 mg PO, single dose.
219721692|NCT02639533|OTHER|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
219149364|NCT01792830|DRUG|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
219232327|NCT04140643|DEVICE|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
219232328|NCT04140643|BEHAVIORAL|Oral hygiene instructions|Oral Hygiene instructions
219555588|NCT01782755|OTHER|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
219555589|NCT01811368|BIOLOGICAL|rituximab|Given IV
219555590|NCT01811368|BIOLOGICAL|ibritumomab tiuxetan|Given IV
219232329|NCT01706666|DRUG|bortezomib|Given SC
219555591|NCT01811368|BIOLOGICAL|anti-thymocyte globulin|Given IV
219555592|NCT01811368|RADIATION|total nodal irradiation|Undergo TLI
219555593|NCT01811368|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
219555594|NCT01811368|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
219555595|NCT01811368|DRUG|cyclosporine|Given PO or IV
219555596|NCT01811368|DRUG|mycophenolate mofetil|Given PO or IV
219721693|NCT00120484|DRUG|Vitamin B12|
219721694|NCT02537470|DRUG|Biphasic Remogliflozin Etabonate|Experimental Drug
219721695|NCT02537470|OTHER|Placebo|Placebo Comparator
219721696|NCT04645056|OTHER|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
219721697|NCT02387918|DRUG|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
219721698|NCT02387918|DEVICE|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
219721699|NCT02049879|DRUG|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
219721700|NCT03942055|DEVICE|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
219721701|NCT05194488|DEVICE|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
219721702|NCT05194488|DRUG|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
219721703|NCT05194488|DEVICE|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
219149365|NCT06025357|DIETARY_SUPPLEMENT|L-Citrulline supplementation|4 weeks of L-Citrulline supplementation (10 grams/day).
219721704|NCT03407482|DRUG|GDC-0853|Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
219149366|NCT06025357|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline Cellulose supplementation.
219149367|NCT04220827|DRUG|Paclitaxel|Given IP
219149368|NCT01630772|OTHER|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
219149369|NCT01630772|OTHER|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
219149370|NCT03568292|OTHER|Best Practice|Receive standard of care
219149371|NCT03568292|OTHER|Laboratory Biomarker Analysis|Correlative studies
219149372|NCT03568292|DEVICE|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
219149373|NCT03568292|OTHER|Questionnaire Administration|Ancillary studies
219149374|NCT04585074|PROCEDURE|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
219149375|NCT04585074|PROCEDURE|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
219149376|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
219149377|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
219149378|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
219149379|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
219149380|NCT01865149|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
219149381|NCT05678972|OTHER|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
219149382|NCT02887625|DRUG|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
219149383|NCT02887625|DRUG|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c \<7.0%
219149384|NCT00771446|BIOLOGICAL|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
219149385|NCT00771446|OTHER|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
219149386|NCT05072743|DEVICE|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
219721705|NCT02741778|PROCEDURE|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
219721706|NCT02741778|PROCEDURE|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
219149387|NCT01583712|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
219721707|NCT00533988|DEVICE|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
219721708|NCT00162734|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
219721709|NCT00627978|DRUG|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
219721710|NCT03967327|DRUG|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
219721711|NCT03967327|DRUG|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
219721712|NCT00446277|PROCEDURE|cataract surgery|
219721713|NCT02285192|RADIATION|18F-Fluorodeoxyglucose (18F-FDG)|
219721714|NCT02285192|DEVICE|PET/CT imaging|
219721715|NCT02285192|DEVICE|PET/MRI imaging|
219721716|NCT05413551|DRUG|Low-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
219721717|NCT05413551|DRUG|Standard dose of isoniazid|15 mg/kg oral tablet (up to 900 mg)
219721718|NCT05413551|DRUG|High-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
219721719|NCT03442569|DRUG|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
219555597|NCT02951195|DRUG|VX-152|Tablet for oral administration.
219555598|NCT02951195|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
219555599|NCT02951195|DRUG|IVA|Tablet for oral administration.
219555600|NCT02951195|DRUG|Placebo|Placebo matched to VX-152.
219555601|NCT02951195|DRUG|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
219555602|NCT05002881|OTHER|Moringa oleifera (E-HS-01)|One capsule to be taken stat
219555603|NCT05002881|OTHER|Placebo|One capsule to be taken stat
219555604|NCT00793234|DRUG|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
219555605|NCT00793234|DRUG|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
219555606|NCT01848717|DEVICE|MINTLIFT®|
219555607|NCT03052855|OTHER|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
219721720|NCT03442569|DRUG|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
219721721|NCT03442569|DRUG|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
219721722|NCT05089357|BIOLOGICAL|AbobotulinumtoxinA|Participants received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U \[0.05 mL per injection site\] of study drug into 5 injection sites intramuscularly.
219721723|NCT04844775|BIOLOGICAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
219721724|NCT04844775|BIOLOGICAL|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)"
219721725|NCT04844775|BIOLOGICAL|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
219721726|NCT03734185|OTHER|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
219721727|NCT06971354|BEHAVIORAL|Biofeedback|Three sessions of biofeedback before and after a standardized meal.
219721728|NCT06971354|DIETARY_SUPPLEMENT|Placebo|Three sessions of placebo followed by standardized meal.
219721729|NCT04240704|DRUG|JBH492|Anti-CCR7 antibody-drug conjugate (ADC)
219721730|NCT06106997|RADIATION|brain radiotherapy|brain radiotherapy planned on synthetic CTs
219721731|NCT04549428|DRUG|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
219721732|NCT06417411|DRUG|Aspirin 100mg|Daily use of low dose aspirin.
219721733|NCT05325008|DRUG|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
219555608|NCT05838456|DEVICE|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
219555609|NCT00810706|DRUG|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
219555610|NCT00423709|PROCEDURE|Allogeneic Blood Stem Cell Transplantation|
219555611|NCT00423709|DRUG|Fludarabine|
219555612|NCT00423709|DRUG|Melphalan|
219555613|NCT06260501|OTHER|super-wet technique|Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
219555614|NCT03658148|PROCEDURE|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
219555615|NCT06277050|DRUG|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
219721734|NCT05325008|OTHER|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
219721735|NCT06059846|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets.
219721736|NCT06059846|DRUG|Imipenem-cilastatin|Sterile powder for reconstitution administered as IV.
219232330|NCT01706666|DRUG|cyclophosphamide|Given PO
219232331|NCT01706666|DRUG|lenalidomide|Given PO
219721737|NCT06059846|DRUG|Dummy Infusion|0.9% sodium chloride administered as IV infusion.
219721738|NCT06059846|DRUG|Dummy Tablets|TBP-PI-HBr matching dummy tablets.
219721739|NCT02193425|DRUG|F-18FDG|18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
219721740|NCT02193425|DEVICE|MRI|Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
219721741|NCT04376229|OTHER|Registry|Registry of cancer patients who receive proton radiation therapy
219555616|NCT06277050|DRUG|Maintenance Therapy with Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
219149388|NCT01583712|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
219149389|NCT04826445|OTHER|Data collection|Imaging collection
219149390|NCT00870207|BEHAVIORAL|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
219149391|NCT03114267|OTHER|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
219232332|NCT01706666|OTHER|laboratory biomarker analysis|Correlative studies
219232333|NCT01706666|DRUG|dexamethasone|Given PO
219232334|NCT01706666|PROCEDURE|quality-of-life assessment|Ancillary studies
219232335|NCT01249209|DEVICE|lifestyle advice|
219232336|NCT02732132|DRUG|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
219232337|NCT02732132|DRUG|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
219555617|NCT02719704|BEHAVIORAL|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
219555618|NCT02719704|BEHAVIORAL|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
219555619|NCT03934827|DRUG|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
219555620|NCT03934827|DRUG|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
219555621|NCT00971919|OTHER|questionnaire administration|
219555622|NCT00971919|PROCEDURE|assessment of therapy complications|
219555623|NCT00971919|PROCEDURE|psychosocial assessment and care|
219555624|NCT00971919|PROCEDURE|quality-of-life assessment|
219721742|NCT06485336|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
219721743|NCT06485336|DRUG|Placebo|Each tablet will be taken once daily for 84 days.
219721744|NCT05542056|OTHER|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
219721745|NCT05651919|BIOLOGICAL|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
219721746|NCT05651919|BEHAVIORAL|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
219721747|NCT05651919|BEHAVIORAL|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
219721748|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
219721749|NCT03678753|DRUG|Placebo|Matching Placebo
219721750|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 3 times daily for 8 weeks
219721751|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 6 times daily for 8 weeks
219721752|NCT06975748|DRUG|STSP-0902 Placebo|Eye drop, 3 or 6 times daily for 8 weeks
219721753|NCT06559189|BIOLOGICAL|CD19x22 CAR T|The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
219721754|NCT05211986|DRUG|IMM01-STEM|IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
219721755|NCT06198010|OTHER|Best Practice|Receive enhanced usual care
219721756|NCT06198010|OTHER|Educational Intervention|Receive ASCENT guide
219721757|NCT06198010|OTHER|Questionnaire Administration|Ancillary studies
219721758|NCT06198010|OTHER|Electronic Health Record Review|Ancillary studies
219721759|NCT06198010|PROCEDURE|Health Telemonitoring|Attend video or phone calls with a CHW and/or PCM
219721760|NCT06198010|BEHAVIORAL|Cancer Pain Management|Receive personalized pain management plan
219721761|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
219721762|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in newly implanted CI recipients with SSD.
219721763|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural loudness mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
219721764|NCT02099734|BEHAVIORAL|Questionnaires|
219721765|NCT02099734|OTHER|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
219721766|NCT05167721|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
219721767|NCT05167721|OTHER|Placebo|Placebo administered intrathecally
219721768|NCT00871013|DRUG|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 \& 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
219721769|NCT00871013|DRUG|Velcade|Given by vein, Days 1, 5, 8, 11
219721770|NCT00871013|DRUG|Thalidomide|Given by mouth at bedtime, Days 5-8
219721771|NCT00871013|DRUG|Dexamethasone|Given by mouth, once per day Days 5-8
219721772|NCT00871013|DRUG|Cisplatin|Given by vein, Days 5-8 continuous infusion
219721773|NCT00871013|DRUG|Adriamycin|Given by vein, days 5-8 continuous infusion
219721774|NCT00871013|DRUG|Cyclophosphamide|Given by vein days 5-8 continuous infusion
219721775|NCT00871013|DRUG|Etoposide|Given by vein days 5-8 continuous infusion
219721776|NCT06091241|PROCEDURE|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
219721777|NCT06091241|PROCEDURE|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
219721778|NCT05752487|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
219721779|NCT02457091|BEHAVIORAL|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
219149392|NCT05763524|PROCEDURE|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
219149393|NCT02620813|DRUG|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
219149394|NCT02620813|DRUG|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
219149395|NCT00158769|DRUG|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
219149396|NCT01652417|DRUG|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
219149397|NCT06968221|DEVICE|Bioabsorbable Staple Line Reinforcemen|cingular Bioabsorbable Staple Line Reinforcement
219149398|NCT00390273|DRUG|Metformin|
219149399|NCT04578392|PROCEDURE|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
219149400|NCT04578392|PROCEDURE|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
219149401|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
219149402|NCT02672722|DRUG|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
219149403|NCT02672722|OTHER|Exercise|
219149404|NCT02672722|OTHER|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
219149405|NCT03230942|OTHER|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
219149406|NCT03230942|OTHER|Pos-operative rehabilitation|Physical therapy treatment
219721780|NCT02457091|BEHAVIORAL|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
219721781|NCT02748772|DRUG|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
219721782|NCT02748772|DRUG|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
219149407|NCT05766189|BEHAVIORAL|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
219149408|NCT02997280|DRUG|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
219149409|NCT03316521|DRUG|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
219721783|NCT03356093|OTHER|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
219721784|NCT03238131|DRUG|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
219721785|NCT03238131|DRUG|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
219149410|NCT06453317|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
219149411|NCT06453317|BIOLOGICAL|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
219149412|NCT05545111|DRUG|NBI-1117568|Active treatment with orally administered NBI-1117568
219149413|NCT05545111|DRUG|Placebo|Placebo matching NBI-1117568
219149414|NCT06633614|DEVICE|Supervised prehabilitation programme|Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
219149415|NCT05894005|OTHER|Immersive Virtual Reality (IVR)|Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route.
219555625|NCT06616090|BEHAVIORAL|Nurse Implemented Infant-Mother Attachment Security Program|The intervention will draw on video-feedback of mother-infant interactions during the well-child visit. Nurses will videotape the dyad during routine visit in the Family Health Center and show short clips to mothers during the session in order to provide mother positive feedback on their sensitive caregiving. Additionaly, intervention mothers will be exposed to the reminders (e.g., pictures, posters, short film screenings) reflecting maternal sensitivity and secure attachment in the waiting rooms of the intervention Family Health Centers.
219555626|NCT06300827|OTHER|Structured digital-based training|The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
219555627|NCT05230602|DIETARY_SUPPLEMENT|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
219721786|NCT04976725|OTHER|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
219721787|NCT01243281|DRUG|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
219149416|NCT05894005|OTHER|Traditional 2-D Video|Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.
219149417|NCT06028074|DRUG|GIM122|GIM-122 administered IV once every 3 weeks or every 2 weeks
219721788|NCT03091439|DRUG|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
219721789|NCT03091439|DRUG|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
219149418|NCT04956757|OTHER|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
219149419|NCT06140953|DRUG|Trimetazidine|trimetazidine at dose 20 mg three times daily to be taken by intervention group
219149420|NCT06140953|DRUG|Conventional therapy|conventional therapy
219149421|NCT06140953|DRUG|Placebo|placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only
219149422|NCT06971848|OTHER|Drug skin tests (investigating hypersensitivity to a biotherapy)|allergologic skin tests (prick tests and intradermal tests)
219149423|NCT06647017|DEVICE|Volta tAN System|Transcutaneous auricular neurostimulation (tAN)
219149424|NCT06647017|DEVICE|SHAM Volta tAN System|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
219721790|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
219721791|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
219149425|NCT06821399|DIAGNOSTIC_TEST|Fundus Examination|Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
219149426|NCT06821399|DIAGNOSTIC_TEST|Metabolomics analysis|Conduct metabolomics testing at enrollment.
219149427|NCT04168541|OTHER|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
219149428|NCT06173765|OTHER|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
219232338|NCT05364385|DRUG|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
219555628|NCT02073006|DIETARY_SUPPLEMENT|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
219555629|NCT06204016|DRUG|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
219721792|NCT05598736|DEVICE|FlowOx 2.0|-40mmHg intermittent negative pressure for 60 minutes per day
219721793|NCT03808766|OTHER|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
219721794|NCT02198352|DRUG|BIBN 4096 BS - in single rising doses|
219721795|NCT02198352|DRUG|Placebo|
219149429|NCT06173765|OTHER|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
219721796|NCT00482092|DRUG|Prochymal®|Prochymal® IV infusion
219721797|NCT00482092|DRUG|Placebo|Prochymal® Placebo-matching IV infusion
219721798|NCT00776256|DIETARY_SUPPLEMENT|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
219721799|NCT05324696|DEVICE|autoinflation device|The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
219721800|NCT00822471|BEHAVIORAL|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
219721801|NCT06328088|DIETARY_SUPPLEMENT|Non vegetarian|Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
219721802|NCT02347618|RADIATION|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
219721803|NCT04075149|DRUG|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
219721804|NCT02425085|PROCEDURE|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
219721805|NCT02425085|PROCEDURE|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
219721806|NCT04023708|DRUG|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
219721807|NCT06430489|DRUG|Nitrous oxide|inhaled nitrous oxide (1 hour at 50% concentration)
219721808|NCT06430489|DRUG|Medical air|inhaled medical air (1 hour)
219721809|NCT02943213|DRUG|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
219721810|NCT01762787|DRUG|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
219721811|NCT01762787|DRUG|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
219721812|NCT01762787|DRUG|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
219149430|NCT06173765|OTHER|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
219555630|NCT06204016|DRUG|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
219721813|NCT01762787|DRUG|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
219721814|NCT01762787|DRUG|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
219721815|NCT00080262|DRUG|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
219149431|NCT04930159|BEHAVIORAL|Facilitated group support|Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.
219149432|NCT04930159|BEHAVIORAL|1:1 Peer Support|1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.
219721816|NCT01481493|BIOLOGICAL|BT061|subcutaneous administration of the monoclonal antibody BT061
219721817|NCT01481493|BIOLOGICAL|Placebo|subcutaneous injection of placebo
219721818|NCT00003723|DRUG|gemcitabine hydrochloride|Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
219721819|NCT04784689|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine
219721820|NCT01529996|PROCEDURE|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
219721821|NCT04507321|DRUG|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
219721822|NCT04507321|DRUG|[14C]-GSK3640254 intravenous infusion|\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
219721823|NCT04507321|DRUG|[14C]-GSK3640254 powder|\[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
219721824|NCT03561207|DIAGNOSTIC_TEST|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
219721825|NCT03579537|OTHER|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
219149433|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 20-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
219149434|NCT06016478|DIETARY_SUPPLEMENT|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219149435|NCT06016478|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
219149436|NCT04923724|DEVICE|tourniquet|tourniquet is a device used during total knee surgery.
219149437|NCT04923724|DEVICE|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
219149438|NCT05790837|BEHAVIORAL|"Computer prompt Stand up for your Health®"|"The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions."
219149439|NCT02265276|DRUG|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
219149440|NCT02265276|DRUG|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
219555631|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
219555632|NCT02877017|BEHAVIORAL|Family safety reporting intervention|family safety reporting intervention for families and providers
219555633|NCT02943993|DRUG|Edoxaban|Prescribed according to approved label
219555634|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
219555635|NCT04178096|OTHER|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
219555636|NCT05843890|BEHAVIORAL|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
219555637|NCT05843890|BEHAVIORAL|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
219555638|NCT04317820|BEHAVIORAL|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
219555639|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
219555640|NCT04658238|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
219555641|NCT04658238|OTHER|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
219555642|NCT05809466|OTHER|Vegan diet|A self-composed 12 week fully plant-based diet
219555643|NCT05809466|OTHER|Resistance exercise|Biweekly resistance exercise for 12 weeks
219555644|NCT05809466|OTHER|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
219555645|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
219555646|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
219721826|NCT03579537|OTHER|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
219721827|NCT03965364|DEVICE|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
219721828|NCT00523575|DIETARY_SUPPLEMENT|Cubitan|400 ml/d
219721829|NCT02756442|OTHER|Respiratory disorder assessment during sleep|
219721830|NCT03399084|DRUG|Ferric carboxymaltose|750 mg/15 mL
219721831|NCT01590875|DRUG|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
219721832|NCT00174668|DRUG|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
219721833|NCT00174668|DRUG|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
219721834|NCT00174668|DRUG|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
219721835|NCT04581512|DRUG|EP0042|EP0042 Oral 20 mg 50 mg capsules
219721836|NCT06121505|RADIATION|low-dose radiation therapy and stereotactic body radiation therapy|Patients will receive radiation therapy.
219721837|NCT06121505|DRUG|chemotherapy|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
219721838|NCT06121505|DRUG|Sintilimab|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
219721839|NCT03509090|PROCEDURE|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
219721840|NCT03509090|PROCEDURE|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
219721841|NCT01819662|OTHER|Enhanced standard management|Echocardiogram followed by letter to GP about results.
219721842|NCT01819662|OTHER|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
219721843|NCT01819662|OTHER|Standard management|Usual care
219721844|NCT02957643|DRUG|Iron|oral treatment
219721845|NCT02482844|OTHER|pacemaker implantation|
219721846|NCT02482844|OTHER|holter implantation|
219721847|NCT01214720|DRUG|bevacizumab [Avastin]|Intervenous repeating dose
219721848|NCT00323219|DRUG|Cefazolin and Moxifloxacin|See Detailed Description.
219721849|NCT02347787|BEHAVIORAL|IMPaCT|"The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
219721850|NCT02347787|OTHER|Usual care|
219149441|NCT06131268|DRUG|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
219721851|NCT05534672|OTHER|Rapamycin|Rapamycin in liquid administered orally
219149442|NCT06833411|DRUG|Prednisone|Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
219149443|NCT06833411|DRUG|Prednisone|Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
219721852|NCT05534672|OTHER|Placebo|Placebo in liquid administered orally
219721853|NCT06524518|DRUG|Chemotherapy combined with immunization|MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
219721854|NCT02399020|BEHAVIORAL|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
219721855|NCT04501692|PROCEDURE|VivaSight|see above
219721856|NCT04501692|PROCEDURE|Videolaryngoscopy|see above
219721857|NCT00709670|PROCEDURE|MSCT and stress echocardiography|tests MSCT and stress echocardiography
219721858|NCT02416141|DRUG|fast release oro dispersible tramadol 50 mg|idem arm 1
219721859|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
219721860|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
219149444|NCT06832761|BEHAVIORAL|Personalized lifestyle intervention|The lifestyle intervention in Group A comprises three parts (1) three individual consultations with a trained lifestyle coach, (2) a voucher program to encourage brain healthy activities, and (3) access to an online self-management tool for dementia risk reduction (www.breinzorg.nl).
219721861|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
219721862|NCT01456117|DRUG|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
219721863|NCT01170650|DRUG|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
219721864|NCT01170650|DRUG|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
219721865|NCT01170650|DRUG|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
219721866|NCT01170650|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
219721867|NCT02049632|PROCEDURE|Omission of axillary clearance|
219721868|NCT01059851|DRUG|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast
219721869|NCT04992533|PROCEDURE|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
219721870|NCT04992533|PROCEDURE|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
219721871|NCT03972228|COMBINATION_PRODUCT|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
219721872|NCT04245163|BEHAVIORAL|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
219721873|NCT07117643|OTHER|Ischemic Preconditioning|"The ischemic procedure will be carried out before the start of the WanT and eccentric exercises procedures and muscle damage in accordance with the detailed description of the RIPC procedure. Four-fold filling of the flotation flange will be performed by 5 minutes to the value of 200 mm Hg with 5 minutes' rest interval near the attachment of the initial straight thigh muscle. All performed procedures will be carried out under the Doppler USG control to perform full arterial blood flow restriction.~The whole research will be carried out in the Laboratory in morning hours. Each participant will be in a hydrated state and before the first meal."
219721874|NCT07117110|DIETARY_SUPPLEMENT|Supplement|Group will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
219721875|NCT07117110|OTHER|Tomato soup|Group will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil.
219721876|NCT07117864|COMBINATION_PRODUCT|T-DXd concurrent brain radiotherapy|T-DXd：5.4mg/kg ivgtt Q3w SRT/WBRT
219721877|NCT07120048|DEVICE|Edwards INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the Edwards INSPIRIS RESILIA Aortic Valve
219721878|NCT07117695|OTHER|Referral to the Duke Cardiometabolic Prevention Clinic|Patients who are referred to the cardiometabolic prevention clinic within the intervention arm will be evaluated first by a cardiology provider (as each patient has a history of ASCVD). On this initial visit, the cardiology provider will assess the patient's risk factor profile - to identify the presence of co-morbid conditions or uncontrolled risk factors. The need for additional referrals to other clinicians within the cardiometabolic clinic will specifically outlined criteria. These referrals will be offered to the patient and facilitated after the first visit. Preventive care will follow routine, evidence-based care. Clinicians within the cardiometabolic prevention clinic will meet bi-weekly to discuss enrolled patients, thus every individual in the intervention arm will receive coordinated, multi-specialty care.
219721879|NCT07120165|OTHER|Demographic data collection|Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history
219721880|NCT07120165|OTHER|Ophthalmological history|Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment
219721881|NCT07120165|OTHER|Ophthalmological data at each examination|Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.
219721882|NCT07120165|OTHER|Potential adverse events|Potential adverse events: halos, photophobia, stinging, infections, etc.
219721883|NCT07120360|OTHER|Gender-Based Microaggression Awareness and Prevention Psychoeducation Program|The psychoeducation program consisted of six modules aiming to increase awareness of microaggressions, develop coping and assertiveness skills, enhance critical thinking regarding gender roles, and reduce gender role stress. The program included theoretical knowledge, experiential learning, assertiveness training, and stress management strategies.
219721884|NCT05213130|OTHER|Information|A reminder to inform donors that their blood has saved patient's life in a questionnaire.
219721885|NCT00031993|DRUG|erlotinib hydrochloride|Given PO
219721886|NCT00031993|OTHER|laboratory biomarker analysis|Correlative studies
219149445|NCT04765111|DRUG|Acalabrutinib|Given PO
219721887|NCT00295685|DRUG|Antacids|
219149446|NCT04765111|BIOLOGICAL|Rituximab|Given IV
219149447|NCT04094038|DRUG|Olimel N12|A mixture of glucose, lipids, amino acids.
219721888|NCT05955833|DIAGNOSTIC_TEST|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
219721889|NCT02366416|BEHAVIORAL|Exercise training|Physical activity
219721890|NCT07123558|DIAGNOSTIC_TEST|High resolution anoscopy|to study biomarkers for anal cancer screening
219721891|NCT07044570|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
219721892|NCT07044570|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
219721893|NCT07044570|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
219721894|NCT07046338|GENETIC|Lentiviral TYF-ARSA correction of patient's autologous HSCs|Infusion of lentiviral TYF-ARSA modified autologous HSCs at 1\~10x10\^6 gene-modified cells per kg body weight.
219721895|NCT07045545|PROCEDURE|- Group A: Platelet-rich fibrin membrane prepared intraoperatively and applied over neourethra|In this arm, a platelet-rich fibrin membrane will be prepared intraoperatively from the patient's blood using centrifugation. The prepared PRF membrane will then be applied directly over the neourethra following urethroplasty to promote healing and tissue regeneration.
219721896|NCT07045545|PROCEDURE|Group B: Ventral dartos flap rotated over neourethra|Participants in this arm will undergo hypospadias repair with the application of a ventral dartos fascia flap. The procedure involves elevating a vascularized flap of ventral dartos fascia from the penile shaft, rotating it over the neourethra to provide additional tissue coverage and promote healing. This flap helps in reducing the risk of fistula formation and enhances vascular support to the neourethra. The surgical steps include dissecting the dartos fascia carefully, rotating it over the neourethral reconstruction, and securing it in place, followed by standard postoperative care and follow-up.
219721897|NCT04792892|OTHER|Questionnaires|Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
219721898|NCT07125911|DRUG|Ibuprofen 400 mg (if necessary)|Single oral dose of 400 mg ibuprofen administered in a blinded capsule. Prior to dosing, baseline pulpal sensibility tests (cold test with Endo-Ice and Electric Pulp Test) and pain rating (VAS) will be recorded on a contralateral healthy tooth and the target tooth with symptomatic irreversible pulpitis. The drug is given orally and tests are repeated 30 minutes after ingestion. Participants are monitored for adverse effects. Participants who cannot take NSAIDs are excluded
219721899|NCT07125911|DRUG|Paracetamol 500 mg|A single oral dose of 500 mg paracetamol administered in a blinded capsule. Baseline pulpal sensibility testing (cold test with Endo-Ice and Electric Pulp Test) and pain level assessment using a Visual Analogue Scale (VAS) will be performed on both the tooth with symptomatic irreversible pulpitis and a contralateral healthy tooth prior to administration. The same tests will be repeated 30 minutes after ingestion to evaluate any masking effect on test results.
219721900|NCT07118917|OTHER|Prehabilitation|Patients with COVID-19 history postponed for the surgery according to multidisciplinary decision.
219721901|NCT07118917|OTHER|No postponement|Patients who were COVID negative proceeded for surgery
219555647|NCT04880954|PROCEDURE|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
219555648|NCT04880954|OTHER|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
219555649|NCT05647291|DEVICE|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
219555650|NCT05647291|DRUG|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
219721902|NCT07123051|DEVICE|right colectomy|Robotic-assisted right colectomy with the DEXTER robotic surgery system
219721903|NCT07124377|OTHER|A complete physical examination of all body systems, including height and body weight|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721904|NCT07124377|OTHER|Neurological examination includes motor strength testing; sensory testing with pinprick, light touch, temperature, and proprioception; deep tendon reflexes; and gait assessment.|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721905|NCT07124377|DIAGNOSTIC_TEST|Electrocardiogram (12-lead ECG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721906|NCT07124377|DIAGNOSTIC_TEST|24-Hour Holter Monitoring|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721907|NCT07124377|DIAGNOSTIC_TEST|"Color Doppler echocardiography with two-dimensional strain (longitudinal strain)"|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721908|NCT07124377|OTHER|The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721909|NCT07124377|OTHER|questionnaire, the NIS-LL (Neuropathy Impairment Score in the Lower Limbs)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721910|NCT07124377|OTHER|COMPASS-31 (Composite Autonomic Symptom Score-31)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721911|NCT07124377|DIAGNOSTIC_TEST|Electromyogram (EMG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219149448|NCT04094038|DRUG|Glucose IV|Glucose 5%
219149449|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
219149450|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
219149451|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
219149452|NCT06222567|DEVICE|15 minutes pumping with INITIATE program|15 minutes pumping with INITIATE program
219149453|NCT06222567|DEVICE|5 minutes extra pumping with MAINTAIN program|Additional 5 minutes extra pumping with MAINTAIN program
219149454|NCT05334004|DRUG|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
219149455|NCT04854863|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
219149456|NCT01402479|DRUG|Ramipril|ramipril 2.5mg twice a day
219149457|NCT06409299|DRUG|Azithromycin 40 MG/ML|Maintenance Antibiotic treatment
219149458|NCT06409299|OTHER|Placebo|Placebo
219721912|NCT07124377|DIAGNOSTIC_TEST|[99mTc]Tc-DPD scintigraphy|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
219721913|NCT07124377|DIAGNOSTIC_TEST|Laboratory assessments|Laboratory assessments include blood and urine sample collection for serum chemistry, hematology, and urinalysis, with specific biomarker analyses (troponin T, NT-proBNP, Kappa, and Lambda light chains
219721914|NCT07086651|DRUG|Enzalutamide|As provided in real-world setting
219721915|NCT07086651|DRUG|Apalutamide|As provided in real-world setting
219721916|NCT07086183|OTHER|Observation|Observation of intraoperative and postoperative outcomes
219721917|NCT07083843|BEHAVIORAL|Exercise|Intervention, will receive home based exercise multi times per week for 6 months
219721918|NCT07083843|OTHER|Standard medical treatment|Control group will receive the usual standard care.
219721919|NCT07113210|DRUG|pilocarpine HCL ophthalmic solution|Qlosi will be given to participants and quality of life will be determined.
219721920|NCT07117201|BEHAVIORAL|Culturally Tailored Cooking Classes|Cooking skills session will be offered by the Delicious Legacy Program. The Delicious Legacy program is a culturally tailored, community-based nutrition and wellness intervention designed to promote health equity. Rooted in the intergenerational transmission of knowledge, the program emphasizes family socialization practices related to food, health beliefs, and caregiving. It integrates evidence-based nutritional education with ancestral foodways to address diet-related chronic illnesses while fostering cultural pride and resilience. Through interactive workshops, individuals engage in hands-on learning that reinforces traditional roles in food preparation and shared meals as sites of emotional support and identity formation. Dr. Haynes will lead the cooking sessions and create cardiometabolic-appropriate recipes.
219721921|NCT07117201|BEHAVIORAL|Prescription Produce Plan|The standard PPP includes three major parts. 1) Screening and personalized referrals/support for social needs including food, housing, health insurance and transportation by a community health worker. 2) Bi-weekly wellness visits with an MHWP team of interprofessional healthcare students, supervised by a clinical faculty, and guided by the participants' health and social needs and interests. They include education and SMART-EST goals around nutrition, physical activities, chronic disease management, care coordination, and/or recipes. 3) Delivery of a bag of fresh fruits and vegetables as well as heart healthy food items every two weeks over a period of 12 months. The produce bags will be made by the Underground Kitchen, a local non-profit organization creating curated bags of healthy food items and recipes to support the prevention and management of chronic diseases.
219721922|NCT07118033|PROCEDURE|Specific Manual Therapy|Participants in this group receive a standardized physiotherapy program (exercise and education) plus 5 minutes of targeted lumbar postero anterior mobilizations. These mobilizations are selected using the Algo K decision algorithm, which guides the therapist to choose the most appropriate technique based on the patient's pain response during preliminary movement tests.
219721923|NCT07118033|PROCEDURE|Non specific Manual Therapy|Participants in this group receive the same physiotherapy program, but the additional 5 minutes of mobilization are applied to the upper thoracic spine (T4-T7), away from the symptomatic lumbar region. This sham mobilization mimics the manual therapy without targeting the affected area or following the algorithm's logic.
219149459|NCT00925899|DRUG|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
219721924|NCT07121465|BEHAVIORAL|Education group|"First stage: Pregnant women will be administered a Personal Information Form, the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale. Second stage: In this stage, pregnant women will be given a 60-minute breastfeeding education session.~Third stage: This stage will take place one week after the second stage, and pregnant women will receive baby care training. The training will be conducted face-to-face in the training room of the hospital where the study will be conducted, using the training manual prepared by the researchers according to Mercer's theory as a guide.~Fourth stage: In this stage, pregnant women will again be administered the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
219149460|NCT00925899|DRUG|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
219721925|NCT07121465|BEHAVIORAL|Control group|"First stage: In this stage, pregnant women will be informed about the study and their voluntary written consent will be obtained. They will then complete a Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale.~Second stage: Pregnant women will be administered the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
219721926|NCT07121426|OTHER|Lower limb Intensive Functional Training|LIFT will help the child in motor learning, skill progression and resistance training to target the strength, proprioception and coordination impairments of the lower extremities. Motor learning will be based on Strength domain (Cycling) . Balance and Coordination domain involves activities such as (ball kicking with alternate legs and Static standing) Proprioception domain (Vertical jumping, sit to stand and cursing) while applying knee-immobilizers if needed.
219721927|NCT07121426|OTHER|Conventional physical therapy|Stretching followed by Strengthening program and traditional gait training at clinical setting. Stretching muscles were hip flexors, hip adductors, hamstrings and calf and stretching applied for 30 sec with 30 sec rest for 3-5 times for each muscle group with in pain limit followed by strengthening exercise for week muscle which includes the strengthening of anti-gravity muscles of lower limb they are: Quadriceps, Gluteus maximus and soleus performed in 3 groups. Each group contain 10 rep for each week muscle group.
219721928|NCT07119684|BEHAVIORAL|Short-Duration Walking Exercise|articipants performed three 10-minute walking sessions per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
219721929|NCT07119684|BEHAVIORAL|Long-Duration Walking Exercise|Participants performed one continuous 30-minute walking session per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
219721930|NCT07119255|PROCEDURE|PRP Pharmacopuncture|Participants in the PRP pharmacopuncture arm will receive a single administration of platelet-rich plasma (PRP) via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
219721931|NCT07119255|PROCEDURE|Placebo Pharmacopuncture|Participants in the placebo pharmacopuncture arm will receive a single administration of normal saline via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
219149461|NCT05049434|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
219149462|NCT05049434|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
219149463|NCT02198469|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
219149464|NCT02198469|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
219149465|NCT00683696|DEVICE|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
219149466|NCT02396316|DRUG|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
219149467|NCT02396316|DRUG|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
219149468|NCT00835952|DRUG|ATX-101|ATX-101 single doses
219149469|NCT05627336|DIAGNOSTIC_TEST|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
219149470|NCT01234363|DEVICE|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
219555651|NCT05647291|DEVICE|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
219555652|NCT05363241|PROCEDURE|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
219555653|NCT05363241|PROCEDURE|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
219555654|NCT01408888|BIOLOGICAL|LY2189265|Administered subcutaneously
219555655|NCT01408888|DRUG|Sitagliptin|Administered orally
219555656|NCT06249893|OTHER|Point-of-care vascular ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
219555657|NCT01990807|DRUG|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
219555658|NCT03700398|DEVICE|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
219555659|NCT03700398|DEVICE|first WLI|the routine in the clinical practice
219555660|NCT04425577|DIAGNOSTIC_TEST|Transabdominal Ultrasound|Transabdominal Ultrasound
219555661|NCT03166904|DRUG|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
219555662|NCT03209167|BEHAVIORAL|Questionnaire|Two study-specific questionnaires
219555663|NCT06070545|OTHER|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
219555664|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
219555665|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
219555666|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
219555667|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
219555668|NCT00264381|DRUG|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
219555669|NCT04395196|DIETARY_SUPPLEMENT|Choline bitartrate|Provided in beverage form
219149471|NCT03724578|DRUG|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
219149472|NCT03724578|DRUG|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
219555670|NCT04395196|DIETARY_SUPPLEMENT|Placebo|Provided in beverage form
219149473|NCT03724578|DRUG|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
219149474|NCT04581733|DRUG|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
219149475|NCT02189252|DRUG|Epanova|
219149476|NCT02189252|DRUG|Lovaza|
219149477|NCT03941119|OTHER|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
219555671|NCT05916248|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
219555672|NCT05916248|BIOLOGICAL|PD-1 inhibitor|pembrolizumab
219555673|NCT06166264|OTHER|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
219555674|NCT06166264|OTHER|Control group|The participants will receive information regarding health education.
219555675|NCT04542694|DRUG|Favipiravir|200 mg coated tablets
219555676|NCT04542694|DRUG|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
219555677|NCT04746079|BEHAVIORAL|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
219555678|NCT00217724|DIETARY_SUPPLEMENT|glutamine|Given orally
219555679|NCT00217724|OTHER|placebo|Given orally
219555680|NCT03490916|DRUG|Acetazolamide|Administration of Acetazolamide
219555681|NCT03490916|DRUG|Placebo|Administration of Placebo
219555682|NCT00969124|DEVICE|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
219555683|NCT04022824|OTHER|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
219555684|NCT04022824|OTHER|Non-OSA|Patients without OSA (apnea hypopnea index \<15) based on sleep study
219555685|NCT05344716|DEVICE|Laser|Intraurethral and vaginal laser treatment
219555686|NCT05081336|DRUG|Statin|Statin +/- ezetimib +/- Alirocumab
219555687|NCT05690815|DRUG|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
219555688|NCT06103279|DRUG|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
219555689|NCT05897385|DRUG|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
219555690|NCT05897385|DRUG|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
219555691|NCT05633186|BEHAVIORAL|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
219555692|NCT05633186|BEHAVIORAL|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
219149478|NCT00840177|DRUG|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
219555693|NCT05633186|BEHAVIORAL|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
219721932|NCT07121283|DEVICE|True AI|True output from bone age AI
219721933|NCT07121283|DEVICE|Fake AI|Randomized output from bone age AI
219721934|NCT07120607|BIOLOGICAL|CD7 CAR-γδT cell（QH106）|Allogenic CD7 CAR-γδT cell，Intravenous on day0; dose escalation (3+3) : dose 1 (1 × 10\^8 CAR+ cells) , dose 2 (3 × 10\^8CAR+ cells/kg，dose 3 (6× 10\^8 CAR+ cells）;
219721935|NCT07120607|DRUG|Fludarabine (FLU)|Intravenous fludarabine 30\~50 mg/m\^2/day on days-5, -4, and -3；
219149479|NCT00840177|DRUG|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
219149480|NCT00840177|DRUG|pravastatin sodium|1,280 mg/day given orally on days 1-8
219149481|NCT01391832|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
219149482|NCT01391832|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
219149483|NCT01391832|DEVICE|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
219721936|NCT07120607|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
219149484|NCT03618524|OTHER|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
219555694|NCT05633186|BEHAVIORAL|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
219555695|NCT02167594|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
219555696|NCT02167594|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
219555697|NCT04237350|BEHAVIORAL|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
219555698|NCT01535911|OTHER|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
219555699|NCT02926651|DRUG|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
219555700|NCT02926651|DRUG|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
219555701|NCT04413968|DIAGNOSTIC_TEST|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
219555702|NCT04413968|DIAGNOSTIC_TEST|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
219555703|NCT04413968|DIAGNOSTIC_TEST|Stool collection|Stool collection in children
219555704|NCT05066568|DEVICE|Active Tracranial Direct Current Stimulation|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
219555705|NCT05066568|OTHER|Hypnotic analgesia suggestion|The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
219555706|NCT05066568|BEHAVIORAL|Rest|The patient is asked to remain seated still for 20 minutes.
219721937|NCT07120737|DEVICE|H.A.L.T. MAX spectacles|The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression
219721938|NCT07119606|DIAGNOSTIC_TEST|SHANK3 mutation|blood sampling for diagnostic test
219721939|NCT07119970|BIOLOGICAL|Additional blood sampling|At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis
219721940|NCT07119515|BEHAVIORAL|Third-Wave CBT via Teletherapy|Twelve weekly 40-minute remote sessions via video conferencing, including mindfulness, behavioral activation, and exposure therapy.
219149485|NCT04787653|DEVICE|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
219149486|NCT04787653|DEVICE|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
219149487|NCT05052450|OTHER|Observational|Patients data were collected throughout the following time
219149488|NCT01154985|DRUG|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
219149489|NCT01154985|DRUG|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
219149490|NCT01154985|DRUG|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
219149491|NCT04949503|DRUG|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
219232339|NCT05364385|DRUG|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
219232340|NCT00059384|BEHAVIORAL|Concentration-controlled therapy|
219232341|NCT00145145|BIOLOGICAL|MAGE-3.A1 peptide and CpG 7909|
219232342|NCT05330000|DRUG|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
219232343|NCT05330000|DRUG|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
219721941|NCT07119515|BEHAVIORAL|Third-Wave CBT In-Person|Twelve weekly 40-minute face-to-face sessions with identical third-wave CBT content.
219721942|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Single subcutaneous dose of GB-0895
219721943|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Multiple subcutaneous doses of GB-0895
219721944|NCT07116889|DRUG|Placebo (SC)|Single subcutaneous dose of placebo
219721945|NCT07116889|DRUG|Placebo (SC)|Multiple subcutaneous doses of placebo
219721946|NCT07120633|OTHER|AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients|After chemotherapy, the tumors of the patients in the experimental group were re-graded to determine the basic burden status of the tumors. It should include imaging diagnosis, physical examination, laboratory tests of blood, assessment of bone marrow MRD and evaluation of the toxic and side effects of chemotherapy, etc
219721947|NCT07120347|OTHER|Remote Ambient Sensor System|Remote sensors (motion, door contact) deployed in participants' home connected through raspberry pi and mobile hotspot
219721948|NCT07119073|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 50 mg dose of Cox-1301 during each sequence. Subjects will serve as their own control.
219721949|NCT07116798|OTHER|Exercise|Strengthening Exercises Based on Proprioceptive Neuromuscular Facilitation Patterns
219721950|NCT07116798|OTHER|Exercise|Plyometric Exercises
219721951|NCT07116928|DRUG|ganagliflozin|50 mg Once daily, 120 weeks
219721952|NCT07116928|DRUG|Placebo|50 mg Once daily, 120 weeks
219721953|NCT07119151|DEVICE|Dental Implant|Dental Implant placement and loading.
219721954|NCT07120672|OTHER|patients were monitored for reentubation for 48 hours.|patients were monitored for reentubation for 48 hours.
219721955|NCT07120672|OTHER|weaning group|patients were monitored for reentubation for 48 hours.
219721956|NCT07122531|OTHER|Medium chain triglyceride oil|Supplementation with 15 g of medium chain triglyceride oil, a food product commercially available over-the-counter in regular grocery stores, emulsified in beverage of choice, twice daily (morning and evening) for 12 weeks.
219721957|NCT07123896|DEVICE|Normal treatment with catheter ablation or medicine|Routine clinical care with catheter ablation and/or medicine; real-world clinical cases
219721958|NCT07123896|DRUG|Drug Treatment|Routine clinical care with medicine; real-world clinical cases
219721959|NCT07123610|BEHAVIORAL|Mediterranean Diet Education Program|"The intervention consists of a 4-week Mediterranean Diet Education Program designed specifically for nurses working rotating shifts.~The program included four weekly group sessions, each lasting approximately 60 minutes, delivered in-person by a registered dietitian with training in behavioral change and clinical nutrition. Sessions are interactive and supported by visual and printed educational materials.~Participants receive a printed handbook including a food pyramid graphic, portion guides, weekly shopping lists, and sample menus tailored to shift work schedules. They also gain access to a moderated online discussion group and receive weekly motivational text messages to reinforce key messages.~No food is provided directly."
219721960|NCT07122804|OTHER|Assessment|Within the scope of the study, without any intervention, data regarding the participants' hyperventilation symptoms and physical capacities will be evaluated.
219232344|NCT03406390|PROCEDURE|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
219232345|NCT02481011|DRUG|antithrombotic drugs|
219149492|NCT04117789|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
219149493|NCT04117789|BEHAVIORAL|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
219149494|NCT04117789|OTHER|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
219149495|NCT02711436|DEVICE|Computed Tomography Scan|
219149496|NCT02711436|DEVICE|Fast Magnetic Resonance Imaging|
219232346|NCT03489356|BEHAVIORAL|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
219232347|NCT00428714|DRUG|enzastaurin|Administered orally
219232348|NCT04728282|PROCEDURE|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
219232349|NCT04728282|PROCEDURE|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
219232350|NCT01681511|DEVICE|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
219232351|NCT01681511|DEVICE|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
219232352|NCT04725032|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
219232353|NCT04725032|DRUG|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
219721961|NCT07122284|DIAGNOSTIC_TEST|13C-Urea Breath Test|Participants underwent the 13C-urea breath test following a standardized protocol to detect active Helicobacter pylori (H. pylori) infection. After an overnight fast (≥8 hours), baseline breath samples were collected by exhaling gently through a straw. Participants then ingested 75 mg of 13C-labeled urea dissolved in 50 mL of citric acid solution to delay gastric emptying and maximize urease exposure. A second breath sample was collected 30 minutes post-ingestion using identical procedures.
219721962|NCT07122284|DIAGNOSTIC_TEST|Hydrogen-Methane Breath Test|Participants underwent a standardized hydrogen-methane breath test to evaluate for small intestinal bacterial overgrowth (SIBO) or carbohydrate malabsorption. After a 12-hour overnight fast, baseline breath samples were collected via controlled end-expiratory exhalation. Participants then ingested a substrate solution.
219721963|NCT07122726|PROCEDURE|Otago and PNF exercise|"Otago Exercise:~This 6-week protocol focuses on strengthening and balance exercises. It starts with supported exercises and progresses to unsupported ones. Exercises include knee flexors, extensors, and hip abductors with ankle weights, ankle plantar and dorsiflexors, knee bends, backward stepping, walking and turning, sideways walking, tandem stance, and one-leg stance. Repetitions increase over time, from 10-20 reps with support to 30 reps without support.~PNF Exercise The PNF protocol consists of 6 levels, progressing from simple to complex exercises. Level 1 involves D1/D2 patterns for ankle and hip with light resistance, while Level 2 focuses on seated D1/D2 patterns for the lower limb. Levels 3-6 introduce more dynamic exercises, including arm reaches while standing, PNF walking, dynamic step-ups, walking on unequal terrain, and obstacle navigation. The protocol emphasizes approximation, stabilization, resistance, and dynamic reversals to improve proprioception \& balance."
219721964|NCT07122726|PROCEDURE|Otago Exercise|Knee Flexors, Knee Extensors, Hip-abductors- 10 reps of each Exercise with ankle weights to provide muscle resistance. For ankle planter flexors and dorsi flexors starting from 20 repetitions at week 1 with hold support and ending at 30 repetitions without any support on 6th week. For knee bends starting with 10 reps at week 1 and ending at 30 reps without support at 6th week. Backward stepping 10 times 2 steps backward at week 1 progressing to 10 times x 4 Steps x No Support at week 6 gradually. Walking and Turning Around- (make a figure of 8), twice, first with support and then without support. Sideways Walking- 10 steps, 4 times x first with support and then without support over the time of 6 weeks. Tandem Stance- 10 seconds first with support and then without support. Tandem Walk/ 20 reps first with support and then without support over the period of 6 weeks.
219232354|NCT00390845|DRUG|SB681323|15 milligrams (mg)/day
219232355|NCT00390845|DRUG|Placebo|
219232356|NCT04733417|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
219232357|NCT04733417|DRUG|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
219232358|NCT04813133|OTHER|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
219232359|NCT04813133|OTHER|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
219232360|NCT04813133|OTHER|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
219232361|NCT04875767|DEVICE|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
219232362|NCT01072838|RADIATION|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
219232363|NCT01072838|DEVICE|Contura MLB Breast Brachytherapy Catheter|
219232364|NCT03153176|BEHAVIORAL|Training|Training program 30 hours accumulated before, during and after intervention
219721965|NCT07123948|DIAGNOSTIC_TEST|Wechsler Intelligence Test, performed by educated psychologists|"At the age of six, parents of children who meet the inclusion criteria will receive a notification about the study from the responsible paediatrician. If they agree to participate, they will sign an informed consent form. They will then be invited to the clinic for a neurological and neurodevelopmental assessment. The neurological examination will be conducted by the principal investigator or collaborators who are paediatric specialists. The neurodevelopmental evaluation will be performed by a qualified psychologist using the Wechsler Intelligence Test.~The Wechsler Intelligence Test for Children - Fourth Edition is a clinical tool for measuring the intelligence of children aged 6 to 16 years and 11 months. It assists in identifying specific learning difficulties, hyperactivity disorder, speech and language challenges, and intellectual impairments. The test comprises 15 subtests."
219721966|NCT07122388|DIAGNOSTIC_TEST|Questionnaires about autism spectrum disorders and sleep and PSG.|Recruitment of subjects with autism spectrum disorder at all developmental ages and of all severity levels.
219721967|NCT07122388|DIAGNOSTIC_TEST|ADOS-2, ADI-R, SRS-2, PSG|Recruitment of subjects with autism spectrum disorder at all developmental ages and all severity levels.
219721968|NCT07122778|DIETARY_SUPPLEMENT|Controlled energy-deficit diet|Participants receive a prepared diet providing approximately 50% of their estimated daily energy expenditure to induce a sustained energy deficit
219721969|NCT07122778|DIETARY_SUPPLEMENT|Habitual diet with surplus snacks|Participants continue their normal diet with the addition of high-calorie snack items to achieve an approximate daily energy surplus
219721970|NCT07123909|DEVICE|Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.|The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month
219721971|NCT07123428|DRUG|TRD205|TRD205 tablet
219721972|NCT07123428|DRUG|Placebo|TRD205 placebo tablet
219721973|NCT07121816|DEVICE|ECG watch|ECG watch in palpitation assessment
219721974|NCT07123870|DRUG|Sevofluorane|In this group of patients, \<0.5 MAC sevoflurane will be used in combination with TIVA. (TIVA method described above)
219149497|NCT03825978|BEHAVIORAL|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
219149498|NCT04295915|DEVICE|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
219149499|NCT01485653|DRUG|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
219149500|NCT00566735|DRUG|Razadyne|The starting dose of study medication is 4 mg twice a day
219149501|NCT00566735|DRUG|Placebo|4 mg, 2 times a day
219149502|NCT05986734|DRUG|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
219721975|NCT07123870|DRUG|Desflurane|In this group of patients, \<0.5 MAC Desflurane will be used in combination with TIVA.
219721976|NCT07123870|DRUG|Total Intravenous Anesthesia(TIVA)|In this group, TIVA will be applied with the combination of BIS-guided propofol + remifentanil.
219149503|NCT00402896|DRUG|ZD6474|300 mg/day orally for 10 weeks.
219149504|NCT00654589|DRUG|Deferasirox|
219721977|NCT07123116|DRUG|Shenbai Granules|Dosage: bag 10g per , administered twice daily continuously for 180 days.
219721978|NCT07123116|DRUG|Placebo|Dosage: 10g per bag, administered twice daily continuously for 180 days.
219721979|NCT07121842|DIAGNOSTIC_TEST|Extended MRI|The MRI protocol for every clinical follow-up MRI scan is extended with 15 minutes to add the APTw-CEST scan.
219721980|NCT07123207|DIETARY_SUPPLEMENT|Bacillus subtilis Capsules|"Bacillus subtilis is a type of probiotic. Studies have found that supplementation with Bacillus subtilis can effectively maintain the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping the structure and function of the microbiota.~Bacillus subtilis capsules are a Bacillus supplement containing 3×10⁹ CFU of Bacillus subtilis per capsule. Patients in the Bacillus subtilis supplementation group take Bacillus subtilis capsules orally once a day, one capsule each time, for 12 weeks."
219721981|NCT07122934|DIAGNOSTIC_TEST|Assessment of cervico-cerebral arterial occlusion pattern|Assessment of cervico-cerebral arterial occlusion pattern for the development of a radiological score
219721982|NCT07118332|DRUG|Psilocybin (drug)|25mg of Psilocybin will be given to all subject
219721983|NCT07122453|DRUG|CNTX-3001|non-opioid analgesic
219721984|NCT07122453|DRUG|Placebo|Placebo product
219721985|NCT07124273|PROCEDURE|Standardized Mandibular Anesthesia Protocol|Participants receive an inferior alveolar nerve block (IANB) using 1.8 ml 4% articaine with 1:100,000 epinephrine (Ultracaine DS Forte) via a 27-gauge dental needle, followed by buccal and lingual infiltration anesthesia after 5 minutes. Topical 10% lidocaine spray is applied prior to injection. All procedures are performed by the same clinician between 09:00-12:00. Salivary cortisol, pulse oximetry, and pain assessments are conducted before and after the anesthesia.
219721986|NCT07125131|OTHER|Gamification-Enhanced Problem-Based Learning|An educational intervention combines principles of problem-based learning (PBL) with game design elements including scores, leaderboards, digital badges, challenges, immersive experiences, feedback and rewards into problem-based learning.
219149505|NCT05514275|DRUG|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
219149506|NCT00925587|DRUG|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
219149507|NCT00274417|DRUG|dutasteride|
219149508|NCT05602285|DEVICE|Dislodgement device|Breakaway device that prevents IV dislodgement
219721987|NCT07125131|OTHER|Conventional didactic lecture (usual practice)|A didactic teaching approach in which course content is delivered to nursing students primarily through PowerPoint presentation by lecturer.
219721988|NCT07125066|DRUG|Sodium phenylbutyrate|open-label design with doses of sodium phenylbutyrate
219721989|NCT07125274|DIAGNOSTIC_TEST|Biomarker-guided diagnostic tests|mRNA-Signature from blood; immunophenotyping from blood; MBLA from sputum, PATHFAST-LAM and EclLAM from sputum, stool, urine; CRISPR-Cas from blood; stool PCR; QuantiFERON(R)-TB Gold Plus.
219721990|NCT07125001|OTHER|Ataulfo mango|4 weeks of Ataulfo mango intake
219721991|NCT07124325|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device and online dashboard for remote pregnancy care
219721992|NCT07124104|BEHAVIORAL|Positive Psychotherapy-Based Self-Compassion Training|Participants in the experimental group will receive Positive Psychotherapy-Based Self-Compassion Training, while participants in the control group will not receive any intervention.
219721993|NCT07125989|DEVICE|non-invasive ventilation|During the patient's first three respiratory rehabilitation sessions, each test on the cycle ergometer will be performed at 70% of maximum power (defined during the initial oxygen consumption (VO2) test) with ventilatory assistance at a different intensity (Low, moderate or high intensity).
219721994|NCT07125872|BIOLOGICAL|CD19 t-haNK- IV Administration|"N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory T cells. N-803 SQ differs from other cytokine therapies due to its improved pharmacokinetic profile, enhanced in vivo activity, and reduced toxicity.~CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and eliminate CD19-expressing B-cell malignancies. These therapies differ from traditional chemotherapy or small molecule inhibitors by leveraging the patient's immune system to achieve targeted cytotoxicity. Their mechanism of action involves direct binding to the CD19 antigen on malignant B cells, leading to immune-mediated cell death."
219721995|NCT07124182|OTHER|shewing gum|Chewing gum is a cost-effective practice that can provide comfort to women. A Pap smear is an important test. Women experiencing pain, anxiety, or other symptoms may discourage testing. Chewing gum can reduce these sensitivities.
219721996|NCT07125430|OTHER|strengthening exercise|a strengthening exercise program will be carried out for three weeks
219721997|NCT07125430|OTHER|shock wave|3 sessions of shock wave therapy, frequency of one session per week
219721998|NCT07125443|DRUG|"Prospective iNO Administration (After Group)"|Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.
219721999|NCT07125443|OTHER|"No Intervention Retrospective Before Group"|Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.
219722000|NCT07125391|DRUG|Cohort A|received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy
219722001|NCT07124962|PROCEDURE|Root Canal Therapy|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
219722002|NCT07124962|PROCEDURE|Platelet-Rich Plasma (PRP) Revascularization|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
219722003|NCT07123662|BIOLOGICAL|Gamma-Delta T cell injection|Experimental group: Peripheral intravenous infusion of γδ T cells
219555707|NCT05066568|OTHER|Active tDCS + Hypnotic analgesia suggestion|"Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance."
219555708|NCT05066568|OTHER|Sham tDCS + Hypnotic analgesia suggestion|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
219555709|NCT02997878|BIOLOGICAL|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
219722004|NCT07123662|OTHER|Standard prophylactic treatment|Standard prophylactic treatment
219232365|NCT03153176|BEHAVIORAL|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
219232366|NCT03153176|BEHAVIORAL|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
219555710|NCT02786953|BEHAVIORAL|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
219149509|NCT01175317|PROCEDURE|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
219555711|NCT02088333|BEHAVIORAL|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
219555712|NCT02088333|BEHAVIORAL|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
219722005|NCT07121907|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
219149510|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
219149511|NCT00445952|OTHER|clinical observation|
219149512|NCT00445952|PROCEDURE|management of therapy complications|
219149513|NCT02368626|DEVICE|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
219149514|NCT02089763|BIOLOGICAL|pegylated recombinant human arginase|
219149515|NCT02164240|DRUG|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
219149516|NCT02164240|DRUG|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
219555713|NCT03394833|OTHER|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
219555714|NCT02241798|OTHER|oxygen|O2 by nasal prongs
219555715|NCT01745068|OTHER|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
219555716|NCT05399056|BEHAVIORAL|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
219555717|NCT05399056|BEHAVIORAL|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
219555718|NCT04785963|BEHAVIORAL|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
219555719|NCT04785963|BEHAVIORAL|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
219555720|NCT04785963|BEHAVIORAL|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
219555721|NCT02483507|OTHER|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
219555722|NCT02375750|DEVICE|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
219555723|NCT02375750|OTHER|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
219555724|NCT00252564|DRUG|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
219555725|NCT00252564|DRUG|Oxaliplatin|85 mg/m2 on Days 1 and 15
219555726|NCT00252564|DRUG|Leucovorin|400 mg/m2 on Days 1 and 15
219555727|NCT00252564|DRUG|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
219555728|NCT00252564|DRUG|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
219555729|NCT02173964|DRUG|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
219555730|NCT02173964|DRUG|water|same amount of water for pinverin administration
219555731|NCT04333264|PROCEDURE|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
219555732|NCT04333264|PROCEDURE|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
219555733|NCT00135187|DRUG|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
219555734|NCT00135187|DRUG|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
219555735|NCT00135187|DRUG|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
219555736|NCT00994604|DRUG|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
219555737|NCT02039635|DIETARY_SUPPLEMENT|Korean Red Ginseng|Given Orally
219555738|NCT02039635|DIETARY_SUPPLEMENT|Placebo|Given Orally
219555739|NCT03513549|DRUG|Loxapine 10 MG|
219722006|NCT07119398|COMBINATION_PRODUCT|Oxytocin plus Foley Catheter|Intravenous oxytocin and a transcervical Foley catheter
219722007|NCT07119398|DRUG|Oxytocin|Intravenous oxytocin
219722008|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
219722009|NCT00049595|BIOLOGICAL|bleomycin sulfate|
219722010|NCT00049595|BIOLOGICAL|filgrastim|
219722011|NCT00049595|BIOLOGICAL|pegfilgrastim|
219722012|NCT00049595|DRUG|ABVD regimen|
219722013|NCT00049595|DRUG|BEACOPP regimen|
219722014|NCT00049595|DRUG|cyclophosphamide|
219722015|NCT00049595|DRUG|dacarbazine|
219722016|NCT00049595|DRUG|doxorubicin hydrochloride|
219722017|NCT00049595|DRUG|etoposide|
219722018|NCT00049595|DRUG|prednisone|
219722019|NCT00049595|DRUG|procarbazine hydrochloride|
219722020|NCT00049595|DRUG|vinblastine sulfate|
219722021|NCT00049595|DRUG|vincristine sulfate|
219722022|NCT05429840|DRUG|MT1980|single dose
219722023|NCT05429840|DRUG|Placebo|single dose
219722024|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
219722025|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
219722026|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
219722027|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
219722028|NCT05286762|DRUG|Placebo|Subjects will be randomized at Visit 2 to Placebo
219722029|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
219722030|NCT06937619|DRUG|Risankizumab|Subcutaneous Injection
219722031|NCT06938529|DRUG|VCT220|Small molecule GLP-1RA tablet, film coated
219722032|NCT06938529|DRUG|Placebo|VCT220 Placebo tablet
219722033|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
219722034|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
219722035|NCT03383575|DRUG|Azacitidine|Given IV or SC
219722036|NCT03383575|DRUG|Enasidenib|Given PO
219722037|NCT03383575|OTHER|Quality-of-Life Assessment|Ancillary studies
219722038|NCT03537963|OTHER|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
219722039|NCT03537963|OTHER|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
219722040|NCT03537963|OTHER|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
219722041|NCT03537963|OTHER|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
219722042|NCT03537963|OTHER|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
219722043|NCT03537963|OTHER|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
219722044|NCT06948565|OTHER|observational study|This observational study aims to describe the clinical practices and the outcome of patients admitted in ICU.
219722045|NCT06950190|BEHAVIORAL|Low-Intensity Walking Intervention|Participants in the experimental group will be asked to take part in a home-based, walking program. Each participant will receive a pedometer and will be instructed to increase their baseline daily step count by 100%. For example, if a participant typically walks 3,000 steps per day, they will be asked to increase their activity to 6,000 steps per day. Step counts will be regularly monitored, and participants will receive encouragement and support from study staff to help maintain adherence to the walking goals. In addition to the exercise intervention, participants in this group will undergo cognitive testing using the Montreal Cognitive Assessment (MoCA) at four timepoints: baseline, 6 months, 9 months, and 12 months. They will also complete self-reported questionnaires related to cognitive function at these same intervals. This group is designed to evaluate whether increased physical activity can improve or preserve cognitive function in patients undergoing chemotherapy.
219722046|NCT06950190|BEHAVIORAL|Control Group Intervention|Participants in the control group will receive standard care and will not be given any specific exercise instructions. They will be provided with pedometers to track their daily steps, but they will not be asked to increase or change their usual level of physical activity. These participants will continue with their routine activities and cancer care as directed by their treating physicians. Like the intervention group, they will complete the Montreal Cognitive Assessment (MoCA) at baseline, 6 months, 9 months, and 12 months, as well as self-reported questionnaires about cognitive function at each timepoint. This group will serve as a comparator to determine the impact of the walking intervention on cognitive outcomes.
219722047|NCT07125014|PROCEDURE|Observational study|This is an observational study with no experimental or therapeutic interventions administered to participants. All data were collected retrospectively from existing hospital records for patients who underwent ERCP between January 2023 and December 2023 at Lady Reading Hospital, Peshawar. No drugs, devices, or procedures were assigned to participants as part of this research.
219722048|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + vehicle|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with vehicle drug.
219722049|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + aspirin|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with aspirin.
219722050|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + vehicle|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with vehicle drug.
219722051|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + aspirin|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with aspirin.
219734744|NCT04264195|OTHER|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
219734745|NCT04264195|OTHER|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
219734746|NCT00000446|DRUG|sertraline (Zoloft)|
219734747|NCT02521194|BEHAVIORAL|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
219734748|NCT04933058|DRUG|IV acetaminophen|Pain management
219734749|NCT04933058|DRUG|IV fentanyl|Pain management
219149517|NCT05132816|DIAGNOSTIC_TEST|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
219149518|NCT00490802|DRUG|Oxytocin|Intranasal Oxytocin
219722052|NCT02626611|DRUG|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
219722053|NCT02626611|DRUG|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
219722054|NCT04568109|BEHAVIORAL|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
219722055|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
219722056|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
219722057|NCT02813447|DRUG|Sertraline|
219722058|NCT02813447|DRUG|Placebo|
219722059|NCT05607459|OTHER|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
219722060|NCT05607459|BEHAVIORAL|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
219722061|NCT05607459|OTHER|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
219722062|NCT05607459|OTHER|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
219722063|NCT01192698|DRUG|IV interferon|IV interferon 5MU during anhepatic phase
219722064|NCT05850689|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
219722065|NCT05850689|DRUG|Placebo|Matching capsules administered orally, once daily
219722066|NCT06260748|DRUG|Chenodeoxycholic acid|250mg capsules
219722067|NCT06260748|DRUG|Chenodeoxycholic acid Placebo|Placebo to match
219555740|NCT05530811|DRUG|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
219149519|NCT00490802|DRUG|Placebo|Placebo Comparator
219555741|NCT05530811|DRUG|Bupivacaine|0.5% bupivacaine
219722068|NCT06495554|DIAGNOSTIC_TEST|Measurement of circulating tumor-DNA|Liquid biopsies will be collected at baseline and prospectively during follow-up to measure circulating tumor-DNA.
219722069|NCT06495554|OTHER|Collection of patient-reported outcomes|Patient-reported outcomes will be collected at baseline and prospectively during follow-up.
219722070|NCT06495554|OTHER|Algorithmically determined telephone interview with a nurse|Dependent on the patient's responses on the patient-reported outcome measures.
219722071|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
219722072|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
219722073|NCT01334047|BIOLOGICAL|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
219722074|NCT06198413|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
219722075|NCT04667169|PROCEDURE|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
219722076|NCT04667169|PROCEDURE|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
219722077|NCT04041310|BIOLOGICAL|GAd-209-FSP low dose|GAd20-209-FSP IP, low dose
219149520|NCT06338241|COMBINATION_PRODUCT|Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin|The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.
219722078|NCT04041310|BIOLOGICAL|MVA-209-FSP low dose|MVA-209-FSP IP, low dose
219722079|NCT04041310|BIOLOGICAL|GAd-209-FSP high dose|GAd20-209-FSP IP, high dose
219722080|NCT04041310|BIOLOGICAL|MVA-209-FSP high dose|MVA-209-FSP IP, high dose
219722081|NCT04041310|BIOLOGICAL|GAd20-209-FSP, RP2D|GAd20-209-FSP IP, RP2D
219722082|NCT04041310|BIOLOGICAL|MVA-209-FSP, RP2D|MVA-209-FSP IP, RP2D
219722083|NCT04041310|DRUG|KEYTRUDA®|anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
219722084|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
219722085|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
219722086|NCT05326100|OTHER|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
219722087|NCT05326100|DEVICE|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
219722088|NCT05326100|DEVICE|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
219722089|NCT05277259|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
219722090|NCT05277259|OTHER|Kinesiotaping|Elastic band to be used to stretch the upper trapezius muscle in the desired direction.
219722091|NCT05277259|OTHER|Conventional Physical Therapy|Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
219149521|NCT06338241|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
219149522|NCT04979299|OTHER|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
219149523|NCT02843217|BEHAVIORAL|Lifestyle, screening|
219149524|NCT00200213|BEHAVIORAL|portion or unportioned food|
219149525|NCT05519813|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
219722092|NCT03846232|OTHER|No intervention|No intervention
219722093|NCT03400553|DIAGNOSTIC_TEST|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
219722094|NCT00517062|DRUG|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
219722095|NCT00517062|DRUG|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
219722096|NCT03698916|DRUG|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
219722097|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
219722098|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
219722099|NCT01769872|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
219722100|NCT04220281|DRUG|Propofol|propofol infusion during surgery
219149526|NCT05519813|DRUG|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
219149527|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
219149528|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
219149529|NCT01519752|DRUG|Placebo|Placebo applied to affected area once a day for 28 days
219149530|NCT03737591|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
219722101|NCT04220281|DRUG|Nitroglycerin|nitroglycerin infusion during surgery
219722102|NCT04781985|PROCEDURE|cystoscopy|extraction of the bladder stone via suprapubic incision
219722103|NCT04706403|BEHAVIORAL|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
219722104|NCT05220995|GENETIC|protocol|ovarian stimulation protocols on euploid rates were compared.
219722105|NCT04989738|BEHAVIORAL|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
219722106|NCT04989738|BEHAVIORAL|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
219722107|NCT04858529|DRUG|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
219722108|NCT04858529|DRUG|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
219722109|NCT03475563|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
219722110|NCT05998499|OTHER|Description|This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit
219722111|NCT00182637|DRUG|bortezomib|
219722112|NCT01050842|DRUG|bicalutamide|Given orally
219722113|NCT01050842|DRUG|raloxifene|Given orally
219722114|NCT01050842|PROCEDURE|quality-of-life assessment|Ancillary study
219722115|NCT03118271|DEVICE|lumbar traction|
219722116|NCT03118271|PROCEDURE|spinal manipulation|
219722117|NCT03118271|PROCEDURE|surgery|
219722118|NCT03850301|DRUG|XBD173|7 days treatment
219722119|NCT03850301|DRUG|Etifoxine|7 days treatment
219722120|NCT06963983|DEVICE|Rehabilitation using virtual reality|During the four physiotherapy (PT) sessions (60 min for each session), a set of exercises from the conventional PT is replaced by multiple short sessions of 30 minutes each, where the patient will be equipped by a set of motion trackers mounted on a belt and on a set of straps to be worn around both arms and both forearms. The patient will also hold a controller in each hand and wear a commercial VR headset on his head. Then, thanks to the headset, the patient will be able to experience a set of VR environments, where he or she will be guided through a set of exergames. His/her movements in the real world will be used to move his/her avatar's body in the virtual world, and the exergames will be designed to push him/her to perform the motions required by the therapy in order to go through the games. Various strategies, including a virtual coach will also appear to prevent the patient from doing potentially hazardous movements.
219722121|NCT05229601|DRUG|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
219722122|NCT06964711|DRUG|GW117 ODT|Sublingual route ， 0.5mg/1mg/2mg/4mg，QD
219722123|NCT06964711|DRUG|Placebo|GW117 Placebo matching for Sublingual route ，QD
219722124|NCT04896021|DIAGNOSTIC_TEST|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
219722125|NCT04896021|DIAGNOSTIC_TEST|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
219722126|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
219555742|NCT04943887|BEHAVIORAL|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
219555743|NCT02836587|BEHAVIORAL|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
219555744|NCT04561115|BIOLOGICAL|Gamunex-C|Intravenous infusion.
219555745|NCT04561115|BIOLOGICAL|IVIG-PEG|Intravenous infusion.
219722127|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
219555746|NCT00743145|DRUG|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
219555747|NCT00743145|DRUG|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
219555748|NCT00743145|DRUG|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
219555749|NCT00743145|DRUG|Naltrexone|Naltrexone (12mg/70kg)
219555750|NCT00743145|DRUG|Placebo naltrexone|Naltrexone (0mg)
219555751|NCT04508205|DRUG|CGB-400|BID application
219555752|NCT02093377|DEVICE|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
219722128|NCT05402085|DIETARY_SUPPLEMENT|High Protein Diet|Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
219722129|NCT05402085|DIETARY_SUPPLEMENT|High Fat Diet|Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
219722130|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-Low Glycemic Index Diet|Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
219722131|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-High Glycemic Index Diet|Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
219722132|NCT05628389|BEHAVIORAL|Educational materials|Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
219722133|NCT05628389|BEHAVIORAL|Phone counseling|Cessation counseling to address insufficient patient self-efficacy and motivation.
219722134|NCT05628389|DRUG|Nicotine Replacement Therapy|Nicotine patches to address nicotine withdrawal symptoms in patients.
219722135|NCT05628389|BEHAVIORAL|Provider training|Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
219722136|NCT05628389|BEHAVIORAL|Electronic reminders|Electronic reminders to address the lack of integration of AAA/AAC into practice.
219722137|NCT05199272|DRUG|23ME-00610|23ME-00610 given by IV infusion
219722138|NCT05419011|BIOLOGICAL|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
219722139|NCT05419011|PROCEDURE|Biopsy Procedure|Undergo biopsy
219722140|NCT05419011|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219722141|NCT05419011|PROCEDURE|Colonoscopy|Undergo SOC colonoscopy
219722142|NCT05419011|DRUG|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
219555753|NCT06840470|DRUG|Imiquimod 5% Topical Cream|Participants will apply this cream to one side of the face 3 times a week for up to 8 weeks. The cream will be applied before bedtime. The imiquimod should be washed off with mild soap and water after 6-10 hours. Participants will have baseline and follow-up visits that will include photographs of the lesions.
219555754|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
219555755|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
219149531|NCT02961569|PROCEDURE|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
219555756|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
219555757|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
219555758|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
219555759|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
219555760|NCT05909436|DRUG|GLS-012|"In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
219555761|NCT05909436|DRUG|GLS-010|"In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
219722143|NCT05419011|DRUG|Placebo Administration|Given SC
219722144|NCT05419011|OTHER|Questionnaire Administration|Ancillary studies
219722145|NCT05623085|OTHER|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
219722146|NCT05623085|OTHER|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
219722147|NCT04241718|DEVICE|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
219149532|NCT00686855|DRUG|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
219149533|NCT00686855|DRUG|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
219555762|NCT02416180|DEVICE|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
219555763|NCT02416180|DEVICE|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
219555764|NCT02416180|DEVICE|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
219555765|NCT04219527|PROCEDURE|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
219734750|NCT03661580|BEHAVIORAL|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
219149534|NCT04773327|OTHER|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
219149535|NCT00085436|BIOLOGICAL|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
219149536|NCT00085436|BIOLOGICAL|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
219232367|NCT04798534|BEHAVIORAL|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
219232368|NCT02717819|DIETARY_SUPPLEMENT|Protein|Daily intake of supplement
219555766|NCT03368482|BEHAVIORAL|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
219149537|NCT00085436|BIOLOGICAL|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
219555767|NCT03368482|BEHAVIORAL|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
219555768|NCT03645876|DRUG|SHR-1210|200mg
219232369|NCT02717819|DIETARY_SUPPLEMENT|Placebo|Daily intake of supplement
219232370|NCT02717819|OTHER|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
219555769|NCT03645876|DRUG|BP102|7.5mg/kg
219555770|NCT03645876|DRUG|oxaliplatin|130mg/m2
219555771|NCT03645876|DRUG|capecitabine|1000mg/m2
219555772|NCT03645616|DIAGNOSTIC_TEST|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
219555773|NCT03645616|DIAGNOSTIC_TEST|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
219555774|NCT03645616|DIAGNOSTIC_TEST|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
219555775|NCT04432077|BEHAVIORAL|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
219555776|NCT01842555|OTHER|Registry|Registry
219555777|NCT02319603|DRUG|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
219555778|NCT02319603|DRUG|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
219555779|NCT00610506|DRUG|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
219555780|NCT05874648|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
219555781|NCT01170715|DRUG|Etanercept|self-administered for 52 weeks
219555782|NCT01460030|DRUG|Cinacalcet HCl|Oral administration
219555783|NCT02687789|OTHER|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
219555784|NCT02687789|OTHER|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
219555785|NCT02647853|DRUG|TAT4 Gel concentration A|
219555786|NCT02647853|DRUG|TAT4 Gel concentration B|
219555787|NCT02647853|DRUG|Placebo|
219555788|NCT01505049|DRUG|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
219555789|NCT04771767|DRUG|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
219555790|NCT04771767|BEHAVIORAL|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
219722148|NCT05463055|RADIATION|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
219722149|NCT03819205|OTHER|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
219722150|NCT04581746|OTHER|questionnaire|bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
219722151|NCT04766333|BEHAVIORAL|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
219722152|NCT04766333|BEHAVIORAL|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
219722153|NCT03583346|DRUG|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
219722154|NCT03583346|DRUG|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
219722155|NCT06784765|PROCEDURE|Intervention Group|Preventive pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin (10 mg/m2) and doxorubicin (2.1 mg/m2) + perioperative chemotherapy (FLOT regimen) +gastrectomy with D2 lymphadenectomy
219722156|NCT06784765|PROCEDURE|Control Group|Retrospective cohort receiving standard perioperative chemotherapy (FLOT regimen) + gastrectomy with D2 lymphadenectomy
219722157|NCT00298194|DRUG|Z-338|
219722158|NCT02090595|BEHAVIORAL|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
219555791|NCT03486938|DRUG|Placebo Oral Tablet|Placebo oral tablet
219555792|NCT03486938|DRUG|AGB101 220 mg tablet|220 mg AGB101 active compound
219555793|NCT04162171|RADIATION|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
219555794|NCT02571634|DRUG|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
219555795|NCT03904836|DRUG|Tobramycin|5 milligrams per kilogram intravenous for one dose
219555796|NCT03933267|OTHER|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
219555797|NCT03933267|OTHER|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
219555798|NCT06679725|DIETARY_SUPPLEMENT|Wild ginseng extract|This ginseng extract was manufactured and provided by the Korea Food Research Institute (sponsor). It is extracted from red ginseng. Red ginseng is generally considered to have greater biological effects and fewer side effects than white or fresh ginseng.
219722159|NCT02090595|BEHAVIORAL|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
219722160|NCT00639379|DEVICE|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
219722161|NCT00639379|DEVICE|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
219722162|NCT01452087|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
219722163|NCT00263536|PROCEDURE|Interpersonal Psychotherapy|
219722164|NCT04268524|COMBINATION_PRODUCT|drug: miltefosine with thermotherapy|see previous
219722165|NCT06486779|OTHER|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
219722166|NCT06182995|BEHAVIORAL|Usual Care post-Intensive Care Unit (ICU)|routine clinic visits
219722167|NCT06182995|BEHAVIORAL|Anticipating Decline and Providing Therapy (ADAPT)|routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
219722168|NCT03528031|OTHER|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
219722169|NCT03754647|DIETARY_SUPPLEMENT|Vitamin C|One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
219722170|NCT03994432|BEHAVIORAL|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
219722171|NCT06848218|OTHER|Music Therapy|"This procedure is carried out using headphones installed in the child's ears. The music will be activated if the child is in the Music group, and will not be activated but present if the child is not in the Music group.~NIV implementation will begin after 10 min of listening. The listening period will continue until the nadir period (when the music is slowest, for maximum relaxation), until 10 min after the start of the NIV."
219722172|NCT06848218|PROCEDURE|Setting Up NIV|Non invasive ventilation is set up in several stages, with the help of at least two caregivers. The patient will be placed in a half-seated position or seated. Installation begins with the placement of the non invasive ventilation mask harness around the child's head, followed by the application of the mask to the face, held by a caregiver. Once the mask has been applied, ventilation is started by connecting the non invasive ventilation circuit to the mask. The harness is then tightened by the second caregiver.
219722173|NCT03712852|PROCEDURE|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
219722174|NCT03712852|PROCEDURE|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
219722175|NCT03712852|PROCEDURE|CAF treated patients|Patients will be treated by coronally advanced flap
219722176|NCT04894188|RADIATION|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
219722177|NCT04894188|DRUG|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
219722178|NCT04894188|PROCEDURE|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
219722179|NCT05225363|BIOLOGICAL|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
219722180|NCT05225363|DRUG|Cyclophosphamide|Given IV
219722181|NCT05225363|DRUG|Fludarabine|Given IV
219722182|NCT05404061|OTHER|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1"
219722183|NCT03549260|BIOLOGICAL|LIB003|LIB003 or placebo
219722184|NCT02582632|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet
219722185|NCT02582632|DRUG|dasabuvir|Tablet
219722186|NCT02636452|OTHER|cardiopulmonary exercise test|
219722187|NCT00344825|DRUG|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
219722188|NCT03298061|DRUG|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
219722189|NCT03298061|DRUG|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
219722190|NCT01326936|BEHAVIORAL|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
219722191|NCT00801268|DRUG|tripterygium wilfordii|TW，60mg/d
219722192|NCT00801268|DRUG|Emodin|100mg/d
219722193|NCT00894725|PROCEDURE|laparoscopic left colonic resection|laparoscopic colonic resection
219722194|NCT00894725|PROCEDURE|open left colonic resection|conventional open colonic resection
219722195|NCT04286958|DRUG|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
219722196|NCT01960478|BIOLOGICAL|(for each intervention)|
219722197|NCT01960478|OTHER|Blood test|
219722198|NCT03346512|PROCEDURE|Cardiac surgery|Cardiac surgery
219722199|NCT02383173|OTHER|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
219722200|NCT02383173|OTHER|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
219149538|NCT04038814|PROCEDURE|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
219149539|NCT04038814|PROCEDURE|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage"
219232371|NCT02717819|DIETARY_SUPPLEMENT|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
219232372|NCT01463475|PROCEDURE|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
219722201|NCT01507727|DRUG|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
219722202|NCT01507727|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
219722203|NCT04498507|DIAGNOSTIC_TEST|HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life
219722204|NCT01801332|DIETARY_SUPPLEMENT|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
219722205|NCT01801332|DIETARY_SUPPLEMENT|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
219722206|NCT01297244|DRUG|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
219722207|NCT03677401|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
219722208|NCT03677401|DRUG|Placebo Tablets|Placebo Tablets
219722209|NCT05935020|OTHER|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
219722210|NCT05935020|OTHER|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
219722211|NCT05935020|BEHAVIORAL|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
219149540|NCT03555214|OTHER|Manual Therapy based on soft tissues|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique."
219149541|NCT03555214|OTHER|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
219232373|NCT03473041|PROCEDURE|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
219232374|NCT03473041|PROCEDURE|TVT-O|midurethral transobturator vaginal tape
219232375|NCT04074252|DEVICE|Lofstrand Crutches|Device: Set of Lofstrand Crutches
219232376|NCT04074252|DEVICE|Axillary Crutches|Device: Set of Axillary Crutches
219232377|NCT02326220|DRUG|Placebo|
219232378|NCT02326220|DRUG|Alirocumab|
219722212|NCT04000256|BEHAVIORAL|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
219722213|NCT05935488|OTHER|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
219722214|NCT01196611|BEHAVIORAL|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
219722215|NCT01196611|BEHAVIORAL|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
219722216|NCT01177410|DRUG|Placebo|placebo capsules once daily for 12 weeks
219722217|NCT01177410|DRUG|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
219722218|NCT01177410|DRUG|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
219722219|NCT04697901|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
219722220|NCT04697901|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
219722221|NCT02000271|PROCEDURE|Vaginal packing|
219722222|NCT02000271|PROCEDURE|No vaginal packing|
219722223|NCT02323815|DIETARY_SUPPLEMENT|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
219722224|NCT02323815|BEHAVIORAL|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
219722225|NCT05643690|DIAGNOSTIC_TEST|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
219722226|NCT01846871|DRUG|Tivozanib|
219722227|NCT01230008|RADIATION|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
219722228|NCT05382728|DRUG|TY-9591|"The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219722229|NCT05382728|DRUG|placebo Osimertinib|"The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219722230|NCT05382728|DRUG|Osimertinib|"The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219232379|NCT02114515|BEHAVIORAL|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
219232380|NCT02114515|BEHAVIORAL|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
219232381|NCT02114515|BEHAVIORAL|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
219555799|NCT06679725|DIETARY_SUPPLEMENT|Placebo|The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring
219555800|NCT06315660|BEHAVIORAL|Cognitive Miljeu Therapy|TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
219232382|NCT00286325|DRUG|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
219555801|NCT06315660|BEHAVIORAL|Virtual Reality based CBT for Anxiety|The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
219149542|NCT03555214|OTHER|Manual Therapy based on structural techniques|"Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique."
219149543|NCT03555214|OTHER|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique."
219149544|NCT01668940|OTHER|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
219149545|NCT01668940|OTHER|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
219149546|NCT01668940|OTHER|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
219149547|NCT05340114|DEVICE|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
219149548|NCT01460446|DEVICE|Aviva Expert blood glucose meter|
219149549|NCT01460446|DEVICE|Aviva Nano blood glucose meter|
219149550|NCT04616963|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
219555802|NCT01332968|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
219149551|NCT04616963|DRUG|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
219149552|NCT03356223|DRUG|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
219149553|NCT05573334|DEVICE|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
219149554|NCT04574349|PROCEDURE|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
219232383|NCT00002294|DRUG|Fluconazole|
219555803|NCT01332968|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
219555804|NCT01332968|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
219555805|NCT01332968|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
219555806|NCT01332968|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
219555807|NCT01332968|DRUG|Bendamustine|Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
219555808|NCT01332968|DRUG|Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
219555809|NCT00893776|OTHER|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
219722231|NCT05382728|DRUG|placebo TY-9591|"The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
219149555|NCT04521530|OTHER|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
219149556|NCT04521530|OTHER|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
219149557|NCT03960606|COMBINATION_PRODUCT|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
219149558|NCT03960606|COMBINATION_PRODUCT|Placebo|PUR1900 placebo
219149559|NCT01507038|DRUG|YH14617|1mg once weekly
219149560|NCT01507038|DRUG|YH14617|1.6mg once weekly
219555810|NCT02664792|OTHER|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
219555811|NCT01087034|DEVICE|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
219555812|NCT01087034|RADIATION|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
219555813|NCT01087034|OTHER|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
219555814|NCT04002869|DIAGNOSTIC_TEST|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
219555815|NCT03480022|DRUG|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
219555816|NCT03480022|DRUG|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
219555817|NCT06016582|DEVICE|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
219555818|NCT06679322|DRUG|Androtriol Injection (High-dose group)|Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
219555819|NCT06679322|DRUG|Androtriol Injection (Low-dose group)|Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
219149561|NCT01507038|DRUG|YH14617|2mg once biweekly
219149562|NCT01507038|DRUG|Placebo|Once weekly
219149563|NCT04414995|DRUG|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
219149564|NCT04414995|DRUG|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
219149565|NCT04414995|DRUG|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
219149566|NCT01867216|DRUG|Placebo|Administered orally as capsules
219149567|NCT01867216|DRUG|LY2922470|Administered orally as capsules
219149568|NCT01556724|DRUG|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
219149569|NCT02190097|OTHER|Paleolithic diet|see procedures section for more details
219149570|NCT02190097|OTHER|American Diabetes Association diet|see procedures section
219149571|NCT01318382|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
219555820|NCT06679322|DRUG|Hydroxypropyl-β-cyclodextrin injection|Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
219555821|NCT00640926|DRUG|Radezolid|300 mg/day, orally for 7-10 days
219555822|NCT00640926|DRUG|Radezolid|450 mg/day orally for 7-10 days
219555823|NCT00640926|DRUG|Radezolid|900 mg/day orally for 7-10 days
219555824|NCT02321839|DRUG|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
219555825|NCT03922750|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
219555826|NCT03922750|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
219555827|NCT02828566|DRUG|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
219555828|NCT02828566|DRUG|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
219555829|NCT02828566|DRUG|IN saline 0.9%|Intranasal 0.9% normal saline
219555830|NCT02828566|DRUG|IV saline 0.9%|Intravenous 0.9% normal saline
219555831|NCT05158660|DEVICE|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
219722232|NCT02092103|PROCEDURE|Cord Milking|See description in cord milking arm.
219722233|NCT04208711|OTHER|biological sample|whole blood sample
219149572|NCT01599104|DRUG|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
219149573|NCT01599104|DRUG|Olmesartan|Olmesartan 20 mg capsule one daily
219722234|NCT02794311|OTHER|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
219722235|NCT02890888|OTHER|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
219722236|NCT04856618|BIOLOGICAL|Massive Transfusion of Allogeneic Blood|Massive Transfusion of Allogeneic Blood, \> pRBCs
219722237|NCT02773628|DEVICE|Acar'up system|
219722238|NCT02773628|DEVICE|Acar'up placebo system|
219722239|NCT00442156|PROCEDURE|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
219722240|NCT06309758|OTHER|Breinzorg|"The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner)."
219722241|NCT04874168|DEVICE|TAP block|bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
219722242|NCT01834794|BEHAVIORAL|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
219722243|NCT05202431|BEHAVIORAL|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
219722244|NCT04400747|DRUG|Vitamin D3|one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
219722245|NCT00315315|PROCEDURE|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
219722246|NCT00315315|PROCEDURE|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
219722247|NCT00315315|PROCEDURE|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
219722248|NCT00012246|BIOLOGICAL|carcinoembryonic antigen peptide 1-6D|
219149574|NCT01599104|DRUG|Placebo|Placebo to LCZ696 or Olmesartan
219149575|NCT02639091|DRUG|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
219149576|NCT02639091|DRUG|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
219149577|NCT02639091|DRUG|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
219149578|NCT03396146|OTHER|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
219232384|NCT04568213|DRUG|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
219232385|NCT04565652|DEVICE|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
219722249|NCT00012246|BIOLOGICAL|incomplete Freund's adjuvant|
219722250|NCT00012246|BIOLOGICAL|sargramostim|
219722251|NCT03791021|DIAGNOSTIC_TEST|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
219722252|NCT03791021|DIAGNOSTIC_TEST|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
219722253|NCT03791021|DIAGNOSTIC_TEST|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
219722254|NCT03791021|DIAGNOSTIC_TEST|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
219149579|NCT03396146|OTHER|Fecal sample|Fecal sample at inclusion
219149580|NCT02772263|OTHER|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
219149581|NCT00714714|DRUG|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
219722255|NCT01909102|BEHAVIORAL|ACT-based intervention|
219722256|NCT01909102|BEHAVIORAL|usual care|
219722257|NCT05363904|OTHER|Observation|Questionnaires, Clinical Scores, Biomaterial Sampling
219722258|NCT00357162|DRUG|belinostat|Given IV
219722259|NCT04510168|DRUG|11C-ER176|PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
219722260|NCT04510168|DRUG|[F-18]MK-6240|PET imaging to measure tau; target imaging dose of 4 to 5 mCi
219722261|NCT04510168|DRUG|Florbetaben|PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
219722262|NCT04510168|OTHER|Magnetic Resonance Imaging|Brain MRI
219722263|NCT02852044|BEHAVIORAL|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
219722264|NCT02852044|BEHAVIORAL|Exercise|One hour of cycling at 50% of maximal power output
219722265|NCT02852044|OTHER|Dorsal Hand Vein Cannulation (heated hand technique)|
219149582|NCT00714714|DRUG|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
219149583|NCT00019747|DRUG|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
219149584|NCT00019747|PROCEDURE|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
219149585|NCT00019747|OTHER|Placebo|oral placebo once daily
219149586|NCT02461264|DRUG|Single red blood packed cells Transfusion|
219149587|NCT02461264|DRUG|Two packed red blood cells Transfusion|
219149588|NCT04479865|DRUG|Aricept 5mg Tablet|1 tablet once daily
219149589|NCT04479865|DRUG|Aricept 10mg Tablet|1 tablet once daily
219149590|NCT04479865|DRUG|DA-5207 150mg|1 patch once weekly
219149591|NCT04479865|DRUG|DA-5207 170mg|1 patch once weekly
219149592|NCT00073684|BEHAVIORAL|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
219149593|NCT00073684|BEHAVIORAL|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
219722266|NCT02852044|OTHER|Venous Cannulation|
219722267|NCT02738515|DRUG|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
219722268|NCT02738515|DRUG|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
219722269|NCT00986141|PROCEDURE|Surgery|Selective Laser Trabeculoplasty for glaucoma
219722270|NCT00986141|PROCEDURE|Selective Laser Trabeculoplasty|Glaucoma Treatment
219149594|NCT00073684|BEHAVIORAL|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
219149595|NCT00073684|BEHAVIORAL|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
219149596|NCT00073684|BEHAVIORAL|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
219149597|NCT01317446|DRUG|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
219149598|NCT01925469|DRUG|Benzocaine|
219149599|NCT01925469|DRUG|Saline spray|A saline spray will be used in the placebo group
219149600|NCT04701879|OTHER|Spine decompression with core stability exercises|"* 50 minutes per session~* Decompression with core stability on alternate days for 8 visits."
219149601|NCT04701879|OTHER|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
219149602|NCT00091650|DRUG|Olanzapine|
219149603|NCT00091650|DRUG|placebo|
219149604|NCT02313363|DEVICE|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
219722271|NCT04241731|DRUG|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
219722272|NCT04241731|DRUG|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
219722273|NCT02960789|OTHER|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
219722274|NCT02960789|OTHER|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
219722275|NCT02960789|DEVICE|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
219722276|NCT02960789|OTHER|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
219722277|NCT02960789|DEVICE|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
219722278|NCT05852288|DIAGNOSTIC_TEST|Inflammatory markers|Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
219722279|NCT02375997|OTHER|Palliative care|Early nutrition intervention and psychological intervention
219722280|NCT02617862|PROCEDURE|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
219722281|NCT02617862|DEVICE|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
219149605|NCT02467946|DRUG|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
219149606|NCT02377726|BEHAVIORAL|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
219149607|NCT02377726|BEHAVIORAL|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
219149608|NCT02377726|BEHAVIORAL|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
219149609|NCT00269789|DRUG|Ritalin|
219149610|NCT00269789|DRUG|OROS Methylphenidate HCl|
219149611|NCT00269789|DRUG|Placebo|
219149612|NCT01853410|DEVICE|gekoTM|
219149613|NCT02780440|BEHAVIORAL|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
219149614|NCT02780440|BEHAVIORAL|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
219149615|NCT02780440|BEHAVIORAL|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
219149616|NCT06435637|DIETARY_SUPPLEMENT|Collagen protein|Ingestion of 40, 20, 20 and 20 gram of collagen protein right after and every 2 hours after a bout of exercise
219149617|NCT06435637|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
219149618|NCT04933526|DRUG|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
219149619|NCT04933526|DRUG|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
219149620|NCT05662449|DEVICE|Syndesmosis fixation using Activascrew|as described prior
219149621|NCT02382328|DRUG|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
219149622|NCT02382328|DRUG|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
219149623|NCT03797924|DRUG|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
219232386|NCT05443698|DEVICE|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
219232387|NCT02699099|DIETARY_SUPPLEMENT|Vitamin A|Oral administration of Vitamin A (1 dose)
219232388|NCT02699099|BIOLOGICAL|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
219555832|NCT01471951|OTHER|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
219555833|NCT02387034|BEHAVIORAL|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
219555834|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
219555835|NCT06228196|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
219555836|NCT02985398|BIOLOGICAL|ALD403 (Eptinezumab)|
219555837|NCT01992341|DRUG|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
219722282|NCT02617862|DEVICE|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
219722283|NCT05527522|COMBINATION_PRODUCT|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
219722284|NCT05527522|OTHER|standard practice|The patients received the usual treatment and clinical practice
219722285|NCT03033043|DEVICE|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
219149624|NCT03797924|BEHAVIORAL|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
219149625|NCT00773370|BEHAVIORAL|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
219149626|NCT00773370|BEHAVIORAL|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
219149627|NCT01801514|DEVICE|Computed Tomography scan|Routine Computed Tomography scan
219149628|NCT00226772|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
219722286|NCT01118923|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
219722287|NCT01118923|DIETARY_SUPPLEMENT|Placebo|3 placebo-tablets daily for 12 weeks
219722288|NCT04443829|BIOLOGICAL|CD19CAR T-cells|Infusion with: CD19CAR T-cells
219149629|NCT00226772|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
219722289|NCT02057991|OTHER|educational intervention|Watch an educational video
219722290|NCT02057991|PROCEDURE|CAM exercise therapy|Watch a mindfulness exercise video
219722291|NCT02057991|OTHER|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
219722292|NCT02057991|OTHER|questionnaire administration|Ancillary studies
219722293|NCT02057991|OTHER|laboratory biomarker analysis|Correlative studies
219722294|NCT00694343|DRUG|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
219722295|NCT00694343|DRUG|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
219722296|NCT00357604|DRUG|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
219722297|NCT00357604|DRUG|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
219722298|NCT04656665|DRUG|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
219722299|NCT01422447|OTHER|regular intervention|the subjects in the control group live in the used model
219722300|NCT01422447|OTHER|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
219722301|NCT03608085|BEHAVIORAL|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;"
219722302|NCT03608085|BEHAVIORAL|Patient Heart failure MTM intervention|"The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
219722303|NCT01124474|OTHER|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
219722304|NCT06139640|OTHER|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
219722305|NCT05003999|DEVICE|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
219722306|NCT05003999|DEVICE|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
219149630|NCT04996680|DEVICE|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
219722307|NCT00924482|DEVICE|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
219149631|NCT04996680|OTHER|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
219232389|NCT02699099|BIOLOGICAL|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
219722308|NCT04508985|OTHER|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
219149632|NCT04996680|DEVICE|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
219149633|NCT00693121|DRUG|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
219149634|NCT00693121|DRUG|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
219149635|NCT06155877|BEHAVIORAL|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
219149636|NCT06155877|BEHAVIORAL|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
219232390|NCT02699099|BIOLOGICAL|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
219232391|NCT06143124|DRUG|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
219722309|NCT04508985|OTHER|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
219149637|NCT05284565|DEVICE|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
219149638|NCT00947635|DIETARY_SUPPLEMENT|Dietary intervention - supplements|Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
219149639|NCT01914913|BIOLOGICAL|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
219149640|NCT06408493|BEHAVIORAL|MYCardio-PEER|MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
219149641|NCT06361953|DEVICE|EEG Neurofeedback|neurofeedback training over five weeks, comprising 15 sessions. Each neurofeedback training session lasted 30 minutes.
219149642|NCT04544904|DEVICE|PAARx|Prescription Physical Activity Programming Application
219149643|NCT04544904|DEVICE|JM|Joint Management (JM) web-based joint management resource.
219149644|NCT01549756|BEHAVIORAL|bulletin board and teleophone depth interview|qualitative based research
219232392|NCT00667732|DRUG|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
219555838|NCT01992341|DRUG|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
219555839|NCT04842435|DRUG|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
219555840|NCT04842435|DRUG|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
219555841|NCT01172912|BIOLOGICAL|filgrastim|
219555842|NCT01172912|BIOLOGICAL|pegfilgrastim|
219555843|NCT01172912|DRUG|carboplatin|
219555844|NCT01172912|DRUG|cisplatin|
219555845|NCT01172912|DRUG|dexamethasone|
219555846|NCT01172912|DRUG|etoposide|
219555847|NCT01172912|DRUG|ifosfamide|
219555848|NCT01172912|OTHER|high-dose chemotherapy with autologous stem cell rescue|
219555849|NCT01172912|OTHER|laboratory biomarker analysis|
219555850|NCT01172912|PROCEDURE|autologous hematopoietic stem cell transplantation|
219555851|NCT01172912|PROCEDURE|peripheral blood stem cell transplantation|
219555852|NCT04257695|BEHAVIORAL|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
219555853|NCT06000163|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the skin, which is non-invasive, and skin thickness and blood flow parameters will be measured.
219555854|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
219555855|NCT05827263|DEVICE|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
219555856|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
219555857|NCT03210038|DRUG|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
219555858|NCT03210038|DRUG|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
219555859|NCT03946436|DEVICE|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
219555860|NCT03946436|OTHER|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
219555861|NCT00286533|PROCEDURE|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
219555862|NCT00286533|PROCEDURE|Questionnaires|Questionnaires are used.
219555863|NCT02941159|BIOLOGICAL|SF2000SD|This is an intergrase inhibitor
219555864|NCT02941159|BIOLOGICAL|Placebo|
219555865|NCT03660787|DRUG|Seroguard|Seroguard 0.41 g/L solution
219555866|NCT03660787|DRUG|Placebo|Saline
219555867|NCT04164758|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
219555868|NCT04164758|OTHER|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
219555869|NCT04164758|DRUG|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
219555870|NCT06149949|OTHER|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
219555871|NCT03195387|DRUG|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
219555872|NCT00467805|PROCEDURE|Light therapy|
219722310|NCT00515190|DRUG|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
219722311|NCT01948778|DEVICE|oXiris™ filter|
219722312|NCT01948778|DEVICE|Toraymyxin Filter|
219722313|NCT01948778|DEVICE|Standard of Care|
219722314|NCT05205395|DIAGNOSTIC_TEST|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
219722315|NCT00243061|DRUG|cediranib maleate|Given orally
219722316|NCT03010865|DRUG|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
219722317|NCT03010865|DRUG|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
219722318|NCT00875667|DRUG|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
219722319|NCT00875667|DRUG|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
219722320|NCT03751787|OTHER|cranial osteopathy|two sessions at three weeks intervals
219722321|NCT03751787|OTHER|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
219722322|NCT04241523|DRUG|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight \<60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
219555873|NCT06478745|OTHER|Retrospective and prospective cohort|"* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia."
219722323|NCT00894647|DRUG|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
219722324|NCT00894647|DRUG|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
219149645|NCT06100458|OTHER|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
219149646|NCT03573518|DRUG|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
219149647|NCT03573518|DRUG|Vehicle|Placebo
219722325|NCT01913470|DRUG|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
219149648|NCT03677349|PROCEDURE|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
219722326|NCT00412451|DRUG|ocriplasmin|Intravitreal injection, single administration
219722327|NCT00412451|OTHER|Sham injection|Sham intravitreal injection
219555874|NCT06478745|OTHER|Focus group, semi-structured interviews and Photovoice|The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
219555875|NCT06478745|OTHER|Systematic review|No patient recruitment required
219149649|NCT01308567|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
219149650|NCT01308567|DRUG|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
219722328|NCT02950584|OTHER|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
219722329|NCT02950584|OTHER|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
219722330|NCT04285684|DRUG|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
219722331|NCT04361045|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
219722332|NCT01139372|OTHER|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
219722333|NCT02269449|DEVICE|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
219722334|NCT02269449|DEVICE|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
219722335|NCT02269449|PROCEDURE|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
219722336|NCT02269449|PROCEDURE|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
219555876|NCT03417427|DRUG|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
219555877|NCT03417427|DRUG|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
219555878|NCT00697827|DEVICE|Interspinous Spacer device|Device: In-Space
219555879|NCT00697827|DEVICE|Interspinous Process Distraction Device|Device: X STOP
219555880|NCT00247013|BEHAVIORAL|Breast Cancer Screening Compliance|
219722337|NCT00923702|BIOLOGICAL|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
219722338|NCT00748930|OTHER|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
219149651|NCT01308567|DRUG|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
219149652|NCT06103149|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
219149653|NCT03200626|PROCEDURE|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
219149654|NCT04135040|DIETARY_SUPPLEMENT|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
219149655|NCT02823938|OTHER|existing database on data collection.|This is an observational study on an existing database.
219149656|NCT03780686|DRUG|Norepinephrine, dopamine|drugs to decrease bleeding
219555881|NCT02386007|DRUG|DW-3101_150mg|
219555882|NCT02386007|DRUG|DW-3101_300mg|
219149657|NCT00977158|PROCEDURE|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
219555883|NCT02386007|DRUG|DW-3101_600mg|
219555884|NCT02386007|DRUG|Placebo|
219555885|NCT05686993|DRUG|Cinnarizine|Cinnarizine oral 30mg TDS
219555886|NCT05686993|DRUG|NIFEdipine ER|Nifedipine oral 60mg daily extended release
219555887|NCT04021511|OTHER|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
219149658|NCT00493350|PROCEDURE|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
219149659|NCT00542789|DRUG|Esomeprazole|20mg once daily oral
219149660|NCT00542789|DRUG|Placebo|once daily oral
219232393|NCT00667732|DRUG|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
219149661|NCT03462823|DEVICE|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
219149662|NCT03462823|DEVICE|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
219232394|NCT02725372|DRUG|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
219232395|NCT02725372|DRUG|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
219722339|NCT02365129|OTHER|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
219722340|NCT06444100|PROCEDURE|Impact of structural training on child abuse|"A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training."
219722341|NCT04145934|BEHAVIORAL|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
219722342|NCT00862901|DEVICE|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
219722343|NCT03426488|BEHAVIORAL|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
219722344|NCT01243125|DRUG|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
219722345|NCT01243125|DRUG|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
219722346|NCT05874297|OTHER|Best Practice|Receive standard of care
219555888|NCT04780451|DIETARY_SUPPLEMENT|Omega-3 supplementation in recreational runners|Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
219149663|NCT05956613|PROCEDURE|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
219149664|NCT06349655|DRUG|Azvudine|Antiviral drug
219555889|NCT01326351|PROCEDURE|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
219722347|NCT05874297|BEHAVIORAL|Internet-Based Intervention|Access to enhanced Cook for your life website
219722348|NCT05874297|OTHER|Questionnaire Administration|Ancillary studies
219232396|NCT01213940|BEHAVIORAL|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
219232397|NCT01213940|PROCEDURE|bariatric surgery|bariatric surgery for weight loss
219232398|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
219232399|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
219149665|NCT06349655|DRUG|Paxlovid|Antiviral drug
219149666|NCT01263613|PROCEDURE|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
219149667|NCT03595852|DRUG|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
219149668|NCT03595852|DRUG|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
219149669|NCT00929760|BEHAVIORAL|specialised renal care|"* Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
219149670|NCT05391464|PROCEDURE|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
219232400|NCT02284607|DRUG|Placebo|Matching placebo to MHAA4549A administration
219232401|NCT03890484|BEHAVIORAL|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
219232402|NCT03890484|BEHAVIORAL|Peer Type - Close Friends|Participants drink with 2 close friends
219722349|NCT05898373|DRUG|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
219232403|NCT01472159|BEHAVIORAL|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
219232404|NCT06369844|OTHER|Pressure injury education|Pressure injury education will be provided to participants in the intervention group in three separate sessions covering the topics of Pressure Injury Definition and Classification, Risk Assessment, Prevention, and Care.
219555890|NCT01326351|PROCEDURE|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
219555891|NCT01326351|BEHAVIORAL|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
219555892|NCT02856776|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D provided in capsule form
219555893|NCT02311894|DRUG|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
219555894|NCT03770130|DRUG|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
219555895|NCT03770130|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment
219555896|NCT04756739|DEVICE|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
219555897|NCT04645186|DEVICE|bone graft substitute|Filling bone defects in current clinical practice
219555898|NCT00662896|DRUG|naproxcinod 375 mg bid|naproxcinod 375 mg bid
219555899|NCT00662896|DRUG|naproxcinod 750 mg bid|naproxcinod 750 mg bid
219555900|NCT00662896|DRUG|naproxen 250 mg bid|naproxen 250 mg bid
219555901|NCT00662896|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
219555902|NCT00662896|DRUG|ibuprofen 600 mg tid|ibuprofen 600 mg tid
219555903|NCT05975112|DIAGNOSTIC_TEST|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
219555904|NCT00702507|DRUG|0.25 % Miconazole Nitrate Ointment|Topical Application
219555905|NCT00960596|BEHAVIORAL|Health promotion and health education for smoking habits|We provide the education to intervention group.
219555906|NCT00013364|BEHAVIORAL|Talker variability|
219555907|NCT04207333|BEHAVIORAL|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
219555908|NCT06180395|OTHER|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
219555909|NCT06180395|OTHER|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
219555910|NCT04396392|BEHAVIORAL|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
219555911|NCT00052923|BIOLOGICAL|filgrastim|
219555912|NCT00052923|BIOLOGICAL|rituximab|
219555913|NCT00052923|DRUG|carmustine|
219555914|NCT00052923|DRUG|cyclophosphamide|
219555915|NCT00052923|DRUG|etoposide|
219555916|NCT00052923|PROCEDURE|peripheral blood stem cell transplantation|
219555917|NCT00052923|RADIATION|radiation therapy|
219555918|NCT05079555|DEVICE|Robotic rehab|Patients using the robotic platform SWalker
219555919|NCT00000623|DRUG|Deferoxamine|
219555920|NCT00000623|DRUG|Deferiprone|
219555921|NCT00000623|DRUG|Arginine|
219555922|NCT00000623|DRUG|Sildenafil|
219555923|NCT00000623|DRUG|Decitabine|
219555924|NCT02323555|OTHER|Paramedic telephone consultation|
219555925|NCT02810223|BIOLOGICAL|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
219555926|NCT05727579|OTHER|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
219555927|NCT00594503|DRUG|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
219555928|NCT01647321|BEHAVIORAL|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
219149671|NCT01153880|DRUG|Retapamulin|Prescription sales claim of retapamulin
219149672|NCT01153880|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
219149673|NCT00382681|DEVICE|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
219149674|NCT00382681|DEVICE|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
219722350|NCT05898373|DRUG|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
219722351|NCT05898373|DRUG|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
219722352|NCT05898373|DRUG|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
219722353|NCT00977873|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
219722354|NCT00977873|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
219722355|NCT01302171|DRUG|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
219722356|NCT01302171|PROCEDURE|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
219722357|NCT03509597|BEHAVIORAL|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
219722358|NCT03509597|BEHAVIORAL|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
219722359|NCT03509597|BEHAVIORAL|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
219722360|NCT03509597|BEHAVIORAL|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
219149675|NCT01714492|DEVICE|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
219149676|NCT04108923|DEVICE|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
219149677|NCT04108923|PROCEDURE|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
219149678|NCT05481242|OTHER|retrospective observational study|retrospective observational study
219149679|NCT05863481|PROCEDURE|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
219149680|NCT01437605|DRUG|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
219149681|NCT01437605|DRUG|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
219149682|NCT01112670|DRUG|Sitagliptin|sitagliptin 100 mg x 1 dose
219149683|NCT01112670|DRUG|atorvastatin|atorvastatin 40 mg x 5 doses
219149684|NCT06518876|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
219149685|NCT02213744|DRUG|MM-302|
219149686|NCT02213744|DRUG|Gemcitabine|
219149687|NCT02213744|DRUG|Capecitabine|
219149688|NCT02213744|DRUG|Vinorelbine|
219149689|NCT02213744|DRUG|Trastuzumab|
219149690|NCT03973892|DIAGNOSTIC_TEST|Cere|Magnetic Rseonance imaging for brain tumour follow-up
219149691|NCT03454529|OTHER|Laboratory Biomarker Analysis|Correlative studies
219149692|NCT03454529|DRUG|Simvastatin|Given PO
219149693|NCT02120430|OTHER|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
219149694|NCT03895346|BEHAVIORAL|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
219149695|NCT03895346|BEHAVIORAL|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
219149696|NCT02825368|BIOLOGICAL|MMR|0.5 mL, subcutaneous
219149697|NCT02825368|BIOLOGICAL|Tdap|0.5 mL, intramuscular
219149698|NCT02825368|OTHER|Diphtherinum®|
219722361|NCT02327247|DRUG|Felodipine|Extended Release Tablets, 10mg
219722362|NCT02327247|DRUG|PLENDIL®|Extended Release Tablets, 10mg
219722363|NCT06049277|OTHER|Mulligan techniques with manual traction|group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
219722364|NCT06049277|OTHER|McKenzie extension exercises with manual traction|group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
219722365|NCT05140980|OTHER|Data collection|evaluation of women's knowledge concerning sexuality
219722366|NCT01033370|DRUG|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
219722367|NCT03132259|DRUG|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
219722368|NCT03132259|DRUG|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
219722369|NCT00738517|DEVICE|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
219722370|NCT00050427|DRUG|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
219722371|NCT00050427|DRUG|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
219722372|NCT02143778|DEVICE|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
219722373|NCT05719597|OTHER|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
219722374|NCT05719597|OTHER|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
219722375|NCT04517058|OTHER|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
219722376|NCT05706402|DRUG|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
219722377|NCT05706402|DRUG|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
219722378|NCT04938674|DEVICE|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
219722379|NCT03623490|OTHER|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
219722380|NCT06632860|DRUG|68Ga-TATE-RGD|Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
219722381|NCT06632860|DRUG|18-FDG|Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
219149699|NCT02825368|OTHER|Pertussinum®|
219149700|NCT02825368|OTHER|Tetanotxicum®|
219149701|NCT02825368|OTHER|Morbilinum®|
219149702|NCT02825368|OTHER|Ourlianum®|
219149703|NCT02825368|OTHER|Sterile saline|0.5 mL, intramuscular
219149704|NCT02825368|OTHER|Sugar pellets|
219149705|NCT00557024|PROCEDURE|RFA|radiofrequency ablation
219149706|NCT00557024|PROCEDURE|radiotherapy after RFA|radiotherapy after RFA
219149707|NCT02909413|DRUG|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
219149708|NCT02909413|DRUG|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
219149709|NCT02282267|DRUG|Gefitinib|Iressa 250mg oral daily
219149710|NCT04134611|DEVICE|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
219722382|NCT00625378|DRUG|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
219149711|NCT04134611|DEVICE|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
219149712|NCT02931214|DRUG|GMI-1359|
219149713|NCT02931214|DRUG|Placebo|
219149714|NCT03606915|BEHAVIORAL|pain evaluation|collect CSF during spinal anesthesia
219722383|NCT05339061|DEVICE|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
219722384|NCT03270241|DEVICE|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
219722385|NCT03391323|DEVICE|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
219722386|NCT03391323|DEVICE|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
219722387|NCT04386148|PROCEDURE|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
219722388|NCT05787509|DRUG|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
219722389|NCT02639559|DRUG|BL-8040|
219722390|NCT02639559|PROCEDURE|Leukapheresis|
219722391|NCT02639559|PROCEDURE|Hematopoietic cell transplant|
219722392|NCT01692756|DRUG|Kenalog or placebo|
219149715|NCT05016830|DEVICE|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
219149716|NCT01820780|OTHER|Natriuretic peptides levels to J7 and J14|
219149717|NCT01820780|OTHER|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
219149718|NCT01820780|OTHER|Phone calls in 6 months and 12 months|
219149719|NCT01820780|OTHER|Natriuretic peptides levels at 6 months|
219149720|NCT01820780|OTHER|Consultation with the general doctor or the cardiologist to J30 with blood results|
219149721|NCT01593319|DRUG|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
219149722|NCT01593319|DRUG|Natrium chloride|Placebo injection of Natrium chloride solution
219149723|NCT03813433|OTHER|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
219149724|NCT00223067|DRUG|TAIZ|
219149725|NCT00450359|PROCEDURE|breast imaging study|
219149726|NCT00450359|PROCEDURE|comparison of screening methods|
219149727|NCT00450359|PROCEDURE|radiomammography|
219232405|NCT00241826|PROCEDURE|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
219232406|NCT00241826|PROCEDURE|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
219555929|NCT01647321|BEHAVIORAL|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
219555930|NCT05529238|BEHAVIORAL|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
219149728|NCT04033107|DRUG|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
219149729|NCT04033107|DRUG|Metformin|Participants will orally take metformin 4g daily.
219555931|NCT00068042|DRUG|Pegvisomant|
219555932|NCT00068042|DRUG|Sandostatin LAR|
219555933|NCT03710551|OTHER|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
219555934|NCT03710551|OTHER|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
219555935|NCT06348277|BEHAVIORAL|Mindfulness plus mood monitoring|mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
219555936|NCT06348277|BEHAVIORAL|Mood monitoring|mobile app that prompts for mood monitoring three times per day
219555937|NCT01321177|BEHAVIORAL|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model"
219555938|NCT01321177|BEHAVIORAL|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management"
219555939|NCT04049097|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
219555940|NCT01924247|BEHAVIORAL|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
219555941|NCT01924247|BEHAVIORAL|Standard treatment by family physician|Standard treatment by family physician.
219555942|NCT06109337|DIAGNOSTIC_TEST|drow blood|Participants will be taken peripheral blood about 5 ml
219555943|NCT02013050|DRUG|SGX942|
219555944|NCT02013050|DRUG|Placebo|
219555945|NCT02086838|DRUG|Theragran Hematinic|
219555946|NCT02086838|DRUG|low molecular weight iron dextran|
219555947|NCT02686567|PROCEDURE|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
219555948|NCT02686567|PROCEDURE|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
219555949|NCT00271973|DRUG|Oxycodone|
219149730|NCT06419569|OTHER|high power laser|Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
219555950|NCT01285076|OTHER|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
219555951|NCT02737462|DRUG|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
219555952|NCT06678594|PROCEDURE|Calcium modification|"Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy"
219555953|NCT04117880|DRUG|Ataluren|Oral
219555954|NCT01690260|DRUG|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
219555955|NCT01690260|PROCEDURE|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
219555956|NCT06236880|DRUG|GM-2505|IV
219555957|NCT02712294|OTHER|Neuromuscular Electrical Stimulation|
219555958|NCT00908180|BIOLOGICAL|alemtuzumab|
219555959|NCT00908180|BIOLOGICAL|donor lymphocytes|
219555960|NCT00908180|DRUG|carmustine|
219555961|NCT00908180|DRUG|cyclosporine|
219555962|NCT00908180|DRUG|cytarabine|
219555963|NCT00908180|DRUG|etoposide|
219555964|NCT00908180|DRUG|melphalan|
219555965|NCT00908180|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219555966|NCT04526080|DEVICE|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
219555967|NCT04526080|DEVICE|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
219555968|NCT01970592|BEHAVIORAL|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
219555969|NCT03711357|RADIATION|980 nm diode laser|980 nm high power diode laser device.
219555970|NCT03711357|OTHER|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
219555971|NCT02202057|OTHER|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
219555972|NCT02202057|OTHER|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
219555973|NCT01711801|DRUG|Placebo|Single ascending dose
219555974|NCT01711801|DRUG|RO5545965|Single ascending dose
219555975|NCT01711801|DRUG|RO5545965|Single dose, in fed and fasted state
219555976|NCT03407222|OTHER|Text messages|Text messages which encourage the increment of daily step count
219555977|NCT03980522|DRUG|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
219555978|NCT01675973|DRUG|RANEXA|500mg BID up to 1000mg BID
219555979|NCT05721092|OTHER|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
219722393|NCT01692756|DRUG|Kenalog then Placebo|
219722394|NCT01692756|DRUG|Kenalog|
219722395|NCT01692756|DRUG|Placebo|
219232407|NCT03572894|DEVICE|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~* T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~* T1 : Vt 8 mL/Kg of PBW during 5 minutes~* T2 : Vt 10 mL/kg of PBW during 5 minutes~* T3 : Vt 6 mL/kg of PBW during 5 minutes~* T4 : A single recruitment maneuver~Data will be recorded at each step."
219232408|NCT04216641|DIETARY_SUPPLEMENT|Adapted food intervention|Adapted food intervention
219232409|NCT00420368|DIETARY_SUPPLEMENT|No food supplement|
219232410|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: fortified spread|
219232411|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|
219232412|NCT02656199|PROCEDURE|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
219555980|NCT05616455|DRUG|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
219555981|NCT05616455|DRUG|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
219555982|NCT00769496|DRUG|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
219555983|NCT01970917|DEVICE|Olixia pure eye drops|
219555984|NCT01970917|DEVICE|Placebo|0.9% physiological saline solution
219555985|NCT00245986|PROCEDURE|Blood draw|
219555986|NCT02077335|RADIATION|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
219555987|NCT04641403|PROCEDURE|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
219555988|NCT06447441|OTHER|Placebo|Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
219555989|NCT06447441|OTHER|Cholecalciferol|Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
219555990|NCT04892147|BEHAVIORAL|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
219555991|NCT00498264|BEHAVIORAL|walking program, resistance muscular exercise|
219555992|NCT04491838|DRUG|Pozelimab|Single subcutaneous (SC) injection
219555993|NCT02343796|OTHER|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
219555994|NCT02343796|DEVICE|everStick|GC, Belgium
219555995|NCT01299779|DRUG|PEG-SD|"PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients."
219555996|NCT01299779|DRUG|PEG-ELS|"* 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
219555997|NCT01554111|DRUG|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
219555998|NCT01554111|DRUG|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
219555999|NCT01554111|DRUG|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
219722396|NCT03880565|DEVICE|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
219722397|NCT03880565|DEVICE|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
219722398|NCT02969018|DRUG|PF-06700841|
219722399|NCT02969018|OTHER|Placebo|
219722400|NCT02292251|BEHAVIORAL|Device-assisted therapy|
219722401|NCT02292251|BEHAVIORAL|Therapy-based occupational therapy|
219722402|NCT01723605|PROCEDURE|insitu repair|closure of the uterine incision while the uterus initu
219722403|NCT01723605|PROCEDURE|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
219722404|NCT00367458|DRUG|Atorvastatin|80 mg atorvastatin oral daily
219722405|NCT00367458|DRUG|Placebo|patients will be administered placebo
219556000|NCT00338390|DRUG|Abacavir|Change tenofovir to abacavir
219149731|NCT06419569|OTHER|low level laser|patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
219149732|NCT06419569|OTHER|conventional physical therapy|the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
219149733|NCT01405807|DRUG|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
219149734|NCT01557855|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
219722406|NCT01731496|OTHER|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
219722407|NCT01731496|OTHER|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
219149735|NCT03465527|DRUG|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
219149736|NCT04290572|DRUG|Isotretinoin capsules|Jelly capsules of isotretinoin
219149737|NCT04504786|OTHER|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
219722408|NCT01616927|DRUG|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
219722409|NCT02556788|DRUG|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
219722410|NCT02556788|DRUG|Placebo Cream|Placebo cream applied once daily during 12 weeks.
219722411|NCT04664309|OTHER|No intervention|No intervention
219722412|NCT01381640|DRUG|Marketed paracetamol|marketed formulation
219149738|NCT04504786|OTHER|Control|Participants maintained their daily activities.
219149739|NCT00779870|OTHER|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
219149740|NCT02206750|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219149741|NCT02206750|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219149742|NCT01582100|DEVICE|Reletex|Neuromodulation device worn on the wrist
219232413|NCT04707599|OTHER|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
219232414|NCT00016107|DRUG|estramustine phosphate sodium|Given orally
219232415|NCT00016107|DRUG|docetaxel|Given IV
219232416|NCT00016107|BIOLOGICAL|bevacizumab|Given IV
219232417|NCT00016107|OTHER|laboratory biomarker analysis|Correlative studies
219232418|NCT00036140|DRUG|Investigational drug|
219722413|NCT01381640|DRUG|Experimental paracetamol formulation|Experimental formulation
219722414|NCT06095531|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
219722415|NCT02217033|OTHER|'R' (Electro-kinetically altered beverage)|
219722416|NCT02217033|OTHER|Placebo (water)|
219722417|NCT02334189|BEHAVIORAL|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
219722418|NCT03943082|BEHAVIORAL|Cancer Educational Materials|Receive FRP brochure
219722419|NCT03943082|OTHER|Follow-Up Care|Receive follow-up phone call
219722420|NCT03943082|BEHAVIORAL|Questionnaire|Ancillary studies
219722421|NCT03524144|OTHER|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
219722422|NCT06229834|PROCEDURE|Chiropractic Care|The chiropractic care protocol can be personalized to the patient's clinical needs and follows the scope of chiropractic care practice in the Commonwealth of Massachusetts and the State of Connecticut. Components of the chiropractic intervention include: posture correction / spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation (i.e. chiropractic adjustment) / mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports.
219734751|NCT03661580|BEHAVIORAL|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
219232419|NCT01319344|DRUG|Eplerenone|25 mg o.d. per os
219556001|NCT00338390|DRUG|Didanosine|Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
219556002|NCT00338390|DRUG|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
219556003|NCT06185244|BEHAVIORAL|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
219149743|NCT00421070|PROCEDURE|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
219556004|NCT06185244|BEHAVIORAL|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
219556005|NCT05263505|DRUG|Baricitinib 2 MG [Olumiant]|Two tabs daily
219556006|NCT05263505|DRUG|Methotrexate|Target dose: 20mg weekly
219556007|NCT05263505|DRUG|Azathioprine|Target dose: 2mg/kg daily
219722423|NCT06229834|BEHAVIORAL|Headache Health Education|"Participants randomized to the HHE arm will receive 14 interactive 15-minute education sessions delivered via video conference.~To partially control for attention and expectation associated with chiropractic care, participants randomized to the control group will receive a modified version of a headache education intervention we employed in our pilot study. Participants randomized to HHE will receive 14 interactive 15-minute education sessions delivered via VA or MGB Teams. Material to be covered will focus on pre-defined migraine-specific topics, compared with the control for our pilot study, in addition to greater contact time, HHE will be delivered in a more interactive manner utilizing active learning principles known to support adult learning. We will also utilize publicly available short videos (e.g., from the American Headache Society) followed by scripted discussions with the participant. Example topics include the physiology of migraine or the contribution of life."
219722424|NCT05553912|BEHAVIORAL|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
219722425|NCT03521596|OTHER|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
219722426|NCT03361345|DRUG|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
219722427|NCT03361345|DRUG|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
219722428|NCT01857518|OTHER|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"* Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging"
219722429|NCT04655872|DRUG|[14C]TPN171H|A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
219556008|NCT05263505|DRUG|Mycophenolate|Target Dose: 1g twice daily
219556009|NCT03261817|BEHAVIORAL|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
219556010|NCT03261817|BEHAVIORAL|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
219722430|NCT00471120|OTHER|P2x7 assay|compare P2X7 assay to biopsy
219722431|NCT01017497|RADIATION|Stereotactic Radiosurgery|PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
219149744|NCT00130156|DRUG|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
219149745|NCT00130156|DRUG|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
219149746|NCT00130156|DRUG|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
219149747|NCT03415360|PROCEDURE|cryoablation|cryoablation of nerve responsible for phantom limb pain
219149748|NCT04592575|OTHER|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
219149749|NCT00654316|BIOLOGICAL|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
219149750|NCT02652091|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
219149751|NCT02652091|DEVICE|BETACONNECT device|Used to apply Betaseron.
219149752|NCT04700189|DEVICE|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
219149753|NCT01733095|DRUG|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
219149754|NCT01294215|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
219149755|NCT01178034|GENETIC|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
219149756|NCT04676334|DRUG|Rucaparib|Rucaparib will be administered daily.
219149757|NCT02259543|OTHER|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
219149758|NCT00448734|DRUG|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
219232420|NCT00774605|DRUG|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
219232421|NCT00774605|DRUG|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
219556011|NCT00913536|OTHER|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
219556012|NCT04721145|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
219556013|NCT03501420|OTHER|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
219556014|NCT03501420|OTHER|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
219556015|NCT03501420|OTHER|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
219556016|NCT03266276|OTHER|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
219556017|NCT05590676|DRUG|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
219556018|NCT05826301|OTHER|Percutaneous neuromodulation in tibial nerve|The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
219556019|NCT05826301|OTHER|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK"
219734752|NCT04928404|PROCEDURE|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
219734753|NCT00666471|PROCEDURE|MICE|MICE
219734754|NCT00666471|PROCEDURE|SPA ligation|SPA ligation
219734755|NCT06695897|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
219734756|NCT03614780|BEHAVIORAL|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
219734757|NCT02355470|BEHAVIORAL|GIFTSS|Universal education and brief counseling regarding sexual violence
219734758|NCT02355470|BEHAVIORAL|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
219734759|NCT01275937|DRUG|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
219734760|NCT01275937|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
219734761|NCT07056413|PROCEDURE|BRILMA block|20 ml 0.25 % bupivacaine was injected into the fascial plane between the serratus anterior muscle and the external intercostal muscle at T4 level.
219149759|NCT00448734|DRUG|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
219149760|NCT02624258|BIOLOGICAL|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
219149761|NCT00404573|DRUG|RGH-188|
219722432|NCT02473601|DRUG|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
219722433|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Professional Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
219722434|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Lay Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
219722435|NCT04790201|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
219149762|NCT01426698|PROCEDURE|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
219149763|NCT03795194|DRUG|ampicillin/clavulanate|FDA-approved antibiotic
219149764|NCT01040689|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
219149765|NCT01040689|DRUG|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
219149766|NCT01040689|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
219149767|NCT01040689|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
219149768|NCT01040689|DRUG|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
219149769|NCT01812096|OTHER|Subcutaneous bortezomib|
219149770|NCT01812096|OTHER|Intravenous bortezomib|
219149771|NCT04174768|PROCEDURE|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
219149772|NCT06214442|OTHER|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
219149773|NCT00158782|DRUG|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
219149774|NCT00158782|DRUG|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
219149775|NCT01185561|BEHAVIORAL|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
219149776|NCT03570437|DRUG|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
219149777|NCT03570437|DRUG|Cediranib|20 mg per day
219149778|NCT03570437|DRUG|Olaparib|Olaparib tablets, 300 mg twice-daily
219149779|NCT04447482|DEVICE|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
219149780|NCT04447482|PROCEDURE|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
219149781|NCT00105807|BEHAVIORAL|participation in low intensity exercise|
219232422|NCT06402292|PROCEDURE|OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL|25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
219722436|NCT05606016|BEHAVIORAL|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
219149782|NCT00105807|BEHAVIORAL|participation in art and music activities|
219232423|NCT04084262|DEVICE|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
219232424|NCT03507998|DRUG|CGX1321|CGX1321 capsules for oral administration
219232425|NCT01130870|DEVICE|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
219149783|NCT01058785|BIOLOGICAL|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
219149784|NCT01824420|DRUG|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
219232426|NCT01130870|DEVICE|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
219556020|NCT05568758|OTHER|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
219556021|NCT05568758|OTHER|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
219556022|NCT06662617|OTHER|modified thoracoabdominal nerve block through perichondrial approach|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
219556023|NCT06662617|OTHER|Transversus Abdominal Plane block|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral TAP block application, USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline . After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
219149785|NCT01824420|DRUG|Detrusitol 4mg QD|Control group
219149786|NCT03032913|PROCEDURE|Blood samples|Blood samples for both group
219149787|NCT03032913|PROCEDURE|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
219149788|NCT02432950|DIETARY_SUPPLEMENT|Dietary Intervention|Participate in the PNP
219149789|NCT02432950|OTHER|Educational Intervention|Participate in the PNP
219149790|NCT02432950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219149791|NCT02432950|OTHER|Quality-of-Life Assessment|Ancillary studies
219149792|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
219149793|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
219149794|NCT01488734|DIETARY_SUPPLEMENT|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
219149795|NCT01488734|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
219556024|NCT01931345|BEHAVIORAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
219556025|NCT01931345|BEHAVIORAL|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
219556026|NCT04970862|PROCEDURE|reversion surgery|reversion surgery
219556027|NCT05449080|DIAGNOSTIC_TEST|Karyotype|Patients were subjected to karyotype to determine their genotype
219556028|NCT02661022|DRUG|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
219556029|NCT02661022|DRUG|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
219556030|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
219556031|NCT03886363|BEHAVIORAL|MBSR|Described previously
219556032|NCT05619796|PROCEDURE|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
219734762|NCT07056413|OTHER|Standard intravenous analgesia.|Standard intravenous analgesia.
219734763|NCT06751992|DRUG|Conversion to extended-release tacrolimus|Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
219149796|NCT01488734|DRUG|Placebo|Placebo for the fortified mushroom arms
219149797|NCT02616900|DEVICE|eSight Eyewear|primary intervention
219149798|NCT00338650|DRUG|adalimumab|
219149799|NCT02075736|PROCEDURE|KTP laser|
219722437|NCT05606016|BEHAVIORAL|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
219722438|NCT05606016|BEHAVIORAL|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
219722439|NCT02650557|PROCEDURE|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
219722440|NCT06510582|DRUG|Bevacizumab 2 mg/kg|Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
219722441|NCT06510582|DRUG|Bevacizumab 4 mg/kg|Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
219722442|NCT02842099|DRUG|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
219722443|NCT02842099|DRUG|X|Capecitabine
219722444|NCT04560218|DRUG|sublingual Misoprostol|apply drug by Anesthesiologist
219722445|NCT04560218|DRUG|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
219722446|NCT03670628|DEVICE|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
219722447|NCT03670628|OTHER|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
219722448|NCT01431846|BEHAVIORAL|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
219722449|NCT01651884|DEVICE|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
219722450|NCT01651884|DEVICE|Transcranial Direct Current Stimulation (Neuroconn)|
219722451|NCT01899885|PROCEDURE|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
219722452|NCT00741949|DRUG|Propofol|Sedation in TCI with propofol
219149800|NCT02075736|PROCEDURE|TUR-P|device
219149801|NCT02403297|DEVICE|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
219149802|NCT02813369|DRUG|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
219232427|NCT01130870|DEVICE|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
219722453|NCT00741949|DRUG|Placebo|Isotonic saline solution infusion
219722454|NCT04307563|BEHAVIORAL|Mindfulness session|1.5 hour weekly session with health educator
219734764|NCT06751992|DRUG|Maintenance of immediate-release tacrolimus|Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
219149803|NCT02813369|DRUG|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
219149804|NCT02499159|DRUG|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
219149805|NCT02499159|DRUG|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
219149806|NCT00002287|DRUG|Zidovudine|
219149807|NCT00002036|DRUG|Anti-HIV Immune Serum Globulin (Human)|
219149808|NCT00036244|DRUG|RG1068 (Synthetic Human Secretin)|
219149809|NCT01477255|BEHAVIORAL|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
219232428|NCT04718285|DRUG|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
219232429|NCT04718285|DRUG|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
219149810|NCT00710775|PROCEDURE|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
219722455|NCT03240380|BEHAVIORAL|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
219722456|NCT03240380|BEHAVIORAL|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
219232430|NCT04718285|DRUG|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
219722457|NCT00057070|PROCEDURE|Smoking cessation information, collection, and dissemination|
219722458|NCT02614014|BEHAVIORAL|Cognitive-behavior interventional program|
219722459|NCT02691663|DIETARY_SUPPLEMENT|Oral bicarbonate supplementation|
219722460|NCT02691663|DIETARY_SUPPLEMENT|Placebo|
219556033|NCT05619796|RADIATION|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
219149811|NCT05384366|DRUG|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
219149812|NCT04079244|BEHAVIORAL|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
219149813|NCT04079244|BEHAVIORAL|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
219149814|NCT04373434|BEHAVIORAL|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
219149815|NCT04373434|BEHAVIORAL|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
219149816|NCT03903614|BEHAVIORAL|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
219149817|NCT03903614|BEHAVIORAL|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
219149818|NCT00752713|PROCEDURE|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
219149819|NCT00133458|DRUG|Albendazole|
219149820|NCT06025318|DRUG|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
219149821|NCT03976557|DEVICE|BIP CVC|Central venous access with noble metal coated CVC
219149822|NCT03976557|DEVICE|Standard CVC|Central venous access with standard uncoated CVC
219149823|NCT04294862|DRUG|TNP-2092|TNP-2092 for injection 100mg/vial
219149824|NCT06232889|DIAGNOSTIC_TEST|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
219149825|NCT02564744|DRUG|Debio 1562|Administered as IV Infusion.
219149826|NCT02564744|DRUG|Rituximab|Administered as IV Infusion.
219149827|NCT03204396|DRUG|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
219149828|NCT03204396|DRUG|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
219149829|NCT01190007|DRUG|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
219149830|NCT03109795|DRUG|Clonidine Pill|sympathetic nerve activity blockade
219232431|NCT03305172|BEHAVIORAL|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
219722461|NCT02271542|DRUG|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
219722462|NCT01164605|DRUG|Raltegravir|60 tablets (30-day supply)
219722463|NCT06264622|DIETARY_SUPPLEMENT|Low dose|2 tablets per day during the morning for 12 weeks.
219722464|NCT06264622|DIETARY_SUPPLEMENT|High dose|2 tablets per day during the morning for 12 weeks.
219722465|NCT06264622|DIETARY_SUPPLEMENT|Placebo|2 tablets per day during the morning for 12 weeks.
219722466|NCT06296849|BEHAVIORAL|Financial Incentive Treatment (FIT)|In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
219722467|NCT05312060|DEVICE|PC Pneumatic compression|Pneumatic compression of the operated limb
219722468|NCT05312060|OTHER|AE Antithromboembolic exercises|Exercises for the edema
219722469|NCT01334775|PROCEDURE|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
219556034|NCT05619796|OTHER|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
219556035|NCT04000776|DIAGNOSTIC_TEST|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
219149831|NCT03109795|DRUG|Hydrochlorothiazide|Blood pressure-lowering control condition
219149832|NCT04277715|BEHAVIORAL|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
219556036|NCT04000776|DIAGNOSTIC_TEST|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
219556037|NCT04000776|DIAGNOSTIC_TEST|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
219149833|NCT03753841|OTHER|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
219722470|NCT03683901|DEVICE|TENS|Electrical Stimulation
219722471|NCT03683901|DEVICE|t-NMES|Electrical Stimulation
219722472|NCT03683901|OTHER|No stimulation|No stimulation
219722473|NCT05210946|DRUG|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
219149834|NCT02076451|DRUG|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
219722474|NCT03324958|DEVICE|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
219722475|NCT03324958|OTHER|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
219722476|NCT05722795|DRUG|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
219722477|NCT01104298|DRUG|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
219722478|NCT01104298|DRUG|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
219722479|NCT05424198|PROCEDURE|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
219722480|NCT06069609|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
219722481|NCT06069609|DEVICE|Acuvue Oasys 1-Day for Astigmatism|Acuvue Oasys 1-Day for Astigmatism
219722482|NCT03892733|BEHAVIORAL|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
219722483|NCT02371005|RADIATION|Cone Beam Computed Tomography (CBCT)|
219722484|NCT06398587|DRUG|Onvansertib|Given PO
219722485|NCT06398587|DRUG|Gemcitabine|Given IV
219722486|NCT06398587|DRUG|Nab-paclitaxel|Given IV
219722487|NCT06398587|PROCEDURE|Electrocardiography|Undergo electrocardiography
219722488|NCT06398587|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219149835|NCT01694446|OTHER|Intraduodenal glucose or fructose|
219149836|NCT02954016|DEVICE|ePass|Subject is implanted with the device for up to 3 years.
219149837|NCT02378337|OTHER|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
219149838|NCT00643929|DRUG|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
219149839|NCT02641990|DRUG|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
219556038|NCT04000776|OTHER|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
219149840|NCT02641990|DRUG|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
219149841|NCT02594735|DRUG|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
219232432|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
219556039|NCT01085669|DEVICE|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
219722489|NCT06398587|PROCEDURE|Positron Emission Tomography|Undergo PET
219722490|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219722491|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo tumor biopsy
219722492|NCT06398587|PROCEDURE|Computed Tomography|Undergo CT
219722493|NCT00186511|BEHAVIORAL|workbook/journal on coping with breast cancer|
219722494|NCT00186511|BEHAVIORAL|supportive expressive group therapy using videoconferencing|
219722495|NCT05115253|BEHAVIORAL|HAPA behavioural counselling + SMS text message boosters|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
219722496|NCT05115253|DEVICE|JITAI|EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
219722497|NCT01092156|BEHAVIORAL|Education|Education on Infant-led latching
219722498|NCT00768677|DRUG|topiramate|
219722499|NCT02177292|RADIATION|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
219722500|NCT00899275|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219149842|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
219722501|NCT03281915|PROCEDURE|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
219722502|NCT03281915|PROCEDURE|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
219722503|NCT01716156|DRUG|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
219722504|NCT01716156|DRUG|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
219722505|NCT03925220|BEHAVIORAL|The SUPPER Project|Substance Use Promoted by Eating family meals Regularly
219556040|NCT02707276|DEVICE|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
219722506|NCT03925220|BEHAVIORAL|Improving nutrition and physical activity among youth|A brief intervention focused on improving nutrition and physical activity among youth
219722507|NCT03814356|DRUG|Methylphenidate|IV MPH
219556041|NCT02707276|DEVICE|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
219149843|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
219149844|NCT02962791|PROCEDURE|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
219556042|NCT03448692|DRUG|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
219556043|NCT02742701|OTHER|diagnosis|Measurement of glycosuria
219722508|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
219722509|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
219722510|NCT04074512|DRUG|copper histidinate|copper histidinate for subcutaneous injection
219722511|NCT05221866|BEHAVIORAL|Empowering Patient to Steer Their Pain Management After Surgery|Participants will be randomized to receive the consumer health informatics app (UControlPain) versus an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or participants.
219722512|NCT05221866|BEHAVIORAL|Provider-facing Prescription Aid|Providers will be given information to inform a participant-centered post-discharge pain management plan. This tool will be activated once half the subjects are enrolled. Participants will be masked when the provider-facing tool is turned on.
219722513|NCT05561140|DRUG|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
219722514|NCT05561140|OTHER|Placebo|Placebo
219722515|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
219149845|NCT02962791|DEVICE|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
219556044|NCT04155840|DRUG|Copanlisib|Given IV
219556045|NCT04155840|BIOLOGICAL|Rituximab|Given IV
219556046|NCT04155840|DRUG|Bendamustine|Given IV
219556047|NCT04411017|PROCEDURE|Endoscopy|Colonoscopy
219556048|NCT02459886|DRUG|BIIB054|IV infusion
219149846|NCT02962791|DEVICE|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
219149847|NCT02962791|DEVICE|Echocardiography|Standard Echocardiography will de bone for patient
219149848|NCT04567407|DRUG|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
219149849|NCT01316263|BIOLOGICAL|Olaratumab|Administered IV
219556049|NCT02459886|DRUG|Placebo|IV infusion
219556050|NCT03702816|DRUG|GE180 PET Scan|GE180 PET Scan
219556051|NCT00001217|DRUG|pre-surgical chemotherapy|
219722516|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
219722517|NCT05658731|RADIATION|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
219722518|NCT05658731|OTHER|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
219722519|NCT05658731|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
219722520|NCT06216873|OTHER|multiple trauma|Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
219722521|NCT05199480|DRUG|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
219722522|NCT05199480|DRUG|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
219722523|NCT06961058|OTHER|referral to telehealth treatment|the intervention tested will be referral to get outpatient treatment via telehealth. Participants in the telehealth arm will receive the intervention.
219722524|NCT06961058|OTHER|referral to in person treatment|participants in the in person arm will be referred to in person OUD treatment after they leave the ED
219722525|NCT05568706|DRUG|EDP-938|Subjects will take EDP-938 once daily for 5 days
219722526|NCT05568706|DRUG|Placebo|Subjects will take matching placebo, once daily for 5 days
219722527|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
219722528|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
219722529|NCT05536297|DRUG|avacincaptad pegol|Intravitreal Injection
219722530|NCT05250037|PROCEDURE|Home spirometry|Undergo spirometry measurements
219722531|NCT05250037|PROCEDURE|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
219722532|NCT05250037|OTHER|Questionnaire Administration|Complete questionnaires
219722533|NCT04225871|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
219722534|NCT01944774|DRUG|Nemonoxacin 500 mg|IV Infusion, once daily for 7\~14 days
219149850|NCT00475319|DRUG|placebo|comparison of different dosages of drug
219149851|NCT00475319|DRUG|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
219149852|NCT00475319|DRUG|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
219149853|NCT01318655|DRUG|NKTR-118|Tablet, Oral, Once daily
219149854|NCT01318655|DRUG|Placebo|Tablet, Oral, Once daily
219149855|NCT04969172|DRUG|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
219149856|NCT02080650|DEVICE|Mesenchymal-marker based ferrofluid (c-MET)|
219149857|NCT02080650|DEVICE|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
219149858|NCT03470142|PROCEDURE|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
219232433|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
219556052|NCT02825316|BEHAVIORAL|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
219149859|NCT03470142|PROCEDURE|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
219149860|NCT06250413|OTHER|FMT|Capsulated oral auto fecal microbiota transplant
219149861|NCT06250413|OTHER|Placebo|Capsulated hot chocolate powder
219149862|NCT06250413|DRUG|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
219149863|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
219149864|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
219149865|NCT05311137|PROCEDURE|Radiofrequency ablation|Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
219149866|NCT03511651|PROCEDURE|PEEP|Two PEEP levels will be used during mechanical ventilation.
219149867|NCT02599935|DIETARY_SUPPLEMENT|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
219149868|NCT02599935|OTHER|standard treatment|No other than standard treatment
219149869|NCT02599935|OTHER|educational structured counseling|Nutritional counseling leaded to patient and caregivers
219149870|NCT02472782|DRUG|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
219149871|NCT00886951|DRUG|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
219149872|NCT01222910|DRUG|Valacyclovir hydrochloride|
219556053|NCT02825316|BEHAVIORAL|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
219556054|NCT01478516|PROCEDURE|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
219556055|NCT02361736|DRUG|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
219556056|NCT02361736|DRUG|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
219556057|NCT04509232|PROCEDURE|Silver diamine fluoride|"Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
219556058|NCT04509232|PROCEDURE|Silver diamine fluoride and glass ionomer|"* 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
219556059|NCT04987749|DEVICE|intermittent theta burst stimulation|stimulatory protocol
219722535|NCT01944774|DRUG|Nemonoxacin 650 mg|IV Infusion, once daily for 7\~14 days
219722536|NCT01944774|DRUG|Moxifloxacin 400 mg|IV Infusion, once daily for 7\~14 days
219722537|NCT04095637|DEVICE|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
219722538|NCT06961838|OTHER|Inspiratory muscle training programme|In addition to their standard treatment, individuals in the inspiratory muscle training group will participate in inspiratory muscle training for a total of 30 minutes with a threshold loading device (POWERbreathe®) for 15 minutes twice a day, 5 days a week for 4 weeks under the supervision of a physiotherapist.
219149873|NCT04370418|DRUG|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
219149874|NCT01075217|DRUG|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
219149875|NCT01075217|DRUG|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
219149876|NCT05702658|BEHAVIORAL|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
219149877|NCT02969863|DEVICE|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
219149878|NCT02969863|DEVICE|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
219149879|NCT02969863|OTHER|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
219149880|NCT02969863|OTHER|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
219149881|NCT04072653|PROCEDURE|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
219149882|NCT06518538|DRUG|CPI-613, modified Folfirinox|"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"
219149883|NCT03737240|DRUG|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
219149884|NCT03737240|DRUG|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
219556060|NCT01785615|DRUG|Atorvastatin|80mg
219556061|NCT01785615|OTHER|Placebo|80mg
219556062|NCT01984606|DRUG|Empagliflozin|Empagliflozin once daily
219556063|NCT01984606|DRUG|Placebo|Placebo matching empagliflozin
219556064|NCT01984606|DRUG|Sitagliptin|Sitagliptin once daily
219556065|NCT01984606|DRUG|Placebo|Placebo matching sitagliptin
219556066|NCT03428945|DRUG|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
219556067|NCT03428945|DRUG|Placebo|Placebo tablet identical to active drug
219556068|NCT05926245|DIETARY_SUPPLEMENT|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
219556069|NCT05926245|DIETARY_SUPPLEMENT|Placebo Solution|Empty nanoparticles
219556070|NCT01746654|DRUG|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
219556071|NCT01746654|DRUG|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
219556072|NCT01746654|DRUG|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
219556073|NCT01746654|DRUG|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
219556074|NCT02474654|DRUG|Bupivicaine|15mg
219556075|NCT02474654|DRUG|Fentanyl|15mcg
219556076|NCT02474654|DRUG|Epimorphine|150mcg
219556077|NCT02474654|DRUG|Normal Saline|0.3 ml
219556078|NCT02474654|DRUG|Normal Saline|30ml
219556079|NCT02474654|DRUG|Normal Saline|100 ml
219556080|NCT02474654|DRUG|Ropivicaine|100 ml
219556081|NCT02474654|DRUG|Epinephrine|600 mcg
219556082|NCT02474654|DRUG|Ketorolac|30 mg
219556083|NCT02474654|DRUG|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
219556084|NCT03827005|DIETARY_SUPPLEMENT|L-arginine|NOW Foods, Bloomingdale, IL
219556085|NCT03827005|DIETARY_SUPPLEMENT|Placebo|InHealth Specialty Pharmacy, Fargo, ND
219556086|NCT01953172|DIETARY_SUPPLEMENT|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
219556087|NCT01953172|OTHER|Placebo|Placebo
219556088|NCT00337558|DRUG|Solifenacin succinate|tablet
219556089|NCT00337558|BEHAVIORAL|Simplified bladder training|Instructions
219556090|NCT04753541|OTHER|no intervention|this is not an interventional study
219556091|NCT03749915|DEVICE|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
219556092|NCT03749915|DRUG|Ametop|Tetracaine Hydrochloride Gel 4%
219149885|NCT03737240|DRUG|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
219149886|NCT04164056|DEVICE|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
219722539|NCT06961838|OTHER|control group|Individuals in the control group will continue their standard treatment. No changes will be made in the medical treatments (type, dosage and frequency) of the individuals in both groups (the inspiratory muscle training group and the control group) during the study.
219722540|NCT01188447|PROCEDURE|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
219722541|NCT02941497|BEHAVIORAL|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
219722542|NCT02714647|BEHAVIORAL|Attentional prime|
219722543|NCT02714647|BEHAVIORAL|Sham prime|
219722544|NCT01837342|PROCEDURE|Surgical reserction|
219722545|NCT01837342|OTHER|Radiological percutaneous drainage and washing drainage|
219722546|NCT00254085|DRUG|Insulin Aspart|
219722547|NCT02460731|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion
219722548|NCT06290713|DRUG|Tadalafil|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
219722549|NCT06290713|DRUG|Placebo|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
219722550|NCT06290713|OTHER|Exercise Training|The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
219722551|NCT03815305|DRUG|Centella Asiatica Extract|centlla asiatica oral drug at 1100 mg dose
219722552|NCT03815305|DRUG|Topical CA|1% centella asiatica ointment
219149887|NCT04722588|OTHER|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
219722553|NCT03815305|DRUG|Petroleum jelly|vaseline album
219722554|NCT00112333|PROCEDURE|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
219722555|NCT03325439|DRUG|Brivaracetam (BRV) intravenous (iv)|"Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment."
219722556|NCT03325439|DRUG|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
219722557|NCT01179516|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
219722558|NCT01179516|DRUG|Placebo|Vortioxetine placebo-matching capsules
219149888|NCT04075942|PROCEDURE|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
219149889|NCT00080639|OTHER|physiologic testing|
219149890|NCT00080639|PROCEDURE|study of high risk factors|
219149891|NCT00364013|DRUG|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
219149892|NCT00364013|DRUG|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
219232434|NCT03864159|OTHER|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
219556093|NCT04883788|OTHER|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
219556094|NCT02086617|OTHER|ultrasound of aorta|
219556095|NCT05380050|BEHAVIORAL|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
219556096|NCT05380050|BEHAVIORAL|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
219556097|NCT02311517|DRUG|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
219556098|NCT02311517|DRUG|Normal Saline|
219556099|NCT03888534|DRUG|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
219556100|NCT03900039|DEVICE|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
219556101|NCT02571257|DRUG|Gemcabene|1-300 mg tablet, QD, 56 days
219556102|NCT02571257|DRUG|Gemcabene|3-300 mg tablets, QD, 56 days
219556103|NCT02571257|DRUG|Placebo|
219556104|NCT01597349|DRUG|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
219556105|NCT02287220|DEVICE|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
219556106|NCT00000380|DRUG|GHRH|
219556107|NCT00240734|DRUG|Epoetin alfa|
219556108|NCT03319394|BEHAVIORAL|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
219556109|NCT03319394|BEHAVIORAL|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
219556110|NCT03346902|DRUG|EB-001|Injection of EB-001 into area of scarring (forehead)
219556111|NCT03346902|DRUG|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
219556112|NCT04553406|DRUG|SPR720|Capsules for oral administration
219556113|NCT04553406|DRUG|Placebo|Capsules for oral administration
219556114|NCT04553406|DRUG|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
219149893|NCT04155177|PROCEDURE|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
219149894|NCT01434862|DRUG|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
219149895|NCT01434862|DEVICE|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
219149896|NCT01434862|DRUG|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
219149897|NCT06259474|COMBINATION_PRODUCT|Hypopressive Exercises and (heat therapy, medication, and progressive strength training)|20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
219556115|NCT00772148|DRUG|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
219149898|NCT00006224|DRUG|gemcitabine hydrochloride|
219149899|NCT03586817|DRUG|Palonosetron|75 mcg during the anesthesia
219149900|NCT03586817|DRUG|Fosaprepitant|150 mg during the anesthesia
219149901|NCT00011531|PROCEDURE|Prevention of Pressure Ulcers|
219149902|NCT05172388|OTHER|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
219149903|NCT01591304|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
219232435|NCT03864159|OTHER|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
219232436|NCT00364455|DRUG|Epoetin alfa|
219232437|NCT02282215|BIOLOGICAL|CLT-008|Single intravenous infusion
219232438|NCT02282215|BIOLOGICAL|G-CSF|Daily subcutaneous injections
219556116|NCT00772148|DRUG|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
219149904|NCT04339855|OTHER|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
219149905|NCT01962844|DIETARY_SUPPLEMENT|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
219149906|NCT01962844|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months
219149907|NCT06277401|OTHER|Neuromuscular training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
219149908|NCT06277401|OTHER|High-load strength training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
219149909|NCT05124847|BEHAVIORAL|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
219232439|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
219232440|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
219556117|NCT03546738|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
219556118|NCT03546738|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
219556119|NCT03546738|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
219232441|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
219149910|NCT05124847|BEHAVIORAL|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
219149911|NCT06488079|OTHER|Summary Label|The Nutri-Score Front-of-Pack nutritional label
219149912|NCT06488079|OTHER|Nutrient-specific label|The NutrInform Battery Front-of-Pack nutritional label
219149913|NCT06488079|OTHER|No label|Conventional food educational flyer
219149914|NCT01430858|DEVICE|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
219722559|NCT05624541|DIAGNOSTIC_TEST|Measurements|All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
219722560|NCT00369759|OTHER|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
219722561|NCT03297697|PROCEDURE|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
219722562|NCT03297697|PROCEDURE|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
219722563|NCT03297697|PROCEDURE|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
219722564|NCT03965650|OTHER|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
219722565|NCT03965650|OTHER|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
219722566|NCT01460472|BIOLOGICAL|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
219722567|NCT01460472|OTHER|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
219149915|NCT01430858|OTHER|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured."
219722568|NCT04045171|DRUG|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
219722569|NCT02036723|DRUG|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
219722570|NCT02036723|DRUG|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
219722571|NCT06101446|OTHER|Lavander Aromatherapy|Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
219722572|NCT06151938|DRUG|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
219722573|NCT04976972|DEVICE|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
219722574|NCT04976972|PROCEDURE|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
219149916|NCT05544643|DEVICE|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
219149917|NCT00396513|DRUG|Simvastatin|
219149918|NCT00396513|DRUG|Simvastatin and Metformin|
219149919|NCT00396513|DRUG|Metformin|
219149920|NCT00199966|DRUG|Divalproex sodium extended release|
219149921|NCT03174171|DRUG|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
219149922|NCT02831712|DIETARY_SUPPLEMENT|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
219149923|NCT04575740|DEVICE|PAP|Positive airway pressure to treat sleep apnea
219149924|NCT02658370|DEVICE|animated home-based exercises (Wii-fit)|
219149925|NCT02658370|PROCEDURE|conventional home-based exercise program|
219149926|NCT05878158|DRUG|Simvastatin|pulpotomy of immature permanent teeth
219722575|NCT03125733|PROCEDURE|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
219722576|NCT03349515|DRUG|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
219722577|NCT03349515|DRUG|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
219722578|NCT04151732|BEHAVIORAL|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
219722579|NCT04151732|OTHER|Hormonal factors|Hormonal factors - selfreported in the 1990's
219722580|NCT04151732|OTHER|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
219722581|NCT04151732|OTHER|Anthropometric measures|Height, length, BMI
219722582|NCT02503865|DRUG|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
219722583|NCT02503865|DIETARY_SUPPLEMENT|"Analimentary detoxication"|Vegetable and salt diet
219722584|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
219722585|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
219556120|NCT03573336|DRUG|Vilaprisan (BAY1002670)|Intake orally, once daily
219556121|NCT03573336|DRUG|Matching Placebo|Intake orally, once daily
219556122|NCT04444141|BIOLOGICAL|AK104|The subjects will receive AK104 till disease progression or for a maximum of 24 months.
219722586|NCT05999968|DRUG|Abemaciclib|Administered orally.
219149927|NCT04655859|DIAGNOSTIC_TEST|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
219149928|NCT02947958|OTHER|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
219232442|NCT01412736|DRUG|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
219556123|NCT03391505|BEHAVIORAL|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
219556124|NCT03391505|BEHAVIORAL|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
219556125|NCT03391505|BEHAVIORAL|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
219556126|NCT03298880|DEVICE|Supine VM VAD|Valsalva strain delivered using VAD
219722587|NCT05999968|DRUG|Darolutamide|Administered orally.
219722588|NCT05999968|DRUG|LHRH agonist/antagonist|Physician's choice. Administered in accordance with the prescribing information.
219556127|NCT03298880|DEVICE|Supine VAD manometer|supine Valsalva strain delivered using manometer
219556128|NCT03298880|OTHER|Modified VM VAD|modified VM using VAD
219556129|NCT03298880|OTHER|Modified VM Manonmeter|Postural modified position VM using manometer
219556130|NCT06095180|OTHER|corticosteroid injection|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
219149929|NCT02947958|OTHER|Hospital (control)|The patient will keep his usual care at the tertiary care.
219149930|NCT01742481|BEHAVIORAL|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
219149931|NCT04469855|DRUG|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
219722589|NCT06199492|DEVICE|tVisio-1|Standard of Care Biopsy
219722590|NCT04557761|DEVICE|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
219722591|NCT04557761|DEVICE|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
219149932|NCT02242695|DRUG|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
219149933|NCT02242695|DRUG|Canesten vaginal tablets|one vaginal tablet for 7 days
219149934|NCT03802318|DRUG|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
219149935|NCT02368171|OTHER|measure exhaled carbon monoxide and nitric oxide|
219556131|NCT06095180|OTHER|dry needling|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
219556132|NCT06095180|OTHER|exercise|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
219556133|NCT05762016|PROCEDURE|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
219556134|NCT00563394|DRUG|ofloxacin|400 mg twice a day for 14 days
219556135|NCT00563394|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
219556136|NCT01071551|BEHAVIORAL|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
219556137|NCT01071551|BEHAVIORAL|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
219556138|NCT03345043|BIOLOGICAL|VAL-339851|Escalating dose levels
219556139|NCT03345043|OTHER|Placebo|Saline
219556140|NCT03493919|BIOLOGICAL|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
219556141|NCT03493919|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
219556142|NCT01506349|DIETARY_SUPPLEMENT|gluten|4 grams of gluten.
219556143|NCT01506349|DIETARY_SUPPLEMENT|Placebo|
219556144|NCT01781312|DIETARY_SUPPLEMENT|ProTectis|
219556145|NCT01781312|DIETARY_SUPPLEMENT|Gastrus|
219556146|NCT03924154|DRUG|RVT-1201|RVT-1201 600 mg immediate-release tablet
219556147|NCT03924154|DRUG|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
219556148|NCT02512328|DEVICE|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
219556149|NCT04045015|DIETARY_SUPPLEMENT|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
219556150|NCT04587245|OTHER|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
219149936|NCT03583125|DRUG|EOC317|tablet(s) PO
219149937|NCT00643071|DRUG|Tacrolimus|Oral
219149938|NCT00585533|DRUG|Erlotinib (Tarceva)|Erlotinib
219149939|NCT04496050|DRUG|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
219149940|NCT03003845|OTHER|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
219149941|NCT03003845|OTHER|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
219149942|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
219149943|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
219556151|NCT01402934|PROCEDURE|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
219556152|NCT04121533|DIETARY_SUPPLEMENT|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
219556153|NCT04121533|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
219556154|NCT04121533|DIETARY_SUPPLEMENT|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
219556155|NCT04218994|OTHER|Flossing technique|Subjects instructed on flossing technique
219556156|NCT04438434|DRUG|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
219149944|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
219722592|NCT02496429|DEVICE|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
219722593|NCT06372561|DRUG|Mineral trioxide aggregate (dressing material)|MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
219149945|NCT01238744|DIETARY_SUPPLEMENT|Control drink|Control drink
219556157|NCT04438434|DRUG|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
219556158|NCT04438434|OTHER|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
219556159|NCT04640194|PROCEDURE|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
219556160|NCT04640194|DRUG|Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
219556161|NCT04640194|DRUG|Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
219556162|NCT01777815|DEVICE|NeoChord DS1000 Artificial Chordae Delivery System|
219556163|NCT00344643|DEVICE|Silicone Hydrogel Soft Contact Lenses|
219556164|NCT00801515|DRUG|Maraviroc|150 mg twice per day
219556165|NCT02895841|OTHER|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
219556166|NCT01107028|OTHER|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
219556167|NCT02934334|OTHER|Observational|
219556168|NCT01132417|DRUG|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
219556169|NCT01686217|DRUG|ASP015K ER|oral extended release (ER) at three dosing levels
219556170|NCT01686217|DRUG|ASP015K IR|oral immediate release (IR)
219556171|NCT02269735|DRUG|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
219556172|NCT02269735|BIOLOGICAL|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
219556173|NCT02269735|DRUG|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
219556174|NCT02269735|BIOLOGICAL|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
219556175|NCT02269735|DRUG|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
219149946|NCT01368016|DRUG|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
219149947|NCT01368016|DRUG|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
219149948|NCT01254188|DRUG|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
219149949|NCT04929587|OTHER|This is a observational research, there is no intervention|This is a observational research, there is no intervention
219149950|NCT05454163|OTHER|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
219722594|NCT06372561|DRUG|Melatonin (dressing material)|melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
219722595|NCT02422758|DEVICE|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
219722596|NCT02422758|OTHER|Passive Prewarming|
219722597|NCT00619463|BEHAVIORAL|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
219722598|NCT00619463|BEHAVIORAL|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
219722599|NCT02642900|PROCEDURE|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
219722600|NCT02642900|DRUG|Nystatin 100.000 units|Control group treated with nystatin
219722601|NCT02585765|DRUG|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
219722602|NCT02585765|DRUG|Placebo|8 weeks of daily placebo capsules.
219722603|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
219722604|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
219722605|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
219722606|NCT00962962|BEHAVIORAL|Exercise and Diet|"* Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~* Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
219722607|NCT00218959|BEHAVIORAL|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).
219722608|NCT00218959|BEHAVIORAL|treatment as usual|
219722609|NCT01290328|DRUG|Epoetin Alfa|150 units/kg/weekly
219722610|NCT05073315|DRUG|Adalimumab|Participants will receive subcutaneous (SC) injection of adalimumab
219722611|NCT05073315|DRUG|ABP 501|Participants will receive SC injection of ABP 501
219722612|NCT01610843|OTHER|Survey|Longitudinal surveys
219722613|NCT04240873|BIOLOGICAL|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis
219722614|NCT04240873|OTHER|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
219722615|NCT01529268|DRUG|DR cysteamine bitartrate capsule|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
219149951|NCT01369498|DRUG|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
219149952|NCT01369498|DRUG|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
219556176|NCT06177405|DRUG|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
219149953|NCT00534300|DRUG|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
219556177|NCT05806177|DRUG|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
219722616|NCT01529268|OTHER|DR cysteamine bitartrate placebo|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
219722617|NCT05290675|DIAGNOSTIC_TEST|Quantra QPlus System|Whole blood coagulation testing system
219722618|NCT03181555|OTHER|Exploratory|
219722619|NCT00807872|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
219722620|NCT03502109|OTHER|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
219722621|NCT05598268|BIOLOGICAL|T3011|T3011 will be administered through IV drip
219722622|NCT02522741|BEHAVIORAL|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
219722623|NCT02122276|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
219722624|NCT00085579|BIOLOGICAL|aldesleukin|
219149954|NCT00534300|DRUG|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
219149955|NCT01394510|DRUG|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
219556178|NCT05806177|DRUG|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
219556179|NCT00663234|DRUG|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
219556180|NCT02993562|DRUG|Levothyroxine|Normal treatment with levothyroxine.
219556181|NCT00065962|DRUG|secretin, synthetic porcine|
219149956|NCT00622219|OTHER|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
219149957|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
219232443|NCT04015505|BEHAVIORAL|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
219722625|NCT00085579|BIOLOGICAL|sargramostim|
219232444|NCT05997563|DRUG|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
219722626|NCT00085579|PROCEDURE|adjuvant therapy|
219722627|NCT03692962|BEHAVIORAL|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
219722628|NCT03692962|OTHER|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
219556182|NCT00065962|DRUG|secretin, biologically derived porcine|
219556183|NCT01888107|DRUG|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
219722629|NCT02280954|DRUG|Indocyanine Green (ICG)|
219722630|NCT02960906|DRUG|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
219149958|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
219149959|NCT01428297|DRUG|BPR277 ointment (controlled application)|
219149960|NCT01428297|DRUG|Placebo (Vehicle)|
219232445|NCT00509756|DRUG|FXR-450|capsule, single oral doses from 10 mg to 450 mg
219232446|NCT00509756|DRUG|Placebo|capsule similar to active drug
219556184|NCT01888107|DRUG|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
219556185|NCT01888107|DRUG|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
219556186|NCT01994980|DRUG|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
219556187|NCT02188407|DRUG|Sevoflurane|MAC 3-5 V% during surgery
219556188|NCT02188407|DRUG|Propofol|Propofol group (P group)- The group anaesthesied with propofol
219722631|NCT02960906|DRUG|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
219722632|NCT02960906|DRUG|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
219722633|NCT02960906|DRUG|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
219722634|NCT01486433|DRUG|Simvastatin|40 mg (1 tablet) simvastatin once a day
219722635|NCT01486433|DRUG|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
219149961|NCT01428297|DRUG|BPR277 ointment|
219149962|NCT01428297|DRUG|Placebo (Vehicle)|
219149963|NCT01428297|DRUG|BPR277|
219149964|NCT01428297|DRUG|Placebo (Vehicle)|
219149965|NCT02867670|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
219149966|NCT02990546|DRUG|midodrine|Midodrine will be given to treatment arm as enteral medication
219149967|NCT02990546|OTHER|Standard of Care|Patients in the control arm will receive standard of care for septic shock
219149968|NCT05007678|DRUG|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
219232447|NCT02759575|DRUG|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
219232448|NCT02759575|RADIATION|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
219232449|NCT02759575|DRUG|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
219556189|NCT04164706|DEVICE|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
219556190|NCT04164706|OTHER|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
219556191|NCT03332433|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
219722636|NCT01486433|DRUG|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
219722637|NCT00464464|BEHAVIORAL|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
219556192|NCT05259657|BEHAVIORAL|Lymfit Intervention|"Participants will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The research team will reach out to the participant via videoconferencing and help them to: download the Fitbit smartphone application; log-in using the anonymous study identification information; and pair their Fitbit with their smartphone application.~A kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed, plus an acceptability assessment survey."
219722638|NCT05710822|DEVICE|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
219722639|NCT01779661|OTHER|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
219722640|NCT01779661|OTHER|Infant Massage|Infant Massage
219722641|NCT04170933|PROCEDURE|Magnetic recanalization|"1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support."
219556193|NCT05259657|BEHAVIORAL|Wait-list control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
219722642|NCT05737147|DEVICE|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
219556194|NCT03613038|BEHAVIORAL|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
219556195|NCT01709903|DRUG|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
219556196|NCT01709903|DRUG|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
219722643|NCT05711147|PROCEDURE|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
219556197|NCT01709903|DRUG|Placebo to QVA149|Placebo to QVA149 with SDDPI
219556198|NCT01709903|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
219556199|NCT02258035|OTHER|Blood draw|Sampling of 100-150 ml of blood
219556200|NCT06405854|OTHER|Exercise|Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
219556201|NCT00271115|BEHAVIORAL|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
219149969|NCT00911521|DRUG|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
219149970|NCT01973816|DRUG|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
219149971|NCT01973816|PROCEDURE|rectal shaving; rectal disc excision; colorectal resection|
219149972|NCT01973816|DRUG|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
219149973|NCT01973816|DRUG|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
219149974|NCT01124734|DRUG|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
219556202|NCT04728828|BIOLOGICAL|Serological COVID-19 vaccine immunogenicity|Serological test
219149975|NCT01124734|DRUG|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
219149976|NCT03948997|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
219149977|NCT02779062|OTHER|Interview|Interview
219149978|NCT04614636|DRUG|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
219556203|NCT00096460|DRUG|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
219722644|NCT05711147|PROCEDURE|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
219722645|NCT02076841|DEVICE|interferon beta-1a|Administered as specified in the treatment arm
219722646|NCT05817604|RADIATION|SBRT|"Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme."
219722647|NCT04023253|DRUG|Mirabegron|Mirabegron 25 mg
219722648|NCT04023253|DRUG|Solifenacin|Solifenacin 5 mg
219149979|NCT04614636|DRUG|Cyclophosphamide|Lympho-conditioning Agent
219149980|NCT04614636|DRUG|Fludarabine|Lympho-conditioning Agent
219149981|NCT04614636|DRUG|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
219149982|NCT04614636|DRUG|Elotuzumab|Monoclonal Antibody
219722649|NCT03737019|BEHAVIORAL|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
219149983|NCT01338675|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
219149984|NCT03631953|DRUG|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
219556204|NCT00096460|DRUG|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
219556205|NCT00096460|RADIATION|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days."
219556206|NCT00096460|DRUG|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
219556207|NCT00096460|PROCEDURE|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
219556208|NCT00096460|PROCEDURE|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
219149985|NCT03631953|DRUG|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
219149986|NCT03631953|BIOLOGICAL|Blood sample|Therapeutic biomarkers
219149987|NCT03631953|DEVICE|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
219149988|NCT00107159|BIOLOGICAL|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
219149989|NCT01579370|OTHER|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
219556209|NCT00096460|DRUG|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
219149990|NCT01579370|OTHER|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
219149991|NCT01579370|OTHER|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
219556210|NCT00096460|DRUG|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
219556211|NCT06139133|DRUG|Placebo supplementation|Placebo
219556212|NCT06139133|DRUG|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
219556213|NCT04164030|BEHAVIORAL|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
219556214|NCT04164030|BEHAVIORAL|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
219556215|NCT06485284|BEHAVIORAL|El Camino|"El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships."
219556216|NCT06485284|BEHAVIORAL|Life skills program|Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
219556217|NCT03961828|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
219556218|NCT00809705|DRUG|Placebo|sc once weekly for 12 weeks
219556219|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
219556220|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 12 weeks
219556221|NCT01756885|DRUG|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
219556222|NCT01756885|DRUG|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
219722650|NCT03737019|OTHER|Control, no intervention|Control, no interventions.
219722651|NCT05993104|DIAGNOSTIC_TEST|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
219722652|NCT05993104|OTHER|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
219722653|NCT04145817|GENETIC|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
219722654|NCT04145817|GENETIC|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
219722655|NCT04145817|BEHAVIORAL|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
219722656|NCT00781950|DIETARY_SUPPLEMENT|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
219722657|NCT00781950|DIETARY_SUPPLEMENT|Placebo|Wheat and Mixed Dietary Oils
219722658|NCT02641834|OTHER|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
219722659|NCT02641834|OTHER|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
219722660|NCT00780832|BEHAVIORAL|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
219556223|NCT01756885|BEHAVIORAL|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
219556224|NCT06391450|DRUG|Empagliflozin 10 MG|Oral
219149992|NCT01579370|OTHER|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
219149993|NCT04149808|DEVICE|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
219556225|NCT06391450|DRUG|Placebo|Oral
219722661|NCT00780832|DRUG|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
219722662|NCT03826615|DRUG|Gabapentin|Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
219722663|NCT03094728|DIAGNOSTIC_TEST|HLA cross matching|"HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
219722664|NCT05362084|PROCEDURE|lumbar medial branch block|lumbar medial branch block
219722665|NCT03006679|DRUG|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
219722666|NCT03006679|DRUG|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
219722667|NCT02993900|DEVICE|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
219722668|NCT05926531|DEVICE|CBTI online programe|20 MIN VR RELAX PROGRAME
219722669|NCT03673358|BEHAVIORAL|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
219149994|NCT04149808|DEVICE|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
219149995|NCT03482011|DRUG|Mirikizumab|Administered SC
219149996|NCT03482011|DRUG|Placebo|Administered SC
219149997|NCT05425862|DRUG|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
219149998|NCT05425862|DRUG|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
219149999|NCT01598870|OTHER|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
219556226|NCT00545428|PROCEDURE|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
219556227|NCT02061358|DRUG|UV-4B 3 mg|Oral solution, single dose
219556228|NCT02061358|DRUG|UV-4B 10 mg|Oral solution, single dose
219556229|NCT02061358|DRUG|UV-4B 30 mg|Oral solution, single dose
219556230|NCT02061358|DRUG|UV-4B 90 mg|Oral solution, single dose
219556231|NCT02061358|DRUG|UV-4B 180 mg|Oral solution, single dose
219556232|NCT02061358|DRUG|UV-4B 360 mg|Oral solution, single dose
219556233|NCT02061358|DRUG|UV-4B 720 mg|Oral solution, single dose
219556234|NCT02061358|DRUG|UV-4B 1000 mg|Oral solution, single dose
219556235|NCT02061358|DRUG|Placebo|Oral solution, single dose
219556236|NCT05605652|PROCEDURE|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
219556237|NCT01071876|DRUG|BF2.649|1 capsule in the morning before breakfast
219556238|NCT01071876|DRUG|Placebo|1 capsule in the morning before breakfast
219556239|NCT06366113|OTHER|Pulmonary rehabilitation|"Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education"
219556240|NCT06179641|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.
219556241|NCT06179641|PROCEDURE|IPACK block|The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
219556242|NCT02213705|BIOLOGICAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
219556243|NCT02849951|DRUG|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
219556244|NCT02849951|DRUG|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
219556245|NCT01374945|DEVICE|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
219556246|NCT03850522|BIOLOGICAL|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
219556247|NCT01209988|DRUG|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
219556248|NCT01209988|OTHER|No medication|No medication
219556249|NCT05862987|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
219556250|NCT05862987|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
219556251|NCT05590039|DEVICE|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
219556252|NCT03035643|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
219556253|NCT05594095|DRUG|PIK3CA inhibitor|PIK3CA inhibitor
219556254|NCT05594095|DRUG|AKT inhibitor|AKT inhibitor
219556255|NCT05594095|DRUG|Carrelizumab|Pd-1 mab
219556256|NCT05594095|DRUG|Famitinib|VEGFR inhibitor
219556257|NCT05594095|DRUG|Fluzoparib|PARP inhibitor
219556258|NCT05594095|DRUG|Dalpiciclib|CDK4/6 inhibitor
219556259|NCT05594095|DRUG|SHR-A1811|HER2 ADC
219556260|NCT05594095|DRUG|Everolimus|mTOR inhibior
219556261|NCT05594095|DRUG|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
219556262|NCT05594095|DRUG|Goserelin|For premenopause
219556263|NCT05594095|DRUG|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
219556264|NCT05594095|DRUG|Sorafenib|RTK Inhibitor
219556265|NCT05594095|DRUG|Apatinib|Apatinib 250mg po qd
219150000|NCT03877198|DEVICE|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
219150001|NCT03877198|DEVICE|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
219150002|NCT01226849|DRUG|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
219150003|NCT05297175|DEVICE|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
219150004|NCT03741049|DEVICE|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
219150005|NCT03741049|DEVICE|Seldinger technique (plastic laryngeal model)|Melker Set
219150006|NCT03741049|DEVICE|Surgical technique (plastic laryngeal model)|Scalpel and speculum
219150007|NCT03741049|DEVICE|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
219556266|NCT05594095|DRUG|SHR-A1921|TROP2 ADC
219150008|NCT03741049|DEVICE|Surgical technique (porcine laryngeal model)|Scalpel and speculum
219150009|NCT06413095|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
219150010|NCT06413095|COMBINATION_PRODUCT|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
219150011|NCT06413095|COMBINATION_PRODUCT|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
219556267|NCT05594095|DRUG|SHR-A2102|NECTIN4 ADC
219556268|NCT05594095|DRUG|SHR-A2009|HER3 ADC
219556269|NCT05594095|DRUG|SHR-1167|PARP1i
219556270|NCT05594095|DRUG|SHR-6209|CDK4i
219556271|NCT05594095|DRUG|bevacizumab|bevacizumab
219556272|NCT04773600|DRUG|Roflumilast Cream|Roflumilast cream 0.15% for topical application
219556273|NCT04773600|DRUG|Vehicle cream|Vehicle cream for topical application
219556274|NCT03157869|DEVICE|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
219556275|NCT03157869|OTHER|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
219556276|NCT04070222|OTHER|Hysteroscopy|"1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
219556277|NCT06531122|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
219556278|NCT06531122|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
219722670|NCT03038139|OTHER|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
219722671|NCT03038139|OTHER|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
219722672|NCT03491917|DEVICE|DBT plus S-View|DBT plus S-View images
219150012|NCT04431375|BIOLOGICAL|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
219150013|NCT04431375|DRUG|Tenofovir|Tenofovir \[antiviral\] 300mg PO once a day .
219150014|NCT04431375|OTHER|Fecal Mircobiota Transplantation|FMT for 7 days
219722673|NCT03491917|DEVICE|FFDM alone|FFDM alone images
219722674|NCT00250003|BEHAVIORAL|Preventive home visits|
219722675|NCT04831112|DRUG|Honey|Dressing of necrotizing fascitis wounds with honey.
219722676|NCT04831112|COMBINATION_PRODUCT|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
219722677|NCT00069745|DRUG|Satraplatin|
219722678|NCT00069745|DRUG|Prednisone|
219722679|NCT03040531|DIETARY_SUPPLEMENT|Genistein aglycone|27mg bid in tablets
219722680|NCT03040531|DRUG|Alendronate Oral Tablet|70 mg/week in tablets
219722681|NCT03040531|DIETARY_SUPPLEMENT|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
219722682|NCT00657605|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
219722683|NCT01449487|DRUG|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
219722684|NCT01449487|DRUG|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
219722685|NCT06047327|DIAGNOSTIC_TEST|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
219722686|NCT06047327|DIAGNOSTIC_TEST|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
219722687|NCT04776772|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
219722688|NCT04776772|DIETARY_SUPPLEMENT|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
219722689|NCT00395382|DRUG|Alendronate|70mg weekly orally
219722690|NCT00395382|DRUG|Placebo|weekly orally
219722691|NCT04069520|OTHER|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks."
219722692|NCT04069520|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
219722693|NCT01068912|DRUG|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
219722694|NCT01068912|DRUG|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
219722695|NCT01068912|DRUG|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
219722696|NCT00512863|DRUG|Humira (adalimumab)|
219722697|NCT04423874|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
219722698|NCT04423874|DIAGNOSTIC_TEST|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
219722699|NCT04423874|BEHAVIORAL|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
219722700|NCT04423874|DIAGNOSTIC_TEST|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
219722701|NCT06853145|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129-MRI: Patients will undergo hyperpolarized Xe129-MRI at the University of Virginia Radiology Imaging Core (Charlottesville, VA, USA). The entire procedure visit takes approximately 3 hours based on our team's experience.
219722702|NCT04611815|PROCEDURE|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
219722703|NCT04611815|DIAGNOSTIC_TEST|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
219722704|NCT04611815|DIAGNOSTIC_TEST|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
219722705|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
219722706|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
219722707|NCT01452256|DRUG|Desflurane|4-6 Vol %
219722708|NCT01452256|DRUG|Propofol|TIVA to achieve BIS value of 40-60
219722709|NCT02745730|OTHER|Glucose|
219722710|NCT02745730|OTHER|Fructose|
219722711|NCT02745730|OTHER|Sucralose|
219722712|NCT02745730|OTHER|Allulose|
219232450|NCT02410109|BEHAVIORAL|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
219232451|NCT05308589|DEVICE|CPPF|Continuous Postoperative Pericardial Flush
219232452|NCT05356676|OTHER|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
219232453|NCT05356676|OTHER|Combination Therapy|"1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
219232454|NCT06989359|DRUG|ADX-038|siRNA duplex oligonucleotide
219232455|NCT05184062|DRUG|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
219232456|NCT05184062|DRUG|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
219232457|NCT01558544|PROCEDURE|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
219232458|NCT04851197|OTHER|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
219232459|NCT04919395|DEVICE|Clip device for Nexplanon Removal|The clip device will be used to assist in the removal procedure to remove the Nexplanon implant from the subject.
219232460|NCT04919395|PROCEDURE|Standard of Care procedure|The participants Nexplanon will be removed per standard of care.
219232461|NCT06597591|DEVICE|VR headset|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
219722713|NCT02178332|OTHER|Yhteispeli, whole school programme|
219722714|NCT02178332|OTHER|Two theoretical lectures|
219722715|NCT04032223|PROCEDURE|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
219722716|NCT00118287|DRUG|azacitidine|Given SC or IV
219722717|NCT00118287|BIOLOGICAL|etanercept|Given SC
219722718|NCT05143502|DRUG|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
219722719|NCT05143502|DRUG|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
219722720|NCT05143502|DRUG|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
219722721|NCT06803654|DRUG|BTOS-HA|Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA) administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
219722722|NCT06803654|DRUG|Lumify®|Brimonidine tartrate ophthalmic solution 0.025%, administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
219722723|NCT05537571|DRUG|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
219722724|NCT05537571|DRUG|Placebo|Sodium chloride, solution for injection
219722725|NCT01922583|DRUG|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
219722726|NCT02698293|DRUG|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
219722727|NCT02698293|DRUG|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
219722728|NCT02698293|OTHER|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
219722729|NCT01860989|DRUG|KAE609|KAE609 75mg single dose
219722730|NCT01860989|DRUG|KAE609|KAE609 150mg single dose
219722731|NCT01860989|DRUG|KAE609|KAE609 225mg single dose
219722732|NCT01860989|DRUG|KAE609|KAE609 300mg single dose
219722733|NCT03391895|OTHER|Home based exercise program|Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
219722734|NCT03391895|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
219150015|NCT03794635|BEHAVIORAL|Weekly 45 minute Sessions|"The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention."
219150016|NCT00210691|DRUG|Risperidone|
219150017|NCT04216394|PROCEDURE|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
219150018|NCT01302236|DRUG|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
219232462|NCT06597591|DEVICE|Tablet|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
219232463|NCT06362291|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
219232464|NCT06362291|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
219722735|NCT00941343|DRUG|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
219722736|NCT01512888|GENETIC|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
219722737|NCT01512888|DRUG|Busulfan|Given intravenously (IV).
219722738|NCT01512888|DEVICE|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
219722739|NCT04812158|OTHER|standard ankle physiotherapy or rehabilitation for chronic ankle instability|6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
219722740|NCT03028441|OTHER|Placebo|Placebo
219722741|NCT03028441|BIOLOGICAL|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
219722742|NCT01685437|BIOLOGICAL|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
219722743|NCT04142827|DEVICE|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
219722744|NCT06476249|OTHER|without|without
219722745|NCT04483037|DRUG|Bowklean|assigned intervention
219722746|NCT01886560|DRUG|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
219722747|NCT01886560|DRUG|Placebo|Tablets placebo one PO per day for 12 weeks
219150019|NCT02721901|BEHAVIORAL|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
219150020|NCT02721901|BEHAVIORAL|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
219722748|NCT04093076|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
219722749|NCT04093076|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
219722750|NCT04093076|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
219722751|NCT05370482|DEVICE|Focal laser ablation|MRI-guided focal laser ablation for prostate cancer
219722752|NCT06147154|OTHER|16S rRNA amplicon sequencing and untargeted metabolomics|"16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes."
219722753|NCT06177353|OTHER|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
219722754|NCT03770455|DRUG|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
219722755|NCT03770455|DRUG|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
219722756|NCT02955082|DRUG|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
219722757|NCT03735342|OTHER|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
219722758|NCT02475447|DRUG|Asimadoline|kappa-opioid receptor agonist
219722759|NCT02475447|DRUG|Placebo|placebo-matched control
219722760|NCT04880317|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
219722761|NCT04880317|DIAGNOSTIC_TEST|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
219722762|NCT04880317|DIAGNOSTIC_TEST|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
219722763|NCT00223821|DRUG|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
219722764|NCT00223821|BEHAVIORAL|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
219722765|NCT05414188|BEHAVIORAL|Pulmonary rehabilitation|Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
219722766|NCT02790177|DRUG|Hyaluronic Acid|
219722767|NCT02790177|DRUG|NORMAL SALINE|
219722768|NCT01801540|DIETARY_SUPPLEMENT|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
219722769|NCT01578265|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
219722770|NCT01578265|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
219722771|NCT02602327|DRUG|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
219722772|NCT02602327|DEVICE|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
219722773|NCT03676829|DEVICE|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
219722774|NCT04705584|DRUG|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
219722775|NCT04705584|DRUG|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
219722776|NCT04705584|DRUG|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
219722777|NCT01753063|BEHAVIORAL|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
219722778|NCT01753063|BEHAVIORAL|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
219722779|NCT02777788|DRUG|JinFuKang|treated with chemotherapy
219722780|NCT02777788|DRUG|XingZaoRuanJian|treated with chemotherapy
219722781|NCT02777788|DRUG|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
219722782|NCT00207688|DRUG|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
219722783|NCT00207688|DRUG|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
219722784|NCT00207688|DRUG|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
219722785|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
219722786|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
219722787|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
219722788|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
219722789|NCT03463447|DEVICE|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
219722790|NCT03463447|DEVICE|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
219722791|NCT00562341|OTHER|Bariatric Surgery|one time lapb-band gastric bypass surgery
219722792|NCT04146883|DRUG|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
219722793|NCT04302597|PROCEDURE|Staples|Skin closure using surgical stapler.
219722794|NCT04302597|PROCEDURE|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
219722795|NCT01039675|DRUG|500mcg/25mcg once daily|GSK573719/GW642444
219722796|NCT01039675|DRUG|Placebo once daily|Inactive, excipients only
219722797|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
219722798|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
219722799|NCT01990781|DRUG|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
219722800|NCT01990781|DRUG|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
219722801|NCT01990781|DRUG|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
219722802|NCT01990781|DRUG|N: Normal saline (placebo)|Normal saline: 2ml
219722803|NCT03555929|DRUG|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
219150021|NCT01336543|DRUG|Chemotherapy following concurrent Chemoradiotherapy|"1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
219150022|NCT03700294|DRUG|ADCT-601|Intravenous (IV)
219150023|NCT06353165|DRUG|Stannous fluoride toothpaste|product containing 0.45% stannous fluoride
219150024|NCT06353165|DRUG|Colgate Dental Cream|product containing 0.76% sodium monofluorophosphate
219150025|NCT01510977|DRUG|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
219150026|NCT01510977|DRUG|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
219150027|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
219150028|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
219150029|NCT02012569|DRUG|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
219150030|NCT02012569|DRUG|Placebo|
219150031|NCT02538107|DRUG|Methoxy-polyethyleneglycol epoetin beta|
219722804|NCT03555929|DRUG|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
219722805|NCT05695391|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
219722806|NCT06389461|OTHER|4th Ventricular Compression Technique|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
219722807|NCT06389461|OTHER|"Sham Therapy"|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
219722808|NCT06867003|OTHER|physical therapy with bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
219722809|NCT06867003|OTHER|physical therapy without bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
219722810|NCT02845427|DEVICE|closed suction drain|using closed suction drain system postoperative
219722811|NCT02845427|PROCEDURE|no suction drain|the surgical wound will be closed with no suction drain
219722812|NCT06261242|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
219722813|NCT06977633|BEHAVIORAL|Temporary Insulin Suspension|Participants will suspend insulin delivery from their personal insulin pumps for up to 3 hours. Insulin suspension is temporary and participant-driven under supervision.
219722814|NCT06977633|DEVICE|Glucose and ketone sensor|The participants wear a prototype continuous glucose-ketone monitoring (CGM-CKM) device using painless hydrogel microneedles for 4 hours.
219722815|NCT01171599|BEHAVIORAL|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web \& text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
219150032|NCT04672018|OTHER|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
219722816|NCT07037680|DRUG|Anlotinib|"For patients treated with conventional Intensity-Modulated Radiation Therapy (IMRT), the median prescribed dose was 60 Gy/30 fractions (range: 50.0-70.0 Gy, in 25-35 fractions) (median BED10 72 Gy, range: 60-84 Gy) to the planning target volume (PTV). As for patients with IMRT-based simultaneously integrated boost (SIB), the median prescribed dose was 59.92 Gy/28 fractions (range: 50.0-70.0 Gy, in 25-33 fractions) (median BED10 72.74 Gy, range: 60-84 Gy) to the planning gross tumor volume (PGTV), and 50.4 Gy/28 fractions (range: 45-59.4 Gy, in 25-33 fractions) (median BED10 59.47 Gy, range: 53.1-70.1 Gy) to the PTV. It should be noted that the PTV in the SIB group contains the PGTV.~Anlotinib was administered orally concurrently with the first day of radiotherapy, at a dose of 12 mg for a maximum of three cycles. Each cycle was defined as 2 weeks on-treatment followed by 1 week off-treatment. If intolerance occurs, the dose may be reduced to 8-10 mg/day or stopped."
219722817|NCT07043686|DRUG|Cerebrolysin treatment|The patients will receive Cerebrolysin treatment, 10 days consecutively, 30 ml/day, intravenous infusion diluted up to 100 ml of 0.9% saline in 15 minutes.
219722818|NCT07043686|OTHER|Standard treatment (including neurorehabilitation) of acute ischemic stroke|"Standard treatment entails acute ischemic stroke reperfusion treatment according to international guidelines and local policies, instituting secondary preventive treatment, a proper management of stroke risk factors and neurorehabilitation according to patient's needs: locomotor physiotherapy, occupation therapy, speech therapy, and neuropsychological assessment."
219722819|NCT07044830|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP)
219722820|NCT07046325|DRUG|dexametedomidine|1\. Group DB: are administered Ultrasound guided STB with bupivacaine and dexametidomedine.
219722821|NCT07046325|DRUG|Bupivacain|2\. Group B: are administered Ultrasound guided STB with bupivacaine.
219722822|NCT06728488|OTHER|PENG Block|The patients in the PENG block group will provide their consent. Standard monitoring will be applied. The patients will be positioned supine. After antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The linear ultrasound probe will be placed in the transverse plane over the AIIS. The position of the ultrasound probe will be verified by visualizing the iliopectineal eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle. Using a Stimuplex® A 100 mm 20 gauge needle (Braun Melsungen AG, Melsungen, Germany) with the in-plane technique, the needle will be inserted laterally to medially into the space between the psoas tendon and the pubic ramus. Negative aspiration will be performed to ensure no blood is aspirated, and then 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be injected to perform the PENG block. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
219722823|NCT06728488|OTHER|PENG block and pulse radiofrequency ablation|After obtaining consent, the patients in the PENG block and pulse radiofrequency ablation group will be brought into the operating room. Standard monitoring will be applied (ECG, SpO2, NIBP). The patients will be positioned supine. After performing the necessary aseptic and antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The Boston Scientific unified echogenic 10cmx10mmx20G (0.9mm) radiofrequency cannula will be advanced until it makes contact with the superior ramus near the iliopectineal eminence. Pulse radiofrequency ablation will be performed with two cycles of 90 seconds each, and after each cycle, the needle will be moved 2 mm medially. After pulse radiofrequency ablation, 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be applied. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
219722824|NCT07051928|DIAGNOSTIC_TEST|c-FLIP expression on MDSC|Longitudinal c-FLIP expression on circulating MDSC
219722825|NCT06733376|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.
219722826|NCT06733376|BEHAVIORAL|Prolonged Exposure|Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.
219150033|NCT04672018|DRUG|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
219150034|NCT04367272|PROCEDURE|First Arthroplasty|First Knee
219150035|NCT04367272|PROCEDURE|Second Arthroplasty|Second Knee
219150036|NCT05631938|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
219150037|NCT05393726|PROCEDURE|Ultrasound-Guided Suprainguinal Fascia Iliaca Block Versus Lumbar Erector Spinae Plane Block|"Suprainguinal Fascia Iliaca Block group will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~Lumbar Erector Spinae Plane Block group will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40 ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~control group will underwent surgery under general anesthesia and receive the perioperative routine protocol of analgesia"
219150038|NCT04224142|DIETARY_SUPPLEMENT|PKU sphere|"PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU).~It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA.~It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe."
219150039|NCT05473364|DRUG|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
219150040|NCT05530109|OTHER|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
219150041|NCT00126997|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
219150042|NCT00389012|PROCEDURE|exercise therapy|
219150043|NCT00389012|PROCEDURE|walking rehabilitation|
219150044|NCT01954407|BEHAVIORAL|Smoking-Related Messages|
219150045|NCT02728349|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
219232465|NCT02321137|PROCEDURE|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
219722827|NCT06733376|BEHAVIORAL|Skills Training for Affective and Interpersonal Regulation|Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.
219150046|NCT05913869|BEHAVIORAL|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
219150047|NCT06973681|DRUG|BGM0504|Administered SC
219150048|NCT06973681|DRUG|BGM0504|Administered SC
219150049|NCT06973681|DRUG|BGM0504|Administered SC
219150050|NCT06973681|DRUG|Placebo|Administered SC
219150051|NCT06972940|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
219150052|NCT06973941|OTHER|Virtual reality relaxation|"10-minute VR relaxation application, part of the app Nature Treks VR by Greenergames (released on May 21, 2019), used with a Metaquest head-mounted display"
219150053|NCT06973941|OTHER|Guided imagery relaxation|10-minute guided imagery relaxation where an investigator reads a dream journey
219150054|NCT06972706|DIETARY_SUPPLEMENT|Shatavari|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
219232466|NCT02321137|PROCEDURE|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
219722828|NCT03033706|PROCEDURE|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
219722829|NCT03033706|PROCEDURE|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
219722830|NCT03033706|PROCEDURE|Brain tumor excision|Brain tumor excision under general anesthesia
219722831|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
219722832|NCT01039441|PROCEDURE|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
219722833|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
219722834|NCT01039441|OTHER|normal saline|
219722835|NCT03780192|DEVICE|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
219722836|NCT03157791|DRUG|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
219722837|NCT07125625|DIETARY_SUPPLEMENT|Experimental arm: probiotic|a dietary supplement containing L. Rhamnosus GG 1x1010 CFU plus L. Plantarum 299V. 1x1010 CFU
219722838|NCT07125625|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrine)
219722839|NCT07125794|PROCEDURE|Original Denis Browne splint|Patients who were managed with the original Denis Browne splint.
219722840|NCT07125794|PROCEDURE|Modified Denis Browne splint|Patients who were managed with the modified Denis Browne splint.
219722841|NCT07124507|DIETARY_SUPPLEMENT|PICOZYME ET|The investigational product is a dietary supplement containing aldehyde dehydrogenase (ALDH), administered orally twice daily (one packet in the morning and one in the evening) for 3 months before meals.
219722842|NCT07122297|PROCEDURE|Retraction cord|"A thin cord (type 00) was soaked in 15% ferric sulfate ferric sulfate hemostatic solution and carefully packed into the gingival sulcus. After 3 minutes, the cord was removed and the sulcus was rinsed. This is a traditional mechanical gingival displacement method."
219722843|NCT07122297|PROCEDURE|Retraction paste in capsule form|A retraction paste was applied using a capsule tip placed around the gingival margin. The paste remained in place for 3 minutes and was then rinsed off with air-water spray. This is a non-traumatic chemical displacement technique.
219722844|NCT07122297|PROCEDURE|Retraction paste in injector form|Retractrion paste in injector form with compression cap (15% aluminum chloride) was injected into the sulcus, and a cotton compression cap was placed over the tooth. Patients gently bit on the cap for 3 minutes to apply pressure. Afterward, the paste and cap were removed and the area was rinsed. This method combines chemical and slight mechanical displacement.
219722845|NCT07122297|PROCEDURE|Diode Laser|A 810-nm diode laser with a 400-micron fiber optic tip was used in contact mode to ablate the sulcular epithelium. The laser was operated at 1.0 W with pulsed settings. The procedure was completed by wiping the area with saline to remove residues. This technique enables precise, bloodless gingival retraction with minimal trauma.
219722846|NCT07126041|OTHER|Prescription for Action (SPHERES Model)|"A system-level intervention consisting of:~* a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater;~* structured monthly prescription guides targeting service improvements across three priority program areas;~* monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange."
219722847|NCT06400914|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear.
219150055|NCT06972706|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
219150056|NCT06972706|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
219150057|NCT06973421|DRUG|Utidelone Capsules|60 mg/m2 orally, days 1 to 5, per cycle
219150058|NCT06973421|DRUG|Fruquintinib Capsules|5 mg orally, days 1 to 14, per cycle
219150059|NCT06974084|DRUG|Maraviroc (MVC)|Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet
219150060|NCT06974084|DRUG|Atorvastatin, 10mg, 20mg, 40mg|Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg
219150061|NCT06974084|DRUG|Placebo, Maraviroc|Placebo of Maraviroc, 300mg
219722848|NCT06400914|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear.
219150062|NCT06974084|DRUG|Placebo, Atorvastatin|Placebo of Atorvastin, 10mg
219232467|NCT06621771|OTHER|Music intervention|Participants will engage in a step-by-step piano training consisting in playing piano pieces designed to involve all 5 digits of the paretic hand and increasing in complexity. They will be using a Musical Instrument Digital Interface (MIDI) piano program called Synthesia to display musical pieces on a computer screen that is adapted for people with no music reading abilities and will be playing on a touch sensitive piano keyboard. The supervised session will also be complemented with a unsupervised home program consisting of piano sequence exercises comprising short excerpts of the same musical pieces practiced during the supervised sessions and they will receive a roll-up flexible piano
219722849|NCT06941818|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
219722850|NCT06947720|PROCEDURE|stenting|All individuals are anesthetized, with local or general anesthesia depending on the patient's level of cooperation. During the surgery, heparin must be injected intravenously to control the activated clotting time between 250-300 seconds. The surgery is performed via the femoral artery, and the choice of stent type and size, as well as any required equipment, are determined by the intervention personnel themselves.
219722851|NCT06954831|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
219722852|NCT06954831|RADIATION|Hypofractionated External Beam Radiation Therapy|Undergo UF-WBI with CB
219722853|NCT06954831|OTHER|Questionnaire Administration|Ancillary studies
219722854|NCT06954831|RADIATION|Radiation Boost|Undergo UF-WBI with CB
219722855|NCT06954831|RADIATION|Whole Breast Irradiation|Undergo UF-WBI with CB
219722856|NCT02831777|DEVICE|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
219722857|NCT01211171|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
219722858|NCT06946966|OTHER|Reformer Pilates|Reformer Pilates
219722859|NCT06946966|OTHER|Pilates control|Pilates control
219722860|NCT06946966|OTHER|pilates online pilates|pilates online pilates
219722861|NCT07125560|BEHAVIORAL|MyBRUSH module|oral health education module that comprises of booklet for educational material, oral health talk, toothbrushing demonstration and return demonstration, and small group discussion
219722862|NCT07125560|BEHAVIORAL|BEGIN program|BEGIN program that comprise of toothbrushing demonstration and return demonstration
219722863|NCT07124754|DIAGNOSTIC_TEST|Multimodal Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in T1 Gastric Cancer|"This intervention involves the use of a custom-built artificial intelligence (AI) diagnostic model that integrates multimodal data-including clinical variables, histopathological features, and imaging data-to predict lymph node metastasis in patients with T1-stage gastric cancer.~The model provides risk probability scores and classification outputs that assist physicians in diagnostic decision-making.~The AI system will be compared with physician performance at different levels of experience (resident, attending, senior) to assess its impact on diagnostic accuracy and clinical decision support."
219722864|NCT05155033|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
219150063|NCT06973707|BEHAVIORAL|Passive Digital Tools|Dynamic organizational chart of care team members Guide to general medicine service Plan for the day
219150064|NCT06973707|BEHAVIORAL|Active Digital Tools|Guide: why patient engagement is important Sample questions with answers Ability to create, organize, and store questions to ask the medical team; reminder to ask them during rounds Electronic journal function with categories: symptoms, emotions, function, what I learned; reminder to share with medical team during rounds
219150065|NCT06972511|COMBINATION_PRODUCT|neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases|neoadjuvant apadamide plus ADT: apadamide 240 mg qd po + leuproprolirelin 3.75mg subcutaneous injection once every month. After 4 months of neoadjuvant therapy, radical prostate cancer + extended lymph node dissection, lymph node dissection to the level of bilateral common iliac arteries, and radiotherapy for metastases was completed within 3 months after surgery.Postoperative adjuvant ADT therapy, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
219150066|NCT06972511|DRUG|Standard ADT treatment|leuproprolirelin 3.75mg subcutaneous injection once every month, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
219150067|NCT06972693|GENETIC|BRCA testing|BRCA 1 and 2 testing
219150068|NCT06974045|OTHER|Single-stage LC + LCBDE|Choledochotomy and transductal common bile duct exploration or transcystic choledochoscopy and common bile duct exploration
219150069|NCT06974071|OTHER|Local cold therapy.|It will be applied by means of a refrigerated unit based on gel pack, these units will be stored in the refrigerator of the Unit, which is kept between 2 - 6 degrees, the application protocol is described in Annex B, this was reviewed in conjunction with quality nurses of the Cardiovascular Unit, to avoid biases.
219232468|NCT06621771|OTHER|Occupational Therapy|Participants will receive conventional occupational therapy treatment (e.g., mobility, ADL, IALD, information session), excluding treatments focusing specifically on arm and hand motor recovery.The supervised session will also be complemented with an unsupervised home program consisting of assignments related to occupational therapy exercises and/or IALD/ADLs.
219232469|NCT07012889|DRUG|lidocaine infusion|The lidocaine group will receive initial intravenous bolus dose of 1.5mg/kg lidocaine over 10 min, followed by a continuous infusion of 1.5 mg/kg/h lidocaine until the end of surgery. The dose of lidocaine will be calculated according to ideal body weight. The placebo group will be administered normal saline at the same volume, infusion rate and timing.
219232470|NCT07012889|OTHER|Placebo|The placebo group will be administered normal saline 0.9% at the same volume, infusion rate and timing as lidocaine in the lidocaine group
219722865|NCT05155033|DRUG|Aldesleukin|Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
219722866|NCT05672459|DRUG|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
219722867|NCT05672459|DRUG|Fludarabine phosphate|Given by IV (vein)
219722868|NCT05672459|DRUG|Cyclophosphamide|Given by IV (vein)
219722869|NCT05672459|PROCEDURE|leukapheresis|Given by IV (vein)
219722870|NCT04338204|DRUG|tofacitinib|Observational study
219722871|NCT05020275|DIAGNOSTIC_TEST|Blood Samples|"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"
219722872|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
219722873|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
219722874|NCT05508256|DEVICE|CE-marked Catheter Ablation|Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.
219722875|NCT06398691|DEVICE|Nazal CPAP|
219722876|NCT06398691|DEVICE|Heated humidified high-flow air support with nasal cannula|
219722879|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
219722880|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
219722881|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
219722882|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
219722883|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
219722884|NCT00398905|DRUG|Enoxaparin|40 mg once daily (40 mg total daily dose)
219722885|NCT04720833|DIETARY_SUPPLEMENT|dried plum|Dried plum
219722886|NCT04720833|DIETARY_SUPPLEMENT|Calcium and vitamin D|Calcium and vitamin D supplement
219722887|NCT04762589|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
219722888|NCT04762589|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
219722889|NCT05203679|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver.
219722890|NCT06318715|PROCEDURE|modified deep extubation (mDE)|The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.
219722891|NCT06318715|PROCEDURE|standard awake extubation|awake extubation (AE) is still considered the standard practice.
219722892|NCT01010100|DRUG|Acarbose (Glucobay, BAYG5421)|50 mg TID
219722893|NCT01010100|DRUG|Placebo|50 mg TID
219722894|NCT02466542|DRUG|Placebo group|Patients will receive regular general anesthesia
219722895|NCT02466542|DRUG|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
219722896|NCT04664088|PROCEDURE|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
219722897|NCT04664088|DRUG|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
219722898|NCT03128086|PROCEDURE|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
219722899|NCT05420740|DEVICE|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
219722900|NCT00134719|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
219722901|NCT00134719|BIOLOGICAL|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
219150070|NCT06974071|OTHER|Lavender oil.|"Lavender essential oil will be used by applying 5 drops in a sterile dressing 15x15 which will be placed on the side of the patient's bedside at 10 cm from the patient.~To maintain the safety of the patients and ensure the quality of the products, two essential oils will be chosen, certified by the Institute of Public Health (ISP), the first one Lavender essential oil, body and aromatherapy use of the Weleda brand, with sanitary authorization N° 154C-15 and the essential oil Doterra, sanitary authorization N° 2832C-6/21, with authorization by the Food and Drugs Administration (FDA), in charge of ensuring the quality of substances that are marketed from the United States to the rest of the world.~These oils will be subjected to a characterization process, choosing the one with the highest quality and purity, through the protocol sent by the Scientific and Technological Nucleus in Bioresources (BioRen), which are specified in section 5.10."
219722902|NCT00134719|BIOLOGICAL|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
219722903|NCT00134719|BIOLOGICAL|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
219722904|NCT00134719|BIOLOGICAL|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
219722905|NCT00134719|BIOLOGICAL|M-M-R®II|One subcutaneous dose at 12-15 months of age
219722906|NCT00134719|BIOLOGICAL|Varivax®|One subcutaneous dose at 12 to 15 months of age
219722907|NCT00134719|BIOLOGICAL|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
219722908|NCT03310515|BEHAVIORAL|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
219722909|NCT03310515|OTHER|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
219722910|NCT03310515|OTHER|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
219722911|NCT01765491|OTHER|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
219722912|NCT01765491|OTHER|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
219722913|NCT02214082|OTHER|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
219722914|NCT01331902|OTHER|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
219722915|NCT01331902|OTHER|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
219722916|NCT01203371|DRUG|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
219722917|NCT01203371|DRUG|Tamsulosin|0,4 mg/day
219150071|NCT06972433|PROCEDURE|single visit root canal treatment|Root canal procedure performed in a single visit using ProTaper file system, sodium hypochlorite irrigation, and lateral compaction with gutta-percha and sealer. Final restoration with GIC.
219150072|NCT06972433|PROCEDURE|Multiple visit root canal treatment|Root canal procedure performed over two or more visits using the same instrumentation and irrigation protocol. Canals are medicated between appointments before obturation and restoration.
219722918|NCT04866108|DRUG|fruquintinib plus capecitabine|oral fruquintinib plus capecitabine
219722919|NCT03439839|DRUG|iptacopan|iptacopan bid orally administered
219722920|NCT03439839|COMBINATION_PRODUCT|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
219722921|NCT02355834|OTHER|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
219722922|NCT06552026|DEVICE|repeated transcranial magnetic stimulation|repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
219722923|NCT03247114|OTHER|Water|Water, 300 ml at room temperature
219722924|NCT03247114|OTHER|Glucose|Glucose, 50 grams in 300 ml water at room temperature
219722925|NCT03247114|OTHER|Fructose|Fructose, 50 grams in 300 ml water at room temperature
219722926|NCT03247114|OTHER|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
219722927|NCT03247114|OTHER|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
219722928|NCT00990288|DRUG|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
219722929|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
219722930|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
219722931|NCT04663672|OTHER|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
219722932|NCT04663672|OTHER|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
219722933|NCT04663672|OTHER|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
219232471|NCT07013292|DRUG|SKYCLARYS (omaveloxolone)|"Skyclarys is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 and over. Opaque capsule with RTA 408 printed in white ink on the light green body and 50 printed in white ink on the blue cap. Capsules (size 0) measure 21.7 ± 0.3 mm in length and the outer diameter of the cap is 7.64 ± 0.06 mm. Omaveloxolone should be initiated and monitored by physicians experienced in treating patients with patients with Friedreich's ataxia. The recommended dose is 150 mg omaveloxolone (3 x 50 mg capsules) once daily."
219232472|NCT07013240|DRUG|Botulinum toxin injection|"Intervention will be made immediately after surgery, still under general anesthesia, by the cardiac surgeon, after suture.~Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®, Allergan aesthetics) diluted in 1 mL of saline to enable injection of 5 IU at each point, every centimeter, at 1 cm of each scar side.~An equivalent volume of saline will be injected under the same modalities in the other part of the scar."
219722934|NCT04663672|BEHAVIORAL|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
219722935|NCT05037383|OTHER|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
219722936|NCT05124184|DEVICE|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
219722937|NCT05124184|DEVICE|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
219722938|NCT01886157|PROCEDURE|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
219722939|NCT01886157|PROCEDURE|Corticosteroid injection|Standard trigger finger corticosteroid injection.
219722940|NCT06288178|DIETARY_SUPPLEMENT|Bread consumption|There were four groups: whole wheat (WWB), buckwheat (BWB), corn bread (CB) and reference bread.
219722941|NCT03979989|DRUG|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
219722942|NCT03979989|DRUG|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
219722943|NCT00723944|DEVICE|Osseotite Certain Prevail|Root form titanium dental implant
219722944|NCT00723944|DEVICE|Osseotite Certain|Dental implant without the lateralized design
219722945|NCT04947722|BEHAVIORAL|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
219722946|NCT03799367|DEVICE|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
219722947|NCT03274258|BIOLOGICAL|Ipilimumab|Given IV
219722948|NCT03274258|BIOLOGICAL|Nivolumab|Given IV
219722949|NCT06093711|DIAGNOSTIC_TEST|Description|All patients were briefed about the research purpose and procedure. They were also informed about the following points: (1) participation is voluntary, (2) they can withdraw from the study at any stage without explanation, (3) the data will be used only for scientific purposes and will not be shared with third parties, and (4) they will remain anonymous throughout the research. Informed consent was obtained from those who agreed to participate. It took each participant 20-25 minutes to fill out the data collection tools.
219722950|NCT01803386|DEVICE|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
219722951|NCT04461392|DIAGNOSTIC_TEST|Cardiorespiratory exercise test|"* Cardiorespiratory exercise test to evaluate the exercise tolerance~* Cardiac imaging for the assessment of the left atrium anatomy and function."
219722952|NCT03945890|OTHER||
219722953|NCT05177094|DRUG|LY3526318|Administered orally
219722954|NCT05177094|DRUG|Placebo|Administered orally
219722955|NCT03546959|OTHER|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
219722956|NCT03546959|OTHER|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
219722957|NCT03546959|DRUG|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
219722958|NCT01620099|DRUG|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
219722959|NCT06553820|BEHAVIORAL|Intervention group I, Yoga 20 minutes x2 pr week|App-based MediYoga exercises, 20 minutes per session, twice a week for a total of 10 weeks.
219722960|NCT06553820|BEHAVIORAL|Intervention Group II, Yoga 40 minutes x2 pr week|App-based MediYoga exercises, 40 minutes per session, twice a week for a total of 10 weeks.
219722961|NCT06553820|OTHER|Control Group, No intervention|standard of care only
219150073|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
219150074|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
219150075|NCT06973889|BIOLOGICAL|Helicobacter pylori eradication therapy|12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day).
219150076|NCT06972589|DEVICE|Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
219150077|NCT06972589|DEVICE|Conventional mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
219150078|NCT06972680|DRUG|Bupivacaine Liposomes(BL)|Prior to surgery, an interscalene brachial plexus block was performed, injecting the preset volume of 0.5% bupivacaine liposomes according to the Bayesian optimal interval method.
219150079|NCT06965634|DEVICE|Lung ultrasound|Lung ultrasonography ; lung ultrasonography will be applied in 4 quadrants according to the LUS protocol and LUS score will be created.
219150080|NCT06973343|DRUG|Group A|Sintilimab 200mg Bevacizumab 7.5mg/kg Oxaliplatin 130mg/m2 Capecitabine 1250mg/m2
219150081|NCT06973343|DRUG|Group B|Sintilimab 200mg Bevacizumab 7.5mg/kg Irinotecan 150mg/m2 Capecitabine 1250mg/m2
219232473|NCT04281017|DRUG|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
219722962|NCT02400736|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
219722963|NCT02400736|OTHER|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
219722964|NCT00778414|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
219722965|NCT00899457|GENETIC|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
219722966|NCT00899457|OTHER|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
219722967|NCT00899457|OTHER|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
219150082|NCT06973850|BEHAVIORAL|The Self-Efficacy Building Nursing Program|"Intervention Description~The Self-Efficacy Building Nursing Program is a structured, theory-based educational intervention grounded in Bandura's Self-Efficacy Theory. It aims to enhance participants' confidence in their ability to perform daily foot self-care behaviors and perceive their risk of complications accurately. The content includes:~Educational modules on diabetes and foot health.~Training on daily foot inspection, hygiene, nail and skin care, and appropriate footwear.~Motivational strategies, goal setting, and problem-solving skills.~Video demonstrations, live discussions, and Q\&A sessions with a diabetes nurse educator.~The program will be delivered over four weekly virtual sessions, each lasting approximately 45-60 minutes, via a user-friendly telehealth platform (e.g., Zoom or WhatsApp Video). Follow-up support and reminders will be provided through weekly text messages and phone check-ins."
219150083|NCT06973759|DEVICE|Bright light therapy|Exposure to blue-enriched white light for 15-30 minutes a day for 8 weeks
219150084|NCT06973759|DEVICE|Dim red light|Exposure to dim red light for 15-30 minutes a day for 8 weeks.
219150085|NCT06972836|PROCEDURE|modified pericardial window|(H) shaped lines done by diathemy hoke above phrenic nerve then the upper and lower pericardial flabs reflelected outward in upper and lower directions respectively then 3 large clips applied on each angle of the reflected pericardial anlgles then heavy non absorbable suture is taken from the centre of the free reflected edge to adjacent upper and lower pericardium
219150086|NCT06972836|PROCEDURE|traditional pericardial window|A portion of pericardium (2 cm diameter) was resected anterior to the phrenic nerve by diathermy hook
219150087|NCT06973278|PROCEDURE|SMILE|Small Incision Lenticule Extraction
219150088|NCT06973278|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
219232474|NCT04281017|DRUG|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
219232475|NCT06698484|DRUG|CAR-T cells|2×10\^6 CAR T cells/kg
219150089|NCT06243796|PROCEDURE|Flap fixation technique|After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
219232476|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
219722968|NCT00899457|PROCEDURE|bronchoscopy|Collection of breath condensate.
219722969|NCT04488185|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
219722970|NCT04488185|OTHER|Placebo|Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
219722971|NCT02242006|OTHER|serial serum sampling for quantification of drug concentration|
219722972|NCT05702268|DRUG|ICP-332|Tablet, 40 mg
219722973|NCT05702268|DRUG|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
219232477|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
219232478|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
219232479|NCT06442748|DRUG|Levetiracetam|Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
219232480|NCT01553214|DRUG|Filgrastim|Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.
219232481|NCT01553214|DRUG|Dexamethasone|Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
219232482|NCT06919718|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|2,000 IU Vitamin D
219232483|NCT06919718|OTHER|Placebo|Placebo
219232484|NCT05640895|PROCEDURE|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
219232485|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
219232486|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
219232487|NCT06415227|DRUG|Vericiguat|The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
219150090|NCT00786006|DRUG|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
219232488|NCT04445337|DRUG|Stellate Ganglion Block|"An injection of local anesthetic into the front of the neck. SGB involves placing a small tube into the front of your neck, toward nerves at the back of your neck. This is done with the help of an x-ray machine or ultrasound device. The tube is left in place so you can get medication thru it for five days. Then the tube is taken out.~The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block. These medications are approved by the Food and Drug Administration (FDA)."
219722974|NCT00705822|DRUG|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
219722975|NCT00705822|DRUG|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
219150091|NCT00786006|DRUG|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
219232489|NCT03659136|DRUG|Xentuzumab|Intravenous infusion
219232490|NCT03659136|DRUG|Placebo|Intravenous infusion
219232491|NCT03659136|DRUG|Everolimus|Tablet
219232492|NCT03659136|DRUG|Exemestane|Tablet
219232493|NCT06170983|DRUG|Azithromycin|500 mg once daily for 3 days
219232494|NCT06170983|DIAGNOSTIC_TEST|Biopsy|Skin punch biopsy
219232495|NCT06170983|OTHER|Skin inflammation model|LPS- or imiquimod induced skin inflammation
219722976|NCT04665232|DRUG|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
219722977|NCT01956942|DEVICE|Micropulse Laser Trabeculoplasty|
219722978|NCT01956942|DEVICE|Selective Laser Trabeculoplasty|
219150092|NCT04655131|DIETARY_SUPPLEMENT|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
219232496|NCT02316821|DRUG|RTA 402|
219722979|NCT00209820|BEHAVIORAL|Supervised Nordic Walking|
219232497|NCT02316821|DRUG|Placebo|
219722980|NCT00209820|BEHAVIORAL|Unsupervised Nordic Walking|
219722981|NCT00209820|BEHAVIORAL|Advice to stay active|
219722982|NCT01407419|OTHER|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
219722983|NCT01407419|OTHER|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
219722984|NCT01724190|DRUG|Vitamin D|
219722985|NCT01724190|DRUG|Placebo|
219232498|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
219232499|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
219150093|NCT04290117|BEHAVIORAL|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
219150094|NCT04290117|BEHAVIORAL|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
219150095|NCT04148040|PROCEDURE|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
219150096|NCT00971022|BEHAVIORAL|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
219150097|NCT00971022|BEHAVIORAL|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
219150098|NCT00441636|DEVICE|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
219150099|NCT00310154|DRUG|docetaxel|
219150100|NCT00310154|DRUG|gefitinib|
219722986|NCT00138294|BIOLOGICAL|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
219722987|NCT00992836|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
219722988|NCT02463877|PROCEDURE|Minimally-Invasive Procedure|Laparoscopy
219722989|NCT05639868|OTHER|Video-assisted CPR|Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.
219722990|NCT05639868|OTHER|Telephone-assisted CPR|Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
219722991|NCT01864694|BEHAVIORAL|TLC-Diet|Participants receive diet intervention through an automated telephone system
219722992|NCT01864694|BEHAVIORAL|WEB-Diet|Participants receive diet intervention through a web-based system
219722993|NCT01864694|OTHER|Assessment-only control|Assessment-only control
219722994|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
219722995|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
219722996|NCT04694638|OTHER|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
219150101|NCT00310154|OTHER|laboratory biomarker analysis|
219150102|NCT00310154|RADIATION|radiation therapy|
219150103|NCT05068362|DEVICE|Auricular reconstruction|Medpor implant for treatment of microtia
219232500|NCT04276740|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~* MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~* MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~* MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~* MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~* Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
219232501|NCT04276740|OTHER|Placebo|Placebo
219722997|NCT01643187|DIETARY_SUPPLEMENT|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
219150104|NCT01198028|DRUG|Erlotinib|Given PO
219150105|NCT03624166|DRUG|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
219722998|NCT01643187|DIETARY_SUPPLEMENT|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
219722999|NCT05474209|OTHER|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
219723000|NCT02557789|DRUG|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
219150106|NCT03624166|DRUG|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
219150107|NCT06362278|OTHER|multi-omics studies|15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
219232502|NCT01346826|DRUG|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
219232503|NCT01346826|DRUG|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
219723001|NCT02786667|DRUG|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
219723002|NCT02786667|DRUG|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
219723003|NCT00739570|DEVICE|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
219723004|NCT05552131|DEVICE|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
219150108|NCT01576952|DRUG|ISV-303|Bromfenac in DuraSite
219150109|NCT01576952|OTHER|DuraSite Vehicle|DuraSite Vehicle
219150110|NCT04470401|DRUG|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
219150111|NCT04470401|DRUG|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
219150112|NCT05454228|BEHAVIORAL|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
219723005|NCT01617967|DRUG|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
219723006|NCT04137315|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
219723007|NCT00552903|BEHAVIORAL|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
219723008|NCT06169085|DRUG|Leritrelvir|Oral
219723009|NCT05703776|BEHAVIORAL|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
219150113|NCT06328985|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
219150114|NCT06328985|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
219150115|NCT06328985|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
219150116|NCT02601170|BIOLOGICAL|Platelet-Rich Plasma Intra-Articular Injection|
219150117|NCT02601170|DRUG|Hyaluronic Acid Viscosupplementation|
219150118|NCT05484297|BEHAVIORAL|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
219232504|NCT01346826|DRUG|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
219232505|NCT05560061|OTHER|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
219723010|NCT00005585|DRUG|cyclophosphamide|Given IV
219723011|NCT00005585|DRUG|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
219723012|NCT00005585|DRUG|daunorubicin hydrochloride|Given IV
219723013|NCT00005585|DRUG|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
219150119|NCT05484297|BEHAVIORAL|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
219150120|NCT06974032|DRUG|Xylocaine jelly 2%|To determine if a 6cc of 2% lidocaine jelly decreases pain of paracervical block injection before IUD placement in nulliparous women
219150121|NCT06974032|DRUG|Surgilube|To determine if the placebo gel increases pain of paracervical block injection before IUD placement in nulliparous women
219150122|NCT05132842|OTHER|Survey Administration|Complete a Survey
219150123|NCT01010919|DIETARY_SUPPLEMENT|Chicory root extract|
219150124|NCT01145248|DEVICE|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
219150125|NCT01145248|DEVICE|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
219723014|NCT00005585|DRUG|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
219723015|NCT00005585|DRUG|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
219723016|NCT00005585|DRUG|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
219150126|NCT02214693|DRUG|DA-1229|
219150127|NCT00295074|PROCEDURE|neuropsychologic testing|
219150128|NCT00028093|DRUG|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
219150129|NCT00028093|DRUG|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
219150130|NCT04998903|PROCEDURE|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
219150131|NCT00777816|DRUG|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
219150132|NCT00777816|DRUG|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
219150133|NCT05664100|DRUG|FX-345|Single intratympanic injection of FX-345
219150134|NCT05664100|DRUG|Placebo|Single intratympanic injection of placebo
219150135|NCT04407780|OTHER|No interventions are planned|Non applicable
219150136|NCT04645394|DIETARY_SUPPLEMENT|Aronia melanocarpa|Administered once (acute study)
219150137|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
219150138|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
219150139|NCT04645394|DIETARY_SUPPLEMENT|Placebo|Administered once (acute study)
219723017|NCT00005585|DRUG|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
219723018|NCT00005585|DRUG|thioguanine|Given orally
219723019|NCT00005585|DRUG|vincristine sulfate|Given IV
219723020|NCT04764539|BEHAVIORAL|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
219723021|NCT03228914|DRUG|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
219723022|NCT03228914|DRUG|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
219723023|NCT00977184|PROCEDURE|50 HZ Repetitive TMS|
219723024|NCT00977184|PROCEDURE|Sham rTMS|
219723025|NCT05434676|DEVICE|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
219723026|NCT04763720|BEHAVIORAL|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
219723027|NCT06125782|DRUG|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
219723028|NCT06125782|DRUG|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
219723029|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
219723030|NCT02827708|DRUG|semaglutide|Oral administration once daily.
219723031|NCT02827708|DRUG|placebo|Oral administration once daily.
219723032|NCT04100187|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
219723033|NCT01783782|BEHAVIORAL|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
219150140|NCT01526642|DEVICE|Non Invasive Ventilation|NIV during night
219723034|NCT01783782|DRUG|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
219723035|NCT01783782|DRUG|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
219150141|NCT04689425|DRUG|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
219150142|NCT04689425|DRUG|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
219150143|NCT00582478|BEHAVIORAL|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
219150144|NCT01597258|DRUG|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
219150145|NCT04210765|DRUG|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
219150146|NCT06028984|DEVICE|Intervention app|An app-based intervention for depression
219150147|NCT06028984|OTHER|Control app|An app with non-therapeutic content
219150148|NCT01470040|DRUG|discontinuation of aspirin therapy|discontinuation of aspirin therapy
219150149|NCT01470040|DRUG|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
219150150|NCT04425616|OTHER|Exercise|"At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
219150151|NCT04425616|BEHAVIORAL|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
219150152|NCT04425616|OTHER|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
219150153|NCT06615869|DRUG|Molnupiravir|Oral Administration.
219723036|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
219723037|NCT02087683|OTHER|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
219723038|NCT00474032|DRUG|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
219723039|NCT04329741|BEHAVIORAL|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
219723040|NCT02063269|DRUG|Rivastigmine|9-18mg/rivastigmine for 52 weeks
219723041|NCT06013085|BEHAVIORAL|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
219723042|NCT06088446|PROCEDURE|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
219723043|NCT01266928|DRUG|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
219723044|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
219723045|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
219723046|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
219723047|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
219723048|NCT04259242|PROCEDURE|SRP|scaling and root planing with ultrasonic scaler and manual instruments
219723049|NCT00361244|DRUG|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
219723050|NCT00361244|DRUG|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
219723051|NCT00361244|DRUG|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
219723052|NCT05858229|DRUG|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
219723053|NCT05176574|BEHAVIORAL|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
219150154|NCT04954196|DRUG|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
219150155|NCT04954196|DRUG|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
219150156|NCT06044545|DIAGNOSTIC_TEST|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
219150157|NCT03062137|DIAGNOSTIC_TEST|blood gas sampling|
219150158|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
219150159|NCT05719077|BEHAVIORAL|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
219150160|NCT05977634|BEHAVIORAL|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
219150161|NCT05977634|DEVICE|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
219150162|NCT06034665|OTHER|Exercise|All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
219150163|NCT06034678|BEHAVIORAL|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
219150164|NCT00928213|DRUG|Progesterone|40 units daily admission
219150165|NCT00928213|DRUG|Low molecular weight Heparin|40-80 mg/day
219150166|NCT00928213|DRUG|No Drug|no treatment
219723054|NCT03081078|BEHAVIORAL|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
219723055|NCT03081078|OTHER|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
219150167|NCT06490003|DRUG|Fluoro Uracil|Esophageal cancer chemotherapy（First line treatment)
219232506|NCT05560061|OTHER|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
219723056|NCT04358562|DRUG|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
219723057|NCT04358562|DRUG|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
219723058|NCT05866328|OTHER|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
219723059|NCT05364255|DRUG|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
219723060|NCT03079583|DIETARY_SUPPLEMENT|Intervention-group|Biofortified Rice is grown by foliar Zn application
219723061|NCT03079583|DIETARY_SUPPLEMENT|Control-group|Control Rice with normal zinc levels
219723062|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
219723063|NCT04841876|OTHER|rugby matches|standard rugby-7s match
219723064|NCT03165903|BEHAVIORAL|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
219150168|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
219150169|NCT00039455|BIOLOGICAL|trastuzumab|Given IV
219723065|NCT03165903|BEHAVIORAL|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
219723066|NCT01137812|DRUG|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
219723067|NCT01137812|DRUG|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
219723068|NCT01137812|DRUG|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
219723069|NCT01137812|DRUG|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
219723070|NCT00086125|DRUG|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
219723071|NCT00753142|DRUG|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
219723072|NCT00753142|DRUG|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
219723073|NCT01168440|DRUG|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
219723074|NCT00042978|BIOLOGICAL|oblimersen sodium|Given IV
219723075|NCT00042978|DRUG|carboplatin|Given IV
219150170|NCT00039455|DRUG|alvocidib|Given IV
219150171|NCT00039455|OTHER|laboratory biomarker analysis|Correlative studies
219150172|NCT00039455|OTHER|pharmacological study|Correlative studies
219150173|NCT06613204|BEHAVIORAL|STELLA-FTD Control|Participants receive information about FTD and support via weekly group video-conference-based meetings.
219150174|NCT06613204|BEHAVIORAL|STELLA-FTD Test|The test group receives a information and support, but with a focus that is different from the Control Group
219150175|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
219150176|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
219150177|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
219150178|NCT06668467|BEHAVIORAL|Mindfulness-based Stress Reduction|An 4-week Mindfulness-based stress reduction training programme
219150179|NCT06615375|BIOLOGICAL|Shigella4V2|Shigella4V2 is a tetravalent bioconjugate vaccine
219150180|NCT06615375|BIOLOGICAL|Placebo|Phosphate-buffered saline
219150181|NCT06383442|OTHER|L-HIIT|the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
219150182|NCT06383442|OTHER|M-HIIT|the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
219150183|NCT06673316|OTHER|Design thinking workshop|The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice.
219150184|NCT05909566|OTHER|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
219150185|NCT05909566|DEVICE|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
219150186|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
219150187|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
219150188|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
219150189|NCT00981630|BIOLOGICAL|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
219150190|NCT02487316|DRUG|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
219150191|NCT06677281|OTHER|Systematic Review of COVID-19's Impact on Pregnancy Outcomes|This study is a systematic review of existing literature that examines the effects of COVID-19 on pregnancy outcomes, including maternal health, neonatal health, and obstetric complications. It synthesizes data from various studies to provide an overview of the potential risks associated with COVID-19 infection during pregnancy. This intervention does not involve any new clinical trials or direct patient interaction.
219723076|NCT00042978|DRUG|etoposide|Given IV
219723077|NCT02537925|DRUG|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
219723078|NCT02537925|DRUG|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
219723079|NCT02537925|RADIATION|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
219723080|NCT04393428|OTHER|[TIMP-2]*[IGFBP-7]|\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
219723081|NCT04621760|BEHAVIORAL|HIV Prevention Decision Support Tool (DST)|The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.
219150192|NCT06676124|DIETARY_SUPPLEMENT|Piper crocatum Extract Cookie|Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction
219150193|NCT06676124|DIETARY_SUPPLEMENT|Placebo Comparator|Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
219150194|NCT05836285|OTHER|ARRC|Eligible for ARRC and managed in ARRC unit
219723082|NCT04621760|BEHAVIORAL|Standard Counseling|Participants in this arm will receive usual care.
219723083|NCT05951842|DRUG|anesthetic method|Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
219723084|NCT05234333|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
219723085|NCT01953276|DEVICE|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
219723086|NCT04664114|BEHAVIORAL|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
219150195|NCT05836285|OTHER|Usual Care|Eligible for ARRC but managed elsewhere as no ARRC bed available
219150196|NCT06092138|DEVICE|Wearable Device|Whether to use wearable devices.
219723087|NCT06322303|OTHER|Placebo (CBD 0%)|Participants are required to vaporize placebo at 0% CBD concentration
219723088|NCT06322303|OTHER|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
219723089|NCT06322303|OTHER|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
219723090|NCT02421211|DRUG|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
219723091|NCT02421211|DRUG|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
219723092|NCT02421211|DRUG|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
219723093|NCT05595954|OTHER|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
219232507|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
219150197|NCT06864299|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
219150198|NCT04848090|DIAGNOSTIC_TEST|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
219150199|NCT07008898|PROCEDURE|Midurethral sling placed before robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
219150200|NCT07008898|PROCEDURE|Midurethral sling placed after robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
219150201|NCT05799963|DEVICE|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
219150202|NCT06676397|PROCEDURE|Blood Punction|venous blood sampling
219150203|NCT06676605|DIETARY_SUPPLEMENT|Withania somnifera|The experimental supplement administered to patients in this study was Withania somnifera, commonly known as ashwagandha. It is classified as a dietary supplement and is regulated similarly to pharmaceutical medications. The supplement has been authorized for commercialization and use by the Food and Drug Administration (FDA). Participants received the supplement in the form of 500 mg capsules, taken daily over a 40-day period, following the manufacturer's instructions. The range of the recommended daily dose is between 240 and 600 mg. The purpose of administering this supplement was to evaluate its impact on various health parameters, including serum lipid concentrations and body composition, in the study's participants.
219150204|NCT06676605|OTHER|Placebo Intervention|The product administered to the placebo group was designed to simulate the appearance and administration of the experimental supplement but without containing any active ingredients. Participants in the placebo group received capsules/tablets filled with starch rice. These capsules were taken daily over the same 40-day period as the experimental group, ensuring that the placebo group followed identical administration and monitoring procedures. The use of starch rice capsules aimed to serve as a neutral control, allowing for a comparison between the effects of the actual Withania somnifera supplement and the placebo.
219150205|NCT06676696|DRUG|Continue low dose calcineurin inhibitor (CNI)|CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study
219150206|NCT06676696|DRUG|Calcineurin inhibitor withdrawal at 6 months|CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
219150207|NCT05251493|DRUG|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
219150208|NCT05251493|DRUG|Iron sucrose|iron sucrose 100 mg/mL
219150209|NCT06676930|DEVICE|Colonoscopy With Computer-Aided Detection|Use of Computer-Aided Detection During Colonoscopy
219150210|NCT06676930|PROCEDURE|Colonoscopy without Computer-Aided Detection|Colonoscopy without Computer-Aided Detection (AI)
219150211|NCT06677216|PROCEDURE|Botulinum Toxin, Type A|All participants will receive a solution of BTX-A (Xeomin, Merz Pharma GmbH, Frankfurt am Main, Germany) in the masseter and temporalis muscles (total of 100 units reconstituted with 4cc unpreserved 0.9% sodium chloride). The injection will be provided by the same maxillofacial surgeon. The participants are asked to clench their teeth to determine the site of the most intense muscle activity in the masseter and temporal muscles with palpation. Intramuscular BTX-A injections are administered on both sides at the location of the most intense muscle activity of the masseter (80 units) and temporalis (20 units).
219150212|NCT06871774|DEVICE|Single Perclose Pro vascular closure device|Use of a single Perclose device for pre-closure of vascular access site after removal of TAVR sheath.
219150213|NCT06871774|DEVICE|Dual Perclose vascular closure device|Use of two Perclose devices for pre-closure of vascular access site after removal of TAVR sheath.
219150214|NCT07019506|OTHER|Cardiac rehabilitation|Sessions are conducted individually in accordance with cardiac rehabilitation guidelines, with a frequency of 2-3 times per week, each lasting 1 hour. Intensity is progressively increased on a weekly basis, with adaptations made according to each patient's specific needs. A total of 20 sessions are delivered, focused on improving the patient's cardiovascular capacity
219150215|NCT06328127|BEHAVIORAL|PATH|PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
219150216|NCT06630299|DRUG|ISL/LEN|Tablet administered orally
219150217|NCT06630299|DRUG|Antiretroviral Combinations|2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
219150218|NCT06630390|DRUG|Daridorexant 50 mg|Administered consistent with labeling from the US Food and Drug Administration.
219150219|NCT06630390|OTHER|Placebo|Identical appearing to daridorexant
219150220|NCT06630546|DEVICE|first generation iStent (Glaukos, San Clemente, CA, USA) insertion|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
219150221|NCT06630546|DEVICE|phacoemulsification|A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
219150222|NCT07023107|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride
219150223|NCT07023107|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine
219150224|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine
219150225|NCT07023120|DRUG|Dexamethasone 4mg|perineural 4mg Dexamethasone
219150226|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|10ml 0.2% Ropivacaine
219150227|NCT06873763|DRUG|Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab|Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.
219150228|NCT06701201|DRUG|SynKIR-110|Autologous T cells Transduced with Mesothelin KIR-CAR
219150229|NCT06701201|DRUG|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
219150230|NCT07060053|OTHER|sesame oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
219150231|NCT07060053|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
219150232|NCT05299762|DEVICE|INFUSE™ Bone Graft|Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
219150233|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
219150234|NCT03554382|OTHER|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
219150235|NCT06302101|BEHAVIORAL|chair-based exercises|"Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises."
219150236|NCT06302101|BEHAVIORAL|cognitive exercises|Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
219150237|NCT05199571|BIOLOGICAL|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
219150238|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
219723094|NCT05595954|DIAGNOSTIC_TEST|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
219150239|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
219150240|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
219150241|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
219150242|NCT06245954|OTHER|simulated training|Simulation training of bronchoscopists by means of simulators and extracorporeal lungs
219150243|NCT06245954|OTHER|traditional bedside teaching|TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
219150244|NCT02964611|BEHAVIORAL|Observational Study|This is an observational study.
219150245|NCT05054309|DIETARY_SUPPLEMENT|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
219232508|NCT04995601|DEVICE|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
219232509|NCT05667012|OTHER|Educational videos|There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
219232510|NCT06067958|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
219232511|NCT06067958|DRUG|Saline|Intranasal administration of saline 0.9% will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
219723095|NCT05595954|DIAGNOSTIC_TEST|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
219232512|NCT06720181|DIAGNOSTIC_TEST|MRI|Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain
219723096|NCT05595954|DIAGNOSTIC_TEST|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
219723097|NCT05595954|DIAGNOSTIC_TEST|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
219723098|NCT05595954|OTHER|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
219723099|NCT05595954|DIAGNOSTIC_TEST|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
219723100|NCT05595954|DIAGNOSTIC_TEST|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
219723101|NCT05796817|DEVICE|Ventilator modification|The ventilator modification will be fitted to a ResMed Lumis 150, Breas® Nippy 4+ or Vivo 1, 2 or 3 ventilator. The participants oxygen level will be measured with and without the modification in place at their baseline ventilation, and with 1, 2 and 3 litres oxygen extra to their baseline. the researcher will then leave the modification on and slowly reduce the oxygen going into the ventilator, maintaining the participants SP02 at an acceptable level (\>95%)
219150246|NCT04095221|DRUG|Prexasertib|"DOSE LEVELS FOR PATIENTS \> 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
219150247|NCT04095221|DRUG|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
219150248|NCT03215927|DRUG|Abatacept|Abatacept 125mg subcutaneous weekly
219150249|NCT03215927|OTHER|Placebo|Placebo
219150250|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
219150251|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
219150252|NCT05344599|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.
219150253|NCT05344599|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit
219150254|NCT05344599|DIAGNOSTIC_TEST|Urine Testing|Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine
219150255|NCT05344599|DIAGNOSTIC_TEST|Blood laboratory Testing|"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"
219232513|NCT05179109|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
219723102|NCT04576546|DIETARY_SUPPLEMENT|D-chiro-inositol|Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
219150256|NCT04263792|DRUG|[18F]fluoropropyl-trimethoprim|\[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
219150257|NCT04163614|OTHER|IBPS-Guided Ultrafiltration|Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
219150258|NCT05363137|OTHER|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
219150259|NCT05363137|OTHER|Standard care|The physiotherpy treatment will be standard care
219150260|NCT05051436|DRUG|Mirabegron 50 MG|Mirabegron 50 mg/day will be administered for 14 weeks.
219150261|NCT05051436|DRUG|Tadalafil 10 MG|Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
219723103|NCT04576546|DIETARY_SUPPLEMENT|Myo-inositol|Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
219723104|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
219723105|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
219723106|NCT04602000|BIOLOGICAL|Placebo|Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
219723107|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
219150262|NCT05051436|DRUG|Placebo|Placebo will be administered for 14 weeks after baseline procedures.
219232514|NCT05693272|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
219232515|NCT05693272|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
219723108|NCT04602000|BIOLOGICAL|Placebo|Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
219232516|NCT06415357|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.
219232517|NCT06415357|BEHAVIORAL|Motivational Text Messaging (MTM)|Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.
219232518|NCT06415357|BEHAVIORAL|Standard ART Counseling|All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
219232519|NCT05700279|PROCEDURE|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
219232520|NCT05700279|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
219232521|NCT00353106|BEHAVIORAL|Interview|30-minute interviews of participating patients and their caregiver(s).
219232522|NCT00353106|BEHAVIORAL|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
219232523|NCT01668355|OTHER|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
219150263|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
219150264|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
219150265|NCT06126510|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
219150266|NCT05700006|DRUG|Aromatase inhibitor|Standard of care anastrozole, exemestane, or letrozole
219232524|NCT00162006|DRUG|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
219232525|NCT06193915|DEVICE|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
219232526|NCT06193915|PROCEDURE|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
219232527|NCT01439399|DRUG|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
219232528|NCT01439399|DRUG|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
219232529|NCT01439399|DRUG|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
219232530|NCT01439399|DRUG|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
219232531|NCT01190488|BEHAVIORAL|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
219723109|NCT03729440|BEHAVIORAL|development of complications or not|assessment of development of complications
219232532|NCT01190488|BEHAVIORAL|Active Comparator|TAU
219232533|NCT05839743|OTHER|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
219723110|NCT06118320|DRUG|Potassium sodium hydrogen citrate|"Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels."
219723111|NCT02967887|DRUG|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
219723112|NCT01324180|DRUG|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
219723113|NCT01324180|DRUG|Vincristine|1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
219150267|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
219150268|NCT03889925|DRUG|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
219150269|NCT03889925|BIOLOGICAL|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
219150270|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Exposed to Passive Smoking|This study is designed to evaluate the relationship between passive smoking and the vital parameters of children undergoing deep sedation. Additionally, the study aims to comprehensively assess and document the entire treatment process from start to finish by using the RASS, MASS, and PAED scales for postoperative evaluation.
219150271|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Not Exposed to Passive Smoking|This study is designed to measure the differences in vital parameters of children undergoing deep sedation who are not exposed to passive cigarette smoke at home. Furthermore, the study aims to comprehensively evaluate and document the entire treatment process from start to finish using the RASS, MASS, and PAED scales for postoperative assessment.
219150272|NCT06833203|DRUG|Amantadine+ Pregabalin|Two hours preoperative, patient will receive two capsules, one of them is Amantadine (Amantadine Hydrochloride) 100 mg and the other is Pregabalin (Lyrica) 75 mg and continued on both of them twice daily for 5 days postoperative.
219150273|NCT06833203|DRUG|Pregabalin|Two hours preoperative, the patient will receive two capsules, one of them is pregabalin 75 mg, and the other is a placebo capsule similar to the amantadine capsule and continued on both of them twice daily for 5 days postoperative.
219150274|NCT05116085|DRUG|Tislelizumab|Administered intravenously
219150275|NCT06732778|OTHER|Pain Neuroscience Education (PNE)|"PNE was planned online for clients 1 week before menstruation in the form of speaking sessions in a presentation format. The training will be conveyed in relation to pain during menstruation. Visual aids, examples and metaphors will be used to improve patient understanding in the training. Ankle sprain picture, speeding bus picture, action potential picture, picture showing membrane resting potential, rusty nail picture, whole body nervous system picture, neuromatrix picture, lion and lion cub picture that helps explain stress responses, curious neighbors picture etc. will be used. The training session is planned to last between 2 and 4 hours.~The distribution of pain neuroscience training topics will be implemented in the order given below, with 10 main headings.~* Pain and the Biopsychosocial Model~* Injury and pain are not equivalent, pain is a brain output rather than an input~* Action potential, normal electrical activity of nerves and conduction~* Biological process of ion chann"
219150276|NCT06732778|OTHER|Control Group (CG)|The control group will not receive any training or practice.
219150277|NCT05376878|OTHER|Copper Cu 64-DOTA-Trastuzumab|Given IV
219150278|NCT05376878|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219232534|NCT05839743|OTHER|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
219232535|NCT05839743|OTHER|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
219723114|NCT01324180|DRUG|Dexamethasone|"* 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15"
219150279|NCT05376878|DEVICE|Positron Emission Tomography|Undergo PET/MRI
219150280|NCT05376878|BIOLOGICAL|Trastuzumab|Given IV
219150281|NCT05376878|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219150282|NCT04522271|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
219150283|NCT04522271|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
219150284|NCT05436561|DRUG|MBF-RIC|Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
219150285|NCT06834516|DEVICE|ClearSight baby cuff|Noninvasive device for continuous blood pressure monitoring
219150286|NCT06829797|DRUG|Neoadjuvant Therapy(QL1706+SOX Chemotherapy)|Preoperative QL1706 combined with SOX regimen (4 cycles) → Radical surgery (D2) → Postoperative QL1706 combined with SOX regimen (4 cycles). QL1706 (50mg/2mL) , at a dose of 5mg/kg, the desired volume of drug is withdrawn and slowly infused into an IV bag of 0.9% NaCl, prepared as a diluent with a final concentration of 1-10mg/mL, mixed, and infused intravenously, Q3W, administered on the first day of each cycle.
219150287|NCT06829797|DRUG|Neoadjuvant Therapy(SOX Chemotherapy)|Preoperative SOX regimen (4 cycles) → radical surgery (D2) → postoperative SOX regimen (4 cycles).
219150288|NCT06829797|PROCEDURE|Radical surgery (D2)|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
219150289|NCT06829797|DRUG|Drug: Adjuvant therapy(QL1706+SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of QL1706+SOX chemotherapy.
219150290|NCT06829797|DRUG|Drug: Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
219150291|NCT06499324|DRUG|BTA group|It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
219150292|NCT06499324|DRUG|Placebo group|It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
219150293|NCT03382145|OTHER|No intervention|No intervention
219150294|NCT06831253|OTHER|injections of Platelet-Rich Plasma in lacrimal gland|injections of Platelet-Rich Plasma in lacrimal gland
219150295|NCT05937750|DRUG|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
219723115|NCT01324180|DRUG|PEG-asparaginase|"* 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
219723116|NCT01324180|DRUG|Doxorubicin|60 mg/m\^2/day IV over 15 minutes on day 2
219150296|NCT05937750|OTHER|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study|Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
219150297|NCT05457972|DRUG|Estradiol|Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
219150298|NCT05457972|DEVICE|Vaginal Moisturizer|Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
219150299|NCT05143632|DEVICE|ClearSight|The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
219150300|NCT04469699|DRUG|Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
219150301|NCT04469699|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
219150302|NCT04897880|DRUG|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
219150303|NCT04453020|DEVICE|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
219150304|NCT01000623|DRUG|venlafaxine|Given orally
219150305|NCT01000623|DRUG|placebo|Given orally
219150306|NCT01000623|PROCEDURE|hypnotherapy|Practice hypnosis
219150307|NCT01000623|PROCEDURE|mind-body intervention procedure|Practice focused attention
219150308|NCT03101917|DEVICE|The Microtable® Stereotactic System|x
219150309|NCT06276465|DRUG|Darolutamide 300 mg|2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
219150310|NCT06276465|RADIATION|Stereotactic body radiation therapy|Over one week,30 Gy in 3 fractions of 10 Gy
219150311|NCT06276465|DRUG|Androgen deprivation therapy|Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
219723117|NCT01324180|DRUG|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
219723118|NCT06091033|DIETARY_SUPPLEMENT|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
219723119|NCT06091033|DIETARY_SUPPLEMENT|placebo|1,000 mg of a placebo for 8 weeks
219150312|NCT04084223|OTHER|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
219232536|NCT00286832|PROCEDURE|PET scan|One extra PET scan after 1 cycle of treatment.
219232537|NCT06049199|OTHER|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
219723120|NCT02901860|OTHER|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
219723121|NCT01025050|PROCEDURE|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
219723122|NCT00471354|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
219150313|NCT06522061|DEVICE|Stream™ Platform|Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
219150314|NCT05430997|DEVICE|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
219150315|NCT05430997|DEVICE|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
219150316|NCT03073941|DEVICE|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
219150317|NCT03073941|DEVICE|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
219150318|NCT05250310|BEHAVIORAL|Chair Yoga|Yoga poses performed in a chair
219150319|NCT04586270|DRUG|TAS0612|oral tablets
219150320|NCT05988749|OTHER|Biofourmis Digital Platform|The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
219150321|NCT05261633|DEVICE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
219723123|NCT03522168|DRUG|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
219723124|NCT03522168|DRUG|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
219723125|NCT00211094|DRUG|Dapoxetine|
219723126|NCT00265291|DRUG|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
219150322|NCT06302660|DIAGNOSTIC_TEST|Breath test|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath.
219150323|NCT06302660|DIAGNOSTIC_TEST|Saliva sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of saliva.
219723127|NCT04855812|DEVICE|MyoMo|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
219723128|NCT04855812|OTHER|Myo-SB|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
219723129|NCT04855812|OTHER|Control|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
219723130|NCT03494179|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
219150324|NCT06302660|DIAGNOSTIC_TEST|Blood sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of blood.
219150325|NCT06302660|DIAGNOSTIC_TEST|Urine sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of urine.
219150326|NCT06302660|DIAGNOSTIC_TEST|Stool sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of stool.
219723131|NCT02949453|BEHAVIORAL|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
219723132|NCT03050489|PROCEDURE|On-Pump CABG.|Standard On-Pump CABG.
219723133|NCT03050489|PROCEDURE|Off-Pump CABG.|Standard Off-Pump CABG.
219723134|NCT03050489|PROCEDURE|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
219723135|NCT02573467|DRUG|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
219723136|NCT02573467|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
219723137|NCT02328274|PROCEDURE|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
219723138|NCT02153827|OTHER|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
219723139|NCT02153827|OTHER|General Shoulder exercise|general exercise consisting of active shoulder movements
219723140|NCT00991432|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
219723141|NCT02583009|DRUG|PAC-14028 cream 0.1%|Topical application
219723142|NCT02583009|DRUG|PAC-14028 cream 0.3%|Topical application
219723143|NCT02583009|DRUG|PAC-14028 cream 1.0%|Topical application
219723144|NCT02583009|DRUG|PAC-14028 cream vehicle|Topical application
219723145|NCT05560321|OTHER|Sani24|Disinfectant
219723146|NCT05560321|OTHER|Routine Disinfection|Routine disinfection at the study hospital
219723147|NCT04088955|OTHER|DigiMeds|Digitized Capecitabine
219723148|NCT02518269|PROCEDURE|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
219723149|NCT05762679|DIAGNOSTIC_TEST|Imaging|Phase 1 is an imaging biomarker study.
219723150|NCT00144885|BEHAVIORAL|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
219723151|NCT02228122|DEVICE|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
219723152|NCT04339972|DEVICE|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
219723153|NCT04339972|DEVICE|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
219723154|NCT01748682|OTHER|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
219723155|NCT03745469|DEVICE|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
219723156|NCT05565547|DEVICE|META|The META device is used for a comprehensive ophthalmic examination.
219723157|NCT05565547|DEVICE|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
219723158|NCT04790799|OTHER|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
219723159|NCT05491889|BIOLOGICAL|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
219723160|NCT00127010|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
219723161|NCT05327738|BIOLOGICAL|Atezolizumab|Given IV
218987417|NCT04157439|OTHER|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
219723162|NCT05327738|PROCEDURE|Biopsy|Undergo biopsy
219723163|NCT05327738|DRUG|Cabozantinib S-malate|Given PO
219723164|NCT05327738|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
219723165|NCT01116843|DRUG|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
219723166|NCT04995107|DEVICE|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
219723167|NCT05698212|DIAGNOSTIC_TEST|MetriDx|Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
219723168|NCT05227235|OTHER|3D Telemedicine|Clinical consultation with patient performed with 3D Telemedicine
219723169|NCT05227235|OTHER|2D Telemedicine|Clinical consultation with patient performed with 2D Telemedicine as standard of care
219723170|NCT05790681|DRUG|Insulin icodec|Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
219723171|NCT03986268|DRUG|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
219723172|NCT01420978|PROCEDURE|CSF Diversion|CSF drainage
219150327|NCT06302660|DIAGNOSTIC_TEST|Health-related Quality of life questionnaires|Participants will attend an outpatient clinic and complete validated healthy-related quality-of-life questionnaires.
219150328|NCT05252884|DIAGNOSTIC_TEST|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
219150329|NCT05252884|DRUG|routine postoperative calcium and calcitriol|The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
219150330|NCT03712813|DEVICE|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
219150331|NCT05465187|OTHER|Non applicable|Non applicable
219150332|NCT05649930|OTHER|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
219150333|NCT03400085|OTHER|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
219150334|NCT04709601|DRUG|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
219150335|NCT05240586|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
219150336|NCT05240586|PROCEDURE|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
219232538|NCT02830893|DEVICE|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
219723173|NCT05331833|RADIATION|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
219723174|NCT02942407|DRUG|apixaban|oral anticoagulant
219723175|NCT02942407|DRUG|warfarin|oral anticoagulant
219723176|NCT02750423|PROCEDURE|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
219723177|NCT02750423|PROCEDURE|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
219723178|NCT00891397|DRUG|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
219723179|NCT00891397|OTHER|Placebo|Sugar pill
219723180|NCT01666977|DRUG|AMG 386|15mg/kg
219723181|NCT01666977|DRUG|AMG 386|30 mg/kg
219723182|NCT01666977|DRUG|AMG 386 Placebo|AMG 386 Placebo
219723183|NCT01666977|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
219723184|NCT01666977|DRUG|Carboplatin|Carboplatin AUC 6
219723185|NCT00528151|DRUG|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
219723186|NCT03060928|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
219723187|NCT03060928|PROCEDURE|Micro-perforations|Biological stimulation with micro-perforations
219723188|NCT03060928|PROCEDURE|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
219723189|NCT05467202|DRUG|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
219723190|NCT05480371|DEVICE|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
219723191|NCT05480371|DEVICE|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
219723192|NCT03611270|DEVICE|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
219723193|NCT03616587|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
219723194|NCT03616587|DRUG|AZD9833|Part B: AZD9833 monotherapy expansion.
219723195|NCT03616587|DRUG|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
219723196|NCT03616587|DRUG|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
219723197|NCT03616587|DRUG|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
219723198|NCT03616587|DRUG|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
219723199|NCT03616587|DRUG|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
219723200|NCT03616587|DRUG|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
219723201|NCT03616587|DRUG|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
219723202|NCT03616587|DRUG|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
219150337|NCT05240586|PROCEDURE|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
219150338|NCT05361369|DRUG|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
219150339|NCT06232304|BEHAVIORAL|TEACH|TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
219150340|NCT06814288|DRUG|Botulinum toxin A|Twenty keloid patients will be injected botulinum toxin A intralesional every 4 weeks.
219150341|NCT06814288|DRUG|Triamcinolone Acetonide|Twenty keloid patients will be injected triamcinolone acetonide intralesional every 4 weeks.
219150342|NCT05684432|OTHER|No intervention|No intervention
219150343|NCT05021328|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
219150344|NCT05021328|DRUG|Anlotinib|Anlotinib 12 mg/d, d1-14, q3w.
219150345|NCT05021328|DRUG|SBRT 7Gy✖️5 QD|SBRT 7Gy✖️5 QD
219150346|NCT06434402|BEHAVIORAL|Behavioral Intervention|Write about cancer experiences
219150347|NCT03215095|DRUG|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
219150348|NCT03215095|RADIATION|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
219150349|NCT03755102|DRUG|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
219723203|NCT03616587|DRUG|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
219723204|NCT03616587|DRUG|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
219723205|NCT03616587|DRUG|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
219723206|NCT03616587|DRUG|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
219150350|NCT03755102|DRUG|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
219150351|NCT06374836|DRUG|Phenylephrine|"At the OR, the patient will be sedated and have a transoesophageal echo (TEE) catether inserted, which is part of standard clinical care. When a patient becomes hypotensive and the attending anesthesiologist decides to infuse any of the following drugs (phenylephrine, ephedrine, norepinephrine, nitroprusside, or nicardipine), before infusion, the anesthesiolgist will acquire with TEE 10 beats of the thoracic ascending and descending aorta respectively. This is defined as one measurement. Five minutes after infusion the same measurement is repeated. A maximum of 10 measurements (5 before and 5 after infusion of a drug) per patient will be performed.~We want to explicitly mention that for study purposes the surgery or anesthesia will never be prolonged or modified, nor will any drugs be give for study purposes."
219150352|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
219150353|NCT05869890|DEVICE|MOSES laser system|A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
219150354|NCT01758328|DRUG|busulfan|
219150355|NCT01758328|DRUG|melphalan|
219150356|NCT01758328|DRUG|fludarabine|
219150357|NCT01758328|BIOLOGICAL|anti-thymocyte globulin (ATG)|
219150358|NCT01758328|PROCEDURE|a T cell depleted stem cell transplant|
219150359|NCT04617314|DRUG|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
219150360|NCT04548024|DEVICE|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
219150361|NCT00304031|DRUG|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
219150362|NCT00304031|RADIATION|Concurrent radiation therapy|60 Gy in 2 Gy fractions
219150363|NCT00304031|DRUG|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
219723207|NCT05485558|DRUG|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
219723208|NCT05485558|DRUG|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
219723209|NCT05485558|DRUG|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
219723210|NCT06248671|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
219723211|NCT06248671|DRUG|Placebo|Each tablet will be taken once daily for 84 days
219723212|NCT06248671|DRUG|Atorvastatin 20mg|Each tablet will be taken once daily for 84 days.
219723213|NCT03522259|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
219723214|NCT02921022|DRUG|Gemcitabine|
219723215|NCT02921022|DRUG|Nab-paclitaxel|
219723216|NCT02921022|DRUG|PEGPH20|
219723217|NCT05098483|PROCEDURE|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
219723218|NCT05098483|PROCEDURE|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
219723219|NCT05098483|PROCEDURE|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
219150364|NCT00304031|DRUG|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
219150365|NCT06530758|OTHER|Altered ASRS format, without shading and with grouping|Participants will be asked to complete the ASRS form without shading and with grouping.
219150366|NCT06530758|OTHER|Altered ASRS format, with shading and without grouping|Participants will be asked to complete the ASRS form with shading and without grouping.
219723220|NCT06836128|DRUG|N-acetyl cysteine|N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.
219723221|NCT06836128|DRUG|Metfomin|metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.
219723222|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
218987418|NCT04401085|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
218987419|NCT04401085|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
218987420|NCT04962204|BEHAVIORAL|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
218987421|NCT01925105|OTHER|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
218987422|NCT04481867|PROCEDURE|densah bur|osseodensification densah bur
218987423|NCT01419678|OTHER|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
218987424|NCT03368794|BEHAVIORAL|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
218987425|NCT03368794|BEHAVIORAL|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
218987426|NCT04779060|DRUG|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
218987427|NCT04779060|DRUG|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
218987428|NCT04779060|DRUG|saline|normal saline will be mixed with bupivacaine intrathecally
218987429|NCT05907876|OTHER|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
218987430|NCT02155062|OTHER|Whole grain rye|
218987431|NCT02155062|OTHER|Whole grain wheat|
218987432|NCT02155062|OTHER|Refined cereal|
218987433|NCT00300391|DRUG|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
218987434|NCT00300391|OTHER|Saline placebo|control arem
218987435|NCT06495827|OTHER|No different intenvention|No different intenvention
218987436|NCT04730284|OTHER|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
218987437|NCT02025621|DRUG|Levosimendan|
218987438|NCT02025621|DRUG|Placebo|matching placebo
218987439|NCT00739674|DRUG|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB"
218987440|NCT00739674|BEHAVIORAL|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)"
218987441|NCT03673033|PROCEDURE|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
218987442|NCT04012983|DIAGNOSTIC_TEST|gingival crevicular fluid level|gingival crevicular fluid collection
218987443|NCT05349175|DEVICE|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
219150367|NCT06530758|OTHER|Altered ASRS format, without shading and without grouping|Participants will be asked to complete the ASRS form without shading and without grouping.
219150368|NCT06548607|DRUG|RD06-04 or RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
219150369|NCT06439017|OTHER|Questionaire|The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
219150370|NCT06455826|DRUG|VP-001|A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
219232539|NCT02830893|BEHAVIORAL|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
219232540|NCT01277302|DRUG|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
219232541|NCT04894136|PROCEDURE|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
219232542|NCT03514667|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
219723223|NCT00355719|DRUG|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
219723224|NCT00355719|DRUG|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
219723225|NCT00355719|DRUG|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
219150371|NCT04250883|OTHER|Low intra-abdominal pressure|8 mmHg
219150372|NCT04250883|OTHER|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
219150373|NCT04250883|OTHER|Standard intra-abdominal pressure|14 mmHg
219150374|NCT04250883|OTHER|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
219150375|NCT05969574|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
219150376|NCT05969574|DIAGNOSTIC_TEST|Blood test AMH|Measurement of AMH performed on the day of first consultation
219150377|NCT05733442|OTHER|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
219150378|NCT05733442|OTHER|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
219150379|NCT03624712|DIAGNOSTIC_TEST|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
219150380|NCT04926181|DRUG|Apalutamide|240 mg once daily, for a 28 day cycle
219150381|NCT04926181|BIOLOGICAL|Cetrelimab|480 mg given through intravenous infusion (IV) on day 1 of every 28-day treatment cycle and administered over a 60-minute infusion
219150382|NCT04701307|BIOLOGICAL|Dostarlimab|Given IV
219150383|NCT04701307|DRUG|Niraparib|Given PO
219150384|NCT03048279|BEHAVIORAL|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
219232543|NCT03514667|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
219232544|NCT03243838|DRUG|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
219232545|NCT05185674|OTHER|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
219232546|NCT03627572|OTHER|No intervention|Not applicable (no intervention)
219723226|NCT05830279|GENETIC|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
219723227|NCT05830279|OTHER|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
219723228|NCT03754543|OTHER|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
219232547|NCT04443556|DRUG|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
219232548|NCT04443556|OTHER|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
219723229|NCT03754543|OTHER|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
219723230|NCT03754543|OTHER|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
219723231|NCT00634972|DRUG|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
219723232|NCT00634972|DRUG|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
219150385|NCT04505371|BEHAVIORAL|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
219150386|NCT06506045|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of known non-functional and functional implanted shunts will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
219150387|NCT03927027|DRUG|Isosulfan Blue|Given SC
219150388|NCT03927027|PROCEDURE|Axillary Lymph Node Dissection|Undergo ALND
219150389|NCT03927027|PROCEDURE|Mapping|Undergo ARM
219150390|NCT03927027|OTHER|Quality-of-Life Assessment|Ancillary studies
219150391|NCT03927027|OTHER|Questionnaire Administration|Ancillary studies
219150392|NCT04527822|OTHER|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
219150393|NCT02803801|BEHAVIORAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
219150394|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
219150395|NCT04391101|DRUG|Convalescent plasma|400-500ml convalescent plasma
219150396|NCT01188655|DRUG|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
219723233|NCT00634972|DRUG|placebo|
219723234|NCT00117819|DRUG|[123I]ß CIT and SPECT imaging|To assess \[123I\]ß CIT and SPECT imaging
219150397|NCT01555099|DRUG|AZD5423|oral inhaled
219150398|NCT01555099|DRUG|Budesonide|oral inhaled
219150399|NCT01555099|DRUG|Placebo|oral inhaled
219150400|NCT04241354|BIOLOGICAL|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
219232549|NCT01666171|DRUG|metformin hydrochloride|
219232550|NCT01666171|OTHER|clinical observation|
219232551|NCT01666171|OTHER|diagnostic laboratory biomarker analysis|
219232552|NCT01666171|OTHER|imaging biomarker analysis|
219232553|NCT01666171|OTHER|medical chart review|
219232554|NCT01666171|PROCEDURE|digital mammography|
219232555|NCT05652452|OTHER|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
219723235|NCT00774748|DEVICE|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
219723236|NCT04385992|DRUG|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
219232556|NCT05652452|OTHER|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
219150401|NCT04425668|BEHAVIORAL|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
219150402|NCT04425668|OTHER|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
219150403|NCT05721105|OTHER|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
219150404|NCT05563740|OTHER|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
219150405|NCT01277250|BEHAVIORAL|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
219150406|NCT02326987|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
219150407|NCT02326987|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
219150408|NCT00897169|OTHER|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
219232557|NCT06213363|DRUG|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
219232558|NCT04565873|DIAGNOSTIC_TEST|TSH|retrospective TSH level
219232559|NCT01581333|DRUG|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
219232560|NCT01581333|DRUG|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
219723237|NCT06030882|OTHER|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
219723238|NCT04072471|DRUG|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
219150409|NCT00897169|OTHER|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
219150410|NCT02703246|PROCEDURE|abdominal morcellation|patients will be randomized to receive abdominal morcellation
219150411|NCT02703246|PROCEDURE|vaginal morcellation|patients will be randomized to receive vaginal morcellation
219150412|NCT03059394|DEVICE|Non intervention study|Test - Retest of measurements
219150413|NCT00027729|BIOLOGICAL|etaracizumab|
219150414|NCT03022994|OTHER|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
219150415|NCT03368768|OTHER|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
219150416|NCT04565028|BEHAVIORAL|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
219150417|NCT05869123|RADIATION|Online adaptive radiotherapy|PTV with 5 margins covers CTV
219723239|NCT04072471|DRUG|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
219723240|NCT00866320|DRUG|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
219150418|NCT03694691|DIAGNOSTIC_TEST|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
219150419|NCT05915546|DRUG|Emraclidine|Tablets
219150420|NCT05012241|DIAGNOSTIC_TEST|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
219150421|NCT00798642|BEHAVIORAL|Hypnotherapy|8 weeks of gut-directed hypnotherapy
219150422|NCT00798642|BEHAVIORAL|Standard care|8 weeks of standard of care
219150423|NCT00798642|BEHAVIORAL|Mind Body Therapy|8 weeks of mind-body therapy
219150424|NCT05083728|DIAGNOSTIC_TEST|CT|Clinicians are free to choose the adult subjects in whom a non-contrast calibrated CT-scan will be performed as a part of routine clinical care. The decision to order a noncontrast CT-scan of the shoulder must be made prior to, and independently from, the decision to enroll the patient.
219150425|NCT04780035|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
219150426|NCT04780035|OTHER|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
219150427|NCT00412308|PROCEDURE|Tidal volume used in mechanical ventilation|
219150428|NCT05726604|OTHER|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
219150429|NCT01823536|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
219150430|NCT00000994|DRUG|Zidovudine|
219150431|NCT02582736|DRUG|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
219360977|NCT05310214|OTHER|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
219150432|NCT02582736|DRUG|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
219150433|NCT02582736|DRUG|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
219150434|NCT02582736|DRUG|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
219150435|NCT04044807|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
219150436|NCT06357559|DEVICE|OCTA|Optical Coherence Tomography Angiography
219150437|NCT05670834|GENETIC|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
219150438|NCT05670834|DIAGNOSTIC_TEST|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
219150439|NCT05636332|DIAGNOSTIC_TEST|12 lead Electrocardiogram|12 lead Electrocardiogram
219150440|NCT03648762|BEHAVIORAL|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
219150441|NCT03648762|BEHAVIORAL|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
219150442|NCT03648762|BEHAVIORAL|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
219150443|NCT04861233|OTHER|No Intervention|This is a non-interventional study.
219150444|NCT00338442|DRUG|VariZIG™|Biological / Vaccine
219150445|NCT03791892|OTHER|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
219150446|NCT03791892|OTHER|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
219150447|NCT05886218|DEVICE|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
219150448|NCT02135679|RADIATION|Radiotherapy|
219150449|NCT00326144|DRUG|Quetiapine fumarate|
219150450|NCT04112069|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
219150451|NCT04112069|OTHER|Usual Care|Usual care
219723241|NCT06544590|DEVICE|taVNS|TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
219723242|NCT06544590|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
219150452|NCT00306397|DRUG|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
219150453|NCT01875848|DRUG|buprenorphine/naloxone|partial opioid agonist
219150454|NCT01875848|DRUG|opioid dose escalation|up to 25% increase in patient's current opioid dose
219150455|NCT00030238|DRUG|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
219150456|NCT00030238|DRUG|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
219150457|NCT06285149|DRUG|Icaritin|This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
219150458|NCT00006368|RADIATION|yttrium Y 90-edotreotide|
219150459|NCT01186159|DRUG|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
219150460|NCT01782170|DRUG|Iocide Oral Rinse|
219150461|NCT01782170|DRUG|Placebo|
219150462|NCT00973115|DRUG|Simvastatin CR|
219150463|NCT00864552|DRUG|Kogenate (BAY14-2222)|Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
219150464|NCT05099549|DRUG|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
219150465|NCT05099549|BIOLOGICAL|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
219150466|NCT06278870|DRUG|disitamab vedotin|disitamab vedotin 2mg/kg iv q2w
219150467|NCT06278870|DRUG|Pyrotinib|pyrotinib 400mg po q28d
219150468|NCT06278870|DRUG|trastuzumab|trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
219150469|NCT06278870|DRUG|Pertuzumab|pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
219150470|NCT06278870|DRUG|taxane drug|Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
219150471|NCT02872480|OTHER|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
219150472|NCT05100589|DIETARY_SUPPLEMENT|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
219150473|NCT05100589|DIETARY_SUPPLEMENT|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
219150474|NCT00526006|DRUG|esomeprazole|40 mg od for 8 wks
219150475|NCT05324878|OTHER|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
219150476|NCT01510236|BEHAVIORAL|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
219232561|NCT05935072|BEHAVIORAL|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON\_Calibré: control condition with a calibrated test meal; CON\_AdLib: control condition with an ad libium test meal; EX\_Calibré: exercise condition with a calibrated test meal; EX\_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
219723243|NCT05518552|OTHER|Manual lumbar traction|Patient in the group were treated with manual traction
219150477|NCT03612375|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219150478|NCT03612375|OTHER|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219150479|NCT04925336|OTHER|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
219150480|NCT00484055|DRUG|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
219150481|NCT00484055|PROCEDURE|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
219150482|NCT04803409|DEVICE|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
219150483|NCT03815136|OTHER|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
219150484|NCT03815136|OTHER|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
219150485|NCT00589277|BEHAVIORAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
219150486|NCT00589277|BEHAVIORAL|Standard care counseling + standard materials|Standard messages for quitting smoking
219150487|NCT03762434|OTHER|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
219150488|NCT03345901|DRUG|Pemafibrate|0.2 mg orally BID - twice daily
219150489|NCT03345901|DRUG|Placebo|orally BID - twice daily
219150490|NCT01696916|PROCEDURE|6-minute walking test|submaximum exercise test
219150491|NCT00722046|BIOLOGICAL|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
219150492|NCT00722046|BIOLOGICAL|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
219150493|NCT00722046|BIOLOGICAL|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
219150494|NCT00722046|DRUG|Placebo|Placebo every 60 days (10 doses total)
219150495|NCT00722046|BIOLOGICAL|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
219150496|NCT00722046|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
219150497|NCT05107024|DEVICE|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
219150498|NCT05107024|DEVICE|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
219150499|NCT03822520|DRUG|Celecoxib|Celecoxib 400mg capsule
219150500|NCT03822520|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet
219150501|NCT03822520|OTHER|Water|Pure water 150ml
219150502|NCT06524973|OTHER|Telemedicine|Attend telehealth self-management coaching sessions
219150503|NCT06524973|OTHER|Counseling|Attend telehealth self-management coaching sessions
219150504|NCT06524973|OTHER|Best Practice|Receive standard of care
219150505|NCT06524973|OTHER|Questionnaire Administration|Ancillary studies
219150506|NCT06524973|OTHER|Inrweview|Ancillary studies
219150507|NCT04897945|BEHAVIORAL|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
219150508|NCT06553053|OTHER|"Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
219232562|NCT01275872|OTHER|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
219232563|NCT05283200|BEHAVIORAL|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
219150509|NCT06553053|OTHER|"Nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
219150510|NCT04938752|DRUG|DA-2811|single dose administration (one tablet once a day)
219150511|NCT04938752|DRUG|DA-2811-R|single dose administration (one tablet once a day)
219150512|NCT03348722|OTHER|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
219150513|NCT03348722|PROCEDURE|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
219150514|NCT03348722|RADIATION|Radiotherapy|External radical radiotherapy or brachitherapy
219150515|NCT03348722|PROCEDURE|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
219150516|NCT05959590|DRUG|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
219150517|NCT04296019|DRUG|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
219150518|NCT05455424|DRUG|Niraparib Oral Product|Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
219150519|NCT05455424|OTHER|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
219150520|NCT06124066|DRUG|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
219150521|NCT02731755|OTHER|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
219150522|NCT02731755|OTHER|Control|60g cream of rice
219150523|NCT04423146|OTHER|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
219150524|NCT01951508|DRUG|Methylphenidate|60mg per os, single dose
219150525|NCT01951508|DRUG|Modafinil|600mg per os, single dose
219150526|NCT01951508|DRUG|MDMA|125mg per os, single dose
219150527|NCT01951508|DRUG|Placebo|per os
219150528|NCT06147167|DEVICE|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
219150529|NCT06147167|DEVICE|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
219150530|NCT06147167|DEVICE|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
219232564|NCT05283200|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
219723244|NCT05518552|OTHER|Prone traction|Patient in the group were placed on prone traction
219723245|NCT01676662|DEVICE|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
219232565|NCT05283200|BEHAVIORAL|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
219232566|NCT06580990|PROCEDURE|specific neck exercises with the Spinetrack|This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack
219232567|NCT06580990|PROCEDURE|specific neck exercises|This group will receive a telerehabilitation programme with exercise for the deep neck musculature
219232568|NCT00961597|PROCEDURE|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
219723246|NCT01676662|DEVICE|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
219723247|NCT03933033|DEVICE|Fractional Erbium Yağ Laser|Multiple sessions of Fractional Erbium Yağ Laser
219723248|NCT03933033|PROCEDURE|Platelet Rich Plasma|Multiple injections of Platelet Rich Plasma
219723249|NCT06575452|DIAGNOSTIC_TEST|Blood, urine and tumoral tissue samples|Blood, urine and tumoral tissue samples
219723250|NCT06575452|DIAGNOSTIC_TEST|Tumoral tissue samples|tumoral tissue samples
219723251|NCT06462612|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
219723252|NCT06462612|DRUG|Placebo|Matching capsules administered orally, once daily
219150531|NCT03400254|DRUG|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
219150532|NCT03400254|DRUG|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped."
219150533|NCT03698396|BIOLOGICAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
219150534|NCT02250235|OTHER|Health risk information|
219150535|NCT06320912|DEVICE|The intraparenchymal portal vein covered stent|The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
219150536|NCT06320912|DEVICE|TIPS Covered Stent System GORE|The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
219150537|NCT03508518|OTHER|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
219150538|NCT03508518|OTHER|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
219150539|NCT01039948|BIOLOGICAL|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
219150540|NCT01039948|DRUG|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
219150541|NCT02672930|DEVICE|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
219150542|NCT00908505|PROCEDURE|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
219150543|NCT02231983|GENETIC|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
219150544|NCT04645147|BIOLOGICAL|EBV gp350-Ferritin Vaccine|A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.
219150545|NCT04645147|OTHER|Matrix-M1|Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
219150546|NCT03019614|DRUG|Hydrocortisone|Generic hydrocortisone
219150547|NCT03019614|DRUG|Chronocort|Modified formulation of hydrocortisone
219150548|NCT06445257|DRUG|zanubrutinib 160 mg BID orally|The ZRMT induction and maintenance regimen
219150549|NCT05849311|DRUG|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
219150550|NCT05849311|DRUG|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
219723253|NCT03704207|OTHER|nNO testing|Collection of already performed clinical data and nNO testing
219150551|NCT02655588|BEHAVIORAL|Interactive Media-Based Problems Solving Treatment|
219150552|NCT04730362|DEVICE|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
219150553|NCT04730362|DEVICE|supraglottic airway|supraglottic airway
219150554|NCT04730362|DRUG|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
219232569|NCT00961597|PROCEDURE|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
219232570|NCT04172688|DIETARY_SUPPLEMENT|Prebiotic oligofructose-enriched inulin|Synergy1
219723254|NCT04777760|DRUG|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
219723255|NCT04777760|DRUG|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
219232571|NCT04172688|DIETARY_SUPPLEMENT|Placebo maltodextrin|Equicaloric dose of maltodextrin
219232572|NCT00386399|DRUG|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
219232573|NCT01523184|DRUG|Placebo Capsule|This is the placebo capsule
219232574|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
219150555|NCT04586309|BEHAVIORAL|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~1. Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~2. Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~3. First Day of Verification of Correct Practice and Further Instruction.~4. Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~5. Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
219150556|NCT02628171|OTHER|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
219150557|NCT02628171|OTHER|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
219150558|NCT04801563|OTHER|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
219150559|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
219232575|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
219232576|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
219232577|NCT01043614|BEHAVIORAL|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
219232578|NCT02283086|BEHAVIORAL|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
219232579|NCT02860702|OTHER|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
219232580|NCT02860702|OTHER|Human/Bovine Milk|Bovine milk derived fortification
219232581|NCT05095077|DRUG|Tadalafil 40 MG|Single dose on study day 1/2
219232582|NCT05095077|DRUG|Placebo|Identical to active IMP
219232583|NCT01184027|BEHAVIORAL|nutrition /swallowing counseling|general nutrition and swalling information
219232584|NCT01184027|BEHAVIORAL|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
219232585|NCT01184027|BEHAVIORAL|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
219232586|NCT03776604|DRUG|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
219232587|NCT04128956|DRUG|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
219232588|NCT01128673|DEVICE|mRI|
219232589|NCT00005867|BIOLOGICAL|bleomycin sulfate|
219232590|NCT00005867|DRUG|CHOP regimen|
219232591|NCT00005867|DRUG|cyclophosphamide|
219232592|NCT00005867|DRUG|doxorubicin hydrochloride|
219232593|NCT00005867|DRUG|etoposide|
219232594|NCT00005867|DRUG|mitoxantrone hydrochloride|
219232595|NCT00005867|DRUG|prednisolone|
219232596|NCT00005867|DRUG|vincristine sulfate|
219232597|NCT02462447|DRUG|11C-sarcosine|Radiotracer injection for PET/CT scan
219232598|NCT02462447|DRUG|11C-choline|Radiotracer injection for PET/CT scan
219232599|NCT04662320|DEVICE|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
219232600|NCT00647699|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
219232601|NCT00647699|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
219232602|NCT03696563|DEVICE|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
219232603|NCT03696563|OTHER|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
219232604|NCT06585579|DEVICE|Mucogyne Ovule|In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)
219232605|NCT06160375|DIAGNOSTIC_TEST|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
219232606|NCT04113226|DRUG|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
219723256|NCT00002835|BIOLOGICAL|Bleomycin Sulfate (BLM)|
219723257|NCT00002835|BIOLOGICAL|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
219723258|NCT00002835|BIOLOGICAL|Recombinant Interferon Alfa|
219150560|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
219150561|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
219150562|NCT04218110|DRUG|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
219150563|NCT04178239|DIAGNOSTIC_TEST|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
219150564|NCT00799396|DRUG|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
219150565|NCT00799396|DRUG|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
219150566|NCT03828240|OTHER|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
219150567|NCT05677061|DEVICE|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
219150568|NCT05677061|DEVICE|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
219150569|NCT00320762|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
219150570|NCT04734132|DIETARY_SUPPLEMENT|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
219150571|NCT04734132|DIETARY_SUPPLEMENT|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
219150572|NCT02768545|DRUG|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
219150573|NCT02003469|DEVICE|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
219150574|NCT03510676|DEVICE|NiTiDES|
219150575|NCT01218698|DRUG|Losartan Potassium Tablets|
219232607|NCT04113226|DRUG|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
219723259|NCT00002835|DRUG|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
219723260|NCT00002835|DRUG|Cisplatin (CDDP)|
219150576|NCT01149369|DRUG|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
219150577|NCT01149369|DRUG|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
219150578|NCT04511767|OTHER|Do not take any interventions|Do not take any interventions
219150579|NCT00083902|DRUG|Thalidomide|
219150580|NCT00083902|DRUG|Dexamethasone|
219723261|NCT00002835|DRUG|Cyclophosphamide|
219150581|NCT05531708|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
219150582|NCT05531708|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
219150583|NCT05531708|DRUG|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
219150584|NCT02106182|DRUG|Silodosin|
219150585|NCT02106182|OTHER|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
219150586|NCT02106182|OTHER|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
219150587|NCT02106182|OTHER|12 weeks|
219150588|NCT03567252|BEHAVIORAL|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
219150589|NCT01429805|DEVICE|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
219150590|NCT04837976|OTHER|Semi-structured interviews and a consensus workshops using nominal group techniques.|Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
219723262|NCT00002835|DRUG|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
219723263|NCT00002835|DRUG|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
219723264|NCT00002835|DRUG|Idarubicin|
219723265|NCT00002835|DRUG|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
219723266|NCT00002835|DRUG|Leucovorin Calcium|
219723267|NCT00002835|DRUG|Melphalan|
219723268|NCT00002835|DRUG|Methotrexate|
219723269|NCT00002835|DRUG|Methylprednisolone|
219723270|NCT00002835|DRUG|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
219723271|NCT00002835|DRUG|Vincristine Sulfate|
219150591|NCT04085874|BEHAVIORAL|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
219150592|NCT04085874|BEHAVIORAL|Nutrition counseling from standard health services care|once nutrition counselling from health services
219150593|NCT03592602|PROCEDURE|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
219150594|NCT01332045|PROCEDURE|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
219150595|NCT01332045|PROCEDURE|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
219150596|NCT00629096|PROCEDURE|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
219150597|NCT02242487|DRUG|CVT-301|
219150598|NCT03216213|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
219150599|NCT03216213|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
219150600|NCT01599793|DRUG|cabozantinib|Given PO
219150601|NCT01599793|OTHER|laboratory biomarker analysis|Correlative studies
219150602|NCT01599793|PROCEDURE|magnetic resonance imaging|Undergo MRI
219150603|NCT05150912|OTHER|Manual therapy|strching neck
219150604|NCT03112135|DRUG|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
219150605|NCT03112135|DRUG|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
219150606|NCT03112135|DRUG|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
219150607|NCT04370314|OTHER|Dental prosthetics|Implant-supported crowns
219150608|NCT05369936|OTHER|Aromatherapy|Lavender will be inhaled through three phases
219150609|NCT05369936|OTHER|Placebo|Vapors of the distal water will be inhaled through three phases
219723272|NCT00002835|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
219723273|NCT00002835|RADIATION|Radiation Therapy|
219150610|NCT04235738|OTHER|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
219150611|NCT04400136|DRUG|Lansoprazole oral tablets 30 mg|Post operative prescription
219150612|NCT04522466|DRUG|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
219150613|NCT01296815|DRUG|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
219232608|NCT04113226|OTHER|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,…) on which treatment may impact.
219232609|NCT04113226|OTHER|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
219723274|NCT06478186|DRUG|triamcinolone acetonide extended-release injectable suspension; TCA-ER|Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
219150614|NCT01794858|OTHER|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
219150615|NCT02115828|DRUG|Vismodegib|
219150616|NCT05294393|DRUG|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
219232610|NCT05483478|COMBINATION_PRODUCT|mobile health combined Multi-course Program|mobile health combined Multi-course Program
219723275|NCT06478186|DRUG|Triamcinolone Acetonide- Immediate Release;TCA-IR|Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
219723276|NCT00087802|DRUG|gemcitabine/Eloxatin (GEMOX)|GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]
219723277|NCT00087802|DRUG|carboplatin/paclitaxel (CP)|"CP \[carboplatin/paclitaxel - 21 day cycle\]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]"
219150617|NCT05294393|DRUG|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
219150618|NCT05294393|DRUG|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
219150619|NCT00204672|DRUG|Achipex|
219150620|NCT02129595|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
219150621|NCT02129595|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
219150622|NCT03434496|DEVICE|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
219150623|NCT02930954|DRUG|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
219150624|NCT02930954|DRUG|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
219150625|NCT02930954|DRUG|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
219150626|NCT03769870|DRUG|Teneligliptin 20mg/day|cross-over
219150627|NCT03769870|DRUG|Atorvastatin 40mg/Day|cross-over
219150628|NCT03769870|DRUG|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
219150629|NCT04436900|PROCEDURE|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
219150630|NCT00995696|BEHAVIORAL|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
219150631|NCT04761016|OTHER|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
219150632|NCT04761016|OTHER|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
219150633|NCT01245400|DEVICE|Z-Lig|ACL replacement
219150634|NCT01245400|DEVICE|allograft|ACL replacement
219150635|NCT02799875|OTHER|Higher permissive hypercapnia|"* pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;"
219150636|NCT02799875|OTHER|Lower Permissive Hypercapnia|"* pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;"
219150637|NCT03810859|BIOLOGICAL|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
219232611|NCT03902327|DIETARY_SUPPLEMENT|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
219232612|NCT03902327|DIETARY_SUPPLEMENT|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
219232613|NCT02430259|DRUG|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
219232614|NCT00413283|BIOLOGICAL|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
219232615|NCT00413283|DRUG|Placebo|Placebo subcutaneous injection.
219232616|NCT00413283|DRUG|Gemcitabine|Intravenous infusion
219232617|NCT00413283|DRUG|Carboplatin|Intravenous infusion
219723278|NCT05166096|DRUG|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
219150638|NCT00012805|PROCEDURE|Telephone Monitoring|
219150639|NCT03122236|BEHAVIORAL|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
219150640|NCT03122236|BEHAVIORAL|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
219232618|NCT00413283|DRUG|Cisplatin|Intravenous infusion
219723279|NCT05166096|DRUG|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
219723280|NCT02660099|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
219723281|NCT00692016|DRUG|Naproxen sodium|Administered under fasting condition
219723282|NCT00692016|DRUG|Naproxen sodium|Administered under fed condition
219723283|NCT05361837|PROCEDURE|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
219723284|NCT05361837|PROCEDURE|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
219723285|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
219723286|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
219723287|NCT03755466|DRUG|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
219723288|NCT03755466|DRUG|"Biologics"|To examine the effects of biologics in RA patients
219723289|NCT03755466|DRUG|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
219723290|NCT04724057|DEVICE|AutocathFFR|The MedHub Autocath FFR device is a software only medical device. The FFR is computed from several standard DICOM format 2D angiography images retrieved from the C-arm imaging system, which display the structure of the vessels. The MedHub AutocathFFR device software analyzes these images and automatically (without the need for user selection or markings) and computes and displays the FFR on the viewed blood vessel.
219150641|NCT03122236|DEVICE|Sham Transcranial Direct Current Stimulation (Sham tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
219150642|NCT03122236|DEVICE|Active Transcranial Direct Current Stimulation (Active tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
219150643|NCT03447236|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
219150644|NCT01715636|DRUG|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
219723291|NCT01014676|DIETARY_SUPPLEMENT|Probiotic|
219723292|NCT01014676|OTHER|Placebo|
219723293|NCT02529332|DIETARY_SUPPLEMENT|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
219723294|NCT00120744|DRUG|Ondansetron Oral Disintegrating Tablet|
219723295|NCT00303953|DRUG|belinostat|Given IV
219723296|NCT05942222|BIOLOGICAL|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
219723297|NCT05942222|BIOLOGICAL|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
219723298|NCT06530693|OTHER|OPUS-i algorithm|A novel pre-hospital algorithm.
219723299|NCT02661971|DRUG|Docetaxel|Docetaxel 50 mg/m², d1
219723300|NCT02661971|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m², d1
219150645|NCT04466904|DRUG|IBI362|Administrated by subcutaneous injection
219150646|NCT04466904|DRUG|Placebo|Administrated by subcutaneous injection
219150647|NCT04466904|DRUG|Dulaglutide|Administrated by subcutaneous injection
219150648|NCT00631579|DRUG|Rasburicase (SR29142)|
219150649|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
219723301|NCT02661971|DRUG|Calciumfolinat|Leucovorin 200 mg/m², d1
219723302|NCT02661971|DRUG|5-Fluorouracil|5-FU 2600 mg/m², d1
219723303|NCT02661971|BIOLOGICAL|Ramucirumab|Ramucirumab 8mg/kg, d1
219723304|NCT03651492|BEHAVIORAL|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
219723305|NCT00717080|PROCEDURE|IOL surgery|IOL surgery using capsular tension ring (AURORING)
219723306|NCT00717080|PROCEDURE|IOL surgery|IOL surgery without CTR
219723307|NCT01909271|BEHAVIORAL|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
219723308|NCT01909271|OTHER|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
219723309|NCT03052673|DRUG|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
219723310|NCT03052673|DRUG|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
219723311|NCT00056264|DRUG|Infliximab|
219723312|NCT00594737|DRUG|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
219723313|NCT05788198|OTHER|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment."
219723314|NCT00019123|DRUG|thalidomide|
219723315|NCT04678102|DRUG|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
219723316|NCT00387127|DRUG|Lapatinib oral tablets|Lapatinib is administered orally once daily.
219150650|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
219150651|NCT05064930|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
219723317|NCT00387127|DRUG|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
219723318|NCT00387127|DRUG|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
219723319|NCT04396275|OTHER|Food-1|Cooked whole navy beans (300 kcal)
219723320|NCT04396275|OTHER|Food-2|Cooked whole yellow split peas (300 kcal)
219723321|NCT04396275|OTHER|Food-3|Cooked rice considered as control (300 kcal)
219723322|NCT03590002|DEVICE|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
219723323|NCT05763316|OTHER|CRIB II|Calculate Clinical Risk Index for Babies II score
219723324|NCT05763316|OTHER|SNAP-II|Calculate Score for Neonatal Acute Physiology II
219150652|NCT02397317|RADIATION|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
219150653|NCT04129658|BEHAVIORAL|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
219150654|NCT04040413|PROCEDURE|bariatric surgery|All bariatric procedures
219150655|NCT00636207|DRUG|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
219150656|NCT00636207|DRUG|Placebo|Placebo dry powder inhaler
219150657|NCT01591239|BEHAVIORAL|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
219150658|NCT01591239|BEHAVIORAL|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
219150659|NCT03068078|DIETARY_SUPPLEMENT|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
219150660|NCT04356430|DRUG|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
219150661|NCT04356430|DRUG|Prednisone|5 mg oral low dose prednisone, once daily
219150662|NCT04356430|DRUG|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
219150663|NCT02272452|DEVICE|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
219723325|NCT05763316|OTHER|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
219723326|NCT05763316|OTHER|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
219723327|NCT05763316|OTHER|MSNS|Calculate Modified Sick neonatal Score
219723328|NCT05763316|OTHER|nSOFA|Calculate neonatal sequential organ failure assessment
219723329|NCT01370915|DRUG|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
219723330|NCT01370915|DRUG|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
219723331|NCT05789342|DRUG|GP681|GP681, tablet, oral
219723332|NCT05789342|DRUG|Rosuvastatin|Rosuvastatin, tablet, oral
219723333|NCT05789342|DRUG|Digoxin|Digoxin, tablet, oral
219723334|NCT05789342|DRUG|Itraconazole|Itraconazole, capsule, oral
219723335|NCT05789342|DRUG|Oseltamivir|Oseltamivir, capsule, oral
219723336|NCT01713127|DRUG|remifentanil infusion|
219723337|NCT01713127|DRUG|Placebo|
219723338|NCT01642966|DRUG|Prasugrel|Prasugrel 10mg/day for 15 days
219723339|NCT01642966|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
219723340|NCT02891330|BEHAVIORAL|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
219723341|NCT02095860|DRUG|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
219232619|NCT01117402|RADIATION|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
219232620|NCT04627168|DEVICE|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
219232621|NCT02354417|BIOLOGICAL|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
219150664|NCT06549582|OTHER|Taohong Tongluo Xiaoban Prescription|"Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose"
219150665|NCT06549582|OTHER|Fundamental medical treatment|The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
219150666|NCT04034771|DRUG|Melatonin 10 MG Oral Tablet|Melatonin tablets
219150667|NCT04034771|DRUG|Propofol|propofol amp
219150668|NCT04034771|DRUG|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
219150669|NCT05035966|OTHER|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
219150670|NCT00214266|DRUG|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
219150671|NCT03691922|PROCEDURE|Erector Spinae Plane (ESP) Block|"1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
219150672|NCT03691922|PROCEDURE|Periarticular Infiltration (PAI)|"1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
219150673|NCT04008550|PROCEDURE|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
219150674|NCT00382850|PROCEDURE|Nissen fundoplication|
219150675|NCT01736514|DRUG|febuxostat|oral
219150676|NCT01736514|DRUG|Allopurinol|oral
219150677|NCT00026234|DRUG|floxuridine|Given intra-arterially
219723342|NCT06296693|DEVICE|Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
219723343|NCT02581423|DRUG|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
219723344|NCT03485456|DRUG|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
219723345|NCT02263690|PROCEDURE|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
219723346|NCT02263690|PROCEDURE|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
219723347|NCT02263690|PROCEDURE|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
219723348|NCT02369250|DRUG|Rosuvastatin|Rosuvastatin, is a statin group of drug.
219723349|NCT02369250|BIOLOGICAL|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
219723350|NCT01786109|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
219723351|NCT01786109|DRUG|Placebo|Placebo will match study drug; taken as one dose orally with water.
219723352|NCT05599932|DRUG|Siremadlin|HDM201 capsule
219723353|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
219723354|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
219723355|NCT05719688|DEVICE|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
219723356|NCT00191880|DRUG|atomoxetine|
219150678|NCT00026234|DRUG|dexamethasone|Given intra-arterially
219232622|NCT04150016|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
219232623|NCT02499991|BEHAVIORAL|memory|keep track of social events in diary for memory recall. Used by treatment group
219723357|NCT02974504|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
219723358|NCT02974504|DRUG|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
219723359|NCT01741662|OTHER|neuropsychological evaluation|
219723360|NCT04433312|OTHER|Questionnaire|The questionnaire is developed based on a literature review and clinical experience. Initial testing of the questionnaire will be performed with 20 patients to assess the reliability and inter-rater variations. After initial testing, the final questionnaire will be formulated. The first sector of the questionnaire includes patient demographics and baseline characteristics; the second sector is regarding patient clinical condition, diagnosis, and scheduled surgery. The following sector examines the process of delivering the cancellation to the patient and requirements for re-scheduling. Patients will be classified into satisfied or dissatisfied according to the responses in this sector. The following sector addresses the course of care after cancellation and whether the patient conducted the surgery elsewhere or not. The last sector explores the impact of cancellation on patient health, career, and financial aspects.
219723361|NCT01615718|PROCEDURE|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
219723362|NCT01615718|PROCEDURE|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
219723363|NCT05478746|DEVICE|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
219723364|NCT05478746|OTHER|Control - no intervention|No intervention; participants only receive routine care.
219723365|NCT04606719|PROCEDURE|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
219723366|NCT06375889|OTHER|blood test|During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
219723367|NCT02096224|DRUG|Sevoflurane|Sevoflurane will be used.
219723368|NCT02096224|DRUG|Desflurane|Desflurane will be used
219723369|NCT00588224|OTHER|3D ultrasound|measurement of stomach volume by 3D ultrasound
219723370|NCT03324009|DIAGNOSTIC_TEST|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
219723371|NCT03073447|OTHER|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
219723372|NCT04761991|DIAGNOSTIC_TEST|CMR and CTCA with CT-FFR|multi-parametric CMR assessment and CT coronary angiography with FFR assessment
219723373|NCT00200824|DRUG|Soy Isoflavone Nutritional Supplements|
219150679|NCT00026234|DRUG|oxaliplatin|Given IV
219150680|NCT00026234|DRUG|capecitabine|Given orally
219150681|NCT00882934|OTHER|Induction to efficient treatment|Informative letters.
219150682|NCT00882934|OTHER|Doubt to the efficacy of treatment|Informative letters.
219150683|NCT00882934|OTHER|Induction to ineffective treatment|Informative letters
219150684|NCT01837940|DIETARY_SUPPLEMENT|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
219150685|NCT01837940|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
219150686|NCT05676450|DIAGNOSTIC_TEST|cell-free DNA|Given by IV (vein)
219232624|NCT03680768|OTHER|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
219232625|NCT03100851|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
219232626|NCT02639234|BIOLOGICAL|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
219232627|NCT02639234|DRUG|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
219232628|NCT01326624|DEVICE|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
219150687|NCT03663036|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
219150688|NCT06114745|DRUG|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
219232629|NCT04554199|DEVICE|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
219232630|NCT01547689|BIOLOGICAL|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
219232631|NCT01435499|BIOLOGICAL|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
219232632|NCT01435499|DRUG|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
219232633|NCT02020200|DRUG|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.
219232634|NCT02020200|DRUG|Placebo|
219232635|NCT02001649|GENETIC|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
219232636|NCT02001649|GENETIC|SNP genotyping|
219232637|NCT00246129|DRUG|Campath|Monoclonal antibody induction therapy
219232638|NCT00246129|DRUG|Daclizumab|Monoclonal antibody induction therapy
219150689|NCT06114745|DRUG|Placebo|Placebo will be administered through IV infusion
219150690|NCT00149864|DRUG|Mycophenolate sodium (enteric coated)|
219150691|NCT06145568|OTHER|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
219150692|NCT01576484|DRUG|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
219232639|NCT02704026|OTHER|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
219232640|NCT03469258|DRUG|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
219232641|NCT06328725|DRUG|EN001|"Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals."
219232642|NCT04205669|DRUG|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
219232643|NCT03590496|DIETARY_SUPPLEMENT|Calcium-Propionate 500mg|Calcium-Propionate capsules
219723374|NCT04498104|OTHER|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
219150693|NCT01576484|DRUG|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
219232644|NCT03590496|OTHER|Placebo|Placebo capsules without any active ingredient
219232645|NCT02005172|DEVICE|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
219232646|NCT06121739|BEHAVIORAL|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
219232647|NCT05413200|DRUG|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
219232648|NCT02402270|DRUG|NuLYTELY® (PEG 3350)|
219232649|NCT02402270|DRUG|ECP-019|
219232650|NCT02402270|DRUG|MoviPrep® (PEG 3350)|
219232651|NCT00009191|DRUG|Sertraline [Zoloft]|
219232652|NCT00327730|DRUG|Eperisone|
219232653|NCT03950661|OTHER|Walking|
219232654|NCT04111159|DRUG|HSK3486|Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
219723375|NCT00834938|OTHER|No intervention|No intervention
219723376|NCT05252975|OTHER|Setup and Imaging for at CT radiation planning|Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
219232655|NCT04111159|DRUG|Propofol|Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
219723377|NCT05141799|DEVICE|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
219150694|NCT05254535|OTHER|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
219723378|NCT06370975|DRUG|3% hypertonic Saline|"the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
219150695|NCT06571747|BEHAVIORAL|Cardiovascular-Focused Nudge Communication|Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.
219150696|NCT04565925|DRUG|Sildenafil Citrate|Sildenafil 20mg TID for 4 weeks
219150697|NCT04565925|DRUG|Placebo|Placebo (Lactose) TID for 4 weeks
219150698|NCT04474301|OTHER|Survey Administration|Complete survey
219150699|NCT06777498|OTHER|Whole Grain Intervention then fruits and vegetables|"TREATMENT 1: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
219150700|NCT06777498|OTHER|Fruit and Vegetable Intervention and then whole grains|"TREATMENT 1: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
219150701|NCT02245100|OTHER|Cytology specimen|Correlative studies
219150702|NCT02245100|OTHER|Laboratory biomarker analysis|Correlative studies
219150703|NCT06410885|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
219150704|NCT02995252|OTHER|Blood draws|
219150705|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
219150706|NCT02995252|OTHER|Knowledge Index Questionnaire|
219723379|NCT06370975|DRUG|Ringer's lactated solution|"the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
219150707|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
219150708|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
219150709|NCT03381053|DRUG|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
219150710|NCT01943799|BIOLOGICAL|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
219150711|NCT01943799|DRUG|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
219150712|NCT04594759|DRUG|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
219150713|NCT01691326|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
219150714|NCT01691326|BIOLOGICAL|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
219232656|NCT00087256|DRUG|Celecoxib|
219232657|NCT00087256|OTHER|placebo|
219232658|NCT00236470|DRUG|risperidone|
219232659|NCT00003754|DRUG|cyclophosphamide|
219232660|NCT00003754|DRUG|thalidomide|
219232661|NCT03340259|PROCEDURE|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
219723380|NCT06370975|DRUG|0.9% Normal saline|"the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
219723381|NCT02286830|DRUG|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
219150715|NCT03559348|DRUG|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
219150716|NCT03532711|DRUG|fluorouracil|chemotherapy treated patients
219150717|NCT03220425|DRUG|Insulin detemir|
219150718|NCT03220425|DRUG|NPH insulin|
219150719|NCT03811574|DRUG|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
219150720|NCT03811574|DRUG|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
219150721|NCT03087578|OTHER|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
219150722|NCT03087578|DRUG|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
219150723|NCT01832480|DRUG|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
219150724|NCT01832480|DRUG|MTZ 2 g|MTZ 2 g
219150725|NCT03378141|BEHAVIORAL|Maternal Nutrition Behavior change|Counseling and community mobilization
219150726|NCT01806116|DRUG|decitabine|
219150727|NCT05609032|BEHAVIORAL|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
219150728|NCT02825485|PROCEDURE|Voiding cystourethrogram|
219150729|NCT04696575|BIOLOGICAL|Atezolizumab|Given IV
219150730|NCT04696575|DRUG|Carboplatin|Given IV
219150731|NCT04696575|DRUG|Etoposide|Given IV
219723382|NCT05484167|DRUG|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
219723383|NCT05484167|DRUG|Placebo|A nasal gel with no active ingredients
219723384|NCT03838874|DRUG|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
219150732|NCT04696575|DRUG|Lamivudine|Given PO
219723385|NCT03838874|DRUG|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
219723386|NCT06302283|OTHER|Survey|Survey (online or paper) on caregiving burden and bereavement
219723387|NCT03476512|OTHER|Adherence Education|Patients were given adherence education to resolve the identified deficits
219150733|NCT06014424|DRUG|CBD|Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
219150734|NCT06014424|OTHER|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
219150735|NCT04489823|DEVICE|AVP III|Transcatheter closure of a paravalvular leak using AVP III
219150736|NCT05378815|PROCEDURE|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
219150737|NCT05378815|PROCEDURE|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
219150738|NCT00958633|DRUG|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group:~* escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
219150739|NCT00958633|DRUG|Bupropion XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group:~* bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
219150740|NCT03104439|DRUG|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
219150741|NCT03104439|DRUG|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
219150742|NCT03104439|RADIATION|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
219150743|NCT04343885|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
219723388|NCT05378321|DIAGNOSTIC_TEST|Non-invasive diagnostic testing|Non-invasive diagnostic testing consists of the use of the FibroScan device and the calculation of non-invasive blood-based scores for the diagnosis of NAFLD
219150744|NCT04343885|DRUG|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
219150745|NCT06496230|BEHAVIORAL|Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder|Two-pronged intervention model: 1) behavioral intervention utilizing interoceptive exposures and cognitive behavioral therapy for insomnia and, 2) mobile application that facilitates medication adherence.
219150746|NCT01243619|DRUG|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
219150747|NCT03819816|OTHER|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
219150748|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
219150749|NCT01919645|OTHER|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
219150750|NCT03213327|DEVICE|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
219150751|NCT04287894|DRUG|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
219150752|NCT04287894|DRUG|Tremelimumab|Per day 75mg
219150753|NCT04287894|DRUG|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
219723389|NCT05100342|DIAGNOSTIC_TEST|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
219150754|NCT04287894|DRUG|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
219150755|NCT04287894|RADIATION|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
219150756|NCT04287894|PROCEDURE|Resection|After CIT-CRT
219232662|NCT02670408|PROCEDURE|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
219232663|NCT00000872|DRUG|Abacavir sulfate|
219723390|NCT05029063|DRUG|Rivaroxaban 10 MG|Identical comparator drug
219723391|NCT06508827|DRUG|Iron dextran 1000 mg IV|Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
219723392|NCT06495489|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
219150757|NCT03994705|BIOLOGICAL|Descartes-11|CAR T-Cells
219150758|NCT03994705|DRUG|Fludarabine|Pre-conditioning chemotherapy
219150759|NCT03994705|DRUG|Cyclophosphamide|Pre-conditioning therapy
219723393|NCT05893823|DIAGNOSTIC_TEST|Pelvis CT scan|Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.
219723394|NCT06964737|BIOLOGICAL|Anti-GARP Chimeric Antigen Receptor-T Cells|Given intracavitary
219150760|NCT06041516|DRUG|ADCT-701|ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
219150761|NCT06973369|OTHER|LEININGER THEORY BASED CREATIVE DRAMA EDUCATION METHOD|The effects of Leininger theory-based creative drama training given to nursing students for five weeks on the students' cultural sensitivity and effectiveness levels will be determined.
219150762|NCT06973369|OTHER|TRADITIONAL EDUCATION METHOD|Leininger theory training will be given to nursing students for five weeks and its effects on the students' cultural sensitivity and effectiveness levels will be determined.
219150763|NCT06974240|OTHER|Experimental Group|The training sessions were carried out following a strict order. The first phase was dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, videos were shown and participants answered targeted questions asked by the Nao Robot to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, which re-enacted the situations seen in the videos, involving all the members of the group in turn. During the last phase, participants were asked to share experiences in their lives in which they had used or could have used the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
219232664|NCT00000872|DRUG|Nelfinavir mesylate|
219232665|NCT00000872|DRUG|Nevirapine|
219232666|NCT00000872|DRUG|Lamivudine|
219232667|NCT00000872|DRUG|Stavudine|
219232668|NCT00000872|DRUG|Zidovudine|
219232669|NCT01197924|OTHER|IRMf Bold|IRMf BOLD of the working memory
219723395|NCT06964737|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
219232670|NCT04403178|DIAGNOSTIC_TEST|Radiographic examination with a Migration of > 40 %|Radiographic examination
219232671|NCT05710614|DIETARY_SUPPLEMENT|Animal protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.
219232672|NCT05710614|DIETARY_SUPPLEMENT|Plant Protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
219232673|NCT02994498|DRUG|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
219150764|NCT06974240|OTHER|control group|The entire intervention was carried out in a group entirely mediated by an operator without the use of a social robot. The first phase is dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, stories were read and participants answered target questions to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, in which all members of the group participated in turn, recalling the situations seen in the videos. During the last phase, participants were asked to share experiences from their lives in which they used or could use the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
219150765|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
219150766|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous
219150767|NCT06973772|BIOLOGICAL|Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
219150768|NCT06974344|DRUG|Octreotide (drug)|Continuous intravenous octreotide acetate infusion initiated at hepatic reperfusion during living donor liver transplantation (LDLT). The initial dose is 1 mcg/kg/hr, titrated intraoperatively based on portal venous flow (PVF) and hepatic artery flow / resistive index (RI) measurements. The infusion continues postoperatively in the ICU until stable graft hemodynamics are achieved (target PVF \<5 mL/min/g and presence of diastolic hepatic arterial flow). Dose adjustments are permitted for efficacy or safety concerns, with all modifications documented. The intervention is administered via central venous access using standard infusion protocols
219232674|NCT00484198|DRUG|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
219723396|NCT06964737|PROCEDURE|Chest Radiography|Undergo chest x-ray
219723397|NCT06964737|PROCEDURE|Echocardiography Test|Undergo ECHO
219150769|NCT06974344|PROCEDURE|Splenic Artery Ligation (SAL)|Intraoperative ligation of the splenic artery performed during living donor liver transplantation (LDLT) using non-absorbable suture material (e.g., polypropylene). The ligation is typically placed near the splenic artery origin for maximal portal flow modulation, with exact positioning determined by surgeon assessment of vascular anatomy and intraoperative hemodynamics (targeting portal venous flow \<5 mL/min/g). The procedure is performed under direct visualization during the transplant operation, with post-ligation Doppler ultrasound confirmation of hemodynamic response within 60 minutes of biliary anastomosis.
219150770|NCT06973967|BEHAVIORAL|delirium|Postoperatively, patients were monitored for delirium for seven days.
219150771|NCT06974214|OTHER|FAM-ICU|This multi-component intervention comprises several concrete and manageable components and operationalizing patient- and family-centered care principles in clinical practice.
219150772|NCT06973122|PROCEDURE|combined paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block|paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block
219150773|NCT06973122|PROCEDURE|laparoscopic assisted transversus abdominis plane block|laparoscopic assisted transversus abdominis plane block
219150774|NCT06973213|OTHER|core exercises|the intervention group underwent approximately 45 minutes of core stabilization exercises daily.
219232675|NCT00484198|DRUG|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
219232676|NCT00484198|DRUG|Rivoglitazone|1.0 mg tablet administered orally, once daily
219723398|NCT06964737|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219723399|NCT06964737|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219232677|NCT00484198|DRUG|Rivoglitazone|1.5 mg tablet administered orally, once daily
219723400|NCT06964737|PROCEDURE|Pheresis|Undergo apheresis
219723401|NCT06964737|PROCEDURE|Surgical Procedure|Undergo surgery and placement of CSF reservoir
219723402|NCT05575011|DRUG|BIIB115|Administered as specified in the treatment arm
219723403|NCT05575011|DRUG|BIIB115-Matching Placebo|Administered as specified in the treatment arm
219723404|NCT05920005|DRUG|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
219723405|NCT05920005|DRUG|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
219723406|NCT04412889|BIOLOGICAL|BCMA/CD19 dual-target CAR-T cell immunotherapy|The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
219723407|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 1）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219360978|NCT05310214|OTHER|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
219723408|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 2）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219723409|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 3）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219360979|NCT03567148|PROCEDURE|PRF|Applying to the palatal wounds
219723410|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 4）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219150775|NCT06974123|DRUG|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis|"Patients clinically diagnosed with radiation proctitis of CTCAE grade I-II will receive oral administration. Three dose groups of Teslanbai bacteria are tentatively planned, formulated as capsules with viable bacterial counts per capsule of ≥1107 CFU, 1108 CFU, and 1\*109 CFU, respectively. A 3+3 dose-escalation design will be adopted. Each dose group will enroll 3 subjects. If 1 subject experiences a grade ≥3 adverse reaction, 3 additional patients will be added. If 2 subjects exhibit adverse reactions, enrollment into higher dose groups will be discontinued. The final dosage for subsequent use of Teslanbai bacteria will be determined based on efficacy and safety data.~Approximately 9 subjects are planned for enrollment. After determining the optimal dosage, investigators and sponsors will decide whether to proceed to Phase II based on the study results and external data."
219150776|NCT06974123|DRUG|Teslanbai oral therapy|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis
219150777|NCT06973824|OTHER|Frequency of disease recurrence|To collect data of pituitary disease recurrence
219150778|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
219150779|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 20 minutes at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11)
219150780|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
219150781|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 30 seconds at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11). However the electrodes will be kept for 20 minutes to mask the stimulation
219150782|NCT06973590|DEVICE|Blood flow restriction (BFR)|BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). The pressure system remains inflated throughout active training phases and is systematically deflated during inter-exercise intervals.
219150783|NCT06973590|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
219150784|NCT06973590|DEVICE|Sham blood flow restriction (Sham-BFR)|Sham BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). But the pressure system remains deflated throughout active training and resting phases.
219150785|NCT06973590|DEVICE|Sham transcutaneous electrical nerve stimulation (Sham-TENS)|Sham TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching. But the stimulator will only be applied for the first and last 30 seconds.
219150786|NCT06973590|BEHAVIORAL|Low-intensity resistance training (LIRT)|The LIRT protocol utilizes 20% of one-repetition maximum (1-RM) as the standardized training load. LIRT including leg extensions, leg presses, and load-bearing squats focused on the affected limb. Each resistance exercise consists of 3 sets of 20 repetitions with rest intervals.
219150787|NCT06972602|DRUG|Topotecan|Intravitreal injection of topotecan at a dosage of 100μg was performed at week 1.Then based on the tumor response and vitreous seeding, it will be decided whether to continue the injection by ophthalmologists.
219150788|NCT06972602|OTHER|Collection of aqueous humor|Patients' aqueous humor samples will be collected for Inflammatory factor testing and IOP control every 4 weeks.
219150789|NCT06972602|OTHER|Electroretinogram|Electroretinogram was performed every 4 weeks.
219150790|NCT06974370|RADIATION|Active Surveillance|Following systemic therapy, participants will undergo active surveillance with brain MRI every 3 months. Radiation therapy will only be initiated if disease progression is observed on imaging, at the discretion of the treating physician.
219150791|NCT06973499|DIAGNOSTIC_TEST|Microbiome Profiling and Symptom Assessment|"GERD symptom assessment: Standardized GERD-Q questionnaire to evaluate reflux symptoms (heartburn, acid regurgitation) and high-risk behaviors.~Microbiome analysis: 16S rDNA sequencing of upper gastrointestinal and intratumoral microbiota."
219360980|NCT03567148|PROCEDURE|Essix retainer|Applying to the palatal wounds
219360981|NCT03567148|PROCEDURE|Ozone therapy|Applying to the palatal wounds
219360982|NCT03567148|PROCEDURE|LLLT|Applying to the palatal wounds
219360983|NCT03567148|PROCEDURE|Collagen fleece|Applying to the palatal wounds
219723411|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 5）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219723412|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 6）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219232678|NCT01965990|OTHER|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
219232679|NCT00001615|DRUG|Corticosteroid|
219150792|NCT06972628|DRUG|Administering Lutetium-177-PSMA-617 (PLUVICTO)|The study begins with a first cohort of three participants, each receiving a dose of 100 millicuries (mCi). After administration, participants are monitored for any dose-limiting toxicities (DLTs) during a predefined observation window. If fewer than two participants experience a DLT in a given cohort, the dose will be escalated for the next group. The dose escalation schedule is structured as follows: the second cohort receives 130 mCi (a 30% increase), the third cohort receives 162.5 mCi (a 25% increase), and the fourth cohort receives 200 mCi, a dose that is already FDA-approved and clinically accepted for mCRPC. This stepwise escalation continues until the 200 mCi dose is reached, or until two or more DLTs are observed in any cohort. If that occurs, escalation stops immediately, and the maximum tolerated dose is considered to be the previous lower dose. This becomes the optimal tolerated dose (OTD). After identifying the OTD, additional participants will be enrolled for treatment.
219150793|NCT06973109|DRUG|Romosozumab|Monthly subcutaneous injection (210 mg total dose) administered as two separate 105 mg injections, one per arm. Administered for 12 months to female patients ≥65 years undergoing spine surgery.
219150794|NCT06973109|DRUG|Alendronate (Fosamax)|Weekly oral dose (70 mg) administered for 12 months. Used as active comparator in control arm of study.
219150795|NCT06973109|DRUG|Placebo Romosozumab|Monthly subcutaneous injections mimicking romosozumab in appearance and administration schedule. Administered to control group.
219150796|NCT06973109|DRUG|Placebo Alendronate|Weekly oral placebo pill mimicking alendronate. Administered to treatment group.
219150797|NCT06967220|OTHER|Single leg training|All subjects will train one leg twice daily.
219150798|NCT06973694|DEVICE|Bulbicam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~26 grids glaucoma screening perimetry 64 grids full perimetry (NeuroField64) Pupil and Relative Afferent Pupil Defect (RAPD) assessment Semi-automatic ptosis (droopy eyelid) grading Video-based nystagmus test Dynamic acuity and contrast sensitivity test Dark adaptation test Smooth pursuit eye movements Saccade movements Eye fixation stability BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
219150799|NCT06973174|BIOLOGICAL|Premature neonates with invasive infection caused by Bacillus cereus|The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.
219150800|NCT06973382|BEHAVIORAL|Comprehensive Pulmonary Rehabilitation Program|"Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Continuous or interval training (15-30 minutes)~* 5-minute cool-downesistance Exercise Component~Mode: Dumbbell exercises + cycle ergometry~Frequency: 3 sessions per week~Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Training session (10-20 minutes)~* 5-minute cool-down"
219150801|NCT06973382|BEHAVIORAL|Standard Pulmonary Rehabilitation|"xercise Components:~Aerobic Exercise~Mode: Walking or jogging~Resistance Exercise~Mode: Elastic bands or dumbbells~Training Parameters:~Session Duration: ≥35 minutes (combined aerobic + resistance)~Frequency: 3-5 sessions per week~Program Duration: 12 weeks"
219150802|NCT06974422|BEHAVIORAL|Partial weight bearing during aerobic exercise training|Partial weight bearing (25% weight support) during the moderate intensity aerobic exercise training on the antigravity treadmill
219150803|NCT06974422|BEHAVIORAL|Full weight bearing during aerobic exercise training|Full weight bearing (100% weight loading, 0% weight support) during moderate intensity aerobic exercise training on the antigravity treadmill.
219150804|NCT06974422|DRUG|Regular oral anti-diabetic medications.|Participants in the control group (group C) received regular oral anti-diabetic medications.
219150805|NCT06973018|BEHAVIORAL|eRehabCog|eRehabCog is a manualised internet delivered compensatory cognitive rehabilitation program (10 weeks, 1 hour per week, 10 hours in total). It is designed to improve patient self efficacy and participation in everyday life activities through compensatory strategy learning
219232680|NCT03340961|DRUG|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
219232681|NCT03340961|DRUG|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
219232682|NCT03340961|DRUG|Oraycea® (doxycycline) Capsules|Oral Treatment
219232683|NCT03340961|DRUG|Placebo Capsules|Oral Treatment
219232684|NCT05122026|DRUG|Rifapentine|As included in arm/group description
219232685|NCT05122026|DRUG|Isoniazid|As included in arm/group description
219360984|NCT01044966|DRUG|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
219232686|NCT05300594|DIETARY_SUPPLEMENT|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
219232687|NCT05300594|DIETARY_SUPPLEMENT|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
219232688|NCT04929509|OTHER|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
219232689|NCT04929509|OTHER|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
219232690|NCT04929509|OTHER|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
219232691|NCT01853384|BIOLOGICAL|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
219232692|NCT01853384|OTHER|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
219232693|NCT00001628|DRUG|Angiotensin II type 1 receptor antagonists|
219232694|NCT04022707|OTHER|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
219232695|NCT04022707|OTHER|Educational control|Lectures on health and fitness
219232696|NCT00525616|DRUG|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
219232697|NCT01221402|DRUG|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
219723413|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 7）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219723414|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 8）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219723415|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 9）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
219723416|NCT02490579|BEHAVIORAL|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
219723417|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
219232698|NCT00024245|DRUG|pralatrexate|
219232699|NCT00024245|DRUG|probenecid|
219232700|NCT01039506|DRUG|CPT-11 based regimens|
219232701|NCT05765526|DEVICE|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
219723418|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
219723419|NCT04808037|DRUG|Belantamab mafodotin|Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
219723420|NCT02768181|BEHAVIORAL|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
219723421|NCT02768181|DIETARY_SUPPLEMENT|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
219150806|NCT06973018|BEHAVIORAL|CogMed QM|CogMed QM is an internet delivered training program (5 weeks, 2 hours per week, 10 hours in total) designed to improve patients working memory
219150807|NCT06973564|DRUG|JAB-23E73|Oral administration
219150808|NCT06973564|DRUG|JAB-23E73|Oral administration
219150809|NCT06973564|DRUG|JAB-23E73|Oral administration
219150810|NCT06973915|OTHER|AI model for movement and pain assessment in low back pain|This intervention involves developing an artificial intelligence (AI) model to objectively assess four physical parameters relevant to low back pain (LBP): 1) sit-to-stand performance, 2) trunk range of motion, 3) gait pattern, and 4) facial expression-based pain levels during movement. The AI model processes video recordings of participants performing these tasks to extract movement and facial data, providing standardized measurements. The tool is designed to assist physiotherapists in clinical decision-making by offering consistent and accurate assessments compared to traditional observational methods.
219150811|NCT06972537|DRUG|Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g administered four times a day (QID), with each infusion lasting for 4 hours.
219150812|NCT06972537|DRUG|Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g administered three times a day (TID), with each infusion lasting for 3 hours.
219150813|NCT03739372|OTHER|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
219150814|NCT05026476|DIETARY_SUPPLEMENT|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
219150815|NCT06692283|DRUG|denifanstat|Tablet
219150816|NCT06692283|DRUG|Placebo|Matching tablet
219150817|NCT06073093|DRUG|SAR441566|Tablet
219150818|NCT06073093|DRUG|Placebo|Tablet
219150819|NCT06042166|BEHAVIORAL|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
219150820|NCT06368453|DEVICE|INSTI® HIV Self-Test|"Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing."
219150821|NCT05831007|GENETIC|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
219150822|NCT02177318|DRUG|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
219150823|NCT01192633|DRUG|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
219150824|NCT00148434|BEHAVIORAL|Patient-held guideline for hypertension|
219150825|NCT05475106|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
219150826|NCT00597103|OTHER|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
219150827|NCT00597103|OTHER|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
219150828|NCT00597103|OTHER|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
219150829|NCT00995150|DRUG|LNG20|levonorgestrel-releasing intrauterine system for contraception
219150830|NCT00995150|DRUG|Mirena|Mirena intrauterine system
219150831|NCT02833272|BEHAVIORAL|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
219150832|NCT01463046|DRUG|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
219150833|NCT01463046|DRUG|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
219150834|NCT01463046|DRUG|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
219723422|NCT02768181|DIETARY_SUPPLEMENT|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
219723423|NCT04474106|DEVICE|Shock waves|The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.
219723424|NCT04474106|DEVICE|dummy head|The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
219723425|NCT00699751|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
219723426|NCT00699751|DRUG|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
219723427|NCT00699751|DRUG|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
219723428|NCT01148732|PROCEDURE|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
219723429|NCT01148485|OTHER|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
219723430|NCT00649688|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
219723431|NCT00649688|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
219150835|NCT01373346|PROCEDURE|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
219150836|NCT01499654|DRUG|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
219150837|NCT02964195|DRUG|Rifaximin|ALFA WASSERMANN S.p.A.
219150838|NCT03934658|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
219150839|NCT03934658|DEVICE|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
219150840|NCT05076058|DIETARY_SUPPLEMENT|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
219150841|NCT05076058|OTHER|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
219150842|NCT01141010|OTHER|Language|Plain language without psychological intervention
219150843|NCT01141010|OTHER|Language|Psychological linguistic intervention will be given
219150844|NCT00005027|DRUG|becatecarin|
219150845|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
219150846|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
219150847|NCT03639350|BEHAVIORAL|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
219150848|NCT03639350|BEHAVIORAL|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
219150849|NCT00551980|BEHAVIORAL|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
219150850|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
219150851|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
219150852|NCT03470662|OTHER|Care bundle|Care bundle
219150853|NCT04540822|OTHER|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
219150854|NCT04540822|OTHER|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
219150855|NCT02705183|RADIATION|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
219150856|NCT01395758|DRUG|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
219232702|NCT06470152|PROCEDURE|Correction strategy in reference to our PI-dependent clustering of sagittal alignment|For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
219232703|NCT06470152|PROCEDURE|Correction strategy in reference to the SAAS score|"This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1."
219232704|NCT05147207|PROCEDURE|Superpath Approach|This is a minimally invasive surgical approach for THA.
219232705|NCT04794244|BEHAVIORAL|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
219232706|NCT01205126|DRUG|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
219232707|NCT01205126|DRUG|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
219232708|NCT01205126|DRUG|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
219232709|NCT03728452|PROCEDURE|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
219232710|NCT03230448|OTHER|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
219232711|NCT03340662|DRUG|CC-122|CC-122
219232712|NCT03340662|DRUG|Itraconazole|CYP3A Inhibitor
219232713|NCT03340662|DRUG|Fluvoxamine|CYP1A2 Inhibitor
219232714|NCT03340662|DRUG|Rifampin|CYP3A Inducer
219232715|NCT01617811|PROCEDURE|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
219232716|NCT00486954|DRUG|Lapatinib|6 pills at 250 mg each once daily
219150857|NCT01395758|DRUG|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
219150858|NCT02906735|PROCEDURE|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
219150859|NCT00433199|DRUG|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
219150860|NCT00433199|DRUG|Placebo|Placebo Control
219150861|NCT00893425|DRUG|ramipril|
219150862|NCT01166152|BEHAVIORAL|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
219150863|NCT04141865|DEVICE|Xen|Xen microstent implantation
219150864|NCT04141865|DEVICE|Aqueous shunt|Aqueous shunt implantation
219150865|NCT00705328|BEHAVIORAL|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
219150866|NCT00705328|BEHAVIORAL|Recreation Coordination Model (REC)|Recreation coordination service delivery
219150867|NCT00705328|BEHAVIORAL|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
219150868|NCT00357097|DRUG|Ropinirole|
219150869|NCT03366701|OTHER|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
219150870|NCT00794118|OTHER|As per clinical practice|As per clinical practice
219150871|NCT06300424|DRUG|almonertinib|110mg qd
219150872|NCT06300424|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
219723432|NCT03206138|BIOLOGICAL|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
219723433|NCT03206138|BIOLOGICAL|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
219723434|NCT02313714|DEVICE|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
219723435|NCT02313714|DEVICE|Sham|very low electric muscular stimulation
219723436|NCT03575156|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219723437|NCT03575156|BIOLOGICAL|urine sample|6 ml
219723438|NCT00377481|DRUG|darbepoetin alfa|30 micrograms sc weekly (2 doses)
219723439|NCT00377481|DRUG|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
219150873|NCT06300424|DRUG|Nab paclitaxel|135 mg/m2, d1,d8 every 3 weeks
219150874|NCT00838253|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
219150875|NCT00838253|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
219150876|NCT00838253|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
219150877|NCT00838253|DRUG|Placebo|Placebo continuous i.v. infusion for 24 hours
219150878|NCT01460563|DRUG|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
219150879|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
219150880|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
219150881|NCT06839144|DRUG|Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)|"\- Intervention Arm: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor). Name: Propranolol (slow-Release) and Etodolac.~Propranolol Dosage Schedule:~5 days pre-surgery: 20mg twice daily (BID), Day of surgery: 80mg BID,~1-week Post-surgery: 40mg BID, week 2-11 post-surgery: 20mg BID.~Etodolac Dosage Schedule:~5 days pre-surgery until 3 weeks post-surgery: 400mg BID.~Administration Route: Oral."
219150882|NCT06839144|DRUG|Placebo (Matching for Propranolol & Etodolac)|\- Placebo Arm: Placebo (Matching for Propranolol \& Etodolac). Inert placebo tablets matching propranolol and etodolac in appearance and dosing schedule. Administration Route: Oral.
219150883|NCT04305405|DRUG|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
219150884|NCT03968354|BIOLOGICAL|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"* Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
219150885|NCT02647268|DRUG|Oxytocin|Oxytocin, 10-5M solution
219150886|NCT02647268|DRUG|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
219150887|NCT00371085|BEHAVIORAL|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
219150888|NCT04728724|DRUG|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
219150889|NCT04728724|DRUG|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
219150890|NCT06235424|DRUG|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
219150891|NCT06235424|DRUG|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
219150892|NCT05560659|DRUG|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
219232717|NCT00486954|DRUG|Paclitaxel|Infusion at 80 mg/m2 weekly
219723440|NCT01054248|DRUG|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
219723441|NCT01054248|DRUG|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
219723442|NCT01054248|DRUG|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
219723443|NCT05713448|OTHER|No intervention|No intervention
219723444|NCT02411136|DRUG|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
219723445|NCT02411136|DRUG|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
219723446|NCT00807404|PROCEDURE|histopathologic examination|
219150893|NCT00529659|DRUG|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
219150894|NCT00529659|DRUG|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
219150895|NCT04512651|OTHER|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
219150896|NCT04512651|OTHER|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
219150897|NCT00064012|DRUG|bortezomib|
219150898|NCT00064012|DRUG|docetaxel|
219150899|NCT00262730|DRUG|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
219150900|NCT00262730|DRUG|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
219150901|NCT00262730|RADIATION|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
219150902|NCT00095667|DRUG|lapatinib ditosylate|Given orally
219150903|NCT00095667|OTHER|laboratory biomarker analysis|Correlative studies
219150904|NCT03887650|DRUG|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
219150905|NCT03887650|DRUG|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
219150906|NCT01170962|DRUG|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
219150907|NCT01170962|DRUG|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
219150908|NCT01170962|DRUG|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
219150909|NCT01170962|DRUG|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
219232718|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
219723447|NCT00807404|PROCEDURE|optical coherence tomography|
219150910|NCT01170962|DRUG|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
219150911|NCT01503749|DRUG|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
219150912|NCT01503749|OTHER|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
219150913|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
219150914|NCT06972745|PROCEDURE|Ultrabrief pulse electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the right hemisphere, using ultrabrief pulses (≤0.3 ms).
219150915|NCT06972745|PROCEDURE|Brief pulse Electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the temporal hemisferes, using brief pulses (≥0.5 ms).
219150916|NCT06972316|OTHER|The Global postural reeducation|The Global postural reeducation (GPR) is a series of postures and gentle active movements are performed aimed at stretching shortened muscles, decompressing and aligning joints, with breath¬ing contro
219150917|NCT06972316|OTHER|Traditional treatments|Thermotherapy (hot packs) , Dynamic neck exercises, stretching exercise and posture advice
219150918|NCT05102656|OTHER|Best Practice|Physician conversations occur in-person
219150919|NCT05102656|PROCEDURE|Discussion|Physician conversations occur via video call
219150920|NCT05102656|OTHER|Questionnaire Administration|Ancillary studies
219150921|NCT05253118|DRUG|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
219150922|NCT05253118|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
219232719|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
219723448|NCT02475837|DRUG|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
219723449|NCT02475837|DRUG|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
219723450|NCT01505335|DEVICE|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
219723451|NCT00985790|BIOLOGICAL|Influenza vaccine GSK2321138A|Intramuscular injection
219723452|NCT00985790|BIOLOGICAL|Fluarix™|Intramuscular injection
219150923|NCT06195475|OTHER|high vs low tidal volume|The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.
219150924|NCT06306768|DEVICE|Activity Monitoring|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
219150925|NCT05714696|BEHAVIORAL|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
219150926|NCT05714696|BEHAVIORAL|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
219150927|NCT01872026|DRUG|ASP7991|oral
219150928|NCT03445598|BEHAVIORAL|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
219150929|NCT03445598|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
219232720|NCT05727111|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
219232721|NCT05727111|BEHAVIORAL|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
219232722|NCT00903214|DRUG|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
219232723|NCT00903214|GENETIC|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
219232724|NCT00903214|PROCEDURE|axillary lymph node biopsy|
219723453|NCT05015634|OTHER|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
219723454|NCT05015634|OTHER|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
219723455|NCT05792488|BEHAVIORAL|Coach|Coaching to a healthy lifestyle
219723456|NCT05792488|BEHAVIORAL|App|The app will coach people to a healthy lifestyle
219723457|NCT05792488|OTHER|Standard of care|Patients will receive standardized lifestyle advice by their specialist
219150930|NCT03445598|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
219150931|NCT03589651|DRUG|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
219150932|NCT03589651|DRUG|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
219150933|NCT03589651|DRUG|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
219232725|NCT00903214|PROCEDURE|digital image analysis|
219232726|NCT00903214|PROCEDURE|needle biopsy|
219232727|NCT00903214|PROCEDURE|sentinel lymph node biopsy|
219232728|NCT00903214|PROCEDURE|therapeutic conventional surgery|
219232729|NCT01751295|DRUG|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
219232730|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
219360985|NCT05773677|DIETARY_SUPPLEMENT|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
219723458|NCT06971939|COMBINATION_PRODUCT|NT-501/revakinagene taroretcel-lwey|NT-501 is surgically implanted into the vitreous cavity to continuously release recombinant human ciliary neurotrophic factor (CNTF).
219150934|NCT02576340|DRUG|otilonium bromide|otilonium bromide was administered before the procedure
219723459|NCT06965309|DRUG|HN2301 injection|Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
219723460|NCT02179619|DEVICE|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
219723461|NCT02179619|DEVICE|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
219723462|NCT02111044|DRUG|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
219723463|NCT02111044|DRUG|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
219723464|NCT02111044|DRUG|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
219723465|NCT02111044|DRUG|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
219723466|NCT02839317|BIOLOGICAL|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
219723467|NCT00867880|DRUG|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
219723468|NCT01449084|PROCEDURE|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
219723469|NCT01449084|OTHER|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
219723470|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
219723471|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
219150935|NCT00553189|DRUG|ABT-888|
219150936|NCT00553189|DRUG|Topotecan|
219150937|NCT01406028|BEHAVIORAL|Phone calls|Phone calls to offer emotional support
219723472|NCT03393572|DRUG|Bupivacaine 0.25%|Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
219723473|NCT03393572|DRUG|Magnesium sulphate.|Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
219723474|NCT03393572|DRUG|nalbuphine|Patients will receive intraperitoneal 5 mg nalbuphine
219723475|NCT04012645|PROCEDURE|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
219723476|NCT04012645|PROCEDURE|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
219723477|NCT04124965|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
219150938|NCT02961179|BEHAVIORAL|Increased dairy product|
219150939|NCT02961179|BEHAVIORAL|Dietary counselling|
219150940|NCT00059241|BEHAVIORAL|Parent-child communication education|
219150941|NCT00059241|BEHAVIORAL|Service learning|
219150942|NCT00059241|BEHAVIORAL|Classroom health curriculum|
219723478|NCT04486144|OTHER|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
219150943|NCT00829751|DEVICE|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
219150944|NCT00829751|DEVICE|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
219150945|NCT01830946|OTHER|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
219150946|NCT01830946|OTHER|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
219150947|NCT01830946|OTHER|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
219723479|NCT02184156|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
219723480|NCT02184156|DRUG|4 mL injection of Placebo|
219723481|NCT03789006|DRUG|Antithymocyte Immunoglobulin (Rabbit)|Induction agent for living donor kidney transplantation
219723482|NCT03789006|DRUG|Interleukin 2 Receptor Antagonist|Induction agent for living donor kidney transplantation
219723483|NCT04754295|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
219723484|NCT04754295|OTHER|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
219723485|NCT03665324|OTHER|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
219150948|NCT03393117|DRUG|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
219150949|NCT03393117|DRUG|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
219150950|NCT03393117|DRUG|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
219150951|NCT03393117|DRUG|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
219150952|NCT00696618|DRUG|Fleet Enema|hyper-osmolar preparation
219150953|NCT00696618|DRUG|tap water enema|hypo-osmolar preparation
219150954|NCT00696618|DRUG|Normosol-R enema|iso-osmolar preparation
219150955|NCT03400969|DEVICE|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
219150956|NCT03400969|DEVICE|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
219150957|NCT03400969|DEVICE|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
219150958|NCT02674750|DRUG|CUDC-907|
219150959|NCT02095899|DRUG|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
219150960|NCT01156935|OTHER|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
219150961|NCT01685606|BIOLOGICAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
219150962|NCT02852681|DRUG|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
219150963|NCT01029717|DEVICE|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
219150964|NCT01029717|DEVICE|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
219150965|NCT01029717|DEVICE|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
219150966|NCT05803850|DRUG|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
219150967|NCT01815450|DRUG|BLI1100|BLI1100 topical cream
219150968|NCT01815450|DRUG|BLI1100 - modified formulation|BLI1100 topical cream
219150969|NCT01815450|DRUG|Placebo|Placebo topical cream
219150970|NCT03413748|PROCEDURE|Elective Cesarean Section|lower segment cesarean section
219150971|NCT03413748|OTHER|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
219150972|NCT03477149|DEVICE|Easyx|Embolization will be done with Easyx liquid agent.
219150973|NCT00138619|DRUG|vildagliptin|
219150974|NCT02590952|DRUG|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
219150975|NCT01039142|DRUG|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
219150976|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
219150977|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
219150978|NCT00758433|DRUG|Placebo patch|Placebo patch q.d. 24 hours for 7 days
219360986|NCT05029557|BEHAVIORAL|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
219723486|NCT05324202|DEVICE|Cynosure Cynergy Nd:YAG Laser 1064nm|The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
219150979|NCT03150238|OTHER|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
219150980|NCT01199705|BIOLOGICAL|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
219150981|NCT01415349|DRUG|SSP-002358|1 mg, oral, once
219150982|NCT01415349|DRUG|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
219150983|NCT02032069|OTHER|no intervention|
219150984|NCT02047981|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
219150985|NCT02047981|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
219150986|NCT00739518|PROCEDURE|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
219150987|NCT04257136|DRUG|VBI-S|VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
219150988|NCT01105169|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
219150989|NCT01105169|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
219150990|NCT00096915|DRUG|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
219150991|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
219150992|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
219150993|NCT01616459|BIOLOGICAL|Synflorix™|Intramuscular injection
219150994|NCT01616459|BIOLOGICAL|Prevnar 13™|Intramuscular injection
219150995|NCT01616459|BIOLOGICAL|Infanrix hexa™|Intramuscular injection
219150996|NCT03953859|GENETIC|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
219150997|NCT04580420|DRUG|DCR-PHXC|Monthly dosing throughout study period
219150998|NCT03089866|DRUG|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
219150999|NCT04980755|OTHER|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
219151000|NCT06375668|DIETARY_SUPPLEMENT|Probiotic|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
219151001|NCT06375668|OTHER|Placebo|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
219151002|NCT04926571|DRUG|Dexamethasone Oral|New users of Dexamethasone
219151003|NCT00118066|DIETARY_SUPPLEMENT|calcitriol|Given orally
219151004|NCT00118066|PROCEDURE|observation|No initial intervention
219151005|NCT05375344|BEHAVIORAL|Exercise Group|Home-based exercise group intervention
219151006|NCT06552533|OTHER|Resistance Exercises with Plyometric exercises|"We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.~Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane).After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises,Plyometric Ankle Jumps Ankle Circles"
219151007|NCT06552533|OTHER|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will be maintained, the therapist will assure that the targeted musculature will being maximally loaded
219151008|NCT05594576|PROCEDURE|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
219151009|NCT05594576|PROCEDURE|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
219151010|NCT06051175|OTHER|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
219151011|NCT06051175|OTHER|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
219151012|NCT06051175|OTHER|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
219151013|NCT06051175|OTHER|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
219151014|NCT06051175|OTHER|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
219151015|NCT02422095|PROCEDURE|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
219151016|NCT02422095|PROCEDURE|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
219151017|NCT03817060|PROCEDURE|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
219151018|NCT03817060|PROCEDURE|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
219151019|NCT06677268|PROCEDURE|rehabilitation|Patients will undergo a respiratory rehabilitation program (24 exercise sessions of 90 minutes each, three times a week for 8 weeks and up to 9 therapeutic education workshops of 1 hour of the patient\&#39;s choice)
219151020|NCT07048743|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
219151021|NCT05741827|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention focusing on diet and physical activity
219151022|NCT07060417|DRUG|Empagliflozin|Empagliflozin 10 mg, encapsulated to match the placebo, will be used.
219151023|NCT07060417|DRUG|Placebo|Matching placebo will be used.
219151024|NCT07060911|DEVICE|Lung monitoring with the Neola device|Lung monitoring with the Neola device
219151025|NCT07059988|OTHER|Stable isotope tracers|Deuterium-labelled non-radioactive stable isotopes of glucose, phenylalanine and glycerol.
219151026|NCT07059988|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition infused a rate corresponding to 100% of measured energy expenditure, started after blood sampling during a baseline fasting period.
219151027|NCT07060014|DRUG|Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months|The study drugs will be administered per the regimen defined in the NAPOLI-3 clinical trial. Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months.
219151028|NCT06898346|BEHAVIORAL|Nutrition Education|The treatment group will receive nutrition education (NE) and counseling 6 times. The 1st and 6th counselling sessions will be administered by a Registerd Dietitan in a health facility (weeks 21-22 and weeks 31-32). Four (4) bi-weekly follow-ups between these 2 sessions will be administered by Field Assistants (weeks 23, 25, 27 and 29) at the participant's home. NE will focus on dietary diversity and minimum meal frequency (Daniel et al, 2016; Gyimah et al., 2021), protein and energy intakes (Ota et al, 2015), intake of iron-rich foods (Otoo and Adam, 2016), guidelines for pregnancy with an emphasis on appropriate weight gain (Abubakar et al, 2016), and appropriate ingredients and food preparation methods required to optimize nutrition.
219151029|NCT06843330|DEVICE|blood glucose meter; blood lactate meter|Blood lactate level measured by finger-stick with over the counter meter. Blood glucose level measured by finger-stick.
219151030|NCT06842966|DRUG|4-MUST|128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.
219151031|NCT06842966|DRUG|Placebo|Placebo tablet.
219151032|NCT06498518|DRUG|IMM-101, Pembrolizumab, Gemcitabine|Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle
219360987|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
219360988|NCT05506397|OTHER|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
219360989|NCT04623645|DEVICE|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
219723487|NCT00874133|PROCEDURE|Acupuncture|Acupuncture treatment for 12 weeks.
219723488|NCT00874133|DRUG|Motilium|20 mg motilium thrice daily
219723489|NCT02115477|PROCEDURE|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
219151033|NCT07061119|OTHER|Conventional treatment|"Trampolinejumping:5times. Gym ball exercise:5reps'Sensory diet:- Joint compressions: 1 set x 10reps on limbs, neck, and head region.~Deeppressure:1 setx10reps. Balance board exercises."
219151034|NCT07061119|OTHER|cawthorne cooksey exercises|"Cawthorne Cooksey exercises~* Start with low to moderate intensity.~* Gradually increase range, speed, and Complexity over time~* Trampoline jumping- Gym ball exercise- Sensory diet~* Cawthorne Cooksey exer cise Training~Phase1-In bed exerercises:- Eye movements:~1)Up and down 2)Side to side 3)Moving finger away from face~* Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed~* bending forward and backward~* turning from side to side.~  --Shoulder shrugging and circling~* Bending forward and picking up objects from the ground~* Phase 3 - Standing:~* Eye, Head, Shoulder movements~* Throwing ball from hand to hand, hand under knee~* Switch to sitting to standing and turning around in between.~* Phase 4 - Walk: with eyes closed and open:~* Across room~* Slope and Stairs"
219151035|NCT06756477|BEHAVIORAL|mindfulness group|Online training will be implemented 2 times a week for 8 sessions. A 30-45 minute reminder training will be given 1 month after the training. Mindfulness-Based Healthy Living Behaviors Education (MTSYDE) booklet will be sent online to guide students' home practices. Taking into account the possibility of forgetting and demotivation in students, audio recordings will be used, reminder messages will be sent and counseling will be given regarding the program. A post-test will be administered 1 month after the reminder training.
219151036|NCT06756477|OTHER|control group|Menstruation-specific Healthy Living Behaviors training of 30-45 minutes in 8 sessions 2 times a week will be provided online. A standard training booklet will be sent 1 month after the training as a reminder. Standard reminder messages will be sent considering the possibility of forgetting and demotivation in students. A post-test will be administered 1 month after the reminder training.
219151037|NCT06770998|DEVICE|EEG-neurofeedback training|15 training sessions (twice/week) plus two booster training sessions added to treatment as usual.
219151038|NCT06770998|DEVICE|Sham training|15 sham sessions (twice/week) plus two sham booster sessions added to treatment as usual.
219151039|NCT07061405|OTHER|Multidisciplinary management associated with mobile application Doado|multidisciplinary program including physiotherapists, rheumatologists, physical medicine and rehabilitation specialists, occupational physicians, psychologists, etc., associated with Doado mobile application
219151040|NCT07061405|OTHER|Physiotherapy management alone associated with mobile application Doado|monodisciplinary physiotherapy rehabilitation program consisting of active treatment with a physiotherapist associated with Doado mobile application
219151041|NCT07061132|OTHER|AI-Based Interview Simulation|The intervention group participated in a structured, text-based job interview simulation supported by ChatGPT-4o, using nine standardized prompts based on ICN (2008) and ICM (2024) core competencies. Developed by experts in simulation and nursing education, the intervention aimed to enhance self-efficacy and reduce interview-related anxiety. Each session lasted 15-20 minutes and concluded with structured feedback provided by ChatGPT. Participants were also offered an optional preparation guide with 40 reflective questions across themes such as communication, anxiety, and self-awareness. This preparation was not mandatory and not included in the simulation time.
219151042|NCT06337227|DIAGNOSTIC_TEST|lncRNA signature analyses|Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
219151043|NCT05419076|RADIATION|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
219151044|NCT05419076|PROCEDURE|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
219151045|NCT02398825|DRUG|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
219151046|NCT06738251|DRUG|SHR-A2102 for Injection|SHR-A2102 for Injection.
219151047|NCT06738251|DRUG|Docetaxel Injection|Docetaxel Injection.
219151048|NCT06738251|DRUG|Paclitaxel Injection|Paclitaxel Injection.
219151049|NCT06738251|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
219151050|NCT06738251|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection.
219151051|NCT06450301|PROCEDURE|Endometrial Biopsy|"An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and~generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example)."
219151052|NCT03710798|DIETARY_SUPPLEMENT|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
219151053|NCT01643499|DRUG|oxaliplatin|Given IV
219151054|NCT01643499|DRUG|irinotecan hydrochloride|Given IV
219151055|NCT01643499|DRUG|leucovorin calcium|Given IV
219151056|NCT01643499|DRUG|fluorouracil|Given IV
219151057|NCT01643499|OTHER|laboratory biomarker analysis|Correlative studies
219151058|NCT02682485|DRUG|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
219151059|NCT02682485|PROCEDURE|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
219151060|NCT02682485|DRUG|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
219151061|NCT02871206|BIOLOGICAL|Fluad|
219151062|NCT02871206|BIOLOGICAL|Fluzone|
219151063|NCT03643939|DEVICE|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
219151064|NCT03643939|DEVICE|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
219151065|NCT04894565|PROCEDURE|rehabilitation|physical therapy 24 hrs after surgery
219151066|NCT00089544|DRUG|Dacarbazine|Given IV
219151067|NCT00089544|DRUG|Doxorubicin Hydrochloride|Given IV
219151068|NCT00089544|BIOLOGICAL|Filgrastim|Given subcutaneously
219151069|NCT00089544|DRUG|Ifosfamide|Given IV
219151070|NCT00089544|OTHER|Laboratory Biomarker Analysis|Correlative studies
219151071|NCT00089544|RADIATION|Radiation Therapy|Undergo radiotherapy
219151072|NCT00089544|DRUG|Thalidomide|Given orally
219151073|NCT00089544|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219151074|NCT00014040|DRUG|Nitric Oxide and INOpulse Delivery System|
219151075|NCT03807908|OTHER|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
219151076|NCT03807908|OTHER|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
219151077|NCT00227994|DRUG|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
219151078|NCT00227994|DRUG|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
219151079|NCT01331044|DIETARY_SUPPLEMENT|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
219151080|NCT01331044|DIETARY_SUPPLEMENT|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
219151081|NCT01150383|OTHER|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
219151082|NCT01150383|OTHER|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
219151083|NCT03821246|DRUG|Atezolizumab|Given IV
219151084|NCT03821246|DRUG|Tocilizumab|Given IV
219151085|NCT03821246|DRUG|Etrumadenant|Given Orally
219151086|NCT03500393|BEHAVIORAL|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
219151087|NCT03500393|BEHAVIORAL|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
219151088|NCT03803605|BIOLOGICAL|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
219151089|NCT03803605|DRUG|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
219151090|NCT05680389|DRUG|Minocycline|100 mg twice daily for 3 months
219151091|NCT05680389|DRUG|Placebo|twice daily for 3 months
219151092|NCT03046810|DEVICE|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
219151093|NCT05150106|OTHER|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
219723490|NCT04351971|OTHER|Intervention Group|The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.
219151094|NCT00477308|PROCEDURE|salvage therapy|
219723491|NCT04351971|OTHER|Placebo group|The technique consists of placing the patient in the supine position, one hand is located in the arches of the atlas, the other hand is located in the occipital. The therapist's shoulder is located in the anterior region. This position is maintained for 5 minutes without exerting pressure.
219723492|NCT00002874|DRUG|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
219723493|NCT00002874|RADIATION|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
219723494|NCT00002874|DRUG|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
219723495|NCT01732900|OTHER|Morphology|Embryos selected for transfer will be based upon morphology alone.
219723496|NCT01732900|OTHER|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
219151095|NCT03097770|BIOLOGICAL|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
219723497|NCT03602781|DRUG|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
219151096|NCT00945607|OTHER|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
219151097|NCT00233090|DRUG|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
219151098|NCT00233090|DRUG|Placebo|daily dose of placebo for four weeks.
219151099|NCT06444958|DIAGNOSTIC_TEST|observational study without any intervention component.|"extracting and analyzing the following data:~Outpatient department records: Diagnoses, treatments, patient demographics Inpatient admission records: Admission diagnoses, treatments, patient outcomes (discharged, transferred, died) Mortality records: Causes of death for pediatric patients"
219151100|NCT01745016|DIETARY_SUPPLEMENT|Placebo|
219151101|NCT01745016|DIETARY_SUPPLEMENT|Beta-alanine|
219151102|NCT01186549|DRUG|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
219151103|NCT01186549|DRUG|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
219151104|NCT01186549|DRUG|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
219151105|NCT01186549|DRUG|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
219151106|NCT01186549|DRUG|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
219151107|NCT05886634|DRUG|Etrumadenant|Will be administered PO daily for 24 weeks
219151108|NCT05886634|DRUG|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
219151109|NCT04351386|DEVICE|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
219151110|NCT01892683|DRUG|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
219151111|NCT01622868|OTHER|Laboratory Biomarker Analysis|Correlative studies
219151112|NCT01622868|DRUG|Lapatinib Ditosylate|Given PO
219723498|NCT03602781|DRUG|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
219723499|NCT04558528|DIAGNOSTIC_TEST|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
219723500|NCT00387842|PROCEDURE|Laparoscopic surgery|
219723501|NCT00387842|PROCEDURE|Conventional surgery|
219723502|NCT05926492|DRUG|Surufatinib plus chemotherapy|"Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
219723503|NCT05926492|DRUG|Chemotherapy|"1\) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
219723504|NCT03251105|DEVICE|supraglottic airway intubation|
219151113|NCT01622868|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219151114|NCT01622868|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219151115|NCT04339348|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
219151116|NCT04339348|DRUG|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
219151117|NCT04339348|DRUG|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
219151118|NCT03891927|DIETARY_SUPPLEMENT|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
219151119|NCT04261465|DRUG|Olaparib|PARP INHIBITOR
219151120|NCT04261465|DRUG|Paclitaxel|Chemotherapy
219151121|NCT04261465|DRUG|Carboplatin|Chemotherapy
219151122|NCT02761239|DEVICE|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
219151123|NCT05639777|DRUG|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
219151124|NCT05639777|OTHER|control group|That will receive the same volume of 2 ml of intranasal normal saline
219151125|NCT02424318|DRUG|Topiramate|topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
219151126|NCT03017183|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
219151127|NCT03017183|PROCEDURE|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
219151128|NCT04425629|DRUG|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
219151129|NCT02726828|DRUG|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
219151130|NCT02726828|DRUG|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
219151131|NCT02726828|DRUG|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
219151132|NCT03113617|PROCEDURE|Computed Tomography|Undergo PET/CT
219151133|NCT03113617|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
219151134|NCT03113617|OTHER|Laboratory Biomarker Analysis|Correlative studies
219151135|NCT03113617|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219151136|NCT05806255|DEVICE|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
219723505|NCT00690651|PROCEDURE|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
219723506|NCT00690651|PROCEDURE|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
219723507|NCT04393012|OTHER|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
219151137|NCT05810194|DEVICE|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
219232731|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
219232732|NCT05889832|DIAGNOSTIC_TEST|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
219232733|NCT01765855|DRUG|Betrixaban single oral dose|
219151138|NCT05810194|DRUG|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
219232734|NCT04702594|BEHAVIORAL|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
219232735|NCT02050815|DRUG|MEK162|
219232736|NCT06144723|DRUG|HS-20105|Administered intravenously every 21 days.
219232737|NCT04130282|BIOLOGICAL|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
219232738|NCT04257500|DRUG|Etonogestrel/ethinyl estradiol vaginal ring|16 weeks of continuous use of contraceptive vaginal ring
219232739|NCT05581394|DEVICE|BabySat V3|Evaluation of Accuracy of BabySat V3
219232740|NCT03331978|BEHAVIORAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
219232741|NCT00638456|DRUG|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
219232742|NCT00638456|DRUG|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
219232743|NCT00419172|DRUG|Deferasirox|
219232744|NCT00419172|DRUG|Rifampicin|
219232745|NCT03564184|BEHAVIORAL|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
219232746|NCT03564184|BEHAVIORAL|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
219232747|NCT03564184|OTHER|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
219232748|NCT04989023|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
219232749|NCT02204202|DRUG|[18F]FDG|10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
219232750|NCT02204202|DRUG|[18F]ISO-1|8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
219232751|NCT00903981|DRUG|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
219151139|NCT05810194|DRUG|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
219151140|NCT03157401|DRUG|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
219232752|NCT00903981|DRUG|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
219151141|NCT03157401|DRUG|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
219151142|NCT03157401|DRUG|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
219232753|NCT00903981|DRUG|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
219232754|NCT03236779|OTHER|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
219232755|NCT02917148|OTHER|Peripheral Venipuncture or Blood draw from Central Line|
219723508|NCT01626313|BEHAVIORAL|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
219151143|NCT03262623|OTHER|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
219151144|NCT03262623|OTHER|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
219151145|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
219723509|NCT03828383|DEVICE|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
219723510|NCT03828383|DEVICE|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
219723511|NCT00540267|OTHER|No Intervention|No Intervention
219723512|NCT02858258|DRUG|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
219151146|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
219151147|NCT01958866|DRUG|Tinospora Crispa-extract Product|
219151148|NCT01958866|DRUG|Acetaminophen|
219151149|NCT01958866|OTHER|Placebo|
219151150|NCT02474394|DEVICE|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
219151151|NCT02474394|DEVICE|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
219151152|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
219151153|NCT05263336|DRUG|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
219151154|NCT01323686|OTHER|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
219232756|NCT03108430|OTHER|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
219232757|NCT02751294|DRUG|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
219232758|NCT02751294|DRUG|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
219232759|NCT02751294|DRUG|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
219232760|NCT00552461|DRUG|rituximab|IV, 1000 mg, two weeks, 2 times
219723513|NCT02858258|DRUG|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
219723514|NCT02858258|DRUG|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
219723515|NCT02858258|DRUG|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
219723516|NCT05122715|DEVICE|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
219232761|NCT04562883|OTHER|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
219232762|NCT02499809|OTHER|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
219232763|NCT00264888|DRUG|PTC124|
219232764|NCT00673088|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
219232765|NCT02183402|DRUG|Digoxin|
219232766|NCT02183402|DRUG|BI 1356|
219232767|NCT03206398|DEVICE|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
219232768|NCT01271361|PROCEDURE|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
219151155|NCT03209778|OTHER|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
219151156|NCT01279798|BIOLOGICAL|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
219151157|NCT02290470|DRUG|Olanzapine|"* Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
219151158|NCT02290470|DRUG|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
219232769|NCT01271361|PROCEDURE|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
219232770|NCT00805792|DRUG|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
219232771|NCT00514670|OTHER|Alcohol-based hand sanitizer & quaternary ammonium wipes|
219232772|NCT03015688|RADIATION|x-ray images|
219232773|NCT03674788|DEVICE|Transcatheter valve intervention|
219232774|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219723517|NCT04713995|OTHER|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
219151159|NCT05355623|PROCEDURE|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
219151160|NCT01016522|DIETARY_SUPPLEMENT|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
219151161|NCT02925351|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219151162|NCT02925351|RADIATION|Fluorine F 18 Clofarabine|Given IV
219151163|NCT02925351|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219151164|NCT02205853|OTHER|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
219151165|NCT02205853|OTHER|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
219232775|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219232776|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219232777|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219232778|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219232779|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
219232780|NCT00635635|BEHAVIORAL|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
219232781|NCT00635635|BEHAVIORAL|Music Audio|Music only audio to be listened to 5x per week
219232782|NCT02462278|DEVICE|TempuRing|
219232783|NCT05640245|DRUG|Sonelokimab|randomized treatment; parallel group
219232784|NCT05640245|DRUG|Placebo|randomized treatment; parallel-group
219232785|NCT05640245|DRUG|Adalimumab|randomized treatment; parallel-group
219232786|NCT05309057|DIETARY_SUPPLEMENT|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
219232787|NCT00304642|DRUG|dapivirine (TMC120) vaginal gel|
219232788|NCT03060785|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|
219232789|NCT04159545|OTHER|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
219232790|NCT00667953|DRUG|Gleevec|Gleevec (600 mg) daily.
219232791|NCT00667953|DRUG|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
219723518|NCT00308685|DRUG|Albuterol|Albuterol 90mcg
219723519|NCT00308685|DRUG|Placebo|Placebo
219723520|NCT06413329|BEHAVIORAL|preoperative physical activity level within 3 months|The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
219723521|NCT00321412|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
219151166|NCT02653508|BEHAVIORAL|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
219151167|NCT02653508|BEHAVIORAL|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
219151168|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
219151169|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
219151170|NCT06290882|PROCEDURE|Robotic Heller Myotomy|Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.
219151171|NCT06290882|PROCEDURE|Peroral Endoscopic Myotomy|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
219151172|NCT03388281|OTHER|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
219151173|NCT05001529|BIOLOGICAL|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
219151174|NCT02489695|DRUG|Axitinib|axitinib 10mg twice a day
219151175|NCT03999671|OTHER|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
219151176|NCT03999671|OTHER|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
219151177|NCT04085094|DIETARY_SUPPLEMENT|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
219151178|NCT04085094|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
219151179|NCT04085094|DIAGNOSTIC_TEST|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
219151180|NCT04085094|OTHER|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
219232792|NCT05179772|DRUG|Olanzapine|Olanzapine (2.5 mg to 20 mg)
219232793|NCT01596985|PROCEDURE|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
219151181|NCT04257071|BEHAVIORAL|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
219151182|NCT04257071|BEHAVIORAL|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
219151183|NCT03658408|DRUG|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
219151184|NCT03658408|DRUG|placebo|2.5 mg sugar pill given orally 4 times a day
219151185|NCT03524534|OTHER|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
219151186|NCT03524534|OTHER|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
219151187|NCT00973986|DRUG|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
219151188|NCT05831969|DRUG|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
219151189|NCT03221023|DRUG|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
219151190|NCT03221023|DRUG|Saline Solution|Individuals in the control arm will receive intrawound saline solution
219151191|NCT04125433|BEHAVIORAL|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
219151192|NCT05346523|DEVICE|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
219151193|NCT01149707|DRUG|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
219151194|NCT01149707|DRUG|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
219151195|NCT01149707|DRUG|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
219151196|NCT01149707|DRUG|Placebo Enema|Placebo Enema, once-daily, intrarectally
219151197|NCT05447975|OTHER|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
219151198|NCT00610649|DRUG|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
219151199|NCT00610649|DRUG|Placebo|Orally administered matching placebo capsules.
219151200|NCT01808768|DRUG|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
219151201|NCT02250430|DRUG|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
219151202|NCT01292252|BIOLOGICAL|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
219151203|NCT01292252|BIOLOGICAL|Placebo|Saline solution
219151204|NCT02236793|DRUG|BioChaperone PDGF-BB|
219151205|NCT02236793|OTHER|Standard of Care|
219151206|NCT02582086|OTHER|BOR15001L7|Active cream with 5% 15019L0
219151207|NCT02582086|OTHER|Placebo|Placebo Cream with 0% 15019L0
219151208|NCT05517616|DRUG|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
219151209|NCT01449123|DRUG|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
219151210|NCT02071836|BEHAVIORAL|Right Turns web application|
219151211|NCT02071836|BEHAVIORAL|Treatment as usual|
219151212|NCT05762159|OTHER|data collected|"data collected:~* Morphological data of the patients~* Data of the erector block realization~* Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
219151213|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
219151214|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
219151215|NCT06044467|DRUG|Placebo - Study Part One|Placebo Comparator
219151216|NCT06044467|DRUG|Placebo - Study Part Two|Placebo Comparator
219151217|NCT00414544|DEVICE|CosmetaLife|Dermal filler
219151218|NCT00414544|DEVICE|Restylane|Dermal filler
219151219|NCT05346978|DIETARY_SUPPLEMENT|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
219151220|NCT05346978|DIETARY_SUPPLEMENT|Placebo|collagen colored with green pigment used in the food industry
219151221|NCT00580112|DRUG|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
219151222|NCT00580112|DRUG|Trabectedin|Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
219723522|NCT01957800|BEHAVIORAL|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
219151223|NCT01267383|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
219151224|NCT01888848|DIETARY_SUPPLEMENT|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
219151225|NCT01888848|DIETARY_SUPPLEMENT|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
219151226|NCT02520908|PROCEDURE|HSCT|Hematopoietic stem cell transplantation
219151227|NCT02520908|OTHER|Standard Care|
219151228|NCT06006949|DRUG|Roxadustat|Roxadustat (150 mgqod)
219151229|NCT06006949|DRUG|Luspatercept|Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg)
219151230|NCT03875040|BEHAVIORAL|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
219151231|NCT00373386|DRUG|growth hormone|Growth Hormone treatment
219151232|NCT05512182|DRUG|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
219151233|NCT02713906|DEVICE|X-Ray Knee Guide group|
219151234|NCT02271854|DRUG|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
219151235|NCT02271854|DRUG|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
219723523|NCT01957800|BEHAVIORAL|Usual Care|Participants will record their weight and complete surveys online.
219723524|NCT06060886|DRUG|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
219723525|NCT06060886|DRUG|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
219151236|NCT02450344|BEHAVIORAL|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
219151237|NCT02450344|BEHAVIORAL|Passive health promotion|An electronic package of information related to alcohol
219151238|NCT03884296|BIOLOGICAL|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
219151239|NCT04760938|BEHAVIORAL|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
219151240|NCT04760938|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
219151241|NCT06414850|BEHAVIORAL|Animal Assisted Therapy (AAT)|A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
219151242|NCT05119764|PROCEDURE|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
219151243|NCT00281554|DRUG|RSD1235|IV
219151244|NCT03259516|DRUG|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
219151245|NCT03259516|DRUG|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
219723526|NCT05838170|DRUG|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
219723527|NCT05838170|OTHER|Vehicle control gel|Aqueous gel
219151246|NCT03259516|DRUG|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
219151247|NCT03259516|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
219151248|NCT03259516|DRUG|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
219151249|NCT03259516|DRUG|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
219151250|NCT03259516|DRUG|Sildenafil|20 mg per os three times a day during the whole course of treatment
219151251|NCT03259516|DRUG|Melphalan|2 mg per os daily during the whole course of treatment
219151252|NCT01101594|DRUG|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
219151253|NCT03976570|BEHAVIORAL|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
219151254|NCT02285413|BIOLOGICAL|DC vaccination|DC vaccination without cisplatinum
219151255|NCT02285413|BIOLOGICAL|DC vaccination with cisplatinum|DC vaccination with cisplatinum
219151256|NCT00240149|DRUG|Regular Insulin via Insulin-Glucose Algorithm|
219723528|NCT03694652|BEHAVIORAL|PACE|Patient-centered Assessment and Counseling for Exercise \[PACE\] program
219151257|NCT04981158|PROCEDURE|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
219151258|NCT04981158|PROCEDURE|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
219151259|NCT03917303|DRUG|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
219151260|NCT03917303|DRUG|standard step-up care|conventional step-up care starting with corticosteroids
219723529|NCT03694652|BEHAVIORAL|Diet|Motivating healthy dietary habits
219723530|NCT03694652|OTHER|App|Using an app to deliver communication to the participant.
219723531|NCT03694652|OTHER|Face-to-face|Using in person meetings and/or phone communication with the participant.
219723532|NCT03158311|DRUG|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
219723533|NCT03158311|DRUG|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
219723534|NCT01849809|PROCEDURE|Gamma Ventral Capsulotomy|
219723535|NCT01018953|DRUG|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
219723536|NCT02665455|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
219723537|NCT03331588|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
219723538|NCT03331588|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
219723539|NCT05814497|OTHER|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
219723540|NCT05814497|OTHER|Graphesthesia|Trace numbers on skin.
219723541|NCT05814497|OTHER|Divided attention|Divide attention between two noxious stimuli.
219723542|NCT01922414|DEVICE|Laser|Patients will undergo laser lithotripsy durin PNL
219723543|NCT01922414|DEVICE|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
219723544|NCT02756468|OTHER|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
219151261|NCT01631851|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
219151262|NCT03003624|DEVICE|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
219151263|NCT03003624|DEVICE|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
219151264|NCT03003624|DEVICE|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
219151265|NCT02381470|DRUG|Faropenem|Faropenem 600mg
219151266|NCT02381470|DRUG|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
219151267|NCT02381470|DRUG|Cefadroxil|Cefadroxil 1g
219151268|NCT02381470|DRUG|Rifampicin|Rifampicin 10mg/kg
219723545|NCT06126978|DEVICE|Vibration Therapy (Galileo Dela Interface)|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
219723546|NCT06126978|DEVICE|Mirror Therapy ( Mirror Box)|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
219723547|NCT04393948|RADIATION|Phase 1|Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
219723548|NCT04393948|RADIATION|Phase 1|Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
219723549|NCT04393948|RADIATION|Phase 2|Arm A - No irradiation
219723550|NCT04393948|RADIATION|Phase 2|Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
219723551|NCT04393948|RADIATION|Phase 2|Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
219723552|NCT02622685|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
219723553|NCT02622685|DRUG|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
219723554|NCT02622685|DRUG|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
219723555|NCT02622685|DRUG|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
219151269|NCT04194749|OTHER|Digital Media Based Physical Therapy|This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
219723556|NCT00004897|BIOLOGICAL|recombinant interferon alfa|
219723557|NCT00004897|DRUG|cisplatin|
219723558|NCT00004897|DRUG|fluorouracil|
219151270|NCT04194749|OTHER|Traditional Physical Therapy|This intervention is a 12 week therapist supervised clinic-based therapy protocol.
219151271|NCT00117702|DRUG|Tacrolimus|day 0-100, then taper
219151272|NCT00117702|DRUG|Everolimus|day 0-56
219151273|NCT02390544|DRUG|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
219723559|NCT00004897|DRUG|hydroxyurea|
219151274|NCT00316836|PROCEDURE|mammography|
219723560|NCT00004897|DRUG|leucovorin calcium|
219151275|NCT02473419|DRUG|Vayarin|
219723561|NCT00004897|PROCEDURE|conventional surgery|
219723562|NCT00004897|RADIATION|radiation therapy|
219723563|NCT02452411|BEHAVIORAL|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
219723564|NCT02131688|DRUG|Mitoxantrone Hydrochloride Liposome|
219723565|NCT04115228|DEVICE|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
219723566|NCT04029597|BEHAVIORAL|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
219151276|NCT02473419|DRUG|Placebo|
219151277|NCT02529995|DRUG|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
219151278|NCT02529995|DRUG|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
219151279|NCT01885806|DEVICE|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
219723567|NCT05072951|DIAGNOSTIC_TEST|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
219723568|NCT04510753|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
219723569|NCT04510753|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
219723570|NCT04510753|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
219151280|NCT01885806|DEVICE|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
219151281|NCT06148727|DEVICE|Dental implant placement|Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed
219723571|NCT00645931|BEHAVIORAL|protein and calorie controlled diet and self-hypnotic relaxation|daily
219151282|NCT06148727|DEVICE|Bar attachment|Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
219151283|NCT05744193|OTHER|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
219151284|NCT05090930|DEVICE|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
219151285|NCT05090930|DEVICE|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
219151286|NCT01599117|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
219151287|NCT01599117|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
219151288|NCT05549869|DIAGNOSTIC_TEST|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
219151289|NCT05628493|BEHAVIORAL|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
219151290|NCT05700630|BIOLOGICAL|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
219151291|NCT05700630|DRUG|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
219151292|NCT01998711|BEHAVIORAL|Memory group|Five 1-1.5 hour weekly session of memory training
219151293|NCT03202199|DEVICE|PET/MRI|2 PET/MRI examinations
219151294|NCT02916758|OTHER|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
219151295|NCT01077934|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
219151296|NCT04928248|OTHER|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
219151297|NCT03996278|OTHER|Grafalon|None interventional study but there are two groups
219151298|NCT01032486|DRUG|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
219151299|NCT00137371|DRUG|PVC (daily for 21 days, 7 days off)|
219723572|NCT04253860|DEVICE|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
219723573|NCT00415259|DEVICE|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
219151300|NCT00137371|DRUG|PVC (twice weekly)|
219151301|NCT06108778|DEVICE|MRI|Investigations as CT,MRI.serum ammonia and lactate
219151302|NCT03696966|DIETARY_SUPPLEMENT|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
219151303|NCT03696966|BEHAVIORAL|Low-Calorie Diet|Restrict calorie intake daily
219151304|NCT03696966|BEHAVIORAL|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
219151305|NCT05323266|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
219151306|NCT05323266|DEVICE|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
219151307|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
219723574|NCT00415259|DEVICE|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
219723575|NCT06980337|OTHER|Conventional treatment program|"Ultrasound, hot packs, cervical postural stretching and strengthening exercise will be done for all groups.~Stretching Exercises Posture correction exercises training will include stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles and, sternocleidomastoid.~Strengthening Exercises Exercises will include Chin Tucks exercise and Neck isometric exercises"
219723576|NCT06980337|OTHER|Scapulothoracic exercises|Scapulothoracic exercises It is a strengthening exercises of the serratus anterior muscle, as well as the middle and inferior fibres of the trapezius muscle
219151308|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
219151309|NCT03410966|PROCEDURE|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
219151310|NCT05688644|DEVICE|InterStim II|Sacral neuromodulation
219151311|NCT01090544|DEVICE|Nasal Insufflation|Breathing therapy
219151312|NCT00523237|DRUG|Raltegravir|400 mg Twice daily for 24 weeks
219151313|NCT04352283|DEVICE|Preprocedural ultrasound exam of lumbar spine|Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
219151314|NCT00620997|DRUG|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
219151315|NCT00620997|DRUG|saline drops|saline drops continuously PRN for up to 7 days
219151316|NCT05081570|DEVICE|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
219151317|NCT01698125|PROCEDURE|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
219151318|NCT04395378|DEVICE|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
219151319|NCT00171184|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
219151320|NCT00171184|DRUG|Placebo|Placebo tablet once daily with sham titration
219151321|NCT01472146|DRUG|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
219151322|NCT00819325|DRUG|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
219151323|NCT00819325|DRUG|oral hypoglycemic agents|sulfonylurea or metformin
219151324|NCT03474822|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
219151325|NCT02627183|PROCEDURE|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
219151326|NCT02627183|BEHAVIORAL|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
219723577|NCT06980337|OTHER|Kendall exercises|"The exercise techniques used by Kendell were as follows:~1\. Stretching of the Cervical Extensors: By sitting with the head down and putting both hands across the occipital area, the cervical extensors can be stretched by adopting a flex neck position 2- Strengthening of the Deep Cervical Flexors Positioning supine with the chin tucked in and lifting the head for 2 to 8 s 3- Strengthening the Shoulder Retraction Maintaining an upright posture, keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula 4-Stretching the Pectorals muscle Assigning both hands on the occipital area and pulling the elbows back up (bilateral) and performance arm abduction and external rotation (unilateral)."
219723578|NCT02629302|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
219723579|NCT02629302|OTHER|standard therapy|standard physiotherapy, speech therapy and occupational therapy
219151327|NCT01845532|DRUG|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)
219151328|NCT01845532|DRUG|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
219151329|NCT00233337|DRUG|Co-artemether|
219151330|NCT00623792|BEHAVIORAL|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
219151331|NCT04326192|DEVICE|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
219151332|NCT01120418|DRUG|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
219151333|NCT04910555|OTHER|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
219723580|NCT01928771|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
219151334|NCT03933605|DRUG|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
219151335|NCT03933605|DRUG|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
219151336|NCT02882035|OTHER|OFA|
219151337|NCT01236001|DRUG|Lacosamide|
219151338|NCT05944003|PROCEDURE|Resuscitative thoracotomies|Resuscitative thoracotomies is an effective life saving measure in appropriate populations \[1-8\]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% \[1-8\]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT \[1-
219151339|NCT02840422|DEVICE|ARTHRUM H 2%|ARTHRUM H 2%
219151340|NCT00253110|DRUG|risperidone|
219151341|NCT00253110|DRUG|haloperidol|
219151342|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
219151343|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
219151344|NCT00117936|COMBINATION_PRODUCT|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
219151345|NCT00067353|DRUG|Fluoride varnish|
219151346|NCT01371968|DRUG|alfentanil|Alfentanil is administered intravenously at the end of surgery.
219151347|NCT04272645|DRUG|Abemaciclib 200 MG|200 MG orally BID Days 1-21
219151348|NCT04272645|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
219151349|NCT04272645|DRUG|Abemaciclib 150 MG|150 MG orally BID Days 1-21
219151350|NCT02986269|PROCEDURE|general anesthesia across LMA|general anesthesia across LMA
219151351|NCT02986269|PROCEDURE|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
219151352|NCT02986269|PROCEDURE|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
219151353|NCT04348617|OTHER|Moderate exercise|50 minutes of moderate exercise on treadmill
219151354|NCT04348617|OTHER|Rest|50 minutes of rest or sedentary activity
219151355|NCT05652244|DEVICE|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
219151356|NCT05652244|DEVICE|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
219723581|NCT01928771|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
219723582|NCT03932331|DRUG|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
219723583|NCT04518059|PROCEDURE|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
219151357|NCT01836133|DRUG|Erlotinib 150 mg|
219151358|NCT01674699|DEVICE|EXCOR Pediatric|Ventricular Assist Device
219151359|NCT00024063|DRUG|orantinib|
219151360|NCT04377815|OTHER|General Public cohort|No intervention is being tested
219151361|NCT02883660|GENETIC|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
219151362|NCT01003405|DRUG|KUC-7483|
219151363|NCT05877469|OTHER|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
219151364|NCT05877469|OTHER|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
219151365|NCT05376436|DIAGNOSTIC_TEST|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
219151366|NCT04303325|DRUG|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
219151367|NCT04303325|DRUG|Saline Solution|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
219151368|NCT00003834|DRUG|fluorouracil|
219151369|NCT00003834|DRUG|leucovorin calcium|
219151370|NCT00003834|DRUG|oxaliplatin|
219151371|NCT01717820|DIETARY_SUPPLEMENT|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
219151372|NCT06451016|DIETARY_SUPPLEMENT|Vitamin D supplements|70 mcg/day (equal to 2800 IU) of cholecalciferol
219151373|NCT06451016|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
219723584|NCT06981715|OTHER|Conservative treatment|"Night Splint Resting splint fixing the ankle in neutral position~Worn every night before going to bed, used for 6-8 hours~Objective: To reduce the pressure on the median nerve~Exercise Programme:~Applied 1-2 times a day~Each exercise 10 repetitions, 2 sets~Content:~Nerve mobilisation exercises (median nerve sliding and stretching)~Wrist stretching and flexor-extensor tendon sliding exercises~Finger opening-closing, fist making exercises"
219151374|NCT01891084|DRUG|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
219151375|NCT01891084|DRUG|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
219723585|NCT06981715|OTHER|ESWT|"ESWT Protocol:~Device Radial ESWT device Area of application Wrist volar surface (carpal tunnel area) Parameters Frequency: 5 Hz 4 Bar Number of beats 2000 pulses/session Application time 5-10 minutes per session"
219151376|NCT01891084|DRUG|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
219151377|NCT03437369|DRUG|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
219151378|NCT03437369|OTHER|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
219151379|NCT04217850|OTHER|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
219151380|NCT04217850|OTHER|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
219151381|NCT05845528|DEVICE|s-tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
219151382|NCT05845528|DEVICE|a- tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
219151383|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
219151384|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
219151385|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
219151386|NCT02881203|DEVICE|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
219151387|NCT02881203|DEVICE|RPM|Varian Real-time Position Management (RPM) system
219151388|NCT05475041|PROCEDURE|Major liver resection|Major liver resection (3 or more contiguous segments)
219151389|NCT05475041|PROCEDURE|Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
219151390|NCT04002622|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
219151391|NCT04202393|BEHAVIORAL|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
219151392|NCT04202393|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
219151393|NCT04589520|BEHAVIORAL|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
219151394|NCT03419013|OTHER|New adhesive strip|This strip is made of a newly developed adhesive
219151395|NCT03300492|OTHER|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."
219151396|NCT03855397|OTHER|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
219151397|NCT03855397|OTHER|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
219723586|NCT06981715|OTHER|Kinesiotaping|Kinesio taping was performed with the Button hole technique described by Dr Kenzo Kase. In this technique, a kinesio tape was measured and cut from the medial and lateral epicondyle level on the palmar side of the forearm, from the base of the proximal phalanges to the epicondyles of the humerus on the dorsal side of the forearm. The tape was folded and the midpoint was found, 2 short incisions were made and 2 button holes were obtained through which the 3rd and 4th finger would pass. The paper behind the band was torn and the 3rd and 4th fingers were passed through the holes. The patient's wrist was brought to extension and radial deviation and the tape was glued with a slight (15-25%) tension towards the medial epicondyle on the palmar side of the forearm. Then the wrist was flexed and ulnar deviated and the tape was glued with a slight (15-25%) tension towards the lateral epicondyle.
219723587|NCT01937117|PROCEDURE|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
219723588|NCT01937117|DRUG|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
219723589|NCT01937117|DRUG|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
219151398|NCT03855397|OTHER|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
219151399|NCT04459897|OTHER|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
219151400|NCT04291092|DRUG|Immunotherapy|Immunotherapy for brain metastasis
219151401|NCT04291092|RADIATION|WBRT|local therapy for brain metastasis
219151402|NCT04291092|DRUG|Chemotherapy|Chemotherapy for brain metastasis
219151403|NCT00621569|BEHAVIORAL|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
219151404|NCT00621569|BEHAVIORAL|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
219151405|NCT05083702|PROCEDURE|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
219151406|NCT05083702|PROCEDURE|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
219151407|NCT05157724|PROCEDURE|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
219151408|NCT03941067|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
219151409|NCT02444416|PROCEDURE|blood sample|
219151410|NCT02829931|RADIATION|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
219151411|NCT02829931|DRUG|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
219151412|NCT02829931|DRUG|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
219151413|NCT02829931|DRUG|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
219151414|NCT04160429|PROCEDURE|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
219151415|NCT04160429|OTHER|Medical Chart Review|Review of medical chart
219151416|NCT04160429|OTHER|Questionnaire Administration|Complete questionnaire
219151417|NCT04126707|DRUG|[14C] HQP1351|Orally, single dose of 30mg
219151418|NCT01130194|OTHER|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
219151419|NCT01997944|BIOLOGICAL|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
219151420|NCT01997944|BIOLOGICAL|Pegasys|180 mcg dosing every week
219151421|NCT01943916|DEVICE|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
219151422|NCT01943916|DEVICE|Imagio gray scale ultrasound|gray scale ultrasound alone
219151423|NCT04592250|OTHER|Survey Administration|Complete survey
219151424|NCT03646279|DEVICE|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
219151425|NCT04871750|DIETARY_SUPPLEMENT|Soy protein|Daily consumption for 24 weeks
219151426|NCT04871750|DIETARY_SUPPLEMENT|Casein protein|Daily consumption for 24 weeks
219723590|NCT05722236|BEHAVIORAL|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
219151427|NCT00372450|PROCEDURE|management of therapy complications|
219151428|NCT00372450|PROCEDURE|quality-of-life assessment|
219151429|NCT01366664|DRUG|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
219151430|NCT01366664|DRUG|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
219151431|NCT05274217|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
219151432|NCT03802149|DRUG|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
219151433|NCT02990949|OTHER|Timing of trigger|
219723591|NCT05722236|OTHER|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
219723592|NCT01455519|DRUG|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
219723593|NCT01455519|DRUG|Sugar pill|Sugar pill
219360990|NCT05566002|DIAGNOSTIC_TEST|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
219723594|NCT00193908|DRUG|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
219723595|NCT00193908|DRUG|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
219723596|NCT00193908|RADIATION|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
219151434|NCT06497894|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.
219151435|NCT06497894|DRUG|Hormone Replacement Therapy (HRT)|Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.
219151436|NCT06497894|BEHAVIORAL|Sleep Hygiene|Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
219151437|NCT02261467|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
219151438|NCT02261467|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
219151439|NCT06973044|DEVICE|Checkpoint Cardio wireless continuous monitoring device|Continuous monitoring of respiratory rate and heart rate
219151440|NCT00590551|OTHER|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
219151441|NCT02717117|OTHER|Soup meal|Soup meal as above
219151442|NCT06840574|DIETARY_SUPPLEMENT|Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid|27 mg vitamin C, organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, and calcium stearate
219151443|NCT06840574|DIETARY_SUPPLEMENT|Low Dose Vitamin C|27 mg ascorbic acid
219151444|NCT06840574|DIETARY_SUPPLEMENT|High Dose Vitamin C|500 mg ascorbic acid
219151445|NCT06409286|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow
219151446|NCT03914859|BIOLOGICAL|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
219151447|NCT06647628|DRUG|MK-1708|MK-1708 oral suspension
219151448|NCT06647628|DRUG|Placebo|Placebo oral suspension
219151449|NCT01726842|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
219723597|NCT03065660|DRUG|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
219151450|NCT02781766|OTHER|Thrombin generation measurement.|
219151451|NCT02998450|DRUG|IMR-687|1 of 6 possible single doses administered orally following overnight fast
219151452|NCT02998450|DRUG|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
219151453|NCT06972758|DRUG|Certirobell®|Patients enrolled in the study will initiate oral administration of Certirobell® between 4 to 6 weeks after hepatic resection. The medication will be taken for a duration of 92 weeks, twice daily at approximately 12-hour intervals. The initial dosage is 1.0 mg per dose (twice daily). For patients with a Child-Pugh score of 6, the starting dose will be reduced to 0.75 mg per dose (twice daily). At each visit, the blood concentration of Certirovel will be measured, and the investigator will adjust the dosage as needed to maintain levels within the target range of 3-8 ng/mL. If HCC recurrence is confirmed during treatment, the administration of the drug will be discontinued.
219723598|NCT03065660|DRUG|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
219723599|NCT05486273|OTHER|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
219723600|NCT05486273|OTHER|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
219151454|NCT06974331|BEHAVIORAL|Multimedia Protocol about Asthma Control|Addressing this multifaceted problem is essential for the well-being of individuals and communities worldwide. Therefore, this study aims to evaluate the effect of multimedia protocol about asthma control on asthmatic children's adaptation in the era of climate.
219151455|NCT06150079|PROCEDURE|Pes-Guided PEEP titration|Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (PL = PEEP - Pes). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
219151456|NCT05854433|OTHER|Non-interventional study|No intervention will be administered as part of this study.
219151457|NCT00074633|BEHAVIORAL|Health at Every Size (HAES)|
219151458|NCT00074633|BEHAVIORAL|Diet (Traditional, moderate energy restriction)|
219151459|NCT00704626|OTHER|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
219151460|NCT00704626|OTHER|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
219151461|NCT04890821|DEVICE|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
219151462|NCT02824159|OTHER|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
219151463|NCT02824159|OTHER|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
219151464|NCT02824159|OTHER|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
219151465|NCT02824159|OTHER|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
219151466|NCT02824159|GENETIC|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
219151467|NCT02824159|GENETIC|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
219151468|NCT02824159|OTHER|Biological statement|"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
219151469|NCT02824159|OTHER|Clinical examination|"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
219151470|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
219151471|NCT05566587|OTHER|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
219232794|NCT01596985|PROCEDURE|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
219723601|NCT01271855|DRUG|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
219723602|NCT01271855|DRUG|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
219151472|NCT04139538|PROCEDURE|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
219151473|NCT00301990|BIOLOGICAL|aldesleukin|
219151474|NCT00301990|BIOLOGICAL|bevacizumab|
219151475|NCT00415389|BEHAVIORAL|interactive educational program|2-session interactive stroke educational program
219151476|NCT00415389|BEHAVIORAL|usual medical care|standard educational materials and usual care
219151477|NCT00603356|DRUG|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
219151478|NCT03140735|OTHER|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
219151479|NCT03140735|OTHER|Control group without heart disease|Control group without heart disease
219232795|NCT02684656|PROCEDURE|Hemodialysis|Hemodialysis \>/=4h
219232796|NCT02684656|PROCEDURE|Hemodiafiltration|Hemodiafiltration \>/=4h, \> 20l convection
219723603|NCT02528227|OTHER|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
219723604|NCT02528227|OTHER|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
219723605|NCT02528227|OTHER|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
219723606|NCT02528227|OTHER|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
219723607|NCT02528227|OTHER|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
219723608|NCT02528227|OTHER|Feeding Safety|Part of Health and Safety Curriculum
219723609|NCT02528227|OTHER|Car Seat Safety|Part of Health and Safety Curriculum
219723610|NCT02528227|OTHER|Bath Safety|Part of Health and Safety Curriculum
219723611|NCT02528227|OTHER|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
219723612|NCT02528227|OTHER|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
219723613|NCT02528227|OTHER|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
219723614|NCT04979013|OTHER|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
219723615|NCT01617109|DIETARY_SUPPLEMENT|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
219723616|NCT01617109|OTHER|Placebo|administered as 5 pills daily or as 2 snack bars
219723617|NCT03910946|DRUG|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
219723618|NCT06381843|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
219723619|NCT06381843|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
219723620|NCT06569355|DRUG|VCT220|A small molecule GLP-1R agonist tablet, orally administration, once daily
219723621|NCT06569355|DRUG|Placebo|Placebo tablet
219723622|NCT06811844|DRUG|Two-cycle induction chemotherapy + immunotherapy|Two cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
219723623|NCT06811844|DRUG|Three-cycle induction chemotherapy + immunotherapy|Three cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
219723624|NCT05382962|BEHAVIORAL|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
219723625|NCT04211896|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
219723626|NCT04211896|DRUG|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
219723627|NCT04663516|OTHER|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
219723628|NCT00097968|DRUG|everolimus|
219723629|NCT03844737|DEVICE|VisuXL®|Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
219723630|NCT04705753|DIETARY_SUPPLEMENT|Cretan IAMA|Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
219723631|NCT05877105|OTHER|Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle|VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
219723632|NCT06298149|BEHAVIORAL|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
219723633|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
219723634|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
219723635|NCT03092232|DRUG|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
219723636|NCT03092232|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
219723637|NCT02150005|PROCEDURE|Periodontal treatment|
219723638|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
219723639|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
219232797|NCT00299676|DRUG|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
219232798|NCT02035852|OTHER|MRI|3T MRI vs. 7T MRI
219232799|NCT00520663|DRUG|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
219723640|NCT03658967|DRUG|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
219151480|NCT05663918|BEHAVIORAL|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
219151481|NCT04441593|BEHAVIORAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
219151482|NCT04441593|BEHAVIORAL|Treatment as Usual|Psychoeducation and Information about Treatment Resources
219151483|NCT04021381|DIETARY_SUPPLEMENT|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
219151484|NCT04021381|DIETARY_SUPPLEMENT|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
219151485|NCT01850017|DRUG|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
219151486|NCT01514734|DRUG|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
219151487|NCT04861012|DEVICE|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
219151488|NCT00815750|OTHER|Information Gathering|An information gathering phase leading to development of a new decision aid.
219151489|NCT00815750|OTHER|Decision Aid|To test the newly developed decision aid.
219151490|NCT01535833|PROCEDURE|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
219232800|NCT02464072|PROCEDURE|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
219232801|NCT02464072|PROCEDURE|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
219723641|NCT03658967|DRUG|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
219723642|NCT06988488|DRUG|Elranatamab|Specified dose on specified days
219723643|NCT06988488|DRUG|Mezigdomide|Specified dose on specified days
219151491|NCT02747602|DRUG|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
219151492|NCT02747602|DRUG|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
219151493|NCT02747602|DRUG|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
219151494|NCT01787760|DEVICE|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
219151495|NCT01787760|DEVICE|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
219151496|NCT01787760|DEVICE|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
219151497|NCT03512756|DRUG|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
219151498|NCT03512756|DRUG|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
219151499|NCT04291586|OTHER|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
219151500|NCT04291586|OTHER|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
219151501|NCT02726490|DRUG|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
219151502|NCT02726490|DRUG|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
219151503|NCT00060099|BIOLOGICAL|HspE7|
219232802|NCT02464072|PROCEDURE|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
219232803|NCT02167191|BEHAVIORAL|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
219723644|NCT06988488|DRUG|Dexamethasone|Specified dose on specified days
219723645|NCT01952951|DRUG|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
219723646|NCT01952951|RADIATION|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
219723647|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
219723648|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
219723649|NCT04863521|OTHER|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
219723650|NCT01452347|DRUG|warfarin 1mg|comparator warfarin
219723651|NCT01452347|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
219723652|NCT01452347|DRUG|dabigatran etexilate low dose|active treatment (low)
219723653|NCT01452347|DRUG|warfarin 5mg|comparator warfarin
219723654|NCT01452347|DRUG|dabigatran etexilate high dose|active treatment (high)
219723655|NCT01452347|DRUG|warfarin 3mg|comparator warfarin
219723656|NCT02265835|OTHER|no intervention|no intervention
219723657|NCT06862960|DRUG|Ozanimod|A sphingosine-1-phosphate receptor regulator
219723658|NCT06862960|DRUG|Conventional medication|Conventional medications for moderate AD
219723659|NCT06998199|OTHER|Dual Task Balance Exercise|"The content of the DT training is summarized below with 30 minutes of routine PT. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.~1. Walking 3 m on hard/soft ground while performing a motor task (carrying an empty box) and then combined with a cognitive task (saying the names of some fruits and vegetables),~2. Sitting on a Pilates ball for 1 min with eyes open/closed while performing a motor task (arms flexed to 90 degrees) and then combined with a cognitive task (saying the names of friends)~3)2-feet Jumping forward with both feet for 3 m while performing a motor task (carrying an empty box) then with a cognitive task (naming the colors in the room)~4)Standing on one leg for 30 s while arms abducted to 90 degrees and then combined with a cognitive task (saying the names of relatives)~5)Sit-to-stand using a stool 15 repetitions with a motor task (carrying an empty box) and then with a cognitive task (saying the names vegetables etc)"
219151504|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
219151505|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
219151506|NCT00736853|DRUG|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
219723660|NCT06998199|OTHER|Vestibular Stimulation|The child will place in sitting position on the swing and his hands grasping the ropes at the sides then the therapist stand behind him and begin pushing the platform in fast and jerky movement in back and front, side to side and in spinning directions with the child trying to maintain his balance in all different directions. The subject will receive pushing for each direction for five minutes; the total mechanical vestibular session duration was 15 minutes with 30 minutes of routine physical therapy. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.
219151507|NCT03566186|OTHER|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
219151508|NCT03566186|OTHER|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
219151509|NCT03566186|OTHER|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
219151510|NCT03419325|GENETIC|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
219723661|NCT06675708|DIETARY_SUPPLEMENT|Creatine|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups
219723662|NCT06675708|DIETARY_SUPPLEMENT|Dextrose|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
219723663|NCT07008638|DRUG|Bortezomib|Bortezomib at assigned study dose in mg/m2 will be given subcutaneously on days 1, 4, 8, and 11
219723664|NCT07008638|DRUG|CPX-351|CPX-351 given intravenously on day 1, 3, and 5
219723665|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
219723666|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
219723667|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
219151511|NCT03419325|DIAGNOSTIC_TEST|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
219723668|NCT07012343|RADIATION|Photodynamic Therapy with Conventional Methylene Blue|Methylene Blue mediated photodynamic therapy
219723669|NCT07012343|DRUG|urea 40% cream|40% Urea cream with occlusion
219723670|NCT07015671|DRUG|10 mg Torsemide tablet|Single dose 10 mg Torsemide tablet
219723671|NCT07015671|DRUG|25 mg Aldactone (Spironolactone) tablet|Single dose 25 mg Aldactone® (Spironolactone) tablet
219723672|NCT07015671|DRUG|FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet|Single dose FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet
219151512|NCT00092937|DRUG|Busulfan|
219723673|NCT03119974|DRUG|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
219723674|NCT04356924|BEHAVIORAL|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
219723675|NCT04356924|BEHAVIORAL|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
219723676|NCT04174261|DRUG|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
219723677|NCT04174261|PROCEDURE|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
219723678|NCT04174261|DRUG|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
219723679|NCT07046182|BIOLOGICAL|CEP + Dasatinib + Azacitidine|CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma
219723680|NCT07044869|PROCEDURE|FACILITATED POSITIONAL RELEASE TECHNIQUE|Participants in experimental group A receive FPRT as a main intervention along with piriformis stretches. 30 minutes' session starts with application of 10 minutes hot pack, followed by FPRT and stretches respectively. For FPRT, the patient position was prone with the hip flexion approximately (60°-90°) and abduction. The therapist was seated on the side that was affected, and the treated leg was hanging off the table with the knee bent resting on the therapist thigh. The painful tender area was felt in the piriformis muscle's belly around midway between the greater trochanter and the inferior lateral angle of sacrum. At the point when tender area was palpated, therapist applied ischemic pressure over the area with finger pads. Pressure hold for 1 minute and two repetitions were performed (2 minutes' pressure for whole was given). After that piriformis stretches were performed with 5reps\*5 sec hold\*1set.
219151513|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
219151514|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
219151515|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
219151516|NCT00917241|DRUG|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
219232804|NCT00587756|PROCEDURE|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
219232805|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
219232806|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
219232807|NCT00813709|DRUG|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
219232808|NCT00813709|DRUG|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
219723681|NCT07044869|PROCEDURE|MANUAL MYOFASCIAL RELEASE TECHNIQUE|Experimental Group B participants received MFRT as a main intervention along with application of hot pack and piriformis stretches. They also received 30 min session started with application of hot pack for 10 minutes followed by MFRT and piriformis stretches. For application of MFRT patient was in prone lying position. The therapist was standing at the affected/unaffected side of the patient. Myofascial release was provided, using the therapist's palm, finger pads or elbow directly on the piriformis muscle, pressure was provided on the tender area directly and held for a while (60 seconds approx.) and 3 repetitions were performed. Back and forth little kneading motions were applied in accordance with the muscle fiber's direction. After MFRT piriformis stretches were performed with frequency of 5 repetitions \*5 second hold\* 1 set.
219723682|NCT07044895|OTHER|Diode laser and Immediate implant|patients with non-restorable teeth in the maxillary esthetic zone will be included in this prospective single-arm study. The non-restorable tooth will be atraumatically extracted and immediate implant placement will be placed. The extraction socket will be sealed with diode laser photocoagulation and customized healing abutments fabrication.
219723683|NCT07049133|OTHER|T-DXd toxicity marker identification|to find potential predictive markers associated with T-DXd-related toxicities
219723684|NCT07046052|OTHER|continuous infusion of levobupivacaine|Participants in this arm will receive a continuous infusion of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both arms of the study.
219232809|NCT03627156|BEHAVIORAL|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
219723685|NCT07046052|OTHER|Programmed Intermittent Bolus of Levobupivacaine|Participants in this arm will receive a timed pre-set bolus dose of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both groups.
219723686|NCT07046546|PROCEDURE|Thyroid artery embolization|A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules
219232810|NCT02753075|DEVICE|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
219232811|NCT02753075|DEVICE|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
219723687|NCT07045272|BEHAVIORAL|Experimental|The intervention team provides lifestyle guidance to the subjects according to the behavioural intervention programme, and the subjects record information on diet, exercise and weight on the platform on a daily basis. Subjects are required to learn relevant health education knowledge on the platform by themselves, and they can also exchange experience in the group and receive motivational counselling from the instructors.
219723688|NCT07045610|DIAGNOSTIC_TEST|re-biopsy tumor with primary ALK tKI resistance for NGS|Lung cancer patients who initially use ALK TKI as first-line treatment will be invited to enroll and sign the consent form. Only those who meet the criteria for primary resistance or rapid progression will proceed with tumor sample collection for genetic analysis. Alternatively, patients who develop primary resistance or rapid progression after using ALK TKI and are about to undergo tumor re-biopsy can also sign the subject consent form to be included in this study.
219151517|NCT00917241|DRUG|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
219232812|NCT02753075|OTHER|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
219723689|NCT07044505|PROCEDURE|Uterine Lavage|Saline is introduced into the uterine cavity and retrieved during surgery to collect cells and fluid for downstream molecular and cellular analyses.
219232813|NCT02753075|DRUG|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
219723690|NCT07048184|DEVICE|Negative Pressure Wound Therapy (NPWT) Dressings|During wound closure, skin glue is not permitted as this interferes with the NPWT suction mechanism. The NPWT is a mesh-based dressing that will be applied following the transparent occlusive dressing as per the manufacturer's instructions. Patients assigned to NPWT will have their dressing connected to a suction device (ActiV.A.C.®, KCI) providing a constant negative pressure of 125mmHg and left in situ for between 5 and 7 days. The dressings and suction device are all CE-marked medical devices that are being used within their intended usage.
219723691|NCT07048184|DEVICE|Standard Absorbent Dressings|The wound will be closed as per the standard surgical technique and the operating surgeon's preference. Following wound closure of sarcoma tumour resection, standard absorbent dressing will be applied as per local protocols and the pre-op plan
219723692|NCT07049809|COMBINATION_PRODUCT|Focal Muscle Vibration|"The focal vibration machine will be used. The device has 6 muted transducers that generate power between 30-300 Hz, but for this study we will use between 100-150 Hz for 30 minutes.~The application of the 6 transducers or heads is at the level of the lower extremities, since those muscle groups present the most clinical correlation with functional parameters such as gait and balance. 3 transducers will be placed on one leg (vastus medialis, vastus lateralis and rector anterior) and the other 3 transducers on the other leg, on the same muscles. To speed up the intervention program and cover more participants, 4 focal vibration machines will be used. Each participant wil use 1 machine and 6 transducers, so during the 30 minutes that the intervention lasted, the groups will be of 4 participants with t"
219723693|NCT07049809|OTHER|Multicomponent Exercise|The program consists of a multi-component approach, integrating aerobics, resistance, and balance training. The weekly schedule include three intervention days: one day focused on aerobic exercise, one day dedicated to resistance training and one day centered on balance training. The combined program is individualized based on the intrinsic capabilities of each individual.
219723694|NCT07052071|PROCEDURE|TAVI|Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive method for replacing the aortic valve in patients with severe aortic stenosis. The procedure involves the placement of a bioprosthetic valve within the patient's degenerated aortic valve via a catheter.
219723695|NCT07052526|OTHER|Prevention|Conventional Hydrophobic Sealant (Helioseal F - Control) will be used as a positive control; applied to partially erupted molars with and without bonding in a split-mouth design.
219151518|NCT03319706|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
219151519|NCT03319706|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
219151520|NCT01607372|DRUG|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
219232814|NCT04151147|PROCEDURE|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
219232815|NCT04151147|PROCEDURE|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
219151521|NCT01607372|DEVICE|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
219151522|NCT01607372|OTHER|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
219151523|NCT00551876|DRUG|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
219151524|NCT00551876|DRUG|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
219151525|NCT06392633|PROCEDURE|spastic hand sugery|Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
219151526|NCT06392633|DRUG|Botulinum Toxin A|Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
219151527|NCT03942835|OTHER|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
219151528|NCT03942835|OTHER|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
219151529|NCT03942835|OTHER|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
219151530|NCT02336776|OTHER|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
219151531|NCT04666857|OTHER|early motor intervention|infants with CHD after open heart surgery will receive early intervention
219151532|NCT01964937|BIOLOGICAL|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
219151533|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
219151534|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
219151535|NCT01964937|BIOLOGICAL|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
219151536|NCT01964937|BIOLOGICAL|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
219151537|NCT00297674|DRUG|Intravenous Clarithromycin|
219151538|NCT00035841|DRUG|TLK286|
219151539|NCT01779999|OTHER|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
219151540|NCT06248788|DEVICE|PoC Device|PoC Device for Testing Salivary IgA
219232816|NCT00941447|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
219232817|NCT00941447|BEHAVIORAL|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
219723696|NCT07052526|OTHER|Prevention of caries|Embrace WetBond sealant will be applied to partially erupted first permanent molars using a split-mouth design with and without bonding agent.
219723697|NCT07052526|OTHER|Prevention therapy|DENU Seal applied using a split-mouth design to evaluate bonding and non-bonding application outcomes from retention and caries prevention
219723698|NCT07052201|DRUG|Dexamethasone|"DART regimen group (cumulative dose 0.89 mg/kg over 10 days): intravenous dexamethasone administered as follows:~0.075 mg/kg/dose every 12 hours for 3 days 0.05 mg/kg/dose every 12 hours for 3 days 0.025 mg/kg/dose every 12 hours for 2 days 0.01 mg/kg/dose every 12 hours for 2 days, then discontinue.~If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
219723699|NCT07052201|DRUG|Dexamethasone|"Low-dose tapering regimen group (cumulative dose 0.45 mg/kg over 3 days): intravenous dexamethasone administered as follows:~0.1 mg/kg/dose every 12 hours on Day 1 0.075 mg/kg/dose every 12 hours on Day 2 0.05 mg/kg/dose every 12 hours on Day 3 If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
219723700|NCT07052201|DRUG|Dexametasone|"Medium-dose tapering regimen group (cumulative dose 2.35 mg/kg over 7 days): intravenous dexamethasone administered as follows:~0.5 mg/kg/dose once daily for 3 days 0.25 mg/kg/dose once daily for 3 days 0.1 mg/kg/dose once daily for 1 day If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
219723701|NCT07052409|DIETARY_SUPPLEMENT|Inkomazi|Pasteurized fermented milk
219723702|NCT07057440|OTHER|High-dose Nicotine Pouch|"A High Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions.~After 20 minutes pouches are removed from the oral cavity and disposed."
219723703|NCT07057440|OTHER|Low Dose Nicotine Pouch|A Low Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
219723704|NCT07057440|OTHER|Placebo Pouch|A Placebo Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
219723705|NCT07056491|OTHER|mRNA level of REST4 in serum;|"1. mRNA level of REST4 in serum The mRNA expression level of REST4 was measured in serum-derived exosomes using RT-qPCR at the time of patient enrollment.~2. Computed tomography angiography (CTA) Baseline maximum internal diameter of the abdominal aortic aneurysm (AAA) was determined by CTA at enrollment. During follow-up, CTA was performed to assess the increase in maximum AAA diameter."
219734765|NCT06756165|BEHAVIORAL|Mental health screening|Participants in the intervention arm will receive a mental health screening, referral, and counselling program by trained LHWs and BHU staff. LHWs will screen 120-170 WRA using PHQ-2 and GAD-2. Screen-positive WRA will be referred to BHUs, where trained doctors will reassess them using PHQ-9 and GAD-7. Those with mild to moderate anxiety or mild to moderately severe depression will receive two counselling sessions (initial and follow-up), each lasting at least 20 minutes, covering psychoeducation, awareness, and coping strategies. Severe cases will be referred to tertiary care for specialized mental health services. Mild cases will be advised to join resilience-building sessions. All WRA will attend two of three monthly group sessions by LHWs (20-25 WRA, 2 hours each), focusing on mental health literacy and coping strategies, including those related to climate change stressors like floods.
219723706|NCT07055776|COMBINATION_PRODUCT|non-invasive vagus nerve stimulation (nVNS)|Group 1 will receive non-invasive vagus nerve stimulation (nVNS) targeting the auricular branch of the vagus nerve (ABVN) using a TENS device with specialized ear clip electrodes. The electrodes will be placed on the cymba conchae or tragus region of the ear, where the ABVN is accessible. The stimulation parameters will be set to a frequency of 1 Hz (significantly reduced migraine headache), pulse width of 200-300 µs, and intensity adjusted to a strong but comfortable level without causing pain, applied for 15-30 minutes per session, 5 days a week for 12 weeks, based on protocols supported by evidence from studies such as Badran et al. (2018) and Yakunina et al. (2017), which demonstrated positive neuromodulatory effects through auricular stimulation. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
219723707|NCT07055776|COMBINATION_PRODUCT|non-invasive transcutaneous electrical nerve stimulation (TENS)|Group 2 will receive non-invasive transcutaneous electrical nerve stimulation (TENS) applied to the other areas to target other nerves stimulation (e.g., neck, upper trapezius, or occipital area). Surface electrodes will be placed paravertebrally, using a conventional TENS protocol: frequency of 20-25 Hz, pulse width of 200-300 µs, and intensity set to produce a strong but comfortable tingling sensation without muscle contraction. Each session will last 20-30 minutes, administered 5 days a week for 12 weeks. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
219723708|NCT07056231|DIETARY_SUPPLEMENT|Caffeine|A single oral dose of 3 mg of caffeine per kilogram of body weight form approximately 60 minutes before performance testing. Supplied by Oxford Vitality, ISO-certified.
219723709|NCT07056231|DIETARY_SUPPLEMENT|Placebo|polydextrose used as Placebo
219723710|NCT07056582|DRUG|Dexmedetomidine|patients in this group will receive nebulized Dexmedetomidine before onset of surgery
219151541|NCT05135013|DRUG|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration"
219151542|NCT02202395|DRUG|LTS 0.25mg|use LTS 0.25mg/d
219151543|NCT02202395|DRUG|LTS 0.5mg|use LTS 0.5mg/d
219151544|NCT02202395|DRUG|LTS 1.0mg|use LTS 1.0mg/d
219151545|NCT02202395|DRUG|Placebo|use placebo once daily
219151546|NCT04586686|PROCEDURE|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
219151547|NCT04586686|PROCEDURE|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
219151548|NCT01441934|DRUG|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
219151549|NCT01441934|DRUG|Sugar pills|placebo t.i.d.
219151550|NCT02439827|BEHAVIORAL|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
219151551|NCT04759066|DEVICE|HEALiX|HEALiX is a non-restraint patient safety device
219151552|NCT00222326|BEHAVIORAL|Pelvic floor muscle training and lifestyle modification|
219232818|NCT00941447|BEHAVIORAL|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
219723711|NCT07056582|DRUG|Ketamine|patients in this group will receive nebulized ketamine before onset of surgery
219723712|NCT07056582|DRUG|0.9%sodium chloride|patients in this group will receive nebulized 0.9% normal saline before onset of surgery
219723713|NCT07056699|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (10 mg/day)
219151553|NCT01970891|DEVICE|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
219151554|NCT01892553|DEVICE|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
219151555|NCT00010309|BIOLOGICAL|MART-1 antigen|
219151556|NCT00010309|BIOLOGICAL|gp100 antigen|
219151557|NCT00570219|DRUG|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
219151558|NCT00030888|DRUG|7-hydroxystaurosporine|
219723714|NCT07056699|DRUG|Pioglitazone 15 MG and 30mg|Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)
219723715|NCT07056699|OTHER|Placebo|Inert placebo for Pioglitazone
219723716|NCT07057206|DEVICE|PFM-guided cortical stimulation|Abbott Eterna IPG and Lamitrode 44 paddles with accessory extensions and clinical programmers
219723717|NCT07057349|DRUG|[18F]CSB-321|\[18F\]CSB-321 is a PET imaging agent that is bound to released granzyme B from T-cells
219723718|NCT07056075|DEVICE|Nasal PAP Ventilation System|medical devices that provide nasal positive airway pressure ventilation during endoscopy
219723719|NCT07056075|DEVICE|Low Flow Oxygen|low flow oxygen though nasal cannula
219151559|NCT04618614|DEVICE|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
219232819|NCT00942500|PROCEDURE|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
219151560|NCT04618614|DEVICE|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
219232820|NCT00392652|DRUG|oral microencapsulated diindolylmethane|Given PO
219232821|NCT00037934|DEVICE|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
219232822|NCT00037934|OTHER|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
219232823|NCT04195919|DRUG|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
219232824|NCT04195919|DRUG|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
219723720|NCT07056075|DEVICE|Capnometry|capnometry measurement
219723721|NCT07055672|COMBINATION_PRODUCT|Modified WalkFlex DB Splint (Intervention Arm)|"Application of the Modified WalkFlex Denis Browne (DB) Splint~Children with corrected idiopathic clubfoot will use the Modified WalkFlex DB Splint for maintenance. This splint allows knee and some hip movement and includes a detachable bar for walking. It will be used after Ponseti casting, and patients will be followed at 1 and 3 months to check splint tolerance, maintenance of correction (using Pirani score), and any signs of relapse"
219232825|NCT04372732|DIAGNOSTIC_TEST|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
219723722|NCT07055880|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
219723723|NCT07055880|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
219723724|NCT07056569|DEVICE|047_TD Dermatitis cream twice a day for 28 days|047\_TD Dermatitis cream will be applied twice a day for 28 days on the affected skin zone in sufficient amount of cream and let it dry.
219723725|NCT07055893|BIOLOGICAL|Rabies vaccine|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
219723726|NCT07055893|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
219723727|NCT07055737|COMBINATION_PRODUCT|supervised aerobic activities|Participants performed supervised aerobic activities including warm-up (15 min), brisk walking, jogging, or cycling (30 min), squats on exercise ball (10 min), and cool down (5 min). Sessions were conducted three times a week
219723728|NCT07055737|COMBINATION_PRODUCT|Barre group performed light warm-up|Barre group performed light warm-up (15 min), lower abdominal crunches, leg raises, wall push-ups, and planks (3 sets each), followed by cool-down stretches (5 min). Sessions were conducted three times a week.
219723729|NCT02591368|PROCEDURE|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
219723730|NCT02591368|PROCEDURE|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
219723731|NCT02591368|PROCEDURE|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
219723732|NCT06933472|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.7g to 9.0g
219151561|NCT04618614|DEVICE|Sham control|Sham stimulation of the right primary somatosensory cortex
219151562|NCT00461747|DRUG|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
219151563|NCT00461747|DRUG|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
219151564|NCT00461747|DRUG|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
219151565|NCT04301635|PROCEDURE|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
219723733|NCT06933472|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g
219723734|NCT05642325|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
219723735|NCT05642325|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
219734766|NCT01903200|DRUG|FK949E|Oral
219734767|NCT04177199|OTHER|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
219151566|NCT05729672|BEHAVIORAL|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
219723736|NCT07125105|BEHAVIORAL|Adapted Physical Activity Only|This intervention consists of 10 individual Adapted Physical Activity (APA) sessions over five weeks, each lasting 45 to 60 minutes. Sessions are delivered by a trained APA instructor and focus on muscle strengthening, endurance, and body awareness. Exercises are tailored to the functional capacities and fatigability of patients living with Myasthenia Gravis. The delivery format includes a mix of in-person and remote sessions, with individualized adaptation based on patient needs.
219723737|NCT07125105|BEHAVIORAL|Adapted Physical Activity + Art Therapy|This intervention includes 10 individualized sessions of APA integrated with movement-based Art Therapy, delivered over five weeks (45-60 minutes each). The program incorporates creative and expressive methods (e.g., role play, improvisation, dramatized movement, dramatherapy) within a therapeutic physical activity framework. It is designed to support both physical functioning and psychosocial well-being. The artistic dimension is adapted to the patients' preferences and capacities, as identified during the baseline anamnesis interview.
219723738|NCT06152081|DEVICE|LumiCare rinse|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.
219151567|NCT04653935|BEHAVIORAL|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
219151568|NCT04653935|BEHAVIORAL|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
219151569|NCT05082714|DRUG|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
219151570|NCT05082714|DRUG|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
219151571|NCT00976625|PROCEDURE|Aortic Valve Replacement|Surgical valve replacement of the aorta
219151572|NCT01041417|DRUG|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
219151573|NCT01041417|DRUG|Placebo|Saline injection
219151574|NCT02113072|DRUG|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
219151575|NCT02113072|DRUG|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
219151576|NCT02113072|DRUG|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
219151577|NCT03226899|DRUG|Lesinurad|200 mg oral tablet
219151578|NCT03226899|DRUG|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
219151579|NCT03226899|DRUG|Placebo|matching placebo oral tablet
219151580|NCT03226899|DRUG|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
219151581|NCT03226899|DRUG|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
219151582|NCT02299375|DRUG|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
219151583|NCT02299375|DRUG|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
219151584|NCT02299375|DRUG|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
219151585|NCT02108236|DEVICE|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
219151586|NCT03760627|BEHAVIORAL|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
219151587|NCT03760627|BEHAVIORAL|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
219723739|NCT06152081|DEVICE|QLF Inspektor Pro Imaging|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
219151588|NCT03618134|BIOLOGICAL|Durvalumab|Given IV
219151589|NCT03618134|PROCEDURE|Modified Radical Neck Dissection|Undergo modified radical neck dissection
219151590|NCT03618134|OTHER|Quality-of-Life Assessment|Ancillary studies
219232826|NCT02245620|DRUG|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
219232827|NCT02245620|DRUG|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
219232828|NCT04528602|PROCEDURE|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
219232829|NCT04528602|PROCEDURE|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
219232830|NCT00101387|OTHER|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
219232831|NCT00101387|OTHER|Lumbar PENS|As above
219232832|NCT00101387|OTHER|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
219232833|NCT00101387|OTHER|Control PENS + exercise|as above
219232834|NCT01040299|DEVICE|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
219232835|NCT01040299|DEVICE|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
219723740|NCT02896842|DRUG|Posology dose modification|
219151591|NCT03618134|OTHER|Questionnaire Administration|Ancillary studies
219151592|NCT03618134|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219151593|NCT03618134|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
219723741|NCT02896842|OTHER|active comparator|
219151594|NCT03618134|BIOLOGICAL|Tremelimumab|Given IV
219232836|NCT01040299|OTHER|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
219723742|NCT05492240|OTHER|i-STRONGER|An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
219734768|NCT02473874|DEVICE|Skin Spect dermoscope|Skin imaging
219151595|NCT05184946|DRUG|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
219734769|NCT02473874|DEVICE|Spatially modulated quantitative|Skin imaging
219734770|NCT05611736|OTHER|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
219151596|NCT03093298|OTHER|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
219151597|NCT06193005|OTHER|no intervention|no intervention
219151598|NCT02840006|PROCEDURE|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
219151599|NCT02840006|PROCEDURE|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
219151600|NCT00704184|DRUG|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
219151601|NCT00704184|DRUG|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
219151602|NCT00704184|DRUG|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
219151603|NCT00704184|DRUG|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
219151604|NCT00866203|DRUG|HDS vs ProMECE/CytaBOM|
219151605|NCT00666068|OTHER|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
219723743|NCT05492240|OTHER|Usual Care|Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
219723744|NCT02642679|DEVICE|Opticell Ag|Opticell Ag+ applied to STSG donor site
219151606|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
219151607|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
219151608|NCT00592241|DEVICE|"Adi Insulin Pump Usability"|no intervention
219151609|NCT04781439|PROCEDURE|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
219151610|NCT02378155|DEVICE|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
219151611|NCT01764464|DRUG|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
219151612|NCT01764464|DRUG|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
219151613|NCT03995498|OTHER|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
219151614|NCT03995498|OTHER|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
219151615|NCT03995498|OTHER|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
219151616|NCT03039361|BEHAVIORAL|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
219151617|NCT01388881|OTHER|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
219151618|NCT02701257|DEVICE|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
219723745|NCT02763748|PROCEDURE|Laparoscopic endoscopy combined surgery|
219151619|NCT02701257|DEVICE|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
219151620|NCT02701257|DRUG|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
219151621|NCT02701257|DRUG|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
219151622|NCT02701257|DEVICE|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
219151623|NCT02701257|DEVICE|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
219151624|NCT03366636|BEHAVIORAL|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1\. Thinking about the future~* 2\. Present actions to achieve future success~* 3\. Safeguarding one's future~* 4\. Creating a Healthy Life Plan~* 5\. Navigating service systems"
219723746|NCT02763748|PROCEDURE|laparoscopic and endoscopic cooperative surgery|
219723747|NCT02763748|PROCEDURE|Single-arch laparoscopic and endoscopic cooperative surgery|
219723748|NCT04411095|OTHER|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
219723749|NCT02148770|DEVICE|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
219723750|NCT01454557|OTHER|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
219723751|NCT00371631|BIOLOGICAL|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
219723752|NCT03930108|OTHER|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
219151625|NCT02118675|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
219151626|NCT02118675|OTHER|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
219151627|NCT02118675|OTHER|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
219151628|NCT02118675|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
219151629|NCT02118675|OTHER|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
219151630|NCT02118675|OTHER|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
219151631|NCT02118675|OTHER|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
219232837|NCT04706442|OTHER|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
219232838|NCT02166723|DEVICE|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
219723753|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
219723754|NCT01112267|DRUG|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
219151632|NCT02487927|BEHAVIORAL|weaning|T piece
219151633|NCT02147054|DRUG|Rocuronium|
219151634|NCT02147054|DRUG|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
219151635|NCT00765271|DRUG|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
219151636|NCT00765271|DRUG|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
219151637|NCT00765271|DRUG|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
219723755|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
219723756|NCT01112267|DRUG|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
219723757|NCT02731859|DEVICE|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
219723758|NCT05378542|BEHAVIORAL|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
219723759|NCT03889795|DRUG|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
219723760|NCT03889795|DRUG|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
219723761|NCT03889795|DRUG|Digoxin|Digoxin oral pill will be taken once daily.
219723762|NCT04103606|DEVICE|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
219723763|NCT04566731|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
219723764|NCT04566731|DEVICE|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
219734771|NCT05611736|OTHER|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
219734772|NCT04017975|DRUG|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
219151638|NCT01735019|DRUG|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
219151639|NCT01047852|PROCEDURE|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
219151640|NCT03187860|PROCEDURE|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
219151641|NCT03187860|OTHER|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
219151642|NCT02738320|OTHER|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
219151643|NCT04600440|BIOLOGICAL|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
219151644|NCT04578496|DRUG|Afamelanotide|
219151645|NCT05357469|DEVICE|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
219151646|NCT05357469|DEVICE|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
219151647|NCT00174434|DRUG|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
219151648|NCT00174434|DRUG|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
219151649|NCT06075212|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
219151650|NCT00253734|BIOLOGICAL|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
219151651|NCT00253734|BIOLOGICAL|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
219151652|NCT02694666|OTHER|Controlled whole-body vibration training|The intervention is an 8-week program
219151653|NCT00150241|DRUG|CP-526,555 (varenicline)|
219151654|NCT04916145|DEVICE|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
219151655|NCT02697877|DRUG|Regadenoson|
219151656|NCT03473340|DRUG|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
219151657|NCT03473340|DRUG|Placebo Capsule|"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
219151658|NCT05362110|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
219151659|NCT05362110|DRUG|RLD2002|Take it once daily for 8 weeks orally.
219151660|NCT05362110|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
219151661|NCT05362110|DRUG|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
219151662|NCT02163252|BEHAVIORAL|Standard|
219151663|NCT02163252|BEHAVIORAL|Early Intervention|
219151664|NCT03322124|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
219734773|NCT04017975|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
219151665|NCT03322124|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
219151666|NCT02299752|PROCEDURE|single-gloving system|single-gloving system was used during Catheterization
219151667|NCT02299752|PROCEDURE|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
219151668|NCT01495624|OTHER|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
219151669|NCT01495624|OTHER|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
219151670|NCT06331494|DRUG|Butylphthalide|Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
219151671|NCT06331494|DRUG|Placebo|Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
219151672|NCT06521541|BEHAVIORAL|Multimodal prehabilitation program|Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
219151673|NCT06521541|BEHAVIORAL|ERAS program|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
219151674|NCT05239650|DRUG|HLX07|1000mg
219151675|NCT05239650|DRUG|HLX10|200mg
219151676|NCT05239650|DRUG|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
219151677|NCT00040313|DRUG|pegaptanib sodium (Macugen)|
219151678|NCT02245555|DRUG|Tamsulosin|
219151679|NCT01608347|DRUG|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
219151680|NCT01608347|DRUG|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
219151681|NCT01401023|DRUG|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
219151682|NCT05493449|COMBINATION_PRODUCT|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
219232839|NCT02166723|DEVICE|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
219232840|NCT05615506|PROCEDURE|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
219734774|NCT04921163|DIETARY_SUPPLEMENT|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
219151683|NCT05493449|COMBINATION_PRODUCT|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
219151684|NCT06192043|BEHAVIORAL|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
219151685|NCT03394885|DRUG|Atezolizumab|1200mg IV q3weeks
219232841|NCT05180175|DRUG|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
219734775|NCT04921163|DIETARY_SUPPLEMENT|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
219734776|NCT01245049|BIOLOGICAL|Boostrix PolioTM|Single dose, intramuscular administration.
219734777|NCT01245049|BIOLOGICAL|RepevaxTM|Single dose, intramuscular administration.
219734778|NCT01245049|BIOLOGICAL|PriorixTM|Single dose, intramuscular or subcutaneous administration.
219734779|NCT00450749|OTHER|placebo|Given PO
219734780|NCT00450749|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
219151686|NCT03394885|DRUG|Carboplatin|5-6mg/ML IV q3 weeks
219151687|NCT03394885|DRUG|Paclitaxel|70-80 mg/m2 IV q1 week
219151688|NCT03394885|DRUG|Bevacizumab|15 mg/kg IV q3 weeks
219151689|NCT05100784|BIOLOGICAL|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
219151690|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (combination)|
219151691|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
219151692|NCT02515305|DRUG|Placebo gel (combination)|
219151693|NCT05674149|DEVICE|camera|photographs using multi-spectral camera
219151694|NCT04654598|OTHER|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
219151695|NCT01925365|DIETARY_SUPPLEMENT|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
219151696|NCT01925365|DIETARY_SUPPLEMENT|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
219734781|NCT00450749|OTHER|laboratory biomarker analysis|Correlative studies
219734782|NCT00450749|DRUG|lycopene|Given PO
219723765|NCT04566731|BEHAVIORAL|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
219151697|NCT05688592|PROCEDURE|PET-CT|"This is a before-and-after study (not a clinical trial)~* in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~* in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
219151698|NCT05849233|OTHER|no intervention|no intervention
219232842|NCT00889473|DRUG|Larazotide acetate|gelatin capsule
219232843|NCT00889473|DRUG|Placebo|gelatin capsule
219232844|NCT00889473|DIETARY_SUPPLEMENT|Gluten 900 mg|gelatin capsule
219232845|NCT04418609|OTHER|further processing of health data|further processing of biological materials and health related personal data for research
219723766|NCT04928339|DRUG|Bupivacaine Injection|10mL of 0.25% bupivacaine
219723767|NCT04928339|DRUG|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
219723768|NCT04928339|OTHER|Saline|25mL saline control
219723769|NCT05638737|DRUG|AZD4831|AZD4831
219723770|NCT05638737|OTHER|Placebo|Placebo
219723771|NCT03990844|DIETARY_SUPPLEMENT|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
219723772|NCT05743374|OTHER|Normal diet|These patients will be given advice about a normal healthy diet.
219723773|NCT05743374|DIETARY_SUPPLEMENT|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
219723774|NCT00142597|DEVICE|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
219723775|NCT00142597|OTHER|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
219723776|NCT06173843|OTHER|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
219723777|NCT03641924|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
219723778|NCT04333498|BEHAVIORAL|Feedback on DBS Concentrations|The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
219723779|NCT01565694|DRUG|Solifenacin succinate|Oral suspension administered once a day via syringe.
219723780|NCT05862584|OTHER|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
219723781|NCT06118073|OTHER|Headspace|Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.
219723782|NCT06118073|PROCEDURE|Total Knee Replacement|Participant will have total knee replacement surgery
219723783|NCT05017155|DRUG|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
219723784|NCT05017155|DRUG|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
219723785|NCT06963450|DIAGNOSTIC_TEST|Taking photos of a baby's eye|Taking photos of a baby's eye and using the color of the sclera to estimate the bilirubin level, which determines if the baby is significantly jaundiced.
219723786|NCT06963398|DRUG|HS-10529|Participants in all subjucts will receive HS-10529
219723787|NCT06963320|DRUG|H001 Capsule 200mg-qd|H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.
219723788|NCT06963320|DRUG|Enoxaparin Sodium Injection|Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days
219723789|NCT06963320|DRUG|H001 Capsule 300mg-qd|H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.
219723790|NCT06963320|DRUG|H001 Capsule 200mg-bid|H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.
219723791|NCT06963931|BEHAVIORAL|Change4Better (C4B) mobile app|The content of the C4B app is designed to teach key CBT strategies to address gambling behaviors. The content targets concerns that people with gambling problems often experience (gambling debts, cognitive distortions related to gambling - for example, how unrelated events might be related to gambling outcomes). We have designed the content such that people using the app can see the pattern of progress, identify mistakes and setbacks, and learn from common experiences of people with gambling disorder
219723792|NCT06963502|DRUG|HS-10370|Participants will receive HS-10370 dose 1 administered orally
219723793|NCT06963502|DRUG|HS-20117|Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.
219723794|NCT06963502|DRUG|Adebrelimab|Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle
219723795|NCT06963502|DRUG|Capecitabine|Participants will receive Capecitabine administered orally
219723796|NCT06963502|DRUG|Oxaliplatin|Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.
219723797|NCT06963502|DRUG|Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan|Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.
219723798|NCT06963502|DRUG|HS-20093|Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle
219723799|NCT06963502|DRUG|platinum (cisplatin or carboplatin)|Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.
219151699|NCT03813706|PROCEDURE|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
219723800|NCT02727803|BIOLOGICAL|Allogeneic Natural Killer Cell Line NK-92|Given IV
219723801|NCT02727803|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219723802|NCT02727803|DRUG|Busulfan|Given IV
219723803|NCT02727803|DRUG|Clofarabine|Given IV
219723804|NCT02727803|DRUG|Cyclophosphamide|Given IV
219723805|NCT02727803|DRUG|Fludarabine Phosphate|Given IV
219723806|NCT02727803|OTHER|Laboratory Biomarker Analysis|Correlative studies
219723807|NCT02727803|DRUG|Melphalan|Given IV
219723808|NCT02727803|BIOLOGICAL|Rituximab|Given IV
219723809|NCT02727803|RADIATION|Total-Body Irradiation|Undergo total body irradiation
219723810|NCT02727803|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
219723811|NCT06963879|DEVICE|Bgaze Therapy|BGaze Therapy is a digital intervention by Braingaze designed to enhance attention and memory in individuals with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). It uses an interactive video game controlled through eye-tracking, allowing users to play using only their gaze. The therapy is based on research linking eye vergence and pupil responses to cognitive processing-physiological markers that may indicate neurodegeneration. During gameplay, these responses are modulated, potentially inducing gamma brain oscillations associated with reduced AD pathology. Patients play at care-center for 5-10 minutes daily over two months. Equipment is provided, and both in-person and remote support ensure usability. The game adapts difficulty in real time and provides feedback to keep users engaged and stimulate cognitive function.
219723812|NCT06963879|DIAGNOSTIC_TEST|Bgaze Attention Task|For the validation of diagnosis of AD with vergence method the Attention Test (B-Gaze) will be used. This is an odd ball paradigm where visual target has to be detected among blue distractors. The test consist of 100 trials of 1 second and last about 3 minutes. The task uses remote eye infra-red tracking to measure eye vergence. Subjects merely have to fixate at the computer screen during the task.
219723813|NCT05416203|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
219723814|NCT05035693|DEVICE|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
219723815|NCT06059066|PROCEDURE|Standard number of injection sites|200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.
219723816|NCT06059066|PROCEDURE|Reduced number of injection sites|200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.
219723817|NCT01787903|DEVICE|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
219232846|NCT04543188|DRUG|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
219232847|NCT04543188|DRUG|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
219232848|NCT04543188|DRUG|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
219723818|NCT06149013|DEVICE|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
219723819|NCT06149013|OTHER|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
219723820|NCT00409760|DRUG|valsartan+amlodipine combination, valsartan, amlodipine|
219723821|NCT00780039|DRUG|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
219734783|NCT03600727|DRUG|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
219734784|NCT03600727|DRUG|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
219734785|NCT05343429|DRUG|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
219734786|NCT05343429|DRUG|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
219734787|NCT00877864|BEHAVIORAL|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
219734788|NCT00877864|BEHAVIORAL|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
219734789|NCT00877864|BEHAVIORAL|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
219723822|NCT00780039|DRUG|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
219723823|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
219723824|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
219723825|NCT00541229|DRUG|Comparator: Placebo|sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
219723826|NCT06145074|DRUG|Propranolol|Oral administration.
219723827|NCT06145074|DRUG|Placebo|Oral administration.
219723828|NCT01807520|BIOLOGICAL|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
219723829|NCT01807520|BIOLOGICAL|Placebo|Placebo was provided in pre-filled 1 mL syringes.
219723830|NCT05134818|OTHER|observer tool|comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
219723831|NCT01000714|DRUG|Psirelax|
219723832|NCT01797185|DRUG|SPARC1104 modified dose regimen I|Subjects who exited study CLR\_09\_21
219723833|NCT01797185|DRUG|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
219723834|NCT01797185|DRUG|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
219723835|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
219723836|NCT04248569|DRUG|Nivolumab|"1. Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~2. Drug: 3mg/kg and 480mg IV"
219723837|NCT04248569|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~2. Drug: 1mg/kg IV"
219723838|NCT04387214|OTHER|survey|online survey
219723839|NCT02305459|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
219723840|NCT02305459|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
219723841|NCT03590470|OTHER|Implementation of a nurse-led model of care|A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
219723842|NCT05932030|OTHER|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
219723843|NCT01147835|DIETARY_SUPPLEMENT|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
219723844|NCT06469268|DEVICE|Epro software|EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
219723845|NCT00799669|BEHAVIORAL|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
219723846|NCT00799669|OTHER|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
219723847|NCT00799669|OTHER|preventive intervention|
219723848|NCT00799669|OTHER|questionnaire administration|
219723849|NCT06337409|DRUG|Generic empagliflozin 25 mg film-coated tablets|Empagliflozin 25 mg film-coated tablets
219723850|NCT03097159|PROCEDURE|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
219723851|NCT03168087|OTHER|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
219723852|NCT03215615|PROCEDURE|Periodontal surgery|Coronally advanced flap for root coverage
219723853|NCT03215615|PROCEDURE|Total Etch adhesive|Total-etch adhesive system (two step)
219723854|NCT03215615|PROCEDURE|Universal Adhesive|One-step self-etching adhesive system
219723855|NCT03215615|PROCEDURE|Nanofilled Composite|Partial nanofilled-resin composite restoration
219723856|NCT03215615|PROCEDURE|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
219723857|NCT04293965|DRUG|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
219723858|NCT04293965|DRUG|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
219151700|NCT01351272|DRUG|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
219151701|NCT01351272|DRUG|Placebo|
219151702|NCT00414999|DRUG|TG100801|
219232849|NCT05656456|OTHER|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
219151703|NCT00376519|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
219151704|NCT00376519|DRUG|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
219151705|NCT00376519|DRUG|fludarabine phosphate|Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
219151706|NCT00376519|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
219232850|NCT01102426|DRUG|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
219232851|NCT01102426|DRUG|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
219232852|NCT03656822|DIAGNOSTIC_TEST|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
219232853|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
219232854|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
219232855|NCT03656822|DIAGNOSTIC_TEST|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
219232856|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
219232857|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
219723859|NCT04293965|OTHER|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
219232858|NCT00213317|PROCEDURE|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
219232859|NCT02607176|DRUG|Heweizhixie capsule|3 #, Tid, Oral for 3 days
219232860|NCT01245998|DRUG|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
219723860|NCT04201210|OTHER|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
219723861|NCT04201210|OTHER|Matched sibling donor transplantation|10/10 HSCT - matched family donor
219723862|NCT01149967|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
219723863|NCT01713738|DRUG|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
219723864|NCT00167271|BEHAVIORAL|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
219723865|NCT02832999|DRUG|sub cutaneous liraglutide|Liraglutide 1.2mg/day
219723866|NCT02832999|DRUG|Oral Vildagliptin|Vildagliptin 50mg/day
219723867|NCT03423472|BEHAVIORAL|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
219723868|NCT03423472|BEHAVIORAL|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
219723869|NCT03423472|BEHAVIORAL|Standart of care|Government standard of care for nutrition education through the Health Development Army
219232861|NCT01245998|DRUG|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
219232862|NCT05843526|DEVICE|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
219232863|NCT00375323|DRUG|NovoSeven|
219232864|NCT04180072|DRUG|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
219232865|NCT04180072|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
219232866|NCT02714998|DRUG|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
219232867|NCT02714998|PROCEDURE|salpingectomy|Laparoscopic unilateral salpingectomy
219232868|NCT06288750|DEVICE|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
219232869|NCT06288750|DEVICE|No indocyanine green|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
219232870|NCT04361617|BEHAVIORAL|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
219232871|NCT03260270|DIAGNOSTIC_TEST|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
219232872|NCT04405180|DRUG|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
219232873|NCT04405180|DRUG|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
219232874|NCT05585827|BEHAVIORAL|Online cognitive behavioral therapy|"The e-CBT treatment manual is an adjusted version of a previously published treatment manuals for neuropsychiatric symptoms in PD, which is tailored to the preferences and needs for each participant. This manual encompass both modules from manuals for depression in PD and anxiety in PD. Individualization is ensures by including several interventions modules in the manual, wherein 5 sessions are considered core modules, and four modules that can be offered depending on the patients individual needs. The participant may include partners or caregivers. The treatment is schedules to be completed within 13 weeks, with maximum ten sessions during this period. Following each e-CBT session, the participant will be asked to complete a short survey evaluating the acceptability and relevance of the session, and evaluate the therapeutic alliance."
219232875|NCT05955885|DRUG|Flurbiprofen Oral Lozenge|This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
219232876|NCT05955885|DRUG|Difflam|This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
219232877|NCT05955885|DRUG|Flurbiprofen 8.75 MG|This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
219232878|NCT06030739|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
219232879|NCT01193205|BEHAVIORAL|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
219232880|NCT01752959|DRUG|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
219232881|NCT01752959|DRUG|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
219232882|NCT05281081|DRUG|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
219232883|NCT02311413|DRUG|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
219232884|NCT02311413|DRUG|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
219232885|NCT01338506|BEHAVIORAL|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
219232886|NCT01466569|DRUG|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
219232887|NCT01466569|DRUG|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
219232888|NCT03847545|DRUG|Fampridine|sustained-release tablet 10 mg morning and evening.
219232889|NCT03265132|BIOLOGICAL|anakinra|sub cutaneous injection
219232890|NCT03265132|DRUG|Placebo|sub cutaneous injection
219232891|NCT04723615|OTHER|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
219232892|NCT04723615|OTHER|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
219232893|NCT04723615|OTHER|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
219151707|NCT00376519|PROCEDURE|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
219151708|NCT00376519|PROCEDURE|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
219151709|NCT00376519|RADIATION|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
219151710|NCT05498363|BIOLOGICAL|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
219151711|NCT03949335|DEVICE|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
219151712|NCT03949335|DEVICE|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
219151713|NCT01212991|DRUG|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
219151714|NCT01212991|DRUG|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
219151715|NCT01926977|DRUG|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
219151716|NCT01926977|DRUG|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
219151717|NCT05727397|DRUG|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
219151718|NCT05727397|DRUG|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
219151719|NCT04616911|PROCEDURE|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
219151720|NCT04616911|PROCEDURE|LIFT|Ligation of the intersphincteric fistula tract
219151721|NCT05006092|DEVICE|ENDOMIND|CADe system for Polyp detection
219151722|NCT04744402|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
219151723|NCT01897272|BEHAVIORAL|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
219151724|NCT03843021|OTHER|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
219151725|NCT03484611|DRUG|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
219151726|NCT03484611|DRUG|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
219151727|NCT03484611|DRUG|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
219151728|NCT03484611|PROCEDURE|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
219151729|NCT03484611|DRUG|Progesterone|vaginal prontogest 400 mg twice daily
219151730|NCT02531152|DRUG|Latanoprost|
219151731|NCT02531152|DRUG|SAR366234|
219232894|NCT04723615|OTHER|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
219232895|NCT02481856|DRUG|SQ tree SLIT-tablet|
219151732|NCT00801983|DEVICE|Alternative Keyboard|Subjects use either a typical or alternative keyboard
219151733|NCT05148897|OTHER|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
219151734|NCT02447874|DRUG|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours"
219151735|NCT02447874|DRUG|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
219151736|NCT02447874|DRUG|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
219232896|NCT02481856|DRUG|Placebo|
219232897|NCT03498365|BEHAVIORAL|MCDA|Experimental decision support
219232898|NCT03498365|BEHAVIORAL|Delphi|Standard support
219232899|NCT00291941|BIOLOGICAL|Henogen HBV vaccine|20µg, Month 0, 2 and 6
219232900|NCT00291941|BIOLOGICAL|FENDRIX|20 µg,Months 0, 1, 2 and 6
219232901|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
219723870|NCT03779607|OTHER|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
219723871|NCT05575427|DRUG|Minocycline|The patients will receive minocycline oral between 7-28 days
219723872|NCT05575427|DRUG|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
219723873|NCT05575427|DRUG|Placebo|Capsule without active compound
219151737|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
219151738|NCT04287114|BEHAVIORAL|Acute exercise|Acute exercise with different exercise intensities
219151739|NCT06280105|DRUG|Cadonilimab+regorafenib|cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first
219151740|NCT02449070|DRUG|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
219151741|NCT02043054|DRUG|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
219151742|NCT02043054|DRUG|Sitagliptin|Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
219151743|NCT04257435|BEHAVIORAL|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
219232902|NCT02334605|DEVICE|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
219232903|NCT02334605|DEVICE|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
219232904|NCT04024709|PROCEDURE|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
219232905|NCT06462378|RADIATION|Proton therapy|External beam proton therapy combined with standard cisplatin and brachytherapy
219232906|NCT01435720|BIOLOGICAL|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
219723874|NCT02714959|DRUG|Proleukin|
219723875|NCT01168479|RADIATION|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
219723876|NCT01168479|RADIATION|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
219723877|NCT01069640|BIOLOGICAL|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
219723878|NCT01875237|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
219723879|NCT01875237|DRUG|Melphalan|140 mg/m2 by vein on Day -2.
219723880|NCT01875237|DRUG|Alemtuzumab|50 mg by vein on Day -1.
219723881|NCT01875237|PROCEDURE|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10\^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
219723882|NCT01875237|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
219723883|NCT01875237|DRUG|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
219723884|NCT01875237|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
219723885|NCT01875237|PROCEDURE|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10\^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
219734790|NCT00877864|BEHAVIORAL|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
219734791|NCT00877864|BEHAVIORAL|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
219734792|NCT00877864|BEHAVIORAL|Control|No exercise program provided by the study
219734793|NCT05756907|BIOLOGICAL|SON-1010|SON-1010 +/- Atezolizumab
219723886|NCT01875237|DRUG|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
219151744|NCT04257435|BEHAVIORAL|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
219151745|NCT05210257|OTHER|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
219151746|NCT05210257|OTHER|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
219151747|NCT03542630|DIAGNOSTIC_TEST|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
219151748|NCT03542630|OTHER|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
219151749|NCT03542630|OTHER|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
219151750|NCT05319522|BEHAVIORAL|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
219151751|NCT03032224|PROCEDURE|Resection of the esophagus and the gastroesophageal junction|
219151752|NCT00086775|BIOLOGICAL|alemtuzumab|
219151753|NCT00086775|BIOLOGICAL|rituximab|
219151754|NCT00086775|DRUG|fludarabine phosphate|
219151755|NCT04134078|DRUG|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
219151756|NCT04942249|OTHER|No intervention|No intervention
219151757|NCT05633628|BEHAVIORAL|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
219151758|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
219151759|NCT04375813|DRUG|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
219151760|NCT04375813|DRUG|Placebos|placebo capsules visually identical to eRapa oral capsules
219151761|NCT01037634|DRUG|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
219151762|NCT04190316|OTHER|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
219151763|NCT05053113|DEVICE|Activity Monitor|Monitor physical activity with FitBit
219151764|NCT05053113|DEVICE|Activity Monitor|Wear accelerometer
219232907|NCT01435720|BIOLOGICAL|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
219151765|NCT05053113|OTHER|Educational Intervention|Receive educational newsletter
219151766|NCT05053113|OTHER|Survey Administration|Ancillary studies
219151767|NCT05053113|BEHAVIORAL|Telephone-Based Intervention|Receive phone call from health coach
219151768|NCT06680752|BIOLOGICAL|ARD103|ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
219151769|NCT06680752|DRUG|Cyclophosphamide|iv administration for lymphodepletion
219151770|NCT06680752|DRUG|Fludarabine|iv administration for lymphodepletion
219151771|NCT00050375|DRUG|oregovomab|
219151772|NCT07037771|DRUG|zodasiran Injection|ARO-ANG3 Injection
219151773|NCT07037771|DRUG|Placebo|sterile normal saline (0.9% NaCl)
219151774|NCT07044102|OTHER|Patients Undergoing Low Tidal Volume Ventilation During CABG|Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass
219151775|NCT07044102|OTHER|Patients Undergoing Apneic Ventilation During CABG|"Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass"
219232908|NCT01435720|BIOLOGICAL|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
219232909|NCT01435720|BIOLOGICAL|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
219232910|NCT04031794|DEVICE|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
219232911|NCT00325845|PROCEDURE|Synvisc viscosupplementation|
219232912|NCT03975361|OTHER|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
219232913|NCT01137682|DRUG|Pasireotide|"* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
219232914|NCT01137682|DRUG|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
219151776|NCT06890065|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
219232915|NCT01137682|DRUG|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
219232916|NCT00722865|DRUG|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
219232917|NCT00323778|DRUG|Hyalgan|
219232918|NCT03044756|DRUG|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
219232919|NCT05770206|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
219723887|NCT01875237|DRUG|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
219723888|NCT01875237|BEHAVIORAL|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
219151777|NCT06888115|DRUG|CS0159|Single oral dose of CS0159 4mg
219151778|NCT06886451|OTHER|ML-based intervention|For each patient, a ML model will predict the risk of vomiting within the next 96 hours. Patients will then receive care pathway-consistent interventions based on the ML model predictions.
219151779|NCT06740890|DRUG|Olanzapine-samidorphan + exercise|8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise
219151780|NCT05135000|DRUG|LTP001|LTP001, 6 mg, was administered orally once daily in the morning
219151781|NCT05135000|DRUG|Placebo|Placebo to LTP001 was administered once daily in the morning
219151782|NCT06526299|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219151783|NCT06526299|PROCEDURE|Bone Scan|Undergo bone scan
219151784|NCT06526299|PROCEDURE|Computed Tomography|Undergo SPECT/CT and CT
219151785|NCT06526299|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
219151786|NCT06526299|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219232920|NCT05770206|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
219232921|NCT01002586|OTHER|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
219232922|NCT01002586|OTHER|Walking exercise program|walking exercise program
219232923|NCT01543945|DRUG|Dexamethasone|4 mg iv before induction for high and extremely high risk
219232924|NCT01543945|DRUG|Ondansetron|4 mg iv before ended surgery 30 min
219232925|NCT01543945|DRUG|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
219232926|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
219232927|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
219232928|NCT03624114|PROCEDURE|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
219232929|NCT04617847|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
219232930|NCT05323643|DEVICE|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
219232931|NCT00244751|DRUG|GI262570 0.5 mg|GI262570 0.5 mg
219723889|NCT01374789|DRUG|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
219723890|NCT01374789|DRUG|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
219151787|NCT06526299|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT
219723891|NCT00979511|OTHER|milk and exercise|"* milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise"
219723892|NCT03558672|DEVICE|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
219723893|NCT00743262|DEVICE|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
219723894|NCT00421733|DRUG|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
219723895|NCT00421733|DRUG|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
219151788|NCT06526299|OTHER|Questionnaire Administration|Ancillary studies
219151789|NCT06526299|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
219151790|NCT06893211|DRUG|Tirzepatide|Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It will be administered via subcutaneous injection once weekly in a dose-titration scheme: starting at 2.5 mg, and increased every 4 weeks by 2.5 mg up to a maximum of 15 mg, based on tolerability. The medication will be supplied in prefilled pens identical in appearance to placebo pens.
219151791|NCT06893211|DRUG|Placebo|Placebo will be administered via subcutaneous injection once weekly using pens that are visually indistinguishable from those used for tirzepatide. Dose escalation will follow the same schedule (2.5 mg-equivalent increments every 4 weeks) to preserve blinding integrity.
219151792|NCT03129555|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219151793|NCT03129555|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219151794|NCT03129555|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219151795|NCT03129555|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219151796|NCT07054892|BEHAVIORAL|FAAM - Activities of Daily Living (ADL) Subscale|The FAAM score is scientifically validated and allows for the assessment of foot and ankle functional ability
219723896|NCT00421733|DRUG|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
219723897|NCT02898441|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
219723898|NCT06194669|OTHER|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
219723899|NCT06413394|OTHER|environmental education|environmental education
219723900|NCT06485180|PROCEDURE|Active comparator|"Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort."
219723901|NCT03429205|OTHER|No external heating used during surgery|Deviation from external heating for all surgery standard
219723902|NCT03429205|OTHER|External heating blanket used during surgery|Standard external heating plan used in all surgery types
219151797|NCT07053358|GENETIC|LX111 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.
219151798|NCT07054099|BIOLOGICAL|MG1111 (Barycela inj.)|MG1111 (Barycela inj.)
219151799|NCT07054099|BIOLOGICAL|VARIVAX™|Varivax™
219151800|NCT07054840|BEHAVIORAL|Capsaicin 0.1% cream combined with a heat pack and applied to the lower leg|Capsaicin is applied to the skin of one of the lower legs, then covered with a heat pack that is secured to the leg with self-adhesive wrap.
219151801|NCT07056192|OTHER|Structured education group|Structured education group
219232932|NCT00244751|DRUG|GI262570 1.0 mg|GI262570 1.0 mg
219232933|NCT00244751|DRUG|Placebo|Placebo
219232934|NCT04213235|BEHAVIORAL|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
219723903|NCT04368910|DRUG|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
219723904|NCT04368910|DRUG|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
219723905|NCT02810327|GENETIC|Genetic Sequencing|Sequencing of the SERPINA1 gene
219723906|NCT02265744|DRUG|BMS-931699|
219723907|NCT02265744|DRUG|Placebo matching BMS-931699|
219723908|NCT04505917|DRUG|dinoprostol|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
219723909|NCT04505917|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
219723910|NCT04505917|DRUG|placebo|2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
219723911|NCT04983732|DRUG|FL-101-Intravenous|150 mg administered via the IV route
219723912|NCT04983732|DRUG|FL-101-Subcutaneous|150 mg administered via the SC route
219723913|NCT04181645|DRUG|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
219723914|NCT05098990|DRUG|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
219723915|NCT05098990|DRUG|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
219723916|NCT04698486|OTHER|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
219723917|NCT06403501|DRUG|Clascoterone|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
219151802|NCT06887660|OTHER|Orthodontic diagnosis|"Initial Assessment Orthodontic residents assessed each patient based on their existing knowledge of speech therapy. They rated the necessity for a speech therapy consultation on a scale from 1 to 10, with 1 indicating not necessary and 10 indicating absolutely necessary.~Protocol-Guided Assessment The same residents then reassessed the same patients using the Interdisciplinary Orofacial Evaluation Protocol. After this evaluation, they again rated the necessity for a speech therapy consultation using the same 1 to 10 scale.~Speech-therapist Evaluation Subsequently, a speech therapy specialist independently evaluated each patient using the same protocol and provided their rating for the necessity of a speech therapy consultation on the same scale."
219151803|NCT06741085|DRUG|osimertinib|oral EGFR-TKI
219151804|NCT06741085|RADIATION|stereotactic radiosurgery (SRS)|"0-20mm-18Gy x 1, 21Gy x 1 ,9Gy x 3~20mm or larger- 9Gy x 3, 6Gy x 5, 5Gy x 5"
219151805|NCT06724640|DRUG|VH4011499 Injection|VH4011499 Injection will be administered either subcutaneously or intramuscularly.
219151806|NCT06724640|DRUG|Placebo for VH4011499 Injection|Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
219151807|NCT07060001|DIAGNOSTIC_TEST|5hmC Biomarker|The 5hmC marker will be used to determine treatment modality post-induction therapy. After Week 4 of standard-of-care therapy (either HMA-based treatment or intensive induction chemotherapy), 5hmC biomarker testing will be performed. If MRD is positive, patients will continue the same standard-of-care treatment or crossover to the other arm of the study. If MRD is negative, patients will proceed with consolidation (either HSCT or continue on same treatment). For patients receiving HMA-based treatment, blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy. For patients receiving intensive chemotherapy blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy.
219151808|NCT07060001|DRUG|Venetoclax|Venetoclax is a BCL-2 inhibitor FDA Approved for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine.
219151809|NCT07060001|DRUG|Decitabine 20 mg/m²/day for 5 days|Decitabine is a nucleoside metabolic inhibitor that is administered as an intravenous infusion over a 1-3 hours.
219151810|NCT07060001|DRUG|Azacitidine (AZA)|Azacitidine can be given as a sub-cutaneous injection or intravenously.
219151811|NCT07060001|DRUG|Cytarabine (Ara-C)|Cytarabine is FDA approved chemotherapy (pyrimidine analog) infusion that is frequently used with other drug such as anthracycline to treat acute myeloid leukemia, acute lymphoblastic leukemia. Common side effects include low counts, immune suppression, nausea, neutropenic fever.
219151812|NCT07060001|DRUG|Anthracycline|Anthracyclines are chemotherapy infusions which topoisomerase II inhibition. Other than having side effects similar to cytarabine, it may cause weakening of heart pumping function few years later. Both of these medications may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.
219151813|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd|Standard-Dose Palbociclib + Endocrine therapy
219151814|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|Standard-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
219151815|NCT07061717|DRUG|Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|High-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
219151816|NCT07060378|DEVICE|Contrast-enhanced endobronchial ultrasound|Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.
219723918|NCT06403501|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
219723919|NCT00299221|DRUG|Tacrolimus|tacrolimus
219723920|NCT00299221|DRUG|combination therapy|MMF
219723921|NCT00720200|BEHAVIORAL|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
219723922|NCT00720200|BEHAVIORAL|Usual Care|Family Members receiving usual care/clinical interaction
219723923|NCT01666600|DRUG|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
219723924|NCT01666600|RADIATION|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
219723925|NCT01297790|OTHER|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
219723926|NCT01297790|OTHER|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
219723927|NCT01297790|OTHER|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
219723928|NCT04086459|DEVICE|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
219723929|NCT05161936|DRUG|Lumasiran|Lumasiran will be administered by SC injection.
219723930|NCT05161936|DRUG|Placebo|Placebo will be administered by SC injection.
219723931|NCT01086475|DRUG|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
219151817|NCT07060287|PROCEDURE|Clock-Guided Minimally Invasive Surgery|All participants underwent video-assisted thoracoscopic surgery (VATS) for pulmonary nodule resection. Nodule localization was performed using a clock-guided anatomical positioning technique with a 3D reconstruction system. The surgical procedure included wedge resection, segmentectomy, or lobectomy based on clinical judgment.
219151818|NCT07061704|BIOLOGICAL|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses.|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first. Chemotherapy + Immune Checkpoint Inhibitor (ICI): Administered via intravenous infusion once every 3 weeks.
219232935|NCT02368288|DRUG|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
219232936|NCT05450159|BEHAVIORAL|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
219232937|NCT05450159|BEHAVIORAL|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
219232938|NCT06142799|PROCEDURE|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
219232939|NCT06091709|OTHER|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
219232940|NCT06091709|OTHER|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
219232941|NCT04120623|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
219232942|NCT04120623|DRUG|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
219232943|NCT00729261|PROCEDURE|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
219232944|NCT00729261|PROCEDURE|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
219232945|NCT00741923|OTHER|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
219232946|NCT03722732|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
219232947|NCT05129722|DRUG|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
219232948|NCT05129722|DRUG|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
219232949|NCT03417479|OTHER|Gabapentin|
219232950|NCT00548444|BIOLOGICAL|MVA85A|Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
219232951|NCT00548444|OTHER|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
219232952|NCT05782894|DRUG|Remimazolam besylate|0\~2.0mg/kg/h
219232953|NCT05782894|DRUG|Propofol|0.3\~4.0mg/kg/h
219232954|NCT05782894|DRUG|Remifentanil|1.5\~12μg/kg/h
219232955|NCT02730624|DRUG|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
219232956|NCT04136990|PROCEDURE|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
219232957|NCT04136990|PROCEDURE|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
219232958|NCT00426205|BIOLOGICAL|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
219232959|NCT06081608|DIAGNOSTIC_TEST|kidney function test|blood sample for kidney function test
219723932|NCT01086475|DRUG|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
219723933|NCT05371197|DRUG|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
219723934|NCT00999011|PROCEDURE|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
219723935|NCT00999011|PROCEDURE|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
219723936|NCT01158404|DRUG|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
219723937|NCT01158404|DRUG|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
219723938|NCT03949231|DRUG|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
219723939|NCT04763408|DRUG|Lenvatinib|Oral capsules.
219151819|NCT07060586|PROCEDURE|Sphenopalatine Ganglion Block|A bilateral transnasal sphenopalatine ganglion block with cotton tips soaked in a mixture of 0.5 mL lidocaine 4% and 0.5 mL ropivacaine 0.5% plus injection through the cotton tips of an additional 1 mL of the mixture. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
219151820|NCT07060586|PROCEDURE|Sham Block|A sham block with two bilaterally inserted cotton tips not reaching the posterior part of the nasopharyngeal making not contact with the ganglion. Cotton tips are soaked in 1 mL placebo (saline) and have a total of 1 mL saline injected through the cotton tips. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
219151821|NCT07061769|DEVICE|SHIFT|SHIFT is a low intensity PEMF cranial device. It has been designated as a Non-Significant Risk device by the FDA.
219151822|NCT07061431|DIETARY_SUPPLEMENT|High Dose of Vitamin C with ir without 50 mg of flavonoids|The anti-inflammatory and anti-platelet efficacy and synergy of a supplement containing high dose (1 g) of vitamin C and a low dose (50 mg) citrus and rose bioflavonoids (VCF), was assessed in platelets of blood samples collected from healthy subjects, prior the oral administration (t=0 days) and just after this administration for 1 month (VCF Group), VERSUS the findings from the same procedure contacted for a supplement containing only high dose (1 g) of vitamin C (VC Group)
219151823|NCT04873102|DRUG|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
219151824|NCT07060521|OTHER|soft tissue mobilization|massage
219151825|NCT07060521|OTHER|Self Stretching|self stretching
219151826|NCT07060105|OTHER|Hypertonic Saline ( 3% Sodium Chloride Saline)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
219151827|NCT07060105|OTHER|Normal Saline (0.9% NaCl)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
219151828|NCT07061041|OTHER|Strength training|"The group will perform one workout per week consisting of 3 series of the Romanian deadlift exercise of 10 repetitions. Each repetition will be performed at a specific pace - 3s in eccentric contraction and 1s in concentric contraction. The aforementioned exercise, the Romanian deadlift, will be performed by the subjects on a platform (elevation) in order to achieve maximum range of motion."
219151829|NCT07061041|OTHER|Streching group|The group performed one training session per week consisting of 2 sets of 60 seconds of static stretching
219151830|NCT07060131|DEVICE|Far Infrared Eye Masks|Using far-infrared eye masks on the acupoints around the eyes, including Jingming, Taiyang, Sibai, Tongziliao, and Si Zhu Kong to assess whether there is an improvement in the symptomatic indicators of dry eye disease.
219151831|NCT07059702|OTHER|There will be no intervention.|There will be no intervention. This is an observational study that uses EEG and FDG-PET results as parameters. These investigations will b e performed on a clinical basis.
219151832|NCT07060326|OTHER|Survey using a questionnaire.|REDCap Survey
219151833|NCT04930289|DEVICE|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
219151834|NCT04930289|DEVICE|BAROGuard|"The BAROguard (the System) is ultraportable hypothermic preservation and transport system intended for use with donor lungs. BAROguard is a legally marketed, FDA cleared medical device in the United States. The intended organ storage time for BAROguard™ is up to 8 hours."
219151835|NCT06838806|DIAGNOSTIC_TEST|blood draw|Plasma samples will be collected in NTU Hospital or NTUCC. ChLIA kits and all other reagents will be provided by Volition. ChLIA analysis of samples will be performed by a Volition designated laboratory in Taiwan( NTU Centres of Genomic and Precision Medicine).
219151836|NCT07061834|DEVICE|Biofeedback training|The intervention consists of biofeedback training using the Nexus 10 device, which provides real-time feedback on physiological signals including galvanic skin response and peripheral temperature. Participants undergo sessions where they learn to consciously regulate their autonomic nervous system activity by observing and modifying these signals. This training aims to improve stress regulation and enhance physiological self-control. Unlike other biofeedback interventions, this protocol focuses on combined skin conductance and temperature measures delivered through the Nexus 10 system over multiple sessions.
219151837|NCT07061834|OTHER|control group|The control group received no intervention.
219151838|NCT05051657|DIETARY_SUPPLEMENT|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
219151839|NCT03005678|DRUG|Denosumab|active treatment group
219151840|NCT03005678|DRUG|Alendronate|comparator
219151841|NCT06385340|OTHER|Lipikar Baume AP+M|• Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
219151842|NCT04415879|OTHER|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
219151843|NCT04415879|OTHER|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
219151844|NCT06908226|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
219723940|NCT04763408|DRUG|Sorafenib|Oral tablets.
219723941|NCT00326040|DEVICE|Glaucoma Surgery|
219723942|NCT03360487|RADIATION|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
219723943|NCT03360487|RADIATION|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
219723944|NCT03360487|RADIATION|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
219723945|NCT03971526|OTHER|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
219151845|NCT06913010|OTHER|No interventions.|This is an observational study with no interventions.
219151846|NCT02021799|DIETARY_SUPPLEMENT|Moringa and Lactobacillus rhamnosus GR-1|
219151847|NCT06941155|BEHAVIORAL|Gamified-Combined Cognitive Bias Modification|A gamified version of the combined cognitive bias modification (CBM-C) intervention, which includes both attention and interpretation bias modification tasks. The attention component is a modified dot-probe task, and the interpretation component consists of OCD-related scenarios with word-completion exercises. Gamification elements such as feedback and visual rewards are embedded to enhance motivation and engagement. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
219151848|NCT06941155|BEHAVIORAL|Standard Combined Cognitive Bias Modification|A standard version of the combined cognitive bias modification (CBM-C) intervention, consisting of attention and interpretation bias tasks without gamification features. The attention task is a modified dot-probe paradigm, and the interpretation task involves OCD-related scenarios followed by word-completion exercises. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
219151849|NCT06941155|BEHAVIORAL|Placebo|A placebo version of the standard CBM-C intervention that retains the same structure and timing but omits all active bias modification elements. The attention task (modified dot-probe) presents probes equally behind threat and neutral stimuli, and the interpretation task includes OCD-related scenarios with word-completion items that lead to neutral outcomes. No manipulations are applied to shift cognitive bias. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
219151850|NCT04268550|DRUG|Selpercatinib|Given PO
219151851|NCT06951815|DEVICE|Hearing aids programmed to each participant's hearing loss.|This study is not investigating the efficacy of hearing aids, rather it is investigating the effect of adjusting hearing on cognitive resources, listening effort, and fatigue.
219151852|NCT01109745|OTHER|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
219151853|NCT01109745|OTHER|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
219151854|NCT06233565|DRUG|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
219151855|NCT06233565|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
219151856|NCT06233565|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
219151857|NCT06134089|BEHAVIORAL|Perceived Effectiveness Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
219151858|NCT06134089|BEHAVIORAL|Perceived Shareability Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
219151859|NCT04948866|BEHAVIORAL|ADRD-PC Program|Included in arm/group descriptions
219151860|NCT05341739|OTHER|Pre-operative Stereotactic Radiosurgery|Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
219151861|NCT05894798|OTHER|Acupuncture|Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
219151862|NCT02763319|DRUG|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
219151863|NCT02763319|DRUG|Tafasitamab|Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
219723946|NCT01123525|DRUG|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
219723947|NCT02454582|DEVICE|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
219723948|NCT00505362|PROCEDURE|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
219723949|NCT02289378|DRUG|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
219723950|NCT02839460|PROCEDURE|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
219723951|NCT02384460|DRUG|SD-101-6.0 cream|applied topically once a day for 90 days
219723952|NCT02384460|DRUG|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
219151864|NCT02763319|DRUG|Bendamustine (BEN)|
219151865|NCT04073199|PROCEDURE|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
219151866|NCT04073199|PROCEDURE|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
219151867|NCT00063713|DRUG|VELCADE TM (bortezomib) for Injection|
219151868|NCT00737035|BEHAVIORAL|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
219151869|NCT00737035|BEHAVIORAL|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
219151870|NCT03049319|DEVICE|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
219151871|NCT03049319|DEVICE|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
219151872|NCT03049319|DEVICE|Psoriashield|The psoriashield will be applied to patient's back.
219151873|NCT03049319|DEVICE|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
219151874|NCT03049319|DEVICE|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
219151875|NCT03049319|DEVICE|Xtrac laser|The Xtrac laser will be applied to patient's back.
219151876|NCT00507338|PROCEDURE|PCI|early PCI for NSTEMI; primary PCI for STEMI
219151877|NCT01010685|PROCEDURE|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
219151878|NCT03359317|BEHAVIORAL|jogging|Jogging as instructed for 1 year
219151879|NCT03039244|OTHER|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
219151880|NCT03039244|OTHER|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
219151881|NCT03039244|DEVICE|Diode Laser|
219723953|NCT04105660|OTHER|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
219723954|NCT04105660|OTHER|Standard monitoring|Standard monitoring including clinical parameters and BIS index
219723955|NCT05824676|DEVICE|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
219723956|NCT05824676|DEVICE|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
219723957|NCT01060111|DRUG|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
219723958|NCT01060111|DRUG|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
219723959|NCT01060111|DRUG|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
219723960|NCT01277068|PROCEDURE|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
219723961|NCT01004393|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
219723962|NCT02116062|DEVICE|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
219723963|NCT02116062|DEVICE|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
219723964|NCT02116062|DEVICE|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
219723965|NCT03281538|DRUG|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
219723966|NCT01691742|DRUG|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
219723967|NCT01691742|DRUG|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
219723968|NCT01691742|DRUG|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
219723969|NCT04000711|OTHER|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
219723970|NCT04000711|OTHER|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
219151882|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
219151883|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
219151884|NCT01285986|PROCEDURE|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
219151885|NCT03990285|DRUG|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
219151886|NCT05806060|DRUG|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
219151887|NCT05806060|DRUG|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
219151888|NCT05806060|DRUG|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
219151889|NCT05806060|DRUG|VEGFR and TPC|VEGFR bevacizumab and TPC
219151890|NCT06009120|OTHER|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
219151891|NCT04151082|DRUG|Methylprednisolone|Given IV
219151892|NCT04151082|DRUG|Prednisone|Given PO
219151893|NCT04151082|OTHER|Quality-of-Life Assessment|Ancillary studies
219151894|NCT04151082|OTHER|Questionnaire Administration|Ancillary studies
219151895|NCT03117023|DRUG|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
219151896|NCT03364595|PROCEDURE|plate fixation|ORIF of the radial head fracture
219151897|NCT03364595|PROCEDURE|replacement|replacement of the radial head fracture
219151898|NCT03260010|DRUG|Fosfomycin|Infectofos 5 g
219151899|NCT04252586|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
219723971|NCT02105142|BEHAVIORAL|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
219723972|NCT02105142|BEHAVIORAL|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
219723973|NCT02105142|BEHAVIORAL|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
219723974|NCT04031768|OTHER|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
219723975|NCT06262373|DIAGNOSTIC_TEST|Ultrasound|Ultrasound based observational study
219723976|NCT05476718|OTHER|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
219723977|NCT05476718|OTHER|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
219723978|NCT00848315|BEHAVIORAL|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
219151900|NCT04954638|OTHER|endodontic desinfection|"* outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation"
219151901|NCT01873313|DRUG|Ropivacaine|
219151902|NCT06324903|OTHER|echocardiography and percutaneous cardiac catheterization|pre- cardiac catheterization, intraprocedural and post-catheterization echocardiography.
219151903|NCT03926936|DRUG|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
219151904|NCT06545565|DRUG|sodium acetate group will receive sodium acetate in the neonatal PN.|This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
219232960|NCT04671875|DRUG|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
219151905|NCT06545565|DRUG|sodium chloride group will receive sodium chloride in the neonatal PN.|This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
219151906|NCT06282822|OTHER|Transthoracic echocardiography|All enrolled patients underwent noninvasive transthoracic echocardiography.
219151907|NCT02767765|DRUG|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
219151908|NCT01318967|DRUG|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
219151909|NCT01318967|OTHER|Placebo|
219151910|NCT01951170|DRUG|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
219151911|NCT01305252|DRUG|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
219151912|NCT01305252|DRUG|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
219151913|NCT04980274|OTHER|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
219151914|NCT03015311|DRUG|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
219151915|NCT03015311|DRUG|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
219151916|NCT00700986|DRUG|AZD9056|Oral tablet, 800mg, one single administration
219151917|NCT00700986|DRUG|Placebo|Single dose
219151918|NCT02275377|OTHER|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
219151919|NCT02275377|OTHER|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
219723979|NCT02746731|OTHER|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
219723980|NCT02746731|OTHER|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
219723981|NCT03723239|DEVICE|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
219723982|NCT03921437|RADIATION|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
219723983|NCT02420574|DRUG|albendazole BENDEX|randomized clinical trial with 2 parallel arms
219151920|NCT03266081|DRUG|0.75% bupivacaine|topical anesthetic
219151921|NCT03450200|OTHER|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
219723984|NCT02420574|DRUG|albendazole OVIS|
219151922|NCT03450200|OTHER|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
219151923|NCT00681213|DRUG|Tacrolimus/Sirolimus|
219151924|NCT00681213|DRUG|Tacrolimus/MMF|
219151925|NCT00681213|DRUG|Neoral/Sirolimus|
219151926|NCT04743440|DEVICE|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
219151927|NCT05146375|BIOLOGICAL|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
219151928|NCT06033118|DRUG|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
219151929|NCT03298724|BEHAVIORAL|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
219151930|NCT01933802|BIOLOGICAL|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
219151931|NCT05445440|DRUG|Methotrexate|Specified dose on specified days
219151932|NCT05445440|DRUG|Leucovorin|Specified dose on specified days
219151933|NCT05445440|DRUG|BMS-986371|Specified dose on specified days
219151934|NCT05445440|DRUG|Sulfasalazine|Specified dose on specified days
219151935|NCT06371170|DRUG|Rivaroxaban|Oral anticoagulation
219151936|NCT03068624|BIOLOGICAL|Aldesleukin|Given SC
219723985|NCT04553094|OTHER|Endurance training|Aerobic circuit training
219723986|NCT04553094|OTHER|Muscle building training|Muscle strengthening circuit training
219723987|NCT04999020|DRUG|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
219723988|NCT04999020|DRUG|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
219723989|NCT01865773|PROCEDURE|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
219723990|NCT04664296|OTHER|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
219723991|NCT04664296|OTHER|Phone call interview|less than 15 minutes phone call
219151937|NCT03068624|BIOLOGICAL|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
219151938|NCT03068624|DRUG|Cyclophosphamide|Given IV
219151939|NCT03068624|BIOLOGICAL|Ipilimumab|Given IV
219151940|NCT01807481|DRUG|Mircera|Once Monthly Mircera
219151941|NCT01647581|DEVICE|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
219151942|NCT01647581|DEVICE|NO hemoclip placement|No hemoclip placement (placebo / sham)
219151943|NCT04512482|DRUG|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
219151944|NCT04512482|OTHER|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
219151945|NCT02395744|OTHER|Paclitaxel administration using the OPC|
219151946|NCT00181311|PROCEDURE|hysterectomy|
219723992|NCT01635140|RADIATION|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
219723993|NCT01635140|RADIATION|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
219723994|NCT04530123|DRUG|Placebo|TAK-101 placebo-matching intravenous infusion
219723995|NCT04530123|DRUG|TAK-101|TAK 101 intravenous infusion
219723996|NCT04530123|DIETARY_SUPPLEMENT|Gluten|Powder form (vital wheat gluten)
219723997|NCT03608969|OTHER|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
219723998|NCT03279315|DIETARY_SUPPLEMENT|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
219723999|NCT03359083|OTHER|Correlation|Correlation between assesment parameters
219724000|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
219724001|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
219151947|NCT05792293|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
219151948|NCT05792293|OTHER|Placebo|Placebo
219151949|NCT01105117|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
219151950|NCT01105117|DRUG|Flolan®|per Prescribing Information
219151951|NCT05752175|DRUG|WPV01|WPV01 tablets
219151952|NCT05752175|DRUG|Placebo|Placebo tablets
219151953|NCT06092255|RADIATION|Postoperative radiotherapy for SVZ|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
219232961|NCT03150758|DEVICE|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
219724002|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
219151954|NCT06266936|OTHER|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
219232962|NCT03150758|DEVICE|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
219232963|NCT03150758|DEVICE|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
219232964|NCT03150758|DEVICE|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
219724003|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
219724004|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
219724005|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
219724006|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
219724007|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
219724008|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
219724009|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
219724010|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
219724011|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
219724012|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
219724013|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
219724014|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
219724015|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
219724016|NCT05309005|BEHAVIORAL|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
219151955|NCT02330458|PROCEDURE|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall \>3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
219151956|NCT00446459|DRUG|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
219151957|NCT04999917|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
219151958|NCT05779215|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
219151959|NCT03791593|DRUG|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
219151960|NCT03296540|DRUG|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
219151961|NCT03296540|DRUG|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
219151962|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
219151963|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
219724017|NCT05309005|BEHAVIORAL|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
219724018|NCT02495675|DEVICE|High flow nasal cannulas|Comparison of different flow levels
219724019|NCT02495675|DEVICE|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
219724020|NCT02448043|DRUG|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
219724021|NCT02448043|OTHER|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
219724022|NCT04341051|OTHER|Case|Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
219724023|NCT02320292|OTHER|Quality-of-Life Assessment|Ancillary studies
219724024|NCT02320292|BIOLOGICAL|Rituximab|Given IV
219724025|NCT02320292|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
219724026|NCT05621473|DEVICE|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
219724027|NCT04542564|DEVICE|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
219724028|NCT04542564|OTHER|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
219724029|NCT05745298|DEVICE|Xcite Clinical Station|The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
219724030|NCT03595891|OTHER|Non-Interventional|Non-Interventional
219724031|NCT03983005|PROCEDURE|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
219724032|NCT02219204|PROCEDURE|Acupuncture|
219724033|NCT02219204|OTHER|Herbal treatment|
219724034|NCT01251458|DRUG|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
219724035|NCT06545864|DRUG|Streptokinase Injection|250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
219724036|NCT06545864|DEVICE|Penumbra System|"which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing"
219724037|NCT04806425|DRUG|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
219724038|NCT04806425|DRUG|Placebo|normal saline is given in same volume to normal saline group over the same duration
219724039|NCT04947787|BEHAVIORAL|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
219724040|NCT04947787|BEHAVIORAL|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
219724041|NCT00932802|DRUG|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
219724042|NCT01967953|PROCEDURE|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
219724043|NCT04938947|DEVICE|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
219724044|NCT04938947|OTHER|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
219724045|NCT04938947|OTHER|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
219724046|NCT06033664|BEHAVIORAL|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
219724047|NCT00997126|DRUG|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
219724048|NCT00997126|DRUG|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
219724049|NCT03970512|DEVICE|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
219724050|NCT01305629|BEHAVIORAL|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
219724051|NCT04924790|BEHAVIORAL|COVID-19 Pandemic|Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
219151964|NCT00137722|BEHAVIORAL|Education of providers and their staff|
219724052|NCT03967314|OTHER|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
219724053|NCT03967314|OTHER|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
219724054|NCT02120079|DRUG|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
219724055|NCT02120079|DRUG|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
219724056|NCT02120079|DIAGNOSTIC_TEST|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
219724057|NCT04184908|DRUG|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
219151965|NCT00137722|BEHAVIORAL|Case management|
219151966|NCT00137722|BEHAVIORAL|Payment for desired behaviors|
219151967|NCT03311893|PROCEDURE|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
219151968|NCT00079846|DRUG|Implitapide|
219151969|NCT04788212|BEHAVIORAL|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
219724058|NCT04184908|OTHER|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
219724059|NCT03536962|OTHER|no intervention|no intervention
219724060|NCT02242110|BEHAVIORAL|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
219724061|NCT02817204|BEHAVIORAL|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
219724062|NCT02817204|BEHAVIORAL|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
219724063|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
219724064|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
219151970|NCT03556449|DIAGNOSTIC_TEST|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
219151971|NCT05591872|DRUG|LD+I+TRB|Same as in the arm description
219151972|NCT00634075|DRUG|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
219151973|NCT00634075|DRUG|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
219151974|NCT00397475|DRUG|Colecalciferol|
219151975|NCT00809068|DRUG|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
219151976|NCT00809068|DRUG|tibolone|tibolone 2.5 mg daily 23 weeks
219151977|NCT02040831|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
219151978|NCT02040831|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
219151979|NCT00004149|DRUG|arsenic trioxide|
219151980|NCT00687856|PROCEDURE|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
219151981|NCT05546710|DEVICE|miraDry treatment|The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
219151982|NCT01311622|DRUG|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
219151983|NCT01311622|DRUG|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
219151984|NCT01644032|OTHER|Teleconsultation|Teleconsultation between paramedics and an EMS physician
219724065|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
219151985|NCT05985590|DRUG|BMS-986278|Specified dose on specified days
219151986|NCT05985590|DRUG|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
219151987|NCT04530149|DRUG|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
219151988|NCT04530149|DRUG|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
219151989|NCT04530149|DRUG|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
219151990|NCT00829036|DEVICE|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
219151991|NCT05900505|OTHER|Social Navigator|The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
219151992|NCT00244673|BIOLOGICAL|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
219151993|NCT00808405|DRUG|acyclovir|400mg taken orally three times daily for 5 days
219151994|NCT00808405|DRUG|matching placebo|matching placebo taken orally three times daily for 5 days.
219151995|NCT02809794|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
219151996|NCT01514149|DRUG|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
219151997|NCT01514149|DRUG|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
219151998|NCT04977700|BEHAVIORAL|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
219151999|NCT04653506|DRUG|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
219152000|NCT04653506|DRUG|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
219724066|NCT03152890|DRUG|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
219152001|NCT03610594|OTHER|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
219152002|NCT04962750|DEVICE|Low level laser therapy|Low level laser therapy from suitable machine
219232965|NCT05205213|OTHER|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
219232966|NCT04508777|BEHAVIORAL|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
219232967|NCT03072706|DEVICE|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
219152003|NCT04962750|OTHER|Sham device|The device wasn't working
219152004|NCT01057459|OTHER|laboratory biomarker analysis|Correlative studies
219232968|NCT03072706|OTHER|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
219232969|NCT04296734|BEHAVIORAL|Mothers and Babies|Mothers \& Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers \& Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
219232970|NCT03407976|DRUG|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
219232971|NCT03407976|DRUG|Pembrolizumab|200 mg Q3 weeks IV
219232972|NCT01262456|DRUG|Desmopressin|
219724067|NCT02111356|DEVICE|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
219724068|NCT00236678|DRUG|Epoetin alfa|
219724069|NCT02282033|DEVICE|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
219724070|NCT04242134|DEVICE|Drug-coating balloon|Provisional stenting technique with DCB
219152005|NCT00391898|DRUG|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
219152006|NCT00391898|DRUG|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
219152007|NCT05561452|OTHER|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
219232973|NCT01262456|DRUG|Placebo|
219232974|NCT01727193|DRUG|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
219232975|NCT01727193|DRUG|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
219232976|NCT01264874|DRUG|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
219724071|NCT05409638|BEHAVIORAL|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
219724072|NCT05683496|DRUG|lonigutamab|subcutaneous injection
219232977|NCT01264874|OTHER|placebo|For 3 years IU every 50 days
219232978|NCT00120107|DRUG|Black Tea|
219232979|NCT05785650|DIAGNOSTIC_TEST|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
219232980|NCT03553225|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
219232981|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
219232982|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
219724073|NCT05683496|DRUG|Placebo|subcutaneous injection
219724074|NCT05334979|OTHER|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
219724075|NCT06406296|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
219724076|NCT06246955|BEHAVIORAL|Behavioral Intervention: Group Therapy Session|Attend virtual group therapy sessions
219724077|NCT06246955|OTHER|Survey Administration|Ancillary study
219724078|NCT03912519|PROCEDURE|Parallel placement of 16 gauge electrodes|Parallel technique
219724079|NCT03912519|PROCEDURE|Perpendicular placement with 22 gauge electrodes|Perpendicular technique
219724080|NCT02787369|DRUG|ACY-1215|
219724081|NCT02787369|DRUG|Ibrutinib|
219724082|NCT02787369|DRUG|Idelalisib|
219724083|NCT05459532|DRUG|Molnupiravir 200 mg|The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
219152008|NCT05561452|OTHER|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
219152009|NCT05561452|OTHER|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
219152010|NCT00143234|DRUG|Amlodipine/atorvastatin single pill|
219152011|NCT00749749|DRUG|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
219152012|NCT00749749|DRUG|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
219152013|NCT04834219|PROCEDURE|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
219152014|NCT04834219|PROCEDURE|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
219724084|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
219724085|NCT03034928|DEVICE|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
219152015|NCT01962090|OTHER|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
219152016|NCT01962090|OTHER|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
219152017|NCT03229044|GENETIC|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
219152018|NCT00000493|DRUG|propranolol|
219152019|NCT00000493|DRUG|hyaluronidase|
219152020|NCT01178632|DRUG|Passiflora|01 tablet Passiflora p.o., b.i.d.
219724086|NCT03034928|DEVICE|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
219724087|NCT03034928|DEVICE|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
219724088|NCT03034928|DEVICE|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
219724089|NCT02818803|OTHER|Propolis|
219724090|NCT02818803|DRUG|Miconazole|
219724091|NCT01835756|DEVICE|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
219724092|NCT01835756|DEVICE|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
219724093|NCT05283447|OTHER|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
219724094|NCT05283447|OTHER|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
219724095|NCT06814054|DIAGNOSTIC_TEST|Carotid Artery Corrected Flow Time measurement|"* The cFT is defined as the time between the onset of systolic flow until closure of the aortic valve corrected for the HR and has been found to correlate with the intravascular volume.~* carotid ultrasound imaging will be performed 10 minutes before induction of general anesthesia in the preoperative holding area.~* Ultrasound measurements will be performed under a vascular setting with a 6.0 to 13.0MHz linear array transducer~* The right common carotid artery cFT will be measured in supine position with their heads tilted 30° to the left~* After that, a pulse wave Doppler will be chosen, and the sampling frame will be positioned at an angle of less than 60° in the region of the carotid artery with the best color flow to acquire the blood flow spectrum."
219724096|NCT06814054|DIAGNOSTIC_TEST|Inferior vena cava collapsibility index|"* The IVC will be examined while the patient has been spontaneously, quietly breathing and lying in the supine position for at least 5 min before assessment.~* A two-dimensional image of the IVC as it entered the right atrium will be obtained through the paramedian long-axis view via a subcostal approach using a curvilinear phased array probe (2-5 MHz)~* Then, using M-mode imaging produced at a medium sweep speed, changes in IVC diameter with breathing will be evaluated 2 to 3 cm distal to the right atrium.~* During the same respiratory cycle, measurements will be made of the IVC's greatest expiratory diameter (dIVC expiration) and lowest inspiratory diameter (dIVC inspiration). The formula IVCCI = (dIVC expiration - dIVC inspiration) × 100/dIVC expiration will be used to determine IVCCI as a percentage. (12)~* IVCCI will be assessed by the same trained anesthesiologist who was blinded to postin duction hemodynamic measurements."
219724097|NCT04620538|DIAGNOSTIC_TEST|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
219152021|NCT01178632|DRUG|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
219152022|NCT04045886|BEHAVIORAL|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
219152023|NCT02918279|DRUG|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
219152024|NCT02918279|DRUG|Placebo|Administered once daily subcutaneously (s.c., under the skin)
219360991|NCT04652804|BEHAVIORAL|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
219360992|NCT04652804|BEHAVIORAL|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
219724098|NCT02112552|DRUG|Paclitaxel|Given IV
219724099|NCT02112552|DRUG|Carboplatin|Given IP
219152025|NCT00329251|BIOLOGICAL|Hepatitis A|
219152026|NCT00329251|BIOLOGICAL|Hepatitis B|
219152027|NCT00329251|BIOLOGICAL|Influenza|
219152028|NCT00329251|BIOLOGICAL|Pneumococcal|
219152029|NCT00329251|BIOLOGICAL|Tetanus-diphteria|
219724100|NCT02112552|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
219724101|NCT02112552|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219724102|NCT02112552|OTHER|Quality-of-Life Assessment|Ancillary studies
219152030|NCT00329251|BIOLOGICAL|Varicella|
219152031|NCT00329251|BIOLOGICAL|Measles-Mumps-Rubella|
219152032|NCT04378361|DEVICE|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
219152033|NCT00309907|BIOLOGICAL|etanercept|Given IV and subcutaneously
219152034|NCT00309907|DRUG|methylprednisolone|Given IV and orally
219152035|NCT00244855|OTHER|pharmacological study|Correlative studies
219152036|NCT00244855|BIOLOGICAL|rituximab|Given IV
219152037|NCT00244855|DRUG|dexamethasone|Given IV
219152038|NCT00244855|OTHER|laboratory biomarker analysis|Correlative studies
219152039|NCT05608343|DRUG|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
219152040|NCT05608343|DRUG|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
219152041|NCT04816487|DRUG|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
219724103|NCT02112552|OTHER|Laboratory Biomarker Analysis|Correlative studies
219724104|NCT00016172|DRUG|pegylated liposomal doxorubicin hydrochloride|
219724105|NCT00016172|DRUG|picoplatin|
219724106|NCT04384874|OTHER|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
219724107|NCT06493942|OTHER|BioCoat® by Premier®|BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
219724108|NCT06493942|OTHER|UltraSeal XT™ plus by Ultradent|UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
219724109|NCT06169397|DRUG|XTMAB-16|XTMAB-16 infusion
219724110|NCT04714580|OTHER|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
219724111|NCT05311163|PROCEDURE|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
219724112|NCT01220063|RADIATION|Radiation|10 Gy for 4 times (total 40 Gy)
219724113|NCT01220063|DRUG|Irinotecan|40 mg/m² : Day 1 and day 8
219724114|NCT00104715|DRUG|antiandrogen therapy|
219724115|NCT00104715|DRUG|docetaxel|
219724116|NCT00104715|DRUG|goserelin acetate|
219724117|NCT00104715|PROCEDURE|orchiectomy|
219724118|NCT06312930|DEVICE|Transcranial pulse stimulation|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
219724119|NCT04752462|BEHAVIORAL|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
219152042|NCT00599716|DRUG|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
219152043|NCT00599716|DRUG|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
219152044|NCT00660439|BEHAVIORAL|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
219152045|NCT02957981|BEHAVIORAL|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
219152046|NCT02957981|BEHAVIORAL|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
219152047|NCT06110416|OTHER|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
219724120|NCT00393146|DRUG|GW856553|Study drug
219724121|NCT05716022|DIAGNOSTIC_TEST|Blood Collection|Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.
219360993|NCT04652804|BEHAVIORAL|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
219724122|NCT05716022|DIAGNOSTIC_TEST|Bronchoscopy|Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
219360994|NCT01180933|DIETARY_SUPPLEMENT|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
219724123|NCT05311969|OTHER|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
219724124|NCT02965456|DRUG|IDP 121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
219724125|NCT02965456|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
219724126|NCT02583477|DRUG|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
219724127|NCT02583477|DRUG|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
219724128|NCT00002308|DRUG|Stavudine|
219724129|NCT01587404|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
219724130|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 1
219724131|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 2
219724132|NCT04465955|OTHER|Sham Comparator|Sham Comparator
219724133|NCT00410527|DRUG|Merrem|
219724134|NCT04607759|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume two capsules for eight weeks
219724135|NCT02273453|DRUG|Songha® Night|
219724136|NCT02273453|DRUG|Oxazepam|
219724137|NCT02273453|DRUG|Placebo|
219232983|NCT03877783|DIETARY_SUPPLEMENT|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
219232984|NCT03877783|BEHAVIORAL|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
219232985|NCT03877783|OTHER|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg."
219232986|NCT04389788|DEVICE|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
219232987|NCT04389788|DEVICE|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
219232988|NCT03845881|DRUG|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
219152048|NCT03966508|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
219360995|NCT01180933|DIETARY_SUPPLEMENT|folate|400 µg per day
219724138|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing"
219152049|NCT01895023|DRUG|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
219152050|NCT01895023|DRUG|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
219724139|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing"
219724140|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing"
219724141|NCT06473129|BEHAVIORAL|Food for Life Culinary Workshops|Whole food, plant based 2hr workshop, which includes background information on diabetes, how to shop for food, etc and then a culinary demonstration and tasting of whole food, plant based dishes.
219724142|NCT03090269|DRUG|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
219152051|NCT01895023|DRUG|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
219152052|NCT01093430|PROCEDURE|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
219152053|NCT01093430|PROCEDURE|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
219152054|NCT00727922|DRUG|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
219152055|NCT03101410|BEHAVIORAL|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
219152056|NCT03101410|BEHAVIORAL|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
219152057|NCT06214117|DRUG|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
219152058|NCT06214117|DRUG|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
219152059|NCT00428519|DRUG|Placebo|Placebo for 14 days
219152060|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
219152061|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
219152062|NCT01760109|DRUG|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
219152063|NCT03953222|DEVICE|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
219152064|NCT04853602|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
219152065|NCT01061203|DRUG|Grazax|Treatment with 75.000 SQ-T once daily
219152066|NCT01061203|DRUG|Placebo|Tablet with no active grass component.
219152067|NCT06131892|OTHER|Defibrillation|Defibrillation
219152068|NCT03653169|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site. In this study, individuals will receive 10 treatments with intermittent theta burst stimulation (twice daily for 5 days).
219152069|NCT05622396|PROCEDURE|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
219152070|NCT00869258|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
219152071|NCT00869258|RADIATION|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
219152072|NCT02838199|DEVICE|SAPIEN 3|
219152073|NCT02838199|PROCEDURE|SAVR|
219152074|NCT02050763|BEHAVIORAL|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
219152075|NCT01336439|DRUG|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
219152076|NCT01641198|DEVICE|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
219152077|NCT01641198|DEVICE|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
219152078|NCT01641198|DEVICE|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
219724143|NCT00849329|DRUG|lapatinib|1250mg lapatinib
219724144|NCT00849329|DRUG|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
219724145|NCT05442632|DRUG|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
219152079|NCT04193410|BEHAVIORAL|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
219152080|NCT01396837|DEVICE|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
219152081|NCT02621632|DEVICE|(Socknleg)To done of a novel compression system|To done a novel compression system.
219152082|NCT03301025|DRUG|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
219152083|NCT03301025|DRUG|placebo|given a placebo identical capsule once one hour before anesthesia
219152084|NCT05957900|BEHAVIORAL|Multisensory stimulation module|"* Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~* Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~* Vestibular Stimulation; neonates placed in a hammock for 3 min.~* Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~* Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~* Olfactory Stimulation for 3 min. using mother's milk.~* Auditory Stimulation listening to mother's heart beats for 3 min."
219152085|NCT02928874|BEHAVIORAL|% COMPX (low ED vs. high ED preload)|
219152086|NCT02928874|BEHAVIORAL|EAH (low ED vs. high ED snacks)|
219152087|NCT03823196|DIETARY_SUPPLEMENT|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
219152088|NCT03823196|DIETARY_SUPPLEMENT|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
219152089|NCT00413257|DRUG|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
219152090|NCT00413257|DRUG|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
219152091|NCT00413257|DRUG|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
219152092|NCT06555718|BEHAVIORAL|The Peer Support Program|Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.
219152093|NCT06555718|BEHAVIORAL|Standart care|The standard care provided by the institution will continue.
219152094|NCT01032798|DRUG|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
219152095|NCT03615417|DEVICE|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
219152096|NCT03615417|DEVICE|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
219152097|NCT02600520|DRUG|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
219152098|NCT02600520|DRUG|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
219152099|NCT02600520|DRUG|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
219152100|NCT01068743|DRUG|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
219152101|NCT01068743|DRUG|metformin|Tablets, Oral, 850 mg, once daily, single dose
219152102|NCT01068743|DRUG|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
219152103|NCT01431586|DRUG|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
219152104|NCT03634280|OTHER|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
219152105|NCT00464399|DRUG|everolimus|
219152106|NCT03221478|OTHER|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
219152107|NCT03221478|OTHER|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
219152108|NCT03221478|OTHER|Kinesio Taping with tension|Kinesio Taping with tension
219152109|NCT05032794|OTHER|Unrestricted diet before colonoscopy|Free diet, without restrictions
219724146|NCT05442632|DRUG|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
219724147|NCT06210295|COMBINATION_PRODUCT|Laboratory investigtions|To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
219724148|NCT03608332|DEVICE|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
219734794|NCT04230239|DRUG|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
219724149|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
219724150|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
219152110|NCT05032794|OTHER|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
219724151|NCT01419925|BIOLOGICAL|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
219724152|NCT01419925|BIOLOGICAL|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
219152111|NCT05032794|DRUG|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
219152112|NCT00139672|DRUG|PD-217,014|
219152113|NCT00851669|BEHAVIORAL|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
219152114|NCT00851669|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
219152115|NCT03484065|OTHER|Questionnaire quality of life|
219152116|NCT03926039|BEHAVIORAL|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
219152117|NCT01406223|DRUG|Varenicline|
219152118|NCT01406223|DRUG|Bupropion|
219152119|NCT01406223|DRUG|Nicotine patches|
219152120|NCT01406223|OTHER|Placebo varenicline|
219152121|NCT01406223|OTHER|Placebo bupropion|
219152122|NCT01406223|OTHER|Placebo patch|
219152123|NCT01667302|DRUG|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
219152124|NCT00479635|DRUG|TPI 287|160 mg/m2 every three weeks for six cycles
219152125|NCT00479635|DRUG|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
219152126|NCT02514278|DRUG|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2"
219152127|NCT02514278|RADIATION|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
219152128|NCT02514278|PROCEDURE|Local excision in good responders|"If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
219724153|NCT01419925|BIOLOGICAL|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
219724154|NCT01419925|BIOLOGICAL|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
219724155|NCT01327703|DRUG|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
219734795|NCT02151604|DRUG|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
219734796|NCT01572688|DRUG|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
219734797|NCT05860530|DRUG|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
219152129|NCT02514278|PROCEDURE|Rectal excision in bad responders|
219152130|NCT02514278|DRUG|Capecitabine|1600 mg/m2 daily 5 days/7
219152131|NCT05765019|OTHER|Spinal mobilization|Spinal mobilization and core stabilization exercise
219152132|NCT05765019|OTHER|Core stabilization exercise|Stabilization exercises for the spine
219152133|NCT02869334|DEVICE|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
219152134|NCT02869334|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
219152135|NCT02869334|BEHAVIORAL|Auditory Remediation|Computer program designed to improve discrimination between sounds
219152136|NCT02869334|BEHAVIORAL|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
219152137|NCT05282472|DIAGNOSTIC_TEST|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
219152138|NCT05282472|DIAGNOSTIC_TEST|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
219734798|NCT05860530|DRUG|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
219734799|NCT00991562|DRUG|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
219734800|NCT01279993|PROCEDURE|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
219734801|NCT04469283|OTHER|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
219724156|NCT01327703|DRUG|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
219724157|NCT04235075|DEVICE|ECG/PCG and ultrasound signal acquisition|"The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants."
219724158|NCT01131585|PROCEDURE|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
219724159|NCT01131585|DRUG|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
219724160|NCT01131585|DRUG|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
219724161|NCT05914285|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
219724162|NCT05914285|DRUG|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
219724163|NCT00927082|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
219724164|NCT03833258|BEHAVIORAL|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
219724165|NCT00812097|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
219724166|NCT00004785|DRUG|dexamethasone|
219152139|NCT04478851|BEHAVIORAL|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
219152140|NCT00078624|OTHER|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
219152141|NCT00078624|OTHER|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
219152142|NCT01831700|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
219152143|NCT01831700|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
219152144|NCT02219724|DRUG|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
219152145|NCT02200094|DRUG|Low dose of Telmisartan, once daily|
219152146|NCT02200094|DRUG|High dose of Telmisartan, once daily|
219152147|NCT01869543|OTHER|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
219152148|NCT01869543|OTHER|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
219152149|NCT02416115|DRUG|Ramosetron|Ramosetron was given iv.
219152150|NCT02416115|DRUG|Naloxone|Naloxone added to PCA was given iv.
219152151|NCT02416115|DRUG|saline|Saline was given iv.
219152152|NCT02416115|DRUG|Morphine|Morphine in the PCA was given iv.
219152153|NCT03029598|DRUG|Carboplatin|Given IV
219152154|NCT03029598|OTHER|Laboratory Biomarker Analysis|Correlative studies
219152155|NCT03029598|BIOLOGICAL|Pembrolizumab|Given IV
219152156|NCT00664690|DRUG|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
219152157|NCT00664690|DRUG|placebo|placebo given preop and BID postop
219152158|NCT02928354|DRUG|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
219724167|NCT00004785|DRUG|methylprednisolone|
219724168|NCT00317369|DRUG|OPC-6535(Tetomilast)|
219724169|NCT03516981|BIOLOGICAL|Pembrolizumab|200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
219724170|NCT03516981|BIOLOGICAL|Favezelimab|200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
219724171|NCT03516981|DRUG|Lenvatinib|20 mg lenvatinib capsules administered orally once daily
219724172|NCT03516981|DRUG|Quavonlimab|Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
219724173|NCT03108690|DRUG|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
219724174|NCT03108690|OTHER|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
219724175|NCT01656746|PROCEDURE|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
219724176|NCT00890318|DRUG|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
219724177|NCT00890318|OTHER|ketoconazole|Tablet, see Arm Description for intervention information.
219724178|NCT00890318|DRUG|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
219724179|NCT05331898|BEHAVIORAL|Education|the education given increased the rational drug use of the parents.
219724180|NCT00819195|DRUG|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
219724181|NCT05133570|DEVICE|vista care|Prospective, open-label, multi-centre study evaluating the performance of the VistaCare® wound healing device in routine practice.
219724182|NCT03432429|OTHER|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
219724183|NCT00849472|DRUG|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
219724184|NCT00849472|DRUG|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
219724185|NCT00849472|PROCEDURE|surgery|neoadjuvant surgery for breast cancer
219152159|NCT02928354|DRUG|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
219152160|NCT02928354|DRUG|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
219152161|NCT00296868|DRUG|ascorbic acid (vitamin C) versus placebo|
219152162|NCT05101954|PROCEDURE|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
219152163|NCT05101954|PROCEDURE|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
219152164|NCT05877807|DRUG|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
219152165|NCT05877807|OTHER|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
219152166|NCT03272087|DEVICE|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
219152167|NCT03272087|DEVICE|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
219724186|NCT00849472|DRUG|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
219724187|NCT02173951|DRUG|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d"
219152168|NCT05176054|OTHER|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
219152169|NCT05700487|OTHER|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
219152170|NCT04350541|OTHER|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
219152171|NCT04350541|OTHER|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
219152172|NCT05451095|DRUG|BI 474121|BI 474121
219152173|NCT05451095|DRUG|Placebo|Placebo
219152174|NCT05451095|DRUG|Ketamine hydrochloride|Ketamine hydrochloride
219152175|NCT02853565|DRUG|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
219152176|NCT01790672|DIETARY_SUPPLEMENT|Ethanol|Vodka Absolut
219152177|NCT01790672|OTHER|Water|Lemon-flavored water
219152178|NCT01790672|DIETARY_SUPPLEMENT|Alcoholized wine|Wine 13º or wine 8º
219152179|NCT01790672|DIETARY_SUPPLEMENT|De-alcoholized wine|Wine 0º
219724188|NCT06465901|OTHER|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
219724189|NCT06465901|OTHER|Intraoperative wound wash (e.g. Granudacyn)|Intraoperative wound wash (e.g. Granudacyn)
219724190|NCT06465901|OTHER|DACC surgical wound dressing (e.g. Leukomed Sorbact)|DACC surgical wound dressing (e.g. Leukomed Sorbact)
219724191|NCT02918799|BEHAVIORAL|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
219724192|NCT00291915|DRUG|Adalimumab|
219724193|NCT00291915|DRUG|Methotrexate|
219724194|NCT06141681|OTHER|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
219724195|NCT00902967|DRUG|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
219152180|NCT02413866|BEHAVIORAL|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
219152181|NCT02413866|BEHAVIORAL|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
219152182|NCT00939510|BIOLOGICAL|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
219152183|NCT00939510|DRUG|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
219152184|NCT00939510|OTHER|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
219152185|NCT05834270|DRUG|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
219152186|NCT05834270|DRUG|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
219152187|NCT04133337|DRUG|Apatinib|Apatinib Mesylate Tablets
219152188|NCT04133337|DRUG|SHR-1210|Camrelizumab for Injection
219152189|NCT01402830|OTHER|Visual analogue scales (EVAs)|This scale measures the pain intensity.
219232989|NCT03845881|DRUG|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
219724196|NCT00902967|DRUG|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
219152190|NCT03110965|BEHAVIORAL|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
219152191|NCT01612169|BEHAVIORAL|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
219152192|NCT01612169|BEHAVIORAL|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
219152193|NCT03546998|DIAGNOSTIC_TEST|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
219152194|NCT02933944|BIOLOGICAL|TG02-treatment|
219152195|NCT02933944|DRUG|Pembrolizumab|
219152196|NCT03487172|DEVICE|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
219152197|NCT03487172|DEVICE|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
219152198|NCT01558986|PROCEDURE|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
219152199|NCT01558986|PROCEDURE|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
219152200|NCT03278587|OTHER|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
219152201|NCT03278587|OTHER|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
219152202|NCT03278587|OTHER|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
219152203|NCT04731948|DIETARY_SUPPLEMENT|Folic Acid|400µg Folic Acid per day for 16 weeks
219152204|NCT04731948|DIETARY_SUPPLEMENT|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
219152205|NCT04731948|DIETARY_SUPPLEMENT|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
219152206|NCT04731948|DIETARY_SUPPLEMENT|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
219232990|NCT02662816|DEVICE|Proton magnetic resonance spectroscopy (1H MRS)|
219232991|NCT02662816|OTHER|a protein rich breakfast at home|
219232992|NCT02662816|OTHER|a protein rich lunch at the Clinical Investigation Center|
219232993|NCT03654482|DEVICE|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
219232994|NCT02661958|DRUG|S6G5T-3|once a day topical cream
219232995|NCT02661958|DRUG|S6G5T-1|once a day topical cream
219724197|NCT00825175|BEHAVIORAL|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
219724198|NCT00825175|DEVICE|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
219724199|NCT03544164|OTHER|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
219724200|NCT05132946|PROCEDURE|Nerve block|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
219724201|NCT04424680|BEHAVIORAL|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
219724202|NCT04099420|BEHAVIORAL|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
219724203|NCT05293834|BEHAVIORAL|Virtual Reality Aggression Prevention Training (VRAPT)|"VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)"
219724204|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
219724205|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
219724206|NCT05433350|DRUG|Acoziborole|"Two different mode of administration will be used during the study depending on the body weight and on the step of the study:~whole tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 whole or crushed tablets for paediatric patients weighing 10 to 40 kg in step 2"
219724207|NCT05709132|BEHAVIORAL|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
219724208|NCT06034392|DEVICE|CHAMP App|CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.
219724209|NCT04373525|OTHER|Genome analysis|Venous blood will be obtained for later genome analysis
219724210|NCT06436924|DEVICE|Left Atrial Appendage Device Implant|The Watchman Device is implanted into the left atrial appendage and is designed to close it off and keep blood clots from escaping that area.
219724211|NCT00338078|DEVICE|nocturnal oxygen treatment from oxygen concentrators|
219724212|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
219152207|NCT05089526|DRUG|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
219152208|NCT05089526|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
219152209|NCT04431297|OTHER|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
219724213|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions
219724214|NCT01767415|DRUG|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
219152210|NCT06176391|DEVICE|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
219232996|NCT02661958|DRUG|S6G5T-5|once a day topical cream
219232997|NCT02661958|DRUG|S6G5T-6|once a day topical cream
219232998|NCT02661958|DRUG|S6G5T-7|once a day topical cream
219232999|NCT02661958|DRUG|S6G5T-8|once a day topical cream
219233000|NCT03860129|DRUG|Isoflurane|Group A: Isoflurane (0.5 MAC)
219233001|NCT03860129|DRUG|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
219724215|NCT04530851|PROCEDURE|ERAS|"* Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea"
219724216|NCT04912817|OTHER|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
219724217|NCT04912817|OTHER|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
219152211|NCT06258824|DIAGNOSTIC_TEST|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
219724218|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium and saffron extract|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
219724219|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
219724220|NCT06183190|OTHER|No intervention|No intervention
219724221|NCT04892277|BIOLOGICAL|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
219724222|NCT04892277|DRUG|Bendamustine|Given IV
219724223|NCT04892277|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219152212|NCT05496842|BEHAVIORAL|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
219152213|NCT02083692|DRUG|Metformin|
219152214|NCT00263952|BIOLOGICAL|bee venom|
219152215|NCT00799552|DRUG|RX-10045|RX-10045 eye drop
219152216|NCT00799552|DRUG|Placebo|Placebo eye drop
219152217|NCT03113266|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219152218|NCT04247074|BIOLOGICAL|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
219152219|NCT04247074|BIOLOGICAL|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
219233002|NCT03860129|DRUG|Desflurane|Group C: Desflurane (0.5 MAC)
219360996|NCT01180933|DIETARY_SUPPLEMENT|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
219360997|NCT01180933|DIETARY_SUPPLEMENT|placebo|only vitamins and minerals as recommended, but no fish oil or folate
219360998|NCT03634800|DRUG|Nivolumab 240mg|Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.
219360999|NCT03634800|RADIATION|Radiation therapy|Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
219361000|NCT03118596|DEVICE|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
219361001|NCT03118596|DEVICE|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
219361002|NCT04831333|OTHER||
219361003|NCT03714490|RADIATION|SCPRT|Short-course preoperative radiotherapy(SCPRT), which consists of 5 Gy x 5f and 4Gy for boost on the GTV with MRI-simulation alone.
219152220|NCT04193969|DIAGNOSTIC_TEST|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
219724224|NCT04892277|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219152221|NCT04193969|DIAGNOSTIC_TEST|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
219152222|NCT04193969|DIAGNOSTIC_TEST|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
219152223|NCT04193969|DIAGNOSTIC_TEST|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
219152224|NCT04193969|DIAGNOSTIC_TEST|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
219152225|NCT02059382|BEHAVIORAL|ChiRunning training|
219152226|NCT02059382|BEHAVIORAL|unblinded accelerometer|
219152227|NCT02059382|BEHAVIORAL|participation in online social network|
219152228|NCT02059382|BEHAVIORAL|participation in study website|
219152229|NCT02059382|BEHAVIORAL|Technology support for behavior change|
219152230|NCT01855334|DRUG|Spironolactone|
219152231|NCT01855334|DIETARY_SUPPLEMENT|L-arginine|
219152232|NCT01855334|DRUG|Placebo|
219152233|NCT02720965|OTHER|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
219152234|NCT00006517|DEVICE|bright light box|10,000 lux bright light therapy
219152235|NCT00006517|DEVICE|dawn simulator|gradual rise in bedroom illumination prior to wake-up
219152236|NCT00006517|DEVICE|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
219724225|NCT04892277|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219152237|NCT00006517|DEVICE|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
219152238|NCT00006517|DEVICE|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
219152239|NCT01895699|OTHER|Contrast agent|
219724226|NCT04892277|PROCEDURE|Computed Tomography|Undergo CT
219724227|NCT04892277|DRUG|Cyclophosphamide|Given IV
219724228|NCT04892277|DRUG|Fludarabine|Given IV
219724229|NCT04892277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219152240|NCT00995904|DRUG|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
219152241|NCT00995904|DRUG|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
219152242|NCT00995904|DRUG|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
219152243|NCT02490254|OTHER|Surveillance card|
219152244|NCT06647784|OTHER|pulmonary aeration in supine and ventral decubitus|The addition of repeated periods of 30 minutes of lateralization of 30° amplitude in dorsal decubitus and in ventral decubitus in patients with moderate to severe ARDS. Included patients will benefit from sessions of lateral decubitus for 30 minutes on each side (with an inclination of 30°) with alternation right/left (total one hour). During this period, the upper part of the bed will be inclined by 30°. Patients will then be positioned in strict prone position for a period of 6 hours after which, the same pattern of alternating lateral decubitus will be applied for 12 hours while the patient is still in the prone position. After reversal in supine position, an observation period of 1 hour will be respected before carrying out the last measurements. The total duration of the intervention will be 20 hours.
219152245|NCT02943590|DRUG|Placebo|A pill taken once a day
219152246|NCT02943590|DRUG|Atorvastatin|A pill taken once a day
219152247|NCT05782231|BEHAVIORAL|GetActive+|10-week group mind body program focused on improving self-report, performance-based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota-based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
219724230|NCT04892277|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
219724231|NCT00572481|PROCEDURE|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
219724232|NCT05853887|BEHAVIORAL|iNUDGE|Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
219724233|NCT02265653|DRUG|BIIL 284 BS tablet C|
219724234|NCT02265653|DRUG|BIIL 284 BS tablet D|
219724235|NCT02265653|DRUG|BIIL 284 BS WIF tablet|
219724236|NCT02691572|PROCEDURE|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
219724237|NCT02691572|DRUG|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
219724238|NCT02691572|DRUG|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
219724239|NCT02691572|PROCEDURE|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
219724240|NCT02691572|PROCEDURE|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
219233003|NCT02140879|DIETARY_SUPPLEMENT|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
219233004|NCT02140879|DIETARY_SUPPLEMENT|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
219233005|NCT05662930|BEHAVIORAL|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
219233006|NCT05662930|BEHAVIORAL|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
219233007|NCT05662930|BEHAVIORAL|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
219152248|NCT05733364|DIETARY_SUPPLEMENT|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
219152249|NCT05733364|OTHER|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
219233008|NCT05662930|BEHAVIORAL|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
219233009|NCT05662930|BEHAVIORAL|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
219233010|NCT05662930|BEHAVIORAL|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
219233011|NCT01368484|DIETARY_SUPPLEMENT|Sunflower oil|1500 mg sunflower/day for 10 weeks
219152250|NCT03557411|DRUG|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
219152251|NCT02685189|OTHER|Previous exposure to stannsoporfin|No intervention in this protocol
219152252|NCT03615495|DEVICE|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
219724241|NCT02691572|PROCEDURE|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
219152253|NCT03049969|DEVICE|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
219152254|NCT04567043|BEHAVIORAL|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
219152255|NCT04567043|BEHAVIORAL|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
219233012|NCT01368484|DIETARY_SUPPLEMENT|Docosahexanoic acid|1500mg/day for 10 weeks
219724242|NCT02691572|PROCEDURE|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
219724243|NCT02691572|DRUG|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
219724244|NCT02691572|DRUG|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
219724245|NCT02691572|PROCEDURE|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
219724246|NCT00714480|DRUG|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
219724247|NCT00714480|DRUG|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
219724248|NCT00714480|DRUG|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
219152256|NCT03071081|DRUG|TOP1288|Oral TOP1288
219152257|NCT03071081|DRUG|Placebo to TOP1288|Oral placebo to TOP1288
219724249|NCT00661440|DRUG|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
219724250|NCT01142921|DEVICE|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
219724251|NCT01142921|DEVICE|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
219724252|NCT01422902|OTHER|Plasticity-based Cognitive Training|
219233013|NCT02718885|DIETARY_SUPPLEMENT|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
219233014|NCT02718885|DIETARY_SUPPLEMENT|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
219233015|NCT04546555|DEVICE|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
219233016|NCT04546555|OTHER|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
219233017|NCT04546555|OTHER|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
219233018|NCT03770897|PROCEDURE|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
219724253|NCT01422902|OTHER|Non-plasticity-based Training|Computer games
219233019|NCT03770897|PROCEDURE|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
219233020|NCT03137849|OTHER|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
219233021|NCT03137849|OTHER|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
219724254|NCT03148340|DIAGNOSTIC_TEST|VIPS Monitoring|Bioimpedance asymmetry
219724255|NCT02327481|PROCEDURE|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
219233022|NCT03137849|OTHER|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
219233023|NCT05298540|BEHAVIORAL|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
219724256|NCT02327481|PROCEDURE|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
219724257|NCT06441799|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
219724258|NCT06441799|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
219724259|NCT05890820|OTHER|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
219724260|NCT01257438|DEVICE|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
219724261|NCT01257438|DEVICE|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
219724262|NCT04520100|BEHAVIORAL|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
219724263|NCT04520100|BEHAVIORAL|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
219724264|NCT05503069|BEHAVIORAL|Interventions with social and cultural components|"Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study."
219724265|NCT02085551|DEVICE|Mechanical Thrombectomy by the Indigo System|
219724266|NCT03370302|DRUG|TAK-228|TAK-228 Capsules.
219724267|NCT01370889|DRUG|resveratrol|Given PO
219724268|NCT01370889|OTHER|laboratory biomarker analysis|Correlative studies
219724269|NCT04217356|BIOLOGICAL|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
219724270|NCT04217356|DRUG|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
219724271|NCT04217356|DRUG|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
219724272|NCT01011725|DRUG|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
219724273|NCT01011725|DRUG|Placebo|Placebo oral tablet b.i.d for 12 weeks
219724274|NCT02916329|OTHER|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
219724275|NCT02474706|DRUG|Cefoxitin|
219724276|NCT02474706|DRUG|imipenem|
219724277|NCT01428128|DRUG|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
219724278|NCT00452257|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
219152258|NCT04794959|DIAGNOSTIC_TEST|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
219152259|NCT03639558|DRUG|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
219152260|NCT03639558|DRUG|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
219152261|NCT06086561|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
219152262|NCT04176380|BIOLOGICAL|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
219152263|NCT03085498|OTHER|No intervention|no intervention
219152264|NCT05993351|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
219152265|NCT05993351|DIAGNOSTIC_TEST|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
219152266|NCT05993351|BEHAVIORAL|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
219152267|NCT05156892|DRUG|SUBA-itraconazole|150 mg BD
219152268|NCT05156892|DRUG|Tamoxifen|"Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study"
219152269|NCT06972368|DEVICE|tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of home-based transcranial Direct Current Stimulation (tDCS), administered twice daily for 30 minutes over 7 consecutive days. Each session will use a 2mA current with a SNAPstrap™ montage targeting the left dorsolateral prefrontal cortex (F3) with the anode and the right DLPFC (F4) with the cathode. Sessions include a 30-second ramp-up and ramp-down. The total delivered charge will be 48 coulombs.~Enhancement component:~Each session will be paired with cognitive and emotional enhancement strategies:~Emotion regulation script (DBT-inspired, personalized and pre-written based on a moderately dysregulated situation).~Cognitive training via Lumosity, targeting executive functions and memory."
219152270|NCT06972368|PROCEDURE|Treatment as Usual (TAU)|"Description:~Throughout the study, participants are required to maintain stable pharmacological and psychotherapeutic regimens, defined as:~No changes in medications or therapy for at least 6 weeks after tDCS initiation.~TAU is provided by participants' regular treating physician or mental health professional, independent of the study team.~TAU includes psychotropic medication, psychotherapy, and case management, as clinically indicated."
219152271|NCT06972368|PROCEDURE|Psychoeducation|"All participants receive access to a structured online psychoeducation program before randomization.~This includes:~* Short videos (8-14 minutes each) covering BPD, depression, neuromodulation, therapeutic success factors, and tDCS.~* Multiple-choice quizzes (MCQs) to ensure comprehension.~* Delivered in French with English subtitles. Designed to improve understanding of BPD and associated treatments, including the rationale for tDCS."
219152272|NCT06972368|DEVICE|Sham-tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of sham tDCS, with identical scheduling and device setup as the active condition. The session mimics real tDCS (same SNAPstrap montage, ramp-up and ramp-down of 30 seconds), but no current is delivered after the initial 30 seconds.~Enhancement component:~Participants follow the same emotional regulation script and Lumosity cognitive training during"
219724279|NCT04071886|BEHAVIORAL|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
219724280|NCT04071886|BEHAVIORAL|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
219724281|NCT03893214|BEHAVIORAL|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
219724282|NCT03893214|BEHAVIORAL|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
219152273|NCT06974162|DIAGNOSTIC_TEST|Metagenomic sequencing of aqueous humor|Metagenomic Sequencing on aqueous humor surplus to diagnostic requirements
219724283|NCT05729191|BIOLOGICAL|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
219724284|NCT06159036|DEVICE|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
219724285|NCT04508075|BIOLOGICAL|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
219724286|NCT04508075|BIOLOGICAL|Placebo|Placebo manufactured by PT. Bio Farma
219724287|NCT06025370|OTHER|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
219724288|NCT06523790|BEHAVIORAL|Yoga|Participants in the yoga group will attend 90-minute yoga sessions, 3 times per week, for 8 months. The sessions will include a combination of asanas (postures), pranayama (breathing exercises), and meditation.
219724289|NCT06523790|BEHAVIORAL|Brisk walking|Participants in the brisk walking group will engage in one-hour fast-paced walking sessions, 6 times per week, for 8 months. The walking regimen is designed to improve cardiovascular fitness, endurance, and support weight loss.
219724290|NCT02710747|GENETIC|CYP2C9;VKORC1|
219152274|NCT06974162|DIAGNOSTIC_TEST|Ocular Imaging|Ocular imaging with anterior segment OCT, laser flare photometry, confocal microscopy and colour fundus photography.
219152275|NCT06972849|DRUG|Caffeine citrate|Clinically indicated for apnea of prematurity.
219152276|NCT05180591|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
219152277|NCT05180591|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
219233024|NCT00070421|PROCEDURE|complementary or alternative medicine procedure|
219724291|NCT00679601|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
219724292|NCT02663505|PROCEDURE|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
219724293|NCT00918450|DRUG|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
219724294|NCT03185507|DEVICE|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
219724295|NCT01888588|DRUG|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
219724296|NCT04846257|OTHER|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
219724297|NCT05594238|BEHAVIORAL|Telephone Engagement|Brief phone session with a study counselor.
219724298|NCT05594238|BEHAVIORAL|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
219724299|NCT05594238|BEHAVIORAL|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
219724300|NCT06255743|DIAGNOSTIC_TEST|Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies|determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
219724301|NCT01648959|OTHER|EEG Recording|
219724302|NCT04143048|OTHER|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
219152278|NCT01834703|PROCEDURE|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
219152279|NCT01834703|PROCEDURE|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
219152280|NCT00158028|DRUG|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
219152281|NCT00158028|DRUG|Placebo|placebo match in identical tablets
219152282|NCT00303836|DRUG|cyclophosphamide|Given IV
219152283|NCT00303836|DRUG|fludarabine phosphate|Given IV
219152284|NCT00303836|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219233025|NCT00070421|PROCEDURE|management of therapy complications|
219233026|NCT00070421|PROCEDURE|psychosocial assessment and care|
219233027|NCT05260944|DEVICE|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
219233028|NCT05260944|DEVICE|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
219233029|NCT05260944|OTHER|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
219152285|NCT00303836|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
219152286|NCT00303836|BIOLOGICAL|gp100 antigen|Given SC
219152287|NCT00303836|BIOLOGICAL|MART-1 antigen|Given SC
219152288|NCT00303836|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
219152289|NCT00303836|BIOLOGICAL|filgrastim|Given SC
219152290|NCT00303836|BIOLOGICAL|aldesleukin|Given IV
219152291|NCT03534869|PROCEDURE|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
219152292|NCT03534869|DRUG|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
219152293|NCT04168801|DIETARY_SUPPLEMENT|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
219152294|NCT00465192|DRUG|estradiol, 10 mcg|
219152295|NCT00465192|DRUG|estradiol, 25 mcg|
219152296|NCT00465192|DRUG|placebo|
219152297|NCT03238391|PROCEDURE|Ischemic preconditioning|It is mentioned before in arm/group descriptions
219233030|NCT00916656|BIOLOGICAL|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
219152298|NCT03560934|DRUG|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
219152299|NCT06499246|PROCEDURE|Donor Parathyroid|Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
219152300|NCT02528188|DRUG|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
219152301|NCT02528188|BIOLOGICAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
219233031|NCT00916656|BIOLOGICAL|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
219233032|NCT00986505|DRUG|Lidocaine|Intravenous lidocaine once a week
219724303|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
219152302|NCT02528188|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
219152303|NCT02083575|DRUG|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
219152304|NCT02083575|DRUG|deferiprone , deferesarox|iron chelator
219152305|NCT04092231|BEHAVIORAL|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
219152306|NCT01844492|BEHAVIORAL|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
219724304|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
219724305|NCT03884764|PROCEDURE|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
219724306|NCT03884764|PROCEDURE|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
219152307|NCT01844492|OTHER|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
219152308|NCT04992364|OTHER|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
219233033|NCT02500433|OTHER|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
219233034|NCT02500433|OTHER|Conventional therapy|
219152309|NCT06389266|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of rTMS with functional magnetic resonance imaging allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.
219233035|NCT05926557|PROCEDURE|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
219233036|NCT05926557|PROCEDURE|NSMD|Only mechanical debridement with curettes and scaler peek tips
219233037|NCT03392844|OTHER|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
219152310|NCT06972654|PROCEDURE|Group Nalupnine|Patients will receive a unilateral ultrasound-guided pericapsular nerve group (PENG) block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml nalbuphine (20 mg), with total volume 22ml.
219233038|NCT04121234|OTHER|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
219724307|NCT04120779|DEVICE|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
219724308|NCT04759547|DEVICE|handheld ultrasound-assisted technique|Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
219724309|NCT04759547|OTHER|conventional palpation-guided technique|The interspinous space is detected by palpation
219724310|NCT01495247|DRUG|BEZ235|Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
219152311|NCT06972654|PROCEDURE|Group Dexamethasone|Patients will receive a unilateral ultrasound-guided PENG block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml dexamethasone (8 mg), with total volume 22ml.
219152312|NCT03343197|DRUG|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
219152313|NCT03343197|DRUG|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
219152314|NCT02592954|DRUG|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
219152315|NCT02592954|DRUG|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
219152316|NCT04333329|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
219724311|NCT01495247|DRUG|Paclitaxel|"The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
219724312|NCT06058156|DRUG|SAR444656 (KT-474)|Oral Tablet
219724313|NCT06058156|DRUG|Placebo|Oral Tablet
219724314|NCT04023552|DRUG|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
219724315|NCT04023552|DRUG|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
219724316|NCT04180696|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled
219724317|NCT04180696|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
219724318|NCT06638385|PROCEDURE|DCE + SPACE SHIELD|Patients receive a DCE with implantation of a space-expanding shield.
219152317|NCT02779517|OTHER|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
219152318|NCT02779517|OTHER|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
219152319|NCT00993369|OTHER|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
219152320|NCT06051786|DRUG|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
219152321|NCT06051786|DRUG|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
219152322|NCT02808585|DRUG|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
219152323|NCT02808585|DRUG|Placebo Injection|Four weekly subcutaneous injections of placebo.
219152324|NCT03998280|DEVICE|Assessment|Neck proprioception and postural stability
219152325|NCT02994173|DRUG|Oxycodone|Current clinical practice, used as a control in this study
219152326|NCT02994173|DRUG|S-Ketamine 0.25|dosage
219152327|NCT02994173|DRUG|S-Ketamine 0.5|dosage
219152328|NCT02994173|DRUG|S-Ketamine 0.75|dosage
219152329|NCT01353170|OTHER|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
219152330|NCT06238869|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.
219152331|NCT06238869|BEHAVIORAL|Music Therapy|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
219152332|NCT06238869|BEHAVIORAL|Health education|Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.
219152333|NCT05567822|DRUG|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
219152334|NCT05567822|DRUG|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
219152335|NCT01692730|BEHAVIORAL|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
219152336|NCT01692730|BEHAVIORAL|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
219724319|NCT06638385|PROCEDURE|DCE + CP|Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
219724320|NCT03895489|DEVICE|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
219724321|NCT03895489|DEVICE|Stryker|Stryker Triathlon Total Knee prosthesis
219724322|NCT03895489|DEVICE|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
219724323|NCT00424008|DRUG|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
219724324|NCT00424008|DRUG|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
219724325|NCT00963508|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
219724326|NCT00963508|DRUG|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
219724327|NCT03104023|PROCEDURE|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
219724328|NCT03104023|COMBINATION_PRODUCT|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
219724329|NCT02664493|DRUG|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
219724330|NCT02759458|DEVICE|Smith & Nephew Healicoil Anchor|
219724331|NCT02759458|DEVICE|Smith & Nephew Twinfix Anchor|
219724332|NCT03565289|DIAGNOSTIC_TEST|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
219734802|NCT00563563|DRUG|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
219724333|NCT03406663|BEHAVIORAL|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
219152337|NCT02298751|BEHAVIORAL|Cue Exposure Treatment|
219152338|NCT02081274|PROCEDURE|Surgery for congenital heart disease|
219152339|NCT03599453|PROCEDURE|Biopsy|Undergo Biopsy
219152340|NCT03599453|PROCEDURE|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
219152341|NCT03599453|DRUG|Celecoxib|Given by mouth
219152342|NCT03599453|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given intravenously
219152343|NCT03599453|DRUG|Rintatolimod|Given intravenously
219152344|NCT03599453|BIOLOGICAL|Pembrolizumab|Given intravenously
219152345|NCT00933400|DIAGNOSTIC_TEST|CT Coronary Angiography (CTCA)|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
219152346|NCT00933400|PROCEDURE|Traditional Strategy|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
219152347|NCT02457845|BIOLOGICAL|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
219152348|NCT00328835|PROCEDURE|Brief Elevation of IOP|
219152349|NCT06212141|DEVICE|VisCalor Bulk,VOCO,Germany|"It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec."
219152350|NCT06212141|DEVICE|Admira Fusion x-tra,VOCO,Germany|"Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds."
219152351|NCT06212141|DEVICE|Filtek One Bulk,3M,Germany|"Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations."
219233039|NCT06160453|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
219724334|NCT03406663|BEHAVIORAL|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
219724335|NCT05662995|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
219233040|NCT06160453|DEVICE|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
219724336|NCT05522530|OTHER|Assessment scale|Evaluation scale to carry out its cross-cultural adaptation and study its validity
219724337|NCT06805097|OTHER|Self-assessment of bleeding events|After each transfusion, the patient completes a daily bleeding event self-assessment (adapted from the WHO bleeding event scale) until the next transfusion or over a period of 10 days.
219233041|NCT04506047|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
219152352|NCT04658914|BIOLOGICAL|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
219152353|NCT04658914|BIOLOGICAL|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
219233042|NCT05033756|DRUG|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
219724338|NCT02331420|PROCEDURE|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
219724339|NCT02331420|BEHAVIORAL|Medical therapy|"* Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~* Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~* Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~* Programs for diet and lifestyle modification, including reduced overall energy and fat intake (\<30% total fat, \<10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~* low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
219152354|NCT01843101|DEVICE|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
219152355|NCT03661957|PROCEDURE|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
219724340|NCT02593864|DEVICE|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
219724341|NCT00699127|BEHAVIORAL|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
219724342|NCT01282788|DIETARY_SUPPLEMENT|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
219233043|NCT05033756|DRUG|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
219724343|NCT04739709|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
219724344|NCT04739709|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
219233044|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
219233045|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
219734803|NCT00563563|BEHAVIORAL|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
219734804|NCT02783937|BIOLOGICAL|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
219152356|NCT03661957|PROCEDURE|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
219152357|NCT00716859|DRUG|Timolol|Timolol 0.5% dosed twice-daily
219152358|NCT00716859|DRUG|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
219152359|NCT02088424|OTHER|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
219233046|NCT00277277|BEHAVIORAL|Healthium|
219233047|NCT02399449|DRUG|Brand sodium ferric gluconate|brand product
219233048|NCT02399449|DRUG|Generic sodium ferric gluconate|generic product
219233049|NCT05711433|PROCEDURE|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
219233050|NCT02993094|DRUG|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
219233051|NCT02993094|DRUG|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
219233052|NCT02516202|DRUG|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
219233053|NCT02516202|DEVICE|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
219233054|NCT02516202|OTHER|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
219233055|NCT02516202|OTHER|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
219233056|NCT03595670|OTHER|standardized questionnaires|standardized questionnaires concerning the perception
219152360|NCT03750968|DRUG|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
219152361|NCT03750968|DIETARY_SUPPLEMENT|Control Group|Placebo ingredients: Safflower oil
219152362|NCT05862610|DRUG|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
219152363|NCT05862610|DRUG|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
219152364|NCT06323902|PROCEDURE|Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation|In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
219152365|NCT04125810|BIOLOGICAL|Probiotic|Probiotic
219152366|NCT04125810|OTHER|Placebo|Placebo
219152367|NCT02400099|DIETARY_SUPPLEMENT|High-protein low calorie diet|
219724345|NCT01697046|DRUG|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
219724346|NCT02640209|BIOLOGICAL|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
219152368|NCT02400099|DIETARY_SUPPLEMENT|Control low calorie diet|
219724347|NCT01614223|PROCEDURE|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
219724348|NCT01614223|DRUG|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
219724349|NCT01181479|DRUG|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
219724350|NCT01181479|DRUG|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
219724351|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Post-Workout Supplement|The Post-Workout Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
219724352|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|The Maltodextrin Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
219724353|NCT04359212|DRUG|thromboprophylaxis with low-molecular-weight heparin or fondaparinux|thromboprophylaxis with low-molecular-weight heparin or fondaparinux
219361004|NCT03714490|RADIATION|CRT|Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.
219152369|NCT02400099|OTHER|Anthropometrical measurements|
219152370|NCT02400099|OTHER|Body composition|
219152371|NCT02400099|OTHER|8-h metabolic profile|
219152372|NCT02400099|OTHER|Liver biopsy|
219152373|NCT04093908|OTHER|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
219152374|NCT01347125|DEVICE|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
219152375|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
219724354|NCT02969278|PROCEDURE|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
219152376|NCT00700336|DRUG|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
219152377|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
219152378|NCT00970658|DRUG|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
219152379|NCT00970658|DRUG|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
219724355|NCT02969278|PROCEDURE|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
219152380|NCT04747743|OTHER|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
219152381|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
219152382|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
219152383|NCT04294329|PROCEDURE|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
219152384|NCT04294329|DRUG|Bupivacaine|Bupivacaine
219152385|NCT04294329|DRUG|Saline|normal saline
219724356|NCT00019071|DRUG|chemotherapy|
219724357|NCT00019071|DRUG|cladribine|
219152386|NCT05833906|DRUG|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
219152387|NCT05833906|DRUG|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
219152388|NCT05833906|DRUG|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
219152389|NCT05833906|DRUG|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
219152390|NCT05833906|DRUG|Placebo|Placebo comparator.
219152391|NCT04701866|OTHER|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
219724358|NCT00019071|RADIATION|radiation therapy|
219724359|NCT02978807|PROCEDURE|Point of care and venous screening|
219724360|NCT02705703|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
219724361|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using HAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of HAP-containing toothpaste twice daily for 1 month.
219724362|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using Zn Mg HAP-containing)|Toothbrushing using standardised technique and pear-sized amount of Zn Mg HAP-containing toothpaste twice daily for 1 month.
219724363|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using FAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of FAP-containing toothpaste twice daily for 1 month.
219152392|NCT03762213|DEVICE|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
219152393|NCT03762213|DEVICE|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
219152394|NCT05515900|DIETARY_SUPPLEMENT|Sodium|Daily sodium supplementation of 2000 mg.
219152395|NCT05515900|DIETARY_SUPPLEMENT|HMB|Daily HMB supplementation of 3 g.
219152396|NCT05515900|OTHER|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
219152397|NCT03336515|DEVICE|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
219152398|NCT03336515|DEVICE|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
219152399|NCT03336515|BEHAVIORAL|Group A-General Recommendation|General recommendation not sleeping in supine position
219152400|NCT02190578|DEVICE|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
219152401|NCT06112977|PROCEDURE|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
219152402|NCT03131869|OTHER|Thickened Beverages Nectar|Thickened beverages in nectar consistency
219152403|NCT03131869|OTHER|Thickened Beverage Honey|Thickened beverages in honey consistency
219152404|NCT01115959|DRUG|valproic acid|treatment of 1 month dosage of 400 mg BID
219152405|NCT01115959|DRUG|placebo bid|
219152406|NCT05401474|DEVICE|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
219152407|NCT05401474|DEVICE|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
219152408|NCT05401474|DEVICE|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
219152409|NCT02708927|OTHER|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
219152410|NCT02708927|OTHER|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
219152411|NCT02024685|BEHAVIORAL|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
219152412|NCT02024685|BEHAVIORAL|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
219152413|NCT02509637|DEVICE|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
219152414|NCT02509637|OTHER|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
219724364|NCT02272101|DIETARY_SUPPLEMENT|Vitamin D versus placebo|Cross-over design
219724365|NCT01045200|OTHER|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
219724366|NCT00759096|DEVICE|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
219152415|NCT02509637|OTHER|Control|
219152416|NCT02509637|OTHER|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
219152417|NCT02509637|OTHER|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
219152418|NCT02509637|OTHER|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
219724367|NCT05462678|BEHAVIORAL|Cognitive Rehabilitation|Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
219724368|NCT05462678|BEHAVIORAL|Combined Rehabilitation|Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
219724369|NCT05462678|BEHAVIORAL|Motor Rehabilitation|Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
219724370|NCT01276652|BEHAVIORAL|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
219724371|NCT05359068|DRUG|SPH3127 tablet|1 tablet
219724372|NCT05359068|DRUG|SPH3127 tablet|2 tablets
219724373|NCT05359068|DRUG|SPH3127 tablet|4 tablets
219724374|NCT05359068|DRUG|Valsartan|1 valsartan capsule
219724375|NCT05359068|DRUG|SPH3127 tablet|2 tablets
219233057|NCT03595670|OTHER|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
219724376|NCT05359068|DRUG|Valsartan|1 valsartan capsule
219724377|NCT00334919|BEHAVIORAL|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
219724378|NCT02226900|PROCEDURE|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
219233058|NCT01531413|OTHER|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
219724379|NCT02226900|PROCEDURE|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
219233059|NCT03597152|DIETARY_SUPPLEMENT|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
219233060|NCT03597152|DIETARY_SUPPLEMENT|Placebo|Inert placebo custom manufactured for the sponsor
219233061|NCT05430555|BIOLOGICAL|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
219233062|NCT05659836|DEVICE|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
219724380|NCT05151614|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
219233063|NCT02365402|DRUG|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
219233064|NCT00839085|DRUG|GSE|grape seed extract (100 mg/6h), PO
219233065|NCT00839085|DRUG|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
219233066|NCT02451072|DRUG|Placebo|Capsules containing mannitol looking identical to LSD per os
219233067|NCT02451072|DRUG|LSD|100µg per os, single dose
219233068|NCT02451072|DRUG|Ketanserin|40mg per os, single dose looking identical to LSD per os
219233069|NCT00337610|DRUG|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
219233070|NCT00337610|DRUG|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
219233071|NCT01278914|BIOLOGICAL|Dendritic Cells (DC) prostate|
219724381|NCT06241443|OTHER|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
219724382|NCT06241443|OTHER|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
219724383|NCT03237754|DEVICE|tDCS device from neuroConn|weak electrical direct current stimulation
219724384|NCT02373072|DRUG|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
219724385|NCT02373072|DRUG|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
219724386|NCT02373072|DRUG|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
219724387|NCT02680275|DRUG|Dead Sea Peloid Gel|intravaginally
219724388|NCT04249778|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
219724389|NCT04249778|DRUG|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
219734805|NCT02783937|DRUG|Saline|Injection of saline SC injection twice daily for five consecutive days
219734806|NCT04495478|DRUG|Ramucirumab - IV|Administered IV.
219734807|NCT04495478|DRUG|Placebo - IV|Administered IV.
219734808|NCT04495478|DRUG|Ramucirumab - SC|Administered SC.
219734809|NCT04495478|DRUG|Placebo - SC|Administered SC.
219734810|NCT07055763|COMBINATION_PRODUCT|Nigella sativa (black seed)|Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects.
219734811|NCT07056829|DEVICE|Mandibular Advancement Appliance (Invisalign MA)|"Clear aligner system with integrated buccal precision wings to posture the mandible forward.~Advancement protocol: 2 mm increments every 8 weeks. Total active treatment duration: \~8.15 months, followed by retention phase. Patients instructed to wear aligners ≥20 h/day, removing only for eating and oral hygiene."
219734812|NCT07056829|DEVICE|Activator Appliance|"Traditional removable functional appliance fabricated on a standardized bite registration.~Patients instructed to wear appliance 24 h/day except during meals and sports. Total active treatment duration: \~7.15 months, followed by retention phase."
219724390|NCT05920226|DEVICE|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
219724391|NCT05920226|DIAGNOSTIC_TEST|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
219724392|NCT03233217|BIOLOGICAL|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
219152419|NCT02509637|DEVICE|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
219152420|NCT02509637|OTHER|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
219152421|NCT02309034|BEHAVIORAL|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
219152422|NCT02309034|BEHAVIORAL|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
219152423|NCT02309034|OTHER|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
219152424|NCT00915564|DRUG|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
219152425|NCT00915564|OTHER|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
219152426|NCT03876210|COMBINATION_PRODUCT|PK101|PK101-001 + PK101-002 (combination)
219724393|NCT03233217|BIOLOGICAL|QIV-SD by SC|SC, injected into the upper arm (posterior region)
219724394|NCT03233217|BIOLOGICAL|QIV-HD by SC|SC, injection into the upper arm (posterior region)
219724395|NCT03436927|OTHER|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
219724396|NCT03436927|OTHER|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
219724397|NCT02530242|DEVICE|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
219152427|NCT03876210|DRUG|PK101-001, PK101-002|coadministration
219233072|NCT00952640|DIETARY_SUPPLEMENT|vitamin A|high dose vitamin A, 200.000 IU
219724398|NCT02530242|DEVICE|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
219152428|NCT01524952|DEVICE|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
219152429|NCT00411216|OTHER|Control exercises|saccadic eye movements against a plain background; no head movements
219152430|NCT00411216|OTHER|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
219152431|NCT00417950|DRUG|Acarbose|
219152432|NCT02828943|BEHAVIORAL|IMT with High Resistance EMT|
219152433|NCT02828943|BEHAVIORAL|IMT with Low Resistance EMT|
219152434|NCT02376842|BEHAVIORAL|Severe sepsis early warning best practice alert|
219152435|NCT02376842|BEHAVIORAL|Standard care|
219152436|NCT01291381|DRUG|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
219152437|NCT01291381|DRUG|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
219152438|NCT04044651|DRUG|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
219152439|NCT04044651|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
219152440|NCT00217841|DRUG|Aurograb|
219724399|NCT00283959|DRUG|migalastat HCl|
219724400|NCT05993143|DRUG|Ivermectin|Round and white tablets
219724401|NCT05993143|DRUG|Placebo|Round and white tablets
219724402|NCT05225831|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
219724403|NCT05225831|DRUG|Cyclophosphamide,Fludarabine|Given
219724404|NCT03275922|DRUG|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
219152441|NCT06150508|BEHAVIORAL|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
219724405|NCT03275922|DRUG|ZNS|Zolmitriptan Nasal Spray
219724406|NCT05591755|DRUG|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
219724407|NCT05591755|DRUG|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
219724408|NCT05591755|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
219724409|NCT05591755|DRUG|Experimental: Vehicle ophthalmic solution|Experimental: Vehicle ophthalmic solution
219152442|NCT06027489|BEHAVIORAL|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
219724410|NCT03535688|DRUG|D-cycloserine|200 mg twice daily
219724411|NCT03535688|DRUG|Placebo|twice daily
219152443|NCT06027489|BEHAVIORAL|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
219152444|NCT05003778|OTHER|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
219233073|NCT04943640|OTHER|kinesio taping|Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
219233074|NCT04943640|OTHER|rigid taping|The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
219724412|NCT04441398|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
219724413|NCT04441398|DRUG|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
219724414|NCT05175365|BEHAVIORAL|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
219724415|NCT01922193|DRUG|Highly Purified Urofollitropin|for injection
219724416|NCT01922193|DRUG|Recombinant Human Follitropin Alfa|for injection
219724417|NCT00433290|DRUG|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
219724418|NCT00433290|DRUG|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
219724419|NCT00583544|DRUG|TC-2216|Multiple ascending dose groups will be explored.
219724420|NCT01060956|OTHER|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
219724421|NCT01060956|OTHER|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
219724422|NCT00308347|DRUG|MK0954, losartan / Duration of Treatment: mean 3.4 years|
219724423|NCT00308347|DRUG|Placebo / Duration of Treatment: mean 3.4 years|
219724424|NCT00554723|DRUG|NeuroAid|4 capsules 3 times daily, for three months
219724425|NCT00554723|DRUG|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
219724426|NCT03217097|DRUG|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
219724427|NCT03217097|DRUG|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
219724428|NCT00004055|BIOLOGICAL|filgrastim|
219724429|NCT00004055|DRUG|paclitaxel|
219724430|NCT00004055|DRUG|topotecan hydrochloride|
219724431|NCT00571090|PROCEDURE|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
219724432|NCT00335075|DRUG|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
219724433|NCT00335075|DRUG|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
219724434|NCT03875417|PROCEDURE|liver resection|resection of one or more HCC nodules within the liver
219724435|NCT03875417|PROCEDURE|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
219724436|NCT03875417|PROCEDURE|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
219724437|NCT04248179|DRUG|Ropivacaine injection|Ropivacaine 5mg/ml
219724438|NCT04248179|DRUG|Saline 0.9%|Saline 0.9%
219152445|NCT05003778|OTHER|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
219152446|NCT05003778|OTHER|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
219152447|NCT03809312|DRUG|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
219724439|NCT04248179|DRUG|Sufentanil and PONV prophylaxis|30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
219152448|NCT03809312|DRUG|Placebos|Placebos BID x 10 days
219152449|NCT06113770|OTHER|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
219152450|NCT06113770|OTHER|preparation of the tooth to receive CAD CAM PMMA custom made crown|"* Open the interproximal contacts .~* The tooth should be reduced circumferentially by approximately 0.5-1mm .~* The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~* Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~* The final crown will be cemented using glass ionomer cement ."
219152451|NCT06005857|OTHER|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
219152452|NCT06005857|OTHER|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
219724440|NCT01483651|DRUG|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
219724441|NCT01483651|DRUG|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
219724442|NCT01989273|DEVICE|Ultrasound of inferior vena cava|
219724443|NCT03876353|OTHER|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
219724444|NCT00315575|PROCEDURE|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
219724445|NCT00500890|DRUG|Carboplatin|350 mg/m\^2 by vein, Over 2 Hours x 2 Days
219724446|NCT00500890|DRUG|Cyclophosphamide|1 g/m\^2 by vein, Over 1 Hour x 2 Days
219724447|NCT00500890|DRUG|Etoposide|100 mg/m\^2 by vein, Over 1 Hour x 5 Days
219724448|NCT00500890|DRUG|Vincristine|1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5
219724449|NCT00500890|RADIATION|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
219724450|NCT00064454|DRUG|OPC-6535 Tablets (drug)|
219724451|NCT06188546|DRUG|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
219152453|NCT03244046|BEHAVIORAL|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
219152454|NCT03244046|BEHAVIORAL|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
219152455|NCT01348217|RADIATION|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
219152456|NCT01348217|RADIATION|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
219152457|NCT01348217|RADIATION|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
219152458|NCT01348217|DRUG|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
219152459|NCT00511160|PROCEDURE|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
219152460|NCT00511160|PROCEDURE|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
219152461|NCT01282840|DRUG|Tolterodine SR|Tolterodine SR 4 mg qd
219152462|NCT02721134|OTHER|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
219152463|NCT02918071|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
219152464|NCT02052219|DRUG|Blisibimod|Blisibimod administered subcutaneously
219152465|NCT02052219|DRUG|Placebo|Placebo administered subcutaneously
219152466|NCT02834598|DEVICE|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
219152467|NCT02094807|DRUG|NSAID|Will be used if other drugs are not tolerated.
219724452|NCT03837938|DRUG|Levopront® syrup 30 mg/5 ml|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
219152468|NCT02094807|PROCEDURE|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
219152469|NCT02094807|DRUG|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
219152470|NCT02094807|DRUG|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
219152471|NCT02094807|PROCEDURE|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
219233075|NCT04943640|OTHER|placebo taping|Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
219233076|NCT01277679|PROCEDURE|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
219233077|NCT04898582|OTHER|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
219233078|NCT05576233|PROCEDURE|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
219233079|NCT00000170|DRUG|Atropine|Atropine
219233080|NCT00000170|DEVICE|Eye Patch|Patching
219724453|NCT03837938|DRUG|Libexin®|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
219724454|NCT00005850|DRUG|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
219724455|NCT00005850|DRUG|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
219724456|NCT00005850|DRUG|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
219724457|NCT01789775|DRUG|Drug: CD07805/47 gel|
219724458|NCT01789775|DRUG|CD07805/47 gel Placebo|
219724459|NCT04737694|DIETARY_SUPPLEMENT|Ketone ester|Oral ketone ester + glucose supplement
219724460|NCT04737694|DIETARY_SUPPLEMENT|Glucose|Glucose supplement
219724461|NCT01481025|DRUG|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
219152472|NCT04423016|DEVICE|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
219152473|NCT04423016|DEVICE|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
219152474|NCT02912208|DRUG|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
219152475|NCT02912208|OTHER|Placebo|The administration is the same of eltrombopag
219724462|NCT01481025|DRUG|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
219152476|NCT03185650|DEVICE|tPAD Device|A novel, transnasal aerosol generator
219152477|NCT03185650|DEVICE|PARI LC Star Nebulizer|Standard oral nebulizer
219152478|NCT04855903|DEVICE|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
219152479|NCT04706052|OTHER|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
219152480|NCT03250052|DRUG|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
219152481|NCT03250052|DRUG|(fimasartan and linagliptin) x 7days|Part A \& Part B: Co-administration of fimasartan and linagliptin
219152482|NCT00237991|BIOLOGICAL|Hepatitis A|
219152483|NCT05106270|DIAGNOSTIC_TEST|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
219152484|NCT01550549|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
219152485|NCT04255290|OTHER|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
219152486|NCT04255290|OTHER|Control group|The subjects included in the control group will perform an eccentric work protocol
219152487|NCT06366984|OTHER|plastibell|plastibell used for circumcision
219152488|NCT06366984|OTHER|open method|open method used for circumcision
219152489|NCT06299228|OTHER|Experimental Group|Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening
219152490|NCT06299228|OTHER|Control Group|Active range of motion, active assisted range of motion and strengthening
219152491|NCT06223048|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
219152492|NCT05308056|DEVICE|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
219152493|NCT05519202|DRUG|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
219724463|NCT01481025|DRUG|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
219152494|NCT04135885|DRUG|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
219152495|NCT04135885|DRUG|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
219152496|NCT02740400|PROCEDURE|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
219152497|NCT02740400|PROCEDURE|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
219152498|NCT03074617|OTHER|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
219724464|NCT03743818|DEVICE|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
219724465|NCT03743818|OTHER|ultrasound|aply ultrasound on the knee
219724466|NCT03743818|DEVICE|hyauluronic acid|aply hyaluronic acid on the knee
219724467|NCT02596672|BEHAVIORAL|The friendly walking group|A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
219724468|NCT05360446|DRUG|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
219724469|NCT05360446|DRUG|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
219724470|NCT01917773|DRUG|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
219724471|NCT01917773|DRUG|Bisacodyl|
219724472|NCT06011226|OTHER|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
219724473|NCT06011226|OTHER|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
219724474|NCT04867148|DEVICE|Inertial measurement unit sensor-based gait analysis system|Gait analysis was performed on 20-m long corridor to collect gait data on more than 23 strides. The gait protocol was performed with an IMU sensor-based gait analysis system (DynaStab™, JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1 SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-Spotfire1, Tibco Spotfire 7.10). The shoe-type data logger included an IMU sensor (IMU-3000™, InvenSense, USA) that measured tri-axial acceleration (up to ± 6 g) and tri-axial angular 136 velocity (up to ± 500˚ s-1) along three orthogonal axes.12,16 The IMU sensors were installed in both shoe outsoles, and the data were transmitted wirelessly to a data acquisition system via Bluetooth®. Shoe sizes were adapted to each participant, with available sizes ranging from 225 mm to 280 mm. The local coordinate system for the IMU sensors included the 140 anteroposterior, mediolateral, and vertical directions.
219724475|NCT02260622|DRUG|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
219724476|NCT02260622|DRUG|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
219724477|NCT00800514|DRUG|amantadine|amantadine twice daily
219724478|NCT00800514|DRUG|amantadine|amantadine 100 mg twice daily
219724479|NCT00504309|DRUG|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
219724480|NCT00504309|DRUG|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
219724481|NCT00504309|DRUG|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
219724482|NCT02301091|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
219724483|NCT02301091|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
219152499|NCT03074617|OTHER|sham field|no electromagnetic field
219152500|NCT00124878|PROCEDURE|Male circumcision|Sleeve circumcision
219724484|NCT02301091|DRUG|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
219724485|NCT02997670|OTHER|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
219724486|NCT03345095|DRUG|Marizomib|Intravenous administration of Marizomib
219724487|NCT03345095|DRUG|Temozolomide|Oral Administration of Temozolomide
219724488|NCT03345095|RADIATION|radiotherapy|60 Gy in 30 fractions over 6 weeks
219724489|NCT01121575|DRUG|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
219724490|NCT01121575|DRUG|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
219361005|NCT03714490|DRUG|CAPOX|Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
219361006|NCT05210179|BIOLOGICAL|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
219152501|NCT03855007|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219152502|NCT03855007|DRUG|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
219152503|NCT03855007|DRUG|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
219152504|NCT03855007|DRUG|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
219152505|NCT04877652|OTHER|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
219152506|NCT01003834|BEHAVIORAL|Computerized brief intervention|Intervention based on Motivational Interviewing technique
219152507|NCT01003834|BEHAVIORAL|Computerized health screening|Behavioral intervention
219152508|NCT01003834|BEHAVIORAL|Computerized assessment|Behavioral intervention
219361007|NCT05210179|BIOLOGICAL|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
219361008|NCT03690310|BIOLOGICAL|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
219361009|NCT03321448|DRUG|TMTP1-ICG|Detection of SLN
219361010|NCT03321448|DRUG|ICG|Detection of SLN
219724491|NCT01121575|DRUG|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
219724492|NCT01121575|DRUG|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
219724493|NCT05539287|DRUG|Lactobacillus-Based Capsule|25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
219724494|NCT02102737|DRUG|6-DIG|injection of 6-DIG
219724495|NCT02102737|PROCEDURE|clamp|hyperinsulinemic euglycemic clamp
219724496|NCT04216004|BEHAVIORAL|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
219724497|NCT04216004|DIETARY_SUPPLEMENT|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
219724498|NCT04216004|OTHER|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
219724499|NCT04216004|OTHER|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
219724500|NCT04375592|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
219724501|NCT01799278|DRUG|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
219724502|NCT00724503|DEVICE|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
219724503|NCT00724503|DRUG|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
219724504|NCT03927716|DRUG|SB206 12%|Topically once daily
219724505|NCT03927716|DRUG|Placebo|Topically once daily
219152509|NCT01003834|BEHAVIORAL|Therapist-delivered motivational intervention|Behavioral intervention
219152510|NCT04250935|DIAGNOSTIC_TEST|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
219724506|NCT02633657|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
219152511|NCT03116620|OTHER|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
219152512|NCT01957124|PROCEDURE|PRF (Platelet-Rich Fibrin)|
219152513|NCT02901197|BEHAVIORAL|Education and Reminder Posters|See arm description
219152514|NCT02901197|OTHER|Policy Change|See arm description
219152515|NCT01646749|DIETARY_SUPPLEMENT|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
219152516|NCT01029587|DRUG|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
219152517|NCT00225004|PROCEDURE|DEXA scan|orto
219724507|NCT06810531|DRUG|Ondanesterone plus dexamethasone combination|"Group D: Ondanesterone 4mg plus dexamethasone 8mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
219724508|NCT06810531|DRUG|ondanesterone plus metoclopramide combination|"Group M: ondanesterone 4mg plus metoclopramide 10 mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
219724509|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
219724510|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
219724511|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
219152518|NCT03133234|DRUG|osimertinib|Oral dose of 80mg once daily
219724512|NCT00627107|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
219724513|NCT01186419|DRUG|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
219724514|NCT04565223|BEHAVIORAL|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
219724515|NCT05907759|DRUG|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
219724516|NCT06232083|RADIATION|PLDR+Cardunizumab|Application of PLDR external irradiation combined with Cardunizumab in recurrent lung cancer, esophageal cancer and cervical cancer.
219724517|NCT01218178|DRUG|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
219724518|NCT01218178|DRUG|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
219724519|NCT00931424|PROCEDURE|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
219724520|NCT04325347|OTHER|Virtual Reality application|Virtual Reality application with a VR goggle
219724521|NCT04970108|DRUG|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
219724522|NCT04970108|DRUG|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
219724523|NCT03982654|DEVICE|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
219724524|NCT03812328|DRUG|SelK2|I.V., single-dose
219724525|NCT03812328|BIOLOGICAL|Enoxaparin|SC, QD for up to 10 ± 2 days
219152519|NCT05900921|DRUG|Trilaciclib|IV infusion, d1
219152520|NCT05900921|DRUG|Carboplatin|IV infusion, d1
219724526|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
219724527|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
219152521|NCT05900921|DRUG|Paclitaxel|IV infusion, d1
219724528|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
219724529|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
219152522|NCT05900921|DRUG|Tislelizumab|IV infusion, d1
219724530|NCT06811415|PROCEDURE|virtual temporomandibular joint reconstruction with costochondral graft|All patients were placed in preoperative occlusion in CASS. The planned rib was harvested in the standard manner through an inframammary incision. The length of the rib was equal to the prefabricated template as calculated in the cranial-maxillofacial 3D reconstruction, and comprised at most 5 mm of cartilage. The cartilage was trimmed and contoured to facilitate the setting of the cartilage side properly into the center of the TMJ fossa. A 4-hole titanium plate was fixed with four bicortical screws as previously planned
219724531|NCT06179940|OTHER|Pairwise food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
219724532|NCT06179940|OTHER|Individual food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
219152523|NCT03969524|DEVICE|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
219152524|NCT04644341|COMBINATION_PRODUCT|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
219152525|NCT04773678|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
219152526|NCT04773678|DRUG|Placebo|Placebo subcutaneous (SC) injection.
219361011|NCT00197197|DRUG|GW873140|
219361012|NCT03333070|DIETARY_SUPPLEMENT|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
219361013|NCT03333070|OTHER|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
219724533|NCT00932711|BEHAVIORAL|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
219152527|NCT05707624|OTHER|video education|In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
219152528|NCT05707624|OTHER|the routine procedure|the routine procedure
219152529|NCT03649113|PROCEDURE|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
219152530|NCT00391196|DRUG|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
219152531|NCT00391196|DRUG|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
219152532|NCT00391196|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
219152533|NCT01761487|DEVICE|Gentamicin and polymyxin E|
219152534|NCT03608995|DIAGNOSTIC_TEST|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
219152535|NCT03608995|DIAGNOSTIC_TEST|Quikcheck fFN ™|\- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
219152536|NCT04080141|DIAGNOSTIC_TEST|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
219724534|NCT04374552|DRUG|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate \&Azithromycin
219152537|NCT04080141|PROCEDURE|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
219152538|NCT05736094|DEVICE|SURF|Dual-frequency ultrasound
219152539|NCT03310866|DEVICE|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
219152540|NCT03310866|DEVICE|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
219152541|NCT06972342|BEHAVIORAL|education|Participants will be intervened after the baseline measurements, including two training classes.
219152542|NCT01086982|DRUG|Octreotide acetate LAR|30 mg, single dose
219724535|NCT04374552|DRUG|Placebo|Drug - placebo
219724536|NCT01607008|OTHER|MRI imaging|"3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment"
219724537|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
219724538|NCT03827798|DRUG|CFZ533|s.c.
219724539|NCT03827798|DRUG|Placebo to CFZ533|s.c.
219152543|NCT01086982|DRUG|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
219361014|NCT02776241|OTHER|water|
219724540|NCT03827798|DRUG|LYS006|p.o.
219724541|NCT03827798|DRUG|Placebo to LYS006|p.o.
219724542|NCT03827798|DRUG|MAS825|s.c.
219724543|NCT03827798|DRUG|Placebo to MAS825|s.c.
219724544|NCT03827798|DRUG|LOU064 25mg|p.o.
219724545|NCT03827798|DRUG|LOU064 100mg|p.o.
219361015|NCT05086445|DRUG|LY3502970|Administered orally
219361016|NCT05086445|DRUG|Placebo|Administered orally
219361017|NCT03909360|PROCEDURE|drainage tube|sub-hepatic drainage tube for laparoscopic cholecystectomy
219361018|NCT03676127|OTHER|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
219724546|NCT03827798|DRUG|Placebo to LOU064|p.o.
219724547|NCT03827798|DRUG|VAY736|s.c.
219724548|NCT03827798|DRUG|Placebo to VAY736|s.c.
219734813|NCT07055958|DRUG|Metformin|Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5. Beyond its well established antihyperglycemic impact, metformin demonstrated anti-oxidant and anti-inflammatory activities contributing its potential benefits in conditions associated with inflammation and oxidative stress. Furthermore, metformin rapidly crosses the blood brain barrier and disperses into several brain regions presenting an ideal therapeutic option for the treatment of PD.
219734814|NCT07055958|OTHER|placebo|placebo of tab. Metformin of same shape
219724549|NCT06821737|DEVICE|Diagnostic ultrasound|A portable wireless ultrasound system (Vscan Air, General Electric Healthcare) with dual probes-linear array (3-12 MHz) for neck scanning and curved array (2-5 MHz) for subxiphoid scanning-will be used. The linear probe is placed transversely on the anterior neck, slid left at the thyroid level to focus on the esophagus, then rotated for longitudinal views. The curved probe is applied subxiphoid, using the liver as a landmark, and tilted left to image the stomach. A positive result is confirmed by visualizing the NGT shadow in the esophagus and stomach, followed by dynamic upsurge fogging after injecting 50cc of air. Ultrasonography and X-ray results will be compared.
219724550|NCT06821737|DEVICE|Diagnostic X-ray|This study will employ chest radiography as the reference standard for verification of correct nasogastric tube placement. Radiographic imaging will be conducted following NGT insertion and interpreted by physicians to verify positional accuracy.
219724551|NCT06856759|GENETIC|Intrathecal injection of AAV-MECP2 for the treatment of Rett syndrome|"For Dose 1, the first 5 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant dose limiting toxicity (DLT) observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~Once the fifth subject in Dose 1 completes the administration and no significant DLT is observed after a follow-up period of at least two weeks, the study dose can be escalated to a higher level.~For Dose 2, the 3 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant DLT observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~DLT definition: see Study Description."
219724552|NCT06659991|DRUG|alcohol condition|Ethanol
219724553|NCT06659991|OTHER|control condition|sparkling water
219724554|NCT05164263|DRUG|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
219724555|NCT00469729|DRUG|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
219724556|NCT01426646|DRUG|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
219724557|NCT01426646|DRUG|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
219724558|NCT04377568|BIOLOGICAL|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
219724559|NCT07006467|DEVICE|Implantation of RFS|Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion
219724560|NCT07056088|DRUG|Insulin Drip Therapy|"Simple randomization will be used for randomization. The participants will be randomized into two groups based on methods of insulin delivery.~* Group A: Insulin drip will be administered at a starting rate of 2 units/hour and titrated to maintain blood glucose levels between 80-180 mg/dL.~* Group B: Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group."
219724561|NCT07056088|DRUG|Insulin boluses|"Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group"
219724562|NCT07124910|COMBINATION_PRODUCT|Epi-ON corneal cross-linking|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light"
219724563|NCT07124559|DRUG|Rifapentine|Dispersible Tablet administered orally
219724564|NCT07124559|DRUG|Isoniazid|Dispersible Tablet administered orally
219724565|NCT07124559|DRUG|Dolutegravir|Tablets and Tablets for oral suspension administered orally
219724566|NCT07124247|DEVICE|Activity registration for one week with an activity monitor (MOX1)|"The participants will be equipped with the MOX activity monitor, which will be attached to the thigh. The device is waterproof, allowing participants to shower and swim, and does not require recharging during the study period.~The MOX will be attached on the same day as the BBS and Handgrip strength measurements, which will take place on a Friday. The following Monday, the 10mWT will be conducted, thus within the same week that the MOX is attached.~The MOX monitor will be worn for one week."
219724567|NCT06168812|DRUG|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
219724568|NCT07124845|OTHER|Focusing on the mind|8 times of multimedia cases videos and focused conversation
219724569|NCT06519097|DRUG|Vitamin E Delta Tocotrienol|"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"
219724570|NCT06519097|OTHER|Placebo|"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"
219724571|NCT06544655|DRUG|BMS-986484|Specified dose on specified days
219724572|NCT06544655|BIOLOGICAL|Nivolumab|Specified dose on specified days
219724573|NCT06544655|DRUG|Oxaliplatin|Specified dose on specified days
219724574|NCT06544655|DRUG|Capecitabine|Specified dose on specified days
219724575|NCT06544655|DRUG|Fluorouracil|Specified dose on specified days
219724576|NCT06544655|DRUG|Calcium folinate|Specified dose on specified days
219724577|NCT06544694|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
219724578|NCT06544694|OTHER|Artificial Tears|Commercially available, preservative-free lubricant eye drops
219724579|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
219724580|NCT04886791|PROCEDURE|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
219152544|NCT06972303|BEHAVIORAL|Instructed bedtime app-guided mindfulness meditation|All participants will access the a smartphone app, and the mindfulness meditation practice may involve techniques such as breathing exercise, imagery, body scan, and relaxation. The investigators will provide instructions for participants who are assigned to practice at bedtime.
219233081|NCT01123174|BEHAVIORAL|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
219233082|NCT02615132|BEHAVIORAL|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
219152545|NCT06972303|BEHAVIORAL|Uninstructed app-guided mindfulness meditation|The guided mindfulness meditation practice will also be based on the same app. The investigators will not provide instructions for participants, and they have complete freedom to use the app as real-world users.
219152546|NCT06972303|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education will be based on recognized, general, non-personalized sleep hygiene advice, for example, recommendations about bedtime routines and use of alcohol and caffeine, tips on creating a sleep-conducive bedroom environment.
219152547|NCT06973408|BEHAVIORAL|Behavioral Treatment|Behavioral support is designed to help participants adhere to the dietary recommendations through personalized coaching and motivational strategies. Participants engage in weekly or bi-weekly coaching sessions, either online or in person, where they receive guidance on overcoming challenges and maintaining dietary changes. The coaching incorporates evidence-based behavior change techniques, such as goal setting, self-monitoring, feedback on performance, problem-solving, and stimulus control. To further support behavior change, participants receive practical tools, including visual aids, educational videos, and structured meal planning resources. The overall goal of behavioral support is to encourage sustainable dietary habits by providing continuous encouragement and individualized strategies.
219152548|NCT06973408|BEHAVIORAL|Food support|Food support, which is provided exclusively to participants in the Optimized Lifestyle Intervention Group, ensures that they have access to key foods required to meet dietary targets. These foods include whole grains such as whole grain bread, oats, and pasta; vegetables in both fresh and frozen forms; fruits and berries, including apples, pears, and frozen berries; legumes such as lentils, beans, and chickpeas; and seafood, including fatty fish, lean fish, and mussels. To facilitate adherence, participants also receive recipes and meal plans that incorporate these foods. Some fresh food items are made available at supermarkets near participants' residences to improve accessibility and convenience. Food support aims to reduce barriers to dietary change by ensuring that participants have the necessary ingredients to follow the SWITCH diet effectively.
219233083|NCT05953909|DRUG|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
219233084|NCT05953909|DRUG|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
219233085|NCT05953909|DRUG|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
219233086|NCT02387385|DEVICE|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
219233087|NCT01554267|DEVICE|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
219233088|NCT04090502|OTHER|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
219233089|NCT04090502|OTHER|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
219233090|NCT00002232|BIOLOGICAL|APL 400-003|
219233091|NCT00869856|DRUG|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
219233092|NCT01275859|DRUG|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
219233093|NCT05702190|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
219233094|NCT05702190|DRUG|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
219724581|NCT04886791|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy
219152549|NCT06973408|BEHAVIORAL|Dietary Advice|Dietary advice consists of a simple document outlining the SWITCH diet, which is based on European and Nordic dietary guidelines. Participants receive this information in written form without any additional guidance, counseling, or support. The SWITCH diet emphasizes increased consumption of whole grains, vegetables, fruits, legumes, and seafood while limiting processed foods, added sugars, and excessive salt.
219152550|NCT00203411|DRUG|Capecitabine (Xeloda)|1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
219152551|NCT00203411|DRUG|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
219152552|NCT06087133|BEHAVIORAL|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
219152553|NCT06087133|OTHER|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
219152554|NCT06049732|DEVICE|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
219152555|NCT05924958|DRUG|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
219152556|NCT03680703|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
219152557|NCT02711293|OTHER|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
219152558|NCT02711293|OTHER|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
219152559|NCT01251354|DRUG|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
219152560|NCT02270645|DEVICE|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
219152561|NCT00492271|DRUG|Friulimicin B|Intravenous, once daily, single dose
219152562|NCT03149991|DRUG|Brexpiprazole|Administration of up to 3mg brexpiprazole
219152563|NCT03149991|DRUG|Ketamine|administration 6 times over two weeks of inhaled ketamine
219152564|NCT03149991|DRUG|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
219152565|NCT06602973|BEHAVIORAL|Rest|Participants will eat breakfast but abstain from exercise
219152566|NCT06602973|BEHAVIORAL|Fed Exercise|Participants will eat breakfast and engage in 30 minutes of physical activity at 75% of their personal V02max.
219152567|NCT06602973|BEHAVIORAL|Fasted Exercise|Participants will engage in 30 minutes of physical activity at their personal 75% V02max after abstaining from breakfast.
219233095|NCT02354144|OTHER|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
219233096|NCT02354144|OTHER|Control gel|A gel not containing carrageenan
219233097|NCT00084825|DRUG|Docetaxel|30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
219233098|NCT00084825|DRUG|Imatinib mesylate|600 mg orally daily
219361019|NCT01415635|DIETARY_SUPPLEMENT|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
219724582|NCT05534984|DRUG|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
219724583|NCT05534984|DRUG|Placebo|"Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
219152568|NCT06501612|OTHER|Continuous Glucose Monitor and Undermyfork App|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
219152569|NCT06501612|OTHER|Continuous Glucose Monitor|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
219152570|NCT05724472|DRUG|rVSV∆G-SEBOV-GP Vaccine or Placebo|rVSV∆G-SEBOV-GP Vaccine or Placebo
219152571|NCT05332054|BIOLOGICAL|Caribou-sponsored investigational therapy|N/A this is an observational study
219152572|NCT02427633|OTHER|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
219152573|NCT02427633|OTHER|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
219152574|NCT02744859|OTHER|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
219152575|NCT03731377|DRUG|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
219152576|NCT06312683|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
219152577|NCT05850026|PROCEDURE|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
219152578|NCT01856335|OTHER|Patient Education|
219152579|NCT01856335|OTHER|exercise: increase physical activity/goal setting|
219152580|NCT06162858|OTHER|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
219152581|NCT01786525|BEHAVIORAL|House Calls|60-minute home based educational intervention which will be administered by a health educator
219152582|NCT01786525|BEHAVIORAL|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
219152583|NCT05264844|OTHER|Masking tape|IV catheters will be fixed with masking tape
219152584|NCT06661590|OTHER|Nutritional Messaging|Dieticians will evaluate nutritional messages created by LLM and Human Experts.
219152585|NCT01278433|BIOLOGICAL|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
219152586|NCT00087880|DRUG|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
219152587|NCT03546608|DRUG|Tepotinib|Participants received a single oral dose of tepotinib in Part 1.
219152588|NCT03163212|DIETARY_SUPPLEMENT|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
219152589|NCT06589830|DRUG|TL938 Capsules|Oral administration
219724584|NCT05534984|DRUG|Tecovirimat Oral Capsule (Open Label)|"* Participants weighing \<3kg - Tecovirimat 533.3mg every 12 hours for 14 days~* Participants weighing 3 kg to less than 6kg- Tecovirimat 50 mg every 12 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
219152590|NCT06589830|DRUG|Trastuzumab|Intravenous (IV) infusion
219152591|NCT06024291|OTHER|8-week HIIT programme|See arm description
219152592|NCT06024291|OTHER|Physical activity recommendation|See arm description
219152593|NCT03856099|DRUG|TTAC-0001|"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"
219152594|NCT06859164|PROCEDURE|Genicular Artery Embolization|Embolization of genicular arteries that demonstrate neoangiogenesis or blush on angiogram.
219233099|NCT03107156|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
219233100|NCT01543789|PROCEDURE|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
219233101|NCT01543789|PROCEDURE|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
219233102|NCT05847114|OTHER|Stres ball|Stress ball compression for 15 minutes during surgery
219152595|NCT06859164|DEVICE|Lipiodol|3:1 emulsion of Lipiodol to Optiray
219152596|NCT06859164|PROCEDURE|Simple angiogram|Simple angiogram of the genicular arteries
219152597|NCT02971943|PROCEDURE|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
219233103|NCT02262988|PROCEDURE|Total knee replacement|Total knee replacement (TKA)
219233104|NCT02583113|DEVICE|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
219724585|NCT03651609|PROCEDURE|Simple decompression of the ulnar nerve|Surgical release 2-3 cm distal to medial epicondyle with minimal-incision technique .
219724586|NCT03651609|BEHAVIORAL|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
219724587|NCT04020263|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
219724588|NCT04020263|DRUG|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
219724589|NCT06040762|OTHER|Best Practice|Receive SOC educational materials
219152598|NCT06677437|OTHER|This is an observational and retrospective study|"It concerns all patients with chronic renal failure awaiting a kidney transplant, and presenting a contraindication to the transplant due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses. They can only receive the kidney transplant after arterial preparation. These patients will be included and will benefit from endovascular preparation for the kidney transplant using a tailor-made arterial stent.~Imaging examinations and follow-up clinical data will be analyzed. Reinterventions and causes of death will be analyzed.~An information sheet will be given to patients; if the patient refuses the use of their data, it will not be collected.~Data collection will be carried out by ARCs or PIs of the centers from medical records. The data will be pseudo-anonymized, entered into a REDCAP database shared between each center."
219233105|NCT04012970|OTHER|Manual spinal mobilisations|
219233106|NCT05302882|BEHAVIORAL|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
219152599|NCT06625346|DRUG|Fixed-Dose Combination of Amlodipine/Valsartan|Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
219233107|NCT05302882|BEHAVIORAL|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
219233108|NCT02773732|DRUG|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
219233109|NCT02773732|DRUG|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
219724590|NCT06040762|OTHER|Exercise Intervention|Receive (P)REHAB exercise program
219233110|NCT02773732|DRUG|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
219233111|NCT02773732|DRUG|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
219233112|NCT06237621|DEVICE|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
219233113|NCT04886674|DIETARY_SUPPLEMENT|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
219233114|NCT01074528|BEHAVIORAL|mindfulness based stress reduction program|8-week mindfulness training program
219361020|NCT05325775|DRUG|ACER-801 50 mg BID|50 mg BID (twice daily)
219724591|NCT06040762|OTHER|App-Based Intervention|Use ExerciseRx app
219724592|NCT06040762|OTHER|App-Based Intervention|Use FitBit app
219724593|NCT06040762|OTHER|Interview|Ancillary studies
219724594|NCT06040762|OTHER|Wearable Activity Tracker|Wear FitBit
219724595|NCT06040762|OTHER|Physical Performance Testing|Ancillary studies
219724596|NCT06040762|OTHER|Questionnaire Administration|Ancillary studies
219724597|NCT06164704|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
219724598|NCT06164704|DRUG|Placebo|Verekitug (UPB-101) matching placebo
219724599|NCT01712464|DRUG|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
219734815|NCT06901089|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the hip joints with an additional two-second tension
219734816|NCT06901089|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
219734817|NCT06901089|OTHER|Exercise|The following exercise will be performed: lunges
219152600|NCT06874192|DRUG|Low-dose colchicine at 0.5mg daily|LODOCO is low-dose colchicine at 0.5mg daily, ii is an FDA approved anti-inflammatory drug, to prevent cardiovascular events in patients with coronary artery disease. LODOCO works by inhibiting microtubule formation and reducing the activity of neutrophils, which play a key role in inflammation.
219724600|NCT04597112|OTHER|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
219724601|NCT04597112|OTHER|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
219152601|NCT06874192|OTHER|Placebo|Matching placebo
219152602|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
219152603|NCT06703944|OTHER|risk model in diagnosis and prognosis|"In this study, we construct and evaluate the bone marrow cytology-based AI model for detection and prognosis of NB.~1. For the diagnostic model, we use AUC metrics to evaluate the model in terms of sensitivity, specificity, accuracy, positive predictive value and negative predictive value at different classification thresholds.~2. For the prognostic model, we use AUC as the performance metric and calculating sensitivity and specificity. Survival curves were constructed according to the Kaplan-Meier method."
219152604|NCT06706752|DIETARY_SUPPLEMENT|Shengbai Oral Formula|Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.
219152605|NCT06706752|OTHER|Inactive Placebo|Inactive placebo will be taken by mouth three times per day for 14 days.
219152606|NCT06708169|BEHAVIORAL|preemptive education provided by anesthesiologists|A preemptive education about 4 stages (prepare, anethesia, surgery, and recovery) by anesthesiologists within 15 minute.
219152607|NCT06882005|BEHAVIORAL|Rested & Ready to Learn|The intervention targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
219152608|NCT06722716|OTHER|Swab collection|Nasopharyngeal swab
219152609|NCT06725823|PROCEDURE|suprascapular nerve block group|A volume of (10 ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) will be injected to both groups.
219152610|NCT06725823|PROCEDURE|shoulder anterior capsular block group|A volume of (10ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40mg) will be injected to both groups.
219152611|NCT06925217|DEVICE|CamAPS HX|The CamAPS HX fully closed-loop system consists of an insulin pump, a continuous glucose monitoring (CGM) sensor, as well as the CamAPS HX app, which resides on a smartphone and communicates wirelessly with the insulin pump.
219152612|NCT06925217|DEVICE|Standard insulin therapy with CGM|Participants will continue their standard insulin therapy with a Freestyle Libre 3 CGM
219152613|NCT06721962|BIOLOGICAL|TRX103|TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.
219152614|NCT06721962|DRUG|Cyclophosphamide|Low dose cyclophosphamide conditioning.
219152615|NCT06728059|DEVICE|Automated Insulin Delivery Adaptive NETwork (AIDANET)|Group A participants will use the AIDANET system at home for 7 days/6 nights. They will continue use of AIDANET system for 18 hours during the hotel session and then use AIDANET+BPS\_RL for 18 hours during the hotel session.
219152616|NCT06728059|DEVICE|AIDANET+ BPS_RL→AIDANET|Group B participant will use the AIDANET+BPS\_RL system for 18 hours during the hotel session and will then use AIDANET system for 18 hours during the hotel session. They will continue to use AIDANET+BPS\_RL system at home for 7 days/6 night and then use the AIDANET system at home for 7 days/6 nights.
219152617|NCT06883123|DRUG|Simbrinza 0.2%-1% Ophthalmic Suspension|brinzolamide and brimonidine tartrate
219152618|NCT06883123|DRUG|Rocklatan 0.02%-0.005% Ophthalmic Solution|netarsudil and latanoprost
219152619|NCT06883123|DRUG|Cosopt PF 2%-0.5% Ophthalmic Solution|dorzolamide hydrochloride and timolol maleate
219152620|NCT06883123|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost
219361021|NCT05325775|DRUG|ACER-801 100 mg BID|100 mg BID (twice daily)
219361022|NCT05325775|DRUG|ACER-801 200 mg BID|200 mg BID (twice daily)
219361023|NCT05325775|DRUG|Placebo|Placebo
219361024|NCT01019018|DEVICE|subtenon block|subtenon block with stevens cannula
219361025|NCT01019018|DEVICE|subtenon block|subtenon block with Olive tip cannula cannula
219361066|NCT01171846|OTHER|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
219724602|NCT02046187|DIETARY_SUPPLEMENT|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
219724603|NCT02046187|RADIATION|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
219724604|NCT02046187|DRUG|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
219724605|NCT04536103|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
219724606|NCT05793125|DEVICE|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
219724607|NCT05208047|DRUG|CGT9486 plus sunitinib|Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
219724608|NCT05208047|DRUG|CGT9486|Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
219724609|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
219724610|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib orally until study stopping rules are met.
219724611|NCT05208047|DRUG|Midazolam|Participants will receive a single-dose of midazolam on Day 1 and Day 16
219724612|NCT05208047|DRUG|CGT9486 plus sunitinib|Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.
219724613|NCT05718518|DRUG|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
219724614|NCT05718518|DRUG|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
219724615|NCT05718518|DRUG|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
219724616|NCT02188732|BEHAVIORAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
219724617|NCT02188732|BEHAVIORAL|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
219724618|NCT02188732|BEHAVIORAL|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
219724619|NCT06519175|OTHER|Conservative treatment|Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.
219724620|NCT06519175|PROCEDURE|Single or multi-stage surgery|Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.
219724621|NCT06519175|PROCEDURE|Amputation|Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
219724622|NCT05417113|DRUG|Liposomal bupivacaine|liposomal bupivacaine
219724623|NCT05417113|DRUG|Bupivacaine|bupivacaine 0.25% in ESP blocks
219724624|NCT01022580|DRUG|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
219724625|NCT01022580|DRUG|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
219724626|NCT00637182|DRUG|Anastrozole|
219724627|NCT05539508|BEHAVIORAL|Psychophysical evaluation|All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
219152621|NCT07053657|DRUG|Dietary Supplement: Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
219152622|NCT07053657|DRUG|Dietary Supplement: Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
219152623|NCT07053306|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
219152624|NCT06750302|DRUG|Methoxyflurane - Penthrox|3ml
219152625|NCT06750302|OTHER|Placebo|saline + one drop of methoxyflurane
219152626|NCT07053293|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
219152627|NCT06083181|DEVICE|Perf-Fix Otologic Gel Patch|Gel patch application
219152628|NCT07055464|PROCEDURE|eTEP-RS Hernia Repair|Laparoscopic retromuscular mesh repair using the enhanced view totally extraperitoneal (eTEP-RS) technique for ventral or incisional hernia.
219152629|NCT07055464|PROCEDURE|IPOM Plus Hernia Repair|Intraperitoneal onlay mesh (IPOM Plus) repair involving laparoscopic fascial defect closure and mesh placement for abdominal wall hernias.
219152630|NCT07061262|PROCEDURE|External Oblique Intercostal Plane Block|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, an external oblique plane block will be performed by the same anesthesiologist under ultrasound guidance, using an external oblique muscle approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the external oblique space.
219724628|NCT00461968|DRUG|Ezetimibe and Simvastatin|
219152631|NCT07061262|PROCEDURE|Subcostal TAP block and spinal anesthesia group (STAP)|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, a subcostal block will be performed by the same anaesthesiologist under ultrasound guidance with a subcostal approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the subcostal space.
219152632|NCT07060092|BEHAVIORAL|Trail Making Task|Participants will perform a modified, life-size version of the Trail Making Test (TMT) while standing upright, either on a stable (force plates) or unstable (balance board) surface. The task involves visually searching for and tracing a sequential path through spatially randomized numerical targets projected onto a large screen using a laser pointer. This dual-task condition simultaneously engages cognitive, visual, and motor planning systems while requiring continuous postural control. The task is designed to elicit suprapostural coordination, capturing the dynamic interplay between postural stability and goal-directed behavior.
219152633|NCT07060092|BEHAVIORAL|Balance board|Participants will maintain an upright stance on a commercially available balance board positioned atop dual force plates. The unstable surface introduces controlled postural instability, requiring continuous sensorimotor adaptation to preserve balance without external support. This condition is administered alone and in combination with the Trail Making Task to simulate dual-task challenges that more closely resemble real-world balance demands.
219152634|NCT05091970|PROCEDURE|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)|Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.
219152635|NCT07059884|OTHER|Exercise intervention|Complete supervised TH progressive resistance exercise sessions
219152636|NCT07059884|OTHER|Telemedicine|Complete supervised TH progressive resistance exercise sessions
219152637|NCT07059884|OTHER|Aerobic Exercise Intervention|Complete unsupervised aerobic exercise sessions
219152638|NCT07059884|OTHER|Dumbbell Exercise Intervention|Receive adjustable-weight dumbbells
219152639|NCT07059884|PROCEDURE|Accelerometry|Wear accelerometer
219152640|NCT07059884|OTHER|Questionnaire Administration|Ancillary studies
219152641|NCT07059884|OTHER|Interview|Ancillary studies
219724629|NCT03600129|PROCEDURE|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
219724630|NCT03600129|DRUG|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
219724631|NCT03600129|DRUG|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
219724632|NCT04529980|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (LGG) Probiotic|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
219724633|NCT04529980|DIETARY_SUPPLEMENT|Placebo|Placebo
219724634|NCT01500096|DRUG|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
219724635|NCT01500096|DIETARY_SUPPLEMENT|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
219152642|NCT07059884|OTHER|Electronic Health Record Review|Ancillary studies
219152643|NCT07059754|DEVICE|Topical Ophthalmic Cooling|Targeted topical ophthalmic cooling treatment using the ETX-4143 cooling device
219152644|NCT07060261|PROCEDURE|Transoral robotic surgery+MRI|During the standard of care MRI, there will be an added T2 and T2 SPACE sequences. These sequences are estimated to take an additional 6 minutes, with no added risk to the patient.
219724636|NCT04649554|DEVICE|Exablate treatment|Ablation
219724637|NCT04651088|DRUG|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
219724638|NCT04651088|DRUG|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
219724639|NCT04651088|DIETARY_SUPPLEMENT|Litholyte|One packet is taken with 170ml of water. Two packets daily.
219724640|NCT04651088|DIETARY_SUPPLEMENT|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
219724641|NCT04651088|DRUG|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
219724642|NCT03706352|PROCEDURE|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
219724643|NCT00229216|DRUG|Tinidazole|
219724644|NCT01734928|DRUG|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
219724645|NCT01734928|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
219724646|NCT01734928|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
219724647|NCT03879109|DRUG|Chemotherapy FOLFIRINOX, 6 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
219724648|NCT03879109|RADIATION|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
219724649|NCT03879109|PROCEDURE|Surgery|"Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)"
219152645|NCT07061197|OTHER|Patient leaflet with the EMA's proposed key information section including qualitative statements.|The standard patient leaflet supplemented with a key information section. This section included qualitative descriptions of the goal of treatment, the main benefits, contraindications, and the most serious side effects. The content was designed to reflect the EMA's proposed format for improving the patient information leaflet.
219152646|NCT07061197|OTHER|Control (standard patient leaflet)|The standard patient information leaflet for a recently approved cancer drug, tivozanib (Fotivda), obtained electronically from the EMA website. The standard patient information does not contain structured benefit information.
219361067|NCT03568019|OTHER|Retrospective study|No subjects will be contacted or recruited. All data will be acquired retrospectively.
219361068|NCT03709381|DRUG|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
219361069|NCT03709381|DRUG|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
219361070|NCT06047704|OTHER|No intervention|No intervention
219361071|NCT05939895|DEVICE|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
219361072|NCT01985672|PROCEDURE|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
219361073|NCT00492973|DRUG|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
219724650|NCT03012945|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
219724651|NCT03012945|DRUG|General anesthesia|General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
219724652|NCT05930938|DRUG|Xevinapant|Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
219724653|NCT05930938|DRUG|Placebo|Xevinapant without active substance
219724654|NCT05930938|DRUG|cetuximab|cetuximab
219152647|NCT07061197|OTHER|Patient leaflet with a key information section providing both qualitative and quantitative information on drug benefits and harms.|The standard patient leaflet, supplemented with a key information section including quantitative data on the drug's main benefits and side effects, presented in a summary table format. This section provided structured information about the indication and goal of treatment, how the drug was studied (the comparator treatment and number of patients enrolled in the clinical trial that supported the drug's approval), and data on the drug's benefits and side effects.
219152648|NCT07059897|BEHAVIORAL|Animation video and mobile phone application|"An animation video scenario and MEKTUP mobile phone application were prepared by the researchers in light of the literature, in line with the National Breast Cancer Screening Program and by taking expert opinions."
219724655|NCT05930938|RADIATION|IMRT|IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
219724656|NCT06959420|OTHER|Questionnaire|Anonymous self-administered questionnaire on the Limesurvey platform.
219724657|NCT04214782|DIAGNOSTIC_TEST|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
219724658|NCT03053323|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
219724659|NCT03600350|BIOLOGICAL|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
219724660|NCT03600350|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
219724661|NCT03600350|DRUG|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
219724662|NCT03643991|OTHER|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
219724663|NCT01051167|DRUG|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
219724664|NCT04599218|OTHER|Prostate Biopsy|Standard of care
219724665|NCT04599218|OTHER|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
219724666|NCT04599218|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
219724667|NCT05412420|OTHER|Patient Self-Reporting of Symptoms|"At baseline, clinical research staff will:~* verify the possibility of an internet connection at the patient's home~* help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~* patients complete questionnaires via app (toxicity; quality of life, medication adherence)~* responses are verified by clinical research staff~* In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~\- patients answer a satisfaction questionnaire"
219724668|NCT04895280|DRUG|Ketorolac|Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
219724669|NCT04895280|DRUG|Marcaine|Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
219724670|NCT04895280|DRUG|Kenalog|Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
219724671|NCT01217450|DRUG|selumetinib|Given orally
219724672|NCT01217450|BIOLOGICAL|cetuximab|Given IV
219724673|NCT01217450|OTHER|laboratory biomarker analysis|Correlative studies
219724674|NCT01217450|OTHER|pharmacological study|Correlative studies
219724675|NCT06780943|OTHER|Biomechanics|"Amputees and controls will be equipped with measurement sensors to record spatio-temporal, kinetic, kinematic, pressure, electromyographic and physiological parameters of gait in the movement analysis laboratory (GRAIL System).~16 Anatolog FSR sensors will be installed in the amputee population (transtibial, transfemoral on the medial, lateral, anterior and posterior parts of the stump, 4 per side, aligned in the proximal/distal axis. The Anatolog sensors have a sampling frequency of 100Hz. Electromyographic data recording is performed by setting up a number of EMGs depending on the healthy population or the level of amputation. Surface electromyography (sEMG) signals will be recorded from 10 muscles on each lower limb for control subjects and transtibial amputees"
219724676|NCT06780943|OTHER|Physiological|Energy consumption (VO2), will be performed using the VO2 Master Pro (VO2 Master Health Sensors Inc., Vernon, British Columbia, CA). Each participant will wear a face mask connected to the VO2 Master, which will measure oxygen consumption in real time during the assessment. The mask will be adjusted to prevent air leakage and ensure accurate measurements.
219724677|NCT06780943|OTHER|Proprioceptive|For amputees, the joint above the amputation will be measured due to the presence of the proximal insertions of the bi-articular muscles and the absence of their distal insertion (i.e., knee joint for transtibial amputees and hip joint for transfemoral amputees).
219724678|NCT04981054|PROCEDURE|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
219724679|NCT01850940|DRUG|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
219724680|NCT01850940|OTHER|conventional thearpy|conventional therapy with salt limitation ,et al
219724681|NCT04937530|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
219724682|NCT04937530|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
219724683|NCT00611156|DIETARY_SUPPLEMENT|ginger|added to a brunch meal
219724684|NCT00611156|DIETARY_SUPPLEMENT|black pepper|Added to a brunch meal
219724685|NCT00611156|DIETARY_SUPPLEMENT|horseradish|Added to a brunch meal
219724686|NCT00611156|DIETARY_SUPPLEMENT|mustard|Added to a brunch meal
219724687|NCT00611156|DIETARY_SUPPLEMENT|placebo|Added to a bruch meal
219724688|NCT03343574|OTHER|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
219724689|NCT03474835|DIAGNOSTIC_TEST|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
219724690|NCT05308693|OTHER|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
219724691|NCT00729001|BIOLOGICAL|Human Rotavirus Vaccine - two different formulations|Two oral doses
219724692|NCT00729001|BIOLOGICAL|Prevnar|Three-dose intramuscular injection (US subjects only)
219724693|NCT00729001|BIOLOGICAL|IPOL|Two-dose intramuscular injection (US subjects only)
219724694|NCT00729001|BIOLOGICAL|Infanrix|Three-dose intramuscular injection (US subjects only)
219724695|NCT00729001|BIOLOGICAL|OmniHIB|Three-dose intramuscular injection (US subjects only)
219724696|NCT00729001|BIOLOGICAL|Pentacel|Three-dose intramuscular injection (Canada only)
219152649|NCT06892379|DRUG|HS-20110 (Phase Ia：Dose escalation )|HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles
219152650|NCT06892379|DRUG|HS-20110 (Phase Ib:Dose expansion )|The recommended dose from the dose-escalation stage and other potential doses will be further explored
219724697|NCT06423027|BEHAVIORAL|Nature-Oriented Chatbots|Nature-oriented chatbots are an intervention with nature-based video delivered by self-developed chatbots
219724698|NCT02971189|DEVICE|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
219724699|NCT01305343|PROCEDURE|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
219724700|NCT01328626|DRUG|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
219724701|NCT04426162|OTHER|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
219724702|NCT00126217|BIOLOGICAL|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
219152651|NCT07059845|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
219152652|NCT07059845|DRUG|Bevacizumab|IV Infusion
219152653|NCT07059845|DRUG|Carboplatin|IV Infusion
219724703|NCT02323334|DRUG|LY3202626|administered orally
219724704|NCT02323334|DRUG|Placebo (Part A, B, C)|administered orally
219724705|NCT02323334|DRUG|Itraconazole|administered orally
219724706|NCT02513082|PROCEDURE|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
219724707|NCT05380596|BEHAVIORAL|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
219724708|NCT01371760|PROCEDURE|Venous PTA|PTA of the internal jugular and/or azygous vein
219724709|NCT01371760|OTHER|Catheter Venography|The patients will undergo catheter venography but not PTA
219724710|NCT06103682|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
219724711|NCT04073576|DEVICE|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
219724712|NCT04073576|DEVICE|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
219152654|NCT05710172|DEVICE|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
219152655|NCT06813430|DEVICE|Non-contact Low Frequency Ultrasound|NCLF-US therapy involves delivering low-frequency (40 kHz), low-intensity (0.1-0.8 W/cm2) ultrasound energy via sterile water mist.
219724713|NCT04715100|OTHER|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
219724714|NCT04370600|DRUG|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
219724715|NCT04370600|DRUG|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
219724716|NCT04234542|OTHER|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
219724717|NCT04234542|OTHER|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
219724718|NCT05018559|BEHAVIORAL|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
219724719|NCT05018559|BEHAVIORAL|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
219724720|NCT02619656|PROCEDURE|CO2 insufflation|Patients were randomized to insufflation with CO2.
219724721|NCT02619656|PROCEDURE|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
219724722|NCT05713370|DIETARY_SUPPLEMENT|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
219724723|NCT03516500|DRUG|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
219724724|NCT03688737|OTHER|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
219724725|NCT03688737|OTHER|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
219152656|NCT06813430|OTHER|Lalonde Protocol (standard of care)|Standard of care local wound therapy using the Lalonde protocol - rinsing the site with clean water, applying a grease layer, wrapping with a one-inch gauze wrap, and securing with Coban tape.
219152657|NCT02788773|DRUG|Durvalumab|
219724726|NCT02237274|OTHER|High altitude exposition|High altitude exposition
219724727|NCT05015179|PROCEDURE|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
219724728|NCT00516854|DRUG|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
219152658|NCT02788773|DRUG|Tremelimumab|
219152659|NCT06085755|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
219152660|NCT06085755|DRUG|Afatinib|Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
219152661|NCT05788536|GENETIC|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~* LD Cohort (lower dose)~* HD Cohort (high dose) - not implemented"
219724729|NCT00552058|BIOLOGICAL|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
219724730|NCT00552058|OTHER|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
219724731|NCT02347007|DIETARY_SUPPLEMENT|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
219724732|NCT02347007|DIETARY_SUPPLEMENT|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
219724733|NCT04172064|DIAGNOSTIC_TEST|Myocardial perfusion scintigraphy|
219724734|NCT00295776|DRUG|Lamictal in the treatment of Post-Herpetic Neuralgia|
219724735|NCT05345587|OTHER|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
219724736|NCT02126202|PROCEDURE|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
219152662|NCT05788536|GENETIC|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
219724737|NCT02233153|OTHER|Elder-Friendly Surgical Unit|
219724738|NCT03521336|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
219724739|NCT03521336|DRUG|Placebo|Saline，Sham operation
219724740|NCT04162483|DEVICE|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
219152663|NCT06924450|DEVICE|1.2 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.2 cm monofilament polypropylene mesh. The modified mesh width is being evaluated for its effect on surgical success, symptom improvement, and postoperative complications.
219152664|NCT06924450|DEVICE|1.0 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.0 cm monofilament polypropylene mesh, which is the standard procedure. This group serves as a comparator to assess the impact of the modified mesh width.
219152665|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
219152666|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
219152667|NCT06937853|DRUG|Ibuprofen 600 mg|A single oral dose of 600 mg ibuprofen will be administered prior to the endodontic procedure to evaluate its preemptive analgesic effect on postoperative dental pain.
219152668|NCT06937853|DRUG|diclofenac sodium|A single oral dose of 100 mg diclofenac sodium will be administered to participants in the Diclofenac Sodium Group prior to the endodontic procedure. This intervention is designed to assess the preemptive analgesic efficacy of diclofenac sodium in the control of postoperative dental pain.
219724741|NCT00325585|BEHAVIORAL|Couples HIV counseling and testing|
219724742|NCT00325585|BEHAVIORAL|Women's relationship-focused HIV counseling and testing|
219724743|NCT03520569|DRUG|Octreotide|we are using it to block insulin secretion from the pancreas
219724744|NCT03520569|DRUG|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
219724745|NCT03520569|DRUG|Dextrose 20% solution|We are using dextrose to maintain glycemia level
219724746|NCT04383015|OTHER|Exercise strategies|Strategies for exercise in type 1 diabetes to maintain glucose control
219724747|NCT00882765|DIETARY_SUPPLEMENT|genistein|Given orally
219724748|NCT01559623|PROCEDURE|retrospective data analysis|retrospective data analysis
219724749|NCT05130697|OTHER|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
219724750|NCT05911386|OTHER|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
219724751|NCT01952678|OTHER|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
219724752|NCT01952678|OTHER|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
219724753|NCT03604627|OTHER|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
219152669|NCT06937853|DRUG|Placebo|A single oral dose of a placebo tablet, identical in appearance to the active drugs, will be administered to participants in the Placebo Group prior to the endodontic procedure. This group serves as the control to evaluate the true analgesic efficacy of the active interventions.
219152670|NCT06949566|OTHER|100 Hz Local Vibration|Participants in this group will receive 100 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
219152671|NCT06949566|OTHER|50 Hz Local Vibration|Participants in this group will receive 50 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
219152672|NCT06949566|OTHER|Sham Local Vibration|Participants in this group will receive sham vibration following the muscle fatigue protocol. The vibration device will be turned on but held near the muscle without making contact for 10 minutes. Participants will be informed that they are being treated with an electromagnetic vibration device.
219152673|NCT04756323|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
219152674|NCT04756323|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
219152675|NCT04756323|BIOLOGICAL|Placebo|placebo
219152676|NCT05094141|OTHER|Virtual reality|Virtual reality game played during port needle access.
219152677|NCT06238752|DRUG|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
219152678|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
219152679|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
219152680|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
219152681|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
219724754|NCT04939389|DIAGNOSTIC_TEST|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
219724755|NCT05827120|DEVICE|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"* Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~* Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~* Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
219724756|NCT05827120|DEVICE|Local catheter directed thrombolysis alone|\- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
219152682|NCT04725890|DEVICE|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
219152683|NCT04356976|DEVICE|Ventralex|Repair of hernia using Ventralex patch in sublay position
219152684|NCT04356976|OTHER|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
219152685|NCT01170026|BEHAVIORAL|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion \& Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
219152686|NCT01170026|BEHAVIORAL|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
219724757|NCT03418675|DRUG|Rexulti|Atypical antipsychotic
219152687|NCT06756646|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise intervention will utilize an ergometer. The program will be conducted 2-3 times per week over a 3-month period.
219152688|NCT06756646|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about COPD self-care and home-based exercise approach.
219152689|NCT06756646|BEHAVIORAL|Blood flow restriction (BFR) intervention|Blood flow restriction (BFR) intervention will combine aerobic exercise on the ergometer with BFR training. The program will be conducted 2-3 times per week over a 3-month period.
219152690|NCT04246372|DRUG|Tofacitinib|Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome
219152691|NCT04514107|OTHER|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
219152692|NCT04514107|OTHER|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
219152693|NCT03414775|OTHER|Nourish|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
219152694|NCT03414775|OTHER|Pediasure|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
219152695|NCT06758440|DRUG|chitosan|Evaluate Effectiveness of hydroxyapatite reinforced chitosan hydrogel in modulation of osseintegration round immediate dental implant in a Randomized single blind control study
219152696|NCT04623008|BEHAVIORAL|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
219152697|NCT06757959|COMBINATION_PRODUCT|Wet Needling|This involve the use of needles to inject a local anesthetics into trigger points or areas of muscle tightness around the knee particularly in the quadriceps surrounding soft tissue implicated in patellofemoral pain syndrome .To reduce localized pain, release muscle tension and improve tissue function.
219152698|NCT06757959|DIAGNOSTIC_TEST|Kinesiotaping|Application of kinesiotape around knee joint or quadricep following a specific technique aimed at reducing pain and improving joint stability . The tape is typically applied to encourge proper movement patterns , reducing swelling and provide sensory feedback to brain. Strengthening exercises : To strenghthen the quadriceps , gluteal muscles and other key stabilizing muscles of lower limbs. This is aimed at reducing the mechanical stress on the joint and improve overall function.
219152699|NCT02936388|PROCEDURE|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
219152700|NCT02936388|PROCEDURE|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
219152701|NCT06162013|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 3000mg/day
219152702|NCT06162013|OTHER|Placebo|Placebo. Identical in taste and appearance as the intervention.
219361074|NCT00492973|DRUG|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
219724758|NCT03418675|DRUG|Placebo|Pill that contains no medicine
219724759|NCT03422718|BEHAVIORAL|Healthy Behavior Texts|Participants receive motivational health behavior texts
219724760|NCT03422718|BEHAVIORAL|No healthy behavior texts|Participants do not receive healthy behavior texts
219724761|NCT03422718|BEHAVIORAL|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
219724762|NCT03422718|BEHAVIORAL|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
219724763|NCT03422718|BEHAVIORAL|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
219152703|NCT05415800|BEHAVIORAL|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
219724764|NCT03422718|BEHAVIORAL|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
219152704|NCT06352775|DIETARY_SUPPLEMENT|Calcium Carbonate|We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
219152705|NCT04781335|DRUG|Dexycu|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
219152706|NCT04781335|DRUG|Standard of Care post operative eye drops (steroid, antibiotic, NSAID)|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
219152707|NCT02098343|DRUG|APR-246|Intravenous infusion.
219152708|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
219152709|NCT05515562|DRUG|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
219152710|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
219152711|NCT06423677|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
219152712|NCT06423677|DEVICE|patient controlled analgesia|intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
219152713|NCT06334575|DRUG|Budesonide|receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
219152714|NCT05314634|BEHAVIORAL|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
219152715|NCT05314634|BEHAVIORAL|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
219152716|NCT06021314|OTHER|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
219152717|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
219152718|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
219724765|NCT03295916|RADIATION|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
219724766|NCT00143351|DRUG|Ziprasidone|
219724767|NCT03555344|OTHER|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
219361075|NCT01988389|DIETARY_SUPPLEMENT|whole apples (WA)|
219724768|NCT01178411|DRUG|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
219361076|NCT01988389|DIETARY_SUPPLEMENT|apple juice (AJ)|
219724769|NCT01178411|DRUG|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
219724770|NCT01129284|DRUG|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
219724771|NCT02216877|DRUG|Mablet 360 mg|
219724772|NCT02216877|DRUG|Placebo|
219152719|NCT06069115|RADIATION|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
219724773|NCT00771602|DRUG|Rituximab|375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
219724774|NCT00771602|DRUG|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
219724775|NCT01629862|DEVICE|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
219724776|NCT01629862|DEVICE|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
219724777|NCT02510482|OTHER|No intervention|
219724778|NCT00298857|DRUG|Valproic acid|
219152720|NCT06069115|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
219152721|NCT06069115|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
219152722|NCT06069115|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
219724779|NCT03278145|GENETIC|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
219152723|NCT06069115|DIAGNOSTIC_TEST|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
219152724|NCT06069115|DIAGNOSTIC_TEST|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
219152725|NCT06069115|OTHER|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
219152726|NCT06346834|BIOLOGICAL|sIPV|One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
219152727|NCT05132205|PROCEDURE|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
219724780|NCT02345343|DRUG|Apixaban|
219724781|NCT01992471|BEHAVIORAL|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
219724782|NCT01992471|BEHAVIORAL|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
219724783|NCT01992471|OTHER|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
219724784|NCT01992471|BEHAVIORAL|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
219152728|NCT06551987|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
219152729|NCT06551987|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
219233115|NCT01827761|BEHAVIORAL|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
219233116|NCT04828109|DEVICE|Virtual Reality|Use of any virtual reality experiences available
219233117|NCT04828109|DEVICE|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
219233118|NCT03791190|OTHER|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
219233119|NCT03791190|OTHER|No-anticoagulation|Patients accepted CRRT without anticoagulant.
219233120|NCT04214457|PROCEDURE|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
219233121|NCT05603949|DEVICE|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
219233122|NCT06475248|OTHER|Placebo Technique|For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).
219152730|NCT05679271|DEVICE|Venous stenting|venous stenting associated to antiaggregation protocol
219152731|NCT05679271|OTHER|Standard of care|observation: no treatment
219724785|NCT01992471|BEHAVIORAL|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
219233123|NCT06475248|OTHER|Stretching technique|"Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally."
219724786|NCT01973400|DIETARY_SUPPLEMENT|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
219724787|NCT01973400|DIETARY_SUPPLEMENT|Placebo|Placebo
219724788|NCT02985710|DEVICE|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
219152732|NCT04987476|BIOLOGICAL|analyzes in singles cells|genome expression analyzes in single cells
219152733|NCT04729816|OTHER|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
219152734|NCT04973566|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
219152735|NCT04973566|DRUG|Etanercept|Etanercept will be administered subcutaneously.
219152736|NCT04973566|DRUG|Hydroxychloroquine|HCQ will be administered orally.
219152737|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
219724789|NCT02985710|PROCEDURE|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
219724790|NCT02985710|PROCEDURE|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
219724791|NCT04954443|PROCEDURE|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
219724792|NCT04871438|DEVICE|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
219724793|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule approximately 30 mcg daily 21 days
219724794|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule 300 mcg daily 21 days
219152738|NCT05219058|PROCEDURE|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
219152739|NCT05219058|PROCEDURE|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
219152740|NCT05219058|PROCEDURE|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
219152741|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
219152742|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
219152743|NCT03779048|BEHAVIORAL|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
219152744|NCT03779048|DRUG|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
219152745|NCT03779048|DRUG|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
219152746|NCT06189131|DEVICE|Ventriject|Ventriject is a non-exercise method for estimating V02Max
219724795|NCT02859012|DRUG|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
219724796|NCT02859012|OTHER|Observation|this group is observational ones.
219724797|NCT02102828|DEVICE|extended compression|Home use of extended compression therapy and aspirin
219724798|NCT02102828|OTHER|Aspirin|standard therapy of aspirin
219724799|NCT00629213|DRUG|acarbose|
219724800|NCT00629213|DRUG|placebo|
219724801|NCT00845182|DRUG|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
219724802|NCT00845182|DRUG|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
219724803|NCT00845182|DRUG|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
219724804|NCT05174507|DRUG|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
219724805|NCT05174507|DRUG|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
219724806|NCT05174507|OTHER|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
219724807|NCT05174507|OTHER|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
219724808|NCT05340660|RADIATION|[ 18 F]PSS232|\[ 18 F\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
219724809|NCT03213236|DIAGNOSTIC_TEST|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
219724810|NCT04039269|OTHER|Preoperative video information|
219724811|NCT02927314|DRUG|CF102|orally q12h
219724812|NCT02927314|DRUG|Placebo|orally q12h
219724813|NCT01625182|DRUG|Fingolimod|Fingolimod 0.5 mg capsules
219724814|NCT01625182|DRUG|Placebo Comparator|Matching placebo capsules
219724815|NCT03380572|DEVICE|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
219724816|NCT03380572|PROCEDURE|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
219724817|NCT01433874|PROCEDURE|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
219724818|NCT01433874|PROCEDURE|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
219724819|NCT01433874|PROCEDURE|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
219724820|NCT01433874|PROCEDURE|Control group|Co2 was removed by passive exsufflation through the port site.
219724821|NCT04783727|DIAGNOSTIC_TEST|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
219724822|NCT00354211|DEVICE|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
219152747|NCT05758246|DRUG|Fisetin-dose 1|20mg/kg once a day for one day.
219152748|NCT05758246|DRUG|Fisetin-dose 2|20mg/kg once a day for two days
219152749|NCT05758246|DRUG|Placebo|Placebo treatment
219152750|NCT06245525|OTHER|This is not an interventional study|This is not an interventional study
219152751|NCT05588479|DIETARY_SUPPLEMENT|Pomegranate extract|Two capsules of pomegranate extract (740 mg) will be taken daily at any time of the day for a period of 12 weeks.
219152752|NCT05588479|DIETARY_SUPPLEMENT|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
219152753|NCT05164536|DRUG|Amyvid|All participants will undergo a single β-amyloid PET scan with Amyvid.
219152754|NCT03224949|OTHER|Blood draw|Patients will have a one time blood draw
219152755|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
219152756|NCT06164613|DRUG|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
219152757|NCT06164613|DRUG|Placebo|400 mg PO Canola oil soft gel capsule
219152758|NCT03952507|DRUG|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
219152759|NCT03952507|DRUG|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
219152760|NCT05632913|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
219152761|NCT05470868|DRUG|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
219152762|NCT00682032|DIETARY_SUPPLEMENT|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
219152763|NCT04922268|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
219152764|NCT04922268|OTHER|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
219152765|NCT04588259|DRUG|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
219152766|NCT04588259|DRUG|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
219152767|NCT04588259|DRUG|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
219724823|NCT05737498|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
219724824|NCT01235819|DRUG|Insulin|Exenatide Sitagliptin
219724825|NCT01235819|DRUG|Sitagliptin|Sitagliptin 100 mg per day oral
219724826|NCT01235819|DRUG|Exenatide|Exenatide 10 micrograms daily twice
219724827|NCT02575625|DEVICE|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
219724828|NCT02575625|BIOLOGICAL|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
219152768|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
219152769|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
219724829|NCT02575625|DEVICE|MRI|Liver MRI
219724830|NCT02920554|PROCEDURE|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
219724831|NCT02920554|PROCEDURE|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
219724832|NCT04428905|OTHER|Quality-of-Life Assessment|Ancillary studies
219724833|NCT04428905|OTHER|Questionnaire Administration|Ancillary studies
219724834|NCT04428905|OTHER|Survivorship Care Plan|Receive personalized care plan/resource manual
219724835|NCT04428905|OTHER|Telemedicine|Participate in telehealth sessions
219724836|NCT04447248|DEVICE|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
219724837|NCT05007444|DRUG|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
219724838|NCT05007444|DRUG|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
219724839|NCT00447278|DRUG|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
219233124|NCT06475248|OTHER|Inhibition of the suboccipital|"Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions."
219233125|NCT04867382|BEHAVIORAL|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
219152770|NCT06104332|DEVICE|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
219152771|NCT06104332|DEVICE|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
219152772|NCT06104332|DEVICE|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
219152773|NCT06104332|DEVICE|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
219152774|NCT06104332|DEVICE|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
219152775|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
219152776|NCT06961929|OTHER|Control Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will not be given an experimental cooling modality.
219152777|NCT06961929|OTHER|Cool water limb immersion|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also immerse their hands and forearms in cool water.
219152778|NCT06961929|OTHER|Skin-Wetting Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also be sprayed with water periodically.
219152779|NCT06963814|DRUG|HC006|Specified dose on specified days
219152780|NCT06963814|DRUG|KEYTRUDA ®( Pembrolizumab)|Specified dose on specified days
219152781|NCT02846506|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
219233126|NCT02548299|OTHER|Nutrition Education|Nutrition classes will be led by a registered dietician.
219233127|NCT02548299|OTHER|Cooking Lecture|
219724840|NCT00447278|DRUG|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
219724841|NCT04821011|DEVICE|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
219724842|NCT04821011|DEVICE|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
219152782|NCT02846506|DRUG|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219152783|NCT02846506|DRUG|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219152784|NCT02846506|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
219152785|NCT05056493|OTHER|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
219152786|NCT05980052|BEHAVIORAL|Physical Activity|Theory-driven behavioral physical activity promotion intervention.
219152787|NCT05222139|BIOLOGICAL|COVID-19 vaccination|Monitoring COVID-19 vaccination
219152788|NCT06781957|DRUG|Gonadotropins Subcutaneos|Gonadotropins s.c. single dose
219152789|NCT04869020|DEVICE|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
219152790|NCT04869020|DEVICE|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
219233128|NCT02548299|OTHER|Cooking Demo|
219233129|NCT02548299|OTHER|Hands-on Cooking|
219233130|NCT02548299|OTHER|e-Coaching|
219233131|NCT00989118|PROCEDURE|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
219233132|NCT03681132|OTHER|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
219233133|NCT01124942|DEVICE|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
219152791|NCT04869020|DEVICE|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
219152792|NCT05878288|DRUG|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
219152793|NCT00761553|OTHER|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
219152794|NCT00761553|DIETARY_SUPPLEMENT|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
219152795|NCT02740283|BEHAVIORAL|glycemic monitoring|
219152796|NCT02740283|DIETARY_SUPPLEMENT|dietary guide|
219152797|NCT06795386|PROCEDURE|Bariatric Surgery|Participants will include people with chronic widespread pain who will undergo bariatric surgery. All participants will receive this intervention and will not be randomized to this or other interventions.
219152798|NCT05912738|OTHER|Interventional therapy|Interventional therapy for postherpetic neuralgia includes nerve blocks, pulsed radiofrequency therapy, etc
219152799|NCT03788590|DEVICE|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
219152800|NCT01168544|DIETARY_SUPPLEMENT|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
219152801|NCT01168544|DIETARY_SUPPLEMENT|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
219152802|NCT01168544|DIETARY_SUPPLEMENT|Vitamin D 800 IU /day|800 IU vit D3/day
219152803|NCT01969981|PROCEDURE|PICC placement with Sherlock 3CG|
219152804|NCT01164098|DRUG|Rituximab|Induction therapy
219152805|NCT00232180|DRUG|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
219152806|NCT01295697|DRUG|EZN-2208|Experimental
219152807|NCT04517136|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
219152808|NCT04517136|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
219152809|NCT04517136|DEVICE|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
219152810|NCT04517136|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
219152811|NCT02486835|DEVICE|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
219152812|NCT02486835|DEVICE|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
219152813|NCT03346616|OTHER|Texting Group|See above in arm/group description
219152814|NCT03346616|OTHER|Non Texting Group|See above in arm/group description
219724843|NCT04821011|DEVICE|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
219724844|NCT01348698|PROCEDURE|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
219724845|NCT01348698|PROCEDURE|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
219724846|NCT03943992|DRUG|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
219724847|NCT03943992|DRUG|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
219724848|NCT03943992|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
219724849|NCT06420583|PROCEDURE|MTA pulpotomy|"1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown."
219724850|NCT06420583|PROCEDURE|Extraction|After complete Anesthetic application in the affected area, non-surgical extraction will be done.
219724851|NCT02595749|DRUG|Oxytocin|
219724852|NCT02595749|DRUG|Placebo|
219724853|NCT00263562|DRUG|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
219724854|NCT00263562|OTHER|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
219724855|NCT02024009|DRUG|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
219724856|NCT02024009|RADIATION|60Gy in 30#|
219724857|NCT02024009|RADIATION|50.4Gy in 28#|
219724858|NCT02024009|DRUG|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
219152815|NCT06199973|DRUG|SHR-A1811|SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
219152816|NCT06199973|DRUG|TAS-102, Regorafenib , Fruquintinib|physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
219152817|NCT04728906|DEVICE|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
219152818|NCT00731497|DEVICE|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
219152819|NCT02271789|OTHER|problematic tooth|problematic tooth
219152820|NCT00310726|OTHER|abrupt weaning at 4 months|abrupt weaning at 4 months
219152821|NCT00310726|OTHER|Continued exclusive breastfeeding|Continued exclusive breastfeeding
219152822|NCT03273777|PROCEDURE|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
219152823|NCT00296361|DRUG|Tacrolimus|immunosuppression
219152824|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
219152825|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
219152826|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
219152827|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
219152828|NCT00386958|DRUG|Povidone-Iodine|
219152829|NCT03452189|DRUG|Vancomycin|Oral vancomycin 250mg capsules
219152830|NCT03452189|OTHER|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
219152831|NCT00194974|DRUG|methyldopa|
219724859|NCT02024009|DRUG|Capecitabine|Given in combination with gemcitabine, known as GemCap.
219152832|NCT00194974|DRUG|labetalol|
219152833|NCT00194974|DRUG|nifedipine|
219152834|NCT00194974|DRUG|clonidine|
219152835|NCT00768235|OTHER|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
219152836|NCT03390296|BIOLOGICAL|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
219152837|NCT03390296|DRUG|Avelumab|Given IV
219152838|NCT03390296|DRUG|Azacitidine|Given IV or SC
219152839|NCT03390296|DRUG|Gemtuzumab Ozogamicin|Given IV
219152840|NCT03390296|DRUG|Glasdegib|Given PO
219152841|NCT03390296|DRUG|Glasdegib Maleate|Given PO
219724860|NCT02024009|DRUG|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
219724861|NCT05791084|OTHER|mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.|The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
219152842|NCT03390296|DRUG|Venetoclax|Given PO
219724862|NCT02072044|DRUG|Anlotinib|Anlotinib p.o. qd
219724863|NCT00947466|DRUG|Buprenorphine|Transdermal patch
219724864|NCT02314429|DEVICE|Vaginal ring releasing lactic acid (racemic mixture)|
219724865|NCT06432426|BEHAVIORAL|Virtual reality training group|Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.
219152843|NCT03390296|DRUG|Azacitidine|Given IV or SC
219152844|NCT03664401|DEVICE|Kerecis Oral™|
219152845|NCT03664401|OTHER|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
219724866|NCT06432426|BEHAVIORAL|Standard physical exercise group|Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
219152846|NCT04030624|DEVICE|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
219152847|NCT06326931|DEVICE|thermal pulsation|Single, in-office bilateral treatment with Systane iLux thermal pulsation
219152848|NCT06326931|OTHER|warm compress|Twice daily, 10-minute at-home treatment with Bruder warm compress mask for 8 weeks
219152849|NCT00140790|DRUG|valsartan|valsartan 40 or 160 (80) mg per day
219152850|NCT00991497|DEVICE|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
219152851|NCT03344536|DRUG|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
219152852|NCT03344536|DRUG|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
219152853|NCT01571596|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
219233134|NCT01124942|DEVICE|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
219152854|NCT04192305|PROCEDURE|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
219152855|NCT04192305|PROCEDURE|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
219152856|NCT00175292|DRUG|Probiotic - VSL#3|
219152857|NCT03419299|OTHER|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
219152858|NCT03020979|DRUG|Apatinib|Patients will take 500mg apatinib daily orally.
219152859|NCT00774904|DRUG|Losartan|Angiotensin II Type 1 Receptor Blockers
219152860|NCT04306718|PROCEDURE|membrane peeling|ERM and ILM are peeled routinely during surgery
219152861|NCT05898152|OTHER|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
219152862|NCT02957006|DEVICE|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
219152863|NCT05996588|DRUG|Propofol 1 % Injectable Suspension|Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
219152864|NCT05996588|DRUG|Sevoflurane|Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
219152865|NCT02928757|OTHER|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
219152866|NCT00767013|OTHER|DSCT, TTE|One assessment each
219152867|NCT04861324|BEHAVIORAL|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
219152868|NCT00214591|DRUG|GALIDA|
219152869|NCT00875160|DRUG|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
219152870|NCT02706717|DRUG|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
219152871|NCT02706717|DRUG|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
219152872|NCT01977638|DRUG|CXD101|Capsules, administered orally
219152873|NCT03420209|BEHAVIORAL|Group applying PNF technique|
219152874|NCT01911169|DRUG|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
219152875|NCT04122937|PROCEDURE|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
219152876|NCT04446078|DEVICE|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
219152877|NCT03873337|BEHAVIORAL|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
219152878|NCT03873337|DRUG|Nicotine patch|All participants will receive 10 weeks of nicotine patch
219152879|NCT02328768|DRUG|Omegaven|
219152880|NCT02512965|RADIATION|20 Gy in 5 fractions|
219152881|NCT02512965|RADIATION|Conventional SBRT: 24 Gy in 2 fractions|
219152882|NCT03401190|DRUG|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
219152883|NCT03401190|DRUG|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
219152884|NCT02888808|OTHER|Gastroscopy|Upper gastrointestinal endoscopy procedure
219152885|NCT00835770|DRUG|dimethyl fumarate|BG00012 capsules
219152886|NCT00835770|DRUG|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
219152887|NCT00226538|DRUG|Phenytoin|
219152888|NCT00226538|DRUG|Rifampicin|
219152889|NCT00226538|DRUG|Diclophenac|
219152890|NCT00226538|DRUG|Fluconazole|
219724867|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
219724868|NCT00886236|DRUG|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
219724869|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
219152891|NCT01185782|DRUG|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
219233135|NCT03731767|PROCEDURE|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
219724870|NCT01286324|DIETARY_SUPPLEMENT|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
219724871|NCT01286324|DRUG|Placebo Tablet|
219724872|NCT04767516|OTHER|no intervention|no intervention
219724873|NCT01770730|DEVICE|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
219724874|NCT04165902|DRUG|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
219724875|NCT05427916|DEVICE|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
219724876|NCT05427916|OTHER|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
219724877|NCT00055107|DRUG|Nitazoxanide|
219724878|NCT06476821|DRUG|BMS-986435|Specified dose on specified days
219724879|NCT03792997|COMBINATION_PRODUCT|combination therapy for high peripheral NK cells|lipid emulsion \& prednisolone \& LMWH
219724880|NCT03517020|DRUG|Torrent's Nebivolol Tablets|
219724881|NCT03517020|DRUG|Forest Pharmaceuticals Inc's Bystolic Tablets|
219724882|NCT02276833|OTHER|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
219724883|NCT05474677|PROCEDURE|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
219724884|NCT03195530|DRUG|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
219724885|NCT02551575|DRUG|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
219724886|NCT02551575|DRUG|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
219152892|NCT01185782|DRUG|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
219152893|NCT05076799|DRUG|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
219724887|NCT02551575|DRUG|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
219724888|NCT06502080|RADIATION|Consolidative radiotherapy|Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
219724889|NCT06502080|DRUG|Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab|Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
219724890|NCT03466372|BEHAVIORAL|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
219724891|NCT00623376|DRUG|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
219724892|NCT00623376|DRUG|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
219724893|NCT05558410|DRUG|Suzetrigine (SUZ)|Tablets for oral administration.
219724894|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
219152894|NCT05076799|DRUG|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
219152895|NCT05076799|DRUG|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
219152896|NCT05076799|DRUG|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
219152897|NCT03222323|DRUG|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
219152898|NCT03222323|DRUG|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
219152899|NCT03222323|DRUG|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
219724895|NCT05558410|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
219152900|NCT03222323|DRUG|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
219152901|NCT03222323|DRUG|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
219152902|NCT00705588|DRUG|Tadalafil|Orally, titrated to maximum 20mg od
219152903|NCT00705588|DRUG|Vardenafil|Orally, titrated to 10 mg bid
219152904|NCT05278871|DEVICE|Constructive Shearwave Interference (CSI)|handheld ultrasound
219152905|NCT05434624|DRUG|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
219152906|NCT05434624|DRUG|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
219152907|NCT03480854|OTHER|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
219152908|NCT02006940|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
219724896|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
219724897|NCT04565288|DRUG|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
219724898|NCT04565288|DRUG|Placebo|Matching placebo (sugar pill)
219724899|NCT05202496|DRUG|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
219724900|NCT05202496|PROCEDURE|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
219724901|NCT04049084|BIOLOGICAL|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
219724902|NCT03560596|BEHAVIORAL|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
219724903|NCT03560596|BEHAVIORAL|Usual Care|standard hypertension treatment recommendations as determined by PCP
219724904|NCT04717180|BEHAVIORAL|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
219724905|NCT04785885|DIAGNOSTIC_TEST|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
219724906|NCT04785885|DIAGNOSTIC_TEST|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
219724907|NCT03161847|OTHER|Non-interventional study|Non-interventional study
219724908|NCT04120675|DIETARY_SUPPLEMENT|Early Harvest Extra Virgin Olive Oil|Participants will take 3 tablespoons on a daily basis
219724909|NCT04953260|OTHER|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
219724910|NCT04953260|OTHER|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
219724911|NCT02277860|BEHAVIORAL|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
219724912|NCT00532857|DRUG|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
219724913|NCT03246854|DRUG|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
219724914|NCT05409612|BIOLOGICAL|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
219724915|NCT05409612|BIOLOGICAL|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
219724916|NCT02866266|OTHER|Retrospective database review|
219724917|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|Roux-en-Y
219724918|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|double tract reconstruction
219724919|NCT03319121|DRUG|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
219724920|NCT03319121|DRUG|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
219724921|NCT04169412|DIAGNOSTIC_TEST|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
219152909|NCT01126918|BEHAVIORAL|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
219152910|NCT02500264|DEVICE|TENS|
219152911|NCT02943629|DEVICE|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
219152912|NCT02943629|DEVICE|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
219152913|NCT02943629|DEVICE|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
219152914|NCT02570568|DEVICE|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
219152915|NCT02570568|DEVICE|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
219152916|NCT02570568|PROCEDURE|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
219152917|NCT03705442|DIETARY_SUPPLEMENT|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
219152918|NCT03705442|DRUG|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
219152919|NCT03352778|RADIATION|IMRT|66Gy by intensity-modulated radiotherapy
219152920|NCT03352778|RADIATION|2DRT|66Gy by 2-dimensional radiotherapy
219152921|NCT03022812|OTHER|Neck-specific exercise|Neck-specific exercise
219152922|NCT03419442|DRUG|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
219152923|NCT03419442|DRUG|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
219724922|NCT05469061|DRUG|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
219152924|NCT03419442|DRUG|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
219152925|NCT04232371|PROCEDURE|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
219152926|NCT04232371|PROCEDURE|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
219152927|NCT04141150|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
219152928|NCT05579054|DIAGNOSTIC_TEST|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
219152929|NCT00861029|DRUG|Pazopanib|Subjects treated with pazopanib
219152930|NCT00861029|OTHER|Placebo for pazopanib|Control for comparison with pazopanib
219152931|NCT00861029|DRUG|Moxifloxacin|Comparator for pazopanib
219152932|NCT00861029|OTHER|Placebo for moxifloxacin|Placebo for moxifloxacin
219152933|NCT02347436|PROCEDURE|24-hr ambulatory blood pressure measurement|
219724923|NCT05469061|DRUG|5-FU|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
219152934|NCT00149838|PROCEDURE|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
219152935|NCT00149838|DRUG|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
219152936|NCT00149838|PROCEDURE|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
219152937|NCT03740009|DRUG|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
219152938|NCT01061151|DRUG|Zidovudine (ZDV)|300 mg twice daily
219152939|NCT01061151|DRUG|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
219724924|NCT05469061|DRUG|cis Platinum|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
219724925|NCT01691807|DRUG|ofatumumab|treatment for NHL
219724926|NCT01691807|DRUG|bendamustine|treatment for NHL
219233136|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation."
219233137|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation."
219724927|NCT03519607|BEHAVIORAL|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
219724928|NCT05012969|DEVICE|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
219724929|NCT03049800|DEVICE|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
219724930|NCT05213351|OTHER|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~1. Right-left discrimination training (lateralization training)~2. Imagination of hand movements (motor imagery):~3. Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
219152940|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
219152941|NCT01061151|DRUG|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
219152942|NCT01061151|DRUG|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
219724931|NCT05213351|OTHER|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
219724932|NCT01279187|DRUG|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
219724933|NCT01279187|DRUG|Placebo|20ug per day, self administered injection, for 7 weeks
219724934|NCT00046943|DRUG|atrasentan hydrochloride|
219724935|NCT02558569|DRUG|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
219152943|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
219152944|NCT01061151|DRUG|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
219152945|NCT01061151|DRUG|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
219724936|NCT02558569|OTHER|NSS|Clear intravenous fluid looks alike local anesthetic.
219724937|NCT00731536|OTHER|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
219724938|NCT02786511|DRUG|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
219152946|NCT01061151|OTHER|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail."
219152947|NCT01061151|OTHER|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
219152948|NCT01061151|OTHER|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
219152949|NCT03813498|BEHAVIORAL|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
219152950|NCT03813498|BEHAVIORAL|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
219152951|NCT01684150|DRUG|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
219724939|NCT03597555|DRUG|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
219724940|NCT03597555|DRUG|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
219724941|NCT04941911|DRUG|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
219724942|NCT04941911|OTHER|Placebo|Sodium chloride 0.9% w/v
219724943|NCT04591132|DEVICE|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
219724944|NCT05516095|DEVICE|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
219724945|NCT05516095|DEVICE|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
219724946|NCT06156267|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
219724947|NCT06156267|DRUG|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
219724948|NCT00933166|DEVICE|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
219724949|NCT05831046|OTHER|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
219724950|NCT01558570|PROCEDURE|Blood Draw|One time blood draw
219724951|NCT06183567|PROCEDURE|Sedoanalgesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
219724952|NCT06183567|PROCEDURE|general anesthesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
219724953|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
219724954|NCT03278782|DRUG|Romidepsin|Given IV
219724955|NCT04402957|DRUG|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
219152952|NCT04811950|DEVICE|Emerald|Complete blood countdevice
219724956|NCT04402957|DRUG|Placebo|0.9% saline solution
219724957|NCT05641363|DRUG|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
219152953|NCT02944188|PROCEDURE|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
219152954|NCT02944188|PROCEDURE|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
219152955|NCT02999022|DRUG|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
219152956|NCT02999022|DRUG|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
219724958|NCT04195347|DRUG|CM4620|IV
219724959|NCT00837447|DEVICE|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
219152957|NCT04217512|DRUG|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
219152958|NCT04217512|DRUG|Pantoprazole high dose|Pantoprazole 1.6 mg\\kg
219152959|NCT04217512|OTHER|Standard hydration|Standard hydration alone
219152960|NCT04217512|DRUG|Cisplatin|Cisplatin
219152961|NCT03264846|DIAGNOSTIC_TEST|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
219724960|NCT00837447|DEVICE|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
219724961|NCT01527981|BEHAVIORAL|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
219724962|NCT04700462|BEHAVIORAL|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
219724963|NCT05354947|DEVICE|Ultrasound Delivery|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
219152962|NCT01117519|DRUG|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
219152963|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
219152964|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
219152965|NCT04135989|DRUG|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
219152966|NCT04135989|DRUG|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
219152967|NCT04114422|OTHER|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
219152968|NCT04434586|DEVICE|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
219152969|NCT02082548|OTHER|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
219152970|NCT03950778|DRUG|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
219152971|NCT01432613|PROCEDURE|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
219152972|NCT05660993|DRUG|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
219152973|NCT03324945|BEHAVIORAL|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
219152974|NCT02147678|DRUG|Etomidate|
219152975|NCT02147678|DRUG|Propofol|
219152976|NCT02147678|DRUG|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
219233138|NCT01326455|DEVICE|Clo-Sur-P.A.D.|"A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1."
219724964|NCT03943485|DEVICE|The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.|The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
219724965|NCT06144801|DEVICE|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
219724966|NCT03959319|OTHER|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
219724967|NCT03959319|OTHER|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
219724968|NCT01102283|DEVICE|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
219152977|NCT02147678|DRUG|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
219152978|NCT00144144|DRUG|Angiotensin II receptor antagonists, Calcium channel blocker|
219152979|NCT01232712|BIOLOGICAL|ImMucin, hGM-CSF|"* Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
219152980|NCT00338624|DRUG|oxybutynin chloride extended release|
219152981|NCT04577612|DRUG|CHI-554|hemp-derived CBD in MCT oil
219152982|NCT00459745|DRUG|Pravafen|
219152983|NCT00459745|DRUG|Pravastatin|
219152984|NCT00459745|DRUG|Fenofibrate|
219152985|NCT02906891|DEVICE|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
219152986|NCT05187975|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
219152987|NCT02634970|DRUG|Ranibizumab|0.5 mg, intravitreal injection
219152988|NCT01206504|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
219152989|NCT00869011|OTHER|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
219152990|NCT00873405|PROCEDURE|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
219152991|NCT00873405|PROCEDURE|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
219152992|NCT05512858|BEHAVIORAL|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
219152993|NCT02722473|BIOLOGICAL|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
219152994|NCT02722473|BIOLOGICAL|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
219152995|NCT06196788|DRUG|Gemcitabine|1000 mg per square meter
219152996|NCT06196788|DRUG|Nab paclitaxel|120 mg per square meter of body-surface area
219233139|NCT05445557|DRUG|RZL-012|small synthetic molecule for submental fat reduction
219233140|NCT05445557|DRUG|Placebo|Placebo
219233141|NCT01448109|DRUG|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
219724969|NCT05930470|OTHER|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
219724970|NCT02286674|OTHER|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
219724971|NCT05573282|OTHER|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
219724972|NCT05399355|DEVICE|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
219724973|NCT05399355|DEVICE|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
219724974|NCT01015196|DRUG|Zavedos|
219724975|NCT01015196|DRUG|Cerubidine|
219724976|NCT03501277|DRUG|Alogliptin|Alogliptin tablets.
219724977|NCT03501277|DRUG|Pioglitazone|Pioglitazone tablets.
219724978|NCT03501277|DRUG|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
219724979|NCT02198131|PROCEDURE|laser therapy|Undergo pulsed dye laser
219724980|NCT02198131|OTHER|questionnaire administration|Ancillary studies
219724981|NCT00729807|DRUG|pentamidine|
219724982|NCT06075290|BEHAVIORAL|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
219152997|NCT03551535|BEHAVIORAL|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
219152998|NCT02559362|BEHAVIORAL|Survey|
219152999|NCT04725305|DEVICE|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
219153000|NCT04725305|PROCEDURE|Standard of care|This method would involve removal of tonsils using electrocautery technique
219153001|NCT03833661|DRUG|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
219153002|NCT06109220|BEHAVIORAL|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
219153003|NCT04875624|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
219153004|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
219153005|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
219153006|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
219153007|NCT01937507|DRUG|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
219153008|NCT05193695|OTHER|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
219153009|NCT03430258|DEVICE|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
219153010|NCT03430258|DEVICE|Conventional oxygen therapy|Conventional oxygen therapy
219153011|NCT02344641|DRUG|Exenatide|
219153012|NCT00757133|PROCEDURE|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
219153013|NCT00757133|PROCEDURE|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
219153014|NCT04792905|DEVICE|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
219153015|NCT04530747|DRUG|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
219153016|NCT04530747|DRUG|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
219153017|NCT00940524|DRUG|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
219153018|NCT03292913|BEHAVIORAL|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
219153019|NCT03292913|BEHAVIORAL|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
219153020|NCT04460313|OTHER|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
219153021|NCT04460313|OTHER|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
219153022|NCT00181740|DRUG|atomoxetine (Strattera)|
219153023|NCT06051955|OTHER|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
219153024|NCT01902784|BEHAVIORAL|Storytelling Interview|
219153025|NCT06148831|DEVICE|Infant Carrier|"The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat)."
219153026|NCT00110864|DRUG|PN2034|
219153027|NCT00110864|DRUG|Insulin|
219153028|NCT02772471|DEVICE|HS-1000|
219153029|NCT03950622|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
219153030|NCT03950622|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
219153031|NCT03817476|DRUG|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
219153032|NCT03817476|DRUG|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
219153033|NCT03817476|DRUG|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
219153034|NCT01001936|DRUG|SKI-606|
219153035|NCT02479217|DRUG|Docetaxel|
219153036|NCT02479217|DRUG|Xeloda|
219153037|NCT04169698|DRUG|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
219153038|NCT04169698|DRUG|Alendronate 70Mg Tab|Bisphosphonates
219153039|NCT02850744|DRUG|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
219153040|NCT02304055|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
219724983|NCT06075290|BEHAVIORAL|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
219153041|NCT02304055|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
219153042|NCT03752151|DEVICE|MARVEL 2 Algorithm Monitor Mode then Adaptive Mode|Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
219153043|NCT00529516|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
219153044|NCT00529516|BIOLOGICAL|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
219153045|NCT00548418|DRUG|Topotecan|
219153046|NCT00548418|DRUG|Cisplatin|
219153047|NCT00548418|DRUG|Bevacizumab|
219153048|NCT03195608|DEVICE|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
219153049|NCT03195608|BEHAVIORAL|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
219153050|NCT03544736|DRUG|Nivolumab|Experimental: Nivolumab
219153051|NCT03544736|RADIATION|Radiotherapy|Radiotherapy
219153052|NCT03544736|DRUG|Chemotherapy|Chemotherapy
219153053|NCT03544736|PROCEDURE|Surgery|Surgery
219153054|NCT05951140|OTHER|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
219153055|NCT01404598|DRUG|naproxcinod 750 bid|naproxcinod 750 bid
219153056|NCT01404598|DRUG|naproxcinod 3000 mg od|naproxcinod 3000 mg od
219153057|NCT01404598|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
219153058|NCT00175864|DRUG|Seletracetam (ucb 44212)|
219153059|NCT04968756|DEVICE|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
219153060|NCT01935544|DEVICE|Botulinum toxin injection|
219153061|NCT06037993|DIETARY_SUPPLEMENT|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
219153062|NCT03639896|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
219153063|NCT03639896|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
219724984|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
219724985|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
219724986|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
219153064|NCT03107117|BEHAVIORAL|Computer Counseling|two computer counseling online programs for a teen and a parent
219153065|NCT03107117|BEHAVIORAL|Standard Care|A referral for substance use counseling
219153066|NCT03241017|DRUG|Durvalumab|Immunotherapy with Durvalumab after ASCT
219153067|NCT04759482|DIAGNOSTIC_TEST|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
219153068|NCT00151567|DRUG|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
219724987|NCT06099600|PROCEDURE|Reconstructive surgery of the anterior cruciate ligament|surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
219724988|NCT01008787|BEHAVIORAL|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
219724989|NCT01008787|BEHAVIORAL|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
219153069|NCT00151567|DRUG|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
219153070|NCT03051165|DEVICE|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
219153071|NCT00052364|DRUG|oxaliplatin|Given IV
219153072|NCT00052364|OTHER|laboratory biomarker analysis|Correlative studies
219724990|NCT01008787|BEHAVIORAL|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
219724991|NCT01008787|BEHAVIORAL|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
219724992|NCT04056468|DRUG|Mobocertinib|Mobocertinib capsule.
219724993|NCT03299309|DRUG|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
219153073|NCT02639910|BIOLOGICAL|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
219153074|NCT02639910|DRUG|Idelalisib|idelalisib dose: 150 mg twice daily orally
219153075|NCT02639910|DRUG|Venetoclax|venetoclax dose: 400 mg once daily orally
219724994|NCT05445336|BEHAVIORAL|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
219724995|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
219724996|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
219153076|NCT00108823|DRUG|Roflumilast|
219153077|NCT04805216|PROCEDURE|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible."
219153078|NCT03922061|BIOLOGICAL|dmLT|double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
219153079|NCT03922061|BIOLOGICAL|fIPV|fractional-dose inactived polio vaccine
219724997|NCT01860404|DRUG|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
219724998|NCT01860404|DRUG|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
219724999|NCT00009555|DRUG|Testosterone|
219153080|NCT01047241|DRUG|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
219153081|NCT03681522|PROCEDURE|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
219153082|NCT03681522|PROCEDURE|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
219153083|NCT03554460|DEVICE|dual-limb NIV|dual-limb NIV was served with servo i ventilator
219153084|NCT02092116|DRUG|Romidepsin|Latency reversing agent
219153085|NCT02092116|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
219153086|NCT02092116|BIOLOGICAL|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
219153087|NCT06154876|DEVICE|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
219153088|NCT05235906|DRUG|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
219153089|NCT04137497|DIAGNOSTIC_TEST|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
219153090|NCT03427632|DRUG|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
219153091|NCT00105092|DRUG|Enzastaurin HCL|
219153092|NCT00681603|DRUG|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
219153093|NCT01471756|PROCEDURE|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
219233142|NCT01448109|DRUG|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
219725000|NCT05906004|DEVICE|Pitch-Patch|Pitch-Patch device used for rotator cuff augmentation/ reinforcement.
219725001|NCT06633289|OTHER|Experimental formula|New hydrolyzed rice protein-based formula
219725002|NCT06633289|OTHER|Control formula|Commercially available amino acid-based formula.
219725003|NCT01761344|OTHER|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
219725004|NCT04668963|DEVICE|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
219725005|NCT00401115|DRUG|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
219725006|NCT00401115|DRUG|MS-R001 (rapamycin)|Intraocular injection in various dosages
219725007|NCT03084484|DIETARY_SUPPLEMENT|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
219725008|NCT03084484|PROCEDURE|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
219725009|NCT01721902|DEVICE|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
219725010|NCT01721902|OTHER|Carrier Solution|Intra-myocardial injection of carrier solution
219725011|NCT05652842|BEHAVIORAL|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
219725012|NCT06549543|OTHER|High Intensity Laser Therapy|HILT is applied per session, with a maximum of 10.0 W, a mean of 5.7 W, a dose of 99 J/cm², and a total energy flux of 2079 J were applied over 6 minutes and 5 seconds on a 21 cm² field on the medial aspect of the knee joint.
219725013|NCT06549543|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS is an analgesic modality of physical therapy
219725014|NCT06549543|OTHER|Hotpacks|Hotpacks is a thermoanalgesia modality of physical therapy
219725015|NCT06549543|OTHER|SHAM - High Intensity Laser Therapy|for control group, sham HILT was applied, with lights on but no laser beam
219233143|NCT05778253|DIAGNOSTIC_TEST|WES and ctDNA detection|WES and ctDNA detection
219233144|NCT02482324|DRUG|ALZT-OP1a|Mast cell stabilizer
219233145|NCT02482324|DRUG|ALZT-OP1b|anti-inflammatory
219725016|NCT03062839|DRUG|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
219725017|NCT05638984|DRUG|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
219725018|NCT05638984|DRUG|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
219725019|NCT02823561|DIETARY_SUPPLEMENT|Garcinia mangostana|
219725020|NCT02823561|BEHAVIORAL|Control group|
219153094|NCT06145867|OTHER|Photobiomodulation therapy|deep red light therapy (670nm)
219153095|NCT00319293|DRUG|Metformin|
219153096|NCT06159569|DEVICE|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
219153097|NCT04593056|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
219153098|NCT04593056|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
219153099|NCT00744913|DRUG|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
219153100|NCT00744913|OTHER|Counselling|Women in this arm of the study will receive standard counseling only.
219153101|NCT02361918|PROCEDURE|Colon surgery|
219153102|NCT00025610|DRUG|carboplatin|
219153103|NCT00025610|DRUG|cyclophosphamide|
219153104|NCT00025610|DRUG|doxorubicin hydrochloride|
219153105|NCT00025610|DRUG|etoposide|
219153106|NCT00025610|DRUG|vincristine sulfate|
219153107|NCT00273624|DRUG|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
219153108|NCT00273624|DRUG|Placebo|placebo
219153109|NCT04887675|DIAGNOSTIC_TEST|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
219153110|NCT04065958|BEHAVIORAL|Yoga-mindfulness|Body-mind therapy
219153111|NCT04065958|BEHAVIORAL|Patient education and physiotherapy|Lectures and physiotherapy
219153112|NCT00016341|BIOLOGICAL|filgrastim|
219153113|NCT00016341|DRUG|cisplatin|
219153114|NCT00016341|DRUG|doxorubicin hydrochloride|
219153115|NCT00016341|DRUG|megestrol acetate|
219153116|NCT00016341|DRUG|paclitaxel|
219153117|NCT00016341|DRUG|tamoxifen citrate|
219153118|NCT06499558|OTHER|Classical Training|Students in the education group will practice family planning education skills in the professional skills laboratory.
219153119|NCT06499558|OTHER|Standard Patient Interviews|Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
219153120|NCT03206684|DRUG|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
219153121|NCT03206684|DRUG|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
219153122|NCT03074331|DRUG|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
219153123|NCT00915239|DRUG|Pantoprazole|40 mg pantoprazole once daily for 28 days
219153124|NCT00915239|DRUG|Placebo|identical placebo once daily for 28 days
219153125|NCT00035828|DRUG|ABX-IL8|
219153126|NCT05228054|PROCEDURE|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
219153127|NCT05228054|PROCEDURE|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
219153128|NCT00741455|PROCEDURE|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
219153129|NCT00741455|DRUG|G-CSF|10 mcg/kg/day on days 5, 6, and 7
219153130|NCT00741455|DRUG|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
219153131|NCT00741455|DRUG|cyclophosphamide|1 g/m2/d IV on days -3 and -2
219153132|NCT00741455|DRUG|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
219153133|NCT00741455|DRUG|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
219153134|NCT03257644|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
219725021|NCT05375799|OTHER|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
219725022|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
219725023|NCT01704859|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219725024|NCT01704859|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219725025|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
219153135|NCT03014375|DRUG|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
219153136|NCT00788034|DRUG|Lu AA21004|5 or 10 mg/day
219153137|NCT00788034|DRUG|Placebo|Once daily
219725026|NCT05225168|PROCEDURE|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
219153138|NCT00843687|DRUG|Risperidone long-acting injectable|
219153139|NCT05733507|PROCEDURE|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
219153140|NCT05733507|PROCEDURE|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
219153141|NCT05494294|PROCEDURE|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
219153142|NCT05494294|PROCEDURE|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
219153143|NCT03469596|DIAGNOSTIC_TEST|MRI sequence|several MRI sequence before and after contrast product injection.
219153144|NCT05519670|DRUG|Niraparib Oral Product|Niraparib + capecitabine treatment
219153145|NCT00077493|DRUG|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
219153146|NCT00077493|PROCEDURE|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
219153147|NCT00077493|PROCEDURE|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
219153148|NCT00077493|PROCEDURE|monoclonal antibody therapy|administered intravenously over 30 minutes.
219153149|NCT06282107|PROCEDURE|BiSAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
219153150|NCT06282107|PROCEDURE|traditional triple antihypertensive treatment|traditional triple antihypertensive treatment
219153151|NCT01319617|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
219153152|NCT03697707|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
219153153|NCT01592448|BEHAVIORAL|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
219153154|NCT02337036|OTHER|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
219153155|NCT02337036|OTHER|Pharmacogenetic|Pharmacogenetic study
219153156|NCT02337036|DRUG|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
219153157|NCT05955989|OTHER|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
219153158|NCT03918967|DRUG|CT-G11|oral tablet of CT-G11 Experimental Drug
219153159|NCT03918967|DRUG|CT-G20|oral tablet of CT-G20 Experimental Drug
219153160|NCT03918967|DRUG|CT-G11 Placebo|oral tablet of Placebo
219153161|NCT03918967|DRUG|CT-G20 Placebo|oral tablet of Placebo
219153162|NCT03991754|PROCEDURE|transcatheter aortic valve implantation|transcatheter aortic valve implantation
219153163|NCT04768712|BEHAVIORAL|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
219153164|NCT03689920|DEVICE|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
219153165|NCT00137995|DRUG|Rituximab|375 mg/m² D-2/D1
219153166|NCT00137995|DRUG|Etoposide|100 mg/m² D1-D2-D3
219153167|NCT00137995|DRUG|Carboplatine|max 800mg D2
219725027|NCT05225168|PROCEDURE|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
219153168|NCT00137995|DRUG|Ifosfamide + Mesna|5 g/m² from D2 to D13
219153169|NCT00137995|DRUG|Cisplatine|100 mg/m² from D1 to D13
219153170|NCT00137995|DRUG|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
219153171|NCT00137995|DRUG|Dexamethasone|40 mg From D1 to D4
219153172|NCT00137995|PROCEDURE|Autologous Stem Cell Transplantation|
219153173|NCT00137995|DRUG|BCNU|300mg/m² on D-6
219153174|NCT00137995|DRUG|Etoposide|200 mg/m² from D-6 to D-3
219153175|NCT00137995|DRUG|Cytarabine|100 mg/m² from D-6 to D-3
219725028|NCT03270488|OTHER|Laser|Laser (power of 3.0w).
219725029|NCT03270488|OTHER|Placebo|Laser (power 0,0w)
219725030|NCT04836130|PROCEDURE|patient specific guide|patient specific guide reduction
219153176|NCT00137995|DRUG|Melphalan|140 mg/m² on D-2
219153177|NCT03980496|DRUG|Omeprazole|
219153178|NCT03753984|OTHER|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
219153179|NCT01284075|BEHAVIORAL|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
219153180|NCT01284075|BEHAVIORAL|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
219153181|NCT01284075|OTHER|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
219153182|NCT02459015|DEVICE|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
219153183|NCT05705856|DRUG|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
219153184|NCT01995903|DIAGNOSTIC_TEST|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
219153185|NCT02419703|DEVICE|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
219153186|NCT01546753|DRUG|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
219153187|NCT01546753|DRUG|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
219153188|NCT01546753|DRUG|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
219153189|NCT02108210|DRUG|Anakinra|
219153190|NCT02108210|DRUG|Placebo|
219233146|NCT02482324|DEVICE|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
219233147|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised CARE program
219725031|NCT04836130|PROCEDURE|conventional technique|conventional anatomical reduction
219725032|NCT02154659|DEVICE|24hr pH monitoring|
219725033|NCT06480955|DEVICE|Cryoablation system|Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.
219725034|NCT02762604|BEHAVIORAL|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
219725035|NCT02762604|BEHAVIORAL|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
219153191|NCT03125863|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
219153192|NCT02652806|DRUG|FG-4592|
219153193|NCT02652806|DRUG|Epoetin Alfa|
219153194|NCT06136351|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
219153195|NCT06136351|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
219153196|NCT06136351|DRUG|Bendamustin|90mg/m\^2 ivgtt, D0 of each 28-day cycle
219153197|NCT01483066|DEVICE|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
219153198|NCT05412199|DEVICE|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
219153199|NCT05412199|DEVICE|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
219153200|NCT05412199|OTHER|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
219153201|NCT00879749|BIOLOGICAL|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
219153202|NCT00879749|BIOLOGICAL|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
219153203|NCT00879749|BIOLOGICAL|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
219153204|NCT00879749|BIOLOGICAL|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
219153205|NCT00879749|BIOLOGICAL|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
219153206|NCT00879749|OTHER|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
219153207|NCT04086966|DRUG|[68Ga]PSMA-PET/MRI or PET/CT|\[68Ga\]PSMA-PET/MRI or PET/CT
219233148|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised TARE program
219725036|NCT03468127|OTHER|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
219153208|NCT04410458|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
219153209|NCT00000834|DRUG|Lamivudine|
219153210|NCT00000834|DRUG|Methotrexate|
219153211|NCT00000834|DRUG|Zidovudine|
219153212|NCT06070337|DEVICE|H-Guard|A novel Haemodialyser primer used for one treatment only
219153213|NCT02725294|OTHER|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
219153214|NCT00000338|DRUG|Lisuride|
219153215|NCT01706354|PROCEDURE|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
219153216|NCT01706354|PROCEDURE|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
219153217|NCT05705505|DRUG|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
219153218|NCT05705505|DRUG|Letrozole 2.5mg|Tablet
219153219|NCT01796236|DEVICE|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
219153220|NCT01796236|DEVICE|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
219153221|NCT05801198|DIETARY_SUPPLEMENT|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
219153222|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
219233149|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo home-based stretching program
219725037|NCT04755478|PROCEDURE|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
219725038|NCT04755478|PROCEDURE|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
219233150|NCT03091842|OTHER|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
219233151|NCT03091842|OTHER|Laboratory Biomarker Analysis|Correlative studies
219233152|NCT03091842|OTHER|Quality-of-Life Assessment|Ancillary studies
219233153|NCT03091842|OTHER|Questionnaire Administration|Ancillary studies
219725039|NCT05823857|OTHER|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
219725040|NCT05823857|OTHER|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
219725041|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
219725042|NCT06038643|BEHAVIORAL|Motivational behavioural intervention and daily activities monitoring|Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.
219725043|NCT06038643|BEHAVIORAL|Active Control|Daily activities monitored through accelerometry.
219725044|NCT05048472|DIAGNOSTIC_TEST|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
219725045|NCT03783806|DIAGNOSTIC_TEST|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
219725046|NCT02944266|OTHER|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
219725047|NCT04519398|GENETIC|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu"
219725048|NCT02990377|BEHAVIORAL|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
219153223|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
219153224|NCT00145314|DRUG|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
219725049|NCT02825459|BEHAVIORAL|Abstinence from e-cigarettes|Abrupt cessation for 6 days
219153225|NCT00546754|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
219153226|NCT00546754|DRUG|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
219153227|NCT06079931|DRUG|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
219153228|NCT04877496|DRUG|History of exposure to anti-CD20 treatment since 01/01/2010|Intravenous treatment history of anti-CD20 treatment since 01/01/2010
219153229|NCT04877496|BIOLOGICAL|Completion of COVID19 vaccine at least 4 weeks ago|Completion of COVID19 vaccination course at least 4 weeks ago.
219153230|NCT03375151|DEVICE|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
219153231|NCT03375151|BEHAVIORAL|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
219153232|NCT03375151|BEHAVIORAL|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
219153233|NCT06169501|BEHAVIORAL|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
219233154|NCT00167999|DRUG|piperacillin-tazobactam|
219725050|NCT05297838|OTHER|Stationary Bike|Stationary Bike while hand is submerged in ice bath
219725051|NCT05297838|OTHER|Virtual Reality (VR) Headset|VR headset containing gameplay
219725052|NCT05297838|OTHER|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
219725053|NCT00762177|DRUG|Fluoride|Brush twice a day for 14 days
219725054|NCT00762177|DRUG|Fluoride, Triclosan|Brush twice daily for 14 days
219725055|NCT00762177|DRUG|Stannous Fluoride|Brush twice daily for 14 days
219725056|NCT05111964|DEVICE|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
219725057|NCT05111964|DIAGNOSTIC_TEST|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
219153234|NCT01622400|OTHER|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
219153235|NCT03569982|OTHER|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
219153236|NCT04762875|BIOLOGICAL|MGTA-145|MGTA-145 will be be administered as an IV infusion
219153237|NCT04762875|BIOLOGICAL|Plerixafor|240 µg/kg subcutaneously
219153238|NCT05857267|DRUG|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
219153239|NCT05857267|DRUG|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
219153240|NCT05444517|PROCEDURE|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
219153241|NCT05444517|PROCEDURE|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
219725058|NCT05876312|DRUG|ADX-038|siRNA duplex oligonucleotide
219725059|NCT05876312|DRUG|Placebo|Saline
219725060|NCT04136366|DRUG|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
219725061|NCT04136366|OTHER|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
219153242|NCT04535882|DIAGNOSTIC_TEST|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
219153243|NCT05105646|PROCEDURE|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
219233155|NCT02008916|DRUG|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
219233156|NCT02008916|DRUG|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
219233157|NCT06648785|DRUG|oxaliplatin|85 mg/m2 oxaliplatin
219233158|NCT06648785|DRUG|Fluoropyrimidine|oral fluoropyrimidine 1000mg/m2
219725062|NCT03052036|PROCEDURE|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
219725063|NCT03052036|PROCEDURE|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
219725064|NCT03052036|OTHER|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
219725065|NCT00191750|DRUG|Pemetrexed|
219725066|NCT06432439|PROCEDURE|microneedling followed by CAF procedures|microneedling will be done on gingiva of RT1 recession tooth in 4 sessions followed by CAF 2months later for root coverage
219725067|NCT06432439|PROCEDURE|CAF procedure|RT1 gingival recession coverage by CAF procedures alone.
219725068|NCT00892255|DEVICE|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
219725069|NCT06188806|OTHER|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
219725070|NCT06188806|OTHER|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
219725071|NCT01470807|DEVICE|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
219725072|NCT01246323|PROCEDURE|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
219153244|NCT04831190|BEHAVIORAL|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
219153245|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
219153246|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
219153247|NCT00311363|DRUG|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
219153248|NCT03830866|BIOLOGICAL|Durvalumab|IV infusion every 4 weeks
219153249|NCT03830866|DRUG|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
219153250|NCT03830866|DRUG|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
219153251|NCT03830866|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
219153252|NCT02034968|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
219153253|NCT03316482|DRUG|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
219153254|NCT04213053|PROCEDURE|strabismus surgery|Lees screen before and after concomitant strabismus surgery
219153255|NCT05316246|DRUG|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
219153256|NCT00156741|DEVICE|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
219153257|NCT00156741|PROCEDURE|Required pacemaker setting|
219153258|NCT02904759|DRUG|Desmopressin|
219153259|NCT02904759|DRUG|Placebo|
219153260|NCT04111328|DRUG|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
219153261|NCT04111328|DRUG|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
219153262|NCT04111328|DRUG|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
219153263|NCT04111328|DRUG|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
219153264|NCT04111328|DRUG|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
219153265|NCT04111328|DRUG|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
219153266|NCT04111328|DRUG|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
219153267|NCT04111328|DRUG|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
219153268|NCT02240446|DEVICE|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
219153269|NCT02240446|DEVICE|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
219153270|NCT00943358|BIOLOGICAL|MF59 H1N1 vaccine|3.75-7.5ug dose
219153271|NCT00943358|BIOLOGICAL|Plain H1N1 vaccine|7.5-15ug
219153272|NCT01897155|OTHER|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
219153273|NCT01897155|OTHER|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
219153274|NCT03532906|DRUG|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
219153275|NCT03532906|DRUG|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
219153276|NCT04974450|DIETARY_SUPPLEMENT|Trigona honey|composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
219153277|NCT04974450|DIETARY_SUPPLEMENT|control|Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
219153278|NCT03416712|OTHER|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
219153279|NCT03433586|DRUG|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
219153280|NCT03433586|DRUG|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
219153281|NCT02929147|DRUG|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
219153282|NCT02929147|DRUG|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
219153283|NCT02929147|DRUG|Placebo|In the Group 3 the PCA will contain placebo.
219153284|NCT03532243|PROCEDURE|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
219153285|NCT05360901|BEHAVIORAL|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
219153286|NCT00988858|DRUG|LY2603618|150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
219153287|NCT00988858|DRUG|Pemetrexed|500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
219153288|NCT04619290|DRUG|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
219153289|NCT04619290|OTHER|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
219153290|NCT06004505|OTHER|Vestibular Rehabilitation|The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
219153291|NCT04286113|BEHAVIORAL|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
219153292|NCT04286113|BEHAVIORAL|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
219233159|NCT03803475|DRUG|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
219725073|NCT06527703|OTHER|no intervention|"Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
219725074|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
219725075|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
219725076|NCT04873583|DRUG|Methylprednisolone|At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose)
219725077|NCT04873583|DRUG|Prednisolone|"Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)"
219725078|NCT04514458|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
219725079|NCT05721742|OTHER|virtually administered dietitian consults for IBS patients.|Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
219153293|NCT04432389|BIOLOGICAL|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
219725080|NCT05721742|OTHER|IBS Group Online Session|IBS online group session run by Happy Bellies Nutrition
219725081|NCT05259033|DRUG|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
219725082|NCT05259033|DRUG|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
219153294|NCT04432389|OTHER|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
219153295|NCT03562884|DRUG|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
219153296|NCT03562884|DRUG|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
219153297|NCT04368663|DRUG|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
219153298|NCT02182336|DRUG|BI 201335 NA|"1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23"
219153299|NCT02182336|DRUG|Caffeine|days 1, 10 and 19
219153300|NCT02182336|DRUG|Warfarin sodium|days 1, 10 and 19
219153301|NCT02182336|DRUG|Vitamin K|days 1, 10 and 19
219153302|NCT02182336|DRUG|Omeprazole|days 1, 10 and 19
219153303|NCT02182336|DRUG|Dextromethorphan hydrobromide|days 1, 10 and 19
219153304|NCT02182336|DRUG|Midazolam HCl solution|Days 3 and 21
219153305|NCT02182336|DRUG|Midazolam HCl oral syrup|days 1, 10 and 19
219153306|NCT02182336|DRUG|Digoxin|Days 2 and 20
219153307|NCT00925210|PROCEDURE|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
219153308|NCT03764475|DRUG|Roflumilast|Roflumilast cream 0.3% for topical application
219153309|NCT00936507|OTHER|Energy Density/Portion Size|
219153310|NCT05629793|OTHER|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
219153311|NCT03380234|OTHER|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
219153312|NCT03380234|OTHER|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.
219153313|NCT03380234|OTHER|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
219153314|NCT03380234|OTHER|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
219153315|NCT00744224|DRUG|Placebo|Single dose of placebo with saline infusion
219153316|NCT00744224|DRUG|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
219153317|NCT00744224|DRUG|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
219153318|NCT05113771|DRUG|Liafensine|Liafensine
219153319|NCT05113771|DRUG|Placebo|Placebo
219153320|NCT04191434|DRUG|Flamboyant 125/12|Flamboyant 125/12 capsule
219153321|NCT04191434|DRUG|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
219153322|NCT04191434|OTHER|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
219153323|NCT04191434|OTHER|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
219153324|NCT01063140|BIOLOGICAL|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
219153325|NCT01063140|BIOLOGICAL|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
219725083|NCT06434883|BEHAVIORAL|Anxiety/Depression Program|Participants will complete the Headspace Anxiety/Depression Program, which is a 21 day program based on CBT, combined with mindfulness. The program is trans-diagnostic in nature (i.e. addresses both anxiety and depression symptoms).
219725084|NCT06434883|OTHER|Waitlist|Participants will continue their regular routines for an 21 day period and will not be assigned to an intervention.
219725085|NCT06471569|BEHAVIORAL|Low/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
219153326|NCT04357951|DRUG|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
219153327|NCT04357951|DRUG|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
219725086|NCT06471569|BEHAVIORAL|High/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
219153328|NCT04357951|BEHAVIORAL|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
219153329|NCT02827474|OTHER|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
219153330|NCT02827474|OTHER|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
219153331|NCT05912088|BEHAVIORAL|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
219153332|NCT05912088|BEHAVIORAL|Control Group|Subjects will receive the usual care advice
219153333|NCT06091865|DRUG|Odronextamab|Odronextamab will be administered by intravenous (IV) infusion
219153334|NCT06091865|DRUG|Rituximab|Rituximab will be administered IV, or subcutaneously (SC)
219153335|NCT06091865|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV as part of chemotherapy
219153336|NCT06091865|DRUG|Doxorubicin|Doxorubicin will be administered IV as part of chemotherapy
219153337|NCT06091865|DRUG|Vincristine|Vincristine will be administered IV as part of chemotherapy
219153338|NCT06091865|DRUG|Prednisone/Prednisolone|Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
219153339|NCT06972667|OTHER|Video to promote colonoscopy|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to have a colonoscopy. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
219153340|NCT06972667|OTHER|Video to promote screening for colorectal cancer with home tests|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to screen for colorectal cancer with a home test. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
219153341|NCT06973538|OTHER|Music-based Calisthenic Exercise|Participants in this group will perform 8 weeks of calisthenic exercises with background music. Each session includes a 10-minute warm-up, 30 minutes of music-based exercises (e.g., seated leg lifts, chair squats, arm curls), and a 10-minute cool-down. Elastic resistance bands will be introduced from week 5 to increase intensity. Music tracks are selected to enhance motivation and engagement.
219725087|NCT06471569|BEHAVIORAL|High/Vig|Aerobic exercise at 75% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
219725088|NCT04210375|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
219725089|NCT04210375|DRUG|Matching Placebo|Vehicle control
219725090|NCT03414866|BEHAVIORAL|EQ-5D-5L QOL questionnaire|Written questionnaire
219725091|NCT05502783|DRUG|fostamatinib|Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin \< 10 g/dL, platelets \< 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
219725092|NCT05813977|DEVICE|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
219725093|NCT05954728|BEHAVIORAL|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
219725094|NCT05954728|BEHAVIORAL|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
219725095|NCT05135169|DRUG|Definity Suspension for Injection|Administration of Definity
219725096|NCT00008424|DRUG|irinotecan hydrochloride|
219725097|NCT04199520|COMBINATION_PRODUCT|surgery combined with systemic therapy|surgery combined with systemic therapy
219725098|NCT04199520|OTHER|systemic therapy|systemic therapy
219725099|NCT01405911|DRUG|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
219725100|NCT01405911|DRUG|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
219725101|NCT01405911|DRUG|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
219725102|NCT01405911|DRUG|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
219725103|NCT01650376|DRUG|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
219725104|NCT01650376|DRUG|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
219153342|NCT06972498|DRUG|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
219153343|NCT06973135|PROCEDURE|Bioceramic sealer root canal obturation|Mandibular molars root canal obturation with bioceramic sealer after non surgical endodontic retreatment and then immediate periapical radiograph will be done to record PAI
219153344|NCT06973135|PROCEDURE|resin sealer root canal obturation|non surgical root canal retreatment of mandibular molar teeth will be done using resin based sealer in obturation and periapical radiograph will be taken immediately to record PAI
219153345|NCT06973057|PROCEDURE|Pulpotomy|The entire coronal pulp will be amputated to the level of canal orifices, after hemostasis, NeoMTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
219153346|NCT06973057|PROCEDURE|Direct pulp capping (DPC)|At the exposure site hemostasis will be achieved, neo MTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
219153347|NCT05510245|DRUG|PF-07081532|One PF-07081532 20 mg tablet, administered orally
219153348|NCT05851391|DRUG|Burst Suppression EEG Target Intravenous Anesthesia|The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
219153349|NCT05851391|DRUG|Seizure Suppression EEG Target Intravenous Anesthesia|is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
219153350|NCT02414204|DRUG|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
219153351|NCT02414204|OTHER|Placebo|Placebo will be over encapsulated to identical to drug comparison
219153352|NCT00586586|BEHAVIORAL|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
219153353|NCT03995992|BEHAVIORAL|sport|10 days of sport (diving or multisport), once training per day
219153354|NCT02689180|DRUG|Placebo|Replacement of furosemide by placebo
219153355|NCT02689180|DRUG|Furosemide|Maintenance of furosemide on usual doses
219153356|NCT04481672|DRUG|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
219153357|NCT05075941|OTHER|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
219153358|NCT01186198|DEVICE|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
219153359|NCT00430872|BEHAVIORAL|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
219153360|NCT03751943|DEVICE|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
219153361|NCT01359436|DEVICE|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
219153362|NCT03861364|DRUG|Propofol|2,4 mg/kg
219153363|NCT03861364|DRUG|Propofol|1,4 mg/kg
219153364|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
219153365|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
219153366|NCT02725762|DEVICE|LT-300 Active (PBM)|
219153367|NCT02725762|DEVICE|LT-300 Inactive (Sham)|
219153368|NCT06397144|DRUG|Paxlovid|Reference 1
219153369|NCT06397144|DRUG|Paxlovid|Reference 2
219153370|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 1
219153371|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 2
219725105|NCT01650376|DRUG|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
219725106|NCT02779296|OTHER|2-Octyl Cyanoacrylate Glue|topical
219153372|NCT01759771|DRUG|Vitamin D3|4,000 IU of VD3 for at least one year
219153373|NCT01759771|DRUG|Placebo|Placebo for at least one year
219153374|NCT02541188|GENETIC|Genetic analysis|
219153375|NCT06553261|PROCEDURE|suturing of leak, lavage, drainage|Operative suturing of the leak, lavage, drainage within a revision surgery.
219153376|NCT06553261|PROCEDURE|Formation of a new anasthomosis|Operative resection of the old leaking anastomosis and formation of a new one.
219153377|NCT06553261|PROCEDURE|Fecal diversion|Formation of a deviating stoma.
219153378|NCT06553911|OTHER|Artificial Intelligence-based medical imaging interpretation|In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
219153379|NCT05861193|PROCEDURE|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
219153380|NCT00204646|DRUG|Adriamycin|
219153381|NCT00204646|DRUG|Ifosfamide|
219153382|NCT00204646|DRUG|Etoposide|
219153383|NCT00204646|DRUG|Carboplatin|
219153384|NCT00505791|DRUG|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure \> 100 mmHg.
219153385|NCT00060684|DRUG|Pixantrone (BBR 2778)|
219153386|NCT00060684|DRUG|fludarabine|
219153387|NCT00060684|DRUG|dexamethasone|
219153388|NCT00060684|DRUG|rituximab|
219153389|NCT02616068|DRUG|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
219153390|NCT02616068|DRUG|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
219153391|NCT02616068|DRUG|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
219153392|NCT02616068|DRUG|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
219153393|NCT03104036|OTHER|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
219153394|NCT03104036|DRUG|Mesalazine 4G Enema|Standard mesalazine enema
219153395|NCT03035994|OTHER|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
219153396|NCT04581850|BEHAVIORAL|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
219153397|NCT04581850|BEHAVIORAL|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
219233160|NCT03803475|DEVICE|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
219725107|NCT05410067|OTHER|Cervicothoracic Junction Mobilization Technique|It is a part of manual therapy technique. Patient would be in prone position with his forehead in the palm of the therapist. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given. For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7. The therapist's thumbs were placed on the posterior surface of the articular process to be mobilized (C7 on the side of restriction), and anteriorly directed oscillatory pressure was applied for unilateral PA mobilization.
219725108|NCT05410067|OTHER|Eccentric Muscle Energy Technique|Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.
219725109|NCT00093028|DRUG|CC-5013 (Revlimid™)|N/A Study Complete
219725110|NCT00093028|DRUG|bortezomib|N/A Study Complete
219725111|NCT05401851|DEVICE|Left Bundel Area Pacing|RV Lead will be placed deep in the interventricular septum
219153398|NCT04581850|OTHER|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences"
219153399|NCT03480451|OTHER|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
219153400|NCT06647641|OTHER|Whole genome sequencing will be performed at the NIH|All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
219153401|NCT04294173|BEHAVIORAL|video education|tracheostomy care will be given to student nurses with video training
219153402|NCT03108703|RADIATION|SBRT|35-40 Gy delivered in 5 fractions
219153403|NCT02575560|OTHER|history data|history data of PFS after 1st line or second line theray
219153404|NCT04843475|DIAGNOSTIC_TEST|Echocardiography|Trans-thoracic Echocardiography
219725112|NCT01182363|BEHAVIORAL|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
219725113|NCT01843231|DEVICE|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
219153405|NCT03098368|DRUG|Rotigotine|
219153406|NCT03098368|DRUG|Placebo|Placebo of rotigotine patch
219153407|NCT01316731|OTHER|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
219153408|NCT01605773|DRUG|repaglinide|Dose individually adjusted and conducted according to labeling
219153409|NCT01605773|DRUG|glyburide|Dose individually adjusted and conducted according to labeling
219153410|NCT05403567|OTHER|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
219153411|NCT03272399|OTHER|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
219153412|NCT04775992|OTHER|gabapentoids|Preemptive analgesia
219153413|NCT00581035|BIOLOGICAL|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
219153414|NCT00581035|BIOLOGICAL|Prevenar|1 dose at 2,3.5,6 and 12 months
219153415|NCT00581035|BIOLOGICAL|Meningitec|1 dose at 2,6 and 12 months
219153416|NCT03872635|OTHER|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
219153417|NCT02918591|DRUG|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
219153418|NCT05720078|RADIATION|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
219233161|NCT03803475|DEVICE|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
219153419|NCT06973616|PROCEDURE|Zirconia crown|A zirconia esthetic crown will be randomly placed on one side of the jaw
219153420|NCT06973616|PROCEDURE|Bioflx crown|A Bioflx esthetic crown will be randomly placed on one side of the jaw
219153421|NCT03942042|DRUG|Ixekizumab|Administered SC
219153422|NCT05576844|BEHAVIORAL|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
219153423|NCT05576844|OTHER|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
219153424|NCT00092027|DRUG|MK0217, alendronate sodium/Duration of Treatment: 6 months|
219153425|NCT00092027|DRUG|Comparator: placebo / Duration of Treatment: 6 months|
219153426|NCT04821336|OTHER|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
219153427|NCT00563537|RADIATION|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
219153428|NCT04141943|OTHER|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
219153429|NCT01834248|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
219153430|NCT01834248|DRUG|Decitabine|Given IV
219153431|NCT01834248|OTHER|Laboratory Biomarker Analysis|Correlative studies
219153432|NCT01834248|DRUG|Poly ICLC|Given SC
219153433|NCT02101190|DRUG|BIA 9-1067|Opicapone, OPC
219153434|NCT03963128|DIETARY_SUPPLEMENT|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
219153435|NCT03963128|DIETARY_SUPPLEMENT|Placebo|Placebo administred every two months
219153436|NCT05640791|DRUG|Cisplatin|25mg/m2；d1, 8, 21 d cycle
219153437|NCT05640791|DRUG|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
219153438|NCT05640791|DRUG|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
219153439|NCT05640791|DRUG|Durvalumab|1000mg；d1, 21 d cycle
219153440|NCT04720014|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
219153441|NCT03848234|DRUG|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
219153442|NCT03848234|DEVICE|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
219153443|NCT02240550|DEVICE|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
219153444|NCT02240550|DEVICE|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
219725114|NCT01843231|OTHER|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
219153445|NCT02399943|DRUG|Trametinib|
219153446|NCT02399943|DRUG|Panitumumab|
219153447|NCT00923871|PROCEDURE|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
219153448|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
219153449|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
219153450|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
219153451|NCT00395603|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
219153452|NCT00395603|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
219153453|NCT00092664|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
219153454|NCT03668288|OTHER|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
219153455|NCT03621917|DEVICE|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
219153456|NCT03143348|PROCEDURE|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
219153457|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 6 peri-operative time points.
219153458|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 7 peri-operative time points
219233162|NCT04672967|DIAGNOSTIC_TEST|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
219725115|NCT00864981|DRUG|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
219725116|NCT00864981|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
219725117|NCT05307107|BEHAVIORAL|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
219153459|NCT03014973|BIOLOGICAL|intra-prostatic concentration of sexual steroids|
219725118|NCT02479282|PROCEDURE|natural cesarean section|
219725119|NCT02479282|PROCEDURE|traditional cesarean section|
219725120|NCT03179267|DEVICE|SNAP40|SNAP40 ambulatory monitoring device
219725121|NCT02319382|RADIATION|PET with the tracer 18F-DPA-714|
219725122|NCT02319382|RADIATION|PET with the tracer 11C-PE2I|
219153460|NCT03014973|PROCEDURE|Trans-rectal biopsy|
219153461|NCT01849055|DRUG|Placebo|Administered orally
219153462|NCT01849055|DRUG|LY3023703|Administered orally
219153463|NCT01849055|DRUG|Celecoxib|Administered orally
219153464|NCT01100125|DRUG|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
219153465|NCT01100125|DRUG|insulin dose increase|insulin dose increase
219153466|NCT01239316|OTHER|Laboratory Biomarker Analysis|Correlative studies
219153467|NCT01239316|OTHER|Pharmacological Study|Correlative studies
219153468|NCT01239316|DRUG|Vismodegib|Given PO
219153469|NCT00901069|DRUG|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
219153470|NCT02910635|DRUG|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
219153471|NCT02910635|DRUG|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
219153472|NCT02910635|DRUG|Placebo|
219153473|NCT05273242|DRUG|Artesunate Injection|"* Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
219153474|NCT04120597|DRUG|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
219153475|NCT04120597|DRUG|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
219153476|NCT02139943|DRUG|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
219153477|NCT02139943|DRUG|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
219153478|NCT02139943|DRUG|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
219153479|NCT04237155|OTHER|Questionnaire|Subjects will complete a verbal material scoring questionnaire
219233163|NCT03481751|DIAGNOSTIC_TEST|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
219153480|NCT04237155|OTHER|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
219153481|NCT00179335|PROCEDURE|Blood drawing to determine drug levels|
219153482|NCT01638039|OTHER|Laboratory Tests|Stool, blood, urine and saliva samples
219153483|NCT06058104|DEVICE|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
219153484|NCT03009994|PROCEDURE|Repair of uterine incision|
219153485|NCT03009994|PROCEDURE|Exteriorization of the uterus|
219153486|NCT03009994|PROCEDURE|Non exteriorization of the uterus|
219153487|NCT02569866|DRUG|Cephalexin|Capsules containing cephalexin/500mg
219153488|NCT02569866|DRUG|Placebo|Capsules containing placebo/500mg
219153489|NCT03798080|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219153490|NCT03798080|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219153491|NCT03798080|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219153492|NCT03339258|DRUG|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
219725123|NCT02319382|OTHER|MRI|Magnetic field
219725124|NCT04387968|DIAGNOSTIC_TEST|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
219725125|NCT06515782|OTHER|Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.|"In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD."
219153493|NCT03339258|DRUG|Placebo|Placebo, or inactive pill.
219153494|NCT04631003|DIAGNOSTIC_TEST|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
219153495|NCT03995446|DEVICE|low-level laser|low level laser emission on specific acupuncture points
219153496|NCT03995446|DEVICE|Sham laser|Sham laser
219153497|NCT03394976|DIAGNOSTIC_TEST|No intervention|No intervention
219153498|NCT03294499|OTHER|Questionnaire|Patients will be asked to complete one off questionnaire.
219153499|NCT05682924|DIAGNOSTIC_TEST|taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry|In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
219153500|NCT04411056|OTHER|Barrier box|Placement of barrier box ( a plastic box for shielding)
219153501|NCT05463003|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
219153502|NCT03716557|DEVICE|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
219153503|NCT03716557|DEVICE|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
219153504|NCT03716557|DEVICE|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
219153505|NCT03838926|DRUG|Trichostatin A|Intravenous Infusion
219153506|NCT05601505|OTHER|circulating tumor DNA|This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
219153507|NCT04786457|BIOLOGICAL|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
219153508|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
219233164|NCT01773746|OTHER|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
219233165|NCT04295382|DEVICE|Software Application|A software application targeting suicidal ideation via interactive exercises.
219233166|NCT03529994|OTHER|Enrollment|All infants enrolled will have work of breathing assessed.
219233167|NCT01948024|DRUG|SAPHRIS|10 mg BID sublingual tablet
219233168|NCT01948024|DRUG|Asenapine|10 mg BID sublingual tablet
219153509|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
219153510|NCT05970991|BEHAVIORAL|Brief Online Training (BOLT) for measurement-based care (MBC)|Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.
219153511|NCT05970991|BEHAVIORAL|Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)|The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.
219153512|NCT05970991|BEHAVIORAL|Live Post-Training Consultation|Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.
219153513|NCT05970991|BEHAVIORAL|Asynchronous Discussion Board|An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
219153514|NCT04239040|PROCEDURE|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
219153515|NCT04239040|BIOLOGICAL|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
219153516|NCT04239040|DRUG|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
219153517|NCT04239040|DRUG|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
219725126|NCT02967575|DEVICE|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible"
219725127|NCT04516876|OTHER|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
219725128|NCT06520280|OTHER|polyamide and 3D printed complete denture|pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use
219153518|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
219153519|NCT06777108|DIETARY_SUPPLEMENT|Inorganic Nitrate|The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.
219153520|NCT05459142|DRUG|Medical Abortion|Medical Abortion
219153521|NCT05328375|BEHAVIORAL|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
219153522|NCT05328375|BEHAVIORAL|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
219153523|NCT05491616|DRUG|Nivolumab|In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
219233169|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
219153524|NCT06474169|OTHER|1 blood sample for each participant|"Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)"
219725129|NCT00238290|DRUG|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
219725130|NCT06214390|PROCEDURE|Single strategy|In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use
219153525|NCT04219826|DRUG|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
219153526|NCT04219826|DRUG|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
219153527|NCT04219826|DRUG|Placebo for CK-3773274|Placebo administered orally
219153528|NCT06025942|BEHAVIORAL|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
219153529|NCT05996497|BEHAVIORAL|behavioral measures|behavioral measures
219153530|NCT05996497|OTHER|Electrophysiological measures|Electrophysiological measures
219153531|NCT05996497|OTHER|Training 1|Training 1
219153532|NCT05996497|OTHER|Training 2|Training 2
219153533|NCT03122886|DIETARY_SUPPLEMENT|Fat Emulsion|Given IV
219725131|NCT06214390|PROCEDURE|Combined strategy|In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine \> 5.2mmol/day \[5\] and 3) urinary urea \> 1.35mmol/kg/day (using the patient's body weight at ICU admission) \[6\], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
219725132|NCT00189670|PROCEDURE|6 TEC q 3 weeks|
219725133|NCT00189670|PROCEDURE|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
219725134|NCT00189670|PROCEDURE|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
219725135|NCT05984459|DIETARY_SUPPLEMENT|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
219725136|NCT06071988|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219725137|NCT06071988|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
219725138|NCT03603704|DRUG|LY3209590|Administered SC
219725139|NCT03603704|DRUG|Placebo|Administered SC
219725140|NCT03868371|DIETARY_SUPPLEMENT|High phosphorous containing meal|A meal with a high phosphorous content
219725141|NCT03868371|DIETARY_SUPPLEMENT|Low phosphorous containing meal|A meal with a low phosphorous content
219725142|NCT03514797|DRUG|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
219725143|NCT03514797|DRUG|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
219725144|NCT02761538|BEHAVIORAL|AVIITAM|"The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~."
219725145|NCT02193152|DRUG|Pazopanib|
219725146|NCT00665639|DRUG|micafungin|IV
219725147|NCT00665639|DRUG|caspofungin|IV
219725148|NCT03878459|DRUG|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
219725149|NCT03878459|DRUG|Placebo|PATIENTS WILL RECEIVE PLACEBO
219725150|NCT01550185|DRUG|eltrombopag olamine|Given PO
219725151|NCT01550185|PROCEDURE|standard follow-up care|Receive standard care
219725152|NCT01003626|PROCEDURE|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
219725153|NCT01003626|DEVICE|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
219725154|NCT03537677|BEHAVIORAL|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
219725155|NCT00222274|BEHAVIORAL|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
219725156|NCT00222274|BEHAVIORAL|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
219725157|NCT05788926|DRUG|TG6050|Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
219725158|NCT03033433|DRUG|DCB-DM101|determination of optimal dose for Stage 2
219725159|NCT01922297|OTHER|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
219725160|NCT01922297|OTHER|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
219725161|NCT06021496|BEHAVIORAL|face to face health education|Face-to-face health education with home visit
219725162|NCT06021496|BEHAVIORAL|online health education|online health education with video call
219725163|NCT00411541|DRUG|vincristine|
219725164|NCT00411541|DRUG|dexamethasone|
219725165|NCT05571488|OTHER|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
219725166|NCT05571488|OTHER|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
219725167|NCT06596486|OTHER|CoolStick|Assessment of block using CoolStick.
219725168|NCT06596486|OTHER|Ethyl Chloride|Assessment of block using ethyl chloride spray
219153534|NCT03122886|OTHER|Placebo|Given IV
219153535|NCT05356234|BEHAVIORAL|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
219153536|NCT04169763|DRUG|Cisplatin|Given IV
219153537|NCT04169763|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219153538|NCT04169763|DRUG|Nelfinavir|Given PO
219233170|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
219233171|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
219233172|NCT01206972|DRUG|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
219233173|NCT03524131|OTHER|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
219233174|NCT03524131|OTHER|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
219725169|NCT06596486|OTHER|Question|Participant will be asked if they felt pain or not.
219725170|NCT01801605|PROCEDURE|rTMS|Active session with stimulation and placebo session with fictive stimulation
219725171|NCT06985875|DEVICE|Multidose mosturizing solution DROP 0.4%|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
219725172|NCT06985875|DEVICE|Multidose mosturizing solution Avizor Eye Drops 0.2% Preserved|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
219725173|NCT06990854|DEVICE|Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China)|"Acupoint prescription: The therapeutic protocol utilized Ashi points (localized to herpetic lesion areas) and Jiaji points (EX-B2, ipsilateral to affected dermatomes).~Acupuncture procedure: For Ashi points, sterile disposable needles (0.25 mm diameter, 40 mm length) were inserted at a 15° angle to a depth of 15-20 mm, without deqi sensation or manual manipulation. For Jiaji points (EX-B2), needles (0.30 mm diameter, 50 mm length) were inserted perpendicularly to a depth of 40-45 mm, with twisting manipulation (90° rotation at 90 cycles/min) until patients felt soreness, numbness, or distension. Electroacupuncture was applied using the Hans-100A device, with dense-disperse wave mode (2/100 Hz) and intensity adjusted to patient tolerance, for 30 minutes."
219233175|NCT03524131|OTHER|current national leaflet|4-sided leaflet
219233176|NCT05011292|BEHAVIORAL|Educational Video about SCB|3-4 minutes video about SCB.
219233177|NCT05011292|BEHAVIORAL|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
219153539|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
219725174|NCT06990854|DRUG|Pharmacotherapy：① Pregabalin ( Lyrica™ ，Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets， Weicai (China) Pharmaceutical Co., Ltd， China）|Patients received protocol-guided therapy consisting of: ① Pregabalin: Initial dose 75 mg twice daily. Dose may be titrated upward to 150 mg twice daily within one week based on therapeutic response and tolerability. Gradual discontinuation is recommended when clinically appropriate, tapered by 100 mg decrements every 3-7 days. ② Methylcobalamin: 5 mg three times daily.
219725175|NCT06990854|PROCEDURE|Streitberger Placebo Needle Set ( Asiamed )|The Streitberger needle, a widely reported placebo needle device in acupuncture RCTs, was applied for sham intervention. This telescoping blunt-tip needle achieves non-penetrating placebo stimulation through its retractable design. Its key advantage lies in evoking a skin-penetrating sensation akin to true needling through tissue compression, while avoiding actual dermal perforation to minimize specific therapeutic effects. Following the perception of needle insertion reported by patients, the device is retracted by approximately 1 mm and connected to electroacupuncture apparatus without electrical stimulation activation.
219725176|NCT02429440|BIOLOGICAL|peptide vaccine|subcutaneous
219725177|NCT02429440|DRUG|Granulocyte Macrophage Colony Stimulating Factor|intradermal
219725178|NCT02429440|DRUG|Montanide ISA-51|subcutaneous
219725179|NCT06989099|PROCEDURE|Immediate Lymphatic Reconstruction (ILR)/|Given by Procedure
219725180|NCT06989099|PROCEDURE|Prophylactic Lymphovenous Bypass (pLVB)|Given by Procedure
219725181|NCT00995878|PROCEDURE|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
219725182|NCT00995878|PROCEDURE|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
219725183|NCT03691532|BEHAVIORAL|Seated control (CON)|Seated rest
219725184|NCT03691532|BEHAVIORAL|Arm cycle exercise (ACE)|Arm cycling at a continuous power output
219725185|NCT03691532|BEHAVIORAL|Liquid meal|Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
219725186|NCT05339438|RADIATION|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
219725187|NCT05965895|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
219725188|NCT05965895|DRUG|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
219725189|NCT03928431|OTHER|Maternal microbiota|See arm descriptions
219725190|NCT06676722|DRUG|SBRT combined with Nimotuzumab followed by Tislelizumab|BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression
219725191|NCT07000955|DRUG|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
219725192|NCT07000955|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
219725193|NCT07000955|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
219725194|NCT05762744|DRUG|Exenatide Injection (before the first FSIGT)|"Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the first frequently sampled intravenous glucose tolerance test.~In this crossover study, participants will also be crossed over to receive saline rather than exenatide: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test."
219725195|NCT05762744|DRUG|Exenatide injection before the second FSIGT)|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the second frequently sampled intravenous glucose tolerance test.
219725196|NCT00789165|DRUG|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
219725197|NCT00789165|DRUG|no therapy|No therapy; this is not a placebo-controlled trial
219725198|NCT04817072|OTHER|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
219725199|NCT07009860|DRUG|Pemvidutide|Pemvidutide 2.4 mg
219725200|NCT07009860|OTHER|Placebo|Subcutaneous injection
219233178|NCT05011292|BEHAVIORAL|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
219725201|NCT07011368|BEHAVIORAL|Intervention Group|"Healthy Lifestyle Recommender Solution (HLRS) will be developed as intervention tool for the trials. It integrates tools (mostly digital): a meal recommender to propose balanced and individually adapted meal plans, physical activity and sleep pattern measures and recommendations, assessment of behavioural/psychological aspects, and motivational features for sustained engagement and adherence.~Within our multi-disciplinary portfolio approach, a set of predominantly eHealth solutions applied during the intervention trials for overweight/obesity prevention, developed in a participatory design approach with relevant stakeholders. This will include the HLRS, thus combining motivational features (nudging, gamification), targeted psychological support, dietary and physical activity advice, though also additional recommendations (healthy eating guidelines...) or education materials will be provided.~Intervention trials/studies."
219725202|NCT07012694|DEVICE|22G Franseen Needle Group|Fine-needle-biopsy (22G Franseen, Boston Scientific, Winston-Salem, USA)
219153540|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
219153541|NCT05302817|COMBINATION_PRODUCT|Hyperpolarized xenon MRI|Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.
219725203|NCT07012694|DEVICE|22G Adapt Needle Group|Fine-needle-biopsy (22G Adapt, Micro.Tech Endoscopy, Nanjing, China)
219725204|NCT02988609|DEVICE|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
219725205|NCT07028710|DRUG|hCG|Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)
219725206|NCT01560416|DRUG|Fulvestrant|
219725207|NCT01560416|DRUG|Ganetespib|
219725208|NCT07040150|DEVICE|Spinal bracing|The semi-rigid spinal brace was developed to enhance patient compliance while maintaining effective curve correction. Patients were instructed to wear the brace for 18-20 h daily.
219725209|NCT06724198|DIETARY_SUPPLEMENT|Psyllium husk|3.66 gram Psyllium husk twice daily for 8 weeks
219725210|NCT07044973|PROCEDURE|Transcranial focused ultrasound thalamotomy|Thalamotomy Using Exblate
219725211|NCT07046442|OTHER|Pulmonary Rehabilitation|The Active Cycle of Breathing Technique (ACBT), is a structured method aimed at restoring normal breathing patterns, improving respiratory muscle efficiency, and reducing airway irritation.
219725212|NCT07044999|OTHER|no intervention|no intervention
219725213|NCT07046013|DIAGNOSTIC_TEST|Lactate dehydrogenase|It's elevation at the time of diagnosis
219153544|NCT05985044|OTHER|Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention|The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
219233179|NCT03927651|DRUG|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
219233180|NCT04255498|DRUG|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
219725214|NCT07044713|OTHER|Hand Puppet|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the hand puppet group. The scales will be filled out by the nurse and the child five minutes before the blood collection. The researcher will benefit from the experiences of the child development specialist and preschool teacher before the research on puppet scenarios. In the interview room outside the blood collection unit, the child's parent will be asked to tell the researcher about the things the child enjoys and likes. The researcher will show the child puppet characters on various themes and the child will be asked to choose the puppet character he/she wants before the blood collection. The puppet scenarios will be improvised in light of the information received from the child's mother and father during the demonstration and will be shaped according to the child's wishes. In this way, the child will turn the scary hospital environment into an entertaining environm
219725215|NCT07044713|OTHER|The Visual Viewing and Coloring Book|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the coloring group. The scales will be filled out by the nurse and the child five minutes before the blood is drawn. The Visual Viewing and Coloring Book consists of pictures that require coloring. The children will be given a book before the blood is drawn and will be asked to draw or color a picture as they prefer during the procedure. The fear scale will be assessed by the nurse and the child five minutes before, during, and five minutes after the procedure. The pain scale will be assessed by the nurse and the child during and five minutes after the procedure. The child will be shown the facial expressions on both the fear scale and the pain scale and asked which one it is, and the score corresponding to the facial expression he/she indicates will be recorded. Mothers will stay with their children during the treatment proce
219725216|NCT07046156|DRUG|Oxybutynin Cl|Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder
219725217|NCT07046156|DRUG|propiverine|Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder
219725218|NCT07046156|DRUG|Tolterodine|Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder
219725219|NCT07050693|DIETARY_SUPPLEMENT|Vitamin + Zinc + micronutrient mixture|a dietary supplement containing Vitamin D, Zinc, Beta glucan WELLMUNE WGP, 2'Fucosyllactose.
219725220|NCT07050693|DIETARY_SUPPLEMENT|Placebo|Placebo is identical to intervention product
219725221|NCT07050836|COMBINATION_PRODUCT|Definity contrast during ultrasound|Definity contrast injection given just prior to brain tumor surgery. Contrast enhanced ultrasound during brain tumor surgical resection to aid in brain tumor visualization.
219153545|NCT06548282|OTHER|Acceptance and commitment therapy|"Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude."
219725222|NCT07045701|COMBINATION_PRODUCT|Epinephrine 4mg nasal powder spray|Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection
219153546|NCT06326645|DRUG|Crofelemer Oral Product|Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
219153547|NCT05537207|DEVICE|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
219153548|NCT05537207|OTHER|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
219725223|NCT07045701|COMBINATION_PRODUCT|Adrenalin 0.5mg Injectable Product|Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.
219725224|NCT07045064|OTHER|Aerobic exercise without medication|"twenty patients will participate in moderate intensity intradialytic aerobic training for 12 weeks. (3 times per week). Using Horizontal electromagnetically braked cycle ergometer during the first half of the dialysis session.~(1) Frequency: received intradialytic, lower-limb, cycling exercise three times per week on alternative days (2) Intensity: the intensity of exercise will be at 12-14 (moderate-intensity: somewhat hard or reports of feeling a little bit tired but still ok to continue) based on the Borg's Perceived Exertion Rating Scale Appendix III (a rating of 6 perceiving no exertion at all to 20 perceiving a maximal exertion of effort) ,Appropriate speed and grade of resistance were adjusted to achieve the required intensity. (3) Time: the duration of each exercise session consisted of a 5-min warm-up in form of circulatory exercise."
219725225|NCT07045064|OTHER|resistive exercise without medication|"Twenty patients will participate in moderate intensity intradialytic resistive training for 12 weeks. (3 sessions per week) using ankle weights.~During session: The warming up phase for 5-minute in form of circulatory exercises, then the main exercise phase and then cooling down phase for 5 minutes. in form of circulatory exercises.~The training protocol consisted of five lower-body resistance exercises using ankle weights 3 days/week, The intensity of the program will be moderate, starting with two sets of each exercise at 60% of each patient's three repetition max (3-RM) strength, progressing to three sets per session, with additional weight added as tolerated"
219725226|NCT07045064|OTHER|circulatory exercise without medication|this group will include 20 patients will participate in circulatory exercises and will be evaluated at the beginning and at the end of the study.
219725227|NCT07048834|OTHER|lidocaine local anesthetic drug|Lidocaine Nerve Block technique
219725228|NCT07048834|OTHER|articaine local anesthetic drug|Articaine Local Infusion technique
219725229|NCT06732388|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219725230|NCT06732388|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219725231|NCT06732388|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
219725232|NCT06732388|DRUG|Itraconazole|Given PO
219725233|NCT06732388|DRUG|Placebo Administration|Given PO
219725234|NCT06732388|OTHER|Questionnaire Administration|Ancillary studies
219725235|NCT06732388|PROCEDURE|Radiofrequency Ablation|Undergo radiofrequency ablation
219725236|NCT07047157|BEHAVIORAL|Video-Based Virtual Reality Education|Participants receive VR-based video training using a headset. The content includes step-by-step instruction on peripheral venous catheterization.
219725237|NCT07047157|BEHAVIORAL|Traditional Education with Demonstration|Participants receive traditional face-to-face instruction and live demonstration of peripheral venous catheterization (PVC).
219725238|NCT07046416|OTHER|Occupation-Based Exercise Program|"In the occupation-based exercise program, while trying to improve the range of motion and muscle strength of the hand, it is aimed to successfully return to daily life activities. For this reason daily activities are used instead of memorized range movements. In this way, the occupation-based exercise program provides a physical recovery in patients with hand injuries, while providing positive improvements in parameters related to the mind and spirit. Patients' participation, motivation and compliance with the treatment are increased in the hand rehabilitation process, which can be challenging for patients.~In addition to the conventional treatment program, the study/experimental group, will be given occupation-based exercises for a total of 4 weeks between the 6th and 10th weeks postoperatively, 2 days a week with a physiotherapist and the other days with a home program."
219725239|NCT07046416|OTHER|Conventional therapy group|Conventional group treatment will be according the early passive hand rehabilitation program. Conventional group will be followed with a cast-splint made by the surgical team for the first 4 weeks within the scope of the conventional treatment program. From the 4th week onwards, the duration of splint use is gradually reduced and is completely discontinued from the 6th week onwards. At the end of the 4th week, depending on the wound condition, contrast bath, scar massage, retrograde massage, active and passive flexion, active extension and tendon shifting exercises are applied as tolerated. After the 6th week, isolated block exercises and stretching exercises are added if there is contracture. Strengthening exercises are started from the 8th-10th week.
219725240|NCT07044856|BEHAVIORAL|distraction with virtual reality|Before the procedure, the patient's vital signs will be checked and pain and anxiety will be assessed. This group will be shown a video using virtual reality glasses during the lumbar puncture procedure. After the intervention, the patient's vital signs will be checked again and pain and anxiety will be assessed.
219725241|NCT07049731|DIETARY_SUPPLEMENT|Protein powder intervention|On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
219725242|NCT07049731|BEHAVIORAL|Resistance exercise intervention|Low-intensity resistance training was conducted 3 times a week.
219725243|NCT07049731|DIETARY_SUPPLEMENT|Placebo control|placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
219725244|NCT06734897|OTHER|music therapy after Cochlear Implantation|The music therapy is specially designed for the rehabilitation of CI-patients. It focuses on learning to distinguish different sound sources, especially when they occur at the same time. Training involves familiarization with different aspects of music such as rhythm, melody, and pitch while at the same time also getting to know the sound of different musical instruments, including singing. The training is also aimed at learning to concentrate on spoken instructions while the music is going on. This latter aim is fundamental to the goal of this study and plays a central role in the therapy.
219725245|NCT06734897|OTHER|no music therapy after Cochlear Implantation|Group C consists of persons who do not receive any music therapy after Cochlear Implantation.
219725246|NCT07055490|PROCEDURE|Interdisciplinary Practice Bundle|interdisciplinary practices were combined in a bundle framework called (5-Ps) to maintain normal process during labor and prevent unnecessary routine interventions, which are (patience, positioning, physiological resuscitation, progress, and preventing urinary harm). These practices implemented from the beginning of the second stage of labor which is started from onset of complete cervical dilatation (10 cm) until delivery with a duration of 2 hours period.
219725247|NCT07055646|DIAGNOSTIC_TEST|Traditional Assistive Technology|Participants in Group 1 utilize traditional, non-digital assistive devices designed to enhance mobility and spatial orientation
219725248|NCT07055646|DIAGNOSTIC_TEST|Digital Assistive Technology|Participants in Group 2 use modern, digital assistive technologies specifically designed to improve navigation, orientation, and real-time decision-making for visually impaired individuals
219725249|NCT07055646|COMBINATION_PRODUCT|Combined Technology Users|Participants in Group 3 use a combination of traditional tools (e.g., cane, magnifiers) alongside modern digital aids (e.g., smart canes, GPS apps). This group is important to examine how integrated usage of both types of technologies
219725250|NCT07056127|OTHER|manual dynamic agitaion|5 mL of 2.5% NaOCl solution will be activated with a well-fitting gutta-percha cone that will be placed to full working length and then will be moved in push-pull strokes of 2 mm amplitude at a frequency of 100 strokes in about 1 min
219153549|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
219153550|NCT05578898|BEHAVIORAL|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
219153551|NCT05331521|DRUG|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
219153552|NCT05331521|DRUG|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
219153553|NCT05331521|RADIATION|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
219153554|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
219233181|NCT04255498|DRUG|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
219153555|NCT04955210|OTHER|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
219725251|NCT07056127|OTHER|ultrasonic activation|5 mL of 5.25% NaOCl solution will be activated with PUI using a #20 endosonic ﬁle that will be driven by an ultrasonic device on medium power setting for 1 minute and inserted 1 mm short of the working length
219725252|NCT07056127|OTHER|xp-endo finisher|5 mL of 5.25% NaOCl solution will be activated with XP-Endo Finisher which will be used in the canal for 1 minute at 800 rpm and 1 Ncm up to the working length and in slow up-and-down movements at 7-8mm length according to the manufacturer's recommendations
219725253|NCT07056127|OTHER|laser|First, root canals will be filled with 0.5 mL of 0.05% ICG dye and left in place for 1 minute as preirradiation time. A #20 laser fiber will be inserted into the root canals to the working length. Then infrared diode laser with a wave length of 810 nm will be used to activate the dye for 30 seconds. For activation, circular movements will be performed along with the fiber removal movement . After the first activation, dye will be reintroduced, the laser fiber will be inserted again, and a new activation cycle of 30 seconds will be performed similarly to the previous one
219725254|NCT07056673|DEVICE|Active CAP therapy|"The patients in the CAP group will receive six sessions of CAP treatment, administered once weekly for six consecutive weeks. If complete clearance of facial acne is achieved before all six sessions, CAP treatment will be discontinued early.~For device selection, the CAP patch trauma therapy device (CAP-PTTD) will be used for lesions located on relatively flat areas of the face. In cases of lesions on areas with greater anatomical curvature (eg, the mandibular angle or near the tragus), the CAP jet trauma therapy device (CAP-JTTD) will be used in combination."
219725255|NCT07056673|DEVICE|sham CAP therapy|the device will be operated with the plasma-generating field disabled, so that no plasma will be produced. Only environmental cues such as sound will be simulated to ensure blinding.
219725256|NCT07056673|OTHER|standard care based on the JAAD acne guidelines|the group will receive standard care based on the JAAD acne guidelines
219153556|NCT06307964|PROCEDURE|Biological sampling|"* A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible"
219153557|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
219153558|NCT02279095|DRUG|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
219153559|NCT02279095|DRUG|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
219153560|NCT02279095|DRUG|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
219153561|NCT02279095|DRUG|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
219153562|NCT06415591|DEVICE|Percutaneous electrical nerve field stimulation|FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
219153563|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
219153564|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
219153565|NCT04225598|DRUG|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
219153566|NCT04225598|DRUG|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
219153567|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
219153568|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
219725257|NCT07057011|DRUG|Paroxetine 20 Mg Oral Tablet|to compare the safety and efficacy of paroxetine alone versus the combination of paroxetine and sildenafil in Premature Ejaculation Patients with genetic polymorphism in the serotonin transporter gene-linked polymorphic region.
219153569|NCT05577624|DRUG|AMG 510|Oral tablet
219153570|NCT05577624|DRUG|Rifampin|Oral capsule
219153571|NCT04805437|DEVICE|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
219153572|NCT04805437|DEVICE|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
219153573|NCT05681702|DRUG|aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
219153574|NCT05681702|DRUG|prasugrel or ticagrelor|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
219153575|NCT04043442|DEVICE|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
219153576|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
219725258|NCT07057375|DEVICE|Pulsed electromagnetic fields Thearpy|Pulsed electromagnetic fields (PEMF) is a non-invasive and non-thermal treatment used to stimulate muscle regeneration, resulting in increased muscle mass and strength.
219725259|NCT07057375|DEVICE|Sham Therapy|Sham Therapy
219725260|NCT07056374|DEVICE|C-REX RectoAid Cath|Adaptive anastomotis
219725261|NCT07056998|PROCEDURE|root canal retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
219725262|NCT07056647|DIETARY_SUPPLEMENT|Staircase Nutritional Intervention|"Fourteen days before admission, different nutritional supplements will be provided according to whether the patient has diabetes and their nutritional status. Patients without diabetes who are malnourished should take enteral nutrition powder mixture three times a day, with each dose providing 265 kCal of energy. Patients without diabetes but at risk of malnutrition should take enteral nutrition powder mixture twice a day. Patients with diabetes who are malnourished should take low - sugar whole - protein enteral nutrition powder three times a day, with each dose providing 250 kCal of energy. Patients with diabetes and at risk of malnutrition should take low - sugar whole - protein enteral nutrition powder twice a day.~During the peri - operative period, a strict 6 - hour fasting of solid food and 2 - hour fasting of clear liquid before surgery is implemented. Two hours after surgery, all patients should take multi - dimensional carbohydrates, which provide 115 kCal of energy. Four ho"
219725263|NCT07056647|DIETARY_SUPPLEMENT|Standard ERAS Diet Management Group|Only nutritional education is provided to patients before admission, without any specific nutritional supplements. During the peri - operative period, patients are required to fast from food and water for 8 hours before surgery. Six hours after surgery, patients are allowed to drink water. They can start consuming liquid food after passing gas from the anus. No specific energy - containing nutritional supplements are given during this period. A nutritional guidance manual is distributed to patients upon discharge, and there are no targeted nutritional interventions or follow - up measures related to energy intake subsequently.
219725264|NCT07057427|DRUG|Nab paclitaxel|Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)
219725265|NCT07057427|DRUG|Docetaxel and Carboplatin|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1)
219725266|NCT07057427|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
219725267|NCT07055711|DIAGNOSTIC_TEST|Peripheral Neuropathic Pain|to find out the association between work-related stress and peripheral neuropathic pain in female breast cancer survivors post-chemotherapy.
219153577|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
219153578|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
219153579|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
219153580|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
219153581|NCT05550129|DRUG|AMG 510|Oral tablet
219153582|NCT05550129|DRUG|Metformin|Oral tablet
219153583|NCT05969704|PROCEDURE|MRI fusion targeted prostatic biopsy|combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
219153584|NCT05969704|PROCEDURE|MRI cognitive targeted prostatic biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
219153585|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
219153586|NCT05460377|BIOLOGICAL|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
219153587|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
219233182|NCT01971255|BIOLOGICAL|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
219725268|NCT00677222|BIOLOGICAL|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
219725269|NCT07056790|DRUG|68Ga-PSMA-CYC|Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.
219725270|NCT07056790|DRUG|CYC|The dose will be 3-4mCi given intravenously.
219725271|NCT07057401|DEVICE|CAD-CAM Manufactured Crowns|Single crowns produced using computer-aided design and milling technology applied to permanent molars.
219725272|NCT07057401|DEVICE|3D Printed Crowns|Single crowns produced using 3D printing technology applied to permanent molars.
219153588|NCT05460377|BIOLOGICAL|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
219153589|NCT04099290|OTHER|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
219153590|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
219153591|NCT02918331|DRUG|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
219153592|NCT02918331|DRUG|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
219153593|NCT02918331|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
219153594|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
219153595|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
219153596|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
219153597|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
219153598|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
219153599|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
219153600|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
219153601|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
219153602|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
219153603|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
219153604|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
219153605|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
219153606|NCT05263284|DRUG|8-Chloroadenosine|Given IV
219153607|NCT05263284|DRUG|Venetoclax|Given PO
219153608|NCT05274048|DRUG|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
219153609|NCT05274048|DRUG|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
219153610|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
219153611|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
219153612|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
219153613|NCT05333445|OTHER|usual care|standard care
219153614|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
219153615|NCT05971303|OTHER|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
219153616|NCT02397083|DRUG|Everolimus|Given PO
219153617|NCT02397083|OTHER|Laboratory Biomarker Analysis|Correlative studies
219153618|NCT02397083|DEVICE|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
219153619|NCT03646045|OTHER|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
219153620|NCT06781840|BEHAVIORAL|Playing Playfully to Overcome Adversity|The intervention will consist of two parts: (a) five 45-minute-long parent group online sessions; and (b) one 30-minute long online guided play session with OTS/OT.The training will consist of asynchronous module and PowerPoint presentations followed by role play and discussions.
219153621|NCT06834399|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 is administered every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, study end, or other discontinuation criteria are met.
219153622|NCT06834399|PROCEDURE|TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization|TATE treatment is given every 21 days. Patients receive two initial cycles. Whether to continue TATE treatment from the third cycle onward is decided by the investigator based on tumor necrosis. If a patient experiences intrahepatic tumor progression (recurrence or new tumors) during follow-up after the third cycle and still meets the treatment criteria, additional TATE treatment may be given.
219725273|NCT07055568|DRUG|iNKT|iNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell
219725274|NCT07055906|BEHAVIORAL|Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE)|VIP-RACE is a brief, strengths-based, video-feedback intervention that targets parental racial-ethnic socialization (RES) motivation and competency in parents of 10-to-14-year-old Latino/a/x/e youth. Intervention sessions include: (1) Youth and parent assessment including videotaped parent-adolescent RES conversations; (2) Parent interview; and (3) Video feedback session during which parents and RES coaches review clips from the RES interaction tasks. Video feedback highlights parents' RES strengths and when sensitively applied, encourages parents to examine missed opportunities for engaging in RES. RES coaches emphasize that through the provision of cultural socialization and preparation for bias messages, parents can help protect their children from the damaging effects of discrimination and support positive racial-ethnic identity development. Parents develop a personalized action plan with goals and have the opportunity to receive up to 3-5 follow-up sessions to strengthen RES skill
219725275|NCT06756308|DRUG|Enasidenib|Enasidenib 100 mg daily on 28-day cycles.
219725276|NCT06756308|DRUG|Rituximab|IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.
219725277|NCT07056322|DIETARY_SUPPLEMENT|200 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725278|NCT07056322|DIETARY_SUPPLEMENT|100 ml milk|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725279|NCT07056322|DIETARY_SUPPLEMENT|100 g banana|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725280|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy and fibers|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725281|NCT07056322|OTHER|Fasting (control)|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725282|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
219725283|NCT07057479|DRUG|Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione|Oral fixed-dose combination tablet containing an SGLT2 inhibitor and a thiazolidinedione, administered once daily. Participants also receive matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day).
219725284|NCT07057479|DRUG|Control Group 1 Intervention - SGLT2 inhibitor monotherapy|Oral tablet containing an SGLT2 inhibitor, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
219725285|NCT07057479|DRUG|Control Group 2 Intervention - Thiazolidinedione monotherapy|Oral tablet containing a thiazolidinedione, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
219725286|NCT07057479|DRUG|Background Therapy (All Groups) - Metformin|Extended-release metformin tablets (≥1000mg daily) continued as background therapy for all participants throughout the study duration.
219725287|NCT01822743|PROCEDURE|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
219725288|NCT01822743|PROCEDURE|sham comparator|
219725289|NCT01179399|DRUG|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
219725290|NCT07057050|OTHER|The designed physiotherapy program|"* Scapular and thoracic mobilization, active assisted and passive exercises, and positioning such as weight bearing on the affected upper limb.~* Strengthening of the shoulder flexors and elbow and wrist extensors.~* Stretching exercises of the spastic muscles (shoulder extensors, elbow and wrist flexors.)"
219725291|NCT07057050|DRUG|The Botulinum toxin injection|The injection of 1000 units per upper extremity will be done into the biceps brachii muscle at 2 sites, and 150 units into the flexor carpi radialis muscle at 1 site per muscle, using anatomical landmarks similar to routine electromyography.
219725292|NCT07057050|OTHER|Task oriented training|The training involves 30 minutes of bilateral functional tasks like carrying a block, grabbing and folding a towel, staking cups upright, holding a glass and drinking water, throwing a ball into a basket, and moving pegs.
219725293|NCT07057050|OTHER|Constrained induced movement therapy|The therapy session focuses on enhancing the affected arm's functional tasks, such as throwing a ball, holding a glass, combing hair, turning on and off a light switch, grasping and releasing blocks, pouring from glass to another, moving cups, and moving pegs. Participants are instructed to wear a restrictive mitt on their non-paretic hand for 6 hours a day for 4 days, 7 weeks, and 12 weeks, with the mitt removed for safety, hygiene, or agreed-on activities.
219725294|NCT07045636|OTHER|PEMF abd Sham (control)|Dental implants receive MED that could (test) or could not (control/SHAM) be activated to emit PEMF
219725295|NCT07045636|DIAGNOSTIC_TEST|Teeth wih gingivits|Comparison with dental implants
219725296|NCT01631253|PROCEDURE|Laparoscopic ovarian cyst enucleation|
219725297|NCT06349278|PROCEDURE|Pancreatic resection and non-anatomic liver resections.|Pancreatic resection and non-anatomic liver resections.
219725298|NCT02387112|DEVICE|Early VAD implantation|Implantation of a left ventricular assist device
219725299|NCT00375297|DRUG|sildenafil|
219725300|NCT04475510|OTHER|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
219725301|NCT02744456|DRUG|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
219725302|NCT02744456|DRUG|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
219725303|NCT02744456|DRUG|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
219153623|NCT06834919|OTHER|Observational|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
219153624|NCT06434506|OTHER|no intervention|No intervention
219153625|NCT06782425|DRUG|XKDCT225|Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
219153626|NCT06780163|DRUG|17β-estradiol 10 mcg|17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
219153627|NCT06780358|DEVICE|AI supported detection of bladder cancer|AI-model-supported detection of bladder cancer during white light cystoscopy
219153628|NCT04183426|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
219725304|NCT01955018|DEVICE|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
219725305|NCT06750185|BIOLOGICAL|BNT317 DL1|Intravenous infusion
219725306|NCT06750185|BIOLOGICAL|BNT317 DL2|Intravenous infusion
219725307|NCT06750185|BIOLOGICAL|BNT317 DL3|Intravenous infusion
219725308|NCT06750185|BIOLOGICAL|BNT317 DL4|Intravenous infusion
219725309|NCT06750185|BIOLOGICAL|BNT317 DL5 (intermediate)|Intravenous infusion
219725310|NCT06750185|BIOLOGICAL|BNT317 DL6 (intermediate)|Intravenous infusion
219725311|NCT06750185|BIOLOGICAL|BNT317 DL7 (additional)|Intravenous infusion
219725312|NCT03334175|DRUG|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
219725313|NCT00566033|BEHAVIORAL|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
219725314|NCT03738215|DRUG|Cariprazine|Cariprazine supplied in capsules
219725315|NCT03738215|DRUG|Placebo|Placebo supplied in capsules
219725316|NCT03150212|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
219725317|NCT03150212|DIETARY_SUPPLEMENT|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
219725318|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
219725319|NCT00667966|DRUG|Placebo|10/20 mg placebo in sequence in respective arm
219725320|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
219725321|NCT00302471|DRUG|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
219725322|NCT00302471|DRUG|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
219725323|NCT00302471|DRUG|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
219725324|NCT00302471|DRUG|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
219725325|NCT02302456|DRUG|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
219725326|NCT02302456|DRUG|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
219725327|NCT04925401|BEHAVIORAL|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
219725328|NCT03018730|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
219725329|NCT00312416|DRUG|Clonidin|
219725330|NCT00312416|DRUG|Brimonidine|
219725331|NCT01695772|DRUG|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
219725332|NCT01695772|DRUG|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
219725333|NCT05047380|BEHAVIORAL|Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality|All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
219725334|NCT03277274|DRUG|TAK-954|TAK-954 intravenous infusion.
219725335|NCT06142552|DRUG|FRSW117|once a week, 50 weeks and as needed
219725336|NCT05752864|BEHAVIORAL|spine manual therapy|The manual treatment method applied to the sacroiliac joint used high-velocity, low amplitude (HVLA).
219725337|NCT05752864|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
219153629|NCT04183426|DIAGNOSTIC_TEST|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
219153630|NCT06781736|BEHAVIORAL|Talking Circle intervention|Talking Circle intervention
219153631|NCT06422702|OTHER|Psychosomatic Symptoms Intervention|Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.
219153632|NCT06422702|OTHER|Extended supportive care|The control group implemented continuity of supportive care based on primary care
219153633|NCT06780904|PROCEDURE|Dry Needling|"Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times."
219153634|NCT06780865|DRUG|Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine|Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
219153635|NCT06780865|DRUG|Placebo-controlled group|Participants are treated with corresponding placebo
219153636|NCT06781996|OTHER|multimodal Resilience© digital companion|"Resilience© is a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app.~Intervention duration : 3 weeks"
219725338|NCT03819699|DRUG|Lu AF20513|Lu AF20513 suspension for injection
219725339|NCT03819699|BIOLOGICAL|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
219725340|NCT06777979|DRUG|Fludarabine|IV
219725341|NCT06777979|DRUG|Cyclophosphamide|IV
219725342|NCT06777979|DRUG|Mesna|IV
219725343|NCT06777979|DEVICE|CD19-CD22 CAR T cell infusion|CAR T cell infusion will be given intravenously, either centrally or peripherally.
219153637|NCT06781996|OTHER|Standard supportive care|standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
219153638|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms)"|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
219153639|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms)"|Transcranial Magnetic Stimulation 5ms
219153640|NCT02188420|DEVICE|"ranscranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms)"|Transcranial Magnetic Stimulation 7ms
219153641|NCT02188420|DEVICE|Transcranial Magnetic Stimulation Time 100ms|Active Compator
219725344|NCT03739554|DRUG|CYC065|intravenous infusion
219725345|NCT03739554|DRUG|Venetoclax|oral capsule
219725346|NCT06577558|DRUG|SR1375 capsule 3mg+regular treatments|SR1375 capsule 3mg QD orally+CAP regular treatments
219725347|NCT06577558|DRUG|SR1375 capsule 1mg+regular treatments|SR1375 capsule 1mg QD orally+CAP regular treatments
219725348|NCT06577558|DRUG|SR1375 capsule 0.3mg+regular treatments|SR1375 capsule 0.3mg QD orally+CAP regular treatments
219725349|NCT06577558|DRUG|Placebo capsule+regular treatments|Placebo capsule QD orally+CAP regular treatments
219725350|NCT07057453|OTHER|Motivation Engagement for Movement and Interactive Nutrition Development|The intervention includes using of fitness bracelets, a gamified mobile app, a web portal, and regular pediatric check-ups to support healthy habits in overweight children (6-11 years). The bracelets track physical activity, while the mobile app monitors energy balance, encouraging movement and healthy eating through challenges and rewards. The web portal provides family education, and pediatric check-ups track progress and overall health outcomes.
219725351|NCT07056777|DRUG|DR30206|Subjects receive DR30206 intravenously
219725352|NCT07056777|DRUG|Oxaliplatin|Subjects receive Oxaliplatin intravenously
219725353|NCT07056777|DRUG|Capecitabine|Subjects take Capecitabine orally
219725354|NCT07056777|DRUG|Calcium Folinate|Subjects receive Calcium Folinate intravenously
219725355|NCT07056777|DRUG|5-FU|Subjects receive 5-FU by Intravenous Bolus
219725356|NCT07056777|DRUG|Irinotecan (CPT-11)|Subjects receive Irinotecan intravenously
219725357|NCT06931002|BIOLOGICAL|Rhinovirus A-16 Infection|All participants will be deliberately infected with Rhinovirus A-16
219725358|NCT01939457|DRUG|Misoprostol|
219725359|NCT05947006|OTHER|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
219725360|NCT05947006|OTHER|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
219725361|NCT01009697|DRUG|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
219725362|NCT01281072|OTHER|vaccine|
219725363|NCT06478563|DRUG|NNC0487-0111 (formulation D)|Participants will receive NNC0487-0111 (formulation D) tablet once daily.
219153642|NCT05644444|DEVICE|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
219153643|NCT05644444|DEVICE|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
219153644|NCT04817670|DRUG|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
219725364|NCT06478563|DRUG|NNC0487-0111 (formulation C)|Participants will receive NNC0487-0111 (formulation C) tablet once daily.
219725365|NCT03921541|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
219725366|NCT03921541|DRUG|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
219153645|NCT04817670|DRUG|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
219153646|NCT04817670|DRUG|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
219153647|NCT04817670|DRUG|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
219725367|NCT06808854|PROCEDURE|Dental implant treatment (variable-thread implants)|Replacement of a missing tooth with a dental implant with variable-thread implants
219725368|NCT06808854|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing tooth with a dental implant with standard implants
219725369|NCT04611412|OTHER|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
219725370|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
219725371|NCT04975919|DRUG|Venetoclax|Given PO
219725372|NCT00000839|DRUG|Didanosine|
219725373|NCT01653262|DRUG|Brivaracetam|
219725374|NCT02975453|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
219725375|NCT02182700|DRUG|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
219725376|NCT02616952|DIETARY_SUPPLEMENT|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
219725377|NCT02616952|BEHAVIORAL|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
219725378|NCT02030639|DRUG|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
219725379|NCT02798952|BIOLOGICAL|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
219725380|NCT04745988|DRUG|Lenvatinib 20mg|Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
219725381|NCT04745988|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
219725382|NCT04745988|DRUG|Lenvatinib 8mg|Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
219725383|NCT04745988|DRUG|Docetaxel|Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
219725384|NCT04745988|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
219725385|NCT04745988|DRUG|Levofolinate|Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
219725386|NCT04745988|DRUG|Fluorouracil|Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
219725387|NCT00420407|DRUG|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
219725388|NCT00420407|DRUG|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
219725389|NCT02424786|OTHER|STOPP/START criteria|Evaluation of medication lists
219725390|NCT05044611|DRUG|Anhydrous Amiloride Hydrochloride|"Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase"
219725391|NCT05044611|DRUG|Placebo|Route of administration : oral the control arm will receive a placebo twice daily during 2 months
219725392|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339|Limosilactobacillus reuteri AMBV339 is a probiotic strain
219725393|NCT06425081|DIETARY_SUPPLEMENT|Humiome B2|Colon-delivered Riboflavin
219725394|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339 + Humiome B2|Combination of supplements used in arm 1 and 2
219725395|NCT06425081|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
219725396|NCT01482728|DRUG|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
219725397|NCT01482728|DRUG|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
219725398|NCT04633447|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
219725399|NCT04633447|DRUG|Placebo|Matching placebo will be administered subcutaneously.
219725400|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
219725401|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
219725402|NCT05417776|DRUG|[68Ga]CBP8|An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
219725403|NCT05417776|DRUG|Dotarem|Dotarem will be administered during MRI portion of study.
219725404|NCT06957847|DEVICE|Blood pressure measurement|The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)
219725405|NCT06957210|BEHAVIORAL|EMDR|Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.
219725406|NCT06957210|DRUG|SSRIs|Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.
219725407|NCT04636307|OTHER|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
219725408|NCT06829160|BEHAVIORAL|Communication with exercise therapist|A personalized exercise program will be designed. The assigned therapist will identify potential barriers to this plan and develop mitigation strategies. The assigned therapist will then make phone contact with participants weekly for the duration of the study. Exercise recommendations will be titrated during calls based on review of activity data.
219725409|NCT06829160|BEHAVIORAL|mHealth-CR|mHealth-CR software (currently, from Corrie Health) will permit 1) participant data entry about exercise; 2) viewing of educational material pertinent to the condition.
219153648|NCT04817670|DRUG|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
219153649|NCT03312907|DRUG|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
219725410|NCT06829160|BEHAVIORAL|Wearable activity monitoring device|Participants will be offered the Fitbit Charge 5. This commercially available product measures physical activity.
219725411|NCT05713630|DRUG|Tranexamic acid (TXA)|Marcan-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo. Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.
219725412|NCT05713630|DRUG|Placebo|Placebo 500 mg consisting of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 mg/mL solution for injection via intravenous (IV) consisting of 0.9% sodium chloride (saline).
219725413|NCT04098081|DRUG|galeterone|Therapeutic
219725414|NCT04098081|DRUG|Gemcitabine|Therapeutic
219725415|NCT05994183|DRUG|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
219725416|NCT05896124|DRUG|2mg CS0159|Oral QD
219725417|NCT05896124|DRUG|Placebo|Oral QD
219725418|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|10mg/kg/day of TMP component
219725419|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|15mg/kg/day of TMP component
219153650|NCT03312907|DRUG|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
219153651|NCT03312907|DRUG|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
219725420|NCT03594838|OTHER|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
219725421|NCT03690544|DRUG|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
219725422|NCT06964490|DEVICE|determination of working length|Compare the effect of WL determination using different apex locator devices (ProPex Pixi, Root ZX, and Raypex 6) on the incidence and intensity of postoperative pain following endodontic retreatment in single-rooted teeth
219725423|NCT00652132|DRUG|cisplatin|
219725424|NCT00652132|DRUG|sodium thiosulfate|
219725425|NCT06964451|PROCEDURE|Extraction tooth|Extraction of MIH Grade 4 molar
219725426|NCT02760511|DIETARY_SUPPLEMENT|Anthocyanin|Capsules with different anthocyanin content
219725427|NCT02760511|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
219153652|NCT03312907|DRUG|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
219153653|NCT03312907|DRUG|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
219725428|NCT01765621|OTHER|DDI+ System and Pharmacogenetic Data|
219725429|NCT02372032|PROCEDURE|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
219725430|NCT02372032|PROCEDURE|ozone therapy|percutaneous intradiscal ozone injection
219725431|NCT03587116|DRUG|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
219725432|NCT03587116|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
219725433|NCT05266950|BIOLOGICAL|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
219725434|NCT04165980|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
219725435|NCT01778985|DRUG|Premarin|
219725436|NCT01778985|OTHER|Placebo|
219725437|NCT02379897|OTHER|Diet|
219725438|NCT06514248|DEVICE|V5med Lung AI|"During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension."
219725439|NCT04197505|BEHAVIORAL|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
219725440|NCT06166641|PROCEDURE|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
219725441|NCT05226689|DEVICE|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
219725442|NCT00088881|BIOLOGICAL|rituximab|Given IV
219725443|NCT00088881|DRUG|prednisone|Given orally
219725444|NCT00088881|DRUG|cyclophosphamide|Given IV
219153654|NCT03312907|DRUG|Steroid Taper|Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
219725445|NCT00088881|DRUG|doxorubicin|Given IV
219725446|NCT00088881|DRUG|vincristine|Given IV
219725447|NCT00088881|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
219725448|NCT00088881|RADIATION|radiation therapy|Undergo radiotherapy
219725449|NCT00088881|PROCEDURE|positron emission tomography|Undergo PET scans
219725450|NCT04567355|BEHAVIORAL|Migraine Manager|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
219725451|NCT05966597|BEHAVIORAL|Written persuasive leaflet|Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.
219725452|NCT05966597|BEHAVIORAL|Standard referral leaflet|Standard referral leaflet provided at the end of the home-based health screening.
219725453|NCT06797466|PROCEDURE|3D imaging technique on the PCNL|Establishing a percutaneous access route for the stone is the first and most important step in PCNL surgery. Choosing the perfect route, position and direction largely depends on surgical experience and the ability to understand renal/peri-renal anatomy. In general, a good CT scan of the abdomen and pelvis and an experienced surgeon are sufficient, but this requires significant time in the learning curve. The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.
219725454|NCT06550453|DRUG|Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
219725455|NCT03761914|BIOLOGICAL|galinpepimut-S|"* Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone."
219725456|NCT03761914|BIOLOGICAL|pembrolizumab|Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
219725457|NCT03761914|OTHER|Montanide|Adjuvant
219725458|NCT03761914|BIOLOGICAL|GM-CSF|Participants receive 70 μg GM-CSF SC on Day -2 and on Day 1 before each GPS injection. The GM-CSF injections occur at the same anatomical site of the next planned study treatment injection.
219725459|NCT02885753|DRUG|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
219725460|NCT02885753|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
219725461|NCT02885753|DRUG|Folinic acid|400 mg/m² in intravenous
219725462|NCT02885753|DRUG|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
219725463|NCT02885753|DRUG|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
219725464|NCT02885753|DRUG|Bevacizumab|5 mg/kg at each cycle in intravenous
219725465|NCT02885753|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
219725466|NCT02885753|DRUG|Irinotecan|150 mg/m² intravenous
219725467|NCT04204642|OTHER|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
219725468|NCT05107934|BIOLOGICAL|RPH-104|solution for subcutaneous injection, 40 mg/mL
219725469|NCT05107934|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
219725470|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219725471|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
219725472|NCT05803499|BEHAVIORAL|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
219725473|NCT05803499|OTHER|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
219153655|NCT05434156|DRUG|ELE-101|ELE-101 solution for intravenous infusion
219725474|NCT06958861|DRUG|Low-dose H057+standard-of-care|Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
219725475|NCT06958861|DRUG|High-dose H057+standard-of-care|Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
219725476|NCT06958861|DRUG|H057 placebo+standard-of-care|Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
219725477|NCT06630338|OTHER|Non-Interventional Study|Non-interventional study
219725478|NCT04926584|DRUG|induction therapy|induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
219725479|NCT04783662|DEVICE|Intraoperative frontal electroencephalogram|Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane
219725480|NCT03079492|DEVICE|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
219153656|NCT05434156|DRUG|ELE-101 Placebo|ELE-101 placebo matching solution for intravenous infusion
219153657|NCT06270615|OTHER|Ambispective validation of machine learning-based predictive model|Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
219153658|NCT06830278|BEHAVIORAL|The SUN Program|"The SUN Program is a manualized bystander program for high-school adolescents. The program includes ten 50-to-60 minute weekly sessions. The central contents of the program include sexual and reproductive rights, sexual violence throughout the lifespan in different contexts, bystander attitudes and behaviors, and empathy. Every session includes psychoeducation components as well as skills-training moments. The sessions must be delivered by two psychologists with supervision.~Session contents are divided as following:~Session 1: Introduction to sexual violence and sexual rights; Session 2: Sexual violence: behaviors and contexts, Session 3: Sexual consent; Session 4: Sexual violence myths; Session 5: Sexual violence in intimate relationships; Session 6: The role of the bystanders; Session 7: The bystander effect; Session 8: Bystander intervention; Session 9: Empathy; Session 10: Summary"
219153659|NCT06192693|DRUG|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
219153660|NCT06192693|DRUG|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
219153661|NCT06821893|DEVICE|Vibrational stimulation|"The auricular stimulation device produces continuous vibrational stimulation directly to the conchae of the auricle. It is designed to stimulate the vagus nerve for neuromodulation to treat a variety of clinical indications. The system includes a pulse generator and an ear electrode device. Participants will use a vibration motor in a custom-created soft plastic clip for the left ear.~Each participant will receive their own device by mail, which they will wear during the the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
219153662|NCT06821893|DEVICE|Sham|"The sham device looks and is used identically to the auricular stimulation device, but does not produce vibrational stimulation. There will be no difference in the usage directions of the sham device compared to the stimulation device.~Each participant will receive their own device by mail, which they will wear during the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
219153665|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
219153666|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
219725481|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
219725482|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
219725483|NCT01631188|DEVICE|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
219725484|NCT02127541|OTHER|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
219725485|NCT05487495|BIOLOGICAL|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
219725486|NCT00001270|DRUG|interleukin-1|
219725487|NCT02131883|BEHAVIORAL|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
219725488|NCT02131883|OTHER|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
219725489|NCT01561105|OTHER|IMPACT|IMPACT is a collaborative care management program for late-life depression
219725490|NCT03480074|PROCEDURE|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
219725491|NCT03480074|PROCEDURE|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
219725492|NCT03480074|PROCEDURE|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
219725493|NCT03763383|PROCEDURE|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
219153667|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
219153668|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
219153669|NCT05948709|OTHER|Incentives for Physical Activity|Participants earn a meal donation and monetary incentives for each day that they reach 7,500 steps. Meals are donated by the investigators on behalf of participants.
219153670|NCT01868490|DRUG|cytokine induced killer cells|at least 10\*9 CIK cells, IV on day 0, 14, 28
219153671|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
219153672|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
219153673|NCT04614311|DRUG|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
219153674|NCT03851445|DRUG|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
219153675|NCT06832345|OTHER|Experimental group|Web-based training will be shared with patient relatives before the patient is discharged. A home visit will be made 2-3 days after the patient is discharged. Data collection forms will be collected by the researcher at each home visit. A total of four home visits and eight telephone follow-ups will be made within two months.
219153676|NCT06786117|OTHER|SLP swallowing exercises|Clinical speech language pathologists will provide standard exercises based on the abnormalities seen on the modified barium swallow. Exercises are expected to include the effortful swallow, the Mendelsohn maneuver, expiratory muscle strength training with the EMST-150, supraglottic swallow, super supraglottic swallow, chin tuck against resistance isokinetic exercise, chin tuck against resistance isometric exercise, Masako maneuver, Shaker isometric head lift exercise, Shaker isokinetic head lift exercise, Falsetto high pitch glide exercise, tongue press exercise
219725494|NCT05524909|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
219725495|NCT05524909|DEVICE|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
219725496|NCT01789021|DEVICE|4 blood glucose monitoring systems|
219725497|NCT03269006|DEVICE|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
219725498|NCT03269006|DEVICE|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
219725499|NCT03269006|DEVICE|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
219725500|NCT03269006|DEVICE|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
219725501|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
219153677|NCT06786117|OTHER|myofunctional exercises|Participants will get a variety of exercises aimed at improving bolus formation, strengthening the seal of the soft palate with the tongue, and habituating nasal breathing. There will also be exercises aimed at stabilizing the epiglottis and strengthening the muscles supporting the lateral pharyngeal walls. Expiratory muscle strength training with the EMST-150 will also be done.
219153678|NCT06785311|BEHAVIORAL|Native Spirit After-School Program|Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
219153679|NCT05702060|PROCEDURE|Radial Artery Puncture Method for Coronary Angiography and Intervention|Radial Artery Puncture Method for Coronary Angiography and Intervention
219153680|NCT06453057|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
219153681|NCT06534125|PROCEDURE|Acupressure Therapy|Undergo self-administered acupressure therapy to planned pressure points
219153682|NCT06534125|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy with acupuncture needles applied to planned pressure points
219153683|NCT06534125|DRUG|Aromatase Inhibition Therapy|Receive SOC AI therapy
219153684|NCT06534125|OTHER|Discussion|Ancillary studies
219153685|NCT06534125|OTHER|Survey Administration|Ancillary studies
219233183|NCT06459544|DIAGNOSTIC_TEST|Bobath Technique with core stability|exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.
219233184|NCT06459544|OTHER|Conventional treatment for balance|like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
219233185|NCT01802619|OTHER|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
219233186|NCT01802619|OTHER|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
219233187|NCT00392197|DRUG|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
219233188|NCT04535440|OTHER|No intervention|No intervention
219725502|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
219725503|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
219725504|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
219725505|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label)
219725506|NCT06278805|OTHER|The reliability and validity study of the T-LUNS|To test the reliability and validity of the T-LUNS, 110 chronic stroke survivors fulfilling the inclusion / exclusion criteria at the 3 study sites will be assessed. The assessment of each patient will include recording of the demographic and clinical characteristics and administration of the T-LUNS as well as the Turkish version of the Stroke Impact Scale 3.0 (SIS). For the assessment of test-retest reliability of the T-LUNS, half of the participants (n= 55) will fill in the T-LUNS again, 2 weeks after the first administration.
219725507|NCT03197155|DRUG|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
219725508|NCT03940677|PROCEDURE|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
219725509|NCT03940677|PROCEDURE|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
219725510|NCT03940677|BEHAVIORAL|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
219725511|NCT03940677|OTHER|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
219725512|NCT03684057|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
219725513|NCT00768859|DRUG|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
219725514|NCT04027387|BIOLOGICAL|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
219725515|NCT00688779|DRUG|AZD8848|Concentrate for nasal spray,solution 60 mg/g
219725516|NCT00688779|DRUG|Placebo|
219725517|NCT05957341|DEVICE|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
219153686|NCT03568994|DRUG|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
219153687|NCT03568994|DRUG|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
219153688|NCT03568994|DRUG|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
219153689|NCT03568994|DRUG|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
219153690|NCT03568994|DRUG|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
219153691|NCT02576574|DRUG|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
219153692|NCT02576574|DRUG|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
219153693|NCT02576574|DRUG|Paclitaxel|Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
219725518|NCT05957341|DEVICE|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
219153694|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
219153695|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
219725519|NCT05957341|DEVICE|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219725520|NCT05957341|DEVICE|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219725521|NCT02737059|DRUG|Naloxegol|25mg daily
219725522|NCT02737059|DRUG|Codeine|30mg 4 times daily
219725523|NCT02737059|DRUG|codeine placebo|4 times daily (placebo will be made to match the codeine)
219725524|NCT02737059|DRUG|naloxegol placebo|placebo will match naloxegol, given daily
219725525|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
219725526|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block+dexamethasone|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic+dexamethasone injection will be made between the fascia and the muscle.
219725527|NCT01078428|OTHER|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
219725528|NCT01078428|OTHER|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
219725529|NCT03924297|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
219725530|NCT01105130|OTHER|Placebo|Given orally
219725531|NCT01105130|DRUG|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
219725532|NCT01105130|DRUG|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
219725533|NCT01546298|OTHER|Patch tests|Patch tests for allergic reaction
219725534|NCT03664141|DRUG|Cannabis oil|Treatment with cannabis oil
219725535|NCT03664141|DRUG|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
219725536|NCT03404167|DRUG|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
219725537|NCT05061355|PROCEDURE|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
219725538|NCT00943904|DEVICE|Interstim implant for SNS|stimulates third sacral nerve root
219725539|NCT02927145|BIOLOGICAL|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
219725540|NCT03451032|OTHER|Non Interventional Study|Non Interventional Study
219725541|NCT05599425|BEHAVIORAL|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
219725542|NCT05599425|BEHAVIORAL|Basic Healthy Living Education|24-session healthy living education program
219725543|NCT00133354|DRUG|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
219725544|NCT00133354|DRUG|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
219725545|NCT00133354|DRUG|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
219233189|NCT01156675|DEVICE|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
219233190|NCT01156675|DEVICE|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
219233191|NCT02151994|DRUG|BIA 5-1058|oral administration
219233192|NCT02151994|DRUG|Placebo|oral administration
219233193|NCT06356532|BEHAVIORAL|intensive care unit diary|The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
219233194|NCT02440438|BIOLOGICAL|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
219233195|NCT00278499|BEHAVIORAL|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
219233196|NCT00278499|BEHAVIORAL|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
219725546|NCT04079725|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
219725547|NCT00169403|PROCEDURE|Deep brain stimulation|
219725548|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
219725549|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
219725550|NCT01363440|DRUG|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
219725551|NCT01363440|PROCEDURE|Macular Laser Photocoagulation|Laser therapy
219725552|NCT02981251|BEHAVIORAL|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
219725553|NCT03017261|DEVICE|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
219725554|NCT00818272|BIOLOGICAL|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
219725555|NCT01597232|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
219725556|NCT01597232|OTHER|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
219725557|NCT01597232|OTHER|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
219725558|NCT02470572|OTHER|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
219725559|NCT02470572|OTHER|Conventional light microscope|Conventional light microscope
219725560|NCT00327535|DRUG|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
219725561|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
219725562|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
219725563|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
219725564|NCT05019053|BEHAVIORAL|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
219725565|NCT04723368|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
219725566|NCT04132180|OTHER|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
219725567|NCT04132180|OTHER|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
219725568|NCT02506036|OTHER|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
219725569|NCT05921500|DRUG|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
219725570|NCT00319891|PROCEDURE|Computer-based Cognitive Training|
219725571|NCT00530075|DRUG|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
219725572|NCT04015687|DRUG|AG-881|Supplied as uncoated tablets.
219725573|NCT04015687|DRUG|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
219725574|NCT03426007|PROCEDURE|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
219725575|NCT03057327|BEHAVIORAL|Improve awareness of checking moles|"Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
219725576|NCT03057327|OTHER|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
219725577|NCT00442689|DRUG|flutamide|250 mg twice daily
219725578|NCT00442689|DRUG|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
219725579|NCT00442689|OTHER|placebo|
219725580|NCT00758043|DRUG|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
219725581|NCT00758043|DRUG|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
219153696|NCT02576574|DRUG|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
219153697|NCT02576574|DRUG|Cisplatin|Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
219153698|NCT02576574|DRUG|Carboplatin|Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
219153699|NCT02576574|DRUG|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
219725582|NCT00758043|BIOLOGICAL|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
219725583|NCT00875459|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
219725584|NCT05669066|BEHAVIORAL|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
219725585|NCT02027571|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
219725586|NCT04869930|OTHER|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
219725587|NCT02313597|PROCEDURE|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
219725588|NCT02313597|PROCEDURE|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
219725589|NCT05438420|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
219725590|NCT05438420|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
219725591|NCT06025461|OTHER|no intervention|no intervention
219725592|NCT01263379|BIOLOGICAL|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
219725593|NCT06355687|DRUG|Melatonin|Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
219725594|NCT06355687|DIETARY_SUPPLEMENT|Vitamin Supplement|Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
219725595|NCT00496327|BIOLOGICAL|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
219725596|NCT05331937|COMBINATION_PRODUCT|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
219725597|NCT02328729|PROCEDURE|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
219725598|NCT02328729|PROCEDURE|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
219725599|NCT02328729|PROCEDURE|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
219725600|NCT02328729|PROCEDURE|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
219725601|NCT02328729|PROCEDURE|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
219725602|NCT02328729|PROCEDURE|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
219725603|NCT05649774|PROCEDURE|Therapy|Only Myofascial Release will be provided
219725604|NCT05649774|PROCEDURE|Taping technique|Only Kinesiotaping will be provided
219725605|NCT05649774|PROCEDURE|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
219725606|NCT05649774|PROCEDURE|SHAM|Placebo Treatment will be given
219725607|NCT06579248|DEVICE|Intraoral Device|Device that circulates cooled water through the oral cavity.
219725608|NCT03693898|OTHER|Observeational|No intervention, observational
219725609|NCT06358989|OTHER|HOMA IR|Homa ir
219725610|NCT04678310|OTHER|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
219725611|NCT01726686|DRUG|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
219725612|NCT01726686|DRUG|Placebo|
219725613|NCT01701648|OTHER|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
219725614|NCT03418207|PROCEDURE|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
219725615|NCT01067235|DRUG|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
219725616|NCT01067235|DRUG|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
219725617|NCT06494813|DIAGNOSTIC_TEST|conventional pcr|conventional pcr to study matrix metalloproteinase -9 gene polymorphismin rheumatoid arthritis
219725618|NCT04522791|BEHAVIORAL|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
219725619|NCT04522791|BEHAVIORAL|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
219725620|NCT04522791|BEHAVIORAL|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
219725621|NCT02201082|PROCEDURE|Airway clearance technique|
219725622|NCT02201082|DRUG|Amikacin nebulization|
219725623|NCT03990688|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
219725624|NCT03990688|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
219725625|NCT04725643|DEVICE|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
219725626|NCT01037465|DRUG|N-acetylcysteine|N-acetylcysteine
219725627|NCT01037465|DRUG|Placebo|Placebo
219725628|NCT01290250|OTHER|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
219725629|NCT01549509|BIOLOGICAL|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10\^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
219725630|NCT02263313|OTHER|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
219725631|NCT04689243|PROCEDURE|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
219725632|NCT04689243|PROCEDURE|red light|red light, 3 times a week.
219725633|NCT03376009|DIAGNOSTIC_TEST|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
219725634|NCT03376009|DIAGNOSTIC_TEST|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
219725635|NCT03376009|DIAGNOSTIC_TEST|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
219725636|NCT03376009|DIAGNOSTIC_TEST|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
219725637|NCT03376009|DIAGNOSTIC_TEST|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
219153700|NCT06469749|BEHAVIORAL|Theory-based and peer-led intervention on Instagram|"A pilot randomized controlled trial of the 12-weeks social media intervention for non-medical use of prescription opioids (NMUPO) among young adults will be developed upon the formative research (Aim 1) grounded in the information-motivation-behavioral-skills (IMB) model. Intervention will be delivered by peer leaders, who are well-trained recovery coaches, via private groups on Instagram. Intervention contents will be tailored to psychosocial factors contributing to NMUPO.~Intervention components. Incorporating Instagram functions, the intervention is planned to include four intervention modules: (1) NMUPO knowledge module, (2) self-care module, (3) virtual goal setting/monitoring module, (4) peer support module. Intervention will be delivered by peer leaders (assisted by clinical psychology trainees a) via private groups operated by their Instagram accounts. The process will be overseen by certificated experts in clinical psychology and addiction treatment."
219153701|NCT06083298|PROCEDURE|control group|patients will be operated under general anesthesia
219153702|NCT06083298|PROCEDURE|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
219153703|NCT06083298|PROCEDURE|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
219153704|NCT05716477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219153705|NCT05716477|OTHER|Survey Administration|Complete survey
219153706|NCT06296147|OTHER|Virtual Reality Headset|The interventions are for supportive care ONLY.
219153707|NCT06296147|OTHER|Aromatherapy Patch|The interventions are for supportive care ONLY.
219153708|NCT06296147|OTHER|Standard of Care|Participant will undergo a transperineal prostate biopsy.
219153709|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
219153710|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
219153711|NCT05044637|DRUG|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
219153712|NCT05501756|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
219153713|NCT00274105|DRUG|telmisartan|
219153714|NCT00274105|DRUG|Placebo|
219153715|NCT04969471|DEVICE|enVast stent|In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
219153716|NCT04969471|PROCEDURE|conventional treatment|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
219153717|NCT05907980|DRUG|ROSE12|ROSE12 as a IV infusion
219153718|NCT05907980|DRUG|Atezolizumab|Atezolizumab as a IV infusion
219153719|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
219153720|NCT06343636|DRUG|VG-3927|Dose Escalation
219153721|NCT06343636|DRUG|Placebo|Dose Escalation
219153722|NCT06343636|DRUG|VG-3927|One Dose Level
219153723|NCT03974854|DRUG|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
219153724|NCT03974854|DRUG|Gemcitabine|chemotherapy with Gemcitabine regimen
219153725|NCT06789835|DEVICE|Fluorescence imaging of disclosed and undisclosed plaque|Teeth are imaged using a fluorescence camera/an intraoral scanner before and after plaque disclosure.
219153726|NCT05613673|OTHER|No intervention - observational study only|No intervention - observational study only
219153727|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
219153728|NCT06788743|DRUG|TIVA ( anesthesia with propofol and remifentanil)|Participants assigned to the TIVA group will receive propofol combined with remifentanil for anesthesia maintenance during the surgery
219153729|NCT06788743|DRUG|VA（anesthesia with sevoflurane and remifentanil）|Participants assigned to the VA group will receive sevoflurane combined with remifentanil for anesthesia maintenance during the surgery.
219725638|NCT03376009|DIAGNOSTIC_TEST|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
219725639|NCT03461809|OTHER|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
219725640|NCT02412319|DRUG|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
219725641|NCT02412319|OTHER|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
219725642|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
219725643|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
219725644|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
219725645|NCT02585492|OTHER|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
219725646|NCT02585492|OTHER|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
219725647|NCT02869139|OTHER|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
219725648|NCT02869139|OTHER|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
219725649|NCT05830747|DRUG|Prednisone|Pre-operative drug administration before third molar surgery
219725650|NCT05830747|DRUG|Placebo|Pre-operative Placebo administration before third molar surgery
219725651|NCT03309111|BIOLOGICAL|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
219725652|NCT02043067|OTHER|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
219725653|NCT04688996|DIAGNOSTIC_TEST|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
219725654|NCT00472381|DRUG|Insulin|Insulin
219725655|NCT01841853|BEHAVIORAL|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
219725656|NCT05381636|PROCEDURE|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
219725657|NCT05381636|DRUG|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
219725658|NCT03363438|OTHER|no intervention survey|there was no intervention this was a survey
219725659|NCT06243159|GENETIC|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
219725660|NCT00062959|BEHAVIORAL|Going Places: School program to prevent problem behavior|
219725661|NCT02528136|DRUG|Carbetocin|
219725662|NCT02528136|DRUG|Oxytocin|
219725663|NCT03938870|OTHER|L-Leucine 13C6|
219725664|NCT01603914|DEVICE|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
219725665|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
219725666|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
219725667|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
219725668|NCT00709800|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
219725669|NCT00709800|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
219725670|NCT02400580|DRUG|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
219725671|NCT02400580|DRUG|placebo|The patients in the placebo arm will receive normal saline.
219725672|NCT00965094|DRUG|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
219725673|NCT00965094|DRUG|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
219725674|NCT00965094|DRUG|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
219725675|NCT00965094|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
219153730|NCT05830058|PROCEDURE|Biospecimen Collection|Undergo blood collection
219153731|NCT05830058|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219153732|NCT05830058|PROCEDURE|Positron Emission Tomography|Undergo PET
219725676|NCT00965094|DRUG|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
219725677|NCT03280680|OTHER|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
219725678|NCT03280680|OTHER|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
219725679|NCT03280680|OTHER|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
219725680|NCT04129801|OTHER|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
219725681|NCT04129801|OTHER|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
219725682|NCT02313272|RADIATION|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
219725683|NCT02313272|DRUG|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
219725684|NCT02313272|DRUG|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.
219725685|NCT01336972|DRUG|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
219725686|NCT01997255|DRUG|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
219153733|NCT05830058|OTHER|Questionnaire Administration|Ancillary studies
219153734|NCT05830058|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219153735|NCT04661982|OTHER|Long-term Follow-up|Undergo long term follow-up
219153736|NCT04661982|OTHER|Questionnaire Administration|Ancillary studies
219153737|NCT04661982|OTHER|Quality-of-Life Assessment|Ancillary studies
219725687|NCT06391515|DIAGNOSTIC_TEST|Blood sample, CRF, thyroid ultrasound|Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
219725688|NCT03865680|DRUG|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
219725689|NCT03865680|DRUG|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
219725690|NCT00576394|DRUG|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
219725691|NCT00576394|DRUG|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
219725692|NCT05759455|DIETARY_SUPPLEMENT|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
219725693|NCT05525715|DRUG|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
219725694|NCT05525715|DRUG|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
219725695|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
219725696|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
219725697|NCT05525715|DRUG|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
219153738|NCT06785623|DIETARY_SUPPLEMENT|Gastrodia elata Blume water extract|Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
219725698|NCT05525715|DRUG|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
219725699|NCT05525715|DRUG|5mg QY201 tablets，BID|5mg QY201 tablets，BID
219725700|NCT05525715|DRUG|10mg QY201 tablets，BID|10mg QY201 tablets，BID
219725701|NCT05525715|DRUG|20mg QY201 tablets，BID|20mg QY201 tablets，BID
219153739|NCT06114602|BEHAVIORAL|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
219153740|NCT02529839|PROCEDURE|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
219153741|NCT02529839|DRUG|Fludarabine|30mg/m2 on days -6 through -3
219153742|NCT02529839|DRUG|Cyclophosphamide|50mg/kg on days -5 through -4
219153743|NCT02529839|DRUG|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
219153744|NCT06772753|DRUG|Placebo|inactive substance
219153745|NCT06772753|DRUG|Psilocybin|active comparator for psychedelic effects
219725702|NCT05525715|DRUG|QY201 placebo，BID|QY201placebo，BID
219725703|NCT04837742|DRUG|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
219725704|NCT04837742|DRUG|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
219725705|NCT04784403|DIAGNOSTIC_TEST|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
219725706|NCT01793909|OTHER|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
219725707|NCT03096990|DRUG|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
219725708|NCT00000665|DRUG|Foscarnet sodium|
219725709|NCT00000665|DRUG|Ganciclovir|
219725710|NCT00407667|DEVICE|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
219725711|NCT04731116|DRUG|Cannabidiol|Oral Cannabidiol 150 mg twice daily during 14 days
219725712|NCT01494974|DEVICE|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
219725713|NCT01494974|DEVICE|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
219153746|NCT06772753|DRUG|Ketamine|psychoactive substance
219153747|NCT06772753|DRUG|Dextromethorphan (DXM)|psychoactive substance
219153748|NCT06772753|DRUG|Dimethyltryptamine (DMT)|psychoactive substance
219153749|NCT06772753|DRUG|Methylenedioxymethamphetamine (MDMA)|psychoactive substance
219153750|NCT06772753|DRUG|Tetrahydrocannabinol (THC)|psychoactive substance
219153751|NCT05727657|DRUG|Satralizumab|120mg subcutaneous Day 0 and Day 14
219153752|NCT05254678|BEHAVIORAL|general exercise|A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
219153753|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).
219153754|NCT03577223|OTHER|Whole Eggs|3 whole eggs per day for 4 weeks
219153755|NCT03577223|OTHER|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
219153756|NCT00891332|DRUG|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
219153757|NCT06009536|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
219725714|NCT05625971|OTHER|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
219725715|NCT03401294|DRUG|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
219725716|NCT06640647|DRUG|HDM1005 injection or placebo|HDM1005 injection or placebo isubcutaneous injection once
219725717|NCT04433975|BEHAVIORAL|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
219233197|NCT04012905|DRUG|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
219233198|NCT05528692|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
219233199|NCT01182532|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
219233200|NCT01182532|DRUG|TCM Syndrome Differentiation and Treatment|"1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
219233201|NCT01182532|OTHER|Western therapy plus TCM treatment|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
219233202|NCT05561491|BIOLOGICAL|ONCOS-102|Oncolytic virus
219233203|NCT05561491|BIOLOGICAL|Balstilimab|Anti PD-1
219233204|NCT03417700|DIETARY_SUPPLEMENT|NW training|NW training
219233205|NCT03417700|DIETARY_SUPPLEMENT|Placebo|training with placebo
219233206|NCT03417700|DIETARY_SUPPLEMENT|HICT|Training and vitamin D
219233207|NCT01219127|OTHER|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
219233208|NCT01840722|OTHER|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
219233209|NCT04337593|DRUG|Basiliximab|20mg d1,8, repeated every 3 weeks
219233210|NCT04337593|DRUG|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
219153758|NCT00257998|PROCEDURE|Mobilization|manualtherapy techniques
219233211|NCT05985200|DRUG|BI 3032950|BI 3032950
219233212|NCT05985200|DRUG|Placebo matching BI 3032950|Placebo matching BI 3032950
219725718|NCT04433975|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
219725719|NCT00232154|DRUG|Zithromax&#153; (azithromycin) 500mg tablets|
219725720|NCT00232154|PROCEDURE|Endoscopic Sinus Surgery|
219725721|NCT00232154|PROCEDURE|Blood sampling for hematology|
219725722|NCT00232154|PROCEDURE|Blood sampling for plasma chemistry profile|
219725723|NCT00232154|PROCEDURE|Serum pregnancy test (for women of child-bearing potential)|
219153759|NCT02548806|DRUG|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
219153760|NCT02548806|DRUG|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
219153761|NCT02548806|DRUG|Catapres 100μg|Catapres tablet 100μg, single dose
219153762|NCT01950780|DRUG|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
219153763|NCT00262782|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
219153764|NCT04010435|DEVICE|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
219233213|NCT03409159|DEVICE|LAAC|Left atrial appendage closure
219233214|NCT03547206|DRUG|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
219233215|NCT03547206|OTHER|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
219233216|NCT03547206|DRUG|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
219233217|NCT03547206|OTHER|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
219233218|NCT01079949|DRUG|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
219725724|NCT04606771|DRUG|Osimertinib + Savolitinib|"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"
219725725|NCT04606771|DRUG|Savolitinib + Placebo|"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"
219725726|NCT04549207|DRUG|Bone modifying agent|Use of bone modifying agent
219725727|NCT04253964|DRUG|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
219725728|NCT04253964|DRUG|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
219725729|NCT04253964|DRUG|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
219725730|NCT04253964|DRUG|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
219725731|NCT04253964|OTHER|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
219725732|NCT04253964|OTHER|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
219725733|NCT04253964|OTHER|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
219725734|NCT04253964|DRUG|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
219725735|NCT04392635|DEVICE|TauTona Pneumoperitoneum Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.
219725736|NCT04392635|PROCEDURE|Standard of Care (SOC)|Standard of Care was used for Veress needle insertion.
219725737|NCT02030418|DEVICE|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
219725738|NCT06637020|DRUG|HDM1005 injection or placebo|Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.
219725739|NCT05844124|OTHER|Exercise for Knee Osteoarthritis Recommendations (Control group)|Patients in this group will receive available exercise recommendations of 150 minutes of moderate intensity exercise per week (30 minutes per day).
219725740|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
219725741|NCT05844124|OTHER|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
219725742|NCT05621798|OTHER|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
219725743|NCT05621798|OTHER|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
219725744|NCT05452226|DEVICE|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
219725745|NCT06495944|DRUG|Dazucorilant|75 mg soft gelatin capsules formulation for oral administration
219725746|NCT06495944|DRUG|Itraconazole|100 mg capsules for oral administration
219725747|NCT04246476|BEHAVIORAL|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
219725748|NCT04246476|BEHAVIORAL|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
219725749|NCT06306183|DIETARY_SUPPLEMENT|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
219725750|NCT06306183|OTHER|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
219153765|NCT04010435|DEVICE|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
219153766|NCT04929067|DRUG|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
219153767|NCT00687713|DRUG|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
219153768|NCT00687713|OTHER|Placebo|Placebo
219153769|NCT01557335|DRUG|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
219153770|NCT01557335|DRUG|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
219153771|NCT03561519|OTHER|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
219153772|NCT03561519|OTHER|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
219725751|NCT03713580|DRUG|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
219725752|NCT04095845|DEVICE|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
219725753|NCT04095845|DEVICE|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
219725754|NCT06635161|DEVICE|Trancranial pulse stimulation (without a stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.
219725755|NCT06635161|DEVICE|Transcranial pulse stimulation (with Neurology stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.
219725756|NCT06635161|DEVICE|Transcranial pulse stimulation (with a sham stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
219725757|NCT04999124|OTHER|Screening and studying characteristics|Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.
219725758|NCT03287063|OTHER|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
219725759|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
219725760|NCT04242745|BEHAVIORAL|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
219725761|NCT04242745|BEHAVIORAL|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
219725762|NCT04046653|DIETARY_SUPPLEMENT|Allin|Dietary supplement
219725763|NCT04046653|DIETARY_SUPPLEMENT|Sulforaphane|Dietary supplement
219725764|NCT04046653|DIETARY_SUPPLEMENT|Placebo|Dietary supplement
219725765|NCT02346422|GENETIC|MYDICAR Phase 1|Single dose of MYDICAR
219725766|NCT02346422|GENETIC|MYDICAR Phase 2|Single dose of MYDICAR
219725767|NCT02346422|GENETIC|Placebo Phase 2 only|Single dose of placebo
219725768|NCT01968317|DRUG|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
219725769|NCT01968317|DRUG|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
219725770|NCT02310347|DRUG|dronabinol|
219725771|NCT02310347|DRUG|Placebo|
219725772|NCT04321499|GENETIC|lung cancer|PCR for SHOX2 and PTGER4
219725773|NCT02216851|DEVICE|Restylane Perlane|Intradermal injection
219725774|NCT02747225|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
219725775|NCT02492919|DEVICE|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
219725776|NCT01873885|DRUG|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
219725777|NCT01873885|DRUG|Experimental: Single IV Infusion Vasomera (PB1046)|
219725778|NCT01227811|DRUG|Darifenacin|Single oral dose Darisec(R) 15.0 mg
219725779|NCT01227811|DRUG|Darifenacin|Single oral dose Enablex(R) 15 mg
219725780|NCT05992038|PROCEDURE|Osteotomy with putty|Synthetic ceramic putty
219233219|NCT01079949|DRUG|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
219233220|NCT01079949|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
219233221|NCT01079949|DRUG|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
219233222|NCT04108104|DRUG|Cyproheptadine|3-month treatment
219233223|NCT04108104|DRUG|Alpress LP|3-month treatment
219233224|NCT02060084|DRUG|a control group|the same dose of luke warm water
219233225|NCT02060084|DRUG|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
219233226|NCT02144285|DRUG|LY3113593|Administered IV
219153773|NCT05594511|PROCEDURE|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
219233227|NCT02144285|DRUG|LY3113593|Administered SC
219233228|NCT02144285|DRUG|Placebo|Administered IV
219233229|NCT02144285|DRUG|Placebo|Administered SC
219233230|NCT01267552|PROCEDURE|Non drains will be placed during operation|Non drains will be placed during operation
219725781|NCT05992038|PROCEDURE|Conventional osteotomy|conventional osteotomy
219725782|NCT02663167|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
219725783|NCT01939392|DEVICE|Renal Denervation (OneShot™ Renal Denervation System)|
219153774|NCT05594511|PROCEDURE|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
219153775|NCT05223517|DEVICE|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
219233231|NCT01267552|PROCEDURE|Closed suction drainage|Closed suction drainage will be placed during operation
219233232|NCT01529632|DRUG|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
219233233|NCT01529632|DRUG|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
219233234|NCT01529632|DRUG|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
219233235|NCT01529632|DRUG|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
219233236|NCT01653392|BIOLOGICAL|Observational Intervention|This is an observational study, therefore no interventions are specified.
219233237|NCT01600196|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
219233238|NCT04998552|RADIATION|Cyberknife|5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
219233239|NCT03040856|DIETARY_SUPPLEMENT|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
219233240|NCT03040856|DIETARY_SUPPLEMENT|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
219233241|NCT03040856|OTHER|Placebo|Placebo capsules containing olive oil
219233242|NCT01942915|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
219233243|NCT01051271|DRUG|midazolam|midazolam 1.5 mg
219233244|NCT00937183|BIOLOGICAL|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
219233245|NCT00937183|BIOLOGICAL|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
219233246|NCT00937183|BIOLOGICAL|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
219233247|NCT04598139|OTHER|Study group|The study group uses a web-based medication error notification system
219233248|NCT03674515|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
219233249|NCT03674515|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
219233250|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
219233251|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
219233252|NCT06662630|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
219233253|NCT06203873|DEVICE|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
219233254|NCT06203873|DEVICE|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
219233255|NCT05552924|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
219233256|NCT00278304|RADIATION|brachytherapy|
219725784|NCT04021355|OTHER|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
219725785|NCT02122952|BIOLOGICAL|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
219725786|NCT02508207|DRUG|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
219725787|NCT02508207|DRUG|Ivacaftor|
219725788|NCT02508207|DRUG|Tezacaftor/Ivacaftor matching placebo|
219725789|NCT02508207|DRUG|Ivacaftor matching placebo|
219725790|NCT01284764|DRUG|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
219725791|NCT06530095|OTHER|prone positioning|prone positioning
219725792|NCT00662701|PROCEDURE|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
219725793|NCT00662701|PROCEDURE|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
219153776|NCT05223517|DEVICE|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
219153777|NCT02390570|OTHER|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
219153778|NCT00872872|DRUG|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
219153779|NCT01761201|DRUG|Levofloxacin|Levofloxacin
219153780|NCT01761201|DRUG|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
219233257|NCT00278304|RADIATION|radiation therapy|
219233258|NCT06452212|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
219233259|NCT04084522|DIETARY_SUPPLEMENT|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
219233260|NCT04084522|DIETARY_SUPPLEMENT|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
219233261|NCT04865172|OTHER|Remote collection of passive and active data for 28 consecutive days|Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
219233262|NCT00598390|DRUG|[11C]MePPEP|
219725794|NCT03997201|PROCEDURE|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
219725795|NCT03707730|DIETARY_SUPPLEMENT|AGY|oral AGY taken prior to meals
219725796|NCT03707730|OTHER|placebo|oral placebo taken prior to meals
219725797|NCT00104260|DRUG|sapropterin dihydrochloride|
219725798|NCT01447472|DRUG|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
219725799|NCT01475500|PROCEDURE|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
219725800|NCT01475500|PROCEDURE|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
219725801|NCT01475500|RADIATION|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
219725802|NCT01475500|OTHER|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
219725803|NCT01475500|PROCEDURE|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
219725804|NCT01475500|PROCEDURE|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
219725805|NCT01475500|PROCEDURE|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
219725806|NCT01475500|PROCEDURE|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
219725807|NCT01475500|PROCEDURE|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
219725808|NCT01475500|PROCEDURE|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
219725809|NCT00940459|DEVICE|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
219153781|NCT04458454|DIAGNOSTIC_TEST|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
219153782|NCT01043601|DRUG|Inhaled PT005|inhaled, twice daily for 1 week duration
219153783|NCT01043601|DRUG|Inhaled Placebo|inhaled, twice daily for 1 week duration
219153784|NCT01043601|DRUG|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
219725810|NCT00940459|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
219725811|NCT00940459|DEVICE|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
219725812|NCT00940459|DEVICE|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
219153785|NCT00238797|DRUG|Gefitinib|
219153786|NCT03772015|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
219153787|NCT06340100|OTHER|find association between vestibular impairment , cognitive fiunction with concussin|SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
219153788|NCT03470376|DIETARY_SUPPLEMENT|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
219153789|NCT03470376|BEHAVIORAL|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
219725813|NCT00940459|DEVICE|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
219725814|NCT00940459|DEVICE|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
219725815|NCT01566825|DRUG|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
219725816|NCT01566825|DRUG|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
219725817|NCT06214715|DEVICE|Philips ultrasonography system|RRI will be measured by renal ultrasonography with a C5-1 convex probe using a Philips ultrasonography model device.
219725818|NCT00179179|DRUG|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
219725819|NCT00179179|BEHAVIORAL|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
219725820|NCT06501937|OTHER|Influencer marketing|Participants watched online survey-imbedded promotional videos featuring influencers
219725821|NCT03423693|OTHER|No any intervention|No any intervention is applied to any groups in this study
219153790|NCT02088372|DEVICE|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
219153791|NCT00067496|DRUG|Modafinil|
219153792|NCT05766540|DRUG|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
219153793|NCT02111889|OTHER|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
219153794|NCT04704258|PROCEDURE|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
219153795|NCT04704258|DEVICE|FLOWer Embolic Protection System|FLOWer Embolic Protection System
219153796|NCT02955407|OTHER|no intervention|observational case-control study
219725822|NCT04017468|DRUG|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
219725823|NCT05087303|OTHER|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
219725824|NCT01857154|DIETARY_SUPPLEMENT|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
219725825|NCT01857154|DIETARY_SUPPLEMENT|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
219725826|NCT01857154|DIETARY_SUPPLEMENT|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
219725827|NCT00896233|PROCEDURE|MRE|"Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
219725828|NCT04280562|DEVICE|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
219233263|NCT03383848|DEVICE|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
219233264|NCT07013227|OTHER|experimental group|Labor pain and comfort level will be measured by applying virtual reality glasses to the control group.
219233265|NCT06683157|DIAGNOSTIC_TEST|not drug|"Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on."
219233266|NCT03650166|OTHER|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
219725829|NCT04280562|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
219153797|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
219153798|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
219153799|NCT02545920|OTHER|no intervention|observational study
219153800|NCT05326971|PROCEDURE|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
219153801|NCT00123903|DRUG|metoprolol xl|
219153802|NCT00123903|DRUG|carvedilol MR|
219153803|NCT00123903|DRUG|lisinopril|
219153804|NCT03631433|DRUG|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
219153805|NCT03631433|DRUG|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
219153806|NCT03999034|DIAGNOSTIC_TEST|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
219153807|NCT00006017|DRUG|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
219153808|NCT04723394|DRUG|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
219725830|NCT00083109|DRUG|Fluorouracil|Given IV
219725831|NCT00083109|OTHER|Pharmacological Study|Correlative studies
219153809|NCT04723394|DRUG|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
219153810|NCT01006434|OTHER|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
219153811|NCT00044863|BIOLOGICAL|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
219153812|NCT00797017|DRUG|fentanyl|Infection, starting with 12mcg/h (flexible dose)
219153813|NCT00797017|DRUG|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
219153814|NCT00797017|DRUG|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
219153815|NCT00797017|DRUG|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
219153816|NCT00797017|DRUG|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
219153817|NCT00797017|DRUG|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
219725832|NCT00083109|DRUG|Suramin|Given IV
219725833|NCT01497093|DRUG|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
219725834|NCT01497093|DRUG|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
219725835|NCT01497093|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
219725836|NCT05381168|DIETARY_SUPPLEMENT|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
219725837|NCT05381168|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
219725838|NCT03406052|BEHAVIORAL|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
219725839|NCT06281613|DEVICE|AMCOP group|Patients were treated with AMCOP for 18 months.
219725840|NCT06281613|DEVICE|High-pull headgear|Patients were treated with high-pull headgear for 18 months.
219153818|NCT00797017|DRUG|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
219153819|NCT03290859|PROCEDURE|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
219233267|NCT03650166|OTHER|Personal BP monitor|Battery-powered BP monitor for personal use
219233268|NCT07013851|DRUG|Dostarlimab|"Patients will be treated in the neoadjuvant setting with dostarlima 500 mg (30') every 3 weeks for 4 cycles.All participants will undergo surgery within 6 weeks following the final dose of neoadjuvant dostarlimab. After surgery, adjuvant chemotherapy, including dostarlimab, will be administered as follows:~Stage II EC:~VBT/EBRT (completed within \>14 weeks after surgery) + Adjuvant dostarlimab 1000 mg Q6W x 9 cycles (54 weeks total).~Stage III EC:~1. Concurrent EBRT+cisplatin followed by carboplatin + paclitaxel OR~2. Sequential: EBRT followed by carboplatin + paclitaxel OR~3. Chemotherapy alone: carboplatin + paclitaxel~   * Adjuvant dostarlimab 500 mg Q3W x 4-6 cycles (in combination with chemotherapy) plus 1000 mg Q6W x 6-7 cycles (54 weeks total)."
219233269|NCT05931406|BEHAVIORAL|Control|A normal working day from of 12h
219233270|NCT05931406|BEHAVIORAL|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
219233271|NCT05931406|BEHAVIORAL|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
219233272|NCT06696508|PROCEDURE|Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty|"After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered"
219233273|NCT06696508|PROCEDURE|Classic Laparoscopic Dismembered Pyeloplasty|the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
219233274|NCT06698380|OTHER|Conventional Physical Therapy|The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
219233275|NCT06698380|OTHER|Mirror Therapy|A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
219725841|NCT05507450|BIOLOGICAL|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
219725842|NCT05507450|BIOLOGICAL|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
219725843|NCT05507450|BIOLOGICAL|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
219153820|NCT03041584|PROCEDURE|Guided placement|implant placement with use of guide
219153821|NCT03041584|PROCEDURE|Non-guided placement|conventional implant placement
219153822|NCT03041584|DEVICE|Astra Tech TX implant|
219153823|NCT02492516|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
219153824|NCT04682418|DEVICE|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
219153825|NCT00007163|DRUG|J695|
219153826|NCT01970813|DEVICE|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
219233276|NCT06699511|BEHAVIORAL|Exercise|Exercise
219233277|NCT06699576|DRUG|HS-20093|HS-20093: administered as an IV infusion
219233278|NCT06699576|DRUG|Anlotinib|Anlotinib: 12mg once daily (QD) orally
219725844|NCT05507450|BIOLOGICAL|Placebo|0.5 mL SC dose of placebo
219725845|NCT01746875|DRUG|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
219153827|NCT01970813|DEVICE|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
219153828|NCT03002428|DRUG|Teriparatide (PF708)|Subcutaneous injection
219725846|NCT01746875|DRUG|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
219725847|NCT00514917|DRUG|Docetaxel|75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
219725848|NCT00514917|DRUG|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
219153829|NCT03002428|DRUG|Teriparatide (Forteo)|Subcutaneous injection
219153830|NCT04884295|DRUG|XVR011|Single dose of XVR011 via intravenous (IV) infusion
219153831|NCT00774397|DRUG|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
219153832|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
219153833|NCT00774397|DRUG|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
219153834|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
219153835|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
219725849|NCT00514917|DRUG|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
219725850|NCT01877954|DRUG|Extra-fine hydrofluoroalkane beclometasone dipropionate|
219725851|NCT01877954|DRUG|Fluticasone propionate|
219725852|NCT00444249|PROCEDURE|White Alcon IOL|Implantation of white Alcon IOL
219725853|NCT00444249|PROCEDURE|Yellow Alcon IOL|Implantation of yellow Alcon IOL
219725854|NCT00444249|PROCEDURE|White Hoya IOL|Implantation of white Hoya IOL
219725855|NCT00444249|PROCEDURE|Yellow Hoya IOL|Implantation of yellow Hoya IOL
219725856|NCT02815956|DEVICE|percutaneous tibial nerve stimulation|
219725857|NCT02815956|DEVICE|Placebo|
219725858|NCT01708525|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
219725859|NCT01708525|OTHER|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
219725860|NCT05298839|DIAGNOSTIC_TEST|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
219725861|NCT06153238|DRUG|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
219725862|NCT06153238|DRUG|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
219725863|NCT06153238|DRUG|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
219725864|NCT02723331|DRUG|Nab paclitaxel|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
219725865|NCT02723331|DRUG|Gemcitabine|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
219233279|NCT06699576|DRUG|Epirubicin|Epirubicin: administered as an IV infusion
219233280|NCT06699576|DRUG|Adebrelimab|Adebrelimab: administered as an IV infusion
219725866|NCT05965934|DRUG|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
219725867|NCT03334097|OTHER|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting."
219725868|NCT03653078|DEVICE|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
219725869|NCT04149353|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
219725870|NCT00632970|DRUG|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
219725871|NCT00632970|DRUG|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
219725872|NCT00632970|DRUG|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
219725873|NCT04041128|DRUG|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
219725874|NCT06468475|DRUG|Magnesium Sulphate infusion|Magnesium sulphate 24 hours apart by intravenous infusion at 250 mg/kg/dose (0.5 mL/kg/dose of injection magnesium sulphate 50% w/v diluted in 5 mL/kg of 5% glucose) over a duration of half an hour by an infusion pump
219725875|NCT01204372|DRUG|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1."
219725876|NCT00309244|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
219725877|NCT00309244|DRUG|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
219725878|NCT01263028|DRUG|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
219725879|NCT03941886|OTHER|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
219725880|NCT03019588|BIOLOGICAL|Pembrolizumab|IV infusion
219725881|NCT03019588|DRUG|Paclitaxel|IV infusion
219725882|NCT00558883|DRUG|acarbose|oral application
219725883|NCT05504421|OTHER|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
219725884|NCT03849456|DRUG|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
219725885|NCT00430859|DRUG|Alkaline Phosphatase|Intravenous over a period of 24 hours
219725886|NCT00430859|DRUG|Placebo|Saline over a period of 24h
219725887|NCT00887588|DRUG|LCZ696|50 mg, 100 mg and 200 mg tablets
219725888|NCT00887588|DRUG|Valsartan|40 mg, 80 mg and 160 mg tablets
219725889|NCT00887588|DRUG|Placebo|matching placebo to LCZ696 and Valsartan
219725890|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
219725891|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
219725892|NCT00290420|DRUG|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
219725893|NCT06507865|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Patients presenting with thoracic vascular disease that may benefit from the placement of TBE device. The target registry population is patients who are treated with TBE at participating sites. TBE treatment is qualified as receiving the TBE aortic component, at a minimum.
219725894|NCT00366535|DRUG|Placebo|4 tabs b.i.d.
219725895|NCT00366535|DRUG|Neurotropin|4 tabs b.i.d.
219153836|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
219725896|NCT00106535|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
219725897|NCT00106535|DRUG|Placebo|IV/month
219725898|NCT00106535|DRUG|Methotrexate|10-25 mg/week
219725899|NCT03468946|OTHER|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
219725900|NCT03468946|OTHER|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
219725901|NCT03468946|OTHER|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
219725902|NCT03468946|OTHER|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
219725903|NCT02575183|DRUG|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
219725904|NCT02575183|DRUG|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
219725905|NCT02575183|BEHAVIORAL|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
219725906|NCT06133504|PROCEDURE|Early Multimodal Therapy|Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.
219725907|NCT06133504|PROCEDURE|Late Multimodal Therapy|Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
219725908|NCT06066528|DRUG|Survodutide|once weekly subcutaneous injection
219725909|NCT06066528|DRUG|Placebo|once weekly subcutaneous injection
219153837|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
219153838|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
219153839|NCT00774397|DRUG|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
219153840|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
219153841|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
219153842|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
219153843|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
219153844|NCT00774397|DRUG|Placebo|Placebo
219153845|NCT00006349|DIETARY_SUPPLEMENT|vitamin E|
219153846|NCT00006349|DRUG|donepezil hydrochloride|
219725910|NCT06259500|OTHER|observational|Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
219725911|NCT05469204|DRUG|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
219725912|NCT05469204|DRUG|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
219725913|NCT05469204|DRUG|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
219725914|NCT05469204|DRUG|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
219233281|NCT06699186|OTHER|Sleep|A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.
219233282|NCT06699186|OTHER|Non-sleep|A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
219233283|NCT06881966|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Patients in the intervention group will consume 2 omega-3 capsules (Omevie) daily, which contain 36% and 24% of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, during a period of 3 months.
219233284|NCT06881966|OTHER|Placebo|The control group who will receive placebo supplementation, over a period of 3 months.The placebo capsules will be olive oil-based and will have the same visual as the omega-3 capsules. They will be developed by Vital Company.
219725915|NCT06533904|PROCEDURE|Percutaneous Cryoablation of Intercostal Nerves|Percutaneous Cryoablation of Intercostal Nerves
219153847|NCT00006349|OTHER|placebo|
219233285|NCT06724419|BEHAVIORAL|Nutrition education-based intervention|The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 60-120 minutes.The aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational interventions, and each participant will be provided with the PMS management booklet.
219153848|NCT04894851|BEHAVIORAL|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
219153849|NCT05343715|BIOLOGICAL|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
219153850|NCT05343715|BIOLOGICAL|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
219153851|NCT05277441|DIAGNOSTIC_TEST|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
219153852|NCT02675829|DRUG|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
219153853|NCT02944760|OTHER|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
219153854|NCT00810849|DRUG|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
219153855|NCT00810849|BIOLOGICAL|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
219153856|NCT02186743|OTHER|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
219153857|NCT04971070|OTHER|Observation and follow-up|Observation and follow-up study
219153858|NCT02010944|DRUG|solifenacin succinate|oral
219153859|NCT02010944|DRUG|mirabegron|oral
219153860|NCT02010944|DRUG|mirabegron/solifenacin succinate|oral
219153861|NCT01965665|DEVICE|MediHoney HCS dressing|
219153862|NCT05397262|OTHER|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
219233286|NCT07052825|PROCEDURE|CTR implantation|Phaco+IOL with CTR implantation
219233287|NCT07099157|DRUG|Brivudine|brivudine 125 mg per dose, once daily, 7 days
219233288|NCT07099157|DRUG|Famciclovir|orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
219233289|NCT07099989|DRUG|Zelquistinel 3 mg|Subjects will receive Zelquistinel 3 mg in fed and fasted state (high fat meal).
219725916|NCT06533904|OTHER|Multi-modal pain regimen|Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
219725917|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplement|Hair growth supplement for women ages 18 - 44
219725918|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70
219153863|NCT05397262|RADIATION|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
219725919|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
219725920|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
219725921|NCT02741817|DRUG|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
219725922|NCT02802722|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
219725923|NCT02802722|BIOLOGICAL|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
219153864|NCT05397262|DRUG|Chemotherapy 5-Fluorouracil|600 mg/m\^2 civ 120h; d 1-5, 29-33
219725924|NCT02802722|RADIATION|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
219725925|NCT02802722|OTHER|Symptom questionnaire|Symptom questionnaire for recent symptom history
219725926|NCT02802722|OTHER|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
219725927|NCT01870037|DRUG|Placebo (PBS-20% sucrose)|
219725928|NCT01870037|DRUG|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
219725929|NCT02685865|DEVICE|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
219725930|NCT02685865|DEVICE|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
219725931|NCT03753542|OTHER|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
219725932|NCT04690647|OTHER|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
219153865|NCT05397262|DRUG|Chemotherapy Cisplatin|20 mg/m\^2; d1-5, 29-33
219725933|NCT04690647|OTHER|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
219725934|NCT04690647|DRUG|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
219153866|NCT00253890|DRUG|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
219153867|NCT00253890|DRUG|Placebo|1-3 at bedtime
219153868|NCT02538458|DRUG|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
219153869|NCT02538458|DRUG|3 % hypertonic saline up to 24H|"* Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
219153870|NCT03466242|DRUG|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
219233290|NCT07099989|DRUG|Zelquistinel 10 mg|Subjects will receive Zelquistinel 10 mg in fed and fasted state (high fat meal).
219725935|NCT05395780|DRUG|MAX-40279|MAX-40279 capsule will be administered orally
219725936|NCT04864067|DRUG|Oxaliplatin|Consolidation Chemotherapy
219725937|NCT04864067|DRUG|5-Fluoracil|Consolidation Chemotherapy
219725938|NCT04864067|DRUG|Leucovorin|Consolidation Chemotherapy
219725939|NCT04864067|DRUG|Capecitabine|Consolidation Chemotherapy
219725940|NCT04864067|RADIATION|5x5 Gy|Neoadjuvant Radiotherapy
219725941|NCT04864067|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
219725942|NCT04864067|PROCEDURE|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
219725943|NCT03573089|DRUG|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
219725944|NCT03573089|DRUG|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
219725945|NCT06482983|PROCEDURE|Mechanical Ventilation Mode|after intubation different ventilation mode (VC,PC,PC-VG)
219725946|NCT06415487|DRUG|Cyclophosphamide|Lymphodepleting agent
219725947|NCT06415487|DRUG|Fludarabine|Lymphodepleting agent
219725948|NCT06415487|DRUG|ACE2016|Allogeneic gamma delta T (gdT) cell therapy
219725949|NCT06415487|DRUG|Pembrolizumab|Immune checkpoint anti-PD-1 antibody
219153871|NCT03466242|DRUG|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
219153872|NCT02355236|DRUG|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
219153873|NCT02355236|DRUG|Celecoxib 200mg|Capsule, o.d.
219153874|NCT02355236|DRUG|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
219153875|NCT02355236|DRUG|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
219153876|NCT03584659|DEVICE|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
219153877|NCT02810236|PROCEDURE|Ultrasound|Ultrasound will be performed.
219153878|NCT02810236|BEHAVIORAL|Discussion|Radiologist will discuss with the patient the findings on mammogram.
219153879|NCT02259049|DIETARY_SUPPLEMENT|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
219153880|NCT02259049|DIETARY_SUPPLEMENT|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
219153881|NCT00225797|DRUG|Oxymorphone Extended Release|
219153882|NCT00077675|DRUG|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
219725950|NCT03496675|BEHAVIORAL|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
219725951|NCT03496675|BEHAVIORAL|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
219725952|NCT03496675|OTHER|Standard care|May include pharmacological and non-pharmacological interventions as locally available
219725953|NCT02359253|OTHER|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
219725954|NCT02359253|OTHER|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
219153883|NCT00077675|DRUG|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
219153884|NCT01863485|DRUG|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
219153885|NCT03787966|OTHER|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
219153886|NCT03787966|OTHER|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
219153887|NCT05965141|DRUG|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
219233291|NCT06945549|DIAGNOSTIC_TEST|18F-FAPI PET Imaging|The ROI of the target lesions was delineated based on 18F-FAPI PET Imaging, and the lesions were divided on the cross section to obtain the lesions SUVmax, SUVmean, SUVpeak, FAPI metabolic volume (FAV), MTV, TBR, and TLG.
219233292|NCT06542289|DEVICE|BlinkER device.|Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
219725955|NCT02359253|OTHER|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
219725956|NCT02359253|OTHER|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
219725957|NCT04359615|DRUG|Favipiravir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
219725958|NCT04359615|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
219725959|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
219725960|NCT03940352|DRUG|HDM201|Capsule
219725961|NCT03940352|BIOLOGICAL|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
219725962|NCT03940352|DRUG|Venetoclax|Tablet
219725963|NCT02021318|DRUG|Roxadustat|Oral tablet.
219725964|NCT02021318|DRUG|Darbepoetin alfa|Subcutaneous or intravenous injection.
219725965|NCT06560320|BEHAVIORAL|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
219725966|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
219725967|NCT06973304|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection.
219725968|NCT04892303|COMBINATION_PRODUCT|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
219725969|NCT05356611|BEHAVIORAL|Engage|Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
219725970|NCT05253469|PROCEDURE|Cryopreserved Aortic Homograft|CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
219725971|NCT05253469|PROCEDURE|Stented/Non stented xenograft|The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
219725972|NCT05253469|PROCEDURE|Mechanical prostheses|The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
219233293|NCT05522569|DRUG|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
219153888|NCT03036176|BEHAVIORAL|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
219153889|NCT03036176|OTHER|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
219725973|NCT03585543|BEHAVIORAL|Voice Crisis Alert V2|Intervention consists of a mHealth app delivered via smartphone
219153890|NCT00083551|DRUG|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
219153891|NCT00083551|DRUG|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
219153892|NCT00083551|DRUG|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
219153893|NCT00083551|DRUG|Cisplatin|"Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) \> 3.0 mg/dl"
219153894|NCT00083551|DRUG|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
219153895|NCT00083551|DRUG|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
219153896|NCT00083551|DRUG|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
219153897|NCT00083551|DRUG|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
219153898|NCT00083551|DRUG|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
219153899|NCT00083551|DRUG|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
219153900|NCT00083551|DRUG|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
219153901|NCT00083551|DRUG|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
219153902|NCT00083551|DRUG|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
219153903|NCT05379075|OTHER|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
219153904|NCT05379075|OTHER|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
219725974|NCT02430233|DRUG|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
219725975|NCT01660542|DRUG|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
219725976|NCT03343028|OTHER|Psychotherapy|
219360773|NCT04704479|DEVICE|EMT|patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
219725977|NCT04092764|DEVICE|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
219725978|NCT04092764|DEVICE|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
219153905|NCT02765100|DRUG|Minocycline|Minocycline 100 mg twice a day
219153906|NCT00961831|DRUG|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
219153907|NCT00961831|DRUG|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
219153908|NCT02675244|PROCEDURE|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
219153909|NCT02675244|PROCEDURE|MVS|MVS will be performed using standard surgical techniques
219153910|NCT00081601|DRUG|CEP-701|
219153911|NCT00162422|DRUG|albuterol|
219153912|NCT02652442|BEHAVIORAL|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
219153913|NCT02652442|BEHAVIORAL|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
219153914|NCT02652442|BEHAVIORAL|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
219153915|NCT04003259|BEHAVIORAL|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
219153916|NCT01065506|BEHAVIORAL|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
219153917|NCT01065506|DRUG|Nicotine Patch|Nicotine Patch
219153918|NCT01065506|BEHAVIORAL|Wellness Program|Wellness Program
219153919|NCT01065506|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise
219153920|NCT02949583|DRUG|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
219153921|NCT02949583|DRUG|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
219153922|NCT03931265|DIAGNOSTIC_TEST|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
219153923|NCT05173324|BIOLOGICAL|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
219153924|NCT05173324|DIAGNOSTIC_TEST|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
219153925|NCT05173324|BIOLOGICAL|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
219153926|NCT00098553|DRUG|everolimus|
219153927|NCT00534183|DRUG|Olanzapine|Olanzapine in dose range of 10-20mg
219153928|NCT00534183|DRUG|Risperidone|Risperidone 1-6mg
219153929|NCT00534183|DRUG|Haloperidol|Haloperidol 10-20mg
219153930|NCT00293293|OTHER|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
219153931|NCT00293293|OTHER|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
219725979|NCT04092764|DEVICE|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
219725980|NCT01935804|DRUG|Pioglitazone|30 mg/daily for 12 months
219725981|NCT01935804|DRUG|Metformin|850 mg/daily for 12 months
219725982|NCT02213575|DRUG|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and 26 week follow-up MRI and PET scans for changes in the paraventricular nucleus.
219725983|NCT03731143|PROCEDURE|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
219725984|NCT02679105|DRUG|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
219725985|NCT02679105|DRUG|ALK diluent|0,3% human albumin
219725986|NCT06098547|PROCEDURE|Liver transplantation|"Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).~Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis."
219725987|NCT00421993|DRUG|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
219725988|NCT00421993|DRUG|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
219725989|NCT00421993|DRUG|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
219725990|NCT00421993|DRUG|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
219725991|NCT03630601|PROCEDURE|Photoacoustic Imaging|Undergo PAI
219725992|NCT06323993|PROCEDURE|Piezoelectric osteotomy|The piezoelectric technique, another window preparation procedure that does not use a round bur, was first introduced to LSFE in 2001 for its high accuracy of osteotomy and low rate of membrane perforation. Later studies demonstrated that the operation time, postoperative reactions, and perforation rate of this procedure are considered to be acceptable compared with rotary bur. Moreover, the piezoelectric technique allows for the lateral bone window to be cut and preserved relatively completely.
219725993|NCT00589264|DIETARY_SUPPLEMENT|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
219725994|NCT00589264|DIETARY_SUPPLEMENT|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
219153932|NCT00293293|OTHER|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
219153933|NCT00293293|DRUG|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
219153934|NCT05384210|DRUG|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
219153935|NCT05384210|DRUG|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
219153936|NCT05384210|DRUG|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
219153937|NCT06383117|DIETARY_SUPPLEMENT|Calcium carbonate|2 capsules containing 600 mg of calcium carbonate each
219153938|NCT06383117|DIETARY_SUPPLEMENT|Placebo Control|2 capsules containing methylcellulose
219153939|NCT02988817|BIOLOGICAL|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
219153940|NCT05369169|BEHAVIORAL|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
219153941|NCT05369169|BEHAVIORAL|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
219725995|NCT03569462|BEHAVIORAL|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
219725996|NCT03569462|BEHAVIORAL|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
219153942|NCT04597658|BEHAVIORAL|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
219153943|NCT04597658|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
219153944|NCT05881317|DEVICE|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
219153945|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis|Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
219153946|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis and acute kidney injury|Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
219725997|NCT03033628|DEVICE|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
219153947|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine miRNA and biochemical parameters|Laboratory examination will be performed to determine miRNA and biochemical parameters.
219153948|NCT04967742|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
219153949|NCT01336946|BEHAVIORAL|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
219153950|NCT01336946|BEHAVIORAL|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
219153951|NCT05945017|DIETARY_SUPPLEMENT|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
219153952|NCT06383793|PROCEDURE|overlap|Π
219153953|NCT01248260|DIETARY_SUPPLEMENT|Folic Acid|4mg of higher strength folic acid once a day until delivery
219153954|NCT00721565|BEHAVIORAL|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
219153955|NCT04238793|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
219153956|NCT04238793|OTHER|Placebo|Normal Saline (0.9%) administered by transforaminal epidural injection
219153957|NCT05199142|DRUG|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
219153958|NCT05199142|DRUG|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
219153959|NCT00946842|DRUG|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
219153960|NCT00946842|DRUG|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
219153961|NCT00946842|DRUG|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
219725998|NCT03033628|DEVICE|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
219153962|NCT00946842|DRUG|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
219153963|NCT00946842|DRUG|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
219153964|NCT00946842|DRUG|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
219153965|NCT01504659|DRUG|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
219153966|NCT01504659|DRUG|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
219153967|NCT04691024|OTHER|Exercise|Spinal stabilization exercises
219153968|NCT04055246|DIETARY_SUPPLEMENT|Inulin|9 grams of food grade inulin added to custom made fiber bars.
219153969|NCT04055246|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
219153970|NCT03674034|OTHER|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
219360774|NCT01160939|OTHER|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
219725999|NCT04079959|PROCEDURE|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
219726000|NCT01980888|DRUG|Idelalisib|150 mg tablet administered orally twice daily
219726001|NCT01980888|DRUG|Bendamustine|Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
219726002|NCT01980888|DRUG|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
219726003|NCT01980888|DRUG|Placebo|Placebo to match idelalisib administered orally twice daily
219726004|NCT03990753|DIAGNOSTIC_TEST|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
219726005|NCT02990962|DRUG|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
219153971|NCT01781585|PROCEDURE|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
219153972|NCT03733119|DRUG|Akt/ERK Inhibitor ONC201|Given PO
219153973|NCT03733119|DIETARY_SUPPLEMENT|Methionine-Restricted Diet|Given PO
219153974|NCT04702256|DRUG|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
219153975|NCT04702256|DRUG|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
219153976|NCT04702256|DRUG|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
219153977|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
219360775|NCT02160392|PROCEDURE|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
219726006|NCT02990962|DRUG|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
219726007|NCT04569370|PROCEDURE|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
219726008|NCT03969420|DRUG|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
219726009|NCT03969420|DRUG|Alvocidib (flavopiridol)|Administered intravenously
219726010|NCT05835700|OTHER|Gasdermin-d|Maternal serum Gasdermin-D levels in preterm labor and healthy pregnant women.
219726011|NCT06470724|BEHAVIORAL|Structural visual approach|"The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient."
219726012|NCT01197027|BEHAVIORAL|Standard counseling|Standard HIV counseling
219726013|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
219726014|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
219726015|NCT05068115|PROCEDURE|Clinical characteristics, diagnosis and treatment, survival status|Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
219726016|NCT05363800|DRUG|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
219726017|NCT02469909|OTHER|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
219726018|NCT02469909|OTHER|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
219726019|NCT02469909|OTHER|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
219726020|NCT02469909|PROCEDURE|immediate decannulation|the tracheostomy tube is removed at once
219726021|NCT02469909|PROCEDURE|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
219726022|NCT04333459|BIOLOGICAL|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
219726023|NCT06612203|DRUG|Debio 0123 and Sacituzumab govitecan|Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
219726024|NCT06989762|DEVICE|Conventional Foley Catheter(Medline)|The Conventional Foley Catheter is a standard urinary catheter used in ICU care to monitor urine output. It does not have intra-abdominal pressure (IAP) monitoring capabilities.
219726025|NCT06989762|DEVICE|Accuryn Foley Catheter|The Accuryn Foley Catheter is an FDA-approved urinary catheter with continuous intra-abdominal pressure (IAP) monitoring capability.
219726026|NCT06307080|DEVICE|Multi-mode thermal ablation device|The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
219726027|NCT06307080|DRUG|Intravenous anti-PD-1 and chemotherapy|intravenous anti-PD-1 and chemotherapy
219726028|NCT06993389|OTHER|Inapplicable|Inapplicable
219726029|NCT04978779|DRUG|VIP152|Weekly IV infusion for 28 day cycles.
219726030|NCT04978779|DRUG|BTKi|Taken per local prescribing information
219726031|NCT06675578|DRUG|Tulsi gel|After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
219726032|NCT06675578|DRUG|Chlorhexidine gel|After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
219153978|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
219153979|NCT02253537|DEVICE|CST001|
219153980|NCT00192946|PROCEDURE|Temporary cardiac resynchronization therapy|
219153981|NCT02545036|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
219153982|NCT05957016|PROCEDURE|CIETAI-R|"1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w"
219153983|NCT04750044|OTHER|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
219233294|NCT05597618|OTHER|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~1. Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~2. Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
219233295|NCT03083678|DRUG|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
219726033|NCT04851717|DRUG|Remimazolam|Remimazolam for intravenous sedation
219726034|NCT07008534|PROCEDURE|Patients receiving computer-guided immediate implant placement and inferior alveolar nerve (IAN) lateralization only.|Standard procedure without Sticky Bone application.
219726035|NCT07008534|PROCEDURE|IAN lateralization with computer-guided immediate implant placement using Sticky Bone|The same as the control with additional application of Sticky Bone as an insulator for enhanced neurosensory disfunction
219726036|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Pain Intensity 3a|PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
219726037|NCT06627582|BEHAVIORAL|PROMIS 29+2|PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
219153984|NCT04750044|OTHER|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
219153985|NCT04960098|PROCEDURE|arthroplasty|patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
219153986|NCT02678936|BIOLOGICAL|PRP|Application of platelet-rich plasma during surgery
219153987|NCT02618486|PROCEDURE|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
219153988|NCT00661869|OTHER|Wellness Program|36 weeks of educational and supportive interventions
219153989|NCT02387242|DRUG|Rifampicin|Single oral dose of rifampicin
219153990|NCT01839526|DRUG|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
219153991|NCT04445870|OTHER|data record|Data record on registers without medical files
219726038|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Nociceptive Pain Quality 5a|5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
219726039|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Neuropathic Pain Quality 5a|5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
219726040|NCT05482165|BEHAVIORAL|Multi-faceted health promotion programme|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses"
219726041|NCT03630354|BEHAVIORAL|Exercise Intervention (supervised)|Complete supervised exercise
219726042|NCT03630354|BEHAVIORAL|Exercise Intervention (unsupervised)|Complete unsupervised exercise
219726043|NCT03630354|OTHER|Informational Intervention|Receive instructional DVD
219726044|NCT03630354|OTHER|Questionnaire Administration|Ancillary studies
219726045|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using the FARAPULSE pulsed high voltage electrical field system in patients with atrial fibrillation|Standard of care 4 pulsed electrical field applications in basket shape and 4 applications in flower shape
219153992|NCT00244959|DRUG|anastrozole|1 mg orally daily for 12 months
219153993|NCT00244959|PROCEDURE|adjuvant therapy|treatment received after breast cancer surgery
219153994|NCT04629625|BIOLOGICAL|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
219153995|NCT04629625|BIOLOGICAL|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
219153996|NCT04629625|BIOLOGICAL|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
219153997|NCT00903851|DRUG|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
219153998|NCT02148185|DRUG|MT-1303|
219153999|NCT02773524|DRUG|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
219154000|NCT02773524|OTHER|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
219154001|NCT05096559|DEVICE|Microcirculation cytocam|Visualization of tongue microcirculation
219154002|NCT04907513|OTHER|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
219154003|NCT02318407|DRUG|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
219154004|NCT02318407|DRUG|Placebo|contains no active drug
219154005|NCT05457049|DIAGNOSTIC_TEST|Molecular residual disease test|OncoMRD Lung
219154006|NCT01634516|BEHAVIORAL|Dietary support|Face to face intervention plus subsequent telephone support
219154007|NCT01634516|BEHAVIORAL|No dietary support|No face to face intervention or subsequent telephone support
219154008|NCT02894658|DEVICE|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
219154009|NCT02894658|PROCEDURE|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
219154010|NCT03231358|BEHAVIORAL|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. Participants receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
219154011|NCT02804425|OTHER|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
219154012|NCT06028282|RADIATION|SPECT|SPECT of thyroid traced with I-131
219154013|NCT06143371|BIOLOGICAL|CAN10|Single dose intravenous or Multiple doses subcutaneously
219154014|NCT06143371|BIOLOGICAL|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
219154015|NCT02972944|PROCEDURE|Laparoscopic cholecystectomy|
219154016|NCT02972944|PROCEDURE|Non-operative treatment|
219233296|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
219233297|NCT05267951|DEVICE|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
219726046|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using a pentaspline pulsed high voltage electrical field system in patients with atrial fibrillation|Experimental treatment delivering 2 pulsed electrical field applications in olive shape, 4 in basket shape and 6 applications in flower shape
219726047|NCT06687928|BIOLOGICAL|CT-P6 SC|A single fixed dose (600 mg) of CT-P6 subcutaneous
219726048|NCT06687928|BIOLOGICAL|EU-Approved Herceptin SC|A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous
219233298|NCT05267951|DEVICE|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
219726049|NCT06870149|OTHER|Dance Rehabilitation Intervention|Cognitive Groove (GERAS DANCE) presents a novel approach to increasing or maintaining independence and quality of life by improving physical performance and mobility using reminiscent music and rhythmic movement in a fun, safe environment. Cognitive Groove was designed to meet the complex needs of older adults with frailty. Our pilot quasi-experimental studies have demonstrated Cognitive Groove results in clinically significant improvements in walking speed by 0.1 m/s with enhanced temporal-spatial walking parameters and improved lower extremity function, including balance and chair stands.
219726050|NCT07020546|PROCEDURE|Ovarian Platelet-rich plasma (PRP) injections|This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
219726051|NCT07022938|DIETARY_SUPPLEMENT|Epineuron|Palmitoylethanolamide (PEA, 300 mg), Superoxide Dismutase (SOD, 70 UI), Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2.5 mg) in one tablet
219726052|NCT07022938|DIETARY_SUPPLEMENT|Placebo Tablets|placebo tablet without active ingredients
219726053|NCT05604313|DEVICE|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
219726054|NCT01537367|BEHAVIORAL|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
219726055|NCT01537367|BEHAVIORAL|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
219726056|NCT01537367|BEHAVIORAL|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
219726057|NCT06453460|DRUG|Letermovir|Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
219154017|NCT05702775|PROCEDURE|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
219154018|NCT05209581|DIAGNOSTIC_TEST|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
219154019|NCT06154746|DIAGNOSTIC_TEST|slit lamb & OCT|"1. The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~2. OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
219154020|NCT04470375|BEHAVIORAL|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
219154021|NCT02239913|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
219154022|NCT02239913|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
219154023|NCT02239913|DRUG|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
219154024|NCT02239913|DRUG|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
219154025|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
219154026|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
219154027|NCT00807937|DRUG|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
219154028|NCT00807937|DRUG|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
219154029|NCT03888768|DRUG|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
219154030|NCT00255359|DRUG|XTL-2125|
219154031|NCT04625231|BEHAVIORAL|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
219154032|NCT05712993|PROCEDURE|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
219154033|NCT00575614|DRUG|prucalopride|1 mg o.d.
219154034|NCT00575614|DRUG|placebo|o.d.
219154035|NCT04139434|DRUG|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
219154036|NCT04139434|DRUG|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
219154037|NCT03877250|DIAGNOSTIC_TEST|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
219233299|NCT05267951|OTHER|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
219233300|NCT03786471|OTHER|Health System-based Dementia Care|Active comparator
219726058|NCT06453460|DEVICE|CMV T Cell Immunity Panel (CMV-TCIP)|Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
219726059|NCT06453460|DIAGNOSTIC_TEST|CMV DNA PCR|Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
219726060|NCT07039734|OTHER|collection of data from medical records|collection of data from medical records
219726061|NCT07040956|DRUG|Tislelizumab|200mg IV Q3W
219726062|NCT07040956|DRUG|Afatinib|Targeted therapy
219726063|NCT07040956|RADIATION|Low dose radiotherapy|Radiotherapy
219726064|NCT07040475|OTHER|Inpatient TCIM therapy|This multicenter, prospective, uncontrolled observational study is evaluating the effects and safety of inpatient TCIM therapy (German: naturheilkundliche Komplextherapie) at three German clinics: Immanuel Hospital Berlin, Klinikum Bamberg, and Evangelical Clinics Essen-Mitte. This therapy, reimbursed by statutory health insurance under certain conditions, combines evidence-informed TCIM approaches such as hyperthermia, exercise therapy, phytotherapy, and dietary interventions including fasting i.a.
219726065|NCT07043361|DRUG|semaglutide|testing the effect of baseline vitamin D on metabolic effects of semaglutide
219154038|NCT03877250|DIAGNOSTIC_TEST|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
219154039|NCT03877250|DIAGNOSTIC_TEST|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
219154040|NCT03877250|DIAGNOSTIC_TEST|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
219154041|NCT06408662|OTHER|mindfulness-based intervention for tics (MBIT)|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practice
219154042|NCT06408662|OTHER|psychoeducation with relaxation and supportive therapy (PRST)|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
219154043|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
219154044|NCT03630055|DRUG|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
219233301|NCT03786471|OTHER|Community-based Dementia Care|Active comparator
219726066|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 4-step egg ladder (muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
219154045|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
219154046|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
219154047|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
219154048|NCT04104776|DRUG|Tulmimetostat|Tulmimetostat dosed once per day orally in 28 day cycles
219154049|NCT04104776|DRUG|Enzalutamide|Enzalutamide dosed once per day orally in 28 day cycles
219726067|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 5-step egg ladder (muffin \[0.75 g of hen's egg protein per portion\], muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
219726068|NCT07047001|DRUG|Vorolanib Tablets|200mg PO QD
219154050|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
219154051|NCT03337399|OTHER|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
219154052|NCT03337399|OTHER|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
219154053|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
219233302|NCT03786471|OTHER|Usual Care|Control
219233303|NCT03346200|DRUG|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
219233304|NCT03346200|DRUG|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
219726069|NCT07047001|DRUG|Vorolanib + Toripalimab|"Vorolanib: 100mg PO QD~Toripalimab: 240mg IV infusion Q3W"
219726070|NCT07046507|DIAGNOSTIC_TEST|Diagnostic procedures|Diagnostic ability of optical coherence tomography in kayser fleischer rings
219726071|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation|Before induction of anaesthesia, electrodes were attached to selected acupoints and energised for 30 min, with the electrical stimulation parameter of dispersed dense wave (2/100 Hz), and the current intensity was based on the maximum current intensity that could be tolerated by the patient.
219154054|NCT04802148|PROCEDURE|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
219233308|NCT04174378|DRUG|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
219233309|NCT04953793|BEHAVIORAL|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
219233310|NCT04953793|OTHER|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
219726072|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation combined with auricular vagus nerve stimulation|Before anaesthesia induction, the electrodes were attached to the selected acupoints and energized for 30 min, with the electrical stimulation parameters of dispersed dense wave (2/100Hz), and the current intensity was based on the maximum current intensity that the patient could tolerate. At the same time, the left ear auricular region was stimulated with a fasciculus nerve stimulator, the electrical stimulation parameters were: pulse width of 250 μs, pulse frequency of 20Hz, every 30s on, 30s off, and then 30s on again, the current intensity was based on the maximum current intensity that the patient could tolerate, for 30min.
219726073|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - traditional|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises, (5) lip and tongue strengthening, (6) practicing a physiological swallowing act.
219726074|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - reduced|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises.
219726075|NCT07045779|BEHAVIORAL|Vocal warm up|The sham treatment program will include exercises from an evidence-based vocal warm up program, with exclusion of the exercises that include active involvement of the tongue or lips. Exercises that will be included are: open mouth approach, glottal fry, producing ascending and descending tones and the hand-over-mouth technique. These exercises aim to improve the dynamics of the extrinsic and intrinsic laryngeal muscles and therefore are expected not to interfere with the content of the OMT program. Furthermore, exercises regarding body posture (no focus on articulators), relaxation and voice onset will be included. This sham treatment program will be provided by the same speech-language pathologist with comparable motivation techniques as those applied in the real OMT programs.
219726076|NCT06726876|DIETARY_SUPPLEMENT|Manuka honey oral rinse.|"Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte"
219233311|NCT01510314|BIOLOGICAL|C-reactive protein and procalcitonin dosages|
219154055|NCT04802148|PROCEDURE|collagen plug|after tooth extraction, the socket was filled with collagen plug
219154056|NCT02537483|DRUG|IDP-120 Gel|Investigational Product: IDP-120 Gel
219154057|NCT02537483|DRUG|IDP-120 Component A|Comparator Product: IDP-120 Component A
219154058|NCT02537483|DRUG|IDP-120 Component B|Comparator Product: IDP-120 Component B
219154059|NCT02537483|DRUG|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
219154060|NCT03588715|DRUG|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
219154061|NCT03588715|DRUG|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
219154062|NCT03083197|DRUG|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
219154063|NCT03083197|DRUG|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
219154064|NCT03083197|DRUG|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
219154065|NCT01703897|DEVICE|Manometry and Impedance analysis|
219154066|NCT05155917|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
219154067|NCT00879463|PROCEDURE|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
219726077|NCT06726876|DRUG|Normal saline rinses.|"Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm."
219726078|NCT07047547|DRUG|Vericiguat|Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.
219726079|NCT06733493|BEHAVIORAL|integrated psychosocial care|Employment of a psychologist in psychotherapeutic training as a member of the multiprofessional team at the ICU ward for the duration of one year. Tasks: Psychosocial Support for staff, patients and their relatives.
219726080|NCT07056855|DRUG|nano hydroxy apatite varnish Intervention (1)|Fygg's professional strength, Fygg, USA
219726081|NCT07056855|DRUG|Potassium Nitrate Gel|Ultradent UltraEZ Desensitizing Gel, Ultradent Inc., USA
219726082|NCT07056855|DRUG|Varnishes, Fluorid|DentKist Charm Varnish 5% Sodium Fluoride Varnish
219726083|NCT07055633|DEVICE|CCT+MBLT|Compensatory Cognitive Training + Morning Bright Light Therapy (Aurora LightPad)
219154068|NCT00879463|PROCEDURE|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
219154069|NCT00510887|DRUG|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
219154070|NCT00510887|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
219154071|NCT00510887|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
219154072|NCT00510887|DRUG|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
219154073|NCT00510887|DRUG|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
219154074|NCT05010655|DEVICE|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
219154075|NCT04783012|PROCEDURE|Catheter removal|Catheter management strategy after surgery
219154076|NCT02882698|BEHAVIORAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
219154077|NCT02882698|BEHAVIORAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
219154078|NCT02882698|BEHAVIORAL|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
219154079|NCT02882698|BEHAVIORAL|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
219154080|NCT06473090|OTHER|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
219154081|NCT06473090|OTHER|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
219154082|NCT01628419|BEHAVIORAL|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
219154083|NCT01828775|OTHER|palliative care|Receive early PCI
219154084|NCT01828775|OTHER|palliative care|Receive delayed PCI
219154085|NCT01828775|PROCEDURE|quality-of-life assessment|Ancillary studies
219154086|NCT01828775|OTHER|survey administration|Ancillary studies
219154087|NCT03100513|DRUG|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
219154088|NCT03100513|DRUG|Polyethylene Glycol|PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
219154089|NCT01542229|BEHAVIORAL|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
219154090|NCT01542229|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
219154091|NCT00254657|DRUG|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
219154092|NCT00254657|DRUG|Placebo|
219154093|NCT03038217|DRUG|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
219726084|NCT07055633|DEVICE|CCT+ION|Compensatory Cognitive Training + Negative Ion Generator (SphereOne)
219726085|NCT07055971|BEHAVIORAL|Experimental: Pain Neuoescience Education Group|The experimental group will receive a pain neuroscience education (PNE) intervention delivered through an in-person, didactic educational model in small groups of 5 to 10 patients. PNE sessions will be conducted once per week for 6 weeks, each lasting approximately 45 to 60 minutes, by a physiotherapist with extensive clinical experience and specialized training in PNE. The content of the sessions will be based on models described in previous studies. Patients will receive detailed information on the neurophysiology and neurobiology of chronic pain and its relationship to fibromyalgia (FM). Pre-prepared PowerPoint presentations will be used to deliver the material in an accessible and engaging manner, employing images, metaphors, anecdotes, and stories to facilitate understanding. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks.
219154094|NCT03038217|PROCEDURE|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
219154095|NCT03038217|PROCEDURE|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
219154096|NCT03038217|OTHER|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
219154097|NCT00971906|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
219154098|NCT00220272|DRUG|SR57667B|
219154099|NCT02214550|DRUG|cyclic microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
219154100|NCT02214550|DRUG|continuous microgestin 1/20|Continuous OC use - Pills containing hormones will be taken every day for 1 year
219154101|NCT04711213|DRUG|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
219154102|NCT04711213|DRUG|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
219154103|NCT04711213|DRUG|Placebo Dose 1|Placebo suspension dose 1
219154104|NCT04711213|DRUG|Placebo Dose 2|Placebo suspension dose 2
219154105|NCT04304924|OTHER|The personalized telephone based intervention|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
219154106|NCT03876249|OTHER|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
219154107|NCT00370019|DRUG|Estradiol/Medroxyprogesterone acetate|
219154108|NCT05238480|DEVICE|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
219154109|NCT05238480|DEVICE|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
219154110|NCT02615769|BEHAVIORAL|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
219726086|NCT07055971|BEHAVIORAL|Active Comparator: Biomedical Education Group|The control group will receive two sessions of biomedical education and general guidance on chronic pain and its management, delivered in small groups of 5 to 10 patients with a duration about 45-60 minute. These sessions will also be conducted by the same physiotherapist who delivers the intervention sessions. Both groups will be instructed to continue their usual care and will be encouraged to engage in therapeutic exercise tailored to their physical limitations. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks
219726087|NCT07055789|OTHER|Combined respiratory muscle training, incorporating both inspiratory and expiratory muscle training|IMT: Inspiratory Muscle Training EMST: Expiratory Muscle Strength Training RMST: Respiratory Muscle Strength Training In this trial we are combining both IMT and EMST in the intervention group.
219154111|NCT02615769|BEHAVIORAL|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
219154112|NCT01981174|PROCEDURE|30-gauge needle|
219154113|NCT01981174|PROCEDURE|32-gauge needle|
219154114|NCT01130246|DRUG|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
219154115|NCT01130246|DRUG|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
219154116|NCT00367159|PROCEDURE|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
219154117|NCT00094822|OTHER|PI Discretion|PI Discretion
219154118|NCT01369004|BEHAVIORAL|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
219154119|NCT05950542|DRUG|Baricitinib|JAK inhibit0rs
219154120|NCT01897870|BEHAVIORAL|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
219154121|NCT03485950|DRUG|Cefepime|Given IV
219154122|NCT03485950|DRUG|Ceftolozane|Given IV
219154123|NCT03485950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219154124|NCT03485950|DRUG|Meropenem|Given IV
219154125|NCT03485950|DRUG|Piperacillin-Tazobactam|Given IV
219154126|NCT03485950|DRUG|Tazobactam|Given IV
219154127|NCT05208125|BIOLOGICAL|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
219154128|NCT05208125|OTHER|Normal saline solution|Intramuscular administration of normal saline solution
219726088|NCT07055997|DEVICE|Robotic-assisted needle localization|Robot-assisted needle localization involves the use of a robotic system to assist with the percutaneous localization of pulmonary nodules under CT guidance. The robotic system provides real-time navigation and increased precision during needle placement, reducing the variability in positioning and improving the accuracy of localization. The system offers automatic adjustments to the needle's trajectory, minimizing the need for manual corrections, and potentially reducing the number of CT scans required. This method is designed to enhance the overall localization success rate and reduce complications associated with traditional manual techniques.
219726089|NCT07055997|PROCEDURE|Manual needle localization|Manual needle localization involves the traditional technique of percutaneous localization of pulmonary nodules under CT guidance without the assistance of robotic systems. The procedure is performed by the physician manually guiding the needle based on real-time CT imaging. The physician adjusts the needle position based on visual cues from the CT scan, which may require multiple attempts for accurate localization.
219726090|NCT07055828|DRUG|Ketamine|Patients received IV ketamine 0.25 mg/kg before Spinal anesthesia as a prophylactic drug
219726091|NCT07055828|DRUG|Intranasal ketamine|Patients received nebulized ketamine at a dose of 0.75 mg/kg adjusted to 5 ml by adding normal saline to be inhaled through a breath-actuated nebulizer
219726092|NCT07055828|DRUG|Normal Saline|Patients received Intravenous Normal saline
219726093|NCT07055828|DRUG|Saline Inhalants|Patients received nebulized Saline
219726094|NCT07055802|COMBINATION_PRODUCT|Inversion Table|Inversion Table group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given an inversion table therapy as a treatment at the angle of 60' for 5 minutes in every session. Two follow ups in a week were taken for total of 04 weeks. Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
219726095|NCT07055802|COMBINATION_PRODUCT|Mulligan flexion biased exercises|experimental group named as Mulligan group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given mulligan technique. It was done at level just below ASIS (at level of L4-L5 spinous process), ten times/session, for 12 sessions three/week every other day for 4 weeks. . Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
219726096|NCT07057362|OTHER|Intraoperative Hemodynamic Monitoring|Continuous intraoperative monitoring of systolic blood pressure and heart rate following spinal anesthesia. Vasopressor usage and total fluid administration will be recorded.
219726097|NCT07056257|PROCEDURE|Scaling-root planning (SRP)|Thirteen sites \[scaling-root planning (SRP)\] were used as a control group.
219726098|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy|Thirteen sites \[scaling-root planning (SRP)+ laser therapy with application of methyl cellulose gel at repeated times weekly for one month\].
219726099|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ omega 3 gel|Thirteen sites \[scaling-root planning (SRP) + omega 3 gel repeated time weekly for one month\].
219726100|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy+ omega 3 gel|Thirteen sites \[combination therapy between scaling-root planning (SRP) + laser + omega 3 gel in repeated time weekly for one month\].
219154129|NCT03011489|DEVICE|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
219154130|NCT00103324|DRUG|lapatinib ditosylate|Given orally
219154131|NCT00103324|OTHER|laboratory biomarker analysis|Correlative studies
219154132|NCT06514937|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
219154133|NCT02142751|DRUG|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
219154134|NCT02142751|DRUG|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
219154135|NCT02142751|DRUG|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
219154136|NCT04350567|OTHER|Sleep Deprivation|On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
219154137|NCT05528380|BEHAVIORAL|LPA + Fitbit Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
219154138|NCT05528380|BEHAVIORAL|Fitbit Only|Participants will receive a Fitbit to track activity levels and participate in 6 brief check-ins to assess any issues with the Fitbit device or app.
219154139|NCT06970847|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA
219154140|NCT05304377|DRUG|ELVN-001|orally once or twice daily
219154141|NCT06130020|BEHAVIORAL|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
219154142|NCT06130020|BEHAVIORAL|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
219154143|NCT06130020|BEHAVIORAL|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
219154144|NCT06645665|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
219154145|NCT06645665|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219154146|NCT04110743|DEVICE|EXPLORER PET/CT|Intervention: PET/CT using different protocols
219154147|NCT04764006|DRUG|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
219154148|NCT04474379|BEHAVIORAL|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
219154149|NCT04821219|OTHER|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
219154150|NCT02133404|DRUG|ASP7991|oral
219154151|NCT02133404|DRUG|Cinacalcet|oral
219154152|NCT02133404|DRUG|Placebo|oral
219154153|NCT01788930|DEVICE|CPAP|
219154154|NCT00979537|DRUG|Nisoldipine Extended-release Tablets, 40 mg|
219154155|NCT00979537|DRUG|Sular Tablets, 40 mg|
219154156|NCT03302819|DIAGNOSTIC_TEST|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
219154157|NCT05908942|DEVICE|Nerve ablation|radiofrequency and phenol ablation of the genicular nerves will be performed
219154158|NCT00390299|BIOLOGICAL|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
219154159|NCT00390299|OTHER|Laboratory Biomarker Analysis|Correlative studies
219154160|NCT00390299|PROCEDURE|Therapeutic Conventional Surgery|Undergo en bloc resection
219154161|NCT00134446|DEVICE|transcranial magnetic stimulation|
219154162|NCT04661410|BEHAVIORAL|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
219233312|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
219233313|NCT05996458|OTHER|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
219233314|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
219233315|NCT00747149|DRUG|Rosuvastatin|Oral
219726101|NCT07057336|DRUG|Conventional Calcium Hydroxide (CH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Conventional calcium hydroxide was retained for 7 days before final obturation.
219726102|NCT07057336|DRUG|Nanocalcium Hydroxide (NCH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Nanocalcium hydroxide was retained for 7 days before final obturation.
219726103|NCT07056660|DEVICE|Active CAP therapy|The CAP group will additionally undergo atmospheric pressure cold plasma (CAP) treatment (plasma-activated gas form, CAP-Activated Gas; patent number: ZL202110209052.X, provided by Xi'an Jiaotong University), once daily for the first five days and every other day thereafter, for a total of 13 sessions. Each session will involve enclosing the target area in a treatment bag sealed with medical adhesive tape; plasma-activated gas rich in ozone (O₃) will be delivered and recirculated for 20 minutes, followed by plasma-activated gas rich in nitric oxide (NO) for an additional 5 minutes, in strict accordance with the standard operating procedures provided by the manufacturer.
219726104|NCT07056660|DEVICE|Sham CAP therapy|In the placebo group, the electric field for plasma generation will remain off, so no plasma will be produced; only operational sounds will be simulated to maintain procedural blinding.
219726105|NCT07056660|OTHER|standard care|The group will receive standard care according to current clinical guidelines
219154163|NCT04661410|BEHAVIORAL|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
219154164|NCT00235508|DRUG|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
219154165|NCT02751138|PROCEDURE|Surgery|Tumor resection
219154166|NCT01898741|RADIATION|24 Gy in 3 fractions|
219154167|NCT05887180|OTHER|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
219154168|NCT00731185|DRUG|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
219154169|NCT00731185|DRUG|Placebo|
219154170|NCT04718688|OTHER|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
219154171|NCT02517450|BEHAVIORAL|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
219154172|NCT02517450|OTHER|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
219154173|NCT03592069|DRUG|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
219154174|NCT03592069|DRUG|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
219154175|NCT02512341|DEVICE|Computer Aided Auscultation (CAA)|
219154176|NCT02665988|DEVICE|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
219154177|NCT02665988|DEVICE|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
219154178|NCT05517564|DRUG|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
219154179|NCT05517564|OTHER|Placebo|Placebo-to-match GM-60106 capsules
219726106|NCT07056010|PROCEDURE|curative minimally invasive gastrectomy with D2+PAND lymphadenectomy|Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer, presenting with PAN metastasis (No. 16 lymph nodes ≥10 mm), will be enrolled. Participants will receive four cycles of conversion immunochemotherapy with a PD-1 inhibitor (Serplulimab) combined with the SOX chemotherapy regimen (oxaliplatin and S-1). After completion of conversion therapy, patients will undergo curative minimally invasive (laparoscopic or robotic) gastrectomy with D2+PAND lymphadenectomy.
219726107|NCT07057284|RADIATION|Orthopantomogram (or a set of Lateral Oblique Radiographs)|A dental assessment will be conducted on eligible participants who still attend annual review appointments in the Oncology Departments at the Royal Manchester Children's Hospital or at The Christie NHS Foundation Trust (approximately 10% of eligible study population). The dental assessment will include the following: a tooth chart, a basic periodontal examination (BPE), a brief orthodontic assessment (incisor, molar and skeletal classification including any asymmetry), caries assessment and an assessment of any dental development disturbances. Clinical photographs of the teeth and face will be taken with a patient's consent. If clinically justified, an OPT will be taken. If cooperation for an OPT proves challenging, lateral obliques as an alternative radiographic image modality will be considered.
219726108|NCT07055659|DIAGNOSTIC_TEST|Oral hygiene assessment|experimental group will be given a plant to water it during 2-minute brushing habit. number of decayed teeth and and status of gingiva with the amount of plaque will be compared between the groups
219726109|NCT07056218|DEVICE|neck ultrasound|ultrasound scan
219726110|NCT07056218|DIAGNOSTIC_TEST|thyroglobulin|blood test
219726111|NCT07051239|OTHER|Closed-loop acoustic stimulation|At-home sleep will be monitored using an EEG headband. Non-awakening auditory stimuli will be delivered during non-rapid eye movement sleep (NREM), timed to the ascending phase of slow waves, using either active or control (sham) conditions.
219726112|NCT07052513|DRUG|Placebo|Intravenous infusion of normal saline.
219726113|NCT07052513|DRUG|M2RLAB 001|Intravenous infusion of M2RLAB 001
219726114|NCT07056270|OTHER|static CT scans|Patients with chronic liver disease and liver cancer received static CT scans before hepatectomy to establish a high-definition CT database.
219726115|NCT01030900|BIOLOGICAL|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
219154180|NCT00970359|BIOLOGICAL|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
219154181|NCT04572191|DIAGNOSTIC_TEST|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
219154182|NCT02095184|DRUG|Anastrozole|1 mg daily
219154183|NCT02095184|DRUG|Letrozole|2.5 mg daily
219154184|NCT01294033|OTHER|Fractional inspired oxygen (FiO2) 0.21|
219154185|NCT01294033|OTHER|Fractional inspired oxygen 0.28|Supplemental oxygen
219726116|NCT01030900|BIOLOGICAL|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
219726117|NCT01030900|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
219726118|NCT05497323|DRUG|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
219154186|NCT05684094|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
219154187|NCT05684094|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
219154188|NCT05498818|DIETARY_SUPPLEMENT|Synaquell|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
219154189|NCT05498818|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
219154190|NCT03268577|OTHER|Internet-Based Intervention|Complete ASA24
219154191|NCT03268577|OTHER|Internet-Based Intervention|Complete ACT24 reporting
219154192|NCT03268577|DEVICE|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
219154193|NCT03268577|OTHER|Questionnaire Administration|Ancillary studies
219154194|NCT01429350|DRUG|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
219154195|NCT01429350|DEVICE|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
219154196|NCT00288392|DRUG|Soluble beta-1,3/1,6-glucan|
219154197|NCT04526834|DRUG|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
219154198|NCT02990117|OTHER|No Intervention|No Intervention
219154199|NCT05817097|DRUG|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
219154200|NCT03161327|DEVICE|ABI using QuantaFlo™|"Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
219154201|NCT02699385|OTHER|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
219154202|NCT02699385|DRUG|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
219154203|NCT02699385|DRUG|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
219154204|NCT00088413|BIOLOGICAL|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
219726119|NCT05497323|DRUG|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
219726120|NCT02485769|DRUG|PF-06650833|Suspension
219726121|NCT02485769|DRUG|Placebo|Suspension
219726122|NCT02485769|DRUG|PF-06650833|Tablet (Modified Release)
219726123|NCT02485769|DRUG|Placebo|Tablet (Modified Release)
219726124|NCT07056114|OTHER|The patients with active or inactive TED|The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score
219726125|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training + Core Stability Exercises|"Participants in Group A will engage in a combined program focusing on upper limb strengthening and trunk stabilization. The core stability component aims to improve neuromuscular control and trunk endurance, while the resistance training targets upper limb muscle strength and shoulder stability.~Core Stability Exercises:~Exercise Description Duration/Repetitions Planks Holding a straight-body position on elbows and toes. 30-60 seconds Bird-Dog Extending one arm and opposite leg, maintaining neutral spine. 5-10 sec/rep, 10-12 reps per side Dead Bug Supine position, extending opposite arm and leg. 3-5 sec/rep, 12-15 reps Bridging Lifting hips off ground, maintaining spinal alignment. 10-15 sec/rep, 12-15 reps Swiss Ball Stability Balance in sitting or leg lift positions using a Swiss ball. 20-30 sec/position, 10-12 reps Progression in core exercises will occur by increasing repetitions, duration, or complexity based on individual capability."
219726126|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training|will perform only the upper limb progressive resistance training protocol as outlined below. This regimen focuses on strengthening the shoulder complex, upper back, and arm muscles to improve muscular performance, endurance, and control. Progressive Resistance Training
219726127|NCT02803541|BEHAVIORAL|12 day mainstream summer camp experience|see arm description
219726128|NCT05556018|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
219726129|NCT03533933|DEVICE|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
219726130|NCT03533933|OTHER|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
219726131|NCT06015100|DRUG|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
219726132|NCT03622840|BEHAVIORAL|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
219726133|NCT06686459|RADIATION|ALL-in-one radiotherapy|ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
219726134|NCT06686459|RADIATION|IMRT|IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
219726135|NCT05355220|DEVICE|Silver Spike Point Therapy (SSPT)|Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium
219726136|NCT05355220|OTHER|Conservative Managment|2 sets of 10 repetitions Bridging, Cat \& cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
219726137|NCT03630900|OTHER|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
219154205|NCT00088413|BIOLOGICAL|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
219154206|NCT00088413|DRUG|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
219154207|NCT06369701|DEVICE|Compressive tissue floss band|Compressive tissue flossing (CTF) is a compressive technique that uses a latex elastic band to compress the tissues and restrict the circulation of fluids in the targeted area for a short time. CTF acts on the mechanoreceptors in the underlying fascial layers, causing blood reperfusion of the compressed tissue, and/or causing fascial shearing and the sliding potential of the fascia to be restored (Starrett \& Cordoza, 2015). Proposed benefits from references include improving joint mobility in the joints of the limbs (Starrett \& Cordoza, 2015), improving muscular power, and decreasing pain with motion (Angelopoulos et al., 2021) (Cage et al., 2022) (Jianhong et al., 2021).
219154208|NCT00922220|OTHER|stationary bike|Participants rode a stationary bike for five minutes
219154209|NCT00922220|OTHER|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
219154210|NCT00922220|OTHER|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
219154211|NCT01094613|DRUG|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
219726138|NCT00441896|DRUG|Ganaxolone|
219726139|NCT00441896|OTHER|Placebo|
219154212|NCT01094613|DRUG|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
219154213|NCT01663584|PROCEDURE|Blood draw|
219154214|NCT00716924|DRUG|Clopidogrel|300 mg
219154215|NCT00716924|DRUG|Clopidogrel|600 mg
219154216|NCT01901081|DEVICE|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
219154217|NCT04177459|BEHAVIORAL|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
219154218|NCT04177459|OTHER|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
219154219|NCT01692483|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
219154220|NCT01692483|DRUG|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
219154221|NCT00418613|DRUG|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
219154222|NCT00418613|DRUG|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
219154223|NCT01850511|PROCEDURE|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
219154224|NCT01850511|DRUG|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
219154225|NCT02332512|DRUG|Apatinib|
219154226|NCT02332512|DRUG|Placebo|
219154227|NCT06446076|BEHAVIORAL|Gamification (Gain/Loss framing)|"Participants will take part in a 6-week game-based program designed to help them reach their daily step goals. They are encouraged to maintain their daily step counts to achieve their daily step target over the 6-week intervention period. The gamification design incorporates two theoretically effective behavioral economics principles, Fresh Start and Loss Aversion. All participants start from the Silver rank (middle rank), and their rank changes based on each final point of the week. The ranks are set from top to bottom as Platinum, Gold, Silver, Bronze, and Blue. In loss framing, if the daily step target is 6000 steps, maintaining 70 points for achieving 6000 steps on day 1, and a deduction of 10 points for not achieving it. In gain framing, achieving 6000 steps on day 1 results in an addition of 10 points, with no increase for not achieving it. After one week, ranks increase if the points at midnight on Sunday are 40 or above, and decrease if below this threshold."
219154228|NCT06446076|BEHAVIORAL|Social support|Participants in this group are asked to designate a family member or friend to provide social support. This supporter is encouraged to check the participant's progress and provide support during the interventional period. The supporter will also receive weekly emails throughout the period, informing them about the participant's daily step counts, achievement status, points, levels, and other relevant information.
219154229|NCT05755100|BEHAVIORAL|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
219154230|NCT04773639|BEHAVIORAL|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
219154231|NCT04773639|BEHAVIORAL|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
219154232|NCT06570213|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line, gold-standard psychotherapy intervention for the treatment of PTSD.
219154233|NCT06570213|DRUG|Stellate Ganglion Block|Stellate Ganglion Blocks are an injection of local anesthetic into the stellate ganglion, a collection of nerves in the side of the neck.
219154234|NCT04410055|BEHAVIORAL|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
219154235|NCT04410055|BEHAVIORAL|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
219154236|NCT04410055|BEHAVIORAL|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
219154237|NCT00590369|DEVICE|KCI -VAC|Negative pressure wound therapy device
219154238|NCT00590369|DEVICE|Versatile One (EZCare)|Negative pressure wound therapy device
219726140|NCT05370118|BEHAVIORAL|Telerehabilitation physical activity behavioral (TPAB) intervention|The intervention includes the behavior change techniques of self-monitoring of behavior, action planning, graded tasks, restructuring the physical and social environment, problem-solving, and prompts/cues.
219726141|NCT06305325|BEHAVIORAL|eHealth Antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
219726142|NCT04015063|OTHER|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
219726143|NCT01350973|DRUG|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
219726144|NCT01350973|DRUG|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
219726145|NCT05870436|DIAGNOSTIC_TEST|Methacholine Choline Provocation Test|Perform methacholine choline provocation test according to the protocol
219726146|NCT02507284|DRUG|SRX246|
219726147|NCT02507284|DRUG|Placebo|
219726148|NCT01088893|DRUG|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
219154239|NCT04325048|DEVICE|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
219154240|NCT03182010|DEVICE|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
219154241|NCT03182010|DEVICE|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
219154242|NCT01923012|DRUG|Vitamin K2 (Menaquinone)|
219154243|NCT00002632|DRUG|paclitaxel|
219154244|NCT02634541|DRUG|Adalimumab|Biologic drug
219154245|NCT02634541|OTHER|PET/CT imaging|PET/CT imaging
219154246|NCT04928703|DRUG|Ketamine|Ketamine IV administration
219154247|NCT01177696|BEHAVIORAL|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
219154248|NCT00632424|DRUG|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
219154249|NCT00295724|DRUG|Bicifadine|
219154250|NCT00939978|DRUG|rhEPO|recombinant human erythropoietin(rhEPO)
219154251|NCT02531113|DRUG|RPC1063|
219154252|NCT03421678|DIAGNOSTIC_TEST|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
219154253|NCT00002049|DRUG|Thymopentin|
219154254|NCT03680417|BIOLOGICAL|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
219154255|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
219154256|NCT06972823|DEVICE|3D printed custom-made mouthguards|Participants in the first group will receive 3D printed custom-made mouthguards
219154257|NCT06972823|DEVICE|Traditional custom-made mouthguards|Participants in the active comparator arm will receive traditional custom-made mouthguards as an intervention
219154258|NCT06974019|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement in nulliparous women
219154259|NCT06974019|DRUG|Lidocaine 1% Injectable Solution|To determine if the unbuffered 1% lidocaine paracervical block offers any less pain control with IUD placement for nulliparous women
219154260|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery
219154261|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods: [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.|GFR will be measured using three methods: \[68Ga\]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.
219154262|NCT06972615|DRUG|intravesical Chemotherapy docetaxel/gemcitabine|intravesical quimiotherapy plus intravenous immunotherapy
219233316|NCT03322579|DEVICE|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
219233317|NCT04436484|DIAGNOSTIC_TEST|Peripheral blood sampling|Non-interventional study
219233318|NCT05361083|DRUG|F18CETO|Injection of F18CETO or O15water followed by PET/CT
219233319|NCT06402916|DIETARY_SUPPLEMENT|Blueberry drink|Blueberry drink equivalent to 240g fresh blueberries.
219233320|NCT06402916|DIETARY_SUPPLEMENT|Placebo drink|Drink containing no active ingredient.
219726149|NCT06516432|PROCEDURE|Parasternal block|In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified.
219726150|NCT06516432|PROCEDURE|Requirement of total dose regarding fentanyl|In case-control groups, obtain measurement of total postoperative fentanyl requirement.
219726151|NCT04849832|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
219726152|NCT04849832|DIETARY_SUPPLEMENT|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
219726153|NCT04849832|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
219726154|NCT04849832|DIETARY_SUPPLEMENT|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
219726155|NCT00744198|PROCEDURE|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
219154263|NCT06974253|PROCEDURE|Nasopalatine Implants, Trans-Sinus Implants, and Trans-Nasal Implants for Full-Arch Rehabilitation|"Pre-surgery (Implant Placement):~Clinical examination, panoramic radiography, film guide creation, and CBCT imaging will be performed. Based on CBCT data and the film guide, bone measurements will be taken, and a treatment plan with virtual implants will be developed. 4-6 pilot holes will be made, adjusting for critical structures like the maxillary sinus, inferior alveolar nerve, and planned implant sites. Full blood count and coagulation tests will be done.~During Surgery:~Implant surgery will be performed under local anesthesia/sedation. Incision and mucosal flap reflection will expose the implant site. A clip will be fixed to the anterior maxilla with screws, connected to the monitoring device. The dynamic navigation system will guide the placement of nasopalatine, trans-sinus, and trans-nasal implants, ensuring optimal placement.~Post-surgery:~Post-operative CBCT will be performed to check the implant positions, confirming the accuracy of the implant placement."
219154264|NCT06972550|PROCEDURE|pronator quadratus sparing|the pronator quadratus was spared when doing orif and the plare was slided beneath it
219154265|NCT03031561|DEVICE|Ultrasound|Undergo standard ultrasound
219154266|NCT03031561|DEVICE|MicoPure ultrasound|Undergo MicoPure ultrasound
219154267|NCT03031561|PROCEDURE|Biopsy of Breast|Undergo breast biopsy or surgical resection
219154268|NCT06594523|DRUG|Denifanstat|Tablet
219154269|NCT06594523|DRUG|Placebo|Matching Tablet
219154270|NCT04543201|BEHAVIORAL|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
219154271|NCT01939171|DRUG|Thymoglobulin|
219154272|NCT06555159|BEHAVIORAL|Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)|Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
219726156|NCT00744198|PROCEDURE|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
219726157|NCT00744198|PROCEDURE|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
219726158|NCT03672825|DRUG|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
219726159|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic lateral suspension with mesh|V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
219726160|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic sacrocervicopexy with mesh|The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
219726161|NCT02290093|DRUG|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
219726162|NCT02290093|DRUG|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
219726163|NCT02290093|DRUG|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
219726164|NCT06767722|BEHAVIORAL|Lifestyle intervention and self-monitoring of blood glucose|The intervention will consist of a lifestyle intervention that comprises advice on diet, exercise, weight management, and self-monitoring of blood glucose (SMBG) with feedback from healthcare professionals on results and insulin treatment if indicated.
219726165|NCT03695588|PROCEDURE|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
219726166|NCT03695588|PROCEDURE|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
219726167|NCT02557997|OTHER|Blood tube bottom analyses|
219726168|NCT05548855|PROCEDURE|Heart Transplant|Patients who have undergone a heart transplant as standard of care (SOC) procedure
219726169|NCT05548855|DEVICE|Cardiac Assistive Device|Patients who have undergone a placement of a cardiac assistive device
219726170|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
219726171|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
219726172|NCT01033071|DRUG|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
219233321|NCT03412045|DEVICE|hyperbaric oxygen therapy|Participants in vaso-occlusive crisis from sickle cell anemia will receive 1-3 hyperbaric oxygen (HBO) sessions depending on response to the therapy. Each session will be approximately 2 hours in length at 2.5 ATM. Minimum time between HBO sessions of 4 hours.
219726173|NCT03022448|OTHER|No Intervention|This is a NIS. No intervention.
219233322|NCT04117477|DRUG|Xylitol|Xylitol dental wipes
219233323|NCT04117477|OTHER|Placebo|Placebo dental wipes
219233324|NCT00212290|DRUG|pioglitazone|
219233325|NCT00212290|DRUG|nateglinide|
219233326|NCT00212290|DRUG|placebo|
219233327|NCT03265847|BEHAVIORAL|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
219726174|NCT03208452|DRUG|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
219726175|NCT03208452|DRUG|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
219726176|NCT04094480|DEVICE|polymeric non absorbable clips|a method to secure appendicular stump
219233328|NCT01513447|DRUG|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
219726177|NCT04094480|OTHER|endoloops|a method to secure appendicular stump
219726178|NCT06392087|DRUG|Methoxyflurane|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
219726179|NCT06392087|OTHER|Standard Care|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
219726180|NCT00254072|PROCEDURE|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
219726181|NCT01824004|DRUG|S-1|
219726182|NCT02492386|DEVICE|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
219726183|NCT01675700|DRUG|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
219233329|NCT00212862|OTHER|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
219726184|NCT01424852|DIETARY_SUPPLEMENT|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
219726185|NCT04439409|DEVICE|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
219726186|NCT00004859|DRUG|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
219726187|NCT00004859|DRUG|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
219726188|NCT00004859|DRUG|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
219233330|NCT06415552|BEHAVIORAL|Mindfulness-Based Stress Reduction|Eight iterations of the MBSR course will be delivered, over a total period of 24 months. Each iteration will take place over 8 weeks. Courses would consist of 8 weekly sessions, led by certified mindfulness instructors. Sessions will include core meditation practices, psychoeducation, and home practices.
219233331|NCT05620654|DRUG|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
219233332|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section.
219233333|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
219233334|NCT00762554|DRUG|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
219233335|NCT05001815|DEVICE|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
219233336|NCT05001815|DEVICE|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
219233337|NCT01276509|DRUG|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
219233338|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
219233339|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
219233340|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
219233341|NCT03161652|DRUG|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
219233342|NCT03161652|DRUG|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
219233343|NCT03161652|DRUG|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
219233344|NCT03161652|DRUG|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
219233345|NCT03161652|DRUG|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
219233346|NCT03161652|DRUG|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
219233347|NCT03161652|DRUG|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
219233348|NCT03161652|DRUG|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
219233349|NCT04985266|DRUG|Palbociclib 125Mg Tab|Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
219233350|NCT04985266|DRUG|Fulvestrant injection|Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
219233351|NCT04985266|DRUG|Tamoxifen|As per clinical guidelines
219233352|NCT04985266|DRUG|Letrozole|As per clinical guidelines
219233353|NCT04985266|DRUG|Exemestane|As per clinical guidelines
219233354|NCT04985266|DRUG|Anastrozole|As per clinical guidelines
219233355|NCT05755178|BEHAVIORAL|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
219726189|NCT00004859|RADIATION|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
219726190|NCT05601973|DRUG|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
219726191|NCT05601973|DRUG|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
219726192|NCT05601973|DRUG|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
219726193|NCT04073407|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
219726194|NCT04073407|DIETARY_SUPPLEMENT|Placebo|placebo
219726195|NCT06755216|BEHAVIORAL|Experimantal group|"In order to identify students who meet the criteria for the study, the PIF and SSSCL will be administered as a pre-test to female students studying in the relevant departments of Karabük University Faculty of Health Sciences.~After providing theoretical information to the students, the cardinal movements of the fetal head within the pelvis during the second stage of labor will be demonstrated in a laboratory setting. Students will be divided into groups of five, and after the demonstration, each student will be asked to perform all stages individually. Approximately 15 minutes will be allocated for each student. Two weeks later, the same students will be brought into the laboratory environment and asked to perform all procedural steps. While performing the steps, a researcher will mark the completed and missing actions on the learner's guide, and any missing steps will be explained to the student and corrected. For the post-test, the Learner's Guide (LG) and SSSCL will be administered"
219726196|NCT07056062|DRUG|Calcium carbonate|2,000 mg PO calcium carbonate as a single dose
219726197|NCT07056725|OTHER|Manual Therapy and Therapeutic Exercises Programs|A treatment based on the combination of Manual Therapy targeting the orofacial region and a therapeutic exercise program focused on either the cervical or orofacial region
219726198|NCT06771700|DIAGNOSTIC_TEST|Intraoperative PRAETORIAN Score|The intraoperative PRAETORIAN Score is calculated based on the additional measurements.
219726199|NCT06847165|DEVICE|Trigeminal Nerve Stimulation (TNS)|In TNS, a weak electric current is applied to the child's forehead overnight while sleeping to gently stimulate the brain. TNS treatment is typically administered at home at bedtime by the parent to the child. The TNS device is small (size of a cell phone) and easy to use. Two thin wires go from the device to a pair of small electrodes that tape onto the forehead like a band-aid. The parent presses three keys on the device and it is ready to go.
219154273|NCT06555159|BEHAVIORAL|Control group: Continuous aerobic physical exercise|Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
219154274|NCT06671561|DEVICE|Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)|Observational data collection
219154275|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
219154276|NCT04022239|DRUG|Bendamustine|Given IV
219154277|NCT04022239|DRUG|Cyclophosphamide|Given IV
219154278|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
219154279|NCT04022239|DRUG|Fludarabine|Given IV
219154280|NCT04022239|DRUG|Melphalan|Given IV
219154281|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
219154282|NCT04022239|BIOLOGICAL|Rituximab|Given IV
219154283|NCT04022239|DRUG|Tacrolimus|Given IV and PO
219154284|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
219154285|NCT06860633|DRUG|Efgartigimod|Dose of 10 mg/kg for IV infusion on days 1, 4, 11 and 18
219154286|NCT03807778|DRUG|Mobocertinib|Mobocertinib capsule.
219154287|NCT06677125|PROCEDURE|Electrical Mallet|The osteotome will be directly attached and pushed by magnetic mallet and a shock wave will be pushed on their tip. The electrical mallet will be imparted to osteotomes a longitudinal movement along a central axis moving up and down toward pilot bone hole providing a driving mechanism of longitudinal movements. Then the sinus lift instruments (Sweden and Martina) will be used to slowly lift the sinus. After that implant will be placed with the help of implant drilling device.
219154288|NCT06677125|PROCEDURE|Densah bur|The implant motor will be adjusted on reverse-densifying mode with 800 to 1200 rpm. According to the desired implant dimension, it will be started with the smallest densah bur. The first densah bur will advanced in densifying mode with bouncing motion in and out movement with copious irrigation until.
219154289|NCT06496958|DEVICE|CO2 insufflation with an abdominal compression device|For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.
219154290|NCT06496958|DEVICE|CO2 insufflation with a sham abdominal compression device|The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.
219154291|NCT06496958|DEVICE|Water exchange colonoscopy|In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
219154292|NCT05685316|DEVICE|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
219154293|NCT06691919|DEVICE|Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement|Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.
219154294|NCT06691919|PROCEDURE|Transgastric Surgical Necrosectomy|Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
219154295|NCT06702059|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Subjects will undergo pre-operative cardiopulmonary exercise testing.
219154296|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219154297|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
219154298|NCT05600556|OTHER|Best Practice|Review imaging on standard computer screen
219154299|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
219154300|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219154301|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
219154302|NCT05600556|OTHER|Virtual Technology Intervention|Review virtual reality images
219154303|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
219154304|NCT04024293|DEVICE|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
219233356|NCT06406049|OTHER|Control group|Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.
219726200|NCT06895148|DEVICE|New ventilator|"The new ventilator order (intervention) was developed using economic behavior theory to decrease the cognitive burden on the ordering provider while enhancing the operability of the order itself. The strategy resulted in a new ventilator order that includes the following changes:~1. Automatic calculation of the PBW based on the most recent height~2. If the height is not available, an order to obtain a height will be generated and the choice of tidal volume will be based on cc/kg PBW~3. Simplify ventilator modes to accurately reflect the standard of care~4. Reduce duplicative information in the monitoring and comments portion of the order~5. Cascade ventilator orders based on mode to enhance visualization."
219726201|NCT06895148|DEVICE|control ventilator|Current ventilator order used by control hospitals
219726202|NCT06895447|DRUG|Pre-operative chemotherapy|Patients will undergo pre-operative drug treatment (any chemotherapy drug or immunotherapy drug are accepted).
219726203|NCT06895447|PROCEDURE|Robotic radical gastrectomy after neoadjuvant therapy|"Eligible participants must have stage III resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma based on imaging studies such as ultrasound endoscopy, CT, or MRI.~Patients will receive 3-4 cycles of neoadjuvant therapy, followed by imaging evaluations to assess the treatment response and determine eligibility for radical D2 gastrectomy. Within 2-6 weeks of the final neoadjuvant treatment cycle, eligible patients will undergo robotic radical gastrectomy."
219726204|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 55% of one repetition maximum load for the specific plantar flexion exercises.
219726205|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 70% of one repetition maximum load for the specific plantar flexion exercises.
219726206|NCT06906848|DIETARY_SUPPLEMENT|Placebo|Oral
219726207|NCT06906848|DIETARY_SUPPLEMENT|Cognizin®|Oral
219726208|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
219726209|NCT05556837|OTHER|Control Cereal|A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured
219154305|NCT04242940|DEVICE|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
219154306|NCT04777851|DRUG|Regorafenib in combination with pembrolizumab|Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
219154307|NCT04777851|PROCEDURE|Loco-regional therapy|"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
219726210|NCT05556837|OTHER|OBG Cereal|A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
219154308|NCT04240808|BIOLOGICAL|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)
219154309|NCT06648031|DRUG|Arm 1 - DehydraTECH-CBD alone|Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule
219154310|NCT06648031|DRUG|Arm 2 - DehydraTECH-semaglutide alone|Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
219154311|NCT06648031|DRUG|Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide|"DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks.~\- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule"
219154312|NCT06648031|DRUG|Arm 4 - Rybelsus medication (semaglutide) alone|Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
219154313|NCT06648031|DRUG|Arm 5- Tirzepatide|Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks
219154314|NCT00130117|DRUG|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
219154315|NCT00130117|DRUG|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
219154316|NCT00130117|OTHER|Placebo|placebo (no active medication)
219154317|NCT03801499|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219154318|NCT06890728|BEHAVIORAL|Culinary focused nutrition education|Culinary focused nutrition education based on MyPlate with an emphasis on taste and enjoyment of healthy foods.
219726211|NCT05556837|OTHER|BBG Cereal|A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
219726212|NCT06946927|DRUG|JMKX001899|JMKX001899 tablet administered orally daily.
219726213|NCT06946927|DRUG|IN10018|IN10018 tablet administered orally daily.
219726214|NCT06946927|DRUG|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
219726215|NCT06946927|DRUG|Carboplatin|IV infusion once every 3 weeks, 4 Cycles
219726216|NCT05571254|OTHER|Data collection|All patients will have a focussed Case Report Form completed collecting routine data describing the prevalence, clinical presentation, assessment, management and ESC risk category of patients, at the time or shortly after the patients ED attendance.
219154319|NCT06890728|BEHAVIORAL|Standard low intensity nutrition education|Provided by a written MyPlate resource
219154320|NCT04449679|OTHER|Patient Monitoring System|Receive RT-CAMSS
219726217|NCT06505642|DEVICE|needle-based confocal laser endomicroscopy|needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
219726218|NCT03495440|BEHAVIORAL|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
219154321|NCT04449679|OTHER|Questionnaire Administration|Complete questionnaires
219154322|NCT04449679|OTHER|Consultation|Receive tailored feedback, including consultation with nurse
219154323|NCT06914648|PROCEDURE|Portal Vein Embolization|Description: Portal Vein embolization with Glue by a transhepatic approach
219154324|NCT06914648|PROCEDURE|Hepatic Vein Embolization|Hepatic Vein Embolization with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
219154325|NCT05062317|DRUG|Leucovorin|Given by PO
219154326|NCT05062317|DRUG|5-FLUOROURACIL|Given by IV
219154327|NCT05062317|DRUG|Oxaliplatin|Given by PO
219154328|NCT05062317|DRUG|Irinotecan|Given by IV
219154329|NCT05062317|DRUG|Capecitabine|Given by IV
219154330|NCT05062317|DRUG|Bevacizumab|Given by IV
219154331|NCT02678572|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
219154332|NCT06925724|DRUG|Ivonescimab|Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)
219154333|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
219154334|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
219154335|NCT06935019|GENETIC|Genome sequencing pre-geneticist evaluation|The intervention is receiving immediate clinical routine GS, prior to evaluation by a medical geneticist. Pre-test counselling will be done by a research genetic counsellor. Results of GS will be returned during the participant's first visit to Genetics Clinic by their clinical team. Subsequent clinical care (including any other clinically indicated genetic testing or workup) will be arranged by the medical geneticist in clinic.
219154336|NCT06937073|BEHAVIORAL|dietary intake guidance and exercise guidance|"In the Fugu Medical WeChat mini program, the intervention plan for the intervention group included: (1) dietary intake guidance and (2) exercise guidance.~1. Dietary intake guidance: The dietary guidance was mainly based on the general dietary guidelines for the elderly issued by the Chinese Nutrition Society.~2. Exercise guidance Exercise guidance included resistance training and balance training."
219154337|NCT06937073|BEHAVIORAL|Control|Participants in the control group only received rehabilitation program articles in the form of images and text through the mobile application. These materials also included dietary intake guidance and exercise instructions. The frequency and intensity of the exercise instructions were sent to the patients at the same time. However, their daily adherence, including whether the training was completed or whether the dietary intake was appropriate, was not checked, verified, or followed up.
219154338|NCT06935253|OTHER|Large Language Model|The intervention is a Large Language Model.
219154339|NCT01523158|BIOLOGICAL|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
219154340|NCT05640154|BEHAVIORAL|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
219154341|NCT03554876|DEVICE|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
219154342|NCT03554876|DEVICE|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
219154343|NCT03554876|DEVICE|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
219154344|NCT05775055|OTHER|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
219154345|NCT05436639|DRUG|SPI-62 dose|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
219154346|NCT04086771|BEHAVIORAL|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
219154347|NCT04086771|OTHER|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
219154348|NCT04079348|DEVICE|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
219154349|NCT04079348|OTHER|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
219726219|NCT03495440|BEHAVIORAL|At-home|Self-study resources paired with regular contact with study personnel.
219726220|NCT06263738|PROCEDURE|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
219726221|NCT06263738|PROCEDURE|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
219726222|NCT04503122|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
219726223|NCT04653064|BEHAVIORAL|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
219154350|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
219154351|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
219154352|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
219154353|NCT06260878|OTHER|Intravenous Ringer's lactate|Intravenous Ringer's lactate
219154354|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
219154355|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
219154356|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
219154357|NCT02160756|DRUG|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
219154358|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
219154359|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
219154360|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
219154361|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
219154362|NCT04339140|DRUG|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
219154363|NCT05590923|DRUG|OLA group: Olanzapine|"OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)."
219154364|NCT05590923|DRUG|DEX group: Dexamethasone|"DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC)."
219154365|NCT06209047|DRUG|Local instillation of gentamicin and Budesonide|Bronchoscopic local instillation of gentamicin and Budesonide
219154366|NCT06209047|DRUG|Local instillation of Levofloxacin and Budesonide|Bronchoscopic local instillation of Levofloxacin and Budesonide
219154367|NCT06209047|PROCEDURE|Bronchoscopic mechanical secretion suction and lavage|Bronchoscopic mechanical secretion suction and lavage
219154368|NCT06209047|PROCEDURE|Sham Bronchoscopy|Bronchoscopy for airway visualization only, no lavage or drug instillation (sham procedure).
219154369|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
219154370|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
219154371|NCT06833905|BEHAVIORAL|Virtual reality: Beach|Session 1 or 2 (counterbalanced): Exposure to a beach landscape
219154372|NCT06833905|BEHAVIORAL|Virtual Reality: Forest|Session 1 or 2 (counterbalanced): Exposure to a forest landscape
219154373|NCT06833905|BEHAVIORAL|Hypnosis: Magic Hand|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: the magic hand
219154374|NCT06833905|BEHAVIORAL|Hypnosis: Pain Manipulation|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: manipulating the pain
219154375|NCT06833905|BEHAVIORAL|Session 1bis - 1 week|Repetition of the Session 1 one week after Session 4
219154376|NCT06833905|BEHAVIORAL|Follow-up|Repetition of the Session 1 three weeks after Session 4
219154377|NCT06700590|BEHAVIORAL|Intensive Treatment|"Participants engage in two preparatory sessions once weekly, lasting 50 minutes each, which focus on psychoeducation and case conceptualization. The core treatment consists of five days of twice-daily sessions delivered over one or two weeks. The first session of the day consists of prolonged exposure (PE). The second session consists of eye movement desensitization and reprocessing (EMDR). Both treatments are performed in strict adherence to their respective manualized protocol. Two closing sessions focus on lessons learned, integration and a prevention plan. The treatment in total lasts 6 weeks and contains 800 minutes of treatment.~To enhance practicality, treatment rotation is allowed and encouraged. Rigorous checks on treatment adhenrence will be implemented."
219726224|NCT04653064|BEHAVIORAL|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
219233357|NCT06406049|BEHAVIORAL|Social network intervention|Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.
219726225|NCT04268511|PROCEDURE|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
219726226|NCT04268511|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
219726227|NCT04520906|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
219726228|NCT00184509|BEHAVIORAL|integrated psychosocial treatment (behavior)|
219154378|NCT06700590|BEHAVIORAL|Treatment as usual|Spaced/weekly treatment consists of a treatment-as-usual condition, increasing the representativeness of the control condition. Treatment duration is 800 minutes, either 13 weeks of 60 minutes (with the last sessions being 80 minutes), or 16 weeks of 50 minutes. All evidence-based treatment modalities of the Dutch guidelines are allowed: PE, EMDR, brief eclectic psychotherapy for PTSD (BEPP), narrative exposure therapy (NET), and imaginary rescripting (ImRs). All have common elements of psychoeducation, imaginal exposure, emotional processing, cognitive restructuring and/or meaning making. Treatment adherence will be monitored throughout the intervention. Therapist rotation is not performed
219154379|NCT04498052|OTHER|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~In period 1:~* An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~* Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~In period 2:~\- Same as period 1 + simple patient reminders in the patient portal.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
219154380|NCT06345976|OTHER|questionnaire|On-line self-questionnaire, in the form of an 18-question form, the link to which is sent by e-mail to patients with albinism who have agreed to take part in the study.
219154381|NCT06749977|DRUG|Remineralization with SAP11-4|The WSL were treated with SAP11-4 according to the manufacturer's instruction
219154382|NCT06749977|DRUG|Remineralization with sodium fluoride varnish|The WSL were treated with sodium fluoride varnish according to the manufacturer's instruction
219154383|NCT06273605|OTHER|Egg Ladder|12 month protocol of graded and gradual egg introduction
219154384|NCT04950868|DRUG|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
219154385|NCT04879524|PROCEDURE|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
219154386|NCT06493032|DEVICE|Gastric Alimetry System|medical device that uses a large sheet of electrodes to assess gastric motility
219154387|NCT05646563|DRUG|NM8074|NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
219154388|NCT05646563|DRUG|Soliris|Complement C5 blocker administered intravenously
219154389|NCT05941637|DRUG|Axitinib 5 MG|Patients will receive Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit - 5mg daily
219154390|NCT06260865|DEVICE|MORA Cure|MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
219154391|NCT06260865|OTHER|Treatment as Usual|In the control group, education is delivered and self-exercise is recommended.
219154392|NCT06640972|DRUG|RDX-002|Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
219154393|NCT06640972|DRUG|Placebo|Matching placebo
219154394|NCT05396872|OTHER|Participant Surveys|Online surveys administered post appointment
219154395|NCT05396872|OTHER|Mobile app|Mobile application installed on mobile device
219154396|NCT03256240|OTHER|side-to-side functional end anastomosis|type of anastomosis
219154397|NCT03256240|OTHER|Kono-S analstomosis|antimesenteric anastomosis
219154398|NCT06558006|DRUG|Predimenol tablet|2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).
219154399|NCT06558006|DRUG|Predimenol tablet + Placebo tablet of Predimenol|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).
219154400|NCT06558006|DRUG|Placebo tablet of Predimenol|2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
219154401|NCT06307782|DIETARY_SUPPLEMENT|whey protein intake before surgery|Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
219154402|NCT06307782|DIETARY_SUPPLEMENT|Water before surgery|Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
219154403|NCT04981730|BEHAVIORAL|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
219154404|NCT06084455|OTHER|Aerobic exercise|30 minutes of aerobic exercise on a stationary bike
219726229|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
219726230|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
219726231|NCT01773902|DIETARY_SUPPLEMENT|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
219726232|NCT00959452|BEHAVIORAL|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
219726233|NCT02439411|DRUG|Trametinib|
219726234|NCT04941898|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
219726235|NCT04630886|DRUG|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
219726236|NCT04630886|DRUG|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
219726237|NCT05850312|DEVICE|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
219726238|NCT05850312|DEVICE|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
219726239|NCT06426888|OTHER|Experimental interventional group 1(scapular stabilization exercise therapy)|"Ball stabilization exercise: While standing close to the wall, the participant will be asked to position her affected hand on the ball and keep the ball from moving as disturbance will be applied in different directions.~Wall push up: While facing wall patient will be asked to place both hands on wall, shoulder width apart. He will be instruct to breath in, bend his elbows, lean into wall and hold this position for one second then breath out slowly push back until arms are straight again Wall slides~• Patient will be asked to lean his head, upper thorax and butts against the wall, place his hands and arms against the wall in high five position."
219726240|NCT06426888|OTHER|Experimental :interventional group II (scapular mobilizations)|"Patient lies on unaffected side close to the edge of the treatment bench with hips and knees bent for stability.~Therapist will start by supporting the patient arm on his/her forearm so that shoulder is in maximally loose pack position.~Then he/she will grab on the scapula with both hands. One hand supports the scapula from cranial around the acromion and scapular spine and other hand from the caudal at the inferior angle of scapula.~Then both hands move the scapula cranially over the thorax into elevation and caudally into the depression, upward/downward rotation as well as retraction and protraction."
219726241|NCT06963723|OTHER|Financial Hardship Screening|Financial Hardship Screening and Financial Needs Assessment
219726242|NCT06963723|OTHER|Enhanced Usual Care|Enhanced Usual Care
219726243|NCT02724644|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
219726244|NCT02724644|BIOLOGICAL|Placebo Comparator|
219154405|NCT06360432|BEHAVIORAL|Dietary modification program|Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.
219154406|NCT06360432|BEHAVIORAL|Exercise training|Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.
219233358|NCT03440177|DRUG|Ramipril|Patients are tested for their normal prescription ramipril medication
219726245|NCT04676776|DRUG|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
219726246|NCT04676776|DRUG|Mifepristone|All participants receive 200 mg mifepristone on day 3
219726247|NCT00228852|DRUG|Busulfan, Fludarabine and ATG|
219726248|NCT02073617|RADIATION|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
219726249|NCT00884949|DRUG|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
219726250|NCT04807296|PROCEDURE|TFLEP|"Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP."
219154407|NCT06360432|BEHAVIORAL|The EatWellLog App|Only participants in the M-health group will be instructed to use the EatWellLog app for daily diet self-management. This App supports participants with SO by providing a structured approach to managing a diet that encourages steady weight loss while maintaining muscle mass, in line with current nutritional recommendations for this demographic. The EatWellLog App has the following features: i) tracking participants' dietary habits by logging meals and snacks from a food list, ii) personalized online coaching and reminders by a multidisciplinary healthcare team, iii) participation of family caregivers through an interactive messaging function, iv) accessing health information via multiple channels, including animations, an at-a-glance display, and a reminder, and v) utilization of game elements, such as educational animations and video games to disseminate health and nutritional information related to SO.
219154408|NCT06421051|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
219154409|NCT04009967|DRUG|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
219154410|NCT05436834|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219154411|NCT05436834|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
219154412|NCT05271435|DEVICE|PAMSys Activity Monitoring System|This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
219154413|NCT05271435|BEHAVIORAL|Motor, Speech, and Handwriting Assessment|"These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).~* 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.~* Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.~* Handwriting Assessment Battery (HAB) (15 minutes) \[Faddy2008\] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.~* Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room."
219154414|NCT05381987|DEVICE|Radial shockwave therapy|Shockwave Storz Medical device, Doulith SD1, Tower (BT)
219726251|NCT04807296|PROCEDURE|m-HoLEP|"The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP"
219726252|NCT06783946|BEHAVIORAL|Meditation|The meditation technique will be comprised of breathing techniques, full body relaxation, color meditation, visualization, and positive affirmations. A physician researcher trained in teaching meditation will conduct virtual meditation sessions with patients enrolled in the study. Participants will practice a daily 20-minute meditation for 2-4 weeks before scheduled surgery (whichever is the maximum length of time from enrollment) to 2 weeks post-operatively using the provided audio guided meditation recordings. Participants will also log completion of daily meditation practice electronically.
219726253|NCT01258855|BIOLOGICAL|Aldesleukin|Given IV
219726254|NCT01258855|OTHER|Laboratory Biomarker Analysis|Correlative studies
219726255|NCT01258855|BIOLOGICAL|Ziv-Aflibercept|Given IV
219726256|NCT03126734|OTHER|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
219726257|NCT04330898|DEVICE|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
219726258|NCT01958684|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
219726259|NCT01958684|DEVICE|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
219726260|NCT01567085|DRUG|Eculizumab|
219726261|NCT04231006|RADIATION|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
219726262|NCT00449969|DEVICE|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
219726263|NCT00449969|DEVICE|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
219726264|NCT06413771|DRUG|Letrozole 2.5mg|Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
219726265|NCT06413771|DRUG|Gonadotropin|Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
219233359|NCT06562972|OTHER|Occlusal equilibration of complete denture using articulating paper|Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.
219233360|NCT06562972|OTHER|Occlusal equilibration of complete denture using occulosense|Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
219233361|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
219361077|NCT00983190|DEVICE|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
219726266|NCT05719389|DRUG|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
219726267|NCT03899493|OTHER|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
219726268|NCT04762199|DRUG|Flt3/MerTK Inhibitor MRX-2843|Given PO
219726269|NCT04762199|DRUG|Osimertinib|Given PO
219726270|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
219726271|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
219726272|NCT03421080|BEHAVIORAL|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
219726273|NCT03421080|BEHAVIORAL|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
219726274|NCT04597333|DRUG|Dinoprostone|Dinoprostone vaginal insert.
219726275|NCT04597333|DEVICE|Cervical ripening balloon.|Double lumen cervical ripening balloon.
219726276|NCT04331171|DEVICE|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
219726277|NCT04029038|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
219726278|NCT04029038|DRUG|Cyclophosphamide|Given IV
219726279|NCT04029038|DRUG|Fludarabine|Given IV
219726280|NCT04348578|OTHER|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
219726281|NCT02360501|DRUG|Docetaxel|75mg/㎡,d1
219726282|NCT02360501|DRUG|Cisplatin|25mg/㎡,d1-3
219726283|NCT02360501|DRUG|Capecitabine|2000mg/㎡,d1-14
219726284|NCT05948982|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
219726285|NCT05180656|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
219726286|NCT03150797|DRUG|Melatonin|Melatonin
219726287|NCT03150797|DRUG|Placebo oral capsule|Placebo
219726288|NCT01232907|DRUG|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
219726289|NCT00652613|RADIATION|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
219726290|NCT00652613|RADIATION|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
219154415|NCT04761939|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0"
219154416|NCT05284240|DEVICE|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
219154417|NCT06782074|OTHER|emotional and neuropsychological assessment|The tests for evaluating emotional-behavioral functioning and quality of life will be self-administered by the patient/caregiver during regular follow-up visits. The cognitive assessment will be conducted by the clinician using standardized tests.
219154418|NCT06782048|DRUG|Placebo|Participants will receive placebo by mouth once each day for a total of 14 days.
219154419|NCT06782048|DRUG|Pyrvinium|Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
219154420|NCT06782048|PROCEDURE|Blood biomarkers analyses|Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.
219154421|NCT06782048|PROCEDURE|Oesophagogastroduodenoscopy (OGD) and biopsy|Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
219154422|NCT06782048|OTHER|Gastric juice, saliva and stool collection and analyses|Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
219154423|NCT05688436|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
219154424|NCT05688436|BIOLOGICAL|Alemtuzumab|Administered as specified in the treatment arm.
219154425|NCT05688436|DRUG|Fingolimod|Administered as specified in the treatment arm.
219154426|NCT05688436|DRUG|Glatiramer acetate|Administered as specified in the treatment arm.
219154427|NCT05688436|BIOLOGICAL|Interferon beta|Administered as specified in the treatment arm.
219154428|NCT05688436|BIOLOGICAL|Natalizumab|Administered as specified in the treatment arm.
219154429|NCT05688436|BIOLOGICAL|Ocrelizumab|Administered as specified in the treatment arm.
219154430|NCT05688436|BIOLOGICAL|Ofatumumab|Administered as specified in the treatment arm.
219154431|NCT05688436|DRUG|Ozanimod|Administered as specified in the treatment arm.
219154432|NCT05688436|BIOLOGICAL|Peginterferon beta-1a|Administered as specified in the treatment arm.
219154433|NCT05688436|DRUG|Ponesimod|Administered as specified in the treatment arm.
219154434|NCT05688436|DRUG|Siponimod|Administered as specified in the treatment arm.
219154435|NCT02987192|DEVICE|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
219154436|NCT02987192|DEVICE|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
219154437|NCT03936660|OTHER|Intense Education Intervention|Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
219154438|NCT06119711|OTHER|No intervention|No intervention
219154439|NCT00214240|DRUG|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
219154440|NCT04757155|BEHAVIORAL|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
219361078|NCT05008094|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole-exome sequencing with the focus on Parkinson's disease loci.
219726291|NCT02887352|OTHER|assessment of problem-solving ability|
219726292|NCT00268398|DRUG|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
219154441|NCT02541565|DRUG|Cyclophosphamide|Given IV
219154442|NCT02541565|DRUG|Doxorubicin Hydrochloride|Given IV
219154443|NCT02541565|OTHER|Laboratory Biomarker Analysis|Correlative studies
219154444|NCT02541565|BIOLOGICAL|Pembrolizumab|Given IV
219154445|NCT02541565|DRUG|Prednisone|Given PO
219154446|NCT02541565|BIOLOGICAL|Rituximab|Given IV
219154447|NCT02541565|DRUG|Vincristine Sulfate|Given IV
219726293|NCT00268398|DRUG|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
219726294|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
219726295|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
219726296|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
219361079|NCT05008094|DIAGNOSTIC_TEST|Microbiota sequencing|Next generation sequencing of microbiota from stool and saliva samples.
219361080|NCT05008094|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.
219361081|NCT05008094|DIAGNOSTIC_TEST|Transcranial ultrasound and Electroencephalography|Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
219233362|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
219233363|NCT03803423|OTHER|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
219233364|NCT06005441|DRUG|CBL-514 injection|Provided as a ready for use injectable CBL-514 solution
219233365|NCT06005441|DRUG|CBL-A1 Injection|Provided as a ready for use injectable CBL-A1 solution
219233366|NCT06005441|DRUG|CBL-A2 Injection|Provided as a ready for use injectable CBL-A2 solution
219233367|NCT06005441|DRUG|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
219726297|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
219233368|NCT06373731|DRUG|Elamipretide|Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks
219233369|NCT06373731|DRUG|Placebo|Subjects will receive once daily SC doses of Placebo 96 weeks
219233370|NCT06791551|DEVICE|active RIPC and tDCS|Preoperative use of a therapeutic device with sleeves fixed on the upper side of both arms, compressing the bilateral brachial arteries to 200mmHg for 5 minutes, resting for 5 minutes, repeating 5 times, recorded as 1 time, training once in the morning and afternoon each day, and continuing treatment for at least 3 days; Administer transcranial electrical stimulation, 2mA, 30min, for 3 days;
219233371|NCT06791551|DEVICE|Sham (No Treatment)|received sham treatment with the same appearance instrument;
219233372|NCT06069544|BIOLOGICAL|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
219233373|NCT06069544|OTHER|Placebo|Isotonic NaCl solution (0.9%)
219233374|NCT01534052|DRUG|Enzalutamide|Oral
219726298|NCT02388100|PROCEDURE|Capillary HbA1c collection|
219726299|NCT02209909|DRUG|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
219726300|NCT02209909|DRUG|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
219726301|NCT00504231|BIOLOGICAL|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
219726302|NCT06557369|DEVICE|reSEES|"The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks."
219726303|NCT05123105|OTHER|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
219726304|NCT05123105|OTHER|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
219726305|NCT05123105|OTHER|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
219726306|NCT01382407|DRUG|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
219726307|NCT04836910|OTHER|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
219726308|NCT04836910|DRUG|Oral contraceptive pills|Hormonal treatment
219726309|NCT04836910|DRUG|Metformin|Insulin resistance treatment
219726310|NCT05556187|OTHER|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
219726311|NCT00101738|DRUG|Myfortic|
219233375|NCT04906759|BEHAVIORAL|Meals plus exercise|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
219233376|NCT04906759|BEHAVIORAL|Meals only|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
219233377|NCT04831398|DIETARY_SUPPLEMENT|melatonin|A 5mg dose of melatonin spay will be delivered sublingually.
219233378|NCT04831398|OTHER|Placebo|10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
219233379|NCT00334438|BIOLOGICAL|rituximab|250mg/m2, IV, Days 1 and 8
219233380|NCT00334438|DRUG|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
219726312|NCT04290676|DRUG|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
219726313|NCT01793454|OTHER|Fraction of inspired oxygen 40%|
219726314|NCT01793454|OTHER|Fraction of inspired oxygen 80%|
219726315|NCT02405208|DEVICE|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
219726316|NCT06169423|OTHER|Educative intervention|"an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
219726317|NCT05072041|DEVICE|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
219726318|NCT03928704|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219726319|NCT03928704|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
219726320|NCT06472765|DIAGNOSTIC_TEST|Vaginal Swab Collection|Vaginal Swab Collection
219726321|NCT03597867|OTHER|Placebo|Artificial tears for 3 days preoperatively
219726322|NCT03597867|DRUG|Dicloftil|Dosing of drug 3 days prior to surgery
219726323|NCT03597867|DRUG|Nevanac|Dosing of drug 3 days prior to surgery
219726324|NCT03597867|DRUG|Indom|Dosing of drug 3 days prior to surgery
219726325|NCT03597867|DRUG|Yellox|Dosing of drug 3 days prior to surgery
219726326|NCT04822415|DRUG|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
219726327|NCT04822415|DRUG|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
219726328|NCT01309880|DEVICE|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
219726329|NCT01309880|DEVICE|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
219726330|NCT03149419|DRUG|Paroxetine|
219726331|NCT03149419|DRUG|Placebo oral capsule|
219726332|NCT04415918|DRUG|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
219726333|NCT02871362|DIETARY_SUPPLEMENT|IQP-AS-118|Take one a day
219726334|NCT02871362|DIETARY_SUPPLEMENT|Placebo|Take one a day
219726335|NCT04995003|GENETIC|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
219726336|NCT04995003|DRUG|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
219726337|NCT04995003|DRUG|Nivolumab Injectable Product|3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
219726338|NCT05129709|BEHAVIORAL|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
219726339|NCT00095771|DRUG|arsenic trioxide|
219726340|NCT00095771|RADIATION|radiation therapy|
219726341|NCT03170440|DEVICE|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
219154448|NCT06215547|DEVICE|Enterra HDE|"Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit"
219154449|NCT04649021|BIOLOGICAL|BNT162b2|Intramuscular injection
219154450|NCT04649021|OTHER|Placebo|Intramuscular injection
219154451|NCT01837238|DIETARY_SUPPLEMENT|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
219154452|NCT01837238|DIETARY_SUPPLEMENT|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
219154453|NCT01819571|DRUG|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
219154454|NCT05242562|DRUG|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
219154455|NCT05242562|DRUG|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
219154456|NCT01526954|DEVICE|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
219154457|NCT02594631|PROCEDURE|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
219154458|NCT02594631|PROCEDURE|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
219154459|NCT02186769|DRUG|Risperdal® Consta®|
219154460|NCT02186769|DRUG|LY03004|
219154461|NCT00010777|PROCEDURE|Multiple Component Mind/Body therapy|
219154462|NCT02724592|DEVICE|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
219154463|NCT02724592|DEVICE|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
219154464|NCT01941758|BIOLOGICAL|trivalent influenza vaccine|
219154465|NCT01941758|OTHER|laboratory biomarker analysis|Correlative studies
219154466|NCT02584829|DRUG|Avelumab|Given IV
219154467|NCT02584829|OTHER|Laboratory Biomarker Analysis|Correlative studies
219154468|NCT02584829|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
219726342|NCT06252935|DEVICE|FormaAid|FormaAid is mainly composed of pure collagen extracted from bovine tendon, it is fabricated in the form of highly dense collagen matrix without chemical cross-linking to act as a barrier excluding epithelium.
219726343|NCT06252935|DEVICE|Bio-Gide|Bio-Gide is a bilayer collagen membrane made of porcine collagen, permits prompt and homogeneous vascularization and so brings about optimal tissue integration and wound stabilization.
219726344|NCT02015715|DRUG|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
219726345|NCT02015715|DRUG|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
219726346|NCT05413460|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
219726347|NCT05557682|OTHER|composite restorative treatment|Restorative treatment using dental materials
219726348|NCT03083379|DEVICE|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes"
219154469|NCT02584829|RADIATION|Radiation Therapy|Undergo radiation therapy
219154470|NCT02584829|BIOLOGICAL|Recombinant Interferon Beta|Given via intra-tumor injection
219154471|NCT04997616|DIETARY_SUPPLEMENT|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
219154472|NCT03118323|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
219154473|NCT02880137|DRUG|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
219726349|NCT03083379|DEVICE|EzPAP® POSITIVE AIRWAY PRESSURE|"* A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes"
219726350|NCT00906581|BEHAVIORAL|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
219726351|NCT04575324|BEHAVIORAL|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
219726352|NCT06389162|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is a type of non-invasive brain stimulation that involves passing a weak current between two electrodes placed on the scalp.
219726353|NCT01756001|DEVICE|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
219726354|NCT01756001|BEHAVIORAL|Daily email, text message, or phone call reminders|
219726355|NCT01756001|BEHAVIORAL|Paid for adherence|
219726356|NCT05548504|RADIATION|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
219726357|NCT05548504|RADIATION|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
219726358|NCT02847767|PROCEDURE|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
219726359|NCT02264041|DRUG|Cilobradine, low dose|
219726360|NCT02264041|DRUG|Cilobradine, high dose|
219726361|NCT02264041|DRUG|Itraconazole|
219726362|NCT05904366|DIAGNOSTIC_TEST|MR Spectroscopy (MRS)|MR Spectroscopy (MRS)
219726363|NCT05904366|DIAGNOSTIC_TEST|MR Elastography (MRE)|MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.
219726364|NCT01002105|DRUG|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
219726365|NCT01002105|OTHER|Control group|psychosocial intervention and placebo for 12 weeks
219154474|NCT02880137|PROCEDURE|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
219154475|NCT05365191|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
219154476|NCT01091740|DEVICE|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
219154477|NCT01091740|DEVICE|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
219726366|NCT04894240|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
219726367|NCT02826499|DEVICE|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
219154478|NCT00348322|DRUG|Systane Free Lubricant Eye Drops|
219154479|NCT00485459|DRUG|Atomoxetine Hydrochloride|
219154480|NCT00485459|DRUG|Placebo|
219154481|NCT05191810|BEHAVIORAL|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
219154482|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
219154483|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
219154484|NCT05255835|DEVICE|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
219154485|NCT05255835|DEVICE|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
219233381|NCT00334438|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
219233382|NCT00334438|RADIATION|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
219726368|NCT02826499|OTHER|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
219726369|NCT02035293|OTHER|PEP|
219726370|NCT03974009|OTHER|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
219154486|NCT03210896|DIETARY_SUPPLEMENT|Orange juice|Sub group I will drink Orange juice and have repeat measures.
219154487|NCT01939899|DRUG|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
219154488|NCT05958836|DEVICE|pacemaker|Micra TPS or traditional PM group
219154489|NCT05576857|OTHER|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
219154490|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg|
219154491|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 75µg|
219154492|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 100µg|
219233383|NCT06633133|PROCEDURE|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
219154493|NCT05674669|DRUG|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
219154494|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
219154495|NCT05772923|RADIATION|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
219154496|NCT05772923|PROCEDURE|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
219154497|NCT00585052|DRUG|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
219154498|NCT00585052|DRUG|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
219154499|NCT06516328|OTHER|Observational|GCF and saliva samples obtained.
219154500|NCT04910698|DRUG|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
219154501|NCT02551536|DRUG|Montelukast|
219154502|NCT02551536|DRUG|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
219154503|NCT02551536|DRUG|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
219154504|NCT05953675|DRUG|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
219154505|NCT05953675|DRUG|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
219154506|NCT05073224|DIAGNOSTIC_TEST|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
219233384|NCT04564898|DRUG|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
219233385|NCT04564898|DRUG|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
219233386|NCT04564898|DRUG|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
219360776|NCT02669472|OTHER|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F\&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
219233387|NCT05159076|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|"The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time."
219233388|NCT06519955|COMBINATION_PRODUCT|Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)|"Weight 50-74.9 kg:~* ropivacaine 100mg/epinephrine 50 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 75-99.9 kg:~* Ropivacaine 150mg/epinephrine 100 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 100+ kg:~* Ropivacaine 200mg/epinephrine 150 mcg/ketorolac 15 mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total"
219233389|NCT03854734|BEHAVIORAL|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
219233390|NCT03854734|BEHAVIORAL|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
219233391|NCT02196259|DRUG|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
219233392|NCT04889326|OTHER|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
219233393|NCT03734432|DEVICE|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
219233394|NCT00576485|PROCEDURE|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
219233395|NCT02992496|DRUG|Ketamine|1mg/kg, 6 applications over 2 weeks
219233396|NCT02992496|DRUG|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
219233397|NCT01394406|DRUG|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
219233398|NCT01394406|DRUG|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
219233399|NCT00215943|DRUG|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
219233400|NCT00215943|DRUG|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
219233401|NCT00215943|DRUG|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
219233402|NCT00215943|DRUG|vincristine|As outlined in VAD Treatment Arm
219233403|NCT00215943|DRUG|adriamycin|As outlined in VAD Treatment arm
219233404|NCT02827851|PROCEDURE|Liposuction|
219233405|NCT02827851|OTHER|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
219233406|NCT02827851|OTHER|Intraarticular administration of autologous SVF|
219233407|NCT01655199|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
219233408|NCT00211276|DRUG|ONTAK (denileukin diftitox)|
219233409|NCT03527329|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
219233410|NCT04683900|OTHER|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
219233411|NCT04683900|OTHER|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
219233412|NCT00360035|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
219233413|NCT00993434|BEHAVIORAL|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
219233414|NCT00993434|BEHAVIORAL|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
219233415|NCT06309641|DIAGNOSTIC_TEST|Blood sample after treatment|Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.
219233416|NCT06309641|OTHER|Case reports|Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
219726371|NCT03974009|OTHER|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
219726372|NCT03974009|OTHER|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
219154507|NCT05073224|OTHER|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
219154508|NCT05073224|OTHER|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
219154509|NCT05073224|DIAGNOSTIC_TEST|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
219154510|NCT05447936|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
219154511|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
219154512|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
219154513|NCT01900249|DRUG|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
219154514|NCT06509243|BIOLOGICAL|tablets Acarizax|sublingual immunotherapy to house dust mites
219154515|NCT06509243|BIOLOGICAL|dupilumab|dupilumab - biologic therapy for atopic dermatitis
219154516|NCT06509243|DRUG|cyclosporine|cyclosporine used in atopic dermatitis
219154517|NCT02387645|PROCEDURE|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
219154518|NCT01690572|DEVICE|Paclitaxel coated balloon catheter|Dilatation of the target lesion
219233417|NCT04532333|DRUG|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
219233418|NCT04532333|DRUG|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
219361082|NCT05008094|DIAGNOSTIC_TEST|ELISA (Enzyme-Linked Immunosorbent Assay)|ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples
219726373|NCT00281801|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
219726374|NCT00281801|PROCEDURE|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
219154519|NCT01690572|DEVICE|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
219154520|NCT05298397|OTHER|EAT-PTSD adapted for youth for anxiety|"This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion."
219154521|NCT03960398|DRUG|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
219154522|NCT00219791|DRUG|glucarpidase (50 Units/kg)|
219154523|NCT00223600|BEHAVIORAL|Nutritional and life style counseling|
219154524|NCT03978728|DEVICE|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
219154525|NCT02837796|PROCEDURE|transobturator tape|
219233419|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
219726375|NCT04786925|OTHER|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
219154526|NCT03929432|DEVICE|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
219154527|NCT03929432|DEVICE|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
219154528|NCT06831474|DRUG|Rivaroxaban 10 MG Oral Tablet|10mg rivaroxaban daily
219154529|NCT06831474|DRUG|Rivaroxaban 20 MG Oral Tablet|20mg rivaroxaban daily
219154530|NCT06097390|DRUG|Semaglutide|Oral administration
219154531|NCT05012072|BEHAVIORAL|The Mastery Lifestyle Intervention|Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
219154532|NCT05662917|BEHAVIORAL|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
219154533|NCT02748954|BEHAVIORAL|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
219154534|NCT02748954|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
219154535|NCT02748954|BEHAVIORAL|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
219154536|NCT02748954|BEHAVIORAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
219154537|NCT02748954|BEHAVIORAL|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
219154538|NCT05188781|DRUG|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
219154539|NCT00609310|DIETARY_SUPPLEMENT|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
219154540|NCT05489484|DEVICE|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
219154541|NCT05650567|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
219154542|NCT05650567|DRUG|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
219154543|NCT02156050|DEVICE|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
219154544|NCT03429998|DRUG|evolocumab|evolocumab 140 mg/biweekly
219154545|NCT03429998|DRUG|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
219154546|NCT03429998|PROCEDURE|LDL apheresis|LDL apheresis biweekly
219726376|NCT04786925|OTHER|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
219726377|NCT02665936|DRUG|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
219726378|NCT02665936|DRUG|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
219726379|NCT02665936|DRUG|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
219726380|NCT03403517|DRUG|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
219726381|NCT03403517|DRUG|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
219154547|NCT01537419|BEHAVIORAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
219154548|NCT01537419|BEHAVIORAL|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
219154549|NCT04004819|DRUG|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
219154550|NCT00420901|DRUG|sildenafil|
219154551|NCT03152344|PROCEDURE|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
219154552|NCT05741996|BEHAVIORAL|Taping|Taping types and brace acute effects for knee osteoartritis
219154553|NCT02860910|BEHAVIORAL|Cognitive Behavioral Group Therapy|
219154554|NCT05822063|DRUG|Lidocaine topical|lidocaine spray
219154555|NCT05822063|OTHER|cold packs|ice packs
219154556|NCT05822063|DEVICE|flash lights|flash lights by camera
219154557|NCT02519517|PROCEDURE|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
219154558|NCT06223113|DEVICE|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
219154559|NCT05126121|DRUG|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
219154560|NCT01351493|DRUG|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
219154561|NCT01351493|DRUG|placebo|placebo Gel, once or twice per day, 12weeks
219154562|NCT02620410|DEVICE|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
219154563|NCT05993507|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
219154564|NCT03678558|OTHER|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
219154565|NCT00444600|DRUG|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
219154566|NCT00444600|DRUG|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
219154567|NCT00444600|DRUG|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
219154568|NCT00444600|DRUG|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
219154569|NCT00481390|PROCEDURE|Cheek cells sample|Cheek cells sample
219154570|NCT00481390|PROCEDURE|Blood sample|Blood sample
219726382|NCT05027282|DEVICE|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
219154571|NCT05132478|OTHER|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
219154572|NCT05132478|OTHER|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
219154573|NCT05386498|PROCEDURE|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
219154574|NCT05386498|PROCEDURE|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
219154575|NCT05386498|PROCEDURE|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
219154576|NCT00106080|BEHAVIORAL|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
219154577|NCT00865436|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
219154578|NCT00865436|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
219154579|NCT03535558|DRUG|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
219154580|NCT03535558|DRUG|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
219154581|NCT03535558|DRUG|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
219154582|NCT05032638|BEHAVIORAL|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
219154583|NCT05032638|BEHAVIORAL|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
219154584|NCT06335472|PROCEDURE|3 nerves pulsed radiofrequency with hydrodissection|"Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt"
219233420|NCT03430609|DIAGNOSTIC_TEST|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
219361083|NCT05008094|DIAGNOSTIC_TEST|Fluorescent correlation spectroscopy (FCS)|Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
219361084|NCT03315351|PROCEDURE|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
219726383|NCT00932854|PROCEDURE|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
219726384|NCT00167570|DEVICE|Prosthetic socket fabricated using selective laser sintering|
219726385|NCT00456612|PROCEDURE|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
219726386|NCT00266812|DRUG|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
219726387|NCT00266812|PROCEDURE|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
219726388|NCT03695094|DRUG|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
219726389|NCT03695094|DRUG|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
219726390|NCT03695094|DRUG|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
219233421|NCT03430609|DIAGNOSTIC_TEST|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
219233422|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
219726391|NCT03695094|DRUG|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
219726392|NCT03695094|DRUG|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
219726393|NCT04139525|BIOLOGICAL|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
219233423|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
219233424|NCT04690309|DRUG|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
219233425|NCT05411471|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
219726394|NCT04139525|BIOLOGICAL|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
219726395|NCT03986541|DIAGNOSTIC_TEST|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
219726396|NCT04038398|PROCEDURE|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
219726397|NCT00205608|DEVICE|Positron Emission Tomography|camera is new
219726398|NCT05000437|OTHER|HIIT|3x/week high intensity interval training for 12 weeks
219726399|NCT01834261|DRUG|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
219726400|NCT01834261|DRUG|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
219726401|NCT02316613|DRUG|Rituximab|
219726402|NCT04568772|DRUG|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
219726403|NCT04568772|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
219726404|NCT04568772|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
219726405|NCT04568772|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
219726406|NCT01166945|DRUG|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
219726407|NCT01166945|DRUG|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
219726408|NCT05838872|DEVICE|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
219726409|NCT01160900|PROCEDURE|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
219726410|NCT02410876|PROCEDURE|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
219726411|NCT02410876|PROCEDURE|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
219726412|NCT01135056|DEVICE|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
219726413|NCT01135056|DRUG|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
219726414|NCT01192360|PROCEDURE|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
219154585|NCT06335472|PROCEDURE|suprascapular nerve pulsed radiofrequency with hydrodissection|"The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt."
219154586|NCT01852071|GENETIC|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
219154587|NCT01852071|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
219154588|NCT01852071|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
219154589|NCT02235272|DRUG|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
219154590|NCT02235272|DRUG|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
219154591|NCT06152939|OTHER|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
219154592|NCT02396602|BEHAVIORAL|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
219154593|NCT01843569|BIOLOGICAL|In Vitro maturation|
219154594|NCT04065802|RADIATION|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
219154595|NCT03319797|DRUG|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
219154596|NCT03701386|PROCEDURE|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
219154597|NCT03701386|PROCEDURE|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
219154598|NCT01116596|DRUG|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
219154599|NCT01414738|RADIATION|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
219154600|NCT01075113|DRUG|sorafenib tosylate|Given orally
219154601|NCT01075113|DRUG|vorinostat|Given orally
219154602|NCT01839331|BIOLOGICAL|4 mL injection of Ampion|4 mL Injection of Ampion
219154603|NCT01839331|BIOLOGICAL|10 mL Injection of Ampion|10 mL Injection of Ampion
219154604|NCT01839331|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
219726415|NCT01192360|PROCEDURE|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
219726416|NCT04398914|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
219726417|NCT04398914|DRUG|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
219154605|NCT01839331|DRUG|10 mL Injection of Placebo|10 mL Injection of Placebo
219154606|NCT04056624|DIETARY_SUPPLEMENT|High carotenoid juice|Juice with high carotenoids
219154607|NCT04056624|DIETARY_SUPPLEMENT|Placebo control - Apple juice|Juice with negligible carotenoids
219154608|NCT03449173|DRUG|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
219154609|NCT00243529|BIOLOGICAL|autologous dendritic cell vaccine|
219154610|NCT00703820|DRUG|Cytarabine|See Detailed Description
219154611|NCT00703820|DRUG|Daunorubicin|See Detailed Description
219154612|NCT00703820|DRUG|Etoposide|See Detailed Description
219154613|NCT00703820|DRUG|Clofarabine|See Detailed Description
219154614|NCT00703820|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219154615|NCT03977935|DEVICE|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
219154616|NCT03565055|BEHAVIORAL|IPCST|"Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care"
219154617|NCT03565055|BEHAVIORAL|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services"
219233426|NCT04371406|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
219233427|NCT04371406|DIETARY_SUPPLEMENT|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
219233428|NCT00750477|DIETARY_SUPPLEMENT|NEM|see Treatment Arms
219233429|NCT00750477|DIETARY_SUPPLEMENT|Placebo|Placebo comparator containing inactives
219233430|NCT00248898|PROCEDURE|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
219233431|NCT00000284|DRUG|Cotinine fumarate|
219233432|NCT04311983|BEHAVIORAL|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
219233433|NCT04311983|BEHAVIORAL|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
219233434|NCT01759459|DRUG|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
219233435|NCT01759459|DRUG|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
219233436|NCT01759459|DRUG|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
219233437|NCT00311545|BIOLOGICAL|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
219233438|NCT01711788|PROCEDURE|Intrabone infusion of umbilical cord blood stem cells|
219233439|NCT03706872|OTHER|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
219233440|NCT05670561|DRUG|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
219233441|NCT05670561|DRUG|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
219233442|NCT04887857|DRUG|CC-486|Specified dose on specified days
219233443|NCT04887857|DRUG|Venetoclax|Specified dose on specified days
219233444|NCT01381549|DRUG|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
219233445|NCT01381549|DRUG|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
219233446|NCT01381549|OTHER|Placebo|saline placebo
219360777|NCT02669472|BEHAVIORAL|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F\&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F\&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
219726418|NCT04398914|DRUG|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
219726419|NCT04398914|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
219726420|NCT04398914|DRUG|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
219726421|NCT04398914|DRUG|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
219726422|NCT04398914|DRUG|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
219726423|NCT04398914|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
219360778|NCT02669472|BEHAVIORAL|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
219726424|NCT05509374|DRUG|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
219726425|NCT05509374|DRUG|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
219726426|NCT05509374|DRUG|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
219726427|NCT05915169|OTHER|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
219726428|NCT02444377|BEHAVIORAL|Interval training|
219726429|NCT00000987|DRUG|Bleomycin sulfate|
219726430|NCT00000987|DRUG|Vincristine sulfate|
219726431|NCT00000987|DRUG|Doxorubicin hydrochloride|
219726432|NCT00000987|DRUG|Zidovudine|
219726433|NCT05343507|DRUG|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
219154618|NCT06015399|PROCEDURE|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
219726434|NCT05343507|DRUG|Placebo|Saline Solution
219154619|NCT06015399|PROCEDURE|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
219154620|NCT03440034|DRUG|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
219154621|NCT05384691|DRUG|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
219154622|NCT01522573|PROCEDURE|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
219154623|NCT00586222|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
219154624|NCT00586222|OTHER|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
219154625|NCT03062332|GENETIC|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
219154626|NCT05951309|DRUG|inofolic combi|The patients in this group were given inofolic combi once a day for 12-16 weeks
219154627|NCT05951309|DRUG|Glucophage 500Mg Tablet|The patients in this group were given glucophage three times a day for 12-16 weeks
219154628|NCT00855400|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
219154629|NCT00855400|PROCEDURE|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
219154630|NCT01730352|DRUG|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
219360779|NCT02007603|DRUG|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
219726435|NCT06310109|OTHER|PICU diary|.The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
219726436|NCT00784927|BIOLOGICAL|rituximab|
219726437|NCT00784927|DRUG|cyclophosphamide|
219726438|NCT00784927|DRUG|dexamethasone|
219726439|NCT00784927|DRUG|lenalidomide|
219726440|NCT01779362|DRUG|Metformin|Titrated to 1000 mg BID
219726441|NCT01779362|DRUG|Liraglutide|Titrated to 1.8 mg/day
219726442|NCT01779362|DRUG|Glargine|Titrated to target fasting glucose \<90 mg/dl
219726443|NCT01779362|DRUG|Placebo|Matching to metformin 1000 mg BI
219726444|NCT05649371|OTHER|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
219726445|NCT01922661|DRUG|REGN1908-1909|
219726446|NCT01922661|OTHER|placebo|
219726447|NCT00714272|DEVICE|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
219726448|NCT00714272|DEVICE|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
219726449|NCT00422461|DRUG|placebo|placebo, oral, tablets, once daily, for 28 days
219726450|NCT00422461|DRUG|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
219726451|NCT00422461|DRUG|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
219726452|NCT00422461|DRUG|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
219726453|NCT01471574|DRUG|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
219726454|NCT01471574|DRUG|Ribavirin|Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
219726455|NCT01471574|DRUG|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
219726456|NCT02590510|DRUG|methotrexate|The quantity of methotrexate is different in the two groups.
219726457|NCT04568512|DIAGNOSTIC_TEST|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
219726458|NCT04568512|DIAGNOSTIC_TEST|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
219726459|NCT01795937|DRUG|Itraconazole|twice daily
219726460|NCT01795937|DRUG|Atorvastatin|single dose
219726461|NCT01795937|DRUG|Faldaprevir|once daily
219726462|NCT01795937|DRUG|Rosuvastatin|single dose
219726463|NCT01795937|DRUG|Faldaprevir|once daily
219726464|NCT00635180|BEHAVIORAL|isometric exercise|
219726465|NCT01459159|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
219726466|NCT00673829|BIOLOGICAL|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
219726467|NCT00673829|BIOLOGICAL|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
219726468|NCT04261595|OTHER|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
219726469|NCT04261595|BEHAVIORAL|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
219726470|NCT04261595|OTHER|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
219726471|NCT05634928|OTHER|collection data|collection data
219726472|NCT01028053|DRUG|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
219726473|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + blood-based HIV self-test|Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
219726474|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + oral fluid HIV self-test|Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
219726475|NCT04097912|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
219726476|NCT04027946|DRUG|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
219726477|NCT04027946|DRUG|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
219726478|NCT04027946|DIAGNOSTIC_TEST|Mesothelin Expression|Testing for mesothelin expression performed at screening
219726479|NCT04027946|DIAGNOSTIC_TEST|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
219154631|NCT01625104|OTHER|Non Intervention|Business as usual
219154632|NCT01625104|OTHER|Agressive Intervention Process Improvement Strategies|
219726480|NCT01763957|BEHAVIORAL|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
219726481|NCT01763957|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
219726482|NCT03383939|DRUG|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
219726483|NCT03383939|DRUG|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
219726484|NCT03347539|DEVICE|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
219726485|NCT02346916|DRUG|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
219726486|NCT00003107|BIOLOGICAL|recombinant interleukin-12|
219726487|NCT00284648|PROCEDURE|Surgical repair Achilles tendon rupture|
219726488|NCT00284648|PROCEDURE|Non-surgical repair Achilles tendon rupture|
219726489|NCT02549378|DEVICE|confocal microscopy|microvessel diameter measured by confocal microscopy
219360780|NCT02007603|DRUG|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
219360781|NCT02007603|PROCEDURE|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
219360782|NCT06548893|OTHER|Group acceptance and commitment therapy (ACT)|Group psychotherapy based on ACT + EPR
219726490|NCT02296697|DEVICE|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
219726491|NCT02296697|DEVICE|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
219726492|NCT02296697|OTHER|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
219726493|NCT03591419|DEVICE|polymer clip|polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
219726494|NCT03591419|DEVICE|endoloop|endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
219726495|NCT05373966|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
219726496|NCT01897389|DRUG|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
219726497|NCT01897389|DRUG|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
219726498|NCT01897389|DRUG|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
219726499|NCT01897389|DRUG|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
219726500|NCT01897389|DRUG|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
219154633|NCT04727840|DRUG|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
219154634|NCT03289468|DIAGNOSTIC_TEST|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
219154635|NCT02796586|OTHER|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
219154636|NCT02586597|DEVICE|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
219360783|NCT02641509|DEVICE|NBI during polypectomy|NBI to perform the polipectomy
219360784|NCT02641509|DEVICE|no NBI during polypectomy|no NBI to perform the polypectomy
219726501|NCT02022527|DRUG|Acetyl Salicylic Acid|
219726502|NCT02022527|DRUG|Warfarin|
219726503|NCT02022527|DRUG|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
219726504|NCT03880890|PROCEDURE|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
219233447|NCT06123936|OTHER|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
219233448|NCT04401943|OTHER|online fatigue intervention|on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
219233449|NCT02565225|BEHAVIORAL|RheumaLive App use|
219233450|NCT02820909|PROCEDURE|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
219233451|NCT02820909|PROCEDURE|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
219233452|NCT00824057|DRUG|AZD6280|oral
219233453|NCT00824057|DRUG|Midazolam|oral
219233454|NCT00824057|DRUG|Caffeine|oral
219233455|NCT00002409|DRUG|Lamivudine/Zidovudine|
219233456|NCT00002409|DRUG|Abacavir sulfate|
219233457|NCT02765984|DEVICE|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
219233458|NCT04221321|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg
219233459|NCT04221321|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
219233460|NCT04221321|DRUG|RAPA114|RAPA114 tablet
219233461|NCT05213585|DRUG|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
219233462|NCT00996164|DRUG|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
219233463|NCT00996164|DRUG|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
219233464|NCT06231667|OTHER|Education|four training sessions were applied to the intervention group
219233465|NCT01228565|OTHER|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
219233466|NCT01228565|OTHER|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
219233467|NCT06139835|BIOLOGICAL|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
219233468|NCT01962402|DRUG|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
219233469|NCT01962402|BEHAVIORAL|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
219233470|NCT00994708|DRUG|esomeprazole|
219233471|NCT00827294|BEHAVIORAL|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
219233472|NCT04594876|OTHER|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
219233473|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
219233474|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
219233475|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
219233476|NCT02556606|DRUG|Midazolam|single 40 min infusion of MID 0.03mg/Kg
219233477|NCT00403845|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219233478|NCT00403845|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219233479|NCT00403845|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219233480|NCT02383693|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
219233481|NCT03147586|DRUG|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
219233482|NCT03147586|DRUG|placebo|placebo
219361085|NCT03315351|OTHER|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy"
219233483|NCT05130099|OTHER|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
219233484|NCT05044286|OTHER|no intervention|no intervention
219233485|NCT05779696|OTHER|No-intervention|This is a non-intervention study.
219233486|NCT04874142|DRUG|YYC506-T|single administration
219233487|NCT04874142|DRUG|YYC506-A|single administration
219233488|NCT04874142|DRUG|YYC506-T + YYC506-A|concomotant administration
219233489|NCT04874142|DRUG|YYC506-A + YYC506-T|concomotant administration
219233490|NCT00169923|DRUG|rosiglitazone|
219233491|NCT02049684|PROCEDURE|Patch|
219233492|NCT00567606|OTHER|Strength/Weight Training & Drug/Supplement|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
219233493|NCT00567606|COMBINATION_PRODUCT|Drug/Supplement only|G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
219726505|NCT01509924|OTHER|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
219726506|NCT04094805|DRUG|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
219726507|NCT04094805|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
219726508|NCT04393844|OTHER|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
219726509|NCT05137613|OTHER|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
219726510|NCT05137613|OTHER|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
219726511|NCT00983957|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
219726512|NCT00983957|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
219726513|NCT04553536|DRUG|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
219726514|NCT00986232|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
219726515|NCT00986232|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
219233494|NCT00578344|DRUG|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
219233495|NCT00578344|BIOLOGICAL|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
219233496|NCT00578344|DRUG|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
219726516|NCT00986232|BIOLOGICAL|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
219726517|NCT02245373|DRUG|Antidepressants|
219726518|NCT02245373|OTHER|Active Monitoring|
219726519|NCT00113685|DRUG|Hypertonic Saline-Dextran Solution|
219726520|NCT00113685|DRUG|Lactated Ringer's Solution|
219726521|NCT03004092|PROCEDURE|blood sample|Twice weekly blood sample, and at every outpatient visit
219726522|NCT00790933|DRUG|Vedolizumab|Vedolizumab intravenous infusion
219726523|NCT00349076|DRUG|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
219233497|NCT02935673|DRUG|lumicitabine|Oral administration of lumicitabine as tablet.
219233498|NCT02935673|DRUG|Placebo|Oral administration of matching placebo.
219233499|NCT03898999|OTHER|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
219726524|NCT00349076|DRUG|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
219726525|NCT01155609|PROCEDURE|quality-of-life assessment|Ancillary studies
219361086|NCT02063035|DRUG|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
219726526|NCT01155609|PROCEDURE|management of therapy complications|Discontinue supplement; treat symptomatically
219726527|NCT01155609|DIETARY_SUPPLEMENT|L-lysine|Given PO
219726528|NCT04280861|OTHER|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
219233500|NCT04349709|BEHAVIORAL|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
219233501|NCT01077440|GENETIC|DNA analysis|DNA analysis will be performed on samples collected.
219233502|NCT01077440|GENETIC|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
219233503|NCT01077440|OTHER|flow cytometry|Flow cytometry will be done on the samples collected.
219233504|NCT01077440|OTHER|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
219233505|NCT04257916|OTHER|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
219233506|NCT04257916|OTHER|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
219233507|NCT02772510|DEVICE|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
219233508|NCT02772510|DEVICE|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
219233509|NCT02635698|OTHER|Optifast|medically-supervised weight management program
219233510|NCT02635698|OTHER|Food-Based|low-energy, low-fat diet
219233511|NCT06220578|DEVICE|Oculus pentacam HR|Examination of corneal parameters by pentacam
219233512|NCT00831194|BEHAVIORAL|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
219233513|NCT01303471|DRUG|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
219233514|NCT02894086|OTHER|database.|database
219233515|NCT01444404|DRUG|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
219233516|NCT03093532|OTHER|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1\) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
219233517|NCT03093532|OTHER|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
219233518|NCT05817292|DIETARY_SUPPLEMENT|Probiotics|Assumption of commercial probiotics
219233519|NCT05817292|OTHER|No intervention|No assumption of probiotics
219233520|NCT02948309|DRUG|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
219233521|NCT02948309|DRUG|Placebo|1ml subcutaneous injection 3 times/week
219233522|NCT03204175|OTHER|FIT Plus|"* Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste"
219233523|NCT03204175|OTHER|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
219233524|NCT04328467|DRUG|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
219233525|NCT04328467|OTHER|Placebo|Placebo; tablet; oral
219233526|NCT00689637|DRUG|AZD3480|AZD3480 capsules qd, 12 days
219233527|NCT00689637|DRUG|Placebo|Placebo capsules qd, 12 days
219233528|NCT00689637|DRUG|Warfarin|Warfarin: single dose on day 6
219233529|NCT02952170|OTHER|MRI|MRI to assess hepatic steatosis
219233530|NCT02903602|BEHAVIORAL|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
219233531|NCT02903602|BEHAVIORAL|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
219233532|NCT02017509|PROCEDURE|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
219726529|NCT04080934|BEHAVIORAL|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
219361087|NCT02063035|DRUG|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
219233533|NCT02017509|PROCEDURE|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
219233534|NCT02017509|PROCEDURE|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
219233535|NCT02017509|GENETIC|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
219233536|NCT01117285|OTHER|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
219233537|NCT01117285|OTHER|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders."
219233538|NCT03064256|BEHAVIORAL|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
219233539|NCT03064256|BEHAVIORAL|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
219233540|NCT00990184|DRUG|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
219233541|NCT00990184|OTHER|placebo|tablet (s) orally given with evening meal
219233542|NCT01558999|DRUG|High concentration SI-614|1 drop in each eye 4 times a day
219233543|NCT01558999|DRUG|Low concentration SI-614|1 drop in each eye 4 times a day
219233544|NCT01558999|DRUG|Vehicle|1 drop in each eye 4 times a day
219233545|NCT03925909|DIETARY_SUPPLEMENT|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
219233546|NCT03284840|DIAGNOSTIC_TEST|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
219233547|NCT03284840|DIAGNOSTIC_TEST|Thyroid size|Thyroid size by ultrasound.
219233548|NCT02769130|DRUG|Losartan|Losartan is given for 12 months
219233549|NCT01521702|DRUG|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
219233550|NCT01521702|PROCEDURE|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
219233551|NCT04897347|DEVICE|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
219233552|NCT04897347|DEVICE|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
219233553|NCT02705885|DIETARY_SUPPLEMENT|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
219233554|NCT02705885|DIETARY_SUPPLEMENT|Placebo IgY|Placebo IgY
219233555|NCT03835416|DIETARY_SUPPLEMENT|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
219233556|NCT05830032|DIETARY_SUPPLEMENT|Soluble corn fibre|As a powdered beverage
219233557|NCT05830032|DIETARY_SUPPLEMENT|Inulin|As a powdered beverage
219233558|NCT05830032|DIETARY_SUPPLEMENT|soluble corn fibre and inulin|As a powdered beverage
219233559|NCT05830032|DIETARY_SUPPLEMENT|Maltodextrin|As a powdered beverage
219361088|NCT06114979|DRUG|Silodosin|Each patient will receive 8 mg of silodosin tablet once daily.
219726530|NCT03395990|PROCEDURE|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
219233560|NCT01792505|BIOLOGICAL|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
219233561|NCT03697018|OTHER|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
219233562|NCT00483457|DRUG|enzyme inhibitor therapy|enzyme inhibitor therapy
219233563|NCT00483457|GENETIC|protein expression analysis|protein expression analysis
219233564|NCT00483457|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
219233565|NCT00483457|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219233566|NCT00483457|PROCEDURE|biopsy|biopsy
219233567|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols and fish oil|4 weeks intervention, 3 times daily
219233568|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols|4 weeks intervention, 3 times daily
219726531|NCT03395990|PROCEDURE|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
219726532|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
219726533|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
219233569|NCT01313988|DIETARY_SUPPLEMENT|Placebo|4 weeks, 3 times daily
219233570|NCT04454112|DEVICE|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
219233571|NCT04470089|DRUG|Myramistin|Oromucosal application
219233572|NCT00755794|DRUG|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
219233573|NCT04078217|DEVICE|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
219233574|NCT04078217|OTHER|Booklet|Home-based exercise program using a paper booklet (not the technology).
219726534|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
219726535|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
219726536|NCT00245570|DRUG|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
219233575|NCT06510946|BEHAVIORAL|(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease|"The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet."
219233576|NCT05758532|BIOLOGICAL|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
219233577|NCT06200909|OTHER|Mindfulness Meditation|8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.
219233578|NCT06200909|OTHER|Psychoeducation|"A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content."
219233579|NCT06200909|OTHER|Wait list control|Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
219233580|NCT04255823|OTHER|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
219233581|NCT04255823|OTHER|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
219361089|NCT06114979|DRUG|Placebo|Each patient will receive placebo tablet.
219361090|NCT04177719|DRUG|Oxytocin|oxytocin will be given intranasally. The order of administration will be counterbalanced
219726537|NCT00245570|DRUG|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
219726538|NCT00245570|DRUG|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
219726539|NCT00245570|DRUG|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
219726540|NCT01829165|DEVICE|rTMS Treatment|MRI-compatible TMS stimulator
219726541|NCT01829165|DEVICE|Sham rTMS Treatment|
219726542|NCT06343883|DEVICE|low-intensity focused ultrasound - low pressure|low-intensity focused ultrasound applied to the S1.
219726543|NCT06343883|DEVICE|low-intensity focused ultrasound - medium pressure|low-intensity focused ultrasound applied to the S1.
219726544|NCT06343883|DEVICE|low-intensity focused ultrasound - high pressure|low-intensity focused ultrasound applied to the S1.
219726545|NCT05417256|DEVICE|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
219726546|NCT05417256|DEVICE|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
219726547|NCT00937911|DRUG|YM150|oral
219726548|NCT03290729|PROCEDURE|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
219726549|NCT01272622|RADIATION|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
219726550|NCT01272622|OTHER|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
219726551|NCT01033227|DRUG|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
219233582|NCT06257563|OTHER|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
219726552|NCT05509673|OTHER|Lipofilling (sublesional fat grafting)|
219726553|NCT01881295|DIETARY_SUPPLEMENT|Placebo control|
219726554|NCT01881295|DIETARY_SUPPLEMENT|Low dose potassium gluconate|
219726555|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potassium gluconate|
219726556|NCT01881295|DIETARY_SUPPLEMENT|High dose potassium gluconate|
219726557|NCT01881295|DIETARY_SUPPLEMENT|Low dose potato|
219726558|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potato|
219726559|NCT01881295|DIETARY_SUPPLEMENT|High dose potato|
219726560|NCT01881295|DIETARY_SUPPLEMENT|High dose French fries|
219726561|NCT01881295|DIETARY_SUPPLEMENT|Basal diet control|
219726562|NCT02142621|OTHER|transpyloric feeding|
219726563|NCT02142621|OTHER|gastric feeding|
219726564|NCT02740010|DEVICE|EDOF Mini WELL Ready IOL|implant
219726565|NCT03191201|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
219726566|NCT03191201|DRUG|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
219726567|NCT03648970|DRUG|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
219726568|NCT02548364|DRUG|Calcifediol|calcifediol treatment
219233583|NCT05585398|DRUG|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
219233584|NCT00708799|OTHER|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
219233585|NCT05822791|DIAGNOSTIC_TEST|Prolonged cardiac monitoring|Prolonged cardiac monitoring
219726569|NCT02548364|DRUG|Placebo|placebo control group
219726570|NCT01805570|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
219726571|NCT01805570|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
219726572|NCT02002208|DRUG|OC000459|Oral CRTH2 antagonist
219726573|NCT03676725|DRUG|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
219726574|NCT03662971|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
219726575|NCT01030575|DRUG|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
219726576|NCT01030575|DRUG|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
219726577|NCT01030575|DRUG|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
219726578|NCT01030575|DRUG|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
219233586|NCT05822791|DIAGNOSTIC_TEST|ECG|Electrocardiogram
219233587|NCT01237977|DRUG|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
219726579|NCT05696158|DEVICE|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
219726580|NCT06531473|PROCEDURE|HoLEP|Patients will be randomized to one of the laser energy groups day of surgery.
219726581|NCT00489268|DEVICE|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
219726582|NCT05560633|OTHER|No intervention|No intervention
219726583|NCT00283582|DRUG|rhTPO|
219726584|NCT02457286|DRUG|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
219726585|NCT02457286|BEHAVIORAL|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
219726586|NCT02457286|DEVICE|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
219726587|NCT01579305|DEVICE|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
219726588|NCT01579305|DEVICE|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
219726589|NCT02227966|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219726590|NCT02227966|DEVICE|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
219154637|NCT05419570|OTHER|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
219726591|NCT05470725|DRUG|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
219726592|NCT06237907|OTHER|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
219154638|NCT05103358|DRUG|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
219154639|NCT03065569|DRUG|Bupivacaine|16 mL of 0.125% bupivacaine
219154640|NCT00541268|DEVICE|ICD|Intracardioverter defibrillators from 2 different manufacturers
219154641|NCT00541268|OTHER|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
219154642|NCT02866968|PROCEDURE|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
219154643|NCT02310113|OTHER|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
219154644|NCT03947346|OTHER|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
219154645|NCT06427863|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
219154646|NCT06427863|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
219154647|NCT04698655|OTHER|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
219154648|NCT04698655|OTHER|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
219726593|NCT06237907|OTHER|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
219154649|NCT04698655|OTHER|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
219154650|NCT00377182|DRUG|Copegus|1000/1200mg po daily for 4 weeks
219726594|NCT05945758|PROCEDURE|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
219233588|NCT01237977|DRUG|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
219233589|NCT05803122|OTHER|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
219233590|NCT02010866|BEHAVIORAL|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
219233591|NCT05529485|PROCEDURE|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
219233592|NCT05658809|PROCEDURE|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
219233593|NCT00286013|DRUG|Association of gemcitabine, oxaliplatin and radiotherapy|
219233594|NCT04867772|OTHER|Home based rehabilitation|
219233595|NCT01728090|OTHER|hand sanitizer|alcohol-based, hydroalcoholic gel
219233596|NCT02152384|DRUG|Insulin Peglispro|Administered SC
219233597|NCT02152384|DRUG|Insulin Lispro|Administered SC
219233598|NCT02152384|DRUG|Insulin Glargine|Administered SC
219233599|NCT00823966|DRUG|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
219233600|NCT04471805|DEVICE|Sham transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
219233601|NCT04471805|DEVICE|Transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
219154651|NCT00377182|DRUG|PEGASYS|180 micrograms sc weekly for 4 weeks
219154652|NCT00377182|DRUG|RO5024048 1500mg|1500mg po bid for 4 weeks
219154653|NCT00377182|DRUG|RO5024048 3000mg|3000mg po bid for 4 weeks
219154654|NCT03531840|DRUG|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
219154655|NCT03531840|DEVICE|ClinOmics|Non-significant risk (NSR) device
219154656|NCT04978233|OTHER|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
219154657|NCT01671449|DRUG|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
219154658|NCT01671449|DRUG|Cisplatin|60 mg/m2/day Day 1
219154659|NCT01671449|DRUG|Oxaliplatin|130 mg/m2/day Day 1
219154660|NCT01477268|DRUG|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
219154661|NCT02545634|DIETARY_SUPPLEMENT|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
219154662|NCT02545634|OTHER|Placebo|
219154663|NCT00770757|DRUG|CC-4047|
219154664|NCT04834648|BEHAVIORAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
219154665|NCT01845844|DRUG|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
219154666|NCT01796067|BEHAVIORAL|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
219154667|NCT01796067|BEHAVIORAL|Basic Health Education|This group will receive the comprehensive basic health education intervention.
219154668|NCT01796067|BEHAVIORAL|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
219154669|NCT01796067|BEHAVIORAL|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
219154670|NCT01152398|BIOLOGICAL|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
219154671|NCT05110105|BEHAVIORAL|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
219154672|NCT05110105|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
219154673|NCT00761605|DRUG|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
219233602|NCT03483714|PROCEDURE|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
219233603|NCT00789971|DRUG|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
219233604|NCT00789971|DRUG|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
219361091|NCT04177719|DRUG|Placebo|Saline placebo will be given intranasally. The order of administration will be counterbalanced
219726595|NCT05945758|PROCEDURE|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
219726596|NCT05026385|BEHAVIORAL|Intervention|Targeted nutrition advice, progressive resistance training exercise, and self-management support
219726597|NCT01777529|BIOLOGICAL|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
219726598|NCT04233580|DEVICE|Amnio Excel + weekly|Amnio Excel + weekly
219726599|NCT04233580|DEVICE|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
219726600|NCT02746380|DRUG|LBAL|Adalimumab
219726601|NCT02746380|DRUG|Humira®|Adalimumab
219726602|NCT06244251|PROCEDURE|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
219726603|NCT06244251|PROCEDURE|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
219726604|NCT04729426|OTHER|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
219726605|NCT02929121|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
219726606|NCT02929121|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
219726607|NCT01694394|DEVICE|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
219726608|NCT02781194|DEVICE|3M™ Bair Hugger™|forced-air warming blanket
219726609|NCT02781194|DEVICE|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
219154674|NCT06433102|OTHER|Visual perceptual training based on the lateral masking paradigm|Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
219154675|NCT00452270|DRUG|Xylometazoline|
219154676|NCT02267824|DEVICE|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
219154677|NCT02267824|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
219154678|NCT00867256|DEVICE|Large Diameter Metal on Metal|
219154679|NCT06294275|BIOLOGICAL|LP-001 Dose 1 (Single)|A single dose of LP-001 (Dose 1) was administered subcutaneously.
219154680|NCT06294275|BIOLOGICAL|LP-001 Dose 2 (Single)|A single dose of LP-001 (Dose 2) was administered subcutaneously.
219154681|NCT06294275|BIOLOGICAL|LP-001 Dose 3 (Single)|A single dose of LP-001 (Dose 3) was administered subcutaneously.
219154682|NCT06294275|BIOLOGICAL|LP-001 Dose 4 (Single)|A single dose of LP-001 (Dose 4) was administered subcutaneously.
219154683|NCT06294275|BIOLOGICAL|LP-001 Dose 5 (Single)|A single dose of LP-001 (Dose 5) was administered subcutaneously.
219154684|NCT06294275|BIOLOGICAL|LP-001 Dose 6 (Single)|A single dose of LP-001 (Dose 6) was administered subcutaneously.
219154685|NCT06294275|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered subcutaneously.
219154686|NCT06294275|BIOLOGICAL|LP-001 Dose 7 (Multiple)|LP-001 (Dose 7) was administered multiple times subcutaneously.
219154687|NCT06294275|BIOLOGICAL|LP-001 Dose 8 (Multiple)|LP-001 (Dose 8) was administered multiple times subcutaneously.
219726610|NCT02441114|DRUG|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
219154688|NCT06294275|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
219154689|NCT01088659|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
219154690|NCT01088659|DRUG|placebo|orally daily, 96 weeks
219154691|NCT01088659|DRUG|tenofovir|245mg po daily, 96 weeks
219154692|NCT06059560|DIETARY_SUPPLEMENT|Nutritional therapy|Intensive nutritional therapy based on real world therapy
219154693|NCT02578836|PROCEDURE|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
219726611|NCT01029483|OTHER|Low carbohydrate diet|Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
219726612|NCT01029483|OTHER|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
219726613|NCT01029483|OTHER|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
219726614|NCT01492803|DIETARY_SUPPLEMENT|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
219726615|NCT01492803|DIETARY_SUPPLEMENT|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
219154694|NCT00204113|DEVICE|Multi-purpose rehabilitation frame|
219154695|NCT00204113|DEVICE|Surface Functional Electrical Stimulation|
219726616|NCT00593645|DRUG|Clofarabine|
219154696|NCT03085394|DRUG|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
219154697|NCT03085394|DRUG|Placebo|Preoperative intravenous administration of 10 ml saline
219154698|NCT00978172|DRUG|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
219154699|NCT02904642|BEHAVIORAL|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
219154700|NCT02904642|BEHAVIORAL|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
219154701|NCT03792620|COMBINATION_PRODUCT|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
219154702|NCT01074567|DRUG|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
219154703|NCT03451721|DEVICE|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
219154704|NCT00775294|DRUG|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
219154705|NCT03750214|DEVICE|Biop Colposcopy System|"The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis"
219154706|NCT03488745|BEHAVIORAL|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
219154707|NCT04011813|OTHER|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
219154708|NCT05915715|OTHER|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
219154709|NCT05915715|OTHER|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
219154710|NCT01985334|DRUG|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
219154711|NCT01985334|DRUG|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
219154712|NCT01985334|DRUG|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
219154713|NCT01985334|DRUG|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
219154714|NCT01985334|DRUG|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
219726617|NCT00593645|DRUG|Cytarabine|
219726618|NCT00593645|DRUG|Thymoglobulin|
219726619|NCT00593645|PROCEDURE|Stem cell infusion|
219726620|NCT05338580|DRUG|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
219726621|NCT01296113|DRUG|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
219726622|NCT02344095|DRUG|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
219726623|NCT02344095|DRUG|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
219726624|NCT02344095|DEVICE|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~\- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
219726625|NCT03364010|BEHAVIORAL|Evaluation of proprioception|Velocity perception and Position perception
219726626|NCT03364010|BEHAVIORAL|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
219726627|NCT03364010|BEHAVIORAL|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
219726628|NCT02902315|OTHER|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
219726629|NCT02902315|OTHER|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
219154715|NCT01985334|DRUG|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
219154716|NCT01985334|DRUG|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
219154717|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
219154718|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
219154719|NCT00914589|DRUG|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
219154720|NCT01747707|DRUG|Docetaxel|
219154721|NCT01747707|DRUG|Cisplatin|
219154722|NCT01747707|DRUG|S-1|
219154723|NCT04657887|BIOLOGICAL|Voncento®|Solution for injection
219154724|NCT05048680|PROCEDURE|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
219154725|NCT05328271|DIETARY_SUPPLEMENT|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
219154726|NCT01831284|PROCEDURE|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
219154727|NCT00257049|DRUG|levofloxacin|
219154728|NCT00055705|BIOLOGICAL|PV701|
219154729|NCT04146519|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
219154730|NCT04146519|OTHER|Placebo|Saline solution
219154731|NCT04153058|PROCEDURE|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
219154732|NCT04153058|PROCEDURE|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
219154733|NCT05125874|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219154734|NCT02007590|DEVICE|Aerosure 25 Hz|Active Aerosure device
219154735|NCT02007590|DEVICE|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
219154736|NCT01290341|DRUG|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
219154737|NCT01290341|DRUG|Placebo|Topical; applied once daily for two weeks.
219154738|NCT02059538|OTHER|Adipose tissue biopsies (omental and subcutaneous) liver|
219154739|NCT02059538|RADIATION|CT-scan|
219154740|NCT02059538|OTHER|Stools sampling|
219154741|NCT02059538|OTHER|DNA sampling|
219154742|NCT02059538|OTHER|Blood sampling|
219154743|NCT02059538|OTHER|Urine sampling|
219154744|NCT02059538|RADIATION|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
219154745|NCT01450163|DRUG|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
219154746|NCT01450163|DRUG|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
219154747|NCT01755936|OTHER|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
219154748|NCT01755936|OTHER|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
219154749|NCT01755936|OTHER|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
219154750|NCT00139984|DEVICE|24 hour blood pressure measurement|
219154751|NCT05820594|BIOLOGICAL|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
219154752|NCT00245791|DRUG|Levofloxacin|
219154753|NCT05397275|OTHER|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
219154754|NCT05397275|OTHER|breathe exercises|breathe exercises
219154755|NCT01919450|DRUG|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
219154756|NCT01919450|RADIATION|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
219726630|NCT02902315|OTHER|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
219726631|NCT02902315|OTHER|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
219726632|NCT03446573|DRUG|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
219726633|NCT03446573|DRUG|TAF based regimen (TBR)|Participants will continue to receive their TBR.
219726634|NCT03954938|BEHAVIORAL|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
219726635|NCT03954938|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
219726636|NCT03954938|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
219726637|NCT05099211|PROCEDURE|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
219726638|NCT05099211|OTHER|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
219726639|NCT05099211|BIOLOGICAL|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
219726640|NCT05099211|OTHER|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
219726641|NCT05099211|OTHER|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests"
219726642|NCT05099211|OTHER|Evaluation 2 post-surgery|"1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training"
219726643|NCT05099211|OTHER|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
219726644|NCT05099211|OTHER|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
219726645|NCT02690740|OTHER|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
219726646|NCT01371565|DRUG|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
219726647|NCT04765072|BEHAVIORAL|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
219726648|NCT04765072|BEHAVIORAL|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
219726649|NCT04270760|DRUG|Olpasiran|Dose 1 Dose 2 Dose 3 Dose 4
219154757|NCT02352909|OTHER|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
219154758|NCT02352909|OTHER|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
219154759|NCT02352909|OTHER|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
219154760|NCT03230903|OTHER|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
219154761|NCT03230903|OTHER|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
219361092|NCT00215605|DRUG|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
219726650|NCT04270760|DRUG|Placebo|Dose 5
219726651|NCT04120324|OTHER|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
219726652|NCT04120324|PROCEDURE|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
219726653|NCT04120324|OTHER|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
219726654|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
219726655|NCT04151498|BEHAVIORAL|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
219726656|NCT04151498|OTHER|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
219726657|NCT02070991|DRUG|Macitentan|oral tablet, 10 mg once daily
219726658|NCT02070991|DRUG|Placebo|matching placebo
219726659|NCT00563212|DRUG|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
219233605|NCT05746468|BEHAVIORAL|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
219726660|NCT05296590|DIAGNOSTIC_TEST|Monocyte Distribution Width (MDW) , observation|Observation of MDW performance blinded to treating clinical teams
219726661|NCT06012695|DRUG|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
219154762|NCT04324099|OTHER|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
219154763|NCT04324099|OTHER|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
219726662|NCT06012695|DRUG|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
219154764|NCT04324099|OTHER|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
219154765|NCT04324099|OTHER|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
219154766|NCT04324099|OTHER|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
219154767|NCT04324099|OTHER|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
219154768|NCT04324099|OTHER|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
219154769|NCT04324099|OTHER|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
219154770|NCT04324099|OTHER|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
219233606|NCT05746468|BEHAVIORAL|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
219233607|NCT01613703|DRUG|ONO-2952|1 mg to 200 mg QD at a single descending dose
219360785|NCT05722379|PROCEDURE|left bundle branch pacing (LBBP)|After recording the His potential, the 3830-69 lead (Medtronic Inc., Minneapolis, MN USA) was sent 1-2 cm forward and downward to find the insertion point of the right side of intra-ventricular septum combined with the pre-rotation impedance and ECG changes. Ultimately, the tip was perpendicularly straightforward posited against the septum to the left septal side .
219360786|NCT05722379|PROCEDURE|Right ventricular pacing (RVP)|Right ventricular pacing (RVP) is the standard treatment for patients with continuous ventricular pacing needs.
219726663|NCT06012695|RADIATION|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
219726664|NCT05930951|DRUG|OBT076|OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
219726665|NCT05930951|DRUG|Balstilimab|Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
219726666|NCT04664387|DIAGNOSTIC_TEST|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
219726667|NCT00940173|DEVICE|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
219726668|NCT00940173|DEVICE|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
219726669|NCT00940173|DEVICE|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
219726670|NCT00940173|DEVICE|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
219726671|NCT04225143|PROCEDURE|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
219726672|NCT04225143|PROCEDURE|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
219726673|NCT02421510|DRUG|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
219726674|NCT02421510|DRUG|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
219154771|NCT04324099|OTHER|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
219233608|NCT05371002|BEHAVIORAL|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
219233609|NCT05371002|OTHER|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
219233610|NCT02142218|DRUG|Nivolumab|
219233611|NCT02745509|OTHER|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
219233612|NCT05982756|DRUG|DAG pre-excitation regimen with Bortezomib|Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
219233613|NCT06240806|OTHER|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
219233614|NCT06240806|OTHER|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
219233615|NCT01285167|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
219233616|NCT05063175|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
219233617|NCT05063175|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
219233618|NCT01558765|OTHER|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
219233619|NCT00915629|DIETARY_SUPPLEMENT|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
219233620|NCT03596775|DRUG|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
219233621|NCT03596775|DRUG|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
219154772|NCT04324099|OTHER|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
219233622|NCT01099878|DEVICE|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
219233623|NCT01099878|DEVICE|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
219233624|NCT00035256|DRUG|teriparatide|
219233625|NCT00035256|DRUG|raloxifene HCl|
219233626|NCT00035256|DRUG|placebo|
219233627|NCT00896740|GENETIC|microarray analysis|
219233628|NCT00896740|PROCEDURE|biopsy|
219233629|NCT03200509|OTHER|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
219233630|NCT03200509|OTHER|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
219233631|NCT05534776|OTHER|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
219726675|NCT02421510|DRUG|Placebo|Placebo, once daily, before the first meal of the day
219726676|NCT03752931|DRUG|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
219726677|NCT03752931|DRUG|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
219154773|NCT04324099|OTHER|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
219726678|NCT02385357|DIETARY_SUPPLEMENT|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
219726679|NCT04406831|PROCEDURE|Blood draw|Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
219726680|NCT00001903|DRUG|RSV Polyclonal Immunoglobulin|
219726681|NCT02489201|DRUG|donafenib tosilate tablets|200mg,bid
219726682|NCT00139516|BEHAVIORAL|self-help|
219154774|NCT04324099|OTHER|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems."
219154775|NCT04324099|OTHER|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
219154776|NCT04324099|OTHER|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
219154777|NCT03377205|DEVICE|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
219154778|NCT03377205|DEVICE|Acumed Fibular Rod System|intramedullary nailing of fibula
219154779|NCT03777696|DRUG|Misoprostol|400 μg of buccal misoprostol
219154780|NCT03777696|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
219154781|NCT03777696|DRUG|placebo to misoprostol|placebo tablets to misoprostol buccal
219154782|NCT03777696|DRUG|placebo to TA|110 ml saline iv
219726683|NCT00139516|DRUG|nicotine replacement therapy|
219726684|NCT00139516|BEHAVIORAL|smoking cessation|
219726685|NCT00827242|DRUG|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
219726686|NCT00827242|DRUG|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
219726687|NCT04022694|BEHAVIORAL|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
219726688|NCT04022694|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
219726689|NCT01843881|DRUG|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
219726690|NCT01843881|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
219726691|NCT02609633|DEVICE|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
219726692|NCT02609633|DEVICE|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
219154783|NCT04329130|DRUG|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
219154784|NCT05619952|DIETARY_SUPPLEMENT|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
219154785|NCT00373373|DRUG|Sorafenib|2 x 400 mg/d
219154786|NCT00373373|DRUG|Placebo|Chemotherapy + Placebo
219154787|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
219154788|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
219154789|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
219154790|NCT03925558|DIETARY_SUPPLEMENT|Probiotics|
219154791|NCT03925558|DIETARY_SUPPLEMENT|Placebo|
219154792|NCT06478238|DRUG|calcium folinate|Intravenous infusion and/or oral therapy
219154793|NCT03830086|DRUG|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
219154794|NCT03830086|DRUG|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
219154795|NCT03830086|DRUG|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
219726693|NCT04186585|DRUG|BP-C2|Oral daily intake
219726694|NCT02557893|BEHAVIORAL|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
219726695|NCT02557893|OTHER|Education|Bimonthly pregnancy education classes
219154796|NCT03830086|DRUG|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
219154797|NCT03830086|DRUG|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
219154798|NCT03830086|DRUG|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
219154799|NCT04688866|OTHER|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
219726696|NCT02557893|OTHER|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
219726697|NCT02919605|DRUG|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
219233632|NCT01079117|DRUG|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
219233633|NCT01079117|DRUG|Slow release oral morphine|
219233634|NCT01079117|DRUG|Methadone|
219233635|NCT05581108|DIETARY_SUPPLEMENT|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
219154800|NCT02931175|DRUG|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
219233636|NCT05581108|DIETARY_SUPPLEMENT|Placebo|matched placebo (2 capsules)
219233637|NCT03368274|DRUG|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
219233638|NCT03761199|OTHER|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
219233639|NCT06121778|OTHER|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
219233640|NCT06399939|BEHAVIORAL|Nap|Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
219233641|NCT06399939|BEHAVIORAL|Wake|Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
219233642|NCT04823156|DIETARY_SUPPLEMENT|Calcium|Daily calcium food supplement.
219233643|NCT01163214|DRUG|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
219233644|NCT01163214|DRUG|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
219154801|NCT01675258|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
219154802|NCT03145155|BEHAVIORAL|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
219233645|NCT03633318|DEVICE|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
219233646|NCT03248076|DRUG|Fentanyl Citrate|1γ/Kg fentanyl
219233647|NCT00847977|DRUG|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
219233648|NCT00847977|DRUG|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
219233649|NCT02084576|DRUG|Nepafenac|One drop in the study eye 3 times daily for 30 days
219726698|NCT02919605|DRUG|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
219726699|NCT02919605|DRUG|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
219726700|NCT02845388|DRUG|Sildenafil citrate|
219233650|NCT02084576|DRUG|Ketorolac|One drop in the study eye 4 times daily for 30 days
219233651|NCT03800771|DEVICE|Cycléo BRAU|Practice dual-task tests.
219233652|NCT03800771|DEVICE|GAITRITE®|Routine practice dual-task tests.
219360787|NCT00624455|DRUG|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
219360788|NCT00624455|DRUG|Placebo|Placebo
219726701|NCT02845388|DRUG|estradiol valerate|
219726702|NCT01192477|OTHER|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
219726703|NCT04574700|OTHER|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
219726704|NCT04574700|OTHER|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
219726705|NCT03565653|OTHER|High dietary salt|\~4,000 mg Na+/day
219726706|NCT03565653|OTHER|Placebo|dextrose
219726707|NCT01381588|OTHER|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
219726708|NCT04688944|OTHER|observation|observation the difference between two groups
219726709|NCT05970211|DEVICE|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
219154803|NCT03145155|BEHAVIORAL|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
219154804|NCT02424071|DRUG|Melatonin|
219154805|NCT02424071|DRUG|placebo|
219154806|NCT02125695|PROCEDURE|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
219154807|NCT02125695|PROCEDURE|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
219154808|NCT02125695|PROCEDURE|Skin Biopsy|As described in the treatment arm
219154809|NCT01620034|RADIATION|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
219154810|NCT03036813|DRUG|voxelotor|
219154811|NCT03036813|OTHER|Placebo|
219154812|NCT00182975|DRUG|DHEA replacement|
219154813|NCT00544752|OTHER|16|indoor temperature of 16 degrees celcius
219154814|NCT00544752|OTHER|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
219154815|NCT00544752|OTHER|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
219154816|NCT00094016|DRUG|beclomethasone dipropionate|
219154817|NCT06251570|OTHER|Evaluation of Dual Task Performance|"The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill."
219154818|NCT02698228|DRUG|Bupivacaine (femoral nerve block)|0.5% bupivacaine
219726710|NCT00899847|PROCEDURE|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
219726711|NCT00899847|PROCEDURE|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
219726712|NCT00899847|DRUG|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
219726713|NCT00899847|DRUG|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
219726714|NCT00899847|DRUG|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
219726715|NCT00899847|DRUG|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
219726716|NCT00899847|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
219154819|NCT02698228|DRUG|Morphine|Intravenous injection of 0.1mg/kg of morphine
219154820|NCT02698228|DEVICE|Ultrasound|
219154821|NCT03993704|DRUG|LHF-535|Oral suspension administered once daily for 14 days
219154822|NCT05045534|DRUG|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
219154823|NCT01102231|DRUG|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
219154824|NCT01102231|DRUG|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
219154825|NCT01102231|RADIATION|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
219360789|NCT05077696|OTHER|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
219154826|NCT03903822|DRUG|PF-06700841|PF-06700841 topical cream
219154827|NCT03903822|DRUG|Vehicle (Placebo)|Vehicle topical cream
219154828|NCT04319432|BEHAVIORAL|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
219233653|NCT03427645|BEHAVIORAL|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
219726717|NCT00899847|BIOLOGICAL|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
219726718|NCT00899847|DRUG|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
219726719|NCT00899847|DRUG|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
219726720|NCT00899847|DRUG|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
219726721|NCT00899847|DRUG|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
219726722|NCT00899847|DRUG|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
219726723|NCT05987540|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
219726724|NCT00471107|DEVICE|DC brain polarization|0.08 mA/cm2
219726725|NCT03632330|DRUG|Dexmedetomidine|Dexmedetomidine group
219233654|NCT05645445|DEVICE|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
219726726|NCT03632330|DRUG|Midazolam|Midazolam group
219726727|NCT03632330|DRUG|Propofol|Propofol group
219154829|NCT03339115|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
219154830|NCT01370343|DRUG|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
219154831|NCT01370343|DRUG|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
219154832|NCT04261231|PROCEDURE|Surgery and anesthesia|Elective surgery in adults
219154833|NCT02752230|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
219233655|NCT01779492|DRUG|GL2907|once a day
219233656|NCT01779492|DRUG|Oxycontine CR 10mg|twice a day
219233657|NCT02197494|DRUG|Valsartan|320mg tablets
219233658|NCT03883178|PROCEDURE|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
219233659|NCT04103333|PROCEDURE|Lumbar Puncture|Administered as specified in the treatment arm.
219726728|NCT03632330|DRUG|Midazolam/Propofol|Midazolam/Propofol group
219726729|NCT01176994|DEVICE|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
219726730|NCT02082093|DEVICE|Telemedicine System|
219726731|NCT02232321|OTHER|PsA MDA|
219726732|NCT01769443|DRUG|bortezomib|Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
219726733|NCT01769443|PROCEDURE|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
219726734|NCT05169944|DRUG|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
219726735|NCT04996264|DRUG|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
219154834|NCT02752230|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
219154835|NCT01957969|DEVICE|Sacral Nerve Stimulation|
219154836|NCT02462616|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
219154837|NCT00233038|PROCEDURE|Ethanol injection into a cyst|
219154838|NCT02546999|DRUG|botox|The agent will be given only once at point zero in the time scheme for the project.
219154839|NCT02546999|DRUG|placebo|The agent will be given only once at point zero in the time scheme for the project.
219154840|NCT01251224|OTHER|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
219154841|NCT01251224|OTHER|Education|This group will receive education about mouse IPM.
219233660|NCT04103333|PROCEDURE|Blood Collection|Administered as specified in the treatment arm.
219233661|NCT00880724|DEVICE|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
219233662|NCT03618888|OTHER|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
219154842|NCT00785512|DRUG|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
219154843|NCT00785512|DRUG|Placebo|Matching placebo tablets, oral administration
219154844|NCT00194714|BIOLOGICAL|HER-2/neu Peptide Vaccine|Given ID
219154845|NCT00194714|OTHER|Laboratory Biomarker Analysis|Correlative studies
219154846|NCT00899015|OTHER|pharmacological study|
219154847|NCT05848531|DRUG|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
219154848|NCT01255501|DRUG|NI-0701|
219154849|NCT01255501|DRUG|Placebo|
219154850|NCT05820269|BEHAVIORAL|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
219154851|NCT05760235|PROCEDURE|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
219154852|NCT02677129|OTHER|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
219154853|NCT01244672|PROCEDURE|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
219154854|NCT01244672|PROCEDURE|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
219154855|NCT03167736|OTHER|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
219154856|NCT03167736|OTHER|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
219154857|NCT03113630|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
219154858|NCT03113630|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
219154859|NCT03113630|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
219154860|NCT03113630|DEVICE|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
219233663|NCT03618888|OTHER|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
219233664|NCT05711589|PROCEDURE|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
219154861|NCT03113630|DEVICE|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
219154862|NCT03113630|DEVICE|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
219154863|NCT00047931|DRUG|VRC-HIVDNA009-00-VP|
219233665|NCT05711589|PROCEDURE|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
219233666|NCT05917756|OTHER|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
219154864|NCT01000831|BIOLOGICAL|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
219154865|NCT03013452|DEVICE|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
219154866|NCT03013452|BEHAVIORAL|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
219154867|NCT00895531|DRUG|Depodur|7.5 mg Depodur via the epidural catheter
219154868|NCT00895531|PROCEDURE|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
219154869|NCT02502344|BEHAVIORAL|healthy lifestyle|food control and intensive exercise to lose weight
219154870|NCT02502344|DRUG|Metformin|use metformin to reduce insulin resistance
219154871|NCT03819829|OTHER|Blood sample|Blood sample
219726736|NCT04996264|DRUG|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
219726737|NCT04996264|DRUG|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
219726738|NCT02574208|PROCEDURE|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
219726739|NCT02574208|PROCEDURE|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
219726740|NCT01926535|PROCEDURE|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
219726741|NCT01926535|DEVICE|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
219726742|NCT06479720|DRUG|Combined pharmacotherapy with Solifenacin and Mirabegron|Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
219726743|NCT06479720|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
219726744|NCT06479720|DRUG|Mirabegron with vaginal estrogen cream|Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
219726745|NCT05852210|OTHER|Infrared Imaging|This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
219726746|NCT03896217|DRUG|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
219726747|NCT03440437|DRUG|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
219154872|NCT01195883|DRUG|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
219154873|NCT01195883|DRUG|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
219233667|NCT05917756|OTHER|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
219233668|NCT00930644|DRUG|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
219233669|NCT05639166|BIOLOGICAL|IBIO123|IBIO123 10 mg
219233670|NCT05639166|OTHER|Placebo|Matching Placebo
219726748|NCT03440437|DRUG|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
219726749|NCT06128226|GENETIC|Blood Sampling|For Tripeptidyl Peptidase 1 enzyme level measurement, blood will be taken from the patient into a 5 mL EDTA tube at Gazi University Faculty of Medicine, Metabolism Laboratory, and for patients with low enzyme activity, the genetic evaluation test will be performed with whole blood at the Gene2Info Laboratory.
219726750|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
219726751|NCT06284304|RADIATION|De-escalated radiotherapy|5 fraction de-escalated dose SBRT protocol
219726752|NCT03483662|BEHAVIORAL|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
219726753|NCT03483662|BEHAVIORAL|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
219154874|NCT03017469|OTHER|ARISE|"1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)"
219154875|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
219154876|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
219726754|NCT04915027|OTHER|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
219726755|NCT04915027|OTHER|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
219726756|NCT05114798|BEHAVIORAL|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
219726757|NCT05114798|BEHAVIORAL|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
219726758|NCT05169268|DRUG|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
219154877|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
219154878|NCT01070940|DRUG|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
219154879|NCT02059616|DRUG|Amlodipine 5mg|Daily oral administration for 8 weeks
219154880|NCT02059616|DRUG|Amlodipine 10mg|Daily oral administration for 8 weeks
219154881|NCT02059616|DRUG|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
219154882|NCT02059616|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
219154883|NCT05463549|OTHER|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
219154884|NCT03119558|DRUG|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
219154885|NCT00529100|DRUG|Pemetrexed Phase 1|300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
219154886|NCT00529100|DRUG|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles."
219154887|NCT00529100|PROCEDURE|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
219154888|NCT00529100|DRUG|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
219154889|NCT00529100|DRUG|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
219154890|NCT01818713|DRUG|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
219726759|NCT05169268|DRUG|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
219726760|NCT05821829|DEVICE|Intravascular litothripsy (IVL)|endovascular treatment of primary common femoral artery atherosclerotic disease with intravascular litothripsy
219726761|NCT03489525|BIOLOGICAL|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
219726762|NCT03489525|BIOLOGICAL|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
219726763|NCT04694885|BEHAVIORAL|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
219154891|NCT03238313|BEHAVIORAL|Plan A|
219154892|NCT03238313|BEHAVIORAL|Toxic Life Cycle of a Cigarette|Video
219154893|NCT01471145|DRUG|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
219154894|NCT00003017|BIOLOGICAL|recombinant interleukin-12|
219154895|NCT05738707|BIOLOGICAL|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
219154896|NCT00295464|DRUG|Betamethasone sodium phos (drug)|
219154897|NCT01407458|OTHER|Upper Limb Exercises|Upper limb exercises
219154898|NCT01407458|OTHER|Normal physical exercises|Exercises usually done by children in physical education classes
219154899|NCT04245644|BEHAVIORAL|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
219154900|NCT03822234|PROCEDURE|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
219154901|NCT01393067|DEVICE|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
219154902|NCT01393067|DEVICE|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
219154903|NCT03580135|DRUG|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
219154904|NCT03580135|DRUG|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
219154905|NCT02009228|PROCEDURE|Ovarian cystectomy|
219726764|NCT02147080|BEHAVIORAL|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
219726765|NCT02147080|BEHAVIORAL|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
219726766|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
219154906|NCT05618132|DIAGNOSTIC_TEST|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
219154907|NCT03210454|OTHER|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
219154908|NCT03210454|OTHER|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
219154909|NCT03540381|OTHER|neoatherosclerosis|
219154910|NCT00422006|PROCEDURE|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
219154911|NCT00422006|PROCEDURE|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
219154912|NCT00422006|BEHAVIORAL|diet|diet
219154913|NCT00422006|OTHER|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
219154914|NCT01565148|DRUG|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
219154915|NCT01565148|DRUG|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
219154916|NCT01565148|DRUG|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
219154917|NCT01565148|DRUG|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
219154918|NCT02414412|DIETARY_SUPPLEMENT|Ulmus macrocarpa water extract|
219154919|NCT02748486|BEHAVIORAL|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
219154920|NCT02748486|BEHAVIORAL|Group discussion|Group discussion of current events
219154921|NCT02748486|BEHAVIORAL|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
219154922|NCT01803139|DEVICE|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
219726767|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
219154923|NCT03832894|DRUG|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
219154924|NCT01763970|RADIATION|SBRT|
219154925|NCT03571711|DRUG|Meropenem Injection|Meropenem is administered as prescribed by treating physician
219154926|NCT03920566|OTHER|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
219154927|NCT04329364|COMBINATION_PRODUCT|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
219154928|NCT04329364|PROCEDURE|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
219154929|NCT05464316|DEVICE|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
219233671|NCT05062226|DIETARY_SUPPLEMENT|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
219233672|NCT01393964|DRUG|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
219726768|NCT01104337|DRUG|Placebo|Treatment consisted of two matching placebo tablets three times a day.
219726769|NCT05066217|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
219726770|NCT05066217|DRUG|Placebo|Placebo will be administered as an oral solution.
219726771|NCT01279200|OTHER|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
219726772|NCT01279200|OTHER|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
219726773|NCT05277766|DRUG|PIPAC with Nal-IRI|Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
219726774|NCT06467344|DRUG|ACDN-01|ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
219726775|NCT06406595|OTHER|Observation|This study is observational, therefore, there is no intervention included.
219726776|NCT05323045|DRUG|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
219726777|NCT04111783|DEVICE|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
219726778|NCT03724344|OTHER|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
219154930|NCT05464316|DEVICE|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
219154931|NCT01061671|DRUG|simvastatin|40 mgms of simvastatin daily
219154932|NCT01061671|DRUG|Placebo|Matched placebo pill daily
219154933|NCT02359370|DRUG|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
219154934|NCT02359370|DRUG|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
219154935|NCT06403956|OTHER|Training with video|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
219726779|NCT04730375|DRUG|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
219726780|NCT06345820|DEVICE|Evolux|Evolux, enhanced monofocal IOL
219726781|NCT06345820|DEVICE|Tecnis Eyhance|Tecnis Eyhance, enhanced monofocal IOL
219726782|NCT00102167|DRUG|gaboxadol|Duration of Treatment -1 day
219726783|NCT03237091|OTHER|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
219726784|NCT03237091|OTHER|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
219726785|NCT03237091|OTHER|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
219726786|NCT03237091|OTHER|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
219726787|NCT03237091|OTHER|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
219726788|NCT04073277|DEVICE|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
219726789|NCT04073277|DEVICE|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
219154936|NCT06403956|OTHER|Training with paint|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
219154937|NCT05368831|DRUG|NST-1024|Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
219726790|NCT04832061|OTHER|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
219726791|NCT05165043|PROCEDURE|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
219726792|NCT04595019|RADIATION|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
219726793|NCT01149538|DRUG|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
219726794|NCT01149538|DIETARY_SUPPLEMENT|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
219726795|NCT01614119|OTHER|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
219726796|NCT00888849|PROCEDURE|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
219726797|NCT00888849|PROCEDURE|Suturing|Suturing
219726798|NCT00106561|DRUG|Spironolactone|
219726799|NCT00106561|DRUG|Irbesartan|
219726800|NCT01400633|DRUG|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
219726801|NCT05687565|DIETARY_SUPPLEMENT|Control group placebo|Dietary suplementation
219726802|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
219726803|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
219726804|NCT03139253|DRUG|amoxicillin|amoxicillin 1000 mg bid. for 14 days
219726805|NCT03139253|DRUG|clarithromycin|clarithromycin 500 mg bid. for 14 days.
219726806|NCT03139253|DRUG|tinidazole|tinidazole 500 mg bid. for 14 days.
219726807|NCT03139253|DRUG|levofloxacin|levofloxacin 500 mg qd. for 14 days.
219726808|NCT03139253|DRUG|furazolidone|furazolidone 100 mg bid. for 14 days.
219726809|NCT03139253|DRUG|tetracycline|tetracycline 750 mg bid. for 14 days.
219154938|NCT05110534|BEHAVIORAL|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
219726810|NCT03139253|DRUG|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
219726811|NCT01254877|DRUG|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
219726812|NCT01254877|DRUG|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
219726813|NCT01254877|DRUG|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
219726814|NCT02904356|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
219726815|NCT01118091|BIOLOGICAL|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
219726816|NCT01118091|BIOLOGICAL|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
219726817|NCT00034385|DRUG|Valganciclovir|
219726818|NCT05319405|DEVICE|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
219154939|NCT05326607|DEVICE|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
219726819|NCT02697422|OTHER|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
219726820|NCT00235313|PROCEDURE|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
219726821|NCT00235313|DRUG|nicotine patch|normal following with a nicotine patch
219726822|NCT00016302|DRUG|prednisone|Given orally
219726823|NCT00016302|DRUG|vincristine sulfate|Given IV
219726824|NCT00016302|DRUG|daunorubicin hydrochloride|Given IV
219726825|NCT00016302|DRUG|asparaginase|Given IM
219726826|NCT00016302|DRUG|methotrexate|Given IT and orally
219726827|NCT00016302|DRUG|cyclophosphamide|Given IV
219726828|NCT00016302|DRUG|cytarabine|Given IV or SC
219154940|NCT05326607|DEVICE|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
219154941|NCT06079515|PROCEDURE|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
219154942|NCT06079515|PROCEDURE|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
219154943|NCT06301204|DRUG|Tranexamic acid injection|tranexamic acid administration 250mg or 500 mg
219154944|NCT06301204|DRUG|Saline|onyl ıv saline (NaCl 0.09%)
219154945|NCT01306786|DRUG|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
219154946|NCT01306786|DRUG|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
219154947|NCT01506934|DRUG|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
219154948|NCT03217669|DRUG|Epacadostat|Epacadostat tablet: 100mg or 300mg
219154949|NCT03217669|DRUG|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
219154950|NCT04095715|OTHER|Haemostasis consultation|Haemostasis consultation
219154951|NCT04095715|BIOLOGICAL|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
219726829|NCT00016302|DRUG|mercaptopurine|Given orally
219233673|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
219233674|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219726830|NCT00016302|DRUG|leucovorin calcium|Given IV or orally
219726831|NCT00016302|DRUG|dexamethasone|Given orally
219726832|NCT00016302|DRUG|doxorubicin hydrochloride|Given IV
219726833|NCT00016302|DRUG|thioguanine|Given orally
219726834|NCT00016302|RADIATION|radiation therapy|Undergo cranial irradiation
219726835|NCT00016302|DRUG|nelarabine|Given IV
219726836|NCT00016302|DRUG|pegaspargase|Given IM
219726837|NCT00016302|RADIATION|radiation therapy|Undergo craniocervical radiotherapy
219726838|NCT00016302|OTHER|pharmacological study|Correlative studies
219726839|NCT00016302|OTHER|laboratory biomarker analysis|Correlative studies
219726840|NCT03170921|OTHER|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
219726841|NCT03170921|OTHER|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
219726842|NCT03170921|OTHER|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
219726843|NCT04377386|DIETARY_SUPPLEMENT|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
219726844|NCT04377386|DIETARY_SUPPLEMENT|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
219726845|NCT06152354|DEVICE|rotary system|crown down technique using Kedo-SG file rotary system using endodontic motor
219726846|NCT06152354|DEVICE|Manual files|instrumentation were done by step back technique using K- file (Mani ) from size 15 to size 35 in quarter pull turn motion apically
219726847|NCT00143143|DRUG|Pregabalin|
219726848|NCT01659541|DEVICE|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
219726849|NCT01659541|PROCEDURE|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
219726850|NCT04825977|OTHER|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
219726851|NCT01873833|DRUG|capecitabine|Given PO
219726852|NCT01873833|DRUG|cyclophosphamide|Given PO
219726853|NCT01873833|DRUG|lapatinib ditosylate|Given PO
219726854|NCT01873833|BIOLOGICAL|trastuzumab|Given IV
219726855|NCT01873833|OTHER|laboratory biomarker analysis|Correlative studies
219726856|NCT03055507|DRUG|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
219726857|NCT03055507|DRUG|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
219726858|NCT03055507|DRUG|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
219726859|NCT03398109|DEVICE|Customized toric IOL for post-DALK atigmatism|
219726860|NCT01272856|DRUG|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
219726861|NCT04805788|RADIATION|Proton Stereotactic Body Radiation Therapy|Undergo SBPT
219726862|NCT04805788|OTHER|Quality-of-Life Assessment|Ancillary studies
219726863|NCT01467804|DRUG|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
219726864|NCT01467804|DRUG|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
219726865|NCT03983109|DEVICE|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
219726866|NCT03428204|PROCEDURE|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
219726867|NCT03428204|PROCEDURE|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
219726868|NCT04225520|DEVICE|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
219726869|NCT04225520|DEVICE|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
219726870|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
219726871|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
219233675|NCT01393964|DRUG|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
219233676|NCT01393964|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
219233677|NCT02416349|OTHER|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
219233678|NCT02416349|OTHER|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
219233679|NCT03240471|PROCEDURE|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
219233680|NCT03240471|PROCEDURE|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
219233681|NCT02125799|DEVICE|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
219233682|NCT05923606|DEVICE|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
219233683|NCT05923606|DEVICE|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
219233684|NCT05798065|PROCEDURE|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
219233685|NCT01974258|DRUG|Cobimetinib|Escalating dose
219233686|NCT01974258|DRUG|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
219233687|NCT01974258|DRUG|Onartuzumab|Administered by IV infusion every 2 weeks
219233688|NCT01974258|DRUG|Vemurafenib|Orally administered twice daily
219233689|NCT03879538|DRUG|Nitrous Oxide|A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
219233690|NCT03879538|DRUG|Oxygen|A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
219233691|NCT00241618|DRUG|Pegylated interferon alpha 2|
219726872|NCT06239597|BEHAVIORAL|occupation-based lifestyle intervention|9 week lifestyle course
219726873|NCT06239597|OTHER|Other courses|Other courses in the same university, during the same academic years.
219726874|NCT04556825|DRUG|PRP|After the arthroscopic operation was completed, a local PRP with 4ml was injected
219726875|NCT04556825|DRUG|normal saline|After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
219726876|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
219726877|NCT02502448|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
219233692|NCT00241618|DRUG|Ribavirin|
219726878|NCT02502448|DRUG|hydroxyethyl starch (HES 130/0.6)|
219726879|NCT05574049|DRUG|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
219726880|NCT05574049|OTHER|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
219726881|NCT00739219|DEVICE|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
219233693|NCT04756271|BIOLOGICAL|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
219233694|NCT02173288|DRUG|Standard medical therapy|
219233695|NCT02173288|DRUG|Tolvaptan|
219233696|NCT02173288|DRUG|Midodrine|
219233697|NCT01072045|DRUG|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
219233698|NCT01072045|DRUG|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
219233699|NCT02116075|PROCEDURE|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
219233700|NCT02116075|PROCEDURE|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
219233701|NCT01159236|DRUG|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
219233702|NCT01159236|DRUG|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
219233703|NCT01159236|DRUG|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
219233704|NCT01159236|DRUG|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
219233705|NCT01159236|DRUG|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
219233706|NCT01159236|DRUG|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
219233707|NCT06269731|BEHAVIORAL|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
219726882|NCT05635760|BEHAVIORAL|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
219726883|NCT05635760|BEHAVIORAL|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
219726884|NCT00424164|DRUG|lapatinib ditosylate|
219726885|NCT00424164|DRUG|tamoxifen citrate|
219726886|NCT00424164|OTHER|pharmacological study|
219726887|NCT03341429|DRUG|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
219726888|NCT03341429|DRUG|Placebo|Daily subcutaneous injection
219726889|NCT00195793|DRUG|fenofibrate|
219726890|NCT00195793|DRUG|ezetimibe|
219726891|NCT00195793|DRUG|atorvastatin|
219154952|NCT05431114|DIAGNOSTIC_TEST|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
219154953|NCT06321458|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
219154954|NCT06321458|BEHAVIORAL|Usual care|Usual care
219154955|NCT02845050|DRUG|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
219154956|NCT02845050|DRUG|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
219154957|NCT02845050|PROCEDURE|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
219154958|NCT04465734|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
219154959|NCT04465734|DRUG|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
219154960|NCT04465734|DRUG|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
219154961|NCT04835870|DRUG|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
219154962|NCT04835870|DRUG|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
219154963|NCT04835870|DRUG|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
219154964|NCT04835870|DRUG|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
219233708|NCT06041165|DRUG|JS401|Single dose of JS401 by subcutaneous (sc) injections
219233709|NCT06041165|DRUG|Placebo|Calculated volume to match active treatment
219233710|NCT02142725|DRUG|LT-02|four times per day
219726892|NCT06373939|DEVICE|Digital lung auscultation|"Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope.~Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients."
219154965|NCT04835870|DRUG|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
219154966|NCT04835870|DRUG|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
219154967|NCT01673555|DRUG|GSK1278863|GSK1278863
219154968|NCT01673555|DRUG|Placebo|Placebo
219154969|NCT05921708|OTHER|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
219154970|NCT05921708|OTHER|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
219154971|NCT05921708|OTHER|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
219154972|NCT05921708|OTHER|Assessment4|Body-Cathexis Scale (BCS)
219154973|NCT05921708|OTHER|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
219154974|NCT05904925|OTHER|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
219154975|NCT00955695|DRUG|erlotinib hydrochloride|
219154976|NCT00955695|DRUG|gefitinib|
219154977|NCT00955695|OTHER|questionnaire administration|
219154978|NCT00955695|PROCEDURE|quality-of-life assessment|
219154979|NCT00955695|RADIATION|whole-brain radiation therapy|
219154980|NCT03359889|DRUG|PraxbindTM|Drug
219233711|NCT02142725|DRUG|LT-02|two times per day
219233712|NCT02142725|DRUG|Placebo|four times per day
219233713|NCT04207372|DIETARY_SUPPLEMENT|whey protein isolate|whey protein isolate
219233714|NCT04207372|DIETARY_SUPPLEMENT|Zein|zein protein
219233715|NCT04207372|OTHER|protein-free|protein free
219233716|NCT02246699|DEVICE|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
219233717|NCT02246699|OTHER|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
219233718|NCT01407874|DRUG|Placebo|Oral dose administered daily for 84 days.
219726893|NCT06373939|DEVICE|Pulse oximetry measurement|"Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger.~Comparators:~1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger.~2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up."
219154981|NCT05593159|OTHER|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
219154982|NCT05593159|OTHER|RM-GIC|RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
219154983|NCT05593159|OTHER|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
219154984|NCT05593159|OTHER|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
219154985|NCT05593159|OTHER|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
219154986|NCT05593159|OTHER|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
219154987|NCT01199575|DRUG|Revlimid|
219154988|NCT01199575|DRUG|Rituximab|
219154989|NCT00475501|DRUG|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
219154990|NCT00475501|DRUG|Finasteride|5 mg, oral, once/day, for 52 weeks
219154991|NCT00475501|OTHER|Placebo|Placebo
219154992|NCT00223795|DEVICE|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
219154993|NCT00513526|BIOLOGICAL|Gardasil|week 0, 8, 24, 128
219154994|NCT06193850|OTHER|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
219154995|NCT02738372|OTHER|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
219154996|NCT05176106|BEHAVIORAL|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
219154997|NCT05167656|OTHER|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
219233719|NCT01407874|DRUG|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
219154998|NCT05167656|OTHER|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
219154999|NCT05167656|OTHER|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
219233720|NCT01407874|DRUG|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
219233721|NCT01669356|OTHER|Parenteral supplement with enteral nutrition for patients after esophagectomy|
219233722|NCT01669356|OTHER|Enteral Nutrition alone for patients after esophagectomy|
219155000|NCT04732338|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
219155001|NCT05202912|DRUG|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
219155002|NCT05202912|DRUG|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
219155003|NCT04426500|DRUG|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
219155004|NCT04426500|DRUG|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
219155005|NCT04426500|DRUG|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
219233723|NCT01344980|PROCEDURE|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
219233724|NCT01344980|PROCEDURE|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
219726894|NCT06373939|DEVICE|Non invasive body temperature measurement|"Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480).~Comparators:~1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen.~2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system."
219726895|NCT03899090|BEHAVIORAL|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
219726896|NCT03899090|BEHAVIORAL|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
219726897|NCT06512233|DRUG|LMW Heparin 5000 U/ML-Aspirin 75 MG|Arm 1
219726898|NCT06512233|DRUG|LMW Heparin 5000 U/ML|Arm 2
219726899|NCT03182712|DIETARY_SUPPLEMENT|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
219726900|NCT03182712|DIETARY_SUPPLEMENT|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
219726901|NCT00769405|DRUG|fluorouracil|Given IV
219726902|NCT00769405|DRUG|leucovorin calcium|Given IV
219726903|NCT00769405|DRUG|oxaliplatin|Given during surgery
219726904|NCT00769405|PROCEDURE|hyperthermia treatment|Given intraperitoneally during surgery
219726905|NCT04588272|DEVICE|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
219726906|NCT03296345|DRUG|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
219726907|NCT03977688|DEVICE|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
219726908|NCT02524678|DRUG|Placebo|
219726909|NCT02524678|DRUG|URC102|
219726910|NCT03893708|BEHAVIORAL|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
219155006|NCT00160914|BEHAVIORAL|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
219155007|NCT00694447|PROCEDURE|Acupuncture|
219155008|NCT01803555|DRUG|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
219155009|NCT01803555|DRUG|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
219155010|NCT01803555|DRUG|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
219155011|NCT01803555|DRUG|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
219155012|NCT00886756|DRUG|AZD8529|Oral
219726911|NCT03893708|BEHAVIORAL|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
219726912|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
219726913|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
219726914|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
219726915|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
219726916|NCT02322515|OTHER|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
219726917|NCT02322515|OTHER|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
219726918|NCT02867488|OTHER|Soybean oil in salad dressing|
219155013|NCT00886756|DRUG|Placebo|Oral
219155014|NCT03014947|DRUG|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
219155015|NCT03014947|DRUG|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
219155016|NCT03014947|DRUG|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
219726919|NCT04583826|DEVICE|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
219726920|NCT04967703|PROCEDURE|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
219726921|NCT04967703|PROCEDURE|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
219726922|NCT04967703|PROCEDURE|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
219726923|NCT00907114|DRUG|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
219726924|NCT00907114|DRUG|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
219726925|NCT02068599|DRUG|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
219726926|NCT02068599|DRUG|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
219726927|NCT02282384|DRUG|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
219726928|NCT02282384|OTHER|Placebo|
219726929|NCT01871727|DRUG|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
219726930|NCT02959606|DRUG|Sarpogrelate SR 300mg|
219726931|NCT02959606|DRUG|Clopidogrel|
219726932|NCT03650608|DRUG|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
219726933|NCT03650608|DRUG|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
219726934|NCT03650608|DRUG|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
219155017|NCT01457612|DIETARY_SUPPLEMENT|Strawberry|20g twice per day (BID) in beverage
219155018|NCT01457612|DIETARY_SUPPLEMENT|Placebo1|Placebo Beverage 1 without fiber
219155019|NCT01457612|DIETARY_SUPPLEMENT|Placebo2|Placebo Beverage 2 with Fiber
219155020|NCT04951362|DRUG|intranasal spray ivermectin|intranasal spray of saline
219155021|NCT01551355|BEHAVIORAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
219726935|NCT03650608|DRUG|Placebo Ophthalmic solution|Placebo
219726936|NCT01106950|BIOLOGICAL|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
219726937|NCT01106950|DRUG|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
219726938|NCT01106950|DRUG|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
219726939|NCT01106950|DRUG|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
219726940|NCT01106950|PROCEDURE|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
219726941|NCT01106950|DRUG|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
219726942|NCT04769401|OTHER|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
219726943|NCT04769401|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
219726944|NCT00356421|DRUG|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
219726945|NCT00356421|DRUG|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
219726946|NCT02694250|DEVICE|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
219726947|NCT04291833|BEHAVIORAL|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
219726948|NCT04291833|BEHAVIORAL|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
219726949|NCT04291833|BEHAVIORAL|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
219155022|NCT02409667|BIOLOGICAL|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
219155023|NCT01925339|DEVICE|Test (immediate restoration)|Test (immediate restoration)
219155024|NCT01925339|DEVICE|Control: delayed restoration|Control: delayed restoration
219155025|NCT05344924|DRUG|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
219155026|NCT04638322|OTHER|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
219155027|NCT02617069|BIOLOGICAL|botulinum toxin injection|
219155028|NCT02617069|BIOLOGICAL|0.9% normal saline injection|
219155029|NCT02617069|DEVICE|Implantable loop recorder|
219155030|NCT02971085|PROCEDURE|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
219155031|NCT01538719|DRUG|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
219155032|NCT01538719|OTHER|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
219155033|NCT05623553|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
219155034|NCT06014216|OTHER|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
219155035|NCT06014216|OTHER|Water|Water from tap, one cup given by recovery nurses.
219155036|NCT03399669|DRUG|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
219155037|NCT00967434|DRUG|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
219155038|NCT00967434|DRUG|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
219155039|NCT00967434|DRUG|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
219155040|NCT02280148|PROCEDURE|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
219155041|NCT02280148|DEVICE|Driving Simulator|
219726950|NCT05950126|OTHER|pain catastrophizing scala|"The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high."
219155042|NCT02280148|DRUG|Propofol|2mg / kg
219155043|NCT04764994|DEVICE|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
219155044|NCT04764994|OTHER|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
219726951|NCT00501085|DEVICE|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
219155045|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
219726952|NCT04449809|BEHAVIORAL|Exercise program|3x per week group monitored group exercise sessions
219155046|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
219155047|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
219155048|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
219155049|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
219155050|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
219155051|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
219155052|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
219155053|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
219726953|NCT06479057|OTHER|Supportive Care Pathway|All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
219726954|NCT04026516|DEVICE|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
219726955|NCT03898609|OTHER|Dietary intervention|3 weeks
219726956|NCT01468961|BEHAVIORAL|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
219155054|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours|Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
219155055|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours|Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
219233725|NCT01344980|BEHAVIORAL|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
219155056|NCT02378896|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
219155057|NCT02378896|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
219155058|NCT06465446|BIOLOGICAL|Tislelizumab|IV infusion
219155059|NCT06465446|BIOLOGICAL|IMM01|2.0mg/kg, IV infusion
219155060|NCT06465446|DRUG|Bendamustine|IV infusion
219155061|NCT06465446|DRUG|Gemcitabine|IV infusion
219155062|NCT00044057|DRUG|YM872 (zonampanel), t-PA (alteplase)|
219155063|NCT03348917|DRUG|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
219155064|NCT03348917|DRUG|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
219155065|NCT03348917|DRUG|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
219155066|NCT04545918|DEVICE|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
219155067|NCT03427346|PROCEDURE|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
219155068|NCT03427346|PROCEDURE|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
219155069|NCT03657030|DRUG|CVN424|SAD / MAD
219155070|NCT03657030|DRUG|Placebo|Placebo
219155071|NCT04045938|OTHER|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
219155072|NCT06103916|OTHER|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
219155073|NCT04083664|DIAGNOSTIC_TEST|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
219155074|NCT01896349|OTHER|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
219233726|NCT01344980|BEHAVIORAL|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
219726957|NCT02958527|DRUG|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
219155075|NCT01896349|DRUG|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
219155076|NCT01896349|DRUG|sertraline|
219155077|NCT01896349|DRUG|paroxetine|
219155078|NCT01896349|DRUG|Citalopram|
219155079|NCT01896349|DRUG|escitalopram|
219155080|NCT01896349|DRUG|fluvoxamine|
219155081|NCT01896349|DRUG|Venlafaxine|
219155082|NCT01896349|DRUG|Duloxetine|
219155083|NCT01896349|DRUG|Bupropion|
219155084|NCT01896349|DRUG|Lithium|
219155085|NCT01896349|DRUG|Risperidone|
219155086|NCT01896349|DRUG|tranylcypromine|
219155087|NCT01896349|DRUG|Imipramine|
219155088|NCT01896349|DRUG|amitriptyline|
219155089|NCT01896349|DRUG|Clomipramine|
219155090|NCT01896349|DRUG|nortriptyline|
219155091|NCT01896349|DRUG|trazodone|
219155092|NCT01896349|DRUG|Mirtazapine|
219155093|NCT01896349|DRUG|sulpiride|
219155094|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental|Combination of pre-probiotic
219233727|NCT00088166|DRUG|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
219233728|NCT00088166|DRUG|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
219726958|NCT00004083|DRUG|cisplatin liposomal|
219726959|NCT02706548|BEHAVIORAL|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
219726960|NCT02706548|BEHAVIORAL|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
219726961|NCT02321150|PROCEDURE|Cautery|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points."
219726962|NCT02321150|PROCEDURE|Sutures|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
219155095|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Inert compound
219155096|NCT05239013|DRUG|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
219155097|NCT04580316|BEHAVIORAL|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
219155098|NCT04580316|BEHAVIORAL|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
219155099|NCT04877340|DEVICE|needle punction|EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
219155100|NCT06093204|OTHER|Dietary evaluation|Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
219155101|NCT02703558|DRUG|Phenazopyridine|
219155102|NCT02703558|DRUG|Fluorescein|
219155103|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
219726963|NCT03092037|PROCEDURE|Blood draw|The Investigators will collect serum and whole blood from participants.
219726964|NCT04076215|BEHAVIORAL|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
219726965|NCT04076215|DEVICE|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
219726966|NCT03033212|OTHER|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
219726967|NCT03033212|OTHER|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
219155104|NCT05983575|DEVICE|Placebo|Placebo
219155105|NCT06336031|OTHER|blood-injection-injury (BII) phobia stimuli|498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
219155106|NCT06336031|OTHER|neutral stimuli|498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
219155107|NCT06280157|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
219155108|NCT03697876|DRUG|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
219155109|NCT03697876|DRUG|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
219155110|NCT06677372|DIAGNOSTIC_TEST|Body temperature measurement|Comparative analysis of temperature between esophageal temperature and skin temperature
219155111|NCT06676007|OTHER|Gd-IgA1 test|collect and test Gd-IgA1 test in enrolled subjects
219155112|NCT06677034|OTHER|Exercise|Mobile Game-Based Exercise Training
219155113|NCT06677008|DEVICE|Disposable endoscopic linear cutter stapler|Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
219155114|NCT06676553|DEVICE|Radiofrequency ablation alone, re-denervation to main and/or branch renal artery|Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
219155115|NCT06676553|PROCEDURE|Radiofrequency ablation alone, no further renal denervation|No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
219155116|NCT06676527|OTHER|Follow-up study of the treated cohort|For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
219726968|NCT04773977|DRUG|IBI362 liquid formulation|Administered by subcutaneous injection
219726969|NCT04773977|DRUG|IBI362 lyophilized powder|Administered by subcutaneous injection
219726970|NCT04607616|BEHAVIORAL|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
219726971|NCT04607616|BEHAVIORAL|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
219726972|NCT04607616|DIAGNOSTIC_TEST|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
219726973|NCT04607616|BEHAVIORAL|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
219726974|NCT04607616|BEHAVIORAL|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
219726975|NCT04317846|OTHER|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
219726976|NCT00962455|OTHER|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
219726977|NCT00962455|OTHER|usual practice|Usual practice regarding spirometry execution in family practice
219726978|NCT02722135|DRUG|Volasertib|
219726979|NCT02245386|RADIATION|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
219726980|NCT05812989|BEHAVIORAL|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
219726981|NCT05812989|BEHAVIORAL|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
219726982|NCT03587857|OTHER|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
219726983|NCT04460235|BIOLOGICAL|Prevenar 13 + Pneumovax 23|Cohort study A before modification of vaccination national guidelines
219726984|NCT04460235|BIOLOGICAL|PREVENAR20|"Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination.~Cohort study B"
219726985|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
219726986|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
219726987|NCT01571986|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation
219726988|NCT02177578|DRUG|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
219726989|NCT02177578|RADIATION|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
219726990|NCT02177578|RADIATION|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
219726991|NCT06963697|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Neoantigen synthetic long peptide vaccines are composed of synthetic long peptides which are 8-35 amino acids in length and designed to induce immune responses to cancer neoantigens identified by exome sequencing. Neoantigen synthetic long peptide vaccines will be co-administered with poly-ICLC, an innate immune adjuvant capable of activating TLR3 and other pathways.
219726992|NCT06959303|BEHAVIORAL|Teach Back Education|Discharge training will be given to patients who underwent coronary angiography with the Teach-Back method.
219726993|NCT02821793|OTHER|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
219726994|NCT02821793|OTHER|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
219726995|NCT02814019|DRUG|Idebenone 150 mg film-coated tablets|
219726996|NCT02814019|DRUG|placebo|
219726997|NCT01486394|OTHER|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
219726998|NCT00250718|DRUG|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
219726999|NCT00250718|DRUG|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
219727000|NCT00250718|DRUG|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
219727001|NCT00250718|DRUG|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
219727002|NCT00250718|DRUG|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
219727003|NCT01194700|DRUG|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
219727004|NCT01194700|DRUG|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
219727005|NCT01194700|DRUG|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
219727006|NCT01194700|DRUG|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
219727007|NCT01890005|DRUG|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
219727008|NCT01890005|DRUG|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
219155117|NCT06677476|OTHER|mobile application training|Researchers compiled literature information and used their expertise to create mobile application content. This content will be downloaded to mobile phones via mobile application software and participants will be trained.
219727009|NCT06245707|DRUG|prednisone,methylprednisone and cyclophosphamide|In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
219727010|NCT06245707|DRUG|Rituximab|The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
219727011|NCT00513630|DRUG|Glipizide|
219727012|NCT00513630|DRUG|Metformin|
219727013|NCT01666314|DRUG|Orteronel|Orteronel tablets
219727014|NCT01666314|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
219727015|NCT01666314|DRUG|Prednisone|Prednisone 5 mg
219727016|NCT00167947|DRUG|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
219727017|NCT00167947|DRUG|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
219155118|NCT06676410|OTHER|ICF|Application of Informed Consent Form.
219727018|NCT00167947|DRUG|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
219727019|NCT05879172|DEVICE|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
219727020|NCT05879172|DEVICE|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
219727021|NCT00309179|DRUG|E7820 plus cetuximab|Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
219727022|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
219727023|NCT00652041|DRUG|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15
219727024|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
219727025|NCT01076933|PROCEDURE|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
219727026|NCT01076933|PROCEDURE|sham rTMS|sham rTMS
219727027|NCT04279600|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
219727028|NCT04279600|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
219727029|NCT04279600|OTHER|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
219155119|NCT06676410|BEHAVIORAL|Eligibility Assessment|Assessment of inclusion, exclusion and discontinuation criteria.
219727030|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
219727031|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
219727032|NCT06230770|BEHAVIORAL|Bleeding data|Participants will report their daily bleeding patterns
219727033|NCT05521698|DRUG|Apalutamide|Given PO
219727034|NCT05521698|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219727035|NCT05521698|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219727036|NCT05521698|DRUG|Placebo Administration|Given PO
219727037|NCT05521698|OTHER|Questionnaire Administration|Ancillary studies
219727038|NCT05521698|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
219727039|NCT06347588|OTHER|Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA|Blood sample at baseline, week 4, month 3, 6, 9,12.
219727040|NCT00435721|BEHAVIORAL|Psychoeducation|
219727041|NCT06470906|DIETARY_SUPPLEMENT|Probiotic Group|The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.
219727042|NCT06470906|DIETARY_SUPPLEMENT|Placebo Group|The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
219727043|NCT06786234|DRUG|STP938|At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
219727044|NCT05573035|BIOLOGICAL|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
219727045|NCT04761120|DEVICE|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
219727046|NCT04761120|DEVICE|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
219155120|NCT06676410|OTHER|Demographic data|Collection of demographic data.
219155121|NCT06676410|DIAGNOSTIC_TEST|Weight, height and BMI|Weight and height measurement and body mass index calculation.
219155122|NCT06676410|OTHER|Vital Signs|HR, BP and FR and T°, in addition to oximetry.
219155123|NCT06676410|DIAGNOSTIC_TEST|Medical evaluation|Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
219155124|NCT06676410|DIAGNOSTIC_TEST|Safety exam|Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
219155125|NCT06676410|DIAGNOSTIC_TEST|Pregnancy test|β-HCG in urine in non-sterile women
219155126|NCT06676410|DIAGNOSTIC_TEST|Serology|HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
219155127|NCT06676410|OTHER|Randomization|Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
219727047|NCT04761120|DEVICE|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
219727048|NCT04761120|DEVICE|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
219727049|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
219727050|NCT00901498|DRUG|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
219727051|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
219727052|NCT00901498|DRUG|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
219727053|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
219727054|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
219727055|NCT00689143|DRUG|sargramostim|
219727056|NCT04043026|DRUG|Statin|Any statin therapy
219727057|NCT03081169|DRUG|Enoxaparin Sodium 150 MG/ML Prefilled Syringe|The same drugs and dosages will be used in both groups, with only the timing being different
219727058|NCT03081169|DRUG|Heparin|The same drugs and dosages will be used in both groups, with only the timing being different
219727059|NCT01737086|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and zinc sulphate|
219727060|NCT01737086|DIETARY_SUPPLEMENT|placebo|
219233729|NCT02671266|DRUG|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
219233730|NCT02671266|DRUG|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
219233731|NCT00666705|DRUG|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
219233732|NCT00666705|DRUG|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
219233733|NCT00666705|DRUG|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
219233734|NCT00666705|DRUG|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
219233735|NCT01812330|DRUG|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
219233736|NCT01812330|DRUG|Ticagrelor|90mg Bid
219233737|NCT05870085|BEHAVIORAL|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
219233738|NCT01540591|DRUG|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
219727061|NCT01410253|OTHER|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
219727062|NCT01410253|OTHER|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
219727063|NCT01410253|OTHER|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
219727064|NCT01410253|OTHER|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
219155128|NCT06676410|DIAGNOSTIC_TEST|Apoptosis markers|Caspases and Annexin V.
219155129|NCT06676410|DIAGNOSTIC_TEST|Cell activation markers|PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
219155130|NCT06676410|DIAGNOSTIC_TEST|Inflammation markers|ultrasensitive CRP, D-dimer.
219155131|NCT06676410|DIAGNOSTIC_TEST|Proviral DNA:|Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
219155132|NCT06676410|DIAGNOSTIC_TEST|HIV-specific antibodies|Anti-HIV-1 specific antibody titers in plasma.
219155133|NCT06676410|DIAGNOSTIC_TEST|HIV viral load (RNA)|Performed on plasma.
219233739|NCT01540591|DRUG|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
219233740|NCT05224232|DEVICE|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
219233741|NCT05224232|DEVICE|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
219233742|NCT05323032|DEVICE|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
219233743|NCT05404997|DEVICE|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
219233744|NCT05404997|OTHER|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
219233745|NCT00053300|DRUG|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
219233746|NCT00053300|PROCEDURE|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
219233747|NCT00687297|DRUG|vandetanib induction|100 mg daily by mouth
219233748|NCT00687297|DRUG|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
219727065|NCT01158677|PROCEDURE|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
219727066|NCT02860078|DEVICE|Ultrasound|Location and function of sacral epidural space with ultrasound
219727067|NCT02860078|DEVICE|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
219727068|NCT04849013|DRUG|Placebo|Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
219727069|NCT04849013|DRUG|Mescaline 100mg|"Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219727070|NCT04849013|DRUG|Mescaline 200mg|"Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219727071|NCT04849013|DRUG|Mescaline 400mg|"Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219727072|NCT04849013|DRUG|Mescaline 800mg|"Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219727073|NCT04849013|DRUG|Mescaline 800mg + Ketanserin 40mg|"Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose"
219727074|NCT02542527|PROCEDURE|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
219155134|NCT06676410|BEHAVIORAL|Codivir® Training|The participant is trained to self-inject Codivir®
219155135|NCT06676410|DRUG|Dispensing Codivir®|the participant receives Codivir®
219155136|NCT06676410|OTHER|Codivir® Accounting|The Codivir® used since the last visit is accounted for
219155137|NCT06676410|OTHER|Concomitant medication|Record of concomitant medications used.
219155138|NCT06676410|OTHER|Adverse events|Collection and recording of adverse events.
219155139|NCT06676410|DRUG|Antiretrovirals|"Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day"
219155140|NCT06676865|DIAGNOSTIC_TEST|the palm print test|"The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation."
219155141|NCT06677463|DEVICE|Virtual Reality|Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process
219155142|NCT06677073|BEHAVIORAL|High-intensity interval training|High-intensity interval training
219155143|NCT06677073|BEHAVIORAL|Maximal fat oxidation exercise|Maximal fat oxidation exercise
219155144|NCT06676800|DRUG|Yiqi Gubiao pill|Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
219155145|NCT06676800|DRUG|Yiqi Gubiao Pill placebo|The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
219155146|NCT05756699|DIAGNOSTIC_TEST|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
219155147|NCT04924218|PROCEDURE|endoscopic surgical intervention|The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
219233749|NCT00687297|DRUG|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
219233750|NCT00687297|DRUG|Placebo|
219727075|NCT02596087|OTHER|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
219727076|NCT03304288|DRUG|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
219727077|NCT03304288|DRUG|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
219727078|NCT00136474|DRUG|Amifostine|Given 30-60 minutes prior to daily radiation therapy
219727079|NCT00136474|RADIATION|Radiation Therapy|Daily radiation therapy
219727080|NCT03723954|DEVICE|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
219727081|NCT03723954|DEVICE|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
219727082|NCT05312112|DRUG|Venetoclax|Observational study of venetoclax in AML
219727083|NCT05312112|DRUG|Gilteritinib|Observational study of gilteritinib in AML
219727084|NCT00466219|DRUG|Ribavirin|
219727085|NCT00466219|DRUG|Pegylated interferon alpha2a|
219727086|NCT02015104|BIOLOGICAL|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
219727087|NCT02015104|BIOLOGICAL|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
219155148|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
219155149|NCT05396794|BEHAVIORAL|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
219155150|NCT05396794|BEHAVIORAL|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
219155151|NCT06870682|BEHAVIORAL|ROBUST|During a 4-week intervention, participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. This intervention can be distinguished from others since it integrates both motor and sensory function, with focus on sensory processing. It combines robot-based therapy, a transfer package to daily activities, and a home program.
219155152|NCT06676787|OTHER|Transportation Voucher, Comunity engagement and microplannnig support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. This is in addition to support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
219155153|NCT06676787|OTHER|Direct Facility Funding, Community Engagement, and Microplaning Support|Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly performance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
219155154|NCT06676787|OTHER|Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly oerformance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
219155155|NCT02474147|OTHER|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
219155156|NCT02474147|OTHER|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
219155157|NCT06057480|DEVICE|APM|Investigational programming software module, the Assisted Programming Module (APM)
219155158|NCT01827787|DRUG|Eribulin|
219155159|NCT06607588|OTHER|Not applicable- observational study|Not applicable- observational study
219155160|NCT06618664|DRUG|SHR-8068|SHR-8068: injection, 50 mg/10 mL, intravenous infusion
219155161|NCT06618664|DRUG|Adebrelimab|Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
219155162|NCT06618664|DRUG|Bevacizumab|Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
219155163|NCT06618664|DRUG|Sintilimab|Sintilimab: injection, 100 mg/10 mL, intravenous infusion
219155164|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
219155165|NCT03472755|OTHER|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
219155166|NCT03482635|DRUG|Spesolimab|Solution for infusion
219155167|NCT03482635|DRUG|Placebo|Solution for infusion
219155168|NCT06625931|DRUG|NTCB01-1|3 Days infusion
219155169|NCT06625931|DRUG|NTCB-P|3 Days infusion
219155170|NCT06629155|DIAGNOSTIC_TEST|Infrared oculography|Eye movements will be captured through infrared oculography and processed via in-house algorithms.
219233751|NCT00687297|DRUG|Vandetanib maintenance|300 mg daily by mouth
219233752|NCT04927468|PROCEDURE|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
219155171|NCT01116180|DRUG|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
219155172|NCT01116180|DRUG|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
219233753|NCT04927468|PROCEDURE|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
219233754|NCT00688415|DRUG|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
219727088|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
219155173|NCT06699953|OTHER|Observational study in patients receiving fentanyl for surgery|"This observational study enrolls patients receiving fentanyl, a drug routinely administered during surgery under general anesthesia. The primary difference in the investigators' research protocol is the inclusion of a 5-minute interval between fentanyl administration and the induction of general anesthesia. Fentanyl will be given in two boluses of 2 mcg/kg (ideal body weight), spaced 2 minutes apart, totaling 4 mcg/kg. If the participant remains conscious, an additional 2 mcg/kg bolus will be administered after 2 minutes. Additionally, participants will complete a drug-liking questionnaire before the first bolus and every 30 seconds until anesthesia induction, rating how much they liked the drug on a 0-100 scale."
219155174|NCT06708754|DEVICE|Photobiomodulation (PBM) Therapy|"PBM is a low-intensity form of light therapy and employs visible or near-infrared (NIR) light generated from a laser or Light Emitting Diode (LED).~In this study, PBM will be delivered using an LED device emitting 660 and 850nm with the purpose of research. The output power typically ranges from 5 to 200 mW with wavelengths ranging 600-1,000nm."
219155175|NCT06708754|DEVICE|Sham PBM|Sham PBM will be delivered using a matching shame device that emits no output power.
219155176|NCT06728579|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|eight weekly two-hour MORE sessions
219155177|NCT06728579|OTHER|Questionnaires|filled out up to 24 weeks
219155178|NCT06728579|BEHAVIORAL|Supportive Psychotherapy (SG)|eight weekly two-hour SG sessions
219155179|NCT06889688|DRUG|Camrelizumab+Apatinib+Eribulin|Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
219155180|NCT06889688|DRUG|Physician's choice chemotherapy|Physician's Choice Chemotherapy
219155181|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by bone tumor resection
219155182|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by aseptic loosening of orthopaedic hardware
219155183|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by trauma-related conditions
219155184|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
219155185|NCT04223297|PROCEDURE|lung ultrasound|"The lung ultrasound will be performed by following the  Blue protocol "
219155186|NCT06754137|DIAGNOSTIC_TEST|AI-Assisted Fracture Detection System|The intervention involves the use of an AI-assisted fracture detection system (Aidoc or Gleamer BoneView), which is integrated into the hospital's Picture Archiving and Communication System (PACS). These AI tools analyze X-ray images in real time, highlighting potential fracture sites for physician review. The AI output serves as an additional aid, while the final diagnosis remains the responsibility of the physician.
219155187|NCT06754137|DIAGNOSTIC_TEST|Standard Physician-Interpreted Fracture Detection|Physicians interpret X-ray images using their standard diagnostic practices without any assistance from AI. This represents the traditional approach to diagnosing fractures.
219155188|NCT06761534|OTHER|Screening of comprehensive geriatic assessment.|The participants are screened before anti-tumor therapy with a comprehensive assessment screening tool developed for elderly cancer patients, which is more suitable for individualized decision-making in anti-tumor treatment.
219155189|NCT06761534|OTHER|the G8 assessment|The G8 is a rapid geriatric screening test that takes only a few minutes to complete. It is used as a calibration standard to validate the novel screening tool in this study.
219155190|NCT06761534|OTHER|Comprehensive Geriatric Assessment (CGA)|The participants screened as a high frailty risk will undergo CGA to determine the most appropriate treatment plan.
219727089|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
219727090|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
219155191|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
219155192|NCT06735950|BEHAVIORAL|Volunteering in Place Program|Implementation of the VIP Program consists of 4 steps guided by the Social Ecological Model (SEM) with Interpersonal interventions guided by Social Cognitive Theory (SCT), and will be implemented over a 6-month period by research supported Volunteer Coordinators. The four steps of the VIP Program are: Step 1: Stakeholder Team, Staff and Family Education; Step 2: Assessment of AL Environment and Residents Abilities and Interests; Step 3: Ongoing Implementation of the Volunteer Plan; and Step 4: Reassessment of the Volunteer Activity. Participants will volunteer three time per week for approximately 30 minutes.
219155193|NCT06735950|BEHAVIORAL|Recreational activity|The Recreational Activities group intervention will consist of similar staff education regarding the benefits of engaging residents in meaningful activities as described in Step 1 above, without other steps associated with the VIP Program. The Recreational Activities group will be exposed to a research team RA coordinator who will provide a current events activity (reviewing the daily newspaper) for the participants in the RA group three times per week for approximately 30 minutes as an attention control.
219155194|NCT06897514|DIAGNOSTIC_TEST|Prediction algorithm for intraoperative hypotension|All participants will receive five non-invasive monitoring during their surgery. Data from these monitoring device will be put into the prediction algorithm.
219233755|NCT03949257|DEVICE|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
219155195|NCT06555757|OTHER|Height, weight, and BMI|Height, weight measurement and BMI calculation
219155196|NCT06555757|OTHER|Medical history|Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
219155197|NCT06555757|OTHER|Physical examination|Brief physical examination
219155198|NCT06555757|DIAGNOSTIC_TEST|Venous blood samples|Venous blood samples, to include WCC, HB, CRP and NTproBNP
219155199|NCT06555757|OTHER|Resting vital signs|HR, BP, RR, oxygen saturations on air)
219727091|NCT07019051|DIAGNOSTIC_TEST|Transthoracic Echocardiographic Evaluation|Non-invasive transthoracic echocardiography will be performed prior to the initiation of continuous veno-venous hemodiafiltration (CVVHDF) in ICU patients. The evaluation includes measurements of LVOT VTI, MAPSE, TAPSE, S' wave velocity, and E/e' ratio to assess cardiac function and estimate the risk of hemodynamic instability. The procedure will be conducted at the bedside using standard parasternal and apical windows by trained intensive care physicians or cardiologists. No contrast, sedation, or invasive monitoring will be used.
219233756|NCT04370561|PROCEDURE|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
219233757|NCT04370561|PROCEDURE|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
219233758|NCT01228734|DRUG|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
219233759|NCT01228734|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
219233760|NCT01228734|DRUG|Folinic Acid|FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
219233761|NCT01228734|DRUG|5Fluorouracil|5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
219233762|NCT01109979|DRUG|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
219233763|NCT01109979|DRUG|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
219233764|NCT03587415|DIAGNOSTIC_TEST|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
219233765|NCT06470633|DRUG|Adebrelimab|Adebrelimab 1200mg iv q3w
219233766|NCT06470633|PROCEDURE|High Intensity Focused Ultrasoun（HIFU）|HIFU treatment at lesion site
219233767|NCT06470633|DRUG|Cyclophosphamide|600mg/m2 iv q3w
219233768|NCT06470633|DRUG|Epirubicin|90mg/m2 iv q3w
219233769|NCT06470633|DRUG|Docetaxel|75mg/m2 iv q3w
219233770|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
219155200|NCT06555757|DIAGNOSTIC_TEST|Transthoracic echocardiogram|LVEF, IVC collapsibility, LV filling pressure, PA pressure
219155201|NCT06555757|OTHER|Sound recordings|Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
219155202|NCT06555757|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound
219233771|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
219233772|NCT03331536|PROCEDURE|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
219233773|NCT03331536|PROCEDURE|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
219233774|NCT01997866|OTHER|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
219233775|NCT01997866|OTHER|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
219155203|NCT06555757|OTHER|KCCQ questionnaire|Kansas City Cardiomyopathy Questionnaire
219155204|NCT06555757|OTHER|ASCEND-HF score|An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
219155205|NCT06555757|OTHER|Composite Everest congestion score|A shortened version of the original 18-point score from the EVEREST trial
219155206|NCT06555757|DIAGNOSTIC_TEST|Bio impedance and total body water measurement|Bio impedance and total body water measurement using TANITA device
219155207|NCT06215183|OTHER|Music therapy|Women applying for IUD application will receive music therapy for 5 minutes before the procedure, during the IUD application, and for 5 minutes after the procedure.
219233776|NCT03954860|OTHER|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
219233777|NCT03954860|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
219233778|NCT03954860|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
219233779|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
219233780|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-2|Taking 7 capsules a day for six months
219233781|NCT04301752|DIAGNOSTIC_TEST|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
219233782|NCT01005030|OTHER|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
219233783|NCT04018300|DIETARY_SUPPLEMENT|Ferrous sulfate|65 mg Fe as ferrous sulfate
219155208|NCT06754163|DRUG|Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)|"Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet."
219155209|NCT06903234|DRUG|Iptacopan|Adult patients with PNH treated with iptacopan
219155210|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
219155211|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
219155212|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
219155213|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
219155214|NCT03918694|DIETARY_SUPPLEMENT|Vitamin C|Daily use of Vit C tablets
219155215|NCT03918694|DIETARY_SUPPLEMENT|Placebo|Daily use of placebo tablets
219155216|NCT04898829|DIETARY_SUPPLEMENT|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~\- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~\- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
219155217|NCT00025324|BIOLOGICAL|filgrastim|
219155218|NCT00025324|DRUG|carboplatin|
219155219|NCT00025324|DRUG|cyclophosphamide|
219155220|NCT00025324|DRUG|etoposide|
219233784|NCT04018300|DIETARY_SUPPLEMENT|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
219155221|NCT00025324|DRUG|thiotepa|
219155222|NCT00025324|PROCEDURE|autologous bone marrow transplantation|
219155223|NCT00025324|PROCEDURE|bone marrow ablation with stem cell support|
219155224|NCT00025324|PROCEDURE|conventional surgery|
219155225|NCT00025324|PROCEDURE|peripheral blood stem cell transplantation|
219155226|NCT00025324|RADIATION|radiation therapy|
219155227|NCT06922786|DEVICE|Hemadsorption filter|"Plasma titers neurodepressing drug:~* At admission to the hospital (standard of care)~* 2 hours after admission (+/- 15 minutes)~* 4 hours after admission (+/- 15 minutes)~* 6 hours after admission (+/- 15 minutes)~* 8 hours after admission (+/- 15 minutes)~* Just before start hemadsorption~Hemadsorption via dialysis catheter in patients still fulfilling inclusion criteria 8 hours after admission.~Subsequent plasma titers pre- and post-hemadosorption filter:~* 15 minutes after start of hemadsorption (+ 15 minutes)~* 4 hours after start of hemadsorption (+/- 15 minutes)~* 8 hours after start of hemadsorption (+/- 15 minutes)~* 12 hours after start of hemadsorption (+/- 15 minutes)~* 16 hours after start of hemadsorption (+/- 15 minutes)~* 20 hours after start of hemadsorption (+/- 15 minutes)~* 24 hours after start of hemadsorption (+/- 15 minutes)~* Every other 24 hours until cessation of hemadsorption or normalization of the plasma titer (+/- 15 minutes)"
219233785|NCT04018300|OTHER|Placebo|Contains maltodextrin.
219233786|NCT03128099|BEHAVIORAL|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
219233787|NCT00005654|DRUG|clomiphene citrate|
219233788|NCT00005654|DRUG|metformin|
219233789|NCT01102699|DRUG|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
219233790|NCT06322368|OTHER|Myofunctional and respiratory training program|The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
219233791|NCT06322368|OTHER|Range of motion and thermal and mechanical stimulation exercising|The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
219233792|NCT02280759|DRUG|Gelatin Tannate|
219233793|NCT02280759|DRUG|Placebo|Placebo consists of an identical formulation, except active substance
219233794|NCT05334433|PROCEDURE|Local anesthesia injection|Local anesthesia administration
219727092|NCT07037862|DRUG|ENTR-601-44|intravenous infusion
219727093|NCT07037862|DRUG|ENTR-601-44 - matching placebo|intravenous infusion
219727094|NCT07046728|OTHER|Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL|Observationnal study with clincal data collection to evaluate the efficiency and the tolerability of DAROMUN
219727095|NCT07045454|DRUG|MHB118C for Injection|IV administration by Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219727096|NCT07046117|DRUG|Tezepelumab|injection with Tezepelumab every 4 weeks
219155228|NCT00431704|DRUG|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
219155229|NCT00431704|DRUG|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
219155230|NCT00431704|DRUG|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
219155231|NCT06107894|BIOLOGICAL|Tumor-infiltrating lymphocytes|After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
219155232|NCT06107894|DRUG|IL-2|IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
219155233|NCT01304277|BIOLOGICAL|agalsidase alfa|
219155234|NCT05335798|DEVICE|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
219155235|NCT05335798|DEVICE|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
219161476|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh use Synecor™ Hybrid Mesh (BD, USA): A macroporous mesh combining polypropylene with a bioresorbable layer that degrades over time, leaving a durable support structure to promote tissue integration."
219233795|NCT01841385|OTHER|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
219233796|NCT01474356|OTHER|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
219233797|NCT01680432|DIETARY_SUPPLEMENT|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
219233798|NCT01680432|DIETARY_SUPPLEMENT|Regular Cheese|
219233799|NCT03345706|PROCEDURE|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
219727097|NCT07044661|PROCEDURE|Unilateral ARM|ARM is performed to the dependent lung only. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
219161477|NCT06833723|OTHER|Retrospective Data Collection and Analysis|This is a retrospective study involving the collection and analysis of existing clinical data from breast cancer patients who received immunotherapy or neoadjuvant immunotherapy between January 1, 2015, and September 30, 2023. No new interventions are administered as part of this study. The data includes diagnostic puncture tissue, residual tumor tissue post-surgery, blood samples, and imaging data. These samples are analyzed using multi-omics approaches (proteomics, transcriptomics, metabolomics) and advanced imaging techniques (imaging mass cytometry and spatial transcriptomics) to build a predictive model for immunotherapy efficacy.
219161478|NCT06830408|DRUG|radionuclide therapy with 177Lu-PSMA-I&T|Standard PSMA RLT with 7-8 GBq i.v. infusion of 177Lu-PSMA-I\&T performed every 6-8 weeks for 4-6 cycles, or until progression or complete response.
219161479|NCT06790888|COMBINATION_PRODUCT|Ripertamab/Eltrombopag|Ripertamab, a novel anti-CD20 monoclonal antibody, in combination with Eltrombopag . Ripertamab is administered intravenously at a dose of 375 mg/m² BSA on Day 1 . If the participant remains in remission at the 3-month mark, an additional intravenous dose of 375 mg/m² Ripertamab is administered. Eltrombopag are given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
219161480|NCT06790888|DRUG|Eltrombopag|Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
219161481|NCT06831955|OTHER|Exercise Therapy|The exercise regimen consists of a non-linear aerobic exercise program of 3-4 sessions per week. During days of FMD no exercise will be prescribed.
219727098|NCT07044661|PROCEDURE|Bilateral ARM|ARM is performed to both lungs. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
219727099|NCT07047690|DRUG|Nemolizumab|Subcutaneous Injection
219727100|NCT07047690|DRUG|Placebo|Subcutaneous Injection
219161482|NCT06831955|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet|The FMD is a plant-based, low-carbohydrate, low-caloric diet of 4 days , with the fourth day being the day of chemo/immunotherapy. A total of 6 FMD cycles will be administered over the treatment period of 20 weeks.
219727101|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Mango|Low-glycemic breakfast of 80 grams of oats prepared with 473mL water and sweetened with 146 grams of mango.
219727102|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Mango|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 262 grams of mango.
219727103|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Table Sugar|Low-glycemic breakfast of 80 grams of oats prepared with 473mL of water and sweetened with 20 grams of table sugar.
219727104|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Table Sugar|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 36 grams of table sugar.
219727105|NCT07044453|DRUG|Gem/Nabpaclitaxel infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. If the anatomopathological analysis shows a lesion classified as T3-4 or N+ or R1, an adjuvant chemotherapy based on Gemcitabine with Nab Paclitaxel will be proposed for a period of 3 months.
219727106|NCT07044453|DRUG|mFOLFIRINOX infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. In that setting the patients will receive mFOLFIRINOX adjuvant chemotherapy 3 months.
219727107|NCT07047196|DEVICE|HS-20116|Innovative chitosan-based biomaterial intended for intra-articular injection
219727108|NCT07047196|DEVICE|Medical Chitosan (for intra-articular injection)|Medical chitosan for intra-articular injection
219727109|NCT06741670|BEHAVIORAL|Breastfeeding|The routine practice of the Breastfeeding Group is to place the infants in their mother's arms and start breastfeeding 1 minute before the procedure. Then, the nurse will take the heel blood.
219727110|NCT06741670|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The infants in the Vibration Group will be placed in their mother's arms and vibration will be applied 30 seconds before the routine application, and vibration will be applied during the 10-second waiting phase while the nurse performs the heel prick blood collection procedure.
219727111|NCT06741670|OTHER|Breastfeeding+Vibration|"The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage.~The routine practice for the Breastfeeding+Vibration Group babies will be started by holding them in their mother's arms and breastfeeding will be started 1 minute before the application. At the same time, vibration will be applied 30 seconds before the application and vibration will be applied in a 10-second waiting phase while the nurse performs the heel prick procedure."
219233800|NCT03345706|PROCEDURE|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
219233801|NCT00952003|DRUG|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
219233802|NCT06254976|BEHAVIORAL|exercise|2 weeks of home exercise
219233803|NCT06254976|BIOLOGICAL|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
219233804|NCT00774592|BEHAVIORAL|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
219233805|NCT00774592|BEHAVIORAL|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
219727112|NCT06734104|OTHER|Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. Following the pre-test, the students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the interactive video to the students in the experimental group. After one week of interactive video training for the experimental group, a post-test will be administered to all students.
219155236|NCT04086017|OTHER|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
219233806|NCT00774592|BEHAVIORAL|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
219155237|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
219155238|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
219155239|NCT06775912|DRUG|RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
219233807|NCT00774592|BEHAVIORAL|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
219233808|NCT00774592|BEHAVIORAL|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
219727113|NCT06734104|OTHER|Non-Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from the students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. After the pre-test, the 60 students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the non-interactive video to the students in the active control group. After one week of watching the non-interactive video, a post-test will be administered to all students.
219727114|NCT07045298|DEVICE|Libre 2 rt-CGM|Freestyle Libre 2 consists of a sensor applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin's surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor continuously reads interstitial glucose readings every minute and syncs with the Freestyle View app. The hypoglycemia alarm will be set to \< 80 mg/dl (for prevention of low blood glucose levels). Participants will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm. The hyperglycemia alarm will be set at 300 mg/dl. Participants will call the research team if they experience repeated episodes \> 300 mg/dl (more than 2 episodes in a single day or 2 or more episodes in consecutive days). The research team will instruct the participant to check with their physician for a possible new insulin regimen, but they will be allowed to remain in the study.
219727115|NCT07045298|DIAGNOSTIC_TEST|POC BG + Blinded CGM|Standard of care point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the study participation for up to 3 months.
219727116|NCT07055620|OTHER|Mediterranean diet|The group that will be applied the Mediterranean diet will be prepared with diet lists that include 35-40% carbohydrate, 15-20% protein and 35-45% fat (\>50% Monounsaturated Fatty Acid (MUFA)) of daily energy. The Mediterranean diet pyramid will be explained to the participants who will be applied the Mediterranean diet, and the portions and frequency of olive oil, nuts, olives, fish, yogurt, fruits and vegetables that they should consume will be planned by the dietitian. The Mediterranean diet pyramid recommends the frequency of foods that should be consumed daily, weekly and monthly. It recommends consuming fish and seafood at least twice a week, 2 portions of white meat, 2-4 portions of eggs, less than 2 portions of red meat, 1 portion or less of processed meat and less than 3 portions of dessert. It is recommended to consume 2 portions of dairy products, 1-2 portions of oil seeds and nuts, more spices, herbs, garlic and onions on a daily basis.
219155240|NCT06777069|PROCEDURE|Leucocyte and platelet rich fibrin membrane application|Leukocyte and platelet rich membrane, obtained by centrifuging 10 ml of venous blood collected from the patient's antecubital vein, was sutured to the donor sites.
219155241|NCT03867747|RADIATION|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
219155242|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
219155243|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
219155244|NCT05808608|DRUG|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
219155245|NCT05808608|DRUG|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
219155246|NCT02460900|DRUG|Varenicline|
219155247|NCT02460900|BEHAVIORAL|Positively Smoke Free|
219155248|NCT02460900|DRUG|Placebo|
219155249|NCT02460900|BEHAVIORAL|Standard of Care|
219155250|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
219155251|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
219155252|NCT05722522|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
219155253|NCT05722522|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
219155254|NCT04527887|DRUG|Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
219155255|NCT04527887|OTHER|ProLong™ collagen plugs|The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
219155256|NCT00248456|DRUG|Calcipotriol plus betamethasone dipropionate ointment|
219155257|NCT05165485|DRUG|Revefenacin|Revefenacin 175 mcg administered once daily for 84 days via nebulization
219155258|NCT05165485|DRUG|Tiotropium|Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
219155259|NCT05165485|DRUG|Revefenacin Placebo|Placebo for Revefenacin administered once daily for 84 days via nebulization
219155260|NCT05165485|DRUG|Tiotropium Placebo|Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
219155261|NCT04888637|DIAGNOSTIC_TEST|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
219155262|NCT04888637|BEHAVIORAL|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
219155263|NCT04888637|BEHAVIORAL|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
219155264|NCT00987025|BEHAVIORAL|Telehealth|Use of telehealth blood pressure station every week
219155265|NCT00987025|BEHAVIORAL|Educational materials|Control
219155266|NCT06832943|PROCEDURE|Unicorn system|Patients with airway stenosis undergo stent placement with the help of RBS.
219155267|NCT05676203|DRUG|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
219155268|NCT05676203|DRUG|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
219155269|NCT05676203|DRUG|Docetaxel|Docetaxel
219155270|NCT06831656|OTHER|Placebo-Pre|No dietary supplementation prior to undergoing the placebo supplement
219155271|NCT06831656|DIETARY_SUPPLEMENT|Placebo-Post|14 days of supplementation with 25 mg/day hemicellulose crystalline
219155272|NCT06831656|OTHER|Tetraselmis chuii-Pre|No dietary supplementation prior to undergoing the tetraselmis chuii supplement
219155273|NCT06831656|DIETARY_SUPPLEMENT|Tetraselmis chuii-Post|14 days of supplementation with 25 mg/day tetraselmis chuii
219155274|NCT05741879|BEHAVIORAL|Gamified exercise training|"Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s)."
219155275|NCT05741879|BEHAVIORAL|Standard Care|This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
219155276|NCT03237481|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
219155277|NCT03237481|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
219155278|NCT03237481|DRUG|Saline placebo|Saline placebo by instillation
219155279|NCT03237481|DEVICE|Luer-lock applicator|Applicator for instillation
219155280|NCT03237481|DEVICE|Vial access device|Device for withdrawal of drug product
219155281|NCT03501719|DRUG|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
219155282|NCT03439891|BIOLOGICAL|Nivolumab|Given IV
219155283|NCT03439891|DRUG|Sorafenib|Given PO
219155284|NCT05972473|DRUG|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
219155285|NCT05972473|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
219155286|NCT06265961|OTHER|Education|"In line with the Papadopoulos Tilki Taylor cultural competence development model used in the research, a training presentation titled overview and basic concepts of intercultural nursing will be held at the beginning of the intervention in order to increase the cultural knowledge levels of nurses. In order to test the effectiveness of the bibliotherapy method, training will be given online via Google Meet to both groups (both study and control) at the beginning of the research."
219155287|NCT06265961|OTHER|Bibliotherapy|"The intervention consists of 1 online intercultural nursing training, 2 book and 2 short story reading activities and 1 film evaluation to be carried out over a 3-month period.~After the training, the nurses in the study group will be asked to read the introductions of the books on the reading list and choose 2 books that they feel close to and that they have not read before. Participants will complete readings and assignments (evaluation form, reflective thought essay) asynchronously in time periods convenient to them.~In addition to books, a supporting film will be used to raise awareness. At the end of the movie, they will be asked to write on their notes how they can relate to intercultural nursing, how they can behave when faced with similar situations, and what differences there are between their ideas about intercultural nursing before and after the movie."
219233809|NCT00774592|BEHAVIORAL|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
219233810|NCT00001004|DRUG|Tumor Necrosis Factor|
219233811|NCT00001004|DRUG|Interferon gamma-1b|
219727117|NCT07055620|OTHER|Standard diet|When writing the weight loss diets applied to the individuals in the standard diet group, it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat, as specified in the Turkish Nutrition Guide (TUBER). It will be planned that 10% (preferably 7-8%) of the total energy from fat will come from saturated fats (fat found in animal foods, butter, tallow, tail fat), 12-15% from monounsaturated fats (olive oil, hazelnut oil, rapeseed oil) and 7-10% from polyunsaturated fats (corn, soy, sunflower and cottonseed oils containing n-6 fatty acids and fish, fish oil, walnut, flaxseed containing n-3 fatty acids). It will be stated that this ratio is 1 part solid oil, 1 part any vegetable oil and 1.5 or 2 parts olive oil among the oil types.
219727118|NCT07055620|OTHER|standard diet and time-restricted feeding|In time-restricted nutrition, the focus is on when the food is consumed rather than the type of food. However, in medical nutrition treatment of obesity, the content of the meals is also important along with the time (Soran and Öney 2022). As stated in the Turkish Nutrition Guide (TÜBER), it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat (Ministry of Health, 2022). A time-restricted nutrition model will be implemented from intermittent fasting diet models. The time restriction will be planned as 8 hours of eating and 16 hours of fasting, suitable for the lifestyle of the individuals. The feeding time for individuals who agree to participate in the study will be determined as 11.00-12.00 and 19.00-20.00. Individuals will be given 2 main meals and the first meal will start with breakfast or lunch according to their wishes.
219727119|NCT07056868|PROCEDURE|extraperitoneal colostomy|Patients in this group will undergo extraperitoneal stoma creation using the arcuate line approach. This technique involves creating a stoma through the extraperitoneal space by accessing the posterior sheath at or below the arcuate line, thereby avoiding direct peritoneal entry. The goal is to reduce the risk of parastomal hernia by maintaining abdominal wall integrity and preventing intra-abdominal content herniation around the stoma.
219727120|NCT07056868|PROCEDURE|transperitoneal colostomy|Patients in this group will receive a conventional transperitoneal stoma. In this approach, the stoma is brought out through the abdominal wall via a peritoneal opening, which is the standard method used in colorectal surgery. This technique serves as the control for evaluating whether the arcuate line approach offers improved outcomes, particularly in reducing parastomal hernia incidence.
219727121|NCT04210089|DEVICE|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee"
219727122|NCT04210089|DEVICE|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
219727123|NCT01729091|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
219727124|NCT01729091|BIOLOGICAL|Elotuzumab|Given IV
219727125|NCT01729091|OTHER|Laboratory Biomarker Analysis|Correlative studies
219727126|NCT01729091|DRUG|Lenalidomide|Given PO
219727127|NCT01729091|DRUG|Melphalan|Given IV
219727128|NCT01729091|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
219727129|NCT01729091|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
219727130|NCT04464083|DIAGNOSTIC_TEST|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
219155288|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
219155289|NCT04543773|DEVICE|rTMS|rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
219155290|NCT05786248|OTHER|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
219155291|NCT05178745|DRUG|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
219155292|NCT05178745|DRUG|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
219727131|NCT04514549|DEVICE|Emerald|The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
219727132|NCT05618626|OTHER|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
219155293|NCT05178745|DRUG|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
219155294|NCT01067287|DRUG|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
219727133|NCT06210711|BEHAVIORAL|Treatment as Usual|Standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. At BUMC and FH/MCW, this may include an evaluation by a licensed psychologist or psychiatrist and continued follow-up psychotherapy and/or medication as needed. At BSWMC Temple this may include an evaluation by a licensed psychiatrist and follow up treatment as needed. In all locations this therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care.
219727134|NCT06210711|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes. The treatment is manualized and has been successfully implemented and evaluated in other challenging environments (i.e., Emergency Department. Trauma center). Brief PE includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo/behavioral exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises. This discussion addresses patients' unrealistic beliefs about themselves and the world. In addition, patients are given homework to complete between each session (breathing practice, listening to the session recording, and completing behavioral exposures).
219727135|NCT04423367|DRUG|bortezomib/dexamethasone|Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
219155295|NCT01067287|BIOLOGICAL|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
219155296|NCT04068844|BEHAVIORAL|Exercise training|Exercise training, either whole body or isolated single leg
219155297|NCT06219187|OTHER|Questionnaire completion|"To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data"
219155298|NCT02665195|OTHER|saliva specimen|
219155299|NCT02665195|BEHAVIORAL|questionnaire|
219155300|NCT03309748|PROCEDURE|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
219155301|NCT03309748|DEVICE|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
219155302|NCT06235242|BIOLOGICAL|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
219155303|NCT06589466|OTHER|Surgery|this study in observational study, no intervention.
219155304|NCT06681090|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
219155305|NCT06681090|DEVICE|980 nm diode laser|First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
219155306|NCT03535922|OTHER|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
219155307|NCT02746081|DRUG|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
219155308|NCT05925881|PROCEDURE|Surgical Repair of Large to Massive Rotator Cuff Tears|Surgical procedure to reconstruct the rotator cuff
219155309|NCT05281510|DRUG|Vesatolimod|Administered orally
219155310|NCT05281510|BIOLOGICAL|VRC07523LS|Administered intravenously
219155311|NCT05281510|BIOLOGICAL|CAP256V2LS|Administered intravenously
219233812|NCT04894942|OTHER|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
219155312|NCT05423379|DEVICE|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
219155313|NCT02581215|DRUG|mFOLFIRINOX|"mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
219155314|NCT02581215|DRUG|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
219155315|NCT02581215|OTHER|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
219155316|NCT05836116|OTHER|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
219155317|NCT03827304|DEVICE|Virtual Reality Distraction for Burns patients|Patients wore a VR headset while undergoing a burns dressing change
219155318|NCT05406258|DEVICE|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
219155319|NCT05406258|DEVICE|Standard Self-Catheterization Mirror|Following training, participants will have a standard, hospital-provided mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
219155320|NCT00199407|DRUG|Istradefylline (KW-6002)|
219155321|NCT02663778|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
219155322|NCT02663778|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
219155323|NCT02663778|BEHAVIORAL|Flexibility training|stretches to improve flexibility
219155324|NCT02663778|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
219155325|NCT02663778|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
219155326|NCT01108003|DRUG|broccoli sprout extract|Given orally
219155327|NCT01108003|OTHER|laboratory biomarker analysis|Correlative studies
219155328|NCT01108003|OTHER|Mango Juice|given orally
219155329|NCT00803387|DRUG|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
219155330|NCT01778907|OTHER|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
219155331|NCT03435367|DEVICE|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
219155332|NCT03435367|DEVICE|iPad Tablet|iPad with headphones
219155333|NCT04846959|DRUG|Risankizumab|Subcutaneous Injection
219155334|NCT04846959|DRUG|Comparator|Subcutaneous or Intravenous Injection
219155335|NCT03112174|DRUG|Ibrutinib|Administered orally once daily
219155336|NCT03112174|DRUG|Venetoclax|Administered orally once daily
219155337|NCT03112174|DRUG|Placebo Oral tablet to match Venetoclax|Administered orally once daily
219155338|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
219155339|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
219155340|NCT06134882|BEHAVIORAL|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
219155341|NCT06134882|BEHAVIORAL|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
219155342|NCT06134882|BEHAVIORAL|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
219155343|NCT06134882|BEHAVIORAL|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
219155344|NCT06134882|BEHAVIORAL|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
219155345|NCT06134882|BEHAVIORAL|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
219155346|NCT06441136|OTHER|PhoRTE Program|Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.
219155347|NCT06441136|OTHER|University of California Los Angeles (UCLA) Loneliness Scale|A questionnaire measuring levels of loneliness.
219155348|NCT06441136|OTHER|Social Disconnectedness Scale|A questionnaire that asks about social network size and the frequency of social activities attended.
219155349|NCT06441136|OTHER|Patient Health Questionnaire 9|A questionnaire measuring levels of depression.
219155350|NCT06441136|OTHER|Aging Voice Index|A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.
219155351|NCT06441136|OTHER|The Edmonton Frail Scale|A questionnaire that measures frailty levels.
219155352|NCT06441136|OTHER|Vocal Effort Scale|A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.
219155353|NCT06441136|OTHER|Montreal Cognitive Assessment|A screening tool used to test for cognitive impairment.
219155354|NCT06441136|OTHER|Voice Handicap Index-10|A questionnaire used to measure quality of life impact of dysphonia.
219727136|NCT05399134|DIETARY_SUPPLEMENT|Modified Functional Foods|"Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre."
219727137|NCT05399134|DIETARY_SUPPLEMENT|Control Functional Foods|Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.
219727138|NCT06469125|PROCEDURE|Endoscopic Prostate Interventions for Anatomic Enucleation|The intervention in this study involves performing anatomic endoscopic enucleation of the prostate (AEEP) using different energy sources. Following the enucleation, the resected prostate tissue will be morcellated within the bladder using various morcellators to remove the enlarged prostate tissue minimally invasively. The process will also involve evaluating and categorizing any resulting bladder injuries using the BICEP classification system.
219727139|NCT02740582|DRUG|Tolcapone|
219727140|NCT02740582|DRUG|Placebo|
219727141|NCT01579877|DIETARY_SUPPLEMENT|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
219727142|NCT01579877|DIETARY_SUPPLEMENT|Placebo herbal extract granule|The Yukmijihwang-tang\_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
219155355|NCT06441136|OTHER|Voice Problem Impact Scales|A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.
219155356|NCT06441136|OTHER|Cough Severity Index|A 10 question survey asking to rate severity of cough.
219155357|NCT06441136|PROCEDURE|Laryngoscopy|Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.
219155358|NCT06441136|OTHER|Acoustic, perceptual, and aerodynamic assessments|Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
219155359|NCT01365598|DRUG|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
219155360|NCT01131780|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
219155361|NCT00687167|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
219155362|NCT00687167|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
219155363|NCT05381233|OTHER|Gross motor function classification System (GMFCS)|assessment
219155364|NCT05381233|OTHER|Arabic Version of Zarit burden Inventory measure|assessment
219155365|NCT05381233|OTHER|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
219155366|NCT04987021|DEVICE|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
219155367|NCT02343913|DEVICE|PAC checklist|
219155368|NCT06267690|PROCEDURE|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
219155369|NCT04259450|DRUG|14 mg AFM24|14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155370|NCT04259450|DRUG|40 mg AFM24|40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155371|NCT04259450|DRUG|80 mg AFM24|80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155372|NCT04259450|DRUG|160 mg AFM24|160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155373|NCT04259450|DRUG|320 mg AFM24|320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155374|NCT04259450|DRUG|480 mg AFM24|480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219155375|NCT04259450|DRUG|720 mg AFM24|720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
219361093|NCT02218229|DEVICE|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
219155376|NCT00989183|OTHER|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
219155377|NCT01335828|DEVICE|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
219727143|NCT06964399|OTHER|Reminiscence therapy|Reminiscence Therapy can be applied as 1 or 2 sessions per week and the longest is 1.5 hours, so it will be applied for 5 weeks, 3 days a week (Monday, Wednesday, Friday) with 2 sessions per day. Each session is planned to last an average of 1.5 hours according to the answers from the elderly. The elderly individuals in the experimental group will be divided into 3 groups. Each group will consist of 15 people. The sessions will include, respectively, getting to know each other, childhood, places lived, holidays-festivals, foods-cooking, unforgettable historical periods, favorite music, movies specific to the period, family life-values in life-achievements, evaluation and closing topics.
219727144|NCT04901052|DIETARY_SUPPLEMENT|n-3 supplementation group|n-3 supplementation group (1.5g of omega 3)
219727145|NCT04901052|DIETARY_SUPPLEMENT|Placebo group|Placebo group (sunflower oil)
219727146|NCT05291481|BEHAVIORAL|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
219727147|NCT04060745|OTHER|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
219727148|NCT04060745|OTHER|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
219727149|NCT03022630|OTHER|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
219727150|NCT03022630|OTHER|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
219727151|NCT00358800|DEVICE|REMStar Auto with C-Flex|
219727152|NCT03382171|OTHER|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
219155378|NCT01534494|DRUG|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
219155379|NCT05356689|OTHER|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
219155380|NCT00075933|DRUG|ARQ 501|
219155381|NCT03319680|OTHER|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
219155382|NCT00924807|DRUG|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
219155383|NCT04336059|PROCEDURE|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
219155384|NCT04601974|GENETIC|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
219161483|NCT06831955|DRUG|SOC|Four cycles of an intravenous infusion of pembrolizumab (200 mg) once every 3 weeks plus paclitaxel (80 mg per square meter of body-surface area once weekly) plus carboplatin (at a dose based on an area under the concentration-time curve of 1.5 mg per milliliter per minute) once weekly in the first 12 weeks, followed by four cycles of epirubicin (90 mg per square meter) plus cyclophosphamide (600 mg per square meter) once every 2 weeks plus pembrolizumab 400mg every 6 weeks or pembrolizumab 200mg every 3 weeks in the subsequent 8 weeks.
219161484|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
219727153|NCT05362175|DEVICE|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
219727154|NCT04557345|DIAGNOSTIC_TEST|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
219161485|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
219727155|NCT04557345|DIAGNOSTIC_TEST|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
219727158|NCT05411549|BEHAVIORAL|Diet Modification to Adopt Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
219727159|NCT02465047|OTHER|Self-help booklet|See Arm/Group Description
219727160|NCT01533220|DRUG|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
219727161|NCT01533220|DRUG|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
219727162|NCT05431790|DEVICE|Absorbable interface screws manufactured by Natong Biotechnology|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
219727163|NCT05431790|DEVICE|Absorbable interface screws manufactured by INION.|Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland
219727164|NCT03197935|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
219727165|NCT03197935|DRUG|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
219727166|NCT03197935|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
219727167|NCT03197935|DRUG|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
219727168|NCT03197935|DRUG|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
219727169|NCT03197935|DRUG|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
219727170|NCT03197935|DRUG|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
219727171|NCT03159949|OTHER|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
219727172|NCT03159949|OTHER|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
219727173|NCT04058912|GENETIC|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
219727174|NCT02455089|OTHER|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
219727175|NCT05406895|DRUG|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
219727176|NCT04122495|DIETARY_SUPPLEMENT|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
219727177|NCT04122495|DIETARY_SUPPLEMENT|Placebo|Oral administration of maltodextrin daily for 4-weeks
219727178|NCT01768273|DRUG|Midazolam|
219727179|NCT01768273|DRUG|PA-824|
219727180|NCT00494884|DRUG|vildagliptin|
219161486|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine|2.7 mg.kg IV every 4 weeks
219161487|NCT05551117|DRUG|Abiraterone|1000 mg once daily
219361094|NCT01820715|DRUG|600㎍ of DA-3030 Injection|
219361095|NCT01820715|DRUG|Placebo|
219727181|NCT01801527|BEHAVIORAL|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
219727182|NCT02834897|RADIATION|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
219727183|NCT02603029|OTHER|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
219727184|NCT02603029|OTHER|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
219727185|NCT00365963|DEVICE|Comprehensive Health Enhancement Support System|computer based support and education
219161488|NCT05551117|DRUG|Enzalutamide|160 mg daily
219161489|NCT05860816|OTHER|Survey|Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
219161490|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
219727186|NCT03091491|DRUG|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
219727187|NCT03091491|DRUG|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
219727188|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum|Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
219155385|NCT03872310|DEVICE|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
219155386|NCT05669170|BEHAVIORAL|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
219155387|NCT05669170|DRUG|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
219155388|NCT00002270|DRUG|Interferon alfa-2b|
219155389|NCT00002270|DRUG|Zidovudine|
219155390|NCT00825630|DRUG|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
219155391|NCT00825630|DRUG|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
219155392|NCT00825630|DRUG|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
219155393|NCT00825630|DRUG|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
219155394|NCT01991301|DRUG|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
219155395|NCT04965415|BEHAVIORAL|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
219155396|NCT04965415|BEHAVIORAL|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
219155397|NCT05872724|DRUG|Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|"* Radiation therapy:~  1\. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy."
219155398|NCT05872724|DRUG|Chemoradiotherapy (small pelvic) + Zimberelimab|"Radiation therapy:~1\. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy."
219155399|NCT04140331|DEVICE|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
219361096|NCT00880256|BEHAVIORAL|mindfulness-based stress reduction|An 8-week course in mindfulness training
219727189|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with local tissues|Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
219727190|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis|A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
219727191|NCT06218784|DRUG|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
219727192|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
219727193|NCT06218784|DRUG|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
219727194|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
219727195|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
219727196|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
219727197|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
219727198|NCT06218784|DRUG|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
219727199|NCT02331407|DEVICE|Robotic arm therapy|Training with the ReoGo device
219727200|NCT00546273|BIOLOGICAL|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
219155400|NCT02553161|DRUG|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
219155401|NCT02553161|BEHAVIORAL|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
219155402|NCT05114967|OTHER|mPAS questionnaire|The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
219155403|NCT02125110|DEVICE|MRI|
219155404|NCT02125110|OTHER|neuropsychological assessment|
219155405|NCT02851667|BEHAVIORAL|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
219727201|NCT00546273|BIOLOGICAL|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
219155406|NCT02617771|DRUG|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
219161491|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
219161492|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
219161493|NCT06783790|DRUG|Avapritinib, azacitidine, Venetoclax|"A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles"
219161494|NCT06787014|OTHER|Histopathological review|Histopathological review
219161495|NCT06835114|PROCEDURE|CABG|CABG
219161496|NCT06835114|PROCEDURE|LIMA on lay patch|Left internal mammary artery harvesting with on lay patch on left anterior descending coronary artery
219161497|NCT06835114|PROCEDURE|Safenous vein patch|Safenous vein patch on left anterior descending artery
219161498|NCT06786169|OTHER|psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
219161499|NCT05977712|OTHER|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
219161500|NCT05977712|OTHER|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
219161501|NCT05977712|OTHER|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
219161502|NCT05977712|OTHER|Eye examination|Eye fundus photo, OCT and OCT-A exams
219161503|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
219161504|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
219233813|NCT05445050|DIAGNOSTIC_TEST|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
219233814|NCT03286907|BEHAVIORAL|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
219233815|NCT03286907|BEHAVIORAL|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
219233816|NCT03286907|BEHAVIORAL|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
219727202|NCT00546273|BIOLOGICAL|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
219727203|NCT00546273|BIOLOGICAL|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
219727204|NCT00546273|BIOLOGICAL|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
219155407|NCT00434304|DRUG|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
219155408|NCT05262738|DRUG|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
219155409|NCT05262738|DRUG|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
219155410|NCT00639860|DEVICE|OSSIX-Plus|resorbable collagen membrane
219155411|NCT01804387|DRUG|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
219155412|NCT01804387|DRUG|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
219155413|NCT04418973|OTHER|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
219155414|NCT02356341|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
219233817|NCT03293043|DEVICE|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
219233818|NCT03806205|OTHER|regular follow-up|we give a regular follow-up and supervision on the study group
219233819|NCT00774878|DRUG|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
219233820|NCT00774878|DRUG|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
219233821|NCT03456856|DRUG|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
219727205|NCT00211939|DRUG|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
219233822|NCT03711279|DRUG|SHR-1210 plus Apatinib|SHR-1210 200 mg q3w+ Apatinib 500 mg qd
219233823|NCT03711279|DRUG|ADM plus IFO or IFO alone|ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
219233824|NCT03608436|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
219233825|NCT03608436|DRUG|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
219233826|NCT04534738|BEHAVIORAL|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
219233827|NCT06248255|OTHER|Pads|Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
219727206|NCT00211939|DRUG|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
219727207|NCT00211939|DRUG|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
219727208|NCT05099445|DRUG|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
219727209|NCT03722628|DIAGNOSTIC_TEST|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
219727210|NCT05160285|DRUG|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
219727211|NCT00860431|DRUG|AST-120|6g/day (3 times a day)
219727212|NCT01496443|DRUG|TAK-875 and Glimepiride|
219155415|NCT02374463|BEHAVIORAL|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
219155416|NCT02374463|BEHAVIORAL|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
219155417|NCT04372316|DRUG|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
219155418|NCT00920738|OTHER|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
219155419|NCT00920738|OTHER|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
219155420|NCT03504423|DRUG|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
219155421|NCT03504423|DRUG|Folfirinox|Folfirinox
219155422|NCT02837211|BEHAVIORAL|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
219155423|NCT02837211|BEHAVIORAL|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
219155424|NCT02538653|OTHER|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
219155425|NCT02538653|OTHER|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
219155426|NCT04334746|OTHER|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
219155427|NCT03177044|BEHAVIORAL|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
219155428|NCT01183936|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
219155429|NCT01183936|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
219155430|NCT03079700|BIOLOGICAL|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
219155431|NCT01814839|DRUG|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
219155432|NCT01814839|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
219155433|NCT01471691|DRUG|ranibizumab 0.5mg|Standard dose
219155434|NCT01471691|DRUG|ranibizumab 1.0mg|High dose
219155435|NCT06516315|PROCEDURE|Preoperative ultrasound examination.|Preoperative ultrasound examination performed the day before or the day of surgery.
219155436|NCT06516315|PROCEDURE|Peroperatoire angiography procedure and QFR analysis|Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
219155437|NCT01586936|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
219155438|NCT02894879|DEVICE|BreatheMAX®|"Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
219155439|NCT02894879|OTHER|Routine treatment|"Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
219155440|NCT00637585|DRUG|Fexofenadine|
219155441|NCT05212181|DEVICE|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
219155442|NCT01808339|DRUG|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
219233828|NCT05015699|DEVICE|HT Supreme|HT Supreme ( R\&D by Sinomed, Tianjin, China)
219727213|NCT02129881|BIOLOGICAL|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
219727214|NCT03886324|COMBINATION_PRODUCT|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
219727215|NCT04578977|BEHAVIORAL|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
219727216|NCT00076609|DRUG|PHY906|
219727217|NCT00076609|DRUG|capecitabine|
219727218|NCT03751748|DEVICE|AFR implantation|Implantation of atrial flow regulator (AFR) device
219727219|NCT03751748|DEVICE|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
219727220|NCT05829733|DEVICE|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
219727221|NCT06539650|OTHER|Fractal Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
219727222|NCT06539650|OTHER|Isochronus Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
219727223|NCT06539650|OTHER|Self Paced|The intervention consists in a single session of strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at at participants' own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
219727224|NCT00443287|DRUG|ataciguat (HMR1766)|oral administration
219727225|NCT00443287|DRUG|placebo|oral administration
219727226|NCT00443287|DRUG|cilostazol|oral administration
219727227|NCT05113602|DEVICE|URGOnight|EEG dry electrodes portable device
219727228|NCT05113602|DEVICE|Enobio|EEG wet electrodes portable device
219727229|NCT00559117|DRUG|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
219727230|NCT02661373|DRUG|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
219727231|NCT02661373|DRUG|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
219727232|NCT03458091|DEVICE|THRIVE|Oxygenation during apnea using transversal humidified oxygen
219727233|NCT03458091|DEVICE|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
219727234|NCT04322045|DIAGNOSTIC_TEST|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
219727235|NCT00727337|BEHAVIORAL|LACE-computer|Computerized Auditory Training
219727236|NCT00727337|BEHAVIORAL|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
219727237|NCT00727337|BEHAVIORAL|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
219727238|NCT00727337|BEHAVIORAL|Lace-DVD|DVD based Auditory Training
219727239|NCT04847921|DRUG|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
219727240|NCT06130202|DEVICE|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
219727241|NCT00574951|DRUG|motesanib diphosphate|
219727242|NCT04094636|BEHAVIORAL|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
219727243|NCT04094636|BEHAVIORAL|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
219727244|NCT01901588|DRUG|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
219727245|NCT01901588|OTHER|Placebo|intraoperative dose of intravenous placebo
219727246|NCT01567020|OTHER|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
219727247|NCT02580344|DRUG|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
219727248|NCT02396797|BEHAVIORAL|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
219727249|NCT02396797|BEHAVIORAL|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
219727250|NCT02475057|DRUG|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
219155443|NCT01808339|DRUG|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
219155444|NCT03586258|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
219155445|NCT03586258|OTHER|Brain Imaging|Anatomical, diffusion, and/or functional MRI
219155446|NCT03586258|OTHER|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
219155447|NCT04045782|DRUG|single arm|switch from originator (Humira) to biosimilar (Imraldi)
219155448|NCT03311737|COMBINATION_PRODUCT|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
219155449|NCT03311737|COMBINATION_PRODUCT|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
219155450|NCT00804648|DRUG|Timolol Maleate in Sorbate|0.5%
219155451|NCT00804648|DRUG|Timolol hemihydrate|0.5%
219155452|NCT00804648|DRUG|Timolol maleate gel forming solution|0.5%
219155453|NCT01643616|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
219155454|NCT01643616|DRUG|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
219155455|NCT01643616|DRUG|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
219155456|NCT01643616|DRUG|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
219155457|NCT01643616|DEVICE|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
219155458|NCT01643616|DEVICE|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
219155459|NCT02622568|DRUG|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
219233829|NCT00476294|OTHER|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
219233830|NCT01655082|DRUG|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
219155460|NCT02622568|PROCEDURE|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
219155461|NCT01116635|DRUG|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
219155462|NCT05076942|RADIATION|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
219155463|NCT05076942|DRUG|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
219155464|NCT06322446|OTHER|Exercise|16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
219155465|NCT04644679|DIAGNOSTIC_TEST|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
219155466|NCT04644679|DIAGNOSTIC_TEST|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
219155467|NCT02061501|OTHER|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
219233831|NCT01655082|DRUG|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
219233832|NCT00907959|DRUG|BZL101|Oral BZL101 20 grams/day (10 grams BID).
219155468|NCT02061501|OTHER|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
219155469|NCT05018013|DRUG|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
219155470|NCT05018013|DRUG|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
219155471|NCT05018013|DRUG|Placebo to Ammoxetine|Placebo to Ammoxetine
219155472|NCT05018013|DRUG|Placebo to Duloxetine|Placebo to Duloxetine
219155473|NCT00162344|DRUG|Technetium Tc99m Sestamibi|
219155474|NCT00031785|DRUG|megestrol acetate|
219155475|NCT00031785|RADIATION|radiation therapy|
219155476|NCT03847259|DIAGNOSTIC_TEST|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
219155477|NCT04613700|DRUG|Secretin|Native hormone
219155478|NCT04613700|OTHER|Placebo|Saline
219360790|NCT02602730|BEHAVIORAL|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
219360791|NCT02602730|BEHAVIORAL|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
219360792|NCT05196945|DRUG|vonoprazan fumarate + amoxicillin|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
219727251|NCT02475057|DRUG|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
219727252|NCT02475057|DEVICE|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
219727253|NCT02202720|DRUG|Sevoflurane|Short term sedation with sevoflurane in ICU
219727254|NCT05034978|OTHER|no intervention|evaluating the performance of a novel point-of-care test
219727255|NCT05017948|OTHER|Risk score based intervention|Targeted interventions based off of risk score software
219727256|NCT01795131|DIETARY_SUPPLEMENT|Vitamin B12|
219727257|NCT01795131|DIETARY_SUPPLEMENT|Placebo|
219727258|NCT01160744|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
219727259|NCT01160744|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
219727260|NCT01160744|DRUG|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
219727261|NCT01160744|DRUG|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
219727262|NCT01160744|DRUG|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
219727263|NCT01160744|DRUG|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
219727264|NCT02056288|DRUG|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
219727265|NCT02056288|DRUG|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
219727266|NCT01557816|DRUG|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
219727267|NCT01557816|DRUG|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
219155479|NCT04576975|DRUG|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
219155480|NCT04576975|DRUG|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
219155481|NCT04576975|DRUG|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
219155482|NCT05000424|OTHER|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
219155483|NCT05000424|OTHER|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
219155484|NCT00532142|DRUG|Intravitreal Triamcinolone|
219155485|NCT00532142|PROCEDURE|Radial Optic Neurotomy|
219155486|NCT00532142|OTHER|Placebo - Sham Intravitreal Injection|
219155487|NCT00374192|DRUG|Eszopiclone|3 mg per day
219155488|NCT00374192|DRUG|Placebo|Placebo
219155489|NCT05436119|DIETARY_SUPPLEMENT|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
219155490|NCT01727375|OTHER|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
219155491|NCT04741113|OTHER|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
219727268|NCT05898880|OTHER|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
219727269|NCT05898880|OTHER|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
219727270|NCT05898880|OTHER|Control group|No intervention will be made in the control group.
219727271|NCT02301429|DEVICE|Model 20105|implant and follow-up of study device
219727272|NCT05655572|OTHER|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
219727273|NCT05655572|OTHER|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
219727274|NCT02080728|DRUG|Ropivacaine 500mg/100ml Naropeine|
219727275|NCT02080728|DRUG|0.9% sodium chloride BAXTER|
219727276|NCT05086172|BEHAVIORAL|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
219727277|NCT01359280|BEHAVIORAL|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
219155492|NCT00858117|BIOLOGICAL|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
219155493|NCT00858117|BIOLOGICAL|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
219155494|NCT00371787|DEVICE|Soft contact lens|Soft contact lens
219155495|NCT02798367|BEHAVIORAL|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
219155496|NCT02798367|DRUG|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
219155497|NCT02798367|DRUG|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
219155498|NCT01240434|PROCEDURE|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
219155499|NCT02415088|PROCEDURE|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
219155500|NCT02415088|PROCEDURE|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
219155501|NCT03277534|OTHER|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
219155502|NCT03277534|OTHER|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
219155503|NCT03002675|DRUG|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
219155504|NCT02355275|PROCEDURE|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
219155505|NCT04460807|DRUG|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
219155506|NCT04460807|OTHER|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
219155507|NCT03323775|DIAGNOSTIC_TEST|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
219727278|NCT01359280|BEHAVIORAL|General Health Counseling|5 sessions of health improvement counseling
219155508|NCT04860401|DEVICE|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
219155509|NCT03955575|DRUG|Liraglutide 6 MG/ML|Liraglutide as injections.
219727279|NCT01359280|BEHAVIORAL|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
219727280|NCT01818648|DRUG|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
219727281|NCT01818648|DRUG|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
219727282|NCT00800150|DRUG|fludarabine phosphate|
219155510|NCT03955575|DRUG|Colesevelam|3 x 625 miligram 2 times a day.
219155511|NCT01462149|DRUG|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
219727283|NCT00800150|DRUG|melphalan|
219727284|NCT00800150|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219727285|NCT00800150|RADIATION|intensity-modulated radiation therapy|
219727286|NCT00800150|RADIATION|tomotherapy|
219727287|NCT00800150|RADIATION|total marrow irradiation|
219727288|NCT00800150|RADIATION|total nodal irradiation|
219727289|NCT01038895|DRUG|Ramipril|tablet; 10 mg; od; 3 months
219727290|NCT01038895|DRUG|Experimental|tablet; 300 mg; od; 3 months
219727291|NCT03473158|DEVICE|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
219727292|NCT03473158|PROCEDURE|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
219727293|NCT03473158|PROCEDURE|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
219727294|NCT01502072|DRUG|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
219727295|NCT01502072|DRUG|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
219155512|NCT01462149|DRUG|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
219155513|NCT05801367|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
219155514|NCT05801367|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
219155515|NCT04677192|COMBINATION_PRODUCT|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
219155516|NCT02233595|RADIATION|Chemoradiation|
219155517|NCT03285542|DEVICE|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
219155518|NCT03285542|DEVICE|Staples|staples for skin closure
219155519|NCT01816672|DEVICE|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
219727296|NCT00500110|DRUG|Docetaxel|30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
219155520|NCT01816672|OTHER|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
219155521|NCT04961021|PROCEDURE|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
219155522|NCT01854385|DRUG|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
219155523|NCT00329862|PROCEDURE|Laparoscopic Truncal Vagotomy|
219360793|NCT05196945|DRUG|Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate|Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
219727297|NCT00500110|DRUG|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
219727298|NCT00500110|DRUG|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
219727299|NCT00500110|DRUG|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
219727300|NCT00000538|BEHAVIORAL|diet, fat-restricted|
219727301|NCT05066139|OTHER|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
219727302|NCT01121458|DRUG|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP\< 80 mmHg), hypertension (SBP\>150 mmHg), tachycardia (120 beats per minute), bradycardia (\<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
219727303|NCT02363127|DRUG|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
219727304|NCT02363127|DRUG|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
219360794|NCT01815229|PROCEDURE|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
219360795|NCT00292500|DEVICE|Automated distal anastomotic device|CABG
219360796|NCT02672085|PROCEDURE|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
219727305|NCT02207179|DEVICE|LumaScan Image Guided Surgery|
219727306|NCT05363085|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
219727307|NCT00151073|DRUG|Zoledronic acid|
219727308|NCT00151073|DRUG|Estramustine|
219727309|NCT00151073|DRUG|Docetaxel|
219727310|NCT06499909|OTHER|Hypnosis|The patient will receive a course of hypnosis
219727311|NCT04676646|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
219727312|NCT04676646|DRUG|Placebo|Placebo comparator
219727313|NCT04676646|OTHER|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
219727314|NCT02217982|DRUG|Simethicone|
219727315|NCT02217982|DRUG|Loperamide|
219727316|NCT02217982|OTHER|Peanut Butter|
219155524|NCT01534741|OTHER|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
219155525|NCT01534741|DEVICE|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
219155526|NCT01797354|BEHAVIORAL|Cognitive-behavioral therapy and hypnosis group|
219155527|NCT01797354|BEHAVIORAL|Support group|
219155528|NCT05469841|OTHER|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
219155529|NCT01472900|DEVICE|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
219155530|NCT01472900|DRUG|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
219727317|NCT05412901|OTHER|discrimination task|Participants perform a discrimination task while their brain activity is recorded with EEG. Beta power will be estimated using spectral decomposition techniques, zooming in on subject specific bands in temporospatial windows of interest, and correlated with (1) WM content, (2) decision outcome, and (3) behavioral performance (i.e., accuracy and RT).
219727318|NCT02773823|BEHAVIORAL|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
219727319|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
219155531|NCT02966275|DEVICE|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
219155532|NCT02966275|DEVICE|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
219155533|NCT05079126|DRUG|Trans Sodium Crocetinate|Single IV Bolus
219155534|NCT05079126|DRUG|Placebo|Single IV Bolus
219155535|NCT02080754|OTHER|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
219155536|NCT02080754|OTHER|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
219155537|NCT03392038|PROCEDURE|Thin ADM|Use of soft tissue allograft for root coverage
219155538|NCT03392038|PROCEDURE|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
219155539|NCT03072316|OTHER|3D surface imaging|3D photography
219155540|NCT03072316|OTHER|semi-structured interview|qualitative analysis using semi structured interview
219155541|NCT03072316|OTHER|applanation tonometry|measurement of breast compressibility
219155542|NCT05848817|DEVICE|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
219360797|NCT02672085|PROCEDURE|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
219727320|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
219727321|NCT05615441|DEVICE|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
219727322|NCT05615441|DEVICE|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
219727323|NCT06523946|BEHAVIORAL|Diabetes Prevention Program (DPP) (shortened)|The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
219727324|NCT03537456|DEVICE|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
219727325|NCT01684800|DRUG|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
219727326|NCT01684800|DRUG|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
219727327|NCT01684800|DRUG|C: Placebo|1 orally disintegrating tablet every night during study period
219727328|NCT03611062|BEHAVIORAL|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
219727329|NCT03611062|BEHAVIORAL|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
219727330|NCT02909595|DEVICE|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
219727331|NCT02909595|DEVICE|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
219727332|NCT01127360|DRUG|Bevacizumab|Intravitreal injections
219155543|NCT04014179|DIAGNOSTIC_TEST|Xpert HCV Viral Load Fingerstick|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.
219155544|NCT04014179|DIAGNOSTIC_TEST|Aptima HCV Quant DX Assay|"The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.~The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment."
219155545|NCT02808351|DRUG|Berberine|
219727333|NCT01127360|DRUG|Ranibizumab|Intravitreal injections
219727334|NCT03123588|DRUG|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
219727335|NCT03123588|DRUG|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
219727336|NCT03123588|DRUG|Placebo|Anagrelide-placebo administered orally BID
219727337|NCT03123588|DRUG|Placebo|Ruxolitinib-placebo administered orally BID.
219727338|NCT04126668|DRUG|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
219727339|NCT05430295|PROCEDURE|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
219727340|NCT05430295|PROCEDURE|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
219155546|NCT00277355|DRUG|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
219155547|NCT00277355|DRUG|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
219155548|NCT02097394|DRUG|Combizym|Combizym( 1 tablet, po, tid)
219155549|NCT02097394|DRUG|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
219155550|NCT02097394|DRUG|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
219155551|NCT00538759|DEVICE|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
219727341|NCT00004032|BIOLOGICAL|ALVAC-hB7.1|Given IP
219727342|NCT00004032|BIOLOGICAL|recombinant interferon gamma|Given IP
219727343|NCT00004032|OTHER|laboratory biomarker analysis|Correlative studies
219727344|NCT02117817|DRUG|BKM120|
219727345|NCT02117817|DRUG|Nabpaclitaxel|Given IV
219727346|NCT02993302|DRUG|1α-D3|patients were given PTU and 1α-D3
219155552|NCT00538759|OTHER|Sham Control|
219155553|NCT00006241|BIOLOGICAL|filgrastim|
219727347|NCT02993302|DRUG|Placebos|patients were given PTU and placebos
219727348|NCT03279965|DIAGNOSTIC_TEST|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
219155554|NCT00006241|DRUG|chemotherapy|
219727349|NCT00508300|PROCEDURE|Epidural analgesia|Thoracic epidural analgesia until day 2
219727350|NCT00508300|PROCEDURE|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
219727351|NCT05406999|DRUG|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
219727352|NCT05406999|DRUG|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
219727353|NCT05406999|DRUG|Prednisolone tablets|5 mg once daily, orally.
219727354|NCT05406999|DRUG|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
219727355|NCT05406999|DRUG|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
219727356|NCT05406999|DRUG|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
219727357|NCT05406999|DRUG|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
219360798|NCT02098954|DRUG|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
219727358|NCT05406999|DRUG|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
219155555|NCT00006241|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219155556|NCT00006241|PROCEDURE|peripheral blood stem cell transplantation|
219155557|NCT00006241|RADIATION|radiation therapy|
219155558|NCT05680649|OTHER|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
219155559|NCT05530161|OTHER|hypocalcemia|hypocalcemia or normocalcemia
219155560|NCT04733833|DRUG|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
219155561|NCT04733833|DRUG|Standard of care|Standard of care
219155562|NCT04040296|OTHER|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 2 hours of AKI detection. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
219155563|NCT02984332|OTHER|Lower limb immobilisation (leg brace)|
219155564|NCT04152421|OTHER|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
219155565|NCT00004243|DRUG|docetaxel|
219155566|NCT00004243|DRUG|oxaliplatin|
219155567|NCT01538914|PROCEDURE|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
219155568|NCT01538914|PROCEDURE|PCA|Postoperative pain is controlled with intravenous PCA.
219155569|NCT02979808|DEVICE|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
219155570|NCT06220097|DRUG|Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells|Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
219155571|NCT03200808|DRUG|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
219155572|NCT04204993|DEVICE|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
219155573|NCT00421889|DRUG|belinostat|
219155574|NCT00421889|DRUG|Paclitaxel|
219727359|NCT05406999|PROCEDURE|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
219727360|NCT02324322|DEVICE|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
219155575|NCT00421889|DRUG|Carboplatin|
219155576|NCT04244500|PROCEDURE|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
219155577|NCT02065024|DIETARY_SUPPLEMENT|b-cryptoxanthin plus phytosterols|
219155578|NCT04215172|DRUG|Macrolides|administration of azithromycin three times weekly for six months
219155579|NCT03224390|OTHER|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
219155580|NCT03803748|DEVICE|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
219360799|NCT06202573|PROCEDURE|rhinoplasty|patients who have a step counter and we do not motivate them to walk
219360800|NCT02173119|OTHER|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
219360801|NCT02794220|DEVICE|CN electronic cigarette 10 mg|Inhalation
219155581|NCT03021369|DEVICE|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
219360802|NCT02794220|DEVICE|CN electronic cigarette 15 mg|Inhalation
219727361|NCT02324322|OTHER|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
219727362|NCT02324322|OTHER|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
219727363|NCT01755637|DRUG|Albendazole|Albendazole tablets 400 mg
219727364|NCT01814332|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
219727365|NCT01814332|DRUG|Placebo|Placebo compound treatment for comparison with IP
219727366|NCT00668564|PROCEDURE|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
219727367|NCT00668564|DRUG|Cyclophosphamide|"Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours"
219727368|NCT00668564|DRUG|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
219727369|NCT00668564|DRUG|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
219727370|NCT05551897|DRUG|Camizestrant|Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
219727371|NCT05551897|DRUG|Itraconazole|Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
219727372|NCT04048083|BEHAVIORAL|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
219155582|NCT01604161|DRUG|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
219155583|NCT02153541|DRUG|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
219155584|NCT02153541|OTHER|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
219155585|NCT02073578|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
219155586|NCT00098319|DRUG|Folic acid (0.4mg vs. 4.0mg)|
219155587|NCT04549831|GENETIC|Massive parallel sequencing of host genome|Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
219155588|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
219155589|NCT00350792|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
219155590|NCT00350792|DRUG|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
219360803|NCT02794220|DEVICE|Nicorette Inhalator 15 mg|Inhalation
219360804|NCT02794220|OTHER|Cigarette|Inhalation
219360805|NCT03750851|OTHER|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
219155591|NCT03054415|PROCEDURE|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
219155592|NCT06001190|DIETARY_SUPPLEMENT|probiotic:Lactobacillus crispatus|We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
219155593|NCT00623987|DRUG|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
219155594|NCT03262831|OTHER|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
219155595|NCT03262831|PROCEDURE|Blood draw|"* Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
219727373|NCT04048083|BEHAVIORAL|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
219727374|NCT04048083|BEHAVIORAL|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
219727375|NCT04048083|OTHER|No trainings|Healthy controls without any kind of training
219727376|NCT00027443|DRUG|Muromonab-CD3|
219727377|NCT00027443|DRUG|Cyclosporine|
219727378|NCT01283425|DEVICE|InsuPatch|Heaters for single use and a permanent control unit.
219727379|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
219727380|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.
219727381|NCT03356561|BIOLOGICAL|Placebo|Participants will receive placebo via IM route.
219155596|NCT03262831|BEHAVIORAL|FACT-G questionnaire|"* 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much"
219155597|NCT03262831|PROCEDURE|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
219155598|NCT03262831|BEHAVIORAL|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
219155599|NCT03262831|BEHAVIORAL|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
219155600|NCT03820050|DEVICE|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
219155601|NCT02315456|PROCEDURE|capsulorhexis|
219155602|NCT05528549|OTHER|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
219155603|NCT03279861|DRUG|Entresto|First line therapy in Entresto arm
219727382|NCT05349266|BIOLOGICAL|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
219727383|NCT06195215|OTHER|Peer Counselling|7 weeks peer counselling process will be carried out.
219727384|NCT03701087|DRUG|Vitamin D|2800 IU daily till 26 weeks of pregnancy
219727385|NCT06466772|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
219727386|NCT06466772|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
219727387|NCT06466772|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
219727388|NCT02141724|OTHER|Positioning consultation|Assessment of pain,bedsores and postural troubles
219727389|NCT02468375|DRUG|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
219727390|NCT01096186|DRUG|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
219727391|NCT01096186|DRUG|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
219727392|NCT01096186|DRUG|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
219727393|NCT01096186|DRUG|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
219727394|NCT03316560|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
219727395|NCT06259838|OTHER|no intervention|no intervention
219727396|NCT00884000|DRUG|Genotropin|
219727397|NCT00884000|DRUG|Zomacton|
219727398|NCT04037956|PROCEDURE|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
219155604|NCT03279861|DRUG|Valsartan|"First line therapy in usual meds arm"
219155605|NCT03988023|BIOLOGICAL|Ampion|4 mL injection of Ampion
219155606|NCT03988023|DRUG|Saline|Saline solution, 4 mL, single intra-articular injection
219155607|NCT04857294|PROCEDURE|TMJ unilateral discectomy|All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
219155608|NCT00682708|DIETARY_SUPPLEMENT|PlumpyNut|
219155609|NCT00682708|DIETARY_SUPPLEMENT|PlumpyDoz|
219727399|NCT04037956|PROCEDURE|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
219727400|NCT01367756|DRUG|RO4995819|multiple oral doses, Days 10-16
219727401|NCT01367756|DRUG|citalopram|multiple oral doses, Days 1-16
219727402|NCT01367756|DRUG|placebo|multiple oral doses, Days 10-16
219727403|NCT01123564|DRUG|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
219727404|NCT01123564|RADIATION|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
219727405|NCT06107673|DRUG|Dalpiciclib|Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
219727406|NCT06107673|DRUG|Aromatase inhibitor|AI: Take according to the instructions provided.
219727407|NCT06107673|DRUG|Docetaxel injection|Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
219727408|NCT06107673|DRUG|Epirubicin Hydrochloride Injection|Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
219727409|NCT06107673|DRUG|Cyclophosphamide injection|Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
219155610|NCT00925977|DRUG|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
219155611|NCT00925977|DRUG|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
219155612|NCT00780351|DEVICE|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
219155613|NCT03631238|DIAGNOSTIC_TEST|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
219155614|NCT05621499|DRUG|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
219155615|NCT05621499|DRUG|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
219155616|NCT05621499|DRUG|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
219155617|NCT04577924|OTHER|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
219155618|NCT00004440|DRUG|ibuprofen|
219155619|NCT00585624|DIETARY_SUPPLEMENT|Impact Advanced Recovery|Nutritional supplement
219155620|NCT00585624|DIETARY_SUPPLEMENT|No supplement|No supplement
219155621|NCT00530569|PROCEDURE|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
219155622|NCT00527540|DRUG|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
219155623|NCT04226664|PROCEDURE|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
219155624|NCT00241241|DRUG|pegylated interferon-alfa 2a|
219155625|NCT01064336|DRUG|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
219155626|NCT03611972|DIETARY_SUPPLEMENT|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
219155627|NCT00533910|DRUG|Rifaximin|550mg BID rifaximin for 8 weeks
219155628|NCT00533910|DRUG|placebo|same as the experimental arm
219155629|NCT06127147|DEVICE|IMT|The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
219727410|NCT02203786|DRUG|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
219155630|NCT06127147|DEVICE|Sham-IMT|The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
219155631|NCT01721343|BEHAVIORAL|telephone-based intervention|Undergo telephonic monitoring
219155632|NCT01721343|OTHER|case management|Participate in an individualized conditioning program with an RCM
219155633|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
219155634|NCT01721343|PROCEDURE|physical therapy|Participate in an individualized conditioning program with an RCM
219155635|NCT01721343|OTHER|questionnaire administration|Ancillary studies
219155636|NCT01721343|PROCEDURE|quality-of-life assessment|Ancillary studies
219155637|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care
219155638|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care
219727411|NCT02203786|DRUG|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
219727412|NCT02203786|DRUG|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
219727413|NCT02203786|DRUG|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
219727414|NCT02203786|BEHAVIORAL|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
219727415|NCT00947388|DRUG|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
219727416|NCT00947388|BIOLOGICAL|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
219727417|NCT04673695|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
219727418|NCT04673695|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
219727419|NCT02011763|BIOLOGICAL|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
219155639|NCT01721343|OTHER|educational intervention|Participate in an individualized conditioning program with an RCM
219155640|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM
219155641|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM
219155642|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
219155643|NCT06964035|PROCEDURE|Aortic valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~8 Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
219727420|NCT02765971|OTHER|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
219727421|NCT02765971|DRUG|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
219727422|NCT02765971|DRUG|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
219155644|NCT05896774|DRUG|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
219155645|NCT06536530|BEHAVIORAL|Exergame-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
219155646|NCT06536530|BEHAVIORAL|Cognitive-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
219155647|NCT06536530|BEHAVIORAL|Wait-List|Participants will not train with any program and they will not assist to any specific session or intervention
219155648|NCT06013423|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219155649|NCT06013423|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
219155650|NCT06013423|DRUG|Cyclophosphamide|Receive IV
219155651|NCT06013423|DRUG|Cyclosporine|Receive IV or PO
219155652|NCT06013423|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
219727423|NCT05611424|GENETIC|FT-003|Administered via intraocular injection.
219727424|NCT01545466|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
219727425|NCT00047632|DRUG|Interferon gamma-1b|100 mcg, SQ, 3x per week
219727426|NCT00122187|DEVICE|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
219727427|NCT02061592|DEVICE|etafilcon A|
219727428|NCT02061592|DEVICE|etafilcon A|
219727429|NCT05877664|DRUG|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
219727430|NCT03338023|DRUG|LY2963016|Administered SC
219727431|NCT03338023|DRUG|Lantus®|Administered SC
219727432|NCT03338023|DRUG|Insulin Lispro|Administered SC
219727433|NCT05733533|DRUG|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
219727434|NCT05733533|DRUG|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
219727435|NCT01491932|DRUG|AFQ056|AFQ056 will be supplied as oral capsules.
219727436|NCT05371223|DRUG|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
219155653|NCT06013423|PROCEDURE|Echocardiography|Undergo ECHO
219155654|NCT06013423|DRUG|Fludarabine Phosphate|Receive IV
219155655|NCT06013423|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219155656|NCT06013423|DRUG|Mycophenolate Mofetil|Receive IV
219727437|NCT05335265|OTHER|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
219155657|NCT06013423|OTHER|Survey Administration|Ancillary studies
219155658|NCT06013423|DRUG|Thiotepa|Receive IV
219155659|NCT06013423|RADIATION|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
219155660|NCT06013423|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
219155661|NCT01306864|DEVICE|Hemospray Kit|Hemostasis of Arterial GI Bleeding
219155662|NCT03443661|DRUG|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
219155663|NCT00126308|DEVICE|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
219155664|NCT00126308|DEVICE|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
219155665|NCT00396084|DRUG|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
219155666|NCT00396084|DRUG|Isoniazid|Isoniazid 300 mg/day x 7 days.
219155667|NCT00396084|DRUG|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
219155668|NCT00396084|DRUG|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
219155669|NCT00396084|DRUG|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
219155670|NCT03477695|DEVICE|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
219155671|NCT01502969|BIOLOGICAL|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
219155672|NCT01502969|BIOLOGICAL|cell culture medium in absence of virus|Placebo
219155673|NCT03767907|BEHAVIORAL|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
219155674|NCT03767907|BEHAVIORAL|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
219155675|NCT02502708|DRUG|Indoximod|Indoximod will be administered orally twice daily.
219155676|NCT02502708|DRUG|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
219155677|NCT02502708|RADIATION|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
219155678|NCT02502708|DRUG|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
219155679|NCT02502708|DRUG|Etoposide|Etoposide will be administered orally daily.
219155680|NCT03522337|OTHER|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
219155681|NCT03522337|OTHER|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
219155682|NCT02708108|BEHAVIORAL|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
219155683|NCT02708108|BEHAVIORAL|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
219155684|NCT05188430|DEVICE|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
219727438|NCT00387309|DRUG|Methylnaltrexone (MOA-728)|
219727439|NCT00005684|DRUG|warfarin|
219727440|NCT00005684|DRUG|heparin|
219727441|NCT00382473|BEHAVIORAL|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
219727442|NCT03398382|DIETARY_SUPPLEMENT|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
219155685|NCT05188430|OTHER|Placebo|Oral administration: 3 tablets twice a day before the main meals
219727443|NCT03398382|DIETARY_SUPPLEMENT|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
219155686|NCT03185338|BEHAVIORAL|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
219155687|NCT03185338|BEHAVIORAL|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
219155688|NCT03185338|BEHAVIORAL|Active school recess|Teachers will design games and activities and will encourage children for being active
219155689|NCT03185338|BEHAVIORAL|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
219155690|NCT03185338|BEHAVIORAL|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
219155691|NCT03882502|OTHER|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
219155692|NCT04528472|OTHER|Acupuncture Treatment|stimulate acupoints to accelerate recovery
219155693|NCT04528472|OTHER|Regular Treatment|Oral Medicine and Rehabilitation Treatment
219155694|NCT02568683|DRUG|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
219155695|NCT02568683|DRUG|Vincristine|VCR administered intravenously
219155696|NCT04434677|RADIATION|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
219155697|NCT04434677|RADIATION|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
219155698|NCT00386516|DRUG|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
219155699|NCT00386516|DRUG|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
219155700|NCT03381781|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
219155701|NCT03381781|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
219155702|NCT03381781|DRUG|Cytarabine|15mg/m\^2,hypodermic injection,q12h,d1-7
219155703|NCT02190643|BEHAVIORAL|Cessation counseling with adherence focus|
219155704|NCT02190643|BEHAVIORAL|Cessation counseling without adherence focus|
219155705|NCT01548170|DRUG|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
219155706|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
219155707|NCT01548170|DRUG|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
219155708|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
219155709|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
219155710|NCT04564196|PROCEDURE|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
219155711|NCT02241538|DEVICE|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
219155712|NCT02241538|DEVICE|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
219155713|NCT02241538|DEVICE|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
219155714|NCT02241538|DEVICE|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
219155715|NCT01736215|DRUG|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
219155716|NCT01024881|PROCEDURE|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
219155717|NCT01024881|PROCEDURE|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
219155718|NCT01581372|OTHER|Pharmacist care|Pharmacist prescribing, education, drug management
219155719|NCT04340479|DIAGNOSTIC_TEST|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
219155720|NCT02346526|PROCEDURE|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
219155721|NCT02346526|PROCEDURE|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
219155722|NCT02346526|PROCEDURE|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
219155723|NCT02346526|DRUG|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
219727444|NCT03398382|DIETARY_SUPPLEMENT|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
219727445|NCT03398382|DIETARY_SUPPLEMENT|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
219727446|NCT01642849|DIETARY_SUPPLEMENT|high protein diet|6 months on HP diet
219155724|NCT02346526|PROCEDURE|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
219155725|NCT05221281|BEHAVIORAL|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
219155726|NCT05221281|BEHAVIORAL|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
219155727|NCT01840826|OTHER|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
219155728|NCT06020313|DIETARY_SUPPLEMENT|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
219155729|NCT02652689|RADIATION|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
219155730|NCT02209415|BEHAVIORAL|standard follow-up|Outpatient clinic visits
219155731|NCT02209415|PROCEDURE|PET/CT and EUS|PET/CT and EUS
219155732|NCT00194896|DRUG|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
219155733|NCT00194896|DRUG|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
219155734|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
219155735|NCT02405013|DRUG|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
219155736|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
219155737|NCT02405013|DRUG|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
219155738|NCT01006577|PROCEDURE|side-to-end anastomosis|Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
219727447|NCT01642849|DIETARY_SUPPLEMENT|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
219727448|NCT03041337|DIAGNOSTIC_TEST|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
219233833|NCT06129981|BEHAVIORAL|Imaginary exposure therapy augmented by vocal feedback|"The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site."
219233834|NCT01606098|PROCEDURE|Surgery of the primary tumour|Surgical resection of the colon tumour
219233835|NCT01606098|DRUG|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
219233836|NCT03481985|OTHER|Fenestration status|The exposure variable will be status of the Fontan fenestration
219727449|NCT04055298|DEVICE|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
219155739|NCT01006577|PROCEDURE|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
219155740|NCT00663624|DRUG|aspart insulin|subcutaneous aspart insulin every 2 hours
219155741|NCT00663624|DRUG|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
219155742|NCT01248936|DRUG|RO5185426|
219155743|NCT06967051|DRUG|Tetrahydrocannabinol (10 mg)|10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule
219155744|NCT06967051|DRUG|Tetrahydrocannabinol (25 mg)|25 mg of THC provided as a softgel capsule.
219155745|NCT06967051|DIAGNOSTIC_TEST|Pupillary Light Reflex (PLR) Test|SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)
219155746|NCT06967051|DIAGNOSTIC_TEST|Pupillometer|NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.
219155747|NCT06243094|DRUG|Antibiotic|All antibiotic therapy characteristics are monitored.
219155748|NCT05933213|DRUG|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
219155749|NCT05933213|DRUG|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
219155750|NCT05933213|DRUG|Glucocorticoids|glucocorticoids
219155751|NCT00258297|DRUG|gefitinib|
219155752|NCT00258297|PROCEDURE|conventional surgery|
219155753|NCT00258297|PROCEDURE|enzyme inhibitor therapy|
219155754|NCT00258297|PROCEDURE|neoadjuvant therapy|
219155755|NCT00258297|PROCEDURE|protein tyrosine kinase inhibitor therapy|
219155756|NCT00258297|PROCEDURE|surgery|
219233837|NCT02542696|DRUG|APL-130277|"Used to treat up to 5 OFF episodes per day"
219233838|NCT06477549|DRUG|Bendamustine Hydrochloride|Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
219233839|NCT06477549|DRUG|Ruxolitinib|Days -7 through -2: ruxolitinib 5 mg tid per os
219233840|NCT02624830|DRUG|Sulfonylurea|See Arm description.
219233841|NCT01379885|BEHAVIORAL|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
219233842|NCT01379885|BEHAVIORAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
219233843|NCT00201825|DRUG|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
219233844|NCT00201825|DRUG|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
219233845|NCT00738348|DRUG|sivelstat|sivelstat sodiumhydrate
219233846|NCT00738348|DRUG|glucose|glucose
219233847|NCT05919732|DRUG|Bupivacaine, Dexmedetomidine, Caffeine, Tylenol|bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
219727450|NCT02907957|DEVICE|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
219155757|NCT04556981|BIOLOGICAL|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
219155758|NCT04556981|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
219727451|NCT02907957|PROCEDURE|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
219727452|NCT05448547|RADIATION|Radiotherapy or surgery|see arm/ group description
219727453|NCT05448547|OTHER|initial observation|see arm/ group description
219727454|NCT05448547|DRUG|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
219727455|NCT03507283|PROCEDURE|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
219727456|NCT00685698|DRUG|TG-873870 (Nemonoxacin)|750 mg
219727457|NCT02213107|DRUG|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"
219727458|NCT05061706|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
219727459|NCT05061706|DRUG|Placebo|Matching capsules administered orally, once daily.
219727460|NCT00724893|BIOLOGICAL|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
219727461|NCT00724893|DRUG|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
219727462|NCT06787144|DRUG|ELVN-001|Orally once or twice daily
219155759|NCT06565065|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant
219155760|NCT06565065|OTHER|Sham Light Touch|A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.
219155761|NCT06565065|OTHER|Exercise Protocol|A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.
219155762|NCT05770427|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
219155763|NCT05742815|OTHER|No intervention|This is an observational collection of data from purchased donor milk samples
219155764|NCT01750866|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
219155765|NCT01750866|DRUG|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
219155766|NCT01750866|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
219155767|NCT05305846|DEVICE|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
219155768|NCT00180258|DEVICE|Cardiac Resynchronization Therapy with & without defibrillator|
219233848|NCT05919732|DRUG|Propofol, rocuronium, caffeine, Tylenol, bupivacaine|"propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)"
219233849|NCT02066155|BEHAVIORAL|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
219233850|NCT02066155|BEHAVIORAL|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
219233851|NCT06432023|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diagnostic and research scanning using magnetic resonance imaging.
219727463|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
219727464|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
219727465|NCT05455398|PROCEDURE|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
219727466|NCT05455398|PROCEDURE|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
219727467|NCT01640106|DIETARY_SUPPLEMENT|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
219727468|NCT01640106|DIETARY_SUPPLEMENT|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
219727469|NCT04251494|DIAGNOSTIC_TEST|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
219155769|NCT04835181|BEHAVIORAL|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
219727470|NCT04251494|DIAGNOSTIC_TEST|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
219727471|NCT04251494|DIAGNOSTIC_TEST|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
219727472|NCT04251494|OTHER|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
219155770|NCT04835181|BEHAVIORAL|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
219155771|NCT06057116|OTHER|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
219155772|NCT01595334|DRUG|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm
219155773|NCT01595334|DRUG|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
219155774|NCT01297101|DRUG|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
219233852|NCT02137785|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
219155775|NCT00355095|DRUG|Erythropoietin|intravenous daily 3.3 \*10\^4 Units, duration 3 days
219155776|NCT01061034|DRUG|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
219155777|NCT00068601|DRUG|cyclophosphamide|Part of planned chemotherapy regimen
219155778|NCT00068601|DRUG|goserelin acetate|Given subcutaneously
219155779|NCT02000349|OTHER|PGD|PGD using Next generation sequencing
219155780|NCT01691846|DRUG|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
219155781|NCT01691846|DRUG|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
219155782|NCT02093312|DIETARY_SUPPLEMENT|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
219155783|NCT00049790|DRUG|recombinant human Angiostatin protein|
219155784|NCT00049790|DRUG|paclitaxel|
219155785|NCT00049790|DRUG|carboplatin|
219155786|NCT04643899|DEVICE|Muscle Electrostimulation|"* Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
219155787|NCT06150287|OTHER|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
219233853|NCT02137785|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
219233854|NCT02137785|DEVICE|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
219233855|NCT01420198|BEHAVIORAL|Lifestyle intervention|Increased physical activity and improved food habits
219360806|NCT03750851|OTHER|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
219155788|NCT05521061|DIETARY_SUPPLEMENT|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
219155789|NCT02434744|DRUG|KD026|Dosed in combination
219155790|NCT02434744|DRUG|Placebo|Dosed in combination
219155791|NCT02434744|DRUG|Metformin|Drug prescribed by each subject's prescribing physician
219155792|NCT03742050|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
219155793|NCT04948801|DRUG|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
219155794|NCT04290013|DRUG|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
219155795|NCT04290013|DRUG|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
219155796|NCT00971724|DRUG|Placebo|Oral administration, once daily, for 15 days
219155797|NCT00971724|DRUG|Prednisolone|Oral administration
219155798|NCT03635151|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
219155799|NCT03635151|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
219155800|NCT05330234|DEVICE|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
219155801|NCT05848609|DIAGNOSTIC_TEST|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
219155802|NCT01823133|DRUG|gemigliptin only|gemigliptin 50mg qd on day 1\~7
219155803|NCT01823133|DRUG|rosuvastatin only|rosuvastatin 20mg qd on day 1\~7
219727473|NCT04251494|OTHER|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
219155804|NCT01823133|DRUG|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
219155805|NCT00519389|BIOLOGICAL|H5N1 VLP Vaccine|Two doses - Day 0 \& Day 28
219155806|NCT00519389|BIOLOGICAL|Placebo|Two doses - Day 0 \& Day 28
219155807|NCT03314675|DEVICE|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
219155808|NCT02541461|PROCEDURE|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
219155809|NCT03429972|DEVICE|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
219155810|NCT03429972|DRUG|Paclitaxel|80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
219727474|NCT04342585|DRUG|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
219727475|NCT04342585|DEVICE|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
219727476|NCT02331121|BEHAVIORAL|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
219727477|NCT02331121|BEHAVIORAL|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
219727478|NCT05159011|BEHAVIORAL|AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)|information about genetic testing through technology
219727479|NCT04183478|DRUG|K-001|K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
219727480|NCT04183478|OTHER|placebo|Placebo which looks the same as K-001 in apparence
219727481|NCT01937338|DRUG|AZD7624|nebuliser solution; 20 mg/mL for inhalation
219727482|NCT01937338|DRUG|Placebo|nebuliser solution for inhalation
219727483|NCT02749929|OTHER|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
219727484|NCT02749929|OTHER|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
219727485|NCT03051009|DRUG|Desmopressin ODT 25 μg|
219727486|NCT03051009|DRUG|Desmopressin ODT 50 μg|
219727487|NCT04077398|DRUG|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
219727488|NCT01294072|DIETARY_SUPPLEMENT|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
219727489|NCT01294072|DIETARY_SUPPLEMENT|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
219727490|NCT01294072|OTHER|No intervention|no treatment
219727491|NCT01708837|DRUG|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
219727492|NCT01222351|DRUG|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
219727493|NCT04251936|BEHAVIORAL|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
219727494|NCT04251936|BEHAVIORAL|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
219727495|NCT05343169|BEHAVIORAL|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
219727496|NCT05343169|BEHAVIORAL|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly \~2 hr. group sessions + ongoing access to video archive of recorded trainings.
219727497|NCT05343169|BEHAVIORAL|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions \> 1x/wk.
219727498|NCT05343169|BEHAVIORAL|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions \> 1x/wk.
219727499|NCT03770975|PROCEDURE|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
219155811|NCT01877343|DEVICE|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
219155812|NCT01137708|DRUG|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
219155813|NCT01137708|DRUG|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
219155814|NCT05592028|DEVICE|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
219155815|NCT02820116|DRUG|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
219155816|NCT00440011|DRUG|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
219155817|NCT00440011|DRUG|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
219155818|NCT01837472|DRUG|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
219155819|NCT01837472|DRUG|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
219727500|NCT03770975|PROCEDURE|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
219727501|NCT01804335|DRUG|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
219727502|NCT03889262|OTHER|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
219727503|NCT03889262|OTHER|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
219727504|NCT03080714|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
219155820|NCT00822367|DIETARY_SUPPLEMENT|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
219727505|NCT03080714|DEVICE|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
219727506|NCT00088101|DRUG|STA-5312|
219727507|NCT05219786|BEHAVIORAL|Appendicitis Decision Support Tool|Viewing of a decision support tool.
219727508|NCT05219786|BEHAVIORAL|Control Infographic|Viewing of a standardized infographic
219727509|NCT03545581|OTHER|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
219727510|NCT03545581|OTHER|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
219727511|NCT02326688|OTHER|Kinematic analysis of trunk compensation|
219155821|NCT05487118|DEVICE|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
219155822|NCT05487118|DEVICE|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
219727512|NCT02105857|OTHER|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
219155823|NCT03609008|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
219155824|NCT03609008|DRUG|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
219155825|NCT03741517|RADIATION|18F-FDG-PET|Fludeoxyglucose F18
219155826|NCT03741517|RADIATION|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
219155827|NCT03741517|RADIATION|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
219155828|NCT03741517|OTHER|Core needle biopsy|Core needle biopsy of metastatic lesions
219155829|NCT03741517|OTHER|Phlebotomy|Phlebotomy from peripheral vein
219155830|NCT02035670|OTHER|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
219155831|NCT01193894|OTHER|Profermin|Medical Food (food for special medical purposes)
219155832|NCT01193894|OTHER|Fresubin|Medical food (food for special medical purposes)
219155833|NCT03208491|OTHER|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
219155834|NCT03208491|OTHER|usual care|usual care of patient
219155835|NCT03373708|DRUG|Epirubicin|100mg/m2
219155836|NCT03373708|DRUG|Cyclophosphamide|600mg/m2
219155837|NCT03373708|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
219155838|NCT03373708|DRUG|Goserelin acetate|3.6mg every month
219155839|NCT03373708|DRUG|Tamoxifen|10mg twice daily oral
219155840|NCT03373708|DRUG|Letrozole|2.5mg every daily oral
219155841|NCT03760354|DRUG|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
219155842|NCT03760354|OTHER|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
219727513|NCT04134312|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
219155843|NCT00004387|PROCEDURE|fetal nigral transplantation|
219155844|NCT05207241|OTHER|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
219155845|NCT06971432|PROCEDURE|Group SAPB|Using ultrasound guidance, the needle is advanced in-plane at approximately 45° toward the fifth rib. For the superficial SAPB, the local anesthetic is injected anteriorly to the serratus anterior in the plane created with the latissimus dorsi muscle. The thoracodorsal artery runs in this plane, and while care should be taken not to puncture this vessel, the spread of the injectate around the vessel confirms the appropriate injection plane. For the deep SAPB, the local anesthetic is injected anteriorly to the rib and deep to the serratus anterior. Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment. All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered.
219727514|NCT04578054|OTHER|Flying transport|Patient care who requires flying transport
219727515|NCT06633510|DEVICE|massimo group|masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
219155846|NCT06971432|PROCEDURE|Group SAPB + LIA|"SAPB is applied similarly to the other group.Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment.At the end of the surgical procedure, while the incision line is still open, a catheter will be placed in the subcutaneous tissue, at the most lateral part of the incision. A 0.20% bupivacaine solution will be prepared and at the end of the operation, a 10 ml bolus will be administered, followed by a 2 ml/hour infusion for 48 hours.~All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered."
219155847|NCT06342999|PROCEDURE|Fetal Aortic Valvuloplasty Procedure|Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.
219155848|NCT06342999|DEVICE|Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter|Balloon Catheter
219155849|NCT06342999|DEVICE|Trek RX and Mini Trek RX Coronary Dilatation Catheter|Coronary Dilation Catheter
219155850|NCT02837497|OTHER|ICU-RESUS CPR Improvement Bundle|"1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings"
219155851|NCT02072213|DRUG|GL2702 GLARS-NF1|0.4mg once a day
219155852|NCT02072213|DRUG|Omix Ocas|0.4mg once a day
219155853|NCT00014599|DRUG|paclitaxel|
219155854|NCT05272046|PROCEDURE|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
219155855|NCT05272046|DEVICE|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
219155856|NCT04507945|DRUG|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
219155857|NCT00687622|DRUG|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
219155858|NCT02615210|DEVICE|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
219155859|NCT04234776|DRUG|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
219155860|NCT04234776|DIAGNOSTIC_TEST|Cognition|Composite tools
219155861|NCT04234776|OTHER|Suicide risk|MADRS (10) and HAM-D (3)
219155862|NCT04234776|OTHER|Depression thoughts|EPD
219155863|NCT04234776|OTHER|Quality of life and disability|Quality of life and disability
219155864|NCT04234776|OTHER|Clinical and epidemiological factors|Variables and categories
219155865|NCT04234776|DEVICE|Safety of ketamine IM|Vital signs
219155866|NCT04234776|OTHER|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
219155867|NCT06012331|PROCEDURE|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
219155868|NCT06012331|PROCEDURE|Blood Clot (BC)|"1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
219155869|NCT03617978|PROCEDURE|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
219727516|NCT06633510|OTHER|standart group|intraoperative fluid deficit is calculated according to the 4-2-1 rule by summing up the hourly basal fasting level, intraoperative losses depending on the degree of tissue trauma (1-2mlt/kg/h in small-sized surgeries, 2-4mlt/kg/h in medium-sized surgeries, 4-8mlt/kg/h in large-sized surgeries), blood losses, urine and losses from the nasogastric tube. Fluid is given in this way.
219727517|NCT04076137|OTHER|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
219727518|NCT03778333|BIOLOGICAL|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
219727519|NCT05024942|PROCEDURE|Transfemoral TAVR (Transcatheter aortic valve replacement)|Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
219727520|NCT04534946|OTHER|This is not an intervention study|This is not an intervention study
219727521|NCT05509621|OTHER|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
219727522|NCT05509621|OTHER|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
219727523|NCT05509621|OTHER|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
219727524|NCT05509621|OTHER|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
219155870|NCT01717677|PROCEDURE|radical prostatectomy|
219155871|NCT01717677|RADIATION|percutaneous radiation therapy|
219155872|NCT01717677|RADIATION|permanent seed implantation|
219155873|NCT01717677|PROCEDURE|Active Surveillance|
219155874|NCT04152694|OTHER|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
219155875|NCT03837431|DIAGNOSTIC_TEST|Skin slit|Skin slit microscopy, RDT and PCR
219155876|NCT03837431|DIAGNOSTIC_TEST|Dental broach|Dental broach RDT and PCR
219155877|NCT03837431|DIAGNOSTIC_TEST|Tape disc|Tape disc PCR
219155878|NCT03426839|DIAGNOSTIC_TEST|Coagulation tests|
219155879|NCT05075213|BEHAVIORAL|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
219155880|NCT05075213|BEHAVIORAL|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
219155881|NCT05075213|BEHAVIORAL|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
219155882|NCT01268813|OTHER|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
219155883|NCT00711217|OTHER|Medical Food|twice daily
219155884|NCT00711217|OTHER|Drink mix calorically similar to experimental product|twice daily
219155885|NCT05345951|BEHAVIORAL|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
219155886|NCT05345951|BEHAVIORAL|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
219155887|NCT05486897|OTHER|None, pure observational study|None, pure observational study
219727525|NCT05509621|OTHER|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
219727526|NCT02867826|DEVICE|Cap|Cap-assisted endoscopy
219727527|NCT01993368|OTHER|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
219727528|NCT03934307|DRUG|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
219727529|NCT03934307|DRUG|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
219727530|NCT03934307|DRUG|Irbesartan|Irbesartan will be administered orally.
219155888|NCT03435770|DEVICE|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
219155889|NCT04152317|DRUG|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
219155890|NCT04152317|DRUG|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
219155891|NCT00995306|DRUG|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
219155892|NCT02336386|DRUG|CDD|Chemotherapy
219155893|NCT02336386|DRUG|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
219155894|NCT02711059|PROCEDURE|parathyroidectomy|surgical treatment of hyperparathyroidism
219155895|NCT02793154|DRUG|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
219233856|NCT03659942|OTHER|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
219233857|NCT01223014|DRUG|AZD2423|AZD2423
219155896|NCT02793154|DRUG|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
219155897|NCT00969137|DRUG|saline|intravenous saline
219233858|NCT03132909|OTHER|Feelings Determination|Determine the feelings of doctors caring for their colleagues
219233859|NCT00558441|DEVICE|IVMRI|Intra Vascular Magnetic Resonance Imaging
219233860|NCT05392972|BEHAVIORAL|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
219233861|NCT01864980|PROCEDURE|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
219233862|NCT01864980|PROCEDURE|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
219233863|NCT02377544|DIETARY_SUPPLEMENT|Probiotic|
219727531|NCT03934307|DRUG|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
219727532|NCT02487485|DRUG|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
219727533|NCT02487485|DRUG|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
219155898|NCT00969137|DRUG|Nicotine|Intravenous nicotine
219155899|NCT04985136|DRUG|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
219155900|NCT04985136|DRUG|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
219155901|NCT04985136|DRUG|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
219155902|NCT04985136|DRUG|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
219727534|NCT02487485|DRUG|Placebo|Placebo oral dose
219155903|NCT01361945|DRUG|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
219155904|NCT01323231|BEHAVIORAL|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
219155905|NCT03641703|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
219155906|NCT04292132|PROCEDURE|Implant placement|interforaminal placement of 2 implants
219155907|NCT04292132|PROCEDURE|immediate loading|immediate loading with a locator retained mandibular overdenture
219155908|NCT04292132|PROCEDURE|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
219155909|NCT00616668|DEVICE|Air- Limb|
219155910|NCT04585412|DRUG|Palonosetron|Pharmacokinetic study under fasting conditions
219155911|NCT01000597|DRUG|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
219155912|NCT04380467|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
219155913|NCT06215092|OTHER|Psychological assessment|Psychological assessment of cognitive and social-emotional functioning.
219155914|NCT04783246|BEHAVIORAL|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
219155915|NCT04783246|OTHER|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
219155916|NCT04820361|DRUG|Cannabis sativa L., folium cum flore|Muscle Relaxation
219155917|NCT04820361|DRUG|Placebo|Muscle Relaxation
219155918|NCT02283242|DRUG|Galantamine|Oral use for 12 weeks
219155919|NCT02283242|DRUG|Placebo (for galantamine)|Oral use for 12 weeks
219155920|NCT06233500|PROCEDURE|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used"
219155921|NCT02703701|BEHAVIORAL|Physician at triage|A physician embedded at triage
219155922|NCT02703701|OTHER|Usual Care|No physician at triage
219155923|NCT03399916|BEHAVIORAL|Prompt sent|
219155924|NCT04113798|OTHER|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
219155925|NCT04113798|OTHER|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
219155926|NCT04113798|OTHER|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
219233864|NCT02377544|OTHER|Placebo|
219727535|NCT03630887|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
219727536|NCT00476541|DRUG|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
219727537|NCT01784536|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
219727538|NCT04958590|RADIATION|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
219727539|NCT06304727|OTHER|clinical data review|Medical records review to gather and analyze demographic, clinical, care and virological data
219233865|NCT02715388|DEVICE|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
219727540|NCT02072993|DRUG|AZD1979|Single dose, oral solution administration
219727541|NCT02072993|DRUG|Placebo to match|Single dose, oral solution administration
219727542|NCT03472677|OTHER|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
219727543|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
219727544|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
219727545|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
219727546|NCT03472677|DRUG|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
219727547|NCT02945046|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
219727548|NCT02945046|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
219727549|NCT00086463|DRUG|Iloprost or placebo|
219155927|NCT04113798|BEHAVIORAL|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
219727550|NCT04433026|DIAGNOSTIC_TEST|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
219727551|NCT01619449|PROCEDURE|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
219727552|NCT03113136|BEHAVIORAL|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
219727553|NCT03113136|BEHAVIORAL|High wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
219233866|NCT03390166|BIOLOGICAL|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
219233867|NCT03390166|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
219233868|NCT03855384|DRUG|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
219155928|NCT04113798|BEHAVIORAL|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
219155929|NCT04113798|OTHER|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
219155930|NCT06335446|OTHER|Novel mapping algorithm|Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
219155931|NCT00212134|DEVICE|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
219155932|NCT00212134|DEVICE|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
219155933|NCT04912791|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
219155934|NCT02728765|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
219155935|NCT04597203|DEVICE|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
219155936|NCT04597203|DRUG|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
219155937|NCT05485389|OTHER|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
219155938|NCT05684354|OTHER|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
219155939|NCT00645034|DRUG|placebo|placebo by mouth as a single dose
219155940|NCT00645034|DRUG|sildenafil|sildenafil 100 mg by mouth as a single dose
219155941|NCT01030107|BEHAVIORAL|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
219155942|NCT01030107|BEHAVIORAL|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
219155943|NCT03664960|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
219155944|NCT06394375|DRUG|Dexmedetomidine|OFA
219155945|NCT06394375|DRUG|Fentanyl|Given as analgesia in opioid balanced anesthesia (control) group
219233869|NCT03855384|DRUG|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
219727554|NCT03113136|BEHAVIORAL|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
219727555|NCT05009771|DRUG|Intravenous patient-control analgesia|At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
219727556|NCT05009771|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
219727557|NCT02675452|DRUG|AMG 176|Study Drug
219727558|NCT02675452|DRUG|Azacitidine|Non-investigational product
219727559|NCT02675452|DRUG|Itraconazole|Non-investigational product
219233870|NCT00926107|DRUG|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
219233871|NCT03125148|DEVICE|Enteral stenting|Enteral stent for malignant duodenal obstruction
219233872|NCT06404736|DRUG|Bispecific antibody (bsAb) targeting PD-1 and CLTA-4|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
219233873|NCT06404736|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
219233874|NCT06404736|DRUG|Carboplatin|Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
219233875|NCT01500070|DEVICE|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
219233876|NCT04251325|OTHER|Basic Life Support Courses|4 hours basic life support courses for laypersons
219233877|NCT06498323|DRUG|tenecteplase|Intravenous thrombolytic agents administration
219233878|NCT00648466|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
219233879|NCT00648466|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fasting
219233880|NCT00500604|DRUG|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
219233881|NCT00500604|DRUG|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
219233882|NCT00500604|DRUG|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
219233883|NCT02418065|OTHER|training on ergonomic bicycle|
219233884|NCT02418065|DRUG|Testosterone|
219233885|NCT02418065|DRUG|Oral nutritional supplementation|
219233886|NCT02418065|DRUG|n3 polyunsaturated fatty acid|
219155946|NCT04761536|OTHER|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
219155947|NCT05729997|OTHER|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
219155948|NCT06294834|OTHER|Part 1 of intervention A - Wheelchair skills training modules|"Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair"
219233887|NCT03575494|OTHER|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
219233888|NCT01381445|DRUG|GW870086 0.2%|White to slightly coloured opaque cream
219233889|NCT01381445|DRUG|GW870086 2%|White to slightly coloured opaque cream
219233890|NCT01381445|DRUG|Clobetasol Propionate|White cream
219233891|NCT01381445|DRUG|Placebo|White to slightly coloured opaque cream
219727560|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
219727561|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
219233892|NCT05649891|OTHER|Emergency Manual|Collection of crisis checklists and fact sheets
219233893|NCT05100511|DEVICE|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
219233894|NCT05100511|DEVICE|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
219233895|NCT02304445|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
219233896|NCT02304445|RADIATION|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
219233897|NCT00309673|DRUG|lidocaine / Prilocaine|
219233898|NCT00787475|OTHER|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
219233899|NCT01553617|DRUG|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
219233900|NCT01553617|DRUG|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
219727562|NCT06964503|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
219727563|NCT06964594|PROCEDURE|vNOTES adnexal surgery|New minimalinvasive technique
219155949|NCT06294834|OTHER|Part 2 of intervention A - Asynchronous feedback from a remote trainer|Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
219233901|NCT03001635|DRUG|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
219233902|NCT03001635|DRUG|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
219233903|NCT04722471|DRUG|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
219727564|NCT06963372|DEVICE|True filter (4w) → Washout (2w) → Sham filter (4w)|Used a true filter for 4 weeks, followed by a 2-week washout, then used a sham filter for 4 weeks.
219727565|NCT06963372|DEVICE|Sham filter (4w) → Washout (2w) → True filter (4w)|Used a sham filter for 4 weeks, followed by a 2-week washout, then used a true filter for 4 weeks.
219727566|NCT03853837|DIAGNOSTIC_TEST|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
219727567|NCT02325453|PROCEDURE|Robotic Surgery|Surgical procedure performed with a robotic system.
219727568|NCT02325453|PROCEDURE|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
219727569|NCT02325453|PROCEDURE|Open Surgery|Traditional approach for gastric cancer.
219727570|NCT02919345|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
219727571|NCT02919345|DRUG|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
219727572|NCT02164188|BEHAVIORAL|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
219727573|NCT00999570|OTHER|Specialty training for knee surgeons|
219727574|NCT06411808|BEHAVIORAL|Sensory-Adapted Dental Environment|The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
219727575|NCT01320098|BEHAVIORAL|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
219727576|NCT01320098|BEHAVIORAL|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
219727577|NCT01320098|BEHAVIORAL|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
219727578|NCT04498117|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
219727579|NCT04498117|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
219727580|NCT04498117|DRUG|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
219727581|NCT04498117|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
219727582|NCT04498117|DRUG|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
219727583|NCT06388226|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
219727584|NCT06388226|DEVICE|Leg sham therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
219727585|NCT00840853|GENETIC|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
219727586|NCT00840853|DRUG|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
219727587|NCT00448149|DRUG|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
219727588|NCT00448149|DRUG|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
219727589|NCT02836106|OTHER|Butter|Butter with jam and three slices of bread
219727590|NCT02836106|OTHER|Cheese|Cheese with jam and three slices of bread
219727591|NCT02836106|OTHER|Whipped cream|Whipped cream with jam and three slices of bread
219727592|NCT02836106|OTHER|Sour cream|Sour cream with jam and three slices of bread
219727593|NCT06235957|OTHER|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
219727594|NCT06235957|OTHER|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
219727595|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
219727596|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
219727597|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
219727598|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
219727599|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
219727600|NCT03923842|DRUG|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
219727601|NCT03923842|DRUG|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
219155950|NCT06294834|OTHER|Intervention B: Education on wheelchair provision|Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
219155951|NCT03401138|OTHER|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
219233904|NCT02206607|DRUG|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
219727602|NCT02939781|DEVICE|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
219727603|NCT04267328|PROCEDURE|Elective Orthopedic Surgery|Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
219727604|NCT01386177|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
219727605|NCT01386177|DRUG|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
219727606|NCT01386177|DRUG|placebo|capsules identical to MDMA or doxazosin
219727607|NCT06183528|PROCEDURE|Pericapsular Nerve Group (PENG) Block|With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
219727608|NCT06128239|BEHAVIORAL|Caring Contacts|Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
219727609|NCT04230304|BIOLOGICAL|Daratumumab|Given IV
219727610|NCT04230304|DRUG|Ibrutinib|Given PO
219727611|NCT02650349|OTHER|fMRI|
219727612|NCT05230407|OTHER|Visual analog scale (VAS) assesment of pain|Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
219727613|NCT06585072|DIAGNOSTIC_TEST|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.
219727614|NCT06028230|DRUG|SAR444656 (KT-474)|Oral Tablet
219727615|NCT06028230|DRUG|Placebo|Oral Tablet
219155952|NCT01616888|DEVICE|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
219155953|NCT05054920|OTHER|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
219233905|NCT02206607|DRUG|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
219233906|NCT02206607|DRUG|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
219233907|NCT02206607|DRUG|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
219727616|NCT06462573|DRUG|locally infilterating anaethesia like lidocaine|which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
219727617|NCT06462573|DRUG|general anaethesia|"which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
219727618|NCT06731244|OTHER|Usual Care Group|Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.
219727619|NCT06731244|OTHER|shared decision-making process|"The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).~The shared decision-making process will be conducted as follows:~* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;~* Step 2: Communicating risks, benefits and consequences to the patient;~* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed."
219727620|NCT04257253|OTHER|Targeted exercise program|Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
219727621|NCT04257253|OTHER|General exercise program|Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
219727622|NCT05424211|DEVICE|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
219727623|NCT05685004|BIOLOGICAL|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
219727624|NCT05685004|PROCEDURE|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
219727625|NCT05685004|RADIATION|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
219727626|NCT05685004|DRUG|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
219727627|NCT05805605|BIOLOGICAL|Peripheral Blood Stem Cell Transplant|On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.
219727628|NCT05805605|DRUG|Allopurinol 300 MG|300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
219727629|NCT05805605|DRUG|Fludarabine|30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
219727630|NCT05805605|DRUG|Cyclophosphamide|Administered as a 2 hour IV infusion on day -6, +3, and +4.
219727631|NCT05805605|BIOLOGICAL|Bone Marrow Cell Transplant|On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.
219727632|NCT05805605|RADIATION|Total Body Irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
219727633|NCT05805605|DRUG|Sirolimus Pill|"All participants begin +5 to day +60.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg)."
219727634|NCT05805605|DRUG|Mycophenolate Mofetil|"All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours."
219727635|NCT05089916|DRUG|Osimertinib|Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
219727636|NCT05089916|RADIATION|Radiotherapy|"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"
219727637|NCT01459549|PROCEDURE|Roux-en-Y hepaticojejunostomy|All participants received routine perioperative care and followed the same surgical principles: removing affected liver segments, clearing stones, correcting strictures, and then restoring bile drainage. The primary indications for hepatectomy were unilobar or segmental diseases and the presence of the following lesions in the affected liver segment or lobe: 1) multiple stones with biliary strictures that cannot be cured via choledochoscopy, 2) atrophy, fibrosis, and multiple abscesses, and 3) suspicious neoplasia. Biliary exploration was routinely conducted to facilitate stone removal, rectify strictures, and assess the functionality of the Oddi sphincter. Following this, patients would be evaluated for eligibility and assigned accordingly. The sole distinction between the two arms was performing RYHJ or maintaining the common bile duct for bile drainage.
219727638|NCT03753906|DEVICE|Osmed® hydrogel expander implantation|Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
219727639|NCT04894708|PROCEDURE|colonoscopy|addition of polyp detection algorithm by Fujifilm
219727640|NCT02001883|DRUG|Association low-dose statin and nutraceuticals|
219727641|NCT00513539|DRUG|porfimer sodium|
219727642|NCT00513539|PROCEDURE|biliary stenting|
219155954|NCT05054920|OTHER|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
219155955|NCT05054920|OTHER|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
219155956|NCT01616472|DRUG|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
219155957|NCT01893970|BEHAVIORAL|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
219155958|NCT01893970|BEHAVIORAL|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
219155959|NCT05301543|BEHAVIORAL|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
219155960|NCT05301543|BEHAVIORAL|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
219155961|NCT06119048|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
219155962|NCT03013504|DRUG|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
219155963|NCT03013504|DRUG|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
219155964|NCT03013504|DRUG|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
219155965|NCT03013504|DRUG|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
219155966|NCT03013504|DRUG|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
219155967|NCT06643507|OTHER|Connective tissue graft|regenerative properties
219155968|NCT06643507|BIOLOGICAL|ALB-PRF|regenerative properties
219155969|NCT03350542|DEVICE|SYNERGY 48 mm|A drug eluting coronary stent system
219155970|NCT05005728|COMBINATION_PRODUCT|vudalimab + carboplatin + cabazitaxel|Vudalimab IV, carboplatin IV, cabazitaxel IV
219155971|NCT05005728|COMBINATION_PRODUCT|vudalimab + olaparib|Vudalimab IV, olaparib oral
219155972|NCT05005728|BIOLOGICAL|vudalimab monotherapy|Vudalimab IV
219155973|NCT05005728|COMBINATION_PRODUCT|vudalimab + docetaxel|Vudalimab IV, docetaxel IV
219155974|NCT05005728|COMBINATION_PRODUCT|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
219155975|NCT04873245|BEHAVIORAL|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
219155976|NCT04873245|DRUG|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
219155977|NCT00774852|DRUG|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
219155978|NCT00774852|DRUG|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
219155979|NCT00774852|DRUG|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
219233908|NCT00879710|DRUG|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
219727643|NCT04718753|BEHAVIORAL|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
219155980|NCT00774852|DRUG|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
219155981|NCT00774852|DRUG|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
219155982|NCT00774852|DRUG|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
219155983|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
219233909|NCT04165018|PROCEDURE|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
219727644|NCT05869409|BEHAVIORAL|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
219727645|NCT04955925|DIAGNOSTIC_TEST|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
219727646|NCT00761800|DRUG|Lactic acid|
219727647|NCT04058691|DEVICE|Surgical repair|Open surgery
219727648|NCT02981641|RADIATION|Intraoperative radiotherapy (IORT)|Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1
219727649|NCT02981641|DRUG|Sequential chemotherapy|Sequential chemotherapy
219727650|NCT02981641|RADIATION|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
219727651|NCT02981641|DRUG|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
219727652|NCT03355456|PROCEDURE|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
219727653|NCT06364527|DEVICE|Aptar Digital Health respiratory disease management platform|The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
219727654|NCT02512562|DRUG|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
219727655|NCT02512562|DRUG|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
219155984|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
219155985|NCT04026594|OTHER|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
219155986|NCT04026594|OTHER|Relaxation group|control group
219155987|NCT04999826|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
219155988|NCT04999826|OTHER|Quality-of-Life Assessment|Ancillary studies
219155989|NCT04999826|OTHER|Questionnaire Administration|Complete questionnaires
219155990|NCT06986161|OTHER|Mango|Mango beverage
219155991|NCT06986161|OTHER|Control Beverage|Italian Ice beverage
219155992|NCT00899899|GENETIC|microarray analysis|
219155993|NCT00899899|GENETIC|reverse transcriptase-polymerase chain reaction|
219155994|NCT00899899|OTHER|laboratory biomarker analysis|
219155995|NCT03206554|DRUG|Ropivacaine|Large volume local anaesthetic intraarticularly
219155996|NCT03206554|OTHER|Saline|sham injection
219155997|NCT03997916|DEVICE|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
219155998|NCT03997916|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
219155999|NCT04310358|OTHER|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
219156000|NCT04310358|OTHER|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
219156001|NCT05936411|DEVICE|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
219156002|NCT05936411|DEVICE|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
219156003|NCT01761552|DRUG|Sugammadex Reversal|
219156004|NCT01761552|DRUG|Atropine/Neostigmine|
219156005|NCT06216860|BEHAVIORAL|Laughter Yoga|In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
219156006|NCT04193579|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
219156007|NCT04193579|BEHAVIORAL|Control Treatment|Standard of Care
219156008|NCT04754425|PROCEDURE|Biopsy|Undergo biopsy
219156009|NCT04754425|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow
219156010|NCT04754425|DRUG|Erdafitinib|Given PO
219156011|NCT06168474|OTHER|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
219156012|NCT06168474|OTHER|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
219156013|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
219156014|NCT00000919|DRUG|Indinavir sulfate|
219156015|NCT00000919|DRUG|Lamivudine/Zidovudine|
219156016|NCT00000919|DRUG|Ritonavir|
219156017|NCT00000919|DRUG|Hydroxyurea|
219727656|NCT02512562|DRUG|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
219727657|NCT01938937|DEVICE|Transcranial bright light device|
219727658|NCT01938937|DEVICE|Transcranial sham device|
219727659|NCT00610519|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
219727660|NCT00610519|DIETARY_SUPPLEMENT|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
219727661|NCT02069314|DIETARY_SUPPLEMENT|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
219727662|NCT02069314|DIETARY_SUPPLEMENT|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
219727663|NCT01055327|DRUG|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
219727664|NCT01055327|DRUG|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
219156018|NCT00000919|DRUG|Abacavir sulfate|
219156019|NCT00000919|DRUG|Amprenavir|
219156020|NCT00000919|DRUG|Nelfinavir mesylate|
219156021|NCT00000919|DRUG|Efavirenz|
219156022|NCT00000919|DRUG|Lamivudine|
219156023|NCT00000919|DRUG|Stavudine|
219727665|NCT01055327|DRUG|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
219727666|NCT02468453|DEVICE|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
219727667|NCT00623129|OTHER|questionnaire administration|
219727668|NCT00623129|PROCEDURE|electroacupuncture therapy|
219727669|NCT00623129|PROCEDURE|management of therapy complications|
219727670|NCT00623129|PROCEDURE|quality-of-life assessment|
219156024|NCT00000919|DRUG|Zidovudine|
219727671|NCT03821597|PROCEDURE|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
219727672|NCT03821597|PROCEDURE|No sequential compression.|No sequential compression devices are applied.
219727673|NCT05661968|OTHER|Online educational program|The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
219727674|NCT04344444|DRUG|Hydroxychloroquine|tablets provided as described in Arm B
219727675|NCT04344444|DRUG|Azithromycin|tablets provided as described in Arm C
219156025|NCT00000919|DRUG|Didanosine|
219156026|NCT01339234|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
219156027|NCT04562844|OTHER|sociale cognition|several social cognition test
219727676|NCT04100057|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
219156028|NCT02858882|OTHER|Screening|Screening of elite swimmers
219156029|NCT01275105|DRUG|Vehicle|one drop in each eye at designated visits
219156030|NCT01275105|DRUG|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
219156031|NCT01275105|DRUG|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
219156032|NCT01275105|DRUG|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
219156033|NCT05919446|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
219156034|NCT05919446|BEHAVIORAL|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
219233910|NCT05702788|DRUG|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
219727677|NCT04100057|BEHAVIORAL|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
219727678|NCT02098551|OTHER|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
219727679|NCT00013325|PROCEDURE|Cardiac Disease|
219727680|NCT03003468|DRUG|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
219727681|NCT03003468|DRUG|MK-3475|200mg IV
219727682|NCT03003468|DRUG|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
219156036|NCT05256290|DRUG|silevertinib (BDTX-1535) monotherapy|Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
219156037|NCT03796884|DRUG|Linaclotide|Given PO
219156038|NCT03796884|OTHER|Placebo|Given PO
219156039|NCT06540898|BEHAVIORAL|Mindfulness-Based Eating and Movement Program|"This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states."
219156040|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
219156041|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
219156042|NCT06363253|OTHER|No specific intervention|"Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well."
219156043|NCT03151655|BEHAVIORAL|MATTeRS Video|Narrative-based video intervention and accompanying workbook
219727683|NCT01076517|DEVICE|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
219156044|NCT03151655|BEHAVIORAL|Didactic Video|Education only video
219156045|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
219156046|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
219156047|NCT06666972|DIAGNOSTIC_TEST|PCR MTB/NTM|• The Polymerase chain reaction (PCR) MTB/NTM MDR-TB test is an innovative technology that offers a cutting-edge approach to the precise diagnosis of tuberculosis and nontuberculous mycobacterial infections (NTM).
219156048|NCT00648011|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
219156049|NCT00648011|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
219156050|NCT03833648|OTHER|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
219233911|NCT05702788|DRUG|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
219233912|NCT05702788|OTHER|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
219727684|NCT00150553|DRUG|Extended-release carbamazepine|
219727685|NCT01560702|DRUG|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
219727686|NCT01560702|BIOLOGICAL|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
219727687|NCT01717508|BEHAVIORAL|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
219727688|NCT00997529|DRUG|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
219233913|NCT05748184|DEVICE|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
219233914|NCT05748184|DEVICE|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
219727689|NCT01384409|DRUG|KW-3357|Intravenous infusion once a day
219727690|NCT02114684|DRUG|moxifloxacin|\[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
219727691|NCT02195323|BIOLOGICAL|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
219727692|NCT05419258|DEVICE|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
219727693|NCT00990769|OTHER|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
219727694|NCT06255548|OTHER|Immersive virtual reality group|The children in the IVR group were offered two video games from the Oculus Quest gallery. These games were Ocean Rift and Epic Roller Coaster-T-Rex Kingdom. Ocean Rift is the world's first VR water safari park. It has 12 different marine animals such as dolphins, sharks, and turtles and a habitat. Here one can visit a vibrant underwater world that extends all the way to the Arctic and Atlantis. Epic Roller Coaster-T-Rex Kingdom takes one on a roller coaster ride through the Age of Dinosaurs. There are more than 10 species of dinosaurs such as terrestrial, flying, herbivorous and carnivorous.
219727695|NCT06255548|OTHER|Music group|In musical interventions, it is recommended to play music chosen by individuals. Disposable ear pads were used for each child and the headphones were cleaned after each intervention.
219727696|NCT04373733|DRUG|Favipiravir|Anti-viral
219727697|NCT04373733|OTHER|Standard of care management|Standard of care management for COVID-19
219727698|NCT02516436|DRUG|BEMA Buprenorphine NX|Buprenorphine with naloxone
219727699|NCT02516436|DRUG|Buprenorphine|Buprenorphine
219727700|NCT01320449|DRUG|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
219727701|NCT01320449|BEHAVIORAL|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
219727702|NCT01320449|OTHER|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
219727703|NCT05391152|DEVICE|robotic assisted total knee replacement|the study group used robotic-arm assisted total knee replacement.
219727704|NCT05391152|DEVICE|traditional total knee replacement|the control group used traditional total knee replacement
219727705|NCT04625972|DRUG|AZD7442|Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
219727706|NCT04625972|DRUG|Placebo|Single dose (× 2 IM injections) of saline placebo on Day 1.
219727707|NCT03457584|PROCEDURE|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
219727708|NCT03457584|PROCEDURE|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
219727709|NCT02919332|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
219727710|NCT02919332|RADIATION|Fludeoxyglucose F-18|Given IV
219727711|NCT02919332|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
219727712|NCT01794416|PROCEDURE|Thoracoscopic epicardial ablation|
219727713|NCT01794416|PROCEDURE|Endocardial catheter ablation|
219727714|NCT01794416|DEVICE|Implantable loop recorder|
219727715|NCT06522802|DIAGNOSTIC_TEST|balance tests, reaction time evaluation|Only 3 tests were applied to participants
219727716|NCT06390215|BEHAVIORAL|School Readiness Coaching Intervention|Two 1-hr School Readiness Coaching Session
219727717|NCT02641353|DRUG|Apremilast Tablet|30 mg tablet
219727718|NCT02641353|DRUG|Apremilast Oral Suspension|30 mg oral suspension
219727719|NCT03259308|DRUG|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
219727720|NCT03259308|DRUG|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
219727721|NCT00694122|DRUG|Lantus (glargine)|Described in Arm Description
219727722|NCT01767285|DRUG|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
219727723|NCT01095770|PROCEDURE|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
219727724|NCT01095770|PROCEDURE|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
219727725|NCT01095770|DEVICE|Reveal XT|Reveal XT implantable loop recorder monitored group
219727726|NCT01095770|DEVICE|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
219727727|NCT00436709|BIOLOGICAL|bevacizumab|
219727728|NCT00436709|BIOLOGICAL|pegfilgrastim|
219727729|NCT00436709|DRUG|cyclophosphamide|
219727730|NCT00436709|DRUG|doxorubicin hydrochloride|
219727731|NCT00436709|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219156051|NCT05158153|OTHER|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
219156052|NCT05158153|DRUG|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
219156053|NCT00481182|DRUG|fosamprenavir + ritonavir + methadone|
219156054|NCT05763277|DIAGNOSTIC_TEST|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
219156055|NCT06290609|DEVICE|Vibrotactile Coordinated Reset|The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
219156056|NCT03840668|DEVICE|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
219156057|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
219156058|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
219156059|NCT05527717|PROCEDURE|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
219156060|NCT05527717|PROCEDURE|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
219156061|NCT06140615|DEVICE|Ultrasound|Ultrasound of lungs
219156062|NCT06376383|PROCEDURE|Tonsillectomy|Standard tonsillectomy
219156063|NCT06376383|PROCEDURE|Tonsillotomy|Tonsillotomy
219156064|NCT05518396|DIAGNOSTIC_TEST|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
219156065|NCT05015010|DRUG|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
219156066|NCT06676644|DRUG|adjuvanted|adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
219156067|NCT06676644|DRUG|non-adjuvanted|non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
219156068|NCT06675968|PROCEDURE|Direct Suture|A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
219156069|NCT06675968|PROCEDURE|Transosseus Suture|A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
219156070|NCT06677294|PROCEDURE|Placenta remove|This is an observational study. No intervention was performed
219727732|NCT00436709|OTHER|flow cytometry|
219727733|NCT00436709|OTHER|immunoenzyme technique|
219727734|NCT00436709|OTHER|immunologic technique|
219727735|NCT00436709|OTHER|laboratory biomarker analysis|
219727736|NCT00436709|PROCEDURE|adjuvant therapy|
219727737|NCT00436709|PROCEDURE|immunoscintigraphy|
219727738|NCT02517229|OTHER|Parabolic flight|
219727739|NCT02517229|OTHER|balance control measurements|
219727740|NCT02517229|DEVICE|electromagnetic maneuverable postural platform|
219727741|NCT05563974|OTHER|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
219727742|NCT03549195|PROCEDURE|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
219727743|NCT03549195|PROCEDURE|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
219727744|NCT03549195|PROCEDURE|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
219727745|NCT00003090|BIOLOGICAL|aldesleukin|
219727746|NCT01053052|DEVICE|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
219727747|NCT05135325|BEHAVIORAL|Patient portal message|Portal message encourages patients to donate blood
219727748|NCT05135325|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
219727749|NCT01532375|DIETARY_SUPPLEMENT|Kochujang|Kochujang (32g/day) for 12weeks.
219727750|NCT01532375|DIETARY_SUPPLEMENT|placebo|placebo(32g/day) for 12weeks
219727751|NCT05742750|DRUG|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
219727752|NCT03237663|BIOLOGICAL|The oral O1 / O139 cholera vaccine (enteric capsules)|
219727753|NCT00809146|DRUG|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
219727754|NCT00809146|DRUG|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
219727755|NCT06471166|DIAGNOSTIC_TEST|Amh hormone|Ovarian reserve
219233915|NCT05748184|DEVICE|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
219233916|NCT03979040|BEHAVIORAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
219233917|NCT03979040|BEHAVIORAL|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Depression (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
219727756|NCT02663440|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
219727757|NCT02663440|BIOLOGICAL|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
219727758|NCT02663440|DRUG|Temozolomide|Temozolomide
219727759|NCT00194090|DRUG|celecoxib|
219727760|NCT03020888|DEVICE|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
219727761|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 Low Dose
219727762|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 High Dose
219727763|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
219156071|NCT06676761|PROCEDURE|nipple sparing mastectomy without reconstruction|nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
219156072|NCT06214897|DIETARY_SUPPLEMENT|C-RUSF (Ready-to-use Supplemental Food with added Choline)|Ready-to-use Supplemental Food with added Choline
219156073|NCT06214897|DIETARY_SUPPLEMENT|S-RUSF (Ready-to-use Supplemental Food without added Choline)|Standard Ready-to-use Supplemental Food
219156074|NCT06679530|OTHER|Mindful Music Listening (MML)|Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
219156075|NCT05579392|DEVICE|Bright Light Therapy|Device: Bright Light Therapy Retimer
219727764|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch High Dose
219727765|NCT04505111|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
219156076|NCT05579392|DEVICE|Placebo Retimer Device|Device: Placebo Retimer Device with no bright light therapy
219156077|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
219156078|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
219156079|NCT06936449|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells
219156080|NCT06936449|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
219233918|NCT01662713|DEVICE|OFDI|Imaging of skin
219233919|NCT03541369|DRUG|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
219233920|NCT03204357|OTHER|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
219233921|NCT03204357|OTHER|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
219233922|NCT06377137|BEHAVIORAL|Small-sided soccer games groups (SSSG)|Physical exercise intervention
219233923|NCT06377137|BEHAVIORAL|Traditional soccer training groups (TSG)|Physical exercise intervention
219233924|NCT04724265|BIOLOGICAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
219233925|NCT04789174|DRUG|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
219233926|NCT04789174|DRUG|Placebo|Placebo
219727766|NCT04505111|OTHER|Enhanced Recovery After Surgery|ERAS protocol
219727767|NCT05212142|BEHAVIORAL|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
219233927|NCT06147466|DEVICE|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
219233928|NCT00602732|BEHAVIORAL|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
219233929|NCT00602732|BEHAVIORAL|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
219233930|NCT03985397|OTHER|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
219233931|NCT04788407|DRUG|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
219233932|NCT04788407|DRUG|Placebo|Subjects will receive placebo TID for 7 days
219233933|NCT02173990|DRUG|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
219233934|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
219233935|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
219233936|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
219233937|NCT00696241|DRUG|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
219233938|NCT00696241|DRUG|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
219233939|NCT03927118|PROCEDURE|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
219233940|NCT04607356|DEVICE|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
219727768|NCT05212142|BEHAVIORAL|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
219727769|NCT01198548|DRUG|leucovorin calcium|Given IV
219727770|NCT01198548|BIOLOGICAL|bevacizumab|Given IV
219727771|NCT01198548|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
219727772|NCT01198548|DRUG|fluorouracil|Given IV
219727773|NCT01198548|DRUG|oxaliplatin|Given IV
219727774|NCT01198548|OTHER|pharmacological study|Correlative studies
219727775|NCT05926193|DIETARY_SUPPLEMENT|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
219727776|NCT04464902|DEVICE|brace1|The brace1 can provide resistance when patients want to extend their knee.
219727777|NCT04464902|DEVICE|brace2|The brace1 can't provide resistance when patients want to extend their knee.
219727778|NCT04464902|OTHER|No Intervention|Control Group don't have any brace.
219727779|NCT06122051|RADIATION|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
219727780|NCT06122051|DIAGNOSTIC_TEST|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
219727781|NCT02539693|DRUG|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
219727782|NCT02539693|DRUG|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
219727783|NCT02539693|DRUG|Lidocaine|3 ml lidocaine 1% is injected at each block site
219727784|NCT02539693|PROCEDURE|Pilonidal sinus|Removal of pilonidal sinus
219727785|NCT02679092|DRUG|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
219727786|NCT02679092|DRUG|Mifepristone|200 mg PO on the day prior to D\&E
219727787|NCT02679092|DEVICE|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
219727788|NCT02269488|DRUG|MEDI3250|MEDI3250
219156081|NCT06932926|DRUG|Egg shell hydrogel|"I. Nano-eggshell powder preparation: After cleaning, A small crack will be made in each eggshell to split it into two halves to evacuate the content. The eggshells will be disinfected in a hot water at 100°C for 10 minutes to facilitate the detachment of the inner membrane. They will be exposed to steam sterilization. Then they will be crushed using a sterile mortar and pestle. The crushed particles will be milled using a zirconia ball-milling machine at 200 rpm . This will result in a nano-sized eggshell powder to incorporate them into a gel form.~II. Preparation of eggshell hydrogel formulations: through dispersing a suitable concentration of egg shell powder in distilled water, followed by dissolving the gelling agent; sodium carboxymethyl cellulose at a concentration of 5-10% under continuous stirring. The formed hydrogel will be kept at 8°C for a period of 24 hours before further use. This will produce a paste of consistency that is appropriate for handling and application."
219156082|NCT06932926|DRUG|Fluoride varnish|five percent sodium fluoride varnish (Charm varnish -Dentkist- Korea).
219233941|NCT04607356|OTHER|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
219233942|NCT01742832|DRUG|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
219233943|NCT01742832|DRUG|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
219156083|NCT06940492|OTHER|Dry needling|Dry needling is a force-based manipulation technique used by health care providers. Force-based manipulation describes when forces external to the body are passively applied to tissue with a therapeutic intent. During dry needling, a filiform needle (i.e., one without medication) is inserted into a muscle to target a trigger point, often times with the intent of eliciting a localized twitch response
219727789|NCT03834298|OTHER|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
219156084|NCT05678088|BEHAVIORAL|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
219156085|NCT05678088|BEHAVIORAL|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
219156086|NCT03971448|DEVICE|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
219156087|NCT03971448|DEVICE|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
219233944|NCT02518399|OTHER|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
219233945|NCT02518399|OTHER|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
219233946|NCT01778803|DRUG|defactinib|
219233947|NCT01778803|DRUG|Paclitaxel|
219233948|NCT04271813|DRUG|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
219233949|NCT05329142|DIAGNOSTIC_TEST|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
219233950|NCT01589341|OTHER|laboratory biomarker analysis|Correlative studies
219233951|NCT04913532|RADIATION|Hypofractionation with simultaneous integrated boost|Hypofractionation with simultaneous integrated boost
219727790|NCT06818708|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). If the same pattern holds for the RELAY device as for previously tested peripheral nerve stimulators, we will maximize frequency, minimize pulse duration, and have participants adjust the amplitude, as needed.
219727791|NCT03764553|DRUG|Liposomal Irinotecan|Iv liposomal irinotecan
219727792|NCT03764553|DRUG|Carboplatin|IV Carboplatin
219727793|NCT03764553|DRUG|Capecitabine|PO Capecitabine
219727794|NCT03764553|DRUG|Oxaliplatin|IV Oxaliplatin
219727795|NCT03764553|DRUG|5-fluorouracil|IV 5-fluorouracil
219727796|NCT03764553|DRUG|Leucovorin|IV Leucovorin
219233952|NCT01888484|BIOLOGICAL|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
219233953|NCT01683188|DRUG|vemurafenib + HD IL-2|
219233954|NCT03887611|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
219727797|NCT06219122|BEHAVIORAL|Creative arts and psychomotor therapies intervention for people with personality disorders|a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
219727798|NCT03401333|BEHAVIORAL|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
219156088|NCT04708509|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
219156089|NCT04870645|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
219156090|NCT04870645|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
219156091|NCT04870645|DRUG|Gadolinium-Chelate|Contrast agent
219156092|NCT04870645|DRUG|Iopamidol|Contrast agent
219156093|NCT04888169|DEVICE|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
219156094|NCT04888169|DEVICE|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
219156095|NCT04888169|DEVICE|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
219156096|NCT04888169|DEVICE|SMART Mobile App - Control|Participants will only answer questions.
219156097|NCT04046224|BIOLOGICAL|ST-920|Single dose of investigational product ST-920
219156098|NCT04650386|BEHAVIORAL|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
219156099|NCT03647423|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
219156100|NCT03647423|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219156101|NCT03647423|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219727799|NCT01245062|DRUG|GSK1120212|MEK inhibitor
219156102|NCT03647423|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
219156103|NCT03647423|BIOLOGICAL|GI-6301|Brachyury yeast
219156104|NCT03647423|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
219156105|NCT03647423|DRUG|Avelumab|injection
219156106|NCT03647423|DRUG|Cetuximab|Injection
219156107|NCT03647423|DRUG|Cyclophosphamide|Capsules
219156108|NCT03647423|RADIATION|SBRT|Stereotactic body radiation therapy
219156109|NCT04170062|DEVICE|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
219156110|NCT04170062|DEVICE|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
219156111|NCT05720884|DEVICE|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
219156112|NCT05720884|DEVICE|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
219156113|NCT05002257|OTHER|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
219156114|NCT05002257|OTHER|No music therapy|Usual care
219156115|NCT06472492|BEHAVIORAL|Adjuvant yoga intervention|The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
219156116|NCT05146427|DEVICE|Slow-wave enhancement|A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.
219727800|NCT01245062|DRUG|Chemotherapy|Investigator Choice of DTIC or paclitaxel
219727801|NCT06825559|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in this open label study
219727802|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
219233955|NCT01515501|PROCEDURE|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
219233956|NCT06575725|BIOLOGICAL|Balstilimab|Given IV
219233957|NCT06575725|PROCEDURE|Biopsy|Undergo biopsy
219233958|NCT06575725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219233959|NCT06575725|BIOLOGICAL|Botensilimab|Given IV
219233960|NCT06575725|PROCEDURE|Computed Tomography|Undergo CT
219233961|NCT06575725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219233962|NCT06575725|DRUG|Regorafenib|Given PO
219233963|NCT02757469|DRUG|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
219233964|NCT04198441|DEVICE|Wound dressing|Clean wound, fill wound, dress wound
219233965|NCT03347396|DRUG|BIVV009|Sutimlimab was administered as intravenous (IV) infusion.
219233966|NCT06509308|OTHER|Psychological Questionnaires|Patients will be asked to complete a series of questionnaires regarding disease expectations, cognitions, and representations of their health status. Additionally, sociodemographic data and clinical variables will be collected from medical records.
219233967|NCT00010868|DRUG|Omega-3 Fatty Acids|
219233968|NCT02399202|DRUG|osilodrostat|
219233969|NCT00221988|DRUG|Levetiracetam (Keppra)|
219233970|NCT04347148|PROCEDURE|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
219233971|NCT04347148|PROCEDURE|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
219233972|NCT05514184|DIETARY_SUPPLEMENT|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
219727803|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
219233973|NCT04780607|DEVICE|mitral valve repair|different repair techniques to construct rheumatic mitral valve lesion
219233974|NCT02962024|DRUG|Morphine Sulfate|
219233975|NCT02962024|DRUG|Bupivacaine Hydrochloride|
219233976|NCT06352307|OTHER|Diagnosis of ACM|Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
219727804|NCT06855875|PROCEDURE|autogenous tooth graft combined with bovine bone|unilateral alveolar cleft which will be repaired using autogenous tooth graft combined with bovine bone .
219727805|NCT06855875|PROCEDURE|bovine bone|unilateral alveolar cleft which will be repaired using bovine bone .
219727806|NCT06092151|DEVICE|Silver diamine fluoride|silver diamine fluoride - maximum 1 drop to be applied per visit (manufacturer advises this would treat up to 5 teeth)
219727807|NCT06092151|PROCEDURE|Usual dental care|Usual restorative or preventative care determined by the child's dentist - for examples fillings or crowns
219727808|NCT06859593|DIAGNOSTIC_TEST|Upper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test|Upper Extremity Exercise Capacity
219727809|NCT02837653|BEHAVIORAL|Physical Activity Counselling|
219727810|NCT02837653|OTHER|Therapeutic Exercise for LBP|
219233977|NCT01780428|DRUG|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
219233978|NCT01780428|DRUG|Placebo|
219233979|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
219233980|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
219233981|NCT05547724|OTHER|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
219233982|NCT02399072|OTHER|No intervention|No intervention administered in this study
219233983|NCT06100406|OTHER|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
219233984|NCT02947880|DRUG|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
219233985|NCT02947880|DRUG|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
219360807|NCT03750851|OTHER|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
219727811|NCT02837653|OTHER|Superficial Thermotherapy|
219727812|NCT03289000|DEVICE|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
219727813|NCT06518993|DEVICE|Total hip arthroplasty with a Trinity cup and a Meije Duo cementless stem|Subjects clinically suitable for a primary THR surgery with Trinity cup and Meije Duo cementless femoral stem.
219727814|NCT03834883|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
219727815|NCT03834883|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
219727816|NCT06524531|PROCEDURE|Pulsed RF Neuromodulation|RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.
219727817|NCT06524531|BIOLOGICAL|Leukocyte-Rich PRP Injection|Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
219727818|NCT06524531|PROCEDURE|Physiotherapy Alone|Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
219727819|NCT01398527|OTHER|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
219727820|NCT05147571|DEVICE|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
219727821|NCT05147571|DEVICE|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
219727822|NCT07030270|PROCEDURE|Surfactant Administration through Laryngeal or Supraglottic Airway|"Surfactant Administration through Supraglottic Airway Devices~* Air-Q3 size 0 for neonates: \< 2 kilograms~* i-gel supraglottic airway size 1 for neonates: ≥ 2 kilograms"
219727823|NCT07030270|PROCEDURE|Surfactant Administration through Thin Catheter|Thin Catheter
219727824|NCT07030309|OTHER|Gastroschisis|"Gastroschisis (GS) is a congenital abdominal wall defect in which the intestine is located outside the abdominal cavity. The prevalence of the GS classifies it as a rare disease (ORPHA:2368) Pregnancy complicated by gastroschisis is associated with an increased risk of serious perinatal complications.~The presence of accompanying intestinal anomalies (atresia, necrosis, perforation, and volvulus), which qualifies the defect in the cGS (complex gastroschisis) group, as opposed to sGS (simple gastroschisis), where these anomalies are absent.~cGS is associated with significantly increased neonatal morbidity and mortality when compared to sGS."
219727825|NCT05407896|OTHER|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
219156117|NCT05146427|DEVICE|Sham device|A headband that measures slow-wave activity during sleep but has no auditory stimulation.
219156118|NCT05736159|DIAGNOSTIC_TEST|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
219156119|NCT05736159|DIAGNOSTIC_TEST|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
219156120|NCT04961164|DIETARY_SUPPLEMENT|Resistant Potato Starch, Corn Starch|Consume resistant potato starch at study period 1, then consume corn starch at study period 2.
219156121|NCT04961164|DIETARY_SUPPLEMENT|Corn Starch, Resistant Potato Starch|Consume corn starch at study period 1, then consume resistant starch at study period 2.
219156122|NCT06756282|PROCEDURE|Pacemaker and defibrillator|only patients with pacemaker implantation will be evaluated in the study
219156123|NCT00777582|DRUG|AZD2281|Oral single dose formulation
219156124|NCT04295317|DRUG|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
219156125|NCT04295317|DRUG|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
219156126|NCT03702842|DEVICE|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
219156127|NCT03702842|OTHER|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
219156128|NCT06757231|BEHAVIORAL|Nurse Counseling Based on the Chronic Care Model (CCM)|"This intervention involves personalized nurse counseling for patients diagnosed with Inflammatory Bowel Disease (IBD) based on the Chronic Care Model. The intervention includes:~Biweekly phone consultations and weekly informational messages to provide education and support for symptom management, stress reduction, and quality-of-life improvement.~An educational booklet to aid self-management. Follow-ups to assess progress, address concerns, and provide guidance on IBD management strategies."
219156129|NCT04404569|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
219727826|NCT05898633|DRUG|Recombinant fragment of human surfactant protein D (rfhSP-D)|Administration of rfhSP-D
219727827|NCT07036562|BEHAVIORAL|Time-restricted eating and high-intensity interval training|1-month intense periods of maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum), separated by 3-month maintenance periods of time-restricted eating on 5 days per week and minimum 1 HIIT session per week. Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly during intense periods, and once monthly during maintenance periods. The intervention period will be 12 months in total.
219156130|NCT01703078|DRUG|Ingenol once daily for two consecutive days|
219156131|NCT06694025|BIOLOGICAL|Efluelda Tetra Pre-filled syringe|Suspension for injection in a pre-filled syringe
219156132|NCT06040190|DRUG|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
219156133|NCT06040190|DRUG|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
219156134|NCT06040190|DIETARY_SUPPLEMENT|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
219156135|NCT06040190|OTHER|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
219727828|NCT07032480|BEHAVIORAL|Survey-Based Assessment|Participants completed standardized questionnaires including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Neck Disability Index (NDI) to evaluate psychological and functional outcomes associated with sleep quality. No experimental intervention was administered.
219727829|NCT07039331|DIETARY_SUPPLEMENT|Short Term Fasting|Short Term Fasting during the first three cycles of NACT (36h before and 24h after the end of each cycle of CT).
219727830|NCT07039331|OTHER|Free Diet|Ordinary diet during the first three cycles of NACT without any change.
219727831|NCT06710288|DRUG|Gemcitabine|Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
219727832|NCT06710288|BIOLOGICAL|N-803|Dose: fixed dose of 1.2 mg subcutaneously (SC) Frequency: administered on Day 1 and Day 15 of each cycle starting at Cycle 2 (every 4 weeks) and when the last dose of M-CENK is administered, N-803 will be administered on Days 1 and 15 of the same cycle followed by 3 additional doses, 2 weeks apart (total of 5 N-803 doses).
219727833|NCT06710288|BIOLOGICAL|M-CENK|Dose: 0.15 to 0.75 × 109 cells per infusion intravenously (IV) Frequency: administered on Day 1 of each cycle as long as M-CENK cells are available.
219727834|NCT07043907|DRUG|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy
219727835|NCT07045246|PROCEDURE|Coenzyme Q 10|Patients received Coenzyme Q 10 as a graft material in unilateral maxillary alveolar cleft
219727836|NCT07045246|PROCEDURE|iliac bone graft|iliac bone used as a graft for alveolar cleft reconstruction
219727837|NCT07046364|DRUG|Remimazolam|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.
219727838|NCT07046364|DRUG|Normal Saline|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.
219727839|NCT07046065|DEVICE|Non-cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer without cyclopegia
219727840|NCT07046065|DEVICE|Non-cycloplegic conventional subjective refraction|Performed with Vision-R™
219727841|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
219727842|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
219727843|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-R™)|Performed with Vision-R™
219727844|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-S™)|Performed with Vision-S™
219727845|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
219727846|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
219727847|NCT07046065|DEVICE|Cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer with cyclopegia
219727848|NCT07046065|DEVICE|Non-cycloplegic Retinoscopy|Performed with a retinoscope without cycloplegia
219727849|NCT07046065|DEVICE|Cycloplegic retinoscopy|Performed with a retinoscope with cycloplegia
219727850|NCT07045025|OTHER|No Clinical Intervention - Analysis of Previously Acquired CBCT Scans|This study does not involve any clinical or therapeutic intervention. It is solely based on the retrospective analysis of previously acquired CBCT scans from patients who have undergone root canal treatment. No drugs, devices, or procedures are administered or applied to participants as part of this study.
219727851|NCT07044765|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
219727852|NCT07044765|DRUG|Comparator 2|Metformin 1000mg
219727853|NCT07044765|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
219727854|NCT07046299|PROCEDURE|Endovascular Therapy Plus Best Medical Treatment|Participants assigned to the endovascular therapy arm will receive EVT in addition to best medical treatment. EVT must be initiated within 24 hours of symptom onset and completed within 3 hours of groin puncture. After evaluating vascular anatomy, neurointerventionalists will determine the most appropriate strategy based on the presence of proximal stenosis, occlusion morphology, and vessel tortuosity. Permitted interventions include mechanical thrombectomy, stent thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, and stent implantation. The choice of treatment approach is left to the discretion of the treating physician, and combinations of techniques are allowed.
219727855|NCT07046299|DRUG|Best Medical Treatment Alone|Participants in this arm will receive best medical treatment and maximal supportive care according to current stroke guidelines, without the use of mechanical thrombectomy or any intra-arterial intervention.
219727856|NCT07045506|OTHER|UVC insertion|"UVC insertion was performed under sterile conditions according to the unit protocol by a senior NICU physician. For preterm deliveries, written informed consent was obtained from a parent before enrollment in the study. In emergency cases, where the neonate required immediate UVC insertion upon admission to the NICU, a waiver of informed consent was applied. In such instances, parents were informed as soon as possible about their infant's participation in the study, provided with written information, and asked for their consent to include their infant's data in the analysis, with the option to give consent via telephone if they were unable to be present in person.~After UVC insertion, anteroposterior and lateral thoracoabdominal radiographs were performed to verify the position of the UVC tip."
219727857|NCT07046754|OTHER|type of consultation|urgence care, permance care
219727858|NCT07045662|BEHAVIORAL|Multidisciplinary Assessment|"The participants in the multidisciplinary assessment were followed by multidisciplinary teams from the study target-units, by individual and collective interviews, which mirror the care protocol. The frequency of individual visits was at least every six months by a nurse, a physician, and a nutritionist.~Regarding the collective activities, the educational groups met for approximately 1 hour and 30 minutes on monthly basis over a period of six months. Considering that there were two FHU in the IG, each team held one activity per month.~For the development of the collective activities, methods recognized for intensifying integration and participation, such as using simple language and confirming the participants' understanding of the information covered in the group were recommended."
219727859|NCT07046533|PROCEDURE|(pulpotomy)|non invasive technique depends on remove only the coronal pulp tissue instead of remove all pulp tissue
219727860|NCT07046533|PROCEDURE|root canal treatment|invasive technique depends on remove all radicular and coronal pulp tissue
219727861|NCT07044427|OTHER|Strength and balance training in combination with a treadmill-based pertubation intervention|Patients receive a personalized home-based training plan with strength and balance exercises to be carried out three times a week for six months. In addition, treadmill-based pertubation training is carried out at 2 timepoints.
219727862|NCT07044492|BEHAVIORAL|Virtual Reality (VR) with Debriefing|Participants will receive a weekly 5-minute VR session featuring immersive experiences of residents' lives within the facility, followed by a 25-minute debriefing discussion in small groups of 5\~6 participants. This will continue for three weeks.
219727863|NCT07040943|BIOLOGICAL|IL-22BP|During the injection of IL-22BP, there were three dose groups, namely 50 μg, 100 μg, and 150 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL22BP injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be inoculated 1 month after the 4th dose.
219727864|NCT07046390|DRUG|nerve block with bupivacaine 0.25%|0.25% bupivacaine
219727865|NCT07046390|DRUG|No intervention|No intervention
219727866|NCT07045844|DIETARY_SUPPLEMENT|Pasteurized Donor Milk for Insufficient Breastfeeding|"Participants receive pasteurized donor human milk (pHDM) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
219727867|NCT07045844|DIETARY_SUPPLEMENT|Preterm Formula for Insufficient Breastfeeding|"Participants receive preterm formula (PTF) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
219727868|NCT07045844|DIETARY_SUPPLEMENT|Routine fortification|Randomization 2 will be conducted when the total daily intake of human milk (including own mother's milk \[OMM\] and/or donor pasteurized human milk \[pHDM\] ) reaches between 60-120 mL/kg
219727869|NCT07045844|DIETARY_SUPPLEMENT|Rescue fortification|Randomization 2 will be conducted: Add fortifiers when the body weight is below the 10% growth curve.
219727870|NCT07046377|PROCEDURE|ACB - IPACK|will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block, as well as infiltration of the space between the popliteal artery and the capsule of the posterior knee (IPACK) block.
219727871|NCT07046377|PROCEDURE|GNB - IPACK|will recieve spinal anesthesia and US guided Genicular nerves block and IPACK block.
219727872|NCT06726174|DRUG|ECCEC|0.5-1x10\^6 cells/300 uL, intracameral injection.
219156136|NCT06040190|RADIATION|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
219360808|NCT03750851|OTHER|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
219360809|NCT05162066|DRUG|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
219727873|NCT07044752|BEHAVIORAL|Anxiety Prevention Intervention|community and school based, delivered by peers from the community to educate and lower anxiety symptoms among youth
219727874|NCT07044752|BEHAVIORAL|Anxiety Intervention|5-session social and behavioral intervention about managing anxiety symptoms
219727875|NCT07046481|OTHER|Physical activity|One or two physical activities according to the participant´s preferences will be selected and prescribed and specified for frequence and intensity. The selected activity/-ies could be of any type, as long as they increase the heart rate. The activity/-ies should be performed regularly during 12 weeks, A training diary will be used to monitor and register the activities.
219360810|NCT01072344|DRUG|Chamomile (Matricaria recutita)|500 mg 3 times daily
219156137|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
219156138|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
219156139|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
219156140|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
219156141|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
219156142|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
219156143|NCT04919590|BEHAVIORAL|This is Quitting|Text message-based intervention for quit vaping support.
219156144|NCT04919590|OTHER|Assessment only control|Assessment only
219156145|NCT04919590|OTHER|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
219156146|NCT06417229|DRUG|BMS-986365|Specified dose on specified days
219156147|NCT06417229|DRUG|Rabeprazole|Specified dose on specified days
219156148|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
219727876|NCT07046026|BEHAVIORAL|Standard work pace|On two consecutive days, participants will work at a standard pace of one box per minute during the box carrying protocol
219727877|NCT07046026|BEHAVIORAL|Additional rest breaks|On two consecutive days, participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
219727878|NCT07057310|DRUG|semaglutide or tirzepatide|Semaglutide and tirzepatide will be dosed as per prescription labels
219727879|NCT07057310|BEHAVIORAL|Lifestyle modification intervention|All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
219156149|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
219156150|NCT06526741|OTHER|Longitudinal data collection|This is an observational ambispective non-interventional registry collecting longitudinal real-world data only. There is no intervention.
219156151|NCT02631603|DRUG|Placebo|Administer Placebo as anti-inflammatory
219156152|NCT02631603|DRUG|Prednisolone|Administer Prednisolone as anti-inflammatory
219156153|NCT03239626|RADIATION|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
219360811|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
219727880|NCT06794411|BEHAVIORAL|Intervention group: Food habits and physical activity program|"5 dynamic face-to-face sessions to promote healthy eating and regular physical activity. The 5 sessions are structured based on the pedagogical approach of Seeing, Judging and Acting (Gibson, 1999; Rodríguez-Bailón, et al., 2016). This methodology provides a logical structure to achieve nutritional and physical activity self-analysis. It is applied based on 3 stages:~* 1st reflective stage: to raise awareness about the importance of following healthy eating and physical activity habits and identify to what extent families are close to the healthy recommendations in relation to these two habits (first two sessions).~* 2nd: more active stage, to acquire strategies and learn to put these recommendations into practice in their day-to-day lives (session 3th and 4th session).~* 3th: to plan specific actions to address and transform some aspects of improvement by freely assuming one's own commitment proposals with the aim of modifying the presented reality, if deemed appropriate (last session)."
219727881|NCT06794411|BEHAVIORAL|Usual Care Group|They will be evaluated on baseline, final and follow up, and they will recieved basic nutritional and physical activity information.
219727882|NCT06878092|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus is a brief, potentially scalable psychological intervention developed by the World Health Organization and is delivered by non-specialised helpers. In brief, the intervention is based on cognitive behavioural therapy (CBT) techniques and typically consists of five weekly, ninety-minute sessions. Participants are taught the following techniques during the sessions: stress management, problem-solving, behavioural activation, and accessing social support. The effectiveness of both the individual and group formats of the PM+ intervention have been shown in a number of large definitive RCTs. For the purposes of this study, an adapted version of PM+ will be used to match the exposure between the two active intervention arms. There will be six, weekly seventy-five-minute sessions
219727883|NCT06878092|BEHAVIORAL|Problem Management Plus with Emotional Processing Module (PM+EP)|To more directly address symptoms of traumatic stress, an adapted version of PM+ containing Emotional Processing module will be trialed in this study. The PM+ strategies discussed above are identical across both interventions apart from the additional module. The Emotional Processing module aims to provide a safe environment for participants to engage in the emotional processing of both positive and negative memories. During the additional session, participants will be asked to imagine significant memories as pieces of a jigsaw puzzle; participants will be asked to illicit three memories, two positive/pleasurable and one negative/frightening. Participants will be assisted in processing these memories through discussing the puzzle pieces, the thoughts and emotions that come with the memory, and future perspectives. Participants will be asked to rate the intensity of emotions before and after they talk about their memories each time they are brought up.
219727884|NCT06878092|OTHER|Care as usual|The comparison group will receive care as usual (CAU) only. CAU for forcibly displaced youth (under 18) in Sweden corresponds to primary health care, education, social protection services, and specialized psychological treatment programs. However, adults are only able to access care that cannot be deferred. Once the individual has received their residence permit, they are able to access all healthcare. Upon first arriving in Sweden, refugees are referred to a municipality by the Swedish Board of Migration (Migrationsverket) until they have their residence permit. The municipality is responsible for education and social services while the regions are responsible for health care. In the regions, primary care is responsible for the first line of treatment but can also refer to the child and adolescent mental health services (CAMHS) if needed. Unaccompanied children might either be placed in families or in residential facilities and benefit from the same systems as accompanied children.
219727885|NCT07056972|OTHER|Discontinuation of surveillance|The intervention is discontinuation of current surveillance policies which consist of annual imaging with MRI/MRCP and clinical assessment.
219727886|NCT00525356|DEVICE|Medtronic Talent Stent-Graft-System|
219727887|NCT06473805|PROCEDURE|VISTA technique and 3D printed PMMA implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the sub nasal area and plan the position, size and thickness of PMMA implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
219156154|NCT06088888|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
219156155|NCT05736432|DIETARY_SUPPLEMENT|Blueberries|Experimental condition
219156156|NCT05736432|DIETARY_SUPPLEMENT|Placebo|Placebo condition
219156157|NCT02237417|DRUG|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
219360812|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
219156158|NCT02237417|DRUG|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
219156159|NCT02237417|OTHER|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
219156160|NCT01143298|DRUG|LEO 27847 oral solution|
219156161|NCT04156581|DRUG|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
219156162|NCT04156581|DRUG|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
219156163|NCT04156581|OTHER|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
219156164|NCT03602612|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
219156165|NCT03602612|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
219156166|NCT03602612|BIOLOGICAL|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
219156167|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
219727888|NCT06473805|PROCEDURE|VISTA technique and 3D printed PEEK implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the subnasal area and plan the position, size and thickness of PEEK implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
219727889|NCT07056426|OTHER|Exercises|"Joint mobilization exercises:~-Active ankle range of motion exercises~Ankle strengthening with resistance band (Thera-band®):~* Resisted dorsiflexion~* Resisted plantar flexion~* Resisted inversion~* Resisted eversion~* Leg muscle strengthening exercises:~* Heel raises (standing)~* Heel raises (sitting)~* Toe raises (standing)~* Toe raises (sitting)~Hip and pelvis stabilizer muscle strengthening exercises:~* Pelvic bridge~* Side leg lifts with hip and knee at 0°~* Side leg lifts with hip and knee at 90°~Stretching exercises:~* Calf stretch with towel~* Gastrocnemius stretch (standing)~* Soleus stretch (standing)~* Anterior compartment leg stretch~These exercises will be applied three times a week in 40-minute sessions, for a total of 12 sessions."
219727890|NCT07056426|OTHER|ESWT|"The Extracorporeal Shock Wave Therapy (ESWT) will be administered once a week for a total of four sessions. Each session will deliver 2000 pulses at a pressure of 2.5 bar and a frequency of 8 Hz using radial shock wave technology. The total energy flux density per session is planned to be approximately 200 mJ/mm².~Patients will be positioned in a supine lying position during the treatment. A generous amount of ultrasound gel will be applied to the medial tibial border and surrounding tissues to ensure effective transmission of shock waves and patient comfort.~The application of shock waves will follow the clinical focusing principle: treatment will start from the point of greatest tenderness and maximal pain on the medial tibial border, progressing in a circular motion from medial to lateral. The treatment area will typically cover a region approximately 2-4 cm in width and 4-8 cm in length."
219156168|NCT03960463|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
219156169|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
219156170|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
219156171|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
219156172|NCT05794581|DRUG|CT-868|CT-868
219156173|NCT05794581|DRUG|Placebo|Placebo as SC Injection
219156174|NCT05794581|DRUG|Victoza|Victoza as active comparator as SC Injection
219156175|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
219156176|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
219156177|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
219156178|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
219156179|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
219156180|NCT05137587|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
219156181|NCT05137587|DRUG|propofol|propofol
219156182|NCT05137587|DRUG|ketamine|ketamine
219156183|NCT05370105|OTHER|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
219156184|NCT05568615|DRUG|MT-1186|Suspension
219156185|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
219727891|NCT07056426|OTHER|Deep Tissue Massage|The deep tissue massage begins with the patient lying on their side, the affected leg on top, knee flexed at about 45 degrees, and the medial surface of the tibia facing upward. The sensitive line along the medial tibia is identified by palpation, and the area is prepared with petroleum jelly. The massage starts with 4-5 superficial strokes along the medial calf using the palm, followed by 2-3 deep strokes to assess muscle tone and patient tolerance. Moderate pressure is applied with the thumb perpendicular to the tibial line, moving slowly from just above the medial malleolus toward the medial tibial plateau. Then, the thumb shifts one finger width posteriorly and moves upward along the soleus muscle with similar pressure. These two steps are repeated 6-8 times, each lasting 10-15 seconds, with pain adjusted to 7-8 on the VAS scale. A 10-second rest is given between applications, and the massage ends with 4-5 superficial strokes.
219727892|NCT07056296|DEVICE|3D Maxillary Expansion with 3 expansion screws|In patients requiring maxillary expansion, after randomization and allocation for each to receive which expander, appliance will be cemented. In the 3-way group (A), 3 screw activations will be delivered by the care giver to expand the maxillary arch in 3D manner correcting the collapsed arch anteriorly.
219727893|NCT07056296|DEVICE|3D Maxillary Expansion using modified Fan expander with springs|For the fan expander with palatal springs (B) , spring activation will be done by the operator after cemenation intraorally, then the care giver too will just activate one fan screw. Also 3D expansion evaluation was done.
219727894|NCT07055841|DRUG|Adebrelimab|1200mg, intravenous infusion, D1， Every three weeks, there are two cycles in total.
219727895|NCT07055841|DRUG|TP regimen|TP regimen: Docetaxel 75 mg/m2, intravenous infusion, D1， Cisplatin 75 mg/m2, intravenous infusion, D1， Every three weeks, there are two cycles in total.
219727896|NCT07055841|PROCEDURE|Surgery or radiotherapy|Surgery or radiotherapy should be performed 1-4 weeks after the completion of neoadjuvant therapy.
219727897|NCT01225302|DRUG|Linifanib|Low dose linifanib (once a day)
219727898|NCT01225302|DRUG|Linifanib|High dose linifanib (once a day)
219727899|NCT01225302|DRUG|Carboplatin|Given on Day 1 of every 21-day cycle
219727900|NCT01225302|DRUG|Paclitaxel|Given on Day 1 of every 21-day cycle
219727901|NCT01981252|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
219727902|NCT04179630|BIOLOGICAL|Aldafermin (NGM282)|Single 3 mg dose
219727903|NCT02137811|OTHER|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
219727904|NCT00314106|BIOLOGICAL|Melanoma Reactive TIL|
219156186|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
219156187|NCT05844566|DEVICE|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
219156188|NCT06296173|OTHER|"Protective open-lung extubation"|Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
219156189|NCT06296173|OTHER|Conventional extubation|Emergence using 100% FiO2, dorsal decubitus position with assistance or manual bag ventilation without PEEP
219156190|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
219156191|NCT06254040|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
219156192|NCT06254040|DIETARY_SUPPLEMENT|mixture of extracts and DHA|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
219156193|NCT04520061|BEHAVIORAL|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
219156194|NCT06513338|DRUG|Eculizumab|eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
219360813|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
219727905|NCT00314106|DRUG|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
219727906|NCT00314106|BIOLOGICAL|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
219727907|NCT00314106|DRUG|Fludarabine|25 mg/m\^2/day intravenous x 5 days
219727908|NCT00314106|RADIATION|1200 total body irradiation (TBI)|1200 cGY total body radiation
219727909|NCT07056816|OTHER|Interactive Doll|"Interactive Doll: Their hearts beat and they say hello as soon as you put it on your finger because they know it's really yours! They also have a different personality and reactions when they open and close your finger. With sensors in their head, mouth and belly, Fingerlings respond to your touch and will respond to you. You can also shake them and turn them upside down for even more reactions because they love to monkey around. And their positive tail can hang down or flip up so they can sit on your table or shelf. Kids will play with the Interactive Doll during the inhalation treatment."
219727910|NCT07056816|OTHER|Interactive Robot|Interactive Robot: It has an interactive design that improves children's music listening and learning skills. It attracts children's attention with its vibrant colors and cute design, and teaches them while having fun. It has a voice imitation feature and a response feature that makes different sounds when its head is touched. Children will play with the Interactive Robot during inhalation treatment.
219360814|NCT04009941|DRUG|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
219360815|NCT00599807|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
219727911|NCT07056348|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled will undergo stimulation parameters tuning of deep brain stimulation electrode leads. All subjects will participate in a series of experiments to evaluate the stimulation effects on movement of face and upper extremities, swallowing, and speech abilities.
219727912|NCT02859116|PROCEDURE|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
219727913|NCT01392937|DEVICE|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
219727914|NCT01392937|DEVICE|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
219727915|NCT01301092|BIOLOGICAL|LY2189265|administered intravenous, subcutaneous or intramuscular
219727916|NCT01603160|BEHAVIORAL|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
219727917|NCT03366584|DIETARY_SUPPLEMENT|Beta carotene|Beta carotene 25,000 IU
219727918|NCT03366584|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU
219156195|NCT04610853|DIAGNOSTIC_TEST|rotational thromboelastometry|ROTEM will be conducted and DIC score calculated within 24 hours after the diagnosis of Sepsis as well as on day 3 and 5 of ICU stay
219156196|NCT05000021|BEHAVIORAL|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
219156197|NCT05000021|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
219156198|NCT04385940|DIETARY_SUPPLEMENT|Ddrops® products, 50,000 IU, Oral|Vitamin D3
219156199|NCT04385940|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 1000IU
219156200|NCT05588414|PROCEDURE|Standardization of the sentinel node detection procedure|All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
219156201|NCT06282770|DEVICE|Laser Diode Brace|The device is a brace with laser diodes. The braces light up and the red light has therapeutic abilities.
219727919|NCT03366584|DIETARY_SUPPLEMENT|Zinc|Zinc 50 mg
219727920|NCT03366584|DRUG|Dexamethasone|Dexamethasone 6 mg
219727921|NCT03546543|PROCEDURE|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
219727922|NCT03827642|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
219727923|NCT03827642|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
219727924|NCT03827642|DRUG|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
219727925|NCT03827642|DRUG|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
219727926|NCT01271738|PROCEDURE|Remove tumor only|No additional margins (tissue) removed at the initial surgery
219156202|NCT06282770|DEVICE|Sham Laser Diode Brace|The Sham brace has no therapeutic ability and will act as a placebo.
219156203|NCT03207594|OTHER|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
219156204|NCT03207594|OTHER|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
219360816|NCT02256930|DRUG|M518101|
219360817|NCT02256930|DRUG|M518101 Vehicle|
219360818|NCT02256930|OTHER|Sodium lauryl sulfate|
219360819|NCT02256930|OTHER|Saline|
219360820|NCT00962026|DRUG|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
219360821|NCT05147480|OTHER|internet-based mother-baby yoga|Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
219360822|NCT04439955|DRUG|CBD|300 mg CBD
219360823|NCT01356550|DRUG|RO4917838|single oral dose
219727927|NCT01271738|PROCEDURE|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
219727928|NCT01065441|BIOLOGICAL|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10\^7 cells
219727929|NCT01065441|PROCEDURE|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
219727930|NCT01065441|BIOLOGICAL|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10\^7 cells
219727931|NCT01065441|BIOLOGICAL|AlloStim|intravenous AlloStim-TM at doses between 1 x 10\^7 to 1 x 10\^9 cells
219727932|NCT01065441|BIOLOGICAL|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
219727933|NCT01065441|BIOLOGICAL|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10\^7 cells.
219727934|NCT01065441|BIOLOGICAL|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
219727935|NCT01845857|BEHAVIORAL|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
219727936|NCT03217825|DRUG|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
219156205|NCT03207594|OTHER|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
219156206|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
219156207|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
219156208|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
219156209|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
219233986|NCT03060525|BEHAVIORAL|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
219233987|NCT01932632|OTHER|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
219233988|NCT05225753|DIAGNOSTIC_TEST|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
219233989|NCT00476385|DRUG|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
219233990|NCT01013584|DIETARY_SUPPLEMENT|cholecalciferol|daily dose
219233991|NCT00090519|DRUG|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
219727937|NCT03217825|DRUG|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt.
219727938|NCT03795909|DRUG|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
219727939|NCT03795909|DRUG|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
219727940|NCT05850507|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
219727941|NCT05850507|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
219156210|NCT05124249|DIAGNOSTIC_TEST|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
219156211|NCT05124249|PROCEDURE|PCI|Patients who undergoing PCI
219156212|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
219156213|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
219156214|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
219156215|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
219156216|NCT02992015|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
219156217|NCT04246203|OTHER|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
219156218|NCT04922021|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
219727942|NCT00168532|DRUG|Sulfamethoxazole-Trimethoprim|
219727943|NCT03321032|DEVICE|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
219727944|NCT03321032|DEVICE|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
219727945|NCT06050772|BEHAVIORAL|Immersive Virtual Reality Reminiscence|a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world
219727946|NCT06050772|BEHAVIORAL|Traditional Reminiscence Therapy|RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
219727947|NCT04344093|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
219727948|NCT04002895|DRUG|Foliglurax|Single oral dose of 80 mg \[14C\]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from \[14C\]-foliglurax powder for oral solution)
219727949|NCT00369018|DRUG|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
219727950|NCT00853047|DRUG|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
219727951|NCT00853047|DRUG|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
219727952|NCT00853047|DRUG|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
219727953|NCT06061419|OTHER|Huel Powder|Huel Powder v3.0 white, vanilla flavour
219727954|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.
219727955|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.
219727956|NCT04792268|OTHER|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
219727957|NCT02571231|DEVICE|HFV + and - VG|High frequency ventilation with and without volume guarantuee
219727958|NCT05208190|DRUG|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
219727959|NCT05208190|DRUG|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
219727960|NCT04999397|OTHER|standards clinical management|outcomes seen in cardiac injuries post clincal care
219727961|NCT02687737|PROCEDURE|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
219727962|NCT02687737|PROCEDURE|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
219156219|NCT04922021|DRUG|LEO 138559 placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
219156220|NCT06835517|BEHAVIORAL|Theory of Dissonance|The design of this intervention will consist of presenting information that generates dissonance with the subjects' attitudes and beliefs about clinical errors. Dissonance will be intensified by experiential experiences through simulations that provide compelling information that supports the idea of accepting honest errors as learning opportunities within the framework of a Just Culture.
219233992|NCT00090519|DRUG|placebo|QD oral for up to 36 months
219727963|NCT02687737|PROCEDURE|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
219727964|NCT02687737|BEHAVIORAL|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
219727965|NCT02863042|PROCEDURE|Repair Deltoid Tendon|
219727966|NCT02863042|OTHER|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
219727967|NCT06244901|DEVICE|Ankle Exoskeleton|Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
219727968|NCT06244901|OTHER|Normal walking|Normal walking for twenty minutes on real-world terrain every day for a week.
219727969|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
219727970|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
219727971|NCT02324595|PROCEDURE|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
219727972|NCT06097572|DIAGNOSTIC_TEST|Intranasal food challenge|Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein
219156221|NCT06835517|BEHAVIORAL|Theory of Reasoned Action|"The intervention will consist of the presentation, to the different groups, of testimonies, narratives, statements and analysis of everyday clinical practice situations that promote a change in the so-called subjective norms (a person's beliefs about whether significant people in his or her life approve or disapprove of a specific behavior) in relation to the acceptance of honest mistakes (including learning and improving health care from error)."
219156222|NCT06835790|DIAGNOSTIC_TEST|Ph-measurement|Ph measurement before and after the surgery
219156223|NCT06835790|OTHER|Questionnaires|GERD-HRQL Reflux symptom index scale before and after surgery
219156224|NCT06835790|DIAGNOSTIC_TEST|gastroduodenal transit|Imaging test that uses the properties of X-rays - after the administration of a radiopaque contrast agent (usually barium) - to visualize the upper digestive tract: the esophagus, stomach, and duodenum (the upper segment of the small intestine).
219727973|NCT06097572|DIAGNOSTIC_TEST|Mast cell activation test|Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
219727974|NCT03451968|OTHER|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
219727975|NCT06461559|DEVICE|antegrade infusion of ileostomy content|infusing the contents of ileostomy output back into intestine of the patient
219727976|NCT00727064|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
219727977|NCT00727064|DRUG|Venlafaxine Extended Release (VEN ER)|
219727978|NCT00346528|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
219727979|NCT00346528|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
219727980|NCT00151515|DRUG|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
219727981|NCT00126737|OTHER|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
219727982|NCT00126737|OTHER|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
219727983|NCT01926392|DRUG|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
219727984|NCT01926392|DRUG|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
219727985|NCT07055724|BIOLOGICAL|Eque-cel CAR-T Therapy|Participants in this arm receive a single infusion of Eque-cel at a dose of 1.0 x 10\^6 CAR-T cells/kg following lymphodepletion preconditioning with fludarabine and cyclophosphamide. Eque-cel is a fully human BCMA-targeted CAR-T cell therapy designed to recognize and eliminate BCMA-expressing cells.
219727986|NCT04539366|PROCEDURE|Biopsy Procedure|Undergo biopsy
219156225|NCT06790901|PROCEDURE|LUNG ULTRASOUND|Determination of atelectsis By Lung Ultrasound Score
219156226|NCT06792162|DRUG|Carilizumab and Apatinib|After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
219727987|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219727988|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219727989|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219727990|NCT04539366|DRUG|Cyclophosphamide|Given IV
219727991|NCT04539366|PROCEDURE|Echocardiography Test|Undergo ECHO
219727992|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
219727993|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
219156227|NCT06783127|DRUG|Olaparib|Olaparib given according the clinical practice to BRCA positive mCRPC patients
219156228|NCT06833684|DEVICE|ICE Treatment|Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
219727994|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
219727995|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
219727996|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219727997|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
219727998|NCT06684002|OTHER|Pilates training|Participants in the Pilates group attended supervised 60-minute sessions twice weekly for eight weeks, led by a certified physiotherapist trained by the Australian Institute of Pilates and Physiotherapy.
219727999|NCT06684002|OTHER|Standard prenatal care and ergonomic advice|The control group received standard prenatal care and ergonomic advice, and did not participate in any exercise training.
219728000|NCT06706102|BIOLOGICAL|Biological tests|Biological tests : cell quantification et characterization
219728001|NCT06706102|DIAGNOSTIC_TEST|MRI|MRI
219728002|NCT06706102|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests
219728003|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
219156229|NCT06833684|PROCEDURE|TAI Standard-of-Care Treatment|Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
219728004|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
219728005|NCT06914869|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
219728006|NCT06914869|DRUG|Carbamazepine|Carbamazepine will be administered per schedule specified in the arm description.
219728007|NCT06914869|DRUG|Efavirenz|Efavirenz will be administered per schedule specified in the arm description.
219728008|NCT06773507|BIOLOGICAL|BC008-1A 900mg|BC008-1A 900mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
219728009|NCT06773507|BIOLOGICAL|BC008-1A 1200mg|BC008-1A 1200mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
219728010|NCT05257707|DIAGNOSTIC_TEST|Molecular biology|"Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples."
219728011|NCT06735014|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs
219728012|NCT06735014|DIAGNOSTIC_TEST|Plasma neurofilament light chain (NfL) quantification|Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
219156230|NCT04906343|PROCEDURE|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
219156231|NCT06783530|BEHAVIORAL|Splint Therapy with Enhanced Doctor-Patient Communication|A structured communication protocol aimed at improving doctor-patient interaction and treatment adherence.
219156232|NCT06783530|DEVICE|Splint Therapy|A custom-fitted occlusal splint designed to alleviate symptoms of temporomandibular disorders (TMD).
219156233|NCT06835179|RADIATION|SBRT|SBRT short course radiotherapy (total dose 30-60 Gy, completed in 3-5 sessions)
219156234|NCT06835179|DRUG|PD-1 Inhibitors|Tislelizumab (200mg on day 1)
219156235|NCT06835179|DRUG|CapeOX + bevacizumab|intravenous administration of bevacizumab (7.5mg/kg on day 1), oxaliplatin (135mg/m² on day 1), as well as oral capecitabine (1g/m² twice daily from day 1 to day 14)
219156236|NCT03817684|DRUG|BPN14770|Drug BPN14770
219156237|NCT03817684|DRUG|Placebo|Placebo
219156238|NCT04626479|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
219156239|NCT04626479|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
219728013|NCT03213704|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219156240|NCT04626479|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
219156241|NCT04626479|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
219156242|NCT04626479|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
219156243|NCT04626479|DRUG|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
219156244|NCT05588700|BEHAVIORAL|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
219728014|NCT03213704|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
219728015|NCT03213704|PROCEDURE|Bone Scan|Undergo a bone scan
219728016|NCT03213704|PROCEDURE|Computed Tomography|Undergo a CT scan
219728017|NCT03213704|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
219728018|NCT03213704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219728019|NCT03213704|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy
219728020|NCT03213704|PROCEDURE|X-Ray Imaging|Undergo an x-ray
219728021|NCT03597594|DRUG|Anti-thymocyte globulin (rabbit)|given intravenously
219728022|NCT03597594|DRUG|Busulfan|given intravenously
219728023|NCT03597594|DRUG|Fludarabine|given intravenously
219728024|NCT03597594|DRUG|Thiotepa|given intravenous infusion
219728025|NCT03597594|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219728026|NCT03597594|OTHER|Donor Lymphocyte Infusion|given intravenous infusion
219156245|NCT05588700|BEHAVIORAL|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
219156246|NCT05588700|BEHAVIORAL|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
219728027|NCT02860000|DRUG|Alisertib|Given PO
219161505|NCT02837510|BEHAVIORAL|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
219728028|NCT02860000|DRUG|Fulvestrant|Given IM
219728029|NCT02860000|OTHER|Laboratory Biomarker Analysis|Correlative studies
219728030|NCT06932666|OTHER|Diet A group|Diet high in fiber (\> 40g/10MJ), high in resistant starch (\> 10g/10MJ), and containing large food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
219728031|NCT06932666|OTHER|Diet B group|Diet low in fiber (\< 10g/10MJ), low in resistant starch (\< 3g/10MJ) and containing small food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
219156247|NCT06832800|COMBINATION_PRODUCT|MDT|"（actually not combination product, but have to select that option in order to delete warning in study desine）MDT method for sNH with the description as follow： 1. diagnosis of neonatal hemolysis：~The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they met one criterion from Category A or two criteria from Category B:~Category A:~1. Positive DAT~2. Significantly elevated ETCOc;~3. Significant morphological abnormalities~Category B:~1. Positive release test;~2. Elevated ETCOc;~3. COHb \> 1.2%;~4. Hb \< 140 g/L or Hct) \< 40%;~5. Ret \> 6%. 2.Exchange transfusion (ET) therapy for sNH： any of the following criteria are met:~(1) TSB ≥ the current ET threshold; (2) TSB \> (ET - 2) mg/dL or the increase of TSB \> 0.5 mg/dL/h, accompanied by abnormal aEEG findings; (3) TSB \> (ET - 2) mg/dL or \> 0.5 mg/dL/h, accompanied by a BIND score of 4-6; (4) Presence of clinical manifestations of acute ABE; (5) BIND score of 7-9."
219156248|NCT06832800|OTHER|control (current management)|"Control (current) method for sNH (severe neonatal hemolysis) with the description as follow：~1. Diagnosis of neonatal hemolysis： The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they have positive Direct Antiglobulin Test (DAT) or positive release test result.~2. Exchange transfusion (ET) therapy for sNH： The neonatal subjects with symptom of hyperbilirubinemia are treated with ET therapy if their Total serum bilirubin (TSB) reaches or exceeds the current exchange transfusion threshold;"
219156249|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
219156250|NCT03035500|OTHER|Educational Intervention|Receive health education
219156251|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
219156252|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
219156253|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
219156254|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
219156255|NCT06834256|BEHAVIORAL|intermittent fasting|Group A participants followed the IF diet for 6 weeks . intermittent fasting , specifically time-restricted feeding (TRF), involves consuming all of one's energy requirements inside an 8-h.The fasting interval was designated as 16 h, and the other 8-h was the eating period . During the 8-h eating window, the patient consumes a well-balanced meal consisting of 55%-65% carbs, 7%-20% protein, and 15%-30% fat .
219156256|NCT06834256|BEHAVIORAL|low volume high intensity interval training|. Group B engaged in low-volume HIIT exercise (aerobic activity) three times weekly for six weeks. The exercise routine consisted of a 5-min warm-up phase at 70% of MHR, followed by four intervals of 2-min maximum effort cycling sessions (4 × 2 HIIT) compared to a sub-maximal workload at 85%-90% of MHR. The participants engaged in four work bouts, with each bout lasting around 4 min and followed by a 4-min rest period. During the workouts, the participants maintained an HR of 60%-70% of their MHR. This resulted in 8 min of intense physical activity during each training session. Additionally, there was a 5-min cooling down phase at 70% of the MHR. The treatment's intensity was adapted based on the modified Bruce protocol.
219156257|NCT06830356|RADIATION|Dose escalation of radiation therapy, based on somatostatin receptor PET imaging|Radiation treatment with higher doses than the standard and defined using PET imaging
219156258|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
219728032|NCT06935812|OTHER|Bimanual Exercise|The bimanual exercise group consists of exercises that involve movements in which both hands are used simultaneously. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
219728033|NCT06935812|OTHER|Finger Exercise|The finger exercise group consists of exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
219728034|NCT06935812|OTHER|Virtual Reality|The virtual reality exercise group consists of hand-tracking game exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
219728035|NCT06943144|OTHER|Dual task Training|In dual-task training, participants walk while performing cognitive tasks such as object identification, counting backward, or solving math problems. These exercises aim to improve coordination, attentional control, and dual-task performance by simultaneously engaging cognitive and motor functions. Training sessions are held twice a week, each lasting 30 minutes with breaks for rest and reflection. Tasks vary in complexity to progressively challenge participants and enhance both cognitive processing and gait stability.
219728036|NCT06943144|OTHER|Embodied Learning|Participants in the embodied learning group engage in activities such as yoga, painting, sensory play, physical storytelling, gesture-based learning, and creative storytelling. These exercises use full-body movement to support learning and cognitive development. Examples include using gestures to reinforce concepts, acting out stories to blend movement with narrative, and engaging in yoga for focus and calmness. Art and sensory activities further promote creativity and tactile exploration. Sessions are held twice a week, lasting 45 to 60 minutes, and are tailored to individual needs and progress.
219728037|NCT05479045|BIOLOGICAL|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
219728038|NCT05479045|DRUG|Toripalimab-tpzi|240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
219156259|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
219156260|NCT04577911|OTHER|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
219728039|NCT06944223|OTHER|Kidney stone formers|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
219728040|NCT06944223|OTHER|Control cohort|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
219728041|NCT06951490|DEVICE|PillSense™|The PillSense™ System is a prescription only device consisting of a reusable receiver and single-use ingestible capsule, intended to be used for the detection of blood in the upper gastrointestinal tract.
219728042|NCT06259890|OTHER|measurement of salt intake|measurement of salt intake without intervention
219728043|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
219728044|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
219728045|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
219728046|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
219728047|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
219728048|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
219728049|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
219728050|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
219156261|NCT06557161|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219156262|NCT06557161|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219728051|NCT02563210|OTHER|airway resistance measurement|assessment of airway resistance
219156263|NCT06557161|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
219156264|NCT03133182|DRUG|Polypharmacy|Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery
219156265|NCT03314753|OTHER|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
219156266|NCT01285999|DEVICE|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
219156267|NCT01285999|DEVICE|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
219156268|NCT05861076|OTHER|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
219156269|NCT05861076|OTHER|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
219156270|NCT05861076|OTHER|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
219728052|NCT04212065|DRUG|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
219728053|NCT05095792|OTHER|Observational - no intervention|This is an observational study with no intervention.
219728054|NCT06694623|PROCEDURE|Apically positioned flap|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures.
219728055|NCT06694623|PROCEDURE|Apically positioned flap with FGG strip|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures. FGG strip was sutured to the apical end of recipient bed.
219728056|NCT04840771|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
219728057|NCT06002074|BEHAVIORAL|Stress Management and Resilience Training Program|One-on-one stress management and resilience consultation by a certified SMART trainer followed by self-guided on-line training consisting of 4 modules.
219728058|NCT04527731|DEVICE|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
219728059|NCT05192785|PROCEDURE|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
219156271|NCT06829407|OTHER|injection time|give an injection
219156272|NCT06829407|OTHER|palm stimulator|give an injection
219156273|NCT06829407|OTHER|injection time and palm stimulator|give an injection
219728060|NCT01229670|OTHER|exercise|"* 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
219728061|NCT00160615|DRUG|Levetiracetam|"* Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use"
219728062|NCT03166631|DRUG|BI 891065|Part A, Part B
219728063|NCT03166631|DRUG|BI 754091|Part B
219728064|NCT00060385|DRUG|CHOP regimen|
219728065|NCT00060385|DRUG|EPOCH regimen|
219728066|NCT00060385|DRUG|cyclophosphamide|
219728067|NCT00060385|DRUG|doxorubicin hydrochloride|
219728068|NCT00060385|DRUG|etoposide|
219728069|NCT00060385|DRUG|prednisone|
219728070|NCT00060385|DRUG|vincristine sulfate|
219728071|NCT00060385|RADIATION|radiation therapy|
219728072|NCT06455280|DRUG|Siplizumab|Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
219728073|NCT06580769|OTHER|Physical activity|Implementation of a physical activity program, executed through immersive virtual reality
219728074|NCT03983369|DEVICE|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
219728075|NCT03983369|OTHER|Placebo|Placebo
219728076|NCT05855551|OTHER|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
219728077|NCT05855551|BEHAVIORAL|Behavior change communication (BCC)|"The BCC strategy has two different components:~* Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, …) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~* Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
219728078|NCT05855551|OTHER|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
219728079|NCT05855551|OTHER|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
219156274|NCT06832228|DRUG|Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）|"All patients will receive the PPR regimen (a total of 4-6 cycles, 28 days for each cycle):~* pomalidomide: 4 mg, orally, once daily from Day 1 to Day 21.~* Rituximab: 375 mg/m², administered on Day 1.~* PD-1: 200 mg, administered on Days 1."
219156275|NCT06284408|OTHER|Centralized Screening Unit Implementation|The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
219161506|NCT06436274|BIOLOGICAL|GARDASIL®9|GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
219728080|NCT01558505|DEVICE|PEB|paclitaxel-eluting balloon angioplasty
219728081|NCT01558505|DEVICE|POBA|conventional balloon angioplasty
219728082|NCT03683537|DIAGNOSTIC_TEST|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
219728083|NCT04731662|BEHAVIORAL|Short sleep|6-hours time-in-bed during weeknights
219728084|NCT04731662|BEHAVIORAL|Variable short sleep|Variable hours of time-in bed during weeknights
219728085|NCT06329622|COMBINATION_PRODUCT|low-protein diet + Ketosteril|low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
219728086|NCT06329622|DIETARY_SUPPLEMENT|low-protein diet|low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
219728087|NCT05397405|DRUG|PCSK9 inhibitor|The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
219728088|NCT04160221|OTHER|12 hours interval|Time interval between treatments
219728089|NCT04160221|OTHER|24 hours interval|Time interval between treatments
219156276|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
219728090|NCT05503732|OTHER|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
219728091|NCT05503732|OTHER|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
219728092|NCT06964243|DEVICE|transcranial magnetic stimulation (TMS)|A brief, short, and repeated magnetic field is generated by 2 copper coils inducing an electric current that will propagate within the targeted cortical areas.
219156277|NCT06829433|OTHER|No intervention|Observational cross-sectional study
219156278|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
219156279|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
219156280|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
219156281|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
219156282|NCT03742245|DRUG|Olaparib|PARP inhibitor
219156283|NCT03742245|DRUG|Vorinostat|HDAC inhibitor
219156284|NCT06549946|BIOLOGICAL|Ixovex-1|Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
219156285|NCT06549946|BIOLOGICAL|Pembrolizumab|Humanised antibody
219156286|NCT03915418|PROCEDURE|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
219728093|NCT06964321|PROCEDURE|intercostal tube drainage|intercostal tube drainage in managing massive malignant pleural effusion (MPE).
219728094|NCT06964321|PROCEDURE|big tail catheter drainage|big tail catheter drainage in managing massive malignant pleural effusion (MPE).
219728095|NCT06964321|PROCEDURE|ultrasound-guided aspiration|ultrasound-guided aspiration in managing massive malignant pleural effusion (MPE).
219156287|NCT06262529|OTHER|Cerebral MRI|Cerebral MRI at 72h / 3 months / 12 months
219156288|NCT06497439|DRUG|Silfamin|2 tablets of Silfamin 150 mg twice daily
219156289|NCT06497439|DRUG|Placebo tablet of Silfamin|2 tablets of Silfamin Placebo twice daily
219156290|NCT05630053|DEVICE|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
219156291|NCT05630053|DEVICE|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
219156292|NCT06117020|DRUG|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
219156293|NCT06389539|OTHER|SBD111 medical food|SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
219156294|NCT06389539|OTHER|Placebo|Placebo
219156295|NCT05469815|BEHAVIORAL|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
219156296|NCT05558527|BEHAVIORAL|social support|social support is provided in the form of social touch (hand holding)
219156297|NCT03970057|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
219156298|NCT03970057|OTHER|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
219156299|NCT04499690|BEHAVIORAL|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
219156300|NCT06360705|DEVICE|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
219156301|NCT06720298|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
219161507|NCT06436274|BIOLOGICAL|Menveo®/Menactra®|Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
219161508|NCT03188796|DRUG|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
219728096|NCT04274465|DIAGNOSTIC_TEST|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
219728097|NCT06963970|OTHER|Remote Community Health Worker support|trained/certified community health worker supporting care partner remotely
219728098|NCT06964178|DEVICE|Experimental: antimicrobial photodynamic therapy (aPDT) after extraction of third molar|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-extraction site for 60 seconds before suturing, to promote healing and disinfection
219728099|NCT05064670|BEHAVIORAL|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
219728100|NCT01562691|PROCEDURE|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
219728101|NCT01562691|PROCEDURE|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
219728102|NCT01562691|PROCEDURE|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
219728103|NCT05348694|DIETARY_SUPPLEMENT|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
219728104|NCT05348694|DIETARY_SUPPLEMENT|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
219728105|NCT04310228|DRUG|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
219728106|NCT04310228|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
219728107|NCT04310228|DRUG|Tocilizumab|The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
219728108|NCT04908527|BEHAVIORAL|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
219728109|NCT05465876|BIOLOGICAL|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
219156302|NCT06433297|PROCEDURE|INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS|"After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique."
219728110|NCT04148755|PROCEDURE|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
219728111|NCT00284934|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
219728112|NCT00284934|DRUG|Tacrolimus|
219728113|NCT00284934|DRUG|Corticosteroids|At a dose of at least 5 mg/day.
219728114|NCT06024161|OTHER|Weight gain|≥5% weight gain
219728115|NCT06024161|OTHER|Weight loss|≥5% weight loss after arthroplasty
219728116|NCT06024161|OTHER|Weight unchanged|\<5% weight change after arthroplasty
219728117|NCT00358579|DRUG|Adrenaline|1 mg
219728118|NCT00358579|DRUG|Vasopressin|40 IU
219156303|NCT02993315|BIOLOGICAL|nDC vaccination|
219156304|NCT02993315|BIOLOGICAL|placebo injection|
219728119|NCT03202550|DRUG|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
219728120|NCT03202550|DRUG|Placebo Comparator|Placebo oral pills
219728121|NCT05031130|OTHER|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
219728122|NCT03309605|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
219156305|NCT04483089|DEVICE|Transcatheter heart valve procedure|Transcatheter treatment of TR with Abbott TriClip™.
219156306|NCT02437123|BEHAVIORAL|The Cedar Project mHealth intervention|
219728123|NCT03309605|DRUG|Placebo|Placebo
219728124|NCT05332795|DRUG|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
219728125|NCT05332795|DRUG|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
219728126|NCT03638271|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
219728127|NCT02131493|DRUG|S-1, Gemcitabine|
219728128|NCT05076123|OTHER|Modified Constraint Induced Therapy and Threshold Electrical Stimulation|M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes.
219728129|NCT00864513|DRUG|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
219161509|NCT03188796|DRUG|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
219161510|NCT04740775|DEVICE|LiquiBand Exceed|Cyanoacrylate glue for closure of surgical wounds
219156307|NCT04302259|DEVICE|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
219156308|NCT04139668|DRUG|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
219156309|NCT04139668|BEHAVIORAL|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
219728130|NCT03160807|DRUG|Levofloxacin|Levolet 500 mg OD for 5 days
219728131|NCT03160807|DRUG|Levofloxacin|Levolet 500 OD for 10 days
219156310|NCT06527066|COMBINATION_PRODUCT|Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
219156311|NCT06527066|OTHER|Gel Sérum Biocompatível All.me Beauty®|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
219156312|NCT03718065|DRUG|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
219156313|NCT03718065|DRUG|Placebo|Placebo comparator.
219156314|NCT03746327|DRUG|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
219161511|NCT04740775|DEVICE|LiquiBand Rapid|Cyanoacrylate glue for closure of surgical wounds
219161512|NCT05155137|DRUG|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
219161513|NCT05155137|BEHAVIORAL|Stroke Riskometer|Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
219161514|NCT05205174|DEVICE|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
219161515|NCT05419505|DRUG|CCH-aaes|Administered by subcutaneous injection.
219161516|NCT05419505|DRUG|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
219161517|NCT05683392|DEVICE|t:slim X2 insulin pump with Control-IQ technology 2.0|t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
219161518|NCT03358875|DRUG|Tislelizumab|Tislelizumab administered by intravenous (IV) infusion
219161519|NCT03358875|DRUG|Docetaxel|Docetaxel administered as an IV infusion over 1 hour
219161520|NCT03599648|BEHAVIORAL|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
219161521|NCT03599648|BEHAVIORAL|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
219161522|NCT05191667|DRUG|AN0025|250 mg or 500 mg Q.D., oral administration
219161523|NCT05530551|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
219161524|NCT04256798|DRUG|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
219161525|NCT04256798|DRUG|Oxygen|Oxygen 80-100%
219161526|NCT04256798|DRUG|Oxygen|Oxygen 21-30 %
219156315|NCT06190392|OTHER|MODS Modified simplified diagnostic strategy|"The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied."
219156316|NCT05154448|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
219233993|NCT04783025|BEHAVIORAL|Blended Gaming COVID-19 Training System (BGCTS)|"BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training."
219233994|NCT04783025|BEHAVIORAL|Usual care, infection control briefing|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
219233995|NCT05298813|BIOLOGICAL|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
219233996|NCT05298813|OTHER|Placebo|Matching Placebo
219233997|NCT02161146|DRUG|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
219233998|NCT02161146|DRUG|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
219233999|NCT02161146|DRUG|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
219234000|NCT02871661|DRUG|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
219728132|NCT05938010|DEVICE|Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
219728133|NCT05403515|OTHER|foot massage|foot massage
219156317|NCT05154448|OTHER|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
219156318|NCT06071858|BEHAVIORAL|Care Coordination|"* The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed.~* The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care.~* The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization."
219156319|NCT06071858|BEHAVIORAL|Individual Peer Support|• Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.
219156320|NCT06071858|BEHAVIORAL|Digital Outreach|• mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.
219156321|NCT06071858|BEHAVIORAL|Cognitive Remediation|"* For participants identified as needing and/or wanting support around cognition.~* The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities."
219234001|NCT02871661|OTHER|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
219234002|NCT02871661|DEVICE|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
219234003|NCT04870398|PROCEDURE|Vital Pulp therapy-Partial pulpotomy|Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
219234004|NCT03628313|OTHER|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
219234005|NCT00309751|DRUG|Pitavastatin|Pitavastatin 4 mg QD
219234006|NCT00309751|DRUG|Atorvastatin|Atorvastatin 20 mg
219728134|NCT05403515|OTHER|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
219728135|NCT04832308|BEHAVIORAL|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
219728136|NCT02083263|DEVICE|Bilevel|3 months
219728137|NCT02083263|DEVICE|PEP mask|3 months
219728138|NCT04472208|DEVICE|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
219728139|NCT04124510|DRUG|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
219728140|NCT00069329|DRUG|anakinra|daily injection of subcutaneous injection
219728141|NCT01562444|OTHER|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
219728142|NCT02201576|DRUG|Bortezomib|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
219728143|NCT02201576|DRUG|Plasma exchanges and intravenous immunoglobulins|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
219728144|NCT03736369|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
219156322|NCT06071858|BEHAVIORAL|Multi-Family Group Therapy|"* Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician.~* Each group may include 5-8 families and include a mixture of in-person and virtual formats.~* These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics."
219156323|NCT05291286|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
219156324|NCT05291286|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
219156325|NCT04090528|BIOLOGICAL|pTVG-HP|pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
219156326|NCT04090528|BIOLOGICAL|pTVG-AR|pTVG-AR is a plasmid DNA
219156327|NCT04090528|DRUG|Pembrolizumab|Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
219156328|NCT04562688|OTHER|CICADAS only|Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. The NB-TCT exercises are adaptive with the task difficulty adjusting on a trial-to-trial and session-by-session basis to the abilities of each individual. A second set of computerized assessments was administered following the intervention period. Participants had to log in to access these assessments and exercises using a study provided username that contained no personally identifiable information.
219156329|NCT04562688|OTHER|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
219156330|NCT04562688|OTHER|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
219156331|NCT04732117|DRUG|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
219156332|NCT04732117|DRUG|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
219156333|NCT03025789|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
219156334|NCT02307812|DRUG|Ramucirumab|Administered intravenously (IV)
219156335|NCT02307812|DRUG|Paclitaxel|Administered IV
219156336|NCT05286385|DEVICE|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
219728145|NCT03736369|DRUG|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
219728146|NCT03736369|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
219728147|NCT03736369|DRUG|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
219728148|NCT00227955|DRUG|Imipramine|
219728149|NCT00227955|BEHAVIORAL|Interpersonal Psychotherapy|
219728150|NCT01795755|BEHAVIORAL|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
219728151|NCT01795755|BEHAVIORAL|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
219728152|NCT01163565|DEVICE|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
219728153|NCT05244837|DRUG|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
219728154|NCT05244837|DRUG|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
219728155|NCT05244837|DRUG|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
219728156|NCT05244837|DRUG|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
219234007|NCT05537012|DIAGNOSTIC_TEST|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
219728157|NCT05244837|DRUG|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
219728158|NCT05415787|OTHER|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
219728159|NCT05415787|OTHER|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
219728160|NCT04761354|PROCEDURE|Unilateral adrenalectomy|
219728161|NCT05552495|DRUG|CKD-386(4) F1|1 Tablet
219728162|NCT05552495|DRUG|CKD-386(4) F2|1 Tablet
219728163|NCT05552495|DRUG|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
219728164|NCT06434779|DEVICE|JETi 6F and 8F Thrombectomy system|To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
219728165|NCT01769118|DRUG|Caffeine|Caffeine will be given according to departmental protocol
219156337|NCT05286385|DEVICE|CP1150 NF|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
219156338|NCT05286385|DEVICE|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
219156339|NCT05286385|DEVICE|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
219156340|NCT04733040|DRUG|MOR202|MOR202 will be administered as an intravenous infusion
219156341|NCT00658827|OTHER|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
219728166|NCT02620111|DIETARY_SUPPLEMENT|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
219728167|NCT02620111|DIETARY_SUPPLEMENT|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
219728168|NCT05050838|OTHER|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
219728169|NCT00666978|BEHAVIORAL|smoking cessation intervention|
219728170|NCT00666978|DRUG|bupropion hydrochloride|
219728171|NCT00666978|GENETIC|gene expression analysis|
219728172|NCT00666978|GENETIC|polymerase chain reaction|
219728173|NCT00666978|OTHER|counseling intervention|
219728174|NCT00666978|OTHER|educational intervention|
219728175|NCT00666978|PROCEDURE|psychosocial assessment and care|
219728176|NCT05039593|OTHER|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
219728177|NCT04561609|OTHER|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
219728178|NCT04561609|OTHER|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
219156342|NCT06471257|COMBINATION_PRODUCT|Budesonide/Albuterol metered dose inhaler, MDI|Combination Product (Drug + Device)
219156343|NCT06471257|COMBINATION_PRODUCT|Albuterol sulfate metered dose inhaler, MDI|Combination Product (Drug + Device)
219156344|NCT05384249|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219156345|NCT05384249|DRUG|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219156346|NCT02789228|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
219156347|NCT06049589|DIETARY_SUPPLEMENT|Coconut Oil|Coconut oil rinsing
219156348|NCT06049589|DRUG|Chlorhexidine mouthwash|Chlorhexidine rinsing
219156349|NCT06049589|OTHER|Water mouthwash|Control with water rinsing
219156350|NCT02723955|DRUG|feladilimab (GSK3359609)|
219156351|NCT02723955|DRUG|GSK3174998|
219156352|NCT02723955|DRUG|Pembrolizumab|
219234008|NCT05162339|OTHER|No intervention was made|No intervention was made
219234009|NCT03609099|DRUG|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
219234010|NCT03609099|DRUG|Placebo|once a day oral treatment during 3 days.
219728179|NCT02386579|PROCEDURE|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
219728180|NCT04332185|PROCEDURE|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
219728181|NCT01341548|DRUG|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
219728182|NCT03005574|BEHAVIORAL|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
219728183|NCT03005574|BEHAVIORAL|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
219728184|NCT01124539|DRUG|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
219728185|NCT02487706|DRUG|Dolutegravir|Dolutegravir 50mg/day per 5 days
219728186|NCT05166928|DEVICE|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
219728187|NCT01590966|DRUG|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
219728188|NCT01590966|DRUG|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
219728189|NCT04240847|PROCEDURE|Skin incision|Skin incision on medial or lateral to tibial tubercle
219728190|NCT06359522|DEVICE|NIRS monitor|NIRS monitoring data will be collected to determine organ perfusion.
219728191|NCT03055195|DRUG|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
219728192|NCT03055195|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
219728193|NCT03615898|OTHER|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
219728194|NCT01665378|DIETARY_SUPPLEMENT|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
219728195|NCT01665378|DIETARY_SUPPLEMENT|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
219728196|NCT01665378|DIETARY_SUPPLEMENT|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
219728197|NCT02568423|DRUG|Mirikizumab - IV|Administered IV
219156353|NCT02723955|DRUG|Docetaxel|
219156354|NCT02723955|DRUG|Pemetrexed|
219156355|NCT02723955|DRUG|Paclitaxel plus Carboplatin|
219728198|NCT02568423|DRUG|Mirikizumab - SC|Administered SC
219728199|NCT02568423|DRUG|Placebo - IV|Administered IV
219728200|NCT02568423|DRUG|Placebo - SC|Administered SC
219728201|NCT01908842|DRUG|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
219728202|NCT01908842|DRUG|BNX sublingual film|Buprenorphine/naloxone sublingual film
219728203|NCT01908842|DRUG|Buprenorphine|Buprenorphine sublingual tablets
219156356|NCT02723955|DRUG|Gemcitabine plus Carboplatin|
219156357|NCT02723955|DRUG|Fluorouracil (5-FU) plus carboplatin or cisplatin|
219156358|NCT02723955|DRUG|Dostarlimab|
219156359|NCT02723955|DRUG|Cobolimab|
219156360|NCT02723955|DRUG|Bintrafusp alfa|
219156361|NCT06750263|OTHER|Balance exercise with clamshell|balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
219728204|NCT00197483|DRUG|Pergolide (drug)|
219728205|NCT00249041|DRUG|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
219728206|NCT00249041|DRUG|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
219728207|NCT03828669|BEHAVIORAL|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
219728208|NCT02184247|DRUG|anhydrous theophylline, 350 mg|
219728209|NCT02184247|DRUG|anhydrous theophylline, 300 mg|
219728210|NCT05875077|DRUG|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
219728211|NCT05875077|DRUG|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
219156362|NCT06750263|OTHER|Balance exercise|Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
219728212|NCT00677287|BIOLOGICAL|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
219728213|NCT00390351|DEVICE|optical coherence tomography|
219728214|NCT00038610|DRUG|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
219728215|NCT00038610|DRUG|Cyclophosphamide|300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
219728216|NCT00038610|DRUG|Doxorubicin|50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
219728217|NCT00038610|DRUG|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
219728218|NCT00038610|DRUG|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
219728219|NCT00038610|DRUG|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
219728220|NCT00038610|DRUG|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
219728221|NCT00038610|DRUG|Mesna|600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
219728222|NCT00038610|DRUG|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
219728223|NCT01027416|DRUG|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
219728224|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
219728225|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
219728226|NCT05362019|DRUG|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
219728227|NCT05362019|OTHER|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
219728228|NCT05362019|OTHER|Family Planning Service|routine family planning service and contraceptive service.
219728229|NCT02894138|DRUG|alteplase|
219728230|NCT02894138|DRUG|Placebo|
219728231|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
219728232|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
219728233|NCT01692587|OTHER|Protein restrictive diet|To begin a reduced protein diet
219728234|NCT05640635|PROCEDURE|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
219728235|NCT05640635|PROCEDURE|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
219234011|NCT03650465|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
219728236|NCT01277731|DRUG|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
219728237|NCT05702619|DRUG|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
219728238|NCT05702619|DIAGNOSTIC_TEST|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
219728239|NCT05702619|DIAGNOSTIC_TEST|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
219728240|NCT05702619|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
219728241|NCT05702619|DIAGNOSTIC_TEST|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
219728242|NCT05702619|DIAGNOSTIC_TEST|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
219728243|NCT05702619|OTHER|Baseline bloods - for germline testing|"Arm 1 -~* 1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~* 1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~* Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~* Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
219728244|NCT05702619|OTHER|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
219728245|NCT05702619|OTHER|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
219728246|NCT00950092|DEVICE|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
219728247|NCT01045265|OTHER|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
219728248|NCT02605694|DRUG|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
219728249|NCT02605694|DRUG|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
219728250|NCT02605694|DRUG|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)"
219156363|NCT04999085|OTHER|Supportive care interventions|Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
219156364|NCT06142890|OTHER|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
219156365|NCT06142890|OTHER|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
219156366|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
219156367|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
219728251|NCT02605694|DRUG|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
219156368|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
219156369|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
219728252|NCT02774720|BEHAVIORAL|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
219728253|NCT02774720|BEHAVIORAL|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
219728254|NCT02930941|DRUG|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
219728255|NCT02930941|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
219728256|NCT03173508|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
219728257|NCT03173508|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
219728258|NCT04319536|OTHER|no intervention|self-sampling
219728259|NCT05100147|PROCEDURE|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
219728260|NCT02979054|DEVICE|T4020|
219728261|NCT02979054|DEVICE|Placebo|
219728262|NCT00289978|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
219728263|NCT00289978|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
219728264|NCT00289978|DRUG|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
219728265|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
219728266|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
219728267|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
219728268|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
219156370|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
219156371|NCT06761638|COMBINATION_PRODUCT|Rhythmic Auditory Stimulation Therapy|Rhythmic auditory stimulation (RAS) is a therapeutic technique that uses rhythmic auditory cues, like a metronome or music, to improve motor control and coordination. It is often used in rehabilitation for conditions such as stroke, Parkinson's disease, and other movement disorders to enhance gait and other motor functions through the synchronization of movements to auditory rhythms.
219156372|NCT06761638|COMBINATION_PRODUCT|Task-Specific Training|Task-specific training is a rehabilitation approach that involves practicing specific tasks or activities to improve the performance of those tasks. It is based on the principle that repetitive practice of functional tasks enhances neuroplasticity, leading to better motor skills and functional recovery, especially in stroke and neurological rehabilitation.
219156373|NCT05896683|DRUG|Lazertinib|Lazertinib will be administered orally.
219156374|NCT06815250|BEHAVIORAL|Influenza and Tdap Vaccination Educational and Learning Module|Influenza and Tdap learning and educational module delivered via website. The module will cover importance of vaccination for both pregnant women and infant, safety and efficacy of the influenza and TdaP vaccines, timing of vaccination, and addressing common concerns and misconceptions.
219156375|NCT04907474|DRUG|tropicamide-phenylephrine fixed combination ophthalmic solution|Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
219156376|NCT06835491|DRUG|Amiodarone|Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.
219156377|NCT04077073|DEVICE|ReIn-Hand|ReIn-Hand assists the hand opening
219156378|NCT04077073|DEVICE|Robot|Robot supports the shoulder load
219156379|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
219156380|NCT06784323|BEHAVIORAL|Catered diet|For a period of 8 weeks the participant will receive catered food, the study team will provide the participants breakfast, lunch and dinner. Participants will receive catered food for 3 daily meals, and record daily food intake. Catered diet will be sent to participants' homes on a weekly basis. The diet will consist of primarily whole foods with few additives, with a focus on Hispanic cultural foods.
219156381|NCT06784323|BEHAVIORAL|Diet guidance sessions|Participants will receive virtual weekly diet guidance with a dietitian regarding food safety preparation methods and cooking practices. Patients will receive weekly gift cards for grocery stipend. On average, initial counseling session with dietitian will last 30 minutes, and 7 follow-up sessions will last 20 minutes.
219156382|NCT06784323|BEHAVIORAL|Dietary counseling|Participants will receive dietary counseling weekly on Zoom for up to 30 minutes. Dietitian will meet with participants to explain benefits of adhering to diet therapy.
219728269|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200 mg Q2W
219728270|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q3W
219728271|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q2W
219728272|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200mg Q2W
219728273|NCT05587647|OTHER|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress"
219728274|NCT04249635|DIETARY_SUPPLEMENT|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
219728275|NCT00645138|PROCEDURE|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
219728276|NCT00645138|PROCEDURE|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
219728277|NCT04324697|PROCEDURE|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
219728278|NCT05281640|BEHAVIORAL|Affect Dysregulation intervention|See relevant study arm for description
219728279|NCT05281640|BEHAVIORAL|Negative Self Concept intervention|See relevant study arm for description
219728280|NCT05281640|BEHAVIORAL|Disturbed Relationships intervention|See relevant study arm for description
219728281|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal brushing|Duodenal mucosal brushing will be performed at duodenal bulb.
219728282|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal biopsy|Duodenal mucosal biopsy will be performed at duodenal bulb.
219728283|NCT00267319|DRUG|Glatiramer acetate|
219728284|NCT00720083|DRUG|cisplatin|Given IV
219728285|NCT00720083|DRUG|vandetanib|Given orally
219728286|NCT00720083|RADIATION|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
219156383|NCT06784323|BEHAVIORAL|Feedback sessions|Participants will be involved in one-time 50-minute feedback session over Zoom with dietitian and principal investigator. During the session, participants will discuss preferred foods/recipes during active disease, likeability of recipes, ease of recipe preparation, dietary adherence, and healthy food affordability.
219156384|NCT04301089|DEVICE|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
219156385|NCT06830148|OTHER|Post-frenotomy manual manipulation|Parents assigned to the treatment group will be instructed to perform post-frenotomy stretches and exercises four times daily, after every other feed, until the time of their postoperative visit 2-3 weeks later.
219156386|NCT06549634|DRUG|Daratumumab|Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration
219156387|NCT06366672|BIOLOGICAL|JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection|live, nonreplicating vaccine delivered according to the FDA approved package insert
219728287|NCT01341938|DRUG|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
219728288|NCT01341938|BEHAVIORAL|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
219728289|NCT01341938|BEHAVIORAL|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
219728290|NCT01967277|DEVICE|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
219156388|NCT06366672|PROCEDURE|Phlebotomy|Research blood draw
219156389|NCT06366672|PROCEDURE|Research bronchoscopy|Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.
219156390|NCT06366672|PROCEDURE|Skin punch biopsy|Skin punch biopsy performed with topical anesthesia.
219156391|NCT06366672|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration performed with local anesthesia.
219728291|NCT01967277|DEVICE|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
219728292|NCT04017910|DEVICE|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
219728293|NCT01676350|PROCEDURE|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
219728294|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
219728295|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
219728296|NCT03539198|DRUG|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
219728297|NCT03539198|RADIATION|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
219728298|NCT01975649|DRUG|Tribulus Terrestris|patients will use 750 mg/day during 120 days
219728299|NCT01975649|OTHER|Placebo|patients will use placebo pills with the same shape of the drug
219728300|NCT00585585|DRUG|betahistine dihydrochloride|oral, 50-300 mg, daily
219728301|NCT06260839|PROCEDURE|magnetic resonance neurography|preoperative magnetic resonance neurography and assisted design of surgical approach
219728302|NCT06260839|PROCEDURE|no magnetic resonance neurography|Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
219728303|NCT06323720|OTHER|Quantitative Sensory Testing|Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
219728304|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
219728305|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
219728306|NCT00103506|DRUG|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
219728307|NCT02288871|RADIATION|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
219156392|NCT03873779|DEVICE|The ZELTIQ System|Participants received cryolipolysis treatment in submental and submandibular areas using the CoolSculpting System and CoolMini applicator for fat layer reduction on Day 0, which was followed with a radiofrequency treatment performed 12 weeks after CoolSculpting.
219156393|NCT03860272|DRUG|Botensilimab|An Fc-engineered anti-CTLA-4 monoclonal antibody
219156394|NCT03860272|DRUG|Balstilimab|A fully human monoclonal anti-PD-1 antibody
219156395|NCT00766584|OTHER|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
219156396|NCT06084221|BEHAVIORAL|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
219156397|NCT06084221|BEHAVIORAL|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
219156398|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
219728308|NCT05916924|OTHER|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
219156399|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
219156400|NCT05144321|OTHER|Impact of environment upon obstetrical|Impact of environment upon obstetrical
219156401|NCT05144321|OTHER|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
219156402|NCT04270526|DRUG|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
219728309|NCT00585169|DRUG|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
219728310|NCT05740384|DEVICE|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
219728311|NCT05214950|DEVICE|ORI monitoring|Oxygen reserve index monitoring during the surgery
219728312|NCT00710970|DRUG|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
219728313|NCT01028560|BIOLOGICAL|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
219156403|NCT04270526|DRUG|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
219156404|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
219156405|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
219156406|NCT04188379|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
219156407|NCT04188379|OTHER|Placebo|Intravenous infusion of placebo
219156408|NCT06780735|PROCEDURE|The margin-positive rate using the localization technique|Localization of breast cancer using indocyanine green fluorescence (ICG-F)
219156409|NCT03043599|RADIATION|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
219156410|NCT03043599|DRUG|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
219156411|NCT03043599|DRUG|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
219728314|NCT01028560|OTHER|Standard of care|standard of care asthma and allergy treatment
219728315|NCT05656976|OTHER|Provision of self sampling device by the GP|In a group of 45 GP practices, over a course of 9 months, all long-term unscreened women with a GMD will be addressed by their GP when they consult for any reason. The GP will discuss the pros and cons of screening for cervical cancer, the various options for screening for cervical cancer including the possibility of using a SSD. For this, the GP can use on accessible brochure and video materials. After the woman agrees, she is given a self-taking kit that she can use when and where it suits her and send it to the lab with the prepaid envelope. The woman is informed of the result of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g. via letter, by phone or during the next consultation).
219156412|NCT06234943|OTHER|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
219156413|NCT06789614|DRUG|intravenous CYCLIZINE ,Metaclopromide|US giuded measure of GRV in bariatrics surgery upon recieving drugs of study
219156414|NCT05704283|DEVICE|Ultrasound Imaging|Undergo 3D-US
219156415|NCT05428033|DRUG|centanafadine capsule|capsule
219156416|NCT05428033|OTHER|placebo capsule|capsule
219156417|NCT06004167|RADIATION|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
219156418|NCT02740491|OTHER|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
219156419|NCT05793593|OTHER|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
219156420|NCT05793593|OTHER|Colorectal Cancer (CRC) education alone|CRC education alone.
219156421|NCT05780528|OTHER|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
219156422|NCT05780528|OTHER|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
219156423|NCT05780528|OTHER|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
219156424|NCT06099249|DEVICE|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
219156425|NCT06958159|PROCEDURE|Endoscopic Stricturotomy|"Endoscopic stricturotomy is performed using either a needle knife or an insulated-tip (IT) knife (Olympus, Tokyo, Japan), selected based on the location and morphology of the stricture. Electrosurgical cutting is delivered using the Endo Cut I mode on an ERBE VIO 300D or VIO 3 electrosurgical unit (Erbe Elektromedizin, Germany), with standardized settings: Effect 3, Cut Duration 1, Cut Interval 3.~Radial incisions are initially made across the stricture, followed by circumferential cutting in non-ulcerated areas to relieve luminal narrowing. The goal is to achieve adequate stricture opening while minimizing the risk of perforation."
219156426|NCT06958159|PROCEDURE|Endoscopic Balloon Dilation|"Endoscopic balloon dilation is performed using a Controlled Radial Expansion (CRE) balloon (Boston Scientific, USA). The size of the balloon is selected based on the estimated diameter of the stricture, presence or absence of ulceration, and the anatomical location.~The balloon is gradually inflated under endoscopic visualization to a maximum diameter of 12-20 mm, tailored to the baseline luminal narrowing. The balloon is maintained at full inflation for 60 seconds to achieve controlled and uniform dilation of the stricture."
219156427|NCT03295747|DRUG|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
219156428|NCT06958198|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
219156429|NCT06958198|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
219156430|NCT06958198|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
219728316|NCT05656976|OTHER|Provision of self sampling device by letter|In the second arm, a second group of 45 GP practices in Flanders will be recruited. With the intervention of the Centre for Cancer Prevention (Flanders), 25 at randomly selected long-term unscreened women with a Global Medical Form (in dutch: 'Globaal Medisch Dossier, GMD) in one of these practices will receive an envelope containing a letter of invitation from their GP for cervical cancer screening, a brochure with the advantages and disadvantages of cervical cancer screening and more specifically the use of a self-taking kit, and a self-taking kit. If the woman wishes, she can use the kit when and where it suits her and send it to the lab with the pre-paid envelope. As in arm A, the woman will be informed of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g., by letter, by phone or during the next consultation). All women will receive a study-related reminder letter after 4 months.
219728317|NCT01894646|RADIATION|Positron Emission Tomography (PET) Imaging|
219728318|NCT03055221|DRUG|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
219728319|NCT04264962|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
219728320|NCT04264962|OTHER|Routine medical care|Routine medical care
219728321|NCT03614585|BEHAVIORAL|12 weeks of High-intensity Interval Training|Cardiovascular exercise
219728322|NCT03614585|BEHAVIORAL|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
219728323|NCT04401631|DEVICE|Blood Collection|"Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)"
219728324|NCT01243424|DRUG|linagliptin|linagliptin tablets 5mg QD
219728325|NCT01243424|DRUG|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
219728326|NCT01243424|DRUG|linagliptin placebo|linagliptin placebo
219728327|NCT01243424|DRUG|glimepiride placebo|glimepiride placebo
219728328|NCT02598999|DRUG|ALX-009|Solution for inhalation administered through nebulization
219728329|NCT02598999|DRUG|OSCN-|Solution for inhalation administered through nebulization
219728330|NCT02598999|DRUG|bLF|Solution for inhalation administered through nebulization
219728331|NCT02598999|DRUG|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
219728332|NCT05862441|DRUG|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
219156431|NCT06958198|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
219156432|NCT02229812|DRUG|alteplase|
219156433|NCT05693129|DRUG|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
219156434|NCT00290069|DRUG|Tacrolimus|
219728333|NCT05862441|DRUG|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
219728334|NCT02011464|DRUG|Exparel|Exparel is infiltrated into posterior compartment for pain control
219728335|NCT02011464|OTHER|Saline|Saline is infiltrated into posterior compartment for control
219728336|NCT03973593|BEHAVIORAL|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
219728337|NCT00732693|DRUG|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
219728338|NCT00732693|DRUG|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
219728339|NCT01390935|OTHER|guideline adherence|guideline adherence of physician
219728340|NCT02645708|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
219728341|NCT02645708|PROCEDURE|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
219156435|NCT00290069|DRUG|Rapamycin|
219156436|NCT02002845|DEVICE|robotic surgery using the da Vinci Surgical System|
219156437|NCT02566902|DEVICE|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
219156438|NCT02566902|DEVICE|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
219156439|NCT02566902|DRUG|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
219156440|NCT02566902|PROCEDURE|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
219156441|NCT02566902|PROCEDURE|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
219156442|NCT04138316|DRUG|Candesartan|Treatment with Candesartan
219156443|NCT00321867|PROCEDURE|Graft augmented posterior repair|Posterior repair with graft
219156444|NCT00321867|PROCEDURE|Control|Native tissue repair
219156445|NCT05488080|BEHAVIORAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
219728342|NCT05001503|DEVICE|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
219728343|NCT05991479|OTHER|Pilates exercises|"Pilates exercises:~The subjects will receive Pilates training (3 sessions/week) for 8 weeks. The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork)."
219156446|NCT06360458|DRUG|Methylprednisolone sodium succinate|Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
219156447|NCT06360458|DRUG|Placebo (normal saline)|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
219234012|NCT03512782|OTHER|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
219728344|NCT05991479|OTHER|Traditional physical therapy programme:|"All patients will receive a traditional physical therapy programme consisting of 45 minutes per session of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles. Strengthening exercises for hip, knee, ankle, and foot muscles. Deep friction massage for scar management."
219728345|NCT01368770|OTHER|Coronary CTA|Coronary CTA using standard protocols
219728346|NCT01368770|OTHER|Stress MPI SPECT|Stress MPI using standard protocols
219728347|NCT03896360|BEHAVIORAL|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
219728348|NCT03896360|BEHAVIORAL|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
219728349|NCT00754039|DRUG|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
219234013|NCT05532072|DRUG|Rapamycin|Rapamycin plus Methylprednisolone
219234014|NCT05532072|DRUG|Methylprednisolone|Methylprednisolone Alone
219728350|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
219728351|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
219728352|NCT00397930|PROCEDURE|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
219728353|NCT00397930|PROCEDURE|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
219728354|NCT01215240|DEVICE|Peritoneal dialysis|Prophylactic peritoneal dialysis
219728355|NCT03843970|DRUG|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
219728356|NCT03843970|DRUG|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
219728357|NCT00805220|OTHER|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
219728358|NCT01972971|OTHER|patient education|one by one patient education
219234015|NCT03388736|BEHAVIORAL|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
219234016|NCT02189759|OTHER|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
219728359|NCT02296801|DRUG|Letrozole|
219728360|NCT02296801|DRUG|palbociclib|
219728361|NCT03043820|DRUG|Raloxifene|Oral selective estrogen receptor modulator (SERM).
219728362|NCT03043820|DRUG|Placebo|Tablets identical in form and color to intervention.
219728363|NCT03012152|PROCEDURE|Standard conservative breast surgery|
219728364|NCT03012152|PROCEDURE|Oncoplastic breast surgery|
219728365|NCT06040450|OTHER|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
219728366|NCT04468009|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
219728367|NCT05540600|DRUG|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
219728368|NCT05540600|DRUG|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
219728369|NCT03682393|DRUG|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
219728370|NCT03682393|DRUG|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
219728371|NCT05573737|OTHER|education|education about ubilical cord care
219728372|NCT01441414|BIOLOGICAL|PF-04856884|15 mg/kg/week intravenously \[IV\] until toxicity or disease progression
219728373|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
219728374|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
219728375|NCT01881633|DRUG|ISU302|
219728376|NCT01881633|DRUG|Placebo|
219728377|NCT05639439|DEVICE|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
219728378|NCT05639439|DEVICE|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
219728379|NCT05639439|DEVICE|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
219728380|NCT05639439|DEVICE|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
219728381|NCT01820104|DRUG|lansoprazole, 30 mg per day for 6 days|
219728382|NCT03737032|DEVICE|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
219728383|NCT03737032|DEVICE|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
219728384|NCT03737032|DEVICE|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
219728385|NCT01377311|PROCEDURE|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
219728386|NCT02441257|PROCEDURE|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
219728387|NCT02441257|PROCEDURE|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
219728388|NCT04286503|DRUG|Carrimycin|Carrimycin
219728389|NCT04286503|DRUG|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
219728390|NCT04286503|DRUG|basic treatment|basic treatment
219728391|NCT01773889|DRUG|Denileukin Diftitox/SC Pegylated IFNα-2a|
219728392|NCT04955093|DEVICE|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
219728393|NCT05181631|OTHER|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
219728394|NCT01141868|BEHAVIORAL|Internet Intervention|online treatment for insomnia
219728395|NCT03749174|PROCEDURE|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
219728396|NCT03834259|PROCEDURE|sitting position|keeping the patient in a sitting position after spinal anaesthesia
219728397|NCT03834259|PROCEDURE|supine position|keeping the patient in supine position after spinal anaesthesia
219728398|NCT00732459|DEVICE|Electro-acupuncture preconditioning|electro-acupuncture
219728399|NCT03391154|DRUG|levothyroxin|90 female received levothroxine
219728400|NCT00272558|DRUG|Carboplatin and Vinorelbine|
219728401|NCT02058407|DRUG|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
219728402|NCT02058407|DRUG|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
219728403|NCT02058407|DRUG|Placebo solution|Matching placebo to GSK2793660 solution
219728404|NCT02058407|DRUG|Placebo capsule|Matching placebo to GSK2793660 capsule
219728405|NCT03882372|DEVICE|Nasal high flow|See arm description.
219728406|NCT00295412|DRUG|quetiapine (drug)|
219728407|NCT05267002|PROCEDURE|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
219156448|NCT06122298|OTHER|fMRI|A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.
219156449|NCT06122298|OTHER|Ecological Momentary Assessment|studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour
219156450|NCT05938426|DEVICE|ET-101|Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
219156451|NCT05938426|DEVICE|Sham Device|Sham device has only cognitive function test excluding training programs.
219156452|NCT02411084|BIOLOGICAL|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
219156453|NCT02411084|BIOLOGICAL|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
219156454|NCT03825575|DEVICE|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
219156455|NCT01238042|DRUG|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
219156456|NCT05883696|OTHER|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~1. Assessments of palliative care needs~2. Initiating palliative care 2D. End of life care.~3. After death. In this study only the first part of the S-PCG will be used."
219156457|NCT05990452|DRUG|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
219156458|NCT00459212|DRUG|GTI-2040|Given IV
219156459|NCT00459212|PROCEDURE|pharmacological study|Correlative study
219156460|NCT00459212|PROCEDURE|laboratory biomarker analysis|Correlative study
219156461|NCT04879368|DRUG|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
219156462|NCT04879368|BIOLOGICAL|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
219156463|NCT04879368|DRUG|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
219156464|NCT04879368|DRUG|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
219156465|NCT04879368|DRUG|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
219156466|NCT04879368|DRUG|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
219156467|NCT02652585|DRUG|Naltrexone|
219156468|NCT02652585|DRUG|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
219156469|NCT04291638|BEHAVIORAL|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
219728408|NCT00337961|PROCEDURE|Optic Nerve Sheath Fenestration|
219728409|NCT02731768|BEHAVIORAL|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
219156470|NCT04291638|BEHAVIORAL|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
219156471|NCT03000595|DRUG|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
219156472|NCT03000595|DRUG|Placebo|The vehicle cream
219156473|NCT04209712|BIOLOGICAL|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
219728410|NCT02731768|BEHAVIORAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
219728411|NCT02731768|DEVICE|Fitbit Zip|
219728412|NCT02731768|DEVICE|Digital body weight scale|
219728413|NCT03646188|DRUG|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
219728414|NCT03646188|DRUG|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
219728415|NCT03646188|DRUG|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
219728416|NCT03646188|DRUG|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
219728417|NCT03646188|DRUG|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
219728418|NCT01271829|DIETARY_SUPPLEMENT|Avocado supplement|Calories from avocados replace calories of the control lunch
219728419|NCT01271829|DIETARY_SUPPLEMENT|Avocado included|Calories from avocados will be added to calories from the control lunch
219728420|NCT05001412|DRUG|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
219728421|NCT01451788|DEVICE|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
219728422|NCT01638299|DEVICE|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
219728423|NCT00252473|DEVICE|MedTec S-frame Immobilization Masks|
219728424|NCT00617903|DRUG|Azelaic acid|15% foam to be applied topically twice daily
219728425|NCT00617903|DRUG|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
219728426|NCT01544075|BEHAVIORAL|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
219728427|NCT01544075|BEHAVIORAL|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
219156474|NCT03941665|DEVICE|Gelronate|Gel for topical use
219156475|NCT03941665|OTHER|Aloevera|Gel for topical use
219728428|NCT00281853|PROCEDURE|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
219728429|NCT05768464|DRUG|Toripalimab|240mg intravenously every 3 weeks
219156476|NCT05412017|DIAGNOSTIC_TEST|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
219156477|NCT05239156|DEVICE|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
219156478|NCT03676413|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
219156479|NCT03676413|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
219156480|NCT03676413|DRUG|Placebo|twice daily inhalation throughout the study
219728430|NCT05768464|DRUG|Axitinib|5mg orraly twice daily
219728431|NCT05156125|DRUG|VTX002|Dose A tablet administered orally once daily
219728432|NCT05156125|DRUG|VTX002|Dose B Tablet administered orally once daily
219728433|NCT05156125|DRUG|Placebo|Placebo Tablet for VTX002 administered orally once daily
219728434|NCT04863807|PROCEDURE|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
219728435|NCT06053476|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
219728436|NCT06053476|PROCEDURE|Single-shot paravertebral block|At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
219728437|NCT06053476|PROCEDURE|Late chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system"
219728438|NCT06053476|PROCEDURE|Early chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system"
219728439|NCT00768638|DRUG|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
219728440|NCT00768638|DRUG|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
219728441|NCT03110276|DRUG|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
219728442|NCT03110276|DRUG|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
219728443|NCT00556959|DRUG|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
219728444|NCT00556959|DRUG|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
219728445|NCT00556959|DRUG|placebo|placebo tablets for 8 weeks
219728446|NCT02996786|DIETARY_SUPPLEMENT|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
219728447|NCT02996786|OTHER|Placebo|Consisting of corn starch and carboxymethyl cellulose
219728448|NCT03166956|DIETARY_SUPPLEMENT|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
219728449|NCT05145036|BEHAVIORAL|Tai-Chi|Tai Chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty.
219728450|NCT05145036|BEHAVIORAL|Comprehensive training|There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down.
219728451|NCT05993325|BIOLOGICAL|AdCLD-CoV19-1 OMI|3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
219728452|NCT05993325|BIOLOGICAL|Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)|1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle
219728453|NCT00471042|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
219728454|NCT01332162|DEVICE|Biventricular pacing|All patients will be pacing during two years
219728455|NCT01332162|DEVICE|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
219728456|NCT05075772|DRUG|BI 765080|BI 765080
219728457|NCT01685554|DEVICE|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
219728458|NCT01685554|DEVICE|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
219728459|NCT04303637|BEHAVIORAL|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
219728460|NCT00858052|DEVICE|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
219728461|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
219728462|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
219728463|NCT01225744|DRUG|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA \> 2 m2 ."
219728464|NCT01225744|DRUG|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
219728465|NCT01225744|DRUG|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
219728466|NCT01225744|DRUG|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
219728467|NCT02917499|DEVICE|TMS|Transcranial magnetic stimulation
219728468|NCT01286649|OTHER|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
219728469|NCT01286649|OTHER|Cell medium|Cell medium
219728470|NCT02843386|DRUG|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
219728471|NCT02843386|OTHER|Intensive surveillance|"Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
219728472|NCT00158457|DRUG|Tenofovir (TDF)|
219728473|NCT00158457|DRUG|Emtricitabine (FTC)|
219728474|NCT00158457|DRUG|Efavirenz (EFV)|
219728475|NCT05189197|DRUG|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
219728476|NCT01677065|DRUG|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
219728477|NCT01677065|DRUG|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
219728478|NCT01058005|DRUG|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
219728479|NCT01058005|DRUG|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
219728480|NCT01058005|DRUG|glatiramer acetate|20 mg subcutaneous injection once daily
219156481|NCT05688423|BEHAVIORAL|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
219728481|NCT05848375|PROCEDURE|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
219728482|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
219728483|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
219728484|NCT04162275|DRUG|Finamine tablets|taken Finamine tablets orally
219728485|NCT04162275|DRUG|Placebo tablets|taken Placebo tablets orally
219728486|NCT00927186|DRUG|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
219728487|NCT00927186|DRUG|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
219728488|NCT02298283|DRUG|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
219728489|NCT02298283|DRUG|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
219728490|NCT02298283|DRUG|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
219728491|NCT02298283|DRUG|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
219728492|NCT02298283|DRUG|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
219728493|NCT02298283|DRUG|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
219234017|NCT02189759|OTHER|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
219728494|NCT02298283|DRUG|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
219728495|NCT02298283|DRUG|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
219728496|NCT02298283|DRUG|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
219728497|NCT02298283|RADIATION|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
219728498|NCT01698008|OTHER|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
219728499|NCT03968627|OTHER|Rehabilitative intervention|intensive multidisciplinar rehabilitation
219728500|NCT00520442|DRUG|ibuprofen|
219728501|NCT00520442|DRUG|acetamin w codeine|
219728502|NCT00949663|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
219728503|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
219728504|NCT00949663|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
219728505|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
219728506|NCT01436292|DRUG|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS."
219728507|NCT00332098|BEHAVIORAL|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
219156482|NCT05688423|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
219156483|NCT03951142|DRUG|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
219728508|NCT00332098|BEHAVIORAL|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
219728509|NCT02287025|DRUG|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
219728510|NCT02287025|OTHER|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
219728511|NCT02287025|OTHER|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
219728512|NCT00385229|DRUG|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
219728513|NCT05690191|DRUG|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
219728514|NCT05690191|DRUG|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
219728515|NCT05690191|DRUG|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
219728516|NCT03494192|OTHER|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
219728517|NCT03494192|OTHER|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
219728518|NCT00006135|DRUG|acyclovir|
219728519|NCT03099863|DRUG|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
219728520|NCT03099863|PROCEDURE|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
219728521|NCT03099863|DRUG|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
219728522|NCT03407911|OTHER|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
219728523|NCT01706380|BEHAVIORAL|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
219728524|NCT01706380|BEHAVIORAL|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
219728525|NCT02145520|DRUG|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
219728526|NCT02145520|OTHER|placebo|use of placebo with standard therapy
219728527|NCT05832814|BEHAVIORAL|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
219728528|NCT05832814|BEHAVIORAL|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
219728529|NCT06134895|DRUG|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
219728530|NCT06134895|DRUG|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
219728531|NCT01271166|DRUG|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
219156484|NCT05185245|PROCEDURE|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
219156485|NCT04880876|DRUG|25mg Eluxadoline|Oral Tablets
219156486|NCT04880876|DRUG|100mg Eluxadoline|Oral Tablets
219156487|NCT03303651|PROCEDURE|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
219156488|NCT03303651|PROCEDURE|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
219728532|NCT00799864|DRUG|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
219728533|NCT00799864|DRUG|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
219728534|NCT00799864|DRUG|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
219728535|NCT00799864|DRUG|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
219728536|NCT00799864|DRUG|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
219728537|NCT00799864|DRUG|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
219728538|NCT02659228|DEVICE|EEG recording|EEG recording with anesthetic (DIPRIVAN)
219728539|NCT02659228|DRUG|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
219156489|NCT04501744|DRUG|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
219156490|NCT04501744|DRUG|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
219156491|NCT04501744|DRUG|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
219156492|NCT04501744|DRUG|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
219156493|NCT04501744|DRUG|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
219156494|NCT04501744|DRUG|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
219156495|NCT04501744|DRUG|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
219156496|NCT03340857|OTHER|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
219156497|NCT00476346|DIETARY_SUPPLEMENT|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
219156498|NCT02657733|DEVICE|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
219156499|NCT02657733|DEVICE|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
219156500|NCT02657733|DEVICE|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
219156501|NCT02036424|DRUG|Ozurdex|intravitreal steroid
219156502|NCT02036424|DRUG|Bevacizumab|antiVEGF
219156503|NCT05773313|BEHAVIORAL|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
219156504|NCT01905462|OTHER|Data Collection|Analyses of data collected within the CPRD GOLD database.
219156505|NCT01905462|BIOLOGICAL|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
219156506|NCT02748317|DRUG|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
219156507|NCT03966846|DIETARY_SUPPLEMENT|Kefir|
219156508|NCT03966846|DIETARY_SUPPLEMENT|Milk|
219156509|NCT04050644|DRUG|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
219728540|NCT06384703|DIAGNOSTIC_TEST|Taking blood for kit study|Taking blood for kit study (Elisa kit)
219728541|NCT05100966|OTHER|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
219728542|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
219156510|NCT04050644|DRUG|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
219728543|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
219728544|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
219728545|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
219728546|NCT03536377|OTHER|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
219728547|NCT00910741|DRUG|Nanoplatin (NC-6004) and Gemcitabine|
219728548|NCT02346370|DRUG|PEGylated recombinant human hyaluronidase PH20|
219728549|NCT02346370|DRUG|Docetaxel|
219728550|NCT02200575|DRUG|Telmisartan|
219728551|NCT02734147|DRUG|Ascorbic Acid|
219728552|NCT02734147|OTHER|Normal Saline|
219728553|NCT03024164|OTHER|Treatment following current guidelines|Treatment following current guidelines
219728554|NCT06009497|DRUG|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
219728555|NCT06009497|DRUG|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
219728556|NCT05931601|DRUG|Noradrenaline|See arm description
219728557|NCT06179680|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
219728558|NCT05611905|COMBINATION_PRODUCT|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
219728559|NCT05611905|DRUG|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
219728560|NCT04080232|DEVICE|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
219728561|NCT06150014|DRUG|Placebo|TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
219728562|NCT06150014|DRUG|TQA3605 tablets|TQA3605 inhibits viral replication.
219728563|NCT06150014|DRUG|Entecavir dispersible tablets|Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
219156511|NCT04421924|PROCEDURE|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
219728564|NCT06150014|DRUG|Tenofovir disoproxil fumarate tablet|Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
219728565|NCT06150014|DRUG|Tenofovir alafenamide fumarate tablet|Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
219728566|NCT06960616|OTHER|Changes in traditional follow-up|Traditional follow-up includes the following visits after activation: 1-week, 1-month, 3-months, 6-months and 1 year. With the intervention used, the 1-week follow-up is removed.
219728567|NCT06960616|OTHER|Population mean mapping|Traditional mapping at activation involves the measurement of at least 5 electrodes (both T-levels and C-levels). The intervention uses a population mean mapping strategy where there is a pre-set dynamic range of 46 CL with a spot check of C-levels.
219156512|NCT04421924|PROCEDURE|standard of care|2\) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
219156513|NCT04847414|DIAGNOSTIC_TEST|HbA1C, other investigations|we will do some necessary investigations for prospective group
219156514|NCT01634893|DRUG|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
219728568|NCT05098236|OTHER|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
219728569|NCT05098236|OTHER|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
219728570|NCT06290024|DEVICE|A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function|Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
219728571|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
219728572|NCT03528577|DRUG|Zero-dose|Treatment A
219728573|NCT03528577|DRUG|90 mcg of PROAIR® HFA|Treatment B
219728574|NCT03528577|DRUG|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
219728575|NCT03528577|DRUG|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
219728576|NCT06236997|DRUG|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
219728577|NCT06236997|RADIATION|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
219728578|NCT06236997|DRUG|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
219728579|NCT02407977|OTHER|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
219156515|NCT00713063|BEHAVIORAL|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
219156516|NCT00713063|BEHAVIORAL|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
219156517|NCT00711581|DEVICE|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
219156518|NCT00332241|DRUG|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
219156519|NCT00332241|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
219156520|NCT04667780|DRUG|Colchicine|Colchicine tablet 0.5 mg
219156521|NCT04667780|DRUG|Standard COVID-19 care|As per the hospital guidelines
219156522|NCT03984357|DRUG|PD-1 blocking antibody|"1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
219156523|NCT03984357|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
219156524|NCT03984357|DRUG|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
219728580|NCT04882215|BEHAVIORAL|GMT combined with WMU Training|"GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial."
219728581|NCT04263532|DEVICE|Modified BiPAP A40 with Vector Algorithm (Vector)|The Modified BiPAP A40 with Vector Algorithm (Vector) is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
219728582|NCT04263532|DEVICE|Modified BiPAP A40 with Standard of Care Settings|The Modified BiPAP A40 with Standard of Care settings is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
219728583|NCT03911687|BEHAVIORAL|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
219728584|NCT01931631|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
219728585|NCT01931631|BEHAVIORAL|ADA diet|Diet in accordance with the American Diabetes Association
219728586|NCT03110432|DRUG|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
219728587|NCT03110432|DRUG|Standard lipid lowering therapy|drug use according to the respective product labelling
219728588|NCT04098302|DRUG|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
219728589|NCT04098302|DRUG|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
219728590|NCT05123417|DIAGNOSTIC_TEST|Follow up|Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
219728591|NCT03067415|DRUG|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
219728592|NCT03067415|DRUG|D565(Latanoprost 50㎍/㎖)|D565 once daily
219728593|NCT06359561|DEVICE|cervical lead placement|implant of cervical lead neurostimulation, using saluda medical devices
219728594|NCT04998110|OTHER|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
219728595|NCT01810952|DRUG|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
219728596|NCT01810952|DRUG|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
219728597|NCT01810952|DRUG|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
219156525|NCT03984357|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
219156526|NCT03647969|DRUG|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
219728598|NCT01290731|DRUG|TMC435|100-mg capsule once daily for 12 weeks
219728599|NCT01290731|DRUG|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
219728600|NCT01290731|DRUG|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
219728601|NCT03390192|DEVICE|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
219156527|NCT03647969|DRUG|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
219156528|NCT03647969|DRUG|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
219156529|NCT03647969|DRUG|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
219156530|NCT00131638|DRUG|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
219156531|NCT00131638|DRUG|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
219156532|NCT02378597|BEHAVIORAL|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
219156533|NCT00802464|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
219156534|NCT00802464|BIOLOGICAL|Placebo|2 vaccinations at Months 0 and 2 with placebo
219156535|NCT03669913|OTHER|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
219156536|NCT01871324|BEHAVIORAL|Lifestyle counseling|group therapy
219156537|NCT00468806|DRUG|GSK598809, using [11C]-(+)-PHNO|
219156538|NCT00402246|OTHER|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
219156539|NCT00402246|OTHER|In-Office Care|Routine in-office care
219156540|NCT02797444|OTHER|semi-structured interviews|
219156541|NCT00739531|DEVICE|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
219156542|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fasted|
219156543|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fed|
219156544|NCT02133820|DRUG|12 hourly capsule strong painkiller with antagonist fasted)|
219156545|NCT02133820|DRUG|4 mg 12 hourly capsule strong painkiller with antagonist fed|
219156546|NCT01111513|DRUG|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
219156547|NCT01111513|DRUG|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
219156548|NCT01111513|DRUG|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
219156549|NCT06229301|PROCEDURE|AI-predicted Nomogram|
219156550|NCT05984212|DRUG|Ultrasound guided rectus sheath block with dexmedetomidine|Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)
219156551|NCT05984212|DRUG|Ultrasound guided rectus sheath block with normal saline|Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)
219156552|NCT03122158|DRUG|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
219156553|NCT02298452|DEVICE|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
219156554|NCT00710567|DEVICE|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
219156555|NCT02262767|DRUG|PF-06649751|Experimental Pfizer compound.
219156556|NCT02262767|DRUG|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
219156557|NCT06298305|DEVICE|Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software|Quantib Prostate is an AI-driven solution that provides an intuitive workflow for assessment of prostate MRI. The product integrates essential prostate MRI reading features into one workflow making it easy for the user to read, assess and report each patient case from within the same software interface. With automatic forwarding in place, the software preprocesses the MRI right after scanning. This allows the user to access calculations and analysis immediately when they open the software interface. Thanks to these features, the professional may experience an accelerated workflow, making it easier to manage their heavier workload.
219156558|NCT06523205|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples."
219156559|NCT05443542|DEVICE|Virtual Reality|Game to be played is a commercially available VR game
219156560|NCT05443542|OTHER|Control intervention|Sodoku, crossword puzzles
219156561|NCT03513367|OTHER|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
219728602|NCT03390192|DEVICE|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
219728603|NCT00285675|DRUG|DN-101 (calcitriol) - Drug|
219728604|NCT04027621|DEVICE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
219156562|NCT03513367|OTHER|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
219156563|NCT01913691|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
219156564|NCT06514417|OTHER|US-guided external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner."
219156565|NCT00861770|OTHER|Ultrafiltration|Ultrafiltration based on standard of care.
219728605|NCT04027621|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
219728606|NCT00143520|DRUG|Rivoglitazone|
219728607|NCT00143520|DRUG|Pioglitazone|
219728608|NCT00143520|DRUG|Placebo|
219728609|NCT05821595|DRUG|JYB1907|for injection
219728610|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|TID
219728611|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|QID
219156566|NCT00861770|OTHER|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
219156567|NCT05286489|COMBINATION_PRODUCT|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
219728612|NCT00560638|DRUG|vehicle of loteprednol etabonate|TID or BID according to the randomization
219728613|NCT03057301|DEVICE|iCare home tonometer|All subjects will be taught to use the home care tonometer.
219728614|NCT04619082|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
219728615|NCT05571592|DRUG|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
219728616|NCT05571592|DRUG|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
219728617|NCT05970406|OTHER|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
219728618|NCT01399099|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
219728619|NCT05396170|PROCEDURE|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
219728620|NCT06140641|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
219728621|NCT05235607|BIOLOGICAL|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
219728622|NCT05232526|OTHER|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
219728623|NCT05232526|DEVICE|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
219728624|NCT03248804|BEHAVIORAL|Soy group|
219728625|NCT03248804|BEHAVIORAL|Non-soy group|
219728626|NCT01668537|BIOLOGICAL|LF formulation of IMVAMUNE®|
219728627|NCT01668537|BIOLOGICAL|FD formulation of IMVAMUNE®|
219728628|NCT04772235|DRUG|Repotrectinib|"Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib."
219728629|NCT04772235|DRUG|Osimertinib|"Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib"
219728630|NCT03848468|PROCEDURE|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
219728631|NCT02083211|DRUG|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
219728632|NCT02083211|DEVICE|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
219728633|NCT00183898|DRUG|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
219156568|NCT04038736|DEVICE|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
219156569|NCT05121467|OTHER|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
219156570|NCT05121467|OTHER|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
219728634|NCT03506126|OTHER|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
219728635|NCT01828684|OTHER|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
219156571|NCT05121467|OTHER|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
219156572|NCT05121467|OTHER|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
219156573|NCT01714960|DRUG|MRZ-99030 eye drops 5mg/mL|
219156574|NCT01714960|DRUG|MRZ-99030 eye drops 20mg/mL|
219728636|NCT01828684|OTHER|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
219728637|NCT02580552|DRUG|Cobomarsen|
219728638|NCT03331406|OTHER|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
219728639|NCT00601237|BEHAVIORAL|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
219728640|NCT00601237|BEHAVIORAL|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
219728641|NCT01838889|BEHAVIORAL|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
219728642|NCT00051727|BEHAVIORAL|Bridges to High School Project|
219728643|NCT05025917|DIETARY_SUPPLEMENT|Shatavari|Shatavari root powder
219728644|NCT05025917|DIETARY_SUPPLEMENT|Magnesium stearate|Magnesium stearate powder
219728645|NCT02974426|RADIATION|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
219728646|NCT02974426|RADIATION|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
219728647|NCT02974426|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
219728648|NCT02417181|OTHER|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
219728649|NCT00897845|GENETIC|RNA analysis|
219728650|NCT00897845|GENETIC|microarray analysis|
219728651|NCT00897845|OTHER|immunohistochemistry staining method|
219728652|NCT00897845|OTHER|laboratory biomarker analysis|
219728653|NCT05064800|DRUG|Dabigatran|A single dose of Dabigatran on Day 1
219728654|NCT05064800|DRUG|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
219728655|NCT05064800|DRUG|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
219728656|NCT04909255|DRUG|mirabegron|use beta-3 agonist for sjogren syndrome patient
219728657|NCT04909255|DRUG|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
219728658|NCT00854854|BIOLOGICAL|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
219728659|NCT01158586|DRUG|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
219728660|NCT03307070|BEHAVIORAL|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
219728661|NCT03307070|OTHER|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
219728662|NCT02411955|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
219728663|NCT02411955|DRUG|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
219728664|NCT02411955|DRUG|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
219728665|NCT00629642|DRUG|Solifenacin Succinate|Oral, 10mg
219728666|NCT00629642|DRUG|Solifenacin Succinate|Oral, 5mg
219728667|NCT00629642|DRUG|Oxybutynin Hydrochloride|Oral, 15mg
219728668|NCT00629642|DRUG|Placebo|Oral
219728669|NCT04294238|BEHAVIORAL|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
219728670|NCT04867070|DIAGNOSTIC_TEST|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
219728671|NCT03044561|DRUG|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
219728672|NCT03044561|DRUG|matching placebo|orally, 4 times per day for 21 days
219728673|NCT00663143|PROCEDURE|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
219728674|NCT04477486|DRUG|Ibrutinib|Capsule; Oral
219728675|NCT04477486|DRUG|Venetoclax|Tablet; Oral
219728676|NCT06100835|OTHER|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
219728677|NCT04813874|DRUG|Nitrous Oxide|Nitrous Oxide Inhalational Agent
219728678|NCT04813874|PROCEDURE|Neuraxial analgesia|Epidural Labor Analgesia Placement
219156575|NCT01714960|DRUG|Placebo to MRZ-99030 eye drops|
219156576|NCT05296213|DRUG|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
219156577|NCT05296213|DRUG|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
219728679|NCT06493565|DEVICE|Routine endoscopic anastomosis inspection|"The routine care pathway for early detection of anastomotic leakage includes:~* C-reactive protein guided imaging~* Rectoscopy of the anastomosis three to six days after surgery~* Rectoscopy of the anastomosis two to three weeks after surgery"
219728680|NCT00512083|DRUG|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
219156578|NCT05296213|DRUG|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
219234018|NCT02189759|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
219728681|NCT02130011|OTHER|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
219156579|NCT05043272|BIOLOGICAL|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
219156580|NCT03308292|OTHER|Exercise|Aerobic exercise program
219156581|NCT05178459|DIAGNOSTIC_TEST|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
219728682|NCT04724200|DIAGNOSTIC_TEST|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
219728683|NCT05451888|BEHAVIORAL|Spa treatment|A 40 minute period of lying in the spa treatment pool
219728684|NCT02966925|DEVICE|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
219728685|NCT04869917|BEHAVIORAL|Decision Aid intervention|"* Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
219728686|NCT04869917|BEHAVIORAL|Text Messaging intervention|"* Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
219728687|NCT04869917|BEHAVIORAL|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
219728688|NCT04107363|PROCEDURE|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
219728689|NCT04107363|OTHER|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
219728690|NCT05797090|DRUG|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
219728691|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
219728692|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
219728693|NCT05632900|PROCEDURE|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
219728694|NCT00779883|BIOLOGICAL|ISF35|Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.
219156582|NCT04718909|DRUG|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
219156583|NCT04718909|DRUG|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
219156584|NCT04623567|DRUG|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
219156585|NCT04623567|DRUG|Metformin|The metformin tablets (500mg) will be administrated.
219156586|NCT04425863|DRUG|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
219728695|NCT05565404|BEHAVIORAL|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
219728696|NCT05565404|PROCEDURE|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
219728697|NCT00513864|DRUG|Dextromethorphan|one time dose - 0.3mg/kg PO
219728698|NCT00513864|DRUG|Codeine|one time dose - 2mg/kg PO
219728699|NCT00513864|DRUG|Morphine|one time dose - 0.15mg/kg IV
219728700|NCT04915066|OTHER|Medical data collection|Collection of medical data from patients'medical records
219728701|NCT03745456|DIAGNOSTIC_TEST|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
219156587|NCT04425863|OTHER|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
219156588|NCT04425863|OTHER|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
219728702|NCT01524458|PROCEDURE|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
219728703|NCT04038658|BEHAVIORAL|Move-It|
219728704|NCT00372515|DRUG|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
219728705|NCT03335267|DRUG|CPX-351|Cytarabine:Daunorubicin Liposome Injection
219728706|NCT02923622|OTHER|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
219728707|NCT02923622|OTHER|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
219728708|NCT02923622|OTHER|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
219728709|NCT05022862|BEHAVIORAL|Usual Care|Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
219156589|NCT06358534|BEHAVIORAL|psychoeducation based on acceptance and commitment therapy|psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
219156590|NCT02987816|DEVICE|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
219156591|NCT02987816|DEVICE|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
219156592|NCT06450496|BEHAVIORAL|Positive parenting on-line program|Positive parenting on-line program focused on parenting and personal competences relevant for parents with adolescents exhibiting mental health problems
219156593|NCT04218890|DIAGNOSTIC_TEST|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
219156594|NCT01902147|OTHER|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
219156595|NCT05398224|DRUG|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
219156596|NCT00735852|DRUG|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
219156597|NCT03096236|DEVICE|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
219156598|NCT05656664|DIETARY_SUPPLEMENT|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
219156599|NCT05656664|OTHER|Placebo|Placebo group to assess arsenic metabolite excretion
219156600|NCT00642850|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
219156601|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
219156602|NCT04807790|OTHER|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
219156603|NCT02926794|BEHAVIORAL|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
219156604|NCT02926794|BEHAVIORAL|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
219234019|NCT02189759|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
219728710|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy alone|Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
219156605|NCT02926794|BEHAVIORAL|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
219156606|NCT02926794|BEHAVIORAL|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
219156607|NCT05038618|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
219156608|NCT05500326|DRUG|Ivermectin Tablets|"ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
219156609|NCT06149819|OTHER|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
219156610|NCT03418805|DRUG|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
219156611|NCT03418805|DRUG|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
219728711|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy plus Financial Incentives|Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
219728712|NCT01853085|DRUG|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
219728713|NCT00502879|DRUG|Enbrel (etanercept)|
219728714|NCT01078545|DRUG|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
219728715|NCT05230927|OTHER|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
219728716|NCT02497755|BEHAVIORAL|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
219728717|NCT02497755|DEVICE|smartphone|
219728718|NCT01303497|DRUG|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
219728719|NCT01303497|DRUG|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV"
219728720|NCT00561327|DRUG|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
219728721|NCT02864914|DRUG|Empagliflozin|drug
219728722|NCT02864914|DRUG|DPP-4 inhibitors|drug
219728723|NCT03695835|DRUG|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
219728724|NCT03695835|DEVICE|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
219728725|NCT01774370|DRUG|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
219728726|NCT05436288|DRUG|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
219728727|NCT02736214|BEHAVIORAL|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
219728728|NCT03948386|DRUG|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
219728729|NCT03948386|DRUG|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
219728730|NCT03948386|DRUG|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
219728731|NCT02128750|OTHER|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
219728732|NCT02763358|DEVICE|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
219728733|NCT03645447|DIAGNOSTIC_TEST|Taste test|A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.
219728734|NCT02804646|DRUG|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
219728735|NCT02804646|DRUG|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
219728736|NCT01937442|DRUG|Thalidomide Celgene™|200mg once daily and by mouth
219728737|NCT03886623|PROCEDURE|4-day systematic oral hygiene|he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
219728738|NCT03886623|OTHER|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
219728739|NCT00350506|DEVICE|64 Channel VCT|
219728740|NCT03510702|DIAGNOSTIC_TEST|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
219728741|NCT03794063|OTHER|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
219728742|NCT01436500|DRUG|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
219728743|NCT01436500|DRUG|Placebo|Sterile water with 5% Dextrose
219728744|NCT00500929|DRUG|CMI X-11S|
219728745|NCT01910532|DRUG|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
219728746|NCT05444127|OTHER|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
219728747|NCT05444127|OTHER|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
219728748|NCT05444127|OTHER|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
219728749|NCT00222261|DRUG|aspirin|Aspirin 160 mg once daily for two years
219728750|NCT00222261|DRUG|clopidogrel|clopidogrel 75 mg once daily for two years
219728751|NCT01604200|BEHAVIORAL|focus group|key informant review
219728752|NCT06093503|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
219728753|NCT06093503|DRUG|Osimertinib|Oral: Tablet
219728754|NCT06093503|DRUG|Cisplatin|IV Infusion
219728755|NCT06093503|DRUG|Carboplatin|IV Infusion
219728756|NCT06093503|DRUG|Pemetrexed|IV Infusion
219728757|NCT01109381|DRUG|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
219728758|NCT00331149|DRUG|Ropinirole prolonged release|
219728759|NCT00331149|DRUG|ropinirole immediate release|
219728760|NCT00581997|DRUG|QAX576|
219728761|NCT00581997|DRUG|Placebo|
219728762|NCT03967665|DRUG|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
219728763|NCT04253678|DRUG|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
219728764|NCT01761227|DRUG|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
219728765|NCT01761227|DRUG|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
219728766|NCT03949114|BEHAVIORAL|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
219728767|NCT03949114|BEHAVIORAL|nursing care|Traditional post-operative nursing care
219728768|NCT03949114|BEHAVIORAL|rehabilitation|"1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
219728769|NCT01487161|DRUG|FX006|Single 3 mL intra-articular injection
219728770|NCT01487161|DRUG|TCA IR|Single 1 mL intra-articular injection
219728771|NCT04759092|DEVICE|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
219728772|NCT06196827|GENETIC|LX101|Subretinal Administration
219728773|NCT06377540|DRUG|Pembrolizumab|"Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year."
219728774|NCT06377540|PROCEDURE|Autologous stem cell transplant|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
219728775|NCT06377540|DRUG|Carmustine|Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
219728776|NCT06377540|DRUG|Etoposide|Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
219234020|NCT05389618|OTHER|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
219728777|NCT06377540|DRUG|Cytarabine|Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
219728778|NCT06377540|DRUG|Melphalan|Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
219728779|NCT02465970|DEVICE|STARSTIM|"Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session"
219728780|NCT02465970|DEVICE|sham TDCS|
219728781|NCT01624207|DRUG|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
219728782|NCT01624207|DRUG|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
219728783|NCT01117545|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Six sessions of EFT
219728784|NCT04425395|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
219728785|NCT04425395|BEHAVIORAL|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
219156612|NCT03418805|DRUG|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
219156613|NCT02549170|BIOLOGICAL|HYQVIA|Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
219156614|NCT02549170|BIOLOGICAL|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
219156615|NCT02549170|BIOLOGICAL|IGIV GAMMAGARD LIQUID/KIOVIG|Participants will receive GAMMAGARD LIQUID/KIOVIG
219156616|NCT02549170|BIOLOGICAL|IGIV GAMUNEX®-C|Participants will receive GAMUNEX®-C
219156617|NCT06090786|DIAGNOSTIC_TEST|MRD assessment|Bone marrow withdrawal for MRD quantification
219156618|NCT00827346|DRUG|Clopidogrel|600 mg now
219156619|NCT00827346|DRUG|Clopidogrel|600 mg now and 600 mg in 3 hours
219728786|NCT04425395|DIAGNOSTIC_TEST|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
219728787|NCT04425395|DIAGNOSTIC_TEST|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
219728788|NCT02569242|DRUG|Nivolumab|
219728789|NCT02569242|DRUG|Docetaxel/Paclitaxel|
219156620|NCT00827346|DRUG|Clopidogrel|900 mg now
219156621|NCT00827346|DRUG|Clopidogrel|600 mg now and 300 mg in 3 hours
219156622|NCT00898846|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
219156623|NCT05106946|BIOLOGICAL|ThisCART22 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
219156624|NCT05973812|DIETARY_SUPPLEMENT|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
219156625|NCT05973812|DIETARY_SUPPLEMENT|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
219156626|NCT01448317|DRUG|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219234021|NCT04809376|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
219234022|NCT04809376|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
219234023|NCT04809376|DRUG|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
219234024|NCT04809376|DRUG|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
219728790|NCT00689052|DRUG|pramipexole ER|
219728791|NCT00689052|DRUG|placebo|
219728792|NCT04838028|PROCEDURE|TEP|Laparoendoscopic totally extraperitoneal mesh repair of groin hernia
219728793|NCT04838028|PROCEDURE|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
219728794|NCT04838028|PROCEDURE|Other or unspecified laparoendoscopic groin hernia repair|"Other refers to any laparoendoscopic mesh repair specified as not being either TEP or TAPP, eg, intraperitoneal onlay mesh (IPOM)."
219728795|NCT06975865|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet -Route of administration:Oral
219728796|NCT06975865|DRUG|Placebo|Pharmaceutical form:Tablet -Route of administration:Oral
219728797|NCT02221414|DRUG|Linagliptin/Metformin FDC|
219728798|NCT02221414|DRUG|Linagliptin|
219728799|NCT02221414|DRUG|Metformin|
219728800|NCT02846428|DRUG|5-Fluorouracil|5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
219728801|NCT02846428|DRUG|Capecitabine|Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
219728802|NCT02846428|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
219728803|NCT02846428|DRUG|Docetaxel|Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
219728804|NCT02846428|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
219728805|NCT04810156|DRUG|Mycophenolate Mofetil|Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day
219728806|NCT04810156|DRUG|Solu-Medrol|2 mg/kg/day
219728807|NCT04810156|DRUG|Ursodeoxycholic acid|Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight
219728808|NCT04810156|DRUG|Prednisone tablet|Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
219728809|NCT05625464|OTHER|SCTP|Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
219728810|NCT04331405|BIOLOGICAL|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
219728811|NCT00080106|BIOLOGICAL|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
219728812|NCT00080106|OTHER|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
219728813|NCT05542602|BEHAVIORAL|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
219728814|NCT02310607|OTHER|Not an interventional study|Not an interventional study
219728815|NCT01249196|DRUG|SK-PC-B70M|for dosage
219728816|NCT06237491|DRUG|177Lu-LNC1003 Injection group 1|The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219728817|NCT06237491|DRUG|177Lu-LNC1003 Injection group 2|The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219728818|NCT06237491|DRUG|177Lu-LNC1003 Injection group 3|The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
219728819|NCT03362320|PROCEDURE|double layer fixation|
219728820|NCT03362320|PROCEDURE|single layer fixation|
219728821|NCT04679246|BEHAVIORAL|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
219728822|NCT00929032|RADIATION|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
219156627|NCT01448317|DRUG|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
219156628|NCT01448317|DRUG|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219156629|NCT01448317|DRUG|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
219156630|NCT03107546|DEVICE|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
219156631|NCT03107546|OTHER|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
219156632|NCT04804046|DIETARY_SUPPLEMENT|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
219156633|NCT04804046|OTHER|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
219156634|NCT02722551|DEVICE|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
219728823|NCT04557644|OTHER|7-items-questionnaires addressing CI, disgust and empathy|7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
219728824|NCT04557644|OTHER|Saarbrucken Personality questionnaire (SPQ) addressing empathy.|Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
219728825|NCT04557644|OTHER|10-items-questionnaire addressing previous dermatological conditions, intensity of itch|10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
219728826|NCT04557644|OTHER|ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions|ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
219728827|NCT00498732|DEVICE|CPAP|CPAP treatment for 4 weeks
219156635|NCT00960024|BEHAVIORAL|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
219728828|NCT03319888|DEVICE|CPAP|continuous positive pressure in the airway
219728829|NCT03319888|OTHER|conservative treatment|conservative treatment group with lifestyle modifications
219728830|NCT01346683|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
219728831|NCT03228407|PROCEDURE|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
219728832|NCT03228407|DIAGNOSTIC_TEST|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
219728833|NCT03228407|DIAGNOSTIC_TEST|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
219728834|NCT01741818|OTHER|Measuring IVC collapsibility index by bedside ultrasonography|
219728835|NCT00893295|OTHER|informational intervention|
219728836|NCT00893295|OTHER|medical chart review|
219728837|NCT00893295|OTHER|screening questionnaire administration|
219728838|NCT00893295|OTHER|study of socioeconomic and demographic variables|
219728839|NCT00893295|PROCEDURE|barium enema injection|
219728840|NCT00893295|PROCEDURE|colon imaging study|
219728841|NCT00893295|PROCEDURE|screening colonoscopy|
219728842|NCT00893295|PROCEDURE|sigmoidoscopy|
219728843|NCT03812250|PROCEDURE|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
219728844|NCT03812250|PROCEDURE|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
219156636|NCT00960024|BEHAVIORAL|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
219156637|NCT05150067|OTHER|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
219728845|NCT01609140|DRUG|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
219728846|NCT01609140|DRUG|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
219728847|NCT01609140|DRUG|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
219728848|NCT01609140|DRUG|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
219728849|NCT01609140|DRUG|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
219728850|NCT01609140|DRUG|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
219728851|NCT01456338|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
219728852|NCT01456338|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
219728853|NCT01727154|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
219728854|NCT04992286|OTHER|questionnaire|questionnaire to evaluate fragility
219728855|NCT04992286|OTHER|accelerometer|To evaluate physical activity level
219728856|NCT02819375|DRUG|Propofol|1 mg/kg propofol
219728857|NCT02819375|DRUG|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
219728858|NCT02819375|DRUG|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
219728859|NCT03650270|DRUG|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
219728860|NCT00003474|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219728861|NCT00368485|DEVICE|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
219728862|NCT03639051|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
219728863|NCT03639051|OTHER|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
219728864|NCT04899128|DRUG|Pyrotinib|Pyrotinib-based therapy
219728865|NCT01351558|OTHER|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
219728866|NCT01351558|OTHER|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
219728867|NCT01351558|OTHER|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
219728868|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
219728869|NCT05960656|OTHER|Placebo|Inert tablet
219728870|NCT06996626|DEVICE|Revealed Alerts|Bedside reveal of alerts generated by the alerting system
219728871|NCT06996626|DEVICE|Unrevealed Alerts|Alerts will be generated but not revealed.
219728872|NCT06517017|DRUG|Isatuximab|Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.
219728873|NCT07039565|OTHER|Stretching and strengthening exercises|Strengthening exercises were progressively performed for three sets, with 10 to 15 repetitions. The stretching part of the exercises was done with the purpose of increasing the flexibility of the pectoralis and the cervical neck extensors muscles (pectoralis stretch, chin tuck). Exercises have been approved to be effective on the lengthening of the pectoralis minor, activation of the lower trapezius/middle trapezius, serratus anterior, and improvement of the posture
219728874|NCT07039565|OTHER|Diaphragm release technique|the patient will positioned in the supine position. The therapist stand at the head of the patient. The therapist make manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist is gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously
219156638|NCT05150067|OTHER|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
219156639|NCT01062087|DRUG|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
219728875|NCT07044739|BEHAVIORAL|Patient Education on the Use of Anti-Embolic Stockings|"The researcher will provide verbal information to the patients with the educational material titled Use of Anti-Embolic Stockings, the stages of wearing anti-embolic stockings will be shown to the patients, and the educational material will be left next to the patients in the intervention group. The educational content covers the purpose of using anti-embolic stockings, how to use them, and the points to be considered during use."
219728876|NCT07045753|DEVICE|Transcatheter edge to edge repair|mitral valve transcatheter edge-to-edge repair
219728877|NCT07046000|DIAGNOSTIC_TEST|MRI|MRI to assess graft maturation
219156640|NCT01266122|BEHAVIORAL|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
219234025|NCT06163300|DIAGNOSTIC_TEST|MRI advanced techniques|Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
219728878|NCT07046169|OTHER|Ultrasound-Guided Volume Assessment and Decongestion Strategy (UVADS)|Unique Combination: Simultaneously tracks IVC collapsibility index (\>50%) + pulmonary B-line counts (≤5) to guide therapy, unlike studies using either metric alone.Thresholds Tested: Compares ESC consensus thresholds (IVC \<2.1cm) vs. exploratory Asian-optimized thresholds (IVC \<1.8cm) in Subgroup B.
219728879|NCT07046169|OTHER|clinical assessment|Discharge based on symptoms/signs alone: Clinical congestion score ≤2 + NYHA class ≤II
219728880|NCT07045207|OTHER|LLM-MDT|Leveraging large language models (LLMs) to Generate Multidisciplinary Team (MDT) Treatment Recommendations
219728881|NCT07056465|BEHAVIORAL|Intermittent Carbohydrate Restriction (ICR) Protocol|A novel intermittent carbohydrate restriction (ICR) protocol involving two consecutive low-carbohydrate days (approximately 10% total energy from carbohydrate) followed by five non-restricted days per week, sustained over a 4-week period. Participants receive individualised dietary guidance and support materials to promote adherence in free-living conditions
219728882|NCT07055919|DEVICE|Structural Heart Surgery Assist System|Following femoral venous access and transseptal puncture, the steerable guide catheter and transcatheter mitral valve clip system are inserted and mounted onto the Structural Heart Surgery Assist System. The surgeon manipulates the joystick and controls on the operator console, guided by real-time animations on the human-machine interface that confirm the direction and range of device motion. Under fluoroscopic (DSA) and echocardiographic guidance, the system assists in performing edge-to-edge mitral valve repair. The procedure achieves regurgitation reduction by either creating a double-orifice configuration (A2/P2 segments) or approximating the opposing leaflets at the A1/P1 or A3/P3 regions.
219728883|NCT07055919|DEVICE|Manual MitraClip G4|Manual MitraClip G4
219728884|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with an animal-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
219728885|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with a plant-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
219728886|NCT07057245|OTHER|Control arm - cornstarch|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
219728887|NCT07055698|DIAGNOSTIC_TEST|The Navicular Height Drop (NHD) test|Evaluating the test's responsiveness and minimal clinically important difference (MCID) can help determine its clinical relevance in monitoring treatment outcomes.
219728888|NCT07057271|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
219728889|NCT07057271|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
219728890|NCT07056452|PROCEDURE|hydrodissection technique|injecting a solution of physiological saline containing 0.5% lidocaine along the cutting line
219728891|NCT07055932|BEHAVIORAL|"Interactive Oral Health Education Program"|"The interactive program in this study is distinguished by its multi-modal, hands-on approach and its sustained, bi-weekly delivery over two months, whereas most other school-based interventions rely on a single lecture or short-term animation. Specifically, our program:~Combines interactive lectures with live demonstrations (brushing/flossing on models), group discussions, and educational puzzles to reinforce learning through active participation rather than passive listening.~Uses anatomical tooth-and-gum replicas alongside PowerPoint slides and photographs to bridge theory and practice within each 30-45-minute session.~Addresses periodontal risk factors (e.g., smoking, diet) in dedicated sessions, integrating behavioural change techniques (e.g., problem-solving brainstorming, personalized feedback) rather than focusing solely on plaque removal.~Is delivered in six sessions (one every 10 days) to maximize retention and allow for iterative skill practice, unlike brief brush-along"
219156641|NCT05435313|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
219156642|NCT05435313|DRUG|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
219156643|NCT05435313|DRUG|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
219156644|NCT05435313|DRUG|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
219728892|NCT04075656|BEHAVIORAL|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
219156645|NCT05435313|DRUG|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
219156646|NCT05435313|DRUG|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
219156647|NCT03756571|OTHER|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
219156648|NCT03756571|OTHER|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
219156649|NCT00978042|DEVICE|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
219156650|NCT02379819|DEVICE|Nucleus Hybrid L24 Implant|
219234026|NCT00042926|OTHER|immunohistochemistry staining method|
219234027|NCT00042926|PROCEDURE|conventional surgery|
219234028|NCT00042926|PROCEDURE|lymphangiography|
219728893|NCT04075656|BEHAVIORAL|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
219728894|NCT05136430|BEHAVIORAL|Self-Regulation strategies + large changes (SR)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
219728895|NCT05136430|BEHAVIORAL|Healthy Lifestyle Education (LE)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
219728896|NCT05136430|OTHER|Smoking Cessation Treatment|The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
219728897|NCT04753177|DRUG|Ribocyclib, fulvestrant, triptorelin|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
219728898|NCT04753177|DRUG|Doxorubicin, cyclophosphamide, paclitaxel|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
219728899|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
219728900|NCT03539705|OTHER|There is no intervention|There is no intervention
219728901|NCT06549114|DRUG|Leniolisib|The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
219728902|NCT05860400|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
219728903|NCT05860400|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
219728904|NCT05860400|DRUG|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
219728905|NCT05860400|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
219728906|NCT05860400|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
219728907|NCT04876950|COMBINATION_PRODUCT|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
219728908|NCT05379985|DRUG|RMC-6236|Oral Tablets
219728909|NCT00816673|DRUG|placebo Circadin|Placebo tabs of Prolonged release melatonin
219728910|NCT00816673|DRUG|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
219728911|NCT05516966|DRUG|HRS9531|Administrated SC
219728912|NCT05516966|DRUG|Placebo|Administrated SC
219728913|NCT05516966|DRUG|Dulaglutide Injection|Administrated SC
219728914|NCT04837846|OTHER|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
219728915|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
219728916|NCT04825587|PROCEDURE|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
219234029|NCT00042926|PROCEDURE|radionuclide imaging|
219234030|NCT00042926|PROCEDURE|sentinel lymph node biopsy|
219728917|NCT05228015|DRUG|IK-930|tablets for oral administration
219728918|NCT05228015|DRUG|Osimertinib|tablets for oral administration
219728919|NCT03554473|DRUG|M7824|Arm A \& B: 2400mg intravenous (IV) over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
219728920|NCT03554473|DRUG|Topotecan|Arm B: 1 mg/m(2) intravenous (IV) over 30 minutes days 1-5 on a 3-week cycle.
219728921|NCT03554473|DRUG|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m(2) by mouth (PO) days 1-5 on a 4-week cycle.
219728922|NCT03554473|DIAGNOSTIC_TEST|EKG|Screening and baseline.
219728923|NCT03554473|DIAGNOSTIC_TEST|CT scan|Computed tomography (CT) scan performed at Screening and after every 2 cycles (6 weeks) per Study Calendar for Arm B 3.5.2, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
219728924|NCT03554473|DIAGNOSTIC_TEST|PET scan|Positron emission tomography (PET) not mandatory - If a computed tomography (CT) scan is not sufficient to assess response, a PET scan may be added per Study Calendar for Arm A 3.5.1, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
219728925|NCT03554473|DRUG|Acetaminophen|For infusion related reaction, 500-1000 mg by mouth (PO) prior to infusion.
219728926|NCT03554473|DRUG|Antihistamines|As medically indicated.
219728927|NCT03554473|DRUG|Diphenhydramine|For infusion related reaction, 50 mg by mouth (PO) prior to infusion.
219728928|NCT03554473|DRUG|Dexamethasone|As medically indicated.
219728929|NCT03554473|DRUG|Epinephrine|As medically indicated.
219728930|NCT05893030|PROCEDURE|anesthesia guided by sedation and analgesia monitoring|"Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~* Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~* or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~* or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~* Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25."
219728931|NCT05893030|PROCEDURE|anesthesia performed according only to the clinical judgment of the anesthetist as usual practice|Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
219728932|NCT02704832|OTHER|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
219728933|NCT01501513|DRUG|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
219728934|NCT01501513|DRUG|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
219728935|NCT01501513|DRUG|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
219728936|NCT03834116|DEVICE|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
219728937|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate (Formulation 725: Water soluble.Contains sorbitol)
219728938|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)
219728939|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)
219728940|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)
219728941|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Isolate in water formulation|Pure CBD as crystalline powder (\>99% purity) (Formulation 625 Not water soluble)
219728942|NCT04971837|DIETARY_SUPPLEMENT|CBD matching Placebo|Matching Placebo
219728943|NCT04618965|DRUG|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
219728944|NCT04618965|DRUG|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
219728945|NCT04618965|DRUG|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
219728946|NCT06482424|OTHER|intervention group|"Actions to be taken to the Intervention Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.~Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a number two label will be attached to the bottle."
219728947|NCT04113486|OTHER|Blood test|About 4 ml of blood draw
219728948|NCT03004131|DRUG|Azelastine hydrochloride + fluticasone propionate nasal spray|
219728949|NCT03004131|DRUG|Placebos|
219728950|NCT03004131|DRUG|fluticasone propionate nasal spray + loratadine|
219728951|NCT03606590|DEVICE|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
219728952|NCT03606590|DRUG|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
219728953|NCT03456297|OTHER|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
219728954|NCT00567580|RADIATION|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
219728955|NCT00567580|RADIATION|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
219728956|NCT00567580|DRUG|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
219728957|NCT00567580|DRUG|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
219728958|NCT03297060|OTHER|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
219728959|NCT05501717|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
219728960|NCT05501717|DRUG|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
219728961|NCT06240143|DRUG|Ipilimumab|intradermal
219728962|NCT06240143|DRUG|Nivolumab|intradermal
219728963|NCT06240143|DRUG|Nivolumab|intravenous
219728964|NCT04524923|OTHER|visual motor integration|investigate the relation between touch screen usage and visual motor integration in preschoolers
219728965|NCT04524923|OTHER|Quality of life assessment|investigate the relation between touch screen usage and Quality of life assessment in preschoolers
219728966|NCT04524923|OTHER|Cognitive Functioning|investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
219728967|NCT06957782|DRUG|⁶⁸Ga-FAPI-46|All patients will be administered with 1.5 MBq/kg ⁶⁸Ga-FAPI-46. ⁶⁸Ga-FAPI-46 will be injected intravenously followed by a flush injection of 10 mL of saline following routine procedures.
219728968|NCT06964581|BEHAVIORAL|Cognitive treatment delivered via telerehabilitation.|Three hours of cognitive rehabilitation per week, carried out independently and remotely using a computerized device, which is pre-programmed according to the patient's specific needs.
219728969|NCT06964581|BEHAVIORAL|In-person cognitive treatment.|Three hours of in-person cognitive rehabilitation per week using a computerized device. The participant will perform cognitive exercises on the computerized device in the presence of the therapist, who will activate the device (using credentials specifically created for them) and select the appropriate activity to administer at each session.
219728970|NCT06964659|DIETARY_SUPPLEMENT|Sulforaphan-Smart® formula|Volunteers will intake a daily dose of Sulforaphan-Smart® pill for 12 weeks (84 days)
219728971|NCT06964659|OTHER|Control (placebo) group|Volunteers will intake a daily dose of placebo pill for 12 weeks (84 days)
219728972|NCT06963515|PROCEDURE|Magnetic Resonance Imaging|3T Magnetic Resonance Imaging
219728973|NCT06963788|DRUG|Chlorhexidine 0,12%|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
219728974|NCT06963788|DRUG|0,9% Chloride Sodium|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
219728975|NCT06963788|DRUG|Silver nanoparticles mouthwash|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
219728976|NCT06964607|DRUG|Sodium-glucose cotransporter-2 Inhibitors|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated, plus one of the available sodium-glucose co-transporter-2 Inhibitors in Egypt (Empagliflozin or Dapagliflozin), irrespective of the presence or absence of diabetes mellitus or type of heart failure(HFrEF, HFmEF, HFpEF).
219728977|NCT06964607|DRUG|Conventional treatment|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated without adding sodium-glucose co-transporter-2 inhibitors.
219728978|NCT06963645|DEVICE|AR rehabilitation app|The intervention will consist of an 8-week home rehabilitation program during which the participant will have 1) a total of 7 weekly remote video visits with a therapist and 2) daily at-home exercises using the AR headset with rehabilitation app, done independently.
219728979|NCT06119412|OTHER|blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.|Each participant will have their blood pressure measured with two different techniques.
219728980|NCT06964373|DEVICE|Cervical Ripening Balloon|30 milliliter Foley balloon
219728981|NCT06964373|DEVICE|Osmotic Dilators|Dilapan-S
219728982|NCT06964529|BIOLOGICAL|Concentrated PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
219728983|NCT06964529|BIOLOGICAL|Injectable PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
219728984|NCT06963762|BEHAVIORAL|Conventional rehabilitation will be applied|Conventional rehabilitation will be applied for 30 minutes, 4 times a week for 4 weeks.
219728985|NCT06963762|BEHAVIORAL|Mirror therapy will be applied along with conventional rehabilitation|In addition to conventional rehabilitation, patients in the experimental group will receive mirror therapy for 30 minutes, 4 times a week for 4 weeks.
219234031|NCT00042926|RADIATION|technetium Tc 99m sulfur colloid|
219234032|NCT02198300|PROCEDURE|Coronary angioplasty with stent implantation|
219728986|NCT06963424|PROCEDURE|Erector Spinae Plane Block|lumbar erectro spinae block
219728987|NCT06964204|BEHAVIORAL|Kangaroo Care|"Kangaroo care practice will be carried out in 3 stages: preparation, implementation and recording stage. Vital signs of the baby such as body temperature, heart rate, respiratory rate will be evaluated and necessary materials such as hats and covers will be prepared. In the implementation phase; the general condition of the baby will be checked, clothing and position will be adjusted, and then the baby will be transferred to the mother. After the baby is placed, his/her back will be covered with a blanket and the mother will be asked to support the baby's back with one hand and the hips with the other. When 60 minutes are completed, kangaroo care will be terminated. After the baby is placed, vital signs and general condition will be evaluated and all nursing observations will be recorded. For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization."
219728988|NCT06964204|BEHAVIORAL|Kangaroo Care+lullabies|For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization.
219728989|NCT06963918|DEVICE|Expiratory muscle strength training|After the 4-week wait-to-start period during which they will not receive any intervention, will participants undergo a 4-week respiratory training program using the EMST150™ device (Expiratory Muscle Strength Trainer). EMST therapy sessions will be completed at home on 5 days (of the patients choosing) per week, performing five sets of five forceful exhalations through the EMST150™. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Following the training period, patients will be observed for an additional 4 weeks to assess the sustainability of the potential training effects.
219728990|NCT06964152|DIAGNOSTIC_TEST|Computational electrocardiography and cardiac computed tomography mapping|Use of non-invasive computational ECG and cardiac CT models to localize arrhythmia origins
219728991|NCT06322862|OTHER|Indocyanine green|Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
219728992|NCT01658878|BIOLOGICAL|Nivolumab|
219728993|NCT01658878|DRUG|Sorafenib|
219728994|NCT01658878|DRUG|Ipilimumab|
219728995|NCT01658878|DRUG|Cabozantinib|
219728996|NCT05691439|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
219728997|NCT05691439|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
219728998|NCT00382070|DRUG|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
219728999|NCT00382070|OTHER|Placebo|Placebo tablet taken orally once daily for 5 years
219729000|NCT06114550|OTHER|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
219156651|NCT03062813|DRUG|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
219729001|NCT06114550|OTHER|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
219729002|NCT04947267|DRUG|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
219729003|NCT04947267|DRUG|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
219729004|NCT01552889|BEHAVIORAL|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
219156652|NCT03062813|DRUG|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
219156653|NCT04263519|DRUG|Tacrolimus|Oral Immunosuppressant
219156654|NCT02118064|BIOLOGICAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
219156655|NCT05204394|DRUG|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
219156656|NCT05204394|OTHER|Standard of Care|Any oral 1st line approved HIV treatment regimen
219234033|NCT02198300|DRUG|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
219156657|NCT04728568|DRUG|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
219156658|NCT03172234|OTHER|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
219156659|NCT03172234|DRUG|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
219234034|NCT05473117|DIAGNOSTIC_TEST|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
219729005|NCT05197621|BIOLOGICAL|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
219729006|NCT00312962|BEHAVIORAL|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
219729007|NCT00312962|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
219729008|NCT03083730|OTHER|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
219729009|NCT01517776|DRUG|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
219729010|NCT01517776|DRUG|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
219729011|NCT06633406|OTHER|Age-appropriate Wechsler Intelligence Test|"2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)"
219729012|NCT06633406|OTHER|Disruptive Behavior Disorders Rating Scale|Dutch version of the Disruptive Behavior Disorders Rating Scale
219729013|NCT06633406|OTHER|Social Responsiveness Scale|"3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)"
219729014|NCT04088357|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
219729015|NCT04088357|DRUG|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
219729016|NCT05080543|DRUG|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
219729017|NCT05715346|DRUG|LEV102 1.0%|Oxymetazoline ophthalmic gel
219729018|NCT05715346|DRUG|LEV102 2.0%|Oxymetazoline ophthalmic gel
219729019|NCT05715346|DRUG|Vehicle|Vehicle ophthalmic gel
219156660|NCT03172234|DRUG|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
219156661|NCT04771780|DRUG|KHK7791|oral administration
219156662|NCT04597684|PROCEDURE|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
219234035|NCT02667366|BEHAVIORAL|Tel-PT|
219156663|NCT04597684|PROCEDURE|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
219156664|NCT01574794|OTHER|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
219156665|NCT01574794|OTHER|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
219156666|NCT05264168|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
219234036|NCT02667366|BEHAVIORAL|TAU and text messages|
219234037|NCT03582566|BEHAVIORAL|Phonological Awareness|Earobics training
219234038|NCT03582566|BEHAVIORAL|Working Memory|Cogmed training
219234039|NCT03582566|BEHAVIORAL|Phonological Awareness + Working Memory|Earobics + Cogmed training
219234040|NCT03582566|BEHAVIORAL|Active Control|Spashmath
219729020|NCT03843216|OTHER|observation|patients not treated
219729021|NCT03843216|OTHER|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
219729022|NCT03843216|DEVICE|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
219729023|NCT01838811|BEHAVIORAL|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
219729024|NCT04685122|PROCEDURE|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
219729025|NCT00071331|DRUG|Tolvaptan|
219729026|NCT01291875|PROCEDURE|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
219729027|NCT01291875|PROCEDURE|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
219729028|NCT03957057|DRUG|Iron Carboxymaltose|Intravenous iron carboxymaltose application
219156667|NCT05264168|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
219729029|NCT03957057|DRUG|Iron Isomaltoside|Inravenous iron isomaltoside application
219729030|NCT03957057|DRUG|Ferrous sulphate|Oral ferrous sulphate application
219729031|NCT00795405|BEHAVIORAL|Exposure to sporting events|Exposure to sporting events
219729032|NCT00795405|BEHAVIORAL|No exposure to sporting events|No exposure to sporting events
219234041|NCT02067819|DEVICE|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
219156668|NCT04966416|DIETARY_SUPPLEMENT|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
219156669|NCT04966416|DIETARY_SUPPLEMENT|Placebo|Glucose in gelatine capsules.
219234042|NCT02067819|DEVICE|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
219234043|NCT00800176|DRUG|Placebo|po daily for 12 weeks
219234044|NCT00800176|DRUG|RO4998452|2.5mg po daily for 12 weeks
219234045|NCT00800176|DRUG|RO4998452|5mg po daily for 12 weeks
219234046|NCT00800176|DRUG|RO4998452|10mg po daily for 12 weeks
219234047|NCT00800176|DRUG|RO4998452|20mg po daily for 12 weeks
219729033|NCT05520177|DRUG|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
219729034|NCT05520177|DRUG|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
219729035|NCT04654052|DRUG|Clopidogrel|Clopidogrel during 11 months
219729036|NCT04654052|DRUG|Previous treatment|non-intervention
219156670|NCT03632616|OTHER|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, 6 and 12 months post-intervention.
219156671|NCT06516861|DRUG|Magnesium Sulfate 20 MG/ML|Administered intravenously with a dose of 30 mg/kg
219156672|NCT06516861|DRUG|Lidocaine IV|Administered intravenously with a dose of 1.5mg/Kg
219156673|NCT06516861|DRUG|saline solution|Administered intravenously with 20 ml
219156674|NCT00595790|BIOLOGICAL|IC51|
219729037|NCT00004485|DRUG|cyclosporine|
219156675|NCT00708188|DEVICE|Multidetector raw CT|Multidetector raw CT
219156676|NCT01014273|PROCEDURE|Percutaneous Coronary Intervention|
219156677|NCT02650544|DRUG|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
219234048|NCT00800176|DRUG|RO4998452|40mg po daily for 12 weeks
219234049|NCT04614805|BEHAVIORAL|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
219234050|NCT04755972|OTHER|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
219729038|NCT00004485|DRUG|fludarabine|
219729039|NCT00004485|DRUG|mycophenolate mofetil|
219729040|NCT00004485|PROCEDURE|Bone Marrow Transplantation|
219729041|NCT01142687|DIETARY_SUPPLEMENT|dihydrocapsiate capsule|"* Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
219729042|NCT02454764|DRUG|Tenofovir + Interferon alpha 2b|
219729043|NCT02454764|DRUG|Tenofovir disoproxil Fumarate|
219729044|NCT01172301|DIETARY_SUPPLEMENT|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
219729045|NCT04743596|DEVICE|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
219729046|NCT04981561|DRUG|GATE-251|Single dose of GATE-251
219729047|NCT04981561|DRUG|Placebo|Placebo
219729048|NCT05328895|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
219729049|NCT06042660|OTHER|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
219729050|NCT04644757|OTHER|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
219729051|NCT05082155|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
219729052|NCT05082155|DRUG|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
219729053|NCT05014230|DIETARY_SUPPLEMENT|Open Placebo|Zeebo
219729054|NCT05014230|OTHER|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
219729055|NCT04545138|OTHER|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
219729056|NCT04545138|OTHER|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
219729057|NCT02082483|OTHER|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
219729058|NCT02357485|BIOLOGICAL|ADSC|Single injection of ADSC
219729059|NCT02797535|PROCEDURE|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
219729060|NCT04209842|DEVICE|gastric balloon|non surgical weight loss via placement of gastric balloon
219729061|NCT03874403|PROCEDURE|DSA|The changes on DSA on NIVATS and VATS
219729062|NCT02459925|BEHAVIORAL|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
219729063|NCT02459925|BEHAVIORAL|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
219729064|NCT00145327|DRUG|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
219729065|NCT00145327|DRUG|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
219729066|NCT00661154|DRUG|Bevacizumab|2-12microCi IV injection
219729067|NCT05881330|DEVICE|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
219156678|NCT02650544|DRUG|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
219729068|NCT02802865|DRUG|Clomiphene|
219156679|NCT01777750|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
219156680|NCT01501604|DRUG|BKM120|100 MG PO QD in cycles of 28 days
219156681|NCT05075083|BIOLOGICAL|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
219156682|NCT04452318|DRUG|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
219729069|NCT02802865|DRUG|Letrozole|
219729070|NCT05931900|DEVICE|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
219729071|NCT05071833|DIETARY_SUPPLEMENT|Peppermint oil.|Peppermint oil.
219729072|NCT05071833|OTHER|Placebo|Placebo
219156683|NCT04452318|DRUG|Placebo|SC or IM injections
219156684|NCT06093243|OTHER|data collection|data collection
219234051|NCT04755972|OTHER|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
219729073|NCT06458166|OTHER|Assessment of low frequency fatigue using low frequency eletrical stimulation|Pre-programmed muscle electrical stimuli will be applied via Myocene® software using 3 electrodes: 1 cathode (5 x 10 cm) placed transversely over the proximal quadriceps femoris, and 2 anodes (5 x 5 cm) over the distal vastus medialis and vastus lateralis. Sixteen sets of stimuli will be administered with 5 seconds between sets. Each set consists of a single pulse, a train of 5 stimuli at 20 Hz, and a train of 18 stimuli at 120 Hz, with 1-second intervals between. The stimulation intensity starts at 25 mA and increases by 1 mA per set, reaching 40 mA in the final set. The Myocene® software calculates the ratio of low- to high-frequency evoked forces within each set. The outcome (Powerdex) is the median value of these 16 ratios for each leg. This evaluation will be conducted on both legs, taking 2 minutes per leg.
219156685|NCT04456725|BEHAVIORAL|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
219156686|NCT04456725|BEHAVIORAL|Control|Usual care
219156687|NCT04320771|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
219156688|NCT04666493|OTHER|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
219156689|NCT00665340|DRUG|Placebo|Matching placebo
219156690|NCT00665340|DRUG|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
219156691|NCT05758012|DRUG|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
219234052|NCT04755972|OTHER|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
219729074|NCT05051358|PROCEDURE|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
219729075|NCT06314035|OTHER|COPD Patient Decision Aid|Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
219729076|NCT06314035|OTHER|General Health Coaching Intervention|The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
219729077|NCT04102644|OTHER|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
219729078|NCT06366958|PROCEDURE|excision of dorsal wrist ganglion|open and arthroscopic excision of dorsal wrist ganglion
219156692|NCT05758012|DRUG|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
219156693|NCT03632759|DRUG|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
219156694|NCT03632759|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
219156695|NCT06449859|DRUG|TQC2938 Injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
219156696|NCT06449859|DRUG|TQC2938 Placebo|TQC2938 Placebo is a placebo comparator
219156697|NCT02831361|DRUG|Gemigliptin|
219156698|NCT02831361|DRUG|Gemigliptin placebo|
219156699|NCT02831361|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
219156700|NCT02831361|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
219156701|NCT00543816|DRUG|MK0767|
219234053|NCT04000399|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
219234054|NCT03511495|DIAGNOSTIC_TEST|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
219234055|NCT01666821|OTHER|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
219234056|NCT02429973|DRUG|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
219729079|NCT06165653|BEHAVIORAL|5-Minute, Audio-Recorded Guided Mediation Practice|"Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others"
219729080|NCT01728961|DRUG|Artemether/Lumefantrine (AL)|
219729081|NCT00762788|DEVICE|senofilcon A|1 week extended wear contact lens
219729082|NCT00762788|DEVICE|lotrafilcon A|1 week extended wear contact lens
219729083|NCT00762788|DEVICE|lotrafilcon B|1 week extended wear contact lens
219729084|NCT00762788|DEVICE|balafilcon A|1 week extended wear contact lens
219729085|NCT00762788|DEVICE|comfilcon A|1 week extended wear contact lens
219729086|NCT00762788|DEVICE|etafilcon A|1 week extended wear contact lens
219729087|NCT04416685|PROCEDURE|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
219729088|NCT04416685|PROCEDURE|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
219729089|NCT04416685|PROCEDURE|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
219729090|NCT04236466|DEVICE|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
219729091|NCT04236466|DEVICE|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
219729092|NCT02992431|BEHAVIORAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
219729093|NCT02992431|OTHER|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
219729094|NCT04096885|DIAGNOSTIC_TEST|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
219729095|NCT01454063|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
219729096|NCT01454063|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
219156702|NCT06135246|DEVICE|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
219234057|NCT01691677|DRUG|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
219156703|NCT06135246|OTHER|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
219156704|NCT05338307|DIETARY_SUPPLEMENT|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
219234058|NCT01691677|DRUG|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
219729097|NCT04337073|DRUG|Propofol|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
219729098|NCT04337073|DRUG|normal saline|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
219729099|NCT05125627|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
219729100|NCT05125627|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
219729101|NCT06088628|DIAGNOSTIC_TEST|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
219729102|NCT01426659|BEHAVIORAL|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
219729103|NCT03098407|DRUG|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
219729104|NCT03098407|DRUG|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
219729105|NCT03008577|OTHER|Change in ambient operating room temperature|
219729106|NCT03818932|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
219729107|NCT03818932|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
219729108|NCT03818932|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
219729109|NCT03818932|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
219729110|NCT03818932|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
219729111|NCT03818932|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
219729112|NCT04803435|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
219729113|NCT04803435|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
219729114|NCT02074137|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
219729115|NCT02074137|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
219729116|NCT02074137|DRUG|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
219729117|NCT04819620|DRUG|PN-232|Active Drug
219729118|NCT04819620|DRUG|Placebo|Matching Placebo
219729119|NCT02669537|DEVICE|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
219729120|NCT02532946|BEHAVIORAL|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
219729121|NCT03588000|OTHER|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
219729122|NCT05803954|OTHER|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
219156705|NCT01154387|DRUG|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
219729123|NCT05803954|OTHER|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
219156706|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
219156707|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
219156708|NCT01154387|DRUG|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
219156709|NCT01154387|DRUG|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
219156710|NCT01154387|DRUG|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
219156711|NCT03638674|OTHER|DXA + CT|Two dual-energy X-ray scans + CT scan
219156712|NCT03196882|DRUG|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
219156713|NCT03196882|DRUG|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
219156714|NCT03196882|DRUG|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
219156715|NCT03840122|OTHER|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
219729124|NCT05803954|OTHER|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
219729125|NCT00045955|DRUG|Fexofenadine, Comparator = Montelukast|
219729126|NCT02021604|DRUG|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
219729127|NCT02391584|DEVICE|XprESS|Balloon dilation of the Eustachian tube
219729128|NCT02391584|OTHER|Control|Continued medical management
219729129|NCT04619030|OTHER|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
219729130|NCT04619030|OTHER|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
219729131|NCT05992740|DEVICE|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
219729132|NCT03926598|BEHAVIORAL|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
219729133|NCT03926598|BEHAVIORAL|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
219156716|NCT03840122|OTHER|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
219156717|NCT06342154|BEHAVIORAL|Endorphin Massage|The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
219156718|NCT00405054|DRUG|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
219156719|NCT05866978|BEHAVIORAL|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
219156720|NCT04132141|OTHER|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
219156721|NCT01695954|DRUG|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
219156722|NCT01695954|DRUG|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
219156723|NCT01695954|DRUG|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
219156724|NCT01695954|DRUG|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
219156725|NCT06407882|BEHAVIORAL|Conductive Exercises|Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
219234059|NCT02739100|DRUG|Triferic|
219234060|NCT01202513|DRUG|Bimatoprost 0.03% topical ophthalmic solution|
219729134|NCT03926598|BEHAVIORAL|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
219156726|NCT06407882|BEHAVIORAL|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
219156727|NCT03921866|DRUG|Palbociclib|Palbociclib
219156728|NCT02782507|BEHAVIORAL|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon \& Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
219729135|NCT03926598|BEHAVIORAL|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
219729136|NCT03926598|BEHAVIORAL|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
219729137|NCT06225752|DRUG|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
219729138|NCT06225752|DRUG|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
219729139|NCT03418974|DRUG|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
219729140|NCT03418974|DRUG|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
219729141|NCT03418974|DRUG|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
219729142|NCT00710554|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219729143|NCT00710554|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
219729144|NCT00108537|DRUG|bupropion and transdermal patch|
219729145|NCT00108537|DRUG|transdermal patch and nicotine inhaler|
219729146|NCT02003027|DRUG|BT injection|
219729147|NCT04294849|OTHER|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
219729148|NCT04294849|OTHER|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
219729149|NCT04294849|OTHER|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
219729150|NCT04294849|BEHAVIORAL|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
219729151|NCT00335192|DRUG|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
219729152|NCT00335192|DRUG|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
219156729|NCT04328727|DRUG|eltrombopag|Tablet 25mg and 12.5mg
219156730|NCT04328727|DRUG|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
219729153|NCT00335192|DRUG|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
219729154|NCT05595395|DRUG|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
219729155|NCT05595395|DRUG|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
219729156|NCT03854448|DEVICE|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
219729157|NCT00552162|PROCEDURE|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
219729158|NCT00552162|PROCEDURE|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
219729159|NCT04224051|DRUG|Metformin|Metformin target dose 2 g daily
219729160|NCT04224051|OTHER|Standard care|Abdominal aortic aneurysm surveillance
219729161|NCT05562635|COMBINATION_PRODUCT|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
219156731|NCT04328727|DRUG|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
219156732|NCT03888105|DRUG|Odronextamab|Administered by intravenous (IV) infusion
219156733|NCT06329973|DRUG|Fruquintinib in combination with Sintilimab and CAPEOX|Different doses of fruquintinib combined with sintilimab and CAPEOX
219156734|NCT04487431|DRUG|BAY1817080|Oral single dose
219156735|NCT04487431|DRUG|[14C]BAY1817080|Oral single dose
219156736|NCT00522782|DRUG|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
219729162|NCT05562635|COMBINATION_PRODUCT|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
219729163|NCT05562635|COMBINATION_PRODUCT|Placebo intervention|Application of placebo without CBD
219729164|NCT00657501|DRUG|testosterone gel|once daily transdermal gel, 300 mcg
219729165|NCT00657501|DRUG|placebo gel|once daily transdermal placebo gel
219729166|NCT04354688|DEVICE|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
219729167|NCT03243188|OTHER|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
219729168|NCT05485350|DRUG|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
219729169|NCT05485350|DRUG|penpulimab|200mg, ivgtt, d1, q3w
219729170|NCT05485350|RADIATION|SBRT|55-180Gy
219729171|NCT04366583|DEVICE|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
219729172|NCT04366583|DEVICE|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
219729173|NCT02957227|DEVICE|No intervention is part of this study but patients use an EEG device during observational data collection.|
219729174|NCT02491450|DRUG|Heterosofir|1 tablet contains 400 mg sofosbuvir
219729175|NCT02491450|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
219729176|NCT03128164|DRUG|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
219729177|NCT04258098|DRUG|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
219729178|NCT03915054|DRUG|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
219729179|NCT03915054|DRUG|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
219729180|NCT01433978|DRUG|Eltrombopag|
219729181|NCT01433978|DRUG|Avatrombopag|
219729182|NCT01433978|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
219156737|NCT00522782|DEVICE|Nitric Oxide Analyzer|Niox NO analyzer
219156738|NCT03684044|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
219156739|NCT03684044|OTHER|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
219156740|NCT03581357|BEHAVIORAL|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
219156741|NCT03581357|BEHAVIORAL|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
219156742|NCT00411034|DRUG|OROS Hydromorphone HCI|
219729183|NCT04228315|DRUG|Primaquine|radical cure dosing
219729184|NCT06110182|DIETARY_SUPPLEMENT|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
219156743|NCT03703336|BIOLOGICAL|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
219156744|NCT03703336|BIOLOGICAL|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
219729185|NCT05092503|DRUG|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
219729186|NCT05092503|DRUG|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
219729187|NCT03203707|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
219729188|NCT02722603|DRUG|gabapentin|75 mg/ml gabapentin syrup
219729189|NCT02722603|DRUG|tramadol|100 mg/ml tramadol oral drops
219729190|NCT02722603|OTHER|placebo tramadol|placebo tramadol oral drops
219729191|NCT02722603|OTHER|placebo gabapentin|placebo gabapentin syrup
219729192|NCT02618733|DRUG|Ticagrelor|90mg, twice a day
219729193|NCT02618733|DRUG|Clopidogrel|75mg, once a day
219729194|NCT02266862|RADIATION|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
219156745|NCT06045845|DIETARY_SUPPLEMENT|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
219156746|NCT06045845|DIETARY_SUPPLEMENT|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
219156747|NCT00418496|DRUG|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
219156748|NCT00418496|DRUG|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
219234061|NCT00687869|BEHAVIORAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
219729195|NCT00315029|BEHAVIORAL|evidence based decision aid|evidence based decision aid
219729196|NCT00315029|BEHAVIORAL|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
219729197|NCT03115658|BEHAVIORAL|Physical Activity|12 week print based intervention
219729198|NCT02018887|DRUG|LY2969822|Capsules administered orally
219729199|NCT02018887|DRUG|Placebo|Capsules administered orally
219729200|NCT01339182|DRUG|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
219729201|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
219729202|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
219729203|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
219729204|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
219234062|NCT00687869|BEHAVIORAL|Case management|Usual stroke aftercare plus patient-information-notes
219234063|NCT05473806|DRUG|Pioglitazone 15 Mg Oral Tablet|24weeks dose
219234064|NCT05473806|DRUG|Evogliptin 5mg|24weeks dose
219234065|NCT01489774|DRUG|Placebo|single and multiple dose
219156749|NCT00595413|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
219156750|NCT00595413|DRUG|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
219156751|NCT00595413|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
219156752|NCT00595413|BIOLOGICAL|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
219156753|NCT02376244|OTHER|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
219234066|NCT01489774|DRUG|CJ-12406|single and multiple dose
219234067|NCT04486820|OTHER|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
219234068|NCT03528603|OTHER|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
219234069|NCT03528603|OTHER|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
219729205|NCT05416281|OTHER|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
219729206|NCT02246985|DIETARY_SUPPLEMENT|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
219729207|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
219729208|NCT02246985|DIETARY_SUPPLEMENT|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
219729209|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
219729210|NCT05891327|DIETARY_SUPPLEMENT|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
219729211|NCT05891327|DIETARY_SUPPLEMENT|Placebo|Placebo
219729212|NCT01035307|GENETIC|gene expression analysis|
219729213|NCT01035307|GENETIC|microarray analysis|
219729214|NCT01035307|GENETIC|proteomic profiling|
219729215|NCT01035307|OTHER|laboratory biomarker analysis|
219729216|NCT04376632|DIETARY_SUPPLEMENT|Pecan ADD|Raw pecan halves without dietary substitution instructions
219729217|NCT04376632|DIETARY_SUPPLEMENT|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
219729218|NCT04053452|DIAGNOSTIC_TEST|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
219729219|NCT04053452|DIAGNOSTIC_TEST|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
219729220|NCT01421134|DRUG|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
219234070|NCT00336791|DRUG|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle."
219234071|NCT00336791|DRUG|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle."
219729221|NCT01421134|DRUG|Placebo|Placebo
219729222|NCT05507229|BIOLOGICAL|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
219729223|NCT05507229|BIOLOGICAL|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
219729224|NCT02959892|DRUG|Amphetamine|Amphetamine tablets.
219729225|NCT02959892|DRUG|TAK -041|TAK-041 oral suspension.
219729226|NCT02959892|DRUG|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|\[11C\]PHNO injection.
219729227|NCT06009354|OTHER|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
219729228|NCT06025058|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
219729229|NCT00580294|DRUG|Oxymorphone|IV PO
219729230|NCT05424809|BEHAVIORAL|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
219729231|NCT02399800|PROCEDURE|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
219729232|NCT02399800|PROCEDURE|No Celiac Block|EUS but no celiac block performed
219729233|NCT02399800|DRUG|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
219729234|NCT03148925|BIOLOGICAL|SELA-070|Sub-cutaneous injection, multiple dose
219729235|NCT03148925|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
219729236|NCT04607447|BEHAVIORAL|low intracranial pressure strategy treatment|"1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression"
219234072|NCT00336791|DRUG|Doxorubicin|FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
219234073|NCT00336791|DRUG|Paclitaxel|80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
219729237|NCT04607447|DRUG|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
219729238|NCT04617223|PROCEDURE|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
219729239|NCT03364686|BIOLOGICAL|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
219729240|NCT00954655|GENETIC|mutation analysis|
219234074|NCT00336791|DRUG|Epirubicin|FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
219234075|NCT04318834|OTHER|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
219234076|NCT05437653|OTHER|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
219234077|NCT05437653|OTHER|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
219234078|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
219234079|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
219729241|NCT00954655|GENETIC|polymorphism analysis|
219729242|NCT00954655|OTHER|laboratory biomarker analysis|
219729243|NCT00791882|BEHAVIORAL|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
219729244|NCT03255590|BEHAVIORAL|Configuration task|Training the impaired hand on a configuration task
219729245|NCT01104272|DEVICE|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
219729246|NCT04656080|BEHAVIORAL|CPET exercise testing|"* The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
219729247|NCT01098357|DRUG|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
219729248|NCT01098357|DRUG|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
219729249|NCT01098357|DRUG|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
219729250|NCT01098357|DRUG|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
219729251|NCT04983498|DRUG|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
219156754|NCT02376244|OTHER|Standard care|Standard care cardiac rehabilitation according to current guidelines
219156755|NCT04149002|BEHAVIORAL|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
219156756|NCT04149002|OTHER|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
219156757|NCT05537935|DRUG|Low Dose Naltrexone|Participants will start with 3mg LDN orally administered daily for one week, with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided with a 4-week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which are seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
219156758|NCT03908060|DRUG|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
219156759|NCT03908060|DRUG|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
219156760|NCT05322252|DRUG|Mifepristone|200mg orally
219156761|NCT05322252|DRUG|Misoprostol|Per clinician
219156762|NCT03498768|OTHER|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
219156763|NCT06288334|OTHER|1-3 Cetirizine Pharmacokinetic samples|Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
219156764|NCT03440346|OTHER|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
219156765|NCT03427021|DRUG|Oxaliplatin|Infusion
219156766|NCT01327664|BIOLOGICAL|AIN457|
219156767|NCT05363436|DRUG|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
219156768|NCT01119313|DRUG|LAS 41002|LAS 41002, once daily
219156769|NCT01119313|DRUG|Active|Active, once daily
219156770|NCT05891366|DRUG|WAL0921|Investigational product WAL0921
219156771|NCT05891366|DRUG|Placebo|Placebo product
219156772|NCT04629950|DRUG|Rimegepant|Active Agent
219156773|NCT04629950|DRUG|Placebo|Placebo Comparator
219156774|NCT05634499|DRUG|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
219156775|NCT04111471|DIETARY_SUPPLEMENT|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
219156776|NCT04111471|DIETARY_SUPPLEMENT|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
219156777|NCT03233633|DRUG|Medical Marijuana|oral capsule, high ratio CBD:THC
219156778|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd), then high carbohydrate diet|Sixty % of the energy content is based on fat, then sixty % of the energy content is based on carbohydrates
219156779|NCT02088853|DIETARY_SUPPLEMENT|high carbohydrate diet, then high fat diet|Sixty % of the energy content is based on carbohydrates, then sixty % of the energy content is based on fat
219156780|NCT02508038|PROCEDURE|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
219156781|NCT02508038|DRUG|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
219156782|NCT05315258|DRUG|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
219156783|NCT05189223|BEHAVIORAL|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
219156784|NCT05189223|BEHAVIORAL|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine, methadone, or naltrexone prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
219729252|NCT04983498|DRUG|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
219156785|NCT05768802|DEVICE|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
219156786|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
219729253|NCT04983498|OTHER|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
219156787|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
219729254|NCT04983498|OTHER|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
219234080|NCT03898505|OTHER|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
219234081|NCT00974805|DRUG|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
219729255|NCT04295265|DEVICE|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
219729256|NCT01032278|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
219729257|NCT01032278|BEHAVIORAL|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
219729258|NCT00917982|OTHER|vision therapy|
219729259|NCT00158470|DRUG|efavirenz|
219729260|NCT00158470|DRUG|didanosine|
219729261|NCT00158470|DRUG|lamivudine|
219729262|NCT00094666|DRUG|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
219729263|NCT00094666|DRUG|Comparator: placebo / Duration of Treatment - 6 weeks|
219156788|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
219234082|NCT03112005|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
219234083|NCT03112005|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
219234084|NCT03680287|DRUG|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
219234085|NCT06100159|DEVICE|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
219234086|NCT00004080|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
219234087|NCT00004080|PROCEDURE|conventional surgery|
219234088|NCT04615416|BEHAVIORAL|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
219234089|NCT05906966|OTHER|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
219729264|NCT01260753|DRUG|UR-63325|UR-63325
219729265|NCT01260753|DRUG|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
219729266|NCT01260753|DRUG|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
219729267|NCT05486702|OTHER|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
219729268|NCT03058016|OTHER|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
219729269|NCT02358395|DRUG|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
219729270|NCT02358395|DRUG|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
219729271|NCT03428555|BEHAVIORAL|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
219729272|NCT03428555|BEHAVIORAL|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
219729273|NCT00324194|DRUG|MGCD0103|MGCD0103 oral dose given 2 times per week.
219729274|NCT06339762|BEHAVIORAL|Self-Compassion Training|Self-Compassion Training
219729275|NCT05854264|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
219156789|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
219156790|NCT05949190|DRUG|Azithromycin|1g dose
219156791|NCT05949190|DRUG|Albendazole|400mg dose
219156792|NCT05949190|DRUG|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
219156793|NCT05949190|BEHAVIORAL|Cognitive behavioral therapy|Novel program developed for illiterate end-users
219156794|NCT05949190|OTHER|Insecticide-treated mosquito net|Bed net to prevent malaria
219156795|NCT02131597|DRUG|Guadecitabine|Given SC
219234090|NCT03247595|DIETARY_SUPPLEMENT|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
219234091|NCT03247595|OTHER|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
219234092|NCT03247595|OTHER|Dulcolax Tablets|4 Dulcolox Tablets
219729276|NCT05854264|DIETARY_SUPPLEMENT|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
219729277|NCT02809781|BIOLOGICAL|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
219156796|NCT04818138|DEVICE|Narrowband UVB phototherapy|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
219156797|NCT04818138|DEVICE|Broadband UVB phototherapy|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
219156798|NCT05917509|DRUG|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
219156799|NCT05917509|DRUG|Cabotegravir (CAB) LA|CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
219156800|NCT05917509|DRUG|Rilpivirine (RPV) LA|RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
219156801|NCT05635123|OTHER|No intervention|This is a prospective observational study with no intervention.
219156802|NCT01198145|DRUG|sulfasalazine|Given orally
219156803|NCT01198145|OTHER|placebo|Given orally
219156804|NCT05474105|DIETARY_SUPPLEMENT|Oral nutritional supplement|Daily drink 125 ml together with meal
219156805|NCT00127049|DRUG|gemcitabine, ifosfamide, cisplatin, G-CSF|
219156806|NCT02639975|DRUG|PBF-677|once daily oral administration
219156807|NCT02639975|DRUG|Placebo|once daily oral administration
219156808|NCT02449863|OTHER|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
219156809|NCT03324035|DRUG|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
219234093|NCT04919499|DRUG|BI 765128|BI 765128
219234094|NCT04919499|OTHER|Sham comparator|Sham comparator
219234095|NCT07026071|OTHER|Positional Release Technique|Positional Release Technique will be repeated 3 times in each session for each muscle with an aim to produce a decrease in perceived pain and an increase in pressure tolerance Iliopsoas Quadratus Lumborum Hamstrings
219729278|NCT02809781|DRUG|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
219729279|NCT05161156|COMBINATION_PRODUCT|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
219729280|NCT05161156|COMBINATION_PRODUCT|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
219729281|NCT05161156|COMBINATION_PRODUCT|Placebo|A single dose of placebo
219729282|NCT03712618|BIOLOGICAL|Platelet Transfusion - LONG Platelet Transfusion|Platelets transfused over 4-HOURS
219729283|NCT03712618|BIOLOGICAL|Platelet Transfusion - SHORT Platelet Transfusion|Platelets transfused over 60-minutes
219729284|NCT00047268|DRUG|cytarabine|
219729285|NCT00047268|DRUG|mercaptopurine|
219729286|NCT00047268|OTHER|laboratory biomarker analysis|
219729287|NCT00047268|PROCEDURE|allogeneic bone marrow transplantation|
219729288|NCT00047268|PROCEDURE|biopsy|
219729289|NCT00047268|PROCEDURE|peripheral blood stem cell transplantation|
219729290|NCT04213638|OTHER|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
219729291|NCT04213638|OTHER|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
219729292|NCT00001082|DRUG|Levocarnitine|500 mg tablet taken orally daily
219729293|NCT00001082|DRUG|Adefovir dipivoxil|120 mg tablet taken orally daily
219729294|NCT00001082|DRUG|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
219729295|NCT00626860|BIOLOGICAL|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
219729296|NCT04725981|PROCEDURE|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
219729297|NCT06122961|OTHER|No treatment given|No treatment given
219729298|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
219729299|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
219729300|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
219729301|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
219729302|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
219729303|NCT00004163|DRUG|Trastuzumab|
219729304|NCT02737787|BIOLOGICAL|WT1 Vaccine|
219729305|NCT02737787|DRUG|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
219156810|NCT03324035|DRUG|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
219156811|NCT03324035|DRUG|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
219156812|NCT06006052|COMBINATION_PRODUCT|regeneration technique|clinical procedure of regenerative endodontic as AAE mentioned using different material in each group
219156813|NCT01274299|PROCEDURE|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
219156814|NCT00035971|DRUG|raloxifene HCI and alendronate Na|
219156815|NCT05086354|BEHAVIORAL|JUMP|Warm-up, stretching, jumping rope, cool-down
219156816|NCT03757572|OTHER|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
219156817|NCT03757572|OTHER|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
219156818|NCT00891436|DRUG|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
219156819|NCT00891436|DRUG|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
219156820|NCT01697969|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
219156821|NCT00081250|DIETARY_SUPPLEMENT|creatine monohydrate|Given orally
219156822|NCT00081250|OTHER|placebo|Given orally
219156823|NCT02768467|PROCEDURE|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
219156824|NCT02768467|PROCEDURE|No Stitches|Subject will not receive stitches post buccal mucosa removal.
219729306|NCT02737787|BIOLOGICAL|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
219729307|NCT05208632|OTHER|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
219729308|NCT01936974|DRUG|Gemcitabine|Patient to receive gemzar
219729309|NCT01936974|DRUG|Bevacizumab|Patient to receive avastin
219729310|NCT01936974|DRUG|Carboplatin|Patient to receive carboplatin
219729311|NCT01936974|DRUG|Cisplatin|Patient to receive cisplatin
219729312|NCT01936974|DRUG|Oxaliplatin|Patient to receive Oxaliplatin
219156825|NCT01561989|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
219156826|NCT01561989|OTHER|questionnaire administration|Ancillary studies
219156827|NCT01561989|BIOLOGICAL|trivalent influenza vaccine|Given IM
219729313|NCT00986583|DRUG|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
219729314|NCT04323566|DRUG|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
219729315|NCT05783765|BEHAVIORAL|Heightened Drive to Eat|Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
219156828|NCT00314860|DRUG|ropinirole Extended Release (XR)|
219156829|NCT02655458|DRUG|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
219156830|NCT02655458|DRUG|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
219156831|NCT02655458|OTHER|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
219156832|NCT02655458|OTHER|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
219156833|NCT00484913|PROCEDURE|abdominal hot compress|
219156834|NCT03135184|DEVICE|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
219156835|NCT06497374|DRUG|Efgartigimod Alfa Injection|Efgartigimod+IVMP; IVMP; Efgartigimod
219156836|NCT06497374|DRUG|High-dose intravenous methylprednisolone|Efgartigimod+IVMP; IVMP; Efgartigimod
219234096|NCT07026071|OTHER|Stretching Exercises|These exercises will be performed with three repetitions per set, three sets per visit and with 30 seconds hold and 30 seconds rest Iliopsoas Quadratus Lumborum Hamstrings
219729316|NCT04584554|BEHAVIORAL|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
219729317|NCT06057428|PROCEDURE|Decompressive surgery|Decompressive surgery for lumbar spinal stenosis
219234097|NCT06699862|BEHAVIORAL|High Intensity Interval Training|Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature
219234098|NCT06699862|BEHAVIORAL|High Intensity Interval Training with Competition|Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
219156837|NCT05284136|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
219156838|NCT05284136|DRUG|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
219234099|NCT06317168|DIAGNOSTIC_TEST|Mean awake ambulatory BP measurements|Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
219234100|NCT04129450|OTHER|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
219234101|NCT04129450|OTHER|Usual PCP care|Usual one on one PCP care for chronic lower back pain
219234102|NCT02609789|DRUG|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
219234103|NCT02609789|DRUG|Placebo|0.9 percent (%) normal saline.
219729318|NCT03958604|PROCEDURE|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
219729319|NCT02253238|BEHAVIORAL|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
219729320|NCT02253238|BEHAVIORAL|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
219156839|NCT05291104|DIETARY_SUPPLEMENT|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
219156840|NCT03010813|PROCEDURE|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
219234104|NCT00132925|DRUG|Triamcinolone|
219234105|NCT04757961|BEHAVIORAL|LifeStories|The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
219234106|NCT01282983|DIETARY_SUPPLEMENT|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
219234107|NCT01282983|DIETARY_SUPPLEMENT|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
219360824|NCT02641535|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
219360825|NCT02641535|DEVICE|BC membrane protective garment|
219729321|NCT02253238|OTHER|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
219729322|NCT02253238|BEHAVIORAL|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
219729323|NCT02253238|BEHAVIORAL|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
219729324|NCT02506439|DIETARY_SUPPLEMENT|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
219729325|NCT02506439|DIETARY_SUPPLEMENT|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
219729326|NCT02506439|DIETARY_SUPPLEMENT|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
219729327|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
219729328|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
219729329|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
219729330|NCT01087619|PROCEDURE|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
219729331|NCT05610839|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
219729332|NCT02113046|PROCEDURE|pancreatico-jejunal anastomosis|
219729333|NCT02113046|PROCEDURE|traditional anastomosis|
219729334|NCT00063999|DRUG|Carboplatin|Given IV
219729335|NCT00063999|DRUG|Cisplatin|Given IV
219729336|NCT00063999|DRUG|Doxorubicin Hydrochloride|Given IV
219729337|NCT00063999|BIOLOGICAL|Filgrastim|Given SC
219729338|NCT00063999|OTHER|Laboratory Biomarker Analysis|Correlative studies
219729339|NCT00063999|DRUG|Paclitaxel|Given IV
219729340|NCT00063999|BIOLOGICAL|Pegfilgrastim|Given SC
219729341|NCT00063999|OTHER|Quality-of-Life Assessment|Ancillary studies
219729342|NCT01466231|DRUG|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
219729343|NCT02634697|BEHAVIORAL|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
219729344|NCT02192086|OTHER|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
219729345|NCT02192086|OTHER|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
219729346|NCT01647880|DRUG|Verum arm receiving Gilenya®|
219729347|NCT01647880|DRUG|Active Comparator receiving Extavia®|
219729348|NCT00976300|DRUG|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
219729349|NCT00976300|DRUG|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
219729350|NCT04593329|DRUG|TIRADENTES ASSOCIATION|Tiradentes association tablet
219729351|NCT04593329|DRUG|DIPYRONE|Dipyrone 500 mg
219729352|NCT04593329|DRUG|TRAMADOL|Tramadol 50 mg
219729353|NCT04593329|OTHER|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
219729354|NCT04593329|OTHER|DIPYRONE PLACEBO|Dipyrone placebo tablet
219729355|NCT04593329|OTHER|TRAMADOL PLACEBO|Tramadol placebo capsule
219729356|NCT01866735|OTHER|Standardized Rehabilitation Therapy|
219729357|NCT01171573|PROCEDURE|Venepuncture|Venepuncture - Taking blood
219729358|NCT01458145|BEHAVIORAL|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
219729359|NCT03306121|DRUG|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
219729360|NCT03306121|DRUG|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
219729361|NCT00031005|PROCEDURE|modified stem cell transplant|
219729362|NCT00816270|PROCEDURE|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
219729363|NCT02096536|DRUG|Vancomycin|vancomycin administration based on decision of treating physician
219729364|NCT00968942|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
219360826|NCT02641535|DEVICE|NBC mask|
219729365|NCT00968942|DRUG|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
219156841|NCT02778828|DRUG|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
219729366|NCT03556176|BEHAVIORAL|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
219729367|NCT03556176|BEHAVIORAL|Quiet rest|Quiet rest during 30 min
219729368|NCT01895647|DEVICE|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
219729369|NCT03767894|DEVICE|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
219729370|NCT03767894|DEVICE|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
219729371|NCT04243837|DRUG|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
219729372|NCT04243837|DRUG|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
219729373|NCT05481281|DRUG|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
219729374|NCT05481281|DRUG|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
219729375|NCT02555098|DEVICE|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
219729376|NCT02555098|DEVICE|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
219729377|NCT02845492|OTHER|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
219729378|NCT02845492|OTHER|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
219729379|NCT02558751|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
219729380|NCT02558751|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
219729381|NCT03849989|PROCEDURE|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
219729382|NCT05236127|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
219729383|NCT05236127|OTHER|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
219729384|NCT04215575|DEVICE|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
219729385|NCT04215575|DEVICE|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
219729386|NCT02280499|DEVICE|standard PROMOS prosthesis|
219729387|NCT01903044|PROCEDURE|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
219156842|NCT00392249|BEHAVIORAL|Supervised Treatment of Schizophrenia by a family member|
219156843|NCT02195297|OTHER|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
219156844|NCT00697489|PROCEDURE|correction of POP plus preventive continence procedure|
219156845|NCT00697489|PROCEDURE|POP surgery followed by eventual incontinence procedure|
219156846|NCT01598259|DRUG|Melatonin|po 1 hour before bedtime
219156847|NCT01598259|OTHER|placebo|po, 1 hour before bed
219156848|NCT01381406|DRUG|TIO|Patients receiving tiotropium bromide at index within the study period.
219156849|NCT01381406|DRUG|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
219156850|NCT05575622|DEVICE|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
219156851|NCT00677469|DRUG|Cholestyramine|2 grams BID
219156852|NCT00677469|DRUG|Cholestyramine|1 gram BID
219156853|NCT00677469|DRUG|Placebo powder|1 gram BID
219156854|NCT03447249|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
219156855|NCT03447249|DRUG|IVA|Participants received IVA orally once daily in the evening.
219156856|NCT03447249|DRUG|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
219729388|NCT04799665|DIAGNOSTIC_TEST|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
219729389|NCT02882516|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
219729390|NCT00120848|BIOLOGICAL|HPV 16/18 VLP AS04|
219729391|NCT05916066|DIETARY_SUPPLEMENT|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
219729392|NCT06240559|DEVICE|External imaging panel|The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.
219729393|NCT00977561|DRUG|figitumumab|Figitumumab (20 mg/kg)
219729394|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
219729395|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
219729396|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
219729397|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
219156857|NCT02818335|DRUG|LY3023414 Reference Fasted|Administered Orally
219156858|NCT02818335|DRUG|LY3023414 Test Fasted|Administered Orally
219156859|NCT02818335|DRUG|LY3023414 Test Fed|Administered Orally
219156860|NCT04760834|OTHER|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
219156861|NCT05424796|COMBINATION_PRODUCT|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
219156862|NCT05424796|COMBINATION_PRODUCT|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
219729398|NCT05610267|DEVICE|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
219729399|NCT05648916|OTHER|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
219729400|NCT02826551|DRUG|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
219729401|NCT02826551|OTHER|Ice|
219729402|NCT02826551|DRUG|Percocet|
219729403|NCT02826551|DEVICE|Knee Brace and Crutches|
219729404|NCT03830970|DIETARY_SUPPLEMENT|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
219729405|NCT03830970|DIETARY_SUPPLEMENT|White Rice|Minute Rice Long Grain White Rice
219729406|NCT01482286|DRUG|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
219729407|NCT01482286|BEHAVIORAL|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
219729408|NCT01482286|BEHAVIORAL|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
219156863|NCT05424796|DEVICE|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
219234108|NCT06103721|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
219234109|NCT06103721|DRUG|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
219234110|NCT04120064|DRUG|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
219234111|NCT05132088|DRUG|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
219234112|NCT05132088|DRUG|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
219156864|NCT05293431|OTHER|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
219156865|NCT05293431|OTHER|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
219156866|NCT01086826|DRUG|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
219156867|NCT01086826|DRUG|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
219156868|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
219156869|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
219161527|NCT06230640|DIAGNOSTIC_TEST|In vitro medical diagnostic device TEG6s® Platelet Mapping|"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."
219234113|NCT04765540|BEHAVIORAL|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station"
219234114|NCT04765540|BEHAVIORAL|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement"
219234115|NCT04765540|BEHAVIORAL|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
219234116|NCT02534129|DRUG|Difinsa53|Difinsa53 cream is applied to one half of radiation field
219234117|NCT02534129|DRUG|Aquaphor|Aquaphor is applied to one half of radiation field
219234118|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
219234119|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
219234120|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
219234121|NCT04369664|DRUG|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
219729409|NCT04199039|OTHER|Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction|"When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes."
219729410|NCT04561531|OTHER|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
219729411|NCT04942509|BEHAVIORAL|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
219234122|NCT04369664|DRUG|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
219729412|NCT02825537|DEVICE|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
219156870|NCT03930420|BEHAVIORAL|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
219156871|NCT04854772|BEHAVIORAL|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
219156872|NCT00144066|DRUG|platinum-based chemotherapy alone (up to six cycles)|
219156873|NCT00144066|DRUG|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
219156874|NCT06518070|DIAGNOSTIC_TEST|Cerviray AI|Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.
219156875|NCT03079817|OTHER|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
219156876|NCT03079817|OTHER|Proprioceptive Drills|Active balance and proprioception drills
219156877|NCT04595305|DEVICE|Cardiac resynchronization therapy by CRT-P or CRT-D implantation|Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
219156878|NCT05188118|DRUG|Cabozantinib|60mg oral once daily for 12 weeks
219156879|NCT05188118|DRUG|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
219156880|NCT05188118|DRUG|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
219156881|NCT05188118|DRUG|Lenvatinib|18mg oral once daily for 12 weeks
219156882|NCT05188118|DRUG|Everolimus|5mg oral once daily for 12 weeks
219156883|NCT05712694|DRUG|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
219156884|NCT05712694|OTHER|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
219156885|NCT05320666|BEHAVIORAL|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
219156886|NCT01388361|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
219156887|NCT01388361|DRUG|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
219156888|NCT01388361|DRUG|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
219156889|NCT03481608|OTHER|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
219156890|NCT03481608|OTHER|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
219161528|NCT03860805|PROCEDURE|Laparoscopic tubal ligation|Laparoscopic tubal ligation
219161529|NCT03860805|PROCEDURE|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
219161530|NCT05169489|BIOLOGICAL|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
219161531|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
219161532|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
219161533|NCT04887259|BIOLOGICAL|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
219161534|NCT04887259|BIOLOGICAL|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
219161535|NCT03212404|DRUG|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
219161536|NCT05008926|DRUG|Naloxegol|Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
219161537|NCT05008926|DRUG|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
219161538|NCT02380612|DEVICE|ReCell Treatment|
219161539|NCT02380612|PROCEDURE|Skin Graft|
219161540|NCT05846984|BEHAVIORAL|Learning Skills Together Intervention|Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.
219156891|NCT06261606|OTHER|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131"
219156892|NCT05079646|OTHER|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
219156893|NCT01514344|DRUG|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
219156894|NCT01514344|BIOLOGICAL|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
219156895|NCT05033938|PROCEDURE|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
219729413|NCT02825537|OTHER|No use of compression stocking|No use of compression stocking
219729414|NCT02540434|DEVICE|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
219729415|NCT02540434|OTHER|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
219729416|NCT02540434|DRUG|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
219729417|NCT04453254|OTHER|Whole Food Meal|Isocaloric/ macronutrient whole food meal
219729418|NCT04453254|OTHER|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
219729419|NCT03134638|DRUG|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
219729420|NCT03134638|DRUG|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
219729421|NCT03134638|DRUG|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
219729422|NCT03134638|DRUG|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
219729423|NCT03134638|DRUG|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
219729424|NCT03134638|DRUG|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
219729425|NCT01261377|DEVICE|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
219234123|NCT04369664|DRUG|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
219729426|NCT01261377|DRUG|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
219729427|NCT01261377|DEVICE|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
219729428|NCT01526746|DRUG|Tasimelteon|20mg capsule, once
219729429|NCT01526746|DRUG|Tasimelteon|20mg, once
219729430|NCT04696770|BEHAVIORAL|Mindfulness|Mindfulness techniques will be taught to the participants
219234124|NCT03840200|DRUG|Ipatasertib|Ipatasertib will be administered orally.
219729431|NCT00083707|DRUG|Thalidomide|
219729432|NCT03826004|DRUG|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
219729433|NCT03826004|DRUG|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
219729434|NCT03366415|DRUG|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
219729435|NCT03366415|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
219729436|NCT03366415|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
219234125|NCT03840200|DRUG|Rucaparib|Rucaparib will be administered orally.
219234126|NCT01298219|DRUG|Lubiprostone|24 mcg administered orally twice daily (BID)
219234127|NCT01298219|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
219234128|NCT05522777|OTHER|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
219234129|NCT04105764|DRUG|Rocuronium|DEEP block to PTC 1-3
219234130|NCT04105764|DRUG|Rocuronium bromide|MODERATE block to TOF1-2
219234131|NCT04620122|OTHER|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
219234132|NCT02248753|DRUG|Pharmacological cardioversion - Flecainide|
219234133|NCT02248753|PROCEDURE|Electrical cardioversion|
219234134|NCT02248753|DRUG|Metoprolol|
219234135|NCT02248753|DRUG|Verapamil|
219234136|NCT02248753|DRUG|Digoxin|
219234137|NCT02248753|DRUG|Pharmacological cardioversion - Amiodarone|
219234138|NCT05230823|BEHAVIORAL|CR with added BWLT|12 week outpatient cardiac rehab (CR) program consisting of twice-weekly supervised exercise and risk factor modification (e.g. smoking cessation, support with medication). Concurrently, the patients will attend a weekly behavioural weight loss treatment (BWLT). Weekly goal-setting facilitated by the interventionist will focus on behavioural changes in nutrition and moderate calorie reduction while also emphasizing physical activity consistent with an individualized CR exercise prescription. Patients will track caloric intake, weekly exercise, weekly weight, and success/challenges with other health goals (e.g., challenging negative thoughts, body image, mindful eating, etc.) using a daily health diary. ASPIRE-AF will be delivered virtually to small groups (8-12 patients) by senior PhD students with advanced training in cognitive-behavioural therapy and motivational communication principles.
219234139|NCT06791018|OTHER|Exercise|Participants will be asked to use a cancer-specific exercise mobile app for 12 weeks. The program is designed to achieve the goal of exercising for at least 90 minutes per week, including aerobic exercise three times a week and resistance training twice a week. While exercise equipment is not required, the app supports the optional use of an elastic resistance band or a pair of dumbbells. The app comes with various features to support the exercise journey. Participants will be able to track their progress through periodic testing, access a library of resources that includes information on exercise, and log any additional workouts they perform outside the app. The exercise prescription will be tailored to daily fatigue levels that will be rated before each workout. This ensures that the program is customized to meet individual needs and abilities.
219234140|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
219234141|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
219234142|NCT06187350|DEVICE|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score \> 7 will be double-reviewed as normal.
219156896|NCT05033938|PROCEDURE|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
219156897|NCT01070069|DEVICE|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
219156898|NCT01070069|DEVICE|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
219156899|NCT01070069|DEVICE|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
219156900|NCT05876143|DEVICE|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
219156901|NCT00002542|DRUG|CMF regimen|
219156902|NCT00002542|DRUG|cyclophosphamide|
219156903|NCT00002542|DRUG|doxorubicin hydrochloride|
219234143|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with low protein content|Young-child formula with low protein content
219234144|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
219234145|NCT04142398|OTHER|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
219234146|NCT04142398|PROCEDURE|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
219234147|NCT04142398|OTHER|Laboratory Biomarker Analysis|Correlative studies
219234148|NCT04142398|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
219234149|NCT04142398|PROCEDURE|Physical Examination|Undergo targeted physical exam
219234150|NCT04142398|OTHER|Questionnaire Administration|Ancillary studies
219156904|NCT00002542|DRUG|epirubicin hydrochloride|
219156905|NCT00002542|DRUG|fluorouracil|
219156906|NCT00002542|DRUG|methotrexate|
219156907|NCT00002542|DRUG|tamoxifen citrate|
219156908|NCT00002542|RADIATION|radiation therapy|
219156909|NCT02668250|PROCEDURE|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
219156910|NCT02668250|PROCEDURE|Usual Care|Patients receive the usual care.
219234151|NCT02372734|OTHER|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
219729437|NCT03366415|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
219729438|NCT00674232|DRUG|600 mcg misoprostol|single dose of misoprostol taken orally
219729439|NCT00674232|PROCEDURE|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
219729440|NCT00202995|DRUG|Glatiramer Acetate|20 mg s.c. daily
219234152|NCT05755698|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
219234153|NCT03380143|BEHAVIORAL|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
219234154|NCT03380143|BEHAVIORAL|Standard Practice|Community development intervention
219234155|NCT05513417|DEVICE|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
219729441|NCT00202995|DRUG|Betaseron|250 mg every other day
219729442|NCT00202995|DRUG|Rebif|44 ug 3 times a week
219156911|NCT05386953|DRUG|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
219729443|NCT04386837|OTHER|Turkish Aphasia Rapid Test|Same
219729444|NCT00000975|DRUG|Itraconazole|
219729445|NCT00084279|DRUG|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
219729446|NCT00792389|OTHER|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
219729447|NCT00792389|OTHER|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
219729448|NCT00852982|BEHAVIORAL|Exercise|Nordic walking, with walking poles, five hours per week during four months
219156912|NCT05386953|DRUG|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
219156913|NCT00419341|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration|
219234156|NCT05504720|DRUG|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
219234157|NCT05504720|DRUG|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
219729449|NCT00565760|DRUG|Q8003|Capsules
219729450|NCT00565760|DRUG|Placebo|Capsules
219729451|NCT00003501|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219729452|NCT00051350|OTHER|CARB|
219729453|NCT04479384|OTHER|Manual therapy - osteopathic techniques|"* HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases"
219729454|NCT02787798|DRUG|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
219729455|NCT02787798|DRUG|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
219729456|NCT02787798|PROCEDURE|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
219729457|NCT02285309|PROCEDURE|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
219729458|NCT01968785|RADIATION|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
219729459|NCT01968785|RADIATION|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
219729460|NCT04367935|DRUG|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
219156914|NCT06003517|PROCEDURE|Screening with PSI check list|Screening PSI with institutional check list
219156915|NCT00168753|DRUG|Alefacept|IM
219156916|NCT02792374|OTHER|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
219156917|NCT01499199|DRUG|Dolutegravir|50mg Once Daily
219156918|NCT01281163|DRUG|Akt Inhibitor MK2206|Given PO
219156919|NCT01281163|OTHER|Laboratory Biomarker Analysis|Correlative studies
219156920|NCT01281163|DRUG|Lapatinib Ditosylate|Given PO
219156921|NCT01281163|OTHER|Pharmacogenomic Study|Correlative studies
219729461|NCT03492268|BIOLOGICAL|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
219729462|NCT00117000|DRUG|testosterone undecanoate|
219729463|NCT02645162|BEHAVIORAL|Community-based Preschool|"* Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village."
219729464|NCT04313439|OTHER|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
219729465|NCT06344286|DIETARY_SUPPLEMENT|Minimal enteral nutrition|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
219729466|NCT06344286|DIETARY_SUPPLEMENT|Distilled water|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
219729467|NCT02333968|BEHAVIORAL|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
219156922|NCT01281163|OTHER|Pharmacological Study|Correlative studies
219234158|NCT05504720|DRUG|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
219234159|NCT03497156|DRUG|Lercanidipine|Patients are tested for their normal prescription lercanidipine medication
219234160|NCT05489770|DIETARY_SUPPLEMENT|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid has been used as a supplement since 1991 with no reports of adverse effects received by the Manufacturer.
219234161|NCT05489770|DIETARY_SUPPLEMENT|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom
219234162|NCT04276259|DRUG|Buprenorphine|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~6 hours) and an oral placebo tablet.
219729468|NCT06197295|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
219729469|NCT06197295|DRUG|Combination pharmacotherapy|Solifenacin 5mg and Mirabegron 25mg
219729470|NCT03950388|BEHAVIORAL|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
219234163|NCT04276259|DRUG|Naltrexone|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours) and a saline IM injection.
219234164|NCT04276259|DRUG|Oral Placebo|Oral placebo: to match the oral naltrexone.
219234165|NCT04276259|DRUG|IM Placebo|IM saline placebo: to match the i.v. buprenorphine.
219729471|NCT03757676|BEHAVIORAL|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
219156923|NCT00000699|DRUG|Inosine pranobex|
219156924|NCT00000699|DRUG|Ribavirin|
219234166|NCT04276259|DEVICE|Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.|Participants will receive two blocks of each TBS form. During the first block, stimulation intensity will be gradually escalated in 5% increments (from 80% to 110% rMT) in order to enhance tolerability. In all conditions, the investigators will apply 600 pulses of theta burst at 110% RMT. Each block of iTBS will consist of 20 trains, each lasting 2s with intertrain intervals of 8s, for a total of 192s. Each block of cTBS will consist of one continuous train of 40s. The sTBS will make use of two surface electrodes placed on the scalp.
219156925|NCT00344994|DRUG|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
219156926|NCT03799783|DRUG|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
219156927|NCT02020252|BEHAVIORAL|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
219156928|NCT03276871|PROCEDURE|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
219156929|NCT03276871|DEVICE|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
219156930|NCT01811407|BEHAVIORAL|Precommitment announcement|
219156931|NCT01811407|BEHAVIORAL|Results announcement|
219234167|NCT04556227|BEHAVIORAL|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
219156932|NCT01811407|BEHAVIORAL|Walking program|
219156933|NCT02897882|OTHER|Lung transplant|Pain evaluation
219156934|NCT00879060|DRUG|Spironolactone|spironolactone 50mg daily
219156935|NCT00879060|DRUG|Placebo|inactive placebo pill daily
219156936|NCT05936177|OTHER|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
219156937|NCT05796323|OTHER|No intervention.|The subjects will complete a survey related to workplace violance.
219156938|NCT03307278|BIOLOGICAL|House dust mite|As a stimulant to induce inflammasome activation
219156939|NCT02539225|DRUG|Ramucirumab|Administered IV
219156940|NCT02539225|DRUG|Placebo|Administered IV
219156941|NCT02539225|DRUG|S-1|Administered PO
219156942|NCT02539225|DRUG|Oxaliplatin|Administered IV
219156943|NCT02539225|DRUG|Paclitaxel|Administered IV
219156944|NCT00974831|OTHER|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
219156945|NCT00974831|OTHER|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
219156946|NCT04784026|OTHER|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
219156947|NCT04784026|OTHER|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
219156948|NCT04784026|OTHER|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
219156949|NCT04804930|PROCEDURE|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
219156950|NCT05957653|DRUG|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
219729472|NCT03757676|BEHAVIORAL|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
219729473|NCT03757676|BEHAVIORAL|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
219729474|NCT03264950|DIAGNOSTIC_TEST|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
219729475|NCT03656575|BIOLOGICAL|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
219729476|NCT05275244|DEVICE|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
219729477|NCT06449248|OTHER|Checking of appropriateness of OLP diagnosis|The above mentioned interventions will be carried out through the accurate analysis of patients' clinical records
219729478|NCT00640432|DRUG|Diclofenac|75 mg oral capsule twice daily for 7 days
219156951|NCT05957653|DRUG|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
219729479|NCT00640432|DRUG|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
219729480|NCT02588755|PROCEDURE|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
219729481|NCT02588755|PROCEDURE|TACE|TACE alone
219156952|NCT01339130|BEHAVIORAL|Computerized tests and Electrophysiological measurements|"* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
219156953|NCT04766034|BEHAVIORAL|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
219156954|NCT03638440|DRUG|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
219156955|NCT06335628|DEVICE|Geistlich Fibro-Gide®|Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.
219156956|NCT06298786|DIAGNOSTIC_TEST|Functional 6-minute mastication test|All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
219156957|NCT05884775|OTHER|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
219156958|NCT06155708|DIETARY_SUPPLEMENT|Ketone|\- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
219156959|NCT06155708|DIETARY_SUPPLEMENT|Water|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
219156960|NCT05655819|DRUG|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
219156961|NCT05655819|DRUG|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
219729482|NCT02642276|OTHER|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
219729483|NCT04145271|DEVICE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
219729484|NCT02955550|DRUG|rhIL-2|Human recombinant Interleukin-2
219729485|NCT02955550|BIOLOGICAL|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
219729486|NCT01049672|DRUG|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
219729487|NCT01049672|DRUG|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
219729488|NCT01127477|DRUG|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
219156962|NCT05026749|DRUG|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
219156963|NCT05026749|OTHER|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
219729489|NCT04875273|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
219729490|NCT04875273|DEVICE|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
219729491|NCT02818062|BIOLOGICAL|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
219729492|NCT03786055|BEHAVIORAL|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
219156964|NCT05941234|OTHER|Biological biomarker analysis|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
219156965|NCT06530212|PROCEDURE|SGJIB|sleeve gastrectomy with jejunoileal bypass with anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction.
219156966|NCT06530212|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.
219156967|NCT06290427|DEVICE|DaVinci RAPN|Robot-assisted Partial Nephrectomy with DaVinci® Surgical System
219156968|NCT06290427|DEVICE|Hugo RAS RAPN|Robot-assisted Partial Nephrectomy with Hugo™ RAS System
219729493|NCT05254210|DEVICE|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
219729494|NCT05663593|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
219729495|NCT05663593|DRUG|Placebo, tablet|Matching placebo
219729496|NCT01457430|DRUG|Icatibant|30 mg subcutaneous dose of Icatibant
219729497|NCT01636544|PROCEDURE|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
219729498|NCT04677036|OTHER|No intervention is given|No intervention given
219156969|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their primary care physician (PCP). This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
219156970|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
219156971|NCT05657119|BEHAVIORAL|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
219234168|NCT06107335|DRUG|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
219234169|NCT06107335|DRUG|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
219729499|NCT01765881|DRUG|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
219729500|NCT01765881|DRUG|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
219729501|NCT03705611|DIAGNOSTIC_TEST|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
219729502|NCT03705611|BEHAVIORAL|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
219729503|NCT03598764|PROCEDURE|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
219729504|NCT03598764|PROCEDURE|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
219729505|NCT04947904|OTHER|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
219729506|NCT01047397|DRUG|1278863A|25mg, 50mg, 100mg
219729507|NCT01047397|DRUG|Placebo|matching placebo
219729508|NCT06059079|OTHER|No Intervention|No Intervention
219729509|NCT04844346|DIETARY_SUPPLEMENT|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
219729510|NCT04844346|DIETARY_SUPPLEMENT|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
219729511|NCT04844346|BIOLOGICAL|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
219729512|NCT04055389|DRUG|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
219729513|NCT04055389|OTHER|Placebo|No study drug
219156972|NCT05657119|BEHAVIORAL|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
219729514|NCT04903509|DRUG|BI 1820237|BI 1820237
219729515|NCT04903509|DRUG|Placebo|Placebo
219729516|NCT04903509|DRUG|Saxenda®|Saxenda®
219729517|NCT04903509|DRUG|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
219729518|NCT02103946|PROCEDURE|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
219729519|NCT02103946|PROCEDURE|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
219729520|NCT01983904|DEVICE|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
219729521|NCT00529581|DRUG|C105|
219729522|NCT03167398|BIOLOGICAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
219729523|NCT02455323|OTHER|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
219729524|NCT02455323|OTHER|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
219156973|NCT05657119|BEHAVIORAL|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement"
219156974|NCT05657119|BEHAVIORAL|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
219729525|NCT02455323|OTHER|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
219729526|NCT02455323|OTHER|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
219729527|NCT00137280|BEHAVIORAL|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
219729528|NCT02173366|BEHAVIORAL|Change Club Intervention|
219729529|NCT05483634|DRUG|Vaginal estrogen supplement|Daily vaginal estrogen supplement, then twice per week. Continue for three months.
219729530|NCT05483634|PROCEDURE|Platelet-rich plasma injection|Monthly platelet-rich plasma injection for three months
219729531|NCT05484557|DRUG|Apixaban|treatment for 6 to 12 weeks
219729532|NCT05484557|DRUG|Enoxaparin Sodium|treatment for 6 to 12 weeks
219156975|NCT01701986|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
219156976|NCT01701986|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic BMT or PBSCT
219156977|NCT01701986|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219729533|NCT05001165|OTHER|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
219729534|NCT03116867|OTHER|sonosalpingography|transvaginal ultrasound with saline infusion
219729535|NCT04000724|BEHAVIORAL|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
219729536|NCT04000724|BEHAVIORAL|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
219729537|NCT04000724|BEHAVIORAL|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
219156978|NCT01701986|DRUG|Busulfan|Given IV
219156979|NCT01701986|DRUG|Clofarabine|Given IV
219156980|NCT01701986|DRUG|Gemcitabine Hydrochloride|Given IV
219156981|NCT01701986|DRUG|Mycophenolate Mofetil|Given IV then PO
219156982|NCT01701986|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
219156983|NCT01701986|OTHER|Pharmacological Study|Correlative studies
219156984|NCT01701986|BIOLOGICAL|Rituximab|Given IV
219156985|NCT01701986|DRUG|Tacrolimus|Given IV then PO
219156986|NCT03783026|DRUG|Apremilast|Tablets for oral administration
219156987|NCT04814186|DRUG|Tafamidis|61 mg, once daily, oral administration, for 12 months.
219729538|NCT02507999|DEVICE|Flotrac|Flotrac guided intervention
219729539|NCT00455455|DRUG|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
219729540|NCT00455455|DRUG|ReNu Multiplus Multipurpose Solution|lens care system
219156988|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
219156989|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
219156990|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
219156991|NCT05255146|DEVICE|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
219729541|NCT06473428|BEHAVIORAL|respiratory muscle training|Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
219156992|NCT06075446|BEHAVIORAL|ACT Raising Safe Kids|American Psychological Association ACT Raising Safe Kids
219156993|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
219156994|NCT03632941|BIOLOGICAL|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
219156995|NCT03632941|BIOLOGICAL|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
219156996|NCT06083649|BEHAVIORAL|The AI-assisted tool used in this study was called Dental Monitoring (DM).|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
219156997|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
219156998|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
219156999|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
219157000|NCT02376049|DRUG|Pimecrolimus cream|
219157001|NCT02376049|DRUG|Betamethasone dipropionate cream|
219729542|NCT06473428|BEHAVIORAL|Expiratory Muscle Training|Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
219729543|NCT06473428|BEHAVIORAL|Placebo-Controlled Expiratory Muscle Training|Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
219729544|NCT01208909|PROCEDURE|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
219157002|NCT02376049|DRUG|Clobetasol propionate cream|
219157003|NCT02376049|DRUG|Glaxal Base cream vehicle|
219157004|NCT06775938|OTHER|resident exam|Resident exam in May 2024.
219157005|NCT05374395|BEHAVIORAL|Peer Recovery Support-Delivered Dropout Prevention enhancement|Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
219157006|NCT04043455|DRUG|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
219157007|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
219157008|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
219157009|NCT04043455|DRUG|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
219157010|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
219157011|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
219157012|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
219157013|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
219157014|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
219157015|NCT04147585|OTHER|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
219157016|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310
219157017|NCT03947827|DRUG|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
219157018|NCT03447379|DRUG|P2Y12 antagonist monotherapy|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
219157019|NCT03447379|DRUG|Aspirin plus P2Y12 antagonist|DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
219157020|NCT05194917|OTHER|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
219729545|NCT06116032|DIAGNOSTIC_TEST|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
219729546|NCT00481104|DRUG|Tesofensine|
219729547|NCT01196234|DRUG|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
219729548|NCT01196234|DRUG|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
219729549|NCT02523638|DRUG|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
219729550|NCT03312166|DEVICE|Compression device|"interventions on patient are :~* surgical excision of ear lobe keloid~* application of compression device on sutured skin"
219729551|NCT03228576|COMBINATION_PRODUCT|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
219729552|NCT06016660|OTHER|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
219729553|NCT03006575|RADIATION|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
219729554|NCT03006575|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
219729555|NCT02039570|OTHER|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
219729556|NCT01827943|DRUG|Temsirolimus|Temsirolimus
219729557|NCT03570138|DEVICE|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
219729558|NCT03570138|DEVICE|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
219729559|NCT00736736|OTHER|Additional Hip Muscle Strengthening to Leg Press Exercise|
219729560|NCT00736736|OTHER|Leg Press Exercise|
219157021|NCT05194917|OTHER|Control Motivational Message|"One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code."
219157022|NCT06364059|PROCEDURE|Decompressive craniectomy with evacuation of subdural hematoma|Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
219157023|NCT06130163|PROCEDURE|endoscopic retrograde cholangiopancreatography|endoscopical clearance of the common bile duct
219161541|NCT05846984|BEHAVIORAL|Caregiver Healthy Living Intervention|Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
219729561|NCT01029873|DRUG|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
219729562|NCT01029873|BIOLOGICAL|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
219729563|NCT04992741|OTHER|education and motivational interview|The control group will remain subject to the routine process without any intervention.
219729564|NCT01356485|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
219729565|NCT01356485|DRUG|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
219729566|NCT06500689|DRUG|Allisartan Isoproxil/Sustained-Release Indapamide|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
219729567|NCT06500689|DRUG|Allisartan Isoproxil|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
219729568|NCT05141747|DRUG|MRG002|Administrated intravenously
219729569|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|The total dose of iron sucrose was 1,000 mg. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
219729570|NCT00236964|DRUG|Oral Iron + Erythropoietin|Oral iron 325 mg three time daily for 29 days. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
219729571|NCT06331481|OTHER|Fullicular fluid for cytology and biocemical analysis|"The fullicular fluid in the oocyte retrieval process is consider to medical waste. This fluid contains a verity of proteins, mitochondria and verity of cells.~The investigators using this fluid to learn about the evironment of the oocyte and its quality."
219729572|NCT04063137|DIETARY_SUPPLEMENT|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
219161542|NCT06486597|DIETARY_SUPPLEMENT|Meal|Liquid meal
219729573|NCT05549453|DEVICE|Nexstim SNBT use|Active device use
219729574|NCT05938192|PROCEDURE|vaccination|Patients will have surgery (followed by vaccination) for managing HPV-related lesions
219729575|NCT05670197|OTHER|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
219157024|NCT05386134|DEVICE|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
219729576|NCT05357378|DEVICE|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
219729577|NCT05357378|DEVICE|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes CORAIL® or DePuy Synthes ACTIS™ Total Hip System in combination with DePuy Synthes PINNACLE™Complete Acetabular Hip System.~* Zimmer Biomet Taperloc®, Zimmer Z1™ Cementless Femoral Hip Stem System or Zimmer Biomet AVENIR® Complete Hip System in combination with Zimmer Biomet G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew ANTHOLOGY® Total Hip System in combination with Smith \& Nephew R3® Acetabular System"
219729578|NCT06091345|DRUG|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%
219729579|NCT06091345|BIOLOGICAL|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl
219729580|NCT06091345|OTHER|Standard Medical Treatment|Standard Medical Treatment
219729581|NCT05853913|BEHAVIORAL|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
219729582|NCT05872945|DIAGNOSTIC_TEST|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
219729583|NCT06460051|PROCEDURE|Maxillary nerve block|Ultrasound-guided, suprazygomatic approach, infrazygomatic window
219729584|NCT04786600|DEVICE|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
219729585|NCT04786600|DRUG|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
219729586|NCT03774654|GENETIC|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2."
219729587|NCT01140373|BIOLOGICAL|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
219729588|NCT01140373|DRUG|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
219729589|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Received liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20 ml)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. Receive liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20ml.
219729590|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Receive standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg.)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. A mixture of standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg was received.
219729591|NCT05071898|DRUG|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
219729592|NCT04689009|DEVICE|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
219729593|NCT04689009|PROCEDURE|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
219729594|NCT05011383|DRUG|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
219157025|NCT05436106|BEHAVIORAL|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app."
219157026|NCT06207396|DIAGNOSTIC_TEST|serum and urine analysis|Spiking will be analyzed by immunoassay testing and high-resolution screening
219157027|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
219157028|NCT00724334|DRUG|SAR302503 (TG101348)|orally administered, once a day
219729595|NCT04579198|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
219729596|NCT04445571|PROCEDURE|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
219729597|NCT01266083|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
219729598|NCT01266083|BIOLOGICAL|GM-CSF|subcutaneous injection
219157029|NCT05570006|DRUG|ABBV-668|Oral Capsule
219157030|NCT06780059|RADIATION|Adjuvant Radiotherapy|Postoperative Radiotherapy with 3D-CRT and IMRT Techniques Following R0 Resection in BoPT and MPT Patients
219157031|NCT06780059|PROCEDURE|R0 resection|Patients who received R0 resection (complete resection without tumor margin)
219157032|NCT06781528|OTHER|Ultrasound evaluation|All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
219157033|NCT06834802|PROCEDURE|PRF|PRF membrane will be used for soft tissue grafting around implant
219729599|NCT01266083|OTHER|Montanide|adjuvant
219729600|NCT06544148|DEVICE|Electrical impedance tomography|In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
219729601|NCT06963385|DIAGNOSTIC_TEST|Radiomics|To correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk
219157034|NCT06834802|PROCEDURE|Human amniotic membrane|Human amniotic membrane will be used for soft tissue grafting around implan
219157035|NCT06834802|PROCEDURE|No grafting|No soft tissue grafting around implant
219157036|NCT06145802|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
219157037|NCT06782438|OTHER|artificial intelligence algorithm|to apply an artificial intelligence algorithm to treat the imaging
219157038|NCT06779929|DRUG|Tirzepatide|Tirzepatide
219157039|NCT06779929|DRUG|Dulaglutide|Dulaglutide
219157040|NCT06785844|DRUG|Botulinum Toxin A (Botox )|Botulinum Toxin injection
219729602|NCT06963866|BIOLOGICAL|autologous stem cell transplantation|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT). Prior to ASCT, the patients underwent 3-4 cycles of induction chemotherapy.
219729603|NCT06963866|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused 3 days after ASCT at a target dose of ≥2.0×10\^6 cells/kg.
219729604|NCT05397873|DEVICE|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
219729605|NCT00153478|BEHAVIORAL|Brief Motivational Counseling|
219157041|NCT06783231|BEHAVIORAL|Identifying with the aggressor|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the aggressor' group will be asked to try to identify, understand and adopt the point of view of Lori (the perpetrator)
219161543|NCT06274879|DRUG|Gemcitabin, Cisplatin and Durvalumab|CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
219157042|NCT06783231|BEHAVIORAL|Identifying with the victim|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the victim' group will be asked to try to identify, understand and adopt the point of view of Sophia (the victim)
219157043|NCT06783231|BEHAVIORAL|Neutral|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The control group will be asked to pay attention to the story's details and to try and remember as much details as they can.
219157044|NCT05086406|OTHER|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
219157045|NCT04968990|DEVICE|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
219157046|NCT04968990|DRUG|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
219157047|NCT04968990|PROCEDURE|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
219157048|NCT04968990|PROCEDURE|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
219729606|NCT05137340|OTHER|Nasal continuous positive airway pressure|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NCPAP within 30 minutes of birth. Under NCPAP, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
219729607|NCT05137340|OTHER|Non-invasive positive pressure ventilation|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NIPPV within 30 minutes of birth. Under NIPPV, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
219729608|NCT06099275|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
219729609|NCT02187055|DRUG|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
219729610|NCT02187055|DRUG|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
219729611|NCT02187055|BIOLOGICAL|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
219729612|NCT04159480|DEVICE|Experimental - Cogito Companion|Cogito Companion
219729613|NCT04159480|BEHAVIORAL|Active Control|Use of MyCAP
219729614|NCT03520387|PROCEDURE|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
219729615|NCT03520387|PROCEDURE|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
219729616|NCT03520387|BEHAVIORAL|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
219729617|NCT03520387|BEHAVIORAL|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
219729618|NCT03336866|DRUG|Placebo|Normal saline
219729619|NCT03336866|DRUG|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
219729620|NCT06081062|BIOLOGICAL|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
219729621|NCT06081062|DRUG|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
219729622|NCT03185351|DRUG|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
219729623|NCT03185351|DRUG|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
219729624|NCT03185351|DRUG|Midazolam|0.03 mg/kg of midazolam by I.V. route
219729625|NCT06063343|DRUG|KAND145|In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
219729626|NCT06063343|DRUG|Placebo|Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
219729627|NCT03402087|DRUG|Methotrexate|Specified dose on specified days
219729628|NCT03402087|DRUG|Leucovorin|Specified dose on specified days
219729629|NCT03402087|DRUG|BMS-986165|Specified dose on specified days
219729630|NCT00373087|DRUG|entacapone|entacapone
219729631|NCT00373087|DRUG|l dopa versus placebo|l dopa versus placebo
219234170|NCT06107335|DEVICE|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
219157049|NCT04968990|PROCEDURE|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
219157050|NCT05327543|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
219157051|NCT05327543|BEHAVIORAL|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
219157052|NCT06783166|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
219157053|NCT06783166|DRUG|Acetazolamide 500mg|Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
219157054|NCT06792357|OTHER|Vagal Active Tone Application Procedure|"First section; A video will be created that includes pictures and visuals describing the vagus nerve, explaining its benefits, and providing information about its effects and usage during the birth process.~Second section; Deep breathing and focus exercises;~Feather Breath:~Candle Breath: The pregnant woman inhaled and exhaled as if she was trying to blow out a candle.~Relaxation Breath: Deep breath Third section; Body relaxation exercises; Fourth section; Facial muscle relaxation exercises; Fifth section; Neck and larynx muscle relaxation exercises;"
219157055|NCT06701903|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
219157056|NCT06701903|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
219234171|NCT05487300|DRUG|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
219729632|NCT04322695|BEHAVIORAL|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
219729633|NCT00541775|DRUG|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
219729634|NCT00541775|DRUG|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
219729635|NCT00541775|DRUG|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
219157057|NCT06701903|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
219157058|NCT06784622|DRUG|Treatment as usual|Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
219157059|NCT06294912|OTHER|Plasmodium falciparum|Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
219729636|NCT00541775|DRUG|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
219729637|NCT00032487|DRUG|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
219729638|NCT00032487|DRUG|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
219157060|NCT06294912|DRUG|MK-7602|Capsules to be administered orally.
219157061|NCT06294912|DRUG|Artemether/lumefantrine|Tablets to be administered orally as definitive antimalarial treatment.
219157062|NCT06294912|DRUG|Primaquine|Tablets to be administered orally as definitive antimalarial treatment.
219157063|NCT06294912|DRUG|Artesunate|Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
219157064|NCT06294912|DRUG|Atovaquone/proguanil|Tablets to be administered orally as definitive antimalarial treatment.
219729639|NCT00032487|DRUG|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
219729640|NCT00032487|DRUG|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
219157065|NCT06831279|OTHER|EXERCISE|Conventional Physiotherapy + Dual-Task Approach During Walking and Balance Exercises:
219157066|NCT06090266|DRUG|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
219729641|NCT00270166|DRUG|epoetin alfa|
219729642|NCT02323061|PROCEDURE|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
219729643|NCT02269605|OTHER|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
219729644|NCT02269605|DRUG|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
219729645|NCT02269605|DRUG|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
219157067|NCT06090266|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
219157068|NCT03066843|DRUG|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
219157069|NCT03066843|DEVICE|Blue light therapy|Subjects will be exposed to blue light
219157070|NCT04703686|DRUG|Obinutuzumab|1000mg - prephase - one infusion at D-3
219157071|NCT04703686|DRUG|RO7082859|2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
219157072|NCT06832488|BEHAVIORAL|Diet|To compare the total food and energy intake of the diet with textures that require reduced oral processing versus the diet with textures that require increased oral processing by measuring weight before and after consumption of each meal and snack
219157073|NCT06834061|PROCEDURE|Ultrasound|All patients underwent high-resolution real-time sonography of the carpal tunnel (both hands) using an Ultrasound (US) machine and a 12 MHz linear array transducer. US examination will be performed before and 3 months after surgery.
219157074|NCT06832605|BEHAVIORAL|MBCT group|"MBCT is a systematic training in mindfulness meditation techniques to teach participants skills to prevent relapse/recurrence of depression. Treatment includes weekly 2-hour classes over an 8-week period with home exercises, a full day of practice (6 hours long, adapted for online delivery), and 4 booster sessions offered every 3 months from the start of the programme.~Standard pharmacological treatment usually provided to patients suffering depression."
219157075|NCT06832605|BEHAVIORAL|MBCT self-help|"The 'MBCT self-help' is based on the book 'The Mindfulness Way: An 8-week plan to free yourself from depression and emotional stress'. The book presents the 8-week MBCT course as a self-help booklet. Participants are asked to guide themselves using the self-help book. The book provides elaborate and practical mindfulness guidelines that can be exercised each week, as well as questions to help with reflection, ways to check progress and valuable feedback from others who have undertaken this MBCT programme.~Standard pharmacological treatment usually provided to patients suffering depression."
219157076|NCT06832605|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering depression.
219157077|NCT06832553|OTHER|surgical incision drep|To compare the efficacy of surgical incision with silk plaster in ETT fixation.
219157078|NCT06449053|PROCEDURE|ORGANIZATIONAL|A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
219157079|NCT05777954|OTHER|Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage|"Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques"
219157080|NCT05777954|OTHER|Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines|Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
219161544|NCT06274879|PROCEDURE|Biliary Radiofrequency Ablation|Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks
219729646|NCT04309448|BEHAVIORAL|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
219729647|NCT03044288|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
219729648|NCT03044288|OTHER|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
219729649|NCT03808454|DRUG|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
219729650|NCT03808454|OTHER|Rehabilitation|strengthening ex, posture training,...
219729651|NCT03808454|COMBINATION_PRODUCT|PRP+Rehabilitation|combine PRP and Rehabilitation
219729652|NCT04891653|DRUG|BR790|Subjects will receive oral administration of BR790.
219729653|NCT06126575|DRUG|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
219729654|NCT05249465|BEHAVIORAL|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
219729655|NCT05249465|BEHAVIORAL|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
219729656|NCT05249465|BEHAVIORAL|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
219157081|NCT03726554|DEVICE|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
219729657|NCT05249465|BEHAVIORAL|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
219157082|NCT03726554|DEVICE|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
219157083|NCT05593341|OTHER|Opioid education in person|"The presentation and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
219729658|NCT00090428|BEHAVIORAL|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
219729659|NCT00090428|BEHAVIORAL|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
219729660|NCT04939935|DRUG|Metformin XR|Extended release metformin.
219729661|NCT04939935|OTHER|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
219729662|NCT06342752|DIAGNOSTIC_TEST|Breath test|Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
219729663|NCT06342752|OTHER|Throat swabs|A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
219729664|NCT06342752|OTHER|Placental samples|After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
219161545|NCT06274879|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography with stenting|ERCP with stenting are applied at baseline and as clinically indicated
219729665|NCT06342752|OTHER|Vaginal swab|A vaginal swab will be taken before birth for microbiome analysis.
219729666|NCT06342752|OTHER|Endotracheal aspirates|Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
219729667|NCT02123875|OTHER|Physiotherapy|
219161546|NCT03433911|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
219161547|NCT03433911|PROCEDURE|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
219729668|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
219729669|NCT02563431|DEVICE|SYSTAM - SP-ED|"* Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
219729670|NCT02563431|DEVICE|Ultrasling ER 15°Donjoy - 4P-ED|"* Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
219729671|NCT02455011|BIOLOGICAL|REMD-477|
219729672|NCT05737745|BEHAVIORAL|Self-monitoring|Tracking physical activity and fruit/vegetable intake.
219729673|NCT05737745|BEHAVIORAL|Group-dynamics|Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.
219729674|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Standard|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of physical activity.
219729675|NCT05737745|BEHAVIORAL|Newsletters- Standard|Weekly newsletters support attainment of physical activity and nutrition goals.
219729676|NCT05737745|BEHAVIORAL|Newsletters- Yoga|Weekly newsletters support attainment of physical activity and nutrition goals, while including mindfulness principles.
219729677|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Yoga|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of yoga.
219729678|NCT03626675|PROCEDURE|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
219729679|NCT00859846|PROCEDURE|Arterial line placement|"The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted."
219729680|NCT04308135|DIAGNOSTIC_TEST|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
219729681|NCT04308135|DIAGNOSTIC_TEST|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
219729682|NCT04308135|DIAGNOSTIC_TEST|lab investigations|Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
219729683|NCT04308135|DIAGNOSTIC_TEST|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
219729684|NCT04308135|DIAGNOSTIC_TEST|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
219729685|NCT04308135|DIAGNOSTIC_TEST|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test."
219729686|NCT04308135|DIAGNOSTIC_TEST|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
219729687|NCT04308135|DIAGNOSTIC_TEST|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
219729688|NCT04308135|DIAGNOSTIC_TEST|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
219729689|NCT04308135|OTHER|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
219729690|NCT04308135|OTHER|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
219729691|NCT04308135|OTHER|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
219157084|NCT05593341|OTHER|Opioid education via video|"The video and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
219234172|NCT06235567|DRUG|Dextenza 0.4Mg Ophthalmic Insert|This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
219729692|NCT02520466|DIETARY_SUPPLEMENT|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
219729693|NCT03122665|DRUG|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
219729694|NCT03122665|DRUG|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
219729695|NCT02850562|BEHAVIORAL|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
219729696|NCT02850562|BEHAVIORAL|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
219729697|NCT00723242|DRUG|Viraferon-peg and Rebetol|
219157085|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
219157086|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test (without giving result)|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
219729698|NCT02547935|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
219729699|NCT02547935|DRUG|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
219729700|NCT02547935|DRUG|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
219729701|NCT01647685|DRUG|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
219157087|NCT06782685|DRUG|Irinotecan liposoma|Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1
219157088|NCT06782685|DRUG|oxaliplatin|Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1
219157089|NCT06782685|DRUG|bevacizumab|5mg/kg，i.v.，d1
219157090|NCT06782685|DRUG|5-FU|2400mg/m\^2, i.v.，46h
219157091|NCT06782685|DRUG|LV|400mg/m\^2, i.v.，d1
219157092|NCT06782685|DRUG|Irinotecan Liposomal|70mg/m\^2, i.v.，d1
219234173|NCT06235567|DRUG|topical prednisolone acetate 1% (PredForte) eye drops|The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
219729702|NCT01647685|DRUG|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
219157093|NCT06782685|DRUG|Irinotecan Liposomal|Phase II recommended dose
219157094|NCT06782685|DRUG|Oxaliplatin|Phase II recommended dose
219729703|NCT01647685|DRUG|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
219729704|NCT02487836|DEVICE|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
219729705|NCT03599466|DRUG|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
219729706|NCT03599466|DRUG|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
219729707|NCT03168997|DRUG|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
219729708|NCT03068520|DIAGNOSTIC_TEST|PET MR|PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
219729709|NCT05508594|DRUG|CT001|Intranasal
219157095|NCT06785909|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. fear of movement, pain catastrophizing, sense of coherence, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress) and inflammatory mediators.
219157096|NCT06784271|DIETARY_SUPPLEMENT|Phenylcapsaicin|2.5mg of Phenylcapsaicin
219157097|NCT06784271|DIETARY_SUPPLEMENT|Placebo|Placebo
219157098|NCT06788977|DEVICE|external Trigeminal Nerve Stimulation|"External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.~The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes."
219157099|NCT04578808|OTHER|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
219729710|NCT05508594|DRUG|Placebo|Intranasal
219729711|NCT05508594|DRUG|Sufentanil|Intranasal
219729712|NCT05508594|DRUG|Ketamine|Intranasal
219729713|NCT03461861|DRUG|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
219729714|NCT03461861|OTHER|Placebo|Placebo, oral capsule given once-daily.
219729715|NCT02416271|DRUG|Teriparatide|Administered SC
219729716|NCT02416271|DRUG|Alendronate|Administered orally
219729717|NCT02416271|DIETARY_SUPPLEMENT|Calcium|Administered orally
219157100|NCT06778174|OTHER|observational study|"The interventions are not determined by the study, which is purely observational on real world data."
219157101|NCT06778499|OTHER|Plyometric training for experimental group|The experimental groups will undergo 3 interventions a week, with one session lasting 90 minutes. The experimental group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of plyometric training, and 15 minutes of relaxation stretching.
219157102|NCT06778499|OTHER|Traditional training for control group|The control group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of general training, and 15 minutes of relaxation stretching.
219157103|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
219157104|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
219157105|NCT04843332|BEHAVIORAL|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
219157106|NCT02544074|BEHAVIORAL|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
219157107|NCT02544074|BEHAVIORAL|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
219157108|NCT00788684|DRUG|rituximab|IV infusion once weekly for four doses
219157109|NCT00788684|DRUG|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
219157110|NCT03137095|OTHER|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.
219157111|NCT03137095|OTHER|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
219157112|NCT03646604|DRUG|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
219157113|NCT05782972|DRUG|dapagliflozin (Forxiga)|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
219157114|NCT05661942|DRUG|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
219729718|NCT02416271|DIETARY_SUPPLEMENT|Vitamin D|Administered orally
219729719|NCT02416271|DRUG|Placebo-Oral|Administered orally
219157115|NCT05661942|OTHER|Placebo|Placebo/ no calcium pre-treatment.
219157116|NCT05532241|DEVICE|fixed metal orthodontic appliance|fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))
219157117|NCT05532241|DEVICE|fixed non-metal orthodontic appliance|fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))
219157118|NCT05532241|PROCEDURE|oral hygiene|conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)
219157119|NCT05532241|DRUG|Chlorhexidine mouthwash|conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
219157120|NCT04266041|DIAGNOSTIC_TEST|High-density electroencephalogram (HD-EEG)|This study will focus on obtaining a special type of high-density scalp electroencephalography (HD-EEG) recordings in patients with neurological disorders (i.e., epilepsy, brain tumor, stroke, etc.) and appropriately matched controls. HD-EEG is a scalp EEG which uses up to 256 channels compared to the standard 21 channels used for routine clinical applications. The reason for using more channels to record is for more precise localization of epileptogenic foci and/or more precise mapping of brain functions. This type of EEG requires the use of patient's own MRI scan to precisely localize activity. Therefore, all patients and controls getting an HD-EEG will require a structural MRI scan.
219157121|NCT04511455|DRUG|Cabozantinib|Cabozantinib 60 mg/day peroral
219157122|NCT04780568|DRUG|Osimertinib|Given PO
219157123|NCT04780568|DRUG|Tegavivint|Given IV
219161548|NCT05796492|DEVICE|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
219161549|NCT05796492|DEVICE|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
219161550|NCT05626725|DEVICE|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
219161551|NCT02214381|DRUG|Myocet|
219161552|NCT02214381|DRUG|Cyclophosphamide|
219161553|NCT02214381|DRUG|Paclitaxel|
219729720|NCT02416271|DRUG|Placebo-SC|Administered SC
219729721|NCT01411371|PROCEDURE|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
219729722|NCT01411371|DRUG|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
219157124|NCT05488496|BEHAVIORAL|Nature-based social intervention (NBSI), referred as Friends in Nature (FiN)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
219157125|NCT05488496|BEHAVIORAL|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
219729723|NCT07057024|OTHER|Clinical and eye movements|"Eye tracking in virtual reality environment:~Clinical and psychometric assessment :~* Auto-assessment scales : State-Trait Anxiety Inventory (STAI-TRAIT/ STAI-STATE), Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS)~* Hetero-assessment scales : Mini International Neuropsychiatric Interview (MINI DSM version 5), Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS)"
219157126|NCT03121469|DEVICE|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
219157127|NCT05526963|OTHER|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
219157128|NCT05526963|BEHAVIORAL|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
219157129|NCT06389474|BIOLOGICAL|INM004|Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
219157130|NCT06389474|OTHER|Placebo|Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
219157131|NCT02567201|OTHER|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
219157132|NCT02567201|OTHER|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
219157133|NCT04306380|OTHER|no intervention, database study|data collection from EMR for database
219157134|NCT05396443|BEHAVIORAL|Black Girls for Wellness Telehealth|Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
219157135|NCT04497168|DRUG|Citalopram 20mg|20mg daily
219234174|NCT06790095|DRUG|Cyclosporine (CsA)|Intravenous (IV) injection, loading dose of 2.5 mg/kg (diluted in 0.9% NaCl to a final volume of 50 ml) given over 2 hours, immediately followed by a continuous IV infusion of of 5 mg/kg/day (diluted in 0.9% NaCl to a final volume of 250 ml) for 3 days (72-hour).
219234175|NCT06790095|DRUG|Placebo|"Intravenous (IV) injection of 0.9% NaCl with the same dosing strategy as CsA: loading dose given over 2 hours, immediately followed by a continuous IV infusion for 3 days (72-hour)."
219729724|NCT06898463|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|0.1 mg/kg oral melatonin was administered twice
219729725|NCT06898463|DRUG|Ketamine|0.3 mg/kg intravenous ketamine was administered during anesthesia induction.
219157136|NCT04497168|DRUG|Placebo|matching placebo pills
219157137|NCT03731455|DEVICE|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
219157138|NCT04933903|DRUG|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
219157139|NCT04933903|DRUG|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
219157140|NCT04933903|RADIATION|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
219157141|NCT06365385|OTHER|Carbohydrate-last meal pattern|Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
219157142|NCT06365385|OTHER|Carbohydrate-first meal pattern|White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
219729726|NCT06143397|DEVICE|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
219729727|NCT06143397|DEVICE|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
219729728|NCT06143397|DEVICE|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
219729729|NCT06143397|BEHAVIORAL|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
219729730|NCT03137004|DRUG|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
219729731|NCT03137004|DRUG|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
219729732|NCT02929004|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
219729733|NCT00176137|PROCEDURE|preoperative radiochemotherapy|
219729734|NCT07056933|OTHER|Minoxidil solution iontophoresis|The half of the scalp of the participants will be treated with 5% minoxidil solution through Iontophoresis that will be applied at small low voltage (typically 10 V or less) continuous constant current (typically 0.5 mA/cm2 or less) to push a charged drug into skin or other tissue, twice daily at home.
219729735|NCT07056933|OTHER|saline solution iontophoresis|The other half of the scalp of the participants will be treated with placebo saline solution ( control) with the current application.
219729736|NCT04526561|PROCEDURE|Latissimus dorsi flap|Breast reconstruction
219729737|NCT04526561|PROCEDURE|Thoracodorsal artery perforator flap to breast|Breast reconstruction
219729738|NCT04526561|PROCEDURE|Deep inferior epigastric perforator flap|Breast reconstruction
219729739|NCT06068400|BIOLOGICAL|BCMA/GPRC5D double CAR-T|BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.
219157143|NCT04354636|DRUG|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
219157144|NCT04354636|OTHER|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
219157145|NCT05430373|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
219157146|NCT05320614|OTHER|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
219157147|NCT05320614|OTHER|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
219157148|NCT05132114|DIAGNOSTIC_TEST|Lugol's iodine test|Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)
219157149|NCT03189524|DRUG|Zanubrutinib|Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
219157150|NCT05800574|RADIATION|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
219157151|NCT05800574|RADIATION|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
219157152|NCT05800574|DRUG|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
219157153|NCT05607719|DRUG|Bevespi|Two puffs twice a day
219157154|NCT05607719|DRUG|Bretzri|Two puffs twice a day
219157155|NCT04955821|DIAGNOSTIC_TEST|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
219157156|NCT02980276|DRUG|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
219157157|NCT02980276|OTHER|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
219157158|NCT06008912|OTHER|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
219157159|NCT06008912|OTHER|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
219157160|NCT06371833|DEVICE|Shoulder Arthroplasy with PRIMA humeral stem|Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
219157161|NCT02124668|DRUG|Enzalutamide|oral
219157162|NCT04357288|OTHER|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
219157163|NCT04357288|OTHER|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
219157164|NCT05894967|BEHAVIORAL|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately \~80% contrast threshold) across all training sessions.
219729740|NCT02927483|DIETARY_SUPPLEMENT|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
219729741|NCT02927483|DIETARY_SUPPLEMENT|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
219729742|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
219729743|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
219729744|NCT04692688|DRUG|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
219157165|NCT05894967|BEHAVIORAL|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
219157166|NCT05894967|BEHAVIORAL|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
219157167|NCT05894967|BEHAVIORAL|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
219157168|NCT05894967|BEHAVIORAL|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
219157169|NCT05894967|BEHAVIORAL|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
219161554|NCT05333978|DEVICE|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
219729745|NCT04692688|DRUG|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
219729746|NCT05882903|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
219729747|NCT05882903|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
219729748|NCT03965299|DEVICE|VERUM TTNS|"* Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
219729749|NCT03965299|DEVICE|SHAM TTNS|"* Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
219729750|NCT05966194|DRUG|RRx-001|RRx-001 for injection (4 mg or 8 mg)
219729751|NCT05966194|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy of up to 72 Gy
219729752|NCT05966194|DRUG|Cisplatin for injection 100 mg/m2|Cisplatin for injection 100 mg/m2
219729753|NCT05040542|OTHER|maternal exposure during pregnancy|maternal exposure during pregnancy (e.g., environmental exposures and maternal inflammatory states)
219729754|NCT03808467|BEHAVIORAL|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
219729755|NCT03808467|OTHER|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
219729756|NCT04512183|OTHER|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
219157170|NCT05894967|BEHAVIORAL|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
219157171|NCT05894967|BEHAVIORAL|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
219157172|NCT05894967|BEHAVIORAL|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
219157173|NCT05894967|BEHAVIORAL|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
219157174|NCT05894967|BEHAVIORAL|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
219157175|NCT05894967|BEHAVIORAL|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
219157176|NCT05894967|BEHAVIORAL|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
219157177|NCT04384250|DIAGNOSTIC_TEST|Whole Exome Sequencing|Genetic study of patients
219157178|NCT06814678|BEHAVIORAL|Interactive Exergaming with Otago Exercise Program|Participants will receive a 12-week structured program combining interactive exergaming and Otago Exercise Program. Sessions include balance training, strength exercises, and functional mobility activities delivered through interactive gaming platforms, supervised by trained instructors.
219161555|NCT05333978|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
219729757|NCT04512183|OTHER|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
219729758|NCT03735498|OTHER|Psychological Intervention|Promote effective coping and reduce caregiving burden
219729759|NCT01253356|DEVICE|IABP|Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
219729760|NCT05760677|DRUG|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
219729761|NCT05760677|DRUG|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
219729762|NCT00713180|PROCEDURE|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
219729763|NCT02609906|DEVICE|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
219234176|NCT03736265|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
219234177|NCT00060268|DRUG|HPPH|iv
219234178|NCT05384522|OTHER|blood samples collection|Blood samples will be drawn at baseline and at 6 and 12 months from baseline
219729764|NCT02609906|DEVICE|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
219729765|NCT06214962|BEHAVIORAL|(multiple training modalities, MTM)|"1. Invite experts to discuss the course content of each unit of MTM, and then invite teachers to take pictures , and combine them into one course for the benefit of the elderly in the institution.~2. Select 3 units to try out in the dementia base, and make corrections based on the feedback of the elders and the base staff.~3. Continue to complete other units based on the experience of the first 3 units.~(2) In the Rizhao part, experts are mainly used to develop various course modules suitable for the elderly with dementia in Rizhao, and each module unit is tested on the elderly with dementia and then revised The planning task is mainly to establish a solution strategy. The method is to set up an activity course module planning or design group to develop various course modules suitable for Rizhao demented elders."
219729766|NCT03785847|DIAGNOSTIC_TEST|Ventica|Impedance pneumography measurement
219729767|NCT00480311|OTHER|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
219729768|NCT05675020|BEHAVIORAL|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
219729769|NCT06222294|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
219729770|NCT06222294|DRUG|Propofol Medium and Long Chain Fat Emulsion Injection|Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
219729771|NCT04250402|PROCEDURE|Resection|Radical resection.
219729772|NCT02014103|DRUG|Prograf|Administration of each formulation will be determined by sequence.
219729773|NCT02014103|DRUG|Tacrolimus, Sandoz|Administration of each formulation will be determined by sequence.
219729774|NCT02014103|DRUG|Tacrolimus, Reddy Laboratory|Administration of each formulation will be determined by sequence.
219729775|NCT02014103|DRUG|Tacrolimus, Mylan|Administration of each formulation will be determined by sequence.
219729776|NCT02014103|DRUG|Tacrolimus, Accord|Administration of each formulation will be determined by sequence.
219157179|NCT06814678|OTHER|Control Group with Usual Care|Participants will maintain their regular activities at community centers or facilities, including cognitive therapy, oral exercises, and upper limb training programs, during the 12-week study period
219729777|NCT02014103|DRUG|Tacrolimus, Pancea Biotech Limited|Administration of each formulation will be determined by sequence.
219729778|NCT06496100|DRUG|Triticum Aestivum|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
219729779|NCT06496100|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
219729780|NCT04165486|DRUG|ION464|ION464 will be administered by IT injection.
219729781|NCT04165486|DRUG|Placebo|ION464-matching placebo will be administered by IT injection.
219157180|NCT06757283|BIOLOGICAL|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
219157181|NCT06502145|DRUG|Azacitidine Level -1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
219157182|NCT06502145|DRUG|Azacitidine Level 0|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
219157183|NCT06502145|DRUG|Azacitidine Level 1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
219234179|NCT04746690|OTHER|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
219234180|NCT04282018|DRUG|BGB-10188|Administered as specified in the treatment arm
219234181|NCT04282018|DRUG|Zanubrutinib|Administered as specified in the treatment arm
219234182|NCT04282018|DRUG|Tislelizumab|Administered as specified in the treatment arm
219157184|NCT06502145|DRUG|Iadademstat Level -1|75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
219157185|NCT06502145|DRUG|Iadademstat Level 0|75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
219157186|NCT06502145|DRUG|Iadademstat Level 1|100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
219157187|NCT04300647|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
219234183|NCT05499507|BEHAVIORAL|COH|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
219729782|NCT06957366|OTHER|PAUSE Perioperative DOAC Management|PAUSE management is simple and easy to apply as patients having a high-bleed-risk surgery/neuraxial procedure interrupt DOACs for 2 days before and 2 days after surgery without heparin bridging or DOAC level testing.
219729783|NCT06957366|OTHER|ASRA Perioperative DOAC Management|ASRA management is more complex, requiring 72-120 hours DOAC interruption and, in selected patients, pre-operative heparin bridging and DOAC level testing.
219729784|NCT05265637|DEVICE|Visian|Visian implantable collamer lens (ICL)
219729785|NCT06260618|DEVICE|Gelfoam|GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
219729786|NCT06260618|DEVICE|Chitodex|"The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile."
219729787|NCT06019819|OTHER|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
219729788|NCT06019819|OTHER|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
219729789|NCT06964126|OTHER|Horticulture activities|In the study, the elderly individuals in the experimental group will have a total of 8 sessions of gardening activities once a week (on Thursday) for 2 months. Before the gardening activities, the garden and environment will be prepared by the researcher, the elderly individuals will be informed about the day's activities and, if necessary, videos about the activities will be watched and photographs related to the sessions will be shown.
219157188|NCT04300647|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
219157189|NCT06815224|DEVICE|Sonar|Abdominal sonar
219157190|NCT03657212|DRUG|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
219157191|NCT03408613|PROCEDURE|Positive Airway Pressure|See arm/group description
219157192|NCT03408613|PROCEDURE|Supplemental Oxygen|See arm/group description
219157193|NCT03408613|PROCEDURE|Sham|See arm/group description
219157194|NCT06784479|DRUG|Remimazolam and Propofol|Application of Remimazolam and Propofol to induce sleep
219157195|NCT06784479|DRUG|Propofol|Application of Propofol to induce sleep
219157196|NCT06784479|DRUG|Midazolam and propofol|Application of Midazolam and Propofol to induce sleep
219157197|NCT05423483|BEHAVIORAL|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
219157198|NCT02476695|DEVICE|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
219234184|NCT05499507|BEHAVIORAL|COH+|Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
219234185|NCT05987956|DRUG|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
219234186|NCT05987956|DRUG|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
219729790|NCT06964048|DEVICE|Cold Atmospheric Plasma treatment|Participants in the intervention group will be treated with cold plasma therapy with Plasana One®, as an add-on to the standard of care.
219729791|NCT06964022|OTHER|Sham-BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a sham-BFR intervention with 20mmHg exercise pressure.
219157199|NCT02476695|DEVICE|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
219157200|NCT02476695|DEVICE|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
219157201|NCT05402280|BEHAVIORAL|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
219157202|NCT06786806|OTHER|Gamified Infection Control Education Program|A four-week educational program integrating gamification techniques such as physical games, case studies, and escape rooms to teach infection control practices.Designed to enhance engagement, learning motivation, and cognitive achievement among nursing students.
219157203|NCT06786806|OTHER|Traditional Lecture-Based Instruction|Standard didactic teaching method focusing on infection control principles without incorporating gamification. Served as the comparator to evaluate the effectiveness of the gamified program.
219729792|NCT06964022|OTHER|BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a BFR intervention with an exercise pressure corresponding to 60% of the individual LOP.
219729793|NCT06964386|OTHER|The traditional physical therapy rehabilitation exercises|"It included 30 minutes of exercises as:~* Incorporated stretching (adductors, calf, and hamstring muscles)~* Range of motion for hip, knee, and ankle joints.~* Core stability exercises.~* climbing stairs and weight-bearing activities for strengthening, such as sit-to-stand and attaining standing position by half kneeling"
219729794|NCT06964386|OTHER|balance training on traditional balance board|Balance training included: - Side stepping - Stepping backward - Changing the center of gravity in one-foot balance.
219729795|NCT06964386|OTHER|program on special form of balance board|"Standing holding on the sticks of balance board (first by two sticks, then graduated by one stick).~2- Changing the grasp of hand on sticks (reciprocal catching the sticks by right and left hand).~3- Stride standing on balance board. 4- Make exercises advanced by remove sticks and throwing the ball. 5- All previous exercises do with eye closed and eye opened"
219729796|NCT06964542|PROCEDURE|Multicomponent exercise intervention|Patient will be under the complete supervision of physical therapist in a clinical setup.A total of 18 sessions of supervised multicomponent exercise training, thrice a week on alternate days for 6 consecutive weeks, session will be of 45 mins. Multicomponent exercise training including strength and progressive resistance training exercises, actvities will inc. Seated Marching,heel raises,toe raises, sit - to-stand. And balance training activities will involve tandem stands,single leg stance,weight shifting and resistance activities including weight lifting according to feasibility.
219729797|NCT06964542|PROCEDURE|Non Supervised|In non supervised group , patient will receive all the intervention with the help of exercise diary and guidance provided by the physical therapist. Patient will perform 18 sessions, thrice a week on alternative days, for 6 consecutive days for 45 mins. In diary patient is provided the tick mark table in which patient will mark the attendance on days ptn will perform the exercise. Diary is a complete guidance for home based exercise program which include QR based videos of performance of all exercises and complete guidelines are provided in urdu for the better understanding along with pictorial information. In this program activities that patient will perform includes; stairs climbing, sit to stand, leg raises, side stepping, leg raises with weight on ankles starting from 1kg to 3kg. Walk starting from 20 minutes to 40 minutes till 6 weeks. Resistance and other activities will be included.
219729798|NCT06963333|BEHAVIORAL|Breathing guided exercise|Breathing guided exercise are divided into six sections: relaxing standing, two fields breathing, regulating lung and kidney, turning side finger, running kidney hall and nourishing qi and collecting gong. Exercise time: 5 days a week, 1 to 2 times a day, a total of 24 weeks.
219729799|NCT06963333|BEHAVIORAL|Flat walking training|Flat walking training can be performed either outdoors or on flat indoor surfaces at a steady pace of 80 to 120 steps per minute for at least 30 minutes each session, raising the heart rate to the target range and maintaining it for over 10 minutes. This should be done 3 to 5 times a week, with 1 to 2 sessions each day, for a total of 24 weeks. The intensity of the exercise is moderate. The target heart rate based on heart rate reserve is calculated as (maximum heart rate during exercise - resting heart rate) × (40-60)% + resting heart rate.
219729800|NCT06160440|DRUG|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
219729801|NCT05299632|DIAGNOSTIC_TEST|99mTc-MIBI planar imaging and SPECT/CT.|Participants will undergo a Tc-MIBI scan and management will be as per the finding of the Tc MIBI scan which is the standard of care.
219157204|NCT04050176|BEHAVIORAL|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
219157205|NCT04050176|BEHAVIORAL|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
219234187|NCT05898789|BEHAVIORAL|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
219234188|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat positive control|Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
219729802|NCT05299632|DIAGNOSTIC_TEST|F- 18PSMA PET/CT imaging study|F-18 PSMA is an FDA-approved imaging agent used for PET/CT for evaluating metastatic prostate cancer. The findings of the images of F-18 PSMA will be shared with the referring /treating surgeon. However, the findings will not influence the management.
219234189|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat negative control|Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
219234190|NCT06314425|PROCEDURE|Immediate dental implants placements on fresh sockets after tooth extraction|Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to be placed within the fresh extraction sockets. The immediate implants are placed using a minimally invasive technique without vertical releasing incisions. Implant placements are performed following the SDS osteotomy protocol after sulcus marginal and crestal incision or flapless surgery. The same surgeon places implants for all patients. Infected sites are debrided using piezo surgery touch.
219729803|NCT02169401|DEVICE|Implantation with the commercially available Axium Neurostimulator|
219729804|NCT02149160|DRUG|FRM-0334|
219729805|NCT02149160|DRUG|Placebo|
219729806|NCT05980455|DEVICE|Enterra® Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
219729807|NCT04289298|BEHAVIORAL|Engage-A|Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
219729808|NCT04289298|OTHER|Training and utilizing Engage-A therapy|Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
219729809|NCT00620035|DRUG|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
219729810|NCT04889651|DRUG|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
219729811|NCT04889651|DRUG|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
219729812|NCT05067244|DRUG|MDMA|MDMA assisted psychotherapy
219729813|NCT01292265|BIOLOGICAL|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
219729814|NCT05299970|OTHER|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
219729815|NCT05792930|BEHAVIORAL|cognitive-behavioral therapy and biofeedback therapy|Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
219157206|NCT06790628|PROCEDURE|Fibula free flap|"surgical technique used in reconstructive surgery where a segment of the fibula bone, along with its blood vessels, is taken from the lower leg and transplanted to reconstruct defects in the mandible due to its length, strength, and ability to support dental implants.~The blood vessels are connected to nearby vessels at the reconstruction site to ensure the bone's survival and integration.~The procedure is highly versatile and often referred to as the gold standard for mandibular reconstruction."
219157207|NCT06790212|DRUG|Ivonescimab|20mg/kg Q3W，D1
219234191|NCT05006703|BEHAVIORAL|Breathe for Teens (Breathe4T)|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
219729816|NCT04558138|OTHER|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
219729817|NCT03588429|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
219729818|NCT03588429|DRUG|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
219729819|NCT04970589|OTHER|Mango|400g of mango/day
219729820|NCT04970589|DIETARY_SUPPLEMENT|Probiotics|1 probiotics capsule/day
219157208|NCT06790212|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2，D1，Q3W；
219157209|NCT06790212|DRUG|Capecitabine|Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
219157210|NCT06285682|DIETARY_SUPPLEMENT|OliPhenolia®)|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
219157211|NCT03845829|PROCEDURE|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
219157212|NCT02824029|DRUG|Ibrutinib|Given PO
219157213|NCT02824029|OTHER|Laboratory Biomarker Analysis|Correlative studies
219157214|NCT02824029|OTHER|Pharmacological Study|Correlative studies
219157215|NCT03806465|OTHER|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
219157216|NCT03806465|OTHER|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
219729821|NCT04970589|OTHER|Placebo|1 Placebo capsule/day
219729822|NCT04481438|OTHER|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
219729823|NCT05792722|PROCEDURE|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
219729824|NCT05792722|PROCEDURE|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
219729825|NCT04989517|DRUG|AT193|Topical
219157217|NCT03806465|OTHER|Community mortality surveillance|A verbal autopsy will be performed
219157218|NCT06790355|DEVICE|multi-cancer early detection|Blood collection for multi-cancer early detection（MCED）, followed by clinical diagnosis based on the results of MCED and standard-of-care screening
219729826|NCT03574714|OTHER|Extracellular pH|Extracellular pH gradient
219729827|NCT04377919|DIETARY_SUPPLEMENT|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
219729828|NCT04377919|DIETARY_SUPPLEMENT|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
219729829|NCT04632342|DRUG|HL301 tablet 300mg|"* Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day"
219729830|NCT04632342|DRUG|Placebo of HL301 tablet|2 tablets at once, three times a day
219729831|NCT01629563|DRUG|PGL4001 5 mg|PGL4001 5 mg daily administration
219729832|NCT01629563|DRUG|PGL4001 10 mg|PGL4001 10mg daily administration
219729833|NCT03165500|DRUG|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
219729834|NCT03165500|DRUG|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
219729835|NCT03165500|DRUG|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
219729836|NCT03165500|PROCEDURE|Third molar extraction|Anxious patients in need of third molar extraction
219729837|NCT00283985|DRUG|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
219729838|NCT00283985|DRUG|Methotrexate|3 gr/m2 at J1
219729839|NCT00283985|DRUG|Dexamethasone|40 mg/ per os at J1, J2 and J4.
219729840|NCT00283985|DRUG|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
219729841|NCT06076226|OTHER|No intervention, observation study|No intervention, observation study
219729842|NCT06391086|DEVICE|NaviFUS® Neuronavigation-guided focused ultrasound system|The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
219729843|NCT01063582|OTHER|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
219729844|NCT01063582|PROCEDURE|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
219729845|NCT00454142|DRUG|pazopanib hydrochloride|Given PO
219729846|NCT00454142|OTHER|pharmacological study|Correlative studies
219729847|NCT00454142|PROCEDURE|computed tomography|Correlative studies
219729848|NCT02560415|DEVICE|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
219729849|NCT02560415|BEHAVIORAL|Comparator|Treatment as usual
219729850|NCT02569905|DRUG|parecoxib sodium|parecoxib sodium 40mg
219729851|NCT02569905|DRUG|flurbiprofen|flurbiprofen 50mg
219729852|NCT02569905|DRUG|saline|normal saline
219729853|NCT02726269|DRUG|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
219729854|NCT02726269|DRUG|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
219729855|NCT00004201|DRUG|carboplatin|
219729856|NCT00004201|DRUG|cisplatin|
219729857|NCT00004201|DRUG|gemcitabine hydrochloride|
219729858|NCT04132466|DEVICE|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
219729859|NCT02362932|OTHER|Sanitation|Shared sanitation
219729860|NCT01599676|DIETARY_SUPPLEMENT|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
219729861|NCT01599676|DIETARY_SUPPLEMENT|Non essential amino acid|Non essential amino acid supplementation
219729862|NCT06341283|DRUG|Abemaciclib and Letrozole/Anastrozole|Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
219729863|NCT06341283|DRUG|Letrozole or Anastrozole|Take the treatment with Letrozole or Anastrozole.
219729864|NCT06341283|DRUG|Abemaciclib and Fulvestrant|Take the treatment with Abemaciclib and Fulvestrant at the same time.
219729865|NCT06341283|DRUG|Fulvestrant|Take the treatment with Fulvestrant only.
219729866|NCT04986813|DRUG|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
219729867|NCT04986813|OTHER|Normal Saline|100 ml
219729868|NCT05890586|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
219729869|NCT05890586|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219729870|NCT03989570|PROCEDURE|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
219161556|NCT05792540|DRUG|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
219729871|NCT03989570|PROCEDURE|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
219729872|NCT03989570|OTHER|control group|placebo
219729873|NCT03769974|BEHAVIORAL|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
219729874|NCT03769974|BEHAVIORAL|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
219729875|NCT03769974|BEHAVIORAL|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
219729876|NCT03611465|OTHER|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
219729877|NCT03611465|OTHER|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
219729878|NCT00353015|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
219729879|NCT00353015|DRUG|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
219729880|NCT03216291|BEHAVIORAL|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
219729881|NCT03216291|DEVICE|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
219729882|NCT03008330|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
219729883|NCT03513146|PROCEDURE|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
219729884|NCT02415803|DRUG|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
219729885|NCT02415803|DRUG|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
219729886|NCT02415803|DRUG|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
219729887|NCT02545127|DRUG|Merotocin|Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
219729888|NCT02545127|DRUG|Placebo|Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
219729889|NCT05259176|DEVICE|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
219729890|NCT05259176|DEVICE|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
219729891|NCT05259176|DEVICE|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
219729892|NCT01447771|BEHAVIORAL|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
219161557|NCT05792540|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
219729893|NCT04594083|DEVICE|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
219729894|NCT04594083|DEVICE|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
219729895|NCT01553500|DIETARY_SUPPLEMENT|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
219729896|NCT01553500|BEHAVIORAL|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
219729897|NCT00664040|OTHER|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
219729898|NCT00664040|OTHER|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
219729899|NCT00664040|OTHER|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
219729900|NCT00664040|OTHER|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
219729901|NCT04686409|BIOLOGICAL|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
219729902|NCT01245751|BIOLOGICAL|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
219729903|NCT02196909|OTHER|motor function and strength assessment|
219729904|NCT02196909|OTHER|NMR assessment|
219729905|NCT02196909|OTHER|24h urine and serum collection|
219729906|NCT05150886|DIAGNOSTIC_TEST|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
219729907|NCT05788328|DRUG|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
219729908|NCT05788328|DRUG|Rosuvastatin|Rosuvastatin as oral tablet
219729909|NCT05788328|DRUG|PF-07081532|PF-07081532 as oral tablets
219729910|NCT02227264|DRUG|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
219729911|NCT02227264|PROCEDURE|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
219729912|NCT00882388|DRUG|aspirin|aspirin 100 mg qd for 7 days
219729913|NCT00882388|DRUG|celecoxib|celecoxib 200 mg bid \* 7 days
219729914|NCT00882388|DRUG|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
219729915|NCT00882388|DRUG|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
219729916|NCT00882388|DRUG|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
219729917|NCT06021444|DEVICE|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
219729918|NCT06021444|DEVICE|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
219157219|NCT06786481|BEHAVIORAL|Educational with milnacipran|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
219161558|NCT05792540|DRUG|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
219729919|NCT03315689|DRUG|Vehicle|Vehicle Topical Solution
219729920|NCT03315689|DRUG|ATI-50002|ATI-50002 Topical Solution
219729921|NCT05448027|DEVICE|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
219729922|NCT05448027|DEVICE|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
219729923|NCT04624997|OTHER|biological sample|biological sample
219729924|NCT02197104|DRUG|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
219729925|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
219729926|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
219729927|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
219729928|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
219729929|NCT00985192|DRUG|everolimus|
219729930|NCT00985192|OTHER|laboratory biomarker analysis|
219729931|NCT01498666|DIETARY_SUPPLEMENT|L. reuteri protectis|1 tablet once daily for 4 weeks
219729932|NCT01498666|DIETARY_SUPPLEMENT|Placebo tablet|1 tablet once daily for 4 weeks
219729933|NCT02296359|BIOLOGICAL|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
219729934|NCT00669331|DRUG|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
219729935|NCT00669331|DRUG|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
219729936|NCT03929055|DEVICE|Physiological assesment|"1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound"
219729937|NCT02707744|OTHER|no intervention|
219729938|NCT02429739|BEHAVIORAL|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
219729939|NCT04402814|DIAGNOSTIC_TEST|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
219729940|NCT01610401|DRUG|Metformin|metformin 500 mg three times a day, for 3 days
219729941|NCT01610401|DRUG|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
219729942|NCT01610401|DRUG|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
219729943|NCT03699800|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
219729944|NCT05055336|OTHER|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
219729945|NCT05055336|OTHER|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
219729946|NCT02133677|DRUG|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
219729947|NCT06253208|PROCEDURE|postoperative pain|Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
219729948|NCT00509600|DRUG|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
219729949|NCT01161121|DRUG|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
219157220|NCT06786481|BEHAVIORAL|Locally Directed Therapy|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
219157221|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophil creatinine index will be calculated
219157222|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophi creatinine index will be calculated in all patients
219157223|NCT06791590|PROCEDURE|intermittent oro-esophageal|A disposable gastric tube was used to perform enteral nutrition support therapy, and contraindications were evaluated again. Inform the patient and family members of the precautions for intermittent feeding through oral tube, and play the video of the operation process to make them actively cooperate with the operation.
219729950|NCT01161121|DRUG|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
219729951|NCT04865458|DRUG|HEC89736|HEC89736 tablets QD every 28 days for each cycle
219729952|NCT02549300|OTHER|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
219729953|NCT00252889|DRUG|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
219729954|NCT05939609|OTHER|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
219729955|NCT05939609|OTHER|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
219729956|NCT05939609|OTHER|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
219729957|NCT02405637|DRUG|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
219729958|NCT02405637|DRUG|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
219729959|NCT06500728|DIAGNOSTIC_TEST|Fluorescein and Indocyanine green Angiography|The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
219729960|NCT06500728|DIAGNOSTIC_TEST|High-resolution Optical Coherence Tomography|The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
219729961|NCT06500728|DIAGNOSTIC_TEST|Angio-Optical Coherence Tomography|The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
219729962|NCT04514276|OTHER|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
219729963|NCT06277830|DEVICE|Wearable sensor|Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
219729964|NCT01346241|BEHAVIORAL|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
219157224|NCT06791590|PROCEDURE|Naso-intestinal tube nutrition support|For patients at risk of repeated aspiration and regurgitation, and for patients with gastric nutritional intolerance that cannot be improved by gastrointestinal motivity drugs, indwelling intestinal tube and retropyloric feeding are given.
219157225|NCT06575296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219157226|NCT06575296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219157227|NCT06575296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219157228|NCT06575296|PROCEDURE|Echocardiography|Undergo ECHO
219157229|NCT06575296|OTHER|Electronic Health Record Review|Ancillary studies
219157230|NCT06575296|OTHER|Quality-of-Life Assessment|Ancillary studies
219157231|NCT06575296|OTHER|Questionnaire Administration|Ancillary studies
219157232|NCT06575296|DRUG|Revumenib|Given PO
219157233|NCT06833814|DRUG|Prednisone|Either 150 mg over 3 days or 250 mg over 7 days or 350 mg over 10 days
219157234|NCT06523088|DRUG|PN20|Six dose levels of PN20 will be evaluated
219157235|NCT06523088|DRUG|Placebo|Placebo of PN20
219157236|NCT03613740|DRUG|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
219157237|NCT03613740|DRUG|Placebo|Intervention will be administered 30 minutes before breakfast.
219157238|NCT02802995|DRUG|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
219729965|NCT05172310|DRUG|68Ga-FAPI-46|"* \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
219729966|NCT05172310|DEVICE|PET/CT|"* Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~* PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~* At 60 minutes post injection, a whole-body PET will be acquired."
219729967|NCT02614027|OTHER|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
219729968|NCT02614027|OTHER|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
219729969|NCT03794544|DRUG|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
219729970|NCT03794544|COMBINATION_PRODUCT|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
219157239|NCT05447507|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
219157240|NCT05447507|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
219157241|NCT04853706|DIAGNOSTIC_TEST|3d cam|The 3D-CAM is a short interview that uses verbal responses and allows completion of the Confusion Assessment Method (CAM) diagnostic algorithm
219157242|NCT04853706|DIAGNOSTIC_TEST|DSM 5|The DSM-5 is the gold standard for diagnosing delirium. But proper use requires professional psychiatric background and training.
219157243|NCT04196504|DEVICE|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
219157244|NCT02333513|DRUG|Lomustine/Vincristine/Procarbazine|
219157245|NCT01443845|DRUG|Roflumilast|Roflumilast 500 µg, oral administration, once per day
219157246|NCT01443845|DRUG|Placebo|Dose-matched placebo, oral administration, once per day.
219157247|NCT00538122|DEVICE|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
219157248|NCT02627469|BEHAVIORAL|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
219157249|NCT02627469|DEVICE|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
219157250|NCT02627469|DEVICE|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
219157251|NCT02825641|DRUG|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
219157252|NCT02825641|DRUG|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
219157253|NCT02917343|BEHAVIORAL|mirror therapy and repetitive task training|
219729971|NCT03794544|COMBINATION_PRODUCT|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
219729972|NCT03794544|COMBINATION_PRODUCT|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
219729973|NCT02550210|DEVICE|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
219729974|NCT05232305|DIETARY_SUPPLEMENT|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
219157254|NCT02060955|BIOLOGICAL|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
219157255|NCT02060955|DRUG|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
219157256|NCT01753986|BEHAVIORAL|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
219157257|NCT01753986|BEHAVIORAL|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
219157258|NCT02847689|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
219157259|NCT02847689|BEHAVIORAL|Control Treatment|Standard of Care
219157260|NCT01947634|OTHER|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
219157261|NCT01277614|BEHAVIORAL|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
219157262|NCT04930718|OTHER|Thumb active Exercises|Active específico exercises; Reeducation program
219157263|NCT03386539|DRUG|Everolimus|Everolimus tablet
219157264|NCT03386539|DRUG|Tacrolimus|Tacrolimus capsule or liquid suspension
219157265|NCT03386539|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
219157266|NCT00520546|OTHER|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
219157267|NCT00520546|OTHER|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
219157268|NCT02613546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
219157269|NCT02613546|BEHAVIORAL|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
219157270|NCT04167020|DEVICE|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
219157271|NCT05027607|PROCEDURE|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
219157272|NCT04446598|DEVICE|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
219157273|NCT04446598|DRUG|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
219157274|NCT03401372|DRUG|Doxycycline|Oral doxycycline 100mg twice daily
219157275|NCT03401372|DRUG|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
219157276|NCT03401372|DRUG|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
219157277|NCT03401372|DRUG|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
219157278|NCT03921580|OTHER|Control Canned Tuna|210 g/day
219157279|NCT03921580|OTHER|Enriched Canned Tuna Variety 1|210 g/day
219157280|NCT03921580|OTHER|Enriched Canned Tuna Variety 2|210 g/day
219157281|NCT03769571|BEHAVIORAL|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
219157282|NCT03080324|DRUG|Fentanyl sublingual|Fentanyl sublingual
219157283|NCT03080324|DRUG|Fentanyl ev|Fentanyl ev
219234192|NCT03095261|BEHAVIORAL|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
219234193|NCT03095261|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
219234194|NCT03095261|BEHAVIORAL|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
219234195|NCT03095261|BEHAVIORAL|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
219234196|NCT00265252|DRUG|Alendronate|
219234197|NCT01362309|DRUG|d-cycloserine.|50 mg administered on two occasions.
219234198|NCT05541185|BIOLOGICAL|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
219234199|NCT05541185|BIOLOGICAL|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
219234200|NCT05541185|BIOLOGICAL|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
219157284|NCT03080324|DRUG|Placebo sublingual|Placebo sublingual
219157285|NCT03080324|DRUG|Placebo ev|Saline
219157286|NCT02101281|DRUG|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
219157287|NCT02101281|DRUG|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
219157288|NCT04626011|PROCEDURE|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
219157289|NCT04992585|DEVICE|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
219157290|NCT05372146|PROCEDURE|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
219157291|NCT01969461|BEHAVIORAL|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
219157292|NCT06350812|DRUG|PB-119|Administered subcutaneously once a week
219234201|NCT05458271|DEVICE|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
219234202|NCT05458271|PROCEDURE|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
219234203|NCT01250717|DRUG|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
219729975|NCT03848351|BEHAVIORAL|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
219157293|NCT06350812|DRUG|Placebo|Administered subcutaneously once a week
219157294|NCT01671267|BEHAVIORAL|Strength training|
219234204|NCT01250717|DRUG|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
219234205|NCT01250717|DRUG|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
219234206|NCT01250717|DRUG|Zoladex|Given subcutaneously for 4 doses every three months
219234207|NCT01250717|DRUG|Casodex|Taken orally once a day for 6 months
219729976|NCT03848351|PROCEDURE|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
219157295|NCT01671267|BEHAVIORAL|Ergonomic|
219157296|NCT01699152|DRUG|TG02 citrate|TG02 citrate capsules
219729977|NCT05010967|OTHER|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
219729978|NCT05010967|OTHER|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
219729979|NCT03106402|DRUG|topical bromfenac sodium hydrate|
219729980|NCT06253429|DRUG|Thioctic Acid 333 MG Oral Capsule|Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
219157297|NCT00180505|DEVICE|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
219157298|NCT00174382|DRUG|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
219729981|NCT06253429|DRUG|Captopril 25Mg Tab|Oral angiotensin-converting enzyme inhibitors
219729982|NCT00676052|DRUG|GSK233705 12.5mcg|Once daily via dry powder inhaler
219729983|NCT00676052|DRUG|GSK233705 25mcg|once daily via dry powder inhaler
219729984|NCT00676052|DRUG|GSK233705 50mcg|Once daily via dry powder inhaler
219729985|NCT00676052|DRUG|GSK233705 100mcg|Once daily via dry powder inhaler
219729986|NCT00676052|DRUG|GSK233705 200mcg|Once daily via dry powder inhaler
219729987|NCT00676052|DRUG|Placebo|Once daily via dry powder imhaler
219729988|NCT04557137|DRUG|Somatostatin analog|120 mg ipstyl every 28 days
219729989|NCT02334410|DEVICE|Whole body vibration (WBV)|Side-alternating WBV
219729990|NCT02361684|BEHAVIORAL|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
219729991|NCT02361684|OTHER|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
219729992|NCT00661219|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
219729993|NCT00661219|DRUG|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
219729994|NCT02569775|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
219729995|NCT00221325|DRUG|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
219729996|NCT03300336|BEHAVIORAL|STRIDE|Implementation of STRIDE inpatient hospital mobility program
219729997|NCT01495273|PROCEDURE|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
219729998|NCT01495273|PROCEDURE|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
219729999|NCT03987880|PROCEDURE|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
219730000|NCT03987880|PROCEDURE|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
219730001|NCT02246036|DEVICE|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
219730002|NCT01034527|OTHER|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
219157299|NCT04050969|PROCEDURE|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
219730003|NCT03708289|RADIATION|DXA scan|total and hip and spine dual energy x-ray absorptiometry
219730004|NCT03708289|OTHER|Achilles bone US|
219730005|NCT03708289|OTHER|Medical body composition measurements|
219730006|NCT03708289|OTHER|Resting energy expenditure measurement|
219730007|NCT01197235|DRUG|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
219730008|NCT01197235|DRUG|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
219234208|NCT01250717|PROCEDURE|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
219234209|NCT06571292|DEVICE|Intensive training with robotic exoskeleton for upper limbs|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
219234210|NCT06571292|DEVICE|Task specific training|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
219234211|NCT06569589|DIAGNOSTIC_TEST|23NaMRI Scan|23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
219234212|NCT06569589|DIETARY_SUPPLEMENT|Potassium Chloride (KCl)|K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level
219234213|NCT06570993|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
219234214|NCT00372099|DRUG|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
219234215|NCT04250181|OTHER|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
219234216|NCT00588042|DEVICE|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
219234217|NCT00588042|DEVICE|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
219157300|NCT04050969|PROCEDURE|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
219157301|NCT00002755|BIOLOGICAL|filgrastim|
219157302|NCT00002755|DRUG|CMF regimen|
219157303|NCT00002755|DRUG|cyclophosphamide|
219157304|NCT00002755|DRUG|doxorubicin hydrochloride|
219157305|NCT00002755|DRUG|fluorouracil|
219157306|NCT00002755|DRUG|methotrexate|
219157307|NCT00002755|DRUG|tamoxifen citrate|
219157308|NCT00002755|DRUG|thiotepa|
219157309|NCT00002755|PROCEDURE|autologous bone marrow transplantation|
219157310|NCT00002755|PROCEDURE|peripheral blood stem cell transplantation|
219157311|NCT00002755|RADIATION|low-LET cobalt-60 gamma ray therapy|
219157312|NCT00002755|RADIATION|low-LET electron therapy|
219157313|NCT00002755|RADIATION|low-LET photon therapy|
219157314|NCT05724420|BEHAVIORAL|STRIVE course delivery|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
219157315|NCT04153110|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219157316|NCT04153110|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
219157317|NCT04641741|DRUG|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
219157318|NCT04175899|OTHER|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
219234218|NCT04636099|DEVICE|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
219234219|NCT04287361|OTHER|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
219157319|NCT04223388|DIETARY_SUPPLEMENT|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
219157320|NCT04223388|OTHER|Placebo|Placebo product, serving size = 1 capsule/day
219157321|NCT05537675|OTHER|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
219157322|NCT06375603|OTHER|Ultrasound scans|Clinical experts will conduct non-invasive ultrasound scans from the specified nerve or plane block views and record the acquired data.
219157323|NCT03949101|DRUG|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
219157324|NCT03949101|DRUG|atropine 0.01% eye drop|use one drop into subconjunctiva
219157325|NCT01611246|DEVICE|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
219157326|NCT00296036|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Given orally
219157327|NCT00296036|DRUG|urea/lactic acid-based topical cream|Applied topically
219157328|NCT00296036|OTHER|placebo|Given orally or applied topically
219157329|NCT03428620|OTHER|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
219157330|NCT03428620|OTHER|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
219730009|NCT06516731|DIETARY_SUPPLEMENT|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
219730010|NCT03612700|OTHER|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
219157331|NCT01482975|OTHER|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
219157332|NCT01482975|OTHER|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
219157333|NCT02716246|BIOLOGICAL|UX111|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
219157334|NCT02716246|DRUG|Prophylactic Immunomodulatory (IM) Therapy|
219157335|NCT02716246|DRUG|Optimized Prophylactic IM Therapy|
219157336|NCT02716246|DRUG|Adjuvant IM Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
219157337|NCT03067116|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
219234220|NCT04512560|BEHAVIORAL|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
219234221|NCT04512560|BEHAVIORAL|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
219234222|NCT05491837|OTHER|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
219234223|NCT05491837|OTHER|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
219730011|NCT01960842|DRUG|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
219730012|NCT01960842|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
219730013|NCT01960842|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
219730014|NCT01960842|DEVICE|J-tube|jejunal tube
219730015|NCT01301001|DRUG|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
219730016|NCT01301001|DRUG|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
219730017|NCT00578058|OTHER|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
219730018|NCT05663788|OTHER|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
219730019|NCT03053830|DRUG|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
219730020|NCT04784780|DRUG|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
219730021|NCT04784780|DRUG|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
219730022|NCT06251830|DIAGNOSTIC_TEST|MRI exam with Magnetic Resonance Fingerprinting|"Acquisition of MRI data with technique Magnetic Resonance Fingerprinting"
219157338|NCT03067116|DIAGNOSTIC_TEST|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
219730023|NCT01641666|DRUG|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
219730024|NCT01641666|DRUG|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
219730025|NCT01641666|DRUG|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
219730026|NCT03612895|BEHAVIORAL|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
219730027|NCT03612895|BEHAVIORAL|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
219157339|NCT03067116|DIAGNOSTIC_TEST|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
219234224|NCT06512116|DRUG|SIBP-A17|"Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design."
219234225|NCT05847634|DEVICE|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
219234226|NCT02164578|DRUG|Rivaroxaban|
219234227|NCT02164578|DRUG|Aspirin|
219234228|NCT05426434|DRUG|Dihydroartemisinin-Piperaquine (DP)|DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
219234229|NCT05426434|DRUG|Sulfadoxine pyrimethamine (SP)|SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
219234230|NCT02507297|DEVICE|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
219234231|NCT01018992|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
219157340|NCT03067116|OTHER|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
219234232|NCT01018992|DRUG|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
219234233|NCT05886465|DRUG|Atezolizumab|1200 mg, iv.drip, Q3W
219234234|NCT05886465|DRUG|Bevacizumab|15mg/kg, iv.drip, Q3W
219234235|NCT05886465|PROCEDURE|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
219730028|NCT03612895|BEHAVIORAL|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
219157341|NCT03315481|PROCEDURE|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
219157342|NCT03315481|PROCEDURE|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
219157343|NCT01723631|DEVICE|Trap Myelin Test|
219157344|NCT05246124|OTHER|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
219730029|NCT00378560|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
219157345|NCT01858831|DRUG|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
219234236|NCT03029585|DRUG|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
219234237|NCT03029585|DRUG|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
219234238|NCT03029585|DRUG|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
219234239|NCT03029585|DRUG|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
219234240|NCT03029585|DRUG|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
219234241|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
219234242|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
219234243|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
219234244|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
219234245|NCT01092325|DRUG|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
219730030|NCT00378560|BIOLOGICAL|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
219730031|NCT06272682|PROCEDURE|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
219730032|NCT06272682|PROCEDURE|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
219730033|NCT00976391|BIOLOGICAL|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
219730034|NCT00976391|DRUG|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
219730035|NCT05285163|BEHAVIORAL|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
219157346|NCT01858831|DRUG|Atovaquone|Atovaquone
219157347|NCT06803407|OTHER|Home exercise|The study group will be given exercises that include temporomandibular joint and neck as a home exercise program.
219730036|NCT05812157|DIETARY_SUPPLEMENT|Daily dietary supplementation with Fibruline|Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
219730037|NCT05812157|DRUG|Anti-IL-17 therapy|Patients in both groups will be on anti-IL-17 therapy
219157348|NCT06803407|OTHER|Patient education|Information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to avoid, posture training
219157349|NCT01596933|DIETARY_SUPPLEMENT|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
219157350|NCT01596933|DIETARY_SUPPLEMENT|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
219730038|NCT02867852|DRUG|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
219730039|NCT02852434|DRUG|Lidocaine Gel (2%)|
219730040|NCT02852434|DRUG|Lidocaine Paracervical Block (1%)|
219730041|NCT05708222|DEVICE|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
219730042|NCT06194994|BEHAVIORAL|Parent Management Training|Behavioral parent training program aimed at increasing compliance and positive behaviours while decreasing disruptive behaviours
219730043|NCT06194994|BEHAVIORAL|Tuning Your Temper|Cognitive behavioural treatment for children focusing on arousal reduction, problem solving and cognitive restructuring.
219730044|NCT03631121|DRUG|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
219730045|NCT04574557|DIAGNOSTIC_TEST|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
219730046|NCT03203512|DIETARY_SUPPLEMENT|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
219730047|NCT03203512|DIETARY_SUPPLEMENT|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
219730048|NCT06193967|BEHAVIORAL|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
219730049|NCT06193967|BEHAVIORAL|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
219730050|NCT02783989|OTHER|white wine|A dietary beverage: a market white wine, 13º alcohol
219730051|NCT02783989|DIETARY_SUPPLEMENT|tyrosol|tyrosol in capsules
219730052|NCT06634615|OTHER|VR patient education video|The educational video is created by converting the information provided by the service nurses into a video when the patient is admitted to the ward for surgery. The video will show a 2-3 minute animation of a nurse giving information. In a patient room, the service nurse will come to the newly admitted patient and explain the concept of cholecystectomy, the reasons for removing the gallbladder, how laparoscopic cholecystectomy is performed, the advantages of laparoscopic surgery compared to open surgery, the preparation process before and on the day of surgery, the conditions to be monitored after surgery, the importance of nutrition and fluid intake, defecation, the importance of early mobilization and discharge.
219157351|NCT03403413|DEVICE|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
219157352|NCT01019213|OTHER|Septal pacing|Septal lead activated
219157353|NCT01019213|OTHER|His lead activated|His lead will be activated 80 ms before septal lead
219157354|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).
219157355|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive and behavioral influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
219157356|NCT03655262|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
219157357|NCT02309996|BEHAVIORAL|Supervisor Training Program|
219157358|NCT03201822|OTHER|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
219730053|NCT06634615|OTHER|VR family interview|Patients will have a 5-minute video call with their families in a 360° designed home environment using virtual reality glasses in the operating room waiting area.
219730054|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin|Drugs was given a few days after multimodal thermal therapy
219730055|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin|Drugs was given a few days after multimodal thermal therapy
219730056|NCT02931110|DRUG|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
219730057|NCT04346238|OTHER|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
219730058|NCT00910390|OTHER|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
219730059|NCT00910390|OTHER|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
219157359|NCT03201822|OTHER|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
219157360|NCT03201822|OTHER|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
219157361|NCT03201822|OTHER|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
219157362|NCT00996229|BEHAVIORAL|Caloric restriction|20-30% CR for 6 months
219157363|NCT00996229|DIETARY_SUPPLEMENT|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
219157364|NCT00996229|DIETARY_SUPPLEMENT|Placebo|Daily corn oil capsules for 6 months
219157365|NCT00996229|DIETARY_SUPPLEMENT|Resveratrol|daily resveratrol for 6 months
219157366|NCT03966898|DRUG|SHR6390 Tablets|SHR6390 Tablets
219157367|NCT03966898|DRUG|Placebo Tablets|Placebo Tablets
219157368|NCT03966898|DRUG|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
219730060|NCT00910390|OTHER|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
219730061|NCT00250861|DRUG|Rituximab|
219730062|NCT00250861|DRUG|Aldesleukin|
219730063|NCT05551221|DRUG|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
219730064|NCT05551221|DRUG|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
219730065|NCT05551221|DRUG|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
219730066|NCT00327132|DRUG|Omeprazole, Amoxicillin, Clarithromycin|
219730067|NCT01145222|DRUG|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
219730068|NCT01145222|DRUG|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
219730069|NCT01145222|DRUG|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
219730070|NCT01145222|DRUG|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
219730071|NCT00454402|DRUG|Alfuzosin|
219730072|NCT03266484|DIETARY_SUPPLEMENT|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
219157369|NCT04081779|OTHER|Survivorship Care Plan|Receive patient-generated SCP
219157370|NCT04081779|OTHER|Educational Intervention|Receive telephone-based educational counseling session
219157371|NCT04081779|OTHER|Questionnaire Administration|Ancillary studies
219157372|NCT04081779|OTHER|Supportive Care|Receive generic information on survivorship care
219730073|NCT03266484|DIETARY_SUPPLEMENT|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
219730074|NCT01507389|DRUG|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
219730075|NCT01571609|OTHER|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."
219157373|NCT02505321|OTHER|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
219157374|NCT02505321|PROCEDURE|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
219157375|NCT03501264|BEHAVIORAL|Online Game|LGBTQ Bullying game
219157376|NCT03501264|BEHAVIORAL|LGBTQ Resources|This group receives LGBTQ Resources
219157377|NCT05555719|DEVICE|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
219157378|NCT05555719|DEVICE|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
219157379|NCT01579968|DRUG|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
219157380|NCT03292120|OTHER|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
219157381|NCT04748939|BIOLOGICAL|recombinant subunit herpes zoster vaccine|vaccine administration
219157382|NCT02076568|BEHAVIORAL|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
219157383|NCT01833923|DRUG|anlotinib|oral medicine.
219730076|NCT02053584|DEVICE|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
219730077|NCT02053584|DEVICE|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
219730078|NCT01427946|DRUG|IPI-504|
219730079|NCT01427946|DRUG|Everolimus|
219730080|NCT01011283|DRUG|decitabine|decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
219730081|NCT01011283|DRUG|azacitidine|azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
219157384|NCT00780949|OTHER|intestinal biopsies|intestinal biopsies during routine endoscopy
219730082|NCT00950924|DEVICE|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
219730083|NCT00950924|DEVICE|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
219730084|NCT00132483|BEHAVIORAL|Instruction in physical training program|Instruction in physical training program.
219730085|NCT02822287|DRUG|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
219730086|NCT03233685|BEHAVIORAL|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
219730087|NCT03233685|BEHAVIORAL|Normal Training|Normal training routine
219730088|NCT02933476|DEVICE|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
219730089|NCT01556100|DRUG|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
219730090|NCT00416754|OTHER|counseling intervention|subjects will receive genetic counseling
219730091|NCT01272895|DEVICE|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
219730092|NCT04091308|OTHER|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
219730093|NCT04091308|OTHER|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
219157385|NCT00903539|DEVICE|SecurAcath Securement System|Subcutaneous catheter securement system
219157386|NCT05953870|OTHER|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
219157387|NCT00830934|PROCEDURE|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
219157388|NCT00830934|PROCEDURE|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
219730094|NCT04091308|OTHER|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
219730095|NCT05391074|DIETARY_SUPPLEMENT|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
219730096|NCT05391074|DIETARY_SUPPLEMENT|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
219730097|NCT02604667|OTHER|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
219730098|NCT02604667|OTHER|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
219730099|NCT02911467|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
219730100|NCT02911467|DEVICE|MRI|MRI scan following the Pyruvate injection
219730101|NCT00693459|DEVICE|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
219730102|NCT00665886|DEVICE|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
219730103|NCT00665886|DEVICE|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
219730104|NCT04447066|OTHER|No intervention|No intervention - VHIT will be used but without intervention
219730105|NCT04378088|OTHER|Validation of CEBuS|Validation of a new score for bubbles in the colon.
219730106|NCT02610257|DEVICE|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
219730107|NCT04865978|DRUG|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
219730108|NCT04865978|DRUG|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
219730109|NCT04865978|DEVICE|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
219730110|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
219730111|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
219730112|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
219730113|NCT01009242|OTHER|Placebo IV|"Single dose:~Placebo IV"
219730114|NCT01009242|OTHER|Placebo SC|"Single dose:~Placebo SC"
219730115|NCT01009242|DRUG|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
219730116|NCT01009242|DRUG|Methotrexate|Individual stable doses of methotrexate.
219730117|NCT05638139|BIOLOGICAL|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
219730118|NCT06691516|PROCEDURE|horizontal and vertical bone augmentation using computer guided cortical shell technique|Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides
219730119|NCT06691516|PROCEDURE|free hand cortical shell technique in anterior 3d defect|vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
219730120|NCT06014892|DEVICE|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
219730121|NCT06014892|DEVICE|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
219730122|NCT06014892|BEHAVIORAL|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
219730123|NCT06014892|BEHAVIORAL|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
219730124|NCT03835117|DRUG|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
219730125|NCT03835117|OTHER|Placebo|Inactive placebo comparator
219730126|NCT02192697|DRUG|ASP8273|Oral administration
219730127|NCT06444542|BEHAVIORAL|Guardant Shield|Blood-based colorectal cancer screening
219730128|NCT03365908|PROCEDURE|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
219730129|NCT03365908|DRUG|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
219730130|NCT05949216|BEHAVIORAL|Musical engagement sessions|Musical engagement sessions will be 2 hours long and involve improvisation and sight-reading of sheet music. Participants will supply their own instrument of choice to play. There will be four sessions total.
219730131|NCT05712889|DRUG|VIP236 (Q3W)|VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
219730132|NCT05712889|DRUG|VIP236 (Q2W)|VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
219730133|NCT04900935|BEHAVIORAL|POISE|POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
219730134|NCT01584388|DRUG|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
219730135|NCT04572841|DRUG|SAR441344|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
219730136|NCT04572841|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
219730137|NCT03847090|DRUG|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
219730138|NCT03847090|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
219730139|NCT03362957|DEVICE|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
219730140|NCT03362957|DIAGNOSTIC_TEST|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
219730141|NCT00428077|BIOLOGICAL|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
219157389|NCT04047719|DIAGNOSTIC_TEST|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
219234246|NCT01092325|DRUG|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
219730142|NCT00428077|GENETIC|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
219730143|NCT01433588|DEVICE|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
219730144|NCT01433588|OTHER|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
219730145|NCT04010253|DEVICE|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
219730146|NCT04010253|OTHER|Autogenic drainage|Manual aiway clearance by autogenic drainage
219730147|NCT02544815|DRUG|Digoxin|Digoxin 0.25 mg pills
219730148|NCT02544815|DRUG|Placebo|Placebo pills
219730149|NCT05198362|OTHER|Placebo|Inactive comparator
219730150|NCT05198362|DRUG|Tesomet|Fixed-dose combination
219730151|NCT00609973|DRUG|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
219730152|NCT00609973|DRUG|Placebo|Placebo bid for 6 months
219730153|NCT01414829|PROCEDURE|Gastroscopy|The reason for gastroscopy will be not related to the study
219730154|NCT04935294|DRUG|Danicopan|Oral tablet.
219730155|NCT06054464|DRUG|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
219730156|NCT06054464|DRUG|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
219730157|NCT06054464|DRUG|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
219730158|NCT02668315|BIOLOGICAL|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
219730159|NCT03039985|DEVICE|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
219730160|NCT03039985|DEVICE|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
219730161|NCT01225224|DRUG|peficitinib|oral
219730162|NCT01225224|DRUG|Placebo|oral
219730163|NCT05068830|DRUG|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
219730164|NCT05068830|DRUG|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
219730165|NCT05068830|DRUG|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
219730166|NCT05908656|PROCEDURE|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
219730167|NCT06333652|DRUG|Ravulizumab|Intravenous infusion 100 mg/ml
219730168|NCT06481969|PROCEDURE|Conventional IVF|Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.
219730169|NCT06481969|PROCEDURE|Lower abdominal liposuction and preparation of SVF|After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.
219730170|NCT06481969|PROCEDURE|Ovarian injection|Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
219730171|NCT01115621|OTHER|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
219730172|NCT05288257|BEHAVIORAL|Learning Module|Safe Cholecystectomy Learning Module
219730173|NCT00005774|DRUG|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
219730174|NCT00005774|DRUG|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
219234247|NCT00430586|DRUG|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
219234248|NCT00430586|DRUG|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
219234249|NCT03301597|BIOLOGICAL|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
219234250|NCT03301597|DRUG|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
219234251|NCT00126620|DRUG|erlotinib hydrochloride|
219234252|NCT00126620|DRUG|sorafenib tosylate|
219234253|NCT05326685|OTHER|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
219234254|NCT01506700|DEVICE|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
219234255|NCT05959902|OTHER|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
219157390|NCT02974465|PROCEDURE|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
219157391|NCT02974465|PROCEDURE|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
219157392|NCT02974465|PROCEDURE|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
219157393|NCT01672060|BEHAVIORAL|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
219234256|NCT05959902|OTHER|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
219234257|NCT01442207|PROCEDURE|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
219234258|NCT01442207|PROCEDURE|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
219234259|NCT02409888|BEHAVIORAL|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
219234260|NCT02409888|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
219234261|NCT02409888|OTHER|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
219234262|NCT02409888|OTHER|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
219360858|NCT04460755|OTHER|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219234263|NCT04255004|DEVICE|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
219234264|NCT04824456|PROCEDURE|bilateral sagittal split osteotomy using separators.|The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.
219234265|NCT02568202|OTHER|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
219234266|NCT00441168|DRUG|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
219234267|NCT00441168|DRUG|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
219234268|NCT00441168|DRUG|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
219234269|NCT00441168|DRUG|vincristine|vincristine: 0.4mg IV push on days 1 to 4
219234270|NCT03868774|PROCEDURE|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
219234271|NCT00459849|PROCEDURE|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
219234272|NCT00785031|OTHER|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
219234273|NCT03909100|DEVICE|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
219234274|NCT04252157|OTHER|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
219234275|NCT04252157|OTHER|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
219234276|NCT04252157|OTHER|Control|no kinesio or tape will be applied
219234277|NCT00893009|DRUG|Theophylline|100 mg twice a day
219234278|NCT00893009|DRUG|Placebo|Placebo
219234279|NCT00807599|PROCEDURE|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
219730175|NCT04308694|DRUG|Pharmacy-based methadone administration and dispensing|Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
219730176|NCT01941056|BIOLOGICAL|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
219730177|NCT01941056|OTHER|laboratory biomarker analysis|Correlative studies
219730178|NCT04267315|PROCEDURE|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
219730179|NCT04267315|PROCEDURE|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
219730180|NCT04267315|OTHER|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
219730181|NCT03780725|DRUG|BI 754111|Solution for infusion
219730182|NCT03780725|DRUG|[89Zr]Zr-BI 754111|Solution for infusion
219730183|NCT03780725|DRUG|BI 754091|Solution for infusion
219730184|NCT00543465|DRUG|MK0782|
219730185|NCT04168710|DRUG|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
219730186|NCT04168710|OTHER|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
219730187|NCT05967910|OTHER|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
219730188|NCT02794779|DRUG|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
219730189|NCT00347945|PROCEDURE|Pencil Push-ups|
219157394|NCT01672060|BEHAVIORAL|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
219157395|NCT06520332|PROCEDURE|Dental Implant Surgery - short implant group (less than or equal to 6mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
219157396|NCT06520332|PROCEDURE|Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
219157397|NCT04705675|BEHAVIORAL|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
219157398|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
219157399|NCT03572075|PROCEDURE|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
219157400|NCT03572075|PROCEDURE|standard care protocol|the treatment is the same as usual in our center
219157401|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
219157402|NCT02158819|DEVICE|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
219157403|NCT04965272|DRUG|Cariprazine 0.75 mg/day|Oral Capsule
219157404|NCT04965272|DRUG|Cariprazine 1.5 mg/day|Oral Capsule
219157405|NCT04965272|DRUG|Cariprazine 3.0 mg/day|Oral Capsule
219157406|NCT04965272|OTHER|Placebo|Oral Capsule
219157407|NCT05434273|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
219730190|NCT00347945|PROCEDURE|Office-based Vision Therapy|
219157408|NCT05434273|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
219157409|NCT00002697|BIOLOGICAL|filgrastim|
219157410|NCT00002697|BIOLOGICAL|sargramostim|
219157411|NCT00002697|DRUG|carboplatin|
219157412|NCT00002697|DRUG|etoposide|
219157413|NCT00002697|DRUG|ifosfamide|
219157414|NCT00002697|PROCEDURE|autologous bone marrow transplantation|
219157415|NCT00002697|PROCEDURE|bone marrow ablation with stem cell support|
219157416|NCT00002697|PROCEDURE|peripheral blood stem cell transplantation|
219157417|NCT00002697|RADIATION|radiation therapy|
219157418|NCT00774124|OTHER|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
219157419|NCT00774124|OTHER|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
219157420|NCT03434587|PROCEDURE|Syndactyly|Syndactyly
219157421|NCT03434587|PROCEDURE|Reduction and inmobilization|Closed reduction and inmobilization with splint
219157422|NCT01828554|DRUG|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
219730191|NCT00347945|PROCEDURE|Placebo Office-based Vision Therapy|
219730192|NCT02553070|OTHER|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
219234280|NCT00807599|DRUG|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
219730193|NCT03559309|DIAGNOSTIC_TEST|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
219730194|NCT03242733|OTHER|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
219730195|NCT00294788|BIOLOGICAL|Fluvax|
219730196|NCT00294788|DRUG|PCC® (Lactobacillus fermentum VRI 003)|
219730197|NCT04281719|OTHER|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
219730198|NCT04919343|BEHAVIORAL|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
219730199|NCT04919343|BEHAVIORAL|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
219730200|NCT03888079|DRUG|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
219730201|NCT03888079|DRUG|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
219730202|NCT00113126|DRUG|Treatment interruption|
219157423|NCT02172872|DRUG|standard combination chemotherapy|"1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days"
219730203|NCT04828525|DRUG|Dexamethasone|adjuvant dexamethasone treatment
219730204|NCT04828525|DRUG|normal saline|placebo
219730205|NCT03148639|BEHAVIORAL|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
219730206|NCT03148639|OTHER|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
219730207|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
219157424|NCT02172872|DRUG|decitabine|"1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
219157425|NCT01651767|DRUG|Placebo|Form=suspension, route=oral.
219157426|NCT01651767|DRUG|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
219157427|NCT04797923|DRUG|1. Treatment: IP chemotherapy + Systemic chemotherapy|1\. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
219234281|NCT02802332|BEHAVIORAL|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
219730208|NCT03360968|PROCEDURE|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
219730209|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
219730210|NCT02587286|OTHER|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
219730211|NCT00191152|DRUG|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
219730212|NCT00191152|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
219730213|NCT00191152|DRUG|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
219730214|NCT00140114|DRUG|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
219730215|NCT00114777|DRUG|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
219730216|NCT00114777|DRUG|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
219730217|NCT00114777|DRUG|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
219730218|NCT05895500|DRUG|Injection for SC administration (120mg/syringe)|Injection
219730219|NCT05895500|DRUG|Tablet (50mg/tablet), oral|Tablet
219730220|NCT04448080|DEVICE|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
219730221|NCT04219774|PROCEDURE|Endovascular intervention|Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
219730222|NCT04219774|DRUG|Aspirin and Clopidogrel (maximal medical Therapy)|Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
219730223|NCT05771623|DEVICE|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
219730224|NCT05771623|BEHAVIORAL|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
219157428|NCT04797923|PROCEDURE|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2\. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles."
219730225|NCT03238872|BEHAVIORAL|Cognitive Behavioural Therapy|
219730226|NCT03238872|OTHER|Treatment as usual|
219730227|NCT03090295|DEVICE|Palpation and Accuro|Identify placement for spinal
219730228|NCT01334853|OTHER|No drug will be used|Biomarker
219730229|NCT01334853|OTHER|No drug will be used|Biomarker
219730230|NCT01986322|BIOLOGICAL|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
219730231|NCT01986322|BIOLOGICAL|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
219730232|NCT02717715|BEHAVIORAL|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
219730233|NCT06162234|OTHER|observational|none (observational study)
219730234|NCT03447145|DRUG|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
219730235|NCT05428228|OTHER|TP1|Participants will be administered TP1 during one of the experimental visits.
219730236|NCT05428228|OTHER|TP2|Participants will be administered TP2 during one of the experimental visits.
219730237|NCT05428228|OTHER|Placebo|Participants will be administered placebo during one of the experimental visits.
219730238|NCT02106559|DRUG|porfimer sodium|Given IV
219730239|NCT02106559|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
219730240|NCT02106559|DRUG|photodynamic therapy|Undergo PDT
219730241|NCT00333307|DRUG|recombinant human relaxin|
219730242|NCT00629239|DRUG|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
219730243|NCT00629239|DRUG|Placebo|
219730244|NCT01851369|DRUG|TRC102|Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
219730245|NCT01851369|DIAGNOSTIC_TEST|CT scan|CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).
219730246|NCT01851369|OTHER|Lomotil|If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.
219730247|NCT01851369|OTHER|Prochlorperazine|If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.
219730248|NCT01851369|OTHER|Metoclopramide|If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.
219730249|NCT01851369|OTHER|5-HT3 antagonist|If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
219730250|NCT01851369|OTHER|Aprepitant|If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
219730251|NCT01851369|PROCEDURE|Biopsy|Tumor biopsies will be optional during the escalation phase.
219730252|NCT00928005|BEHAVIORAL|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
219730253|NCT00928005|BEHAVIORAL|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
219730254|NCT02453191|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
219730255|NCT02453191|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
219730256|NCT00007501|BIOLOGICAL|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
219157429|NCT02753738|DRUG|Escitalopram|Tablet 10mg, 21 days
219157430|NCT02753738|DRUG|Placebo|Tablet, 21 days
219157431|NCT02753738|OTHER|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
219730257|NCT00007501|BIOLOGICAL|Placebo|Placebo vaccine
219730258|NCT02526394|BIOLOGICAL|Meningococcal vaccine|Meningococcal vaccination
219730259|NCT02526394|DRUG|Pertussis containing vaccine|Pertussis containing vaccination
219730260|NCT04651374|DEVICE|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
219730261|NCT05163535|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
219730262|NCT05163535|OTHER|ELPIDA®|Elsulfavirine capsules
219730263|NCT02326090|DRUG|cis-UCA ophthalmic solution 1.0%|
219730264|NCT02326090|DRUG|cis-UCA ophthalmic solution 2.5%|
219730265|NCT02326090|DRUG|Placebo ophthalmic solution|
219157432|NCT02753738|BEHAVIORAL|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
219730266|NCT02636322|DRUG|Cyclophosphamide|Given IV
219730267|NCT02636322|DRUG|Doxorubicin Hydrochloride|Given IV
219730268|NCT02636322|DRUG|Etoposide|Given IV
219730269|NCT02636322|DRUG|Ibrutinib|Given PO
219730270|NCT02636322|DRUG|Lenalidomide|Given PO
219157433|NCT02753738|BEHAVIORAL|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
219157434|NCT04646031|DRUG|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
219157435|NCT02877797|DEVICE|Cap|cap assisted esophagogastroduodenoscopy
219157436|NCT05899270|OTHER|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
219157437|NCT05899270|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
219234282|NCT05145348|BIOLOGICAL|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
219234283|NCT04635657|OTHER|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
219234284|NCT00078832|DRUG|anastrozole|aromatase inhibitor
219234285|NCT00078832|DRUG|placebo|Arimidex placebo
219234286|NCT00505427|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|
219234287|NCT04927507|BEHAVIORAL|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
219730271|NCT02636322|DRUG|Prednisone|Given PO
219730272|NCT02636322|BIOLOGICAL|Rituximab|Given IV
219730273|NCT02636322|DRUG|Vincristine Sulfate|Given IV
219730274|NCT00512044|PROCEDURE|Local anesthesia (pudendal block)|local anesthesia as indicated
219730275|NCT00512044|PROCEDURE|general anesthesia (spinal and general)|general according to guidelines
219730276|NCT02696577|DRUG|Low dose aspirin|
219730277|NCT02696577|DRUG|Omega 3|
219730278|NCT02502071|DRUG|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
219730279|NCT02336503|DRUG|BBI-4000 Gel, 5%|BBI-4000 Gel, 5%
219730280|NCT02336503|DRUG|BBI-4000 Gel, 10%|BBI-4000 Gel, 10%
219730281|NCT02336503|DRUG|BBI-4000 Gel, 15%|BBI-4000 Gel, 15%
219730282|NCT02336503|DRUG|Vehicle|Placebo, BBI-4000 Gel, 0%
219730283|NCT06427174|DRUG|Fascia iliaca block|For the group who will receive the fascia iliaca block …. After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
219730284|NCT06427174|DRUG|Caudal block|second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
219730285|NCT00682838|BEHAVIORAL|Self-management|Self-management
219730286|NCT00682838|BEHAVIORAL|Telemonitored care|Telemonitored care
219730287|NCT00581789|DRUG|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
219730288|NCT02957123|DRUG|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
219730289|NCT02912520|DRUG|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
219730290|NCT03969758|DRUG|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
219730291|NCT03969758|DRUG|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
219730292|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
219730293|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
219730294|NCT00984633|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
219730295|NCT00984633|DRUG|Propofol|4-10 mg/kg/hr maintenance anesthesia
219730296|NCT00375310|DRUG|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"
219730297|NCT00375310|PROCEDURE|Radiotherapy|1.8 Gy CTV daily for 5 weeks
219234288|NCT01097811|DRUG|Erythromycin|250 mg orally q.i.d.
219234289|NCT01097811|DRUG|Neomycin|1 g orally q.i.d.
219234290|NCT03924362|PROCEDURE|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
219730298|NCT02968875|DEVICE|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
219234291|NCT01736488|DRUG|Fimasartan|Fimasartan 60mg
219730299|NCT02968875|OTHER|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
219730300|NCT04394559|BEHAVIORAL|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
219730301|NCT04394559|BEHAVIORAL|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
219730302|NCT04394559|BEHAVIORAL|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
219730303|NCT04394559|BEHAVIORAL|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
219730304|NCT03095976|PROCEDURE|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
219234292|NCT01736488|DRUG|Atenolol|Atenolol 50mg
219730305|NCT02539407|OTHER|Pharmacokinetics|
219730306|NCT04916665|DRUG|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
219730307|NCT03488485|DRUG|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
219730308|NCT06213805|PROCEDURE|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
219730309|NCT06209086|DEVICE|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
219730310|NCT01210443|DRUG|Sitaxentan|sitaxentan sodium 100 mg
219730311|NCT04174820|OTHER|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
219730312|NCT03730701|BEHAVIORAL|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
219730313|NCT06330519|DRUG|Dexamethasone sodium phosphate injection|Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
219730314|NCT06330519|OTHER|1,1,1,2 tetrafluoroethane|EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
219730315|NCT06330519|OTHER|intraoral soft tissue cryotherapy|Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
219730316|NCT00290628|DRUG|anti-thymocyte globulin|
219730317|NCT00290628|DRUG|busulfan|
219234293|NCT01662388|DEVICE|Separation ring|Separation ring placed along with automatrix band
219234294|NCT01662388|DEVICE|automatrix band|band placed with a tightening device
219234295|NCT03076853|OTHER|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
219234296|NCT02469025|OTHER|Manual caudal traction mobilization in resting position|
219234297|NCT02469025|OTHER|Manual caudal traction mobilization in end range position|
219234298|NCT02469025|OTHER|Selftreatment|Each subject is advice to do some exercises at home
219234299|NCT02499094|OTHER|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
219234300|NCT03713476|OTHER|Motor task training|motor task specific training
219234301|NCT05548049|DEVICE|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
219730318|NCT00290628|DRUG|cyclophosphamide|
219730319|NCT00290628|DRUG|cyclosporine|
219730320|NCT00290628|DRUG|filgrastim|
219157438|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
219157439|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
219157440|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
219157441|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
219157442|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
219157443|NCT05598554|OTHER|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
219157444|NCT05598554|OTHER|information|A one-session training was provided on the effects of exercise on quality of life.
219157445|NCT03221959|DEVICE|Medical Device Vittamed 205|Intracranial pressure measurement
219157446|NCT06384820|DRUG|cemiplimab|Administered Intravenous (IV) infusion every three weeks (Q3W)
219157447|NCT06384820|DRUG|fianlimab|IV infusion Q3W
219157448|NCT03428698|DEVICE|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
219157449|NCT03214185|PROCEDURE|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
219157450|NCT03214185|GENETIC|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
219157451|NCT03214185|OTHER|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
219157452|NCT04611932|DRUG|CKD-330 Tab. and D090 Tab.|1T
219157453|NCT04611932|DRUG|CKD-333 Tab.|1T
219157454|NCT05444075|OTHER|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
219730321|NCT00290628|DRUG|melphalan|
219730322|NCT00290628|DRUG|methylprednisolone|
219730323|NCT00290628|DRUG|mycophenolate mofetil|
219730324|NCT00290628|PROCEDURE|radiation therapy|
219730325|NCT00290628|PROCEDURE|umbilical cord blood transplantation|
219730326|NCT01309100|DEVICE|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
219730327|NCT01309100|DEVICE|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
219730328|NCT01309100|DEVICE|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
219730329|NCT00400205|DRUG|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
219730330|NCT00400205|DRUG|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
219730331|NCT00400205|DRUG|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
219730332|NCT03808909|OTHER|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
219730333|NCT00299754|DRUG|Misoprostol|
219730334|NCT01084135|DRUG|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
219730335|NCT01084135|OTHER|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
219730336|NCT03335566|DRUG|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
219730337|NCT03335566|DRUG|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
219730338|NCT00663351|DEVICE|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
219730339|NCT00663351|DEVICE|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
219730340|NCT00675363|PROCEDURE|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
219730341|NCT00675363|PROCEDURE|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
219730342|NCT05310643|DRUG|Nivolumab|"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."
219730343|NCT05310643|DRUG|Ipilimumab|Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
219730344|NCT06779604|PROCEDURE|Infraclavicular Block with Dexmedetomidine and Dexamethasone|"Infraclavicular block with Dexmedetomidine and Dexamethasone was performed at least 30 min before the start of the operation. The patient was positioned in a supine position arms at the sides or in 90 degree abduction, head turned to the other side. Infraclavicular block was performed with the lateral sagittal technique, while the USG probe was placed under the clavicle and medial to the coracoid process, providing a brachial plexus image in the form of a hyperechoic outer ring and hypoechoic circles, like a classic honeycomb image. A local anesthetic mixture was injected with a 100 mm block needle with negative aspiration and its spread in tissue planes was observed.~If the VAS score was 3 or above, tramadol 1 mg kg-1 was administered as an analgesic drug."
219730345|NCT06964308|PROCEDURE|thoracoscopic pleural biopsy.|This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.
219730346|NCT00545948|DRUG|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
219730347|NCT00545948|DRUG|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
219730348|NCT03467945|DRUG|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
219730349|NCT03467945|DRUG|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
219730350|NCT03467945|DRUG|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
219730351|NCT01810107|PROCEDURE|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
219730352|NCT05996731|PROCEDURE|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
219730353|NCT01509807|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
219730354|NCT01509807|DRUG|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
219730355|NCT04877054|BEHAVIORAL|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
219730356|NCT04877054|BEHAVIORAL|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
219730357|NCT01718067|DEVICE|VAKÜM system|15 minutes, twice a day.
219730358|NCT01718067|OTHER|conventional manual ELTGOL technique|20 minutes twice a day
219157455|NCT05065203|PROCEDURE|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
219730359|NCT06278649|BEHAVIORAL|Relaxation and Guided Imagery|Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
219730360|NCT05301777|DEVICE|Computed tomography|Computed tomography
219730361|NCT02830633|PROCEDURE|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
219730362|NCT02830633|PROCEDURE|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
219730363|NCT04723069|DRUG|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
219730364|NCT04723069|DRUG|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
219730365|NCT02673385|OTHER|Brazelton scale|
219730366|NCT01559285|DRUG|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
219730367|NCT01559285|DRUG|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
219730368|NCT01559285|DRUG|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
219730369|NCT06581666|OTHER|No special intervention, all participants will be asked to complete same set of questionnaire.|No special intervention, all participants will be asked to complete same set of questionnaire.
219157456|NCT01343459|RADIATION|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy"
219157457|NCT03951805|DRUG|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
219730370|NCT04599335|DEVICE|2% HA|2% HA
219730371|NCT00114478|DRUG|Epinephrine|
219730372|NCT00114478|DRUG|albuterol (salbutamol)|
219730373|NCT03075943|DIETARY_SUPPLEMENT|InSea2|Daily supplement: 2 capsules of InSea2
219730374|NCT03075943|DIETARY_SUPPLEMENT|Placebo|Daily supplement: 2 capsules of Placebo
219730375|NCT02975700|DRUG|PLX3397|1000 mg/day (400 mg in the morning and 600 mg in the evening)
219730376|NCT03384485|DIAGNOSTIC_TEST|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
219730377|NCT03568071|DRUG|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
219730378|NCT03568071|DRUG|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
219730379|NCT04981756|OTHER|observation|This observational study does not have any intervention.
219730380|NCT04501445|BEHAVIORAL|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
219730381|NCT05660538|DRUG|Suzetrigine|Tablets for oral administration.
219730382|NCT05660538|DRUG|Pregabalin|Capsules for oral administration.
219730383|NCT05660538|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
219157458|NCT03951805|DRUG|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
219157459|NCT01765231|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
219730384|NCT05660538|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
219730385|NCT05415527|OTHER|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
219730386|NCT02082288|OTHER|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) \>35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) \>4 (2) No of good quality embryos \<3 (0) 3-5 (1) \>5 (2) No of embryos transferred -------- (0) ≤2 (1) \>2 (2)"
219157460|NCT01765231|DRUG|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
219157461|NCT05216770|OTHER|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
219157462|NCT05216770|DRUG|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
219157463|NCT05104294|DIAGNOSTIC_TEST|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
219157464|NCT05104294|DIAGNOSTIC_TEST|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
219157465|NCT00215397|DRUG|Formoterol Fumarate|
219730387|NCT04518410|BIOLOGICAL|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
219730388|NCT04518410|BIOLOGICAL|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
219730389|NCT04518410|BIOLOGICAL|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
219730390|NCT04518410|BIOLOGICAL|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
219730391|NCT04518410|DRUG|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
219157466|NCT06171412|BEHAVIORAL|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
219157467|NCT05976581|BEHAVIORAL|Electronic alert|An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
219157468|NCT05976581|BEHAVIORAL|Structured communication of test results|A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
219234302|NCT05548049|DEVICE|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
219157469|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a physiotherapist|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Initially guided and supervised every 3 months by a physiotherapist.
219157470|NCT05682872|BEHAVIORAL|Adequacy of the environment|A home study and the environment will be made to diagnose fall risks. Guided and supervised by a occupational therapist during a home visit.
219157471|NCT05682872|BEHAVIORAL|Polypharmacy review|Assessment of the medication that patients receives related to fall risks proposing its adjustment. Revised by a primary care doctor different from care routine.
219157472|NCT05682872|BEHAVIORAL|Health education related to falls prevention (4 sessions)|"SESSION 1: Fall Risk factors. Pharmacology. Nutrition and falls (Primary Care Doctor and Primary Care Nurse)~SESSION 2: Accident prevention through environmental modification (Occupational Therapist)~SESSION 3: Importance of physical exercise to prevent falls (Physiotherapist)~SESSION 4: Footwear and foot care. How to react to a fall?: what to do and how to get up? (Primary Care Nurse)"
219157473|NCT05682872|BEHAVIORAL|General Assement|General assessment (feet, footwear, nutrition, cognitive/psychological, social of risk factors) carried out by Primary Care Doctor and Primary Care Nurse
219157474|NCT05682872|BEHAVIORAL|Evaluation of patients by an expert group|Evaluation of the patient by an expert group (Primary care doctor, primary care nurse, polypharmacy review doctor, occupational therapist, frailty group) and decision-making for correction of fall risk factors.
219157475|NCT05682872|BEHAVIORAL|Information brochures on the importance of physical exercise|Integrated Assistance Process for prevention falls in elderly. Benefits of physical exercise and fall prevention at home. Prepared by the Junta de Comunidades de Castilla-La Mancha and Servicio de Salud de Castilla-La Mancha.
219157476|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a primary care doctor or primary care nurse|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Supervised by primary care doctor o primary care nurse according to passport recommendations.
219157477|NCT05682872|BEHAVIORAL|Regular assessment and follow-up by primary care doctor and primary care nurse|General assessment related to falls with the established protocols at primary care routine.
219157478|NCT05682872|BEHAVIORAL|Health education related to falls prevention (1 session)|There will be a single session. The session will cover the following topics: Fall Risk factors. Pharmacology. Nutrition and falls. Accident prevention through environmental modification. Importance of physical exercise to prevent falls. Footwear and foot care. How to react to a fall?: what to do and how to get up?
219157479|NCT04583423|DRUG|MK-3655|MK-3655 50, 100 or 300 dose for injection
219157480|NCT04583423|DRUG|Placebo|Matching placebo to MK-3655
219234303|NCT01144533|PROCEDURE|isotonic saline injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
219234304|NCT01144533|PROCEDURE|steroid injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
219730392|NCT04518410|DRUG|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
219730393|NCT04518410|BIOLOGICAL|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
219157481|NCT02462460|DEVICE|MRI|
219157482|NCT02462460|BEHAVIORAL|Optional Screening Questionnaire|
219234305|NCT01144533|PROCEDURE|sodium hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
219234306|NCT01144533|PROCEDURE|steroid and hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
219730394|NCT04518410|BIOLOGICAL|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
219730395|NCT04518410|BIOLOGICAL|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
219730396|NCT04518410|DRUG|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
219730397|NCT04518410|DRUG|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730398|NCT04518410|DRUG|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730399|NCT04518410|DRUG|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730400|NCT04518410|DRUG|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
219730401|NCT04518410|DRUG|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
219730402|NCT04518410|DRUG|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730403|NCT04518410|DRUG|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
219730404|NCT04518410|DRUG|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730405|NCT04518410|DRUG|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730406|NCT04518410|DRUG|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
219730407|NCT04518410|BIOLOGICAL|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
219730408|NCT03462563|DEVICE|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
219730409|NCT03462563|DEVICE|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
219730410|NCT04835753|DEVICE|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
219730411|NCT04835753|OTHER|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
219730412|NCT05153434|DRUG|ARD-101|Twice Daily, Oral Administration
219730413|NCT05704036|DRUG|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
219730414|NCT05704036|DRUG|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
219730415|NCT02223130|BEHAVIORAL|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
219730416|NCT01284088|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
219730417|NCT01284088|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
219157483|NCT05509855|GENETIC|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
219157484|NCT04472793|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
219730418|NCT04860583|OTHER|Renal ultrasound|
219730419|NCT01740427|DRUG|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219730420|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
219730421|NCT01740427|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
219730422|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
219157485|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
219157486|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
219157487|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
219234307|NCT01106885|BEHAVIORAL|Medication Care Management (MCM)|"* Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
219730423|NCT05890677|PROCEDURE|Surgical Intervention|LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
219730424|NCT05890677|PROCEDURE|Conservative Complex Physical Decongestion Therapy|Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
219730425|NCT06462586|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
219730426|NCT06462586|DRUG|Placebo|Matching capsules administered orally, once daily
219730427|NCT04796207|DIETARY_SUPPLEMENT|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season.
219730428|NCT04796207|DIETARY_SUPPLEMENT|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season."
219234308|NCT01106885|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"* Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each"
219730429|NCT04443608|DRUG|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
219730430|NCT04443608|DRUG|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
219730431|NCT04828967|OTHER|Hypnosis|Hypnosis is added to the conventional group
219730432|NCT01738178|DRUG|Caffeine|
219730433|NCT01738178|DRUG|Placebo|
219730434|NCT00115388|PROCEDURE|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
219730435|NCT01663376|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 \~3x10e8 cells
219730436|NCT01501097|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
219730437|NCT03394573|OTHER|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
219730438|NCT03394573|OTHER|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
219234309|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219234310|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219730439|NCT02838238|DRUG|Capecitabine|
219730440|NCT02838238|DRUG|Placebo|
219730441|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
219730442|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
219730443|NCT05443854|DRUG|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
219730444|NCT05443854|BEHAVIORAL|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
219730445|NCT05443854|OTHER|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
219730446|NCT05443854|OTHER|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
219730447|NCT04203056|DRUG|Aripiprazole Lauroxil|12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through
219730448|NCT04203056|DRUG|ARI-ORAL|oral aripiprazole
219730449|NCT04203056|DRUG|AL-NCD|Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
219730450|NCT06449664|BEHAVIORAL|ADT-train|A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
219730451|NCT03509584|RADIATION|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
219730452|NCT03509584|DRUG|nivolumab|administration of nivolumab
219730453|NCT03509584|DRUG|Ipilimumab|administration of ipilimumab
219730454|NCT05701735|BEHAVIORAL|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
219730455|NCT02473744|OTHER|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
219730456|NCT00001931|DRUG|N-0923|
219730457|NCT04113993|DRUG|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
219730458|NCT04113993|DRUG|Placebo|Identically packaged placebo capsule daily
219730459|NCT03100292|OTHER|Sleeve gastrectomy or Roux-en-Y gastric bypass|
219730460|NCT01972984|DRUG|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
219730461|NCT01044199|BIOLOGICAL|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
219730462|NCT01044199|BIOLOGICAL|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
219730463|NCT05788380|OTHER|EXERCİSE|EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
219730464|NCT00303797|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
219730465|NCT00303797|DRUG|sorafenib tosylate|
219730466|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
219730467|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
219730468|NCT04267042|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
219730469|NCT04267042|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
219730470|NCT04267042|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
219730471|NCT04864769|DIETARY_SUPPLEMENT|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
219730472|NCT04864769|DIETARY_SUPPLEMENT|Soy protein isolate|Ingestion of 35 g Soy protein isolate
219730473|NCT04864769|DIETARY_SUPPLEMENT|Whey protein isolate|Ingestion of 35 g Whey protein isolate
219730474|NCT04864769|DIETARY_SUPPLEMENT|Water|Ingestion of water (control)
219730475|NCT00165698|DRUG|menatetranone|15 mg three times a day orally for 12 months
219730476|NCT00165698|DRUG|alfacalcidol|0.25 μg twice a day orally for 12 months
219730477|NCT01107457|BIOLOGICAL|Ixekizumab|Administered subcutaneously
219730478|NCT01107457|DRUG|Placebo|Administered subcutaneously
219730479|NCT05013775|DIAGNOSTIC_TEST|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
219730480|NCT05013775|DIAGNOSTIC_TEST|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
219730481|NCT03679884|DRUG|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
219730482|NCT03679884|DRUG|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
219730483|NCT03679884|DRUG|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
219730484|NCT03679884|DRUG|Placebo|Matching placebo film-coated tablets
219730485|NCT04585360|OTHER|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)"
219730486|NCT01793922|PROCEDURE|PD|pneumodilation
219730487|NCT01793922|PROCEDURE|POEM|peroral endoscopic myotomy
219730488|NCT02204735|BEHAVIORAL|Eat majority of calories in the morning|
219730489|NCT02204735|BEHAVIORAL|Eat the majority of calories in the evening|
219730490|NCT05330377|DRUG|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
219730491|NCT05330377|DRUG|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
219730492|NCT05330377|DRUG|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
219730493|NCT05330377|DRUG|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
219730494|NCT05330377|DRUG|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
219730495|NCT03294655|BEHAVIORAL|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
219730496|NCT04994236|DRUG|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
219730497|NCT00362609|DRUG|pantoprazole|
219730498|NCT00311805|BIOLOGICAL|Autologous Stem Cells (CD34+)|Intramuscular Injections
219730499|NCT00508846|BEHAVIORAL|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
219730500|NCT05138640|OTHER|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
219730501|NCT01746160|DRUG|C1 Implant|Patients treated with dental implants.
219730502|NCT00559351|PROCEDURE|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
219730503|NCT00559351|DRUG|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
219730504|NCT00559351|RADIATION|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
219730505|NCT03897192|DRUG|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
219730506|NCT02622022|DRUG|Morphine hydrochloride|
219730507|NCT02622022|OTHER|Placebo|
219730508|NCT03572114|DIAGNOSTIC_TEST|3Tesla MRI|"1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~4. conventional FLAIR sequence"
219730509|NCT03572114|BEHAVIORAL|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
219730510|NCT03572114|BEHAVIORAL|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
219730511|NCT03572114|BEHAVIORAL|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
219730512|NCT03572114|BEHAVIORAL|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
219730513|NCT01807104|PROCEDURE|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
219730514|NCT01807104|PROCEDURE|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
219730515|NCT05618847|DEVICE|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
219730516|NCT05618847|OTHER|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
219730517|NCT05033600|DEVICE|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
219157488|NCT05094609|BIOLOGICAL|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
219730518|NCT02278237|BEHAVIORAL|VME Group|Received inhaler education through VME (virtual education module)
219730519|NCT02137681|DRUG|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
219730520|NCT01663805|DRUG|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
219730521|NCT03084679|OTHER|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
219730522|NCT03084679|OTHER|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
219730523|NCT03084679|OTHER|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
219157489|NCT05094609|BIOLOGICAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
219157490|NCT05946551|DRUG|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
219157491|NCT05946551|DRUG|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
219730524|NCT00443326|DRUG|AMG 714|Dosing Regimen is 6 Doses over 3 Months
219730525|NCT06294353|DEVICE|WELT-ED (CBT based DTx)|The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner. It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder. Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits. By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms. This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
219730526|NCT06294353|BEHAVIORAL|Standard Treatment|In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits. Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period. However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
219157492|NCT05946551|DRUG|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
219157493|NCT05946551|DRUG|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
219157494|NCT05460793|DEVICE|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
219730527|NCT01416051|DIETARY_SUPPLEMENT|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
219730528|NCT01416051|OTHER|Placebo|100% milk fat
219730529|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
219730530|NCT04483947|DRUG|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
219234311|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219234312|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219234313|NCT01884207|OTHER|MRI|
219730531|NCT04483947|OTHER|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
219730532|NCT05280808|DEVICE|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
219157495|NCT00603954|DRUG|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
219157496|NCT00603954|DRUG|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
219157497|NCT03425734|DRUG|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
219157498|NCT00737542|DRUG|lidocaine|
219157499|NCT00737542|DRUG|NACL 0.9%|
219157500|NCT04366908|DRUG|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
219157501|NCT04366908|DRUG|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
219157502|NCT03000049|OTHER|bedside blood culture|
219234314|NCT06275841|DRUG|vepdegestrant|experimental
219234315|NCT06275841|DRUG|esomeprazole|Experimental treatment to assess an endpoint
219234316|NCT03477799|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
219234317|NCT01670877|DRUG|Neratinib|
219234318|NCT01670877|DRUG|Fulvestrant|
219234319|NCT01670877|DRUG|Trastuzumab|
219234320|NCT01670877|PROCEDURE|Tumor biopsy|-Optional at baseline and disease progression
219234321|NCT01670877|PROCEDURE|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
219730533|NCT06100445|BEHAVIORAL|Semi structured interviews|Gaining qualitative data
219730534|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
219730535|NCT00484900|DRUG|Co-Arinate FDC|
219730536|NCT00484900|DRUG|Coartem|
219730537|NCT01374464|OTHER|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
219730538|NCT05067270|DRUG|Sodium Citrate|Administered SC infusion.
219730539|NCT05067270|DRUG|Treprostinil|Administered SC infusion.
219730540|NCT05067270|DRUG|Humalog diluent|Administered SC infusion.
219730541|NCT05067270|DRUG|Magnesium Chloride|Administered SC infusion.
219730542|NCT04692051|DRUG|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
219730543|NCT04692051|DRUG|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
219157503|NCT00006330|DRUG|Digoxin|
219157504|NCT00006330|DRUG|Hawthorn|
219157505|NCT03792204|DIAGNOSTIC_TEST|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
219157506|NCT05952895|PROCEDURE|Conventional quadrant-wise scaling and root planing (SRP)|SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
219157507|NCT05660941|DRUG|Lispro|Ultra rapid Lispro
219157508|NCT05660941|DRUG|Lispro|Conventional Lispro
219157509|NCT04364451|OTHER|Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase|Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).
219157510|NCT00971269|DEVICE|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
219730544|NCT05577104|PROCEDURE|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
219157511|NCT05859152|OTHER|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
219157512|NCT05859152|OTHER|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
219234322|NCT06354725|OTHER|Plyometric|Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
219234323|NCT05293093|OTHER|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
219234324|NCT02464215|PROCEDURE|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
219234325|NCT02464215|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
219234326|NCT05658900|OTHER|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
219234327|NCT05658900|OTHER|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
219234328|NCT05509881|DEVICE|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
219234329|NCT05509881|DEVICE|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
219234330|NCT01308879|BEHAVIORAL|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
219234331|NCT04432155|DRUG|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
219234332|NCT04432155|DRUG|Placebo|30% oxygen, and 70% nitrogen
219234333|NCT00268697|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
219234334|NCT00268697|DRUG|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
219234335|NCT00268697|DRUG|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
219234336|NCT00689416|DRUG|rosuvastatin|40 mg, tablet, once daily for 3 months.
219730545|NCT05577104|PROCEDURE|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
219730546|NCT06132750|OTHER|No intervention|No intervention
219730547|NCT02050295|PROCEDURE|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
219730548|NCT02050295|PROCEDURE|Sham washout|Infusion of saline to maintain catheter patency.
219157513|NCT02628678|DIETARY_SUPPLEMENT|FOS|
219730549|NCT02050295|DRUG|Saline|
219730550|NCT04419974|DIAGNOSTIC_TEST|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
219730551|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
219730552|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
219730553|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
219234337|NCT00689416|DRUG|placebo|40 mg, tablet, once daily for 3 months
219234338|NCT00576550|DRUG|Urea|Urea cream applied twice daily up to six months
219234339|NCT00576550|DRUG|betamethasone valerate|Application once daily for two weeks
219234340|NCT00576550|DRUG|betamethasone valerate|Application twice daily for two weeks
219234341|NCT00950456|BIOLOGICAL|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
219234342|NCT00113529|DRUG|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
219234343|NCT00187356|PROCEDURE|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
219234344|NCT01411605|BEHAVIORAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
219234345|NCT04184271|DRUG|38% silver diamine fluoride|Topical application of SDF to teeth
219234346|NCT03315195|DIETARY_SUPPLEMENT|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
219234347|NCT04478552|PROCEDURE|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
219234348|NCT04478552|PROCEDURE|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
219234349|NCT06100354|OTHER|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
219730554|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
219730555|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
219730556|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
219730557|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
219730558|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
219730559|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
219730560|NCT00469027|BIOLOGICAL|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
219730561|NCT06814093|PROCEDURE|Robotic surgery|Robotic surgery for radical resection of middle and low rectal cancer
219730562|NCT06814093|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for radical resection of middle and low rectal cancer
219730563|NCT04309630|PROCEDURE|intercostal block|pain control by intercostal block
219730564|NCT04309630|PROCEDURE|erector spina plane block|pain control by erector spina plane block
219730565|NCT03591796|DEVICE|HFOV|Ventilated infants were randomized to HFOV
219730566|NCT03591796|DEVICE|CMV|Ventilated infants were randomized to CMV.
219730567|NCT01767389|OTHER|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
219730568|NCT01767389|OTHER|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
219730569|NCT01767389|OTHER|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
219730570|NCT07045623|OTHER|centralized management and education group|If assigned to the test group (centralized management and education group), two instructors, one nurse and one nutritionist, will receive an hour of diabetes and high blood pressure 1:15, and will receive an hour of lipid disorder disease and impact 1:15 group education. You will receive a total of 2 hours of education, and you will receive 1 hour of lipid abnormality education conducted in 0 months through a visit in the third month. The dyslipidemia education was conducted in the form of 1:15 small group education or 1:87 group education, which was conducted in 0 months. In particular, the 1:87 form of large-scale education will be operated as a dialogue-oriented lecture that asks and answers questions, and will be conducted by doctors. And in 2 months and 4 months, education on diabetes, high blood pressure, and dyslipidemia will be shortened for 3 minutes through non-face-to-face management phone calls, not face-to-face.
219234350|NCT04505215|OTHER|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
219234351|NCT04505215|OTHER|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
219234352|NCT04505215|OTHER|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
219234353|NCT04371029|OTHER|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
219234354|NCT03605147|DIETARY_SUPPLEMENT|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
219234355|NCT03605147|DIETARY_SUPPLEMENT|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
219234356|NCT00004400|DRUG|testosterone|
219234357|NCT05258929|OTHER|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
219234358|NCT05739409|BIOLOGICAL|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
219234359|NCT04202263|DRUG|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
219234360|NCT04202263|DRUG|Placebos|Placement of minocycline cream 0%
219234361|NCT02825550|DEVICE|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
219234362|NCT01505309|DEVICE|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
219234363|NCT03425500|PROCEDURE|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
219234364|NCT03425500|PROCEDURE|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
219234365|NCT03425500|DEVICE|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
219234366|NCT03989609|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
219234367|NCT03989609|DRUG|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
219234368|NCT02791308|DRUG|Pimecrolimus Cream 1% (Valeant)|
219234369|NCT02791308|DRUG|Vehicle cream|
219234370|NCT02791308|DRUG|Pimecrolimus Cream, 1%|
219234371|NCT02212275|DRUG|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
219234372|NCT00111865|BEHAVIORAL|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
219234373|NCT02669056|OTHER|5-HT measurement|
219234374|NCT02669056|OTHER|cerebral MRI|
219234375|NCT02669056|OTHER|Video recording|
219234376|NCT02669056|OTHER|EEG|
219234377|NCT02669056|OTHER|growth curves|
219234378|NCT02669056|OTHER|ASQ questionnaire|
219234379|NCT02082639|BIOLOGICAL|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
219234380|NCT02082639|BIOLOGICAL|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
219234381|NCT00042939|BIOLOGICAL|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
219234382|NCT00042939|DRUG|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
219234383|NCT00042939|DRUG|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
219234384|NCT05481008|DEVICE|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
219730571|NCT07044375|BEHAVIORAL|Going Places|Going Places is a community driven intervention to increase transportation self-efficacy among low-income youth, enabling access to community-based programs that promote physical activity and improve long term cardiometabolic health. The intervention incorporates a multi-level approach that includes 1) workshops on navigating local transportation systems; 2) field trips and participatory assets mapping activities; and 3) youth transportation advocacy.
219730572|NCT07046598|BEHAVIORAL|Drop Jump Protocol|A standardized drop jump (DJ) protocol involving 100 total jumps from a 60 cm platform. Participants performed five sets of 20 jumps, with a 10-second rest between jumps and a 2-minute rest between sets. The protocol was designed to induce muscle damage through eccentric loading.
219157514|NCT01066026|PROCEDURE|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
219157515|NCT01066026|DRUG|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
219157516|NCT05143996|DRUG|CLN-049|\[FLT3\] x \[CD3\] bispecific T cell engager
219157517|NCT05426317|OTHER|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
219157518|NCT06966648|OTHER|Core stabilization on stable surfaces|Participants will perform a structured core stabilization training program on stable surfaces, such as the floor and rigid foam blocks. The program includes functional exercises targeting trunk control, postural alignment, and balance, delivered three times per week over a 7-week period.
219157519|NCT06966648|OTHER|Core stabilization on unstable surfaces|Participants will perform the same structured core stabilization training program as the stable surface group, but on unstable surfaces such as BOSU balls and wobble boards. The intervention is designed to challenge balance, proprioception, and core muscle activation. Sessions are conducted three times per week over a 7-week period.
219157520|NCT00885924|DRUG|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
219157521|NCT00885924|DRUG|Placebo|NaCl 0.9%
219157522|NCT00890305|DRUG|CT-011|
219157523|NCT00890305|DRUG|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
219157524|NCT04164940|OTHER|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
219157525|NCT04042207|DEVICE|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
219157526|NCT04042207|DEVICE|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
219157527|NCT00103363|OTHER|cytology specimen collection procedure|
219157528|NCT00103363|OTHER|physiologic testing|
219157529|NCT00103363|PROCEDURE|annual screening|
219157530|NCT00103363|PROCEDURE|study of high risk factors|
219157531|NCT00310635|BIOLOGICAL|Meningococcal C conjugate vaccine|
219157532|NCT03727958|DIAGNOSTIC_TEST|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
219157533|NCT03727958|DIAGNOSTIC_TEST|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
219157534|NCT02641938|DRUG|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
219234385|NCT03349476|DEVICE|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
219234386|NCT00795639|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
219234387|NCT00795639|DRUG|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
219730573|NCT07056439|DRUG|HRS-1738 Injection|HRS-1738 injection.
219730574|NCT05937282|DRUG|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
219730575|NCT05937282|DRUG|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
219730576|NCT05937282|DRUG|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
219730577|NCT05937282|DRUG|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
219730578|NCT07056985|OTHER|Ankle joint mobilization technique|Combined posterior and lateral mobilization techniques
219157535|NCT02641938|DRUG|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
219157536|NCT05984589|BEHAVIORAL|RISE Personalized Self-Management Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
219157537|NCT05984589|BEHAVIORAL|Standardized Self-Management Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the occupational therapy (OT) interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
219157538|NCT02480205|DEVICE|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes"
219157539|NCT05814146|DRUG|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions"
219157540|NCT05814146|DEVICE|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
219157541|NCT00760136|PROCEDURE|Computed Tomography|CT imaging of bilateral knee
219157542|NCT04105712|BEHAVIORAL|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
219157543|NCT01838343|OTHER|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
219157544|NCT03408041|OTHER|Medical file data extraction|Medical file data extraction
219360859|NCT04460755|OTHER|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219730579|NCT07056985|OTHER|Placebo|Placebo interventions simulated with superficial hand contact and minimal manipulation
219730580|NCT07055815|DIAGNOSTIC_TEST|Progression of Myopia|The widespread use of digital devices among children has raised concerns about the potential impact on their eye health. Excessive screen time can cause prolonged near focus, reduced outdoor time, and increased blue light exposure, all of which may contribute to myopia progression. Understanding the relationship between digital screen time and myopia progression is crucial for developing effective prevention and intervention strategies to mitigate the growing burden of myopia in children.
219730581|NCT07057154|DEVICE|Hbg and RDW|Hbg and RDW as prognstic indicator in critical ill patients
219730582|NCT01365572|DEVICE|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
219730583|NCT06765889|BEHAVIORAL|Mindfulness intervention|The mindfulness intervention will consist of three tracks of mindfulness practice adapted from a traditional Mindfulness-Based Stress Reduction (MBSR) protocol. The three mindfulness tracks will incorporate essential elements of mindfulness practice: a) cultivating attentional stability by directing focus to present-moment bodily experiences (Moore et al., 2012), and b) fostering mindful meta-awareness by nonreactively and nonjudgmentally observing and accepting experiences (Dahl et al., 2015).
219157545|NCT00580866|DEVICE|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
219157546|NCT04163042|BEHAVIORAL|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
219157547|NCT00609336|DRUG|gemcitabine hydrochloride|Given IV
219157548|NCT00609336|DRUG|docetaxel|Given IV
219157549|NCT00609336|DRUG|capecitabine|Given PO
219157550|NCT00609336|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219157551|NCT00609336|DRUG|oxaliplatin|Given IV
219157552|NCT00609336|PROCEDURE|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
219157553|NCT00609336|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
219157554|NCT00609336|OTHER|laboratory biomarker analysis|Correlative studies
219157555|NCT03018561|OTHER|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
219157556|NCT02238483|DRUG|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
219157557|NCT02238483|DRUG|Placebo|Inhaled placebo solution
219157558|NCT00006446|PROCEDURE|Training in parenting skills and communication|
219157559|NCT04014634|DRUG|Methylprednisolone|Single GON injection with methylprednisolone
219157560|NCT04014634|OTHER|Placebo|Single GON-injection with NaCl
219234388|NCT01308099|DEVICE|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
219234389|NCT03518450|PROCEDURE|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
219234390|NCT03518450|PROCEDURE|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
219234391|NCT03518450|PROCEDURE|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
219234392|NCT03607578|BEHAVIORAL|Other: Control Group - Minimal Intervention|Basic Campaign Folder
219157561|NCT02477605|DEVICE|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
219157562|NCT02477605|DEVICE|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
219157563|NCT02477605|PROCEDURE|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
219157564|NCT02215707|BIOLOGICAL|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
219157565|NCT06177444|DRUG|Antibiotic|Postoperative antibiotic treatment
219157566|NCT03476811|DRUG|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
219157567|NCT03476811|DEVICE|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
219157568|NCT01322477|OTHER|F18-FDG PET/CT|
219157569|NCT02574455|DRUG|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
219157570|NCT02574455|DRUG|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
219157571|NCT02574455|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
219157572|NCT02574455|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
219157573|NCT02574455|DRUG|Vinorelbine|25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
219730584|NCT06765889|BEHAVIORAL|Control condition|The sham meditation group will aim to be indistinguishable from meditation practice for newcomers (Zeidan et al., 2015). Non-specific elements of meditation, such as a soothing instructor's voice and terminology designed to create the expectation of authentic mindfulness meditation for those unfamiliar with the practice, will be emphasized. However, the instructions will deliberately exclude the training of the two fundamental cognitive/meta-cognitive processes crucial in mindfulness practice. This intentional omission will involve 1) removing any attentional stability by providing participants with no specific point to anchor their attention and 2) offering no guidance on cultivating mindful meta-cognitive qualities of attention. Participants in the mindfulness group will be taught to observe and accept their present-moment experience without judgment or reaction. In contrast, sham instructions will provide no such guidance.
219730585|NCT06756139|PROCEDURE|cognitive behavioural therapy mobile application|The CBT mobile application enables patients to conduct cognitive therapy independently.
219730586|NCT06756139|DRUG|Flupentixol and Melitracen Tablets|patients take Flupentixol and Melitracen Tablets
219730587|NCT04551131|DRUG|Ruxolitinib|Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
219730588|NCT04551131|DRUG|Dexamethasone|Given intravenously (IV) or orally (PO) twice a day for 8 weeks
219730589|NCT04551131|DRUG|Etoposide|Given intravenously (IV) once a week for 8 weeks
219730590|NCT06838936|OTHER|Binaural Beats|Mobile application for binaural beats listening
219730591|NCT06729957|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients engage in substance use treatment by increasing motivation and reducing barriers to accessing treatment. The care navigator helps the patient engage in the treatment plan established by the mental health care coordinator.
219730592|NCT06917508|DRUG|EDP-323|Subjects will receive EDP-323 once daily on Days 5-15
219157574|NCT03914664|DIAGNOSTIC_TEST|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
219157575|NCT03914664|DIAGNOSTIC_TEST|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
219157576|NCT05261139|DRUG|nirmatrelvir|PF-07321332
219157577|NCT05261139|DRUG|ritonavir|ritonavir
219157578|NCT02387866|DRUG|AG-221|
219157579|NCT06973655|OTHER|Social Work support|Participants enrolled during the treatment phase at their clinic will receive social work support for 6 months from the time of enrollment. They will have an intake appointment with the social worker before or during their initial fracture clinic visit to assess their needs, identify goals that they can address with the support of the social worker, and collaboratively formulate a personalized care plan tailored to their specific circumstances. The social worker will then implement the plan, which may involve educating participants and their support network, coordinating delivery of care and benefits, making referrals to community services, advocating for the participant, and providing emotional support and brief counselling. The social worker will be accessible to participants for 6 months post-enrollment, following up via telephone, telemedicine or in-person to evaluate the effectiveness of the care plan and offer sustained ongoing support.
219157580|NCT04804241|DRUG|Senicapoc|10 mg oral tablet
219157581|NCT04804241|OTHER|Placebo Tablet|Placebo Oral Tablet
219157582|NCT02677896|DRUG|Enzalutamide|Oral
219157583|NCT02677896|DRUG|Placebo|Oral
219157584|NCT06089057|BEHAVIORAL|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
219234393|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
219730593|NCT06917508|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
219730594|NCT06917508|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
219730595|NCT06917508|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
219730596|NCT06951048|OTHER|Group I (Neural Mobilization)|"Participants will undergo a neural mobilization program targeting the sciatic, femoral, and tibial nerves. Exercises are designed to promote nerve sliding through specific movement patterns and are performed bilaterally. Each nerve mobilization is applied in 4 sets of 10 repetitions, three times per week on non-consecutive days, with 30-second rest intervals.~Sciatic nerve: Performed in side-lying; ankle dorsiflexion with neck extension followed by dorsiflexion release and neck flexion.~Femoral nerve: In side-lying; simultaneous movements of the hip, knee, and neck in flexion and extension.~Tibial nerve: In supine; coordinated ankle, toe, and cervical spine movements with controlled hip/knee positioning."
219730597|NCT06951048|OTHER|Group II (Neural Mobilization + Dynamic Stretching)|Participants in this group will engage in the same neural mobilization protocol applied in Group I, combined with a structured dynamic stretching program targeting lower extremity flexibility and neuromuscular performance. The dynamic exercises include active straight leg raises (SLR), vertical jumps, and 10-meter sprints. Each activity will be performed in three sets of ten repetitions, aiming to enhance muscular activation, mobility, and functional readiness.
219730598|NCT06951048|OTHER|Group III (Dynamic Stretching Only)|This group will engage exclusively in a dynamic stretching protocol comprising active straight leg raises (SLR), vertical jump exercises, and 10-meter sprint drills. Each exercise will be performed in three sets of ten repetitions, focusing on enhancing lower extremity mobility, muscle activation, and functional movement capacity without any neural mobilization intervention.
219730599|NCT00232921|DRUG|caudal volume 1|
219730600|NCT00232921|BIOLOGICAL|caudal volume 2|
219730601|NCT00232921|DRUG|caudal volume 3|
219730602|NCT06949111|RADIATION|radiotherapy|Radiotherapy: Administer three-dimensional conformal/intensity-modulated/TOMO radiotherapy with a conventional fractionation schedule of 36-41.4 Gy in 20-23 fractions (1.8 Gy per fraction).
219157585|NCT06089057|BEHAVIORAL|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
219157586|NCT06490770|DIAGNOSTIC_TEST|Gait analysis, Magnetic Resonance Imaging|Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
219157587|NCT03429582|DEVICE|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
219157588|NCT03429582|DEVICE|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
219157589|NCT03429582|DEVICE|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
219157590|NCT06212271|DRUG|Colchicine|See arm description.
219157591|NCT06212271|DRUG|Placebo|See arm description.
219157592|NCT04557228|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplements
219157593|NCT04557228|DIETARY_SUPPLEMENT|Phosphatidylserine|4 weeks of phosphatidylserine supplements
219157594|NCT04724421|DRUG|Voxelotor|tablet or powder for oral suspension
219157595|NCT06560125|OTHER|Standard care|Treatment appropriate for wound condition
219157596|NCT04455841|DRUG|INCB000928|INCB000928 will be administered at protocol defined dose.
219157597|NCT04455841|DRUG|ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
219157598|NCT01813812|DRUG|DA-6034|
219157599|NCT01813812|DRUG|Rebamipide 300mg|
219157600|NCT02390986|DRUG|LON002|Extension study to provide continuing access to LON002 medication.
219157601|NCT05647070|PROCEDURE|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
219157602|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
219157603|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
219730603|NCT06949111|DRUG|CAPOX|4 cycles, Oxaliplatin 130 mg/m², Capecitabine 825 mg/m²
219730604|NCT06949111|DRUG|Capecitabine|Administer Capecitabine at a dose of 825 mg/m², twice daily, orally on radiotherapy days
219730605|NCT06949111|DRUG|Iparomlimab and Tuvonralimab Injection|IV, 5 mg/kg every 3 weeks
219730606|NCT00411658|DEVICE|Investigational Device|
219730607|NCT00411658|DEVICE|Experimental|
219730608|NCT00411658|OTHER|Cryopreserved|
219730609|NCT02421965|BEHAVIORAL|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
219730610|NCT02421965|BEHAVIORAL|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
219730611|NCT06396299|OTHER|No intervention|No intervention
219730612|NCT02616302|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
219730613|NCT03278340|BEHAVIORAL|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
219730614|NCT03278340|BEHAVIORAL|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
219730615|NCT06097481|BEHAVIORAL|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
219157604|NCT01666704|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
219730616|NCT06097481|OTHER|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
219730617|NCT05894746|DIETARY_SUPPLEMENT|gluten-free|see info in arm description
219730618|NCT05894746|DIETARY_SUPPLEMENT|probiotic|see info in arm description
219730619|NCT05894746|DIETARY_SUPPLEMENT|gluten|see info in arm description
219730620|NCT05206604|DRUG|PF-07295324|Ointment
219730621|NCT05206604|DRUG|PF-07259955|Cream
219730622|NCT05956392|BEHAVIORAL|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
219730623|NCT05500131|BEHAVIORAL|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
219730624|NCT05370144|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
219730625|NCT05235256|PROCEDURE|bilateral sphenopalatine ganglion block|peripheral n block
219730626|NCT05235256|PROCEDURE|bilateral greater occipital nerve block|bilateral greater occipital nerve block
219730627|NCT05235256|DRUG|lidocaine plus dexamethasone|lidocaine plus dexamethasone
219730628|NCT03439878|DIETARY_SUPPLEMENT|Galactose|Co-ingestion of d-galactose with a high-fat meal
219730629|NCT03439878|DIETARY_SUPPLEMENT|Glucose|Co-ingestion of d-glucose with a high-fat meal
219730630|NCT01665105|DEVICE|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
219730631|NCT02793778|DRUG|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
219730632|NCT02793778|DRUG|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
219730633|NCT00709345|BEHAVIORAL|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
219730634|NCT00709345|BEHAVIORAL|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
219157605|NCT00593866|RADIATION|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
219157606|NCT00593866|DRUG|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
219157607|NCT00726544|DRUG|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
219157608|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
219157609|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
219157610|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
219730635|NCT06197711|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions."
219730636|NCT00293982|BEHAVIORAL|Physician knowledge of parental expectations for the visit|
219730637|NCT04408209|PROCEDURE|Convalescent Plasma|"Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~1. the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~2. the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)"
219730638|NCT03556384|DRUG|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
219730639|NCT03787212|DEVICE|MiBo ThermoFlo|Test Device
219730640|NCT03787212|DEVICE|Bruder Mask|Control Device
219234394|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
219234395|NCT02297854|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
219234396|NCT01159314|PROCEDURE|Baerveldt Device surgical Procedure|Implant surgery
219234397|NCT03122444|DRUG|Imipramine|Imipramine will be given daily for 21-30 days.
219234398|NCT01074996|DRUG|S-1|40-60mg bid , days 1-14, every 3 weeks
219234399|NCT01074996|DRUG|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
219234400|NCT02634528|DRUG|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
219234401|NCT02634528|DRUG|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
219234402|NCT04188353|DEVICE|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
219234403|NCT04188353|DRUG|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
219234404|NCT00798837|RADIATION|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
219234405|NCT03846817|OTHER|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
219234406|NCT04631874|DRUG|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
219234407|NCT02525744|DRUG|LY900014|Administered SC
219234408|NCT02525744|DRUG|Insulin Lispro (Humalog)|Administered SC
219234409|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
219234410|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
219234411|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
219234412|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
219730641|NCT04605146|BEHAVIORAL|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
219730642|NCT05240976|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
219730643|NCT05240976|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
219234413|NCT02938286|DEVICE|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
219234414|NCT02938286|DRUG|AHES|Topical application at test region I-IV under occlusion for 15 minutes
219234415|NCT01709045|OTHER|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
219234416|NCT01709045|RADIATION|Dual-Energy Computed Tomography (DECT)|
219234417|NCT01709045|OTHER|Ultrasound|
219234418|NCT01709045|OTHER|Transcranial doppler|
219234419|NCT00346359|BIOLOGICAL|anti-thymocyte globulin|
219234420|NCT00346359|DRUG|busulfan|
219234421|NCT00346359|DRUG|fludarabine phosphate|
219234422|NCT00346359|DRUG|methotrexate|
219234423|NCT00346359|DRUG|tacrolimus|
219234424|NCT00346359|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219234425|NCT00346359|PROCEDURE|peripheral blood stem cell transplantation|
219234426|NCT02536534|OTHER|Correlation assessment|
219234427|NCT04417907|DRUG|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
219234428|NCT04417907|DRUG|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
219234429|NCT04417907|DRUG|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
219234430|NCT04417907|DRUG|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
219234431|NCT00202228|DRUG|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
219234432|NCT06327997|BIOLOGICAL|Fast CAR T cells|This study designed three dose groups, each with a dosage of 5.0 × 10\^5/kg、1.0×10\^6/kg、5.0×10\^6/kg
219234433|NCT00674765|DRUG|Seroquel|400 mg/day
219234434|NCT00674765|DRUG|Placebo|400 mg/day
219234435|NCT02370953|DEVICE|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
219730644|NCT05802537|BEHAVIORAL|Home-based exergame program|The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.
219157611|NCT05447871|PROCEDURE|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
219157612|NCT05447871|PROCEDURE|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
219157613|NCT05447871|DRUG|Bupivacaine 0.25%|bupivacaine 0.25%
219157614|NCT00539734|DRUG|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
219157615|NCT01945125|OTHER|rhTSH Group|Patients receiving rhTSH for RIT stimulation
219157616|NCT02206269|DEVICE|Alair System|The Alair system is used for doing bronchial thermoplasty.
219157617|NCT03320746|DEVICE|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
219157618|NCT03991286|DIETARY_SUPPLEMENT|Astaxanthin 8 mg|experimental
219157619|NCT03991286|OTHER|placebo|Matching placebo pill
219157620|NCT03837886|DIETARY_SUPPLEMENT|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
219157621|NCT03837886|DIETARY_SUPPLEMENT|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
219157622|NCT00004104|BIOLOGICAL|liposomal interleukin-2|
219157623|NCT00004104|BIOLOGICAL|polyvalent melanoma vaccine|
219157624|NCT00004104|BIOLOGICAL|recombinant interferon alfa|
219157625|NCT04982536|DEVICE|VMCore Biopsy System|Prostate Examine
219157626|NCT04982536|DEVICE|Standard of Care Biopsy Needle|Prostate Examine
219157627|NCT03175861|OTHER|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
219157628|NCT06411743|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
219157629|NCT06411743|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
219157630|NCT02120222|DRUG|selinexor|Given PO
219157631|NCT02120222|OTHER|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
219157632|NCT01350024|PROCEDURE|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
219157633|NCT01350024|PROCEDURE|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
219157634|NCT01620203|OTHER|No intervention/treatment is given|
219157635|NCT04110223|GENETIC|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
219730645|NCT05802537|BEHAVIORAL|Online education on fall prevention and musculoskeletal health management|The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
219730646|NCT05548452|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
219730647|NCT05548452|DRUG|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
219730648|NCT06334341|BEHAVIORAL|Computer-based simulation training for providers|"A Computer-Based Simulation training for providers, based on the Centers for Disease Control and Prevention Guide for Healthcare Professional: Discussing Sexual Health with Your Patients, current PrEP information, and the Social Cognitive Theory. This is a single-session, 30-minute training module contains educational information with animated narration about PrEP, how to take a sexual health history, understanding internal bias, potential patient barriers to PrEP as well as recorded video-simulated encounters, in which providers view different types of patient/provider interactions."
219730649|NCT06334341|BEHAVIORAL|Best Practice Alert|A Best Practice Alert will alert providers to patients who are part of the Centers for Disease Control and Prevention PrEP priority populations.
219730650|NCT06334341|BEHAVIORAL|HIV Risk Assessment|A risk assessment tool that considers the behaviors - i.e., types of sexual activities, protective behaviors (condoms, PrEP, ART), and other factors (HIV status, sexually transmitted infections) of the respondent.
219730651|NCT06334341|BEHAVIORAL|PrEP Informational Video|A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.
219730652|NCT03186157|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
219730653|NCT03186157|PROCEDURE|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
219730654|NCT06023368|DRUG|Num Vapocoolant Spray|Spray applied around port prior to access
219730655|NCT06023368|DRUG|EMLA Cream|cream applied around the port prior to access
219157636|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
219157637|NCT02942862|DRUG|Orcein staining|Prognostic value of venous emboli detected by orcein staining
219157638|NCT05378828|DEVICE|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
219157639|NCT05378828|OTHER|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
219157640|NCT01464034|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
219157641|NCT01464034|DRUG|Pomalidomide|PO daily on Days 1-21, every 28 Days
219157642|NCT01464034|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
219157643|NCT02058875|DRUG|Myfortic®|
219157644|NCT02058875|DRUG|Neoral®|
219157645|NCT02058875|DRUG|Cellcept®|
219157646|NCT02058875|DRUG|Prednisone|
219157647|NCT06322316|PROCEDURE|The Ultrasound-guided Retrolaminar Block Group|"The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture."
219157648|NCT06322316|PROCEDURE|The Ultrasound-guided Erector Spinae Plane Block Group|"The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected."
219157649|NCT03631550|DEVICE|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
219157650|NCT03631550|DEVICE|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
219157651|NCT00991107|DRUG|HE3286|HE3286 20 mg (10 mg BID) for 28 days
219157652|NCT01741441|PROCEDURE|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
219157653|NCT02395913|DRUG|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
219157654|NCT02395913|DRUG|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
219157655|NCT02395913|DRUG|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
219157656|NCT02395913|DRUG|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
219157657|NCT02806934|PROCEDURE|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
219157658|NCT04739527|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
219157659|NCT04385056|BIOLOGICAL|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
219730656|NCT03508297|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
219730657|NCT04193176|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
219730658|NCT04193176|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
219730659|NCT04229381|PROCEDURE|Physical Therapy|Undergo physical therapy
219730660|NCT04229381|OTHER|Quality-of-Life Assessment|Ancillary studies
219730661|NCT04229381|OTHER|Questionnaire Administration|Ancillary studies
219730662|NCT04229381|PROCEDURE|Relaxation Therapy|Undergo progressive muscle relaxation
219730663|NCT03811119|DEVICE|MANTA vascular closure device|Collagen based vascular closure device
219730664|NCT03811119|DEVICE|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
219730665|NCT05085756|BEHAVIORAL|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
219730666|NCT01691911|PROCEDURE|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
219730667|NCT05861453|DRUG|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
219730668|NCT06636331|OTHER|Continuous Suprainguinal Fascia Iliaca Compartment Block|Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
219730669|NCT06636331|OTHER|Continuous Epidural|Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
219730670|NCT02218151|OTHER|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
219730671|NCT02218151|OTHER|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
219730672|NCT06053411|DRUG|Diclofenac|25 mg capsule
219730673|NCT06053411|DIETARY_SUPPLEMENT|curcumin|2,000 mg tablet
219730674|NCT05649553|BEHAVIORAL|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
219730675|NCT05940636|OTHER|Activity-based rehabilitation+electrical stimulation|Balance training will occur three times per week for four weeks, totaling 12 two-hour sessions. In both groups, you will be asked to stand on a force plate while playing visual feedback training (VFT) games as part of the standing balance training. A force plate is similar to a bathroom scale that you can stand on which measures your body sway during movement. Visual feedback training (VFT) is a type of activity that includes weight-shifting movements in the upright stance. VFT will be done in both groups. There will be different games as shown in figure 1 and the order of the games will be randomly chosen in each session. During each game, there will be targets that will be presented on the screen and you will have to navigate toward them . You will be able to rest between games as needed.
219730676|NCT04725903|RADIATION|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
219730677|NCT04725903|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam therapy
219730678|NCT04725903|OTHER|Quality-of-Life Assessment|Ancillary studies
219157660|NCT02704507|DRUG|Triamcinolone|topical application nightly to half the face for 4 weeks
219157661|NCT02704507|DRUG|Tretinoin|topical application nightly for 8 weeks
219157662|NCT02704507|DRUG|Emollient|topical application nightly to half the face for 4 weeks
219730679|NCT04725903|OTHER|Survey Administration|Ancillary studies
219157663|NCT03565315|BIOLOGICAL|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
219157664|NCT03565315|BIOLOGICAL|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
219157665|NCT00462358|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
219157666|NCT00462358|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
219157667|NCT01625234|DRUG|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
219730680|NCT02370394|BEHAVIORAL|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
219730681|NCT03302611|BEHAVIORAL|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
219730682|NCT01148420|DRUG|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
219730683|NCT01148420|DRUG|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
219730684|NCT05249920|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
219730685|NCT05249920|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
219730686|NCT02042001|DRUG|Immediate switch to TDF/FTC/RPV|
219730687|NCT02042001|DRUG|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
219730688|NCT01996540|OTHER|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
219730689|NCT01842178|PROCEDURE|scratching|"Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control."
219730690|NCT00685282|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
219730691|NCT00856102|BEHAVIORAL|Exercise|Home-base walking program
219730692|NCT00856102|BEHAVIORAL|Control|Usual care
219730693|NCT01927289|PROCEDURE|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
219730694|NCT01846143|BIOLOGICAL|pBCAR3-phosphopeptide|
219730695|NCT01846143|BIOLOGICAL|pIRS2-phosphopeptide|
219730696|NCT01846143|BIOLOGICAL|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
219730697|NCT03367585|DIETARY_SUPPLEMENT|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
219730698|NCT03367585|OTHER|Physical exercise|Strength exercise
219157668|NCT01625234|DRUG|Phase II: X-396 (ensartinib)|Expanded Cohort
219157669|NCT04162444|DIAGNOSTIC_TEST|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
219157670|NCT04162444|DIAGNOSTIC_TEST|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
219157671|NCT04162444|DIAGNOSTIC_TEST|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
219157672|NCT04162444|OTHER|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors"
219730699|NCT00188838|BEHAVIORAL|Psychoeduction|
219730700|NCT00188838|BEHAVIORAL|Cognitive-Behavioral Therapy|
219730701|NCT01014156|DRUG|epoprostenol|titration up to 4 ng/kg/min
219730702|NCT03796130|PROCEDURE|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
219730703|NCT00218894|PROCEDURE|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
219730704|NCT05826158|DIAGNOSTIC_TEST|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
219730705|NCT03927430|PROCEDURE|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
219730706|NCT00260390|DRUG|Testoviron|
219730707|NCT02398474|DRUG|TFP block ropivacaine|
219730708|NCT02398474|DRUG|ropivacaine infiltration of the iliac crest bone|
219730709|NCT04679025|OTHER|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
219730710|NCT02383485|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
219730711|NCT02383485|BEHAVIORAL|After-school program|Supervised recreational program with token economy
219730712|NCT05298501|OTHER|No intervention/exposure|No interventions/exposures will be administered or evaluated
219730713|NCT02255695|OTHER|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
219730714|NCT05655897|DEVICE|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
219730715|NCT00601016|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
219730716|NCT00520572|DRUG|AZD9056|
219730717|NCT00520572|DRUG|Etanercept|
219730718|NCT00520572|DRUG|Placebo|
219730719|NCT02181621|DEVICE|Iodosorb|Cadexomer iodine gel
219730720|NCT02181621|DEVICE|Solosite gel|Hydrogel
219730721|NCT02697929|DRUG|sugammadex|
219730722|NCT02697929|DRUG|Neostigmine|
219730723|NCT04635163|OTHER|None intervention|None intervention
219730724|NCT02585102|OTHER|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
219730725|NCT02585102|OTHER|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
219730726|NCT00908388|DEVICE|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
219161559|NCT04975178|BIOLOGICAL|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
219730727|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
219730728|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
219730729|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
219730730|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
219730731|NCT02327780|OTHER|FODMAP diet|
219730732|NCT01217138|DEVICE|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
219730733|NCT00795795|PROCEDURE|Preimplantation Genetic Screening|Preimplantation Genetic Screening
219730734|NCT00795795|PROCEDURE|IVF without PGS|IVF without PGS
219730735|NCT04951453|OTHER|None (observational)|None (observational)
219730736|NCT03845673|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
219730737|NCT03845673|DIETARY_SUPPLEMENT|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
219730738|NCT00919490|DRUG|ABT-333|Tablet, see arms for interventional description
219730739|NCT00919490|DRUG|Placebo|Tablet, see arms for interventional description.
219730740|NCT01652105|DIETARY_SUPPLEMENT|Standard diet versus standard VLCD (Prodimed)|
219730741|NCT00274794|BIOLOGICAL|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
219730742|NCT00274794|BIOLOGICAL|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
219730743|NCT03387046|DIETARY_SUPPLEMENT|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
219730744|NCT03387046|DRUG|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
219730745|NCT03387046|BIOLOGICAL|IFN beta-1a|IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
219730746|NCT03387046|DRUG|Methylprednisolone|Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
219730747|NCT06299072|OTHER|Survey|Quantitative questionnaire
219730748|NCT03561740|DRUG|capecitabine|additional metronomic chemotherapy of capecitabine
219730749|NCT04078516|DIAGNOSTIC_TEST|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
219730750|NCT04078516|DIAGNOSTIC_TEST|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
219730751|NCT04078516|DIAGNOSTIC_TEST|Heart rate variability|4 measurements of heart rate.
219730752|NCT04078516|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
219730753|NCT04078516|DIAGNOSTIC_TEST|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
219730754|NCT04078516|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
219730755|NCT04078516|DIAGNOSTIC_TEST|Questionnaires|Questionnaires for detecting painful neuropathy
219730756|NCT04078516|DIAGNOSTIC_TEST|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
219730757|NCT02320825|RADIATION|single-fraction SRS|
219730758|NCT02320825|RADIATION|high-dose hypofractionated SRS|
219730759|NCT02320825|BEHAVIORAL|Quality of Life Measures|
219730760|NCT04336800|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 min, contrast free scan that non-invasively provides three metrics of liver health namely liver fat, iron and fibro-inflammation
219730761|NCT05135780|OTHER|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
219161560|NCT04975178|BIOLOGICAL|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
219161561|NCT01293357|DRUG|LEO 90105|Ointment
219161562|NCT06009653|BEHAVIORAL|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
219161563|NCT06009653|BEHAVIORAL|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
219161564|NCT06009653|DRUG|Placebo|Participants will receive placebo subcutaneous injections.
219161565|NCT06009653|DRUG|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
219730762|NCT05135780|OTHER|Social education|"* Intervention in children:~  * During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~ * The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~ * Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~* Family intervention:~  * Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~ * Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~ * Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
219730763|NCT06450340|BEHAVIORAL|Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
219730764|NCT00929097|OTHER|Implementation aids|"* Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education"
219730765|NCT00929097|OTHER|Control|Dissemination of guidelines
219730766|NCT01512537|RADIATION|Narrowband UVB|UVB 3 times a week
219730767|NCT01512537|DIETARY_SUPPLEMENT|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
219730768|NCT00120250|DRUG|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
219730769|NCT02968290|PROCEDURE|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
219730770|NCT02968290|DEVICE|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
219730771|NCT02968290|DEVICE|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
219730772|NCT03710733|RADIATION|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
219730773|NCT03710733|RADIATION|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
219730774|NCT04555369|GENETIC|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
219730775|NCT06428474|OTHER|Health education|Oral health education program designed for orphans children
219730776|NCT05333744|DRUG|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
219730777|NCT05333744|DRUG|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
219161566|NCT03429803|DRUG|DAY101|28 day cycle, oral, once per week
219161567|NCT03206320|DRUG|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
219161568|NCT05152784|DEVICE|Octaray catheter|A high density diagnostic catheter used for substrate and activation mapping.
219161569|NCT05152784|DEVICE|Standard of care|VT ablation guided by substrate-mapping alone.
219730778|NCT04443777|OTHER|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
219730779|NCT03794323|DRUG|BI 764122|Tablet
219730780|NCT03794323|DRUG|Placebo|Tablet
219730781|NCT02623270|DEVICE|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
219730782|NCT02623270|DEVICE|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
219730783|NCT01404260|DRUG|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
219730784|NCT01404260|DRUG|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
219730785|NCT00961012|PROCEDURE|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
219730786|NCT04541342|PROCEDURE|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
219730787|NCT00008268|BIOLOGICAL|filgrastim|
219730788|NCT00008268|DRUG|melphalan|
219730789|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
219157673|NCT04162444|DIAGNOSTIC_TEST|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve"
219157674|NCT04162444|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
219157675|NCT04162444|DIAGNOSTIC_TEST|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads"
219157676|NCT04381975|BEHAVIORAL|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
219157677|NCT04381975|BEHAVIORAL|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
219157678|NCT00566072|BEHAVIORAL|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
219157679|NCT00345150|DRUG|Ng-monomethyl-L-arginine (drug)|
219157680|NCT03761472|BIOLOGICAL|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
219157681|NCT03761472|BIOLOGICAL|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
219730790|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
219730791|NCT02677285|OTHER|Different type of wound|
219157682|NCT05769764|OTHER|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
219730792|NCT01438944|DRUG|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
219730793|NCT01894360|DRUG|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
219730794|NCT00205634|DRUG|Biaxin ( clarithromycin)|
219730795|NCT02565186|DRUG|Lasmiditan|oral tablet
219730796|NCT04370847|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
219730797|NCT04370847|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
219730798|NCT04370847|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
219157683|NCT05946421|DEVICE|exhaled breath analysis|non invasive technology to measure components of exhaled breath
219157684|NCT05572060|DRUG|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
219157685|NCT05572060|OTHER|standardized protocol|standardized protocol
219157686|NCT00871130|PROCEDURE|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
219157687|NCT02729506|PROCEDURE|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
219157688|NCT02729506|PROCEDURE|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
219157689|NCT05043805|DRUG|Dextromethorphan|add on therapy
219157690|NCT05043805|OTHER|placebo|add on therapy
219157691|NCT03372473|DRUG|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
219157692|NCT03372473|DRUG|Montelukast|Montelukast 5mg
219157693|NCT05798273|PROCEDURE|intra-arterial injection|"All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
219157694|NCT05798273|DEVICE|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
219157695|NCT05798273|OTHER|Radiopharmacon Contrast agent|Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
219157696|NCT00364702|DRUG|methylphenidate|
219730799|NCT04370847|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
219730800|NCT04370847|RADIATION|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
219730801|NCT04370847|OTHER|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
219157697|NCT05265481|DEVICE|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
219157698|NCT05265481|DEVICE|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
219157699|NCT05265481|DEVICE|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
219730802|NCT04370847|OTHER|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
219730803|NCT04370847|DRUG|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
219730804|NCT04370847|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
219730805|NCT04370847|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
219234436|NCT02370953|PROCEDURE|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
219234437|NCT05756101|DEVICE|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
219730806|NCT05586087|OTHER|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (\>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
219730807|NCT04719923|BEHAVIORAL|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
219730808|NCT00231933|BEHAVIORAL|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
219730809|NCT00231933|BEHAVIORAL|Community integration (CI)|CI includes recovery group sessions and community integration activities.
219730810|NCT00231933|BEHAVIORAL|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
219730811|NCT02852733|OTHER|end-of-life emergencies' management|
219730812|NCT01159353|DRUG|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
219730813|NCT01159353|DRUG|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
219730814|NCT03994120|OTHER|RTMS|Altering the connectivity of trans-synaptic pathways
219730815|NCT00510562|PROCEDURE|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
219730816|NCT00510562|PROCEDURE|Sham/Placebo|A laying on of hands with no treatment being performed.
219730817|NCT05659420|BEHAVIORAL|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
219730818|NCT03122366|DIAGNOSTIC_TEST|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
219730819|NCT05496699|BEHAVIORAL|Mckenzie Exercises|"1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position"
219157700|NCT01566968|OTHER|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
219157701|NCT01566968|OTHER|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
219157702|NCT01566968|OTHER|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
219234438|NCT06180109|DRUG|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
219157703|NCT04353531|DEVICE|High-flow nasal cannula|High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.
219157704|NCT04353531|DEVICE|Surgical mask|A procedure mask will be used to cover patient's face after HFNC is initiated.
219157705|NCT04353531|PROCEDURE|bronchoscopy examination|is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube
219157706|NCT04353531|PROCEDURE|intubation|Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.
219234439|NCT06180109|DRUG|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
219234440|NCT04421456|DRUG|GWP42003-P|oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
219157707|NCT04353531|PROCEDURE|tracheostomy|A tracheostomy is a medical procedure - either temporary or permanent - that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.
219730820|NCT05496699|BEHAVIORAL|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
219730821|NCT04886609|DEVICE|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
219157708|NCT04353531|DEVICE|nebulization|A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs
219157709|NCT04353531|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange.
219157710|NCT05229835|OTHER|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
219157711|NCT05180851|DRUG|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
219730822|NCT05257018|DRUG|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
219730823|NCT04268966|DRUG|Brincidofovir|
219157712|NCT00051571|DRUG|SGN-15|
219157713|NCT00051571|DRUG|Docetaxel|
219157714|NCT01083316|DRUG|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
219157715|NCT01083316|DRUG|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
219157716|NCT01083316|DRUG|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
219157717|NCT00000587|PROCEDURE|erythropoietin, recombinant|
219157718|NCT00000936|DRUG|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
219157719|NCT00000936|DRUG|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
219157720|NCT00000936|DRUG|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
219157721|NCT00074919|BIOLOGICAL|alglucosidase alfa|20 mg/kg qow
219157722|NCT04141514|OTHER|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
219157723|NCT04553770|DRUG|Anastrozole|Given PO
219157724|NCT04553770|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219157725|NCT04553770|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219157726|NCT04200365|DRUG|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
219157727|NCT02570191|DRUG|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
219157728|NCT01544270|DIETARY_SUPPLEMENT|Yogurt-like snacks|twice a day 120 g for four weeks
219157729|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
219157730|NCT00542035|DRUG|Placebo; oral|dose 1, dose 2
219157731|NCT00542035|DRUG|Placebo; oral|dose 1
219157732|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
219234441|NCT04421456|DRUG|Placebo|oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
219730824|NCT05688709|BEHAVIORAL|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
219157733|NCT04222686|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
219157734|NCT04222686|DRUG|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
219157735|NCT02692417|DEVICE|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
219157736|NCT00282971|DRUG|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
219157737|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
219157738|NCT05369507|BEHAVIORAL|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
219157739|NCT02725086|DRUG|Leucostim®|
219157740|NCT02725086|DRUG|Neupogen®|
219157741|NCT02945098|OTHER|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
219157742|NCT02945098|OTHER|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
219157743|NCT00533546|DRUG|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
219157744|NCT03365895|PROCEDURE|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
219157745|NCT03365895|OTHER|Laboratory Biomarker Analysis|Correlative studies
219157746|NCT03365895|PROCEDURE|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
219730825|NCT05610761|BEHAVIORAL|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
219157747|NCT03365895|OTHER|Questionnaire Administration|Ancillary studies
219730826|NCT05610761|BEHAVIORAL|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
219730827|NCT00601185|PROCEDURE|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
219730828|NCT04824287|OTHER|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
219730829|NCT01293955|DRUG|JOINS 200mg|1 tablet at each time, 3 times a day
219730830|NCT01293955|DRUG|Placebo|placebo of Joins 200mg
219730831|NCT02585180|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
219730832|NCT02585180|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
219730833|NCT02868528|GENETIC|chromosome screening with NGS technology|
219157748|NCT03435666|DRUG|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
219157749|NCT03435666|DRUG|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
219157750|NCT04713735|DIETARY_SUPPLEMENT|Control: Placebo|Placebo
219157751|NCT04713735|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|600 mg
219157752|NCT04404686|DRUG|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
219157753|NCT04404686|DRUG|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
219157754|NCT04987294|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
219157755|NCT04987294|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
219157756|NCT05143658|PROCEDURE|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
219157757|NCT00242359|DRUG|omalizumab|
219157758|NCT02441881|DEVICE|Venefit|Endovenous radiofrequency device
219157759|NCT02441881|DEVICE|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
219157760|NCT02441881|DEVICE|Endovenous Radiofrequency|Endovenous radiofrequency device
219157761|NCT03567798|DIETARY_SUPPLEMENT|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
219157762|NCT03567798|OTHER|Placebo|Placebo
219161570|NCT05294809|BEHAVIORAL|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
219161571|NCT05294809|BEHAVIORAL|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
219161572|NCT05294809|BEHAVIORAL|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
219161573|NCT05322590|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
219157763|NCT04730713|DEVICE|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
219157764|NCT03858413|DIAGNOSTIC_TEST|No intervention|No intervention
219157765|NCT00211419|DRUG|Anecortave Acetate 15 mg|
219157766|NCT00211419|DRUG|Triamcinolone Acetate 4 mg|
219157767|NCT00211419|PROCEDURE|Photodynamic Therapy with Verteporfin|
219730834|NCT04234230|OTHER|Prevalence Survey|Questionnaire survey on self-management
219730835|NCT02908321|BEHAVIORAL|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
219730836|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
219730837|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
219157768|NCT00211419|PROCEDURE|Thermal Laser|
219157769|NCT00847834|DRUG|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
219730838|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
219730839|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
219730840|NCT04623060|OTHER|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
219730841|NCT00353574|DRUG|Darusentan|Darusentan capsules administered orally once daily
219730842|NCT00183391|DRUG|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
219730843|NCT00183391|DRUG|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
219730844|NCT03922971|OTHER|Option 1: National comparison|Ability to view center's rate compared with all others.
219730845|NCT03922971|OTHER|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
219730846|NCT00649571|DRUG|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
219730847|NCT00649571|DRUG|Adoxa Tablets 100 mg|100mg, single dose fasting
219730848|NCT00647023|DRUG|metformin|1000 mg metformin x 2 daily during 8 months
219730849|NCT05192083|BEHAVIORAL|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
219730850|NCT03978208|DRUG|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
219730851|NCT03978208|OTHER|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
219730852|NCT03978208|DRUG|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
219730853|NCT03978208|DRUG|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
219157770|NCT00847834|DRUG|Irbesartan 150mg|Once a day
219730854|NCT04867330|OTHER|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
219730855|NCT04697992|DRUG|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
219730856|NCT04697992|DRUG|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
219157771|NCT05911581|OTHER|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
219157772|NCT05911581|OTHER|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
219157773|NCT02318134|PROCEDURE|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
219157774|NCT02318134|DRUG|normal saline|Normal saline via a nasoduodenal tube.
219157775|NCT04307511|DRUG|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
219157776|NCT04307511|DRUG|Aspirin|Aspirin
219157777|NCT04900766|DRUG|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
219730857|NCT02460380|DRUG|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
219730858|NCT02460380|OTHER|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
219730859|NCT04744532|DRUG|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
219730860|NCT04744532|DRUG|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
219730861|NCT01986751|DRUG|Clonidine|
219730862|NCT01986751|DRUG|ropivacaine|
219730863|NCT02388789|OTHER|active movement|same as arm description
219157778|NCT03010631|DRUG|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
219157779|NCT03010631|DRUG|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
219157780|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
219157781|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
219157782|NCT00293358|DRUG|carboplatin|
219157783|NCT00293358|DRUG|cisplatin|
219730864|NCT01478087|DEVICE|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
219730865|NCT03566550|DIAGNOSTIC_TEST|MRI scans|Repeated MRI scans imaging digestion of standard meals
219730866|NCT00485849|DRUG|Atomoxetine Hydrochloride|
219157784|NCT00293358|DRUG|etoposide phosphate|
219157785|NCT00293358|DRUG|ifosfamide|
219730867|NCT02618187|DRUG|SER-287|
219730868|NCT02618187|DRUG|Placebo|
219730869|NCT02618187|DRUG|Placebo Pre-Treat|
219157786|NCT00293358|PROCEDURE|adjuvant therapy|
219157787|NCT00293358|PROCEDURE|conventional surgery|
219157788|NCT00293358|PROCEDURE|neoadjuvant therapy|
219157789|NCT00293358|RADIATION|radiation therapy|
219234442|NCT00274287|DRUG|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
219234443|NCT00623844|BEHAVIORAL|physical activity|activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
219234444|NCT06285058|DIAGNOSTIC_TEST|No interventions|The high-throughput extraction of large amounts of quantitative image features from medical images
219234445|NCT05151016|DRUG|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
219157790|NCT02497716|DRUG|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
219157791|NCT04827524|OTHER|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
219157792|NCT01985542|DRUG|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
219157793|NCT01255670|DRUG|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
219157794|NCT02269475|DRUG|MEDI3250|MEDI3250
219157795|NCT02269475|DRUG|Placebo|Placebo
219730870|NCT02618187|DRUG|Vancomycin Pre-Treat|
219730871|NCT02614768|DEVICE|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
219730872|NCT00052715|DRUG|poly ICLC|
219730873|NCT05511480|BEHAVIORAL|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
219730874|NCT05511480|BEHAVIORAL|No interference|No interference through the continuation of learning same motor skill
219730875|NCT05311982|DEVICE|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
219730876|NCT05311982|DEVICE|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
219730877|NCT05311982|DEVICE|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
219730878|NCT04202783|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
219730879|NCT05708378|OTHER|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
219730880|NCT05708378|OTHER|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
219730881|NCT00100750|DRUG|Gemcitabine Hydrochloride|Given IV
219157796|NCT05949359|OTHER|Nintendo RingFit-augmented exercise program|"Participants in the NRE group received an 8-week exercise training program using the Nintendo RingFit (60 minutes for each session, two sessions a week). In each session, the participants first performed 5 minutes of walk-up exercises (i.e., simple jogging), followed by 50 minutes of Nintendo RingFit exercises and 5 minutes of cool down exercises.~The exercise intensity, in terms of repetitions, holding time of the exercise and advancement to difficult tasks, progressed gradually in 8 weeks."
219157797|NCT04649996|PROCEDURE|Appendectomy|comparison between operative and conservative treatment
219157798|NCT00199082|DRUG|Adriamycin|
219157799|NCT00199082|DRUG|Cyclophosphamide|
219157800|NCT00199082|DRUG|Cytarabine|
219157801|NCT00199082|DRUG|Dexamethasone/Prednisolone|
219730882|NCT00100750|DRUG|Tipifarnib|Given PO
219730883|NCT00100750|OTHER|Laboratory Biomarker Analysis|Correlative studies
219730884|NCT04841798|OTHER|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
219730885|NCT03673228|BEHAVIORAL|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
219730886|NCT03673228|BEHAVIORAL|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
219730887|NCT03673228|DRUG|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
219730888|NCT02084186|OTHER|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
219730889|NCT02084186|OTHER|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
219730890|NCT00467467|DRUG|Alfuzosin Hydrochloride|
219730891|NCT00033475|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219730892|NCT05264675|PROCEDURE|primary suture|Primary suture of the EPL-tendon
219730893|NCT05264675|PROCEDURE|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
219157802|NCT00199082|DRUG|VP16|
219157803|NCT00199082|DRUG|Ifosfamide|
219157804|NCT00199082|DRUG|Methotrexate|
219157805|NCT00199082|DRUG|G-CSF|
219157806|NCT00199082|DRUG|Rituximab|
219157807|NCT00199082|DRUG|Vincristine/Vindesine|
219157808|NCT00199082|PROCEDURE|Irradiation (in specific conditions)|
219730894|NCT05500846|DEVICE|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
219730895|NCT04480580|DIAGNOSTIC_TEST|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
219157809|NCT01996605|DRUG|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
219157810|NCT01996605|DRUG|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
219157811|NCT01996605|DRUG|Placebo|placebo will be administered spinally
219157812|NCT01472003|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
219157813|NCT01472003|DRUG|ABT-806i|ABT-806i will be administered by intravenous infusion.
219157814|NCT06019923|OTHER|No intervention|No intervention
219157815|NCT04317794|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
219157816|NCT06859684|DRUG|Durvalumab|Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined by the investigator); during maintenance therapy: 1500 mg Q4W
219157817|NCT06859684|DRUG|hepatic arterial infusion chemotherapy (HAIC)|hepatic arterial infusion chemotherapy (HAIC) : GemCis regimen was adopted, with the specific regimen as follows: cisplatin 60 mg/m2 on the first day, arterial infusion for half an hour, gemcitabine 1000 mg/m2 on the first day, arterial infusion for half an hour, repeated once every 3 weeks, and 4-6 cycles of treatment (the specific number of cycles was determined by the investigator according to the patient's condition).
219730896|NCT01163500|DIETARY_SUPPLEMENT|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
219730897|NCT01163500|OTHER|Placebo|Placebo controlled (dextrin)
219730898|NCT00186797|PROCEDURE|Allogeneic stem cell transplant|
219730899|NCT00186797|DRUG|Fludarabine, Cyclophosphamide|
219730900|NCT01063881|DRUG|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
219234446|NCT05151016|DRUG|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
219157818|NCT06859684|DRUG|Lenvatinib|Lenvatinib 8mg (weight \<60 kg) or 12mg (weight ≥60 kg) oral QD, during combination therapy, starting on day 3 of each 3-week cycle (determined by the investigator)
219157819|NCT04220229|DRUG|Cabozantinib S-malate|Given PO
219157820|NCT04220229|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
219157821|NCT02286154|DRUG|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
219157822|NCT05349331|PROCEDURE|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
219157823|NCT05925140|DRUG|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
219157824|NCT05925140|DRUG|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
219157825|NCT05925140|DRUG|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
219157826|NCT05925140|OTHER|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if \>80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
219157827|NCT07007260|DIETARY_SUPPLEMENT|niacinamide supplementation|Patients will take niacinamide supplementation (500mg) every day for 1 year
219157828|NCT06315179|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy (EGD) with biopsy|Esophagogastroduodenoscopy (EGD) is a test procedure to examine the lining of the esophagus, stomach, and first part of the small intestine.
219157829|NCT06315179|DIAGNOSTIC_TEST|Colonoscopy w/ biopsy|Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
219157830|NCT01207492|DRUG|nilotinib|Taken orally twice daily
219157831|NCT02769858|DEVICE|Light therapy|Light therapy glasses
219157832|NCT06693804|OTHER|Digital Otoscope and Ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination and magnification during physical examinations.
219157833|NCT06693804|OTHER|Conventional otoscope and ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination during physical examinations.
219157834|NCT07071103|RADIATION|Low-dose radiotherapy to the intestine (ILDR)|A single total dose of 1 Gy irradiation targeting the jejunum and ileum. Primary tumor or metastatic lesions that are within the irradiation field are irradiated concurrently.
219234447|NCT04117659|OTHER|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
219234448|NCT04955886|DRUG|Surufatinib(HMPL-012)|Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
219234449|NCT03522688|DRUG|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
219234450|NCT03522688|DRUG|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
219234451|NCT03114592|OTHER|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
219730901|NCT06169670|DEVICE|Viality|"Viality is a lipoaspirate wash system designed to be used in the operating room in conjunction with, and attached to, a user-provided liposuction cannula, a vacuum source, and a waste canister.~Viality is to be used to filter and wash aspirated, harvested autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is to be used without any additional manipulation. Viality is not intended to process autologous adipose tissue other than for aesthetic body contouring uses."
219730902|NCT01851512|DRUG|T-R (Test-Reference drug)|
219730903|NCT01851512|DRUG|R-T (Reference-Test drug)|
219730904|NCT05351034|DEVICE|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
219730905|NCT03749863|PROCEDURE|Serial PRP injections|Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
219730906|NCT01981928|DRUG|ASP7962|Oral
219730907|NCT01981928|DRUG|Placebo|Oral
219730908|NCT01446653|BEHAVIORAL|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
219730909|NCT01446653|BEHAVIORAL|Video|Video arm will provide information via documentary video
219730910|NCT01446653|BEHAVIORAL|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
219730911|NCT06132997|PROCEDURE|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
219730912|NCT06132997|PROCEDURE|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
219730913|NCT00005922|BEHAVIORAL|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
219730914|NCT00005922|DRUG|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
219157835|NCT07071103|DRUG|PD-1/PD-L1 monoclonal antibodies|Pre-progression immunotherapy regimen continues or switches to an alternative PD-1/PD-L1 monoclonal antibody according to clinical guidelines.PD-1/PD-L1 monoclonal antibody will be given 1 day after ILDR at a 3-week interval.
219157836|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
219157837|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
219730915|NCT00005922|OTHER|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
219730916|NCT01666405|DEVICE|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
219730917|NCT00576342|DRUG|AL-3862+timolol ophthalmic suspension|
219730918|NCT00576342|DRUG|Dorzolamide+timolol ophthalmic solution|
219157838|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
219730919|NCT01489358|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
219730920|NCT02730286|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
219730921|NCT03434366|DRUG|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
219157839|NCT01871675|DRUG|IPI-145|
219157840|NCT01871675|DRUG|Rituximab|
219157841|NCT01871675|DRUG|Bendamustine|
219157842|NCT00675246|DRUG|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
219157843|NCT05290597|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
219157844|NCT05786482|BEHAVIORAL|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
219730922|NCT03434366|DRUG|ketamine|intranasal ketamine for treatment for autism spectrum disorder
219730923|NCT03434366|DRUG|Saline|intranasal saline for treatment for autism spectrum disorder
219730924|NCT00736476|BIOLOGICAL|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
219730925|NCT00736476|BIOLOGICAL|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
219730926|NCT02845180|PROCEDURE|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
219730927|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
219730928|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
219730929|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
219730930|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
219730931|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
219730932|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
219730933|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
219730934|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
219730935|NCT05581264|BEHAVIORAL|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
219730936|NCT05845190|OTHER|aerobic exercises|aerobic exercises in form of walking on treadmill
219730937|NCT05845190|OTHER|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
219730938|NCT00502515|DRUG|SSR180575|Oral, once daily dosing
219730939|NCT00502515|DRUG|Placebo|Oral, once daily dosing
219730940|NCT02018809|BEHAVIORAL|Medication Adherence Partner|
219730941|NCT02018809|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
219730942|NCT03066557|PROCEDURE|TACE and Apatinib|TACE and Apatinib 250mg po qd
219730943|NCT03066557|PROCEDURE|TACE|TACE
219730944|NCT05807750|OTHER|Post-discharge income supplement|$300 income supplement
219730945|NCT05807750|OTHER|Enhanced care planning|Enhanced care planning provided by a nurse care manager
219730946|NCT03518203|DRUG|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
219730947|NCT00129558|DRUG|PT-523 for Injection|
219730948|NCT00002370|DRUG|Itraconazole|
219730949|NCT03511066|DRUG|CT-P27 90 mg/kg|Influenza A treatment drug.
219157845|NCT05786482|BEHAVIORAL|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
219157846|NCT06247371|BEHAVIORAL|Decision aid|The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
219730950|NCT03511066|DRUG|CT-P27 45 mg/kg|Influenza A treatment drug.
219234452|NCT01278511|OTHER|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
219730951|NCT03511066|DRUG|Placebo|Placebo.
219157847|NCT06062069|DRUG|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
219730952|NCT01270867|DEVICE|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
219730953|NCT00625729|BIOLOGICAL|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
219157848|NCT06062069|DEVICE|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
219157849|NCT06062069|DRUG|CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
219157850|NCT05391750|BIOLOGICAL|Tocilizumab|Given IV
219234453|NCT00330135|DRUG|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
219730954|NCT00625729|BIOLOGICAL|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
219730955|NCT00625729|BIOLOGICAL|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
219730956|NCT00625729|DRUG|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
219730957|NCT00625729|DRUG|fludarabine phosphate|Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
219730958|NCT00360854|DRUG|erlotinib hydrochloride|
219730959|NCT00360854|GENETIC|mutation analysis|
219157851|NCT05391750|DRUG|Venetoclax|Given PO
219234454|NCT00330135|DRUG|placebo injection|placebo injection - 1 injection
219234455|NCT02596542|OTHER|Water immersion|Different temperatures of cold water immersion will be assessed
219730960|NCT00360854|GENETIC|polymorphism analysis|
219730961|NCT00360854|OTHER|laboratory biomarker analysis|
219730962|NCT00360854|OTHER|pharmacological study|
219730963|NCT00360854|RADIATION|radiation therapy|
219730964|NCT04560309|DRUG|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
219730965|NCT04560309|DRUG|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
219730966|NCT05085405|BEHAVIORAL|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
219730967|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
219730968|NCT05085405|BEHAVIORAL|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
219730969|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
219730970|NCT04146909|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
219730971|NCT05645185|DIAGNOSTIC_TEST|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
219730972|NCT01737619|PROCEDURE|Computed Tomography|Undergo PET/CT
219730973|NCT01737619|DRUG|Indocyanine Green Solution|Given via superficial and deep cervical injection
219157852|NCT06429605|DRUG|duloxetine|In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
219157853|NCT06060158|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 sessions
219157854|NCT05443594|DEVICE|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
219730974|NCT01737619|OTHER|Laboratory Biomarker Analysis|Correlative studies
219730975|NCT01737619|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
219730976|NCT01737619|PROCEDURE|Lymphadenectomy|Undergo full lymphadenectomy
219730977|NCT01737619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219730978|NCT05755945|OTHER|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
219157855|NCT05443594|DEVICE|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
219157856|NCT06464458|OTHER|management on hydroxyurea by therapeutic pharmacological monitoring|"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."
219157857|NCT06423183|BEHAVIORAL|A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)|Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
219730979|NCT05856747|DRUG|TBP-PI-HBr|TBP-PI-HBr tablets.
219157858|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
219157859|NCT01853748|DRUG|Trastuzumab|
219157860|NCT01853748|DRUG|Paclitaxel|
219157861|NCT01853748|DRUG|Trastuzumab emtansine|
219157862|NCT05115968|PROCEDURE|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
219157863|NCT03575013|DRUG|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
219157864|NCT03575013|DRUG|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
219157865|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
219730980|NCT03623100|BEHAVIORAL|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
219730981|NCT03623100|BEHAVIORAL|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
219730982|NCT01783236|DRUG|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
219730983|NCT01783236|DRUG|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
219730984|NCT00002246|DRUG|Stavudine|
219730985|NCT00239291|DRUG|Gefitinib, radiotherapy|
219730986|NCT04915300|DRUG|Apabetalone|Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.
219730987|NCT04915300|DRUG|Placebo|Placebo p.o. (tablets) BID for 24 weeks treatment period.
219730988|NCT06293859|OTHER|Probiotic oat flakes|2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
219730989|NCT06293859|OTHER|Conventional oat flakes|Commercial oat flakes
219730990|NCT01509209|DRUG|Pseudoephedrine / Levocetirizine|tablet, BID everyday
219730991|NCT05999370|BEHAVIORAL|Nutrition|"The nutrition intervention will be based on needs assessed by indirect calorimetry, patient-generated subjective global assessment, and 24hr recall conducted at baseline, enabling individualized caloric and protein targets.~Deficits in nutrient intake will be addressed with one-on-one dietary counselling and supplementation at baseline in a quantity that matches the estimated deficit in intake. Adherence will be monitored using 24-hr recalls and weight status by the dietitian weekly."
219730992|NCT05999370|BEHAVIORAL|Exercise|The exercise intervention will include both a resistance and an aerobic component to be performed a total of 5 times a day, 5 times per week, 5 minutes each session, totaling 125 minutes per week. The ability to perform exercises as prescribed will be monitored with a weekly in-person or virtual supervised session.
219730993|NCT05371093|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
219730994|NCT05371093|DRUG|Cyclophosphamide|Administered intravenously
219730995|NCT05371093|DRUG|Fludarabine|Administered intravenously
219730996|NCT05371093|DRUG|Lenalidomide|Administered orally
219730997|NCT05371093|DRUG|Rituximab|Administered intravenously
219730998|NCT05371093|DRUG|Doxorubicin|Administered intravenously
219730999|NCT05371093|DRUG|Vincristine|Administered intravenously
219731000|NCT05371093|DRUG|Prednisone|Administered orally
219731001|NCT05371093|DRUG|Bendamustine|Administered intravenously
219731002|NCT02362412|DRUG|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
219157866|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
219157867|NCT03342027|DRUG|Bupropion|medication for smoking cessation
219157868|NCT03342027|BEHAVIORAL|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
219157869|NCT03342027|OTHER|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
219157870|NCT05958719|DRUG|Chidamide|chidamide 30mg biw, p.o, 21 days for a cycle.
219731003|NCT05103566|DEVICE|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
219731004|NCT06539351|OTHER|Skin biopsy|4mm skin punch biopsy
219731005|NCT06964438|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation training twice daily (30 minutes per session), during postoperative days 1-4. The training will be carried out using a handheld device. Training will be carried out by the participant themselves, with researcher supervision until independently able to do so.
219731006|NCT06964438|DIETARY_SUPPLEMENT|Protein supplement drink|"Whey protein isolate drink, to provide a total of 60 g protein per day (2 x30 g).~The supplement will be provided in a powder form to participants. Participants will be asked to consume the supplement around the time of NMES training."
219731007|NCT06963294|DRUG|Ketamine|Ketamine will be administered as an intravenous infusion at 0.1 mg/kg/hour during surgery
219731008|NCT06964724|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy with stent retriever
219731009|NCT06043570|DEVICE|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
219157871|NCT05958719|DRUG|Azacitidine|75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.
219157872|NCT05958719|DRUG|liposomal mitoxantrone|12mg/m2， d1,21 days for a cycle.
219157873|NCT05958719|DRUG|prednisone|60mg/m2，d1-5,21 days for a cycle.
219157874|NCT03566043|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
219157875|NCT05583136|DEVICE|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
219731010|NCT03722888|DEVICE|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
219731011|NCT00810745|PROCEDURE|starr|stapled transanal rectal resection
219731012|NCT00000483|DRUG|estrogen|
219731013|NCT00000483|DRUG|clofibrate|
219731014|NCT00000483|DRUG|dextrothyroxine sodium|
219731015|NCT00000483|DRUG|niacin|
219731016|NCT05020522|DIAGNOSTIC_TEST|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
219731017|NCT05020522|DIAGNOSTIC_TEST|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
219731018|NCT05020522|DIAGNOSTIC_TEST|Plasma methylation signature (ctMethSig)|Blood sample.
219731019|NCT05812599|OTHER|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
219731020|NCT06222424|OTHER|outpatient prescription issues|Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
219731021|NCT01541254|DEVICE|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
219731022|NCT00656812|DRUG|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
219731023|NCT00656812|DRUG|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
219157876|NCT05583136|DEVICE|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
219157877|NCT05583136|DEVICE|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
219234456|NCT03683212|PROCEDURE|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
219234457|NCT02586961|DRUG|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
219157878|NCT06462118|DRUG|Astegolimab|Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
219157879|NCT03863288|PROCEDURE|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
219157880|NCT03863288|DRUG|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
219234458|NCT02586961|DRUG|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
219731024|NCT06289218|DEVICE|interferential current|IFC plus exercise
219731025|NCT06289218|OTHER|kinesio taping|KT plus exercise
219731026|NCT06289218|OTHER|exercise|exercise only
219731027|NCT04622319|DRUG|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
219731028|NCT04622319|DRUG|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
219731029|NCT06195163|DRUG|Transdermal Gel in Sachet Dosage Form|Transdermal testosterone gel application prior to ovarian stimulation in the study group.
219731030|NCT06195163|DRUG|No pretreatment|No pretreatment prior to the ovarian stimulation in the control group.
219731031|NCT05103332|DRUG|Indapamide|Indapamide administered orally
219731032|NCT05103332|DRUG|Amlodipine|Amlodipine administered orally
219731033|NCT05103332|DRUG|Olmesartan|Olmesartan administered orally
219731034|NCT05103332|DRUG|Placebo|Placebo administered by SC injection
219731035|NCT05103332|DRUG|Zilebesiran|Zilebesiran administered by SC injection
219731036|NCT06351189|DEVICE|Observation|Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
219731037|NCT05611047|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
219731038|NCT05611047|OTHER|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
219731039|NCT05611047|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog©
219731040|NCT05611047|BEHAVIORAL|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
219731041|NCT05611047|OTHER|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
219731042|NCT05611047|OTHER|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
219731043|NCT02478788|DRUG|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
219731044|NCT02478788|DRUG|Placebo|Pills with no medication in it
219731045|NCT04028505|DRUG|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
219731046|NCT03870321|OTHER|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
219731047|NCT02218268|DRUG|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
219731048|NCT02218268|DRUG|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
219731049|NCT04419142|PROCEDURE|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
219731050|NCT04419142|PROCEDURE|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
219731051|NCT04469530|DRUG|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
219731052|NCT04469530|DRUG|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
219731053|NCT04469530|DRUG|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
219731054|NCT04469530|DRUG|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
219731055|NCT06560905|DRUG|68Ga-PSMA|This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
219731056|NCT03651336|DEVICE|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
219731057|NCT05800847|DRUG|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
219731058|NCT05800847|DRUG|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
219731059|NCT04791020|DRUG|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
219731060|NCT04791020|DRUG|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
219731061|NCT02051283|OTHER|RFA|RFA
219157881|NCT03863288|DRUG|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
219157882|NCT03863288|DRUG|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
219157883|NCT03863288|DRUG|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
219157884|NCT03863288|DRUG|Placebo|Placebo intranasal spray liquid administration
219157885|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
219157886|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
219157887|NCT06026319|DRUG|CD79b-19 CAR T cells|Intravenous infusion
219157888|NCT06026319|DRUG|Cyclophosphamide|Intravenous infusion
219731062|NCT06549374|OTHER|blood sampling|"After informing eligible patients (or their trusted support person, relative/guardian/curator where applicable) and in the absence of any opposition, they are included in the research.~Blood samples from an arterial catheter already in place will be taken every day from D1 to D7, then every 72 hours until discharge from intensive care, or until D28. For each of these samples, a maximum volume of 4 ml will be collected in a heparinized tube. Samples will not be taken if the hemoglobin level is below 7g/dl. For patients undergoing controlled surgery, the D1 sample will be taken as soon as possible after induction of anaesthesia.~Patients will be monitored until discharge from intensive care, or until D28 at the latest. Apart from the blood samples included in this study, all other examinations will be carried out as part of routine management. Data will be collected exclusively from medical records."
219731063|NCT06100042|DRUG|BDP/FF/G|"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."
219731064|NCT04906421|DRUG|TVB-2640|Oral dose, tablet
219731065|NCT04906421|OTHER|Placebo|Oral dose, tablet
219731066|NCT02084342|DRUG|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
219731067|NCT02084342|DRUG|normal saline|100ml, IV for 30min,before incision.
219157889|NCT06026319|DRUG|Fludarabine|Intravenous infusion
219157890|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
219157891|NCT06826742|DRUG|Intravenous line (IV) Methadone|"Subjects will receive standardized spinal anesthesia without intrathecal morphine (intrathecal 1.6-2 mL 0.75% bupivacaine + dextrose, 15 mcg fentanyl) and intravenous methadone (0.2mg/kg total body weight up to max dose of 20 mg, with saline added to make total volume 2 mL)~The Intravenous line (IV) methadone will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
219731068|NCT02084342|DRUG|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
219157892|NCT06826742|DRUG|Intrathecal Morphine|"Subjects will receive standardized spinal anesthesia with intrathecal morphine 150 micrograms and no methadone (2cc dose of IV normal saline)~The Intravenous line (IV) saline will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
219157893|NCT06715306|OTHER|Oral treatment|Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).
219234459|NCT02586961|DRUG|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
219234460|NCT02586961|DRUG|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
219731069|NCT00000335|DRUG|Morphine|
219731070|NCT02602197|DRUG|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
219731071|NCT02602197|DRUG|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
219731072|NCT00669344|DRUG|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
219731073|NCT00669344|DRUG|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
219731074|NCT03180372|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
219731075|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|
219731076|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
219731077|NCT05644418|DEVICE|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
219731078|NCT01221909|DRUG|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
219731079|NCT01221909|DRUG|saline solution|5cc saline solution
219731080|NCT00204789|DRUG|Difluoromethylornithine|
219731081|NCT01125748|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
219731082|NCT01125748|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
219731083|NCT01125748|DRUG|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
219157894|NCT06780397|DIAGNOSTIC_TEST|Joint ultrasonography|"Patients will undergo rheumatologic visits at baseline and scheduled follow-ups.~Rheumatologic visit procedures:~* collection of patients' anamnesis of rheumatologic diaseases.~* identification of painful and/or swollen joints and enthesis.~* evaluation of joint and enthesis pain.~* joint ultrasonography and assessment of joint structures and enthesis."
219234461|NCT01161706|OTHER|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
219234462|NCT00054730|DRUG|CX516 (Ampalex®)|
219234463|NCT02241642|DEVICE|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
219234464|NCT00925327|OTHER|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
219731084|NCT01641432|BEHAVIORAL|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
219157895|NCT06780397|OTHER|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0|"Patients will undergo dermatologic visits at baseline and scheduled follow-ups.~Dermatologic visit procedures:~* collection of patients' oncologic anamnesis and general personal and lifestyle information.~* administration of the quality of life questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0) to assess the impact of rheumatologic adverse events on patients' quality of life."
219161574|NCT05322590|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
219731085|NCT01641432|BEHAVIORAL|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
219731086|NCT02405962|BEHAVIORAL|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
219731087|NCT02405962|BEHAVIORAL|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
219731088|NCT01454999|BEHAVIORAL|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
219731089|NCT00839826|DRUG|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
219731090|NCT00839826|DRUG|Enoxaparin|40 mg bid
219731091|NCT02928432|DRUG|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
219731092|NCT02757014|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
219731093|NCT01028391|DRUG|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
219731094|NCT01028391|DRUG|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
219731095|NCT01028391|DRUG|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
219731096|NCT06462872|OTHER|observational study|It is an observational study
219731097|NCT03996213|OTHER|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
219731098|NCT03996213|OTHER|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
219731099|NCT04691232|BIOLOGICAL|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
219731100|NCT00477022|DEVICE|Vasotrain-447|
219731101|NCT03640377|DRUG|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
219731102|NCT01817478|OTHER|microbiologic sample|
219731103|NCT05833932|DRUG|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
219161575|NCT06194214|DRUG|Pirtobrutinib|Administered Orally.
219731104|NCT01408498|DRUG|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
219731105|NCT05466253|PROCEDURE|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
219161576|NCT06194214|DRUG|Digoxin|Administered Orally.
219161577|NCT06231381|DRUG|HB0034|Anti-IL-36R antibody
219161578|NCT06231381|OTHER|Placebo|non-biologically active drug
219161579|NCT06331130|DIAGNOSTIC_TEST|Computed Tomography|Computed Tomography done according to Clinical Practice to assess mesenteric involvment
219157896|NCT06780202|DRUG|medrol dosepak|"Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg)."
219157897|NCT06780202|DRUG|HYDROcodone Oral Tablet|This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
219157898|NCT06834464|DRUG|Nanohydroxyapatite paste|nanohydroxyapatite paste will be applied with a brush on the surface of the teeth
219157899|NCT06834464|DRUG|HCl liquid|HCl liquid will be applied for 60 seconds prior to application of nanohydroxyapatite paste in certain groups
219157900|NCT06834464|DRUG|microabrasion|the material will be applied on the surface of teeth then microabrasion will be done with a rubber cup for 60 seconds
219157901|NCT06780813|BEHAVIORAL|Supplemental oxygen therapy|In this grou participants will receive supplemental oxygen in the form of a Venturi mask upon low oxygen saturation in oximetry (SaO2\<95%) and a nasal oxygen mask in all other cases during the first 2 postoperative days
219157902|NCT05741034|DEVICE|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
219157903|NCT05741034|OTHER|Control|No-treatment control
219157904|NCT06786104|OTHER|VIDEO-PEDS|Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.
219731106|NCT05922280|OTHER|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
219731107|NCT05922280|OTHER|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
219731108|NCT01227395|DRUG|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
219731109|NCT00593255|DRUG|soluble human insulin|
219731110|NCT00593255|DRUG|insulin aspart|
219731111|NCT00593255|DRUG|insulin NPH|
219731112|NCT03964129|PROCEDURE|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
219731113|NCT01090206|DIETARY_SUPPLEMENT|Vitamin D and calcium|Doses will be based on Vitamin D levels
219731114|NCT00668408|OTHER|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
219157905|NCT06786104|OTHER|VIDEO-PEDS pilot|This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.
219157906|NCT06786104|OTHER|Focus Group|Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
219157907|NCT06782529|DRUG|Triamcinolone Acetonide Low Dose|"Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)"
219157908|NCT06782529|DRUG|Triamcinolone Acetonide Standard Dose|"Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)"
219731115|NCT00668408|OTHER|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
219731116|NCT04650945|OTHER|isCGM group|As previously described
219731117|NCT01673945|DEVICE|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
219731118|NCT03432962|OTHER|no intervention - recoding of food recall only|recoding of food recall
219731119|NCT02722291|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
219731120|NCT04721262|DEVICE|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
219731121|NCT01325766|OTHER|Yoga|Yoga 2 sessions per week for 8 weeks
219157909|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
219157910|NCT06783894|BEHAVIORAL|exercise (elliptical training)|twenty irritable bowel syndrome men with sexual dysfunction ( weak erection of penis or erectile dysfunction) will perform ellpitical physical activity (40 minutes on elliptical trainer three times weekly. the duration of physical activity will be 12 weeks.
219161580|NCT05600972|PROCEDURE|FSH priming|Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
219731122|NCT02025036|DRUG|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
219731123|NCT02025036|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
219731124|NCT02025036|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
219731125|NCT05033457|PROCEDURE|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
219731126|NCT01398475|DRUG|LY3009104|Administered orally
219731127|NCT04299620|DEVICE|Digital Image Analysis|Analysis of images
219731128|NCT04299620|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
219731129|NCT04299620|PROCEDURE|Transrectal Ultrasound|Undergo transrectal ultrasound
219731130|NCT01341041|BIOLOGICAL|chlorine dioxide|one time wash with 50ppm CD solution
219731131|NCT01341041|BIOLOGICAL|saline|one time wash with 50-100 cc normal saline
219731132|NCT05367830|BEHAVIORAL|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
219731133|NCT02455180|DRUG|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
219731134|NCT06398639|OTHER|Polygenic Risk Score (PRS)|"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."
219731135|NCT01574560|BEHAVIORAL|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
219731136|NCT01574560|BEHAVIORAL|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
219161581|NCT04273555|DRUG|[18F]-FDG|\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
219161582|NCT02645487|RADIATION|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
219161583|NCT05982769|BEHAVIORAL|Endurance Training 3 times per week|endurance training will be performed from home 3 times per week under the supervision of the research team.
219161584|NCT05982769|BEHAVIORAL|Resistance Exercise|resistance training will be performed from home 2 times per week under the supervision of the research team.
219161585|NCT05982769|BEHAVIORAL|Standard of Care|continue usual activity
219161586|NCT03569176|DEVICE|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
219161587|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
219731137|NCT00105508|DRUG|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
219731138|NCT00105508|DRUG|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
219157911|NCT06788860|PROCEDURE|Tri-directional Ultrasound-guided Needle Knife Release|"This procedure involves ultrasound-guided tri-directional needle knife release for the treatment of trigger finger. Local anesthesia using 3-5 ml of 1% lidocaine and 0.25% bupivacaine will be administered for patient comfort. It aims to ensure precise tissue dissection while minimizing risks and improving outcomes.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
219731139|NCT00086307|DRUG|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
219731140|NCT00086307|DRUG|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
219731141|NCT00683384|DRUG|Etanercept (Enbrel)|
219731142|NCT06466265|DRUG|DNP002|Anti-CEACAM6 monoclonal antibody
219157912|NCT05786391|OTHER|Flat position|Flat patient position during the cystoscopy
219157913|NCT05786391|OTHER|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
219157914|NCT05786391|DEVICE|Insufflation|Insufflation to 15 mm Hg
219157915|NCT06788574|DEVICE|TECAR device: MCRR. The sign producer is an INDIBA® 448 kHz RF device that has a vaginal/ or rectum electrode (made in Barcelona, Spain)|TECAR (Transfer Electrical, Capacitive, and Resistive) is originally used in Italy. TECAR therapy is a radiofrequency (RF) therapy, which produces high-frequency waves. RF can be capacitive or resistive The capacitive mode (CET) generates energy in electrolyte-rich soft tissues such as muscles and vascular or lymphatic tissues . The resistive mode (RET) directs energy to deeper tissues that contain more fat and fibers (such as bones, ligaments, and tendons;
219157916|NCT06788574|PROCEDURE|pelvic floor exercises|pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each
219157917|NCT06788574|DEVICE|Sham device|sham treatment by Tecar device for 15 min without producing any waves.
219157918|NCT06788665|DEVICE|Medical Device Dermalyser|Dermalyser is an Artificial Intelligence (AI) application (app) that allows medical professionals to take pictures of cutaneous lesions with the help of a smartphone camera. A dermatoscope is connected to the smartphone camera and is used to take the digital image of cutaneous lesions with suspicion of melanoma. Based on image processing algorithms, the app does a detailed analysis of the captured cutaneous lesion. In this clinical investigation, the objective is to test the device performance in a prospective setting in patients with a suspicion of primary cutaneous melanoma, to validate the added AI component. The intended purpose of the device is not to replace the physician's assessment, but rather to assist physicians in their assessment. Consequently, the final device should be regarded as a second opinion to augment clinical decision-making. The ultimate aim is to develop a tool that may augment clinical decision-making.
219157919|NCT06814184|BEHAVIORAL|app-based nurse-led virtual diabetes care|A nurse-led, app-based behavioral intervention consisting of (1) education via MyChart messaging, (2) problem solving with an action plan via phone, and (3) remote patient monitoring via mySugr app to identify the need to adjust treatment
219157920|NCT04105335|DRUG|MTL-CEBPA|Intravenous administration
219234465|NCT01694199|DEVICE|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
219731143|NCT03888274|DEVICE|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
219731144|NCT03334266|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
219731145|NCT03334266|OTHER|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
219731146|NCT03334266|OTHER|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
219731147|NCT02926612|OTHER|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
219731148|NCT00120874|BEHAVIORAL|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
219731149|NCT00120874|DRUG|Memantine|Patients receive 10 milligrams of memantine twice daily.
219731150|NCT00425139|BEHAVIORAL|Re-Mission|
219731151|NCT02130141|DIETARY_SUPPLEMENT|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
219731152|NCT02130141|OTHER|Dietary counselling|Usual snacks are limited.
219731153|NCT03975114|DRUG|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
219731154|NCT03975114|DRUG|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
219731155|NCT03975114|DRUG|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
219157921|NCT04105335|DRUG|Pembrolizumab|Intravenous administration
219731156|NCT00922389|PROCEDURE|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
219731157|NCT00922389|DRUG|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
219731158|NCT00922389|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
219731159|NCT03407586|DIAGNOSTIC_TEST|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
219731160|NCT00845000|DRUG|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
219157922|NCT03108443|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
219157923|NCT00411905|DRUG|Bortezomib|
219157924|NCT04620187|DRUG|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
219157925|NCT04620187|RADIATION|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
219157926|NCT04620187|DRUG|Standard of Care Chemotherapy|Intravenous injection
219157927|NCT06832670|OTHER|intervention|Participants in the intervention group will receive vaccine education, video animation and game practice.
219157928|NCT06832670|OTHER|active comparator|There will be no intervention in this group. It will continue its active education.
219157929|NCT06535542|GENETIC|Whole Genome Sequencing|Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
219157930|NCT06679556|DRUG|Strength A Sublingual Minoxidil|One single dose of Strength A sublingual minoxidil
219157931|NCT06679556|DRUG|Strength B Sublingual Minoxidil|One single dose of Strength B sublingual minoxidil
219157932|NCT05029258|PROCEDURE|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
219157933|NCT05029258|DIAGNOSTIC_TEST|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
219157934|NCT06835361|DRUG|Clotrimazole+Lactulose.|Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)
219157935|NCT06835361|DRUG|Canesten (Clotrimazole)|Vaginal tablets containing clotrimazole (100 mg)
219157936|NCT06835361|DRUG|Lactulose|Vaginal suppositories containing lactulose (300 mg)
219157937|NCT03713528|DRUG|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
219157938|NCT03271762|DEVICE|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
219157939|NCT03271762|PROCEDURE|cardiac surgery|mitral valve repair or mitral valve remplacement
219157940|NCT05470595|DRUG|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
219157941|NCT04688450|DEVICE|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
219234466|NCT01694199|DEVICE|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
219234467|NCT04810104|DRUG|AZD0328|Active study drug
219731161|NCT00845000|DRUG|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
219731162|NCT00845000|DRUG|Placebo|Placebo capsule, oral, at hour 0 of treatment period
219731163|NCT00845000|DRUG|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
219731164|NCT00845000|DRUG|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
219731165|NCT03107000|PROCEDURE|Trabeculectomy|Incisional surgery for glaucoma
219731166|NCT03107000|PROCEDURE|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
219731167|NCT03022214|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
219731168|NCT03022214|DIETARY_SUPPLEMENT|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
219731169|NCT04428593|DRUG|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
219157942|NCT05367245|DRUG|Cal-Mag Butyrate|Supplements
219157943|NCT05367245|DRUG|Placebo|Only Cal-Mag but no Butyric acid
219157944|NCT06559345|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219234468|NCT04810104|DRUG|Placebo|Non-active study drug
219234469|NCT02785822|DRUG|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
219157945|NCT06559345|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219157946|NCT06559345|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
219157947|NCT06301477|OTHER|Resistant Starch|7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption
219157948|NCT06301477|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
219157949|NCT06786416|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
219157950|NCT03599843|BEHAVIORAL|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
219157951|NCT06347393|DIAGNOSTIC_TEST|Mammography and Breast Ultrasound|Patients will be scanned using mammography and Breast Ultrasound for Breast Cancer Screening
219157952|NCT06788145|BEHAVIORAL|Social Support Single-Session Intervention|Single-session intervention to increase self-efficacy, social support, help-seeking, and recovery-oriented behaviors to address disordered eating.
219157953|NCT02514525|DEVICE|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
219157954|NCT03442244|DRUG|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
219157955|NCT03442244|DRUG|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
219157956|NCT04529707|BEHAVIORAL|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
219157957|NCT04120766|DRUG|Nicorandil|20 mg po qd
219157958|NCT04120766|DRUG|Placebo|Matching tablet
219157959|NCT06791343|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.
219157960|NCT06484478|OTHER|Wearable technology monitoring|Observational study (no intervention delivered)
219157961|NCT06464172|OTHER|Acute Oral gamma-aminobutyric acid (Natural Health Product in Canada)|1800 mg (3 capsules of 600mg) of GABA taken at the research center under the supervision of the research team.
219157962|NCT06464172|OTHER|Acute Placebo|A capsule filled with powdered sugar taken under the supervision of the research team.
219157963|NCT06785220|OTHER|ORAL FACIAL FACILITATION|"A group will receive oral facial facilitation which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)"
219157964|NCT06785220|OTHER|ORAL MOTOR THERAPY|"B group will receive oral motor therapy which included exercise for given,~1. A volcano bubbles~2. Party blower target~3. Bubble blowing~4. Curly straws"
219157965|NCT06785220|OTHER|ORAL FACIAL FACILITATION WITH ORAL MOROR THERAY|"C group will receive oral facial facilitation and oral motor therapy which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)~5. A volcano bubbles~6. Party blower target~7. Bubble blowing~8. Curly straws"
219157966|NCT06395051|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone monoester supplement (395 mg/kg body mass)
219157967|NCT06395051|DIETARY_SUPPLEMENT|Placebo|The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
219157968|NCT06525532|OTHER|follow up|performing a 3 Tesla MRI of the operated foot
219157969|NCT03346538|DRUG|Continuous infusion high-dose MCI-186|intravenous injection
219157970|NCT03346538|DRUG|Continuous infusion low-dose MCI-186|intravenous injection
219157971|NCT03346538|DRUG|Continuous infusion placebo|intravenous injection
219157972|NCT03346538|DRUG|Approved dosing regimen MCI-186|intravenous injection
219157973|NCT03346538|DRUG|Approved dosing regimen placebo|intravenous injection
219157974|NCT04930432|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
219157975|NCT06785545|DIAGNOSTIC_TEST|CA19-9|All patients Ca19-9 levels calculated from their urinary samples
219157976|NCT06783608|BEHAVIORAL|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). Patients were asked to measure and record their blood glucose value before breakfast. The yoga session was started 30 minutes after breakfast, and after the session was completed, they were asked to measure and record their blood glucose value again at 120 minutes after breakfast.
219157977|NCT04533503|DEVICE|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
219157978|NCT06046443|DRUG|LB54640|Oral daily administration
219157979|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
219161588|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
219234470|NCT02785822|DRUG|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
219234471|NCT02270606|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219731170|NCT04428593|DRUG|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
219731171|NCT04428593|DRUG|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
219157980|NCT01353313|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
219157981|NCT01353313|DRUG|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
219157982|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
219157983|NCT06356662|DRUG|Tenofovir Disoproxil Fumarate|take tenofovir disoproxil fumarate 300mg/d
219157984|NCT05371327|BEHAVIORAL|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
219157985|NCT02879162|DRUG|Durvalumab|
219157986|NCT02879162|DRUG|Tremelimumab|
219157987|NCT06398340|OTHER|High Calorie Meal Intervention|Subjects will receive a unhealthy meal high in calorie, sugar and fat
219157988|NCT06398340|OTHER|Low Calorie Meal Intervention|Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre
219157989|NCT05997602|DRUG|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
219157990|NCT06234033|BEHAVIORAL|Discrimination Acuity test|Estimating the just-noticeable difference of auditory loudness and vibrotactile displacement to fit a psychometric function for each modality with parameters: threshold, slope, sensitivity, and response criterion.
219157991|NCT06234033|DIAGNOSTIC_TEST|Transiently Evoked Otoacoustic Emission|Examination of integrity of outer hair cells in the inner ear; with and without contralateral suppression.
219157992|NCT06234033|OTHER|Questionnaires|Caregiver questionnaires send to parents online to acquire demographic information Autism Quotient (AQ), Child Behavior Checklist (CBCL6-16), Sensory Profile 2 (SP-2).
219157993|NCT06234033|BEHAVIORAL|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|Estimates intelligence quotient
219157994|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ASD|Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2)
219157995|NCT06234033|OTHER|Electroencephalography (EEG) with auditory or vibrotactile stimuli|Two paradigms will be used: an auditory frequency tagging paradigm with interspersed pitch oddballs and a classical sensory gating paradigm with either vibrotactile stimuli or auditory clicks.
219157996|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ADHD|ADHD-Rating Scale (ADHD-RS)
219157997|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
219157998|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
219157999|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
219158000|NCT05062889|DRUG|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
219234472|NCT02270606|DRUG|fluorouracil|Given IV
219234473|NCT02270606|DRUG|oxaliplatin|Given IV
219234474|NCT02270606|DRUG|leucovorin calcium|Given IV
219234475|NCT02270606|PROCEDURE|therapeutic conventional surgery|Undergo total mesorectal excision
219234476|NCT00972114|PROCEDURE|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
219234477|NCT00972114|PROCEDURE|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
219234478|NCT00972114|PROCEDURE|CABG alone|Coronary artery bypass graft surgery alone
219234479|NCT01449760|OTHER|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
219234480|NCT01449760|OTHER|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
219234481|NCT00220649|DRUG|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
219234482|NCT04721483|PROCEDURE|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
219731172|NCT04428593|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
219731173|NCT00335621|DRUG|Inhaled Tiotropium|
219731174|NCT04002427|DRUG|Intravenous Infusion|30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
219731175|NCT04002427|DRUG|Inhaled dose|A single inhalation on one occasion.
219731176|NCT00295243|DRUG|Topotecan|
219731177|NCT05374993|DEVICE|3TBA|Induce third molar tooth bud agenesis
219731178|NCT00511290|OTHER|no generic names|
219731179|NCT06017375|OTHER|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
219731180|NCT00300495|DRUG|Amiodarone|Perioperative orally administered
219731181|NCT00300495|OTHER|Control arm, standard care|Control
219731182|NCT02166788|PROCEDURE|Inguinal Lymphadenectomy|
219158001|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
219731183|NCT02166788|PROCEDURE|Ilio-inguinal Lymphadenectomy|
219731184|NCT04364971|PROCEDURE|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
219731185|NCT03833843|DIAGNOSTIC_TEST|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
219731186|NCT00002836|BIOLOGICAL|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
219731187|NCT00002836|DRUG|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
219731188|NCT00002836|DRUG|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
219731189|NCT00002836|DRUG|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
219731190|NCT00002836|DRUG|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
219731191|NCT00002836|DRUG|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
219731192|NCT00002836|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
219731193|NCT03368560|OTHER|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
219731194|NCT03632720|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
219731195|NCT03632720|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
219731196|NCT03632720|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
219731197|NCT03632720|BIOLOGICAL|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
219731198|NCT03632720|BIOLOGICAL|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
219731199|NCT03896932|OTHER|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
219731200|NCT04806945|DRUG|HLX10|IV infusion.
219158002|NCT05062889|DRUG|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
219731201|NCT04806945|DRUG|Paclitaxel|IV infusion
219731202|NCT04806945|DRUG|Cisplatin|IV infusion
219731203|NCT04806945|DRUG|Carboplatin|IV infusion
219731204|NCT04806945|DRUG|Placebo to HLX10|IV infusion
219731205|NCT06397066|PROCEDURE|White light endoscopy group|White light endoscopy observe the characteristics of mucosa under white light
219731206|NCT06397066|PROCEDURE|Magnifying endoscopy group|NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
219731207|NCT00682435|DRUG|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
219731208|NCT02739646|DEVICE|Functional MRI scan|7.0 Tesla functional MRI scan
219158003|NCT05062889|DRUG|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
219158004|NCT05062889|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
219158005|NCT05062889|DRUG|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
219731209|NCT06034314|DRUG|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
219731210|NCT00664677|DRUG|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
219731211|NCT06091605|PROCEDURE|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
219731212|NCT00112853|DRUG|tipifarnib|Given orally
219731213|NCT00112853|DRUG|etoposide|Given orally
219731214|NCT00902525|DRUG|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
219158006|NCT05062889|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
219158007|NCT05062889|DRUG|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
219158008|NCT05062889|DRUG|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
219158009|NCT05062889|DRUG|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
219158010|NCT06783023|OTHER|validity and reliability study|In the study, which will include at least 24 individuals with CIED determined by power analysis, unassisted arm exercise capacity and arm function/endurance, maximum arm exercise capacity, double product, heart recovery, comorbidity level, hand grip strength, fear of movement, activities of daily living and quality of life will be evaluated.
219158011|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
219158012|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
219158013|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
219158014|NCT06502262|DRUG|Bupivacaine Hydrochloride|patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.
219158015|NCT06502262|DRUG|Fentanyl|patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally
219158016|NCT06502262|DRUG|Dexmedetomidine|patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally
219158017|NCT04358276|OTHER|Computer-Assisted Intervention|Complete online course
219158018|NCT04358276|DEVICE|Dermatoscope|Receive dermatoscope
219731215|NCT00290238|DEVICE|Vertis Percutaneous Neuromodulation Therapy (PNT)|"* Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
219731216|NCT00290238|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"* Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
219731217|NCT02186171|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection once a month.
219731218|NCT02186171|DRUG|Placebo|Administered by subcutaneous injection once a month.
219731219|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
219731220|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
219731221|NCT05730673|DRUG|700mg leronlimab weekly dose|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
219731222|NCT05730673|DRUG|80mg Regorafenib at week 1|Regorafenib is a small-molecule multiple kinase inhibitor
219158019|NCT04358276|OTHER|Educational Intervention|Receive study packet
219158020|NCT04358276|OTHER|Educational Intervention (Physician)|Receive physician directed letter and educational package
219158021|NCT04358276|OTHER|Questionnaire Administration|Ancillary studies
219158022|NCT04358276|OTHER|Text Message|Receive text messages
219158023|NCT06789289|DRUG|TQC2938 injection|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
219158024|NCT06789289|DRUG|TQC2938 injection Placebo|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
219234483|NCT04266821|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
219234484|NCT03051074|BEHAVIORAL|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
219234485|NCT03051074|BEHAVIORAL|Comparison|Watching a relaxing film for up to 90 minutes
219234486|NCT04459572|DIAGNOSTIC_TEST|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
219158025|NCT06782880|PROCEDURE|Fecal microbiota transplantation (FMT)|To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
219158026|NCT05149157|OTHER|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
219158027|NCT02865226|OTHER|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
219234487|NCT00110032|DRUG|EF5|Given IV
219234488|NCT00110032|PROCEDURE|conventional surgery|Undergo surgery
219234489|NCT00110032|PROCEDURE|positron emission tomography|Undergo PET
219234490|NCT00110032|RADIATION|fluorine F 18 EF5|Given IV
219234491|NCT00110032|OTHER|pharmacological study|Correlative studies
219234492|NCT04552015|DIAGNOSTIC_TEST|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
219234493|NCT06427239|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
219234494|NCT06427239|DRUG|Adebrelimab|Adebrelimab will be administrated per dose level in which the patients are assigned
219234495|NCT02466958|DRUG|levomilnacipran|antidepressant
219234496|NCT02466958|DRUG|Placebo|an inactive drug
219234497|NCT04895774|OTHER|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
219234498|NCT04895774|OTHER|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
219234499|NCT04895774|OTHER|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
219234500|NCT02362386|DEVICE|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
219234501|NCT04620642|BIOLOGICAL|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
219234502|NCT03938207|DIAGNOSTIC_TEST|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
219234503|NCT03938207|DIAGNOSTIC_TEST|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219731223|NCT05730673|DRUG|120mg Regorafenib at week2|Regorafenib is a small-molecule multiple kinase inhibitor
219234504|NCT03938207|DIAGNOSTIC_TEST|TCM pattern|We want to use TCM pattern to investigate the difference among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
219234505|NCT03938207|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease will take to do the DNA Exome sequencing.
219234506|NCT03938207|DIAGNOSTIC_TEST|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
219234507|NCT03938207|DIAGNOSTIC_TEST|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
219234508|NCT03938207|DIAGNOSTIC_TEST|HLA typing|Using HLA typing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219234509|NCT03938207|DIAGNOSTIC_TEST|Full-length 16S Amplicon Sequencing|Using Full-length 16S Amplicon Sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219731224|NCT05730673|DRUG|160 mg Regorafenib at week 3|Regorafenib is a small-molecule multiple kinase inhibitor
219731225|NCT03166254|DRUG|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
219731226|NCT03166254|BIOLOGICAL|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
219731227|NCT03166254|PROCEDURE|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
219731228|NCT03166254|DRUG|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
219731229|NCT03166254|PROCEDURE|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
219731230|NCT03166254|PROCEDURE|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
219731231|NCT05695482|OTHER|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
219731232|NCT05695482|OTHER|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
219731233|NCT05111119|BEHAVIORAL|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information"
219731234|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
219158028|NCT02865226|OTHER|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
219158029|NCT04452955|BIOLOGICAL|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
219158030|NCT05659030|OTHER|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
219158031|NCT05986526|PROCEDURE|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
219158032|NCT05986526|PROCEDURE|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
219158033|NCT06828757|DRUG|nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy|Oral suspension of nanocrystalline megestrol is taken orally once a day until disease progression or 12 weeks (maximum duration of 12 weeks) PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
219158034|NCT06828757|DRUG|PD-1/L1 inhibitor combined with chemotherapy|PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
219158035|NCT06689839|DEVICE|F2 Filter and Delivery System|Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
219158036|NCT06689839|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
219731235|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
219731236|NCT00055965|DRUG|carboplatin|
219731237|NCT00055965|DRUG|cisplatin|
219731238|NCT00055965|DRUG|gemcitabine hydrochloride|
219731239|NCT07004192|DRUG|HCG injection|5000 IU hCG injection
219731240|NCT07004192|OTHER|No intervention|No hCG administered in this group.
219731241|NCT05970796|BEHAVIORAL|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
219731242|NCT06868667|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate.
219731243|NCT06868667|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody.
219731244|NCT06868667|DRUG|Bortezomib|Proteasome Inhibitor.
219731245|NCT06868667|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity.
219731246|NCT02851524|OTHER|posturography|
219731247|NCT04967417|DRUG|Pemetrexed, Carboplatin, Pembrolizumab|"* Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg"
219731248|NCT04967417|DRUG|Paclitaxel, Carboplatin, Pembrolizumab|"* Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg"
219731249|NCT06690931|DEVICE|Brain-Computer Interface with FES and VR|"The intervention utilizes the recoveriX PRO system. This is a neurofeedback therapy device that combines Brain-Computer Interface based motor imagery, functional electrical stimulation (FES), and virtual reality (VR). This approach enables participants to engage in motor imagery exercises while receiving real-time feedback based on neural signals.~Participants will complete a total of 24 recoveriX sessions, scheduled at 6 sessions per week, with each session lasting 1 hour."
219731250|NCT06690931|DEVICE|Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback|"The participants will train the Motor Imagination (MI) combined with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback. Feedback provided to the patients will not be linked to the neural signals.~The amount of stimulation delivered by the feedback devices (FES and VR) will be similar to the experimental group."
219731251|NCT07018258|PROCEDURE|Erector Spinae Plane (ESP) Block|Ultrasound-guided bilateral erector spinae plane (ESP) block performed at the T7 vertebral level. The intervention will be applied in three different patient positions-lateral, prone, or sitting-prior to laparoscopic cholecystectomy.
219731252|NCT00985374|DRUG|RAD001|5mg or 10mg po daily
219731253|NCT00985374|DRUG|RG1507|16mg/kg iv every 3 weeks
219731254|NCT06693492|DEVICE|Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention|Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
219731255|NCT05330429|DRUG|Magrolimab|Administered intravenous infusion
219731256|NCT05330429|DRUG|Bevacizumab|Administered intravenous infusion
219158037|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
219158038|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
219158039|NCT06831539|DRUG|PEGLyte bowel preparation|"Volunteers will be administered 4L of PEG bowel preparation. The following instructions will be provided with the prescription:~1. Fill the supplied container containing the bowel cleanse powder with lukewarm water (to facilitate dissolution) to the 4-liter fill line. The solution is clear and colourless when reconstituted to a final volume of 4 liters.~2. After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. The solution is more palatable if chilled prior to drinking. When reconstituted use within 48 hours.~3. Attempt to drink a maximum of 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters has been consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously.~4. The first bowel movements should occur approximately one hour after the start of bowel cleanse administration. Continue drinking until the watery stool is clear and free of solid matter."
219158040|NCT06475352|DRUG|FOLFOX regimen|Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
219158041|NCT06475352|DRUG|CAPOX regimen|Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
219158042|NCT06828926|BEHAVIORAL|Tai Chi|The Tai Chi program content is based on the Harvard Medical School (HMS) Guide to Tai Chi, developed by clinical scientist Dr. Peter M. Wayne. Each participant will receive a workbook that describes the philosophy, evidence, and practice of Tai Chi, along with a video series for home practice that features the exercises from the HMS Guide to Tai Chi program. The in-person classes will be led by the PI and delivered weekly over 8 weeks, with 75-minute sessions. The in-person and video series will include an introduction to the principles of practice and tips on establishing and maintaining a practice, followed by a series of warm-up exercises, Tai Chi movements, and cool-down exercises. The Tin-person (and offer virtual live sessions for those who cannot attend in-person) over 8 weeks, accompanied by a workbook and video-recorded practices to promote self-management.
219158043|NCT06791031|DRUG|inclisiran|"Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group."
219158044|NCT06507579|DEVICE|Hydra transcatheter aortic valve (THV) series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
219158045|NCT05672667|DRUG|intravenous oxytocin|Oxytocin given by intravenous route
219158046|NCT05672667|DRUG|intranasal oxytocin|Oxytocin given by intranasal administration
219158047|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB).
219158048|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)
219158049|NCT06784557|DRUG|Atorvastatin 40mg|High intensity HMG-CoA reductase inhibitor
219158050|NCT06784557|DRUG|Atorvastatin 20mg+Ezetimibe 10mg|Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
219158051|NCT06830668|DRUG|Regimen：BIC+FTC+TAF|"Same-day restart of BIC+FTC+TAF among HIV patients who experienced discontinuation from previous NNRTI-based regimens"
219158052|NCT06816069|DEVICE|VOLNEWMER|Monopolar radiofrequency device
219158053|NCT03286868|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
219158054|NCT03286868|DEVICE|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
219158055|NCT05377840|BEHAVIORAL|Psychologist-administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For psychologist-administered CBT: Participants will have individual weekly sessions (virtually) lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
219234510|NCT03938207|DIAGNOSTIC_TEST|Epigenomic|Using Epigenomic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219731257|NCT05330429|DRUG|Irinotecan|Administered intravenous infusion
219731258|NCT05330429|DRUG|Fluorouracil|Administered intravenous infusion
219731259|NCT05330429|DRUG|Leucovorin|Administered intravenous infusion
219731260|NCT01294930|OTHER|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
219731261|NCT07028086|DRUG|VAM_GROUP|Mitoxantrone Liposome 24mg/m², IV, administered as a single dose or divided doses at the investigator's discretion based on the patient's condition; Azacitidine 75mg/m², IV drip, Day 1 to Day 7; Venetoclax 100mg on Day 1, 200mg on Day 2, and 400mg on Day 3 to Day 14.
219731262|NCT07028424|DRUG|Nal-IRI|NAL-IRI 50 mg/m2, administered over 80-100 minutes, on day 1 of a 14-days cycle
219731263|NCT07028424|DRUG|Ciprofloxacin|6 capsules/cycle : 500 mg twice daily on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
219731264|NCT07028424|DRUG|Paclitaxel|80 mg/m2 weekly on days 1, 8, 15 of each 28-days cycle (at the discretion of investigator)
219158056|NCT05377840|BEHAVIORAL|Self-Administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For self-administered CBT: Participants will be given a book written for patients on CBT for IBD with instructions on how to self-administer CBT.
219158057|NCT06788522|DRUG|Suvorexant|Suvorexant pills (10-20 mg)
219158058|NCT06788522|DRUG|Placebo|Matching placebo pills
219158059|NCT04157322|DIAGNOSTIC_TEST|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
219158060|NCT06828744|OTHER|Exercise|Participants in this group will follow an exercise and stretching program for five weeks, performed three times per week.
219158061|NCT06828744|OTHER|Exercise plus Joint Mobilization|Participants in this group will follow a five-week exercise and stretching program, performed three times per week, in combination with an ankle joint mobilization program.
219158062|NCT06726772|BEHAVIORAL|Group Psychotherapy|Group psychotherapy based on Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) elements
219158063|NCT03789747|OTHER|As a observational study, there is no intervention.|As a observational study, there is no intervention.
219731265|NCT07028424|DRUG|Gemcitabine|1,000 mg/m2 intravenously (IV) over 30 minutes weekly on days 1, 8, 15 of each 28-days cycle
219731266|NCT07028424|DRUG|Oxaliplatin|60 mg/m2 (starting 2 hours later, administered over 110-130 minutes) on day 1
219731267|NCT07028424|DRUG|Leucovorin|"As part of NALIRIFOX -for 8 cycle treatment: (L + D racemic form) 400 mg/m2 on day 1 (equivalent to 200 mg/m2 levoleucovorin) (starting 30 minutes after oxaliplatin, administered over 25-35 minutes)~As part of LV5FU2 maintenance treatment: 400 mg/m2 IV infusion over 30 min on day 1 (equivalent to 200 mg/m2 levoleucovorin). LV could be administered over 2 hours to oxaliplatin according to The National Thesaurus of Digestive Oncology (TNCD) https://www.snfge.org/sites/www.snfge.org/files/tncd/2024-05/tncd\_chap-09-cancer-pancre%CC%81as\_2024-05-17\_1.pdf, at investigator's discretion"
219731268|NCT07028424|DRUG|5-Fluorouracil|"As part of NALIRIFOX -for 8 cycle treatment: 2400 mg/m² IV initiated on day 1, with continuous infusion over 46 hours (no bolus infusion with 5-FU)~As part of LV5FU2 maintenance treatment: 400 mg/m2 bolus over 10 min then 2,400 mg/m2 IV infusion over 46h"
219731269|NCT07028424|OTHER|Placebo|6 capsules/cycle : 500 mg twice daily (morning and evening; 12 hours should elapse between two doses) on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
219731270|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program Only (Control)|Participants in the control group will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks.
219731271|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program + the Diabetes Prevention Program (DPP)|Participants will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks. Additionally, participants will be registered for a free, year-long YMCA membership and enrolled in the DPP. Through the DPP, participants will receive health education, coaching, and peer support via 26 virtual group sessions over a year.
219158064|NCT03272438|DEVICE|Accelerometer|Participants use an accelerometer to monitor their steps activity
219158065|NCT03272438|BEHAVIORAL|Step goal|Participants are given a daily step goal to aim for
219158066|NCT03272438|BEHAVIORAL|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
219158067|NCT03272438|BEHAVIORAL|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
219158068|NCT06784856|OTHER|PICC AR APP|"This study utilized Vuforia software and Unity 2022 LTS as the primary development platforms to create an AR-Enhanced and Game-Assisted Teaching curriculum. The designed PICC AR Exploration APP was developed for both iOS and Android platforms. The PICC-related content was based on the 8th Edition of the Infusion Therapy Standards of Practice published by the Infusion Nurses Society (INS) in 2021 and the 2022 Clinical Guidelines for Vascular Access Devices.~The required items for PICC care procedures were photographed and used to create 3D object elements and animations for developing AR scenarios and interactive gaming elements. The design and content of the PICC AR Exploration APP are described as follows:~Game Design Concept:~The PICC AR Exploration APP includes a learning unit system and a quiz unit system:~Learning Unit System Content:~Topic 1: Updates to guidelines and an introduction to clinical applications. Topic 2: PICC catheter care, dressing change steps, and techni"
219158069|NCT06784856|OTHER|Classroom Teaching and Case Sharing|"Introduction to Updated CVAD-PICC Guidelines and Clinical Applications~PICC Catheter Care Management of Common PICC-Related Complications Case Sharing on PICC Complication Management: Researchers"
219158070|NCT06829355|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Thymalfasin: 4.8 mg, administered subcutaneously twice weekly.
219158071|NCT06829355|DRUG|Regorafenib (BAY 73-4506)|Regorafenib: Start at 80 mg once daily, orally, taken at a fixed time for 2 consecutive weeks and then stopped for 1 week. If the patient tolerates it well, increase to 120 mg/d in Cycle 2.
219158072|NCT06829355|DRUG|Tislelizumab (BGB-A317)|Tislelizumab: 200 mg, iv.gtt, single infusion, 21 days as a cycle, Day 1.
219158073|NCT06788678|BEHAVIORAL|MOVED|MOVED includes 8 self-guided, web-based sessions administered over 4 weeks. Web-based sessions include 3 core components: (1) elicit moral elevation, (2) engage in reflection about moral elevation response, and (3) set a behavioral goal that is inspired by the moral elevation exercise.
219158074|NCT06788678|OTHER|Supportive Care Control|A present-centered, nondirective intervention that aims to control for the nonspecific therapeutic effects of supportive care. In this case, the effects of engaging in regular web-based sessions that convey information about PTSD symptoms. Sessions will include psychoeducation materials about PTSD symptoms, functioning, and resources for dealing with related stressors. Key components of MOVED will be strictly excluded.
219158075|NCT06788171|RADIATION|Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy|PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.
219158076|NCT06788171|DRUG|Bevacizumab|Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.
219158077|NCT06788171|DRUG|Capecitabine|Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
219731272|NCT06687018|OTHER|Kaltenborn mobilisation|Kaltenborn mobilisation Grade 3 along with common treatment for 3 minutes, repeated 3 sets with rest of 1 minutes, three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises.
219158078|NCT06788171|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
219158079|NCT06788171|DRUG|Sintilimab|Sintilimab: 200mg, d1, q3w, 6 cycles.
219158080|NCT06834412|DIAGNOSTIC_TEST|68Ga-Pentixafor and 18F-FDG PET/CT Scan|The imaging agent 68Ga-Pentixafor and 18F-FDG used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is about 4; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
219158081|NCT06834048|OTHER|observation alone|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
219158082|NCT06791928|BEHAVIORAL|Peer distribution of self testking kits|Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
219158083|NCT05306041|DRUG|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
219158084|NCT05306041|DRUG|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
219158085|NCT05306041|DRUG|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
219158086|NCT06831617|OTHER|AI-based low dose CBCT reconstructed images system|Participants in the experimental group undergo AI-based low dose (radiation dose is 1/6th of the dose used in the clinic) CBCT reconstructed images guided lung puncture procedures.
219158087|NCT06831617|OTHER|Conventional CBCT images system|Participants in the experimental group undergo conventional CBCT images guided lung puncture procedures.
219158088|NCT06791005|DRUG|Preoperative Injection of Carbon Nanoparticles|1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
219158089|NCT06791005|DRUG|Intraoperative Injection of Carbon Nanoparticles|Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
219158090|NCT06790277|DEVICE|Mepilex Border Sacrum dressings|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
219158091|NCT06790277|DEVICE|Polyurethane foams (Pink Pad)|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
219158092|NCT02984124|BEHAVIORAL|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
219158093|NCT02984124|BEHAVIORAL|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
219158094|NCT06586216|DRUG|PF-07817883|Experimental
219158095|NCT06833216|OTHER|Genetic variation|To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.
219158096|NCT06783803|DIAGNOSTIC_TEST|Linkage Analysis|WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies
219158097|NCT06835296|DRUG|YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.|Dose: Ascending doses (SAD stage: 200, 800, 1600, or 3200 mg; MAD stage: two dosages will be determined based on the results from the SAD stage) Mode of administration: Oral, once daily.
219158098|NCT06786143|BEHAVIORAL|Esmadem Education Model|"Application Application of the Research The implementation of the research was done in 3 steps.~Step 1: In the first stage of the research, after the risky pregnant women who come to the polyclinic are informed about the study, the participants who agree to participate and meet the criteria for inclusion in the research will be determined by randomization. After the pregnant women assigned to the training or control group sign the voluntary consent form and their consent is obtained, Personal InformationForm, Mishel Uncertainty in Illness Scale Depression-Anxiety-Stress Scale Depression-Anxiety-Stress Scale (DASÖ-21) scales will be applied. After the first interviews, the study group will be informed about the sessions and the training will start via zoom.~In educational sciences, since the number of groups is between 2-20 people in the acquisition of target behaviors at the conceptual level, two training groups will be created and 15 pregnant women will be in the first group, 15 preg"
219158099|NCT06835855|OTHER|Passive Viewing Task|Infants will complete a computer-based task in which they view facial displays of emotion (angry, happy, sad, neutral) while an eye tracker records their gaze.
219158100|NCT06835855|OTHER|Interaction Task|Mother and infants will also complete a standardized interaction task during which we assess infant gaze and psychophysiology. The task consists of three stages, each of which lasts three minutes. For the first stage (Free Play 1), infants sit in a highchair and mothers are asked to play with their baby as they normally would, without any toys or other objects. In the second stage (Sad), mothers are asked to think about times when they are sad or depressed and do not feel able to effectively play with their child. They are instructed to look at their child but speak in a monotone and minimize body movement or any physical contact with the infant. In the third stage (Free Play 2), mothers again interact with their infants normally for three minutes.
219158101|NCT04524390|DRUG|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
219158102|NCT04524390|OTHER|Placebo|Identical to maralixibat except for the active drug substance
219158103|NCT05666362|DRUG|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
219158104|NCT05666362|DRUG|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
219158105|NCT05840003|RADIATION|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
219731273|NCT06687018|OTHER|Mulligan mobilisation|Mulligan mobilisation with 10 repetitions with 3 sets and three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises
219731274|NCT06714448|DRUG|Sodium valporate|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
219731275|NCT07033338|BEHAVIORAL|Occupational Activities and Finger Exercise Program|The intervention group received the program three days a week (Wednesday, Thursday, and Friday), once daily, with sessions held from 10:00 to 12:00 in the morning and from 14:00 to 16:00 in the afternoon. The participants were divided into two subgroups (13 participants in the first group, 12 in the second). The intervention consisted of a combined occupational activities and finger exercise program. Each session began with finger exercises, followed by occupational activities. The finger exercises involved movements requiring the participation of the fingers, hands, and arms, and were performed in 10 progressive steps. These movements were designed to promote engagement without causing fatigue or discomfort in elderly participants. Occupational activities included threading beads, completing line patterns, sewing buttons, assembling wooden blocks, performing cutting exercises, limited painting, dough manipulation, cutting and gluing, wrapping rope, tying rope between two points, stack
219731276|NCT07034131|OTHER|Osteo-Buddy|"Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with:~1. Evaluating their risk level of osteoporosis~2. Recommending screening and referrals~3. Lifestyle interventions through motivation, education and tailored guidance~As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data."
219731277|NCT07034131|OTHER|Usual Care|Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'
219731278|NCT07038967|OTHER|Coloured photography|Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.
219731279|NCT07038967|OTHER|Fluorescein angiography|Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:
219158106|NCT04655235|GENETIC|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
219158107|NCT06014775|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
219158108|NCT04751526|DEVICE|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
219158109|NCT04751526|DEVICE|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
219158110|NCT05412615|PROCEDURE|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
219731280|NCT07038967|OTHER|Optical coherence tomography|Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.
219731281|NCT07041450|DIAGNOSTIC_TEST|Digital MoCA|A digital version of the Montreal Cognitive Assessment used to evaluate cognitive function. Administered on a tablet at Visit 1 or Visit 2 (randomized).
219731282|NCT07041450|DIAGNOSTIC_TEST|XpressO|A digital cognitive pre-screening tool used to screen for cognitive function. Administered on a tablet at Visit 1.
219731283|NCT07041450|DIAGNOSTIC_TEST|MoCA|The standard paper-baed Montreal Cognitive Assessment used to evaluate cognitive function. Administered at Visit 1 or Visit 2 (randomized), opposite the digital MoCA.
219731284|NCT07041450|DIAGNOSTIC_TEST|Blood-based Biomarkers (BBM)|Participants provide a blood sample that is analyzed for Alzheimer's disease-related biomarkers, including PrecivityAD2 and MTBR. These biomarkers are used to assess the biological stage of disease and support diagnostic triage and eligibility assessment for disease-modifying therapy (DMT)
219731285|NCT07041450|OTHER|Amyloid Treatment Screening Tool (ATST)|A questionnaire administered to assess eligibility for amyloid-targeted therapies. Both clinician and patient-centered versions are used.
219731286|NCT07041450|OTHER|MoCA Brain Health Questionnaire (MBHQ)|A questionnaire designed to capture participants' physical health, emotional well-being, diet, exercise, and social engagement as it relates to cognitive health. Responses are used as part of exploratory analyses to evaluate associations with cognitive status and Alzheimer's disease diagnosis.
219731287|NCT07041450|OTHER|MoCA Medical Questionnaire|A structured questionnaire administered to participants to gather information on their medical history, including prior diagnoses, medications, and other health conditions. This data helps to contextualize cognitive symptoms and support diagnostic decision-making in the study.
219731288|NCT07041450|OTHER|Functional Activities Questionnaire+ (FAQ+)|A questionnaire designed to assess the participant's ability to perform daily activities, providing insights into their functional status and cognitive impairment. It is a longer version of the original FAQ questionnaire. It is used as part of the screening and exploratory analysis to better understand the relationship between functional abilities and Alzheimer's disease progression.
219731289|NCT07040306|DRUG|Methimazole(MMI)|Determine the enrolled GD patients and adjust the dosage of methimazole according to the 2016 American Thyroid Association guidelines. Conduct thyroid function, liver function, TRAb, and blood routine tests during outpatient follow-up to observe the treatment effect and provide medication guidance.
219731290|NCT02968394|DRUG|omalizumab|
219731291|NCT07045220|BEHAVIORAL|TTMCR|A trans-theoretical model (TTM)- based multidisciplinary CR program (TTMCR) to improve behavior change and cardiac rehabilitation outcomes
219731292|NCT07044726|DRUG|Povidone-Iodine|Providone-Iodine for periurethral preparation
219731293|NCT07044726|DRUG|Sterile water|Sterile water for periurethral preparation
219731294|NCT07046130|BEHAVIORAL|Resistance Training|The mininum resistance training volume (12 sets/week) will be applied.
219731295|NCT07045922|BEHAVIORAL|Motor-Cognitive Training Program|"Participants assigned to the intervention group participated in a structured motor-cognitive training program in addition to their regular physical education (PE) classes. The training was designed to integrate physical movement with cognitive engagement in a game-based format, suitable for the preschool age group.~The program was conducted twice weekly for eight weeks, with each session lasting approximately 25-30 minutes. Activities progressed in complexity over time, incorporating elements of motor planning, executive functioning, and balance control. Sessions consisted of:~Warm-up phase: Light aerobic activities such as jogging, dynamic stretching, and coordination drills (e.g., knee pulls, toe walking).~Main training phase:~Activities targeting core cognitive-motor domains:~Running drills (forward, backward, lateral)~Jumping and landing mechanics~Ball handling and coordination tasks (e.g., passing, tennis ball exercises)~Balance and proprioceptive challenges (e.g., walking"
219731296|NCT07045922|OTHER|Regular Physical education classes|Participants in the control group continued with their regularly scheduled physical education (PE) classes as mandated by the school curriculum. They did not receive any additional motor-cognitive or structured exercise training. Furthermore, they were instructed not to engage in any external physical activity programs outside of the regular PE sessions throughout the study duration. This restriction was monitored to ensure group consistency.
219731297|NCT07045857|BEHAVIORAL|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence
219158111|NCT05412615|PROCEDURE|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
219158112|NCT06360640|DRUG|APC148 and Placebo|IV infusion
219158113|NCT05820789|OTHER|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
219158114|NCT05921032|OTHER|Exercise intervention|8 weeks of exercise with two session in a week
219158115|NCT05766657|DIETARY_SUPPLEMENT|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
219158116|NCT05766657|DIETARY_SUPPLEMENT|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
219158117|NCT06547905|DEVICE|Ostomy Leakage Detection System|A system that is used to detect ostomy leaks
219158118|NCT04689607|OTHER|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
219158119|NCT04689607|OTHER|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
219158120|NCT04605458|COMBINATION_PRODUCT|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
219158121|NCT04605458|COMBINATION_PRODUCT|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
219158122|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
219158123|NCT06085274|PROCEDURE|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
219158124|NCT02949284|DRUG|Abiraterone Acetate|Given PO
219158125|NCT02949284|DRUG|Androgen Receptor Antagonist ARN-509|Given PO
219158126|NCT02949284|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC
219731298|NCT07046208|OTHER|physiothreapy protocol|Aerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test).
219731299|NCT07046273|DRUG|F027|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
219731300|NCT07046273|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
219731301|NCT07044882|PROCEDURE|conventional osteotome technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with regular manual osteotomes.
219158127|NCT02949284|DRUG|Prednisone|Given PO
219158128|NCT02949284|OTHER|Quality-of-Life Assessment|Ancillary studies
219158129|NCT02949284|OTHER|Questionnaire Administration|Ancillary studies
219158130|NCT02949284|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219158131|NCT05587361|DRUG|Propranolol|Propranolol Capsule; 40 mg IR
219158132|NCT05587361|DRUG|Nicotine Patch|Nicotine Patch; 14 mg
219731302|NCT07044882|PROCEDURE|Hydrodynamic Piezoelectric technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with Hydrodynamic Piezoelectric technique.
219731303|NCT07045415|BEHAVIORAL|Pelvic Floor Muscle Exercises.|A structured pelvic floor muscle training (PFME) program provided by a nurse, based on EAU and AUA guidelines, consisting of 20-minute sessions delivered 3 times a week
219731304|NCT07044791|BEHAVIORAL|Nutritional counseling. No drug treatment will be administered in this study.|Nutritional counseling. No drug treatment will be administered in this study.
219158133|NCT05587361|DRUG|Placebo Propranolol|Placebo Capsule, no active ingredients
219158134|NCT05587361|DRUG|Placebo Patch|Placebo Patch, no active ingredients
219158135|NCT05928169|DRUG|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
219158136|NCT02839070|OTHER|Sleep/Wake Schedule|Timing of sleep and wake
219161589|NCT05766878|DEVICE|implants placement|The intervention will consist of placement of two types of short implants (one with traditional machined collar and one with anodized collar). After their healing period, the prosthetic rehabilitation will be made.
219161590|NCT05551403|DEVICE|Eyes-closed rest-EEG registration|Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions
219161591|NCT05551403|DEVICE|Transcranial Magnetic Stimulation during EEG and EMG registrations|Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols
219158137|NCT05398250|BEHAVIORAL|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
219158138|NCT05398250|BEHAVIORAL|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation"
219158139|NCT02274805|PROCEDURE|Adults presenting for surgery in the neck area|
219158140|NCT01630850|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
219158141|NCT01630850|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
219158142|NCT01582893|DEVICE|HCO1100|Dialysis
219158143|NCT01582893|DEVICE|P210H|Dialysis
219158144|NCT04663399|OTHER|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
219158145|NCT03004664|BEHAVIORAL|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
219158146|NCT03004664|BEHAVIORAL|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
219158147|NCT04328038|OTHER|Survey|Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
219161592|NCT05551403|DEVICE|Photic stimulation during eyes-closes EEG registration|Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
219731305|NCT07045376|OTHER|evidence-based multi-strategy educational training program on surgical smoke|"Based on evidence from the literature, the content of the evidence-based multi-strategy educational training program includes:~Providing a surgical smoke protection handbook and displaying environmental education posters.~Using an official LINE account to disseminate knowledge about surgical smoke, protective techniques, and related information.~Organizing a hands-on workshop on surgical smoke hazard prevention, allowing participants to practice operating smoke evacuation equipment."
219731306|NCT07044960|DRUG|KHN702 tablet or placebo|Subject will receive a single KHN702 tablet or matching placebo orally in fasted state.
219731307|NCT07044960|DRUG|KHN702 tablet or placebo|All participants will receive KHN702 tablet or matching placebo orally once a day for 7 days in fasted state.
219731308|NCT07046650|COMBINATION_PRODUCT|cisplatin-based chemotherapy|Patients were required to have a creatinine clearance of more than 60 and to receive standard doses of cisplatin and gemcitabine (gemcitabine 1000mg /m2 on day 1.8 and cisplatin 70 mg /m2 on day 1, q3w). A total of 4-6 courses of treatment were performed.
219731309|NCT07045714|PROCEDURE|Unilateral Laminotomy with Bilateral Lumbar Decompression (ULBLD)|Unilateral laminotomy with bilateral lumbar decompression (ULBLD) using endoscopic uniportal technique
219731310|NCT07044947|DRUG|Oteseconazole (VT-1161) 150mg capsule|Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2
219731311|NCT06729073|DRUG|Diclofenac sodium gel|topical administration
219731312|NCT06729073|DRUG|Diclofenac diethylamine 1.16% gel|Topical administration
219731313|NCT07046715|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
219731314|NCT07046715|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
219731315|NCT07046715|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
219731316|NCT07046715|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
219731317|NCT07044609|DRUG|Clonidine extended release oral suspension|The study is blinded and the active clonidine extended-release oral suspension will look just like the placebo comparator.
219731318|NCT07044609|DRUG|Placebo|Placebo suspension
219731319|NCT07046091|BEHAVIORAL|20-minute mindfulness-based breathing exercise|Mindfulness-based approaches help to focus attention and teach individuals strategies for coping with challenging situations, accepting experiences, building self-confidence, and disengaging. Mindfulness-based practices increase an individual's level of awareness and distance them from current or potential stress factors. In recent years, non-pharmacological complementary and integrative interventions have become more widely used in disease management. Studies supporting the use of mindfulness-based interventions, particularly for the management of acute and chronic pain, have demonstrated biological and psychological improvements. In this study, the aim of the 20-minute mindfulness-based breathing exercise program is to reduce dyspnea and fatigue levels and improve sleep quality in heart failure patients who face many challenging situations. After a pre-test, the experimental group will receive the mindfulness-based breathing exercise program. The program will last for 6 weeks, with e
219731320|NCT07046091|BEHAVIORAL|Control (Standard treatment)|No intervention would be applied to patients in this group and only pre-test and post-test data would be collected.
219731321|NCT07044986|OTHER|no intervention|no intervention
219731322|NCT05583305|DIAGNOSTIC_TEST|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
219731323|NCT05583305|DIAGNOSTIC_TEST|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
219731324|NCT05583305|DIAGNOSTIC_TEST|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
219731325|NCT07045259|OTHER|The Neuromuscular Exercise Training program|The Neuromuscular Exercise Training program will be carried out in groups of 5 people for 45 minutes/2 days/8 weeks. The exercise program will consist of warm-up, loading and cooling phases. The warm-up phase will consist of flexibility exercises, mini squat and roll down etc. exercises to prepare the individual for exercise. The loading phase will consist of a cognitive-based neuromuscular exercise program aiming to provide stabilization, increase in balance, neuroplasticity and motor control and is planned to include strengthening exercises, stabilization exercises, balance-proprioceptive exercises and neuromuscular control exercise training with visual feedback. The exercises will progress gradually from easy to difficult with increasing repetition and set numbers.
219731326|NCT07045259|OTHER|Exergaming Exercise Training|In our study, Xbox 360 Kinect game console and Kinect sensor will be used within the scope of Exergaming. Exergaming program will be carried out in groups of 5 people for 45 minutes/ 2 days/ 8 weeks. It will consist of warm-up, loading and cooling phases. The games to be used for the Exergaming program were selected from games that include locomotor and cognitive repetitive tasks. Just Dance, a movement-based dance/rhythm game accompanied by dance choreography, will be preferred in the warm-up phase. In the loading phase, games such as Reflex Ridge, River Rush, Ralleyball from Microsoft Kinect Adventures game series for lower extremity functions; Bowling, Table Tennis, Swim Out, Fruit Ninja from Microsoft Kinect Sports game series for upper extremity functions will be included. As the sessions progress, game levels will be gradually made more difficult, progressing from easy to difficult.
219731327|NCT07045688|DRUG|Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
219158148|NCT06306755|PROCEDURE|Risk Assessment and Individualized Surveillance|"1. An epidemiological questionnaire-based risk assessment for UGIC conducted prior to the endoscopic examination;~2. Individuals identified as high-risk receive the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Individualized reexamination and surveillance strategy will be given to participants diagnosed with premalignant lesions, based on evaluation of risk progression using endoscopic characteristics, pathological diagnosis, and biomarkers."
219158149|NCT06306755|PROCEDURE|Universal screening|"1. A questionnaire investigation;~2. All participants undergo the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment."
219158150|NCT05568082|DRUG|AMG 510|Oral tablet
219158151|NCT05568082|DRUG|Itraconazole|Oral capsule
219158152|NCT02217904|DRUG|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
219158153|NCT02217904|DRUG|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
219158154|NCT02217904|DRUG|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
219158155|NCT02217904|DRUG|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
219158156|NCT02217904|DRUG|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
219158157|NCT02217904|DRUG|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
219158158|NCT05930782|DRUG|Piperaquine Tetraphosphate uncoated tablets|Piperaquine tetraphosphate hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
219158159|NCT05930782|DRUG|Piperaquine Tetraphosphate dispersible granules|Piperaquine tetraphosphate dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
219158160|NCT05949801|DRUG|Neucardin|10 days IV infusion of 0.6 ug/kg/day
219158161|NCT05949801|DRUG|Placebo|10 days IV infusion of 0 ug/kg/day
219158162|NCT06170307|OTHER|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
219158163|NCT05534165|DRUG|Tecovirimat|600 mg po BID
219158164|NCT05534165|DRUG|Placebo|identical placebo 600 mg po BID
219731328|NCT07045688|DRUG|Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
219731329|NCT07045688|DRUG|Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
219731330|NCT07046286|PROCEDURE|Compare the two brands of radiofrequency ablation catheters for the treatment of lower limb varicose veins.|"1. Surgical Procedures: Standardized radiofrequency ablation (GSV/SSV closure) was carried out in both groups by the same team. Catheter parameters were set as 120°C and 1 cm/min withdrawal speed. The treatment segment of the great saphenous vein was required to be \>1 cm from the skin before anesthesia. For calf varicose veins, treatment was done after great saphenous vein ablation.~   * Experimental Group: Utilized Xianruida's catheter with advanced features. Surgical and device - related information was recorded.~  * Control Group: Used Medtronic's catheter. Similar data were recorded as in the experimental group.~2. Postoperative Management: Consistent for both groups.~   * Compression: Applied elastic bandage + Class II compression stockings.~  * Medication: Patients took oral anticoagulants and painkillers as needed, with usage details recorded during follow - up."
219158165|NCT03791112|DRUG|BPI-16350|BPI-16350 capsules administered orally
219158166|NCT05600088|DEVICE|CryoTherapy System (CTS)|local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
219158167|NCT03344276|DIAGNOSTIC_TEST|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
219158168|NCT03344276|DIAGNOSTIC_TEST|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
219158169|NCT03344276|PROCEDURE|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
219158170|NCT06075771|DRUG|Carbidopa Levodopa|Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
219158171|NCT06075771|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
219158172|NCT06267768|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
219158173|NCT05338970|DRUG|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
219158174|NCT05338970|DRUG|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W
219158175|NCT06216509|DEVICE|Endoscopic ultrasound pressure measurement|all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
219158176|NCT06803966|OTHER|Post Operative Analgesia|"Group A will receive local wound infiltration at port sites with inj bupivacaine (bupivacaine Hydrochloride) 0.5 %~Group B will receive Transversus Abdominal Plane Block on both sides by inj bupivacaine (bupivacaine Hydrochloride) 0.25%"
219158177|NCT06802666|RADIATION|short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with AK112 regimen for 6 cycles.
219158178|NCT06802666|DRUG|Ivonescimab|AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W)
219158179|NCT06802666|DRUG|capecitabine|1000mg/m2, bid, po, d1-14,q3w
219158180|NCT06802666|DRUG|oxaliplatin|130mg/m2, ivgtt, d1,q3w
219158181|NCT06802666|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
219158182|NCT06750341|DRUG|QLC7401|QLC7401 combined with lipid-lowering agents
219158183|NCT06750341|DRUG|Placebo|Placebo combined with lipid-lowering agents
219161593|NCT05328557|DRUG|CUG252|CUG252 will be administered by subcutaneous (SC) injection
219161594|NCT05328557|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection
219161595|NCT05874102|OTHER|Sidelying|Position sidelying then Upright
219161596|NCT05874102|OTHER|Upright|Position upright then sidelying
219161597|NCT04637594|DRUG|Pembrolizumab|Given IV
219161598|NCT04637594|DRUG|Nivolumab|Given IV
219161599|NCT04637594|DRUG|Atezolizumab|Given IV
219161600|NCT04637594|DRUG|Durvalumab|Given IV
219161601|NCT04637594|DRUG|Avelumab|Given IV
219161602|NCT05124925|BIOLOGICAL|Ianalumab|Ianalumab VAY736 150mg/1ml Solution for injection
219161603|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
219161604|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
219161605|NCT03494504|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
219731331|NCT07045805|DRUG|QL1706 combined with paclitaxel and bevacizumab|"Phase 1:~Plan to enroll 6 subjects to receive QL1706 7.5 mg/kg, paclitaxel 150 mg/m², and bevacizumab 7.5 mg/kg, d1, Q3W. Subjects will undergo a 3-week Dose-Limiting Toxicity (DLT) evaluation period.~If ≥2 DLTs occur among the 6 subjects, QL1706 5 mg/kg will be selected as the Recommended Phase 2 Dose (RP2D) for Phase 2.~Otherwise, QL1706 7.5 mg/kg will be the RP2D for Phase 2.~Phase 2:~Plan to enroll 54-60 subjects. Starting from Cycle 1, QL1706 will be administered intravenously at the RP2D determined in Phase 1. Subjects will receive:~QL1706 (RP2D) Paclitaxel 150 mg/m² Bevacizumab 7.5 mg/kg All agents administered on day 1 of each Q3W cycle. Treatment Duration for All Subjects: Continues until disease progression, intolerable toxicity, withdrawal of informed consent, death, or initiation of new antitumor therapy-whichever occurs first."
219731332|NCT07048405|OTHER|Cooling|Participants will undergo cold exposure during the baseline and final visits (2.5 hours each visit), as well as throughout the 10-day cold acclimation period (2 hours per day). This will be achieved using water-perfused blankets set to individualized temperatures, selected to elicit comparable physiological responses across participants.
219731333|NCT07048405|PROCEDURE|Biopsies|"Under local anesthesia, biopsies will be obtained from the following sites:~* Brown adipose tissue from the supraclavicular (collarbone) region, guided by computed tomography (CT).~* White adipose tissue from the abdominal (periumbilical) area.~* Skeletal muscle from the outer thigh, specifically the vastus lateralis.~These biopsies will be performed both before and after the 10-day cold acclimation protocol."
219731334|NCT07048405|RADIATION|Injection of 18F-FDG|Intravenous injection of 18F-FDG will be performed after 2 hours of cold exposure. This will be followed by a 30min dynamic total PET/CT scan while cold exposed using water-perfused blankets. These procedures will take place before and after the 10 day-cold acclimation protocol.
219731335|NCT07048405|OTHER|Indirect calorimetry|Participants will rest quietly while oxygen consumption and carbon dioxide production are continuously recorded using a indirect calorimeter. These data will be used to calculate energy expenditure and respiratory exchange ratio. This procedure will take place before and after the 10 day-cold acclimation protocol.
219731336|NCT07048405|OTHER|Electromyogram|Skin surface electrodes will be placed on major skeletal muscles to measure shivering and muscle activity during both warm and cold conditions. This procedure will take place before and after the 10 day-cold acclimation protocol.
219731337|NCT07048405|OTHER|Core and skin temperature monitoring|"Participants will ingest an electronic capsule that wirelessly and continuously monitors core body temperature. This procedure will be conducted before and after the 10-day cold acclimation protocol.~Additionally, wireless temperature sensors will placed at multiple standardized sites on the body to measure skin temperature. This procedure will be performed before, during, and after the 10-day cold acclimation protocol."
219731338|NCT07057180|OTHER|Observation by the Researcher and Self-evaluations by nurses|Observation by the Researcher
219158184|NCT06788548|PROCEDURE|combined endoscopic-laparoscopic sentinel lymph node navigation surgery|"1. Determination of tumor location and sentinel lymph node: endoscopic staining (2mg indocyanine green, four-quadrant submucosal injection) was used to determine the location of the lesion during laparoscopic surgery combined with endoscopic localization to ensure effective and safe resection margins. The staining technique was used to identify the sentinel lymph nodes basin, and en bloc resection of the lymph node basin biopsy was performed.~2. Standard of lymph node basin dissection: All sentinel nodes are located within the lymphatic basin, which is considered the primary lymphatic drainage area for each patient. Follow the SENORITA trail criteria\[9\], lymphatic basin is delineated by the distribution of dye within the lymphatic channels, as seen in dye mapping. The proximal extent of the lymphatic basin is demarcated by the fatty tissue adjacent to the stomach wall, while the distal boundary is marked by the most distant stained node from the stomach."
219731339|NCT07057180|BEHAVIORAL|This involves nurses' self-assessment of their caregiving behaviors and perceptions|This refers to the clinical observation performed by the nurse researcher
219731340|NCT07056361|DEVICE|Direct cortical stimulation and deep brain stimulation of motor thalamus|All participants enrolled will undergo implantation of deep brain stimulation electrode leads for treatment of movement disorders. In addition to standard-of-care subcortical mapping using micro-electrode recording (MER) and macrostimulation mapping during DBS placement, cortical local field potentials (LFPs) will be simultaneously recorded from primary motor (M1) and somatosensory (S1) cortical areas by placement of a temporary strip electrode (1X6) in the subdural space. The strip electrode over M1 will be used to produce motor evoked potentials to contralateral hand muscles from direct cortical stimulation (DCMEPs). Cortical and subcortical LFPs will be obtained alongside electromyographic (EMG) data while the patient performs contralateral upper extremity movement tasks and a variety of articulation exercises.
219234511|NCT03938207|DIAGNOSTIC_TEST|Metabolomics|Using Metabolomics from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219731341|NCT07056907|PROCEDURE|Lumbar drain placement|This intervention involves temporary cerebrospinal fluid (CSF) drainage via lumbar drain in acute ischemic stroke patients with MRI-confirmed hemodynamic failure. The lumbar drain is inserted at the bedside or in a procedural suite under sterile conditions and connected to a pressure-regulated, closed drainage system. Drainage is continuous for 48-72 hours, with volume and pressure carefully monitored. This intervention is distinct in targeting stroke patients without hydrocephalus, using CSF drainage as a novel method to improve cerebral perfusion and vascular reserve. The effect is evaluated with serial BOLD-CVR MRI performed before and after the drainage period, making this one of the first interventional stroke studies to use functional MRI as a physiological endpoint.
219731342|NCT07056595|DRUG|Finerenone|Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg/day
219731343|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
219731344|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
219731345|NCT05771493|OTHER|Measurement of baseline characteristics|Calculation of the correlation between BMI, WC and PI
219158185|NCT06788548|PROCEDURE|Laparoscopic D2 radical gastrectomy|Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
219158186|NCT06477042|OTHER|Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score|Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
219158187|NCT05871892|DIAGNOSTIC_TEST|18F-FDGal PET/CT or PET/MRI|All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
219158188|NCT04540913|DEVICE|RHA 3|Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.
219158189|NCT04540913|DEVICE|Restylane-L|Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
219158190|NCT05809271|DRUG|MDMA 120 mg + MDMA 60 mg|An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
219158191|NCT05809271|DRUG|MDMA 120 mg + placebo|An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.
219158192|NCT05809271|DRUG|Placebo|An oral placebo will be administered followed by a placebo two hours later.
219158193|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
219158194|NCT06478121|OTHER|Data and Blood collection|Data and Blood collection
219158195|NCT06478121|OTHER|MRI|MRI (optional)
219158196|NCT06821230|BEHAVIORAL|Dyadic mindfulness|The dyadic mindfulness intervention group will receive 8 weekly 90-min sessions, with a total of 12 contact hours. The intervention will be delivered in a small group format with 6-8 dyads each and led by a certified yoga instructor with mindfulness qualifications. The program content mindfulness meditation, mindful breathing, and yoga sequences with warm-up and cool-down and each component is modified to pair-based practices.
219158197|NCT06820944|OTHER|dark chocolate|Consumption of 100 g/day of 72% dark chocolate bar for 14 days consecutively
219158198|NCT06820944|OTHER|white chocolate|Consumption of 80 g/day of white chocolate bar for 14 days consecutively
219161606|NCT03719924|DRUG|Onivyde|onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
219161607|NCT03719924|DRUG|Paclitaxel|Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
219731346|NCT00862589|OTHER|GLP-1 infusion|physiological effect of GLP-1
219731347|NCT02994680|DEVICE|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
219161608|NCT05523635|DEVICE|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
219161609|NCT06221930|BEHAVIORAL|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
219731348|NCT02994680|OTHER|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
219158199|NCT06699901|OTHER|Massive Transfusion Group|This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
219158200|NCT06699901|OTHER|Control Group|This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
219158201|NCT05607030|COMBINATION_PRODUCT|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.
219158202|NCT05607030|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
219234512|NCT03938207|DIAGNOSTIC_TEST|Environmental Toxic|Using Environmental Toxic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219731349|NCT02994680|OTHER|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
219731350|NCT06173648|DEVICE|Laser and ICG solution.|Intervention consists of addition of a combined laser absorption solution and infrared diode laser. The solution is introduced into the prepared pulp chamber and root canals, allowed to dwell for 1 minute, followed by exposure to the laser energy delivered via a fiber optic introduced into the root canal, and while activating the laser at 2.5 watts of optical output with a pulse duration of 100 msec and a pulse gap of 300 msec, the solution and residual structures in the root and pulp chamber are exposure over the course of 30 seconds, moving and relocating the fiber tip throughout the canals and chamber during that time. The laser is halted and a wait time of 30 seconds is applied. The laser fiber is then reintroduced and another 30 second exposure, repeating the same settings and technique.
219731351|NCT07056387|OTHER|A nurse-led community-based sailing programme|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
219731352|NCT07056387|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
219731353|NCT07056530|BEHAVIORAL|Telenursing Counseling|Structured weekly phone-based counseling sessions delivered by a trained nurse for 8 weeks, focusing on medication adherence, healthy lifestyle behaviors, stress management, and self-monitoring of blood pressure.
219731354|NCT00394667|DRUG|Tesofensine|
219731355|NCT05963230|OTHER|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
219731356|NCT04462172|DEVICE|FNS|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
219731357|NCT04462172|DEVICE|MCS|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
219731358|NCT00123877|DRUG|GPX-100 (13-deoxydoxorubicin)|
219731359|NCT00306722|DRUG|AQUAVAN® (fospropofol disodium) Injection|
219731360|NCT03572218|BEHAVIORAL|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
219731361|NCT03572218|BEHAVIORAL|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
219731362|NCT02937922|OTHER|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
219158203|NCT05607030|DRUG|SOC Antibiotics|Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
219158204|NCT05607030|DRUG|Experimental Antibiotics|After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
219731363|NCT02937922|OTHER|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
219731364|NCT02937922|OTHER|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
219731365|NCT03110835|RADIATION|Radioiodine|Administration of radioiodine
219731366|NCT02037074|DRUG|Drug: EVP-6308|Arms 1, 2, 3
219158205|NCT06755099|DRUG|Botox|"The patient will be placed in gynecological position. Subsequently, the patient will be anesthetized with propofol bolus, a total of 270 mg IV sterilization of valval area with antiseptic solution then digital examination to assess the spasm of intriotus and vaginal walls under lowest possible doses then increasing the doses to allow for intra vaginal injection of Botox under full sedation. Pacik technique will be adopted for Botox Injection in the vagina .~. One vial of frozen Botox 100 U will be diluted with 2 mL saline, without foaming or shaking the vial, giving a concentration of 2.5 U/0.05 mL . Using a small sized speculum and after bending the needle to 30° to facilitate injection into sub mucosal area,1 mL (50 U) of Botox will be injected into the right bulbocavernosus then into the left side ."
219158206|NCT06755099|DEVICE|Radiofrequency|"Patients will be placed in prone position. After proper disinfection, the ischial spine (IS) and insertion point of the sacrospinous ligament will be identified using fluoroscopy medial to IS. 5 ml Lidocaine 2 % will be used to apply local anesthesia to the skin at the expected entry point for the radiofrequency cannula. Then a 20 G, 10 cm long and 1 cm active tip radiofrequency cannula will be introduced gradually utilizing 2 Hz motor stimulation until pudendal nerve is identified visually by the occurrence of contraction of the external anal sphincter muscle.~Subsequently, pulsed radiofrequency lesioning at temperature limit of 42 C will be applied bilaterally to the pudendal nerves for 240 s (2 cycles of 120 s) after applying local anesthesia using 2 cm 2% lidocaine in its vicinity."
219158207|NCT06764758|PROCEDURE|Endodontic treatment|Root-canal therapy applied in asymptomatic teeth with deep carious lesion required endodontic treatment.
219158208|NCT06764758|PROCEDURE|Restorative treatment|Composite resin restoration applied in teeth previously applied endodontic treatment.
219158209|NCT04928001|OTHER|internet based iCBT program, Youth Thrive|iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
219158210|NCT06364358|BEHAVIORAL|Computerized CKD Education|The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.
219158211|NCT06364358|BEHAVIORAL|Usual Hospital Care|Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
219158212|NCT01722695|OTHER|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
219158213|NCT01693120|DEVICE|Medtronic Phased RF Ablation System|Phased RF ablation
219158214|NCT05863598|BEHAVIORAL|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
219158215|NCT05863598|BEHAVIORAL|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
219158216|NCT06436833|DRUG|2-Liter polyethylene glycol plus elobixibat|Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
219158217|NCT06436833|DRUG|4-Liter polyethylene glycol|Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
219158218|NCT04097743|BEHAVIORAL|Coping Statement|Daily practice of coping statement
219158219|NCT06803940|PROCEDURE|clear aligner|closing of spacing in anterior teeth with clear aligner therapy
219158220|NCT06803940|PROCEDURE|orthodontic treatment|conventional fixed orthodontic appliance
219158221|NCT04654585|OTHER|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
219731367|NCT02037074|DRUG|Placebo|Arm 4
219731368|NCT02249780|PROCEDURE|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
219731369|NCT02249780|PROCEDURE|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
219731370|NCT02249780|PROCEDURE|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
219158222|NCT04654585|OTHER|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
219158223|NCT06798740|DEVICE|Sugita Titanium Aneurysm Clip II|Aneurysm clipping is a surgical procedure used to treat brain aneurysms.
219158224|NCT04153565|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
219158225|NCT04153565|DRUG|Pemetrexed|Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
219158226|NCT04153565|DRUG|Cisplatin|Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
219158227|NCT05236296|BEHAVIORAL|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
219158228|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
219158229|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
219158230|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
219158231|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
219158232|NCT01741363|OTHER|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
219158233|NCT01741363|OTHER|FIT only|HPSA+FIT compared with FIT alone.
219731371|NCT02249780|DRUG|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
219731372|NCT00286455|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
219731373|NCT00286455|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
219731374|NCT00286455|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
219731375|NCT06215937|OTHER|No Intervention|No intervention
219731376|NCT06117137|DRUG|SGLT2 inhibitor|"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"
219731377|NCT01852136|DEVICE|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
219731378|NCT01852136|DEVICE|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
219731379|NCT01852136|DEVICE|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
219731380|NCT03939832|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
219731381|NCT03362593|DRUG|MEDI7219|Experimental Drug
219731382|NCT03362593|DRUG|Placebo|Placebo
219731383|NCT03362593|DRUG|Formulation without Active Drug|Formulation without Active Drug
219731384|NCT02054949|DRUG|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
219731385|NCT04853875|DRUG|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
219731386|NCT04853875|DRUG|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
219731387|NCT04652843|PROCEDURE|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
219158234|NCT06255262|DRUG|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
219158235|NCT06255262|DRUG|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
219158236|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
219158237|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
219158238|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
219158239|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
219731388|NCT04652843|PROCEDURE|Coloscopy|Coloscopy for colonic biospsies collection
219731389|NCT04394832|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
219731390|NCT06466044|BEHAVIORAL|Auricular acupressure in concha area|The method of pressing beans on auricular points is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, relevant auricular points are selected, and appropriate stimulation such as kneading, pressing, pinching and pressing is given to the seeds of Vaccaria seed attached to the concha auricularis, so that the auricular points can produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
219731391|NCT06466044|BEHAVIORAL|Auricular acupressure in earlobe|The auricular point pressing bean method is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, the relevant auricular points are selected, and the seeds attached to the ear lobe, which is the least innervated part of vagus nerve, are given appropriate stimulation such as kneading, pressing, pinching and pressing, so that the auricular points produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
219731392|NCT04601909|DRUG|FX-322|active comparator
219731393|NCT04601909|OTHER|placebo|placebo
219731394|NCT02594878|DRUG|Pamidronatdinatrium|
219731395|NCT02594878|OTHER|Natrium chloride 9mg/ml|
219731396|NCT06713317|DRUG|HLB3-002|Recombinant Hyaluronidase
219731397|NCT06713317|DRUG|0.9% NaCl|0.9% Normal saline
219731398|NCT06499948|DRUG|Treatment with Spironolactone followed by Dapagliflozin followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
219731399|NCT06499948|DRUG|Treatment with Dapagliflozin followed by Spironolactone followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
219731400|NCT05546931|BEHAVIORAL|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
219731401|NCT05546931|OTHER|WebMD|Smartphone-based application for health education and/or monitoring.
219158240|NCT01479647|DRUG|PH-797804|Tablet, 24 mg, single dose
219158241|NCT06191939|BEHAVIORAL|Mindful Self-Compassion for Lung Cancer (MSC-LC)|"The overall goal of this 10-week, group-based, virtually-delivered, psychosocial intervention is to enhance recognition and responsiveness to difficult thoughts and emotions and to build self-compassion skills that facilitate patients' ability to turn inward to those thoughts and feelings with mindfulness, connectedness, and self-kindness. Each weekly session is designed to be 90 minutes and follows an agenda with highly structured scripts covering self-compassion topics (e.g., pain of disconnection, listening with compassion), which are carefully organized to build upon one another. In each session, didactic topics (e.g., What is self-compassion?) taught by trained interventionists lead into guided experiential learning practices (e.g., guided meditation), which are then followed by inquiry into the participants' direct experiences of the practices. The treatment manual is adapted based on the Mindful Self-Compassion Teacher Guide (from the Center for Mindful Self-Compassion)."
219158242|NCT06191939|OTHER|Enhanced standard of care with waitlist|Participants in the enhanced standard of care control condition will be provided with an information sheet from the NCI about how to find helpful organizations and resources in their community. Self-report will be used to describe any supportive care services pursued by the participant. Additionally, control participants will be added to a waiting list for receiving the MSC-LC intervention program. After completing all questionnaire assessments (16 weeks following study entry), the study team will offer the MSC-LC intervention program to participants on the waiting list.
219158243|NCT02479906|DEVICE|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
219158244|NCT02479906|DEVICE|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
219158245|NCT06791135|OTHER|Health and Life in Balance|"Health and Life in Balance is an intervention for patients 65 years and older, with 2 or more chronic diseases, and an increased care need. It involved for the patient to meet with a district nurse during 1-2 meetings to set up a care plan and then have scheduled follow-ups during 6 months. During the 1-2 meetings they went through ICAN discussion aid to discuss aspects of capacity and workload in the patient's life and healthcare. The district nurse and the patient's GP had improved communication during the intervention period.~No use of drugs or devices was part of the intervention."
219158246|NCT06791135|OTHER|Care as usual|Care as usual
219731402|NCT05546931|BEHAVIORAL|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
219731403|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support before the introduction of systemic oncology treatment
219731404|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
219731405|NCT06623188|OTHER|Auricular neuromodulation|3 neuromodulation sessions over 12 weeks
219731406|NCT06623188|OTHER|Sham auricular neuromodulation|3 neuromodulation sessions over 12 weeks
219731407|NCT06908889|OTHER|Skin's lesion patients|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
219731408|NCT06908889|OTHER|Skin's lesion vulunteers|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
219731409|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
219234513|NCT03938207|DIAGNOSTIC_TEST|Medical Image|Using Medical Image from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
219234514|NCT03400748|DEVICE|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
219234515|NCT02054208|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
219234516|NCT02054208|OTHER|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
219234517|NCT01604122|OTHER|No drug|No drug.
219731410|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
219731411|NCT06885268|DRUG|noradrenaline infusion for management blood pressure|A single concentration of noradrenaline (10 μg/ml) will be initiated 15-60 seconds prior to the induction of anaesthesia, then titrated and maintained until 4 hours after surgery to meet pre-specified mean arterial pressure (MAP) targets. The drug infusion will be started at a dose of 0.01 μg/kg/min and will be titrated to a maximum of 0.1 μg/kg/min. Anaesthesiologists will be advised to use the lowest possible dose of noradrenaline. Avoidance of MAP decreases of \>20% from baseline values or \<60-70 mm Hg will be required in both groups. Individual baseline MAP value will be defined as resting blood pressure obtained in at least two measurements at the surgery ward on the day before surgery. Noradrenaline will be administered peripherally in all patients who do not have a central venous catheter in place.
219731412|NCT06885268|COMBINATION_PRODUCT|standard blood pressure management|Patients in the control group will receive standard blood pressure management reactive to blood pressure values. In the light of the current ESA/ESC 2022 guidelines, all patients in the control group will be treated to avoid MAP \<60-70 mm Hg. Ephedrine boluses (5 mg each, up to 25 mg total intravenous dose) will be recommended as a first-line hypotension treatment. Subsequent treatment will involve administering peripheral noradrenaline. Notwithstanding, there is a variation in clinical practice regarding the choice and timing of vasopressors and fluids to be administered during and after surgery, therefore, hypotension treatment will not be further protocolized to increase the feasibility and generalizability of the trial.
219731413|NCT06932471|DRUG|MY008211A tablets|MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d
219158247|NCT05701709|DRUG|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
219234518|NCT01604122|OTHER|No drug|No drug.
219731414|NCT06939439|DRUG|Tislelizumab + SOX Chemotherapy|The intervention in this study involves the use of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, in combination with the standard SOX chemotherapy regimen for postoperative adjuvant therapy in patients with stage III gastric or gastroesophageal junction adenocarcinoma who are ctDNA-MRD positive. Tislelizumab is administered at a dose of 200 mg intravenously every 3 weeks for a total duration of 1 year, alongside 6-8 cycles of SOX chemotherapy. The SOX regimen includes oxaliplatin (130 mg/m² intravenously every 3 weeks) and tegafur, with the dose of tegafur determined based on body surface area and administered orally twice daily for 14 days every 3 weeks.
219731415|NCT06939439|DRUG|SOX Chemotherapy|The control group will receive standard SOX chemotherapy alone, serving as an active comparator to evaluate the incremental benefit of adding tislelizumab. This design ensures a rigorous comparison while maintaining alignment with current standard-of-care practices.
219731416|NCT06942611|DEVICE|transcranial electrical stimulation treatment.|Stimulation targeting the primary motor cortex, current intensity is 1-2mA, duration is 30 minutes, once daily for 5 consecutive days
219731417|NCT06938971|OTHER|Exercise training|Participants allocated to the exercise intervention group will receive standard care plus an exercise intervention. The exercise intervention will consist moderate-to-high intensity supervised and unsupervised home-based exercise training (bicyling, walking, or running) 5 times/week for 18 weeks.
219731418|NCT02428647|DIETARY_SUPPLEMENT|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
219731419|NCT02428647|DIETARY_SUPPLEMENT|preventive zinc supplement|7 mg zinc daily as dispersible tablet
219731420|NCT02428647|DIETARY_SUPPLEMENT|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
219731421|NCT02428647|DIETARY_SUPPLEMENT|preventive placebo supplement|dispersible daily placebo tablet
219158248|NCT06471322|DEVICE|Continuous Glucose Monitoring (CGM)|Patients will wear a continuous glucose monitor upon discharge from the hospital for six months
219158249|NCT06471322|OTHER|Standard of Care|Standard of Care - retrospective review
219158250|NCT05234853|DRUG|PUR001|Monoclonal antibody
219158251|NCT02262468|RADIATION|x ray|
219158252|NCT05056402|BIOLOGICAL|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
219158253|NCT05056402|BIOLOGICAL|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
219158254|NCT02632071|DRUG|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
219158255|NCT02632071|DRUG|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
219731422|NCT02428647|DIETARY_SUPPLEMENT|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
219158256|NCT05209477|OTHER|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application"
219158257|NCT05350592|DRUG|Tocilizumab|Single bolus
219731423|NCT02428647|DIETARY_SUPPLEMENT|placebo powder|placebo powder
219731424|NCT05894564|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
219731425|NCT05894564|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219731426|NCT03882801|DRUG|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
219731427|NCT03882801|DRUG|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
219731428|NCT06380400|BEHAVIORAL|Foot bath|Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
219731429|NCT06369662|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|CD155 expression by flow cytometric immunophenotyping
219731430|NCT06369662|DIAGNOSTIC_TEST|Complete blood count|Complete blood count with peripheral blood smear examination
219731431|NCT06369662|DIAGNOSTIC_TEST|Bone marrow aspiration|Bone marrow aspiration at both diagnosis and follow up of patients
219731432|NCT06369662|DIAGNOSTIC_TEST|Cytogenetic testing|Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
219731433|NCT06369662|DIAGNOSTIC_TEST|FLT3-ITD using High resolution melting curve (HRM) analysis|Detection of FLT3-ITD mutation in AML patinets
219731434|NCT01091883|DEVICE|Exablate treatment|MR Guided Focused Ultrasound
219731435|NCT01091883|RADIATION|Radiation|External Beam Radiation
219731436|NCT06454487|OTHER|Isometric Hand Grip Training|IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).
219731437|NCT06454487|OTHER|CR|Standard of Care
219158258|NCT05350592|DRUG|Dobutamine|Continous weight-adjusted infusion
219158259|NCT05350592|DRUG|NaCl 0.9%|Placebo comparator and diluent
219158260|NCT03948867|DRUG|Hydroxyurea|Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
219158261|NCT03948867|DIAGNOSTIC_TEST|Elevated Arm TCD Examination|"TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months."
219234519|NCT06031506|DEVICE|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
219234520|NCT03388957|DRUG|Propranolol|This drug will be given before the extraction procedure
219234521|NCT03388957|DRUG|Midazolam|This drug will be given before the extraction procedure
219731438|NCT05165966|BIOLOGICAL|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
219731439|NCT05165966|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
219731440|NCT02912611|PROCEDURE|Education and Protocol based management|
219731441|NCT00615316|DRUG|Guaraná|Guaraná extract 75mg/day
219731442|NCT00615316|DRUG|Placebo|Placebo 1tab/d
219731443|NCT06324578|DIAGNOSTIC_TEST|AT Testing|Analysis of blood specimens and neck ultrasonography
219731444|NCT04574505|DIETARY_SUPPLEMENT|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
219731445|NCT04574505|DIETARY_SUPPLEMENT|Placebo|Placebo
219731446|NCT02117154|DEVICE|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
219731447|NCT06348212|DIETARY_SUPPLEMENT|Lactobacillus paracasei PS23|2 caps daily use
219731448|NCT06348212|DIETARY_SUPPLEMENT|microcrystalline cellulose|2 caps daily use
219731449|NCT02137356|RADIATION|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
219731450|NCT02137356|DRUG|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
219731451|NCT02137356|DRUG|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
219731452|NCT04607785|DRUG|Miswak mouthwash group|Twice daily for seven days for two months
219731453|NCT04607785|DEVICE|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
219731454|NCT04026451|DEVICE|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
219731455|NCT04026451|BEHAVIORAL|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
219731456|NCT04026451|DRUG|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
219731457|NCT04026451|PROCEDURE|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
219731458|NCT05804292|OTHER|Questionnaire administration|Questionnaire administration
219731459|NCT03884036|BIOLOGICAL|Vitamin D|Vitamine D
219158262|NCT03948867|DIAGNOSTIC_TEST|Normal Arm TCD Examination|TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
219731460|NCT01794169|DRUG|Azacitidine|
219731461|NCT01794169|DRUG|DA|
219731462|NCT05639205|DIAGNOSTIC_TEST|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
219731463|NCT03416933|OTHER|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
219731464|NCT04252118|BIOLOGICAL|MSCs|3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
219731465|NCT03279419|DIAGNOSTIC_TEST|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
219731466|NCT01389284|DRUG|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
219731467|NCT01389284|DRUG|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
219158263|NCT05339113|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
219158264|NCT06326125|BEHAVIORAL|TICK-B|TICK-B as art-based distraction
219158265|NCT06326125|DRUG|TKTX-Cream|TKTX-Cream as local anesthesia cream
219158266|NCT06326125|OTHER|TICK-B and TKTX-C|TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
219731468|NCT01389284|DRUG|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
219731469|NCT01389284|DRUG|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
219234522|NCT00361088|DRUG|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
219731470|NCT01144351|DRUG|ELND002|
219731471|NCT01144351|DRUG|Placebo|
219731472|NCT00476788|DEVICE|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
219731473|NCT01845415|BEHAVIORAL|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
219731474|NCT01845415|BEHAVIORAL|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
219731475|NCT01925820|DRUG|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
219731476|NCT05359757|OTHER|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions"
219731477|NCT05359757|OTHER|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions"
219731478|NCT04633304|DEVICE|EndoAVF System for endovascular AV fistula creation|AV fistula creation
219731479|NCT03532490|DRUG|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
219731480|NCT03532490|DRUG|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
219731481|NCT00409227|DRUG|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
219731482|NCT00409227|DRUG|placebo|placebo once a day for 3 months or stone free
219731483|NCT04421664|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
219731484|NCT04421664|DRUG|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
219731485|NCT03548415|DRUG|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
219234523|NCT00361088|DRUG|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
219158267|NCT05623163|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
219158268|NCT01285635|DRUG|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
219158269|NCT01285635|DRUG|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
219158270|NCT04689685|OTHER|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
219158271|NCT00505934|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
219234524|NCT01930188|DRUG|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
219234525|NCT01930188|DRUG|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
219234526|NCT01930188|DRUG|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
219234527|NCT01930188|DRUG|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
219234528|NCT02514824|DRUG|MLN0128|Investigational mTOR kinase inhibitor
219731486|NCT03548415|DRUG|Placebo|Placebo administered subcutaneously.
219731487|NCT02914678|OTHER|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
219731488|NCT04138082|OTHER|Exposition to high-dB soundtrack|Already stated
219731489|NCT01803737|BEHAVIORAL|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
219731490|NCT01803737|BEHAVIORAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
219731491|NCT04558853|DRUG|autologous NK cells|Autologous ex vivo expanded and activated NK cells
219731492|NCT03123562|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
219731493|NCT03824054|PROCEDURE|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
219731494|NCT02913859|RADIATION|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
219731495|NCT02913859|DRUG|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
219731496|NCT01506336|DRUG|masitinib|masitinib 12 mg/kg/day
219731497|NCT01506336|DRUG|sunitinib|sunitinib 50 mg/day
219731498|NCT05414253|DEVICE|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
219731499|NCT06501183|BIOLOGICAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
219731500|NCT01304719|BEHAVIORAL|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
219731501|NCT01304719|BEHAVIORAL|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
219731502|NCT05963919|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
219731503|NCT05963919|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
219731504|NCT05963919|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
219731505|NCT05963919|OTHER|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
219234529|NCT01406041|BIOLOGICAL|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
219158272|NCT04080336|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
219234530|NCT02173457|DRUG|Chiglitazar|Take orally
219234531|NCT02173457|DRUG|Sitagliptin|Take orally
219234532|NCT02675322|DRUG|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
219234533|NCT02675322|OTHER|Placebo|Placebo with no chemical effects.
219234534|NCT04131855|OTHER|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
219234535|NCT04131855|OTHER|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
219234536|NCT01564472|OTHER|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
219234537|NCT04955054|DIAGNOSTIC_TEST|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
219234538|NCT03150589|DRUG|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
219234539|NCT03150589|DRUG|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
219158273|NCT04080336|DRUG|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
219234540|NCT03937752|OTHER|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
219158274|NCT04080336|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
219158275|NCT05032534|DEVICE|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
219158276|NCT05032534|DEVICE|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
219158277|NCT03305146|GENETIC|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR\_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."
219234541|NCT02841449|BEHAVIORAL|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
219234542|NCT02841449|BEHAVIORAL|Rehydrated|Participants rehydrate after the heat tent procedure
219234543|NCT04976829|DEVICE|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
219234544|NCT01020435|OTHER|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
219234545|NCT01020435|OTHER|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
219158278|NCT03496103|BIOLOGICAL|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
219158279|NCT00209742|DRUG|UFT|P.O. everyday
219158280|NCT00209742|DRUG|USEL/Leucovorin|P.O. everyday
219158281|NCT00209742|DRUG|Krestin|P.O. everyday
219158282|NCT03050814|DRUG|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
219234546|NCT00914056|DRUG|lactulose|withdrawal of lactulose
219234547|NCT00160758|PROCEDURE|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
219234548|NCT03576378|DRUG|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
219234549|NCT03851809|DRUG|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
219234550|NCT01000649|DRUG|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
219234551|NCT01000649|DRUG|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
219234552|NCT01000649|DRUG|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
219234553|NCT01000649|OTHER|Placebo|Isotonic saline infused.
219234554|NCT04817345|DRUG|Plerixafor|Subcutaneous
219234555|NCT03397147|BEHAVIORAL|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
219234556|NCT00425971|DRUG|BMEC-1217B|
219731506|NCT04442750|PROCEDURE|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
219731507|NCT04442750|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
219731508|NCT04442750|DRUG|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
219731509|NCT04442750|DRUG|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
219234557|NCT03015428|OTHER|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
219234558|NCT00346398|BIOLOGICAL|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
219234559|NCT00346398|BIOLOGICAL|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
219234560|NCT00668226|DRUG|Lactic acid (Dermacid)|
219234561|NCT05032651|DEVICE|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
219731510|NCT04442750|DRUG|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
219731511|NCT01942980|RADIATION|Radiation therapy Brain metastasis in breast cancer|Radiation
219731512|NCT04456283|BEHAVIORAL|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
219731513|NCT04717583|PROCEDURE|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
219731514|NCT03914014|OTHER|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
219234562|NCT00969007|BEHAVIORAL|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
219234563|NCT00458094|BEHAVIORAL|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
219234564|NCT00458094|BEHAVIORAL|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
219234565|NCT01450774|DRUG|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
219234566|NCT01450774|DRUG|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
219731515|NCT03914014|OTHER|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
219158283|NCT03050814|BIOLOGICAL|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
219158284|NCT03050814|DRUG|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
219731516|NCT02832947|DRUG|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
219731517|NCT01749566|DRUG|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
219731518|NCT03283995|OTHER|Cardiac Volume Monitoring VolumeView|hemodynamic measure
219731519|NCT03283995|DEVICE|echocardiography|hemodynamic measure
219731520|NCT00463775|DRUG|Topiramate|SSRI plus topiramate SSRI plus placebo
219731521|NCT02329275|PROCEDURE|Testicular biopsy|
219731522|NCT04429971|OTHER|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
219158285|NCT03050814|DRUG|5-Fluorouracil (FU)|400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
219158286|NCT03050814|DRUG|Leucovorin|400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
219731523|NCT04429971|OTHER|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
219731524|NCT01603511|DEVICE|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
219731525|NCT05682469|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
219234567|NCT05790759|OTHER|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
219234568|NCT02607956|DRUG|DTG|50 mg tablets administered orally, once daily
219234569|NCT02607956|DRUG|F/TAF|200/25 mg tablets administered orally, once daily
219731526|NCT05682469|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
219731527|NCT01052142|BIOLOGICAL|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
219731528|NCT06024265|DRUG|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
219731529|NCT00025311|DRUG|topotecan hydrochloride|
219731530|NCT03255499|BEHAVIORAL|Exercise|Exercise
219731531|NCT03255499|BEHAVIORAL|Cognitive|Cognitive
219731532|NCT03255499|BEHAVIORAL|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
219731533|NCT03443544|PROCEDURE|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
219731534|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
219158287|NCT03050814|DRUG|Oxaliplatin|85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
219158288|NCT03050814|DRUG|Capecitabine|625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
219158289|NCT03050814|DRUG|5-Fluorouracil (FU)|2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
219158290|NCT02692469|PROCEDURE|Duodenal Switch|Bariatric procedure
219158291|NCT02692469|PROCEDURE|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
219158292|NCT02014129|DRUG|LY2835219|Administered orally
219158293|NCT05304546|DRUG|Pembrolizumab|Solution for IV
219158294|NCT05304546|DRUG|Encorafenib|Oral QD
219158295|NCT05304546|DRUG|Binimetinib|Oral BID
219158296|NCT03465813|BEHAVIORAL|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
219158297|NCT00164216|DRUG|mefloquine plus artesunate|
219158298|NCT05137236|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
219158299|NCT05137236|BIOLOGICAL|mRNA-1283.211|Sterile liquid for injection
219731535|NCT02520440|DEVICE|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
219731536|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
219731537|NCT00002226|DRUG|SU5416|
219731538|NCT01560988|DRUG|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
219731539|NCT01560988|DIETARY_SUPPLEMENT|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
219158300|NCT05137236|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219731540|NCT03225222|DIAGNOSTIC_TEST|biopsy|prostate biopsy
219731541|NCT04093700|DEVICE|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
219731542|NCT02455856|DRUG|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
219158301|NCT05137236|BIOLOGICAL|mRNA-1283.529|Sterile liquid for injection
219158302|NCT04454879|DRUG|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
219158303|NCT02317874|DRUG|Carboplatin|Given IV
219158304|NCT02317874|DRUG|Paclitaxel|Given IV
219158305|NCT02317874|DRUG|Talazoparib|Given PO
219158306|NCT02487069|PROCEDURE|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
219158307|NCT02487069|PROCEDURE|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
219158308|NCT02487069|PROCEDURE|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
219158309|NCT02487069|DRUG|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
219158310|NCT02487069|DRUG|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
219158311|NCT02487069|DRUG|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
219158312|NCT02487069|DRUG|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
219158313|NCT05101941|PROCEDURE|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
219731543|NCT02455856|DRUG|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
219731544|NCT01407978|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
219731545|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
219158314|NCT00580593|DEVICE|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
219158315|NCT00580593|OTHER|sham-NIPPV|a sham-device
219158316|NCT05589441|DRUG|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
219731546|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
219731547|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
219158317|NCT05589441|DRUG|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
219158318|NCT02515071|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219158319|NCT02515071|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219158320|NCT06451770|DRUG|VERVE-201|Intravenous (IV) infusion
219158321|NCT04014439|DIAGNOSTIC_TEST|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
219234570|NCT02607956|DRUG|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
219731548|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
219234571|NCT02607956|DRUG|DTG Placebo|Tablets administered orally, once daily
219731549|NCT01428973|DRUG|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
219731550|NCT01428973|DRUG|Sirolimus|Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
219731551|NCT01292473|DRUG|Placebo|Placebo was supplied lyophilized in vials.
219731552|NCT01292473|DRUG|Omalizumab|Omalizumab was supplied lyophilized in vials.
219731553|NCT01216280|DRUG|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
219731554|NCT01216280|DRUG|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
219731555|NCT01216280|DRUG|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
219731556|NCT02194088|DRUG|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
219731557|NCT02194088|DRUG|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
219731558|NCT06174532|PROCEDURE|Traditional Medthod|Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
219731559|NCT06174532|PROCEDURE|Virtual surgical planning|Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
219731560|NCT03630510|OTHER|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
219731561|NCT04242654|PROCEDURE|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
219731562|NCT02238327|PROCEDURE|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
219731563|NCT02238327|PROCEDURE|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
219731564|NCT02238327|PROCEDURE|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
219731565|NCT02238327|PROCEDURE|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
219731566|NCT02238327|RADIATION|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
219234572|NCT02607956|DRUG|F/TAF Placebo|Tablets administered orally, once daily
219234573|NCT02607956|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
219158322|NCT04014439|DIAGNOSTIC_TEST|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
219158323|NCT05835934|DRUG|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
219731567|NCT02238327|PROCEDURE|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
219158324|NCT04282824|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
219158325|NCT04282824|PROCEDURE|Computed Tomography|Undergo PET/CT
219158326|NCT04282824|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
219158327|NCT04282824|DIETARY_SUPPLEMENT|Monosodium Glutamate|Given PO
219158328|NCT04282824|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219158329|NCT04238858|BIOLOGICAL|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
219158330|NCT02930200|BEHAVIORAL|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
219158331|NCT02930200|BEHAVIORAL|QuitGuide|NCI QuitGuide Treatment App
219158332|NCT02930200|BEHAVIORAL|Smart-T|Smart-Treatment App
219158333|NCT03331575|RADIATION|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
219158334|NCT01310348|DEVICE|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
219158335|NCT01310348|DEVICE|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
219158336|NCT04255706|DEVICE|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
219158337|NCT04255706|DEVICE|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
219158338|NCT04255706|DEVICE|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
219158339|NCT00334776|BIOLOGICAL|MART-1 antigen|
219158340|NCT00334776|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
219158341|NCT00334776|BIOLOGICAL|therapeutic autologous dendritic cells|
219158342|NCT00334776|BIOLOGICAL|tyrosinase peptide|
219158343|NCT00415402|DRUG|Vitamin D3|
219158344|NCT02531737|DRUG|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
219158345|NCT02531737|DRUG|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
219158346|NCT00972075|DRUG|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
219158347|NCT00972075|DRUG|placebo|one tablet per day 2 hours before going to bed
219158348|NCT05119855|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
219158349|NCT05119855|BIOLOGICAL|mRNA-1273 Vaccine|mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
219158350|NCT00414024|DRUG|Tegaserod|
219158351|NCT01972724|DRUG|Pioglitazone|Pioglitazone tablets
219158352|NCT01972724|DRUG|Metformin|Metformin as prescribed in clinical practice
219731568|NCT02238327|PROCEDURE|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
219731569|NCT01933516|DRUG|GP2013|GP2013
219731570|NCT01128920|BEHAVIORAL|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
219158353|NCT01972724|DRUG|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
219158354|NCT06191016|DEVICE|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
219158355|NCT06191016|DEVICE|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
219158356|NCT06392412|BEHAVIORAL|fi-VR Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
219158357|NCT06392412|BEHAVIORAL|Traditional Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
219731571|NCT01128920|OTHER|No intervention - assessment-only condition|No intervention is assigned in this condition
219731572|NCT01008527|DRUG|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
219731573|NCT01008527|BIOLOGICAL|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
219731574|NCT01008527|BIOLOGICAL|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
219731575|NCT02950974|DRUG|Sterofundin|Fluid loading
219731576|NCT02950974|DRUG|NSS|Fluid loading
219731577|NCT00548691|DRUG|Ferric Carboxymaltose|
219731578|NCT00548691|DRUG|Standard Medical Care (SMC)|
219731579|NCT01011231|PROCEDURE|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
219731580|NCT05055427|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
219731581|NCT03702595|OTHER|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
219731582|NCT04334681|PROCEDURE|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
219731583|NCT04334681|PROCEDURE|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
219731584|NCT00049309|DIETARY_SUPPLEMENT|dietary intervention|
219731585|NCT00049309|DIETARY_SUPPLEMENT|flaxseed|
219731586|NCT00458705|DRUG|bortezomib|
219731587|NCT00458705|DRUG|dexamethasone|
219731588|NCT00458705|DRUG|pegylated liposomal doxorubicin hydrochloride|
219158358|NCT06211972|BEHAVIORAL|OpiVenture|"OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up."
219158359|NCT00944593|DIETARY_SUPPLEMENT|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
219158360|NCT00944593|DIETARY_SUPPLEMENT|Normal Saline|200ml Normal Saline 0.9%
219158361|NCT02168400|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
219731589|NCT00458705|DRUG|thalidomide|
219731590|NCT05038514|OTHER|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
219731591|NCT04195672|DEVICE|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
219234574|NCT03121417|BIOLOGICAL|Nivolumab|240 mg given IV
219234575|NCT02837419|BEHAVIORAL|Health related Quality of life EQ-5D|Quality of Care
219158362|NCT06160791|DRUG|Ruxolitinib|Administered Orally (PO)
219158363|NCT06160791|DRUG|Etoposide|Administered IV
219234576|NCT00103857|DRUG|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
219731592|NCT04884074|PROCEDURE|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
219158364|NCT06160791|DRUG|Dexamethasone|Administered PO or IV
219731593|NCT04884074|PROCEDURE|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
219158365|NCT06160791|PROCEDURE|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
219158366|NCT06160791|PROCEDURE|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
219158367|NCT06160791|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219158368|NCT00335036|DEVICE|ICD lead implant|Randomization of ICD lead type at implant
219158369|NCT00335036|DEVICE|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
219158370|NCT06299098|DRUG|Trevogrumab-Part A|Administered IV or SC in Part A
219158371|NCT06299098|DRUG|Trevogrumab-Part B and Part C|Administered SC in Part B, Part C
219234577|NCT00103857|DRUG|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
219158372|NCT06299098|DRUG|Garetosmab|Administered IV in Part B
219158373|NCT06299098|DRUG|Semaglutide|Administered SC in Part B and Part C
219158374|NCT06299098|DRUG|Matching Placebo-Part A|Administered IV or SC in Part A
219158375|NCT06299098|DRUG|Matching Placebo-Trevogrumab|Administered SC in Part B and Part C
219158376|NCT06299098|DRUG|Matching Placebo-Garetosmab|Administered IV in Part B
219158377|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
219158378|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
219158379|NCT04086745|DRUG|Baricitinib|Administered orally.
219158380|NCT04086745|DRUG|TNF Inhibitor|Administered SC
219158381|NCT05300022|OTHER|TeKnO T1D: Parents|app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
219158382|NCT05608564|PROCEDURE|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
219158383|NCT05608564|PROCEDURE|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
219158384|NCT01254006|DRUG|forskolin, rutin and vitamins B1 and B2|
219158385|NCT03898024|DRUG|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
219158386|NCT03898024|DRUG|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
219158387|NCT02872675|DIETARY_SUPPLEMENT|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
219158388|NCT02872675|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator: Maltodextrin.
219158389|NCT00945789|DRUG|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
219158390|NCT00945789|PROCEDURE|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
219731594|NCT03963622|OTHER|Respiratory Mechanics|"Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets."
219731595|NCT03963622|OTHER|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.
219158391|NCT00945789|BIOLOGICAL|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
219158392|NCT00111813|DRUG|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
219158393|NCT00111813|DRUG|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
219158394|NCT03649243|DRUG|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
219158395|NCT02292329|DIETARY_SUPPLEMENT|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
219158396|NCT02292329|DIETARY_SUPPLEMENT|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
219731596|NCT00935207|OTHER|Pediatric Pain Diary|Pain diary designed for pediatric patients
219731597|NCT02172261|DRUG|BI 10773|
219731598|NCT02172261|DRUG|Glimepiride|
219731599|NCT05521282|DRUG|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
219731600|NCT05233059|BEHAVIORAL|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
219731601|NCT05233059|BEHAVIORAL|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
219731602|NCT05233059|BEHAVIORAL|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
219731603|NCT06000904|OTHER|Exergame-based balance training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
219731604|NCT06000904|OTHER|Upper limb and trunk training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
219731605|NCT02505672|RADIATION|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
219731606|NCT00638391|DRUG|Anastrozole|
219731607|NCT04794478|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
219731608|NCT00209638|DRUG|irinotecan|
219731609|NCT00209638|DRUG|S-1|
219731610|NCT06181058|BEHAVIORAL|escape room game|Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
219731611|NCT02931227|PROCEDURE|temperature obtained by the non-invasive method of zero-heat flux|
219731612|NCT02931227|PROCEDURE|esophageal temperature|
219731613|NCT02931227|PROCEDURE|intracerebral temperature|
219731614|NCT02931227|PROCEDURE|arterial temperature|
219731615|NCT04843839|DRUG|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
219158397|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
219158398|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
219158399|NCT01228669|DRUG|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
219158400|NCT03926442|OTHER|Italian Herb meal|Italian Herb in active breakfast meal
219731616|NCT04843839|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
219731617|NCT05758142|DIETARY_SUPPLEMENT|Potassium Chloride|Oral administration of potassium chloride tablets
219731618|NCT05758142|OTHER|Placebo|Oral administration of inert placebo tablets
219731619|NCT03976141|DIAGNOSTIC_TEST|mri|knee mri
219158401|NCT03926442|OTHER|Cinnamon Meal|Cinnamon in active breakfast meal
219158402|NCT03926442|OTHER|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
219731620|NCT00306280|DEVICE|Phototherapy|
219731621|NCT01518036|DRUG|somatropin|2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
219731622|NCT01518036|DRUG|somatropin|4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
219731623|NCT02683798|DIETARY_SUPPLEMENT|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
219731624|NCT02683798|DIETARY_SUPPLEMENT|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
219731625|NCT02091830|DRUG|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
219731626|NCT02091830|OTHER|Physiotherapy|
219731627|NCT02091830|DRUG|Cortisone Injection|
219731628|NCT02091830|OTHER|Others|
219731629|NCT03357445|OTHER|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
219731630|NCT05604157|OTHER|Use of Tourniquet|Application of tourniquet or not in adults undergoing a primary total knee replacement.
219731631|NCT05800626|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|ERCP performed for clinical practice
219731632|NCT05597605|DEVICE|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
219158403|NCT03926442|OTHER|Placebo meal|Placebo in breakfast meal
219158404|NCT03084549|DRUG|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
219158405|NCT03084549|DRUG|Administration of placebo|Administration of placebo in the margins of the episiotomy
219731633|NCT00002809|BIOLOGICAL|anti-thymocyte globulin|
219731634|NCT00002809|BIOLOGICAL|filgrastim|
219731635|NCT00002809|BIOLOGICAL|sargramostim|
219731636|NCT00002809|BIOLOGICAL|therapeutic immune globulin|
219731637|NCT00002809|DRUG|cyclophosphamide|
219731638|NCT00002809|DRUG|methotrexate|
219731639|NCT00002809|DRUG|tacrolimus|
219731640|NCT00002809|PROCEDURE|allogeneic bone marrow transplantation|
219731641|NCT00002809|RADIATION|radiation therapy|
219158406|NCT01020643|DRUG|controlled administration of propofol|comparison of propofol sedation
219731642|NCT02926846|DRUG|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
219731643|NCT02926846|DRUG|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
219731644|NCT03001739|DRUG|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
219158407|NCT02660970|OTHER|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
219158408|NCT02660970|OTHER|Placebo-band|Children will have to wear a 'placebo-wristband'
219731645|NCT02170012|DRUG|PF-06743649|20 mg tablet once daily dosing for 14 days
219731646|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219731647|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
219731648|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219731649|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
219731650|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219731651|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
219731652|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219731653|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
219731654|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
219731655|NCT00337194|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
219731656|NCT00337194|OTHER|placebo|Given IV
219731657|NCT00337194|DRUG|vinorelbine tartrate|Given IV
219731658|NCT00337194|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
219731659|NCT00337194|DRUG|gemcitabine hydrochloride|Given IV
219731660|NCT00337194|OTHER|laboratory biomarker analysis|Correlative studies
219731661|NCT00337194|OTHER|pharmacological study|Correlative studies
219731662|NCT03188705|DRUG|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
219731663|NCT03188705|DRUG|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
219731664|NCT01640561|BEHAVIORAL|MISC|The Mediational Interventions for Sensitizing Caregivers
219731665|NCT01640561|BEHAVIORAL|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
219731666|NCT02019537|PROCEDURE|Steroid injection into the subacromial space|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
219731667|NCT02019537|PROCEDURE|Allogeneic PRP injection into the subacromial space|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
219731668|NCT05628272|OTHER|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10\^8, once a week
219731669|NCT05628272|DRUG|application of granulocyte stimulating factor|application of granulocyte stimulating factor
219731670|NCT02794805|DEVICE|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
219731671|NCT04776876|BIOLOGICAL|Retifanlimab|Given IV
219731672|NCT04776876|DRUG|Telotristat Ethyl|Given PO
219731673|NCT00393380|DRUG|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
219158409|NCT02660970|DRUG|Iberogast|Children will have to take Iberogast drops
219158410|NCT02660970|OTHER|Placebo-drops|Children will have to take placebo-drops
219731674|NCT04738162|DRUG|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
219731675|NCT00602784|BIOLOGICAL|IC41|
219731676|NCT05045599|BEHAVIORAL|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
219731677|NCT03428854|DRUG|LNG-IUS|Levnorgestrel containing IUD
219731678|NCT01674855|DRUG|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
219731679|NCT01674855|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
219731680|NCT00766103|OTHER|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
219731681|NCT03904186|BEHAVIORAL|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
219731682|NCT03904186|BEHAVIORAL|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
219731683|NCT01717859|DRUG|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
219731684|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219731685|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219731686|NCT04590183|DRUG|FK-506 (Drug)|Twice a day
219731687|NCT04590183|DRUG|Prednisolone Acetate 1% Oph Susp|Four times a day
219731688|NCT03114397|DEVICE|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
219731689|NCT03114397|DEVICE|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
219731690|NCT04389671|DRUG|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
219731691|NCT01870570|OTHER|Reference Glucose|
219731692|NCT01870570|OTHER|Food Product A: Corn Flakes|
219731693|NCT01870570|OTHER|Food Product B: Ginger Bread|
219158411|NCT01661569|OTHER|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
219731694|NCT01870570|OTHER|Food Product C:Sandwiched Breakfast Biscuit|
219731695|NCT01870570|OTHER|Food Product D: Crackers Nature|
219731696|NCT01870570|OTHER|Food Product E: Breakfast Biscuit|
219731697|NCT01870570|OTHER|Food Product F: White Bread|
219731698|NCT04429594|OTHER|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
219731699|NCT01111292|DRUG|Inositol|Given PO
219731700|NCT01111292|OTHER|Placebo|Given PO
219158412|NCT00171431|DRUG|Tegaserod|
219158413|NCT05998330|BEHAVIORAL|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
219158414|NCT00570700|DRUG|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
219731701|NCT03881800|OTHER|titration- blood sample|Ceftazidime titration
219731702|NCT03357705|PROCEDURE|alveolar ridge preservation with synthetic bone|after tooth extraction
219731703|NCT03357705|PROCEDURE|alveolar ridge preservation with bovine collagen|after tooth extraction
219731704|NCT01954173|RADIATION|3D conformal radiation therapy|Undergo conformal radiation therapy
219731705|NCT00673114|BIOLOGICAL|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
219731706|NCT01487785|DRUG|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
219731707|NCT01260792|OTHER|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
219731708|NCT01260792|OTHER|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
219731709|NCT00271570|DRUG|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
219731710|NCT00271570|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
219731711|NCT06274476|OTHER|implant placement|ridge splitting piezo surgery and implant placement
219158415|NCT04374916|DEVICE|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
219158416|NCT04374916|DEVICE|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
219158417|NCT06477848|OTHER|Integrated Behavioral Health System with SUD Resources|This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
219158418|NCT02102841|PROCEDURE|Skin biopsy|
219158419|NCT02102841|PROCEDURE|Skin suction blister|
219158420|NCT02102841|BIOLOGICAL|Mantoux test|
219158421|NCT03818893|DRUG|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
219158422|NCT05580380|OTHER|Limited Relationship|In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
219158423|NCT05580380|OTHER|Enhanced Relationship|A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
219158424|NCT00198315|COMBINATION_PRODUCT|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
219158425|NCT00198315|PROCEDURE|Tumor surgical excision|Patients have their tumor surgically removed.
219158426|NCT02189915|DRUG|Creatine monohydrate|
219158427|NCT05467904|OTHER|Xltranplus, Xltran|Xltranplus and Xltran are full hemp flower formulations
219158428|NCT00567489|DRUG|Physioneal|Physioneal 40 or Physioneal 35
219158429|NCT00567489|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
219158430|NCT00567489|DRUG|Extraneal|7.5% Icodextrin
219158431|NCT00567489|DRUG|Nutrineal|Amino Acids 1.1%
219158432|NCT05967065|DIAGNOSTIC_TEST|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
219158433|NCT03148496|DEVICE|Biologic Mesh|Biologic mesh placed during surgery
219158434|NCT03148496|PROCEDURE|Small Bites|0.5 cm x 0.5 cm sutures used
219234578|NCT00103857|DRUG|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
219234579|NCT00103857|DRUG|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
219234580|NCT00103857|DRUG|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
219158435|NCT03148496|PROCEDURE|Large Bites|1.0 x 1.0 sutures used
219731712|NCT02636491|DEVICE|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
219158436|NCT00979563|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
219158437|NCT06307301|DRUG|Abatacept Injection [Orencia] and Proleukin (aldesleukin)|Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
219158438|NCT02764242|OTHER|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
219158439|NCT02764242|OTHER|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
219158440|NCT04346732|OTHER|Vapocoolant spray|Vapocoolant spray
219158441|NCT06133049|DRUG|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
219158442|NCT06133049|DRUG|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
219158443|NCT06133049|DRUG|No DMTs|Women with MS not exposed to any DMTs during pregnancy
219731713|NCT02636491|DEVICE|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
219731714|NCT00419432|OTHER|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
219731715|NCT00419432|OTHER|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
219158444|NCT00332813|BEHAVIORAL|HIV Risk Behavior Intervention|
219158445|NCT01952769|BIOLOGICAL|MDV9300|"The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
219158446|NCT03877016|PROCEDURE|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
219158447|NCT01367405|PROCEDURE|Surgical decompression|Surgical decompression within 24 hour postinjury
219158448|NCT01367405|PROCEDURE|Conservative treatment|Usual conservative treatment without surgery
219158449|NCT04115683|OTHER|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
219158450|NCT04115683|OTHER|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
219158451|NCT06188377|DEVICE|measured by a impedance analyzer|the healthy chinese neonates will be measured by a impedance analyzer, and will be compared with that of other ethnicity whose data have been reported by literatures.
219158452|NCT03628235|BEHAVIORAL|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
219731716|NCT00198614|DRUG|Carvedilol versus Metoprolol|
219158453|NCT02550691|PROCEDURE|blood sampling|A blood sample will be taken on subject carrying specific genotype
219234581|NCT00103857|DRUG|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
219731717|NCT06170866|BEHAVIORAL|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
219731718|NCT04086615|DEVICE|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
219731719|NCT04086615|DEVICE|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
219731720|NCT06274437|DRUG|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219731721|NCT06274437|DRUG|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219731722|NCT06274437|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
219731723|NCT05548777|DRUG|Andexanet alfa|Andexanet alfa
219158454|NCT00779636|DRUG|Desloratadine|Desloratadine 10 mg daily x 28 days
219158455|NCT00779636|DRUG|Placebo|Placebo daily x 28 days
219158456|NCT00644475|DRUG|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
219158457|NCT00644475|DRUG|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
219158458|NCT01215552|DRUG|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
219234582|NCT05307653|PROCEDURE|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
219731724|NCT05548777|DRUG|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
219731725|NCT05922098|OTHER|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
219158459|NCT04695197|DRUG|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
219731726|NCT02828085|BIOLOGICAL|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
219731727|NCT01991535|DEVICE|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
219158460|NCT04695197|DRUG|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
219158461|NCT06048172|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
219158462|NCT02372253|DRUG|Verapamil|
219158463|NCT02372253|DRUG|Placebo|
219731728|NCT01991535|DEVICE|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
219731729|NCT01991535|DEVICE|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
219731730|NCT01217047|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
219158464|NCT05300542|OTHER|Topical Placebo Cream|Application of test products before and after irradiation
219158465|NCT05300542|OTHER|Topical Cream with 0.5% Active|Application of test products before and after irradiation
219158466|NCT05300542|OTHER|Topical Cream with 1% Active|Application of test products before and after irradiation
219158467|NCT00925886|PROCEDURE|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
219731731|NCT01217047|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
219731732|NCT01217047|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
219731733|NCT01217047|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
219731734|NCT04465305|PROCEDURE|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
219731735|NCT04465305|PROCEDURE|plasty treatment|patients with tarlov cysts treated by plasty nerve root
219731736|NCT02583061|OTHER|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
219731737|NCT05529173|DRUG|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
219731738|NCT05529173|DRUG|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
219731739|NCT06567873|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
219731740|NCT05574764|BEHAVIORAL|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
219731741|NCT03442465|BEHAVIORAL|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
219158468|NCT00247208|DEVICE|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
219234583|NCT05307653|PROCEDURE|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
219234584|NCT05307653|PROCEDURE|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
219731742|NCT03442465|BEHAVIORAL|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
219731743|NCT03442465|BEHAVIORAL|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
219731744|NCT03442465|DIAGNOSTIC_TEST|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
219158469|NCT00247208|DEVICE|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
219158470|NCT04127669|DRUG|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
219234585|NCT05764395|DRUG|Rigosertib|Given by mouth
219234586|NCT05764395|BIOLOGICAL|Pembrolizumab|Given by IV
219234587|NCT05764395|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219158471|NCT04127669|DRUG|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
219158472|NCT05073562|DIETARY_SUPPLEMENT|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
219158473|NCT05073562|BEHAVIORAL|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
219158474|NCT05073562|DRUG|Mebendazole Pill|One-time deworming treatment with mebendazole.
219731745|NCT03442465|DIAGNOSTIC_TEST|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
219731746|NCT03442465|DIAGNOSTIC_TEST|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
219731747|NCT03767231|DIAGNOSTIC_TEST|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
219731748|NCT05432960|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
219731749|NCT05432960|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution)
219731750|NCT05783960|OTHER|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
219731751|NCT04702672|DIETARY_SUPPLEMENT|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
219731752|NCT04702672|DIETARY_SUPPLEMENT|100% Lean-baking barley®|"Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
219731753|NCT04702672|DIETARY_SUPPLEMENT|100% regular barley|"Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
219731754|NCT05233917|DIETARY_SUPPLEMENT|Olive oil use|Olive oil, 25-30g/d by day for 6 month
219731755|NCT05233917|DIETARY_SUPPLEMENT|MLCT oil use|MLCT oil, 25-30g/d by day for 6 month
219731756|NCT04072432|DRUG|RBT-3|intravenous administration
219731757|NCT04460794|BEHAVIORAL|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
219158475|NCT05073562|OTHER|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
219158476|NCT05446363|DEVICE|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
219158477|NCT03912961|OTHER|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
219731758|NCT04460794|OTHER|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
219731759|NCT01744418|DEVICE|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
219731760|NCT05220930|OTHER|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
219731761|NCT05220930|OTHER|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
219158478|NCT01069471|BIOLOGICAL|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
219234588|NCT05764395|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219731762|NCT05927298|OTHER|Non-interventional|Standard of care intervention
219234589|NCT05764395|PROCEDURE|Biopsy|Undergo tissue biopsy
219234590|NCT00004939|DRUG|,4-diaminopyridine|
219731763|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
219731764|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
219731765|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
219731766|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
219731767|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
219731768|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
219234591|NCT03093064|DRUG|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
219731769|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
219234592|NCT03093064|OTHER|Placebo: normal saline|Normal saline, intravenous infusion
219234593|NCT04154085|OTHER|Psychotherapy|Group psychotherapy
219234594|NCT01005914|DRUG|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
219731770|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
219731771|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
219731772|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
219731773|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
219731774|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
219731775|NCT02363491|DRUG|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
219731776|NCT04121013|OTHER|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
219158479|NCT04962477|OTHER|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
219158480|NCT03569072|RADIATION|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
219158481|NCT02879760|BIOLOGICAL|Ad-MAGEA3|Intramuscular injection
219158482|NCT02879760|BIOLOGICAL|MG1-MAGEA3|Intravenous infusion
219234595|NCT01005914|DRUG|cytarabine|Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
219158483|NCT02879760|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219234596|NCT01005914|DRUG|dexamethasone|Day 1-4; 11-14: 40 mg daily
219234597|NCT01005914|DRUG|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
219234598|NCT01005914|DRUG|imatinib mesylate|600 mg/day
219234599|NCT01005914|DRUG|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
219234600|NCT01005914|DRUG|methylprednisolone|Day 1-3: 50mg IV BID
219234601|NCT01005914|DRUG|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
219234602|NCT01005914|DRUG|vincristine sulfate|Day 4 \& 11: 2 mg IV
219234603|NCT01141075|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
219234604|NCT01240785|DRUG|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
219234605|NCT01240785|DRUG|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
219234606|NCT02815345|DEVICE|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
219234607|NCT02978183|BIOLOGICAL|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
219234608|NCT02978183|DRUG|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
219731777|NCT02203760|DRUG|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
219731778|NCT02203760|DRUG|Pazopanib|Pazopanib 800 mg orally once daily
219731779|NCT01477411|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
219731780|NCT01477411|DRUG|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
219731781|NCT03132272|DEVICE|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
219731782|NCT00003685|PROCEDURE|fatigue assessment and management|
219731783|NCT00003685|PROCEDURE|nausea and vomiting therapy|
219731784|NCT00003685|PROCEDURE|pain therapy|
219731785|NCT00003685|PROCEDURE|quality-of-life assessment|
219731786|NCT00003685|RADIATION|radiation therapy|
219731787|NCT02000037|DEVICE|IR Reflexotherapy|"18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study"
219731788|NCT02000037|BEHAVIORAL|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
219731789|NCT02822755|OTHER|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
219731790|NCT01530997|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
219731791|NCT01530997|DRUG|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
219731792|NCT01530997|PROCEDURE|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
219731793|NCT05156242|DEVICE|Active-tDCS priming MCE|tDCS is used to enhance cortical excitability before motor control exercises.
219731794|NCT05156242|DEVICE|Sham-tDCS priming MCE|tDCS will be set at 0 mA for 20 minutes before motor control exercise.
219731795|NCT05156242|DEVICE|NMES priming MCE|NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.
219731796|NCT05156242|OTHER|Conventional physical therapy|Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
219731797|NCT03075631|OTHER|Questionnaire|Questionnaires
219731798|NCT04089085|BEHAVIORAL|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
219731799|NCT05274035|DRUG|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
219731800|NCT02470871|BIOLOGICAL|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
219731801|NCT02470871|BIOLOGICAL|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
219158484|NCT04767698|DRUG|Belimumab|200 mg SC weekly for 36 months
219158485|NCT04767698|DRUG|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
219158486|NCT04767698|DRUG|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
219158487|NCT00485329|OTHER|Papain|15,000 USP U/ml
219158488|NCT00485329|OTHER|Papain|30,000 USP U/ml
219158489|NCT00485329|OTHER|Papain|60,000 USP U/ml
219158490|NCT01563380|BIOLOGICAL|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
219158491|NCT06407258|BEHAVIORAL|SLEEPAC|"6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs."
219158492|NCT04746131|DRUG|IMM0306|IMM0306 is an bi-specific antibody
219158493|NCT00780234|PROCEDURE|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
219158494|NCT00780234|PROCEDURE|quantitative high resolution CT scan|High resolution CT scan of the chest
219161610|NCT05612789|BEHAVIORAL|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
219161611|NCT05612789|BEHAVIORAL|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
219731802|NCT01103518|DRUG|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
219731803|NCT05555693|OTHER|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
219731804|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
219158495|NCT00780234|DRUG|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
219158496|NCT05161429|DRUG|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
219158497|NCT05161429|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
219158498|NCT05161429|DRUG|Basal Insulin|degludec, detemir, glargine and NPH
219158499|NCT05161429|DRUG|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
219158500|NCT05161429|DRUG|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
219158501|NCT04997213|OTHER|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
219158502|NCT04997213|OTHER|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
219158503|NCT00957242|DRUG|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
219158504|NCT00957242|DRUG|placebo|Oral placebo (1mg or 2.5mg)
219158505|NCT02940951|OTHER|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
219158506|NCT02940951|OTHER|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
219158507|NCT05074069|PROCEDURE|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
219158508|NCT03059212|DEVICE|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
219158509|NCT03059212|BEHAVIORAL|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
219158510|NCT05563168|DRUG|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
219158511|NCT04838496|DRUG|FOLFOXIRI Protocol|"FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age."
219158512|NCT01976312|OTHER|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
219158513|NCT01976312|DRUG|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
219158514|NCT04680520|OTHER|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
219158515|NCT04680520|OTHER|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
219731805|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
219731806|NCT00965991|DRUG|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
219731807|NCT00965991|DRUG|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
219731808|NCT05573009|BEHAVIORAL|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
219731809|NCT02181738|DRUG|Nivolumab|Specified dose on specified days
219731810|NCT02181738|DRUG|Doxorubicin|Specified dose on specified days
219158516|NCT04834141|OTHER|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
219158517|NCT00746343|BEHAVIORAL|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
219158518|NCT00746343|BEHAVIORAL|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
219158519|NCT04513314|DRUG|Valproate|Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
219158520|NCT04513314|DRUG|Quetiapine|Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
219158521|NCT04513314|OTHER|Standard of Care|Standard of Care is a combination of IV dexmedetomidine (D), midazolam (M), ketamine (K) and propofol (P), at the discretion of treating physician.
219158522|NCT03945123|DIETARY_SUPPLEMENT|Red ginseng|Red ginseng tablet 120g
219158523|NCT01286714|DEVICE|CLIP OST|
219158524|NCT04048382|BEHAVIORAL|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
219158525|NCT04048382|OTHER|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
219158526|NCT04131153|PROCEDURE|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
219158527|NCT04131153|PROCEDURE|radiofrequency ablation|Conventional radiofrequency ablation
219158528|NCT02009215|DRUG|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
219158529|NCT03159273|DIETARY_SUPPLEMENT|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
219158530|NCT04426916|OTHER|Spondylolisthesis|Spondylolisthesis at a single level
219158531|NCT03671252|DRUG|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
219158532|NCT03671252|DRUG|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
219158533|NCT03671252|OTHER|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
219158534|NCT03671252|PROCEDURE|TME operation|TME operation
219158535|NCT03671252|PROCEDURE|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
219158536|NCT01657604|DRUG|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
219731811|NCT02181738|DRUG|Vinblastine|Specified dose on specified days
219731812|NCT02181738|DRUG|Dacarbazine|Specified dose on specified days
219158537|NCT01657604|DRUG|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
219158538|NCT05208242|DRUG|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
219158539|NCT05208242|DRUG|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
219158540|NCT03807752|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
219158541|NCT03807752|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
219234609|NCT03560154|OTHER|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
219731813|NCT03776786|BIOLOGICAL|TY014|TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
219731814|NCT03776786|OTHER|0.9% Saline|Placebo
219158542|NCT01139944|GENETIC|DNA methylation analysis|
219158543|NCT01139944|GENETIC|polymerase chain reaction|
219158544|NCT01139944|OTHER|laboratory biomarker analysis|
219158545|NCT00212693|DRUG|ONO-2506PO|
219158546|NCT01205048|DEVICE|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
219158547|NCT01205048|DEVICE|Juvederm® Ultra|24mg/mL
219234610|NCT02132195|DRUG|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
219731815|NCT00581204|DEVICE|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
219731816|NCT02689479|PROCEDURE|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
219731817|NCT02689479|BIOLOGICAL|11C-5-HTP|150-400 MBq \[11C\]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
219731818|NCT02689479|PROCEDURE|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
219731819|NCT02689479|PROCEDURE|Mixed-Meal Tolerance Test (MMTT)|
219731820|NCT02689479|PROCEDURE|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
219731821|NCT02689479|PROCEDURE|Glomerular Filtration Rate Testing|
219731822|NCT02689479|PROCEDURE|Blood draw|
219158548|NCT03964870|DIAGNOSTIC_TEST|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
219731823|NCT00855478|DEVICE|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
219158549|NCT01037985|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
219731824|NCT06469372|DEVICE|Cardiac amyloidosis deep learning model|This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
219158550|NCT01037985|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
219158551|NCT02730871|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
219158552|NCT02730871|DRUG|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
219158553|NCT02730871|DRUG|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
219158554|NCT03489187|DEVICE|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
219158555|NCT01298934|DRUG|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
219234611|NCT03343041|DIETARY_SUPPLEMENT|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
219234612|NCT03343041|DIETARY_SUPPLEMENT|Standard enteral nutrition|standard enteral nutrition
219731825|NCT01053468|BEHAVIORAL|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
219158556|NCT00823472|DRUG|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
219158557|NCT06137105|DRUG|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
219158558|NCT01754636|OTHER|No intervention|
219158559|NCT05908669|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
219158560|NCT01609218|DRUG|LY2140023|
219158561|NCT01609218|DRUG|Aqueous activated charcoal|
219158562|NCT03035396|DEVICE|Diassess Influenza A and B Test|
219234613|NCT02805075|OTHER|Fructooligosaccharide|Given PO
219234614|NCT02805075|OTHER|Laboratory Biomarker Analysis|Correlative studies
219731826|NCT01053468|BEHAVIORAL|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
219158563|NCT06854471|OTHER|Placebo beverage, kiwi-strawberry flavor|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose
219158564|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158565|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158566|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158567|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158568|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 2|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158569|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158570|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158571|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219731827|NCT05472298|BEHAVIORAL|self-management intervention|lifestyle modification, goal setting, coaching and peer support, problem-solving
219731828|NCT00001818|DRUG|Hydroxyurea|
219731829|NCT02298491|DRUG|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
219731830|NCT05420025|OTHER||
219731831|NCT04710433|DEVICE|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
219731832|NCT04710433|OTHER|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
219731833|NCT03255954|OTHER|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
219731834|NCT04886037|OTHER|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
219731835|NCT00793065|OTHER|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
219731836|NCT00793065|OTHER|Medical Home redesign|Implementation of NCQA Level III Medical Home
219731837|NCT00002619|BIOLOGICAL|filgrastim|
219731838|NCT00002619|DRUG|carboplatin|
219731839|NCT00002619|DRUG|thiotepa|
219158572|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
219158573|NCT06684782|OTHER|Screening for symptoms of restless leg syndrome|The patients will be screened for restless leg syndrome by clinical questioning.
219158574|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
219158575|NCT03281694|DRUG|Placebo|placebo skin patch and placebo oral solution
219158576|NCT03281694|DRUG|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
219158577|NCT03281694|DRUG|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
219158578|NCT03281694|DRUG|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
219158579|NCT04428112|BEHAVIORAL|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
219731840|NCT00002619|PROCEDURE|autologous bone marrow transplantation|
219731841|NCT00002619|PROCEDURE|peripheral blood stem cell transplantation|
219731842|NCT03606070|DIAGNOSTIC_TEST|PET-MRI|"* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
219731843|NCT01837888|DEVICE|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
219731844|NCT02656342|DRUG|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
219731845|NCT02656342|DRUG|Placebo|Predicted to have no enhancing effect
219731846|NCT03066076|DRUG|Antithyroid Drug|Antithyroid drug
219731847|NCT03066076|PROCEDURE|Total thyroidectomy|Operation
219731848|NCT04920292|DRUG|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
219731849|NCT04920292|DRUG|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
219158580|NCT04428112|BEHAVIORAL|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
219158581|NCT06859372|BEHAVIORAL|Nurturing Care Family Navigator|The Nurturing Care Family Navigator (NCFN) is a comprehensive barrier-focused and long-term family-centered intervention that will offer screenings for food insecurity, referrals to community resources, and follow-up with families experiencing very low or low food security in the past 12 months. The goal of the NCFN is to increase knowledge (cognitive factors) and self-efficacy (behavioral factors) to navigate barriers across the four pillars of food insecurity by securing enrollment and sustaining engagement with a set of community nurturing care services (environmental factors) to improve levels of food security, and ultimately maternal-child health and nutrition outcomes of low-income families during the postpartum phase.
219234615|NCT00376324|DRUG|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
219234616|NCT01317914|OTHER|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
219731850|NCT03430570|BEHAVIORAL|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
219731851|NCT05089175|DRUG|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
219731852|NCT02046200|DRUG|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
219158582|NCT06676852|BEHAVIORAL|Primary palliative care|Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
219731853|NCT02046200|DRUG|Placebo|Matched placebo
219731854|NCT02046200|DRUG|Alcohol|
219731855|NCT03753503|BEHAVIORAL|exercise|exercised three times a week in the 8-week HIIT program
219731856|NCT03753503|BEHAVIORAL|conventional physical therapy|
219731857|NCT03865251|DEVICE|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
219731858|NCT04599257|DEVICE|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
219731859|NCT02172599|BEHAVIORAL|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
219731860|NCT03902990|OTHER|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
219158583|NCT07004374|DEVICE|a percussion massage gun|Participants receive percussion massage therapy (33 Hz) applied to the quadriceps and gastrocnemius muscles using a handheld massage device for 5 minutes per muscle group.
219234617|NCT05352555|DEVICE|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
219731861|NCT03902990|OTHER|Treadmill Training|Standard treadmill training
219731862|NCT03902990|OTHER|Standard exercise programme|Standard exercise programme for Parkinson Disease
219731863|NCT05528666|OTHER|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
219731864|NCT05528666|OTHER|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
219731865|NCT01413646|DIETARY_SUPPLEMENT|Walnut Supplementation|Eight weeks of walnut supplementation
219731866|NCT01413646|DIETARY_SUPPLEMENT|No walnut supplementation|Eight weeks without walnut supplementation
219731867|NCT02614664|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
219731868|NCT04275414|DRUG|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
219731869|NCT04331379|DEVICE|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
219731870|NCT04331379|DEVICE|Taping Alone|Horizontal tape alone.
219731871|NCT01691482|DRUG|Albuterol/salbutamol|Albuterol/salbutamol (daily)
219731872|NCT01691482|DRUG|Ipratropium|Ipratropium (daily)
219731873|NCT01111487|DEVICE|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
219731874|NCT05299450|DIETARY_SUPPLEMENT|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
219731875|NCT05299450|BEHAVIORAL|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
219731876|NCT05299450|OTHER|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
219731877|NCT00096408|PROCEDURE|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
219731878|NCT00096408|PROCEDURE|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
219731879|NCT01987674|DIETARY_SUPPLEMENT|Pre-meal protein drink|
219731880|NCT01987674|OTHER|Water drink|
219731881|NCT03097471|DEVICE|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
219158584|NCT07004374|DEVICE|specially designed stainless-steel instruments|Participants receive instrument-assisted soft tissue mobilization (IASTM, Graston technique) applied to the quadriceps and gastrocnemius muscles using stainless steel tools with standardized techniques (Sweep, Fan, Brush) for 6 minutes.
219158585|NCT04992390|BEHAVIORAL|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
219158586|NCT02792114|DRUG|Cyclophosphamide|
219158587|NCT02792114|BIOLOGICAL|Mesothelin-targeted T cells|
219158588|NCT02792114|DRUG|AP1903|
219158589|NCT02807779|DRUG|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
219158590|NCT02807779|DEVICE|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
219158591|NCT02807779|DEVICE|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
219158592|NCT07034092|DEVICE|ePATH System will be used to create an endoAVF|An endoAVF will be created in subjects that need fistulas for hemodialysis
219158593|NCT07041242|PROCEDURE|"ligament reconstruction using the single-bundle over-the-top technique"|"Patients who have undergone anterior cruciate ligament reconstruction using the single-bundle over-the-top technique with gracilis and semitendinosus tendons, combined with a lateral extra-articular tenodesis, will be enrolled"
219158594|NCT07043751|DRUG|TQB6411 injection|TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.
219731882|NCT06478940|DRUG|3 mixtatin pulpotomy|pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
219731883|NCT06478940|DRUG|MTA pulpotomy|pulp treatment with applying MTA
219158595|NCT06724809|DRUG|eculizumab|Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.
219158596|NCT01740531|BIOLOGICAL|S-303 Treated Red Blood Cells (RBCs)|
219158597|NCT01740531|BIOLOGICAL|Conventional, untreated Red Blood Cells|
219158598|NCT06738056|DEVICE|Nerivio|Remote electrical neuromodulation (REN) wearable device for the treatment of migraine. The device delivers electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
219158599|NCT06891235|OTHER|Biologic testing for THC|Participants will be asked to complete at-home urine test(s) and a series of oral fluid tests.
219161612|NCT06819397|OTHER|post isometric relaxation|the athlete will be given instructions to perform a 7-second isometric contraction in the direction of horizontal abduction at about 25% of peak effort, while the examiner will apply an opposing force at the distal humerus.
219161613|NCT06819397|OTHER|cross friction soft tissue mobilization|by identifying the fascia restriction, patients in group B will be treated with the cross friction soft tissue mobilization approach, which comprised applying a low load and prolonged stretch through the knuckles or elbows to the constricted fascia. The therapist will then give the contralateral side of rotation resistance for ten seconds
219161614|NCT04881162|DEVICE|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
219161615|NCT03938168|DIAGNOSTIC_TEST|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
219161616|NCT05557370|BIOLOGICAL|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
219161617|NCT04013555|DRUG|N-acetylcysteine (NAC)|Flavored effervescent formulation
219161618|NCT04013555|DRUG|Placebo|Flavored effervescent formulation designed to mimic NAC
219161619|NCT04013555|DRUG|Tryptophan|Oral slurry form
219731884|NCT05754112|OTHER|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
219731885|NCT02112175|DRUG|Lenalidomide|
219731886|NCT04728464|PROCEDURE|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
219731887|NCT03987607|DEVICE|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
219731888|NCT01111188|DRUG|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
219731889|NCT01111188|DRUG|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
219731890|NCT04874441|DIAGNOSTIC_TEST|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
219731891|NCT01183286|BEHAVIORAL|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
219731892|NCT01183286|BEHAVIORAL|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
219731893|NCT01146444|OTHER|UV A and B irradiation|UV irradiation
219731894|NCT00395512|DRUG|Alogliptin|Alogliptin tablets.
219731895|NCT00395512|DRUG|Pioglitazone|Pioglitazone tablets.
219731896|NCT00395512|DRUG|Placebo|Matching placebo tablets.
219731897|NCT03303066|DRUG|FG-4592|Oral
219158600|NCT06893146|BEHAVIORAL|Reduction of Sedentary Behavior|The intervention group will receive an intervention that will include two group sessions, bimonthly phone calls and a face-to-face visit with the study nurse. Phone calls will be made every two months using motivational interviewing techniques with the aim of educating on habits and behaviors that reduce sedentary lifestyles, addressing needs and concerns on an individual basis, and enhancing patients motivation, well-being and quality of life. The same purpose is served by the face-to-face visit that will be conducted in the third month of the study. The study's interventions have a personalized approach, which considers individual preferences and needs to consolidate the new habits acquired in the long term. The active intervention has a duration of 6 months and will be carried out by nursing professionals.
219158601|NCT06893146|BEHAVIORAL|Educational support|Every two months, this group will receive detailed written information about healthy lifestyle habits via email, emphasizing the importance of maintaining an active lifestyle. Additionally, they will be provided with standard educational material on the management of type 2 diabetes.
219158602|NCT07051980|DEVICE|Supraglottic Oxygen Delivery via an Endotracheal Tube|patients use the Supraglottic Oxygen Delivery via an Endotracheal Tube
219158603|NCT06846138|DIETARY_SUPPLEMENT|Polyherbal Formulation (PHF)|"Description: A polyherbal formulation with known beneficial effects on gut microbiota and metabolic regulation. The formulation contains selected plant extracts studied for their hypoglycemic, antioxidant, and gut microbiota-modulating properties.~Administration: Oral, daily dosage as per study protocol. Supplier: Arya Vaidya Pharmacy (AVP), Coimbatore, India (GMP-certified)."
219234618|NCT05352555|OTHER|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
219731898|NCT03303066|DRUG|Placebo|Oral
219731899|NCT03275272|DIAGNOSTIC_TEST|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
219731900|NCT04576949|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
219731901|NCT04576949|DRUG|Placebo|film-coated oral tablets containing matched placebo
219731902|NCT04576949|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
219731903|NCT04188509|DRUG|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
219731904|NCT00279513|DRUG|Traumeel S|
219731905|NCT03855839|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
219731906|NCT03855839|DEVICE|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
219731907|NCT00051142|DRUG|Travoprost|
219731908|NCT00051142|DRUG|Latanoprost|
219234619|NCT05223309|OTHER|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
219234620|NCT05990556|PROCEDURE|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
219234621|NCT03853941|BEHAVIORAL|Intervention|Theory-based communication training programme delivered to healthcare professionals
219234622|NCT05601167|DRUG|nirmatrelvir/ritonavir|Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
219234623|NCT05601167|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
219234624|NCT05796271|DRUG|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
219234625|NCT01790659|DRUG|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
219234626|NCT01790659|DRUG|Paromomycin|Paromomycin alone
219234627|NCT01772212|DRUG|Terbinafine 250 mg|Test product
219234628|NCT01772212|DRUG|Terbinafine 250 mg|Reference product
219234629|NCT05371821|DEVICE|Echocardiography|Echocardiographic parameters in obese and overweight
219234630|NCT03394105|DRUG|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
219234631|NCT05794074|DIETARY_SUPPLEMENT|luteine and zeaxanthine|luteine and zeaxanthine
219234632|NCT05794074|DIETARY_SUPPLEMENT|luteine|luteine
219234633|NCT05794074|DIETARY_SUPPLEMENT|zeaxanthine|zeaxanthine
219234634|NCT05794074|DIETARY_SUPPLEMENT|Placebo|Placebo
219158604|NCT06846138|OTHER|Placebo|"Type: Placebo Comparator Description: A placebo formulation that matches PHF in appearance, texture, and administration schedule.~Administration: Oral, daily dosage as per study protocol."
219158605|NCT06846138|DRUG|Metformin (Standard Treatment for Type 2 Diabetes)|"Description: Metformin is an FDA and EMA-approved antihyperglycemic medication that improves glycemic control by reducing hepatic glucose production and enhancing insulin sensitivity.~Administration: Oral, per standard dosing guidelines. Availability: Provided to all participants per the national reimbursement scheme for T2D patients in Latvia."
219158606|NCT07070271|OTHER|Respiratory neurophysiological facilitation techniques|The respiratory neurophysiological facilitation techniques in form of (anterior basal lift, intercostal stretch, abdominal co-contraction) once a day for 5 days.
219234635|NCT01709006|RADIATION|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
219234636|NCT03065400|DRUG|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
219234637|NCT03773497|OTHER|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
219234638|NCT03773497|OTHER|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
219234639|NCT03773497|OTHER|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
219234640|NCT03773497|OTHER|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
219234641|NCT02102724|DIETARY_SUPPLEMENT|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
219234642|NCT02102724|DIETARY_SUPPLEMENT|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
219234643|NCT05485493|BEHAVIORAL|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
219234644|NCT05485493|OTHER|healthy nutrition education|60-minute single session healthy eating training
219158607|NCT07070271|OTHER|conventional chest physical therapy|conventional chest physical therapy program in form of (postural drainage, chest percussion, vibration and suction if needed) once a day for 5 days.
219158608|NCT06749028|DIETARY_SUPPLEMENT|Intervention Arm: Omega-3 + Phospholipids.|Intervention Arm: Omega-3 + Phospholipids.
219158609|NCT06749028|DIETARY_SUPPLEMENT|Comparator Arm: Omega-3 alone.|Comparator Arm: Omega-3 alone.
219158610|NCT07061067|PROCEDURE|Lumbar Spine Surgery|Patients undergoing lumbar spine surgery Presenting symptoms include lumbar back pain, lumbar radiculopathy, neurogenic claudication, lower-extremity weakness, bowel or bladder symptoms, and duration of symptoms.
219731909|NCT06501261|BEHAVIORAL|CALM psychotherapy|psychotherapy sessions
219731910|NCT06184763|OTHER|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
219731911|NCT04195477|BEHAVIORAL|vDPP|virtual Diabetes Prevention Program
219731912|NCT01084720|DRUG|V0034 CR|
219731913|NCT00205062|PROCEDURE|PET-CT|
219731914|NCT02527083|DRUG|Propofol|
219731915|NCT02527083|DRUG|Sevoflurane|
219158611|NCT07057648|DEVICE|Shape-sensing Robotic-assisted Bronchoscopy (ssRAB)|"Diagnostic procedure using the ION endoluminal system (Intuitive Surgical, Sunnyvale, CA) for navigation and tissue sampling of peripheral pulmonary nodules. The procedure involves:~1. Pre-procedure 3D navigation planning using thin-section chest CT~2. Shape-sensing catheter navigation to target nodules~3. Real-time position monitoring with fiber optic sensors~4. Tissue sampling using various tools (biopsy needles, forceps, brush, or cryobiopsy)~5. Optional radial endobronchial ultrasound (rEBUS) confirmation~6. Fluoroscopic guidance when needed~The procedure is performed under deep sedation or general anesthesia through an endotracheal tube."
219158612|NCT07058948|RADIATION|lattice radiation therapy|"Eligible patients will receive treatment using a medical linear accelerator. Within the largest tumor's gross tumor volume (GTV), spheres (0.5 - 3 cm in diameter) will be created as high - dose targets (LRT targets), spaced 2.0 - 5.0 cm apart. The LRT targets must be drawn within the GTV, avoiding blood vessels, with a margin of at least 1 cm from the GTV edge and a volume ratio of 1% - 10% of the GTV.~For a single lesion, the D95 of the GTV will be ≥1 Gy per fraction, and the D95 of the LRT target will be 8 - 12 Gy per fraction, while keeping the single - fraction dose to organs at risk as low as possible. All other irradiated metastases will receive low - dose radiotherapy at 100 - 300 cGy × 5 fractions. Brain and bone metastases will be treated with palliative radiotherapy as per clinical routine and are not included in the low - dose radiotherapy. Immunotherapy will be administered during or within one week after radiotherapy."
219158613|NCT06455215|BEHAVIORAL|Community garden activities|The gardens in the intervention group will receive an 8-week intervention that includes 1) educational materials, 2) healthy cooking demonstrations, food and transportation support and 3) garden social activities. The control group will be asked to abstain from intervention activities. The control group will receive the delayed 8-week intervention one month after the intervention group.
219158614|NCT07062393|BEHAVIORAL|Traditional Counseling → MAR Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
219731916|NCT02527083|DRUG|Remifentanil|
219234645|NCT03072862|DEVICE|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
219234646|NCT06034977|DRUG|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
219234647|NCT01790100|DRUG|VX-135|12 weeks of VX-135
219234648|NCT01790100|DRUG|Ribavirin|12 weeks of ribavirin
219731917|NCT02527083|DRUG|Ketamine|
219731918|NCT02726295|DRUG|E. coli Nissle 1917(Mutaflor®)|
219731919|NCT02726295|DRUG|Placebo|
219731920|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
219731921|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
219731922|NCT00407030|DRUG|Placebo|Placebo
219731923|NCT03017287|DEVICE|GlucoMe App|Assessment of the the GlucoMe App
219731924|NCT04489056|GENETIC|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
219731925|NCT03193307|DRUG|Microgynon® 30|Run in period \& Treatment Period
219731926|NCT03193307|DRUG|BI 409306|Day 18 \& 29 (Treatment Period)
219731927|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
219731928|NCT03845868|OTHER|Dietary and environmental exposure (Observational study)|
219731929|NCT05449262|OTHER|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
219731930|NCT05449262|OTHER|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
219731931|NCT01129895|BEHAVIORAL|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
219731932|NCT02829957|DRUG|Apixaban|10mg BID for 7 days, then 5mg BID for three months
219731933|NCT02829957|DRUG|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
219731934|NCT05469308|OTHER|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
219731935|NCT05558254|OTHER|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
219158615|NCT07062393|BEHAVIORAL|MAR Counseling → Traditional Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
219158616|NCT07064512|OTHER|Endogenous heating|Exercise was used as the endogenous heating modality, the participant cycled at 60% of his VO2max until rectal temperature reached 39°C
219158617|NCT07064512|OTHER|Exogenous heating|Hot-water immersion was used as the exogenous heating modality, where the participants sat immersed in a water bath at 43.5 ± 0.5°C and remained submerged until rectal temperature reached 39°C.
219158618|NCT07064694|PROCEDURE|Hybrid Parastomal Endoscopic Repair (HyPER)|Combined laparoscopic and open surgical approach involving adhesiolysis, hernia sac excision, intraperitoneal mesh fixation, and stoma revision or relocation as indicated. Standard mesh used was DynaMesh-IPST®; in selected cases, a cost-effective modification with macroporous polypropylene mesh and omental interposition was applied.
219161620|NCT05361187|DEVICE|BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device|The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
219731936|NCT01181765|BIOLOGICAL|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
219731937|NCT02576366|DRUG|Voriconazole|
219731938|NCT02576366|DRUG|Rifampin|
219731939|NCT00158431|PROCEDURE|Arthroscopy plus Medical Management|Arthroscopic Surgery
219731940|NCT00158431|OTHER|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
219731941|NCT01578720|DRUG|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
219731942|NCT05684614|OTHER|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
219731943|NCT05684614|OTHER|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
219731944|NCT05684614|OTHER|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
219731945|NCT00842036|BEHAVIORAL|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
219731946|NCT00842036|BEHAVIORAL|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
219731947|NCT00842036|BEHAVIORAL|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
219161621|NCT05833789|DEVICE|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
219161622|NCT00999193|PROCEDURE|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
219161623|NCT00999193|PROCEDURE|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
219731948|NCT00000544|BEHAVIORAL|diet therapy|
219731949|NCT03219736|PROCEDURE|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
219731950|NCT03219736|DEVICE|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
219731951|NCT03219736|PROCEDURE|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
219731952|NCT02086045|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
219731953|NCT01370538|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
219731954|NCT00875901|RADIATION|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
219731955|NCT00875901|RADIATION|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
219731956|NCT04193527|DRUG|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
219731957|NCT03135795|DRUG|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
219731958|NCT03135795|DRUG|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
219731959|NCT03135795|DRUG|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
219731960|NCT03135795|DRUG|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
219731961|NCT03135795|DRUG|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
219731962|NCT03135795|DRUG|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
219731963|NCT03135795|DRUG|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
219731964|NCT04573075|PROCEDURE|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
219731965|NCT04573075|PROCEDURE|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
219731966|NCT04573075|PROCEDURE|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
219731967|NCT02366130|DRUG|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
219731968|NCT02366130|DRUG|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
219731969|NCT02366130|DRUG|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
219731970|NCT01574495|OTHER|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
219731971|NCT00251966|DRUG|Esomeprazole|
219161624|NCT00999193|OTHER|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
219161625|NCT04906213|DRUG|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
219731972|NCT05128344|DRUG|AMZ002 injectable solution, 0.5mg/mL|Injectable solution
219731973|NCT05128344|DRUG|Vigabatrin, oral|Oral administration
219731974|NCT00000810|DRUG|Delavirdine mesylate|
219731975|NCT00000810|DRUG|Zidovudine|
219731976|NCT00000810|DRUG|Didanosine|
219731977|NCT03044912|DRUG|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
219731978|NCT01415687|DRUG|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
219731979|NCT01415687|DRUG|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
219731980|NCT00567112|DRUG|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
219731981|NCT00567112|DRUG|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
219234649|NCT02203513|DRUG|LY2606368|105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
219731982|NCT00567112|DRUG|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
219731983|NCT00567112|DRUG|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
219161626|NCT04906213|DRUG|Placebo|10Mg Placebo Tab
219731984|NCT04740879|BEHAVIORAL|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
219731985|NCT06796062|DRUG|Psilocybin|One capsule (1 mg, 20 mg, or 30 mg) administered once orally
219731986|NCT05807893|DRUG|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
219731987|NCT04702750|BEHAVIORAL|Targeted memory reactivation (odors)|I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
219731988|NCT04702750|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
219731989|NCT03562637|BIOLOGICAL|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
219731990|NCT03562637|DEVICE|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
219234650|NCT01196364|OTHER|Dietary Supplement: water with noncalorie sweetener|
219158619|NCT06769997|DEVICE|Optilume® BPH Catheter System|The technology is based on a device/drug combination consisting of two catheters: the Optilume BPH Prostatic Pre-dilation Catheter which is a non-drug coated catheter used to start commissurotomy between the lateral lobes of the prostate and the Optilume BPH Prostatic Dilatation DCB Catheter which is a drug coated catheter used to complete the commissurotomy and transfers drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Hence, the device applies a mechanical dilatation to open prostatic urethral lumen to increase urine flow, followed by the transfer of paclitaxel drug to inhibit cell proliferation and maintain this dilatation.
219158620|NCT06769997|DEVICE|Rezum Water Vapor Therapy|The Rezum system is minimally invasive therapy for LUTS secondary to BPH. The system injects water vapor at 103°C generated by radiofrequency to create thermal energy via a transurethral approach. The vapor disperses through the tissue interstices within the treatment zone (transition zone). The injection of vapor last for approximatively 9 seconds and the number of injections depends on the prostate volume and length of the prostatic urethra.
219158621|NCT07064551|BEHAVIORAL|Cognitive behavioural therapy-based stepped-care intervention|After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]). Mild symptoms (PHQ-9=5-9): 6 weekly low intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderate symptoms (PHQ-9=10-14): 6 weekly high intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderately severe symptoms (PHQ-9≥15): high intensity individual or group CBT-based intervention. Trained peer supporters will be matched to participants to walk them through the process with regular follow-up.
219158622|NCT07064551|OTHER|Self-management booklet|The booklet incorporates components of behavioural activation, which encourages participants to engage in meaningful activities in daily life to change their mood. Trained research assistants will regularly check in with the participants to monitor their depressive symptoms.
219161627|NCT05650411|DEVICE|LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).|Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
219161628|NCT05650411|DRUG|P2Y12 inhibitor-based SAPT after short DAPT|Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
219161629|NCT05650411|DRUG|Conventional DAPT|6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
219161630|NCT05369182|DIAGNOSTIC_TEST|Invasive physiologic assessment|"All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.~In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed."
219161631|NCT05369182|DIAGNOSTIC_TEST|Intravascular imaging|By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS \[Boston Scientific, Natick, Massachusetts, USA\] or OCT \[Abbott Vascular\], St. Paul, MN, USA\]).
219161632|NCT05307835|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
219161633|NCT05307835|BIOLOGICAL|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
219161634|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
219161635|NCT04420078|PROCEDURE|Catheter Ablation|Ventricular fibrillation substrate
219731991|NCT03562637|OTHER|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
219731992|NCT05905055|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
219731993|NCT05905055|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
219731994|NCT05905055|DRUG|BAT|Dosage of BAT will be based per site's standard of care
219731995|NCT03168815|DEVICE|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
219731996|NCT02315326|DRUG|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
219158623|NCT07065084|PROCEDURE|Virtual Reality glasses|"In the study, the patients in the intervention group were fitted with VR goggles by the researcher immediately after the spinal anesthesia was administered by the researcher during the operation in hernia patients who received spinal anesthesia for the study, when the patient was placed on the operating table and given the operating position, just before the surgical incision started. The procedures were performed without interfering with anesthesia and general operating room functioning. When the surgical incision was to be made, videos were started to be watched from the VR glasses simultaneously. During the 20 minute procedure, the licensed product Relax with Nature with music background with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel screen resolution display unit, China) was watched with virtual reality application. Patients were shown videos of lakes, forests, waterfalls, rivers and beaches. In the studies, it was stated that these videos"
219731997|NCT02315326|DRUG|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
219731998|NCT02315326|DRUG|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
219731999|NCT02315326|DRUG|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
219732000|NCT04421768|BEHAVIORAL|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
219158624|NCT07071181|DIETARY_SUPPLEMENT|Original flavour kefir|"Participants will consume 250ml of original flavour kefir daily for 4 weeks. According to the manufacturer, packed with billions of live cultures to support Gut health."
219158625|NCT07071181|OTHER|Milk|Participants will consume 250 ml milk daily for 4 weeks. This milk will not contain any live cultures.
219158626|NCT07071857|DIAGNOSTIC_TEST|ECG CT angiography|Preoperative: electrocardiography-gated computed tomographic angiography.
219158627|NCT07071857|DIAGNOSTIC_TEST|TTFM|Intraoperative: TTFM after weaning from cardiopulmonary bypass and just before sternal closure.
219234651|NCT01196364|OTHER|Activity: With noncalorie sweetener or glucose|
219732001|NCT04684485|DRUG|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
219732002|NCT04684485|DRUG|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
219732003|NCT04684485|DRUG|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
219732004|NCT04684485|DRUG|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
219732005|NCT04535011|BEHAVIORAL|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
219732006|NCT04535011|BEHAVIORAL|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
219234652|NCT05431322|DRUG|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
219158628|NCT07071857|DIAGNOSTIC_TEST|computed tomography of the aorta and/or grafts|computed tomography of the aorta and/or grafts within 2 weeks after surgery.
219158629|NCT07070882|DRUG|Methylprednisolone|Patients will receive a tapered dose of methylprednisolone with the standard of care pain management
219158630|NCT07069920|DEVICE|BRDE33-100|BRDE33-100 will be injected once at Visit 2 (Baseline).
219158631|NCT07069920|DEVICE|Soonsoofill|Soonsoofill will be injected once at Visit 2 (Baseline).
219158632|NCT07071662|OTHER|delivery mode|To observe the different modes of delivery and evaluate the characteristics of the patients as well as maternal and fetal well being in the post partum period.
219158633|NCT07069686|PROCEDURE|Ultrasound guided airway nerve block for Endotracheal intubation|Glossopharyngeal nerve block: 1.5 mL 2% lidocaine, ultrasound probe on lateral neck below mandible, landmark = hyoid bone, tilt cephalad to target pharyngeal wall near tonsil; right side needle inserted out-of-plane from superior probe edge to avoid artery. Bilateral superior laryngeal nerve blocks: out-of-plane at lateral thyroid cartilage, orient probe medially, inject 1 mL 2% lidocaine into thyrohyoid membrane between hyoid and thyroid cartilage using 25-G 25 mm needle. Bilateral recurrent laryngeal nerve blocks: translaryngeal out-of-plane, locate cricothyroid membrane below thyroid cartilage, insert 25-G 25 mm needle 1.5 cm, confirm air backflow, inject 2 mL 2% lidocaine.
219158634|NCT07069686|PROCEDURE|lidocaine topical anesthesia for Endotracheal intubation|will receive topical lidocaine 10% spray directly on the tongue and oropharynx without exceeding toxic doses.
219158635|NCT07070934|BIOLOGICAL|CAR-T|The T cells are genetically modified to expressa chimeric antigen receptor targeting BCMA andare infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
219158636|NCT07070934|BIOLOGICAL|ASCT|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT).
219158637|NCT07070843|OTHER|Control Group: Standard Eye Care Group|There is no established protocol or guideline for eye care in the intensive care unit where the study will be conducted. Routine eye care involves the use of sterile gauze and sterile saline. During routine suctioning procedures, patients' eyes are not closed. If a patient is unable to achieve full eyelid closure, their eyes are covered with an eye patch or sterile gauze. The Schirmer test will be administered to both eyes on the first day (prior to the first eye care intervention), as well as on the fifth, seventh, and tenth days after eye care is performed. Signs and symptoms of eye infection and chemosis will be evaluated daily after the second eye care procedure. Data for this group will be collected, and the administration and documentation of eye care will be monitored.
219158638|NCT07070843|OTHER|Intervention Group 1: Eye Care Using an Eye Care Kit|Eye care will be performed using an eye care kit. All nursing staff in the intensive care unit will receive training regarding the contents and usage of the kit. Patients in this group will receive eye care solely using the kit, following a 4-times-daily care protocol. For patients with lagophthalmos, eyes will be covered using the eye closure pad provided in the kit. The Schirmer test will be performed on both eyes on the first day prior to the initial eye care intervention, and on the fifth, seventh, and tenth days following eye care, with results recorded. Signs of infection and chemosis will be assessed daily after the second eye care session. Data collection will be done using , and eye care administration will be tracked.
219158639|NCT07070843|OTHER|Intervention Group 2: Eye Care According to an Eye Care Protocol|"* All ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving care under the protocol.~* Patients' ocular risk factors will be assessed daily, followed by eye care based on the protocol.~* Changes in ocular condition will be assessed and documented, and ICU physicians will be informed as necessary.~* In cases of incomplete eyelid closure, eyes will be covered upon physician notification.~* Patients will be assessed daily for signs of eye infection and conjunctival edema in accordance with the protocol. If signs of infection or complications occur during the day, they will be marked with a (+) symbol on the form.~* The Schirmer test will be applied on the first day (prior to the initial eye care session) and after eye care on days 5, 7, and 10, with results documented."
219158640|NCT07070843|OTHER|Intervention Group 3: Eye Care Using Both the Eye Care Protocol and the Eye Care Kit|"* ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving this combined care.~* Eye care will be performed using the Eye Care Kit developed by the researchers in accordance with the protocol.~* Patients will be assessed for ocular risk factors daily, and eye care will be provided according to the management guidelines of the protocol.~* In cases of incomplete eyelid closure, the eyes will be covered with physician knowledge.~* Patients will be assessed daily for signs of infection and conjunctival edema as per the protocol. Any signs of infection or complications will be marked with a (+) on the form.~* The Schirmer test will be performed on both eyes before the first eye care session on day 1, and following eye care on days 5, 7, and 10, with results recorded."
219158641|NCT07070102|OTHER|blood samples|2 blood samples of 1 mL
219158642|NCT07070908|DEVICE|Antrum calibration|For antral calibration, a 50 cc balloon catheter was used to guide the staple line.
219158643|NCT07070908|PROCEDURE|Fudus calibration|"Fundus transection was performed 1 cm from the fat pad in calibrated cases (an anatomically constant area near the short gastric vessels that contains minimal fat and facilitates dissection toward the diaphragmatic crus)."
219158644|NCT07070908|PROCEDURE|No antrum calibration|In patients without antrum calibration, gastric transection was performed 5 cm from the pylorus.
219158645|NCT07070908|PROCEDURE|No fundus calibration|"Fundus transection was performed adjacent to the fat pad in no calibrated cases."
219158646|NCT07069764|DEVICE|Doctor smile 635nm For Arm 1|Participants will receive low-level laser therapy using a diode laser with a wavelength of 635 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
219158647|NCT07069764|DEVICE|Doctor smile 980 nm For Arm2|Participants will receive low-level laser therapy using a diode laser with a wavelength of 980 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
219158648|NCT07071584|DEVICE|Cutaneous Prosthesis Control System|Prosthesis control system using a multi-electrode cutaneous sensor array
219158649|NCT07066735|DEVICE|ESWT|Transperineal Shockwaves that are applied once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)
219158650|NCT07066735|DRUG|Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin|1capsule tob be taken twice daily for one month.
219158651|NCT07070531|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a transdiagnostic, emotion-focused cognitive-behavioral treatment designed to address a range of emotional disorders, including anxiety, depression, and related conditions. It targets core mechanisms such as emotional avoidance, cognitive rigidity, and maladaptive emotion regulation strategies. The UP consists of structured modules focused on increasing emotional awareness, cognitive flexibility, and exposure to emotionally evocative situations. By addressing common underlying processes across disorders, the UP enhances treatment efficiency and applicability in both individual and group formats. Its flexibility makes it suitable for diverse populations and settings, including community and clinical contexts.
219732007|NCT04535011|BEHAVIORAL|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
219732008|NCT05769335|OTHER|eCR|Eating time window from 8:00 to 16:00
219732009|NCT05769335|OTHER|dCR|Eating time window from 12:00 to 20:00
219732010|NCT05769335|OTHER|CR|Eating time window from 8:00 to 20:00
219732011|NCT06963541|OTHER|No intervention; Observational study|No interventions are associated with either group. This is an observational study without experimental procedures.
219732012|NCT06964763|PROCEDURE|surgery + laser|laser
219732013|NCT06964763|PROCEDURE|surgery + fibrine glue|fibrine glue
219158652|NCT07071064|BEHAVIORAL|Food Box + Nutrition Classes|The Nutrition Security Intervention is a 12-month project enrolling 400 adults across four sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. Individuals receiving this intervention will receive bi-weekly food boxes, containing 15-20 pounds of fresh produce, grains, and legumes. They will also participate in a bi-weekly nutrition class, led by a Registered Dietician.
219158653|NCT07071064|BEHAVIORAL|Food Box Only|The intervention is a 12-month project enrolling 400 adults across four partner sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. In this intervention, participants will receive a bi-weekly food box only (no nutrition education) during the intervention period. They will have the opportunity to participate in the educational component after the completion of the intervention period.
219158654|NCT07070622|DRUG|patients were assigned to receive TNT or iTNT management|TNT or iTNT
219732014|NCT06171399|BEHAVIORAL|"All Natural descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732015|NCT06171399|BEHAVIORAL|"Gluten-free descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732016|NCT06171399|BEHAVIORAL|"Vegan descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732017|NCT06171399|BEHAVIORAL|"100% Organic descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732018|NCT06171399|BEHAVIORAL|"Handcrafted descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219158655|NCT07070557|OTHER|neutrophil lymphocyte ratio and platelet lymphocyte ratio|explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients
219158656|NCT07071571|DEVICE|neuromonitoring|new neuromonitorin device will use
219158657|NCT07070648|DRUG|POLA-R-CHP|Pola-R-CHP treatment for 6 cycles (IPI score 2-5)
219158658|NCT07070739|DRUG|HSK44459 tablets|Orally, twice a day
219158659|NCT07070635|OTHER|Nutritional intervention with Fermented Seaweed Enriched English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea + 1 g fermented seaweed) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
219158660|NCT07070635|OTHER|Nutritional intervention with Control English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
219158661|NCT07069634|OTHER|Individual training using the Teach Back Method|"Day 1 (Monday): Patients are introduced to the study; consent forms are signed, and initial forms are completed. An educational booklet is provided and explained. General information about hemodialysis and treatment is delivered using the Teach-Back Method.~Day 2 (Wednesday): Patients recall previous session topics; unclear points are clarified. Education focuses on fluid and dietary restrictions and the importance of adherence, using the Teach-Back Method.~Day 3 (Friday): Patients summarize previous content; the researcher reinforces unclear areas. Education covers medication adherence and lifestyle habits, again using the Teach-Back Method."
219158662|NCT07069998|OTHER|virtual assistant|Programming codes that interpret atrial fibrillation symptoms and design management plans based on algorithms that reflect the European Society of Cardiology (ESC) 2024 guidelines and the expertise of consultant cardiologists, finally checked and approved by a cardiologist.
219158663|NCT07069998|OTHER|Standard AF care|AF care provided via the National Health System (NHS) standard AF care system
219158664|NCT07070583|PROCEDURE|Stent placement|Patients with an aorto-iliac occlusion will receive a stent, according to standard care
219158665|NCT07070453|PROCEDURE|Non-surgical periodontal treatment|Removal of deposits above and below the gum line using hand or ultrasonic tools and thorough smoothing of root surfaces to discourage re-accumulation of bacteria.
219158666|NCT07070453|PROCEDURE|Scaling and root planing + aPDT|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light, and oxygen to generate reactive oxygen species (ROS) that kill bacteria.
219158667|NCT07069933|DRUG|Standard care +itraconazole 200mg|Is an antifungal used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals.
219158668|NCT07069933|DRUG|Chemotherapy|Standard Care (in control arm)
219158669|NCT07070011|COMBINATION_PRODUCT|EC/EP + ICIs|Collect blood samples from patients with small cell lung cancer before receiving immunotherapy combined with chemotherapy.
219158670|NCT07070505|OTHER|Experimental|"* Before applying hand massage, the individual/patient's hand or arm will be evaluated for thrombus, phlebitis, ecchymosis, hematoma, deterioration in skin integrity and change in skin color in order to determine whether there is a risk.~* Hand massage application is a massage performed with western technique that includes five basic classical massage manipulations including efflorescence, petrissage, friction, tapotment and vibration.~* Massage should be performed in a way that creates light pressure on the individual, then the applied pressure should be gradually increased."
219158671|NCT07071493|DEVICE|tPBM Group, taVNS Group, Combined Treatment Group: Stimulation Program (5 Weeks)|"Stimulation Program (5 Weeks) Each participant will follow one of the following programs, assigned randomly, five days a week for a total duration of five weeks.~tPBM Group: Participants will receive transcranial photobiomodulation (tPBM) for 15 minutes per day.~taVNS Group: Participants will receive transcutaneous auricular vagus nerve stimulation (taVNS) for 15 minutes per day.~Combined Treatment Group: Participants will simultaneously receive both tPBM and taVNS for 15 minutes per day."
219158672|NCT07069842|DIAGNOSTIC_TEST|Multiplex Immunofluorescence Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment.Meanwhile, detect the expression of cytokines, NLR, PLR, SII, and tumor markers in peripheral blood.Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.In situ hybridization with chromogenic detection was performed to assess the EBER status.
219158673|NCT07069842|DIAGNOSTIC_TEST|Co-Immunoprecipitation (Co-IP) Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment
219158674|NCT07069842|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.
219732019|NCT06171399|BEHAVIORAL|"Made with live resin descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732020|NCT06171399|BEHAVIORAL|"Fast-acting descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732021|NCT06171399|BEHAVIORAL|"Relax descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732022|NCT06171399|BEHAVIORAL|"Energy Boost descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732023|NCT06171399|BEHAVIORAL|No descriptor (control)|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
219732024|NCT03070886|DRUG|Bicalutamide|Given orally (PO)
219732025|NCT03070886|DRUG|Degarelix|Given IM
219732026|NCT03070886|DRUG|Docetaxel|Given IV
219732027|NCT03070886|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219732028|NCT03070886|DRUG|Flutamide|Given PO
219158675|NCT07069842|DIAGNOSTIC_TEST|In situ hybridization with chromogenic detection|In situ hybridization with chromogenic detection was performed to assess the EBER status.
219158676|NCT07070466|DRUG|Ivonescimab|Humanized immunoglobulin G1 monoclonal antibody
219158677|NCT07070466|DRUG|5-Fluorouracil|Nucleoside metabolic inhibitor
219158678|NCT07070466|DRUG|Oxaliplatin|Platinum-based drug and organoplatinum complex
219158679|NCT07070466|DRUG|Leucovorin|5-formyl derivative of tetrahydrofolic acid
219158680|NCT07070245|PROCEDURE|Instrument assisted soft tissue mobilization|The treatment protocol will be two sessions. given per week for 4 weeks.
219158681|NCT07070245|PROCEDURE|Positional release|The treatment protocol will be two sessions. given per week for 4 weeks.
219158682|NCT07070245|PROCEDURE|Exercises|The treatment protocol will be two sessions. given per week for 4 weeks.
219158683|NCT07070414|BEHAVIORAL|Brief Negotiation Interview intervention (BNI) (adapted)|A brief motivational interview designed to increase motivation to reduce alcohol and/or cannabis use and engagement in treatment referral.
219158684|NCT07071038|DRUG|Switch|Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively. The choice of AI in the first line setting will be at the discretion of the treating oncologist. If side effects persist after the 1st line switch, the participant will have the option to switch to another AI not yet tried, or to tamoxifen at 20mg daily
219732029|NCT03070886|DRUG|Goserelin|Given IM
219158685|NCT07071038|OTHER|Guideline Directed Intervention (GDI)|"Subjects in this group will receive a guideline-directed intervention GDI using medication and/or non-medication treatment options according to the National Comprehensive Cancer Network (NCCN) supportive care guidelines. A GDI Book was created for this trial that lists treatment options and resources for each of the common side effects of hormonal therapy and is available for providers and staff to help select treatment options. For less common side effects with limited evidence-based options, treatment will be determined in collaboration with the treating provider and PI, using best available evidence."
219732030|NCT03070886|DRUG|Goserelin Acetate|Given IM
219732031|NCT03070886|OTHER|Laboratory Biomarker Analysis|Correlative studies
219732032|NCT03070886|DRUG|Leuprolide|Given intramuscularly (IM)
219732033|NCT03070886|DRUG|Leuprolide Acetate|Given IM
219732034|NCT03070886|DRUG|Nilutamide|Drug
219732035|NCT01017315|DRUG|Baby talcum|50 grams apply locally prior cast application
219732036|NCT03528850|OTHER|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
219732037|NCT03934879|BEHAVIORAL|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
219732038|NCT03934879|OTHER|Regular School Activities|Students will participate in regular school activities.
219732039|NCT01945242|DRUG|Alogliptin|Alogliptin tablets
219732040|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intravenous infusion over 15 min
219158686|NCT03897127|DRUG|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
219732041|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intramuscular injection
219732042|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 250 mg given by intramuscular injection
219732043|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 60 min
219732044|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 30 min
219732045|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 15 min
219158687|NCT03897127|DRUG|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
219158688|NCT03897127|DRUG|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3"
219158689|NCT04939246|RADIATION|Stereotactic ablative body radiation therapy|Single-fraction of stereotactic ablative body radiation (SABR) therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian Linac). The prescription dose is dependent on the anatomic location of the lesion and based on previously published safety data.
219158690|NCT04994509|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
219158691|NCT04994509|DRUG|Subcutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
219158692|NCT04994509|DRUG|F/TAF|Tablets administered orally
219158693|NCT04994509|DRUG|F/TDF|Tablets administered orally
219158694|NCT04994509|DRUG|Placebo SC LEN|Administered via SC injections
219158695|NCT04994509|DRUG|PTM Oral LEN|Tablets administered orally
219158696|NCT04994509|DRUG|PTM F/TAF|Tablets administered orally
219158697|NCT04994509|DRUG|PTM F/TDF|Tablets administered orally
219158698|NCT05020756|DIETARY_SUPPLEMENT|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
219158699|NCT06923267|DIAGNOSTIC_TEST|No Pressure Support No Positive End Expiratory Pressure Spontaneous Breathing Trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing both the positive end-expiratory pressure (PEEP) and the pressure support to 0 cmH2O, for 15 minutes.
219158700|NCT06923267|DIAGNOSTIC_TEST|Pressure Support Spontaneous Breathing trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing the positive end-expiratory pressure (PEEP) to 0 cmH2O and the pressure support to 7 cmH2O, for 15 minutes. A 10-minute washout period is left before the start of the next SBT modality.
219158701|NCT06923267|DIAGNOSTIC_TEST|Humidified High Flow Spontaneous Breathing Trial|The spontaneous breathing trial is carried out with humidified high flow ventilator mode set at 50 liters per minute for 15 minutes. The patient will be connected to the ventilator via a specific connector enabling the administration of humidified high flow. A 10-minute washout period is left before the start of the next SBT modality.
219732046|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
219732047|NCT03499665|BEHAVIORAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
219732048|NCT03499665|BEHAVIORAL|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
219732049|NCT03499665|BEHAVIORAL|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
219158702|NCT03411369|DIETARY_SUPPLEMENT|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
219158703|NCT03411369|OTHER|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
219158704|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) combined with face-to-face videoconferencing sessions with a therapist in BF-GROw group|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022)combined with face-to-face videoconferencing sessions with a therapist (blended) . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. BF-GROw group will receive a treatment module every 10-12 days. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
219732050|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 1|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
219732051|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 2|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
219732052|NCT06466603|DIETARY_SUPPLEMENT|Placebo Group|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
219732053|NCT04518670|DEVICE|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
219732054|NCT04381377|DRUG|azoximer bromide|Investigational medicinal product
219732055|NCT04381377|OTHER|Placebo|Placebo
219732056|NCT06050512|DRUG|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
219732057|NCT06050512|DRUG|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
219732058|NCT06050512|DRUG|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
219732059|NCT02478502|DRUG|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
219732060|NCT02512445|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
219732061|NCT02512445|BEHAVIORAL|Supportive Care Therapy|Supportive therapy
219732062|NCT05050214|DRUG|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
219732063|NCT03142958|DEVICE|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
219732064|NCT05420454|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
219732065|NCT05420454|DRUG|Carboplatin|AUC 6, d1, q3w ,6 cycles
219732066|NCT05420454|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
219158705|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) supported by the App developed which contains the EMA and EMI tools in iGROw group.|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022) supported by the App developed which contains the Ecological Momentary Assessment (EMA) and Ecological Momentary Intervention (EMI) tools . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
219158706|NCT03638427|DIAGNOSTIC_TEST|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
219158707|NCT02181660|DRUG|Gilteritinib|oral
219161636|NCT05831683|OTHER|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
219161637|NCT05788848|BEHAVIORAL|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
219732067|NCT05420454|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
219732068|NCT05420454|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
219234653|NCT05114811|PROCEDURE|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
219732069|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
219732070|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
219732071|NCT05420454|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
219732072|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
219732073|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
219732074|NCT05420454|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
219732075|NCT01170130|DRUG|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
219732076|NCT05768711|DRUG|Venetoclax|Combination of Azacitidine and Venetoclax
219732077|NCT02819544|DRUG|Sodium chloride administration|Sodium chloride administration
219732078|NCT02819544|DRUG|Ropivacaine administration|Ropivacaine administration
219732079|NCT05655169|PROCEDURE|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied."
219732080|NCT05655169|PROCEDURE|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
219732081|NCT05655169|OTHER|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
219732082|NCT06276348|GENETIC|Whole genome sequencing|Standard diagnostic whole genome sequencing will be performed.
219158708|NCT06953284|OTHER|KINESOTAPING|Kinesio Taping (KT) is commonly used in sport injuries, in neurology and oncology patients following the surgical protocols, and for paediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception.7-9 Although its mechanism of action has not been fully understood, it is believed that activation of the cutaneous receptors could influence neuromuscular functions.10 The cutaneous sensory system provides preliminary information about limb positions and muscle forces to the central nervous system for monitoring and controlling limb movements, planning actions, and providing fluent movement.11 Common causes of unilateral spastic CP are middle cerebral artery infarct, hemi-brain atrophy, periventricular lesions, and brain malformations that disturb the integrity of the motor areas. Middle cerebral artery infarctions can particularly impair the somatosensory sy
219158709|NCT06953284|OTHER|Functional Electrical Stimulation|This systematic review is the first to examine the effect of FES on activity in children with CP using only randomized trials.However, evidence was limited with only 5 trials being included. This limited evidence suggests that FES is effective, that is, it is better than no FES intervention, but that it is no more effective than activity training, that is, practicing the activity without FES will be just as effective. Furthermore, no evidence was found on whether any benefits are maintained beyond the intervention period because even though a follow-up measurement was reported for 2 studies, the authors failed to provide data. Even though the review was restricted to the highest standard of evidence, randomized trials, firm conclusions cannot be made. This is primarily because of the absence of group data (means and SD) in the papers, preventing a meta-analysis. This poor reporting is disappointing given that 3 of the 5 trials were published within the last 5 years. Therefore, we may b
219732083|NCT06276348|GENETIC|BeginNGS test|Genomic sequencing that screens for 434 genetic diseases.
219732084|NCT06276348|GENETIC|WES|Whole exome sequencing will be performed.
219732085|NCT05698628|PROCEDURE|Distal perfusion catheterization|Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
219732086|NCT05661734|DRUG|Suzetrigine|Tablets for oral administration.
219732087|NCT04569097|OTHER|standard of care lingual strengthening|standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
219158710|NCT02089698|DEVICE|Mini-flared|Mini-flared Kelman tip
219158711|NCT02089698|DEVICE|Reversed tip|Reversed Kelman tip
219732088|NCT03037008|DEVICE|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
219732089|NCT01670149|DRUG|Rifaximin|Tablets
219732090|NCT01670149|DRUG|Placebo|Tablets
219732091|NCT06032715|BEHAVIORAL|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
219732092|NCT06651190|OTHER|Pain Caregiver Resource (PainCaRe)|The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
219732093|NCT04150757|DRUG|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
219732094|NCT05720520|OTHER|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
219732095|NCT03968003|DIETARY_SUPPLEMENT|Inulin|The intervention group (group A) consumed 10 g of inulin extracted from Thai Jerusalem artichoke by our patent technique (Patent no. 15858) administered once daily before dinner. The placebo group (group B) received isocaloric maltodextrin, while the dietary fiber advice group (group C) received guidance based on age-appropriate intake recommendations.
219732096|NCT01775709|DEVICE|PE tube with Duckbill Valve|PE tube with Duckbill Valve
219732097|NCT05694637|BEHAVIORAL|Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
219732098|NCT05694637|DRUG|Varenicline|Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
219732099|NCT04304703|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
219732100|NCT00536614|GENETIC|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
219158712|NCT03764787|COMBINATION_PRODUCT|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
219158713|NCT02051491|DEVICE|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
219158714|NCT02051491|DEVICE|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
219158715|NCT01700296|BEHAVIORAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
219158716|NCT06334666|OTHER|Encourage using pedometer|MASLD patient used pedometer recording actively with encourage by care provider or investigator
219158717|NCT03795220|DRUG|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
219158718|NCT03795220|DRUG|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
219158719|NCT03795220|DRUG|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
219158720|NCT03795220|DRUG|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
219158721|NCT03757949|OTHER|Laboratory Biomarker Analysis|Correlative studies
219158722|NCT03757949|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive SIM PO
219158723|NCT03757949|OTHER|Placebo Administration|Given PO
219158724|NCT03757949|OTHER|Quality-of-Life Assessment|Ancillary studies
219158725|NCT03757949|OTHER|Questionnaire Administration|Ancillary studies
219158726|NCT05289310|OTHER|Normobaric hypoxia (NH)|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
219158727|NCT05289310|OTHER|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
219158728|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
219158729|NCT06489262|BEHAVIORAL|"Healthy Together (Juntos)"|"Parent-adolescent dyads will log in to a secured website for six months. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in approximately weekly (during the first 3 months), and monthly (during the following 3 months) 20-30-minute sessions regarding the family's progress throughout the intervention period."
219158730|NCT05642598|BEHAVIORAL|Pivot for Vape|"Pivot for Vape vaping cessation smartphone app and program"
219732101|NCT01765998|DRUG|Probiotic|Clinical evaluation according to the Crohn's activity scale
219732102|NCT01765998|DRUG|Placebo|
219158731|NCT05348889|DRUG|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
219732103|NCT05276453|DEVICE|GMove Suit|12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
219732104|NCT05276453|BEHAVIORAL|Normal therapy|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
219732105|NCT05265676|DRUG|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
219732106|NCT05265676|DRUG|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
219732107|NCT03402412|OTHER|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
219158732|NCT06312904|PROCEDURE|paravertebral block|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.
219158733|NCT06312904|PROCEDURE|Local infiltration anesthesia|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.
219158734|NCT06779851|DRUG|BPT567|Immunocytokine infusion
219158735|NCT06686602|OTHER|No drug|This is a non-interventional study and no study drug will be administered.
219158736|NCT06694857|DRUG|HA filler|patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. Patients are limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
219158737|NCT04418271|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
219158738|NCT06703177|DRUG|SHR-1826|SHR-1826
219158739|NCT06703177|DRUG|SHR-4642|SHR-4642
219158740|NCT06703177|DRUG|SHR-9839|SHR-9839
219158741|NCT06703177|DRUG|SHR-8068|SHR-8068
219158742|NCT06703177|DRUG|Bevacizumab Injection|Bevacizumab Injection
219158743|NCT06703177|DRUG|Fluorouracil Injection|Fluorouracil Injection
219158744|NCT06703177|DRUG|Calcium Folinate Injection|Calcium Folinate Injection
219158745|NCT06703177|DRUG|Adebrelimab Injection|Adebrelimab Injection
219732108|NCT02978768|OTHER|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
219732109|NCT02978768|DEVICE|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
219732110|NCT02978768|DEVICE|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
219732111|NCT03542357|DRUG|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219732112|NCT03542357|DRUG|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219732113|NCT03542357|DRUG|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219732114|NCT01951027|DRUG|GX-G3 12.5 μg/kg or Placebo|Single SC injection
219732115|NCT01951027|DRUG|GX-G3 25 μg/kg or Placebo|Single SC injection
219158746|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
219234654|NCT05114811|PROCEDURE|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
219234655|NCT03183856|DEVICE|Morning walk|a end-effector typed gait robot with a saddle
219732116|NCT01951027|DRUG|GX-G3 50 μg/kg or Placebo|Single SC injection
219732117|NCT01951027|DRUG|GX-G3 100 μg/kg or Placebo|Single SC injection
219732118|NCT02939664|DEVICE|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
219234656|NCT03183856|OTHER|no Morning walk|ambulation voluntary or with a help of walker
219234657|NCT02751125|DRUG|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
219732119|NCT02939664|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
219732120|NCT00053742|DRUG|Modified Vaccinia Virus Ankara TBC-MVA|
219732121|NCT00062504|DRUG|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
219732122|NCT04616352|OTHER|Resistance to cefuroxime|Non susceptibility in vitro testing
219158747|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
219158748|NCT05678699|BEHAVIORAL|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1\) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries"
219158749|NCT05678699|BEHAVIORAL|Doula|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1. health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~2. care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania."
219158750|NCT05678699|BEHAVIORAL|Standard Care|Participants receive standard care without quality interventions or doula care
219158751|NCT01495806|DRUG|Glucomannan|2 x 5g
219158752|NCT01495806|DRUG|placebo|glucose 5 g
219158753|NCT06062017|DIETARY_SUPPLEMENT|Water and Potassium supplementation|All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium chloride powder.
219158754|NCT05573048|DEVICE|Trans-Perineal Grid|A small square piece of plastic with many holes in it placed between the legs to help guide the path of the interventional instruments and to facilitate the prostate intervention. The guide grid will help with needle placement using the grid technology.
219158755|NCT05833360|DEVICE|Exai oncRNA blood test|A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
219234658|NCT05390710|COMBINATION_PRODUCT|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
219234659|NCT02513667|DRUG|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
219234660|NCT02513667|RADIATION|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
219234661|NCT00976651|DRUG|human menopausal gonadotropin|200 IU per day in the late follicular phase
219234662|NCT04717570|DEVICE|Foldax TRIA Mitral Valve|Mitral Valve Replacement
219234663|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
219234664|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
219732123|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
219234665|NCT03745170|DRUG|Sintilimab|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
219732124|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
219732125|NCT02208622|DIETARY_SUPPLEMENT|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
219732126|NCT00033345|DRUG|Indole-3-carbinol|400 mg pill taken daily
219732127|NCT00033345|DRUG|Indole-3-carbinol|800 mg pill taken daily
219732128|NCT00033345|OTHER|Placebo|Placebo pill taken daily during run-in period
219732129|NCT00670384|BIOLOGICAL|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
219158756|NCT06094426|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
219732130|NCT00670384|BIOLOGICAL|Placebo|Sublingual drops
219732131|NCT01026038|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
219732132|NCT05587153|OTHER|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
219732133|NCT03360669|OTHER|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
219158757|NCT01643070|DRUG|Capecitabine, Oxaliplatin|Induction chemotherapy - Induction XELOX (Capecitabine 1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - XELOX RT (Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.)
219158758|NCT01643070|RADIATION|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
219158759|NCT04389372|BEHAVIORAL|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
219158760|NCT06113666|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
219158761|NCT06113666|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
219158762|NCT05885529|OTHER|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
219158763|NCT04804358|BEHAVIORAL|Exposition Test|"During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system."
219158764|NCT03738553|DEVICE|MRI|Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI
219158765|NCT03738553|DRUG|Trastuzumab|Single dose of Trastuzumab prior to surgery
219732134|NCT03360669|OTHER|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
219732135|NCT03601052|DRUG|Remlarsen|Intradermal injection at site of one excisional wound
219732136|NCT03601052|DRUG|Placebo|Intradermal injection at site of second excisional wound
219732137|NCT01402466|BEHAVIORAL|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
219732138|NCT01402466|BEHAVIORAL|Project Bridge|Arm 2
219732139|NCT00837330|DRUG|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
219732140|NCT05122819|PROCEDURE|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
219158766|NCT06780254|DRUG|MH-001|capsules
219158767|NCT06780254|DRUG|Placebo|capsules
219158768|NCT02702869|PROCEDURE|cleft lip repair|
219158769|NCT02702869|PROCEDURE|cleft palate repair|
219158770|NCT02702869|PROCEDURE|oronasal fistula repair|
219158771|NCT02702869|PROCEDURE|pharyngoplasty|
219158772|NCT02702869|PROCEDURE|gingivoperiosteoplasty|
219158773|NCT02702869|PROCEDURE|LeFort-1 maxillary repositioning|
219158774|NCT02702869|PROCEDURE|rhinoplasty|
219158775|NCT02702869|PROCEDURE|myringotomy and tympanostomy tube placement|
219158776|NCT02702869|OTHER|speech therapy|
219158777|NCT02702869|PROCEDURE|orthodontia|
219158778|NCT02702869|PROCEDURE|presurgical orthopedics|
219158779|NCT02702869|DEVICE|sound amplification for hearing|
219158780|NCT05985902|OTHER|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
219158781|NCT05985902|OTHER|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
219234666|NCT03745170|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
219234667|NCT03745170|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
219234668|NCT03745170|DRUG|placebo|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
219732141|NCT02509702|BEHAVIORAL|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
219158782|NCT06536192|OTHER|Model group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam."
219158783|NCT04278586|BEHAVIORAL|Live-Online M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
219158784|NCT04278586|BEHAVIORAL|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
219158785|NCT05403723|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
219158786|NCT05403723|DRUG|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
219158787|NCT05403723|DRUG|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
219234669|NCT04345068|BEHAVIORAL|Calm Meditation Mobile App|The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
219234670|NCT04345068|BEHAVIORAL|Health Education Podcast Mobile App|The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
219158788|NCT05403723|DRUG|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
219234671|NCT06445244|DIETARY_SUPPLEMENT|Alpha-ketoglutarate supplied as 1000mg capsule|AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
219732142|NCT03432689|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
219732143|NCT03432689|DRUG|Cycloserine|Cycloserine 100mg
219732144|NCT03432689|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
219732145|NCT05873621|PROCEDURE|ICG-guided lymphadenectomy|Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
219732146|NCT04833608|DEVICE|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
219732147|NCT04833608|DEVICE|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
219732148|NCT00408915|DRUG|Continuous Subcutaneous Lisuride Infusion|
219732149|NCT03667729|BEHAVIORAL|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
219732150|NCT06547801|DIETARY_SUPPLEMENT|2'-Fucosyllactose|3 g/day of powder orally once daily
219732151|NCT06547801|DIETARY_SUPPLEMENT|Maltodextrin|3 g/day of powder orally once daily
219732152|NCT01529216|DEVICE|DIAMOND System|Electrical stimulation to the fundus
219732153|NCT01348490|DRUG|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
219732154|NCT01184118|DRUG|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
219732155|NCT04626531|OTHER|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
219732156|NCT04626531|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
219732157|NCT00073047|DRUG|Daclizumab|
219732158|NCT00711204|DRUG|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
219732159|NCT03816826|OTHER|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
219158789|NCT05403723|DEVICE|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
219158790|NCT05231655|DIAGNOSTIC_TEST|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
219158791|NCT06397547|OTHER|Flipped Learning|Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
219158792|NCT00263718|DRUG|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
219158793|NCT05676645|DRUG|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
219732160|NCT01300065|DEVICE|Experimental- Soflens|A new pair of lenses will be worn each day while the subject is in the study
219732161|NCT01300065|DEVICE|Marketed - Soflens|A new pair of lenses will be worn each day while the subject is in the study.
219732162|NCT00307255|DRUG|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
219732163|NCT00307255|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
219158794|NCT05540535|OTHER|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
219158795|NCT05540535|OTHER|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
219732164|NCT03853200|DRUG|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
219732165|NCT03853200|DRUG|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
219732166|NCT03853200|OTHER|EDTA|17% EDTA irrigation solution
219732167|NCT00686218|DRUG|imatinib mesylate|Given orally
219732168|NCT00686218|DRUG|panobinostat|Given orally
219732169|NCT00686218|GENETIC|polymerase chain reaction|Testing
219732170|NCT00686218|GENETIC|protein expression analysis|Testing
219732171|NCT00686218|GENETIC|western blotting|Testing
219732172|NCT00686218|OTHER|flow cytometry|Testing
219732173|NCT00686218|OTHER|laboratory biomarker analysis|Testing
219732174|NCT00686218|OTHER|pharmacological study|Testing
219732175|NCT03389750|DRUG|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
219732176|NCT01117350|DRUG|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
219732177|NCT01117350|DRUG|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
219732178|NCT01117350|DRUG|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
219732179|NCT06541028|BEHAVIORAL|Rapid-Start ART (RS-ART)|ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
219732180|NCT04902144|OTHER|Electronic Health Record Review|Medical data collected
219732181|NCT04902144|OTHER|Questionnaire Administration|Complete questionnaires
219732182|NCT04902144|BEHAVIORAL|Behavioral Intervention|Receive coaching
219732183|NCT03106805|PROCEDURE|early insertion|insertion at 4th postpartum week
219732184|NCT03106805|PROCEDURE|late insertion|insertion at 6th postpartum week
219732185|NCT02129556|DRUG|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
219732186|NCT01049828|OTHER|No intervention|No treatment for tinnitus will occur in this study.
219732187|NCT06165965|DRUG|SGLT2 inhibitor|SGLT2 dual inhibitor
219732188|NCT01006408|PROCEDURE|Low Level Laser|Low Level Laser twice a week for 8 weeks
219732189|NCT01006408|PROCEDURE|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
219732190|NCT02958670|OTHER|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
219732191|NCT02211157|DRUG|BIBR 796 BS|
219732192|NCT02211157|DRUG|Placebo|
219732193|NCT02211157|OTHER|high fat breakfast|
219732194|NCT04102982|DRUG|Camrelizumab|Patients will be treated with camrelizumab alone.
219732195|NCT04102982|OTHER|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
219732196|NCT05228340|PROCEDURE|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
219158796|NCT04301726|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
219158797|NCT04301726|DRUG|Placebo oral tablet|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
219158798|NCT03089125|BEHAVIORAL|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness"
219158799|NCT03089125|OTHER|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
219158800|NCT05994209|DEVICE|quitSTART Mobile Application|Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
219158801|NCT05994209|BEHAVIORAL|Chatbot Feature in quitSTART Mobile Application|In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
219158802|NCT06472609|BEHAVIORAL|enhanced interactive education|The present study is a prospective randomized open-label study. Patients with diabetes mellitus who have HbA1c% more than 9% during the recent 1 year are enrolled. The intervention group receives, besides routine medical control of diabetes,enhanced interactive education program through weekly phone call for 12 weeks.
219158803|NCT05351281|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
219158804|NCT05587530|BEHAVIORAL|Treatment engagement and retention intervention for suicidal clients|The manualized behavioral intervention for treatment engagement and retention of suicidal clients will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1). In addition to factors identified by stakeholders, if deemed feasible and acceptable during phase 1, the intervention will include structured phone outreach, shared decision-making, and peer support.
219158805|NCT05306080|DRUG|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
219158806|NCT06226220|PROCEDURE|Sacral neuromodulation|Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
219158807|NCT06402942|OTHER|Gamified occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
219234672|NCT06445244|BEHAVIORAL|Behavioral: Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
219234673|NCT03738384|DEVICE|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
219732197|NCT02608606|DRUG|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
219732198|NCT05028088|DRUG|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
219732199|NCT02452658|OTHER|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
219732200|NCT05944510|DRUG|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
219732201|NCT05944510|DRUG|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
219732202|NCT00954135|DRUG|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
219732203|NCT00954135|DRUG|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
219158808|NCT06402942|OTHER|Classic occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
219158809|NCT06389188|PROCEDURE|RHB Group|The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
219158810|NCT04605198|BEHAVIORAL|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.
219158811|NCT04605198|BEHAVIORAL|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
219158812|NCT06131541|PROCEDURE|autogenous tooth graft|undemineralized autogenous tooth graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
219158813|NCT06131541|PROCEDURE|autogenous bone graft|autogenous bone graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
219158814|NCT04038957|DRUG|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
219158815|NCT00319267|DRUG|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
219158816|NCT06748716|DEVICE|Blue-blocking glasses|The investigators hypothesize that blue-blocking glasses (intervention) is more effective than placebo.
219158817|NCT06748716|DEVICE|Clear glasses|Clear-lensed glasses are placebo
219158818|NCT03591770|BIOLOGICAL|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
219158819|NCT05777902|DRUG|Ozanimod Oral Capsule|We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
219158820|NCT03859830|DEVICE|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
219158821|NCT03859830|DEVICE|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
219158822|NCT05091957|OTHER|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
219158823|NCT05091957|OTHER|Usual Care|Participants in both groups will receive a written summary of available resources
219732204|NCT06257121|DEVICE|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
219732205|NCT04039438|OTHER|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
219732206|NCT00574353|RADIATION|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
219732207|NCT05587751|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test to measure lung function
219732208|NCT05587751|DIAGNOSTIC_TEST|Plethysmography|Pulmonary function test to measure lung volume
219732209|NCT05720975|DEVICE|iNstroke|Patients to undergo thromboaspiration with iNstroke.
219732210|NCT00334399|DRUG|Miglitol|
219732211|NCT02946996|DRUG|Metformin|
219732212|NCT02946996|OTHER|OPC|OPC is a derivative of grape seed extract
219732213|NCT06181851|OTHER|Analysis of microbiome and metabolomics|Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
219732214|NCT02898506|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
219732215|NCT02898506|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
219732216|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
219732217|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
219732218|NCT07000513|BEHAVIORAL|ITEST-LAI|The ITEST-LAI intervention includes male peer-led HIVST distribution and promotion, linkage to male-friendly clinics for confirmatory testing and follow-up care, peer support and technical assistance to address implementation challenges, and continuous monitoring and feedback for male peer educators and research facilitators (MPERFs).
219732219|NCT01887392|OTHER|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
219732220|NCT06726239|OTHER|Progressive relaxation exercises|The aim of relaxation exercises is to help individuals recognize the difference between tension and relaxation and to enable them to relax in situations of stress. These exercises are performed with light background music and verbal instructions, allowing patients to mentally focus on the process. The progressive relaxation technique involves the voluntary contraction and subsequent relaxation of muscle groups, typically starting from the hands and progressing to the feet, with each muscle group activated in sequence. During the exercise, the instructions and steps from the 'Relaxation Exercises' CD published by the Turkish Psychologists Association will be followed.
219732221|NCT02600793|DRUG|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
219732222|NCT07045350|PROCEDURE|Platelet-rich fibrin (PRF)|Application of autologous platelet-rich fibrin (PRF) prepared from peripheral blood with or without the addition of 4 mg dexamethasone directly into the blood collection tube prior to centrifugation. PRF was applied into the extraction socket after impacted mandibular third molar surgery. The test group received PRF prepared from blood enriched with dexamethasone, while the control group received standard PRF without dexamethasone, to evaluate postoperative pain, edema, and trismus.
219732223|NCT07046455|DRUG|Sacituzumab Govitecan (SG)|After enrollment, before subjects receive TROP-2 ADC treatment, after 2 cycles of treatment, and at the time of progression, in these three phases, subjects will undergo 89Zr-DFO-hSR7 and 18F-FDG examinations once respectively (subjects will first undergo the 18F-FDG examination, and then the 89Zr-DFO-hSR7 examination within 1 week).
219732224|NCT07045961|OTHER|Supervised Station-Based Strength Circuit Training & Self-directed aerobic training|"Anaerobic training sessions follow a circuit design alternating upper body, lower body, and core exercises with dumbbells, barbells, and kettlebells. Participants complete 3 sets of 10-15 repetitions per exercise, performed consecutively without rest, at 60-80% of their one-repetition maximum (1RM). Two participants perform the same exercise simultaneously at each station. Load progression is applied by increasing resistance by 10% after successfully completing 3 sets of 12 repetitions across two consecutive sessions.~Sessions begin with a 5-minute warm-up at 50-65% of maximal heart rate (HRmax), followed by nine resistance exercises: kettlebell squats, static plank, bench press, weighted lunges, quadruped superman, seated row, weighted glute bridge, leg raises, and shoulder press. Exercises alternate muscle groups to optimize recovery.~Additionally, participants engage in self-selected aerobic exercise (walking, running, rowing, swimming, or stationary cycling) twice weekly at 65-80"
219732225|NCT07045961|OTHER|Music Medicine|During the warm-up phase, participants will engage in individual passive music listening, tailored to their personal musical preferences. The music will be delivered via MP3 players or smartphones, where a personalized playlist containing the participant's favorite tracks has been preloaded. Subsequently, during the circuit training session, a group background music playlist will be played through speakers. This heterogeneous playlist is compiled based on the collective musical preferences of all participants. Finally, during the cool-down phase, a common background music selection will be used, featuring a different repertoire from earlier phases. The cool-down will include guided muscle relaxation and breathing exercises assisted by the background music.
219158824|NCT01998984|DRUG|ingenol mebutate|
219158825|NCT01998984|OTHER|Placebo|
219158826|NCT06306027|BEHAVIORAL|Web-based education|The patient discharged after knee arthroplasty surgery will attend a follow-up appointment 15 days later, and during this visit, they will be granted permission to resume work. The patient will receive detailed information about accessing, entering, and using the web-based training. Scales with pre-test data will be completed by the patient. They will be encouraged to log in at least twice a week, and the patient will be monitored for a total of 1 month (4 weeks). After one month, the patient will be asked to fill out the scales again.
219158827|NCT05649982|BEHAVIORAL|ALVA|Behavioural digital self-help intervention
219158828|NCT06103825|DRUG|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
219158829|NCT06103825|DRUG|Placebo|Placebo :QD，PO，Day 1-Day 84
219158830|NCT05939427|OTHER|NGAGE tool|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
219158831|NCT04122456|RADIATION|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
219158832|NCT04122456|OTHER|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
219158833|NCT04354337|BEHAVIORAL|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
219158834|NCT04009005|BEHAVIORAL|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
219158835|NCT06239155|DRUG|AST-3424|liquid formulation for Intravenous infusion
219158836|NCT05085990|BIOLOGICAL|TARA-002|Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
219158837|NCT03784924|DIAGNOSTIC_TEST|MRI prostate|MRI and laboratory biomarkers
219158838|NCT04925375|DRUG|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
219158839|NCT04925375|OTHER|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
219158840|NCT06282172|DEVICE|Treatment with BTL-785-7|Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
219158841|NCT03532880|DRUG|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219158842|NCT03532880|DRUG|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219158843|NCT03532880|DRUG|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219158844|NCT03532880|DRUG|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219158845|NCT03532880|DRUG|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219158846|NCT03532880|DRUG|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
219732226|NCT07045129|OTHER|Cold water immersion|10 sessions of 15-minute Cold water bath (12°C) after the 10 first physiotherapy sessions.
219234674|NCT05746234|BEHAVIORAL|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
219732227|NCT07045129|OTHER|Hot water immersion|10 sessions of 30 to 45-minute hot water bath (12°C) after the 10 first physiotherapy sessions.
219732228|NCT07045129|OTHER|Physiotherapy only|Control group. Patients of this group will follow the classic rehabilitation treatment proposed by the physiotherapist and physician of Aspetar without thermal intervention.
219158847|NCT03532880|RADIATION|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
219158848|NCT01843374|DRUG|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
219158849|NCT01843374|DRUG|Placebo|Placebo is to be administered as an IV solution, followed by observation.
219158850|NCT06582212|DEVICE|Mymovesmatter mobile application|Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
219158851|NCT03397108|OTHER|The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use|This observational study enrolled women with IBD, and some of them were receiving a treatment with anti-TNF monoclonal antibody, which was prescribed by their responsible prescribers at a standard dose and dosing interval.
219158852|NCT02097758|DEVICE|Transcatheter device closure|"Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size"
219158853|NCT05231421|BEHAVIORAL|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
219158854|NCT04649008|DIAGNOSTIC_TEST|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
219158855|NCT04649008|DIAGNOSTIC_TEST|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
219158856|NCT04649008|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
219158857|NCT06007495|DEVICE|Investigational full-face mask with expiratory washout|With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation
219158858|NCT06007495|DEVICE|Conventional full-face mask - single-limb|With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation
219158859|NCT06007495|DEVICE|Conventional full-face mask - dual-limb|With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
219158860|NCT06031649|DEVICE|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
219158861|NCT06815042|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP) Injection|Participants will receive autologous PRP injections prepared from their own blood to treat elbow tendinopathy. PRP is a plasma product with a 3-5 times higher platelet concentration than normal blood, containing growth factors such as TGF-β, PDGF, IGF, and EGF, which are known to promote tissue repair and regeneration. The PRP will be injected directly into the affected tendon area to evaluate its clinical effectiveness and the relationship between platelet concentration, growth factors, and treatment outcomes.
219234675|NCT02429115|OTHER|Mentoring|Six months of peer-mentoring.
219234676|NCT03158415|BEHAVIORAL|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
219732229|NCT07044921|DRUG|Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl|"Irinotecan Liposomes (II) injection：Intravenous infusion, 60 mg/m2, Day 1, Q2W. The recommended initial dosage of irinotecan liposomes (II) for patients with the UGT1A1 \* 28/\* 6 homozygous mutation is 47.1 mg/m2.~Cetuximab injection：Intravenous infusion, 500 mg/m2, Day 1, Q2W. Bevacizumabl: Intravenous infusion, 5mg/kg, Day 1, Q2W."
219732230|NCT06734026|BEHAVIORAL|Cafe Therapy|Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher. Participants will complete at least 18 sessions of training within the time frame. Participants will run the Café with supervision from a researcher, serving customers prepackaged food and drinks per our protocol, along with guidance and direction from a therapist, once a week. Participants will be responsible for interacting with customers and arranging supplies. On a weekly basis, participants will be asked how they feel (for example tired, stressed, overwhelmed, etc) before and after their session and to rate how well they performed in the café.
219732231|NCT07045324|DEVICE|Vagus Nerve Stimulation (nVNS)|Arm 1 (Vagus Nerve Stimulation (nVNS)) is an experimental intervention, as it tests a novel approach (non-invasive vagus nerve stimulation) for trigger point treatment.
219732232|NCT07045324|PROCEDURE|Ischemic Compression|Arm 2 (Ischemic Compression) is an active comparator, as it uses a standard treatment (trigger point massage) commonly applied for myofascial pain.
219732233|NCT07045324|BEHAVIORAL|Exercise (Control)|Arm 3 (Exercise (Control)) is explicitly labeled as the control group in your document, using a standard exercise program, which aligns with an active comparator (since it's an active intervention rather than a placebo or no intervention).
219732234|NCT06727227|DRUG|trastuzumab deruxtecan|T-DXd
219732235|NCT07046247|PROCEDURE|Microvascular decompression for trigeminal neuralgia|Microvascular decompression for trigeminal neuralgia comparing two different forms to apply the Teflon implant
219732236|NCT07045597|DRUG|intranasal normal saline for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal normal saline equivalent volume who take midazolam intranasal by dose 1 ml saline by insulin syringe as a control group
219732237|NCT07045597|DRUG|intranasal midazolam for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal midazolam by dose 0.2 mg/kg
219732238|NCT07055750|DIAGNOSTIC_TEST|Knee Pain With High-Impact Workouts|Individuals who have been attending the gym regularly for at least 3 months having knee pain will be assessed With High-Impact Workouts
219158862|NCT06814600|DIAGNOSTIC_TEST|Transient elastometry|"Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) will be measured by transient liver elastometry Fibroscan to evaluate hepatic steatosis and fibrosis in all patients at baseline. Absence of steatosis S0 is defined as CAP \<248 dB/m, mild steatosis S1 with CAP \< 268 dB/m, and moderate to severe steatosis ≥ S2 is defined as CAP \>280 dB/m. Liver fibrosis will be evaluated using the liver stiffness measurement (LSM) in kPa7."
219158863|NCT06581419|DRUG|IAP0971|Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.
219158864|NCT02574728|DRUG|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
219158865|NCT02574728|DRUG|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
219158866|NCT02574728|DRUG|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
219158867|NCT02574728|DRUG|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
219158868|NCT06434701|DIAGNOSTIC_TEST|Nasopharyngeal swab sampling for COVID-19|The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
219158869|NCT04997096|OTHER|Exercise|16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
219158870|NCT04997096|OTHER|Attention Control|Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
219158871|NCT06109038|OTHER|Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions)."
219158872|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).
219158873|NCT06785922|PROCEDURE|Stomach biopsy for gastric microbiota|Stomach biopsy for gastric microbiota testing (16S RNA sequencing)
219158874|NCT02204085|DRUG|GO-203-2c|
219158875|NCT02204085|DRUG|GO-203-2c + Decitabine|
219732239|NCT07055581|DRUG|Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance|"Drug: Durvalumab~Induction Phase: Durvalumab (1500mg D1 IV Q3W) combined with EP \[cisplatin or alternatively Carboplatin (AUC 5-6 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks\] for minimum two cycles prior to thoracic radiotherapy Consolidation Phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities or for a maximum of 24 months, whichever occurs first.~Drug: Chemotherapy Concomitant chemoradiotherapy consists of further four cycles Etoposide (100 mg/m² D1-3), cisplatin (75 mg/m² D1) /carboplatin (AUC 5-6 D1) q3w~Radiation: Thoracic Radiotherapy Radiotherapy to the primary tumor is recommended to start with the 3rd cycle of EP, which can be delayed appropriately per investigator's decision. 60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) or other biologically equivalent regimens will be delivered."
219732240|NCT07056738|DIAGNOSTIC_TEST|imaging|OCT, OCTA, RNFL-OCT, fundus autofluorescence, fundus imaging, flaremeter, fundus and slit lamp examination
219732241|NCT06734754|DEVICE|fetal heart sound listening|The pregnant women in the experimental group and their partners listened to fetal heart sounds for 7 days. After obtaining pre-test data from the participants in the intervention group, the midwifery intervention to be implemented was explained. A fetal heart rate monitoring device, which will be given to couples to listen to the fetal heart sound before sleep, was introduced. They were told that they had to listen to the fetal heart sound at least 7 times using this device. A supporting application was downloaded to the pregnant woman's phone for the installation of the fetal heart rate monitoring device. The way of using the application and the operation steps were introduced. It was explained to the couples that the application can detect the baby's heartbeat within seconds thanks to its smart search technology, and also provides step-by-step guidance by giving live feedback.
219732242|NCT00757900|BIOLOGICAL|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
219732243|NCT04826731|OTHER|Incentive Spirometer/Respiratory Exerciser|"A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device."
219732244|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
219732245|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
219732246|NCT06134700|PROCEDURE|Laparoscopic Surgery|"* Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision"
219732247|NCT04077359|DIAGNOSTIC_TEST|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
219158876|NCT04200729|DRUG|Irrigation with PVI|The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
219158877|NCT04200729|PROCEDURE|Usual care|The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (\> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
219158878|NCT06241703|PROCEDURE|ICCAUT|For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
219158879|NCT06241703|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
219732248|NCT00448032|DRUG|PPM-204|
219732249|NCT00696150|PROCEDURE|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
219732250|NCT00696150|PROCEDURE|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
219732251|NCT00696150|PROCEDURE|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
219732252|NCT06271980|OTHER|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
219732253|NCT06211790|DRUG|Anlotinib, Everolimus and Tislelizumab|Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
219732254|NCT06903130|DIAGNOSTIC_TEST|Blood samples for sNfL and sGFAP levels|Blood samples for sNfL and sGFAP levels
219732255|NCT06926842|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly subcutaneously.
219732256|NCT06926842|OTHER|Placebo|Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
219732257|NCT05892718|DRUG|HCB101|HCB101 administered via. intravenous (IV) infusion.
219732258|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
219732259|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
219732260|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
219732261|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
219732262|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
219732263|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
219732264|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
219732265|NCT06097273|BIOLOGICAL|mRNA-1083|Suspension for injection
219732266|NCT06097273|BIOLOGICAL|Placebo|0.9% sodium chloride suspension for injection
219732267|NCT06097273|BIOLOGICAL|Influenza Vaccine|Commercially available formulation (Suspension for injection \[pre-filled syringe\])
219732268|NCT06097273|BIOLOGICAL|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
219732269|NCT03020082|DRUG|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
219732270|NCT03020082|DRUG|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
219732271|NCT03020082|DRUG|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
219732272|NCT03020082|DRUG|RBV|RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
219732273|NCT06470828|DRUG|TAK-861|Oral tablet.
219732274|NCT06470828|DRUG|Placebo|TAK-861-matching placebo tablet.
219732275|NCT04740424|DRUG|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
219732276|NCT00551356|DRUG|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
219234677|NCT02762201|PROCEDURE|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
219234678|NCT02762201|PROCEDURE|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
219158880|NCT06391931|DRUG|Cipepofol|0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
219158881|NCT06391931|DRUG|Propofol|3.0 mg/kg induce + 5.0 mg/kg/h maintain
219158882|NCT06295289|DEVICE|Hybrid Closed-loop Insulin Delivery System|The Hybrid Closed-loop Insulin Delivery System system consisted of a Medtronic pump, a continuous glucose monitoring system（SIBIONICS®）and an open-source algorithm integrated into the phone. Insulin pump therapy group consisted of a Medtronic pump, and a continuous glucose monitoring system（SIBIONICS®). The difference between the two groups is that the artificial pancreas system automatically regulates the basal rate to maintain blood glucose in a target range.
219158883|NCT06295289|DEVICE|Insulin pump|Participants used conventional insulin pumps to control blood glucose, At the same time, a continuous glucose monitoring system was used to monitor glucose changes. Health care providers adjust the insulin dose of patients according to their blood glucose level.
219158884|NCT03734393|OTHER|HIVD+/R+|Liver from an HIV-infected deceased donor
219158885|NCT00280228|BEHAVIORAL|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
219158886|NCT00280228|BEHAVIORAL|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
219234679|NCT01503970|DEVICE|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
219234680|NCT00726505|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
219234681|NCT04452383|DRUG|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
219158887|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
219234682|NCT04452383|DRUG|propofol|effect of IV propofol alone for patients undergoing DISE surgery
219234683|NCT02508441|DRUG|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
219234684|NCT02372318|DRUG|Nalmefene|18mg of Nalmefen will be administered orally
219234685|NCT02372318|DRUG|Placebo|Placebo tablet
219234686|NCT01590134|DIETARY_SUPPLEMENT|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
219732277|NCT00551356|DRUG|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
219732278|NCT03181009|DRUG|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
219732279|NCT03181009|DRUG|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
219732280|NCT06936501|DIETARY_SUPPLEMENT|Traditional flavor ONS (vanilla or strawberry, by choice)|Receives a traditional flavor ONS (vanilla or strawberry, by choice) on days 1 and 2, then switches to a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 3 and 4.
219732281|NCT06936501|DIETARY_SUPPLEMENT|Refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice)|Receives a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 1 and 2, then switches to a traditional flavor ONS (vanilla or strawberry, by choice) on days 3 and 4.
219732282|NCT01355367|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
219732283|NCT06214481|DRUG|Rocatinlimab|Administered SC.
219732284|NCT05664815|BIOLOGICAL|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
219732285|NCT05664815|OTHER|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~* Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~* For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~* Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
219732286|NCT00773110|DRUG|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
219732287|NCT00773110|DRUG|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
219732288|NCT01932424|DEVICE|Pelorus 1500|a bedside blood propofol measurement device
219732289|NCT01932424|DRUG|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
219732290|NCT02323581|DEVICE|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
219732291|NCT02323581|DEVICE|Endovascular treatment of Aortic Arch Aneurysms|"An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively."
219732292|NCT05272774|BEHAVIORAL|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
219732293|NCT06695676|DIAGNOSTIC_TEST|Global Longitudinal Strain|Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
219732294|NCT02883933|OTHER|Data collection|
219732295|NCT06694350|DRUG|Pembrolizumab+Flutamide|Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
219158888|NCT03624972|BEHAVIORAL|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
219158889|NCT03624972|BEHAVIORAL|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
219158890|NCT03456076|DRUG|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
219158891|NCT03456076|DRUG|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
219234687|NCT01590134|DRUG|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
219234688|NCT05371899|DRUG|Chiauranib|Take Chiauranib 50mg orally once daily
219234689|NCT01331408|DEVICE|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
219158892|NCT03456076|DRUG|Vinorelbine|Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
219158893|NCT03456076|DRUG|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
219158894|NCT03456076|DRUG|Pemetrexed|"Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
219158895|NCT03456076|DRUG|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
219234690|NCT01650051|DRUG|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
219158896|NCT06491017|DEVICE|MI-E Intervention protocol|"The endotracheal tube cuff will be inflated to 40 cmH2O and MI-E device will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set.~Before initiation of the MI-E intervention protocol, the investigators will carry out a short-period test to find the appropriate MI-E settings to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min. Concretely, inspiratory and expiratory time will always be set at 4 seconds and 2 seconds, respectively, and inspiratory flow will always be in slow mode. Once the appropriate inspiratory pressure will be found, the expiratory pressure will be initially set to exceed in 30 cmH2O the inspiratory pressure and, if required, this will be increased by 5 cmH2O until achieving a PEF ≥80 L/min with a maximum expiratory pressure of 70 cmH2O."
219732296|NCT03514693|PROCEDURE|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
219732297|NCT03514693|PROCEDURE|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
219732298|NCT00138242|DRUG|carboplatin|
219732299|NCT00138242|DRUG|docetaxel|
219732300|NCT00138242|PROCEDURE|adjuvant therapy|
219732301|NCT05212935|BIOLOGICAL|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
219732302|NCT04594603|OTHER|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
219732303|NCT01872208|BIOLOGICAL|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
219732304|NCT04082442|DRUG|Evolocumab|420 mg evolocumab.
219732305|NCT04082442|DRUG|Placebos|Matching placebo.
219732306|NCT06582641|BEHAVIORAL|Peer Group Connection - Middle School (PGC-MS)|Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
219732307|NCT06027892|RADIATION|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
219732308|NCT06027892|RADIATION|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
219732309|NCT05761483|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
219732310|NCT02605538|BIOLOGICAL|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
219732311|NCT03076164|DRUG|Trametinib|Trametinib 1.5mg once daily by mouth
219732312|NCT03076164|DRUG|Erlotinib|Erlotinib 75mg once daily by mouth
219234691|NCT01650051|DRUG|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
219234692|NCT01450397|BIOLOGICAL|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
219234693|NCT04806906|DRUG|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
219732313|NCT00226044|DRUG|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
219732314|NCT06222047|OTHER|breast milk|give breast milk before the OG catheter insertion
219732315|NCT06222047|OTHER|dextrose|give %20 dextrose before the OG catheter insertion
219732316|NCT02676622|DRUG|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
219732317|NCT02676622|OTHER|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
219732318|NCT02676622|DRUG|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
219732319|NCT02676622|OTHER|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
219732320|NCT02676622|DRUG|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
219732321|NCT01622335|DRUG|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
219732322|NCT01622335|OTHER|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
219732323|NCT02015936|BEHAVIORAL|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
219732324|NCT02015936|OTHER|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
219732325|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Tobramycin Sulfate|Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
219732326|NCT04662632|DRUG|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
219732327|NCT04662632|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
219732328|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Vancomycin Hydrochloride|Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
219732329|NCT01902303|DRUG|Matching Placebo|Sublingual micro dosing of placebo for 7 days
219732330|NCT01902303|DRUG|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
219732331|NCT03274349|PROCEDURE|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
219732332|NCT03274349|PROCEDURE|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
219732333|NCT04634903|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
219158897|NCT06491017|DEVICE|Standard MI-E setting|"Cough Assist E70 device (Philips Respironics, USA, Andover, Massachusetts) will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set. During the 1-minute pause between sets, the patient will be reconnected to the ventilator to avoid desaturation and de-recruitment during procedures. PEEP will remain stable during the protocol.~The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause."
219158898|NCT06476197|DEVICE|SAT-003|Device: SAT-003(Software) Using SAT-003 for 12 weeks
219158899|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
219158900|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
219158901|NCT05698758|DRUG|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
219732334|NCT04634903|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
219732335|NCT04634903|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
219732336|NCT02821000|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219732337|NCT00875407|OTHER|Scintigraphy in 123I-IBZM|
219732338|NCT05673655|DRUG|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
219732339|NCT05673655|DRUG|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
219732340|NCT05376553|DRUG|Cemiplimab|350mg intravenous infusion over 30 minutes
219732341|NCT05376553|DRUG|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
219732342|NCT05376553|DRUG|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
219732343|NCT02347956|PROCEDURE|Reduced port robotic distal gastrectomy|
219732344|NCT04162314|DRUG|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
219732345|NCT04162314|DRUG|Placebos|Placebos
219158902|NCT03517917|OTHER|Tumour tissue collection|Collection of tumour tissue and blood
219158903|NCT05660603|OTHER|control|patients will receive standard general anesthesia
219158904|NCT05660603|PROCEDURE|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
219158905|NCT05660603|PROCEDURE|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
219158906|NCT05660603|DEVICE|Ultrasound|ultrasound
219732346|NCT00394472|DRUG|AZD3355|
219732347|NCT04457778|DRUG|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
219732348|NCT04457778|DRUG|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
219234694|NCT04106739|DEVICE|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
219732349|NCT04457778|DRUG|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
219158907|NCT03576521|COMBINATION_PRODUCT|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
219158908|NCT03576521|COMBINATION_PRODUCT|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
219158909|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
219234695|NCT04549688|PROCEDURE|high-intensity focused ultrasound, HIFU|see above
219234696|NCT04364399|BIOLOGICAL|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
219234697|NCT04364399|BIOLOGICAL|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
219234698|NCT00912964|DRUG|Mirabegron|Mirabegron tablets
219234699|NCT00912964|DRUG|Placebo|Matching mirabegron placebo tablets.
219234700|NCT06239532|DRUG|HAIC+TAE|Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
219234701|NCT06239532|DRUG|Tislelizumab|Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
219234702|NCT06239532|DRUG|Surufatinib|Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
219234703|NCT05398289|DRUG|4-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
219234704|NCT05398289|DRUG|6-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
219234705|NCT02724501|BEHAVIORAL|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
219234706|NCT02724501|PROCEDURE|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
219732350|NCT03112369|BEHAVIORAL|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
219158910|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
219158911|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
219158912|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
219234707|NCT04405310|BIOLOGICAL|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
219234708|NCT04405310|OTHER|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
219234709|NCT05461053|DRUG|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
219234710|NCT01932203|DRUG|aspirin|100mg once a day
219234711|NCT01932203|DRUG|cilostazol|200mg once a day
219732351|NCT03112369|BEHAVIORAL|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
219732352|NCT04570280|OTHER|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
219732353|NCT04570280|OTHER|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
219158913|NCT06088589|BEHAVIORAL|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
219158914|NCT04433078|DRUG|Doxycycline|100 MG Tablet
219158915|NCT04433078|DRUG|Placebo|Placebo Tablet
219158916|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
219158917|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
219158918|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
219158919|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
219158920|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
219158921|NCT03090763|GENETIC|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
219158922|NCT03990649|DRUG|Soticlestat|Soticlestat tablets
219158923|NCT03990649|DRUG|Placebo|Soticlestat matching placebo tablets
219158924|NCT01296646|DRUG|Naltrexone|50 mg oral naltrexone once/day
219158925|NCT01296646|BEHAVIORAL|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
219158926|NCT01296646|DRUG|Placebo|An inactive pill to control for non-pharmacological responses.
219158927|NCT03565523|OTHER|Beetroot|Containing 385 mg nitrate
219158928|NCT03565523|OTHER|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
219158929|NCT05075694|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
219234712|NCT06455683|PROCEDURE|Glaucoma Surgery|"One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment"
219234713|NCT02738307|OTHER|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
219158930|NCT05075694|OTHER|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
219234714|NCT02978716|DRUG|Trilaciclib|G1T28
219234715|NCT02978716|DRUG|Gemcitabine|Gemcitabine
219732354|NCT04570280|OTHER|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
219732355|NCT03701178|OTHER|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
219732356|NCT04359680|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
219732357|NCT04359680|DRUG|Placebo|Placebo administered orally twice daily for six weeks
219732358|NCT04359680|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
219158931|NCT03849352|BEHAVIORAL|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
219158932|NCT01612312|PROCEDURE|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
219158933|NCT01612312|PROCEDURE|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
219158934|NCT02612844|DRUG|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
219234716|NCT02978716|DRUG|Carboplatin|Carboplatin
219732359|NCT06124677|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
219732360|NCT02245893|PROCEDURE|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
219732361|NCT00893581|DRUG|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
219732362|NCT00893581|DRUG|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
219732363|NCT00893581|OTHER|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
219732364|NCT00832962|GENETIC|Genotyping|Whole blood sample
219732365|NCT00832962|OTHER|Usual prophylaxis|Prophylactic anti-RhD
219732366|NCT04143438|PROCEDURE|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
219732367|NCT02319083|PROCEDURE|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
219732368|NCT04430621|DRUG|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
219732369|NCT00002316|DRUG|Lobradimil|
219732370|NCT00002316|DRUG|Amphotericin B|
219732371|NCT04129970|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
219732372|NCT02716142|DRUG|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
219732373|NCT02716142|DRUG|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
219732374|NCT00360100|DRUG|Zmax|
219732375|NCT00831896|BIOLOGICAL|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
219732376|NCT03254147|DRUG|warfarin|warfarin
219732377|NCT03254147|DRUG|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
219732378|NCT03254147|DRUG|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
219732379|NCT03254147|DRUG|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
219732380|NCT03254147|DRUG|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
219732381|NCT03931785|DRUG|MD-7246|Oral tablet
219732382|NCT03931785|DRUG|Placebo|Matching oral tablet
219732383|NCT01812018|DRUG|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
219732384|NCT01812018|DRUG|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
219158935|NCT02612844|DRUG|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
219158936|NCT03244449|OTHER|No apply|
219732385|NCT01812018|DRUG|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
219732386|NCT03521609|BEHAVIORAL|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
219732387|NCT02504775|DRUG|Mejoral® 500 Tablets|500 mg tablet of paracetamol
219732388|NCT02504775|DRUG|Tylenol® Caplets|500 mg tablet of paracetamol
219732389|NCT02534623|PROCEDURE|Spinal anesthesia|
219732390|NCT02534623|PROCEDURE|General anesthesia|
219158937|NCT05558423|BEHAVIORAL|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
219158938|NCT02724956|DEVICE|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
219732391|NCT02534623|DRUG|bupivacaine|
219732392|NCT02534623|DRUG|fentanyl|
219732393|NCT02534623|DRUG|propofol|
219732394|NCT02534623|DRUG|sevoflurane|
219732395|NCT05171335|DRUG|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
219732396|NCT05171335|PROCEDURE|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
219732397|NCT03142204|DRUG|[18F]F-AraG|Single dose IV injection of \[18F\]F-AraG for each imaging day.
219732398|NCT04605588|DRUG|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
219732399|NCT04605588|DRUG|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
219732400|NCT04605588|DRUG|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
219732401|NCT04605588|DRUG|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
219732402|NCT04605588|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
219732403|NCT04605588|DRUG|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
219732404|NCT01230814|DRUG|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
219732405|NCT01230814|DRUG|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
219732406|NCT02527265|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
219732407|NCT02330263|DIETARY_SUPPLEMENT|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
219732408|NCT01573728|BEHAVIORAL|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
219732409|NCT01573728|BEHAVIORAL|Public Health Exercise|At least 150 minutes at moderate intensity
219732410|NCT03816137|BIOLOGICAL|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732411|NCT03816137|BIOLOGICAL|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732412|NCT03816137|BIOLOGICAL|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
219732413|NCT03816137|BIOLOGICAL|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732414|NCT03816137|BIOLOGICAL|Mosaic SOSIPs|Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732415|NCT03816137|BIOLOGICAL|763 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732416|NCT03816137|BIOLOGICAL|AMC011 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
219732417|NCT02182453|DRUG|BI 10773 - single rising dose|
219732418|NCT02182453|DRUG|Placebo|
219732419|NCT02835521|PROCEDURE|Reception|
219732420|NCT02835521|DRUG|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
219732421|NCT04802915|PROCEDURE|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
219732422|NCT04491708|OTHER|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
219732423|NCT04512625|BIOLOGICAL|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
219732424|NCT03428269|OTHER|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
219732425|NCT03428269|OTHER|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
219732426|NCT00170755|DRUG|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
219732427|NCT04630626|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
219732428|NCT04630626|OTHER|ACDF|Historical ACDF control data
219732429|NCT01748552|DRUG|Placebo|Administered orally as capsules
219158939|NCT02724956|DEVICE|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
219158940|NCT02724956|DEVICE|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
219158941|NCT05928637|DRUG|D745, D759, D150|QD, PO for 5 days
219158942|NCT02134951|DRUG|Ketamine|intravenous infusion of saline solution with ketamine
219158943|NCT02134951|DRUG|Normal saline|Normal saline will be used for placebo in this group
219158944|NCT03807661|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
219158945|NCT03807661|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
219158946|NCT04015349|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
219158947|NCT05927896|DIAGNOSTIC_TEST|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
219234717|NCT03908775|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
219234718|NCT03908775|DEVICE|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
219732430|NCT01748552|DRUG|LY2922083|Administered orally as capsules
219732431|NCT01330524|DRUG|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
219732432|NCT01330524|OTHER|placebo|2mg placebo
219732433|NCT02738398|RADIATION|FDG PET/CT|
219732434|NCT05169957|DRUG|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
219732435|NCT05169957|DRUG|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
219732436|NCT05169957|PROCEDURE|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
219732437|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
219732438|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
219732439|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
219732440|NCT01526369|DRUG|Trastuzumab|
219732441|NCT01526369|DRUG|Paclitaxel|
219732442|NCT01526369|DRUG|Lapatinib|
219732443|NCT03723525|COMBINATION_PRODUCT|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
219158948|NCT01535690|OTHER|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
219158949|NCT02773693|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
219158950|NCT02773693|BEHAVIORAL|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
219158951|NCT02773693|BEHAVIORAL|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
219158952|NCT02005406|DEVICE|Experimental group and control groupl|JET
219158953|NCT03532165|DIAGNOSTIC_TEST|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
219234719|NCT01974102|BEHAVIORAL|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
219158954|NCT05408572|BIOLOGICAL|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
219158955|NCT04066725|DRUG|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
219234720|NCT01974102|BEHAVIORAL|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
219234721|NCT06251336|OTHER|UroialTM Plus|Nutraceutical
219732444|NCT03723525|COMBINATION_PRODUCT|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4\<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
219732445|NCT06256874|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219158956|NCT04066725|DRUG|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
219158957|NCT04066725|DRUG|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
219158958|NCT04071756|DRUG|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
219158959|NCT04071756|OTHER|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
219158960|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
219158961|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
219158962|NCT04508010|OTHER|IVR|Participants will receive an IVR survey
219158963|NCT04508010|OTHER|CATI|Participants will receive a CATI survey
219158964|NCT06302920|DEVICE|Kinesiotape|Lymphatic correction technique
219158965|NCT06107101|DRUG|Mepolizumab|100mg of mepolizumab every 4 weeks subcutaneously for 6 months
219158966|NCT02941484|PROCEDURE|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
219158967|NCT02941484|PROCEDURE|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
219158968|NCT03217240|PROCEDURE|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
219158969|NCT03217240|OTHER|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
219158970|NCT03217240|OTHER|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
219158971|NCT01522794|DRUG|NOX-H94|single i.v. infusion
219158972|NCT01522794|DRUG|Placebo solution|single i.v. infusion
219158973|NCT06464224|BEHAVIORAL|low respiratory effort|patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)
219158974|NCT06464224|BEHAVIORAL|high respiratory effort|patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
219158975|NCT02634892|DEVICE|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
219158976|NCT04667858|DEVICE|Home Ovulation Test|Visual read home ovulation test
219158977|NCT03304041|DIETARY_SUPPLEMENT|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
219158978|NCT03304041|DIETARY_SUPPLEMENT|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
219158979|NCT00324350|DRUG|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
219158980|NCT02647905|DEVICE|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
219234722|NCT06251336|OTHER|Placebo|Placebo sachet
219732446|NCT05463471|DRUG|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
219732447|NCT05463471|DRUG|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
219732448|NCT03149380|BEHAVIORAL|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
219732449|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
219234723|NCT03510052|BEHAVIORAL|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
219234724|NCT00333372|DRUG|Z-338|
219234725|NCT02295189|DRUG|Ketorolac Tromethamine|anti-inflammatory injection
219234726|NCT02295189|DRUG|Triamcinolone Acetonide|corticosteroid injection
219234727|NCT05474313|BEHAVIORAL|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
219234728|NCT05474313|BEHAVIORAL|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
219234729|NCT00054938|DRUG|pravastatin|
219234730|NCT00054938|DRUG|aspirin|
219234731|NCT00054938|DRUG|ramipril|
219732450|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
219732451|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
219732452|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
219732453|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
219732454|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
219732455|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
219732456|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
219732457|NCT05861401|GENETIC|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
219732458|NCT02596893|DRUG|GED-0301|
219732459|NCT02596893|DRUG|Placebo|
219732460|NCT01679665|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
219732461|NCT01679665|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
219732462|NCT05541471|DRUG|VX-548|Tablets for oral administration.
219234732|NCT00054938|DRUG|Vitamins: B6, B12, and folate|
219234733|NCT00054938|BEHAVIORAL|heart health educational program|
219234734|NCT01971112|DIETARY_SUPPLEMENT|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
219234735|NCT00840775|DEVICE|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
219234736|NCT02349516|DRUG|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
219234737|NCT05811273|OTHER|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
219234738|NCT05811273|OTHER|Control group|general exercises
219234739|NCT05590559|DRUG|Morphine|Opiates
219234740|NCT05590559|OTHER|Ultrasound-guided erector spinae plane block|PVB
219234741|NCT03709849|DRUG|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
219234742|NCT03709849|DRUG|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
219234743|NCT00003087|DRUG|cisplatin|
219234744|NCT00003087|DRUG|paclitaxel|
219234745|NCT00003087|PROCEDURE|surgical procedure|
219234746|NCT00003087|RADIATION|radiation therapy|
219234747|NCT02966249|DRUG|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
219234748|NCT02966249|DRUG|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
219234749|NCT02966249|DRUG|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
219234750|NCT02966249|DRUG|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
219234751|NCT02966249|DRUG|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
219234752|NCT02966249|DRUG|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
219732463|NCT05541471|DRUG|Midazolam|Syrup for oral administration.
219732464|NCT05541471|DRUG|Digoxin|Tablets for oral administration.
219732465|NCT06092957|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
219732466|NCT06092957|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
219732467|NCT06092957|RADIATION|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
219732468|NCT06092957|RADIATION|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
219158981|NCT00133250|DRUG|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
219158982|NCT00133250|OTHER|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
219158983|NCT01762475|DRUG|Sildenafil|
219158984|NCT02015520|DRUG|Clazakizumab|
219158985|NCT02015520|DRUG|Placebo (Matching with Clazakizumab)|
219158986|NCT01294956|OTHER|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
219158987|NCT01294956|OTHER|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
219158988|NCT01746641|DRUG|Remifentanil|
219158989|NCT01746641|DRUG|Propofol|
219158990|NCT02065193|BEHAVIORAL|ADOS/ADI-R/Clinical assessment|
219158991|NCT02932579|OTHER|Pharmacogenomic Testing|Saliva collection (5mL)
219158992|NCT02932579|DRUG|Ibuprofen|400 mg
219158993|NCT02932579|DRUG|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
219158994|NCT02932579|DRUG|acetominophen|650 mg
219158995|NCT02932579|DRUG|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
219158996|NCT03791008|OTHER|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
219158997|NCT04542005|BEHAVIORAL|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
219158998|NCT02846909|DRUG|Progesterone|400mg progesterone pessaries
219158999|NCT06347640|BIOLOGICAL|induced bleeding|revascularization of tooth is achieved by induced bleeding
219159000|NCT06347640|BIOLOGICAL|plasma rich fibrin|revascularization of tooth is achieved by plasma rich fibrin
219159001|NCT04174742|DRUG|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
219159002|NCT04207294|OTHER|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
219159003|NCT04207294|OTHER|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
219159004|NCT05920746|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
219159005|NCT04995718|OTHER|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
219159006|NCT02146716|OTHER|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
219159007|NCT01739907|OTHER|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
219159008|NCT01676558|DRUG|131I-rituximab|
219159009|NCT01602640|DRUG|Morphine infusion|Conventional dose
219159010|NCT01602640|DRUG|Fentanyl and Midazolam infusion|Conventional dose
219159011|NCT01515436|OTHER|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
219159012|NCT01515436|OTHER|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
219159013|NCT05901896|OTHER|there are no intervention|no intervention
219159014|NCT05177939|DRUG|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
219159015|NCT05177939|DRUG|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
219159016|NCT00764335|PROCEDURE|total hip arthroplasty one side|unilateral total hip arthroplasty
219159017|NCT00764335|PROCEDURE|total hip arthroplasty both sides|bilateral total hip arthroplasty
219159018|NCT03640195|OTHER|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
219161638|NCT02209350|PROCEDURE|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
219732469|NCT06092957|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
219732470|NCT05647382|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
219732471|NCT01727427|DRUG|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
219732472|NCT03112187|DRUG|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
219159019|NCT01499992|PROCEDURE|Standard physical therapy program PLUS aquatic physical therapy|2\. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
219732473|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
219159020|NCT01499992|OTHER|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
219732474|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
219159021|NCT02283749|BIOLOGICAL|Xofigo|This is a radio-isotope
219159022|NCT03288753|OTHER|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
219159023|NCT03288753|BEHAVIORAL|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
219159024|NCT03288753|BEHAVIORAL|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
219159025|NCT03288753|BEHAVIORAL|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
219732475|NCT01103115|DIETARY_SUPPLEMENT|Placebo|placebo tablets
219732476|NCT01324466|DRUG|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
219732477|NCT01324466|DRUG|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
219732478|NCT02759263|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
219732479|NCT03052257|BEHAVIORAL|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
219732480|NCT03052257|BEHAVIORAL|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
219732481|NCT03052257|BEHAVIORAL|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
219732482|NCT03052257|BEHAVIORAL|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
219732483|NCT04667728|DEVICE|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
219732484|NCT00038246|DRUG|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
219159026|NCT02308319|DRUG|Tenofovir disoproxil fumarate|300mg q.d. per oral
219159027|NCT01159275|DRUG|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
219159028|NCT01159275|DRUG|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
219159029|NCT02849054|DEVICE|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
219159030|NCT02849054|DEVICE|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
219159031|NCT02849054|DEVICE|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
219159032|NCT02849054|DEVICE|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
219234753|NCT02613403|DRUG|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
219234754|NCT02613403|DRUG|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
219732485|NCT00038246|DRUG|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
219732486|NCT00038246|DRUG|Paclitaxel (Taxol)|100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
219732487|NCT00004228|DRUG|asparaginase|Given IV
219732488|NCT00004228|DRUG|cyclophosphamide|Given IV
219732489|NCT00004228|DRUG|cytarabine|Given IV
219159033|NCT03775785|DIETARY_SUPPLEMENT|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
219159034|NCT03698084|PROCEDURE|venepuncture|sample collection for analysis
219159035|NCT03698084|PROCEDURE|nasopharyngeal swab|sample collection for analysis
219732490|NCT00004228|DRUG|daunorubicin hydrochloride|Given IV
219732491|NCT00004228|DRUG|dexamethasone|Given IV
219732492|NCT00004228|DRUG|doxorubicin hydrochloride|Given IV
219732493|NCT00004228|DRUG|leucovorin calcium|Given IV
219732494|NCT00004228|DRUG|mercaptopurine|Given IV
219732495|NCT00004228|DRUG|methotrexate|Given IV
219732496|NCT00004228|DRUG|prednisone|Given IV
219732497|NCT00004228|DRUG|thioguanine|Given PO
219732498|NCT00004228|DRUG|vincristine sulfate|Given IV
219732499|NCT00004228|RADIATION|radiation therapy|
219159036|NCT01095822|DRUG|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
219159037|NCT01610297|DRUG|ICL670|Oral dose of ICL670 at 10 mg/kg daily
219159038|NCT06083155|DIAGNOSTIC_TEST|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
219159039|NCT06083155|OTHER|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
219159040|NCT05412316|OTHER|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
219159041|NCT04502901|DRUG|KX0826|investigational AR antagonist
219159042|NCT04502901|OTHER|Placebo|Placebo of KX-826
219234755|NCT02280031|DRUG|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
219234756|NCT02280031|DRUG|Placebo|Capsule containing placebo pill with lactose
219732500|NCT03816917|OTHER|cutaneous parameters of psoriasis (exposure)|characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
219732501|NCT03816917|OTHER|comorbidity (exposure)|medical and medication history, current and previous comorbidity
219732502|NCT03816917|OTHER|family history (exposure)|Family history of PsC, PsA, IBD, AS, and uveitis
219732503|NCT03816917|OTHER|lifestyle (exposure)|"* Intoxications~* Lifestyle: occupation and injuries, sport and physical hobbies"
219732504|NCT03816917|OTHER|patient reported outcomes (exposure)|VAS-score on fatigue, PsC severity, joint pain and general well-being
219732505|NCT03816917|OTHER|inflammatory markers (exposure)|Measurements of inflammatory and bone remodeling markers in serum and plasma
219732506|NCT03816917|OTHER|genetic (exposure)|Assessment of known HLA- and SNP-associations with PsA or PsA
219732507|NCT01529112|DRUG|Lenvatinib|
219732508|NCT01529112|DRUG|Lenvatinib matched placebo|
219732509|NCT01529112|DRUG|BSC|
219732510|NCT00558480|DRUG|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
219732511|NCT00558480|DRUG|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
219732512|NCT03765359|DRUG|metforminhydrochloride|metformin 500 mg tablets and insulin
219732513|NCT03765359|DRUG|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
219732514|NCT03279068|OTHER|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
219732515|NCT02255279|BIOLOGICAL|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
219732516|NCT02255279|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
219732517|NCT03859856|OTHER|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
219732518|NCT04928066|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219732519|NCT04928066|DRUG|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
219732520|NCT04928066|DRUG|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
219732521|NCT03718403|DRUG|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
219732522|NCT01120444|DEVICE|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
219732523|NCT01120444|DEVICE|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
219159043|NCT02014831|DRUG|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
219159044|NCT02014831|DRUG|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
219159045|NCT00002446|DRUG|Posaconazole|
219159046|NCT00002446|DRUG|Fluconazole|
219159047|NCT01929759|DRUG|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
219159048|NCT00117026|DRUG|Placebo|Placebo for benfotiamine
219159049|NCT00117026|DRUG|Benfotiamine|300mg/day
219159050|NCT05715437|DRUG|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
219159051|NCT05715437|DRUG|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
219159052|NCT00574834|DRUG|Ramipril|Ramipril 20 mg once daily for 6 months
219159053|NCT00574834|DRUG|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
219159054|NCT00574834|DRUG|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
219159055|NCT00364117|BEHAVIORAL|Timely Discharge (Remote Presence Technology)|
219159056|NCT02121002|DRUG|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
219159057|NCT02121002|DRUG|Voltaren Topical Gel, 1%|Opaque, white gel
219159058|NCT02121002|DRUG|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
219159059|NCT03647241|DEVICE|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
219159060|NCT03647241|DEVICE|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
219159061|NCT03647241|PROCEDURE|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
219159062|NCT03128359|DRUG|Busulfan|Given IV
219159063|NCT03128359|DRUG|Cyclophosphamide|Given IV
219732524|NCT02846454|OTHER|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
219159064|NCT03128359|DRUG|Fludarabine Phosphate|Given IV
219234757|NCT05295706|BEHAVIORAL|Counterfactual Intervention|"The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate."
219732525|NCT02846454|OTHER|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
219732526|NCT00252148|BIOLOGICAL|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
219732527|NCT03607695|OTHER|Gait training|Walking on a treadmill and receiving audio cues to improve gait
219159065|NCT03128359|PROCEDURE|Hematopoietic Cell Transplantation|Undergo PBSC HCT
219159066|NCT03128359|OTHER|Laboratory Biomarker Analysis|Correlative studies
219159067|NCT03128359|DRUG|Melphalan Hydrochloride|Given IV
219159068|NCT03128359|DRUG|Mycophenolate Mofetil|Given IV or PO
219159069|NCT03128359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
219159070|NCT03128359|OTHER|Quality-of-Life Assessment|Ancillary studies
219159071|NCT03128359|DRUG|Tacrolimus|Given IV
219159072|NCT03128359|RADIATION|Total-Body Irradiation|Undergo TBI
219159073|NCT01007396|OTHER|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
219159074|NCT01408524|DRUG|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
219159075|NCT01408524|DRUG|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
219159076|NCT00937131|DRUG|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
219159077|NCT04878328|BEHAVIORAL|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
219159078|NCT04553458|DEVICE|Radiofrequency ablation|Radiofrequency ablation of the tumour
219159079|NCT04553458|DRUG|Trance-arterial chemoembolization|Trance-arterial chemotherapy
219732528|NCT06433063|DIAGNOSTIC_TEST|F-MISO PET|Evaluation of tumor hypoxia with F-MISO PET
219732529|NCT00884598|DRUG|cilengitide|
219732530|NCT00884598|OTHER|pharmacological study|
219732531|NCT00884598|RADIATION|radiation therapy|
219732532|NCT01333566|BEHAVIORAL|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
219732533|NCT01333566|BEHAVIORAL|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
219732534|NCT04627753|DRUG|Rituximab, lenalidomide|Maintenance for 2 years
219732535|NCT03268161|DIAGNOSTIC_TEST|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
219732536|NCT02741193|DEVICE|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
219732537|NCT01032343|DIETARY_SUPPLEMENT|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
219732538|NCT01032343|DIETARY_SUPPLEMENT|Gelatine|One capsule daily for 3 months
219732539|NCT01640535|DRUG|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
219732540|NCT01640535|DRUG|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
219159080|NCT04553458|PROCEDURE|Liver resection|non-anatomical or anatomical liver resection
219159081|NCT04553458|COMBINATION_PRODUCT|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
219159082|NCT04553458|DRUG|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
219159083|NCT04553458|DRUG|Systemic chemotherapy|Systemic chemotherapy
219159084|NCT04553458|DRUG|Sorafenib|Sorafenib
219159085|NCT04553458|DIETARY_SUPPLEMENT|Viscum|Viscum for HCC
219159086|NCT04553458|DRUG|Symptomatic treatment|Symptomatic treatment
219159087|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
219159088|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
219159089|NCT04290819|DIETARY_SUPPLEMENT|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
219159090|NCT04290819|DIETARY_SUPPLEMENT|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
219159091|NCT01697059|DRUG|Piperacillin + Amoxicillin|
219159092|NCT02590432|DRUG|Linaclotide|Linaclotide capsules, orally, once daily.
219159093|NCT02448576|RADIATION|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
219159094|NCT05875987|DEVICE|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219159095|NCT04172207|OTHER|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
219732541|NCT01640535|DRUG|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
219159096|NCT01291446|DIETARY_SUPPLEMENT|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
219159097|NCT00335049|DEVICE|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
219159098|NCT00335049|DEVICE|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
219159099|NCT03283371|DRUG|Natalizumab|As specified in the treatment arm.
219159100|NCT03283371|OTHER|Placebo|As specified in treatment arms.
219159101|NCT01596296|DEVICE|Transcervical foley catheter|16 French foley catheter insertion
219159102|NCT01596296|DRUG|Dinoprostone 10mg|Dinoprostone vaginal insertion
219159103|NCT04351828|PROCEDURE|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
219159104|NCT05015608|DRUG|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
219732542|NCT05017402|DRUG|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
219732543|NCT02567032|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
219732544|NCT02567032|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
219732545|NCT00036465|BEHAVIORAL|Treatment regimen change|
219732546|NCT03402581|DEVICE|c-mac laryngoscope|type of laryngoscopes
219732547|NCT06035198|OTHER|Stroke|No intervention
219732548|NCT05137145|DRUG|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
219732549|NCT05137145|DRUG|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
219732550|NCT00118859|BEHAVIORAL|Integrative care for low back pain|
219159105|NCT05015608|DRUG|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
219159106|NCT01881412|DRUG|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
219159107|NCT01881412|OTHER|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
219159108|NCT00243503|DRUG|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
219159109|NCT03048994|DIETARY_SUPPLEMENT|Glutamine|"* Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
219159110|NCT03048994|DIETARY_SUPPLEMENT|Placebo|"* Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
219159111|NCT04704323|DRUG|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
219159112|NCT01777009|PROCEDURE|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
219159113|NCT05307536|COMBINATION_PRODUCT|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
219732551|NCT00118859|BEHAVIORAL|Conventional treatment for low back pain|
219732552|NCT06500221|BEHAVIORAL|incentive spirometry|The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
219732553|NCT02502383|BEHAVIORAL|ACTION PAC|School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
219732554|NCT02502383|BEHAVIORAL|Communication with parents|A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.
219732555|NCT00366613|PROCEDURE|Cataract surgery with Perfect Capsule and Sodium Chloride|
219732556|NCT00327431|GENETIC|Cheek swab samples for DNA|
219732557|NCT02555358|DRUG|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
219732558|NCT02555358|DRUG|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
219732559|NCT03167424|DEVICE|Treatment of restenosis|Treatment of in-stent restenosis
219732560|NCT00477724|BEHAVIORAL|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
219732561|NCT00477724|OTHER|sedentary control group|control group with no specific training
219159114|NCT05307536|COMBINATION_PRODUCT|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
219159115|NCT00786513|OTHER|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
219159116|NCT00786513|OTHER|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
219159117|NCT02612142|BEHAVIORAL|physical exercise|endurance-training or stretching (sham exercise)
219159118|NCT06266845|BEHAVIORAL|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
219159119|NCT06266845|BEHAVIORAL|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
219159120|NCT06510595|OTHER|Active Treatment Arm|"Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force."
219159121|NCT06510595|OTHER|Control Treatment Arm|The child will wear a brace as a conservative treatment method.
219159122|NCT04279366|BEHAVIORAL|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
219159123|NCT02410018|DEVICE|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
219159124|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in plasma after DNAse digestion.|Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).
219159125|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in blood or plasma.|HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
219732562|NCT00363467|DRUG|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
219732563|NCT00363467|DRUG|Leukapheresis|leukapheresis
219732564|NCT00363467|DRUG|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
219732565|NCT00363467|PROCEDURE|Stem cell reinfusion|autologous stem cell transplant
219732566|NCT01137565|DRUG|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
219732567|NCT01137565|DRUG|Placebo|Placebo to AMG 853
219159126|NCT04600752|DRUG|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
219159127|NCT03076515|DEVICE|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
219159128|NCT03076515|DEVICE|Sham Nerivio Migra|electrical stimulation- shame mode
219159129|NCT00933426|DRUG|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
219159130|NCT00933426|DRUG|Paclitaxel|50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
219159131|NCT03348371|OTHER|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
219159132|NCT06067035|OTHER|Imaging|Imaging data from patients with small-vessel liver tumours will be compared with histological data.
219159133|NCT01346982|DRUG|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
219159134|NCT02301208|DRUG|Nedaplatin|Nedaplatin combine with IMRT
219159135|NCT02301208|DRUG|Cisplatin|Cisplatin combine with IMRT
219732568|NCT01899287|BEHAVIORAL|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
219732569|NCT06386549|BEHAVIORAL|tele-rehabilitation|Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
219732570|NCT00001311|DEVICE|heparin-surface modified intraocular lens|
219732571|NCT05666856|BEHAVIORAL|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
219732572|NCT05666856|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
219732573|NCT00152854|DRUG|Acetaminophen|acetaminophen 1g po qid
219159136|NCT05004558|OTHER|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
219732574|NCT00152854|DRUG|acetaminophen|acetaminophen 1g po qid for 7 days
219732575|NCT00152854|DRUG|placebo, sugar pill|
219732576|NCT04250675|DEVICE|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
219159137|NCT05989932|OTHER|Upadacitinib|Real-world on the use of Upadacitinib
219732577|NCT04250675|DEVICE|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
219732578|NCT03750084|OTHER|questionary|The intervention consists of a digitally distributed questionary.
219732579|NCT01791400|DRUG|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
219732580|NCT01791400|DRUG|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
219732581|NCT00527748|DEVICE|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
219732582|NCT05032599|BIOLOGICAL|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
219732583|NCT03410537|DRUG|Taurine|
219159138|NCT01947790|DRUG|pioglitazone group|
219159139|NCT01947790|DRUG|Metformin group|
219159140|NCT06800040|BEHAVIORAL|Memory training|Memory training
219159141|NCT04626180|PROCEDURE|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
219159142|NCT04626180|PROCEDURE|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
219732584|NCT03410537|DRUG|Placebo|
219732585|NCT02612467|OTHER|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
219732586|NCT02612467|OTHER|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
219732587|NCT05316051|DEVICE|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
219732588|NCT02324907|DEVICE|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
219159143|NCT00521755|DEVICE|Seraffix LTB|laser soldering for soft tissue wounds
219159144|NCT02216552|DIETARY_SUPPLEMENT|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
219159145|NCT02216552|DIETARY_SUPPLEMENT|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
219159146|NCT01203995|BEHAVIORAL|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
219159147|NCT01203995|BEHAVIORAL|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
219159148|NCT05401513|OTHER|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
219234758|NCT05134103|BEHAVIORAL|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
219234759|NCT05134103|OTHER|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
219234760|NCT02018549|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
219234761|NCT00038038|DRUG|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
219732589|NCT01598220|BEHAVIORAL|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
219732590|NCT01598220|OTHER|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
219732591|NCT02376335|BIOLOGICAL|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
219732592|NCT02376335|OTHER|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
219732593|NCT06368362|BEHAVIORAL|Benign cognitive bias modification for interpretation|Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.
219159149|NCT04403789|OTHER|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
219159150|NCT04403789|BEHAVIORAL|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
219159151|NCT03245424|DRUG|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
219159152|NCT01189331|DEVICE|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
219159153|NCT04192916|DRUG|DOACs|Direct Oral Anticoagulants
219234762|NCT00038038|PROCEDURE|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
219234763|NCT02470806|DEVICE|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
219732594|NCT06368362|BEHAVIORAL|Pain-related cognitive bias modification for interpretation|Pain-related cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as pain-related.
219732595|NCT02719860|DIETARY_SUPPLEMENT|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
219732596|NCT02719860|DIETARY_SUPPLEMENT|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
219732597|NCT02719860|DIETARY_SUPPLEMENT|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
219732598|NCT02164721|DEVICE|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
219732599|NCT03043937|OTHER|registry|
219732600|NCT03479346|DRUG|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219732601|NCT03479346|DRUG|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
219732602|NCT01467284|BEHAVIORAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
219732603|NCT01467284|BEHAVIORAL|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
219732604|NCT00276393|DRUG|Basal insulin|
219732605|NCT01975584|BEHAVIORAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
219159154|NCT04622722|OTHER|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
219732606|NCT05364489|DRUG|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
219732607|NCT01093885|DRUG|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
219732608|NCT01091415|PROCEDURE|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
219159155|NCT04622722|OTHER|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
219159156|NCT02374307|OTHER|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
219159157|NCT00999167|DRUG|HPN-100|Part B: 6 mL BID for 16 weeks.
219159158|NCT00999167|DRUG|Placebo|Part B: same as experimental arm
219732609|NCT05750004|PROCEDURE|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
219732610|NCT02868710|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
219732611|NCT01935505|BEHAVIORAL|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
219159159|NCT03722316|OTHER|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
219732612|NCT01935505|DRUG|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
219732613|NCT01935505|BEHAVIORAL|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
219159160|NCT03722316|OTHER|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
219159161|NCT03989024|DRUG|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
219732614|NCT01935505|BEHAVIORAL|Consulting+Telephone+Drug intervention|Include all the above interventions
219732615|NCT06569277|OTHER|A mobile application|Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
219732616|NCT06569784|DRUG|[14C]HSK31858|A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
219732617|NCT01520662|OTHER|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
219732618|NCT04787120|DEVICE|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
219732619|NCT02533674|DRUG|Gemcitabine plus PM060184|
219732620|NCT06570408|BEHAVIORAL|Western Ontario and McMaster University Osteoarthritis Index (WOMAC)|1\. WOMAC is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales
219732621|NCT06570408|BEHAVIORAL|Visual Analogue Scale (VAS)|2\. VAS is one of the pain rating scales used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms.
219234764|NCT02470806|DEVICE|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
219234765|NCT01147471|DEVICE|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
219234766|NCT01147471|PROCEDURE|operative rib fixation surgery|
219234767|NCT05120336|DEVICE|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
219234768|NCT05120336|DEVICE|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
219234769|NCT00880074|DRUG|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
219234770|NCT00880074|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219234771|NCT00880074|PROCEDURE|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
219234772|NCT02888821|BEHAVIORAL|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
219234773|NCT02579915|BEHAVIORAL|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
219234774|NCT02579915|BEHAVIORAL|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
219732622|NCT06570408|DIAGNOSTIC_TEST|Kellgren Lawrence Grading Scale (KL score)|3\. KL score is the most widely used clinical tool for the radiographic diagnosis of OA.Each radiograph was assigned a grade from 0 to 4,
219732623|NCT06570408|BEHAVIORAL|Quality of Life Questionnaires and Assessments:|4\. Quality of Life Questionnaires and Assessments: include quality of life, intestinal tract, conscious assessment of pain relief.etc.
219234775|NCT04561089|DIAGNOSTIC_TEST|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
219234776|NCT00003041|DRUG|pyrazoloacridine|
219234777|NCT01217099|DRUG|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
219732624|NCT04266314|DEVICE|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
219732625|NCT04266314|OTHER|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
219732626|NCT02799290|BIOLOGICAL|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
219234778|NCT01217099|DRUG|azithromycin|control patients were iv azithromycin for 5 days.
219234779|NCT03836651|OTHER|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
219234780|NCT03836651|OTHER|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
219234781|NCT01584674|DEVICE|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
219234782|NCT00384514|DEVICE|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
219234783|NCT05866354|DRUG|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
219234784|NCT00003984|BIOLOGICAL|lintuzumab|
219234785|NCT00268333|DRUG|fluorouracil|
219234786|NCT00268333|DRUG|leucovorin calcium|
219234787|NCT00268333|DRUG|oxaliplatin|
219234788|NCT00268333|PROCEDURE|neoadjuvant therapy|
219732627|NCT02799290|BIOLOGICAL|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
219732628|NCT04315207|BEHAVIORAL|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
219732629|NCT04315207|BEHAVIORAL|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
219732630|NCT05033535|DRUG|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
219732631|NCT05033535|DRUG|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
219732632|NCT01744626|DRUG|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
219732633|NCT01744626|DRUG|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
219732634|NCT02123511|DRUG|acetylcysteine|Oral rinse
219732635|NCT02123511|OTHER|placebo|Oral rinse
219732636|NCT02123511|OTHER|quality-of-life assessment|Ancillary studies
219732637|NCT02123511|OTHER|questionnaire administration|Ancillary studies
219732638|NCT06164600|DIETARY_SUPPLEMENT|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
219732639|NCT06164600|DRUG|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
219732640|NCT00265005|DRUG|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
219732641|NCT03903770|DEVICE|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
219732642|NCT06344169|DRUG|Sebacoyl Dinalbuphine Ester|SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance
219732643|NCT06344169|DRUG|Morphine|A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
219159162|NCT03989024|DRUG|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
219159163|NCT00198146|DRUG|Zenapax|
219159164|NCT02554786|DRUG|Indacaterol acetate/Mometasone furoate|
219159165|NCT02554786|DRUG|Mometasone furoate|
219159166|NCT02554786|DRUG|Salmeterol xinafoate/fluticasone propionate|
219159167|NCT05293548|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
219159168|NCT05293548|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
219159169|NCT02934789|PROCEDURE|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
219159170|NCT02934789|DRUG|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
219234789|NCT03020498|BIOLOGICAL|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
219234790|NCT03020498|BIOLOGICAL|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
219732644|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
219732645|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
219732646|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
219732647|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
219732648|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
219732649|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
219732650|NCT00392275|DRUG|Ofloxacin 0.3%|
219732651|NCT00392275|DRUG|Ciprofloxacin 0.3%|
219732652|NCT00392275|DRUG|Levofloxacin 0.5%|
219159171|NCT05052996|DRUG|ISL|Capsules administered orally without regard to food
219159172|NCT05052996|DRUG|LEN|Tablets administered orally without regard to food
219159173|NCT05052996|DRUG|B/F/TAF|Tablets administered orally without regard to food
219159174|NCT05052996|DRUG|ISL/LEN FDC|Tablets administered orally without regard to food
219159175|NCT01485406|BIOLOGICAL|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
219159176|NCT01485406|BIOLOGICAL|Synflorix™|1 dose administered intramuscularly
219159177|NCT04438343|OTHER|Impairment-specific and augmented intervention|Balance and lower extremities strength training
219732653|NCT00392275|DRUG|Ofloxacin 400mg|
219732654|NCT00392275|DRUG|Ciprofloxacin 400mg|
219732655|NCT00392275|DRUG|Levofloxacin 250mg|
219732656|NCT01951456|BEHAVIORAL|Resistance training|
219732657|NCT01951456|BEHAVIORAL|Health and Wellness|
219732658|NCT02688335|DEVICE|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
219732659|NCT02441699|BEHAVIORAL|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
219732660|NCT03615534|OTHER|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
219732661|NCT03615534|OTHER|Placebo|
219732662|NCT03615534|DRUG|Fenofibrate|
219732663|NCT03615534|DIETARY_SUPPLEMENT|Wax Matrix Extended Release Niacin (WMER Niacin)|
219234791|NCT01094106|DRUG|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
219234792|NCT01094106|DRUG|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
219234793|NCT03725020|OTHER|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
219234794|NCT02558205|RADIATION|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
219234795|NCT02558205|RADIATION|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
219234796|NCT02467985|PROCEDURE|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
219234797|NCT00004496|DRUG|alpha-melanocyte stimulating hormone|
219234798|NCT04743388|BIOLOGICAL|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
219234799|NCT04743388|BIOLOGICAL|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
219234800|NCT01403285|DRUG|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
219234801|NCT01403285|BIOLOGICAL|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
219234802|NCT01403285|BIOLOGICAL|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
219732664|NCT03581747|DEVICE|Nevisense|Measurement of electrical impedance
219732665|NCT00604383|DRUG|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
219732666|NCT00604383|DRUG|placebo|1 tablet, orally, daily, up to 42 months
219732667|NCT05688657|DEVICE|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
219732668|NCT05688657|DEVICE|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
219234803|NCT01403285|DRUG|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
219234804|NCT01294644|DRUG|Deoxycholic acid injection|
219732669|NCT03640182|OTHER|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
219234805|NCT01294644|DRUG|Placebo|Phosphate buffered saline placebo for injection
219234806|NCT01492127|BIOLOGICAL|Blood test|Blood test
219234807|NCT01811615|OTHER|alcohol-free experimental mouth rinse|
219732670|NCT01383824|DEVICE|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
219732671|NCT05375266|OTHER|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
219732672|NCT06092983|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
219234808|NCT01811615|OTHER|alcohol-containing mouth rinsing|
219234809|NCT02992652|DRUG|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
219234810|NCT02188459|DRUG|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
219732673|NCT06092983|DRUG|HS-10383 Placebo|HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
219732674|NCT00163735|DRUG|Administration of wine fined with potential food allergens|
219732675|NCT04998149|DEVICE|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?\_pos=3\&\_sid=d6e52e63c\&\_ss=r
219732676|NCT06190665|DEVICE|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
219732677|NCT06190665|DEVICE|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
219732678|NCT02681042|PROCEDURE|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
219732679|NCT02681042|DEVICE|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
219732680|NCT05928208|DIAGNOSTIC_TEST|no intervention|no intervention
219732681|NCT04297267|DRUG|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
219732682|NCT04297267|DRUG|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
219732683|NCT01122680|DRUG|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
219732684|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
219732685|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
219732686|NCT01122680|DRUG|Placebo|placebo inhalation solution
219732687|NCT06221254|BEHAVIORAL|COBMINDEX digital application|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
219732688|NCT06221254|BEHAVIORAL|Human therapist (Control)|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
219732689|NCT00004856|BIOLOGICAL|trastuzumab|Given IV
219732690|NCT00026403|DRUG|cisplatin|
219732691|NCT00026403|DRUG|gemcitabine hydrochloride|
219732692|NCT00026403|RADIATION|radiation therapy|
219732693|NCT04032262|DIAGNOSTIC_TEST|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
219732694|NCT04032431|BEHAVIORAL|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
219732695|NCT04604366|DRUG|misoprostol|it stimulates uterine contractions
219732696|NCT02618395|DRUG|SPARC001A|
219732697|NCT02618395|DRUG|SPARC001B|
219732698|NCT02618395|DRUG|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
219732699|NCT00576407|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
219732700|NCT00225758|DRUG|Lapatinib|1500 mg po daily for 26 weeks or longer
219732701|NCT06207851|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
219732702|NCT05265364|RADIATION|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
219732703|NCT02980900|DIETARY_SUPPLEMENT|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
219732704|NCT02980900|DIETARY_SUPPLEMENT|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
219159178|NCT04438343|OTHER|Conventional physical therapy|Trunk and upper extremity training
219159179|NCT02902471|OTHER|Forced oscillations measure|
219159180|NCT02698813|BIOLOGICAL|umbilical cord mesenchymal stem cells and hyaluronic acid|
219159181|NCT02698813|DRUG|hyaluronic acid|
219159182|NCT04295993|DRUG|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
219159183|NCT04295993|DRUG|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
219159184|NCT01340417|OTHER|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
219159185|NCT03704727|DIETARY_SUPPLEMENT|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
219159186|NCT04810767|OTHER|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
219159187|NCT01086813|DRUG|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
219159188|NCT04175405|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
219159189|NCT06647082|DEVICE|Pediatric Knee Exoskeleton|The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
219159190|NCT00475930|DRUG|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
219159191|NCT00475930|DRUG|Comfort Bath cloths (placebo cloths)|self applied three times weekly
219159192|NCT04206813|DRUG|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
219159193|NCT04206813|DRUG|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
219159194|NCT04206813|DRUG|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
219732705|NCT02980900|DIETARY_SUPPLEMENT|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
219732706|NCT02980900|DIETARY_SUPPLEMENT|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
219159195|NCT06142786|BEHAVIORAL|Enhancing the individualized upper alpha frequency band and suppressing the lower alpha band.|Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.
219159196|NCT06142786|BEHAVIORAL|Sham neurofeedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
219159197|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
219159198|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219159199|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219159200|NCT05902312|DEVICE|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
219159201|NCT05522868|DRUG|SB17170|SB17170 capsules, Oral administration 21days/cycle
219159202|NCT06230744|BEHAVIORAL|Lifestyle|All participants will receive diet and exercise goals and coaching.
219159203|NCT06230744|BEHAVIORAL|Lifestyle II|All participants will receive diet and exercise goals and coaching.
219159204|NCT06070428|OTHER|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
219159205|NCT06070428|OTHER|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
219159206|NCT05593666|DRUG|LXE408|Film-coated tablets
219159207|NCT05593666|OTHER|Placebo|Placebo film-coated tablets
219159208|NCT05593666|DRUG|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
219732707|NCT06372483|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
219732708|NCT06372483|DRUG|Placebo|VMX-C001 matched placebo
219732709|NCT06372483|DRUG|Rivaroxaban 20 mg Oral Tablet|Fxa DOAC
219732710|NCT06372483|DRUG|Apixaban 5 mg Oral Tablet|Fxa DOAC
219159209|NCT05797545|DIAGNOSTIC_TEST|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
219159210|NCT03351699|DRUG|MK-4250|MK-4250 tablets for oral administration
219159211|NCT05172596|BIOLOGICAL|PHE885|Intravenous (IV) infusion
219159212|NCT04704284|DIAGNOSTIC_TEST|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
219159213|NCT06406348|DRUG|ALIA-1758|Intravenous or subcutaneous doses
219159214|NCT06406348|OTHER|Placebo|Intravenous or subcutaneous doses
219159215|NCT06117306|DRUG|3,4 Methylenedioxymethamphetamine|1 MDMA session
219159216|NCT06117306|BEHAVIORAL|Prolonged Exposure|12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
219159217|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
219732711|NCT06372483|DRUG|Edoxaban 60 mg Oral Tablet|Fxa DOAC
219159218|NCT05224765|OTHER|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
219159219|NCT06549192|OTHER|20 meter shuttle run test|20 Meter Shuttle Run Test: Subjects run distance of 20 meters round trip. Running speed is monitored at certain intervals with help of a tape recorder that gives a signal. Subjects start running when they hear first beep and must reach other line(one foot must cross the line) by second beep. When they hear second signal, they return to starting line. The speed, which is slow at beginning, gradually increases every 10 seconds. The subject adjusts his/her pace so that he/she is on the other line at the second signal. If subject misses one signal and catches second signal, test continues. If subject misses two signals in row and doesn't reach line at other signal, test is terminated. At end of test, aerobic power values are calculated from VO2max estimation table in ml/kg/min according to number of sit-ups run. At end of test, marks obtained by athlete are calculated and VO2max value of subject is calculated in ml/kg/min from evaluation table.
219159220|NCT05624554|DRUG|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
219732712|NCT00756444|DRUG|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
219732713|NCT00756444|DRUG|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
219159221|NCT05624554|DRUG|Fludarabine|25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
219159222|NCT05624554|DRUG|Cyclophosphamide|250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
219159223|NCT05624554|DRUG|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
219159224|NCT05624554|BIOLOGICAL|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
219732714|NCT00756444|DRUG|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
219732715|NCT04579419|DRUG|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
219732716|NCT04579419|DRUG|Normal Saline|0.9 NaCl
219234811|NCT03750682|OTHER|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
219159225|NCT05624554|BIOLOGICAL|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
219159226|NCT05624554|BIOLOGICAL|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
219159227|NCT05624554|BIOLOGICAL|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
219159228|NCT01542593|DEVICE|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
219234812|NCT03750682|OTHER|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
219159229|NCT03366870|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
219234813|NCT00184444|BEHAVIORAL|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
219234814|NCT00184444|BEHAVIORAL|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
219732717|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
219732718|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
219732719|NCT02380157|DRUG|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
219732720|NCT02380157|DRUG|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
219732721|NCT00122863|DRUG|Duloxetine Hydrochloride|
219732722|NCT00122863|DRUG|placebo|
219732723|NCT00083447|DRUG|TransMID™|
219732724|NCT01018056|DRUG|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
219732725|NCT01018056|DRUG|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
219159230|NCT03366870|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
219159231|NCT06530056|OTHER|Costovertebral Mobilization+Conventional Therapy|"Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks"
219732726|NCT01018056|DRUG|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
219159232|NCT06530056|OTHER|Conventional Therapy|"Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session"
219732727|NCT06033859|DIAGNOSTIC_TEST|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
219732728|NCT06033859|DIAGNOSTIC_TEST|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
219732729|NCT06033859|PROCEDURE|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
219159233|NCT01922830|DIETARY_SUPPLEMENT|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
219159234|NCT01922830|DIETARY_SUPPLEMENT|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
219159235|NCT04319874|DRUG|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
219159236|NCT04319874|DRUG|Chemotherapy|Subjects are treated with conventional chemotherapy
219159237|NCT04319874|DRUG|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
219159238|NCT02962141|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
219159239|NCT02962141|DEVICE|Balloon Dilatation Catheter|Control group
219159240|NCT04165967|DRUG|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
219159241|NCT04244318|BEHAVIORAL|Video-feedback ODISEA 3.0|Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).
219159242|NCT04244318|BEHAVIORAL|ODISEA-DTP: parental therapy|Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).
219159243|NCT04244318|BEHAVIORAL|Treatment as usual|"Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia"
219159244|NCT00224510|DRUG|lamotrigine|
219159245|NCT00946413|BEHAVIORAL|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
219159246|NCT00946413|BEHAVIORAL|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
219159247|NCT00547352|DRUG|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
219159248|NCT00547352|DRUG|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
219159249|NCT03206515|DEVICE|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
219159250|NCT03206515|DEVICE|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
219159251|NCT01571466|DRUG|Vaccination|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
219159252|NCT01571466|DRUG|Placebo|3 immunisations at week 0, 4 and 16
219159253|NCT05003843|DEVICE|Indigo Aspiration System|Indigo Aspiration System
219159254|NCT01655888|DRUG|Tremelimumab|Tremelimumab is administered as endovenous infusion
219159255|NCT03086161|BEHAVIORAL|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
219159256|NCT03086161|BEHAVIORAL|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
219159257|NCT02597751|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
219732730|NCT04269785|DEVICE|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
219732731|NCT04269785|DEVICE|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
219159258|NCT05718089|OTHER|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
219234815|NCT04317937|OTHER|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
219234816|NCT04317937|OTHER|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
219234817|NCT04317937|OTHER|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
219732732|NCT06637384|DRUG|Hyaluronic Acid (HA)|Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
219159259|NCT05718089|OTHER|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
219159260|NCT05718089|OTHER|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
219159261|NCT02570022|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
219159262|NCT02570022|PROCEDURE|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
219159263|NCT02570022|DRUG|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
219159264|NCT00041938|DRUG|aspirin|325 mg per day
219159265|NCT00041938|DRUG|Warfarin|INR 2.5-3.0; target INR 2.75
219159266|NCT03101930|DRUG|Liraglutide|subcutaneous liraglutide daily
219159267|NCT03101930|DRUG|Sitagliptin|oral sitagliptin daily
219159268|NCT03101930|OTHER|hypocaloric diet|Reduced calorie intake to achieve weight loss.
219159269|NCT03101930|DRUG|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
219159270|NCT03101930|DRUG|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
219159271|NCT01340716|OTHER|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
219159272|NCT01340716|OTHER|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
219159273|NCT04775654|DIETARY_SUPPLEMENT|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
219159274|NCT04775654|OTHER|Placebo|Two capsules containing an inert material.
219159275|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
219159276|NCT06648226|BEHAVIORAL|Climate swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more climate-friendly products (e.g., with a A or B climate label)."
219732733|NCT06637384|DRUG|Corticosteroid Injection|Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
219732734|NCT04879732|DEVICE|ACTIS|ACTIS Hip stem
219732735|NCT06640582|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
219732736|NCT06640582|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219732737|NCT06640582|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219732738|NCT06640582|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
219732739|NCT06640582|DRUG|Pembrolizumab|Intravenous (IV) infusion
219732740|NCT03142334|BIOLOGICAL|Pembrolizumab|IV infusion
219732741|NCT03142334|DRUG|Placebo|IV infusion
219159277|NCT06648226|BEHAVIORAL|Combined health and climate swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or climate-friendliness) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
219159278|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
219159279|NCT01576107|OTHER|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
219159280|NCT01576107|OTHER|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
219159281|NCT00496743|DEVICE|Low-dose total skin electron beam therapy (4 Gy)|
219159282|NCT02847013|DRUG|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
219159283|NCT02847013|PROCEDURE|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
219159284|NCT06409117|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
219159285|NCT00087139|DRUG|ixabepilone|Given IV
219159286|NCT01888744|DRUG|GnRH agonist|
219159287|NCT01888744|DRUG|GnRH antagonist|
219159288|NCT01888744|DRUG|hP-hMG|
219159289|NCT01888744|DRUG|Human chorionic gonadotropin|induction of final oocyte maturation
219159290|NCT01888744|DRUG|Progesterone|
219732742|NCT06638164|OTHER|Control|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
219732743|NCT06638164|OTHER|Virtual reality glasses|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
219732744|NCT03852693|OTHER|Histopathological review|Histopathological review
219732745|NCT03982693|DRUG|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
219732746|NCT03982693|OTHER|Placebo|Placebo infusions consist of 500 ml normal saline.
219732747|NCT06641752|DIAGNOSTIC_TEST|Blood drop sampling|The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
219732748|NCT06639737|PROCEDURE|preoperative stroke volume optimization|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
219732749|NCT06639737|PROCEDURE|Post induction stroke volume optimization|Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
219732750|NCT06642532|DEVICE|TCD group|Transcranial Doppler ultrasound to examine bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window
219732751|NCT06539260|DRUG|Vitamin D|Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
219732752|NCT06539260|DRUG|Placebo|Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
219732753|NCT03603184|DRUG|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
219732754|NCT03603184|DRUG|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
219234818|NCT04317937|OTHER|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
219234819|NCT03357237|OTHER|medical device|"patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo"
219234820|NCT06196294|BIOLOGICAL|Cell therapy for solid tumors|Transfer γδT cells into patients for anti-ancer therapy.
219234821|NCT01986348|DRUG|Selinexor|One cycle is 28 days (4 weeks).
219732755|NCT03603184|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
219732756|NCT03603184|DRUG|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
219732757|NCT03071965|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
219732758|NCT03071965|PROCEDURE|Surgery|Surgery to implant device for NT-501
219732759|NCT03071965|PROCEDURE|Surgery|Sham surgery
219732760|NCT06440746|DRUG|Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)|Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
219732761|NCT06440746|DRUG|SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL|Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
219732762|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
219732763|NCT06248177|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
219732764|NCT06248177|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
219732765|NCT02065804|DRUG|Bupivacaine|injection, once, 5 min
219732766|NCT04103970|BEHAVIORAL|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
219732767|NCT05618613|DRUG|Elacestrant|Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
219732768|NCT05618613|DRUG|Onapristone|Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
219732769|NCT05587998|DRUG|Morphine|Participants will receive IV dose of Morphine as stated in arm description.
219234822|NCT02548585|DRUG|MEDI0382|MEDI0382 administered subcutaneously.
219234823|NCT02548585|DRUG|Placebo|Placebo administered subcutaneously.
219732770|NCT05587998|DRUG|AZD4041|Participants will receive oral doses of AZD4041 as stated in arm description.
219732771|NCT05587998|OTHER|Placebo|Participants will receive oral doses of placebo as stated in arm description.
219732772|NCT04149457|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
219732773|NCT04149457|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
219732774|NCT05763862|GENETIC|Genetic testing|Same information as details in the experimental arm.
219732775|NCT05013229|DRUG|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
219732776|NCT05013229|DRUG|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
219732777|NCT05013229|DRUG|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
219732778|NCT03964909|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
219732779|NCT03964909|PROCEDURE|Magnetic Resonance Imaging|Undergo CVR MRI
219732780|NCT03964909|PROCEDURE|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
219732781|NCT06512727|BEHAVIORAL|PROACTIVE Intervention|Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent self-management (SM) education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
219732782|NCT05290818|DEVICE|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
219732783|NCT05290818|DEVICE|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
219732784|NCT03445845|DRUG|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
219732785|NCT03445845|DRUG|TNF blocker|"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
219732786|NCT03445845|BIOLOGICAL|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
219732787|NCT06126653|DRUG|Low Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
219732788|NCT06126653|DRUG|High Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
219732789|NCT06126653|DRUG|Placebo|Titratable, liquid formulation, taken orally.
219159291|NCT04386772|PROCEDURE|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
219159292|NCT04386772|PROCEDURE|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
219159293|NCT00222924|BEHAVIORAL|weight loss/ exercise|
219159294|NCT04515641|DRUG|Islatravir|Two ISL 30 mg capsules taken by mouth.
219159295|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
219159296|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
219159297|NCT05336864|OTHER|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
219159298|NCT05336864|OTHER|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL) and C-reactive protein (CRP)"
219159299|NCT05336864|OTHER|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year outcomes).
219159300|NCT05336864|OTHER|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
219159301|NCT05336864|OTHER|Processed electroencephalogram (pEEG) monitoring|Processed EEG substudy to explore the relationship between processed EEG-derived depth of anesthesia metrics and cerebral autoregulatory function.
219234824|NCT02757911|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
219732790|NCT04705337|DRUG|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
219732791|NCT04705337|OTHER|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
219732792|NCT06962085|PROCEDURE|sacral erector spinae plane block group|In the block group, bilateral sacral erector spinae plane block (10 mL 0.25% bupivacaine (Marcaine %0,5. AstraZeneca Ltd, İstanbul, Türkiye) + 5 mL 1% lidocaine (Lidon 100 mg/ 5mL. ONFARMA İlaç San. Ve Tic. A.Ş, Ankara, Türkiye) will be performed in the lateral position with the help of ultrasound before surgery.
219234825|NCT00841711|BEHAVIORAL|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
219234826|NCT00629564|DRUG|Esomeprazole|20mg oral
219234827|NCT00629564|DRUG|Esomeprazole|15 minute intravenous infusion
219234828|NCT02875730|PROCEDURE|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
219234829|NCT02875730|PROCEDURE|CMRI|Cardiac Magnetic Resonance Imaging
219234830|NCT00011102|BEHAVIORAL|Weight Gain Prevention for Women Project|
219234831|NCT01355692|DEVICE|Nd: YLF laser treatment|grid selective retinal treatment
219234832|NCT03876886|DRUG|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
219234833|NCT03876886|DRUG|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
219732793|NCT06962085|DRUG|Opioid Analgesics|Sacral arrector spine block will not be performed in this group. After general anesthesia, hemodynamic values (noninvasive blood pressure, heart rate, peripheral oxygen saturation) and total remifentanil (Rentanil 2 mg. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use will be recorded during the operation. Additionally, numerical pain scores and total meperidine (Aldine 100mg/2mL. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use at 0, 2, 4, 6, 12 and 24 hours after the operation will be recorded. At the 24th hour, the Turkish version of the Quality of Recovery-15 (QoR-15T) Questionnaire will be filled out and recorded.
219732794|NCT06961513|OTHER|Women's health physiotherapy|Women's health physiotherapy for pelvic-floor dysfunction
219732795|NCT04650841|DRUG|Placebo Cream with Naloxone|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
219732796|NCT04650841|DRUG|Control Cream with Naloxone|Participants will be informed that the spray is saline.
219732797|NCT04650841|DRUG|Placebo Cream with Saline|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
219732798|NCT04650841|DRUG|Control Cream with Saline|Participants will be informed that the spray is saline.
219732799|NCT04717908|DRUG|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
219732800|NCT04717908|DRUG|Pyrazinamide|1500 mg daily
219732801|NCT04717908|DRUG|Linezolid|600 mg daily
219732802|NCT04717908|DRUG|Cycloserine|≤50kg 500 mg daily, \>50kg 750mg daily;
219732803|NCT04717908|DRUG|Clofazimine|100 mg daily;
219732804|NCT06342960|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
219234834|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*4cycles
219732805|NCT06342960|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219732806|NCT06641401|PROCEDURE|Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture|All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
219732807|NCT06643546|OTHER|theoretical training|received only theoretical breastfeeding training
219732808|NCT06643546|OTHER|model simulation training|theoretical breastfeeding training and model simulation training accompanied by scenarios
219732809|NCT06643546|OTHER|live-simulation|theoretical breastfeeding training and live simulation training with scenarios
219732810|NCT06645262|OTHER|Cryotherapy|cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
219732811|NCT04139499|PROCEDURE|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
219732812|NCT04139499|PROCEDURE|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
219732813|NCT00610948|BIOLOGICAL|panitumumab|Given IV
219732814|NCT00610948|DRUG|everolimus|Given orally
219732815|NCT00610948|DRUG|fluorouracil|Given IV
219732816|NCT00610948|DRUG|leucovorin calcium|Given IV
219234835|NCT03876886|DRUG|Carboplatin|carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
219234836|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*8cycles
219234837|NCT03942107|PROCEDURE|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
219234838|NCT03942107|PROCEDURE|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
219234839|NCT01211509|DRUG|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
219234840|NCT02913300|DRUG|Lignocaine 1% concentration solution|
219234841|NCT02913300|DRUG|Lignocaine 2% concentration solution|
219234842|NCT00316797|DRUG|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
219732817|NCT00610948|DRUG|oxaliplatin|Given IV
219732818|NCT01536509|BEHAVIORAL|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
219234843|NCT02050555|DIETARY_SUPPLEMENT|Placebo|
219234844|NCT02050555|DIETARY_SUPPLEMENT|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
219234845|NCT01201837|DRUG|Placebo|Weekly injection
219234846|NCT01201837|DRUG|CER-001|Weekly injection
219234847|NCT02935894|DRUG|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
219234848|NCT02935894|OTHER|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
219234849|NCT02935894|DRUG|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
219234850|NCT02698956|DEVICE|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
219234851|NCT03734978|DIAGNOSTIC_TEST|Diagnosis|biochemistry
219234852|NCT03230084|DEVICE|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
219234853|NCT05954247|DRUG|DWJ1543|DWJ1543
219234854|NCT05954247|DRUG|DWC202216|DWC202216
219234855|NCT03224988|DEVICE|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
219234856|NCT01602302|DRUG|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
219234857|NCT04218877|OTHER||There will be no intervention, only observation
219234858|NCT02033174|OTHER|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
219234859|NCT02033174|OTHER|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
219234860|NCT01499251|DRUG|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
219234861|NCT01499251|DRUG|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
219159302|NCT05434962|DEVICE|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms"
219159303|NCT05973461|DEVICE|Exercise and virtual reality|Riding a cycle ergometer while experiencing virtual reality
219159304|NCT05973461|OTHER|Riding a cycle ergometer|Riding on a cycle ergometer without experiencing virtual reality
219159305|NCT05394285|DRUG|Hetrombopag|"The first anti-tumor treatment cycle (multicenter, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd anti-tumor treatment cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after anti-tumor treatment for 14 days."
219159306|NCT04448158|DIAGNOSTIC_TEST|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
219159307|NCT06354140|DRUG|Tegafur|Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
219159308|NCT00536341|DRUG|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
219234862|NCT01499251|DRUG|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
219234863|NCT01696500|DRUG|Intravenous immunoglobulin|
219234864|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
219234865|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
219234866|NCT03242863|OTHER|Food proportionality|Proportions of high and low energy dense foods manipulated
219234867|NCT04267952|BEHAVIORAL|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
219234868|NCT04267952|BEHAVIORAL|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
219234869|NCT00895076|DRUG|dexamethasone|iontophoretic patch and injection
219732819|NCT01536509|BEHAVIORAL|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
219732820|NCT06345118|BEHAVIORAL|Otago exercise program|"The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme"
219732821|NCT01449032|BIOLOGICAL|MSC|No of cells after culture expansion
219732822|NCT01449032|BIOLOGICAL|Saline|3 cc saline
219732823|NCT06085209|DEVICE|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
219732824|NCT06085209|DEVICE|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
219732825|NCT06085209|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
219732826|NCT04769778|DRUG|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
219159309|NCT00536341|DRUG|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
219159310|NCT00536341|DRUG|Fludarabine|25 mg/m2 on Days 1, 2, and 3
219159311|NCT01637246|DRUG|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
219159312|NCT04652583|DEVICE|Earstim - Active Stimulation|Intramuscular stimulation
219159313|NCT04652583|DEVICE|Earstim - Sham Stimulation|Sham stimulation
219159314|NCT04077164|OTHER|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
219159315|NCT04372004|DIAGNOSTIC_TEST|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
219159316|NCT01846936|PROCEDURE|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
219159317|NCT01846936|PROCEDURE|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
219159318|NCT01846936|PROCEDURE|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
219159319|NCT00629850|DEVICE|Powerlung Performer|Inspiratory/Expiratory muscle trainer
219159320|NCT03201562|DRUG|Aceclidine+tropicamide combination|Ophthalmic Solution
219159321|NCT03201562|DRUG|Aceclidine|Ophthalmic Solution
219159322|NCT03201562|DRUG|Vehicle|Ophthalmic Solution
219159323|NCT00393484|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
219159324|NCT00393484|DRUG|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
219234870|NCT02998658|DEVICE|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
219234871|NCT02998658|DEVICE|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
219234872|NCT03570970|DRUG|Banapenem|Banapenem to be used anti-infection
219159325|NCT00393484|DRUG|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
219159326|NCT00393484|DRUG|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
219159327|NCT03576742|DIAGNOSTIC_TEST|potential biomarkers|facs analysis, microbiome analysis
219159328|NCT00065260|DRUG|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
219159329|NCT00065260|DRUG|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
219159330|NCT00065260|DRUG|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
219234873|NCT02424201|DRUG|Misoprostol|experimental
219159331|NCT05198531|DRUG|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
219234874|NCT02424201|DRUG|vitamin c|control
219234875|NCT02383043|DRUG|Cocaine|
219234876|NCT02383043|DRUG|Sustained Release d-Amphetamine|
219234877|NCT00348361|DRUG|Fluticasone Propionate|
219234878|NCT02551705|OTHER|functional Imaging|Brain responses associated with emotional memory will be investigated
219234879|NCT02709044|DRUG|Ringer lactate|
219234880|NCT03758248|GENETIC|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.
219234881|NCT03731741|DRUG|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
219732827|NCT06569264|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
219159332|NCT05198531|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
219732828|NCT06569264|PROCEDURE|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
219732829|NCT03892915|COMBINATION_PRODUCT|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
219159333|NCT05198531|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
219159334|NCT05198531|DRUG|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
219159335|NCT00001277|DRUG|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
219159336|NCT00001277|DRUG|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
219234882|NCT00128765|BEHAVIORAL|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
219234883|NCT00128765|BEHAVIORAL|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
219234884|NCT00128765|BEHAVIORAL|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
219234885|NCT03941977|DEVICE|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
219234886|NCT03941977|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
219732830|NCT06327256|DRUG|BI 3000202|BI 3000202
219732831|NCT06327256|DRUG|Placebo|Placebo-matching BI 3000202
219732832|NCT06327256|DRUG|Midazolam|Midazolam
219234887|NCT03941977|BIOLOGICAL|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
219234888|NCT05331872|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
219234889|NCT06699693|PROCEDURE|ultrasonography-guided PENG block|This study aimed to evaluate the effect of ultrasonography-guided PENG block prior to joint mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment, in comparison with a control group
219234890|NCT06699693|OTHER|Mobilization|The mobilization methods encompassed the scapula and clavicular joints, in addition to the glenohumeral (GH) joint, taking into consideration their biomechanical interactions. These exercises were supervised and administered by the physiotherapist during each session. Additionally, the patients were provided with a home exercise program that included exercises for posture, thera band, and finger ladder, with instructions to perform 10-15 repetitions twice a day independently \[
219159337|NCT03718598|BEHAVIORAL|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
219159338|NCT01381471|DRUG|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
219159339|NCT00715494|BEHAVIORAL|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
219159340|NCT00826852|DRUG|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
219159341|NCT00132964|DEVICE|Below knee walking cast|Not required
219159342|NCT00132964|DEVICE|Removable ankle brace|not required
219159343|NCT02178098|DRUG|ETC-1002|ETC-1002 capsules taken once daily
219159344|NCT02178098|DRUG|Placebo|Placebo capsules taken once daily
219159345|NCT03743506|DIAGNOSTIC_TEST|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
219159346|NCT03743506|DIAGNOSTIC_TEST|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
219159347|NCT02265432|BEHAVIORAL|General physical activity educational materials|
219159348|NCT02265432|DEVICE|Wearable activity tracking devices (fitbit)|
219159349|NCT02265432|OTHER|online map|
219159350|NCT02265432|OTHER|Personalized text messages|
219159351|NCT01044303|DRUG|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
219159352|NCT01411592|OTHER|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
219159353|NCT01411592|OTHER|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
219159354|NCT00301652|DRUG|mycophenolate mofetil|MMF,1.0g/d
219159355|NCT01603758|DRUG|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
219159356|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
219159357|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
219159358|NCT01058499|BEHAVIORAL|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
219159359|NCT04865146|DEVICE|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
219159360|NCT01849978|BEHAVIORAL|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
219159361|NCT01849978|BEHAVIORAL|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
219159362|NCT01849978|BEHAVIORAL|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
219159363|NCT01849978|BEHAVIORAL|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
219159364|NCT05900765|DRUG|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
219159365|NCT01519037|DRUG|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
219159366|NCT01519037|DRUG|Placebo oral tablet|one tablet of placebo
219159367|NCT04385680|DRUG|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
219159368|NCT00003612|BIOLOGICAL|trastuzumab|
219159369|NCT00003612|DRUG|carboplatin|
219159370|NCT00003612|DRUG|paclitaxel|
219159371|NCT01109524|DRUG|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
219159372|NCT01109524|DRUG|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
219159373|NCT01109524|DRUG|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
219159374|NCT02407834|OTHER|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
219732833|NCT05482243|DIETARY_SUPPLEMENT|Whey protein|Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
219159375|NCT02407834|OTHER|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
219159376|NCT02407834|OTHER|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
219732834|NCT02746939|BEHAVIORAL|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
219732835|NCT02890186|DEVICE|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
219732836|NCT02890186|OTHER|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
219732837|NCT05995366|DRUG|ABBV-903|Solution; Oral
219732838|NCT03399123|OTHER|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
219732839|NCT04631978|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
219159377|NCT02407834|OTHER|S4|Immersion in Saline solution for 20 minutes, during 7 days.
219159378|NCT06516250|OTHER|Virtual serious game GEMAS|Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
219159379|NCT00111085|DRUG|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
219732840|NCT01181128|DRUG|Factor VIII (rFVIIIFc)|
219732841|NCT01181128|DRUG|Advate®|
219732842|NCT02371252|DRUG|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
219732843|NCT03309059|DEVICE|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
219732844|NCT03309059|DEVICE|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
219159380|NCT00111085|DRUG|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
219159381|NCT00111085|DRUG|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
219159382|NCT00111085|DRUG|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
219159383|NCT06514027|DRUG|BEBT-109 Capsules|BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
219159384|NCT06514027|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
219159385|NCT06514027|DRUG|Carboplatin Injection|Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
219159386|NCT06514027|DRUG|Cisplatin Injection|Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
219159387|NCT01553058|DRUG|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
219159388|NCT01553058|DRUG|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
219159389|NCT01553058|OTHER|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
219159390|NCT00110929|DRUG|AMG 073|
219732845|NCT03309059|DEVICE|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
219732846|NCT02813720|RADIATION|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
219732847|NCT01362270|DEVICE|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
219732848|NCT01362270|DEVICE|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
219732849|NCT05901961|DRUG|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
219732850|NCT05901961|DRUG|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
219732851|NCT05901961|DRUG|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
219732852|NCT06309329|BEHAVIORAL|Strength at Home Parents|Strength at Home parents is an 8 week trauma-informed and cognitive behavioral tele-health group intervention that aims to improve parenting behaviors and overall parent-child and family functioning among U.S. military Veterans with post-traumatic stress disorder symptoms
219732853|NCT06309329|BEHAVIORAL|VA treatment as usual|VA treatment as usual includes referral to the online resources at veterantraining.va.gov/parenting .
219732854|NCT02298569|BEHAVIORAL|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
219732855|NCT00715897|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
219732856|NCT01867476|OTHER|Automated Adherence Monitoring System|
219159391|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
219159392|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
219159393|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
219159394|NCT06412770|BEHAVIORAL|Tai chi|Participants will be asked to do Tai Chi for 30 minutes three times a week
219159395|NCT06412770|BEHAVIORAL|Tai Chi imagery|Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
219159396|NCT06412770|OTHER|no-intervention|The comparison group will be given usual care
219159397|NCT03101371|DRUG|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
219159398|NCT03101371|PROCEDURE|Standard of care catheter insertion|Catheter inserted right out of package.
219159399|NCT02903199|DIETARY_SUPPLEMENT|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
219159400|NCT02903199|DIETARY_SUPPLEMENT|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
219159401|NCT02903199|DIETARY_SUPPLEMENT|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
219159402|NCT02650791|DRUG|Tranexamic Acid|
219159403|NCT03493724|OTHER|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
219159404|NCT00975039|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
219159405|NCT04900636|DEVICE|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
219159406|NCT00002383|DRUG|Saquinavir|
219159407|NCT03237416|DRUG|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
219159408|NCT03237416|DRUG|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
219159409|NCT03237416|DRUG|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
219159410|NCT00194610|DRUG|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
219159411|NCT00194610|OTHER|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
219159412|NCT03019913|OTHER|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
219732857|NCT02802085|DEVICE|VEGA Knee|TKA
219159413|NCT02743195|DIETARY_SUPPLEMENT|Polyphenol/prebiotic blend|
219159414|NCT04854395|DRUG|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
219159415|NCT02745340|OTHER|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
219159416|NCT00031694|DRUG|paclitaxel|Given IV
219159417|NCT00031694|DRUG|bryostatin 1|Given IV
219159418|NCT05123742|DIAGNOSTIC_TEST|COVID-19 Testing|Testing for the SARS-CoV-2 virus
219732858|NCT02318277|DRUG|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
219732859|NCT02318277|DRUG|INCB024360|INCB024360: Oral daily dosing
219732860|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
219159419|NCT00338572|BEHAVIORAL|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
219159420|NCT00338572|BEHAVIORAL|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
219159421|NCT03240978|BEHAVIORAL|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
219234891|NCT06699147|DEVICE|Hyaluronic Acid (HA)|6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis
219234892|NCT06699667|DIAGNOSTIC_TEST|Computed tomography|
219732861|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
219732862|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
219732863|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
219732864|NCT01520714|DEVICE|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
219732865|NCT01213771|PROCEDURE|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
219732866|NCT04505280|DRUG|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
219732867|NCT04757844|DEVICE|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
219159422|NCT03778242|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
219732868|NCT03855371|DRUG|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
219159423|NCT03778242|DRUG|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
219159424|NCT02150967|DRUG|BGJ398 (infigratinib)|Capsule for oral use
219159425|NCT00018603|DRUG|guanfacine|
219159426|NCT05799742|PROCEDURE|Bilateral hernioplasty|
219159427|NCT00006431|BIOLOGICAL|DC RCC-RNA|
219732869|NCT03855371|DRUG|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
219732870|NCT03299335|OTHER|Blood collection|assay of CPK and anti-cN-1A antibodies
219732871|NCT02810132|DRUG|Metformin|See above
219159428|NCT03359967|DRUG|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
219234893|NCT06699329|DRUG|Enlicitide Decanoate|multiple doses, oral tablet
219234894|NCT06699329|DRUG|Semaglutide|multiple doses, oral tablet
219732872|NCT02810132|DRUG|Placebo|See above
219732873|NCT00185900|DRUG|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
219234895|NCT06699316|OTHER|Individualized prognostic counselling|Individualized prognostic counselling on life expectancy using the prognostic model 'OncologIQ Palliative'
219234896|NCT06699537|DIETARY_SUPPLEMENT|probiotic product|During the study, subjects take one sachet of Lactobacillus rhamnosus LRa05 daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the intervention.
219234897|NCT06699537|DIETARY_SUPPLEMENT|Maltodextrin|During the study, subjects in the control group take one sachet of maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the 8-week trial.
219732874|NCT00185900|DRUG|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
219732875|NCT01077895|PROCEDURE|CVVH|"CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
219159429|NCT02076659|DRUG|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
219234898|NCT06698679|OTHER|No intervention|There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
219732876|NCT01077895|PROCEDURE|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
219732877|NCT01077895|PROCEDURE|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
219159430|NCT02076659|DRUG|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
219159431|NCT02556138|DEVICE|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
219159432|NCT00698919|OTHER|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
219159433|NCT02545738|DRUG|Liraglutide|active treatment
219159434|NCT02545738|DRUG|placebo|placebo
219159435|NCT00490100|DRUG|Increlex|
219159436|NCT04005287|DRUG|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
219159437|NCT04005287|DRUG|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
219159438|NCT04005287|DRUG|Placebo Low Dose|Topical Solution
219159439|NCT04005287|DRUG|Placebo High Dose|Topical Solution
219732878|NCT05253534|DEVICE|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
219159440|NCT03498196|DRUG|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
219159441|NCT02752503|DRUG|Nalmefene|
219159442|NCT04187599|DEVICE|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
219159443|NCT01989741|OTHER|Sleep restriction|4 hours sleep by night during one week
219159444|NCT03063866|DRUG|Propofol|Propofol 1 mg/kg i.v
219159445|NCT03063866|DRUG|Midazolam|Midazolam 3 mg i.v
219159446|NCT03063866|DRUG|Fentanyl|fentanyl 0.5 ug/kg
219159447|NCT02247817|DEVICE|Hybrid CRT-D/P implantation|
219159448|NCT00996749|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
219159449|NCT00996749|OTHER|bone scan|Correlative studies
219159450|NCT00996749|OTHER|dual x-ray absorptometry|Correlative studies
219159451|NCT00996749|OTHER|laboratory biomarker analysis|Correlative studies
219159452|NCT00996749|PROCEDURE|biopsy|Correlative studies
219159453|NCT04019444|BIOLOGICAL|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
219159454|NCT04019444|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
219159455|NCT04019444|BIOLOGICAL|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
219159456|NCT05239182|DRUG|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
219159457|NCT05239182|DRUG|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
219159458|NCT05239182|DRUG|Gemcitabine|cytotoxic chemotherapy agent
219159459|NCT05239182|DRUG|Abraxane|cytotoxic chemotherapy agent
219159460|NCT00903162|DRUG|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
219159461|NCT00903162|DRUG|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
219159462|NCT00903162|DRUG|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
219159463|NCT00047528|DRUG|Alcon Investigational Agent|
219159464|NCT03467529|OTHER|Non interventional study|Non interventional study
219159465|NCT00997490|DRUG|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
219159466|NCT00997490|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
219159467|NCT03333018|DRUG|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
219732879|NCT04613570|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
219732880|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
219732881|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Orsiro DES)|stenting
219732882|NCT02390375|DRUG|DW-0929|5/10mg
219732883|NCT02390375|DRUG|DW-0929|10/10mg
219159468|NCT03333018|DRUG|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
219159469|NCT03333018|DRUG|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
219159470|NCT03776500|DRUG|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
219159471|NCT03776500|DRUG|Placebo|matching placebo supplied as powder for oral solution
219159472|NCT01865474|DRUG|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
219159473|NCT01865474|DRUG|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
219159474|NCT05477316|RADIATION|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
219159475|NCT05161585|DIAGNOSTIC_TEST|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
219159476|NCT02960204|DRUG|Emricasan|
219159477|NCT02960204|DRUG|Placebo|
219159478|NCT02134106|DRUG|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
219159479|NCT02134106|DRUG|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
219159480|NCT00475241|BEHAVIORAL|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
219159481|NCT00475241|BEHAVIORAL|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
219159482|NCT02044809|DRUG|Cannabidiol|
219159483|NCT02044809|DRUG|Placebo|
219159484|NCT03933800|DEVICE|High flow nasal cannula|High flow nasal cannula therapy
219159485|NCT03933800|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure therapy
219159486|NCT06374004|OTHER|Exercise Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes.
219159487|NCT06374004|OTHER|Thoracic Mobilization Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes. Thoracic mobilization will be applied to segments where passive accessory movement is insufficient or painful. 30 repetitions/4 sets will be applied to each determined segment. Thoracic mobilization will be performed with the patient lying prone position.
219159488|NCT05663502|PROCEDURE|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
219159489|NCT06488781|DRUG|Azithromycin|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
219159490|NCT06488781|DRUG|Placebo|Placebo given in place of other two active drugs
219159491|NCT01154439|DRUG|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
219159492|NCT01154439|DRUG|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
219732884|NCT02390375|DRUG|DW-0929|20/10mg
219732885|NCT02390375|DRUG|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
219159493|NCT01154439|DRUG|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
219159494|NCT01154439|DRUG|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
219159495|NCT01154439|DRUG|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
219159496|NCT00173524|BEHAVIORAL|PharmacoEconomic Assessment|Collecting PE data.
219732886|NCT02390375|DRUG|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
219732887|NCT02390375|DRUG|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
219732888|NCT06386120|OTHER|PEEP setting strategy|The attending physician selects different PEEP setting strategies
219732889|NCT03666793|OTHER|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
219732890|NCT00754559|DRUG|Tocilizumab|8mg/kg iv every 4 weeks
219732891|NCT01663987|DRUG|tiotropium bromide|18 mcg once a day (QD)
219732892|NCT01663987|DRUG|Placebo|once a day (QD)
219159497|NCT05115058|OTHER|relex Smile module|
219159498|NCT03087708|DRUG|Naloxegol|Given PO
219159499|NCT03087708|OTHER|Placebo|Given PO
219159500|NCT03087708|OTHER|Laboratory Biomarker Analysis|Correlative studies
219159501|NCT03087708|OTHER|Quality-of-Life Assessment|Ancillary studies
219159502|NCT06978166|OTHER|Just-In-Time Adaptive Interventions (JITAIs)|JITAIs are digital interventions that aim to deliver support to a user when the person is most in need and receptive to the intervention. In this study, multiple JITAIs will be tested and refined through completion of an iterative series of randomized trials that are interspersed with qualitative participant interviews. The purpose of each JITAI under investigation is to improve engagement with the Wysa for Chronic Pain app.
219159503|NCT06978166|BEHAVIORAL|Wysa for Chronic Pain|Wysa for Chronic Pain is an app-based digital mental health intervention that uses a behavioral activation framework and encourages users to work toward pain acceptance. The intervention also includes cognitive behavioral therapy, mindfulness, and sleep tools.
219159504|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
219159505|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
219159506|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
219159507|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
219159508|NCT05180344|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
219159509|NCT06025383|DIETARY_SUPPLEMENT|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
219234899|NCT06699095|DEVICE|Telerehabilitation|Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
219234900|NCT06700031|DEVICE|Inertial measurement unit|A sensor, an inertial measurement unit (IMU), will be attached to the thigh when the individual is on the postoperative ward and will be worn throughout the hospital stay. The IMU measures 7.9 x 3.2 x 0.8 cm and records body positions, movements, and gait parameters.
219732893|NCT05418920|PROCEDURE|left-opening single-flap technique|left-opening single-flap technique
219732894|NCT05418920|PROCEDURE|double-flap group technique|double-flap group technique
219732895|NCT01829503|DRUG|decitabine and cytarabine|
219732896|NCT01829503|OTHER|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
219159510|NCT06025383|DIETARY_SUPPLEMENT|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
219234901|NCT06698965|DRUG|Chemotherapy （Etoposide and Carboplatin）|"Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle."
219234902|NCT06698965|DRUG|Immunotherapy （Envafolimab）|Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
219234903|NCT06698965|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
219732897|NCT04305652|OTHER|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
219732898|NCT00002238|DRUG|Interferon beta-1b|
219159511|NCT06187298|DIETARY_SUPPLEMENT|A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care|(Enterophytol® PLUS) alongside standard of care
219159512|NCT06815653|DRUG|Psilocybin 25mg|Psilocybin PEX010 is an investigational drug provided in capsule form, containing a 25 mg dose of synthetic psilocybin. The product is manufactured under Good Manufacturing Practice (GMP) standards to ensure purity, potency, and consistency. Each participant will receive a single oral dose of 25 mg psilocybin in a hydroxypropyl methylcellulose (HPMC) capsule. The intervention is administered once during the study session, with the effects expected to last approximately 4 to 6 hours.
219159513|NCT06860113|PROCEDURE|T-tilting of the patient during surgery|Patients will be placed at the T-Tilt position (15 degrees Trendelenburg and 15 degrees away from the surgical side kidney) during surgery.
219159514|NCT06860113|PROCEDURE|standard lithotomy position|Patients will be placed in regular lithotomy position with operating table at 0 degrees of tilting.
219159515|NCT06864988|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
219159516|NCT06864988|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
219159517|NCT04674293|DRUG|Revelisa|Thrombolytic therapy for patients with ischemic stroke
219159518|NCT07000552|OTHER|EFT intervention|The intervention groups will be followed up for 4 weeks and 4 EFT therapies will be applied, one session per week.
219159519|NCT06372067|DEVICE|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
219159520|NCT06372067|DEVICE|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
219159521|NCT06920693|DRUG|GB-7624|Study Drug GB-7624
219159522|NCT06920693|DRUG|Placebo|Placebo
219234904|NCT06699420|DRUG|Qishenyiqi dripping pills 1 bag, three times a day|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
219732899|NCT00002238|DRUG|Zidovudine|
219732900|NCT05077111|PROCEDURE|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
219732901|NCT05077111|PROCEDURE|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
219732902|NCT04236947|BEHAVIORAL|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
219732903|NCT01016041|DEVICE|everolimus stent|stenting
219732904|NCT01016041|DEVICE|paclitaxel stent|stenting
219732905|NCT06021379|DRUG|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
219732906|NCT05254860|PROCEDURE|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
219732907|NCT06447051|OTHER|Kasai Surgery|As per institute treatment protocol
219159523|NCT06867445|PROCEDURE|Minimally invasive pelvic exenteration|If all criteria are met, patients are registered. The patient is enrolled before the surgery, at the time of pelvic evaluation under anaesthesia. A diagnostic laparoscopic assessment can be performed before the operation to exclude peritoneal metastasis. The experimental procedure in this protocol involves the use of a minimally invasive approach (robot-assisted or laparoscopic) for performing pelvic exenteration.
219159524|NCT01456013|DEVICE|RenalGuard Therapy|Induced Diuresis with matched replacement
219159525|NCT01456013|DRUG|Standard Therapy|Standard of care for patients at risk of CIN
219159526|NCT05009862|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
219159527|NCT05009862|DRUG|Placebo|placebo
219159528|NCT05009862|DRUG|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
219159529|NCT07021872|BEHAVIORAL|Tele-Positive Affect Intervention|A 4-week intervention consisting of eight skills aimed at enhancing positive affect, delivered via telephone by trained facilitators. Participants will learn skills such as gratitude, mindfulness, and positive reappraisal, with sessions held twice a week.
219159530|NCT07021872|BEHAVIORAL|Tele-Behavioral Activation Intervention|A 4-week intervention designed to promote engagement in meaningful activities, delivered through telephone by trained facilitators. The intervention will include behavior monitoring, activity planning, and social skills enhancement, with sessions held twice a week.
219159531|NCT07021872|BEHAVIORAL|Tele-Friendly Visit|An active control condition consisting of telephone-delivered friendly visits. Participants will engage in social conversation and activities to provide companionship without any specific skills training aimed at reducing loneliness. The intervention will be held within 4-week.
219159532|NCT06712004|DRUG|Bevifibatide citrate injection|Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.
219234905|NCT06699420|DRUG|Placebo 1 bag, three times a day|Placebo, 1 bag once, three times a day, 12 months
219234906|NCT06698913|PROCEDURE|Rotational Therapy|Sample1- Ventilator settings where adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment for both sides. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O. Sample2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT.
219732908|NCT02852746|BEHAVIORAL|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
219159533|NCT06709859|DRUG|Afatinib plus chemotherapy as conversion treatment|Patients with unresectable EGFR sensitive mutation-positive stage III NSCLC will receive 3-4 cycles of afatinib plus chemotherapy as the conversion treatment, and then surgery will be provided for patients who are suitable for primary tumor resection.
219159534|NCT06717152|DRUG|SJP-0132|Aqueous eye drop, one drop each time and four times each day, 8 weeks in treatment period in SJP-0132 group.
219159535|NCT06717152|DRUG|Placebo|Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.
219159536|NCT07036198|BEHAVIORAL|Customizable personalized normative feedback (CPNF)|The CPNF intervention allows individuals to explore normative feedback for a wider variety of referent groups so that PNF is a truly personalized and engaging experience.
219159537|NCT07036198|BEHAVIORAL|Personalized normative feedback (PNF)|Correcting misperceptions about peers' alcohol use behaviors and contrasting one's own use to the actual norms of their peers.
219159538|NCT07036198|BEHAVIORAL|Attention-Matched Control (AMC)|Participants in the AMC condition will complete all measures at the same time as participants in the CPNF condition but will not receive any information on drinking norms. Instead, participants in the AMC will receive normative feedback on sleep health, video game use, and gambling behaviors, and will similarly be able to choose the normative referent groups they wish to view feedback on for these behaviors. The AMC will thus serve as a non-treatment comparison that controls for assessment reactivity and effects of history and maturation.
219732909|NCT03413917|OTHER|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
219732910|NCT04803903|DEVICE|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
219732911|NCT04825899|OTHER||
219732912|NCT00004015|DRUG|sodium borocaptate|
219732913|NCT00004015|PROCEDURE|adjuvant therapy|
219732914|NCT01823887|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
219732915|NCT02662465|PROCEDURE|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
219732916|NCT06178913|OTHER|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
219732917|NCT03864549|DIETARY_SUPPLEMENT|Femina II|2 capsules per day until delivery
219159539|NCT07048015|OTHER|Hot Water Foot Bath|Hot Water Foot Bath:When the water temperature reached 40 ° C, the elderly person's feet were placed in the foot bath tub. The elderly person's feet were kept in the water for 20 minutes.
219159540|NCT01303445|DRUG|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
219159541|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
219234907|NCT06699407|DRUG|Qishenyiqi dripping pills|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
219234908|NCT06699407|DRUG|Placebo|Placebo, 1 bag once, three times a day, 12 months
219732918|NCT03864549|OTHER|Placebo|2 capsules per day until delivery
219732919|NCT05174702|RADIATION|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
219732920|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
219732921|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
219732922|NCT00676689|DEVICE|SAPIEN Transcatheter Valve Implantation|Device Implantation
219732923|NCT03109392|DRUG|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
219732924|NCT03109392|DRUG|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
219159542|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
219159543|NCT01303445|DRUG|Omeprazole alone|omeprazole 80 once daily for 7 days
219159544|NCT02462499|DRUG|Inspra (eplerenone)|
219159545|NCT07063433|DRUG|Gluma Desensitizer|Each sensitive tooth will be cleaned with a polishing paste, rinsed with water and air dried. Two coats of Gluma Desensitizer will be applied using a disposable brush applicator following the manufacturer's instructions and left untouched for 30-60 minutes.
219159546|NCT07063433|DRUG|Bioactive glass|The NSK Prophymate Neo will be utilized to dispense Sylc dry powder, which comprises calcium sodium phosphosilicate, onto the sensitive areas. The air stream will be carefully adjusted to 40-46 psi in accordance with the manufacturer's instructions. The handpiece will be maintained at a constant distance of 3-4 mm from the tooth surface, positioned at 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth, using a circular motion.
219159547|NCT07063433|DRUG|Fluoride varnish|The application of a single dose of Bifluorid 10 (by VOCO) will be carried out using a micro brush. A thin coat of varnish will be applied to the tooth surface, and it will be left in place for 10-20 seconds before being air-dried.
219732925|NCT03109392|DRUG|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
219732926|NCT04460261|OTHER|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
219732927|NCT03721965|DRUG|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
219732928|NCT03721965|DRUG|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
219732929|NCT06377592|OTHER|Sample collection without intervention|No Intervention
219732930|NCT06446323|DRUG|0.2 ml dose of sucrose|Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
219159548|NCT06774612|OTHER|ChatGPT-4o|OpenAI's ChatGPT-4o large language model with chat interface.
219732931|NCT06220266|DRUG|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
219732932|NCT06220266|DRUG|Diet control & life style modification|Diet control \& life style modification
219732933|NCT00563316|DRUG|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
219732934|NCT00563316|DRUG|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
219732935|NCT00906750|BIOLOGICAL|FluMist|FluMist is a live attenuated intranasal influenza vaccine
219732936|NCT00906750|BIOLOGICAL|Inactivated influenza vaccine|Inactivated influenza vaccine
219159549|NCT07070544|DEVICE|Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on|"Electromagnetic Field Therapy:~* Frequency: 50 Hz~* Intensity: 5-30 mT~* Duration: 30 minutes/session~* Frequency: 3 sessions/week for 8 weeks~Customized Foot Insoles:~* Individually tailored based on foot pressure mapping and deformity.~* Designed to offload pressure points and support foot arches.~Standard Care:~• Wound care, glycemic control, and patient education as per institutional protocol."
219159550|NCT07070817|DRUG|Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection|"Ultrasound-guided injection of BoNT-A (specific dosage, e.g., 100 units) into target salivary glands ( parotid and submandibular glands) at baseline."
219159551|NCT07070817|DRUG|Control (Normal saline)|"Intervention: Participants receive routine swallowing rehabilitation training only.~Details of training: The training includes standard techniques to improve swallowing function, such as oral motor training, empty swallowing exercises, and ice stimulation. The frequency and duration of training are consistent across all participants in this arm to ensure standardization."
219159552|NCT07071831|DEVICE|RetroPerc®|The RetroPerc® will be used to obtain renal access.
219159553|NCT07070778|OTHER|Upper Extremity Aerobic Exercise Training Program|12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.
219159554|NCT07070388|DEVICE|end-effector robotic training|For the robotic training sessions, a haptic wrist robot known as the Wristbot was used (ReWing, Genova, Italy). The training protocol consisted of an eccentric contraction-based exercise. Participants trained 3x per week for 4 consecutive weeks for approximately 25-mins per session.
219159555|NCT06893016|DRUG|RAY1225|RAY1225 will be administered SC
219159556|NCT06893016|DRUG|Placebo|Placebo will be administered SC.
219159557|NCT07070024|DRUG|Vitamin C|Topical ascorbic acid powder, (1,000 mg/mL) mixed with saline will be applied over the gingiva for 10 minutes.
219159558|NCT07070024|DEVICE|Microneedling|MN will be achieved using a Dermapen device. c) The device allows for adjustable penetration depth, ranging from 0.2 mm to 3 mm, based on the gingival thickness. d) The needle tip comprises 12 to 24 needles arranged in rows, providing six-speed modes that span from 412 cycles/min at the lowest speed to 700 cycles/min at the highest speed. e) The Dermapen will be positioned perpendicular to the gingival surface, and microneedling will be executed horizontally, vertically, and diagonally approximately four to five times f) Across the entire hyperpigmented gingival surface until subtle microbleeding and mild erythema became evident Each individual will be undergoing a total of three treatment sessions of microneedling, spaced out by 10 days
219159559|NCT07070024|DEVICE|Diode laser|"Energy output, pulse duration, and focal distance will be determined based on manufactures instruction. b) Patient, doctor and assistant will wear protective glass before starting the procedure. c) Depigmentation will be carried out using semiconductor Sirolaser Blue With proper isolation, depigmentation procedure will be done. e) Laser ablation will be started from the mucogingival junction toward the free gingival margin, including interdental papilla. f) The laser beam will be applied using the brush technique, as described by Tal (Tal et al.,2003) and the tip will be kept in motion all the time. g) Remnants of the ablated tissue will be removed using sterile gauze dampened with saline solution"
219159560|NCT07070024|PROCEDURE|scalpal|Employing surgical blade number 15c, the gingival epithelium in the pigmented area will be excised. c) The blade will be oriented roughly parallel to the elongated axis of the teeth. d) A meticulous assessment of the revealed connective tissue surface will be performed, and any residual tissue tags will be removed with surgical scissors. e) Hemorrhage control will be managed by applying a pressure pack, and after achieving hemostasis, a periodontal dressing (a non-eugenol zinc oxide dressing) will be administered to cover the wound for one week.
219159561|NCT07071168|BEHAVIORAL|hearing-physical activity training|In this study, the intervention was designed to span 10 weeks. Based on our previous study, participants will attend hearing training 30 minutes/day, 5 days/week, The physical activity program will be performed at moderate intensity, 60 min/day, 3 days/week.39
219159562|NCT07079046|DIETARY_SUPPLEMENT|Intervention 1: Satisens®|A dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers.
219159563|NCT07079046|DIETARY_SUPPLEMENT|Intervention 2: Placebo|Identical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch.
219732937|NCT05520450|BEHAVIORAL|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
219360860|NCT04460755|OTHER|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
219732938|NCT02262273|OTHER|Data Collection|Colleciton of data from medical records only
219159564|NCT07078370|DEVICE|ATEV with ESS|Patients will be implanted with a single Acellular Tissue Engineered Vessel with External Support Structure bypass (single proximal and distal anastomoses) to the second or third coronary artery bypass target
219732939|NCT01171937|DRUG|Risperidone|children get randomized to either placebo or active risperidone
219732940|NCT01171937|DRUG|Placebo|Children get randomized to either placebo or risperidone
219732941|NCT05610150|DEVICE|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
219732942|NCT05610150|DEVICE|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
219732943|NCT06500936|OTHER|SMS|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
219732944|NCT02468700|DRUG|Dexamethasone|
219732945|NCT02468700|OTHER|Placebo Vehicle|
219732946|NCT01217411|PROCEDURE|Cognitive Assessment|Ancillary studies
219732947|NCT01217411|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219732948|NCT01217411|OTHER|Laboratory Biomarker Analysis|Correlative studies
219732949|NCT01217411|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219732950|NCT01217411|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219732951|NCT05406570|PROCEDURE|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
219159565|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
219732952|NCT05406570|PROCEDURE|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
219732953|NCT02573896|DRUG|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
219732954|NCT02573896|BIOLOGICAL|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
219732955|NCT02573896|DRUG|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
219732956|NCT04910503|DRUG|Dexamethasone intravitreal implant|Implant every 4 months if necessary
219732957|NCT04910503|DRUG|Fluocinolone Acetonide Intravitreal Implant|Implantation
219732958|NCT05736614|BEHAVIORAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
219732959|NCT05736614|BEHAVIORAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
219732960|NCT05026619|OTHER|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
219732961|NCT05026619|OTHER|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
219732962|NCT05026619|OTHER|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
219732963|NCT05554003|DRUG|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
219732964|NCT04899466|DEVICE|ActiGraft|Whole blood clot (WBC) gel
219732965|NCT06358443|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese + Vitamin D ampulles + Calcium
219732966|NCT03503799|OTHER|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
219732967|NCT05272696|DRUG|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
219732968|NCT05272696|PROCEDURE|surgery|Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.
219732969|NCT05272696|RADIATION|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
219732970|NCT05272696|DRUG|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
219732971|NCT06963593|DRUG|Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen|Megestrol Acetate Nanocrystal Oral Suspension Group: Nanocrystal Megestrol Acteate Oral Suspension (QD, up to 16 weeks from the initiation of immuno-chemotherapy) + PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
219732972|NCT06963593|DRUG|First-Line Standard Immuno-Chemotherapy Regimen|PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
219159566|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
219159567|NCT06955234|DIETARY_SUPPLEMENT|Berbevis supplement|This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
219159568|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
219159569|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
219159570|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
219159571|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 tablet orally once daily for 6 weeks.
219159572|NCT05686408|DRUG|Placebo|Patients will take 1 tablet orally once daily for 6 weeks.
219159573|NCT05810259|DEVICE|Caravan Wellness app|Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
219234909|NCT06698393|PROCEDURE|Suture 3.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 3.0 Diameter.
219732973|NCT06964646|DRUG|Vaginal Hyal gel 2.5g|vaginal gel 2.5g
219732974|NCT06964334|DRUG|Lansoprazole|oral lansoprazole (1 mg/kg per day, max. 30 mg bid)for 14 day
219732975|NCT06964334|DRUG|amoxicillin|amoxicillin (50 mg/kg per day, max. 1 g bid) for 14 day
219732976|NCT06964334|DRUG|clarithromycin|oral clarithromycin (15 mg/kg per day, max. 500 mg bid) for 14 day
219732977|NCT06964334|DRUG|vitamin D|vitamin D therapy of 4000-5000 units daily in patients over 12 months old.
219732978|NCT02458300|OTHER|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
219732979|NCT02458300|OTHER|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
219732980|NCT02458300|OTHER|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
219732981|NCT02458300|OTHER|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
219732982|NCT02458300|OTHER|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
219732983|NCT06406478|BEHAVIORAL|Schedule Change|This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.
219732984|NCT06406478|BEHAVIORAL|No Schedule Change|The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
219732985|NCT06084286|BIOLOGICAL|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
219732986|NCT04595370|DRUG|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
219732987|NCT04595370|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
219159574|NCT06247332|OTHER|Review of available clinical data sources related to use cases|There will be a review of available clinical data sources related to use cases. In addition, this information will be complemented by a cohort of anonymized retrospective data of 100 cases obtained from the clinical information resulting from the assistance to COVID-19 patients managed by the Primary Care Health District of Sevilla Norte and the Infectious Diseases Department of the Virgen Macarena University Hospital
219732988|NCT04438512|DRUG|Midomafetamine|Administration of 80 or 120 mg midomafetamine HCl in combination with manualized therapy and a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively
219159575|NCT02576509|DRUG|Nivolumab|Specified Dose on Specified Days
219159576|NCT02576509|DRUG|Sorafenib|Specified Dose on Specified Days
219159577|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
219159578|NCT06830083|RADIATION|Hypofractionated Radiation Therapy|Hypofractionation regimen: Total dose to the chest wall and the regional lymph nodes is 4050 cGy, and each fraction consists of 270 cGy per day(daily, Monday through Friday )
219159579|NCT06830083|RADIATION|Conventional fraction radiotherapy|Total dose of plan tumor volume is 5000 cGy，and each fraction will consist of 200 cGy per day. 25 fractions(daily, Monday through Friday) to the chest wall and to the supraclavicular (with or without axillary) lymph nodes.
219159580|NCT06832033|OTHER|Exercise|12 weeks of concurrent training, which is understood as a combination of strength and aerobic exercises, not necessarily in the same training session. The weekly frequency will be 3 times per week. The aerobic component of the session will last between 30 and 50 minutes (increasing as the weeks go by) and the strength work will be made up of 8 exercises (3 upper body and 5 lower body). The intensity of the training will be individualized and always moderate.
219159581|NCT02627508|DRUG|Pregnenolone|orally administered Pregnenolone capsules
219159582|NCT02627508|DRUG|Placebo|orally administered placebo capsules
219159583|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block|For the block, the ultrasound (USG)probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site. After the block site is confirmed, 30 ml of 0.25% bupivacaine (Marcain 0.5%® AstraZeneca, England) will be administered. The block catheter (Perifix® Braun, Germany) will then be inserted to block area
219732989|NCT04438512|BEHAVIORAL|Psychotherapy|Manualized therapy performed by therapist team
219732990|NCT06125548|OTHER|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
219732991|NCT03925714|OTHER|life style|life sryle control only
219732992|NCT03925714|DRUG|Metformin|metformin twice daily
219732993|NCT03925714|DRUG|Nigetella salivata|NS twice daily
219732994|NCT02745405|OTHER|Fat Suit|Participants wear a fat suit.
219732995|NCT02745405|OTHER|Control Condition|Participants wear same clothing as intervention, but in their own size.
219732996|NCT05352113|DRUG|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
219732997|NCT05352113|PROCEDURE|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219732998|NCT05352113|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
219732999|NCT05352113|DRUG|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
219733000|NCT04560114|DRUG|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary."
219161639|NCT02209350|PROCEDURE|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
219733001|NCT05497882|BEHAVIORAL|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
219733002|NCT03492112|DEVICE|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
219733003|NCT03492112|DRUG|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
219733004|NCT03492112|DRUG|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
219733005|NCT03536065|BEHAVIORAL|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
219733006|NCT03536065|BEHAVIORAL|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
219733007|NCT01219075|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
219161640|NCT02209350|DRUG|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
219161641|NCT06755203|OTHER|Operating Room Simulation Training|"The intervention involves high-fidelity OR simulations focusing on critical areas of patient safety, including:~Communication Skills: Emphasizing clear communication during surgical procedures.~Stress Management: Training participants to manage stress effectively in high-pressure situations.~Protocol Adherence: Practicing adherence to the WHO Surgical Safety Checklist. Risk Assessment: Identifying and mitigating potential safety risks in simulated scenarios"
219733008|NCT01219075|OTHER|placebo|Given orally
219733009|NCT01219075|OTHER|questionnaire administration|Ancillary studies
219733010|NCT01219075|PROCEDURE|magnetic resonance imaging|Correlative studies
219733011|NCT01219075|PROCEDURE|biopsy|Correlative studies
219733012|NCT01219075|OTHER|immunohistochemistry staining method|Correlative studies
219733013|NCT01219075|OTHER|laboratory biomarker analysis|Correlative studies
219733014|NCT01219075|PROCEDURE|mammography|Correlative studies
219733015|NCT03383133|DRUG|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
219733016|NCT05791149|DIAGNOSTIC_TEST|saliva tube|1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
219733017|NCT05199155|BIOLOGICAL|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
219733018|NCT01341990|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
219733019|NCT01341990|DEVICE|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
219733020|NCT01341990|DEVICE|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
219733021|NCT03269786|DIAGNOSTIC_TEST|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
219733022|NCT03269786|DEVICE|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
219733023|NCT06563349|DRUG|Intravenous magnesium sulfate|Intraoperative intravenous magnesium sulfate infusion.
219733024|NCT06563349|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
219733025|NCT00077012|DRUG|QLT0074|
219733026|NCT00077012|DRUG|Photodynamic therapy|
219733027|NCT01701635|BEHAVIORAL|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
219733028|NCT01701635|BEHAVIORAL|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
219733029|NCT04933227|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
219733030|NCT04933227|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
219733031|NCT04933227|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
219733032|NCT04933227|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
219733033|NCT03014388|OTHER|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
219733034|NCT03014388|OTHER|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
219733035|NCT05623514|COMBINATION_PRODUCT|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
219733036|NCT05028660|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
219733037|NCT06203964|OTHER|No intervention|No intervention
219733038|NCT01678690|DRUG|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
219733039|NCT01751685|BEHAVIORAL|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
219733040|NCT01751685|OTHER|Control|monthly educational lectures on various topics
219733041|NCT04351815|BEHAVIORAL|Short term prehabilitation (2 weeks)|"* Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
219733042|NCT04351815|OTHER|No specific intervention|"* Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
219733043|NCT00694161|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
219733044|NCT02505971|DRUG|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
219234910|NCT06698393|PROCEDURE|Suture 6.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 6.0 Diameter.
219234911|NCT05934175|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
219234912|NCT05934175|BEHAVIORAL|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
219733045|NCT02505971|DRUG|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
219733046|NCT06305065|PROCEDURE|KUNWU Navigation TKA procedure|"In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization."
219733047|NCT06305065|PROCEDURE|CORI Surgical System TKA procedure|The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).
219159584|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block + Serratus Anterior Plane Block|For ESPB, USG probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site and 30 ml of 0.25% bupivacaine (Marcain®) will be administered. The block catheter (Perifix®) will be inserted. For SAPB, the USG probe will be placed parasagittal to the mid-axillary line at the 5th-6th rib level and the anechoic shadow of the costa together with the latissumus dorsi and serratus anterior muscles will be visualized. Then using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the serratus anterior muscle and the block site will be confirmed and 30 ml of 0.25% bupivacaine will be administered.
219159585|NCT03746054|COMBINATION_PRODUCT|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
219159586|NCT03746054|COMBINATION_PRODUCT|usual clinical practice|usual clinical practice in each center
219159587|NCT06791616|PROCEDURE|Colonoscopy|Surveillance colonoscopy
219159588|NCT06791213|OTHER|Digital Multimedia Health Education|"This study aims to investigate the effectiveness of digital multimedia in reducing pain, enhancing medication adherence, and improving pain control satisfaction among patients. The goal is to overcome the limitations of busy healthcare providers, allowing patients to learn independently, understand pain and analgesic use, dispel myths about pain medications, and enhance pain control, ultimately improving self-care capabilities, pain control satisfaction, and quality of life."
219733048|NCT06305065|PROCEDURE|Conventional TKA procedure|Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
219733049|NCT00002051|DRUG|Thymopentin|
219733050|NCT01940146|DRUG|SPARC Placebo|Placebo
219733051|NCT01940146|DRUG|SPARC1310 I|SPARC1310 I
219733052|NCT01940146|DRUG|SPARC1310 II|SPARC1310 II
219733053|NCT01940146|DRUG|SPARC1310 III|SPARC1310 III
219733054|NCT02186067|OTHER|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
219733055|NCT01113957|DRUG|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
219733056|NCT01113957|DRUG|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
219733057|NCT01113957|DRUG|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
219733058|NCT01249443|DRUG|vorinostat|Given PO
219161642|NCT03517553|DEVICE|EMS users in ESRD|use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
219161643|NCT06753825|DEVICE|Radiofrequency|radiofrequency treatment
219161644|NCT06753825|DRUG|flunarizine|flunarizine oral treatment
219733059|NCT01249443|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219733060|NCT01249443|OTHER|pharmacological study|Correlative studies
219733061|NCT01249443|DRUG|carboplatin|Given IV
219733062|NCT01249443|DRUG|paclitaxel|Given IV
219733063|NCT02273466|DRUG|Desipramine tablet|
219733064|NCT02273466|DRUG|Crobenetine infusion|
219733065|NCT02273466|DRUG|Placebo infusion|
219733066|NCT05095337|DRUG|[14C]SHR1459|Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
219733067|NCT03790969|DEVICE|26 gauge needle|smaller gauge needle
219733068|NCT03790969|DEVICE|23 gauge needle|control group
219733069|NCT05181657|BEHAVIORAL|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
219733070|NCT04902066|OTHER|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
219159589|NCT06790875|DEVICE|Airway Pressure Release Ventilation (APRV)|In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.
219159590|NCT06790537|DRUG|Pregabalin 75 mg|75 mg of pregabalin will be given at night for the intervention group along with emollient local application
219159591|NCT06790537|OTHER|Placebo Oral Capsule|placebo capsule will be identical in appearance to the pregabalin capsule. it will be given at the same time of the day like pregabalin. same Emollient which is used in the Intervention arm will be applied locally on the areas of itching, morning after bathing .
219159592|NCT06787833|OTHER|Questionnaire|to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3).The same questionnaire was refilled at the end of the week in which music was played (T4).
219159593|NCT06787833|OTHER|listening to music|Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes)23,55, Mozart's Serenata Notturna KV239 (12.50 minutes)18,19, and Pachelbel's Canon in D major (6.16 minutes)24,25 were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period.
219159594|NCT06772415|DRUG|GenSci122 tablet 50mg|Orally Once Daily
219159595|NCT06772415|DRUG|GenSci122 tablet 250mg|Orally Once Daily
219159596|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
219159597|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
219159598|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
219159599|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
219159600|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
219159601|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
219159602|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
219159603|NCT05873062|DRUG|AUT00201|Single oral dose
219159604|NCT05873062|DRUG|Placebo|Single oral dose
219159605|NCT05782010|DEVICE|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
219159606|NCT05522231|DRUG|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
219159607|NCT05522231|DRUG|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
219159608|NCT05522231|DRUG|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
219159609|NCT06546657|OTHER|Breakfast|Breakfast meal
219159610|NCT03254589|DRUG|Methotrexate|See arm descriptions
219159611|NCT03254589|DRUG|Sulfasalazine|See arm description
219159612|NCT03254589|DRUG|Other DMARDs|See arm
219159613|NCT06173362|DRUG|Abiraterone|Given abiraterone
219159614|NCT06173362|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219159615|NCT06173362|DRUG|Darolutamide|Given darolutamide
219159616|NCT06173362|DRUG|Prednisone|Given prednisone
219159617|NCT01999062|OTHER|IMRT + CT + MR scan|
219159618|NCT05039177|DRUG|ERAS-007|Administered orally
219159619|NCT05039177|DRUG|Encorafenib|Administered orally
219159620|NCT05039177|DRUG|Cetuximab|Administered via intravenous infusion
219159621|NCT05039177|DRUG|Palbociclib|Administered orally
219159622|NCT05589220|OTHER|Music Intervention|Music therapy carried out with MUSIC CARE©
219159623|NCT05589220|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
219733071|NCT04902066|OTHER|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
219733072|NCT03297827|OTHER|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
219159624|NCT03595059|DRUG|ABBV-155|Intravenous (IV) Infusion
219159625|NCT03595059|DRUG|Paclitaxel|Intravenous (IV) Infusion
219159626|NCT03595059|DRUG|Docetaxel|Intravenous (IV) Infusion
219159627|NCT06651255|PROCEDURE|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
219733073|NCT04779723|PROCEDURE|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
219733074|NCT04726488|PROCEDURE|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
219733075|NCT04726488|PROCEDURE|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
219733076|NCT01978574|BEHAVIORAL|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
219733077|NCT01978574|BEHAVIORAL|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
219733078|NCT04701320|DRUG|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
219733079|NCT04701320|DRUG|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
219733080|NCT01594684|DEVICE|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
219733081|NCT01594684|DEVICE|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
219733082|NCT01594684|DEVICE|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
219733083|NCT01594684|DEVICE|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
219733084|NCT03053999|OTHER|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
219159628|NCT06651255|PROCEDURE|Standard of care management|Standard of care management
219159629|NCT04847479|BEHAVIORAL|COVID-19 self-test|Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.
219159630|NCT04847479|BEHAVIORAL|COVID-19 test referral|Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
219159631|NCT05078528|DEVICE|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
219733085|NCT03053999|OTHER|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
219159632|NCT01285479|DRUG|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
219733086|NCT05132452|DIAGNOSTIC_TEST|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
219159633|NCT03725722|DRUG|Delgocitinib cream|Cream for topical application
219159634|NCT03725722|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219733087|NCT05187637|DRUG|intravenous iron|One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
219733088|NCT04947280|RADIATION|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
219159635|NCT05154825|OTHER|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
219159636|NCT05663034|BEHAVIORAL|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
219159637|NCT05663034|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
219159638|NCT01600014|DRUG|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
219733089|NCT05823454|DRUG|Different drug dosage|Choice of Anesthesia
219733090|NCT04214236|DEVICE|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
219733091|NCT04214236|OTHER|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
219733092|NCT06376227|PROCEDURE|with or without Left Colic Artery Preservation|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
219159639|NCT01600014|DRUG|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
219159640|NCT02872025|DRUG|Pembrolizumab|Injected intralesionally
219733093|NCT02470767|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
219733094|NCT03460964|DEVICE|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
219733095|NCT03460964|DRUG|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
219733096|NCT04002557|OTHER|Interview-Questionnaire|Questionnaire
219733097|NCT04007874|DRUG|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
219733098|NCT04007874|DRUG|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
219733099|NCT05697003|DRUG|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
219733100|NCT05697003|DRUG|ADVAIR DISKUS 100/50|2 inhalations in one study period
219733101|NCT05558670|OTHER|PET-fMRI-EEG|Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
219733102|NCT04636944|OTHER|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
219733103|NCT06604598|DRUG|IBU-PCT-DEX|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
219159641|NCT02872025|BIOLOGICAL|Intralesional mRNA 2752|Injected intralesionally
219733104|NCT06604598|DRUG|IBU-PCT-placebo|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
219733105|NCT06604598|DRUG|PCT-placebo-placebo|Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
219733106|NCT00394537|DRUG|Labetalol 10mg iv|
219733107|NCT00800384|DEVICE|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
219733108|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with Fluorescent Cholangiography|Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
219733109|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with White Light Imaging|As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
219733110|NCT06812013|OTHER|assessment of foot print and balance|"For static and dynamic balance assessment, Biodex Medical Systems Inc., Shirley, New York, USA (serial n.: 13020193) was used. The device consists of a circular foot platform that permits tilting in all directions, height-adjustable support rails, height adjustable display screen, and a printer. Balance assessment by the Biodex system is a valid and reliable objective measurement.~For assessment of foot print symmetry Tekscan HR walkway Mat™ pressure measurement system, Tekscan Inc. USA will be use. It is made up of a digital mat inserted into a wooden walkway, sensors (4 senses/cm2) embedded in the mat, and a computer running the Tekscan Software (version 7) for data extrapolation."
219159642|NCT05759533|PROCEDURE|Corrected carotid flow time, IVC diameter|Corrected carotid flow time correction: is the carotid systole time, with heart rate correction applied IVC Collapsibility Index measurement is a reliable predictor of intraoperative hypotension within 30 minutes of spinal anesthetic administration
219161645|NCT03271151|DRUG|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
219733111|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
219733112|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
219733113|NCT01433770|DRUG|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
219733114|NCT02119000|DRUG|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
219733115|NCT02119000|DRUG|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
219733116|NCT02857959|DRUG|Benzathine Penicillin G|
219733117|NCT03361072|DIETARY_SUPPLEMENT|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
219733118|NCT05052645|PROCEDURE|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
219733119|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian yogurt|Vegetarian yogurt alternative will be uesd.
219733120|NCT06696222|DIETARY_SUPPLEMENT|Placebo|Ordinary diet with dairy based yogurt
219733121|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian meat alternative|Vegetarian meat alternative consumed
219733122|NCT06696222|DIETARY_SUPPLEMENT|Ordinary meat diet|Ordinary meat diet used as placebo
219159643|NCT04510064|DRUG|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
219159644|NCT04510064|PROCEDURE|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
219733123|NCT05274451|BIOLOGICAL|LYL797|LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy
219733124|NCT06687044|BEHAVIORAL|Sleep restriction|Go to bed before 23pm
219733125|NCT06687044|BEHAVIORAL|Stimulation control|Avoid drugs, alcohol, caffeine, and nicotine
219159645|NCT05923944|BEHAVIORAL|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
219733126|NCT06687044|BEHAVIORAL|Cognitive therapy|Listen to 30 minutes of soothing music every night for 8 weeks
219733127|NCT06687044|BEHAVIORAL|Sleep principles discussion|The principles of sleep hygiene are discussed, but without the application of stimulus control or sleep restriction
219733128|NCT00651807|DRUG|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
219733129|NCT00651807|DRUG|Placebo|Every day one tablet up to 8 weeks
219733130|NCT07031635|OTHER|Hydrotherapy (Warm Shower)|Pregnant women who met the inclusion criteria and agreed to participate in the intervention group received a warm shower once cervical dilation reached 5 cm. Based on their preference, participants either stood or sat during the 30-minute shower.
219733131|NCT07046104|OTHER|implant retained overdenture prosthesis|implant retained only prosthesis
219733132|NCT07046104|OTHER|implant canine retained overdenture prosthesis|prosthesis retention from implant and canine
219733133|NCT06889493|BIOLOGICAL|Seneca Valley Virus-001 (SVV-001)|"SVV-001 will be administered intratumorally as a single dose on Day 1; or as multiple doses on Days 1, 15, 29, 43, 57, and 71. The virus dose levels per SVV-001 treatment are as follows:~* 2.2 × 10\^8 Viral Genomes (VG) (starting dose)~* 2.2 × 10\^9 VG~* 2.2 × 10\^10 VG"
219733134|NCT06889493|DRUG|Nivolumab|Nivolumab will be administered via intravenous (IV) injection at a dose of 240 mg, once every two weeks starting on Day 15 until Day 85 during SVV-001 therapy. Nivolumab will be administered once every four weeks during the maintenance period for up to 2 years.
219733135|NCT06889493|DRUG|Ipilimumab|Ipilimumab will be administered via intravenous (IV) injection at a dose of 1 mg/kg, once every six weeks starting on Day 15 until Day 85 during SVV-001 therapy. Participants will continue on 1 mg/kg ipilimumab IV every 6 weeks for two additional doses or unacceptable toxicity and/or participant withdrawal.
219159646|NCT05923944|BEHAVIORAL|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
219159647|NCT06248008|DRUG|ASC40|ASC40 tablets orally once daily
219159648|NCT06439537|OTHER|Semi-structured questionnaire|All patients recruited to the study will undergo a semi-structured questionnaire within 36 hours of admission
219159649|NCT06439537|OTHER|Post-operative interview|All patients recruited to the study will undergo a semi-structured interview once they have reached post-operative day 7 or over
219159650|NCT04039841|DIAGNOSTIC_TEST|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
219159651|NCT05810051|BEHAVIORAL|Cardiac rehabilitation|"The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training."
219159652|NCT06536270|OTHER|A validation and reproducibility study with a cross-sectional component|The primary intervention in this study involves adapting and validating the eNutri web-based Food Frequency Questionnaire and Diet Quality Score for the Turkish population.
219159653|NCT01923506|RADIATION|stereotactic body radiation therapy|Undergo SBRT
219159654|NCT01923506|PROCEDURE|quality-of-life assessment|Ancillary studies
219159655|NCT01923506|OTHER|laboratory biomarker analysis|Correlative studies
219159656|NCT06810687|DRUG|Methenamine Hippurate 1g BD|Antibiotic prophylaxis
219159657|NCT06810687|OTHER|Antibiotic prophylaxis|Antibiotic prophylaxis
219234913|NCT05406713|DRUG|Pembrolizumab|400 mg intravenously
219733136|NCT07045038|DEVICE|Acupuncture LLLT:|"Acupuncture LLLT:~This mode of therapy will be conducted for study group B as follows:~A therapeutic unit (M6 MLS from ASA laser, Italy) with wavelength 905 nm, output 5-20 MW, laser beam spot size 0.785 cm2, energy density 91 J/cm2, energy delivered 28 J, and frequency 500HZ. Laser probe will be placed in intercostal space both anteriorly and posteriorly on chest wall.~Each acupuncture point will be stimulated with a laser for 60 s, three weekly sessions over 12 successive weeks. Anterior chest wall acupuncture points are {LU1, LU2, CV17, (Ren17)}, posterior chest wall from a prone or setting position of the patient {UB13, (BL13), UB 17(BL17)}."
219159658|NCT04063709|DIAGNOSTIC_TEST|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
219159659|NCT05657743|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
219159660|NCT04507503|DRUG|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
219159661|NCT03554265|DRUG|Somatropin|Genotropin given by injection
219159662|NCT05579743|OTHER|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
219159663|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
219159664|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
219159665|NCT05464329|DRUG|Mosunetuzumab|Provided by Genentech.
219159666|NCT05464329|DRUG|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
219159667|NCT05464329|DRUG|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
219159668|NCT02432963|OTHER|Laboratory Biomarker Analysis|Correlative studies
219159669|NCT02432963|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
219159670|NCT02432963|BIOLOGICAL|Pembrolizumab|Given IV
219159671|NCT05235464|OTHER|Standard meal|Standard meal
219159672|NCT05235464|OTHER|High animal protein meal|Meal with high animal protein content
219159673|NCT05235464|OTHER|High plant protein meal|Meal with high plant protein content
219159674|NCT05235464|OTHER|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
219234914|NCT06911788|DRUG|Vepdegestrant (Reference)|Participants will receive a single intravenous (IV) dose of Vepdegestrant on Period 1 Day 1
219234915|NCT06911788|DRUG|Vepdegestrant (Test)|Participants will receive a 200 mg single oral dose of Vepdegestrant tablet formulation on Period 2 Day 1
219234916|NCT06910293|DIAGNOSTIC_TEST|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.
219159675|NCT06761755|OTHER|hot pack , K taping , Progressive muscle relaxation|"Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days"
219159676|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol
219159677|NCT06786390|OTHER|Rehabilitation protocol without FES|Subjects belonging to the control group will follow the rehabilitation protocol without FES
219159678|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol
219159679|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
219159680|NCT05663294|RADIATION|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
219159681|NCT05663294|RADIATION|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
219159682|NCT03328455|BEHAVIORAL|Inhibitory control training|Cognitive training is inhibitory task-related.
219159683|NCT03328455|BEHAVIORAL|Knowledge-based training|Training is not inhibitory task-related.
219159684|NCT05386238|BEHAVIORAL|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
219159685|NCT05386238|BEHAVIORAL|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
219159686|NCT05989347|DRUG|Dapagliflozin 10mg|10 mg tablets for oral administration daily throughout chemotherapy treatment
219733137|NCT07045038|OTHER|Blood flow restricted resistance exercise:|"The subject will warm up and cool down for at least five to seven minutes each, (before and after exercise).~The patients will perform blood flow restricted resistance exercise (BFRRE) at 40-80% of 1RM with 50% limb occlusion pressure (LOP), while placing cuff on midthigh and perform four sets of bilateral knee extension exercise, each set consist of 15 repetitions with 30-60 second rest in between sets and relieve cuff pressure in rest period, three weekly sessions over 12 successive weeks"
219733138|NCT07045038|DRUG|Medical treatment|"All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).~Also all patients will adhere to routine cardiac rehabilitation:~The patients will enroll in CR program for 12 weeks, three times per week for 12 week. Moderate-intensity treadmill exercise training achieving a target heart rate of 40-60% of HR reserve (calculated from pre-exercise symptom-limited treadmill exercise stress test by modified Bruce protocol). The duration of each session was 30- 45 minutes (5-10 minutes of treadmill warm up, followed by 20-30 minutes of aerobic continuous treadmill training and terminated by 5-10 minutes of cooling down"
219733139|NCT07056478|DRUG|Denosumab (Prolia)|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
219159687|NCT06819280|BIOLOGICAL|GT307 injection|GT307 injection to treat Advanced Colorectal Cancer
219159688|NCT05057897|BIOLOGICAL|AZD1222|10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
219159689|NCT04714320|DRUG|Placebo|ISIS 757456 matching placebo administered by SC injection.
219733140|NCT07056478|DRUG|Zoledronic acide (Aclasta)|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
219733141|NCT06786052|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 3 months.
219733142|NCT06786052|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 3 months.
219733143|NCT01094093|DRUG|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
219733144|NCT03404375|DEVICE|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
219733145|NCT06764654|PROCEDURE|Dental implant placement|Placement of two dental implants in the jaw.
219733146|NCT06145555|BEHAVIORAL|Acute psychological sleep stabilization|See above (arm description)
219733147|NCT06145555|BEHAVIORAL|Sleep hygiene education|See above (arm description)
219159690|NCT04714320|DRUG|IONIS-AGT-LRx|IONIS-AGT-LRx administered by SC injection.
219159691|NCT05327829|COMBINATION_PRODUCT|External non-invasive stimulation|The participants are randomized into the block design of sham or tACS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.
219159692|NCT05327829|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
219159693|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
219159694|NCT06788041|OTHER|Hamman experience|There will be a circuit in the Hammam Al Andalus baths with baths in all pools (warm, hot or cold water) and sauna for 30 minutes. The time in each pool will be determined by the sensation and tolerance of each participant. In addition, participants will receive foam with aromatic oils on the participant's body (arms, trunk and legs). This foam will be left for about 10 minutes on the participant's body, while a manual body therapy is performed. The force to be applied will be very weak, a superficial rubbing will be performed to prepare the tissue, followed by a maintained pressure and then sliding pressures are performed. The application time should not exceed 15 minutes.
219733148|NCT01293877|PROCEDURE|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
219733149|NCT04968145|OTHER|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
219733150|NCT06025227|DRUG|Etrasimod|tablets
219733151|NCT04484701|DRUG|68Ga-PSMA-11|PET/CT scan with radiotracer 68Ga-PSMA-11
219733152|NCT03724227|DRUG|ACE-011|ACE-011 will be administered subcutaneous injection
219733153|NCT05222789|PROCEDURE|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
219733154|NCT05995561|OTHER|no intervention is planned.|no intervention is planned.
219733155|NCT03000803|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
219733156|NCT03000803|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
219733157|NCT06064526|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical records
219733158|NCT02845349|DRUG|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
219733159|NCT02845349|DRUG|Placebo|A placebo comparator will be used in one subset of patients.
219733160|NCT02562040|PROCEDURE|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
219733161|NCT02562040|BEHAVIORAL|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
219733162|NCT04997421|DEVICE|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
219733163|NCT04997421|DEVICE|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
219159695|NCT06788041|OTHER|Massage|Duration of 45 minutes. A complete dorsal and ventral body massage will be performed, with superficial maneuvers at a slow pace of traditional massage.
219159696|NCT06788041|OTHER|Placebo Comparator|The person will be instructed to stay for 45 minutes during which he/she will receive different electrotherapy techniques with the devices disconnected, a mobile device that simulates a beep will be placed so that the patient believes that the device is connected.
219161646|NCT03271151|OTHER|Placebo|Placebo to compare outcomes against Duloxetine
219733164|NCT04775524|BEHAVIORAL|Storytelling Through Music (STM)|6 week expressive arts-based program
219733165|NCT04775524|BEHAVIORAL|Wait List / Storytelling Through Music-Hybrid|2 week song listening program
219161647|NCT05052281|BEHAVIORAL|Mothers and Babies (MB) Course|The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.
219161648|NCT05052281|BEHAVIORAL|Just in Time Intervention (JITI) Content|"Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day."
219733166|NCT03342794|PROCEDURE|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
219161649|NCT05052281|DEVICE|Biostamp nPoint Device|During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
219159697|NCT06792318|DIAGNOSTIC_TEST|FAPI PET-CT|"FAPI PET-CT imaging protocol:~Single dose 68Ga/18F-FAPI (2 MBq/kg)~Two imaging sessions:~First: 10 and 30 minutes post-injection Second: 60 and 80 minutes post-injection Ultra-low dose CT for attenuation correction and anatomical localization"
219159698|NCT05804708|DRUG|GH001|GH001 is administered via inhalation
219159699|NCT06155292|BEHAVIORAL|Standard Communication Email|This is a standard quarterly email communication without personalized performance metrics.
219159700|NCT06155292|BEHAVIORAL|Personalized Report Card Email|This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.
219159701|NCT06155292|BEHAVIORAL|Bottom-Up Framing|"The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback."
219159702|NCT06790433|DEVICE|Vibraject|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis. The Vibraject was activated after aspiration to deposit the solution slowly at approximately 50 seconds. Following cartridge deposition, the operator adjusted the participant to an upright seated position
219159703|NCT06790433|DEVICE|Dentapen|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis (needle placement). The Dentapen was activated after aspiration to deposit the solution at a medium rate (1 mL/60 s) using the ramp-up mode. Following cartridge deposition, the operator adjusted the participant to an upright seated position
219159704|NCT06322706|DRUG|ABSK021|ABSK021 oral
219159705|NCT06322706|DRUG|Omeprazole|Omeprazole oral
219159706|NCT06792214|DRUG|Nirmatrelvir/ritonavir|Paxlovid PO BID for 5 days + standard of care
219159707|NCT06792214|DRUG|Remdesivir|Veklury IV daily for 5 days + standard of care
219159708|NCT05659459|DRUG|KIN001|Oral tablet
219159709|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
219159710|NCT05982132|OTHER|anthropometric measurement|Measurement of weight and other anthropometrics data
219159711|NCT03088813|DRUG|Irinotecan liposome injection|IV
219159712|NCT03088813|DRUG|Topotecan|IV
219234917|NCT06924398|DRUG|Postoperative EGFR-TKI Therapy|"A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.~Before formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.~If the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment."
219234918|NCT06276660|OTHER|BCTT|"Participants will complete the Buffalo Concussion Treadmill Test, which involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
219733167|NCT00863460|RADIATION|cranial radiotherapy|40 Gy
219733168|NCT00863460|DRUG|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
219159713|NCT06443684|DIAGNOSTIC_TEST|MRD|MRD（LC-10）include 10 lung cancer-related driver gene mutation site
219159714|NCT05183542|DRUG|Bone scan|Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale \< 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
219733169|NCT00863460|DRUG|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
219733170|NCT02684474|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
219733171|NCT06445595|OTHER|patients with traumatic brain injury|Patients will be contacted by phone
219159715|NCT05113264|DEVICE|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
219159716|NCT06032208|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 5 and ending at the end of dialysis week 28. This will allow us to compare patient reported symptoms in weeks 1-4 on their usual dialyzer with with their symptoms on the Theranova dialyzer.
219159717|NCT05864118|DIAGNOSTIC_TEST|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
219159718|NCT05864118|DIAGNOSTIC_TEST|COVID-19 antibody test|COVID-19 antibody test
219733172|NCT05504083|DRUG|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
219733173|NCT05504083|DRUG|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
219159719|NCT03172624|DRUG|Nivolumab|nivolumab 3 mg/kg every 2 weeks
219159720|NCT03172624|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
219159721|NCT06029426|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
219159722|NCT06029426|DRUG|Placebo|Placebo will be administered orally
219733174|NCT03735901|DRUG|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
219733175|NCT03735901|DRUG|Matching placebo|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
219733176|NCT00355550|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
219733177|NCT00355550|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
219733178|NCT03189511|DRUG|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
219733179|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
219733180|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
219733181|NCT05311410|OTHER|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
219733182|NCT05311410|PROCEDURE|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
219733183|NCT02262221|OTHER|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
219733184|NCT04125758|BEHAVIORAL|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
219733185|NCT04125758|BEHAVIORAL|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
219733186|NCT04210076|BEHAVIORAL|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
219733187|NCT04210076|BEHAVIORAL|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
219733188|NCT01534715|DRUG|IMGN529|
219733189|NCT02369679|DEVICE|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
219733190|NCT02369679|DEVICE|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
219733191|NCT03357172|BIOLOGICAL|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
219733192|NCT03357172|BIOLOGICAL|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
219733193|NCT03357172|BIOLOGICAL|Blood sample|Before donation
219733194|NCT03357172|BIOLOGICAL|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
219733195|NCT03788928|DIAGNOSTIC_TEST|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
219733196|NCT04987450|DRUG|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
219733197|NCT03002857|DEVICE|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
219733198|NCT03002857|DEVICE|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
219733199|NCT03002857|DEVICE|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
219159723|NCT05910554|DRUG|Metformin|Patients randomized to metformin will be assigned the active arm.
219159724|NCT05910554|DRUG|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
219161650|NCT05872919|OTHER|SMS reminder massages about adherence|SMS three-times per week in the first six weeks and twice per week in the second six weeks reminding the patient about adherence to prescribed medication
219161651|NCT01338389|DIETARY_SUPPLEMENT|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
219159725|NCT04527146|OTHER|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
219159726|NCT04527146|OTHER|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the Penn Chart/Epic electronic medical record dashboard.
219159727|NCT04527146|OTHER|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
219159728|NCT05254509|OTHER|Occupational Therapy|Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
219159729|NCT05254509|OTHER|Occupational Therapy +Virtual Reality|The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
219159730|NCT06707337|OTHER|Brief Self-compassion Program|Brief Self-compassion Program will be held in a face-to-face hospital environment for the patients with colorectal cancer in the experimental group. This training program has been developed based on the concepts of Mindfulness-Based Compassionate Living and Mindfulness-Based Stress Reduction Programs. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the mindfulness-based model. The training program was created in a certain flow, based on the introduction to a short self-compassion program (1 sessions), the importance of self-compassion and self-care in the cancer experience (1 sessions), a self-compassionate approach to challenging emotions and situations (1 sessions). There are 3 sessions in the program and the frequency of sessions is 3 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 patients with colorectal cancer in the experimental group.
219159731|NCT02379520|GENETIC|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10\^7 cells/m2, DL2-3×10\^7 cells/m2, and DL3-1×10\^8 cells/m2, DL4- 2 to 3×10\^8 cells/m2, DL5- 0.8 to 1×10\^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion \& nivolumab \& HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) \& no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
219159732|NCT02379520|DRUG|Cytoxan|500mg/m\^2/day x 3 days (on days -4, -3 and -2)
219733200|NCT04612231|BEHAVIORAL|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
219733201|NCT04612231|BEHAVIORAL|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
219733202|NCT04960943|DRUG|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
219733203|NCT02756091|OTHER|No study-specific intervention|
219733204|NCT01265147|DRUG|Cisplatin|40mg/m2/w
219733205|NCT01265147|DRUG|Nedaplatin|40mg/m2/w
219159733|NCT02379520|DRUG|Fludarabine|30mg/m\^2/day x 3 days (on days -4, -3, and -2)
219159734|NCT02379520|BIOLOGICAL|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
219161652|NCT01338389|DIETARY_SUPPLEMENT|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
219161653|NCT06777160|PROCEDURE|Collecting data from patients who underwent arthroplasty and cement was used|Collecting data that may change in cement reaction before, during and after surgery from patients who underwent arthroplasty and cement use and taught it to artificial intelligence.
219161654|NCT04247165|DRUG|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
219161655|NCT04247165|DRUG|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
219733206|NCT06353932|OTHER|keeping the endotracheal tube cuff pressure within a certain range|The endotracheal tube cuff pressures of the study group patients were kept within the range of 20-25 cm H2O.
219733207|NCT01890538|DRUG|Administration of 100 mg dimenhydrinate intravenous|
219161656|NCT04247165|DRUG|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
219733208|NCT01890538|DRUG|2 g piracetam intravenous|
219733209|NCT05706285|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
219733210|NCT02225795|OTHER|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF"
219733211|NCT05179005|DEVICE|RibFix Advantage|Intrathoracic rib fracture stabilization
219159735|NCT06347211|DEVICE|Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm|"Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
219159736|NCT01865110|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
219159737|NCT01865110|DRUG|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
219159738|NCT01865110|DRUG|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
219159739|NCT01865110|DRUG|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
219159740|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
219159741|NCT04713982|DRUG|Deutetrabenazine|Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
219159742|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
219159743|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
219159744|NCT04910776|DRUG|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
219733212|NCT02500342|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
219733213|NCT02500342|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
219733214|NCT06255938|DIAGNOSTIC_TEST|smears|PCR smears for HPV testing will be performed
219733215|NCT00903344|DRUG|Vitamin D3|4000IU vitamin D3 tablet taken daily
219733216|NCT00903344|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
219733217|NCT01272778|DRUG|Lorazepam|Oral capsule, 0.2 mg, single acute dose
219159745|NCT03363854|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
219159746|NCT03363854|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
219733218|NCT01272778|DRUG|Lorazepam|oral capsule, 0.5 mg, single acute dose
219733219|NCT01272778|DRUG|Lorazepam|oral capsule, 1.0 mg, single acute dose
219733220|NCT01272778|DRUG|Lorazepam|oral capsule, 2.0 mg, single acute dose
219159747|NCT01903811|DRUG|Carfilzomib|Given IV
219159748|NCT01903811|DRUG|Dexamethasone|Given IV
219159749|NCT01903811|OTHER|Laboratory Biomarker Analysis|Correlative studies
219159750|NCT06745856|DRUG|5-fluorouracil|Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.
219159751|NCT06745856|DRUG|placebo|Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
219733221|NCT01272778|DRUG|Placebo|oral capsule, single acute dose
219733222|NCT03747263|PROCEDURE|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
219159752|NCT06745154|PROCEDURE|Biospecimen Collection|Undergo nasal swab collection
219159753|NCT06745154|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
219159754|NCT06745154|OTHER|Interview|Ancillary studies
219159755|NCT06745154|DRUG|Nicotine Replacement|Given nicotine patches, gum, or lozenges
219159756|NCT06745154|BEHAVIORAL|Smoking Cessation Intervention|Receive access to the Ohio Tobacco Quit Line
219159757|NCT06745154|OTHER|Survey Administration|Ancillary studies
219159758|NCT06745154|OTHER|Tobacco Cessation Counseling|Participate in counseling sessions
219159759|NCT05651659|OTHER|TIME model in the prevention and treatment of crises in frail community-dwelling people|TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
219159760|NCT04003948|DRUG|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
219159761|NCT04468776|DRUG|Zolpidem|Zolpidem, as prescribed by physician
219159762|NCT04468776|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
219159763|NCT04468776|DRUG|Trazodone|Trazodone, as prescribed by physician
219159764|NCT02690064|DIETARY_SUPPLEMENT|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
219159765|NCT02690064|DIETARY_SUPPLEMENT|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
219159766|NCT02690064|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
219159767|NCT02865668|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
219159768|NCT02865668|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
219159769|NCT02865668|DRUG|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
219159770|NCT04731467|DRUG|CM-24 and Nivolumab - Dose Escalation|Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
219159771|NCT04731467|DRUG|CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
219159772|NCT04731467|DRUG|CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
219159773|NCT04731467|DRUG|Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
219733223|NCT03486106|OTHER|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
219733224|NCT03486106|OTHER|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
219159774|NCT04731467|DRUG|Nivolumab and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
219159775|NCT03079024|DEVICE|Targeted Cognitive Training|"1. Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an \~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~2. Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory."
219159776|NCT03079024|DEVICE|General Cognitive Exercises|The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
219159777|NCT03079024|OTHER|Coordinated Specialty Care for First Episode Psychosis|Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
219159778|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant function|Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
219733225|NCT03486106|DRUG|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
219733226|NCT03862053|DRUG|Manuka honey|manuka eyedrops applied to the ocular surface
219733227|NCT01031615|BEHAVIORAL|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
219733228|NCT01031615|BEHAVIORAL|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
219733229|NCT00874809|DEVICE|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
219733230|NCT01524705|DRUG|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
219733231|NCT01524705|DRUG|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
219733232|NCT01524705|DRUG|Prandial insulin|Aspart or glulisine or lispro
219733233|NCT01524705|DRUG|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
219733234|NCT00008333|DRUG|vinorelbine tartrate|
219733235|NCT01755156|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
219159779|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of auditory function|The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
219159780|NCT04817462|PROCEDURE|Liver biopsy|The study population is patients with either haemophilia A or B who have previously been administered gene therapy treatment in one of three specific gene therapy clinical trials. In this study they will have a liver biopsy performed to take up to 3 samples for laboratory analysis.
219733236|NCT01755156|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
219159781|NCT05471908|BEHAVIORAL|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
219159782|NCT05471908|BEHAVIORAL|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
219159783|NCT06475261|DEVICE|Tissue Oximetry with ForeSight|Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer
219159784|NCT05176366|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
219159785|NCT06819605|DRUG|Dabrafenib and trametinib (combination)|"This clinical study investigates the combination of Dabrafenib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) and Trametinib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) as a treatment for \[specific condition\]. The treatment will be administered until disease progression or intolerable toxicities occur. Both medications should be taken at least 1 hour before or 2 hours after a meal, at the same time each day. If a dose is missed, it should be taken within 12 hours of the scheduled time. If less than 12 hours remain before the next dose, the missed dose should not be taken. Both medications should be taken in combination with the scheduled dose of Dabrafenib at either morning or evening and must not be chewed or crushed.~Each treatment cycle lasts 30 days. At the end of each cycle, follow-up assessments will include clinical examination, laboratory tests to evaluate drug safety, and imaging studies to a"
219159786|NCT06819930|OTHER|Physical Assessments, Questionnaires, and Accelerometry for Fibromyalgia evaluation|This study involves a combination of functional tests, questionnaires, and activity measurement using accelerometers. The functional tests include the six-minute walk test (6MWT), handgrip strength dynamometry, and the 8-foot up \&amp; go test. Participants will also complete validated questionnaires assessing symptoms, quality of life, and psychosocial impact. Additionally, accelerometers will be used to objectively measure physical activity levels throughout the study period
219159787|NCT03612648|RADIATION|Three Fraction Accelerated Partial Breast Irradiation|"* TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
219159788|NCT03612648|PROCEDURE|Partial mastectomy|-Standard of Care
219161657|NCT04247165|DRUG|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
219733237|NCT01755156|DRUG|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
219733238|NCT01755156|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
219733239|NCT01755156|DRUG|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
219733240|NCT01755156|DRUG|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
219733241|NCT02144246|OTHER|Non-hormonal period|
219733242|NCT02144246|DRUG|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
219733243|NCT03049397|OTHER|Communication Intervention|Complete Enhancing Connections program
219733244|NCT03049397|OTHER|Questionnaire Administration|Ancillary studies
219733245|NCT00090402|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
219733246|NCT00090402|DIETARY_SUPPLEMENT|Lipoic Acid|Lipoic acid capsule
219733247|NCT00090402|OTHER|Fish Oil Placebo|Soybean oil placebo capsule
219733248|NCT00090402|OTHER|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
219733249|NCT00382928|DEVICE|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
219733250|NCT06353516|DRUG|Propofol|delivered via intravenous route
219733251|NCT06353516|DRUG|Sevoflurane|delivered via inhalation route
219733252|NCT04772924|BEHAVIORAL|fasting|more than 12 hour of fasting as ceremony of Ramadan
219733253|NCT04772924|BEHAVIORAL|not fasting|preferred not to take long term fasting
219733254|NCT04040855|OTHER|Medication review|Multi-professional medication review
219159789|NCT06425796|DIETARY_SUPPLEMENT|Adiposity and Iron Requirements in Pregnancy (ADIPREG)|"Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered."
219159790|NCT06133062|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
219159791|NCT06133062|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
219159792|NCT06133062|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
219159793|NCT05142618|OTHER|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
219159794|NCT05142618|OTHER|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
219159795|NCT06040892|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
219159796|NCT06040892|DIAGNOSTIC_TEST|FRASIMAT Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
219159797|NCT06040892|DIAGNOSTIC_TEST|Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
219159798|NCT06040892|OTHER|spatial hearing rehabilitation program|The tool makes it possible to propose rehabilitation programs adapted to the performance and expectations of each child. This program will manipulate both the ambient sound with varying background noise to simulate daily life environments (i.e. making auditory detection more or less complex), and also manipulate virtual immersive environment (i.e. giving more or less relevant visual cues related to real sound location).
219159799|NCT05444335|DEVICE|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
219159800|NCT04794608|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
219159801|NCT02476864|DRUG|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
219159802|NCT02476864|DRUG|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
219159803|NCT03438188|OTHER|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
219159804|NCT02705287|OTHER|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
219159805|NCT02705287|OTHER|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
219159806|NCT01141309|DRUG|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
219159807|NCT03578198|DRUG|Rituximab + MG4101|"1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)"
219733255|NCT02691377|DEVICE|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
219159808|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
219159809|NCT05523882|DIAGNOSTIC_TEST|point-of-care ultrasound|"All participants will receive the same ultrasound education through attendance of the ultrasound course arranged by PLO-e. The educations intervention consists of three teaching seminars delivered over three months, a curriculum of 10 POCUS applications, an online learning platform providing educational support before, during, and after the teaching sessions (see Figure 2).~The online platform includes videos demonstrating the performance of POCUS, suggestions for additional literature, assignments to support the development of skills, self-quizzes to focus attention of learning outcomes and specific actioncards for each of the 10 POCUS applications framing the examinations in the clinical context. In addition, the online platform provides participants access to webinars and communication with other participants and teachers"
219159810|NCT06798961|PROCEDURE|Ablation|Patient treated with an ablation to eliminate the accessory conduction pathway in the heart.
219159811|NCT06798961|PROCEDURE|Standard of care without ablation|Patient diagnosed with accessory pathway but elected against cardiac ablation as a treatment option at the time of diagnosis.
219159812|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab|Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
219159813|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy with or without Bevacizumab|Bevacizumab, 15mg/kg，every 21 day
219159814|NCT05986565|BEHAVIORAL|Families Moving Forward (FMF) Teacher adapted training|The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
219159815|NCT01218490|PROCEDURE|ovarian cancer surgery|
219159816|NCT04795856|DRUG|[11C] acetate|PET Tracer
219159817|NCT04053842|DIAGNOSTIC_TEST|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.
219159818|NCT04053842|DRUG|[18F]PSMA-1007 Injection|\[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
219159819|NCT04053842|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
219159820|NCT04053842|DIAGNOSTIC_TEST|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
219159821|NCT05993416|DRUG|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (\>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing \< 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
219159822|NCT06796374|DIETARY_SUPPLEMENT|Fisetin|"A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
219733256|NCT02691377|DEVICE|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
219733257|NCT01534403|BIOLOGICAL|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
219733258|NCT01530256|BIOLOGICAL|ALD518|160 mg IV q 4 weeks for 4 doses
219733259|NCT01530256|BIOLOGICAL|ALD518|320 mg IV q 4 weeks for 4 doses
219733260|NCT01530256|BIOLOGICAL|ALD518|640 mg IV q 4 weeks for 2 doses
219733261|NCT00946036|DRUG|Sertraline Hydrochloride|
219733262|NCT01084759|DRUG|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
219733263|NCT01084759|DRUG|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
219733264|NCT01528774|OTHER|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
219733265|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
219733266|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
219159823|NCT06796374|DIETARY_SUPPLEMENT|Fisetin + Quercetin|"A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
219159824|NCT04234217|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
219733267|NCT06032598|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 84 days
219733268|NCT04461535|DRUG|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
219733269|NCT02596984|DRUG|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
219234919|NCT06276660|OTHER|Dynamic ExIT|The modified EXiT test will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
219733270|NCT06039800|OTHER|No intervention|No intervention
219159825|NCT04234217|OTHER|Niacin|Suppression of lipolysis by niacin infusion
219234920|NCT06951412|OTHER|Foot Reflexology Massage|Reflexology Massage
219234921|NCT06952270|OTHER|plyometric exercise|Upper limb plyometric exercise (proprioceptive neuromuscular facilitation of extensor and flexor pattern, external rotation exercise at 90º-90º, chest throw, external rotation and overhead and wall flexion).
219234922|NCT06952270|OTHER|Strength training exercise|Strength training exercises (Squats, Stair climbing and jumps, Bench Press, Push-ups, Core Exercises (Plank, Bridge)).
219234923|NCT05222906|DRUG|Venglustat|tablet; oral
219234924|NCT05222906|DRUG|imiglucerase|sterile lyophilized product; intravenous
219733271|NCT04919551|DRUG|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
219733272|NCT00370136|DRUG|ultrasound contrast|
219733273|NCT02244528|DRUG|Sildenafil|
219733274|NCT02004275|DRUG|pomalidomide|given PO
219733275|NCT02004275|DRUG|ixazomib|given PO
219159826|NCT06841016|OTHER|Virtual Nephrologist|Quality improvement (QI) pilot of an interactive, conversational virtual healthcare agent to educate and engage patients with advanced CKD about transplantation
219733276|NCT02004275|DRUG|dexamethasone|given PO
219733277|NCT03690999|DIETARY_SUPPLEMENT|Placebo|Placebo product
219733278|NCT03690999|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement
219733279|NCT05224648|DEVICE|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
219733280|NCT05224648|DEVICE|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
219159827|NCT05114720|DRUG|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
219733281|NCT05539911|DRUG|Fentanyl|50 mic fentanyl added as an adjuvant
219733282|NCT03908008|DRUG|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
219733283|NCT03908008|DRUG|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
219733284|NCT03912805|BIOLOGICAL|botulinum toxin, Type A|topical liniment
219733285|NCT03912805|BIOLOGICAL|Vehicle|Vehicle Formulation
219159828|NCT05114720|DRUG|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
219733286|NCT04621786|DEVICE|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
219733287|NCT02440399|DRUG|Tramadol hydrochloride|Please see arm description
219733288|NCT02440399|DRUG|Morphine|Please see arm description
219733289|NCT02440399|DRUG|Paracetamol|
219733290|NCT02440399|DRUG|Diclofenac|
219733291|NCT02440399|DRUG|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
219733292|NCT00841074|DRUG|chlorhexidine|0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
219733293|NCT00841074|DRUG|Placebo mouthwash|Placebo mouthwash spray application of \~1.3 ml twice a day.
219733294|NCT03815604|BEHAVIORAL|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
219733295|NCT03815604|BEHAVIORAL|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
219733296|NCT05257161|DEVICE|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
219733297|NCT05257161|DEVICE|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
219733298|NCT04356001|PROCEDURE|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
219733299|NCT03307096|PROCEDURE|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
219733300|NCT03307096|PROCEDURE|FURS|Parents are treated by FURS
219733301|NCT00292370|DRUG|Open Label (OL) Paroxetine|Open-label Paroxetine
219733302|NCT00292370|DRUG|Placebo|Double-blind placebo taken with OL paroxetine
219733303|NCT00292370|DRUG|Quetiapine|Double-blind quetiapine taken with OL paroxetine
219733304|NCT06433544|OTHER|6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
219733305|NCT01210911|DRUG|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
219733306|NCT01210911|DRUG|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
219733307|NCT01210911|DRUG|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
219733308|NCT01210911|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
219733309|NCT03899597|DRUG|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
219733310|NCT03899597|OTHER|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
219733311|NCT02635789|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
219733312|NCT02635789|DRUG|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
219159829|NCT06959238|OTHER|Temel beden farkındalığı terapisi|Individuals in the TBFT group will receive a total of 16 exercise sessions, with individual exercises 2 days a week for the first 2 weeks and group exercises 2 days a week for the next 6 weeks. The purpose of the individual sessions is to aim for the participant to learn the TBFT exercises and to prepare the participant for the group sessions. In individual sessions, the person learns body scanning and develops awareness about their own body. The participant continues the exercises they learned in the individual session at home. At this stage, the participant is assigned a notebook and is asked to write down their experiences of the exercises they do at home in this notebook. The participant who completes the individual sessions continues with the group sessions. The purpose of the group sessions is to provide interaction within the group and to establish a bond of trust between the individuals in the group with the interaction obtained. The fact that the participants do exercises toge
219159830|NCT05590169|OTHER|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
219159831|NCT06840951|DEVICE|rTMS|rTMS is a non-invasive procedure that uses electromagnetic field pulses to stimulate regions of the brain. rTMS can induce excitatory and inhibitory neural activity in the neural circuits of the motor cortex.
219159832|NCT06840951|BEHAVIORAL|CBT|CBT for OCD is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaviour. CBT will be conducted in a group setting according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions with step-by-step strategies.
219159833|NCT06636500|DRUG|CG001419|Oral doses
219159834|NCT06636500|DRUG|Placebo|Oral doses
219159835|NCT00670046|DRUG|valproic acid|given orally
219159836|NCT00670046|OTHER|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
219159837|NCT06051032|DEVICE|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
219159838|NCT06051032|DEVICE|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
219159839|NCT06249412|DEVICE|MI-E with PEP function activated during the pause|PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
219159840|NCT06249412|DEVICE|MI-E without PEP function activated during the pause|The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
219159841|NCT04194710|BIOLOGICAL|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
219159842|NCT04194710|PROCEDURE|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
219159843|NCT00003042|BIOLOGICAL|filgrastim|
219159844|NCT00003042|DRUG|cisplatin|
219159845|NCT00003042|DRUG|cyclophosphamide|
219159846|NCT00003042|DRUG|doxorubicin hydrochloride|
219159847|NCT00003042|DRUG|melphalan|
219159848|NCT00003042|DRUG|mesna|
219159849|NCT00003042|DRUG|paclitaxel|
219159850|NCT00003042|DRUG|tamoxifen citrate|
219159851|NCT00003042|PROCEDURE|bone marrow ablation with stem cell support|
219159852|NCT00003042|PROCEDURE|conventional surgery|
219159853|NCT00003042|PROCEDURE|peripheral blood stem cell transplantation|
219159854|NCT06397625|OTHER|Percutaneous electrical neurostimulation (Placebo)|"Group I (Control), will be operated with the same procedure but without electric current, and using placebo needles of the same size (Streitberger Placebo-Needle ® , Asiamed, Pullach, Germany)"
219161658|NCT04247165|RADIATION|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~* Prescription dose shall be according to the following specifications:~* A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~* Pauses are accepted but the treatment should be delivered within 10 calendar days.~* PTV should be covered by 95% isodose (PTV D99% \>95%)."
219161659|NCT03067467|DRUG|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
219733313|NCT02961582|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
219733314|NCT02961582|OTHER|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
219159855|NCT06397625|OTHER|Percutaneous electrical neurostimulation|The Group II and III electrostimulation procedure is called peripheral nerve stimulation and is known as an echo-guided peripheral nerve stimulation technique using a blunt, dry needle (active electrode). The intervention will be performed on the pudendal nerve, in an area where there is no risk of perforating any vascular-nerve bundle. The invasive technique will be performed by a physiotherapist expert in musculoskeletal and peripheral nervous system ultrasound and specialized in invasive techniques, with two years of experience in the sector. The needle will be introduced through the anterior (perineum).
219159856|NCT02300298|DRUG|Nintedanib|Nintedanib
219159857|NCT02300298|DRUG|Docetaxel|Docetaxel
219159858|NCT06793956|DRUG|Sintilimab and Linperlisib Combination Treatment|Sintilimab administered via intravenous infusion; Linperlisib administered orally.
219159859|NCT06848127|OTHER|Self-questionnaires|All subjects (healthy volunteers and all patients) will complete a battery of self-questionnaires, assessing emotional dysregulation, traumatic symptoms, alteration of the sense of self, sensitivity to social rejection, dissociative symptoms, child abuse, functional repercussions of the disorders, depressive and anxiety symptoms and Impulsivity.
219159860|NCT06848127|OTHER|Cognitive assessment|Completion of cognitive assessment, consisting of verbal fluency tasks , emotional Hayling, a dissociative associative memory retrieval task, a negative priming task and a heart rhythm detection task. The tasks of associative-dissociative memory retrieval, negative priming and heart rhythm detection will be coupled with a physiological recording, via a Biopac, to measure the change in skin conductance, body temperature and heart rate. The negative priming task will also be associated with the recording of eye movements allowing an indirect measurement of attentional orientation.
219159861|NCT06848127|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed (between visits V1 and V2 for all subjects and between V3 and V4 for the 4 groups of patients) in order to assess emotional and symptomatic dynamics in a daily life context through a connected wath. During 7 days, subjects will be invited, via their smartphone, to carry out daily semi-random readings (indicated by smartphone notifications) of their subjective emotional experiences (10 once/day), but also spontaneous (by reporting emotions deemed intense immediately afterwards that they take place).
219159862|NCT06848127|OTHER|Semi-structured interviews ITI and DSCID-II|"ITI International Trauma Interview is a semi-structured interview consisting of one part allocated to the description of a traumatic event and two parts addressing the symptoms of PTSD (i.e. reliving, avoidance and alteration of wakefulness) and the symptoms of the disturbance of self-organization.~The SCID-II Structured Clinical Interview for DSM-IV Personality Disorder is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-IV."
219159863|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
219159864|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
219159865|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
219159866|NCT00710294|DEVICE|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
219159867|NCT05171985|PROCEDURE|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
219161660|NCT03067467|DRUG|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
219161661|NCT06763042|DEVICE|Mindfulness-based Life Management Social Robots|Mindfulness-based life management contents for pediatric patients operated by Social Robots
219161662|NCT06763770|BEHAVIORAL|Managing Your Health (MYH)|The Managing Your Health intervention consists of six weekly videoconference calls with a peer mentor and five self-management educational modules within a mobile application. The first call is to get to know each other, share survivorship stories, identify self-management strengths and weaknesses, and select goals for participation in the intervention. The remaining five weekly calls cover a self-management topic each week, including understanding your survivorship care plan, navigating the healthcare system and insurance, managing the emotional aspects of survivorship, negotiating family and significant other involvement in care, and engaging in healthy lifestyle behaviors.
219234925|NCT04843371|DIAGNOSTIC_TEST|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
219733315|NCT01210209|OTHER|genome-wide association study|
219733316|NCT00676754|PROCEDURE|Statens Serum Institut RT23 2TU tuberculin|
219733317|NCT00132912|DRUG|SCH 530348|
219733318|NCT05342688|BEHAVIORAL|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
219733319|NCT04743895|DEVICE|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
219733320|NCT05130957|OTHER|Massage Application with clove oil|The experimental group is given a massage with clove oil,
219733321|NCT05130957|OTHER|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
219733322|NCT05889000|OTHER|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
219733323|NCT04799639|DRUG|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
219733324|NCT00440739|DRUG|etoricoxib|etoricoxib 120 mg
219733325|NCT00440739|DRUG|flavoxate|flavoxate 200 mg 3 times
219733326|NCT00440739|DRUG|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
219733327|NCT00440739|DRUG|placebo|placebo once and placebo 3 times
219733328|NCT00465283|DRUG|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
219733329|NCT04760236|BIOLOGICAL|Oral Cholera Vaccine Simplified (OCV-S)|"* Manufacturer: EuBiologics Co., Ltd.~* Oral administration"
219733330|NCT04760236|BIOLOGICAL|Shanchol™|"* Manufacturer: Shantha Biotechnics~* Oral administration"
219733331|NCT01232842|GENETIC|cytogenetic analysis|
219733332|NCT01232842|OTHER|HUMARA assay|
219733333|NCT01232842|OTHER|fluorescence activated cell sorting|
219159868|NCT06521411|BEHAVIORAL|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
219159869|NCT01723267|OTHER|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
219159870|NCT01723267|OTHER|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
219234926|NCT05241873|DRUG|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
219733334|NCT01232842|OTHER|laboratory biomarker analysis|
219733335|NCT00005078|DRUG|carboplatin|
219159871|NCT06409897|OTHER|Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation|Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
219234927|NCT05241873|DRUG|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
219234928|NCT05241873|DRUG|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
219733336|NCT00005078|DRUG|paclitaxel|
219733337|NCT00005078|DRUG|tirapazamine|
219733338|NCT00752362|DEVICE|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
219733339|NCT00752362|DEVICE|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
219733340|NCT00752362|DEVICE|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
219733341|NCT00782379|DRUG|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
219733342|NCT00782379|DRUG|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
219733343|NCT00782379|DRUG|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
219733344|NCT00782379|DRUG|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
219733345|NCT00782379|DRUG|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
219733346|NCT00782379|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
219733347|NCT00782379|PROCEDURE|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
219733348|NCT00151463|DRUG|sildenafil citrate|
219159872|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
219159873|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
219159874|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
219159875|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
219159876|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
219159877|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
219159878|NCT00790894|DRUG|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
219159879|NCT00790894|DRUG|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
219159880|NCT00361205|DEVICE|Electronic Monitoring cap|
219159881|NCT03285763|DRUG|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
219159882|NCT03961451|DEVICE|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
219159883|NCT04419857|DIETARY_SUPPLEMENT|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
219159884|NCT06146374|OTHER|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
219159885|NCT06146374|DRUG|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
219159886|NCT03593642|DRUG|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
219159887|NCT03593642|DRUG|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
219159888|NCT04407975|OTHER|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
219159889|NCT04407975|OTHER|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
219159890|NCT04148170|PROCEDURE|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
219159891|NCT00086359|DRUG|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
219159892|NCT00086359|DRUG|Lamivudine/zidovudine|one pill twice daily
219159893|NCT00086359|DRUG|Lopinavir/ritonavir|four pills twice daily
219234929|NCT03011801|BEHAVIORAL|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
219159894|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
219234930|NCT03011801|BEHAVIORAL|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
219733349|NCT01183182|DEVICE|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
219733350|NCT02898675|DEVICE|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
219733351|NCT02898675|DEVICE|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
219733352|NCT04695782|RADIATION|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
219733353|NCT05667402|DRUG|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
219733354|NCT05667402|DRUG|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
219733355|NCT02551809|BIOLOGICAL|UB-311|Intramuscular injection
219733356|NCT02551809|DRUG|Placebo|Intramuscular injection
219733357|NCT03777176|DRUG|Dasiglucagon|Glucagon analog
219733358|NCT03777176|OTHER|Standard of Care|Standard of care according to site and/or country
219159895|NCT06158204|BEHAVIORAL|Lifestyle Intervention|"Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day"
219733359|NCT02284854|DRUG|BIA 2-093|
219733360|NCT02284854|DRUG|Carbamazepine|
219733361|NCT00322426|DEVICE|Sensory Cueing Device|
219733362|NCT05230654|DRUG|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
219733363|NCT05230654|DRUG|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
219733364|NCT01133977|DRUG|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
219733365|NCT01133977|DRUG|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
219733366|NCT01133977|DRUG|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
219733367|NCT06535776|OTHER|Matrix Rhythm Therapy|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
219733368|NCT06535776|OTHER|Home-based Exercise|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
219159896|NCT05438160|DEVICE|Clinical Learning Study smartphone app (i.e., the study app)|The study app is designed to provide 7-weeks of the medication tracking and educational components in a clinical learning study version of CT-155. This design allows inferences to be made about the usability and acceptability of these components of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
219234931|NCT05473130|DEVICE|Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System
219733369|NCT05532163|DRUG|Natalizumab|Administered as specified in the treatment arm
219733370|NCT01546779|DEVICE|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
219733371|NCT03385642|DEVICE|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
219733372|NCT05996705|OTHER|Determining the relationship of fatigue with some parameters|Determining the relationship of fatigue with physical function, pain values at rest and in motion, gender, age, pain, disease activity, gender and disease duration in RA patients.
219733373|NCT03606213|BIOLOGICAL|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
219733374|NCT03606213|BIOLOGICAL|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
219234932|NCT04765020|BEHAVIORAL|Experimental: moderate to high-intensity exercise|"Four parts:~1. Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~2. Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~3. Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~4. Activity trackers with individual movement goals that will be adjusted every two weeks"
219733375|NCT03606213|BIOLOGICAL|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
219733376|NCT03606213|DEVICE|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
219733377|NCT01560559|PROCEDURE|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
219733378|NCT00662038|DRUG|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
219733379|NCT06564480|DEVICE|MI-R1 lower limb walking machine assisted training device|The training is conducted under partial weight support training conditions, performing passive movements on the lower limbs through motor drive, improving the joint activity of the patient's hip and knee joints, and achieving sitting, standing, and walking functions.
219733380|NCT06564480|OTHER|Walking rehabilitation training under the guidance of therapists|Each patient undergoes training under the guidance of a rehabilitation therapist
219159897|NCT05193552|DRUG|Hizentra|subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
219159898|NCT06250283|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol (500 mg)
219159899|NCT06250283|DIETARY_SUPPLEMENT|Placebo|Placebo (500 mg)
219159900|NCT05506085|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
219159901|NCT05685108|DEVICE|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
219159902|NCT05685108|DEVICE|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
219159903|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (5-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
219159904|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) CAPS-A hypernasality rating of 1 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
219159905|NCT03230747|DEVICE|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
219159906|NCT06624371|DRUG|Atovaquone|"Atovaquone oral suspension (750 mg/5mL) will be administered with meals on an outpatient basis.~Patients 13 years and older will receive atovaquone 750 mg PO BID, the standard pediatric dosing for Pneumocystis Jirovecii Pneumonia (PJP) prevention and treatment.~For those aged 2-12 years, atovaquone will be dosed at 30mg/kg once daily. The maximum dose for children under 12 will be 1500 mg."
219159907|NCT06624371|RADIATION|Radiation Therapy|54-60 Gy in 1.8 Gy daily fractions of MRI-guided proton radiotherapy using intensity-modulated pencil-beam scanning technology to match the target will be used.
219159908|NCT04754022|OTHER|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
219159909|NCT04754022|OTHER|Liberal transfusion strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
219159910|NCT05261828|BEHAVIORAL|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
219159911|NCT05261828|BEHAVIORAL|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
219159912|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
219159913|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
219159914|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
219159915|NCT05163301|BEHAVIORAL|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
219159916|NCT06533540|BIOLOGICAL|TPX-115(allogeneic fibroblasts)|Intradermal injection of TPX-115(allogeneic fibroblasts)
219159917|NCT04136535|DRUG|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
219159918|NCT04136535|DRUG|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
219159919|NCT04136535|DRUG|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
219159920|NCT03716336|OTHER|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
219159921|NCT03716336|OTHER|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
219159922|NCT03716336|DIETARY_SUPPLEMENT|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
219159923|NCT03772652|OTHER|Observation|Soft tissue implant measurements
219159924|NCT04481074|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
219159925|NCT06564753|DRUG|Drug: Placebo daily and orally|• Placebo comparator
219159926|NCT06564753|DRUG|NA-931, dose 1, daily and orally|"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
219159927|NCT06564753|DRUG|NA-931, dose2, daily and orally|"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
219159928|NCT06564753|DRUG|NA-931 dose 3, daily and orally|"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
219159929|NCT06564753|DRUG|NA-931 dose 4, daily and orally|"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
219159930|NCT05048914|DRUG|Ibuprofen|treatment of acute migraine attack
219159931|NCT03086863|DEVICE|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
219159932|NCT03086863|DEVICE|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
219159933|NCT01675999|OTHER|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
219159934|NCT01675999|OTHER|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
219234933|NCT01538056|DEVICE|Fenestrated Endovascular Graft or Company Manufactured Terumo Aortic Fenestrated TREO Endovascular Graft|PMEG endovascular graft with fenestrations or the Company Manufactured Terumo Aortic Fenestrated TREO Abdominal Stent Graft System to allow for blood flow to vital visceral vessels such as the renal arteries, celiac, and SMA (Superior Mesenteric Artery).
219234934|NCT03682289|DRUG|Ceralasertib|Given orally
219159935|NCT01675999|OTHER|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
219159936|NCT00088738|DRUG|[18F] SPA-RQ|
219159937|NCT00321152|OTHER|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
219159938|NCT02555475|OTHER|community based hepatitis C care and treatment|
219159939|NCT03039803|PROCEDURE|uterine closure during cesarean section|
219159940|NCT01463176|BEHAVIORAL|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
219159941|NCT05882617|OTHER|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
219234935|NCT03682289|DRUG|Olaparib|Given orally
219733381|NCT06055699|OTHER|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
219733382|NCT06055699|OTHER|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
219733383|NCT01251211|DRUG|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
219234936|NCT03682289|DRUG|Durvalumab|Given intravenously (IV)
219159942|NCT00431834|DEVICE|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
219159943|NCT00431834|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
219733384|NCT02531711|OTHER|Diet A|Experimental analgesic dietary intervention
219733385|NCT02531711|OTHER|Diet B|Healthy comparator diet
219733386|NCT00397046|DRUG|neratinib|HKI-272
219733387|NCT06107686|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
219733388|NCT06135012|DEVICE|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
219733389|NCT06135012|OTHER|Scalpel|Transection of pancreatic tissue with scalpel.
219159944|NCT05967429|DIAGNOSTIC_TEST|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
219159945|NCT05967429|DIAGNOSTIC_TEST|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
219234937|NCT02301117|DRUG|TAS-102|
219234938|NCT02805023|BIOLOGICAL|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
219234939|NCT02805023|BIOLOGICAL|Control medium|Intramuscular injections - single treatment session
219234940|NCT04620733|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
219234941|NCT04620733|DRUG|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
219234942|NCT04620733|DRUG|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
219234943|NCT03924193|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
219234944|NCT03924193|BEHAVIORAL|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
219234945|NCT03924193|OTHER|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
219234946|NCT02446860|DRUG|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
219733390|NCT01749293|PROCEDURE|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
219733391|NCT01749293|DRUG|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
219733392|NCT01749293|DRUG|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
219159946|NCT03312322|OTHER|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
219159947|NCT03312322|OTHER|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
219159948|NCT03312322|OTHER|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
219159949|NCT03628885|BEHAVIORAL|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
219159950|NCT03628885|BEHAVIORAL|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
219159951|NCT05055752|DRUG|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
219159952|NCT05715398|DRUG|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
219159953|NCT06222983|PROCEDURE|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
219159954|NCT04710849|DIAGNOSTIC_TEST|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
219159955|NCT01066767|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
219159956|NCT05310916|DRUG|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
219159957|NCT05310916|DRUG|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
219733393|NCT01749293|RADIATION|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
219733394|NCT01749293|DRUG|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
219733395|NCT02607163|DRUG|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
219733396|NCT02607163|DRUG|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
219159958|NCT05634382|DRUG|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
219159959|NCT05634382|PROCEDURE|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
219159960|NCT04556539|DRUG|SC10914|400mg TID, oral admination on fasting condition
219234947|NCT05655260|OTHER|Comparison of chemotherapy vs. chemoradiotherapy|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
219733397|NCT06034431|OTHER|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
219733398|NCT05579522|PROCEDURE|Fat graft injection|Fat graft injection in the interdental papilla.
219733399|NCT05579522|PROCEDURE|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
219733400|NCT02250573|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
219733401|NCT04125719|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO
219733402|NCT04125719|DRUG|Nivolumab|Nivolumab infusion
219733403|NCT03418363|DIETARY_SUPPLEMENT|DHEA Oral Capsule|Daily 100mg DHEA supplement
219733404|NCT03418363|OTHER|Placebo Oral Capsule|Daily oral capsule
219159961|NCT02461628|BEHAVIORAL|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
219234948|NCT05655260|OTHER|Comparison of VBT vs. WPRT|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
219234949|NCT06306222|DEVICE|Laser lithotripsy|Ureteroscopic laser lithotripsy
219234950|NCT04789018|OTHER|Educational Intervention|Attend virtual genetics board
219234951|NCT04789018|OTHER|Survey Administration|Complete survey
219159962|NCT01955226|OTHER|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
219159963|NCT01955226|OTHER|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
219234952|NCT04789018|OTHER|Interview|Complete interview
219234953|NCT02929758|BEHAVIORAL|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
219733405|NCT02898831|OTHER|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
219733406|NCT01291160|DEVICE|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
219733407|NCT01291160|OTHER|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
219733408|NCT01975285|DRUG|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
219733409|NCT01975285|DRUG|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
219733410|NCT05388175|DEVICE|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
219733411|NCT05388175|DEVICE|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
219733412|NCT02993341|DRUG|Tranexamic Acid|
219733413|NCT02993341|OTHER|Saline Wash|
219733414|NCT03074643|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
219733415|NCT03074643|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
219159964|NCT00000777|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219234954|NCT05589129|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
219234955|NCT05589129|DIETARY_SUPPLEMENT|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
219733416|NCT03074643|DIETARY_SUPPLEMENT|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
219733417|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
219733418|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
219733419|NCT06477510|PROCEDURE|non-surgical periodontal therapy|change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
219733420|NCT02105870|DRUG|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
219733421|NCT02920567|DRUG|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
219159965|NCT04106869|OTHER|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
219159966|NCT04106869|OTHER|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
219733422|NCT02920567|DRUG|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
219733423|NCT03748563|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
219733424|NCT05919251|BEHAVIORAL|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
219733425|NCT01401075|DRUG|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
219733426|NCT01401075|DRUG|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
219733427|NCT06369051|OTHER|Self-employment support intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
219733428|NCT05112588|BEHAVIORAL|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
219733429|NCT03275610|GENETIC|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
219733430|NCT02487355|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
219234956|NCT02032134|BIOLOGICAL|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
219733431|NCT02487355|DRUG|Magnesium Sulphate|Magnesium Sulphate 50 mg
219733432|NCT02487355|DRUG|Bupivacaine|1ml/kg of 0.25%of bupivacaine
219733433|NCT02487355|DRUG|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
219733434|NCT00474968|DEVICE|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
219733435|NCT00474968|DEVICE|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
219733436|NCT00441740|DRUG|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
219733437|NCT00441740|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
219733438|NCT00441740|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
219733439|NCT00441740|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
219733440|NCT02491060|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
219733441|NCT02491060|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
219733442|NCT05849974|OTHER|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
219733443|NCT03719937|DEVICE|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
219733444|NCT06433011|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
219733445|NCT06433011|DRUG|r-tPA|Pulse spray and infusion
219159967|NCT02167958|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care."
219733446|NCT06401772|BEHAVIORAL|Intracranial Hypotension Targeted(IHT) Body Posture|IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
219733447|NCT01750281|DRUG|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
219733448|NCT01750281|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
219733449|NCT01750281|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
219733450|NCT01750281|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
219733451|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
219733452|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
219733453|NCT05446155|DIAGNOSTIC_TEST|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
219733454|NCT02326246|OTHER|multi-parametic MRI|
219733455|NCT03154112|DEVICE|Measurement of oxygen consumption and caloric expenditure|This study will involve an \~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
219733456|NCT03502772|OTHER|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
219733457|NCT03502772|OTHER|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
219733458|NCT03569007|DRUG|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
219733459|NCT03569007|DRUG|Matching Placebo|enteric-coated beads in gelatin capsules
219733460|NCT05099588|OTHER|Other: observational study|Observational study
219733461|NCT00183612|DRUG|Olanzapine|
219733462|NCT00948935|DRUG|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
219733463|NCT00567801|PROCEDURE|conventional embolectomy/thrombectomy|
219733464|NCT00567801|PROCEDURE|embolectomy/thrombectomy with controlled reperfusion|
219733465|NCT02594852|DEVICE|+ laser|Use of laser in the treatment
219733466|NCT04727827|OTHER|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
219733467|NCT01634750|DRUG|ManNAc|Single dose
219733468|NCT04559672|PROCEDURE|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
219733469|NCT04559672|PROCEDURE|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
219733470|NCT01061710|DRUG|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
219733471|NCT04071483|PROCEDURE|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
219733472|NCT01081938|DRUG|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
219733473|NCT01081938|DRUG|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
219159968|NCT02167958|DRUG|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
219159969|NCT02167958|DRUG|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
219159970|NCT02167958|RADIATION|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
219159971|NCT02167958|OTHER|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
219159972|NCT02167958|DRUG|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
219159973|NCT02167958|DRUG|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
219159974|NCT02167958|DRUG|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is \> 1,000/mm3 for three consecutive days.
219159975|NCT00175812|DRUG|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
219159976|NCT00175812|DRUG|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
219159977|NCT00175812|DRUG|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
219733474|NCT00482456|DRUG|Nitrous oxide|
219733475|NCT00201773|DRUG|Exemestane|25 mg orally once per day for 16 weeks.
219733476|NCT00201773|DRUG|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
219733477|NCT00201773|OTHER|Correlative studies|
219733478|NCT05391087|OTHER|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
219733479|NCT05391087|OTHER|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
219733480|NCT03917264|PROCEDURE|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
219733481|NCT03917264|OTHER|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
219733482|NCT01851304|DIETARY_SUPPLEMENT|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
219733483|NCT01851304|DIETARY_SUPPLEMENT|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
219733484|NCT03087123|BEHAVIORAL|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
219733485|NCT03156621|DRUG|Alirocumab|Alirocumab SC Q2W
219733486|NCT03156621|DRUG|Placebo|Matching placebo SC Q2W
219733487|NCT05023174|PROCEDURE|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
219733488|NCT05023174|PROCEDURE|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
219733489|NCT02533128|DRUG|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
219733490|NCT02533128|DRUG|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
219159978|NCT01073358|PROCEDURE|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
219159979|NCT00439413|DRUG|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
219159980|NCT00439413|DRUG|Placebo|Matching placebo via transdermal system
219159981|NCT00439413|BEHAVIORAL|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
219159982|NCT05857930|DRUG|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
219159983|NCT05857930|DRUG|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
219159984|NCT03556085|DEVICE|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
219159985|NCT02054923|PROCEDURE|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
219159986|NCT02054923|BEHAVIORAL|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
219159987|NCT03614273|DRUG|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
219159988|NCT03614273|DRUG|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
219733491|NCT03757715|DRUG|Bupivacaine|20 mL of 1.3% bupivacaine
219733492|NCT03757715|DRUG|Dexamethasone|2 mg dexamethasone
219159989|NCT04930406|OTHER|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
219159990|NCT00621634|DIETARY_SUPPLEMENT|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
219159991|NCT00621634|DIETARY_SUPPLEMENT|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
219733493|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
219733494|NCT00281580|DRUG|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
219733495|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
219733496|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
219733497|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
219733498|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
219733499|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
219733500|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
219733501|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
219733502|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
219733503|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
219733504|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
219733505|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
219733506|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
219733507|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
219733508|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
219733509|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
219733510|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
219733511|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
219733512|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
219733513|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
219733514|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
219733515|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
219733516|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
219733517|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
219733518|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
219733519|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
219159992|NCT05387044|RADIATION|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
219159993|NCT00933712|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
219159994|NCT00792636|DRUG|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
219159995|NCT00792636|DRUG|sumatriptan tablet|sumatriptan 85mg
219159996|NCT00792636|DRUG|naproxen sodium tablet|Naproxen sodium 500mg
219159997|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
219159998|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botox®)|
219159999|NCT00265200|DRUG|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
219160000|NCT04579250|BIOLOGICAL|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
219160001|NCT04059042|BEHAVIORAL|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
219160002|NCT05188300|PROCEDURE|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
219160003|NCT04264013|BEHAVIORAL|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
219160004|NCT04264013|BEHAVIORAL|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
219160005|NCT06272058|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
219160006|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
219733520|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
219160007|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
219160008|NCT06958666|DEVICE|Digital Inhaled Therapy Management|"The subjects will be trained on their inhalation techniques with the Digital Medication Administration Device consists of an inhalation device with a display and inhalation technique assessment module. The device will show a standardized video demonstration and will evaluate the subjects' inhalation technique. A printed report will be available afterwards.~A home-based inhalation management service package will be provided to the subjects including a digital sensor that records the time, frequency, and key inhalation technique parameters for each use of metered-dose inhalers or dry powder inhalers, and automatically synchronizes the data to the cloud. The data is then analyzed for adherence and technique performance. Based on the data, subjects will receive medication reminders and voice alerts for any technique errors on the app provided with the package. Visual charts of medication adherence and inhalation technique will be available to reinforce self-management."
219160009|NCT06958666|DEVICE|Inspiratory Muscle Training|The subjects will receive standardized verbal training and demonstration of inhalation techniques and any questions will be answered Inspiratory muscle training equipment, ancillary software, inspiratory muscle training plan, and equipment user guide will be sent home with the patient.
219160010|NCT05672095|PROCEDURE|Biopsy|Undergo needle or core biopsy
219160011|NCT05672095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219733521|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
219733522|NCT03640988|DEVICE|dermaPACE|Shockwave application
219733523|NCT00337688|DEVICE|isometric joystick|isometric joystick
219733524|NCT01266057|DRUG|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
219733525|NCT01266057|DRUG|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
219733526|NCT01266057|DRUG|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
219733527|NCT01655212|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
219733528|NCT04385836|DRUG|alpha one antitrypsin inhalation|\- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
219733529|NCT02427217|BIOLOGICAL|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
219733530|NCT03302936|DRUG|Phenazopyridine|to be given preoperatively
219733531|NCT03107299|OTHER|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
219733532|NCT02520947|DEVICE|BIS|Bispectral index monitoring
219733533|NCT02520947|DRUG|Desflurane|volatile agent for maintenance of anesthesia
219733534|NCT05130021|DRUG|MAX-40279-01|MAX-40279-01 50mg/70mg
219733535|NCT05130021|DRUG|regorafenib|regorafenib
219733536|NCT04739774|DRUG|CHF6001 DPI|Single dose of CHF6001
219733537|NCT04739774|DRUG|Itraconazole|Repeated doses of oral Itraconazole
219733538|NCT01433965|DRUG|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
219733539|NCT00170365|BEHAVIORAL|Restorative Yoga|
219733540|NCT01550965|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
219733541|NCT03240432|DEVICE|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
219733542|NCT01235416|DRUG|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
219733543|NCT05897502|BEHAVIORAL|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
219733544|NCT04656431|DRUG|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
219160012|NCT05672095|DRUG|Niraparib|Given PO
219160013|NCT05672095|OTHER|Questionnaire Administration|Ancillary studies
219160014|NCT05672095|DIETARY_SUPPLEMENT|Selenium|Given IV
219160015|NCT04711135|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
219160016|NCT06517355|OTHER|In this research, the procedure under study is represented:|"* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.~* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation."
219160017|NCT06359379|DRUG|Ropidoxuridine|Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
219160018|NCT06341088|PROCEDURE|unilateral suture sacro-hysteropexy|patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.
219160019|NCT06341088|PROCEDURE|bilateral suture sacro-hysteropexy|patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable suture and bilaterally suspended to the anterior longitudinal ligament.
219733545|NCT04656431|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
219733546|NCT03760640|DRUG|LY900014|Administered SC
219733547|NCT03760640|DRUG|Insulin Lispro|Administered SC
219733548|NCT03683498|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
219733549|NCT04495998|DIAGNOSTIC_TEST|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
219733550|NCT03016403|BEHAVIORAL|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
219733551|NCT03016403|BEHAVIORAL|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
219733552|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
219733553|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
219733554|NCT02812537|OTHER|patients with conduct disorders|interview with a specialist
219733555|NCT05344274|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
219733556|NCT05344274|BIOLOGICAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
219733557|NCT05344274|DIAGNOSTIC_TEST|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
219733558|NCT01602458|PROCEDURE|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
219733559|NCT01602458|PROCEDURE|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
219733560|NCT00621322|BIOLOGICAL|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
219733561|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
219733562|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
219733563|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
219160020|NCT03708627|DRUG|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
219160021|NCT06271356|BEHAVIORAL|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
219160022|NCT04415060|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
219160023|NCT04415060|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
219160024|NCT00473902|BEHAVIORAL|Training|
219160025|NCT00473902|DRUG|Creatine Monohydrate, Conjugated Linoleic Acid|
219160026|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|Patients in the TEAS group, the acupoints are bilateral neiguan (PC6), Zusanli (ST 36), Hegu (L14) and Waiguan (SJ5) acupoints. The treatment will consist of two phases: a 30-minute stimulation administered 30 minutes before anesthesia induction, and a 30-minute stimulation session once daily on postoperative days 1, 2, and 3. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. Patients in the sham group will receive electrode attachment but without stimulation.
219160027|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
219160028|NCT04239092|DRUG|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
219160029|NCT04239092|DRUG|Irinotecan|Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.
219733564|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
219160030|NCT04239092|DRUG|Temozolomide|Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.
219160031|NCT04239092|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
219160032|NCT04239092|DRUG|Topotecan|Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
219160033|NCT03594396|DRUG|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
219733565|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
219733566|NCT00930332|DRUG|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
219733567|NCT00930332|OTHER|questionnaire administration|within 48 hours of registration
219733568|NCT00930332|PROCEDURE|management of therapy complications|if required
219733569|NCT06483217|BEHAVIORAL|Patient-directed follow up|Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
219160034|NCT03594396|DRUG|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
219160035|NCT05241041|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
219160036|NCT05241041|DEVICE|auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously.
219160037|NCT05241041|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
219160038|NCT02942355|DRUG|anastrozole|Anastrozole by mouth daily
219160039|NCT02942355|DRUG|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
219160040|NCT03593733|OTHER|Photobiomodulation Therapy|Photobiomodulation Therapy
219160041|NCT03593733|OTHER|Cold Water Immersion|Cold Water Immersion
219160042|NCT02244411|BEHAVIORAL|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
219234957|NCT05266209|OTHER|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
219234958|NCT02489799|BEHAVIORAL|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
219234959|NCT02489799|BEHAVIORAL|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
219160043|NCT02244411|BEHAVIORAL|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
219234960|NCT02195219|PROCEDURE|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
219234961|NCT02195219|OTHER|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
219234962|NCT06585059|DRUG|TQB2928 injection + Almonertinib Mesilate Tablets|"TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug."
219234963|NCT04909593|DEVICE|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
219234964|NCT00215709|DRUG|docetaxel|
219234965|NCT06343662|BEHAVIORAL|MERAKI_ABI|"The music therapy session will focus on the themes of reidentification and involvement. The aim is to accompany the patient during the illness process, allowing them to express their emotional state, relate to music, promote listening and communication between family members, help and value preserved abilities, and promote personal involvement in the rehabilitation process.~The session will work with songs, taking into account musical preferences."
219234966|NCT01525459|PROCEDURE|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
219160044|NCT02244411|BEHAVIORAL|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
219160045|NCT02244411|OTHER|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
219160046|NCT06006611|DRUG|Azvudine|Received antiviral treatment with azvudine
219160047|NCT02709304|DRUG|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
219234967|NCT01525459|OTHER|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
219234968|NCT01241448|DRUG|LY2409021|Administered Orally
219234969|NCT01241448|DRUG|Placebo|Administered Orally
219234970|NCT06165497|BEHAVIORAL|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
219234971|NCT06165497|OTHER|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
219234972|NCT00430911|DRUG|Radiotherapy|
219160048|NCT02709304|DRUG|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
219160049|NCT00963404|RADIATION|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
219160050|NCT03268213|BIOLOGICAL|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
219160051|NCT03276403|DEVICE|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
219160052|NCT01077986|DRUG|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
219160053|NCT01077986|DRUG|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
219160054|NCT01077986|DRUG|Everolimus|Everolimus will be administered daily, starting on day 1.
219160055|NCT00998881|DRUG|Teneligliptin 20 mg|
219160056|NCT00998881|DRUG|Placebo|
219160057|NCT02621086|DIETARY_SUPPLEMENT|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
219160058|NCT04751838|OTHER|no intervention|no intervention
219234973|NCT03530735|OTHER|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day."
219234974|NCT02092285|DRUG|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
219733570|NCT04299425|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
219160059|NCT01896310|DEVICE|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
219160060|NCT05172323|DEVICE|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
219733571|NCT05447858|OTHER|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
219733572|NCT05447858|OTHER|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
219733573|NCT01514435|DEVICE|Electroconvulsive therapy|treatment for major depression
219733574|NCT01514435|DEVICE|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
219733575|NCT00310479|DEVICE|Magnetic Resonance Spectroscopy (3Tesla)|
219733576|NCT05235828|BEHAVIORAL|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
219160061|NCT05172323|OTHER|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
219160062|NCT03372070|DEVICE|cNEP|soft silicon collar applied to anterior neck with negative pressure
219234975|NCT01825785|DRUG|Romosozumab|Administered by subcutaneous injection
219160063|NCT01629316|BEHAVIORAL|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
219160064|NCT01629316|BEHAVIORAL|Standard of care - control arm|The control arm is standard of care for each subject.
219160065|NCT02848794|DRUG|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
219160066|NCT00017472|BIOLOGICAL|apolizumab|Given IV
219160067|NCT00017472|OTHER|laboratory biomarker analysis|Correlative studies
219160068|NCT00017472|OTHER|pharmacological study|Correlative studies
219160069|NCT05439395|DEVICE|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
219160070|NCT05565508|PROCEDURE|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
219160071|NCT05565508|PROCEDURE|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
219234976|NCT01825785|DRUG|Placebo|Administered by subcutaneous injection
219234977|NCT04721600|DEVICE|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
219234978|NCT04759378|DIAGNOSTIC_TEST|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
219234979|NCT04998825|DIETARY_SUPPLEMENT|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
219234980|NCT04998825|OTHER|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
219160072|NCT06107023|BEHAVIORAL|Action observation training|6 weeks, three days a week.
219160073|NCT06107023|BEHAVIORAL|sham action observation training|6 weeks, three days a week.
219733577|NCT06522529|OTHER|Multifaceted implementation strategy|The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
219733578|NCT03686982|OTHER|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
219733579|NCT03686982|OTHER|Placebo Bar|No active ingredients
219733580|NCT05488353|DRUG|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
219733581|NCT02591407|PROCEDURE|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
219733582|NCT02591407|PROCEDURE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
219733583|NCT00705965|BEHAVIORAL|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
219733584|NCT00705965|BEHAVIORAL|Information session|One information session about living with heart disease.
219160074|NCT04680767|DRUG|LY3502970|Administered orally.
219160075|NCT04680767|DRUG|[¹⁴C]-LY3502970|Administered orally.
219160076|NCT01964534|DRUG|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
219234981|NCT05077046|OTHER|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
219160077|NCT01964534|DRUG|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
219160078|NCT01964534|DRUG|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
219160079|NCT02006758|DEVICE|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
219160080|NCT02611609|BIOLOGICAL|MultiStem|
219160081|NCT02611609|BIOLOGICAL|MultiStem|
219160082|NCT02611609|BIOLOGICAL|Placebo|
219234982|NCT02917434|DIETARY_SUPPLEMENT|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
219234983|NCT01219751|DRUG|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
219733585|NCT00705965|OTHER|Usual cardiological care|Usual cardiological care
219733586|NCT03367351|BEHAVIORAL|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
219733587|NCT03367351|BEHAVIORAL|Social Support|Engagement in peer-led CGM specific discussion boards
219733588|NCT03367351|BEHAVIORAL|Standard of Care|Standard of Care - serves as the control group for the treatment arm
219733589|NCT05685407|DRUG|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
219733590|NCT05685407|OTHER|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
219733591|NCT02694055|OTHER|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
219733592|NCT02694055|OTHER|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
219733593|NCT02694055|OTHER|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
219160083|NCT05243784|BEHAVIORAL|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
219160084|NCT03399604|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
219160085|NCT03405714|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"
219160086|NCT04788641|DRUG|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
219160087|NCT04788641|DRUG|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
219160088|NCT04788641|DRUG|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
219160089|NCT02530216|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
219160090|NCT00038454|DRUG|Hemolink (hemoglobin raffimer IV solution)|
219160091|NCT06181695|DRUG|Sufentanil|Administration of intranasal sufentanil
219234984|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
219733594|NCT02694055|OTHER|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
219733595|NCT02694055|OTHER|Training of primary health centre staff|"Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management"
219733596|NCT00180700|BEHAVIORAL|Hypnosis|
219733597|NCT00892450|DRUG|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
219234985|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
219733598|NCT05196503|BIOLOGICAL|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
219733599|NCT04494737|BEHAVIORAL|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
219234986|NCT02382185|OTHER|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
219733600|NCT04494737|BEHAVIORAL|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
219733601|NCT03834662|DRUG|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
219733602|NCT01326637|OTHER|Patient Overview Document|"The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
219733603|NCT01578746|PROCEDURE|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
219733604|NCT01578746|PROCEDURE|Anterior approach|The use of anterior approach in total hip arthroplasty
219733605|NCT01501500|DRUG|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
219733606|NCT01501500|DRUG|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
219733607|NCT06035549|BEHAVIORAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
219733608|NCT03241550|DRUG|isavuconazonium sulfate - intravenous|IV infusion
219733609|NCT03241550|DRUG|isavuconazonium sulfate - oral|Oral
219160092|NCT01869179|BEHAVIORAL|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
219160093|NCT01869179|BEHAVIORAL|Wait-list control group|
219160094|NCT02740231|DRUG|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
219160095|NCT02740231|DEVICE|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
219160096|NCT02462759|DRUG|Nusinersen|Administered by intrathecal injection.
219160097|NCT02462759|PROCEDURE|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
219160098|NCT04267458|OTHER|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
219160099|NCT04396782|OTHER|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
219160100|NCT04396782|OTHER|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
219160101|NCT03693937|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
219160102|NCT03821636|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
219160103|NCT03821636|PROCEDURE|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
219160104|NCT01000480|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
219160105|NCT01000480|DRUG|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
219234987|NCT02382185|DRUG|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
219733610|NCT01391299|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
219733611|NCT01391299|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
219733612|NCT02319915|DRUG|Tranexamic Acid|
219733613|NCT02319915|DRUG|Adrenalin|
219733614|NCT06642779|BEHAVIORAL|VFQ- 25 (Visual Function Questionnaire)|VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
219733615|NCT06642779|DIAGNOSTIC_TEST|Optical Biometry|Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
219160106|NCT01000480|RADIATION|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
219733616|NCT06642779|DIAGNOSTIC_TEST|Slit lamps / Fundoscopy / Biomicroscopy|The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
219733617|NCT06642779|DIAGNOSTIC_TEST|UDVA|Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
219733618|NCT06642779|DIAGNOSTIC_TEST|CDVA|Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
219733619|NCT06642779|DIAGNOSTIC_TEST|UIVA / DCIVA|Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
219733620|NCT06642779|DIAGNOSTIC_TEST|UNVA / DCNVA|Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
219733621|NCT06642779|DIAGNOSTIC_TEST|Manifest Refraction|Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
219733622|NCT06642779|DIAGNOSTIC_TEST|IOP|Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
219733623|NCT06642779|DIAGNOSTIC_TEST|VADC|Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
219160107|NCT03490045|OTHER|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
219160108|NCT03490045|OTHER|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
219160109|NCT05295342|BEHAVIORAL|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
219160110|NCT05295342|BEHAVIORAL|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
219234988|NCT02382185|DEVICE|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
219234989|NCT01371227|DRUG|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
219234990|NCT04999800|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
219234991|NCT04999800|DRUG|Anlotinib|Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
219234992|NCT04526171|BEHAVIORAL|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
219234993|NCT04254965|OTHER|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
219234994|NCT04254965|DEVICE|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
219234995|NCT04972318|PROCEDURE|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
219234996|NCT04972318|PROCEDURE|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
219234997|NCT01094600|DRUG|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
219234998|NCT03476954|OTHER|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
219234999|NCT02440919|OTHER|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
219235000|NCT02440919|OTHER|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
219733624|NCT06642779|DIAGNOSTIC_TEST|CSDC|Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
219733625|NCT06642779|DIAGNOSTIC_TEST|CSV-1000|"Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)"
219733626|NCT06642779|DIAGNOSTIC_TEST|Tear film stability|Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
219733627|NCT06642779|DEVICE|IOL implantation|The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
219733628|NCT06641622|DIAGNOSTIC_TEST|Prediction of delayed graft function|Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
219733629|NCT06641934|OTHER|No intervention; Observational study|No intervention
219733630|NCT01704989|PROCEDURE|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
219733631|NCT01704989|DRUG|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
219733632|NCT05500534|DEVICE|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
219733633|NCT05500534|OTHER|Laser lithortripsy|Standard laser lithotripsy
219160111|NCT05295342|BEHAVIORAL|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
219160112|NCT02561702|OTHER|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
219733634|NCT06642870|OTHER|Non-interventional study|The study will consist of focus groups and a large scale patient survey
219733635|NCT06367153|DRUG|BI 1569912|BI 1569912
219733636|NCT06367153|DRUG|repaglinide|repaglinide
219733637|NCT06367153|DRUG|midazolam|midazolam
219733638|NCT06367153|DRUG|bupropion|bupropion
219733639|NCT01655069|DRUG|Solifenacin succinate suspension|Oral suspension
219733640|NCT06582771|DRUG|Sotorasib|Sotorasib 960 mg (8 pills) daily
219160113|NCT02561702|DRUG|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
219160114|NCT06284642|DRUG|Urokinase|On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
219160115|NCT06284642|DRUG|Placebo|On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
219160116|NCT06438094|PROCEDURE|Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
219160117|NCT06438094|PROCEDURE|Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
219160118|NCT00829634|DRUG|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
219160119|NCT00829634|DRUG|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
219160120|NCT04162457|DIETARY_SUPPLEMENT|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
219160121|NCT04162457|DIETARY_SUPPLEMENT|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
219733641|NCT05694208|BEHAVIORAL|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
219733642|NCT03041870|DEVICE|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
219160122|NCT04162457|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
219160123|NCT04162457|DIETARY_SUPPLEMENT|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
219160124|NCT05398055|DRUG|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
219160125|NCT05398055|DRUG|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
219160126|NCT05742126|DRUG|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
219160127|NCT05742126|DRUG|Placebo|Matching placebo
219160128|NCT05742126|DRUG|Heparin sodium injection|Matching positive control
219160129|NCT01188369|DRUG|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
219160130|NCT01188369|DRUG|placebo drug|Intravenous infusion, colour identical to levosimendan
219160131|NCT04400734|OTHER|No intervention, observational study|no intervention
219160132|NCT04802382|DRUG|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
219160133|NCT04802382|DIAGNOSTIC_TEST|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
219160134|NCT04802382|PROCEDURE|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
219160135|NCT04802382|PROCEDURE|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
219160136|NCT04802382|DIAGNOSTIC_TEST|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
219160137|NCT04802382|DIAGNOSTIC_TEST|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
219160138|NCT04802382|OTHER|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
219160139|NCT04802382|DIAGNOSTIC_TEST|PK test|PK test will be performed on day 1 only (only in Brazil sites)
219160140|NCT04802382|DIAGNOSTIC_TEST|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
219160141|NCT04802382|DIAGNOSTIC_TEST|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
219160142|NCT04802382|OTHER|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
219160143|NCT04802382|DIAGNOSTIC_TEST|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
219160144|NCT04802382|PROCEDURE|ECG|patients will undergo an ECG examination on days 1, and day 28
219160145|NCT04802382|OTHER|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
219160146|NCT04802382|DRUG|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
219160147|NCT04802382|DRUG|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
219160148|NCT02922088|DEVICE|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
219160149|NCT01763853|DRUG|4% albumin|
219160150|NCT01132560|GENETIC|RNA analysis|
219160151|NCT01132560|GENETIC|gene expression analysis|
219160152|NCT01132560|GENETIC|reverse transcriptase-polymerase chain reaction|
219160153|NCT01132560|OTHER|laboratory biomarker analysis|
219160154|NCT01145729|BEHAVIORAL|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
219160155|NCT04743362|DIAGNOSTIC_TEST|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
219160156|NCT04743362|DIAGNOSTIC_TEST|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
219160157|NCT04743362|DIAGNOSTIC_TEST|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
219160158|NCT04743362|DIAGNOSTIC_TEST|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
219160159|NCT04743362|DIAGNOSTIC_TEST|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
219160160|NCT04743362|DIAGNOSTIC_TEST|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
219160161|NCT04743362|DIAGNOSTIC_TEST|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
219160162|NCT04743362|DIAGNOSTIC_TEST|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
219160163|NCT01294020|DRUG|Tacrolimus|Oral capsule
219160164|NCT01294020|DRUG|Tacrolimus prolonged release|Oral capsule
219235001|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
219235002|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
219235003|NCT03145142|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
219235004|NCT03145142|PROCEDURE|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
219733643|NCT05075681|DRUG|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
219733644|NCT04249739|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
219733645|NCT02159404|BIOLOGICAL|Immunotherapy|
219733646|NCT04771871|DRUG|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
219733647|NCT04771871|DRUG|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
219733648|NCT04771871|DRUG|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
219733649|NCT04771871|DRUG|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
219160165|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
219160166|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
219160167|NCT03306082|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
219160168|NCT01352429|RADIATION|Proton Therapy|
219160169|NCT01352429|RADIATION|IMRT|
219160170|NCT03568188|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
219160171|NCT03568188|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
219160172|NCT03568188|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
219160173|NCT03568188|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
219235005|NCT02494076|DRUG|EzPAP|
219235006|NCT02494076|OTHER|Standard Care|
219235007|NCT03518047|DRUG|risankizumab|rizankizumab subcutaneous (SC) infusion
219235008|NCT03518047|DRUG|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
219235009|NCT02857686|PROCEDURE|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
219733650|NCT03883451|OTHER|Helmet Model|helmet model worn by football players
219733651|NCT06380530|PROCEDURE|Deformity correction|Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
219160174|NCT03568188|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
219160175|NCT03568188|BIOLOGICAL|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
219160176|NCT03568188|BIOLOGICAL|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
219160177|NCT04902391|OTHER|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
219160178|NCT04448366|BEHAVIORAL|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
219160179|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.
219160180|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.
219160181|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intramuscularly.
219160182|NCT05370820|OTHER|No intervention|Control group with no administration of Tranexamic Acid.
219160183|NCT04531475|DRUG|X842|X842 capsules
219160184|NCT04531475|DRUG|X842 Placebo|X842 placebo-matching capsules
219160185|NCT04531475|DRUG|Lansoprazole|Lansoprazole capsules
219160186|NCT04531475|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
219160187|NCT04779216|DRUG|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
219160188|NCT04779216|DRUG|Placebo|Placebo Injection monthly for 12 months
219160189|NCT04779216|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
219235010|NCT02857686|PROCEDURE|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
219160190|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
219160191|NCT02616562|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
219160192|NCT02616562|DRUG|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
219160193|NCT02616562|DRUG|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once-weekly.
219160194|NCT05644730|DEVICE|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
219235011|NCT00278395|DRUG|Vorinostat|Given orally
219160195|NCT01051635|DRUG|LMP400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
219160196|NCT01051635|DRUG|LMP776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
219160197|NCT05430334|COMBINATION_PRODUCT|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
219160198|NCT05430334|COMBINATION_PRODUCT|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
219160199|NCT05430334|COMBINATION_PRODUCT|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
219160200|NCT05430334|COMBINATION_PRODUCT|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
219160201|NCT05430334|COMBINATION_PRODUCT|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
219160202|NCT05430334|COMBINATION_PRODUCT|e-liquid 6|30/70 PG/VG ratio with nicotine concentration 0mg/ml
219160203|NCT05430334|COMBINATION_PRODUCT|e-liquid 7 and e-liquid 8|e-liquid 7: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 8: 30/70 PG/VG ratio with nicotine concentration 8mg/ml protonated
219160204|NCT05430334|COMBINATION_PRODUCT|e-liquid 9 and e-liquid 10|e-liquid 9: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 10: 70/30 PG/VG ratio with nicotine concentration 4mg/ml protonated
219235012|NCT01961934|DRUG|Sodium Acetate C11 PET/CT Imaging|
219235013|NCT04135183|PROCEDURE|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
219235014|NCT06390176|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG powder|Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
219733652|NCT05639803|DRUG|PEGIFNα1b|100μg/vial
219733653|NCT05639803|DRUG|Placebo|0.5ml/vial
219733654|NCT06362642|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
219733655|NCT06362642|DRUG|Itraconazole|Antifungal treatment that is a potent inhibitor of CYP3A4.
219733656|NCT06031051|DEVICE|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
219733657|NCT05373836|DIAGNOSTIC_TEST|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
219160205|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
219160206|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
219160207|NCT06239701|BEHAVIORAL|LPA+Fitbit Intervention|"1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
219160208|NCT06239701|BEHAVIORAL|Fitbit Only|"1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
219160209|NCT06499051|OTHER|cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanisms|self-administered questionnaires
219160210|NCT03348150|PROCEDURE|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
219160211|NCT03348150|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
219160212|NCT04895748|DRUG|DFF332|Hif2alpha inhibitor
219160213|NCT04895748|DRUG|RAD001|mTOR inhibitor
219160214|NCT04895748|DRUG|PDR001|anti-PD-1
219160215|NCT04895748|DRUG|NIR178|Adenosine A2A antagonist receptor
219160216|NCT01837875|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
219160217|NCT01837875|BEHAVIORAL|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
219160218|NCT01837875|BEHAVIORAL|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
219160219|NCT01837875|BEHAVIORAL|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
219160220|NCT01083342|DRUG|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
219160221|NCT01626612|PROCEDURE|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
219160222|NCT01626612|PROCEDURE|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
219160223|NCT05499351|BIOLOGICAL|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
219733658|NCT05093166|DRUG|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
219733659|NCT01595178|BEHAVIORAL|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
219733660|NCT05477641|PROCEDURE|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
219733661|NCT05477641|PROCEDURE|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
219733662|NCT03288935|BEHAVIORAL|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).
219733663|NCT03288935|BEHAVIORAL|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
219733664|NCT03062436|OTHER|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
219733665|NCT03062436|DIAGNOSTIC_TEST|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
219160224|NCT05499351|BIOLOGICAL|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
219235015|NCT06390176|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
219235016|NCT06390176|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
219235017|NCT03096496|OTHER|QoL questionnaires|Quality of life questionnaires
219235018|NCT04389684|OTHER|Psycho-Social Questionnaire|Patients, after enrollmenet in the study, receive a paper questionnaire during the month following COVID19 related confinement and all the material to send it back to the institution. They receive the same questionnaire 3 months later with all the material to send it back to the institution. The intervention is the same for all patients wether their treatment was modified or not.
219235019|NCT05530083|BEHAVIORAL|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
219733666|NCT06399471|DEVICE|Microprocessor prosthetic knee|Microprocessor prosthetic knees for use in a transfemoral prosthesis
219733667|NCT05347797|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
219733668|NCT05738291|DRUG|BI 1839100|BI 1839100
219733669|NCT05738291|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
219733670|NCT05738291|DRUG|midazolam|midazolam
219733671|NCT05738291|DRUG|digoxin|digoxin
219733672|NCT05738291|DRUG|rosuvastatin|rosuvastatin
219733673|NCT05860296|DRUG|SLC-391|SLC-391 is an AXL inhibitor
219733674|NCT05860296|BIOLOGICAL|pembrolizumab|Immunotherapy
219733675|NCT05087680|BEHAVIORAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
219733676|NCT05087680|BEHAVIORAL|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
219733677|NCT06083467|DIAGNOSTIC_TEST|Brain MRI Scan|MRI scan of the brain
219733678|NCT06083467|BEHAVIORAL|Neurologic exam|Neurologic exam and assessments, including video interview
219733679|NCT05792462|DRUG|Baricitinib|Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
219160225|NCT05499351|BIOLOGICAL|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
219160226|NCT05499351|BIOLOGICAL|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
219160227|NCT05758597|DRUG|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
219160228|NCT05758597|DRUG|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
219160229|NCT02847780|DEVICE|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
219160230|NCT02847780|DEVICE|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
219160231|NCT06417346|PROCEDURE|Laparoscopic TEP Repair|Laparoscopic TEP Repair performed
219160232|NCT06417346|PROCEDURE|Open Technique (Lichtenstein)|Open Technique (Lichtenstein) performed
219160233|NCT00151424|DRUG|asenapine|Asenapine 5-10mgBID
219160234|NCT00151424|DRUG|Placebo|Matched against asenapine and olanzapine
219160235|NCT00151424|DRUG|Olanzapine|10-20 mg QD
219160236|NCT00001017|DRUG|Fluconazole|
219160237|NCT00001017|DRUG|Amphotericin B|
219160238|NCT02415140|OTHER|Rate of depression|
219235020|NCT05530083|BEHAVIORAL|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
219235021|NCT00551187|BIOLOGICAL|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
219235022|NCT00551187|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
219160239|NCT04159493|DRUG|Estriol|Vaginal Application
219160240|NCT04159493|DRUG|Placebo|Vaginal Application
219160241|NCT02633267|BEHAVIORAL|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
219160242|NCT02633267|BEHAVIORAL|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
219160243|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
219160244|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
219160245|NCT00522951|DRUG|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
219160246|NCT05628792|DIAGNOSTIC_TEST|CT|Ultra High Resolution CT scan
219160247|NCT05429307|OTHER|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
219160248|NCT01157663|OTHER|Adapted balance training|during 8 weeks
219160249|NCT01157663|OTHER|Balance Training|Balance training with unipedal standing during 8 weeks
219160250|NCT01576029|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
219160251|NCT01576029|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
219160252|NCT01827917|BIOLOGICAL|rabies vaccine|Injection on day 0、7、21
219160253|NCT00479700|DRUG|SAM-531|
219160254|NCT05127681|RADIATION|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
219160255|NCT05127681|BIOLOGICAL|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
219160256|NCT05127681|RADIATION|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
219160257|NCT05127681|OTHER|medical data collection|Data of healthy men is already available
219160258|NCT01771731|DRUG|Cannabis|
219160259|NCT01747486|BIOLOGICAL|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
219160260|NCT05237453|RADIATION|Photons|MR-guided adaptive radiotherapy
219160261|NCT00220519|DRUG|Lactobacillus GG|
219160262|NCT00010725|DRUG|MAK|
219160263|NCT00010725|DRUG|Vitamin Supplements|
219160264|NCT01230450|PROCEDURE|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
219160265|NCT01230450|OTHER|stand standard mid-urethral sling (TVT-O)|
219160266|NCT00704314|DRUG|Simvastatin|80 mg Simvastatin daily for 8 weeks
219160267|NCT00704314|DRUG|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
219160268|NCT03251222|DRUG|Dexmedetomidine|Intranasal aplication of dexmedetomidine
219160269|NCT03251222|OTHER|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
219160270|NCT03066115|DRUG|L-NMMA|See arm description.
219235023|NCT00551187|BIOLOGICAL|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
219235024|NCT01588847|PROCEDURE|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
219235025|NCT01588847|PROCEDURE|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
219235026|NCT03740737|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
219235027|NCT03740737|OTHER|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
219235028|NCT02375243|DRUG|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
219235029|NCT05671211|OTHER|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
219235030|NCT05671211|OTHER|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
219235031|NCT04929600|DRUG|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
219160271|NCT03066115|DRUG|Ketorolac|See arm description.
219160272|NCT03066115|DRUG|Ascorbic Acid|See arm description.
219160273|NCT03066115|PROCEDURE|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
219160274|NCT03066115|PROCEDURE|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
219160275|NCT00976495|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
219160276|NCT00976495|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
219160277|NCT00976495|DRUG|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
219160278|NCT05821569|OTHER|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
219235032|NCT04929600|DRUG|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
219235033|NCT05217758|DRUG|Mifepristone|1200 mg/day, once daily, 7 days
219235034|NCT05217758|DRUG|Placebo|Placebo, once daily, 7 days
219235035|NCT06526442|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.
219235036|NCT00947895|DRUG|Methylprednisolone|IV 1000 mg daily for 3 days
219235037|NCT00947895|DRUG|ACTH|IM ACTH 80 mg/day for 5 days.
219235038|NCT00947895|OTHER|IV placebo|IV placebo (saline) daily for 3 days.
219235039|NCT00947895|OTHER|IM placebo|IM placebo (saline) daily for 5 days.
219733680|NCT06007248|DIAGNOSTIC_TEST|Protocol-defined Examinations|Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
219160279|NCT05821569|OTHER|Biological nurturing|Adoption of biological nurturing approach to breastfeed
219160280|NCT00033098|DRUG|Metyrapone|
219160281|NCT01879189|BEHAVIORAL|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
219160282|NCT05952258|DEVICE|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
219160283|NCT05952258|DEVICE|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
219160284|NCT05364216|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
219160285|NCT05364216|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
219160286|NCT05364216|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
219160287|NCT00331136|DRUG|Pyronaridine-Artesunate|Once a day for 3 days
219160288|NCT05280275|DRUG|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
219160289|NCT05280275|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
219235040|NCT02243449|PROCEDURE|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
219235041|NCT02243449|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
219235042|NCT00759798|DRUG|Fludarabine|25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
219235043|NCT00759798|DRUG|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
219733681|NCT05965466|PROCEDURE|Distal gastrectomy and radical resection|Distal gastrectomy and Roux-en-Y anastomosis
219733682|NCT05965466|PROCEDURE|Total gastrectomy and radical resection|Total gastrectomy and Roux-en-Y anastomosis
219733683|NCT06707038|BEHAVIORAL|AATAP intervention|AATAP is a program created to address the barriers that Black patients face when accessing transplantation. AATAP providers resources in cultural congruency, trust, psychosocial support, and health literacy to provide patients with the individualized support needed to access the kidney transplant waitlist
219733684|NCT03371225|DEVICE|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
219733685|NCT03371225|PROCEDURE|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
219733686|NCT03371225|DEVICE|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
219733687|NCT03371225|PROCEDURE|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
219733688|NCT00986102|DRUG|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
219733689|NCT06325852|OTHER|DBS programing|The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
219733690|NCT06800183|DRUG|Four-Chamber Tartrazine Patch across 3 Body Sites|This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
219733691|NCT06083493|DEVICE|LIFUP excitation|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
219733692|NCT06083493|DEVICE|LIFUP inhibition|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
219733693|NCT06378190|BIOLOGICAL|CAR-T cells therapy|CAR-T cells therapy
219160290|NCT05280275|DRUG|Lenalidomide|Lenalidomide will be administered per os.
219160291|NCT05280275|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
219160292|NCT04308083|PROCEDURE|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
219160293|NCT02860741|BEHAVIORAL|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
219160294|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
219160295|NCT05452525|DRUG|CKD-379 I|1 tablet administration under fed condition
219733694|NCT06633666|DEVICE|Acupuncture|"1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)"
219733695|NCT05828901|OTHER|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
219733697|NCT06431646|BEHAVIORAL|A web-based education intervention developed for university students with PMS|The web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
219733698|NCT04344860|DRUG|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
219733699|NCT04344860|DRUG|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
219733700|NCT02060188|DRUG|Ipilimumab|Specified dose on specified days
219733701|NCT02060188|DRUG|Nivolumab|Specified dose on specified days
219733702|NCT02060188|DRUG|Cobimetinib|Specified dose on specified days
219733703|NCT02060188|DRUG|Daratumumab|Specified dose on specified days
219733704|NCT02060188|DRUG|BMS-986016|Specified dose on specified days
219733705|NCT06077747|PROCEDURE|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
219160296|NCT05452525|DRUG|CKD-379 II|1 tablet administration under fed condition
219160297|NCT05452525|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
219160298|NCT01859559|PROCEDURE|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
219160299|NCT01859559|PROCEDURE|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
219160300|NCT02681900|BEHAVIORAL|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
219160301|NCT02681900|BEHAVIORAL|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
219160302|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
219160303|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
219160304|NCT05783570|BIOLOGICAL|EU307 CAR-T Cell|"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"
219160305|NCT02321514|DEVICE|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
219160306|NCT02743910|OTHER|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
219160307|NCT02743910|OTHER|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
219160308|NCT01038011|DRUG|drug treatment|
219160309|NCT00332917|DRUG|Pardoprunox|12-42 mg
219160310|NCT01859416|DIETARY_SUPPLEMENT|Oral nutritional supplement|
219160311|NCT02032849|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
219160312|NCT02032849|DEVICE|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
219160313|NCT03396900|DRUG|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
219160314|NCT03396900|OTHER|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
219160315|NCT05631210|OTHER|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
219235044|NCT00759798|DRUG|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
219733706|NCT03270163|DIAGNOSTIC_TEST|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
219733707|NCT03270163|DIAGNOSTIC_TEST|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
219733708|NCT03270163|DIAGNOSTIC_TEST|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
219733709|NCT06009978|DEVICE|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
219733710|NCT04598919|DRUG|Saracatinab|125 mg once daily by mouth for 24 weeks
219733711|NCT04598919|DRUG|Placebo|once daily by mouth for 24 weeks
219733712|NCT06641440|DRUG|Prednisone|patients will be treated for three months in the two groups with the two different protocols for three months both
219733713|NCT06637475|DEVICE|Electric stimulation|"Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals."
219160316|NCT02258815|DRUG|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
219160317|NCT02662894|DRUG|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
219160318|NCT02662894|DRUG|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
219160319|NCT02662894|DRUG|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
219235045|NCT04223323|DIETARY_SUPPLEMENT|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
219235046|NCT04223323|DIETARY_SUPPLEMENT|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
219160320|NCT02662894|DRUG|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
219160321|NCT02988037|BEHAVIORAL|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
219160322|NCT00153569|BIOLOGICAL|Tyrosinase, MAGE-3, GnTV|
219160323|NCT03954210|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
219160324|NCT03954210|BEHAVIORAL|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
219160325|NCT03954301|DIAGNOSTIC_TEST|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
219160326|NCT06554756|OTHER|Saliva, serum and GCF sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
219160327|NCT01231802|DRUG|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
219160328|NCT01231802|DRUG|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
219160329|NCT01231802|DRUG|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
219160330|NCT01231802|DRUG|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
219235047|NCT06268782|BEHAVIORAL|Rehabilitate your core|The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
219235048|NCT02932280|DRUG|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
219235049|NCT00849446|DEVICE|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
219733714|NCT06640452|OTHER|RecoveryFun system|The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
219235050|NCT02148120|DRUG|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
219733715|NCT06639113|BEHAVIORAL|Self-administration medicines|Management of drugs' administration by the patient
219235051|NCT02148120|DRUG|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
219235052|NCT02148120|DRUG|Placebo|
219235053|NCT01307306|DRUG|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
219235054|NCT01307306|DRUG|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
219235055|NCT06001515|DEVICE|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
219733716|NCT06643910|BIOLOGICAL|Single drug group A|9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
219733717|NCT06643910|BIOLOGICAL|Combined treatment group B|9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
219733718|NCT06644976|PROCEDURE|femoral neck CRIF|femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
219733719|NCT02213536|RADIATION|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
219160331|NCT01215344|DRUG|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
219160332|NCT01215344|DRUG|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
219160333|NCT01215344|DRUG|Dexamethasone|20 mg the day before and the day after receiving VELCADE
219160334|NCT01215344|DRUG|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
219160335|NCT01215344|DRUG|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
219160336|NCT01215344|DRUG|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
219160337|NCT01215344|DRUG|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
219160338|NCT02058017|DRUG|OPB-51602|
219733720|NCT02657941|BEHAVIORAL|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
219733721|NCT02657941|BEHAVIORAL|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
219733722|NCT03390673|DRUG|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
219733723|NCT03390673|DRUG|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
219733724|NCT03225989|DRUG|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
219160339|NCT05725135|DRUG|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
219160340|NCT03608475|OTHER|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
219160341|NCT03608475|OTHER|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
219160342|NCT01130727|OTHER|green tea extract|1.21g of green tea extract (965 mg of flavonols)
219160343|NCT01130727|OTHER|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
219160344|NCT01130727|OTHER|placebo|placebo
219160345|NCT01130727|OTHER|low polyphenol cocoa extract|placebo
219160346|NCT04484935|DRUG|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
219160347|NCT03600051|DEVICE|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
219160348|NCT03072914|PROCEDURE|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
219160349|NCT01216722|OTHER|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
219160350|NCT02219568|PROCEDURE|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
219160351|NCT02219568|DEVICE|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
219160352|NCT04504708|DRUG|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
219160353|NCT03437850|OTHER|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
219160354|NCT01387906|DRUG|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
219235056|NCT06001515|DEVICE|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
219235057|NCT05601362|DEVICE|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
219160355|NCT03432858|DRUG|Vancomycin|Vancomycin - 1-gram dosing
219160356|NCT03432858|DRUG|Cefazolin|2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
219160357|NCT03432858|DRUG|Saline Solution|Placebo
219160358|NCT04011631|PROCEDURE|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
219160359|NCT02190981|DEVICE|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
219733725|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
219733726|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
219733727|NCT06289881|DRUG|Sildenafill-Test product|Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
219733728|NCT06289881|DRUG|Sildenafill-Reference product|Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
219733729|NCT00601107|DRUG|Doxercalciferol|
219733730|NCT00601107|DRUG|Placebo|
219733731|NCT00384150|DRUG|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
219733732|NCT05349773|PROCEDURE|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
219733733|NCT03004495|DRUG|CHF5259 and CHF6001|b.i.d. for 14 days
219733734|NCT03004495|DRUG|CHF5259 + placebo|b.i.d. for 14 days
219733735|NCT03004495|DRUG|CHF6001 + placebo|b.i.d. for 14 days
219733736|NCT03004495|OTHER|Placebo|b.i.d. for 14 days
219733737|NCT03791697|OTHER|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
219733738|NCT02430610|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
219733739|NCT02430610|DEVICE|NanoKnife|
219160360|NCT05075486|BEHAVIORAL|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
219160361|NCT05231317|OTHER|Plant-based diet|16 days with all foods provided
219160362|NCT05231317|OTHER|Western diet|16 days with all foods provided
219160363|NCT02382744|DEVICE|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
219160364|NCT02382744|DEVICE|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
219160365|NCT03208881|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
219235058|NCT05601362|DEVICE|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
219160366|NCT00000924|DRUG|Ritonavir|
219160367|NCT00000924|DRUG|Nelfinavir mesylate|
219733740|NCT00874016|DEVICE|Airtraq|Intubation using Airtraq
219733741|NCT00874016|DEVICE|Direct Laryngoscopy|Intubation using direct laryngoscopy
219733742|NCT00285714|PROCEDURE|3D stereophotogrammetric imaging|
219160368|NCT00000924|DRUG|Nevirapine|
219160369|NCT00000924|DRUG|Stavudine|
219160370|NCT00000924|DRUG|Didanosine|
219160371|NCT05264012|PROCEDURE|Neurosurgery|Neurosurgery
219160372|NCT00584246|DRUG|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
219160373|NCT00584246|DRUG|Placebo|50 - 150 mg po qhs for 2 months
219733743|NCT00285714|PROCEDURE|3D CT-imaging with cone-beam CT|
219733744|NCT00285714|PROCEDURE|Case report form|
219733745|NCT03902210|BEHAVIORAL|Online Yoga|60 minutes per week of online yoga through Udaya.com
219733746|NCT03902210|BEHAVIORAL|Podcast|60 minutes per week of podcasts
219733747|NCT00777673|DRUG|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~\- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~\- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
219733748|NCT05052307|DRUG|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
219733749|NCT05052307|DRUG|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
219733750|NCT05052307|DRUG|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
219733751|NCT05052307|DRUG|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
219733752|NCT00445120|DRUG|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
219733753|NCT00445120|DRUG|placebo (sugar)|Placebo will be administered to patients once daily for six months
219733754|NCT00510471|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219733755|NCT06131593|DRUG|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
219733756|NCT06131593|DRUG|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
219733757|NCT03587103|BEHAVIORAL|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
219733758|NCT03587103|BEHAVIORAL|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
219733759|NCT03587103|BEHAVIORAL|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
219733760|NCT00655798|DIETARY_SUPPLEMENT|Placebo|plain yogurt and capsules containing cellulose
219733761|NCT00655798|DIETARY_SUPPLEMENT|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
219733762|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
219733763|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
219733764|NCT03839680|PROCEDURE|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
219160374|NCT04156789|DIAGNOSTIC_TEST|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
219160375|NCT01189942|DRUG|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
219733765|NCT06410807|OTHER|Focus groups|The present study consists of 5 focus groups over 3 waves to inform the development and refinement of internet-based mindfulness (iMBSR) and lifestyle education (iLifeEd) protocols for use in future clinical trials. 50% females and 50% minoritized participants will be recruited to ensure representation across sex and race. For all focus groups, adults (over the age of 50 years) who report SCD will be recruited. Specifically, the Everyday Cognition Questionnaire (E-Cog) will be administered to quantify informant-reported deficits in cognitive functioning.
219733766|NCT05839821|BEHAVIORAL|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
219733767|NCT05839821|BEHAVIORAL|F-noRAS|finger-tapping without listening to RAS
219733768|NCT05839821|BEHAVIORAL|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
219733769|NCT05839821|BEHAVIORAL|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
219733770|NCT05839821|BEHAVIORAL|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
219733771|NCT05839821|BEHAVIORAL|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
219733772|NCT05714631|OTHER|Placebo Patch|Transdermal placebo patch
219733773|NCT05714631|DRUG|4% Lidocaine Patch|Transdermal patch
219733774|NCT02241772|DRUG|TA-8995|
219733775|NCT02241772|DRUG|Placebo|
219733776|NCT04785807|OTHER|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
219733777|NCT01982227|DRUG|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
219160376|NCT01094184|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
219160377|NCT01094184|DRUG|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
219160378|NCT01094184|DRUG|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
219160379|NCT04355221|PROCEDURE|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
219160380|NCT06220149|DIAGNOSTIC_TEST|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
219160381|NCT01093820|DRUG|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
219160382|NCT06257680|BIOLOGICAL|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
219160383|NCT05166070|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
219160384|NCT00868504|OTHER|no intervention|no intervention
219160385|NCT04659018|BIOLOGICAL|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
219160386|NCT03892564|DRUG|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
219160387|NCT03892564|DRUG|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
219160388|NCT03892564|DRUG|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
219160389|NCT03892564|DRUG|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
219160390|NCT03892564|DRUG|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
219160391|NCT06520306|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
219160392|NCT03197116|OTHER|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
219160393|NCT03197116|OTHER|No other|No additional reminder will be offered
219160394|NCT00070694|DRUG|MDL100.907|
219160395|NCT04325685|DRUG|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
219160396|NCT04325685|DRUG|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
219160397|NCT04325685|DRUG|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
219160398|NCT04144595|DIAGNOSTIC_TEST|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
219160399|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
219160400|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
219160401|NCT05324943|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
219160402|NCT04944407|PROCEDURE|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
219160403|NCT04944407|PROCEDURE|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
219733778|NCT01906164|DRUG|ALS-008176|
219733779|NCT01906164|DRUG|Placebo|
219733780|NCT04667429|OTHER|Food|HEC83518 40mg will be taken orally fasted or with food
219733781|NCT04667429|DRUG|HEC83518|HEC83518 will be taken orally before sleep for 15 days
219733782|NCT04667429|DRUG|placebo|The placebo will be administered before sleep for 15 days.
219733783|NCT05111769|DRUG|Recombinant human brain natriuretic peptide|1\. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
219160404|NCT02568826|DRUG|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
219160405|NCT06864065|BEHAVIORAL|Emotion regulation task (fNIRS recording during the emotional regulation task)|No drugs were used in this study. All participants perform an emotion regulation task. More precisely, they have to down regulate negative emotions elicited by negative pictures using a cognitive reaprasal strategy. To this end, they have to change the meaning of the picture they are watching in order to decrease motional intensity.
219160406|NCT06990789|BEHAVIORAL|effective self-applied ear massage|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
219160407|NCT06990789|BEHAVIORAL|Sham Comparator|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
219160408|NCT06242236|OTHER|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
219160409|NCT06676683|DRUG|Usage of Statin in diabetic patients|The use of statin in diabetic patients not known to have Atherosclerotic cardiovascular disease in a low income community
219160410|NCT06676215|DIETARY_SUPPLEMENT|IAA mix supplement|The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.
219160411|NCT06676215|OTHER|Complementary food comprised of rice and legumes|Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
219160412|NCT06677255|DRUG|VUM02 Injection (UC-MSCs)+BAT|"The dose-escalation phase (phase I):~Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week.~The dose-expansion phase (phase II):~-Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses."
219160413|NCT06677255|OTHER|The control group with Best Available Therapy (BAT)|According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
219160414|NCT06716190|DRUG|BI 3731579|BI 3731579
219160415|NCT06716190|DRUG|Placebo matching BI 3731579|Placebo matching BI 3731579
219160416|NCT06716190|DRUG|Midazolam|Midazolam
219160417|NCT06717906|DIAGNOSTIC_TEST|Endoscopic Ultrasound|If sigmoidoscopy is warranted as per clinical indication, the consenting patients shall undergo endoscopic ultrasound (EUS) using a radial echo-endoscope during the same sitting of sigmoidoscopy without incurring any additional cost to the patient. Total rectal wall thickness in anterior and posterior wall shall be measured in upper, middle and lower rectum with assessment of vascularity (Modified Limberg scale). The maximal wall thickness including maximum mucosal and submucosal thickness shall be noted and compared to total wall thickness measured by transabdominal ultrasound (TAS) and Transperineal ultrasound (TPUS). On sigmoidoscopy, rectal inflammation shall be measured by ulcerative colitis endoscopic index of severity (UCEIS) in rectum. Biopsy seal be taken as standard protocol to document histologic inflammation (measured by Nancy histologic index) which is known to predict future risk of relapse.
219235059|NCT04475406|OTHER|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
219733784|NCT03465605|DIAGNOSTIC_TEST|frailty test|questionnaire
219733785|NCT00224354|BIOLOGICAL|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
219733786|NCT00224354|BIOLOGICAL|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
219733787|NCT00224354|BIOLOGICAL|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
219160418|NCT07037927|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
219160419|NCT07045142|DRUG|Atorvastatin|Participants will receive atorvastatin 20 mg daily.
219160420|NCT07045142|DRUG|Metformin|Participants will receive metformin 1000 mg daily.
219160421|NCT07045142|DRUG|Placebo|Participants will receive placebo 1000 mg daily, mimicking the appearance of metformin without containing active ingredients.
219733788|NCT00224354|DRUG|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
219733789|NCT00224354|BIOLOGICAL|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
219733790|NCT00776425|DRUG|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
219733791|NCT00700089|BEHAVIORAL|Assertive intervention|8-20 assertive contacts after suicide attempt
219733792|NCT00700089|OTHER|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
219733793|NCT03112850|DEVICE|Hearing aid|LOF hearing aid
219733794|NCT03112850|BEHAVIORAL|Auditory Training|
219733795|NCT05303974|OTHER|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
219733796|NCT05431751|DIETARY_SUPPLEMENT|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
219733797|NCT05099276|DRUG|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
219733798|NCT05099276|DRUG|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
219733799|NCT04168138|DRUG|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
219733800|NCT05615961|DIETARY_SUPPLEMENT|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
219733801|NCT05615961|DIETARY_SUPPLEMENT|Placebo|Placebo Tablets
219160422|NCT06716112|DEVICE|Vagus Nerve Stimulation (VNS) Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers active VNS stimulation.
219733802|NCT00676962|BEHAVIORAL|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
219733803|NCT02257021|DRUG|BILR 355 BS|
219733804|NCT02257021|DRUG|Tipranavir|
219733805|NCT02257021|DRUG|Low dose of ritonavir|
219733806|NCT02257021|DRUG|High dose of ritonavir|
219160423|NCT06716112|DEVICE|Sham VNS Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers sham VNS stimulation.
219733807|NCT00147537|DRUG|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
219733808|NCT00147537|DRUG|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
219733809|NCT00147537|DRUG|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
219733810|NCT00147537|DRUG|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
219733811|NCT00147537|DRUG|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
219733812|NCT00147537|DRUG|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
219733813|NCT00147537|DRUG|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
219733814|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
219733815|NCT05469178|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
219733816|NCT05469178|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.
219733817|NCT05469178|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
219733818|NCT05469178|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
219733819|NCT03041480|DIAGNOSTIC_TEST|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
219733820|NCT05922735|BEHAVIORAL|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
219733821|NCT00406731|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
219733822|NCT00406731|DRUG|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
219733823|NCT00406731|DRUG|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
219733824|NCT00406731|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
219733825|NCT00406731|DEVICE|Goldmann applanation tonometer|Intraocular pressure measurements
219733826|NCT00406731|DEVICE|HP-CMS patient monitor|blood pressure and pulse rate measurements
219733827|NCT00406731|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
219733828|NCT06130033|DEVICE|Neuromonitoring|"Multimodal Neuromonitoring:~Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen"
219733829|NCT00013299|DEVICE|Prevention of Diabetic Ulcers|
219733830|NCT00699166|DRUG|DNK333|25 mg and 100 mg oral doses, each taken twice daily
219733831|NCT05866601|OTHER|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
219733832|NCT05151965|PROCEDURE|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
219733833|NCT05151965|PROCEDURE|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
219733834|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
219733835|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
219733836|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
219733837|NCT05351489|DRUG|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
219733838|NCT02523040|DRUG|Lenalidomide|
219733839|NCT01183637|DEVICE|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
219160424|NCT06716112|BEHAVIORAL|Upper Extremity Rehabilitation|"Rehabilitation training will be functional and activity-based, focusing on six task categories: reaching and grasping objects, gross movements with objects, flipping objects, inserting objects, self-feeding, and opening and closing containers.~Three 90-minute training sessions per week will be administered by a licensed occupational therapist, over two six-week treatment blocks. Sessions will be paired with either active or sham VNS administration."
219160425|NCT04320251|PROCEDURE|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
219160426|NCT07048795|OTHER|No Intervention: Observational Cohort|No intervention
219160427|NCT07063381|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 6 months.
219160428|NCT07064486|DRUG|BGM0504|Administered SC
219160429|NCT07064486|DRUG|BGM0504|Administered SC
219160430|NCT07064486|DRUG|Semaglutide|Administered SC
219160431|NCT07071844|DRUG|Trifluridine/tipiracil|35 mg/m², orally
219733840|NCT01183637|PROCEDURE|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
219733841|NCT05217966|RADIATION|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
219160432|NCT07071844|DRUG|Bevacizumab|5 mg/kg, intravenous route
219160433|NCT07071740|DEVICE|ventral hernia repair|Robotic-assisted incisional or primary ventral hernia repair with the DEXTER robotic surgery system
219160434|NCT07066267|OTHER|Experimental|Autologous adipose stem cell mitochondrial transfer to mature oocytes along with intracytoplasmic sperm injection (ICSI). The intervention is also termed as Adipose Stem Cell ENergy Transfer (ASCENT).
219160435|NCT07064148|BEHAVIORAL|Self-Myofascial Release (SMR) Program|The intervention involves a structured 6-week Self-Myofascial Release (SMR) program using foam rollers and massage balls. Participants perform standardized SMR exercises targeting major muscle groups relevant to golf performance, including the calves, hamstrings, glutes, back, shoulders, and thoracic spine. The intervention is conducted three times per week, with each session lasting approximately 30 minutes. Exercises are demonstrated and monitored by certified instructors. The control group continues regular physical activities without SMR.
219160436|NCT07064148|BEHAVIORAL|Golf-Related Video Viewing (Attention Control)|Participants in the control group did not receive any self-myofascial release (SMR) intervention. They followed the same daily training schedule, accommodation, and meals as the SMR group. Instead of engaging in SMR exercises, participants in the control group engaged in supervised viewing of golf-related instructional videos or documentaries three times per week, approximately 30 minutes per session, after 7:00 PM in a designated classroom. This viewing schedule was matched in timing and frequency to the SMR group's intervention sessions. No flexibility, mobility, or soft tissue techniques were included in the control group's activities. The sessions were conducted collectively in the same setting and at the same time as the SMR group to control for attention and environmental bias. Attendance and compliance were closely monitored by supervisors to ensure adherence.
219733842|NCT02006654|DRUG|Placebo|Once daily, matching placebo capsules, orally
219733843|NCT02006654|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
219733844|NCT05396391|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q2w
219733845|NCT03176199|DRUG|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
219733846|NCT03176199|DRUG|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
219733847|NCT01298466|DRUG|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
219733848|NCT01391949|BEHAVIORAL|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
219733849|NCT01391949|BEHAVIORAL|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
219733850|NCT00478140|BIOLOGICAL|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
219733851|NCT00478140|OTHER|laboratory biomarker analysis|Correlative studies
219733852|NCT03116815|OTHER|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
219733853|NCT02077712|DRUG|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
219733854|NCT01933425|DRUG|rocuronium|
219733855|NCT01933425|DRUG|sugammadex|
219160437|NCT07070687|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Low-frequency electrical stimulation (800Hz) applied at CV2/S3 regions twice daily for 7 days using MMK520i device
219160438|NCT07071155|DRUG|Momelotinib|The investigators will randomize the first 10 patients to receive 200 mg momelotinib (MMB) monotherapy for first 3 cycles with addition of HMA starting cycle 4 (Arm A, n=5) versus starting with MMB-HMA combination both starting in cycle 1 (Arm B, n=5). The regimen used for the next 8 patients (Arm C- expansion) will be determined after an interim analysis of Arms A and B at week 12 after the first 10 participants have been randomized.
219160439|NCT07071155|DRUG|Azacitidine|75 mg/m2, days 1-5 in a 28-day cycle
219160440|NCT07071155|DRUG|Decitabine|20mg/m2, days 1-5 in a 28-day cycle
219160441|NCT07069790|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|Baseline measurements of neuromuscular function and hemodynamic responses will be performed. Baroreflex sensitivity will be assessed using a neck collar applying positive and negative pressures to stimulate the carotid baroreceptors, thereby modulating baroreflex activity in a dose-dependent manner. Mechanoreflex activation will then be evaluated using the passive leg movement (PLM) technique. After the PLM, participants will perform four fatigue tasks, each followed by 2 minutes of post-exercise circulatory occlusion (PECO). Tasks involve isometric quadriceps contractions at 20% of maximal voluntary contraction (MVC) during 1 min (block 1), 2 min (blocks 2 and 3) and until failure (block4). Neuromuscular function will be assessed through MVC changes and quadriceps twitch responses. Mean arterial pressure (MAP) will be recorded continuously. Metaboreflex activity will be determined by plotting post-PECO changes in peripheral fatigue against the change in MAP during PECO phases.
219160442|NCT07070297|DRUG|XKH001 Injection|Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.
219160443|NCT07077564|DRUG|Sac-TMT|Sacituzumab govitecan 5 mg/kg every 2 weeks on Day 1 of each cycle（IV）
219160444|NCT07078110|PROCEDURE|Material: Filtek Z250 (3M ESPE, USA)|"Group I (Incremental Technique):~Material: Filtek Z250 (3M ESPE, USA) Applied in 2 mm incremental layers, light-cured for 40 seconds per increment."
219733856|NCT01933425|DRUG|placebo|
219160445|NCT07078110|PROCEDURE|Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA|"Group II (Bulk-Fill Technique):~Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA Applied in a single increment (up to 4 mm) and light-cured for 40 seconds."
219733857|NCT05697692|DRUG|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
219733858|NCT05697692|DRUG|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
219733859|NCT04999293|DRUG|Ticagrelor|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
219733860|NCT04492293|DRUG|ICP-192|ICP-192 is a white, round, uncoated table
219733861|NCT03471949|OTHER|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
219733862|NCT00429455|BEHAVIORAL|Survey|3-Part Questionnaire
219733863|NCT04108260|DRUG|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
219733864|NCT05516407|DRUG|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
219733865|NCT00225602|BEHAVIORAL|Assertive Community Treatment|
219733866|NCT00225602|BEHAVIORAL|Treatment in Community Mental Health Center|
219733867|NCT01570582|DRUG|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
219733868|NCT06478615|PROCEDURE|Coring out Fistulectomy with Closure of Internal Sphincter Opening|The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
219160446|NCT07078318|OTHER|Pelvic floor rehabilitation|Participants in this group will receive standard pelvic floor rehabilitation. This includes education about pelvic floor anatomy and function, supervised pelvic floor muscle training (Kegel exercises), relaxation techniques, and manual release of trigger points if necessary. The aim is to improve muscle strength, coordination, and reduce pelvic floor hypertonicity contributing to dyspareunia.
219160447|NCT07078318|OTHER|Diaphragmatic Breathing Exercises|In addition to the standard pelvic floor rehabilitation, participants in this group will practice diaphragmatic breathing exercises. These exercises focus on deep, slow nasal inhalation using the diaphragm, encouraging abdominal expansion while minimizing chest movement. Sessions are performed twice daily for 10 minutes. This technique is aimed at promoting parasympathetic activation, reducing anxiety, and improving autonomic regulation.
219160448|NCT07078318|OTHER|Diaphragm Manual Therapy|an additional manual therapy intervention targeting the diaphragm. Diaphragm manual therapy involves hands-on techniques applied to the thoracic and abdominal regions to reduce fascial restrictions, improve diaphragmatic mobility, and support deeper, more effective breathing. The therapy is delivered for 15 minutes at the start of each weekly session by a trained physiotherapist.
219160449|NCT06426134|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)|1x50g ingestion of pure dGK
219160450|NCT06426134|OTHER|Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride|Isocaloric carbohydrate control (active control)
219160451|NCT03416088|BEHAVIORAL|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
219160452|NCT03416088|BEHAVIORAL|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
219160453|NCT03416088|BEHAVIORAL|Body motion|Exercise or body postural changes
219160454|NCT06834893|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
219160455|NCT04932122|PROCEDURE|Dorsal wrist ganglion alone (DWG)|Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
219160456|NCT04932122|PROCEDURE|DWG/PIN|Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
219160457|NCT04077086|DEVICE|Spectacles|Intervention group children in middle school Year 1 will receive spectacles in December 2024. Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone 32 months (December 2024 - July 2027) of treatment by the endpoint of the trial.
219160458|NCT06834477|OTHER|Computed Tomography|low-dose CT is taken
219160459|NCT02604277|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
219160460|NCT02604277|BEHAVIORAL|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
219160461|NCT02604277|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
219160462|NCT02604277|BEHAVIORAL|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education \& Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education \& Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
219160463|NCT04307381|DRUG|Donidalorsen|Donidalorsen administered SC
219160464|NCT06830447|OTHER|low-frequency fatigue|Low frequency fatigue tested with myocene
219160465|NCT03181477|DEVICE|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
219160466|NCT06829745|OTHER|Laughter Yoga|Laughter yoga is applied to the intervention group patient 2 hours after the burn dressing. It is applied every other day for 30 minutes after dressing for three weeks.
219235060|NCT04475406|OTHER|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
219235061|NCT04475406|OTHER|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
219235062|NCT00433706|PROCEDURE|Control position by 3DOBI before the fraction|
219235063|NCT00433706|PROCEDURE|Standard imaging|
219235064|NCT00082667|DRUG|gefitinib|
219235065|NCT00082667|PROCEDURE|Surgery|
219235066|NCT00409903|DRUG|Eprosartan|
219160467|NCT06292208|BIOLOGICAL|IBD0333|This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
219160468|NCT06265597|OTHER|Healthy Nutrition and Yoga Program|"* Healthy Nutrition Program~  * At the beginning of the Healthy Nutrition and Yoga Program by the researcher give education to families and children in 3 sessions (Importance of Nutrition in School Age, Obesity in School Age, Nutrition Recommendations for Obese Children).~ * Providing individual counseling to children every 2 weeks from the start of the Healthy Nutrition Program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~ * After the 2nd session of the healthy nutrition education and from the beginning of the Yoga Program, in the 2nd, 4th, 6th, 8th and 10th weeks, children are asked to keep a food diary for 2 weekdays and 1 weekend (Thursday-Friday-Saturday) and planning is made according to reaching basic healthy nutrition behavior goals.~* Yoga Program \*Children's yoga is applied to each group twice a week for 12 weeks."
219160469|NCT06834087|PROCEDURE|Laser-Assisted Gingival Depigmentation|This intervention involves the use of a diode laser (970 nm wavelength, 2.0 W power, continuous mode) with a 200 µm fiber tip. The laser is applied in a sweeping motion over the pigmented gingiva in contact mode for 30 seconds per site to achieve depigmentation.
219160470|NCT06834087|DRUG|Photodynamic Therapy with Conventional Methylene Blue|This intervention consists of applying a 0.1% methylene blue solution to the pigmented gingiva for 2 minutes before activation with a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site. This is followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
219160471|NCT06834087|DRUG|Photodynamic Therapy with Methylene Blue Nanoparticles|This intervention involves the application of 0.1% methylene blue nanoparticles to the pigmented gingiva for 2 minutes to allow deeper tissue penetration. It is then activated using a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site, followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
219160472|NCT06785116|DRUG|Placebo|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
219160473|NCT06785116|DRUG|Dapagliflozin 10mg Tab|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
219160474|NCT06792617|OTHER|Mobility (Central or Femoral Cannulation)|"Functional Mobility \& ADL's~1. Assisted sitting with progression to unassisted; ADL's~2. Assisted standing with progression to unassisted; ADL's~   1. VitalGo bed will be used if unsafe/unable to perform assisted standing.~  2. Leg press (VitalGo bed)~3. Ambulation; ADL's"
219160475|NCT06792617|OTHER|Resistance Training|Repetitions will be counted and documented per session per structured exercise.
219235067|NCT01286311|BEHAVIORAL|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
219235068|NCT00265902|PROCEDURE|diagnostic imaging|
219235069|NCT05397509|OTHER|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
219235070|NCT05397509|OTHER|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
219235071|NCT03034863|BEHAVIORAL|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
219235072|NCT03034863|BEHAVIORAL|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
219235073|NCT05676372|PROCEDURE|CRC+HIPEC|Sample prelevation of cytoreductive surgery
219160476|NCT06830304|BEHAVIORAL|Multi-level Education and Navigation Program for Gastrointestinal Cancer Screening|"This multi-level intervention consists of two major components implemented at community, healthcare provider, and individual levels:~Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills~3. Individual level: Tailored educational materials and one-on-one counseling~Navigation Component:~1. Patient needs assessment and barrier identification~2. Personalized navigation services including:~Appointment scheduling assistance Transportation coordination Insurance/financial counseling Reminder calls/messages Social/psychological support"
219160477|NCT06830304|BEHAVIORAL|Health education|"Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills"
219160478|NCT06787313|OTHER|precision palliative care|Participants receive precision palliative care based on scale screening result.
219160479|NCT05198583|OTHER|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
219160480|NCT04948489|DRUG|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
219160481|NCT04948489|DRUG|Placebo|Placebo capsule everyday for 12 months
219733869|NCT06478615|PROCEDURE|Lay Open Fistulotomy and Primary Sphincter Repair|Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
219733870|NCT03438656|BEHAVIORAL|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
219733871|NCT00730600|PROCEDURE|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
219160482|NCT05559736|DEVICE|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
219235074|NCT01472796|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
219235075|NCT01472796|DRUG|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
219235076|NCT01819857|DRUG|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
219235077|NCT01819857|DRUG|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
219733872|NCT02245724|BIOLOGICAL|Stem Cell|Autologous bone marrow mononuclear cell transplantation
219733873|NCT04799717|BEHAVIORAL|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
219733874|NCT05692557|DEVICE|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
219733875|NCT05692557|PROCEDURE|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
219733876|NCT03931811|DEVICE|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
219733877|NCT03931811|OTHER|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
219160483|NCT03485430|BEHAVIORAL|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
219160484|NCT01216176|DRUG|Anastrozole|
219160485|NCT01216176|DRUG|AZD0530 (saracatinib)|
219160486|NCT01216176|DRUG|Placebo|
219160487|NCT04631406|BIOLOGICAL|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
219160488|NCT03231878|DRUG|MIN-102|MIN-102 treatment
219160489|NCT03231878|DRUG|Placebos|Placebo
219160490|NCT03760744|PROCEDURE|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
219160491|NCT03760744|PROCEDURE|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
219235078|NCT01819857|DRUG|Zofran 8 mg|intravenous administration of 8 mg ondansetron
219160492|NCT05310019|OTHER|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
219160493|NCT05310019|OTHER|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
219160494|NCT03410875|DRUG|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
219160495|NCT03410875|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
219160496|NCT05225402|DRUG|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
219160497|NCT04272736|DIETARY_SUPPLEMENT|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
219160498|NCT06204432|DRUG|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
219160499|NCT06204432|DRUG|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
219160500|NCT06204432|OTHER|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
219160501|NCT04694339|OTHER|Survey|Survey
219160502|NCT03620786|DEVICE|Sonablate HIFU device|In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
219160503|NCT06118788|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
219160504|NCT01976247|DEVICE|High Intensity Focused Ultrasound Device|
219160505|NCT01976247|DEVICE|Noninvasive Cryolipolysis Device|
219160506|NCT06464055|DRUG|Dose Escalation|Drug: GQ1010
219160507|NCT06464055|DRUG|Dose Expansion1|Drug: GQ1010 dose 1
219160508|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose 2
219160509|NCT06464055|DRUG|Dose Expansion3|Drug: GQ1010 dose 3
219160510|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
219160511|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
219160512|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
219160513|NCT02975505|OTHER|Strict blood pressure control|Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
219160514|NCT06831877|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
219160515|NCT06831877|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
219160516|NCT06833398|PROCEDURE|Arthroscopic Simple Biceps Tenotomy:|"Arthroscopic Simple Biceps Tenotomy: This procedure involves an arthroscopic release of the LHB tendon from its attachment at the superior glenoid labrum. It is a quick and simple technique that does not require implants or extensive postoperative rehabilitation. The main drawback is the potential for developing a Popeye deformity, where the biceps muscle bulges due to distal migration, as well as occasional muscle cramps."
219160517|NCT06833398|PROCEDURE|Anchor Tenotomy Technique:|Anchor Tenotomy Technique: This is a novel arthroscopic method where, after releasing the LHB tendon, it is anchored in place to prevent distal migration. The goal of this technique is to avoid the Popeye deformity and improve cosmetic outcomes while maintaining functional integrity. This procedure is technically more challenging and may involve a longer operative time compared to simple tenotomy.
219733878|NCT00684554|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
219733879|NCT00052897|BIOLOGICAL|HspE7|
219733880|NCT01269320|DRUG|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
219733881|NCT04808895|DRUG|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
219235079|NCT01324648|BEHAVIORAL|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
219733882|NCT04808895|DRUG|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
219733883|NCT01155310|DRUG|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
219733884|NCT01155310|DRUG|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
219160518|NCT06160882|OTHER|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
219160519|NCT06160882|PROCEDURE|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
219160520|NCT05515224|OTHER|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
219160521|NCT05515224|OTHER|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
219160522|NCT03398148|DRUG|risankizumab IV|risankizumab intravenous (IV) infusion
219160523|NCT03398148|DRUG|placebo for risankizumab|placebo for risankizumab
219160524|NCT03398148|DRUG|risankizumab SC|risankizumab subcutaneous (SC) injection
219160525|NCT04690322|DRUG|Eloctate|Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
219160526|NCT04690322|DRUG|Adynovate|Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
219160527|NCT04690322|DRUG|Emicizumab|Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
219160528|NCT05583708|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
219160529|NCT05583708|DRUG|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
219733885|NCT05336760|DIAGNOSTIC_TEST|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
219733886|NCT05336760|DIAGNOSTIC_TEST|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
219160530|NCT05833516|DIAGNOSTIC_TEST|Cardiac Catheterization|"The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study."
219160531|NCT05499741|DEVICE|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
219160532|NCT02400359|DRUG|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
219160533|NCT02400359|DRUG|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
219733887|NCT05336760|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
219733888|NCT05336760|DIAGNOSTIC_TEST|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
219733889|NCT02660346|DRUG|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
219733890|NCT02660346|DRUG|Vancomycin|Control Arm Treatment
219733891|NCT02660346|DRUG|Ceftaroline|Study Arm Treatment
219733892|NCT04972175|DRUG|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
219733893|NCT04972175|DRUG|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
219733894|NCT04217057|DRUG|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
219733895|NCT04332393|DRUG|Metformin|Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
219733896|NCT06964295|DEVICE|Macintosh videolaryngoscope|Used to perform nasotracheal intubation under general anesthesia. The Macintosh videolaryngoscope is introduced orally to visualize the glottis, and a preformed nasotracheal tube is inserted through the nostril.
219733897|NCT06964295|DEVICE|Flexible bronchoscope|Used to perform nasotracheal intubation under general anesthesia. The bronchoscope is inserted through a lubricated nasotracheal tube and advanced into the trachea.
219733898|NCT06964568|DRUG|PD-1 inhibitor|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
219733899|NCT06964568|RADIATION|TDLN-sparing radiotherapy|Tumor draining lymph nodes-sparing radiotherapy 50.4Gy/28Fx
219733900|NCT06964568|RADIATION|Unlimited radiotherapy|Unlimited radiotherapy 50.4Gy/28Fx
219733901|NCT06964347|DEVICE|Ropivacaine 0.2% + nerve stimulator set|Patients will receive a continuous local anesthetic (LA) infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will receive a low-frequency peripheral nerve stimulation (PNS) via a nerve stimulator set to the pre-determined setting of adequate clinical response (determined in the preoperative area).
219733902|NCT06964347|DRUG|Ropivacaine 0.2%|Patients will receive a continuous local anesthetic infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will have an inactive PNS button for the purposes of blinding.
219160534|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can effect pain, craving, and anxiety.
219160535|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
219160536|NCT02791230|DRUG|Tafamidis|Soft gel capsules administered once a day for 60 months
219160537|NCT01259401|BEHAVIORAL|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
219160538|NCT01259401|BEHAVIORAL|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
219160539|NCT06190899|DRUG|Gedatolisib|Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
219160540|NCT06190899|DRUG|Darolutamide|Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
219160541|NCT02049034|OTHER|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
219733903|NCT06964477|BEHAVIORAL|XR-Based Leisure Intervention|"The XR-based leisure intervention was developed based on occupational therapy principles and the therapeutic use of leisure to support engagement, volition, and emotional regulation in individuals with chronic mental illness. The intervention content was designed using the AR2VR platform and the MAKAR marker-based AR development system. Leisure scenarios were created by capturing real-world environments using 360-degree panoramic video and embedding interactive elements, such as contextual prompts, virtual objects, and multimedia cues, to enhance immersion and engagement.~Sessions are guided by trained occupational therapists and follow a standardized protocol to ensure consistency. A simple cardboard VR viewer is used to reduce sensory overload and avoid adverse effects common with electronic head-mounted displays, such as dizziness or nausea. Activities target various leisure domains, including physical movement, creative expression, social activities, and cognitive play. Weekly con"
219733904|NCT03589053|DEVICE|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
219733905|NCT03589053|DEVICE|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
219160542|NCT02049034|OTHER|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
219160543|NCT05138393|OTHER|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
219160544|NCT05138393|OTHER|Observation|Non-specific physical activity 60 minutes per day.
219160545|NCT05233098|DEVICE|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
219160546|NCT05698329|DRUG|AIV007|Periocular injection
219733906|NCT05656573|DRUG|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area)."
219160547|NCT04076293|DRUG|HM15912|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
219160548|NCT04076293|DRUG|Placebo|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
219160549|NCT04107948|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
219160550|NCT04107948|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
219160551|NCT05281718|DRUG|Factor IX|Factor IX is on of the substrates of emicizumab.
219160552|NCT05777759|DEVICE|Restylane Lyft with Lidocaine|hyaluronic acid
219160553|NCT05777759|DEVICE|Juvederm Voluma XC|hyaluronic acid
219160554|NCT06381427|OTHER|Interdisciplinary decision-making for perioperative care|Interdisciplinary decision-making for perioperative care involving a cardiologist, anesthesiologist, and surgeon in collaboration with the primary care physician. Decisions include determining whether surgery is feasible or if patient optimization is necessary first. Subsequently, targeted postoperative visits by a heart failure nurse and appropriate postoperative care, also after discharge from the hospital, through the primary care physician.
219160555|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
219160556|NCT06497712|OTHER|Hypnosis|Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
219160557|NCT04201834|DRUG|Risperidone|capsule or tablet, 0.5 mg
219160558|NCT04201834|DEVICE|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
219160559|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
219160560|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
219160561|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
219160562|NCT06241482|PROCEDURE|Enhanced recovery after surgery|"The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment"
219160563|NCT06241482|PROCEDURE|Conventional therapy|Conventional therapy in neurocritical care.
219235080|NCT01324648|BEHAVIORAL|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
219235081|NCT01324648|OTHER|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
219235082|NCT00000532|BEHAVIORAL|diet, fat-restricted|
219235083|NCT00446576|DRUG|Epoetin Alfa|
219235084|NCT02226237|PROCEDURE|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
219733907|NCT06380504|BEHAVIORAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs"
219160564|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.
219160565|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle
219160566|NCT04082637|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
219160567|NCT06402318|DEVICE|A&M Breathalyzer PROTECT Kiosk|The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.
219160568|NCT00212355|DRUG|NPC-02|zinc acetate
219235085|NCT02226237|PROCEDURE|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
219733908|NCT05784597|DRUG|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
219160569|NCT05624606|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5410|Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
219733909|NCT02552654|BEHAVIORAL|Stress Film|Film scene with severe physical and sexual violence.
219733910|NCT02552654|DRUG|Hydrocortisone|10mg
219733911|NCT02552654|DRUG|Placebo|
219733912|NCT02014454|DRUG|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
219733913|NCT04849000|DRUG|SHR-1209|SHR-1209
219733914|NCT04849000|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
219733915|NCT03238157|DRUG|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
219160570|NCT05624606|BIOLOGICAL|Quadrivalent Recombinant Influenza vaccine RIV4|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
219733916|NCT06964139|OTHER|Surgical video grading|Videos of fellow surgical cases will be randomized in sequence and provided to a masked grader who will review cases and record primary and secondary endpoints.
219733917|NCT01311583|BEHAVIORAL|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
219160571|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza Standard Dose QIV-SD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
219160572|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose QIV-HD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
219160573|NCT06241794|PROCEDURE|Group M-TAPA|Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.
219160574|NCT06241794|PROCEDURE|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
219160575|NCT04349826|DRUG|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
219160576|NCT04349826|DRUG|Cefixime|cefixime 20-30 mg/kg/day for 7 days
219160577|NCT04349826|DRUG|Placebo|cefixime-matched placebo for 7 days
219160578|NCT05437380|DIAGNOSTIC_TEST|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
219160579|NCT03661359|OTHER|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
219160580|NCT05123365|DRUG|N-Acetylcysteine|Given PO
219160581|NCT05947344|DRUG|STI-8591|Four dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg, 60mg and 80mg. Expansion is planned in two dose groups of 40mg and 60mg.
219160582|NCT05629936|OTHER|Digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups
219160583|NCT05757206|DIAGNOSTIC_TEST|Syn-One Test|Participating subjects will have three small skin punch biopsies.
219160584|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
219160585|NCT06515418|DRUG|Oral Azelaprag (BGE-105)|Capsules
219160586|NCT06515418|DRUG|Oral Placebo for Azelaprag (BGE-105)|Capsules
219160587|NCT06515418|DRUG|Tirzepatide|Subcutaneous Injection
219160588|NCT06515418|DRUG|Tirzepatide Placebo|Subcutaneous Injection
219160589|NCT04418115|OTHER|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
219160590|NCT06453005|PROCEDURE|SMART Hall Technique or procedure|"The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure."
219160591|NCT04310735|BEHAVIORAL|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
219160592|NCT04104321|DRUG|Aramchol free acid|Aramchol 300 mg BID
219160593|NCT04104321|DRUG|Placebo|Placebo BID
219160594|NCT03481777|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
219160595|NCT03481777|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
219160596|NCT05275959|OTHER|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
219160597|NCT02977819|OTHER|Meditation practice|18 months
219160598|NCT02977819|OTHER|Learning English as a foreign language|18 months
219235086|NCT05214521|DEVICE|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
219235087|NCT06401590|DIAGNOSTIC_TEST|FROZEN SENTINEL LYMPH NODE BIOPSY|FROZEN SENTINEL LYMPH NODE BIOPSY
219733918|NCT03306290|DRUG|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
219733919|NCT02489045|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
219733920|NCT01282554|DEVICE|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
219733921|NCT02690376|DEVICE|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
219733922|NCT02676427|PROCEDURE|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
219733923|NCT01309191|OTHER|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
219160599|NCT05840055|BEHAVIORAL|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
219160600|NCT02064517|DEVICE|MTA|Creation of a barrier apicale in the MTA
219733924|NCT01309191|OTHER|Placebo|
219160601|NCT02064517|DEVICE|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
219160602|NCT03150914|DRUG|Sirolimus|mTOR inhibitor or placebo
219160603|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)|Comparison of these micro RNAs with the micro RNAs extracted from oral swabs (in Fetal Alcohol Spectrum Disorder group)
219160604|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from bucal swabs (act added for research).|Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group
219160605|NCT06380153|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
219160606|NCT06515080|DIAGNOSTIC_TEST|Near Red Infrascopy|Monitor of regional cerebral oxygen saturation
219160607|NCT05696080|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219160608|NCT05696080|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
219733925|NCT02974231|RADIATION|Intensity-modulated radiation therapy|
219160609|NCT05696080|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
219160610|NCT05696080|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219160611|NCT05152394|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
219160612|NCT02724228|DRUG|BMN 111|BMN 111 will be administered subcutaneously daily.
219160613|NCT05189418|DEVICE|Ambulatory blood pressure monitoring (ABPM)|Periodic (quarterly) 48h ABPM evaluation during follow-up
219160614|NCT05189418|DEVICE|Home blood pressure monitoring (HBPM)|Periodic (monthly) 7-day HBPM, both during awake and sleep spans, during follow-up
219160615|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
219160616|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
219160617|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
219160618|NCT05868330|PROCEDURE|Interscalene Catheter|Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol
219733926|NCT01596244|BEHAVIORAL|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
219733927|NCT05759364|DRUG|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
219733928|NCT05759364|DRUG|Placebo|Placebo
219733929|NCT04401293|DRUG|Enoxaparin|Full Dose LMWH anticoagulation therapy
219733930|NCT04401293|DRUG|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
219733931|NCT01813643|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
219733932|NCT01813643|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
219733933|NCT02713620|BIOLOGICAL|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
219160619|NCT05868330|PROCEDURE|Exparel Single Shot Interscalene Block|Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
219733934|NCT06301152|DEVICE|high intensive laser|high-intensity laser ,three times in a week, for three weeks, 9 session
219733935|NCT06301152|DEVICE|extracorporeal shock wave therapy|extracorporeal shock wave therapy, once a week, for three weeks ,3 times,
219733936|NCT04042428|DRUG|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
219733937|NCT04481282|DRUG|Terbutaline|2.5mg po tid for 12 weeks
219733938|NCT04481282|DRUG|Danazol|200mg po bid for 12 weeks
219733939|NCT01666613|DRUG|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
219733940|NCT01666613|DRUG|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
219733941|NCT01666613|DRUG|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
219733942|NCT01666613|DRUG|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
219733943|NCT02712242|OTHER|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
219733944|NCT02712242|OTHER|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
219733945|NCT02712242|OTHER|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
219733946|NCT01019551|DRUG|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
219733947|NCT01019551|BIOLOGICAL|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
219733948|NCT06114966|OTHER|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
219733949|NCT04503200|PROCEDURE|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
219733950|NCT04503200|PROCEDURE|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
219160620|NCT06418321|DEVICE|Investigational device|The participants' hearing status will be evaluated using the investigational device.
219160621|NCT06418321|OTHER|Audiometer|Participants' hearing thresholds are tested with an audiogram.
219160622|NCT06418321|DEVICE|Otomicroscopy|The status of the participants' ear canals and tympanic membranes are checked.
219160623|NCT06418321|OTHER|REM (Real Ear Measurements)|The acoustic properties of the participants' ears will be measured during the interventions.
219160624|NCT05849012|OTHER|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
219160625|NCT05849012|OTHER|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
219160626|NCT06447129|OTHER|Exercise|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist."
219160627|NCT06447129|OTHER|Neuromuscular electrical stimulation|The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
219160628|NCT05945719|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
219160629|NCT01698840|DIETARY_SUPPLEMENT|Vitamin D|
219160630|NCT01698840|DIETARY_SUPPLEMENT|Placebo|
219733951|NCT02855983|PROCEDURE|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
219733952|NCT05177263|OTHER|Placebo|Sterile Water
219733953|NCT05177263|DRUG|10% Oral Dextrose Solution|10% Oral Dextrose Solution
219733954|NCT05177263|DRUG|20% Oral Dextrose Solution|20% Oral Dextrose Solution
219733955|NCT05177263|DRUG|30% Oral Dextrose Solution|30% Oral Dextrose Solution
219733956|NCT03111732|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
219733957|NCT03111732|DRUG|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
219733958|NCT03111732|DRUG|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
219733959|NCT01108055|DRUG|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
219733960|NCT01108055|DRUG|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
219733961|NCT02504385|DEVICE|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
219733962|NCT02504385|OTHER|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
219733963|NCT06163638|BEHAVIORAL|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
219733964|NCT01366105|DEVICE|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
219733965|NCT00964444|DEVICE|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
219733966|NCT00063232|DRUG|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
219733967|NCT04674800|BIOLOGICAL|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
219733968|NCT03339453|DRUG|Nasal Glucagon|Administered nasally
219733969|NCT03339453|DRUG|Intramuscular Glucagon|Administered IM
219160631|NCT05853822|OTHER|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
219733970|NCT00328809|DRUG|spironolactone|spironolactone administered to ESRD patients at low dose
219733971|NCT02644811|DRUG|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
219160632|NCT05853822|OTHER|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
219160633|NCT05768373|DEVICE|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
219160634|NCT05768373|DEVICE|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
219235088|NCT00838448|BEHAVIORAL|Exercise|Exercise performed on a treadmill for 20-30 minutes
219235089|NCT01632085|DEVICE|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
219733972|NCT02644811|DRUG|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
219733973|NCT02644811|PROCEDURE|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
219733974|NCT02644811|DRUG|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
219733975|NCT02644811|DRUG|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
219160635|NCT05956821|DRUG|SIACI of cetuximab and bevacizumab|Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
219160636|NCT06409026|DRUG|Sotatercept|As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
219160637|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
219160638|NCT05468736|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
219160639|NCT06516302|DRUG|GR1802|GR1802 will be administered SC.
219160640|NCT06516302|DRUG|Placebo|The placebo will be administered SC.
219235090|NCT06378281|OTHER|Modified teach-to-goal informed consent|Enhanced procedure to improve informed consent in vulnerable populations.
219235091|NCT04818476|PROCEDURE|diagnostic endoscopic resection|diagnostic endoscopic resection
219733976|NCT02644811|DEVICE|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
219733977|NCT02644811|DEVICE|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
219733978|NCT03043469|OTHER|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
219733979|NCT03043469|OTHER|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
219733980|NCT03043469|OTHER|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
219235092|NCT01572896|BEHAVIORAL|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
219160641|NCT03954184|BEHAVIORAL|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
219733981|NCT03043469|OTHER|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
219160642|NCT03398200|BIOLOGICAL|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
219160643|NCT03398200|OTHER|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
219160644|NCT06172933|BEHAVIORAL|Move with Meaning|Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
219160645|NCT04519177|BEHAVIORAL|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
219160646|NCT06398613|DIAGNOSTIC_TEST|extended pelvic lymph node dissection (ePLND)|Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively in both arms of the study. In arm A all patients will undergo ePLND, in arm B only patients with positive PSMA PET/CT will undergo ePLND
219160647|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
219160648|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
219160649|NCT03744975|DRUG|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
219160650|NCT03744975|DRUG|Placebos|Participants will receive 1oral Placebo capsule
219160651|NCT05080972|BEHAVIORAL|in-the-kNOW mobile app|"in-the-kNOW is a mobile app with restricted access through a single-use registration code.~The app will be developed with regular input from Black women enrolled in Atlanta Healthy Start Initiative (AHSI).~The app will have culturally- and contextually targeted HIV prevention and optimal sexual health messaging.~Each participant will have 4 months to engage with the app, with e-reminders in time intervals preferred by the participants (a minimum of 3 times per week) via push notifications. During the 4-month study period, participants will receive push notifications to encourage the use of all app domains: My Logger, My Test, My Resources, and My Circle.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
219160652|NCT05080972|BEHAVIORAL|Control|"The control condition will be a one-time virtual women's health counseling session with a healthcare provider. Participants will get information on~1. Sexual Transmitted Infections (STI)/HIV prevention,~2. Family planning, and~3. General health promotion (e.g., exercise and diet).~The control condition provides access to HIV prevention materials that are publicly available but that do not offer the dynamic and individually customized features of the health communication/new media research approach proposed herein.~Control group participants will continue to receive the usual care associated with Atlanta Healthy Start Initiative (AHSI) enrollment.~The control group will not have access to intervention content (e.g. commodity ordering) until after the study has concluded.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
219160653|NCT04793906|OTHER|Iron supplement with a lunch meal containing beef|Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
219160654|NCT04793906|OTHER|Iron supplement with a lunch meal containing plant-based alternative|Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
219733982|NCT03043469|OTHER|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
219733983|NCT03043469|OTHER|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
219733984|NCT03043469|OTHER|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
219733985|NCT03043469|OTHER|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
219160655|NCT06517771|OTHER|Online aerobic exercise|Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
219160656|NCT06083064|DIAGNOSTIC_TEST|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
219733986|NCT03043469|OTHER|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
219733987|NCT03043469|OTHER|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
219733988|NCT03043469|DIAGNOSTIC_TEST|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
219733989|NCT03043469|OTHER|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
219733990|NCT03043469|OTHER|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
219160657|NCT06083064|OTHER|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
219160658|NCT06083064|OTHER|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
219160659|NCT05478525|DRUG|GLY-200|0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
219733991|NCT03043469|OTHER|Breath-hold test|Holding the breath a few times for as long as possible.
219733992|NCT03043469|OTHER|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
219733993|NCT03043469|OTHER|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
219733994|NCT02769052|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
219733995|NCT04595578|DEVICE|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
219160660|NCT05478525|DRUG|GLY-200|1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
219160661|NCT05478525|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
219160662|NCT05478525|DRUG|Placebo|1 placebo capsule BID for 14 days (n=4)
219160663|NCT05478525|DRUG|Placebo|2 placebo capsules BID for 14 days (n=4)
219160664|NCT05478525|DRUG|Placebo|4 placebo capsules BID for 14 days (n=4)
219160665|NCT05355168|DRUG|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
219160666|NCT06129409|DRUG|NT-0796|Orally administered capsules
219160667|NCT05321381|OTHER|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
219160668|NCT06749652|DEVICE|firm silicone stent insertion|Insertion of firm silicon ureteral stent (Percuflex Plus)
219160669|NCT06749652|DEVICE|Soft silicone ureteral stent insertion|Soft silicone ureteral stent insertion
219160670|NCT06748352|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
219160671|NCT06748352|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
219160672|NCT04375605|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
219160673|NCT04375605|DRUG|Calcium folinate|Day 1 q2w: 200 mg/m² IV over 2 hours
219160674|NCT04375605|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
219160675|NCT04375605|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 2 hours
219160676|NCT04375605|RADIATION|Radiation|25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy
219733996|NCT06603831|PROCEDURE|patients treated using 3D technology and Patient-Specific Instrumentation|"3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
219733997|NCT06603831|PROCEDURE|Patients treated with conventional surgery, without using 3D technology|"Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
219733998|NCT01491165|PROCEDURE|stem cell transplantation through interventional procedures|one time interventional procedures
219160677|NCT04375605|DRUG|Oxaliplatin during radiotherapy|Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours
219160678|NCT04375605|DRUG|5-Fluorouracil during radiotherapy|day 1 - 33: 225 mg/m²/day IV continuously
219160679|NCT01649271|DRUG|Herceptin|3-weekly
219160680|NCT01649271|DRUG|afatinib|at MTD level
219160681|NCT01649271|DRUG|trastuzumab|3-weekly
219160682|NCT01649271|DRUG|Herceptin|weekly
219160683|NCT01649271|DRUG|afatinib|at MTD level
219160684|NCT01649271|DRUG|afatinib|escalating dose
219160685|NCT05672615|OTHER|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
219160686|NCT05672615|OTHER|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
219160687|NCT05672615|OTHER|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
219160688|NCT05672615|OTHER|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
219160689|NCT05672615|OTHER|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
219160690|NCT03753074|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
219160691|NCT05647252|DRUG|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
219733999|NCT06401551|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
219734000|NCT06401551|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
219734001|NCT06401551|PROCEDURE|Cataract Surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
219734002|NCT03772340|DRUG|Tradipitant|Oral capsule
219734003|NCT03772340|DRUG|Placebo|Oral capsule
219734004|NCT02388256|DEVICE|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
219734005|NCT02388256|OTHER|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
219734006|NCT06564766|OTHER|Debriefing|"In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement."
219734007|NCT01153542|DRUG|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
219160692|NCT05647252|BEHAVIORAL|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
219160693|NCT01489813|DRUG|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
219160694|NCT01489813|DRUG|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
219160695|NCT06339801|DEVICE|MiVu|All patients will undergo mucosal impedance (MI) measurement using the MiVu™ Mucosal Integrity Testing System (Diversatek Healthcare, Inc.).
219734008|NCT01153542|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
219734009|NCT06089746|OTHER|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
219734010|NCT06240208|BEHAVIORAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
219160696|NCT06138093|DEVICE|Sealing device|Intratracheal tracheostomy sealing
219160697|NCT06138093|DEVICE|No device|Open tracheostomy wound
219160698|NCT05644002|BEHAVIORAL|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
219734011|NCT00370955|PROCEDURE|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
219734012|NCT05592743|DRUG|Vorasidenib|Oral therapy
219734013|NCT00576745|PROCEDURE|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
219734014|NCT00576745|DEVICE|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
219734015|NCT02754037|RADIATION|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
219734016|NCT02754037|OTHER|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
219734017|NCT02754037|RADIATION|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
219734018|NCT06123676|DEVICE|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
219734019|NCT04139902|DRUG|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
219734020|NCT04139902|DRUG|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
219734021|NCT03885206|OTHER|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
219734022|NCT01027754|DRUG|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
219734023|NCT01027754|DRUG|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
219734024|NCT03796286|OTHER|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
219734025|NCT03796286|OTHER|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
219734026|NCT03796286|OTHER|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
219734027|NCT02637674|PROCEDURE|Uterus Transplant|
219734028|NCT02411045|BEHAVIORAL|Take and send a selfie|Direction to take and send a selfie.
219734029|NCT02411045|BEHAVIORAL|Workout gears|Direction to wear workout gears.
219734030|NCT02411045|BEHAVIORAL|Exercise|Direction to complete a 30 minute workout.
219160699|NCT05644002|BEHAVIORAL|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
219160700|NCT05963737|PROCEDURE|PS setting strategy in pressure-support ventilated patients|Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).
219734031|NCT06023264|PROCEDURE|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
219734032|NCT06306157|DRUG|Low dose naltrexone|While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
219734033|NCT06306157|DRUG|Placebo sugar capsules|The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
219734034|NCT00523666|DRUG|Galantamine (Reminyl®)|8mg - 24mg
219160701|NCT06313788|OTHER|Possession of a customized placebo analgesic band-aid prior to vaccination or injection|Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
219734035|NCT00523666|DRUG|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
219734036|NCT05121922|BEHAVIORAL|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
219734037|NCT00326495|DRUG|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
219734038|NCT00326495|DRUG|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
219734039|NCT05386836|DEVICE|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
219160702|NCT04913870|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers treatment for 2 years.
219160703|NCT04913870|OTHER|Placebo|Placebo administration for 2 years.
219160704|NCT04842500|BEHAVIORAL|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
219160705|NCT05614934|DRUG|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
219160706|NCT05614934|DRUG|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
219160707|NCT05614934|DRUG|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
219160708|NCT06180967|DRUG|Midazolam Syrup|Administered Orally.
219160709|NCT06180967|DRUG|Midazolam Solution|Administered IV bolus.
219160710|NCT06180967|DRUG|Pirtobrutinib|Administered Orally.
219160711|NCT00540787|DEVICE|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
219160712|NCT00540787|DRUG|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
219160713|NCT00540787|DEVICE|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
219160714|NCT02632760|DRUG|Ferric carboxymaltose|treatment for Iron deficient anaemia
219160715|NCT02632760|DRUG|Placebo|placebo - no active drug
219160716|NCT05756075|BEHAVIORAL|Aerobic exercise training|Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
219160717|NCT06017999|DRUG|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
219160718|NCT06017999|DRUG|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
219160719|NCT05906264|BEHAVIORAL|Tele-intervention|Tele-intervention every week to check compliance and encourage the rehabilitation
219160720|NCT05686967|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
219160721|NCT05686967|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
219160722|NCT05686967|BEHAVIORAL|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
219734040|NCT00344669|DRUG|Albendazole 400 mg, given 6 monthly|
219734041|NCT03211845|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
219734042|NCT01855568|PROCEDURE|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
219734043|NCT01855568|PROCEDURE|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
219734044|NCT03092011|DRUG|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
219734045|NCT03092011|DRUG|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
219734046|NCT01654250|DRUG|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
219734047|NCT01654250|DRUG|Placebo|Placebo
219734048|NCT01862029|DRUG|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
219734049|NCT00660959|DRUG|lixivaptan|oral capsule
219734050|NCT00660959|DRUG|placebo|oral capsule
219734051|NCT00710788|DRUG|sevelamer phosphate-binders|1600 mg/day for 2 years
219734052|NCT00710788|DRUG|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
219734053|NCT01723839|DRUG|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
219734054|NCT03380481|OTHER|observational only-no intervention|Observational only and no predesigned interventions in this study.
219734055|NCT00403065|DRUG|dexamethasone|
219734056|NCT00403065|PROCEDURE|quality-of-life assessment|
219734057|NCT00403065|RADIATION|radiation therapy|
219734058|NCT04422834|OTHER|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
219734059|NCT01919476|OTHER|Bagel|
219734060|NCT01919476|OTHER|Cream Cheese|
219734061|NCT01919476|OTHER|Almond Butter|
219734062|NCT04880889|DRUG|BL 3000|capsule 500 mg
219734063|NCT04880889|DRUG|Reference Pantogar|capsule
219734064|NCT04880889|DRUG|BL3000 Placebo|capsule 500 mg
219734065|NCT04880889|DRUG|Pantogar - Placebo|capsule
219734066|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet once daily
219734067|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet once daily
219734068|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet two times a day
219734069|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet two times a day
219734070|NCT00504556|DRUG|warfarin|warfarin tablets
219734071|NCT01778231|DIETARY_SUPPLEMENT|Nutrof Total|Antioxidant and trace element supplement
219734072|NCT01778231|DIETARY_SUPPLEMENT|Placebo|
219734073|NCT01713322|BEHAVIORAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
219734074|NCT01713322|BEHAVIORAL|No pain management education|Control - parents receive general information about childhood immunization.
219160723|NCT04661566|BEHAVIORAL|"Basic Education (Education)"|All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
219160724|NCT04661566|BEHAVIORAL|"Narrative Videos (Narratives)"|The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
219160725|NCT04661566|BEHAVIORAL|"Skills Building Videos (Skills)"|The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
219160726|NCT04661566|BEHAVIORAL|"Interactive Scenarios (Scenarios)"|The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
219160727|NCT04661566|BEHAVIORAL|"Future Life Planning Tool (Future)"|The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
219160728|NCT04661566|BEHAVIORAL|"Epidemiological Risk Scenario (Risk)"|The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
219160729|NCT05621889|PROCEDURE|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
219160730|NCT02466815|DRUG|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
219734075|NCT04957927|DRUG|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
219734076|NCT03280615|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
219734077|NCT03280615|DIETARY_SUPPLEMENT|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
219734078|NCT05356429|OTHER|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
219734079|NCT05041582|DEVICE|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
219734080|NCT05041582|DRUG|Citalopram|total 3 months, since 2-4 weeks after stroke
219734081|NCT05041582|BEHAVIORAL|Rehabilitation|hospitalized rehabilitation, 3 hours daily
219734082|NCT05671679|OTHER|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
219734083|NCT05671679|OTHER|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
219734084|NCT00144508|DRUG|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
219734085|NCT00144508|OTHER|current treatment|continue current treatment
219734086|NCT03373513|PROCEDURE|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
219734087|NCT03373513|PROCEDURE|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
219160731|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
219734088|NCT01138306|GENETIC|gene expression analysis|
219734089|NCT01138306|GENETIC|mutation analysis|
219734090|NCT01138306|OTHER|flow cytometry|
219734091|NCT01138306|OTHER|laboratory biomarker analysis|
219734092|NCT00339365|BEHAVIORAL|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
219235093|NCT01572896|BEHAVIORAL|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
219235094|NCT01581320|DRUG|Test group|Once a month, administration of DP-R206 \& placebo for 16 weeks
219235095|NCT01581320|DRUG|Reference group|Once a month, administration of Bonviva \& placebo for 16 weeks
219235096|NCT06037577|DRUG|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
219235097|NCT06037577|DRUG|Placebo|Placebo Comparator
219235098|NCT00027209|DRUG|prempro|
219235099|NCT03368105|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
219235100|NCT05333835|DRUG|HR17031 injection|HR17031 injection
219235101|NCT05333835|DRUG|INS068 injection|INS068 injection
219235102|NCT05333835|DRUG|SHR20004 injection|SHR20004 injection
219235103|NCT06298747|OTHER|Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
219235104|NCT06035627|OTHER|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
219235105|NCT00506025|DIETARY_SUPPLEMENT|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
219235106|NCT00506025|DIETARY_SUPPLEMENT|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
219235107|NCT06201949|OTHER|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
219235108|NCT06201949|OTHER|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
219235109|NCT03303547|DIAGNOSTIC_TEST|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
219235110|NCT04499898|DRUG|Carvedilol|Carvedilol
219235111|NCT04499898|PROCEDURE|Endoscopic band ligation|Endoscopic band ligation
219235112|NCT02386085|PROCEDURE|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
219235113|NCT02430909|BIOLOGICAL|Bimekizumab|"* Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion"
219734093|NCT00339365|BEHAVIORAL|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
219235114|NCT02430909|BIOLOGICAL|Certolizumab Pegol|"* Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
219235115|NCT02430909|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion"
219235116|NCT04651426|DEVICE|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
219235117|NCT02441829|DRUG|Eleclazine|Eleclazine tablets administered orally in morning with food
219734094|NCT01693237|OTHER|Group psychotherapy|20 sessions of systemic and narrative group therapy
219734095|NCT01693237|OTHER|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
219734096|NCT01386645|OTHER|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
219160732|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
219160733|NCT05636553|OTHER|Massage|Individualised treatment using massage techniques such as longitudinal gliding, transverse gliding, digital ischemic pressure, transverse frictions, and transverse gliding.
219235118|NCT03262714|OTHER|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
219160734|NCT06279650|OTHER|Self-hypnosis|The HYlaDo intervention comprises 8 90-minute sessions. Session 1 offers psycho-education on pain and medical hypnosis. Sessions 2 to 7 offer brief introductions followed by hypnosis induction, during which the CBT elements (exposure and cognitive restructuring) to be worked on during the session are introduced. The sessions are aimed at managing: 2- anxiety and mood; 3- pain dramatization; 4- and 5- pain perception; 6- kinesiophobia; 7- future projection and resource mobilization. Session 8 provides feedback and recommendations for independent practice. Each hypnosis follows the same pattern: induction, deepening, CBT-based hypnotic work, post-hypnotic suggestions and return to wakefulness, explanations of the exercise and recommendations for independent practice.
219160735|NCT06279650|OTHER|Psycho-education and cognitive Bahavioral therapy (CBT)|The psychoeducation-CBT intervention for pain and anxiety/depression consists of 8 90-minute sessions. It has already been implemented in HMR's pain clinic, and controls both the effects of time and repetition of measures, as well as non-specific factors including expectations associated with receiving active treatment, therapeutic relationship, frequency of encounters, and participation in a manualized intervention. It is designed to inform participants about pain, its costs, neurophysiology, nature and impact. It includes general information on pain, as well as information tailored to the participants' particular type of pain. The sessions are interactive, with the therapist stimulating discussion of the educational content and its relevance to the participants' lives.
219160736|NCT05265728|DRUG|Natalizumab|Administered as specified in the treatment arm
219160737|NCT04392050|OTHER|Interview|Complete interview
219160738|NCT04392050|OTHER|Focus Group|Attend focus groups
219160739|NCT04392050|OTHER|Questionnaire Administration|Ancillary studies
219160740|NCT03433469|DRUG|Osimertinib|Given PO (orally)
219160741|NCT03433469|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219160742|NCT06058000|DRUG|1.5% QLM3003|QLM3003 topical cream
219160743|NCT06058000|DRUG|2% QLM3003|QLM3003 topical cream
219160744|NCT06058000|DRUG|Vehicle (Placebo)|Vehicle topical cream
219160745|NCT06111313|RADIATION|FTLEAD|In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.
219160746|NCT06111313|DRUG|Ultra-Short-Term Androgen Deprivation Therapy with Relugolix|Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.
219160747|NCT06111313|RADIATION|HypoLEAD|In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.
219160748|NCT06111313|DRUG|ADT Standard of Care|Participants will receive ADT as per standard of care (SOC).
219160749|NCT06750237|OTHER|Stable surface and Isometrics|will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week
219160750|NCT06750237|OTHER|Unstable surface and isometrics|and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
219160751|NCT05641974|BEHAVIORAL|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
219160752|NCT05831189|DRUG|RBX2660|RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
219160753|NCT06026111|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
219160754|NCT06026111|BEHAVIORAL|Moderate-Intensity Continuous Training (MICT)|Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
219160755|NCT05532059|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
219235119|NCT03262714|OTHER|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
219235120|NCT03262714|OTHER|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
219235121|NCT04510493|DRUG|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
219235122|NCT04510493|DRUG|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
219235123|NCT04604717|OTHER|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
219235124|NCT02981953|DEVICE|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
219235125|NCT05651802|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
219235126|NCT05651802|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
219235127|NCT05651802|DRUG|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
219235128|NCT01900015|DRUG|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
219160756|NCT05532059|DRUG|gemcitabine and cisplatin|gemcitabine and cisplatin
219160757|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
219160758|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
219160759|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
219160760|NCT03821844|BEHAVIORAL|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
219160761|NCT05983237|DRUG|Fluzoparib Camrelizumab Temozolomide|Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
219160762|NCT04433299|OTHER|no intervention, observational|no intervention, observational
219160763|NCT06402604|BEHAVIORAL|Aerobic exercise training|See above in arm group descriptions.
219160764|NCT06402604|BEHAVIORAL|Mindfulness Based Stress Reduction training|See above in arm group descriptions.
219160765|NCT05744245|OTHER|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
219160766|NCT04910308|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
219160767|NCT05874570|DRUG|Esomeprazole|Proton pump inhibitor
219160768|NCT05874570|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219235129|NCT01900015|DRUG|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
219235130|NCT03660527|OTHER|Not refered|No intervention was refered.
219235131|NCT00774826|DRUG|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
219235132|NCT00774826|DRUG|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
219160769|NCT05874570|DRUG|Tetracycline|Antibiotics for H. pylori eradication
219160770|NCT05874570|DRUG|Doxycycline|Antibiotics for H. pylori eradication
219160771|NCT05874570|DRUG|Metronidazole|Antibiotics for H. pylori eradication
219235133|NCT00774826|DRUG|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
219235134|NCT00383812|DRUG|Intravitreal Bevacizumab|
219734097|NCT01386645|OTHER|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
219734098|NCT01386645|DRUG|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
219235135|NCT06523686|PROCEDURE|Guided bone regeneration|Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
219235136|NCT02504762|PROCEDURE|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
219235137|NCT02504762|PROCEDURE|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
219734099|NCT03977298|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
219734100|NCT03977298|PROCEDURE|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
219734101|NCT06521593|PROCEDURE|Applying a tourniquet for either a short or long time during total knee replacement|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
219734102|NCT01972178|DRUG|PRC-4016|
219734103|NCT01972178|DRUG|Placebo|
219734104|NCT01972178|DRUG|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
219734105|NCT00432991|DRUG|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
219734106|NCT00432991|DRUG|Saline Placebo|0.5 mL, IM (in the muscle), one time
219734107|NCT03759197|DRUG|188-0551 Spray|Topical Spray containing active drug
219734108|NCT03759197|DRUG|Vehicle Spray|Topical Spray containing no active drug
219734109|NCT04738669|OTHER|mHealth|The mHealth intervention includes telephonic call and SMS.
219734110|NCT04738669|BEHAVIORAL|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
219734111|NCT00974532|DIETARY_SUPPLEMENT|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
219734112|NCT00974532|DIETARY_SUPPLEMENT|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
219734113|NCT04109482|BIOLOGICAL|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
219160772|NCT05066542|BEHAVIORAL|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
219160773|NCT05066542|BEHAVIORAL|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
219160774|NCT00817037|DRUG|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
219160775|NCT00817037|DRUG|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
219160776|NCT00817037|DRUG|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
219235138|NCT02889900|DRUG|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
219734114|NCT04109482|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
219734115|NCT04109482|DRUG|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
219734116|NCT01489826|DRUG|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
219734117|NCT01489826|OTHER|Cremophor|Drug vehicle.
219734118|NCT03418480|DRUG|BNT113|Intradermal vaccine
219734119|NCT01991574|DRUG|Calcium acetate|
219734120|NCT01991574|DIETARY_SUPPLEMENT|Iron Hydroxide Adipate|
219734121|NCT01991574|DRUG|Placebo|methylcellulose capsules
219734122|NCT03142451|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
219235139|NCT02769754|DEVICE|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
219235140|NCT02769754|OTHER|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
219235141|NCT04338568|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
219235142|NCT06226623|DIETARY_SUPPLEMENT|Coconut|Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
219734123|NCT03142451|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
219734124|NCT01755754|COMBINATION_PRODUCT|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
219734125|NCT01755754|DEVICE|Female Condom|Female condom
219160777|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
219160778|NCT05364944|DRUG|Debio 4126|Intramuscular (IM) injection
219235143|NCT01821599|OTHER|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
219235144|NCT01821599|OTHER|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
219235145|NCT02198105|DEVICE|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length."
219235146|NCT02346786|DIETARY_SUPPLEMENT|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
219235147|NCT02346786|DIETARY_SUPPLEMENT|tap water|
219734126|NCT01758471|DRUG|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
219734127|NCT01758471|DRUG|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
219734128|NCT00901563|DRUG|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
219734129|NCT00901563|OTHER|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
219734130|NCT01141790|OTHER|Music and voice message|
219734131|NCT00941395|OTHER|Survey Administration|Complete surveys
219734132|NCT04859231|OTHER|Control|Cow's milk-based formula
219734133|NCT04859231|OTHER|Investigational|Cow's milk-based formula with added source of enriched whey protein
219734134|NCT02016885|DRUG|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
219734135|NCT02016885|DRUG|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
219160779|NCT05364944|DRUG|Sandostatin LAR|Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
219160780|NCT05364944|DRUG|Somatuline ATG|Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
219160781|NCT02605837|DRUG|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
219160782|NCT02605837|DRUG|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
219160783|NCT05670002|DIETARY_SUPPLEMENT|Milk supplement|Children will take the milk supplement for a period of 6 months. During the intervention, anthropometry data, Zinc Protoporphyrin levels, dietary intake, any illness will be recorded.
219160784|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
219160785|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
219160786|NCT02652260|DRUG|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
219160787|NCT02652260|DRUG|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
219160788|NCT02652260|DRUG|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
219235148|NCT00630409|DRUG|Gemcitabine|800 mg IV day 1 and 8
219235149|NCT00630409|DRUG|Doxil|24 mg/m2 every 21 days IV
219235150|NCT05238337|DRUG|[14C]-PBI-200|\[14C\]-radio-labeled-PBI-200
219235151|NCT03422705|DEVICE|Optimised programming|Optimised programming to avoid RV pacing when possible.
219235152|NCT03422705|DRUG|Lisinopril|Uptitration of lisinopril
219235153|NCT03422705|OTHER|Standard care|No pacemaker adjustment or medical therapy
219235154|NCT06322589|DIETARY_SUPPLEMENT|SOD like Super Drink|consume 1 bottle per day
219235155|NCT06322589|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
219235156|NCT04836871|COMBINATION_PRODUCT|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
219235157|NCT04785794|BIOLOGICAL|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
219235158|NCT04785794|OTHER|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
219235159|NCT01557439|DRUG|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
219235160|NCT03607851|DRUG|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
219235161|NCT03607851|DRUG|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
219235162|NCT03607851|DRUG|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
219235163|NCT00690313|DRUG|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
219235164|NCT02453269|BEHAVIORAL|Transdisciplinary program|
219235165|NCT03681067|DRUG|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
219235166|NCT03681067|DRUG|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
219235167|NCT04876430|DRUG|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
219235168|NCT01689740|DRUG|Active Placebo Dose MDMA-assisted therapy (25 mg)|Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.
219160789|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
219235169|NCT01689740|DRUG|Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
219235170|NCT01689740|DRUG|Open-Label Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
219235171|NCT01689740|BEHAVIORAL|Psychotherapy|Non-directive psychotherapy will be conducted throughout the study.
219734136|NCT02016885|DRUG|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
219160790|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
219235172|NCT00249366|DRUG|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
219734137|NCT02016885|DRUG|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
219235173|NCT00249366|DRUG|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
219235174|NCT00629993|BEHAVIORAL|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
219235175|NCT02814409|DRUG|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
219235176|NCT02814409|DRUG|Intravenous Tenecteplase|IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
219235177|NCT01477866|DIETARY_SUPPLEMENT|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
219235178|NCT01477866|OTHER|conventional therapy|conventional therapy for colon-rectal cancer
219235179|NCT01859689|RADIATION|brachytherapy|Undergo image-guided HDR brachytherapy
219235180|NCT01859689|RADIATION|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
219235181|NCT01859689|OTHER|laboratory biomarker analysis|Correlative studies
219235182|NCT05553730|BEHAVIORAL|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
219235183|NCT05636345|OTHER|pain science education|A full day of pain science education
219235184|NCT00595725|OTHER|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
219235185|NCT02269072|DRUG|Testosterone|Testosterone cream applied daily for two weeks
219235186|NCT02269072|DRUG|Nesiritide|Administered IV once during the study
219235187|NCT02269072|DRUG|Leuprolide|Administered twice during the study by injection
219235188|NCT02269072|DRUG|Anastrozole|Daily pill for 8 weeks
219235189|NCT02269072|DRUG|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
219235190|NCT00074932|BIOLOGICAL|Myozyme|20 mg/kg
219734138|NCT02016885|OTHER|Vehicle|Vehicle Topical Wipes
219734139|NCT06570499|OTHER|Implant impression|definitive impressions on implants
219160791|NCT06667648|PROCEDURE|cupping session|Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
219160792|NCT06815107|OTHER|questionnary|On day 1 of an ureteral double J stenting, each participant will receive the first USSQ questionnaire, in the French validated version. This questionnaire will be completed at home, one week after the intervention and returned at the following consultation or hospitalization.
219160793|NCT06815107|OTHER|USSQ survey|if the stent is removed less than 6 months later, the second USSQ survey, in the French validated version will be given to the patient when removing the stent. This questionnaire will be completed at home one week after removal of the stent and return to the referent hospital. If the patient does not return the second questionnaire, our team may contact them by phone to complete it.
219160794|NCT06072378|BEHAVIORAL|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
219160795|NCT06760741|GENETIC|Multigene panel|"Germline Genetic Testing: Germline genetic testing will be performed on all patients with pancreatic cancer (PC) using a custom multigene panel. This panel includes 25 candidate genetic variants of interest and 13 clinically recognized genes associated with a higher risk of PC.~DNA Extraction: Germline DNA will be extracted from peripheral blood samples using the QIAamp DNA Blood Kit (Qiagen, Redwood City, CA, USA) following the manufacturer's instructions. The concentration of double-stranded DNA will be measured using a fluorometric method (Qubit, Thermo Fisher Scientific)."
219235191|NCT05341713|BIOLOGICAL|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
219235192|NCT02558907|OTHER|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
219235193|NCT00047684|BEHAVIORAL|Brief Integrative Therapy|
219235194|NCT06255132|DEVICE|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
219235195|NCT05941156|BIOLOGICAL|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
219734140|NCT01649583|DEVICE|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
219734141|NCT00949078|DRUG|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
219734142|NCT04016428|BEHAVIORAL|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
219734143|NCT04016428|BEHAVIORAL|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
219734144|NCT02365064|DEVICE|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
219734145|NCT06532344|DRUG|ONO-7913|Specified dose on specified days
219734146|NCT06532344|DRUG|ONO-4538|Specified dose on specified days
219235196|NCT02090478|OTHER|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
219235197|NCT02090478|OTHER|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
219235198|NCT02835209|OTHER|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
219235199|NCT01692652|DRUG|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
219235200|NCT01692652|OTHER|warm compress only group|
219235201|NCT01602900|DRUG|GSK356278|Investigational Medicinal Product
219235202|NCT01602900|DRUG|Rolipram|Challenge Agent
219734147|NCT06532344|DRUG|Oxaliplatin|Specified dose on specified days
219734148|NCT06532344|DRUG|Levofolinate|Specified dose on specified days
219734149|NCT06532344|DRUG|Irinotecan|Specified dose on specified days
219734150|NCT06532344|DRUG|Fluorouracil|Specified dose on specified days
219734151|NCT01688401|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
219734152|NCT00562198|DRUG|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
219734153|NCT00562198|DRUG|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
219734154|NCT01818310|BIOLOGICAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
219734155|NCT01818310|BIOLOGICAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
219734156|NCT01818310|BIOLOGICAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
219734157|NCT01818310|PROCEDURE|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
219734158|NCT01901757|DRUG|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
219734159|NCT01901757|DRUG|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
219734160|NCT04343768|DRUG|Hydroxychloroquine|This Drug will be used in all arms.
219734161|NCT04343768|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms.
219734162|NCT04343768|DRUG|Interferon Beta-1A|This drug will be only used in Arm 1.
219734163|NCT04343768|DRUG|Interferon Beta-1B|This drug will be only used in Arm 2.
219734164|NCT00780598|DRUG|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
219734165|NCT03177070|DRUG|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
219734166|NCT04714177|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
219734167|NCT04714177|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
219235203|NCT01090739|DEVICE|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
219235204|NCT04078373|BEHAVIORAL|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
219734168|NCT04105257|DIAGNOSTIC_TEST|All patients|Comparison of the results of the CTP with MRI
219734169|NCT03146793|DRUG|Sodium Thiosulfate|25g intravenously 3 times per week
219734170|NCT04477512|DRUG|Cabozantinib|Supplied by Exelixis
219734171|NCT04477512|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
219734172|NCT04477512|DRUG|Abiraterone acetate|Commercially available
219734173|NCT04477512|DRUG|Prednisone|Commercially available
219734174|NCT04477512|PROCEDURE|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
219734175|NCT02595437|DRUG|Triferic|
219734176|NCT04658680|DRUG|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
219734177|NCT02758080|OTHER|Matching on the basis of molecular analysis|
219734178|NCT02758080|OTHER|Matching on the basis of physician's choice|
219734179|NCT04238182|OTHER|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
219734180|NCT04238182|OTHER|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
219734181|NCT00676637|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
219734182|NCT00676637|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
219235205|NCT04078373|BEHAVIORAL|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
219734183|NCT04226105|DRUG|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
219734184|NCT04226105|DRUG|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
219734185|NCT01531803|DRUG|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
219734186|NCT01531803|DRUG|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
219734187|NCT04403893|OTHER|HANARO biliary stent placement|HANARO biliary stent placement
219734188|NCT05914259|OTHER|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
219734189|NCT05296655|OTHER|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
219734190|NCT05296655|OTHER|Reflux finding score|laryngoscopy with a score RFS
219734191|NCT00538278|OTHER|Database|database
219734192|NCT05795712|OTHER|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
219734193|NCT04704128|OTHER|Salivic sample|Collection of total saliva not stimulated
219734194|NCT04990310|DRUG|[14C]-CORT113176|\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
219235206|NCT03578744|PROCEDURE|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
219235207|NCT00924755|DEVICE|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
219235208|NCT05396755|PROCEDURE|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
219235209|NCT03741634|OTHER|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
219235210|NCT04610125|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
219235211|NCT04610125|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
219235212|NCT04610125|PROCEDURE|Leukapheresis|Leukapheresis
219235213|NCT04745338|DEVICE|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
219235214|NCT04745338|DIETARY_SUPPLEMENT|low calolric diet|low caloric diet (1200cal/day)
219235215|NCT01166191|RADIATION|Radiotherapy|Radiotherapy
219235216|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
219235217|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
219235218|NCT03500406|DEVICE|RestoreX|Penile traction therapy in the straight position
219235219|NCT03500406|OTHER|Control|No treatment
219235220|NCT03678792|DRUG|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
219235221|NCT03678792|DRUG|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
219235222|NCT03678792|DRUG|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
219235223|NCT01062438|GENETIC|DNA analysis|
219235224|NCT01062438|GENETIC|RNA analysis|
219235225|NCT01062438|GENETIC|gene expression analysis|
219235226|NCT01062438|GENETIC|gene rearrangement analysis|
219235227|NCT01062438|GENETIC|mutation analysis|
219235228|NCT01062438|OTHER|laboratory biomarker analysis|
219235229|NCT02855762|OTHER|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
219235230|NCT03691441|PROCEDURE|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
219235231|NCT03691441|RADIATION|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
219235232|NCT03691441|DRUG|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
219235233|NCT03691441|PROCEDURE|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
219235234|NCT02410278|DRUG|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
219235235|NCT02410278|DRUG|montelukast|As described in the treatment arm
219235236|NCT02410278|DRUG|Placebo|Matched placebo
219235237|NCT01856062|DRUG|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
219235238|NCT01856062|DRUG|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
219235239|NCT03695185|DRUG|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
219235240|NCT03695185|DRUG|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
219235241|NCT05962099|BEHAVIORAL|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
219235242|NCT02584257|OTHER|methacholine chloride|
219235243|NCT02584257|DRUG|placebo ProAir HFA|
219235244|NCT02584257|DRUG|ProAir HFA|
219235245|NCT02584257|DRUG|Lupin albuterol HFA MDI|
219235246|NCT02584257|DRUG|placebo Lupin albuterol HFA MDI|
219235247|NCT03823690|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
219235248|NCT03823690|DEVICE|The pyloro-duodenal stent|As listed in the arms description
219235249|NCT05104684|OTHER|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
219235250|NCT05104684|OTHER|routine medical treatment|medical treatment
219235251|NCT01064609|PROCEDURE|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
219235252|NCT01064609|PROCEDURE|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
219235253|NCT01684540|OTHER|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
219235254|NCT01684540|DRUG|Sinupret forte|
219235255|NCT00457834|DEVICE|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
219734195|NCT05810649|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
219734196|NCT05775575|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
219734197|NCT04744129|DRUG|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
219734198|NCT04744129|DRUG|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
219734199|NCT01594814|PROCEDURE|RFA|radiofrequency ablation of slow pathway or accesory pathway
219734200|NCT03881878|DRUG|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
219160796|NCT06760741|DIAGNOSTIC_TEST|Other|"1. Characterization of Suspected Pancreatic Cancer Lesions:~   Characterization of suspected pancreatic cancer (PC) lesions identified by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) in patients undergoing screening since 2014. This includes lesion type (solid or cystic), rapid cyst growth exceeding 4 mm per year, location, size, potential assessment of resectability, lobulocentric parenchymal atrophy, and Wirsung duct dilation. Clinically relevant suspected lesions will be defined as solid lesions, intraductal papillary mucinous neoplasms (IPMN), cystic lesions ≥10 mm, and cystic lesions with mural nodules.~2. Determination of CA 19-9 and Glycated Hemoglobin:~Measurement of CA 19-9 levels and glycated hemoglobin (HbA1c) as part of the diagnostic and monitoring process."
219160797|NCT06760741|DIAGNOSTIC_TEST|miRNA measurement in blood|"Analysis of miRNA Expression in plasma:~The expression of circulating miRNAs (in plasma) will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The signature includes two miRNAs (miR-33a-3p and miR-320a) combined with CA 19-9."
219160798|NCT06760741|GENETIC|Generation of 3D Pancreatic Organoids|"Generation of 3D Pancreatic Organoids for Complementary Analyses:~3D pancreatic organoids will be generated for complementary analyses involving in vitro functional studies to evaluate the pathogenicity of novel genes (selected based on the results of the multigene panel). These organoids will be developed from surgical samples obtained from five patients undergoing surgery as part of clinical care."
219160799|NCT06315543|DIETARY_SUPPLEMENT|Drink water|Increase drinking water by 1650mL per day (3 bottles of 550mL bottled water)
219160800|NCT06761313|DRUG|Triple combination formula|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks."
219160801|NCT06761313|DRUG|Bimatoprost .03% sterile ophthalmic solution|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate 0.2%(1 drop twice a day), Timolol Maleate 0.5% (1 drop twice a day) and Bimatoprost 0.3% (1 drop at night). At the first visit a complete ophthalmolgical exam which includes ocular surface items (conjunctival hiperemia, keratitis and tear film break up time). Questionnaires are performed (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire) to assess information about ocular surface adverse effects, quality of life and treatment adherence. Glaucoma exams as retinography, perimetry, optic nerve OCT (optical coherence tomography), central corneal thickness are performed on all patients to evaluate disease's control. This procedure will be repeated at all visits: baseline and within 4, 8, 12 weeks."
219160802|NCT06385119|DRUG|Plixorafenib|Oral Tablet
219160803|NCT06385119|DRUG|Cobicistat|Oral Tablet
219160804|NCT06068868|DRUG|ABBV-787|Intravenous (IV) Infusion
219160805|NCT05453565|OTHER|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
219160806|NCT05453565|OTHER|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
219734201|NCT03881878|DRUG|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
219734202|NCT02062255|DRUG|Aspirin|
219734203|NCT02062255|DIETARY_SUPPLEMENT|Omega 3 FFA|
219160807|NCT05918484|DEVICE|Intermittenly scanned continuous glucose monitoring|"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L \>70%~* Glycemic management index \<7%~* Coefficient of variation \<36%"
219160808|NCT05918484|OTHER|MODY genetic diagnostic test|"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."
219734204|NCT03023683|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
219734205|NCT04314180|DEVICE|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
219734206|NCT03958097|COMBINATION_PRODUCT|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
219734207|NCT00450840|DRUG|Simvastatin|
219734208|NCT03902483|DEVICE|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
219734209|NCT04869410|PROCEDURE|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
219734210|NCT04869410|PROCEDURE|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
219734211|NCT02540902|DEVICE|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
219734212|NCT02773537|DRUG|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
219734213|NCT02773537|DRUG|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
219160809|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
219160810|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
219235256|NCT01735214|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
219235257|NCT01577875|DEVICE|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
219734214|NCT02773537|DRUG|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
219734215|NCT05591287|PROCEDURE|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
219734216|NCT01840163|OTHER|Static version of CanSORT tool|
219734217|NCT01840163|OTHER|CanSORT Online Tool|
219734218|NCT02542579|GENETIC|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
219734219|NCT03223805|OTHER|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
219734220|NCT05531344|DEVICE|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
219734221|NCT05531344|DRUG|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
219734222|NCT01366014|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
219734223|NCT01366014|DRUG|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
219734224|NCT01366014|DRUG|Placebo; oral|matching placebo
219734225|NCT00276315|BIOLOGICAL|Botulinum toxin type A|
219734226|NCT00383565|DRUG|romidepsin|Given IV
219734227|NCT05820555|BEHAVIORAL|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
219734228|NCT05820555|BEHAVIORAL|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
219734229|NCT03990337|DEVICE|Ultrasound|Ultrasonography of cricoid cartilage.
219734230|NCT00748527|DRUG|carboplatin|Given IV
219734231|NCT00748527|DRUG|decitabine|Given IV
219734232|NCT03090542|DIETARY_SUPPLEMENT|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
219160811|NCT06122844|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K2 and K3. Each lesson lasts for approximately 30-40 minutes.
219160812|NCT05322525|DRUG|ON101 Cream|"Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day"
219160813|NCT05056246|DRUG|AMG 133|Solution for SC injection
219160814|NCT04046848|DRUG|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
219160815|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
219160816|NCT04713618|OTHER|Survey|Complete surveys
219160817|NCT03894917|OTHER|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
219160818|NCT04647435|DRUG|APSCTC|APSCTC + Toragesic® placebo + Tramal® placebo
219160819|NCT04647435|DRUG|Toragesic®|APSCTC placebo + Toragesic® + Tramal® placebo
219160820|NCT04647435|DRUG|Tramal®|APSCTC placebo + Toragesic® placebo + Tramal®
219160821|NCT06414317|PROCEDURE|Assessment of Distress|Undergo psychological distress screening
219160822|NCT06414317|OTHER|Consultation Visit|Attend consultations
219160823|NCT06414317|OTHER|Nutritional Assessment|Undergo malnutrition screening
219160824|NCT06414317|OTHER|Questionnaire Administration|Ancillary studies
219160825|NCT06414317|OTHER|Supportive Care|Receive access to bladder cancer ENST
219160826|NCT06414317|OTHER|Supportive Care|Attend virtual support group meetings
219734233|NCT06549127|DEVICE|Soft Wearable Robot|This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
219160827|NCT06789926|OTHER|Intervention Group|Attending a 4-hour ACT workshop, and after attending participants will utilize the remaining course time to independently access the LINE platform. The platform will feature pre-recorded guided audio files for relaxation, emotional videos, and psychological cards.
219160828|NCT06783348|DRUG|177Lu-PSMA-617|Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
219160829|NCT05055778|BEHAVIORAL|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
219160830|NCT06784739|OTHER|Blood sampling|Venous blood sampling
219160831|NCT06784739|OTHER|Mucosal sampling|Saliva and nasal secretions
219160832|NCT06784739|DIAGNOSTIC_TEST|PCR-test|RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
219160833|NCT06783439|OTHER|Ultrasound|The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.
219734234|NCT06536855|BIOLOGICAL|Gardasil 9|"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."
219734235|NCT03364257|DIAGNOSTIC_TEST|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
219734236|NCT03636269|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
219160834|NCT05729256|BEHAVIORAL|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
219160835|NCT05729256|BEHAVIORAL|Brief Advice and Information|Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
219160836|NCT04659408|DIETARY_SUPPLEMENT|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
219160837|NCT04659408|DIETARY_SUPPLEMENT|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
219160838|NCT03190174|DRUG|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
219160839|NCT03190174|BIOLOGICAL|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
219160840|NCT06197165|OTHER|Targeted Shiatsu|"demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu"
219160841|NCT06785532|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
219160842|NCT03899961|DRUG|Oxytocin|Oxytocin 2.5 U i.v.
219160843|NCT03899961|DRUG|Carbetocin|Carbetocin 100 µg i.v.
219160844|NCT06787911|DRUG|Donafeib with Sintilimab|Patients receive Donafenib and PD-1 antibody Sintilimab
219160845|NCT05057091|OTHER|Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation|For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure
219160846|NCT05057091|OTHER|Group 2- Side-Lying Lumbar Spinal Manipulation|The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.
219160847|NCT06834711|DRUG|N-Acetyl Cysteine|The root canals were irrigated with 3 mL N-acetyl Cysteine (NAC)(200 mg/ml) in N-acetyl Cysteine group in the final irrigation.
219160848|NCT06834711|DRUG|Chlorhexidine|The root canals were irrigated with 3 ml %2 chlorhexidine in chlorhexidin group in the final irrigation.
219160849|NCT05656911|DRUG|Zabedosertib (BAY1834845)|Oral administration, two times a day
219160850|NCT05656911|DRUG|Placebo to zabedosertib (BAY1834845)|Oral administration, two times a day
219160851|NCT01229098|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
219160852|NCT04142476|OTHER|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
219160853|NCT06832176|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic constipation.
219160854|NCT06832176|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
219734237|NCT03636269|DRUG|Placebo|IV placebo administered three times/week
219734238|NCT03992482|DRUG|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
219161663|NCT06763770|BEHAVIORAL|The Usual Care + Educational Control|The Usual Care + Educational Control group will receive weekly emails with links to the Health Links developed by the Children's Oncology Group for use in survivorship care. Access to these Health Links reflects the current state of clinical care available to survivors. These Health Links were developed as patient education materials to cover relevant self-management and survivorship care topics. The weekly messages will align with the content of the modules from Managing Your Health to provide similar information, including Introduction to Long-Term Follow-Up (Module 1), Finding and Paying for Healthcare (Module 2), Emotional Issues (Modules 3 and 4), Educational Issues, Diet and Physical Activity, Skin Health, Reducing the Risk of Second Cancers, and Male/Female Health Issues (Module 5).
219235258|NCT02602548|OTHER|Culture|Specimens will be obtained and sent to the lab for cultures.
219734239|NCT03992482|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
219734240|NCT05441345|OTHER|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
219734241|NCT02940119|DEVICE|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
219734242|NCT02063438|PROCEDURE|Pericostal suture technique|
219235259|NCT04760028|PROCEDURE|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
219235260|NCT00547326|PROCEDURE|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
219734243|NCT02063438|PROCEDURE|Intracostal suture technique|
219734244|NCT01507103|BIOLOGICAL|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
219734245|NCT01507103|DRUG|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
219160855|NCT06835426|OTHER|Single intravenous injection of the radiotracer|"* only in case of 18F-FDG as PET-tracer: blood glucose level is measured;~* single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group:~  * breast cancer group: 0.8 MBq/kg of 18F-FDG~ * prostate cancer group: 1 MBq/kg 18F-PSMA~ * thyroid cancer group: 1 MBq/kg of 18F-FDG~ * parathyroid adenoma group: 1 MBq/kg of 18F-Choline~ * head \& neck cancer group: 1 MBq/kg of 18F-FDG~ * skin cancer group: 4 MBq/kg of 18F-FDG~ * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG~ * genitourinary malignancies group: 1 MBq/kg of 18F-FDG~ * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG~ * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG~ * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F~ * Gastrointestinal group: 1 MBq/kg of 18F-FDG~ * Thoracovascular group: 1MBq/kg of 18F-FDG"
219160856|NCT06835426|DIAGNOSTIC_TEST|Imaging resected specimen using the high-resolution PET-CT specimen imager|"* the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin;~* additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;"
219160857|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
219160858|NCT06833827|DEVICE|Catheter-directed thrombectomy (CDT)|The intervention consists of immediate thrombectomy (thrombectomy with any approved device) without systemic/locally administered thrombolysis. Thrombectomy is performed via jugular or femoral venous access according to the instructions for use for the particular device. The catheter is advanced over a preplaced guidewire across the right heart into the pulmonary arteries to the location of proximal thrombus. Procedural therapeutic anticoagulation with heparin is administered. After removal of the dilator, the thrombus is extracted by controlled volume aspiration through an aspiration catheter using a syringe or dedicated aspiration system, with multiple aspirations performed as needed. Procedural objectives will be clearly stated prior to the intervention and patient's clinical and hemodynamic status and residual thrombus will guide the investigators to determine when to terminate the procedure. Treatment success is defined as clear evidence of right ventricular recompensation.
219160859|NCT06833827|DRUG|thrombolysis therapy|Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated fragmentation of the thrombus by lytic medication given systemically.
219160860|NCT06835504|DRUG|Ketamine hydrochloride|Sub-dissociative ketamine, IV
219160861|NCT06835504|DRUG|Morphine sulphate|Morphine, IV
219160862|NCT06784635|BEHAVIORAL|In person|Participant dyads will meet in person for a mock clinical interview, seated at a desk opposite their counterpart. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
219160863|NCT06784635|BEHAVIORAL|Online interaction|Participant dyads will meet online in a mock clinical interview, via an encrypted video call, seated at a desk. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
219160864|NCT06785649|OTHER|Lavender herbal tea|The participant will be allocated 14 pieces of lavender tea bags consisting of 2 grams and originating from Turkey. During 14 days, the participant will be advised to use 2 g of lavender herb brewed in 300 mL hot water for 10-15 minutes in the morning and evening. Participants will be able to use 1 lavender tea bag twice a day.
219235261|NCT00547326|PROCEDURE|Treatment with placebo|Treatment with placebo
219235262|NCT02763657|OTHER|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
219235263|NCT01762839|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
219235264|NCT01762839|DRUG|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
219235265|NCT01762839|DRUG|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
219235266|NCT00020527|DRUG|caspofungin acetate|
219235267|NCT03921775|DRUG|Remimazolam Tosilate|For induction and maintenance of general anesthesia
219235268|NCT03921775|DRUG|Propofol|For induction and maintenance of general anesthesia
219235269|NCT01933945|PROCEDURE|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
219160865|NCT06784206|DRUG|Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy|"Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death"
219160866|NCT06792370|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (for children with MAM)|Each child with MAM will be supplemented with RUTF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks.
219160867|NCT06792370|DIETARY_SUPPLEMENT|Ready-to-use supplementary food|Each child with MAM will be supplemented with RUSF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery
219160868|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 1|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
219160869|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Standard dose|Each child with SAM will be treated with a standard dose (according to the national protocol for the integrated management of acute malnutrition in Burkina Faso) for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery.
219160870|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 2|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until the child is no longer severely malnourished and does not have nutritional oedema then 100-130 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
219160871|NCT06785142|DIETARY_SUPPLEMENT|Functional Shot|60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins
219160872|NCT06785142|DIETARY_SUPPLEMENT|Placebo Shot|Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients
219160873|NCT06397963|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
219160874|NCT06833658|OTHER|Experimental: Aromatherapy with essential oil intervention|Aromatherapy, customized to meet the psychological needs of pancreatic cancer patients, was employed as part of the intervention. A senior aromatherapist developed the protocol, selecting pleasant essential oils diluted at a ratio of 1-2 drops in 70ml of water. The aromatherapy was administered twice daily for one hour each session using an aromatherapy diffuser.During aromatherapy, nurses should inspect patients every 30 minutes to ensure comfort, and take immediate action if discomfort is reported.
219160875|NCT06833658|OTHER|Control Group 0.9% Isotonic Saline|1\. Pre - operation: Present pancreatic cancer knowledge, such as causes, common symptoms, treatment methods, and the need for surgery. Answer patients' queries promptly to reduce their fear of the disease and surgery. 2. Post - operation: Report the surgical outcome, explain common post - op complications and solutions to relieve negative emotions. 3. Post - operation: Intensify post - op education on drainage tube care, activity guidelines, disease knowledge, and diet advice. Strengthen mental health education, encourage family members to show more concern for patients, and enhance family support. 4. Pre - discharge: Provide discharge instructions to patients and their families. Guide patients who need tube removal and suture removal after discharge to make online appointments for outpatient follow - up.
219160876|NCT04747314|DRUG|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
219160877|NCT04747314|OTHER|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
219235270|NCT01933945|DRUG|Sorafenib (Nexavar, BAY43-9006)|
219235271|NCT03956927|OTHER|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
219235272|NCT03956927|OTHER|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
219235273|NCT03693989|DRUG|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
219235274|NCT03693989|DRUG|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~\- Route of administration: topical ophthalmic"
219235275|NCT01073722|DEVICE|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
219734246|NCT01507103|OTHER|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
219734247|NCT06541080|DIAGNOSTIC_TEST|Shallow Whole Genome Sequencing (sWGS)-GIPXplore|GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
219160878|NCT06272435|DIETARY_SUPPLEMENT|Multiplier|Subjects will consume 1 Liter (2 servings) of commercially available Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
219160879|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free|Subjects will consume 1 Liter (2 servings) of experimental Sugar Free Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
219160880|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free with Amino Acids|Subjects will consume 1 Liter (2 servings) of commercially available Sugar Free Hydration Multiplier product that contains amino acids at a rate of 250 milliliters per 7.5 minutes.
219160881|NCT06272435|DIETARY_SUPPLEMENT|Water|Subjects will consume 1 Liter of water at a rate of 250 milliliters per 7.5 minutes.
219160882|NCT05849168|BEHAVIORAL|Exercise training|Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
219160883|NCT04070560|PROCEDURE|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
219160884|NCT04070560|PROCEDURE|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
219160885|NCT06292988|PROCEDURE|Total Thyroidectomy|Total thyroidectomy
219160886|NCT06393699|PROCEDURE|composite restoration|different types of resin composite restorations will be used to restore NCCL
219160887|NCT05411744|DRUG|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
219160888|NCT04345016|DEVICE|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
219160889|NCT06025994|OTHER|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
219160890|NCT03503344|DRUG|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
219160891|NCT03503344|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219235276|NCT01073722|DEVICE|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
219235277|NCT00457314|BEHAVIORAL|Exercise|Regular exercise training
219235278|NCT02591082|DEVICE|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
219734248|NCT06541080|DIAGNOSTIC_TEST|methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay|Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
219734249|NCT02044146|DRUG|Ticagrelor, Prasugrel, Clopidogrel|
219160892|NCT02780388|DRUG|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
219160893|NCT02780388|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
219160894|NCT05236582|DRUG|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
219160895|NCT05107401|BEHAVIORAL|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
219734250|NCT03008213|DRUG|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
219734251|NCT05001555|DRUG|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
219734252|NCT05001555|DRUG|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
219235279|NCT01017159|DRUG|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
219734253|NCT00298701|BIOLOGICAL|ALK Grass tablet|
219734254|NCT05674565|DRUG|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
219734255|NCT05674565|DRUG|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
219734256|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
219734257|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
219734258|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
219734259|NCT00324545|BEHAVIORAL|Medium-intensity Minimally-directive Counseling|
219734260|NCT05213221|DRUG|Envafolimab|300mg, subcutaneous injection, q3w
219734261|NCT05213221|PROCEDURE|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
219734262|NCT05213221|DRUG|Lenvatinib|8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
219734263|NCT04304248|DRUG|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
219160896|NCT06328751|DEVICE|Case group|Meditation will be taught through a video played on a Samsung® gear VR virtual reality glasses with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
219160897|NCT06328751|BEHAVIORAL|Active control group|Meditation will be taught through a video played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
219160898|NCT06328751|BEHAVIORAL|Passive control group|Meditation will be taught through a audio played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
219160899|NCT06133322|BEHAVIORAL|Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
219160900|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219160901|NCT03356990|DIETARY_SUPPLEMENT|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
219734264|NCT03844035|DIAGNOSTIC_TEST|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
219734265|NCT03837535|PROCEDURE|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
219734266|NCT03641677|DEVICE|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
219160902|NCT05568069|DEVICE|Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)|An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
219160903|NCT04184089|DEVICE|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
219734267|NCT03641677|PROCEDURE|Lung Transplant|Orthotopic single or double lung transplantation.
219734268|NCT01390519|OTHER|everolimis|
219734269|NCT04535362|DRUG|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
219734270|NCT02419911|PROCEDURE|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
219734271|NCT02419911|DEVICE|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
219734272|NCT02419911|DEVICE|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
219160904|NCT04184089|DEVICE|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
219160905|NCT04184089|DEVICE|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
219160906|NCT04656925|BEHAVIORAL|Contingency management|Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
219160907|NCT00977691|PROCEDURE|PBSC Transplant|PBSC transplant
219160908|NCT00977691|DRUG|Alemtuzumab|alemtuzumab
219734273|NCT05470296|BEHAVIORAL|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
219734274|NCT03791060|DRUG|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
219160909|NCT00977691|DRUG|Sirolimus|sirolimus
219734275|NCT00200083|DEVICE|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
219734276|NCT03774810|DRUG|Zolpidem tartrate|Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
219734277|NCT02212977|DEVICE|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
219734278|NCT02212977|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
219734279|NCT01604031|BIOLOGICAL|B-CLL Vaccine|Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
219734280|NCT01604031|DRUG|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
219734281|NCT00092469|BIOLOGICAL|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
219734282|NCT04767412|DEVICE|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
219734283|NCT00330278|DRUG|Cefazolin|
219160910|NCT00977691|DRUG|Cyclophosphamide|cyclophosphamide
219160911|NCT00977691|PROCEDURE|Low Dose Irradiation|low dose irradiation
219160912|NCT06734923|OTHER|Questionnaire (28 questions)|demographic data, information-seeking behavior, platform use and online consultation habits, trust and impact, and interest in additional resources
219734284|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
219734285|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
219734286|NCT00554580|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
219734287|NCT00554580|PROCEDURE|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
219734288|NCT03061851|BEHAVIORAL|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
219734289|NCT03061851|OTHER|Maltose app|"1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query."
219734290|NCT01641783|DRUG|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
219734291|NCT02715752|DIETARY_SUPPLEMENT|Gene-Eden-VIR/Novirin|
219160913|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
219160914|NCT04440176|BIOLOGICAL|Saline|Placebo
219160915|NCT05923125|BEHAVIORAL|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
219160916|NCT04640441|OTHER|Sit-to-stand care|"1. Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20\~30 min, once daily.~2. Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20\~30min, once daily.~3. Stepping exercise and sit-to-stand exercise, 20\~30min, once daily."
219160917|NCT06782763|DEVICE|Repetitive transcranial magnetic stimulation device|Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
219160918|NCT05954962|DRUG|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
219160919|NCT05954962|DRUG|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
219235280|NCT01079104|DEVICE|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
219734292|NCT03709589|OTHER|Modified Early Warning Score|Modified Early Warning Score
219734293|NCT02848352|OTHER|Placebo nasal spray|
219734294|NCT02848352|OTHER|Film Sequence|
219734295|NCT03116087|DRUG|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
219734296|NCT03116087|DRUG|Placebo|Placebo patch
219160920|NCT06508801|OTHER|Blood flow restriction training|The BFR Intervention will consist of 75 repetitions; reps (set 1: 30 reps, sets 2 - 4: 15 reps with 30 s of rest between sets and 1 minute between exercises) at 20-30% of 10 repetition maximum (RM). BFR training will be performed during toe raises, lunges and single leg stance exercises on unstable surfaces (i.e., foam, Dyna disc, balance disc, and BOSU-ball®) as tolerated by the participant.
219160921|NCT06508801|OTHER|Instability Resistance Training|The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
219160922|NCT05887700|DEVICE|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
219160923|NCT04219696|OTHER|Reactive balance training|A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
219160924|NCT05605015|BEHAVIORAL|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
219160925|NCT04608045|DRUG|CPX-POM|CPX-POM
219160926|NCT04781959|DRUG|Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
219160927|NCT04781959|DRUG|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
219160928|NCT03575052|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
219734297|NCT00943202|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
219734298|NCT00943202|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
219734299|NCT05942989|OTHER|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
219160929|NCT03575052|DRUG|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
219160930|NCT05631574|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
219160931|NCT05795634|BEHAVIORAL|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
219160932|NCT06419777|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
219160933|NCT06273683|OTHER|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
219160934|NCT06273683|OTHER|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
219235281|NCT01079104|PROCEDURE|Standard Medical Therapy|Standard of care treatment
219235282|NCT03146845|DEVICE|ALLEVYN Life Non-Bordered|Foam Dressing
219235283|NCT03146845|DEVICE|Standard Care|Foam Dressing
219235284|NCT05243602|DRUG|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
219235285|NCT05243602|DRUG|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
219734300|NCT03286803|BIOLOGICAL|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
219734301|NCT04250974|OTHER|electroacupuncture|acupuncture with electricity
219734302|NCT00499538|DRUG|SKI-606|
219734303|NCT05328232|OTHER|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
219734304|NCT00593073|BEHAVIORAL|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
219734305|NCT00593073|BEHAVIORAL|General Reminder Message|General CRC health education message and reminder to get screened.
219734306|NCT02567292|OTHER|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
219734307|NCT00290758|DRUG|placebo|Given orally
219734308|NCT00290758|DRUG|genistein|Given orally
219160935|NCT06773663|COMBINATION_PRODUCT|Al18F-NOTA-Pentixafor PET/CT|"Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability."
219160936|NCT06772519|DEVICE|green colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
219160937|NCT06772519|DEVICE|blue colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
219160938|NCT06772519|DEVICE|colorless (transparent) lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
219160939|NCT06775236|DRUG|SYS6010 jnjection|SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
219160940|NCT06775236|DRUG|monotherapy chemotherapy|Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
219160941|NCT06775236|DRUG|SYH2051 tablets|SYH2051 is a Selective ATM protein kinase inhibitor
219160942|NCT06776627|OTHER|Adapted physical activity (APA)|Adapted program: aerobic capacity, strength, endurance, flexibility, balance and proprioception tests. APA sessions take place over 12 weeks. There will be 2 to 3 sessions per week. Course of a session: - Warm-up: 10-15min: cycling or walking. - Moderate-intensity endurance activity: cycling, walking or swimming: 10min, the duration will be increased gradually up to a minimum of 30min at the end of the program. - Muscle strengthening: with polyarticular or monoarticular exercises targeting the upper limbs or lower limbs in alternation and sheathing. At the beginning: 8 exercises per session and 8 repetitions, 1 time per week. Objective will be to increase the number of repetitions and then integrate other exercises to reach 10 exercises with 12 repetitions, 2 times per week. - Stretching and balance: learning to stretch the muscle groups worked and then working on proprioception (bipodal, monopodal station, then double task). - Quiet time: relaxation through breathing 5 min.
219160943|NCT03103321|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
219160944|NCT03103321|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
219160945|NCT03103321|OTHER|Best Practice|Undergo usual care
219160946|NCT03103321|OTHER|Quality-of-Life Assessment|Ancillary studies
219160947|NCT03103321|OTHER|Questionnaire Administration|Ancillary studies
219160948|NCT03103321|OTHER|Survey Administration|Ancillary studies
219160949|NCT03103321|OTHER|Laboratory Biomarker Analysis|Correlative studies
219160950|NCT05784935|DEVICE|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
219160951|NCT04247542|DRUG|Ibezapolstat|Investigational antibacterial agent
219160952|NCT04247542|DRUG|Vancomycin|Active comparator
219160953|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
219160954|NCT04517357|DRUG|Fluzoparib|Fluzoparib monotherapy
219160955|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
219734309|NCT00290758|OTHER|laboratory biomarker analysis|Correlative studies
219734310|NCT03675555|DRUG|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
219734311|NCT03675555|DRUG|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
219734312|NCT03675555|DRUG|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
219734313|NCT06190015|BIOLOGICAL|Advanced platelet rich fibrin (APRF) clots|15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
219734314|NCT06190015|DEVICE|Enamel matrix derivative (EMD) group|After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
219160956|NCT06799130|OTHER|instrument-assisted soft tissue mobilization|instrument-assisted soft tissue mobilization
219734315|NCT00003812|BIOLOGICAL|filgrastim|
219160957|NCT06799130|OTHER|Muscle energy technique|Muscle energy technique
219160958|NCT04153162|DEVICE|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
219160959|NCT05514002|BIOLOGICAL|Fluzone Quadrivalent|Intramuscular
219160960|NCT05514002|BIOLOGICAL|Flublok Quadrivalent|Intramuscular
219160961|NCT06781073|DRUG|Nimotuzumab|Nimotuzumab in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
219160962|NCT06781073|DRUG|Paclitaxel|175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
219160963|NCT06781073|DRUG|Cisplatin|50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
219160964|NCT06781073|DRUG|Placebo|Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
219160965|NCT06781944|DRUG|Cyclophosphamide (CTX)|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min"
219160966|NCT06781944|DRUG|Glucocorticoids|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days."
219160967|NCT06779760|PROCEDURE|parathyroidectomy|"The FLUOBEAM® LX apparatus consists of a camera with a built-in light emitter (750-800 nm) and detector (800-830 nm) connected to a processor with an indication-oriented software (Fluosoft®). The processor captures the emitted light, allowing display of PTG images in real time. The camera is placed in a sterile sheath and is held perpendicularly at 8 cm from the target tissue with operating lights, all background lights, and any ambient light being extinguished. The reported depth of tissue penetration of near-infrared light is limited to a maximum of 3 mm only with no observed differences between superior and inferior PTGs \[10\]. This highlights the importance of a major surgical technical point reaching the correct plane of dissection namely, the pre-vertebral fascia to maximize the chances of eliciting an adequate signal from parathyroid tissue. The correct application of the technology has demonstrated a success rate of signal elicitation of 90%-100% \[11\]. The ability of near-infr"
219160968|NCT06779786|OTHER|Group 1 (Aromatherapy Groups):|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of eucalyptus sttriodora (Group 1) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% eucalyptus sttriodora (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
219160969|NCT06779786|OTHER|Group 2 (Aromatherapy Groups):|Group 2(Aromatherapy Groups): Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of medicanal lavandula (Group 2) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% medicanal lavandula (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
219160970|NCT06779786|OTHER|Group 3 (Placebo Control Group)|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of sesame oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the earlobe from top to bottom with the thumb and index finger for four minutes, and again apply 2 ml of sesame oil into the palm. The group was given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands together with the drops.
219734316|NCT00003812|DRUG|carboplatin|
219734317|NCT00003812|DRUG|etoposide|
219734318|NCT00003812|DRUG|paclitaxel|
219734319|NCT00003812|DRUG|topotecan hydrochloride|
219734320|NCT00003812|RADIATION|radiation therapy|
219734321|NCT05573360|OTHER|NGF5-A test formulation|One drop of investigational product instilled on the eye
219734322|NCT05573360|OTHER|NGF4-B test formulation|One drop of investigational product instilled on the eye
219734323|NCT05573360|OTHER|NGF6-B test formulation|One drop of investigational product instilled on the eye
219734324|NCT05573360|OTHER|NGF6-E test formulation|One drop of investigational product instilled on the eye
219734325|NCT05573360|OTHER|Systane eye drop|One drop of commercial product instilled on the eye
219734326|NCT02681432|DRUG|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
219734327|NCT02681432|PROCEDURE|No HIPEC|Cytoreductive surgery without HIPEC
219734328|NCT04914000|BEHAVIORAL|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
219160971|NCT06779916|DIAGNOSTIC_TEST|Blood test|"16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit.~At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken."
219160972|NCT06779916|DIAGNOSTIC_TEST|Urine test|Urine samples will be taken at the inclusion visit and at each follow-up visit.
219160973|NCT04998123|DEVICE|SeizureStop Device|Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
219160974|NCT04118452|BEHAVIORAL|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR (Electronic Medical Record) by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
219160975|NCT06803693|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
219160976|NCT06803693|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
219160977|NCT06803693|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219160978|NCT06803693|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219160979|NCT06803693|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
219160980|NCT06803693|DRUG|Zanubrutinib|Zanubrutinib PO will be administered as per the schedule specified in the respective arm.
219160981|NCT06803693|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
219160982|NCT06803693|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
219160983|NCT06803368|BIOLOGICAL|baseline anti-HBs titer|Patients with baseline anti-HBs titer\<100 mIU/ml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.
219160984|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 single dose as oral suspension.
219160985|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 multiple doses daily as oral suspension.
219160986|NCT06368440|DRUG|Placebo|Participants will receive matching doses of placebo as oral suspension.
219160987|NCT04077567|DRUG|TS-152|30mg,80mg
219160988|NCT05330130|DRUG|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
219160989|NCT05330130|DRUG|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
219734329|NCT03720275|GENETIC|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
219734330|NCT04040673|PROCEDURE|thyroid lobectomy|routine surgical removal of thyroid for biopsy
219734331|NCT04040673|DEVICE|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
219734332|NCT01429623|DRUG|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
219160990|NCT05778656|BEHAVIORAL|Cardiovascular Risk Prevention with a Mediterranean Dietary Pattern Reduced in Saturated Fat|Eight-week behavioral intervention consisting of a Mediterranean dietary pattern with elimination of red and processed meat
219734333|NCT01429623|DRUG|Placebo|Placebo comparator
219734334|NCT03831555|BEHAVIORAL|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
219734335|NCT05714228|PROCEDURE|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
219734336|NCT05714228|PROCEDURE|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
219734337|NCT02217553|DRUG|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
219734338|NCT00004931|DRUG|leucovorin calcium|Given IV
219734339|NCT00004931|DRUG|fluorouracil|Given IV
219160991|NCT06739824|DIAGNOSTIC_TEST|Conventional Treatment(CI)|Patients receive a corticosteroid injection followed by conventional treatment, such as standard physical therapy exercises focused on range of motion and strengthening, without the specific manual techniques of the Spencer method.
219160992|NCT06739824|COMBINATION_PRODUCT|Spencer Technique (CI)|Patients receive a corticosteroid injection followed by the Spencer technique, which involves a series of specific manual mobilization maneuvers aimed at improving shoulder mobility and reducing pain.
219160993|NCT06102460|DIETARY_SUPPLEMENT|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
219160994|NCT06102460|DIETARY_SUPPLEMENT|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
219160995|NCT06102460|DIETARY_SUPPLEMENT|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
219160996|NCT06102460|DIETARY_SUPPLEMENT|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
219160997|NCT05937425|OTHER|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
219160998|NCT05097599|DRUG|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
219160999|NCT05097599|DRUG|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
219161000|NCT05097599|DRUG|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
219161001|NCT05097599|DRUG|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
219161002|NCT05097599|DRUG|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
219161003|NCT05097599|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
219734340|NCT00004931|DRUG|oxaliplatin|Given IV
219161004|NCT05097599|DRUG|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
219734341|NCT00004931|OTHER|laboratory biomarker analysis|Correlative studies
219734342|NCT03556280|DEVICE|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
219734343|NCT03556280|DEVICE|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
219734344|NCT01169909|DRUG|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
219734345|NCT04189588|DRUG|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
219734346|NCT04189588|DRUG|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
219734347|NCT04189588|DRUG|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
219734348|NCT02256800|GENETIC|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
219161005|NCT05998278|PROCEDURE|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction\_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
219235286|NCT03403153|BEHAVIORAL|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
219235287|NCT01942772|DEVICE|Ankle-Foot Orthosis|
219235288|NCT04527965|OTHER|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
219161006|NCT06480981|DRUG|Noribogaine|Noribogaine capsules
219161007|NCT04123379|DRUG|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
219161008|NCT04123379|DRUG|BMS-813160|300mg oral twice a day for 28 days
219161009|NCT04123379|DRUG|BMS-986253|2400mg once by injection
219161010|NCT06436157|OTHER|Enhanced education|"In addition to the education conducted as part of usual care, the nurse will: 1) provide basic education on GCT; and 2) if the patient is eligible and agreeable to GCT, place a referral to GCT (if not already ordered).~Patients will also be provided with written materials reinforcing the key messages of GCT education, designed to be understandable to individuals without a medical background. Nurses will also conduct a follow-up nudge by sending an in basket message via electronic medical record to ensure that the referrals are processed by the referral coordinators."
219161011|NCT06436157|OTHER|Usual care education|"A brief introduction to GCT will be provided in accordance with the information covered in the chemo education binder, which is the current standard of care at Enloe Regional Cancer Center. As per the usual care, referrals for genetic testing will be clinician-initiated without the proactive involvement of the RN."
219161012|NCT06170580|DIAGNOSTIC_TEST|Conventional duplex|Conventional carotid duplex measurement
219161013|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
219161014|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
219161015|NCT06799806|DEVICE|virtual reality device|20 minutes session with virtual reality device
219161016|NCT05288283|DRUG|GWP42003-P|oral solution
219235289|NCT04527965|OTHER|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
219235290|NCT04527965|OTHER|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
219235291|NCT02939742|DRUG|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
219161017|NCT05288283|DRUG|Placebo|oral solution
219161018|NCT05368662|OTHER|Quality of life and sleep questionnaire|Evaluation of quality of life and quality of sleep by questionnaires
219161019|NCT05002647|OTHER|NO intervention|There is no intervention
219161020|NCT04709380|OTHER|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
219161021|NCT04709380|DRUG|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
219161022|NCT03511118|DRUG|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161023|NCT03511118|DRUG|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219235292|NCT02939742|DRUG|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
219161024|NCT03511118|DRUG|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161025|NCT03511118|DRUG|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161026|NCT03511118|DRUG|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161027|NCT03511118|DRUG|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219235293|NCT03946631|DIAGNOSTIC_TEST|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
219734349|NCT02256800|GENETIC|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
219734350|NCT02256800|GENETIC|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
219734351|NCT02256800|GENETIC|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
219734352|NCT02256800|DRUG|bevacizumab (Avastin)|bevacizumab as target therapy
219734353|NCT02256800|DRUG|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
219161028|NCT03511118|DRUG|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161029|NCT03511118|DRUG|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161030|NCT03511118|DRUG|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161031|NCT03511118|DRUG|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161032|NCT03511118|DRUG|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161033|NCT03511118|DRUG|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161034|NCT03511118|DRUG|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161035|NCT03511118|DRUG|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161036|NCT03511118|DRUG|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161037|NCT03511118|DRUG|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161038|NCT03511118|DRUG|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161039|NCT03511118|DRUG|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161040|NCT03511118|DRUG|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161041|NCT03511118|DRUG|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219734354|NCT02256800|DRUG|Leucovorin|combined with 5-FU
219161042|NCT03511118|DRUG|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161043|NCT03511118|DRUG|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161044|NCT03511118|DRUG|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161045|NCT03511118|DRUG|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161046|NCT03511118|DRUG|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161047|NCT03511118|DRUG|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161048|NCT03511118|DRUG|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219734355|NCT02256800|DRUG|5-FU|combined with irinotecan
219734356|NCT00793611|BEHAVIORAL|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
219734357|NCT00793611|OTHER|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
219734358|NCT03944005|PROCEDURE|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
219161049|NCT03511118|DRUG|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161050|NCT03511118|DRUG|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161051|NCT03511118|DRUG|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161052|NCT03511118|DRUG|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161053|NCT03511118|DRUG|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219734359|NCT03944005|PROCEDURE|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
219734360|NCT02597361|DRUG|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
219734361|NCT02597361|DRUG|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
219734362|NCT06291961|GENETIC|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
219734363|NCT02334254|DRUG|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
219734364|NCT02334254|DRUG|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
219734365|NCT00002101|DRUG|Ethambutol hydrochloride|
219734366|NCT00002101|DRUG|Clarithromycin|
219734367|NCT00002101|DRUG|Rifabutin|
219734368|NCT05616780|OTHER|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
219734369|NCT00885898|PROCEDURE|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
219734370|NCT00885898|PROCEDURE|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
219734371|NCT02526316|BIOLOGICAL|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16\_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
219734372|NCT02526316|BIOLOGICAL|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16\_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
219734373|NCT04431778|DRUG|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
219161054|NCT03511118|DRUG|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161055|NCT03511118|DRUG|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161056|NCT03511118|DRUG|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219734374|NCT04431778|DRUG|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
219161057|NCT03511118|DRUG|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161058|NCT03511118|DRUG|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161059|NCT03511118|DRUG|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
219161060|NCT03388775|OTHER|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
219161061|NCT05086744|DRUG|Iptacopan|Iptacopan 200 mg BID given orally (capsule)
219161062|NCT05227144|DRUG|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
219161664|NCT06763211|PROCEDURE|Chlorhexidine Hair Bath|Intervention group 1 will have a hair bath with 5 ml of chlorhexidine gluconate solution 2 times consecutively. Intervention group 2 will first be given a hair bath using the patient's soap or shampoo. Afterwards, the hair will be bathed 2 times consecutively with 5 ml chlorhexidine gluconate solution. Hair bath will be given to the control group using the patient's own soap or shampoo. Surgical site infection follow-up form, laboratory findings form, vital signs form, culture follow-up form will be filled out before and after banyadon. Additionally, cultures will be taken from the surgical area with hair immediately after bathing, on the 2nd post-operative day, and on the day the stitches are removed.
219161063|NCT06787820|BEHAVIORAL|Music intervention|The musical intervention conducted at the senior home focused on the development of rhythmic and vocal skills, as well as the creation of educational experiences that promoted the acquisition of these competencies. To achieve this, both conventional percussion instruments, such as claves, tambourines, woodblocks, and triangles, and unconventional elements, such as buckets played with drumsticks, sheets of paper, spoons, ribbons, elastic bands, and a parachute, were used to mark the rhythm during the singing sessions. The selected songs were chosen based on the musical styles mentioned by the participants during the pre-intervention interview. Furthermore, participants were given the opportunity to showcase their progress at the end of the activity, with the aim of sharing these achievements with family and friends at the home.
219161064|NCT06787157|OTHER|Prediction Model Construction|
219161065|NCT06787534|OTHER|No Interventions|
219161066|NCT06785363|OTHER|pumped technique for ilio-lumbar ligament release|Patient position: the patient lying supine or side lying Therapist position: standing on one side of patient. Hand grip: one hand placed on posterior region of iliac crest (close to attachment of ilio-lumbar ligament) while other hand stabilize the medial part of thigh. Therapist force: therapist pulling patient's thigh posteriorly.
219161067|NCT06785363|OTHER|Hot Packs|postnatal women will be treated by hot packs for 20 minutes three times per week for 8 weeks.
219161068|NCT06785987|DRUG|Continuous Lidocaine Infusion|Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
219161069|NCT06785987|DRUG|intermittent fentanyl infusion|Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
219161070|NCT06785987|DRUG|Continuous remifentanil Infusion|Maintained with sevoflurane and continuous remifentanil infusion under dosage: 3-5μg /kg/hr
219161071|NCT06790654|BEHAVIORAL|Text-message based motivational interviewing|Participants will receive weekly text messages during the pilot study period, initiated and managed by MItrained interviewers. Each text message exchange will begin with a short, MI-consistent prompt developed with input from focus groups of mothers who have previously breastfed. These prompts will address common breastfeeding barriers. Following the initial prompt, MI-trained trainers will engage with participants through text exchanges that utilize the core MI OARS skills (open-ended questions, affirmations, reflections, or summaries) to facilitate change talk.
219161072|NCT05929976|OTHER|No intervention|No intervention
219161073|NCT06163989|DRUG|TheaLoz Duo Eyedrop|TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
219161074|NCT06789848|DRUG|Ligufalimab|Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
219161075|NCT06789848|DRUG|Cadonilimab|Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
219734375|NCT01141543|DRUG|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
219734376|NCT06032975|OTHER|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
219734377|NCT02104011|DRUG|Propranolol|
219734378|NCT02985775|BIOLOGICAL|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
219734379|NCT06172049|OTHER|treatment|the actual treatment CRC patients have reveived
219734380|NCT01658735|DEVICE|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
219734381|NCT01658735|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
219734382|NCT01658735|DEVICE|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
219734383|NCT04032327|DRUG|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
219734384|NCT04032327|DRUG|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
219734385|NCT00216658|DRUG|fentanyl|
219734386|NCT03065738|OTHER|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
219734387|NCT01348906|PROCEDURE|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
219734388|NCT02998125|PROCEDURE|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
219734389|NCT01436890|DRUG|Revamilast|Tablet. Low dose, Once daily for 12 weeks
219734390|NCT01436890|DRUG|Revamilast|Medium dose, Once daily for 12 weeks
219734391|NCT01436890|DRUG|Revamilast|High dose, Once daily for 12 weeks
219161076|NCT03982082|PROCEDURE|Physical Therapy|Undergo physical therapy
219161077|NCT03982082|OTHER|Questionnaire Administration|Ancillary studies
219161078|NCT03982082|PROCEDURE|Ultrasound|Undergo ultrasound via MuscleSound technology
219161665|NCT02707120|DRUG|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
219161666|NCT02707120|DRUG|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
219161667|NCT05587036|DRUG|Rifaximin|Rifaximin oral tablet, 550 mg, twice daily, two-weeks
219734392|NCT01436890|DRUG|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
219734393|NCT01694186|DRUG|FAI insert|
219734394|NCT01694186|DRUG|Sham injection|
219734395|NCT05571163|DRUG|AMG 510|Tablets
219734396|NCT00124033|PROCEDURE|Transcystic Stenting (Facilitated ERCP)|
219734397|NCT02307435|BIOLOGICAL|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
219734398|NCT04365881|OTHER|Cross-sectional observational study|Survey
219734399|NCT01431573|BEHAVIORAL|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
219734400|NCT01431573|DEVICE|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
219161079|NCT06792058|DEVICE|"Mechanomiograph: The gold standard of quantitative monitoring"|"The gold standard of quantitative monitoring is mechanomyography (MMG), which measures the force of contraction of the adductor pollicis muscle following ulnar nerve stimulation. MMG responses are accurate and reproducible. However, the complex and bulky devices are only suitable for research use, are not suitable for clinical use and are not commercially available."
219161080|NCT06792058|DEVICE|Electromiograph|Another type of monitor is the electromyograph, which can be seen as an alternative to mechanomyography because of its accuracy. This technique measures muscle activity as a summation of the action potentials of muscle fibres. This activity is proportional to the strength of the muscle contraction. The most commonly innervated nerve is also the ulnar nerve, which innervates the abductor digiti minimi and the first dorsalis interosseus muscles. During the measurements, electrical signals from these muscles are detected. EMG has several advantages over other monitoring techniques. It does not require immobilisation of the hand, thumb immobility is not a problem, no preload is required, and hypothermia does not affect the hand as much as other neuromuscular monitors. The TetraGraph (Senzime AB, Sweden) is a portable EMG-based neuromuscular minitor for which the manufacturers received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
219161081|NCT06789458|PROCEDURE|Professional mechanical plaque control|"thisThe first step in therapy is aimed at guiding behavior change by motivating the patient to undertake successful removal of supragingival dental biofilm and risk factor control and may include the following interventions:~* Interventions to improve the effectiveness of oral hygiene \[motivation, instructions (oral hygiene instructions, OHI)~* Professional mechanical plaque removal (PMPR), which includes the professional interventions aimed at removing supragingival plaque and calculus, as well as possible plaque-retentive factors that impair oral hygiene practices.~* Adjustment of faulty restoration and polishing~* The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques."
219161082|NCT06100237|DRUG|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
219161083|NCT06100237|DRUG|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
219161084|NCT06100237|DRUG|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
219161085|NCT06783049|BEHAVIORAL|Cerebrovascular Disease Secondary Prevention Smart Management System|The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.
219161668|NCT05587036|DIETARY_SUPPLEMENT|Placebo|Placebo oral tablet, twice daily, two-weeks
219734401|NCT01431573|DRUG|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
219734402|NCT00926705|DRUG|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
219734403|NCT00926705|DRUG|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
219734404|NCT02350998|DRUG|OTO-201|
219734405|NCT01259024|DEVICE|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
219734406|NCT04693715|DRUG|RNS60|RNS60 injection solution
219734407|NCT04693715|DRUG|Placebo|Placebo injection solution
219734408|NCT02631031|DRUG|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
219734409|NCT06497829|DIETARY_SUPPLEMENT|geranylgeraniol|GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
219734410|NCT03403127|DIAGNOSTIC_TEST|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
219161086|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 10 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
219161087|NCT05254002|DRUG|Empagliflozin|oral administration, once daily
219161088|NCT05254002|DRUG|Empagliflozin Placebo|Matching placebo to empagliflozin oral administration, once daily
219161089|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 20 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
219161090|NCT05254002|DRUG|Finerenone Placebo|Matching Placebo to Finerenone oral administration once daily
219161091|NCT04393532|DEVICE|Su2ura Approximation Device|the use of the study device during a laparoscopic surgery
219161092|NCT04393532|PROCEDURE|Laparoscopic hernia repair surgery|repairing primary umbilical hernia in a laparoscopic procedure using the study device.
219161093|NCT01704079|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
219161094|NCT01704079|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
219161095|NCT05422924|BEHAVIORAL|Web-based platform. (My Viva Plan)|Participants will use a web-based platform (i.e. My Viva Plan®) to improve physical function, nutrition and mindfulness.
219161096|NCT04300231|DRUG|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
219161097|NCT04300231|DRUG|Liposomal bupivacaine|20 ml
219161098|NCT04300231|DRUG|bupivacaine 0.125%|40 mL
219161099|NCT04300231|DRUG|bupivacaine 0.5%|60 mL
219161100|NCT04300231|DRUG|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
219161101|NCT04300231|DRUG|injectable saline|40 mL
219161102|NCT04763356|OTHER|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
219161103|NCT03068663|OTHER|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
219161104|NCT05273723|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: You planned to walk today in the park at 3pm."
219161105|NCT04959838|BEHAVIORAL|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
219161106|NCT04965181|BEHAVIORAL|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
219161107|NCT04965181|DRUG|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
219161108|NCT04965181|BEHAVIORAL|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
219161109|NCT04965181|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
219161110|NCT04827979|BIOLOGICAL|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant"
219161111|NCT04827979|BIOLOGICAL|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
219161669|NCT04847999|DIETARY_SUPPLEMENT|Dark chocolate|Dark chocolate
219734411|NCT06361446|DRUG|Zonisamide 50 MG|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
219734412|NCT06361446|DRUG|Propranolol|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
219734413|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
219734414|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
219734415|NCT01657500|OTHER|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
219734416|NCT01657500|OTHER|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
219734417|NCT00631241|PROCEDURE|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
219734418|NCT00631241|PROCEDURE|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
219734419|NCT04817800|DRUG|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
219734420|NCT05792345|PROCEDURE|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
219734421|NCT05792345|PROCEDURE|Control|Infiltration by surgeon
219161112|NCT04827979|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
219161113|NCT06775249|BEHAVIORAL|ICE Mindfulness Program|The ICE Mindfulness Program is a tailored, self-paced intervention designed for crew members in isolated and confined environments. It includes a three-week pre-departure online course with videos, audio, and cognitive exercises promoting mindfulness, flexibility, and creativity, requiring 15-30 minutes daily. Delivered via email, it blends elements from Mindfulness-Based Stress Reduction and the Langerian approach. Participants receive new content daily, focusing on stress reduction and adaptation in extreme settings. Pre-departure, the PI leads a 1.5-hour interactive session with group meditation. During the mission, bi-weekly booster sessions are conducted by the ESA MD, supplemented by ongoing access to training materials. Exercises include meditations, mindful discussions, and cognitive tasks, with flexibility to fit participant schedules. The program will be available in Italian, French, and English.
219734422|NCT02669641|DIETARY_SUPPLEMENT|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
219734423|NCT03015779|OTHER|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
219161114|NCT06798311|BEHAVIORAL|SUPPORT workbook|"The SUPPORT workbook contains a template for how pelvic floor physical therapy is delivered in the typical in-person setting with a combination of education, bladder re-training exercises, pelvic floor stretching and core strengthening. To aid in the demonstration of physical therapy exercises, the workbook includes QR-coded links to videos of a physical therapist performing the exercises in an ideal form. The videos include audio instruction to ensure that patients can learn the concepts in either visual, auditory or written form. The cognitive behavioral therapy (CBT) portion of the workbook is adapted from the standardized CBT protocol and includes short introductions and exercises pertaining to cognitive flexibility, behavioral activation and social support. The total time commitment for the program is 2-hours per week.~Patients also will be given access to a custom programmed GPT trained on the SUPPORT workbook and given instructions on empathetic communication techniques."
219161115|NCT04500301|OTHER|Preemptive Pharmacogenomic Testing|The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
219161116|NCT06772259|DEVICE|Palm Stimulator|The apparatus is 1.6 cm in diameter and 4 cm long. It has a cylindrical, non-slippery and easy-to-grasp structure for maximum contact with the palm
219161117|NCT06772259|OTHER|Cartoon|The cartoon was projected on a blank wall in the intervention room with a projection device. The cartoon was played in preparation for the PIK procedure and children were allowed to watch it until the procedure was completed.
219161118|NCT06754839|DEVICE|Percutaneous left ventricular assist device(Ventiflow LP)|The PCI will be completed with the support of percutaneous left ventricular assist device(Ventiflow LP).
219161119|NCT06754839|DEVICE|VA-ECMO|The PCI will be completed with the support of Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
219161670|NCT06358339|OTHER|TEEM|The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
219734424|NCT03728231|OTHER|Complete blood count|taking blood sample from venous blood
219734425|NCT02998320|DRUG|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
219734426|NCT05900349|OTHER|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
219734427|NCT05900349|OTHER|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
219734428|NCT00063362|DRUG|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
219734429|NCT00063362|DRUG|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
219734430|NCT00063362|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
219161120|NCT05056545|BEHAVIORAL|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
219161121|NCT04164472|BEHAVIORAL|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
219734431|NCT00063362|DRUG|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
219734432|NCT00470808|DRUG|POMx|
219734433|NCT03477591|OTHER|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
219734434|NCT03477591|OTHER|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
219734435|NCT03477591|OTHER|Sham information|Educational information not specific to PSA testing or cancer screening
219734436|NCT04993768|DRUG|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219734437|NCT04993768|DRUG|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219161122|NCT06763133|OTHER|Cold Water Spray Application|Cold water spray application after endonasal endoscopic surgery.
219161123|NCT06763133|OTHER|Clinical routine practice|The process of giving 2 cc of water to patients with a syringe as a clinical routine practice.
219161124|NCT06444529|DRUG|Apraclonidine Hydrochloride Ophthalmic Solution|Investigational ophthalmic solution applied topically to the eye with a dropper bottle
219734438|NCT04993768|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219734439|NCT04993768|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
219734440|NCT03748472|PROCEDURE|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
219734441|NCT03748472|PROCEDURE|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
219734442|NCT04645030|DIAGNOSTIC_TEST|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.
219734443|NCT04645030|DIAGNOSTIC_TEST|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
219734444|NCT00968045|DRUG|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
219734445|NCT04179656|DRUG|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
219734446|NCT00808756|DIETARY_SUPPLEMENT|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
219161125|NCT06444529|DRUG|Vehicle|Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
219161126|NCT04431050|DIAGNOSTIC_TEST|Point of care testing of respiratory viruses.|Single use point of care diagnostic device.
219734447|NCT00808756|OTHER|Standard infant formula.|Standard infant formula.
219734448|NCT00619242|DRUG|sorafenib|2 tablets with water by mouth twice a day for two weeks.
219734449|NCT03102528|OTHER|No intervention|No intervention
219734450|NCT01250327|DEVICE|Melody|insertion of a pulmonic valved stent
219734451|NCT01250327|DEVICE|bare stent|insertion of a bare metal stent
219734452|NCT01250327|PROCEDURE|Surgery|conventional surgery methode
219734453|NCT05877365|DIETARY_SUPPLEMENT|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
219734454|NCT06223009|DRUG|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
219734455|NCT06223009|OTHER|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
219734456|NCT02067156|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
219734457|NCT02621853|DEVICE|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
219734458|NCT04797481|PROCEDURE|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
219734459|NCT04797481|PROCEDURE|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
219235294|NCT02206906|BEHAVIORAL|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
219734460|NCT03133780|DRUG|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
219161127|NCT03215069|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
219161128|NCT03215069|DRUG|Placebo oral capsule|Placebo PO daily
219161129|NCT06793553|DRUG|Induction therapy|2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
219161130|NCT06791980|OTHER|CM-TCM|To assess the long-term effects of integrated case management model involving traditional Chinese medicine (CM-TCM) model. The persons participating will be invited to enroll in this stage, and they will be assigned to receive either the usual care or a usual care plus integrated 3-month CM-TCM
219161131|NCT05882253|OTHER|Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)|An advanced imaging software that supports improved prostate cancer detection and diagnosis
219161132|NCT02991807|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
219235295|NCT00185692|PROCEDURE|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
219235296|NCT00185692|DRUG|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
219235297|NCT00185692|DRUG|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
219734461|NCT03133780|DRUG|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
219734462|NCT04991597|OTHER|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
219734463|NCT04991597|OTHER|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
219734464|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
219734465|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
219734466|NCT06396403|OTHER|Collection of venous blood samples|collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
219734467|NCT04034056|DRUG|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
219734468|NCT06246721|BEHAVIORAL|Self-management of vaginal pessary|Self-management of vaginal pessary
219734469|NCT06354764|OTHER|no intervention|no intervention
219734470|NCT04401475|BIOLOGICAL|SOC plus 15mg/kg EB05 IV|Standard of care plus single IV infusion of 15mg/kg of EB05.
219734471|NCT04401475|OTHER|SOC plus Placebo IV|Standard of care plus a single IV infusion of placebo.
219734472|NCT05144997|DRUG|Lorlatinib|ALK-positive NSCL treatment
219734473|NCT00358280|DRUG|Ropivacaine|
219734474|NCT00358280|DRUG|Bupivacaine|
219734475|NCT03422471|OTHER|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
219734476|NCT04506710|BEHAVIORAL|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
219734477|NCT00449007|DRUG|fluoxetine|6 months
219734478|NCT00449007|DRUG|bupropion|6 months
219734479|NCT05683275|OTHER|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
219734480|NCT05683275|OTHER|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
219734481|NCT05683275|OTHER|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
219734482|NCT03073304|DRUG|Crystalloid based prime solution|Crystalloid based prime solution
219734483|NCT03073304|DRUG|Erythrocyte based prime solution|Erythrocyte based prime solution
219734484|NCT02221297|DIETARY_SUPPLEMENT|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
219734485|NCT03941262|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
219734486|NCT03941262|DRUG|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
219734487|NCT03941262|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
219734488|NCT00940511|BEHAVIORAL|Coordinated care|
219161133|NCT02991807|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
219161134|NCT06430658|COMBINATION_PRODUCT|Tislelizumab (BGB-A317) with chemoradiotherapy|Different sequences and methods of treatment to convert surgery
219161135|NCT06834022|DEVICE|Transcranial direct current stimulation|tDCS will be used according to instructions for use in migraine headache (supraorbital and M1 stimulation), 1 mA, 20 min, 10 sessions
219161136|NCT06834022|PROCEDURE|Acupuncture|Acupuncture will be semistandardized, (every patient is stimulated over Li4, St36, Li3 + patient specific acu-points), 10 sessions
219161137|NCT05041556|OTHER|Case-control study of clinical outcomes|A case-control questionnaire will be administered at the home of cases and controls
219734489|NCT00930787|DEVICE|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
219734490|NCT00930787|DEVICE|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
219734491|NCT02993432|DEVICE|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
219161138|NCT05041556|OTHER|Case-control study of mortality outcome|A case-control questionnaire will be administered at the home of cases and controls
219161671|NCT03217006|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
219161672|NCT03217006|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
219161673|NCT02879448|DEVICE|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
219161674|NCT02879448|DEVICE|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
219161675|NCT04999202|DRUG|BAY2416964|Oral, twice or three times daily
219161676|NCT04999202|DRUG|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
219161677|NCT04999202|DRUG|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
219161678|NCT05952076|DIETARY_SUPPLEMENT|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
219161679|NCT05952076|DIETARY_SUPPLEMENT|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
219161680|NCT02915575|OTHER|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (\<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
219161681|NCT02915575|OTHER|Usual Care|Participants will be discharged as per usual ward discharge protocols.
219161682|NCT00006786|BIOLOGICAL|bevacizumab|
219161683|NCT00006786|DRUG|fluorouracil|
219161684|NCT00006786|DRUG|irinotecan hydrochloride|
219161685|NCT00006786|DRUG|leucovorin calcium|
219161686|NCT05128968|PROCEDURE|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
219161687|NCT04164784|BEHAVIORAL|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
219161139|NCT04605913|COMBINATION_PRODUCT|Modified GCN+TTF treatment|The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
219161140|NCT06490809|OTHER|Physiotherapy|Parkinson\&#39;s upper extremity rehabilitation generally consists of stretching, strengthening, coordination, recreational activities and skill activities. Exercises will be prescribed by the clinical specialist physician and physiotherapist.
219161141|NCT06844474|DRUG|SHR-1826；Adebrelimab；SHR-8068；Bevacizumab|"Drug:~Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks.~Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks."
219161142|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
219161143|NCT06818019|DRUG|Stopping dupilumab|Stopping dupilumab with no dose-reducing or interval of time-increasing strategy
219161144|NCT06846944|OTHER|Breathing/relaxation intervention|"Ladybug TECHNIQUE is a breathing/relaxation intervention performed in children aged 5 to 10 years and consists of telling the story of a ladybug performing 4 moves and visualizing and performing breathing techniques independently. Afterwards, a drawing is invited.~SUNRISE TECHNIQUE is a breathing/relaxation intervention performed in children aged 10 to 15 years and consists of having the child imagine a favorite place. Then they are invited to reflect on the experience either verbally or through writing or drawing."
219161145|NCT06846580|PROCEDURE|brachiobasilic AVF|perform 2 stage brachiobasilic AVF in hemodialysis patients with central venous stenosis
219161146|NCT00560599|DRUG|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
219161147|NCT00560599|BEHAVIORAL|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
219161148|NCT00560599|DRUG|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
219161149|NCT04975087|OTHER|Patients group|Patients will complete the mentioned questionnaires.
219161150|NCT01771484|DEVICE|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
219161151|NCT02845466|BIOLOGICAL|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
219161152|NCT02845466|DEVICE|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
219161153|NCT02845466|DEVICE|Placebo Dressing|Inactive wound dressing.
219161154|NCT06613906|DEVICE|Healsea Children nasal spray|dosage: 1 puff in each nostril twice daily during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
219161155|NCT03755141|DRUG|Herzuma|Herzuma + Treatment of Physician's Choice
219161156|NCT03399292|DRUG|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
219161157|NCT05842057|BIOLOGICAL|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
219161158|NCT05842057|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
219161688|NCT05363449|DRUG|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
219161689|NCT05363449|DRUG|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
219235298|NCT00185692|DRUG|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
219235299|NCT00185692|DRUG|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
219734492|NCT02993432|DRUG|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
219734493|NCT00002135|DRUG|Ganciclovir|
219734494|NCT06148285|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
219235300|NCT00185692|DRUG|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
219734495|NCT01880775|DRUG|Prilocaine|experimental
219734496|NCT01880775|DRUG|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
219734497|NCT04367454|OTHER|Use of Personal Protective Equipment|As described in the arm descriptions
219734498|NCT00259701|DEVICE|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
219734499|NCT02924402|BIOLOGICAL|XmAb13676|Biological
219161159|NCT03812874|DRUG|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
219161160|NCT03812874|DRUG|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
219161161|NCT01697930|DRUG|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of \[18F\] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the \[18F\] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
219161162|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Neutral-Relaxing)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).
219161163|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Drug)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.
219161164|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Non-Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.
219161165|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
219161166|NCT03206372|OTHER|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
219161167|NCT03206372|OTHER|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
219161168|NCT05306509|BEHAVIORAL|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
219161169|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
219161170|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
219161171|NCT01615393|DRUG|ribavirin [Copegus]|Single oral dose of 400 mg tablets
219161172|NCT01615393|DRUG|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
219161173|NCT03424499|PROCEDURE|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
219235301|NCT00185692|DRUG|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
219161174|NCT03424499|PROCEDURE|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
219161175|NCT03424499|DIAGNOSTIC_TEST|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
219161176|NCT02543125|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
219161177|NCT02543125|DEVICE|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
219161178|NCT04687293|DEVICE|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
219161179|NCT02058108|DRUG|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
219161180|NCT02058108|DRUG|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
219161181|NCT01154192|DRUG|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
219161182|NCT01154192|DRUG|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
219161183|NCT03746613|DEVICE|HEARO|Robotic system for otological procedures
219161184|NCT02380105|BEHAVIORAL|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
219161185|NCT02380105|DEVICE|Interocclusal Appliances|Patients were treated using interocclusal appliances
219161186|NCT00054210|DRUG|carboplatin|
219161187|NCT00054210|DRUG|paclitaxel|
219161188|NCT00054210|DRUG|paclitaxel poliglumex|
219161189|NCT04759833|DRUG|Prucalopride|Prucalopride oral solution or oral tablets.
219161190|NCT04759833|OTHER|Placebo|Prucalopride-matching placebo oral solution or oral tablets.
219161191|NCT06221137|PROCEDURE|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
219161192|NCT06221137|PROCEDURE|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
219235302|NCT00185692|DRUG|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
219235303|NCT00185692|DRUG|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
219161193|NCT05683418|DRUG|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
219161194|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
219161195|NCT02191085|PROCEDURE|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
219161196|NCT02686528|OTHER|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
219161197|NCT02686528|OTHER|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
219161198|NCT03684980|DRUG|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
219235304|NCT03996577|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
219235305|NCT03996577|DRUG|placebo|the control group will be given the same volume of saline.
219235306|NCT04489914|DEVICE|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
219235307|NCT04657718|DEVICE|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
219161199|NCT03684980|DRUG|Rituximab|Patients will be treated with rituximab 500 mg/m\^2.
219235308|NCT04127747|DRUG|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
219235309|NCT04127747|DRUG|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
219235310|NCT03214614|DRUG|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
219235311|NCT03214614|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
219235312|NCT03214614|DRUG|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
219235313|NCT03214614|DRUG|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
219734500|NCT03897010|DEVICE|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
219734501|NCT03246594|DEVICE|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
219734502|NCT03246594|DEVICE|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
219734503|NCT04957082|BEHAVIORAL|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
219734504|NCT04957082|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
219734505|NCT02719366|DEVICE|comfilcon A Extended Range test lens|contact lenses
219734506|NCT02719366|DEVICE|comfilcon A control lens|contact lenses
219734507|NCT02241915|PROCEDURE|Open Colorectal Surgery|
219734508|NCT02241915|PROCEDURE|Laparoscopic Surgery|
219734509|NCT04130425|DEVICE|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
219734510|NCT04130425|DEVICE|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
219161200|NCT03684980|DRUG|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
219161201|NCT03684980|DRUG|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
219161202|NCT05903495|DEVICE|Deep Brain Stimulation|randomized, sham-controlled, partial crossover study investigating DBS, targeting the nucleus accumbens (NAc) and ventral internal capsule (VC), for participants with severe, treatment refractory OUD.
219161203|NCT01875744|DRUG|Polyethylene glycol 4000|
219161204|NCT03953001|DEVICE|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
219161205|NCT03953001|DRUG|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
219161206|NCT03953001|DRUG|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
219161207|NCT06517459|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
219161208|NCT00818246|DEVICE|Sham light|
219161209|NCT00818246|DEVICE|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
219161210|NCT05293808|DRUG|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
219161211|NCT05293808|DRUG|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
219161212|NCT05293808|DRUG|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
219161213|NCT03083067|DRUG|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
219161214|NCT03083067|DRUG|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
219161215|NCT01121991|DRUG|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
219235314|NCT00405834|DEVICE|Envision® Patient Support System|
219161216|NCT01104675|DRUG|ENMD-2076|275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
219161217|NCT01409824|OTHER|CDSS|Clinical Decision Support System
219161218|NCT00692042|DRUG|AZD1704|One dose, by mouth
219161219|NCT00409838|DRUG|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
219161220|NCT00409838|DRUG|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
219161221|NCT00409838|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
219161222|NCT00409838|DRUG|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
219235315|NCT04017598|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
219734511|NCT04130425|DEVICE|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
219734512|NCT06232031|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219734513|NCT04739345|DRUG|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
219734514|NCT03159442|DRUG|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
219734515|NCT03159442|DRUG|Placebo|Powder for inhalation administered via single dose DPI
219734516|NCT01260311|DRUG|Fesoterodine|Any dose of Fesoterodine
219734517|NCT01558375|DRUG|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
219235316|NCT04017598|DIETARY_SUPPLEMENT|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
219235317|NCT04017598|DIETARY_SUPPLEMENT|Placebo of microcrystalline cellulose|placebo
219161223|NCT00409838|DRUG|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
219161224|NCT04498234|PROCEDURE|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
219161225|NCT02847715|DEVICE|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
219161226|NCT05358457|BEHAVIORAL|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
219161227|NCT01619410|BIOLOGICAL|Linezolid|Linezolid 600 mg every 12 hours for 7 days
219161228|NCT01619410|BIOLOGICAL|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
219161229|NCT00143949|DRUG|enalapril|
219161230|NCT00143949|DRUG|losartan|
219161231|NCT05957731|OTHER|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
219161232|NCT05957731|OTHER|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
219161233|NCT05957731|OTHER|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
219161234|NCT01864889|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
219235318|NCT06275256|PROCEDURE|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
219235319|NCT06275256|DEVICE|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
219161235|NCT02586090|BEHAVIORAL|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
219161236|NCT02586090|BEHAVIORAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
219161237|NCT05459233|PROCEDURE|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
219161238|NCT05459233|PROCEDURE|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
219235320|NCT03571906|BEHAVIORAL|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
219235321|NCT04448613|OTHER|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
219161239|NCT01250769|DEVICE|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
219161240|NCT01250769|DEVICE|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
219235322|NCT03442998|OTHER|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
219734518|NCT01558375|DRUG|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
219734519|NCT05823883|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
219734520|NCT05813834|PROCEDURE|Genicular Nerves Block|US guided genicular nerves block
219161241|NCT05960994|OTHER|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
219161242|NCT02011854|DEVICE|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
219161243|NCT02011854|DEVICE|Acupuncture|
219161244|NCT03220100|OTHER|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
219161245|NCT00962702|DEVICE|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
219161246|NCT04140526|DRUG|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
219161247|NCT04140526|DRUG|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
219161248|NCT04140526|DRUG|Docetaxel|Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
219161249|NCT02769819|DEVICE|Flexible fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
219161250|NCT02885636|DRUG|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
219161251|NCT02885636|OTHER|Saline placebo|Saline inhaled through a nebulizer as a single dose
219161252|NCT01571804|DRUG|Placebo|to receive two identical placebo capsules 1 hr before surgery
219161253|NCT01571804|DRUG|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
219161254|NCT01571804|DRUG|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
219161255|NCT06521944|BIOLOGICAL|RSV Vaccine|RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation
219161256|NCT06521944|OTHER|Non-exposure to RSV Vaccine|Pregnant individuals who are not exposed to the RSV vaccine
219161257|NCT06220123|DRUG|SHR-2004|Investigational product arm: SHR-2004
219161258|NCT06220123|DRUG|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
219161259|NCT06969105|OTHER|Music|Prior to randomization, all participants will pre-select their preferred music genre. If randomized to the music group, their preferred music genre will be played for a 10 minute duration.
219235323|NCT03442998|OTHER|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
219161260|NCT03891316|DIAGNOSTIC_TEST|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
219161261|NCT03895515|DRUG|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
219161262|NCT04368312|OTHER|No intervention|No intervention, just of questionnaire including validated tests
219734521|NCT04342546|DEVICE|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
219734522|NCT04898543|BIOLOGICAL|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)|M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
219734523|NCT04898543|BIOLOGICAL|N-803 (Cohort 2 part B)|N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
219734524|NCT04898543|OTHER|Apheresis collection of MNCs (part A)|Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
219734525|NCT03464448|DRUG|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
219734526|NCT03494842|DEVICE|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
219734527|NCT03494842|DEVICE|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
219161263|NCT00767559|DRUG|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
219235324|NCT02597166|DRUG|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
219235325|NCT00184743|DRUG|somatropin|
219161264|NCT00767559|DRUG|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
219161265|NCT00767559|DRUG|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
219161266|NCT01448512|BEHAVIORAL|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
219161267|NCT01448512|OTHER|Usual Care|4 time matched sessions focused on health education
219161268|NCT05744596|OTHER|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
219161269|NCT05643456|PROCEDURE|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
219161270|NCT02184806|PROCEDURE|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
219161271|NCT02184806|PROCEDURE|heterotopic graft|"1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen"
219161272|NCT02809989|DRUG|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
219161273|NCT02538341|BIOLOGICAL|Herpes Zoster (HZ) Vaccine|
219161274|NCT02538341|DRUG|Placebo|
219161275|NCT03548857|OTHER|Lung transplantation|Single or double lung transplantation in patients with COPD
219161276|NCT04806529|DRUG|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
219161277|NCT04806529|DRUG|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
219161278|NCT00550823|DEVICE|Cardiac CT 0BRILLIANT 64|Cardiac CT
219161279|NCT06235541|DRUG|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
219161280|NCT07071246|DRUG|Rituximab Injection|low dose of rituximab intravenously
219161281|NCT07077759|OTHER|Online self-compassion intervention|Participants in the intervention group will receive five consecutive weekly sessions, with each session lasting 2 hours (totaling 10 hours). Each session will include an introduction, guided exercises, group discussions and home practice.
219161282|NCT07078539|OTHER|Kaltenborn Mobilization Group|"Participants in this group will receive Kaltenborn mobilization techniques applied to the talocrural and subtalar joints. Mobilizations will be performed as Grade III passive accessory glides for 10 repetitions per joint, each sustained for 15 seconds with a 10-second rest interval~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
219161283|NCT07078539|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan mobilization with movement (MWM) techniques applied to the talocrural and subtalar joints. Mobilizations will be applied as 3 sets of 10 repetitions per joint with 1-minute rest between sets.~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
219734528|NCT04188626|BEHAVIORAL|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
219734529|NCT01609387|DIETARY_SUPPLEMENT|Fit For me|
219161284|NCT07077538|DRUG|Amino acid peritoneal dialysis solution|After breakfast daily, use a bag of amino acid (15) peritoneal dialysis solution (2L), followed by treatment with glucose peritoneal dialysis solution (lactate).
219161690|NCT03636334|BEHAVIORAL|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
219161691|NCT03069859|DRUG|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
219161692|NCT03069859|DRUG|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
219161693|NCT01046136|DRUG|guaifenesin (Mucinex)|bid 7 days
219161694|NCT01046136|DRUG|placebo|bid 7 days
219161695|NCT06450366|DRUG|Enlicitide Decanoate|Administered orally.
219161696|NCT06450366|DRUG|Ezetimibe|Administered orally.
219161697|NCT06450366|DRUG|Bempedoic Acid|Administered orally.
219161698|NCT06450366|OTHER|Placebo for Enlicitide Decanoate|Administered orally.
219161699|NCT06450366|OTHER|Placebo for Ezetimibe|Administered orally.
219734530|NCT01609387|DIETARY_SUPPLEMENT|Davitamon|
219734531|NCT06041828|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
219734532|NCT06041828|OTHER|Standard oral hygiene|Standard oral hygiene instructions
219161285|NCT07078240|OTHER|Falls risk - Artificial Intelligence Recommender (FAIR)|"FAIR is an alert system built into the hospital's electronic medical record system. It is an adaptation of a machine learning model for fall risk calculation built in another hospital in Singapore. FAIR combines multiple patient-specific variables to identify if a patient is at increased risk of falling during their inpatient stay, marking them as a 'falls risk'.~Based on the 'flag' raised, the nurse will be instructed to prioritise her falls risk assessment of the patient (If deemed 'high risk') or to do so subsequently as a lower priority once other pressing patient care issues are resolved (if deemed 'low risk').~That way, it ensures the requirements of each patient receiving a falls risk assessment as scored through mWHeFRA are still met, with FAIR allowing nurses to better prioritise their focus and attention on the patient that most needs the assessment at point of admission,"
219161286|NCT07078240|OTHER|modified Western Health Falls Risk Assessment Tool (mWHeFRA)|The mWHeFRA is the hospital's standard falls risk assessment tool. All nurses are expected to be proficient in its use to guide their risk assessment of patients
219161287|NCT07077161|DRUG|Cabozantinib|For patients using 40mg the experimental regimen consists of 60mg once daily for 2 days followed by 1 skipping day (60-60-0 mg). For patients using 20mg the experimental regimen consists of 60mg once daily for 1 day followed by 2 skipping days (60-0-0 mg).
219161288|NCT07076771|OTHER|Coronary Angiography|All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
219161289|NCT07076771|OTHER|Syntax Score|The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
219161290|NCT06894680|OTHER|Stepped care|"It is a systematic, staged approach to delivering care based on the severity of a condition and the patient's response to treatment. In this model, less intensive interventions are provided first, and only those who do not improve progress to more intensive treatments.~In clinical research, stepped-care is classified as an adaptive intervention, where treatment is adjusted based on pre-specified criteria, making it patient-centered and resource-efficient."
219161291|NCT06894680|OTHER|Treatment as usual|Clients that are considered to be depressed are offered counselling by the Nurses who are the first point of contact. Depending on the severity of symptoms the client are then referred to the medical officer at the HIV clinic for assessment and offered counselling services by the counsellors. if symptoms are severe and considered to need specialist care the medical officer will refer to a specialist(psychiatrist) outside the HIV care facility.
219161292|NCT07078851|DEVICE|Fractional Picosecond Laser Treatment|Compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval Number: H20063466) was applied to the face. After 60 minutes, it was cleaned thoroughly in preparation for treatment. The subjects lay flat on the treatment bed, and the face was disinfected twice. Treatment was performed using the Picsure Focus Lens (Cynosure, USA, Registration Certificate Number: National Medical Device Import 20153242702) with the following parameters: 6mm spot size, focus filter, 755nm wavelength, energy of 6.0J/cm², and 2Hz frequency. The endpoint response was skin flushing and mild edema. Immediately after the operation, recombinant human epidermal growth factor (Kanghesu, 20000IU/4ml/vial, Shanghai Haohai Biological Technology Co., Ltd.) was applied externally, followed by wet compresses with saline gauze combined with cold spray for 30 minutes. The subjects were required to apply recombinant human epidermal growth factor to the entire facial skin twice a day (one vial each
219161293|NCT07078851|DEVICE|gold microneedle treatment|The face was topically anesthetized with compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval No. H20063466). After 60 minutes, the cream was cleaned off thoroughly to prepare for treatment. The subject was positioned supine on the treatment bed, and the face was disinfected twice. Gold microneedle radiofrequency treatment was performed using the NDPRD00009-E 3DEEP Phased RF治疗仪 (Eedy Med, Israel). The gold microneedle handpiece was disinfected with 95% medical ethanol. Under sterile conditions, the microneedle tips were installed, and the treatment parameters were set as follows: Cheeks mode with Intensif method, microneedle length 0.8-2.0 mm (length \<1.5 mm for forehead, temporal region, and zygomatic bone prominences); RF output time 180 ms; RF power 6-16 W. The operator held the device vertically and applied it evenly across the treatment area in a grid pattern, ensuring gentle contact with the skin to avoid excessive pressure. Any untreated gaps
219161700|NCT06450366|OTHER|Placebo for Bempedoic Acid|Administered orally.
219734533|NCT01428141|DRUG|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
219734534|NCT05392660|OTHER|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
219734535|NCT03237312|PROCEDURE|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
219734536|NCT03237312|BIOLOGICAL|Antimullerian hormone|"1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
219734537|NCT01798823|PROCEDURE|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
219734538|NCT02169999|OTHER|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
219161294|NCT07077551|DRUG|NALIRIFOX|A cycle will be repeated every 14 days. G-CSF prophylaxis will be allowed after each cycle. Patients will undergo re-staging studies every 8 weeks. Patients will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
219161295|NCT07070947|DIAGNOSTIC_TEST|sEMG|The spectral characteristics in the amplitude domain will be recorded through the root mean square (RMS, unit: μV) or the mean power frequency (MPF, unit: Hz) of the musculature to be evaluated by means of EMGs, with the electrodes placed parallel to the muscle fibers of the temporal, masseter, and suprahyoid muscles. Standardized EMGs will be recorded and compared in resting position and during maximum voluntary clenching
219161296|NCT06920498|DRUG|PF-07941944|Oral formulation
219161297|NCT06920498|DRUG|Placebo|Oral formulation
219161298|NCT06920498|DRUG|Midazolam|Oral formulation
219161299|NCT06164275|PROCEDURE|Biopsy|Undergo tumor biopsy
219161300|NCT06164275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219161301|NCT06164275|PROCEDURE|Computed Tomography|Undergo CT scan
219161302|NCT06164275|DRUG|Dacarbazine|Given IV
219161303|NCT06164275|DRUG|Doxorubicin|Given IV
219161304|NCT06164275|PROCEDURE|Echocardiography|Undergo echocardiography
219161305|NCT06164275|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219161306|NCT06164275|BIOLOGICAL|Pembrolizumab|Given IV
219734539|NCT05734807|DRUG|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
219734540|NCT05734807|DRUG|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
219734541|NCT05734807|DRUG|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
219161307|NCT06164275|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219161308|NCT06164275|DRUG|Vinblastine|Given IV
219161309|NCT06937814|DIETARY_SUPPLEMENT|Humiome ® Post LB|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
219161310|NCT06937814|OTHER|Placebo|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
219161311|NCT04680065|BIOLOGICAL|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
219161312|NCT04680065|PROCEDURE|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
219161313|NCT04402294|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Participants undergo resting-state and task-based fMRI to identify individualized transcranial magnetic stimulation (TMS) targets and determine optimal and sub-optimal stimulation frequencies. Additional fMRI scans are performed after each neuromodulation phase to assess changes following three days of stimulation at the optimal and sub-optimal frequencies.
219161314|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants first receive multiple rTMS frequencies during an fMRI scan to assess brain responses and determine individualized optimal and sub-optimal stimulation frequencies. They then complete two neuromodulation intervention periods, receiving rTMS at the identified optimal and sub-optimal frequencies. Each frequency is administered over three consecutive days, with the order of conditions randomized and counterbalanced.
219161315|NCT06948578|DEVICE|Thread embedding-acupuncture|TEA is performed once at bilateral ST36 (perpendicular insertion) and BL13 (oblique insertion toward EX-B1) using absorbable PDO thread (CARA® 30G × 38 mm). Standard aseptic procedures are followed. Bleeding is controlled, and insertion sites are covered. Participants continue their routine pharmacological COPD treatment.
219161316|NCT06948578|DEVICE|Sham thread-embedding acupuncture|Sham TEA involves taping needles onto the surface of bilateral ST36 and BL13 without skin penetration or thread insertion. The direction toward EX-B1 is mimicked without actual insertion. All procedures, including marking and aseptic preparation, are performed identically to maintain blinding. Participants continue their routine pharmacological COPD treatment.
219161317|NCT06946186|BEHAVIORAL|Virtual Senior Center - GrandPad|The Virtual Senior Center engages older adults in programs and services online with the help of a GrandPad.
219161318|NCT06946186|BEHAVIORAL|Virtual Senior Center - No GrandPad|Participants will be given information to access the website when they are able from their own phone, tablet, or computer.
219161319|NCT00012454|DRUG|E-Selectin nasal spray|
219161320|NCT06951594|DEVICE|Robotic|The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It provides surgeons with consistent insertion speed and force. The system consists of a drive unit connected to a touch screen control console and foot pedal interface. The surgeon secures the base to the skull with two pre-loaded self-drilling bone screws. The drive unit is placed into the base and the adjustable drive head is coupled to a CI electrode. Before insertion begins, the surgeon selects the desired speed of insertion. the surgeon controls the electrode insertion forward and reverse motion via foot pedal while guiding the electrode array into the cochlea with standard CI instrumentation. Upon the completion of electrode array insertion, the drive head and unit are uncoupled from the electrode lead and removed from the patient for disposal.
219161321|NCT06785935|DEVICE|Needle knife|ultrasonography-guided percutaneous A1 pulley release using a needle knife
219161322|NCT06785935|DRUG|Corticosteroid: Betamethasone|ultrasonography-guided corticosteroid injection under the A1 pulley
219734542|NCT01237405|DRUG|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
219161323|NCT06702527|PROCEDURE|Mitral transcatheter edge-to-edge repair|Mitral transcatheter edge-to-edge repair with the PASCAL system
219161324|NCT03481660|DRUG|Brolucizumab|Intravitreal injection
219161325|NCT03481660|DRUG|Aflibercept|Intravitreal injection
219161701|NCT05660356|DRUG|Growth Hormone|Pfizer provided GH therapy
219734543|NCT05154162|DIAGNOSTIC_TEST|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
219734544|NCT05154162|PROCEDURE|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
219161326|NCT04927234|DEVICE|geko™ therapy|Neuro-muscular electrical stimulation of the peroneal nerve
219161327|NCT05540938|DRUG|Wangbi granules|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
219161328|NCT05540938|DRUG|Wangbi granules simulant|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
219161329|NCT06313671|DIAGNOSTIC_TEST|Perfusion index|"The perfusion index (PI) is derived from the plethysmography signal and represents the ratio of pulsatile to non-pulsatile light absorbance of the plethysmography signal.~PPG signal."
219235326|NCT00761332|DRUG|teriparatide|treatment will be prescribed according to usual standard of care
219235327|NCT00761332|DRUG|antiresorptives|treatment will be prescribed according to usual standard of care
219235328|NCT00651599|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
219734545|NCT05154162|PROCEDURE|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
219734546|NCT03584386|DEVICE|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
219734547|NCT01444170|DIETARY_SUPPLEMENT|dicreatinol sulfate|nutritional supplement
219734548|NCT01444170|DRUG|placebo sugar pill|
219734549|NCT05740592|PROCEDURE|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
219734550|NCT05345158|PROCEDURE|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
219734551|NCT04419350|PROCEDURE|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
219734552|NCT00369863|DRUG|Triamcinolone acetonide|
219161330|NCT04343703|BEHAVIORAL|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
219161331|NCT04343703|BEHAVIORAL|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
219161332|NCT04343703|BEHAVIORAL|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
219161333|NCT04343703|BEHAVIORAL|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
219161334|NCT05932212|DRUG|AK104|AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
219161335|NCT05932212|DRUG|AK104+ Paclitaxel+Cisplatin or Carboplatin|AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
219235329|NCT00651599|DRUG|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
219734553|NCT00066170|DRUG|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
219734554|NCT00066170|DRUG|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
219734555|NCT00066170|DRUG|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
219734556|NCT00066170|DRUG|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
219161702|NCT05660356|DRUG|Placebo|Pfizer provided placebo
219235330|NCT01020578|OTHER|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
219235331|NCT03384342|DEVICE|Narrow-band UV-B therapy|"* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
219235332|NCT01740284|DRUG|Grazax + Aerius|
219235333|NCT01740284|DRUG|Grazax + placebo|
219734557|NCT05257044|DRUG|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
219734558|NCT05257044|OTHER|Placebo|Placebo
219161336|NCT06144827|DEVICE|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
219734559|NCT03817515|DRUG|ABI-009|Sirolimus Albumin-bound Nanoparticles
219734560|NCT01297114|DRUG|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
219161337|NCT06144827|DEVICE|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
219161338|NCT05369299|DEVICE|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
219161339|NCT05369299|DEVICE|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
219161340|NCT05938296|DRUG|BS006 Injection|BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
219161341|NCT04543903|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219161342|NCT06023719|DEVICE|DISC Care|Medical device to prevent disc herniation recurrence
219161343|NCT06375044|DRUG|SIM0500|Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
219161344|NCT05431270|DRUG|Mavrostobart (PT199)|Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
219161345|NCT05431270|DRUG|Tislelizumab|Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
219161346|NCT05431270|DRUG|Gemcitabine + nab-Paclitaxel|Dosing is per Standard of Care.
219161347|NCT05431270|DRUG|Docetaxel|Dosing is per Standard of Care.
219161348|NCT05431270|DRUG|Pemetrexed|Dosing is per Standard of Care.
219161349|NCT05431270|DRUG|Gemcitabine|Dosing is per Standard of Care.
219161350|NCT05431270|DRUG|Carboplatin + Pemetrexed|Dosing is per Standard of Care.
219161351|NCT05431270|DRUG|Pembrolizumab + Carboplatin + Pemetrexed|Dosing is per Standard of Care.
219161352|NCT04555967|DEVICE|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
219161353|NCT04065048|OTHER|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
219161354|NCT04065048|OTHER|Non-soy based diet|Diet of identical composition to the soy diet with the exception of soy.
219734561|NCT00552500|DRUG|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
219734562|NCT00098293|DRUG|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
219734563|NCT00098293|DRUG|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
219734564|NCT00098293|DRUG|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
219734565|NCT03451305|OTHER|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
219734566|NCT01730976|DIETARY_SUPPLEMENT|Vitamin D 2,000 I.U.|
219161355|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
219161356|NCT06493851|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel."
219161357|NCT06582589|DEVICE|Healsea Children|Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
219161358|NCT03396341|OTHER|Salvia sample|salvia sample
219161359|NCT03396341|BEHAVIORAL|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
219161360|NCT05978414|OTHER|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
219161361|NCT05978414|OTHER|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
219734567|NCT02742974|DEVICE|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
219235334|NCT04004754|DRUG|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
219235335|NCT03029156|DEVICE|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
219235336|NCT03029156|DEVICE|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
219235337|NCT06222437|DRUG|Semaglutide|effectiveness of semaglutide in PCOS
219235338|NCT00711022|DEVICE|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
219161362|NCT06564610|PROCEDURE|Transversus abdominis block|The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
219161363|NCT06564610|PROCEDURE|Erector spinae block|The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
219161364|NCT06564610|PROCEDURE|Bariatric surgery|Laparoscopic bariatric procedure will be performed
219734568|NCT01370642|DRUG|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
219734569|NCT01370642|DRUG|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
219734570|NCT01370642|BIOLOGICAL|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
219734571|NCT01370642|DRUG|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
219734572|NCT05253235|BEHAVIORAL|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
219734573|NCT05253235|OTHER|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
219734574|NCT02071654|DEVICE|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
219734575|NCT01928576|DRUG|Azacitidine|
219734576|NCT01928576|DRUG|Entinostat|
219734577|NCT01928576|DRUG|Nivolumab|
219734578|NCT01928576|DRUG|CC-486 300|
219734579|NCT01796470|DRUG|Entospletinib|Entospletinib tablets administered orally twice daily
219161365|NCT06564610|DEVICE|Endotracheal intubation|An endotracheal tube will be inserted as a part of general anesthesia to all patients
219161366|NCT06564610|DRUG|Propofol|The patients will receive propofol for induction of anesthesia
219161367|NCT06814405|PROCEDURE|Home patient management|with support therapy, Granulocyte growth factor, blood transfusion
219161368|NCT06814405|OTHER|Hospital patient management|all procedures and exams needed
219161369|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
219161370|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
219161371|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
219161372|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
219734580|NCT01796470|DRUG|Idelalisib|Idelalisib tablets administered orally twice daily
219734581|NCT00370604|DEVICE|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
219734582|NCT00370604|DEVICE|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
219734583|NCT03810794|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
219734584|NCT03810794|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
219235339|NCT03544047|DRUG|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
219235340|NCT04446949|OTHER|Register follow-up|Number of adverse pregnancy outcomes
219235341|NCT03861884|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
219734585|NCT05863364|DRUG|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
219734586|NCT05863364|DRUG|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
219734587|NCT01927861|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
219734588|NCT00987935|DRUG|Sorafenib|400 mg twice daily
219734589|NCT00987935|DRUG|BIBF 1120|Twice daily
219734590|NCT04883554|OTHER|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
219734591|NCT04883554|OTHER|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
219161373|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
219161374|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
219161375|NCT04799197|BEHAVIORAL|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
219161376|NCT05734196|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
219161377|NCT02944955|DRUG|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
219161378|NCT04032535|DRUG|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
219161379|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization
219161380|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
219161381|NCT06521840|DEVICE|Masimo RAD 67|This is an observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture). The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone.
219161382|NCT05943743|OTHER|Google form|"* Self-administrated Questionnaire will be used for online survey. A pilot study was conducted on 30 sample size to check the reliability of questionnaire via statistical test.~* A Five-point Likert scale (strongly disagree, disagree somewhat, Neutral, agree somewhat, strongly agree)"
219161383|NCT06815484|OTHER|Intervention group with physical activity programme|Programme comprising active breaks to be incorporated into daily life, supervised group physical activity sessions with personalised advice and a motivational interview with a physical activity professional to encourage regular physical activity.
219161384|NCT06815484|OTHER|Recommendations of the World Health Organisation|The World Health Organisation's recommendations on physical activity, which recommend at least 150 minutes a week of moderate-intensity activity or 75 minutes of high-intensity activity, and highlight the importance of limiting sedentary behaviour.
219161385|NCT05400200|DIAGNOSTIC_TEST|questionnary administration|questionary
219161386|NCT06815393|OTHER|Intratechal Morphine|Prior to induction, the patient will be positioned seated, and morphine will be slowly injected intrathecally at a dose of 5 μg/kg, adjusted to the L4-L5 or L3-L4 intervertebral space using a 27G pencil point spinal needle. The injection will be administered over approximately 10 seconds
219161387|NCT06815393|OTHER|Transversalis Fascia Plane Block|Prior to induction, patients will be positioned supine, and bilateral transversus abdominis plane (TAP) block will be performed with the aid of ultrasound. As the blocking agent, 20 cc of 0.25% bupivacaine will be used bilaterally.
219734592|NCT01089543|DRUG|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
219734593|NCT01089543|DRUG|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
219734594|NCT01089543|DRUG|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
219734595|NCT01089543|DRUG|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
219161388|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Standard of care targeted therapy
219161389|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Second-line targeted therapy
219161703|NCT03706521|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
219161704|NCT02437422|BIOLOGICAL|SANGUINATE|Single two-hour infusion of SANGUINATE
219161705|NCT02109601|OTHER|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
219734596|NCT03325803|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
219734597|NCT03325803|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
219734598|NCT03325803|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
219734599|NCT03325803|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
219161390|NCT04280523|DRUG|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
219161391|NCT04437498|DEVICE|sham stimulation|non invasive vagal nerve stimulation
219161392|NCT04437498|DEVICE|nVNS|active vns stimulation
219161393|NCT02347995|OTHER|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
219161394|NCT02347995|OTHER|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
219161395|NCT05104697|DEVICE|Transcranial Magnetic Stimulation|All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
219161396|NCT06320743|DEVICE|NIRS ,Ventilation parameters|"NIRS ,Ventilation parameters :~Until the patient is taken to the operating table and leaves the operating table routine monitoring parameters, BIS values ,cerebral and peripheral NIRS values, until the patient is intubated and extubated ventilation parameters These parameters; 0. min (before induction), 1. min after induction, pre-post intubation, 5. min, 10. min, 20. min, 30. min, 45. min, 60. min, 90. min after connecting to the ventilator. It will then be noted at 1 hour intervals, and finally at the 5th minute after extubation."
219161397|NCT06320743|DEVICE|Oxygen concentration|"Oxygen concentration :~Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%"
219161398|NCT06390163|OTHER|Sensory-Motor Integration Training|An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
219161399|NCT06755294|PROCEDURE|Vestibular incision subperiostal tunnel technique|"The VISTA (Vestibular Incision Subperiosteal Tunnel Access) technique is a minimally invasive surgical approach for root coverage. A single vertical incision is made, often at the labial frenulum for optimal access, reaching the periosteum to elevate a subperiosteal tunnel. This tunnel is extended beyond the mucogingival junction and interproximally under each papilla to enable tension-free coronal repositioning of the gingiva.~An autologous connective tissue graft, harvested and de-epithelialized from the palate, is introduced into the tunnel. Before placement, teeth are etched (orthophosphoric or hydrofluoric acid depending on surface type). Sutures (6-0 polypropylene) stabilize the graft, with additional composite fixation on treated teeth. The vertical incision is closed using 5-0 sutures, ensuring proper stabilization and healing. This approach minimizes trauma, promotes healing, and achieves effective root coverage."
219161400|NCT06755294|PROCEDURE|CAF|"The Coronally Advanced Flap (CAF) is an effective technique for root coverage in single or multiple gingival recession cases with adequate apical keratinized tissue thickness and height. Following the De Sanctis and Zucchelli protocol (2007), two horizontal incisions are made 3 mm apart, with placement 1 mm apical to the recession height. Vertical beveled incisions extend into the alveolar mucosa, and a flap is elevated in three stages: partial thickness at the papilla, full thickness to the buccal bone table, and apical partial thickness to release muscle fibers for mobility.~An autologous connective tissue graft (≥1 mm thick) is harvested from the palatal or retromolar area, de-epithelialized, and shaped to the recession size. The anatomical papillae are de-epithelialized, and the graft is sutured apically to the CEJ using 6-0 Polyglactin 910. Sling sutures (6-0 polypropylene) stabilize the flap 2 mm coronally to the CEJ, ensuring optimal positioning and healing."
219161401|NCT06765096|OTHER|Educational Virtual Reality Model|Participants will receive one session on educational virtual reality (VR) model for pelvic floor anatomy.
219161402|NCT03845465|BEHAVIORAL|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
219161403|NCT03845465|BEHAVIORAL|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
219161404|NCT06785584|DRUG|Ensartinib|receive neoadjuvant treatment with ensartinib 225 mg once a day, po. for 2 consecutive cycles (56 days) to evaluate possibility of surgery, or discontinue the treatment because of disease recurrence or intolerable toxicity
219161405|NCT06782503|OTHER|Mind-Body Medicine Training Program|"The 4-day training includes lectures and small group participation. Lecture topics cover information on a variety of mind--body techniques and the small groups allow participants to practice the techniques. The 2-day practicum will teach staff the ways in which they can share the skills they have learned one-on-one with parolees and families of parolees. The practicum lectures will provide a review of the mind-body skills and examples of practical applications. The practicum will also include breakout sessions to allow participants to practice their skills. The four 2-hour group consultation sessions will allow time for the trained staff to share their experiences as they teach these skills to others and ask any questions that may arise. These consultations will support the ongoing sharing of mind-body medicine skills with the parolees and the families of parolees.~Edit"
219734818|NCT02743858|OTHER|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.
219734819|NCT02743858|OTHER|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
219734820|NCT02743858|BEHAVIORAL|Quality of Life Questionnaire|
219734821|NCT02743858|OTHER|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
219734822|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
219734823|NCT04405388|DRUG|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
219734824|NCT04405388|DRUG|Spermidine|Spermidine will be given orally as capsule (4mg/day)
219734825|NCT02805348|DRUG|Bixalomer|Oral
219235409|NCT00900302|OTHER|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
219734826|NCT03812172|DRUG|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
219734827|NCT05680636|DIAGNOSTIC_TEST|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
219734828|NCT03004183|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
219734829|NCT03004183|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
219734830|NCT03004183|RADIATION|SBRT|Low-dose SBRT
219734831|NCT03004183|DRUG|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
219734832|NCT04964466|BIOLOGICAL|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
219734833|NCT04964466|BIOLOGICAL|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
219734834|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
219734835|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
219734836|NCT04288531|DIETARY_SUPPLEMENT|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
219734837|NCT05063136|DRUG|Capecitabine+endocrine therapy|Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
219734838|NCT05063136|DRUG|Placebo+endocrine therapy|Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
219734839|NCT04583553|DIAGNOSTIC_TEST|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
219734840|NCT06212323|OTHER|Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.|"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients on the study are recommended to undergo the following standard of care surveillance protocol:~* Complete Blood Count (CBC), Complete Metabolic Panel (CMP), myeloma blood tests (serum kappa/lambda light chains, monoclonal protein evaluation, immunoglobulin levels), to be done monthly for first year, and then every two months for the second year.~* WB DW-MRIs every 6 months during the study period.~* 24-hour urine Immunofixation/electrophoresis is expected to be completed approximately every 6 months.~* Bone marrow biopsy will be performed annually during the study time-period."
219734841|NCT04953169|OTHER|Biobank Video|The video describes the process of biobanking with visuals
219734842|NCT04953169|OTHER|Non-Video|The non-video group will receive a written informed consent
219734843|NCT06369545|OTHER|EXERCISE|All participants included in this group will receive Exercises
219734844|NCT06369545|OTHER|TENS|All participants included in this group will receive TENS
219734845|NCT06369545|OTHER|ESWT|All participants included in this group will receive ESWT
219734846|NCT06413134|DEVICE|TheraPAP|TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.
219734847|NCT06413134|DEVICE|APAP|Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
219734848|NCT04785352|DIETARY_SUPPLEMENT|Nutrition Intervention|One egg per day for six months
219734849|NCT04785352|BEHAVIORAL|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
219734850|NCT02762890|DRUG|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
219734851|NCT02762890|DRUG|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
219734852|NCT05994534|DRUG|Cysteamine Bitartrate|Single dose, tablets at current therapeutic dose
219734853|NCT05994534|DRUG|N-Acetylcysteine Amide|Single dose, oral solution
219734854|NCT00495781|PROCEDURE|%-hypo (laboratory parameter, functional iron deficiency)|
219734855|NCT00495781|PROCEDURE|CHr (laboratory parameter, functional iron deficiency)|
219734856|NCT00495781|PROCEDURE|RET-HE (laboratory parameter, functional iron deficiency)|
219734857|NCT01543230|DEVICE|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
219734858|NCT02576704|DEVICE|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
219734859|NCT05457205|OTHER|Electrical neuromodulation|Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
219734860|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
219734861|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
219734862|NCT06119204|OTHER|Oviva programme|Total diet replacement for insulin-treated patients
219734863|NCT06119204|OTHER|Usual care|NHS 12 week weight loss programme
219734864|NCT04409769|OTHER|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
219734865|NCT01213251|DEVICE|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
219235410|NCT00900302|OTHER|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
219235411|NCT00900302|PROCEDURE|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
219235412|NCT05647538|PROCEDURE|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
219235413|NCT02099409|DEVICE|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
219235414|NCT05687825|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
219235415|NCT02434991|DEVICE|Barostat|"* During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment."
219235416|NCT02535585|DEVICE|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
219235417|NCT02535585|DEVICE|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
219235418|NCT03122860|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
219235419|NCT03122860|OTHER|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
219235420|NCT03122860|OTHER|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
219734866|NCT01213251|DEVICE|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
219734867|NCT03355092|DEVICE|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
219734868|NCT01825252|BEHAVIORAL|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
219734869|NCT01825252|BEHAVIORAL|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
219235421|NCT01138657|BIOLOGICAL|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
219734870|NCT01121029|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
219734871|NCT01992939|OTHER|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
219235422|NCT01138657|DRUG|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
219235423|NCT01138657|DRUG|Placebo|Administered by subcutaneous injection
219235424|NCT05990868|DRUG|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
219235425|NCT03679299|OTHER|Observational - No intervention|See outcomes
219235426|NCT03511781|RADIATION|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
219734872|NCT01992939|OTHER|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
219734873|NCT06098352|BEHAVIORAL|PEBL Continuous Performance Task|A PEBL version of the Conners Continuous Performance Task
219235427|NCT01357902|DRUG|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
219235428|NCT00882323|DRUG|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
219235429|NCT04480957|BIOLOGICAL|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
219296594|NCT01593332|DRUG|Rituximab|two 500 mg rituximab infusions 2 weeks apart
219734874|NCT03084900|OTHER|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
219235430|NCT04480957|BIOLOGICAL|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
219235431|NCT04480957|BIOLOGICAL|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
219235432|NCT04480957|BIOLOGICAL|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
219734875|NCT04216550|DRUG|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
219734876|NCT02529488|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
219734877|NCT00666614|OTHER|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
219235433|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
219235434|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
219235435|NCT04480957|OTHER|Placebo|Sterile 0.9% saline
219235436|NCT02055079|DRUG|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
219235437|NCT02055079|DRUG|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
219235438|NCT02578004|OTHER|biochemical and molecular analysis|
219734878|NCT00666614|OTHER|Normal Hospital Environment|Normal Hospital Environment
219734879|NCT03768050|OTHER|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
219734880|NCT02698787|DEVICE|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
219235439|NCT00001255|DRUG|ADA PBSC|
219235440|NCT00001255|DRUG|ADA Umbilical Cord Blood Cells|
219235441|NCT00001255|DRUG|Transduced Lymphocytes|
219235442|NCT06153784|DRUG|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
219235443|NCT04901585|PROCEDURE|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
219296595|NCT01593332|DRUG|Rituximab|500mg,two times with two weeks interval
219296596|NCT00417261|DRUG|ATF936|
219296597|NCT00417261|DRUG|AXT914|
219296598|NCT02295553|DRUG|Ketamine|
219296599|NCT02295553|DRUG|Propofol|
219296600|NCT01869387|DEVICE|Non-invasive ventilation|
219296601|NCT01493011|DEVICE|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
219734881|NCT02698787|DEVICE|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
219235444|NCT02166684|DEVICE|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
219235445|NCT03610685|DRUG|Prednisolone|Given daily for 2 weeks
219235446|NCT03610685|DRUG|Placebo oral capsule|Given daily for 2 weeks
219235447|NCT01396629|PROCEDURE|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
219235448|NCT03067337|DEVICE|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
219235449|NCT03067337|DEVICE|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
219235450|NCT01473459|PROCEDURE|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
219235451|NCT01473459|PROCEDURE|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
219235452|NCT02579109|OTHER|memory test|
219235453|NCT00799331|DRUG|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
219235454|NCT00799331|DRUG|placebo|Oral suspension.
219235455|NCT04155814|DRUG|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
219235456|NCT04155814|DRUG|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
219235457|NCT05376839|DRUG|Cedirogant|Capsule, Oral
219235458|NCT02684994|BEHAVIORAL|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
219235459|NCT02045914|OTHER|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
219235460|NCT05868356|DRUG|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
219235461|NCT05868356|DRUG|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
219235462|NCT00591136|DRUG|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
219235463|NCT05904210|DRUG|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
219235464|NCT03392805|BEHAVIORAL|physical activity|beginning of regular physical activity under the supervision of a coach
219235465|NCT00999336|DRUG|Betrixaban|80 mg betrixaban qd for 8 days
219235466|NCT06341946|DEVICE|Endoscopic third ventriculostomy|role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
219235467|NCT00529529|DRUG|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
219235468|NCT00529529|DRUG|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
219235469|NCT00529529|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
219235470|NCT00529529|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
219734882|NCT00324857|BEHAVIORAL|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
219734883|NCT00324857|BEHAVIORAL|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
219734884|NCT00324857|BEHAVIORAL|MI plus Decision aid|Patient viewed the video and then underwent MI.
219734885|NCT00324857|OTHER|Attention control|patients received a booklet.
219296602|NCT02279628|DRUG|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
219296603|NCT02279628|DRUG|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
219235471|NCT02788994|DEVICE|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
219235472|NCT02788994|DEVICE|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
219235473|NCT03500809|PROCEDURE|Aqueous release of the wound|"1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
219235474|NCT03858556|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
219235475|NCT03858556|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
219235476|NCT03858556|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219235477|NCT03858556|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
219235478|NCT03858556|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219235479|NCT03858556|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
219235480|NCT03858556|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
219235481|NCT03858556|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
219235482|NCT01394835|DRUG|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
219235483|NCT01394835|DRUG|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
219235484|NCT01394835|DRUG|AAT|Inhalation twice daily' 160mg
219235485|NCT00007306|DRUG|Parathyroid hormone ointment|
219235486|NCT05125549|DRUG|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
219235487|NCT05125549|DRUG|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
219235488|NCT04618211|DRUG|Deucrictibant|deucrictibant soft capsules for oral use
219235489|NCT04618211|DRUG|Placebo|Matching placebo capsules for oral use
219235490|NCT00000497|BEHAVIORAL|diet, sodium-restricted|
219235491|NCT00000497|BEHAVIORAL|diet, reducing|
219235492|NCT05193526|OTHER|No intervention|No intervention
219235493|NCT00960206|DEVICE|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
219235494|NCT00960206|DEVICE|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
219235495|NCT00960206|DEVICE|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
219235496|NCT02334917|PROCEDURE|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
219235497|NCT04950920|DRUG|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
219235498|NCT04950920|DRUG|d-borneol|60 μg d-borneol OR， Bid
219296604|NCT03284047|DRUG|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
219296605|NCT02940405|DRUG|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
219296606|NCT02940405|DRUG|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
219296607|NCT05184023|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
219296608|NCT05184023|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
219734886|NCT03696186|DRUG|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
219734887|NCT03696186|DRUG|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
219734888|NCT03696186|DRUG|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
219235499|NCT04221711|DEVICE|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
219235500|NCT04221711|PROCEDURE|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
219235501|NCT00157105|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
219734889|NCT03696186|DRUG|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
219734890|NCT03696186|DRUG|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
219734891|NCT03696186|DRUG|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
219734892|NCT02459600|OTHER|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
219734893|NCT02661347|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
219734894|NCT02661347|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
219734895|NCT04245579|OTHER|Multifactorial Memory Training Program (UMAM method)|
219235502|NCT03094546|DIETARY_SUPPLEMENT|Polyamine|12 months of polyamine supplementation (6 capsules/day)
219235503|NCT03094546|DIETARY_SUPPLEMENT|Placebo|12 months of placebo intake (6 capsules/day)
219235504|NCT02339259|OTHER|Observation|
219235505|NCT05655000|PROCEDURE|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
219296609|NCT02194673|OTHER|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
219734896|NCT04562805|DEVICE|DynamX Bioadaptor|DynamX Bioadaptor Treatment
219734897|NCT04562805|DEVICE|Resolute Onyx|Resolute Onyx Treatment
219734898|NCT00594308|DRUG|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
219734899|NCT00594308|DRUG|Fludarabine|25mg/m2/day for 5 consecutive days
219734900|NCT00594308|DRUG|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
219734901|NCT00594308|DRUG|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
219734902|NCT00594308|DRUG|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
219734903|NCT00295503|DRUG|bevacizumab|15 mg/kg IV every 3 weeks
219734904|NCT00295503|DRUG|cisplatin|75 mg/m2 IV every 3 weeks
219734905|NCT00295503|DRUG|pemetrexed|500 mg/m2 every 3 weeks
219734906|NCT06355141|OTHER|oral assessment|observational oral assessment
219734907|NCT03453515|BEHAVIORAL|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
219734908|NCT03453515|BEHAVIORAL|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
219734909|NCT01245023|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
219734910|NCT01245023|PROCEDURE|Placebo-surgery|skin incisions without laparoscopy or related procedures
219734911|NCT00693511|BEHAVIORAL|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
219734912|NCT00693511|BEHAVIORAL|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
219734913|NCT06372041|DEVICE|transcranial Alternating Current Stimulation|tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
219734914|NCT02673060|DRUG|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
219734915|NCT01557244|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
219734916|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
219734917|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
219734918|NCT01557244|DRUG|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
219734919|NCT01557244|DRUG|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
219734920|NCT01557244|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
219734921|NCT01557244|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
219734922|NCT02571881|PROCEDURE|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
219734923|NCT02571881|DRUG|Oxycodone|
219734924|NCT02571881|DRUG|oxycodone-naloxone|
219734925|NCT00438282|BEHAVIORAL|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
219734926|NCT06325631|PROCEDURE|Intra-articular injection to lumbar facet joint|to treat low back pain caused by facet joint syndrome
219734927|NCT05183984|DRUG|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
219734928|NCT05183984|DRUG|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
219734929|NCT05183984|DRUG|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
219734930|NCT01313676|DRUG|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
219734931|NCT01313676|DRUG|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
219734932|NCT01313676|DRUG|vilanterol|25mcg given once daily via novel dry powder inhaler
219734933|NCT01313676|OTHER|Placebo|placebo comparator once daily via novel dry powder inhaler
219734934|NCT03312114|DRUG|Avelumab|Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
219734935|NCT02295579|OTHER|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
219296610|NCT02194673|OTHER|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
219734936|NCT04627974|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
219734937|NCT00944645|DRUG|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
219734938|NCT00944645|DRUG|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
219734939|NCT06564727|PROCEDURE|Uniportal VATS approach|Uniportal VATS resection for simple pulmonary aspergilloma
219734940|NCT06564727|PROCEDURE|VATS approach|VATS resection for complex pulmonary aspergilloma
219734941|NCT04441515|DEVICE|Ipod with music|music of patient's preference provided 2 hours daily
219734942|NCT04441515|DEVICE|ipod with books to listen|2 hours of daily listening to books
219734943|NCT04441515|DEVICE|ipod only with usual care|participants given device only
219734944|NCT03995147|DRUG|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
219734945|NCT03995147|DRUG|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
219734946|NCT04560296|BEHAVIORAL|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
219734947|NCT04560296|BEHAVIORAL|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
219734948|NCT05988229|OTHER|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
219235506|NCT03111706|PROCEDURE|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
219235507|NCT00392899|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
219235508|NCT04253951|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
219235509|NCT03234959|DEVICE|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
219235510|NCT03234959|OTHER|Infant Massage|Infants will received IM by their parents
219235511|NCT04787198|DRUG|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
219235512|NCT04787198|DRUG|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
219235513|NCT02813174|BEHAVIORAL|Compassionate Mind Training from Compassion-Focused Therapy|
219235514|NCT02553148|OTHER|Need for children's palliative care|Need for children's palliative care
219235515|NCT03136822|OTHER|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
219235516|NCT03136822|DEVICE|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
219235517|NCT00162318|DRUG|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
219235518|NCT02394912|DEVICE|vena cava filter implantation (LUMIFI with Crux VCF System)|
219235519|NCT00814749|PROCEDURE|midureteral sling|midureteral sling
219235520|NCT00814749|OTHER|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
219235521|NCT02629666|BEHAVIORAL|ERS and/or Self-management Strategies|
219235522|NCT02444962|DEVICE|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
219235523|NCT06432257|DEVICE|head mounted magnifying glass assistance|When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
219235524|NCT04588207|DRUG|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
219235525|NCT02729246|PROCEDURE|Laparoscopic Gastric Bypass|
219235526|NCT03121885|BEHAVIORAL|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
219235527|NCT03121885|OTHER|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
219235528|NCT03607591|OTHER|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
219235529|NCT03376763|DRUG|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
219235530|NCT01873898|DEVICE|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
219235531|NCT03187704|OTHER|HEPA air filtration|Air filters were placed in participant homes
219296611|NCT02194673|OTHER|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
219296612|NCT03725085|DRUG|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
219235532|NCT06363604|PROCEDURE|VOMEI + PVI + linear ablation of mitral isthmus|The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
219235533|NCT06363604|PROCEDURE|Posterior wall isolation|PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
219235534|NCT00637663|DRUG|Entecavir|entecavir 0.5 mg QD
219235535|NCT00637663|DRUG|Lamivudine|lamivudine 100 mg QD
219235536|NCT05862402|DRUG|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
219235537|NCT05110794|DRUG|LY3502970|Administered Orally.
219734949|NCT03537729|BEHAVIORAL|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
219734950|NCT03537729|BEHAVIORAL|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
219734951|NCT03829488|DRUG|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
219235538|NCT01106807|DRUG|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
219235539|NCT01106807|DRUG|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
219235540|NCT01106807|DRUG|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
219235541|NCT01106807|DRUG|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
219235542|NCT03822806|OTHER|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
219235543|NCT03075878|DRUG|ALXN1830|Administered via IV infusion.
219235544|NCT01705756|DRUG|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
219235545|NCT01868061|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
219235546|NCT01868061|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
219235547|NCT02612285|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
219734952|NCT03829488|DRUG|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
219734953|NCT05968742|BEHAVIORAL|Abstinence of oral hygiene on select teeth|Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
219734954|NCT01480765|DRUG|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
219734955|NCT01480765|DRUG|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
219734956|NCT01480765|DRUG|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
219734957|NCT01480765|DRUG|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
219734958|NCT04668599|OTHER|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
219734959|NCT05599321|DIAGNOSTIC_TEST|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
219734960|NCT06457217|DIAGNOSTIC_TEST|Magnetic resonance spectroscopic imaging|High-resolution 3D metabolic imaging was performed using the SPICE 1H-MRSI sequence.
219734961|NCT02933151|DIETARY_SUPPLEMENT|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
219734962|NCT03153293|DRUG|rAAV2-ND4|a Single IVT Injection
219734963|NCT00002482|BIOLOGICAL|antibody therapy|
219734964|NCT00002482|BIOLOGICAL|biological therapy|
219734965|NCT00002482|BIOLOGICAL|muromonab-CD3|
219734966|NCT00002482|DRUG|cyclophosphamide|
219734967|NCT04178863|DEVICE|CATS Tonometer|latanoprost vs. timolol
219734968|NCT04178863|DRUG|Latanoprost|latanoprost IOP reduction
219734969|NCT05142644|PROCEDURE|ultrasound|An extra ultrasound performed during pregnancy
219734970|NCT02909114|RADIATION|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
219734971|NCT03967574|DEVICE|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
219734972|NCT01013870|DRUG|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
219734973|NCT01013870|DRUG|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
219235548|NCT05661240|DEVICE|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
219734974|NCT00002046|DRUG|Zidovudine|
219734975|NCT02441816|DRUG|Aflibercept|
219734976|NCT02441816|OTHER|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
219734977|NCT00785447|OTHER|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
219734978|NCT04989166|DIETARY_SUPPLEMENT|Nano-curcumin|Nano-curcumin soft gels
219734979|NCT04989166|DRUG|Placebo|Placebo
219734980|NCT00423462|BEHAVIORAL|Brief dynamic psychotherapy|
219734981|NCT00918398|DRUG|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
219734982|NCT00918398|DRUG|AZD1981|514 mg oral solution, single dose
219734983|NCT00918398|DRUG|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
219734984|NCT00918398|DRUG|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
219734985|NCT01065805|BIOLOGICAL|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
219734986|NCT00059280|BIOLOGICAL|Myozyme|20 mg/kg qow or 40mg/kg qow
219734987|NCT03615430|PROCEDURE|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
219235549|NCT05661240|DRUG|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
219235550|NCT00805441|DRUG|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
219235551|NCT00805441|DRUG|Placebo|Daily by oral route for 12 weeks
219235552|NCT01739972|DRUG|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
219734988|NCT03615430|PROCEDURE|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
219734989|NCT01045239|DEVICE|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
219734990|NCT01045239|DEVICE|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
219734991|NCT05609058|DEVICE|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
219734992|NCT01345903|PROCEDURE|therapeutic conventional surgery|Undergo robotic-assisted surgery
219734993|NCT00770094|DEVICE|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
219734994|NCT00770094|DEVICE|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
219734995|NCT00770094|DEVICE|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
219734996|NCT00626665|DRUG|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
219734997|NCT05382325|BIOLOGICAL|MK-1484|Subcutaneous (SC) injection
219734998|NCT05382325|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
219734999|NCT03709030|DIAGNOSTIC_TEST|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
219735000|NCT05416632|DIAGNOSTIC_TEST|Athrometer|Arthrometer
219735001|NCT03048019|DRUG|Tirofiban|Patients will receive Tirofiban during the PCI procedure
219735002|NCT03048019|DRUG|Cangrelor|Patients will receive Cangrelor during the PCI procedure
219735003|NCT05226000|DRUG|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
219735004|NCT04121871|OTHER|No intervention|Not required
219735005|NCT00978185|OTHER|medical chart review|
219235553|NCT01739972|DRUG|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
219235554|NCT04520321|DRUG|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
219235555|NCT04520321|OTHER|Vehicle (placebo)|Placebo
219235556|NCT00853957|DRUG|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
219235557|NCT00853957|DRUG|Amlodipine|Amlodipine 5 mg titrated to 10mg
219296613|NCT03471351|DRUG|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
219735006|NCT00978185|OTHER|questionnaire administration|
219735007|NCT00978185|PROCEDURE|acupressure therapy|
219735008|NCT00978185|PROCEDURE|quality-of-life assessment|
219735009|NCT00978185|PROCEDURE|sham intervention|
219735010|NCT00978185|PROCEDURE|standard follow-up care|
219735011|NCT01627912|OTHER|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink \[white wine or red wine or 12.5% ethanol or water\]/kg of individual, parallel with a standardized meal.
219735012|NCT04308993|PROCEDURE|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
219735013|NCT03684785|DRUG|Cavrotolimod|Intratumorally dosed cavrotolimod.
219735014|NCT03684785|BIOLOGICAL|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
219735015|NCT03684785|BIOLOGICAL|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
219735016|NCT03684785|DRUG|Cavrotolimod|Subcutaneously dosed cavrotolimod
219735017|NCT06296030|BEHAVIORAL|POOF ACT program|The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
219735018|NCT06296030|BEHAVIORAL|Classic ACT program|This protocol is for a classic, non-adapted ACT intervention.
219735019|NCT03400787|DEVICE|Latera Implant|Treatment with implant
219235558|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
219735020|NCT03400787|DEVICE|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
219735021|NCT04469946|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
219235559|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
219735022|NCT01889563|OTHER|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
219235560|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
219235561|NCT05188378|BIOLOGICAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
219235562|NCT05188378|BIOLOGICAL|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
219235563|NCT01569399|OTHER|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
219235564|NCT04258891|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
219235565|NCT03103945|DEVICE|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
219235566|NCT01519557|DRUG|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
219235567|NCT01519557|DRUG|Placebo|Placebo
219235568|NCT02158806|DRUG|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
219235569|NCT02158806|DRUG|Placebo|Matching placebo capsule containing inert bulking agent
219235570|NCT01898299|DEVICE|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
219235571|NCT01898299|DEVICE|Sham tDCS|Sham (inactive) tDCS treatment
219235572|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
219235573|NCT04899557|PROCEDURE|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
219235574|NCT00126958|PROCEDURE|urinary analysis|
219235575|NCT05469516|DEVICE|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~\- Non-invasive treatment of Axillary Hyperhidrosis"
219735023|NCT03912415|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
219235576|NCT05469516|DEVICE|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
219235577|NCT00598234|DRUG|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
219235578|NCT04990037|DRUG|CAN04|Administered intravenously
219235579|NCT04990037|DRUG|FOLFIRINOX|Administered intravenously
219235580|NCT04780685|BIOLOGICAL|hMSC|IV administration
219235581|NCT02054351|DRUG|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
219296614|NCT03471351|BIOLOGICAL|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
219735024|NCT03912415|BIOLOGICAL|Bevacizumab|IV infusion
219735025|NCT03912415|DRUG|Paclitaxel|IV infusion
219735026|NCT03912415|DRUG|Cisplatin (or Carboplatin)|IV infusion
219735027|NCT03912415|OTHER|Placebo|Placebo
219735028|NCT05781503|BEHAVIORAL|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
219735029|NCT05781503|OTHER|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
219735030|NCT00597792|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
219735031|NCT01990352|DRUG|Pegylated liposomal doxorubicin|Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
219735032|NCT01856660|BEHAVIORAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.
219735033|NCT01856660|BEHAVIORAL|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
219735034|NCT01257893|DRUG|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
219735035|NCT01257893|DRUG|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
219735036|NCT01429935|DRUG|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
219735037|NCT01429935|DRUG|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
219735038|NCT01429935|OTHER|placebo|capsules contain starch
219735039|NCT00678574|DRUG|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
219735040|NCT01282138|DRUG|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
219735041|NCT01282138|OTHER|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
219735042|NCT00618566|BEHAVIORAL|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
219735043|NCT00348374|DRUG|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
219735044|NCT00348374|DRUG|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
219735045|NCT03608007|DRUG|X-396 Capsule|225 mg once daily
219735046|NCT01644331|DRUG|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
219735047|NCT01644331|DRUG|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
219735048|NCT05684198|DEVICE|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
219735049|NCT04482920|DIAGNOSTIC_TEST|p-aminohippurate clearance study|To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
219735050|NCT04482920|DIAGNOSTIC_TEST|Iohexol infusion|To measure glomerular filtration rate (GFR)
219735051|NCT05398848|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
219735052|NCT05398848|BIOLOGICAL|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
219735053|NCT01631929|OTHER|One bag|Infusion of dextrose and electrolytes using one bag
219735054|NCT01631929|OTHER|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
219735055|NCT02062008|DEVICE|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
219735056|NCT04760457|PROCEDURE|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
219735057|NCT04760457|PROCEDURE|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
219735058|NCT04760457|PROCEDURE|Implant immediate loading|Four mini implants will be immediately loaded.
219735059|NCT04760457|PROCEDURE|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
219735060|NCT02327143|DRUG|LY2835219|Administered orally
219735061|NCT02327143|DRUG|¹³C₈-LY2835219|Administered IV
219735062|NCT05450120|OTHER|Functional Rehabilitation|Functional rehabilitation protocol
219735063|NCT05450120|OTHER|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
219735064|NCT02447406|DRUG|AZD6094|
219735065|NCT02447406|DRUG|docetaxel|
219735066|NCT00714363|PROCEDURE|LASIK|Refractive surgery
219735067|NCT00714363|PROCEDURE|SBK|Refractive surgery
219735068|NCT01254539|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
219735069|NCT01254539|PROCEDURE|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
219735070|NCT01254539|PROCEDURE|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
219735071|NCT01585207|DRUG|vigabatrin|3 tablets, bid for 8 weeks
219735072|NCT03489083|OTHER|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
219735073|NCT03489083|OTHER|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
219735074|NCT03426852|OTHER|No intervention|No intervention
219735075|NCT00721890|DIETARY_SUPPLEMENT|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
219235582|NCT02056379|DRUG|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
219735076|NCT00742690|DRUG|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
219735077|NCT00742690|DRUG|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
219735078|NCT02956564|PROCEDURE|intrauterine intervention|choose different surgeries according to different causes
219735079|NCT04858347|DEVICE|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
219735080|NCT03355261|PROCEDURE|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
219735081|NCT03355261|PROCEDURE|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
219735082|NCT03355261|PROCEDURE|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
219735083|NCT03355261|PROCEDURE|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
219296615|NCT06399133|OTHER|Warm water intake|Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.
219735084|NCT02070380|DRUG|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
219735085|NCT02070380|DRUG|Dotarem|Dotarem administered at 0.1 mmol/kg
219735086|NCT02070380|DRUG|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
219735087|NCT03850431|BEHAVIORAL|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
219735088|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
219735089|NCT03850431|BEHAVIORAL|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
219735090|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
219735091|NCT05479227|PROCEDURE|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
219735092|NCT00130559|PROCEDURE|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
219735093|NCT01210599|DRUG|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
219735094|NCT04348058|BEHAVIORAL|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
219235583|NCT02056379|DRUG|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
219735095|NCT04348058|BEHAVIORAL|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
219735096|NCT03673982|BEHAVIORAL|iCASK|Materials and support to aid transitions
219235584|NCT02340806|DEVICE|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
219235585|NCT06387550|PROCEDURE|Eccentric Training|Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
219735097|NCT04891861|DRUG|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
219735098|NCT05795660|BIOLOGICAL|platelet rich plasma|platelet rich plasma injection
219235586|NCT02819609|PROCEDURE|myomectomy|Myomectomy as part of routine clinical care
219235587|NCT02819609|PROCEDURE|endometrial ablation|Endometrial ablation as part of routine clinical care
219735099|NCT06005636|DIAGNOSTIC_TEST|Test delirium state|use scale to test whether ischemic stroke patients have post-stroke delirium
219735100|NCT03939494|BEHAVIORAL|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
219735101|NCT01857115|DRUG|Carfilzomib|
219735102|NCT01857115|DRUG|Cyclophosphamide|
219735103|NCT01857115|DRUG|Dexamethasone|
219235588|NCT02819609|PROCEDURE|uterine artery embolization|Uterine artery embolization as part of routine clinical care
219735104|NCT02258919|PROCEDURE|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
219235589|NCT02819609|PROCEDURE|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
219735105|NCT02258919|PROCEDURE|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
219735106|NCT05957094|DRUG|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
219735107|NCT05957094|OTHER|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
219735108|NCT02105012|DRUG|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
219735109|NCT02105012|DRUG|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
219735110|NCT02105012|DRUG|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
219235590|NCT00452452|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
219235591|NCT03535636|OTHER|Polysomnography|Sleep architecture will be assessed by polysomnography
219235592|NCT02751957|BEHAVIORAL|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
219235593|NCT04878679|OTHER|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
219235594|NCT04878679|OTHER|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
219235595|NCT04878679|OTHER|Control group|No physical activity
219235596|NCT00848952|OTHER|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
219235597|NCT04069455|OTHER|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
219235598|NCT00213759|DRUG|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
219235599|NCT00213759|DRUG|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
219235600|NCT01303744|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
219235601|NCT01303744|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
219235602|NCT01303744|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
219735111|NCT02105012|DRUG|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
219735112|NCT02105012|DRUG|Placebo MDI|Placebo MDI administered as 2 inhalations BID
219235603|NCT01303744|DRUG|Placebo|oral tablet, once a day in the morning for 12 weeks
219735113|NCT04029662|BEHAVIORAL|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
219235604|NCT04399772|BEHAVIORAL|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
219235605|NCT04399772|BEHAVIORAL|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
219735114|NCT00936039|BEHAVIORAL|unloading|2 weeks of unloading of a single leg
219743371|NCT05040386|BEHAVIORAL|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
219735115|NCT03670433|OTHER|Cost analysis of medication reconciliation|"1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
219735116|NCT06496971|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
219235606|NCT03477214|DIAGNOSTIC_TEST|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
219235607|NCT06681350|DEVICE|Ocular surface imaging|Telemedical examination of high-resolution, all-in-focus images of the cornea, sclera, conjunctiva, and lid margins for montioring of postoperative complications
219235608|NCT07013162|PROCEDURE|High power diode laser + SRT|2W laser will be applied to periodontal pockets
219235609|NCT07013162|PROCEDURE|Low diode diode laser + SRT|A 0.5W low laser is applicated to periodontal pockets after mechanical debridement
219235610|NCT07013162|PROCEDURE|Curettage (SRT) only|Mechanical debridement for pocket
219235611|NCT06692998|OTHER|Rehabilitation|Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
219235612|NCT06694441|OTHER|Light Exposure|The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
219235613|NCT06694441|OTHER|Placebo|Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
219235614|NCT06699745|BEHAVIORAL|Music intervention|In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.
219235615|NCT06699745|BEHAVIORAL|white noise intervention|White noise will be played at a decibel level appropriate for the children in the group.
219235616|NCT06699017|OTHER|Continuous anterior chest compression|CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
219235617|NCT06700200|DEVICE|taVNS|transauricular vagus nerve stimulation
219235618|NCT06699043|PROCEDURE|nanocrystalline hydroxyapatite in putty form|"decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty)."
219735117|NCT06496971|DRUG|Microbubble|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
219235619|NCT06699043|PROCEDURE|Demineralized Bone Matrix allograft putty|decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
219235620|NCT06699121|DRUG|LB-P8 low-dose|One capsule QD (1×10\^10 CFU/day) oral administration
219235621|NCT06699121|DRUG|LB-P8 high-dose|One capsule QD (1×10\^11 CFU/day) oral administration
219235622|NCT06699121|DRUG|Placebo|One capsule QD oral administration
219235623|NCT06698627|DEVICE|Daily Disposable Continence Device|The Poise® Impressa® is an over-the-counter intravaginal device for women over the age of 21 years with SUI. It is a disposable, one-time use tampon-like device that comprises a core, cover, and applicator. The device is inserted and removed like a vaginal tampon and comes in three sizes.
219235624|NCT06698627|DEVICE|Monthly Disposable Continence Device|The Revive® is another over the counter vaginal insert for the treatment of SUI. This is a self-deployable, double-loop pessary device.
219235625|NCT00264654|DRUG|BRL29060A|
219235626|NCT00264654|DRUG|paroxetine hydrochloride hydrate|
219235627|NCT06699355|DRUG|Enlicitide Decanoate|Oral administration
219235628|NCT06699355|DRUG|Atorvastatin|Oral administration
219235629|NCT06699719|BEHAVIORAL|Expressive writing|"Participants are asked to complete four 20-minute sessions of a writing task on consecutive days, which is sent to their email address via an online link. Participants are instructed for the next 20 minutes to please use the provided box to write their very deepest thoughts and feelings about a negative issue or personal problem that they are currently being affected by. In their writing, they are encouraged to let go and explore their emotions and thoughts regarding this issue or problem, and to not worry about spelling or grammar. They are asked to consider setting a timer or have a clock handy to make sure they write for 20 minutes. Instructions are accompanied by a text box, which allows participants to write freely for the allotted time."
219235630|NCT06700317|DEVICE|HSS1|Surgery performed using HSS1
219235631|NCT06699069|OTHER|Control or Euthyroid group|Fed on normal standard diet
219235632|NCT06699069|OTHER|Hypothyroid group|Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
219735118|NCT06496971|DEVICE|Low-Intensity Focused Ultrasound|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
219735119|NCT03436420|DRUG|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
219235633|NCT06699069|OTHER|Hypothyroid group received exercise|Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
219235634|NCT05082948|OTHER|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
219235635|NCT05082948|OTHER|Non suture|Standard placement of stent without suture fixation
219235636|NCT00463944|BEHAVIORAL|Effect of an electronic voting system|
219235637|NCT03582085|BIOLOGICAL|Bacillus Calmette Guerin Vaccine|Experimental
219235638|NCT03582085|BIOLOGICAL|Saline Injection|Placebo
219235639|NCT05219708|DIETARY_SUPPLEMENT|Calorie protein supplement|Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure
219235640|NCT05219708|OTHER|Control|Standard of care for heart failure
219235641|NCT06857279|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219235642|NCT06857279|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219235643|NCT06857279|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
219235644|NCT06903455|OTHER|Fit-folk cardio dance|"Fitfolk is a new cardiovascular dance discipline that combines fitness exercises with music and dance from Chilean and Latin American folklore. This discipline promotes physical and emotional well-being and celebrates national folklore."
219235645|NCT06903455|OTHER|Conventional physical exercise|conventional physical exercise program that uses resistance exercise and cardiorespiratory training
219235646|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
219235647|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
219235648|NCT05620979|BEHAVIORAL|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
219235649|NCT06936696|BEHAVIORAL|Broad Target Speech Recast|"Broad Target Speech Recasts (BTSR) is a speech intervention technique in which an adult immediately recasts a child's incorrect articulation by providing a corrected version of the word in a naturalistic, meaningful context. Unlike traditional articulation therapy, which focuses on isolated sound drills, BTSR integrates correction seamlessly into conversation without requiring the child to repeat or imitate the model.~This approach is rooted in principles of implicit learning, where repeated exposure to accurate speech models facilitates phonological development over time. BTSR differs from traditional minimal pair or phonetic placement techniques in that it does not involve explicit instruction or direct prompts for self-correction. Instead, it provides high-frequency, naturalistic exposure to correct phoneme production within functional language use."
219296616|NCT06399133|OTHER|High-fiber diet|After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
219735120|NCT02988388|PROCEDURE|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
219235650|NCT06936696|BEHAVIORAL|Traditional Speech Therapy|"Traditional Speech Therapy is clinician-led and includes structured, drill-based approaches. Techniques such as placement cues, direct feedback, and reinforcement are used to help children achieve correct articulation. The structured nature of this approach is often more effective in remediating persistent speech errors than parent-implemented strategies alone.~This study examines whether the combination of parent-implemented BTSR and clinician-led traditional articulation therapy leads to improved speech sound production and long-term maintenance of correct articulation in elementary-aged DHH children."
219235651|NCT03127605|DRUG|Inotuzumab Ozogamicin|
219235652|NCT01003743|DEVICE|endolumenal tissue approximation|
219235653|NCT05722912|DRUG|Ruxolitinib|Ruxolitinib Cream
219235654|NCT03070301|DRUG|LEE011|LEE011 200 mg daily
219235655|NCT03070301|DRUG|everolimus|everolimus 5 mg daily or 2.5mg daily
219235656|NCT04858295|DEVICE|Texting|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
219235657|NCT04858295|DEVICE|mHealth app|Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
219235658|NCT03016091|DRUG|Pembrolizumab|anti PD-L1
219235659|NCT06023615|OTHER|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
219235660|NCT04520256|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
219235661|NCT04520256|BEHAVIORAL|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
219743372|NCT05040386|OTHER|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
219743373|NCT04050839|OTHER|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
219743374|NCT04050839|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
219235662|NCT04520256|BEHAVIORAL|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
219235663|NCT04520256|BEHAVIORAL|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
219235664|NCT04520256|BEHAVIORAL|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
219235665|NCT04520256|BEHAVIORAL|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
219235666|NCT06200792|DEVICE|eSense device|eSense device for monitoring electrodermal activity. Visual analogic scale (VAS) for pain and discomfort; TOL-R tests for investigating working performances.
219235667|NCT06051864|DEVICE|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
219235668|NCT06051864|DEVICE|Sham Device|Placebo comparator sham device (no active stimulation)
219235669|NCT06168045|DIAGNOSTIC_TEST|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
219235670|NCT05054751|DRUG|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
219235671|NCT05054751|DRUG|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
219235672|NCT02705196|GENETIC|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
219235673|NCT02705196|DRUG|gemcitabine|chemotherapy
219235674|NCT02705196|DRUG|nab-paclitaxel|chemotherapy
219235675|NCT02705196|BIOLOGICAL|atezolizumab|anti-PD-L1 antibody
219235676|NCT05492786|BEHAVIORAL|Alert|Non-interruptive best practice alert in the electronic health record
219235677|NCT05492786|BEHAVIORAL|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
219235678|NCT05492786|BEHAVIORAL|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
219235679|NCT05492786|BEHAVIORAL|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
219235680|NCT06083051|DEVICE|6Fr Percuflex ureteral stents|The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
219235681|NCT06083051|DEVICE|6Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
219235682|NCT06083051|DEVICE|4.8Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
219235683|NCT06083051|DEVICE|4.8Fr Percuflex ureteral stents|The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
219235684|NCT04228068|OTHER|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
219235685|NCT04228068|OTHER|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
219235686|NCT04228068|OTHER|Conventional care|The control group will receive the usual care provided by the healthcare system.
219235687|NCT06155487|DRUG|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
219743375|NCT05781308|DRUG|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
219743376|NCT05781308|DRUG|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
219743377|NCT05781308|DRUG|Atezolizumab|1200 mg every 3 weeks
219743378|NCT05817175|PROCEDURE|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
219743379|NCT05338320|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
219743380|NCT05338320|DRUG|Intrathecal morphine|General anesthesia and intrathecal morphine
219743381|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
219743382|NCT05670184|DRUG|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
219743383|NCT05670184|DRUG|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
219235688|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 100 mg
219235689|NCT06155487|DRUG|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
219235690|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 200 mg
219235691|NCT06155487|DRUG|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
219235692|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 300 mg
219235693|NCT06155487|DRUG|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
219235694|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 400 mg
219235695|NCT06155487|DRUG|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
219235696|NCT06155487|DRUG|Placebo|Oral Tablet,Single dose of Placebo 600 mg
219235697|NCT06155487|DRUG|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
219235698|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 800 mg
219235699|NCT06155487|DRUG|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
219235700|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
219235701|NCT06155487|DRUG|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
219235702|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
219235703|NCT06155487|DRUG|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
219235704|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
219235705|NCT05562492|DEVICE|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
219235706|NCT05562492|OTHER|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
219235707|NCT06721663|OTHER|Multisensory environment stimulation therapy|A Multi Sensory Environment is a dedicated space or room where sensory stimulation can be controlled (intensified or reduced), presented in isolation or combination, packaged for active or passive interaction
219235708|NCT06721663|OTHER|selected physical therapy intervention|therapeutic balance training and functional therapeutic exercises
219235709|NCT06721728|BEHAVIORAL|Oral health educational program|Flyer distributed on the children with data about oral hygiene measures as well as diet advice related to their condition, in addition to modeling the correct tooth brushing habits using a cast and tooth brush.
219235710|NCT03553056|OTHER|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
219235711|NCT03553056|OTHER|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
219235712|NCT05759143|BEHAVIORAL|Nest Platform|Patient- and clinician-facing portal via secure link
219235713|NCT06721390|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 12 weeks.
219235714|NCT06721390|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 12 weeks.
219235715|NCT05400525|DIETARY_SUPPLEMENT|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
219235716|NCT05400525|OTHER|Placebo control|3g Maltodextrin (i.e. DE 10) daily
219235717|NCT05054517|DIETARY_SUPPLEMENT|Glutamine|Oral Supplement
219235718|NCT05181839|DRUG|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
219735121|NCT02512159|PROCEDURE|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
219235719|NCT05967156|DRUG|Empagliflozin10Mg Tab|10 mg daily
219735122|NCT02512159|PROCEDURE|Healing|"Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
219735123|NCT01386320|PROCEDURE|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
219735124|NCT01386320|PROCEDURE|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
219735125|NCT00270075|DRUG|epoetin alfa|
219735126|NCT01911325|DRUG|Buparlisib|
219735127|NCT01911325|DRUG|Buparlisib matching placebo|
219735128|NCT01911325|DRUG|Docetaxel|
219735129|NCT03276481|DIAGNOSTIC_TEST|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
219235720|NCT05625438|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
219235721|NCT06492226|DRUG|NKF-INS(A)|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
219235722|NCT06492226|DRUG|EU-NovoRapid®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
219235723|NCT06492226|DRUG|US-NovoLog®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
219235724|NCT03458494|OTHER|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
219235725|NCT03458494|OTHER|Low-fat diet|Participants will receive meals with a low content of total fat.
219296617|NCT06399133|OTHER|Abdominal massage|Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
219235726|NCT06794723|DIETARY_SUPPLEMENT|5-strain probiotic plus prebiotic natural health product|"The investigational product is a 5-strain probiotic plus prebiotic natural health product for patients with Type 2 diabetes. Other ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening. There is ≥ 2 billion AFU per dose in total."
219235727|NCT06794723|OTHER|Placebo|"Ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening."
219235728|NCT06802328|DRUG|Foralumab TZLS-401 50 µg|"Foralumab 50 µg/dosing day for patients who have failed current therapies. Patients will be dosed in 3-week cycles, with foralumab dosing on Days 1, 3 and 5 of the first and second weeks, followed by a rest week. Patients will receive Day 1 doses of nasal foralumab under supervision at the Center for Clinical Investigation at BWH."
219235729|NCT04526587|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
219235730|NCT04526587|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219235731|NCT04526587|OTHER|Medical Chart Review|Patient's electronic health records are reviewed
219235732|NCT04810351|OTHER|observational study|There is no intervention. It is an observational study
219735130|NCT03276481|DIAGNOSTIC_TEST|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
219735131|NCT03276481|DIAGNOSTIC_TEST|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
219735132|NCT03276481|BEHAVIORAL|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
219235733|NCT04764695|DIAGNOSTIC_TEST|D2O dilution technique|Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
219235734|NCT02713217|OTHER|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
219235735|NCT02713217|OTHER|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
219235736|NCT06296277|OTHER|Intraoperative mechanical ventilation for surgery|Any IMV during general anesthesia for surgery
219235737|NCT03457168|PROCEDURE|Treatment of elevated asleep SBP mean|To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
219235738|NCT04396717|BIOLOGICAL|Pritumumab|Pritumumab IgG1 human monoclonal antibody
219235739|NCT02880293|DRUG|melphalan|melphalan (140 mg/m2 IV on day -7)
219235740|NCT02880293|DRUG|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
219235741|NCT02880293|DRUG|thiotepa|thiotepa (5 mg/kg IV on day -67)
219235742|NCT02880293|DRUG|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
219735133|NCT02619812|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
219735134|NCT02619812|DRUG|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
219235743|NCT02880293|DRUG|Mesna|
219235744|NCT02880293|DRUG|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
219235745|NCT02880293|DRUG|Filgrastim|
219235746|NCT02880293|DRUG|Tacrolimus|
219235747|NCT06395987|PROCEDURE|Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.|Use Of Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.
219235748|NCT02221934|DEVICE|Altius|Electrical signal
219735135|NCT02619812|OTHER|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
219735136|NCT00981175|BIOLOGICAL|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
219735137|NCT00981175|BIOLOGICAL|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
219735138|NCT01834651|DRUG|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
219735139|NCT01242046|DIETARY_SUPPLEMENT|Caffeine|400 mg of caffeine in tablet form
219735140|NCT01242046|DIETARY_SUPPLEMENT|Placebo|Inert tablet
219735141|NCT05961384|DRUG|baxdrostat|a blood pressure lowering drug, oral dose
219735142|NCT02924116|DEVICE|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
219735143|NCT01197105|BIOLOGICAL|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
219735144|NCT02728726|DRUG|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
219735145|NCT02728726|DRUG|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
219735146|NCT01060969|DRUG|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
219735147|NCT01060969|DRUG|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
219735148|NCT03444688|OTHER|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
219235749|NCT05290155|DRUG|anti-CD7 CAR-T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
219235750|NCT05109065|DIAGNOSTIC_TEST|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
219235751|NCT05109065|DIAGNOSTIC_TEST|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
219235752|NCT05109065|DIAGNOSTIC_TEST|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
219235753|NCT05109065|DIAGNOSTIC_TEST|Vitals|Height and weight will be measured in order to calculate BMI.
219235754|NCT05109065|DIAGNOSTIC_TEST|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
219235755|NCT05109065|DIAGNOSTIC_TEST|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
219235756|NCT05109065|DIAGNOSTIC_TEST|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
219235757|NCT05109065|DIAGNOSTIC_TEST|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
219235758|NCT04410003|BIOLOGICAL|Fecal microbial transplant|Fecal microbial transplant
219235759|NCT05715957|OTHER|No intervention|No intervention
219235760|NCT06847997|OTHER|Addition of telemedicine to standard medical dispatching process (Experimental Group)|In the experimental group, the same approach is used, with the addition of telemedicine using video calls. Callers are invited to use their smartphone camera to enable real-time video assessment. The medical dispatcher sends a secure link (via a platform provided by Enovacom, Nomadeec, Bordeaux, France) to the caller's smartphone, allowing video streaming through a secure internet connection. Once the link is validated by the caller, the live video feed from the smartphone camera is transmitted directly to the dispatcher's computer screen, providing a visual evaluation to support clinical decision-making.
219235761|NCT04440579|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
219235762|NCT04440579|PROCEDURE|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
219235763|NCT04440579|PROCEDURE|Standard Cystoscopy|Patient will undergo standard cystoscopy
219235764|NCT03809169|PROCEDURE|Rapid on-site evaluation (ROSE)|Pathologist on site for direct evaluation of specimen adequacy
219235765|NCT03809169|PROCEDURE|Slim bronchoscope without a guide sheath|peripheral endobronchial ultrasound performed with a slim bronchoscope (3.0 mm outer diameter with a 1.7mm channel) combined with a radial ultrasound probe but without the use of a guide sheath.
219235766|NCT03809169|PROCEDURE|Standard pEBUS with guide sheath|Using a flexible bronchoscope with minimal outer diameter of 4.2mm.
219235767|NCT03121261|DRUG|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
219735149|NCT03444688|DEVICE|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
219735150|NCT00000778|DRUG|Isoniazid|
219735151|NCT00000778|DRUG|Pyridoxine hydrochloride|
219735152|NCT00000778|DRUG|Levofloxacin|
219735153|NCT02559960|DRUG|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
219735154|NCT02884960|PROCEDURE|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
219735155|NCT03592992|DRUG|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
219735156|NCT03592992|DRUG|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
219735157|NCT05813483|OTHER|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
219735158|NCT05813483|OTHER|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
219235768|NCT03121261|DRUG|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
219235769|NCT05045664|RADIATION|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
219235770|NCT05045664|RADIATION|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
219235771|NCT05045664|DRUG|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
219235772|NCT05045664|DRUG|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
219735159|NCT04289272|BEHAVIORAL|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
219735160|NCT00693108|DRUG|Transdermal testosterone|
219735161|NCT02011997|PROCEDURE|patients undergo cVATS segmentectomy|
219735162|NCT02011997|PROCEDURE|Patients undergo cVATS lobectomy|
219735163|NCT01681303|DRUG|AST-120|
219735164|NCT03578263|DRUG|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
219735165|NCT03578263|DRUG|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
219235773|NCT02795052|PROCEDURE|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
219235774|NCT02004834|DRUG|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
219235775|NCT05928689|DRUG|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
219235776|NCT05928689|BEHAVIORAL|Reminder|Reactivation of misophonia trigger memory
219235777|NCT05928689|BEHAVIORAL|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
219235778|NCT05928689|DRUG|Placebo|Matching placebo tablet
219735166|NCT03578263|DRUG|ergometrine|intramuscular ergometrine 0.2 mg.
219735167|NCT02303938|BEHAVIORAL|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
219735168|NCT05986058|BEHAVIORAL|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
219735169|NCT05875610|DRUG|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
219735170|NCT05875610|DRUG|Gabapentin 400 mg|Gabapentin 400 mg capsules
219735171|NCT06005831|OTHER|sandbag|The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
219735172|NCT04065256|OTHER|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
219735173|NCT04065256|OTHER|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
219735174|NCT04483219|DRUG|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
219735175|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
219735176|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
219735177|NCT01379937|BIOLOGICAL|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
219735178|NCT01379937|BIOLOGICAL|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
219735179|NCT02440529|BEHAVIORAL|Intervention|Discussion
219735180|NCT02440529|BEHAVIORAL|Verbal Group|Detailed Discussion
219735181|NCT06366919|DIAGNOSTIC_TEST|Alexander Technique (AT)|The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance
219735182|NCT06366919|DIAGNOSTIC_TEST|Feldenkrais Technique (FT)|The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
219735183|NCT06430411|PROCEDURE|Radical prostatectomy|Removal of the prostate and seminal vesicles.
219735184|NCT06430411|RADIATION|Prostate irradiation|Radiation therapy of the prostate.
219735185|NCT06430411|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases.
219735186|NCT06430411|RADIATION|Irradiation of metastases|Radiation therapy of metastases.
219735187|NCT06430411|DRUG|Abiraterone acetate|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735188|NCT06430411|DRUG|Enzalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735189|NCT06430411|DRUG|Darolutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735190|NCT06430411|DRUG|Apalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735191|NCT06430411|DRUG|Docetaxel|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735192|NCT06430411|DRUG|Lutetium-PSMA|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735193|NCT06430411|DRUG|Androgen deprivation treatment|Administered as part of multimodal treatment for oligometastatic prostate cancer
219735194|NCT00741221|DRUG|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
219735195|NCT00741221|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
219735196|NCT01104870|DRUG|UT-15C|oral
219735197|NCT06467058|DEVICE|DABQ questionnaire versus Actigraph as reference method|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
219735198|NCT05020119|DRUG|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
219735199|NCT02006615|DEVICE|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
219735200|NCT02006615|DEVICE|rTMS|To modulate brain cortex
219735201|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
219735202|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk|125 ml UHT milk given to placebo group
219735203|NCT01515254|BEHAVIORAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
219735204|NCT04287556|DIAGNOSTIC_TEST|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
219735205|NCT04287556|DIAGNOSTIC_TEST|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
219735206|NCT04287556|DIAGNOSTIC_TEST|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
219735207|NCT00404300|DRUG|Optivate|Plasma-derived Factor VIII
219735208|NCT05566054|DRUG|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
219735209|NCT05566054|DRUG|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
219735210|NCT05566054|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
219735211|NCT04985682|BIOLOGICAL|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
219735212|NCT00501943|DRUG|Avonex (Interferon beta 1a)|
219735213|NCT00501943|DRUG|Riluzole|
219161743|NCT02954211|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
219161744|NCT02954211|BEHAVIORAL|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
219161745|NCT02320877|DEVICE|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
219161746|NCT03261908|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219735214|NCT00501943|DRUG|Placebo|
219735215|NCT02134808|DRUG|Creatine|Creatine is a nutritional supplement.
219735216|NCT02134808|DRUG|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
219735217|NCT06537466|DIETARY_SUPPLEMENT|Mediterranean diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
219735218|NCT06537466|DIETARY_SUPPLEMENT|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
219735219|NCT04052126|OTHER|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
219735220|NCT02317042|DEVICE|Juno|Juno device set to ST mode with participant's current therapy settings.
219161747|NCT05057936|BIOLOGICAL|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
219735221|NCT02317042|DEVICE|Juno|Juno device set to AutoEPAP iVAPS mode.
219735222|NCT02317042|DEVICE|Juno|Juno device set to Fixed EPAP iVAPS mode.
219735223|NCT06429085|DEVICE|Rex robotic assisted balance exercises|Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
219735224|NCT05118438|OTHER|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
219735225|NCT03093246|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
219735226|NCT03093246|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
219735227|NCT03093246|OTHER|Placebo|Placebo pills over a period of 180 days
219161748|NCT01541436|DEVICE|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
219161749|NCT00643188|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
219161750|NCT00643188|OTHER|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
219161751|NCT05106075|PROCEDURE|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
219735228|NCT03093246|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
219735229|NCT00043680|DRUG|Celecoxib|
219161752|NCT00426829|DRUG|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
219161753|NCT00426829|RADIATION|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
219161754|NCT00000749|BIOLOGICAL|rgp120/HIV-1 SF-2|
219161755|NCT03237975|BEHAVIORAL|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
219161756|NCT03237975|OTHER|Routine health education|The control group will receive routine health education.
219161757|NCT05819242|DIAGNOSTIC_TEST|Angulus|Smartphone app
219161758|NCT02755259|DRUG|Acetazolamide|
219161759|NCT02755259|DRUG|Placebo|
219161760|NCT01766154|DRUG|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
219161761|NCT04110054|DRUG|S-600918|Tablets for oral administration
219161762|NCT04110054|DRUG|Placebo to S-600918|Tablets for oral administration
219735230|NCT03644446|BIOLOGICAL|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
219735231|NCT05338450|DRUG|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
219161763|NCT04363866|DRUG|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
219161764|NCT04363866|DRUG|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
219735232|NCT05338450|DRUG|Placebo|Placebo equivalent to experimental arm
219735233|NCT00005898|DRUG|anti-thymocyte globulin|
219735234|NCT00005898|DRUG|cyclophosphamide|
219735235|NCT00005898|DRUG|cyclosporine|
219735236|NCT00005898|DRUG|filgrastim|
219735237|NCT00005898|DRUG|fludarabine|
219735238|NCT00005898|DRUG|methylprednisolone|
219735239|NCT06548620|DRUG|RD06-04 cell infusion|CAR T Cells
219735240|NCT06548295|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|"Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks"
219735241|NCT06548295|COMBINATION_PRODUCT|conservative treatment|"The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues"
219735242|NCT01008046|DRUG|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
219735243|NCT01008046|DRUG|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
219735244|NCT04206943|BIOLOGICAL|Car-T Cell Therapy|"Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
219161765|NCT05021341|DIETARY_SUPPLEMENT|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
219735245|NCT00079781|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
219735246|NCT00079781|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
219735247|NCT03386058|DEVICE|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
219735248|NCT04641975|DRUG|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
219735249|NCT04641975|DRUG|Placebo|Oral/ Oral Suspension
219735250|NCT00592527|DRUG|insulin detemir|
219735251|NCT03543020|RADIATION|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
219735252|NCT04403126|OTHER|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
219735253|NCT02920047|DRUG|Fimasartan/Amlodipine|Treatment B
219735254|NCT02920047|DRUG|Fimasartan + Amlodipine|Treatment A
219735255|NCT05489458|PROCEDURE|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
219735256|NCT05489458|PROCEDURE|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
219735257|NCT04304196|OTHER|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
219735258|NCT04304196|OTHER|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
219735259|NCT00087672|DRUG|CC-5013|10 mg orally (2 capsules) daily
219735260|NCT02220400|DRUG|Ketamine|
219735261|NCT03374956|DRUG|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
219735262|NCT03374956|DRUG|Liraglutide|dose of 3 mg subcutaneous daily
219735263|NCT03374956|DRUG|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
219735264|NCT03374956|DRUG|Phentermine|15-37.5 mg oral daily
219735265|NCT01546987|DRUG|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
219735266|NCT01546987|DRUG|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
219735267|NCT01546987|DRUG|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
219735268|NCT01546987|RADIATION|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
219735269|NCT06540495|BEHAVIORAL|Salaso Virtual Exercise Program|Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
219735270|NCT03059888|DRUG|Abatacept Injection|Subcutaneous administration of abatacept
219735271|NCT04975165|PROCEDURE|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
219735272|NCT05398666|DEVICE|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
219735273|NCT05398666|DEVICE|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
219735274|NCT02520362|DRUG|denosumab|subcutaneous injection
219161766|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
219161767|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
219735275|NCT02520362|DRUG|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
219161768|NCT05021341|DIETARY_SUPPLEMENT|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
219735276|NCT06639815|OTHER|clinical and radiographic examination|clinical and radiographic examination
219161769|NCT02711865|BIOLOGICAL|IGF1R antibody MK0646|
219735277|NCT06566365|OTHER|Subcostal Transversus Abdominis Plane Block|After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
219735278|NCT06581692|OTHER|This is a routine procedure, no intervention will be provided.|This is a routine procedure, no intervention will be provided.
219735279|NCT03596983|BEHAVIORAL|Sleep Intervention|"* Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)"
219161770|NCT02711865|OTHER|Saline solution|
219161771|NCT05371275|DRUG|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
219161772|NCT00093015|DRUG|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
219735280|NCT03596983|BEHAVIORAL|Week 2 Intervention|"* Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)"
219735281|NCT03381651|RADIATION|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
219735282|NCT03381651|RADIATION|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
219735283|NCT02663570|DRUG|Melatonin|
219735284|NCT03024671|OTHER|Patch test application|test patch with cosmetic product will be applied to the back
219735285|NCT06043765|DEVICE|real repetitive transcranial magnetic stimulation (rTMS)|real rTMS -- 3 sessions a week/7 weeks (21 sessions)
219735286|NCT06043765|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|sham rTMS - 3 sessions a week/7 weeks (21 sessions)
219735287|NCT06043765|BEHAVIORAL|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
219735288|NCT05287685|BEHAVIORAL|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
219235779|NCT04944836|DRUG|Clomiphene Citrate|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
219235780|NCT04944836|PROCEDURE|Rotator Cuff Repair|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
219235781|NCT03565640|DEVICE|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
219235782|NCT03565640|DEVICE|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
219235783|NCT05941715|DRUG|Aflibercept 40 MG/ML|treat-and-extend
219235784|NCT05941715|DRUG|Faricimab 120 MG/ML|treat-and-extend
219235785|NCT05324605|PROCEDURE|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
219235786|NCT05169580|DRUG|Pociredir oral capsule(s)|Participants will receive Pociredir
219235787|NCT06149416|DEVICE|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
219235788|NCT05953415|DEVICE|active iTBS|Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
219735289|NCT05287685|BEHAVIORAL|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
219735290|NCT00920270|DRUG|nebulized colistin|nebulized colistin 75 mg every 12 hours
219735291|NCT00920270|DRUG|antibiotics|conventional parenteral antibiotics
219161773|NCT00093015|DRUG|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
219735292|NCT04541693|DEVICE|Full revision|Both cup and stem require revision
219735293|NCT04541693|DEVICE|Cup revision|Only the cup requires revision
219735294|NCT04541693|DEVICE|Stem revision|Only the stem requires revision
219735295|NCT04284436|BEHAVIORAL|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
219735296|NCT05222581|DEVICE|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
219735297|NCT06162312|OTHER|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
219161774|NCT03836378|PROCEDURE|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
219161775|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
219161776|NCT06635902|OTHER|Placebo|Isotonic normal saline
219161777|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
219235789|NCT05953415|DEVICE|sham iTBS|Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
219235790|NCT06039566|DRUG|IV N-acetylcysteine|N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
219235791|NCT06039566|DRUG|IV Placebo|Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
219735298|NCT05887661|PROCEDURE|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
219735299|NCT04578418|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
219735300|NCT04578418|OTHER|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
219735301|NCT04578418|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation twice daily
219735302|NCT06636851|DEVICE|Pacemaker and defibrillator|Permenant pacemaker implantation with lead fixed to the RV Septal location
219735303|NCT06636851|DEVICE|Pacemaker and defibrillator|Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
219735304|NCT06642987|DRUG|Vonoprazan Test 20mg|1 tablets orally once a day
219735305|NCT06642987|DRUG|Vonoprazan Reference 20mg|1 tablets orally once a day
219735306|NCT06644872|OTHER|Bedrest|Investigation of the effect of short-term bed rest (3 hours) on heart function, measured by cardiac magnetic resonance, in healthy participants ( males and females)
219735307|NCT01932463|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
219735308|NCT03093870|DRUG|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219735309|NCT03093870|DRUG|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
219735310|NCT03093870|DRUG|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
219735311|NCT01660685|BEHAVIORAL|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
219735312|NCT01660685|BEHAVIORAL|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
219735313|NCT01660685|BEHAVIORAL|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
219735314|NCT01660685|BEHAVIORAL|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
219735315|NCT00980629|DRUG|M516102|Twice a day
219735316|NCT00980629|DRUG|placebo|Twice a day
219735317|NCT02921282|GENETIC|Genotype dopamine|Laboratory investigations of nicotine reinforcement
219735318|NCT02921282|GENETIC|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
219735319|NCT00005775|DRUG|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
219735320|NCT00005775|DRUG|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
219161778|NCT01261052|DEVICE|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
219161779|NCT01261052|DEVICE|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
219161780|NCT06635564|DIAGNOSTIC_TEST|Viscoelastic testing|viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
219735321|NCT04008069|DRUG|Sarilumab|Sarilumab 200 mg administered subcutaneously
219735322|NCT04008069|DRUG|Placebo|Placebo administered subcutaneously
219735323|NCT03227627|DEVICE|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
219735324|NCT03227627|OTHER|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
219735325|NCT00005995|DRUG|shark cartilage extract AE-941|
219735326|NCT02767687|OTHER|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
219735327|NCT02155972|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotic supplement
219735328|NCT02155972|OTHER|Placebo|Placebo capsules
219735329|NCT04213339|BEHAVIORAL|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
219735330|NCT01345942|DRUG|RO5428029|Single oral dose
219735331|NCT01843504|BIOLOGICAL|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
219735332|NCT01843504|OTHER|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
219735333|NCT03847805|OTHER|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
219735334|NCT03847805|OTHER|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
219735335|NCT02145611|DRUG|Glibenclamide|Glibenclamide
219735336|NCT02145611|DRUG|Vildagliptin|Vildagliptin
219735337|NCT01235117|DRUG|azacitidine|
219735338|NCT01235117|OTHER|laboratory biomarker analysis|
219161781|NCT03814369|DEVICE|AmplifEYE|AmplifEYE colonoscopy
219161782|NCT06796543|RADIATION|Consolidative radiation therapy (cRT)|Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.
219735339|NCT05860868|DRUG|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
219735340|NCT05860868|DRUG|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
219735341|NCT05853159|OTHER|Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy
219735342|NCT02983942|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
219735343|NCT02983942|DIETARY_SUPPLEMENT|Routine diet|Routine diet is given without blood ketone requirement
219735344|NCT02201628|DEVICE|Nasopharyngeal and oesophageal temperature probes|
219161783|NCT05471128|PROCEDURE|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
219735345|NCT00803907|DRUG|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
219735346|NCT00997191|PROCEDURE|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
219735347|NCT00997191|DRUG|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
219161784|NCT00294840|DEVICE|PET-CT|
219161785|NCT05493969|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
219161786|NCT05493215|DRUG|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
219735348|NCT00997191|DRUG|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
219235792|NCT06363487|DRUG|Semaglutide, 0.5 mg/mL|Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
219735349|NCT02134028|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
219735350|NCT01891838|PROCEDURE|Volume controlled ventilation|
219735351|NCT01891838|PROCEDURE|Pressure-controlled ventilation|
219735352|NCT02517138|OTHER|Parabolic flight|
219735353|NCT02517138|OTHER|Measurements of eye movements and perception|
219735354|NCT06278298|DEVICE|Shockwave|CDT and different dose of shockwave
219735355|NCT06278298|OTHER|CDT|CDT
219735356|NCT00305279|OTHER|Dietary|Dietary
219735357|NCT00305279|OTHER|Dietary|Dietary
219735358|NCT00305279|OTHER|Dietary|Dietary
219735359|NCT01347957|OTHER|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
219161787|NCT05090813|DEVICE|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
219161788|NCT05370794|DRUG|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
219161789|NCT05370794|DRUG|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
219161790|NCT01408849|DRUG|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
219161791|NCT01408849|DRUG|Omeprazole|Standard therapy
219161792|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
219735360|NCT01347957|OTHER|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
219735361|NCT01585701|BIOLOGICAL|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
219161793|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
219161794|NCT04421469|DRUG|Triprilimab(JS001)|"1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment."
219735362|NCT01935154|DRUG|Vx-001|
219735363|NCT01935154|DRUG|Placebo|
219735364|NCT06333158|DIETARY_SUPPLEMENT|Cholesfytol NG|3 capsules a day with dinner.
219735365|NCT06333158|OTHER|Placebo|3 capsules a day with dinner
219735366|NCT01029197|BEHAVIORAL|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
219735367|NCT01029197|OTHER|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
219735368|NCT03486639|OTHER|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
219735369|NCT03115463|OTHER|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
219735370|NCT00819832|PROCEDURE|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
219735371|NCT00819832|PROCEDURE|Vertebroplasty|Medical cement will be injected into broken back bone.
219735372|NCT00819832|DEVICE|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
219735373|NCT01002729|OTHER|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI \< 30 given Oseltamivir
219735374|NCT01002729|OTHER|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI \> 40 given Oseltamivir
219735375|NCT04062604|OTHER|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
219735376|NCT02229292|DRUG|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
219735377|NCT02229292|DRUG|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
219735378|NCT02636036|BIOLOGICAL|enadenotucirev|
219735379|NCT02636036|BIOLOGICAL|nivolumab|
219735380|NCT00338000|DRUG|Epoetin alfa|
219735381|NCT04885010|DIETARY_SUPPLEMENT|probiotics|participants will be given probiotics twice a day for 15 days
219735382|NCT04885010|DIETARY_SUPPLEMENT|placebo|participants will be given a placebo twice a day for 15 days
219735383|NCT03656614|DRUG|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
219161795|NCT00632203|DRUG|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
219161796|NCT01411631|DIETARY_SUPPLEMENT|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
219161797|NCT02641912|OTHER|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
219161798|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
219161799|NCT05713526|BEHAVIORAL|Telehealth service|Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
219161800|NCT03928522|DRUG|hand mixed vancomycin|hand mixed vancomycin powder into cement
219161801|NCT03928522|DRUG|hand mixed tobramycin|hand mixed tobramycin into cement
219161802|NCT03928522|DEVICE|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
219161803|NCT05350904|OTHER|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
219161804|NCT06464393|DRUG|ketamine-lidocaine-dexmedetomidine|Patients will be administered 0,8 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations just before induction of anesthesia.
219161805|NCT06464393|DRUG|fentanyl|Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
219161806|NCT01150916|PROCEDURE|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
219161807|NCT00039234|BIOLOGICAL|aldesleukin|
219161808|NCT00039234|DRUG|histamine dihydrochloride|
219161809|NCT04287985|DRUG|Dose-Placebo|Unit Dose Strength - 0.9%.
219161810|NCT04287985|DRUG|Low Dose-VIS649|Dose Level = Low
219161811|NCT04287985|DRUG|Medium Dose-VIS649|Dose Level = Medium
219161812|NCT04287985|DRUG|High Dose-VIS649|Dose Level = High
219161813|NCT01737489|BEHAVIORAL|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
219161814|NCT01737489|BEHAVIORAL|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
219161815|NCT05751785|OTHER|Physical Therapy|All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
219161816|NCT05751785|DEVICE|Shockwave Therapy|A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
219235793|NCT06363487|OTHER|Placebo, 0.9% NaCl 1.5mL|Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
219235794|NCT05683821|BEHAVIORAL|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~* SmokefreeTXT (if ready to set a quit date in the next 14 days)~* Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~* Daily Challenges (if not ready to quit, but willing to make some changes)"
219235795|NCT05683821|DRUG|Nicotine replacement therapy sampling|"Participants may request:~* Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~* Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
219235796|NCT05683821|COMBINATION_PRODUCT|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
219735384|NCT03656614|DRUG|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
219235797|NCT05683821|COMBINATION_PRODUCT|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
219235798|NCT05683821|COMBINATION_PRODUCT|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
219235799|NCT05683821|BEHAVIORAL|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
219235800|NCT01811459|DRUG|Quetiapine|PO
219235801|NCT01811459|DRUG|Haloperidol|IV
219235802|NCT01811459|DRUG|Placebo|PO or IV
219235803|NCT06288685|PROCEDURE|percutaneous A1 pulley release|Treatment trigger finger by release A1 pulley by percutaneous procedure
219235804|NCT06288685|DRUG|Triamcinolone|Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
219235805|NCT00264576|BIOLOGICAL|Influenza Virus Vaccine|
219235806|NCT01921166|DRUG|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
219235807|NCT01921166|DRUG|Leuprolide flare|Leuprolide flare ovulation induction
219735385|NCT03656614|DRUG|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
219735386|NCT04269187|DRUG|Theophylline|Theophylline oral 200 mg daily for 12 days
219735387|NCT00666575|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
219735388|NCT00666575|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
219735389|NCT03378934|DRUG|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
219735390|NCT03378934|DRUG|Standard treatment|Standard treatment for 12±1 weeks.
219735391|NCT03378934|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
219735392|NCT03378934|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
219735393|NCT01400152|DEVICE|Additional active warming|Chemical heat pad applied to the upper torso
219735394|NCT05377814|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
219735395|NCT06010108|BEHAVIORAL|Heroes for Her|Market outreach intervention- daily awareness creation through public market announcements, and distribution of educational fliers in local dialects. Community women will also be involved in the spread awareness through door to door approach. Thee will be repeated radio jingles to promote awareness. Interested women and girls will be provided with screening and vaccination services at a designated community health facility. All samples will be returned to the facility by the women and sent to a designated laboratory for testing. Participants contact information will be collected for follow up
219735396|NCT06010108|BEHAVIORAL|The Reach Initiative|School based intervention-The Reach Initiative involves the organisation of the Mother-Daughter Day (MDD) by Mother-Daughter Planning Committee (MDPC) who are volunteer young school girls and their mothers and provision of a Key-Card which is a cervical cancer awareness card attached to a key chain for awareness creation. HPV vaccination and HPV -self sampling will be carried out in private rooms within the venue of the intervention and all samples will be sent to designated laboratory for testing. Participants contact information will be collected for follow up and communication of results
219235808|NCT00990132|DEVICE|Home mechanical ventilation|Nocturnal non-invasive ventilation
219235809|NCT00990132|DEVICE|Long term oxygen therapy|LTOT established as per national guidelines
219235810|NCT02659059|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219235811|NCT02659059|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
219235812|NCT02659059|DRUG|Platinum Doublet Chemotherapy|
219235813|NCT02470312|PROCEDURE|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
219735397|NCT06010108|BEHAVIORAL|W.H.I.T.E project|Community based intervention- This will involve the engagement of women's trade unions and organisations in the community to create awareness and women and girls interested in the uptake of HPV prevention services will be directed to receive these services at a designated community facility accessible to women and girls in the community. Participants contact details will be collected for follow uo and communication of results
219161817|NCT05751785|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm\^2 that is applied in a serpentine manner over the site of injury.
219161818|NCT03762772|DRUG|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
219735398|NCT06010108|BEHAVIORAL|Project Shield|Utilization of community based structures (pharmacy and health center)- The intervention will involve the creation of a branded self-sampling kit for HPV screening and a free vaccination voucher to encourage mother-daughter uptake of cervical cancer prevention measures. Awareness will be raised through banners at the points of access of the vaccines and kits, use of jingles, and the involvement of the Community Development Association (CDA) to help mobilize girls, women and the men. Women and girls will be referred to community health centers to receive the HPV vaccination and carry out the screening
219735399|NCT06010108|BEHAVIORAL|Project SHADE|"Community-based approach- health education of girls and women. The use of a uniquely designed bag Eno Iban to package and distribute the self-collection tool, vaccination of the adolescent girls. Screening and HPV will be provided at designated areas within the community for women and girls. A simple app (d-SHADE) will be used to collect data of the girls and women by the health professionals and volunteers, as well as send the reminders for next screening dates and test results"
219735400|NCT06010108|BEHAVIORAL|Operation Reach Her (ORH) program|"Faith based approach- Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention, and the benefits of screening and HPV vaccination. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. The self-sampling kit would be distributed to women aged 30-65 in mobile tents stationed in churches in Akoka and HPV vaccinations would be administered to girls aged 9-14 in mobile tents stationed at churches and mosques in Akoka, Lagos"
219735401|NCT06010108|BEHAVIORAL|Project Care|Community pharmacy intervention-Trained community volunteers will be involved in creating awareness of HPV prevention services and cervical cancer. There will be distribution of cervical cancer self-sampling kits to community pharmacies which will serve as service points for screening (self-collection point) and vaccination point for girls in the community,
219735402|NCT02800746|DRUG|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
219735403|NCT02800746|DRUG|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
219735404|NCT01946646|DRUG|S-1-CCRT|
219735405|NCT01923974|DRUG|Melatonin 10 mg|
219735406|NCT01923974|DRUG|Melatonin 100 mg|
219735407|NCT01923974|DRUG|Placebo|
219735408|NCT03376412|DEVICE|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
219735409|NCT02448173|BIOLOGICAL|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
219735410|NCT02448173|PROCEDURE|Surgery|Surgical resection of Stage II colon cancer
219735411|NCT04969107|PROCEDURE|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
219161819|NCT04953273|OTHER|Vigitrauma|Case management algorithm using early phone contact
219235814|NCT02470312|DEVICE|MediGuide|
219735412|NCT04969107|PROCEDURE|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
219735413|NCT02187081|PROCEDURE|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
219735414|NCT02187081|PROCEDURE|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
219735415|NCT00021359|DRUG|dexamethasone|
219735416|NCT00021359|DRUG|isotretinoin|
219735417|NCT02226783|DRUG|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
219735418|NCT02226783|DRUG|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
219735419|NCT02226783|DRUG|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
219735420|NCT03555097|PROCEDURE|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
219735421|NCT02261532|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219735422|NCT05124236|RADIATION|preoperative radiosurgery|single fraction radiosurgery
219735423|NCT05124236|RADIATION|postoperative hypofractionated stereotactic radiotherapy|5 fraction stereotactic radiotherapy /fractionated radiosurgery
219735424|NCT03413449|DIAGNOSTIC_TEST|Frailty model|"1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk"
219735425|NCT06439706|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling kit
219735426|NCT06439706|BEHAVIORAL|Group Education|Small-group education led by bilingual health educator
219735427|NCT03242070|OTHER|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
219735428|NCT02842281|OTHER|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
219735429|NCT02842281|OTHER|Maltodextrin|Polysaccharide produced from starch
219735430|NCT06549868|BEHAVIORAL|Yoga-based bedtime routine|"Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period."
219735431|NCT05725525|BEHAVIORAL|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
219735432|NCT05756309|DEVICE|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
219735433|NCT02777190|DRUG|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
219735434|NCT00707304|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
219735435|NCT00707304|DRUG|Placebo|Oral, twice per day
219735436|NCT02708368|OTHER|blood withdrawal|3 times
219735437|NCT00127543|BEHAVIORAL|Medication Education for Children|
219735438|NCT04757857|DRUG|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
219735439|NCT04562519|DEVICE|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
219735440|NCT06571071|OTHER|De-Stress and Chill Gummies-U001|Two gummies in sequence daily after meal for 60 days
219735441|NCT06571071|OTHER|De-Stress and Chill Gummies-I001|Two gummies in sequence daily after meal for 60 days
219735442|NCT06571071|OTHER|Placebo Gummies-001|Two gummies in sequence daily after meal for 60 days
219161820|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
219161821|NCT05205798|BEHAVIORAL|Washout period|No interventional food consumption for 1 week
219735443|NCT04801693|DRUG|BI 1819479|BI 1819479
219735444|NCT04801693|DRUG|Placebo|Placebo
219735445|NCT03063164|DEVICE|Intralase IFS150|Intralase flap creation
219735446|NCT03063164|DEVICE|Visumax|Visumax flap creation
219735447|NCT04421001|DEVICE|I-port use|patient will use I-port device fo 2 months
219735448|NCT02005926|PROCEDURE|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
219735449|NCT03030209|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
219735450|NCT01452789|DRUG|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
219735451|NCT01452789|DRUG|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
219735452|NCT01340170|DEVICE|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
219735453|NCT05912725|PROCEDURE|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
219161822|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
219235815|NCT02470312|PROCEDURE|EP|
219735454|NCT03878602|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
219735455|NCT03878602|PROCEDURE|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
219735456|NCT03186924|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
219735457|NCT05456217|OTHER|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
219735458|NCT01289587|BEHAVIORAL|Physical activity intervention|36 sessions of physical activity offered at different frequencies
219735459|NCT02443129|DEVICE|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
219735460|NCT00198744|BEHAVIORAL|Medifast FIT! for Kids|
219735461|NCT00198744|BEHAVIORAL|standard recommendations for dietary intake in children|
219735462|NCT00198744|BEHAVIORAL|both diet plans with and without a parent dieting|
219735463|NCT03901209|DEVICE|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
219735464|NCT00624078|DRUG|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
219235816|NCT03471637|OTHER|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
219235817|NCT01633359|DRUG|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
219235818|NCT01633359|DRUG|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
219235819|NCT04693013|DEVICE|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
219235820|NCT00700557|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
219235821|NCT00700557|DIETARY_SUPPLEMENT|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
219235822|NCT03976102|BIOLOGICAL|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
219235823|NCT03976102|OTHER|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
219235824|NCT03527888|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219235825|NCT00965471|DRUG|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
219235826|NCT00965471|DRUG|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
219235827|NCT02233075|DRUG|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
219235828|NCT01970072|DRUG|Remimazolam Tosylate|
219235829|NCT01970072|DRUG|Midazolam|
219235830|NCT04057300|DRUG|Ticagrelor 90mg|Ticagrelor tablet
219235831|NCT04057300|DRUG|Clopidogrel 75mg|Clopidogrel tablet
219235832|NCT04057300|DRUG|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
219235833|NCT04110392|DIETARY_SUPPLEMENT|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
219235834|NCT05449756|OTHER|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
219735465|NCT05039385|OTHER|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
219735466|NCT02285244|DRUG|sotrastaurin acetate|Given PO
219735467|NCT02285244|OTHER|pharmacological study|Correlative studies
219735468|NCT02285244|OTHER|laboratory biomarker analysis|Correlative studies
219735469|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
219735470|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
219235835|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
219235836|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
219235837|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
219735471|NCT01554852|DRUG|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
219735472|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
219735473|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
219735474|NCT01554852|DRUG|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
219735475|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
219735476|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
219735477|NCT01554852|DRUG|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
219735478|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
219735479|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
219735480|NCT03722030|OTHER|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
219735481|NCT03722030|BEHAVIORAL|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
219735482|NCT03722030|OTHER|Mid-point Measures|Accelerometer (steps)
219735483|NCT03722030|OTHER|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
219735484|NCT05223712|OTHER|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
219735485|NCT01628809|BEHAVIORAL|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
219735486|NCT03272893|BEHAVIORAL|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
219735487|NCT06300684|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
219161823|NCT02638337|DRUG|Ospemifene|60 mg tablet
219161824|NCT02638337|DRUG|Placebo|Tablet identical to the ospemifene tablet without drug
219161825|NCT02988089|DRUG|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
219161826|NCT02988089|DRUG|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
219161827|NCT02988089|DRUG|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
219161828|NCT02988089|DRUG|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
219161829|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
219161830|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
219161831|NCT03248505|DEVICE|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
219235838|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
219235839|NCT03662737|DIAGNOSTIC_TEST|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
219735488|NCT03733483|BEHAVIORAL|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
219735489|NCT03385486|BIOLOGICAL|TBX-3400|Autologous transfusion
219735490|NCT03435315|OTHER|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
219735491|NCT03435315|OTHER|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
219735492|NCT03666702|OTHER|Upper limb physiotherapy programme|Web-based physio programme
219735493|NCT03666702|OTHER|Usual care|Usual physiotherapy care
219735494|NCT00449800|DRUG|ceftriaxone|
219735495|NCT03125356|OTHER|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
219735496|NCT03480516|DEVICE|SDF|38% silver diamine fluoride solution
219735497|NCT03480516|DEVICE|Fluoride varnish|5% sodium fluoride varnish
219735498|NCT03785132|PROCEDURE|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
219161832|NCT03248505|DEVICE|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
219161833|NCT03248505|OTHER|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
219161834|NCT03248505|DEVICE|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
219161835|NCT03248505|DEVICE|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
219161836|NCT03248505|OTHER|Placebo TENS|TENS device turned on, but with zero amplitude.
219161837|NCT05673746|PROCEDURE|Acupuncture|acupuncture administration
219161838|NCT05673746|DRUG|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
219161839|NCT00920972|DRUG|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
219161840|NCT00920972|DRUG|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
219161841|NCT00920972|DRUG|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
219161842|NCT00920972|DRUG|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
219161843|NCT06436326|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear."
219161844|NCT06436326|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
219235840|NCT01491100|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
219735499|NCT03077308|PROCEDURE|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
219735500|NCT05136521|DRUG|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
219735501|NCT05136521|DRUG|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
219735502|NCT03954873|OTHER|Glucagon-like peptide 2|Human glucagon-like peptide 2
219735503|NCT03954873|OTHER|Saline|Placebo
219735504|NCT03954873|OTHER|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
219735505|NCT03954873|OTHER|Insulin|Actrapid (insulin) for lowering plasma glucose
219735506|NCT05999851|DEVICE|Arterial applanation tonometry|Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
219735507|NCT05999851|DEVICE|In vivo endothelial glycocalyx measurement|The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
219735508|NCT05999851|DIAGNOSTIC_TEST|Serum markers of angiogenesis and endothelial dysfunction|ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
219735509|NCT05999851|DIAGNOSTIC_TEST|Blood chemistry test|Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
219735510|NCT05999851|DIAGNOSTIC_TEST|Serum xanthine oxidase activity|Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
219735511|NCT06356597|DRUG|Tislelizumab with Fruquintinib, Metronidazole|"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."
219735512|NCT04338620|DRUG|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
219735513|NCT04338620|DRUG|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
219735514|NCT00240773|DRUG|acetaminophen|4 grams daily for six months
219735515|NCT00240773|DRUG|naproxen|750 mg daily for 12 months
219235841|NCT02894216|PROCEDURE|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
219735516|NCT00240773|DRUG|acetaminophen|4 grams daily for 12 months
219735517|NCT00240773|DRUG|naproxen|750 mg daily for six months
219735518|NCT00540761|DEVICE|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
219735519|NCT04088292|DRUG|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
219735520|NCT04088292|DEVICE|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
219735521|NCT05732363|DEVICE|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
219735522|NCT05732363|RADIATION|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
219735523|NCT03776240|DRUG|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
219735524|NCT03776240|DRUG|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
219735525|NCT03776240|DRUG|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
219735526|NCT01392196|PROCEDURE|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
219735527|NCT04352530|OTHER|Health Communication|Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
219735528|NCT03838705|PROCEDURE|hypoxia|It was accepted that hypoxia developed in patients with SpO2\< 92 or falling over 20% compared to preoperative values.
219735529|NCT03838705|PROCEDURE|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
219735530|NCT02214732|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
219735531|NCT00472641|DRUG|Ziprasidone/Geodon|Ziprasidone/Geodon
219735532|NCT00176215|PROCEDURE|survival failure of more than 20 %|
219735533|NCT01025895|PROCEDURE|acl reconstruction - double bundle technique|
219735534|NCT01025895|PROCEDURE|acle reconstruction - single bundle technique|
219735535|NCT04509011|DEVICE|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
219735536|NCT02325895|OTHER|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
219735537|NCT04144764|OTHER|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
219735538|NCT04144764|OTHER|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
219735539|NCT00239980|DRUG|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
219735540|NCT05865249|OTHER|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
219735541|NCT00377806|DRUG|Diclofenac gel|
219735542|NCT05907499|DRUG|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
219735543|NCT05907499|DRUG|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
219735544|NCT05907499|DRUG|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
219735545|NCT05907499|DRUG|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
219735546|NCT02588534|DEVICE|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
219735547|NCT02588534|OTHER|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
219735548|NCT04044287|DRUG|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
219161845|NCT06436326|OTHER|Blood glucose meters (BGM)|"Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
219161846|NCT05165459|DEVICE|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
219735549|NCT04044287|DRUG|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
219735550|NCT00451984|BIOLOGICAL|Twinrix|
219161847|NCT00578916|DRUG|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
219161848|NCT01340066|DRUG|UISH001|sublingual dosing, 1 drop 3 times a day
219161849|NCT01340066|DRUG|matching placebo|sublingual dosing,1 drop 3 times a day
219735551|NCT00451984|BIOLOGICAL|interleukin-2|
219735552|NCT00150527|DRUG|Citalopram|40 mg, pill, single dose
219735553|NCT00150527|DRUG|Escitalopram|20 mg, pill, single dose
219735554|NCT00150527|DRUG|Dexamethasone|1 mg, pill, single dose
219735555|NCT00150527|BEHAVIORAL|Cold Pressor Test|single test
219735556|NCT00139035|DRUG|cyclosporine A|
219735557|NCT02178189|OTHER|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
219735558|NCT02178189|OTHER|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
219735559|NCT02988557|PROCEDURE|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
219735560|NCT02988557|DEVICE|treadmill|walking on a treadmill with a sloped surface
219735561|NCT02979158|PROCEDURE|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
219735562|NCT02979158|PROCEDURE|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
219735563|NCT03693508|DRUG|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
219735564|NCT04615988|OTHER|blood draw and questionnaire completion|questionaires provided to subjects during visits while on study and baseline one tube of blood drawn
219735565|NCT04615988|OTHER|questionnaire completion, blood collection|questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
219235842|NCT03467594|BEHAVIORAL|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
219235843|NCT05203003|OTHER|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
219235844|NCT01163929|DRUG|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
219735566|NCT00103753|DRUG|deferiprone|
219735567|NCT05706675|PROCEDURE|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
219735568|NCT03374904|BEHAVIORAL|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
219735569|NCT03374904|BEHAVIORAL|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
219735570|NCT02622594|DRUG|Aminolevulinic Acid (ALA)|
219735571|NCT02622594|DEVICE|Environ Cosmetic Roller|
219735572|NCT02622594|DEVICE|BLU-U IIlluminator|
219735573|NCT03702374|DRUG|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
219735574|NCT03702374|OTHER|Placebo|It consists in a capsule with 100mg of magnesium oxide.
219735575|NCT03807167|OTHER|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
219735576|NCT03807167|OTHER|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
219735577|NCT03807167|OTHER|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
219735578|NCT03807167|OTHER|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
219735579|NCT03807167|OTHER|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
219735580|NCT03807167|OTHER|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
219735581|NCT03807167|OTHER|walking speed test|The patient is timed to walk 10m. A speed \<1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
219735582|NCT03807167|OTHER|accelerometer presentation|accelerometer presentation and pose
219735583|NCT03807167|OTHER|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
219735584|NCT03807167|OTHER|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
219735585|NCT03807167|OTHER|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
219735586|NCT03807167|OTHER|executive function|"* Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~* Trail Making Test (TMT): This test is used to assess mental flexibility.~* Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~* Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
219735587|NCT03807167|OTHER|MRI|An MRI lasting 30 minutes is programmed
219735588|NCT03807167|OTHER|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
219735589|NCT05285150|OTHER|Survey|It´s a survey
219735590|NCT01189227|PROCEDURE|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
219735591|NCT01189227|PROCEDURE|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
219735592|NCT03211832|OTHER|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
219735593|NCT00908908|DRUG|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
219735594|NCT02277366|PROCEDURE|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
219735595|NCT06097988|DEVICE|ABIO3419|Intra-articular injection
219735596|NCT03535519|DRUG|Methotrexate|standard of care treatment with methotrexate
219735597|NCT01885234|OTHER|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
219735598|NCT01885234|OTHER|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
219735599|NCT03686722|DRUG|Metformin|Metformin is used primarly in treatment of diabetes type II
219735600|NCT03686722|DRUG|Daclatasvir|Daclatsvir is a direct acting antiviral drug
219735601|NCT06514729|PROCEDURE|Adopting different ventilation modes during the operation|The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
219735602|NCT01608308|DRUG|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
219735603|NCT01608308|DRUG|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
219735604|NCT06437366|BEHAVIORAL|Nurse-Led Heart Math Training Program|"he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress."
219735605|NCT03849612|DEVICE|AID System|AID system
219735606|NCT03849612|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
219735607|NCT00558493|DRUG|Clevudine|clevudine 30 mg qd for 24 seeks
219735608|NCT01064284|DRUG|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
219735609|NCT01064284|DRUG|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
219735610|NCT04642066|OTHER|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
219735611|NCT04642066|OTHER|No cold water immersion|People without cold water immersion
219735612|NCT01311011|PROCEDURE|SCT|SCT
219735613|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
219735614|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
219735615|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
219735616|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
219735617|NCT06048705|DRUG|GSK3901961|GSK3901961 was administered.
219735618|NCT06048705|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
219735619|NCT06048705|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
219735620|NCT06838988|DIAGNOSTIC_TEST|Transcutaneous ultrasound|"The ultrasonographic characteristics of the subcutaneous nodules were evaluated using an ultrasound machine (Venue Go™, wide-band linear array ultrasound probe (hockey stick shape), frequency range between 6.7 MHz and 18.0 MHz, from GE HealthCare Illinois, United States).~The procedure for capturing images at the location of the lesion of interest is as follows:~* Brightness mode (B-mode): Record at least 4 images using a depth of 2 cm.~* Color Doppler mode: Record images along the vertical axis (1 image) and along the horizontal axis (1 image). The two axes mentioned above must be perpendicular to each other.~* Video recording: Capture at least 10 seconds of video in both Brightness mode and Color Doppler mode."
219735621|NCT05478707|DRUG|Dulaglutide|GLP1-RA
219735622|NCT05478707|DRUG|Placebo|Saline placebo
219735623|NCT05478707|BEHAVIORAL|exercise training|supervised high intensity interval training
219735624|NCT05063383|OTHER|This study does not involve any interventions|This study does not involve any interventions
219735625|NCT05940246|BEHAVIORAL|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
219735626|NCT03072849|PROCEDURE|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
219735627|NCT03072849|DRUG|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
219735628|NCT01016015|BIOLOGICAL|Cixutumumab|Given IV
219735629|NCT01016015|OTHER|Laboratory Biomarker Analysis|Correlative studies
219735630|NCT01016015|DRUG|Temsirolimus|Given IV
219735631|NCT04867590|DEVICE|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
219735632|NCT04867590|DEVICE|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
219735633|NCT03221296|BEHAVIORAL|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
219735634|NCT03683199|PROCEDURE|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
219735635|NCT05569889|PROCEDURE|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
219735636|NCT03917836|DIAGNOSTIC_TEST|endoscopy and histology|diagnostic evaluation of chronic gastritis
219735637|NCT06054880|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
219735638|NCT06054880|OTHER|Saline injection 0.9%|Placebo
219735639|NCT05330546|PROCEDURE|Densah burs|using Densah burs to prepare implant osteotomy
219735640|NCT05330546|PROCEDURE|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
219735641|NCT04648241|BIOLOGICAL|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
219735642|NCT04648241|BIOLOGICAL|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
219735643|NCT02057666|DRUG|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
219735644|NCT02057666|DRUG|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
219735645|NCT06244199|BEHAVIORAL|T2CR Intervention|The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
219735646|NCT06244199|OTHER|Usual Care|Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
219735647|NCT04925440|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.
219235845|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
219235846|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
219735648|NCT04925440|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn-starch and magnesium stearate only.
219735649|NCT03563612|DEVICE|cpap|application of cpap to the non-dependent lung, during one lung ventilation
219235847|NCT04555694|DRUG|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
219735650|NCT04726904|PROCEDURE|Sacral neuromodulation in conventional implantation technique|Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
219735651|NCT00323544|DRUG|zidovudine and lamivudine (Combivir®)|
219735652|NCT00323544|DRUG|emtricitabine and tenofovir DF|
219735653|NCT04845971|DIETARY_SUPPLEMENT|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
219735654|NCT06874985|BEHAVIORAL|Lived experience video campaign|Participants in the selected villages will be shown a two-minute video developed specifically for the Lived Experience Communication Campaign in addition to usual awareness they receive for cancer screening mobilisation. The video will feature personal narratives from cancer survivors and local leaders emphasizing the importance of early detection and screening.
219735655|NCT06400745|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
219735656|NCT06400745|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
219735657|NCT06400745|PROCEDURE|Cataract surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
219735658|NCT03042637|DRUG|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
219735659|NCT04835597|BEHAVIORAL|Behavioral Assessment|Complete movement assessment
219735660|NCT04835597|OTHER|Electronic Health Record Review|SAE data is collected
219735661|NCT06501209|BEHAVIORAL|5A-5R-based counselling session|"The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit."
219735662|NCT06501209|BEHAVIORAL|Counseling through mobile phone call and text message|Participants will get weekly a phone call and a text message
219161850|NCT02789020|DRUG|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
219161851|NCT02789020|OTHER|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
219161852|NCT02789020|DEVICE|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
219161853|NCT02789020|DEVICE|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
219161854|NCT02789020|OTHER|Physical Function Performance Test|This test will be performed at baseline and one year.
219161855|NCT06530628|BEHAVIORAL|Adult patients resident in Pavillon C of the Pierre Garraud Hospital|"Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents."
219161856|NCT04523688|BIOLOGICAL|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
219735663|NCT02602145|OTHER|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
219735664|NCT05770973|OTHER|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
219735665|NCT05845255|DEVICE|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
219735666|NCT03948789|PROCEDURE|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
219735667|NCT03948789|PROCEDURE|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
219735668|NCT01965483|RADIATION|once-weekly breast irradiation|
219735669|NCT04128215|BEHAVIORAL|Control Period|Participants completed an 8-week control period of normal lifestyle.
219735670|NCT04128215|BEHAVIORAL|Exercise Period|Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.
219735671|NCT03487458|PROCEDURE|Rib Fixation Surgery|Rib Fixation Surgery
219735672|NCT03527979|PROCEDURE|IVF/ICSI|IVF/ICSI
219161857|NCT04523688|DRUG|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
219161858|NCT04317885|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
219161859|NCT01691079|DRUG|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
219161860|NCT01691079|DRUG|Placebo|Inhaled placebo administered before exercise.
219161861|NCT05334199|DEVICE|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
219161862|NCT03794024|DEVICE|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
219161863|NCT03794024|DEVICE|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
219161864|NCT06105125|DEVICE|Rigenera + bone substitute|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. A small punch of connective tissue will be harvested from the palate in the premolar region. Then the graft will be mechanically dissociated using the Rigenera Machine System rotating speed to 80 rpm, in 1.0 ml sterile physiologic solution. After dissociation, the cellular suspension will be passed through a disposable grid with 100 hexagonal blades filtering cells and components of extracellular matrix with a cut-off of 50 um in an average time of 90 s. Finally, part of the suspension containing AMGs will be seeded on the scaffold material and subsequently compacted within the defect. Flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
219235848|NCT04555694|DRUG|Loteprednol Etabonate|Used to treat inflammation of the eye
219735673|NCT00839579|OTHER|1x4 min interval|Aerobic interval training
219735674|NCT01926509|DRUG|MK-8892|
219735675|NCT01926509|DRUG|Placebo for MK-8892|
219735676|NCT05686486|OTHER|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
219735677|NCT02445365|DEVICE|AutoRIC device|
219735678|NCT01882829|DRUG|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
219735679|NCT03008473|DEVICE|video laryngoscope and chest CT iminge|
219735680|NCT03008473|DEVICE|Conventional intubation of uniblocker|
219735681|NCT01100580|DIETARY_SUPPLEMENT|low salt diet|Daily salt intake less than 4 g/day
219735682|NCT01100580|DIETARY_SUPPLEMENT|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
219735683|NCT00800345|DRUG|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
219735684|NCT00800345|DRUG|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
219735685|NCT06794359|PROCEDURE|Minimally Invasive Coronary Artery Bypass Grafting|Minimally Invasive Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through left anterior thoracotomy. On or off pump approach will be determined by the surgeon. For on pump cases, femoral canulation will be performed and aortic cross clamp will be used. Off Pump cases will be performed using Medtronic Octopus and Starfish NS. Intra operative Transit time flow measurement will be performed in all cases.
219735686|NCT06794359|PROCEDURE|Coronary artery bypass surgery|Procedure: Conventional Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through classical total sternotomy. On or off pump approach will be determined by the surgeon. Intra operative Transit time flow measurement will be performed in all cases.
219735687|NCT02831335|OTHER|MRI|Perform MRI studies
219735688|NCT02831335|OTHER|MRI|Perform MRI studies
219735689|NCT02831335|OTHER|MRI|Perform MRI studies
219735690|NCT02831335|OTHER|Group 4|Perform MRI studies
219235849|NCT04555694|DRUG|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
219235850|NCT00230009|BEHAVIORAL|Brief motivational intervention|
219235851|NCT04641156|OTHER|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
219235852|NCT02227888|DRUG|N91115|S nitrosoglutathione reductase inhibitor
219235853|NCT02834624|DRUG|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
219235854|NCT02834624|DRUG|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
219235855|NCT00092456|BIOLOGICAL|rotavirus vaccine, live, oral, pentavalent|Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
219735691|NCT04878757|BEHAVIORAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
219735692|NCT05626777|DRUG|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
219735693|NCT05626777|DRUG|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
219735694|NCT05119335|DRUG|Oral NKT2152|Oral HIF2α inhibitor
219735695|NCT06634862|OTHER|Normatec Air Compression|Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
219735696|NCT06634862|OTHER|Soft Tissue Mobilization|The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
219735697|NCT06634862|OTHER|Percussive therapy|Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
219735698|NCT06636422|DRUG|Motherwort injection|Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
219735699|NCT02469961|DRUG|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
219735700|NCT02469961|DRUG|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
219235856|NCT00092456|BIOLOGICAL|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
219235857|NCT00456235|DRUG|Mycophénolate Mofétil|
219235858|NCT00456235|DRUG|Ciclosporine A|
219235859|NCT00456235|DRUG|Tacrolimus|
219235860|NCT01368549|OTHER|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
219235861|NCT06202547|BIOLOGICAL|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
219235862|NCT02952235|OTHER|SPF50+|Sun protection
219235863|NCT02952235|OTHER|SPF100+|Sun protection
219235864|NCT03522909|OTHER|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   \- Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate"
219235865|NCT04783389|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
219235866|NCT04783389|DRUG|Placebo|Placebo subcutaneous (SC) injection.
219735701|NCT02469961|OTHER|Interscalene block|Interscalene block is used for the main anesthetic for the case
219735702|NCT02935036|DRUG|ADPS topical product|topical product
219735703|NCT02935036|DRUG|Placebo Control|topical product
219735704|NCT06844812|OTHER|This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.|This is not an interventional study. Patients diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), for whom methylphenidate treatment is planned, have been invited to participate in the study. The patients have been enrolled in follow-up, and our contact information has been provided to them. As part of routine care, patients have been called in once a month. Necessary dosage adjustments have been made in accordance with medical guidelines, without any intervention for the study. Patients with complaints or those who needed to be seen earlier have been seen in between. As a result, the patients were followed for a total of 3 months for this study. Serum samples for oxidative stress markers were collected at baseline (before treatment started) and at the 3rd month (after treatment began).
219735705|NCT05018507|OTHER|Data collection only|No intervention, just data collection from system machines
219735706|NCT01442285|BEHAVIORAL|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
219735707|NCT02347865|DRUG|AMG 162 - Prolia|500 patients
219735708|NCT02347865|DRUG|AMG 162 - Prolia|250 patients, one year later
219735709|NCT00464529|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
219735710|NCT00368849|DRUG|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
219735711|NCT00368849|DRUG|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
219735712|NCT06500897|DEVICE|VEST|External MEsh Support for safein vein
219735713|NCT02571543|DRUG|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
219735714|NCT06309797|DEVICE|Interdental brush+HA|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
219735715|NCT06309797|DEVICE|Interdental brush|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
219735716|NCT05280314|DRUG|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
219735717|NCT05280314|DRUG|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
219735718|NCT02885922|DRUG|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
219161865|NCT06105125|DEVICE|Bone substitute alone|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. The defect will be filled with the same bone substitute employed in the test group. Finally, flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
219161866|NCT00806169|DRUG|triamcinolone and bevacizumab|
219161867|NCT02376530|BEHAVIORAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
219161868|NCT02376530|BEHAVIORAL|Price Changes|Price changes will be present during shopping session.
219161869|NCT02331745|DRUG|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
219161870|NCT02331745|DRUG|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
219161871|NCT05327049|OTHER|no intervention|treatment of deep carious lesions
219161872|NCT05327049|DEVICE|diode laser|laser light for cavity disinfection
219161873|NCT05327049|DIETARY_SUPPLEMENT|Aloe Vera|herbal dietary supplement for treatment of deep carious lesions
219161874|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
219161875|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
219735719|NCT04202211|BIOLOGICAL|FMT oral|lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
219735720|NCT04202211|BIOLOGICAL|FMT enema|lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
219735721|NCT04202211|OTHER|Placebo oral|placebo given orally (10 capsules) twice weekly for total of 8 weeks
219735722|NCT04202211|OTHER|Placebo enema|placebo given via enema (1) twice weekly for total of 8 weeks
219735723|NCT03635996|DRUG|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
219161876|NCT05588817|GENETIC|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
219161877|NCT05990816|DIAGNOSTIC_TEST|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
219735724|NCT03635996|DEVICE|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
219735725|NCT02797548|DRUG|Aspirin only|Aspirin only during surgery
219735726|NCT02797548|DRUG|No antiplatelet therapy|No antiplatelet therapy will be during surgery
219735727|NCT06377748|OTHER|Facilitated tucking position|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
219735728|NCT06377748|DEVICE|ShotBlocker|Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
219735729|NCT06377748|COMBINATION_PRODUCT|Combined facilitated tucking and ShotBlocker|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
219235867|NCT04843956|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided biopsy|"Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)"
219235868|NCT00804765|OTHER|Therapeutic education|Intensive training individual and collective teaching
219235869|NCT00804765|OTHER|Follow-up|classical follow-up with two individual consultations
219235870|NCT00451906|DRUG|Platinum-based chemotherapy|As prescribed
219235871|NCT00451906|DRUG|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
219235872|NCT03918187|DRUG|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
219235873|NCT03918187|DRUG|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
219235874|NCT03918187|DRUG|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
219235875|NCT04004923|PROCEDURE|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
219235876|NCT04004923|PROCEDURE|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
219235877|NCT05261100|OTHER|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
219235878|NCT05261100|OTHER|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
219235879|NCT06234449|PROCEDURE|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
219235880|NCT04388748|BEHAVIORAL|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
219235881|NCT05591378|OTHER|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
219235882|NCT05591378|OTHER|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
219235883|NCT02014298|RADIATION|non-ablative fractional laser|3 treatments with 4-6 weeks interval
219235884|NCT02014298|OTHER|control|observation, comparison to laser-treated area
219235885|NCT02127645|PROCEDURE|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
219235886|NCT02127645|PROCEDURE|LRT-TEM|TEM following 46 Gy RT
219235887|NCT02127645|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
219235888|NCT02127645|PROCEDURE|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
219235889|NCT03538834|DIETARY_SUPPLEMENT|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
219235890|NCT03538834|DIETARY_SUPPLEMENT|Control|Placebo
219735730|NCT02834442|DRUG|MT-7117|
219735731|NCT02834442|DRUG|Placebo|
219235891|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
219735732|NCT03612414|DIETARY_SUPPLEMENT|Aqualief|Three tablets/day
219235892|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
219235893|NCT05299099|DRUG|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
219235894|NCT05299099|DRUG|RCN301|RCN301 will be injected continuously for 3 days.
219235895|NCT06026826|DEVICE|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219235896|NCT06026826|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219235897|NCT03872661|DRUG|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
219235898|NCT03872661|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
219235899|NCT03872661|DRUG|Pemetrexed|Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
219735733|NCT03612414|DIETARY_SUPPLEMENT|Placebo|Three tablets/day
219735734|NCT04885712|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
219735735|NCT04885712|DRUG|Pioglitazone 15mg|Subjects take the investigational products once a day for 24 weeks.
219735736|NCT04885712|DRUG|Pioglitazone 30 mg|Subjects take the investigational products once a day for 24 weeks.
219735737|NCT04885712|DRUG|Pioglitazone 15mg Placebo|Subjects take the investigational products once a day for 24 weeks.
219735738|NCT04885712|DRUG|Pioglitazone 30mg Placebo|Subjects take the investigational products once a day for 24 weeks.
219235900|NCT03872661|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
219235901|NCT03872661|PROCEDURE|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
219235902|NCT05472194|BEHAVIORAL|InSchool Training Program|The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.
219235903|NCT05472194|BEHAVIORAL|Regular school activities|Children in the control group will be playing with the regular school activities.
219235904|NCT03471390|OTHER|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
219235905|NCT03267069|OTHER|survey|surveys will be administered at inclusion and follow-ups
219235906|NCT01578278|DRUG|Bepotastine besilate formulation|Nasal Spray
219235907|NCT01578278|DRUG|Fluticasone propionate|Nasal Spray
219235908|NCT01578278|DRUG|Bepotastine besilate-fluticasone propionate|Nasal Spray
219235909|NCT01578278|DRUG|Placebo Comparator|Nasal Spray
219235910|NCT02121808|PROCEDURE|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
219235911|NCT02121808|PROCEDURE|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
219235912|NCT03126266|RADIATION|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
219235913|NCT04593004|DEVICE|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
219235914|NCT04593004|OTHER|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
219235915|NCT03670771|DIAGNOSTIC_TEST|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
219735739|NCT04885712|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
219735740|NCT06507644|PROCEDURE|light curettage|Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
219735741|NCT06507644|OTHER|Pre irradiation of 1 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
219735742|NCT06507644|OTHER|Pre irradiation of 3 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
219735743|NCT06507644|OTHER|topical application of 8% methyl aminolevulinate photosensitizer MAL|Participants will be treated with 8% topical MAL photosensitizer
219735744|NCT06507644|OTHER|topical application of 16% methyl aminolevulinate photosensitizer (MAL)|Participants will be treated with 16% topical MAL photosensitizer
219735745|NCT06507644|DEVICE|Visible light source|Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
219735746|NCT02916914|OTHER|Q2 feeding|Infants are going to be fed every 2 hours
219735747|NCT03607136|OTHER|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
219735748|NCT02402231|DRUG|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
219735749|NCT05058456|DEVICE|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
219735750|NCT04534725|DRUG|Interferon alfa|intranasal spray
219735751|NCT04534725|DRUG|Selinexor|oral tablet
219735752|NCT04534725|DRUG|Lenzilumab|intravenous infusion
219235916|NCT04521647|DRUG|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
219235917|NCT04820023|DRUG|BBT-176, QD|BBT-176 given orally alone, QD
219235918|NCT04820023|DRUG|BBT-176, BID|BBT-176 given orally alone, BID
219235919|NCT06678048|DRUG|Arsenous Acid plus Chemotherapy|Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
219235920|NCT06579287|DRUG|SHJ002|Topical ophthalmic
219235921|NCT06579287|DRUG|Atropine|Topical ophthalmic
219235922|NCT06348394|OTHER|Intracardiac Echocardiography|Transesophageal echocardiography will be performed under general anesthesia.
219235923|NCT05066230|DRUG|KSI-301|Intravitreal injection
219235924|NCT05066230|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
219235925|NCT05872958|DRUG|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
219235926|NCT05872958|OTHER|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
219735753|NCT00374985|DRUG|Docetaxel, Oxaliplatin|weekly doses
219235927|NCT05690477|PROCEDURE|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
219235928|NCT04827602|OTHER|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
219235929|NCT01976156|DIETARY_SUPPLEMENT|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
219235930|NCT01976156|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
219235931|NCT02173561|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
219235932|NCT02173561|BEHAVIORAL|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
219235933|NCT00002761|BIOLOGICAL|filgrastim|
219235934|NCT00002761|BIOLOGICAL|recombinant interferon gamma|
219235935|NCT00002761|DRUG|busulfan|
219235936|NCT00002761|DRUG|cyclophosphamide|
219235937|NCT00002761|DRUG|cyclosporine|
219235938|NCT00002761|DRUG|cytarabine|
219235939|NCT00002761|DRUG|idarubicin|
219235940|NCT00002761|PROCEDURE|peripheral blood stem cell transplantation|
219735754|NCT00374985|PROCEDURE|Radiotherapy|regular fractions
219735755|NCT05527314|DRUG|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
219735756|NCT05527314|DRUG|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
219161878|NCT05490524|DEVICE|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
219161879|NCT02129283|BEHAVIORAL|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
219161880|NCT02986984|OTHER|There is no intervention|There are no interventions
219161881|NCT06124911|OTHER|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
219161882|NCT06124911|OTHER|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
219161883|NCT05917275|DRUG|Amlodipine|4 weeks of Amlodipine
219161884|NCT05917275|DRUG|Olmesartan|4 weeks of Olmesartan
219161885|NCT05917275|DRUG|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
219161886|NCT05917275|DRUG|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
219161887|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention|"A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month."
219161888|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention|The Enhanced TCBD/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
219161889|NCT05422742|PROCEDURE|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
219161890|NCT05422742|PROCEDURE|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
219161891|NCT03092726|DRUG|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
219235941|NCT04970966|DEVICE|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
219235942|NCT04970966|DEVICE|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
219235943|NCT02800135|DRUG|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
219735757|NCT05527314|DRUG|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
219735758|NCT05527314|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
219161892|NCT03092726|DRUG|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
219735759|NCT05527314|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
219161893|NCT04403711|OTHER|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
219161894|NCT04403711|OTHER|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
219161895|NCT04718350|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
219161896|NCT04718350|DRUG|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
219161897|NCT04656210|RADIATION|MRI|Non conventional MRI (35 minutes)
219735760|NCT01404065|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
219735761|NCT04882605|GENETIC|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
219735762|NCT04882605|GENETIC|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
219735763|NCT04882605|GENETIC|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
219735764|NCT01407133|DEVICE|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
219161898|NCT04656210|OTHER|neuropsychological tests|Standardized and quantified neuropsychological assessment
219161899|NCT06241456|DRUG|FT825|FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
219161900|NCT06241456|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
219161901|NCT06241456|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
219161902|NCT06241456|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
219161903|NCT06241456|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion at planned dose levels.
219161904|NCT06241456|DRUG|Cisplatin|Cisplatin will be administered as an IV infusion at planned dose levels.
219161905|NCT06241456|DRUG|Cetuximab|Cetuximab will be administered as an IV infusion at planned dose levels.
219161906|NCT02754115|OTHER|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
219161907|NCT05875974|DRUG|JZP258 (XYWAV)|"Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect.~IH Cohort: Initiate dosage per XYWAV label and titrate to effect.~Narcolepsy \>9-Gram Cohort: XYWAV titrated to a dosage of \>9 to 12 grams."
219161908|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
219161909|NCT06413693|DRUG|PF-07293893|A single dose of PF-07293893 administered orally as tablets
219161910|NCT06413693|DRUG|Placebo|A single dose of Placebo administered orally as tablets that look the same as PF-07293893
219161911|NCT04950127|DRUG|Linerixibat|Participants will receive linerixibat.
219161912|NCT04950127|DRUG|Placebo|Participants will receive placebo.
219161913|NCT06049459|DEVICE|Optical Correction|Optical correction (if needed)
219235944|NCT03072238|DRUG|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
219235945|NCT03072238|DRUG|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
219161914|NCT06049459|DEVICE|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
219161915|NCT03238755|OTHER|Cardiac MRI/MRS|whole blood, plasma, and serum
219161916|NCT03330795|BIOLOGICAL|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection, and cryopreserved for later marrow transplantation. BMT conditioning and transplantation will start at least 8 weeks or more post lung transplant - once the participant is clinically judged suitable to undergo BMT conditioning and transplantion.
219735765|NCT01407133|DEVICE|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
219735766|NCT00251654|PROCEDURE|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
219735767|NCT05178654|DRUG|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
219735768|NCT04392362|DRUG|Adenosine|A vial of adenosine with 6mg
219735769|NCT05781750|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib
219161917|NCT06964256|BEHAVIORAL|Abdominal breathing exercises|"Control group: conventional rehabilitation treatment. Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks Experimental group: Conventional rehabilitation treatment sEMG monitoring of lower abdominal breathing training.~The conventional rehabilitation treatment method is the same as above; The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder befor"
219161918|NCT06964256|OTHER|Control group: intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks
219161919|NCT06964256|BEHAVIORAL|Experimental group: intermittent catheterization|Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks. The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder before training, the patient to take a supine position, hip and knee flexion 60 degrees (for those who cannot maintain hip and knee flexion in the lower limbs, family members can assist), at the same time, the electrodes are attached to both
219161920|NCT06964256|OTHER|Control group and experimental group: acupuncture treatment|Acupuncture treatment uses acupuncture to act on the acupuncture points in the lower abdomen and lumbosacral region to improve the patient's urination function
219161921|NCT03772561|DRUG|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
219161922|NCT06190197|DRUG|Prophylactic antibiotics postoperatively.|Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
219161923|NCT04069013|PROCEDURE|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
219235946|NCT03072238|DRUG|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
219735770|NCT05781750|DRUG|placebo|Subcutaneous injection of placebo
219735771|NCT00365820|DRUG|Tegaserod|
219735772|NCT05552573|BIOLOGICAL|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
219735773|NCT05552573|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
219735774|NCT05552573|BIOLOGICAL|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
219735775|NCT04919473|BIOLOGICAL|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
219735776|NCT03752073|DEVICE|Trans-cervical cervical balloon|Insertion of Foley Catheter
219735777|NCT03752073|DEVICE|Hygroscopic cervical dilator|Insertion of Dilapan-s
219735778|NCT03635866|DIAGNOSTIC_TEST|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
219735779|NCT02224079|DRUG|BIIB 722 CL|
219735780|NCT02224079|DRUG|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
219735781|NCT00534586|DRUG|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
219735782|NCT00534586|DRUG|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
219735783|NCT00534586|DRUG|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
219735784|NCT00534586|DRUG|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
219735785|NCT00670514|BEHAVIORAL|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
219161924|NCT05064735|DRUG|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
219161925|NCT05064735|DRUG|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
219735786|NCT00670514|BEHAVIORAL|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
219735787|NCT03027050|PROCEDURE|T-PRF|Applied for treatment of periodontal bone loss.
219735788|NCT03027050|PROCEDURE|Open Flap Debridement alone|
219735789|NCT01837953|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
219735790|NCT01837953|BEHAVIORAL|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
219735791|NCT01428713|DRUG|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
219735792|NCT01428713|DRUG|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
219735793|NCT02039206|DEVICE|Deep TMS|1Hz Stimulation
219735794|NCT05181696|DIAGNOSTIC_TEST|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
219735795|NCT02062346|DRUG|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
219735796|NCT02062346|DRUG|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
219735797|NCT02062346|DRUG|Placebo|Intravenous infusion of saline
219735798|NCT00862277|BIOLOGICAL|Menactra®|0.5 mL, Intramuscular (from a previous study)
219735799|NCT00862277|BIOLOGICAL|Menomune®|0.5 mL, Intramuscular (from a previous study)
219735800|NCT06006221|BEHAVIORAL|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
219235947|NCT03072238|DRUG|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
219735801|NCT01052428|DRUG|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
219735802|NCT01052428|DRUG|Placebo|Placebo 100 mg once a day for 2 years
219735803|NCT00871000|BIOLOGICAL|Boostrix Polio™ 711866|Single dose, intramuscular administration.
219735804|NCT00871000|BIOLOGICAL|Priorix Tetra TM 208136|Single dose, subcutaneously.
219235948|NCT00112827|RADIATION|total marrow irradiation|Undergo irradiation
219735805|NCT00871000|BIOLOGICAL|Tetravac TM|Single dose, intramuscular administration.
219735806|NCT00092742|DRUG|MK0663, etoricoxib|
219735807|NCT00092742|DRUG|Comparator: Diclofenac sodium|
219735808|NCT00707369|DRUG|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
219735809|NCT00707369|DRUG|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
219735810|NCT02455726|DIETARY_SUPPLEMENT|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
219735811|NCT02455726|DIETARY_SUPPLEMENT|Fructose|Oral fructose 10 g twice a day
219735812|NCT02455726|DRUG|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
219735813|NCT02455726|DRUG|Pregabalin|Pregabalin 25 mg at 8 pm
219735814|NCT01745302|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
219735815|NCT01745302|DRUG|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
219735816|NCT06569927|PROCEDURE|Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.|Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
219235949|NCT00112827|DRUG|melphalan|Given IV
219235950|NCT00112827|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
219235951|NCT00112827|BIOLOGICAL|filgrastim|Given IV
219235952|NCT00112827|GENETIC|fluorescence in situ hybridization|Correlative studies
219235953|NCT00112827|GENETIC|cytogenetic analysis|Correlative studies
219235954|NCT00112827|DRUG|cyclophosphamide|Given IV
219235955|NCT00112827|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
219235956|NCT00112827|DRUG|lenalidomide|Given orally
219235957|NCT05856955|BEHAVIORAL|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
219235958|NCT05856955|BEHAVIORAL|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
219735817|NCT06570083|BEHAVIORAL|Mobile Exercise Support|Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
219735818|NCT06570083|BEHAVIORAL|Self-help physical activity booklet|Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
219735819|NCT06258512|OTHER|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
219735820|NCT03408808|PROCEDURE|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
219735821|NCT03408808|PROCEDURE|Aspiration alone|Aspiration of the ganglion
219161926|NCT06286774|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
219161927|NCT06782243|DRUG|Moderate-Intensity Statins|Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.
219161928|NCT06782243|DRUG|High-Intensity Statins|Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.
219161929|NCT03459677|BEHAVIORAL|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
219161930|NCT03459677|OTHER|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
219161931|NCT03380390|DRUG|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
219161932|NCT03380390|DEVICE|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
219161933|NCT02886286|DRUG|Bupivacaine|Patient-activated intrathecal bolus for incident pain
219161934|NCT02886286|DRUG|Opioid|Patient-activated intrathecal bolus for incident pain
219161935|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
219161936|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
219161937|NCT02009813|PROCEDURE|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
219161938|NCT05097417|COMBINATION_PRODUCT|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
219161939|NCT05097417|PROCEDURE|ablation|Patients will be treated with ablation in the primary tumor sites
219735822|NCT03090035|DRUG|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
219161940|NCT00374959|DRUG|ceftriaxone|
219161941|NCT00374959|DEVICE|Endotracheal tube for aspiration of subglottic secretions.|
219161942|NCT01362153|DRUG|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
219161943|NCT01362153|DRUG|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
219161944|NCT02941575|OTHER|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
219161945|NCT02941575|OTHER|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
219161946|NCT02035904|DRUG|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
219161947|NCT02035904|DRUG|saline|patient controlled infusion from the 2nd day after surgery
219161948|NCT02035904|DRUG|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
219161949|NCT02035904|DEVICE|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
219235959|NCT05684120|BEHAVIORAL|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
219235960|NCT01682447|OTHER|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
219235961|NCT01863368|OTHER|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
219735823|NCT03090035|DRUG|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
219735824|NCT04432298|DRUG|Pamrevlumab|Sterile liquid for injection
219735825|NCT04432298|DRUG|Placebo|Sterile liquid for injection
219735826|NCT04187690|DRUG|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
219735827|NCT04187690|DRUG|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
219735828|NCT02451007|DRUG|lurbinectedin (PM01183)|
219735829|NCT03997591|OTHER|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
219735830|NCT01118637|BEHAVIORAL|StopPulling.com|subsidized access to an interactive self-help website for TTM
219161950|NCT02035904|DRUG|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
219161951|NCT02035904|DRUG|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
219161952|NCT00044564|DRUG|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
219161953|NCT02376790|DRUG|Etanercept|Etanercept was administered by subcutaneous injection once a week
219161954|NCT02376790|DRUG|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
219161955|NCT02376790|DRUG|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
219161956|NCT02376790|DRUG|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
219161957|NCT05450458|DRUG|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
219161958|NCT03205436|OTHER|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
219161959|NCT04552509|RADIATION|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
219161960|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
219161961|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
219161962|NCT05069974|DRUG|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
219161963|NCT05069974|DRUG|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
219161964|NCT05056077|OTHER|Counseling|Receive support person coaching
219161965|NCT05056077|OTHER|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with a history of cancer
219235962|NCT01863368|OTHER|Systane® ULTRA lubricant eyedrops|
219235963|NCT01863368|OTHER|OPTIVE® lubricating eyedrops|
219735831|NCT06243250|DIAGNOSTIC_TEST|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
219735832|NCT02241031|BIOLOGICAL|MPs|MPs are generated from cord blood using a combination of cytokines.
219735833|NCT02241031|DRUG|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
219735834|NCT05298969|PROCEDURE|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
219735835|NCT03241160|OTHER|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
219161966|NCT05056077|BEHAVIORAL|Health Education|Receive health coaching
219161967|NCT05056077|OTHER|Health Promotion and Education - Direct Text Messaging|Receive text messages
219161968|NCT05056077|OTHER|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
219161969|NCT05056077|OTHER|Questionnaires|Quality of Life and Behavioral Questionnaires
219161970|NCT02794480|DEVICE|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
219161971|NCT02794480|DEVICE|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
219161972|NCT02794480|DEVICE|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
219235964|NCT04750902|DRUG|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
219235965|NCT04750902|DRUG|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
219235966|NCT04750902|DRUG|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
219235967|NCT04750902|DRUG|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
219735836|NCT04157582|OTHER|Pilates training|"1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
219735837|NCT04157582|OTHER|Conventional physical therapy|"1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
219735838|NCT04952688|OTHER|OCT- Angiographie|Ophthalmological examinations
219735839|NCT02543385|DRUG|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
219735840|NCT02801227|DRUG|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
219735841|NCT02801227|DRUG|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
219735842|NCT00000437|DRUG|Naltrexone Tablet and Nicotine Patch|
219735843|NCT00000437|DRUG|Naltrexone Tablet and Placebo Patch|
219735844|NCT00000437|DRUG|Placebo Tablet and Nicotine Patch|
219735845|NCT00000437|DRUG|Placebo Tablet and Placebo Patch|
219735846|NCT05411900|DRUG|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
219735847|NCT05411900|DRUG|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
219161973|NCT03037892|DRUG|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
219161974|NCT03037892|DRUG|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
219161975|NCT03037892|DRUG|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
219161976|NCT00262301|DRUG|recombinant human C1 inhibitor|IV
219161977|NCT00262301|DRUG|Placebo|IV
219161978|NCT02023710|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
219161979|NCT02023710|DRUG|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
219161980|NCT02023710|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
219161981|NCT04251013|DEVICE|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
219235968|NCT02415335|DRUG|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
219235969|NCT02415335|DRUG|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
219235970|NCT00819078|DRUG|Bupropion|300 mg/d
219235971|NCT00819078|DRUG|Placebo|no dosage
219235972|NCT01993342|OTHER|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
219735848|NCT06281002|DEVICE|conventional impression stone casts digitization|"Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files."
219735849|NCT06281002|DEVICE|digital scanning with coupled scanning aiding device|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
219735850|NCT06281002|DEVICE|Digital Implant Model assessment of accuracy|The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
219735851|NCT02156505|PROCEDURE|placement of double bare stent|
219735852|NCT02156505|DEVICE|DoubleBare stent|
219735853|NCT05468177|COMBINATION_PRODUCT|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
219735854|NCT02925143|OTHER|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
219161982|NCT04251013|DEVICE|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
219161983|NCT00015067|DRUG|Methylphenidate|
219161984|NCT04770649|BIOLOGICAL|COVID-19 vaccine|Any vaccine for COVID-19
219161985|NCT01017146|DRUG|Tazarotene foam|Tazarotene foam once a day application to the face
219161986|NCT01017146|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
219161987|NCT02241070|BEHAVIORAL|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
219161988|NCT04850586|OTHER|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
219161989|NCT00901901|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
219161990|NCT00901901|DRUG|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
219161991|NCT00901901|DRUG|Placebo|Matching erlotinib placebo 150 mg once daily
219161992|NCT01347892|OTHER|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
219161993|NCT01886729|OTHER|transcranial direct current stimulation (tDCS)|
219161994|NCT01942018|PROCEDURE|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
219161995|NCT01172418|DRUG|Alemtuzumab|Alemtuzumab used as part of combined Induction.
219235973|NCT01993342|OTHER|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
219735855|NCT04524429|PROCEDURE|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
219735856|NCT05127200|DEVICE|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
219735857|NCT06292507|OTHER|MYOFASCIAL STRETCH|Group A 10 participants will receive Myofascial Stretching
219235974|NCT00755248|PROCEDURE|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
219735858|NCT06292507|OTHER|CONTRACT-RELAX TECHNIQUE|group B 10 participants will receive Control-Relax Stretching Technique.
219161996|NCT01172418|DRUG|Daclizumab|Daclizumab used as part of combined induction.
219161997|NCT01172418|DRUG|Thymoglobulin|Thymoglobulin used as part of combined induction.
219161998|NCT01739270|PROCEDURE|supraclavicular brachial plexus block|
219235975|NCT05538156|PROCEDURE|Control group|Vitrectomy and gas tamponade without internal limiting membrane peeling
219735859|NCT01234376|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy
219735860|NCT02046876|OTHER|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
219735861|NCT01034657|DRUG|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
219735862|NCT01034657|DRUG|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
219735863|NCT02674256|DRUG|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
219735864|NCT02674256|OTHER|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
219735865|NCT06517511|DRUG|Selinexor Oral Tablet [Xpovio]|Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
219735866|NCT06517511|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
219735867|NCT04295928|BEHAVIORAL|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
219735868|NCT00379379|DEVICE|electroacupuncture|
219735869|NCT02544087|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
219735870|NCT02544087|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
219735871|NCT02544087|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
219735872|NCT05542901|DIAGNOSTIC_TEST|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
219735873|NCT01862965|DRUG|PredEver|Firstline treatment with prednisone and Everolimus
219735874|NCT06045286|RADIATION|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
219735875|NCT06045286|DRUG|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
219161999|NCT05171777|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
219162000|NCT05344807|DIAGNOSTIC_TEST|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
219162001|NCT02522312|OTHER|No Intervention|No drug is administered in this study
219162002|NCT06045208|OTHER|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
219162003|NCT06045208|OTHER|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
219162004|NCT04405921|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
219162005|NCT04405921|DRUG|Azithromycin 250 MG|orally or via gastric tube
219162006|NCT01306500|PROCEDURE|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
219735876|NCT05299957|DIAGNOSTIC_TEST|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
219735877|NCT02242903|DRUG|LY3079514|Administered SC
219735878|NCT02242903|DRUG|LY3079514|Administered IV
219735879|NCT02242903|DRUG|Placebo|Administered SC
219735880|NCT02242903|DRUG|Placebo|Administered IV
219735881|NCT01408108|PROCEDURE|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
219735882|NCT01408108|PROCEDURE|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
219735883|NCT04504669|DRUG|AZD8701|FOXP3 antisense oligonucleotide
219735884|NCT04504669|BIOLOGICAL|Durvalumab|anti PDL-1 monoclonal antibody
219735885|NCT05315583|OTHER|Collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
219735886|NCT05823077|OTHER|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
219235976|NCT05538156|PROCEDURE|Intervention group|Vitrectomy, internal limiting membrane peeling and gas tamponade
219235977|NCT05152992|BEHAVIORAL|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
219735887|NCT05823077|OTHER|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
219735888|NCT05102838|OTHER|Anti-virus treatment|Anti-virus treatment
219735889|NCT05365464|DRUG|Progesterone Pill|Orally active progesterone
219735890|NCT05365464|DRUG|hCG|Given by subcutaneous injection
219735891|NCT03250195|DIAGNOSTIC_TEST|PET/MRI|PET/MRI scan
219735892|NCT02417480|BEHAVIORAL|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
219735893|NCT02417480|BEHAVIORAL|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
219735894|NCT03932383|DEVICE|Custom CPAP mask|Modified CPAP mask based on 3D image capture
219735895|NCT01433081|DRUG|Placebo infusion of .9 normal saline|administration of .9 normal saline
219735896|NCT01433081|DRUG|administration of magnesium sulfate|administration of magnesium sulfate
219735897|NCT06276075|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
219735898|NCT02589912|DEVICE|Nucleus Profile ABI541 Auditory Brainstem Implant|
219162007|NCT04434742|OTHER|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
219162008|NCT04434742|OTHER|Usual care|Social call was given to this group.
219162009|NCT00092300|DRUG|MK0966, rofecoxib|
219162010|NCT00092300|DRUG|Comparator: valdecoxib|
219235978|NCT03733756|PROCEDURE|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
219735899|NCT01205737|BIOLOGICAL|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
219735900|NCT01205737|BIOLOGICAL|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
219735901|NCT00970177|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
219735902|NCT03769948|OTHER|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
219735903|NCT02417337|PROCEDURE|Root Canal Treatment|A standardized endodontic procedures performed.
219735904|NCT02417337|DRUG|Paracetamol|
219735905|NCT02417337|DRUG|Ibuprofen|
219735906|NCT02417337|DRUG|Mefenamic acid|
219735907|NCT02417337|DRUG|Diclofenac|
219735908|NCT02305615|OTHER|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
219735909|NCT02305615|COMBINATION_PRODUCT|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
219735910|NCT04296682|PROCEDURE|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
219162011|NCT00632749|DRUG|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
219162012|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
219162013|NCT00632749|DRUG|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
219162014|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
219735911|NCT01895179|OTHER|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
219735912|NCT01895179|OTHER|Grazing|Grazing involves eating meals spread out over the course of the day.
219735913|NCT00388141|BEHAVIORAL|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
219162015|NCT00339131|DRUG|Ultratrace iobenguane I 131|
219162016|NCT01645033|OTHER|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
219235979|NCT03733756|PROCEDURE|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
219735914|NCT03258957|OTHER|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
219735915|NCT04588558|DEVICE|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
219735916|NCT04588558|OTHER|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
219735917|NCT04588558|DEVICE|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
219735918|NCT02813512|DRUG|ADSCs|Autologous ADSCs
219735919|NCT01988558|DRUG|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
219162017|NCT01645033|OTHER|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
219162018|NCT03373448|DEVICE|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
219162019|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
219162020|NCT04386356|DEVICE|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
219162021|NCT03624335|PROCEDURE|ECC|Early clamping of the umbilical cord
219162022|NCT03624335|PROCEDURE|DCC|Delayed clamping of the umbilical cord
219162023|NCT03624335|PROCEDURE|Blood Test 6hours|Blood Test 6hours
219162024|NCT03624335|PROCEDURE|Blood Test 24hours|Blood Test 24hours
219162025|NCT03624335|PROCEDURE|Blood Test 48hours|Blood Test 48hours
219162026|NCT03624335|PROCEDURE|Blood Test 28days|Blood Test 28days
219162027|NCT06364683|OTHER|Survey study|The data collection tools to be used in the study will be filled. It does not include any invasive or non-invasive intervention.
219162028|NCT05383859|BEHAVIORAL|Intervention|"1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call."
219162029|NCT03947684|DEVICE|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
219162030|NCT01136876|DRUG|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
219235980|NCT02006914|DIETARY_SUPPLEMENT|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
219162031|NCT01136876|DRUG|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
219162032|NCT03281616|BEHAVIORAL|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
219235981|NCT02165202|DRUG|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
219235982|NCT02165202|DRUG|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
219235983|NCT03441256|DEVICE|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
219735920|NCT01988558|DIETARY_SUPPLEMENT|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
219735921|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
219735922|NCT01504542|BIOLOGICAL|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
219235984|NCT03441256|DEVICE|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
219235985|NCT03272815|DEVICE|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
219235986|NCT03272815|DEVICE|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
219735923|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
219735924|NCT03955185|PROCEDURE|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
219735925|NCT03955185|PROCEDURE|open abdominal surgery|Traditional open abdominal radical hysterectomy
219735926|NCT02191397|DRUG|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
219735927|NCT02191397|DRUG|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
219735928|NCT02191397|DRUG|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
219735929|NCT02191397|DRUG|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
219735930|NCT06237764|OTHER|No intervention|No intervention.
219735931|NCT05472181|DEVICE|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
219735932|NCT05472181|BEHAVIORAL|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
219735933|NCT01113814|DEVICE|FibroScan|
219162033|NCT01241916|DEVICE|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
219162034|NCT01241916|DEVICE|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
219162035|NCT01320657|DEVICE|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
219162036|NCT04128319|DRUG|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
219162037|NCT00251576|DRUG|A-Phase: tirofiban; Z-Phase simvastatin|
219162038|NCT00251576|DRUG|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
219162039|NCT00251576|DRUG|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
219735934|NCT01113814|DEVICE|Acoustic Radiation Force Impulse (ARFI)- Imaging|
219735935|NCT00549211|DRUG|GSK557296|
219735936|NCT05085847|OTHER|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.
219735937|NCT05085847|OTHER|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
219735938|NCT04629521|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
219735939|NCT04629521|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
219735940|NCT05554224|DIAGNOSTIC_TEST|To propose diagnostic tests for liver diseases before surgical decisions.|Observational although patients are candidates for metabolic surgery.
219735941|NCT02981160|OTHER|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
219235987|NCT01773707|DRUG|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
219235988|NCT01773707|DRUG|Placebo|Saline given as 30 minute IV infusion
219235989|NCT01255709|DRUG|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
219235990|NCT01255709|DRUG|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
219235991|NCT01255709|DRUG|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
219235992|NCT01420328|DRUG|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
219235993|NCT01420328|DRUG|Placebo|Placebo treatment for 6 weeks
219235994|NCT04148794|BEHAVIORAL|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
219235995|NCT02287948|DEVICE|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1\) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
219235996|NCT04416100|DIAGNOSTIC_TEST|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
219235997|NCT04416100|DIAGNOSTIC_TEST|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
219235998|NCT04416100|BIOLOGICAL|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
219235999|NCT04151888|DEVICE|Foley catheter|Thin sterile tube will be inserted in choana
219236000|NCT03402399|OTHER|Molecular analysis|Blood test
219236001|NCT02837705|OTHER|blood draw|
219236002|NCT02529605|DIETARY_SUPPLEMENT|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
219236003|NCT02529605|DIETARY_SUPPLEMENT|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
219236004|NCT02575014|DRUG|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
219236005|NCT01141985|DEVICE|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
219236006|NCT03927963|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
219735942|NCT06345703|DRUG|Placebo|NS-136 matching placebo
219735943|NCT06345703|DRUG|NS-136 tablet|Investigational product NS-136
219735944|NCT06525454|BEHAVIORAL|Personalized coaching messages for blood glucose and emotions|For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
219735945|NCT03240445|DRUG|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
219735946|NCT03240445|DRUG|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
219735947|NCT03240445|DRUG|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
219735948|NCT04551924|DRUG|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
219735949|NCT04551924|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
219735950|NCT05264584|DRUG|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
219735951|NCT05264584|DRUG|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
219735952|NCT05264584|DRUG|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
219735953|NCT01623284|DRUG|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
219236007|NCT03927963|DRUG|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
219735954|NCT01623284|DRUG|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
219735955|NCT01905267|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
219735956|NCT00558207|DRUG|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
219735957|NCT00558207|DRUG|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
219735958|NCT03888482|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
219735959|NCT03888482|DEVICE|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
219735960|NCT03721107|BIOLOGICAL|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
219735961|NCT03721107|OTHER|Placebo|Placebo control
219735962|NCT04792970|DRUG|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
219735963|NCT02511158|PROCEDURE|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
219735964|NCT06436521|BEHAVIORAL|Positive Cognitive Behavioral Therapy|Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
219735965|NCT06436521|BEHAVIORAL|Traditional Cognitive Behavioral Therapy|Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
219735966|NCT00449852|BEHAVIORAL|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
219735967|NCT06269601|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
219735968|NCT02824549|DEVICE|FreeStyle Libre Flash Glucose Monitoring|
219735969|NCT02554474|BEHAVIORAL|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
219735970|NCT02554474|BEHAVIORAL|Same intervention with a 9-week delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
219735971|NCT01977976|PROCEDURE|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
219735972|NCT05675293|DEVICE|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
219735973|NCT05675293|DRUG|ORAL ANTIBIOTIC|Oral Antibiotic
219735974|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
219735975|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
219735976|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
219735977|NCT01766089|DRUG|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
219735978|NCT01766089|DRUG|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
219735979|NCT04171869|OTHER|no intervention|observational study, no intervention
219735980|NCT00873886|DRUG|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
219735981|NCT00873886|PROCEDURE|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
219735982|NCT03272165|DRUG|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
219735983|NCT03272165|DRUG|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
219735984|NCT02770365|DRUG|estrace cream (Perrigo)|
219735985|NCT02770365|DRUG|estrace cream (Reference)|
219735986|NCT02770365|DRUG|Placebo cream|
219162040|NCT00251576|DRUG|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
219162041|NCT00251576|DRUG|Duration of Treatment: Z-Phase, 2 years.|
219162042|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
219162043|NCT04065113|PROCEDURE|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
219162044|NCT04065113|PROCEDURE|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
219162045|NCT00839241|DEVICE|Bellovac ABT|Bellovac ABT (autologous blood)
219162046|NCT00839241|PROCEDURE|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
219162047|NCT00976937|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219735987|NCT03000751|OTHER|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
219162048|NCT00976937|DRUG|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219162049|NCT00976937|DEVICE|Pen auto-injector|
219162050|NCT00976937|DRUG|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
219162051|NCT00976937|DRUG|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
219162052|NCT00976937|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
219162053|NCT02317965|OTHER|Maternal Blood Draw|Maternal Blood Draw
219735988|NCT03000751|OTHER|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
219735989|NCT03000751|OTHER|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
219236008|NCT00801528|DRUG|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
219236009|NCT02797899|DEVICE|Platelet Rich Fibrin|Native growth factors
219236010|NCT03788278|DEVICE|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
219236011|NCT01655498|DEVICE|vaginal bowel control system (LivSure)|
219236012|NCT04492085|OTHER|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
219236013|NCT02270502|DEVICE|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
219236014|NCT02270502|OTHER|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
219735990|NCT04316650|BEHAVIORAL|Evaluation Scales|"* PATHOS / PEACCE : hypersexuality diagnostic scale~* PDQ-4+: Personality Diagnostic Questionnaire version 4~* AUDIT~* Life trajectory : THQ~* Cognitive function (MoCA, Stroop)~* ISDSS: and self report of sexual activity and desire~* BARS: Brief Adhesion Rating Scale (treatment observance)~* SF-36 scale : quality of life~* BDI-II : Beck Depression Inventory~* BSSI ; Beck suicidal Inventory~* Cognitive functioning evaluation : Molest and Rape Scale~* Empathy: EMPAT~* Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~* Baratt Impulsivity Scale~* CSBI~* Static 99 and Stable 2007"
219735991|NCT04316650|OTHER|osteodensitometry|Osteodensitometry
219735992|NCT04316650|BIOLOGICAL|blood samples|"* Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~* Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~* Kydney function~* Blood count~* Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~* Biological Measurements of Plasma Prolactin level"
219735993|NCT04316650|OTHER|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
219735994|NCT04316650|GENETIC|Blood and saliva samples|Blood and saliva samples
219735995|NCT02991859|DRUG|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
219735996|NCT02991859|DRUG|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
219735997|NCT02991859|DRUG|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
219735998|NCT02991859|DRUG|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
219735999|NCT05835596|DEVICE|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
219736000|NCT03763266|OTHER|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
219736001|NCT03763266|OTHER|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
219736002|NCT03674450|BEHAVIORAL|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
219736003|NCT03320083|BEHAVIORAL|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
219736004|NCT05259540|DRUG|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
219736005|NCT01584297|DRUG|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
219736006|NCT06082817|DRUG|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
219736007|NCT03607786|PROCEDURE|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
219236015|NCT02270502|OTHER|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
219736008|NCT03607786|PROCEDURE|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
219736009|NCT03825666|OTHER|ProvideXtra® Fresenius Kabi|Improving wellbeeing
219736010|NCT00002461|BIOLOGICAL|filgrastim|
219736011|NCT00002461|BIOLOGICAL|sargramostim|
219736012|NCT00002461|DRUG|carmustine|
219736013|NCT00002461|DRUG|cisplatin|
219736014|NCT00002461|DRUG|cyclophosphamide|
219736015|NCT00002461|DRUG|etoposide|
219736016|NCT00002461|PROCEDURE|autologous bone marrow transplantation|
219736017|NCT00002461|PROCEDURE|in vitro-treated bone marrow transplantation|
219736018|NCT00002461|PROCEDURE|peripheral blood stem cell transplantation|
219736019|NCT00002461|RADIATION|radiation therapy|
219736020|NCT06103799|BEHAVIORAL|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
219736021|NCT01065766|DRUG|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
219736022|NCT00712075|BEHAVIORAL|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
219736023|NCT00712075|BEHAVIORAL|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
219736024|NCT00712075|BEHAVIORAL|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
219736025|NCT02268305|DRUG|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
219736026|NCT02268305|OTHER|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
219736027|NCT04223687|OTHER|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
219736028|NCT04223687|OTHER|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
219736029|NCT03004677|BEHAVIORAL|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
219736030|NCT03004677|OTHER|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
219736031|NCT02787174|OTHER|Asthma Medication Adherence Education|
219736032|NCT05522829|BIOLOGICAL|SCTV01E-1 on D0|Day 0; intramuscular injection
219736033|NCT05522829|BIOLOGICAL|SCTV01E-1 on D28|Day 28; intramuscular injection
219736034|NCT05522829|BIOLOGICAL|SCTV01E-1 on D150|Day 150; intramuscular injection
219736035|NCT05522829|BIOLOGICAL|SCTV01E on D0|Day 0; intramuscular injection
219736036|NCT05522829|BIOLOGICAL|SCTV01E on D28|Day 28; intramuscular injection
219736037|NCT05522829|BIOLOGICAL|SCTV01E on D150|Day 150; intramuscular injection
219736038|NCT05522829|BIOLOGICAL|SCTV01E-1 on D120|Day 120; intramuscular injection
219736039|NCT05522829|BIOLOGICAL|SCTV01E on D120|Day 120; intramuscular injection
219736040|NCT00490412|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
219736041|NCT00490412|OTHER|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
219736042|NCT00425854|DRUG|BIBW 2992|high dose once daily
219736043|NCT05474716|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
219736044|NCT00202852|OTHER|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
219736045|NCT00202852|DRUG|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
219736046|NCT00202852|BIOLOGICAL|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
219736047|NCT00202852|DRUG|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
219736048|NCT05417386|DRUG|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
219236016|NCT05804552|DEVICE|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
219236017|NCT01668498|DRUG|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
219236018|NCT01668498|DRUG|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
219236019|NCT06416605|PROCEDURE|Maxillary Alveolar Ridge Augmentation|using tooth graft or bone graft to increase alveolar ridge width to be able to insert dental implant
219236020|NCT05185102|OTHER|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
219236021|NCT05045456|DEVICE|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
219236022|NCT01379677|DRUG|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
219236023|NCT01379677|DRUG|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
219236024|NCT05278117|PROCEDURE|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
219236025|NCT05894551|OTHER|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
219236026|NCT05894551|OTHER|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
219236027|NCT05894551|OTHER|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
219236028|NCT01301183|DRUG|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
219236029|NCT01301183|DRUG|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
219736049|NCT05417386|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219736050|NCT05417386|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219736051|NCT05417386|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219736052|NCT05417386|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
219736053|NCT05417386|DRUG|NIS793|Given by intravenous infusion
219736054|NCT05417386|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
219736055|NCT05417386|DRUG|Capecitabine|Taken Orally as part of Chemoradiation
219736056|NCT05417386|RADIATION|Radiation Therapy|Radiation Therapy as part of Chemoradiation
219736057|NCT05417386|PROCEDURE|Surgery|Surgical removal of tumor
219736058|NCT01378273|DRUG|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
219736059|NCT01378273|OTHER|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
219736060|NCT03907579|BEHAVIORAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
219736061|NCT06269666|DEVICE|P200TxE|SLO and OCT imaging
219736062|NCT03546257|DEVICE|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
219736063|NCT03814629|DRUG|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
219236030|NCT04514094|DRUG|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
219236031|NCT04514094|PROCEDURE|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
219236032|NCT05177029|DRUG|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
219236033|NCT05177029|DRUG|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
219236034|NCT01330745|OTHER|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
219236035|NCT06453759|PROCEDURE|Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei|"The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts."
219236036|NCT03799757|DRUG|40ml of 0.25% bupivacaine|
219236037|NCT03799757|DRUG|40ml of 0.9% normal saline|
219236038|NCT00473031|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
219736064|NCT01505803|DIETARY_SUPPLEMENT|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
219736065|NCT01505803|DIETARY_SUPPLEMENT|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
219736066|NCT01505803|DIETARY_SUPPLEMENT|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
219736067|NCT06140238|DRUG|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
219736068|NCT06140238|DRUG|Normal saline|Normal saline administration 15 minutes before start surgical operation
219736069|NCT00195611|DRUG|Prevenar|
219736070|NCT02042144|DRUG|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
219736071|NCT03944876|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
219162054|NCT05506436|DEVICE|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
219236039|NCT00473031|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
219736072|NCT03944876|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
219736073|NCT06964230|DRUG|T3D-959|"Experimental:~T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning."
219736074|NCT06964230|OTHER|Placebo Comparator|Placebo used to compare to T3D-959 drug
219236040|NCT00473031|BEHAVIORAL|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
219236041|NCT01072149|DRUG|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
219236042|NCT01072149|DEVICE|placebo|placebo
219236043|NCT04977089|DIAGNOSTIC_TEST|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
219236044|NCT05779254|DRUG|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
219236045|NCT01566552|DRUG|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
219236046|NCT01781923|BEHAVIORAL|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
219236047|NCT01781923|BEHAVIORAL|Small group social skills training|Meet once per week for duration of 40 weeks.
219736075|NCT06963892|BEHAVIORAL|Neuromuscular Exercise Programme (GLA:D®-based|Participants underwent supervised neuromuscular exercise sessions based on the Good Life with osteoArthritis in Denmark (GLA:D®) programme. Exercises targeted dynamic joint stability, balance, proprioception, functional movements, and muscle strengthening. Sessions were held once weekly, lasting approximately 60 minutes each, over six consecutive weeks. The intervention was tailored progressively to each participant's capabilities, symptoms, and pain tolerance.
219736076|NCT06963892|BEHAVIORAL|Usual Physiotherapy Care (NHS Standard)|Participants received standard NHS physiotherapy care for hip or knee osteoarthritis. This included routine joint mobility exercises, strengthening activities, general education, and advice. Sessions were delivered in outpatient clinics following standard practice without specific emphasis on neuromuscular control training. Frequency and duration-matched usual clinical care.
219236048|NCT03763409|DRUG|Losartan Potassium|active drug
219236049|NCT03763409|OTHER|placebo|placebo
219236050|NCT06207383|DEVICE|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
219236051|NCT06207383|PROCEDURE|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
219236052|NCT06207383|PROCEDURE|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
219736077|NCT06964516|PROCEDURE|The group using the whole-breast bandaging method|Use 1 to 2 pieces of sterile loose gauze to knead into a gauze ball, press it on the residual cavity. Then, continue to use 5 to 8 pieces of loose gauze to stack gauze balls within a diameter of 5 cm around the wound for bandaging. Finally, apply compression bandaging with an elastic bra. The time for compression bandaging with the elastic bra is 24 hours.
219736078|NCT06964516|PROCEDURE|The group using the local bandaging method|Knead one or two pieces of loose gauze into a gauze ball to replace multiple gauze balls and place it in the residual cavity. Then, use elastic medical adhesive tape for local compression and sticking. Finally, place a pure cotton clean towel inside the elastic bra and wear the elastic bra for just one day.
219736079|NCT05534607|BEHAVIORAL|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
219736080|NCT05308862|BEHAVIORAL|Care process for assessements of risks|Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
219736081|NCT02738697|DRUG|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
219736082|NCT02738697|PROCEDURE|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
219736083|NCT06494371|BIOLOGICAL|LCAR-HL30 cells|Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
219736084|NCT05800002|PROCEDURE|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
219736085|NCT05800002|PROCEDURE|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
219736086|NCT06525870|DRUG|85%TCA topical application|85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
219736087|NCT06525870|DRUG|3% acetic acid|3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
219736088|NCT00582452|OTHER|Telephone survey|Telephone survey
219736089|NCT06122493|DRUG|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
219736090|NCT06122493|DRUG|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
219736091|NCT06122493|DRUG|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
219736092|NCT06122493|RADIATION|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
219736093|NCT00180453|DEVICE|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
219736094|NCT00180453|DEVICE|Coronary artery stent placement|Coronary artery stent placement
219736095|NCT00997815|DRUG|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
219736096|NCT00997815|DRUG|Normal saline injection|Using normal saline 2.5 ml injected in control side
219236053|NCT04392856|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
219736097|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
219736098|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
219736099|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
219736100|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
219736101|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg\_
219736102|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
219736103|NCT00135161|PROCEDURE|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
219736104|NCT03189433|DRUG|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
219736105|NCT00725231|BIOLOGICAL|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
219736106|NCT00725231|DRUG|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
219736107|NCT05652140|OTHER|Data collections|Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
219736108|NCT06471517|DEVICE|Somatosensory feedback|Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
219736109|NCT05782244|DRUG|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
219736110|NCT05782244|DRUG|Placebo|Placebo, oral, TID
219736111|NCT05782244|DRUG|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
219736112|NCT05782244|DRUG|Sildenafil high dose|Sildenafil 80 mg, oral, TID
219736113|NCT05783349|BIOLOGICAL|Unique blod sample|sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
219162055|NCT05506436|OTHER|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
219162056|NCT00854191|DEVICE|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
219162057|NCT05925920|DRUG|ENT-03|single dose of active drug
219736114|NCT04011189|PROCEDURE|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
219736115|NCT04011189|OTHER|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
219736116|NCT04011189|DEVICE|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
219736117|NCT04787042|BIOLOGICAL|ST-067|ST-067 is an engineered variant of human interleukin-18.
219736118|NCT04787042|BIOLOGICAL|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
219736119|NCT04787042|BIOLOGICAL|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
219736120|NCT03121274|PROCEDURE|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
219736121|NCT00068848|BEHAVIORAL|Quick start oral contraceptive initiation|
219736122|NCT01209468|DEVICE|monobloc oral appliance|one piece oral appliance
219736123|NCT01209468|DEVICE|twinblock oral appliance|two-piece oral appliance
219736124|NCT03512158|OTHER|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
219736125|NCT03954730|OTHER|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
219736126|NCT03954730|OTHER|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
219736127|NCT03947021|RADIATION|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
219736128|NCT03947021|DEVICE|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
219736129|NCT04755062|BEHAVIORAL|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
219736130|NCT03163264|BEHAVIORAL|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
219736131|NCT03163264|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
219736132|NCT06329336|BEHAVIORAL|Social Emotional Competence for Children and Parents|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
219162058|NCT05925920|DRUG|Placebo|single dose of placebo comparator
219162059|NCT05297851|DRUG|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
219162060|NCT05297851|DRUG|Control|Standard treatment accordind to the routine clinical practice
219162061|NCT00268671|DRUG|Docetaxel|
219162062|NCT05508243|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
219162063|NCT03407846|PROCEDURE|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
219162064|NCT05640180|DRUG|Finerenone (Kerendia, BAY94-8862)|Retrospective cohort analysis using randomized clinical trials data.
219162065|NCT05640180|DRUG|Sodium-glucose cotransporter-2 inhibitors (SGLT2i)|Retrospective cohort analysis using United States Optum Electronic Health Records data.
219162066|NCT04856826|DEVICE|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
219162067|NCT03067142|OTHER|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
219162068|NCT01404182|BIOLOGICAL|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
219162069|NCT05004597|OTHER|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
219162070|NCT01011946|DEVICE|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
219162071|NCT01203813|OTHER|Electronic Decision Support|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
219162072|NCT03427034|DEVICE|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
219162073|NCT01644916|PROCEDURE|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
219162074|NCT01644916|PROCEDURE|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
219162075|NCT04818931|DRUG|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
219162076|NCT04705311|OTHER|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
219162077|NCT04705311|BEHAVIORAL|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
219162078|NCT02332577|DRUG|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
219162079|NCT02332577|DRUG|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
219162080|NCT02332577|DRUG|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
219162081|NCT02332577|DRUG|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
219162082|NCT03988842|DRUG|Alteplase|Lyophilized powder for reconstitution in 50mg vials
219162083|NCT03988842|DRUG|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
219162084|NCT03988842|DRUG|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
219162085|NCT03988842|DRUG|Apixaban|Apixaban tablet
219162086|NCT03055689|BEHAVIORAL|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
219162087|NCT03055689|BEHAVIORAL|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
219736133|NCT04453007|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
219736134|NCT04453007|BEHAVIORAL|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
219736135|NCT05677126|DRUG|Tralement|Tralement with Manganese
219736136|NCT05677126|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
219736137|NCT00276003|DRUG|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
219736138|NCT03923998|DRUG|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
219162088|NCT03306368|BEHAVIORAL|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
219162089|NCT00563446|DRUG|Darbepoetin alfa|
219162090|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
219162091|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
219162092|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
219162093|NCT00352976|DRUG|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
219736139|NCT03923998|RADIATION|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
219736140|NCT03923998|PROCEDURE|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
219736141|NCT05091450|BEHAVIORAL|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
219162094|NCT00352976|DRUG|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
219162095|NCT00352976|PROCEDURE|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
219162096|NCT00352976|PROCEDURE|Bone Marrow Transplantation|A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
219162097|NCT00352976|DRUG|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
219162098|NCT00352976|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
219162099|NCT05708144|DIAGNOSTIC_TEST|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
219162100|NCT01227265|DRUG|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
219162101|NCT01227265|DRUG|Placebo|Preladenant-matching placebo oral tablet taken twice daily
219162102|NCT04497766|DRUG|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
219162103|NCT04497766|DRUG|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
219736142|NCT04968600|PROCEDURE|total knee arthroplasty|Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
219736143|NCT06163807|DRUG|Antiasthmatic|real-life
219736144|NCT05572216|PROCEDURE|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
219736145|NCT05259722|DRUG|Delgocitinib|Cream for topical application 20 mg/g
219736146|NCT05259722|DRUG|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
219162104|NCT04758416|PROCEDURE|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
219162105|NCT04758416|DRUG|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
219162106|NCT03060317|BEHAVIORAL|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
219162107|NCT06696716|DRUG|ONO-4059|Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
219162108|NCT06696716|DRUG|ONO-4059 placebo|Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
219162109|NCT01448681|OTHER|No Interventions|
219162110|NCT06675136|PROCEDURE|Biopsy|Undergo tumor biopsy
219162111|NCT06675136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219162112|NCT06675136|PROCEDURE|Computed Tomography|Undergo CT
219162113|NCT06675136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219162114|NCT06675136|OTHER|Medical Device Usage and Evaluation|Given PIPAC
219162115|NCT06675136|DRUG|Nab-paclitaxel|Given IP
219162116|NCT06675136|DRUG|Paclitaxel|Given IV
219162117|NCT06675136|OTHER|Questionnaire Administration|Ancillary studies
219162118|NCT06675136|BIOLOGICAL|Ramucirumab|Given IV
219162119|NCT07005063|DEVICE|FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
219162120|NCT06871397|OTHER|Biopsychosocial Cognitive Behavioral Intervention|"The study intervention is based on a biopsychosocial approach (considers the interaction between: biological factors such as physical health, fetal development and physiological changes; psychological factors such as stress management, emotions and thoughts; and social factors such as couple relationships, social support and the maternal role) with cognitive-behavioral strategies designed to promote comprehensive well-being during pregnancy and the postpartum. Techniques such as psychoeducation, reflection and self-observation, cognitive restructuring, problem solving, stress inoculation, progressive muscle relaxation, guided visualizations and mindfulness are applied.~The program consists of 10 modules focused on different areas: introduction to the study, mindfulness and breathing techniques, physical and mental health at different stages of pregnancy, fetal development and prenatal attachment, couple relationship, preparation for childbirth and postpartum, and care of the newborn."
219162121|NCT06726434|PROCEDURE|Surgical neurotomy (SN)|"Surgical neurotomy will be performed under general anesthesia according to the previous description. Muscle relaxant drugs will not be used in order to prevent any interference with the intraoperative electrical stimulation.~The patient will be placed in a prone position and a vertical cutaneous incision will be made at the popliteal fossa location.~The tibial nerve will be dissected and the motor nerve branches of the soleus, gastrocnemius, tibialis posterior and flexor hallucis longus will be identified with intraoperative tripolar electrical stimulation. The selected motor nerve branches will be partially sectioned over a 5mm length under the microscope. The extent of nerve section will be determined according to the degree of spasticity and to the intraoperative residual muscular contraction under electrical stimulation"
219162122|NCT06726434|PROCEDURE|Cryoneurotomy (CN)|"After the use of an aseptic technique with 2% chlorhexidine, betadine application and a local anesthesia with lidocaine 1% (3ml), percutaneous cryoneurotomy will be performed with METRUM CRYOFLEX device guided by ultrasound with 1.2mm cryoprobe at -89°C placed through a #16 angio guide. Electrical stimulation will be performed to confirm tibial nerve contact at 0.8 mV.~The ice ball will be repositioned to two spots along the nerve. Each lesion will be treated for 2min cryoneurolysis at -89°C, followed by 2min without freezing (passive defreezing period) and 2min of cryoneurolysis at -89°C, based on cryotherapy for pain management."
219162123|NCT07056803|DRUG|Oral semaglutide|Starting dose 3 mg for a month, followed by 7 mg for a month increased up to 14 mg a month
219736147|NCT00962650|DEVICE|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
219736148|NCT02624089|DRUG|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
219736149|NCT02624089|DRUG|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
219736150|NCT02402036|DRUG|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
219736151|NCT03026725|OTHER|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate \& Fluoride
219736152|NCT03026725|OTHER|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
219736153|NCT03811873|DIAGNOSTIC_TEST|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
219736154|NCT03811873|OTHER|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
219736155|NCT02744547|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
219736156|NCT04871945|DIAGNOSTIC_TEST|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
219736157|NCT00362323|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
219736158|NCT00362323|DRUG|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
219736159|NCT02466581|DRUG|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
219736160|NCT02466581|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
219736161|NCT02466581|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
219736162|NCT02466581|BIOLOGICAL|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
219736163|NCT02667834|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
219736164|NCT02667834|BEHAVIORAL|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
219736165|NCT02381327|DEVICE|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
219736166|NCT02233088|BEHAVIORAL|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
219736167|NCT02233088|OTHER|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
219736168|NCT02233088|OTHER|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
219736169|NCT05486286|DEVICE|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
219736170|NCT03727581|DIAGNOSTIC_TEST|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
219736171|NCT06516848|OTHER|High Intensity Inspiratory Muscle Training Group (H-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 80% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
219736172|NCT06516848|OTHER|Low Intensity Inspiratory Muscle Training Group (L-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
219736173|NCT01463345|OTHER|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels \>7.5 g/dl.
219736174|NCT01463345|OTHER|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels \> 9.0 g/dl.
219736175|NCT00313898|DRUG|sildenafil (viagra)|
219736176|NCT00622063|DRUG|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
219736177|NCT00494156|DRUG|heparin|
219736178|NCT00494156|DRUG|aspirin and clopidogrel|
219736179|NCT06034275|DRUG|VIP943 (QW)|VIP943 will be administered by IV Infusion weekly
219736180|NCT06034275|DRUG|VIP943 (BIW)|VIP943 will be administered by IV Infusion bi-weekly
219736181|NCT01848808|DIETARY_SUPPLEMENT|Wobenzym PS|
219736182|NCT01848808|DIETARY_SUPPLEMENT|Placebo|
219736183|NCT01185366|DRUG|Everolimus|10 mg by mouth once a day.
219736184|NCT01185366|DRUG|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
219736185|NCT03466164|BEHAVIORAL|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
219736186|NCT02668419|DEVICE|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
219736187|NCT02668419|OTHER|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
219736188|NCT02708706|DRUG|hyaluronic acid (hyruan)|2cc hyaluronic acid
219736189|NCT02708706|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
219736190|NCT04078399|DRUG|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
219736191|NCT02544724|BIOLOGICAL|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
219736192|NCT05125432|DEVICE|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
219736193|NCT01514175|DRUG|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
219736194|NCT01514175|DRUG|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
219736195|NCT04049565|DIAGNOSTIC_TEST|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
219736196|NCT03799120|DRUG|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
219736197|NCT03799120|OTHER|Placebo|Placebo
219162124|NCT07056803|DRUG|subcutaneous semaglutide|subcutaneous semaglutide can be started at 0,25 mg a week for a month, to be increased at 0,5 mg a week, up to 1 mg a week
219162125|NCT07071025|BEHAVIORAL|Preventing Postpartum Onset Distress (P-POD)|P-POD contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules are designed to educate pregnant women about perinatal anxiety (psychoeducation), teach women to change their thinking patterns (cognitive restructuring), and guide women through testing their dysfunctional beliefs and fears (behavioral experiments). Each of these modules engage the pregnant woman in various self-guided exercises to consolidate the lessons learned. In addition, three partner-directed modules are designed to educate partners about perinatal anxiety, coach partners on providing emotional and social supports to pregnant women at risk for perinatal anxiety, and prepare partners for developmentally normative changes in their relationships following birth. Modules are designed to be completed weekly during the second trimester.
219162126|NCT07071025|BEHAVIORAL|Anxiety Education (ANX-ED)|ANX-ED educates women and their partners about seven anxiety and related disorders. ANX-ED contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules and three partner-directed modules will educate participants about generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobia, obsessive-compulsive disorder, and posttraumatic stress disorder. Specifically, modules will include the diagnostic criteria, prevalence, and etiology of the disorders. They will also include animated examples of mothers experiencing the disorders described in each module. Each module engages the pregnant woman (or partner) in various self-guided exercises to consolidate the material learned.
219162127|NCT07070713|DRUG|FOLFOXIRI + QL1706 + Bevacizumab|FOLFOXIRI(Irinotecan 165mg/m², iv, d1; Oxaliplatin 85mg/m², iv, d1; (Levo) Folinic Acid (200) 400mg/m², iv, d1; total 5-FU 2400mg/m², iv gtt (continuous for 48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Bevacizumab (5mg/kg, i.v., Q2W)
219162128|NCT07070713|DRUG|FOLFOX+QL1706+Cetuximab|FOLFOX (Oxaliplatin 85mg/m², iv gtt (for 2h), d1; (Levo) Folinic Acid (200) 400mg/m², iv gtt (for 2h), d1; 5-FU 400mg/m², iv, followed by 2400mg/m², iv gtt (continuous for 46-48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Cetuximab (500mg/m², i.v., Q2W).
219162129|NCT07071818|PROCEDURE|Colpocleisis Group|Participants will undergo colpocleisis surgery as part of routine clinical care. The study involves transperineal ultrasound (TPUS) to measure the vesicourethral angle preoperatively and postoperatively, along with assessments for de novo stress urinary incontinence, POP-Q staging, PFDI-20 questionnaire, and stress testing.
219162130|NCT07064863|DRUG|Gemcitabine + BCG|Patients will receive a single intravesical instillation of gemcitabine (2000 mg) at week 0 followed by weekly BCG (50 mg of TICE strain) for a total of 5 instillations. Biopsy will be conducted within three months of completing the induction phase.
219162131|NCT07064863|DRUG|BCG (TICE strain)|Patients will receive intravesical BCG (50 mg, TICE strain) at weekly intervals for a total of 6 instillations. Biopsy will be performed within 3 months of completing the induction phase.
219162132|NCT07069816|RADIATION|Scintigraphy|non invasive method in which the test meals and acquisition procedures have been standardized and the results are largely operator independent
219162133|NCT07069816|RADIATION|Scintigraphy|Non invasive method in which the test meals and acquisition procedures have been standardized
219162134|NCT05028582|DRUG|Roflumilast Foam 0.3%|Roflumilast foam 0.3%
219162135|NCT05028582|DRUG|Vehicle Foam|Vehicle foam matched to roflumilast 0.3% foam.
219162136|NCT07077486|DRUG|Methylprednisolone (Corticosteroid)|In addition to conventional treatment (methyl-40mg or less /d), the treatment group also received hydroxychloroquine (100mg-200mg each time twice a day), and thalidomide (50mg-100mg each time once a day) could be added as appropriate.
219736198|NCT02774278|DRUG|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
219736199|NCT01691313|DRUG|Vanoxerine|single oral dose
219736200|NCT01691313|DRUG|Placebo|single oral dose
219736201|NCT06277726|OTHER|Emotional freedom technique group|Emotional freedom technique will be applied to women in this group before intrauterine device application.
219736202|NCT06277726|OTHER|Music group|Women in this group will wear headphones and listen to music throughout the intrauterine device application.
219162137|NCT07077486|DRUG|Immunosuppressant other than CYC|The control group only received conventional treatment (methyl 40 mg/d or less), and other traditional immunosuppressants (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine, etc.). No more than 3 types of immunosuppressant should be added during the whole treatment period, and the dose should not exceed 30% from the baseline period)
219162138|NCT07077486|DRUG|Telitacicept Freeze-dried powder Injection 80mg|Telitacicept is a TACI-Fc fusion protein, a type of drug used to treat autoimmune diseases. It works by targeting two key proteins, BLyS and APRIL, which are involved in the development and function of B cells, a type of white blood cell. By blocking these proteins, telitacicept can help to reduce B cell activity and suppress the immune system's overactivity in autoimmune diseases. Subcutaneous injection dose ranges from 80mg once a week to 160mg once a week.
219162139|NCT07077486|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide iv injection is used for severe complications of systemic lupus erythematosus 400mg twice a week
219162140|NCT07078188|BEHAVIORAL|PEG training|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0, 1, and 3 months.). The intervention group will be trained on PEG use before discharge at the first interview.
219162141|NCT07078188|OTHER|Control|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0.,1. ve 3. monts).
219162142|NCT07076901|BEHAVIORAL|Psychological Support|A structured psychological intervention aimed at alleviating preoperative anxiety. It included one-on-one counseling, providing detailed information about the surgical procedure, introducing relaxation techniques and music therapy, and sharing success stories from previous patients to boost confidence. Support was provided via phone or WeChat video by a qualified psychological counselor.
219162143|NCT07076901|BEHAVIORAL|Supervised Exercise Program|A daily guided exercise regimen including two components: 1) General physical conditioning consisting of at least 40 minutes of moderate-intensity aerobic and resistance training (e.g., brisk walking, jogging, cycling). 2) Respiratory function training consisting of abdominal breathing (5 times/hour) and balloon-blowing exercises (10 times/day). Patient adherence was monitored daily via a WeChat group.
219162144|NCT07076901|BEHAVIORAL|Lifestyle and Dietary Modification|Focused on optimizing preoperative habits. Nutritional guidance involved a high-protein, high-vitamin diet with six smaller, frequent meals per day to adapt to post-surgery conditions. Lifestyle guidance included advising smoking and alcohol cessation and ensuring 6-8 hours of sleep per night. Daily dietary and sleep status were reported and monitored via a WeChat group.
219162145|NCT07076901|OTHER|Routine Perioperative Care|Consisted of standard care practices before, during, and after surgery. Preoperative care included health education and fasting instructions. Intraoperative care included body temperature maintenance and vital signs monitoring. Postoperative care included 12-hour ECG monitoring, gradual reintroduction of a clear liquid diet 24 hours post-surgery, encouragement of early mobilization, and standard nursing for catheters and wounds.
219162146|NCT07076628|DRUG|Propofol|Propofol infusion with remifentanil
219162147|NCT07076628|DRUG|Remimazolam|Remimazolam infusion with remifentanil
219736203|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
219736204|NCT05644509|BIOLOGICAL|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
219736205|NCT05662943|DRUG|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
219736206|NCT05673850|DRUG|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
219736207|NCT00408447|DRUG|Busulfan|Busulfan 4 mg/kg/d x 4d
219736208|NCT00408447|DRUG|Fludarabine|Fludarabine 30 mg/m2/d x 6d
219736209|NCT00408447|DRUG|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
219736210|NCT00408447|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
219736211|NCT02122523|PROCEDURE|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
219736212|NCT02449577|OTHER|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
219736213|NCT02449577|OTHER|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
219736214|NCT02449577|OTHER|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
219736215|NCT02449577|OTHER|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
219736216|NCT02449577|OTHER|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
219736217|NCT02449577|OTHER|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
219736218|NCT02449577|OTHER|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
219736219|NCT02449577|OTHER|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
219736220|NCT02449577|OTHER|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
219736221|NCT02449577|OTHER|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
219736222|NCT02449577|OTHER|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
219736223|NCT01538407|OTHER|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
219736224|NCT01312675|DEVICE|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
219736225|NCT00065546|OTHER|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
219736226|NCT00065546|OTHER|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
219736227|NCT00065546|OTHER|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
219736228|NCT03580187|DRUG|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
219736229|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
219736230|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
219736231|NCT00127933|DRUG|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
219736232|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
219736233|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
219736234|NCT01101555|DRUG|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
219736235|NCT01101555|OTHER|Placebo|Placebo will be given to one member of each cohort.
219736236|NCT00881244|DRUG|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
219736237|NCT02422901|DRUG|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
219736238|NCT01339013|DEVICE|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
219736239|NCT01783938|BIOLOGICAL|Nivolumab|
219736240|NCT01783938|BIOLOGICAL|Ipilimumab|
219736241|NCT01872936|DRUG|Miravirsen|
219736242|NCT01872936|DRUG|Telaprevir|
219736243|NCT01872936|DRUG|Ribavirin|
219736244|NCT03753477|DRUG|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
219736245|NCT03753477|DRUG|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
219736246|NCT05372900|OTHER|Test Product|Whey Protein Isolate with Mulberry leaf extract
219736247|NCT05372900|OTHER|Control Product|Wheat Protein Hydrolysate
219736248|NCT04324489|DRUG|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
219736249|NCT04400955|DIAGNOSTIC_TEST|Audiometry tablet diagnostic tool and web-based test|as above
219736250|NCT06265805|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219736251|NCT06265805|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219162148|NCT07078357|BIOLOGICAL|StrepIncor|This arm will include 25/50/100/200 µg compared to placebo
219162149|NCT07078357|OTHER|Placebo|A placebo (aluminum adjuvant) will be administered and compared to the other study arms
219162150|NCT07076732|OTHER|Coronary Angiography|Coronary angiograms will be acquired digitally for quantification.
219162151|NCT07076732|OTHER|SYNTAX Score|Upon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions.
219162152|NCT06826859|DRUG|Daily aspirin (ASA)|162mg aspirin taken daily
219162153|NCT06826859|DRUG|Split dose aspirin (ASA)|81mg aspirin q12hours
219162154|NCT07077265|DRUG|Norepinephrine (0.1 μg/kg/min)|The patients will receive norepinephrine infusion at a rate 1 mL/kg/hour of 6 mcg/mL solution.
219736252|NCT06265805|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219236054|NCT04392856|BEHAVIORAL|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
219236055|NCT02784834|DRUG|dimethyl fumarate|
219236056|NCT02602002|DRUG|Remifentanil|IV
219236057|NCT02602002|DRUG|Placebo|Placebo
219236058|NCT00048477|DRUG|L-NMMA and Sodium Nitrite|
219236059|NCT00635752|OTHER|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
219236060|NCT00635752|OTHER|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
219236061|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
219236062|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
219236063|NCT02720705|DRUG|Dexmedetomidine|oral dexmedetomidine
219236064|NCT02720705|DRUG|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
219236065|NCT00080119|DRUG|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
219236066|NCT00080119|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
219736253|NCT00548561|DRUG|Dexrazoxane|
219236067|NCT00080119|DRUG|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
219236068|NCT01062165|DRUG|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
219236069|NCT05908136|OTHER|restorative materials|two types of composite with strip crown in primary molars
219236070|NCT05749315|OTHER|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
219236071|NCT05749315|OTHER|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
219236072|NCT01919489|DRUG|Liraglutide + OADs|Liraglutide subcutaneously daily
219236073|NCT01919489|DRUG|Glargine + OADs|Glargine once daily subcutaneously
219236074|NCT04187456|DRUG|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
219236075|NCT04187456|DRUG|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
219236076|NCT00507845|DRUG|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
219236077|NCT01322386|DRUG|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
219236078|NCT00670852|PROCEDURE|X-rays and CT scan|CT Scan x-rays
219236079|NCT03800563|DEVICE|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
219236080|NCT04161976|DRUG|LY900027|LY900027 administered to participants with T1DM using CSII.
219236081|NCT04161976|DRUG|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
219236082|NCT04119700|PROCEDURE|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
219236083|NCT04119700|PROCEDURE|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
219236084|NCT03448302|RADIATION|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
219236085|NCT06299345|OTHER|Motor imagery training|MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
219236086|NCT06299345|OTHER|NO motor imagery training|The participants performed the physical task only. It is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
219236087|NCT00950235|BEHAVIORAL|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
219236088|NCT00950235|OTHER|Usual Care|Standard nutrition counseling from Health Plan
219236089|NCT04794465|DIAGNOSTIC_TEST|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
219236090|NCT00883272|DIETARY_SUPPLEMENT|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
219236091|NCT05804734|DRUG|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
219236092|NCT04873986|DIAGNOSTIC_TEST|Scoliosis Tele-Screening Test|Scoliosis Tele-Screening test will be applied to children by parents at home. Participants with moderate and high risks will be invited to the physical examination to the centers or virtual assessment via e-mail. The researchers will be evaluated the TRACE and Adams' test from the photo and sent their opinions to the parents via e-mail.
219236093|NCT01928888|DRUG|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
219236094|NCT01928888|DRUG|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
219236095|NCT01928888|DRUG|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
219236096|NCT00068809|PROCEDURE|Short Cycle Antiretroviral Therapy|
219236097|NCT03441464|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
219236098|NCT05890781|PROCEDURE|Skin biopsy|Skin biopsy
219236099|NCT05890781|PROCEDURE|Fresh tumor sample|Fresh tumor sample
219236100|NCT05890781|BIOLOGICAL|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
219236101|NCT05890781|PROCEDURE|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
219162155|NCT07077265|DRUG|Norepinephrine (0.07 μg/kg/min)|The patients will receive NE infusion at a rate 1 mL/kg/hour of 4.2 mcg/mL solution.
219162156|NCT07078916|BEHAVIORAL|Motor-Cognitive Training Group (OLBA + BlazePod™)|Arm 1 participant will receive the One-leg-balance activity using visual feedback BlazePod technology as a dual motor-cognitive task training.
219162157|NCT07078916|BEHAVIORAL|Motor Training Group (OLBA Only)|Arm 2 participant will receive a the One-leg-balance activity as a single motor task.
219162158|NCT07077941|OTHER|Integrative care|Joint care of mother and child by just one healthcare professional
219162159|NCT07078669|DEVICE|Polyglactin 910 (Dyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture dyed (violet) with colorants such as D\&C Violet No. 2 present.
219162160|NCT07078669|DEVICE|Polyglactin 910 (Undyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture Undyed
219162161|NCT07077694|PROCEDURE|Root Canal Retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
219162162|NCT06815926|DIETARY_SUPPLEMENT|Probiotic|"Food supplement based on probiotics in capsule format. Dose: 1 capsule/day.~The active capsules contain probiotic strains at ≥1×10\^9 cfu/dose and excipient."
219162163|NCT06815926|DIETARY_SUPPLEMENT|Placebo|"Food supplement in capsule format. Dose: 1 capsule/day.~The placebo capsules contain only excipient (probiotics are not included)."
219162164|NCT07071753|BEHAVIORAL|Video tutorial|At the onset of the intervention, all participants will receive tutorial videos via text, covering Instacart account setup, online item selection, and SNAP-eligible stores, aiming to improve digital literacy in grocery shopping. The video was developed by our team, reviewed by SNAP-Ed partners, and available in English and Spanish. Despite being considered helpful during the pilot, nearly half of the participants reported not receiving or watching the tutorial video. To address this, we will call all participants within the trial's first week to provide technical assistance, including step-by-step instructions on redemption of the free delivery membership. Phone follow-ups were well-received during the pilot. Also, an intervention package will be mailed to all participants as material to be referred to in the calls and throughout the intervention. Those receiving the grocery list component will receive shopping lists and recipes printed and via SMS, to aid online grocery ordering in si
219162165|NCT07071753|BEHAVIORAL|Delivery fee waiver|All participants will receive a 12-week Instacart+ Membership e-gift card, eliminating the online delivery fee for orders \>$35.
219162166|NCT07071753|BEHAVIORAL|Texting|Participants randomized to this component will receive 2 text messages weekly via EZ text to enhance their perception of behavioral control and trust in online grocery services. Text messages, deemed acceptable during our pilot, will be actionable, informed by constructs of the Theory of Planned Behavior, and tailored to assist shoppers using Instacart delivery services. We will deliver 24 short text messages (\<160 characters), on Friday afternoons and Mondays, each with one or more of the purposes rooted in behavior change techniques: increasing salience of the benefits of online grocery, modeling steps in behavior change, giving facts to address mistrust or improve control, asking questions to promote engagement, adding anonymized quotations from the pilot participants to reinforce social norms.
219162167|NCT07071753|BEHAVIORAL|Financial incentive|"Participants randomized to this component (alone or in combination with another experimental condition) will receive $1 for each dollar spent on fresh, frozen, or canned FVL loaded onto Instacart Fresh Funds, verified based on the submitted online grocery receipt or data from Instacart. The incentive applies to online purchases only and will not be earned for in-store transactions. A maximum weekly matched incentive will be set to $10, following the local FV incentive NYC (Get the Good Stuff). Fresh Funds earned, supported by Instacart Health, is an infrastructure integrated with retailer payment systems. Incentives will only be used for purchases of healthier foods (FVL) predetermined by the research team, as it has been used by FV prescription programs."
219162168|NCT07071753|BEHAVIORAL|Grocery list with instant shoppable SNAP-Ed recipes|Participants randomized to this component will receive weekly SNAP-Ed-based meal plans with instant shoppable grocery lists tailored to household size, dietary, and cultural preferences. All recipes will emphasize FVL-based eating patterns with Hispanic cuisine influences that have FVL as primary ingredients. Grocery lists organized by store department and recipe, will reflect the nearest available in-store unit. For example, if one recipe calls for 1 cup of flour, a small flour bag will be added to the list. Weekly meal plans will be shared via text as a photo and mailed as hard copies, with instant shoppable lists generated through Instacart's List feature as a hyperlink. Links to the instant shoppable list will be shared via text. Upon clicking, grocery items will be pre-filled automatically in the participant's online shopping cart. Participants can modify items and quantities before checking out.
219162169|NCT07071077|BEHAVIORAL|Web-Based Storytelling Intervention|The Web-based storytelling group will access stories and educational materials on the study website.
219162170|NCT07071077|BEHAVIORAL|Group-Based Storytelling Plus Intervention|The storytelling plus group will watch the stories in a group setting, share their experiences and have educational sessions led by a health coach.
219162171|NCT06917404|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous injection, 2 mg/kg twice weekly for 6 weeks
219162172|NCT06917404|DRUG|Placebo|Placebo, subcutaneous injection, twice weekly for 6 weeks
219162173|NCT06929663|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
219736254|NCT01713140|OTHER|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
219162174|NCT06937866|DRUG|Zanzalintinib|Three zanzalintinib doses of 40mg, 60mg or 100mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuously for 28 day cycles.
219162175|NCT06937866|DRUG|Etoposide Capsule|Oral daily for 21 days of each 28 day cycle.
219162176|NCT03482245|OTHER|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 442 nm) such that it produces 1700 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject. Those subjects assigned to blue light will be asked to shine this small portable blue enriched light on themselves from 0800 to 2000 for 3 days."
219162177|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
219162178|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
219162179|NCT04956341|DEVICE|Auricular acupuncture|Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.
219162180|NCT04956341|OTHER|Standard treatment|Standard treatment from Primary Care Manager (PCM) or Mental Health or both
219236102|NCT05890781|PROCEDURE|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
219236103|NCT04830345|BIOLOGICAL|ATGC-100 100U|Clostridium botulinum toxin type A
219236104|NCT04830345|BIOLOGICAL|Botox 100U|Clostridium botulinum toxin type A
219236105|NCT00871494|DRUG|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
219236106|NCT02690792|OTHER|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
219236107|NCT02690792|DIETARY_SUPPLEMENT|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
219736255|NCT00498485|DRUG|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
219736256|NCT00498485|DRUG|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
219736257|NCT05538468|OTHER|Assessment|Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
219736258|NCT00066937|DRUG|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
219736259|NCT00066937|DRUG|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
219736260|NCT00066937|BEHAVIORAL|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
219736261|NCT00066937|BEHAVIORAL|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
219736262|NCT03306381|OTHER|Dietary intervention|Elimination of certain products.
219736263|NCT04607382|DRUG|LEP|LEP dosage up to the discretion of the treating gynecologists.
219736264|NCT04607382|DRUG|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
219736265|NCT03072875|DEVICE|CAMS-RAS|
219736266|NCT03478787|DRUG|risankizumab|Subcutaneous (SC) injection
219736267|NCT03478787|DRUG|secukinumab|Subcutaneous (SC) injection
219736268|NCT05142085|DIETARY_SUPPLEMENT|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
219736269|NCT05142085|OTHER|placebo|This treatment will be assigned to 2 out of 5 patients
219736270|NCT05396781|DRUG|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
219236108|NCT04590625|DRUG|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
219236109|NCT04590625|DRUG|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
219162181|NCT06241664|DEVICE|AEYE-DS Software|An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
219162182|NCT03388788|RADIATION|PET Imaging|Positron Emission Tomography (PET) imaging for research.
219162183|NCT03388788|BEHAVIORAL|Circadian Study Protocol|5-day circadian study schedule
219162184|NCT03388788|DRUG|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
219162185|NCT03388788|DRUG|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
219162186|NCT03388788|DRUG|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
219162187|NCT05206747|DEVICE|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
219162188|NCT05206747|DEVICE|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
219162189|NCT06113640|DRUG|levodopa-carbidopa|Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
219162190|NCT06113640|DRUG|Montelukast|Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
219162191|NCT05769595|BIOLOGICAL|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
219162192|NCT05769595|DRUG|Placebo|IV infusion
219162193|NCT04175639|BEHAVIORAL|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
219162194|NCT00186992|RADIATION|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
219162195|NCT00353483|PROCEDURE|Peripheral blood draw|
219162196|NCT00353483|PROCEDURE|Breast tissue collection|
219162197|NCT00353483|PROCEDURE|Bone marrow biopsy|
219162198|NCT03683069|DRUG|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
219162199|NCT06257472|DEVICE|Virtual Reality Headset|Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
219162200|NCT06106451|BEHAVIORAL|Standard of Care plus Enhanced Patient Education|Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
219162201|NCT06106451|BEHAVIORAL|Motivational Interviewing Intervention|Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
219162202|NCT06106451|BEHAVIORAL|Home-Based Activity Program plus Motivational Interviewing Intervention|Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
219162203|NCT06474611|BEHAVIORAL|Patient nudge|Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
219236110|NCT04590625|DRUG|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
219236111|NCT04590625|DRUG|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
219236112|NCT01598389|OTHER|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
219736271|NCT05396781|DEVICE|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
219162204|NCT06472414|BEHAVIORAL|Individualized Counselling Sessions|Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
219236113|NCT02032004|BIOLOGICAL|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
219236114|NCT02032004|OTHER|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
219236115|NCT02601859|DRUG|Lithium Carbonate|
219236116|NCT03560804|DRUG|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
219236117|NCT03560804|DRUG|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
219736272|NCT04093284|DEVICE|The needle-free jet injector|Continuous insulin therapy for 9 days
219736273|NCT04221152|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
219736274|NCT03832088|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale performed for balance disorder
219736275|NCT03832088|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test for walking speed
219736276|NCT03832088|DIAGNOSTIC_TEST|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
219736277|NCT03832088|DIAGNOSTIC_TEST|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
219736278|NCT02016508|DRUG|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
219736279|NCT01506375|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
219736280|NCT01506375|BIOLOGICAL|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
219736281|NCT04086667|OTHER|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
219736282|NCT04356443|DEVICE|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
219736283|NCT01539525|BEHAVIORAL|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
219736284|NCT01539525|OTHER|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
219736285|NCT03483220|DIAGNOSTIC_TEST|MRI brain|"1\. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
219736286|NCT02410174|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
219736287|NCT06255587|OTHER|Screening|cross sectional
219736288|NCT00190892|DRUG|olanzapine|
219736289|NCT00190892|DRUG|carbamazepine|
219236118|NCT02183272|DRUG|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
219736290|NCT05415111|PROCEDURE|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
219736291|NCT05415111|PROCEDURE|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
219736292|NCT05415111|PROCEDURE|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
219736293|NCT01712074|DRUG|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
219736294|NCT01712074|OTHER|Placebo|Placebo QD
219736295|NCT05150288|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
219736296|NCT06419309|OTHER|Dietary intervention|"Four different dietary interventions are planned.~* Gluten-free, lactose-free diet,~* Diet enriched with Aronia Melanocarpa,~* Gluten-free, lactose-free and enriched with Aronia Melanocarpa diet,~* Healthy diet"
219736297|NCT00797901|OTHER|Collaborative Care|
219736298|NCT02268851|DRUG|TGR-1202|Capsules taken whole daily with water and with food
219736299|NCT02268851|DRUG|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
219236119|NCT02183272|DRUG|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
219236120|NCT06508762|DRUG|VX-993|Tablet and Suspension for Oral Administration.
219236121|NCT06509555|OTHER|non-intervention|non-intervention
219236122|NCT00391066|DRUG|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
219236123|NCT00391066|DRUG|FCR|Dose, schedule, and duration specified in protocol
219236124|NCT01331174|DEVICE|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
219236125|NCT00963924|DRUG|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
219236126|NCT00963924|DRUG|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
219236127|NCT00963924|BEHAVIORAL|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
219236128|NCT00074425|DRUG|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
219236129|NCT00074425|DRUG|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
219236130|NCT00074425|DRUG|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
219236131|NCT03662841|PROCEDURE|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
219236132|NCT03875729|BIOLOGICAL|teplizumab|Treatment
219236133|NCT03875729|BIOLOGICAL|Placebo|Control
219236134|NCT06465537|GENETIC|BD113vVLP|CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
219236135|NCT01474759|BEHAVIORAL|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
219236136|NCT01474759|BEHAVIORAL|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
219236137|NCT01474759|OTHER|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
219236138|NCT01474759|BEHAVIORAL|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
219236139|NCT03340922|DEVICE|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
219236140|NCT03340922|DEVICE|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
219236141|NCT03037827|PROCEDURE|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
219162205|NCT06472414|BEHAVIORAL|Educational Women-Focused Sessions|Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.
219236142|NCT03037827|DEVICE|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
219236143|NCT06413459|OTHER|Luminex; scRNAsec|Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
219236144|NCT02764320|OTHER|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
219236145|NCT02764320|OTHER|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
219236146|NCT05297097|DIETARY_SUPPLEMENT|Trulacta breastmilk supplement|one supplement daily
219236147|NCT01742585|DRUG|ASP1585|oral
219236148|NCT01742585|DRUG|placebo|oral
219236149|NCT05008003|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
219236150|NCT05008003|DIETARY_SUPPLEMENT|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
219236151|NCT05303324|DRUG|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
219236152|NCT03780634|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
219236153|NCT03780634|DRUG|PD-1 antibody|200mg intravenously every 3 weeks
219236154|NCT03780634|DRUG|Sorafenib|400 mg Bid Po
219236155|NCT03853889|PROCEDURE|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
219236156|NCT06063915|DEVICE|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
219236157|NCT06063915|OTHER|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
219236158|NCT03220815|PROCEDURE|Drilling at low speed|
219236159|NCT03220815|PROCEDURE|Conventional drilling at high speed|
219236160|NCT05328817|DRUG|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
219236161|NCT02398539|DRUG|Silver Nitrate|Silver Nitrate Sticks
219236162|NCT02398539|DRUG|Triamcinolone|0.5% cream
219236163|NCT01405508|DRUG|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
219236164|NCT01405508|DRUG|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
219236165|NCT01405508|DRUG|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
219236166|NCT01405508|OTHER|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
219236167|NCT00866541|DEVICE|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
219236168|NCT06244563|DEVICE|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
219236169|NCT06244563|DEVICE|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
219236170|NCT06244563|PROCEDURE|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
219236171|NCT06244563|PROCEDURE|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
219236172|NCT02767037|DEVICE|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
219236173|NCT02767037|GENETIC|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
219236174|NCT00476957|DEVICE|Stent|Stent implantation
219236175|NCT00476957|DEVICE|Stent|Stent implantation
219162206|NCT06472414|BEHAVIORAL|Supervised Exercise Training Sessions|Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
219162207|NCT03769168|DRUG|Secukinumab|Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.
219162208|NCT03117751|DRUG|Prednisone|Given orally (PO).
219162209|NCT03117751|DRUG|Vincristine|Given intravenously (IV).
219162210|NCT03117751|DRUG|Daunorubicin|Given IV.
219162211|NCT03117751|DRUG|Pegaspargase|Given IV or intramuscularly (IM) .
219162212|NCT03117751|DRUG|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
219162213|NCT03117751|DRUG|Cyclophosphamide|Given IV.
219162214|NCT03117751|DRUG|Cytarabine|Given IV or by subcutaneous injection (SQ).
219162215|NCT03117751|DRUG|Mercaptopurine|Given PO.
219162216|NCT03117751|DRUG|Dasatinib|Given PO.
219162217|NCT03117751|DRUG|Methotrexate|Given IV.
219162218|NCT03117751|DRUG|Blinatumomab|Given IV.
219162219|NCT03117751|DRUG|Ruxolitinib|Given PO.
219162220|NCT03117751|DRUG|Bortezomib|Given IV or subcutaneously (SQ).
219162221|NCT03117751|DRUG|Dexamethasone|Given PO.
219162222|NCT03117751|DRUG|Doxorubicin|Given IV.
219162223|NCT03117751|DRUG|Etoposide|Given IV.
219162224|NCT03117751|DRUG|Clofarabine|Given IV.
219162225|NCT03117751|DRUG|Vorinostat|Given PO.
219162226|NCT03117751|DRUG|Idarubicin|Given IV.
219162227|NCT03117751|DRUG|Nelarabine|Given IV.
219162228|NCT03117751|DRUG|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
219162229|NCT03117751|DRUG|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
219162230|NCT03117751|DRUG|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
219162231|NCT05093179|PROCEDURE|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
219162232|NCT05093179|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
219162233|NCT05383079|DRUG|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
219162234|NCT05383079|DRUG|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
219162235|NCT04620239|DRUG|padeliporfin VTP|During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
219162236|NCT02204098|BIOLOGICAL|Mammaglobin-A DNA Vaccine|
219162237|NCT02204098|PROCEDURE|Optional biopsy|
219162238|NCT05344378|BEHAVIORAL|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
219162239|NCT04941287|BIOLOGICAL|Atezolizumab|Given IV
219736300|NCT00754286|OTHER|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
219736301|NCT00754286|OTHER|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
219162240|NCT04941287|PROCEDURE|Biopsy|Undergo tumor biopsy
219162241|NCT04941287|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219736302|NCT02474901|BIOLOGICAL|Quadrivalent Live Attenuated Influenza Vaccine|
219736303|NCT03123107|DRUG|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
219736304|NCT02539394|DRUG|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
219162242|NCT04941287|DRUG|Cobimetinib|Given PO
219162243|NCT04941287|PROCEDURE|Computed Tomography|Undergo a CT scan
219736305|NCT02539394|OTHER|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
219736306|NCT03614988|OTHER|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
219736307|NCT03614988|OTHER|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
219162244|NCT04941287|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219162245|NCT04941287|DRUG|Varlilumab|Given IV
219736308|NCT01472835|DRUG|Midazolam|Used for anxiolysis
219736309|NCT01472835|DRUG|Fentanyl|Used for analgesia and as a sedative
219736310|NCT04995926|PROCEDURE|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
219736311|NCT02595554|RADIATION|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
219736312|NCT02595554|DRUG|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
219736313|NCT02595554|PROCEDURE|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
219736314|NCT02595554|DRUG|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
219736315|NCT04483232|BIOLOGICAL|Ear canal swab|Ear canal swab
219736316|NCT04180878|BEHAVIORAL|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
219736317|NCT04180878|BEHAVIORAL|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
219736318|NCT00320580|DRUG|norelgestromin/ethinyl estradiol|
219736319|NCT01044693|DRUG|Placebo|Placebo capsule
219736320|NCT01044693|DRUG|Nebivolol 5 mg|Nebivolol 5mg single oral dose
219736321|NCT01044693|DRUG|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
219736322|NCT01044693|DRUG|Sildenafil25 mg|Sildenafil 25 mg single oral dose
219736323|NCT04545372|OTHER|aerobic exercise|
219736324|NCT00747071|DRUG|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
219736325|NCT03450135|BEHAVIORAL|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
219736326|NCT03450135|BEHAVIORAL|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
219736327|NCT03372915|BEHAVIORAL|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
219736328|NCT03372915|BEHAVIORAL|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
219736329|NCT05431907|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
219736330|NCT01864096|DRUG|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
219736331|NCT01864096|DRUG|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
219736332|NCT03685240|BEHAVIORAL|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
219736333|NCT00430664|PROCEDURE|Pleurodesis with either talc or iodopovidone|
219736334|NCT05492903|BEHAVIORAL|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
219736335|NCT01250314|OTHER|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
219736336|NCT01250314|OTHER|Biological, biochemical and genetic samples|"\*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
219736337|NCT04455295|DEVICE|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
219162246|NCT04209985|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
219162247|NCT04735627|DEVICE|Levodopameter|There are several minimally-invasive sensors being developed that can detect levodopa levels in the capillary blood, sweat, and interstitial fluid.
219162248|NCT05874206|DEVICE|Cratos™ Stent Graft|Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
219162249|NCT05904470|DRUG|Bemnifosbuvir|550 mg administered orally once a day (QD) for 8 weeks
219162250|NCT05904470|DRUG|Ruzasvir|180 mg administered orally once a day (QD) for 8 weeks
219162251|NCT06530641|DRUG|Custodiol Htk Soln|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Custodiol crystalloid cardioplegia.
219162252|NCT06530641|DRUG|Buckberg Cardi-Braun|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Buckberg blood cardioplegia.
219236176|NCT05951335|OTHER|m-Health Transition Care Program|The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
219236177|NCT01424345|DRUG|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
219236178|NCT01424345|DRUG|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
219236179|NCT02159352|DRUG|Daclatasvir|
219236180|NCT02159352|DRUG|Darunavir|
219236181|NCT02159352|DRUG|Ritonavir|
219236182|NCT02159352|DRUG|Lopinavir/Ritonavir|
219236183|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
219236184|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
219236185|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
219736338|NCT01248390|BEHAVIORAL|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
219736339|NCT01968408|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
219736340|NCT01968408|DIETARY_SUPPLEMENT|Placebo|
219736341|NCT00620802|DRUG|CGT-2168|(CGT-2168, one capsule each daily)
219736342|NCT00620802|DRUG|Plavix|(clopidogrel, 75 mg)
219736343|NCT04063904|DRUG|Mifepristone|One 200 mg pill (oral)
219736344|NCT04063904|DRUG|Misoprostol|Two 400 mcg pills (sublingual)
219736345|NCT05830643|BEHAVIORAL|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
219736346|NCT05830643|BEHAVIORAL|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
219736347|NCT00017186|DRUG|epirubicin hydrochloride|
219736348|NCT00017186|DRUG|gemcitabine hydrochloride|
219736349|NCT02495935|DEVICE|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
219736350|NCT02495935|DEVICE|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
219736351|NCT01760980|DRUG|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
219736352|NCT01760980|DRUG|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
219736353|NCT03158779|COMBINATION_PRODUCT|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
219736354|NCT01084486|DRUG|Metformin|
219736355|NCT00991003|PROCEDURE|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
219736356|NCT00991003|PROCEDURE|Conventional Colonoscopy|
219236186|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
219236187|NCT03046888|PROCEDURE|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
219236188|NCT04101045|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
219236189|NCT04309578|DRUG|Trastuzumab, Capecitabine and Cisplatin|"* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
219236190|NCT03259126|DEVICE|SCUT|Two different home made curtains were attached to the angiographic table
219236191|NCT00237809|DRUG|D-serine|D-serine (30 mg/kg)
219236192|NCT00237809|BEHAVIORAL|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
219236193|NCT00237809|DRUG|Placebo|Placebo D-serine Drug
219236194|NCT00237809|BEHAVIORAL|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
219236195|NCT05597215|RADIATION|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
219236196|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
219236197|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
219236198|NCT05066022|BIOLOGICAL|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
219236199|NCT00240175|OTHER|No Intervention|No Intervention
219236200|NCT04243941|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
219236201|NCT02417376|DEVICE|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
219236202|NCT02417376|DEVICE|Gracey curettes|set of 7 instruments number #1-14
219736357|NCT03028922|DEVICE|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
219736358|NCT05025371|OTHER|Systemic immune-inflammatory markers|Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)
219736359|NCT02205359|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
219736360|NCT02205359|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
219736361|NCT02820103|BEHAVIORAL|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
219736362|NCT02820103|BEHAVIORAL|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
219736363|NCT02820103|BEHAVIORAL|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
219236203|NCT04250623|OTHER|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
219236204|NCT00764582|DRUG|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
219236205|NCT00764582|DRUG|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
219236206|NCT02669576|BEHAVIORAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
219236207|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
219236208|NCT05832593|OTHER|Immunohistochemistry|Immunohistochemical expression of ERCC1
219236209|NCT01253798|OTHER|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
219236210|NCT02434705|OTHER|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
219236211|NCT01297595|DRUG|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
219236212|NCT02745756|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
219236213|NCT02745756|BIOLOGICAL|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
219236214|NCT06510855|DEVICE|DurAVR™ THV System|DurAVR™ THV System - Transcatheter Aortic Valve Implantation (TAVI) Procedure
219236215|NCT03637075|OTHER|intranasal insulin|intranasal administration of insulin (160 IU)
219236216|NCT03637075|OTHER|Placebo|placebo intranasal administration
219236217|NCT00871715|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
219236218|NCT00871715|BEHAVIORAL|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
219236219|NCT00871715|BEHAVIORAL|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
219236220|NCT04919668|BEHAVIORAL|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
219236221|NCT02237937|DRUG|Paroxetine|
219236222|NCT02237937|DRUG|Sertraline|
219236223|NCT02237937|DRUG|Citalopram|
219236224|NCT02237937|DRUG|Venlafaxine|
219236225|NCT02237937|DRUG|Amitriptyline|
219236226|NCT02237937|DRUG|Escitalopram|
219236227|NCT02237937|DRUG|Amitriptylinoxide|
219236228|NCT02237937|DRUG|Nortriptyline|
219236229|NCT02237937|DRUG|Trimipramine|
219236230|NCT04637100|OTHER|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
219236231|NCT04637100|OTHER|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
219236232|NCT00071500|DEVICE|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
219236233|NCT03015220|DRUG|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
219236234|NCT03015220|DRUG|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
219236235|NCT00923169|DRUG|Anti-Transforming Growth Factor-beta (GC 1008)|
219236236|NCT01670526|DRUG|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
219236237|NCT05667311|DEVICE|ECG|Finapres electrocardiography machine
219236238|NCT01966679|DRUG|AZD7325|
219236239|NCT01966679|DRUG|Placebo|
219236240|NCT02717208|BIOLOGICAL|HL036|
219236241|NCT02717208|BIOLOGICAL|Vehicle|
219236242|NCT02398955|DEVICE|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
219236243|NCT04592926|DEVICE|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
219236244|NCT04592926|OTHER|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
219236245|NCT03572907|OTHER|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
219236246|NCT02214095|DRUG|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
219236247|NCT02214095|DRUG|lactose capsules|
219236248|NCT01745666|OTHER|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
219236249|NCT01745666|OTHER|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
219236250|NCT02291549|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
219236251|NCT02291549|DRUG|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
219236252|NCT02291549|PROCEDURE|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
219236253|NCT00919815|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
219736364|NCT04113980|OTHER|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
219736365|NCT04113980|OTHER|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
219736366|NCT04113980|OTHER|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
219736367|NCT04303403|DRUG|Trametinib|Taken orally once daily
219736368|NCT04303403|DRUG|Ruxolitinib|Taken orally twice daily
219736369|NCT00573820|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
219736370|NCT02112227|OTHER|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
219736371|NCT02427672|DEVICE|Transcranial direct current stimulation|
219736372|NCT02427672|DEVICE|Sham transcranial direct current stimulation|
219736373|NCT00067873|BEHAVIORAL|Diet|
219736374|NCT00067873|BEHAVIORAL|Aerobic exercise|
219736375|NCT00067873|BEHAVIORAL|Resistance exercise|
219736376|NCT04595812|DRUG|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
219736377|NCT04595812|DRUG|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
219736378|NCT04595812|DRUG|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
219736379|NCT04595812|PROCEDURE|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
219736380|NCT01570907|DRUG|Quetiapine Fumarate|25 mg tablet
219736381|NCT05900310|DIAGNOSTIC_TEST|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
219736382|NCT02405065|DRUG|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
219736383|NCT02815254|OTHER|High intensity functional exercise|
219736384|NCT02815254|OTHER|Low intensity functional exercise|
219736385|NCT06549920|RADIATION|Internal mammary node irradiation|Irradiation of the internal mammary nodes in intercostal space 1-4.
219736386|NCT00236197|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
219736387|NCT00236197|DRUG|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
219736388|NCT04330339|BEHAVIORAL|Fasting|Fasting
219736389|NCT04779593|OTHER|Clinical examination|Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
219736390|NCT04779593|OTHER|SF36 questionnaire|"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life)."
219162253|NCT06787404|DRUG|Ephedrine|5 milligrams of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
219162254|NCT06787404|DRUG|Noradrenalin|5 micrograms of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
219162255|NCT06788483|BEHAVIORAL|An self-regulated flipped classroom strategy|The self-regulated flipped classroom strategy was developed based on the self-regulated learning theory (Zimmerman, 2002) and the flipped classroom model (Bishop \& Verleger, 2013).
219162256|NCT01885676|DEVICE|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
219162257|NCT01885676|OTHER|Saline Solution|Saline Solution mesotherapy micro injection
219162258|NCT05534581|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
219236254|NCT00919815|DRUG|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
219162259|NCT05534581|DEVICE|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
219236255|NCT01489683|DRUG|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
219236256|NCT01489683|DRUG|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
219162260|NCT06785376|BEHAVIORAL|DIY (Do It Yourself)|DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
219162261|NCT06785376|BEHAVIORAL|TRUST|TRUST is a single-session HIV self-testing training with facilitator
219162262|NCT06785376|BEHAVIORAL|SOC|standard of care single-session, low threshold peer/near-peer navigation to PrEP.
219162263|NCT05857644|DRUG|PF-07923568|One time dose of 4 capsules taken orally.
219162264|NCT03324984|DRUG|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
219162265|NCT03324984|DRUG|0.75% bupivacaine|Bupivacaine is used on label
219162266|NCT06199700|DRUG|Esketamine hydrochloride|Intravenous infusion of Ketamine
219162267|NCT04661683|OTHER|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
219162268|NCT04661683|OTHER|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
219162269|NCT04661683|OTHER|Clean Room Air|Exposure to room air for a duration of 60 minutes.
219162270|NCT06461676|DRUG|Ventrix Bio Extracellular Matrix|VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
219162271|NCT06785558|DRUG|Anticholinergic therapy|Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
219162272|NCT06829511|OTHER|Questionnaire and Physical Exam|Cardiac Self-Efficacy Scale (CSES) 36-Item Short Form Survey (SF-36) Symptom Distress Scale (SDS)
219162273|NCT06373211|DRUG|Immunoglobulins IV (CLAYRIG)|"Patients will be treated with cycles of :~\- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"
219162274|NCT06373211|DRUG|Cyclophosphamide IV|"Patients will be treated with cycles of :~\- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"
219162275|NCT06373211|DRUG|Methylprednisolone IV|"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"
219162276|NCT04096014|DIETARY_SUPPLEMENT|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
219236257|NCT01000467|DRUG|probucol|group 3: 250 mg 1 tablet in the morning and evening
219236258|NCT01000467|DRUG|probucol|group 1: 250 mg
219236259|NCT01000467|DRUG|probucol|group 2: 250 mg 2 tablets at once in the morning
219236260|NCT05244954|DRUG|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
219236261|NCT05244954|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
219236262|NCT00147615|DRUG|Eplerenone|
219162277|NCT04096014|OTHER|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
219162278|NCT06783517|PROCEDURE|cerabone|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone graft (cerabone®,Botiss biomaterial) will be added to the implant
219162279|NCT06783517|PROCEDURE|cerabone®plus|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone substitute with sodium hyaluronate graft (cerabone®plus,Botiss biomaterial) will be added to the implant
219162280|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
219162281|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
219162282|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
219162283|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
219162284|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
219162285|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
219162286|NCT06792032|OTHER|peer mentoring with mobile application|peer mentoring with mobile application
219162287|NCT01536886|DRUG|LEO 90100|
219162288|NCT01536886|DRUG|Betamethasone plus calcipotriol|
219162289|NCT01536886|DRUG|Ointment vehicle|
219162290|NCT01536886|DRUG|LEO 90100 vehicle|
219162291|NCT05256862|OTHER|Data collection|"Data collection~* on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~* on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
219162292|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
219736391|NCT04779593|OTHER|AIMS2_SF questionnaire|At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
219736392|NCT04779593|OTHER|WOMAC questionnaire|At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
219736393|NCT04779593|OTHER|EQ-5D-5L questionnaire|At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
219736394|NCT04779593|BIOLOGICAL|Blood Sample Complete blood count|Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
219736395|NCT04779593|BIOLOGICAL|Blood Sample Iron panel|Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
219736396|NCT04779593|BIOLOGICAL|Blood Sample Fasting Glucose|Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
219736397|NCT04779593|BIOLOGICAL|Blood sample lipid panel|Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
219736398|NCT04779593|BIOLOGICAL|Blood sample liver panel|Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
219736399|NCT04779593|BIOLOGICAL|Blood sample C reactive protein|Blood sample C reactive protein at D0 and M24/end follow-up visit
219736400|NCT04779593|PROCEDURE|Bloodletting - control group|Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
219736401|NCT04779593|BIOLOGICAL|BioBank|Blood sample will be collected for BioBank at D0, M12 and M24.
219162293|NCT06029179|DRUG|sodium zirconium cyclosilicate (SZC)|60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
219162294|NCT06029179|DRUG|sodium polystyrene sulfonate|60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
219736402|NCT04779593|OTHER|Medico-economical|Medico-economic data will be collected at each follow up visit.
219736403|NCT04779593|PROCEDURE|Bloodletting - experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit."
219736404|NCT06539663|COMBINATION_PRODUCT|OmniLenz®|OmniLenz® applied for 1 week in all patients after development of corneal perforation
219736405|NCT00667589|DRUG|urea 40% cream|urea 40% cream applied twice per day to affected areas
219736406|NCT00667589|DRUG|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
219736407|NCT00667589|DRUG|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
219736408|NCT00667589|DRUG|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
219736409|NCT05301231|DIAGNOSTIC_TEST|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
219736410|NCT05301231|DIAGNOSTIC_TEST|Epi-genomics|"* blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)"
219736411|NCT05301231|DIAGNOSTIC_TEST|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
219736412|NCT05301231|DIAGNOSTIC_TEST|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
219736413|NCT05301231|BEHAVIORAL|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support"
219736414|NCT02792257|DRUG|Dronabinol (Marinol®)|5mg - 10mg daily dose
219736415|NCT02792257|DRUG|Placebo|Daily dose
219736416|NCT01893762|BIOLOGICAL|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
219162295|NCT03236441|DEVICE|RIPC|Remote ischemic preconditioning
219162296|NCT03236441|DEVICE|Sham-RIPC|Control
219162297|NCT04533386|BEHAVIORAL|Multi-component intervention strategy|Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
219162298|NCT04705779|BEHAVIORAL|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
219162299|NCT04705779|BEHAVIORAL|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
219162300|NCT02611180|PROCEDURE|Skin punch biopsy|
219162301|NCT02611180|PROCEDURE|Peripheral blood draw|
219162302|NCT06334562|DRUG|SUGAMMADEX SODIUM 100 Mg in 1 mL|The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
219162303|NCT06334562|DRUG|Neostigmine|Neostigmine is 50 μg/kg
219162304|NCT05076448|PROCEDURE|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
219736417|NCT01893762|BIOLOGICAL|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
219736418|NCT00553475|DRUG|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
219162305|NCT05076448|PROCEDURE|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
219162306|NCT05076448|PROCEDURE|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
219162307|NCT05599789|DRUG|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
219162308|NCT06787027|PROCEDURE|Manual Lymphatic Drainage technique|Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.
219162309|NCT06787027|PROCEDURE|Conventional Treatment group|patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.
219162310|NCT05328661|DIAGNOSTIC_TEST|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
219162311|NCT03746769|BIOLOGICAL|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
219162312|NCT03746769|DRUG|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
219162313|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
219162314|NCT06820840|OTHER|SHOFU Block HC Hard|Cementation of hybrid ceramic onlay (SHOFU Block HC Hard) on carious molars.
219162315|NCT06820840|OTHER|SHOFU Ceramage|Cementation of hybrid resin composite onlay (SHOFU Ceramage) on carious molars.
219162316|NCT06829446|PROCEDURE|Extra-PV extensive ablation|Extra-PV extensive ablation
219162317|NCT06829446|PROCEDURE|Repeat same PVI and linear ablation as the first procedure|Repeat same PVI and linear ablation as the first procedure
219162318|NCT06783634|DRUG|Dexamethasone|Group 2 (dexamethasone group) single intra venous high dose of dexamethasone 1mg/kg with maximum dose of 100 mg.
219162319|NCT06783634|DRUG|Placebo|Group 1 (Control group) will receive normal saline as a placebo.
219162320|NCT06786741|BEHAVIORAL|AER for Stronger Communities|3 week rapid intervention aimed at reducing stress.
219162321|NCT06786741|OTHER|Placebo Comparator|3 week short video program (control)
219162322|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
219736419|NCT00553475|DRUG|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
219736420|NCT00553475|DRUG|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
219736421|NCT05975125|DRUG|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
219736422|NCT03072342|PROCEDURE|Intensive Periodontal Treatment|
219736423|NCT03072342|PROCEDURE|Control Periodontal Treatment|
219736424|NCT02713841|DRUG|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
219736425|NCT02713841|DRUG|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
219736426|NCT03842800|OTHER|MRI|Patients and volunteers will receive an MRI.
219736427|NCT03842800|DRUG|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
219736428|NCT05250726|BIOLOGICAL|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
219736429|NCT04921800|PROCEDURE|Anterior Cervical Discectomy & Fusion|Participants are undergoing previously scheduled anterior cervical discectomy \& fusion for single level or multiple level cervical disease
219736430|NCT04921800|DEVICE|Application of ADAM mechanoacoustic skin sensor|Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
219736431|NCT05545488|DEVICE|Virtual reality|I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
219736432|NCT06761612|BIOLOGICAL|FDA approved mRNA vaccines|This study is non-interventional as participants will have received an FDA approved mRNA COVID-19 vaccine prior to entering the study. The study protocol does not determine or allocate receipt of vaccine
219736433|NCT01733693|DRUG|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
219736434|NCT01733693|DRUG|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
219736435|NCT04028960|DRUG|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
219736436|NCT04028960|DEVICE|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
219736437|NCT03188029|DIAGNOSTIC_TEST|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
219736438|NCT05208320|BEHAVIORAL|Adherence|"Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months"
219736439|NCT04264585|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
219736440|NCT04264585|BEHAVIORAL|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
219736441|NCT04264585|BEHAVIORAL|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
219736442|NCT02043860|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
219236263|NCT03980236|DEVICE|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
219236264|NCT05123755|DRUG|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
219236265|NCT05123755|DRUG|AV-001 Placebo Injection|D-PBS
219236266|NCT05652114|BEHAVIORAL|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
219236267|NCT01763307|DRUG|RECONVAL CREAM|
219236268|NCT01763307|DRUG|PLACEBO|
219236269|NCT03210298|COMBINATION_PRODUCT|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
219236270|NCT02626494|DRUG|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
219236271|NCT02626494|DRUG|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
219236272|NCT06275802|BEHAVIORAL|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
219736443|NCT02043860|PROCEDURE|Autologous Transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
219736444|NCT02043860|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.
219736445|NCT02043860|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
219736446|NCT01101048|DRUG|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
219736447|NCT01101048|DRUG|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
219736448|NCT02113215|PROCEDURE|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
219736449|NCT02032784|DRUG|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
219736450|NCT02032784|OTHER|No Octreotide|No drug
219736451|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
219736452|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
219736453|NCT05791591|DIETARY_SUPPLEMENT|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
219736454|NCT01791296|DRUG|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
219162323|NCT06831435|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
219162324|NCT05997186|PROCEDURE|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
219162325|NCT04701437|BEHAVIORAL|Peer mentor|Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
219162326|NCT04701437|BEHAVIORAL|Standard of care|Passive referral to a HCV provider
219162327|NCT01025089|DRUG|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
219162328|NCT01727518|OTHER|As the LEAD study is an observational cohort study, there is no intervention to report.|As the LEAD study is an observational cohort study, there is no intervention to report.
219236273|NCT06275802|BEHAVIORAL|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
219236274|NCT01795989|DEVICE|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
219236275|NCT06084988|BIOLOGICAL|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
219236276|NCT03149484|DEVICE|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
219236277|NCT03149484|OTHER|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
219236278|NCT03335059|COMBINATION_PRODUCT|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
219236279|NCT04850092|OTHER|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
219162329|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
219162330|NCT02152137|DRUG|efatutazone|Given PO
219162331|NCT02152137|DRUG|paclitaxel|Given IV
219162332|NCT04878354|DRUG|Tree SLIT-tablet|Sublingual allergy immunotherapy tablets
219162333|NCT04878354|DRUG|Placebo SLIT-tablet|Placebo
219162334|NCT04422652|DRUG|Bupropion|Bupropion is an anti-depressant medication.
219162335|NCT04422652|BEHAVIORAL|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
219162336|NCT04422652|DRUG|Placebo|Double-blind placebo.
219236280|NCT00025376|DRUG|PS-341|
219236281|NCT00025376|PROCEDURE|Tumor Biopsy|
219162337|NCT04422652|OTHER|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
219236282|NCT04206618|DRUG|Teriparatide|1 subcutaneous injection daily for 12 months
219236283|NCT04206618|DRUG|Denosumab|1 subcutaneous injection every 6 months for 12 months
219236284|NCT04182217|OTHER|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
219236285|NCT03432871|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
219236286|NCT01970527|BIOLOGICAL|Ipilimumab|Given IV
219236287|NCT01970527|OTHER|Laboratory Biomarker Analysis|Correlative studies
219236288|NCT01970527|OTHER|Pharmacological Study|Correlative studies
219236289|NCT01970527|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219236290|NCT05333757|OTHER|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
219236291|NCT01846078|DEVICE|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
219236292|NCT01964547|DRUG|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
219236293|NCT01964547|DRUG|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
219236294|NCT05690178|OTHER|Deep Tissue Massage|The Deep Tissue Massage lasted 45 minutes. The entire therapy included 4 treatments over a period of 2 weeks. The interval between treatments was 3 days. The conducted therapy included techniques for: quadratus lumborum muscle, erector spinae muscle, thoracolumbar fascia, iliopsoas muscle. All techniques were performed on both sides of the patient's body.
219236295|NCT03715634|DRUG|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
219236296|NCT03715634|DRUG|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
219162338|NCT05510232|DEVICE|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
219162339|NCT05510232|DEVICE|A treatment group that will have headset on and will watch a non-VR video|"Oculus headset will deliver VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-14. The selected videos will be the same for both the cast and suture/pin removal groups."
219162340|NCT05510232|DEVICE|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Oculus headset will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities.
219162341|NCT05708911|DEVICE|Pharyngeal exerciser|Pharyngo-esophageal manometry during lateral fluoroscopy
219162342|NCT06051305|BEHAVIORAL|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
219162343|NCT05461781|PROCEDURE|distal radial access|primary percutaneous coronary intervention via distal radial access
219162344|NCT05461781|PROCEDURE|conventional transradial access|primary percutaneous coronary intervention via conventional transradial access
219162345|NCT05808504|OTHER|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
219162346|NCT05808504|OTHER|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
219236297|NCT03715634|DRUG|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
219236298|NCT03715634|DRUG|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
219236299|NCT04447287|DRUG|ASP8062|Oral
219236300|NCT04447287|DRUG|Placebo ASP8062|Oral
219236301|NCT04447287|DRUG|buprenorphine/naloxone|Sublingual
219236302|NCT03648749|BEHAVIORAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
219162347|NCT05808504|OTHER|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
219162348|NCT05808504|PROCEDURE|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
219162349|NCT05808504|PROCEDURE|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
219162350|NCT05666167|BEHAVIORAL|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
219162351|NCT06522022|BEHAVIORAL|Culturally Responsive SBIRT for OB|"SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools"
219162352|NCT06522022|BEHAVIORAL|Brief Screening for PTSD|This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
219162353|NCT05720338|DEVICE|19 French Blake Drain|19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
219162354|NCT04759443|OTHER|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
219162355|NCT04609553|BEHAVIORAL|Usual care including ROR|Usual care which includes ROR.
219162356|NCT04609553|BEHAVIORAL|Text messages|3 text messages per week and one interactive text per month.
219162357|NCT04609553|BEHAVIORAL|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
219162358|NCT04335643|BEHAVIORAL|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
219162359|NCT04615819|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
219162360|NCT04615819|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
219162361|NCT05569967|OTHER|Spinal stabilization training through telerehabilitation|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
219162362|NCT05569967|OTHER|Spinal stabilization training face-to-face|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
219162363|NCT06065995|DEVICE|StoMakker|A mobile application that offers age dependent information, a peer support platform and a game
219162364|NCT01631214|BIOLOGICAL|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
219162365|NCT01631214|DRUG|Alendronate|Alendronate 70 mg tablet taken once a week
219162366|NCT01631214|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
219162367|NCT01631214|DRUG|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
219162368|NCT03805594|DRUG|Lutetium Lu 177-PSMA-617|Given IV
219162369|NCT03805594|BIOLOGICAL|Pembrolizumab|Given IV
219162370|NCT02611505|DRUG|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
219162371|NCT05476575|OTHER|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
219162372|NCT05348863|BEHAVIORAL|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
219162373|NCT01558804|OTHER|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
219162374|NCT05145452|DIETARY_SUPPLEMENT|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
219162375|NCT05931861|DEVICE|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
219236303|NCT04772963|GENETIC|blood sample|During the arteriography a peripheral venous sampling
219236304|NCT04406701|OTHER|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
219736455|NCT01791296|OTHER|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
219736456|NCT06094829|OTHER|Oral cytobrush|Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek
219736457|NCT03164707|DIAGNOSTIC_TEST|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
219736458|NCT05399342|OTHER|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
219736459|NCT02541487|DIETARY_SUPPLEMENT|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
219736460|NCT01905683|DRUG|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
219736461|NCT00992394|DRUG|etanercept|etanercept 50 mg once weekly as requested.
219736462|NCT00992394|DRUG|etanercept|etanercept 25 mg or 50 mg as requested.
219736463|NCT04345432|DRUG|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
219736464|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA containing composite|Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
219736465|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA-free composite|Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
219162376|NCT06476847|BEHAVIORAL|PrEP persistence|A light touch, once off, low cost. lay counsellor led intervention, designed to focus decision making around HIV prevention addressing present bias, salience and over optimism. The intervention package consists of evidence informed reminders, commitment pledges and planning prompts.
219236305|NCT00613405|OTHER|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
219736466|NCT05738889|DEVICE|Vacuum-formed retainers|vacuum-forming machine and vacuum formed plates
219736467|NCT05738889|DEVICE|Hawley retainers|Acrylic based hawley retainers
219736468|NCT06138080|DIAGNOSTIC_TEST|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
219736469|NCT01959971|DRUG|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
219736470|NCT01959971|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
219736471|NCT00246207|DRUG|CONCERTA (OROS methylphenidate hydrochloride)|
219736472|NCT00588276|RADIATION|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
219736473|NCT01435915|DRUG|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
219736474|NCT01420003|PROCEDURE|Bone Marrow Aspiration|3 per study
219736475|NCT01420003|PROCEDURE|Tonsil Biopsy|Optional upon completion of study
219736476|NCT03983655|DEVICE|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
219736477|NCT05476848|DIAGNOSTIC_TEST|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
219736478|NCT01395537|DRUG|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
219736479|NCT01395537|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
219736480|NCT01395537|DRUG|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
219736481|NCT04588363|OTHER|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
219736482|NCT00537082|DRUG|FTY720|Administered orally once daily for 6 months
219736483|NCT00537082|DRUG|Placebo|Administered orally once daily for 6 months
219736484|NCT02568254|DEVICE|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
219736485|NCT02568254|DEVICE|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
219736486|NCT02568254|DEVICE|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
219736487|NCT00655746|DRUG|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
219736488|NCT03325257|OTHER|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
219736489|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Mineralocorticoid receptor antagonists, 3) Potassium supplementation,
219736490|NCT06933875|BEHAVIORAL|Clinical Decision Support Tool|Deliver prognostic information and evidence-based decision support at the point of care
219736491|NCT03645681|DEVICE|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
219736492|NCT03755154|DRUG|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
219736493|NCT03755154|DRUG|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
219736494|NCT05229354|BIOLOGICAL|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
219736495|NCT05229354|BIOLOGICAL|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
219736496|NCT02958072|OTHER|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
219736497|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered."
219736498|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
219736499|NCT06027398|DIAGNOSTIC_TEST|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
219736500|NCT01994005|BEHAVIORAL|Facebook|Facebook page with contraception information used for counseling
219736501|NCT01994005|BEHAVIORAL|Pamphlet|Contraceptive knowledge pamphlets
219736502|NCT03169374|DEVICE|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
219736503|NCT01793129|DEVICE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
219736504|NCT01793129|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
219736505|NCT06211868|BEHAVIORAL|Digital wearable and AI-human symbiotic lifestyle intervention|Digital wearable and AI-human symbiotic lifestyle intervention
219736506|NCT03681093|DRUG|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
219236306|NCT00613405|OTHER|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
219236307|NCT04197622|DRUG|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
219162377|NCT05806814|BIOLOGICAL|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
219236308|NCT02147093|DEVICE|Test (multi-focal)|contact lens was to be worn a daily wear.
219236309|NCT02147093|DEVICE|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
219736507|NCT03681093|DRUG|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
219162378|NCT04112316|DRUG|Liothyronine|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
219162379|NCT04112316|OTHER|Placebo|A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.
219162380|NCT02945072|PROCEDURE|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
219162381|NCT02945072|PROCEDURE|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
219162382|NCT05863546|OTHER|Traditional treatment|The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
219162383|NCT05863546|DEVICE|Therapeutic ultrasound|US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
219162384|NCT06261801|OTHER|Medication Group|Participants in the medication group would take 150-mg pregabalin capsules (manufactured by Pfizer Pharmaceuticals Co., Ltd) orally twice daily (total daily dose, 300 mg) for 4 weeks.
219736508|NCT03681093|DRUG|Placebo|Placebo once daily administered orally as tablet
219736509|NCT06633549|OTHER|Home Accidents Prevention Training|Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
219736510|NCT06633549|OTHER|Control Group|Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
219736511|NCT01704573|DRUG|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
219736512|NCT05175378|OTHER|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
219736513|NCT05033561|BIOLOGICAL|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
219736514|NCT05440565|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
219736515|NCT05440565|DIAGNOSTIC_TEST|APCS score|APCS score can concentrate the high-risk population.
219736516|NCT05280860|PROCEDURE|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
219736517|NCT05901207|DIAGNOSTIC_TEST|blood test|blood test
219736518|NCT05298046|DRUG|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
219736519|NCT05298046|OTHER|Other: Placebo|Placebo single ascending dose IV infusion.
219162385|NCT06261801|OTHER|EA Group|Acupoints selection: Ashi acupoint, Sibai acupoint (ST2), Xiaguan acupoint (ST7), and Dicang acupoint (ST4) on the affected side. Acupoints for the diseased branches (all taken from the affected side): eye branch and Tongziliao point (GB1), the maxillary branch is taken from the Quanliao point (SI18), and the mandibular branch is taken from the Jiache point (ST6).Shenting point (DU24), Baihui point (DU20), Hegu point (LI4), Waiguan point (TE5), Yanglingquan point (GB34), and Taichong point (LR3) on the affected side Operation: The EA apparatus will be applied on the Ashi point and (LI4 - TE5). The treatment will last for 30 minutes and the electrical stimulation will be set as 2/100Hz in frequency.
219162386|NCT06261801|OTHER|EA+Medication Group|Participants in the EA+Medication group would receive both EA and medical treatement. The acupoints and their location, needles, the settings of the EA device are the same as EA Group's; in the meanwhile, the medication and its dosage is the same as Medication Group's.
219162387|NCT06539156|OTHER|DVT prophyllaxis|VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations
219162388|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool|Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
219162389|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT)|iCBT, as described above, using only the traditional, detailed therapist manual.
219162390|NCT04947553|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
219162391|NCT04947553|DRUG|Placebo|Placebo tablets, taken twice daily
219162392|NCT05944809|DRUG|rhTPO|"Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)"
219236310|NCT03246724|DRUG|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
219236311|NCT03246724|DRUG|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
219736520|NCT03629717|PROCEDURE|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
219236312|NCT03246724|DRUG|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
219736521|NCT03629717|DRUG|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
219736522|NCT03629717|PROCEDURE|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
219736523|NCT03629717|DRUG|Calcium|1200mg daily
219736524|NCT03629717|DRUG|Vitamin D|800 IU daily
219162393|NCT05891782|BEHAVIORAL|HAPA-based Multidomain Fall Risk Management|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 stages.~Stage 1: The main format will be group lectures and scenario simulation, each intervention will have a duration of 30 to 45 minutes. Intervention content will utilize BCT \[5.1, 5.3, 5.5, 5.6, 9.3, 15.1\] .~Stage 2: This stage will utilize mostly group lectures or one-to-one interviews, to provide an action and coping plan to participants for fall risk management. This will apply BCT \[1.1-1.4, 4.1\] at week 4.Firstly, individualized targets will be established. Secondly, professionals and participants will collaborate to develop an implementation plan.~Stage 3:Recovery self-efficacy will be implemented as group discussions, with each intervention lasting 15-30 minutes. Maintenance will be implemented in one-to-one interviews, with each intervention lasting 15-30 minutes.Finally, the consolidation and outlook will provide the foundation for the habit formation of healthy behaviors."
219162394|NCT05891782|BEHAVIORAL|Regular health education lectures|Weeks 1-4 will be provided with fall-related regular health education lectures. Weeks 5-16 will have regular activities according to the daily arrangement of the nursing home. Meanwhile, telephone, WeChat, or face-to-face interviews will be conducted fortnightly, to understand the needs of the participants. During the process, staff will provide usual care such as vital signs monitoring, disease treatment, medication prescription, and health record maintenance.
219162395|NCT03857620|OTHER|Best Practice|Receive usual care
219162396|NCT03857620|OTHER|Informational Intervention|Receive OPTI-Surg program materials
219162397|NCT03857620|OTHER|Questionnaire Administration|Ancillary studies
219162398|NCT03857620|OTHER|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
219162399|NCT05361447|DRUG|Diazepam|5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
219162400|NCT02473250|DRUG|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
219162401|NCT02473250|DRUG|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
219736525|NCT06363981|DEVICE|Active rTMS over the left DLPFC and over the left DMPFC|Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
219736526|NCT06363981|DEVICE|Active rTMS over the left DLPFC|Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
219736527|NCT06363981|DEVICE|Sham rTMS|Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
219736528|NCT03435107|DRUG|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
219736529|NCT05130281|BEHAVIORAL|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
219736530|NCT05130281|BEHAVIORAL|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
219736531|NCT05130281|BEHAVIORAL|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
219736532|NCT05130281|BEHAVIORAL|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
219736533|NCT06249672|OTHER|Local excision|Organ preservation after RCT (radiochemotherapy) of rectal cancer
219736534|NCT04481659|PROCEDURE|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
219736535|NCT04481659|COMBINATION_PRODUCT|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
219162402|NCT04450797|DEVICE|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
219162403|NCT04450797|DEVICE|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
219162404|NCT03054623|PROCEDURE|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
219162405|NCT06353178|BEHAVIORAL|Cancer Connect Program|Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.
219162406|NCT05229900|DRUG|SGN-ALPV|Given into the vein (IV; intravenously)
219162407|NCT02861430|PROCEDURE|Immunochemistry and molecular biology on sentinel lymph node specimen|
219162408|NCT04798651|BIOLOGICAL|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219162409|NCT04798651|BIOLOGICAL|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
219162410|NCT03059069|DRUG|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
219162411|NCT03059069|DRUG|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
219162412|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
219736536|NCT06497088|DEVICE|Nasotrak System|"Device: The Nasotrak System~The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.~The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition."
219736537|NCT06268717|OTHER|Ground pork containing alpha-gal|150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
219736538|NCT06268717|OTHER|Pork meat not containing alpha-gal|150 grams of cooked, ground pork meat not containing alpha-gal sugar
219736539|NCT01446588|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
219736540|NCT04566510|OTHER|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
219736541|NCT04566510|OTHER|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
219736542|NCT04566510|BEHAVIORAL|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
219736543|NCT01558414|PROCEDURE|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
219736544|NCT01558414|PROCEDURE|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
219736545|NCT01558414|PROCEDURE|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
219736546|NCT03167710|OTHER|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
219736547|NCT03167710|OTHER|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
219736548|NCT05462496|PROCEDURE|Biopsy|Pre-treatment tumor biopsy
219736549|NCT05462496|DRUG|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
219736550|NCT05462496|DRUG|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
219736551|NCT05462496|DRUG|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
219736552|NCT05462496|DRUG|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
219736553|NCT05462496|PROCEDURE|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
219736554|NCT02006836|DIETARY_SUPPLEMENT|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
219736555|NCT02006836|DIETARY_SUPPLEMENT|Glucose|We dissolved 50 g of glucose in 200 ml water.
219736556|NCT02006836|OTHER|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
219736557|NCT02006836|DRUG|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
219736558|NCT02006836|DRUG|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
219736559|NCT04950907|DIAGNOSTIC_TEST|vats|Use uniportal tubeless VATS to obtain the biopsy
219736560|NCT04950907|DIAGNOSTIC_TEST|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
219736561|NCT01699685|DRUG|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
219736562|NCT01699685|DRUG|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
219736563|NCT01699685|DRUG|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
219236313|NCT03246724|DRUG|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
219162413|NCT01822652|GENETIC|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
219162414|NCT01822652|GENETIC|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
219162415|NCT01822652|DRUG|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
219162416|NCT01822652|DRUG|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
219162417|NCT01822652|DRUG|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
219162418|NCT01822652|GENETIC|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
219162419|NCT06775535|DEVICE|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
219236314|NCT03782870|DIAGNOSTIC_TEST|echocardiography, lab tests|
219236315|NCT05121259|OTHER|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
219162420|NCT05103033|BEHAVIORAL|Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)|The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
219162421|NCT05103033|BEHAVIORAL|Attentional Placebo Control|Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
219162422|NCT04093362|DRUG|Futibatinib|Oral tablets
219162423|NCT04093362|DRUG|Cisplatin|IV infusion
219162424|NCT04093362|DRUG|Gemcitabine|IV infusion
219162425|NCT05896878|DIETARY_SUPPLEMENT|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
219162426|NCT05265312|OTHER|START diabetes prevention clinical pathway|"The diabetes prevention clinical pathway will focus on the following steps:~1. Screen/test - testing of eligible patients for prediabetes/diabetes~2. Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~3. Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~4. Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~5. Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes."
219162427|NCT04047810|BIOLOGICAL|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
219162428|NCT06319144|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
219162429|NCT06319144|OTHER|0.9% sodium chloride solution|Patients in the control group were infused intravenously with 0.9% sodium chloride solution in the PACU.
219162430|NCT04468399|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
219162431|NCT04468399|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
219162432|NCT06161753|BEHAVIORAL|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
219162433|NCT02281097|OTHER|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
219162434|NCT02281097|OTHER|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
219162435|NCT06781567|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
219162436|NCT06826287|OTHER|7T MR exam|a 7 Tesla MRI scan, with a functional and anatomical dedicated protocol
219162437|NCT06826287|OTHER|clinical assessment|A comprehensive clinical assessment before the MRI exam.
219162438|NCT04256707|DRUG|Selinexor 100 mg|"100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)"
219162439|NCT04256707|DRUG|Docetaxel|75 mg/m\^2 IV
219162440|NCT04256707|DRUG|Pembrolizumab|200 mg IV
219162441|NCT04256707|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV"
219162442|NCT04256707|DRUG|Selinexor 40 mg|\- 2 × 20-mg tablets (Tablet A)
219162443|NCT04256707|DRUG|Selinexor 80 mg|\- 4 × 20-mg tablets (Tablet A)
219162444|NCT04256707|DRUG|Selinexor 60 mg|\- 3× 20-mg tablets (Tablet A)
219162445|NCT06098677|DIETARY_SUPPLEMENT|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
219162446|NCT06098677|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
219162447|NCT06789536|OTHER|training nurses to prescribe nicotine substitutes, to adapt doses and to transmit to the outpatient physician and/or nurse nurse to facilitate the continuation of treatment|Nurses will undergo training sessions provided by the smoking cessation team to learn how to prescribe nicotine replacement therapy, adjust dosages, and forward a referral letter to the patient's primary care physician and/or community nurse for continuity of care. They will receive a dosage adjustment guide to share with patients. Upon completing the training, nurses will be authorized to prescribe nicotine replacement therapy using the hospital's prescription software.
219162448|NCT05236595|OTHER|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
219162449|NCT03433339|DEVICE|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
219162450|NCT03433339|DEVICE|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
219162451|NCT06223659|DRUG|Eutectic Mixture of Local Anesthetics|Apply topically to skin
219162452|NCT06223659|DRUG|Placebo Administration|Apply topically to skin
219162453|NCT06223659|OTHER|Questionnaire Administration|Ancillary studies
219162454|NCT06267586|DIETARY_SUPPLEMENT|PeptiSleep|Plant protein hydrolysate
219162455|NCT06267586|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
219162456|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
219162457|NCT06456866|OTHER|interpretation|interpretation of blood gases samples
219162458|NCT03525288|RADIATION|PSMA -PET/CT simulation|"* PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
219162459|NCT03525288|RADIATION|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
219162460|NCT06737406|DRUG|Topical 5% fluorouracil cream|Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)
219162461|NCT06737406|DRUG|Topical 0.005% calcipotriol ointment|Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
219162462|NCT06737406|DRUG|Placebo|A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.
219162463|NCT06737406|DRUG|Placebo|A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
219162464|NCT06739070|OTHER|Plyometric|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
219236316|NCT04645849|BIOLOGICAL|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
219236317|NCT03494413|DIAGNOSTIC_TEST|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
219162465|NCT06739070|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
219162466|NCT06739070|OTHER|Control group (no intervention)|In control group no intervention would be given. Initial test would be performed at 4th and 8th week and then results would be compared with experimental group.
219162467|NCT05332340|DRUG|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
219236318|NCT03494413|DIAGNOSTIC_TEST|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
219236319|NCT02934932|DRUG|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
219236320|NCT02046304|DRUG|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
219236321|NCT02046304|RADIATION|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
219162468|NCT06738381|BEHAVIORAL|Digital intervention and motivational counselling|A single sesstion of motivational interviewing and access to a digital plattform for a six months period
219162469|NCT06328504|COMBINATION_PRODUCT|Cashew immunotherapy|Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
219162470|NCT04670081|DRUG|Psilocybin|25 mg, p.o.
219162471|NCT04670081|DRUG|Psilocybin|5 mg, p.o.
219162472|NCT04670081|DRUG|Nicotinamide|100 mg, p.o.
219162473|NCT06736652|OTHER|Parabolic flight|Preflight each individual was exposed to the 3 Other Interventions and monitored for changes in behavioral performance and neurophysiological responses. In-flight the same monitoring was conducted during partial-gravity (0.25, 0.5. 0.75g) and microgravity (\~0g).
219162474|NCT03717415|DRUG|Rebastinib|Administered orally
219162475|NCT03717415|DRUG|Carboplatin|Administered by IV infusion
219162476|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment and application of H42® hydrogel to the peri-implant pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
219162477|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of periodontal pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant.
219162478|NCT06740123|PROCEDURE|Non-surgical periodontal treatment and application of H42® hydrogel to the periodontal pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
219162479|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of peri-implant pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant.
219162480|NCT03137771|RADIATION|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
219162481|NCT03137771|DRUG|Docetaxel|Given IV
219162482|NCT03137771|DRUG|Gemcitabine|Given IV
219162483|NCT03137771|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
219162484|NCT03137771|DRUG|Pemetrexed Disodium|Given IV
219162485|NCT03137771|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
219162486|NCT03137771|DRUG|Erlotinib Hydrochloride|Given PO
219236322|NCT03715985|DRUG|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
219236323|NCT00222898|PROCEDURE|DNA analysis of pancreatic cyst fluid / buccal swab|
219162487|NCT03137771|DRUG|Pembrolizumab|Given IV
219162488|NCT06738615|DIAGNOSTIC_TEST|Pressure volume loop evaluation|During the left heart catheterization there are catheters which are introduced into the left ventricle to measure left ventricular pressures and into the coronary arteries to assess their patency. This study will require the placement of an additional specialized catheter made into the left ventricle to measure the change of pressure and volume during the cardiac cycle. This will allow the measurement of heart muscle stiffness.
219162489|NCT06738615|DIAGNOSTIC_TEST|cardiovascular magnetic resonance imaging|Patients will undergo standard cardiovascular magnetic resonance imaging of their heart to measure their heart size, heart function, and severity of mitral regurgitation. In addition, contrast will be administered and heart tissue will be assessed for scarring or fibrosis.
219162490|NCT06738615|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|A CPET will be performed to objectively measure a patient ability to perform exercise.
219162491|NCT06738615|DIAGNOSTIC_TEST|Kansas City Cardiomyopathy Questionairre|This is a short questionnaire which objectively quantifies symptom burden
219162492|NCT06739928|DRUG|Irinotecan liposome (II) combined with adebrelimab and carboplatin|Irinotecan liposome (II) + adebrelimab + carboplatin
219162493|NCT06739928|DRUG|etoposide combined with adebrelimab and carboplatin|etoposide + adebrelimab + carboplatin
219162494|NCT03401853|OTHER|Laboratory Biomarker Analysis|Correlative studies
219162495|NCT03401853|BIOLOGICAL|Pembrolizumab|Given IV
219162496|NCT03401853|BIOLOGICAL|Rituximab|Given IV
219162497|NCT03401853|BIOLOGICAL|Obinutuzumab|Given IV
219162498|NCT01898494|PROCEDURE|Transoral surgery|Undergo transoral surgical resection
219162499|NCT01898494|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
219162500|NCT01898494|DRUG|cisplatin|Given IV
219162501|NCT01898494|DRUG|carboplatin|Given IV
219162502|NCT06795061|BEHAVIORAL|Peer-Supported Exercise with Professional Guidance|Participants will engage in small, peer-supported exercise groups (4-6 individuals) to coordinate weekly sessions (e.g., running, cycling, yoga). A professional coach provides knowledge-based guidance remotely, focusing on safe exercise techniques, injury prevention, basic nutrition, and motivation strategies, but does not conduct in-person training sessions. The aim is to improve adherence to physical activity and enhance mental well-being through peer accountability and evidence-informed coaching.
219236324|NCT04663256|OTHER|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
219236325|NCT04090632|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
219736564|NCT04482803|DRUG|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
219736565|NCT00582829|OTHER|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
219736566|NCT00582829|OTHER|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
219736567|NCT00582829|OTHER|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
219736568|NCT03876548|DEVICE|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
219736569|NCT03849235|DIETARY_SUPPLEMENT|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
219736570|NCT04250389|OTHER|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
219736571|NCT05227014|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
219736572|NCT03015948|DRUG|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
219736573|NCT03015948|DRUG|Placebo|a single dose of placebo (n=2) for each dose cohort .
219736574|NCT01744366|DRUG|Degarelix|
219736575|NCT01744366|DRUG|Goserelin|
219736576|NCT01449994|DEVICE|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
219736577|NCT00001789|DRUG|BG9588|
219162503|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
219162504|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
219162505|NCT05744960|BEHAVIORAL|Communication training|Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
219162506|NCT05744960|BEHAVIORAL|financial Incentive|Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
219162507|NCT06583135|OTHER|Sleep hygiene education and motivational interviewing|The intervention group, will receive face-to-face sleep hygiene training and then 4 online motivational interviews will be held within 6 weeks. The online motivational interviews will be implemented in the 1st week (interview 1), 2nd week (interview 2), 4th week (interview 3), and 6th week (interview 4).
219162508|NCT06583135|OTHER|face-to-face sleep hygiene training|The control group receive face-to-face sleep hygiene training
219162509|NCT04073290|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
219162510|NCT04073290|DRUG|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
219162511|NCT04073290|DRUG|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
219162512|NCT06495190|DIETARY_SUPPLEMENT|Blueberry|50 g/d blueberry powder supplement
219162513|NCT06495190|BEHAVIORAL|Walking|Five 45-min walking sessions per week
219162514|NCT06495190|DIETARY_SUPPLEMENT|Placebo|50 g/d placebo powder supplement
219162515|NCT06495190|BEHAVIORAL|Stretching|Five 45-min stretching sessions per week
219236326|NCT06510972|PROCEDURE|Strategy for continuing oral intake|Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
219162516|NCT04544969|DRUG|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
219162517|NCT05792137|OTHER|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
219162518|NCT05792137|OTHER|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
219162519|NCT05504226|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily for 52 weeks.
219162520|NCT05504226|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.
219162521|NCT04514497|PROCEDURE|Biopsy|Undergo tumor biopsy
219162522|NCT04514497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219162523|NCT04514497|PROCEDURE|Computed Tomography|Undergo CT
219162524|NCT04514497|DRUG|Elimusertib|Given PO
219162525|NCT04514497|DRUG|Irinotecan Hydrochloride|Given IV
219162526|NCT04514497|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219162527|NCT04514497|DRUG|Topotecan Hydrochloride|Given IV
219162528|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
219162529|NCT06787118|DRUG|CBD oil|Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
219162530|NCT06787118|DRUG|Placebo|Patients will receive placebo for a total of 12 weeks.
219236327|NCT06510972|PROCEDURE|Fasting strategy|The patient will not be able to ingest liquids or solid food.
219236328|NCT01662505|DRUG|Volasertib|Patient to receive volasertib
219236329|NCT02633085|DEVICE|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
219162531|NCT06784596|OTHER|Teleconsulting supported training|Patients in this group will be provided with training the day before surgery, on the morning of surgery and on the day of discharge, and will receive teleconsulting services at the 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th and 12th weeks after discharge. will be given.
219162532|NCT06785610|DIETARY_SUPPLEMENT|Capsulase®|Capsulase® supplement daily administration after surgery
219236330|NCT04813666|DIAGNOSTIC_TEST|Urinary LAM ELISA:|
219162533|NCT06782568|DIAGNOSTIC_TEST|Ultrasound Scan|Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
219162534|NCT03969446|DRUG|Decitabine|Given IV
219162535|NCT03969446|BIOLOGICAL|Pembrolizumab|Given IV
219162536|NCT03969446|DRUG|Venetoclax|Given PO
219162537|NCT06159985|PROCEDURE|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
219162538|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
219162539|NCT05629169|OTHER|No intervention applied - observational study only|Observational study only. All head impacts will be assessed using video footage.
219236331|NCT01320800|BEHAVIORAL|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
219236332|NCT01320800|BEHAVIORAL|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
219236333|NCT02594709|RADIATION|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
219736578|NCT02202265|DIETARY_SUPPLEMENT|Olive oil|30ml a day of olive oil
219736579|NCT02202265|DIETARY_SUPPLEMENT|Nuts|30g a day of nuts
219736580|NCT02202265|DIETARY_SUPPLEMENT|Control diet|Diet based on standard guidelines
219736581|NCT01395602|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly
219736582|NCT01395602|OTHER|placebo|1 pill twice weekly
219736583|NCT00165308|DRUG|Tamoxifen|Given orally, daily for one year.
219736584|NCT02376855|OTHER|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
219736585|NCT00000726|DRUG|Foscarnet sodium|
219736586|NCT05624957|DRUG|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
219736587|NCT05624957|DRUG|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
219736588|NCT02267525|DRUG|Velusetrag|
219736589|NCT02267525|DRUG|Placebo|
219736590|NCT01729429|BEHAVIORAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
219736591|NCT01729429|BEHAVIORAL|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
219736592|NCT02012777|DRUG|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
219736593|NCT01832038|DRUG|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
219736594|NCT04241432|DEVICE|vibrating platform|Use of two different types of vibrating platform
219736595|NCT04484662|OTHER|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
219736596|NCT05281653|BEHAVIORAL|Neuromuscular exercise Training|Progressive neuromuscular exercise training
219736597|NCT05281653|BEHAVIORAL|Routine training sessions|Routine training sessions
219162540|NCT05066009|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consistent contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
219162541|NCT05066009|DEVICE|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
219162542|NCT05066009|OTHER|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
219162543|NCT04906200|OTHER|Best Practice|Receive usual care
219736598|NCT05517785|OTHER|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
219736599|NCT03492294|DIAGNOSTIC_TEST|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
219736600|NCT02072057|DRUG|Ruxolitinib|
219736601|NCT04985110|DRUG|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
219736602|NCT04985110|DRUG|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
219736603|NCT01125644|DRUG|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
219736604|NCT00998959|BEHAVIORAL|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
219736605|NCT00998959|BEHAVIORAL|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
219736606|NCT02913573|DEVICE|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
219736607|NCT02913573|DRUG|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
219736608|NCT02976844|PROCEDURE|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
219736609|NCT06300632|OTHER|geriatric locomotive syndrome|Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
219736610|NCT02167126|DEVICE|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
219736611|NCT02167126|DEVICE|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
219736612|NCT06272929|DEVICE|doppler ultrasound|doppler US
219736613|NCT01893814|DIETARY_SUPPLEMENT|Probiotics|
219736614|NCT01893814|DIETARY_SUPPLEMENT|Control|
219736615|NCT01267136|DRUG|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
219736616|NCT01267136|DRUG|Tramadol suspension|Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
219736617|NCT03823482|DRUG|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
219736618|NCT00456911|BEHAVIORAL|Fat and carbohydrate controlled diet|
219736619|NCT02755883|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
219736620|NCT02755883|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
219236334|NCT04892251|COMBINATION_PRODUCT|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
219236335|NCT04892251|BEHAVIORAL|MORE|Mindfulness-Oriented Recovery Enhancement
219236336|NCT01564498|OTHER|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
219236337|NCT03153306|DRUG|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
219236338|NCT06510673|DRUG|Platelet rich plasma|Platelet-rich plasma for the heel
219236339|NCT06510673|OTHER|High power LASER|High power LASER sessions for the heel
219236340|NCT06510673|OTHER|Shockwave therapy|Shockwave therapy sessions for the heel
219236341|NCT06510673|OTHER|Ice application|Ice application for the heel
219236342|NCT06510673|OTHER|Sham LASER|Sham LASER for the heel
219236343|NCT02544191|DRUG|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
219236344|NCT03479892|DRUG|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
219236345|NCT03479892|DRUG|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
219236346|NCT02314975|DEVICE|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
219236347|NCT02314975|DEVICE|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
219236348|NCT02314975|OTHER|Fixed appliance only|Fixed appliance treatment only
219236349|NCT00502294|DRUG|Visilizumab (HuM291; Nuvion®)|
219236350|NCT04859062|DRUG|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
219162544|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
219162545|NCT04906200|OTHER|Survey Administration|Complete survey
219162546|NCT05798585|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
219162547|NCT06030609|DRUG|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
219162548|NCT06030609|DRUG|Normal saline|The patient will receive NSS with D5W as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
219162549|NCT03263026|DRUG|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
219162550|NCT03263026|OTHER|R-CHOP + placebo|R-CHOP + placebo
219162551|NCT05253833|DRUG|AR882 Dose 1|Solid Oral Capsule
219162552|NCT05253833|DRUG|AR882 Dose 2|Solid Oral Capsule
219162553|NCT05253833|DRUG|Allopurinol Tablet|Solid tablet
219162554|NCT06752382|DRUG|Experimental drug|Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
219162555|NCT02661893|DRUG|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
219162556|NCT02661893|DRUG|Rifampin|Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
219162557|NCT05769660|DRUG|BEY1107|Administer twice daily, PO, 4-week continuous dose.
219162558|NCT05769660|COMBINATION_PRODUCT|Temozolomide|Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
219162559|NCT03148743|BIOLOGICAL|Fecal microbiota|fecal microbiota transplantation
219162560|NCT06301997|DIETARY_SUPPLEMENT|ZAX.1400.P03|ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
219162561|NCT06301997|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
219162562|NCT06792929|DEVICE|virtual reality glasses group|Patients will wear virtual reality glasses throughout the ultrasound-guided fine needle aspiration biopsy procedure.
219162563|NCT06797167|DEVICE|Injections of a filler gel containing cross-linked hyaluronic acid|"Vaginal Filler will be administered according to Investigator's judgment and Instruction For Use (IFU) to correct hypotrophy, improve the shape and increase the volume of the female external genital areas (labia majora). Vaginal Filler is a resorbable medical device available in packages containing 2 sterile pre-filled mono-use syringes of 1 ml with pre-assembled plunger rod and backstop, containing 25 mg/g cross-linked hyaluronic acid.~The injection is performed by medical personnel at visit V0 in one or both sides of the superficial subcutaneous layer of the labia majora, along its longitudinal axis.The dosage to be used for the individual case is at the doctor's discretion. An anesthetic may be applied (lidocaine 2% injection only in the cannula access point) to the affected area before the IP injection.~In order to maintain the results achieved, an eventual touch-up could be performed one months after the first treatment in the same areas of the first injection, at visit V2."
219162564|NCT06789224|DEVICE|CATUVAB|inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates
219162565|NCT06685601|DEVICE|tPBM（active）|During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.
219162566|NCT06685601|DEVICE|tPBM（sham）|During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.
219162567|NCT05070013|DEVICE|Deep Brain Stimulation|All participants will undergo three 1-week interventions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
219236351|NCT04859062|OTHER|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
219236352|NCT01562184|DEVICE|Sham tDCS device|Sham tDCS
219236353|NCT01562184|DEVICE|Soterix tDCS device|Active tDCS
219236354|NCT02255474|DEVICE|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
219236355|NCT02255474|DEVICE|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
219236356|NCT02255474|DEVICE|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
219236357|NCT06360978|DRUG|Docetaxel|Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
219236358|NCT02790632|DRUG|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
219236359|NCT02790632|DRUG|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
219236360|NCT04251988|DEVICE|Oculus Go VR|virtual reality headset
219236361|NCT02191540|DRUG|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
219236362|NCT02725697|OTHER|TCM treatment|
219236363|NCT04665583|OTHER|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
219236364|NCT02779426|BEHAVIORAL|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
219236365|NCT00610337|DRUG|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
219236366|NCT00610337|PROCEDURE|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
219236367|NCT04863339|DRUG|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
219236368|NCT04863339|DRUG|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
219236369|NCT03098199|DRUG|300IU Gonal-F|\<1.5 AMH group
219236370|NCT03098199|DRUG|150IU Menopur|\<1.5 AMH group
219236371|NCT03098199|DRUG|225IU Gonal-F|1.6-2.5 AMH group
219236372|NCT03098199|DRUG|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
219236373|NCT03098199|DRUG|150IU Gonal-F|2.6-6.9 AMH group
219236374|NCT03098199|DRUG|75IU Gonal-F|\>7.0 AMH group
219236375|NCT06211595|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
219236376|NCT03142490|OTHER|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
219236377|NCT03142490|OTHER|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
219236378|NCT03430518|DRUG|Durvalumab|1.12g given IV on day 1 every 21 day cycle
219236379|NCT03430518|DRUG|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
219162568|NCT06794528|OTHER|RehbeCa mobile application|The system consists of a mobile application (to be used by patients) and a web application (to be used by physiotherapists) that allows monitoring of the patient's performance without the need for attendance, thus facilitating telerehabilitation. The mobile application consists of a serious game that aims to induce the patient to perform neck exercises, adapting to their capacity and evolution at all times through artificial intelligence. The patient's interaction with the mobile application is based on the integration of a vision-based head-tracker to track the movements of the patient's head. The web application aims to provide professionals with a tool to monitor the evolution of their patients through the data captured by the mobile application.
219162569|NCT06794528|OTHER|Home exercise program|Set of therapeutic exercises to be carried out at home. They are taught face-to-face, and also printed on a leaflet that is delivered to the participant.
219162570|NCT06795477|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
219162571|NCT06795477|BEHAVIORAL|Interpretable MI|Participants receive interpretable machine intelligence assistance to complete the medication verification tasks.
219162572|NCT06795477|BEHAVIORAL|Uninterpretable MI|Participants receive uninterpretable (i.e., black-box) machine intelligence assistance to complete the medication verification tasks.
219162573|NCT05139914|DRUG|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
219162574|NCT05139914|OTHER|Placebo|Placebo capsule for 6 weeks
219162575|NCT06792669|OTHER|Simulation training to evaluate the participants' manual skill improvement|
219162576|NCT06830655|OTHER|Fatigue Protocol|"After the warm-up, each participant will be assigned the easiest route of their skill level on the Kilter Board with a 15-degree wall incline. Participants will start the route from the initial holds and finish it with the need to touch the top hold with both hands. They will be instructed to climb as quickly and smoothly as possible. After reaching the last hold, they will descend along the same route to the initial holds without touching the ground. The procedure will be repeated until the participant reports fatigue that prevents further climbing. Any stoppage by the participant during the protocol will not be allowed to last longer than 5 seconds, will be recorded, and categorized as either isometric contraction or rest time, depending on the nature of the stoppage, which will be established during records analyzing."
219162577|NCT06797219|DEVICE|Low Level Laser Therapy for Intraventricular Hemorrhage of Prematurity|The experimental arm will be administered treated with the study device. It will be 10 mW/cm\^2 of 650nm laser through use of a novel laser device given for 5 minutes twice daily for 12 days.
219162578|NCT06837532|DRUG|Ultrasound-guided rectus sheath block|Patients will receive ultrasound-guided rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the end of surgery.
219162579|NCT06837532|DRUG|Surgical rectus sheath block|Patients will receive a surgical rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the time of closure.
219162580|NCT06837532|DRUG|Local anesthesia infiltration|Patients will receive local anesthesia infiltration at the end of surgery.
219162581|NCT06837844|DRUG|Intrathecal Dexmedetomidine|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
219162582|NCT06837844|DRUG|Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
219162583|NCT06837844|DRUG|Intrathecal Dexmedetomidine + Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
219162584|NCT03739996|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
219162585|NCT03739996|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs were not provided by the study. Participants obtained NRTIs outside of the study through routine care.
219162586|NCT03739996|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
219162587|NCT03739996|BIOLOGICAL|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
219162588|NCT03739996|DRUG|Standard of Care (SOC) ART|SOC ART was not provided by the study. Participants obtained SOC ART outside of the study through routine care.
219162589|NCT04667663|DRUG|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
219162590|NCT04667663|DRUG|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
219162591|NCT04667663|DRUG|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
219162592|NCT04667663|DRUG|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
219162593|NCT02553642|DRUG|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~\- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
219162594|NCT02553642|DRUG|Nivolumab plus Ipilimumab|"Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
219162595|NCT06844929|OTHER|Podcast Group|Providing breastfeeding education via podcast
219162596|NCT06844929|OTHER|Brochure Group|Providing standard breastfeeding education using brochures
219162597|NCT02155010|DRUG|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
219162598|NCT02155010|DRUG|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
219162599|NCT03484416|DRUG|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
219162600|NCT00894543|DRUG|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
219162601|NCT00894543|OTHER|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
219736621|NCT02722330|DEVICE|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
219736622|NCT05426681|DRUG|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
219162602|NCT03111160|PROCEDURE|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
219736623|NCT02096380|DRUG|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
219736624|NCT02096380|DRUG|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
219736625|NCT01934231|DRUG|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
219736626|NCT06424119|BEHAVIORAL|Traditional Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to TCR arm, they will attend 36 sessions of the program at one of three locations.
219736627|NCT06424119|BEHAVIORAL|Intensive Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm, they will attend 72 sessions of the program at one of three locations.
219162603|NCT03111160|PROCEDURE|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
219162604|NCT00942487|DRUG|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
219162605|NCT00942487|DRUG|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
219162606|NCT02022800|OTHER|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
219162607|NCT03056183|BEHAVIORAL|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
219162608|NCT02421380|DRUG|Hyperpolarized Pyruvate|
219162609|NCT05223959|BEHAVIORAL|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
219162610|NCT01652820|DRUG|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
219162611|NCT01652820|DRUG|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
219162612|NCT05023993|OTHER|Exercise Intervention|Complete home exercise
219162613|NCT05023993|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Given PO
219162614|NCT04686253|OTHER|not appliable|not appliable
219162615|NCT05152264|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
219162616|NCT05152264|OTHER|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
219162617|NCT02935998|DRUG|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
219736628|NCT06424119|OTHER|C2life® Food|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm with food, they will receive the food at the beginning of the second week of their respective program. Food will be delivered by mail weekly for a total of 11 weeks to the patient's home address.
219736629|NCT04733482|BEHAVIORAL|Cosmetic care|
219162618|NCT04508972|DEVICE|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
219162619|NCT06314763|DRUG|Rivaroxaban 20mg|Single dose on day 1 and day 16
219162620|NCT06314763|DRUG|Sotorasib 960mg|Daily dose from day 3 till day 16
219162621|NCT05673434|BIOLOGICAL|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
219162622|NCT06271616|PROCEDURE|Echocardiography Test|Undergo echocardiography
219162623|NCT06271616|DRUG|Ibrutinib|Given PO
219162624|NCT05749523|BEHAVIORAL|Exercise|Exercise vs non-exercise
219162625|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
219736630|NCT04921306|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
219162626|NCT00809939|DRUG|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
219162627|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
219162628|NCT00809939|DRUG|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
219162629|NCT03144518|OTHER|Positive Affect Intervention|See Previous Description
219162630|NCT03144518|OTHER|Neutral Control Intervention|See Previous Description
219162631|NCT03144518|BIOLOGICAL|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
219162632|NCT01989455|DRUG|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
219162633|NCT01989455|DRUG|Placebo|Placebo: normal saline solution.
219162634|NCT02574442|DEVICE|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
219162635|NCT05771350|PROCEDURE|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
219162636|NCT05771350|PROCEDURE|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
219162637|NCT05771350|PROCEDURE|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
219162638|NCT05444426|OTHER|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
219162639|NCT00448669|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
219162640|NCT00448669|DRUG|Placebo Oral Tablet|
219736631|NCT04921306|DRUG|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
219736632|NCT01314248|DEVICE|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
219736633|NCT05679934|OTHER|Exercise Program|Stretching and strengthening exercises will be applied to the participants
219736634|NCT00101400|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
219362199|NCT06335615|BEHAVIORAL|Brief Acceptance Intervention|The intervention consist of explanations and exercises about acceptance of stress. The intervention starts with a welcome, after which participants do jumping jacks and then breath through a straw to induce an uncomfortable experience. Next, a Chinese finger trap is used to show the automatic, but often not useful, reaction to avoid stress. Participants then watch a short video that introduces the concept of acceptance, and they do a short, guided meditation. Afterwards, they do the straw exercise again, but this time with instruction to examine and allow uncomfortable experiences. The session ends with a recap and the introduction of the home exercise. Participants install an app that reminds them every hour to do a three-second meditation in which they pay attention to their breathing and body in an accepting way.
219162641|NCT04762238|OTHER|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
219162642|NCT02776475|PROCEDURE|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
219162643|NCT02614235|DEVICE|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
219162644|NCT01363492|BIOLOGICAL|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
219162645|NCT00468702|DEVICE|CoaguChek S|
219162646|NCT02395978|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
219162647|NCT02395978|DRUG|placebo|Placebo contained corn starch.
219162648|NCT03771352|DEVICE|RxSight RxLAL|The patients will be assessed for 6 months
219162649|NCT00011986|DRUG|Paclitaxel|Given IV
219162650|NCT00011986|DRUG|Carboplatin|Given IV
219162651|NCT00011986|DRUG|Gemcitabine Hydrochloride|Given IV
219162652|NCT00011986|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|
219162653|NCT00011986|DRUG|Topotecan Hydrochloride|Given IV
219162654|NCT00011986|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219162655|NCT03438903|DEVICE|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
219162656|NCT03338816|DRUG|Givosiran|Givosiran by SC
219162657|NCT03338816|DRUG|Placebo|Matching placebo (normal saline \[0.9% NaCl\]) by SC
219162658|NCT00445315|DRUG|PF-00868554|300 mg BID
219162659|NCT00445315|DRUG|PF-00868554|450 mg BID
219162660|NCT00445315|DRUG|PF-00868554|100 mg BID
219162661|NCT00445315|DRUG|PF-00868554|300 mg TID
219162662|NCT00445315|DRUG|Placebo|Placebo
219236380|NCT01535352|BEHAVIORAL|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
219162663|NCT03285386|BEHAVIORAL|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
219162664|NCT03285386|BEHAVIORAL|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
219162665|NCT02746549|OTHER|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
219162666|NCT05953623|BIOLOGICAL|Albumin|In the first phase of the study, a 3 + 3 dose-escalation study with 7 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg, 0.55g/kg, 0.60g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation. In the second phase of the study, at the maximum safe dose determined in the first phase, an additional 15 to 20 patients will be enrolled for intra-arterial albumin infusion.
219162667|NCT03999853|DRUG|BKR-017|BKR-017
219162668|NCT04094168|DRUG|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
219162669|NCT04094168|DRUG|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
219236381|NCT01535352|BEHAVIORAL|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
219236382|NCT01229176|BIOLOGICAL|Vi-CRM197 vaccine|
219236383|NCT01229176|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
219236384|NCT01229176|BIOLOGICAL|Pneumococcal conjugate vaccine|
219236385|NCT01528683|RADIATION|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
219236386|NCT06041932|DRUG|Carvedilol|Carvedilol
219236387|NCT06041932|DRUG|Pentoxifylline|Pentoxiphylline
219162670|NCT03032406|DRUG|Hydroxychloroquine|Hydroxychloroquine
219162671|NCT03032406|DRUG|Everolimus|Everolimus
219162672|NCT03833167|BIOLOGICAL|Pembrolizumab|400 mg IV infusion
219236388|NCT01894737|OTHER|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
219236389|NCT01894737|OTHER|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
219162673|NCT03833167|DRUG|Placebo|Placebo-matched IV infusion
219162674|NCT03997864|DRUG|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
219236390|NCT01127737|BEHAVIORAL|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
219236391|NCT01127737|BEHAVIORAL|Placebo|Completed surveys
219236392|NCT00078156|BEHAVIORAL|Behavior Therapy|
219236393|NCT04921540|PROCEDURE|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
219236394|NCT04921540|PROCEDURE|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
219236395|NCT00234676|DRUG|Premarin ®|Premarin ® 0.625 mg per day orally
219236396|NCT03130946|DEVICE|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
219236397|NCT03130946|DEVICE|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
219236398|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|"* Day 0: presentation of the study~* During pregnancy between Day 0 and 36-38SA: inclusion~* During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~* Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~* In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~* In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~* In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
219236399|NCT01082159|PROCEDURE|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
219236400|NCT00788606|DRUG|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
219236401|NCT04348357|OTHER|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
219236402|NCT04348357|OTHER|Office visit|Patient comes to the office to receive routine postoperative care
219236403|NCT05514678|BEHAVIORAL|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
219236404|NCT06245902|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
219236405|NCT06245902|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
219236406|NCT06245902|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
219236407|NCT06245902|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
219236408|NCT06245902|DRUG|Matching Placebo|Two Placebo capsules
219236409|NCT01295099|DRUG|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
219236410|NCT01295099|RADIATION|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
219236411|NCT01295099|DRUG|Triamcinolone|TAC 10mg in 1ml injected intralesional
219236412|NCT01446640|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
219236413|NCT05643222|DEVICE|red tint contact lenses|to compare the performance of these lenses.
219236414|NCT02367794|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
219236415|NCT02367794|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
219236416|NCT02367794|DRUG|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
219236417|NCT02367794|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
219362200|NCT06335615|BEHAVIORAL|Psychoeducation|In the psychoeducation, participants learn about the stress response, mindfulness, and acceptance. For this, they are guided through a vignette about a student who struggles with stress and then develops a more accepting stance towards it. The psychoeducation explains how acceptance can help to deal with stress but does not instruct participants to apply this in their own life.
219362201|NCT02531646|RADIATION|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
219736635|NCT06088914|DEVICE|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
219736636|NCT06088914|DEVICE|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
219162675|NCT03997864|DRUG|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
219162676|NCT05187442|OTHER|questionnaire, interview|The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited.
219162677|NCT05329194|DRUG|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
219162678|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
219162679|NCT06501911|DRUG|Bicalutamide|Participants will receive daily oral bicalutamide for six (6) months. The dose will be determined by the cohort to which the participant is enrolled as well as the toxicities experienced by previously enrolled cohorts.
219162680|NCT06501911|RADIATION|Intensity-modulated radiation therapy (IMRT)|Participants will receive 35 Gy delivered in 10 fractions, administered once daily on weekdays.
219162681|NCT06040710|DEVICE|POSEIDON size estimation software with the EndoMind polyp detection system|Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
219162682|NCT03606837|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
219162683|NCT03606837|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
219236418|NCT00882050|DRUG|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
219236419|NCT00882050|DRUG|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
219236420|NCT00882050|DRUG|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
219236421|NCT00834379|DRUG|pravastatin sodium|40 mg Tablet
219236422|NCT00834379|DRUG|Pravachol®|40 mg tablet
219236423|NCT03803657|DEVICE|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
219236424|NCT02442557|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injection
219236425|NCT02442557|OTHER|placebo comparator|intravenous injection
219236426|NCT00681226|DRUG|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
219236427|NCT00115167|DRUG|Placebo|Q4W
219236428|NCT00115167|DRUG|Darbepoetin alfa|Q4W
219236429|NCT02010684|BEHAVIORAL|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
219236430|NCT02214914|DRUG|BI 11634 drinking solution|
219236431|NCT02214914|DRUG|BI 11634 tablet|
219236432|NCT02214914|DRUG|Placebo|
219236433|NCT04249115|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
219236434|NCT05062070|DRUG|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
219236435|NCT05062070|DRUG|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
219236436|NCT01947114|DRUG|Propofol|
219236437|NCT01947114|DRUG|Ketamine|
219236438|NCT01947114|DRUG|Remifentanil|
219236439|NCT02364648|DIETARY_SUPPLEMENT|MitoQ|Mitochondria targeted antioxidant
219736637|NCT03906955|BEHAVIORAL|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
219736638|NCT03906955|BEHAVIORAL|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
219736639|NCT00032331|PROCEDURE|PET Imaging|
219736640|NCT00032331|PROCEDURE|CT scan|
219736641|NCT02082782|PROCEDURE|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
219736642|NCT01807741|DRUG|Asenapine|Available in 5 and 10 mg.
219736643|NCT01807741|DRUG|Placebo|
219736644|NCT05546372|DEVICE|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
219736645|NCT05546372|DEVICE|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
219736646|NCT04787016|OTHER|Pilate training|Pilates is an exercise training program used to build core strength and flexibility.
219736647|NCT04427111|DEVICE|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
219162684|NCT06430281|OTHER|Manual therapy|A manual force will be applied to a manikin positioned on a chiropractic treatment table. The force exerted during the manual therapy must align with the trial label indicated on the Manual Therapy Force Perception \[MTFP\] scale.
219236440|NCT02364648|DIETARY_SUPPLEMENT|Placebo|Placebo
219236441|NCT02399111|DEVICE|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
219236442|NCT00135278|PROCEDURE|CSF Drainage|See Detailed Description
219236443|NCT00135278|PROCEDURE|No CSF Drainage|See Detailed Description
219236444|NCT03717233|DEVICE|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
219236445|NCT05920538|DRUG|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
219236446|NCT05920538|OTHER|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
219236447|NCT06501027|BEHAVIORAL|Mindfulness Based Self Compassion|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
219236448|NCT06318572|BEHAVIORAL|Psychological intervention|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
219736648|NCT06199830|DIAGNOSTIC_TEST|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
219736649|NCT03239054|BEHAVIORAL|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
219736650|NCT03239054|BEHAVIORAL|Control group|Information will be given as part of standard care
219736651|NCT04565353|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
219736652|NCT00684294|BIOLOGICAL|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
219736653|NCT05428670|DRUG|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
219736654|NCT05428670|DRUG|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
219736655|NCT01829763|DRUG|injection botox|
219736656|NCT04613089|OTHER|Natural History|Natural History and Clinical Follow Up.
219736657|NCT00216931|DRUG|iloprost|
219736658|NCT06421441|OTHER|Self Management Skills Training|Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
219736659|NCT06202989|DRUG|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
219736660|NCT06202989|OTHER|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
219736661|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
219736662|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
219736663|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
219736664|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
219736665|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
219736666|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
219736667|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
219736668|NCT04555733|DRUG|Lemborexant|Lemborexant oral tablets.
219736669|NCT05670340|DEVICE|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
219736670|NCT05670340|DEVICE|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
219736671|NCT05333965|DEVICE|Lens A (lehfilcon A lens)|Daily wear for 1 month.
219736672|NCT05333965|DEVICE|Lens B (comfilcon A lens)|Daily wear for 1 month.
219736673|NCT05855278|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
219736674|NCT04922879|BEHAVIORAL|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
219736675|NCT02320552|OTHER|No intervention|no intervention
219736676|NCT01975480|DRUG|Desvenlafaxine|
219736677|NCT04802785|DRUG|Citicoline|Citicoline 500 mg (Vitaae®) per os
219736678|NCT04802785|DRUG|Cytochrome C6|Cytochrome10 mg per os
219736679|NCT04802785|DRUG|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
219736680|NCT04802785|DRUG|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
219736681|NCT04802785|DRUG|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
219162685|NCT05261620|DIETARY_SUPPLEMENT|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity \[DPPH (2,2-diphenyl-1-picrylhydrazyl) test\] and phenolic profiles \[HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis\] will be performed for wine selection for the clinical trial.
219162686|NCT01948661|DIETARY_SUPPLEMENT|Mirtoselect® + Meriva®|
219162687|NCT01948661|DIETARY_SUPPLEMENT|Placebo|
219162688|NCT03894566|OTHER|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
219162689|NCT04471974|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219162690|NCT04471974|DRUG|Enzalutamide|Given PO
219162691|NCT04471974|BIOLOGICAL|Pembrolizumab|Given IV
219162692|NCT03271489|DRUG|Elagolix|Film-coated 300 mg tablets
219162693|NCT03271489|DRUG|Estradiol /norethindrone acetate (E2/NETA)|Estradiol 1 mg/norethindrone acetate 0.5 mg capsules
219162694|NCT03271489|OTHER|E2/NETA Placebo|Placebo capsules
219162695|NCT03271489|OTHER|Elagolix Placebo|Film-coated placebo tablets
219162696|NCT05445466|DEVICE|High-Definition Transcranial Electrical-Current Stimulation|Non-frequency dependent transcranial electrical stimulation condition for 5 days of twice a day treatment
219162697|NCT05445466|DEVICE|High-Definition Transcranial Alternate-Current Stimulation|Active-control stimulation condition will target alpha (10 Hz) for 5 days of twice a day treatment
219162698|NCT05445466|DEVICE|High-Definition Personalized Beta-Gamma Electrical Stimulation|Personalized beta-gamma electrical stimulation for 5 days of twice a day treatment
219162699|NCT06288230|BIOLOGICAL|vesemnogene lantuparvovec|Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
219162700|NCT02860130|DRUG|Prismocitrate 18|Modality of CVVHDF
219162701|NCT02860130|OTHER|No Anticoagulation|Modality of CVVHDF
219162702|NCT06148142|BEHAVIORAL|Pharmacy based health promotion|This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; third at 12 months and , end-line survey at 18 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
219162703|NCT06779474|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy
219162704|NCT06488261|BIOLOGICAL|AVR-RD-02|No study drug is administered in this study. Subjects who received AVR-RD-02 in a separate parent trial will be evaluated in this trial for long-term safety.
219162705|NCT06041802|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab and berahyaluronidase alfa for SC administration.
219162706|NCT06181617|OTHER|Quality of life assessment|Quality of life assessment
219162707|NCT03915964|DRUG|Baricitinib|Administered orally.
219162708|NCT03915964|DRUG|TNF Inhibitor|Administered SC
219162709|NCT06216535|DRUG|Escitalopram|Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
219162710|NCT06216535|DRUG|Placebo|Inactive placebo comparator
219162711|NCT06010342|DRUG|TL118 Capsule|Oral administration
219162712|NCT04421235|BEHAVIORAL|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
219736682|NCT04802785|DRUG|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
219736683|NCT04802785|DRUG|Domperidone Oral Product|Domperidone 1 tablet per os
219736684|NCT04802785|DRUG|Simethicone|3-4 capsules per os
219736685|NCT04802785|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
219736686|NCT04802785|DRUG|Magnesium hydroxide|magnesium hydroxide 30 mg per os
219736687|NCT04802785|DRUG|Probiotic Formula|1 capsule per os.
219736688|NCT04802785|DRUG|Melatonin 5 mg|Melatonin 5 mg per os.
219736689|NCT02312128|OTHER|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
219736690|NCT02312128|RADIATION|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
219736691|NCT02312128|OTHER|Grip Strength|Grip strength measurement
219736692|NCT02312128|OTHER|VAS Score|Measurement pain according to the visual analogue scale (VAS)
219736693|NCT02312128|OTHER|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
219736694|NCT00382863|DEVICE|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
219736695|NCT00382863|DRUG|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
219236449|NCT06318572|BEHAVIORAL|Placebo|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
219236450|NCT00882375|DRUG|Nicotine|Nicotine administered using novel NRT user instructions
219236451|NCT00882375|DRUG|Placebo|Placebo administered using novel NRT user instructions
219236452|NCT05458544|DRUG|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
219236453|NCT00091572|DRUG|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
219236454|NCT00091572|DRUG|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
219236455|NCT01695044|DRUG|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
219236456|NCT05885516|PROCEDURE|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
219236457|NCT02942771|DRUG|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
219236458|NCT02942771|DRUG|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
219236459|NCT02942771|DRUG|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
219236460|NCT02942771|DRUG|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
219236461|NCT02942771|DRUG|Placebo|0.9% sodium chloride
219236462|NCT00798863|PROCEDURE|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
219236463|NCT01453764|PROCEDURE|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
219236464|NCT00803985|PROCEDURE|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
219236465|NCT00803985|PROCEDURE|Lichtenstein|Operation for primary inguinal hernias i men
219236466|NCT03506802|RADIATION|18F-FHBG|Given IV
219236467|NCT03506802|BIOLOGICAL|Aldesleukin|Given SC
219236468|NCT03506802|BIOLOGICAL|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
219236469|NCT03506802|PROCEDURE|Computed Tomography|Undergo PET/CT
219236470|NCT03506802|BIOLOGICAL|Filgrastim|Given SC
219236471|NCT03506802|OTHER|Laboratory Biomarker Analysis|Correlative studies
219236472|NCT03506802|DRUG|Lenalidomide|Given PO
219236473|NCT03506802|PROCEDURE|Leukapheresis|Undergo leukapheresis
219236474|NCT03506802|DRUG|Melphalan|Given IV
219236475|NCT03506802|DRUG|Plerixafor|Given SC
219236476|NCT03506802|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219236477|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head \& neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
219236478|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
219236479|NCT00884676|DRUG|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."
219236480|NCT00884676|DRUG|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
219736696|NCT01067911|DIETARY_SUPPLEMENT|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
219736697|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
219736698|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
219736699|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
219736700|NCT02168439|DRUG|Dexmedetomidine|
219736701|NCT02168439|DRUG|Midazolam|
219736702|NCT02157727|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
219736703|NCT06569979|OTHER|Survey|"The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question."
219162713|NCT03358693|DRUG|Anti-TNF|Subject receives anti-TNF antibodies open-label as per guidelines
219162714|NCT03358693|DRUG|Anti-IL12/23|Subject receives anti-IL12/23 antibodies open-label as per guidelines
219162715|NCT03358693|DRUG|Anti-IL17|Subject receives anti-IL17 antibodies open-label as per guidelines
219162716|NCT03358693|DRUG|Dupilumab|Subject receives Dupilumab open-label as per guidelines
219162717|NCT03358693|DRUG|Anti-IL23|Subject receives anti-IL23 antibodies open-label as per guidelines
219162718|NCT03358693|DRUG|Baricitinib|Subject receives Baricitinib open-label as per guidelines
219162719|NCT03358693|DRUG|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
219162720|NCT03358693|DRUG|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
219162721|NCT03358693|DRUG|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
219162722|NCT03358693|DRUG|Lebrikizumab|Subject receives Lebrikizumab open-label as per guidelines
219162723|NCT03358693|DRUG|Nemolizumab|Subject receives Nemolizumab open-label as per guidelines
219162724|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
219162725|NCT06828705|OTHER|datscan scintigraphy|Semi-quantitative analysis on Datscan imaging scintigraphy
219162726|NCT06364644|BEHAVIORAL|Community Champions|The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
219162727|NCT06364644|BEHAVIORAL|Homegrown Heroes|Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
219162728|NCT06104319|DRUG|GSK4532990|GSK4532990 will be administered
219162729|NCT05030272|DEVICE|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
219162730|NCT05030272|BEHAVIORAL|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
219236481|NCT05107453|DRUG|Levobupivacaine|"The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
219236482|NCT05041894|OTHER|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
219236483|NCT01049490|BIOLOGICAL|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
219236484|NCT02315209|DEVICE|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
219236485|NCT06360367|BEHAVIORAL|HI-FLY Curriculum|Participants receive the standard HI-FLY Curriculum over 6 weeks.
219236486|NCT06360367|BEHAVIORAL|HI-FLY Curriculum + PortionSize Ed app|Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
219236487|NCT00044759|DRUG|Piperacillin/Tazobactam (Tazocin)|
219236488|NCT06470945|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
219236489|NCT06470945|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
219236490|NCT04932083|DRUG|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
219236491|NCT04932083|DRUG|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
219236492|NCT04932083|DRUG|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
219236493|NCT04932083|DRUG|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
219236494|NCT04419571|PROCEDURE|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
219236495|NCT01186809|BIOLOGICAL|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
219162731|NCT05030272|DRUG|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
219236496|NCT03305185|COMBINATION_PRODUCT|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
219236497|NCT03305185|DEVICE|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
219236498|NCT04851782|DEVICE|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
219236499|NCT03014037|PROCEDURE|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
219236500|NCT03014037|PROCEDURE|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
219236501|NCT04895085|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
219236502|NCT02761356|OTHER|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
219236503|NCT00230906|PROCEDURE|Haemodialysis with either low or high flux membranes|
219236504|NCT05232357|DRUG|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
219162732|NCT05030272|BEHAVIORAL|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
219162733|NCT05030272|DRUG|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
219162734|NCT05030272|DRUG|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
219162735|NCT01620684|DRUG|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
219162736|NCT01620684|DRUG|placebo|placebo capsules
219162737|NCT02272816|DRUG|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
219162738|NCT01551953|BEHAVIORAL|Tai chi|12 week tai chi class
219162739|NCT01551953|BEHAVIORAL|Mind-body breathing|12 week breathing class
219162740|NCT01551953|BEHAVIORAL|Education|12 week education class
219162741|NCT00686504|DRUG|AZD2066|single dose of oral dose, 3 times per subject
219162742|NCT00686504|DRUG|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
219162743|NCT04222946|OTHER|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
219162744|NCT00826657|DIETARY_SUPPLEMENT|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
219162745|NCT00826657|DIETARY_SUPPLEMENT|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
219162746|NCT05278533|DIETARY_SUPPLEMENT|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
219162747|NCT05278533|DIETARY_SUPPLEMENT|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
219162748|NCT03169894|DRUG|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
219162749|NCT00099931|DRUG|vildagliptin|
219162750|NCT02789215|BEHAVIORAL|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
219162751|NCT00972439|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|
219162752|NCT00972439|DRUG|Oral Contraceptive: Ovcon Fe®|
219162753|NCT05136157|DRUG|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
219162754|NCT05527912|DRUG|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
219162755|NCT00580918|OTHER|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
219162756|NCT01460667|DRUG|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
219162757|NCT01460667|DRUG|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
219162758|NCT00753480|DRUG|D4064A|
219236505|NCT02591056|DEVICE|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
219162759|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
219162760|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
219162761|NCT01967836|DEVICE|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
219162762|NCT03452982|OTHER|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
219162763|NCT03481816|BIOLOGICAL|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
219162764|NCT03481816|BIOLOGICAL|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
219162765|NCT03481816|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
219162766|NCT01704196|DRUG|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
219162767|NCT01704196|DRUG|Placebo|
219162768|NCT01449617|DRUG|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
219162769|NCT04943419|DIAGNOSTIC_TEST|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
219162770|NCT04223258|DEVICE|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
219236506|NCT02591056|DEVICE|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
219162771|NCT04223258|OTHER|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
219162772|NCT00752453|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
219162773|NCT00752453|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
219162774|NCT00752453|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
219162775|NCT01811394|RADIATION|protons|Treatment is performed using 16 x 4 GyE protons
219162776|NCT01811394|RADIATION|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
219162777|NCT04393389|DEVICE|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
219162778|NCT02362867|DEVICE|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
219162779|NCT04185636|DEVICE|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
219162780|NCT01279668|DRUG|Montelukast|10mg tablets, once per day for 28 days.
219162781|NCT01279668|DRUG|Placebo|tablets, once per day for 28 days.
219162782|NCT06528925|OTHER|Virtual reality goggles|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggle (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) that is compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system and minimizes sound loss in the supine position. With the virtual reality glasses, nature landscapes with relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
219162783|NCT03640949|DRUG|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
219162784|NCT03640949|DRUG|Methylprednisolone|40 mg methylprednisolone once
219736704|NCT06569446|OTHER|There is no intervention. This a qualitative study to explore barriers to rectal irrigation|"This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer."
219736705|NCT06571916|BEHAVIORAL|Brief-SfSL|"Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them"
219736706|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with no arthroscopy|The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
219736707|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with arthroscopy|After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
219736708|NCT00237627|DRUG|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
219162785|NCT03640949|DRUG|NaCl|Placebo
219162786|NCT04668638|OTHER|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
219162787|NCT01627652|OTHER|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
219162788|NCT02778659|DRUG|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
219236507|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
219236508|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
219236509|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose open label
219236510|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose
219236511|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
219236512|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily low dose
219162789|NCT02778659|DRUG|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
219162790|NCT06345404|DRUG|Soquelitinib|Tablets
219162791|NCT06345404|DRUG|Placebo|Soquelitinib matching placebo tablets
219162792|NCT04873869|DRUG|NBI-921352|Administered orally
219162793|NCT04873869|DRUG|Placebo|Administered orally
219162794|NCT05375162|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
219162795|NCT05375162|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
219162796|NCT05375162|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
219162797|NCT05375162|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
219236513|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
219236514|NCT05894291|OTHER|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
219736709|NCT00237627|DRUG|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
219736710|NCT00237627|DRUG|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
219736711|NCT02685436|DRUG|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
219736712|NCT02040012|DRUG|AZP-531|
219736713|NCT02040012|DRUG|Placebo|
219736714|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
219736715|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
219736716|NCT03570385|DEVICE|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
219736717|NCT00605657|DRUG|Valproic Acid|Oral administration of valproic acid
219736718|NCT00605657|PROCEDURE|CT Scan|CT scans were done before and after treating the patient with valproic acid
219736719|NCT00605657|PROCEDURE|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
219736720|NCT03733782|DIETARY_SUPPLEMENT|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
219736721|NCT00658073|PROCEDURE|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
219736722|NCT00658073|PROCEDURE|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
219736723|NCT01053065|DRUG|Atorvastatin - Cholestyramine - Sitosterol|
219736724|NCT02180672|DRUG|Nasal Fluticasone|One spray per nostril, per day.
219736725|NCT02180672|DRUG|Placebo|One spray per nostril, per day.
219736726|NCT06192797|PROCEDURE|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
219736727|NCT06192797|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
219236515|NCT05894291|OTHER|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
219236516|NCT04015050|OTHER|milk based infant formula|Cows milk ased infant formula
219236517|NCT06671353|BEHAVIORAL|video decision aid|video decision aid for advance care planning
219236518|NCT02426931|DEVICE|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
219236519|NCT02426931|DEVICE|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
219236520|NCT03029299|DEVICE|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
219236521|NCT05144659|PROCEDURE|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
219236522|NCT05144659|PROCEDURE|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
219236523|NCT04433091|DRUG|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
219236524|NCT04433091|OTHER|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
219236525|NCT07009600|DRUG|immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)|
219236526|NCT03229291|DRUG|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
219236527|NCT03229291|DRUG|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
219236528|NCT07009197|OTHER|Instrument Assisted Soft Tissue Mobilization|the treatment will start by disinfect the instrument between patients to avoid transfer of infections. It is recommended to disinfect the instrument with intermediate-level disinfectants (e.g. isopropyl alcohol), then wash it with soap and water to remove any residuals of the chemical disinfectant off the instrument. If the tools contacts blood, bodily fluids, mucous membranes, or non-intact skin then disinfecting it with high-level disinfectant should be done .IASTM will be done at 30-60 degrees angle for 40-120 seconds+ radiational therapy
219236529|NCT07009197|OTHER|traditional therapy|the patients will receive traditional therapy in the form of ultrasound, scar massage, and stretching exercises.
219236530|NCT04097535|OTHER|PET/MRI|Imaging scan
219236531|NCT02265354|BEHAVIORAL|Collective-Intelligence computer tailored health communication|
219236532|NCT02265354|BEHAVIORAL|Rule-based computer tailored health communication|
219236533|NCT06696105|DRUG|Resin infiltration|"Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization."
219236534|NCT06696105|DRUG|Vanish XT varnish (resin modified glass ionomer restoration)|Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
219236535|NCT06698562|OTHER|Distraction with Virtual reality glassess|the injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. The patient and the physician wore protective goggles during the whole procedure to prevent possi
219236536|NCT06698562|OTHER|Distraction with Virtual reality glassess + LLLT|The injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
219736728|NCT01218256|OTHER|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
219736729|NCT01963832|DRUG|Fluoxetine|
219736730|NCT01963832|DRUG|Placebo|
219736731|NCT01963832|PROCEDURE|eCMIT|
219736732|NCT01963832|PROCEDURE|Usual Care|
219736733|NCT02837952|DRUG|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
219736734|NCT02837952|DRUG|Placebo|Placebo
219736735|NCT05653011|OTHER|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
219736736|NCT05305703|OTHER|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
219736737|NCT05305703|OTHER|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
219736738|NCT05638217|COMBINATION_PRODUCT|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
219736739|NCT01362530|DRUG|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
219736740|NCT01362530|DRUG|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
219736741|NCT01362530|DRUG|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
219736742|NCT01362530|DRUG|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
219736743|NCT01362530|DRUG|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
219736744|NCT01362530|DRUG|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
219736745|NCT01362530|DRUG|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
219736746|NCT01362530|DRUG|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
219736747|NCT02718482|DRUG|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
219736748|NCT02718482|DRUG|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
219736749|NCT03611361|DEVICE|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
219736750|NCT00930800|OTHER|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
219736751|NCT03471286|DRUG|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
219736752|NCT06427642|BIOLOGICAL|Mononuclear cells|UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
219736753|NCT06427642|DEVICE|Mild hypothermia therapy|Mild hypothermia therapy via hypothermia therapy apparatus
219736754|NCT06427642|DEVICE|Breathing support technique|Breathing support via ventilator
219736755|NCT06427642|PROCEDURE|Total parenteral nutrition|Liquid nutrition injected directly into the bloodstream
219236537|NCT06698562|OTHER|Tell Show Do Group + LLLT|The injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. During the whole procedure, the patient wore virtual glasses and the physician wore protective go
219236538|NCT06698562|OTHER|Tell Show Do Group|In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
219736756|NCT06014723|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
219736757|NCT05294146|DRUG|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
219736758|NCT01941342|PROCEDURE|Pancreatoduodenectomy|
219736759|NCT01941342|PROCEDURE|ENBD and Pancreatoduodenectomy|
219736760|NCT01941342|PROCEDURE|EBD and Pancreatoduodenectomy|
219736761|NCT01941342|PROCEDURE|PTCD and Pancreatoduodenectomy|
219736762|NCT03291236|OTHER|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
219736763|NCT03757117|DRUG|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
219736764|NCT03757117|BEHAVIORAL|Peer navigation|Transgender women community peer navigation
219736765|NCT04315961|DRUG|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
219736766|NCT04214444|BIOLOGICAL|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
219736767|NCT05882331|PROCEDURE|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
219736768|NCT04250363|BIOLOGICAL|PfSPZ Challenge|Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
219736769|NCT04250363|DRUG|Palcebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
219736770|NCT04250363|DRUG|M5717 30 mg|Participants received 30 mg single oral dose of M5717 capsule on Day 1.
219736771|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 1.
219736772|NCT04250363|DRUG|M5717 80 mg|Participants received 80 mg single oral dose of M5717 capsule on Day 1.
219736773|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 1.
219736774|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 1.
219736775|NCT04250363|DRUG|Placebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
219736776|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 5.
219736777|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 5.
219736778|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 5.
219736779|NCT01485198|PROCEDURE|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
219736780|NCT01485198|DRUG|Acetaminophen|Acetaminophen (750mg orally TID) administration
219162798|NCT05375162|BEHAVIORAL|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
219162799|NCT05646329|BEHAVIORAL|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
219162800|NCT06611059|DEVICE|PSG|Two replicas of each scapula are made. The scapulae are drilled with a commercial guide and with an in-house guide separately
219162801|NCT02113176|DRUG|Minocycline|
219162802|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
219162803|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
219162804|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219162805|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
219162806|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
219162807|NCT06676501|PROCEDURE|ExAblate|Transcranial focused ultrasound thalamotomy
219162808|NCT07008287|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
219162809|NCT05676827|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
219236539|NCT06698783|DIETARY_SUPPLEMENT|Fortimel|In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
219236540|NCT06700252|OTHER|Vestibular Rehabilitation|This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.
219236541|NCT06700252|OTHER|Traditional Protocol|This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
219236542|NCT06698718|PROCEDURE|Periodontal basic treatment|Accept periodontal basic treatment
219236543|NCT06698432|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
219236544|NCT06699485|DIETARY_SUPPLEMENT|Low carb diet|Low-carbohydrate diet contains (\<26% carbohydrates) or less than 130 g/d
219236545|NCT02625168|DRUG|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
219236546|NCT02625168|DRUG|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
219236547|NCT01771081|DRUG|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
219236548|NCT05424952|OTHER|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
219236549|NCT01366976|DRUG|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
219236550|NCT00300339|DRUG|SL650472, Clopidogrel|
219236551|NCT02540915|OTHER|Standard of Care - Registry|Standard of Care - Registry
219236552|NCT03622372|PROCEDURE|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
219236553|NCT03622372|DEVICE|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
219236554|NCT03622372|DEVICE|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
219236555|NCT00307489|DRUG|tenofovir DF|300 mg tablet, once daily (QD)
219236556|NCT00307489|DRUG|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
219236557|NCT01592422|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
219162810|NCT05676827|DIAGNOSTIC_TEST|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, Gamma-aminobutyric acid (GABA), Tumor Necrosis Factor α (TNF-α), CGRP, SERT, interleukin 1B, interleukin 6, interleukin 8, interleukin 10 and interleukin 17A.
219162811|NCT06872320|DRUG|Lactobacillus Rhamnosus|Lactobacillus Rhamnosus (Lactobacillus Rhamnosus, MoProbi-LR Capsules, Drug permit license 052531); Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
219162812|NCT06872320|DRUG|Placebo|Maltodextrin comparable in color. Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
219236558|NCT01592422|OTHER|Best Supportive Care|Best Supportive Care in the absence of disease progression
219236559|NCT03361202|OTHER|blood sampling|"* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge."
219236560|NCT04800263|DRUG|SHR-1905|SHR-1905 will be injected subcutaneously
219236561|NCT04800263|DRUG|Placebo|Placebo will be injected subcutaneously
219236562|NCT03425175|OTHER|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
219236563|NCT01690000|DRUG|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
219236564|NCT02065297|OTHER|1 blood sample|
219236565|NCT02065297|OTHER|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
219236566|NCT01714908|OTHER|Erlotinib w Concurrent Radiotherapy|
219162813|NCT07011940|BEHAVIORAL|Along With Me|Along With Me is a therapeutic app that delivers cognitive behavior therapy and mindfulness-based psychoeducation and skills, grief normalization, and exercises to address perinatal grief and to reduce trauma symptoms related to the experience of perinatal loss. The Along With Me only arm will deliver the app-based intervention only.
219162814|NCT07011940|BEHAVIORAL|Peer Guide|The peer guide will provide light touch reminders, opportunities to debrief, and resource navigation support, similar to community health navigator interventions provided remotely through insurers.
219162815|NCT04605783|DIETARY_SUPPLEMENT|Travelan®|Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
219236567|NCT01714908|OTHER|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
219162816|NCT04605783|OTHER|Placebo|Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
219162817|NCT06384963|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
219162818|NCT06384963|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
219162819|NCT06872593|PROCEDURE|CPAP-withdrawal|7-day-long CPAP-withdrawal
219162820|NCT06872593|DIAGNOSTIC_TEST|Test Sequence|Test Sequence M or D as specified in arm description
219162821|NCT06696066|BEHAVIORAL|PRS Program|The Peer Recovery Support program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
219162822|NCT00976105|DRUG|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
219162823|NCT00976105|DRUG|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
219162824|NCT07023380|DIAGNOSTIC_TEST|Assay directed diet change|Functional T cell assay(s) will be performed on research subjects' peripheral blood using four foods known to commonly cause Eosinophilic esophagitis - milk, soy, egg, and wheat. Response magnitude to foods in vitro will influence whether a subject's physician chooses to recommend the subject AVOID the food or continue to CONSUME the food. Disease response to the diet changes will be evaluated in standard-of-care follow up endoscopy.
219162825|NCT06877273|BEHAVIORAL|CIRCuiTS-MS|The intervention is a blended treatment combining therapist support with carrying out tasks in CIRCuiTS™ digital cognitive remediation software. This software provides opportunities to practice a range of cognitive tasks and adaptively adjusts task difficulty. CIRCuiTS™ is much used in psychosis. Based on collaborative workshops with people with MS, participants for this trial will be asked to attend two 1-hour therapy sessions (in person or on MS Teams) and 1 hour of independent tasks each week for 12 weeks. Participants with reduced ability to operate a mouse quickly or dexterously will be offered a modified programme omitting tasks that require these abilities. The therapist will be an Assistant Psychologist trained in CIRCuiTS™ delivery and in appropriate adjustments to the needs of people with MS. They will follow a manualised template and will receive weekly supervision from an experienced clinical psychologist.
219162826|NCT07032259|DEVICE|BioXclude Amnion Chorion Membrane|A resorbable allograft membrane derived from dehydrated human amnion and chorion tissue. The membrane is placed over peri-implant bony defects during guided bone regeneration to act as a biological barrier and promote tissue healing.
219162827|NCT07032259|DEVICE|Collagen Membrane|A resorbable xenograft membrane derived from porcine collagen. The membrane is placed over peri-implant bony defects during guided bone regeneration to support space maintenance and facilitate bone regeneration.
219162828|NCT06309134|BEHAVIORAL|Healthy Families Bright Futures Program|Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
219162829|NCT06885710|BIOLOGICAL|LioCyx-M|Each patient will receive LioCyx-M infusion every one or two weeks, while continuing their existing nucleos(t)ide analog treatment.
219162830|NCT06729567|OTHER|Spinal block level analysis|Relation of the dose of hyperbaric bupivacaine to resulting spinal block level is to be assessed. Conventional dose cases (more than 9mg and less than 13mg) will be included in analysis.
219162831|NCT06729567|OTHER|data collection|Intervention is to acquire and analyse anonymous perioperative data. After identification of the eligible cases, statistical analysis will be performed.
219736781|NCT05518981|DEVICE|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
219736782|NCT03351959|RADIATION|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
219736783|NCT05601063|BEHAVIORAL|Winterlight Speech Assessment|Digital assessment of speech and language abilities
219736784|NCT05698992|OTHER|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
219736785|NCT03021005|BEHAVIORAL|HIV Self-testing|
219736786|NCT01704560|OTHER|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
219236568|NCT04714359|DRUG|Midomafetamine HCl|Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.
219236569|NCT02749253|OTHER|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
219236570|NCT03242239|BIOLOGICAL|ALT02|
219236571|NCT03242239|BIOLOGICAL|EU-licensed Herceptin|
219236572|NCT03242239|BIOLOGICAL|US-licensed Herceptin|
219236573|NCT01527643|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
219236574|NCT01697605|DRUG|BGJ398|
219236575|NCT00239642|DRUG|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
219236576|NCT00239642|DRUG|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
219236577|NCT00239642|DRUG|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
219236578|NCT00911716|BIOLOGICAL|bevacizumab|
219236579|NCT00911716|DRUG|cyclophosphamide|
219236580|NCT00911716|DRUG|docetaxel|
219236581|NCT00911716|PROCEDURE|adjuvant therapy|
219236582|NCT00842959|DEVICE|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
219236583|NCT00842959|DEVICE|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
219236584|NCT03277456|BIOLOGICAL|MVA-NP+M1|Intramuscular injection of novel vaccine
219236585|NCT05771285|OTHER|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
219236586|NCT04998266|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
219236587|NCT04998266|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
219236588|NCT05728372|DRUG|Copper Cu 64-DOTA-pembrolizumab|Given IV
219236589|NCT05728372|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219236590|NCT05728372|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219236591|NCT01975701|DRUG|BGJ398|Capsule for oral use.
219236592|NCT04249700|DEVICE|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
219236593|NCT02717780|DRUG|Fentanyl and sevoflurane|
219236594|NCT02717780|DRUG|Remifentanil and desflurane|
219236595|NCT00242086|PROCEDURE|CT, PET and MRI|
219236596|NCT00892970|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
219736787|NCT04046952|DEVICE|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
219736788|NCT04046952|DEVICE|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
219736789|NCT05598307|DRUG|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
219736790|NCT05598307|DRUG|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
219736791|NCT05598307|DRUG|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
219736792|NCT03401580|DRUG|Viena II 160/10|once daily
219736793|NCT03401580|DRUG|Viena II 190/10|once daily
219236597|NCT00892970|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
219236598|NCT03108222|OTHER|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
219236599|NCT00997152|DRUG|JTT-654|Tablets
219736794|NCT03401580|DRUG|Viena II 160/12|once daily
219736795|NCT03401580|DRUG|Viena II 190/12|once daily
219736796|NCT03201380|OTHER|TEP scanner with choline|
219236600|NCT00997152|DRUG|JTT-654 Placebo|Tablets
219236601|NCT02958826|OTHER|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
219362202|NCT04642014|BIOLOGICAL|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
219362203|NCT00114062|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
219162832|NCT02274142|PROCEDURE|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
219162833|NCT02274142|PROCEDURE|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
219162834|NCT02274142|DEVICE|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
219162835|NCT02274142|DEVICE|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
219162836|NCT07048223|BEHAVIORAL|Expiratory Muscle Training|"In the expiratory muscle training group, participants will receive a respiratory exercise program consisting of breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, expiratory muscle training (EMT) will be performed using the POWERbreathe EX1 device at 50% of each participant's measured maximal expiratory pressure (MEP).~Participants will be instructed to perform 25 repetitions per session, structured as 5 cycles of 5 breaths with 1-minute rest intervals between each cycle. The training will be performed daily at home for a duration of 8 weeks. Compliance will be monitored through exercise tracking forms.~To ensure progressive loading, MEP will be reassessed every 10 days, and the resistance of the device will be adjusted accordingly. Participants will be invited for in-person interim evaluations at these 10-day intervals to update their training parameters."
219236602|NCT02896673|PROCEDURE|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
219236603|NCT00091520|DRUG|Nesiritide|
219236604|NCT04497818|OTHER|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
219236605|NCT02391259|DRUG|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
219236606|NCT02391259|DRUG|Placebo|contains no active drug
219236607|NCT04540952|DEVICE|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
219236608|NCT04540952|DEVICE|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
219236609|NCT05467267|PROCEDURE|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
219236610|NCT02143713|DRUG|Elagolix|Elagolix tablets administered orally
219736797|NCT03399747|DRUG|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
219736798|NCT01019057|PROCEDURE|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
219736799|NCT03692026|PROCEDURE|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
219736800|NCT03692026|DRUG|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
219736801|NCT01991886|DEVICE|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
219736802|NCT02197065|DRUG|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
219736803|NCT02197065|DRUG|Placebo|
219736804|NCT02174445|DRUG|Imatinib|Imatinib, 400 to 800 mg p.o., daily
219736805|NCT02174445|DRUG|Nilotinib|300mg p.o., twice-daily
219736806|NCT00000472|DRUG|tissue plasminogen activator|
219736807|NCT00000472|DRUG|heparin|
219736808|NCT00085020|BIOLOGICAL|trastuzumab|
219736809|NCT00085020|DRUG|lapatinib ditosylate|
219736810|NCT00276380|DRUG|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
219736811|NCT00276380|DRUG|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
219736812|NCT00276380|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
219736813|NCT02748174|BEHAVIORAL|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
219736814|NCT03568123|DEVICE|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
219736815|NCT03568123|DEVICE|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
219736816|NCT03207087|DEVICE|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
219736817|NCT06547359|DRUG|Obicetrapib 10mg|tablets
219236611|NCT00976053|PROCEDURE|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
219236612|NCT03563170|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219162837|NCT07048223|BEHAVIORAL|Sham Expiratory Muscle Training|"In the sham expiratory muscle training group, participants will perform a respiratory exercise program including breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, sham expiratory muscle training will be administered using the POWERbreathe EX1 device set at 10% of the participant's measured maximal expiratory pressure (MEP), providing minimal resistance.~Participants will be instructed to perform the exercises daily at home for a period of 8 weeks. Compliance will be monitored through exercise tracking forms. No progressive loading or resistance adjustments will be made during the intervention period."
219162838|NCT07054658|PROCEDURE|Allogenic Bone Ring Graft With Simultaneous Implant Placement|A surgical procedure involving vertical ridge augmentation using an allogenic bone ring combined with simultaneous dental implant placement in the posterior mandible. The technique allows one-stage treatment of vertical bone defects without the need for autogenous bone harvesting.
219162839|NCT06788886|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219162840|NCT06788886|OTHER|Exercise Intervention|Participate in walking routines
219162841|NCT06788886|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219162842|NCT06788886|OTHER|Questionnaire Administration|Ancillary studies
219162843|NCT06788886|PROCEDURE|Respiratory Therapy|Participate in breathing sessions
219162844|NCT03582722|DRUG|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
219162845|NCT03582722|DRUG|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
219162846|NCT03582722|DIETARY_SUPPLEMENT|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
219162847|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
219162848|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
219162849|NCT07055854|BEHAVIORAL|Mindful After Cancer Program|The Mindful After Cancer Program provides education, mindfulness training, and peer support to help cancer survivors navigate sexual and body image concerns.
219162850|NCT07056049|BEHAVIORAL|High dosage, high intensity motor rehabilitation|Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks.
219162852|NCT06619912|DRUG|Dexmedetomidine nasal spray|Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 30 minutes before induction.
219162853|NCT06884722|BEHAVIORAL|Behavioral task of social perception (stage 1)|Patients with Parkinson disease and healthy volunteer are engaged in a social perception behavioral task.
219162854|NCT06884722|OTHER|Functional magnetic resonance imaging: 3 Tesla magnetic resonance imaging (stage 2)|"Patients with Parkinson disease and healthy volunteer are assessed by functional magnetic resonance imaging while they are engaged in a social perception behavioral task.~2 times for patients with Parkinson disease (during ON-levodopa and OFF-levodopa) Once for healthy volunteer"
219162855|NCT06884722|OTHER|Neurological and neuropsychological assessments|Patients with Parkinson disease and healthy volunteer will undergo a neurological and neuropsychological assessment with several evaluations: weight, height, medical history, global cognitive performance (MoCA and BREF score), apathy (LARS score), depression (BDI-II score), social cognition (mini-SEA), and quality of life (PDQ39 self-questionnaire).
219162856|NCT06884722|OTHER|Neurological assessments of Parkinson's disease symptoms and caregiver burden|Patients with Parkinson disease will undergo a neurological assessment of motor and non-motor symptoms of Parkinson's disease (MDS-UPDRS III \& IV scale and MDS-NMS scale) and caregiver burden (Zarit scale).
219162857|NCT07061301|DEVICE|Usual Care group|Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
219162858|NCT07061301|DEVICE|Technological group|Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
219162859|NCT07059910|DIAGNOSTIC_TEST|Search for thyroid disorders|TSH , FT3 , FT4
219162860|NCT07059910|DIAGNOSTIC_TEST|Laboratory test|Search for anti thyroid antibodies
219236613|NCT03563170|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
219236614|NCT03563170|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
219236615|NCT03563170|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
219236616|NCT03563170|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219236617|NCT03563170|DRUG|Cyclophosphamide|anhydrous
219236618|NCT03563170|DRUG|5-Fluorouracil|5-FU; Fluorouracil
219236619|NCT03563170|DRUG|Leucovorin|Leucovorin calcium salt
219236620|NCT03563170|DRUG|nab-Paclitaxel|ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
219236621|NCT03563170|DRUG|Sorafenib|NEXAVAR® tablets, for oral use
219236622|NCT03563170|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
219236623|NCT03563170|BIOLOGICAL|Aldoxorubicin hydrochloride|HCl
219236624|NCT03563170|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219236625|NCT03563170|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
219236626|NCT03563170|BIOLOGICAL|GI-6207|CEA yeast vaccine
219162861|NCT07059910|DRUG|Steroid and eltrombopage|See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?
219162862|NCT07059507|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
219162863|NCT06751225|DEVICE|One week replacement soft contact lenses|One week replacement soft contact lenses
219162864|NCT07057219|OTHER|Exercise|SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
219162865|NCT07057219|OTHER|Exercise|The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
219162866|NCT07059221|DRUG|SHR-A2102|Administration by intravenous infusion
219162867|NCT07059221|DRUG|Adebrelimab|Administration by intravenous infusion
219162868|NCT07059221|DRUG|Cetuximab|Administration by intravenous infusion
219162869|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Lactulose.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
219162870|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Sodium phosphate.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
219162871|NCT06758206|BEHAVIORAL|Flywheel Resistance Training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
219162872|NCT06758206|BEHAVIORAL|Traditional resistance training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 to 12 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at moderate and high intensities (6 to 10 on the OMNI-RES scale).
219162873|NCT07066020|BEHAVIORAL|Telehealth-delivered Physical Activity Program for Children with ASD|This is a 16-week, theory-driven (Social Cognitive Theory \& Self-Determination Theory) behavioral intervention delivered remotely to caregivers of children with ASD. The program is facilitated by trained therapists via videoconference in small groups and consists of weekly 45-minute sessions. Core components include personalized exercise prescription, collaborative goal-setting, behavior change support, and safety education. Caregivers are coached to guide their child in three 30-40 minute physical activity sessions per week. To provide individualized support, therapists conduct two 10-minute one-on-one phone consultations per family based on biweekly activity logs submitted by caregivers.
219162874|NCT07066020|BEHAVIORAL|In-Person Supervised Physical Activity Program|This is a 16-week, structured, in-person physical activity intervention for children with ASD. The program consists of three 40-minute sessions per week delivered on-site at a partner school by certified physical education instructors. The curriculum is manualized and includes an Individualized Motor Protocol, Structured Group Sessions, and Behavior Change Support. Instructors provide direct, hands-on correction and feedback during sessions, adjusting task difficulty in real-time to match each child's individual capabilities and needs.
219236627|NCT03563170|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219236628|NCT03563170|DRUG|Cetuximab|ERBITUX® injection, for IV infusion)
219236629|NCT03563170|BIOLOGICAL|N-803|Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
219236630|NCT02167230|PROCEDURE|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
219236631|NCT02167230|PROCEDURE|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
219236632|NCT00021333|BIOLOGICAL|filgrastim|
219236633|NCT00021333|DRUG|cisplatin|
219236634|NCT00021333|DRUG|paclitaxel|
219236635|NCT00021333|RADIATION|radiation therapy|
219236636|NCT03411408|DEVICE|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
219236637|NCT03411408|RADIATION|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
219236638|NCT05487937|OTHER|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
219236639|NCT00401050|PROCEDURE|chiropractic manipulative therapy|
219236640|NCT00401050|PROCEDURE|knee exercises|
219236641|NCT00401050|PROCEDURE|Graston Instrument Soft Tissue Mobilization (GISTM)|
219236642|NCT03918733|PROCEDURE|surgical treatment|surgical treatment will be done of failed root canal treated teeth
219236643|NCT03918733|PROCEDURE|Non surgical retreatment|Non surgical retreatment will be done.
219236644|NCT04264156|COMBINATION_PRODUCT|Lucinactant for Inhalation|A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
219236645|NCT04264156|OTHER|nCPAP Only|Nasal continuous positive airway pressure (nCPAP) alone
219236646|NCT01768572|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
219236647|NCT01768572|DRUG|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
219236648|NCT01768572|DRUG|hydroxychloroquine|Dispensed according to local practice.
219236649|NCT01768572|DRUG|methotrexate|Dispensed according to local practice.
219236650|NCT01768572|DRUG|sulfasalazine|Dispensed according to local practice.
219236651|NCT01768572|DRUG|leflunomide|Dispensed according to local practice.
219236652|NCT01768572|DRUG|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
219236653|NCT01768572|DRUG|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
219236654|NCT01241032|DRUG|Udenafil|200mg Single Oral Dose of
219236655|NCT01241032|DIETARY_SUPPLEMENT|Alcohol|Alcohol 39g / 240ml
219236656|NCT02771561|PROCEDURE|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
219236657|NCT02255006|DEVICE|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
219362204|NCT01617941|DRUG|BGG492|
219736818|NCT06547359|DRUG|Ezetimibe 10mg|tablets
219736819|NCT02719730|BEHAVIORAL|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
219736820|NCT06564402|BEHAVIORAL|Positive Mental Rehearsal|After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
219736821|NCT06564402|BEHAVIORAL|Mental Rehearsal|After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
219736822|NCT06564402|BEHAVIORAL|Exposure|All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
219736823|NCT03411187|DEVICE|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
219736824|NCT03411187|DEVICE|direct exhaust|direct exhaust through the trocar.
219736825|NCT05350267|BEHAVIORAL|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
219162875|NCT07066020|OTHER|General Health Education Materials|This is a minimal intervention control. Participants in this group do not receive a structured or guided physical activity program. At the beginning of the study, caregivers are provided with a one-time, webinar-style session on general pediatric health topics (e.g., nutrition, sleep hygiene) and an exercise guidance manual. These materials are for optional, independent use by the caregivers, and no active monitoring or follow-up is provided by the research team regarding their use.
219162876|NCT07070167|DRUG|Intratracheal administration of surfactant|Intratracheal administration of pulmonary surfactant with any of the approved methods: (a) via endotracheal tube in a mechanically-ventilated infant, (b) with the INSURE method (intubation-surfactant-extubation), or (c) with LISA method (through a thin catheter inserted intratracheally in a spontaneously breathing infant, supported with CPAP)
219162877|NCT07071480|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
219162878|NCT07071480|DEVICE|Sham device|Sham headband-style device. Participants assigned to use this device will be told they are receiving therapy for 30 minutes. However, no therapy is being provided.
219162879|NCT07071220|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
219162880|NCT07071220|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
219162881|NCT07070141|DIAGNOSTIC_TEST|Diagnostic work up|None intervention
219162882|NCT07070791|OTHER|Upper Extremity Aerobic Exercise Training|12 weeks of upper extremity aerobic exercise training, 3 sessions per week, 25 minutes per session.
219162883|NCT07070791|OTHER|Upper Extremity Progressive Resistance Exercise Training|Upper extremity progressive resistance training was gradually increased over 12 weeks using elastic resistance bands.
219162884|NCT07071467|OTHER|Scaling and root planing with sodium hypochlorite and hyaluronic acid|Sodium hypochlorite gel was applied first for 30 seconds, then followed by subgingival instrumentation of the site. Then, 1.8% hyaluronic acid (1.6% cross-linked, 0.2% natural hyaluronic acid ) was applied subgingivally into the periodontal pocket to seal the site.
219162885|NCT07071467|PROCEDURE|Scaling and root planing|Pockets were treated with sub-gingival scalling and root planning alone.
219236658|NCT02255006|DEVICE|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
219162886|NCT07070986|PROCEDURE|RESC|"If randomized in the RESC group, interventional group, patient will receive a 20 minutes session of cutaneous resonance stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale (VAS) at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery).~During the RESC session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
219162887|NCT07070986|OTHER|NSCS|"If randomized in the NSCS group, interventional group, patient will receive a 20 minutes session of non-specific cutaneous stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery)~During the NSCS session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
219162888|NCT07070960|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
219162889|NCT07070921|DEVICE|Foley catheter|Drainage of urine from the bladder by transurethral catheterization with an indwelling Foley catheter of patients in need of a Foley catheter for 3 to 14 days.
219162890|NCT07070999|BIOLOGICAL|GB221|GB221
219162891|NCT07071129|DEVICE|Virtual Reality Stimulation|VR 1 hour sessions will consist of an exposure to a non-invasive visual stimulation where the subject will be sitting wearing a VR headset.
219162892|NCT07069946|OTHER|traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of traditional physical therapy program : Includes: Strengthening, Stretching, Balance, Postural Control, Functional Mobility and Gait Training.~* 30 minutes of seven different weight-bearing exercises program of exercises with three of those being repeated on the left and right sides to make a total of ten exercises, each held for 3 minutes, the exercises include: hamstring stretch, calf stretch, half kneeling balance, static squat, bridge, four point kneeling and four point kneeling with leg extension the exercises include: : Hamstring stretch,Calf stretch , Half kneeling balance , Static Squat, Bridge, Four point kneeling with leg extension, and Four point kneeling."
219162893|NCT07069946|OTHER|neuromuscular electrical stimulation , traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of the same traditional physical therapy as the control group.~* 30 minutes of the same weight-bearing exercises program as the control group adding to it the neuromuscular electrical stimulation on: Tibialis anterior, Quadriceps, Paraspinal muscles.~* NMES Parameters :~  * Device: Everyway-EV-906.~ * Frequency: 30-35 Hz (to optimize muscle endurance and motor unit recruitment).~ * Pulse Width: 250-300 µs.~ * Intensity: Adjusted to elicit visible muscle contraction without discomfort (submaximal, (25-30 mA).~ * Electrode Placement:~    * Lower Limb: Tibialis anterior (for dorsiflexion) and quadriceps (for knee stability) during weight-bearing (El-Shamy and El Kafy, 2021).~   * Trunk: Paraspinal muscles (for postural control) during static squats and bridging"
219162894|NCT07071701|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine
219162895|NCT07071701|BIOLOGICAL|Influenza vaccine|Influenza vaccine
219162896|NCT07071272|OTHER|breast-MRI and CEM|Participants will undergo a breast MRI followed by CEM for local breast cancer staging
219162897|NCT07069868|OTHER|Telehealth|During cycle one, participants will be asked about fevers, mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Symptoms will be graded according to Common Terminology Criteria for Adverse Events. A new adverse event of grade one or higher will be reported to a provider. An adverse event grade two or higher above baseline and/or experiencing cancer related symptoms above baseline, the findings will be reported to a Provider.
219162898|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO)|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO air purifiers in households for two weeks.
219162899|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO) + filters|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO and filters air purifiers in households for two weeks, to understand the effects comparing with PCO.
219162900|NCT07071922|OTHER|No intervention|Observational one-time questionnaire study without intervention
219162901|NCT07070375|DRUG|HRS-8427|HRS-8427
219162902|NCT07070401|DEVICE|Commercial AR/VR Headset with Calming App|Commercial AR/VR Headset with Calming App in addition to Pharmacologic Standard of Care
219162903|NCT07070401|OTHER|Pharmacologic Standard of Care Alone|Pharmacologic Standard of Care Alone
219162904|NCT07070570|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray, clinical visit and questionnaires at 10 years after surgery
219162905|NCT07070570|OTHER|Active Check-Up on Demand (ACOD)|X-ray, clinical visit and questionnaires at 10 years after surgery when requested by the patient or healthcare provider.
219162906|NCT07070570|OTHER|Passive Check-Up on Demand (PCOD)|X-ray and clinical visit (without questionnaires) at 10 year when requested by the patient or healthcare provider.
219162907|NCT07071870|PROCEDURE|Stent-screw Assisted Internal Fixation (SAIF)|Implanting vertebral body stents (VBS), followed by insertion of percutaneous, fenestrated, cement-augmented pedicular screws
219162908|NCT07071870|PROCEDURE|Surgical stabilization|Spinal fixation with cement augmented pedicle screws bridging the fractured vertebra
219162909|NCT07070804|OTHER|None-placebo|No interventions performed
219162910|NCT07069959|OTHER|Early assessment of quadriceps muscle strength|Patients will undergo non-invasive assessment of quadriceps muscle strength using manual dynamometry and 3D ultrasound. These assessments will be conducted regularly during their ICU stay to evaluate early recovery. The intervention is part of routine patient care and does not involve additional treatments or procedures.
219162911|NCT07070362|OTHER|None-placebo|This observational cohort study is non-interventional. Perioperative treatment plans are made based on model - suggested results and anesthesiologists' thought processes, without adding new medicines for patients.
219162912|NCT07071506|DRUG|Active drug for chronic migraine treatment.|Standard dose of Fremanezumab, 225 mg (Ajovy) injected subcutaneously
219162913|NCT07071506|DRUG|Placebo Subcutaneous injection|Inactive placebo (saline) injected subcutaneously in the same volume as the active drug
219162914|NCT07071636|DRUG|Peg-IFN α-2b combined with NAs|Peg-IFN α-2b (1.5 μg/kg/week) combined with NAs
219162915|NCT07066410|BIOLOGICAL|intervention 1: endocem|EndoCem, a premixed calcium silicate-based cement (Maruchi, Korea), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, EndoCem is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of EndoCem, followed by immediate restoration with FUJI II ensure a coronal seal.
219162916|NCT07066410|BIOLOGICAL|Intervention 1: biodentine|Biodentine, a tricalcium silicate-based cement (Septodont, France), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, Biodentine is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of Biodentine, followed by immediate restoration with FUJI II to ensure a coronal seal.
219162917|NCT07066514|BEHAVIORAL|AI-Supervised Mobile Exercise Program|This intervention involves the use of an artificial intelligence (AI)-supported mobile application that delivers a personalized exercise program to patients with knee osteoarthritis. The app supervises exercise execution in real time using the device's camera and AI algorithms to track movements, count repetitions, and assess form accuracy. The program includes stretching, strengthening, and range of motion exercises performed 3-4 times per week for 4 weeks. The app provides instructional videos, personalized feedback, reminders, and records user performance. No video or personal images are stored; only anonymized motion data are collected and securely stored.
219162918|NCT07066514|BEHAVIORAL|Booklet-Guided Home Exercise Program|This intervention provides patients with a standardized home exercise program in printed booklet format. The program includes the same evidence-based stretching, strengthening, and range of motion exercises used in the mobile application group, performed 3-4 times per week for 4 weeks. Participants receive one-time in-person instruction on proper form but no ongoing supervision or feedback during the program. Adherence and technique are self-monitored.
219162919|NCT06024174|DRUG|BMS-986466|Specified dose on specified days
219162920|NCT06024174|DRUG|Adagrasib|Specified dose on specified days
219162921|NCT06024174|DRUG|Cetuximab|Specified dose on specified days
219236659|NCT02255006|DRUG|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
219236660|NCT02255006|DRUG|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
219236661|NCT02332525|DEVICE|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
219236662|NCT00391651|DRUG|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
219236663|NCT00391651|DRUG|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
219236664|NCT00949234|DRUG|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
219236665|NCT05230056|BEHAVIORAL|PG|Shoulder Digital therapy
219236666|NCT05230056|BEHAVIORAL|CTRL|Shoulder non-digital therapy
219236667|NCT04464148|DRUG|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
219236668|NCT04464148|DRUG|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
219362205|NCT01617941|DRUG|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
219162922|NCT05091580|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.
219162923|NCT05091580|BEHAVIORAL|Enhanced treatment as usual|Depression screening and referral (as needed)
219162924|NCT07071935|DEVICE|Non-invasive ventilation|Non-invasive ventilation will be started earlier than usual respiratory care guidelines for ALS in the United States.
219162925|NCT07070050|DRUG|Ibuprofen continuous infusion|"1. The first bolus: ibuprofen 400 mg diluted in 0,9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Continuous infusion:~   * Ibuprofen 1200 mg diluted in 0,9% NaCl 300 ml is intravenous injected on the first day with the speed of 1 mg/kg/h (for the ideal body weight) during the remaining 23 hours.~  * On the second day the intravenous infusion of ibuprofen 1600 mg diluted in 0,9% NaCl 400 ml with the speed of 1 mg/kg/h is continued during the 24 hours.~3. Imitation of bolus: Every 8 hours placebo (0, 9% NaCl 200 ml) is intravenous injected to create an imitation of bolus injection. Placebo is injected during the first hour."
219162926|NCT07070050|DRUG|Ibuprofen bolus injection|"1. The first bolus: ibuprofen 400 mg diluted in 0, 9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Bolus injection:~   * Every 8 hours a intravenous bolus of ibuprofen 800 mg diluted in 0,9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~  * On the second day the every 8 hours intravenous bolus of ibuprofen 800 mg diluted in 0, 9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~3. Placebo continuous infusion:~Between the boluses a placebo (0,9% NaCl) continuous intravenous infusion is performed with the speed imitating the speed of ibuprofen infusion in the experimental group."
219162927|NCT07071233|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
219162928|NCT07071233|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
219162929|NCT07070154|BEHAVIORAL|text-messaging based intervention|The 6-week, culture specific, text-messaging based cessation intervention for young adults in Hong Kong consists of 6 sessions: 1) Programme overview, 2) Psychoeducation on the health risks, 3) Social support, 4) Stress management, 5) Craving and withdrawal symptoms management, and 6) Summary and relapse prevention.
219162930|NCT07071545|BEHAVIORAL|Regular physical activity|Moderate-to-vigorous physical activity at least three times per week.
219162931|NCT07071545|BEHAVIORAL|No regular physical activity|The group that did not engage in physical activity according to the guidelines
219162932|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
219162933|NCT07070752|DRUG|GP40321|GP40321, solution for subcutaneous injection, 100 U/mL (GEROPHARM LLC, Russia)
219162934|NCT07070752|DRUG|Apidra® SoloStar®|Apidra® SoloStar®, solution for subcutaneous injection, 100 U/mL (Sanofi-Aventis Deutschland GmbH, Germany)
219236669|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
219162935|NCT07070752|DRUG|RinGlar®|Patients also receive long-acting basal insulin therapy (insulin glargine 100 U/mL) throughout the study
219162936|NCT07071610|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% BID
219162937|NCT07071610|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% BID
219162938|NCT07071610|DRUG|Vehicle|vehicle BID
219162939|NCT07075588|BEHAVIORAL|iTHRIVE intervention|"Integration of three traditionally siloed components:~1. Digitally enabled food access~2. Personalized nutrition support~3. Clinical care-rision of home blood pressure device with app"
219162940|NCT07075588|BEHAVIORAL|Active comparator|"Active comparator arm will receive enhanced usual care that consists of:~1. Standard produce bag~2. Home blood pressure Device without app~3. General dietary advice"
219162941|NCT07074730|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia with local anesthetic infiltration.
219162942|NCT07074730|OTHER|General anesthesia|Patients will receive general anesthesia.
219162943|NCT07075718|DRUG|Gen 2 Travoprost Intracameral Implant|travoprost
219162944|NCT07075718|DRUG|Timolol eye drops 0.5%|timolol 0.5%
219162945|NCT07075718|PROCEDURE|Sham Procedure|sham implant administration
219162946|NCT07075718|OTHER|Placebo eye drops|artificial tears
219162947|NCT07078526|OTHER|Otago Exercise Program|The Otago Exercise Program is a structured, progressive exercise regimen focusing on lower limb strengthening and balance retraining. It is performed twice weekly for six weeks under physiotherapist supervision, complementing standard physiotherapy care.
219162948|NCT07078526|OTHER|Neuromuscular Exercise|The neuromuscular exercise intervention involves functional, proprioceptive, and balance exercises delivered twice weekly for six weeks under supervision, in addition to standard physiotherapy care.
219162949|NCT07078227|OTHER|No intervention is used.|No intervention is used.
219162950|NCT07078487|DEVICE|Pacemaker and defibrillator|Setting the pacemaker base rate at a pre-defined base rate
219162951|NCT07076641|PROCEDURE|rachi morphine anesthesia|Morphine spinal anesthesia is administered before general anesthesia, just after the patient has been admitted to the operating room.
219162952|NCT07076641|PROCEDURE|laparotomy|major digestive or abdominal surgery by laparotomy
219162953|NCT07076641|DRUG|Lidocaine IV|KABI 20 mg/mL solution for injection (ready-to-use ampoule, no dilution). Each ml of solution contains 20 mg lidocaine hydrochloride (monohydrate form), corresponding to 16.22 mg lidocaine.
219162954|NCT07076641|DRUG|Placebo|Sodium chloride (NaCl) FRESENIUS 0.9% solution for infusion. Each ml contains 9 mg sodium chloride.
219162955|NCT07076641|DRUG|MORPHINE|The auxiliary drug on which both experimental strategies are based is MORPHINE: Morphine hydrochloride AGUETTANT 0.1 mg/mL Solution for injection (ready-to-use ampoule) for rachi anesthesia.
219162956|NCT07076953|OTHER|Cherry Seed Massage Group|In the third stage of labor, a cherry pit massage was applied for 15 minutes in the first and second hours. Cherry pits were added to a silk bag to prevent damage to the skin during the massage. The massage application steps were applied as indicated in the hand massage
219736826|NCT05350267|BEHAVIORAL|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
219736827|NCT05960435|OTHER|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
219736828|NCT05960435|OTHER|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
219736829|NCT03473301|BIOLOGICAL|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
219736830|NCT03473301|BIOLOGICAL|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
219736831|NCT03184675|OTHER|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
219736832|NCT03184675|OTHER|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
219736833|NCT05313256|DRUG|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
219736834|NCT05313256|DRUG|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
219736835|NCT04829214|DRUG|OTO-313|Single intratympanic injection
219736836|NCT04829214|DRUG|Placebo|Single intratympanic injection
219736837|NCT06002594|OTHER|group low-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
219162957|NCT07076953|OTHER|Manual Breast Massage|"Manual massage was applied for 15 minutes during the third stage of labor, first and second hour.Manual breast massage steps; Step 1: The breast tissue under and near the armpit is compressed and released like a water pump.~Step 2: Pressure is applied to the breast tissue. Step 3: The breasts are massaged using the fingers and pressed with small circular movements. It is moved clockwise and counterclockwise around the breast and towards the areola with light touches.~Step 4: Both hands are placed under the breast; the breast is moved up and down, left and right, forward and backward.~Step 5: One hand is placed under the breast and the other hand is on the breast; the hands are moved in the opposite direction and a rolling motion is applied to the breast."
219162958|NCT07076745|DIAGNOSTIC_TEST|High-sensitivity C-reactive protein|High-sensitivity C-reactive protein will be done.
219162959|NCT07076745|OTHER|Stiffness Measurement|"Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:~* β-stiffness index.~* Peterson's elastic modulus (Ep).~* Distensibility coefficient (DC).~* Compliance coefficient (CC).~* Strain."
219162960|NCT07078253|OTHER|Produce box program|Each week during the 20-week study period, participants will pick up a box of fresh vegetables. All produce will be provided to the participants at no cost as part of the client choice pantry program. Participants will take home approximately 6 different types of vegetables each week. Participants will choose which vegetables they want from a variety of options.
219162961|NCT07077577|PROCEDURE|Holistic Birth Approach|Holistic Birth Approach involves use of non pharmacological techniques for better labor process management with less experience of pain, fear and maternal satisfaction to women delivering the baby through normal delivery method.
219162962|NCT07076784|DRUG|Icariin|Topical application of 3% icariin solution
219162963|NCT07076784|DRUG|Vehicle Control|Topical application of 3% ethanol solution
219162964|NCT07076602|OTHER|Gait and energy expenditure|"SESSION 1:~Physiotherapy assessment: clinical parameters, length of limb segments, range of motion of the lower limbs, muscle strength of each lower limb joint and trunk.~Measurement of energy expenditure:~6-minute walking test with prosthesis, at a constant submaximal speed, with portable gas exchange analyzer to measure oxygen consumption and a connected device to calculate the Physiological Cost Index.~* During test: recording of heart rate at the start, each minute, at the end then 5 minutes after the end, recording of the effort perceived by the child each minute (Borg scale)~* At the end : questionnaire to assess child level of acceptability regarding the measurement of the O2 (Oxygen) consumption~SESSION 2:~Measurement of kinematic parameters by gait analysis: the child will be requested to walk with their prosthesis and shoes at spontaneous speed and at maximal gait speed.~The second measurement of energy expenditure will be conducted using the same procedure as the first."
219162965|NCT07078721|RADIATION|Total Marrow Irradiation|\- TMI 4 Gy qd on Day -2;
219162966|NCT07078721|DRUG|Fludarabine (FLU)|Flu 30 mg/m² × 5 days on Days -6, -5, -4, -3, -2;
219162967|NCT07078721|DRUG|Melphalan (Mel)|Mel 100 mg/m² qd on Day -1.
219162968|NCT07078084|BEHAVIORAL|Laterality Training|Participants complete a structured laterality training session using a tablet-based application that presents images of hands or feet. Depending on their pain location (shoulder or knee), participants identify whether each image shows a left or right body part. The session consists of 5 one-minute training bouts with 60-second rest intervals between each. The task is designed to engage and retrain cortical body maps associated with the painful region, based on principles of graded motor imagery. Participants are instructed to prioritize accuracy over speed.
219162969|NCT07078084|OTHER|Sham (No Treatment)|Participants in this arm will complete a non-therapeutic cognitive activity by working independently on a standard word-based crossword puzzle for 10 minutes. This task is designed to match the duration and engagement level of the laterality training without influencing sensorimotor processing or cortical body maps. It serves as a sham comparator to help isolate the specific effects of the laterality training intervention.
219162970|NCT07079202|OTHER|kinetic control|Kinetic Control uses the Movement Control Rating System based on motor tests, the purpose of which is to identify the place and direction of uncontrolled movements and exercises to re-educate motor control
219162971|NCT07079202|OTHER|Conventional physical therapy.|This group received only conventional physical therapy. ( TENS, hot backs, Ultrasound,Nerve mobilization ) three sessions per week for 6 weeks.
219162972|NCT07077720|PROCEDURE|genicular nerve block|genicular nerve block with a total of 15 mL of 0.25% bupivacaine preoperatively
219162973|NCT07077720|PROCEDURE|periarticular injection|periarticular injection prepared by the surgical team containing 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin, and 110 mg bupivacaine.
219162974|NCT07077720|PROCEDURE|Addukctor canal block|Addukctor canal block with 15ml %0.25 bupivacaine
219162975|NCT07077720|PROCEDURE|Spinal Anesthesia with Bupivacaine and Morphine|Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
219162976|NCT07076576|OTHER|Yoga Training|The children in the experimental group underwent yoga training for a total of 16 sessions consisting of 45 minutes each session, 2 times a week for 8 weeks.
219162977|NCT07072403|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
219162978|NCT07077603|OTHER|A12 week, twice weekly, small group, online yoga program|A 12 week, twice weekly, small group, online yoga program
219162979|NCT07078279|DEVICE|immersive virtual reality intervention with Meta Quest 3|"The intervention consists of a rehabilitation program based on Immersive Virtual Reality (IVR), specifically designed to improve functional balance in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~The Meta Quest 3 device will be used, a standalone, wireless, high-definition immersive virtual reality system. This device allows the user to fully immerse themselves in interactive virtual environments, blocking out external stimuli and offering an immersive, motivating, and controlled experience."
219736838|NCT06002594|OTHER|group high-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
219736839|NCT06640322|OTHER|Reliability and validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain
219736840|NCT04559464|DEVICE|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
219736841|NCT04559464|DEVICE|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
219736842|NCT05882006|OTHER|gallstones|fellow up if the patients have gallstones
219736843|NCT03254641|DRUG|human chorionic gonadotropin|5000 IE times one
219736844|NCT06284798|DRUG|NNC0650-0013 A|NNC0650-0013 will be administered subcutaneously or intravenously.
219736845|NCT06284798|DRUG|Placebo|Subcutaneous administration.
219736846|NCT06446778|DEVICE|Pipeline embolization device with or without shield technique|The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
219736847|NCT04869124|DRUG|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
219736848|NCT04869124|DRUG|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
219736849|NCT04218682|BEHAVIORAL|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
219736850|NCT01122368|DRUG|micafungin|IV
219736851|NCT01122368|DRUG|placebo|IV
219736852|NCT05659251|COMBINATION_PRODUCT|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
219162980|NCT07078279|OTHER|Intervention with Conventional Balance Physical Therapy|"The Control Group (CG) will receive a standardized conventional physical therapy program focused on balance training, with the goal of improving postural and functional control in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~This treatment is based on traditional exercises recognized within pediatric physical therapy for balance training and is designed to be comparable in time, frequency, and intensity to the experimental group (virtual reality), but without the use of immersive technology."
219162981|NCT07076381|BEHAVIORAL|Brief and solutions-therapy intervention|"Parents will receive three phone counseling sessions over Zoom of 45-60 minutes each from a counselor when their baby is 4-6 weeks old; 10-12 weeks old, and 16-20 weeks old. The date and time of the sessions will be coordinated by phone or e-mail between the parent and their counselor in the week preceding the call. Following their session, parents in this group will receive a brief satisfaction survey over e-mail (Appendix E) that they will be asked to complete within 72 hours."
219162982|NCT07077785|PROCEDURE|Epidural Analgesia|After informed consent and exclusion of contraindications, an epidural catheter will be placed at the L3-L4 interspace in the sitting position using a Tuohy needle. A test dose of 2 mL lidocaine will be administered to confirm correct catheter placement under continuous monitoring of vital signs. Once cervical dilatation reaches 5 cm, 5 mL of 0.2% bupivacaine combined with 25 mcg fentanyl will be administered via the epidural catheter. Additional boluses will be given as needed based on pain assessment. The catheter will be removed 24 hours postpartum.
219162983|NCT07078552|OTHER|ptosis|no intervention
219162984|NCT07078409|BEHAVIORAL|Nudge|When the clinician who ordered the imaging that led to randomization receives the test results, a pre-checked referral order to gynecologic oncology for surgical evaluation will appear in the EHR alongside a brief educational explanation. This will constitute the opt-out default referral order (Figure 3). Clinicians will have the option to unclick the referral to opt out and will be asked to indicate the reason from a pre-populated list of choices; if they do not opt out, the referral to gynecologic oncology will proceed. Imaging findings and referral will be communicated to the patient in keeping with the clinician's usual practice. In keeping with routine practice, referred patients will be contacted by gynecologic oncology's new patient coordinators within 72 hours and offered an appointment within 2 weeks at their preferred location.
219162985|NCT07078799|PROCEDURE|LASIK|Wavefront-guided LASIK is being performed in one eye and Ray-tracing guided LASIK is being performed in the fellow eye
219162986|NCT07078799|PROCEDURE|LASIK|Ray-tracing guided LASIK is being performed in one eye and Wavefront-guided LASIK is being performed in the fellow eye.
219162987|NCT07078149|DEVICE|Robotic-assisted TKA (RATKA).|RATKA was performed using the ROSA® Knee System.
219162988|NCT07078149|PROCEDURE|Conventional manual TKA (mTKA)|mTKA was performed without robot assistance.
219162989|NCT07069881|DEVICE|Sonic-Activated Irrigation|Sonic-activated irrigation was performed using the polymer tip (Eddy™, VDW, Germany) activated by an airscaler handpiece.
219162990|NCT07069881|DEVICE|Passive Ultrasonic Irrigation|Passive ultrasonic irrigation was performed using the ultrasonic tip (ACTEON, France) attached to an ultrasonic device (P5 Newton™, ACTEON, France)
219162991|NCT07076823|DRUG|Canagliflozin|Low-dose cohort: 100 mg qd, taken before the first meal of the day. High-dose cohort: Starting dose of 100 mg qd for 1 week. If tolerated, the dose will escalate to 300 mg qd, taken before the first meal of the day.
219162992|NCT07076368|DRUG|Ropivacaine + Fentanyl|A standard epidural admixture - 0.1% Ropivacaine + 2 mcg/ml fentanyl - will be used.
219162993|NCT07077668|DRUG|A sterile aqueous solution of RAG - 17 preparation (sodium salt)|Patients who meet the inclusion and exclusion criteria are required to come to the hospital at the following time points to complete the intrathecal bolus injection of RAG - 17 for 150 mg: baseline, 60 ± 3 days, 120 ± 3 days, 180 ± 3 days, 240 ± 3 days, 300 ± 3 days, 360 ± 3 days, 450 ± 3 days, 540 ± 3 days.
219162994|NCT07078201|DRUG|Dexmedetomidine|patients received 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL diluted in 12.5 ml preservative-free normal saline, 0.5 ml had been withdrawn).
219162995|NCT07078201|DRUG|fentanyl|patients received 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
219162996|NCT07077772|DRUG|Furosemide intravenous titration based on natriuresis|"Furosemide IV, 20 mg starting dose, titrated every 6 hours based on urinary sodium measured by the LAQUAtwin NA-11 device.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~If natriuresis is \< 70 mmol/L, the furosemide dose will be doubled, with a maximum limit of 200 mg per bolus.~If natriuresis is ≥ 70 mmol/L, the current dose will be maintained.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
219162997|NCT07077772|DRUG|Furosemide intravenous titration based on clinical examination|"Furosemide IV, 20 mg starting dose, titrated every 6 hours clinical evaluation.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~The furosemide dosage will be adjusted based on urine output with a maximum bolus dose of 200 mg. Dose adjustments will be reassessed every 6 hours throughout the study period.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
219162998|NCT07077304|OTHER|observational study|observational study
219736853|NCT05659251|PROCEDURE|Esophagectomy|"Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon."
219736854|NCT05659251|OTHER|sample|"Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery."
219736855|NCT05635409|BIOLOGICAL|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
219736856|NCT06290011|DEVICE|Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
219736857|NCT04592562|DEVICE|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
219736858|NCT06225531|OTHER|Autobiographical Memory Based Intervention|"The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning"
219736859|NCT05974111|DIAGNOSTIC_TEST|blood sampling|At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
219736860|NCT05821088|PROCEDURE|Biopsy|Undergo tissue biopsy
219736861|NCT05821088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219736862|NCT05821088|DRUG|Carboplatin|Given IV
219736863|NCT05821088|PROCEDURE|Computed Tomography|Undergo CT
219736864|NCT05821088|DRUG|Etoposide|Given IV
219736865|NCT05821088|DRUG|Ifosfamide|Given IV
219736866|NCT05821088|DRUG|Lenalidomide|Given PO
219736867|NCT05821088|PROCEDURE|Positron Emission Tomography|Undergo PET
219736868|NCT05821088|BIOLOGICAL|Tafasitamab|Given IV
219736869|NCT06199882|DRUG|SBRT Sequential Surufatinib Combined With Immunotherapy|"1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1\) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
219736870|NCT00940121|DRUG|mirabegron|oral tablet
219736871|NCT00940121|DRUG|mirabegron|IV solution
219736872|NCT05522972|BEHAVIORAL|Video Game Vision Training|A new approach for improving amblyopic vision using video games
219736873|NCT05522972|BEHAVIORAL|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
219162999|NCT07076693|PROCEDURE|Radiotherapy or Surgery|Metastatic lesions were treated with surgical resection or radiotherapy. Surgical duration was determined by investigator assessment and metastatic or primary lesions were resected with palliative intent. Radiation dose and fractionation are 30\~50Gy. Radiation dose, fractionation regimen, and treatment sites for metastatic lesions were determined at the investigator's discretion based on clinical indications.
219163000|NCT07076693|DRUG|Standard Medical Therapy|Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or ivonescimab.
219163001|NCT07076550|DRUG|[225Ac]Ac-A9-3408|Administered IV
219163002|NCT07076550|DIAGNOSTIC_TEST|[68Ga]Ga-A9T-3202|Administered IV
219163003|NCT07077356|BIOLOGICAL|HBV mRNA vaccine|HBV mRNA vaccine
219163004|NCT06215664|BEHAVIORAL|Singularities Game|Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.
219163005|NCT06215664|BEHAVIORAL|Food4Thought|Food4Thought is an attention control condition in which we provide participants with similar amounts of research team contact and program contact as the intervention. Participants will play the game Pick Your Plate! A Global Guide to Nutrition, developed by the Smithsonian Science Education Center. Participants are instructed to build healthy meals using cuisine from around the world while ensuring they stick to a budget and meet all their nutritional needs. Food4Thought will be delivered via Qualtrics.
219163006|NCT07076667|OTHER|Benson's relaxation technique|effects of Benson's relaxation technique 5 days per week for 45 minutes for 8 weeks
219163007|NCT07076667|OTHER|Tai Chi|Tai Chi 5 days per week for 45 minutes for 8 weeks
219163008|NCT07076225|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
219163009|NCT07076225|DRUG|Sitafloxacin (S)|200mg once daily
219163010|NCT07076225|DRUG|Linezolid (L)|600mg once daily
219163011|NCT07076225|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
219163012|NCT07076225|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
219163013|NCT07076225|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
219163014|NCT07076225|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
219163015|NCT07077408|OTHER|iCanCope-NF Youth app|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth.
219163016|NCT07077408|OTHER|iCanCope-NF Youth app + CM|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth. In addition to the standardized orientation and push notifications, this app will also allow users to earn incentives aligned with their program engagement.
219163017|NCT05774483|PROCEDURE|Sentinel Node Biopsy|The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
219163018|NCT05774483|PROCEDURE|Limited Elective Neck Dissection|Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
219163019|NCT07078032|DIAGNOSTIC_TEST|Prediction Model Arm|Lung cancer risk stratification via prediction model integrating: advanced age, lung cancer family history, personal cancer history, childhood coal exposure, asthma history, and food allergy history. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
219163020|NCT07078032|DIAGNOSTIC_TEST|Standard Screening Arm|Participants are screened based on NCCN guideline criteria. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
219163021|NCT07078162|OTHER|Photogramety Orbital Prosthesis|Using 2D photographs to abtain 3D model of orbital defect anatomy
219163022|NCT07078162|OTHER|Conventional impression prosthesis|Conventional impression to an orbital defect then scaning the impression using desktop scanner
219163023|NCT04567615|BIOLOGICAL|Nivolumab|Specified dose on specified days
219163024|NCT04567615|BIOLOGICAL|Relatlimab|Specified dose on specified days
219163025|NCT06907485|DRUG|Aminolevulinic acid hydrochloride|Pediatric patients diagnosed with a new or recurrent brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal will receive aminolevulinic acid hydrochloride prior to surgery for resection of the brain tumor.
219163026|NCT01959698|DRUG|Carboplatin|Given IV
219163027|NCT01959698|DRUG|Carfilzomib|Given IV
219163028|NCT01959698|DRUG|Etoposide|Given IV
219163029|NCT01959698|DRUG|Ifosfamide|Given IV
219163030|NCT01959698|OTHER|Laboratory Biomarker Analysis|Correlative studies
219163031|NCT01959698|OTHER|Pharmacological Study|Correlative studies
219163032|NCT01959698|BIOLOGICAL|Rituximab|Given IV
219163033|NCT05226780|DRUG|NBI-921352|Administered orally
219163034|NCT06912087|DRUG|Zanzalintinib|Experimental receptor tyrosine kinases (RTKs)
219163035|NCT06912087|DRUG|Cetuximab|Food and Drug Administration (FDA) approved monoclonal antibody directed against the epidermal growth factor (EGFR).
219163036|NCT06912087|DRUG|Pembrolizumab|FDA approved monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1)
219163037|NCT03996239|BEHAVIORAL|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
219163038|NCT03996239|OTHER|plasma samples|Plasma samples will be obtained at baseline.
219163039|NCT03996239|OTHER|blood draw|fasting blood
219163040|NCT06919692|BEHAVIORAL|Left lateral recumbent positioning|Left-lateral position is the recommended position of resting in pregnancy. The participants in the intervention group will be advised to practice this position with an intermittent 10-minute stretching after every hour of resting, with no more than 4-hours of this intervention per day.
219163041|NCT06915194|BEHAVIORAL|Text message|Participants receive a text message encouraging glycemic screening
219163042|NCT06915194|BEHAVIORAL|Patient portal message|Participants receive a patient portal message encouraging glycemic screening
219163043|NCT06915194|BEHAVIORAL|Mailed letter|Participants receive a mailed letter encouraging glycemic screening
219163044|NCT07077200|OTHER|Intranasal dexmedetomidine|"This intervention is distinguished by the use of intranasal dexmedetomidine at a standardized dose of 3 mcg/kg, administered non-invasively upon the child's arrival in the preoperative holding area. Unlike other pharmacological methods that often require intravenous access or oral administration, this approach minimizes procedural stress and discomfort, which is particularly advantageous in pediatric populations.~Dexmedetomidine is a selective alpha-2 adrenergic agonist known for its anxiolytic, sedative, and analgesic properties, without causing significant respiratory depression-a key concern with agents like benzodiazepines or opioids. Its intranasal delivery provides a rapid onset of action while maintaining hemodynamic stability, which is critical during the preoperative period.~This intervention is also notable for its comparison with a non-pharmacological strategy-short video viewing-making the study unique in evaluating the relative efficacy of a low-risk pharmacologic option"
219163045|NCT06754124|OTHER|Pilates Group|Pilates training will be given individually for approximately 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all participants will be taught the basic elements of Pilates in 1 session. Pilates training will begin with standing exercises for warming up and centering in the supine position. Training will continue with upper and lower extremity movements. The intensity of the exercises will be increased by using different positions and elastic bands. Stretching exercises and posture exercises will be used during the cool-down period. All exercises will start with 10 repetitions and will be increased to 20 later. Each movement will be shown by the physiotherapist first so that the patients can do the movements correctly. The movements that the patients cannot do will be modified appropriately and applied.
219163046|NCT06754124|OTHER|Control Group|No exercise will be allowed for 8 weeks and routine medication will continue.
219163047|NCT04914247|DRUG|Selexipag|
219736874|NCT05522972|BEHAVIORAL|Occlusion Therapy|Conventional treatment for amblyopia
219163048|NCT06347939|DIAGNOSTIC_TEST|Mediastinal lymph nodes cryobiopsies|EBUS Mediastinal lymph nodes cryobiopsies
219163049|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
219163050|NCT07077928|DEVICE|Pacemaker upgrade|CRT upgrade
219163051|NCT05755672|DRUG|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
219163052|NCT05755672|PROCEDURE|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
219163053|NCT05755672|PROCEDURE|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
219163054|NCT05755672|PROCEDURE|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
219163055|NCT00572169|DRUG|Velcade|Will be given in central venous catheter
219163056|NCT00572169|DRUG|Thalidomide|Capsule taken by mouth
219736875|NCT04635280|DEVICE|any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
219736876|NCT06640608|BEHAVIORAL|ICBT - Internet Based Cognitive Behavioral Therapy|The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
219736877|NCT06641505|BEHAVIORAL|Guiding rehydration|Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
219736878|NCT04082273|DEVICE|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
219736879|NCT04082273|OTHER|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
219736880|NCT06642233|DIAGNOSTIC_TEST|Socio-demographic survey|Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
219736881|NCT06642233|DIAGNOSTIC_TEST|Visual Analogue Scale|VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
219736882|NCT06642233|DIAGNOSTIC_TEST|The World Health Organization Quality-of-Life Scale-BREF questionnaire|The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
219736883|NCT06642233|DIAGNOSTIC_TEST|The International Physical Activity Questionnaire|The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
219736884|NCT06642233|DIAGNOSTIC_TEST|The Neck Disability Index questionnaire|The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
219736885|NCT06642233|DEVICE|Body composition analysis using TANITA device|"TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA."
219736886|NCT06642233|DIAGNOSTIC_TEST|Cervical spine AROM (Active range of motion)|"Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction."
219736887|NCT06642233|DIAGNOSTIC_TEST|Sagittal plane UCS AROM (Upper cervical spine active range of motion)|Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
219736888|NCT06642233|DIAGNOSTIC_TEST|Flexion-Rotation Test|The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
219736889|NCT06642233|DIAGNOSTIC_TEST|Sidebending-Rotation Test|The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
219736890|NCT06642233|DIAGNOSTIC_TEST|Axial rotation test C0-C2|The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
219736891|NCT06642233|DIAGNOSTIC_TEST|Tilting test C0-C1 and C2-C3|The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
219736892|NCT06642233|DIAGNOSTIC_TEST|Craniocervical flexion test|The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
219736893|NCT06642233|DIAGNOSTIC_TEST|Craniovertebral angle|The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
219736894|NCT06643780|DRUG|Denosumab|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
219736895|NCT06643780|DRUG|Zolendronic Acid|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
219736896|NCT06402474|PROCEDURE|sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
219736897|NCT06542341|DEVICE|decoLITE (TN2037)|Red/Near infra red light therapy
219736898|NCT02594956|DEVICE|no nasogastric tube|
219736899|NCT02594956|DEVICE|nasogastric tube|
219736900|NCT06563752|OTHER|Participants will use 3D glasses to view VR educational information|"Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources."
219163057|NCT00572169|DRUG|Dexamethasone|A pill taken by mouth
219163058|NCT00572169|DRUG|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
219163059|NCT00572169|DRUG|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
219163060|NCT00572169|DRUG|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
219163061|NCT00572169|DRUG|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
219163062|NCT04263025|BIOLOGICAL|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
219163063|NCT04263025|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
219163064|NCT04927819|DEVICE|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
219163065|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
219163066|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
219163067|NCT05461352|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
219163068|NCT05461352|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
219163069|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
219163070|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
219163071|NCT04592198|DRUG|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
219163072|NCT05834920|DEVICE|Transcranial pulse stimulation (TPS)|Participants will be treated with the TPS device NEUROLITH (Storz Medical AG). Treatments will be administered for up to 12 sessions within 4 weeks, each session consisting of 6000 TPS pulses of 0.2 mJ/mm².
219163073|NCT05834920|DEVICE|Neurofeedback|Participants will engage in a neurofeedback game designed to increase the ratio of theta/beta frequency bands in electroencephalography measurement. This intervention will be delivered for up to 12 sessions within 4 weeks.
219163074|NCT06780696|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
219163075|NCT06475677|DEVICE|OrthoCor Advanced System|The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
219163076|NCT06789783|DRUG|Lithium Carbonate Capsule|10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
219163077|NCT02314481|DRUG|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
219163078|NCT02314481|DRUG|Vemurafenib|Film coated tablet
219163079|NCT02314481|DRUG|Alectinib|capsule
219163080|NCT02314481|DRUG|Trastuzumab emtansine|Powder for concentrate for solution for infusion
219163081|NCT02950051|DRUG|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
219163082|NCT02950051|DRUG|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
219163083|NCT02950051|BIOLOGICAL|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
219163084|NCT02950051|DRUG|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
219236670|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
219236671|NCT01863082|OTHER|exercise|practice of physical exercise
219236672|NCT01913444|DRUG|Recombinant Antithrombin|
219236673|NCT05722756|OTHER|craniosacral therapy|subtle form of applied touch, type of osteopathy
219236674|NCT02637999|DRUG|PEG IFN alfa-2a|
219236675|NCT02637999|DRUG|Myrcludex B|
219236676|NCT02271841|DEVICE|PVI|Pleth Variability Index
219236677|NCT03727334|BEHAVIORAL|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
219236678|NCT04585048|BEHAVIORAL|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
219236679|NCT03799965|OTHER|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
219236680|NCT03799965|OTHER|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
219236681|NCT00489697|DEVICE|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
219163085|NCT02950051|DRUG|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
219163086|NCT02950051|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
219163087|NCT02950051|DRUG|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
219163088|NCT06395181|BEHAVIORAL|Whole Food Plant-Based Diet|A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
219163089|NCT03012841|DEVICE|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
219163090|NCT05665725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219163091|NCT05665725|PROCEDURE|Computed Tomography|Undergo CT scan
219163092|NCT05665725|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219163093|NCT05665725|BIOLOGICAL|Siltuximab|Given IV
219163094|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
219163095|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
219163096|NCT05609552|COMBINATION_PRODUCT|18F-Pretomanid PET/CT|A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
219163097|NCT05215756|DEVICE|transcutaneous vagal nerve stimulation|The tVNS device will be attached to the left concha of the ear to stimulate the auricular branch of the vagal nerve. Each stimulation will last for 2 minutes.
219163098|NCT04921501|DEVICE|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
219163099|NCT04921501|DEVICE|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
219163100|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
219163101|NCT05423106|DRUG|Placebo|Placebo will be administered as an oral formulation.
219163102|NCT05423106|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
219163103|NCT05423106|DRUG|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
219163104|NCT05423106|DRUG|Entecavir (ETV)|ETV tablet will be administered orally.
219163105|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
219163106|NCT00643656|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
219163107|NCT00643656|DRUG|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
219163108|NCT01688076|PROCEDURE|Botulinum Toxin A|Forehead will be injected with Botox.
219163109|NCT06783192|DRUG|MK-8527|MK-8527 capsule taken by mouth
219163110|NCT06783192|DRUG|LNG/EE|LNG/EE combination tablet taken by mouth.
219163111|NCT06286293|OTHER|Neuropsychological assessment, driving simulator task|Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
219163112|NCT06791447|OTHER|AI-assisted Predictive Model for Dialysis Outcomes|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, dialysis treatment details, and clinical observations, to predict outcomes for dialysis patients. The model employs deep learning algorithms to predict mortality risk, intermediate outcomes such as anemia, blood pressure control, nutrition, and calcium-phosphate metabolism, and helps identify early signs of deterioration. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting patient outcomes and optimizing treatment strategies to improve overall health and survival rates for dialysis patients.
219163113|NCT06785077|PROCEDURE|buccal cells|custom myeloid gene panel (Myelo-Panel) to identify germline mutations predisposing to cancer development (Thermo Fisher Scientific)
219163114|NCT06785077|PROCEDURE|bone marrow cells|"Bone marrow cells (optional, for comparison, only in a limited number of patients):~* morphological analysis~* immunophenotype~* cytogenetics/FISH~* analysis of CHIP by custom gene panel and high sensitivity NGS"
219163115|NCT06785077|PROCEDURE|peripheral blood cells|analysis of CHIP by custom gene panel and high sensitivity NGS
219163116|NCT06785077|PROCEDURE|bone marrow biopsy|"Bone marrow biopsy (optional, for comparison, only in a limited number of patients):~* histology~* immunohistochemistry"
219163117|NCT04491968|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
219163118|NCT04491968|OTHER|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
219163119|NCT03102125|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
219163120|NCT04646200|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
219736901|NCT06563752|OTHER|routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
219736902|NCT05431179|DRUG|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
219736903|NCT05431179|DRUG|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
219736904|NCT05431179|DRUG|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
219736905|NCT05383898|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
219736906|NCT00002011|DRUG|Methoxsalen|
219736907|NCT01774539|OTHER|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
219736908|NCT00948207|BEHAVIORAL|My Living Story|"Components include:~1\. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2\) Edited transcript is delivered in a word format on...;~3\) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4\) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
219736909|NCT00948207|BEHAVIORAL|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
219736910|NCT02990143|PROCEDURE|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
219736911|NCT02431520|PROCEDURE|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
219736912|NCT02431520|PROCEDURE|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
219736913|NCT02384343|DRUG|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
219736914|NCT02384343|DRUG|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
219736915|NCT00004061|BIOLOGICAL|filgrastim|
219736916|NCT00004061|BIOLOGICAL|palifermin|
219736917|NCT00004061|DRUG|cyclophosphamide|
219736918|NCT00004061|DRUG|etoposide|
219736919|NCT00004061|DRUG|ifosfamide|
219736920|NCT00004061|PROCEDURE|peripheral blood stem cell transplantation|
219736921|NCT00004061|PROCEDURE|quality-of-life assessment|
219736922|NCT00004061|RADIATION|radiation therapy|
219736923|NCT02571244|BEHAVIORAL|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
219736924|NCT01593111|OTHER|Environmental Intervention|Home-based environmental intervention
219736925|NCT03565588|BEHAVIORAL|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
219736926|NCT03565588|BEHAVIORAL|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
219736927|NCT06226415|BEHAVIORAL|Rehabilitation therapy|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
219236682|NCT04909099|OTHER|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
219736928|NCT06226415|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219736929|NCT06226415|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
219736930|NCT03997838|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
219736931|NCT03997838|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
219736932|NCT00483509|DRUG|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
219736933|NCT00483509|DRUG|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
219736934|NCT06235970|DEVICE|Transcranial electrical stimulation (tES) including SHAM|Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
219736935|NCT04298333|DRUG|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
219736936|NCT01696214|DRUG|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
219736937|NCT01696214|DRUG|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
219736938|NCT01696214|DRUG|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
219736939|NCT01696214|DRUG|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
219736940|NCT01687205|DRUG|1% Tenofovir Gel|
219736941|NCT03600103|BEHAVIORAL|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
219736942|NCT00007943|DRUG|gemcitabine hydrochloride|
219736943|NCT01775410|DEVICE|Wolverine System to perform atherectomy|
219736944|NCT03847012|OTHER|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
219736945|NCT03822819|DIETARY_SUPPLEMENT|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
219736946|NCT03822819|DIETARY_SUPPLEMENT|placebo capsules|Daily uptake of placebo capsule for three weeks
219736947|NCT02768246|DEVICE|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
219736948|NCT02768246|DEVICE|Face Mask|Classic face mask
219736949|NCT03469609|OTHER|mucous fistula refeeding|Transfer of infants' own stool
219163121|NCT04646200|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
219163122|NCT05096819|OTHER|Patients Using the 6MWT App in the Community|Patients under the care of the cardiovascular clinics in Oxford, who used the Timed Walk app to perform 6MWT in their community during the CODIV19 pandemic period
219163123|NCT05096819|OTHER|Volunteers for 6MWT distance comparison|Volunteers (cardiac patients and hospital staff) who performed 10 6MWT using the TimedWalk app and a trundle wheel simultaneously. Five tests were performed following instructions and 5 were performed introducing errors. Aim is to measure app accuracy under different circumstances.
219163124|NCT05479994|DRUG|BGB-11417|Administered orally
219163125|NCT06382220|DRUG|Bupivacain|drug injection
219163126|NCT00404196|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
219163127|NCT06318507|COMBINATION_PRODUCT|Fecal microbial diversity|Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
219163128|NCT04373226|BEHAVIORAL|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
219163129|NCT05690386|BIOLOGICAL|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
219163130|NCT05690386|DRUG|Somatropin|Once-daily subcutaneous injection of Somatropin
219163131|NCT06782516|DEVICE|System of Care - combination of algorithm and Brief Contact Intervention|Case managers see the Native-RISE algorithm classification and Clinical Providers receive a risk notification. A resource card is provided to the participant.
219736950|NCT05938816|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (\~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
219736951|NCT05938816|BEHAVIORAL|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
219736952|NCT01642667|DRUG|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
219736953|NCT01642667|DRUG|Placebo|
219736954|NCT05875831|BEHAVIORAL|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
219736955|NCT05875831|DIAGNOSTIC_TEST|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
219736956|NCT05856461|PROCEDURE|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
219736957|NCT05856461|PROCEDURE|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
219736958|NCT05856461|PROCEDURE|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
219736959|NCT02572687|DRUG|Ramucirumab|Administered IV
219736960|NCT02572687|DRUG|MEDI4736|Administered IV
219736961|NCT01080547|PROCEDURE|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
219736962|NCT01080547|DRUG|XELOX Chemotherapy|XELOX chemotherapy
219736963|NCT01080547|DRUG|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
219736964|NCT01080547|OTHER|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
219736965|NCT01080547|OTHER|Conventional Perioperative Treatment|Conventional treatment during perioperation period
219736966|NCT01080547|PROCEDURE|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
219736967|NCT02355509|DRUG|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
219736968|NCT02355509|DRUG|Placebo|Placebo pills are given instead of acarbose in this group
219736969|NCT05984862|DEVICE|Bandage|To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
219736970|NCT06523153|BIOLOGICAL|VYD2311|Monoclonal antibody
219736971|NCT06523153|OTHER|Placebo|Matching Placebo
219736972|NCT02338557|DEVICE|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
219163132|NCT06782516|BEHAVIORAL|Active Comparator - Provider notification of risk status|Clinical Providers receive a risk notification and a resource card is provided to the participant.
219163133|NCT06558201|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
219163134|NCT06789575|DRUG|Bupivacaine|the patients will receive the content of a syringe (10 ml of bupivacaine 0.25%)
219163135|NCT06789575|DRUG|Adrenaline|the patients will receive the content of a syringe 15 μg adrenaline
219163136|NCT06789575|DRUG|Lidocaine (drug)|the patients will receive the content of a syringe 70 ml Lidocaine .
219163137|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
219163138|NCT06785779|OTHER|Secukinmab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
219163139|NCT05938101|BEHAVIORAL|Behavioral therapy|Behavioral therapy and psychotherapy
219163140|NCT04607044|DEVICE|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
219163141|NCT05968677|DIETARY_SUPPLEMENT|FSMP|Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
219163142|NCT05968677|OTHER|Nutritional counseling|Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
219163143|NCT04955717|OTHER|Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert|Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
219736973|NCT02338557|DEVICE|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
219736974|NCT00000603|PROCEDURE|stem cell transplantation|
219736975|NCT06571578|DEVICE|Threshold Inspiratory muscle trainer|threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
219736976|NCT06571578|OTHER|posture correction exercises|"conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles"
219736977|NCT03818074|DEVICE|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
219163144|NCT05695053|DEVICE|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
219163145|NCT05695053|OTHER|Placebo|Placebo
219163146|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan, to use with individuals with Down syndrome, that combines two treatment approaches: Cycles Phonological Remediation Approach and Script training, while adapting each to prioritize use of practice words with low vowels given research findings that the low vowels /ɑ/ as in 'hot' and /æ/as in 'hat' are less intelligible than the high vowels /i/ as in 'heat' and /u/ as in 'boot'; also, vowel acoustic analyses that revealed word-intelligibility to improve when the production of the low vowels /ɑ/ and /æ/ had more distinctive second formants/vocal tract resonances (a measure that is associated with tongue front-back movement). Each intervention session will include 40-50 minutes of the adapted 'Cycles Phonological Remediation Approach' focusing on articulatory/phonological training at the syllable/word level, and 10-20 minutes of the adapted Script program for motor training at the sentence level.
219163147|NCT05514769|PROCEDURE|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
219736978|NCT01755403|DRUG|Benznidazole|
219736979|NCT05984992|DRUG|SRN-001|siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
219736980|NCT05984992|DRUG|Placebo|0.9% Sodium Chloride(Normal saline)
219736981|NCT03175588|OTHER|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
219736982|NCT00134498|DRUG|torcetrapib/atorvastatin|
219736983|NCT00134498|DRUG|atorvastatin|
219736984|NCT00452530|DRUG|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
219736985|NCT00452530|DRUG|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
219736986|NCT00452530|DRUG|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
219736987|NCT00452530|DRUG|Apixaban-matching placebo|Oral tablet administered twice daily
219163148|NCT06095050|DEVICE|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
219163149|NCT06095050|OTHER|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
219163150|NCT05403801|BEHAVIORAL|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
219163151|NCT05091476|DEVICE|OPTiC System|OPTiC System procedure
219163152|NCT06829173|DRUG|XRD-0394|Administered orally; small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-PK.
219163153|NCT06829173|RADIATION|Radiation Therapy|"For Cohort A and Cohort B, the neoadjuvant boost radiation dose is 1400cGy delivered over 7 fractions, and the adjuvant radiation dose is 5000cGy delivered over 25 fractions for a total dose of 6400cGy over 32 fractions, accounting for the treatment break between boost and adjuvant RT.~For Cohort C, the radiation dose is 3500cGy delivered over 10 fractions."
219163154|NCT06829173|PROCEDURE|Surgical Resection|Resection of tumor tissue.
219163155|NCT04619680|DRUG|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
219163156|NCT04619680|DRUG|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
219163157|NCT06216080|OTHER|D-FF-OCT analysis of CVC|Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
219736988|NCT02003157|PROCEDURE|hypnosis during embryo transfer or usual transfer procedure|
219736989|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
219163158|NCT06823362|DRUG|Pentoxifylline|400 mg
219163159|NCT06823362|DRUG|Pentoxifylline|400 mg
219163160|NCT06168162|OTHER|titated PEEP to best static compliance|the Intraoperative PEEP will be titrated to best static compliance for each patient
219163161|NCT06835374|PROCEDURE|Per oral endoscopy myotomy (Per oral endoscopy myotomy)|POEM is the procedure to reduce the symptoms of dysphagia, regurgitation.
219163162|NCT06835374|PROCEDURE|Endoscopy procedure|Endoscopy procedure is required to rule out type of reflux disease
219163163|NCT06832462|BEHAVIORAL|Acceptance and Commitment Therapy|"A one-day Acceptance and Commitment Therapy (ACT) will be held with three (3) sessions. The sessions start with ice breaking, and follow by,~The first session will build a therapeutic relationship and icebreaking, using animated video (unwanted guest) presentations to explain how ACT can help manage issues.~The second session will focus on acceptance and defusion concepts, emphasizing the importance of letting go of unproductive emotion-control techniques by using animated video (response ability)~The third session, 'Show Up', will increase awareness of undesirable thoughts and feelings through structured mindfulness exercises and observing surroundings. The therapist will explain the metaphor of dropping the anchor and emphasize the"
219163164|NCT03888989|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
219736990|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
219736991|NCT02893436|PROCEDURE|Surgery with tracheal intubation curarisation|
219736992|NCT00163852|DRUG|Normal saline IV, salt tablets|
219736993|NCT01512173|DRUG|propranolol gel|Topical administration twice daily
219736994|NCT01512173|DRUG|Placebo|Topical administration twice daily
219736995|NCT02239484|DRUG|Tadalafil|
219736996|NCT02239484|DRUG|Tamsulosin|
219736997|NCT02239484|DRUG|Tadalafil + Tamsulosin|
219736998|NCT00492674|DEVICE|APOS biomechanical gait system|
219736999|NCT00492674|PROCEDURE|Physical Therapy|
219737000|NCT01276418|DEVICE|CO2 laser|Ablation and coagulation of soft tissue
219737001|NCT01618708|DEVICE|Synvisc-One (hylan G-F 20)|6-mL IA injection
219737002|NCT01618708|DEVICE|Placebo|6 mL injection of phosphate buffered saline
219737003|NCT03844412|DRUG|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
219737004|NCT03844412|DRUG|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
219737005|NCT03844412|DRUG|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
219737006|NCT03844412|DRUG|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
219737007|NCT05362136|PROCEDURE|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
219737008|NCT05362136|PROCEDURE|no perforation of the sinus floor|standard procedure for sinus floor elevation
219737009|NCT05686252|OTHER|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
219737010|NCT03339765|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
219737011|NCT06626997|DIETARY_SUPPLEMENT|Kombucha tea|"During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2)."
219737012|NCT02501785|BEHAVIORAL|Caregiver Reaction Assessment (CRA)|
219737013|NCT02501785|BEHAVIORAL|The Caregiver Quality of Life - Cancer (CQOLC)|
219737014|NCT02872688|OTHER|GanedenBC30|
219737015|NCT02438085|OTHER|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
219737016|NCT04146207|DRUG|SHR0302|SHR0302 po QD
219737017|NCT04146207|DRUG|Prednisone|Prednisone 1mg/kg/d po
219737018|NCT03319654|DIAGNOSTIC_TEST|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
219737019|NCT04128228|BEHAVIORAL|8-week outpatient treatment|Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
219737020|NCT05453357|DEVICE|iGlucose|The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
219737021|NCT00000738|DRUG|Nimodipine|
219737022|NCT00000738|DRUG|Zidovudine|
219737023|NCT03114644|OTHER|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
219737024|NCT06509074|DRUG|Beta blocker|Pragmatic design. Any beta-blocker with alpha or NO activity may be used
219737025|NCT05358912|DRUG|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
219737026|NCT05358912|DRUG|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
219737027|NCT05358912|PROCEDURE|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
219236683|NCT03335722|BEHAVIORAL|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
219236684|NCT03335722|DEVICE|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
219236685|NCT03335722|DEVICE|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
219236686|NCT04984980|DRUG|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
219236687|NCT02291861|DRUG|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
219236688|NCT02291861|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
219236689|NCT05444777|DRUG|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
219236690|NCT02435498|OTHER|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
219236691|NCT02435498|OTHER|Video|The online video will contain the same information within the website.
219236692|NCT02435498|OTHER|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
219236693|NCT01567176|BIOLOGICAL|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
219236694|NCT03336749|BEHAVIORAL|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
219737028|NCT05358912|PROCEDURE|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
219737029|NCT05358912|OTHER|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
219737030|NCT06466252|BEHAVIORAL|Psychometric Group|There are no interventions
219737031|NCT04056637|OTHER|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
219737032|NCT04056637|DEVICE|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
219236695|NCT03336749|OTHER|Control group|Traditional task-specific training
219236696|NCT06480396|DIAGNOSTIC_TEST|High-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
219236697|NCT06480396|DIAGNOSTIC_TEST|Lower-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
219236698|NCT06365177|OTHER|Physical consultation|"The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation."
219737033|NCT05493345|BEHAVIORAL|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
219737034|NCT06465602|DRUG|Nicotinamide|The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
219737035|NCT06465602|DRUG|Placebo|The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
219737036|NCT00829478|BEHAVIORAL|Decision Aid for Atrial Fibrillation|Single contact educational session
219737037|NCT00829478|OTHER|Usual Care|Usual Care
219163165|NCT06622226|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally.
219163166|NCT06785727|DRUG|Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)|"The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual)."
219163167|NCT06832657|DRUG|JMKX003948 Ophthalmic Suspension|JMKX003948 Ophthalmic Suspension with formulation 1% (15 mg/1.5 mL), 2% (30 mg/1.5 mL), 3% (45 mg/1.5 mL), 5% (75 mg/1.5 mL)
219163168|NCT06832657|DRUG|Placebo|JMKX003948 Ophthalmic Suspension placebo
219163169|NCT04714840|OTHER|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
219163170|NCT04714840|OTHER|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
219163171|NCT04714840|OTHER|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
219163172|NCT03224767|DRUG|Vemurafenib|Given PO
219163173|NCT03224767|DRUG|Cobimetinib|Given PO
219163174|NCT03224767|OTHER|Laboratory Biomarker Analysis|Correlative studies
219163175|NCT03224767|OTHER|Quality-of-Life Assessment|Ancillary studies
219163176|NCT06566040|DEVICE|Wheelchair|Wheelchairs provided to hospital inpatients
219163177|NCT05903794|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
219163178|NCT06834763|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth. PSP provides site-specific placement success prediction scores \[i.e., client's likelihood of success per placement based on machine learning models\] for each youth.
219163179|NCT05710263|PROCEDURE|bariatric embolization|bariatric or left gastric artery embolization
219163180|NCT06270758|DIAGNOSTIC_TEST|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
219163181|NCT06833996|DRUG|Bakuchiol|Apply bakuchiol cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
219163182|NCT06833996|DRUG|Vehicle|Apply vehicle cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
219163183|NCT06835686|BEHAVIORAL|Health Literacy and Culturally Tailored Materials|Participants will receive health literacy-appropriate written information on community resources and weight management
219163184|NCT06835686|BEHAVIORAL|Community-Engaged Health Coaching and Navigation|Participants will receive virtual coaching sessions over a 6-month period from trained Community Health Workers (CHWs). Coaching will include culturally competent information and strategies for weight management, and linking participants to community wellness resources identified in Community Asset Mapping (see below). Coaches will also remotely monitor patients' weight loss and physical activity via online portals to provide patients with tailored support during coaching sessions.
219163185|NCT06835686|BEHAVIORAL|Self-Monitoring and Remote Patient Monitoring of weight and physical activity|Participants will self-monitor weight and physical activity during the 6-month health coaching protocol using a cellular-connected digital weight scale and a Bluetooth-connected wrist-worn fitness tracking device (e.g., Fitbit). Participants will be instructed to weigh themselves and wear a fitness tracker (e.g., Fitbit) daily. Health coaches will remotely monitor weight and physical activity data logged by these devices to incorporate into health coaching sessions.
219163186|NCT06835686|OTHER|Community Asset Mapping (CAM)|The CHW from each intervention community clinic will convene a team of community members, including but not limited to CONNECT participants, that will meet regularly to identify and describe community assets that enable, support, and promote healthy lifestyles related to weight loss and management (e.g., healthy eating and physical activity resources). Community teams will be supported to design and implement Community Action Projects to promote the utilization of community resources identified in the map.
219163187|NCT06835686|OTHER|Primary Care Provider Training|Education sessions will be provided to FQHC providers. The training curriculum is designed to increase healthcare providers' knowledge of evidence-based and guideline-concordant obesity management strategies in primary care settings.
219163188|NCT06835686|OTHER|Obesity Toolkit for Primary Care Providers|We will provide FQHC providers with a toolkit containing additional obesity management resources and information and the community resource guides given to participants to support obesity management.
219163189|NCT06833710|OTHER|Auricular Acupressure|In the experimental group, the Shenmen point (MA-TF1) and Xin point (Xin MA) on both ears were treated with Wangbuliuxing seeds. Initially, the seeds were applied to the left ear for seven days, after which they were switched to the corresponding acupoints on the right ear. Following application, the seeds were pressed daily, once after each meal, with each acupoint being stimulated for 1 minute
219163190|NCT06834503|DRUG|Rivotril®|Rivotril® 2 mg
219163191|NCT06834503|DRUG|Clonazepam TQ 2 mg|Test
219163192|NCT06834243|PROCEDURE|Intermittent Bolus PENG Block|Patients received intermittent bolus administration of the Pericapsular Nerve Group (PENG) Block via a catheter. A researcher manually administered 20 mL of 0.25% bupivacaine every 4 hours over a 24-hour period.
219163193|NCT06834243|PROCEDURE|Continuous Infusion PENG Block|Patients received continuous infusion of the Pericapsular Nerve Group (PENG) Block via a catheter. A pump delivered 5 mL/hour of 0.25% bupivacaine continuously over a 24-hour period.
219163194|NCT03157323|BEHAVIORAL|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
219163195|NCT06830343|DRUG|SYH9017|subcutaneous injection once time in SAD and four times in MAD
219163196|NCT06830343|DRUG|Placebo|subcutaneous injection once time in SAD and four times in MAD
219163197|NCT06830343|DRUG|Wegovy ®|subcutaneous injection once a week
219163198|NCT06833112|DRUG|Secukinumab|The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.
219163199|NCT06833112|DRUG|Adalimumab|The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.
219163200|NCT06825741|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
219163201|NCT05097950|DRUG|Administration of 1 gr paracetamol I.V|Administration of 1 gr paracetamol I.V
219163202|NCT03651895|DRUG|Metformin|The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.
219163203|NCT03651895|DRUG|Placebo|Placebo
219163204|NCT06791746|DRUG|compound Staphylococcal lysostaphin mouthrinse|Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.
219236699|NCT06365177|OTHER|Teleconsultation|"Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it."
219236700|NCT01162564|DEVICE|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
219236701|NCT02444884|DRUG|MLN8237|
219236702|NCT06644391|DIAGNOSTIC_TEST|Carebot AI Bones|The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
219236703|NCT04036773|DIETARY_SUPPLEMENT|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
219236704|NCT02105727|BEHAVIORAL|Community-based salt reduction|
219236705|NCT00825734|DRUG|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
219236706|NCT00825734|DRUG|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
219236707|NCT01731444|DRUG|Phenylephrine|
219236708|NCT00003412|BIOLOGICAL|recombinant interleukin-12|
219236709|NCT01829646|OTHER|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
219236710|NCT01829646|OTHER|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
219236711|NCT01829646|OTHER|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
219236712|NCT02823574|BIOLOGICAL|Nivolumab|
219236713|NCT02823574|BIOLOGICAL|Ipilimumab|
219236714|NCT02823574|OTHER|Placebo|
219236715|NCT06275594|DRUG|Byfavo|For induction and maintenance of sedation
219236716|NCT06275594|DRUG|Midazolam|For induction and maintenance of sedation
219236717|NCT00590759|DEVICE|GORE TAG® Thoracic Endoprosthesis|implant
219236718|NCT02802111|DRUG|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
219737038|NCT03000166|BEHAVIORAL|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
219737039|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737040|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737041|NCT00215657|DRUG|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737042|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737043|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737044|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737045|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737046|NCT00215657|DRUG|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
219737047|NCT05761496|DEVICE|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
219737048|NCT05181735|DRUG|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
219163205|NCT06791746|DRUG|chlorhexidine mouthrinse|Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.
219163206|NCT06784869|DEVICE|Scaling and root surface debritment|Patients with 4-6 mm pocket depth were participated in this study; clinical periodontal parameters (BOP, PLI, PPD, CAL) were recorded at the baseline visit. To ensure sampling accuracy, From the site two papers with GCF were sampled. Following sample collecting for GCF, Every patient received comprehensive mouth supragingival scaling with an ultrasonic scaler (WoodpEEKer® UDS-K) along with dental hygiene recommendations. One week later, the sites were irrigated with normal saline after being scaled and root planed (ScRp) with Gracey curette. Following completion of subgingival instrumentation, each patient returned to the clinic following 1 and 3 months for periodontal parameter recording and GCF collection. Throughout these sessions, every patient received reinstruction to engage in self-oral hygiene practices.
219163207|NCT01447758|DRUG|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
219163208|NCT01447758|DRUG|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
219236719|NCT02802111|DRUG|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
219236720|NCT03233542|BEHAVIORAL|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
219362206|NCT05079997|DEVICE|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
219163209|NCT06030544|DIETARY_SUPPLEMENT|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
219163210|NCT06030544|DIETARY_SUPPLEMENT|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
219163211|NCT06787729|DEVICE|mHealth|The experimental design is composed of three phases: baseline, intervention, and retention. During the first two weeks (baseline), subjects will wear sensors, but no additional features (e.g., feedback, goal-setting, and weekly Zoom calls with clinicians) will be provided. For the next four weeks (intervention), subjects will wear sensors and have access to all intervention features, including weekly Zoom calls and goal-setting with clinicians. They will be encouraged to use the more impaired arm as much as possible. In the final two weeks (retention), the mobile intervention and clinician interactions will be removed, while subjects continue to wear sensors to examine the effects of withdrawing feedback.
219163212|NCT03127722|PROCEDURE|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
219362207|NCT03914976|PROCEDURE|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
219362208|NCT03509519|OTHER|NMES-Millicurrent|Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
219163213|NCT03127722|DEVICE|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
219163214|NCT03127722|PROCEDURE|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
219163215|NCT04309461|BEHAVIORAL|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
219163216|NCT04309461|BEHAVIORAL|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
219163217|NCT05741333|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.
219362209|NCT04957381|BEHAVIORAL|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
219737049|NCT05181735|DRUG|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
219737050|NCT03769467|BIOLOGICAL|Tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
219737051|NCT03769467|BIOLOGICAL|Pembrolizumab|pembrolizumab IV infusion
219737052|NCT03101982|DRUG|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
219737053|NCT04163315|OTHER|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
219737054|NCT02614066|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
219737055|NCT02614066|DRUG|Cyclophosphamide|Administered intravenously.
219737056|NCT02614066|DRUG|Fludarabine|Administered intravenously.
219737057|NCT06029998|DRUG|Bortezomib|sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.
219737058|NCT02096159|DRUG|trimethoprim-sulfamethoxazole|
219163218|NCT04576286|PROCEDURE|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
219163219|NCT02525692|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
219163220|NCT00833872|DRUG|LEO 22811|First-in-man
219163221|NCT00833872|DRUG|placebo solution|
219163222|NCT02396199|DEVICE|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
219163223|NCT00214695|DRUG|Experimental Peritoneal Dialysis Solution|
219163224|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
219163225|NCT06434714|DEVICE|Auricular percutaneous nerve field stimulator|Percutaneous nerve field stimulator device placed on the ear for 5 days
219163226|NCT06434714|DEVICE|Sham auricular percutaneous nerve field stimulator|Non-functioning percutaneous nerve field stimulator device placed on the ear for 5 days
219362210|NCT01080885|BEHAVIORAL|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
219362211|NCT01080885|BEHAVIORAL|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
219163227|NCT05834660|BEHAVIORAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
219163228|NCT04898023|DRUG|zinc-green tea extract-ascorbic acid|Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
219163229|NCT04898023|DRUG|Placebo|Compounded capsules containing microcrystalline cellulose.
219163230|NCT02721381|BEHAVIORAL|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
219163231|NCT01395732|DRUG|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
219362212|NCT00726687|DRUG|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
219737059|NCT02096159|OTHER|placebo|
219737060|NCT03568058|DRUG|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
219737061|NCT03568058|DRUG|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
219737062|NCT04274218|OTHER|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
219737063|NCT04943068|DRUG|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
219737064|NCT04943068|DRUG|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
219737065|NCT06017128|OTHER|sexual counseling based on the PLISSIT model|In the initial follow-up, the experimental group will receive information about total hip replacement surgery and its impact on sexual life based on the PLISSIT model. An educational booklet containing information about total hip replacement surgery, the rehabilitation process, and post-operative sexual life will also be prepared and distributed. In the second follow-up (5-7 days after surgery), the experimental group will be provided with information about home care before discharge and returning to sexual life.
219737066|NCT05226884|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
219737067|NCT05226884|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
219737068|NCT05026632|DRUG|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
219737069|NCT01205308|DIETARY_SUPPLEMENT|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
219737070|NCT06122545|PROCEDURE|Greater Occipital Nerve Block|"Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
219737071|NCT06122545|OTHER|Medical Treatment|Patients who will receive medical treatment
219737072|NCT06122545|DRUG|bupivacaine or onabotulinum toxin A injection.|bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
219737073|NCT03640624|COMBINATION_PRODUCT|Multidisciplinary treatment|"1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
219737074|NCT03640624|COMBINATION_PRODUCT|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
219737075|NCT03985995|DRUG|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
219737076|NCT03985995|DRUG|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
219737077|NCT05248243|PROCEDURE|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
219737078|NCT00642265|PROCEDURE|osteosynthesis|operative treatment
219737079|NCT00642265|OTHER|sling|conservative treatment
219737080|NCT02390388|PROCEDURE|pudendal nerve block|nerve stimulator-guided Pudendal block
219163232|NCT01563341|DEVICE|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
219163233|NCT03854903|DRUG|Palbociclib|Palbociclib is taken orally.
219236721|NCT04422405|PROCEDURE|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
219163234|NCT03854903|DRUG|Bosutinib|Bosutinib is taken orally.
219163235|NCT03854903|DRUG|Fulvestrant|Fulvestrant is given as an intramuscular injection.
219163236|NCT05149534|BEHAVIORAL|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
219163237|NCT05149534|DEVICE|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
219163238|NCT05243836|DEVICE|S.T.O.P® F2|Ocufilcon D, 55% water
219163239|NCT05243836|DEVICE|S.T.O.P® DT|Ocufilcon D, 55% water
219163240|NCT05243836|DEVICE|MiSight®|Omafilcon A (60% water)
219163241|NCT04231708|DRUG|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
219163242|NCT04231708|DEVICE|Active rTMS|10Hz rTMS over the left dlPFC
219163243|NCT04231708|DRUG|Placebo|lactose (inside capsule)
219163244|NCT04231708|DEVICE|Sham rTMS|inactive stimulation over the left dlPFC
219163245|NCT05432765|OTHER|Phenotypic Personalized Medicine Dosing|Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
219163246|NCT05432765|OTHER|Standard of Care Dosing|Providers will decide on the combination of drug doses needed based on their overall assessment per standard of care.
219163247|NCT05871177|DEVICE|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight \[32 mg (HHA) + 32 mg (LHA) / 2 ml\]
219163248|NCT03600155|BIOLOGICAL|Ipilimumab|Given IV
219163249|NCT03600155|BIOLOGICAL|Nivolumab|Given IV
219236722|NCT04884191|DRUG|Pacritinib|Pacritinib
219236723|NCT05670457|DRUG|Diosmin|diosmin 500 mg twice daily
219236724|NCT00003152|BIOLOGICAL|filgrastim|
219163250|NCT06594419|BEHAVIORAL|Healthy Mother Healthy Baby Toolkit|Customized bowl with markings to indicate the recommended amount of food that participants should consume in pregnancy and while exclusively breastfeeding in the first 6 months, as well as how much they should feed their babies at 6-8 months, 9-12 months, and 1-2 years respectively. The toolkit also includes a spoon used to test and ensure adequate thickness of the meals fed to infants \>6mos and a counseling card that indicates the frequency of meals, recommended food groups for meeting daily nutrient needs, and hand hygiene and hygienic food preparation
219163251|NCT06594419|OTHER|Standard of care|The Ethiopian government and Saving Little Lives Initiative (SLL) standard of care includes maternal and infant nutrition education and counseling, iron and folic acid supplementation, as well as training on effective Kangaroo Mother Care (KMC), primarily defined as exclusive breastfeeding and skin-to-skin contact ≥ 8 hours per day-in the event of Low birth weight (LBW) or preterm delivery.
219236725|NCT00003152|BIOLOGICAL|recombinant interferon alfa|
219236726|NCT00003152|DRUG|cyclophosphamide|
219236727|NCT00003152|DRUG|prednisone|
219163252|NCT06545123|BEHAVIORAL|Concurrent exercise training|The experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists
219163253|NCT06039267|OTHER|Gut Microbiome Testing|Stool microbiome testing using shotgun metagenomic sequencing
219163254|NCT04240756|BEHAVIORAL|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
219163255|NCT04240756|DRUG|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
219163256|NCT05307783|DEVICE|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
219163257|NCT04883645|DRUG|Imiquimod 5% Cream|Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
219163258|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
219163259|NCT05847543|OTHER|Stool diaper data and sample collection|Stool diaper data and sample collection
219163260|NCT03176498|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
219163261|NCT03176498|DRUG|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
219163262|NCT06005662|DRUG|Psilocybin|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
219163263|NCT03587688|PROCEDURE|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
219163264|NCT05945537|DRUG|INI-822 (A)|Different dose levels of INI-822
219163265|NCT05945537|OTHER|Placebo (B)|Matching placebo to INI-822
219163266|NCT03837977|DRUG|Liposomal Irinotecan|Arm I
219163267|NCT03837977|DRUG|Fluorouracil|Arm I
219163268|NCT03837977|DRUG|Folinic Acid|Arm I
219163269|NCT03837977|DRUG|Docetaxel|Arm II
219163270|NCT04642599|DEVICE|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
219163271|NCT05754034|DEVICE|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
219163272|NCT05754034|OTHER|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
219163273|NCT02945904|PROCEDURE|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
219163274|NCT05214820|BIOLOGICAL|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
219236728|NCT00003152|DRUG|vincristine sulfate|
219163275|NCT03513939|COMBINATION_PRODUCT|Sernova Cell Pouch|"The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 5 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter)."
219236729|NCT00003152|PROCEDURE|autologous bone marrow transplantation|
219236730|NCT00003152|PROCEDURE|bone marrow ablation with stem cell support|
219236731|NCT00003152|PROCEDURE|peripheral blood stem cell transplantation|
219236732|NCT00003152|RADIATION|radiation therapy|
219236733|NCT04834804|OTHER|Physical activity|12 weeks of exercise training
219362213|NCT00726687|DRUG|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
219362214|NCT01796405|DRUG|Clofarabine|
219362215|NCT05081284|DEVICE|Volume-stable collagen matrix Geistlich Fibro-Gide®|"After tooth extraction and implant insertion the Test group will receive a soft tissue augmentation on the buccal side oh the implant. an envelop flap will be raised and a volume-stable collagen graft will be stabilized with sutures.~Control group will not receive soft tissue augmentation."
219737081|NCT02390388|PROCEDURE|caudal block|caudal block
219737082|NCT03003897|OTHER|Soluble Fiber|Participants receiving soluble fiber.
219737083|NCT03003897|OTHER|Placebo|Participants receiving placebo.
219737084|NCT04488094|DRUG|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
219737085|NCT02874352|DEVICE|high resolution impedance manometry with Automated Impedance Manometry analysis|
219737086|NCT04085003|PROCEDURE|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
219737087|NCT03624036|BIOLOGICAL|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
219737088|NCT03624036|DRUG|Fludarabine|Administered intravenously
219737089|NCT03624036|DRUG|Cyclophosphamide|Administered intravenously
219737090|NCT03409458|DRUG|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
219737091|NCT03409458|BIOLOGICAL|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
219737092|NCT00308282|DRUG|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
219737093|NCT00308282|DRUG|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
219737094|NCT04268212|DIETARY_SUPPLEMENT|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
219737095|NCT04268212|BEHAVIORAL|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
219737096|NCT04663217|OTHER|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
219737097|NCT04612621|DIAGNOSTIC_TEST|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
219737098|NCT00211900|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
219737099|NCT01837095|DRUG|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
219737100|NCT04679818|DRUG|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
219737101|NCT04679818|DEVICE|PMD-200 Nol-guided opioid administration|PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
219737102|NCT00971503|PROCEDURE|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
219737103|NCT00971503|OTHER|Saline injection|Injection of saline solution for 5 days
219737104|NCT02655809|RADIATION|Fluoroscopic examination|
219737105|NCT04411407|DEVICE|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
219737106|NCT04169659|DEVICE|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
219163276|NCT05240807|DIAGNOSTIC_TEST|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
219163277|NCT06182371|BEHAVIORAL|Disengage the breathing circuit|Disengage the breathing circuit when the position of the patient undergoing thoracic surgery changes
219163278|NCT05175352|DRUG|Cendakimab|Specified dose on specified days
219163279|NCT05175352|DRUG|CYP substrates|Specified dose on specified days
219163280|NCT05601219|DRUG|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
219163281|NCT05601219|DRUG|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
219163282|NCT06744998|DEVICE|Hemopatch® (Baxter)|HEMOPATCH® is an absorbable collagen pad intended for sealing and hemostasis
219163283|NCT05030831|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
219163284|NCT06218836|OTHER|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
219163285|NCT06218836|OTHER|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
219163286|NCT05662787|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
219163287|NCT05687903|DRUG|TAK-861|TAK-861 oral tablets
219163288|NCT05687903|DRUG|Placebo|Placebo oral tablets matching TAK-861
219163289|NCT06424132|OTHER|Cold Vest Exposure Period|A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.
219163290|NCT06424132|OTHER|Rewarming Exposure Period|Following cold exposure, the cold vests will be removed, and participants will be offered a warm blanket to ease the transition from cold back to warm temperatures. Participants will then be moved to an adjacent warm room maintained at 30 degrees celsius and asked to return to the resting position of their choice. Participants will then engage in reading and/or digital entertainment for a 3-hour warm exposure period.
219163291|NCT06424132|OTHER|Fasting|Participants will be requested to refrain from food and caloric drinks for 12 hours (starting at 8pm) prior to the study visit. Blood will then be drawn the following morning (between 8 and 9am) 30mins later following a breakfast meal (9:30am- 10am). Participants will be housed in a room with ambient temperature at 25 degrees celsius between the two blood draws.
219163292|NCT06614907|DRUG|QL2108 injection|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
219163293|NCT06614907|DRUG|Dupixent®|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
219163294|NCT04855760|DRUG|REL-1017|REL-1017 tablet
219163295|NCT05613205|BIOLOGICAL|TYP04A Low Dose without Alum investigational vaccine|2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
219163296|NCT05613205|BIOLOGICAL|TYP04B Full Dose without Alum investigational vaccine|2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
219163297|NCT05613205|BIOLOGICAL|TYP03A Low Dose with Alum investigational vaccine|2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
219163298|NCT05613205|BIOLOGICAL|TYP03B Full Dose with Alum investigational vaccine|2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
219163299|NCT05613205|BIOLOGICAL|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
219163300|NCT05613205|BIOLOGICAL|GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
219163301|NCT05864248|DEVICE|Supira System|The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.
219737107|NCT04169659|DEVICE|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
219163302|NCT04791228|DEVICE|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
219163303|NCT04791228|DRUG|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
219163304|NCT04377932|GENETIC|AGAR T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2 DL2: 1x10\^8/m2 DL3: 3x10\^8/m2 DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
219163305|NCT04656158|OTHER|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
219163306|NCT05159791|DIAGNOSTIC_TEST|Invasive coronary blood flow assessment and simulations and fluid dynamic patient specific simulation|The coronary blood flow and its distribution between the anomalous and normal artery will be measured by invasive coronary catheterization. Coronary artery flow will be calculated based on intravascular ultrasound (IVUS) and pressure difference measurements. After the IVUS assessment, a pressure transducer (FFR/iFR probe) will be inserted in the coronary artery for pressure measurements. The measurements will be done in the anomalous and normal coronary arteries in each patient to determine coronary flow distribution. Patient's specific heart parameters will be retrieve from CT, MRI and other diagnostic tests and integrated in the simulation module.
219163307|NCT06126913|OTHER|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
219163308|NCT06309693|PROCEDURE|Quadratus Lumborum (QL) Block|The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
219163309|NCT06309693|PROCEDURE|Enhanced Recovery After Surgical (ERAS) Protocol|Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
219163310|NCT01689935|DRUG|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
219163311|NCT01689935|DEVICE|Red light only|Red Light therapy
219163312|NCT01689935|DEVICE|Blue light only|Blue light only
219163313|NCT05335421|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
219163314|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
219163315|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
219163316|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
219163317|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
219163318|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
219163319|NCT04460352|DRUG|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
219163320|NCT04460352|DRUG|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
219163321|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
219163322|NCT05769478|DRUG|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
219163323|NCT06267183|DRUG|SV001|SV001 ： single-dose
219163324|NCT06267183|DRUG|Placebo|Placebo ： single-dose
219362216|NCT06473038|OTHER|Reduction in Salt and Sugar|150 participants who are grouped under interventions, their data will be collected according to the alterations of sodium and sugar intake and then compared with the control group. Instruments include urine analysis, providing two spot urine samples - first-morning void and last void in the evening before leaving campus, at three-time points - at the start of the study, after 3 months, and after 6 months. This will yield a total of 300 × 2 × 3 = 1800 samples. Urine electrolytes (sodium, potassium, chloride) and creatinine will be measured using the potentiometry method (Alinity Abbott) at the laboratory department of Sunway Medical Centre, Bandar Sunway.
219163325|NCT05746871|DEVICE|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
219163326|NCT05746871|OTHER|standard care|Subjects will continue with their standard care for 5 weeks
219163327|NCT06463795|DEVICE|tDCS|active anodal tDCS
219163328|NCT06463795|DEVICE|Sham tDCS|sham anodal tDCS
219163329|NCT04537247|PROCEDURE|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
219163330|NCT04036188|DRUG|Triamcinolone|Triamcinolone 0.1% daily
219163331|NCT04036188|DIETARY_SUPPLEMENT|Vitamin D3|40,000 IU Vitamin D3 daily
219163332|NCT04036188|DRUG|Placebo|Placebo daily
219163333|NCT04990349|DRUG|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
219163334|NCT05470205|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
219163335|NCT05470205|DRUG|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
219163336|NCT06477900|OTHER|SMS reception|reception of 72 SMS encouraging physical activity and nutritional advice
219163337|NCT06409754|DEVICE|Functional Electrical Stimulation Therapy coupled to a P-300 based Brain-Computer Interface|The intervention involves a BCI control strategy based on a modified version of the classic P300 Donchin Speller Interface, where the matrix of letters and symbols is replaced by a set of pictures including five hand gestures and wrist orientations: hand opening, grasping, pinching, pronation, and supination. This BCI approach is based on the oddball paradigm, relying on conscious recognition by the user of the intensification of a particular target movement picture, within a sequence of other, non-target, random visual stimuli. This process should evoke the P300 component in the event related potential. The aim of the training sessions is to link an action observation/target selection task, mediated by the P300-based BCI, with the practice of a FES-assisted functional task involving the target movement picture selected. Users will be instructed to synchronize their voluntary movements with the ones induced by FES, to achieve the functional target goal.
219163338|NCT06409754|OTHER|Conventional Physical Therapy|Conventional physical and occupational therapy will include sessions of joint mobility, muscle strength, task-specific training, sensitivity reeducation and coordination exercises directed by an experienced professional therapist.
219163339|NCT04934176|OTHER|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
219163340|NCT04934176|OTHER|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
219163341|NCT05195970|OTHER|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
219163342|NCT05241613|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
219163343|NCT04832360|BEHAVIORAL|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
219163344|NCT05794763|BEHAVIORAL|Peer Led Group Intervention|A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
219163345|NCT04869982|BIOLOGICAL|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
219163346|NCT04869982|DRUG|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
219163347|NCT00152698|DRUG|Irbesartan|
219163348|NCT05139316|GENETIC|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
219163349|NCT05139316|OTHER|Placebo|Normal Saline infusion
219163350|NCT05139316|DRUG|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
219163351|NCT05139316|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
219163352|NCT05004610|DRUG|Sodium Lactate Solution|continuous intravenous infusion of molar sodium lactate
219163353|NCT03378739|PROCEDURE|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
219163354|NCT02338947|OTHER|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
219362217|NCT06473038|DEVICE|The potentiometer|The potentiometer is utilized for the quantitative analysis of electrolytes present in urine samples. The potentiometer used for urine electrolytes analysis is a specialized device equipped with electrodes and sensors designed to detect and measure the concentration of specific electrolytes in urine samples. It employs potentiometric principles to generate electrical signals proportional to the concentration of ions present in the sample.
219236734|NCT06332118|OTHER|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
219236735|NCT00022490|DRUG|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
219163355|NCT02338947|OTHER|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
219163356|NCT06443645|DRUG|Anthracycline|as standard of care
219163357|NCT05747651|BIOLOGICAL|Blood sample|Total volume of blood (on each sampling occasion): 54,5mL.
219163358|NCT05747651|BIOLOGICAL|Urine sample|Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.
219163359|NCT05747651|BIOLOGICAL|Saliva sample|Saliva: will be collected in special container for saliva microbiome and methylation.
219163360|NCT05747651|BIOLOGICAL|Stool sample|Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.
219163361|NCT05747651|BIOLOGICAL|Tissue sample|"Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
219163362|NCT06377761|DRUG|Qishen Granules|One package per time, twice a day, 90 days of treatment
219163363|NCT06377761|DRUG|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
219236736|NCT00022490|DRUG|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
219236737|NCT04252638|BEHAVIORAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
219236738|NCT04252638|BEHAVIORAL|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
219236739|NCT06231680|DRUG|Camrelizumab|Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
219236740|NCT06231680|DRUG|Thalidomide 50mg|Thalidomide 50mg，po qd；
219236741|NCT06231680|DRUG|Thalidomide 100mg|Thalidomide 100mg，po qd；
219236742|NCT06231680|DRUG|Thalidomide 200mg|Thalidomide 200mg，po qd；
219236743|NCT06231680|DRUG|Chemotherapy|"Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles."
219236744|NCT03645161|DIAGNOSTIC_TEST|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
219236745|NCT03845517|DRUG|Placebo|Placebo
219236746|NCT03845517|DRUG|PF-06700841 15 mg|PF-06700841 15 mg
219236747|NCT03845517|DRUG|PF-06700841 30 mg|PF-06700841 30 mg
219236748|NCT03845517|DRUG|PF-06700841 45 mg|PF-06700841 45 mg
219236749|NCT01906905|DEVICE|Transcranial Magnetic Stimulation|
219236750|NCT00033241|DRUG|erlotinib hydrochloride|
219236751|NCT00033241|DRUG|gemcitabine hydrochloride|
219236752|NCT03006718|OTHER|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
219236753|NCT06022198|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar Lavage
219236754|NCT03271359|BEHAVIORAL|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
219236755|NCT03271359|BEHAVIORAL|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
219236756|NCT05192902|DEVICE|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
219236757|NCT05192902|DEVICE|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
219236758|NCT00015132|DRUG|Sertraline|
219236759|NCT03391700|DRUG|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
219236760|NCT03391700|DRUG|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
219236761|NCT02841020|PROCEDURE|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
219236762|NCT05873296|BEHAVIORAL|Health Education|The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
219236763|NCT00417885|DRUG|exemestane|25 mg, oral, daily dosing
219236764|NCT00417885|DRUG|sunitinib malate|37.5 mg, oral, continuous dosing, daily
219236765|NCT06356142|DEVICE|Palmar Cooling|Palmar cooling device will be utilized for 2 minutes during rest breaks.
219236766|NCT06356142|DEVICE|Placebo Palmar Cooling|Placebo Palmar cooling device will be utilized for 2 minutes during rest breaks
219236767|NCT03169855|DIAGNOSTIC_TEST|Slit lamp (LOCS III Score)|Diagnostic procedure only
219236768|NCT04699578|DIAGNOSTIC_TEST|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
219236769|NCT06505785|OTHER|The creative drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
219236770|NCT02349815|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
219236771|NCT06387940|OTHER|nEB Diet, followed for 36 hours|nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
219236772|NCT06387940|OTHER|LC25 Diet, followed for 36 hours|LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet
219236773|NCT06387940|OTHER|LCEB Diet, followed for 36 hours|LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
219236774|NCT01461967|DRUG|Placebo|Single ascending doses
219236775|NCT01461967|DRUG|RO5508887|Single ascending doses
219236776|NCT01461967|DRUG|RO5508887|Single doses
219236777|NCT00913055|DRUG|octreotide acetate|subcutaneous implant
219236778|NCT03847727|DRUG|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
219236779|NCT06252454|DRUG|Furosemide 40 mg|Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
219236780|NCT06252454|DRUG|Levodropropizine|Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
219236781|NCT06252454|OTHER|Placebo - saline|Placebo will be used as a comparator
219236782|NCT01595425|DRUG|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
219236783|NCT01595425|DRUG|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
219236784|NCT00607607|DRUG|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
219236785|NCT02469324|BEHAVIORAL|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
219236786|NCT02469324|BEHAVIORAL|Compassionate Mind Training|see above
219236787|NCT03804866|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
219236788|NCT03804866|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
219236789|NCT03804866|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
219236790|NCT01190436|DRUG|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
219236791|NCT00274196|PROCEDURE|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
219236792|NCT00274196|PROCEDURE|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
219236793|NCT01431157|PROCEDURE|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
219236794|NCT01431157|OTHER|No nasal oxygen|Patients will have no intervention for sleep apnea
219236795|NCT02378584|OTHER|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
219236796|NCT02721147|BEHAVIORAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
219163364|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
219163365|NCT05748834|DRUG|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
219163366|NCT05748834|DRUG|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
219163367|NCT06461858|OTHER|cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks
219163368|NCT06461858|OTHER|conventional therapy|Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
219163369|NCT06752824|DEVICE|ANALGESIA NOCICEPTION INDEX MONITORING|INTRACRANIAL SURGERY
219163370|NCT03229811|OTHER|ESRD education + conservative kidney management and ACP education|Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
219163371|NCT04122469|RADIATION|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
219163372|NCT05016700|DIAGNOSTIC_TEST|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
219163373|NCT04703101|DRUG|Capecitabine|Given IV
219236797|NCT02721147|BEHAVIORAL|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
219163374|NCT04703101|DRUG|Fluorouracil|Given IV
219163375|NCT04703101|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219163376|NCT04703101|DRUG|Leucovorin|Given IV
219163377|NCT04703101|DRUG|Oxaliplatin|Given IV
219163378|NCT04703101|OTHER|Quality-of-Life Assessment|Ancillary studies
219163379|NCT04703101|BEHAVIORAL|Surveillance|Undergo NOM
219163380|NCT04703101|PROCEDURE|Total Mesorectal Excision|Undergo TME
219163381|NCT06273137|BEHAVIORAL|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
219163382|NCT06273137|BEHAVIORAL|Supportive psychotherapy (SUP)|Supportive psychotherapy provides a time, attention, and social support control that is similar to a placebo but likely to be perceived as relevant to this population.
219163383|NCT04229056|BEHAVIORAL|Computer-based cognitive rehabilitation (CBCR)|CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
219163384|NCT04229056|BEHAVIORAL|General computer-based cognitive stimulation|For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.
219236798|NCT02721147|BEHAVIORAL|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
219236799|NCT02721147|BEHAVIORAL|Behavioral, Psychological or Informational Intervention|Receive educational information and support
219163385|NCT05580536|BEHAVIORAL|Project Dulce + Dulce Digital|"Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic.~The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes.~The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. .~Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic."
219163386|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).
219163387|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).
219163388|NCT06182124|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
219163389|NCT06182124|BIOLOGICAL|Licensed pneumococcal comparator vaccine|A licensed pneumococcal comparator vaccine
219163390|NCT06401213|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
219163391|NCT06401213|OTHER|Placebo|Matching Placebo-- Normal Saline
219163392|NCT02201108|DRUG|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
219163393|NCT02201108|DRUG|Placebo|Pharmaceutical form:tablet, Route of administration: oral
219163394|NCT05890183|BEHAVIORAL|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
219163395|NCT05890183|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
219163396|NCT05890183|BEHAVIORAL|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.
219163397|NCT05890183|BEHAVIORAL|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.
219163398|NCT05890183|BEHAVIORAL|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
219163399|NCT05193227|DRUG|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
219163400|NCT05193227|DRUG|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
219163401|NCT04274478|DEVICE|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
219163402|NCT02088060|DRUG|Cannabidiol|Cannabidiol capsules
219163403|NCT02088060|DRUG|Olanzapine|Olanzapine capsules
219163404|NCT02088060|DRUG|Placebo Cannabidiol|Placebo cannabidiol capsules
219163405|NCT02088060|DRUG|Placebo Olanzapine|Placebo olanzapine capsules
219163406|NCT06769906|OTHER|Individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will apply continuous glucose monitoring system and receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires.
219163407|NCT04409639|DRUG|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
219163408|NCT06765551|DIAGNOSTIC_TEST|Neuromuscular Ultrasound|Non-invasive ultrasound of peripheral muscles of the upper and lower extremities with additional artificiall intelligence processing of ultrasound images.
219163409|NCT05845424|DRUG|Guideline directed statin therapy|At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
219163410|NCT05845424|DRUG|High intensity statin plus ezetimibe therapy|Rosuvastatin 20 mg + Ezetimibe 10 mg
219163411|NCT06799858|DEVICE|Breast cancer localisation with magnetic seed Sirius Pintuition|Patients with histologically proven non-palpable breast cancer or with histologically proven pathological lymph node will be localised by a magnetic seed Sirius Pintuition.
219163412|NCT04060160|OTHER|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
219163413|NCT04060160|OTHER|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
219163414|NCT05593328|DRUG|Onvansertib|Oral capsule
219163415|NCT05593328|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
219163416|NCT05593328|DRUG|Bevacizumab|IV infusion
219236800|NCT02439892|BEHAVIORAL|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
219236801|NCT02439892|BEHAVIORAL|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
219236802|NCT05931224|DRUG|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
219236803|NCT05931224|DRUG|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
219236804|NCT04063449|DRUG|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
219236805|NCT04063449|DRUG|endostar|Antiangiogenic therapy plus chemotherapy
219236806|NCT03066986|DRUG|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
219236807|NCT03066986|BIOLOGICAL|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined."
219236808|NCT00452894|DRUG|varenicline tartrate|
219236809|NCT04292795|DEVICE|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
219236810|NCT04292795|DEVICE|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
219236811|NCT01366352|DRUG|MNTX tablet (Formulation 1)|
219236812|NCT01366352|DRUG|MNTX tablet (Formulation 2)|
219236813|NCT02060175|DEVICE|Cilotax drug-eluting stents implantation|
219236814|NCT02060175|DEVICE|DESyne drug-eluting stents implantation|
219236815|NCT02450747|DEVICE|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
219236816|NCT03619044|OTHER|2 FES-PET Imaging will be performed:|"* before treatment initiation~* before treatment cycle 3 initiation"
219236817|NCT02209376|BIOLOGICAL|CART-EGFRvIII T cells|
219236818|NCT01722097|DRUG|Rocuronium|
219236819|NCT01722097|DRUG|placebo|
219236820|NCT03071523|PROCEDURE|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
219236821|NCT03071523|PROCEDURE|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
219236822|NCT04471415|DRUG|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
219236823|NCT04471415|BIOLOGICAL|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
219236824|NCT00328120|DRUG|Fulvestrant|500 mg intramuscular injection
219236825|NCT05647941|DIAGNOSTIC_TEST|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
219236826|NCT00408109|DRUG|VRC-AVIDNA036-00-VP|
219236827|NCT01714479|OTHER|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
219236828|NCT01714479|OTHER|Placebo|
219236829|NCT02765204|DRUG|Dapagliflozin|
219236830|NCT02765204|DRUG|Saxagliptin|
219236831|NCT02765204|DRUG|Glucose|
219236832|NCT00005713|BEHAVIORAL|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
219163417|NCT03830177|DRUG|Natural Treatment|Participants will receive a topical treatment formulated with natural ingredients (Lactobacillus sp., honey, and turmeric) and a kit containing all necessary materials, including an instruction handout. The treatment is applied to the scalp, left for roughly 5 minutes, and rinsed off.
219163418|NCT04627948|DIAGNOSTIC_TEST|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
219163419|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
219163420|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
219163421|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
219163422|NCT06738433|DIETARY_SUPPLEMENT|ABB i5|Prebiotic ABB i5 (NextDext®, 5g)
219163423|NCT06738433|DIETARY_SUPPLEMENT|ABB C24|ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
219163424|NCT03087032|DRUG|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
219163425|NCT03087032|DRUG|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
219163426|NCT03602014|DRUG|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
219163427|NCT03602014|OTHER|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
219163428|NCT06782204|DRUG|Paracetamol|At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have blood and urine samples collected 2 hours after administration.
219163429|NCT06478030|DIAGNOSTIC_TEST|questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)|The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
219163430|NCT06091215|DEVICE|Sciton Joule System|Sciton Joule System
219163431|NCT05540002|DEVICE|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
219163432|NCT05540002|DEVICE|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
219163433|NCT06780657|BEHAVIORAL|Online hypopressive exercise training program|The hypopressive exercises were based on recommendations from the literature and consultation with an expert in the field. Each session will be held twice a week for 20-25 minutes. Participants will perform each exercise 10 times during these sessions.
219163434|NCT03289039|DRUG|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
219163435|NCT03289039|DRUG|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
219163436|NCT02961660|DRUG|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
219236833|NCT03529435|BEHAVIORAL|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
219236834|NCT03529435|BEHAVIORAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
219236835|NCT00257309|DRUG|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
219163437|NCT05739175|DEVICE|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
219163438|NCT04732494|BIOLOGICAL|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
219163439|NCT04732494|BIOLOGICAL|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
219163440|NCT04732494|DRUG|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
219163441|NCT05869656|BEHAVIORAL|Fluid restriction|Oral fluid restriction of 1000ml per day
219163442|NCT05869656|BEHAVIORAL|Free fluids|Continue care without any oral fluid restriction
219163443|NCT06351137|OTHER|Intravenous administration|Analgesia is administered intravenously.
219236836|NCT00257309|PROCEDURE|Primary angioplasty|
219236837|NCT02107235|DRUG|oral rigosertib|
219163444|NCT06351137|OTHER|Intranasal administration|Analgesia is administered intranasally using an atomizer.
219236838|NCT02107235|DRUG|cisplatin|
219236839|NCT02107235|RADIATION|Radiotherapy|
219236840|NCT02344706|DEVICE|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
219737108|NCT05838040|OTHER|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
219737109|NCT05838040|OTHER|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
219163445|NCT05653258|OTHER|Lifestyle Intervention|"1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
219163446|NCT05653258|DRUG|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
219163447|NCT05653258|DRUG|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
219163448|NCT05653258|DRUG|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
219163449|NCT05653258|PROCEDURE|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
219163450|NCT04367506|BEHAVIORAL|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
219163451|NCT04367506|BEHAVIORAL|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
219163452|NCT04889430|DRUG|Iptacopan|Iptacopan 200mg twice daily oral
219163453|NCT05986864|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
219163454|NCT06110442|DEVICE|IbexBH Software|A software application applied to radiographs
219163455|NCT06784583|DEVICE|transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception), and one-hour timing. Next, begin the stimulation.~3. Stimulation end: After an hour, the device will be automatically switched off. And the procedure is finished."
219163456|NCT06784583|DEVICE|sham transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception). Next, turn off the stimulation，and one-hour timing.~3. Stimulation end: After an hour, the device will be removed and the procedure is finished."
219163457|NCT05183763|BEHAVIORAL|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
219163458|NCT05183763|BEHAVIORAL|Medication reminder tools|Medication-taking reminder app and pillbox
219163459|NCT04999306|BEHAVIORAL|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
219163460|NCT04999306|BEHAVIORAL|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
219163461|NCT05946109|BEHAVIORAL|ACTIVE-AGE@home|"functional, homebased training program offering basic functional exercises connected to meaningful activities, lifestyle coaching and motivational interviewing; derived from evidence-based training principles . Through a precise application of the FITT-VP\* guidelines, a progressive and balanced program was designed and piloted in different proof-of-concept studies. The uniqueness of the program lies in the multi-component approach which brings together functional exercises for (1) muscle strength/muscle endurance, (2) aerobic endurance, (3) flexibility, motor ability and balance and (4) meaningful daily activities, in a home-based environment.~The frail participants are visited three times a week during 24 weeks with in total 72 sessions. Each session is 1 hour in duration. Thus they receive 72 training hours.~\*(Frequency, Intensity, Time, Type of exercises, Volume and Progression)"
219163462|NCT03434509|OTHER|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
219163463|NCT04639518|OTHER|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
219236841|NCT05792683|DEVICE|lumbar drain|"Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day."
219236842|NCT01128439|OTHER|No intervention|No intervention
219236843|NCT01236144|DRUG|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
219163464|NCT04639518|OTHER|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
219163465|NCT05178810|DRUG|FAB122|Daily dose 100 mg
219163466|NCT05178810|DRUG|Placebo|Daily dose
219163467|NCT04423250|OTHER|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|\- Failure to trace, Lack of product information, absence of product in the operating room
219163468|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
219163469|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
219163470|NCT01485575|PROCEDURE|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
219163471|NCT06151535|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
219163472|NCT05485922|DEVICE|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
219163473|NCT05485922|DEVICE|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
219163474|NCT06153056|DIAGNOSTIC_TEST|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
219163475|NCT03927131|BIOLOGICAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
219163476|NCT03927131|BIOLOGICAL|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
219163477|NCT03927131|BIOLOGICAL|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
219163478|NCT03927131|BIOLOGICAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
219236844|NCT01236144|DRUG|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
219236845|NCT01236144|DRUG|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
219236846|NCT04454723|PROCEDURE|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
219236847|NCT04454723|PROCEDURE|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
219236848|NCT04004832|DIAGNOSTIC_TEST|there is not any intervention procedure|there is not any intervention procedure
219236849|NCT02009332|DRUG|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
219236850|NCT02009332|DRUG|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
219236851|NCT03807934|OTHER|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
219236852|NCT04276649|DRUG|Caltrate|Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
219236853|NCT01912599|DEVICE|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
219236854|NCT01912599|DEVICE|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
219236855|NCT05059145|DRUG|Chlorhexidine Gluconate|Vaginal cream 1%
219236856|NCT05059145|DRUG|Fluconazole|150 mg oral capsule
219236857|NCT03699761|PROCEDURE|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
219236858|NCT03699761|PROCEDURE|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
219236859|NCT01390753|DIETARY_SUPPLEMENT|Human donor milk|
219236860|NCT02077114|BIOLOGICAL|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
219236861|NCT05114499|DRUG|Donepezil|Donepezil 5mg qd
219236862|NCT05114499|DRUG|GV-971|GV-971 450mg bid
219236863|NCT04501588|BEHAVIORAL|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
219236864|NCT04501588|BEHAVIORAL|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
219236865|NCT02611193|PROCEDURE|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
219236866|NCT02611193|PROCEDURE|Simulated manipulative treatment|Simulated Manipulative Treatment
219236867|NCT00087724|DRUG|FK962|
219236868|NCT02283632|PROCEDURE|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
219236869|NCT05656651|BEHAVIORAL|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
219236870|NCT05792475|DIAGNOSTIC_TEST|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
219236871|NCT03386344|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
219236872|NCT03386344|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
219236873|NCT02416947|DIETARY_SUPPLEMENT|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
219737110|NCT06203665|DIAGNOSTIC_TEST|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
219737111|NCT03024632|PROCEDURE|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
219737112|NCT02480361|DEVICE|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
219163479|NCT03927131|BIOLOGICAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
219163480|NCT03927131|BIOLOGICAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
219163481|NCT06831773|RADIATION|Carbon ion combined with photon radiotherapy|PTV1 was first treated with photon radiotherapy (started within 30 days after surgery), with a total dose of 50Gy, 25 times; After photon radiotherapy, PTV2 carbon ion radiotherapy was started, the total dose was 24.8Gy(RBE), 8 times. 3.1Gy(RBE)/fx; 1fx/ day, 5 days/week.
219163482|NCT04434209|DEVICE|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
219163483|NCT04434209|OTHER|Standard of Care|Standard of Care patient management
219163484|NCT06792877|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Intervention is an adapted form of Mindfulness-based stress reduction (MBSR) training virtual class that meets for 10 weeks. The class involves mindfulness training using awareness and focused attention, group discussion of the experience, and mindful movement. The Mindfulness Intervention also includes daily home practice using mindfulness recordings.
219163485|NCT06792877|BEHAVIORAL|Waitlist then mindfulness|Participants in this arm will first wait 10 weeks and then complete a mindfulness course with outcome measures assessed at baseline, after 10 weeks wait list and then after mindfulness course.
219163486|NCT04973657|DRUG|VK0214|API in capsule
219163487|NCT04973657|OTHER|Placebo|API in capsule
219163488|NCT05065138|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
219163489|NCT05827055|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
219163490|NCT05827055|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
219163491|NCT05827055|DRUG|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
219163492|NCT05827055|DRUG|Placebo|Placebo given in vegan. capsules orally three times a day
219163493|NCT06827483|OTHER|Neurocognitive Component|A neurocognitive component will be added to the Y Balance Test
219163494|NCT03471650|DRUG|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
219163495|NCT01673984|DRUG|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
219163496|NCT01673984|DRUG|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
219163497|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
219163498|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
219163499|NCT03044613|DRUG|Nivolumab|240mg or 1 mg/kg administered IV
219163500|NCT03044613|DRUG|Relatlimab|80mg administered IV
219163501|NCT03044613|DRUG|Carboplatin|standard care dose
219163502|NCT03044613|DRUG|Paclitaxel|standard care dose
219163503|NCT03044613|RADIATION|Radiation|standard care dose
219163504|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
219163505|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
219163506|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
219163507|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
219163508|NCT01521052|DEVICE|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
219163509|NCT06243757|OTHER|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
219163510|NCT05018793|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
219163511|NCT05018793|BIOLOGICAL|AlloRx|Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal injection for
219163512|NCT05183490|DRUG|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"
219163513|NCT06844630|OTHER|Preoperative block application (İntersclane Block)|Before surgery, patients will receive a unilateral interscalene block under ultrasound guidance.
219163514|NCT06844630|OTHER|Preoperative block application (Infraspinatus-teres minor interfascial block)|Before surgery, patients will receive a unilateral infraspinatus-teres minor interfascial block under ultrasound guidance.
219163515|NCT06847412|DEVICE|Escalating PEEP|Typically, an initial PEEP of 5 cm H₂O, then PEEP is increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).
219163516|NCT06847412|DEVICE|Sustained inflation|Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.
219163517|NCT06846749|DIETARY_SUPPLEMENT|F75 milk feeds|Standard 'F75' (75 kcal/100 ml) 95 kcal/kg/day 12.05 mg/kg/min glucose
219163518|NCT06846749|DIETARY_SUPPLEMENT|F50 milk feeds|Reduced caloric 'F50' (50kcal/100ml) 63 kcal/kg/day 8.03mg/kg/min glucose
219163519|NCT06846749|DIETARY_SUPPLEMENT|F35 milk feeds|"Reduced caloric 'F35' (35 kcal/100ml)~* 47 kcal/kg/day~* 5.62 mg/kg/min glucose"
219163520|NCT05654922|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
219163521|NCT05654922|OTHER|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
219163522|NCT04437433|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
219163523|NCT05036408|OTHER|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
219163524|NCT05036408|OTHER|Educational Intervention|Attend educational session
219163525|NCT05036408|PROCEDURE|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
219163526|NCT05036408|BEHAVIORAL|Occupational Therapy|Participate in occupational therapy
219163527|NCT05036408|OTHER|Physical Activity|Participate in physical activity
219163528|NCT05036408|PROCEDURE|Physical Therapy|Participate in physical therapy
219163529|NCT05036408|OTHER|Questionnaire Administration|Ancillary studies
219163530|NCT01544855|DIETARY_SUPPLEMENT|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
219163531|NCT04364139|OTHER|MAP goal less than or equal to 92 mm Hg|Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
219163532|NCT04364139|OTHER|MAP goal 102-107 mm Hg|Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
219163533|NCT04364139|DRUG|Ramipril|An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
219163534|NCT04364139|DRUG|Amlodipine|A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
219163535|NCT04364139|DRUG|Metoprolol|A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
219163536|NCT04048681|BEHAVIORAL|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
219163537|NCT04048681|BEHAVIORAL|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
219163538|NCT04048681|BEHAVIORAL|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
219163539|NCT05413889|BEHAVIORAL|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
219163540|NCT01532388|BEHAVIORAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
219163541|NCT01421407|DEVICE|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
219163542|NCT02919449|BIOLOGICAL|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
219163543|NCT02919449|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered every 3 weeks
219163544|NCT03862963|BEHAVIORAL|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
219743692|NCT05274698|BEHAVIORAL|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
219163545|NCT03862963|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
219163546|NCT04255979|DRUG|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
219163547|NCT00257075|DRUG|Risperidone, oral tablets|
219163548|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
219163549|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
219163550|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
219163551|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
219163552|NCT02731846|DRUG|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
219163553|NCT02731846|DEVICE|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
219163554|NCT02731846|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
219163555|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
219163556|NCT00441298|DRUG|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
219163557|NCT00441298|DRUG|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
219163558|NCT00599469|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
219163559|NCT02018900|DIETARY_SUPPLEMENT|Ecologic 825/scFOS|
219163560|NCT02018900|DIETARY_SUPPLEMENT|Placebo|
219163561|NCT00051792|BEHAVIORAL|yoga|
219163562|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
219163563|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
219163564|NCT05802706|OTHER|No intervention.|No intervention.
219163565|NCT06555744|DRUG|ZW191|Administered intravenously
219163566|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
219163567|NCT06064916|DIAGNOSTIC_TEST|Visual Acuity|Monocular and binocular measurement of distance, intermediate, and near visual acuity
219163568|NCT06064916|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
219163569|NCT06064916|OTHER|Intraocular Lens Satisfaction (IOLSAT) Questionnaire|Self-reported post-operative patient satisfaction with vision after surgery
219163570|NCT06064916|OTHER|Quality of Vision After Surgery (QUVID) Questionnaire|Self-reported post-operative patient vision quality after surgery
219163571|NCT06064916|OTHER|Visual Disturbance Questionnaire|Questionnaire of self-reported visual disturbances of patients
219163572|NCT06064916|DIAGNOSTIC_TEST|Topography and Tomography|Topography and tomography measurements with Atlas, iTrace, and/or Pentacam
219163573|NCT02697136|DRUG|CER-001|Recombinant human apoA-I/phospholipid complexes
219163574|NCT02697136|DRUG|Placebo|0.9% Sodium Chloride Injection, USP
219163575|NCT06456944|OTHER|stretching exercises|stretching exercises of the plantar fascia, gastrocnemius and soleus
219163576|NCT06456944|DEVICE|ultrasound|therapeutic ultrasound upon the most painful point on the medial calcaneal tubercle. The parameters involved a pulsed mode (duty cycle 50%) using an intensity of 1.5 W/cm2 and a 1 MHz of frequency for 5 minutes
219163577|NCT06456944|OTHER|rigid tape|low-dye tapping will be done to provide mechanical correction to plantar fascia and medial longitudinal arch
219163578|NCT06456944|OTHER|mobilization|mobilization techniques for the talocrural joint in weight bearing and non-bearing positions and subtalar joint
219163579|NCT06456944|OTHER|myofascial release|deep tissue release of the plantar fascia and flexor hallucis longus in a stretched position of the plantar fascia
219163580|NCT06456944|OTHER|strengthening exercise|strengthening exercise of the plantar intrinsic muscles using short foot exercise and strengthening of the Achilles tendon and windlass mechanism using unilateral heel raise exercises
219163581|NCT05782816|DRUG|Oxytocin|Low dose oxytocin
219163582|NCT05782816|DRUG|Oxytocin|High dose oxytocin
219163583|NCT05468489|DRUG|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
219163584|NCT05468489|DRUG|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
219163585|NCT06445075|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion.
219163586|NCT06445075|DRUG|Placebo|Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo was administered every 4 weeks by intravenous (IV) infusion.
219163587|NCT06445075|DRUG|Tirzepatide|Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide was administered every week by subcutaneous injection.
219163588|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
219163589|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
219163590|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
219163591|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
219163592|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
219163593|NCT00510302|BEHAVIORAL|Questionnaire|Questionnaire regarding melanoma risk-reduction.
219163594|NCT00510302|BEHAVIORAL|Interview|Interview via telephone about topics related to melanoma risk-reduction.
219163595|NCT03829852|DRUG|Regorafenib|Treatment was performed based on physician's discretion
219163596|NCT02523716|OTHER|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
219163597|NCT02523716|OTHER|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
219163598|NCT03338868|OTHER|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
219163599|NCT03338868|OTHER|Physical activity level|assessed by the International Physical Activity Questionnaire-7
219163600|NCT03338868|OTHER|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
219163601|NCT03338868|OTHER|Quality of life|assessed by the Nottingham Health Profile
219236874|NCT02416947|DIETARY_SUPPLEMENT|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
219236875|NCT02416947|DIETARY_SUPPLEMENT|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
219236876|NCT04430400|DIAGNOSTIC_TEST|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level \<500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
219163602|NCT03338868|OTHER|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
219163603|NCT03338868|DIAGNOSTIC_TEST|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
219163604|NCT02664558|DRUG|ubenimex|
219163605|NCT02664558|OTHER|placebo|
219236877|NCT05671055|OTHER|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
219236878|NCT03468348|DRUG|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
219236879|NCT01280721|DRUG|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
219236880|NCT01180400|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
219236881|NCT01180400|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
219236882|NCT05188248|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
219236883|NCT05793580|DEVICE|Vibrant Soundbridge active middle ear implant|active middle ear implant
219236884|NCT05605158|DRUG|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
219163606|NCT03749785|OTHER|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
219163607|NCT03749785|OTHER|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
219163608|NCT02538900|BEHAVIORAL|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
219163609|NCT02538900|OTHER|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
219236885|NCT05605158|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
219236886|NCT05387785|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
219236887|NCT05387785|DRUG|Placebo|Orally administered placebo capsule
219236888|NCT00754533|OTHER|Continuous versus interval training|Influence of different exercise training programs
219236889|NCT04642495|DIAGNOSTIC_TEST|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
219737113|NCT00689286|DEVICE|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
219737114|NCT03688113|BEHAVIORAL|Tinnitus application|Use of tinnitus application
219236890|NCT05362279|OTHER|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
219236891|NCT01249794|PROCEDURE|non invasive ventilation|continuous positive airways pressure
219236892|NCT03704363|DRUG|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
219236893|NCT03704363|OTHER|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
219163610|NCT00004840|DRUG|thyrotropin-releasing hormone|
219163611|NCT05790863|DEVICE|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
219163612|NCT02874534|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
219163613|NCT02874534|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
219163614|NCT02781623|PROCEDURE|MRI|
219163615|NCT02916862|DIETARY_SUPPLEMENT|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
219163616|NCT02916862|COMBINATION_PRODUCT|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
219163617|NCT02916862|DIETARY_SUPPLEMENT|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
219163618|NCT02916862|COMBINATION_PRODUCT|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
219163619|NCT01582646|DRUG|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
219163620|NCT04217746|DEVICE|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
219163621|NCT05008315|OTHER|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
219163622|NCT05008315|OTHER|Direct focused scar release technique|Direct focused scar release technique
219163623|NCT05008315|OTHER|Direct manipulations to visceral structures|Direct manipulations to visceral structures
219163624|NCT05008315|OTHER|pelvic anatomy education|pelvic anatomy education
219163625|NCT05008315|OTHER|sham|sham
219163626|NCT03450434|DRUG|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
219163627|NCT03450434|DRUG|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
219163628|NCT02923180|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
219163629|NCT05198310|DRUG|KPL-404|Humanized monoclonal antibody
219163630|NCT05198310|DRUG|Placebo|Matching placebo
219163631|NCT05672147|BIOLOGICAL|Anti-CD33 CAR T-cells|Given IV
219163632|NCT05672147|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
219163633|NCT04579211|DIAGNOSTIC_TEST|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
219163634|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
219163635|NCT04436107|DRUG|Lenalidomide|Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.
219163636|NCT01095796|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
219163637|NCT01095796|DRUG|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
219163638|NCT01095796|DRUG|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
219163639|NCT01095796|DRUG|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
219163640|NCT06276374|DRUG|Patients who are scheduled to undergo carotid artery stenting|"* Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  \- 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)"
219163641|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
219163642|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
219163643|NCT06230055|DEVICE|Ommaya reservoir|Intrathecal chemotherapy through Ommaya reservoir
219163644|NCT06230055|DRUG|Systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, iv), DS8201(5.4mg/kg, d1, q3w), SG(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w).
219163645|NCT05036070|DEVICE|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
219163646|NCT05036070|DEVICE|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
219163647|NCT02926911|OTHER|Surgery|Surgery +/- radiation choice for endocrine therapy
219163648|NCT02926911|OTHER|Active Monitoring|Choice for endocrine therapy
219163649|NCT00980473|PROCEDURE|Argon Laser Iridoplasty|
219163650|NCT00980473|DRUG|Travatan/ Timolol/Azopt|
219163651|NCT03773835|DRUG|HSK3486|Mmanual IV bolus injection completed in 1 minute.
219163652|NCT02095171|DRUG|PRX002|
219163653|NCT02095171|OTHER|Placebo|
219163654|NCT05998863|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
219163655|NCT05998863|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
219163656|NCT04985812|DRUG|JNJ-67484703|Participants will receive JNJ-67484703.
219163657|NCT04985812|DRUG|Placebo|Participants will receive placebo to JNJ-67484703.
219163658|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
219163659|NCT05512962|DRUG|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
219163660|NCT05512962|DEVICE|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
219163661|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
219163662|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
219163663|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
219163664|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
219163665|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
219163666|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
219163667|NCT03490864|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
219163668|NCT03490864|DIETARY_SUPPLEMENT|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
219163669|NCT03490864|OTHER|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
219163670|NCT03490864|OTHER|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
219163671|NCT06484595|OTHER|Best Practice|Receive SOC supportive care services
219163672|NCT06484595|BEHAVIORAL|Patient Navigation|Receive clinical trial navigator guide services
219163673|NCT06034548|BEHAVIORAL|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
219163674|NCT06456242|BEHAVIORAL|CounsCM+MedCM (Health Rewards)|Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
219163675|NCT06062966|DRUG|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
219163676|NCT05018910|OTHER|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
219163677|NCT03361215|OTHER|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
219236894|NCT00248794|BEHAVIORAL|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
219163678|NCT03954678|BEHAVIORAL|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
219163679|NCT03954678|DIETARY_SUPPLEMENT|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
219163680|NCT05435963|BEHAVIORAL|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
219163681|NCT03709199|DIAGNOSTIC_TEST|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
219163682|NCT03709199|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
219163683|NCT03709199|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
219163684|NCT03709199|DIAGNOSTIC_TEST|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
219163685|NCT03709199|DIAGNOSTIC_TEST|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
219163686|NCT03709199|DIAGNOSTIC_TEST|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
219163687|NCT03709199|DIAGNOSTIC_TEST|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
219163688|NCT03709199|DIAGNOSTIC_TEST|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
219163689|NCT03709199|DIAGNOSTIC_TEST|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
219163690|NCT03709199|DIAGNOSTIC_TEST|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
219163691|NCT03709199|DIAGNOSTIC_TEST|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
219163692|NCT03709199|DIAGNOSTIC_TEST|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
219163693|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
219163694|NCT06965712|DEVICE|Point-of-Care Ultrasound (POCUS)|Participants assigned to this group will receive Point-of-Care Ultrasound (POCUS) evaluations of the lungs and inferior vena cava (IVC) during their hospital stay. The ultrasound will be performed twice: once within 24 hours of hospital admission and once prior to hospital discharge. The POCUS findings will be used to guide clinical management decisions regarding fluid status and decongestion therapy in patients with decompensated heart failure. The procedure is non-invasive, radiation-free, and performed at the bedside.
219163695|NCT04164459|DRUG|Xalost S|One drop one times a day in study eye
219163696|NCT04164459|DRUG|Xalatan|One drop one times a day in study eye
219163697|NCT04164459|DRUG|Taflotan-S|One drop one times a day in study eye
219163698|NCT05766969|DRUG|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
219163699|NCT05766969|DRUG|Placebo|An inactive compound.
219163700|NCT01127373|RADIATION|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
219163701|NCT01127373|BEHAVIORAL|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
219163702|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
219163703|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
219163704|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
219163705|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
219163706|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
219163707|NCT02218060|PROCEDURE|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
219163708|NCT02218060|PROCEDURE|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
219163709|NCT02290613|DRUG|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
219163710|NCT02290613|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
219163711|NCT02713126|DRUG|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
219163712|NCT02713126|DRUG|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
219163713|NCT02713126|DEVICE|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
219163714|NCT02713126|OTHER|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
219163715|NCT03750539|RADIATION|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
219163716|NCT03750539|RADIATION|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
219163717|NCT03750539|PROCEDURE|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
219737115|NCT05752331|BEHAVIORAL|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
219737116|NCT01496703|OTHER|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
219737117|NCT02413346|DRUG|Sarecycline|Administered based on participant's body weight.
219737118|NCT02297035|BEHAVIORAL|Behavioural testing|
219737119|NCT02297035|OTHER|Brain imaging|MRI, PET
219737120|NCT02297035|GENETIC|Genetic screening|APOE, Progranulin
219737121|NCT02403778|DRUG|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
219737122|NCT02403778|DRUG|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
219737123|NCT05318378|DIAGNOSTIC_TEST|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
219737124|NCT04941365|DIAGNOSTIC_TEST|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
219737125|NCT00006215|BIOLOGICAL|filgrastim|
219737126|NCT00006215|DRUG|docetaxel|
219737127|NCT00006215|DRUG|vinorelbine tartrate|
219737128|NCT00398242|DEVICE|above or below elbow cast for the last 3 weeks of treatment|
219737129|NCT06499220|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
219737130|NCT02903381|DRUG|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
219737131|NCT02903381|DRUG|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
219737132|NCT02903381|DRUG|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
219737133|NCT06253728|DIETARY_SUPPLEMENT|High fiber and protein meal|In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
219737134|NCT06253728|DIETARY_SUPPLEMENT|Control|The control meal is low fiber and low protein meal.
219737135|NCT02446938|PROCEDURE|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
219737136|NCT05612607|DRUG|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
219737137|NCT03109925|DEVICE|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
219737138|NCT01316900|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
219737139|NCT01316900|DRUG|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
219737140|NCT01316900|DRUG|GW642444|25 mcg once-daily
219737141|NCT01316900|DRUG|tiotropium bromide|18 mcg once-daily
219743693|NCT06417788|DEVICE|Dental implant placement|Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
219743694|NCT06417788|PROCEDURE|Static guided implant placement|Dental implant placement guided by a stereolithographic pilot drill guide.
219743695|NCT02103179|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
219743696|NCT01390103|OTHER|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
219163718|NCT00100698|DRUG|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
219163719|NCT00100698|DRUG|placebo|placebo subcutaneously once a day, 18 months
219163720|NCT02909192|DEVICE|Light Therapy Device|
219163721|NCT01426412|DRUG|LY3015014 IV|Administered IV over 30-90 minutes
219163722|NCT01426412|DRUG|Placebo IV|Administered IV only over 30-90 minutes
219163723|NCT01426412|DRUG|LY3015014 SC|Administered SC
219163724|NCT01426412|DRUG|Placebo SC|Administered SC
219163725|NCT01420458|DRUG|Experimental|Bioequivalence of two drug formulations
219163726|NCT05950867|DIAGNOSTIC_TEST|ECG + echocardiography|Electrocardiogram and echocardiography
219163727|NCT05950867|OTHER|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
219163728|NCT05406765|DRUG|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
219163729|NCT00831688|DEVICE|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
219163730|NCT00831688|DEVICE|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
219163731|NCT03459989|DIAGNOSTIC_TEST|Ultrasound|Samsung H60 Ultrasound
219163732|NCT02371395|OTHER|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
219163733|NCT04974567|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
219163734|NCT05607199|DRUG|AUR103|Twice Daily
219163735|NCT04452201|BEHAVIORAL|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
219163736|NCT06376058|DRUG|Chloroprocaine 1% Injectable Solution|• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
219163737|NCT06376058|DRUG|Ropivacaine 0.75% Injectable Solution|• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
219163738|NCT06966934|DEVICE|NPA|After sedation, the nasopharyngeal airway (NPA) is inserted when the patient's breathing becomes slightly slow but stable and the eyelash reflex disappears.
219163739|NCT04968405|DEVICE|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
219163740|NCT05633719|OTHER|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
219163741|NCT03865056|DEVICE|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
219163742|NCT03865056|DEVICE|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
219236895|NCT00248794|BEHAVIORAL|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
219236896|NCT00248794|BEHAVIORAL|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
219236897|NCT05444374|DRUG|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
219236898|NCT05444374|DRUG|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
219236899|NCT04362059|DEVICE|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
219236900|NCT04362059|OTHER|Standard of Care|Standard of care treatment for respiratory illness
219236901|NCT02632747|DRUG|Empagliflozin|Empagliflozin will be taken once daily
219236902|NCT02632747|DRUG|Placebo (matching empagliflozin)|Placebo will be taken once daily
219236903|NCT02632747|DRUG|ramipril|Ramipril will be taken once or twice daily
219236904|NCT03213379|DEVICE|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
219236905|NCT05107232|OTHER|MRI|MRI
219236906|NCT03449979|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
219236907|NCT03449979|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
219236908|NCT02732470|OTHER|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
219236909|NCT03095378|PROCEDURE|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
219236910|NCT03095378|PROCEDURE|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
219236911|NCT03095378|PROCEDURE|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
219236912|NCT02069379|DRUG|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
219236913|NCT02069379|DRUG|Placebo|Placebo capsules prepared identically to Metformin capsules
219236914|NCT00420498|DRUG|Atomoxetine (Strattera™)|
219236915|NCT02326493|DEVICE|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
219236916|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
219236917|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
219163743|NCT03818100|RADIATION|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
219163744|NCT03818100|DRUG|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
219163745|NCT03818100|PROCEDURE|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
219163746|NCT05042375|DRUG|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
219163747|NCT05042375|DRUG|pembrolizumab|pembrolizumab 200 mg.
219163748|NCT05042375|DRUG|camrelizumab|Camrelizumab for injection, 200 mg.
219163749|NCT00677391|DRUG|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
219163750|NCT00677391|DRUG|Placebo|Capsules, once daily
219163751|NCT01084707|DRUG|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
219163752|NCT01084707|DRUG|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
219163753|NCT01084707|DRUG|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
219163754|NCT02035631|BEHAVIORAL|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
219163755|NCT02035631|BEHAVIORAL|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
219163756|NCT02035631|BEHAVIORAL|Minimal diet intervention|Some basic diet recommendations
219163757|NCT02035631|BEHAVIORAL|Minimal physical activity intervention|Some basic recommendations on physical activity
219163758|NCT00662519|DRUG|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
219163759|NCT00662519|DRUG|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
219163760|NCT00662519|DIETARY_SUPPLEMENT|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
219163761|NCT00662519|OTHER|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
219163762|NCT00662519|OTHER|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
219236918|NCT01201278|DRUG|Insulin LISPRO|Subcutaneous insulin lispro 8 U
219163763|NCT03052335|DEVICE|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
219163764|NCT03052335|PROCEDURE|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
219163765|NCT03514836|BIOLOGICAL|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
219163766|NCT03514836|DRUG|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
219163767|NCT00715884|DEVICE|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
219163768|NCT00715884|DEVICE|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
219163769|NCT06440642|DEVICE|tonopen|Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
219163770|NCT04870749|DIAGNOSTIC_TEST|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
219163771|NCT02672033|RADIATION|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
219163772|NCT02672033|RADIATION|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
219163773|NCT02672033|OTHER|Laboratory Biomarker Analysis|Correlative studies
219163774|NCT02672033|PROCEDURE|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
219163775|NCT00215787|DRUG|lansoprazole|Lansoprazole 30 mg BID for 1 year
219163776|NCT02671435|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
219163777|NCT02671435|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
219163778|NCT02671435|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
219163779|NCT02671435|DRUG|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
219163780|NCT02671435|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
219163781|NCT06286085|OTHER|Lung function tests|Pulmonary function tests
219163782|NCT06000813|BEHAVIORAL|REACH-Es|REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.
219163783|NCT06000813|BEHAVIORAL|ETAU|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
219163784|NCT06334107|BEHAVIORAL|Exercise|Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
219163785|NCT05192980|OTHER|No Intervention NA|Additional blood sampling (not mandatory)
219163786|NCT03547999|DRUG|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
219163787|NCT03547999|BIOLOGICAL|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
219163788|NCT03547999|BIOLOGICAL|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
219163789|NCT03547999|DRUG|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
219163790|NCT02412748|BEHAVIORAL|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
219163791|NCT02412748|BEHAVIORAL|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
219236919|NCT04195334|DEVICE|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
219236920|NCT03195127|OTHER|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
219236921|NCT03059147|DRUG|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
219163792|NCT00573482|BEHAVIORAL|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
219163793|NCT00573482|BEHAVIORAL|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
219163794|NCT03069313|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
219163795|NCT00738023|DRUG|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
219163796|NCT00738023|DRUG|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
219163797|NCT00738023|DRUG|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
219163798|NCT01577225|DEVICE|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
219163799|NCT01577225|DEVICE|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
219163800|NCT06211556|BEHAVIORAL|Very-low calorie diet|\~800 kcal/day delivered via commercially available diet plan (NUPO).
219163801|NCT00664404|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
219163802|NCT05998252|DEVICE|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
219236922|NCT03059147|DRUG|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
219163803|NCT02351310|DRUG|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
219163804|NCT02351310|GENETIC|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
219163805|NCT04820686|DRUG|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
219163806|NCT04820686|DRUG|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
219163807|NCT04820686|DRUG|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
219163808|NCT00003542|BIOLOGICAL|pegylated interferon alfa|
219163809|NCT01872078|DRUG|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
219163810|NCT01872078|DRUG|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
219163811|NCT04313205|DRUG|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
219163812|NCT01424670|DRUG|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
219163813|NCT01424670|DRUG|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
219163814|NCT00168649|DRUG|Vitamin A|
219163815|NCT00761189|DRUG|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
219163816|NCT00498511|PROCEDURE|upper gastrointestinal endoscopy, colonoscopy|
219163817|NCT04156204|OTHER|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
219163818|NCT04156204|DRUG|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
219163819|NCT01392638|OTHER|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
219163820|NCT01392638|DRUG|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
219163821|NCT00873613|PROCEDURE|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
219163822|NCT01494922|DRUG|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
219163823|NCT00640549|DRUG|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
219163824|NCT00640549|DRUG|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
219163825|NCT04005482|OTHER|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
219236923|NCT03964272|DEVICE|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
219236924|NCT03059056|DRUG|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
219236925|NCT00014508|BIOLOGICAL|sargramostim|
219236926|NCT00014508|DRUG|cyclophosphamide|
219236927|NCT00014508|DRUG|cyclosporine|
219236928|NCT00014508|DRUG|fludarabine phosphate|
219236929|NCT00014508|DRUG|melphalan|
219236930|NCT00014508|PROCEDURE|peripheral blood stem cell transplantation|
219236931|NCT03258099|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219236932|NCT02282137|DRUG|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
219236933|NCT01789593|OTHER|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
219236934|NCT00992030|DRUG|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
219236935|NCT00992030|RADIATION|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
219236936|NCT04432909|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
219163826|NCT03608787|BEHAVIORAL|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
219163827|NCT06077851|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
219163828|NCT05838677|BEHAVIORAL|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
219163829|NCT05838677|OTHER|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
219163830|NCT02444858|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.
219163831|NCT02444858|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
219163832|NCT03692780|DRUG|Careseng 1370|4,000mg granules in sachet
219163833|NCT03692780|DRUG|Placebo|4,000mg granules in sachet
219163834|NCT02891915|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
219163835|NCT02891915|DRUG|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
219163836|NCT02891915|DRUG|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
219163837|NCT02891915|OTHER|Placebo|Placebo
219163838|NCT01910896|DEVICE|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
219163839|NCT04103723|PROCEDURE|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
219163840|NCT02226536|BEHAVIORAL|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
219163841|NCT05237752|DRUG|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
219163842|NCT02300675|BEHAVIORAL|therapeutic education program|
219163843|NCT06111924|OTHER|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
219163844|NCT06111924|OTHER|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
219163845|NCT04362046|PROCEDURE|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
219236937|NCT05569018|BEHAVIORAL|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
219163846|NCT02179268|DRUG|sertraline|50mg, 50-150mg/d,qd for one year
219163847|NCT02179268|DRUG|citalopram|20mg, 20-40mg/d,qd,for one year
219163848|NCT02179268|DRUG|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
219163849|NCT02179268|DRUG|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
219163850|NCT02179268|BEHAVIORAL|control|50min, every week for three months, every month, for nine months
219163851|NCT00750620|DRUG|YM178|oral
219163852|NCT04749784|DIETARY_SUPPLEMENT|High Dose Arterin Cholesterol|240mg active ingredient daily
219163853|NCT04749784|DIETARY_SUPPLEMENT|Low Dose Arterin Cholesterol|120mg active ingredient daily
219163854|NCT04749784|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
219163855|NCT05871112|OTHER|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
219163856|NCT03136042|OTHER|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
219163857|NCT03136042|OTHER|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
219163858|NCT03136042|OTHER|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
219163859|NCT03298074|DRUG|Apatinib|Apatinib, 500mg,po qd for continuous administration
219163860|NCT03298074|DRUG|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
219163861|NCT01091168|DRUG|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
219163862|NCT01091168|DRUG|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
219163863|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
219163864|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
219163865|NCT06071494|OTHER|Tropical fruits|papaya, mango, banana, orange
219163866|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique|"This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery"
219163867|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with double-tract reconstruction|This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
219163868|NCT03730051|DRUG|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
219163869|NCT03730051|DRUG|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
219163870|NCT05928624|DEVICE|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
219163871|NCT05928624|OTHER|Standard of Care|Standard of Care
219163872|NCT05300958|DRUG|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
219163873|NCT07022132|OTHER|Diaphragmatic myofascial release (DMR)|The physiotherapist, positioned on the head side of the supine patient, makes bilateral contact with the pisiform, hypothenar region and the underside of the 7th-10th costal cartilages with the last three fingers. During the inspiration phase, he/she pulls the contact points cephalically and slightly laterally with both hands, accompanying the elevation of the costae. During expiration, it deepens the contact towards the inner costal margin, maintaining resistance. In subsequent breathing cycles, it gradually increases the depth of contact inside the costal margin. The application is performed in 2 sets of 10 deep breaths with 1 minute between them.
219163874|NCT07022132|OTHER|Abdominal hypopressive exercise (AHE)|Each session consists of 6 hypopressive abdominal exercises with a 2-minute recovery period in between, and each exercise is repeated 3 times. This manoeuvre consists of expelling all air until the reserve volume is reached, then holding the breath (expiratory apnoea) and pulling the abdominal wall inwards and cranially by opening the costae without allowing air to enter. Exercises are performed in 6 different positions.
219163875|NCT07022132|OTHER|Conservative treatment|It consists of lumbar flexion and extension, stretching and strengthening exercises for the waist, back and abdominal region.
219163876|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
219163877|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
219163878|NCT07050225|OTHER|Digital Cognitive Training|This digital cognitive training program uses gamified tasks in order to enhance cognitive skills in an engaging manner using machine learning AI algorithms to target the intervention to individual cognitive skill deficits. It consists of personalized gamified cognitive tasks that target individual cognitive deficits associated with ADHD including attention, impulsivity, working memory, and cognitive flexibility.
219163879|NCT07050225|OTHER|Digital Non-cognitive Training Intervention|This is a gamified computer platform lacking cognitive training components.
219163880|NCT07048379|DEVICE|Orthosis|A resting orthosis will be preferred because it keeps the wrist in a neutral position.
219163881|NCT07048379|OTHER|Physical Therapy|Participants will undergo physical therapy for three weeks, including hot packs, TENS, tendon-nerve sliding exercises, stretching and strengthening exercises.
219163882|NCT07060781|PROCEDURE|Posterior Lumbar Spine Decompression|Patients undergoing elective posterior lumbar spine decompression.
219163883|NCT07071389|DIETARY_SUPPLEMENT|Zyxelle|Patients in the study group receive Zyxelle dietary supplement along with the oral contraceptive
219163884|NCT07071389|DRUG|Oral contraceptive|Patients in the study group receive daily dose of estroprogestinic oral contraceptive
219163885|NCT07070492|DEVICE|cataract surgery|cataract surgery receiving Vivity IOL or standard mono focal controls
219163886|NCT07070492|PROCEDURE|retinal surgery|Retinal surgery for visually significant epiretinal membrane
219163887|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
219236938|NCT05569018|BEHAVIORAL|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
219236939|NCT01862224|DRUG|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
219163888|NCT07066631|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
219163889|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
219163890|NCT07064954|BIOLOGICAL|Autologous Cold-Stored Platelets|Two units of autologous platelets will be collected via an apheresis machine that draws blood from an intravenous (IV) line over 1-2 hours, isolates and leukoreduces the platelets by centrifugation and returns the remaining blood back to the patients. Collected autologous platelets will be stored at 1-6℃ without agitation until they are needed during or after surgery or 14 days have elapsed since their collection, after which they will be destroyed as per standard institutional procedures for expired blood products. For the first two platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients will receive their autologous cold-stored platelets. For the third and subsequent doses, patients in the intervention group will receive allogeneic room temperature-stored platelets (standard of care).
219163891|NCT07064954|BIOLOGICAL|Allogeneic Room Temperature-Stored Platelets (Standard of Care)|Allogeneic platelets will be collected by Canadian Blood Services as per their standard operating procedures. Room temperature stored platelets will be stored at 20-24°C with constant agitation for up to 7 days as per current practices. For any platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients in the control group will receive allogeneic platelets as per usual care.
219163892|NCT06900764|DRUG|CAR-T cell|CAR-T cell
219236940|NCT01862224|DRUG|Placebo|Matching placebo once daily (Week 0 to Week 12).
219236941|NCT01862224|DRUG|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
219163893|NCT06901011|PROCEDURE|continuous renal replacement therapy|"Intervention Arm: Effluent dose schedule of 10-20 ml/kg/h after 48 hours of starting dose of 25-35 ml/kg/h, until completing 96 hours~Control Arm Effluent dosage schedule of 25-35 ml/kg/h fixed for 96 hours"
219163894|NCT07071896|OTHER|16 weeks remotely exercise program|16 weeks, twice per week, remotely exercise program
219163895|NCT06884826|PROCEDURE|Desarda technique|Patients will undergo Desarda technique.
219163896|NCT06440135|DRUG|Ziftomenib|Taken orally once per day
219163897|NCT07071597|PROCEDURE|Renal Biopsy|Renal biopsy is performed to clarify the renal pathology.
219163898|NCT07077057|DIAGNOSTIC_TEST|AI-assisted ECG interpretation (PMcardio)|Participants in the experimental arm will undergo 12-lead ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical, Slovakia). The AI algorithm analyzes ECG data in real time to detect patterns suggestive of occlusion myocardial infarction (OMI), including cases not meeting traditional ST-elevation myocardial infarction (STEMI) criteria. In the experimental arm, the AI output is provided immediately to the treating clinician and used as an adjunct to standard ECG interpretation to support timely diagnosis and management decisions.
219163899|NCT07077876|PROCEDURE|Hysteroscopic Resection and Hormonal Therapy|Patients underwent hysteroscopic resection of atypical endometrial hyperplasia (AEH) or grade 1-2 endometrial adenocarcinoma (EAC) using a 15 Fr mini-resectoscope. Depending on the case, the procedure included visual D\&C or a combined technique. At the end of the procedure, a 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) was inserted. In patients with EAC G2 or poor prognostic markers (e.g., MMR deficiency), oral progestin therapy with Megestrol Acetate (160 mg daily) was added. Follow-up included hysteroscopic endometrial biopsy at 3, 6, and 12 months to assess response.
219163900|NCT07078305|DRUG|Regorafenib and tislelizumab|Tislelizumab: 200mg, iv, d1, Q3W; Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
219163901|NCT07078305|DRUG|Regorafenib|Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
219163902|NCT06842303|DEVICE|Magnetic resonance elastography (MRE).|Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure
219163903|NCT06842303|DEVICE|High-resolution diffusion sequence in MRI|High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.
219163904|NCT06918275|PROCEDURE|Laparoscopic isthmocele repair using V-LocTM 180 barbed suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
219163905|NCT06918275|OTHER|Laparoscopic isthmocele repair using Polyglactin 910 vicryl suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
219163906|NCT06932679|OTHER|Assessment of Gait and Visual Exploration|Participants will perform walking tasks involving obstacle crossing while their gait and visual exploration patterns are recorded using wearable sensors and eye-tracking glasses. This is a non-invasive observational study with no therapeutic intervention.
219163907|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy \* 3-10 fractions) for pulmonary lesions, lymph node lesions and visceral lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity is intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219236942|NCT00700999|DRUG|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
219236943|NCT06181513|DRUG|Probiotic Blend Capsule|20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)
219236944|NCT02919865|DEVICE|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
219236945|NCT02618109|BIOLOGICAL|Collection of blood samples|Collection of blood samples
219236946|NCT04182542|DEVICE|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
219236947|NCT03481725|DEVICE|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
219163908|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219163909|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and bone metastatic lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219163910|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219163911|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and bone metastatic lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219163912|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219163913|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
219236948|NCT03481725|DEVICE|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
219236949|NCT04026022|DRUG|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
219236950|NCT04026022|DRUG|Placebo|Placebo plaster in the ER or PACU
219236951|NCT05863871|DRUG|Linperlisib|80 mg, qd
219236952|NCT05250362|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
219236953|NCT02327702|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
219236954|NCT05264311|OTHER|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
219163914|NCT06951399|DRUG|Pembrolizumab (KEYTRUDA®)|IV Pembrolizumab 200 mg combined with pemetrexed and platinum (investigator's choice of cisplatin or carboplatin) every 3 weeks
219163915|NCT07071207|BEHAVIORAL|Text message reminders|daily 8am text messages reminding patients to perform Kegel exercises as per their standard-of-care post-operative discharge instructions.
219163916|NCT07078708|DIETARY_SUPPLEMENT|vitamin D (cholecalciferol) supplementation|Vitamin D supplementation at a dose of 50,000 IU every two weeks along with a daily intake of 1,000 mg of calcium for 12 weeks
219163917|NCT07078708|OTHER|Placebo|Placebo was given for 12 weeks
219163918|NCT06408233|OTHER|Performance Coaching|Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
219163919|NCT05933707|BEHAVIORAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
219163920|NCT04790175|DRUG|Tolvaptan (SAMSCA)|The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.
219163921|NCT03744312|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
219163922|NCT03744312|DRUG|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
219163923|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219163924|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
219163925|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
219163926|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
219163927|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
219163928|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
219236955|NCT05067816|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
219236956|NCT03651271|BIOLOGICAL|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
219236957|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
219236958|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
219236959|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
219163929|NCT05606406|OTHER|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
219163930|NCT06480578|BEHAVIORAL|ISS-SBDOH arm|Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
219163931|NCT05208814|DRUG|TPN171H single dose|10 mg TPN171H taken once
219163932|NCT06261502|DRUG|CBD Oral Solution|Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
219163933|NCT06261502|DRUG|Placebo|Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
219163934|NCT05297734|OTHER|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
219163935|NCT05297734|BEHAVIORAL|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
219163936|NCT03850015|DIAGNOSTIC_TEST|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
219163937|NCT03850015|OTHER|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
219163938|NCT05170269|DRUG|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
219163939|NCT06694948|DRUG|pimicotinib capsules|pimicotinib capsules
219163940|NCT05498376|DEVICE|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
219163941|NCT05498376|DEVICE|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
219163942|NCT02991625|OTHER|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
219163943|NCT02991625|OTHER|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
219163944|NCT02991625|OTHER|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
219163945|NCT05310539|OTHER|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
219163946|NCT05196815|OTHER|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
219163947|NCT05196815|PROCEDURE|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
219163948|NCT05196815|PROCEDURE|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
219163949|NCT05196815|RADIATION|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
219163950|NCT05196815|DRUG|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
219163951|NCT06366451|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
219163952|NCT06366451|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
219163953|NCT06366451|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
219163954|NCT06366451|BIOLOGICAL|AZD9592|Intratumoral microdose injection by the CIVO device.
219163955|NCT06366451|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
219163956|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Rilvegostomig|Intratumoral microdose injection by the CIVO device.
219163957|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Volrustomig|Intratumoral microdose injection by the CIVO device.
219163958|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Sabestomig|Intratumoral microdose injection by the CIVO device.
219163959|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
219163960|NCT04924062|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
219163961|NCT04924062|DRUG|Gemcitabine|Gemcitabine by IV infusion
219163962|NCT04924062|DRUG|Cisplatin|Cisplatin by IV infusion
219163963|NCT04924062|DRUG|Placebo|Placebo to pembrolizumab
219163964|NCT03980509|DRUG|Curcumin|Curcumin is an extract from turmeric
219163965|NCT06761365|DEVICE|LuSeed Aneurysm Embolization System|a permanent intrasaccular implant used for treatment of unruptured intracranial saccular aneurysms (IA) in adult patients according to international guidelines who are indicated for non-emergent endovascular embolization of saccular IAs at the time of presentation.
219163966|NCT05704296|PROCEDURE|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
219163967|NCT05704296|PROCEDURE|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
219163968|NCT05549362|OTHER|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
219163969|NCT06702891|OTHER|Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing|The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
219163970|NCT06261593|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
219163971|NCT06829472|DRUG|melphalan|conditioning regimen with melphalan, busulfan and fludarabine
219163972|NCT06527521|PROCEDURE|Traumatologic surgery|Patients undergoing trauma surgery
219163973|NCT02428192|BIOLOGICAL|Ipilimumab|Given IV
219163974|NCT02428192|OTHER|Laboratory Biomarker Analysis|Correlative studies
219163975|NCT02428192|BIOLOGICAL|Nivolumab|Given IV
219163976|NCT06783582|OTHER|Motivational interviewing based on Pender's health promotion model|In addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
219163977|NCT04562480|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219163978|NCT04562480|OTHER|Quality-of-Life Assessment|Ancillary studies
219163979|NCT04562480|OTHER|Questionnaire Administration|Ancillary studies
219163980|NCT04562480|PROCEDURE|Resection|Undergo surgical resection
219163981|NCT05426213|DEVICE|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
219163982|NCT06788639|BIOLOGICAL|Lisocabtagene maraleucel|According to the United States Prescribing Information
219163983|NCT06782958|DRUG|50mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
219163984|NCT06782958|DRUG|100mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
219163985|NCT06782958|DRUG|150 mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
219163986|NCT06782958|DRUG|200 mg FHND1002（fasting）|Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
219236960|NCT01870687|DRUG|20mg VAC BNO 1095 FCT|
219163987|NCT06782958|DRUG|250mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
219163988|NCT06782958|DRUG|200mg FHND1002(postprandial)|Participants will receive a one-time dose (200 mg) under postprandial conditions
219236961|NCT01870687|DRUG|Placebo|
219236962|NCT05028283|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
219163989|NCT06784258|PROCEDURE|General Anesthesia (control group)|The patient will undergo conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/kg BB. After that the patient will be intubated
219163990|NCT06784258|PROCEDURE|General Anesthesia combined with epidural anesthesia|The patient will undergo epidural anesthesia first with an epidural catheter inserted through a Tuohy needle and ensuring that the length of the multihole epidural catheter that enters the epidural space is 5-6 cm. After that, the patient underwent conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/ kg BW. After that the patient will be intubated. The patient will be given local anesthesia Bupivacaine 0.25% in increments to the desired volume according to the desired height of the segmental block. Local anesthetic medication will be given intermittently every 2 hours
219163991|NCT06830954|DRUG|Group A|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg).
219163992|NCT06830954|DRUG|Reference Group|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg).
219163993|NCT05173818|DRUG|Hyperbaric oxygen at 1.5 ATA|Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
219163994|NCT05173818|DRUG|Sham treatment|"Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent"
219163995|NCT06780592|DRUG|Vebreltinib + Temozolomide|Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
219163996|NCT06780592|DRUG|Temozolomide|Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
219163997|NCT04894110|BIOLOGICAL|EO2002|EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
219163998|NCT04894110|BIOLOGICAL|EO2002 low dose|Low dose of EO2002 (magnetic human corneal endothelial cells)
219163999|NCT04894110|BIOLOGICAL|EO2002 mid dose|Mid dose of EO2002 (magnetic human corneal endothelial cells)
219164000|NCT04894110|BIOLOGICAL|EO2002 high dose|High dose of EO2002 (magnetic human corneal endothelial cells)
219164001|NCT06789939|OTHER|Train the trainer program for MPCC professionals|The intervention will consist on a train the trainer program. 3 professionals from each MPCC will be trained by an educational team. They will then have to implement an IPEP (knowledge of the MPCC, participation in interprofessional MPCC activities, etc.) for students on placement in their MPCC.
219164002|NCT06832423|DIETARY_SUPPLEMENT|Creatine monohydrate|Powder mixed with flavoured water
219164003|NCT06832423|DIETARY_SUPPLEMENT|Placebo|Powder mixed with flavoured water
219164004|NCT06833918|GENETIC|blood sampling|"The followings markers will be investigated in plasma samples:~1. LIPCAR, STAT3 and DDIT3 using quantitative real-time polymerase chain reaction (qRT-PCR)~2. α-SMA using western blot analysis~3. Troponin T using ELISA expression~4. Serum levels of fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C), oxidized low-density lipoprotein (ox-LDL) using chemical methods (spectrophotometry). The Friedewald formula was used to compute low-density lipoprotein cholesterol (LDL-C): LDL-Cholesterol =Total cholesterol- (HDL-Cholesterol +Triglycerides/5)."
219164005|NCT05716165|DEVICE|proprioceptive knee braces|The patient will perform the tests with the knee braces.
219164006|NCT05716165|DEVICE|No knee brace|The patient will perform the tests without the knee brace.
219164007|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
219236963|NCT01706393|DIETARY_SUPPLEMENT|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
219236964|NCT01706393|DIETARY_SUPPLEMENT|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
219236965|NCT06210178|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI scans including abdominal 4D Flow MRI.
219236966|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
219164008|NCT03938532|DEVICE|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
219164009|NCT03938532|DEVICE|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
219164010|NCT04337372|BEHAVIORAL|Effects of shared book reading: Labels|Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
219164011|NCT05925595|DEVICE|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
219164012|NCT04719988|BIOLOGICAL|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
219164013|NCT04719988|PROCEDURE|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
219164014|NCT01983241|BIOLOGICAL|Alpha-1 MP|
219164015|NCT01983241|OTHER|0.9% Sodium Chloride for Injection, USP|
219164016|NCT05418972|DRUG|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
219164017|NCT04172233|BIOLOGICAL|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
219164018|NCT04172233|BIOLOGICAL|placebo|matching placebo
219164019|NCT04432454|DRUG|Lasofoxifene and abemaciclib (VERZENIO (R)).|Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
219164020|NCT06217718|OTHER|Telenursing Interventions|Patient follow-up with phone calls and text messages
219164021|NCT06174285|OTHER|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
219164022|NCT06174285|OTHER|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
219164023|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
219164024|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
219164025|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
219236967|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
219236968|NCT00323895|DEVICE|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
219236969|NCT01795183|DRUG|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
219164026|NCT04309565|BEHAVIORAL|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
219164027|NCT04309565|BEHAVIORAL|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
219164028|NCT06393400|DRUG|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant"
219164029|NCT06393400|DRUG|PEG3350|"Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX"
219164030|NCT06393400|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Gemzar"
219164031|NCT06393400|DRUG|nab-Paclitaxel|"nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Abraxane"
219164032|NCT04246151|DRUG|Vancomycin|Vancomycin capsules
219164033|NCT04246151|DIETARY_SUPPLEMENT|Culturelle|Culturelle capsules
219164034|NCT04246151|DRUG|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
219164035|NCT04246151|DRUG|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
219164036|NCT06426706|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Before the induction of general anesthesia, under aseptic conditions, serratus posterior superior intercostal plane block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
219164037|NCT06426706|PROCEDURE|Paravertebral Block|Before the induction of general anesthesia, under aseptic conditions, paravertebral block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
219164038|NCT05000073|OTHER|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
219164039|NCT05000073|OTHER|dialysis|dialysis
219164040|NCT05945797|DRUG|Dexamethasone 4mg|An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
219164041|NCT00567398|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
219164042|NCT00567398|DRUG|Physioneal|Physioneal 40 or Physioneal 35
219164043|NCT00567398|DRUG|Extraneal|Extraneal - 7.5% Icodextrin
219164044|NCT00567398|DRUG|Nutrineal|Nutrineal - 1.1% Amino Acids
219236970|NCT05759000|DRUG|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
219236971|NCT03424187|DIETARY_SUPPLEMENT|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
219164045|NCT03933384|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
219164046|NCT03933384|DRUG|Entecavir|Entecavir 0.5mg/tab once daily
219236972|NCT01643538|BEHAVIORAL|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
219236973|NCT01643538|BEHAVIORAL|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
219164047|NCT06775925|OTHER|Unilateral robot-assisted therapy (RT)|RT will be performed as an add-on therapy to the clinical routine therapy scheme for 3 x 30 minutes per week for 6 weeks. RT is applied using the ArmeoSpring, an exoskeleton that provides adjustable antigravity weight support for the arm through a system of springs (no actuators).
219164048|NCT06775925|OTHER|Unilateral conventional occupational therapy (OT)|The OT is applied as add-on therapy for 3 x 30 minutes per week for 6 weeks. OT comprises strengthening exercises (concentric and eccentric) with and without resistance, grasping exercises, fine motor training, peg games, and activity-based tasks which are unilaterally doable.
219164049|NCT06776913|DEVICE|Colonoscopy|Standard Colonoscopy with photo documentation and the recording of procedure timing.
219164050|NCT05051813|DEVICE|ANTERION|3 repeat measurements on each of the 3 ANTERION devices and 3 reference devices.
219164051|NCT06026527|DRUG|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
219164052|NCT06026527|DRUG|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
219164053|NCT05827523|DRUG|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
219164054|NCT05857553|OTHER|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
219164055|NCT05857553|OTHER|No Direct Cash Transfer|No intervention
219164056|NCT06038656|DIETARY_SUPPLEMENT|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
219164057|NCT03747042|DRUG|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
219164058|NCT06776120|DIAGNOSTIC_TEST|Fecal chemical test (FIT)|Eligible participants will be instructed to collect their two stool samples within seven days prior to undergoing bowel preparation. These stool samples will be then submitted for a quantitative FIT (OC-SENSOR, EIKEN CHEMICAL, Japan). Colonoscopic observations and histopathological findings will be employed as the definitive reference standards for diagnosis.
219164059|NCT05038345|PROCEDURE|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
219164060|NCT04843865|DIETARY_SUPPLEMENT|Chinese Herbs|Chinese Herbs
219164061|NCT04110977|DEVICE|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
219164062|NCT04871490|DIAGNOSTIC_TEST|Blood test for HPV DNA|All participants will have blood tested for HPV DNA.
219164063|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
219164064|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 1 and 15
219164065|NCT03535727|DRUG|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
219164066|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 1 and 15
219164067|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 1 and 15
219164068|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
219164069|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 4 and 11
219164070|NCT03535727|DRUG|Capecitabine|PO BID; Days 1- 14
219164071|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 4 and 11
219164072|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 4 and 11
219164073|NCT05046444|DIAGNOSTIC_TEST|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
219164074|NCT06781320|DEVICE|stabilization splint|"the patients will receive a stabilization splint fabricated using a fully digital workflow includes:~Intraoral scanning of maxillary and mandibular arches to create a digital model.~Jaw tracking using the Zebris JMA system to record mandibular movements. CAD design of the splint using Exocad software. Fabrication of the splint via 3D printing technology. The FD-SS is designed to provide optimal occlusal stabilization, reduce TMJ stress, and minimize enamel wear over 6 months.~Or the patient will receive stabilization splint fabricated using conventional methods. The intervention includes:~Taking alginate impressions of maxillary and mandibular arches to create plaster casts.~Jaw registration using a Lucia jig and semi-adjustable articulator for proper occlusal adjustment.~Manual fabrication of the splint using polymethyl methacrylate (PMMA) resin. The C-SS is designed to achieve occlusal stabilization and symptom relief for TMD patients over 6 months."
219164075|NCT06764784|PROCEDURE|Freehand Implant Surgery|This intervention involves implant placement performed manually by the surgeon without the use of specialized guides. The procedure relies on the surgeon's clinical judgment and experience to determine the implant's positioning, angulation, and depth.
219236974|NCT01643538|BEHAVIORAL|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
219236975|NCT01643538|BEHAVIORAL|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
219236976|NCT00614354|DRUG|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
219236977|NCT02991118|DRUG|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
219236978|NCT02991118|DRUG|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
219236979|NCT00595959|DEVICE|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
219236980|NCT06251791|OTHER|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
219236981|NCT06251791|OTHER|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
219236982|NCT03676504|BIOLOGICAL|CD19.CAR T Cells|Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
219236983|NCT03676504|DRUG|Fludarabine|3 days of fludarabine 30 mg/m\^2/day
219236984|NCT03676504|DRUG|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m\^2/day
219236985|NCT04373967|DRUG|Victoza®.|Patients will receive Victoza®. Both products will be provided as pen-injector.
219236986|NCT04373967|DRUG|Metformin Hydrochloride|Patients who were receiving metformin prior to study will continue to receive it during the study.
219236987|NCT04373967|DRUG|TQZ2451|Patients will receive TQZ2451.Both products will be provided as pen-injector.
219236988|NCT05017454|DRUG|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
219236989|NCT05017454|DRUG|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
219236990|NCT03190148|OTHER|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
219236991|NCT03190148|OTHER|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
219236992|NCT03190148|OTHER|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
219236993|NCT01892176|DIETARY_SUPPLEMENT|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
219236994|NCT04144088|DRUG|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
219236995|NCT04144088|DRUG|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
219236996|NCT04144088|DRUG|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
219236997|NCT00829400|BEHAVIORAL|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
219236998|NCT00829400|BEHAVIORAL|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
219236999|NCT00263900|DEVICE|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
219237000|NCT04849091|DEVICE|iReadMore|Digital Alexia Therapy
219237001|NCT03434106|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
219237002|NCT03434106|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
219237003|NCT05922774|DEVICE|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
219237004|NCT00446095|DRUG|fostamatinib|200 mg PO BID
219237005|NCT00681135|DEVICE|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
219237006|NCT00681135|DEVICE|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
219237007|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
219237008|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
219237009|NCT03726502|PROCEDURE|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
219237010|NCT03726502|PROCEDURE|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
219164076|NCT06764784|PROCEDURE|Pilot-Drilled Implant Surgery|This intervention utilizes a pilot drill to create an initial guide hole for the implant. The pilot-drilled pathway improves accuracy while still allowing the surgeon flexibility during the procedure. The final implant is placed following sequential drilling.
219164077|NCT06764784|PROCEDURE|Fully Guided Implant Surgery|This intervention employs computer-aided surgical templates created from preoperative imaging data, such as CBCT scans. These guides ensure precise implant positioning, angulation, and depth based on preoperative planning. The approach minimizes variability and enhances accuracy.
219237011|NCT03726502|PROCEDURE|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
219237012|NCT03726502|PROCEDURE|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
219237013|NCT00098735|DRUG|FTY720|
219237014|NCT05567848|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
219164078|NCT03902223|DIAGNOSTIC_TEST|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
219164079|NCT03902223|DIAGNOSTIC_TEST|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
219164080|NCT06780436|DEVICE|3D Transcranial Ultrasound Brain Imaging|The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.
219164081|NCT06781918|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|"DHA \&amp; Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.~Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17."
219164082|NCT06781918|BEHAVIORAL|Psychosocial stimulation|"The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.~During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.~Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation."
219164083|NCT06781346|PROCEDURE|Rhomboid Intercostal Block|In RI block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the medial border of the scapula between the 4th and 5th rib of the patients in the RIB group. In the ultrasound image, the trapezius muscle, rhomboid muscle, intercostal muscles,pleura, and lung were identified. Under the aseptic condition, inserted laterally in the plane of the T5 level guided by an ultrasound probe with an in plane technique. The intravascular injection should be confirmed negative through aspiration, and 1-3 ml of normal saline was injected to divide the rhomboid and intercostal muscle, and a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected After negative aspiration of blood or air, injected into the deep layer of the rhomboid muscle.
219164084|NCT06781346|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards.
219164085|NCT06780020|OTHER|Effects of different interventions using boxing|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component BOX and a 10-minute cool-down with static flexibility exercises.
219164086|NCT06780020|OTHER|Effects of different interventions using taekwondo|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component TKD and a 10-minute cool-down with static flexibility exercises.
219164087|NCT06780020|OTHER|Effects of different interventions using Elastic Band|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component Elastic Band and a 10-minute cool-down with static flexibility exercises.
219164088|NCT05937776|OTHER|Fludeoxyglucose F-18|Given IV
219164089|NCT05937776|OTHER|Gadoterate Meglumine|Given IV
219164090|NCT05937776|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
219164091|NCT05937776|PROCEDURE|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
219164092|NCT06268041|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
219164093|NCT06268041|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
219164094|NCT06763666|DRUG|Cladribine|Given IV
219164095|NCT06763666|DRUG|Cytarabine|Given IV
219164096|NCT06763666|DRUG|G-CSF|Given SC
219164097|NCT06763666|DRUG|Venetoclax|Given PO
219164098|NCT03055377|DRUG|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
219164099|NCT03055377|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
219164100|NCT06763003|OTHER|Music Therapy|The music therapy session described follows a structured and engaging approach, aimed at enhancing the patient's cognitive skills during neurorehabilitation. Here's a summary of the session components: Relaxation Phase, Song Selection, Instrument Selection and Familiarization, Rhythmic Training, Progression and Adjustment, Session Frequency and Customization. This individualized approach aims to enhance patient engagement and recovery by integrating music, rhythm, and therapeutic interaction into the neurorehabilitation process.
219164101|NCT06763003|OTHER|Standard Care (in control arm)|In the control group, participants will receive the standard neurorehabilitation program prescribed by the rehabilitation team, without the addition of music therapy. This will provide a baseline to compare outcomes with the intervention group and evaluate the feasibility and preliminary effects of the music therapy intervention. The usual cognitive rehabilitation program during the subacute stroke period focuses on restoring cognitive abilities such as attention, memory, executive functions, and communication. The control group's daily rehabilitation sessions will last for 45 minutes, mirroring the music therapy group's session duration, ensuring a fair comparison of outcomes across both groups. This comparison will help assess the unique contributions of music therapy on cognitive functions like attention, memory, and executive functions in stroke patients.
219164102|NCT06078696|DRUG|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
219164103|NCT06078696|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
219164104|NCT06078696|PROCEDURE|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
219164105|NCT06078696|PROCEDURE|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
219164106|NCT06078696|DRUG|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).
219164107|NCT06078696|DRUG|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
219164108|NCT06078696|DRUG|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
219164109|NCT06078696|DRUG|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
219164110|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
219164111|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
219164112|NCT03215030|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
219164113|NCT03215030|DRUG|Dexamethasone|Dexamethasone.
219164114|NCT06789900|DRUG|Everolimus (Afinitor®)|Oral dose of everolimus 5 mg once a week for 24 weeks
219164115|NCT06789900|OTHER|Football Fitness Concept|"Structured hybrid exercise training via the football fitness concept organized as a super-vised group training at the University of Southern Denmark, Department of Sports Science and Clinical Biomechanics. Football Fitness concept is designed for participants with little prior experience with football and it is multifaceted training incorporating endurance training, high-intensity interval training (HIIT) and strength training. The training session lasts 60 minutes, and participants will receive two training sessions per week for 24 weeks. Each session is composed of 4 elements: a 15 min warm-up that includes strength and balance exercises, a 15 min period with technical pair-based drills, and a 30-min period with small-sided football drills"
219164116|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
219164117|NCT06788418|PROCEDURE|Wavelight Plus Alcon system|Wavelight Plus Alcon system guided surgery for myopia
219164118|NCT06788418|PROCEDURE|SMILE|Small Incision Lenticule Extraction surgery for myopia
219164119|NCT06788418|PROCEDURE|ICL|Implantable Collamer Lens surgery for myopia
219164120|NCT06300658|DRUG|Stellate ganglion block|Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
219164121|NCT05304468|RADIATION|IMRT|Patients in experimental group received reduced dose IMRT
219164122|NCT05304468|DRUG|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
219164123|NCT05304468|DRUG|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
219164124|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
219164125|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
219164126|NCT05524649|DIETARY_SUPPLEMENT|Placebo|5 drops/day for 3 months of sunflower oil
219164127|NCT05938465|BIOLOGICAL|EXE-346|EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
219164128|NCT05938465|OTHER|Placebo|Placebo contains excipients maltose and silicon dioxide.
219164129|NCT06766942|OTHER|structured sherborne developmental movement program with sensory integration program|In addition to the sensory integration therapy they receive at the rehabilitation center for 45 minutes, two days a week for 12 weeks, the Structured Sherborne Developmental Movement Program will be applied.
219237015|NCT01790542|OTHER|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
219237016|NCT01790542|OTHER|Iron fortified cereal with fruit|
219237017|NCT01790542|OTHER|Meat|
219237018|NCT01916109|DRUG|Gemcitabine|
219237019|NCT01916109|DRUG|Carboplatin|
219237020|NCT01916109|DRUG|Panitumumab|
219237021|NCT01916109|PROCEDURE|radical cystectomy|
219237022|NCT00001806|OTHER|Genetic Education and Counseling|Group Education and Counseling
219237023|NCT00001806|OTHER|Genetic Education and Counseling|Individual Education and Counlseing
219237024|NCT03987815|DRUG|Nivolumab|Nivolumab
219237025|NCT05924373|DRUG|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
219237026|NCT01036932|DRUG|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
219237027|NCT01036932|DRUG|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
219237028|NCT00490906|DRUG|Copaxone|20 mg, subcutaneous injections, taken daily
219237029|NCT00490906|DRUG|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
219237030|NCT00490906|DRUG|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
219237031|NCT00165048|DRUG|Vioxx (Rofecoxib)|
219237032|NCT03032965|DRUG|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
219237033|NCT03032965|DRUG|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
219237034|NCT01821040|DRUG|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
219237035|NCT01821040|DRUG|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
219237036|NCT00636168|DRUG|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
219237037|NCT00636168|DRUG|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
219237038|NCT01634295|DRUG|CKD-828 2.5/40mg|"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
219237039|NCT01634295|DRUG|CKD-828 5/40mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
219237040|NCT01634295|DRUG|CKD-828 5/80mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."
219237041|NCT01634295|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."
219237042|NCT01634295|DRUG|S-amlodipine 5mg|"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."
219237043|NCT02033915|OTHER|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
219237044|NCT02951702|DRUG|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
219237045|NCT01870895|DRUG|YM060|oral
219237046|NCT01870895|DRUG|Placebo|oral
219237047|NCT01622023|PROCEDURE|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
219237048|NCT06473571|OTHER|Intervention Protocol (The 3GT)|"Participants will be asked to identify three things that went well that day and their role for this occurring \[What went well today, and what was your role in making it happen? as adapted from (Sexton \& Adair, 2019)\]. They will be asked to engage in this exercise for 15 days during the evening."
219237049|NCT06473571|OTHER|Control Group|Participants will be asked to reflect on early memories of their life, with no specific prompts provided, for 15 days during the evening. This activity is consistent with prior efficacy studies of 3GT (Seligman et al., 2005).
219237050|NCT04109651|OTHER|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
219164130|NCT06766942|OTHER|sensory integration program group|Sensory integration therapy programmed according to the individual's needs and disabilities will be applied to this group by an occupational therapist at the rehabilitation center for 45 minutes, 2 days a week for 12 weeks.
219164131|NCT06766942|OTHER|control group|This group will not participate in any activities outside of the standard special education program.
219164132|NCT06093126|DRUG|Lemborexant 5 MG|The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
219164133|NCT06769178|OTHER|Virtual Reality based|Participants will receive treatment by a specialist physiotherapist for a total of 16 sessions, 2 days a week on non-consecutive days for 8 weeks. Both groups will receive neurodevelopmental treatment (NGT) for 16 sessions. While the control group will receive traditional balance training in each session, the VR group will play virtual reality-based games.
219164134|NCT06789133|OTHER|PNF exercises and Body weight supported treadmill gait training|"PNF Exercises:~.Proprioceptive neuromuscular facilitation exercises include D1 Flexion and D1 Extension of lower limb ,D2 flexion D2 extension of lower limb .rhythmic initiation ,hold relax ,pelvic pattern and contract relax technique . subjects will perform each exercise for 30sec with resting interval of 30 to 60 seconds Will be provided after completion of each exercise. 3 sessions will be held per week, For 8 weeks~Gait training:~Body weight supported treadmill gait training for 20 minutes 3 sessions per week.~In total all PNF exercises with gait training will be held for 40-45 minutes."
219164135|NCT06789133|OTHER|Body weight supported treadmill gait training and Routine physical therapy|"Body Weight Supported Treadmill Training (BWSTT):~This will include body weight supported treadmill gait training. 10 % BWSTT or 20% BWSTT. The session will of 20 minutes .3 sessions will be Held per week.~Routine physical therapy:~Stretching and strengthening of lower extremities In total all BWSTT along with routine physical therapy protocol will be held for 40-45minutes .3 sessions will be held per week."
219164136|NCT06785337|DRUG|Inhaled nitroglycerin|Inhaled nitroglycerin
219164137|NCT05190991|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
219164138|NCT06766435|DEVICE|i-STAT TBI Test|The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.
219164139|NCT05805774|PROCEDURE|Distal Femur Replacement|Knee surgery to remove the lower part of the femur and knee joint (where the broken bones are) and will replace them with an artificial knee joint (prosthesis).
219164140|NCT05805774|PROCEDURE|Surgical fixation|Knee surgery to fix the fracture, that can use wires, nails, screws, pins or plates to health and fix the bones together.
219164141|NCT06766019|DRUG|Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV|"1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles"
219164142|NCT06766058|OTHER|Carrier oil|Inhaler stick containing 2 drops of carrier oil.
219164143|NCT06766058|OTHER|Asian plant extract blend|Inhaler stick containing 2 drops of Asian plant extract blend.
219164144|NCT06764901|BEHAVIORAL|Online Therapy Chat Service (TCS)|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer).
219164145|NCT06285604|PROCEDURE|Blood transfusion|Transfusion of designated red blood cell products to anemic neonates.
219164146|NCT03701113|DIETARY_SUPPLEMENT|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
219164147|NCT03701113|DIETARY_SUPPLEMENT|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
219164148|NCT04497129|DEVICE|ROMTech PortableConnect|ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.
219164149|NCT04497129|DEVICE|Traditional Rehabilitation and CPM Device|Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
219164150|NCT04621357|RADIATION|Brain MRI|Brain MRI will include differents sequences.
219164151|NCT04621357|BIOLOGICAL|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
219164152|NCT06798285|PROCEDURE|Pars Plana Vitrectomy Standard|Group I: PPV with endoillumination set at 3.2 Lm.
219164153|NCT06798285|PROCEDURE|Pars Plana Vitrectomy 3D|Group II: PPV with endoillumination set at 0.5 Lm.
219164154|NCT06453824|DRUG|MDI-2517|study drug
219164155|NCT06453824|OTHER|Placebo|matching placebo
219164156|NCT05765344|DRUG|Bulevirtide|Administered via subcutaneous injections.
219237051|NCT06202898|OTHER|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
219164157|NCT01718743|DRUG|Ixazomib Citrate|Given PO
219164158|NCT01718743|DRUG|Lenalidomide|Given PO
219164159|NCT01718743|OTHER|Questionnaire Administration|Ancillary studies
219164160|NCT05906030|DIAGNOSTIC_TEST|Diaphragm ultrasound|Diaphragm ultrasound will be used pre- and postoperatively. Diaphragm dysfunction will be diagnosed using the measurements diaphragm thickening fraction, diaphragm excursion and diaphragm density.
219164161|NCT05752747|OTHER|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
219164162|NCT05752747|OTHER|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
219164163|NCT04680897|BEHAVIORAL|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
219164164|NCT04680897|BEHAVIORAL|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
219164165|NCT05214482|DRUG|AK112|IV infusion,Specified dose on specified days
219164166|NCT05214482|DRUG|AK117|IV infusion,Specified dose on specified days
219164167|NCT05214482|DRUG|Chemotherapy|IV infusion,Specified dose on specified days
219164168|NCT06792344|OTHER|anti-CD19 CAR-T cells|Intravenous injection the targeting CD19 CAR T cell
219164169|NCT06792344|DRUG|anti-CD19 CAR-T cells|CD19-targeting CAR-T cells
219164170|NCT05695131|DEVICE|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
219164171|NCT00082186|DRUG|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
219164172|NCT06415474|PROCEDURE|Lymphocyte Phenotyping Procedure|"For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture."
219164173|NCT06798038|DEVICE|radiofrequency ablation|35 Patients will be undergo for radiofrequency ablation which will be applied to each genicular nerve.
219164174|NCT06798038|DRUG|phenol neurolysis|35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
219164175|NCT06798038|DRUG|alcohol neurolysis|35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
219164176|NCT04995835|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
219164177|NCT06800001|OTHER|Physical Activity|Physical Activity is an 8-week practical intervention for managing the stereotyped behavior \& anxiety. Week 1: Introduction - Build engagement with the help of rapport building. Learn \& practice ball-tapping exercise with warm up \& cool down relaxation exercise. Week 2: Calmness- Practice jumping in trampoline exercise and learn balloon breathing exercise that give calmness. Week 3: Focus enhancement-Learn skills of jumping exercise to increase focus and improve impulse. Week 4: Strength, balance, and stress relief -explore the gym ball exercise in different directions that improves emotional regulation. Week 5: self control - Learn strategies for specific jumping patterns that improves impulse control and focus in children with ASD. Week 6: Reduce Stereotyped Behaviors - Learn complex trampoline exercises. Week 7: Skill Reinforcement- Review exercises, increasing speed or direction changes. Week 8: Integration -Encourage playful interaction to maintain engagement \& consolidate skills.
219164178|NCT06790732|DRUG|Saline|Patients received sham PENG block (just 1mL saline).
219164179|NCT06790732|DRUG|Bupivacaine + Dexamethasone|Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
219164180|NCT06417996|OTHER|Digital Group|Once patients are ready for discharge, patients in the digital group will be sent home with the Biobeat digital monitoring kit with written \& oral instructions on how it will be used in maintaining continuity of care which will track ECG (electrocardiogram), HR, NIBP, SPO2, and pain scores. A continuous recording and two-lead ECG patch will be applied and activated at the time of discharge to identify any paroxysmal atrial fibrillation.
219164181|NCT06436755|PROCEDURE|no intervention,this is a observational studies|no intervention,this is a observational studies
219164182|NCT04634435|COMBINATION_PRODUCT|BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2|Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
219164183|NCT05909982|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
219164184|NCT05034354|DEVICE|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A\&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A\&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
219237052|NCT06202898|OTHER|ENTRUST|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
219237053|NCT06202898|OTHER|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
219237054|NCT01960738|OTHER|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
219164185|NCT06083233|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
219164186|NCT06083233|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
219164187|NCT06083233|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
219164188|NCT06083233|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
219164189|NCT06083233|PROCEDURE|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
219164190|NCT06083233|PROCEDURE|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
219164191|NCT06083233|PROCEDURE|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
219164192|NCT06083233|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
219164193|NCT06787898|OTHER|Group R: retrolaminar block performed group|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®) was injected posterior to each lamina (T9, T10), totalling 20 mL
219164194|NCT06787898|OTHER|Group C - Placebo|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®)was injected posterior to each lamina (T9, T10), totalling 20 mL.
219164195|NCT06820424|BIOLOGICAL|Anti-CDH17 CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-CDH17 CAR-T Cells after lymphodepleting therapy.
219164196|NCT06788054|OTHER|intradialysis exercise|moderate intensity aerobic and muscular resistance exercise protocol lasting 12 weeks
219164197|NCT06792487|PROCEDURE|skin biopsy|punch biopsy (6 mm) of lesional psoriasis skin
219164198|NCT06791733|OTHER|Passive static stretching|the intervention consists of passive static stretching of agonist or antagonist muscles between sets
219164199|NCT06792110|DEVICE|Artificial Intelligence Integrated Hearing Aid Use|Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
219164200|NCT06792110|DEVICE|Phonak Infineo Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
219164201|NCT06792110|DEVICE|Oticon Real Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
219164202|NCT05566925|OTHER|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
219164203|NCT06787768|OTHER|Technology Enriched Rehabilitation Gym|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants attend a minimum of two times per week and can attend daily for the two hour group based circuit class.
219164204|NCT06787092|PROCEDURE|bladder cycling|started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 250 cc of sterile saline for 2 hours.
219164205|NCT02488863|OTHER|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
219362218|NCT06473038|DEVICE|Dry Ashing Method Followed by Flame Atomic Absorption Spectrometry (FAAS)|"Dry ashing method involves heating the food samples in a controlled environment to remove organic matter and moisture, leaving behind inorganic residues (ashes) containing the salts and minerals present in the food. Flame Atomic Absorption Spectrometryis utilized to measure the levels of sodium and potassium (components of salt) as well as carbon and hydrogen (components of sugar) in the ashed food samples.~By determining the concentrations of these elements, the salt and sugar content of the food samples can be quantified accurately."
219362219|NCT06419764|DRUG|Spleen Invigorating and Weight Reducing Decoction|"Composition: Raw Astragalus (Huang Qi) 5g, Cang Zhu 5g, Fructus Aurantii Immaturus (Zhi Shi) 3g, Prepared Rhubarb (Shu Jun) 3g, Red Peony Root (Chi Shao Yao) 3g, Crataegus (Shan Zha) 3g, Tribulus (Bai Jie Li) 2g, Cimicifuga (Sheng Ma) 1g.~Granule form, for oral administration. Take 1 dose daily (2 bags, once in the morning and once in the evening, dissolved in water), for a course of 1 month."
219237055|NCT05068050|PROCEDURE|Horse-assisted therapy|"12 horse-assisted therapy sessions (45 mins each) for 6 weeks.~Each session will comprise the next stages:~Groundwork, Approachment and preparation of the horse, Warm up exercises~Development of the main part (riding):~Introduction - beginning: Breathing control and body awareness, maintain sitting (riding position) while walking on the horse, perceiving the movement Exercises for the postural and balance control: Variations in the walking of the horse, realize different figures in the arena (circles, serpentines, change direction…), Stopping and Walking, Arms situation combined with the movement of the horse All exercises are determined in the track design protocol Exercises for the acquisition of motion skills: Finished the riding with relaxation activities. Final part: Dismount the horse, Unsaddled and unbridle, feedback and goodbye procedure."
219237056|NCT05068050|PROCEDURE|Physical exercise|"12 physical exercise sessions (45 mins each) for 6 weeks. Each session Each session Lessons will be held by physical activity professionals. The proposed exercises are focussed on improving the articular movements, aerobic resistance and the proprioception, always on the premises of No Pain.~Lessons will be divided in three parts :~1\. Warmup - 2. Main part - 3. Return to calm~Lessons will be hold online"
219237057|NCT02296593|DEVICE|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
219237058|NCT03705572|DIETARY_SUPPLEMENT|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
219237059|NCT03705572|OTHER|Placebo|Placebo milk drink.
219237060|NCT02707952|DRUG|ABT-493/ABT-530|Co-formulated tablet
219237061|NCT02707952|DRUG|OBV/PTV/r|Co-formulated tablet
219237062|NCT06403410|OTHER|Delirium Prevention Guideline|Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
219237063|NCT01555307|OTHER|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
219237064|NCT01555307|OTHER|Typical group|Seven typical exercises, 10 times each, 3 times a day
219164206|NCT02488863|OTHER|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
219164207|NCT02488863|OTHER|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A\&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
219164208|NCT02488863|OTHER|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
219164209|NCT06789029|DRUG|perineural Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg perineural Dexamethasone
219164210|NCT06789029|DRUG|intravenous Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg intravenous Dexamethasone
219164211|NCT06788366|DRUG|Immunotherapy|First-line regimen according to clinical practice
219164212|NCT06788366|DRUG|Chemotherapy|First-line regimen according to clinical practice
219164213|NCT05873426|DRUG|[14C] ZSP1273|600 mg suspension containing 50μCi of \[14C\]ZSP1273
219164214|NCT06096532|OTHER|75 gm oral glucose load|Consumption of 75 gm oral glucose load in order to test nutrient responsiveness
219164215|NCT05150795|DRUG|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
219164216|NCT05150795|DRUG|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
219164217|NCT06792435|DRUG|XNW27011|"Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.~An accelerated titration scheme will be used for the first two dose levels (0.6 mg/kg and 1.2 mg/kg) starting from 0.6 mg/kg dose as follows:~The first patient will be enrolled for 0.6 mg/kg dose. If the subject shows no significant toxicity in cycle 1 (DLT observation period), the second patient will be enrolled for 1.2 mg/kg.~3 + 3 dose escalation:3 patients will be enrolled to the dose cohort first，If 1 of 3 patients experiences a DLT, up to 3 more patients will be enrolled in the same dose cohort.. If none of the additional 3 patients experiences a DLT, dose escalation will continue to the next dose.Dose escalation will be stopped when 2 or more patients out of 3 to 6 patients at the same dose level experience a DLT."
219164218|NCT06792435|DRUG|XNW27011|Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
219164219|NCT06148818|OTHER|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
219164220|NCT06148818|OTHER|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
219164221|NCT06318403|DRUG|Transdermal estrogen|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
219164222|NCT06318403|PROCEDURE|Rotator Cuff Repair Surgery|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
219164223|NCT06790134|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
219164224|NCT03157167|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219164225|NCT04978597|DRUG|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
219164226|NCT04978597|DRUG|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
219237065|NCT03217123|DEVICE|Deep Brain stimulation|Electrical stimulation at subcortical level
219237066|NCT05660811|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
219737142|NCT05047887|PROCEDURE|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
219164227|NCT06784219|DIAGNOSTIC_TEST|Hindi version of self reported oral health questionnaire|The original 8-item CDC/AAP questionnaire as well as other selected periodontal disease surveillance questions will be translated into Hindi through forward translation, backward translation, and expert committee process to reach a consensus and produce a prefinal version. The prefinal version questionnaire will be pilot tested on a sample of 20 patients to evaluate the overall comprehension by non-professionals. On the basis of responses and evaluation from the participants, the questionnaire will be further refined to build the final version. The final version of the questionnaire will be administered to patients seeking care from out-patient department of department of Periodontics at PGIDS, Rohtak. The participants will be required to fill the questionnaire by themselves prior to periodontal examination, without any help from others.
219164228|NCT06785519|BIOLOGICAL|CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection|Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion
219164229|NCT06792149|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions .
219164230|NCT06792149|OTHER|Adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
219164231|NCT06792149|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience
219237067|NCT05660811|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
219237068|NCT05660811|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
219237069|NCT05660811|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
219164232|NCT05701072|PROCEDURE|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
219164233|NCT05701072|PROCEDURE|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
219737143|NCT05047887|PROCEDURE|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
219737144|NCT01796444|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
219737145|NCT01796444|PROCEDURE|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
219737146|NCT01796444|PROCEDURE|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
219737147|NCT01796444|PROCEDURE|Pathological Evaluation|H\&E and IHC
219737148|NCT01796444|DRUG|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
219737149|NCT01796444|RADIATION|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
219737150|NCT03879577|DRUG|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
219737151|NCT03879577|DRUG|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
219737152|NCT03879577|DRUG|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
219737153|NCT03879577|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
219737154|NCT03879577|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
219737155|NCT03879577|DRUG|LHRH agonist|Administered to all premenopausal patients.
219737156|NCT05363215|DRUG|S-217622|Tablet for oral administration
219737157|NCT01684033|DEVICE|Opti-Free® PureMoist® MPDS|
219737158|NCT01684033|DEVICE|Biotrue™ MPS|
219737159|NCT01684033|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
219737160|NCT04612127|DIETARY_SUPPLEMENT|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
219737161|NCT04853537|DIETARY_SUPPLEMENT|intermittent fasting diet|intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
219737162|NCT05496738|DRUG|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
219737163|NCT05496738|DRUG|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
219737164|NCT05496738|OTHER|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
219737165|NCT05496738|OTHER|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
219737166|NCT04465149|PROCEDURE|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
219737167|NCT06494514|DRUG|nal-IRI+Oxaliplatin+5-FU/LV+PD-1|These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
219737168|NCT06494514|DRUG|Gemcitabine + albumin-paclitaxel+PD-1|These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
219164234|NCT02688712|DRUG|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
219164235|NCT02688712|DRUG|Capecitabine|Antimetabolite chemotherapy
219164236|NCT02688712|DRUG|Fluorouracil|Antimetabolite chemotherapy
219164237|NCT02688712|PROCEDURE|Tumor specific mesorectal excision|Tumor specific mesorectal excision
219164238|NCT06791070|DRUG|Disitamab Vedotin combined with Toripalimab|Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
219237070|NCT02648841|RADIATION|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
219737169|NCT05535088|DEVICE|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
219737170|NCT02483910|BEHAVIORAL|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
219737171|NCT02483910|BEHAVIORAL|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
219737172|NCT03672981|BEHAVIORAL|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
219737173|NCT03672981|OTHER|Quality-of-Life Assessment|Ancillary studies
219737174|NCT03672981|OTHER|Questionnaire Administration|Ancillary studies
219737175|NCT03672981|BEHAVIORAL|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
219737176|NCT02687165|DRUG|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
219737177|NCT01856829|DIETARY_SUPPLEMENT|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
219737178|NCT01856829|OTHER|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
219737179|NCT00257855|DRUG|Lamotrigine|
219737180|NCT01124266|PROCEDURE|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
219737181|NCT01124266|PROCEDURE|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
219164239|NCT06784570|DRUG|levosemindan|In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
219164240|NCT06784570|DRUG|adrenaline,noreadrenaline,dopamine and doputamine|adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
219164241|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplemnt|Hair growth supplement for women ages 18 - 44.
219164242|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70.
219164243|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.
219164244|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
219164245|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Men's Hair Growth Supplement|Hair growth supplement for men ages 25 - 50.
219164246|NCT05587582|OTHER|Survey Administration|Complete a survey
219164247|NCT04079868|BEHAVIORAL|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
219164248|NCT05064813|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR Intervention|MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.
219164249|NCT05064813|BEHAVIORAL|Stress Education Control Condition (SE)|Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
219164250|NCT06786156|BEHAVIORAL|Pecha Kucha Education|"After the first interviews, the participants will be given face-to-face training to count fetal movements in the first stage. The training will last 30-45 minutes. The training content includes a comfortable environment and a suitable position for pregnant women, how to count and what to look for before counting fetal movements. Then, the training will be sent to the pregnant women via WhatsApp. A form will be given to count the fetal movements, and training will be applied using the Pecha Kucha method using smartphones once a week for 4 weeks. Pecha kucha is a presentation method developed to attract and maintain the attention of the audience throughout a series of different presentations. Pecha kucha (P-K), derived from the word meaning chat in Japanese, is to help present creative works with visual images. Pecha kucha training includes position, how to count and what to look for before counting fetal movements. This training will be delivered via WhatsApp with a practical presenta"
219164251|NCT06784297|BIOLOGICAL|IMM01-STEM|The individuals receiving expanded access will receive a treatment identical to the most convenient regimen in the current clinical trial (STEM-META). The treatment will consist of one i.m. injection per week containing 2 mg of total protein in 2 mL, for a total of 4 weeks (4 injections). As more efficacy information accumulates, the treatment plan will be adjusted accordingly to maximize the potential benefit.
219164252|NCT06032793|OTHER|Breathing exercises|Pursed lip breathing, Diaphragmatic breathing and powered breathing
219164253|NCT06787547|DEVICE|IVL(Sonico-CX)|SONICO-CX® balloon matched 1:1 to the reference vessel diameter, was advanced to the target lesion to pretreat
219737182|NCT02948075|DRUG|Quisinostat|
219737183|NCT02948075|DRUG|Paclitaxel|
219737184|NCT02948075|DRUG|Carboplatin|
219737185|NCT02382263|DRUG|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
219737186|NCT02382263|DRUG|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
219737187|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
219737188|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
219737189|NCT04674904|OTHER|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
219737190|NCT04674904|OTHER|Hot pack , TENS , Stretching|"Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
219737191|NCT04147741|DIETARY_SUPPLEMENT|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
219164254|NCT06784245|BEHAVIORAL|TeleActivate|Each session will consist of a warm-up activity (5-10 min), main exercise activity (30-40 min), and cool-down activity (5-10 min) following the guidelines of multicomponent exercise program Vivifrail. Exercise intensity will be controlled based on the Rating of Perceived Exertion (RPE) on the Borg scale and heart rate measured with a smartwatch before, during, and after each exercise session according to the guidelines of the American College of Sports Medicine (ACSM), as explained below. The warm-up and cool-down activities will include stretching and walking in place (9≤RPE≤10 and 40\<55% maximum Heart rate (HRmax). While the main exercise activity will consist of strength, resistance exercise, cardiovascular exercises, and balance exercises (to avoid falls) performed using dumbbells, colour-coded resistance bands (Thera-Band; Hygenic Corp.) and a chair (11\<RPE≤15 and 55\<70 HRmax).
219164255|NCT05873868|OTHER|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
219164256|NCT05873868|OTHER|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
219164257|NCT05873868|OTHER|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
219164258|NCT06791798|OTHER|Ventilator Hyperinflation|In ventilator hyperinflation volume control mode, the ventilator will be set to eight breaths per minute, and the tidal volume will be increased to deliver hyperinflation breaths that are 15 ml/kg, as will be calculated using the predicted body weight. Tidal volume will be increased in 150-ml increments until a peak airway pressure of 40 cmH2O is achieved. Once this pressure is reached, eight mechanical breaths will be delivered to the patient. After this, the ventilator will be reset to pretreatment variables, and the patient will be rested for 30 s. The sequence will be repeated. The treatment will consist of five sets of eight ventilator hyperinflation breaths.
219164259|NCT06791798|OTHER|Vibrocompression|Vibrocompression will be performed by the physical therapist to produce vibration and will be combined with compression of the patient's chest in the expiratory phase. Every vibrocompression will be interrupted at the end of each expiratory phase to allow free inspiration.
219164260|NCT06791798|OTHER|Traditional Chest Physical Therapy Program|Percussion, Postural Drainage, and Suction
219164261|NCT06045234|OTHER|Urine sampling|"Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
219164262|NCT02785042|DEVICE|Heidelberg Spectralis OCT|OCT imaging
219164263|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
219164264|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
219164265|NCT06065189|BIOLOGICAL|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
219164266|NCT03527433|PROCEDURE|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
219164267|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
219164268|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
219164269|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
219164270|NCT06592547|DRUG|Intravenous metoprolol tartrate|An intravenous beta-blockers, recieved FDA approval
219164271|NCT06592547|OTHER|Standard Care (in control arm)|Standard care according to surviving sepsis campaign
219164272|NCT06472089|BEHAVIORAL|BMT-CARE|Therapist-delivered psychosocial intervention comprised of 6 sessions
219164273|NCT06472089|BEHAVIORAL|Usual Care|Meeting a transplant social worker prior to HCT and as needed for extra visits
219164274|NCT06132048|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
219164275|NCT03526835|DRUG|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
219164276|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
219164277|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFIRI|MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
219164278|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFOX|MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
219164279|NCT05145257|DIETARY_SUPPLEMENT|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
219164280|NCT03425201|DRUG|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
219362220|NCT06419764|OTHER|Diet and meal replacements|The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
219743697|NCT06046378|OTHER|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
219164281|NCT06799884|DRUG|Ethinyl Estradiol / Levonorgestrel Oral Tablet|Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel
219164282|NCT06799884|DRUG|Aprocitentan|Film-coated tablet of aprocitentan 25 mg
219164283|NCT06221150|DRUG|Bilateral two level serratus anterior block|A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
219164284|NCT06221150|OTHER|Control group|Intraoperative opioids without regional block
219164285|NCT06557538|DEVICE|Automatic Ankle Brachial Pressure Index device assessment|The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).
219164286|NCT06557538|DEVICE|Manual Ankle Brachial Pressure Index assessment|The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
219164287|NCT01276600|DRUG|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
219164288|NCT06479590|DEVICE|tDCS|The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)
219164289|NCT06479590|OTHER|Sham tDCS|sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application
219164290|NCT06310200|DRUG|Lidocaine Topical 4% Topical Solution|Intranasal administration
219164291|NCT06310200|DRUG|Bitrex|Bittering agent
219164292|NCT06310200|DRUG|normal saline|Placebo
219164293|NCT05942391|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
219164294|NCT04905407|DRUG|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
219164295|NCT04905407|DRUG|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
219164296|NCT04905407|DRUG|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
219164297|NCT05511298|BEHAVIORAL|Relationship Smarts Combo|The intervention is a combination of Mind Matters, Relationship Smarts 4.0, and Money Habitudes curricula, developed by the Dibble Institute
219164298|NCT05186818|DRUG|Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)|Aficamten tablets were administered orally once daily.
219164299|NCT05186818|DRUG|Placebo to match aficamten|Placebo tablets were administered orally once daily.
219237071|NCT02648841|DRUG|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
219237072|NCT02648841|DRUG|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
219237073|NCT00799838|DRUG|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
219164300|NCT05721989|DRUG|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
219164301|NCT05721989|DRUG|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
219164302|NCT05721989|DRUG|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
219164303|NCT04080128|DEVICE|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
219164304|NCT06024096|DRUG|Atorvastatin|"Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination."
219164305|NCT06024096|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
219164306|NCT05136404|DRUG|Selpercatinib|Administered orally
219164307|NCT06149598|BEHAVIORAL|Coughing at the time of biopsy|Patients are asked to cough or not to cough during cervical biopsy.
219164308|NCT01236287|DRUG|Voclosporin|Subjects will receive voclosporin capsules, twice daily
219164309|NCT01954992|DRUG|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
219164310|NCT01954992|DRUG|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
219164311|NCT06262919|DRUG|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
219164312|NCT04187040|PROCEDURE|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs"
219164313|NCT04187040|PROCEDURE|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
219164314|NCT00448240|DRUG|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
219164315|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
219164316|NCT06106178|OTHER|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
219164317|NCT06787859|OTHER|Showing a nature view curtain to type 2 diabetic patients during insulin injection|a nature view curtain
219164318|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
219164319|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
219237074|NCT00799838|DRUG|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
219237075|NCT00799838|DRUG|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
219237076|NCT00027014|DRUG|St. John's Wort|
219237077|NCT00027014|DRUG|oxycodone|
219237078|NCT00027014|DRUG|fentanyl|
219237079|NCT03996798|OTHER|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
219237080|NCT03437655|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
219237081|NCT03437655|PROCEDURE|Relative isolation|Relative isolation with cotton and gauze.
219737192|NCT04147741|OTHER|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
219737193|NCT04147741|OTHER|Endurance Training|\- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
219737194|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
219737195|NCT00951873|DRUG|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
219737196|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
219737197|NCT02289014|OTHER|online stress Management program|Active treatment group
219737198|NCT01528852|DRUG|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
219737199|NCT01528852|DRUG|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
219737200|NCT01528852|OTHER|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
219737201|NCT01018771|PROCEDURE|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
219737202|NCT01018771|PROCEDURE|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
219737203|NCT03397719|BEHAVIORAL|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
219737204|NCT03397719|BEHAVIORAL|Control Group|This group will receive in-vivo parent coaching three hours per week.
219737205|NCT06684678|OTHER|individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
219737206|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"
219737207|NCT06687551|DRUG|filgotinib 200mg/day|"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"
219737208|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"
219737209|NCT06687551|DRUG|Upadacitinib 15 MG|"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"
219737210|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|use of JAK inhibitor at full dose until the end of the protocol
219737211|NCT06687551|DRUG|filgotinib 200mg/day|use of JAK inhibitor at full dose until the end of the protocol
219737212|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|use of JAK inhibitor at full dose until the end of the protocol
219737213|NCT06687551|DRUG|Upadacitinib 15 MG|use of JAK inhibitor at full dose until the end of the protocol
219737214|NCT06691802|DRUG|Shu Fei Tie|Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
219737215|NCT06691802|DRUG|Shu Fei Tie placebo|Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
219737216|NCT06687629|PROCEDURE|Concha bullosa crushing|Concha bullosa crushing
219737217|NCT06687629|PROCEDURE|Concha bullosa resection|Concha bullosa resection
219737218|NCT06689644|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Commercially available product: Mind lab pro
219164320|NCT06792851|DEVICE|Kosmos Bladder Volume Algorithm|Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.
219164321|NCT05417932|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
219164322|NCT05806788|BEHAVIORAL|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
219164323|NCT06222593|DRUG|Bicalutamide in combination with Sunitinib|Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
219164324|NCT01894061|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
219164325|NCT01894061|DEVICE|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
219164326|NCT01894061|OTHER|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
219164327|NCT06793904|DRUG|Aromatase inhibitor Letrozole|2.5 mg tab twice daily from the 3rd day of the cycle for 5 days
219164328|NCT04452864|DEVICE|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
219164329|NCT04452864|DEVICE|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
219164330|NCT06790940|OTHER|No intervention|This is an observational study, no intervention will be implemented.
219164331|NCT06796972|OTHER|Semi-structured interviews with a psychologist|Semi-directed interviews using an interview guide on different themes
219164332|NCT06834334|DEVICE|MM780G|SmartGuard in Medtronic Minimed 780G advaced hybrid closed-loop
219164333|NCT06834334|DEVICE|TTSX2|Control-IQ in Tandem T Slim X2 advanced hybrid closed-loop
219164334|NCT06834334|DEVICE|CamAPS|CamAPS Fx in Ypsopump advanced hybrid closed-loop
219164335|NCT06790043|OTHER|Patient-selected visual art in hospital room|Patient-selected visual art placed in patient's antepartum hospital room
219164336|NCT06790043|OTHER|Routine care|Patient will receive routine care, and will not select, nor have, visual art in their antepartum hospital room.
219164337|NCT05243862|DRUG|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
219164338|NCT05243862|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
219164339|NCT05653232|OTHER|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
219164340|NCT05653232|OTHER|Transmit and Treat (T&T)|For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
219164341|NCT04659993|BEHAVIORAL|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
219237082|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
219237083|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
219164342|NCT06395636|DEVICE|Infection-Prediction Algorithm|This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
219164343|NCT04827563|DEVICE|EndoPAT|An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
219164344|NCT04827563|DEVICE|Blood Pressure Cuff|A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
219164345|NCT04827563|DIAGNOSTIC_TEST|Echocardiogram|A test used to conduct an ultrasound of participant's heart.
219237084|NCT03437655|PROCEDURE|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
219164346|NCT04827563|OTHER|Quality of Life Assessment|A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
219164347|NCT04827563|OTHER|Blood Tests|Routinely collected for all participants who begin carfilzomib treatment.
219164348|NCT05996744|DRUG|Obeldesivir|Tablet administered orally with or without food
219164349|NCT06840301|BEHAVIORAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
219164350|NCT06840301|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219164351|NCT06840301|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
219164352|NCT06840301|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
219164353|NCT06840301|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
219164354|NCT06840301|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants"
219164355|NCT06840301|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
219737219|NCT06689644|DIETARY_SUPPLEMENT|Placebo|A cellulose commonly used as a bulking agent in supplement products
219737220|NCT06689644|BEHAVIORAL|Perceptual decision-making performance|A computerised cognitive task involving rapid visual categorisation of images
219737221|NCT06689644|DEVICE|Electroencephalography|Brain signals are recorded from a 64 channel EEG system during the cognitive task
219737222|NCT06690762|OTHER|Education|It consists of nutrition, physical activity, stress management, relaxation exercises and defecation training.
219737223|NCT06687317|OTHER|Behavioral|KNAP
219737224|NCT06688500|PROCEDURE|Bowel function post Holmium Laser Enucleation of the Prostate|Observing post operative bowel functions among participants who have undergone a HoLEP procedure.
219737225|NCT06691542|DRUG|platelet-rich plasma|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
219737226|NCT06691542|DRUG|Metformin|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
219737227|NCT06691542|OTHER|cryotherapy|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
219737228|NCT06164730|DRUG|VERVE-102|Intravenous (IV) infusion
219737229|NCT06695364|OTHER|survey study|Not all classes were included in the study
219737230|NCT06695078|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219737231|NCT06694961|OTHER|Online Educational Material|Online educational material will be an easy way to reach large number of physicians
219737232|NCT06693947|OTHER|Alpine dairy products|The intervention group will be instructed to eat three portions of alpine dairy products daily. The proposed three portions represent an estimated mean consummation in the study population, taking into consideration the national statistics.
219737233|NCT06694298|DRUG|SYS6020|BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
219737234|NCT06694324|DRUG|Liposomal Doxorubicin (Doxil)|30 mg/m2, d1, IV
219737235|NCT06694324|DRUG|Apatinib|250 mg, qd
219737236|NCT06694324|DRUG|Camrelizumab|200 mg, d1, IV
219737237|NCT06687902|DIAGNOSTIC_TEST|Digital breast tomosynthesis|In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
219737238|NCT06688838|DRUG|Tofacitinib|If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
219737239|NCT06687759|DRUG|[14C]MK-1084|Oral administration
219743698|NCT06046378|OTHER|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
219164356|NCT06840301|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
219164357|NCT06839586|DRUG|CMTS4520 (dietary fiber and probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
219164358|NCT06839586|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
219164359|NCT06228755|BEHAVIORAL|Integrative Medicine Group Visit|Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
219164360|NCT06228755|OTHER|Implementation Strategies|"Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity."
219164361|NCT06106672|DRUG|CNP-106|CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
219164362|NCT06106672|OTHER|Placebo|CNP-106 Placebo
219164363|NCT06793930|BEHAVIORAL|A tailored, optimised, and person-centred critical pathway to promote sustainable lifestyle modification|The TOP-S programme is a nurse-led intervention promoting the maintenance of lifestyle modification
219164364|NCT06793930|OTHER|Brief advice|once-off brief lifestyle advice lasting for 15 minutes
219164365|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of sevoflurane and opioid.
219737240|NCT06689189|OTHER|Blood fluorescence metabolite analysis|This is an observational study and does not involve intervention. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient\&#39;s blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 4 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results, which are pivotal for the timely diagnosis and intervention in septic patients.
219737241|NCT05289453|PROCEDURE|lens extraction by phacoemulsification|lens extraction by phacoemulsification
219737242|NCT06695260|DIAGNOSTIC_TEST|CT scan|CT will be performed when the wrist is under loading compared to normal conditions. scapholunate kinematics will be examines
219737243|NCT06690749|DEVICE|Negative pressure therapy, NPT|"We designed the experiment based on current clinical cases involving negative pressure therapy (NPT) for wounds and related animal studies. In this study, we applied three levels of negative pressure: -105 mmHg, -125 mmHg, and -145 mmHg, each for 10 minutes.~The -125 mmHg dosage was chosen based on findings from a previous study. Similar studies that utilized increments and decrements of 20 mmHg informed our research.~Moreover, to prevent any damage to new capillaries, we established a base dosage of -125 mmHg and refrained from using negative pressure levels exceeding -150 mmHg."
219737244|NCT04009135|BEHAVIORAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
219737245|NCT04009135|BEHAVIORAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
219737246|NCT04009135|OTHER|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
219737247|NCT06691763|BEHAVIORAL|Pythagorean Self-Awareness Intervention for stress management and health promotion|Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
219737248|NCT06689228|OTHER|Rational Drug Use Training|Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.
219737249|NCT06887881|GENETIC|PIMS screening|Couples in the PIMS group will have up to 6 blastocysts screened with PIMS and a single euploid embryo with the optimal state of whole-genome DNA methylation and the highest morphologic score will be selected for the initial transfer
219237085|NCT03437655|PROCEDURE|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
219237086|NCT00909909|RADIATION|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
219237087|NCT00909909|RADIATION|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
219237088|NCT04659382|DRUG|Atezolizumab|Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
219237089|NCT04659382|DEVICE|Therasphere|Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.
219237090|NCT04659382|DRUG|XELOX|standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
219237091|NCT04659382|DRUG|Bevacizumab|standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
219237092|NCT00039884|DRUG|NESP - Novel Erythropoiesis Stimulating Protein|
219237093|NCT02613052|DRUG|normal saline|10 mL of normal saline agitated prior to IV administration
219237094|NCT02613052|DRUG|human albumin|10 mL of 5% albumin agitated prior to IV administration
219237095|NCT02613052|DRUG|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
219237096|NCT02006641|DRUG|Placebo|Once daily, matching placebo capsules, orally
219237097|NCT02006641|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
219237098|NCT03776565|OTHER|Ultrasound|Ultrasound of antrum of stomach
219237099|NCT03165825|DRUG|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
219237100|NCT03165825|DRUG|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
219237101|NCT03611985|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
219237102|NCT03611985|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
219237103|NCT06462248|DRUG|CUCART19|anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
219737250|NCT06887881|GENETIC|PGT-A screening|Couples in the PGT-A group will have up to 6 blastocysts screened with PGT-A and a single euploid blastocyst with the highest morphologic score selected for the initial transfer.
219737251|NCT06753903|PROCEDURE|PCD-CT|Photon-counting detector computed tomography
219737252|NCT00468000|BIOLOGICAL|Ixmyelocel-T|IM injection
219737253|NCT00468000|BIOLOGICAL|Placebo|IM Injection
219737254|NCT02408770|DRUG|ulipristal acetate|selective progesterone receptor modulator
219237104|NCT03930173|DRUG|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
219237105|NCT03930173|DEVICE|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
219237106|NCT01287832|DRUG|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
219237107|NCT01287832|DRUG|Daptomycin|
219237108|NCT00780078|PROCEDURE|extubation|extubation failure in patients intubated orotracheally
219737255|NCT00954538|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
219737256|NCT02318979|DEVICE|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
219237109|NCT03062124|PROCEDURE|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
219237110|NCT00447109|DEVICE|Closed system suction|
219737257|NCT02318979|DEVICE|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
219737258|NCT02318979|DEVICE|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
219737259|NCT02369692|DEVICE|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
219737260|NCT05683626|DRUG|Humira|subcutaneous injection
219737261|NCT01942512|DEVICE|Endovascular treatment of intracranial aneurysm|
219737262|NCT00383851|DRUG|ATN-224|
219737263|NCT00383851|DRUG|Temozolomide|
219737264|NCT05583058|OTHER|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
219737265|NCT05362539|PROCEDURE|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
219737266|NCT05362539|DIAGNOSTIC_TEST|Computed tomography|Computed tomography for patients to exclude bladder lesions
219737267|NCT05362539|GENETIC|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
219737268|NCT05362539|DIAGNOSTIC_TEST|Urine cytology|voided urine cytology for all patients
219164366|NCT04443517|BEHAVIORAL|Emergence from anesthesia with Dexmedetomidine|Infusion of .05 mcg/kg/h of propofol during the final 10-20 minutes of surgery.
219164367|NCT05664516|DRUG|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
219737269|NCT02148627|DRUG|LY3041658 (SC)|Administered SC
219737270|NCT02148627|DRUG|LY3041658 (IV)|Administered as slow IV infusion
219737271|NCT02148627|DRUG|Placebo|Administered as slow IV infusion
219737272|NCT01639521|DRUG|cisplatin|Given IV
219737273|NCT01639521|DRUG|gemcitabine hydrochloride|Given IV
219737274|NCT01639521|DRUG|methotrexate|Given IV
219737275|NCT01639521|DRUG|vinblastine|Given IV
219737276|NCT01639521|DRUG|doxorubicin hydrochloride|Given IV
219737277|NCT01639521|BIOLOGICAL|pegfilgrastim|Given SC
219737278|NCT01639521|OTHER|laboratory biomarker analysis|Correlative studies
219737279|NCT01164969|DRUG|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
219737280|NCT01452217|DRUG|Secretin|Secretin 1 IU/kg over 3 min
219737281|NCT01157429|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
219737282|NCT01157429|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
219737283|NCT01157429|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
219737284|NCT01319461|DEVICE|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
219737285|NCT01319461|DEVICE|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
219737286|NCT03555045|PROCEDURE|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
219737287|NCT03555045|PROCEDURE|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
219737288|NCT05877612|DEVICE|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
219737289|NCT01932580|DRUG|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
219737290|NCT03396458|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
219737291|NCT03396458|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
219737292|NCT03586232|DIETARY_SUPPLEMENT|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
219737293|NCT03586232|DIETARY_SUPPLEMENT|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
219737294|NCT03586232|OTHER|Placebo|A pharmacologically inert preparation
219737295|NCT01580722|PROCEDURE|early reconstruction|patients underwent \< 8 weeks reconstruction after injury
219737296|NCT01580722|PROCEDURE|delay reconstruction|patients underwent \> 8 weeks reconstruction after injury
219737297|NCT02931539|DRUG|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
219737298|NCT02931539|DRUG|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
219164368|NCT05664516|DRUG|Placebo|Nasal solution without oxytocin
219737299|NCT02931539|DRUG|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
219737300|NCT02931539|DRUG|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
219737301|NCT02931539|DRUG|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
219737302|NCT02059642|DRUG|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
219737303|NCT02059642|DRUG|placebo|Placebo 1400 mg administered orally once daily
219737304|NCT03178942|DRUG|Permethrin Cream, 5%|Permethrin Cream 5%
219737305|NCT03178942|DRUG|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
219737306|NCT00490997|DRUG|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
219737307|NCT00490997|DRUG|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
219737308|NCT06929975|BEHAVIORAL|podcast training|In accordance with the established training program for participants, a four-phase podcast listening process aimed at reducing birth fear will be implemented. The first podcast will be launched at the 33rd week of pregnancy, with the goal of helping participants gain information about the childbirth process and reduce their anxiety. Following that, a second podcast will be played at the 34th week of pregnancy, focusing on supporting psychological preparation for childbirth. The third podcast, to be implemented at the 35th week, will address topics such as relaxation techniques and breathing exercises that can be used during labor. Finally, the fourth podcast, played at the 36th week, will emphasize the importance of positive thinking and partner support during labor. To evaluate the effectiveness of the podcast sessions, psychological status and partner support scales will be applied at specific weeks.
219737309|NCT02669108|DEVICE|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
219737310|NCT00775515|PROCEDURE|laparoscopic prostatectomy|laparoscopic prostatectomy
219237111|NCT00582920|RADIATION|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
219237112|NCT01894503|DRUG|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
219237113|NCT04749797|DRUG|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
219237114|NCT04749797|DRUG|Bupivacaine Injection|Used as cranial block for craniotomy surgery
219237115|NCT04749797|DRUG|Saline|Used as cranial block for craniotomy surgery
219237116|NCT00632736|DRUG|Ropinirole XL (formerly CR)|
219237117|NCT01985256|BIOLOGICAL|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
219237118|NCT01985256|DRUG|Toca FC|
219164369|NCT05568225|DRUG|Etavopivat|400 mg once daily
219164370|NCT05555888|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
219164371|NCT05555888|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
219164372|NCT05555888|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219164373|NCT05555888|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
219164374|NCT06420869|DIAGNOSTIC_TEST|Assessment|A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.
219164375|NCT03933059|OTHER|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
219164376|NCT02531841|DRUG|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
219164377|NCT02531841|DRUG|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
219164378|NCT02306954|BIOLOGICAL|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
219164379|NCT02306954|RADIATION|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
219237119|NCT02919059|DRUG|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
219237120|NCT02919059|DRUG|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
219237121|NCT01441596|DRUG|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
219237122|NCT01441596|DRUG|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
219237123|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
219164380|NCT02610673|DEVICE|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
219164381|NCT06005961|BEHAVIORAL|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
219164382|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 1|The study foresees the intake of 1 capsule per day during 56 days
219237124|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
219237125|NCT05401188|OTHER|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
219237126|NCT05401188|OTHER|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
219237127|NCT06165133|OTHER|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
219237128|NCT06165133|OTHER|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
219237129|NCT03024021|DEVICE|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia \[36.5 C\]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
219237130|NCT06455488|PROCEDURE|Ventricular Tachycardia Ablation|This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
219237131|NCT06455488|DEVICE|ICD Implant|A pacemaker or defibrillator implant to prevent SCD
219164383|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 2|The study foresees the intake of 1 capsule per day during 56 days
219237132|NCT06455488|DRUG|Antiarrhythmic drug|Drug therapies
219237133|NCT06455488|DIAGNOSTIC_TEST|EKG|Monitoring EKG testing done on registry patients
219237134|NCT06455488|DIAGNOSTIC_TEST|Cardioversion|Monitoring cardioversions on registry patients
219237135|NCT06455488|DIAGNOSTIC_TEST|Echocardiogram|Monitoring echocardiogram testing done on patients
219237136|NCT01047709|DEVICE|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
219237137|NCT05177432|DEVICE|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
219737311|NCT06896734|DEVICE|Evaluation of the ECG signal in the nominal location and in three alternate positions|Evaluation of the ECG signal in the nominal location and in three alternate positions to determine if the three alternate positions are interpretable.
219737312|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
219737313|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
219164384|NCT06571409|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
219164385|NCT05444192|DEVICE|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
219164386|NCT04522713|BEHAVIORAL|Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material|Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
219737314|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
219737315|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
219737316|NCT06214520|BEHAVIORAL|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
219737317|NCT06214520|BEHAVIORAL|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
219737318|NCT04755725|DEVICE|Epidural catheter|epidural catheter inserted pre induction
219737319|NCT04755725|DEVICE|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
219737320|NCT04938466|DRUG|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
219737321|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
219737322|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
219737323|NCT03061214|DRUG|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
219737324|NCT03061214|DRUG|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
219737325|NCT03061214|DRUG|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
219164387|NCT05634070|DEVICE|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
219164388|NCT02746510|GENETIC|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
219164389|NCT06525311|DRUG|K-808|K-808 single or multi dose extended-release tablets
219164390|NCT05568017|DRUG|peptide receptor radionuclide therapy with Y-90-DOTATOC|Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
219164391|NCT01264289|DRUG|Finasteride|Finasteride Tablets 5 mg
219164392|NCT04570072|DIETARY_SUPPLEMENT|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
219164393|NCT04570072|DIETARY_SUPPLEMENT|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
219164394|NCT01278420|DEVICE|Tecnis MF|30 subjects will be implanted with the Tecnis MF
219164395|NCT01278420|DEVICE|ReSTOR|30 subjects will be implanted with ReSTOR
219164396|NCT05092113|DRUG|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
219737326|NCT03061214|DRUG|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
219164397|NCT04824274|DRUG|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
219737327|NCT03061214|DRUG|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
219737328|NCT03061214|DRUG|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
219737329|NCT05673291|OTHER|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
219737330|NCT04356703|OTHER|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
219737331|NCT02290574|RADIATION|Hyperthermia with concurrent chemo-radiation therapy|
219737332|NCT02973152|PROCEDURE|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
219164398|NCT04824274|DRUG|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
219164399|NCT04824274|PROCEDURE|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
219737333|NCT02973152|PROCEDURE|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
219737334|NCT04314206|DRUG|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
219737335|NCT04314206|DRUG|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
219737336|NCT04205825|OTHER|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
219737337|NCT04759404|OTHER|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
219737338|NCT04759404|OTHER|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
219737339|NCT04501705|DRUG|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
219737340|NCT03810365|BEHAVIORAL|Brief behavioral treatment for insomnia|Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
219737341|NCT03810365|BEHAVIORAL|Healthy Eating Control|Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
219737342|NCT01625078|DEVICE|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
219737343|NCT01357746|PROCEDURE|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
219737344|NCT00600704|PROCEDURE|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
219737345|NCT00600704|PROCEDURE|Free fluid infusion|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
219737346|NCT03137407|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
219737347|NCT03137407|BIOLOGICAL|Placebo|Intramuscular injection
219737348|NCT03629002|BIOLOGICAL|Study of the gene expression profile|qPCR analysis
219737349|NCT00555373|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
219737350|NCT01509404|DRUG|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
219737351|NCT01509404|BIOLOGICAL|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
219737352|NCT01509404|DRUG|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
219737353|NCT04917510|PROCEDURE|Erector spinae block|See experimental arm group description
219737354|NCT04917510|PROCEDURE|Local block|See control and study arm group descriptions for the local block
219737355|NCT02079285|PROCEDURE|EUS-FNA|
219737356|NCT05612295|BEHAVIORAL|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
219737357|NCT05612295|BEHAVIORAL|Self-talk|self-talk sessions include: Session 1 \& 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 \& 8. general practice for learned self-talk techniques.
219737358|NCT00506311|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
219737359|NCT01978015|DRUG|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
219737360|NCT01978015|DRUG|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
219737361|NCT01978015|DRUG|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
219737362|NCT01978015|DRUG|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
219164400|NCT04824274|PROCEDURE|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
219164401|NCT06338319|BEHAVIORAL|Book-Sharing for Toddlers with Clefts (BOOST)|BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
219164402|NCT01540318|PROCEDURE|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
219164403|NCT02686398|BIOLOGICAL|Fluad|
219164404|NCT02686398|BIOLOGICAL|Agrippal|
219164405|NCT04238910|BEHAVIORAL|Maximizing Energy|The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
219164406|NCT04238910|BEHAVIORAL|Health Education|The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
219164407|NCT05623345|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219164408|NCT05623345|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
219737363|NCT04038008|DRUG|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
219737364|NCT04038008|DRUG|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
219737365|NCT04854499|DRUG|Magrolimab|Administered intravenously
219737366|NCT04854499|DRUG|Pembrolizumab|Administered intravenously
219737367|NCT04854499|DRUG|Docetaxel|Administered intravenously
219737368|NCT04854499|DRUG|5-FU|Administered intravenously
219737369|NCT04854499|DRUG|Cisplatin|Administered intravenously
219737370|NCT04854499|DRUG|Carboplatin|Administered intravenously
219737371|NCT04854499|DRUG|Zimberelimab|Administered intravenously
219737372|NCT00107614|DRUG|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
219737373|NCT04632381|DRUG|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
219737374|NCT04632381|DRUG|Placebo|5% dextrose injection, USP
219737375|NCT01532219|BEHAVIORAL|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
219737376|NCT01532219|BEHAVIORAL|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
219737377|NCT06243926|OTHER|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
219737378|NCT04198337|PROCEDURE|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
219737379|NCT02672605|OTHER|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
219737380|NCT03780062|BIOLOGICAL|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
219737381|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies!|Fruits and Vegetables
219737382|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
219737383|NCT00842465|BIOLOGICAL|blood collection for hormonal status analysis|for hormonal status analysis
219737384|NCT00842465|PROCEDURE|breast Biopsy or surgery|breast Biopsy or surgery
219737385|NCT00842465|GENETIC|blood collection|blood collection for prlR gene sequencing
219737386|NCT00842465|OTHER|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
219737387|NCT04705233|OTHER|sputum colour chart|5-point Sputum Colour Chart plus best standard care
219737388|NCT02918630|DRUG|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
219737389|NCT02918630|DRUG|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
219737390|NCT04297735|OTHER|Standard of care group|Visits every 6 months is standard of care.
219737391|NCT04297735|BEHAVIORAL|Telemedicine group|Conduct monthly telemedicine 'skype' visit
219737392|NCT04297735|BEHAVIORAL|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
219737393|NCT01620047|DRUG|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
219164409|NCT02336217|OTHER|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
219164410|NCT02336217|OTHER|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
219164411|NCT05384730|OTHER|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
219164412|NCT05744271|DEVICE|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
219164413|NCT01772472|DRUG|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
219164414|NCT01772472|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
219164415|NCT05774626|BEHAVIORAL|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
219164416|NCT02913196|DRUG|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
219164417|NCT02913196|DRUG|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"
219164418|NCT02913196|DRUG|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"
219164419|NCT02913196|DRUG|Prednisone|Dose: 5 mg BID
219164420|NCT04804202|OTHER|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
219164421|NCT04909619|PROCEDURE|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
219164422|NCT04909619|PROCEDURE|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
219164423|NCT05663931|OTHER|DM Discharge Toolkit|"The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content."
219164424|NCT04057456|OTHER|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
219164425|NCT04057456|OTHER|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
219164426|NCT04057456|DRUG|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
219164427|NCT04057456|OTHER|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
219164428|NCT02842424|DRUG|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
219164429|NCT02571725|DRUG|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
219164430|NCT02571725|DRUG|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
219164431|NCT03295734|BEHAVIORAL|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
219164432|NCT03295734|DRUG|Perindopril|4 mg qd titrated to 8 mg qd perindopril
219164433|NCT03295734|DRUG|Losartan|50 mg qd titrated to 100 qd losartan
219164434|NCT03295734|DRUG|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
219237138|NCT01329107|BEHAVIORAL|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
219237139|NCT03221881|DRUG|Pegylated Liposomal Doxorubicin and docetaxel|
219737394|NCT01620047|DRUG|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
219737395|NCT01620047|DRUG|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
219737396|NCT05982379|OTHER|Technology Based Motivation Program|"A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided."
219164435|NCT03926819|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
219164436|NCT05777486|BEHAVIORAL|TikTok Ads - With Food|TikTok posts from influencers promoting food.
219164437|NCT05777486|BEHAVIORAL|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
219164438|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|"* Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.~* Home programme with parental coaching"
219164439|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|\- Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
219164440|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
219164441|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
219164442|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
219164443|NCT03299322|DRUG|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
219237140|NCT01366456|DEVICE|Moxibustion|Comparison of different kinds of moxibustion
219237141|NCT05827185|BIOLOGICAL|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
219737397|NCT05678127|PROCEDURE|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
219737398|NCT02389738|DRUG|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
219737399|NCT02389738|DRUG|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
219737400|NCT02389738|DEVICE|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
219737401|NCT04652999|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
219164444|NCT03299322|DRUG|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
219164445|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
219164446|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
219164447|NCT03578536|DEVICE|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
219164448|NCT05736185|DEVICE|PEEP selection|Electric impedance tomography-guided PEEP titration
219164449|NCT04431726|DRUG|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
219164450|NCT06194578|OTHER|Sterile Saline|Sterile saline will be administered subcutaneously.
219164451|NCT03552562|DEVICE|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
219164452|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
219164453|NCT03746535|DRUG|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
219164454|NCT06420570|PROCEDURE|Thoracic Surgery|Patients will either undergo thoracic surgery, specifically thoracotomy (traditional method of chest surgery using a large surgical incision) or video-assisted thoracic surgery (minimally invasive method using video cameras)
219164455|NCT04116736|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
219164456|NCT04116736|DEVICE|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
219164457|NCT04349072|DRUG|Mavacamten|Mavacamten Capsules Other names: MYK-461
219164458|NCT04349072|DRUG|Placebo|Placebo
219164459|NCT01748110|BEHAVIORAL|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
219237142|NCT05827185|BIOLOGICAL|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
219164460|NCT01748110|BEHAVIORAL|TRIMM|text message intervention.
219164461|NCT06389435|PROCEDURE|Patients will be randomized to undergo TKR or RTKR|Total knee replacement (control group)
219164462|NCT02623894|OTHER||No intervention study is an observational study
219164463|NCT00186849|DRUG|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
219164464|NCT00186849|PROCEDURE|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
219164465|NCT00731341|PROCEDURE|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
219164466|NCT06212843|OTHER|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
219164467|NCT06212843|OTHER|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
219164468|NCT05869331|PROCEDURE|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
219164469|NCT05869331|PROCEDURE|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
219164470|NCT06020495|DRUG|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
219164471|NCT06020495|DRUG|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
219164472|NCT06538857|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
219164473|NCT06538857|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
219164474|NCT04820894|OTHER|Electronic Medical Record|Medical records are reviewed
219164475|NCT04820894|OTHER|Survey Administration|Complete surveys
219164476|NCT03771105|DRUG|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
219164477|NCT05256745|DRUG|TTP488|Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
219164478|NCT05256745|DRUG|ddAC/ddT|Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
219164479|NCT05256745|DRUG|TC|Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
219237143|NCT05827185|BIOLOGICAL|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
219237144|NCT05827185|BIOLOGICAL|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
219237145|NCT01656512|DRUG|zolendronic acid|"patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg."
219237146|NCT01656512|DRUG|calcium & vitamin D|patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
219237147|NCT01529866|DEVICE|New Abutment Connection implant|New abutment connection implant
219237148|NCT01529866|DEVICE|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
219237149|NCT03566901|DEVICE|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
219237150|NCT03566901|OTHER|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
219237151|NCT02072330|DRUG|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
219237152|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
219164480|NCT05256745|DRUG|TCHP|Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
219164481|NCT05256745|DRUG|Chemotherapy regimen that includes ddAC|can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
219164482|NCT03022708|DEVICE|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
219164483|NCT06232447|OTHER|Cigarette Type Switching|Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of four weeks
219164484|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
219164485|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
219164486|NCT03341156|DRUG|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
219164487|NCT03341156|DRUG|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
219164488|NCT03401879|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
219164489|NCT03401879|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
219164490|NCT03401879|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
219164491|NCT03401879|DEVICE|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
219237153|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
219237154|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
219237155|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
219164492|NCT06475937|DRUG|DM001|Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
219164493|NCT01724242|DRUG|Vaginal DHEA|
219164494|NCT01724242|DRUG|Placebo|
219164495|NCT04093752|DRUG|Tirzepatide|Administered SC
219164496|NCT04093752|DRUG|Insulin Glargine|Administered SC
219164497|NCT04826978|BEHAVIORAL|Auditory environment|Auditory environment
219237156|NCT01673256|DEVICE|SJM Confirm ICM|
219164498|NCT03176888|BEHAVIORAL|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
219164499|NCT03176888|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
219164500|NCT01101451|DRUG|Cisplatin|Given IV
219164501|NCT01101451|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
219164502|NCT01101451|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
219164503|NCT01101451|OTHER|Laboratory Biomarker Analysis|Correlative studies
219164504|NCT01101451|OTHER|Quality-of-Life Assessment|Ancillary studies
219164505|NCT01101451|OTHER|Questionnaire Administration|Ancillary studies
219164506|NCT00004257|DRUG|fluorouracil|
219164507|NCT00004257|DRUG|oxaliplatin|
219164508|NCT00004257|PROCEDURE|conventional surgery|
219164509|NCT00004257|RADIATION|radiation therapy|
219164510|NCT00004559|BEHAVIORAL|dietary polyunsaturated fatty acid|
219164511|NCT06835907|OTHER|Questionnaires|Questionnaires include: the Alcohol Use Disorder Identification Test (AUDIT), Composite Autonomic Symptom Score (COMPASS-31), Depression Anxiety Stress Scale (DASS-21), Drug Desire Questionnaire (DDQ), Drinking Motives Questionnaire short form (DMQ-SF), Mini International Neuropsychiatric Interview (MINI), PROMIS-alcohol, Timeline Follow Back (TLFB) and Visual Analog Scale for craving (VAS).
219164512|NCT05586971|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
219237157|NCT03854565|DIAGNOSTIC_TEST|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
219164513|NCT05586971|DRUG|Allopurinol|Xanthine Oxidase Inhibitor
219164514|NCT05586971|DRUG|Placebo|Matching placebo
219164515|NCT05568381|DEVICE|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
219164516|NCT05568381|OTHER|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
219164517|NCT02240420|BEHAVIORAL|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
219164518|NCT06568341|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Outcome Expectations For Yoga (OEY) Scale
219164519|NCT04381832|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
219164520|NCT04381832|DRUG|Zimberelimab|Zimberelimab is an anti-PD-1 antibody
219237158|NCT04880837|OTHER|Educational Intervention|Attend educational session
219237159|NCT04880837|OTHER|Informational Intervention|Receive handouts
219164521|NCT04381832|DRUG|Quemliclustat|Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
219164522|NCT04381832|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor
219164523|NCT04381832|DRUG|Docetaxel|Docetaxel is type of chemotherapy
219164524|NCT04381832|DRUG|SG|Sacituzumab govitecan is an antibody-drug conjugate
219164525|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
219164526|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
219164527|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
219164528|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
219237160|NCT04880837|OTHER|Survey Administration|Complete surveys
219164529|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
219164530|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
219164531|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
219164532|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
219164533|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
219164534|NCT03819465|DRUG|AZD2936|AZD2936 IV
219164535|NCT04157348|BIOLOGICAL|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
219164536|NCT04157348|BIOLOGICAL|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
219164537|NCT04157348|BIOLOGICAL|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
219164538|NCT04157348|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
219164539|NCT04854096|DRUG|NS-018|Experimental
219164540|NCT04854096|DRUG|Best Available Therapy|Active Comparator
219164541|NCT06095440|OTHER|Hepatorenal Syndrome outcome in Patients at Methodist Health systems|1.2.1. To perform a retrospective analysis of patients with HRS with the aim of comparing various treatment modalities such as vasoconstrictors, albumin, CRRT, Molecular Adsorbent Recirculating System (MARS), and TIPS.
219237161|NCT02358304|DRUG|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
219237162|NCT02358304|DRUG|Placebo|
219237163|NCT04256148|BIOLOGICAL|ALXN1830|Administered via intravenous (IV) infusion
219237164|NCT04256148|OTHER|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
219237165|NCT00911404|BEHAVIORAL|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
219237166|NCT00911404|DIETARY_SUPPLEMENT|High CHO diet|Diet with 55% total calories from carbohydrates.
219164542|NCT06971835|DEVICE|NMP|"The study product is Induce Biologics NMP Fibers and NMP Micro Particulates however, this is observational research that involves standard of care.~NMP is regulated as a human cellular or tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and in 21 CFR Part 1271. Under this regulation it did not require clinical evaluation before it could be used commercially. It is indicated for use as a bone void filler for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the boney structure."
219164543|NCT05306938|BEHAVIORAL|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
219164544|NCT06409884|DEVICE|T-cell activation test using intracellular markers|A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
219164545|NCT06285786|OTHER|Ergonomic Training on Patient Handling Techniques|"Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory."
219164546|NCT04398745|DRUG|Belantamab mafodotin|Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.
219164547|NCT06287736|DEVICE|Spinal Cord Stimulator Implantation (SCS)|Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
219164548|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
219164549|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
219164550|NCT04757610|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
219164551|NCT04757610|BIOLOGICAL|0.5 mg ranibizumab|intravitreal injection
219164552|NCT04757610|PROCEDURE|Sham|intravitreal injection
219164553|NCT02965846|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
219164554|NCT02965846|DRUG|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
219164555|NCT04914442|DIAGNOSTIC_TEST|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
219164556|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.
219164557|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention on healthy lifestyle choices|The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
219164558|NCT04524494|OTHER|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
219164559|NCT04524494|OTHER|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
219164560|NCT04524494|OTHER|urine collection|Midstream Urine collection
219164561|NCT06338540|OTHER|Black color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the black caries color related to history of pain , ICDAS , pulp exposed and microbial load
219164562|NCT06338540|OTHER|dark brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the dark brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
219164563|NCT06338540|OTHER|light brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the light brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
219164564|NCT06338540|OTHER|yellow color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the yellow caries color related to history of pain , ICDAS , pulp exposed and microbial load
219164565|NCT05608213|PROCEDURE|Lenvatinib Plus I-125 Seed Brachytherapy|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients. Iodion-125 seeds will be implanted into the the target lesions (viable intrahepatic tumor and/or vascular tumor thrombus) under CT guidance according to the pre-operative planning within 7 days after lenvatinib administration. Iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
219164566|NCT05608213|DRUG|Lenvatinib|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
219164567|NCT05512052|DEVICE|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
219164568|NCT05512052|DEVICE|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
219164569|NCT05512052|DEVICE|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
219164570|NCT04747561|DRUG|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
219164571|NCT03304834|DEVICE|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
219164572|NCT05617742|DIAGNOSTIC_TEST|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
219164573|NCT02253459|DRUG|UTD1 Injection plus capecitabine|
219164574|NCT02253459|DRUG|Capecitabine|
219164575|NCT04790357|OTHER|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
219164576|NCT04790357|OTHER|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
219164577|NCT00879333|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
219237167|NCT02221011|DEVICE|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
219237168|NCT05615285|OTHER|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
219164578|NCT00879333|DRUG|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
219164579|NCT00879333|DRUG|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
219164580|NCT00154011|DRUG|rosiglitazone (drug)|
219164581|NCT00226018|DEVICE|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
219164582|NCT00226018|DEVICE|Placebo|placebo
219164583|NCT06489041|GENETIC|"Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx"|Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
219164584|NCT04099875|DIAGNOSTIC_TEST|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
219237169|NCT04816305|DEVICE|rTMSc|In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.
219164585|NCT01954836|BEHAVIORAL|initial fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
219164586|NCT01954836|BEHAVIORAL|Secondary fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
219164587|NCT00785915|DRUG|AZD6765|single administration and once daily for 5 days
219164588|NCT00785915|DRUG|Placebo|single administration and once daily for 5 days
219164589|NCT02634450|DEVICE|Alere q|
219164590|NCT03592732|OTHER|Blood sample|Blood sample
219237170|NCT04816305|BEHAVIORAL|Neurofunctional physiotherapy|All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
219237171|NCT04816305|DEVICE|rTMS sham|During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
219164591|NCT03788200|PROCEDURE|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
219164592|NCT03788200|PROCEDURE|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
219164593|NCT02369289|OTHER|bone mineral density test|
219164594|NCT04351932|BIOLOGICAL|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
219164595|NCT04351932|BIOLOGICAL|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
219164596|NCT04351932|BIOLOGICAL|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
219164597|NCT05858580|BEHAVIORAL|Bennett Kids PowerUP Project|Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
219164598|NCT04154384|BEHAVIORAL|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
219164599|NCT04154384|OTHER|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
219164600|NCT04154384|BEHAVIORAL|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
219164601|NCT02256254|DRUG|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
219164602|NCT02256254|DRUG|Placebo|2 placebo capsules every evening for 14 days
219164603|NCT05048186|BEHAVIORAL|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
219237172|NCT03294187|DEVICE|Wrist-worn wearables|See arm/group description.
219164604|NCT05430880|DIAGNOSTIC_TEST|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
219164605|NCT04301596|OTHER|Collection of data|different set of data will be collected over a 6 months period
219164606|NCT00951379|DRUG|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
219164607|NCT00951379|OTHER|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
219164608|NCT00951379|OTHER|laboratory biomarker analysis|Correlative studies
219164609|NCT02467166|DEVICE|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
219164610|NCT04218266|DRUG|BAY2433334|Tablet, taken orally once a day.
219164611|NCT04218266|DRUG|Apixaban|Capsule, taken orally twice a day.
219164612|NCT04218266|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
219164613|NCT04218266|OTHER|Apixaban matching placebo|Capsule, taken orally twice a day.
219164614|NCT00763152|OTHER|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
219164615|NCT02755415|DEVICE|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
219164616|NCT02755415|OTHER|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
219164617|NCT06345586|DRUG|Drospirenone|4 mg tablet once daily
219164618|NCT02742519|DRUG|ivacaftor|
219164619|NCT02742519|DRUG|Placebo|
219164620|NCT01296334|DRUG|morphine LO|intravenous infusion, 10 mg, once, 4 hours
219164621|NCT01296334|DRUG|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
219164622|NCT01296334|DRUG|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
219164623|NCT01296334|DRUG|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
219164624|NCT01296334|OTHER|saline|intravenous infusion, 0.9% saline, once, 4 hours
219164625|NCT01052259|DRUG|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
219164626|NCT04243980|DEVICE|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
219164627|NCT03452085|DEVICE|artificial saliva spray (AS)|cross over design
219164628|NCT03452085|OTHER|maritime throat spray (TT)|cross over design
219164629|NCT05088954|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
219164630|NCT01035034|PROCEDURE|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
219164631|NCT01035034|PROCEDURE|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
219164632|NCT05335642|PROCEDURE|EVAR|Endovascular repair of abdominal aortic aneurysms
219164633|NCT00035308|DRUG|Abetimus sodium (LJP 394)|
219164634|NCT02759016|DRUG|BI 836826|
219164635|NCT02759016|DRUG|Ibrutinib|Standard of Care
219164636|NCT04377308|DRUG|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
219164637|NCT00840229|DRUG|Triamcinolone hexacetonide|20 mg
219164638|NCT00840229|DRUG|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
219164639|NCT03828968|DIAGNOSTIC_TEST|bladder scan|Measurement of vesical volume by bladder scan
219164640|NCT03939312|DRUG|Atogepant|Atogepant Tablets
219164641|NCT02119650|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
219164642|NCT02119650|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
219164643|NCT02119650|DRUG|Pemetrexed|500 mg/m\^2 administered as an intravenous infusion over 10 minutes
219164644|NCT02119650|DRUG|Cisplatin|75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
219164645|NCT03081611|DEVICE|Ram cannula|Ventilatory support for preterm infants using Ram cannula
219164646|NCT03081611|DEVICE|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
219164647|NCT03189472|DEVICE|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
219164648|NCT03189472|DEVICE|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
219164649|NCT02210442|BEHAVIORAL|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
219164650|NCT02210442|OTHER|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
219164651|NCT01721291|DRUG|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
219164652|NCT03336905|OTHER|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
219164653|NCT05035446|PROCEDURE|single-incision plus one-port laparoscopic surgery|The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
219164654|NCT05035446|PROCEDURE|conventional laparoscopic surgery|It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
219164655|NCT02113267|DRUG|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
219164656|NCT02113267|DRUG|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
219164657|NCT05007587|DRUG|Lenvatinib|8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) QD
219164658|NCT05007587|DRUG|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
219164659|NCT05007587|DRUG|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
219164660|NCT05325931|DEVICE|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
219237173|NCT01257724|OTHER|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
219237174|NCT06296784|OTHER|e-health psychoeducation|e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
219237175|NCT01794689|DRUG|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
219237176|NCT01794689|DRUG|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
219237177|NCT01794689|BEHAVIORAL|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
219237178|NCT01794689|BEHAVIORAL|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
219237179|NCT01697956|DRUG|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
219237180|NCT01697956|DRUG|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
219237181|NCT00663429|DRUG|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
219237182|NCT00130026|DRUG|Caffeine|500 mg IV
219237183|NCT02090205|PROCEDURE|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
219237184|NCT02090205|PROCEDURE|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
219237185|NCT02090205|PROCEDURE|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
219237186|NCT02090205|DEVICE|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
219237187|NCT02090205|DEVICE|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
219237188|NCT00149409|DIETARY_SUPPLEMENT|Omacor|
219164661|NCT05325931|DEVICE|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
219164662|NCT02183506|DRUG|Metformin|
219164663|NCT02183506|DRUG|BI 1356 BS|
219164664|NCT05400161|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
219164665|NCT05400161|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
219164666|NCT02261649|DEVICE|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
219164667|NCT02261649|PROCEDURE|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
219164668|NCT02261649|DEVICE|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
219164669|NCT02261649|OTHER|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
219164670|NCT03642106|BEHAVIORAL|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
219164671|NCT01260870|DEVICE|Cotavance Paclitaxel Coated Balloon|
219164672|NCT01260870|DEVICE|Standard balloon angioplasty|
219164673|NCT06375876|BEHAVIORAL|Single-session intervention (SSI)|The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
219164674|NCT06067984|DEVICE|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
219164675|NCT03707236|BEHAVIORAL|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
219164676|NCT03000101|OTHER|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
219164677|NCT03000101|OTHER|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
219164678|NCT04430634|OTHER|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
219164679|NCT04430634|OTHER|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
219164680|NCT04430634|OTHER|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
219164681|NCT04430634|OTHER|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
219164682|NCT04430634|OTHER|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
219164683|NCT04430634|OTHER|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
219164684|NCT04430634|OTHER|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
219164685|NCT04430634|OTHER|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
219164686|NCT02436317|DEVICE|Point Of Care Ultrasound|Examination with an ultrasound machine
219164687|NCT02523443|OTHER|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
219164688|NCT02523443|OTHER|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
219164689|NCT06985303|COMBINATION_PRODUCT|Investigational Combination Product|This investigational therapy combines a proprietary, human-derived cell-based component with a unique blend of small molecules and an enzyme. The components are designed to work synergistically to address the complex pathology of white matter injury. The therapy aims to provide a source for cellular regeneration, support the survival of existing cells, enhance the potential for myelin repair, and modify the inhibitory environment of glial scar tissue. This multi-pronged biological intervention is designed to promote neural regeneration and functional recovery in patients with PVL.
219164690|NCT04772300|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
219164691|NCT04772300|DEVICE|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
219164692|NCT06987539|DRUG|Inebilizumab|Inebilizumab will be administered IV.
219164693|NCT06987097|DRUG|Ambrisentan|After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced to 5 mg/day. If the study drug has reached the maximum allowable dose (two tablets/day) and the patient shows signs of worsening PAH or right heart failure, the clinician may decide to add diuretics (with the type and dosage left at the referring physician's discretion). The number and percentage of patients requiring diuretic combination therapy in both groups will be recorded. Other baseline treatment medications will remain unchanged through follow-up duration.
219164694|NCT06987097|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.
219164695|NCT06988098|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
219164696|NCT06014866|DEVICE|Cardiac pacing|Patient's previously implanted with the INGEVITY+ lead located in the LBBA
219164697|NCT01840566|DRUG|Carmustine|
219164698|NCT01840566|DRUG|Etoposide|
219164699|NCT01840566|DRUG|Cytarabine|
219164700|NCT01840566|DRUG|Melphalan|
219164701|NCT01840566|BIOLOGICAL|Pegfilgrastim|
219164702|NCT01840566|BIOLOGICAL|19-28z T CELLS|
219164703|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
219164704|NCT03651505|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
219164705|NCT00068198|BIOLOGICAL|Dryvax|
219164706|NCT04534400|RADIATION|thoracic CT-scan|Automated measurement
219164707|NCT06998043|BIOLOGICAL|BX004|Bacteriophage
219164708|NCT06998043|OTHER|Placebo|Placebo
219164709|NCT06377358|DEVICE|Tecar Therapy|Tecar Therapy at 1Mhz radiofrequency by the use of a C-400 device. The duration of the treatment will be 5 weeks, where 10 sessions will be carried out, 2 per week
219164710|NCT03922035|OTHER|Best Practice|Receive standard peri-/post-transplant supportive care
219164711|NCT03922035|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
219164712|NCT06866938|DRUG|[177Lu]Lu-PSMA-617 (Pluvicto, Novartis)|"Patients will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis).~One injection every 6 weeks at the dose of 7.4 GBq (±10%)"
219164713|NCT07008781|BEHAVIORAL|Youth-led cancer screening intervention|High school students will be trained as health advocates and then facilitate discussions about cancer screening recommendations and risk factors with adults in their community. High school students (15-18 years old) from the local community will be recruited for this study, and each student will recruit adults that they live with or are part of their community (i.e. parent) who are eligible for cancer screening. The adult plus youth dyads will all undergo the same youth-led intervention in which the youth will utilize motivational interviewing to discuss cancer screening recommendations and risk factors with their adults and help their adults enroll in cancer screening through ScreenNJ, a community organization that aims to increase cancer screening in New Jersey, reduce cancer mortality rates, and reduce disparities.
219164714|NCT06626425|OTHER|Healthy Minds Program App|An 8-week meditation-based well-being training containing content for each of the four pillars of the training program: Awareness, Connection, Insight, and Purpose.
219164715|NCT06626425|OTHER|Hydro Coach App|The Hydro Coach app (HC). A smartphone-based wellness app to ensure proper hydration.
219164716|NCT07013214|BEHAVIORAL|Dual-Task Exercise|This intervention consists of exercises that integrate motor tasks (e.g., balance training, walking) with concurrent cognitive tasks (e.g., counting, verbal fluency, decision-making tasks). The progression of exercises will be tailored to the individual's abilities, gradually increasing the difficulty of both the motor and cognitive components.
219164717|NCT07013214|BEHAVIORAL|Standard Rehabilitation|This intervention consists of conventional exercises aimed at improving balance, gait, posture, and flexibility, without the integration of simultaneous cognitive tasks. The program will focus on established physical therapy techniques for Parkinson's disease.
219164718|NCT06711627|BEHAVIORAL|Standard of Care (SoC)|Standard recommended nutrition and gestational weight gain counseling.
219164719|NCT06711627|BEHAVIORAL|Food Provision|Standard recommended nutrition and gestational weight gain counseling plus food provision.
219164720|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
219164721|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
219164722|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
219164723|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
219164724|NCT07052045|OTHER|One Stop Management|Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.
219164725|NCT07052045|OTHER|Usual care management|Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.
219164726|NCT04774237|DRUG|BRIMOCHOL™|A single drop in each eye at a visit.
219164727|NCT04774237|DRUG|BRIMOCHOL™ F|A single drop in each eye at a visit.
219164728|NCT04774237|DRUG|Carbachol|A single drop in each eye at a visit.
219164729|NCT07067112|BIOLOGICAL|Blood sampling, questionnaire and phone call|The blood sample will drawn after a fasting period of at least 8 hours, and the questionnaire will be auto-administered
219164730|NCT07072429|PROCEDURE|Gastric cancer resection|Any kind of surgical gastric cancer resection
219164731|NCT07070869|BEHAVIORAL|Serious game|"Participation in the serious game SPAMLO-3.0."
219164732|NCT07072871|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum DAD-13|A probiotic supplement (Vipilac®) containing Lactiplantibacillus plantarum DAD-13 administered orally via nasogastric tube, 2 capsules daily for 4 days, intended to modulate immune response and support gut microbiota in ICU sepsis patients.
219164733|NCT07072871|DRUG|Placebo|Placebo capsules containing maltodextrin administered via nasogastric tube (NGT), identical in appearance and schedule to the probiotic group (2 capsules/day for 4 days), alongside standard sepsis care.
219164734|NCT06894745|DRUG|89-zr-dfo-star polyethylene glycol (StarPEG)|Given intravenously (IV)
219164735|NCT06894745|PROCEDURE|Whole Body Positron Emission Tomography (PET)|Imaging procedure
219164736|NCT06894745|PROCEDURE|Specimen Collection|Urine and blood specimens will be collected for correlative studies
219164737|NCT07069855|OTHER|Almond Snack Intervention for Gestational Diabetes|This intervention involves daily consumption of 43 g of whole almonds, split into two portions (afternoon and evening), for 28 days in pregnant women diagnosed with gestational diabetes who habitually consume evening snacks.
219164738|NCT07069855|OTHER|Control (placebo) group|This control involves the daily consumption of a nut-free snack (2 portions) that reflects a 'typical snack' choice among pregnant women with gestational diabetes. It serves as a comparison to assess the specific impact of almond-based evening snacking on overnight glucose regulation.
219164739|NCT07077330|OTHER|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.~Drug: fludarabine and cyclophosphamide Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg"
219164740|NCT07078617|OTHER|Proprioceptive Neuromuscular Facilitation|PNF technique given for 3-4 days/week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
219164741|NCT07078617|OTHER|Soft Tissue Mobilization along with exercise|Soft tissue mobilization along with facial exercise 3- days/ week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
219164742|NCT07076719|DIAGNOSTIC_TEST|Trophectoderm (TE) Biopsy|"* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):~  * Good: AA or AB.~ * Fair: BA, BB, BC.~ * Poor: CB or CC.~* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.~* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.~* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015)."
219237189|NCT02707302|DEVICE|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
219164743|NCT07076719|DIAGNOSTIC_TEST|Non-invasive Preimplantation Genetic Diagnosis|"* DNA Contamination Minimization:~  o SCM was harvested after embryo culture with care taken not to include cellular material.~* Sample Storage:~* Processing for Genetic Analysis:~  6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH)~* Chromosomal Assessment:~* BAC-chip Slides:~* Labeling and Hybridization:~* Scanning and Data Acquisition:~* Data Processing and Analysis:~  8\. Validation and Quality Control~* Robust quality control measures included:"
219164744|NCT07077525|COMBINATION_PRODUCT|Dapagliflozin + Metformin|70 patients with T2DM were treated once daily with Dapa plus Met combination (Dapavildactin plus®, Liptis Pharmaceuticals, Egypt) in a dose titrated from 5 mg Dapa and 1000 mg Met up to a maximum of 10 mg Dapa and 2000 mg metformin as per the standard of care in a physician's practice
219164745|NCT07077525|COMBINATION_PRODUCT|Vildagliptin + Metformin|126 patients with T2DM were treated with Vilda plus Met combination (Gliptus plus®, EVA pharma, Egypt ) in initial daily dose of 50 mg Vilda and 500 mg Met . The medication is titrated gradually up to Vilda 50 mg and metformin 1000 mg twice daily as per the standard of care in a physician's practice
219164746|NCT07077018|DIETARY_SUPPLEMENT|Fasting-mimicking diet (FMD) Group|The FMD will consist of a triweekly 4-day regimen of a plant-based, calorie-restricted (827± 100 kcal on day 1；637 ± 100 kcal on days 2-4), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles. Participants receive the FMD for 2 days prior to and on the day and one day after each cycle of chemotherapy.
219164747|NCT07078006|OTHER|Platelet Rich Fibrin|Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
219164748|NCT07078006|OTHER|Platelet Rich Plasma|Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
219164749|NCT07077473|DRUG|real word drugs|real word drugs
219164750|NCT07076836|DEVICE|Acupuncture|The electroacupuncture parameters were set as follows: frequency at 10 Hz, current intensity at 0.5 mA, pulse width at 50 μs, and each session lasted 30 minutes. On the first day of chemotherapy, electroacupuncture was administered 1-2 hours prior to chemotherapy initiation. From Day 2 to the final day of chemotherapy, electroacupuncture sessions were conducted daily between 2:00 PM and 4:00 PM.
219164751|NCT07076836|DEVICE|sham acupuncture|The sham electroacupuncture group referenced the same acupoints as the electroacupuncture group, but the false acupoint shallow needling method and false electrode method are used, and the treatment time and course are the same as the electroacupuncture group.
219164752|NCT07078123|PROCEDURE|Laparoscopic Donor Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
219164753|NCT07078968|DEVICE|Tri-Membrane Wrap™|Membrane Wrap™
219164754|NCT07078968|DEVICE|Membrane Wrap™|Membrane Wrap™
219164755|NCT07078968|DEVICE|Membrane Wrap-Hydro™|Membrane Wrap-Hydro™
219164756|NCT07078968|OTHER|Standard of Care|Basic care involves debridement, along with local wound care depending on the wound needs. Debridement involves removal of fibrin and devitalized tissue from the base and the borders of the ulcer which is necessary in all treatment plans to reduce the risk of infection and promote healing.
219164757|NCT07076511|OTHER|"Scenario unexpected difficult airway"|"Participants are asked to solve a scenario unexpected difficult airway using a manikin in accordance with current guidelines. The scenario aims for participants to try 3 different techniques in securing the airway before performing emergency front of neck access."
219164758|NCT07077252|DRUG|SCTB39G|SCTB39G,IV
219164759|NCT07078422|DEVICE|Encora Pulse|"The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.~This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration."
219164760|NCT07076316|BEHAVIORAL|Structured Early Rehabilitation Nursing Pathway|A multi-component, phased nursing intervention focused on early and progressive mobilization, respiratory exercises, and psychological support.
219164761|NCT07076316|BEHAVIORAL|Routine Care|Standard nursing care for severe acute pancreatitis patients in the ICU, including monitoring and passive limb mobilization.
219164762|NCT07078474|OTHER|Topical Hyaluronic Acid|Hyaluronic acid was applied topically to the facial skin of healthy participants once daily for a period of 3 weeks. Two application methods were used: on dry skin and on pre-moistened skin. Skin measurements were performed at baseline and after each week of intervention (Week 1, Week 2, and Week 3) to assess hydration and other skin parameters.
219164763|NCT07077824|PROCEDURE|Stellate Ganglion Block Injection with Bupivicaine|Patients will receive left stellate ganglion block US guided after induction of anesthesia and intubation and after insertion of Rt IJV CVL and before skin incision
219237190|NCT02707302|PROCEDURE|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
219164764|NCT07078929|BIOLOGICAL|CD19-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a CD19-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
219164765|NCT07077967|PROCEDURE|Phacoemulsification with EDOF IOLs|Uneventful pseudophakic presbyopic correction with EDOF IOLs
219164766|NCT07079137|OTHER|History, examination, bite documentation, SSS scoring,Baseline labs as per institutional protocol|"Following enrollment, an initial clinical assessment will be conducted in the Emergency Department (ED). This includes history taking, physical examination, documentation of bite characteristics, and calculation of the Snakebite Severity Score (SSS) at presentation. Baseline laboratory investigations will be performed as per institutional protocol.~All participants will undergo serial clinical and laboratory monitoring as per institutional protocol. The development of syndrome-specific core outcomes, including neurotoxicity, haemotoxicity, coagulopathy, local tissue damage, acute kidney injury, and hypotension (Annexure) would be followed-up and evaluations will be conducted at the following time points:~At presentation, Within 3 hours of ED admission, Within 6 hours of ED admission, Within 12 hours of ED admission"
219237191|NCT01115309|DEVICE|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
219237192|NCT03643445|BEHAVIORAL|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
219164767|NCT07077837|OTHER|Study Group|received perceptual learning using plantar hardness discrimination and conventional treatment
219164768|NCT07077837|OTHER|Control|received conventional treatment (balance exercise functional care training
219164769|NCT07076537|DIETARY_SUPPLEMENT|Placebo|Placebo
219164770|NCT07076537|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium, L-theanine and lemon balm extract
219164771|NCT06816693|BEHAVIORAL|tele-CR program|Following the completion of basic characteristics assessment prior to discharge, a 12 weeks tele-CR program was implemented for all participants. The tele-CR program is divided into three parts: motivational interview, App delivery, and self-management and tracking. The motivational interviewing during hospitalization, which involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR App (approximately 30-60 minutes per session). After discharge, the researchers monitored App usage and conducted four follow-up sessions via LINE or telephone at 1, 4, 8, and 12 weeks post-discharge. These follow-ups, lasting approximately 5-15 minutes each, aimed to assess patients' living conditions, resolve any issues promptly, and provide encouragement or praise based on their engagement with the App.
219164772|NCT05134337|DRUG|LOXO-305|Oral LOXO-305
219164773|NCT05134337|DRUG|Itraconazole|Oral itraconazole
219164774|NCT05134337|DRUG|Rifampin|Oral rifampin
219164775|NCT06494618|DEVICE|Radial Extracorporeal Shockwave Therapy|1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
219164776|NCT05828953|DRUG|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
219164777|NCT05828953|DRUG|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
219164778|NCT03591133|DRUG|TS-143|
219164779|NCT03591133|DRUG|Placebo|
219164780|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
219164781|NCT05607121|DEVICE|intermittent theta burst stimulation|transcranial magnetic stimulation
219164782|NCT05607121|DEVICE|continuous theta burst stimulation|transcranial magnetic stimulation
219164783|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
219164784|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
219164785|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
219164786|NCT06829524|DRUG|Satralizumab|Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.
219164787|NCT06629714|OTHER|Exposure: emotional distress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
219237193|NCT03643445|BEHAVIORAL|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
219237194|NCT05475717|DRUG|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
219237195|NCT05700851|DIETARY_SUPPLEMENT|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
219164788|NCT06186206|BEHAVIORAL|Social media interventions for vaccine uptake|"Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates."
219237196|NCT04423796|DEVICE|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
219237197|NCT04423796|OTHER|Early mobilization|Early mobilization by health care professionals without robotic assistance.
219237198|NCT01302158|DRUG|ASP1941|oral
219237199|NCT01302158|DRUG|Glimepiride|oral
219164789|NCT04341376|BEHAVIORAL|Enhanced First Connections|Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
219164790|NCT05274568|DRUG|[18F]UCB-2897|"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."
219164791|NCT06073717|BEHAVIORAL|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
219237200|NCT03961841|RADIATION|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
219164792|NCT06073717|BEHAVIORAL|Motor-cognitive Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
219164793|NCT06073717|BEHAVIORAL|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
219164794|NCT05166954|PROCEDURE|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
219164795|NCT05166954|PROCEDURE|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
219164796|NCT03618160|DRUG|JNJ-64565111|Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
219164797|NCT03618160|DRUG|Placebo|Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
219164798|NCT04499950|DRUG|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
219164799|NCT04499950|BEHAVIORAL|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
219164800|NCT04281134|DEVICE|Summit RC+S System|"Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger."
219164801|NCT04281134|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
219164802|NCT04732052|DEVICE|Transcranial Direct Current Stimulation|non-invasive brain stimulator
219164803|NCT04981977|BEHAVIORAL|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
219237201|NCT03961841|DRUG|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
219237202|NCT03961841|DRUG|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
219237203|NCT00001958|DRUG|Hydroxyurea|
219164804|NCT04981977|BEHAVIORAL|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
219164805|NCT04981977|OTHER|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
219164806|NCT00667030|BEHAVIORAL|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
219164807|NCT05711602|OTHER|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
219164808|NCT05872932|PROCEDURE|gastric balloon implantation|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
219164809|NCT05872932|PROCEDURE|botulinum toxin A injection|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
219237204|NCT00276601|DRUG|arsenic trioxide|
219237205|NCT00276601|DRUG|cytarabine|
219237206|NCT00276601|DRUG|daunorubicin hydrochloride|
219237207|NCT00276601|DRUG|mercaptopurine|
219237208|NCT00276601|DRUG|methotrexate|
219164810|NCT06794476|BEHAVIORAL|Milieu Teaching-AV|In Milieu Teaching-AV, coaches will teach caregivers to engage the child in play or routines around a standardized set of toys, follow the child's attention or communication lead around these toys, and respond to the infant's communication acts by modeling and expanding those communication acts into more sophisticated strategies. While responding to infant communication acts, coaches will slowly move the referent of the infant's lead near the face at approximately the level of the mouth, wait for the infant to shift his/her gaze towards the new referent position if necessary, and provide all models, prompting, and expanding while maintaining placement of the referent near the mouth.
219164811|NCT05323175|DRUG|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
219237209|NCT00276601|DRUG|tretinoin|
219237210|NCT00655824|DRUG|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
219237211|NCT04611334|BEHAVIORAL|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
219237212|NCT00104949|BIOLOGICAL|trastuzumab|
219164812|NCT05323175|OTHER|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
219164813|NCT06055387|BEHAVIORAL|Frailty intervention measures|"Providing specialized guidance:~* Physical Function and Fall History:~  * Prioritizing home safety for those with physical impairments.~ * Arranging rehab consultations when necessary.~* Nutrition:~  * Assessing diets and offering education.~ * Pre-treatment nutritionist assessments.~ * Monitoring weight, intervening if \>5-10% loss, or \>10% loss.~* Social Support:~  * Evaluating the needs of those without family support.~ * Referring to social services and introducing care resources.~* Cognition:~  * Detecting cognitive issues, addressing reversible causes.~ * Assessing decision-making and medication self-administration.~ * Refer to specialists when needed.~* Polypharmacy and Comorbidity:~  * Collecting medication data, ensuring adherence.~ * Noting chronic illnesses.~ * Collaborating with specialists or pharmacists for complex cases.~* Psychological:~  * Providing weekly support for psychological concerns.~ * Refer to specialists for assessments and treatment options."
219164814|NCT02349412|OTHER|Early palliative care|
219164815|NCT03918720|BEHAVIORAL|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
219164816|NCT05394662|DEVICE|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
219164817|NCT05179200|PROCEDURE|Plasmapheresis|Plasma donation
219164818|NCT05179200|PROCEDURE|Whole blood donation|Blood donation
219164819|NCT03611153|DRUG|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
219164820|NCT03611153|DRUG|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
219164821|NCT04536116|DEVICE|Virtual Reality headset|MRI simulation with a Virtual Reality headset
219164822|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
219164823|NCT06157099|DRUG|Atorvastatin|Given PO
219237213|NCT00589628|DRUG|infliximab|5mg/kg/dose IV at 4 week intervals
219237214|NCT00589628|DRUG|infliximab|10mg/kg/dose IV at 4 week intervals
219164824|NCT06157099|DRUG|Placebo Administration|Given orally (PO)
219164825|NCT06157099|PROCEDURE|Computed Tomography|Undergo CT
219164826|NCT06157099|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219164827|NCT06157099|OTHER|Electronic Health Record Review|Ancillary studies
219164828|NCT00979576|DRUG|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2
219164829|NCT00979576|DRUG|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
219164830|NCT00979576|DRUG|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
219164831|NCT00979576|DRUG|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
219164832|NCT00979576|DRUG|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
219164833|NCT05027763|BEHAVIORAL|high-fiber/low fat|high fiber/low fat preoperative diet
219164834|NCT05027763|BEHAVIORAL|fermented|fermented preoperative diet
219164835|NCT04048850|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
219164836|NCT03377543|DRUG|Aspirin|81mg aspirin pill daily at bedtime over a 25 day period
219237215|NCT04078607|BEHAVIORAL|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
219164837|NCT03377543|DRUG|Placebo|81mg non-active pill that looks like aspirin
219164838|NCT02294799|OTHER|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization
219164839|NCT02294799|OTHER|Placebo group|Nonspecific Mandibular Movement.
219164840|NCT04830592|BIOLOGICAL|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
219164841|NCT04830592|BIOLOGICAL|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
219164842|NCT05817344|BEHAVIORAL|Written Exposure Therapy - Integrated|A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
219164843|NCT05468008|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
219164844|NCT04188665|DRUG|MASL|Patients treated with MASL lozenge
219164845|NCT04188665|OTHER|Placebo|Patients treated with placebo lozenge
219164846|NCT04840199|DRUG|Letermovir Oral Tablet|480 mg administered orally once daily with or without food
219237216|NCT04078607|BEHAVIORAL|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
219164847|NCT05014087|DRUG|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
219164848|NCT06386913|OTHER|Training|Measurement-Based Care Training
219164849|NCT01985139|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
219164850|NCT01985139|BIOLOGICAL|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
219164851|NCT05736744|DRUG|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
219164852|NCT05736744|DRUG|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
219164853|NCT05550207|DRUG|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
219237217|NCT04988542|DIETARY_SUPPLEMENT|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
219237218|NCT01862159|PROCEDURE|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
219237219|NCT03353636|DIETARY_SUPPLEMENT|Magnesium|150mg elemental magnesium
219237220|NCT03353636|DIETARY_SUPPLEMENT|Placebo|Rice flour
219237221|NCT00507767|DRUG|dasatinib|Given PO or via PEG tube
219237222|NCT00507767|PROCEDURE|pharmacological study|Correlative studies
219237223|NCT00507767|PROCEDURE|laboratory biomarker analysis|Correlative studies
219237224|NCT05299034|DIAGNOSTIC_TEST|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
219237225|NCT05299034|DIAGNOSTIC_TEST|Non contrast CT+CT angiography|NCCT+CTA
219237226|NCT04784390|DEVICE|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
219237227|NCT04784390|DEVICE|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
219237228|NCT04838860|DRUG|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
219237229|NCT01427400|DRUG|Botulinum Toxin-A|100 Units diluted in 25cc saline
219237230|NCT01427400|DRUG|Saline|Dispensed in a 25cc syringe
219237231|NCT00877305|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
219237232|NCT00877305|OTHER|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
219164854|NCT06540781|PROCEDURE|wet cupping therapy|"The cupping (WCT) procedure consists of five phases:~Primary suction: Using a manual suction pump, air was drawn from glass cups that were positioned on the chosen locations. The skin and subcutaneous tissue swelled as a result of the cups' five minutes of skin contact.~Area disinfection: After disinfecting the cupped areas with povidone-iodine, they were wiped with sterile gauze.~Scarification: Using a sterile number 11 surgical blade, superficial incisions measuring 20-30 gauge in length and 1-2 mm in depth were made on the skin.~Bloodletting and secondary suction: Once again applied to the scarified areas, the previously removed cups created suction using the manual pump which was previously mentioned. In order to fill the cups, blood was drawn from the skin's and subcutaneous tissue's capillaries.~Removing and dressing: After 10 minutes, the cups filled with blood were removed. The application areas were wiped with sterile gauze, and dressings were applied."
219164855|NCT06777394|OTHER|High intensity interval training|"The HIIT program begins with a warm-up, followed by high-intensity repetitions separated by moderate-intensity recovery intervals. High-intensity exercises are performed near maximum effort, while moderate-intensity periods are maintained at 50% effort. HIIT exercises, involving low-skill movements in short bursts, enhance blood sugar regulation and fat-burning capacity.~The HIIT protocol has four phases:~Warm-Up: 10 minutes, gradually increasing to about 60% of maximum heart rate. Intervals: 4 minutes at 85-95% maximum heart rate. Relief/Recovery: 3 minutes at 60% maximum heart rate, repeated four times. Cool Down: 5 minutes, bringing the heart rate down to around 50% of maximum. Three key components determine the success of HIIT: intensity, duration, and recovery period. Exercises include dumbbell and kettlebell exercises, push-ups, squats, jump training, and stationary cycling"
219164856|NCT06777394|OTHER|Routine treatmet|"outine physical therapy includes stretching exercises, exercises to maintain a normal range of motion, and low-intensity and aerobic exercises for the patients.~Low-Intensity Exercise: The effects of low-intensity exercise become noticeable after about 20 minutes, providing a metabolic boost during the activity. Generally, a longer exercise duration further enhances metabolism."
219164857|NCT03654573|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
219164858|NCT03571945|DEVICE|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
219164859|NCT03571945|DEVICE|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
219164860|NCT06022029|DRUG|ONM-501|Intratumoral injection
219164861|NCT06022029|DRUG|Cemiplimab|Intravenous administration of 350 mg
219164862|NCT06780410|DRUG|Bempedoic Acid Tablet|Once daily, oral
219164863|NCT06780410|DRUG|Placebo|Once daily, oral
219164864|NCT04835831|OTHER|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
219164865|NCT06157216|DRUG|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
219164866|NCT06764836|DRUG|IMM27M|Intravenous injection
219164867|NCT06764836|DRUG|IMM2510|Intravenous injection
219164868|NCT06766799|DEVICE|Rebound and Applanation Tonometer|Measurement of Intraocular Pressure
219164869|NCT06766955|OTHER||
219164870|NCT06767215|OTHER|Ice Compress|Ice compress will be applied 5 minutes before butulinium injection
219164871|NCT06767215|OTHER|No ice compress|No ice compress will be applied .
219164872|NCT05215847|DRUG|ARD-101|Twice daily, oral administration
219164873|NCT06678737|OTHER|CBIT +cTBS|10 daily sessions of CBIT plus cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
219164874|NCT06678737|OTHER|CBIT +sham cTBS|10 daily sessions of CBIT plus sham cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
219237233|NCT05892445|BEHAVIORAL|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
219164875|NCT04330326|DRUG|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
219164876|NCT04330326|DRUG|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
219164877|NCT04170946|OTHER|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
219164878|NCT06479785|OTHER|Educational Intervention Program for machine workers|A detailed Educational Intervention Program for marble factory workers working on Machines.
219164879|NCT06479785|OTHER|Educational Intervention Program for manual workers|A detailed Educational Intervention Program for marble factory workers working manually.
219164880|NCT05744401|DRUG|AL002|Administered via intravenous (IV) infusion
219237234|NCT00663819|DEVICE|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
219237235|NCT00663819|PROCEDURE|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
219237236|NCT04871555|OTHER|MRI|structural imaging
219237237|NCT06081738|DRUG|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
219237238|NCT06081738|DRUG|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
219164881|NCT06737822|COMBINATION_PRODUCT|TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment|"TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment."
219164882|NCT06737822|COMBINATION_PRODUCT|Surgery and Adjuvant Treatment|Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
219164883|NCT06218368|BEHAVIORAL|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
219164884|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
219164885|NCT04761302|DRUG|Intravenous ketorolac and oral acetaminophen|ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group
219164886|NCT04761302|DRUG|Intravenous morphine and oral oxycodone|Morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
219164887|NCT06473844|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg once daily from recruitment to hospital discharge
219164888|NCT06473844|DRUG|Placebo|Placebo single tablet once daily from recruitment to hospital discharge
219164889|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
219164890|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
219164891|NCT04939844|DRUG|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
219164892|NCT04023669|DRUG|Prexasertib|IV
219164893|NCT04023669|DRUG|Cyclophosphamide|IV
219164894|NCT04023669|DRUG|Gemcitabine|IV
219164895|NCT04023669|BIOLOGICAL|filgrastim|Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.
219164896|NCT04023669|BIOLOGICAL|peg-filgrastim|Given subcutaneously (SQ). Alternatively, filgrastim may be given.
219164897|NCT02728557|BEHAVIORAL|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
219164898|NCT02728557|BEHAVIORAL|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
219164899|NCT03281902|PROCEDURE|Biopsy|Undergo tumor biopsy
219164900|NCT03281902|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
219164901|NCT03281902|OTHER|Laboratory Biomarker Analysis|Correlative studies
219237239|NCT02313350|DEVICE|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
219237240|NCT02313350|PROCEDURE|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
219237241|NCT02428556|OTHER|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
219237242|NCT02428556|OTHER|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
219237243|NCT02428556|OTHER|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
219164902|NCT05541666|BEHAVIORAL|The Emotional Freedom Technique|The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
219164903|NCT01007383|DRUG|LEO 27847|First in man
219164904|NCT02697123|OTHER|antepartum and postpartum|This is a prospective observational cohort study.
219164905|NCT03897686|DEVICE|"hydrous biopolymer with silver ions Argiform"|2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml
219164906|NCT03897686|DEVICE|saline solution|2 once-weekly intra-articular injections of saline solution 4 ml
219164907|NCT05579327|DRUG|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
219164908|NCT05579327|DRUG|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
219164909|NCT05620641|DRUG|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
219164910|NCT05620641|DRUG|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
219164911|NCT04052516|DRUG|Icosabutate|Icosabutate oral capsule once daily
219164912|NCT04052516|DRUG|Placebo|Matching placebo oral capsule
219164913|NCT04415788|DEVICE|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
219237244|NCT02428556|OTHER|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
219237245|NCT02428556|OTHER|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
219237246|NCT04586348|COMBINATION_PRODUCT|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
219164914|NCT04415788|DEVICE|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
219164915|NCT04415788|DEVICE|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
219164916|NCT04684108|DRUG|SG301|Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
219164917|NCT05790707|PROCEDURE|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
219164918|NCT05790707|DRUG|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
219164919|NCT05679297|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~2. Thermal pain threshold~3. Mechanical detection thresholds for touch~4. Mechanical pain threshold for pinprick stimuli~5. Stimulus-response functions~6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~7. Vibration detection threshold~8. Pressure pain threshold"
219164920|NCT05679297|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
219164921|NCT05679297|OTHER|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
219164922|NCT05679297|OTHER|Follow-up interview|"Structured telephone interview with 3 Questionnaires~1. The german pain questionnaire~2. Questionnaire regarding clinical development since the last visit designed by the investigators~3. German translation of 12-item-allodynia symptom checklist (ASC-12)"
219164923|NCT03416010|BEHAVIORAL|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
219164924|NCT05743621|DRUG|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
219164925|NCT05743621|DRUG|Enzalutamide|160 mg daily PO
219164926|NCT06087614|RADIATION|DE-HyART|The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
219164927|NCT06087614|RADIATION|Standard Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
219164928|NCT06087614|DRUG|Cisplatin injection|Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
219164929|NCT06087614|RADIATION|Standard fractionation (Radiation Oncology preference)|Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
219164930|NCT03948763|BIOLOGICAL|V941|V941 administered IM, Q3W for 9 3-week cycles
219164931|NCT03948763|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
219164932|NCT03625323|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
219164933|NCT03625323|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
219164934|NCT05415436|OTHER|Propofol slow administration|Propofol will be slowly administered over 120 seconds by anesthesia provider
219164935|NCT01745965|DRUG|T-DM1|
219164936|NCT01745965|DRUG|Trastuzumab|
219237247|NCT04586348|COMBINATION_PRODUCT|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
219164937|NCT05573828|PROCEDURE|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
219164938|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
219164939|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
219164940|NCT06269744|BEHAVIORAL|Proactive Screening Outreach|Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
219164941|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
219164942|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
219164943|NCT06170489|BIOLOGICAL|JS004 in combination with Toripalimab|Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
219164944|NCT06170489|DRUG|Bendamustine or gemcitabine|Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
219164945|NCT06798792|OTHER|PechaKucha technique|The Discharge Education course was taught using the PechaKucha technique.
219164946|NCT06798792|OTHER|TeachBack technique|The Discharge Education course was taught using the TeachBack technique.
219164947|NCT05563857|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219164948|NCT05563857|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219164949|NCT03537586|DRUG|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
219164950|NCT03537586|DRUG|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
219164951|NCT03537586|DRUG|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
219164952|NCT03537586|DEVICE|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
219164953|NCT03537586|DEVICE|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
219164954|NCT05508763|GENETIC|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
219164955|NCT05574426|BEHAVIORAL|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
219237248|NCT02302157|BIOLOGICAL|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
219164956|NCT04962126|DRUG|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
219164957|NCT04962126|DRUG|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
219164958|NCT04962126|RADIATION|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
219164959|NCT00753987|DRUG|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
219164960|NCT06790342|DRUG|Cystine|Used for smoking cessation and alcohol reduction
219237249|NCT01502813|DRUG|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
219237250|NCT00725959|BEHAVIORAL|Online social networking HIV prevention|messages about HIV posted in online social networking sites
219237251|NCT01397006|DRUG|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
219237252|NCT00778856|PROCEDURE|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
219237253|NCT04603300|DRUG|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
219237254|NCT04603300|DRUG|Placebo|Fully functional toothpaste containing no immunotherapy agents
219237255|NCT03102632|OTHER|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
219164961|NCT06790342|BEHAVIORAL|Positively Smoke Free|An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
219164962|NCT06790342|OTHER|Placebo|Matched to cystine
219164963|NCT06790342|OTHER|Standard of Care|Standardized brief advice to quit smoking (standard of care)
219164964|NCT06785285|DRUG|Dexmedetomidine|To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
219164965|NCT06783556|DEVICE|The Ear Electroacupuncture of Battlefield Acupuncture (BFA) and paracetamol intravenous therapy|"Electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle insertion was performed perpendicularly at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture uses continuous waves of 2 Hz frequency with an intensity that can be tolerated by the patient for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
219164966|NCT06783556|DEVICE|The sham electroacupuncture and paracetamol intravenous therapy|"Sham electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle only attached using plester (not inserted) at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture device is not turned on. The therapy is carried out for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
219164967|NCT05103904|OTHER|Laboratory Biomarker Analysis|Correlative studies
219164968|NCT05103904|DRUG|Lenvatinib|Given PO
219164969|NCT06782607|DIAGNOSTIC_TEST|Pneumonia Panel by FilmArray|The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
219237256|NCT03004625|DRUG|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
219237257|NCT03004625|DRUG|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
219237258|NCT03004625|DRUG|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
219237259|NCT04639999|OTHER|Echocardiography|LV vortex flow in Echocardiography
219237260|NCT03032198|DEVICE|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
219237261|NCT05266300|GENETIC|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"
219237262|NCT01860300|DRUG|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
219237263|NCT01860300|DRUG|placebo|
219237264|NCT00679406|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
219237265|NCT03413826|BEHAVIORAL|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
219237266|NCT03536845|DRUG|Vitamin D 3|oral drops
219237267|NCT05710757|OTHER|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
219164970|NCT04030130|BEHAVIORAL|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
219164971|NCT03819686|BEHAVIORAL|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching \~20-minutes of videos from the website)
219164972|NCT03819686|BEHAVIORAL|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
219164973|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
219164974|NCT06784102|OTHER|Damon Clear Debonding Plier (the primary intervention being tested in this study).|This clinical trial evaluates two types of orthodontic debonding pliers: the Damon Clear Debonding Plier and the traditional Bracket Remover Debonding Plier. The Damon Clear plier features a third wedging arm, which applies an additional lingual or palatal force in addition to the standard occluso-gingival force. The study is designed to assess and compare pain levels and debonding forces between the two pliers. A total of 40 patients, aged 17-25, were treated with both devices using a split-mouth design. The Damon Clear Plier is tested on one side of the mouth while the Bracket Remover Plier is used on the opposite side. Pain perception was measured immediately after the debonding procedure using the Numerical Rating Scale (NRS), and the forces applied during debonding were measured with a force-sensitive prototype. The study aims to identify the device that provides effective debonding with less pain.
219164975|NCT06396260|OTHER|Diffusion Kurtosis Imaging (DKI)|Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
219164976|NCT06396260|OTHER|Resting State Magnetoencephalography|Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
219164977|NCT05586542|COMBINATION_PRODUCT|DERMASEAL|a novel skin substitute formulated as planar, thin film
219164978|NCT05586542|BIOLOGICAL|Plasma Film|a planar, thin film made from human plasma
219164979|NCT05586542|OTHER|Standard of Care|standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
219164980|NCT06783543|OTHER|Comprehensive detumescence treatment with education video|Comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low elastic bandaging and functional exercise four steps
219164981|NCT06783543|OTHER|Comprehensive detumescence treatment|Three to five times a week, one hour each time
219164982|NCT06787443|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for five weeks
219164983|NCT06787443|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for five weeks
219164984|NCT06784908|OTHER|Yale Pain Stress Task (YPST)|Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.
219164985|NCT04296162|DRUG|Vinorelbine|Vinorelbine chemotherapy (oral)
219164986|NCT04296162|DRUG|Capecitabine|Capecitabine chemotherapy (oral)
219164987|NCT04296162|DRUG|Trastuzumab|Trastuzumab target therapy
219164988|NCT06785740|DRUG|Statin|Statin use
219164989|NCT04505774|DRUG|theraputic heparin|increased dose of heparin above standard of care.
219164990|NCT04505774|DRUG|prophylactic heparin|standard of care dose of heparin
219164991|NCT04505774|DRUG|P2Y12|added P2Y12 inhibitor
219164992|NCT04505774|DRUG|Crizanlizumab Injection|crizanlizumab injection
219164993|NCT04505774|DRUG|SGLT2 inhibitor|sglt2 inhibitor
219164994|NCT06788873|OTHER|Data comparison|"For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit."
219164995|NCT05454215|DEVICE|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
219164996|NCT05454215|DEVICE|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
219164997|NCT05466890|DRUG|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
219164998|NCT05466890|DRUG|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
219237268|NCT05710757|DEVICE|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
219164999|NCT06792474|DRUG|Lidocaine in Saline|Lidocaine infusion 1.5 mg/kg/hr
219165000|NCT06792474|DRUG|Normal saline|Normal saline infusion
219165001|NCT06783920|PROCEDURE|music|music will be played during the copper IUD insertion
219165002|NCT06783920|PROCEDURE|no music|IUD insertion will be done as usual without music
219165003|NCT06790264|PROCEDURE|68Ga-FAPi-46 PET/CT|Study participants will undergo baseline assessments at enrollment with 68Ga-FAPi-46 PET/CT
219237269|NCT05710757|OTHER|myofascial release|Sham MFR.
219237270|NCT06318559|PROCEDURE|3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy|"The operation is performed using the Da Vinci HD robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted.~Then a radical prostatectomy is performed."
219237271|NCT02281266|PROCEDURE|curative resection|
219237272|NCT02281266|DRUG|thymalfasin|1.6mg twice a week, 12 months
219237273|NCT02281266|DRUG|nucleoside analog (suggest to use entecavir)|
219237274|NCT02318810|DRUG|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
219237275|NCT02318810|DRUG|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
219237276|NCT02318810|DRUG|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
219237277|NCT02318810|DRUG|Placebo|Patients receive saline
219237278|NCT03705663|BEHAVIORAL|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
219237279|NCT01450657|DIETARY_SUPPLEMENT|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
219237280|NCT03152435|BIOLOGICAL|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
219237281|NCT04348669|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
219237282|NCT03434600|OTHER|Oxford UKA vs Sigma UKA|
219237283|NCT01307800|DRUG|LY2140023|Administered orally
219237284|NCT01307800|DRUG|Placebo|Administered orally
219237285|NCT01536964|DRUG|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
219237286|NCT01536964|DRUG|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
219237287|NCT06455306|PROCEDURE|Air-polishing with erythritol at different time points|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months
219237288|NCT06455306|PROCEDURE|Single Air-polishing with erythritol|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
219237289|NCT03365232|DEVICE|non custom base attachment|non custom base attachment
219237290|NCT03365232|DEVICE|custom base attachment|custom base attachment
219237291|NCT02892019|DRUG|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
219237292|NCT02892019|DRUG|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
219237293|NCT01667198|PROCEDURE|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
219237294|NCT01667198|BEHAVIORAL|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
219237295|NCT03985566|DIETARY_SUPPLEMENT|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
219237296|NCT03985566|DIETARY_SUPPLEMENT|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
219237297|NCT00689351|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
219237298|NCT00689351|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
219237299|NCT01766206|BIOLOGICAL|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
219237300|NCT03683615|PROCEDURE|repair of orbital floor fractures using resorbable plates|
219237301|NCT01670799|DRUG|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
219237302|NCT03486509|DRUG|Afatinib|afatinb 40mg po bid
219237303|NCT02586272|DEVICE|Daifert|
219237304|NCT02586272|PROCEDURE|Control Group|
219237305|NCT06270862|BEHAVIORAL|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
219237306|NCT06270862|BEHAVIORAL|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
219237307|NCT06270862|BEHAVIORAL|physical exercise|Engage in age-appropriate physical exercises.
219165004|NCT06786208|DRUG|Sunvozertinib|sunvozertinb, a EGFR-TKI, 300mg QD oral
219165005|NCT06790550|OTHER|Music Therapy|Music will be played during the insulin injection process
219165006|NCT06785155|OTHER|Chatbot group|Participants explored the topics using the AI chatbot platform.
219165007|NCT06785155|OTHER|website assisted|Participants explored the topics using the website platform
219237308|NCT06270862|BEHAVIORAL|social interaction|Engage in social discussion with peers in the group.
219237309|NCT06270862|BEHAVIORAL|workshop series|Watch a series of workshops targeting the older adult population.
219165008|NCT06783465|DEVICE|Digital therapeutics session|During the digital therapeutics session, the patient performs tasks by handling objects according to instructions displayed by the device. A camera records the task performance, and the system analyzes the task performance.
219165009|NCT06322615|PROCEDURE|Acupressure Therapy|Undergo acupressure
219165010|NCT06322615|OTHER|Educational Intervention|Receive education session about using acupressure at home
219165011|NCT06322615|OTHER|Electronic Health Record Review|Ancillary studies
219165012|NCT06322615|OTHER|Questionnaire Administration|Ancillary studies
219165013|NCT06037382|OTHER|Mood Triggers App|"The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction."
219165014|NCT05648786|BEHAVIORAL|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
219237310|NCT03967015|OTHER|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
219237311|NCT04494399|DRUG|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
219237312|NCT04494399|DRUG|Ribavirin|5-day course of oral ribavirin 400mg twice daily
219237313|NCT03479918|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
219237314|NCT03479918|DRUG|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
219237315|NCT03479918|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
219237316|NCT03479918|DRUG|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
219237317|NCT05539118|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
219165015|NCT05648786|BEHAVIORAL|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
219165016|NCT06785896|PROCEDURE|Angle Class II unilateral, treated by carriere motion appliance|This treatment was unilateral, with dental composite bites ramps behind canines
219165017|NCT06307873|DIAGNOSTIC_TEST|pre and post operative POP-Q results|Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
219165018|NCT06307873|BEHAVIORAL|pre and post operative PİSQ-12 results|Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
219165019|NCT03654053|DRUG|Placebo Oral Tablet|Placebo taken once nightly at bed time.
219165020|NCT03654053|DRUG|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
219165021|NCT04035174|DIAGNOSTIC_TEST|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
219165022|NCT04035174|DIAGNOSTIC_TEST|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
219165023|NCT05863273|DRUG|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
219165024|NCT06786468|OTHER|Early palliative care integration|The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits
219165025|NCT06786468|DRUG|Standard systemic treatment for advanced lung cancer|Standard systemic treatment for advanced lung cancer
219165026|NCT05616273|OTHER|Mixed Meal Tolerance Test (MMTT)|At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.
219165027|NCT05616273|OTHER|Arginine Stimulation Test (AST)|At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.
219165028|NCT05616273|OTHER|Home Finger Prick Sample|Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
219165029|NCT06790862|DRUG|SHR0302Base gel|SHR0302Base gel.
219165030|NCT06790862|DRUG|SHR0302Base gel placebo|SHR0302Base gel placebo.
219165031|NCT06789380|BEHAVIORAL|Schema therapy|Schema therapy (ST) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bamelis et al., 2014; Sempértegui et al., 2013; Arntz et al., 2022). Eligible programs must adhere to the minimum standards described in the evidence-based literature. ST is an integrative treatment method, originally rooted in cognitive theory, but with additional influences from Gestalt, psychodynamic, and experiential methods. Schema therapy programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions and/or a duration of 12 to 24 months. In addition, in order to be eligible, a schema therapy program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
219165032|NCT06789380|BEHAVIORAL|Mentalization-based treatment|Mentalization-based treatment (MBT) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bateman \& Fonagy, 2008; Bateman \& Fonagy, 2009; Laurenssen et al., 2018; Juul et al., 2023). MBT is rooted in psychodynamic and attachment theory and aims to alter personality pathology by improving mentalizing and enhancing epistemic trust. Eligible programs must adhere to the minimum standards described in the evidence-based literature. MBT programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions or a duration of 12 to 24 months. In additon, in order to be eligible, an MBT program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
219237318|NCT05539118|DRUG|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
219165033|NCT06789380|BEHAVIORAL|Guideline-informed treatment for personality disorders|GIT-PD is a non-theoretical and non-methodological approach, based upon principles derived from common factors across evidence-based treatments for PD. GIT-PD has a flexible approach, enabling tailoring treatment to clinical needs of different types of patients. The treatment duration (start-end) is 12- 18 months. The treatment consists of three distinct phases. First, an assessment phase. Second, a modular treatment phase that offers either group or individual interventions. Third, a follow-up phase with limited treatment and focus on relapse prevention. In order to be eligible, GIT-PD should be less intensive than specialist psychotherapies offered in the control arm at the same location (i.e. MBT or ST). GIT-PD will not include evidence-based psychotherapy for personality disorders as described in previous RCTs.
219165034|NCT06782724|DRUG|Psilocybin therapy|Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
219165035|NCT06471751|OTHER|Inspiratory and Oropharyngeal Muscle Strengthening|"Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device."
219165036|NCT06349564|DEVICE|Pico 4 Enterprise headset with noise cancelling headphones|The device includes a computer tablet and virtual reality headset.
219165037|NCT06629454|DEVICE|Adherence to digital incentive spirometer in the postop period after major chest surgery.|Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
219165038|NCT01939275|RADIATION|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
219165039|NCT01939275|DEVICE|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
219165040|NCT01939275|OTHER|laboratory biomarker analysis|Correlative studies
219165041|NCT01939275|PROCEDURE|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
219165042|NCT05441696|DEVICE|ezCVP measurement|"* Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
219165043|NCT04598854|DEVICE|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
219165044|NCT04598854|DEVICE|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
219165045|NCT06137170|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
219165046|NCT03442101|DRUG|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
219165047|NCT05837936|OTHER|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
219165048|NCT05837936|OTHER|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
219237319|NCT05539118|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
219237320|NCT01903109|DRUG|Cevimeline|
219165049|NCT06023082|DIETARY_SUPPLEMENT|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
219165050|NCT03694002|DRUG|Carboplatin|Given IV
219165051|NCT03694002|DRUG|Paclitaxel|Given IV
219165052|NCT03694002|BIOLOGICAL|Ramucirumab|Given IV
219165053|NCT05622799|BEHAVIORAL|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
219165054|NCT06772961|OTHER|Transcutaneous electrical acupoint stimulation|In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
219165055|NCT06772961|OTHER|Conventional care plan|Conventional care plan
219165056|NCT05220514|DRUG|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
219165057|NCT05220514|DRUG|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
219165058|NCT02662309|DRUG|MPDL3280A|Intravenous infusion
219237321|NCT05208294|DRUG|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
219237322|NCT05208294|DRUG|Placebo|Participants receive an inactive placebo capsule.
219237323|NCT05208294|BEHAVIORAL|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
219237324|NCT05208294|BEHAVIORAL|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
219237325|NCT02740426|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
219237326|NCT00444054|BEHAVIORAL|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
219237327|NCT02736175|DRUG|Dexamethasone|
219237328|NCT02736175|OTHER|Placebo Vehicle|
219237329|NCT03453645|PROCEDURE|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
219237330|NCT00779805|DRUG|Pseudoephedrine hydrochloride 120 mg ER tablets|
219237331|NCT03143036|DRUG|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
219237332|NCT01285882|OTHER|Representations|"1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
219237333|NCT00977678|OTHER|open access gastroscopy|access to gastroscopy without preceding appointment
219165059|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
219165060|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
219165061|NCT05847920|DRUG|SHR-2010 Injection|SHR-2010 Injection
219165062|NCT05847920|DRUG|Placebo|Placebo
219165063|NCT04853212|PROCEDURE|Biopsy|Biopsy during recto-coloscopy
219165064|NCT04133948|DRUG|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
219165065|NCT04133948|DRUG|Nivolumab|2 courses nivolumab 240 mg q3weeks
219165066|NCT04133948|DRUG|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
219165067|NCT03584516|DRUG|Itacitinib|In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
219165068|NCT03584516|DRUG|Placebo|In Part 2, participants will receive matching placebo.
219165069|NCT03584516|DRUG|Methylprednisolone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
219165070|NCT03584516|DRUG|Prednisone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
219165071|NCT06112795|OTHER|Non-Interventional Study|Non-interventional study
219165072|NCT04868110|BEHAVIORAL|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
219165073|NCT06465511|BEHAVIORAL|Supportive clinic|During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.
219165074|NCT06465511|BEHAVIORAL|Control: Self-management|Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
219165075|NCT05701215|DRUG|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
219165076|NCT04082624|BEHAVIORAL|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
219165077|NCT04082624|BEHAVIORAL|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
219165078|NCT04082624|BEHAVIORAL|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
219165079|NCT04082624|BEHAVIORAL|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
219165080|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
219165081|NCT03895541|DIAGNOSTIC_TEST|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
219165082|NCT04823611|DRUG|Part A:Placebo|Placebo solution
219165083|NCT04823611|DRUG|Part A:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
219165084|NCT04823611|DRUG|Part B:Placebo|Placebo solution
219165085|NCT04823611|DRUG|Part B:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
219165086|NCT04823611|DRUG|Part C: Placebo|Placebo solution
219165087|NCT04823611|DRUG|Part C: AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
219165088|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
219165089|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
219165090|NCT06788327|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.
219165091|NCT06788327|DEVICE|Blood Flow Restriction Therapy|"Participants will perform three exercises of the standard exercises protocol with BFRT. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. Each BFRT session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 50% of the maximum occlusion pressure in the first stage and 60% in stages II and III. The participant will perform 75 repetitions per BFRT exercise divided into 4 sets (30, 15, 15, and 15 repetitions). The load intensity during the BFRT exercises will be set near to 3 out of 10 on the Borg's CR10 scale (weak), which corresponds to 30% of a 1RM effort. After each exercise, the cuff will be deflated, and the patient will rest for two minutes."
219165092|NCT06796322|DEVICE|non-invasive blood glucose meter|Blood glucose were detected by non-invasive glucose meter at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
219165093|NCT06796322|DEVICE|fully automatic laboratory biochemical analyzer|Blood glucose were detected by fully automatic laboratory biochemical analyzer using plasma sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
219165094|NCT06796322|DEVICE|fingertip capillary blood glucose meter|Blood glucose were detected by fingertip capillary blood sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
219165095|NCT06793189|DRUG|Obinutuzumab and Orelabrutinib|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).
219165096|NCT06793189|DRUG|Obinutuzumab, Orelabrutinib and Lenalidomide|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).
219165097|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
219165098|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
219165099|NCT05982678|DRUG|Trastuzumab deruxtecan|T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
219165100|NCT06797739|OTHER|Nutritional counselling|Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.
219165101|NCT06797739|OTHER|Diet|Patients will be asked to follow Mediterranean Diet only
219165102|NCT05637307|PROCEDURE|Sentinel node procedure|Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
219165103|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
219165104|NCT04998981|DRUG|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
219165105|NCT04998981|DRUG|Placebo tablet|Placebo tablet x 2 twice daily
219165106|NCT04998981|DRUG|Placebo capsule|Placebo capsule once daily
219165107|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
219237334|NCT00977678|OTHER|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
219165108|NCT04998981|DRUG|Placebo tablet|Placebo tablet twice daily
219165109|NCT04172402|DRUG|TS-1|Intervention is administered to patients in this Arm.
219165110|NCT04172402|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
219165111|NCT04172402|DRUG|Nivolumab|Intervention is administered to patients in this Arm.
219237335|NCT03234478|OTHER|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
219165112|NCT06793436|PROCEDURE|chest wall blocks|The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.
219237336|NCT03531892|DRUG|AJM300|AJM300 film-coated tablets.
219237337|NCT03531892|DRUG|Placebo|Placebo matched to AJM300 tablets.
219237338|NCT03720028|BEHAVIORAL|Observation|Describe communication and sensory profile using standardized tests and observations.
219237339|NCT03720028|BEHAVIORAL|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
219165113|NCT05890300|DEVICE|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
219165114|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
219165115|NCT06840912|OTHER|Pharmacological in addition to electroencephalographic (EEG) biofeedback|Patients with heroin use disorder diagnosed according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition), treated by pharmacological in addition to electroencephalography (EEG) biofeedback after 3 months of abstinence.
219165116|NCT06840912|DRUG|Pharmacotherapy|Patients with heroin use disorder taken as control group matching with patients group treated only by pharmacotherapy
219165117|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
219165118|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
219165119|NCT03849534|DEVICE|Soft occlusal appliance|According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition
219165120|NCT03849534|BEHAVIORAL|Jaw exercises|The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch
219165121|NCT03849534|BEHAVIORAL|Counseling|The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
219165122|NCT02915198|DRUG|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
219237340|NCT03949959|OTHER|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
219237341|NCT01884571|DRUG|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
219165123|NCT02915198|DRUG|Placebo|"For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
219237342|NCT01884571|DRUG|Methylprednisolone|125 mg, IV (in the vein) on day 1.
219165124|NCT04268888|DRUG|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
219165125|NCT04268888|PROCEDURE|TACE/TAE|TACE/TAE (as per local practice)
219165126|NCT05867966|BEHAVIORAL|psychoeduc/self-care/self-hypnosis group|See arm description.
219165127|NCT05526534|DEVICE|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
219165128|NCT05526534|DEVICE|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
219165129|NCT06788951|DIETARY_SUPPLEMENT|administration of oral carbohydrate solution to patients before coronary artery bypass graft surgery|Oral carbohydrate solution will be administered to patients before coronary artery bypass graft operation and its effects on postoperative nausea-vomiting, hunger, thirst, physiological parameters and recovery will be evaluated.
219165130|NCT06788951|OTHER|giving flavored water to patients before coronary artery bypass graft surgery|The effects of flavored water given to patients before coronary artery bypass graft operation on postoperative nausea-vomiting, hunger and thirst,
219165131|NCT06793254|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
219165132|NCT06796153|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219165133|NCT06796153|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219165134|NCT05343390|BEHAVIORAL|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)
219165135|NCT05343390|BEHAVIORAL|Standard implementation package|Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
219165136|NCT06312709|BEHAVIORAL|teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)|teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.
219165137|NCT06312709|OTHER|Health Education|Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
219165138|NCT02253251|GENETIC|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
219165139|NCT04286282|BEHAVIORAL|Group Pyschotherapy|Group psychotherapy
219165140|NCT04286282|OTHER|Depression Standard of Care|Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
219165141|NCT04286282|OTHER|HIV Standard of Care|Standard clinical care for HIV
219165142|NCT06792565|DEVICE|hemodializer|Fresenius Helixone FX5 (61346 Bad Homburg, Germany)
219165143|NCT06792565|DEVICE|hemofilter|Medica (741036 Medolla, Italy)
219237343|NCT01884571|DRUG|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
219237344|NCT01884571|DRUG|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
219237345|NCT01884571|DRUG|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
219237346|NCT06417372|DIAGNOSTIC_TEST|intraoperative fluorescent staining combined with microscopy|Through the modified formulation of sodium fluorescein and methylene blue, the surface of the suspected cut edge of the patient's glioma was stained intraoperatively, and the surgical microscope image acquisition and processing system was used to determine whether the cut edge of the surgically resected tissue was positive or not.
219237347|NCT05448794|OTHER|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
219362221|NCT05441774|DEVICE|Active transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the active condition, stimulator electrodes deliver a mild electrical current to the tragus. Stimulation parameters: stimulation of left tragus via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
219165144|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from three national service dog providers, including K9s For Warriors, Canine Companions, and America's VetDogs. All three providers have an established track record of training and providing service dogs for PTSD, as well as collaborating with the investigative team in research.
219165145|NCT06796920|PROCEDURE|Spinal cord stimulation|Upon completion of the initial assessments, a lumbar spinal cord nerve stimulator and pulse generator will be implanted. Following surgery, based on the patient's recovery status, the patient will be transferred to the respective center for rehabilitation within one to two weeks. Afterward, electrical stimulation therapy will be initiated. Stimulation should be applied at least three days per week. Each day, the total stimulation time should be between 4 and 8 hours. Stimulation Modes: Continuous Stimulation: For example, if 6 hours of stimulation are prescribed, the stimulator will run uninterrupted for 6 hours. Intermittent Stimulation: For instance, a cycle of 40 seconds on and 20 seconds off. If a total of 6 hours of active stimulation is needed, the stimulator must remain on for 9 hours in total to accommodate rest intervals.The ranges for each parameter are as follows:Stimulation Frequency: 2 Hz - 2000 Hz, Pulse Width: 20 μs - 1000 μs, Stimulation Amplitude:Voltage: 0 V - 10 v
219165146|NCT06838715|DRUG|Dexamethasone|Assessing the relation between the level of cytokines (interleukins and tumor necrosis factor alpha) and the development of cardiac complications associated with scorpion envenomation among pediatric patients. and Evaluating the role of the use of Dexamethasone and/or extended anti-venom administration on cardiac function and outcome in pediatric cases.
219165147|NCT04511702|BIOLOGICAL|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
219165148|NCT06424561|BEHAVIORAL|Psychological Intervention Group|"The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers."
219165149|NCT06788704|DRUG|Tadalafil 5mg|Patient recive tadalafil 5mg once daily early post turp
219165150|NCT06788704|DRUG|Placebo|Patient recive placebo once daily early post turp
219165151|NCT05202860|BIOLOGICAL|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
219165152|NCT05202860|BIOLOGICAL|PLACEBO vaccine|Isotonic saltwater sham vaccine
219165153|NCT06428903|DRUG|ADC189 tablet|ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
219165154|NCT06428903|DRUG|ADC189 granules|ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
219165155|NCT06428903|DRUG|ADC189 180mg|ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
219362222|NCT05441774|BEHAVIORAL|Active self-compassion imagery|Self-compassion imagery is both a meditative technique and a component of compassion-focused cognitive therapy. Here, self-compassionate imagery is delivered as standardized audio-recorded instructions.
219165156|NCT06838312|OTHER|Reuse or dispose a polyp trap|Participant hospitals will be separated into two groups, according to their standard clinical practice: A) reuse or B) dispose polyp traps after a colonoscopy with polypectomy. Centres will participate with their current method of using polyp traps. Work dynamics will not change as patients will be recruited from centers that routinely reuse or dispose polyp traps.
219237348|NCT05320874|BIOLOGICAL|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
219237349|NCT01090258|DEVICE|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
219237350|NCT01090258|OTHER|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
219237351|NCT05586165|BEHAVIORAL|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
219237352|NCT05586165|BEHAVIORAL|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
219237353|NCT05586165|BEHAVIORAL|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
219237354|NCT01063465|DEVICE|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
219237355|NCT04457583|DEVICE|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
219237356|NCT06114641|DRUG|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
219165157|NCT02840474|BIOLOGICAL|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
219165158|NCT02840474|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
219165159|NCT06796556|DEVICE|virtual reality exposition|emotional response triggered by exposure to sensory stimuli presented in virtual reality.
219165160|NCT05037526|DEVICE|Dexcom G System|Continuous glucose monitoring system
219237357|NCT01562275|DRUG|Ipatasertib|multiple doses
219165161|NCT05037526|DEVICE|Self monitoring blood glucose|Standard Care
219165162|NCT06841003|DRUG|Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin|Peritoneal antibiotic lavage using a solution of gentamicin/clindamycin in NaCl 0.9%.
219237358|NCT01562275|DRUG|Cobimetinib|multiple doses
219237359|NCT06124118|RADIATION|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
219165163|NCT06834581|DEVICE|Vibrating mesh nebuliser|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128 kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled.
219165164|NCT06834581|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
219165165|NCT06795074|COMBINATION_PRODUCT|Optilume|Dilatation with drug-coated balloon
219165166|NCT06795074|DEVICE|UroMax Ultra|Dilatation with non-coated balloon
219165167|NCT06839690|PROCEDURE|Isometric training of thumb muscles|Isometric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using manual resistance and progress with training against resistance of elastic band and theraband.I
219165168|NCT06839690|PROCEDURE|Eccentric training for thumb muscles|In Group B, eccentric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using unweighted and weighted hammer curls and progress with training using elastic band, dumbbell and theraband.
219165169|NCT06839690|PROCEDURE|Ultrasound|Therapeutic ultrasound for symptom management
219165170|NCT06797804|OTHER|Information Technology-Assisted Horticultural Therapy Program|The intervention involves technology-assisted horticultural therapy sessions conducted once a week, lasting 120 minutes per session, over a total period of 8 weeks
219165171|NCT06271512|OTHER|No Intervention|This is non-interventional study.
219165172|NCT06176469|OTHER|No intervention|No intervention
219165173|NCT06840223|OTHER|Traditional stroke rehabilitation|Personalized traditional stroke rehabilitation programme including spasticity inhibition, sensory-perceptual-motor integration techniques, core stabilization and strengthening exercises, balance training i.e. applied as needed for stroke patients approximately for 45 minutes
219165174|NCT06840223|OTHER|Thoracolumbar fascia release|Thoracolumbar fascia release was performed by physiotherapist for one session. Supine Pelvic Rotation, Supine Arm Elevation, Bending Forward in Sitting Position and Sitting Crossed Arm and Knee Positions were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
219165175|NCT06840223|OTHER|Respiratory exercise|Respiratory exercises were performed by physiotherapist for one session. Pursed-Lip Breathing, Deep Breathing Exercise, Diaphragm Strengthening Exercise and Thoracic Expansion Exercises were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
219165176|NCT06838923|COMBINATION_PRODUCT|Light Paraffin Oil|Embryos in this group will be cultured under conditions using light paraffin oil as an overlay in in vitro fertilization (IVF). The oil serves to protect the culture media from evaporation and temperature fluctuations. Key outcomes, including embryo development, blastocyst formation rate, and pregnancy rate, will be assessed.
219165177|NCT06838923|COMBINATION_PRODUCT|Heavy Paraffin Oil|Embryos in this group will be cultured under conditions using heavy paraffin oil as an overlay in in vitro fertilization (IVF). This study aims to compare the effects of heavy paraffin oil to light paraffin oil in embryo culture, assessing embryo development, blastocyst formation, and pregnancy rates.
219165178|NCT04953780|DRUG|Calaspargase pegol-mknl|Calaspargase pegol-mknl
219165179|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
219165180|NCT06735937|OTHER|Low flow anesthesia|Anesthesia management by using low flow anesthesia
219165181|NCT06736249|DIAGNOSTIC_TEST|Sarcopenic group|The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.
219165182|NCT06736249|OTHER|Muscle harvesting|A piece of discarded muscle during surgery will be collected
219165183|NCT06840275|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|Two intravenous infusions of C2C\_ASC110 1 month apart. The C2C\_ASC110 product contains 110 million cells.
219165184|NCT06840275|OTHER|Cryostor CS10|Two intravenous infusions of CryoStor CS10 1 month apart.
219165185|NCT06838754|OTHER|Whole body vibration therapy|Experimental group will get whole body vibrations. WBV will be performed by the patient while seated on the vibrating plate's base. Five series with a 30-second wait will make up each session. Five minutes and thirty seconds will be spent on vibration, and twenty minutes and thirty seconds will be spent on exercise. 5 Hz will be the frequency utilized. Over the course of two months, 16 classes will be held twice a week.
219165186|NCT06838754|OTHER|Routine physical therapy|Group B will only get routine physical therapy. Walking in all directions, advancing past the point of stability in a variety of positions, including half-kneeling, standing on both soft and hard surfaces, stepping up and down, walking and standing simultaneously, and standing on one leg with eyes open and closed were all part of the postural control exercise. There will be a 20-minute session.As each participant's functional improvement progresses, the intensity of the workout program will progressively rise. There will be 16 sessions in total (two days a week), with 8 sessions for each group.
219165187|NCT00890006|PROCEDURE|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
219165188|NCT06789640|OTHER|Vitamin C|"Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups"
219165189|NCT06789640|OTHER|Placebo|"Placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls"
219165190|NCT04411823|DEVICE|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
219165191|NCT05141903|DIETARY_SUPPLEMENT|Antibiotic|Vancomycin (250 mg/dose), Metronidazole (500 mg/dose)
219165192|NCT05141903|DIETARY_SUPPLEMENT|HMO Concentrate|Concentrated milk fortifiers from donor human milk
219165193|NCT05141903|DIETARY_SUPPLEMENT|Probiotic|B. infantis
219165194|NCT05141903|DIETARY_SUPPLEMENT|Food Supplement|Synthetic powder containing 2'-fucosyllactose (2'-FL) and lactoneotetraose (LNnT)
219165195|NCT06833151|DEVICE|Ultrasound Respiratory Assessment|For lung ultrasound analysis, we selected ultrasound recordings of the right lower lung apex at the costophrenic angle along the right mid-axillary line. Using the open-source image processing tool ImageJ 1.4, the pleural line corresponding to the right lower lung apex was enhanced and its terminal coordinates extracted. During respiration, the right lower lung apex moves with the breathing cycle, and the pleural line exhibits corresponding motion. The terminal coordinates of the pleural line also shift during respiration, and a plot of this displacement against time is generated to create the pleural line sliding displacement curve.
219165196|NCT06202872|DEVICE|Gamma (40 Hz) tACS at the precuneus region|40 Hz tACS applied at a current of 3.2 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
219165197|NCT06202872|DEVICE|Sham tACS at the precuneus region|Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
219165198|NCT04494048|OTHER|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
219165199|NCT05461417|DEVICE|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
219165200|NCT06364371|OTHER|Medical examination|Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
219165201|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
219165202|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
219165203|NCT06384651|DRUG|Intraosseous Vancomycin Injection|"* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus."
219165204|NCT06384651|DRUG|Intravenous Vancomycin|• Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
219165205|NCT04582708|DEVICE|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
219165206|NCT03911388|BIOLOGICAL|G207|Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
219165207|NCT04490720|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
219165208|NCT04490720|DIETARY_SUPPLEMENT|Buckwheat husk extract|consume 1 sachet per day for 2 months
219165209|NCT06843941|OTHER|Music intervention|"In the music group, MusiCure® compositions, which feature soft rhythmic melodies, were chosen. These musical pieces were composed by Danish composer Niels Eje (MusiCure, 2020) and are therapeutic in nature, designed for physical and mental relaxation within a range of 60-80 bpm (Eje, 2020). Literature reviews indicate that the MusiCure® album has positive effects on conditions such as pain, well-being, and anxiety (Fredriksson et al., 2009; Nilsson et al., 2009). The pieces to be used in this study were selected after communication with Niels Eje, and the recommended pieces were Winter, Early Spring, Equator, and Ocean Echoes (MusiCure, 2020). The music was presented hygienically to the participants through headphones and played for 30 minutes in four tracks via an mp3 player."
219165210|NCT03709134|DIAGNOSTIC_TEST|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
219165211|NCT03818191|DRUG|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
219165212|NCT03818191|OTHER|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
219165213|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
219165214|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
219165215|NCT06845956|OTHER|Is it coronary artery embolism|"This observational study categorizes patients with acute myocardial infarction (AMI) into three distinct groups based on their clinical characteristics:~1. Group 1: Patients with atrial fibrillation (AF) and coronary artery embolism (CAE).~2. Group 2: Patients with AF but non-coronary artery embolism myocardial infarction (non-CAE MI).~3. Group 3: Patients without AF and non-coronary artery embolism myocardial infarction (non-CAE MI without AF).~A key innovation of this study compared to previous research is its expanded eligibility criteria for AMI patients. Earlier studies typically focused exclusively on ST-segment elevation myocardial infarction (STEMI). In contrast, this investigation encompasses a broader spectrum of acute myocardial infarction, including both STEMI and non-ST-segment elevation myocardial infarction (NSTEMI). This comprehensive approach enhances the generalizability and applicability of the findings by capturing a wider range of clinical scenarios."
219165216|NCT06357130|OTHER|Questionnaire|A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
219165217|NCT06842797|OTHER|Weighted Blanket|Participants will lie down and be covered with a weighted blanket.
219165218|NCT06842797|OTHER|Non Weighted Blanket|Participants will lie down and be covered with normal weight blanket (non-weighted blanket)
219165219|NCT05233527|PROCEDURE|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
219165220|NCT00909961|DRUG|Zoledronic acid|
219165221|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
219165222|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
219165223|NCT03902951|DRUG|Abiraterone Acetate|Given PO
219165224|NCT03902951|DRUG|Apalutamide|Given PO
219165225|NCT03902951|DRUG|Leuprolide Acetate|Given SC
219165226|NCT03902951|OTHER|Quality-of-Life Assessment|Ancillary studies
219165227|NCT03902951|OTHER|Questionnaire Administration|Ancillary studies
219165228|NCT03902951|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219165229|NCT06450704|OTHER|Physical Exercise|"Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes."
219165230|NCT03490825|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
219165231|NCT03490825|DIETARY_SUPPLEMENT|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
219165232|NCT03490825|OTHER|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
219165233|NCT03490825|OTHER|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
219165234|NCT06172699|DEVICE|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
219237360|NCT06124118|DEVICE|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
219237361|NCT06124118|DRUG|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
219237362|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
219237363|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
219165235|NCT04715399|OTHER|No intervention|No intervention
219165236|NCT05497453|DRUG|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
219237364|NCT05672862|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
219237365|NCT06174779|DRUG|HM11260C|Test drug
219237366|NCT06174779|DRUG|Placebo|Placebo drug
219237367|NCT05582447|OTHER|ektacytometry of red blood cells|Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
219237368|NCT05360199|BEHAVIORAL|PROMs|evaluate the impact of recall bias on post proms scores
219237369|NCT00778141|DRUG|metformin HC1 750 mg extended-release tablets|
219237370|NCT02832219|DIETARY_SUPPLEMENT|Molecular hydrogen|
219237371|NCT02832219|DIETARY_SUPPLEMENT|Placebo|
219237372|NCT01020487|DRUG|Paricalcitol|Paricalcitol capsules taken with water.
219237373|NCT01020487|DRUG|Placebo|Placebo capsules taken with water
219237374|NCT04618575|DRUG|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
219237375|NCT04618575|DRUG|Ursodeoxycholic acid only|Ursodeoxycholic acid only
219237376|NCT06582277|BIOLOGICAL|OVX836 shot|One single administration intramuscularly at Day 1.
219237377|NCT04479020|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy requiring the use an APERIO® or APERIO® Hybrid(17) Thrombectomy device due to an thrombotic occlusion in a distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA)
219237378|NCT04358588|DRUG|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
219237379|NCT01239641|PROCEDURE|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
219165237|NCT05497453|DRUG|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
219165238|NCT05497453|DRUG|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
219165239|NCT05497453|DRUG|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
219165240|NCT06166927|DEVICE|Cuffed endotracheal tube|Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
219165241|NCT06166927|DEVICE|UnCuffed ETT|Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
219237380|NCT04543669|BIOLOGICAL|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
219237381|NCT02400749|DRUG|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
219237382|NCT02400749|DRUG|Placebo|Placebo tablets will be provided to sites in blister cards.
219237383|NCT03647800|BIOLOGICAL|APVO436|APVO436
219237384|NCT02240810|DEVICE|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
219237385|NCT05776329|BEHAVIORAL|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
219165242|NCT05143931|BEHAVIORAL|Home food environment and grocery delivery (AVOID)|Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices
219237386|NCT05776329|BEHAVIORAL|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
219237387|NCT04425252|DRUG|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
219237388|NCT04425252|OTHER|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
219237389|NCT03473665|DRUG|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
219165243|NCT05143931|BEHAVIORAL|Inhibitory control training (RESIST)|Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
219237390|NCT03473665|DRUG|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
219237391|NCT03473665|DRUG|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
219237392|NCT03473665|DRUG|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
219237393|NCT03583944|DRUG|Eribulin Mesylate|Eribulin mesylate IV infusion.
219165244|NCT05143931|BEHAVIORAL|WW|Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
219237394|NCT01092689|DRUG|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
219165245|NCT05344963|DRUG|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
219165246|NCT05799781|DEVICE|MPC closed-loop system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled.
219165247|NCT05799781|DEVICE|t:slim X2 pump with Dexcom G6 CGM and Control IQ|The t:slim pump is a hybrid closed-loop system available to consumers for automated insulin delivery. Control IQ technology automatically adjusts insulin levels based on continuous glucose monitoring (CGM) readings from Dexcom G6.
219362223|NCT05441774|DEVICE|Sham transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the sham condition, stimulator electrodes deliver a mild electrical current to the earlobe. Stimulation parameters: stimulation of left earlobe via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
219362224|NCT05441774|BEHAVIORAL|Sham mental imagery|Draw-a-face-in-imagination is the sham/ control imagery condition. Here, control imagery instructions are delivered as a standardized audio-recording, well-matched to self-compassion imagery for number of words, complexity of language, and duration of the audio instructions.
219237395|NCT05235815|PROCEDURE|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
219237396|NCT01156922|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
219165248|NCT06133439|BEHAVIORAL|Colorectal Screen rates with implementation of evidence-based intervention|Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
219165249|NCT04764500|OTHER|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
219165250|NCT04764500|OTHER|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
219237397|NCT01448447|DEVICE|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
219237398|NCT01448447|DEVICE|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
219237399|NCT04792541|OTHER|HY containing gel; GUM® Afta Clear Gel, Sunstar|
219237400|NCT04792541|OTHER|saline solution|
219165251|NCT04764500|OTHER|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
219237401|NCT05441176|OTHER|Questionnaires|Scoring of the DASH is performed according to references.
219237402|NCT02889172|BEHAVIORAL|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
219237403|NCT01441336|PROCEDURE|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
219237404|NCT01717625|DRUG|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
219362225|NCT00574574|DIETARY_SUPPLEMENT|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
219362226|NCT04663945|BEHAVIORAL|Biobehavioral Tele-rehabilitation Sessions|Biobehavioral tele-rehabilitation sessions
219362227|NCT05352581|DIAGNOSTIC_TEST|BD Veritor At-Home|BD Veritor At-Home rapid self testing
219237405|NCT05145634|OTHER|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
219237406|NCT02446015|DRUG|SYSTANE® ULTRA Lubricant Eye Drops|
219237407|NCT01123005|PROCEDURE|PET Scan|radiation calculated per patient
219237408|NCT01123005|DRUG|EF5|10 mCi, IV
219237409|NCT01123005|DRUG|Carbogen|Calculated per patient
219237410|NCT01123005|DRUG|Dichloroacetate|
219237411|NCT01233245|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
219237412|NCT00553813|DRUG|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
219237413|NCT04694053|PROCEDURE|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
219237414|NCT05350709|OTHER|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
219237415|NCT01705444|DEVICE|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
219237416|NCT03438968|BEHAVIORAL|Exercise training|Cardiac Rehabilitation exercise training
219237417|NCT00275314|DRUG|Valganciclovir|
219237418|NCT04179799|DEVICE|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
219237419|NCT05387629|BEHAVIORAL|Education|Nursing students will be trained through social media.
219237420|NCT05483556|DEVICE|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
219237421|NCT05483556|DEVICE|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
219362228|NCT05352581|DIAGNOSTIC_TEST|BD Veritor Professional|BD Veritor Professional rapid test
219237422|NCT03733860|PROCEDURE|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
219237423|NCT03733860|PROCEDURE|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
219237424|NCT03733860|PROCEDURE|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
219237425|NCT02162927|DIETARY_SUPPLEMENT|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
219237426|NCT02162927|DIETARY_SUPPLEMENT|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
219237427|NCT03374423|PROCEDURE|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
219237428|NCT03374423|PROCEDURE|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
219237429|NCT01024023|DEVICE|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
219237430|NCT01195402|PROCEDURE|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
219237431|NCT06129656|OTHER|Routine diagnostics|Data collection of routine diagnostics
219237432|NCT06129656|OTHER|Routine treatment|Data collection of routine treatment
219237433|NCT06463509|OTHER|Establishment of an in-deepth tumor profiling platform|In-depth tumor profiling beyond genomics
219237434|NCT02020902|OTHER|Cetrizine hydrochloride|As provided on the patient information leaflet
219237435|NCT00362258|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
219165252|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain Russian BCG-I|"* Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
219165253|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain TICE|"* Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
219165254|NCT05152732|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
219165255|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
219165256|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
219165257|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
219165258|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
219237436|NCT02990845|DRUG|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
219237437|NCT01846156|DRUG|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
219237438|NCT01512355|DRUG|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
219165259|NCT05653856|DRUG|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
219165260|NCT06492694|DIETARY_SUPPLEMENT|Fish oil + wild orange essential oil supplement|This supplement contains fish oil and wild orange essential oil as its active ingredients.
219165261|NCT06492694|DIETARY_SUPPLEMENT|Fish oil supplement|This supplement contains fish oil as its active ingredient.
219165262|NCT05632562|DRUG|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
219237439|NCT01512355|DRUG|placebo group|normal saline\_02mcg/kg/hr
219237440|NCT02755909|BEHAVIORAL|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
219237441|NCT01539902|BIOLOGICAL|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
219237442|NCT01539902|DRUG|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
219237443|NCT02933645|DRUG|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
219165263|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
219165264|NCT03805048|PROCEDURE|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
219165265|NCT06770166|OTHER|Physiological serum mouthwash|Physiological serum contains sodium chloride : 0.009 g/ml, sodium 154 (mEq/I), chloride 154 (mEq/I)\].
219165266|NCT06770166|OTHER|Chlorhexidine mouthwash|Chlorhexidine mouthwash contains 0.12% chlorhexidine digluconate and 0.15% benzydamine hydrochloride.
219165267|NCT06770166|OTHER|Chamomile mouthwash|Chamomile mouthwash contains 10% chamomile in physiological serum.
219165268|NCT05671185|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
219165269|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment|Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
219165270|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention|Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
219165271|NCT05520983|BEHAVIORAL|Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
219165272|NCT05520983|OTHER|Strengthening Families|The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
219237444|NCT02933645|DRUG|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
219165273|NCT05520983|OTHER|Virtual psycho-educational discussion groups for caregivers and participants|The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
219165274|NCT05520983|OTHER|Maternal Child Health Bureau (MCHB) Care Coordination|MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
219165275|NCT04720313|DRUG|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
219165276|NCT06329557|BEHAVIORAL|Intervention 1|Intervention 3
219165277|NCT00212433|DRUG|Tagitol V, Lo So, Readi-Cat 2|
219165278|NCT03752294|DRUG|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
219165279|NCT03752294|DRUG|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
219165280|NCT04230408|DRUG|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
219165281|NCT01707030|OTHER|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
219165282|NCT01707030|OTHER|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
219165283|NCT04820855|BEHAVIORAL|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
219165284|NCT04820855|OTHER|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
219165285|NCT02884180|DRUG|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
219165286|NCT02884180|DRUG|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
219165287|NCT04754711|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
219165288|NCT05657106|BEHAVIORAL|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
219165289|NCT05713734|DIAGNOSTIC_TEST|Thrombin generation|Measurement of thrombin generation by ST Genesia
219165290|NCT05713734|DIAGNOSTIC_TEST|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
219165291|NCT05713734|DIAGNOSTIC_TEST|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
219165292|NCT05713734|DIAGNOSTIC_TEST|Coated platelets|Measurement of coated platelets by flow cytometry
219165293|NCT04155541|DRUG|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
219165294|NCT03727061|BIOLOGICAL|Nivolumab|Immunotherapy - Standard of care
219165295|NCT03727061|DRUG|Porfimer Sodium|Given IV
219165296|NCT03727061|PROCEDURE|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
219165297|NCT03727061|OTHER|Quality of Life Assessment|Ancillary Studies
219165298|NCT06739902|DIAGNOSTIC_TEST|Traditional Physiotherapy Group|Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.
219165299|NCT06739902|COMBINATION_PRODUCT|VR + Traditional Physiotherapy Group|Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
219165300|NCT02994316|OTHER|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
219165301|NCT06288412|DRUG|Insulin icodec|Participants will receive insulin icodec subcutaneous (s.c.) once weekly.
219165302|NCT06288412|DRUG|Insulin degludec|Participants will receive insulin degludec s.c. once daily.
219165303|NCT02182479|DRUG|Berodual® via Respimat®, high dose|
219165304|NCT02182479|DRUG|Berodual® via Respimat®, low dose|
219165305|NCT02182479|DRUG|Berodual® via MDI, high dose|
219165306|NCT02182479|DRUG|Placebo Respimat®|
219165307|NCT02182479|DRUG|Placebo MDI|
219165308|NCT04755179|PROCEDURE|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate"
219237445|NCT02933645|RADIATION|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
219237446|NCT02933645|DRUG|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
219165309|NCT04755179|PROCEDURE|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate"
219165310|NCT04755179|PROCEDURE|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
219165311|NCT04755179|PROCEDURE|Direct appendectomy|laparoscopic or open appendectomy as described
219165312|NCT03471559|DRUG|Cannabidiol|single or multiple dosing
219165313|NCT04034095|DRUG|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219165314|NCT04034095|DRUG|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219237447|NCT03630432|BEHAVIORAL|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
219165315|NCT04034095|DRUG|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219237448|NCT03630432|OTHER|Usual Care|Usual Care
219237449|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy|
219237450|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
219237451|NCT02412345|OTHER|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
219237452|NCT02079402|DRUG|Isotonic crystalloids|
219237453|NCT05466760|RADIATION|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
219237454|NCT03761849|DRUG|RO7234292|Intrathecal injection
219237455|NCT03761849|DRUG|Placebo|Intrathecal injection
219165316|NCT04034095|DRUG|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219165317|NCT04034095|DRUG|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219165318|NCT04034095|DRUG|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219165319|NCT04034095|DRUG|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
219165320|NCT02217514|DRUG|Midazolam|
219165321|NCT02217514|DRUG|BI 44370 low dose|
219165322|NCT02217514|DRUG|BI 44370 medium dose|
219165323|NCT02217514|DRUG|BI 44370 high dose|
219165324|NCT00596336|DRUG|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
219165325|NCT00596336|DRUG|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
219165326|NCT00972049|DRUG|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
219165327|NCT00972049|DRUG|Placebo|Capsule administered once orally
219165328|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
219165329|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
219237456|NCT05322447|DRUG|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
219237457|NCT05322447|DRUG|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
219237458|NCT01430416|DRUG|AEB071|
219165330|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
219165331|NCT05844306|PROCEDURE|Computed Tomography|Undergo \[18F\]-FDG PET-CT
219165332|NCT05844306|OTHER|Fludeoxyglucose F-18|Given via injection
219165333|NCT05844306|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
219165334|NCT05844306|DEVICE|Positron Emission Tomography|Undergo \[18F\]-FDG PET-CT
219165335|NCT03740763|DEVICE|Spinal Cord Stimulation (SCS)|SCS for treatment of neuropathic pain
219165336|NCT03740763|OTHER|Physiotherapy|Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
219165337|NCT05371808|OTHER|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
219165338|NCT05371808|OTHER|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
219165339|NCT05371808|OTHER|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
219237459|NCT03001141|OTHER|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
219165340|NCT05569395|OTHER|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
219165341|NCT05569395|OTHER|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
219165342|NCT03728764|OTHER|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
219165343|NCT04835844|DEVICE|CARTO|Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
219165344|NCT04835844|DEVICE|RHYTHMIA|Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
219165345|NCT06398314|RADIATION|Palliative radiotherapy|Hypofractionated radiotherapy
219165346|NCT04121936|OTHER|There will be no intervention|There will be no intervention
219165347|NCT05720780|OTHER|MS group|"All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training"
219165348|NCT05720780|OTHER|C group|All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
219165349|NCT04025359|DRUG|Dronabinol|Dronabinol 2.5 mg
219165350|NCT04025359|DRUG|Dronabinol|Dronabinol 5 mg
219165351|NCT04025359|DRUG|Placebo|Placebo
219165352|NCT05643326|DEVICE|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
219165353|NCT05643326|DEVICE|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
219165354|NCT05464810|DRUG|Letrozole|Given PO
219165355|NCT05464810|DRUG|Simvastatin|Given PO
219165356|NCT04362501|BIOLOGICAL|dupilumab|300mg dupixent SC every two weeks for six months
219165357|NCT04362501|DRUG|placebo|placebo SC injection every two weeks for six months
219165358|NCT01837394|PROCEDURE|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
219165359|NCT01837394|PROCEDURE|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
219165360|NCT01837394|DRUG|Paracetamol|
219165361|NCT01837394|DRUG|Morphine|5 mg as needed
219165362|NCT01837394|DRUG|Ondansetron|4 mg i.v. as needed in the PACU
219165363|NCT01837394|DRUG|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
219165364|NCT01762059|DEVICE|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
219165365|NCT01762059|OTHER|Usual care|
219165366|NCT05562089|DEVICE|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
219165367|NCT02140645|DRUG|linagliptin|non-randomized
219165368|NCT00525954|DRUG|A-002|
219165369|NCT05170620|PROCEDURE|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
219165370|NCT06852534|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
219165371|NCT06852534|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
219165372|NCT06107751|OTHER|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
219165373|NCT06107751|OTHER|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
219165374|NCT04678895|DRUG|Naltrexone|Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
219165375|NCT04678895|DRUG|Placebo|Naltrexone matched placebo capsule.
219165376|NCT06718569|DRUG|Biological or targeted synthetic DMARD|All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases
219165377|NCT06969053|BEHAVIORAL|Mindfulness Intervention Therapy plus Sleep Hygiene Education|Participants will receive a 6-week program combining Mindfulness Intervention Therapy (MIT) and Sleep Hygiene Education (SHE). MIT includes body scan, mindful breathing, breathing space exercises, mindful walking, sitting meditation, loving-kindness meditation, and development of a personalized mindfulness practice plan. Sessions are conducted daily for 50 minutes. SHE provides structured guidance on optimizing sleep schedules, bedroom environment, and reducing stimulants such as caffeine and alcohol.
219165378|NCT06969053|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
219165379|NCT03647956|DRUG|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
219165380|NCT03647956|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
219165381|NCT03647956|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
219165382|NCT03647956|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
219165383|NCT04093895|DRUG|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
219165384|NCT02752659|PROCEDURE|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
219165385|NCT05747196|DEVICE|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
219165386|NCT04814719|DRUG|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
219165387|NCT04814719|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
219165388|NCT06500780|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
219165389|NCT04683315|DRUG|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
219165390|NCT04683315|DRUG|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
219165391|NCT04683315|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
219165392|NCT04275908|DEVICE|MHSAFE app|App to detect presence of mental state
219165393|NCT02892214|PROCEDURE|Pelvic floor physical therapy|
219165394|NCT02892214|DRUG|estriol cream (ovestin)|
219165395|NCT02892214|PROCEDURE|Low-level-laser therapy|
219165396|NCT03767452|DRUG|Xiaflex® 0.58 mg|0.25 mL injections.
219165397|NCT02622984|BEHAVIORAL|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
219165398|NCT02622984|BEHAVIORAL|SBIRT|"Face to face standard intervention considered treatment as usual."
219165399|NCT00252369|DRUG|Infliximab|
219165400|NCT00252369|PROCEDURE|Instillation of fibrin glue|
219165401|NCT00073749|DRUG|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
219165402|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
219165403|NCT03580369|BIOLOGICAL|Ligelizumab|Liquid in vial
219165404|NCT03580369|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
219165405|NCT03580369|OTHER|Placebo|Liquid in vial
219165406|NCT03912831|DRUG|KITE-439|A single infusion of E7 TCR T cells (KITE-439).
219165407|NCT03912831|DRUG|Cyclophosphamide|Administered intravenously.
219165408|NCT03912831|DRUG|Fludarabine|Administered intravenously.
219165409|NCT03912831|DRUG|Interleukin-2|Administered subcutaneously.
219165410|NCT05916001|OTHER|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
219165411|NCT05916001|DIETARY_SUPPLEMENT|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
219165412|NCT05916001|PROCEDURE|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
219165413|NCT01522924|OTHER|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
219237460|NCT06008665|OTHER|Action Observation Therapy and Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
219237461|NCT06008665|OTHER|Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs."
219237462|NCT04645303|DRUG|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
219237463|NCT04645303|DRUG|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
219237464|NCT03933098|BIOLOGICAL|Test Vaccine Vi-DT Typhoid conjugate|"* Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
219237465|NCT03933098|BIOLOGICAL|Control Vaccine Typbar TCV®|"* Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml"
219237466|NCT03344458|DRUG|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
219237467|NCT00062478|DRUG|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
219237468|NCT03840993|DRUG|MT-2990|over 16 weeks
219237469|NCT03840993|DRUG|Placebo|over 16 weeks
219237470|NCT02246556|DEVICE|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
219237471|NCT02246556|OTHER|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
219237472|NCT02246556|DEVICE|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
219237473|NCT04816539|DEVICE|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
219237474|NCT01411683|DEVICE|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
219237475|NCT00543049|DRUG|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
219237476|NCT00543049|DRUG|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
219237477|NCT02975609|RADIATION|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
219237478|NCT02975609|RADIATION|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
219237479|NCT03348800|PROCEDURE|Dental anesthesia|A tooth extraction will be performed
219237480|NCT05670600|OTHER|foot and ankle exercise|"Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
219237481|NCT00551954|DRUG|acarbose|100 mg (tablets) t.i.d.
219237482|NCT00551954|DRUG|placebo|one tablet t.i.d.
219237483|NCT05107921|DRUG|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
219237484|NCT04160871|BEHAVIORAL|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
219237485|NCT04160871|BEHAVIORAL|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
219237486|NCT00002723|DRUG|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
219237487|NCT00002723|DRUG|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
219237488|NCT00002723|DRUG|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
219237489|NCT00004250|BIOLOGICAL|dactinomycin|
219237490|NCT00004250|DRUG|isolated limb perfusion|
219237491|NCT00004250|DRUG|melphalan|
219237492|NCT05340283|PROCEDURE|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
219237493|NCT00728325|BEHAVIORAL|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
219237494|NCT00728325|BEHAVIORAL|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
219237495|NCT00019344|DRUG|alvocidib|
219165414|NCT00224445|DRUG|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
219165415|NCT00224445|DRUG|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
219165416|NCT00224445|DRUG|Ritonavir|Ritonavir 100 mg capsule administered orally QD
219165417|NCT04881175|DEVICE|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
219165418|NCT02824458|DRUG|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
219165419|NCT02824458|DRUG|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
219165420|NCT02824458|DRUG|Placebo|
219165421|NCT00006198|DRUG|thalidomide|
219165422|NCT00006198|PROCEDURE|chemoembolization with doxorubicin/collagen|
219165423|NCT04664270|BEHAVIORAL|e-CBT|e-CBT + Mindfulness + Problem Solving
219165424|NCT04319913|DEVICE|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
219165425|NCT02173717|DRUG|Dabigatran etexilate|150 mg Dabigatran etexilate
219165426|NCT02173717|DRUG|Rifampicin|600 mg Rifampicin
219165427|NCT03041064|OTHER|50/100|SPF
219165428|NCT03041064|OTHER|100/50|SPF
219165429|NCT00766649|DRUG|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
219165430|NCT02886195|DRUG|pemetrexed|500mg/m2 ivgtt d1, per three weeks
219165431|NCT02886195|DRUG|cisplatin|80mg/m2 ivgtt d1, per three weeks
219165432|NCT02886195|DRUG|Erlotinib|150mg po. every day
219165433|NCT04944563|PROCEDURE|Segmentectomy|Patients receive segmentectomy
219165434|NCT04944563|PROCEDURE|Lobectomy|Patients receive lobectomy
219165435|NCT03894436|COMBINATION_PRODUCT|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
219165436|NCT05865834|OTHER|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
219165437|NCT05865834|OTHER|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
219165438|NCT03242148|DEVICE|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
219165439|NCT00859794|OTHER|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
219165440|NCT00859794|OTHER|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
219165441|NCT00859794|OTHER|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
219165442|NCT00859794|OTHER|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
219165443|NCT06541093|BIOLOGICAL|UVAX-1107|Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
219165444|NCT06541093|BIOLOGICAL|UVAX-1197|Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
219165445|NCT06541093|OTHER|Placebo|Saline injection
219165446|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
219165447|NCT06450405|DRUG|Testosterone Cypionate 50 MG/ML Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
219165448|NCT06679959|DRUG|ASC30 Injection, for subcutaneous use or placebo|Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
219165449|NCT07003139|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
219237496|NCT06416345|DEVICE|Cue2Walk|24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
219237497|NCT06416345|OTHER|Usual Care|24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
219237498|NCT00004045|DRUG|exatecan mesylate|
219165450|NCT06871839|DRUG|Lecanemab treatment group|"Lecanemab treatment group: Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.~All subjects in the Lecanemab treatment group receive Lecanemab infusion therapy at a frequency of once every two weeks for a continuous period of 12 months."
219165451|NCT06871839|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
219165452|NCT01837927|DRUG|NVA237|Once daily for 52 weeks
219165453|NCT01837927|DRUG|Tiotropium Respimat®|Once daily for 52 weeks
219165454|NCT07040514|OTHER|Questionnaires of Patient understanding of Pathologist input|"* Benefit Self-Rating Total Score (assessing patient's perceptions of anticipated and actual extent to which they benefitted from the meeting with the pathologist)~* Knowledge Questionnaire Total Score (assessing accuracy of knowledge of their own diagnosis and the diagnostic process in general)~* State-Trait Anxiety Inventory Form Y (Total Scores for state (current) and trait (general) anxiety)"
219165455|NCT06704074|DEVICE|virtual reality (VR) head mounted display|The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.
219165456|NCT06886659|DRUG|Trastuzumab (proposed Trastuzumab biosimilar)|6 mg/kg single intravenous infusion of Trastuzumab of Incepta Pharmaceuticals Ltd
219165457|NCT06886659|DRUG|Herclon|6 mg/kg single intravenous infusion of Trastuzumab of Roche
219165458|NCT07044531|BEHAVIORAL|Training-as-Usual (TAU)|Participants receive the standard Peer Recovery Supporter (PRS) training currently offered by CCAR. This training follows existing certification requirements and does not include any digital modules or facilitated teleconferencing components.
219165459|NCT07044531|BEHAVIORAL|TDPP-A (Asynchronous Platform)|Participants engage with the Thrive Digital Peer Platform (TDPP), a fully asynchronous, self-paced online training program. The content includes 11 interactive modules structured using the Connect → Grow → Apply (CGA) learning framework, featuring peer stories, behavioral exercises, and scenario-based assessments.
219165460|NCT07044531|BEHAVIORAL|TDPP-Z (Asynchronous + Zoom)|Participants use the same asynchronous TDPP platform as the TDPP-A group, with the addition of three live, facilitator-led Zoom sessions. These synchronous group sessions provide opportunities for applied learning, discussion, and skill reinforcement.
219237499|NCT00988429|DRUG|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
219237500|NCT00988429|DRUG|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
219237501|NCT00988429|DRUG|Placebo|Placebo tablet given QD
219237502|NCT04315428|BEHAVIORAL|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
219237503|NCT04315428|BEHAVIORAL|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
219237504|NCT02463292|OTHER|no intervention|no intervention
219237505|NCT02964234|BEHAVIORAL|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
219237506|NCT02964234|BEHAVIORAL|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
219237507|NCT03555617|DRUG|TD-1473|oral capsule/tablet, QD
219237508|NCT03555617|DRUG|Itraconazole|oral solution, QD
219237509|NCT01074229|DRUG|Placebo|placebo injection
219237510|NCT01074229|DRUG|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
219165461|NCT07046767|OTHER|IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap|BioLab Membrane Wrap LiteTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Membrane Wrap LiteTM is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
219165462|NCT07046767|OTHER|IP2: BioLab Tri-Membrane Wrap|BioLab Tri-Membrane WrapTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Tri-Membrane WrapTM is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
219165463|NCT06888687|BEHAVIORAL|Dietetic support|Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
219165464|NCT06888687|DEVICE|Continuous glucose monitoring|Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor.
219237511|NCT01074229|DRUG|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
219237512|NCT01502241|DRUG|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
219165465|NCT06887491|OTHER|Conventional physiotherapy program|Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.
219165466|NCT06887491|OTHER|Conventional physiotherapy program + Dual task program|"Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.~Dual task program: Walking 10 meters (Single task) and basic dual task introduction. Simple motor-motor tasks (e.g., holding a ball while walking). Carrying a half-full water bottle in each hand while walking. Placing or carrying objects accompanied by exercises requiring balance. Counting Counting backwards while walking. Solving simple math problems while walking Complexification of motor-motor and cognitive-motor tasks.~Dual tasks similar to activities of daily living"
219165467|NCT06737510|BEHAVIORAL|Informational brochure on household emergency preparedness|"An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones ."
219237513|NCT01502241|RADIATION|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
219237514|NCT00022399|DRUG|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
219237515|NCT00022399|DRUG|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
219237516|NCT02994329|DEVICE|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
219165468|NCT06737510|BEHAVIORAL|Phone-based household emergency preparedness|A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
219165469|NCT07048418|OTHER|Mailing and completing CLEFT-Q and NOSE questionnaires|Mailing and completing CLEFT-Q and NOSE questionnaires
219165470|NCT07060846|PROCEDURE|Endoscopic lumbar discectomy|Patients will undergo endoscopic lumbar discectomy.
219165471|NCT07060846|PROCEDURE|Open lumbar discectomy|Patients will undergo an open lumbar discectomy.
219165472|NCT07058727|DRUG|Sodium Hypochlorite 2,5%|2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping
219165473|NCT07058727|DRUG|Chlorhexidine|2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group
219165474|NCT07058727|DRUG|Cold Saline|Hemostasis via 4°C saline (1 Min), then standardized pulp capping
219165475|NCT06827379|OTHER|IMT-S (strength)|Composed of 3 sets of 1 minute of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 3 minutes of IMT. The initial load will be individualized according to the MIP, with the load equivalent to 60% of the MIP.
219165476|NCT06827379|OTHER|IMT-R (resistance)|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT. The load will also be individualized according to the MIP, with the load equivalent to 30% of the MIP.
219165477|NCT06827379|OTHER|Sham - IMT|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT with a minimum load of 3cmH2O.
219165478|NCT03413982|OTHER|Registry|Patient registry
219165479|NCT07067671|OTHER|Internal Thoracic Impedance|Internal Thoracic Impedance is a non-invasive an imaging technique which use low alternative current through electrodes placed on a belt positioned at the level of the patient's rib cage. Images are constructed according to conductivity measured.
219165480|NCT06767566|DRUG|Ketamine (Ketalar)|Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
219165481|NCT07072416|OTHER|Aquatic Exercise|Aquatic exercise or hydrotherapy, involving the performance of physical exercise in water, has been determined to have an assortment of beneficial health impacts on healthy individuals and those with chronic diseases. Aquatic exercise has been determined to enhance strength, balance, flexibility, and the quality of life, particularly among groups like postmenopausal women, patients with osteoarthritis, Parkinson's disease, and type 2 diabetes
219165482|NCT07072416|OTHER|Mirror Therapy|Mirror therapy is a type of rehabilitation where visual feedback is employed to induce movement and recovery in an affected limb by asking the patients to observe the reflection of their healthy limb in a mirror, giving the illusion that both limbs are moving normally.
219165483|NCT07072416|OTHER|Designed physical therapy program.|The program will start with 10 minutes of poolside exercises including warming up, active range of motion and stretching followed by 20 minutes of aquatic exercise in the pool. The pool session consists of 20 minutes of active range of motion, stretching and strengthening exercises
219165484|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
219237517|NCT02165696|OTHER|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
219237518|NCT02165696|OTHER|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
219165485|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
219165486|NCT06847139|DRUG|Zinc Sulfate 50 Mg Tab|experimental group will get zinc sulfate
219165487|NCT06847139|DRUG|Folic Acid 5 Mg Oral Tablet|control group will get folic acid
219237519|NCT03009123|OTHER|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
219165488|NCT06754930|DRUG|SHR-1826|SHR-1826 for injection.
219165489|NCT06754930|DRUG|SHR-1316|SHR-1316 for injection.
219237520|NCT01727076|OTHER|Laboratory Biomarker Analysis|Correlative studies
219237521|NCT01727076|OTHER|Pharmacological Study|Correlative studies
219165490|NCT06754930|DRUG|SHR-9839|SHR-9839 for injection.
219165491|NCT06754930|DRUG|SHR-8068|SHR-8068 for injection.
219165492|NCT06754930|DRUG|Ametinib mesylate|Ametinib mesylate.
219165493|NCT06754930|DRUG|BP-102|BP-102 for injection.
219165494|NCT06754930|DRUG|Carboplatin|Carboplatin for injection.
219237522|NCT01727076|BIOLOGICAL|Recombinant Human Interleukin-15|Given SC
219237523|NCT04392648|DRUG|TAK-573|TAK-573 intravenous infusion.
219237524|NCT04392648|DRUG|Pomalidomide|Pomalidomide capsules orally.
219237525|NCT04392648|DRUG|Bortezomib|Bortezomib injection subcutaneously.
219237526|NCT04392648|DRUG|Cyclophosphamide|Cyclophosphamide tablets orally.
219237527|NCT04392648|DRUG|Dexamethasone|Dexamethasone tablets orally.
219237528|NCT02327975|OTHER|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
219237529|NCT02327975|OTHER|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
219237530|NCT02327975|OTHER|Control group|No received intervention.
219237531|NCT04515745|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
219237532|NCT04515745|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
219237533|NCT03669419|DIAGNOSTIC_TEST|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
219237534|NCT01107509|DRUG|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
219237535|NCT00234832|DRUG|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
219237536|NCT00234832|DRUG|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
219165495|NCT07078266|DEVICE|Magnetocardiography examination|"Magnetocardiography (MCG) is a non-invasive, risk-free, and contactless technology that characterizes the local magnetic field signals generated by the electrical activity of the heart.~the magnetic signals used in magnetocardiograms can pass through the body with almost no interference. Therefore, magnetocardiography theoretically offers more clinically useful information, with the advantages of being non-invasive, safe, and fast, enabling earlier and more accurate diagnoses of potential heart diseases."
219165496|NCT07077148|BEHAVIORAL|Facilitated tucking|The upper and lower extremities of the newborns are taken to the midline and positioned in the womb.
219165497|NCT07077148|BEHAVIORAL|Swaddling|The baby is swaddled using the cloths used in the neonatal intensive care unit.
219165498|NCT07078097|OTHER|Traditional Sape' Dayak Music Listening|This intervention is distinguished by its use of the Sape' Dayak, a specific traditional musical instrument from East Kalimantan, Indonesia, known for its gentle, contemplative, and culturally significant sounds. The music utilizes pentatonic melodies that foster a serene and emotionally relaxing environment. Its distinct rhythm (80-85 beats per minute) is also a key feature. The intervention also incorporates a gentle abdominal massage and imagining the infant.
219165499|NCT07078097|OTHER|Brahms' Lullaby Music Therapy|This intervention is distinguished by its use of a globally popular and well-known lullaby composed by Johannes Brahms. The lyrics typically revolve around themes of love and affection, expressing mothers' love and tenderness for their fetuses. Unlike the Sape' Dayak, the specific lullaby will be preselected by the researcher to ensure a homogeneous intervention, with personal lullaby preferences ignored to avoid bias. Participants also engage in gentle abdominal touching and reflection on their unborn children.
219165500|NCT07079176|DRUG|etomidate combined with propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All patients underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the EP group, patients received 50 μg fentanyl, followed by a slow intravenous injection of a propofol-etomidate mixture (10 mL:20 mg etomidate + 10 mL:100 mg propofol) at 0.1-0.2 mL/kg. Supplemental doses of 0.05 mL/kg were administered as needed to maintain sedation throughout the procedure.
219165501|NCT07079176|DRUG|propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the P group, 50 μg fentanyl was administered, followed by a slow intravenous injection of propofol (1-2 mg/kg) after 3 minutes. Supplemental doses of 0.5 mg/kg were administered as needed to maintain sedation throughout the procedure.
219165502|NCT07076914|DRUG|Experimental (Health Canada Approved Proton Pump Inhibitors)|The intervention uses a proton pump inhibitor as a preventative measure
219165503|NCT07076888|OTHER|Aerobic Exercises|"1. Timing of Exercise:~   Aerobic exercises were performed on non-dialysis days. This scheduling avoids post-dialysis fatigue and hypotensive effects, optimizing patient safety and performance.~2. Frequency:~   Patients was engaged in aerobic exercise 3 times per week on non-consecutive days, to allow sufficient recovery time between sessions.~3. Duration of Each Session:~   * Total Duration: Each exercise session was last between 20 to 45 minutes.~  * Warm-Up: 5-10 minutes of low-intensity activity (e.g., slow walking).~  * Main Exercise: 15-30 minutes of moderate-intensity aerobic exercise.~  * Cool-Down:\*5-10 minutes of gradual reduction in intensity.~4. Exercise Modality:~   * Options: Patients may choose between treadmill walking or using a stationary bike, depending on their preference, physical condition.~  * Variety: To maintain engagement and reduce monotony, patients can alternate between treadmill and bike exercises.~5. Intensity:~Use moderate-intensity exercise, aiming for 60-70% of the p"
219237537|NCT00234832|DRUG|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
219237538|NCT02363153|OTHER|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
219165504|NCT07076888|OTHER|Conventional Program|"1\. Breathing Exercises~\- Diaphragmatic Breathing: Instruct patients to place one hand on their chest and the other on their abdomen. They should inhale deeply through their nose, allowing the abdomen to rise, and then exhale slowly through their mouth. This breathing technique has been shown to reduce stress, improve respiratory efficiency, and enhance relaxation . For optimal benefits, patients should practice this for 5-10 minutes, 2-3 times a day.~Stretching Exercises Hamstring Stretch: Instruct patients to sit with one leg extended straight out in front of them and the other leg bent. They should reach towards the toes of the extended leg while keeping their back straight. Hold the stretch for 20-30 seconds and repeat the stretch 2-3 times per leg.~Lower Limb Circulatory Exercises Ankle Pumps: While lying down or seated, instruct patients to alternately point and flex their feet to stimulate circulation and improve lower leg mobility. Perform 20-30 pumps per foot, 2-3 times a day"
219237539|NCT02163499|DRUG|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
219165505|NCT07077499|DEVICE|Pulsed Vacuum Cleaning and Disinfection Device|After manual pre-treatment, instruments were placed into the pulsed vacuum cleaning and disinfection machine (Shandong Xinhua Medical, Model PC-150L). The automated program included pulsed vacuum cleaning, rinsing, thermal disinfection (93°C for 2.5 minutes), and vacuum drying.
219237540|NCT06187155|OTHER|INR self-management|will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
219237541|NCT03189550|PROCEDURE|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
219165506|NCT07077499|DEVICE|Vacuum Ultrasonic Cleaner|After manual pre-treatment, instruments were cleaned in a vacuum ultrasonic cleaner (Shandong Xinhua Medical, Model super-6000) with a multi-enzyme solution for a minimum of 5 minutes. This was followed by a separate process in a spray cleaning and disinfection machine for rinsing and drying.
219165507|NCT07076875|OTHER|Questioner interview|The 2 questionnaires were translated from English to standard Arabic comprised of three sections, general information, including data and sociodemographic factors such as region of residence, parental education level, child age, child sex, and child order between siblings, Barriers to oral health care needs, including frequency and reasons for dental visits, any previous dental treatment, barriers to treatment such as fear of dentist, distance from the dental clinic, expense of an appointment due to health ban, responsibilities towards family members, not being familiar with appointment booking, and no available appointments, and Comprising of interviewer-administered questionnaires with a five-point Likert scale (strongly agree, agree, uncertain, disagree, strongly disagree) to assess the level of patients' satisfaction with the dental services provided.
219165508|NCT07077096|DIAGNOSTIC_TEST|PRISM PCR panel|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
219165509|NCT07077096|DIAGNOSTIC_TEST|Conventional bacterial culture|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
219165510|NCT07078513|OTHER|Active release Technique|Active Release Technique (ART) is a hands-on manual therapy that targets soft tissue restrictions by combining precise pressure with patient-assisted movement. It helps break down adhesions, improve mobility, and reduce pain by restoring normal tissue function.
219165511|NCT07078513|OTHER|Strain counter strain tecnhnique|Strain-Counterstrain is a gentle, passive manual therapy that relieves muscle tension by positioning the body in a pain-free, comfortable posture. The therapist holds this position for about 90 seconds while applying light pressure to tender points, allowing the muscle and fascia to relax and reset.
219165512|NCT07078331|DEVICE|OsteoAdapt DE (0.8 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (0.8 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
219165513|NCT07078331|DEVICE|OsteoAdapt DE (2.0 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (2.0 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
219165514|NCT07078331|DEVICE|Xenograft Bone Graft|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted xenograft bone graft by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
219165515|NCT07076290|DRUG|R-3750|R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)
219165516|NCT07077343|PROCEDURE|AI-Assisted Navigated Hematoma Aspiration|By leveraging AI algorithms for real-time hematoma segmentation, volume calculation, and trajectory optimization, this approach enhances the accuracy of minimally invasive catheter placement and facilitates efficient clot removal under image-guided navigation.
219165517|NCT07077343|PROCEDURE|Conservative Treatment|Compared to surgical hematoma aspiration, conservative treatment relies on medical stabilization and the body's natural clearance mechanisms, and remains the standard of care in many cases of moderate or deep-seated ICH without signs of clinical deterioration.
219165518|NCT07078058|DEVICE|Low level laser|Patients in the low level laser group will be irradiated with visible and near-infra-red lasers at a pulsed mode with a frequency of 35 Hz, peak power of 100 mW, and a spot diameter of 5 mm. The 15-minute sessions were performed three times a week for two months, with each laser having a power density of 0.35 mW/cm2 and an energy density of 32.08 J/cm2.
219165519|NCT07078058|DEVICE|Transcutaneous auricular Vagus nerve stimulation|Patients will receive 30 minutes of transcutaneous vagus nerve stimulation for 2 months, with 5 sessions per week. The antihelix and cymba concha will be sterilized with 75% alcohol, and the electrode will be attached. The device parameters include a wave width of 0.2 ms ± 30%, pulse frequency of 20 Hz, gradually increasing intensity to a tolerable intensity (4-6 mA), and duration of 30 minutes.
219237542|NCT03189550|PROCEDURE|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
219237543|NCT03189550|PROCEDURE|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
219237544|NCT00091676|BIOLOGICAL|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
219165520|NCT07078214|OTHER|Foot Sole Surface Area Measurements|The child's TWB was measured using the BTS P-Walk platform \[2440x740x8 mm, 12,000 sensors\] with an additional 500mm sensor-free mat for accurate start/end measurements. The system focused on foot-ground contact surface area data.Before measurements, the child familiarized herself with the platform through play. All walks were barefoot, with at least 3 attempts per assessment and the clearest data selected. To encourage platform crossing, the child carried a small object to her mother waiting opposite. To prevent upper extremity interference with gait, only return walks (without object) were analyzed for measurement.
219237545|NCT00091676|BIOLOGICAL|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
219237546|NCT05635994|DIAGNOSTIC_TEST|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
219237547|NCT02646878|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
219237548|NCT01412398|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
219237549|NCT03369119|DRUG|Montelukast 4 Mg Oral Granule|
219237550|NCT03369119|DRUG|Placebos|
219237551|NCT00816816|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
219165521|NCT07078214|OTHER|Walking Exercise Program and Implementation Process|The backward walking exercise program was performed on a treadmill at 1±0.2 km/h speed, conducted 5 days per week between 14:00-15:00 hours when the child was most alert according to maternal reports. Initially planned for minimum 5-minute sessions with gradual increases, but the child's short attention span and unfamiliarity with backward walking limited sessions to 3 minutes during first two days. Favorite cartoons displayed via tablet during sessions successfully enabled gradual time increases. Week 1 progressed from 3-5 minutes daily. Weeks 2-5 showed progressive increases to 6-9 minutes with sessions increased to 2 daily, separated by 10-15 minute play breaks. From week 6 onwards, two 10±0.2 minute sessions continued daily. Starting week 3, sessions were restructured as 5 minutes backward + 1 minute forward + 2-7 minutes backward walking to combat attention deficits after 5 minutes, improving exercise efficiency.
219165522|NCT07079007|OTHER|Water|Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.
219165523|NCT07078565|OTHER|Modified-Otago Exercises|Intervention is administered 3 times per week for 4 weeks, with the same baseline therapy as the Tai Chi group.
219165524|NCT07078565|OTHER|Tai Chi|Intervention is administered 3 times per week for 4 weeks, along with baseline therapy (TENS + heating pad).
219165525|NCT07078864|OTHER|Nursing Care Decision Support System|Phase Two involves implementing the Nursing Care Decision Support System. Data will be collected using a Descriptive Information Form, the Nurse Decision-Making Scale (pre-test), and a Semi-Structured Interview Form to explore nurses' views. Nurses will receive two training sessions (totaling 4 hours) covering system use, importance, challenges, and solutions. Training will be held in two groups based on shift schedules. A one-week trial will follow, with the researcher answering questions and providing support via a WhatsApp group. Nurses must use the system for at least 15 days (maximum 30 days due to dissertation timeline). Fifteen days after use ends, the Nurse Decision-Making Scale (post-test) and interviews will assess the system's effectiveness and areas for improvement.
219165526|NCT07076485|RADIATION|Ultrahypofractionated radiation|Given by infusion
219165527|NCT07076485|RADIATION|Moderately hypofractionated radiation|Given by infusion
219165528|NCT07077590|BEHAVIORAL|Open Label Placebo|Any woman who arrive to the labor room is connected to fluids (Hartman's solution), as part of routine care. The study intervention (open placebo) is based on injection of placebo into an infusion bag accompanied by a verbal suggustion. The placebo is 5 ml NaCl 0.9%.
219165529|NCT07076303|DEVICE|Direct Selective Laser Trabuloplasty|Eligible participants will undergo the DSLT procedure to facilitate controlled aqueous outflow. DSLT will consist of 120 shots, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2.4 seconds
219237552|NCT01540474|BIOLOGICAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
219237553|NCT01540474|BIOLOGICAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
219165530|NCT07078383|DEVICE|Rapidlink|The Rapidlink implant is comprised of a Gelweave graft section (gelatin-sealed woven polyester) attached to a stented section (which utilizes nitinol ring stents), with a 'cuff'' feature joined to the stented section of the implant. The implant is supplied pre-loaded in a single use delivery system which compacts the stented section within a polytetrafluoroethylene (PTFE) sheath at the front of the system.
219165531|NCT07077083|DRUG|89Zr-Girentuximab|89Zr-Girentuximab PET
219237554|NCT01540474|BIOLOGICAL|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
219237555|NCT01540474|OTHER|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
219237556|NCT01701089|DRUG|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
219237557|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for 14 days
219237558|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for up to 17 days
219237559|NCT00559871|DRUG|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
219737402|NCT04652999|BEHAVIORAL|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
219165532|NCT07077044|DEVICE|The transcutaneous posterior tibial nerve stimulation device|In addition to their conventional treatment, subjects in both TTNS groups will complete eight weeks of home TTNS treatment (3 sessions per week), and each session will last for 20 minutes. Stimulation will be provided by a portable device (Chattanooga®, ContinuumTM, Hixson, TN, USA). The device will be pre-programmed to apply a bi-phasic squared wave with a pulse width of 200μsec, and a pulse frequency of 20 Hz. These are default settings for TTNS that have been used in previous studies for urinary and fecal incontinence59,62,67. Two self-adhesive electrodes (5 x 5 cm) will be placed over the ankle area, one approximately 3 to 4 cm above the medial tibial malleolus and a second electrode just below the medial malleolus of the same leg.
219165533|NCT07077044|OTHER|PSUS|Handheld US
219165534|NCT07076589|PROCEDURE|FURS|FURS using traditional UAS \& FANS
219165535|NCT07077369|BIOLOGICAL|WGc-0201 injection|WGc-0201 injection
219165536|NCT07077369|DRUG|Tislelizumab|Tislelizumab, 200mg
219165537|NCT07077291|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|A group intervention delivered by a psychiatrist and two assistants. Sessions were 120 minutes, once per week, for 12 weeks. Content included mindfulness exercises such as 3-minute breathing space, body scanning, mindfulness walking, meditation, and cognitive therapy techniques to observe connections between thoughts, emotions, and behavior.
219165538|NCT07077291|DRUG|Escitalopram Hydrobromide|Oral administration of escitalopram hydrobromide tablets, 20mg once daily (qd) for the entire 12-week study duration.
219165539|NCT07077798|DRUG|Sintilimab|Patient receives first adjuvant sintilimab 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 8 cycles
219165540|NCT07077798|DRUG|Lenvatinib|lenvatinib is initiated orally(12 mg for body weight \&gt;= 60kg, 8 mg for body weight \&lt; 60kg daily), 2-4 weeks postoperatively for 6 months.
219165541|NCT07079059|OTHER|Virtual Reality Training|One hour of virtual reality training to be included in students' Anesthesia training prior to the start of their Anesthesia rotation.
219165542|NCT06902272|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* During Neoadjuvant Therapy: Approximately once after four cycles of standard of care Pembrolizumab and platinum doublet therapy.~* Approximately once two weeks before surgery.~* Approximately once three weeks after surgery.~* During Adjuvant Therapy: Approximately once every 12 weeks during standard of care, adjuvant Pembrolizumab therapy.~* Follow-up Period: Approximately once every three months for up to one year."
219165543|NCT06902272|DRUG|Pembrolizumab|Participants will receive standard of care, neoadjuvant Pembrolizumab therapy intravenously (IV) on Day 1 of each three-week cycle, for up to four cycles prior to standard of care surgery. After surgery, low-risk participants may continue standard of care, adjuvant Pembrolizumab therapy for up to six months; high-risk participants may receive standard of care, adjuvant Pembrolizumab therapy for up to 12 months.
219165544|NCT06902272|DRUG|Platinum Doublet Chemotherapy|Participants will receive neoadjuvant platinum doublet chemotherapy intravenously (IV) per standard of care on Day 1 of each three-week cycle for up to four cycles, prior to standard of care surgery. Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine. Participants receiving Gemcitabine therapy will be administered Gemcitabine, per standard of care, on Day 8 of each three-week cycle.
219165545|NCT07076758|OTHER|Transthoracic echocardiography|Transthoracic echocardiography will be done for all patients during their cardiac care unit stay including two-dimensional and color Doppler echocardiography studies. It will be performed in the left lateral position using the parasternal and apical transducer positions. All studies will be technically adequate for scoring endocardial regional wall motion. The following views will be obtained: long-axis parasternal, short-axis parasternal, apical four chamber, apical two-chamber and apical five-chamber views. All the measurements taken will be according to the criteria of the American Society of Echocardiography
219165546|NCT07076654|DRUG|Caffeine (200 mg)|Oral caffeine will be given as 200 mg before spinal anesthesia
219237560|NCT04280978|DIAGNOSTIC_TEST|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
219737403|NCT06421454|DRUG|Melatonin|Pressure Ulcer will be treated with a melatonin cream daily
219737404|NCT06421454|DRUG|Hydrogel|Pressure ulcer will be treated with hydrogel daily as a comparator
219737405|NCT04739215|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
219737406|NCT04739215|DRUG|Placebo|One Placebo capsule daily oral
219737407|NCT00235625|DRUG|Curcuminoids C3 Complex®|
219737408|NCT04332770|OTHER|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
219165547|NCT07076654|DRUG|Placebo|Patient at this arm will receive placebo
219165548|NCT07077135|DEVICE|stimulated group|Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days. Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20).
219165549|NCT07077135|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
219165550|NCT03559049|DRUG|Pembrolizumab|200mg IV every 21 days
219165551|NCT03559049|DRUG|Pemetrexed|500mg/m\^2 IV every 21 days
219165552|NCT03559049|DRUG|Carboplatin|AUC 5 IV every 21 days
219165553|NCT03559049|DRUG|Rucaparib|600mg PO, BID days 1-21 of each 21 day cycle
219165554|NCT07076563|DIETARY_SUPPLEMENT|Functional Ice Cream with Cimarrón Bean Extrudate|"Ice cream containing 10 g of Cimarrón bean extruded (Phaseolus vulgaris L., local variety Cimarrón) 100 g per portion. Participants consume 100 g daily (two 50 g portions, \~2 hours after a main meal) for 4 weeks."
219165555|NCT07076563|DIETARY_SUPPLEMENT|Placebo Ice Cream|Ice cream without Cimarrón bean extrudate, matched in appearance, taste, and texture to the functional ice cream. Participants consume 100 g daily (two 50 g portions) for 4 weeks.
219165556|NCT06618274|BEHAVIORAL|Intervention of oncology research navigator embedded in central oncology navigation|The intervention of oncology research navigator or Oncology research navigator (ORN) is embedded in central oncology navigation cancer care delivery.
219165557|NCT06618274|BEHAVIORAL|Central oncology navigation (SOC)|Central oncology navigation (SOC ) alone.
219165558|NCT07079150|DRUG|Peg IFN-α-2b|In the treatment of Peg IFNα-2b combined with NAs (Peg IFN combined treatment group), the treatment of Peg IFNα-2b should be no less than 48 weeks. The initial therapeutic dose of Peg IFNα-2b and the subsequent adjusted dose will be individualized determined by clinicians based on the specific condition of the patients. In the NAs monotherapy group, entecavir (ETV), tenofovir fumarate disoproxil (TDF), tenofovir propofol fumarate (TAF), and emitenofovir (TMF) were used for treatment for no less than 48 weeks, and Peg IFN was not added or switched for treatment.
219165559|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
219165560|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
219165561|NCT06896136|DRUG|VENBETA6890|Part A will consist of 1 sentinel dosing group of 2 subjects randomized 1:1 to receive VENBETA6890 and will evaluate VENBETA6890 at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
219165562|NCT06896136|DRUG|Placebo|Part A Placebo (saline) will be administered at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
219165563|NCT06896799|OTHER|Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.|Participants who are randomised to eat the protein/fat-based component (scrambled egg) of the meal before the carbohydrate-based component (wholemeal toast) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
219237561|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
219237562|NCT00857311|BIOLOGICAL|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
219237563|NCT00857311|BIOLOGICAL|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
219237564|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
219237565|NCT03470701|OTHER|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
219165564|NCT06896799|OTHER|Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.|Participants who are randomised to eat the carbohydrate-based component (wholemeal toast) of the meal before the protein/fat-based component (scrambled egg) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
219165565|NCT04764357|DEVICE|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
219165566|NCT04764357|OTHER|Alopecia Assessments|Photographs will be taken prior to the use of the scalp cooling system and once at the end of the study. Patients with solid tumors will have additional photographs taken after every 2 cycles of chemotherapy.
219165567|NCT04764357|OTHER|Patient Reported Outcomes Questionnaires|"* Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, after every 2 cycles of chemotherapy, 4 week follow up and end of study.~* Tolerability Questionnaire each time the cooling cap is used and at the end of study"
219165568|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by an interventionist.
219165569|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
219165570|NCT07077954|DRUG|Rivaroxaban|Rivaroxaban used to treat DVT
219165571|NCT07077954|DRUG|Warfarin|warfarin used for DVT
219165572|NCT07078890|PROCEDURE|bone augmentation simultaneous to implant removal|Placement of bone substitutes in the socket simultaneous to implant removal, and reimplantation is performed after 6 months of healing.
219165573|NCT04674306|BIOLOGICAL|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
219165574|NCT04674306|BIOLOGICAL|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
219165575|NCT03576274|BEHAVIORAL|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
219165576|NCT03576274|BEHAVIORAL|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
219165577|NCT03576274|BEHAVIORAL|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
219165578|NCT06915324|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial direct current stimulation (tDCS) is delivered by a device that has a user-friendly interface and a large-button keypad, making it is easy to use at home. The device delivers a weak electrical current of 2.0 mA that is transmitted through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are easily placed through a headset.~The active stimulation session lasts 30 minutes.~The inactive (sham) stimulation session will also last 30 minutes."
219165579|NCT06915324|BEHAVIORAL|Cognitive training|The cognitive training tasks are administered via a computer-based program BrainHQ (Posit Science). There are 20 sessions, each 30 minutes a day, conducted over approximately 4 weeks. The BrainHQ adaptive cognitive training tasks have been previously associated with improved processing speed in other populations.
219165580|NCT06919783|BEHAVIORAL|Health at Every Size in Obstetrics|Individuals are invited to participate in 5 group sessions during pregnancy and the postpartum period. The sessions will last 2-2.5 hours each and will include education on pregnancy, mental health, nutrition, movement, and self-advocacy. The sessions will be administered by an OBGYN/MFM physician and psychologist and include discussion with doulas, registered dieticians with pregnancy and disordered eating experience, and prenatal yoga instructors.
219165581|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
219165582|NCT06924346|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
219237566|NCT00004806|GENETIC|Cystic fibrosis transmembrane conductance regulator|
219237567|NCT05981586|OTHER|Plyometric strengthening exercises|Comparative effects 1
219237568|NCT05981586|OTHER|Isotonic strengthening exercises|Comparative effects 2
219165583|NCT06924346|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
219237569|NCT01587703|DRUG|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
219237570|NCT05090904|DRUG|Brensocatib|Oral tablet
219237571|NCT05090904|DRUG|Placebo|Oral tablet
219237572|NCT00591084|DRUG|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
219237573|NCT00591084|DRUG|placebo|infusion placebo (group B)once a day and continued for 14 days
219237574|NCT00591084|DRUG|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
219237575|NCT02862288|DEVICE|Microwave ablation with Acculis Accu2i pMTA Applicator|
219165584|NCT07079215|DEVICE|Neurostimulation|Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.
219165585|NCT07079215|DEVICE|Sham stimulation|"Control Group (Sham Stimulation, n=12):~Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group."
219165586|NCT06924021|OTHER|Retinal Imaging|"Eligible participants will undergo one retinal imaging session of both eyes for the following:~* Single field stereo color fundus photography (cFP) - pre and post dilation~* Macular spectral domain-optical coherence tomography (SD-OCT)"
219237576|NCT01697982|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
219237577|NCT01697982|BEHAVIORAL|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
219237578|NCT04893824|DEVICE|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
219237579|NCT05971615|OTHER|peripheral venous blood gases|peripheral venous blood gases
219237580|NCT01878955|GENETIC|AMH level difference between patient with PCOS and multicystic ovaries.|
219237581|NCT05849220|DRUG|Dapagliflozin|Dapagliflozin
219237582|NCT05849220|OTHER|Standard of Care|Standard of Care
219237583|NCT06106776|DRUG|Chimeric Antigen Receptor|This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).
219237584|NCT06031493|COMBINATION_PRODUCT|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
219237585|NCT03737188|DEVICE|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
219237586|NCT00554905|PROCEDURE|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
219237587|NCT00554905|PROCEDURE|TACE|TACE first, then RFA within 2 weeks
219743699|NCT03220256|DRUG|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
219743700|NCT06220253|PROCEDURE|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
219743701|NCT06220253|PROCEDURE|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
219743702|NCT01518179|DEVICE|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
219743703|NCT01518179|OTHER|Routine follow up and treatment|Control
219743704|NCT06099639|DRUG|HER3-DXd|5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
219743705|NCT04407117|BEHAVIORAL|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
219743706|NCT05630365|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
219743707|NCT02511743|OTHER|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
219743708|NCT06214325|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
219743709|NCT01455844|DRUG|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
219743710|NCT01455844|OTHER|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
219743711|NCT01455844|DRUG|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
219165587|NCT06931119|DRUG|EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.|"Total Treatment Duration: 1 cycle (1 administration of EMEND® capsules)~* Frequency: Patients will take EMEND® capsules at the start of new ICI.~* Dosing Schedule:~  * Day 1: EMEND® 125 mg, taken orally 1-2 hours before ICI administration.~ * Day 2: EMEND® 80 mg, taken orally in the morning.~ * Day 3: EMEND® 80 mg, taken orally in the morning. During the study period (12 weeks), participant must refrain from using any medications that could potentially interfere with the study's assessment of pruritus symptoms (e.g steroids, antihistamines)~Follow-up 1(7 days after the first capsule of Aprepitant): 12-PSS, safety assessment, QLQ-C30 Follow-up 2: 12-PSS, safety assessment Follow-up 3: 12-PSS, safety assessment Follow-up 4: 12-PSS, QLQ-C30, safety assessment Extended Follow-up: Recurrence of pruritus, long-term safety monitoring, QLQ-C30"
219743712|NCT05807945|DRUG|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
219165588|NCT06932627|PROCEDURE|ILIB|The treatment group receive an intravenous laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 5 Mw, 30 minutes each time,once every other day for 3 consecutive days each week, for 2 weeks (total 6 times in one course)
219165589|NCT06932627|PROCEDURE|Sham Control|The steps for the control group are the same as the treatment group, exceptthat the output power is adjusted to zero intensity.
219165590|NCT06942221|OTHER|usual care|"Patients in the usual care group will be followed up according to the local practice until the end of the study."
219165591|NCT06942221|OTHER|guideline-directed medical therapy|Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.
219165592|NCT03436485|DRUG|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
219165593|NCT03436485|DRUG|Midazolam|orally
219165594|NCT06931483|DEVICE|Transcranial temporal interference stimulation (tTIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
219165595|NCT06931483|DEVICE|Sham transcranial temporal interference stimulation (tTIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.
219743713|NCT05807945|DRUG|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
219165596|NCT06942039|DRUG|Cytarabine IT|Age-based dosing as a part of double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
219743714|NCT02980458|DRUG|Deferiprone 500Mg Tablet|
219743715|NCT02980458|DRUG|Deferiprone 500 MG Oral Tablet [Ferriprox]|
219743716|NCT05952375|DRUG|Chimeric antigen receptor T cell preparation targeting Claudin18.2|Chimeric antigen receptor T cell preparation targeting Claudin18.2
219743717|NCT01922895|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
219743718|NCT01922895|DRUG|Placebo for Probiotic|Capsule manufactured without active ingredients.
219743719|NCT01916226|DRUG|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
219743720|NCT01916226|DRUG|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
219743721|NCT01916226|DRUG|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
219743722|NCT01916226|DRUG|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
219743723|NCT03163667|DRUG|Placebo|oral tablets
219743724|NCT03163667|DRUG|CB-839|oral tablets
219743725|NCT03163667|DRUG|everolimus|oral tablets
219743726|NCT00400322|DRUG|Valganciclovir (Valcyte)|
219743727|NCT00400322|OTHER|Placebo|
219743728|NCT01013259|DRUG|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
219743729|NCT01013259|DRUG|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
219743730|NCT03445442|PROCEDURE|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
219743731|NCT03445442|PROCEDURE|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
219743732|NCT03445442|PROCEDURE|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
219743733|NCT04910165|DRUG|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
219743734|NCT04910165|DRUG|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
219743735|NCT01269437|DRUG|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
219743736|NCT01566565|DRUG|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
219165597|NCT06942039|DRUG|hydrocortisone|Double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
219165598|NCT06942039|DRUG|Cisplatin|Intravenous CISplatin given on Day 1 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
219165599|NCT06942039|DRUG|Vincristine|Intravenous VinCRIStine given on Days 1, 8 \& 15 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
219165600|NCT06942039|DRUG|Etoposide|"Induction: Intravenous Etoposide given on Days 1, 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, cyclophosphamide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Etoposide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Cyclophosphamide and Temozolomide."
219165601|NCT06942039|DRUG|Cyclophosphamide|"Induction: Intravenous high-dose Cyclophosphamide given on Days 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, etoposide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Cyclophosphamide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Etoposide and Temozolomide."
219165602|NCT06942039|DRUG|Mesna|Induction: Intravenous Mesna given at hour 0 of Cyclophosphamide delivery and 3, 6, 9 \& 12 hours post-dose during induction (3 cycles, 1 cycle = 21 days).
219165603|NCT06942039|DRUG|Filgrastim|"Induction: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hrs after last dose of chemotherapy and/or as per institutional guidelines until count recovery.~Consolidation: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hours after last stem cell infusion and/or per institutional guidelienes until count recovery."
219165604|NCT06942039|DRUG|carboplatin|Consolidation: Intravenous Carboplatin given on days -3 \& -2 during consolidation alongside thiotepa and filgrastim.
219165605|NCT06942039|DRUG|Thiotepa|Consolidation: Intravenous Thiotepa given on days -3 \& -2 during consolidation alongside carboplatin and filgrastim.
219165606|NCT06942039|DRUG|Topotecan IT|"Maintenance A (for low-risk patients): IT Topotecan on Day 1 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and ISOtretinoin.~Maintenance B (for high-risk patients): IT Topotecan every 4 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside ISOtretinoin, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
219165607|NCT06942039|DRUG|Tamoxifen|Maintenance A (for low-risk patients): Oral Tamoxifen twice daily, Days 1-28 (max 12 cycles, 1 cycle = 28 days) alongside ISOtretinoin and IT Topotecan.
219165608|NCT06942039|DRUG|ISOtretinoin|"Maintenance A (for low-risk patients): Oral ISOtretinoin twice daily on Days 15-28 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and IT Topotecan.~Maintenance B (for high-risk patients): Oral ISOtretinoin twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
219743737|NCT04942327|BEHAVIORAL|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
219743738|NCT06395766|DIAGNOSTIC_TEST|BREF,MSPSS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL )~2. the Zimet Multidimensional Scale of Perceived Social Support -. The original version on the MSPSS"
219743739|NCT05531942|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
219165609|NCT06942039|DRUG|Celecoxib|Maintenance B (for high-risk patients): Oral Celecoxib twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Temozolomide.
219165610|NCT06942039|DRUG|etoposide phosphate|During Induction and Maintenance B (for high-risk patients), etoposide phosphate may be given for subsequent doses to patients who have experienced etoposide allergic reactions.
219165611|NCT06942039|DRUG|Temozolomide|Maintenance B (for high-risk patients): Oral Temozolomide daily on Days 1-21, every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Celecoxib.
219165612|NCT07077811|PROCEDURE|pulsed field ablation|Medtronic Pulse Select pulsed field ablation
219165613|NCT07077811|DRUG|antiarrhythmic drug|treated with class I or class III antiarrhythmic drugs
219165614|NCT07078071|DEVICE|ECG|Each participant undergoes testing with both the investigation device and the control device simultaneously. The results of the investigation device, which are obtained through pulse wave data analysis at the wrist, are compared to the investigator's interpretation of the ECG.
219165615|NCT06153537|DRUG|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
219165616|NCT05181709|DRUG|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
219165617|NCT05181709|BIOLOGICAL|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
219165618|NCT05181709|BIOLOGICAL|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
219165619|NCT05181709|BIOLOGICAL|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
219165620|NCT05181709|BIOLOGICAL|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
219743740|NCT05531942|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
219743741|NCT05937802|DIETARY_SUPPLEMENT|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
219743742|NCT00143845|PROCEDURE|Reduced intensity conditioning|Busulfan and Fludarabine regimen
219743743|NCT00143845|PROCEDURE|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
219743744|NCT00143845|PROCEDURE|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
219743745|NCT04846998|DRUG|BR9003|"Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it."
219743746|NCT04846998|DRUG|BR9003A|"Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state"
219743747|NCT03758846|BEHAVIORAL|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
219743748|NCT03758846|BEHAVIORAL|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
219743749|NCT03758846|BEHAVIORAL|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
219743750|NCT03758846|BEHAVIORAL|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
219743751|NCT03758846|BEHAVIORAL|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
219743752|NCT00521352|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
219743753|NCT00521352|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
219743754|NCT01485367|DRUG|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
219743755|NCT05032352|DRUG|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
219743756|NCT05032352|OTHER|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
219165621|NCT01722916|DRUG|Hyaluronidase|
219165622|NCT06830122|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
219165623|NCT06830122|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
219165624|NCT05954130|OTHER|Education|Sexual Health in Pregnancy
219165625|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
219165626|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
219165627|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
219165628|NCT03152786|OTHER|Survey Administration|Ancillary studies
219165629|NCT06833450|OTHER|Transabdominal intestinal ultrasound|Transabdominal intestinal ultrasound
219165630|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
219165631|NCT05746117|DEVICE|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
219165632|NCT05746117|DEVICE|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
219165633|NCT06575335|OTHER|Triphala Tooth Wipe|The wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned.
219165634|NCT06575335|OTHER|Chlorhexidine Tooth Wipe|Same as triphala tooth wipe
219165635|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying Breath Test|13C-Spirulina GEBT (Cairn Diagnostics) is non-radioactive, non-invasive breath based test validated against scintigraphy for the measurement of gastric emptying. Patients will be mailed test kits to be done in their homes remotely along with telehealth assistance from the study team. After overnight fast and providing duplicate pre-meal breath samples, the patient consumes 27 grams of re-hydrated, precisely formulated, pasteurized scrambled egg mix containing a dose of 43 mg of 13C (provided by approximately 100 mg of 13C-Spirulina), 6 saltine crackers and 6 ounces (180 mL) of potable water. The caloric value of the meal is approximately 230 kCal.Patient will provide breath samples into provided glass tubes before and after test meal administration which are then mailed back to a central laboratory for analysis by gas isotope ratio mass spectrometry.
219165636|NCT05088590|DIETARY_SUPPLEMENT|Enfagrow® Neuropro Toddler Nutritional Drink|Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
219165637|NCT05088590|DIETARY_SUPPLEMENT|Pediasure® Grow & Gain Protein Shake for Kids|Pediasure® Grow \& Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
219165638|NCT04333290|DRUG|[11C]MeDAS|PET radiotracer
219165639|NCT06829706|DEVICE|Conventional olfactory training device|Conventional olfactory training was designed by Hummel et al. They performed OT using four odors (phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronella, lemon; and eugenol, cloves), which are representative of four odor categories on the odor prism proposed by Henning.
219165640|NCT06829706|DEVICE|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. Its bidirectional airflow and unidirectional pressure characteristics significantly increased the deposition rate of olfactory odors in the olfactory cleft area, making the patient feel stronger in the nasal cavity during olfactory training.
219165641|NCT06829706|DEVICE|Conventional olfactory training device with placebo|Based on the traditional olfactory training device, four olfactory odors are replaced by placebo。
219165642|NCT04923347|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered
219165643|NCT04923347|DEVICE|ELLIPTA|Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
219165644|NCT05105360|PROCEDURE|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
219165645|NCT05105360|PROCEDURE|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
219165646|NCT05014165|OTHER|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
219165647|NCT05014165|OTHER|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
219165648|NCT05014165|OTHER|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
219743757|NCT01422382|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
219743758|NCT01422382|DRUG|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
219743759|NCT00240019|DRUG|Addition of furosemide 20 mg oral bid to baseline regimen|
219743760|NCT01962753|DRUG|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
219743761|NCT06192966|DIETARY_SUPPLEMENT|Food supplement|Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
219743762|NCT06192966|DIETARY_SUPPLEMENT|Placebo|Placebo composed of maltodextrin for 6 months 1 capsule/day
219743763|NCT03615768|COMBINATION_PRODUCT|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
219743764|NCT03615768|DRUG|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
219743765|NCT03615768|DRUG|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
219743766|NCT03376529|DRUG|SPR741|400 mg IV over 1 hour
219743767|NCT03376529|DRUG|Ceftazidime|1.0 gram IV over 1 hour
219743768|NCT03376529|DRUG|Piperacillin/tazobactam|4.5 grams IV over 1 hour
219743769|NCT03376529|DRUG|Aztreonam|1.0 gram IV over 1 hour
219743770|NCT06077279|BEHAVIORAL|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
219743771|NCT02412436|DRUG|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
219743772|NCT06549647|OTHER|low caloric diet|A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
219743773|NCT06549647|OTHER|Placebo laser acupoint stimulation|Placebo laser acupoint stimulation will be used for all participants in group (A).
219743774|NCT06549647|OTHER|Laser Acupuncture|Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
219743775|NCT00323986|DRUG|azithromycin (drug)|
219743776|NCT02658188|DRUG|ASP8825|Oral
219743777|NCT06481813|OTHER|Blood Sampling (2*8mL Tubes)|Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
219743778|NCT06481813|OTHER|PBMC Sampling (1*8mL Tubes)|Patients will be sampled from 1 x 8 mL PBMC
219743779|NCT06481813|OTHER|Paxgene Sampling|Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
219743780|NCT06481813|PROCEDURE|Extended biopsies of tumor lesions|"Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed."
219743781|NCT02102802|DRUG|Midomafetamine|125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose
219743782|NCT02102802|BEHAVIORAL|Therapy|Manualized therapy
219743783|NCT04926285|DRUG|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
219743784|NCT04926285|DRUG|Venetoclax|Venetoclax at 400mg
219743785|NCT04516213|OTHER|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
219743786|NCT05558085|BEHAVIORAL|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
219743787|NCT01323374|DRUG|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
219743788|NCT01323374|DRUG|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
219743789|NCT01323374|DRUG|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
219743790|NCT01323374|DRUG|Placebo|Oral, placebo TID
219743791|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
219743792|NCT00666341|DRUG|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
219743793|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
219743794|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
219165649|NCT05563636|DEVICE|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
219165650|NCT05563636|DEVICE|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
219165651|NCT06251986|OTHER|ofatumumab|This is an observational study, there is no treatment allocation.
219165652|NCT04032899|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
219165653|NCT04032899|DIETARY_SUPPLEMENT|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
219165654|NCT05481658|DRUG|Diphencyprone (DPCP)|topical immunomodulator
219165655|NCT05673499|DEVICE|NIRS/EEG monitoring|The study intervention will be monitoring NIRS and EEG for one hour before surgery, during surgery, and up to 8-24 hours after surgery.
219165656|NCT06335641|DEVICE|External active conductive head cooling|Cooling is applied during the endovascular thrombectomy procedure for a maximum of 120 minutes
219165657|NCT05163899|PROCEDURE|Release of filum terminale|Surgery will be offered to section the filum terminale
219165658|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
219165659|NCT06275919|DRUG|Regorafenib 40 MG Oral Tablet|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
219165660|NCT06275919|DRUG|Local Standard of Care|In this setting there are not drugs with indication. Every site will treat patients as per their experience.
219165661|NCT03109197|OTHER|Biospecimin Collection|
219165662|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
219165663|NCT04393558|DEVICE|ADAM Sensor|ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
219165664|NCT03949881|BIOLOGICAL|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
219165665|NCT05188469|DRUG|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
219165666|NCT05188469|DRUG|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
219165667|NCT05188469|DRUG|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
219165668|NCT05188469|DRUG|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
219165669|NCT05188469|DRUG|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
219165670|NCT04333706|DRUG|Capecitabine|Capecitabine 1000 mg BID
219165671|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg or 200 mg plus Capecitabine|Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
219165672|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg plus Capecitabine|Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
219237588|NCT04034732|BEHAVIORAL|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
219743795|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
219743796|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
219743797|NCT04090749|BEHAVIORAL|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
219743798|NCT02528305|OTHER|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
219743799|NCT01044043|PROCEDURE|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
219743800|NCT05333588|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
219743801|NCT03361007|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
219743802|NCT01299532|DEVICE|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
219743803|NCT00010907|DRUG|NPI-028|
219743804|NCT02285959|DRUG|Bevacizumab|
219743805|NCT04256837|DEVICE|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
219743806|NCT03644758|DIAGNOSTIC_TEST|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
219743807|NCT03644758|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
219743808|NCT03644758|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
219743809|NCT03644758|DIAGNOSTIC_TEST|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
219743810|NCT03644758|DIAGNOSTIC_TEST|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
219743811|NCT01789502|DEVICE|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
219743812|NCT01789502|DEVICE|Plastic stents|Plastic stents were inserted by ERCP
219743813|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
219743814|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
219743815|NCT02853773|OTHER|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
219743816|NCT03643588|DEVICE|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
219743817|NCT03643588|DEVICE|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
219743818|NCT03088111|OTHER|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
219743819|NCT03088111|BIOLOGICAL|Obiltoxaximab|Obiltoxaximab standard of care
219743820|NCT03405753|DIETARY_SUPPLEMENT|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
219743821|NCT03405753|DIETARY_SUPPLEMENT|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
219165673|NCT03424811|DEVICE|Mobile Health Intervention|Mobile health intervention to promote healthy eating.
219743822|NCT00872287|PROCEDURE|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
219743823|NCT00872287|PROCEDURE|SILS|Single transumbilical incision laparoscopic cholecystectomy
219743824|NCT02691494|DRUG|Elagolix|Film-coated tablets
219743825|NCT02691494|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
219743826|NCT02691494|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
219743827|NCT02691494|DRUG|Placebo for Elagolix|Film-coated placebo tablets
219743828|NCT02522221|DRUG|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
219743829|NCT02522221|DRUG|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
219743830|NCT03357497|OTHER|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
219743831|NCT04168411|PROCEDURE|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
219743832|NCT02438397|DRUG|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
219743833|NCT02438397|DRUG|metformin|500 mg tid by Merck
219743834|NCT02438397|DRUG|Acarbose|100mg tid by Bayer
219743835|NCT02627638|OTHER|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
219743836|NCT01961180|DRUG|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
219743837|NCT01961180|DRUG|Placebo|Placebo
219743838|NCT05420337|PROCEDURE|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
219743839|NCT05420337|PROCEDURE|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
219743840|NCT00441935|DEVICE|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
219743841|NCT02557165|PROCEDURE|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
219743842|NCT02397369|OTHER|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
219743843|NCT02397369|BEHAVIORAL|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
219743844|NCT02397369|BEHAVIORAL|Tobacco users:Behavioural therapy Only|"1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
219743845|NCT02397369|OTHER|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
219743846|NCT00787800|DEVICE|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
219743847|NCT00787800|DEVICE|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
219743848|NCT04228003|DIETARY_SUPPLEMENT|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
219743849|NCT02481141|DRUG|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
219743850|NCT02481141|DRUG|Placebo|
219743851|NCT00027300|DRUG|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
219165674|NCT06134479|DRUG|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
219237589|NCT04034732|BEHAVIORAL|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
219237590|NCT05256355|OTHER|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
219237591|NCT04523909|DIAGNOSTIC_TEST|Trajectory of neuroinflammatory proteins in CSF and blood|Kinetics of neuroinflammatory markers in CSF and blood
219237592|NCT01094665|PROCEDURE|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
219237593|NCT00878904|DRUG|epirubicin hydrochloride|
219165675|NCT06134479|DRUG|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
219165676|NCT04455035|OTHER|Comparator: Retrospective Group(Control)|The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.
219165677|NCT04455035|DEVICE|Prospective Group|"The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles."
219165678|NCT06135298|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
219165679|NCT06135298|DRUG|Zoledronic acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
219237594|NCT00878904|DRUG|panobinostat|
219237595|NCT00878904|GENETIC|gene expression analysis|
219237596|NCT00878904|GENETIC|protein expression analysis|
219237597|NCT00878904|GENETIC|western blotting|
219237598|NCT00878904|OTHER|immunologic technique|
219237599|NCT00878904|OTHER|laboratory biomarker analysis|
219237600|NCT00878904|OTHER|pharmacological study|
219237601|NCT05486988|DRUG|Immunotherapy|PD-1/PD-L1 inhibitors
219237602|NCT05486988|DRUG|Chemotherapeutic Agent|2 cycles
219237603|NCT05486988|DRUG|Chemotherapy|4\~6 cycles
219237604|NCT03274934|BEHAVIORAL|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
219237605|NCT03274934|BEHAVIORAL|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
219165680|NCT06135298|DEVICE|CERAMENT BONE VOID FILLER (BVF)|In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
219165681|NCT06286189|DRUG|Placebo oral tablet|Placebo capsule taken 30 min before sleep
219165682|NCT06286189|DRUG|Trazodone Hydrochloride|Trazodone 100 mg 30 min before sleep
219165683|NCT06434610|DRUG|B013|B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
219165684|NCT06434610|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
219165685|NCT06434610|DRUG|Placebo|Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
219165686|NCT06151080|DRUG|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
219165687|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
219165688|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
219165689|NCT01927744|DRUG|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
219165690|NCT01927744|DRUG|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
219165691|NCT01927744|OTHER|Placebo|150 mg by mouth daily continuously until the day before surgery.
219165692|NCT01927744|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
219165693|NCT01927744|BEHAVIORAL|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
219165694|NCT01927744|DRUG|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
219165695|NCT05274425|OTHER|Enerzair 150/50/80 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
219165696|NCT05274425|OTHER|Enerzair 150/50/160 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
219165697|NCT06755190|DIAGNOSTIC_TEST|Diagnostic Test: AI-Based Diagnostic and Prognostic Model for Ocular Diseases|This intervention involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. It integrates multi-modal data, including fundus photography, optical coherence tomography (OCT), and patient clinical records, to provide real-time, precise, and personalized diagnostic support. Unlike other models, this system utilizes a longitudinal patient dataset to predict disease progression and treatment outcomes.Key distinguishing features include: 1. Multi-Modal Data Integration: Combines imaging, clinical, and genetic data for comprehensive analysis. 2. Predictive Capability: Offers advanced prognostic predictions, enabling personalized treatment plans. 3. Deep Learning Framework: Employs state-of-the-art deep learning algorithms for improved diagnostic accuracy and efficiency. 4. Real-World Validation: Validated using a large cohort of diverse patient data, ensuring generalizability and robustness.
219165698|NCT06510491|DRUG|Epcoritamab|Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
219165699|NCT00753090|DEVICE|Vanguard™ Deep Dish Rotating Platform Knee|Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee
219165700|NCT00753090|DEVICE|Vanguard™ Cruciate Retaining Knee|Total knee replacements with the Vanguard Cruciate Retaining Knee
219165701|NCT06244641|OTHER|Auto-questionnaires, hetero-questionnaires and Evoked-potentials|Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
219165702|NCT06776601|BEHAVIORAL|Full process digital therapy intervention package|Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
219165703|NCT04871100|BEHAVIORAL|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
219165704|NCT04871100|BEHAVIORAL|Usual care|referrals to VA care for SUD and anxiety
219165705|NCT04623424|DIAGNOSTIC_TEST|intestinal microbiota|Stoll samples will be tested for different bacteria
219165706|NCT04031677|PROCEDURE|Surgery|Large en-bloc curative-intent surgery
219165707|NCT04031677|DRUG|Preoperative chemotherapy|"* High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same."
219165708|NCT06781086|DRUG|Nimotuzumab|Patients will receive 3 cycles of neoadjuvant treatment with Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
219237606|NCT03274934|BEHAVIORAL|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
219165709|NCT06781086|DRUG|AG regimen|Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
219165710|NCT06781086|DRUG|Placebo|Patients will receive 3 cycles of neoadjuvant treatment with placebo (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant therapy (placebo 400 mg on days 1, 8, and 15 of a 21-day cycle).
219165711|NCT00477958|OTHER|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
219165712|NCT00477958|PROCEDURE|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
219165713|NCT00477958|PROCEDURE|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
219165714|NCT06766006|PROCEDURE|Venoarterial extracorporeal life support (VA ECLS) implant|Implantation of venoarterial extracorporeal life support implant for refractory cardiogenic shock or cardiac arrest of any cause.
219165715|NCT06710002|BEHAVIORAL|Pelvify: Menopause and dyspareunia treatment|"Topics addressed in the Asynchronous Online Telerehabilitation Program would be:~1. What it is and why it hurts during sex. What is dyspareunia?~2. How to recover vaginal elasticity.~3. Massage~4. Self-palpation.~5. Stretching of the pelvic floor muscles.~6. Use of vaginal dilators.~7. Moisturizers and lubricants.~8. Sexual pleasure.~9. Communication with the partner."
219165716|NCT06710002|OTHER|Face to Face Physical Therapy Protocol|"Physical Therapy Protocol will be based on:~1. Health education:~2. CMRF: INDIBA® ACTIV CT8 will be used to apply the radiofrequency~3. Manual therapy: it will be based on performing the Thiele's massage.~4. Vaginal dilators: FEMINAFORM® vaginal dilators will be used."
219165717|NCT06710002|OTHER|Face to Face Protocol Combined With an Asynchronous Telerehabilitation Program|Both, the face to face protocol and the Asynchronous Telerehabilitation Program will be carried on on this group.
219165718|NCT03166150|OTHER|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
219165719|NCT03166150|OTHER|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
219165720|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
219165721|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
219165722|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
219165723|NCT06739161|RADIATION|Sintilimab combined with chemotherapy and local treatment|"Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable."
219165724|NCT06739161|COMBINATION_PRODUCT|Sintilimab combined with chemotherapy only|"Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."
219165725|NCT02216864|PROCEDURE|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
219165726|NCT02960230|BIOLOGICAL|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
219165727|NCT02960230|DRUG|Nivolumab|anti-programmed cell death protein 1 (PD-1) monoclonal antibody
219237607|NCT03948958|OTHER|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
219237608|NCT03948958|OTHER|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
219237609|NCT03948958|OTHER|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
219165728|NCT06066541|BEHAVIORAL|Scorecard|"Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score."
219743852|NCT00027300|DRUG|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
219743853|NCT01568229|DRUG|AMG 747|Three dose levels once-daily oral administration
219743854|NCT01568229|DRUG|Placebo|Once-daily oral administration
219743855|NCT01081574|DRUG|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
219743856|NCT00913835|BIOLOGICAL|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
219743857|NCT00913835|DRUG|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
219165729|NCT06066541|BEHAVIORAL|Social norms|Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).
219165730|NCT06066541|BEHAVIORAL|Messenger effects|Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.
219165731|NCT06066541|BEHAVIORAL|Processing fluency|"Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring."
219237610|NCT03948958|OTHER|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
219237611|NCT03948958|OTHER|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
219743858|NCT00498407|DRUG|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
219743859|NCT06548347|DRUG|Linperlisib|Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
219743860|NCT00833274|BEHAVIORAL|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
219743861|NCT00637156|DEVICE|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
219743862|NCT00637156|DEVICE|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
219743863|NCT05930535|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
219743864|NCT02340546|DEVICE|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
219743865|NCT00000501|BEHAVIORAL|diet, sodium-restricted|
219743866|NCT00000501|BEHAVIORAL|diet, reducing|
219743867|NCT00000501|DRUG|potassium|
219743868|NCT02431026|DEVICE|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
219743869|NCT03757663|BEHAVIORAL|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
219743870|NCT00461812|DRUG|Mometasone|
219743871|NCT00461812|DRUG|Advair|
219743872|NCT01793233|OTHER|Laboratory Biomarker Analysis|Correlative studies
219743873|NCT01793233|OTHER|Questionnaire Administration|Ancillary studies
219743874|NCT01503177|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
219743875|NCT01503177|OTHER|laboratory biomarker analysis|Correlative studies
219743876|NCT01503177|PROCEDURE|single photon emission computed tomography|Correlative studies
219743877|NCT01503177|PROCEDURE|computed tomography|Correlative studies
219743878|NCT06105398|OTHER|clinical evaluation|clinical evaluation tests
219743879|NCT00557739|DRUG|mometasone furoate|Topical 0.1% mometasone furoate
219743880|NCT00557739|DRUG|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
219743881|NCT00557739|DRUG|Vehicle (placebo)|Topical placebo
219743882|NCT03193437|DRUG|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
219165732|NCT06779838|OTHER|Group Emotion Focused Therapy Intervention|The EFT group intervention: Taming the Inner Critic: Emotion-Focused Group Therapy for Eating and Body Concerns. This group is a 10-12 week (number of participants=8-10 +2 sessions) closed therapy group for students seeking support regarding issues related to eating and/or body concerns. Working one-to-one and within the group, group members will be facilitated to recognise and explore some of the difficult emotions underlying and driving eating and/or body related issues. In particular, the group will focus on 'taming' the inner critic, that part of ourselves that criticises or chastises us for not being good enough. By identifying the critic in ourselves and by witnessing it in others, group members will be better positioned to figure out what they really need from themselves at times of difficulty, and thus better able to access self-compassion and self-assertion. There will be some psychoeducation, both around eating and emotions, but this will be largely in a handout format, with
219165733|NCT06779838|OTHER|Treatment as Usual (TAU)|Treatment that would otherwise be offered by the university counselling service (one on one counselling, a group, or signposting to external support).
219237612|NCT04343989|DRUG|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
219237613|NCT04343989|DRUG|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
219237614|NCT04343989|OTHER|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
219237615|NCT01799993|DRUG|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
219237616|NCT01799993|DRUG|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
219237617|NCT01181193|OTHER|Surgery|Craniotomy with total or partial removal of the brain tumor
219237618|NCT01181193|RADIATION|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
219237619|NCT01181193|DRUG|Temozolomide|"1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
219237620|NCT01181193|DRUG|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
219237621|NCT02648737|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).
219237622|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
219237623|NCT05534854|GENETIC|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
219237624|NCT04348799|OTHER|BPD|It is a observation research.we didn't intervene anything.
219237625|NCT02068079|DRUG|Vemurafenib and Trientine|
219237626|NCT02122354|BEHAVIORAL|"Hide and Seek videogame"|
219237627|NCT04271254|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
219237628|NCT04756986|DRUG|malic acid|1% malic acid spray
219237629|NCT04105699|DEVICE|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
219165734|NCT06780839|DRUG|Ensartinib|Patients will receive Ensartinib 225mg QD by MRD test guided, if MRD test shows negative, only ensartinib will be given. if MRD test turns from negative to posive, patients will receive step-up treatment, which is ensartibe plus platinum - based doublet chemotherapy no more than 4 cycles. If MRD test turns from posive to negative, only ensartinib will be given. if MRD test constantly shows positive, MDT will determine the next step ensartib-based therapy.
219237630|NCT03534778|DIAGNOSTIC_TEST|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
219237631|NCT00965393|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
219237632|NCT00965393|DRUG|Placebo|Systemic infusion of placebo (saline)
219237633|NCT00965393|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
219165735|NCT04714671|OTHER|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
219165736|NCT05281484|DRUG|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
219165737|NCT06782126|BEHAVIORAL|BreeZe (Brandwonden en Zelfmanagement)|BreeZe is a self-management support program designed to enhance burn survivors' intrinsic motivation and self-efficacy for self-management after discharge. The intervention is based on the Self-Regulation Theory framework. Key strategies include evidence-based techniques such as goal setting and pursuit, Solution-Focused Brief Therapy, and Motivational Interviewing. The program takes a positive approach to boost motivation and self-efficacy, promoting sustainable behavior change in burn aftercare. BreeZe will be implemented through various strategies, including educating healthcare professionals on self-management, training them in communication skills (e.g., motivational interviewing), and providing materials such as a decision aid tool (self-management web) and a workbook tailored to burn survivors. Burn survivors will use the web to identify and prioritize problems, set personalized goals with their healthcare professional, and create an action plan for goal attainment.
219165738|NCT05276063|DRUG|Linsitinib|Study medication taken twice daily by mouth
219165739|NCT05276063|DRUG|Placebo|Placebo taken twice daily by mouth
219165740|NCT06164197|DEVICE|Lokomat|Robot Assisted Gait Training
219165741|NCT06164197|DEVICE|Thera Trainer Balo|Virtual Reality Based Balance Training Device
219165742|NCT06164197|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
219165743|NCT06552468|DEVICE|AF monitoring by a smartwatch with PPG|The device we used for intervention is a smartwatch (JKwear 1, Chengdu CVhealth Science and Technology Co., Ltd, CN) for collecting watch-recorded-PPG (W-PPG).
219165744|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
219165745|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
219165746|NCT05728489|DRUG|BI 765250|BI 765250
219165747|NCT05728489|DRUG|Placebo|placebo
219237634|NCT02272608|OTHER|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
219165748|NCT05698017|BIOLOGICAL|hOMSC300|Human Oral Mucosa Stem Cells
219237635|NCT01082354|DRUG|recombinant somatropin|as per standard practice
219237636|NCT04945044|DEVICE|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
219237637|NCT04945044|BEHAVIORAL|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
219237638|NCT06335667|DIAGNOSTIC_TEST|mpMRI + Diagnostic TURBT|mpMRI in addition to the TURBT surgical procedure
219237639|NCT03701022|DRUG|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
219237640|NCT02147652|OTHER|Personalized music|
219165749|NCT00984321|BEHAVIORAL|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
219165750|NCT00984321|BEHAVIORAL|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
219165751|NCT00984321|BEHAVIORAL|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
219165752|NCT05807711|DRUG|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
219165753|NCT05733715|DRUG|Pembrolizumab infusion|100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
219165754|NCT05733715|DRUG|Lenvatinib tablet|10mg and 4mg daily for 21 days
219165755|NCT04022343|DRUG|Cabozantinib|Given PO
219165756|NCT04128904|PROCEDURE|IVF|"Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description."
219165757|NCT04128904|PROCEDURE|ICSI|"Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description."
219165758|NCT03055858|DEVICE|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
219165759|NCT04586920|DRUG|LY3509754|Administered orally
219165760|NCT04586920|DRUG|Placebo|Administered orally
219165761|NCT04586920|DRUG|Itraconazole|Administered orally
219165762|NCT04586920|DRUG|Midazolam|Administered orally
219165763|NCT03948490|DEVICE|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
219165764|NCT03948490|DEVICE|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
219165765|NCT03948490|BEHAVIORAL|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
219165766|NCT03948490|BEHAVIORAL|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
219165767|NCT05753410|BEHAVIORAL|Mindful Courage|Self-guided online intervention
219237641|NCT01396122|PROCEDURE|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
219237642|NCT04410445|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
219237643|NCT04410445|BIOLOGICAL|Nivolumab|Specified dose on specified days
219165768|NCT06188247|DEVICE|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
219237644|NCT02259959|DRUG|Single rising doses of BI 1744 CL, solution for oral inhalation|
219237645|NCT02259959|DRUG|Tiotropium, fixed dose, solution for oral inhalation|
219237646|NCT02259959|DRUG|Placebo|
219237647|NCT04944589|PROCEDURE|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
219237648|NCT02454647|DRUG|Induction chemotherapy|
219237649|NCT02454647|RADIATION|Radiotherapy with concurrent chemotherapy|
219237650|NCT02454647|PROCEDURE|Salvage surgery|
219237651|NCT00004662|DRUG|dehydroepiandrosterone|
219237652|NCT04502745|DEVICE|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
219237653|NCT03946345|DRUG|Iohexol Inj 300 MG/ML|"* Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
219237654|NCT01628263|OTHER|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
219237655|NCT02119572|BEHAVIORAL|peer support|
219237656|NCT02119572|OTHER|usual education lectures|
219237657|NCT02159456|OTHER|Continuous enteral feeding via infusion pump|
219237658|NCT02159456|OTHER|Intermittent enteral feeding via gravity-based infusion|
219237659|NCT00582855|DRUG|AQW051|
219237660|NCT00582855|DRUG|Placebo|
219237661|NCT01835847|DRUG|Tipepidine Hibenzate|
219237662|NCT01123356|DRUG|Ofatumumab|"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"
219237663|NCT01123356|DRUG|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
219237664|NCT01531699|DRUG|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
219237665|NCT01531699|OTHER|saline control|single application for up to 6 hours
219237666|NCT01531699|DRUG|Betadine ophthalmic prep solution|single application for up to 6 hours
219165769|NCT06786273|GENETIC|Small RNA sequencing|The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
219165770|NCT06783764|PROCEDURE|PECS II block and transverse thoracic plane block|will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
219165771|NCT06783764|PROCEDURE|Erector Spinae Plane Block|ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)
219165772|NCT06783764|DRUG|bupivacaine 0.25 % injection|injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
219165773|NCT06783764|DRUG|bupivacaine 0.25 % injection|30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
219165774|NCT06791902|DEVICE|Adaptive DBS|Adapting DBS stimulation based on locomotor states
219165775|NCT06349174|PROCEDURE|bronchoscopic lung volume reduction surgery using endobronchial valve|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
219165776|NCT06792591|DEVICE|PEM|Accuracy of PEM in detection of breast cancer
219165777|NCT06790576|OTHER|closed-loop-peak|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-peak (each pulse synchronized to person's peak of theta waveform)
219165778|NCT06790576|OTHER|Open-loop|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: open-loop (TMS pulse delivered without regard to EEG)
219165779|NCT06790576|OTHER|closed-loop-trough|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-trough (each pulse synchronized to trough of theta waveform)
219165780|NCT04788537|BEHAVIORAL|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
219165781|NCT00588185|DRUG|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
219165782|NCT06785662|DRUG|The budesonide nasal irrigation|The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
219165783|NCT06785662|DRUG|The budesonide nasal spray|The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
219165784|NCT06791629|DEVICE|Pulsed Field Ablation|Patients will be treated with pulsed field ablation for atrial fibrillation.
219165785|NCT06791629|DEVICE|Radiofrequency Ablation|Patients will be treated with radiofrequency ablation for atrial fibrillation.
219165786|NCT06627231|DRUG|TEV-56286|Oral capsule
219165787|NCT06627231|DRUG|[14C]-TEV-56286|Oral capsule
219165788|NCT06313827|BEHAVIORAL|Exercise plus Monitoring Group (TG-2)|Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
219165789|NCT06313827|BEHAVIORAL|Exercise plus monitoring and follow-up group (TGF-3)|"Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week."
219165790|NCT06313827|BEHAVIORAL|Exercise Group (CG-1)|Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
219165791|NCT05653674|BEHAVIORAL|Acceptance and commitment approach-based psychoeducation|The psychoeducation based on acceptance and commitment approach reducing psychological distress in nursing students; It has been prepared to increase psychological flexibility, mindfullness and level valuing. A potential approach that has been shown to be effective in reducing psychological distress is one of the third generation cognitive behavioral therapies; acceptance and commitment therapy. Acceptance and commitment-based approaches encourage participants to change their relationship with their thoughts and physical sensations through acceptance, mindfullness, and value-based action mechanisms.
219165792|NCT06799923|PROCEDURE|laser electrode|A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).
219165793|NCT06786442|OTHER|EFFACLAR DUO+M CREAM|twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)
219165794|NCT06788470|DRUG|MSC|Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
219165795|NCT06787456|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.
219165796|NCT06787456|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.
219165797|NCT06787456|OTHER|epidemiological information survey|epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.
219165798|NCT06787456|OTHER|Clinical examinations for high-risk participants|nasopharyngoscopy, head and neck MRI.
219165799|NCT06787456|OTHER|EBV and human genetic sequencing|EB virus and human genetic sequencing for plasma, etc.
219165800|NCT06447519|DRUG|Ca(OH)2 as intracanal medicament|Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
219165801|NCT02815813|BEHAVIORAL|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
219165802|NCT02815813|BEHAVIORAL|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
219165803|NCT06786871|PROCEDURE|IVF treatment|Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
219165804|NCT06782893|BEHAVIORAL|Non-pharmacological cough control therapy|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about chronic cough, introduction to cough suppression and goal setting. Session 2 will cover education about chronic cough in ILD, cough triggers and training in cough suppression techniques. Session 3 will focus on hydration techniques, laryngeal hygiene, and breathing exercises to control coughing. Session 4 will reinforce all aspects of non-pharmacological cough control treatment, and session 5 will explore the sustainability of cough control strategies after the program using real-life case scenarios.
219165805|NCT06782893|BEHAVIORAL|Healthy lifestyle|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about exercise and physical activity. Session 2 will cover education about diet. Session 3 will focus on stress management. Session 4 will cover relaxation techniques, and session 5 will reinforce all aspects previously considered.
219165806|NCT05568537|DRUG|Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)|Piflufolastat F18 will first be given intravenously over about 5 seconds.
219165807|NCT06799871|DEVICE|Dental implant|There is no intervention in the study. The participants have already received dental implant treatment and data will be collected retrospectively regarding the procedure
219165808|NCT06139081|OTHER|Oxygen delivery mode|After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
219165809|NCT03842826|DIAGNOSTIC_TEST|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
219165810|NCT01901094|PROCEDURE|Axillary Lymph Node Dissection (ALND)|
219165811|NCT01901094|RADIATION|Nodal Radiation Therapy|
219165812|NCT01901094|RADIATION|Axillary Radiation Therapy|
219165813|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
219743883|NCT01014312|BEHAVIORAL|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
219165814|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
219165815|NCT05135949|OTHER|Patient Reported Outcomes|Satisfaction, Disabilities of the Shoulder, Arm and Hand
219165816|NCT05135949|OTHER|Strength Test|Handheld dynamometer to measure tricep extension
219165817|NCT04255303|OTHER|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
219165818|NCT05212220|BEHAVIORAL|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
219165819|NCT05212220|BEHAVIORAL|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
219165820|NCT06072404|BIOLOGICAL|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
219165821|NCT02582125|DRUG|ONO-4538|
219743884|NCT01014312|BEHAVIORAL|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
219165822|NCT03995641|DRUG|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
219165823|NCT06422052|OTHER|Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）|H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
219743885|NCT02067598|OTHER|scapular exercise|
219743886|NCT03856918|PROCEDURE|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
219743887|NCT03856918|PROCEDURE|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
219743888|NCT03856918|PROCEDURE|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
219743889|NCT04083079|DRUG|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
219743890|NCT04083079|DRUG|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
219743891|NCT05487378|DIETARY_SUPPLEMENT|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
219743892|NCT04907084|DIETARY_SUPPLEMENT|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
219743893|NCT04907084|DRUG|Fenofibrate|Fenofibrate 160mg pill, taken orally
219743894|NCT06644352|PROCEDURE|different thoracic surgical approaches|Right Versus Left Thoracic Surgical Approaches
219743895|NCT05003336|DRUG|Xiangshao Granules|dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
219743896|NCT05003336|DRUG|Xiangshao Granules Placebo|Xiangshao Granules Placebo
219743897|NCT01509456|DIETARY_SUPPLEMENT|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
219743898|NCT03486470|DIAGNOSTIC_TEST|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
219743899|NCT01778621|DEVICE|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
219743900|NCT05212337|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
219743901|NCT05212337|DRUG|Sodium chloride|Subcutaneous injection with NaCl once
219743902|NCT06602817|OTHER|Exposure: prone position|Exposure: surgery in prone position
219743903|NCT06602817|OTHER|Exposure: Supine position|Exposure: Surgery in supine position
219743904|NCT04658368|PROCEDURE|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
219743905|NCT04658368|PROCEDURE|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
219743906|NCT03053362|DRUG|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
219743907|NCT03053362|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
219743908|NCT05553210|BEHAVIORAL|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
219743909|NCT06569433|PROCEDURE|THERAPEUTIC EXERCISE AND MOBILISATION OF THE FEMORAL NERVE|"the control group that will perform only therapeutic exercise will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist, while the intervention group that will perform therapeutic exercise plus femoral nerve mobilisation will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.~The intervention will last for 6 weeks, during which 60-minute sessions will be held at the centre, measurements will be taken during the six weeks, using standardised questionnaires to evaluate the variables (set out below) and always measuring the range of movement and femoral nerve mobility with the Slump Test on the same day of the week and at the same time of treatment."
219743910|NCT06603311|OTHER|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
219237667|NCT06502678|BIOLOGICAL|Fcr blocker of autoantibodies|in vitro assays, combined with multi-omics approach and in vitro experimental models, will gain insights into the pathogenesis of Systemic Sclerosis (SSc)dissecting the consequences of treatment with Fcblocker on functional and phenotypic cell behavior. Healthy microvascular endothelial cells, fibroblasts and monocytes will be challenged with serum and autoantibodies prior to or upon treatment with Efgartigimod in order to assess both the prevention and the recovery capacity of the FcR blocker. The putative modulatory effect of Efgartigimod on vascular remodeling, endothelial-to-mesenchymal transition, fibroblast-to-myofibroblasts transition and monocyte behavior will be evaluated in in-vitro consolidated assays. Integrated Omics analyses will support and complement the in vitro findings by unveiling potential prognostic signatures and by identifying specific treatment-related profiles that might guide the modulation of the drug usage in order to maximize its beneficial effect
219165824|NCT02485834|PROCEDURE|FDG-PET|
219165825|NCT02485834|PROCEDURE|surgery|
219165826|NCT02485834|DRUG|5-FU|200 mg/m\^2/day IV
219165827|NCT02485834|DRUG|capecitabine|oral 800 mg/m\^2 BID
219165828|NCT02485834|DRUG|docetaxel|30 mg/m\^2 IV
219165829|NCT02485834|DRUG|Irinotecan|50 mg/m\^2 IV
219165830|NCT02485834|RADIATION|3D-CRT|
219165831|NCT02485834|RADIATION|IMRT|
219165832|NCT04176783|DRUG|Opioids|narcotic pain medicine
219165833|NCT04176783|DRUG|Opioid-Free|non narcotoc pain medication
219165834|NCT06778824|DRUG|Takepron|Participants are expected to take a proton-pump inhibitor (PPI) for 12 weeks, with a dosage of 30 mg taken once a day.
219165835|NCT06778824|DRUG|Zoloft 50Mg Tablet|Participants are expected to take a selective serotonin reuptake inhibitor (SSRI) for 12 weeks, with a dosage of 50 mg taken once a day.
219165836|NCT06778824|DRUG|Imipramine Pill|Participants are expected to take tricyclic antidepressants (TCA) for 12 weeks, with a dosage of 25 mg taken twice a day.
219165837|NCT02669069|DEVICE|PS1|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
219165838|NCT02669069|DEVICE|PS2|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
219165839|NCT02669069|DEVICE|PS3|Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
219165840|NCT06444477|OTHER|ITP and cancer|ITP and cancer
219165841|NCT04899115|DRUG|Placebo|Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
219165842|NCT04899115|DRUG|VE303|"Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules."
219237668|NCT00110422|DRUG|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
219237669|NCT00110422|DRUG|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
219237670|NCT00110279|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
219237671|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
219237672|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
219237673|NCT03991325|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
219237674|NCT04201847|DIAGNOSTIC_TEST|Serum test|Serum Fetuin A and fetuin B
219237675|NCT02558322|OTHER|Primary medical care|All study participants receive primary care as usual in the respective region
219237676|NCT05480280|DRUG|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
219237677|NCT05480280|DRUG|Oxaliplatin injection|85mg/m², ivdrip, D1
219237678|NCT05480280|DRUG|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
219237679|NCT05480280|DRUG|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
219237680|NCT02662023|DRUG|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
219237681|NCT02662023|DRUG|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
219237682|NCT06023771|PROCEDURE|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
219165843|NCT04899115|DRUG|oral vancomycin|All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
219165844|NCT03139305|DRUG|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
219165845|NCT03139305|DRUG|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
219165846|NCT03139305|DRUG|Placebo|Intravenous infusion of saline for 72 hours
219165847|NCT05710900|OTHER|Dietary intervention|Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
219165848|NCT05286554|DRUG|gonadotropin releasing hormone-agonist|subcutaneous injection
219165849|NCT05286554|DRUG|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
219165850|NCT03311152|DIAGNOSTIC_TEST|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
219165851|NCT03697070|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
219165852|NCT03697070|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
219165853|NCT05548088|BIOLOGICAL|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6,3E6,6E6,1E7 cells/kg
219165854|NCT04383951|OTHER|Dietary consult for participants in the ketogenic diet arm|An initial consultation with the providers of medically supervised weight loss clinic will be arranged. Participants in the ketogenic diet group will be educated on the concepts of the diet and will be provided with recipes to be utilized at home that adhere to this diet. In addition to the initial consultation, participants in this arm receive additional consultations with these providers with a frequency as determined by the provider.
219165855|NCT04383951|OTHER|Dietary consult for participants in the standard of care arm|For participants in the standard of care arm, an initial consultation with the providers of medically supervised weight loss clinic will be arranged and the discussion will center around portion control using a balanced diet. Participants will receive only one additional consultation with the provider 16 weeks later just prior to the conclusion of the study.
219237683|NCT05719155|DRUG|CKD-379|1 tablet administration under fed condition
219237684|NCT05719155|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
219237685|NCT04394078|OTHER|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
219165856|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
219165857|NCT04913064|OTHER|Questionnaire Administration|Ancillary studies
219165858|NCT04913064|DRUG|White Button Mushroom Extract|Given PO
219165859|NCT06752317|DRUG|Dexamethasone|patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
219165860|NCT06752317|DRUG|Dexmedetomidine|patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
219165861|NCT06754397|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Three most important sequences included axial T2 weighted scan from liver to ampullary region followed by T2 weighted 3D FSE sequence acquired in coronal oblique plane using respiratory triggering by tying bellows over abdomen. After this breath hold HASTE sequence is acquired in coronal plane. Maximum intensity projection (MIP) and thick slab images are also used for interpretation. US, CECT and MRCP scans are interpreted by radiologists blinded to other imaging findings
219165862|NCT05635786|DRUG|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
219165863|NCT05635786|DRUG|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
219165864|NCT03029026|OTHER|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
219165865|NCT03029026|PROCEDURE|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
219165866|NCT03029026|PROCEDURE|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
219237686|NCT02674867|OTHER|Blood draw|
219165867|NCT03029026|RADIATION|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
219237687|NCT04332991|DRUG|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
219237688|NCT04332991|DRUG|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
219237689|NCT01684345|DRUG|Placebo|Solution for subcutaneous injection
219237690|NCT01684345|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
219165868|NCT03029026|PROCEDURE|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
219165869|NCT03029026|PROCEDURE|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
219165870|NCT03029026|OTHER|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
219165871|NCT06528444|DRUG|Grup 1 placebo|placebo 1 capsule (6 mg) /day for 7 days.
219165872|NCT06528444|DRUG|Grup 2 dexametasona|dexamethasone 1 capsule (6 mg)/day for 7 days
219165873|NCT06088732|OTHER|Exercise Session|30 min cycling on bicycle ergometer at 60% peak power output
219165874|NCT06088732|DRUG|Ibuprofen 800 mg|A single oral dose of Ibuprofen
219165875|NCT06088732|OTHER|Rest|Resting for 30 min in chair
219165876|NCT06088732|DRUG|Placebo|Matched placebo
219165877|NCT03379168|DEVICE|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
219165878|NCT03379168|DRUG|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
219165879|NCT03379168|DRUG|Saline|Sterile saline injection will act as a placebo group.
219165880|NCT03743636|DRUG|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
219165881|NCT03743636|DRUG|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
219237691|NCT01684345|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
219237692|NCT00000499|DRUG|chlorthalidone|
219237693|NCT00000499|DRUG|reserpine|
219237694|NCT00000499|DRUG|hydralazine|
219165882|NCT03743636|OTHER|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
219165883|NCT04502446|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
219237695|NCT00000499|DRUG|metoprolol|
219165884|NCT06546371|DEVICE|Spinal cord stimulator|Electrical stimulation of the dorsal horn to reduce chronic pain.
219165885|NCT05979584|DEVICE|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
219237696|NCT04043663|DEVICE|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
219237697|NCT04043663|PROCEDURE|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
219237698|NCT03382535|BEHAVIORAL|Voice therapy|Voice therapy with direct and indirect therapy elements.
219237699|NCT03382535|BEHAVIORAL|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
219237700|NCT03382535|OTHER|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
219237701|NCT02005484|DRUG|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
219165886|NCT05979584|DEVICE|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
219165887|NCT04582760|OTHER|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
219165888|NCT05128838|OTHER|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
219165889|NCT06772636|PROCEDURE|music group|In the music group, the music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
219165890|NCT06772636|PROCEDURE|non music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
219165891|NCT01938547|DRUG|clevidipine|
219165892|NCT05844332|OTHER|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
219165893|NCT05707897|DRUG|TS-142 10 mg|Single-dose of 10 mg of TS-142
219165894|NCT06774469|DEVICE|assigned|Group II: (Normal-US Group): The rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power, for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 30 days. Group V: (Osteoarthritis-US group) after two weeks of chemical induction of osteoarthritis, the rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 44 days.
219165895|NCT06774469|DRUG|Injection, Solution|"Group III: (Osteoarthritis-induced group): For studying the histological changes of the articular knee joint after osteoarthritis induction in the right knee joint before recovery occur. The patellar ligament will be palpated below the patella and a single intra-articular injection of (MIA lateral to the ligament using an insulin syringe will be performed).~The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL). Saline acts as a vehicle for MIA. The rats will be sacrificed after 14 days of MIA injection (1st day of the experiment).~Group IV: (Osteoarthritis-Recovery group): The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL), Saline acts as a vehicle for MIA and will not receive any medication. The rats will be sacrificed after 44 days of MIA injection (1st day of the experiment)."
219165896|NCT06774469|DEVICE|ultrasound|Group I:Sham Comparator (Control group): for studying the normal histological structure of the articular knee joint.
219165897|NCT04497012|DRUG|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
219165898|NCT04497012|DRUG|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
219165899|NCT06786949|OTHER|Questionnaire|All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer
219165900|NCT06786949|DIAGNOSTIC_TEST|Blood samples for biomarker measurement|Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample
219165901|NCT06785831|OTHER|Psyllium|Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.
219165902|NCT06785831|OTHER|Sauerkraut|Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.
219165903|NCT06785831|OTHER|Fresh apples|Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.
219165904|NCT06785831|OTHER|Dried apples|Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.
219165905|NCT04163536|DRUG|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
219165906|NCT04163536|DRUG|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
219165907|NCT06766253|DEVICE|GMA-TULIP|Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
219165908|NCT04547413|BEHAVIORAL|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
219165909|NCT00607776|DRUG|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
219165910|NCT00607776|DRUG|Systane|Drops
219237702|NCT01129011|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
219165911|NCT03564600|OTHER|Aging Back Clinics management|Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
219165912|NCT05839717|PROCEDURE|Blood sampling|A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
219165913|NCT05820477|BEHAVIORAL|FAMS-T1D|Behavioral FAMS-T1D FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.
219165914|NCT05820477|BEHAVIORAL|Digital resources for diabetes|Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
219237703|NCT01129011|DRUG|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
219237704|NCT02416973|DEVICE|Provant|
219165915|NCT05096767|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
219165916|NCT04474847|DRUG|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
219165917|NCT04474847|DRUG|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
219165918|NCT05038566|DEVICE|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
219237705|NCT03214055|DRUG|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
219237706|NCT01545271|DRUG|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
219237707|NCT01545271|DEVICE|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
219165919|NCT06793267|DRUG|Metoclopramide (Maxolon)|Participants will receive 0.15 mg/kg of metoclopramide administered intravenously. The drug will be diluted in 2 ml of solution prior to administration.
219165920|NCT06793267|DRUG|Saline|patients will recive normal saline 0.9% 2ml intravenous
219165921|NCT04970888|OTHER|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
219165922|NCT04970888|OTHER|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
219165923|NCT04970888|OTHER|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
219165924|NCT05438329|DRUG|DB-1305/BNT325|Administered Injection of Vein (I.V.)
219165925|NCT05438329|COMBINATION_PRODUCT|Pembrolizumab|Administered I.V.
219165926|NCT05438329|DRUG|BNT327|Administered I.V.
219165927|NCT04111458|DRUG|BI 1701963|Tablet
219165928|NCT04111458|DRUG|Trametinib|Tablet
219165929|NCT06796179|OTHER|Visible Light Exposure - Treated zones with sunscreen products|The treated zones with sunscreen products were exposed to Visible Light to induce skin pigmentation (144 J/cm²), 15 to 30 minutes after application.
219165930|NCT06796179|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219165931|NCT06792864|DEVICE|OsteoprintCR|Hybrid technique of 3D printed bone matrix based on polycaprolactone with tricalcium beta phosphate
219165932|NCT06792864|DEVICE|SMAR SET GMV Endurance Gentamicin|"Patient undergoing cranioplasty with conventional technique using polymethylmethylmethacrylate-based surgical cement brand SMAR SET GMV Endurance Gentamicin."
219165933|NCT06839404|DRUG|fluid challenge|Fluid bolus of 500 mL of crystalloids given at a constant rate between 10 and 15 minutes
219165934|NCT06832072|OTHER|MR-BLS|In MR group, students attended a 32 minutes course, in groups of four students with one teacher. The course included 22 minutes of individual MR training using headset (HTC Vive Focus 3®) and 10 minutes of debriefing. The individual MR training contained a step-by-step BLS reminder, including chest compression practice. Then, students engaged in a standardized virtual scenario where they interacted with both virtual characters and a physical manikin torso. The headset overlaid digital elements onto the real world, allowing the students to perform BLS while receiving real-time feedback. The feedback system provided visual cues indicating whether their chest compression rate and depth were correct. The teacher-to-student ratio was 1:4
219165935|NCT03749421|OTHER|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
219165936|NCT06794242|OTHER|Body representation|All the participants (controls and patients) in the study will follow the same experimental procedure, which consists of a single virtual reality session involving the estimation of leg length and an object.
219165937|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs alone (20 g of protein equivalent)|cGMP-AAs alone (20 g of protein equivalent)
219165938|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
219165939|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
219165941|NCT06796478|OTHER|Tailored Egoscue Excercises|A. Elbow curls on the wall with abduction B. Elbow curls on the wall with adduction C. Overhead extension D. Open Up arm and chest E. Upper spinal twist. F. Spinal Twist G. Pelvic tilts H. Static back alone and static back with breathing I. Static wall. J. Air Bench Abdominal contraction in the static back position. K. Resisted Abduction L. Abductor press M. Supine groin progression
219165942|NCT06796478|OTHER|Core stabilization excercises|A. Cat Pose \& Camel pose B. Pelvic tilt C. Hip flexor stretches D. Hamstring stretches E. Piriformis stretch F. Prone on elbow
219165943|NCT06839508|OTHER|Radio chemotherapy|The task involves identifying similarities in biopsy samples (prior to radio-chemotherapy treatment) to predict a hypothetical complete response.
219165944|NCT06839781|OTHER|Retirement education|This initiative is structured as a six-week training program designed to support individuals in adapting to the retirement process. By addressing various aspects of retirement, the program aims to ensure that participants transition into this phase of life in a well-prepared and informed manner. The first week will serve as an introduction, providing general information and initiating physical transition training. The second week will focus on health protection and development training. The third week will address social transition training. The fourth week will be dedicated to spiritual transition training. The fifth week will focus on financial transition training. The sixth and final week will bring together previously retired individuals and current participants. This program adopts a holistic approach, aiming to facilitate both the physical and psychosocial adaptation of individuals to the retirement process.
219165945|NCT04188327|PROCEDURE|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
219165946|NCT04188327|PROCEDURE|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
219165947|NCT06322381|PROCEDURE|Reinsertion achilles tendon|Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.
219165948|NCT06322381|PROCEDURE|Zadek osteotomy|lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
219165949|NCT06241209|OTHER|PowerPoint program visual stimulation|Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
219165950|NCT06839313|DRUG|Kenacort A Orabase® pomad , Bristol-Myers Squibb İlaçları Inc. İstanbul , Türkiye|Apply to the injured area 4 times a day
219165951|NCT06839313|COMBINATION_PRODUCT|Hyaluronic acid, Aftamed ® Oral jel , AktiFarma . İstanbul, Türkiye|Apply to the injured area 4 times a day
219165952|NCT06839313|COMBINATION_PRODUCT|St. John's wort oil, Zade Vital; Health&Fitness, Developed With Ege Üniversiesi Argefar|Apply to the injured area 4 times a day
219165953|NCT06796569|DIAGNOSTIC_TEST|systemic immune inflammatory index|Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.
219165954|NCT06833866|DRUG|Hydroxytyrosol|"Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression.~The prescribed FOLFIRI/FOLFOX administer as: Irinotecan 180 mg/m² intravenously (IV) over 90 minutes concurrently with Leucovorin 400 mg/m² IV over 120 minutes, followed by Fluorouracil 400-500 mg/m² IV bolus then 2400-3000 mg/m² IV infusion over 4-6 hours with or without, the designated Biologics, a standard dose of Cetuximab or Bevacizumab will be administered in 2-week cycles until disease progression or un-tolerated toxicity"
219165955|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
219165956|NCT06791941|BIOLOGICAL|Culture of organoids|Culture of organoids prepared from both the primary tumor and the respective relapse, using the material from the prospective part of the study, the response to treatment will be carried out by macroscopic analysis, evaluating the size and number of organoids before and after treatment,
219165957|NCT06837376|OTHER|Education|One 45 minute educational session on the role of carbohydrate in exercise
219165958|NCT06837376|OTHER|Metabolic Testing (Exercise) with shared interpreted results|One 20-30 minute session. Treadmill, warm-up, then at increasing intensities for 3-minute intervals wearing a mouthpiece for measurement of respiratory gasses (oxygen consumption, carbon dioxide production). Testing starts with a 3-minute warm-up at 3.4 mph, 1% grade, increasing every 3 minutes until a respiratory exchange ratio of 1.0 is reached or volitional exhaustion
219165959|NCT04626596|COMBINATION_PRODUCT|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
219165960|NCT06795425|DIETARY_SUPPLEMENT|Postbiotic Active Lifestyle Blend|The active intervention, Postbiotic Active Lifestyle Blend, containing a heat-treated blend of bacterial strains; 2 capsules per day.
219165961|NCT06795425|OTHER|Placebo|The placebo intervention contains no active ingredients and consists of maltodextrin as an inactive ingredient. The capsule matches the appearance and dosage form of the active intervention.
219165962|NCT06790472|BEHAVIORAL|Online Lifestyle Intervention|The Metabolic Wellness Program (MWP) is an established 8-week program that provides participants with health education videos and webinars that focus on evidence-based nutrition, fitness, sleep, and stress intervention, including with CGM, allowing participants to monitor their real-time glucose data and to learn which lifestyle choices are best for their glycemic control and personal metabolic health. The program is also intended to help healthy participants maintain their metabolic health and lower their potential risk of developing cardiometabolic disease, as well as at-risk and pre-diabetic participants preventing the progression to T2D and people with established T2D reverse their condition.
219165963|NCT06790472|DEVICE|Continuous Glucose Monitoring|"CGM measurements begin at enrollment with training provided digitally Participants will be asked to live life as usual whilst wearing the device with initial 10-14 day readings providing baseline data. Participants will participate in the online lifestyle program, which the investigators refer to as the intervention stage. Participants will also receive questionnaires on behavior change at the beginning of week 5. During the final two weeks of the program (weeks 7-8), the final 10-14 days of CGM will be used as comparison data with baseline information."
219165964|NCT06797648|OTHER|data analysis|follow up after 15 months
219165965|NCT06840938|BEHAVIORAL|physiological maneuver|Group A will be subjected to physiological and postural trainings (traditional)
219165966|NCT06840938|DEVICE|Surface Electrical Stimulation|Group B will be subjected to Surface Electrical Stimulation through the use of electrodes and stimulators.
219165967|NCT06840938|COMBINATION_PRODUCT|Surface Electrical Stimulation|Group C will be subjected to both physiological and Surface Electrical Stimulation supports.
219165968|NCT04020978|DIAGNOSTIC_TEST|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
219165969|NCT04172506|DRUG|AK105|Anti-PD-1 antibody
219165970|NCT05870995|DRUG|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
219165971|NCT06645379|OTHER|Platelet-Rich Plasma (PRP) Injections|Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
219165972|NCT06813079|DRUG|Cobimetinib|"Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway.~Participants will take cobimetinib by mouth (orally), once a day on days 1 to 21 followed by a 7-day break of each cycle. A cycle will be 28 days in length."
219165973|NCT06813079|DRUG|Ponatinib|"Ponatinib is a type of drug called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that act as chemical messengers to stimulate cancer cells to grow. Ponatinib blocks and interferes with a number of protein kinases. It is called a multi kinase inhibitor.~Participants will take ponatinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days."
219165974|NCT06813079|DRUG|Brigatinib|"Brigatinib is a type of cancer growth blockers called a tyrosine kinase inhibitor (TKI). It blocks chemical signals (enzymes) from tyrosine kinase proteins. Tyrosine kinases help to send growth signals in cells, so blocking them stops the cell growing and dividing.~Participants will take brigatinib by mouth (orally), once a day for the first 7 days. If participants are able to tolerate the dose during the first 7 days, they will take the doubled dose orally, once a day until end of the cycle (day 8 to day 28). Each cycle will be 28 days in length."
219165975|NCT06813079|DRUG|Colchicine|"Colchicine is an alkaloid that affects the way the body responds to uric acid crystals, and reduces swelling and pain.~On the first day, participants will take two tablets of colchicine by mouth (orally), then one tablet orally one hour later. Starting the second day, participants will take one tablet of colchicine once or twice a day, every day of each cycle. A cycle will be 28 days in length. The study doctor will decide whether participants will take colchicine once or twice a day."
219165976|NCT06813079|DRUG|Selinexor|"Selinexor blocks a protein called CRM1, a protein within the cell, and may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor.~Participants will take selinexor by mouth (orally), once a week on days 1, 8, 15, and 22 of each cycle. A cycle will be 28 days in length."
219237708|NCT03889327|BEHAVIORAL|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
219237709|NCT03889327|BEHAVIORAL|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
219165977|NCT06813079|DRUG|Abemaciclib|"Abemaciclib belongs to a class of medications called kinase inhibitors. Abemaciclib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.~Participants will take abemaciclib by mouth (orally), twice a day, every day of each cycle. A cycle will be 28 days in length."
219165978|NCT06813079|DRUG|Neratinib|"Neratinib is a targeted cancer drug that works on a protein called human epidermal growth factor receptor 2 (HER2). HER2 proteins make cells divide and grow. Some cancers have large amounts of HER2 proteins which can cause cancer cells to divide and grow faster. Neratinib works by locking onto the HER2 on the cancer cells. So it stops the cells from growing.~Participants will take neratinib by mouth (orally), once a day, every day of each cycle. Dose will increase weekly, until week 3. On week 3 and onward, participants will take the same dose. A cycle will be 28 days in length."
219165979|NCT06813079|DRUG|Doxorubicin|"Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2. Cancer cells need this enzyme to divide and grow.~Participants will receive doxorubicin by vein (intravenous infusion or IV) in clinic, over 60-90 minutes, once every cycle. A cycle will be 21 days in length. Participants may receive 6-8 cycles of study drug."
219165980|NCT06813079|DRUG|Etoposide|"Etoposide is a chemotherapy drug that destroys quickly dividing cells, such as cancer cells.~Participants will receive etoposide by mouth (orally), twice a day, on days 1 to 7 of every cycle. On days 8 to 21, there will be no dosing. A cycle will be 21 days in length."
219165981|NCT06813079|DRUG|Ceritinib|"Ceritinib is a tyrosine kinase inhibitor. It works by blocking an enzyme called anaplastic lymphoma kinase (ALK). Ceritinib only works in cancer cells that have an overactive version of ALK.~Participants will take ceritinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days in length."
219165982|NCT05597176|OTHER|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
219165983|NCT05414136|DRUG|BAT1006|Intravenous fluids
219165984|NCT04745299|BIOLOGICAL|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
219165985|NCT04745299|DRUG|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
219165986|NCT04745299|DRUG|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
219165987|NCT06636058|BEHAVIORAL|vCare Intervention (6-month active treatment followed by 6-month maintenance)|"During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks."
219165988|NCT06636058|BEHAVIORAL|vCare Intervention (active treatment after 6 months)|During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
219165989|NCT06636227|DRUG|Diclofenac 100mg|Diclofenac 100mg
219165990|NCT06636227|DRUG|Diclofenac 75mg|Diclofenac 75mg
219165991|NCT06636227|DRUG|Diclofenac 50mg|Diclofenac 50mg
219165992|NCT06636227|DRUG|Placebo control|Placebo control
219165993|NCT06837467|DIAGNOSTIC_TEST|Immunohistochemistry (IHC)|We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
219165994|NCT06795204|DRUG|HSK3486|Study Drug
219165995|NCT06795204|DRUG|Moxifloxacin Hydrochloride|Positive Control
219165996|NCT06795204|DRUG|Placebo|Negative Control
219165997|NCT06237426|DRUG|Methylone|A course of treatment includes 4 weekly doses of TSND-201.
219237710|NCT03012321|DRUG|Olaparib|
219237711|NCT03012321|DRUG|Abiraterone Acetate|
219237712|NCT03012321|DRUG|Prednisone|
219165998|NCT06797479|PROCEDURE|Blood samples for the analysis of sildenafil in plasma|To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
219165999|NCT04249947|BIOLOGICAL|P-PSMA-101 CAR-T cells|P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).
219166000|NCT04249947|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated
219166001|NCT06510907|BEHAVIORAL|mindfulness based stress reduction program|"Mindfulness training will be delivered through a generic 8-week MBSR. The MBSR will consist of weekly 2-hour classes, in which the techniques to various meditations (e.g., body scan, mindful awareness of breathing, body, sounds, thoughts, emotions, and mindful movements) will be taught and discussed. Participants will be asked to meditate for ≥40 minutes every day during the 8-week program as homework. Besides cultivating attention control and a non-judgemental stance to experience, psychoeducation about psychological stress and stress response will also be discussed during the MBSR classes. The MBSR teacher will discuss any difficulties encountered during homework meditations in every class to enhance adherence.~Each MBSR class can have up to 25 participants. The 8-week program will be taught by a qualified MBSR teacher"
219166002|NCT06830694|DRUG|Atezolizumab, Etoposide, Carboplatin, Tarlatamab|Cycle 1\~4 : Atezolizumab 1200 mg IV, carboplatin AUC 5.0 IV, Etoposide 100 mg/m2 IV Cycle 5\~ : Atezolizumab 1200 mg IV, Tarlatamab 1 or 10mg IV
219166003|NCT02404896|DRUG|Metreleptin|Metreleptin open-label treatment
219166004|NCT06827158|OTHER|validity and reliability of the Turkish version of the Dexterity Questionnaire 24 (DextQ-24|"Permission for the Turkish translation and validation of the DextQ-24 questionnaire was obtained from its developer, Tim Vanbellingen. The original English version will be translated into Turkish by two independent translators and then back into English by two native English speakers. After review, the finalized version will be used in the study.~Patients diagnosed with Parkinson's disease (aged 40-80) will complete consent and demographic forms. The Mini-Mental State Examination (MMSE) will exclude those scoring ≤24. Disease staging will follow the Hoehn and Yahr Scale (stages I-IV included). The MDS-UPDRS (sections II and III) will assess disease severity, while the Nine-Hole Peg Test and Hand Dexterity Scale-36 will evaluate hand function. Participants will complete the Turkish DextQ-24, with 30 randomly selected patients retaking it after two weeks for reliability testing. Data collection per participant will take approximately 30 minutes."
219166005|NCT05577858|OTHER|Meat based|Omnivorous diet following dietary guidelines
219166006|NCT05577858|OTHER|Pulse based|Lacto-ovo-vegetarian pulse-based diet following dietary guidelines
219166007|NCT06537739|OTHER|Lumbar manipulation|Participant lies in the supine position, a physiotherapist faces the participant's side that will be manipulated. The participant interlocks their fingers behind their neck. Then the physiotherapist turns the participant on their side and performs a short thrust across the participant's pelvis in a posterior and inferior direction. The manipulation will be carried out on the symptomatic side, based on the participant's indication of the painful side. If the participant is unable to indicate the more symptomatic side, the physiotherapist performing the procedure will select the side. If no audible cavitation occurs during the manipulation, the physiotherapist will attempt to manipulate the opposite side. A maximum of 2 attempts per side will be allowed.
219166008|NCT06537739|OTHER|Positive communication - placebo|"Participants from Group A who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is a very effective method of treating spinal disorders, which will significantly reduce the low back pain you are experiencing (positive communication - placebo)."
219166009|NCT06537739|OTHER|Negative communication - nocebo|"Participants form Group B who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is not an effective method of treating spinal disorders, thus it may temporarily increase the low back pain you are experiencing (negative communication - nocebo)."
219166010|NCT06537739|OTHER|Neutral communication|"Participants from Group C who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation has not been verified for its effectiveness in affecting your level of low back pain (neutral communication)."
219166011|NCT02387853|DRUG|LEO 90100|
219166012|NCT06061965|BEHAVIORAL|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
219166013|NCT06821503|DRUG|LM-108 injection|LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.
219166014|NCT06821503|DRUG|Penpulimab injection|Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.
219166015|NCT06821503|DRUG|Paclitaxel for injection (albumin bound)|Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug
219166016|NCT06821503|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.
219166017|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
219166018|NCT04517903|OTHER|eye rubbing questionnaire|eye rubbing questionnaire at baseline and 15 days later for exploratory phase; at baseline and then validation by a Group Nominal
219166019|NCT03729180|PROCEDURE|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
219166020|NCT03729180|DIAGNOSTIC_TEST|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
219166021|NCT03729180|OTHER|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
219166022|NCT05959733|PROCEDURE|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
219166023|NCT05959733|PROCEDURE|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
219166024|NCT04716634|DRUG|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
219166025|NCT04716634|DRUG|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
219166026|NCT04140721|DRUG|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
219166027|NCT04140721|DRUG|Moxonidine Pill|Moxonidine pill administered for 4 weeks
219166028|NCT05134779|PROCEDURE|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
219166029|NCT04942431|BEHAVIORAL|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
219166030|NCT06793059|DEVICE|SHIELD|Pipeline SHIELD device under study
219166031|NCT06795971|DEVICE|Continuous Positive Airway Pressure|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was delivered to the patient through a face mask connected to an ICU ventilator.~2. PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. PEEP and FiO2 were titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. CPAP was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
219166032|NCT06795971|DEVICE|High-flow nasal oxygen|"1. Oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 50 liters per minute and an FiO2 of 0.5 at initiation. HFNO heating temperature was prespecified at 37°C.~2. FiO2 will be titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. HFNO was applied for at least 2 calendar days."
219237713|NCT02325752|OTHER|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
219166033|NCT06795971|DEVICE|Non-invasive ventilation|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was also delivered to the patient through a face mask connected to an ICU ventilator. The mask most appropriate for the patient will be selected and adjusted to minimize leakage and pressure points.~2. The inspiratory positive airway pressure (pressure support plus PEEP) was initiated between 12 and 14 cm H2O, PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. FiO2 was titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. NIV was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
219166034|NCT06789952|BEHAVIORAL|Mindfulness-Based Stress Reduction|"MBSR is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. It is a practice that is embedded in mind/body and integrative medicine, it combines formal and informal practices of mindfulness.~The formal practices include body scanning, gentle hatha yoga - movements, sitting meditation and walking, meditation. Informal practices include mindfulness of daily activities, such as eating, driving, washing dishes, showering, etc. A variety of other exercises will be used as a support for developing proficiency in the practice of mindfulness. This class places strong emphasis on experiential learning. Each session will include:~* guided instruction while engaging in practices of mindfulness~* opportunity to reflect on experiences and ask questions~* discussion of topics related to the practice of mindfulness as a strategy for reducing stress"
219166035|NCT06789952|BEHAVIORAL|Lifestyle Intervention|"The lifestyle sessions will include the following topics:~Movement -passive stretches and dynamic stretches, cardio HIIT exercise, flexibility and strength, and core and balance.~Nutrition Body - Include healthy eating with whole, clean, and nutritionally balanced meals; menu planning/prepping, snacking and noticing cravings and feelings of fullness or satiety.~Sleep - Include routine for evening, and morning for optimal sleep, logging routines and quality of sleep, tools to aid in falling asleep, and returning to sleep during the night, eating and sleep patterns Nature/Culture/Arts (with Kemper Museum of Contemporary Art - which will also take place during ½ day retreat) includes spending time in nature and journal experiences, reconnecting with the sun, and surround self with nature.~Financial - Focus on financial wellbeing, budgets/adjustments to budgets, and buying/spending patterns.~Cooking - Include healthy foods, smoothies, juices, kitchen appliances."
219166036|NCT06787677|PROCEDURE|PRF|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the PRF group received PRF treatment in automatic mode for 360 s, at a maximum of 42°C, pulse frequency of 2 Hz, and pulse width of 20 ms.
219166037|NCT06787677|PROCEDURE|NB|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the NB group received nerve block with a mixture of 40 mg of triamcinolone and 2 ml of 0.75% bupivacaine with 2 ml of normal saline and 1:100000 epinephrine.
219166038|NCT03096054|DRUG|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
219166039|NCT02959229|DRUG|Lactoferrin|
219166040|NCT02959229|DRUG|Placebo (for Lactoferrin)|placebo in form of distilled water
219166041|NCT02839291|OTHER|quality of life questionaries|
219166042|NCT02839291|DRUG|intravenous or oral bone antiresorptive treatments|
219166043|NCT05265000|DEVICE|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
219166044|NCT02793687|DRUG|Mexidol|50 mg/ml IV solution, 125 mg tablet
219166045|NCT02793687|OTHER|Placebo|Placebo IV solution, Placebo tablet
219166046|NCT05550324|PROCEDURE|Blood draw|One time intravenous blood draw
219166047|NCT06451354|OTHER|Erector spinae plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
219166048|NCT06451354|OTHER|Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
219166049|NCT06451354|OTHER|Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
219166050|NCT03467542|DEVICE|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
219166051|NCT06429618|DIETARY_SUPPLEMENT|Low carbonhydrate diet|Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
219166052|NCT03022656|DEVICE|Active Brace system|
219166053|NCT04077762|PROCEDURE|Radial Access|Radial Access
219166054|NCT04077762|PROCEDURE|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
219166055|NCT04077762|PROCEDURE|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
219166056|NCT05421390|OTHER|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
219237714|NCT05256836|OTHER|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
219237715|NCT01074099|BIOLOGICAL|BMAC|Injection of BMAC into ischemic myocardium during CABG
219237716|NCT01074099|PROCEDURE|CABG only|Control subjects will undergo CABG surgery without BMAC injection
219166057|NCT05421390|OTHER|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
219166058|NCT05739825|OTHER|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
219166059|NCT04271358|BEHAVIORAL|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
219166060|NCT04905446|OTHER|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
219166061|NCT04905446|PROCEDURE|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
219166062|NCT04905446|PROCEDURE|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
219237717|NCT00358722|DRUG|Fermagate|Film coated tablet 500mg
219166063|NCT03323463|DIAGNOSTIC_TEST|F-FMISO PET/CT Scan|All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
219166064|NCT03323463|RADIATION|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
219166065|NCT03323463|DRUG|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
219166066|NCT03323463|DRUG|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
219166067|NCT03323463|DRUG|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
219166068|NCT03323463|RADIATION|Proton Therapy|Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
219166069|NCT04925388|OTHER|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
219166070|NCT04925388|OTHER|conventional method analysis|peritoneal samples will be analysed using conventional method
219166071|NCT06738147|OTHER|pelvic floor muscle training|pelvic floor muscle training (PFMT) for 30 min., 3 sessions/ week in addition to traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
219166072|NCT06738147|OTHER|balance exercises|traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
219166073|NCT06737198|OTHER|without interventios.|without interventios.
219166074|NCT06554951|OTHER|Patients who are candidates for CAR-T cell therapy for hematologic malignancy|This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
219166075|NCT04452877|DRUG|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
219166076|NCT04452877|DRUG|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
219166077|NCT04523376|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
219166078|NCT05805384|DEVICE|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
219166079|NCT06391177|DRUG|Vonoprazan|Oral tablet.
219166080|NCT04547686|BEHAVIORAL|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
219237718|NCT02395588|OTHER|Guideline based care|Patient education using guideline based teaching guides
219237719|NCT01113541|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
219237720|NCT03745651|DRUG|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
219237721|NCT03745651|DRUG|Vehicle cream|Ruxolitinib matching vehicle cream.
219237722|NCT04272099|OTHER|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
219237723|NCT04272099|DEVICE|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
219237724|NCT04272099|OTHER|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
219237725|NCT03516071|DRUG|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
219237726|NCT03516071|DRUG|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
219237727|NCT01230359|DIETARY_SUPPLEMENT|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
219237728|NCT01230359|OTHER|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
219237729|NCT05344209|BIOLOGICAL|UV1|UV1 vaccine
219237730|NCT05344209|DRUG|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
219237731|NCT05344209|DRUG|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
219237732|NCT01494467|DRUG|CD5024|CD5024 1% Cream, once daily
219237733|NCT01494467|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
219237734|NCT04957277|OTHER|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
219237735|NCT00872859|PROCEDURE|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
219237736|NCT03743688|BIOLOGICAL|Influenza Vaccine Recipients|0.5 mL intramuscular injection
219237737|NCT02309892|DRUG|L-DOS47|A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
219166081|NCT04547686|BEHAVIORAL|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
219166082|NCT04836728|BIOLOGICAL|CIK cells injection|CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion, d14, Q3W.
219166083|NCT04836728|DRUG|Sintilimab Injection|200 mg, intravenous infusion, d1, every 3 weeks
219166084|NCT04836728|DRUG|Pemetrexed|500 mg/m\^2, intravenous infusion, d1, every 3 weeks
219166085|NCT04836728|DRUG|Albumin paclitaxel|260 mg/m\^2, intravenous infusion, d1, every 3 weeks
219166086|NCT04836728|DRUG|Carboplatin|AUC 5, intravenous infusion, d1, every 3 weeks
219166087|NCT04676373|DRUG|ALGLUCOSIDASE ALFA|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
219166088|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Enhanced)|Interactive routine is based on tailoring to the participants type of pain and personality.
219166089|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Standard)|Interactive routine is a basic interaction with the voice assistant.
219166090|NCT03679611|DRUG|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
219166091|NCT03679611|DRUG|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
219166092|NCT02395367|PROCEDURE|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
219166093|NCT02395367|RADIATION|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
219166094|NCT02395367|DRUG|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
219166095|NCT03764137|DRUG|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
219166096|NCT03237702|DIETARY_SUPPLEMENT|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
219166097|NCT05268094|DEVICE|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
219237738|NCT02861716|DRUG|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
219166098|NCT05268094|PROCEDURE|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
219166099|NCT06261346|PROCEDURE|Endothelial keratoplasty|"Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes."
219166100|NCT06261346|BIOLOGICAL|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~PRGF incubation lasts 15 minutes. It is a one-time procedure performed on the tissue that will be done in the operating room prior to endothelial keratoplasty."
219166101|NCT06781658|OTHER|Structured rehabilitation intervention|Participants will be prescribed a multi-component SRI which will include education, cervical range of motion exercises, progressive neck strengthening exercises, individualised scapular and upper limb strengthening, task specific hand function training and a physical activity behavioural change intervention. The TIDieR checklist has been used to provide a comprehensive description of this complex intervention. (17).
219166102|NCT06781658|OTHER|Clinical Surveillance|Participants assigned to the clinical surveillance control group will be invited to attend a single, one to one education session which will be supplemented with a written patient information booklet after which they will be scheduled for a 12 week follow up.
219166103|NCT03992664|OTHER|Educational training program|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
219166104|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
219166105|NCT04578171|DRUG|Mepolizumab|100 mg subcutaneous injections every four weeks
219166106|NCT03444701|DRUG|E7130|Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
219237739|NCT02861716|DRUG|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
219166107|NCT03444701|DRUG|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
219166108|NCT05482789|DRUG|Exenatide|10 microgram injected sub-cutaneously once
219166109|NCT06139172|BEHAVIORAL|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
219166110|NCT06139172|OTHER|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
219166111|NCT03793465|DIETARY_SUPPLEMENT|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
219166112|NCT04272619|BEHAVIORAL|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
219166113|NCT04495452|DRUG|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
219166114|NCT04496960|DRUG|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
219166115|NCT04496960|OTHER|Placebo|white, round, film-coated tablet
219166116|NCT05078619|PROCEDURE|No PCI|Omission of PCI of significant coronary artery disease prior to TAVI
219166117|NCT05840809|DRUG|First line tuberculosis treatment|This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
219166118|NCT03089398|PROCEDURE|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
219166119|NCT03089398|DEVICE|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
219166120|NCT03089398|DEVICE|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
219166121|NCT02519452|DRUG|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
219166122|NCT02519452|DRUG|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
219166123|NCT06844149|BEHAVIORAL|CPR; (Cardiac and Psychosocial Rehabilitation) with Cardiac Rehabilitation|This intervention combines an 8-week Cognitive Behavioral Therapy (CBT)-based psychosocial rehabilitation program with a structured Home-Based Cardiac Rehabilitation (CR) program for young adults with Fontan circulation. The CBT component includes weekly 90-minute group sessions focusing on stress management, cognitive restructuring, and social coping skills. The CR component consists of a personalized aerobic exercise plan, starting at 15-30 minutes per session and progressing to 40-60 minutes, with weekly monitoring and adjustments. This combined intervention is provided exclusively to participants in the CPR group
219166124|NCT06844149|BEHAVIORAL|CR; Home-Based Cardiac Rehabilitation|This intervention consists of an 8-week Home-Based Cardiac Rehabilitation (CR) program designed for young adults with Fontan circulation. Participants follow a structured aerobic exercise plan tailored to their cardiopulmonary fitness levels. The program starts with 15-30 minutes of exercise per session, progressing to 40-60 minutes, with intensity set at 60-70% of maximum heart rate. Exercise adherence is monitored through weekly follow-ups, with adjustments made as needed. This intervention is provided to participants in both the CR group and the CPR group but without the Cognitive Behavioral Therapy (CBT) component in the CR-only group.
219166125|NCT06844149|BEHAVIORAL|Usual Care|Participants in the control group received usual care without any additional interventions. They did not participate in the Cognitive Behavioral Therapy (CBT)-Based Psychosocial Rehabilitation or the Home-Based Cardiac Rehabilitation (CR) programs during the study period. After the study was completed, they were given the option to enroll in the CPR program. This group serves as a comparison to evaluate the effectiveness of the interventions in the CPR and CR groups
219166126|NCT06847061|BEHAVIORAL|Pulmonary rehabilitation program|"Participants are expected to engage in the home-based pulmonary rehabilitation routine at least 24 minutes a day, five to six days a week for the entire 12-week study period.~The pulmonary rehabilitation routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time again is 24 minutes, followed by a 4-minute mindful breathing meditation/cool down"
219166127|NCT06074614|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
219166128|NCT06074614|DIAGNOSTIC_TEST|Respiratory related evoked potential|The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
219166129|NCT06074614|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
219166130|NCT05062265|DEVICE|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
219166131|NCT05062265|DEVICE|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
219166132|NCT04626037|BEHAVIORAL|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
219166133|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
219166134|NCT06400433|PROCEDURE|Ultrasound-guided median nerve hydrodissection|Injected wrist will be supinated and slightly dorsiflexed. The transducer of the ultrasound will be placed transversely at the proximal carpal inlet. After sterile preparation, a 22 gauge needle will be inserted using the short-axis technique, in-plane ulnar approach. During hydrodissection, separation of either between the median nerve and flexor retinaculum or between the median nerve and the underlying flexor tendons will be visually confirmed.
219237740|NCT02861716|DRUG|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
219237741|NCT03262389|DRUG|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
219237742|NCT03262389|DRUG|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
219166135|NCT06846060|BEHAVIORAL|Mindfulness-Based Self-Compassion Program|Mindfulness-based intervention programs are a program that includes a special session in which body and mind are integrated, and consists of homework for participants on yoga, meditation and a mindfulness-based approach to vital events in order to be aware of the moment. The conscious awareness-based self-compassion program, created in line with the literature, consists of 8 sessions in total, in groups of 5-8 people, on the same day and time every week. There are specific goals and objectives for each session, and each session also has a separate theme along with its subject.
219166136|NCT05677334|DRUG|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
219166137|NCT05677334|DEVICE|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
219166138|NCT06388590|OTHER|Dragons|The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.
219166139|NCT06388590|OTHER|Standard of Care|Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
219166140|NCT04905537|OTHER|No intervention|It's only observational study. No interventions.
219166141|NCT06848049|OTHER|Mobile Aplication|In this study, individuals will be monitored for 28 days. They will be asked to fill out the Pressure Injury Information Form and the Pressure Injury Skills Checklist for Caregivers to be informed about pressures throughout the study process. The researcher will fill out the Bates-Jensen Wound Assessment Tool to ensure that their pressures are improving. Individuals who will undergo the intervention will use the mobile application. Face-to-face training will be provided to individuals. Individual-specific audio reminders will be based on daily living activities and will be delivered via the mobile application according to changes in individual dependencies. After 30 days, individuals will be asked to fill out the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist. The Bates-Jensen Wound Assessment Tool will be filled out by the researcher.
219166142|NCT06848049|OTHER|Control|In this study, individuals will be monitored for 28 days. In order to monitor their knowledge about pressure injuries, individuals will be asked to complete the Pressure Injury Information Form for Caregivers and the Pressure Injury Skills Checklist to monitor their skill levels about pressure injuries throughout the study period. The Bates-Jensen Wound Assessment Tool will be completed by the researcher to perform a physical examination of the patient and to assess the healing of the individual's pressure injury. Individuals in the control group will be interviewed twice by phone. Individuals with pressure injuries will be trained by a team consisting of a physician, nurse, dietician, and physiotherapist. Individuals will be interviewed twice by phone. After 30 days, individuals will be asked to complete the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist.
219166143|NCT06846619|DEVICE|Intra-Oral Scanning Method|"Intervention Description:~The intra-oral scanning method involves capturing digital impressions of the oral cavity directly using the 3Shape scanner. This method eliminates the need for traditional impression materials, providing a more comfortable and precise imaging process. The digital impressions are then utilized to design and fabricate maxillary dentures using 3D printing technology. The intervention focuses on evaluating patient satisfaction with the dentures in terms of comfort, fit, and aesthetics."
219166144|NCT06846619|DEVICE|Extra orally scanned|The extra-oral scanning method involves creating conventional impressions of the oral cavity using traditional impression materials. These impressions are then scanned externally using the 3Shape scanner to produce digital models. The digital models are used to design and fabricate maxillary dentures through 3D printing technology. This intervention aims to assess patient satisfaction with the dentures based on comfort, fit, and aesthetics.
219166145|NCT05185856|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219166146|NCT05185856|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219166147|NCT06846216|DEVICE|Treatment with BTL-785F and HPM-6000UF Devices|Three treatment sessions will consist of the consecutive application of the BTL-785F and HPM-6000UF devices, delivered 5-10 days apart. Three sessions will consist of the standalone application of the HPM-6000UF device, delivered 2-4 days apart. The treatments with BTL-785 device equipped with BTL-785-3 applicator will last 2-10 minutes and with HPM-6000UF 28 minutes.
219166148|NCT06847659|DIAGNOSTIC_TEST|intraoperative body temperature|Body temperature measurement with esophageal probe
219166149|NCT06373835|DRUG|Emodepside|5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
219166150|NCT03561103|BEHAVIORAL|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
219166151|NCT05783219|DRUG|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
219166152|NCT05783219|OTHER|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
219237743|NCT03262389|DRUG|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
219237744|NCT03262389|DRUG|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
219237745|NCT00899795|GENETIC|cytogenetic analysis|
219237746|NCT00899795|GENETIC|fluorescence in situ hybridization|
219237747|NCT00899795|OTHER|flow cytometry|
219237748|NCT00899795|PROCEDURE|biopsy|
219237749|NCT00801606|DRUG|Zinc|Zinc 20 mg/day
219237750|NCT00801606|DRUG|Micronutrient without zinc|Multimineral 2 RDA
219237751|NCT00801606|DRUG|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
219237752|NCT00801606|DRUG|Placebo|Placebo
219237753|NCT00119782|BEHAVIORAL|Diet|A dietary intervention that will promote lower calorie intake
219237754|NCT00119782|BEHAVIORAL|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
219237755|NCT00119782|BEHAVIORAL|Environment|Increase worksite access to both healthy foods and physical activity
219237756|NCT03740386|DRUG|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
219237757|NCT03955406|PROCEDURE|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
219166153|NCT06845111|OTHER|Therapeutic play|In this context, the pre-school teachers in the container area were contacted and the sessions were held every Wednesday-Thursday (8 sessions in total) for 5 weeks, taking into account their availability hours. Children were included in the programme in groups of 12. Before data collection, the necessary materials were provided and stored in an empty container. It was found appropriate to complete the trainings in kindergartens located in the container city (4). A total of 3 evaluations were carried out: a post-test immediately after the end of the programme and a retention test at the end of the first month.
219166154|NCT03107520|DIAGNOSTIC_TEST|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
219166155|NCT03107520|DRUG|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
219166156|NCT05275075|OTHER|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
219166157|NCT06843915|OTHER|Moderate intensity aerobic exercise|Participants in the MIAE group engaged in a 40-minute supervised session using the StepOne-SCIFIT recumbent stepper machine. The session included a 5-minute warm-up at 25 watts, followed by 30 minutes of moderate-intensity exercise, main-taining a stepping rate of 90-100 steps per minute. The workload was adjusted to keep the participant's heart rate within the target heart rate range (THRR), calculated using the Karvonen formula. During the first three weeks, the exercise intensity was set at 50-59% of heart rate reserve (HRR), and for the remaining three weeks, it was increased to 60-69% of HRR. Polar heart rate monitors were used to assess heart rate before and after each session. Participants kept weekly exercise logs to monitor compliance.
219166158|NCT06843915|OTHER|Home Exercise Program|Home Exercise Program
219166159|NCT06844253|PROCEDURE|INTERVENTION GROUP; TRAINING WITH EXERGAMING|RANDOMIZED CONTROL TRIAL EXERGAMING KINECT 20,000 LEAKS , KINECT BUBBLE POP, KINECT RALLY BALL GROUP 2: TASK ORIENTED TRAINING TRANSFERRING OBJECTS FROM ONE SIDE TO OTHER SIDE OF TABLE CATCHING AND THROWING BALLSIN DIFFERENT DIRECTIONS PICKING UP OBJECTS FROM LESS HIGHTED TABLES.
219237758|NCT03955406|PROCEDURE|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
219237759|NCT06176118|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
219237760|NCT01052272|DRUG|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
219237761|NCT01052272|DRUG|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
219237762|NCT01052272|DRUG|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
219237763|NCT04362618|OTHER|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
219166160|NCT06844253|PROCEDURE|Task oriented training|"The participant will receive task oriented training consisting of different tasks in sitting and standing position.~week1-2 sitting position: throwing and catching balls standing position: picking up glass from less heighted table . week 3-4 sitting position: transferring the plastic rings from one corner of table to another.~standing position: catching balls from multiple directions. wee5-6 sitting position: picking objects from floor standing position: opening drawer from less heighted tables week 7-8 standing position: picking up and transferring bottles, jars at different locations on table standing position: removing stickers from wall time of session: 15-20 reps, 2 sets. 30 minutes of session with 5 minutes rest in between. the intervention will be given for 30 minutes , 3 days a week for total 8 weeks of time period."
219166161|NCT06842511|DRUG|open flap debridement and Hyaluronic Acid-Based Gel application|Hyaluronic Acid-based gel as an adjunctive chemotherapeutic agent
219166162|NCT06842511|PROCEDURE|open flap debridement|periodontal surgery technique
219166163|NCT05560815|PROCEDURE|Any surgical procedure|Might differ for substudies.
219166164|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
219166165|NCT05341661|DEVICE|Butterfly Prostatic Retraction Device|Implantation of the Butterfly device
219166166|NCT06469853|DRUG|MBF-015 16 mg oral capsules|MBF-015 oral capsules HDAC inhibitor
219166167|NCT05939193|PROCEDURE|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
219166168|NCT05939193|PROCEDURE|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
219166169|NCT05939193|DRUG|Forced administration of furosemide|Forced administration of furosemide
219166170|NCT05939193|DRUG|Routine administration of furosemide|Routine administration of furosemide
219166171|NCT05299476|DRUG|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
219166172|NCT06276257|PROCEDURE|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
219166173|NCT06276257|PROCEDURE|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
219166174|NCT05784740|OTHER|12-week precision exercise training|The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
219166175|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
219166176|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
219166177|NCT03737058|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
219166178|NCT02682316|OTHER|dry gauze|
219166179|NCT02682316|DEVICE|The Prevena Incision Management System|
219166180|NCT05693610|DEVICE|Portable OSP|The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
219166181|NCT05693610|DEVICE|Cloud-based OSP|The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
219166182|NCT05938803|BEHAVIORAL|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
219166183|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
219166184|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
219166185|NCT04781621|DEVICE|Robotic Gait Training|Participants will wear an exoskeleton suit and receive robotic gait training with a physical therapist for 90 minutes each week. Robot gait training will include standing and walking activities while wearing the The Ekso Bionics Ekso GT™ robotic exoskeleton. Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor.
219166186|NCT04781621|OTHER|Usual Care Gait Training|Participants receive usual care gait training with a physical therapist for 90 minutes each week. Usual care gait training includes standard gait training involving standing and walking activities such as conventional overground walking, body weight-supported treadmill training (BWSTT), overground body weight-supported overground system, and various assistive devices (e.g., BWSTT, overground with braces, walker, etc.). Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor and number of steps.
219166187|NCT00051545|DRUG|Seocalcitol|
219166188|NCT03915379|DRUG|JNJ-67571244|JNJ-67571244 will be administered.
219166189|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
219166190|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
219166191|NCT04452084|RADIATION|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
219166192|NCT04452084|RADIATION|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
219166193|NCT06580548|DEVICE|CHW-supported telerehabilitation|Participants will receive the Mobile Rehab mobile software, which allows participants to be prescribed personalized rehabilitation strengthening video regimens electronically based on respondent-indicated mobility and activities of daily living functionality
219166194|NCT06580548|OTHER|Usual Care|Participants will be provide a list of local social services resources, including mental health, that participants can use . A callback number will be provided if they have any questions about the services.
219166195|NCT00000958|BIOLOGICAL|MTP-PE/MF59|
219166196|NCT00000958|BIOLOGICAL|Env 2-3|
219166197|NCT01988935|BEHAVIORAL|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
219166198|NCT01988935|BEHAVIORAL|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
219166199|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
219166200|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
219166201|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
219166202|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
219166203|NCT05912556|DEVICE|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
219166204|NCT05912556|DEVICE|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
219166205|NCT05521984|DRUG|Dapagliflozin|Commercially available
219166206|NCT05521984|DRUG|Carmustine|Standard of care
219166207|NCT05521984|DRUG|Topotecan|Standard of care
219166208|NCT05521984|DRUG|Cyclophosphamide|Standard of care
219166209|NCT03630328|DIETARY_SUPPLEMENT|Cogni.Q|AGN
219166210|NCT03630328|OTHER|Placebo|Placebo
219166211|NCT06388980|OTHER|Validated questionnaires and ad hoc questions|validated questionnaires and open questions online through the institution's intranet anonymous
219166212|NCT05832983|BEHAVIORAL|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
219166213|NCT05832983|OTHER|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
219166214|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm."
219166215|NCT00150813|DRUG|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
219166216|NCT05349370|OTHER|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
219166217|NCT06351046|DEVICE|Virtual Reality-based Pain Self-management program|The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
219166218|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
219166219|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
219166220|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
219166221|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
219237764|NCT04362618|BEHAVIORAL|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
219237765|NCT06225323|DRUG|Lidocaine|"Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
219237766|NCT06225323|OTHER|Saline|"Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
219237767|NCT06501508|DEVICE|Stratafix Symmetric|Use of Stratafix Symmetric for primary fascial closure
219237768|NCT01843049|RADIATION|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
219237769|NCT01843049|DRUG|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
219237770|NCT04660110|DRUG|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
219237771|NCT03503500|OTHER|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
219237772|NCT03503500|OTHER|Standard care|"2\. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
219237773|NCT04739306|BIOLOGICAL|CT-P42|2mg/0.05 mL by Intravitreal injection
219166222|NCT06030388|OTHER|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
219166223|NCT06030388|OTHER|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
219166224|NCT00268723|DRUG|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
219166225|NCT00268723|DRUG|Placebo|Placebo MDI QID
219166226|NCT06783101|BEHAVIORAL|Use of smart inhaler to enhance asthma inhaler proficiency|The application of the smart inhaler technology to enhance asthma inhaler proficiency
219166227|NCT06236607|DEVICE|Device specific training|Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.
219166228|NCT06236607|OTHER|Study clinician/educator visit|Participants will receive insulin dose and other diabetes management guidance.
219166229|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
219237774|NCT04739306|BIOLOGICAL|Eylea|2mg/0.05 mL by Intravitreal injection
219237775|NCT02868086|DEVICE|OCT B-scans|
219166230|NCT06341179|BEHAVIORAL|Sleep extension|Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
219237776|NCT02868086|DEVICE|OCT angiography|
219237777|NCT00993278|DIETARY_SUPPLEMENT|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
219237778|NCT00993278|DIETARY_SUPPLEMENT|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
219237779|NCT02912338|BEHAVIORAL|Resistant Training|
219237780|NCT02912338|OTHER|Control Group|
219237781|NCT01809444|DRUG|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
219237782|NCT01809444|DRUG|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
219166231|NCT06281028|DEVICE|SOLACEA-H/HYDROLINK-NVU|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
219237783|NCT02374294|DEVICE|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
219166232|NCT06281028|DEVICE|HYDROLINK-NVU/SOLACEA-H|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
219166233|NCT05554198|BEHAVIORAL|Attend Behavior Parent Training|Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
219166234|NCT03052608|DRUG|Lorlatinib|ALK-positive NSCL treatment
219166235|NCT03052608|DRUG|Crizotinib|ALK-positive NSCL treatment
219166236|NCT03113500|DRUG|Brentuximab Vedotin|Given IV
219166237|NCT03113500|DRUG|Cyclophosphamide|Given IV
219166238|NCT03113500|DRUG|Doxorubicin|Given IV
219166239|NCT03113500|DRUG|Doxorubicin Hydrochloride|Given IV
219166240|NCT03113500|DRUG|Etoposide|Given IV
219166241|NCT03113500|DRUG|Etoposide Phosphate|Given IV
219166242|NCT03113500|OTHER|Laboratory Biomarker Analysis|Correlative studies
219166243|NCT03113500|DRUG|Prednisone|Given PO
219166244|NCT05535257|DEVICE|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
219166245|NCT04204278|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
219166246|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
219166247|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
219237784|NCT04748705|DRUG|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
219166248|NCT05592288|OTHER|PREDIABE-TR mobile app.|"* Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
219166249|NCT05470907|DEVICE|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
219166250|NCT06262594|DRUG|Lemborexant|Drug is administered
219166251|NCT06262594|DRUG|Placebo|Drug is administered
219166252|NCT05249439|OTHER|I-SatPro weight loss programme|I-SatPro weight loss programme: participants advised on I-SatPro dietary change as well as eating patterns, lifestyle change such as exercise, self-care such as advice on sleep and behavioural change strategies.
219166253|NCT05249439|OTHER|Tier 3 weight loss programme|Tier 3 weight loss programme: participants advised to make changes to food choices in accordance with NHS healthy eating advice, eating habits, lifestyle change such as exercise, mindful eating and behavioural change strategies.
219166254|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
219166255|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
219166256|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
219166257|NCT06217068|BEHAVIORAL|Elliptical Activity|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
219166258|NCT06554301|DRUG|empagliflozin in treatment pulmonary aerterial hypertension|On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
219166259|NCT06554301|DRUG|placebo in treatment pulmonary aerterial hypertension|On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
219237785|NCT04748705|DRUG|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
219166260|NCT06569550|DEVICE|Real Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
219166261|NCT06569550|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
219166262|NCT05257980|DIETARY_SUPPLEMENT|Dietary supplement (ONS)|At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
219237786|NCT03258983|OTHER|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
219237787|NCT01077284|DRUG|Febuxostat|Febuxostat capsules
219237788|NCT01077284|DRUG|Allopurinol|Allopurinol capsules
219237789|NCT01077284|DRUG|Placebo|Placebo-matching capsules
219237790|NCT04878809|OTHER|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
219166263|NCT03803904|OTHER|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
219237791|NCT04878809|OTHER|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
219237792|NCT05992584|DRUG|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
219166264|NCT01044069|BIOLOGICAL|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
219166265|NCT05731024|DEVICE|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
219166266|NCT05731024|DEVICE|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
219237793|NCT05863585|DRUG|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
219237794|NCT03612102|BEHAVIORAL|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
219237795|NCT00966745|DRUG|milrinone|
219237796|NCT00966745|DRUG|placebo|
219237797|NCT03003715|PROCEDURE|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
219237798|NCT03003715|PROCEDURE|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
219237799|NCT03003715|PROCEDURE|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
219237800|NCT03003715|OTHER|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
219237801|NCT03757767|OTHER|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
219237802|NCT06301945|DIAGNOSTIC_TEST|Artificial Intelligence Diagnostics|AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
219237803|NCT06301945|DIAGNOSTIC_TEST|Recurrence Prediction Tool|This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
219237804|NCT06359977|OTHER|Quantitative EEG monitoring and beside ultrasound evaluation|After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
219237805|NCT00041639|DRUG|hMN14 (labetuzumab)|
219237806|NCT01529372|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
219237807|NCT04062279|DIAGNOSTIC_TEST|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
219237808|NCT03366571|DRUG|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
219237809|NCT02721849|BEHAVIORAL|Yoga for adolescents|12 week hatha yoga course for adolescents
219237810|NCT02721849|BEHAVIORAL|Yoga for parents|12 week hatha yoga course
219237811|NCT01064180|DRUG|Carvedilol|Carvedilol Tablets 25 mg
219237812|NCT04056598|DIAGNOSTIC_TEST|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
219166267|NCT06500533|DEVICE|rTMS combined with tDCS|"The intervention will last 30 days per patient, where rTMS will be administered on odd numbered days (study day 1, 3, 5, 7, ..29) and tDCS on even numbered days (study day 2, 4, 6, 8, … 30). All patients will start with TMS and finish with home-based tDCS treatment. Both rTMS and tDCS treatments will be administered during working days, from Monday to Friday.~rTMS treatment will be administered by the experienced nurses of the rTMS clinic of each department. The rTMS treatment will profit from ongoing supervision by the Clinical Directors of each TMS clinic, which is in line with treatment as usual.~tDCS will be performed at home by the patients."
219166268|NCT06151314|PROCEDURE|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
219166269|NCT02966613|DEVICE|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
219166270|NCT01376700|BIOLOGICAL|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
219166271|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
219166272|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
219166273|NCT05124613|OTHER|Survey|"Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
219237813|NCT05088122|OTHER|no intervention|no intervention, not applicable
219237814|NCT05813249|DRUG|Rybelsus Oral Product|Oral Semaglutide
219237815|NCT05813249|DRUG|Ozempic Injectable Product|Subcutaneous Semaglutide
219237816|NCT05813249|DRUG|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
219237817|NCT01016730|DRUG|Bortezomib|Given IV
219237818|NCT01016730|OTHER|Laboratory Biomarker Analysis|Correlative studies
219237819|NCT01016730|OTHER|Questionnaire Administration|Ancillary studies
219237820|NCT05789407|DIAGNOSTIC_TEST|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
219237821|NCT00237718|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
219237822|NCT00237718|DRUG|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
219237823|NCT00237718|DRUG|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
219237824|NCT00237718|DRUG|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
219237825|NCT01733199|OTHER|questionnaires|Summons of patients and filling questionnaire.
219237826|NCT06361576|DRUG|Nivolumab|As per product label
219237827|NCT04552184|OTHER|GPOEM|gastric per oral endoscopic pyloromyotomy
219237828|NCT04552184|OTHER|SHAM Procedure|intrapyloric injection of saline solution
219237829|NCT01623180|DEVICE|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
219237830|NCT01623180|DEVICE|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
219237831|NCT04398355|COMBINATION_PRODUCT|acupuncture|acupuncture
219237832|NCT04398355|COMBINATION_PRODUCT|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
219237833|NCT02362100|OTHER|Non operative|non operative treatment
219237834|NCT02362100|PROCEDURE|locking plate surgical fixation|
219237835|NCT01736722|DEVICE|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
219237836|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
219237837|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly placebo plus 800 calcium alone
219237838|NCT02625636|DRUG|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219237839|NCT02625636|DRUG|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219237840|NCT02625636|DRUG|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219237841|NCT01615523|OTHER|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
219237842|NCT05852496|DRUG|Vitamin D|vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
219166274|NCT02488148|BEHAVIORAL|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
219166275|NCT02488148|BEHAVIORAL|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
219237843|NCT03444155|DIETARY_SUPPLEMENT|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
219166276|NCT06518915|DEVICE|baroloop system|Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
219166277|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
219237844|NCT03444155|DIETARY_SUPPLEMENT|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
219237845|NCT00761241|DRUG|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
219166278|NCT04752163|DRUG|DS-1594b|Given DS-1594b PO
219166279|NCT04752163|DRUG|Azacitidine|Given IV or SC
219166280|NCT04752163|DRUG|Cyclophosphamide|Given IV
219166281|NCT04752163|DRUG|Cytarabine|Given IT
219166282|NCT04752163|DRUG|Dexamethasone|Given PO or IV
219166283|NCT04752163|BIOLOGICAL|Filgrastim|Given SC
219166284|NCT04752163|DRUG|Leucovorin|Given IV or PO
219166285|NCT04752163|DRUG|Mesna|Given IV
219166286|NCT04752163|DRUG|Methotrexate|Given IT
219166287|NCT04752163|DRUG|Prednisone|Given PO
219166288|NCT04752163|BIOLOGICAL|Rituximab|Given IV
219166289|NCT04752163|DRUG|Venetoclax|Given PO
219166290|NCT04752163|DRUG|Vincristine|Given IV
219166291|NCT04063514|OTHER|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
219166292|NCT01549899|BEHAVIORAL|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education \& hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
219166293|NCT01549899|BEHAVIORAL|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
219166294|NCT00601900|BIOLOGICAL|Bevacizumab|Given IV
219166295|NCT00601900|OTHER|Laboratory Biomarker Analysis|Correlative studies
219166296|NCT00601900|DRUG|Letrozole|Given PO
219166297|NCT00601900|OTHER|Questionnaire Administration|Ancillary studies
219166298|NCT00601900|DRUG|Tamoxifen Citrate|Given PO
219166299|NCT05873751|BIOLOGICAL|Trumenba Vaccine|Trumenba vaccine given as standard of care
219166300|NCT05873751|BIOLOGICAL|MenACWY Vaccine|MenACWY Vaccine given as standard of care
219237846|NCT00761241|BIOLOGICAL|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
219166301|NCT06121921|OTHER|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%"
219166302|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
219166303|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
219166304|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
219166305|NCT03822845|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
219166306|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
219166307|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
219166308|NCT03705741|BEHAVIORAL|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
219166309|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
219166310|NCT05638308|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
219166311|NCT02500758|PROCEDURE|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
219237847|NCT00761241|RADIATION|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
219237848|NCT00761241|PROCEDURE|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
219237849|NCT06050837|OTHER|No intervention|No intervention
219237850|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
219166312|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
219237851|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
219237852|NCT04243954|DRUG|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
219237853|NCT00109161|DRUG|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
219237854|NCT01484015|DRUG|cefepime hydrochloride|Given IV
219237855|NCT05567029|DRUG|Risankizumab Dose A|Prefilled Syringe
219237856|NCT05567029|DRUG|Risankizumab Dose B|Prefilled Syringe
219166313|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
219166314|NCT02345720|DEVICE|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
219166315|NCT05395403|DEVICE|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
219166316|NCT04893759|DRUG|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
219166317|NCT00274469|DRUG|fulvestrant|500 mg intramuscular injection
219166318|NCT00274469|DRUG|anastrozole|1 mg oral tablet
219166319|NCT03007030|DRUG|Brentuximab Vedotin|Given IV
219166320|NCT03007030|OTHER|Laboratory Biomarker Analysis|Correlative studies
219166321|NCT02317783|DRUG|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
219237857|NCT02368977|DEVICE|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
219237858|NCT05664009|DIETARY_SUPPLEMENT|Redsenol-1 Plus|Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
219237859|NCT05664009|OTHER|Placebo|Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
219237860|NCT02535598|BEHAVIORAL|Normal presentation|All the material will be presented as plain text.
219237861|NCT02535598|BEHAVIORAL|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
219237862|NCT02535598|BEHAVIORAL|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
219237863|NCT02535598|BEHAVIORAL|Enhanced support|Participants are offered daily support through the internet from trained therapists.
219237864|NCT03003923|BEHAVIORAL|Taste exposure|Exposure to the same vegetable
219237865|NCT03003923|BEHAVIORAL|Nutritional education|Eat Well and Strive for Five nutritional education
219166322|NCT02317783|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
219166323|NCT02317783|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
219166324|NCT05847894|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
219166325|NCT05847894|DIAGNOSTIC_TEST|Pulmonary Examination|Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
219237866|NCT03225092|BIOLOGICAL|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
219237867|NCT03296488|DRUG|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
219166326|NCT06969040|OTHER|CBTI + tACS|CBTI + tACS group method: CBTI for about 50 minutes each time, for a total of 6 weeks: ① first interview: enrolment assessment; ② second interview: treatment initiation; ③ third interview: sleep titration and sleep hygiene; ④ fourth interview: sleep titration; ⑤ fifth-seventh interview: sleep titration; ⑥ eighth interview: sleep titration (end of standardised CBTI treatment. tACS true stimulation) : Transcranial alternating current therapy (tACS) was operated during the same period of CBTI, with 3 electrodes, placed in the prefrontal lobe and bilateral mastoid; the stimulation intensity was 77.5 Hz, 15 mA, 40 min each time, once a day, 5 days a week, for 6 weeks.
219166327|NCT06969040|OTHER|CBTI + Sham tACS|CBTI+sham tACS group method: CBTI treatment method was the same as before. tACS pseudo-stimulation: the electrode placement position, stimulation frequency, and time settings were the same as the real stimulation, and the stimulation process only had the output of gradual rising and falling current at the beginning and the last 10s, respectively, so as to make the subjects produce the same subjective feelings as the real stimulation.
219237868|NCT03296488|DRUG|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
219237869|NCT02877680|BEHAVIORAL|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
219237870|NCT00003611|DRUG|acitretin|
219237871|NCT00003611|OTHER|placebo|
219237872|NCT01264484|DEVICE|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
219237873|NCT03563131|DEVICE|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
219237874|NCT03022734|DRUG|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
219237875|NCT03022734|RADIATION|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
219237876|NCT01133678|DRUG|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
219237877|NCT01133678|DRUG|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
219237878|NCT05096741|DEVICE|OCS Liver|Transplanted with a OCS preserved liver
219237879|NCT02545426|OTHER|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
219237880|NCT04659083|DEVICE|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
219237881|NCT00141336|DRUG|Pregabalin|
219166328|NCT06647238|OTHER|Pharmacist Intervention in lipid therapy|Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
219166329|NCT03419572|OTHER|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
219166330|NCT06155721|DEVICE|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
219166331|NCT02318901|DRUG|Pembrolizumab|
219166332|NCT02318901|DRUG|Trastuzumab|
219166333|NCT02318901|DRUG|ado-trastuzumab emtansine|
219166334|NCT02318901|DRUG|Cetuximab|
219166335|NCT06094231|BEHAVIORAL|Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor|The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
219166336|NCT00593489|OTHER|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
219166337|NCT03898310|DIETARY_SUPPLEMENT|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
219166338|NCT03898310|DIETARY_SUPPLEMENT|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
219166339|NCT00000969|DRUG|Zalcitabine|
219166340|NCT00000969|DRUG|Didanosine|
219166341|NCT05694442|OTHER|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
219166342|NCT00611559|BIOLOGICAL|Infanrix™ penta|Subjects received a booster dose
219166343|NCT00611559|BIOLOGICAL|Infanrix™ hexa|Subjects received a booster dose
219166344|NCT04073953|DRUG|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
219166345|NCT04073953|DRUG|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
219166346|NCT04073953|DRUG|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
219166347|NCT03706664|OTHER|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
219166348|NCT04095104|DRUG|Phentermine|Phentermine tablet
219166349|NCT04095104|DRUG|Immediate Release Topiramate|Topiramate tablet
219166350|NCT04095104|DRUG|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
219166351|NCT04095104|DRUG|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
219166352|NCT02057939|DRUG|enzalutamide|160 mg orally once daily for six months
219166353|NCT02057939|DRUG|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
219166354|NCT02057939|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
219166355|NCT02709850|DRUG|IONIS ANGPTL3-LRx|
219166356|NCT02709850|DRUG|Placebo|0.9%NaCl, water, riboflavin
219166357|NCT06423534|BEHAVIORAL|Breastfeeding Health Educational Program|Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
219166358|NCT05845177|PROCEDURE|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
219166359|NCT00084552|RADIATION|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
219166360|NCT00000675|DRUG|CD4-IgG|
219166361|NCT05297136|PROCEDURE|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
219166362|NCT05297136|PROCEDURE|No Stent|No preoperative stenting with distal pancreatectomy alone
219166363|NCT06589258|BIOLOGICAL|Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding|Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
219166364|NCT05662124|OTHER|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
219166365|NCT05110053|DEVICE|Spinal Cord Stimulation|"Spinal Cord stimulation. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
219166366|NCT06821152|DEVICE|Miss Liberty Condom|The Miss Liberty female condom is manufactured by Zhejiang Rui Bo 001 High Polymer Co, Ltd. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The sheath, are made of polyurethane. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. Miss Liberty measures 180mm in length and 78mm in lay-flat width. The device is pre-lubricated with silicone oil. This condom is a similar design (material, length, width) to the USFDA approved FC1 female condom which was discontinued and replaced by FC2.
219237882|NCT06405516|DEVICE|Autologous blood cell salvage with in-house device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
219237883|NCT06405516|DEVICE|Autologous cell salvage with i-Sep SAME device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
219237884|NCT05830305|OTHER|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
219237885|NCT06266676|OTHER|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
219237886|NCT06266676|OTHER|slide presentation|Provide online presentations.
219237887|NCT05609721|OTHER|no intervention, only observational study|no intervention, only observational study
219237888|NCT04581356|DRUG|Voxelotor|daily voxelotor 1500mg oral medication
219237889|NCT05749939|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
219166367|NCT06821152|DEVICE|FC2 condom|The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark of the European Union. The FC2 is pre-qualified by the WHO. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 170mm in length and 80mm in lay-flat width. The device is pre-lubricated with silicone oil. This FC is available in the public health sector in South Africa.
219166368|NCT02412683|OTHER|oxaliplatin|
219166369|NCT02814383|OTHER|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
219166370|NCT06987669|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
219166371|NCT06986824|DEVICE|Pelvic wand|Use of a pelvic wand to perform perineal massage
219237890|NCT04491370|DRUG|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
219237891|NCT05104242|OTHER|Diet low in Advanced Glycation End-Products (AGE)|The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
219237892|NCT05986279|OTHER|Rehab|6 weeks of vestibular rehabilitation guided by the MINDGAPS decision support system
219237893|NCT04080778|DEVICE|magnetic seizure therapy (MST)|MST will be performed with the MagPro XP (120 V) device under anesthesia 2-3 times a week up to 15 sessions.Treatment is performed by magnetic stimulation of both hemispheres inducing a focal stimulation above vertex, using a serial of pulse trains with a frequency of at least 25 Hz but up to 100 Hz for 4-6 s (up to 10 s), which is sufficient to induce a tonic clonic seizure.
219237894|NCT04080778|DEVICE|electroconvulsive therapy (ECT)|ECT will be performed with MECTA 5000Q, 4th generation ECT devices provided by MECTA Corporation under anesthesia 2-3 times a week up to 15 sessions. For initial procedure Seizure Threshold (ST) will be estimated by empiric titration in the first session of each participant. ST will be then determined as by the manufacturer of ECT Device by the titration schedule for the initial titration session. The subsequent treatment sessions were dosed at 6 times the charge of the seizure threshold.
219237895|NCT05748808|BEHAVIORAL|Use of biofeedback and virtual reality in the treatment of aggressive outbursts|Participants are trained to identify their physiological response when they are relaxed and when an outburst is coming. They are treated with cognitive, behavioral and emotional self-regulation therapies for managing anger and learning positive coping skills. Biofeedback toghether with virtual reality help them to improve their recognition and control of emotions.
219237896|NCT05441410|DRUG|Pyronaridine Tetraphosphate, Artesunate Drug Combination|Combination drug for treatment of uncomplicated malaria
219237897|NCT05441410|BIOLOGICAL|PfSPZ Challenge (NF54)|cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation
219237898|NCT05441410|BIOLOGICAL|MVA ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
219237899|NCT05441410|BIOLOGICAL|ChAd63 ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)
219237900|NCT05441410|BIOLOGICAL|Sodium chloride (NaCl) 0.9%|0.9% NaCl solution for injection
219237901|NCT00649402|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
219237902|NCT00649402|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
219237903|NCT01864200|BIOLOGICAL|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
219237904|NCT01864200|BIOLOGICAL|Placebo|Saline placebo
219237905|NCT04997499|BEHAVIORAL|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
219166372|NCT06986850|DEVICE|FeelSync mobile application|Ecological Momentary Intervention focused on cognitive reappraisal for distressing autobiographical memories, with a possibility to choose between distancing and positive reappraisal.
219237906|NCT00074607|DRUG|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
219237907|NCT05185167|DRUG|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
219237908|NCT05185167|DRUG|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
219237909|NCT03488550|BIOLOGICAL|ANX007|Single ascending dose
219166373|NCT06986850|DEVICE|Ecological Momentary Assessment mobile application|Ecological Momentary Assessment used for self-monitoring of emotional states.
219166374|NCT06987617|DEVICE|Menopause App|The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a (peri-)menopausal disorder, through tools such as a symptom diary and guided interactive exercises.
219237910|NCT06117215|OTHER|Data collection|data collection
219237911|NCT06061900|OTHER|Group exercise program|Group fitness program
219237912|NCT00254124|DEVICE|The Diet Plate (R) TM portion control plate and bowl|
219237913|NCT01049152|DEVICE|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
219237914|NCT06464666|PROCEDURE|Renal interlobar artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
219237915|NCT06464666|PROCEDURE|Renal inter-lobular artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
219237916|NCT06253962|OTHER|coronary agiongraphy|severity of coronary atherosclerosis
219166375|NCT06987279|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
219166376|NCT06987279|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
219166377|NCT06987552|DEVICE|Da Vinci SP Surgical System|Da Vinci SP Surgical System
219166378|NCT06987721|DEVICE|Modus ESWT-Focused|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.056 mj/mm, 6 Hz for focused applications. All applications were done with the same device; Modus ESWT.
219166379|NCT06987721|DEVICE|Modus ESWT-Radial|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.1 mj/mm, 10-16 Hz for radial applications. All applications were done with the same device; Modus ESWT.
219166380|NCT06987721|DEVICE|Modus ESWT-Sham|The sham application was made in such a way that the device was set to 0 frequency and power, making only sound. All applications were done with the same device; Modus ESWT.
219166381|NCT06987188|OTHER|Modified Pilate Exercises|Modified Pilates exercises are gentle adaptations of traditional Pilates movements, designed to accommodate various fitness levels, physical limitations, or specific health conditions. These exercises focus on core strength, flexibility, posture, and controlled breathing while reducing strain on joints and muscles. Often recommended for beginners, seniors, or individuals recovering from injury or surgery, modified Pilates may involve the use of props like pillows, resistance bands, or chairs to support proper alignment and ease of movement. By emphasizing slow, mindful motions and personalized adjustments, modified Pilates helps individuals safely build strength, improve mobility, and enhance overall body awareness without the risk of overexertion.
219166382|NCT06987188|OTHER|General Physiotherapy Plan|A general physiotherapy plan for improving trunk control and balance focuses on enhancing core stability, postural alignment, and coordinated movement through targeted exercises and functional activities. The plan typically begins with gentle activation of deep core muscles such as the transverse abdominis and pelvic floor, progressing to dynamic tasks that challenge balance and coordination, like seated weight shifts, bridging, and reaching tasks in various positions (sitting, kneeling, or standing). Balance training may include exercises on unstable surfaces, gait training, and proprioceptive activities to improve body awareness and stability. The physiotherapy approach is individualized, gradually increasing in complexity and intensity as the patient gains strength and confidence, with consistent emphasis on proper technique, breathing, and safety to support overall mobility and independence.
219166383|NCT06987578|OTHER|OMT vs. Ibruprofen|OMT vs. Standard Therapy in the Management of Acute Neck and Low Back Pain in the Emergency Department
219166384|NCT06988111|DEVICE|BIPAP|The second arm (NIV group) will be managed by BIPAP device for post-operative respiratory failure
219166385|NCT06988111|DEVICE|Vapotherm|The first arm (HVNC group) will be managed by Vapotherm device for post-operative respiratory failure
219166386|NCT06988293|PROCEDURE|inguinal hernia repair|İnguinal hernia repair quality of life index
219166387|NCT06987565|DEVICE|Active vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated. Patients will be followed through day 57 to assess durability of the intervention.
219166388|NCT06987565|DEVICE|Sham vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated, however, the vagus nerve will not be stimulated. Patients will be followed through day 57 to assess durability of the intervention.
219166389|NCT06987851|BIOLOGICAL|Divozilimab|Intravenous infusion of BCD-132 every 24 weeks
219166390|NCT06987877|OTHER|No flushing of the nephrostomy|Subjects allocated to the study intervention group will not flush their nephrostomy tube during the duration of the research study
219166391|NCT06987877|OTHER|Flushing of nephrostomy|Subjects assigned to this cohort will flush their nephrostomy catheter once daily with 10 mL of normal saline
219166392|NCT06987994|OTHER|control group( physical therapy)|"Participants will receive conventional physiotherapy 3 times per week for 4 weeks. The treatment includes:~Standing exercises: multidirectional stepping, single- and double-leg stance~Walking exercises: forward, backward, and lateral walking~Weight-shifting exercises: lunges, half-squats, leaning, and reaching"
219166393|NCT06987994|OTHER|Experemental group|In this group the number of Participants are 15 . The experment by using VR sessions will last 30 minutes per session, 3 times per week for 4 weeks . In addition to the same physiotherapy program used in the control group, this group will receive Virtual Reality (VR) training using a Meta Quest 2 headset . Patients will interact with immersive environments designed to stimulate movement and functional tasks.
219166394|NCT06988319|DRUG|Psilocybin (Usona Institute)|Single dose of pharmaceutical grade psilocybin (25 mg) combined with psychotherapy sessions
219166395|NCT06988436|DIAGNOSTIC_TEST|Ultrasound|All the participants were scanned using B mode sonography to determine the fetal biometric parameters (BPD, HC, AC and FL). The machine automatically calculated the estimated fetal weight using the Headlock formula. umbilical artery pulsatility index (UAPI) and pulmonary vein pulsatility index (PVPI) were measured in the study
219166396|NCT06987955|OTHER|Biocoat Pit and fissure sealant|Application of Biocoat
219166397|NCT06987955|OTHER|Fissurit FX Pit and fissure sealant|Application of Fissurit FX
219237917|NCT02077374|DRUG|IDN-6556|25 mg BID for 28 days
219237918|NCT02077374|OTHER|Placebo|Placebo BID for 28 Days
219237919|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
219237920|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
219237921|NCT02742805|DRUG|Omalizumab|Standard of care dose.
219237922|NCT01338532|OTHER|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
219237923|NCT01338532|OTHER|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
219237924|NCT06301620|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
219237925|NCT06301620|BEHAVIORAL|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
219237926|NCT00251199|DRUG|VX-950|
219237927|NCT00251199|DRUG|peginterferon|
219237928|NCT01018550|DRUG|AMG 853|AMG 853 5 mg (BID)
219237929|NCT01018550|DRUG|AMG 853|AMG 853 200 mg (QD)
219237930|NCT01018550|DRUG|AMG 853|AMG 853 25 mg (BID)
219237931|NCT01018550|DRUG|AMG 853|AMG 853 100 mg (BID)
219237932|NCT01018550|DRUG|Placebo|Placebo
219237933|NCT04727099|DEVICE|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
219237934|NCT03979352|DRUG|empagliflozin|Treatment with empagliflozin 25mg orally once a day
219237935|NCT03979352|DEVICE|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
219237936|NCT01992497|DIETARY_SUPPLEMENT|Probiotic|
219166398|NCT06988397|BEHAVIORAL|Physical activity after different type of meals|Standardized physical activity (walking) after consuming one of three meal types (vegetable-based, meat-based, dairy-based). Ultrasound of gastric volume will be performed at 3 and 6 hour between walking sessions.
219166399|NCT06986356|DIETARY_SUPPLEMENT|Test product: Yoghurt|High protein spoonable yoghurt
219166400|NCT06986356|DIETARY_SUPPLEMENT|Placebo|Placebo Jelly
219166401|NCT06699680|DRUG|PRX019|Specified dose on specified days
219166402|NCT06699680|DRUG|Placebo|Placebo
219166403|NCT06878417|DRUG|CBD|The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
219166404|NCT06878417|DRUG|THC|The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
219237937|NCT00927966|DRUG|RAD001|Taken orally once a day.
219237938|NCT00927966|DRUG|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
219237939|NCT05034588|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameter
219237940|NCT04325737|DRUG|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
219166405|NCT06878417|DRUG|Placebo|The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
219166406|NCT06710756|DRUG|[203Pb]Pb-PSV359|\[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
219237941|NCT04325737|DRUG|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
219237942|NCT04558021|DRUG|Niclosamide suspension|200mg/10ml
219237943|NCT04558021|OTHER|Placebo|10ml placebo(absent of niclosamide)
219166407|NCT06710756|DRUG|[212Pb]Pb-PSV359|\[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.
219166408|NCT07041905|PROCEDURE|Total Caries Removal|"Arm 1: Total caries removal (complete excavation to hard dentin)"
219166409|NCT07041905|PROCEDURE|Selective Caries Removal|Partial removal leaving affected dentin near pulp.
219166410|NCT06729710|PROCEDURE|Prism adaptation test|Prism Adapation test for 1 hour in one group, and 4 hours in second group
219166411|NCT06729710|PROCEDURE|other|Surgery based on prism adaptation test of 1 hour in one group and 4 hours in second group
219166412|NCT07076940|OTHER|Mindfulness-based Training Program|The mindfulness-based training program was completed in a total of five sessions (one day per week, 60 minutes, for a total of five consecutive weeks).
219166413|NCT07076940|OTHER|Psychoeducational Program|"The Psychoeducational Program, themed around stress, well-being, and mindfulness, was completed in two sessions (two sessions over five weeks, each lasting 60 minutes)."
219166416|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
219166417|NCT05938023|DRUG|ATL1102 25mg|Dose and scheduled as specified in the Arm description
219166418|NCT05938023|DRUG|ATL1102 50mg|Dose and scheduled as specified in the Arm description
219166419|NCT05938023|DRUG|Placebo|Dose and scheduled as specified in the Arm description
219166420|NCT05649319|PROCEDURE|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
219166421|NCT04075903|BEHAVIORAL|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
219166422|NCT06459141|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
219166423|NCT04533022|DRUG|C21|C21 100 mg BID (twice daily)
219166424|NCT05285007|OTHER|Mobilization with Movement|Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.
219166425|NCT05285007|OTHER|No mobilization with movement and education|Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
219166426|NCT06116409|DRUG|Bupivacain|Bupivacaine was used for postoperative analgesia block.
219166427|NCT06242431|PROCEDURE|Group serratus posterior superior intercostal plane block (SPSIPB)|SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
219166428|NCT06242431|PROCEDURE|Group pectoralis nerve block (PECS-II)|PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
219166429|NCT05050916|DIETARY_SUPPLEMENT|Vitamin D|The High Dose Vitamin D arm will receive 50,000 IU/week of cholecalciferol. The Low Dose Vitamin D arm will receive 4,200 IU/week of cholecalciferol
219166430|NCT05050916|OTHER|Placebo|Cellulose capsule
219166431|NCT05886517|DEVICE|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
219166432|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
219166433|NCT02163447|DRUG|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
219166434|NCT02163447|DRUG|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
219166435|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for infants|
219166436|NCT02163447|DRUG|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
219237944|NCT05434507|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
219166437|NCT06048614|PROCEDURE|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
219166438|NCT06048614|DRUG|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
219166439|NCT06641154|DRUG|GT-UGT1A1-AAV8-02|Intravenous infusion, single dose
219166440|NCT06582706|DRUG|Placebo Comparator|a readily available inert placebo will be used
219166441|NCT06582706|DRUG|Extended Release Niacin|500 mg
219166442|NCT03821233|DRUG|ZW49|"* Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study"
219166443|NCT06240091|DEVICE|DISC-MA|DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
219166444|NCT02419014|DEVICE|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
219166445|NCT02419014|DEVICE|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
219166446|NCT06484985|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
219166447|NCT06407973|DEVICE|OMNI Surgical System|The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
219166448|NCT06407973|DRUG|Latanoprost plus adjunctive glaucoma medication|"* Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator"
219166449|NCT05560529|BEHAVIORAL|DBT|Applying DBT modules in group format over 20 weeks
219166450|NCT05560529|DRUG|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
219166451|NCT05560529|DIAGNOSTIC_TEST|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
219166452|NCT06788652|BIOLOGICAL|Lisocabtagene maraleucel|According to US Prescribing Information
219166453|NCT06792409|DEVICE|Minimally invasive breast augmentation procedure with a trans-axillary approach.|Minimally invasive breast augmentation procedure with a transaxillary approach using Motiva Ergonomix2 Diamond®, Motiva Injector® and Motiva® Inflatable Balloon.
219166454|NCT05113966|DRUG|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
219166455|NCT05113966|DRUG|Sacituzumab Govitecan-hziy|10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
219166456|NCT06791395|DIAGNOSTIC_TEST|Artificial intelligence platform for endocytoscopy|The detected lesions are predicted by artificial intelligence
219166457|NCT06786910|OTHER|Toothpaste with olive oil, trimethylglycine and xylitol|Composition comprising olive oil, trimethylglycine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
219166458|NCT06786910|OTHER|Toothpaste without olive oil, trimethylglycine nor xylitol|Composition without olive oil, without trimethylglycine and without xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
219166459|NCT06792240|DIETARY_SUPPLEMENT|iron supplementation|"The amount of supplementary iron was decided for patients according to the daily requirement (8- 18 mg / day), according to LARN 2012 and (RDAs) for Iron. (25) . This study took in consideration also, the recommendation of the National Institutes of Health iron dietary supplement fact of sheet as reference to calculate iron dose for our candidates because this dose isn't against LARN and more practical to applicate.~The minimum RDA values is applied, which coincides within the LARN daily requirement limits. (7 mg-18 mg of iron per day). Applying the minimum recommended RDA dose, that can satisfy the daily iron requirement by age, approximating it to be adequate for the clinical dose administered orally once a day (e.g. 1.98 g ==\> 2 g, 1.53 g ==\> 1.5 g"
219166460|NCT06792240|DIETARY_SUPPLEMENT|control group|Non intervension: Only restricted low and controlled Phe diet therapy
219166461|NCT06779201|OTHER|Fasting|One-week fasting without limit of water drink (Participants can feel free to drink water )
219166462|NCT06784440|GENETIC|Evaluation of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA)|From the blood samples taken, 2 mL of plasma separated from blood will be stored in EDTA frozen at -80°C. This material will later be processed by NGS run using of CareDX kits. The result will be provided by dedicated software as percentage of donor DNA in relation to recipient DNA.
219166463|NCT05386355|BEHAVIORAL|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
219166464|NCT05386355|OTHER|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
219166465|NCT06783504|DEVICE|PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION|The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
219166466|NCT06783504|DEVICE|Sham percutaneous electrical nerve field stimulation|SHAM (no electrical charge)
219166467|NCT06789744|DEVICE|General Anesthesia (GA)|"Patients will be induced with general anesthesia, consisting of propofol (1.5-2 mg/kg intravenously), rocuronium (1-2 mg/kg intravenously), and fentanyl (1-2 μg/kg intravenously). Anesthesia will be maintained with inhaled sevoflurane or desflurane, adjusted according to BIS values. Remifentanil (0.05-0.2 μg/kg/min) will be administered via continuous infusion, with the infusion rate adjusted to maintain blood pressure and heart rate within ±20% of baseline.~Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode using an Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA). Ventilator settings will be as follows: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and inspired oxygen concentration of 41%."
219166468|NCT06789744|PROCEDURE|Epidural Analgesia( 0.2% ropivacaine)|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine will be administered, followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hour. In pediatric patients, the initial bolus will consist of 0.2% ropivacaine at a dose of 0.5-1 mg/kg, not to exceed 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hour.
219166469|NCT06789744|DEVICE|Paravertebral block ( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For paravertebral blocks, patients will be positioned either sitting or in the lateral decubitus position to fully expose the target area of the spine. The spinous process of the target vertebra will be palpated, and the puncture site identified. Using ultrasound guidance, the paravertebral space will be located. After standard skin preparation, a blunt needle will be advanced perpendicular to the skin. Once the needle tip contacts the transverse process, it will be withdrawn 1-2 mm, and then slightly angled caudally to pass through the paravertebral ligament and enter the paravertebral space. After negative aspiration for blood or cerebrospinal fluid, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 5 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
219166470|NCT06789744|DEVICE|Transversus Abdominis Plane Block (TAP Block)( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For TAP blocks, patients will be positioned supine with the abdomen exposed. Following standard skin preparation, a needle will be advanced perpendicular to the skin using ultrasound guidance, through the external oblique and internal oblique muscles to reach the fascial plane between the transversus abdominis and internal oblique muscles. After negative aspiration for blood, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 10 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
219166471|NCT06789744|PROCEDURE|Intrathecal Morphine|For intrathecal analgesia, adults will receive 0.1-0.2 mg of morphine intrathecally. For pediatric patients, the dose of intrathecal morphine will be 5-10 mcg/kg.
219166472|NCT06789744|DRUG|Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)|For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
219166473|NCT06459583|OTHER|eHealth Platform|The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
219166474|NCT06459583|OTHER|Videoconference Telehealth Platform|Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
219166475|NCT06784362|OTHER|No intervention|This is an observational study
219237945|NCT05325983|OTHER|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
219166476|NCT06143670|DRUG|Stannous fluoride toothpaste|0.454% w/w SnF2
219166477|NCT06143670|DRUG|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
219166478|NCT03373097|BIOLOGICAL|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
219166479|NCT06229964|OTHER|SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
219166480|NCT06229964|OTHER|Sham SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
219166481|NCT03875573|DRUG|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
219166482|NCT03875573|RADIATION|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
219166483|NCT03875573|DRUG|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
219166484|NCT06786182|BEHAVIORAL|PFM Educational Program|A structured telematic educational program covering PFM anatomy, function, and proper activation techniques. Content includes videos, visual guides, and exercises aimed at promoting PFM co-contraction and awareness.
219166485|NCT06789120|OTHER|Instrument-assisted soft tissue mobilization|In the study, the Graston device will be applied to the plantar flexor muscles of the patients. The medial and lateral gastarosoleus muscles and tendon will be applied deeply for 3 minutes, and the soleus muscle will be applied deeply for 90 seconds.
219166486|NCT06789627|OTHER|RPD with PEEK framework|Indirectly CAD/CAM produced PEEK framework
219166487|NCT06789627|OTHER|RPD with metallic framework|Indirectly CAD/CAM produced metallic RPD
219166488|NCT06785974|DRUG|Atorvastatin|Daily 20mg atorvastatin.
219166489|NCT06785974|DRUG|Placebo|Daily Placebo in combination with ICI-therapy
219166490|NCT06784531|DIETARY_SUPPLEMENT|Mitoquinone mesylate (MitoQ)|Four 20 mg MitoQ capsules (80 mg total) are ingested orally.
219166491|NCT06784531|DIETARY_SUPPLEMENT|Placebo|Four placebo (microcrystalline cellulose) capsules are ingested orally.
219166492|NCT06784531|OTHER|Cold Water Hand Immersion|Volunteers place one hand in cold (54°F) water for 30 minutes.
219166493|NCT06784531|OTHER|Cold Air Exposure|Volunteers sit in cold (41°F) air for 90 minutes.
219166494|NCT06786065|OTHER|No intervention (observational study)|No intervention (observational study)
219166495|NCT06792526|OTHER|IVIM Imaging MRF Imaging|IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of Head and Neck Cancer undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage. MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
219166496|NCT06316154|PROCEDURE|Echinococcectomy|Echinococcectomy with subsequent pathomorphological analysis of liver parenchyma next to and in the thickness of the fibrous capsule
219166497|NCT06783816|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
219166498|NCT06790849|DIETARY_SUPPLEMENT|Active 1 ETAS®|300 mg ETAS®
219166499|NCT06790849|DIETARY_SUPPLEMENT|Active 2 ETAS®|1500mg ETAS®
219166500|NCT06790849|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule
219166501|NCT06790745|PROCEDURE|Epidural blood patch|Patients will receive epidural blood patch injection
219166502|NCT06790745|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma rich fibrin injection by Racz catheter
219166503|NCT06785233|DEVICE|Non-Adjustable Intragastric Balloon|Weight Loss with a 12-Month Non-Adjustable Intragastric Balloon is More Effective Compared to a 6-Month Balloon.
219166504|NCT06785233|DEVICE|ORBERA365|endoscopic treatment of overweight and mild obesity using a 12-month non-adjustable intragastric balloon
219166505|NCT04662112|DRUG|NASOX|Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
219166506|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
219166507|NCT03747484|DRUG|Avelumab|Given IV
219166508|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
219166509|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
219166510|NCT06789991|DEVICE|electromyography|electromyographic activity of posterior oblique sling muscles will be measured
219166511|NCT06789276|BEHAVIORAL|Supine position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in either the supine position.
219166512|NCT06789276|BEHAVIORAL|lateral decubitus position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in the lateral decubitus position with the puncture side up.
219166513|NCT05950165|DRUG|CHO-H01|"Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
219166514|NCT05950165|DRUG|CHO-H01 at RP2D|"Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
219166515|NCT05950165|DRUG|Lenalidomide|Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
219166516|NCT06062030|DRUG|DWJ1609|Drug of test group
219166517|NCT06062030|DRUG|DWC202304|Drug of control group
219166518|NCT06783335|DEVICE|Cordella PA Sensor System|"* Patients who receive the Cordella PA Sensor System for monitoring chronic heart failure~* These patients will be monitored for 2 years after receiving the device~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
219166519|NCT06783335|DRUG|Standard of Care Pharmacologic Therapy|"* Patients with chronic heart failure who receive standard medical care without PA pressure monitoring~* These patients will be monitored for 2 years~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
219166520|NCT04477681|OTHER|Data collection|In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, compassionate use/ off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
219166521|NCT06782841|DEVICE|GMA-TULIP Laryngeal Mask|After the anesthesia induction, use the GMA-TULIP laryngeal mask as the airway ventilation device.
219166522|NCT06782841|DEVICE|i-gel Laryngeal Mask|After the anesthesia induction, use the i-gel laryngeal mask as an airway ventilation device.
219166523|NCT06782841|DEVICE|BlockBuster Laryngeal Mask|After the anesthesia induction is over, use the BlockBuster laryngeal mask as the airway ventilation device.
219166524|NCT06310356|DEVICE|Freestyle Libre 3|CGM
219166525|NCT06310356|DEVICE|Glucometer|SMBG
219166526|NCT05847855|DIAGNOSTIC_TEST|Blood collection|Blood collection for fragmentomic profiles of plasma cell-free DNA
219166527|NCT06784609|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
219166528|NCT06787885|DRUG|Levofloxacin + clindamycin|Group 1
219166529|NCT06787885|DRUG|Levofloxacin + cefipime|Group 2
219166530|NCT06787885|DRUG|Moxifloxacin + meronam|Group 3
219166531|NCT06790511|OTHER|bioactive highly filled injectable flowable composite|bioactive highly filled injectable flowable composite
219166532|NCT06790511|OTHER|highly filled injectable flowable composite|highly filled injectable flowable composite
219166533|NCT03233399|DEVICE|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
219166534|NCT03233399|DEVICE|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
219166535|NCT03233399|DEVICE|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
219166536|NCT06789471|DIETARY_SUPPLEMENT|psyllium husk|Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
219166537|NCT06782061|OTHER|DSM17938+Routine clinical treatment|Lactobacillus reuteri DSM17938，5 drops per day by mouth (containing at least 100 million CFU of Lactobacillus reuteri DSM17938)，Routine clinical treatment
219166538|NCT06786598|DIAGNOSTIC_TEST|Cholesterol|Qimica/kit
219166539|NCT05734066|DRUG|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
219166540|NCT01780883|DRUG|melatonin|
219166541|NCT01780883|DRUG|Placebo|Placebo tablets of Circadin®
219166542|NCT04869436|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
219166543|NCT06112171|PROCEDURE|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
219166544|NCT06112171|PROCEDURE|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
219166545|NCT05243069|PROCEDURE|Imaging Technique|Undergo 3D scanning
219166546|NCT04563793|DEVICE|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
219166547|NCT02597946|DRUG|afatinib|
219166548|NCT02597946|DRUG|paclitaxel|
219166549|NCT06779071|DEVICE|NPNP-001|Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.
219166550|NCT06779071|DEVICE|Conjuran|Description: Conjuran 2ml per injection, once a week for 5 injections.
219166551|NCT06778148|OTHER|Ambient AI for clinician documentation|Ambient AI for clinician documentation
219166552|NCT06366373|OTHER|A mental health art exhibition|"The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health."
219166553|NCT06366373|OTHER|printed or online education materials|The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
219166554|NCT06294158|OTHER|Brightness measurement|Measurement of ambience brightness using lux meters
219166555|NCT06294158|OTHER|Sound level measurement|Measurement of ambience sound levels using sound level meters
219166556|NCT04487587|DRUG|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
219166557|NCT04995484|DRUG|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
219166558|NCT05815173|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
219166559|NCT05815173|DRUG|Ladarixin|"Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles."
219166560|NCT05760261|DRUG|Midazolam|Midazolam will be administered.
219166561|NCT05760261|DRUG|GSK3882347|GSK3882347 will be administered.
219166562|NCT00837369|DRUG|Regadenoson|400ug IV bolus injection, single dosage
219166563|NCT02972372|PROCEDURE|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
219166564|NCT02972372|PROCEDURE|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
219166565|NCT05925270|BEHAVIORAL|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
219166566|NCT05925270|BEHAVIORAL|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
219166567|NCT06301919|OTHER|Clinical data|Collecting data from the medical record.
219166568|NCT06301919|OTHER|Imaging data|Collecting data from the medical record.
219166569|NCT06301919|OTHER|Biological data|Collecting data from the medical record.
219166570|NCT05023928|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
219166571|NCT06086171|DRUG|Methadone Hydrochloride|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
219166572|NCT06086171|OTHER|Placebo|Saline solution
219166573|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
219166574|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
219166575|NCT05818228|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
219166576|NCT04578912|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
219166577|NCT04578912|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
219166578|NCT04578912|DEVICE|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
219166579|NCT00216879|DRUG|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
219166580|NCT04659031|DRUG|ABC008|ABC008
219166581|NCT04935320|DRUG|HTL0016878.HCl Solution 10 mg|Oral solution fasted
219166582|NCT04935320|DRUG|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
219166583|NCT06549829|OTHER|Nutritional optimization-led triple prehabilitation Intervention|The nutritional status of the patients was assessed together with the clinical nutritionist to develop an individualized nutritional plan. The experimental group used ordinary dietary supplementation + transoral nutritional supplementation, and the control group used ordinary dietary supplementation. The target energy was basal energy metabolism level \* physical activity level, physical activity level was male: 1.55 female: 1.56; basal energy level was basal metabolism standardized value \* body weight (basal metabolism standardized value for obese patients was 25; basal metabolism standardized value for normal or emaciated patients was 30). Add 600kcal capacity supplement to this. Exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance. Specialized psychological interventions.
219166584|NCT06549829|OTHER|Conventional triple prehabilitation Intervention|Conventional triple prehabilitation: ordinary dietary supplementation; exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance; specialized psychological interventions.
219166585|NCT04058639|PROCEDURE|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
219166586|NCT04058639|PROCEDURE|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
219166587|NCT03711110|OTHER|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
219166588|NCT03711110|OTHER|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
219166589|NCT05796648|BEHAVIORAL|RN-CHeFRx|The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
219166590|NCT04351685|BIOLOGICAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
219166591|NCT04351685|BIOLOGICAL|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
219166592|NCT05058391|BIOLOGICAL|Elaprase|Elaprase IV infusion.
219166593|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
219166594|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
219166595|NCT05160480|DIAGNOSTIC_TEST|Total-body PET imaging|Total-body PET imaging at different timepoints
219166596|NCT02778685|DRUG|Fulvestrant|
219166597|NCT02778685|OTHER|Laboratory Biomarker Analysis|Correlative studies
219166598|NCT02778685|DRUG|Letrozole|Given PO
219166599|NCT02778685|DRUG|Palbociclib|Given PO
219166600|NCT02778685|BIOLOGICAL|Pembrolizumab|Given IV
219166601|NCT01523171|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
219166602|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
219166603|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
219166604|NCT03170141|BIOLOGICAL|Antigen-specific IgT cells|Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3
219166605|NCT06029257|DRUG|Tildrakizumab|As provided in real-world clinical practice.
219166606|NCT06203821|DRUG|NP137|NP137 for the Treatment of Resectable Pancreatic Cancer
219166607|NCT05926024|BEHAVIORAL|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
219166608|NCT05926024|BEHAVIORAL|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
219166609|NCT05926024|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
219166610|NCT05926024|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
219166611|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
219166612|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
219166613|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
219166614|NCT05926024|BEHAVIORAL|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
219166615|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
219166616|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
219166617|NCT05926024|DIAGNOSTIC_TEST|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
219166618|NCT04845945|BIOLOGICAL|PCV15|Blood draw after the vaccination
219166619|NCT00159406|OTHER|Registry and Database|Data Collection
219166620|NCT06776718|PROCEDURE|vNOTES|vNOTES for benign hysterectomy
219166621|NCT06776718|PROCEDURE|vaginal hysterectomy|vaginal hysterectomy for benign hysterectomy
219166622|NCT06776458|OTHER|N/A - Usual Care|Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
219166623|NCT06795256|BEHAVIORAL|Percussion and position change in retrograde intrarenal surgery|To evaluate the effectiveness of this homework on stone clearance rates after RIRC by giving instructions to the patient in the home environment and suggesting percussion (tapping) and movement/position changes to help spontaneous stone passage.
219166624|NCT04046445|DRUG|ATP128|5-6 SC injections
219166625|NCT04046445|DRUG|BI 754091|≥ 7 IV infusions
219166626|NCT04046445|DRUG|VSV-GP128|1 single IV injection
219166627|NCT03833245|BEHAVIORAL|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
219166628|NCT05161715|DRUG|Obicetrapib|10mg obicetrapib
219166629|NCT06318754|DEVICE|Inari Triever Aspiration Catheter|Inari Triever Aspiration Catheter for portomesenteric venous thrombosis
219166630|NCT03944434|DRUG|Ribociclib|ribociclib 600 mg/day orally
219166631|NCT03944434|DRUG|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
219166632|NCT03944434|DRUG|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
219166633|NCT05445700|DEVICE|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
219166634|NCT06751914|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
219166635|NCT06751914|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
219166636|NCT03775109|DRUG|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
219166637|NCT03775109|DRUG|Placebo|100ml 5% Dextrose
219166638|NCT03347383|DEVICE|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
219166639|NCT03743623|DEVICE|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
219166640|NCT03743623|DEVICE|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
219166641|NCT04081714|DRUG|CNM-Au8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.
219166642|NCT04030169|DRUG|Midomafetamine HCl|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
219166643|NCT06093295|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
219166644|NCT05215067|DRUG|AK104|IV infusion,Specified dose on specified days
219166645|NCT05215067|DRUG|Docetaxel|IV infusion,Specified dose on specified days
219166646|NCT06534086|DEVICE|Virtual reality (VR) guided meditation therapy|Tripp application on Meta Quest 3 VR headset
219166647|NCT06534086|OTHER|Treatment as usual|No VR, local anesthetic only
219166648|NCT03226808|DEVICE|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
219166649|NCT04206826|DEVICE|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
219166650|NCT04206826|DEVICE|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
219166651|NCT00830557|OTHER|medical chart review|baseline, 12 month and 36 months
219166652|NCT00830557|OTHER|survey administration|baseline, 6 month, 12 month
219166653|NCT00830557|OTHER|biospecimen collection|baseline
219166654|NCT04876196|OTHER|Selfapy for Bulimia Nervosa|Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
219166655|NCT04867395|BEHAVIORAL|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
219166656|NCT06798272|PROCEDURE|dialysisis with and without glucose in the dialysis|there were assessed three consecutive hemodialysis sessions
219166657|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
219166658|NCT05090124|DRUG|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
219166659|NCT05090124|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
219166660|NCT05703516|OTHER|Capmatinib|There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
219166661|NCT05738746|DIETARY_SUPPLEMENT|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
219166662|NCT05738746|DIETARY_SUPPLEMENT|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
219166663|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
219166664|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
219166665|NCT04982224|DRUG|REGN5093-M114|Administered by intravenous (IV) infusion
219166666|NCT04982224|DRUG|Cemiplimab|Administered by IV infusion
219166667|NCT05691452|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
219166668|NCT06763575|DEVICE|Surgical Glove-Compression Therapy|In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
219166669|NCT06763575|DEVICE|non-compressive plastic gloves|In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
219166670|NCT06772441|DRUG|Androgen deprivation therapy (ADT)|"* Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant"
219166671|NCT05567705|OTHER|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
219166672|NCT06790524|DEVICE|One-piece dental implants with MUA|one-piece dental implants with multi-units abutment mounted on the implants as a single piece provided with different abutment angulation utilizing these implants for All-On-Four prothesis
219166673|NCT06790524|DEVICE|Two-piece dental implants|"Surgical and immediate loading procedures:~On the day of implant placement, patients will receive two-piece implant. After crestal incision and full-thickness flap elevation, the implant sites will be prepared aided by a surgical template. 4 implants will be placed, two aligned in an axial orientation and two will be distally aligned (17 degrees). The standard placement procedure as recommended by the manufacturer will be used. The surgical drills with increasing diameters will be used to prepare the implant sites. Implants will be ideally placed at bone level (or 1 mm deeper depending on the soft tissue thickness). After 3 months as a healing phase, a definitive prosthesis will be fabricated using the same abutments, and the marginal bone loss after the osseointegration phase will be assessed."
219166674|NCT06794034|DEVICE|Intervention|taVNS 25Hz+routine treatment, three times daily, 30 mins
219166675|NCT06794034|DEVICE|Sham Comparator|taVNS 1Hz+routine treatment, three times daily, 30 mins
219166676|NCT06797817|DIETARY_SUPPLEMENT|tributyrin|Participants will receive 1 capsule per day for 12 weeks. Each capsule contains 450 mg of tributyrins. The capsules will have a gelatin coating. In the market, formulations are available with dosages ranging from 200 to 500 mg.
219166677|NCT06797817|OTHER|Placebo|The placebo will consist of potato starch encapsulated under identical conditions to those used for the tributyrin capsules, ensuring adequate blinding of the study.
219166678|NCT06839482|DEVICE|Robotic Assisted Upper Limb Rehabilitation|"The EG will follow a mixed rehabilitation approach for the upper limb, combining Robotic Assisted Upper Limb Rehabilitation and conventional physical therapy (PT) and/or occupational therapy (OT) with a total daily duration of 90 minutes. The Robotic Assisted UL Rehabilitation's session will last 30 minutes, with the following procedure provided:~* First week: alternate between passive mobilization exercises, bilateral mode, and therapist-driven mode.~* Second week: alternate between therapist-driven mode and active-assisted mobilization.~* Third week: alternate between active-assisted mobilization and active mobilization.~* Fourth week: alternate between active-assisted mobilization and active mobilization.~* Fifth week: exclusively perform active mobilization. However, if this proposed progression does not match the patient's motor capabilities, the therapist will optimize the therapeutic program by selecting personalized exercises, following a progressive difficulty approach."
219166679|NCT06839482|OTHER|Control Group (CG)|The CG will follow a conventional occupational therapy (OT) and physical therapy (PT) program for upper limb rehabilitation, with a total daily duration of 90 minutes. Upper limb rehabilitation exercises will be performed with a therapist who will tailor the treatment according to the patient's clinical characteristics and needs. Specifically, upper limb treatment will consist of motor exercises (shoulder, elbow, wrist, and hand) through a mix of individual sessions with both passive and active interventions where possible.
219166680|NCT04842643|BIOLOGICAL|IGSC 20% infusion|IGSC 20% infusion,
219166681|NCT06791681|DRUG|ESO-T01|ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.
219166682|NCT06794281|OTHER|Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result|"O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result.~O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care.~O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation.~O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs.~O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices."
219166683|NCT02226341|DRUG|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
219166684|NCT02226341|DRUG|ACTHar gel|"Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response."
219166685|NCT06796881|OTHER|Instrument assisted soft tissue mobilization|The group will undergo Instrument assisted soft tissue mobilization using M2Tblade, applying it for 40-120 seconds until hyperemia occurs. After treatment, ice packs will be applied for 5 minutes to reduce hyperemia. The therapist will ensure comfort through continuous communication and reporting any discomfort.
219166686|NCT06796881|OTHER|Myofascial release|The therapist will use a cross-hand release technique to release the lumbar spine, ensuring the patient is prone and suitable. They will lean into the patient to the tissue depth barrier, wait, and follow each release, avoiding force or slipping. The technique will be applied for 5 minutes on each side.
219166687|NCT06796881|OTHER|The conventional exercise program|Patients will undergo a 12-session exercise program for 6 weeks, consisting of straight leg raising, bridging exercise, prone hip extension exercise, and abdominal curl exercise. The exercises will be done 3 sets, 10 repetitions each, with 1 minute rest between each set. The abdominal curl exercises involve supine or hook-lying positions with the lumbar spine neutral, with the patient performing a drawing in maneuver to stabilize the abdominal muscles. The progression involves lifting the shoulders, changing arm positions, and holding a weight or medicine ball. The patient's position is hook-lying, maintaining a neutral spinal position.
219166688|NCT02122562|DRUG|Ketamine|Treatment
219166689|NCT06796621|BEHAVIORAL|Building Respectful Online Space (BROS)|Session 1 (40 minutes to 50 minutes): Respectful online relationship (Psychoeducation) using face-to-face approach with 40 minutes to 50 minutes online serious game Session 2 (40 minutes to 50 minutes): Navigating the online world (Psychoeducation) using face-to-face approach with 20 to 30 minutes online music therapy Session 3 (40 minutes to 50 minutes): Behaviour specific cognitions and reflection using face-to-face approach
219166690|NCT06796621|BEHAVIORAL|Healthy diet education program|Session 1 (40 - 50 minutes): Healthy Diet Pyramid (Psychoeducation) using face-to-face approach Session 2 (40 - 50 minutes): Mindful Eating and Healthy Weight Management (Psychoeducation) using face-to-face approach Session 3 (40 - 50 minutes): Healthy Eating Habits for Life (Psychoeducation)using face-to-face approach
219166691|NCT06792890|OTHER|Use Nabla AI Scribe tool provided|"AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.~Nabla leverages its proprietary speech-to-text to transform the conversation into a written context, combined with HIPAA compliant Large Language Models (LLM) like Azure OpenAI's GPT-4. Nabla does not store any audio."
219166692|NCT06792890|OTHER|Use AI Scribe tool provided by Vendor B|AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.
219166693|NCT03924973|BEHAVIORAL|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
219166694|NCT06794385|DRUG|dinoprostone vaginal delivery system|Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
219166695|NCT06794385|DRUG|low dose peroral misoprostol|Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours
219166696|NCT06839716|PROCEDURE|Arm I (Ropivacaine-Poloxamer 407 hydrogel group)|Patients receive intraoperative application of Ropivacaine-Poloxamer 407 hydrogel at the incision site. A mixture of 0.75% Ropivacaine (22.5 mg, 3 mL) and Poloxamer 407-based gel (Welpass, 6 mL) is prepared. The hydrogel is applied as 4 mL between the peritoneum and fascia, and 2 mL is injected subcutaneously around the incision before skin closure. This intervention aims to provide sustained local anesthesia for up to 72 hours.
219166697|NCT06839716|PROCEDURE|Arm II (TAP block group)|"Patients undergo ultrasound-guided subcostal transversus abdominis plane (TAP) block before anesthesia emergence. A total of 30 mL of 0.375% Ropivacaine (15 mL per side) is injected bilaterally between the internal oblique and transversus abdominis muscles. TAP block is a regional anesthesia technique known for effective postoperative pain control, typically lasting 24 to 48 hours.~Both groups receive standardized postoperative analgesia, including IV acetaminophen, fentanyl via patient-controlled analgesia (PCA), and rescue pethidine as needed."
219166698|NCT06813716|OTHER|Neoprene elastic knee sleeve|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
219166699|NCT06813716|OTHER|Neoprene elastic knee sleeve with metal supports|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
219166700|NCT06839417|BEHAVIORAL|Exercise|using squash exercise
219166701|NCT06837623|DRUG|Colchicine Tablets|"Oral colchicine tablets. The dosing regimen is as follows:~* Patients weighing \>70 kg: 0.5 mg twice daily (BID)~* Patients weighing ≤70 kg: 0.5 mg once daily (OD) Administered for 3 months"
219166702|NCT06838910|DRUG|Experimental: tislelizumab+anlotinib|All patients will receive tislelizumab 200mg on Day1 every 3-week plus anlotinib 12mg or 10mg or 8mg on Day 1-14 every 3-week (Q3W) until disease progression.
219166703|NCT06797661|DIAGNOSTIC_TEST|Functional MRI|"11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2).~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
219166704|NCT06797661|DIAGNOSTIC_TEST|FDG-PET|"Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg.~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
219166705|NCT06797661|DIAGNOSTIC_TEST|Structural MRI|"Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight .~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
219166706|NCT06014034|OTHER|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
219166707|NCT06173310|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
219166708|NCT06791993|DRUG|Placebo Capsule|Participants will receive an inert placebo capsule that matches the probiotic capsule in size, shape, and color. The placebo will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
219166709|NCT06791993|DIETARY_SUPPLEMENT|Probiotic with Human Milk Oligosaccharides (HMO)|Participants will receive a dual-strain probiotic containing Human Milk Oligosaccharides (HMO) in capsule form. The probiotic will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
219166710|NCT06794398|DEVICE|V-CPR inside a room when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
219166711|NCT06794398|DEVICE|V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
219166712|NCT06793982|DEVICE|Platelet Rich Plasma Joint Injection|Magellan Autologous Concentration System, ISTO Biologics
219166713|NCT06793982|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
219166714|NCT06795594|PROCEDURE|cheek acupuncture|Cheek Acupuncture
219166715|NCT06795594|DRUG|sufentanil 2 µg/kg + ondansetron 0.2 mg/kg|The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.
219166716|NCT06795620|DRUG|Adipose tissue derived mesenchymal Stroma/stem Cells transplantation|Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
219166717|NCT05457998|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
219166718|NCT05457998|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
219166719|NCT05457998|DIAGNOSTIC_TEST|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
219166720|NCT06472219|DRUG|Prednisolone 30 mg|This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
219166721|NCT06472219|DRUG|Placebo|This a tablet identical to prednisolone.
219166722|NCT06083597|OTHER|Qualitative interview|Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.
219166723|NCT06833671|OTHER|Apple juice|A preoperative carbohydrate load was done two hours before the operation using a10 ml/kg, with a maximal volume of 250 ml of commercial brand of apple juice (glucose 28 g in 250 ml).
219166724|NCT06833671|DRUG|Anhydrous glucose|A preoperative carbohydrate load was done using 1.75mg/kg/dose of anhydrous glucose (Alpha Chmika).
219166725|NCT06833671|OTHER|Water|Patients received water.
219166726|NCT06792630|BEHAVIORAL|laughter therapy intervention|"In addition, patients in the intervention group were given laughter therapy intervention from the 1st day of HSCT, with the mnemonic hihihi (pinyin spelling), hahahaha, eggplant eggplant eggplant, qixi qixi qixi qixi, hahahahahahahahaha, 30 times of the mnemonic as a training session, once a day, from the beginning of the transplantation transfusion +1d to the end of the transplantation transfusion +1d, and then to the end of the transplantation. Patients were discharged from the warehouse, and after discharge, patients were centralized on-line laughter therapy intervention, 1 time/week, repeating 30 times of mnemonics, until 1 year after transplantation."
219166727|NCT06838728|DEVICE|Head Mounted Magnifying Glasses|This study was divided into an experimental group and a control group based on whether a head mounted magnifying glass was used.
219166728|NCT06519669|BIOLOGICAL|GT201 injection|GT201 injection to treat Advanced lung cancer
219166729|NCT00739648|DRUG|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
219166730|NCT00739648|DRUG|Placebo|same frequency as study drug using the same method of delivery
219237946|NCT05325983|OTHER|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
219237947|NCT05469607|DEVICE|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
219237948|NCT02845921|OTHER|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
219237949|NCT02845921|OTHER|leg wrapping|Esmarch bandage is used to wrap each lower limb
219237950|NCT02845921|OTHER|control|no intervention has been done
219166731|NCT06407856|OTHER|conventional therapy|The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks
219237951|NCT03155399|OTHER|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
219237952|NCT03155399|OTHER|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
219237953|NCT03647449|DIETARY_SUPPLEMENT|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
219237954|NCT03647449|BEHAVIORAL|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
219166732|NCT06407856|OTHER|Dual Task Training|Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
219237955|NCT03647449|DIETARY_SUPPLEMENT|Plant-based meal|Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
219237956|NCT04449822|PROCEDURE|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
219237957|NCT04449822|PROCEDURE|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
219237958|NCT01739738|DEVICE|Ureteral Stent|patients who need to receive stent as per standard of care
219237959|NCT02428595|DEVICE|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
219237960|NCT01818999|DRUG|IXABEPILONE|injection
219237961|NCT01818999|RADIATION|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
219237962|NCT02588521|DRUG|AL-794|
219237963|NCT02588521|OTHER|Placebo/Vehicle|Suspension vehicle without active drug
219237964|NCT03374722|DRUG|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
219237965|NCT00424476|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
219237966|NCT00424476|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
219237967|NCT00424476|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
219237968|NCT05504447|OTHER|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
219237969|NCT05504447|OTHER|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
219166733|NCT06795919|PROCEDURE|: delayed surgical repair of alveolar cleft using particulate cortico-cancellous anterior iliac bon|skin incision was marked 2-4 cm from the crest to anterior iliac spine height. This is done to avoid pain at the beltline if the incision is made directly over the anterior ilium. As well as avoid injury to the lateral femoral cutaneous nerve. After the anatomical marking are drawn using betadine solution, the site is injected with local anesthesia at the subcutaneous level. The skin incision line is made parallel to the iliac crest and posterior to the anterior iliac spine. Scalpel blade number 10 is used. The incision of the skin and subcutaneous fat was performed. Blunt dissection is carried out at the level of subcutaneous tissues to separate the fascia from fat. Cautery is used to control any hemorrhage. Using a number 15 blade, fascia was incised which covers the iliac spine. A hypo vascular plane was identified. It is located over the anterior iliac spine, as well as between the insertions of tensor fascia laterally and the external and the transverse abdominal muscles medially
219166734|NCT06518681|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
219166735|NCT06784284|OTHER|Glasgow Outcome Scale -Extended (GOSE)|Questionnaire to cotate the neurological deterioration following mild head trauma. Score from 1 to 8, the higher the number the better the outcome
219178164|NCT06266806|BEHAVIORAL|Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources|Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
219237970|NCT01653106|PROCEDURE|cryotherapy|Receive shaved ice
219237971|NCT01653106|OTHER|questionnaire administration|Participate in PROMS
219237972|NCT01653106|OTHER|pharmacological study|Correlative studies
219237973|NCT05526937|OTHER|Bread|Bread portions of 50 gram available carbohydrates.
219237974|NCT05073393|BEHAVIORAL|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
219166736|NCT03930199|OTHER|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
219166737|NCT06289491|PROCEDURE|Hydrus Microstent|Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
219166738|NCT06289491|PROCEDURE|Incisional goniotomy|Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
219166739|NCT06289491|PROCEDURE|Excisional goniotomy|Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
219166740|NCT04173663|BEHAVIORAL|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
219166741|NCT06839573|OTHER|Experience with virtual reality glasses|"If the group belongs to GE (teaching with in-person simulation in the classroom and teaching with VR headsets), they will also receive the two training sessions described for GC:~30 minutes of individual training through VR (headsets and controllers to perform actions while receiving immediate feedback through VR) before the in-person simulation."
219166742|NCT03503955|OTHER|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
219166743|NCT03503955|OTHER|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
219178165|NCT05092126|BEHAVIORAL|Exercise|Calculate oxygen consumption
219178166|NCT06189209|DRUG|Tenalisib|Tenalisib will be administered 800mg/ 400mg BID, orally
219178167|NCT05916664|BEHAVIORAL|Kinto Care Coaching|Describe the basics of the intervention
219178168|NCT05885464|BIOLOGICAL|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
219178169|NCT04118192|PROCEDURE|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
219178170|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
219178171|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
219166744|NCT06839612|PROCEDURE|Two-point method|In the two-point method, the distal end of the drainage tube was passed over the duodenal and intestinal lumen of the common bile duct during PTCD operation. In the process of sinus dilation, guide wire was sent into the intestinal lumen through the drainage tube, and then the drainage tube was inserted into the intestinal lumen with the extract forceps under the duodenoscope in reverse order to drag the drainage tube into the intestinal lumen before being sent into the guide wire.Clamp the guide wire with the access pliers and slowly draw out the guide wire through the mouth. Expand the outer inlet skin.When the skin was 6mm, the epigastric PTCD tube was removed, the percutaneous nephrostomy dilator was placed through the guide wire, and the patient was instructed to be drawn by the assistant.The mouth end of the guide wire, the surgeon pulls the other end of the guide wire, so that the two ends of the guide wire fix in vitro to form a higher tension to Expand the skin.
219166745|NCT06839612|PROCEDURE|Conventional PTCS|PTCS can be divided into three steps: PTCD, sinus dilation, and lithotomy. In PTCD, we first performed intraoperative fluoroscopy, and punctured the biliary tract at a relatively straight Angle with the target biliary tract as far as possible. The distal end of the indenture drainage tube was inserted into the duodeno-intestinal cavity through the end of the common bile duct. The PTCD drainage tube was indwelled for 3-5 days.When the sinus was mature, we used dilated sheath tubes to dilate the sinus to 14-18Fr at a time, and used the working channel established by the choledochoscope to carry out net basket stone extraction. If large diameter stones were difficult to be extracted through the net basket, mechanical lithotomy was adopted to solve the problem, and conventional anti-inflammation was adopted in all patients after surgery. Cholangiography or epigastric CT were used to confirm complete removal of the stones after lithotomy.
219166746|NCT06506760|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
219166747|NCT06506760|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training). Thirty minutes of ergotherapy. Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
219166748|NCT06839768|PROCEDURE|Standard endoscopic enucleation of the prostate (EEP)|Stabdard EEP will be nerformed using 26 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
219166749|NCT06839768|PROCEDURE|MiLEP|Minimally-invasive laser EEP will be nerformed using 22 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
219166750|NCT05093972|DRUG|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
219166751|NCT05333263|DEVICE|Treadmetrix|Programmable treadmill that delivers controlled postural disturbances
219166752|NCT06797570|OTHER|Communication Strategy for Side Effect Counseling in ADHD Treatment|One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.
219166753|NCT06840197|DIAGNOSTIC_TEST|NG-TestⓇ Monkeypox virus kit|Evaluation of the performance of the rapid diagnostic test (RDT) for the detection of the Mpox virus (NG-TestⓇ Monkeypox virus kit) and comparision with PCR result (reference test)
219166754|NCT06839183|DEVICE|integrated interactive self-care APP|integrated interactive self-care APP
219166755|NCT06839378|PROCEDURE|intravenously inject with 5-FU (400 mg/m2)|5-FU (400 mg/m2) will be injected IV bolus before operation. After CRS, the patients will be treated with cisplatin or cisplatin + docetaxel HIPEC respectively. The tumor tissue samples of patients will be collected before and after HIPEC treatment. The tumor tissue samples before and after HIPEC treatment will be sequenced by Flura-seq using high-throughput sequencing technology, and the changes of newly generated transcripts in tumor tissue during HIPEC will be analyzed. The differentially expressed genes in the cisplatin group and the cisplatin + docetaxel group will be compared to evaluate the effect of different HIPEC regimens on the transient transcriptome of PMP tumor.
219166756|NCT06839677|OTHER|semi-structured interview on Microsoft Teams|Data will be collected through a single semi-structured interview on Microsoft Teams, audio recorded and transcribed in full, and analysed using NVivo V1.6.2.32. Participants' statements will be categorised into semantic categories and subsequently refined into sub-themes and themes through an iterative process.
219237975|NCT03014349|OTHER|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
219166757|NCT06794801|DEVICE|Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）|In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.
219166758|NCT06794801|DEVICE|Conventional Drug coated balloon (DCB)|In the control arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successful lesion preparation (residual stenosis ≤ 30%, no type C dissections, no significant residual plaque burden, no dissection involving the media or adventitia, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no location at the stent distal end, no hematoma, TIMI thrombus burden grade ≤ 2) will be treated with a conventional DCB coated with 3 μg/mm2 paclitaxel. If angiographic and intravascular imaging results are unsatisfactory, a bailout DES will be implanted.
219166759|NCT03426293|OTHER|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
219166760|NCT04958122|DRUG|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
219166761|NCT04958122|DRUG|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
219166762|NCT06836466|OTHER|Google Form-based questionnaire|All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire includes introductory personal, academic, and work experience data about the physicians as gender, age, current specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience.
219166763|NCT06797791|DEVICE|Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation|The experimental stimulation protocol included 3 trains of cTBS with an inter-train interval of 10 min. Each train of cTBS consisted of 600 pulses applied in blocks at the theta frequency (200ms) with a duration of 40 s. A block of pulses consisted of 3 pulses at 50Hz frequency, stimulus intensity being estimated as 80% of the RMT. Stimulation application was performed by positioning the Magventure MMC-140 coil over the vertex (Cz) according to the 10-20 EEG system overlapping bilateral motor and somatosensory cortical areas.
219166764|NCT06793969|PROCEDURE|Swartz sheath with Angioplasty Guidewire-Assisted Technique for PFO tunnel passage|"The angioplasty guidewire is advanced into the left atrium and left superior pulmonary vein (LSPV). The Swartz sheath is then delivered to the left atrium along the 0.014 guidewire through the PFO. Next, the Runthrough guidewire is changed to a 0.035 J-tipped guidewire, which is advanced into the LSPV. Finally, the delivery sheath for the PFO closure device is introduced to the left atrium along the guidewire, and all other toolkits are withdrawn."
219166765|NCT06793969|PROCEDURE|Conventional technique to pass the PFO tunnel|In the conventional group, the PFO closure procedure is performed with a multi-functional catheter and guided by intraprocedural fluoroscopy and ICE
219166766|NCT06795867|BEHAVIORAL|acceptance and commitment therapy|a 'third wave behavioral management
219166767|NCT06740656|OTHER|No Interventions|no intervention
219166768|NCT04847544|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
219166769|NCT04847544|DRUG|Placebo|Placebo administered orally BID for up to 28 days.
219166770|NCT06835153|OTHER|Monthly Performance Feedback with Dashboards (Automated Audit and Feedback)|"Hospital services in the intervention group will receive monthly automated dashboards that provide detailed performance metrics. These include:~The proportion of patients with a discharge letter generated on the day of discharge, The proportion of discharge letters validated on the day of discharge, Median delays for generating discharge letters, Median delays for validating discharge letters. The dashboards are shared with all physicians, nurse managers, and secretarial staff in each service. A designated quality improvement officer is available to assist teams in interpreting the data and implementing organizational changes based on the feedback. The intervention uses real-time data extraction from the hospital's electronic health record system to generate these insights."
219166771|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
219166772|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
219237976|NCT03792178|OTHER|Bulk fill composite|Composite resin dental material
219237977|NCT03792178|OTHER|Nano resin composite|Dental composite material
219237978|NCT04685395|DRUG|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
219237979|NCT01327014|DRUG|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
219237980|NCT01327014|DRUG|Placebo|4 capsules twice a day for 12 weeks.
219237981|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
219166773|NCT06023134|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
219166774|NCT06023134|DIAGNOSTIC_TEST|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
219166775|NCT06363994|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
219166776|NCT06363994|DRUG|Bendamustine Injection|Eligible patients will receive Bendamustine by injection as per the protocol
219166777|NCT06363994|DRUG|Rituximab|Eligible patients will receive Rituximab by injection as per the protocol
219166778|NCT06363994|DRUG|Orelabrutinib Placebo|Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
219166779|NCT04580225|PROCEDURE|Four-Corner Arthrodesis|Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.
219166780|NCT04580225|PROCEDURE|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision|Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
219166781|NCT04223570|DEVICE|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
219166782|NCT02278562|DRUG|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
219166783|NCT02278562|DRUG|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
219166784|NCT02278562|OTHER|placebo|placebo capsules and injection
219166785|NCT04953884|DRUG|wilate|wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
219166786|NCT06238960|OTHER|Telerehabilitation|the patient will undergo 10 session of tele rehabilitation in continuity with traditional physiotherapy
219166787|NCT06238960|OTHER|Traditional rehabilitation|the patient will undergo 16 session of outpatient physiotherapy rehabilitation
219166788|NCT06518759|OTHER|traditional chest techniques|patients will receive traditional chest techniques in the form of percussion and vibration, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks
219166789|NCT06518759|OTHER|Glossopharyngeal breathing exercise|patients will receive Glossopharyngeal breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
219166790|NCT06518759|OTHER|Diaphragmatic breathing exercise|patients will receive diaphragmatic breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
219166791|NCT05000827|DEVICE|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
219166792|NCT05000827|OTHER|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
219166793|NCT05783401|OTHER|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
219166794|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
219166795|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
219166796|NCT06128681|PROCEDURE|Intraairway ultrasound-guided mediastinal opening technique|Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses
219166797|NCT02630823|DRUG|MK-3475|
219166798|NCT02630823|PROCEDURE|Surgical resection (standard of care)|
219166799|NCT02630823|DRUG|Paclitaxel (standard of care)|
219166800|NCT02630823|DRUG|Carboplatin (standard of care)|
219166801|NCT02630823|RADIATION|Radiation (standard of care)|
219166802|NCT02630823|PROCEDURE|Endometrial biopsy|
219166803|NCT02630823|PROCEDURE|Peripheral blood draw|
219166804|NCT05710406|DRUG|Encorafenib|Given PO
219166805|NCT05710406|BIOLOGICAL|Cetuximab|Given IV
219166806|NCT05710406|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219166807|NCT05710406|PROCEDURE|Computed Tomography|Undergo CT
219166808|NCT05710406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219166809|NCT05710406|OTHER|Patient Observation|Undergo observation per usual care
219166810|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
219166811|NCT05130450|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
219166812|NCT06323889|BEHAVIORAL|Modified Alternate Day Fasting|Participants are instructed to fast every other day.
219166813|NCT06323889|BEHAVIORAL|Time-Restricted Eating|Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
219166814|NCT06323889|BEHAVIORAL|Weight-loss counseling|Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
219166815|NCT04534933|DEVICE|Evone|Airway ventilation device
219166816|NCT04534933|DEVICE|Primus|Airway ventilation device
219166817|NCT05037266|BIOLOGICAL|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
219166818|NCT06147830|OTHER|None (Observational study)|Not Applicable since Observational Study
219166819|NCT03708224|BIOLOGICAL|Atezolizumab|Given intravenously (IV)
219166820|NCT03708224|BIOLOGICAL|Tocilizumab|Given IV
219166821|NCT03708224|BIOLOGICAL|Tiragolumab|Given IV
219166822|NCT03169764|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219166823|NCT03169764|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
219166824|NCT03169764|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219166825|NCT03169764|BIOLOGICAL|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
219166826|NCT03169764|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219166827|NCT03169764|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219166828|NCT03169764|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219166829|NCT03169764|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
219166830|NCT03169764|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219166831|NCT03169764|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219166832|NCT03169764|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
219166833|NCT03169764|DRUG|Lovaza|Omega-3-acid ethyl esters
219166834|NCT03169764|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
219237982|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
219237983|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
219166835|NCT03169764|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\]
219166836|NCT03169764|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen (CEA) vaccine
219166837|NCT03169764|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 (HER2) vaccine
219166838|NCT03169764|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219166839|NCT03169764|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1) vaccine
219166840|NCT03169764|BIOLOGICAL|GI-4000|Ras yeast vaccine
219166841|NCT03169764|BIOLOGICAL|GI-6207|CEA yeast vaccine
219166842|NCT03169764|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219166843|NCT03169764|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
219166844|NCT03512314|DRUG|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
219166845|NCT06494683|DRUG|Pueraria lobata radix|The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
219166846|NCT03391466|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
219237984|NCT00657709|BIOLOGICAL|Infanrix Hexa|Routine vaccination
219237985|NCT00657709|BIOLOGICAL|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
219237986|NCT00657709|BIOLOGICAL|Prevenar|Routine vaccination
219237987|NCT00004731|DRUG|Coenzyme Q10|
219166847|NCT03391466|DRUG|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
219166848|NCT03391466|DRUG|Cyclophosphamide|Administered intravenously
219166849|NCT03391466|DRUG|Fludarabine|Administered intravenously
219166850|NCT06518135|OTHER|SLNB group|After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
219166851|NCT05126862|BEHAVIORAL|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
219166852|NCT06443320|OTHER|patient included in experimental groupe will view the video excerpt, a playtime, a drawing activities|Patients included in the videodrama arm will participate in a total of 18 videodrama sessions, with one session per week. Each session will include a patient welcome period, the viewing of a video excerpt (in slow motion or not), a playtime, a drawing period, and a group closing session. For the play and drawing activities, the same materials will be provided in each department and for each group, including small figurines, animals, shapes (such as cubes, triangles, circles), small plush toys, markers, colored pencils, and A4 white sheets of paper.
219166853|NCT06333340|DRUG|Oxytocin|Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
219166854|NCT06333340|DRUG|Carbetocin|Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
219166855|NCT05956145|DRUG|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
219166856|NCT05956145|OTHER|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
219166857|NCT03655132|BEHAVIORAL|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
219166858|NCT06392997|DIAGNOSTIC_TEST|Saliva sample|Saliva sample
219166859|NCT05568004|BEHAVIORAL|Combined exercise|aerobic plus resistance exercise
219166860|NCT05568004|BEHAVIORAL|Aerobic exercise|Only aerobic exercise
219166861|NCT03454750|DRUG|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
219166862|NCT04119284|DEVICE|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
219166863|NCT04995068|RADIATION|Head CT to determine presence of traumatic intracranial lesion|Head CT to determine presence of traumatic intracranial lesion
219237988|NCT02634593|BEHAVIORAL|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
219237989|NCT03845088|PROCEDURE|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
219166864|NCT02478892|OTHER|Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen|Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.
219166865|NCT02478892|OTHER|Blood sample collection for research|Up to 40mL of blood may be collected for analysis at each screening examination.
219166866|NCT04782544|OTHER|Buttermilk Powder|Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
219166867|NCT04782544|OTHER|Anhydrous Milk Fat|Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
219166868|NCT06157437|DEVICE|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
219166869|NCT06334952|DEVICE|transcranial direct current stimulation|Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
219166870|NCT05813496|DRUG|Alpha-Lipoic Acid (ALA)|Oral tablet
219166871|NCT05813496|DRUG|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
219166872|NCT05531643|DEVICE|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
219166873|NCT05531643|DEVICE|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
219166874|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
219166875|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
219166876|NCT05175547|DRUG|Clevidipine|Blood pressure management with Clevidipine
219166877|NCT04972513|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219166878|NCT04972513|PROCEDURE|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
219166879|NCT04972513|PROCEDURE|Oscillometry|Undergo airwave oscillometry
219166880|NCT04972513|PROCEDURE|Spirometry|Undergo spirometry
219166881|NCT04972513|OTHER|Survey Administration|Complete survey
219166882|NCT04972513|PROCEDURE|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
219166883|NCT05678959|DRUG|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
219166884|NCT05678959|DRUG|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
219166885|NCT05797376|DRUG|Rivaroxaban 2.5mg|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
219166886|NCT05777447|PROCEDURE|Mycotic aortic-iliac aneurysms and in situ reconstruction|Surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction
219166887|NCT06297447|OTHER|PNE4Adults - pain science education|Is formerly described under arm descriptions
219166888|NCT06297447|OTHER|Usual care|Is formerly described under arm descriptions
219166889|NCT02764138|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
219166890|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
219166891|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
219166892|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
219166893|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
219166894|NCT05919082|DRUG|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
219166895|NCT05919082|DRUG|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
219166896|NCT03479476|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
219166897|NCT03479476|DRUG|Metformin|Active medication.
219166898|NCT03946527|DRUG|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
219166899|NCT05586737|DRUG|Rituximab|1 gram rituximab twice with two weeks interval
219166900|NCT05153915|DRUG|Tacrolimus granules|Oral
219166901|NCT05153915|DRUG|Tacrolimus granules|Oral
219166902|NCT06781203|BEHAVIORAL|Digitally delivered CBTI (eCBTI)|Based on the existing consensus concerning non-pharmacological treatment of insomnia, Hvil® includes the following treatment components: sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. Intervention duration is approximately six to nine weeks.
219166903|NCT06780514|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|To our knowledge, this is the first study to perform CPET's in Turner Girls aged \<18 years
219166904|NCT06846294|BEHAVIORAL|Diet|Individualised dietary intervention
219166905|NCT06846294|BEHAVIORAL|Diet and physical activity|Obesity prevention: Diet, Diet and physical activity and standard care
219166906|NCT06844760|DEVICE|Hyaluronic Acid (HA)|Subjects will be treated with 2cc of Perleux body at baseline. After 4 weeks, a touch-up injection will be performed to achieve optimal improvement.
219166907|NCT06846229|OTHER|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of diseases. Patients in this cohort will undergo standard examinations, with clinical decisions guided by the recommendations generated by the AI system.
219166908|NCT05672186|BEHAVIORAL|Full-service market intervention|Full-service mobile market implementation: the market will visit intervention sites weekly. The market will carry items from all food groups including fresh, frozen and canned fruits and vegetables, whole grains, dairy/ dairy substitutes, proteins (e.g., frozen meat/fish, beans, eggs), and dry goods (e.g., cooking oil, spices). Prices on the market are affordable, approximately 10% lower than grocery stores.
219166909|NCT05672186|OTHER|No intervention|No intervention
219166910|NCT06845839|DRUG|CAY001|Polyphosphate (PolyP) - silica nanoparticle (SNP) complex
219166911|NCT06845839|OTHER|Placebo|Vehicle - aqueous solution
219166912|NCT05959785|PROCEDURE|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
219166913|NCT05959785|PROCEDURE|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
219166914|NCT03636503|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment
219166915|NCT03636503|DRUG|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
219166916|NCT03636503|DRUG|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
219166917|NCT03636503|DRUG|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
219166918|NCT06844513|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed using the Da Vinci Xi and the HUGO RAS platform
219166919|NCT06844513|PROCEDURE|Partial nephrectomy|partial nephrectomy (PN) using either the Da Vinci Xi platform or the HUGO™ RAS platform
219166920|NCT06201962|OTHER|Massage|Massage applications will be performed for 15 minutes every morning and evening for two days.
219166921|NCT06201962|OTHER|Foot Reflexology|In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
219166922|NCT06201962|OTHER|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
219166923|NCT06846346|DRUG|Ivonescimab|Ivonescimab 20 mg/kg by intravenous (IV) infusion once every 2 weeks until disease progression.
219166924|NCT06846346|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion, every two weeks for 8 cycles followed by 5FU as maintenance therapy until disease progression.
219166925|NCT06846346|DRUG|Irinotecan|180 mg/ m2 IV over 90 min infusion every two weeks for a minimum of 4 cycles
219166926|NCT06846346|DRUG|Paclitaxel|80 mg/m2 IV at D1, D8 and D15, every four weeks (D1=D28)
219166927|NCT03178760|DIAGNOSTIC_TEST|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~1. Age~2. Gender~3. Weight~4. Length~5. Waist Circumference~6. Body mass index"
219166928|NCT05166694|OTHER|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
219166929|NCT05166694|OTHER|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
219166930|NCT05166694|OTHER|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
219166931|NCT06477263|DEVICE|Neurocytotron|Neuronal regeneration treatment
219166932|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
219166933|NCT06113510|RADIATION|Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography|18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.
219166934|NCT06098586|BEHAVIORAL|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
219166935|NCT06098586|PROCEDURE|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
219166936|NCT05050279|DRUG|Delgocitinib capsule|oral capsule
219166937|NCT05050279|DRUG|Placebo capsule|oral capsule
219166938|NCT05912569|PROCEDURE|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
219166939|NCT04044690|DRUG|human immunoglobulin G|human immunoglobulin G administered subcutaneously
219166940|NCT04044690|DRUG|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
219166941|NCT05006430|BIOLOGICAL|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
219166942|NCT05006430|OTHER|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
219166943|NCT05911100|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
219166944|NCT05911100|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
219166945|NCT05911100|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
219166946|NCT05911100|DIAGNOSTIC_TEST|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
219166947|NCT05911100|OTHER|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
219166948|NCT05911100|DIAGNOSTIC_TEST|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
219166949|NCT05911100|OTHER|Indicators characterizing the severity of the underlying disease|"* Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~* Medications taken."
219166950|NCT06208657|DRUG|Paxalisib, Irinotecan, Temozolomide|Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
219237990|NCT05128799|OTHER|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
219237991|NCT01995981|DRUG|Pazopanib|
219237992|NCT02574286|DRUG|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
219237993|NCT02574286|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
219166951|NCT06238323|BEHAVIORAL|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
219166952|NCT05328531|DRUG|Genakumab for Injection|150 mg/1ml/bottle
219166953|NCT05328531|DRUG|Placebo for Genakumab for Injection|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
219166954|NCT05142423|DRUG|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
219237994|NCT04885140|BEHAVIORAL|Feedback-based health education|This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.
219237995|NCT04885140|BEHAVIORAL|Routine health education|Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
219237996|NCT03137446|OTHER|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
219237997|NCT03530644|DEVICE|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
219237998|NCT03530644|DEVICE|P0.1|The investigational medical device will collect spectral Raman data from tissue.
219237999|NCT02619825|DEVICE|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
219238000|NCT02619825|DEVICE|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
219238001|NCT00863902|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
219238002|NCT00863902|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
219238003|NCT04245722|DRUG|FT596|Experimental Interventional Therapy
219238004|NCT04245722|DRUG|Cyclophosphamide|Lympho-conditioning agent
219238005|NCT04245722|DRUG|Fludarabine|Lympho-conditioning agent
219238006|NCT04245722|DRUG|Rituximab|Monoclonal Antibody
219238007|NCT04245722|DRUG|Obinutuzumab|Monoclonal Antibody
219238008|NCT04245722|DRUG|Bendamustine|Conditioning agent
219238009|NCT05726994|BIOLOGICAL|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
219238010|NCT05726994|OTHER|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
219238011|NCT01280656|DRUG|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
219238012|NCT01280656|DRUG|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
219238013|NCT01280656|DRUG|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
219238014|NCT01280656|DRUG|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
219166955|NCT06146218|BEHAVIORAL|Contemplative-Based Resilience Training (CBRT)|The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
219166956|NCT03468426|DRUG|BI 836880|intra-venous infusion
219238015|NCT02595788|OTHER|Change from supine to prone position|Change from supine to prone position
219238016|NCT06500403|DIAGNOSTIC_TEST|liver and stiffness measurement|liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
219238017|NCT00039052|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
219238018|NCT04842006|DRUG|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
219238019|NCT04842006|DIAGNOSTIC_TEST|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
219238020|NCT04842006|RADIATION|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
219238021|NCT04330573|OTHER|No intervention. Observational study|Observational study
219238022|NCT00572494|DEVICE|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
219238023|NCT00572494|DEVICE|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
219238024|NCT06095778|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
219238025|NCT02393456|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
219238026|NCT02393456|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
219238027|NCT03713229|DIAGNOSTIC_TEST|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
219166957|NCT03468426|DRUG|ezabenlimab|intra-venous infusion
219166958|NCT05119985|PROCEDURE|Peripheral vein cannulation|The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance
219166959|NCT05119985|PROCEDURE|Cannulation without ultrasound|Cannulation is done the conventional way without any ultrasound use.
219166960|NCT06267742|DIAGNOSTIC_TEST|Complete Blood Count (CBC) with Differential|CBC with Differential including Monocyte Distribution Width (MDW)
219166961|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
219166962|NCT06530407|OTHER|Static streching exercise|Static stretching exercises were applied to the M. Gastrocnemious and M. Hamstring muscle groups for both groups. The exercises were applied as a set, with three repetitions for 15 seconds on each leg, with a 20-second rest between repetitions. Static stretching was applied by slowly stretching the relevant muscle group to the point of sensitivity, without straining the pain threshold, and waiting in that position. All stretching exercises lasted an average of 6 minutes.
219166963|NCT05065944|BEHAVIORAL|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
219166964|NCT05065944|BEHAVIORAL|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
219166965|NCT04179149|BEHAVIORAL|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of environmental enrichment: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
219166966|NCT04260230|DEVICE|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
219166967|NCT04846595|OTHER|self questionnaire|Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
219166968|NCT03526861|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
219166969|NCT03526861|DRUG|Placebos|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
219166970|NCT05995613|DEVICE|MABOS|The novel pulse oximeter (MABOS) will be placed to acquire two biometrics: blood oxygen saturation and epidermal melanin concentration.
219166971|NCT05995613|DEVICE|Nonin PureSat|An FDA approved pulse oximeter will be placed to acquire blood oxygen saturation.
219166972|NCT04951921|DRUG|Hyperpolarized 13C Pyruvate|Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
219166973|NCT04221750|BEHAVIORAL|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
219166974|NCT04221750|DRUG|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
219166975|NCT04221750|DRUG|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
219166976|NCT04221750|BEHAVIORAL|Healthy Lifestyle|Group educational sessions that focus on healthy diet, exercise, and social support once a month
219166977|NCT04816149|BEHAVIORAL|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
219238028|NCT03493906|OTHER|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
219166978|NCT04816149|BEHAVIORAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
219166979|NCT06347471|DRUG|Artemether-lumefantrine|Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.
219166980|NCT06347471|DRUG|Dihydroartemisinin-Piperaquine|Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
219166981|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
219166982|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
219166983|NCT06739421|PROCEDURE|NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
219166984|NCT06739421|PROCEDURE|NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
219166985|NCT05244915|OTHER|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
219166986|NCT05244915|OTHER|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
219166987|NCT05244915|OTHER|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
219166988|NCT06625489|DRUG|Part A: Placebo|Placebo will be administered.
219166989|NCT06625489|DRUG|Nintedanib|Nintedanib will be administered.
219166990|NCT06625489|DRUG|GSK3915393|GSK3915393 will be administered.
219166991|NCT06771687|BEHAVIORAL|High intensity interval training|A 12-week high intensity interval training program, with 30 minutes of exercise three times a week. The trainings can be completed at home and will be digitally supervised.
219166992|NCT02305147|OTHER|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
219166993|NCT06840132|PROCEDURE|Exercise|7-station exercise protocol was designed, consisting of motor activities progressing from easy to difficult, with the goal of transforming these activities into permanent skills through meaningful tasks. Each station aimed to gradually improve the patient's motor abilities. Patients were allowed to rest between tasks, and the difficulty of the tasks progressively increased based on each patient's capacity. This 7-station protocol was designed for the first time by our own research team
219166994|NCT06840132|PROCEDURE|Exercise|In addition to the task-oriented training program, the group using plastic static ankle-foot orthoses performed the same 7-station exercise protocol as the task oriented training group. However, participants in this group were required to wear custom-made plastic static ankle-foot orthoses while completing the exercises.
219166995|NCT05573945|BEHAVIORAL|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
219166996|NCT05573945|BEHAVIORAL|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
219166997|NCT06798844|DEVICE|Spinal Cord Stimulation|SCS is an established treatment for chronic neuropathic pain and the implantation procedure in this study follows the conventional clinical approach. Under local anaesthesia, a lead electrode is positioned in the spinal epidural space at the Th8-Th10 vertebral levels. The electrode is then connected to an external stimulator (implantable pulse generator, IPG), used for the 3-week external trial stimulation. Upon completion of the core trial, the electrode may either be removed or connected to an internal IPG, after extensive counselling and dependent on the FOG outcome and patient's preference. A subsequent long-term open label phase will evaluate the long-term efficacy and safety of SCS on FOG, with a follow-up period of six months. Electrophysiological recordings of the dorsal spinal cord will be conducted at the end of the external trial stimulation and at the 6-month follow-up.
219166998|NCT06798844|OTHER|Spinal electrophysiological recordings|The sole purpose of the control groups in this study, is to facilitate the interpretation of spinal cord electrophysiological characteristics in PD freezers by providing a comparison with individuals without the condition.
219238029|NCT00610194|DRUG|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
219166999|NCT05090826|DEVICE|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
219167000|NCT05147688|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219167001|NCT05795946|DIETARY_SUPPLEMENT|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
219167002|NCT04249713|DRUG|Brodalumab|Interleukin 17 Receptor A Antagonist
219167003|NCT06637163|DRUG|Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy|Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
219167004|NCT06637163|DRUG|Paclitaxel + Carboplatin + Radiotherapy|Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
219167005|NCT06001177|DRUG|KAN-101|Dose KAN-101 Intravenous (IV) Infusion
219167006|NCT06001177|DRUG|Placebo|Placebo Intravenous (IV) Infusion
219167007|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
219167008|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
219167009|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
219167010|NCT03405740|DEVICE|Remote Patient Management|"1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access"
219167011|NCT03405740|DEVICE|Standard of Care|No intervention
219167012|NCT05452239|DRUG|Eptinezumab|Solution for infusion
219167013|NCT05452239|DRUG|Placebo|Solution for infusion
219167014|NCT05514496|DRUG|NX-019|NX-019 will be administered orally.
219167015|NCT04058626|DIAGNOSTIC_TEST|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
219238030|NCT01775878|DEVICE|Telemonitoring Device|Telemonitoring device was installed in patients' homes
219167016|NCT04058626|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
219167017|NCT04058626|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
219167018|NCT04058626|DIAGNOSTIC_TEST|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
219167019|NCT04058626|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
219167020|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
219167021|NCT03705403|DRUG|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
219167022|NCT03705403|RADIATION|Radiation|Radiotherapy
219167023|NCT04941157|PROCEDURE|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
219167024|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
219167025|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
219167026|NCT02558972|DRUG|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
219167027|NCT02558972|DRUG|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
219167028|NCT02558972|DRUG|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
219167029|NCT02558972|DRUG|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
219167030|NCT04828590|OTHER|No intervention|Due to observational study
219167031|NCT03851367|PROCEDURE|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
219167032|NCT03851367|PROCEDURE|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
219167033|NCT00650104|DRUG|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
219167034|NCT06239792|BEHAVIORAL|Sleep Promotion Program|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
219167035|NCT06321003|DEVICE|OCT (Optical Coherence Tomography)|OCT diagnosis in oral carcinogenesis
219167036|NCT03526354|DRUG|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
219167037|NCT03526354|OTHER|Treatment as Usual|Current antipsychotic medication for 12 weeks
219167038|NCT03979235|DIAGNOSTIC_TEST|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
219167039|NCT06137560|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
219167040|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
219167041|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
219167042|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
219167043|NCT06137560|DEVICE|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
219167044|NCT02498717|DEVICE|GameReady|Cryotherapy and compression
219167045|NCT02498717|OTHER|RICE|SOC ice and elevation
219167046|NCT05032261|DRUG|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
219167047|NCT04575961|DRUG|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
219167048|NCT06967922|BEHAVIORAL|Analytic-Integrative Cognitive Behavioural Therapy|Analytic-Integrative Cognitive-Behavioural Approach: Initial Interview for Information Gathering: comprehensive collection of patient information; Assessment: collection of multidimensional factors; Diagnosis: insomnia and co-morbidities; Analytic-Integrative Analysis for Treatment Decision Making.
219167049|NCT06967922|OTHER|Sleep hygiene education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
219167050|NCT04216381|DIAGNOSTIC_TEST|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
219167051|NCT00084396|DRUG|letrozole|
219167052|NCT00084396|PROCEDURE|conventional surgery|
219167053|NCT05269472|PROCEDURE|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
219167054|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
219167055|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
219167056|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
219167057|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
219167058|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
219167059|NCT01309932|BIOLOGICAL|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
219167060|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
219167061|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
219167062|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
219167063|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
219167064|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
219167065|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
219167066|NCT01309932|DRUG|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
219167067|NCT01309932|DRUG|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
219167068|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
219167069|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
219167070|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
219167071|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
219167072|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
219167073|NCT05386069|DRUG|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
219167074|NCT06175312|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
219167075|NCT06175312|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
219167076|NCT01484353|BEHAVIORAL|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
219167077|NCT04414826|BEHAVIORAL|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
219167078|NCT04414826|BEHAVIORAL|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
219167079|NCT04999592|DRUG|Standard of care without prophylaxis|Administer antibiotics in response to infection
219167080|NCT04999592|DRUG|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
219167081|NCT03162497|DRUG|Azithromycin|Azithromycin 15mg/g eyedrops
219167082|NCT03162497|DRUG|Doxycycline|Doxycycline 100 mg per os
219167083|NCT05747716|DRUG|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
219167084|NCT01467375|DRUG|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
219167085|NCT04277936|DRUG|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
219167086|NCT00197613|DRUG|(A) zidovudine, lamivudine and nevirapine|
219167087|NCT00197613|DRUG|(B) zidovudine, lamivudine and efavirenz|
219167088|NCT00197613|DRUG|(C) zidovudine, didanosine, and nevirapine|
219167089|NCT00197613|DRUG|(D) zidovudine, didanosine, and efavirenz|
219167090|NCT00197613|DRUG|(E) stavudine, lamivudine, and nevirapine|
219167091|NCT00197613|DRUG|(F) stavudine, lamivudine and efavirenz|
219167092|NCT00197613|PROCEDURE|Adherence Strategy Standard of Care (SOC)|
219167093|NCT00197613|PROCEDURE|Adherence Strategy Community-Based DOT|
219167094|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
219167095|NCT02160951|DRUG|LGH447|LGH447, QD
219167096|NCT04850768|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
219167097|NCT04850768|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
219167098|NCT00809497|DRUG|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
219167099|NCT00276796|DRUG|cisplatin|
219167100|NCT00276796|DRUG|paclitaxel|
219167101|NCT00276796|DRUG|topotecan hydrochloride|
219167102|NCT02910713|DEVICE|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
219167103|NCT04756440|BEHAVIORAL|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
219167104|NCT05838469|OTHER|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
219178172|NCT03059030|DEVICE|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
219178173|NCT06799221|BIOLOGICAL|Out-of-specification obecabtagene autoleucel|Out-of-specification (OOS) obecabtagene autoleucel (obe-cel) given as a split-dose infusion based on tumor burden assessment at lymphodepletion according to the United States prescribing information.
219167105|NCT05284071|DEVICE|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
219167106|NCT05486598|DRUG|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
219167107|NCT02421159|BEHAVIORAL|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
219167108|NCT02421159|BEHAVIORAL|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
219178174|NCT05374525|DRUG|APRETUDE|Available as intramuscular injection.
219178175|NCT05374525|DRUG|Cabotegravir OLI|Available as marketed orally administered tablets.
219178176|NCT06243913|PROCEDURE|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
219178177|NCT05642923|DRUG|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
219178178|NCT03199469|GENETIC|Resamirigene bilparvovec|Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
219178179|NCT05332366|DRUG|Delgocitinib cream|Cream for topical application
219178180|NCT05332366|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219178181|NCT05879055|DRUG|PM8002|IV infusion
219178182|NCT05879055|DRUG|FOLFIRI|IV infusion
219178183|NCT05754073|DRUG|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
219178184|NCT05754073|DRUG|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
219178185|NCT05754073|DRUG|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
219178186|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
219178187|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
219167109|NCT03767517|OTHER|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
219167110|NCT03767517|OTHER|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
219167111|NCT06988189|DIAGNOSTIC_TEST|12-lead ECG|12-lead ECG from a conventional ECG machine
219167112|NCT06988189|DIAGNOSTIC_TEST|Continuous long term ambulatory ECG monitoring|Continuous long term ambulatory ECG monitoring using wearable ECG or cardiac monitor
219167113|NCT06988189|DIAGNOSTIC_TEST|Ultra-high-frequency ECG|Ultra-high-frequency ECG acquired using specific acquisition equipment
219167114|NCT06987292|DRUG|IL-17i|IL-17 inhibitors
219167115|NCT06987253|DEVICE|OROXID® forte oral solution|Patients will use OROXID® forte oral solution two to three times daily for 14 days as an adjunct to standard care.
219167116|NCT06987253|DEVICE|OROXID® sensitive oral solution|Patients will use OROXID® sensitive oral solution two to three times daily for 14 days as an adjunct to standard care.
219167117|NCT06987253|OTHER|Standard of Care (SOC)|Patients will receive standard of care meaning proper tooth brushing without the use of any mouthwash or other products aimed at reducing bacteria in the oral cavity.
219167118|NCT06823856|DRUG|Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated table
219167119|NCT06823856|DRUG|Synjardy 12.5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 12.5 mg/1000 mg filmcoated tablets
219167120|NCT03164486|DRUG|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
219167121|NCT05358925|OTHER|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 4-10 minutes long, for a total of \~72 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: symptoms, basic factors about BPD, the naturalistic long term course of BPD, prevalence of BPD and its common comorbid disorders, key principles for recovery, available psychotherapeutic treatment options for BPD, common factors amongst treatments, medications, the interpersonal hypersensitivity model of BPD, and a review of the top 10 tips."
219178188|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
219178189|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
219178190|NCT06242821|OTHER|Standard of Care (SOC)|Patients will continue with their current standard of care treatment.
219178191|NCT06242821|OTHER|Yoga|Patients will be randomized to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
219178192|NCT05453773|OTHER|Questionnaire Administration|Ancillary studies
219178193|NCT05453773|BEHAVIORAL|Tobacco Smoking|Smoke waterpipe tobacco
219178194|NCT01186224|DRUG|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
219178195|NCT03195777|DEVICE|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
219178196|NCT05594693|OTHER|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
219178197|NCT05594693|OTHER|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
219238031|NCT04223674|DIAGNOSTIC_TEST|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
219238032|NCT04413175|OTHER|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
219238033|NCT01589211|BEHAVIORAL|Brief advice|Brief advice of about 10 min accompanied by self-help material
219238034|NCT01589211|BEHAVIORAL|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
219238035|NCT01589211|BEHAVIORAL|Standard cessation course|Cessation course over 6 dates. Group setting.
219238036|NCT04014686|OTHER|No exercise intervention group|no exercise intervention
219167122|NCT05358925|OTHER|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from the first two time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
219238037|NCT04014686|BEHAVIORAL|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
219238038|NCT06197035|PROCEDURE|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
219238039|NCT06197035|PROCEDURE|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
219238040|NCT00409747|DRUG|Minocycline|
219238041|NCT03717558|DRUG|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
219238042|NCT03717558|DRUG|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
219238043|NCT03717558|DRUG|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
219238044|NCT00817739|DRUG|Leuprorelin|Leuprorelin injection
219238045|NCT00817739|DRUG|Flutamide|Flutamide tablets
219167123|NCT05358925|OTHER|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, coping, self-compassion and self-care, stress and anxiety, depression, and healthy sleep habits.
219167124|NCT04937842|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
219167125|NCT06987227|BEHAVIORAL|Intelligent intervention to enhance parent-child connection|"The Intelligent Intervention to Enhance Parent-Child Connection support program is mainly carried out through web pages, Figma software, cloud files and official Line accounts. It can be divided into: the first stage is to provide parents with care knowledge and skills during the hospitalization of premature infants, provide parents with physical and mental support, and encourage parents to establish parent-child connections and prepare for discharge. The second stage is after discharge, continuing to provide premature infants' families with the care guidance needed to respond to the different stages of development of premature infants, including interpersonal support, sleep schedule establishment, crying comfort, premature infant nutrition and couple relationship management, etc., and continue to provide family support, answer questions and track its implementation status."
219167126|NCT06987227|OTHER|Routine care|Premature infants receive routine care during their hospitalization, and general nursing guidance for premature infant discharge care is provided before discharge.
219167127|NCT06988475|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
219167128|NCT06986343|DEVICE|Hyrax|Children in this group are going to use only the Hyrax device.
219167129|NCT06986343|DEVICE|Hyrax and Uplocker Vacuum Device|Children in this group are going to use the Hyrax device and Up-Locker vacuum activator.
219167130|NCT06987214|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
219167131|NCT06863337|DEVICE|CGM|"Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.~Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.~In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation."
219167132|NCT06856551|BEHAVIORAL|Minimal contact control|Participants in the control group received a pamphlet about general dietary and physical activity guidelines.
219238046|NCT03132571|DRUG|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
219238047|NCT03132571|DRUG|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
219238048|NCT03132571|OTHER|Placebo|Oral placebo taken once daily for the course of the study (16 week)
219238049|NCT05688891|OTHER|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
219238050|NCT05688891|OTHER|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
219238051|NCT01741207|DRUG|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
219238052|NCT00165035|DEVICE|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
219238053|NCT00165035|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
219238054|NCT02746783|DRUG|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
219238055|NCT02746783|DRUG|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
219238056|NCT03391778|BIOLOGICAL|ADP adoptive cell therapy|No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219167133|NCT06856551|BEHAVIORAL|Promotion and Prevention Interventions|regulatory focus groups, participants completed a 1-hour educational information session with study staff and received a packet which contained information about energy balance, healthy food choices, exercise recommendations, strategies for weight control, goal setting, and responding to lapses. Participants were encouraged to track their food intake and exercise with a provided log book or free apps (Lose It!; MyFitnessPal). The informational content and intervention procedures were identical except for the framing of messages and tasks. The prevention messages emphasized protecting one's health (e.g., failing to regularly exercise can undermine your weight control program and lead to poor health; if you do not vigilantly follow these behaviors, you will not fulfill your weight control goals or protect your health and well-being; not eating fruits and vegetables results in failure to supply the body with the nutrients it needs). The promotion messages emphasized promoting one's health
219167134|NCT06864468|BEHAVIORAL|Health promotion curricula|3-day summer camp and 9-month health promotion curriculum that focuses on physical activity and nutrition
219167135|NCT06673095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219167136|NCT06673095|PROCEDURE|Excision|Undergo narrow margin excision
219167137|NCT06673095|PROCEDURE|Excision|Undergo wide margin excision
219167138|NCT06673095|OTHER|Survey Administration|Ancillary studies
219167139|NCT06677424|DEVICE|NeuroCatch® Platform 2|The NeuroCatch® Platform 2, a medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information. The device is approved as a medical device by Health Canada.
219167140|NCT03242616|DRUG|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)"
219167141|NCT03242616|DRUG|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
219167142|NCT04150887|DRUG|Cusatuzumab|Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
219167143|NCT04150887|DRUG|Azacitidine|Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
219167144|NCT04150887|DRUG|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
219167145|NCT06188091|BEHAVIORAL|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
219167146|NCT05924256|DRUG|SHR-A1811|SHR-A1811
219238057|NCT06540846|OTHER|No intervention|No intervention since this is an observational study
219167147|NCT05924256|DRUG|SHR 3680 + leuprolide|SHR 3680 + leuprolide
219167148|NCT05924256|DRUG|SHR-A1921|SHR-A1921
219167149|NCT05924256|DRUG|SHR-A1811|SHR-A1811
219167150|NCT06870175|DEVICE|Electronic-Textile-based Electrocardiographic Monitoring|Participants will be invited to wear the Skiin chest band for up to 14 days, as prescribed by their physician. Participants will wear the Skiin chest band in a similar capacity to a conventional Holter monitor.
219167151|NCT06310837|DRUG|Adalimumab Biosimilars Injection|Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
219167152|NCT06310837|DRUG|Corticosteroid|Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
219167153|NCT06310837|DRUG|Immunosuppressive Agents|Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
219167154|NCT02619786|DRUG|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
219167155|NCT06873776|DEVICE|A&L cycling|Participants will complete simultaneous arms and legs cycling for 60min of active cycling. Targeted exercise intensity is 70-85% of the age-predicted maximum heart rate. Cycling resistance will be modified for continuous challenge. A target speed 10% above the highest speed at which each study participant is able to cycle voluntarily without motor, FES, or tSCS assistance will be selected during the first session and maintained throughout all training sessions. Once a participant can complete 60 minutes of continuous cycling at a specific resistance for two consecutive training sessions, the resistance will be increased to the next setting level at the mid-point of the subsequent session. Upon completion of each session, the physical therapists/researcher will complete skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
219167156|NCT06873776|DEVICE|Body weight supported treadmill training (BWSTT)|The physical therapists/researchers will assist the patient with donning any necessary lower extremity braces and a padded walking harness. The patient will be assisted onto the treadmill via a ramp while seated in a wheelchair or by ambulation with physical assistance, clipped into the body weight support system, assisted to stand, and provided the appropriate amount of body weight support to allow for successful stepping for 60 minutes of active walking. During BWSTT, physical therapists/trainers will adjust treadmill speed or incline and the degree of body weight support to challenge participants. Participants will be instructed to exercise with a targeted intensity of 70-85% of the age-predicted maximum heart rate. Upon completion of each session, the harness will be doffed with skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
219167157|NCT04053816|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
219167158|NCT06300892|OTHER|No intervention|samples from the incision site and GI tract collected
219167159|NCT06693817|DEVICE|Wireless skin sensors vital sign monitoring system|The wireless monitoring system will be applied to the newborn and consist of a chest sensor (Anne Arc by Sibel Inc.) and a RAD-7 (Masimo)pulse oximeter limb sensor.
219167160|NCT06693817|DEVICE|Wired vital sign monitoring system|A standard ECG and SpO2 monitoring device will be applied suing the Infinity M540 monitor (Draeger, Germany). The chest sensor will be placed as per standard of care on the newborn's chest and abdomen, and the SpO2 sensor on their hands or feet.
219167161|NCT00909025|DRUG|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
219167162|NCT04526678|DIETARY_SUPPLEMENT|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
219167163|NCT06699264|OTHER|Blood Flow Restriction Training|Pressure cuff is applied to the leg during training for low-load strength training with simultaneous restiction of blood flow
219167164|NCT06699264|OTHER|Training without BFR|Strength training according to experimentral group without simultaneous restriction blood flow
219167165|NCT06146959|DEVICE|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
219167166|NCT06146959|OTHER|Home exercise program|Intrinsic foot strengthening and stretching exercises
219167167|NCT04208126|DEVICE|ECMO|ECMO implantation immediately after ICU admission
219238058|NCT04153357|DEVICE|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
219238059|NCT04153357|DEVICE|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
219238060|NCT04704856|BEHAVIORAL|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
219167168|NCT06692543|OTHER|Active population|1 blood withdraw, questionnaire and tests
219167169|NCT06692543|OTHER|Inactive population|1 blood withdraw, questionnaire and tests
219167170|NCT06641141|PROCEDURE|Induction of Labour|"Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a failed IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia."
219167171|NCT07034885|BEHAVIORAL|Mindfulness-Based Self-Efficacy Development Program|"Mindfulness-Based Self-Efficacy Development Program is a unique intervention model that integrates mindfulness-based practices with self-efficacy theory, structured for postmenopausal women. With the implementation of this research, a holistic and evidence-based intervention model will be presented for physical, psychological and social problems frequently encountered in the postmenopausal period. This program processes mindfulness-based skills such as observing thoughts, body awareness, regulating emotions, coping with stress and developing self-compassion in the axis of self-efficacy development with 8-week structured sessions. In this context, it is anticipated that the study will contribute to scientific knowledge and practices.~In addition, the Mindfulness-Based Self-Efficacy Development Program developed in the study aims not only at symptom management, but also at increasing the individual's perception of control over their own lives, recognizing their internal resources and"
219167172|NCT04954898|DEVICE|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
219238061|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia® bitter|"* ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein"
219238062|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia®|"* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein"
219238063|NCT04876261|DIETARY_SUPPLEMENT|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"* extra virgin olive oil~* 5 mg hydroxytyrosol"
219238064|NCT02111499|DRUG|LAS41004-IMP1|daily topical application
219167173|NCT06710795|DEVICE|MaxTack™ Motorized Fixation Device|All subjects enrolled will receive the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
219238065|NCT02111499|DRUG|LAS41004 IMP2|daily topical application
219238066|NCT02111499|DRUG|LAS41004 IMP3|daily topical application
219238067|NCT02111499|DRUG|LAS41004 IMP4|daily topical application
219238068|NCT02111499|DRUG|LAS41004 IMP6|daily topical application
219238069|NCT02111499|DRUG|LAS41004 IMP5|once daily, topical
219238070|NCT05905068|DRUG|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
219238071|NCT01995214|DRUG|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
219238072|NCT01995214|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
219238073|NCT03400007|DEVICE|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
219238074|NCT03400007|DEVICE|Colpocystodefecography|Colpocystodefecography (CCD)
219238075|NCT00445757|PROCEDURE|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
219238076|NCT00445757|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
219167174|NCT06703814|OTHER|Intraoperative flow-controlled ventilation strategy|"In the FCV group, intraoperative ventilation will be provided with the EVONE (IES Ventinova Medical).PEEP and Ppeak are titrated guided by dynamic compliance, as follows: Starting from a default setting of 5 cmH2O of PEEP and 15 cmH2O of Ppeak, PEEP and Ppeak are equally increased by 1 cmH2O steps and the PEEP value with the highest VT and thus highest dynamic compliance is defined as best PEEP. Subsequently, Ppeak is stepwise (+1 cmH2O) increased until there is no further over-proportional increase in tidal volume (VT) (i.e. measured VT \> expected VT according to measured dynamic compliance), defined as best driving pressure. No recruitment maneuvers are carried out during FCV. With the I:E ratio set to 1:1, flow is adjusted to establish normocapnia (target etCO2 4.5 to 5.8 kPa). FiO2 is adjusted to maintain oxygen saturation (SpO2) \> 92%."
219167175|NCT06703814|OTHER|Intraoperative pressure-controlled ventilation strategy|In the PCV group, intraoperative ventilation will be provided by a standard anesthesia ventilator in use in the respective participating centers. Patients will be ventilated in PCV mode, at the lowest inspired oxygen fraction (FiO2), to maintain oxygen saturation (SpO2) \> 92%. It is left to the discretion of the attending anesthesiologist to use a higher fraction of FiO2. Inspiratory to expiratory ratio is set at 1:1 to 1:2, respiratory rate will be adjusted to target normocapnia (target etCO2 4.5 to 5.8 kPa. VT will be set at 7 to 9 ml/kg predicted body weight (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. Ventilation starts with 5 cm H2O PEEP, and can be increased to 10 cm H2O PEEP.
219167176|NCT06877247|DRUG|[14C] SHR6508 Injection|\[14C\] SHR6508 injection.
219167177|NCT07043738|PROCEDURE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation (aiTBS) will be administered under the supervision of a physician with TMS expertise.
219167178|NCT05242640|OTHER|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
219167179|NCT05242640|OTHER|Exercise|Participants will complete a moderate-intensity walking program
219167180|NCT05242640|OTHER|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
219167181|NCT06733012|DEVICE|Splanchnic nerve block|Catheter based ablation on the right greater splanchnic nerve
219167182|NCT06733012|OTHER|Sham-control procedure|Sham-control ablation procedure
219167183|NCT06741020|DRUG|Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin|Chemotherapy drugs including Oxaliplatin, Fluorouracil,Leucovorin and immunotherapy durgs Adebrelimab will infuse to liver by transarterial catheter toward to the lesion.
219167184|NCT06743997|DRUG|Test Drug (Eutropin Catridge, 48IU/Cartridge)|Liqid somatropin
219167185|NCT06743997|DRUG|Reference Drug (Eutropin, 4 IU/vial)|Lyophilized somatropin
219167186|NCT06747234|OTHER|Oat bran group|Patients consume 28 grams of oat bran daily for two months in addition to their usual medical treatment.
219167187|NCT06747234|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
219167188|NCT05976165|OTHER|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
219167189|NCT06781892|OTHER|Anterior-lateral pad positioning|Defibrillation pads positioned anterior-lateral
219167190|NCT06781892|OTHER|Anterior-posterior pad positioning|Defibrillation pads positioned anterior-posterior
219238077|NCT02626117|DEVICE|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
219238078|NCT02626117|DEVICE|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
219238079|NCT04838509|OTHER|no intervention|retrospective descriptive without intervention
219167191|NCT06781892|OTHER|Double-sequential defibrillation|Combination of anterior-lateral and anterior-posterior pad positioning for a total of 4 pads and 2 shocks.
219167192|NCT06792331|PROCEDURE|vNOTES high uterosacral ligament suspension|Following the entry into the peritoneal cavity via apical colpotomy, a transvaginal retractor was inserted through the vaginal vault and the vaginal access platform was established. The ureters and uterosacral ligaments (USL) were identified via laparoscopic view. Bilateral nonabsorbable sutures were placed by the intermediate portions of the USL at the level of the ischial spines making up a total of 4 stitches (Figure 1). Then, the sutures were slightly weighed to verify proper placement. Then, the V-notes platform was removed and the peritoneum was closed. The aforementioned sutures were fixed to the ipsilateral cardinal ligament stump and the pubocervical fascia on the anterior wall. Finally, the previously mentioned nonabsorbable sutures were attached to the vaginal cuff and tied. Routine postoperative cystoscopy was performed.
219167193|NCT06792331|PROCEDURE|Laparoscopic lateral suspension|The polypropylene mesh used had a width of 2.5 cm and a length of 25 cm. The vaginal cuff was suspended. Blunt dissection was applied to develop vesicovaginal and rectovaginal spaces. The middle part of the mesh was placed flatly in the vesicovaginal space, and fixed with non-absorbable sutures. An atraumatic laparoscopic instrument was inserted through skin incisions of approximately 2-3 mm approximately 3 cm above and 4 cm lateral to the anterior superior iliac spine, followed by perforation only of the aponeurosis of the external oblique muscle and retroperitoneal advancement of the instrument through the lateral abdominal wall. Under laparoscopic visualization, the instrument moved through the bilateral tension-free retroperitoneal tunnels created. The lateral arms of the mesh were secured bilaterally to the aponeurosis of the external oblique muscle and behind the anterior superior iliac spine. Finally, the peritoneum was closed.
219167194|NCT05527093|RADIATION|MRI 3T and MRI 7T|MRI 3T and MRI 7T before and post epilepsy surgery
219167195|NCT03432832|BEHAVIORAL|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
219167196|NCT03432832|BEHAVIORAL|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
219167197|NCT06754579|OTHER|High-Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
219167198|NCT06754579|OTHER|Low Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
219167199|NCT07077512|DRUG|Autoleucel (Relmacabtagene Autoleucel)|Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).
219167200|NCT07077512|DRUG|Sintilimab (PD-1 inhibitor)|Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.
219167201|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
219167202|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
219238080|NCT03385447|BEHAVIORAL|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
219238081|NCT00003996|DRUG|carmustine|
219238082|NCT00003996|DRUG|chemotherapy|
219238083|NCT00003996|DRUG|cisplatin|
219238084|NCT00003996|DRUG|etoposide|
219238085|NCT00003996|RADIATION|radiation therapy|
219238086|NCT00349661|DRUG|impact on VASP test|
219238087|NCT06126887|DEVICE|Incrediwear Daytime Back Brace|Incrediwear Daytime Back Brace
219238088|NCT06126887|DEVICE|Incrediwear Sham Daytime Back Brace|Incrediwear Sham Daytime Back Brace
219238089|NCT06126887|DEVICE|Control Daytime Back Brace|Control Daytime Back Brace
219238090|NCT06126887|DEVICE|Incrediwear 24 Hour Back Brace|Incrediwear 24 Hour Back Brace
219238091|NCT00062907|BIOLOGICAL|Recombinant DNA- pVAX/L523S|
219238092|NCT00062907|BIOLOGICAL|Recombinant adenovirus- Ad/L523S|
219238093|NCT02907905|BIOLOGICAL|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
219238094|NCT03428633|DRUG|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
219238095|NCT03428633|DRUG|Morphine|Morphine intraoperatively and postoperatively
219238096|NCT05577936|DEVICE|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
219238097|NCT05577936|OTHER|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
219238098|NCT03852069|DIETARY_SUPPLEMENT|Inulin|Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
219167203|NCT07078734|OTHER|Foam roller technique|In this intervention group, the patient is given back and forth oscillations using his or her own weight using a foam roller under the supervision of a physiotherapist.
219167204|NCT07078734|OTHER|Mulligan Straight Leg Raise Technique|This intervention consists of the mulligan straight leg raise technique applied to the patient by a physiotherapist.
219167205|NCT06904495|OTHER|Survey of sleep quality and associated factors|Sleep quality and associated factors (anxiety, depression, and pain) will be evaluated through an online survey on the Reseau Morphee platform, through an self-administered evaluation of the patients' pain and sleep difficulties, and a precarity scale.
219167206|NCT05792423|DEVICE|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
219167207|NCT06467864|PROCEDURE|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
219238099|NCT03852069|DIETARY_SUPPLEMENT|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
219238100|NCT05213312|DRUG|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
219238101|NCT05213312|DRUG|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
219238102|NCT05213312|DRUG|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
219238103|NCT05213312|DRUG|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
219238104|NCT05213312|PROCEDURE|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
219238105|NCT04108403|OTHER|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
219238106|NCT04108403|OTHER|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
219238107|NCT04108403|OTHER|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
219238108|NCT04108403|OTHER|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
219238109|NCT01291472|DRUG|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
219238110|NCT03293238|PROCEDURE|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
219238111|NCT03293238|PROCEDURE|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
219238112|NCT03293238|PROCEDURE|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
219167208|NCT06919458|DRUG|Prednisolone 40 mg|Patients will be screened for infection till 90 days from the day of initiation of prednisolone. the three patient arms will be compared for severity scores of the disease, rate and severity of infections, diabetic control, post-treatment outcomes, and mortality.
219238113|NCT03293238|PROCEDURE|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
219238114|NCT04161716|DEVICE|NIRS recording|Patient has a NIRS module during their urodynamic exam.
219238115|NCT02647333|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
219238116|NCT02647333|DIETARY_SUPPLEMENT|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
219238117|NCT00233610|DRUG|Bicalutamide|
219238118|NCT00233610|DRUG|Tamoxifen|
219238119|NCT02300467|DRUG|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
219167209|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Experimental drug: Nanokine 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Nanogen Biopharmaceutical JSC.~Arm 1 (22 volunteers): Nanokineinjection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex® injection 4000 IU will be administered subcutaneously on Day 29."
219167210|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Comparator drug: Eprex® 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Janssen-Cilag Ltd~Arm 2 (22 volunteers): Eprex® injection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex injection 4000 IU will be administered subcutaneously on Day 29.~Total: 44 participants will be recruited in the trial."
219167211|NCT06927739|DRUG|Orticumab|Orticumab treatment for 24 weeks for post MI population
219167212|NCT06927739|DRUG|Placebo|Placebo for 24 weeks for the post MI population
219167213|NCT06927817|DRUG|hyoscine-n-butylbromide, ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
219167214|NCT06927817|DRUG|• hyoscine-n-butylbromide • ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
219167215|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 12.5 mg|1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).
219167216|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 10 mg|2- Reduced dose group: receiving a20% reduced dose of hyperbaric bupivacaine (10 mg hyperbaric bupivacaine + 25 mcg fentanyl).
219167217|NCT04222660|DIETARY_SUPPLEMENT|Blackmores Omega Daily (4 1g capsules per day)|Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
219167218|NCT06077812|BEHAVIORAL|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
219167219|NCT06077812|BEHAVIORAL|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
219167220|NCT06077812|BEHAVIORAL|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
219167221|NCT06786338|DRUG|SGB-9768|SGB-9768 for subcutaneous (SC) injection
219167222|NCT05385965|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
219167223|NCT03116412|PROCEDURE|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
219167224|NCT06833801|DEVICE|Real-Time Blood Data Monitoring System (Device/Software Integration)|"Description: An alert function will be integrated into the hospital's electronic system, allowing healthcare providers to view real-time blood test results of radiation therapy patients. The system will notify both medical staff and patients of abnormal results, prompting timely intervention.~Mode of Delivery: Hospital Information System (HIS) Integration Purpose: Improve treatment safety by reducing delays in managing abnormal blood counts."
219238120|NCT03064594|PROCEDURE|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
219238121|NCT01282957|BEHAVIORAL|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
219238122|NCT01282957|BEHAVIORAL|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
219238123|NCT02115659|DRUG|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
219238124|NCT02115659|DRUG|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
219238125|NCT06509581|DIETARY_SUPPLEMENT|vitamin E|Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
219238126|NCT06509581|OTHER|PLACEBO|placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
219238127|NCT03488043|PROCEDURE|Needle lung biopsy|Needle lung biopsy
219238128|NCT05120674|BEHAVIORAL|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
219238129|NCT05120674|BEHAVIORAL|CPT|Cognitive Therapy for PTSD
219238130|NCT05120674|BEHAVIORAL|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
219238131|NCT05120674|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
219238132|NCT00476463|DRUG|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
219238133|NCT05095974|DEVICE|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
219238134|NCT05095974|DEVICE|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
219238135|NCT05095974|DEVICE|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
219238136|NCT04862598|DEVICE|Oculus Virtual Reality|The patient will receive standard care, augmented with virtual reality. Their post-operative satisfaction score will be recorded.
219238137|NCT03100370|DEVICE|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
219238138|NCT03100370|DEVICE|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
219238139|NCT03100370|DEVICE|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
219238140|NCT03100370|DEVICE|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
219238141|NCT05715632|DRUG|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
219238142|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
219238143|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
219167225|NCT06833801|BEHAVIORAL|Enhanced Patient Education Materials (Behavioral/Educational Intervention)|"Description: Optimized educational pamphlets and multimedia resources will be provided to patients, including clear self-care instructions and guidance on reporting blood test needs during radiation therapy.~Mode of Delivery: Printed materials, multimedia resources, verbal education by medical staff Purpose: Improve patient understanding and engagement in their treatment process."
219167226|NCT06833801|BEHAVIORAL|Internal Warning Signs and Alerts (Behavioral Intervention)|"Description: Physical reminder signs will be placed in high-traffic patient areas (e.g., check-in counters, treatment rooms) to prompt patients to report discomfort or abnormal symptoms, especially related to blood test needs.~Mode of Delivery: Visual reminders placed within the radiation oncology department Purpose: Increase patient awareness and adherence to treatment safety protocols."
219167227|NCT03768440|PROCEDURE|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
219167228|NCT03768440|PROCEDURE|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
219167229|NCT03768440|DRUG|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
219167230|NCT06835829|DEVICE|Transradial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance transradial access hemostasis
219167231|NCT06835829|DEVICE|Distal radial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance distal radial access hemostasis
219167232|NCT06835829|PROCEDURE|Ultrasound-guidance|Ultrasound guidance for distal radial access
219167233|NCT06835829|PROCEDURE|Conventional guidance|Conventional guidance for distal radial access
219167234|NCT04141774|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
219167235|NCT04141774|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
219167236|NCT04141774|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
219167237|NCT04141774|OTHER|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
219167238|NCT06149104|DRUG|sacubitril/valsartan|sacubiril/valsartan
219167239|NCT06817863|OTHER|Digital|This intervention is a self-help digital treatment, delivered via a smartphone application, for adults with co-morbid binge eating and obesity. The app ChangeBite will integrate principles of evidence based treatments for obesity (behavioral weight loss treatment) and binge eating (cognitive behavioral therapy, acceptance and commitment therapy) into a highly personalized, self-guided, program that leverages an artificial conversational agent and Just-In-Time-Adaptive-Interventions (JITAIs).
219167240|NCT06790056|PROCEDURE|duodenal ndoscopic bind ligation|"We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion.~By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions.~We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success.~You are requested to come for follow up for 3 months for endoscopy prodecure."
219167241|NCT06784388|DEVICE|Deep Brain Stimulation(DBS)|During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
219167242|NCT06784388|DRUG|Esketamine|SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
219167243|NCT06721741|OTHER|Nusmile bioflex crowns|The Bioflex crown is a new synthetic crown that has been introduced in pediatric practice. This crown is believed to offer better adaptation, durability, and ease of handling, along with improved aesthetic properties when compared to conventional crowns
219167244|NCT06721741|OTHER|Stainless steel crowns|Preformed metal crowns are a popular and affordable option as a treatment for dental caries. They offer full crown coverage and help to prevent recurrent caries. However, their aesthetic limitation is a notable drawback
219167245|NCT06787079|OTHER|Kinesio Tape|Kinesio tape is a non-invasive therapeutic approach that does not involve any medication. It is often used to support tissue and reduce pain.
219167246|NCT06787079|OTHER|Pilates|Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
219167247|NCT06787079|OTHER|Placebo|Placebo taping will be applied in the same way as kinesio taping, but with plaster tape.
219167248|NCT05460416|DRUG|Acetylsalicylic acid|160mg once a day
219167249|NCT02520063|DRUG|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
219167250|NCT02520063|DRUG|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
219167251|NCT02520063|DRUG|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
219167252|NCT05005221|BEHAVIORAL|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
219167253|NCT05612477|PROCEDURE|Autotransfusion|blood is collected from the surgical field, washed, processed and transfused back into the patient
219167254|NCT06782659|DRUG|ASP-001|Oral liquid suspension of sildenafil
219167255|NCT06782659|DRUG|Viagra|Sildenafil film-coated tablet
219167256|NCT06782659|DEVICE|ASP-001|Bottle/pump containing ASP-001 suspension
219167257|NCT06120621|PROCEDURE|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
219167258|NCT06477107|DEVICE|Soterix® 4x1HD-TDCS|Is intended for inducing cortical neuromodulation for research and treatment purposes.
219167259|NCT06477107|DEVICE|Soterix® 1x1 tDCS|At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.
219167260|NCT06477107|BEHAVIORAL|Cognitive training program|Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation
219167261|NCT06789562|DEVICE|F-18FDG PET/CT and CT|compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
219167262|NCT06791434|DRUG|"Fixed Dose Combination Etoshine MR tablets"|Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
219167263|NCT06791434|PROCEDURE|Dry needling|Thin needle insertion
219167264|NCT06791434|OTHER|Physiotherapy|Exercises
219167265|NCT06790498|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
219167266|NCT06770309|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
219167267|NCT06770309|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
219167268|NCT05439772|DRUG|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
219167269|NCT03803332|BEHAVIORAL|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
219167270|NCT03803332|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
219167271|NCT04521478|DRUG|BI 1358894|BI 1358894
219167272|NCT04521478|DRUG|Placebo|Placebo
219167273|NCT04521478|DRUG|Quetiapine|quetiapine
219167274|NCT06208462|DRUG|Adebrelimab|1200mg，i.v. , q3w
219167275|NCT06208462|DRUG|Lenvatinib|8mg,qd
219167276|NCT06208462|DRUG|Gemcitabine|800 mg/m2，q3w
219167277|NCT06208462|DRUG|Oxaliplatin|85 mg/m2，q3w
219167278|NCT00922870|DEVICE|Cascade|Cascade treatment over 48h
219167279|NCT00922870|OTHER|Standard treatment|Standard therapy
219167280|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
219167281|NCT02926859|DRUG|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
219167282|NCT02926859|DRUG|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
219167283|NCT02643667|DRUG|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
219167284|NCT02643667|PROCEDURE|Radical prostatectomy|-Standard of care
219167285|NCT03326310|DRUG|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
219167286|NCT03326310|DRUG|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
219167287|NCT04210596|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
219167288|NCT06332911|DEVICE|Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+|Cracking-not-debulking technique (SHOCKWAVE IVL)
219167289|NCT05636358|OTHER|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
219167290|NCT06459310|DRUG|Metformin Hydrochloride tablet|Extended release oral tablets, 1000 mg/day, single dose
219167291|NCT06459310|DRUG|Placebo|Oral tablets, 1000 mg/day, single dose
219167292|NCT05642156|PROCEDURE|isolated Ultrafiltration (iso-UF)|isolated Ultrafiltration
219167293|NCT04712994|OTHER|PrEP Optimization Interventions|A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
219167294|NCT03684109|DEVICE|3T MRI Scanner|3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
219167295|NCT06158126|DRUG|Initiating daily oral PrEP during pregnancy|Group 1a will include pregnant women who initiate oral PrEP when already pregnant, at enrollment into the study.
219167296|NCT06158126|DRUG|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
219167297|NCT06158126|DRUG|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) when already pregnant, at enrollment into the study.
219167298|NCT06158126|DRUG|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis and enrollment into the study.
219167299|NCT06314087|OTHER|Placebo + conventional treatment including radiotherapy|Placebo + conventional treatment including radiotherapy
219167300|NCT06314087|COMBINATION_PRODUCT|Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine|The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
219167301|NCT03169777|BIOLOGICAL|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
219167302|NCT03169777|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
219167303|NCT03169777|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219167304|NCT03169777|BIOLOGICAL|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
219167305|NCT03169777|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219238144|NCT06509646|OTHER|Tia Chi Exercise|"• Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
219238145|NCT06509646|OTHER|Frenkel's Exercise|"Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
219238146|NCT01313663|DRUG|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
219238147|NCT01313663|DRUG|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
219238148|NCT06509282|BEHAVIORAL|Concurrent training|"Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual."
219238149|NCT01217736|DRUG|aliskiren|single dose, tablet
219238150|NCT01217736|DRUG|placebo|single dose, tablet
219238151|NCT01217736|DRUG|VTP-27999|single dose, tablet
219238152|NCT03477032|BIOLOGICAL|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
219238153|NCT01961453|DRUG|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
219238154|NCT01961453|DRUG|Placebo capsule|One capsule of placebo administered once daily at 8 am.
219238155|NCT02024477|DRUG|Saxagliptin|5 mg tablet once daily for 12 weeks
219238156|NCT02024477|DRUG|Placebo|1 tablet daily for 12 weeks
219238157|NCT00090064|DRUG|Midomafetamine HCl|125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
219238158|NCT00090064|DRUG|Lactose placebo pill|125 mg followed by a supplemental half-dose of 62.5 mg
219238159|NCT00090064|BEHAVIORAL|Therapy|Non-directive therapy provided by a team of two co-therapists
219238160|NCT01904253|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219238161|NCT01904253|DRUG|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
219238162|NCT01904253|DRUG|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
219238163|NCT04962776|DRUG|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
219238164|NCT04962776|DRUG|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
219238165|NCT04962776|OTHER|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
219238166|NCT03284957|DRUG|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
219238167|NCT03284957|DRUG|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
219238168|NCT03284957|DRUG|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
219238169|NCT03284957|DRUG|Everolimus|Pharmaceutical form: tablet
219238170|NCT03284957|DRUG|Abemaciclib|Pharmaceutical form: tablet
219238171|NCT06005311|DEVICE|Microfluidic chip|The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
219238172|NCT06005311|DEVICE|Density-gradient centrifugation|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
219167306|NCT03169777|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219167307|NCT03169777|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
219167308|NCT03169777|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219167309|NCT03169777|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219167310|NCT03169777|BIOLOGICAL|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
219167311|NCT03169777|DRUG|Lovaza|Omega-3-acid ethyl esters
219167312|NCT03169777|DRUG|oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219167313|NCT03169777|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
219167314|NCT03169777|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
219167315|NCT03169777|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
219167316|NCT03169777|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
219167317|NCT03169777|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219167318|NCT03169777|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
219167319|NCT03169777|BIOLOGICAL|GI-4000|RAS yeast vaccine
219167320|NCT03169777|BIOLOGICAL|GI-6207|CEA yeast vaccine
219167321|NCT03169777|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219167322|NCT03169777|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
219167323|NCT06763406|OTHER|Exercise|Due to the limited research on exercise approaches for pectus excavatum, further investigation in this field is needed. This study aims to explore the impact of Schroth-based exercise therapy on adolescents with pectus excavatum.
219167324|NCT06762925|OTHER|No Interventions|No Interventions
219167325|NCT02692807|PROCEDURE|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
219167326|NCT06784115|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
219167327|NCT05246657|PROCEDURE|EUS-guided Entero-biliary Anastomosis|EUS-guided Entero-biliary Anastomosis
219167328|NCT06332599|DRUG|BQT|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
219167329|NCT06332599|DRUG|PBM4M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
219167330|NCT06332599|DRUG|PBM3M3|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
219167331|NCT06332599|DRUG|PBM2M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
219167332|NCT06332599|DRUG|PBM2M3|PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
219167333|NCT06525740|DRUG|Hydromorphone|Given IT
219167334|NCT06525740|DRUG|Methadone|Given IV
219238173|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
219167335|NCT06525740|OTHER|Questionnaire Administration|Ancillary studies
219167336|NCT05911932|OTHER|Biosample collection.|Blood draw.
219167337|NCT05320432|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
219167338|NCT05320432|DEVICE|Sham|No current applied through pads.
219167339|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
219167340|NCT04767568|DIAGNOSTIC_TEST|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
219167341|NCT04767568|OTHER|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
219167342|NCT04767568|OTHER|stool collection|In cohort B: Stool sample n°1 collected before surgery. Stool sample n°2 collected 1 month after surgery
219167343|NCT06300944|DRUG|saline|A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
219167344|NCT06300944|DRUG|Esketamine|A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
219167345|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Left hemi-back|The treated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219167346|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Right hemi-back|The treated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219167347|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Left hemi-back|The untreated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
219167348|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Right hemi-back|The untreated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
219167349|NCT04827953|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
219167350|NCT04827953|DRUG|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
219167351|NCT04827953|DRUG|NLM-001|NLM-001 will be administered three cycles consecutively followed by two rest cycles.
219167352|NCT04827953|DRUG|Zalifrelimab|Zalifrelimab administration each 6 weeks.
219167353|NCT05641753|DRUG|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
219167354|NCT05641753|DRUG|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
219167355|NCT05641753|DRUG|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
219167356|NCT05641753|DRUG|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
219167357|NCT05641753|DEVICE|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
219238174|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
219238175|NCT06157294|PROCEDURE|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
219238176|NCT06157294|PROCEDURE|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
219238177|NCT04233411|OTHER|Mycoprotein ingestion|
219238178|NCT06146088|BIOLOGICAL|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
219238179|NCT03115879|OTHER|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
219238180|NCT03115879|OTHER|Hip manipulation simulation|Hip manipulation simulation
219238181|NCT02464306|DRUG|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
219238182|NCT00466856|DRUG|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres"
219238183|NCT00466856|RADIATION|yttrium Y 90 resin microspheres|radiation
219238184|NCT05659745|OTHER|VM-02|VM-02 is a personal care product for vaginal health.
219238185|NCT05659745|DIETARY_SUPPLEMENT|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
219238186|NCT05659745|OTHER|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
219238187|NCT05973669|DEVICE|MED-EL Remote Care|Remote cochlear implant support
219238188|NCT06429124|BEHAVIORAL|Dietary Intervention|Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
219238189|NCT06487871|DIETARY_SUPPLEMENT|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
219238190|NCT06487871|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
219238191|NCT03450018|DRUG|SLC-0111|Oral SLC-0111
219238192|NCT03450018|DRUG|Gemcitabine Injection|1000 mg/m\^2 IV
219238193|NCT06029920|OTHER|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
219238194|NCT03528161|OTHER|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
219238195|NCT05118009|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
219238196|NCT02988232|DRUG|Sogyeonghwalhyeol-tang|herbal extract
219238197|NCT02988232|DRUG|Placebo|extract powder with same appearance, odor and color as SGHH
219238198|NCT02450786|DRUG|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
219238199|NCT05704465|BEHAVIORAL|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
219238200|NCT05704465|BEHAVIORAL|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
219238201|NCT04371471|DIAGNOSTIC_TEST|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
219238202|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
219238203|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
219167358|NCT05641753|DEVICE|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
219167359|NCT05641753|DEVICE|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
219167360|NCT06793865|OTHER|Russian Current Stimulation for Anterior Tibial Group|"Parameters were adjusted as the following frequency of 2.5 kHz and 50 bursts per second with 50 pulses per burst. The stimulus was applied for a 10 seconds on period followed by a 10 seconds off period for total treatment time 20 minutes."
219167361|NCT06793865|OTHER|Placebo Russian Current Stimulation for Anterior Tibial Group|Placebo Russian current stimulation was applied to the anterior tibial group without active current for 20 minutes.
219167362|NCT06793865|OTHER|Selected physical therapy exercise for both limbs|The selected physical therapy exercise for both limbs was applied for 40 minutes, including passive, active assisted and active range of motion exercises, stretching of spastic muscles, strengthening of weak muscles (anterior tibial group), and finally functional mobility exercises.
219167363|NCT06796166|BEHAVIORAL|AI-Supported Preoperative Education|This intervention involves the use of a pre-trained AI-powered education platform designed to provide preoperative information to patients undergoing mastectomy. The program delivers structured, interactive education that includes details about the surgical process, postoperative care, and emotional coping strategies. The pre-trained AI system offers standardized responses to patient questions, ensuring consistency and clarity in the information provided, with the goal of reducing fear and anxiety.
219167364|NCT06796166|BEHAVIORAL|Standard Preoperative Education|This intervention consists of standard preoperative education provided by healthcare professionals. Patients receive general information about the surgical procedure, postoperative care, and strategies to manage fear and anxiety. The education is delivered in a traditional, face-to-face format without the use of AI or digital tools.
219167365|NCT06793280|PROCEDURE|intraoperative ICG angiography|Intraoperative ICG angiography to evaluate colonic perfusion
219167366|NCT06793280|PROCEDURE|No intraoperative ICG angiography|Visual evaluation of colonic perfusion
219167367|NCT03875625|PROCEDURE|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
219238204|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
219238205|NCT02655900|OTHER|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
219238206|NCT01027247|DEVICE|Ologen TM|
219238207|NCT00214318|DRUG|Terbutaline plus Metoprolol or carvedilol|
219238208|NCT00515112|DRUG|AndroGel|Androgel 1%, 10g daily
219167368|NCT03875625|BEHAVIORAL|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
219167369|NCT03875625|BEHAVIORAL|Conventional care (control)|receive routine care
219167370|NCT03919981|OTHER|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
219167371|NCT06794567|DIAGNOSTIC_TEST|Genetic Testing|Early access to genetic testing.
219167372|NCT06360575|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219167373|NCT06360575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219167374|NCT06360575|DRUG|Crizotinib|Given PO
219167375|NCT06360575|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
219167376|NCT03963453|OTHER|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
219167377|NCT05717621|DRUG|VTD-101 ointment|Self-administration of VTD-101 ointment (Decitabine ointment)
219167378|NCT04155398|PROCEDURE|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
219167379|NCT05561725|DRUG|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
219167380|NCT05561725|DRUG|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
219167381|NCT06796816|OTHER|Bioelectrical Impedance Vector Analysis (BIVA)|"Bioelectrical Impedance Vector Analysis (BIVA) both in total body mode (Total Body Water) and segmental mode. The device used is the BIA 101 Anniversary by Akern. The BIVA exam will be performed in total body and segmental modes.~For total body mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 4 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the right foot (metatarsal). The cable connected to your instrument will then be connected to the electrodes. After the instrument is switched on, the variables are read and then analysed. For segmental mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 8 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the left hand, 2 on the right foot (metatarsal) and 2 on the left foot."
219238209|NCT00515112|DRUG|placebo|placebo
219238210|NCT04049578|DRUG|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
219238211|NCT04748497|OTHER|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
219238212|NCT06789159|DRUG|VK-2019|VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.
219167382|NCT06333691|DRUG|Calcium Gluconate|to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
219167383|NCT06797349|DIETARY_SUPPLEMENT|First Reference product|dextrose (containing 25 grams of carbohydrates)
219167384|NCT06797349|DIETARY_SUPPLEMENT|Second reference product|dextrose (containing 25 grams of carbohydrates)
219167385|NCT06797349|DIETARY_SUPPLEMENT|Third reference product|dextrose (containing 25 grams of carbohydrates)
219167386|NCT06797349|DIETARY_SUPPLEMENT|First Concept product|Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)
219167387|NCT06797349|DIETARY_SUPPLEMENT|Second Concept product|Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)
219167388|NCT06797349|DIETARY_SUPPLEMENT|Third Concept product|Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)
219167389|NCT06797349|DIETARY_SUPPLEMENT|Fourth Concept product|Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)
219167390|NCT06797349|DIETARY_SUPPLEMENT|Fifth Concept product|Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates
219167391|NCT06797349|DIETARY_SUPPLEMENT|Sixth Concept product|Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates
219167392|NCT06797349|DIETARY_SUPPLEMENT|Seventh Concept product|High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates
219167393|NCT06789796|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg , every 3 weeks
219167394|NCT06789796|DRUG|placebo for QL1604|every 3 weeks
219167395|NCT06789796|DRUG|QL1604|200mg, every 3 weeks
219167396|NCT06789796|DRUG|placebo for Iparomlimab and Tuvonralimab (QL1706)|every 3 weeks
219167397|NCT06791317|OTHER|Checklist|A checklist for the intubation procedure was organised into the categories physiological optimisation, equipment and drugs, team line-up, and contingency plan. This checklist was implemented in the clinic.
219167398|NCT05126901|DRUG|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
219238213|NCT06056726|PROCEDURE|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
219167399|NCT05126901|DRUG|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
219167400|NCT06839040|OTHER|Group 1: ExVerbPsy|A multidisciplinary intervention will be carried out, consisting of an initial phase of individual physiotherapy based on specific active muscle training of the pelvic floor (EMSP). This will be followed by a group-based multi-component physical exercise program with instructions on pelvic floor contraction during the exercises, and psychoeducation sessions to help cope with the fear of increased likelihood of falls and urinary incontinence as a result of aging.
219167401|NCT06839040|OTHER|Group 2: ExVerb|The same procedure as experimental group 1 ExVerbPsy will be performed except for the psychoeducation sessions.
219167402|NCT06839040|OTHER|Group 3: Ex|The same procedure as experimental group 1 ExVerbPsy will be performed but without verbal instructions and psychoeducation sessions.
219167403|NCT05694988|DEVICE|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
219167404|NCT03484702|DRUG|JCAR017|Specified dose on specified days
219167405|NCT01918527|DRUG|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
219167406|NCT01918527|DRUG|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
219167407|NCT06483880|DRUG|Albendazole|Patients will receive albendazole therapy at the recommended dosage.
219167408|NCT06483880|DRUG|Placebo|Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.
219167409|NCT05535062|DEVICE|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
219167410|NCT06794502|DRUG|Herbal medicine|Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
219167411|NCT06794502|OTHER|Tuberculosis (TB) treatment|The patients in anti-TB monotherapy group (Group 2) were given a regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months. This group did not receive any additional therapy.
219167412|NCT06790238|OTHER|gastric surgery and ERAS protocol|Patients under gastric surgery in an ERAS protocol
219167413|NCT06796010|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219167414|NCT06796010|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219167415|NCT03285321|DRUG|Nivolumab|480mg
219167416|NCT03285321|DRUG|Nivolumab|240mg
219167417|NCT03285321|DRUG|Ipilimumab|1mg/kg
219167418|NCT06179901|PROCEDURE|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
219238214|NCT05386537|COMBINATION_PRODUCT|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
219238215|NCT05386537|DEVICE|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
219167419|NCT06179901|PROCEDURE|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
219167420|NCT05194969|DEVICE|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
219167421|NCT05194969|DEVICE|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
219167422|NCT05408611|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
219167423|NCT05408611|OTHER|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
219167424|NCT06504342|DEVICE|Blue-blocking glasses|These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.
219167425|NCT06504342|BEHAVIORAL|Time-restricted eating|Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m
219167426|NCT06504342|DEVICE|Lightly tinted glasses|These lenses block shorter wavelengths of light, mainly ultraviolet light.
219167427|NCT05822193|OTHER|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
219167428|NCT06828874|DRUG|Levornidazole Disodium Phosphate for Injection|1g，once daily, intravenously guttae for 4 to 7 days
219238216|NCT05386537|OTHER|Games only|Using VR-video games only
219167429|NCT06828874|DRUG|Ornidazole and Sodium Chloride Injection|0.5g at a time , 2 times per day, intravenously guttae for 4 to 7 days
219167430|NCT06347536|COMBINATION_PRODUCT|Supported rescue pack|1\) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
219167431|NCT05770947|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
219167432|NCT05770947|BEHAVIORAL|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
219167433|NCT03604263|DEVICE|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
219167434|NCT06840704|DIETARY_SUPPLEMENT|Oral immunonutrition|Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.
219167435|NCT04533061|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
219167436|NCT06840925|DRUG|PRAX-628|Once daily oral
219167437|NCT05745350|DRUG|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
219167438|NCT03900780|PROCEDURE|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
219167439|NCT03900780|PROCEDURE|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
219167440|NCT05670366|DEVICE|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
219167441|NCT05670366|DEVICE|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
219167442|NCT03495297|PROCEDURE|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
219167443|NCT06795828|BEHAVIORAL|Emotional support group|Women who met the inclusion criteria and volunteered to participate in the study and were provided emotional support were administered the Personal Information Form, Visual Analog Scale, State Anxiety Inventory and Surgical Fear Scale via face-to-face interview method on the first day of their hospitalization before the caesarean section (pre-test). This application lasted 15-20 minutes. Enter a brief, descriptive title for this arm of the study.
219167444|NCT06835868|PROCEDURE|Spinal cord stimulation|implantation of electrode which is linked to an implantable impulse generator for the treatment of chronic pain syndromes.
219167445|NCT06839534|BEHAVIORAL|Structured Maternal Voice Program (SMVP)|"Pre-recorded maternal voice messages played via an MP3 player integrated into the infant's incubator. The recordings include recognition messages (I'm so glad to have you) and soothing messages (Rest well, little one, you're safe with me). The intervention is delivered three times daily for five minutes per session over a four-day period."
219167446|NCT06792786|DIAGNOSTIC_TEST|ctDNA detection|"dynamically monitor the changes of ctDNA in patients with esophageal cancer Radiation: Radiotherapy 95% PTV50-50.4Gy/25-28fractions, 1.8-2Gy/1 fractions; 5 days a week; 6 weeks. Chemotherapy:weekly paclitaxel (50mg/m²) in combination with carboplatin (AUC=2) chemotherapy, a total of 4-5 cycles.~Other Names:~Intensity-modulated radiotherapy (IMRT) Drug: Toripalimab Toripalimab (240 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision~Other Names:~Immunotherapy ctDNA detection: The first tissue and blood ctDNA test (T0) before treatment is based on next generation sequencing (NGS) technology, and ctDNA test is based on tumor- prior analysis informed assays method. Blood ctDNA testing after chemoradiotherapy was performed every 3 months"
219167447|NCT06749223|DIAGNOSTIC_TEST|D-dimer test|Blood sample collection for D-dimer testing
219167448|NCT04009343|DRUG|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
219167449|NCT04009343|DRUG|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
219167450|NCT06792604|DEVICE|Anal self-sampling (smear)|Anal self-sampling (smear) at M12, M24 and M36 (each year) for HPV16+ patients at M0 and anal self-sampling (smear) at M36 for HPV16- at M0
219167451|NCT06792604|BEHAVIORAL|HPV questionnaire|HPV questionnaire at each visit M0, M12, M24 and M36 for HPV16-positive patients at M0 and HPV questionnaire at each visit M0, 4 and M36 for HPV16-negative patients
219178198|NCT00391365|PROCEDURE|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
219238217|NCT05386537|OTHER|Control|conventional UE therapy at a rehabilitation facility
219178199|NCT02023866|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
219167452|NCT06792201|DIAGNOSTIC_TEST|SARC-F, Handgrip test, Chair stand test|The SARC-F questionnaire is a simple to use questionnaire consisting of five questions about daily actions.To test the force will be used: Hand-grip test and Chair stand test. The tool used for the hand-grip test is the GRIP-A (Takei). The test is performed on the dominant limb and repeated three times. The position taken by the patient will be: sitting with shoulders and elbows flexed, forearms in neutral position. The Chair stand test measures the time it takes for a patient to get up five times from a sitting position without the help of her upper limbs. The test will be timed.The measurement of lean mass will be carried out by means of a bio impedance meter. This instrument does not measure muscle mass directly but estimates it based on the electrical conductivity of the whole body. Bioimpedance is a method that is easy and safe for the patient to use.
219167453|NCT06796504|PROCEDURE|Procedure/Surgery: Implant Procedure|The SetPoint System (study device)contains a miniaturized stimulator (implnat) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
219167454|NCT06796504|DRUG|Disease-Modifying Therapies (DMTs)|All subjects will continue treatment with standard of care disease-modifying therapies for he duration of the study.
219167455|NCT06796504|DEVICE|Device: Active stimulation|Active stimulation for 1 minute once per day
219167456|NCT06796504|DEVICE|Device: Non-active stimulation|Non-active stimulation for 1 minute once per day
219167457|NCT04271085|OTHER|Observational study|No intervention involved
219167458|NCT06838650|DRUG|Dexmedetomidine|patients will recive of low-dose (0.5 µg/kg) intravenous Dexmedetomidine before general anathesia
219167459|NCT06838650|DRUG|Saline|patients will recive saline
219167460|NCT06839703|DRUG|Dinutuximab beta|Dinutuximab beta is added in different dosages to the standard chemotherapy
219167461|NCT06839443|DIAGNOSTIC_TEST|Retinopathy group|OCT scans and Retinai algorithm will be performed
219167462|NCT06839443|DIAGNOSTIC_TEST|Control group|OCT scans and Retinai algorithm will be performed
219167463|NCT05491122|BEHAVIORAL|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
219167464|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3|
219167465|NCT01728571|DIETARY_SUPPLEMENT|fish oil|
219167466|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
219167467|NCT01728571|DIETARY_SUPPLEMENT|Fish oil placebo|
219167468|NCT06838741|PROCEDURE|otago exercises|"A walking program is given to participants, with the goal of including two 30-minute walking sessions each week (which can be divided into shorter segments, like three ten-minute blocks).~Exercises Start exercises with 10 repetition maximum STRENGTH Knee extensor Hold for 3-5 seconds Knee flexor Hold for 3-5 seconds Hip adductor Hold for 3-5 seconds Ankle planter-flexion Calf raises Ankle dorsiflexion Toe raise BALANCE Knee bends Backwards walking Upto 30 minutes Walking and turning around 5-10 minutes Sideways walking Tandem stance Heel to toe stand Tandem walk One leg stand Heel walking Toe walk Heel toe walking backwards Sit to stand Stair walking"
219167469|NCT06838741|DEVICE|virtual reality|Begin with 20-30 minutes per session and extend to 30-45 minutes as tolerance and endurance improve throughout the program. Exercise sessions will be done for 3 sessions per week.
219167470|NCT06794450|DRUG|Sugammadex 1 mg/kg|Patient in experimental arms will receive i.v. sugammadex 1 mg/kg at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
219167471|NCT06794450|DRUG|Neostigmine + Atropine|Patient in active comparators arms will receive i.v. neostigmine 60 mcg/kg along with 0.4 mg of atropine sulfate per 1 mg of neostigmine at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
219167472|NCT06841042|BIOLOGICAL|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.
219167473|NCT01757665|DEVICE|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
219167474|NCT03025763|OTHER|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
219238218|NCT04003558|OTHER|No interventions|As this is a patient registry, there are no interventions.
219167475|NCT03025763|OTHER|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
219238219|NCT04176549|OTHER|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
219167476|NCT03025763|PROCEDURE|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
219167477|NCT03025763|PROCEDURE|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
219167478|NCT03025763|PROCEDURE|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
219167479|NCT03025763|PROCEDURE|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
219167480|NCT03025763|PROCEDURE|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
219167481|NCT06795737|BEHAVIORAL|Exercise rehabilitation|The experimental group's protocol consists of two stages: in-hospital Phase I and post-discharge self-training. For Phase I, cardiac and rehab specialists assess NYHA classification, muscle strength, and mobility to create an exercise plan, supervised by therapists and nurses. Phase II involves twice-weekly outpatient rehab for 24 sessions and weekly remote guidance with WeChat and wristbands to track vitals, totaling 12 remote sessions. Exercise prescriptions are customized based on 6MWTD outcomes, with ongoing support from rehab staff and nurses.
219238220|NCT04176549|OTHER|Management of termination of pregnancy|Surgical termination of pregnancy
219238221|NCT04176549|OTHER|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
219167482|NCT06795737|BEHAVIORAL|Conventional rehabilitation|"Health Education: Nurses provide manuals on heart failure causes, treatment, diet, exercise (detailing frequency, intensity, duration, types, and safety), and self-monitoring to control group patients.~Outpatient Follow-up: Post-discharge, heart failure patients have follow-ups at 2 weeks, 1 month, 2 months, and 3 months. A multidisciplinary team of doctors, pharmacists, and nurses handles these, with doctors for assessment, pharmacists for medication education, and nurses for self-care assessment and education."
219167483|NCT06839209|DEVICE|Toxclean 1g|1 g of Toxclean once or twice daily for 28 days
219167484|NCT06793228|DRUG|Nanocrystalline Megestrol Acetate|Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
219167485|NCT06793228|DRUG|Tislelizumab|Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
219167486|NCT06793228|DRUG|PTOC|Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
219167487|NCT06640933|DRUG|BIIB091|Administered as specified in the treatment arm.
219167488|NCT06839547|DRUG|Radiotherapy + Novel Anti-tumor Drug|"1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\]~2. Radiotherapy"
219167489|NCT06793241|BIOLOGICAL|CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection|Each subject receive CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells by intravenous infusion
219167490|NCT06835439|BEHAVIORAL|STEPPT Pilot|The pilot STEPPT intervention, which includes (1) education of providers and staff on disparities in referrals and the benefits of physical therapy for spine pain, (2) modifications to the EHR to automate physical therapy referral and delivery of culturally tailored patient education materials related to the physical therapy referral, and (3) enhanced patient health navigation to educate patients on physical therapy and address barriers to attending physical therapy for Hispanic patients with spine pain. Patient education materials were developed using evidence-based guidelines and were culturally and linguistically adapted for Hispanic patients with spine pain.
219167491|NCT06835439|BEHAVIORAL|Standard Care (Control)|Usual care (3-month baseline) includes no provider education, physician-initiated referrals and delivery of standard educational materials, and scheduling for physical therapy by the clinic referrals specialists using standard processes.
219238222|NCT06005116|RADIATION|[68Ga]-NOTA-SGC8|Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate cleanly before irrigation, and then irrigated \[68Ga\]-NOTA-SGC8 into the bladder via catheter for 30 minutes to make full contact between the injection and tumor. After 30 minutes, the injection will be withdrawn and 300ml normal saline will be injected into the bladder to maintain the shape of the bladder.
219238223|NCT04620265|OTHER|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
219167492|NCT06830616|DIAGNOSTIC_TEST|7T MRI brain|A very detailed MRI scan of the brain using a 7T MRI scanner.
219167493|NCT04899024|BEHAVIORAL|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
219167494|NCT04899024|BEHAVIORAL|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
219167495|NCT04899024|BEHAVIORAL|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
219167496|NCT06831799|OTHER|Non applicable, is a patient registry|Non applicable, is a patient registry
219167497|NCT06793319|OTHER|educational app|State Anxiety Inventory was filled out before the training. Atrial Fibrillation training was provided. After the training, the Situationality Anxiety Inventory was filled out again. It was aimed to evaluate the effect of education on anxiety.
219167498|NCT06028529|DEVICE|Exoskeleton|lightweight ground exoskeleton
219167499|NCT05360264|DRUG|Decitabine 50 MG [Dacogen]|DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.
219167500|NCT03484884|DIAGNOSTIC_TEST|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
219167501|NCT05816551|OTHER|Hyperthermia Trial|"Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol."
219167502|NCT05816551|OTHER|Control Trial|"Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol."
219167503|NCT04020276|RADIATION|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
219167504|NCT04958967|DRUG|Furmonertinib 240mg|treated subjects will receive Furmonertinib 240mg/day
219167505|NCT04958967|DRUG|Furmonertinib 160mg|treated subjects will receive Furmonertinib 160mg/day
219167506|NCT04825275|DRUG|Posaconazole Pill|300 mg (three 100 mg tablets) orally
219167507|NCT02475148|DRUG|JNJ 54175446|
219167508|NCT02475148|DRUG|Placebo|
219167509|NCT02475148|OTHER|High fat/high Calorie Breakfast|
219167510|NCT05361993|DRUG|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
219167511|NCT05361993|DEVICE|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
219167512|NCT03915886|DRUG|JNJ-0440|JNJ-0440 tablets will be administered orally.
219167513|NCT03915886|DRUG|Placebo|Matching placebo tablets will be administered orally.
219167514|NCT04311996|OTHER|Friend and target|random assignment to Friend and Target Both condition
219167515|NCT04311996|OTHER|Friend support|random assignment to Friend Provides Support condition
219238224|NCT04620265|OTHER|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
219238225|NCT04620265|OTHER|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
219167516|NCT04311996|OTHER|unfamiliar peer and target|random assignment to Unfamiliar Peer and Target condition
219167517|NCT04311996|OTHER|alone|random assignment to Alone condition
219167518|NCT05481515|DEVICE|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
219167519|NCT05481515|DEVICE|Spectrophotometry|Spectrophotometry will be used to measure skin tone
219167520|NCT04941989|DRUG|HTL0022562|HTL0022562
219167521|NCT04941989|DRUG|Placebo|Placebo
219167522|NCT05139420|OTHER|lifestyle intervention with meal replacement program|participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
219167523|NCT02379156|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
219238226|NCT04620265|OTHER|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
219238227|NCT04620265|OTHER|The conventional exercise program|This group received the conventional exercise program only.
219167524|NCT02379156|OTHER|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
219167525|NCT05713994|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
219167526|NCT05713994|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
219167527|NCT05713994|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
219167528|NCT05713994|DRUG|Lenvatinib|8mg; p.o.; q.d.
219238228|NCT05363839|DRUG|ACH-000029|ACH-000029 will be administered orally via a capsule.
219167529|NCT05713994|DRUG|Sorafenib|400mg; p.o. bid
219167530|NCT05713994|DRUG|Donafenib|200mg; p.o. bid
219167531|NCT05713994|DRUG|Regorafenib|160 mg; p.o.; q.d.
219167532|NCT05713994|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
219167533|NCT05713994|DRUG|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
219238229|NCT05363839|DRUG|Placebo|Placebo will be administered orally via a capsule.
219167534|NCT05994742|DRUG|Rifampicin|Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
219167535|NCT05994742|DRUG|Azithromycin|Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
219167536|NCT05994742|DRUG|Isoniazid|Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
219167537|NCT05994742|DRUG|Pyridoxine Hydrochloride|Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
219167538|NCT05994742|BEHAVIORAL|The Friendship Bench|The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
219167539|NCT05994742|BEHAVIORAL|Care for Child Development|Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
219167540|NCT05994742|BEHAVIORAL|Educational and behaviour-change modules|Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
219167541|NCT05994742|DIETARY_SUPPLEMENT|Reformulated Ready to Use Therapeutic Food|A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
219167542|NCT05994742|OTHER|Standard Care|All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
219167543|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
219167544|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
219167545|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
219167546|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
219167547|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
219167548|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
219167549|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
219167550|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
219167551|NCT05897021|BEHAVIORAL|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
219167552|NCT05897021|BEHAVIORAL|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
219167553|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
219167554|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
219167555|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
219167556|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
219167557|NCT06776029|BIOLOGICAL|Fecal Microbiota Transplantation Capsule|FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.
219167558|NCT06512155|DRUG|Pregabalin|Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
219238230|NCT00051740|BEHAVIORAL|Cognitive Adaptation Therapy (CAT)|
219238231|NCT00051740|BEHAVIORAL|Minimal Environmental Supports (MES)|
219238232|NCT03054194|DRUG|E2730|capsules
219238233|NCT03054194|DRUG|Placebo|capsules
219238234|NCT02741921|DEVICE|VivaSight DL|intubation using VivaSight DL tube
219238235|NCT02741921|DEVICE|conventional double-lumen tube|intubation using conventional double-lumen tube
219167559|NCT06512155|DRUG|Zolpidem|Take zolpidem 10mg qn from two days before surgery to three days after surgery
219167560|NCT04225455|DEVICE|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~\[Green: 5-15 mmol/L; Amber: 4 to \<5mmol/L and \>15 to 20mmol/L; Red: \<4mmol/L and \>20mmol/L\]"
219167561|NCT06347666|BEHAVIORAL|Caregiver coaching|Speech language pathologists will meet with caregivers to talk through strategies to promote child development.
219167562|NCT04975516|DRUG|Chemotherapy|Given chemotherapy
219167563|NCT04975516|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219167564|NCT04975516|PROCEDURE|Computed Tomography|Undergo CT
219167565|NCT04975516|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219167566|NCT04975516|PROCEDURE|Biospecimen Collection|Undergo blood collection
219167567|NCT04975516|OTHER|Questionnaire Administration|Ancillary studies
219167568|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
219167569|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
219167570|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
219167571|NCT02730039|BEHAVIORAL|workshop|
219167572|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
219167573|NCT02730039|BEHAVIORAL|assessments|
219167574|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
219167575|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
219238236|NCT01498406|DIETARY_SUPPLEMENT|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
219167576|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
219238237|NCT02802176|DEVICE|INVOcell device|intra-vaginal culture of embryos using INVOcell device
219238238|NCT02802176|OTHER|Traditional IVF|traditional culture of embryos in-vitro
219238239|NCT06462768|OTHER|Blood sample|Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
219167577|NCT05159583|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
219167578|NCT05159583|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
219167579|NCT02770859|PROCEDURE|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the LES for the treatment of achalasia
219167580|NCT06348849|DEVICE|Low-level laser therapy|Wavelength 980nm (SmartM, Lasotronix, Poland)
219167581|NCT06348849|DRUG|Nanosilver fluoride|Optimized synthesis of Nanosilver Fluoride
219167582|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
219167583|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
219167584|NCT02651324|DRUG|Ketamine|
219167585|NCT02651324|OTHER|Placebo|
219167586|NCT05789147|DEVICE|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
219167587|NCT05789147|DEVICE|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
219167588|NCT05687279|BIOLOGICAL|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
219167589|NCT05687279|OTHER|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
219167590|NCT06847646|OTHER|bioflex crown using hall technique|crowns assessment
219167591|NCT06847646|OTHER|stainless steel crown using hall technique|crown assessment
219167592|NCT06843746|DEVICE|Commercial thermoplastic|The participants received a commercial thermoplastic splint material for splint fabrication.
219167593|NCT06843746|DEVICE|Newly developed low-cost thermoplastic|The participants received a newly developed low-cost thermoplastic splint material for splint fabrication.
219167594|NCT03475108|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
219167595|NCT04525950|PROCEDURE|Navio|New generation computer navigation with haptics and robotics
219167596|NCT04525950|PROCEDURE|Conventional|Total knee arthroplasty using conventional instruments
219167597|NCT06845410|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
219167598|NCT06845410|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
219167599|NCT06845410|DRUG|Immunosuppressive Therapy|Glucocorticoids and/or immunosuppressive agents
219167600|NCT06845410|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
219167601|NCT06845410|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
219167602|NCT06846255|DRUG|Dexamethasone Cyclophosphamide Pulse therapy|33 patients were enrolled in DCP group. They were given Dexamethasone Cyclophosphamide pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
219238240|NCT05018455|OTHER|Fall prevention program training based on Otago principles|balance and strength exercises
219167603|NCT06846255|DRUG|Dexamethasone Azathioprine Pulse therapy|33 patients were enrolled in DAP group. They were given Dexamethasone Azathioprine pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
219167604|NCT05252754|DRUG|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
219167605|NCT05252754|DRUG|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
219167606|NCT05252754|DRUG|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
219167607|NCT06843798|OTHER|Survey|Participants will answer questions of different evaluation surveys via online survey. Sociodemographic information, ergonomic information, musculoskeletal pain etc. will be questioned.
219167608|NCT06844695|OTHER|Art Therapy (Virtual Museum Visit)|Virtual Reality (VR) is a technology that creates simulated settings in which users can interact and experience as if they were physically there.Virtual Reality typically involves the use of a headset or glasses that display the virtual environment, as well as other input devices such as controllers or gloves that allow users to interact with the virtual world
219167609|NCT06843876|OTHER|"digital vaccine platform TM VAX application"|Physicians and healthcare providers and Patients will use the TM-VAX system for at least one week. Investigators will distribute the online questionnaire via Jotform through the LINE application at day 7, which will take around 10-15 minutes to complete. If participants have any questions or encounter any issues with the questionnaire, the research team will provide assistance and answer questions via the LINE application or in-person
219167610|NCT04076735|PROCEDURE|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
219167611|NCT04076735|PROCEDURE|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
219167612|NCT06845982|OTHER|ultrasound-guided transuterine vaginal biopsy (BVTE)|A BVTE is performed under general anaesthetic in the operating theatre on the scheduled day of myomectomy or hysterectomy. It will be directed to the centre of the uterine smooth muscle tumour in question via an exclusively transuterine route to avoid any peritoneal spread. At least 4 to 5 samples will be taken per uterine smooth muscle tumour, with a maximum of 3 tumours to limit the risk of confusion. The woman will then be operated on as planned during the same operation. All surgical specimens will be sent to the Anatomopathology Department of La Timone for anatomopathological diagnosis after immediate formalin embedding during surgery. Surgical specimens will be analysed as usual.
219167613|NCT06845592|RADIATION|total marrow/lymphoid irradiation|Combination of 20 Gy TMLI with Treg/Tcon adoptive immunotherapy in allogeneic cell transplantation
219167614|NCT06846892|PROCEDURE|Exercise|Both groups were given a total of 12 sessions of Williams exercises, two days a week, in 20-minute sessions, accompanied by a physiotherapist. Williams back exercises are an exercise method that aims to increase lumbar flexion and strengthen the abdominal and gluteal muscles. The exercise program included pelvic tilts, single and double knee pulls, partial crunches, hamstring stretches, hip flexor stretches and squats. In addition, the patients continued their Williams exercises at home three days a week.
219167615|NCT06843538|DRUG|Tamsulosin|This intervention will investigate if tamsulosin will decrease postoperative urinary retention. Subjects will be directed to start taking the medication 5-7 days prior to their procedure; as previous studies have shown, this is when tamsulosin reaches its steady state. Patients will continue to take their assigned pills for 7 days postoperatively.
219238241|NCT03310372|RADIATION|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
219238242|NCT03310372|DRUG|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
219238243|NCT00183222|DRUG|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
219238244|NCT00518310|DRUG|Placebo|
219167616|NCT06843538|DRUG|Placebo|This intervention will ensure blinding and an accurate measure of the real effect of tamsulosin.
219167617|NCT06844422|DRUG|Ivonescimab|"1. Phase Ib (Dose Escalation):~   In this phase, patients will receive Ivonescimab in escalating doses, with the aim of determining the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended Phase II dose (RP2D). The dose-escalation process will follow a 3+3 design over a 4-week period to establish the RP2D of Ivonescimab.~2. Phase II (Efficacy Evaluation):~After establishing the RP2D, patients will receive Ivonescimab combined with SBRT and modified FOLFIRINOX chemotherapy."
219167618|NCT06844994|OTHER|Manual Diaphragmatic Technique|The intervention will be given 3 days per week for up to 6 weeks starting assessment with modified Borg scale questionnaire will be asked from the patient to evaluate the patient's dyspnea level. The patient at first will be asked to do 5-6 diaphragmatic breathing in upright position and then will be asked to breathe with the breather device after complete inhalation the patient will blow hard in the device. The patient will be asked to inhale and then hold for 2-3 second and breathe out through the device with the 3 sets with each set including 8 repetitions same cycle with relaxed diaphragmatic breathing between each set
219167619|NCT06844994|OTHER|Lateral Coastal Breathing|The group B will be the lateral coastal breathing that will be given 2 times a day, 3 days per week for up to 6 weeks. The patient will be asked by practitioner to perform 4 to 5 times lateral coastal breathing in suitable sitting or lying position
219167620|NCT04714034|DIAGNOSTIC_TEST|to develop and validate a scale measuring problematic online dating app (ODA) use in sexual minorities|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of scores in the problematic ODA use scale with sexual health and mental health outcomes."
219167621|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
219167622|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
219167623|NCT06845696|OTHER|kinesiotaping|Before applying the tape, the treated area was cleaned and shaved. A Y strip of the tape was used to facilitate muscle contraction of the semispinalis capitis with 15 -25% tension in elongated muscle position and three I strip are used in it to release tight upper trapezius, facilitate middle trapezius and to correct posture. 3 days a week for 4 weeks
219167624|NCT06845696|OTHER|Brugger relief exercise|This protocol includes that the patient is positioned on edge of a chair with his hips abducted, feet externally rotated, his head up, his forearms supinated, and wrists and fingers extended. the participants were instructed to perform scapular retraction with chin tucked in, shoulder external rotation, elbow extension, shoulder abduction, and extension. While actively moving their arms and spreading their fingers externally, patient exhaled through lips 12 reps 4 set for 3 days a week Intervention will be given for 4 weeks
219167625|NCT06846372|DEVICE|occluscence|"The OccluSense handheld is a battery powered device which uses your local wireless network to transmit the recorded data to the OccluSense-iPad-App.~The inductive charger provides wireless power transfer. Fully charged batteries allow up to 4 hours usage of the device."
219167626|NCT06846372|OTHER|patient satisfaction|"• patient satisfaction will be evaluated by using (VAS score) on a line from 0 to 100mm (0 mm is very bad /100 mm is excellent).~Are you satisfied with the esthetic outcome of the treatment? Does the treatment answer to your expectations? Would you choose the same treatment again? Is your ability to chew improved after placement of the implant prothesis? Did you find the complete treatment time too prolonged?"
219167627|NCT06844968|OTHER|Physical effort|The examined rowers will be subjected to an effort on a rowing ergometer, consisting of covering a designated distance in the shortest possible time.
219167628|NCT04820933|DRUG|Doravirine 100 Mg|Doravirine 100 Mg orally dail
219167629|NCT06847919|DIETARY_SUPPLEMENT|Probiotic yogurt group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
219167630|NCT06847919|DIETARY_SUPPLEMENT|Yogurt control group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
219167631|NCT06844136|OTHER|No intervention|No intervention
219167632|NCT06847841|PROCEDURE|Double J Stent Placement|Patient in whom a DJS will be placed for post op drainage
219167633|NCT06847841|PROCEDURE|Percutaneous Feeding Tube Placement|Patient in whom a PrcFT will be placed for post op drainage
219167634|NCT06847555|RADIATION|Radiation|Tumor radiotherapy is a method of treating malignant tumors by using radioactive rays such as alpha, beta, gamma rays produced by radioactive isotopes and x-rays, electron rays, proton beams and other particle beams produced by various x-ray therapy machines or accelerators.
219178200|NCT04840355|DRUG|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
219178201|NCT02648542|OTHER|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
219178202|NCT02648542|DEVICE|transcranial direct current stimulation|Low-current electrical brain stimulation
219178203|NCT02648542|OTHER|Combined CAS and tDCS|Combined auditory and electrical stimulation
219178204|NCT02648542|OTHER|Sham stimulation|Sham stimulation
219178205|NCT05534971|PROCEDURE|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
219167635|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
219167636|NCT06846424|BIOLOGICAL|SCT-001 CAR-T cells|SCT-001 CAR-T cells are autologous-derived CAR-T cell products, which transduce second-generation CAR targeting TAG-72 into patient autologous T cells by lentiviral transfection, and knock out immunosuppressive related genes by CRISPR/Cas9 technology to enhance the anti-tumor function of CAR-T cells.
219167637|NCT05461131|BIOLOGICAL|BPZE1|Live attenuated vaccine
219167638|NCT05461131|BIOLOGICAL|Placebo|Placebo
219167639|NCT05461131|DRUG|Azithromycin|Antibiotic
219167640|NCT05461131|OTHER|Bordetella Pertussis Challenge Strain|Challenge Strain
219167641|NCT06847802|OTHER|Survey|The survey will include statements related to the Domains Addressing healthcare workers/trainees, Critical Care (CC) Academic meetings, At the Workplace, CC Academia, Education of CC Trainees, Professionalism and Misconduct, Administration and Governance in the Workplace and in CC Societies, Environmental and logistic facilities, Publication of Gender metrics, Committee/working group for gender-balance The statements related to the domains will be drafted in the form of a 7-point Likert scale (strongly agree, agree, somewhat agree, neither agree nor disagree, somewhat disagree, disagree, strongly disagree) Statements that achieved consensus and stability will be used to issue the position. The results of the Delphi rounds, position statements, and the manuscript will be reviewed and approved by the panelists before submission for publication
219167642|NCT06099795|DEVICE|eBAM Cov Testing|Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
219167643|NCT06846411|DRUG|Empagliflozin 10 mg|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
219167644|NCT06846411|DRUG|Metformin|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
219167645|NCT02944825|DRUG|Ciprofloxacin|first line prophylactic oral antibiotic
219167646|NCT02944825|DRUG|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
219167647|NCT02944825|DRUG|No Intervention|No intervention
219167648|NCT04437654|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
219167649|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
219167650|NCT06311864|DRUG|Daridorexant 50 mg|As indicated by the physician
219167651|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
219167652|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
219167653|NCT03816631|DRUG|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.
219238245|NCT00518310|DRUG|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
219238246|NCT01945593|BIOLOGICAL|BAX855|Antihemophilic Factor (Recombinant), PEGylated
219167654|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET CT|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
219238247|NCT04466917|DRUG|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
219167655|NCT06120049|DIAGNOSTIC_TEST|[18F]-FE-PE2I PET CT or PET MRI|"\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
219167656|NCT06120049|DIAGNOSTIC_TEST|[123I]-MIBG SPECT CT|"\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
219167657|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET dosimetry scans|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
219167658|NCT04538417|DEVICE|Cooled Radiofrequency Ablation|RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
219167659|NCT06467123|OTHER|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
219238248|NCT04466917|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
219167660|NCT06467123|OTHER|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
219167661|NCT01981031|DRUG|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
219167662|NCT01981031|DRUG|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
219167663|NCT06129214|PROCEDURE|Prepectoral|Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
219167664|NCT06129214|PROCEDURE|Subpectoral|No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
219167665|NCT04549168|DRUG|Lemborexant|Lemborexant 10 mg tablet.
219167666|NCT04549168|DRUG|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
219167667|NCT05130879|BEHAVIORAL|BRAW|"Sessions~1. Happiness and positivity Understanding strengths and resilience and positive attitude~2. Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~3. Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~4. Emotion regulation Preventing and managing conflict Emotion regulation abilities~5. Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~6. Problem solving Problem-solving work-life problems Work-life balance Bringing it together"
219167668|NCT03262779|BIOLOGICAL|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
219167669|NCT03572335|DIAGNOSTIC_TEST|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
219167670|NCT04856332|OTHER|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
219238249|NCT04466917|DRUG|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
219167671|NCT05803993|PROCEDURE|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
219167672|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
219167673|NCT06785259|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219167674|NCT06520384|DEVICE|Radiofrequency|Patients will receive radiofrequency.
219167675|NCT06520384|DRUG|Alcohol 30%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
219167676|NCT06520384|DRUG|Alcohol 50%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
219238250|NCT04466917|DRUG|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
219238251|NCT04221308|DEVICE|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
219238252|NCT04631341|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg every night, for one year
219238253|NCT03709056|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
219238254|NCT03709056|DRUG|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
219238255|NCT02941432|OTHER|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
219238256|NCT00006006|BIOLOGICAL|recombinant interferon alfa|
219238257|NCT00006006|DRUG|thalidomide|
219238258|NCT01621321|DRUG|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
219238259|NCT01621321|DRUG|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
219238260|NCT05046652|BIOLOGICAL|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
219238261|NCT00086723|BIOLOGICAL|recombinant tissue plasminogen activator|
219167677|NCT06520384|DRUG|Alcohol 70%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
219167678|NCT06553235|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
219167679|NCT06553235|BEHAVIORAL|Sleep hygiene education|\- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
219167680|NCT05097001|OTHER|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
219167681|NCT04242602|DEVICE|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
219238262|NCT00086723|DRUG|captopril|
219238263|NCT05070234|GENETIC|Blood collection for genetic analysis|Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
219238264|NCT05691218|DEVICE|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
219238265|NCT05691218|DEVICE|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
219238266|NCT05691218|DEVICE|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
219238267|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
219238268|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
219238269|NCT04024436|DRUG|Futibatinib|Futibatinib 20mg once daily on a 28 day cycle
219238270|NCT04024436|DRUG|Futibatinib plus Fulvestrant|Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
219238271|NCT00873626|DRUG|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
219238272|NCT03241121|BEHAVIORAL|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
219167682|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID then MMF QD|Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
219167683|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID|Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
219167684|NCT06354179|DRUG|LCP-tacrolimus QD + MMF QD then MMF QD|Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
219167685|NCT06354179|DRUG|LCP-tacrolimus QD + MMF BID|Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
219167686|NCT04897438|PROCEDURE|Kidney allograft biopsy depending on donor-derived cell-free DNA levels|Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
219238273|NCT03241121|BEHAVIORAL|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
219238274|NCT03241121|DEVICE|Eating patterns|Data collection on eating patterns via the smartphone app
219238275|NCT03488498|OTHER|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
219238276|NCT02793557|DRUG|FOL-005|Intradermal injection of 50 μl solution
219238277|NCT02793557|OTHER|Placebo|
219238278|NCT05351788|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
219238279|NCT05351788|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
219238280|NCT05351788|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
219238281|NCT05351788|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
219238282|NCT06233422|OTHER|No intervention involved|No intervention involved
219238283|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
219167687|NCT04868227|DIETARY_SUPPLEMENT|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
219167688|NCT02475434|DIETARY_SUPPLEMENT|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
219167689|NCT04749446|OTHER|Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)|"This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures"
219167690|NCT01351545|DRUG|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
219167691|NCT05095740|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
219167692|NCT05095740|DEVICE|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
219167693|NCT05942495|BEHAVIORAL|short-term schema focused group therapy|There are two intervention phases. The first concerns the pre-treatment phase, which consists of five online sessions and three face-to-face sessions. The second intervention phase is the short-term SFGT. The SFGT consists of 17 weekly group sessions.
219238284|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
219238285|NCT05434559|DRUG|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
219238286|NCT03077958|PROCEDURE|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
219238287|NCT00028600|BIOLOGICAL|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
219238288|NCT00028600|BIOLOGICAL|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
219167694|NCT06008392|GENETIC|Pan-genomic Testing|Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).
219167695|NCT05426629|DEVICE|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
219167696|NCT03833622|OTHER|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
219167697|NCT06327061|BEHAVIORAL|Network overdose prevention|Participants are taught overdose prevention methods with network members.
219167698|NCT06327061|BEHAVIORAL|Standard of care health education|Participants will receive the standard of care for overdose prevention.
219167699|NCT03840603|DIAGNOSTIC_TEST|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
219167700|NCT06386783|DRUG|Dexmedetomidine Injection [Precedex]|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
219167701|NCT06386783|DRUG|Fentanyl HCl|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
219167702|NCT01447147|DRUG|Placebo|Placebo capsules once daily
219167703|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
219167704|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
219167705|NCT03946410|DIAGNOSTIC_TEST|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
219167706|NCT03494569|DRUG|Fludarabine|Given IV
219167707|NCT03494569|OTHER|Laboratory Biomarker Analysis|Correlative studies
219167708|NCT03494569|DRUG|Melphalan|Given as per City of Hope Standard Operating Procedure
219167709|NCT03494569|RADIATION|Total Marrow Irradiation|Undergo TMLI
219167710|NCT04983108|OTHER|No Intervention|No intervention. This is an observational Study
219167711|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
219167712|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
219167713|NCT06048484|DRUG|Quemliclustat|100 mg IV
219167714|NCT06048484|DRUG|Etrumadenant|150 mg orally
219167715|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
219167716|NCT04795362|BIOLOGICAL|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
219167717|NCT04992728|OTHER|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
219167718|NCT04889911|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
219167719|NCT04889911|OTHER|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
219167720|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
219167721|NCT03869372|DEVICE|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
219167722|NCT01582711|BEHAVIORAL|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
219167723|NCT01582711|BEHAVIORAL|SMS reminders|Short Message Service (SMS) text reminders
219167724|NCT01582711|DRUG|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
219238289|NCT00028600|DRUG|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
219238290|NCT00028600|DRUG|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
219238291|NCT00028600|DRUG|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
219238292|NCT00028600|DRUG|methotrexate|5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
219238293|NCT00028600|DRUG|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
219238294|NCT00608959|DRUG|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
219167725|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
219167726|NCT05582993|BIOLOGICAL|Vonicog Alfa|Vonicog Alfa administered by intravenous injection.
219167727|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
219167728|NCT04876183|OTHER|Selfapy for Binge Eating Disorder|Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
219167729|NCT05413525|PROCEDURE|ultrasound-guided manual vacuum aspiration (USG- MVA)|USG-MVA was carried out as an outpatient day procedure. Women was given a 400μg oral misoprostol tablet 2-3 hours before the procedure. All patients will be given 500mg naproxen orally an hour before the procedure. During the USG-MVA, all the women were placed in the lithotomy position and aseptically dressed. Speculum was performed to visualize the cervix with PCB performed. USG-MVA was performed using a 60ml charged syringe with a flexible curetteattached to it. Transabdominal USG during MVA was performed. During the procedure, local lidocaine gelwas applied to the cervical canal and over the end of the MVA catheter tip during the insertion.The USG-MVA was stopped as soon as USG confirmed that the uterine cavity was empty, defined as a thin endometrial lining with no evidence of retained products of conception.
219167730|NCT03860961|OTHER|Questionnaire Administration|Ancillary studies
219167731|NCT03860961|OTHER|Survivorship Care Plan|Given survivorship care plan
219167732|NCT03860961|OTHER|Treatment Plan|Given treatment plan
219167733|NCT06480968|DRUG|CTH120|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition)."
219167734|NCT06480968|OTHER|Placebo|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD."
219238295|NCT00608959|DRUG|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
219238296|NCT00416442|DRUG|RSV604|
219238297|NCT05034237|DEVICE|ND;YAG 1064NM LASER|laser hair removal sessions
219238298|NCT04351243|DRUG|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
219238299|NCT04351243|DRUG|Placebo|Normal saline
219238300|NCT03616522|OTHER|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
219238301|NCT01156194|DRUG|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
219238302|NCT01156194|DRUG|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
219238303|NCT01156194|DRUG|Placebo|globule identical to true homeopathy comparators
219238304|NCT01707563|PROCEDURE|skin punch biopsy and molecular biology|
219238305|NCT01707563|OTHER|fibroblast culture and molecular biology|
219238306|NCT02568059|DRUG|Sahastara remedy alcoholic extract|comparison of different dose of drug
219238307|NCT01005602|OTHER|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
219238308|NCT01005602|DRUG|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
219238309|NCT03751761|DRUG|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
219238310|NCT04967014|DRUG|HIP2101|Test drug
219238311|NCT04967014|DRUG|RLD2101|Reference drug
219238312|NCT01612897|OTHER|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
219167735|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
219167736|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
219167737|NCT06500364|DEVICE|LoopLoc Arm|Patients in this intervention will have had a capsular closure performed using a LoopLoc device after their hip arthroscopy.
219238313|NCT01248715|DRUG|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
219238314|NCT01544894|DRUG|Raloxifene|60 mg/d for one year
219167738|NCT06500364|DEVICE|Control Arm|Patients in this intervention will have not had a capsular closure using a LoopLoc device after their hip arthroscopy.
219238315|NCT01544894|DRUG|Strontium ranelate|2 g/d, for one year
219238316|NCT06280599|BEHAVIORAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
219238317|NCT01707277|OTHER|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
219238318|NCT01707277|OTHER|Usual care|Usual pahramacological treatment
219238319|NCT04507347|DRUG|TRC041266|TRC041266 sachet 1500 mg strengths
219238320|NCT04507347|DRUG|Placebo|TRC041266 sachet 1500 mg matching placebo
219167739|NCT05473923|DRUG|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
219167740|NCT06103500|OTHER|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
219238321|NCT06559072|DRUG|Atorvastatin|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
219238322|NCT03741985|BEHAVIORAL|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
219238323|NCT03741985|BEHAVIORAL|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
219238324|NCT05530239|OTHER|Blood sample collection|Blood sample collection
219238325|NCT04440956|DRUG|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
219238326|NCT03486756|BEHAVIORAL|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
219238327|NCT05986851|DRUG|Azeliragon|Oral capsule
219238328|NCT05080556|DRUG|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
219167741|NCT05670821|DRUG|Spesolimab|Spesolimab
219167742|NCT05912504|OTHER|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
219167743|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
219167744|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
219167745|NCT05780814|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
219167746|NCT05780814|BEHAVIORAL|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
219238329|NCT04727463|PROCEDURE|Sphincteroplasty|Overlapping sphincteroplasty
219238330|NCT02364674|RADIATION|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
219238331|NCT02529176|BEHAVIORAL|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
219238332|NCT03771300|BEHAVIORAL|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
219238333|NCT03771300|BEHAVIORAL|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
219167747|NCT05859698|DRUG|Valbenazine|Valbenazine capsules for oral administration
219167748|NCT06315088|OTHER|Einkorn Diet|Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
219167749|NCT06315088|OTHER|Intermediate oral microbiota|Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
219167750|NCT06315088|OTHER|Periodontal health status|Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
219167751|NCT06315088|OTHER|General health status|Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
219167752|NCT06162871|BEHAVIORAL|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
219167753|NCT04199182|BEHAVIORAL|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
219167754|NCT04199182|OTHER|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
219167755|NCT02662062|DRUG|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
219167756|NCT02662062|DRUG|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
219167757|NCT02662062|RADIATION|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
219167758|NCT05839119|DRUG|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
219167759|NCT05839119|COMBINATION_PRODUCT|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
219167760|NCT06311084|OTHER|Imaginator 2.0|Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
219238334|NCT03771300|BEHAVIORAL|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
219238335|NCT01330953|DRUG|Placebo|Single intravenous placebo dose.
219238336|NCT01330953|DRUG|LY2928057|Single intravenous dose.
219167761|NCT04870203|DRUG|baricitinib treatment|4 mg daily during 12 months
219167762|NCT04870203|DRUG|anti-TNF therapy|adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history
219167763|NCT04870203|DRUG|Placebo|40 mg every 2 weeks during 6 months only during Period A
219167764|NCT03988634|DRUG|sacubitril/valsartan|Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
219167765|NCT03988634|DRUG|valsartan|Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
219167766|NCT03988634|DRUG|sacubitril/valsartan matching placebo|Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
219167767|NCT03988634|DRUG|valsartan matching placebo|Valsartan matching placebo was available as tablet form to be taken orally, twice daily
219167768|NCT06311357|DIETARY_SUPPLEMENT|Ensure|Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
219167769|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
219167770|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
219167771|NCT06799910|PROCEDURE|continuous renal replacement therapy (CRRT)|The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups.
219238337|NCT01861509|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
219238338|NCT04400045|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
219238339|NCT04888208|BEHAVIORAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
219238340|NCT04072809|OTHER|No intervention|This study does not involve any interventions.
219167772|NCT06799910|OTHER|Free UF Prescription|The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition.
219167773|NCT06623656|DRUG|Cemiplimab|Intravenously
219167774|NCT06623656|DRUG|Platinum based chemotherapy|Intravenously
219167775|NCT06623656|RADIATION|Stereotactic body radiation therapy|8 Gy times 3 treatment days (Days 1-3)
219167776|NCT01728402|PROCEDURE|blood draw, bone marrow procedure, or tissue biopsy|
219167777|NCT04725240|DRUG|Setmelanotide|Setmelanotide for SC injection
219167778|NCT05643599|DIETARY_SUPPLEMENT|Mad Honey|mad honey (80 mg/kg); (n:6)
219167779|NCT05643599|DIETARY_SUPPLEMENT|Normal Honey|normal honey (80 mg/kg),(n:6)
219167780|NCT05643599|DIETARY_SUPPLEMENT|Control|Control
219167781|NCT05780385|DEVICE|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
219167782|NCT05780385|DEVICE|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
219167783|NCT06282289|BEHAVIORAL|Magnetoencephalography (MEG)|Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
219167784|NCT06282289|OTHER|Cognition development questionnaire|Computerised questionnaires completed by parents
219167785|NCT03905876|OTHER|Questionnaire|Questionnaire to evaluate psychological experience
219167786|NCT05557123|DEVICE|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
219167787|NCT04193917|DIAGNOSTIC_TEST|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
219167788|NCT01918683|RADIATION|TACE transarterial chemoembolization|
219167789|NCT01918683|RADIATION|stereotatic body radiotherapy (SBRT)|
219167790|NCT05555290|COMBINATION_PRODUCT|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
219167791|NCT05555290|COMBINATION_PRODUCT|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
219167792|NCT04107051|DRUG|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
219167793|NCT05899465|DRUG|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
219167794|NCT05899465|DRUG|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
219167795|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
219238341|NCT05901688|OTHER|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord"
219167796|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
219238342|NCT02440698|BEHAVIORAL|Genetic test for personalized nutrition|
219238343|NCT03409276|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
219167797|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
219167798|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
219167799|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
219167800|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
219167801|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
219167802|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
219167803|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
219238344|NCT03409276|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
219238345|NCT03409276|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
219238346|NCT03409276|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
219167804|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219167805|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219167806|NCT06572618|DRUG|Nemtabrutinib|Given PO
219167807|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
219167808|NCT06572618|BIOLOGICAL|Rituximab|Given IV
219167809|NCT06574178|BEHAVIORAL|Dietary Counseling|A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
219167810|NCT04422899|DRUG|AIV007|intravitreal
219167811|NCT02512523|DRUG|Teneligliptin|
219167812|NCT02512523|DRUG|Sitagliptin|
219167813|NCT06281483|OTHER|platelet-rich plasma|Under aseptic conditions, 20 mL of whole blood will be withdrawn from each patient and will be collected in the centrifuge tube prefilled with Anticoagulant Citrate Dextrose (1.5 mL each). A two-stage centrifugation process (double-spin method) will be employed for the preparation of PRP. The first spin is at 100 relative centrifugal force (RCF) (g) for 10 min, while the second spin is at 400 RCF for 10 min. PRP will be injected into the base of the ulcer and the surrounding skin. Group A: will receive treatment that will include PRP application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
219167814|NCT06281483|OTHER|platelet-rich fibrin|20 ml blood will be drawn from each patient by venipuncture under aseptic precautions in four sterile glass tubes of 5-ml capacity without anticoagulant and immediately centrifuged. A single stage centrifugation process, that is (200 g for 8 min), has been found to produce a fibrin clot with the highest platelet and WBC count and highest overall cumulative growth factor yield. Group B: will receive treatment that will include PRF application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
219167815|NCT06281483|OTHER|Surgical debridement, normal saline washing and dressing coverage|Each patient will receive the same conventional debridement and dressing coverage (After opening the bandage, the ulcer will be irrigated with normal saline and will be prepared for debridement as required to remove dead tissues and hyperkeratotic skin. Then, a second wash with normal saline will be done to remove any debris), but without any PRP nor PRF application.
219167816|NCT02249949|DRUG|efatutazone|Given PO
219167817|NCT04256759|DRUG|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
219167818|NCT06374979|BIOLOGICAL|Ixekizumab|Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
219167819|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
219167820|NCT01783626|DEVICE|Evodial|
219167821|NCT01783626|DEVICE|Evodial+ Condition B1|
219167822|NCT01783626|DEVICE|Evodial+ Condition B2|
219167823|NCT01783626|DEVICE|Evodial+ Condition C|
219167824|NCT02097420|DEVICE|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
219167825|NCT06298006|OTHER|Follow-up|Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
219167826|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
219167827|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
219238347|NCT04109209|BEHAVIORAL|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
219238348|NCT04109209|BEHAVIORAL|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
219167828|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
219167829|NCT06571552|PROCEDURE|Single Plasma Exchange followed by Double Filtration Plasmapheresis|Double Filtration Plasmapheresis followed by Single Plasma Exchange
219167830|NCT04713683|DEVICE|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
219167831|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
219167832|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
219167833|NCT06011733|OTHER|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
219167834|NCT06011733|DRUG|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
219167835|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
219167836|NCT05061095|OTHER|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
219167837|NCT05061095|OTHER|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
219167838|NCT02386735|DRUG|Placebo|Three days prednisone 40mg, two days placebo
219167839|NCT02386735|DRUG|Prednisone|Five days prednisone 40mg.
219167840|NCT06051292|OTHER|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
219167841|NCT06051292|OTHER|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
219167842|NCT03414814|DRUG|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
219167843|NCT06219707|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
219167844|NCT03161379|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
219167845|NCT03161379|DRUG|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
219167846|NCT03161379|DRUG|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
219167847|NCT03161379|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
219167848|NCT05219487|DRUG|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
219167849|NCT06455605|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
219167850|NCT06455605|DRUG|2141 V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
219167851|NCT03607513|DRUG|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
219167852|NCT03607513|DRUG|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
219167853|NCT02432560|DRUG|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
219167854|NCT02432560|DRUG|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
219167855|NCT06319716|BEHAVIORAL|Video-Based Diabetes Self-Management Education and Support (DSMES)|The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.
219167856|NCT06319716|BEHAVIORAL|Community Health Worker (CHW) Support|CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.
219167857|NCT04716712|DRUG|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
219167858|NCT04716712|DRUG|Placebo|Matching identical placebo in packaging, appearance, and taste.
219167859|NCT05340816|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
219167860|NCT05340816|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
219167861|NCT03218904|DIETARY_SUPPLEMENT|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
219167862|NCT03218904|DIETARY_SUPPLEMENT|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
219167863|NCT03994627|DRUG|Olaratumab|Administered intravenously (IV)
219238349|NCT03605745|DEVICE|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
219238350|NCT03262753|PROCEDURE|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
219238351|NCT03262753|PROCEDURE|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
219238352|NCT03262753|PROCEDURE|Stent|Primary stent dilation treatment of coarctation of the aorta
219238353|NCT02891018|DEVICE|paclitaxel controlled release balloon catheter Vasoguard TM|
219238354|NCT02891018|DEVICE|paclitaxel release coronary balloon catheter SeQuent Please|
219238355|NCT01279447|DRUG|0.25% Bupivacaine|10cc, single dose, US guided injection
219238356|NCT01279447|DRUG|Normal Saline|10cc, single dose, US guided injection
219238357|NCT03991052|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
219238358|NCT03991052|DEVICE|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
219238359|NCT03338491|BEHAVIORAL|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
219238360|NCT03338491|BEHAVIORAL|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
219167864|NCT05196061|OTHER|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~1. Age~2. Sex~3. Race~4. Ethnicity"
219167865|NCT05196061|OTHER|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
219167866|NCT05196061|OTHER|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
219167867|NCT05196061|OTHER|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
219167868|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
219167869|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
219167870|NCT01351805|OTHER|placebo pill|placebo
219167871|NCT05650710|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
219167872|NCT05859724|BIOLOGICAL|NM26-2198|IL-4R/IL-31 bispecific antibody for subcutaneous administration
219238361|NCT04566120|DRUG|cinnamon extract mouthwash|cinnamon extract mouthwash
219238362|NCT04566120|DRUG|chlorohexidine based mouthwash|chlorohexidine based mouthwash
219238363|NCT00233142|BEHAVIORAL|Expressive writing|Writing as therapeutic intervention
219238364|NCT00233142|BEHAVIORAL|Neutral writing|Non-expressive writing
219238365|NCT02025023|DRUG|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
219238366|NCT02025023|DRUG|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
219238367|NCT02025023|PROCEDURE|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
219167873|NCT05859724|OTHER|Placebo|Placebo for NM26-2198
219167874|NCT06067698|DRUG|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
219167875|NCT06067698|DRUG|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
219238368|NCT02025023|DRUG|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
219167876|NCT05344534|BEHAVIORAL|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
219167877|NCT04353869|BIOLOGICAL|Bio collection|venous blood sampling and collection of urine
219167878|NCT03820830|DRUG|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
219167879|NCT03820830|DRUG|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
219167880|NCT03997968|DRUG|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
219167881|NCT03997968|DRUG|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
219167882|NCT03997968|DRUG|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
219167883|NCT03997968|DRUG|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
219167884|NCT04997473|BEHAVIORAL|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
219167885|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
219167886|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
219167887|NCT05975047|DRUG|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
219167888|NCT05975047|DRUG|Placebo|Participants will receive matching placebo across Part A and B of the study
219167889|NCT06466148|DEVICE|JessieHug|Assessment of JessieHug device when placed on infants.
219167890|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
219167891|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
219167892|NCT05404880|DEVICE|EDWARDS INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
219167893|NCT05734625|DRUG|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
219167894|NCT05734625|DRUG|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
219167895|NCT02504905|DEVICE|TMS|single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
219167896|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
219167897|NCT02813460|DRUG|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
219167898|NCT02813460|DRUG|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
219167899|NCT02813460|DRUG|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
219167900|NCT02813460|DRUG|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
219167901|NCT02813460|DRUG|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
219167902|NCT02813460|DRUG|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
219167903|NCT02813460|DRUG|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
219167904|NCT02813460|DRUG|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
219167905|NCT02813460|DRUG|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
219167906|NCT02813460|DRUG|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
219167907|NCT02813460|DRUG|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
219167908|NCT02813460|DRUG|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
219167909|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
219167910|NCT06477783|DRUG|Teclistamab|Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
219167911|NCT05595447|DRUG|Brentuximab Vedotin 50 MG [Adcetris]|Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
219167912|NCT05826717|OTHER|Apple|20g fructose in \[x\] g of apple
219167913|NCT05826717|OTHER|Mashed apple|20g fructose in \[x\] g of mashed apple
219167914|NCT05826717|OTHER|Apple juice|20g fructose in \[x\] ml apple juice
219167915|NCT05826717|OTHER|Fructose powder in water|20g fructose in \[x\] ml water
219167918|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
219167919|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
219167920|NCT04618016|DEVICE|UHMWPE with Vitamin E|e.motion Pro (PS and UC) with MXE gliding surface
219167921|NCT04618016|DEVICE|UHMWPE without Vitamin E|e.motion Pro (PS and UC) with β-PE gliding surface
219167922|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
219167923|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
219238369|NCT01215253|DRUG|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
219238370|NCT05612113|BEHAVIORAL|Live Supervision + Session Goal Formulation|"Read under Arms"
219238371|NCT05612113|OTHER|Session Goal Formulation|"Read under Arms"
219238372|NCT05702892|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
219238373|NCT04929444|OTHER|Training on vertigo|"Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study"
219238374|NCT05746585|BEHAVIORAL|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
219238375|NCT00674609|DRUG|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
219238376|NCT00674609|DRUG|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
219167924|NCT06794814|BEHAVIORAL|oral exercise|The oral exercise protocol included several physical components, namely neck and shoulder stretching, cheek puffing exercises, tongue exercises, salivary gland massage, and oral diadochokinesis.
219167925|NCT06099184|DRUG|EYP-1901|Intravitreal Injection
219167926|NCT06099184|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
219167927|NCT06245746|BIOLOGICAL|umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)|UCMSC-Exo will be infused intravenously.
219167928|NCT04807738|DEVICE|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The outpatients will be randomized into groups: Individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in the interventional group, uses virtual reality and the new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
219178206|NCT04713774|DEVICE|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
219178207|NCT06397456|BEHAVIORAL|In-Person Patient Education|In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
219178208|NCT06397456|BEHAVIORAL|Commitment to Change|Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
219178209|NCT06397456|BEHAVIORAL|Blood pressure monitoring|Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
219178210|NCT06397456|BEHAVIORAL|Written Patient Education|Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
219178211|NCT06397456|BEHAVIORAL|Text-based reinforcement for CKD self-management|Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
219178212|NCT06397456|BEHAVIORAL|Community-based education session, reinforcement for self-management|"Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection"
219178213|NCT06397456|BEHAVIORAL|Text-based reinforcement for general health self-management|Patient educator will use text messages to send general health management messages
219178214|NCT06170034|BEHAVIORAL|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
219178215|NCT06170034|OTHER|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
219178216|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
219178217|NCT06041867|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
219178218|NCT06041867|DIETARY_SUPPLEMENT|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
219178219|NCT06041867|DIETARY_SUPPLEMENT|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
219167929|NCT04807738|OTHER|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will undergo physical therapy with physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
219167930|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
219167931|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
219167932|NCT05500508|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
219167933|NCT05500508|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
219167934|NCT06637137|DRUG|Iron|Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
219167935|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Sham|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.
219167936|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
219167937|NCT05310253|DRUG|Fludrocortisone|pill of fludrocortisone
219167938|NCT05310253|DRUG|Placebo|placebo pill
219167939|NCT05310253|BEHAVIORAL|Trier Social Stress Test (TSST)|psychosocial stress induction
219167940|NCT05310253|BEHAVIORAL|Placebo Trier Social Stress Test (P-TSST)|control condition
219167941|NCT06182163|BEHAVIORAL|Sedentary time intervention|Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents and young adults (AYAs) with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
219167942|NCT06582758|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
219167943|NCT06582758|BEHAVIORAL|Mindful Pain Management|In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.
219167944|NCT06349213|RADIATION|FDOPA injection before PET imaging|Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.
219167945|NCT06349213|BEHAVIORAL|Time perception tasks|The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations
219167946|NCT06349213|DEVICE|fMRI imaging|Imaging of brain structure during the completion of the time perception task
219167947|NCT06349213|DEVICE|EEG imaging|Recording of neural dynamics during the completion of the time perception task
219167948|NCT06349213|BEHAVIORAL|3 year follow-up|Behavioral and EEG follow-up (for older adults only)
219167949|NCT01904188|DEVICE|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)|The Gene Z device (no longer in use) and now using In-Dx created in our lab, and other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
219167950|NCT06490705|OTHER|tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises|"6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board."
219167951|NCT05703672|DRUG|Varenicline Tartrate|0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
219167952|NCT05703672|DRUG|Placebo|One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
219167953|NCT05703672|OTHER|Electronic cigarette|Nicotine salt pod based e-cigarette in 5% nicotine
219167954|NCT03392181|DRUG|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
219167955|NCT01198366|BIOLOGICAL|AERAS-402 1.5 x 10^10 vp|
219167956|NCT01198366|BIOLOGICAL|AERAS-402 3.0 x 10^10 vp|
219167957|NCT01198366|BIOLOGICAL|AERAS-402 1.0 x 10^11 vp|
219167958|NCT01198366|BIOLOGICAL|Placebo|
219167959|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
219238377|NCT00674609|DRUG|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
219238378|NCT04352894|DIAGNOSTIC_TEST|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
219167960|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
219167961|NCT06371209|PROCEDURE|Modified Amputation|Modified amputation procedure
219167962|NCT06371209|PROCEDURE|Standard Amputation|Standard amputation procedure
219167963|NCT06395038|DRUG|Abatacept plus Aldesleukin|CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
219238379|NCT02174315|BEHAVIORAL|Contingency Management|
219167964|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
219167965|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
219167966|NCT05610878|BIOLOGICAL|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
219167967|NCT05610878|BIOLOGICAL|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
219167968|NCT05610878|OTHER|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
219167969|NCT00931710|DRUG|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
219167970|NCT00931710|DRUG|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
219167971|NCT04936035|DRUG|Placebo|Placebo administered by SC injection
219167972|NCT04936035|DRUG|ALN-AGT01|ALN-AGT01 administered by SC injection
219167973|NCT04493125|DRUG|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
219167974|NCT04493125|DRUG|Placebo|Placebo
219167975|NCT06527313|BEHAVIORAL|Movement Mobilization Concept, Exercise and Tape|Mulligan Concept MWM Mulligan Taping Mulligan Self Home Workout
219167976|NCT06527313|BEHAVIORAL|Sham Movement Mobilization Concept, Exercise and Tape|The technique will be applied to cases in the sham group with only hand contact, without any slippage or rotation in any direction. Then, rigid taping will be applied without any tension or direction, and home exercises will be given.
219167977|NCT06527313|BEHAVIORAL|Special Exercises|"Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips"
219167978|NCT05871346|BEHAVIORAL|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
219167979|NCT05633407|DRUG|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
219167980|NCT05633407|DRUG|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
219167981|NCT06495359|OTHER|immunization education program|The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
219167982|NCT05308069|DEVICE|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
219167983|NCT05308069|DEVICE|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
219238380|NCT05214248|OTHER|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
219238381|NCT03788941|PROCEDURE|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
219238382|NCT05229549|OTHER|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
219167984|NCT05961020|DEVICE|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
219167985|NCT05961020|OTHER|moderate restricted diet|moderate restricted diet
219167986|NCT05378256|OTHER|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
219167987|NCT06309264|DEVICE|Phonak Lumina P90|FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
219167988|NCT06041139|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
219167989|NCT06041139|DIAGNOSTIC_TEST|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
219167990|NCT06041139|DIAGNOSTIC_TEST|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
219167991|NCT06041139|OTHER|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
219167992|NCT06501989|DRUG|Biweekly 5-FLUOROURACIL (5-FU)|5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
219167993|NCT06501989|DRUG|Biweekly Modified FOLFOX6|Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
219167994|NCT06501989|DRUG|Biweekly FOLFIRI|"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."
219167995|NCT06501989|DRUG|mFOLFOXIRI|Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
219167996|NCT05052021|OTHER|Public or Private Sector Patients|No intervention will be done. Two groups of patients will be recruited: patients receiving surgery in the Private Healthcare Sector, and patients receiving surgery in the Public Healthcare Sector
219167997|NCT04659811|DRUG|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
219167998|NCT04659811|PROCEDURE|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
219167999|NCT05609812|DRUG|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
219168000|NCT05609812|DRUG|Placebo|placebo
219168001|NCT06144905|OTHER|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
219238383|NCT05229549|OTHER|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
219238384|NCT03821285|PROCEDURE|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
219238385|NCT05500313|BEHAVIORAL|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
219238386|NCT05500313|BEHAVIORAL|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
219238387|NCT01131325|DRUG|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
219238388|NCT06053983|DEVICE|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
219238389|NCT06053983|DRUG|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
219238390|NCT06053983|DRUG|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
219168002|NCT06611397|DEVICE|Discogen Low pulsed ultrasound treatment|"The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.~The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.~The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge"
219168003|NCT06611397|DEVICE|Discogen Sham Treatment|The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week
219168004|NCT06932978|DEVICE|Provision of smart glasses for environmental control use|To the authors knowledge there has not been a clinical trial that includes the use of smart glasses with environmental controls. The smart glasses were used with environmental control systems that had a USB-C display output.
219168005|NCT03461978|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
219168006|NCT02677051|DRUG|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
219168007|NCT02677051|DRUG|Placebo|
219168008|NCT02669771|DRUG|enzalutamide|oral
219168009|NCT00530153|BEHAVIORAL|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
219168010|NCT00530153|DIETARY_SUPPLEMENT|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
219168011|NCT06217692|OTHER|nutrition education|nutrition education
219168012|NCT05359653|DRUG|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
219168013|NCT05359653|DRUG|Placebo|Matched sugar tablet
219238391|NCT03884478|BEHAVIORAL|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
219238392|NCT05516511|DIAGNOSTIC_TEST|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
219238393|NCT02788708|DRUG|Lenvatinib Mesylate|Given PO
219238394|NCT02788708|DRUG|Paclitaxel|Given IV
219238395|NCT02788708|OTHER|Pharmacological Study|Correlative studies
219238396|NCT02213094|DRUG|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
219238397|NCT02213094|DRUG|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
219168014|NCT06374394|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
219168015|NCT06374394|BIOLOGICAL|COVID-19 mRNA vaccine|1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
219168016|NCT04655677|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
219168017|NCT02990234|PROCEDURE|Capsular Repair|
219168018|NCT02990234|PROCEDURE|No Capsular Repair|
219168019|NCT03902132|OTHER|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
219168020|NCT03902132|OTHER|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
219168021|NCT00226889|DRUG|bosentan|
219168022|NCT00145236|DRUG|Nebivolol|
219168023|NCT02808767|DRUG|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
219168024|NCT02808767|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
219168025|NCT00220038|BEHAVIORAL|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
219168026|NCT02629679|BEHAVIORAL|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
219168027|NCT02629679|BEHAVIORAL|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
219168028|NCT05119543|OTHER|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
219238398|NCT00150852|DRUG|Vancomycin|
219168029|NCT03580200|OTHER|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
219168030|NCT00903474|OTHER|questionnaire administration|
219168031|NCT00903474|OTHER|study of socioeconomic and demographic variables|
219168032|NCT00903474|PROCEDURE|CAM exercise therapy|
219168033|NCT00903474|PROCEDURE|psychosocial assessment and care|
219168034|NCT00903474|PROCEDURE|quality-of-life assessment|
219168035|NCT00903474|PROCEDURE|stress management therapy|
219168036|NCT04866810|BEHAVIORAL|Intervention Arm|High fiber, plant based diet + exercise prescription with ACT sessions
219168037|NCT04866810|BEHAVIORAL|Control|Standard diet and exercise recommendations
219168038|NCT06648850|DRUG|DA-001|Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution
219168039|NCT06648850|OTHER|Placebo|Placebo Topical Solution
219168040|NCT06648850|DRUG|Phenylephrine|Phenylephrine Topical Solution
219168041|NCT06648850|OTHER|Intact5|Cosmetic formulation containing bitter orange extract
219238399|NCT03536520|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219238400|NCT03536520|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219168042|NCT06074354|BEHAVIORAL|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
219168043|NCT06074354|BEHAVIORAL|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
219168044|NCT05179395|DEVICE|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
219168045|NCT01388777|DEVICE|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
219168046|NCT01388777|PROCEDURE|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
219168047|NCT01388777|PROCEDURE|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
219168048|NCT00616031|DRUG|carboplatin|
219168049|NCT00616031|DRUG|nitroglycerin|
219168050|NCT00616031|DRUG|paclitaxel|
219168051|NCT04092205|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
219168052|NCT06522178|OTHER|Patient' ages|Patients were divided into two groups according to their ages.
219168053|NCT06655402|BEHAVIORAL|CARE-CITE|"CARE-CITE is a post-stroke family education program, to support care partners (CPs) in aiding stroke survivors (SS) during rehabilitation. Utilizing autonomy-supportive strategies, CARE-CITE emphasizes empathy, choice, and problem-solving while minimizing controlling language.~The program features a user-friendly web-based platform with interactive videos that guide CPs in providing support for SS. Over four weeks, CPs engage in two virtual home visits and two phone check-ins. During the initial visit, CPs review online modules, set collaborative goals, and co-create a home exercise plan targeting upper extremity (UE) activities. The second and third weeks involve structured phone calls to discuss autonomy-supportive strategies and address challenges.~The final visit reinforces strategies, assesses SS progress, and adjusts rehabilitation goals. Each module is designed to foster motivation and effective practice in daily activities."
219238401|NCT01118429|DRUG|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
219168054|NCT06655402|BEHAVIORAL|Attention Control Group|"Over a similar 4-week period, the SS and CP will receive the same number of structured virtual weekly visits as the CARE-CITE group without the review of CARE-CITE modules.~The CP will receive a brochure with general caregiving information and website resources. At week 1, a separate control group intervention therapist will deliver a 2-hour virtual home visit to evaluate SS UE function and assess safety concerns. Based on SS impairments, a home exercise program will be prescribed for flexibility, strength, and coordination (6-8 exercises, 2 sets of 10 reps). SS will be encouraged to practice daily (targeting 30 min/day). Weeks 2 and 3: CP Phone check-ins \[15-minute\]. The intervention therapist will review safety, assess adverse events, and CP's use of web resources. Week 4 Virtual Home visit (2 hours). Review SS's progress with the UE activity home exercise program, discuss safety concerns, and progress UE exercises as appropriate."
219168055|NCT06655402|OTHER|Actigraph GT3X+|Accelerometry data will be collected using Actigraph GT3X+ wearable sensors, approved by the FDA. The device does not collect or store individually identifiable health information (IIHI), private health information (PHI), or sensitive data. It is not intended for diagnosing, treating, or preventing diseases. These small, wrist-worn monitors document physical movement for physiological monitoring, including tracking movement during sleep. They can analyze circadian rhythms and assess activity in situations where quantifiable analysis of physical motion is needed.
219168056|NCT05413629|OTHER|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
219238402|NCT01118429|DRUG|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
219238403|NCT01219400|DRUG|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
219238404|NCT02261922|DRUG|ticagrelor|
219238405|NCT02261922|DRUG|prasugrel|
219238406|NCT03117218|DIAGNOSTIC_TEST|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
219168057|NCT06097702|DRUG|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
219168058|NCT06097702|DRUG|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 4 sequential days in one of the three doses based on body weight and followed up for 14 days.
219238407|NCT04454125|BEHAVIORAL|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
219238408|NCT04454125|OTHER|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
219238409|NCT01125345|PROCEDURE|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
219168059|NCT06097702|DRUG|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
219168060|NCT03206151|DRUG|CMAB009|for injection only
219168061|NCT03206151|DRUG|Irinotecan|for injection only
219168062|NCT03206151|DRUG|Folinic acid|for injection only
219168063|NCT03206151|DRUG|5-fluorouracil|for injection only
219168064|NCT06986681|OTHER|Big toe muscles strengthening exercises|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol
219168065|NCT06986681|OTHER|Big toe muscles strengthening exercises with neuromuscular training|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises and neuromuscular training protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol.
219168066|NCT06987331|OTHER|haptonomy|"Haptonomy involves a combination of skills taught in 4-8 sessions of 45-60 minutes between 20 and 36 weeks of gestation. An important stage of the three-step haptonomy application is the attachment of the parents to the foetus by touching the foetus in the 20-36th weeks of pregnancy.~Mindfullnes is a mbsr application done in 8 sessions"
219168067|NCT06987331|BEHAVIORAL|Haptonomy application|breastfeeding status
219168068|NCT06987331|BEHAVIORAL|Mindfulness|breastfeeding status
219178220|NCT06205420|DRUG|Injectable composite resin restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
219238410|NCT01189045|BEHAVIORAL|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
219238411|NCT01189045|BEHAVIORAL|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
219238412|NCT01448993|DRUG|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
219238413|NCT01448993|DRUG|Placebo|
219238414|NCT02301299|BEHAVIORAL|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
219238415|NCT03512041|BEHAVIORAL|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
219238416|NCT03512041|BEHAVIORAL|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
219238417|NCT03512041|BEHAVIORAL|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
219238418|NCT03512041|BEHAVIORAL|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
219238419|NCT03512041|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
219238420|NCT03512041|BEHAVIORAL|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
219168069|NCT06987929|PROCEDURE|Hydrodilatation injection|During the procedure, the patient lie supine on an examination couch, with the affected arm in the modified Crass position. All injections were done under image guidance using a Philips EPIQ ultrasound machine with an L18-12 MHz linear array transducer, performed consecutively by 2 rheumatologists or 1 pain medicine anaesthetist, all trained in MSK US. Aseptic technique was used. The transducer was placed at the short axis of the supraspinatus tendon, and the rotator cuff interval and coracohumeral ligament (CHL) were identified. Local anaesthetic (1% lignocaine) was injected subcutaneously to the skin. The therapeutic medication consisted of a mixture of 40 mg triamcinolone (10 mg/ml concentration) and 5ml 1% lignocaine, which was diluted with sterile normal saline into a total of 20mls suspension. The injection was administered using a 22-G 2-inch needle (Stimuplex A) introduced below the CHL adjacent to the long head of biceps tendon, in the in-plane view under US guidance.
219168070|NCT06987929|PROCEDURE|Intra-articular steroid injection (IAI)|Intra-articular corticosteroid injection was performed as a control group. The posterior shoulder approach was used. The patient was positioned in the lateral decubitus or semi-prone position with the affected shoulder at the uppermost position, elbow semi-flexed and the ipsilateral arm resting on a pillow for comfort and stability. The ultrasound transducer is positioned over the long axis of the myotendinous junction of the infraspinatous tendon to view the contours of the posterior glenoid labrum and posterior portion of the humeral head. The injectate was administered using a 21-G hypodermic needle. 40 mg triamcinolone (10 mg/ml concentration) mixed with 1ml of 1% lignocaine was injected into the posterior glenohumeral joint, under ultrasound-guidance. Any adverse reaction that occurred during the procedure was recorded. Following the procedure, the patient was advised to avoid overuse of the injected joint for 24 hours as part of post-injection care.
219168071|NCT06988085|OTHER|Blood sampling|Before and after fludarabine infusion
219168072|NCT05803798|DEVICE|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
219168073|NCT06988007|DEVICE|Whole body MRI|Whole body MRI (ZTE sequence)
219168074|NCT06987760|PROCEDURE|flexible ureteroscope urolithiasis|Using flexible ureteroscope combine with urethral access sheath to treatment urolithiasis
219168075|NCT06987019|OTHER|3D motion capture, wearable devices, and functional outcome measures|Gait evaluation, Hill and Stair Assessment Indices, 6 minute walk test, AMPPro, Timed Up and Go
219168076|NCT06987006|OTHER|Jigsaw education|The Jigsaw Technique (JT) is used as a teaching technique where each student creates pieces of an academic and instructional puzzle, specializes in puzzle groups, and teaches the subject they specialize in to other group members.
219168077|NCT06987006|OTHER|Classical Education Technique|In the classical education method, students listen to the lesson explained by the educator in a classroom environment.
219168078|NCT06988280|DIAGNOSTIC_TEST|Ultrasound-guided transvaginal aspiration of cystic pelvic lesions.|Ultrasound-guided transvaginal aspiration is a minimally invasive procedure used to drain cystic pelvic lesions, such as adnexal cysts or pelvic abscesses. A thin needle is inserted through the vaginal wall under ultrasound guidance to aspirate fluid from the cyst, reducing its size.
219168079|NCT06986629|DEVICE|pulsed electromagnetic therapy|We will use the ASTAR Physio MG 827, a generator and 75 cm solenoid couch, in a pulsed electromagnetic field group. Participants will be placed comfortably in the solenoid, and the device will be turned on and programmed for 20 guesses for 10 minutes, 7 Hz, three times per week for 8 weeks.
219168080|NCT06986629|DEVICE|Photobiostimulation|The therapy will be performed using an ASTAR PhysioGo -As low level laser therapy device with a wavelength of 830 nm, 30 mW power output, and 1 J energy dose. Patients will be supine and wear laser safety goggles. The laser will be applied to six locations over the maxillary or frontal sinuses, administered in a continuous manner for 33 seconds per spot, totaling 198 seconds and 6 J per session
219168081|NCT06986629|OTHER|Self-sinus massage technique|Participants are instructed to perform self-massage to their frontal and maxillary sinuses at home twice daily, in the morning and evening. For the frontal sinus, place the fingers above the eyebrows on either side of the forehead, and gently circular outward massage for three sets of 30 seconds, repeated twice a day.
219168082|NCT03671811|DRUG|Megestrol Acetate|Given PO
219168083|NCT03671811|BIOLOGICAL|Pterostilbene|Given PO
219168084|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219168085|NCT04913805|DRUG|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
219168086|NCT04913805|DRUG|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
219168087|NCT04913805|OTHER|Potassium Chloride|Active control
219168088|NCT06900946|OTHER|gluten|The intervention group will receive 3 grams of gluten powder daily
219168089|NCT06900946|OTHER|cornstarch|The control group will receive 3 grams of cornstarch powder daily
219168090|NCT04890249|DEVICE|Investigational IOL Model C1V000|IOL replaces the natural lens removed during cataract surgery.
219238421|NCT03512041|BEHAVIORAL|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
219238422|NCT02965352|DEVICE|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
219238423|NCT02965352|DEVICE|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
219238424|NCT02965352|DEVICE|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
219238425|NCT06506630|DIETARY_SUPPLEMENT|coenzyme Q10|300 mg capsule twice a day
219238426|NCT06506630|DIETARY_SUPPLEMENT|placebo|300 mg capsule twice a day
219238427|NCT04088305|DRUG|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
219238428|NCT03961178|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
219238429|NCT03961178|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
219238430|NCT05449145|DIETARY_SUPPLEMENT|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
219238431|NCT05449145|DIETARY_SUPPLEMENT|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
219238432|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
219238433|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
219238434|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
219238435|NCT05959226|BEHAVIORAL|Exercise Intervention|"1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
219238436|NCT05959226|DIETARY_SUPPLEMENT|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
219238437|NCT03532568|OTHER|skin biopsy|4mm punch skin biopsy
219238438|NCT03532568|RADIATION|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
219238439|NCT03498456|DRUG|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
219238440|NCT03498456|DRUG|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
219168091|NCT04890249|DEVICE|Investigational IOL Model C2V000|IOL replaces the natural lens removed during cataract surgery.
219168092|NCT04890249|DEVICE|Control IOL Model ICB00|IOL replaces the natural lens removed during cataract surgery.
219168093|NCT06778070|OTHER|Pelvic floor yoga|Pelvic floor yoga
219168094|NCT06778070|OTHER|Physical conditioning|Physical conditioning
219168095|NCT06728176|DRUG|MT1988|Active Drug
219168096|NCT06728176|DRUG|Placebo|Placebo comparator
219168097|NCT04839302|DRUG|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
219168098|NCT06762548|DRUG|DA-007|Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine
219168099|NCT06762548|DRUG|Placebo|Topical placebo solution
219168100|NCT06751329|DRUG|DM002|An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
219168101|NCT06923683|BEHAVIORAL|Treatment for social cognition disorders (T-ScEmo)|T-ScEmo is an evidence-based, multifaceted treatment protocol for poor social cognition and emotion regulation impairments in patients with ABI. T-ScEmo is implemented as standard practice in the Netherlands. In total, the treatment consists of 20 1-hour sessions. The treatment is divided into extended psychoeducation for patient and proxy and 3 modules, including emotion perception (module 1), perspective taking and understanding social information (module 2), and goal-directed social behavior (module 3). These three modules are interdependent and strengthen each other. Therefore, the developers strongly recommend to offer all three modules. The presence of a proxy is required in the first psycho-education session and during the third module. The first and second modules are invariant (10 sessions together), but in the third module, therapists can adjust the content to individual needs and personal goals.
219168102|NCT06931795|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
219238441|NCT06068803|DIETARY_SUPPLEMENT|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
219238442|NCT06068803|DIETARY_SUPPLEMENT|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
219238443|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
219238444|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
219168103|NCT06931795|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
219168104|NCT06931912|BEHAVIORAL|MENBS clinical interventions|"* Monitor: Continuously monitor health-related indicators through regular follow-up.~* Education: Provide health education to improve cognition of patients and their families.~* Nutrition: Assess patients' nutritional risks and develop personalized diet plans.~* Behavior: Recommend appropriate exercise plans to promote physical development.~* Support: Conduct home visits, offer free clinics and establish a support network."
219168105|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active|Transcranial focussed ultrasound to target site
219168106|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Sham|Transcranial focussed ultrasound off
219168107|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active control|Transcranial focussed ultrasound on to control
219238445|NCT06328296|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219238446|NCT06328296|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
219238447|NCT00005771|DEVICE|Visual utrasound feedback|
219238448|NCT00005771|PROCEDURE|Abdominal Hollowing Exercise|
219238449|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 20mg
219238450|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 40mg
219238451|NCT04503629|DRUG|Rabeprazole sodium|Rabeprazole sodium 10mg
219238452|NCT00035919|GENETIC|Mx-dnG1 Retroviral Vector|
219238453|NCT05683639|OTHER|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
219238454|NCT03472118|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
219238455|NCT01956396|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
219238456|NCT00828139|BIOLOGICAL|ziv-aflibercept|Given IV
219238457|NCT00828139|DRUG|topotecan hydrochloride|Given IV
219238458|NCT03539497|DIAGNOSTIC_TEST|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
219238459|NCT03101098|PROCEDURE|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
219238460|NCT03101098|PROCEDURE|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
219238461|NCT01817088|PROCEDURE|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
219168108|NCT06932653|OTHER|SurgPASS - intervention|SurgPASS consists of a preoperative surgical passport used for any patients requiring emergency laparotomy, a simulation training course and local clinical champions.
219238462|NCT01817088|PROCEDURE|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
219238463|NCT00452322|DRUG|Testosterone Substitution by Testosterone Undecanoate i.m.|
219238464|NCT03060356|BIOLOGICAL|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
219238465|NCT03110783|BIOLOGICAL|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
219168109|NCT05478213|DEVICE|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
219238466|NCT01714947|DRUG|[^14C]-alisertib|\[\^14C\]-alisertib oral solution
219238467|NCT01714947|DRUG|alisertib|Alisertib enteric coated tablets
219238468|NCT01922102|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
219238469|NCT01922102|DRUG|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
219238470|NCT01922102|DRUG|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
219168110|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
219168111|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
219168112|NCT06361758|DRUG|Cadonilimab+Lenvatinib|Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
219168113|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
219168114|NCT06537258|BEHAVIORAL|Biofeedback Enhanced Treatment|"At all 4 assessment points (T1-T4), HRV will be measured using the ECG module of the mobile MindWare system at a sampling rate of 500 Hz, and a Skin Conductance Response (SCR) will be collected at a sampling rate of 10 Hz using eSense for iPad. Electrodes to assess SCR and HRV will be attached to patients during an \~10-minute period.~A 5-minute initial baseline assessment will occur first followed by three 5-minute stress trials.~Stress tasks will be audio recorded to measure study fidelity, and participants will be asked to rate their subjective level of stress with each trial. At all assessment points (T1-T4), participants will be provided with stool collection kits to collect a stool sample within 3 days of the laboratory psychophysiological assessment.~At all assessment points (T1-T4), a blood draw of approximately 3 ml of blood will be collected."
219168115|NCT01945762|DRUG|Vandetanib 300 mg|Vandetanib commercial tablets
219168116|NCT05338086|DRUG|MB09 (denosumab biosimilar)|Pre-filled syringe (PFS) 60 mg/mL solution, administered as subcutaneous injection
219168117|NCT05338086|DRUG|EU-Prolia|PFS 60 mg/mL solution, administered as subcutaneous injection
219168118|NCT05338086|DIETARY_SUPPLEMENT|Elemental Calcium|at least 1000 mg daily
219168119|NCT05338086|DIETARY_SUPPLEMENT|Vitamin D|at least 400 IU daily
219168120|NCT04880226|DEVICE|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
219168121|NCT03940703|DRUG|Tepotinib|Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
219168122|NCT03940703|DRUG|Osimertinib|Participants received Osimertinib at a dose of 80 mg orally once daily.
219168123|NCT03879343|OTHER|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
219168124|NCT06765330|DRUG|CHX disinfection|Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
219168125|NCT06765330|DEVICE|Laser Disinfection|After the caries removal procedure, the cavity will be disinfected using an Er,Cr: YSGG laser (EPIC X™, BIOLASE, USA) with 940 nm and 0.1 W output power. The laser tip will be a 400 µm tip with an energy density of 138.12 J/cm in non-contact mode (2 mm distance), 5 s/mm2 sweeping motion.
219168126|NCT06765330|PROCEDURE|Tungsten carbide bur|Carious tissue will be completely removed from the surrounding cavity walls with a tungsten carbide bur, leaving at least 2 mm of peripheral intact tooth structure for good adaptation and sealing of the restoration.
219168127|NCT06765330|PROCEDURE|Polymer bur|Access to the lesion will be achieved using a high-speed handpiece with a sterile high-speed bur. The polymer bur will be used with a low-speed handpiece at 5,000-10,000 RPM to remove carious dentin in sizes RA4, RA6, and RA8 according to the size of the caries lesion. The instrument will be used with a circular, light force starting from the center of the carious lesion towards the periphery as recommended by the manufacturer. Caries removal will be stopped when the instrument is macroscopically worn and blunt and can no longer remove tissue. An excavator will be used to verify if any caries remain at the base of the cavity. If necessary, a new polymer bur will be used to remove the remaining decay.
219168128|NCT06366867|DEVICE|VibrantMinds|VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
219168129|NCT02536118|DEVICE|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
219168130|NCT06229613|DEVICE|medical device for exhaled breath aerosols (XBAs) collection|To evaluate the feasibility of XBAs collection and analysis (index test) using the molecular tests currently in use at San Raffaele Hospital for the detection of respiratory pathogens in clinical samples, compared to upper respiratory secretion and sputum samples, that will be collected using standard procedures and analysed using the same kits (comparator tests).
219168131|NCT04996160|DRUG|Palbociclib|Oral
219168132|NCT04996160|DRUG|Dexamethasone|8 mg/m2/day divided BID, PO, NG, or IV
219168133|NCT04996160|DRUG|Bortezomib|1.3 mg/m2/dose, IV (preferred) or SC
219168134|NCT04996160|DRUG|Doxorubicin|25 mg/m2/dose IV
219168135|NCT06476418|BEHAVIORAL|distraction|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
219168136|NCT03059121|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|
219168137|NCT05148780|DIAGNOSTIC_TEST|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
219168138|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
219168139|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
219168140|NCT06110689|OTHER|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
219168141|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
219168142|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
219238471|NCT04462159|BEHAVIORAL|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
219238472|NCT00677742|OTHER|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
219238473|NCT00677742|OTHER|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
219238474|NCT00518596|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
219238475|NCT02920645|OTHER|AVM-related ICH|
219238476|NCT00463957|DRUG|sildenafil|
219238477|NCT00463957|DRUG|tadalafil|
219238478|NCT00463957|DRUG|placebo|
219238479|NCT00370747|DRUG|Ecabet|ophthalmic solution 2.83%
219238480|NCT00370747|DRUG|Ecabet|ophthalmic solution 3.70%
219238481|NCT00370747|DRUG|Placebo|
219238482|NCT01289899|DRUG|BR-A-657|120, 360mg or placebo 7days
219238483|NCT03420729|PROCEDURE|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
219238484|NCT03420729|DEVICE|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
219238485|NCT00850954|OTHER|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
219238486|NCT00850954|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
219238487|NCT00850954|OTHER|Survey Administration|Ancillary studies
219238488|NCT00101296|DRUG|tipifarnib|Given orally
219238489|NCT00101296|OTHER|pharmacological study|Correlative studies
219238490|NCT00101296|OTHER|laboratory biomarker analysis|Correlative studies
219238491|NCT01330875|OTHER|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
219238492|NCT04054856|DEVICE|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
219238493|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
219238494|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
219238495|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
219238496|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
219238497|NCT00365599|DRUG|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
219238498|NCT00365599|DRUG|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
219238499|NCT00992849|DRUG|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
219238500|NCT05736237|GENETIC|Whole exome sequencing|With Next Generation Sequenzing
219238501|NCT02539602|BEHAVIORAL|The Need to Know students received the N2K curriculum as described previously|
219238502|NCT01176747|DRUG|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
219238503|NCT00814359|DRUG|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
219238504|NCT00814359|DRUG|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
219168143|NCT04985695|DRUG|Epidural analgesia|All patients received local anesthesia (3-5 ml of 2% Lidocaine). During the preoperative induction of anaesthesia a catheter was inserted 4cm into the epidural space. The catheter will be load during the intervention (0.1 ml/kg/h). In postoperative situation, a patient controlled epidural analgesia was introduced with a debit adapted to the arterial pressure.
219168144|NCT04985695|DRUG|Bilateral rectus sheath block|Bilateral rectus sheath block was performed Under general anesthesia and with ultrasound guidance. Rectus sheath block was inserted on each side of the abdomen. All patients received ropivacaine through elastomeric pump
219168145|NCT04985695|PROCEDURE|Laparotomy|A midline sub or supra umbilical laparotomy or xypho-pubian laparotomy
219168146|NCT03576989|DIETARY_SUPPLEMENT|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
219238505|NCT02161588|DRUG|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
219238506|NCT02161588|DRUG|placebo|Once-daily oral administration as tablets.
219238507|NCT00160329|DRUG|Atazanavir|300 mg with ritonavir boosting or 400 mg without
219168147|NCT03576989|OTHER|placebo|placebo contains mineral oil
219168148|NCT06495294|BIOLOGICAL|Whole Blood|2 units of whole blood administered by Ornge AAS
219168149|NCT06495294|BIOLOGICAL|RBC + plasma|2 units of RBC + 2 units of plasma administered by Ornge AAS
219168150|NCT06190678|DRUG|Pirtobrutinib|Administered orally
219168151|NCT05332379|DIAGNOSTIC_TEST|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
219168152|NCT06764953|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
219168153|NCT06764953|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
219168154|NCT04974892|DIAGNOSTIC_TEST|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
219168155|NCT06793631|OTHER|Participants will be interviewed qualitatively about experience of providing/receiving financial support for living costs|There is no intervention for participants. Participants will receive qualitative interviews to explore their experience of financial insecurity
219168156|NCT03176225|PROCEDURE|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
219168157|NCT03176225|DEVICE|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
219168158|NCT03176225|DEVICE|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
219168159|NCT05601726|DRUG|ABD-3001|"Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m²."
219168160|NCT05601726|DRUG|ABD-3001|"For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days."
219168161|NCT04869098|DIETARY_SUPPLEMENT|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
219168162|NCT04869098|DIETARY_SUPPLEMENT|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
219168163|NCT06796725|DEVICE|rTMS|(1) The patient undergoes pseudo stimulus intervention in the first week and real stimulus intervention afterwards, which is blind to the patient. (2) Starting from the second week, true stimulation intervention will be conducted for 4 weeks, with each patient making an appointment for 1 month. On Day 7 after the patient intervention, Day 14, Day 30, Day 60, Day 90, Day 180 scales were used to evaluate follow-up.
219168164|NCT06796725|DRUG|Sibelium|Sibelium 10mg is taken orally every night for 4 weeks each course of treatment. Patients were evaluated and followed up with a scale based on medication intervention, including Day 7, Day 14, Day 30, Day 60, Day 90, and Day 180
219168165|NCT05549726|DRUG|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
219238508|NCT02781233|OTHER|Progressive resistance training|Progressive resistance training program
219238509|NCT02781233|OTHER|Normal daily activities|Usual daily activities
219238510|NCT01072058|DRUG|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
219238511|NCT03401411|BEHAVIORAL|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
219168166|NCT05549726|OTHER|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
219168167|NCT05549726|OTHER|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
219168168|NCT06794268|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
219168169|NCT05989984|DIETARY_SUPPLEMENT|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
219168170|NCT05989984|DIETARY_SUPPLEMENT|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
219168171|NCT06794424|DIAGNOSTIC_TEST|Ziwig Endotest®|Saliva sampling for Endometriosis diagnostic
219168172|NCT06796634|DEVICE|J-plasma|"* Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP.~* Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations:~  * 15 W, 30W, or 45W~ * 2, 5, or 10 seconds.~* The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry."
219168173|NCT05541861|BIOLOGICAL|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168174|NCT05541861|BIOLOGICAL|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168175|NCT05541861|BIOLOGICAL|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168176|NCT05541861|BIOLOGICAL|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168177|NCT05541861|BIOLOGICAL|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168178|NCT05541861|BIOLOGICAL|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
219168179|NCT06792916|PROCEDURE|spermidine and minimally invasive non surgical tecnique|minimally non surgical periodontal therapy will be performed with the adjunct of spermidine based gel
219168180|NCT06792916|OTHER|peridontal therapy (minimally invasive non surgical tecnique)|subgingival instrumentation will be performed according to MINST
219168181|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
219168182|NCT06788158|DRUG|Incobotulinum Toxin A|will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
219238512|NCT03401411|BEHAVIORAL|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
219238513|NCT01320683|DRUG|oxaliplatin|Given IV
219238514|NCT01320683|DRUG|leucovorin calcium|Given IV
219238515|NCT01320683|DRUG|fluorouracil|Given IV
219238516|NCT01320683|BIOLOGICAL|bevacizumab|Given IV
219238517|NCT01320683|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
219238518|NCT01320683|OTHER|laboratory biomarker analysis|Correlative studies
219238519|NCT01320683|OTHER|pharmacological study|Correlative studies
219168183|NCT06788158|DRUG|Glucocorticoid|Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
219168184|NCT06796517|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
219238520|NCT01320683|DRUG|irinotecan hydrochloride|Given IV
219238521|NCT00307671|DRUG|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
219238522|NCT00307671|DRUG|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
219238523|NCT00307671|DRUG|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
219238524|NCT05248269|PROCEDURE|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
219238525|NCT06474234|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
219238526|NCT06474234|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
219238527|NCT02211599|OTHER|15% protein|Meal to provide 15%en from protein.
219238528|NCT02211599|OTHER|30% protein|Meal to provide 30%en from protein.
219238529|NCT02211599|OTHER|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
219238530|NCT00759681|DEVICE|ArterX Surgical Sealant|Apply at the suture site.
219238531|NCT00759681|DEVICE|Gelfoam and Thrombin|Apply at the suture site.
219238532|NCT02426424|DEVICE|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
219238533|NCT02426424|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
219238534|NCT04779047|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
219238535|NCT04779047|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
219238536|NCT04779047|DRUG|Tocilizumab|Tocilizumab 800 mg once.
219238537|NCT04779047|DRUG|Lopinavir/ Ritonavir|Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
219238538|NCT04779047|DRUG|Ivermectin|Ivermectin 36 mg at day 1,3 and 6.
219238539|NCT02321371|DRUG|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
219238540|NCT02321371|DRUG|Lactulose|Continuation of Lactulose therapy for further 48 hours.
219238541|NCT01608919|OTHER|blood tests|thromboelastogram platelet mapping
219238542|NCT01693393|DRUG|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
219238543|NCT03966599|DIAGNOSTIC_TEST|Pain|Patient's pain in order to VAS
219238544|NCT03966599|DIAGNOSTIC_TEST|Hemodynamic changes|changes in hemodynamic states
219238545|NCT01295619|DEVICE|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
219238546|NCT04304898|OTHER|Home spirometry|"* Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
219238547|NCT03663049|DRUG|discontinue statin|Discontinue statin as prescribed for 12 weeks
219238548|NCT02275806|DRUG|Irinotecan|
219238549|NCT02275806|DRUG|Cisplatin|
219238550|NCT04362722|DRUG|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
219238551|NCT03185858|BEHAVIORAL|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
219238552|NCT02920216|DRUG|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
219238553|NCT05843149|BEHAVIORAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
219238554|NCT05843149|BEHAVIORAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
219238555|NCT03439800|OTHER|Mental and Physical Practice|"1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait."
219238556|NCT03439800|OTHER|Physical Practice|"1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
219238557|NCT00476151|DRUG|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
219238558|NCT00476151|DRUG|placebo cream|inactive placebo cream applied two times daily
219238559|NCT05745259|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
219238560|NCT05745259|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
219238561|NCT00003376|DRUG|carboplatin|
219238562|NCT00003376|DRUG|cisplatin|
219238563|NCT00003376|DRUG|doxorubicin hydrochloride|
219238564|NCT00003376|DRUG|methotrexate|
219238565|NCT00003376|DRUG|paclitaxel|
219238566|NCT00003376|DRUG|vinblastine|
219238567|NCT05028322|DRUG|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
219238568|NCT05028322|BIOLOGICAL|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
219238569|NCT02792296|OTHER|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
219238570|NCT02962609|OTHER|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
219238571|NCT02962609|OTHER|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
219238572|NCT04650919|PROCEDURE|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
219238573|NCT04205045|DIAGNOSTIC_TEST|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
219238574|NCT04205045|OTHER|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
219238575|NCT04205045|OTHER|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
219238576|NCT00893477|BIOLOGICAL|rituximab|
219238577|NCT00893477|BIOLOGICAL|sargramostim|
219238578|NCT00893477|GENETIC|gene expression analysis|
219238579|NCT00893477|GENETIC|gene rearrangement analysis|
219238580|NCT00893477|GENETIC|polymerase chain reaction|
219238581|NCT00893477|GENETIC|polymorphism analysis|
219238582|NCT00893477|OTHER|laboratory biomarker analysis|
219238583|NCT01025921|DRUG|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
219238584|NCT01025921|OTHER|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
219238585|NCT01498354|PROCEDURE|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
219238586|NCT01498354|PROCEDURE|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
219238587|NCT03258905|BEHAVIORAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
219238588|NCT03258905|BEHAVIORAL|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
219238589|NCT01476137|DRUG|GSK1120212|MEK inhibitor
219238590|NCT01476137|DRUG|GSK2110183|AKT inhibitor
219238591|NCT03980171|DRUG|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
219238592|NCT03980171|DRUG|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
219238593|NCT03980171|DRUG|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
219168185|NCT06796517|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
219168186|NCT06796517|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
219168187|NCT06796517|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
219168188|NCT06796517|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
219168189|NCT06796517|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
219168190|NCT06794749|OTHER|Action Observation Therapy|Patients received general physiotherapy in addition to action observation therapy (AOT) via telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face to face for 45 minutes.
219168191|NCT06794749|OTHER|Control|Patients received general physiotherapy in addition to action observation therapy (AOT) via face-to-face telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face-to-face for 45 minutes.
219168192|NCT03320707|DRUG|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
219168193|NCT03320707|DRUG|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
219168194|NCT03320707|DRUG|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
219168195|NCT06794710|DRUG|diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids|Patients in this group will receive pharmacological treatment for heart failure.
219168196|NCT06794710|BEHAVIORAL|Close follow-up|High risk patients receive close follow-up
219168197|NCT06794710|BEHAVIORAL|early rehabilitation guidance|Early rehabilitation guidance such as cardiopulmonary exercise tests and cardiac rehabilitation therapy
219168198|NCT01226979|RADIATION|High-dose endorectal brachytherapy (HDRBT)|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
219168199|NCT03931291|DRUG|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
219168200|NCT06247631|OTHER|STOP BANG|The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
219168201|NCT06792656|OTHER|standardized Forest Therapy session (120 min)|standardized, 2-hrs Forest Therapy session following the INFTA Forest Therapy Guiding Sequence
219168202|NCT06797115|DRUG|SGLT-2 inhibitor|T2D patients for whom, in addition to administering any existing antidiabetic regimen, the treating physician decided to initiate SGLT-2 inhibitor therapy (empagliflozin or dapagliflozin) based on standard clinical indications.
219168203|NCT04604977|BEHAVIORAL|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
219168204|NCT05441670|BEHAVIORAL|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
219168205|NCT05441670|BEHAVIORAL|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
219168206|NCT06736288|DRUG|BUCCALIN®|"Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach."
219168207|NCT06736288|OTHER|Placebo|Gastro-resistant tablets containing only excipients). The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
219168208|NCT06160050|BEHAVIORAL|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
219168209|NCT06487910|DEVICE|3D scan measurment|"patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process."
219168210|NCT06796426|DRUG|Plozasiran|25 mg ARO-APOC3 by sc injection administered by healthcare professional
219168211|NCT06791148|RADIATION|Low-dose radiotherapy|2Gy/f，q3w，×4f
219168212|NCT06791148|DRUG|albumin-bound paclitaxel|100-120mg/m2,i.v.,d2,d9,q3w
219168213|NCT06791148|DRUG|AK112|20mg/kg, i.v., d2, q3w
219168214|NCT06793150|DRUG|Remifentanil|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
219168215|NCT06793150|DRUG|dexmedetomidin|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
219168216|NCT06203340|OTHER|Core stabilizasyon and lumbal back school|Lumbal back schooL
219238594|NCT01157442|BEHAVIORAL|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
219168217|NCT06839742|OTHER|Deep Posterior Gluteal Compartment Block|Deep Posterior Gluteal Compartment Block will be performed under USG guidance before neuraxial anesthesia.
219168218|NCT06839742|OTHER|Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block will be performed under USG guidance before neuraxial anesthesia.
219168219|NCT06789549|DRUG|epinephrine nasal drops|Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
219168220|NCT06789549|DRUG|oxymetazoline nasal drops|Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
219168221|NCT06676332|OTHER|motor imagery training|"Children in the study group will receive multisensory motor imagery training program 45 minutes. The training protocol consists of several parts that will be run through every training session according to Kumar et al. (2016):~* Watching videos of selected multisensory motor skills for 10 minutes.~* Mental rehearsal of these motor skills 10 minutes.~* Overt practice of the multisensory motor skills for 25 minutes. On the videos, the performance of the skill by a child aged 8-12 years will be shown. All the exercises will be looped to repeat for six to seven times. While projecting the video on the laptop screen, it will be ensured that the children are in a comfortable seating position and the screen is in their visual field. Repetition of the exercises was based on their ability which could be a minimum of five repetitions per session to a maximum of ten repetitions per exercise session."
219168222|NCT06676332|OTHER|traditional physical therapy|traditional physical therapy training program
219168223|NCT04571970|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
219168224|NCT06780332|DRUG|RDD to Palynziq|Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
219168225|NCT05930431|BEHAVIORAL|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
219168226|NCT05930431|BEHAVIORAL|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
219168227|NCT06835478|BEHAVIORAL|EPURE + : EPURE program|EPURE program will be tested.
219168228|NCT06835478|BEHAVIORAL|EPURE - : Standard practices|This group will receive standard practices to prevent the use of screens in child under 3
219168229|NCT06795698|DRUG|Enoxaparin|enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
219168230|NCT06840847|BEHAVIORAL|Sexual Coercion|This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.
219238595|NCT04549948|PROCEDURE|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
219168231|NCT06091098|OTHER|Dynamic CO2|2% inspired CO2 for 2-4 breaths
219168232|NCT06091098|OTHER|Sham CO2|Air
219168233|NCT05547958|OTHER|Focus group and online survey|"Focus group with parents of children with disabilities or chronic condition will be organized to identify hypotheses regarding their needs in terms of informations exchange with pediatric rehabilitation professionals about the rehabilitation care of their children.~Then, an online survey will be proposed to parents of children with disabilities or chronic condition in France to identify their needs regarding the development of apps that offer the feature to share informations with rehabilitation professionals."
219168234|NCT05262374|PROCEDURE|Procedure/Surgery: Laparoscopic|Surgeon
219168235|NCT05262374|PROCEDURE|Robotic|Versius system.
219168236|NCT06408051|PROCEDURE|Injection of onabotulinumtoxinA into the bladder wall|BTX was injected into the detrusor muscles at 20 sites
219168237|NCT06839456|DEVICE|Phase 1 Dose Level 1|Patients in the first dose level for the CD45RA depleted addback will receive 1 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
219238596|NCT04549948|PROCEDURE|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
219238597|NCT04549948|PROCEDURE|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
219238598|NCT01411176|DRUG|Menthol|20 mL NPO-11 in a prefilled plastic syringe
219238599|NCT01411176|DRUG|Placebo|The placebo is included same additives as active comparator.
219238600|NCT05990088|DEVICE|Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept|The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate
219238601|NCT05990088|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
219238602|NCT01678755|DRUG|ABT-126|ABT-126 Low Dose
219238603|NCT01678755|DRUG|ABT-126|ABT-126 High Dose
219238604|NCT01678755|DRUG|Placebo|Placebo
219238605|NCT05815771|PROCEDURE|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
219238606|NCT05815771|PROCEDURE|Bone Marrow stem cells aspirate|stem cells
219238607|NCT02217891|BEHAVIORAL|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
219238608|NCT03977337|PROCEDURE|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
219238609|NCT01244399|DIETARY_SUPPLEMENT|Inositol|
219238610|NCT01383616|DEVICE|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
219238611|NCT01465399|BIOLOGICAL|Plasma Rich in Growth Factors PRGF-Endoret|
219238612|NCT01465399|PROCEDURE|Conventional closure of the lesion|
219238613|NCT01995565|OTHER|PLR|
219238614|NCT06506552|PROCEDURE|IMA preserving|Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
219238615|NCT06506552|PROCEDURE|IMA sectioning|Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
219238616|NCT03941366|PROCEDURE|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
219238617|NCT02936258|PROCEDURE|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
219238618|NCT02936258|PROCEDURE|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
219238619|NCT02936258|PROCEDURE|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
219238620|NCT05082545|DRUG|SHR-2002 and SHR-1316|Cohort study
219238621|NCT02199444|DRUG|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
219238622|NCT02199444|DRUG|Placebo|
219238623|NCT02104375|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
219238624|NCT02326194|BIOLOGICAL|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
219238625|NCT02326194|BIOLOGICAL|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
219238626|NCT02326194|BIOLOGICAL|placebo (one dose)|placebo, one doses
219238627|NCT02326194|BIOLOGICAL|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
219238628|NCT02443532|BEHAVIORAL|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
219238629|NCT02443532|BEHAVIORAL|Individual education|Usual care (individual consultations as routinely performed)
219238630|NCT01293201|DRUG|STAHIST|STAHIST dosed one tablet, BID
219238631|NCT01293201|DRUG|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
219238632|NCT04733573|DEVICE|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
219168238|NCT06839456|DEVICE|Phase 1 Dose Level 2|Patients in the second dose level for the CD45RA depleted addback will receive 2 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
219168239|NCT06839456|DEVICE|Phase 1 Dose Level 3|"Patients in the third and final dose level for the CD45RA depleted addback will receive 5 X 10\^6 CD45RO+ T cells/kg. All patients in this dose group will be evaluated for acute GVHD at day 100. Based on these findings, the maximum tolerated dose (MTD) will be determined.~Once MTD for the addback cell dose has been determined in Phase 1, subjects with mismatched related donors will then enroll in Phase 2."
219168240|NCT06839456|DEVICE|Phase 2 Maximum Tolerated Dose determined in Phase 1|Patients with mismatched related donors will receive the CD45RA depleted addback at the maximum tolerated dose determined in the Phase 1 portion of the study.
219168241|NCT06839456|DEVICE|Phase 2 Established Dose from prior study, NCT03810196|Patients with unrelated donors will receive the CD45RA depleted addback at the dose 5 X 10\^6 CD45RO+ T cells.
219168242|NCT06839651|COMBINATION_PRODUCT|uc-msc secretome intra cavernous injection|"UC-MSC secretome was obtained from UC-MSC cultures with 80% confluence in serum-free medium after 24 hours of incubation The VEGF level in the secretome given was 1400 pg/ml.~The intervention was the administration of 0.5 mL/site of secretome injection injected intra-cavernous to all subjects using a 22-gauge needle according to a sterile protocol. The same volume was given at bilateral sites of the penile shaft. The intra-cavernous injection sites were in the right and left dorsolateral regions of the penis. After the intervention, tolerability was assessed by observing and questioning the subjects regarding pain during injection."
219168243|NCT06084910|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
219168244|NCT06084910|BEHAVIORAL|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
219168245|NCT06797102|OTHER|Neuromuscular Exercises|Patients in this group received a neuromuscular training protocol along with general treatment for 10 minutes. This included hot packs, lumbar stretches, and ergonomic posture correction divided over 6 weeks The exercises performed included squatting, single leg stance, and balance reach leg and arm exercises with 10 repetitions each. They also did lunge exercises with five repetitions bilaterally, step up and down exercises with 10 repetitions, single leg standing on a balance mat with 10 repetitions and a 10-second hold, single board exercises, and single leg stance with weights and eyes closed for five minutes with a 10-second hold. Additionally, they stood on a wobble board with eyes closed five times with a 10-second hold. The protocol included running on a treadmill and trampoline for five minutes per day, running figure-of-eight patterns, and agility drills at a slow speed for five minutes each.
219168246|NCT06797102|OTHER|Close Chain Exercises|Patients in this group received closed chain exercises for core strengthening along with general treatment for 10 minutes, including hot packs, lumbar stretches, and ergonomic posture correction, divided over 6 weeks. The exercises included sets of squats, lunges, leg presses, wall squats, standing heel raises on a single leg, and single leg dead lifts. Each treatment session lasted 60 minutes, incorporating a warm-up and cool-down period of 10 minutes.
219238633|NCT04862507|OTHER|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
219238634|NCT04862507|DIAGNOSTIC_TEST|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
219238635|NCT05293379|OTHER|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
219238636|NCT02838888|DEVICE|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
219238637|NCT00096278|BIOLOGICAL|Bevacizumab|Given IV
219238638|NCT00096278|DRUG|Fluorouracil|Given IV
219238639|NCT00096278|DRUG|Leucovorin Calcium|Given IV
219238640|NCT00096278|DRUG|Oxaliplatin|Given IV
219238641|NCT00158847|DRUG|fluticasone 500 mcg|
219238642|NCT00158847|DRUG|fluticasone 500 mcg + salmeterol 50 mcg|
219238643|NCT02276937|DRUG|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
219238644|NCT01874717|OTHER|Conscious sedation for dental care|
219238645|NCT01874717|DRUG|midazolam|
219238646|NCT01100372|DRUG|gemcitabine hydrochloride|
219238647|NCT01100372|DRUG|liposome-encapsulated doxorubicin citrate|
219238648|NCT01100372|PROCEDURE|quality-of-life assessment|
219238649|NCT00821093|DRUG|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219238650|NCT00821093|DRUG|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
219238651|NCT00821093|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219238652|NCT00821093|DRUG|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
219238653|NCT01894620|DEVICE|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
219238654|NCT01894620|DEVICE|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
219238655|NCT03395873|DRUG|Avelumab|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
219238656|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
219168247|NCT06830876|DEVICE|Chattanooga Continuum Device|The Chattanooga Continuum (Enovis, Wilmington, DE) is an FDA-approved, multi-functional, dual-channel electrotherapy device that offers adjunctive rehabilitation therapies, including muscle re-education (NMES), pain control, and stimulation of local blood circulation. The device provides a treatment duration of up to 60 minutes, allowing for cycled or continuous therapy. It offers symmetrical and asymmetrical waveform types, adjustable pulse rates of up to 150 Hz, and pulse width durations of up to 400 μs. The device also features off times, channel ramp times, and on time settings. Additionally, the Continuum is equipped with a data and parameter logger, enabling the monitoring of patient usage. It incorporates an automatic lock function to prevent accidental changes in intensity by preventing unintended pressing of the control buttons. The device operates on two AA rechargeable NiMH batteries, and a battery charger and extra batteries are included with the device.
219168248|NCT04675892|PROCEDURE|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
219168249|NCT04675892|PROCEDURE|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
219168250|NCT06829628|BEHAVIORAL|chatbot teaching strategies|Chatbot-Based Learning
219168251|NCT02989935|PROCEDURE|Ventilation|Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
219168252|NCT02989935|PROCEDURE|Parasternal EMG|Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.
219168253|NCT02989935|PROCEDURE|Phrenic magnetic stimulation|Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
219168254|NCT04762641|DRUG|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
219168255|NCT06204237|DRUG|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
219168256|NCT06204237|RADIATION|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
219168257|NCT06836804|OTHER|Sociodemographic Data Form|After inquiring about participants' sociodemographic characteristics, such as name, contact information, age, gender, marital status, education level, income, and place of residence, measurements of height, weight, and waist circumference will be obtained. Then, participants' CVD, psychiatric and other medical conditions, CVD risk factors, health history, and medications they are using will be queried. This information will be recorded in the sociodemographic data form. The sociodemographic data form has been prepared by the researchers.
219168258|NCT06836804|OTHER|Short Form Health Survey|SF-36 is a self-assessment scale and can be completed in five minutes. SF-36 can evaluate both the negative and positive aspects of health. The scale consists of 36 items which are used to assess different health dimensions in 8 subscales: Physical functioning (10 items), social functioning (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items).
219168259|NCT06836804|OTHER|Hospital Anxiety and Depression Scale|The HADS was designed in 1983 to identify anxiety and depression in individuals with physical illnesses. The HADS is a self-reported scale consisting of seven items each for the anxiety and depression subscales. Each item is scored from 0 to 3, and the total score for the anxiety and depression subscales is 21 points. The overall HADS score is obtained by summing the points from both subscales. A total subscale score between 0-7 indicates a normal test result, 8-10 indicates mild anxiety or depression, 11-15 indicates moderate anxiety or depression, and 16-21 indicates severe anxiety or depression. Higher scores represent higher levels of anxiety or depression, and the total HADS score reflects an overall measure of psychological distress. The survey can be completed in 2-5 minutes.
219168260|NCT06836804|OTHER|Illness Intrusiveness Ratings Scale|The IIRS is an easy-to-administer scale designed to predict the psychosocial impact of chronic illness and to document and compare the effectiveness of therapeutic interventions. It consists of 13 questions which are completed by the patient. The scale measures how the limitations imposed by chronic and life-threatening diseases hinder participation in regular activities across 13 important aspects of life: Health, diet, work, active recreation (sports), passive recreation (reading, listening to music), finances, relationships with partners, sexual life, family relationships, other social relationships, self-expression/development, religious expression, and community and civic participation.
219168261|NCT06836804|OTHER|Cardiac Depression Scale|CDS was designed to identify depression in individuals with CVDs. It consists of 26 items across 7 subscales. The subscales address issues such as sleep, uncertainty, mood, hopelessness, immobility, anhedonia, and cognition. The CDS is rated on a 7-point Likert scale, with seven items being reverse-coded. Based on patient feedback and clinical experience, two short forms were developed, each consisting of five questions. Both short forms showed good consistency with the original CDS. The first short form includes questions from the original CDS numbered 12, 24, 21, 10, and 9. The second short form includes questions from the original CDS numbered 12, 4, 25, 21, and 7.
219238657|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
219238658|NCT05791786|OTHER|Patient|affected individuals diagnosed with AFE
219238659|NCT03630653|PROCEDURE|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
219238660|NCT05208788|DIAGNOSTIC_TEST|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
219238661|NCT04922359|DRUG|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
219168262|NCT06826963|OTHER|Aerobic eccentric intervention|This arm will participate in a supervised eccentric cycling training program for three months. The intervention will include two training sessions per week in the first month, increasing to three sessions per week in the following two months. Each session will consist of a warm-up (5 minutes), a main training phase (20-30 minutes), and a cool-down (5-10 minutes). The intensity of training will be gradually adjusted to maintain a perceived exertion rating (RPE) between light and moderate with a target heart rate zone (57-76% of HRmax). Pre- and post-training assessments will evaluate physical function through several tests, body composition and anthropometric indices, muscle strength of upper and lower limbs, questionnaires related to the overall health improvement. Finally, participants will also be monitored for daily physical activity through wearable sensors to track mobility and autonomy.
219168263|NCT04850807|BEHAVIORAL|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
219168264|NCT06836024|DIETARY_SUPPLEMENT|Actazin chewable tablet|Actazin tablets are tableted non-GMO, freeze-dried, green kiwifruit powder from 100% New Zealand-grown green kiwifruit. Currently, kiwifruit extracts (such as Actazin), are marketed in Canada as a natural supplement. It is safe, bioavailable, and has been previously shown to be well tolerated at doses up to 2400 mg.
219238662|NCT04922359|DRUG|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
219238663|NCT03122314|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
219238664|NCT03122314|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
219168265|NCT06836024|DRUG|PEG 3350|a commonly used over the counter laxative in north America. A stool softener.
219168266|NCT06836024|OTHER|Chewable Tablet|Sorbitol-based placebo chewable tablets made by Pharma NZ. Those tablets will have a similar appearance to active Actazin but will not taste the same. This is because the taste of Actazin is a non-altered natural kiwi taste. They will be administered in the same dose and manner as the active Actazin oral chewable tablets.
219168267|NCT06836024|OTHER|Maltodextrin (Placebo)|Maltodextrin powder, administered in the same doses and manner as active PEG 3350 group.
219168268|NCT03413592|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
219168269|NCT03413592|OTHER|Car-following test|Driving with simulator program for DCV measurement
219168270|NCT03413592|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
219168271|NCT06835413|PROCEDURE|1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice 2-Strength and Balance Exercises A- Sit-to-stand B- Heel r|"1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice A- Standing with a decreased base B- Graded reaching in standing~* Feet together and level.~* Semi-tandem stance.~* Tandem stance.~* Stand on one leg.~* Maintain position for longer~* Close eyes.~* Stand on different surfaces e.g. foam rubber mat.~* Minimize hand support \& Aim to increase time without hand support. • Feet placement- narrower, step standing~* Reaching further.~* Reaching in different directions.~* Reaching down to a stool or the floor.~* Reaching for heavier objects.~* Reaching for a full cup of water.~* Standing on a softer surface eg foam rubber mat.~* Stepping while reaching. C- Stepping in different directions D- Walking Practice~* Narrow foot position.~* Longer steps.~* Faster steps.~* Step over objects.~* Choice component e.g. step forward with left foot.~* Incorporate pivoting on the non-stepping foot.~* Use different color"
219168272|NCT06836518|DIAGNOSTIC_TEST|serum sialic acid|measurement of serum sialic acid to evaluate its efficacy in the diagnosis of hepatocellular carcinoma
219168273|NCT06795269|DEVICE|Cryotherapy Compression Machine|The Cryo Pro is a simple to use cold compression therapy product that requires only ice, water and power. It's unique design is convenient to use, provides pain relief and reduces swelling and inflammation, making recovery faster.
219168274|NCT06795269|OTHER|Conservative treatment|Strength and stretch exercises for hip and knee large groups of muscles.
219168275|NCT01868269|DRUG|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
219168276|NCT01868269|DRUG|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
219168277|NCT01868269|DRUG|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
219168278|NCT06796803|DRUG|camrelizumab combined with rivoceranib and HAIC|systemic therapy combined with locoregional theraphy as conversion therapy
219168279|NCT06796803|DRUG|camerlizumab + rivoceranib|systemic therapy
219168280|NCT06643832|OTHER|Rubbing Distraction|gently touching on proximal part of the IV injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.
219168281|NCT06643832|DRUG|Lidocaine (drug)|lidocaine will be used by mixing it with the propofol before intravenous injection
219168282|NCT06643832|OTHER|Saline|intravenous propofol will be given without mixing with any drug (except for 2 ml saline to ensure blindness of the outcome assessor).
219168283|NCT06795347|BEHAVIORAL|Online VIPP-SD|The Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is delivered online in this study. VIPP-SD is a manualized parenting intervention. The online version consists of 12 individual sessions, where the first and hereafter every second session consists of video recordings of mother and child in pre-defined everyday situations. The recordings are reviewed and discussed with the mother/parents during subsequent video-feedback sessions, where positive sequences in the interaction are pointed out by the intervener and form the basis of a discussion of pre-defined themes regarding child signals, attachment, child development, limit setting and sensitive parenting. The 12 sessions are conducted within five months from randomization with weekly or bi-weekly intervals.
219168284|NCT06795347|BEHAVIORAL|Care As Usual|Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.
219168285|NCT06191991|DRUG|Atorvastatin|40 mg
219168286|NCT06191991|DRUG|ALG-055009|0.9 mg
219168287|NCT06191991|DRUG|Rosuvastatin|10 mg
219168288|NCT01653535|BEHAVIORAL|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
219238665|NCT03213587|DRUG|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219168289|NCT06796244|OTHER|Croq'Santé nutrition education program|The Croq'Santé program aims to develop food literacy in children aged 8 to 11 years. It is based on the creation or adaptation of a recipe chosen by the children. The program is designed to run over the course of one school year, with approximately ten sessions. These sessions are delivered in schools by teachers, following a 3-hour training course. Teachers receive an intervention kit that includes a guide for conducting the different sessions, food images, and a mascot, which children can accessorize as they complete sessions and challenges. The sessions are organized around four stages: discover, invent, cook, and taste. Challenges are to be completed at the end of each stage with the child's family. At the end of the program, children are invited to cook and taste their recipe in a dedicated environment.
219168290|NCT06472453|DEVICE|Allograft/Xenograft|"Alveolar ridge preservation of a single extraction socket site with a mixture of demineralized cortical bone substitute vallos® and xenograft Bio-Oss®."
219168291|NCT06472453|DEVICE|Allograft|Alveolar ridge preservation of a single extraction socket site with vallos® (mineralized cortico-cancellous bone substitute)
219168292|NCT04634643|OTHER|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
219168293|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
219168294|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
219168295|NCT05457699|RADIATION|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
219168296|NCT05457699|OTHER|no RT|no SABR, continued systemic therapy per SOC
219168297|NCT03667404|DIETARY_SUPPLEMENT|Resistant maltodextrin|Resistant maltodextrin powder
219168298|NCT03667404|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin powder
219168299|NCT06466122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219168300|NCT06466122|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219168301|NCT06466122|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219168302|NCT06466122|PROCEDURE|Computed Tomography|Undergo CT
219168303|NCT06466122|DRUG|Pirtobrutinib|Given PO
219168304|NCT06466122|DRUG|Venetoclax|Given PO
219168305|NCT04814420|DEVICE|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
219168306|NCT04862975|DRUG|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
219168307|NCT04862975|DRUG|Lamivudine|Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
219168308|NCT04862975|DRUG|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
219168309|NCT04862975|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
219168310|NCT06352866|DRUG|Siltuximab|Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system
219168311|NCT06352866|DRUG|Teclistamab(FDA-approved)|Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
219238666|NCT00879827|BIOLOGICAL|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
219238667|NCT00879827|BIOLOGICAL|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
219168312|NCT02187003|DRUG|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
219168313|NCT02187003|OTHER|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
219168314|NCT05013645|OTHER|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
219168315|NCT05013645|OTHER|Placebo|Gel control product
219168316|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
219168317|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
219168318|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
219168319|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
219168320|NCT04593472|BEHAVIORAL|Sharing Healthcare Wishes in Primary Care (SHARE)|SHARE is a multicomponent communication intervention to proactively engage family members or friends to support advance care planning in primary care.
219168321|NCT04593472|BEHAVIORAL|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
219168322|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
219168323|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
219168324|NCT05402592|DIETARY_SUPPLEMENT|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
219168325|NCT05402592|OTHER|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
219168326|NCT06489600|OTHER|No Rays, Thanks Mineral sunscreen|"Wash your face with standard facewash and apply a pea size amount on the face in the morning.~Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical"
219168327|NCT06782334|DRUG|AMT-116|AMT-116 is an antibody Drug Conjugate (ADC)
219168328|NCT06122285|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
219168329|NCT06419972|OTHER|multimodal physiotherapy programme|The intervention to which the climacteric women will be subjected will consist of a combined program of education and general strength and pelvic floor muscles exercises of 8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min, except for the first one, which will be 90 min.
219168330|NCT02560805|PROCEDURE|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
219168331|NCT02560805|BEHAVIORAL|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
219168332|NCT02560805|PROCEDURE|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
219238668|NCT01941706|BEHAVIORAL|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
219168333|NCT02560805|PROCEDURE|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.
219168334|NCT02560805|DRUG|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
219168335|NCT02560805|DRUG|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
219168336|NCT02560805|DRUG|Losartan|Losartan will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
219168337|NCT02560805|DRUG|Atenolol|Atenolol will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
219238669|NCT04414865|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
219238670|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
219238671|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
219238672|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
219238673|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
219238674|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
219238675|NCT04508829|DRUG|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
219238676|NCT01637194|DRUG|everolimus|Given PO
219238677|NCT01637194|BIOLOGICAL|cetuximab|Given IV
219238678|NCT01637194|OTHER|pharmacological study|Correlative studies
219238679|NCT01637194|OTHER|laboratory biomarker analysis|Correlative studies
219238680|NCT05533788|DRUG|ABSK091 tablet|ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
219238681|NCT02442102|BEHAVIORAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
219238682|NCT03370094|DIAGNOSTIC_TEST|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
219238683|NCT04099576|OTHER|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
219238684|NCT04099576|OTHER|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
219238685|NCT02858206|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
219238686|NCT02858206|DRUG|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
219238687|NCT02858206|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
219238688|NCT02858206|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
219238689|NCT02858206|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
219238690|NCT05546177|OTHER|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
219238691|NCT05546177|OTHER|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
219238692|NCT01417923|DRUG|vitamin D|P.O.4000 units Vit D per day for 6 weeks
219238693|NCT00297713|DRUG|ALTU-238|
219238694|NCT02314000|DEVICE|Precision or Precision Spectra Spinal Cord Stimulator System|
219238695|NCT03239353|DRUG|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
219238696|NCT06502067|DRUG|Analgesia mangement group A,B|1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
219238697|NCT01233089|DEVICE|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
219238698|NCT01233089|DEVICE|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
219238699|NCT01233089|DEVICE|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
219238700|NCT01233089|DEVICE|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
219238701|NCT05306483|PROCEDURE|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
219238702|NCT05306483|PROCEDURE|Ventricular septal defect closure catheter|Catheter closure of VSD
219238703|NCT00255268|DRUG|Goserelin|
219238704|NCT00255268|DRUG|Bicalutamide|
219238705|NCT03345199|OTHER|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
219238706|NCT03837093|DRUG|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
219238707|NCT03837093|DRUG|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
219238708|NCT05245474|COMBINATION_PRODUCT|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
219238709|NCT01840124|PROCEDURE|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
219238710|NCT01072071|DRUG|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
219238711|NCT02222532|DRUG|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
219238712|NCT02222532|DRUG|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
219238713|NCT03927794|OTHER|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
219238714|NCT01027455|DEVICE|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
219238715|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
219238716|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
219238717|NCT01826994|DEVICE|heart type fatty acid binding protein testing|
219238718|NCT01571947|OTHER|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
219238719|NCT00238745|DRUG|Bazedoxifene|
219238720|NCT00238745|DRUG|Placebo|
219238721|NCT00709787|OTHER|Usual Care|Normal care for hypertensive patients with risk factors for CHD
219238722|NCT00134056|DRUG|atrasentan hydrochloride|Given orally
219238723|NCT00134056|DRUG|docetaxel|Docetaxel given IV and prednisone given orally
219238724|NCT00134056|DRUG|prednisone|Docetaxel given IV and prednisone given orally
219238725|NCT00134056|OTHER|placebo|Given orally
219238726|NCT01745835|DRUG|2L Coolprep®|\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
219238727|NCT01745835|DRUG|1L Coolprep® and Bisacodyl|"1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
219238728|NCT04048226|DRUG|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
219238729|NCT04048226|DRUG|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
219238730|NCT02474745|PROCEDURE|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
219238731|NCT02474745|PROCEDURE|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
219238732|NCT06049719|OTHER|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
219238733|NCT01852175|DRUG|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
219238734|NCT01852175|DRUG|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
219238735|NCT00226746|DRUG|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
219238736|NCT03816202|DEVICE|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
219238737|NCT06133595|BEHAVIORAL|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
219238738|NCT06407141|BEHAVIORAL|transcranial pulse stimulation|Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
219238739|NCT06407141|BEHAVIORAL|Sham TMS|Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
219238740|NCT05829668|BEHAVIORAL|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
219238741|NCT05242874|DRUG|Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.
219238742|NCT05242874|DRUG|Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
219238743|NCT03997552|PROCEDURE|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
219238744|NCT03997552|PROCEDURE|marginal approach by palatal incision|Periodontal reconstructive surgery
219238745|NCT03997552|PROCEDURE|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
219238746|NCT05028257|BIOLOGICAL|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
219238747|NCT02555397|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
219238748|NCT03994809|OTHER|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
219238749|NCT05750121|BEHAVIORAL|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
219238750|NCT05583331|PROCEDURE|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
219238751|NCT05583331|PROCEDURE|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
219238752|NCT02850939|BEHAVIORAL|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
219238753|NCT02761317|DRUG|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
219238754|NCT02761317|DRUG|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
219238755|NCT02761317|DRUG|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
219238756|NCT00637104|DEVICE|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
219238757|NCT00637104|DEVICE|Vision Co-Cr stent implant|Implant of the Vision stent
219238758|NCT00681915|DRUG|AZD7325|Oral
219238759|NCT02981329|DRUG|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
219238760|NCT02981329|BEHAVIORAL|Questionnaires|Questionnaires will be completed to assess the impact quality of life
219238761|NCT00168506|DRUG|SSRI|
219238762|NCT00168506|DRUG|CBT|
219238763|NCT00168506|DRUG|CBT/SSRI|
219238764|NCT02131454|OTHER|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
219238765|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
219238766|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
219238767|NCT05871788|DIAGNOSTIC_TEST|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
219238768|NCT01887002|DRUG|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
219238769|NCT01887002|DRUG|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
219238770|NCT05897307|DRUG|Ropivacaine|dexmedetomidine
219238771|NCT03322449|OTHER|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
219238772|NCT03322449|OTHER|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
219238773|NCT02207140|DIETARY_SUPPLEMENT|HOWARU Restore|
219238774|NCT01184105|DRUG|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
219238775|NCT01184105|DRUG|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
219238776|NCT00554814|DRUG|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
219238777|NCT00554814|DRUG|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
219238778|NCT00554814|DRUG|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
219238779|NCT00247507|DRUG|acetylcysteine|
219238780|NCT01048385|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
219238781|NCT01048385|DIETARY_SUPPLEMENT|Placebo|Treated with capsules containing the vehicle (Sesame oil).
219168338|NCT02560805|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) is administered using the gammaCore (ElectroCore) TENS device. The gammaCore device is a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and two buttons to power on the device and for operator control of the stimulation intensity (range 0-40). A small amount of conductive gel is applied to the pair of stainless steel round discs on the device are placed vertically on the skin with the gel. The stimulation is increased until there is a strong vibration and slight muscle contraction in the lower face or neck (usual intensity 15-25). Then the dose is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes of treatment. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
219168339|NCT02560805|DEVICE|Sham Transcutaneous Vagal Nerve Stimulation (tVNS)|A sham device that is identical to the gammaCore device will be provided to participants. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
219168340|NCT04559256|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
219168341|NCT06172764|DIETARY_SUPPLEMENT|Vitamin D supplements along with behavioral modification|"Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
219168342|NCT06172764|COMBINATION_PRODUCT|Topical fluoride application and Vitamin D supplements along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
219168343|NCT06172764|PROCEDURE|Topical fluoride application along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
219168344|NCT04022746|PROCEDURE|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
219168345|NCT04022746|PROCEDURE|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
219168346|NCT06521658|PROCEDURE|Timing of retroflexion|The intervention is the timing of the retroflexion/looping of the colonoscope in the rectum
219168347|NCT04214990|DRUG|Aspirin 100mg|Daily aspirin 100 mg for 5 years
219168348|NCT04214990|DRUG|Placebo oral tablet|Daily placebo for 5 years
219168349|NCT06847620|PROCEDURE|Supraclavicular Brachial Plexus Block|The block will be performed using a portable ultrasound system (sonosite M-turbo USA) with linear high-frequency transducer (12HZ) to get the sonographic anatomy of brachial plexus in the transverse and longitudinal planes.
219168350|NCT06847620|DRUG|Bupivacaine 0.25% 20ml alone|will receive 20 ml of plain bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml of normal saline.
219168351|NCT06847620|DRUG|bupivacaine 0.25% And verapamil|will receive 20 ml of bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml verapamil (equivalent to 5 mg
219168352|NCT06848036|BEHAVIORAL|smart integrated care services|"Provide integrated care services through the 'Hunan Province Integrated Healthcare and Elderly Care Intelligent Service Platform,' including home-based care, mobile medical visits, and remote diagnosis and treatment services."
219168353|NCT04627766|DEVICE|Monitoring with VT-Patch (Connected device manufactured by VitalTracer)|Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
219168354|NCT06847334|DRUG|HLX17|HLX17 will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
219168355|NCT06847334|DRUG|US-sourced Keytruda®|US-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed. After 24 weeks, all subjects in the US-Keytruda® group will receive HLX17 in combination with Pemetrexed until loss of clinical benefit or up to 1 year.
219168356|NCT06847334|DRUG|EU-sourced Keytruda®|EU-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
219168357|NCT06407817|PROCEDURE|Spencer technique|No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)
219168358|NCT06407817|PROCEDURE|reverse distraction technique|No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)
219168359|NCT06847945|PROCEDURE|Sham acupuncture|Patients in the non-meridian and non-acupoint group received sham acupuncture treatment at the position 2cm apart from the sensitized acupoint, once every other day for 30min each time, a total of 3 times for 1 week.
219168360|NCT06847945|PROCEDURE|Acupuncture|Patients in acupoint sensitization group were treated with pseudoacupuncture at the sensitized points once every other day for 30min each time, a total of 3 times for 1 week.
219168361|NCT05345639|DRUG|LRA Loco-regional anesthesia|"Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator."
219168362|NCT05345639|PROCEDURE|Standardized post-operative analgesia protocol|"The pain management protocol in intensive care is as follows:~* paracetamol 1g x 4 per day systematically (apart from the usual contraindications), IV then PO;~* PCA (Patient Controlled Analgesia) with oxycodone or morphine: 1mg bolus, 7min refractory period, maximum 4h dose 20mg.~The PCA is usually maintained until 24-48h after the intervention then relayed by oxycodone 5mg every 4h if EVA \> 3 sublingual and addition of oxycodone LP 10mg x 2 per day if daily intake on PCA \> 20mg.~Remedy molecules in case of ineffective analgesia:~ketoprofen 100mg q12h IV, or 50mg q8h PO; nefopam 20mg every 6h IV or PO; ketamine 1 to 1.5 mg/kg/24H IVSE."
219168363|NCT06053125|PROCEDURE|Adipose Tissue Biopsy|Fat sample collected from abdomen before exercise, immediately after exercise, and 3 hours after exercise
219238782|NCT06002672|DIETARY_SUPPLEMENT|Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).|Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
219238783|NCT06002672|DIETARY_SUPPLEMENT|Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.|100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
219238784|NCT03094442|DRUG|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
219238785|NCT03094442|DRUG|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
219168364|NCT06053125|BEHAVIORAL|Exercise|30 minutes of exercise on a cycle ergometer exercise machine
219168365|NCT06846970|OTHER|Experimental|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, TENS, ultrasound and balneotherapy, five days a week and once a day for four weeks. Exercise, hot pack, TENS, ultrasound therapy, and balneotherapy will be performed under the supervision of a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
219168366|NCT06846970|OTHER|Active Comparator|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, tens and ultrosound therapy five days a week and once a day for four weeks. It was planned to perform exercise, hot pack, tens, ultrasound therapy accompanied by a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
219168367|NCT06845059|OTHER|"11 For Health"|"Participants will participate in the 11 For Health program, consisting of 11 sessions over 11 weeks. The program combines football skills with health education to promote overall health and well-being."
219168368|NCT03896516|OTHER|Placebo|Participants receive Placebo orally twice daily.
219168369|NCT03896516|DRUG|GLWL-01|GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
219168370|NCT01518556|DRUG|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
219168371|NCT04700111|DEVICE|DOT Pattern|DOT Pattern Spectacle Lens
219168372|NCT04700111|DEVICE|Control Spectacles|Control lens
219168373|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
219168374|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
219168375|NCT00186927|BIOLOGICAL|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
219168376|NCT06412016|BEHAVIORAL|Peer Nutritional Counseling + Urban Gardening|Peer nutritional counseling and urban gardens
219168377|NCT04172441|DRUG|dasiglucagon|Glucagon analogue
219168378|NCT04172441|DRUG|Placebo|Placebo for dasiglucagon
219168379|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
219168380|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
219168381|NCT06844279|OTHER|Control Group: Standard Hemodynamic Monitoring|Anesthesia depth monitoring based on hemodynamic values without additional processed EEG guidance.
219168382|NCT06844279|DEVICE|Processed Electroencephalogram (BIS Index)|Anaesthesia depth monitoring according to numeric BIS index values.
219168383|NCT06844279|DEVICE|Processed Electroencephalogram (DSA Mode)|Anaesthesia depth monitoring according to density spectral array functions
219168384|NCT03687528|RADIATION|CT-scanner|After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
219168385|NCT06844578|OTHER|Experimental Group|"specific intervention programme in the experimental group, which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. The programme will be aimed at improving various functional capacities, through specifically designed exercises, including:~* Unipodal stability: Exercises focused on strengthening balance by maintaining a posture on one foot, which is key to preventing falls and improving postural stability.~* Gait re-education: Activities aimed at correcting and adjusting gait technique, promoting an efficient and safe movement pattern.~* Muscle strength: Exercises aimed at muscle strengthening, especially in the lower limbs, to increase endurance and stability during daily activities.~* Stationary walking: Practices that simulate stationary walking, improving cardiovascular endurance and motor coordination."
219238786|NCT01135719|PROCEDURE|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
219238787|NCT05165420|OTHER|Cosmetic product|RV4941A is a face cream product
219168386|NCT06844578|OTHER|Active comparator Group|"which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. Participants who will exclusively receive an intervention based on gerontogymnastics.~This programme will include a series of exercises adapted to the needs of the older adult population, with an emphasis on improving balance, muscle strength, flexibility and motor coordination. These include:~* Shoulder raises~* Hip flexion~* Knee flexion~* Trunk rotations~* Ankle dorsiflexion"
219168387|NCT06396611|BEHAVIORAL|Exercise Training as Intervention|Supervised Exercise Training as an Intervention using Resistance Training.
219238788|NCT06510751|OTHER|CGRP level|CGRP and substance P levels will be analysed by ELISA method in CSF and blood materials.
219168388|NCT06845033|OTHER|LEAP2 infusion|The LEAP2 infusion is a hormone infusion that is different from the placebo (saline) infusion
219168389|NCT06845033|OTHER|Placebo|Placebo infusion (saline) is different from the LEAP2 infusion
219238789|NCT03038490|DIETARY_SUPPLEMENT|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
219238790|NCT04712032|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
219238791|NCT00043459|DRUG|intravenous T900607-sodium|
219238792|NCT01269307|PROCEDURE|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
219238793|NCT01269307|PROCEDURE|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
219238794|NCT02501694|OTHER|Auscultation|Electronic stethoscope
219238795|NCT03369483|OTHER|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
219238796|NCT01231074|DRUG|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
219168390|NCT06847607|DRUG|Iptacopan|Iptacopan
219168391|NCT06847178|DIETARY_SUPPLEMENT|Placebo twice daily in blinding|Administered placebo twice-daily for 12 weeks in blinding
219168392|NCT06847178|DRUG|Low-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
219168393|NCT06847178|DRUG|High-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
219168394|NCT06847178|DRUG|High-dose LCZ300-1 twice daily in open-label|Administered high-dose LCZ300-1 twice-daily for 12 weeks in open-label
219168395|NCT06846437|DRUG|JSKN003|Administered intravenously according to protocol.
219168396|NCT06846437|DRUG|Trastuzumab emtansine (T-DM1)|Administered intravenously according to the approved label.
219238797|NCT06073470|DRUG|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
219238798|NCT00537914|DRUG|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
219168397|NCT06846632|DEVICE|PEEK|placement of PEEK after maxillary sinus lifting
219168398|NCT06846632|DEVICE|titanium meshwork|placement of titanium meshwork after maxillary sinus lifting
219168399|NCT06845137|OTHER|Tactile-Kinesthetic Stimulation (TKS) and Soft Tissue Manipulation (STM)|"Tactile-Kinesthetic Stimulation (TKS): TKS involves the application of tactile (touch) and kinesthetic (movement) stimuli to various parts of the body. This technique aims to enhance sensory awareness and motor control. TKS can include gentle tapping, brushing, or vibration on the skin, joints, or muscles. The sensory input provided through TKS helps in proprioceptive feedback, which is essential for improving body awareness, coordination, and movement patterns. It is often used in neurological rehabilitation to facilitate neuromuscular re-education and in pediatric therapy to promote sensory integration.~Soft Tissue Manipulation (STM): STM involves various manual techniques applied to the soft tissues of the body, including muscles, tendons, ligaments, and fascia. These techniques can range from gentle stretching and mobilization to deeper techniques such as myofascial release, trigger point therapy, and deep tissue massage. STM aims to alleviate muscle tension, improve flexibility,"
219168400|NCT06845137|OTHER|Standard Therapy|Nursing care for preterm neonates involves a higher level of monitoring and specialized support due to their underdeveloped physiological systems. Nurses focus on maintaining thermal regulation through incubators or radiant warmers to prevent hypothermia, as preterm infants are more vulnerable to temperature instability. Respiratory support is critical, often requiring continuous positive airway pressure (CPAP) or mechanical ventilation to assist with immature lungs. Nutritional support is provided through intravenous fluids or gavage feeding (tube feeding) if the infant is not yet able to breastfeed or bottle-feed. Nurses also monitor for complications such as hypoglycemia, infection, and jaundice and administer antibiotics, vitamin K, and eye prophylaxis as needed. Developmentally supportive care is emphasized, including minimizing sensory overload and encouraging kangaroo care (skin-to-skin contact) to support bonding, promote growth, and help regulate the neonate's heart rate, temp
219238799|NCT02312258|DRUG|Placebo|Ixazomib placebo-matching capsules.
219238800|NCT02312258|DRUG|Ixazomib|Ixazomib capsules.
219238801|NCT01217697|DRUG|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
219238802|NCT01217697|DRUG|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
219238803|NCT01204879|BEHAVIORAL|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
219238804|NCT01180959|DRUG|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
219238805|NCT01180959|DRUG|Erlotinib|150 mg by mouth once a day.
219168401|NCT06846593|DEVICE|Semiconductor Embedded Therapeutic Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
219168402|NCT06846593|DEVICE|Placebo Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
219168403|NCT06846593|OTHER|Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections|patients will choose or opt out of these standard of care injections.
219168404|NCT06843811|DRUG|Sirolimus|Sirolimus will be given at a starting dose of 0.8 to 1.3 mg/m2 twice daily, depending on subject age and weight.
219238806|NCT05912998|PROCEDURE|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
219168405|NCT06522464|OTHER|Group A: mCIMT with cross-education|"For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands (18). We'll utilize weight cuffs for every activity."
219168406|NCT06522464|OTHER|Group B: mCIMT without cross-education|For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
219168407|NCT06468501|BEHAVIORAL|Price reduction on healthier foods|Price reduction (10%) on healthier foods based on the UK NPM
219168408|NCT06468501|BEHAVIORAL|Price increase to less healthy foods|Price increase (10%) on less healthy foods based on the UK NPM
219168409|NCT06468501|BEHAVIORAL|Combination of price reduction on healthier foods and price increase on less healthy foods|Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
219168410|NCT06468501|BEHAVIORAL|Control|Existing price structure
219168411|NCT06845254|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.
219168412|NCT06845254|DRUG|placebo capsule|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.
219168413|NCT04674358|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
219168414|NCT04674358|DRUG|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
219168415|NCT06180694|OTHER|Reminiscence therapy|Reminiscence therapies will be applied to individuals with dementia in 45-minute sessions once a week for 8 weeks.
219168416|NCT06502444|BEHAVIORAL|Moving Forward Together Activity Intervention|The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
219168417|NCT06060626|DRUG|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
219168418|NCT06060626|DRUG|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
219168419|NCT03739450|BEHAVIORAL|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
219168420|NCT03739450|BEHAVIORAL|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
219168421|NCT05688410|OTHER|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
219168422|NCT05688410|BEHAVIORAL|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
219168423|NCT06076837|DRUG|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
219168424|NCT06076837|DRUG|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
219238807|NCT03730727|BEHAVIORAL|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
219238808|NCT03730727|DIETARY_SUPPLEMENT|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
219238809|NCT03140709|DRUG|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
219238810|NCT00303537|DRUG|metformin|
219168425|NCT06076837|DRUG|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
219168426|NCT06076837|DRUG|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
219168427|NCT06076837|DRUG|Nab paclitaxel|microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
219168428|NCT06076837|DRUG|Gemcitabine|a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer
219168429|NCT06076837|DRUG|Cisplatin|platinum-based drug indicated for the treatment of advanced cancers
219168430|NCT06527586|DEVICE|soft contact lens|Vision Correction
219168431|NCT04318197|OTHER|Personalized rehabilitation program with electrostimulation|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.
219168432|NCT04318197|OTHER|Global rehabilitation program|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
219168433|NCT05622955|OTHER|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
219168434|NCT06336785|DEVICE|Restylane line of soft tissue fillers and Dysport neuromodulator|Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
219168435|NCT06259396|BEHAVIORAL|The 8x5 Diet|A virtual, dietitian-counselled, healthy dietary pattern defined by its fat intake, its daily eating pattern, keeping adequately hydrated, having a variety of whole grains, fruit and vegetables, and use of certain plant fibres.
219168436|NCT05119972|DRUG|ZSP1603|ZSP1603 administered orally
219168437|NCT05119972|DRUG|Placebo|Placebo administered orally
219168438|NCT06068075|OTHER|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
219168439|NCT04514757|DEVICE|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
219168440|NCT04514757|DEVICE|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
219168441|NCT03394846|BEHAVIORAL|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
219168442|NCT05271578|DEVICE|Standardized Electronic Research Cigarette|Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)
219168443|NCT05271578|DEVICE|Nicotine Research Cigarette|Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
219168444|NCT04746677|DEVICE|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
219168445|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
219168446|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
219168447|NCT05836883|BIOLOGICAL|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
219168448|NCT05836883|OTHER|Local injection of normal saline|Placebo
219168449|NCT02375204|DRUG|paclitaxel|IV
219168450|NCT02375204|DRUG|ifosfamide|IV
219168451|NCT02375204|DRUG|cisplatin|IV
219168452|NCT02375204|DRUG|pegylated G-CSF|IV
219168453|NCT02375204|DRUG|G-CSF|IV
219168454|NCT02375204|DRUG|carboplatin|IV
219168455|NCT02375204|DRUG|etoposide phosphate|IV
219168456|NCT02375204|PROCEDURE|stem cell reinfusion|surgical procedure
219168457|NCT05018832|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219168458|NCT04128566|PROCEDURE|walking stress test|walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
219168459|NCT04916236|DRUG|RMC-4630|"* SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week"
219168460|NCT04916236|DRUG|LY3214996|"* ERK inhibitor~* Powder in capsule~* Administered every day"
219168461|NCT05617872|DRUG|Vinegar 20ml|Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
219168462|NCT05617872|DRUG|Saline (NaCl 0,9 %) (placebo)|Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
219168463|NCT05617872|DRUG|Vinegar 40ml|Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
219168464|NCT06110208|DRUG|CLL1 and CD38 dual-target CAR-T injection|CLL1 and CD38 dual-target CAR-T injection
219168465|NCT06550596|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219168466|NCT06550596|OTHER|Axolotl DualGraft + SOC|Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
219168467|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
219168468|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
219168469|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
219168470|NCT05293041|DRUG|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
219168471|NCT05293041|DRUG|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
219168472|NCT04681105|DRUG|Acetaminophen|Given PO
219168473|NCT04681105|DRUG|Dexamethasone|Given IV
219168474|NCT04681105|DRUG|Diphenhydramine|Given IV or PO
219168475|NCT04681105|BIOLOGICAL|Flotetuzumab|Given IV
219168476|NCT04681105|DRUG|Ibuprofen|Given PO
219168477|NCT04681105|DRUG|Ranitidine|Given IV
219168478|NCT04703322|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
219168479|NCT04273828|PROCEDURE|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
219168480|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
219168481|NCT06220864|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
219168482|NCT04383314|BEHAVIORAL|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
219168483|NCT06275269|PROCEDURE|Ultrasound-Guided|Ultrasound-Guided Triamcinolone Injection
219168484|NCT06275269|PROCEDURE|Translaryngeal Endoscopic Mucosal Injection|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
219168485|NCT06784986|DEVICE|The Conventional Insufflation System|The Conventional Insufflation System employs standard CO2 insufflation techniques for maintaining intra-abdominal pressure during laparoscopic and robotic surgeries. It serves as the base for comparison with the AirSeal® System.
219168486|NCT06784986|DEVICE|AirSeal® System|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple-lumen filtered tube set, and a valve-free trocar (AirSeal® Access Port). This innovative system allows peritoneal access and pneumoperitoneum maintenance without a mechanical seal, reducing CO2 usage and associated complications.
219238811|NCT02817386|OTHER|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
219168487|NCT06786403|DIETARY_SUPPLEMENT|Bromelain|Dietary Supplement: Bromelain 1000 mg/day
219168488|NCT06786403|DIETARY_SUPPLEMENT|Placebo|Placebo (1000 mg/day)
219168489|NCT05373615|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
219168490|NCT06787261|OTHER|saliva sample|saliva sample
219168491|NCT06787261|OTHER|carious tissue samples|carious tissue samples
219168492|NCT06786897|OTHER|Questionnaire and Physical Exam|Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
219168493|NCT06327295|DRUG|ATB1651-102- Cohort 1|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
219168494|NCT06327295|DRUG|ATB1651-102- Cohort 2|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
219168495|NCT06327295|DRUG|ATB1651-102- Cohort 3|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
219168496|NCT06327295|DRUG|ATB1651-102- Cohort 4|Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
219168497|NCT06327295|DRUG|Placebo|participants will receive matching placebo across cohorts 1-4 of the study.
219168498|NCT03108846|DRUG|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
219168499|NCT03108846|DRUG|Placebo|Masked placebo
219168500|NCT03713086|BIOLOGICAL|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
219168501|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
219168502|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
219168503|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
219168504|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
219168505|NCT06078384|DRUG|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
219168506|NCT06078384|DRUG|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
219168507|NCT05652777|DEVICE|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
219168508|NCT05736068|PROCEDURE|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
219168509|NCT05736068|PROCEDURE|Surgical treatment|Closed reduction with or without fixation
219168510|NCT06503237|DRUG|Anti-CD19 CART cells will be given IV at split doses.|Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
219168511|NCT05649956|DRUG|Letrozole|Letrozole 2.5 mg PO daily
219168512|NCT05818033|DEVICE|CARE1.02|Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
219168513|NCT05818033|DEVICE|Single-vision spectacle lens|Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.
219168514|NCT03650764|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
219362229|NCT02486315|DEVICE|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
219168515|NCT03650764|DRUG|Pembrolizumab|Pembrolizumab is commercially available
219168516|NCT03650764|OTHER|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
219168517|NCT03650764|OTHER|FACT H&N|-Screening, start of cycle 2, start of cycle 5
219168518|NCT03650764|PROCEDURE|Peripheral blood|-Baseline
219168519|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
219168520|NCT06770790|OTHER|strain echocardiography|HR, MAP, SBP, and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Two transthoracic 2D echocardiographic examinations will be performed immediately before and 15 minutes after TEA. The examinations include apical four-, two-, and three-chamber projections, mitral and aortic Doppler flow velocities. Standard measurements of left ventricular systolic function include left ventricular volumes (indexed to body surface area, BSA), left ventricular ejection fraction (LVEF) according to the modified Simpson rule, time and velocity integral in the left ventricular outflow tract (TVI-LVOT), and stroke volume (SV) (= π x LVOT radius2 x TVI-LVOT). Stroke volume index (SVI) will be calculated as SV/BSA. Mitral and aortic Doppler flow profiles, left ventricular isovolumetric relaxation time, maximum flow velocity will be recorded for m
219168521|NCT06397612|OTHER|Low Dose|Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
219168522|NCT06772857|DRUG|Metformin|Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
219168523|NCT02396459|DRUG|Triac|Triac, individually titrated dose
219168524|NCT04883775|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
219168525|NCT04883775|DRUG|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
219168526|NCT03836261|DRUG|Acalabrutinib|Acalabrutinib,
219168527|NCT03836261|DRUG|Venetoclax|Venetoclax
219168528|NCT03836261|DRUG|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
219168529|NCT03836261|DRUG|Obinutuzumab|Obinutuzumab
219168530|NCT06351332|DRUG|Azenosertib|WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
219168531|NCT06351332|DRUG|Carboplatin|Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
219168532|NCT06351332|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
219168533|NCT00102921|DRUG|CCX282-B|
219168534|NCT05767229|DRUG|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
219168535|NCT04049747|PROCEDURE|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]
219168536|NCT04049747|PROCEDURE|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
219168537|NCT04049747|PROCEDURE|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
219168538|NCT04049747|PROCEDURE|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
219168539|NCT05426668|OTHER|No Intervention|No Intervention
219168540|NCT00392067|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
219168541|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
219168542|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
219168543|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
219168544|NCT03222128|DEVICE|TAVR|Implantation of the SAPIEN 3
219168545|NCT05464225|DEVICE|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
219168546|NCT05464225|DEVICE|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
219168547|NCT05250544|OTHER|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
219168548|NCT05130840|DIAGNOSTIC_TEST|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
219168549|NCT05130840|DIAGNOSTIC_TEST|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
219168550|NCT05412602|PROCEDURE|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
219168551|NCT05146388|OTHER|EHR-Based Approach|The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of \<= 1mL, optimal tool is 1 mL syringe, 2) for \>1 mL to 5 mL, use a 5 mL syringe, 3) for \>5mL to 10mL, use 10 mL syringe.
219168552|NCT06005129|BEHAVIORAL|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
219168553|NCT06428071|OTHER|standard physical therapy|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks to all the participants
219168554|NCT06428071|OTHER|knee Decompression|continuous mechanical decompression using 20% of the body weight as a traction force for 15 minutes.
219168555|NCT06428071|OTHER|hot pack|hot pack over the treated knee joint will be applied for 20 minutes. this application will be performed while the patient is receiving the decompression session
219168556|NCT05891860|OTHER|Participation in virtual rounds|Virtual participation in daily ICU team rounds
219168557|NCT05251389|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
219168558|NCT04608357|DIAGNOSTIC_TEST|Needle Core Biopsies|Not an interventional study
219168559|NCT05981105|DEVICE|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
219168560|NCT05981105|DEVICE|ambIT pump with sham catheter|sham catheter with no infusion
219168561|NCT04480853|DRUG|Fingolimod|Fingolimod 0.5 mg QD, oral
219168562|NCT05391178|OTHER|Lumiton yarn sleeve|Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
219168563|NCT05391178|OTHER|Lumiton yarn hat|Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
219168564|NCT05391178|OTHER|Lumiton yarn shirt|Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
219168565|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
219168566|NCT00676715|DRUG|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
219168567|NCT00676715|DRUG|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
219168568|NCT00676715|DRUG|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
219168569|NCT05532137|BEHAVIORAL|e-12HR app|"The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~1. Evaluation of the user's MDSS index.~2. Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups)."
219168570|NCT06462339|BEHAVIORAL|Experimental: Intervention Group|The group that will receive pilates training via telerehabilitation
219168571|NCT02075684|PROCEDURE|Renal Biopsy|
219168572|NCT03725735|BEHAVIORAL|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
219168573|NCT01820260|DRUG|Ingenol mebutate gel|
219168574|NCT01820260|DRUG|placebo|
219362230|NCT04588324|DRUG|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
219168575|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
219168576|NCT06555016|BEHAVIORAL|Walking|Overground walking.
219168577|NCT04356027|PROCEDURE|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
219168578|NCT04356027|PROCEDURE|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
219168579|NCT04356027|PROCEDURE|FFR|FFR will be measured
219168580|NCT04356027|OTHER|VFR Analysis|VFR will be calculated offline using the OCT pullback images
219168581|NCT05228197|DIAGNOSTIC_TEST|Biopsy & Imaging|H\&E stained prostate biopsy slides from standard of care treatment
219168582|NCT04786093|RADIATION|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
219168583|NCT04786093|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
219168584|NCT05863416|DRUG|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
219168585|NCT06059118|DRUG|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
219168586|NCT06059118|DRUG|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
219168587|NCT06059118|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
219168588|NCT06059118|DRUG|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
219168589|NCT05464433|DRUG|Tislelizumab combined with Liposomal mitoxantrone hydrochloride|"Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle."
219168590|NCT05464433|DRUG|Maintenance of tislelizumab|Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
219168591|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
219168592|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
219168593|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
219168594|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
219168595|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
219168596|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
219168597|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
219168598|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
219168599|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
219168600|NCT03235271|DEVICE|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
219168601|NCT04831281|DRUG|ATH-1017|Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
219168602|NCT04831281|DRUG|Placebo|Daily subcutaneous injection of Placebo in a pre-filled syringe
219168603|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
219168604|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
219168605|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
219168606|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
219168607|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
219168608|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
219168609|NCT06271694|OTHER|Vestibular Rehabilitation|Standard vestibular rehabilitation
219168610|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
219168611|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
219168612|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
219168613|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
219168614|NCT03992430|DRUG|Eteplirsen|Solution for intravenous (IV) infusion.
219168615|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
219168616|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
219168617|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
219168618|NCT06150664|DRUG|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
219168619|NCT05766371|DRUG|Pembrolizumab|Given IV
219168620|NCT05766371|DRUG|177Lu-PSMA-617|Given IV
219168621|NCT05483764|DEVICE|Ultrasonographic evaluations|"Ultrasonographic evaluations of the talar cartilage will be performed with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) by the same physiatrist according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS).~Ultrasonographic evaluations of the Achilles tendon will be performed by the same physiatrist with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS)."
219168622|NCT04646707|DRUG|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
219168623|NCT04646707|DRUG|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
219168624|NCT05183477|OTHER|fast track|short cut for the request of xrays directly at triage
219168625|NCT05183477|OTHER|normal pathway|x-ray would be required according to doctor's clinical evaluation.
219238812|NCT04053491|PROCEDURE|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
219238813|NCT05167578|BEHAVIORAL|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
219238814|NCT05018065|BEHAVIORAL|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
219238815|NCT00123500|BEHAVIORAL|Diet|Diet
219238816|NCT00123500|BEHAVIORAL|Physical Activity|Physical Activity
219238817|NCT00123500|BEHAVIORAL|Environment|Environment
219238818|NCT00123500|OTHER|Control Group|Control Group
219238819|NCT01735435|OTHER|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
219238820|NCT02696109|BEHAVIORAL|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
219238821|NCT02696109|BEHAVIORAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
219238822|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
219238823|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
219238824|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
219238825|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
219238826|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
219238827|NCT00438048|PROCEDURE|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
219238828|NCT00438048|DRUG|Artificial Saliva|5ml 3 times daily
219238829|NCT05773872|OTHER|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
219238830|NCT05248672|DRUG|CT1812|Study Drug
219238831|NCT01590056|OTHER|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test"
219238832|NCT00796835|DRUG|ER OROS Paliperidone|
219238833|NCT03109899|BEHAVIORAL|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
219238834|NCT06231316|DRUG|Norepinephrine Injection|Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
219238835|NCT04436016|DRUG|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
219238836|NCT04436016|DRUG|Placebo|Mannitol will be encapsulated for adequate blinding.
219238837|NCT02260154|DRUG|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
219238838|NCT02684435|DRUG|Perflutren lipid microsphere|Dosing per approved package label
219238839|NCT02561195|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
219238840|NCT02561195|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
219238841|NCT02394613|DRUG|ANX776|Single intravenous injection
219238842|NCT05049265|BIOLOGICAL|JS007|JS007 only
219238843|NCT02822092|DRUG|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
219238844|NCT04345588|DRUG|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
219238845|NCT06245317|DEVICE|Mechanical Ventilation Mode|Each arm will have a different ventilation mode according to the allocation.
219238846|NCT02813733|PROCEDURE|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
219238847|NCT01175980|OTHER|Laboratory Biomarker Analysis|Correlative studies
219238848|NCT01175980|DRUG|Vorinostat|Given PO
219238849|NCT01451840|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
219238850|NCT01451840|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
219238851|NCT02301286|DRUG|Acetylsalicylic acid|
219238852|NCT02301286|DRUG|Placebo Acetylsalicylic acid|
219238853|NCT00796575|DRUG|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
219238854|NCT00796575|DRUG|placebo tablets|placebo tablets matching active
219238855|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
219238856|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
219238857|NCT01929616|DRUG|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
219238858|NCT04913194|BEHAVIORAL|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
219238859|NCT02216448|OTHER|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
219238860|NCT02216448|OTHER|OR Training|Training on diagnostic knee arthroscopy in the OR
219238861|NCT04445246|DRUG|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
219238862|NCT00186563|PROCEDURE|Micro-plasmapheresis|
219238863|NCT00267774|DEVICE|Fractional flow reserve|
219238864|NCT00267774|PROCEDURE|Angio-guided PCI|
219238865|NCT03455725|DEVICE|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
219238866|NCT03455725|OTHER|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
219238867|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
219238868|NCT05029089|DEVICE|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
219238869|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
219238870|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
219238871|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
219238872|NCT03798132|DIAGNOSTIC_TEST|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
219238873|NCT03423992|BIOLOGICAL|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
219168626|NCT02728076|RADIATION|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
219168627|NCT05581173|DEVICE|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
219168628|NCT05054374|DRUG|Mirdametinib|Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
219168629|NCT05054374|DRUG|Fulvestrant|"The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant"
219168630|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
219168631|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
219168632|NCT04975633|DEVICE|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
219168633|NCT00797719|OTHER|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
219168634|NCT03568487|OTHER|Intensive scapula-focused approach|scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
219168635|NCT03568487|OTHER|Control Therapy|not have any physical training but is encouraged to stay active as usual.
219168636|NCT05909111|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI weekly during the radiation treatment course (5 RMI added to the standard care)
219168637|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
219168638|NCT04089371|DEVICE|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
219168639|NCT04089371|DEVICE|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
219168640|NCT03222102|DEVICE|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
219168641|NCT06512194|DRUG|Psilocybin|The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
219168642|NCT06512194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
219168643|NCT06512194|DEVICE|Sham taVNS|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
219168644|NCT04494555|DEVICE|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
219238874|NCT05427942|DRUG|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
219238875|NCT04167852|BEHAVIORAL|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
219168645|NCT04494555|DEVICE|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
219168646|NCT04494555|DEVICE|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
219168647|NCT06839807|DEVICE|AtMoves Knee System|The AtMoves Knee Stystem is a loading device that is able to exert force in varus and valgus. when these forces are applied during a CT-scan micromotions of the tibial component of the total knee prosthesis can be detected.
219168648|NCT06795503|DRUG|Docetaxel plus cyclophosphamide|Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.
219168649|NCT06795503|DRUG|Epirubicin, cyclophosphamide plus paclitaxel|Patients in the control group received the EC-P regimen chemotherapy, with a cycle length of 21 days, for a total of 8 cycles. The specific treatment was as follows: Epirubicin (E) at a dose of 90 mg/m² and Cyclophosphamide (C) at a dose of 600 mg/m² were administered intravenously on Day 1 of each cycle for the first 4 cycles. This was followed by Paclitaxel (P) at a dose of 80 mg/m², administered intravenously on Days 1, 8, and 15 of each cycle for the subsequent 4 cycles.
219168650|NCT04740671|DRUG|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
219168651|NCT04740671|DRUG|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
219168652|NCT05222945|OTHER|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
219168653|NCT02991534|BEHAVIORAL|CV Toolkit Components|"* Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
219168654|NCT01767311|DRUG|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
219168655|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
219168656|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
219168657|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
219168658|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
219168659|NCT01767311|DRUG|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
219168660|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
219238876|NCT04167852|BEHAVIORAL|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
219238877|NCT05316649|OTHER|Measurement of external blood loss|Measurement of external blood loss
219238878|NCT05316649|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|Serum Hemoglobin concentration
219238879|NCT02893618|DRUG|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
219168661|NCT04647422|BEHAVIORAL|Analysis of executive functioning and of social cognition processes|"Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes"
219168662|NCT02307565|DRUG|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
219168663|NCT02307565|DRUG|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
219168664|NCT04516278|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
219168665|NCT05688293|PROCEDURE|Connective tissue graft|non-surgical periodontal treatment and connective tissue graft
219168666|NCT05688293|PROCEDURE|Free gingival graft|will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
219168667|NCT05688293|PROCEDURE|Non surgical|non-surgical periodontal treatment only
219168668|NCT05350475|RADIATION|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
219168669|NCT05350475|RADIATION|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
219168670|NCT05205928|DRUG|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
219168671|NCT05574309|DEVICE|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
219168672|NCT05574309|DEVICE|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
219168673|NCT05281406|DRUG|Osimertinib|80 mg daily or reduced dose 40 mg daily
219168674|NCT05281406|DRUG|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
219168675|NCT05281406|DRUG|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
219168676|NCT05281406|DRUG|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
219168677|NCT05767281|BEHAVIORAL|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
219168678|NCT05633472|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
219168679|NCT05633472|OTHER|Placebo|Placebo
219168680|NCT06407050|BEHAVIORAL|4 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
219238880|NCT04664179|BIOLOGICAL|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10\^7 cells/m2
219238881|NCT04664179|BIOLOGICAL|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
219168681|NCT06407050|BEHAVIORAL|8 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
219168682|NCT06407050|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
219168683|NCT06028672|DRUG|Toripalimab|200mg q2w intravenous
219168684|NCT06028672|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
219168685|NCT06191666|BEHAVIORAL|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
219168686|NCT06191666|BEHAVIORAL|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
219168687|NCT06191666|BEHAVIORAL|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
219168688|NCT06191666|BEHAVIORAL|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
219168689|NCT03241082|DEVICE|ultrasound|validation of portable ultrasound to measure body composition
219168690|NCT02808676|DIETARY_SUPPLEMENT|Vitamin D3|Dose: 10000 IU, three times per week, orally.
219168691|NCT02808676|OTHER|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
219168692|NCT02808676|OTHER|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
219168693|NCT02808676|OTHER|placebo D3|matching placebo for Vitamin D3
219238882|NCT04664179|BIOLOGICAL|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
219238883|NCT04664179|BIOLOGICAL|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
219238884|NCT04664179|BIOLOGICAL|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
219238885|NCT03444298|DRUG|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
219238886|NCT03444298|DRUG|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
219238887|NCT01571440|DIETARY_SUPPLEMENT|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
219238888|NCT01571440|DIETARY_SUPPLEMENT|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
219238889|NCT04718116|DRUG|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
219238890|NCT04718116|DRUG|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
219168694|NCT02808676|OTHER|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
219168695|NCT02808676|OTHER|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
219168696|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
219168697|NCT06118749|DIAGNOSTIC_TEST|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
219168698|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
219168699|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
219168700|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
219168701|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
219168702|NCT04521699|DEVICE|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
219168703|NCT06527833|PROCEDURE|Non Packing of perianal abscess cavity after drainage|"* All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity."
219168704|NCT06527833|PROCEDURE|Packing of perianal abscess cavity after drainage|an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
219168705|NCT05868772|DEVICE|Active Sentry Handpiece|With low IOP settings
219168706|NCT05868772|DEVICE|Ozil Handpiece|With high IOP settings.
219168707|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
219168708|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
219168709|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
219168710|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
219168711|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
219168712|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
219168713|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
219168714|NCT04804072|OTHER|Primary care|Primary care
219168715|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
219238891|NCT04718116|DRUG|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
219238892|NCT02759406|DEVICE|coronary stent|
219238893|NCT02289885|DEVICE|SonoScape|Ultrasonography device
219238894|NCT01237600|PROCEDURE|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
219238895|NCT02423707|DRUG|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
219238896|NCT02423707|DRUG|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
219238897|NCT01054118|DRUG|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
219238898|NCT01054118|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
219168716|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
219168717|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
219168718|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
219168719|NCT04970511|BEHAVIORAL|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
219168720|NCT04970511|BEHAVIORAL|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
219168721|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
219168722|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
219168723|NCT04554953|DRUG|Combination drug containing fimasartan and statins|"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
219168724|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
219168725|NCT04418245|DIAGNOSTIC_TEST|Imaging by thoracic scanner|Low-dose computed tomography
219168726|NCT04830410|DIETARY_SUPPLEMENT|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
219168727|NCT04830410|DIETARY_SUPPLEMENT|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
219238899|NCT01054118|DRUG|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
219238900|NCT01054118|DRUG|Placebo|Placebo suspension and placebo capsule administered as single doses
219238901|NCT04034966|DEVICE|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
219238902|NCT04335474|PROCEDURE|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
219168728|NCT05775835|OTHER|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
219168729|NCT05775835|OTHER|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
219168730|NCT05775835|OTHER|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
219168731|NCT06365632|DRUG|Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus|An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.
219168732|NCT06365632|PROCEDURE|antegrade appendectomy|An antegrade appendectomy is performed without using Antispike.
219168733|NCT02966548|DRUG|Relatlimab|Specified dose on specified days
219168734|NCT02966548|DRUG|Nivolumab|Specified dose on specified days
219168735|NCT06836648|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
219168736|NCT06008600|DEVICE|Kinocardiography|Smartphone (application with seismocardiography)
219168737|NCT04453189|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
219168738|NCT04453189|DRUG|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
219168739|NCT04453189|DRUG|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
219168740|NCT05969795|DIAGNOSTIC_TEST|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
219168741|NCT05969795|DIAGNOSTIC_TEST|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
219168742|NCT05969795|DRUG|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
219168743|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
219168744|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
219168745|NCT05969795|PROCEDURE|Embryo transfer|The procedure in which embryo is placed in the uterus.
219168746|NCT05969795|DIAGNOSTIC_TEST|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of \> 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
219168747|NCT05969795|DIAGNOSTIC_TEST|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
219168748|NCT06012708|DRUG|KN510 60mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
219168749|NCT06012708|DRUG|KN510 120mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
219168750|NCT06012708|DRUG|KN510 120mg/day + KN713 90mg/day|Once daily with 28 days (4 weeks) as one cycle.
219168751|NCT06012708|DRUG|KN510 120mg/day + KN713 120mg/day|Once daily with 28 days (4 weeks) as one cycle.
219168752|NCT06849674|BIOLOGICAL|Platelet rich plasma (PRP)|Hair grafts will be immersed in autologous Platelwt-richh plasma(PRP) before transplantation.
219168753|NCT06849674|OTHER|Saline|Hair grafts will be immersed in normal saline solution before transplantation.
219168754|NCT06850480|DRUG|JP-1366 simulation tablets|qd, last for 4-8 weeks
219362231|NCT04588324|DRUG|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
219168755|NCT06850480|DRUG|Esomeprazole Magnesium (Nexium) simulation tablets|qd, last for 4-8 weeks
219168756|NCT06495125|DRUG|Avutometinib|Given PO
219168757|NCT06495125|PROCEDURE|Biopsy|Undergo biopsy
219168758|NCT06495125|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219168759|NCT06495125|PROCEDURE|Computed Tomography|Undergo CT
219168760|NCT06495125|DRUG|Defactinib|Given PO
219168761|NCT06495125|BIOLOGICAL|Nivolumab|Given IV
219168762|NCT06495125|PROCEDURE|Positron Emission Tomography|Undergo PET
219168763|NCT05948735|OTHER|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
219168764|NCT05948735|OTHER|Physical Therapy Exercise (PTE) only for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
219168765|NCT02199600|DEVICE|GMK Sphere Knee Replacement|
219168766|NCT06849297|BEHAVIORAL|Aromatherapy during labor|Use of essential oils (diffusion, massage, or infused cloths) during labor to promote relaxation and pain relief.
219168767|NCT06849167|RADIATION|hypofractionated radiotherapy with immunotherapy|Immunotherapy combined with hypofractionated concurrent chemoradiotherapy followed by consolidation immunotherapy
219168768|NCT06848595|PROCEDURE|spine surgery|spine surgery in prone position
219168769|NCT06848595|DRUG|Magnesium sulfate|Patients will receive loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
219168770|NCT06848595|DRUG|Dexmedetomidine|Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
219168771|NCT06848595|DRUG|Normal Saline (0.9% NaCl)|Patients will receive the same volume of normal saline.
219168772|NCT06390410|DRUG|Simufilam|100 mg PTI-125
219168773|NCT06355583|DRUG|EBX-102|EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
219168774|NCT06355583|DRUG|Placebo|The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
219168775|NCT05974462|DRUG|Methylprednisolone 125 MG|125 mg daily for 3 days diluted in saline solution 250 mL
219168776|NCT05974462|OTHER|IV saline solution 0.9%|Saline solution 0.9% 250 mL
219168777|NCT05536128|DRUG|Olaparib|Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
219168778|NCT05536128|DRUG|Fulvestrant|Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
219168779|NCT05141604|OTHER|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
219168780|NCT03480061|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
219168781|NCT05530057|DRUG|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
219362232|NCT04588324|DRUG|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
219168782|NCT05530057|DRUG|Eribulin Mesylate|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
219168783|NCT05655403|BEHAVIORAL|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
219168784|NCT03877796|DEVICE|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
219168785|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
219168786|NCT05241418|DIAGNOSTIC_TEST|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
219168787|NCT06113939|DEVICE|airway clearance|mechanical suctioning of airway secretions
219168788|NCT03042156|RADIATION|Palliative Radiation Therapy|
219168789|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
219168790|NCT04831684|DRUG|Placebo|Participants will be getting placebo for 8 days of dosing.
219168791|NCT04831684|DRUG|GET73|Participants will be getting GET73 for 8 days of dosing.
219168792|NCT05014204|DEVICE|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
219168793|NCT06163586|OTHER|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
219168794|NCT01889199|DRUG|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
219168795|NCT01889199|OTHER|Placebo|Placebo orally each 28 day cycle for 6 cycles
219168796|NCT05689021|DRUG|Abiraterone Acetate/Niraparib|Given PO
219168797|NCT05689021|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
219168798|NCT05689021|PROCEDURE|Bone Scan|Undergo technetium-99m bone scan
219168799|NCT05689021|PROCEDURE|Computed Tomography|Undergo CT scan
219168800|NCT05689021|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219168801|NCT05689021|DRUG|Prednisone|Given PO
219168802|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219168803|NCT05204732|OTHER|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
219168804|NCT05204732|OTHER|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
219168805|NCT00220740|DRUG|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
219168806|NCT00220740|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
219168807|NCT01433315|BEHAVIORAL|sleep restriction|restricted sleep
219168808|NCT06202976|OTHER|Secondary data collection|clinical data
219168809|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
219168810|NCT05611073|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
219168811|NCT05611073|DIAGNOSTIC_TEST|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
219168812|NCT05611073|OTHER|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
219168813|NCT05517278|OTHER|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
219168814|NCT05517278|OTHER|Standard of Care|The control group will receive standard of care.
219168815|NCT05050929|RADIATION|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
219168816|NCT06627530|DRUG|Darolutamide Oral Tablet|darolutamide 600 mg PO BID for 24 weeks
219168817|NCT06627530|DRUG|leuprorelin|leuprorelin depot 22.5 mg SC every 12 weeks
219168818|NCT03941860|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219168819|NCT03941860|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
219168820|NCT03941860|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219168821|NCT03941860|PROCEDURE|Computed Tomography|Undergo CT scan
219168822|NCT03941860|DRUG|Ixazomib Citrate|Given PO
219168823|NCT03941860|DRUG|Lenalidomide|Given PO
219168824|NCT03941860|OTHER|Placebo Administration|Given PO
219168825|NCT03941860|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219168826|NCT03941860|OTHER|Quality-of-Life Assessment|Ancillary studies
219168827|NCT03941860|OTHER|Questionnaire Administration|Ancillary studies
219168828|NCT05876546|DEVICE|Liquid bandage|The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.
219168829|NCT05876546|DEVICE|Saline Solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
219168830|NCT05888311|DEVICE|Liquid bandage|Liquid elastic collodion- and benzethonium chloride-based topical solution
219168831|NCT06532227|OTHER|No intervention|No intervention excepted data collection
219168832|NCT04789486|DRUG|AGuIX|Injected gadolinium-based nanoparticles
219168833|NCT04789486|RADIATION|Radiotherapy|Stereotactic magnetic resonance-guided adaptive radiation therapy
219168834|NCT05242432|BIOLOGICAL|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
219168835|NCT05242432|OTHER|Placebo|Matching Placebo will be administered as an IM injection
219168836|NCT06623110|BIOLOGICAL|RP2 Injection|Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
219168837|NCT04166565|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
219168838|NCT04166565|DRUG|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
219168839|NCT04166565|DRUG|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
219168840|NCT04166565|DRUG|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
219168841|NCT05328648|BEHAVIORAL|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
219168842|NCT05328648|BEHAVIORAL|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
219168843|NCT05190705|DRUG|Loncastuximab Tesirine|Administered by intravenous infusion
219168844|NCT05190705|DRUG|Dexamethasone|Taken orally or administered by intravenous infusion
219168845|NCT04192981|DRUG|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
219168846|NCT04192981|RADIATION|whole brain radiation therapy radiation|30Gy in 10 fractions
219168847|NCT05147779|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219737409|NCT06569654|DEVICE|Saebo splint|"The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball"
219168848|NCT03361748|BIOLOGICAL|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
219168849|NCT05047224|BEHAVIORAL|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
219168850|NCT05047224|BEHAVIORAL|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
219168851|NCT05920304|DEVICE|virtual Hospital at Home (vHaH)|"Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app."
219168852|NCT04075539|OTHER|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
219168853|NCT04075539|OTHER|usual care|A prescription of 6 sessions of outpatient physiotherapy
219168854|NCT03643900|DEVICE|pancreatic duct stenting|Place the pancreatic duct stent
219238903|NCT04335474|PROCEDURE|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
219168855|NCT03643900|DRUG|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
219238904|NCT04828915|OTHER|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
219238905|NCT04828915|OTHER|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
219238906|NCT03397459|DIAGNOSTIC_TEST|Spine teleradiography EOS|
219238907|NCT00173706|DRUG|L-Carnitine Injection|
219168856|NCT06575816|BEHAVIORAL|Augmented Reality Video Intervention|This intervention involves a video intervention using augmented reality (AR) technology to reduce the pain, anxiety and fear children experience during the blood collection process. During the intervention, children watch AR videos to distract and relax them from the blood collection process. These videos are equipped with a variety of entertaining and engaging content and aim to reduce children's psychological stress.
219168857|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
219168858|NCT02374112|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
219168859|NCT02374112|OTHER|Placebo|Placebo supplementation
219168860|NCT04892693|DRUG|Talazoparib Oral Capsule|\- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
219168861|NCT04303377|BIOLOGICAL|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
219168862|NCT04864158|PROCEDURE|TSA-group|Reverse total shoulder arthroplasty followed by standard rehabilitation.
219168863|NCT04864158|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
219168864|NCT06977074|DRUG|PD-1 inhibitor|Two to four cycles of tislelizumab at a dose of 200 mg every three weeks, along with a platinum-based chemotherapy doublet based on the result of ctDNA dynamics
219168865|NCT06977074|DRUG|Platinum Doublet|Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² \[adenocarcinoma\] or nab-paclitaxel 260 mg/m² \[squamous/other subtypes\])
219168866|NCT05184036|DIAGNOSTIC_TEST|Low Vision|"* The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~* The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~* The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
219737410|NCT04845555|OTHER|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
219737411|NCT05524792|OTHER|no interventional study|no interventional study
219168867|NCT06189534|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
219168868|NCT02814838|DRUG|Ladarixin|Ladarixin oral capsule
219168869|NCT02814838|DRUG|Placebo|Placebo oral capsule
219168870|NCT06649019|DEVICE|ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)|Test Lens
219168871|NCT06649019|DEVICE|Dailies Total 1 for Astigmatism (DT1fA)|Control Lens
219168872|NCT02229721|DRUG|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
219737412|NCT05890573|DRUG|Bailing capsule|6 Bailing capsules,po,tid,12 weeks
219737413|NCT06117631|BEHAVIORAL|Centering Parenting|See Arm description.
219737414|NCT06117631|BEHAVIORAL|Bright by Text|See Arm description.
219737415|NCT05074381|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
219238908|NCT01073761|DRUG|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
219737416|NCT05074381|OTHER|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
219737417|NCT03582397|DEVICE|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
219737418|NCT02576197|DIETARY_SUPPLEMENT|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
219737419|NCT02576197|DIETARY_SUPPLEMENT|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
219737420|NCT02013908|PROCEDURE|Acupuncture plus standard ED management|
219737421|NCT02013908|PROCEDURE|Standard ED management alone|
219737422|NCT00001476|DRUG|Gene Therapy Method for CGD|
219737423|NCT00001476|DEVICE|Isolex 300i Magnetic Cell Selector|
219168873|NCT02229721|DRUG|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
219168874|NCT03811366|DRUG|Corticosteroid monotherapy|Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
219168875|NCT06650852|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
219168876|NCT06650852|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
219168877|NCT06650852|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
219168878|NCT06650852|DRUG|Placebo of BRII-179|Placebo of BRII-179 will be given via intramuscular injection
219168879|NCT06650852|DRUG|Placebo of BRII-835|Placebo of BRII-835 will be given via subcutaneous injection
219168880|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
219168881|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
219168882|NCT01361711|BIOLOGICAL|alemtuzumab|Given SC
219168883|NCT01361711|BIOLOGICAL|ofatumumab|Given IV
219168884|NCT01361711|PROCEDURE|biopsy|Correlative studies
219168885|NCT05982717|OTHER|No intervention|As this is an observational study, no intervention will be administered.
219168886|NCT05737160|BIOLOGICAL|Telitacicept|Administered as an SC infusion
219168887|NCT05737160|DRUG|Placebo|Administered as an SC infusion
219168888|NCT02596126|DRUG|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
219168889|NCT02596126|DRUG|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
219168890|NCT01790152|OTHER|Assessment of Therapy Complications|Ancillary studies
219168891|NCT01790152|OTHER|Laboratory Biomarker Analysis|Correlative studies
219168892|NCT01790152|OTHER|Quality-of-Life Assessment|Ancillary studies
219168893|NCT01790152|OTHER|Questionnaire Administration|Ancillary studies
219168894|NCT04923932|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
219737424|NCT03390400|DEVICE|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
219737425|NCT03390400|PROCEDURE|Anterior Capsulotomy|Cataract Surgery
219737426|NCT03390400|PROCEDURE|Lens Fragmentation|Cataract Surgery
219737427|NCT03607669|OTHER|Mangafodipir trisodium|Manganese-based MRI contrast agent
219737428|NCT05384548|BEHAVIORAL|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
219168895|NCT04351555|DRUG|Osimertinib|Oral
219168896|NCT04351555|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
219168897|NCT04351555|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
219168898|NCT04351555|DRUG|Placebo|Oral
219168899|NCT04351555|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
219168900|NCT06370793|OTHER|Patient with schizophrenia without intervention|Patients with schizophrenia identified based on exposures of interest to the study
219168901|NCT03403478|OTHER|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
219168902|NCT03403478|OTHER|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
219238909|NCT02496559|PROCEDURE|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
219238910|NCT04321109|OTHER|Allograft|Corticocancellous mineralized allograft
219238911|NCT04321109|OTHER|Collagen cone|Collagen matrix
219168903|NCT03403478|OTHER|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
219168904|NCT03403478|OTHER|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
219168905|NCT01784575|OTHER|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
219168906|NCT05134324|OTHER|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
219168907|NCT05134324|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
219168908|NCT05134324|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
219737429|NCT02213991|DEVICE|Intraoperative radiotherapy using Intrabeam®|"Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy"
219737430|NCT01548326|DRUG|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
219737431|NCT01548326|DRUG|placebo|one Placebo tablet orally per day for 10 days
219737432|NCT04054180|OTHER|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
219737433|NCT06143423|DRUG|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
219737434|NCT06143423|DRUG|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
219737435|NCT04525469|BEHAVIORAL|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
219737436|NCT05513105|DIAGNOSTIC_TEST|Iron study of neonates|Blood sambles
219737437|NCT03474601|OTHER|Dynamic hormone study and Magnetic resonance imaging|"1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
219737438|NCT03934619|DEVICE|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
219737439|NCT00383032|DRUG|mifepristone|
219737440|NCT05134519|DRUG|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
219737441|NCT01893450|DRUG|Methimazole|
219737442|NCT01893450|DRUG|Bromocriptine|
219737443|NCT01893450|DRUG|Pentoxifylline|
219737444|NCT01160718|DRUG|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
219168909|NCT05134324|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
219168910|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-F8scFv|89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
219168911|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-C9scFv|89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
219168912|NCT06645808|RADIATION|PET/CT scan|IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
219168913|NCT06645652|BEHAVIORAL|Training in observational drawing|"* 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing"
219168914|NCT06645652|BEHAVIORAL|Arts engagement through digital galleries|"* 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing"
219168915|NCT01638026|DRUG|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
219168916|NCT01791816|DRUG|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
219168917|NCT01791816|DRUG|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
219168918|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
219168919|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
219168920|NCT03396588|DRUG|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
219168921|NCT03396588|DRUG|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
219168922|NCT02675959|DRUG|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
219168923|NCT05027386|DRUG|Apatinib, Irinotecan, Temozolomide|"In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 6 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.~In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 6 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred."
219168924|NCT00812461|DRUG|Placebo|as-needed use, tablets, orally, 6 months
219168925|NCT00812461|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
219168926|NCT06810427|DEVICE|CervImage device|"CervImage™, developed by Pensievision, Inc., is an accessible, simple, cost-effective, early detection imaging technology for preventing cervical cancer deaths caused by a lack of screening.~The novel device is a simple-to-operate, point-of-care, all-focus, 3D-imaging device, with clinical relevance to early-stage detection and prevention of cervical cancers. CervImage's proprietary 3D-rendering software, incorporating strategies previously used for high resolution imaging with NASA telescopes, can quantify tissue color, volume and shape. Virtual navigation tools and all-focus imaging enable straightforward use by minimally trained personnel; expert personnel can also benefit from shorter setup times.~The research procedure and evaluation will be incorporated into the scheduled annual pap smear exam or colposcopic gynecologic exam that involves using a vaginal speculum."
219168927|NCT00495885|DRUG|volinanserin (M100907)|oral, one tablet taken around bedtime
219168928|NCT00495885|DRUG|Placebo|oral, one tablet taken around bedtime
219168929|NCT03448510|DEVICE|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
219168930|NCT03448510|DRUG|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
219168931|NCT04408872|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
219168932|NCT04408872|DIAGNOSTIC_TEST|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
219168933|NCT06975670|OTHER|multimedia consent tool|The multimedia consent tool is new and developed for this particular study
219168934|NCT06978907|DEVICE|Monnalisa Touch® Laser Therapy|Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.
219168935|NCT06978907|COMBINATION_PRODUCT|Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)|Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.
219737445|NCT01160718|DRUG|selumetinib|AZD6244 75 mg p.o. bid
219737446|NCT05646693|DIETARY_SUPPLEMENT|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
219168936|NCT03717506|DRUG|GDC 268 Lotion|GDC 268 is a topical lotion
219168937|NCT03717506|DRUG|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
219168938|NCT03717506|DRUG|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
219168939|NCT06980584|PROCEDURE|Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention|Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
219168940|NCT06980584|PROCEDURE|Pulmonary Vascular Interventional Therapy|According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
219168941|NCT01571570|DRUG|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
219168942|NCT01571570|DRUG|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
219168943|NCT01571570|DRUG|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
219168944|NCT01571570|DRUG|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
219168945|NCT01571570|DRUG|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
219168946|NCT06986382|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
219168947|NCT06986382|DRUG|Prednisone/Methylprenisolone|Administered as part of the HSCT conditioning regimen
219168948|NCT06986382|DRUG|Palifermin|Administered as part of the HSCT conditioning regimen
219168949|NCT06986382|DRUG|ATG|Administered as part of the HSCT conditioning regimen
219168950|NCT06986382|DRUG|Clofarabine|Administered as part of the HSCT conditioning regimen
219168951|NCT06986382|DRUG|Melphalan|Administered as part of the HSCT conditioning regimen
219168952|NCT06986382|RADIATION|Total Body Irradiation|200 cGy, administered as part of the HSCT conditioning regimen
219168953|NCT06986382|DRUG|Rituximab|Administered as part of the HSCT conditioning regimen
219168954|NCT06986746|OTHER|Hypertension Crisis Awareness Program|Education materials-consist of description about hypertension crisis, symptoms, causes and preventive measures (emphasizing on healthy lifestyle and physical activity) with pictorial presentation.
219168955|NCT06988137|DEVICE|Kinesio Taping|Elastic therapeutic tape was applied using the ligament correction technique. The tape was reapplied at Day 3 and Day 21 under supervision
219168956|NCT06988137|PROCEDURE|Buddy Taping|Buddy taping involved strapping the injured finger to an adjacent digit using medical tape. Early motion was restricted.
219168957|NCT06988137|DEVICE|Splinting|A custom-molded thermoplastic splint was applied to restrict joint movement and maintain alignment. Patients remained immobilized until Week 3.
219168958|NCT06988072|OTHER|blood sampling|At BKPyV reactivation, at 1 month, 3 months and 12 months
219168959|NCT06988072|OTHER|blood sampling|once
219168960|NCT06988072|OTHER|blood sampling|once
219168961|NCT06987942|BIOLOGICAL|Varicella vaccine+TIV|"* Varicella vaccine: lyophilized powder, subcutaneous injection~* TIV: Inactived, split virion, containing H1N1, H3N2 and BV strains."
219168962|NCT06987942|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous
219168963|NCT06987942|BIOLOGICAL|TIV|Inactived, split virion, containing H1N1, H3N2 and BV strains.
219168964|NCT06332209|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT; Cohen et al., 2017) is an evidence-based, manualized treatment protocol designed to treat posttraumatic stress and co-occurring symptoms such as depression and anxiety in trauma-exposed children and youth and their supportive and non-offending caregivers. TF-CBT is divided into nine cognitive and behavioral components, all of which incorporate gradual exposure to trauma memories and reminders
219168965|NCT06677177|DIETARY_SUPPLEMENT|Nano-water, Tamsulosin Dutasteride|Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
219168966|NCT06677177|DRUG|Regular water, tamsulosin, Dutasteride|Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
219238912|NCT06238310|DIAGNOSTIC_TEST|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
219168967|NCT06986941|BEHAVIORAL|Ballet-Based Dance Therapy|An 8-week ballet-based dance therapy program designed to improve balance, flexibility, peripheral muscle strength, cognitive functions, and overall functional capacity in Parkinson's disease patients. The therapy will be conducted twice a week, with each session lasting approximately 60 minutes. The exercises will be adapted to the participants' physical abilities and will focus on enhancing motor coordination, strength, and stability through ballet-inspired movements.
219238913|NCT01223053|DRUG|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
219238914|NCT01223053|DRUG|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
219238915|NCT01801202|DEVICE|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
219238916|NCT05051709|PROCEDURE|Corrective osteotomy|First metatarsal distal corrective osteotomy
219238917|NCT05051709|PROCEDURE|Fusion of First ray|Fusion of first ray with soft tissue procedure
219238918|NCT04412174|BIOLOGICAL|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
219238919|NCT01199302|BIOLOGICAL|Brodalumab|Administered intravenously once every 4 weeks
219238920|NCT00506896|DRUG|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
219238921|NCT00002090|DRUG|Azithromycin|
219238922|NCT01892007|BEHAVIORAL|Cogmed RM - Online adaptive working memory training|
219238923|NCT01892007|BEHAVIORAL|Cogmed RM - Online non-adaptive (placebo) working memory training|
219238924|NCT04240197|DEVICE|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
219238925|NCT01634165|DRUG|LY2963016|Administered subcutaneously
219238926|NCT01634165|DRUG|Lantus|Administered subcutaneously
219238927|NCT04995588|OTHER|Blood test|Unique blood draw of 45mL for all the participants
219238928|NCT06096727|BEHAVIORAL|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
219238929|NCT06699524|DRUG|in vitro （chemotherapy）|resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.
219238930|NCT06699524|DEVICE|Adjuvant TACE（Adjuvant Transarterial Chemoembolization）|Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
219238931|NCT06700161|OTHER|Obtaining CGF from patients|Periodontal clinical parameters and Annexin and Lipoxin parameters in CGF will be compared between the test and control groups
219238932|NCT03686839|BEHAVIORAL|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
219238933|NCT01575704|OTHER|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
219238934|NCT01575704|OTHER|Mental Training|Memorial/ mental training and relaxation, 5 times per week
219238935|NCT06721468|OTHER|Trout|rainbow trout
219737447|NCT05646693|DRUG|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
219737448|NCT05646693|DRUG|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
219737449|NCT05052892|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
219737450|NCT05167058|DEVICE|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
219238936|NCT06721468|OTHER|Child-centered nutrition phrases|"learn the phrase, trout helps your brain so you can learn and play either through researcher introduction or completing the About Trout! Pond to Plate curriculum"
219238937|NCT06721468|OTHER|Puzzle|presented with a puzzle to solve each week
219238938|NCT05512598|DRUG|HB0034|HB0034, a single dose
219238939|NCT03701607|OTHER|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
219238940|NCT03533894|DEVICE|colic capsule|colic polyp diagnosis
219238941|NCT03820024|BEHAVIORAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
219238942|NCT02880306|OTHER|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
219238943|NCT05737797|PROCEDURE|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
219238944|NCT06331533|DRUG|Botulinum toxin A|Intradermal botulinum toxin A was applied to the treatment side
219238945|NCT06331533|DRUG|Placebo|NaCl was injected into the placebo side
219238946|NCT02450123|DRUG|sunitinib|
219238947|NCT02618564|DRUG|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
219238948|NCT01052870|DRUG|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
219238949|NCT00946998|DRUG|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
219238950|NCT00946998|DRUG|placebo|Placebo tablet will be identical and matched to sertraline tablet.
219238951|NCT00329017|PROCEDURE|Fine needle aspiration|Fine needle aspiration
219238952|NCT03051529|OTHER|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
219238953|NCT01857362|DRUG|Nitisinone 20 mg|Nitisinone 20 mg capsules
219238954|NCT01857362|DRUG|Nitisinone 10 mg|Nitisinone 10 mg capsules
219238955|NCT00664456|DRUG|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
219238956|NCT00664456|DRUG|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
219238957|NCT00664456|RADIATION|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
219238958|NCT00093743|DRUG|fludarabine phosphate|Given IV
219238959|NCT00093743|DRUG|cyclosporine|Given IV or PO
219238960|NCT00093743|RADIATION|total-body irradiation|Undergo TBI
219238961|NCT00093743|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
219238962|NCT00093743|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
219238963|NCT00093743|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
219168968|NCT06986941|OTHER|Standard Care with Exercise Counseling|Participants in the control group will receive standard care for Parkinson's disease, including pharmacological management and routine clinical follow-up. Additionally, they will receive a one-time exercise counseling session and an informational brochure outlining general home-based exercises appropriate for individuals with Parkinson's disease. No supervised or structured exercise sessions will be conducted.
219168969|NCT06678828|OTHER|ClarityDX Prostate|The ClarityDX Prostate report will be shared with the healthcare team of participants randomized into ClarityDX Prostate arm before the healthcare team decides whether to perform an MRI/advanced imaging and/or biopsy.
219168970|NCT06678828|OTHER|ClarityDX Prostate, blinded|ClarityDX Prostate will be run for the control participants. Participants (and healthcare team) in the control arm will be blinded to the ClarityDX Prostate results and will be considered for prostate MRI/advanced imaging and/or biopsy based on standard of care criteria. The result of the ClarityDX Prostate will be unblinded to study teams at the 12 months follow-up visit (± 2 months). The study team will then share the test results with the participant's health care team to assess whether there is a need to change the participant's care path.
219168971|NCT06676774|DRUG|Oxytocin nasal spray|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.
219168972|NCT06676774|OTHER|Placebo|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.
219168973|NCT06702852|DEVICE|NIRS imaging in addition to SOC|The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
219238964|NCT00093743|DRUG|mycophenolate mofetil|Given PO or IV
219238965|NCT05826405|OTHER|No intervention|No intervention, it's an observational study
219737451|NCT05084885|OTHER|Online therapy|Standard counseling provided over the internet.
219737452|NCT00636974|PROCEDURE|Combined spinal epidural anaesthesia|
219238966|NCT05235997|DIETARY_SUPPLEMENT|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
219238967|NCT05235997|OTHER|Placebo|Placebo look alike the experimental product
219238968|NCT02556541|PROCEDURE|IV puncture guided by ultrasound|
219238969|NCT03428009|OTHER|Magnetic Resonance Imaging|Study interventions are minimal risk.
219238970|NCT03414515|DEVICE|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
219737453|NCT02094885|BIOLOGICAL|Bioseal Fibrin Sealant|
219737454|NCT02094885|OTHER|Manual Compression|
219737455|NCT03917901|OTHER|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
219737456|NCT03917901|OTHER|Health Control|Computerized Single-Session Health Information Control
219737457|NCT04498273|DRUG|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
219737458|NCT04498273|DRUG|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
219238971|NCT06057701|OTHER|corrective exercises|"corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door"
219238972|NCT06057701|OTHER|resisted diaphragmatic breathing exercises|"1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly"
219737459|NCT04498273|DRUG|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
219737460|NCT04498273|DRUG|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
219737461|NCT02124421|PROCEDURE|Cytoreductive Surgery (CRS)|Cytoreductive surgery
219737462|NCT02124421|DRUG|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
219737463|NCT02124421|OTHER|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
219737464|NCT02124421|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
219737465|NCT02124421|DRUG|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
219737466|NCT02124421|DRUG|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
219737467|NCT02124421|DRUG|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
219737468|NCT02124421|DRUG|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
219737469|NCT05199038|DRUG|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
219737470|NCT04228653|DEVICE|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
219737471|NCT05369156|OTHER|Chiropractic Care|The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.
219737472|NCT05369156|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
219737473|NCT04747626|DEVICE|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
219737474|NCT00215553|DRUG|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
219737475|NCT00215553|OTHER|B.3 SoC|Standard ARDS management and ICU care
219737476|NCT00215553|DRUG|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
219737477|NCT00215553|DRUG|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
219737478|NCT00215553|DRUG|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
219737479|NCT00215553|DRUG|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
219737480|NCT00215553|DRUG|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
219737481|NCT01450267|DRUG|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
219737482|NCT01450267|DRUG|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
219238973|NCT03978130|OTHER|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
219238974|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
219238975|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
219238976|NCT03227458|OTHER|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
219238977|NCT03227458|OTHER|Placebo|Participants will take placebo daily for 36 weeks.
219238978|NCT03227458|BEHAVIORAL|Exercise|bone-loading exercise on 3 days per week for 38 weeks
219737483|NCT00756314|BEHAVIORAL|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
219737484|NCT02944461|DRUG|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
219737485|NCT03696667|DEVICE|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
219737486|NCT05157763|DRUG|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
219737487|NCT02232932|PROCEDURE|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
219737488|NCT02232932|PROCEDURE|RESECTION|Intent-to-treat R0 liver resection
219737489|NCT02605967|DRUG|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
219737490|NCT02605967|DRUG|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
219737491|NCT02193347|BIOLOGICAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
219737492|NCT02193347|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
219737493|NCT02193347|DRUG|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
219737494|NCT00109070|DRUG|Avastin (bevacizumab)|
219238979|NCT05952908|OTHER|Proficiency-Based Progression simulation training|The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
219238980|NCT05952908|OTHER|Traditional simulation training|The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
219238981|NCT05543759|DIETARY_SUPPLEMENT|Ready-To-Use Therapeutic Food (RUTF)|"* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets RUTF/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
219238982|NCT01535625|DEVICE|Momo stent|Patients with PCI
219238983|NCT01458288|DRUG|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
219238984|NCT00304278|DRUG|Erlotinib (Tarceva)|150 mg daily X 7 weeks
219238985|NCT00304278|DRUG|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
219238986|NCT00304278|RADIATION|Radiation Therapy (RAD)|5 days per week X 7 weeks
219168974|NCT06926348|BEHAVIORAL|Digital Health Technology for Chronic Insomnia|A mobile application designed to support chronic insomnia management through digital self-monitoring of sleep patterns, personalized sleep hygiene education, cognitive strategies, relaxation and mindfulness exercises, and chatbot interactions. Users receive tailored notifications and educational content to encourage healthy sleep behaviors over an 8-week period. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged
219168975|NCT06926348|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive standard sleep hygiene recommendations via a printed educational booklet. They maintain printed sleep diaries for daily self-monitoring throughout the 8-week intervention. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged.
219168976|NCT06733324|BEHAVIORAL|SCERTS (Social Communication, Emotional Regulation, Transactional Support)|"The SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention is a comprehensive, multidisciplinary approach specifically tailored to address the unique needs of children with Autism Spectrum Disorder (ASD) aged 3-6 years. Unlike traditional behavioral therapies such as Applied Behavior Analysis (ABA), SCERTS emphasizes a developmental framework, focusing on enhancing social communication, emotional regulation, and environmental support. It incorporates family involvement and integrates strategies into naturalistic settings, ensuring skill generalization across home, school, and community environments.~This intervention is distinguished by its individualized goals based on each child's developmental profile and its emphasis on fostering meaningful interactions rather than relying on compliance-based methods. SCERTS also incorporates transactional supports, such as modifying the physical and social environment to promote engagement and reduce stress, w"
219168977|NCT06733324|BEHAVIORAL|Behavioral Treatment, Speech Therapy|The control group will be the treatment as usual group receiving conventional behavior therapy and speech therapy
219168978|NCT06892665|DEVICE|Hypotension prediction index|HPI and other haemodynamics parameters, is available to the anaesthetist to view and act upon
219168979|NCT06892665|DEVICE|Non invasive Blood Pressure Monitoring|Anaesthetist will respond to hemodynamic variables using NIBP
219168980|NCT06885047|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
219238987|NCT03490747|BEHAVIORAL|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
219238988|NCT03490747|BEHAVIORAL|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
219238989|NCT05065099|DEVICE|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
219238990|NCT04397822|BIOLOGICAL|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
219238991|NCT03334071|BEHAVIORAL|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
219168981|NCT06885047|BEHAVIORAL|Treatment as usual|TAU consists of eclectic brief treatments, including some CBT or psychodynamic strategies that are applied with adolescents or in conjunction with the caregiver. In all cases, psychoeducation is provided to adolescents and their caregivers. Occasionally, they may be referred to some family therapy intervention. All treatments are brief therapy, provided by clinical psychologists and are intended to address the cognitive, emotional, and family factors that affect the adequate psychosocial functioning of the adolescent.
219168982|NCT06782321|BEHAVIORAL|modified Cognitive Behavioral Therapy (mCBT)|"The theoretical model underling Cognitive Behavioral Therapy (CBT) explains the interaction of thoughts, feelings, and behaviors during life situations. This model suggests that a person's thoughts/feeling/behaviors affect their functioning during life situations. This contrasts with a common belief that one's functioning during life situations is the only way to effect thoughts/feelings/behaviors. Applied to stroke, this model suggests that the stroke survivor can alter his/her functioning during life situations by altering his/her thoughts/feelings/behaviors. The purpose of CBT is to empower the person with the skills to alter his/her thoughts/feelings/behaviors in order to positively affect function in life situations.~The mCBT intervention includes 4 elements: psychoeducation, education about unhelpful thinking, behavioral activation therapy, education on sleep hygiene, and relaxation training."
219168983|NCT06782321|BEHAVIORAL|Occupational or Speech Therapy|"If the participant demonstrates aphasia of any severity level on the Revised Western Aphasia Battery (WAB-R) assessment given at the PRE session, the subject will receive ST, provided by a Speech Language Pathologists (SLP), stroke telerehabilitation. If there is no aphasia, the subject will receive OT stroke telerehabilitation.~The OT and ST stroke telerehabilitation sessions will utilize a similar metacognitive strategy training approach which is focused on enabling the stroke survivor to re-engage with meaningful life activities. In the Occupational Therapy literature this approach is called Cognitive Orientation to Occupational Performance (CO-OP) and in the Speech Language Pathology Literature this approach is called the Life Participation Approach to Aphasia (LPAA).~Telerehabilitation CO-OP and LPAA within the OT or ST session include three common elements: Shared decision-making for goal setting, guidance/coaching from the therapist, and self-evaluation."
219168984|NCT06754683|BEHAVIORAL|8 weeks Self-compassion based psycho-education|The Self-compassion psychoeducational intervention will be utilized as the intervention in this study will be delivered by the first investigator and supervised by the Principal investigator, who has experience in mindfulness and self-compassion practices. It will consist of eight weekly 1.5 hours of face-to-face sessions and 1 hour each week of online sessions. Each session will be according to a specific topic that will cover the objectives of the study, incorporating the concept of self-compassion interventions based on the research literature and input from experts in the field, taking into consideration the needs of the participants. Participants will be required to have at least 80% of attendance for intervention completion.
219168985|NCT06791382|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.
219168986|NCT06926686|PROCEDURE|Autologous tarsus|Surgical implantation of autologous tarsus to the lower eyelid
219168987|NCT06926686|PROCEDURE|Acellular dermal matrix|Surgical implantation of acellular dermal matrix to the lower eyelid
219168988|NCT06902506|BEHAVIORAL|Augmented Music|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
219168989|NCT06902506|BEHAVIORAL|Non-Augmented Music|Same melodic theme without the augmentation.
219168990|NCT06930989|DEVICE|Positive airway pressure (PAP)|Intervention as part of routine clinical care. Data from national registries.
219168991|NCT06785688|DEVICE|Protective gear irradiated by infrared rays|irradiated by infrared rays back brace
219238992|NCT04285151|PROCEDURE|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
219238993|NCT05855499|DEVICE|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
219362233|NCT05544890|PROCEDURE|Exercise|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Therapeutic exercise"
219238994|NCT06379763|OTHER|diaphragmatic breathing exercise|15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
219238995|NCT06379763|OTHER|conventional physiotherapy exercise|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
219238996|NCT01741636|OTHER|educational intervention|Undergo Survivorship Care Planning
219238997|NCT01741636|OTHER|questionnaire administration|Ancillary studies
219238998|NCT01741636|PROCEDURE|quality-of-life assessment|Ancillary studies
219238999|NCT00674258|BIOLOGICAL|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219239000|NCT01520285|DRUG|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
219239001|NCT01520285|DRUG|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
219239002|NCT00507429|DRUG|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
219239003|NCT00507429|DRUG|paclitaxel|200mg/m squared on Day 1
219239004|NCT00507429|DRUG|carboplatin|6 AUC on Day 1 following paclitaxel
219239005|NCT02230709|OTHER|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
219239006|NCT02230709|OTHER|"TENS and dry needling"|Application of TENS current after dry needling technique
219239007|NCT01053897|BIOLOGICAL|GBT009|Intradermal Injection following surgery
219239008|NCT01053897|BIOLOGICAL|Placebo|Intradermal Injection following surgery
219239009|NCT04025762|DEVICE|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
219239010|NCT04025762|DEVICE|Sensor augmented pump therapy|Sensor augmented pump therapy
219239011|NCT02791009|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
219737495|NCT02957903|DRUG|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
219737496|NCT02957903|DRUG|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
219737497|NCT03002909|DEVICE|epidural catheter|
219737498|NCT03002909|DEVICE|preperitoneal catheter|
219737499|NCT05343650|DEVICE|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
219737500|NCT05343650|DEVICE|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
219239012|NCT02791009|OTHER|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
219239013|NCT02791009|OTHER|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
219239014|NCT02791009|OTHER|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
219239015|NCT02791009|OTHER|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
219239016|NCT02791009|OTHER|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
219239017|NCT01593137|DRUG|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
219239018|NCT01593137|DRUG|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
219362234|NCT05544890|PROCEDURE|Manual Therapy|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Manipulation"
219362235|NCT05544890|PROCEDURE|Kinesiotape|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Kinesiotaping"
219168992|NCT04036097|OTHER|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
219168993|NCT04036097|OTHER|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
219168994|NCT06908135|BEHAVIORAL|Independent walking program using walking poles|Participants will independently walk at least 3 times a week for 8 weeks using walking poles
219168995|NCT06908135|BEHAVIORAL|Independent walking program without walking poles|Participants will independently walk at least 3 times a week for 8 weeks without walking poles
219168996|NCT06234267|BEHAVIORAL|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
219168997|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
219168998|NCT06920069|BIOLOGICAL|sIPV|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose
219168999|NCT06920069|BIOLOGICAL|DTaP|Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose
219169000|NCT06920069|BIOLOGICAL|bOPV 1,3|Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose
219169001|NCT06920069|BIOLOGICAL|MMR Vaccine|Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose
219169002|NCT07140692|DEVICE|Vitrectomy|In this single-arm, non-comparative study, patients presenting with vitreous opacities affecting daily activities of living will undergo vitrectomy using the single-use vitrector probe of Vista Ophthalmics for the removal of the vitreous opacities.
219169003|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
219169004|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
219169005|NCT05045183|DEVICE|SoC Adhesive Bandage|On the randomized wound site, a SoC adhesive bandage will be applied.
219169006|NCT05045183|DRUG|Antibiotic Ointment|On the randomized wound site, a antibiotic ointment will be applied.
219169007|NCT05045183|DRUG|Antiseptic Wash|On the randomized wound site, a antiseptic wash will be applied.
219169008|NCT05045183|DEVICE|Hydrocolloid Pad|On the randomized wound site, hydrocolloid pad will be applied.
219169009|NCT03818802|DIETARY_SUPPLEMENT|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
219169010|NCT03818802|DIETARY_SUPPLEMENT|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
219169011|NCT06275529|PROCEDURE|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
219169012|NCT05865899|PROCEDURE|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
219169013|NCT06782581|BEHAVIORAL|Contribution to Caregivers Well-Being|Contribute to caregiver's well-being via household tasks.
219169014|NCT06782581|BEHAVIORAL|Control|factually describe either (1) immediate environment, (2) the weather, or (3) organization of closet
219169015|NCT02829060|DRUG|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
219169016|NCT02829060|DRUG|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
219169017|NCT02829060|DRUG|Ampicillin 2g|Peri-operative dose: 2 grams, IV
219169018|NCT02829060|DRUG|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
219169019|NCT02829060|DRUG|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
219169020|NCT02829060|DRUG|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
219169021|NCT03360838|OTHER|CogCheck|Performance of study participants in the application
219169022|NCT06054529|PROCEDURE|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
219169023|NCT06054529|OTHER|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
219169024|NCT06789887|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy (WET) is a 5-session, trauma-focused intervention in which individuals write about their traumatic experience following scripted instructions.
219169025|NCT06789887|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
219362236|NCT00002508|DRUG|carboplatin|
219362237|NCT00002508|DRUG|etoposide|
219239019|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
219169026|NCT06163014|BEHAVIORAL|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~1. Symptom explanations and facts about frequent symptoms including brief animated explanations~2. Physical energy (sleep, diet and activity)~3. Working with resources and strain in everyday life~4. Values and choices (meaning and existential issues)~5. Thoughts~6. Feelings (emotion regulation)~7. Self-care (attention incl. mindfulness and audio exercises)~8. Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
219169027|NCT06839339|DRUG|AL-001|Administered via suprachoroidal space injection.
219169028|NCT06839339|DRUG|Aflibercept|Intravitreal injection
219169029|NCT04534127|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219169030|NCT06838975|DEVICE|VR Training|Participants in the VR Training Group will undergo a virtual reality-based rehabilitation program designed to improve cognitive, emotional, social, and motor functions. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), using immersive and non-immersive VR systems tailored to individual needs. The program integrates interactive exercises, real-time feedback, and task-oriented training to enhance motor function, cognitive abilities, and patient engagement. Neurophysiological changes will be monitored through EEG, MRI, and motion analysis to assess brain plasticity and functional improvements.
219169031|NCT06838975|OTHER|traditional cognitive and motor rehabilitation following standard clinical practices|Participants in the Active Control Group will receive traditional cognitive and motor rehabilitation following standard clinical practices. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), focusing on conventional physical therapy, cognitive training, and task-oriented exercises to enhance motor function and cognitive abilities. This group serves as a comparison to evaluate the effectiveness of VR-based rehabilitation. Neurophysiological changes will be monitored using EEG, MRI, and motion analysis to assess functional improvements.
219169032|NCT06836570|BIOLOGICAL|Platalet Rich Plasma|Platelet-rich plasma (PRP) is a preparation of autologous human platelet concentration enriched in a small amount of plasma produced by centrifuging a patient's own blood. It is applied to the extraction socket after the extraction of an impacted wisdom tooth.
219169033|NCT06836570|OTHER|Low Level Laser Therapy|Low-level laser therapy is a technology that has been used since the mid-1960s to treat a variety of conditions requiring healing stimulation, pain and inflammation relief, and restoration of function. A single 940 nm diode laser was applied intraorally for 120 seconds (BIOLASE) immediately after the extraction and suturing of an impacted wisdom tooth.
219169034|NCT04929899|BEHAVIORAL|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
219169035|NCT06839391|DRUG|Hyaluronidase|Effect of hyaluronidases in different doses added to bupivacaine on quality of ultrasound-guided TAB block during CS ,
219169036|NCT02868268|OTHER|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
219169037|NCT05926102|GENETIC|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
219169038|NCT05926102|OTHER|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
219169039|NCT06840990|DEVICE|CXC-SP|Standard therapy plus sterile Isotonic ophthalmic solution based on CX-CMC and silk protein, istilled six time a day until complete healing.
219169040|NCT06840990|DEVICE|CTRL|Standard therapy plus sterile ophtalmic isotonic solution for six time a day until complete healing.
219169041|NCT05949060|BEHAVIORAL|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
219169042|NCT06838403|OTHER|Oro motor excercise to study arms and controoled arms|Each child in both groups will receive OME program for 30 minutes three times per week for 6 months.
219169043|NCT05971810|DIETARY_SUPPLEMENT|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
219362238|NCT00002508|PROCEDURE|autologous bone marrow transplantation|
219362239|NCT00002508|PROCEDURE|peripheral blood stem cell transplantation|
219169044|NCT05971810|OTHER|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
219169045|NCT05512975|DIETARY_SUPPLEMENT|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
219169046|NCT05512975|DIETARY_SUPPLEMENT|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
219169047|NCT05512975|DIETARY_SUPPLEMENT|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
219169048|NCT06791421|OTHER|AI-Predictng Model|The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans). The AI model is trained to predict a patient's genotype based on these non-genetic data sources. This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing. There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
219169049|NCT05048628|OTHER|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
219169050|NCT03485547|DRUG|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
219169051|NCT06223503|BEHAVIORAL|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
219169052|NCT06795750|PROCEDURE|neural therapy|Neural therapy (NT) is a therapeutic intervention that uses local anesthetics to alleviate persistent musculoskeletal pain. NT targets the underlying autonomic dysfunction by modulating the autonomic nervous system. The enhancement of autonomic dysfunction leads to controlled microcirculation, the elimination of pain mediators, and the attainment of an anti-inflammatory effect. NT focuses on painful regions, specific segments of these areas, and trigger points, encompassing both local and segmental treatment
219169053|NCT06795750|OTHER|Exercise|The second group received a home exercise program consisting of stretching, strengthening, and aerobic exercises for 30 minutes, three times per week, for a duration of five weeks.
219169054|NCT06796855|DEVICE|Selective Bladder Denervation via Radiofrequency Ablation|Participants in this arm will undergo a single session of selective bladder denervation using radiofrequency ablation (RFA). The procedure is performed under general anesthesia using the Apro Korea AK-F200 system, which delivers radiofrequency energy at four submucosal points in the bladder trigone area. The energy is applied at 25 watts per site for 60 seconds, targeting nerve pathways involved in overactive bladder symptoms. The procedure is conducted using a 19 Fr. rigid cystoscope in lithotomy position, ensuring precise electrode placement. Patients are discharged on postoperative day 1 following urinary ultrasound and post-void residual (PVR) assessment. Follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
219169055|NCT06796855|DRUG|Intravesical Onabotulinum Toxin A Injection|Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19 Fr. rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
219169056|NCT03805464|OTHER|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
219169057|NCT05557864|DEVICE|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
219169058|NCT06797141|OTHER|Vestibular Rehabilitation and Dual task Training and Traditional Physical Therapy|Group A will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 30 minutes and Dual Task Training for 20 minutes along with routine physical therapy of 10 minutes. Treatment session will be given 5 days per week for 8 weeks. Patients will be instructed to perform 2 sets of 5 repetition each Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Dual Task exercises comprising of primary and secondary tasks Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down
219239020|NCT01659697|BEHAVIORAL|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
219239021|NCT02422355|DEVICE|FNS|Surgical intervention using the FNS
219362240|NCT01337128|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
219362241|NCT01337128|PROCEDURE|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
219362242|NCT01337128|PROCEDURE|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
219362243|NCT01337128|PROCEDURE|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
219362244|NCT01337128|PROCEDURE|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
219169059|NCT06797141|OTHER|Vestibular Rehabilitation and Traditional Physical Therapy|"Group B will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 5 days per week for 8 weeks.~Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down"
219169060|NCT05534750|DRUG|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
219169061|NCT05534750|DRUG|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
219169062|NCT05534750|DRUG|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
219169063|NCT00804453|DEVICE|Cartridge blood set|Once a week
219169064|NCT00804453|DEVICE|Standard blood line|Once a week
219169065|NCT06500104|DIETARY_SUPPLEMENT|Kefir peptide|Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
219169066|NCT06500104|DIETARY_SUPPLEMENT|Placebo|Glucose powder
219169067|NCT06173804|OTHER|Adapted Look Ahead Lifestyle Intervention|Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
219169068|NCT06830317|PROCEDURE|Endoscopic Radiofrequency treatment|Treatment with RFA will carried out with focal RFA with a TTS catheter at 12 Joule/cm2 to all visible areas of GAVE under conscious sedation or propofol sedation by experienced team of endoscopists and anesthetists
219169069|NCT06830317|OTHER|QoL EQ5D questionaire|Quality of Life EQ5D (by EuroQol Group) before every RFA treatment and at Follow up visits (3, 6 and 12 months after the first procedure). QoL questionnaire EQ5D The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state
219169070|NCT06125587|DRUG|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
219169071|NCT06125587|DRUG|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
219169072|NCT06780956|OTHER|Conventional|conventional drilling protocol using full sequence
219169073|NCT06780956|OTHER|simplfied|3 burrs for implant placment
219169074|NCT05602506|DRUG|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
219169075|NCT06755489|OTHER|Placebo|530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day
219169076|NCT06755489|OTHER|GABA|530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day
219169077|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
219169078|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
219169079|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
219169080|NCT04178733|DRUG|LY3493269 - SC|Administered SC
219169081|NCT04178733|DRUG|Placebo - SC|Administered SC
219169082|NCT04178733|DRUG|LY3493269 - IV|Administered IV
219169083|NCT02736448|DRUG|Capecitabine|oral low dose of capecitabine
219169084|NCT02736448|DRUG|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
219169085|NCT02736448|DRUG|SS-LAR|long acting octreotide or lanreotide
219169086|NCT03940950|BIOLOGICAL|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
219169087|NCT03940950|DRUG|Placebo|Saline control that contains no active ingredient
219169088|NCT03676582|DIAGNOSTIC_TEST|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
219362245|NCT01337128|PROCEDURE|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
219239022|NCT04065685|OTHER|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
219239023|NCT04065685|OTHER|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
219239024|NCT03362853|DRUG|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
219239025|NCT03362853|DRUG|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
219239026|NCT03362853|DRUG|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
219239027|NCT03362853|DRUG|Placebo oral capsule|Receive a single dose in a fasting state
219239028|NCT05967377|DRUG|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
219239029|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
219239030|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
219239031|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
219239032|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
219239033|NCT05967377|DRUG|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
219239034|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
219239035|NCT05967377|DRUG|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
219239036|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
219239037|NCT05667740|BIOLOGICAL|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
219239038|NCT05667740|BIOLOGICAL|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
219239039|NCT05667740|BIOLOGICAL|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
219239040|NCT05667740|DRUG|Placebo|Saline
219169089|NCT06302361|PROCEDURE|Lymphovenous anastomosis (LVA)|Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
219169090|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
219169091|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
219169092|NCT06115161|DEVICE|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
219169093|NCT04847648|PROCEDURE|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
219169094|NCT04847648|PROCEDURE|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
219169095|NCT04286607|DRUG|Topical roflumilast|Active treatment
219169096|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
219169097|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
219169098|NCT06340347|DRUG|Osivelotor|"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"
219239041|NCT00166075|PROCEDURE|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
219239042|NCT05728619|DRUG|HTMC0435|Oral administration.
219239043|NCT05728619|DRUG|Temozolomide|Oral administration.
219239044|NCT03785756|DRUG|Ibuprofen 300 mg Oral Tablet|2 × 300 mg tablets at Hours 0 and 12
219239045|NCT03785756|DRUG|Ibuprofen 200 mg Oral Tablet|2 × 200 mg tablets at Hours 0, 8, and 16
219239046|NCT03785756|DRUG|Placebo of PR tablet|2 tablets up to four times in 24 hours
219239047|NCT03785756|DRUG|Placebo of IR tablet|2 tablets up to four times in 24 hours
219239048|NCT01706055|BIOLOGICAL|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
219239049|NCT02192645|DRUG|Sanfujiu|
219239050|NCT02192645|DRUG|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
219239051|NCT05851521|DEVICE|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
219239052|NCT05851521|DEVICE|Indwelling catheter|Placement of indwelling catheter
219239053|NCT01996514|DIETARY_SUPPLEMENT|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
219239054|NCT01996514|DIETARY_SUPPLEMENT|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
219239055|NCT01996514|BEHAVIORAL|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
219239056|NCT01996514|BEHAVIORAL|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
219169099|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
219169100|NCT05380583|BEHAVIORAL|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
219169101|NCT05380583|BEHAVIORAL|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
219169102|NCT01974245|DRUG|Cholecalciferol|100,000 IU/week for 12 weeks
219169103|NCT01974245|DRUG|Placebo|100 drops/ week for 12 weeks
219169104|NCT03442413|DRUG|2-[18F]-FA PET/CT|2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
219169105|NCT03442413|DRUG|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
219169106|NCT05471479|DRUG|Activated Charcoal|Activated charcoal
219169107|NCT05471479|OTHER|No activated charcoal|No activated charcoal
219169108|NCT04637763|GENETIC|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
219169109|NCT04637763|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219737501|NCT06424535|OTHER|Chinese medicine for internal or external use、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application of traditional Chinese herbal medicinal cake|"The treatment project a Chinese medicine practitioner based individual needs of the patient, and will be followed by a four-week treatment.~1. Traditional Chinese medicine for internal or external use: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them twice a week for 20 minutes each time.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint once a day~5. Nursing and health education and guidance~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes."
219737502|NCT06424535|OTHER|Western medicine|Patients will receive routine Western medicine treatments as per individual patient's needs. The medications and bandages can vary due to the depth and size of the burn and scald.
219737503|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
219737504|NCT00159874|DRUG|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
219737505|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
219737506|NCT01234714|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
219737507|NCT01234714|PROCEDURE|Major liver resection|Hepatectomy of \>= 3 liver segments
219737508|NCT05439863|DEVICE|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
219737509|NCT04019704|DRUG|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
219737510|NCT04019704|DRUG|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
219737511|NCT01475825|DRUG|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
219737512|NCT01475825|DRUG|Placebo|Placebo vehicle for subcutaneous injection.
219737513|NCT01475825|DRUG|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
219737514|NCT01986023|BEHAVIORAL|SMS- Short Messaging Service|
219737515|NCT03649087|OTHER|Vitrification|Vitrification of ovarian tissue
219737516|NCT02570425|DEVICE|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
219737517|NCT02570425|DEVICE|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
219737518|NCT03622931|DRUG|Standard chemotherapy|Chemotherapy
219169110|NCT04637763|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219169111|NCT03077776|PROCEDURE|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
219169112|NCT03077776|PROCEDURE|Biopsy (optional)|\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
219169113|NCT03077776|PROCEDURE|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
219169114|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
219169115|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
219737519|NCT03622931|DRUG|Romiplostim|
219737520|NCT03622931|DRUG|Placebos|
219737521|NCT00309946|DRUG|cediranib maleate|Given orally
219169116|NCT05004285|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
219169117|NCT04149288|DIETARY_SUPPLEMENT|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
219169118|NCT04149288|DIETARY_SUPPLEMENT|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
219169119|NCT06781541|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
219169120|NCT06781541|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
219239057|NCT04177849|PROCEDURE|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
219239058|NCT04177849|PROCEDURE|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
219239059|NCT01272388|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
219239060|NCT01272388|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
219239061|NCT00874172|DRUG|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
219239062|NCT00874172|DRUG|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
219239063|NCT04232410|DIAGNOSTIC_TEST|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
219737522|NCT03840889|OTHER|Data collection|"he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)"
219737523|NCT05686720|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.
219169121|NCT06781541|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, a total of 12 weeks. Participants used professional Bungy Pump Pole.
219737524|NCT00609349|DEVICE|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
219737525|NCT03631693|PROCEDURE|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
219737526|NCT03631693|PROCEDURE|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
219737527|NCT05534490|OTHER|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
219737528|NCT02096926|DRUG|Placebo|
219737529|NCT02096926|DRUG|Ibuprofen|400 mg PO
219169122|NCT06781541|BEHAVIORAL|Daily life|The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.
219169123|NCT06781541|BEHAVIORAL|Functional general conditioning training|Training sessions were supervised by a certified instructor. Training was carried out at home with individually adjusted resistance depending on age and health. Participants typically performed 10-13 repetitions of a given exercise. 30-second rest intervals were used between exercises. As intended, the training was comprehensive, i.e. including muscles of the arms, legs, trunk, abdomen, chest, balance and flexibility exercises. Basic training equipment was used during the training.
219169124|NCT03744936|OTHER|Feedback|Study team members will conduct interviews with subjects to gather feedback on Atrial Fibrillation experiences
219169125|NCT06780527|OTHER|15% Grape seed extract as dentin pretreatment|using proanthocyanidin-rich grape seed extract as a biomodifier for dentin improved the mechanical properties of dental collagen by cross-linking and dehydrating fibrils. This made the collagen substrate more suitable for hybridization. It also acted as a non-specific MMP-inhibitor, protecting exposed collagen fibrils from biodegradation from dentin proteases.
219169126|NCT06781216|BEHAVIORAL|Motivational interviewing|It is emphasized that motivational interviewing is a feasible intervention that can be used by various health professionals to optimize clinical outcomes in cancer patients and survivors, helping individuals to better cope with the stress they experience related to cancer and improve their quality of life. Considering the benefits of motivational interviewing on individuals diagnosed with cancer, it is anticipated that the intervention planned in the study will improve coping strategies, reduce post-traumatic stress symptoms, and increase the level of post-traumatic growth in women with endometrial cancer.
219169127|NCT03328702|DEVICE|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
219169128|NCT05581758|DRUG|AMG 510|Oral Tablet
219169129|NCT03465592|DRUG|Nivolumab|Administered IV
219169130|NCT05789537|DRUG|SerpinPC|Administered as SC injection.
219169131|NCT06135974|DRUG|LC106|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
219169132|NCT06135974|DRUG|LC115|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
219169133|NCT06135974|DRUG|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
219169134|NCT06135974|DRUG|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
219169135|NCT06304077|OTHER|Forest|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
219169136|NCT06304077|OTHER|Urban|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
219169137|NCT06304077|OTHER|Rural|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
219169138|NCT06845657|OTHER|Hip Abductor Strengthening Exercises|Hip Abductor Strengthening Exercises .1.side lying leg raise 2.clam shell(Frequency: 3 sets 10 reps in session 1-5) 3.standing hip abduction.4.pelvic lift training (Frequency: 3 sets 10 reps in session 6-9) .Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions).total duration is 3 sessions per week for 3 consecutive weeks.
219169139|NCT06845657|OTHER|Conventional Treatment|Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions). Total duration is 3 sessions per week for 3 consecutive weeks
219169140|NCT06847880|DRUG|1: Vitamin C Supplementation|• Vitamin C (Ascorbic Acid): This intervention involves the administration of vitamin C, which is known for its antioxidant properties. The concentration will be 120 mg in 1.2 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.2 ml (20 mg) of the vitamin C. It is hypothesized to accelerate orthodontic tooth movement by reducing oxidative stress and promoting collagen synthesis.
219239064|NCT04232410|DIAGNOSTIC_TEST|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
219239065|NCT06232941|PROCEDURE|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
219239066|NCT01807234|DRUG|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
219239067|NCT01807234|DRUG|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
219239068|NCT01807234|DRUG|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
219239069|NCT04458376|BEHAVIORAL|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
219169141|NCT06847880|DRUG|Vitamin E Supplementation|• Vitamin E (Tocopherol Acetate): This intervention uses vitamin E, another antioxidant, thought to reduce inflammation and support tissue repair, potentially improving the effectiveness of orthodontic treatment by enhancing tissue recovery and reducing side effects. The concentration will be 60 mg in 0.4 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.07 ml (10 mg) of the vitamin E.
219169142|NCT06847880|OTHER|Saline Solution (Control)|Saline Solution (Control): The control group will receive a saline solution, which is a placebo, allowing for the comparison of the effects of vitamin C and vitamin E on orthodontic tooth movement without the influence of additional nutrients.
219169143|NCT06847789|DEVICE|Tensi+|Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
219169144|NCT06146348|BEHAVIORAL|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
219169145|NCT06844292|DEVICE|MINIject with Cataract Surgery|Patients will be randomized to receive either a MINIject implant or a Hydrus Microstunt in conjunction with cataract surgery. If randomized to MINIject, the device will be implanted into the supraciliary space with a minimally invasive ab interno approach. It is designed to be implanted with its head in the anterior chamber and its body in the supraciliary space, leading to improved natural uveoscleral outflow by directing aqueous humor from the anterior chamber to the sub-scleral space. Cataract surgery will be performed with phacoemulsification.
219169146|NCT06844292|DEVICE|Hydrus Microstent with Cataract Surgery|"Patients will be randomized to receive either a Hydrus Microstunt or a MINIject implant in conjunction with cataract surgery. If randomized to Hydrus Microstent, the device will be implanted into Schlemm's canal through the trabecular meshwork in order to dilate and restore the natural aqueous outflow pathway through Schlemm's canal, leading to a reduction of intraocular pressure.~Cataract surgery will be performed with phacoemulsification."
219169147|NCT04833777|DRUG|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
219169148|NCT04833777|DRUG|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
219169149|NCT06847048|PROCEDURE|Thermophore pad warming group|Thermophore pad waa using heel warming
219169150|NCT06847048|PROCEDURE|Warm towel warming group|In this group, to warm the heel, the heel area where the blood would be taken was wrapped with a previously heated towel before heel prick.
219239070|NCT00538629|OTHER|no intervention|no intervention
219239071|NCT00538629|OTHER|no intervention|no intervention
219239072|NCT06544226|DEVICE|UH100|"This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task."
219239073|NCT01803958|RADIATION|partial breast irradiation|
219239074|NCT01803958|RADIATION|whole breast irradiation|
219239075|NCT00629447|DRUG|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
219239076|NCT04054245|DRUG|LOXL2 Inhibitor PAT-1251|Given PO
219239077|NCT04054245|OTHER|Quality-of-Life Assessment|Ancillary studies
219239078|NCT04054245|OTHER|Questionnaire Administration|Ancillary studies
219239079|NCT03071172|DRUG|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
219239080|NCT03071172|DRUG|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
219239081|NCT03071172|DRUG|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
219239082|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
219737530|NCT04156100|DRUG|AGEN1223|AGEN1223 is a bispecific antibody.
219737531|NCT04156100|DRUG|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
219737532|NCT04398225|DRUG|Centanafadine|Extended release capsule
219737533|NCT04045145|DRUG|Crinecerfont|Crinecerfont administered orally for 14 consecutive days.
219737534|NCT01918358|DRUG|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
219737535|NCT01918358|DRUG|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
219737536|NCT01918358|DRUG|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
219737537|NCT01918358|DRUG|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
219737538|NCT01918358|DRUG|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
219737539|NCT01918358|DRUG|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
219737540|NCT05757349|BEHAVIORAL|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
219737541|NCT05757349|BEHAVIORAL|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
219737542|NCT02096887|BEHAVIORAL|Patient Education|"Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet"
219239083|NCT00555620|DRUG|oxaliplatin|Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
219239084|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
219239085|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
219239086|NCT00555620|DRUG|cisplatin|Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
219239087|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
219737543|NCT06549322|OTHER|The exercise in morning|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30"
219737544|NCT06549322|OTHER|The exercise in evening|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30"
219169151|NCT06847048|OTHER|Control group|in this group, heel prick intervention was performed in line with the routine interventions of the clinic.
219169152|NCT03062319|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
219169153|NCT03062319|DRUG|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
219169154|NCT05126147|DRUG|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
219169155|NCT03223961|DRUG|EPREX|60 000 U/week for at least 12 weeks
219169156|NCT05315167|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
219737545|NCT02579057|DRUG|Furosemide Injection Solution (SCP-101)|
219737546|NCT02579057|DRUG|Furosemide Injection Solution, USP|
219169157|NCT06584032|DRUG|fruquintinib|Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
219169158|NCT06584032|BIOLOGICAL|sintilimab|Sintilimab will be intravenously administrated on Day 1 every three weeks.
219169159|NCT06584032|DRUG|paclitaxel|175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
219169160|NCT06584032|DRUG|doxorubicin|60mg/m\^2 via IV infusion, on Day 1 every three weeks.
219169161|NCT05410353|BEHAVIORAL|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing \< 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
219169162|NCT05410353|BEHAVIORAL|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
219239088|NCT03276806|BEHAVIORAL|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
219239089|NCT03276806|BEHAVIORAL|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
219239090|NCT03276806|OTHER|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
219239091|NCT03276806|OTHER|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
219239092|NCT02659488|DRUG|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
219737547|NCT00934388|PROCEDURE|Pre peritoneal mesh placement|
219737548|NCT00934388|PROCEDURE|Laparoscopy|
219239093|NCT01726634|OTHER|Elastic Tapping|
219737549|NCT04426513|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
219239094|NCT02854709|BEHAVIORAL|Sleep extension|Sleep extension by 1 hour for 2 weeks
219239095|NCT05203822|DRUG|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
219239096|NCT05203822|DRUG|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
219239097|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
219239098|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
219239099|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
219239100|NCT03366233|OTHER|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
219239101|NCT03366233|OTHER|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
219239102|NCT00993590|BEHAVIORAL|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
219239103|NCT03843333|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
219239104|NCT03843333|BEHAVIORAL|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
219239105|NCT03843333|OTHER|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
219239106|NCT03843333|OTHER|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
219239107|NCT00399945|DRUG|Tobramycin|
219239108|NCT02632630|DRUG|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
219239109|NCT02632630|DIETARY_SUPPLEMENT|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
219239110|NCT02632630|DRUG|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
219239111|NCT02632630|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
219239112|NCT01345253|DRUG|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
219239113|NCT01345253|DRUG|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
219239114|NCT05819177|OTHER|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
219239115|NCT05747352|OTHER|closed-loop hybrid insulin administration|observational non-interventional study
219239116|NCT03443739|OTHER|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
219239117|NCT00306735|DRUG|Palonosetron|
219239118|NCT01573741|DRUG|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
219239119|NCT03877133|DEVICE|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
219239120|NCT03117842|OTHER|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
219239121|NCT00295100|DRUG|Tamoxifen|
219239122|NCT02018159|DRUG|menotropin|
219239123|NCT04544514|DIAGNOSTIC_TEST|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
219169163|NCT01508312|DRUG|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
219169164|NCT01508312|DRUG|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
219169165|NCT06844370|OTHER|Non-invasive ventilation|Providing ventilation support through non-invasive means
219169166|NCT04533555|GENETIC|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
219169167|NCT04533555|GENETIC|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
219169168|NCT05926804|DRUG|Lansoprazole|14 days of Lansoprazole (30 mg BID) (days 1-14)
219169169|NCT05926804|DRUG|Amoxicillin|7 days of Amoxicillin (1000 mg BID) (days 1-7)
219169170|NCT05926804|DRUG|Clarithromycin|7 days of Clarithromycin (500 mg BID) (days 8-14)
219169171|NCT05926804|DRUG|Metronidazole|7 days of Metronidazole (500 mg BID) (days 8-14)
219169172|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
219169173|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
219169174|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
219169175|NCT06845943|DRUG|HCR-188|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
219169176|NCT06845943|DRUG|Placebo|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
219169177|NCT03775096|DRUG|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
219169178|NCT03648840|BEHAVIORAL|Aversive Cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
219169179|NCT03648840|BEHAVIORAL|Neutral Cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
219169180|NCT03006913|BEHAVIORAL|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
219169181|NCT03006913|BEHAVIORAL|By phone|Patients in the phone arm will receive a scheduled call at their home.
219169182|NCT03006913|BEHAVIORAL|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
219169183|NCT04915495|DIAGNOSTIC_TEST|LuViva Advanced Cervical Scan|Multimodal hyperspectral device
219169184|NCT06225492|DRUG|DaxibotulinumtoxinA 15 units|Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band
219169185|NCT06225492|DRUG|DaxibotulinumtoxinA 20 units|Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band
219169186|NCT04381130|DRUG|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
219169187|NCT05930600|DEVICE|Ultrasonography of Internal Jugular Vein|Non invasive monitoring of fluid responsiveness
219169188|NCT05930600|DEVICE|Doppler Echocardiograhy|Non invasive monitoring of fluid responsiveness
219169189|NCT05418296|DEVICE|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
219169190|NCT04035824|DRUG|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
219169191|NCT04035824|DRUG|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
219239124|NCT00739388|DRUG|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
219169192|NCT05568134|DIAGNOSTIC_TEST|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
219169193|NCT03219697|BEHAVIORAL|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
219169194|NCT05007613|DRUG|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
219169195|NCT05007613|DRUG|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
219169196|NCT05382936|DRUG|SL-901|Patients took study medication daily, with dosage based on their assigned cohort and regimen.
219169197|NCT03175666|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219169198|NCT03175666|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
219169199|NCT03175666|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219169200|NCT03175666|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219169201|NCT03175666|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219169202|NCT03175666|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219169203|NCT03175666|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219169204|NCT03175666|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219169205|NCT03175666|DRUG|Lovaza|omega-3-acid ethyl esters)
219169206|NCT03175666|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
219169207|NCT03175666|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
219169208|NCT03175666|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
219169209|NCT03175666|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219169210|NCT03175666|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)
219169211|NCT03175666|BIOLOGICAL|GI-4000|RAS yeast vaccine
219169212|NCT03175666|BIOLOGICAL|GI-6207|CEA yeast vaccine
219169213|NCT03175666|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219169214|NCT03175666|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
219169215|NCT03143374|DRUG|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
219169216|NCT04584632|DEVICE|Efemoral Vascular Scaffold System (EVSS)|Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
219239125|NCT03896971|DRUG|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
219169217|NCT03703700|DRUG|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
219169218|NCT03703700|DRUG|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
219169219|NCT05400317|DRUG|AD-218|PO, Once daily(QD), 12weeks
219169220|NCT05400317|DRUG|AD-218A|PO, Once daily(QD), 12weeks
219169221|NCT03085004|DRUG|Ethanol|The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
219169222|NCT03085004|DRUG|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
219169223|NCT03085004|DRUG|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
219169224|NCT04236856|DEVICE|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
219239126|NCT04282200|DRUG|Ketorolac|intravenous ketorolac 30 mg every 6 hours
219239127|NCT02366455|PROCEDURE|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
219239128|NCT02366455|PROCEDURE|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
219169225|NCT06221176|BEHAVIORAL|Being Brave|Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
219169226|NCT05673304|RADIATION|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
219169227|NCT05570838|DEVICE|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
219169228|NCT05570838|DEVICE|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
219169229|NCT03323554|DEVICE|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
219169230|NCT03323554|DEVICE|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
219169231|NCT05697211|DRUG|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
219169232|NCT06273228|BEHAVIORAL|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
219169233|NCT05714397|DEVICE|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
219169234|NCT04639401|OTHER|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
219169235|NCT06105463|OTHER|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
219169236|NCT06332482|DEVICE|Implant supported screw retained prosthesis|All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
219169237|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
219169238|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
219169239|NCT06321042|DEVICE|Knee arthroplasty|Knee arthroplasty surgery with perseus orthokey alignment device
219169240|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
219169241|NCT04630262|DEVICE|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
219169242|NCT04630262|DEVICE|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
219169243|NCT03721497|DRUG|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
219169244|NCT05956288|DEVICE|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
219169245|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
219169246|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
219169247|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
219239129|NCT02497547|DRUG|Oxytocin|
219169248|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
219169249|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
219239130|NCT02497547|DRUG|Placebo|
219239131|NCT01828476|DRUG|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
219239132|NCT01828476|DRUG|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
219239133|NCT01828476|DRUG|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
219169250|NCT04807218|BEHAVIORAL|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
219169251|NCT06285409|DRUG|Carbetocin|Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
219169252|NCT06285409|DRUG|Oxytocin|Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
219169253|NCT06285409|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
219169254|NCT06285409|DRUG|Oxytocin|Increasing concentrations of oxytocin from 10-10 M to 10-5 M
219169255|NCT06285409|DRUG|Ergonovine|Increasing concentrations of ergometrine from 10-10 M to 10-5 M
219169256|NCT06285409|DRUG|Carboprost|Increasing concentrations of carboprost from 10-10 M to 10-5 M
219169257|NCT03886311|DRUG|Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]|Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
219169258|NCT03886311|DRUG|Nivolumab IV Soln 100 MG/10ML|NIVOLUMAB 240 mg IV over 30 min q 2 weeks
219169259|NCT03886311|DRUG|Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution|TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
219239134|NCT05619445|OTHER|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
219239135|NCT05619445|OTHER|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
219239136|NCT02067000|BEHAVIORAL|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
219239137|NCT04750447|DEVICE|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
219239138|NCT01767376|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
219169260|NCT05114460|DRUG|Naloxone|Intranasal Naloxone
219169261|NCT05114460|DRUG|Marijuana|Vaped Marijuana
219169262|NCT04700969|OTHER|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
219169263|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
219169264|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
219169265|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
219239139|NCT01767376|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
219239140|NCT01636700|DRUG|Tramadol 2mg/kg|2mg/kg
219169266|NCT03828994|BEHAVIORAL|Tech-PN|"* text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment"
219239141|NCT01636700|DRUG|Saline solution|saline solution- 1 dose
219239142|NCT05769361|BEHAVIORAL|UNST|Strength and balance training using different destabilizing devices
219239143|NCT05769361|BEHAVIORAL|ST|Strength and balance training over firm surfaces
219239144|NCT04387773|DRUG|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
219239145|NCT03600506|DRUG|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
219169267|NCT06130995|DRUG|Relugolix and Enzalutamide|"Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily"
219169268|NCT06494293|OTHER|Data Collection|Collection of medical data from MICU intervention file and patient medical files from participating centres
219737550|NCT05121090|BEHAVIORAL|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
219169269|NCT01195831|DRUG|Xamiol® gel|Once daily application
219169270|NCT01195831|DRUG|Calcipotriol scalp solution|Twice daily application
219169271|NCT06351150|DRUG|Angiotensin II Injection|1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.
219169272|NCT06351150|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection, not containing active ingredients.
219169273|NCT01911091|BEHAVIORAL|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
219169274|NCT05432557|PROCEDURE|external oblique intercostal plain block (EOIP)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
219169275|NCT05432557|PROCEDURE|subcostal transversus abdominis plane block (SCTAP)|The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
219169276|NCT05432557|OTHER|control group|No LA injection
219169277|NCT01857934|DRUG|cyclophosphamide|Given intravenously (IV)
219239146|NCT03600506|DRUG|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
219737551|NCT05292287|DEVICE|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
219737552|NCT02662582|DRUG|Reldesemtiv|Oral tablet
219737553|NCT02662582|DRUG|Placebo|Oral tablet
219737554|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737555|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737556|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737557|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737558|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737559|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
219737560|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
219737561|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
219737562|NCT06551961|DIETARY_SUPPLEMENT|methylcellulose|2.5 and 5 gm Methylcelllose heated to create a gel
219737563|NCT06551961|DIETARY_SUPPLEMENT|inulin|2.5 and 5 gm inulin powder dissolved in water
219737564|NCT06551961|DIETARY_SUPPLEMENT|maltodextrin|2.5 and 5gm maltodextrin dissolved in water
219737565|NCT06059248|OTHER|"the head in the sniffing position "|"Intubation was performed with the head in the  elevation  position"
219737566|NCT04135352|DRUG|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
219169278|NCT01857934|DRUG|topotecan|Given IV
219169279|NCT01857934|BIOLOGICAL|hu14.18K322A|Given IV
219169280|NCT01857934|PROCEDURE|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
219169281|NCT01857934|PROCEDURE|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
219169282|NCT01857934|DRUG|cisplatin|Given IV
219169283|NCT01857934|DRUG|etoposide|Given IV
219169284|NCT01857934|DRUG|doxorubicin|Given IV
219169285|NCT01857934|DRUG|vincristine|Given IV
219169286|NCT01857934|DRUG|busulfan|Given IV
219169287|NCT01857934|DRUG|melphalan|Given IV
219169288|NCT01857934|BIOLOGICAL|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
219169289|NCT01857934|BIOLOGICAL|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
219169290|NCT01857934|RADIATION|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
219169291|NCT01857934|BIOLOGICAL|GM-CSF|Given subcutaneously (SQ)
219169292|NCT01857934|BIOLOGICAL|G-CSF|Given subcutaneously (SQ)
219169293|NCT01857934|DRUG|mesna|Given IV
219169294|NCT01857934|DRUG|levetiracetam|Given IV
219169295|NCT01857934|BIOLOGICAL|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
219737567|NCT04135352|BIOLOGICAL|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
219737568|NCT06640400|DEVICE|Cardiovascular ultrasound|Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
219737569|NCT06639945|DEVICE|transcranial MR-guided focused ultrasound|MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
219737570|NCT06639321|DEVICE|Percutaneous Ventricular Assist System|Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
219737571|NCT06639321|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO provides intraoperative circulatory support during high-risk PCI.
219737572|NCT00511199|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
219737573|NCT00511199|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
219737574|NCT02449447|BEHAVIORAL|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
219737575|NCT02449447|OTHER|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
219737576|NCT05671887|PROCEDURE|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
219737577|NCT00048308|DRUG|pexelizumab|
219737578|NCT04601493|BEHAVIORAL|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
219737579|NCT04601493|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
219737580|NCT03255200|DEVICE|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
219737581|NCT00790660|DRUG|ASP1941|Oral
219737582|NCT00790660|DRUG|Placebo|Oral
219737583|NCT04281576|DEVICE|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
219169296|NCT01857934|DRUG|Isotretinoin|Given orally (PO)
219169297|NCT01857934|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219169298|NCT02094365|DRUG|ALS-008176|
219169299|NCT02094365|DRUG|vehicle|
219169300|NCT05883111|DIAGNOSTIC_TEST|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
219169301|NCT05272618|DIAGNOSTIC_TEST|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
219169302|NCT04165941|BIOLOGICAL|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
219169303|NCT05155319|BIOLOGICAL|UFluA 20 µg each antigen/dose|Low dose
219169304|NCT05155319|BIOLOGICAL|UFluA 60 µg each antigen/dose|High Dose
219169305|NCT05155319|BIOLOGICAL|Placebo|Placebo
219169306|NCT06340932|DEVICE|Iovera|Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration
219169307|NCT06340932|DRUG|Celecoxib|200mg BID
219169308|NCT06340932|DRUG|Acetaminophen|1000mg q8h
219169309|NCT06340932|DRUG|Oxycodone|As needed
219169310|NCT06340932|DRUG|Tramadol|As needed
219169311|NCT06340932|DRUG|Bupivacaine Hydrochloride|20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK
219169312|NCT06340932|DRUG|Acetaminophen 500Mg Cap|500mg q6h prn
219169313|NCT03111290|DEVICE|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
219169314|NCT03111290|DEVICE|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
219169315|NCT04975880|DEVICE|SC+ Hemodialysis System|Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
219737584|NCT04281576|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
219737585|NCT04281576|DRUG|Capecitabine|Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
219737586|NCT04281576|DRUG|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
219737587|NCT04834388|DRUG|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
219737588|NCT06510231|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
219737589|NCT06576570|BEHAVIORAL|Education presentation of surgical ergonomics|During an individual meeting with participant, a brief presentation will be supplied for review.
219169316|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
219169317|NCT03984695|BEHAVIORAL|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
219169318|NCT04638998|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|MRSI is a non invasive imaging technique used to detect neuroinflammation.
219169319|NCT04638998|PROCEDURE|Blood draw|Blood will be drawn to assess systemic inflammation in Gulf War verterans.
219169320|NCT03692676|DEVICE|Spiriva Respimat|soft-mist inhaler
219169321|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
219169322|NCT04491058|DIAGNOSTIC_TEST|SSCT thickness measurement|Thickness measurement with ultrasound
219169323|NCT02218996|OTHER|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
219169324|NCT05997589|BEHAVIORAL|Behavioral Intervention|Receive educational materials
219169325|NCT05997589|OTHER|Educational Intervention|Attend financial health educational program
219737590|NCT06576570|BEHAVIORAL|Summary of Ergonomic Measurement System|Participant will view a video of their movements with a visual guideline highlighting high-risk angles and movements.
219737591|NCT00005021|BIOLOGICAL|filgrastim|
219737592|NCT00005021|DRUG|carboplatin|
219737593|NCT00005021|DRUG|paclitaxel|
219737594|NCT00005021|DRUG|topotecan hydrochloride|
219737595|NCT03081923|DRUG|Durvalumab|anti-PD-L1 mono therapy
219737596|NCT03081923|DRUG|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
219737597|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
219169326|NCT05997589|OTHER|Questionnaire Administration|Ancillary studies
219169327|NCT04044937|DRUG|F-18 Fluoroethyltyrosine (FET)|Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
219169328|NCT04044937|PROCEDURE|Positron Emission Tomography (PET)|All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
219169329|NCT05164367|DRUG|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
219169330|NCT06241950|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219169331|NCT06241950|BIOLOGICAL|imlifidase|IV infusion of Imlifidase
219169332|NCT06786975|DEVICE|Silver Diamine Fluoride|"Tooth will be isolated with cotton rolls, the oral cavity will be dried with small cotton balls and the gingiva around the tooth, and surrounding structures, will be protected with vaseline. Then the silver diamine fluoride solution will be applied to cavitated caries lesions with a micro applicator for one minute approximately. If necessary the solution excess should be removed with a gauze.~Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears."
219169333|NCT06786975|PROCEDURE|Atraumatic Restorative Treatment|Participants will be treated with Atraumatic Restorative Treatment (ART) technique. Glass ionomer will be used for cavity filling (Ketac MolarTM, 3M ESPETM) according to manufacter specifications and will be applied with a spatula, followed by finger pressure using vaseline for a few seconds; for occluso-proximal cavities, a matrix band will be used. The restoration will be protected with vaseline and then the occlusion will be checked with articular paper after the initial adjustment (approximately 5 minutes). Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
219169334|NCT06783270|BIOLOGICAL|TIL therapy|Compared to traditional TIL-therapy, this study will include silencing of the PD-1 coding gene in the TILs using non-viral CRISPR-Cas9 prior to the rapid expansion protocol.
219169335|NCT06784960|BEHAVIORAL|Messages|We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.
219169336|NCT06786845|OTHER|Treatment lege artis|Adequate treatment of sleep disorders at Sleep clinic
219169337|NCT05595629|BEHAVIORAL|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
219169338|NCT05595629|BEHAVIORAL|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
219169339|NCT04143516|DIAGNOSTIC_TEST|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
219169340|NCT04143516|PROCEDURE|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
219169341|NCT04143516|DIAGNOSTIC_TEST|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
219169342|NCT04244656|BIOLOGICAL|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
219169343|NCT05042388|BEHAVIORAL|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
219169344|NCT05042388|BEHAVIORAL|Treatment-As-Usual|Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
219169345|NCT05220033|OTHER|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
219169346|NCT05220033|OTHER|survey administration|Ancillary studies
219169347|NCT05380856|DEVICE|Turning ON the neuromodulator|IPG on
219169348|NCT05380856|DEVICE|Turning OFF the neuromodulator|IPG OFF
219239147|NCT04673305|OTHER|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
219737598|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
219169349|NCT05722067|OTHER|calcium ionophore|The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
219239148|NCT03508882|DRUG|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
219239149|NCT03508882|DRUG|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
219169350|NCT05303714|COMBINATION_PRODUCT|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
219169351|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
219239150|NCT04175834|DRUG|cetrizine|prophylaxis
219239151|NCT04175834|DRUG|diphenhydramine|prophylaxis
219239152|NCT03030053|DIETARY_SUPPLEMENT|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
219239153|NCT03030053|DIETARY_SUPPLEMENT|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
219239154|NCT04283058|DRUG|Ketamine|d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
219239155|NCT05464992|OTHER|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
219239156|NCT03435939|DRUG|Losartan|50 mg/day for 7 days followed by 100 mg/day for 12 weeks
219239157|NCT05729152|OTHER|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
219239158|NCT02577848|DRUG|GLP-1|GLP-1 were taken daily for 7 days
219239159|NCT02577848|DRUG|Placebo|Placebo were taken daily for 7 days
219239160|NCT00946088|DRUG|Progesterone|Progesterone 400 mg per vagina qhs.
219239161|NCT00946088|DRUG|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
219239162|NCT01642030|DRUG|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219239163|NCT01642030|DRUG|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219239164|NCT01642030|DRUG|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
219239165|NCT00999271|OTHER|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes"
219239166|NCT00711776|DRUG|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
219169352|NCT05374837|BEHAVIORAL|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
219169353|NCT04032418|BIOLOGICAL|Pembrolizumab|Given IV
219169354|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
219169355|NCT03149315|DRUG|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
219169356|NCT05559541|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
219169357|NCT05559541|DRUG|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
219169358|NCT00958516|DRUG|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
219169359|NCT04600323|DRUG|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
219169360|NCT04600323|DRUG|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
219169361|NCT05440383|DRUG|KLH-2109|Oral administration
219169362|NCT05440383|DRUG|Leuprorelin|Subcutaneous administration
219169363|NCT06329297|DEVICE|CGM monitor|blood glucose sensor used to monitor interstitial glucose
219169364|NCT06310070|DEVICE|3D Printed Personalized Ostomy Appliance|Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
219169365|NCT05654519|DRUG|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
219169366|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
219169367|NCT06065384|OTHER|experimental group: intensive motor training|Intervention group: receive an extra 6 hours of motor training each week (distributed over the week) for 8 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
219169368|NCT06065384|OTHER|usual care|usual rehabilitation
219239167|NCT00711776|DRUG|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
219239168|NCT06247878|DEVICE|Skiin underwear chest band|Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
219239169|NCT00070161|DIETARY_SUPPLEMENT|EGb761|
219239170|NCT00070161|DRUG|donepezil hydrochloride|
219239171|NCT00070161|PROCEDURE|cognitive assessment|
219239172|NCT00197262|DRUG|GW685698X Aqueous Nasal Spray|
219239173|NCT05043298|DRUG|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
219239174|NCT05043298|DRUG|IBI 360 Injection Sintilimab|IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
219239175|NCT01388621|DRUG|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
219239176|NCT01388621|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
219239177|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
219239178|NCT01388621|DRUG|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
219239179|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
219737599|NCT02739828|BIOLOGICAL|Adalimumab|Adalimumab
219737600|NCT03031730|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219737601|NCT03031730|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219737602|NCT03031730|DRUG|Carfilzomib|Given IV
219737603|NCT03031730|DRUG|Dexamethasone|Given PO
219737604|NCT03031730|DRUG|Dexamethasone Sodium Phosphate|Given IV
219737605|NCT03031730|PROCEDURE|Echocardiography|Undergo echocardiography
219737606|NCT03031730|DRUG|Lenalidomide|Given PO
219737607|NCT03031730|DRUG|Navtemadlin|Given PO
219169369|NCT03841669|BEHAVIORAL|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
219169370|NCT03841669|BEHAVIORAL|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
219169371|NCT05406921|BEHAVIORAL|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
219169372|NCT05414812|BEHAVIORAL|Multi-component oncofertility care intervention|"The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
219169373|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
219169374|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
219169375|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
219169376|NCT05209100|PROCEDURE|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
219169377|NCT06233838|DEVICE|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
219169378|NCT06272994|DIAGNOSTIC_TEST|MRSA Nasal Swab PCR|For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
219169379|NCT04299009|DEVICE|Bright light therapy glasses|Bright light therapy delivered through glasses
219169380|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
219169381|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
219169382|NCT06154408|DIETARY_SUPPLEMENT|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
219169383|NCT06154408|DIETARY_SUPPLEMENT|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
219169384|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
219169385|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
219169386|NCT06272630|DRUG|DWJ1464|DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
219169387|NCT06272630|DRUG|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
219169388|NCT04631276|DRUG|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
219737608|NCT01953354|BIOLOGICAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
219737609|NCT01953354|BIOLOGICAL|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
219737610|NCT03951415|DRUG|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
219737611|NCT03178890|DEVICE|OHMG|Device will be implanted in all enrolled patients.
219737612|NCT01392495|DRUG|Imatinib|200 mg or 400 mg qd
219737613|NCT02167685|DRUG|CMX001|
219737614|NCT03263390|PROCEDURE|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
219737615|NCT03263390|DRUG|Anti Obesity Drugs|Response to FDA approved anti obesity medications
219737616|NCT01570192|DRUG|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
219737617|NCT01570192|DRUG|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
219169389|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
219169390|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
219169391|NCT04733495|OTHER|Counseling|Receive group-based behavioral counseling
219169392|NCT04733495|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary counseling
219169393|NCT04733495|OTHER|Quality-of-Life Assessment|Ancillary studies
219169394|NCT04733495|OTHER|Questionnaire Administration|Ancillary studies
219169395|NCT04733495|OTHER|Resistance Training|Undergo personalized resistance exercises
219169396|NCT05792735|DRUG|Cadonilimab Injection|Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.
219169397|NCT05792735|RADIATION|Short-course radiotherapy|Preoperative short-course radiotherapy (5x5 Gy)
219169398|NCT05792735|DRUG|Consolidation chemotherapy|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
219169399|NCT06032845|DRUG|Tislelizumab|a PD-1 immune check inhibitor
219169400|NCT06032845|DRUG|Lenvatinib|Lenvatinib capsules
219169401|NCT06032845|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
219169402|NCT01567800|OTHER|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
219169403|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
219169404|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
219737618|NCT01570192|DRUG|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
219737619|NCT01570192|DRUG|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
219737620|NCT01570192|DEVICE|tobramycin nebulization|tobramycin nebulization 600mg/day
219737621|NCT02560792|BEHAVIORAL|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
219737622|NCT02560792|BEHAVIORAL|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
219737623|NCT02560792|BEHAVIORAL|Control Condition|Participants receive no information about affective response
219737624|NCT00806026|DRUG|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
219169405|NCT05942586|DIETARY_SUPPLEMENT|Probiotic capsule (L. reuteri PB-W1™), Placebo sachet|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
219169406|NCT05942586|DIETARY_SUPPLEMENT|Prebiotic sachet (Prebiotic Blend), Placebo capsule|Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
219169407|NCT05942586|COMBINATION_PRODUCT|Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
219169408|NCT05942586|DIETARY_SUPPLEMENT|Placebo sachet, Placebo capsule|Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
219169409|NCT05570786|DRUG|Gestrinone|The intradermal gestrinone/placebo pellet will be inserted on the same day as the levonorgestrel intrauterine hormonal device (Kyleena®)
219239180|NCT01388621|DRUG|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
219737625|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
219169410|NCT05570786|DRUG|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol)
219169411|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
219169412|NCT05380570|RADIATION|Occupational radiation exposure|Ionizing radiation in workplaces
219239181|NCT04883541|BEHAVIORAL|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
219239182|NCT04883541|BEHAVIORAL|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
219239183|NCT00608387|BEHAVIORAL|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
219239184|NCT03237741|DRUG|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
219239185|NCT03237741|DRUG|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
219239186|NCT03237741|DRUG|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
219239187|NCT02841085|GENETIC|Genetic sample|Blood sample or saliva collection
219239188|NCT03265262|DIAGNOSTIC_TEST|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
219239189|NCT03948815|OTHER|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
219239190|NCT02067455|OTHER|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
219239191|NCT03456089|DIAGNOSTIC_TEST|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
219239192|NCT03282877|BEHAVIORAL|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
219239193|NCT00586742|PROCEDURE|labral repair|labral repair with suture anchors
219169413|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
219169414|NCT06571903|OTHER|Teaching from videos|Teaching from videos for independent study
219169415|NCT04092387|OTHER|Varying the nicotine content of cigarettes|1\) Altering the nicotine content of the tobacco research cigarettes
219169416|NCT04092387|OTHER|E-Cigarettes|Comparing effects of combining RC2 with EC 1 versus EC2
219169417|NCT06080178|DRUG|Plasma-lyte (static group)|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
219239194|NCT00586742|PROCEDURE|biceps tenodesis|biceps tenodesis with suture anchor
219239195|NCT00586742|PROCEDURE|diagnostic arthroscopy|diagnostic arthroscopy
219239196|NCT06194318|BIOLOGICAL|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
219239197|NCT06194318|BIOLOGICAL|placebo|placebo
219239198|NCT06194318|BIOLOGICAL|candidate vaccine, SCB-1019T|The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain. Antigens are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
219239199|NCT06194318|BIOLOGICAL|AREXVY|AREXVY is a FDA-approved respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Developed by GSK, it targets the prefusion F glycoprotein to protect against lower respiratory tract disease caused by RSV.
219239200|NCT05633849|DIETARY_SUPPLEMENT|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
219239201|NCT05633849|DIETARY_SUPPLEMENT|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
219169418|NCT06080178|DRUG|Norepinephrine (static group)|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
219169419|NCT06080178|DRUG|Plasma-lyte (dynamic group)|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
219169420|NCT06080178|DRUG|Norepinephrine (dynamic group)|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
219169421|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
219169422|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
219169423|NCT04564495|BEHAVIORAL|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
219239202|NCT06315621|DEVICE|Scanning using intraoral scanner with markers|Scanning different types of nasal defects using intraoral scanner with skin markers.
219239203|NCT06315621|DEVICE|Scanning using intraoral scanner without markers|Scanning different types of nasal defects using intraoral scanner without skin markers.
219239204|NCT06315621|DEVICE|Physical Impression|Recording different types of nasal defects using physical impressions
219239205|NCT02755948|BIOLOGICAL|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
219239206|NCT02755948|BIOLOGICAL|Influenza A/California/04/2009-likw (H1N1)|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
219169424|NCT03457675|DEVICE|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
219169425|NCT03457675|OTHER|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
219169426|NCT06495632|DRUG|Motrin and narcotic|See described earlier
219169427|NCT05664074|DRUG|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
219169428|NCT05664074|DRUG|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
219169429|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
219169430|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
219169431|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
219169432|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
219169433|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
219169434|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
219169435|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
219169436|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
219169437|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
219169438|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
219169439|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
219169440|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
219169441|NCT06354543|DEVICE|Cemented joint arthroplasty|Joint replacement with cemented prosthetic components
219169442|NCT05938712|DRUG|Dapagliflozin 10 MG|Semaglutide subcutaneous once weekly for 12 weeks.
219169443|NCT05938712|DRUG|Semaglutide, 1.0 mg/mL|Dapagliflozin oral once daily for 12 weeks.
219169444|NCT04864912|OTHER|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
219169445|NCT04675541|BIOLOGICAL|Afstyla®|Solution for injection
219169446|NCT06385834|OTHER|Morning aerobic exercise|Patients were randomly assigned to morning aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
219169447|NCT06385834|OTHER|Evening aerobic exercise|Patients were randomly assigned to evening aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
219169448|NCT05890807|DIAGNOSTIC_TEST|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
219169449|NCT01765140|DRUG|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
219169450|NCT05737030|DRUG|L-ornithine L-aspartate|Amino acid combination
219169451|NCT02312960|OTHER|Data Collection|No study treatment will be provided in this long term follow up study.
219169452|NCT06288828|BEHAVIORAL|Aerobic exercise + Nutrition consultant|"Participants in the intervention group will engage in 150 minutes of moderate aerobic exercise weekly for 16 weeks, primarily brisk walking or jogging.~For the initial four weeks, they will visit the hospital weekly for guidance and participate in home-based exercise following a protocol totaling 150 minutes of moderate aerobic exercise in the form of brisk walking or jogging. Healthcare professionals will help adjust exercise intensity based on heart rate (60-80% of maximum) and perceived exertion (RPE 12-15), while monitoring vital signs and adverse events.~After, they will transition to a home exercise program for twelve weeks, recording exercise details in a logbook. Weekly follow-up calls will ensure adherence and monitor adverse events.~They will be provided with nutritional recommendations by a dietitian, the same as the control group."
219169453|NCT06288828|BEHAVIORAL|Nutrition consultant|"Participants will maintain their physical activity at the same level as before enrolling in the study.~However, they will be provided with nutritional recommendations by a dietitian, which include 1.2 grams of protein per kilogram of ideal body weight daily and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day. To assess adherence and make necessary adjustments, participants will complete a 3-day food record at the beginning of the study, at week 8, and at the end of the study at week 16. If participants encounter difficulties adhering to the recommended nutritional intake, the dietitian will provide additional guidance to help them meet the requirements."
219169454|NCT06257758|DRUG|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
219169455|NCT00302315|OTHER|Physiotherapy|Thoracic expansion exercises and huffing technique Lower limb exercises TENS with frequency of 120 Hz and pulse width of 60 μs was used for 30 min in every session Connective tissue manipulation (CTM) to the sacral and lumbar regions, Education (proper use of body mechanics during baby caring and daily activities; improving posture; anatomy and functions of the pelvic floor and Knack maneouvre)
219239207|NCT02755948|BIOLOGICAL|Influenza A/Belgium/4217/2015 (H3N2)|Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
219737626|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
219169456|NCT04508192|OTHER|Exercise|Both interventions are simple strength exercises without technical equipment
219169457|NCT04883333|DRUG|LEO 153339|LEO 153339
219169458|NCT04883333|DRUG|Placebo|Placebo
219169459|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
219169460|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
219239208|NCT01488240|PROCEDURE|pulsed dye laser|laser energy
219737627|NCT00806026|DRUG|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
219737628|NCT00806026|DRUG|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
219737629|NCT00806026|DRUG|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
219737630|NCT00635466|PROCEDURE|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
219737631|NCT03180138|BEHAVIORAL|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
219737632|NCT03180138|BEHAVIORAL|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
219737633|NCT06492720|DEVICE|Focused ultrasound (FUS) treatment|The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
219737634|NCT02557919|OTHER|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
219737635|NCT02557919|OTHER|Usual Best Practice|.5 day training on tobacco control and emerging products.
219737636|NCT02776176|PROCEDURE|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
219737637|NCT02776176|PROCEDURE|Traditional Program|traditional standard protocol
219737638|NCT02349828|DRUG|Acyclovir|
219737639|NCT02375256|BIOLOGICAL|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
219737640|NCT02375256|BIOLOGICAL|Placebo|Identical buffer solution in which AERAS-402 is formulated.
219737641|NCT02375256|BIOLOGICAL|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
219737642|NCT04928131|OTHER|No intervention - retrospective observational cohort study|
219239209|NCT01839032|DRUG|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
219239210|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide|
219737643|NCT02100644|DRUG|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
219737644|NCT00000853|BIOLOGICAL|rgp120/HIV-1MN|
219737645|NCT00728182|DRUG|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
219169461|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
219169462|NCT04895358|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
219169463|NCT04895358|DRUG|paclitaxel|IV infusion
219169464|NCT04895358|DRUG|nab-paclitaxel|IV infusion
219169465|NCT04895358|DRUG|liposomal doxorubicin|IV infusion
219169466|NCT04895358|DRUG|capecitabine|oral administration
219169467|NCT04895358|DRUG|normal saline|IV infusion
219169468|NCT04895358|DRUG|dextrose|IV infusion
219169469|NCT06007976|DEVICE|Erchonia® Trident|Low-level laser therapy
219169470|NCT06473688|PROCEDURE|Cholecystectomy|Robotic-assisted and laparoscopic cholecystectomy
219169471|NCT02713607|DRUG|Doxycycline|Given doxycycline to acne subjects
219169472|NCT04843384|OTHER|Reiki|Reiki
219239211|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide + Imiquimod|
219169473|NCT04843384|OTHER|Sham reiki|sham Reiki
219169474|NCT05099315|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
219169475|NCT04965753|DRUG|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
219169476|NCT06472297|DEVICE|The continuous glucose monitoring system|CGM device worn on back of the arm and glucose readings are shown on the participant's smartphone as a continuous data stream.
219169477|NCT05789212|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A-mindfulness, B-yoga, and C-guided walking.
219169478|NCT05789212|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A-mindfulness, B-yoga, and C-guided walking.
219169479|NCT05687539|DIETARY_SUPPLEMENT|Mastiha water|10ml of mastiha water before every meal for one month
219169480|NCT05687539|DIETARY_SUPPLEMENT|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
219169481|NCT06386757|PROCEDURE|Combined Video Laryngoscopy (VL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.
219169482|NCT06386757|PROCEDURE|Combined Direct Laryngoscopy (DL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation
219239212|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Imiquimod|
219239213|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 intra nodal injection|
219239214|NCT06361212|DRUG|Ethoximod|Ethoximod is a S1P1 modulator.
219239215|NCT04528524|OTHER|Questionnaire|QoR-15Dt
219239216|NCT05437328|BIOLOGICAL|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
219239217|NCT00224913|PROCEDURE|Neuromuscular electrical stimulation|
219239218|NCT00224913|PROCEDURE|Voluntary exercise|
219362246|NCT05656209|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
219239219|NCT05910879|BEHAVIORAL|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, …a time when you felt successful and proud of yourself. …You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will… a)…think about things I value about myself, b)…remember things that I have succeeded in, c) …think about what I stand for, or d)…think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
219239220|NCT05910879|BEHAVIORAL|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
219239221|NCT01567150|DEVICE|Novel Dressing|Topical wound dressing
219239222|NCT03420040|DEVICE|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
219239223|NCT03420040|DEVICE|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
219239224|NCT03836885|DRUG|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
219239225|NCT03836885|DRUG|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
219239226|NCT02788435|BEHAVIORAL|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
219239227|NCT04775732|BIOLOGICAL|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
219239228|NCT03603691|DIAGNOSTIC_TEST|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
219239229|NCT03603691|DIAGNOSTIC_TEST|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
219239230|NCT03603691|DIAGNOSTIC_TEST|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
219239231|NCT03603691|DIAGNOSTIC_TEST|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
219169483|NCT04961580|DRUG|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
219169484|NCT06426641|DEVICE|Polyethylene|There is no intervention
219169485|NCT05458011|DRUG|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219169486|NCT05458011|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
219239232|NCT03603691|DIAGNOSTIC_TEST|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
219239233|NCT03603691|DIAGNOSTIC_TEST|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
219239234|NCT04386538|BEHAVIORAL|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
219239235|NCT04386538|BEHAVIORAL|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
219239236|NCT02043652|DRUG|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
219239237|NCT02043652|DRUG|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
219362247|NCT06099938|DRUG|sufentanil, ropivacaine|The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
219737646|NCT00728182|DRUG|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
219169487|NCT06528457|DRUG|ISLA101|ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
219169488|NCT06528457|DRUG|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.
219169489|NCT06528457|OTHER|Placebo|Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
219169490|NCT06045078|OTHER|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
219169491|NCT06045078|OTHER|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
219169492|NCT05106257|BEHAVIORAL|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
219169493|NCT05106257|BEHAVIORAL|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
219169494|NCT05106257|BEHAVIORAL|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
219169495|NCT05106257|BEHAVIORAL|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
219169496|NCT05106257|BEHAVIORAL|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
219169497|NCT04461821|DIAGNOSTIC_TEST|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
219169498|NCT04461821|DIAGNOSTIC_TEST|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
219169499|NCT04461821|DIAGNOSTIC_TEST|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
219169500|NCT04461821|DIAGNOSTIC_TEST|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
219169501|NCT04461821|DIAGNOSTIC_TEST|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
219362248|NCT04319900|DRUG|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
219737647|NCT02236767|DEVICE|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
219737648|NCT01513928|DRUG|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
219737649|NCT01513928|DRUG|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
219737650|NCT01513928|DRUG|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
219737651|NCT01898091|DRUG|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
219737652|NCT01898091|DRUG|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
219737653|NCT05129384|DIETARY_SUPPLEMENT|B. infantis EVC001 or Lactose Placebo|Infant probiotic
219737654|NCT01187875|DIETARY_SUPPLEMENT|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
219737655|NCT01187875|DIETARY_SUPPLEMENT|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
219737656|NCT01187875|DIETARY_SUPPLEMENT|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
219737657|NCT01187875|DIETARY_SUPPLEMENT|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
219169502|NCT06278454|DRUG|NRT6008 Injection + Systematic chemotherapy|"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and selected tumor average absorbed dose."
219169503|NCT05274750|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
219169504|NCT05274750|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
219169505|NCT03636230|DEVICE|Remote Monitoring|Remote Monitoring only + VIRTUES
219169506|NCT03636230|OTHER|Standard of care|In-Clinic visits only
219169507|NCT05410743|DRUG|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
219169508|NCT05410743|DRUG|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.33GBq （90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
219169509|NCT05410743|DRUG|177Lu-LNC1010 3|The patients were intravenously injected with single dose 4.99GBq (135 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
219169510|NCT05410743|DRUG|177Lu-LNC1010 4|Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
219169511|NCT05862688|OTHER|antimicrobial therapy|antimicrobial therapy
219169512|NCT00214721|DRUG|Experimental Peritoneal Dialysis Solution|
219169513|NCT06038630|DRUG|Hyperpolarized Xe129|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
219169514|NCT06038630|OTHER|Oxygen Administration|Oxygen administration
219169515|NCT04251806|DIAGNOSTIC_TEST|neonatal polysomnography|This procedure will allow the detection of sleep-disordered breathing in the neonatal period.
219169516|NCT04251806|DIAGNOSTIC_TEST|2-year Bayley Exam|This procedure will evaluate neurodevelopmental outcomes.
219169517|NCT04251806|DIAGNOSTIC_TEST|2-year polysomnography|This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
219169518|NCT04660435|DIAGNOSTIC_TEST|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
219169519|NCT01823562|DRUG|lyophilized black raspberry confection|Given PO
219169520|NCT01823562|OTHER|laboratory biomarker analysis|Correlative studies
219169521|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low polyphenol diet
219169522|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low ellagitannin diet
219169523|NCT01823562|PROCEDURE|quality-of-life assessment|Ancillary studies
219169524|NCT01823562|OTHER|questionnaire administration|Ancillary studies
219169525|NCT06163482|OTHER|Mixed meal|Each individual will ingest 5 mL/kg of Boost energy drink.
219169526|NCT06289049|OTHER|Experimental|"Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12."
219169527|NCT04936191|DEVICE|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
219169528|NCT05839548|DRUG|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
219169529|NCT05839548|DRUG|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
219169530|NCT03206710|OTHER|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
219169531|NCT03437005|DRUG|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
219169532|NCT03437005|DRUG|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
219169533|NCT06202053|PROCEDURE|Type of surgical incision|"The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest."
219169534|NCT04193787|OTHER|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
219169535|NCT05690633|DEVICE|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
219737658|NCT03830411|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
219169536|NCT06237179|BEHAVIORAL|Exercise Training Intervention|5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
219169537|NCT06237179|BEHAVIORAL|Healthy Living Education|During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
219169538|NCT06574191|DRUG|Topical Diclofenac gel 1%|Topical NSAID
219169539|NCT02634645|PROCEDURE|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
219169540|NCT02634645|PROCEDURE|Esophagectomy|The esophagus is surgically removed
219169541|NCT02634645|DRUG|Chemotherapy|Chemical substances are used to treat cancer
219169542|NCT02634645|RADIATION|Radiation|Cancer cells are destroyed by radiation therapy.
219169543|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
219169544|NCT00929084|OTHER|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
219169545|NCT04288375|RADIATION|Intensity-modulated radiation therapy (IMRT)|The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
219169546|NCT05544084|BEHAVIORAL|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
219169547|NCT05695989|DEVICE|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
219169548|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted
219169549|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted.
219169550|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
219169551|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
219169552|NCT06311656|DRUG|Placebo|Administered orally.
219169553|NCT02384317|DRUG|CCX168|CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
219362249|NCT04319900|DRUG|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
219737659|NCT03830411|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
219737660|NCT03830411|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
219737661|NCT02831036|OTHER|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
219737662|NCT02831036|OTHER|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
219737663|NCT02831036|OTHER|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
219737664|NCT01573793|BEHAVIORAL|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
219737665|NCT01573793|BEHAVIORAL|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
219737666|NCT03531567|BEHAVIORAL|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
219737667|NCT03531567|BEHAVIORAL|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
219737668|NCT04381559|BEHAVIORAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
219169554|NCT05463341|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
219169555|NCT04140708|BEHAVIORAL|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
219169556|NCT03667716|DRUG|COM701|COM701 monotherapy.
219169557|NCT03667716|DRUG|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
219169558|NCT03817021|BEHAVIORAL|ECE Provider|Provide online training for Head Start educators
219169559|NCT03817021|BEHAVIORAL|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
219169560|NCT03817021|BEHAVIORAL|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
219169561|NCT06394037|PROCEDURE|Active surveillance|Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
219169562|NCT04160546|DRUG|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
219169563|NCT04160546|DRUG|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
219169564|NCT03088852|DRUG|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
219169565|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
219169566|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
219169567|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
219169568|NCT06289374|OTHER|Biosample collection|Collection of saliva, urine, blood, breath and quality of life questionnaires.
219239238|NCT04050514|DEVICE|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
219169569|NCT06628895|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
219169570|NCT05939934|DEVICE|Mandibular advancement device treatment|a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
219169571|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
219169572|NCT06399094|OTHER|Lung sound recordings|The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
219169573|NCT05355298|DRUG|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
219169574|NCT05355298|DRUG|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
219169575|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
219239239|NCT00234585|DEVICE|Renal Artery Stent with Protective Device/Drug|
219239240|NCT02073214|OTHER|Probiotic|Standard treatment plus probiotic
219239241|NCT02073214|OTHER|Placebo|Standard treatment plus placebo
219169576|NCT02342782|DRUG|Carmustine|Given IV
219169577|NCT02342782|DRUG|Etoposide|Given IV
219169578|NCT02342782|DRUG|Cytarabine|Given IV
219169579|NCT02342782|DRUG|Melphalan|Given IV
219169580|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
219169581|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
219737669|NCT04381559|BEHAVIORAL|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
219737670|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
219169582|NCT02342782|OTHER|Pharmacological Study|Correlative studies
219169583|NCT05479643|DEVICE|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
219169584|NCT02900924|DEVICE|BioMimics 3D Stent|
219169585|NCT03531463|PROCEDURE|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
219169586|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
219169587|NCT05641948|OTHER|MRI scan|Participants will undergo brain MRI scan at 3 intervals
219169588|NCT04240990|OTHER|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~* TB contact history~* Suggestive TB symptoms in the previous 4 weeks~* Physical examination~* Clinical, anthropometric and biochemical assessment of malnutrition~* Clinical assessment for other non-dietary causes of malnutrition~* Digitalized CXR~* Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~* Mycobacterial culture performed on two GAs~* Abdominal ultrasonography~* QuantiFERON®-TB Gold IGRA~* Monocyte-to-Lymphocyte Ratio (MLR)~* C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
219169589|NCT06501170|OTHER|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes
219169590|NCT06018987|OTHER|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
219169591|NCT06018987|DEVICE|HAC 20L|Subdermal Injections
219169592|NCT05081596|BEHAVIORAL|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
219169593|NCT03652428|DRUG|Gemcitabine|see arm description
219169594|NCT03652428|RADIATION|Hypofractionated Ablative Proton Therapy|see arm description
219169595|NCT02328872|DEVICE|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
219169596|NCT02328872|DEVICE|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
219169597|NCT05581992|DRUG|AMG 510|Oral Tablet
219169598|NCT05581992|DRUG|Omeprazole|Capsule
219169599|NCT05938283|DEVICE|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
219169600|NCT06262334|BEHAVIORAL|The Fade to Fitness Program|The Fade to Fitness Program is a group-based and barbershop-based behavioral intervention to improve health-related quality of life among African American men. The program is unique because it is culturally targeted and individually tailored. The culturally targeted content was developed following barbershop-based focus groups. The Fade to Fitness Program targets four behaviors strongly linked to health-related quality of life among African American men - physical activity, healthy eating, stress management, and depression management. During the group-based portion of the program, Motivational Interviewing is used by the facilitator as a conversational approach to enhance participants\&#39; motivation and commitment towards positive behavior change. The goal is to foster intrinsic motivation among participants to engage in these behaviors. It is individually tailored by encouraging participants to identify personal values and linking them to health promoting behaviors.
219169601|NCT06224517|OTHER|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
219169602|NCT04950192|DEVICE|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
219169603|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
219169604|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
219169605|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
219169606|NCT04705441|BEHAVIORAL|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
219169607|NCT06798142|PROCEDURE|extracorporeal treatment|Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).
219169608|NCT06052150|PROCEDURE|Dental exam and periodontal cleaning if needed|Dental exam and periodontal cleaning if needed
219169609|NCT06170385|BEHAVIORAL|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
219169610|NCT01086527|DRUG|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
219169611|NCT05549037|DRUG|Pembrolizumab, Sintilimab|One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
219169612|NCT06798493|OTHER|Complex Regional Pain Syndrome (CRPS) Severity Score - Self Report|Self-report tool in a questionnaire format to capture CPRS Severity Score.
219169613|NCT06799507|BEHAVIORAL|Interventions Based on Mindfulness|Affirmation, Relaxation, Mindfulness, Meditation, Healthy Lifestyle, Quality Life
219169614|NCT06799507|OTHER|Routine clinical procedure|Routine clinical procedure
219169615|NCT06163157|OTHER|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
219169616|NCT03972813|BEHAVIORAL|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
219169617|NCT03972813|BEHAVIORAL|Information about STDs|Caregivers learn that HPV is an STD.
219169618|NCT03972813|BEHAVIORAL|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
219169619|NCT03972813|BEHAVIORAL|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
219169620|NCT03972813|BEHAVIORAL|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
219169621|NCT03972813|BEHAVIORAL|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
219169622|NCT03972813|BEHAVIORAL|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
219239242|NCT03129009|DRUG|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
219169623|NCT03972813|BEHAVIORAL|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
219169624|NCT05356117|BEHAVIORAL|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
219169625|NCT05356117|BEHAVIORAL|Resistance Training (RT)|Aerobic and resistance exercise
219169626|NCT05356117|BEHAVIORAL|Attention Control (AC|Stretching
219169627|NCT06798558|DRUG|Lu-17-PSMA-617|Lu-17-PSMA-617 administration
219169628|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
219239243|NCT03129009|DRUG|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
219239244|NCT04095338|OTHER|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
219737671|NCT04698447|DIETARY_SUPPLEMENT|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
219169629|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
219169630|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
219169631|NCT05984784|DRUG|Placebo|Drug: Placebo Intravenous Infusion
219169632|NCT05984784|DRUG|IMG-007|Drug: IMG-007 Intravenous Infusion
219169633|NCT02365766|DRUG|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
219169634|NCT02365766|DRUG|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
219169635|NCT02365766|DRUG|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
219169636|NCT02365766|PROCEDURE|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
219169637|NCT06582953|BEHAVIORAL|Turning the Tide Violence Intervention Program (hospital violence intervention program)|TTVIP is already integrated into the regular care of patients who are violently injured and treated at MUSC Charleston. Client advocates provide immediate support, help with communication and provide anti-retaliation messaging to victims of violence and their families, in addition to helping support their healthcare. Patients that opt to be followed for long-term wrap-around services and live in the surrounding 3-county area are supported for months (up to 1 year) after injury and provided mentorship, service referrals (i.e. education, employment, substance abuse, injury recovery, pro-social activities, housing) and mental health services.
219169638|NCT06637319|DEVICE|Ultrasound|Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
219169639|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
219169640|NCT05652569|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
219169641|NCT06638411|BEHAVIORAL|ADHD information workshop|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
219169642|NCT06638411|BEHAVIORAL|ADHD information workshop with nocebo education|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
219169643|NCT06638411|BEHAVIORAL|Sleep workshop|An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
219169644|NCT06641271|DEVICE|Closed Loop Trans-Auricular Vagus Nerve Stimulation System|A closed loop system that delivers stimulation to the vagus nerve via the ear non-invasively following a trigger event.
219169645|NCT06641271|DEVICE|Placebo|A closed-loop vagus nerve stimulation device that can deliver sham stimulation to the ear to simulate stimulation of the vagus nerve.
219169646|NCT04895995|BEHAVIORAL|Daylight dCBT Application|Participants will complete up to four modules of digital intervention delivered in a self-paced format.
219169647|NCT04233021|DRUG|Osimertinib|Osimertinib 80 mg/d
219169648|NCT05896254|DRUG|MAR001|Subcutaneous injection
219169649|NCT05896254|DRUG|Placebo|Subcutaneous injection
219169650|NCT06561152|DRUG|Tagraxofusp|Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)
219169651|NCT06561152|DRUG|Cladribine (CLAD)|Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)
219737672|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
219737673|NCT03509480|PROCEDURE|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
219362250|NCT04319900|DRUG|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
219737674|NCT01401205|OTHER|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
219737675|NCT00567229|BIOLOGICAL|rituximab|
219737676|NCT00567229|DRUG|lenalidomide|
219737677|NCT00567229|GENETIC|microarray analysis|
219737678|NCT00567229|OTHER|flow cytometry|
219737679|NCT00567229|OTHER|laboratory biomarker analysis|
219737680|NCT03729141|DIETARY_SUPPLEMENT|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
219737681|NCT03729141|OTHER|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
219737682|NCT04637347|DEVICE|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
219737683|NCT01455090|DRUG|BMS-650032|
219737684|NCT01455090|DRUG|BMS-790052|
219737685|NCT01455090|DRUG|BMS-791325|
219737686|NCT01455090|DRUG|Ribavirin|
219737687|NCT01630811|DRUG|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
219737688|NCT01630811|OTHER|Placebo|Placebo will be given once daily for 7 days.
219737689|NCT06535737|DRUG|Cabozantinib|Cabozantinib (Cabometyx) 60, 40 and 20 mg
219737690|NCT00979615|DRUG|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
219737691|NCT00979615|DRUG|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
219169652|NCT06561152|DRUG|Cytarabine|Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
219169653|NCT06563167|DIAGNOSTIC_TEST|CXR|CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
219169654|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
219169655|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
219169656|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
219169657|NCT05956002|DRUG|Estraimod Immediate Release (IR)|an immediate release tablet
219169658|NCT05956002|DRUG|Etrasimod Mini Tab in water|very small tablet mixed in water
219169659|NCT05956002|DRUG|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
219169660|NCT05956002|DRUG|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
219169661|NCT05956002|DRUG|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
219169662|NCT04933136|DEVICE|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
219169663|NCT02983760|DEVICE|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
219169664|NCT02983760|DEVICE|CTPA-based strategy|Strategy based on pulmonary angiography
219169665|NCT02983760|DEVICE|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
219169666|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
219169667|NCT05974046|DRUG|[14C]IDV184001AN|\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
219169668|NCT02561923|DRUG|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
219169669|NCT02561923|DRUG|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
219169670|NCT02561923|DRUG|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
219169671|NCT02561923|DRUG|Saline|Saline \[Kcentra saline control or TXA saline control\] on Day 4.
219169672|NCT06024239|DRUG|ABBV-932|Capsule; oral
219169673|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
219169674|NCT06756425|BEHAVIORAL|aerobic exercise program|aerobic exercise program for 3 months with nutritional health awearness sessions
219169675|NCT06756425|BEHAVIORAL|nutritional health awareness sessions|lifestyle changes and nutritional awareness sessions for 3 months twice a week for participants and their parents
219169676|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
219169677|NCT06436703|BIOLOGICAL|Influenza ModRNA Vaccine|Intramuscular injection
219169678|NCT06436703|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|Intramuscular injection
219169679|NCT01220583|DRUG|cisplatin|Given IV
219169680|NCT01220583|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
219169681|NCT01220583|RADIATION|intensity-modulated radiation therapy|Undergo radiotherapy
219169682|NCT04369976|DEVICE|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
219169683|NCT04270474|OTHER|Deprescribing of target anticholinergics|The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
219362251|NCT00772668|DRUG|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
219362252|NCT00772668|DRUG|Bortezomib|Administered intravenously per protocol.
219362253|NCT00772668|DRUG|Cyclophosphamide|Administered intravenously per protocol.
219169684|NCT04270474|OTHER|Usual Care|Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
219169685|NCT04808843|DRUG|Dienogest (BAY86-5258, Visanne)|Following the physicians' decision.
219169686|NCT06549530|DRUG|MVA-BN|All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
219169687|NCT06399757|DRUG|APL-5125|APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
219362254|NCT00772668|DRUG|Prednisone|Administered orally (PO) per protocol.
219362255|NCT06818396|OTHER|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia
219169688|NCT05942001|DRUG|HRS-5041|HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
219169689|NCT06836492|COMBINATION_PRODUCT|VAC，VAC/VII，CAV/IE|Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP
219169690|NCT05724160|OTHER|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
219169691|NCT05724160|OTHER|Physiotherapy Protocol|Routine physiotherapy protocol
219169692|NCT04098640|GENETIC|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
219169693|NCT02681328|OTHER|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
219169694|NCT02681328|OTHER|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
219169695|NCT02681328|OTHER|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
219169696|NCT02681328|OTHER|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
219169697|NCT03433274|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
219169698|NCT03433274|DEVICE|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
219169699|NCT02697396|BEHAVIORAL|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
219169700|NCT02697396|OTHER|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
219169701|NCT02697396|OTHER|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
219169702|NCT06849505|DEVICE|online rTMS|5 Hz rTMS is applied to the MRI-localized hotspot on the affected hemisphere when the patients are performing motor tasks
219169703|NCT06849505|DEVICE|offline rTMS|The patients perform motor tasks after 5 Hz rTMS applied to the MRI-guided hotspot on the affected hemisphere
219169704|NCT06849505|DEVICE|sham rTMS|Sham rTMS is applied to the M1 on the affected hemisphere when the patients are performing motor tasks.
219169705|NCT04668781|PROCEDURE|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
219169706|NCT04668781|PROCEDURE|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
219169707|NCT02181257|COMBINATION_PRODUCT|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
219169708|NCT02181257|OTHER|No intervention in the SOC / Retrospective Chart review.|SOC Retrospective chart review similar to a control group
219169709|NCT04761458|DIAGNOSTIC_TEST|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
219169710|NCT04761458|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
219169711|NCT04761458|DIAGNOSTIC_TEST|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
219169712|NCT04761458|DIAGNOSTIC_TEST|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
219169713|NCT03978871|BEHAVIORAL|Growth Mindset|Growth emotion mindset induction
219169714|NCT03978871|BEHAVIORAL|Brain Education|Brain education
219169715|NCT04072822|DRUG|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
219169716|NCT04072822|DRUG|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
219169717|NCT04072822|DRUG|Placebos|Matching placebo
219169718|NCT03095274|DRUG|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
219169719|NCT03095274|DRUG|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
219169720|NCT03483246|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
219169721|NCT03483246|DRUG|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
219169722|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
219362256|NCT06818396|DRUG|Intrathecal nalbuphine and spinal anesthesia|intrathecal nalbuphine and spinal anesthesia
219362257|NCT06818396|OTHER|Spinal anesthesia|Spinal anesthesia
219362258|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.
219239245|NCT04095338|OTHER|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
219239246|NCT04095338|OTHER|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
219239247|NCT02181881|BEHAVIORAL|DuoPACT|Intervention sessions are administered weekly by a counselor.
219239248|NCT02181881|BEHAVIORAL|Life Steps|Intervention sessions are administered weekly by a counselor.
219239249|NCT02958722|PROCEDURE|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
219239250|NCT02958722|DRUG|physiological solution|
219239251|NCT02958722|DRUG|carbon dioxide|
219239252|NCT00870168|DRUG|chemotherapy|
219239253|NCT00870168|GENETIC|gene expression analysis|
219239254|NCT00870168|OTHER|laboratory biomarker analysis|
219239255|NCT00870168|PROCEDURE|breast biopsy|
219239256|NCT02089425|DRUG|K-103-IP|
219239257|NCT02089425|DRUG|Placebo|Placebo comparator
219239258|NCT04019301|OTHER|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
219239259|NCT04019301|OTHER|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
219239260|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Micro-coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
219239261|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Enteric coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
219239262|NCT01686724|BEHAVIORAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
219239263|NCT01686724|OTHER|Business As Usual|
219239264|NCT01352026|DRUG|Metformin|
219239265|NCT03067870|BIOLOGICAL|Stem Cell Transplantation|"* Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints."
219239266|NCT03967457|DIAGNOSTIC_TEST|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
219239267|NCT03967457|DIAGNOSTIC_TEST|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
219239268|NCT03967457|DIAGNOSTIC_TEST|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
219239269|NCT03967457|DIAGNOSTIC_TEST|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
219239270|NCT02995707|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
219239271|NCT00599625|DRUG|Pravastatin|80mg administered daily for 6 consecutive weeks
219737692|NCT04518657|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
219737693|NCT04518657|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
219737694|NCT04873856|DIETARY_SUPPLEMENT|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
219737695|NCT05393908|PROCEDURE|TAP Block Group|Participants will receive a surgeon administered TAP block.
219362259|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy+Transbronchial cryobiopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
219737696|NCT03430973|BEHAVIORAL|Videos|Videos depicting various aggressive driving and road rage behaviors.
219737697|NCT03430973|BEHAVIORAL|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
219737698|NCT03430973|BEHAVIORAL|Alcohol-related cues|Case of beer or water on passenger seat.
219737699|NCT03430973|BEHAVIORAL|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
219737700|NCT03430973|BEHAVIORAL|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
219737701|NCT03430973|BEHAVIORAL|Video game|Participants will play a racing or neutral video game before driving in the simulator.
219737702|NCT04276701|BIOLOGICAL|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
219737703|NCT04276701|OTHER|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
219737704|NCT04276701|BEHAVIORAL|questionnaires|Food and exercise questionnaires validated by the American heart Association
219737705|NCT06432452|DRUG|Endothelin Receptor Antagonist|Oral capsules twice daily
219737706|NCT06432452|OTHER|Placebo control|Oral capsules twice daily
219169723|NCT04513132|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
219169724|NCT04513132|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
219169725|NCT04391894|DRUG|ECF843|Topical ocular eye drop
219169726|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
219169727|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
219169728|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance elastography (MRE)|Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.
219169729|NCT04591106|DEVICE|Prototype MRE soft flexible passive transducer paddle|The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.
219169730|NCT06581588|DEVICE|THRIVE|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen
219169731|NCT06581588|DEVICE|THRIVE combine nasopharyngeal airway|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
219169732|NCT04987814|OTHER|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
219169733|NCT04987814|OTHER|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
219169734|NCT04987814|OTHER|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
219169735|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
219169736|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
219169737|NCT02323321|DEVICE|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
219169738|NCT00446225|DRUG|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
219169739|NCT00446225|DRUG|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
219737707|NCT05284513|BEHAVIORAL|FH diagnosis program|Uptake of screening, diagnosis, and initiation of care management for FH
219737708|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop and implement tools for quality monitoring|EHR tools to order labs, record results, and document FH care
219737709|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop educational materials|Education regarding guidelines for identification and treatment of FH
219737710|NCT05284513|BEHAVIORAL|Implementation strategy package: Conduct educational outreach visits|Continuing medical education (CME) material for FH that is presented to
219737711|NCT05284513|BEHAVIORAL|Implementation strategy package: Intervene with clinicians and patients to enhance|Notify patients simultaneously with clinicians about the need for screening
219239272|NCT06498232|OTHER|Active Video Based Exercises|Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.
219239273|NCT06498232|OTHER|Stabilization and Strengthening Exercises|Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.
219239274|NCT06498232|OTHER|Waiting List-Spine protection principles training|Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
219239275|NCT01799603|DRUG|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
219239276|NCT02142478|BEHAVIORAL|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
219239277|NCT02142478|BEHAVIORAL|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
219239278|NCT01995292|DEVICE|bronchoscope|
219737712|NCT05284513|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions|Clinical lipid champions
219737713|NCT05284513|BEHAVIORAL|Implementation strategy package: Audit and provide feedback|Provide aggregate level feedback to clinics on diagnosing FH
219737714|NCT05284513|BEHAVIORAL|Implementation strategy package: Stage implementation scale up|Develop the timeline for the stepped-wedge rollout to primary care
219737715|NCT06267508|PROCEDURE|Maternal HIV viral load testing at delivery for VHT risk assessment|Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
219737716|NCT04818086|DRUG|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
219737717|NCT04818086|DRUG|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
219737718|NCT04818086|DRUG|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
219169740|NCT00446225|DRUG|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
219169741|NCT00446225|DRUG|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
219169742|NCT00446225|DRUG|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
219169743|NCT04206540|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Electrical stimulation of the vagus nerve around the external ear using a transcutaneous device. Electrical current will be increased in intensity based on subject feedback of a scale 0-10.~Electrical stimulation will be delivered for 2 minutes once the subject reports the maximum comfortable intensity."
219737719|NCT05157893|DEVICE|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
219737720|NCT01595815|OTHER|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
219737721|NCT01595815|OTHER|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
219737722|NCT01725308|DRUG|FK949E|Taken by mouth (orally).
219737723|NCT01725308|DRUG|Placebo|Taken by mouth (orally).
219239279|NCT01995292|DEVICE|Enk Fiberoptic Atomizer|
219239280|NCT03645213|DEVICE|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
219239281|NCT03645213|DEVICE|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
219239282|NCT00547456|DRUG|Oxygen|Oxygen 2-3L Nasal cannula
219239283|NCT03451903|DRUG|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
219239284|NCT03451903|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
219239285|NCT05852197|DRUG|anticoagulant or antiplatelet drugs|combination of anticoagulant or antiplatelet drugs
219239286|NCT00648895|DRUG|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
219239287|NCT00648895|DRUG|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
219239288|NCT01164319|PROCEDURE|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
219239289|NCT02411175|OTHER|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
219239290|NCT02411175|DRUG|20% ethanol|
219239291|NCT03873376|BEHAVIORAL|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
219239292|NCT03873376|BEHAVIORAL|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
219239293|NCT03873376|BEHAVIORAL|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
219169744|NCT04206540|PROCEDURE|Vagal Stimulation|"Subjects will be asked to do the following in order to stimulate the vagus nerve:~* Cough 6 to 8 forceful coughs~* Have an ice cold wash cloth placed on their face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor is briefly inserted into the back of the mouth touching the bag of the throat.~* Valsalva maneuver: Subjects will be asked to bear down as if having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a device that measures how hard they are blowing. Alternatively, we can have them blow through the barrel of a 10 ml syringe for 15-20 seconds.~* Eating: Subjects will be asked to drink water and/or Ensure that has 220 calories after fasting overnight."
219239294|NCT01062776|BIOLOGICAL|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
219239295|NCT01062776|BIOLOGICAL|Placebo|No dehydration is induced
219239296|NCT05542589|OTHER|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
219239297|NCT05542589|OTHER|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
219239298|NCT01241994|OTHER|AASD dialysis technique|
219239299|NCT04610606|BEHAVIORAL|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
219239300|NCT03180788|PROCEDURE|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
219239301|NCT03180788|PROCEDURE|Traditional ESD|Endoscopic submucosa dissection
219239302|NCT00363389|DRUG|misoprostol and cervical ripening|
219239303|NCT01134497|DRUG|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
219239304|NCT01134497|DRUG|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
219239305|NCT02152111|DIETARY_SUPPLEMENT|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
219239306|NCT02152111|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months.
219239307|NCT02865083|DEVICE|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
219239308|NCT04436965|OTHER|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
219239309|NCT04436965|DRUG|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
219169745|NCT05018871|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
219169746|NCT04450342|DEVICE|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
219239310|NCT04436965|RADIATION|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
219239311|NCT02699398|BEHAVIORAL|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
219239312|NCT02699398|BEHAVIORAL|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
219239313|NCT04430673|OTHER|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
219239314|NCT04527679|DRUG|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
219239315|NCT03796364|DRUG|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
219169747|NCT04450342|PROCEDURE|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
219239316|NCT03796364|DRUG|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
219239317|NCT01290471|DRUG|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
219239318|NCT00841321|DRUG|Ginkgo biloba|120 mg orally twice a day for 12 weeks
219239319|NCT00841321|DRUG|Placebo|One capsule orally twice a day for 12 weeks
219239320|NCT00444730|PROCEDURE|Radical Prostatectomy|Surgical procedure for prostate cancer.
219239321|NCT00444730|PROCEDURE|InterStim Implantation|surgical placement of the interstim
219239322|NCT00444730|PROCEDURE|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
219239323|NCT05795283|DRUG|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
219239324|NCT05795283|DRUG|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
219239325|NCT02041897|PROCEDURE|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
219239326|NCT04434222|DEVICE|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
219239327|NCT01363206|BIOLOGICAL|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
219239328|NCT01363206|BIOLOGICAL|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
219239329|NCT05057767|DRUG|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
219169748|NCT04450342|DEVICE|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
219169749|NCT06266130|DEVICE|Treatment Group Digital Bonding Tray|The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.
219169750|NCT06266130|DEVICE|Control Group Direct Bonding|The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.
219169751|NCT03526874|DRUG|Lidocaine 4% Topical Application Cream [LMX 4]|Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
219239330|NCT03419806|DRUG|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
219239331|NCT03419806|DRUG|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
219362283|NCT06638463|BEHAVIORAL|My Health Coach app|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
219362284|NCT06902896|BIOLOGICAL|FAP immunosuppressive CAR-DC|Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion
219239332|NCT03419806|DRUG|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
219239333|NCT05860218|OTHER|advices|"The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
219239334|NCT05860218|OTHER|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):"
219239335|NCT01598454|DRUG|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
219169752|NCT03526874|DRUG|Lidocaine Hydrochloride 2 mg/mL Injectable Solution|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
219169753|NCT03526874|DRUG|Normal Saline|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
219239336|NCT02637947|DEVICE|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
219239337|NCT02637947|DEVICE|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
219239338|NCT05711745|PROCEDURE|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
219239339|NCT03917342|DEVICE|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
219239340|NCT02867332|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
219239341|NCT02867332|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
219239342|NCT02867332|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
219239343|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
219169754|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
219169755|NCT03379051|DRUG|Venetoclax|BCL-2 Inhibitor
219169756|NCT03379051|DRUG|Umbralisib|PI3K-Delta Inhibitor
219169757|NCT03379051|BIOLOGICAL|Ublituximab|Glycoengineered Anti-CD20 mAb
219239344|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
219239345|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
219239346|NCT04530721|OTHER|no intervention|we don't do any intervention
219239347|NCT00292409|DRUG|Aripiprazole|
219362285|NCT04715555|DEVICE|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
219362286|NCT04715555|DEVICE|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
219362287|NCT04715555|DEVICE|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
219169758|NCT03379051|DRUG|Lenalidomide|Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
219169759|NCT04353310|DRUG|Curcumin|Curcumin 1500mg PO BID
219169760|NCT04353310|OTHER|Placebo|identical in appearance to curcumin
219169761|NCT05741489|DEVICE|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
219169762|NCT02670109|DRUG|Carmustine|300mg/m2, IV, in 3 hours, during day -4
219169763|NCT02670109|DRUG|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
219169764|NCT02670109|DRUG|Carboplatin|1400/m2, IV, in 1 hour, during day -3
219169765|NCT02670109|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
219169766|NCT02670109|DRUG|Busulfan|16mg/kg, Oral, during day -4
219169767|NCT01057433|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
219169768|NCT01057433|DRUG|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
219169769|NCT00910338|DEVICE|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks"
219169770|NCT03314324|DRUG|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
219169771|NCT03314324|DRUG|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
219169772|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
219169773|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 366 in previously dosed participants.
219169774|NCT06630845|DRUG|Fluorodeoxyglucose F18|Given IV as part of routine imaging
219169775|NCT06630845|PROCEDURE|Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)|Imaging procedure
219169776|NCT06630845|PROCEDURE|Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)|Imaging procedure done concurrently with PET/MRI
219169777|NCT06630845|DEVICE|General Electric (GE) SIGNA PET/MR|Imaging device
219169778|NCT05670106|DRUG|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
219169779|NCT05670106|OTHER|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
219169780|NCT05670106|DRUG|68Ga-PSMA-11|Administered single intravenous dose of approximately 150 MBq. Administered dose could not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
219169781|NCT04904094|OTHER|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
219169788|NCT06056297|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
219169789|NCT06056297|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
219169790|NCT05397561|OTHER|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
219169791|NCT06198972|OTHER|Pelvic Pnf exercises|"Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Pelvic patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
219169792|NCT06198972|OTHER|Strength exercises|"3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down Lower extremity movements~* Hip flexion~* Hip extension~* Hip abduction~* Hip adduction~* Knee flexion~* Knee extension Resistance exercise training"
219169793|NCT05440786|DRUG|Abemaciclib|Orally
219169794|NCT05440786|DRUG|Irinotecan|IV
219169795|NCT05440786|DRUG|Temozolomide|Orally
219169796|NCT02811679|DRUG|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
219169797|NCT06109311|DRUG|Orforglipron|Administered orally.
219169798|NCT06109311|DRUG|Placebo|Administered orally.
219169799|NCT06488144|BEHAVIORAL|Health coach|Health Coaching
219169800|NCT06488144|BEHAVIORAL|Remote Incentive Program|Behavioral incentive program including gamification, social incentivization, and monitoring.
219169801|NCT05472792|RADIATION|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
219362288|NCT04715555|OTHER|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
219239348|NCT03811743|BEHAVIORAL|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
219362289|NCT06886802|PROCEDURE|Posterior Uniportal Endoscopic Cervical Decompression|Posterior Uniportal Endoscopic Cervical Decompression
219169802|NCT05472792|DRUG|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
219169803|NCT03468335|DRUG|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
219169804|NCT05404750|BEHAVIORAL|Harm Reduction|Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
219169805|NCT06365086|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the right hemisphere during brain activity patterns associated with strong and weak corticospinal tract activation. Single-pulse TMS will also be applied to the right hemisphere during random brain activity patterns.
219169806|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
219169807|NCT05905640|OTHER|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
219169808|NCT06329583|DIAGNOSTIC_TEST|diaphragmatic breathing|Different positions and techniques for diaphragmatic breathing
219169809|NCT05442671|BEHAVIORAL|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
219169810|NCT05319860|DRUG|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
219169811|NCT05319860|DRUG|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
219169812|NCT03423758|OTHER|Blood sample|Blood sample
219737724|NCT06393985|DRUG|Decitabine, venetoclax and blinatumomab|"Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)"
219737725|NCT05358639|DRUG|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
219362290|NCT06916390|DRUG|Guselkumab|"All patients will receive guselkumab 400 mg intravenous at week 0, week 4, and week 8, followed by subcutaneous guselkumab 200 mg at week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 40, week 44, and week 48.~All subjects will receive concomitant antibiotic treatment with ciprofloxacin 500mg twice daily from randomization through week 4."
219737726|NCT05358639|DRUG|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
219737727|NCT05094102|DEVICE|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
219737728|NCT05094102|DRUG|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
219737729|NCT01340118|DRUG|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
219737730|NCT05269940|DRUG|ZX-101A|oral dosing, once daily
219737731|NCT06015165|DRUG|Analgesia plan for Anes. Group|For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
219737732|NCT06015165|DRUG|Analgesia plan for Surg. Group|For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
219737733|NCT06015165|PROCEDURE|Multi-modal analgesia during the surgery|Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
219737734|NCT04870554|BEHAVIORAL|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
219737735|NCT05811637|OTHER|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
219737736|NCT05811637|OTHER|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
219737737|NCT02364271|OTHER|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
219737738|NCT02364271|BIOLOGICAL|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
219737739|NCT02364271|OTHER|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
219737740|NCT06483828|BEHAVIORAL|Dental Anxiety Coping Module|Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
219737741|NCT04584320|OTHER|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
219737742|NCT05950659|DEVICE|Orpyx Sensory Insole System|The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
219737743|NCT03959904|PROCEDURE|Small stitch|Wound closure will be using small stiches or larger spaced stitches
219737744|NCT03959904|OTHER|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
219737745|NCT03959904|OTHER|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
219737746|NCT03959904|OTHER|Pain Score|A pain score will be recorded following the surgical procedure.
219737747|NCT03959904|OTHER|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
219737748|NCT05867940|BEHAVIORAL|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
219737749|NCT05377671|DIAGNOSTIC_TEST|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
219737750|NCT01637571|DRUG|Dexilant|60mg of Dexilant QD for 12 weeks
219737751|NCT01637571|DRUG|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
219737752|NCT06393426|DRUG|Chinese Herb|Chinese herbal medicine
219737753|NCT01206270|DRUG|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
219737754|NCT01206270|DRUG|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
219169813|NCT04314895|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
219169814|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219169815|NCT05492916|BEHAVIORAL|Diabetes Prevention Program (DPP)|Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.
219169816|NCT05492916|BEHAVIORAL|Community-Supported Agriculture (CSA)|Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
219169817|NCT06011252|DEVICE|Solia S lead with any BIOTRONIK Pacemaker|"* Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III"
219169818|NCT05606575|DEVICE|Nelli|Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.
219169819|NCT01247207|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
219169820|NCT01826331|BEHAVIORAL|Incentives for Participation|Participants will receive three smoking cessation programs
219169821|NCT01826331|BEHAVIORAL|Incentives for Cessation|Participants will have access to a smoking cessation program
219169822|NCT03191981|DRUG|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
219169823|NCT03191981|DRUG|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
219169824|NCT03191981|DRUG|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
219169825|NCT02117752|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
219169826|NCT02117752|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
219169827|NCT02117752|DRUG|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
219239349|NCT03811743|BEHAVIORAL|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
219169828|NCT02117752|DRUG|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
219169829|NCT03751449|OTHER|Educational Intervention|Receive nutrition education
219169830|NCT03751449|BEHAVIORAL|Exercise Intervention|Complete home-based aerobic and resistance exercise program
219169831|NCT03751449|OTHER|Quality-of-Life Assessment|Ancillary studies
219169832|NCT03751449|OTHER|Questionnaire Administration|Ancillary studies
219169833|NCT06969079|BEHAVIORAL|Ba Duan Jin Exercise plus Sleep Hygiene Education|Participants will receive Ba Duan Jin exercise combined with Sleep Hygiene Education. The Ba Duan Jin intervention consists of eight traditional Chinese Qigong movements performed daily for 6 weeks, with each session lasting 50 minutes, accompanied by structured sleep hygiene counseling.
219169834|NCT06969079|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
219169835|NCT04986501|DEVICE|MucoPEG|Experimental
219169836|NCT04986501|DEVICE|Biotene|Active Comparator
219169837|NCT04180059|COMBINATION_PRODUCT|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
219169838|NCT06645925|PROCEDURE|One Step Protocol|FGG will be done simultaneous with implant placement
219169839|NCT06645925|PROCEDURE|Two Steps Protocol|Conventional FGG protocol, prior to implant placement
219169840|NCT05841979|BEHAVIORAL|Moodlifters|Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta \& Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.
219239350|NCT03811743|BEHAVIORAL|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
219737755|NCT02936271|OTHER|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
219737756|NCT02936271|OTHER|Placebo|
219737757|NCT03511209|BEHAVIORAL|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
219737758|NCT03511209|BEHAVIORAL|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
219737759|NCT06069271|OTHER|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
219737760|NCT01743703|OTHER|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
219737761|NCT05810311|DRUG|Roxadustat|"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
219737762|NCT05810311|DRUG|Darbepoietin Alfa|"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
219737763|NCT01505426|DRUG|ASP1941|oral
219737764|NCT01505426|DRUG|metformin|oral, concomitant use
219737765|NCT01505426|DRUG|Placebo|oral
219737766|NCT06565936|RADIATION|PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG|Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
219737767|NCT04947865|OTHER|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
219169841|NCT05841979|BEHAVIORAL|Physical Activity|Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan \& Karlamangla, 2014; Strasser \& Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).
219169842|NCT05841979|BEHAVIORAL|Nature Experiences|Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.
219169843|NCT06986889|PROCEDURE|Conventional radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized conventional radial access for cardiac catheterization.
219169844|NCT06986889|PROCEDURE|Distal radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized distal radial access for cardiac catheterization.
219169845|NCT06988046|DEVICE|Cover spine orthosis (CSO)|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
219169846|NCT06988046|DEVICE|Semi-rigid thoracolumbar orthosis|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
219169847|NCT06987799|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR; CALM-Chicago Study)|This clinical trial will evaluate the effectiveness of the culturally adapted intervention, CALM-Chicago, in a community setting. CALM-Chicago has been previously used in a clinical setting.
219169848|NCT06986499|DEVICE|Hearing Aid Widex SmartRIC MRRLD 440|Receiver in Canal (RIC) hearing aid
219169849|NCT06986499|DEVICE|Own hearing aid|subjects' own hearing aids, any brand, any model
219169850|NCT06987084|COMBINATION_PRODUCT|Bryophyllum pinnatum tea|24 g of B. pinnatum leaves boiled in 250 mL of water for 61 minutes sweetened with 1/2 teaspoon of sugar
219169851|NCT06987084|COMBINATION_PRODUCT|Placebo tea|250 mL of water boiled with 3 g of wheat-bran for 5 minutes sweetened with 1/2 teaspoon of sugar
219169852|NCT06986902|PROCEDURE|Laparoscopic Nissen Fundoplication|a 360° total wrap of the gastric fundus around the esophagus.
219169853|NCT06986902|PROCEDURE|Laparoscopic Toupet fundoplication|a 270° posterior partial wrap of the gastric fundus around the esophagus.
219169854|NCT06986538|PROCEDURE|Clearance with the left side of the SMV as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMV as the medial boundary
219169855|NCT06986538|PROCEDURE|Clearance with the left side of the SMA as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMA as the medial boundary
219169856|NCT06986655|OTHER|Augmented Reality|In this intervention children will play an augmented reality game during the allergy testing procedure. The game will be used as a distraction method to potentially reduce pain and fear, and enhance care satisfaction.
219169857|NCT06987123|DRUG|Toripalimab|Toripalimab 240 mg, administered on the first day, Q3W × 17 cycles
219169858|NCT06987123|DRUG|Capecitabine|Capecitabine 650 mg/m2 twice a day, oral administration, d1-21, Q3W × 17 cycles
219169859|NCT06987123|PROCEDURE|salvage surgery|"The specific steps of high-frequency electrosurgical knife treatment for localized recurrent nasopharyngeal carcinoma are as follows:~1. It must be performed under general anesthesia, with the complete resection of the nasopharyngeal tumor and its sufficient safe boundary through both nasal cavities under the guidance of nasal endoscopy. When marking the surgical margin, the anterior margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper margin can reach about 0.5-1cm to the upper margin of the posterior nostril. The lateral and lower margins are designed individually based on the size and location of the tumor. The basic principle is to ensure a safe margin of 0.5-1.0cm, and then use low-temperature plasma ablation. Ablate the tumor tissue and the normal tissue at the resection margin layer by layer from the upper resection margin to the lower resection margin until no obvious tumor residue was observed with the naked eye.~2. Rinse the surgical c"
219169860|NCT06987266|OTHER|no intervention|no ntervention
219239351|NCT00062270|DRUG|cisplatin|
219239352|NCT00062270|DRUG|docetaxel|
219239353|NCT00062270|DRUG|gefitinib|
219239354|NCT00062270|DRUG|gemcitabine hydrochloride|
219239355|NCT00062270|PROCEDURE|conventional surgery|
219239356|NCT00062270|PROCEDURE|neoadjuvant therapy|
219239357|NCT00062270|RADIATION|radiation therapy|
219239358|NCT01358175|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
219239359|NCT01358175|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
219239360|NCT01358175|DRUG|Placebo|Placebo
219239361|NCT02509754|PROCEDURE|Atrial fibrillation catheter ablation|
219239362|NCT02509754|PROCEDURE|Rate control|Composite of optimal medical therapy and device implantation
219239363|NCT00847223|DRUG|ZARNESTRA (Tipifarnib)|
219239364|NCT01525875|DRUG|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
219737768|NCT04947865|DEVICE|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
219169861|NCT06986408|DEVICE|Earplugs and Eye Masks|"The patients in the experimental group will be given the Informed Consent Form before surgery and the Patient Introduction Form will be applied after permission is obtained. Patients will be given eye masks and earplugs on the nights following surgery and they will be ensured to use them correctly. The General Comfort Scale and the Quality of Recovery Questionnaire (Qor-40) will be applied 24 and 48 hours after surgery."
219169862|NCT05428384|DEVICE|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
219169863|NCT06840821|DRUG|MB0151 for injection|In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .
219169864|NCT03964350|DRUG|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
219169865|NCT03964350|OTHER|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
219169866|NCT06790758|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma-rich fibrin epidural injection by Racz catheter in post-dural puncture headache-guided optic nerve sheath diameter.
219239365|NCT01525875|DRUG|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
219737769|NCT00447369|DRUG|Pregabalin|
219737770|NCT00447369|DRUG|sodium valproate|
219737771|NCT06323473|DIETARY_SUPPLEMENT|Black Maitake Prothera|Mushroom extract; liquid
219737772|NCT04257513|DIAGNOSTIC_TEST|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
219737773|NCT06063031|DIETARY_SUPPLEMENT|Active|Active nutritional supplement plus telerehabilitation
219737774|NCT06063031|OTHER|Placebo|Placebo nutritional supplement plus telerehabilitation
219737775|NCT06106984|DEVICE|Graded motor imagery mobile app|The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
219239366|NCT02831088|DRUG|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
219239367|NCT02831088|DRUG|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
219239368|NCT02831088|DRUG|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
219239369|NCT05398042|DIETARY_SUPPLEMENT|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
219239370|NCT05398042|DIETARY_SUPPLEMENT|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
219239371|NCT05256758|DRUG|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
219239372|NCT05256758|DRUG|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
219239373|NCT03455153|OTHER|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
219239374|NCT04029727|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
219239375|NCT04029727|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
219239376|NCT04172571|BIOLOGICAL|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
219239377|NCT04172571|DRUG|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
219239378|NCT05957822|DRUG|TXA|Tranexamic acid injection 8-10mg/kg
219239379|NCT05957822|DIAGNOSTIC_TEST|TEG6|performing thromboelastography (TEG6)
219239380|NCT02379078|OTHER|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
219239381|NCT02379078|OTHER|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
219239382|NCT02379078|OTHER|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
219239383|NCT03476577|DRUG|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
219239384|NCT04908488|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
219239385|NCT04908488|DEVICE|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
219239386|NCT02627534|PROCEDURE|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
219239387|NCT02627534|PROCEDURE|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
219239388|NCT00003755|DRUG|MKC-1|
219362291|NCT06916390|OTHER|Diet|Subjects randomized to the group with the dietary intervention will be advised to follow a low-UPF, high-fruit diet. Patients will be instructed to restrict the intake of NOVA 4 food products during the first 16 weeks of the trial, and to increase the intake of fruits (minimum 3 servings per day) during the full trial. Dietary education will be provided by certified IBD dietitians, lists of products to avoid, and week menu's will also be provided to increase dietary adherence. Dietary information will be collected with food records and food frequency questionnaires.
219737776|NCT05532657|OTHER|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
219737777|NCT05532657|OTHER|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
219737778|NCT05445323|GENETIC|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
219737779|NCT05445323|GENETIC|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
219737780|NCT05445323|GENETIC|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
219737781|NCT06013800|OTHER|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
219737782|NCT06003621|BIOLOGICAL|Tiragolumab|600mg IV every 21 days from Cycle 1 Day 1
219737783|NCT06003621|BIOLOGICAL|Atezolizumab|1,200mg IV every 21 days from Cycle 2 Day 1
219737784|NCT06054815|DRUG|DA-1241|Route of Administration: Oral, with subjects in a fasting state
219737785|NCT06054815|DRUG|Sitagliptin|Route of Administration: Oral, with subjects in a fasting state
219737786|NCT06054815|DRUG|DA-1241 Placebo|Route of Administration: Oral, with subjects in a fasting state
219737787|NCT06054815|DRUG|Sitagliptin Placebo|Route of Administration: Oral, with subjects in a fasting state
219737788|NCT05685160|DIAGNOSTIC_TEST|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
219737789|NCT05685160|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging of the forefoot
219737790|NCT06585423|DIAGNOSTIC_TEST|Sterile commercially available bandage contact lens|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
219737791|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness <100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
219737792|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness >100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
219737793|NCT05520762|PROCEDURE|A strategy of first choice supraglottic airway|See description in Arms section
219737794|NCT05520762|PROCEDURE|A strategy of first choice endotracheal intubation|See description in Arms section
219737795|NCT06157827|DRUG|LBL-024 for Injection|Initial dose-MTD; Q3W; intravenous infusion
219737796|NCT06157827|DRUG|Etoposide Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
219737797|NCT06157827|DRUG|Carboplatin Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
219737798|NCT06157827|DRUG|Atezolizumab injection|Initial dose; Q3W; intravenous infusion
219737799|NCT06157827|DRUG|Cisplatin injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
219737800|NCT05849662|DRUG|Trametinib|"PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
219737801|NCT05849662|DRUG|Azacitidine|"IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
219737802|NCT05849662|DRUG|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)"
219737803|NCT05849662|DRUG|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)"
219737804|NCT02549638|GENETIC|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
219737805|NCT01602666|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219737806|NCT01602666|DRUG|Carboplatin|Given IV
219169867|NCT06909526|BEHAVIORAL|Mindfulness-based stress reduction :MBSR|The intervention consists of 4 weekly virtual sessions and daily mindfulness exercises at home (between 1-5min of duration each, according to the participant's availability. Each session lasts 1 hour (except the first one, which is 1.5 hours due to discussion of the program's logistics). The sessions follow a brief check-in, a lecture on the week's topic, and a guided practice exercise. For the audio guides, participants can select a short version of the daily practice exercise or a longer one, which they will record in the practice logs. Participants also receive information sheets summarizing the weekly sessions.
219169868|NCT06909526|BEHAVIORAL|Usual care|Subjects will continue with their usual healthcare routine and lifestyle. Upon completion of all study visits, subjects will be given access to the audio guides and information sheets for voluntary at-home practice exercises
219169869|NCT06575686|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219169870|NCT06575686|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219169871|NCT06575686|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219169872|NCT06575686|BIOLOGICAL|Epcoritamab|Given SC
219169873|NCT06575686|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219169874|NCT06575686|DRUG|Tazemetostat|Given PO
219169875|NCT06832644|BEHAVIORAL|Lifestyle Management|All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I.
219169880|NCT06920524|DEVICE|Intervention group IM-IM|The intervention group (IM-IM) will receive a tablet and headphones to listen to music during the toxin injections. Then, during the waiting time, the patient, with or without assistance, will choose the music they wish to listen to, according to their musical tastes. The duration of the music can be modulated according to the duration of the medical procedure to follow.
219169881|NCT06922799|DIAGNOSTIC_TEST|Saliva-Check Buffer test and periodontal charting|Saliva-Check buffer test will be used to perform evaluations on saliva pH, quantity and quality
219169882|NCT06931873|COMBINATION_PRODUCT|SCRT+Capoex+QL706|Using a short-course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 25 Gy (5 Gy/treatment × 5 treatments); 2 weeks of rest after the end of radiotherapy were followed by 4 cycles of Capoex combined with QL706.
219169883|NCT06931873|COMBINATION_PRODUCT|LCRT+Capoex+QL706|Using a long course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 50 Gy (2 Gy/treatment x 25 treatments); a 2-week break at the end of radiotherapy was followed by 4 cycles of Capoex combined with QL706.
219169884|NCT06932692|OTHER|magnetoencephalography|500 patients with Parkinson's disease and essential tremor will undergo magnetoencephalography
219169885|NCT06925945|PROCEDURE|regional anestesia|Modified thoracoabdominal plane block (M-TAPA) and rectus sheath block with local infiltration analgesia
219169886|NCT06928038|BEHAVIORAL|Positioned group|applied a side-lying position (20 minutes) on the occiput side and a prostrate position (15 minutes).
219169887|NCT06931886|OTHER|Inspiratory Muscle Strength Training|Participants will be asked to inhale against a resistance. This resistance will be set to \~55% of their maximal inspiratory ability. Participants will complete 5 sets of 6 breaths (30 total) a day for 5 days a week for 6 weeks.
219239389|NCT05426655|OTHER|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
219169888|NCT06931340|DRUG|Androgen Therapy|Given ADT
219169889|NCT06931340|DRUG|Apalutamide|Given PO
219169890|NCT06931340|DRUG|Docetaxel|Given IV
219169891|NCT06931340|PROCEDURE|Computed Tomography|Undergo CT
219169892|NCT06931340|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219169893|NCT06931340|PROCEDURE|Bone Scan|Undergo Bone Scan
219737807|NCT01602666|DRUG|Etoposide|Given IV
219737808|NCT01602666|DRUG|Ifosfamide|Given IV
219737809|NCT01602666|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219737810|NCT05186077|OTHER|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
219169894|NCT06931340|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
219169895|NCT06931340|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219169896|NCT06931340|OTHER|Questionnaire Administration|undergo Questionnaire Administration
219169897|NCT05519007|OTHER|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
219169898|NCT05519007|OTHER|Saline irrigation|The surgical site will be irrigated with Saline
219169899|NCT05872022|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
219169900|NCT05701748|OTHER|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
219169901|NCT06783972|BEHAVIORAL|Touching|In the second stage of birth, when the baby's head crowns, the mother is allowed to touch the baby's head as much as she wants and with as many fingers as she wants.
219169902|NCT01220154|DRUG|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
219169903|NCT01220154|DRUG|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
219737811|NCT05186077|OTHER|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
219737812|NCT05186077|OTHER|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
219239390|NCT06423976|OTHER|Sequencing study|Sequencing of tumour samples for microbiome analysis and molecular charcterisation.
219239391|NCT04881045|BIOLOGICAL|PF-07257876|CD47-PDL-1 bispecific antibody
219239392|NCT00138645|BEHAVIORAL|MicroDiet|MicroDiet
219239393|NCT00138645|BEHAVIORAL|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
219239394|NCT03921164|PROCEDURE|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
219239395|NCT03921164|PROCEDURE|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
219239396|NCT03921164|PROCEDURE|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
219239397|NCT01107912|DRUG|prasugrel|administered orally, daily for 12 days
219239398|NCT01107912|DRUG|clopidogrel|Administered orally, daily for 12 days
219239399|NCT01263275|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
219239400|NCT02771184|DEVICE|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
219169904|NCT01220154|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
219169905|NCT05975385|DEVICE|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
219169906|NCT04775589|BEHAVIORAL|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
219169907|NCT06039644|DIETARY_SUPPLEMENT|Probiotic|Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
219169908|NCT06039644|OTHER|Placebo|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
219169909|NCT02790931|OTHER|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
219169910|NCT05705440|BIOLOGICAL|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
219169911|NCT05705440|OTHER|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
219169912|NCT06066944|OTHER|Thai Foot Massage|It is the application of Massage through specific techniques and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Thai foot massage is often based on traditional Thai massage techniques. The researcher is duly certified for the administration of Thai Foot Massage.
219169913|NCT01526798|DEVICE|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
219169914|NCT01526798|DEVICE|Conventional high-flux dialyzer|
219239401|NCT00598156|DRUG|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
219239402|NCT00598156|DRUG|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
219239403|NCT02853188|OTHER|venous thromboembolism|
219239404|NCT00098514|DRUG|talotrexin ammonium|
219169915|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
219169916|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
219169917|NCT04661293|BIOLOGICAL|Autologous Muscle Derived Cells (AMDCs)|
219169918|NCT06797310|DRUG|Baricitinib|This study evaluates the use of baricitinib 4 mg once daily for 16 weeks in patients with acute alopecia areata (AA) experiencing active hair shedding. Unlike prior studies focusing on chronic AA with extensive hair loss (SALT ≥ 50), this intervention targets the acute phase, aiming to halt shedding within 4-6 weeks-faster than conventional treatments like corticosteroids. Patients meeting the primary endpoint (iSARS-AA ≤ 20 at week 16) will taper to 2 mg daily for an additional 16 weeks. Scheduled follow-ups at weeks 0, 4, 8, 12, 16, 24, 32, 36, 44, and 52 ensure comprehensive monitoring, distinguishing this study from others with shorter follow-ups or less frequent assessments.
219169919|NCT06792838|DEVICE|Confocal Laser Endomicroscopy|"1. The Endo microscope probe will be prepped in channel #1 and normal saline (30 ml) will be flushed into the duodenal mucosa through channel # 2 which will serve as a control. Inject 1-3ml fluorescein 10% intravenously.~2. The duodenal mucosa is assessed at a minimum of four sites (20 seconds each~3. The first potential allergen will be sprayed via catheter onto the mucosa.~4. After 2 minutes, three different areas of of duodenum will be assessed with the gastroflex probe for fluorescein leakage and cell shedding. If fluorescein leakage and cell shedding are visualized that is considered a positive test,no further allergy testing can be conducted. If the first allergen test is negative, irrigate and repeat steps for the next potential allergen for a maximum of three allergens per patient."
219169920|NCT06789081|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
219169921|NCT06792643|DRUG|Cangrelor|Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.
219169922|NCT06788210|OTHER|Multiprofessional Geriatric Emergency Team applied front-door CGA to identify patients who require inpatient care and those who can safely be discharged.|"In comparison to the precedent studies, this project is characterised by some innovative aspects as regards to the design of intervention:~1. the participation of both a geriatrician and a nurse expert in transitional care, with the consultancy of a social worker when needed, in the management of the elderly patient within ED, adds to the project a greater operational capacity of the multidimensional assessment (CGA) of planning the best care setting for the patient.~2. The proposed CGA model is complete in the analysis of the different domains (social, clinical, functional, cognitive-affective) and achievable in this particular urgent setting.~3. The program examines, unlike other studies, much more variables that can help to define the effectiveness of the intervention.~4. The involvement in the network program of three main hospitals of the Emilia Romagna with a pool of elderly patients afferent to ED of about 20,000 elderly/year per hospital (2019 data prior of Sars Cov2 pandemic)"
219169923|NCT06795321|PROCEDURE|Spinal anesthesia|Patients who preferred spinal anesthesia were included in this group.
219169924|NCT06795321|PROCEDURE|General anesthesia|Patients who preferred spinal anesthesia were included in this group
219169925|NCT06840639|PROCEDURE|Dentoalveolar surgery|Surgery to extract teeth
219169926|NCT05328427|OTHER|Stopping|Discontinuation of nucleoside analogue
219169927|NCT05548426|DRUG|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
219169928|NCT05548426|DRUG|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
219169929|NCT06797752|DEVICE|OCTA Scan|Optical Coherence Tomography Angiography before and after receiving the stellate ganglion nerve block.
219169930|NCT06793332|DRUG|Ivonescimab Combined With TROP2 ADC|Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
219239405|NCT00212888|BIOLOGICAL|Remune and ALVAC|"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
219239406|NCT04822025|BIOLOGICAL|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
219239407|NCT04822025|BIOLOGICAL|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
219239408|NCT03268850|OTHER|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
219239409|NCT03268850|BEHAVIORAL|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
219239410|NCT03268850|BEHAVIORAL|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
219239411|NCT02683317|DIETARY_SUPPLEMENT|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
219737813|NCT05186077|OTHER|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
219737814|NCT04227522|DRUG|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
219737815|NCT04227522|DRUG|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
219737816|NCT01861275|DEVICE|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
219737817|NCT00674843|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
219737818|NCT01444924|DRUG|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
219737819|NCT01444924|DRUG|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
219737820|NCT00694928|DRUG|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
219737821|NCT00694928|DRUG|butoconazole nitrate|semi-solid, single dose
219737822|NCT02743754|OTHER|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
219737823|NCT02743754|OTHER|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
219737824|NCT05118529|OTHER|Routine care|Mobilization to chair
219737825|NCT05591300|DIAGNOSTIC_TEST|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
219737826|NCT03797326|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
219737827|NCT03797326|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle.
219737828|NCT05455658|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
219737829|NCT05455658|BIOLOGICAL|Sargramostim|Given ID
219737830|NCT04754399|DRUG|Cannabidiol (CBD)|"week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food"
219737831|NCT05555576|DIETARY_SUPPLEMENT|Vitamin C|1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
219737832|NCT05555576|OTHER|Placebo|Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
219737833|NCT04933422|DRUG|CM93|oral capsule of CM93 administered once daily
219737834|NCT04462393|OTHER|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
219737835|NCT04565756|DRUG|EXN407|EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
219239412|NCT02683317|DIETARY_SUPPLEMENT|sunflower oil|Sunflower similar to the excipient used in experimental group
219239413|NCT02457078|DIETARY_SUPPLEMENT|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
219239414|NCT02457078|DIETARY_SUPPLEMENT|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
219239415|NCT00957918|DRUG|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
219239416|NCT00957918|OTHER|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
219239417|NCT01901302|DRUG|CB-5945|
219239418|NCT01901302|DRUG|Placebo|
219239419|NCT01124916|PROCEDURE|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
219239420|NCT01124916|PROCEDURE|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
219239421|NCT00834483|DEVICE|Knotless suture for wound closure|Angiotech Quill SRS
219239422|NCT00834483|DEVICE|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
219239423|NCT02158793|PROCEDURE|Craniomaxillofacial allotransplantation|Transplantation of donor face
219239424|NCT02787135|BEHAVIORAL|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
219239425|NCT00995618|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
219239426|NCT00995618|DRUG|Febuxostat|Febuxostat Tablets, 40 mg, QD
219239427|NCT00995618|DRUG|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
219239428|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA+)|Six cooking classes + enhanced elements, such as diabetes-specific nutrition and cooking information, and online educational information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. This arm will have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up. Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
219239429|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA)|Participants will attend cooking and educational sessions once per week for 6 weeks. In addition, they will receive recipes and produce boxes with instructions to prepare the recipe at some point prior to their next class. They will also be invited to the online Google Classroom site where all intervention materials will be housed for their convenience. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up (kits provided at the final cooking class, for a total of 6 fecal samples per participant). Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
219239430|NCT05871489|DRUG|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
219239431|NCT05871489|DRUG|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
219239432|NCT05871489|DRUG|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
219239433|NCT02397226|PROCEDURE|Radiofrequency ablation|
219239434|NCT02397226|PROCEDURE|High ligation/stripping|
219239435|NCT02397226|DEVICE|Radiofrequency ablation catheter|
219239436|NCT02397226|PROCEDURE|Tumescent anesthesia|
219239437|NCT02397226|PROCEDURE|General anesthesia|
219239438|NCT02397226|DEVICE|Vein stripping catheter|
219239439|NCT01442766|DRUG|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
219239440|NCT01442766|DRUG|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
219239441|NCT03014726|COMBINATION_PRODUCT|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
219737836|NCT05377216|DRUG|Stellate Ganglion Block|Left sided percutaneous stellate ganglion block
219737837|NCT01331330|DEVICE|Deep Brain Stimulation|Normal DBS Programming
219737838|NCT01331330|DEVICE|Deep Brain Stimulation|Low Programming
219737839|NCT03069937|DRUG|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
219737840|NCT03069937|DRUG|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
219737841|NCT05614336|BIOLOGICAL|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
219737842|NCT03302429|OTHER|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
219737843|NCT03302429|OTHER|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
219737844|NCT02370862|DRUG|Neostigmine and Glycopyrrolate|
219737845|NCT00231465|DRUG|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
219169931|NCT06839950|OTHER|Calm room|"The calm room combines the effects of music, light, and videos designed with natural atmospheres. Four themes are offered in the calm room: Comfort, Optimism, Freshness, and Lullaby. These themes feature nature videos, combining relaxing images with calm musical ambiance. The lighting can be adjusted by the user, who can choose from a varied color palette. The available lights have a low glare level, and the light intensity can also be adjusted by the user.~They can be used by patients any time they want and for as long as they want."
219169932|NCT06789393|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.5 mcg/kg).
219169933|NCT06789393|DRUG|Bupivacaine|Penile block with bupivacaine 0.25% (0.2 ml/kg)
219169934|NCT06796205|OTHER|Treated zones exposed with Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
219169935|NCT06796205|OTHER|Untreated zone exposed with Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
219169936|NCT06791954|OTHER|Exercise|Clinical pilates program
219169937|NCT06795360|OTHER|discontinuation of weight loss medication|Participants will be studied right before their injectable weight loss medication runs out, and 3 months later
219169938|NCT05831709|OTHER|Exercise program|The intervention consists of a supervised exercise program
219169939|NCT06794944|DRUG|Vancomycin (POC)|Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. Patients will receive 125mg PO every 6 hours for 10 days.
219169940|NCT06794944|DRUG|Fidaxomicin|Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. Patients will receive 200mg PO twice daily for 10 days.
219169941|NCT06796530|PROCEDURE|Cardiopulmonary exercise test (CPET)|Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).
219169942|NCT06796530|PROCEDURE|High-intensity circuit training|The patients will undergo a 10-minute warm-up, followed by \~30 high intensity exercise circuit.
219169943|NCT05947071|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
219169944|NCT05947071|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
219169945|NCT06794957|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
219169946|NCT02780128|PROCEDURE|Biopsy|Needle or incisional tumor biopsy
219169947|NCT02780128|GENETIC|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
219169948|NCT02780128|PROCEDURE|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
219169949|NCT02780128|PROCEDURE|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
219169950|NCT02780128|OTHER|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
219169951|NCT02780128|OTHER|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
219169952|NCT02780128|OTHER|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
219169953|NCT02780128|OTHER|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
219169954|NCT02780128|BEHAVIORAL|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
219169955|NCT02780128|OTHER|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
219169956|NCT02780128|OTHER|Echocardiogram|The participant will have an Echocardiogram (ECHO), an ultrasound of the heart, taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
219169957|NCT02780128|DRUG|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
219169958|NCT02780128|DRUG|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
219169959|NCT06790186|BEHAVIORAL|Perceive, Recall, Plan and Perform intervention Interventions:|The PRPP is a standardized system which determines the impact of information processing on performance of everyday activities. It is a method for assessment of performance mastery, and efficient use of cognitive strategies, as well as a model of intervention to train mastery and cognitive strategy use, in everyday activities. The PRPP assess task performance mastery, as well as cognitive strategy application
219169960|NCT01803438|DEVICE|cryoballoon ablation system|
219169961|NCT01803438|DRUG|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
219169962|NCT06832514|BIOLOGICAL|Serogroup B meningococal vaccine|The 4CMenB vaccine will be administered via two intramuscular (IM) injections in the non-dominant upper arm, with a one month interval.
219169963|NCT06489418|OTHER|Dew Restore Barrier Repair Cream|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical"
219169964|NCT04402489|DRUG|Placebo|Placebo
219169965|NCT04402489|DRUG|MT-7117 Low Dose|MT-7117 Low Dose
219169966|NCT04402489|DRUG|MT-7117 High Dose|MT-7117 High Dose
219169967|NCT06840184|BEHAVIORAL|Cognitive Behavioral Therapy based Intervention|"Session 1: Introduction of CBT, Relationship between events, thoughts and behavior.~Session 2: Psychoeducation about the vicious circle of inactivity and depression, Ladder technique for task management.~Session 3: Problem solving techniques and discussion about them, Decision making techniques through Advantages/ Disadvantages chart.~Session 4: Identifying positive and negative emotions, Cognitive errors were explained.~Session 5: Identifying negative thoughts through Socratic questioning, Finding evidence for and against the thoughts, Challenging negative thought, Cracking firm irrational beliefs.~Session 6: Cognitive restructuring techniques, Finding alternative thoughts."
219169968|NCT06840184|OTHER|No intervention|No intervention was provided to the control group, except for a few members who requested for the therapy, that too after the post assessment.
219169969|NCT06796023|OTHER|Stretching and strengthening exercises for back muscles|Stretching and strengthening exercises for back muscles
219169970|NCT06796023|OTHER|Lumbar stabilization Exercises|Lumbar stabilization Exercises
219169971|NCT06796023|OTHER|Lumbar Manipulation|Lumbar Manipulation
219169972|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
219169973|NCT05902793|DEVICE|Investigational device: V.A.C. VERAFLO™ Dressing Kit|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
219169974|NCT05902793|DEVICE|Comparator device: Negative pressure wound drainage material|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
219169975|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
219169976|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
219169977|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
219169978|NCT06846112|PROCEDURE|Robotic partial nephrectomy|Robotic partial nephrectomy (RPN) is the treatment of choice for organ-confined renal tumors. For to improve functional outcomes, we designed an off-clamp and suture-free approach (SL) to limit the ischemic damage and destruction of the renal parenchyma caused, respectively, by temporary closure of the vessels of the renal hilum and by renorrhaphy (RR) (i.e. by the juxtaposition of the margins of resection of the enucleation bed, which is commonly performed at the end of tumor exeresis using suture threads stopped by surgical clips)
219169979|NCT05216250|BIOLOGICAL|BOTOX|Intramuscular injection
219169980|NCT05216250|DRUG|Placebo for BOTOX|Intramuscular injection
219737846|NCT00231465|DRUG|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
219737847|NCT04817579|DEVICE|Digital photography combined with eLABor_aid shade analyzing software|ELABor\_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
219737848|NCT04817579|DEVICE|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
219737849|NCT04817579|DEVICE|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
219239442|NCT03958305|PROCEDURE|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
219239443|NCT06000371|DEVICE|Vacuum assisted Closure application|Vacuum assisted Closure Application in Diabetic Foot Ulcers
219239444|NCT01068977|DRUG|bevacizumab|Repeating intravenous dose
219239445|NCT01068977|DRUG|MetMAb|Repeating escalating intravenous dose
219239446|NCT01068977|DRUG|MetMAb|Repeating intravenous dose
219169983|NCT06843694|OTHER|video game|The students in the video game group will be given training. The students in this group (n=30) will be divided into 4 groups and each group will have 5 students. The students will be given training about the Video Game (Lifesaver) by the researcher beforehand. The Video Game (Lifesaver-Cankurtaran); is a free video game developed by the Resuscitation Council in English.
219169984|NCT00579124|DEVICE|CliniMACs|T and B Cell depletion
219169985|NCT03854578|DRUG|BI 1358894|Film-coated tablet
219169986|NCT03854578|DRUG|Placebo matching BI 1358894|Film-coated tablet
219169987|NCT03854578|DRUG|Citalopram|Film-coated tablet
219169988|NCT01525966|DRUG|carboplatin|Given IV
219169989|NCT01525966|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219169990|NCT01525966|OTHER|laboratory biomarker analysis|Correlative studies
219169991|NCT06848101|DIETARY_SUPPLEMENT|Carotenoid Group|Treatment will contain 20mg free lutein (10mg/softgel), 4 mg free zeaxanthin (2mg/softgel), 40mg maqui berry extract (20mg/softgel), 6 mg astaxanthin (3 mg/softgel), 80mg bilberry extract (40mg/softgel), flaxseed oil (150mg/softgel), and vitamin E (5IU/softgel)
219169992|NCT06848101|DIETARY_SUPPLEMENT|Control (placebo) group|Flaxseed Oil (330mg)
219169993|NCT06845995|DIETARY_SUPPLEMENT|Synbiotic supplement|Daily synbiotic supplement: The synbiotic supplement (contains both probiotic and prebiotic) that will be used in this study is commercially available; Celebrate Balance. The probiotic will be one capsule daily and consists of lactobacillus acidophilus, Bifidobacterium longum, lactobacillus rhamnosus, and lactobacillus gasser at 28,5 Billion CFUs at manufacture / 15 billion CFUs guaranteed at expiration
219169994|NCT04328844|DRUG|IOA-244|IOA-244 will be administered orally once daily (QD)
219169995|NCT04328844|DRUG|Avelumab Injection|Avelumab will be administered IV every 2 weeks
219169996|NCT04328844|DRUG|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
219169997|NCT04328844|DRUG|Cisplatin|Cisplatin will be administered IV every 3 weeks
219169998|NCT04328844|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
219169999|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
219170000|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
219170001|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
219170002|NCT06846983|DEVICE|Peripheral perfusion index pulse oximeter|Masimo pulse oximeter probe for measuring peripheral perfusion index and predicting success of caudal block
219170003|NCT06847451|DIAGNOSTIC_TEST|Prognostic biomarker as Red Cell Distribution Width|Assessment of prognostic value of Red Cell Distribution Width in septic intensive care unit patients for 28 days mortality.
219170004|NCT05197816|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that adapts to patient activity and/or physiology
219239447|NCT00570622|DRUG|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
219239448|NCT00570622|DRUG|Placebo|Patients receive placebo once a day orally for 9 days
219239449|NCT05584306|DRUG|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
219239450|NCT05584306|DRUG|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
219239451|NCT05584306|DRUG|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
219239452|NCT05584306|OTHER|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
219239453|NCT05584306|OTHER|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
219239454|NCT05584306|OTHER|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
219239455|NCT03276286|DEVICE|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
219239456|NCT01051648|DRUG|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
219239457|NCT03073902|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
219239458|NCT05602272|PROCEDURE|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
219239459|NCT00901459|DEVICE|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
219239460|NCT00901459|DEVICE|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
219239461|NCT00901459|DEVICE|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
219239462|NCT04478409|BIOLOGICAL|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
219239463|NCT01373723|OTHER|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
219239464|NCT05668845|OTHER|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
219239465|NCT05668845|OTHER|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>
219239466|NCT04433052|BEHAVIORAL|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
219239467|NCT01755130|PROCEDURE|Photoacoustic Imaging|Undergo LOUISA 3D
219239468|NCT02633228|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
219239469|NCT01196286|BEHAVIORAL|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
219239470|NCT01196286|BEHAVIORAL|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
219239471|NCT02627586|OTHER|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
219239472|NCT02627586|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
219239473|NCT04970459|BIOLOGICAL|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
219239474|NCT04765046|DEVICE|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
219239475|NCT02085824|DRUG|Enoxaparin|
219239476|NCT02085824|DRUG|rivaroxaban|
219239477|NCT02085824|DRUG|dabigatran|
219239478|NCT05520411|DIETARY_SUPPLEMENT|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
219239479|NCT03210025|DRUG|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
219239480|NCT03210025|DRUG|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
219239481|NCT05334225|OTHER|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
219239482|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
219239483|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
219239484|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
219239485|NCT00668057|DRUG|Placebo|5 mg matching placebo
219239486|NCT00668057|DRUG|Placebo|10 mg matching placebo
219239487|NCT00668057|DRUG|Placebo|20 mg matching placebo
219239488|NCT01634802|OTHER|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
219239489|NCT01634802|OTHER|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
219239490|NCT03204773|DIAGNOSTIC_TEST|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
219239491|NCT03204773|DIAGNOSTIC_TEST|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
219737850|NCT06150443|OTHER|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
219737851|NCT06150443|OTHER|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
219737852|NCT00968968|DRUG|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
219239492|NCT03204773|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|Testing for pain
219239493|NCT03204773|DIAGNOSTIC_TEST|Becks Depression Inventory (BDI)|Screening for depression
219239494|NCT03204773|DIAGNOSTIC_TEST|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
219239495|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~1. Normal result~2. Ultralow or Dysbiotic result~3. Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
219239496|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
219239497|NCT00233545|DRUG|miltefosine|
219737853|NCT00968968|BIOLOGICAL|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
219737854|NCT05354258|DRUG|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
219239498|NCT00233545|DRUG|antimony|
219239499|NCT00694902|DRUG|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
219239500|NCT00694902|DRUG|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
219239501|NCT03256305|DEVICE|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
219239502|NCT03256305|DEVICE|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
219239503|NCT04927949|DRUG|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
219239504|NCT04927949|PROCEDURE|standard PCI|primary PCI without cangrelor
219737855|NCT05354258|DRUG|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
219737856|NCT05354258|DRUG|Amodiaquine|SMC partner drug
219737857|NCT05354258|DRUG|Sulfadoxine pyrimethamine|SMC partner drug
219170005|NCT05098795|BEHAVIORAL|Behavioral Activation (BA)|BA seeks to increase the positive reinforcement patients experience from their natural environment by promoting prosocial and valued experiences. BA has been found to improve substance use treatment retention and adherence, as well as medication adherence in low-income individuals with HIV/AIDS.
219170006|NCT03158805|DRUG|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
219170007|NCT03158805|OTHER|Placebo|Placebo injection
219170008|NCT05988203|BIOLOGICAL|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
219170009|NCT03554109|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219170010|NCT03554109|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219170011|NCT03554109|DRUG|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
219170012|NCT03554109|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
219170013|NCT03554109|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219170014|NCT03554109|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219170015|NCT03554109|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
219170016|NCT03554109|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
219170017|NCT03554109|BIOLOGICAL|GI-6207|CEA yeast vaccine
219170018|NCT03554109|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219170019|NCT03554109|DRUG|Avelumab|Avelumab
219170020|NCT03554109|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219170021|NCT03554109|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
219170022|NCT03554109|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219170023|NCT03554109|DRUG|Doxorubicin HCL|Doxorubicin HCL
219170024|NCT03554109|DRUG|paclitaxel|paclitaxel
219170025|NCT05063994|DRUG|Chronocort|Over-encapsulated hydrocortisone modified-release capsule for oral administration.
219737858|NCT03390491|BEHAVIORAL|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
219737859|NCT03390491|BEHAVIORAL|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
219737860|NCT02801773|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
219737861|NCT02801773|OTHER|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
219170026|NCT05063994|DRUG|Cortef|Over-encapsulated hydrocortisone immediate-release tablet for oral administration.
219170027|NCT05063994|OTHER|Placebo|Matching placebo
219170028|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
219170029|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
219170030|NCT04509427|BEHAVIORAL|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
219170031|NCT04509427|BEHAVIORAL|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
219239505|NCT03277391|PROCEDURE|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
219239506|NCT03277391|DEVICE|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
219239507|NCT02741297|DEVICE|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
219239508|NCT01875016|PROCEDURE|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
219239509|NCT03463122|DEVICE|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
219239510|NCT03463122|OTHER|conventional therapy|conventional therapy for stroke rehabilitation
219239511|NCT00149565|DRUG|IFN-α2b|
219170032|NCT04509427|BEHAVIORAL|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
219170033|NCT04509427|BEHAVIORAL|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
219170034|NCT04509427|BEHAVIORAL|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
219170035|NCT03723772|DRUG|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
219170036|NCT03723772|DRUG|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
219170037|NCT05478837|DRUG|Cyclophosphamide|Given IV
219170038|NCT05478837|DRUG|Fludarabine|Given IV
219170039|NCT05478837|BIOLOGICAL|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
219239512|NCT02959866|OTHER|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
219239513|NCT02718456|BEHAVIORAL|Expedited CD4 testing|
219239514|NCT02718456|BEHAVIORAL|Supplemental peer counseling|
219239515|NCT01212809|DEVICE|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
219239516|NCT01212809|DEVICE|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
219239517|NCT02350426|OTHER|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
219239518|NCT02350426|OTHER|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
219239519|NCT02350426|OTHER|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
219239520|NCT00952523|DRUG|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
219239521|NCT00952523|DRUG|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
219239522|NCT05383586|OTHER|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
219239523|NCT00423215|DRUG|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
219737862|NCT00600782|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
219737863|NCT02380872|PROCEDURE|Connective tissue graft|gingival recession treated with connective tissue graft
219737864|NCT02380872|PROCEDURE|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
219737865|NCT01321645|DRUG|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
219737866|NCT01909401|DRUG|boceprevir|
219737867|NCT00949936|DEVICE|CAdisc™-L (Total Disc Replacement)|
219737868|NCT03782103|DRUG|ZuraPrep Clear Solution|Apply topically.
219737869|NCT03782103|DRUG|ChloraPrep|Apply topically.
219737870|NCT03782103|DRUG|ZuraPrep Vehicle|Apply topically.
219737871|NCT01260415|DRUG|Panitumumab, Oxaliplatin, 5-FU|"* Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours"
219239524|NCT01345708|DRUG|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
219239525|NCT05718492|PROCEDURE|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
219239526|NCT05718492|DRUG|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
219239527|NCT04680559|BEHAVIORAL|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
219239528|NCT04680559|BEHAVIORAL|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
219239529|NCT05540951|DRUG|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
219239530|NCT05540951|DRUG|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
219239531|NCT02391766|BEHAVIORAL|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
219239532|NCT02391766|BEHAVIORAL|usual care|
219239533|NCT03404440|OTHER|L.Reuteri|
219239534|NCT05541341|OTHER|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
219239535|NCT02158845|DRUG|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
219239536|NCT02158845|DRUG|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
219239537|NCT02951806|DRUG|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
219239538|NCT02951806|DRUG|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
219239539|NCT04904731|OTHER|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
219239540|NCT02793752|OTHER|Age|Maternal Age
219239541|NCT03529942|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
219239542|NCT00634348|DRUG|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
219239543|NCT00634348|DRUG|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
219239544|NCT00002094|DRUG|Atevirdine mesylate|
219239545|NCT04239976|DEVICE|FitBit|Wear FitBit for gait assessment test
219239546|NCT04239976|OTHER|Gait Assessment Test|Undergo gait assessment test
219239547|NCT04239976|OTHER|MC5-A Scrambler Therapy|Undergo scrambler therapy
219239548|NCT04239976|OTHER|Quality-of-Life Assessment|Ancillary studies
219239549|NCT04239976|PROCEDURE|Quantitative Sensory Testing|Undergo quantitative sensory test
219239550|NCT04239976|OTHER|Questionnaire Administration|Ancillary studies
219239551|NCT03236727|DRUG|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
219239552|NCT04619823|OTHER|Blood sample collection|Blood sample collection Mosquito collection at home
219239553|NCT02558803|BEHAVIORAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
219239554|NCT04099186|PROCEDURE|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
219239555|NCT02570971|DRUG|Mannitol|
219239556|NCT01483131|OTHER|Exercise training|12 weeks of resistance training twice a week.
219239557|NCT01483131|OTHER|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
219239558|NCT05356065|OTHER|survey administration|Outcome Measures
219239559|NCT05567302|OTHER|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
219239560|NCT05567302|OTHER|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
219239561|NCT04455542|OTHER|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
219239562|NCT04455542|OTHER|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
219239563|NCT04455542|OTHER|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
219239564|NCT06443736|PROCEDURE|Standardized perineal massage|Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
219239565|NCT06443736|BEHAVIORAL|Primary prevention|Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
219239566|NCT04471298|DRUG|Qishenyiqi dripping pills, 6 bags|28 consecutive days
219170040|NCT06757933|COMBINATION_PRODUCT|The Spencer technique|The Spencer technique, which consists of seven different manual movements intended to increase shoulder mobility and lessen pain, was used to treat the participants in this group. The method seeks to improve blood flow, loosen up the shoulder joint and soft tissues, and reduce any tightness or impingement that is causing pain in the sub-acromial area. By re-establishing appropriate shoulder function and movement patterns, the Spencer approach is commonly used to treat disorders including adhesive capsulitis.
219170041|NCT06757933|COMBINATION_PRODUCT|isotonic workouts|This group's members engaged in isotonic workouts that emphasized forward flexion and extension motions. Both concentric (shortening the muscle) and eccentric (lengthening the muscle) motions were used in these exercises. These exercises were designed to increase shoulder range of motion and strengthen the rotator cuff muscles. People with Adhesive Capsulitis may have less pain and have better shoulder function if they perform isotonic workouts, which increase muscular strength and stability.
219170042|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
219170043|NCT05633446|OTHER|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
219170044|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
219170045|NCT05633446|OTHER|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
219170046|NCT04581603|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 \& 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
219170047|NCT04581603|BEHAVIORAL|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
219239567|NCT04471298|DRUG|Qishenyiqi dripping pills, 9 bags|28 consecutive days
219239568|NCT04471298|DRUG|Qishenyiqi dripping pills, 12 bags|28 consecutive days
219239569|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
219239570|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
219239571|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
219239572|NCT04729361|GENETIC|CGH array analysis|CGH array analysis
219239573|NCT06328322|PROCEDURE|Percutaneous Coronary Intervention in Left Main Artery Disease|To investigate and assess the effectiveness and safety of percutaneous coronary intervention in left main coronary artery disease in sitting of acute coronary syndromes.
219239574|NCT03733951|DRUG|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
219239575|NCT01736449|DRUG|Bevacizumab|
219239576|NCT03905512|DRUG|SEL-212|Administered as specified in the treatment arm
219239577|NCT03905512|DRUG|KRYSTEXXA®|Administered as specified in the treatment arm
219239578|NCT04990388|BIOLOGICAL|UX053|mRNA-based biologic
219239579|NCT04990388|OTHER|Placebo|consists of the same components as the formulation buffer for UX053
219239580|NCT04990388|DRUG|Antipyretic|participants will receive oral premedication prior to infusion
219239581|NCT04990388|DRUG|H2 Blocker|participants will receive oral premedication prior to infusion
219239582|NCT04990388|DRUG|H1 Blocker|participants will receive oral premedication prior to infusion
219239583|NCT03421301|DIETARY_SUPPLEMENT|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
219239584|NCT04769141|COMBINATION_PRODUCT|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
219239585|NCT00415688|BEHAVIORAL|Low carbohydrate, ketogenic diet|
219239586|NCT00415688|BEHAVIORAL|Low glycemic index, reduced calorie diet|
219239587|NCT00004784|DRUG|methotrexate|
219239588|NCT00004784|DRUG|ursodiol|
219737872|NCT06131463|DEVICE|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
219737873|NCT00270569|DRUG|PhyxolTM, Cisplatin|
219737874|NCT03087357|OTHER|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
219737875|NCT00930176|BIOLOGICAL|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
219239589|NCT00725972|OTHER|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
219239590|NCT00725972|PROCEDURE|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
219239591|NCT05585632|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219239592|NCT05585632|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219239593|NCT05585632|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219239594|NCT05585632|BIOLOGICAL|mRNA-1045|Formulation for injection
219239595|NCT05585632|BIOLOGICAL|mRNA-1230|Formulation for injection
219239596|NCT02493166|OTHER|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
219239597|NCT00894218|PROCEDURE|Arthroplasty|Hip or knee arthroplasty
219239598|NCT00866619|BIOLOGICAL|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
219239599|NCT00866619|BIOLOGICAL|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
219239600|NCT00866619|BIOLOGICAL|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
219239601|NCT00866619|BIOLOGICAL|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
219239602|NCT00866619|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
219239603|NCT03762278|DIETARY_SUPPLEMENT|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
219737876|NCT02058277|DRUG|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
219737877|NCT04006756|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
219737878|NCT04006756|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
219737879|NCT01363830|BEHAVIORAL|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
219737880|NCT01363830|BEHAVIORAL|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
219737881|NCT01137760|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose daily for 8 weeks
219170048|NCT05514730|BEHAVIORAL|Phase-based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children|PBT is a skills-based protocol that primarily works with caregivers to manage problematic behavior and to teach children healthy information about sex and sexuality. It was designed based on the current empirical knowledge regarding the etiology and treatment of childhood problematic sexual behavior. It is delivered in 12 weekly sessions, with each session lasting approximately 50 minutes.
219170049|NCT05514730|BEHAVIORAL|Treatment-as-Usual (TAU)|The TAU intervention designed for this trial relies largely on the delivery of child-focused treatment techniques, particularly on the development of therapeutic rapport through the utilization of non-directive techniques. These sessions are supplemented with educational materials for the caregiver on child behavior and parenting recommendations. This treatment is designed to be administered over 12 weekly sessions, with each session lasting approximately 50 minutes.
219170050|NCT05831540|OTHER|Discussion|Participate in focus group
219170051|NCT05831540|OTHER|Educational Activity|Undergo training to use CDS tool
219170052|NCT05831540|BEHAVIORAL|Healthcare Activity|Utilize CDS tool
219170053|NCT05831540|OTHER|Survey Administration|Complete survey
219170054|NCT04507555|PROCEDURE|Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing|"The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist."
219170055|NCT04507555|PROCEDURE|Standard care antidepressant selection and dosing|Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
219170056|NCT03542383|DEVICE|High Definition Transcranial Direct Current Stimulation|Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
219170057|NCT03542383|DEVICE|Sham High Definition Transcranial Direct Current Stimulation|Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
219170058|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
219170059|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
219170060|NCT06024122|OTHER|IRM exam|A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
219170061|NCT05877014|OTHER|questionnaires|EQ-5D-5L and SF-12
219170062|NCT05877014|OTHER|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
219170063|NCT05831657|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
219170064|NCT05831657|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
219170065|NCT04966104|BEHAVIORAL|ODYSSEE-vCHAT|Automated digital counselling program with social network support
219170066|NCT05519228|DEVICE|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
219170067|NCT01180634|DRUG|Aeroquin|Inhalation Solution
219170068|NCT01180634|DRUG|Placebo|Inhalation Solution
219170069|NCT06166004|OTHER|Balance Training|Balance Training device with VR
219170070|NCT06166004|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
219170071|NCT06783725|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) is a structured program designed to help individuals with chronic insomnia improve their sleep patterns through mindfulness practices. It combines mindfulness meditation, cognitive behavioral strategies, and sleep education to address the cognitive and physiological factors that disrupt sleep. The therapy emphasizes present-moment awareness, acceptance of sleep difficulties, and the reduction of sleep-related anxiety to promote better sleep quality and overall well-being.
219737882|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
219737883|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
219737884|NCT02027194|DRUG|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
219737885|NCT02027194|DRUG|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
219737886|NCT02027194|DRUG|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
219737887|NCT00440570|DEVICE|Low levels of amplitude-modulated electromagnetic fields|
219737888|NCT00440570|DEVICE|Emitter of low levels of amplitude-modulated electromagnetic fields|
219737889|NCT02167360|DRUG|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
219737890|NCT03406975|DEVICE|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
219737891|NCT03406975|BEHAVIORAL|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
219737892|NCT04877639|DRUG|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
219737893|NCT00220714|DRUG|atypical antipsychotics:oral vs. long-acting route|
219737894|NCT00220714|BEHAVIORAL|Family Psychoeducation|
219737895|NCT03709095|OTHER|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
219239604|NCT03762278|DIETARY_SUPPLEMENT|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
219239605|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
219239606|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
219239607|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
219239608|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
219239609|NCT03560206|BEHAVIORAL|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
219239610|NCT03560206|BEHAVIORAL|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
219239611|NCT00783146|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
219239612|NCT00783146|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
219239613|NCT00783146|DRUG|placebo|placebo, once daily for 15 days
219239614|NCT03987074|DRUG|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
219239615|NCT03987074|DRUG|Firsocostat|Tablets administered orally once daily
219239616|NCT03987074|DRUG|Cilofexor|Tablets administered orally once daily
219239617|NCT00385866|BEHAVIORAL|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
219239618|NCT00385866|BEHAVIORAL|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
219239619|NCT01138969|DRUG|esomeprazole|esomeprazole 20 mg qd for 6 months
219239620|NCT05062343|DEVICE|Dilapan-S|Osmotic dilator
219239621|NCT05062343|DEVICE|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
219239622|NCT04573218|DRUG|Placebo|The placebo contains glucose
219239623|NCT04573218|DIETARY_SUPPLEMENT|250 mg OPP|250 mg Oil Palm Phenolics
219239624|NCT01334606|DEVICE|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
219239625|NCT01334606|DEVICE|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
219239626|NCT01513733|DRUG|tasquinimod|tasquinimod 0.25 mg continuously
219239627|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
219239628|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
219239629|NCT01499979|PROCEDURE|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
219239630|NCT02674399|DRUG|JointStem|
219239631|NCT02674399|DRUG|Synvisc-One|
219239632|NCT02766361|BEHAVIORAL|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
219239633|NCT02766361|OTHER|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
219239634|NCT05435105|BEHAVIORAL|Virtual reality|Distraction method
219239635|NCT05435105|BEHAVIORAL|Local cold-vibration|Distraction method
219239636|NCT05197179|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
219239637|NCT05197179|OTHER|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
219239638|NCT04805008|OTHER|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
219239639|NCT04805008|OTHER|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
219239640|NCT02099188|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
219239641|NCT02099188|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
219239642|NCT02099188|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
219239643|NCT02099188|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
219239644|NCT02099188|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
219239645|NCT02099188|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
219239646|NCT02099188|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
219239647|NCT02099188|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
219239648|NCT02099188|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
219239649|NCT02099188|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
219239650|NCT02590770|BEHAVIORAL|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
219239651|NCT02590770|OTHER|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
219170072|NCT06783725|BEHAVIORAL|Wait-list control|The wait-list control group consists of participants who do not receive the intervention during the initial study period but are placed on a waitlist to receive it after the trial concludes. This group serves as a comparison to evaluate the effectiveness of the intervention while ensuring participants eventually have access to the treatment. It helps control for natural changes over time and the psychological effects of expecting future treatment.
219239652|NCT01858324|OTHER|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
219239653|NCT01929161|DRUG|Oxytocin|24 International Units
219239654|NCT01929161|DRUG|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
219239655|NCT01929161|BEHAVIORAL|Lovingkindness Meditation|
219239656|NCT01929161|BEHAVIORAL|Mindfulness Meditation|
219239657|NCT02128893|DRUG|Isavuconazole|oral
219239658|NCT02128893|DRUG|Esomeprazole|oral
219239659|NCT00007826|BIOLOGICAL|BCG vaccine|
219239660|NCT00007826|BIOLOGICAL|monoclonal antibody 105AD7 anti-idiotype vaccine|
219239661|NCT00007826|DRUG|alum adjuvant|
219239662|NCT02142569|DRUG|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
219239663|NCT02142569|DRUG|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
219239664|NCT02142569|DRUG|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
219239665|NCT02142569|DEVICE|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
219239666|NCT04853654|OTHER|exercise|exercise training for 8 weeks
219239667|NCT01212913|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
219239668|NCT01212913|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
219239669|NCT01212913|DRUG|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
219239670|NCT02138838|DRUG|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
219239671|NCT02138838|DIETARY_SUPPLEMENT|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
219239672|NCT02106078|BEHAVIORAL|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
219239673|NCT02106078|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies"
219737896|NCT03709095|OTHER|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
219737897|NCT03056430|BEHAVIORAL|Training|
219737898|NCT00401830|DRUG|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
219737899|NCT00401830|OTHER|Placebo|Matching placebo tablet administered twice daily
219737900|NCT02425488|BEHAVIORAL|Nursing therapeutics education|"Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1\) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
219737901|NCT03120923|DRUG|Lidocaine 3 cc|
219737902|NCT03120923|DRUG|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
219737903|NCT03120923|DRUG|Triamcinolone Acetonide|
219737904|NCT02623439|DRUG|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
219737905|NCT05156814|DRUG|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
219737906|NCT05156814|DRUG|Duphaston|Duphaston®, 10 mg
219737907|NCT05156814|DRUG|Klimadynon|Cimicifuga racemosa rhizomatum extract
219737908|NCT05156814|DRUG|Divigel|Divigel, 0.1%
219737909|NCT03315559|DRUG|[14C]-GSK2269557 IV infusion|The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
219737910|NCT03315559|DRUG|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
219737911|NCT03315559|DRUG|[14C]-GSK2269557 oral solution|The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
219737912|NCT03802357|PROCEDURE|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
219737913|NCT03378635|DRUG|Dasiglucagon|Glucagon analog
219737914|NCT03378635|DRUG|GlucaGen|Native glucagon
219737915|NCT03378635|DRUG|Placebo|Placebo for dasiglucagon
219737916|NCT05389800|OTHER|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
219737917|NCT02849223|DEVICE|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
219737918|NCT02849223|DEVICE|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
219737919|NCT01098578|DRUG|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
219737920|NCT06279403|DRUG|Toripalimab|Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
219170073|NCT06786221|DEVICE|mini-implant template|"The proposed structure will be made of three main components: a tooth guide part, a gingival guide part, and a steering part. The tooth guide and gingival guide parts are firmly connected by fracture lines. The mini-implant guide part is specifically designed to accommodate the angle and position required for miniscrew insertion. On the basis of the resin guide plate, add a guide hole structure and change it to simulate the patient's actual tooth root condition.~During usage, the guide can be pre-designed in accordance with the desired planting position and direction of the patient's mini-implant, enabling precise guidance during the implantation process. The designed guide's data is inputted into EnvisionTEC Vida 3D printer to create the mini-implant guide. Prior to the implantation of the mini-screw, patients will be informed about the potential risks and required to sign an informed consent form."
219170074|NCT06146842|DRUG|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
219170075|NCT03692611|BEHAVIORAL|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
219170076|NCT03692611|BEHAVIORAL|Comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
219170077|NCT06787989|BIOLOGICAL|BCMA-CD19 cCAR T cells|• BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219170078|NCT04419168|OTHER|cCBT|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.
219170079|NCT04419168|OTHER|m-Education|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
219170080|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
219170081|NCT04814082|DEVICE|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
219170082|NCT04814082|DEVICE|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
219170083|NCT06059144|DRUG|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
219170084|NCT03394079|PROCEDURE|PCI|Percutaneous Coronary Intervention
219170085|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
219170086|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
219170087|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
219170088|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
219170089|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
219170090|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
219170091|NCT05151380|DEVICE|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
219170092|NCT04490915|DRUG|Crinecerfont|CRF type 1 receptor antagonist
219170093|NCT04490915|DRUG|Placebo|Non-active dosage form
219170094|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
219170095|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
219170096|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
219170097|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
219170098|NCT05950243|BEHAVIORAL|Questionnaire|Questionnaire survey for data collection
219170099|NCT04795440|PROCEDURE|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
219170100|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
219170101|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
219170102|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
219170103|NCT04190303|OTHER|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
219170104|NCT05807841|PROCEDURE|percutaneous coronary intervention|IVUS-guided stent implantation
219170105|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
219170106|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
219170107|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
219170108|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
219170109|NCT04027309|DRUG|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
219170110|NCT04027309|DRUG|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
219170111|NCT02829814|DRUG|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
219170112|NCT02829814|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
219170113|NCT06501573|DRUG|SGB-9768|SGB-9768 for sc injection
219170114|NCT06501573|OTHER|Placebo|sterile normal saline (0.9% NaCl) for sc injection
219170115|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
219170116|NCT01280994|DRUG|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
219170117|NCT06211270|BEHAVIORAL|FRESH|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
219170118|NCT04692597|DEVICE|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
219170119|NCT04692597|DEVICE|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
219170120|NCT06335901|DRUG|Drug:Standard therapy|Percutaneous coronary Intervention
219170121|NCT06394414|DRUG|YL201|YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.
219170122|NCT02073994|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
219170123|NCT03002025|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 as SC injection.
219170124|NCT03002025|DRUG|Placebo|Participants will receive matching placebo to JNJ-64304500 as SC injection.
219170125|NCT04793776|BEHAVIORAL|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
219170126|NCT04793776|BEHAVIORAL|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
219170127|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
219170128|NCT06445010|OTHER|Creating Musical Playlist|Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
219239674|NCT02106078|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
219362375|NCT04406870|DRUG|Sirolimus Oral Product|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
219170129|NCT05878561|DRUG|Fimasartan + Indapamide|a fixed dose combination
219170130|NCT05878561|DRUG|Fimasartan + Indapamide placebo|a fixed dose combination
219170131|NCT06231823|OTHER|Extraction|Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
219170132|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
219170133|NCT03786783|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219170134|NCT03786783|DRUG|Carboplatin|Given IV
219170135|NCT03786783|DRUG|Cisplatin|Given IV
219170136|NCT03786783|DRUG|Cyclophosphamide|Given IV
219170137|NCT03786783|DRUG|Dexrazoxane|Given IV
219170138|NCT03786783|BIOLOGICAL|Dinutuximab|Given IV
219170139|NCT03786783|DRUG|Doxorubicin|Given IV
219170140|NCT03786783|DRUG|Etoposide|Given IV
219170141|NCT03786783|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219170142|NCT03786783|DRUG|Isotretinoin|Given PO
219170143|NCT03786783|DRUG|Melphalan|Given IV
219170144|NCT03786783|BIOLOGICAL|Sargramostim|Given SC
219170145|NCT03786783|DRUG|Thiotepa|Given IV
219170146|NCT03786783|DRUG|Topotecan|Given IV
219239675|NCT06372600|DEVICE|Extracorporeal shock wave therapy device|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
219737921|NCT06279403|PROCEDURE|Cytoreductive Nephrectomy|"Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively."
219737922|NCT06279403|DRUG|Axitinib|Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
219737923|NCT03409146|DEVICE|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
219737924|NCT03927755|OTHER|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
219737925|NCT05152095|OTHER|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
219737926|NCT05152095|OTHER|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
219737927|NCT02783963|DEVICE|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
219737928|NCT03996421|DIETARY_SUPPLEMENT|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
219737929|NCT03996421|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
219737930|NCT04902482|DEVICE|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
219737931|NCT05157789|OTHER|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
219737932|NCT01290354|DRUG|Lapatinib|Unlabelled, administered orally
219737933|NCT01290354|DRUG|[11C] lapatinib|Radiolabelled, administered intravenously
219737934|NCT05143515|BEHAVIORAL|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
219737935|NCT02956863|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
219737936|NCT02956863|PROCEDURE|Exercises|Exercise for stretching and strength for neck muscles
219737937|NCT01179620|DRUG|Certoparin|Certoparin
219737938|NCT06497686|DIAGNOSTIC_TEST|mesoscale nonlinear optical gigascope|An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
219737939|NCT06497686|DIAGNOSTIC_TEST|Fluorescence microscope|An optical microscope used to examine the fluorescence signal from stained tissues.
219737940|NCT02446288|DEVICE|TMJ Next Generation|
219737941|NCT02446288|DEVICE|DSG Relaxer|
219737942|NCT02496156|BEHAVIORAL|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
219737943|NCT02496156|BEHAVIORAL|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
219737944|NCT00089583|DRUG|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
219737945|NCT00089583|DRUG|Ritonavir|Ritonavir solution bid
219737946|NCT01005979|DRUG|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
219737947|NCT03778697|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
219170147|NCT03786783|DRUG|Vincristine|Given IV
219170148|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
219170149|NCT01441687|OTHER|laboratory biomarker analysis|Correlative studies
219170150|NCT01441687|PROCEDURE|transrectal prostate biopsy|Undergo prostate biopsy
219737948|NCT05918770|DIAGNOSTIC_TEST|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
219170151|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
219170152|NCT03705104|BEHAVIORAL|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
219170153|NCT00616967|DRUG|carboplatin|Given IV
219170154|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
219170155|NCT00616967|DRUG|vorinostat|Given orally
219170156|NCT00616967|OTHER|placebo|Given orally
219170157|NCT02910583|DRUG|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
219170158|NCT02910583|DRUG|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
219170159|NCT02910583|DRUG|Placebo|placebo capsules to match ibrutinib administered orally once daily
219170160|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
219170161|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
219170162|NCT01331005|DRUG|nepafenac 0.1% drops|One drop three times per day for one year
219170163|NCT01331005|OTHER|Nepafenac Vehicle|Placebo
219170164|NCT05401032|DRUG|Tamsulosin|Oral medication, once a day for 6 months.
219170165|NCT05401032|DRUG|5-hidroxitriptophan|Oral medication, 3 times a day for 6 months.
219170166|NCT05636709|DEVICE|Adacolumn|Non interventional study
219170167|NCT04480645|DEVICE|CivaDerm|radioactive bandage
219170168|NCT05171855|DRUG|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
219170169|NCT05825014|OTHER|No intervention|No intervention
219170170|NCT06057012|DRUG|BRII-296|BRII-296 will be given via intramuscular injection.
219170171|NCT06057012|DRUG|Depo Medrol|Depo Medrol will be given via intramuscular injection.
219170172|NCT04849052|BEHAVIORAL|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
219170173|NCT04849052|BEHAVIORAL|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
219170174|NCT06004531|BEHAVIORAL|Prompting open-ended question promoting sustainability|This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
219170175|NCT06004531|BEHAVIORAL|Sustainability Passage|This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
219239676|NCT06372600|BIOLOGICAL|Platelet-rich plasma|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
219239677|NCT05235685|OTHER|Medical air|Exercise under medical air, both arms exposed.
219239678|NCT05235685|OTHER|Hyperoxia|Exercise under hyperoxia, only experimental arm exposed.
219239679|NCT01653925|OTHER|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
219737949|NCT06481072|OTHER|Digital patient education|This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
219737950|NCT06481072|OTHER|Digital patient education and iCBT|This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
219170176|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
219170177|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
219170178|NCT06532422|PROCEDURE|Partial or total laparoscopic nephrectomy|Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
219170179|NCT06159608|DRUG|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
219170180|NCT06159608|OTHER|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
219170181|NCT05712902|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
219170182|NCT06205615|DRUG|BXP154B|BXP154B will be self-administered topically following wound induction
219170183|NCT06205615|DRUG|Placebo|Placebo will be self-administered topically following wound induction
219170184|NCT06205615|PROCEDURE|Punch Biopsy|Punch biopsy to leg
219170185|NCT05059262|DRUG|Vimseltinib|Administered orally
219170186|NCT05059262|DRUG|Placebo|Administered orally
219170187|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Alpha|Rhythmic alpha stimulation
219170188|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Theta|Rhythmic theta stimulation applied
219170189|NCT06252532|DEVICE|Sham Direct cortical stimulation (DCS)|Arrhythmic stimulation paradigm applied
219170190|NCT06252532|DEVICE|Direct cortical stimulation (DCS) In-Phase Theta|Rhythmic in-phase theta stimulation applied
219170191|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Anti-Phase Theta|Rhythmic anti-phase theta stimulation applied
219239680|NCT01653925|DRUG|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
219239681|NCT03332875|BEHAVIORAL|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
219239682|NCT04994093|OTHER|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
219170192|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
219170193|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
219170194|NCT06569290|BEHAVIORAL|Primer postcard|Inclusion of a mailed primer post card
219170195|NCT06569290|BEHAVIORAL|Control recruitment letter|a recruitment letter without any behaviorally-informed language
219170196|NCT06569290|BEHAVIORAL|Behavioral theory-informed recruitment letter (prospect theory)|the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.
219170197|NCT06569290|BEHAVIORAL|2 phone calls|2 recruitment phone calls made by the call center
219170198|NCT06569290|BEHAVIORAL|4 phone calls|4 recruitment phone calls made by the call center
219239683|NCT00237224|DRUG|Letrozole|
219239684|NCT00780741|PROCEDURE|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
219239685|NCT00780741|PROCEDURE|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
219239686|NCT01314066|DRUG|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
219239687|NCT01314066|DRUG|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
219239688|NCT01120457|DRUG|BMS-936564 (Anti-CXCR4)|
219737951|NCT01229202|DRUG|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
219737952|NCT05538650|BEHAVIORAL|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
219737953|NCT05538650|BEHAVIORAL|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
219239689|NCT01274507|OTHER|Medical tests|All participants will undergo medical tests and will be observed.
219170199|NCT06570525|BEHAVIORAL|NurseNET|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
219239690|NCT02412904|DRUG|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
219239691|NCT02412904|DRUG|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
219239692|NCT06194695|PROCEDURE|drug eluting beads-transcatheter arterial chemoembolization|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
219239693|NCT06194695|DRUG|envatinib plus anti-PD(L)1|oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.
219239694|NCT06357455|DEVICE|Cell Salvage Autotransfusion: SAME™ device|"* Intervention studied: processing of salvaged blood using the SAME™ autotransfusion device~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Treatment group.~All perioperative measures will be performed according to international, national and in-house standards."
219239695|NCT06357455|DEVICE|Cell Salvage Autotransfusion: Autolog™ device|"* Intervention studied: processing of salvaged blood using the Autolog™ (Medtronic) autotransfusion device (in-house standard device).~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Control group~All perioperative measures will be performed according to international, national and in-house standards."
219239696|NCT02993926|DRUG|Enantone|Enantone suspension for injection
219239697|NCT02993926|DRUG|GnRH agonist|A non-Enantone GnRH agonist
219170200|NCT06570525|OTHER|PAL|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
219170201|NCT06571227|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
219239698|NCT00540566|DEVICE|Optical Biopsy imaging|Optical Biopsy imaging
219239699|NCT00860457|DRUG|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
219239700|NCT00860457|DRUG|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
219239701|NCT00860457|DRUG|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
219239702|NCT05333276|DRUG|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
219239703|NCT05813990|OTHER|recostructive ear surgery|recostructive ear surgery in pediatric population
219239704|NCT02442037|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
219239705|NCT02442037|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
219239706|NCT01084772|OTHER|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
219239707|NCT01084772|OTHER|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
219239708|NCT04327089|DRUG|Setanaxib|Nox 1/4 inhibitor
219239709|NCT05982366|OTHER|distal radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
219239710|NCT05982366|OTHER|conventional radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
219239711|NCT01867307|DRUG|Empagliflozin|
219239712|NCT01867307|DRUG|BI 10773|open label
219239713|NCT04705389|OTHER|Samples|blood samples
219239714|NCT01049854|DRUG|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
219239715|NCT01049854|DRUG|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
219239716|NCT01049854|DRUG|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
219239717|NCT01049854|DRUG|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
219737954|NCT03288831|DIETARY_SUPPLEMENT|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
219737955|NCT03288831|DIETARY_SUPPLEMENT|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
219737956|NCT00507507|DRUG|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
219737957|NCT00507507|DRUG|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
219737958|NCT00507507|DRUG|Placebo|Placebo to match FTC taken once daily
219737959|NCT05287100|DRUG|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
219737960|NCT05287100|OTHER|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
219737961|NCT02916433|DRUG|Octreotide|
219737962|NCT03760666|DRUG|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
219737963|NCT04918797|BIOLOGICAL|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
219737964|NCT05847335|BEHAVIORAL|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
219737965|NCT01412983|DEVICE|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
219737966|NCT01412983|DEVICE|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
219737967|NCT01623154|OTHER|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
219737968|NCT03286075|DEVICE|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
219239718|NCT03782285|PROCEDURE|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
219239719|NCT02298998|OTHER|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
219239720|NCT02298998|OTHER|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
219239721|NCT00518206|BIOLOGICAL|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
219239722|NCT00518206|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
219170202|NCT05426408|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging to study coronary microvascular dysfunction|Myocardial perfusion mapping will be investigated after administration of adenosine
219170203|NCT06569719|OTHER|Complex decongestive therapy|Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
219170204|NCT03059407|BEHAVIORAL|Dog therapy only|Canine assisted therapy only during echocardiogram
219170205|NCT03059407|BEHAVIORAL|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
219170206|NCT03059407|BEHAVIORAL|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
219170207|NCT06570278|DIAGNOSTIC_TEST|WGS coupled with MCM|Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
219170208|NCT05597891|DEVICE|Hēlo PE Thombectomy System|Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
219170209|NCT04478734|DRUG|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
219170210|NCT04478734|DRUG|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
219170211|NCT04718389|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
219170212|NCT04718389|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
219170213|NCT04718389|BIOLOGICAL|Benralizumab|Benralizumab will be provided in a single-use PFS.
219170214|NCT04718389|BIOLOGICAL|Placebo|Placebo will be a sterile liquid formulation.
219170215|NCT04718389|DRUG|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
219170216|NCT04718389|DEVICE|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
219239723|NCT05576701|BEHAVIORAL|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
219170217|NCT02193958|DRUG|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle (Cohorts 1-6), Days 1-21 of a 28-say cycle (Cohort 7), Days 1-28 of a 28-day cycle (Cohort 8) or Days 1-21 of a 28-say cycle (Cohort 9). The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
219170218|NCT05800600|DRUG|Venofer|Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
219170219|NCT03205800|DEVICE|Mini-screw|Placement of a mini-screw
219170220|NCT06417541|DIAGNOSTIC_TEST|Diseased patients with an indwelling central venous catheter who is referred to autopsy|Photon counting CT is performed and the results are compared to the results of the autopsy
219170221|NCT06417541|RADIATION|Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast|Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
219170222|NCT04970836|BIOLOGICAL|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
219170223|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
219170224|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
219170225|NCT06097975|DRUG|Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
219170226|NCT06097975|PROCEDURE|Neurosurgery and intracavitary injection nivolumab and ipililumab|The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
219170227|NCT06097975|DRUG|Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary|Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
219239724|NCT05576701|OTHER|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
219239725|NCT04070937|DIAGNOSTIC_TEST|vestibular test 1|videonystagmography
219239726|NCT04070937|DIAGNOSTIC_TEST|vestibular test 2|video head impulse test
219239727|NCT04070937|DIAGNOSTIC_TEST|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
219239728|NCT04070937|DIAGNOSTIC_TEST|audiometry|tonal liminar audiometric thresholds
219239729|NCT04070937|DIAGNOSTIC_TEST|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
219239730|NCT04070937|GENETIC|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
219239731|NCT00000269|DRUG|Pergolide|
219239732|NCT02741557|DRUG|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
219239733|NCT02741557|DRUG|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
219239734|NCT02741557|DRUG|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
219239735|NCT00651326|DRUG|bicalutamide|
219239736|NCT00651326|DRUG|buserelin|
219239737|NCT00651326|DRUG|flutamide|
219170228|NCT04969874|OTHER|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
219170229|NCT05492838|PROCEDURE|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
219170230|NCT03036488|BIOLOGICAL|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
219170231|NCT03036488|DRUG|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
219170232|NCT03036488|DRUG|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
219170233|NCT03036488|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
219170234|NCT03036488|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
219170235|NCT03036488|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
219170236|NCT03036488|DRUG|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
219170237|NCT03036488|BIOLOGICAL|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
219170238|NCT06435117|OTHER|Patient Navigation|CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
219170239|NCT06320756|BEHAVIORAL|Wysa in Hindi|Wysa in Hindi is a blended digital mental health intervention
219170240|NCT06320756|BEHAVIORAL|Individual and group sessions on topics like motivation, coping, wellbeing|Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team
219170241|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
219170242|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
219239738|NCT00651326|DRUG|goserelin|
219239739|NCT00651326|DRUG|leuprolide acetate|
219170243|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
219170244|NCT06498791|OTHER|Venipuncture|Blood drawing
219170245|NCT06498791|OTHER|Questionnaire|Completion of the questionnaire
219170246|NCT06099613|BIOLOGICAL|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
219170247|NCT06055959|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
219170248|NCT05032105|DEVICE|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
219170249|NCT03219307|COMBINATION_PRODUCT|NOVOCART 3D|Matrix associated autologous chondrocyte implant
219239740|NCT00651326|PROCEDURE|neoadjuvant therapy|
219239741|NCT00651326|PROCEDURE|quality-of-life assessment|
219239742|NCT00651326|RADIATION|radiation therapy|"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"
219239743|NCT00651326|DRUG|Docetaxel|
219239744|NCT00051753|DRUG|levofloxacin; amoxicillin/clavulanate|
219239745|NCT04439825|DRUG|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
219239746|NCT04439825|DRUG|Placebo|Saline solution (preservative free)
219239747|NCT00269022|DRUG|SB-705498|
219239748|NCT02573129|OTHER|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
219239749|NCT02573129|OTHER|Red Meat Rich|Mediterranean diet rich in red meat
219239750|NCT04566185|OTHER|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
219170250|NCT03786796|DRUG|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
219170251|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
219170252|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
219170253|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
219170254|NCT05606965|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219170255|NCT05606965|BIOLOGICAL|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
219170256|NCT05606965|BIOLOGICAL|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
219170257|NCT05606965|BIOLOGICAL|Inactivated Influenza Vaccine|Sterile suspension for injection
219170258|NCT05606965|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219170259|NCT05606965|BIOLOGICAL|mRNA-1045|Sterile liquid for injection
219170260|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
219170261|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
219239751|NCT04566185|OTHER|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
219170262|NCT02029443|DRUG|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
219170263|NCT05139862|DEVICE|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
219170264|NCT03534947|DRUG|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
219170265|NCT03534947|DRUG|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
219170266|NCT03534947|PROCEDURE|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
219170267|NCT03534947|OTHER|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
219170268|NCT04478318|DEVICE|uEXPLORER/mCT|Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
219170269|NCT04478318|DEVICE|mCT/uEXPLORER|Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
219170270|NCT05290610|OTHER|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
219170271|NCT04722354|OTHER|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
219170272|NCT04722354|PROCEDURE|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
219170273|NCT04722354|DIETARY_SUPPLEMENT|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
219170274|NCT04722354|OTHER|Placebo|Those in this group will receive placebo (300 mg cornstarch)
219170275|NCT03324464|BEHAVIORAL|Central Executive Training: Working Memory|Computerized working memory training
219170276|NCT03324464|BEHAVIORAL|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
219170277|NCT05747937|DIAGNOSTIC_TEST|Skin biopsy|A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
219170278|NCT05747937|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
219170279|NCT05747937|DIAGNOSTIC_TEST|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
219170280|NCT05747937|DIAGNOSTIC_TEST|Dinamic Sweat Test|Test for the functional assessment of postganglionic sudomotor pathway
219170281|NCT03970278|OTHER|No intervention|No intervention
219170282|NCT04846478|DRUG|Talazoparib|capsule, taken by mouth, once a day
219239752|NCT04566185|OTHER|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
219239753|NCT01303822|BEHAVIORAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
219239754|NCT01799005|DIETARY_SUPPLEMENT|Flavanol (410 mg)|
219239755|NCT01799005|DIETARY_SUPPLEMENT|Control (no flavanols)|
219170283|NCT04846478|DRUG|Tazemetostat|orally as a tablet twice daily.
219170284|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
219170285|NCT04977180|DRUG|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
219170286|NCT06370091|OTHER|Gum of Xylitol|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
219170287|NCT06370091|OTHER|Gum of sugar free|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
219170288|NCT06370091|OTHER|Gum of sugar|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
219170289|NCT06370091|OTHER|Paraffin wax|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
219170290|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
219170291|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
219239756|NCT01973361|DEVICE|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
219239757|NCT01973361|DEVICE|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
219239758|NCT01870336|DEVICE|Combined treatment of medial knee osteoarthritis|
219239759|NCT00835328|DRUG|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
219239760|NCT00835328|DRUG|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
219239761|NCT01425398|DRUG|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
219239762|NCT01425398|DRUG|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
219239763|NCT00623714|DRUG|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
219239764|NCT00623714|DRUG|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
219239765|NCT04917315|DRUG|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
219239766|NCT04917315|DRUG|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
219239767|NCT01354080|OTHER|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
219239768|NCT01354080|OTHER|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
219239769|NCT02384122|DRUG|Octreotide|Two injections of 20 mg will be given monthly.
219239770|NCT05352854|DRUG|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
219239771|NCT01314482|DRUG|Minocycline|200mg bd for 3 days before surgery
219239772|NCT00772902|DRUG|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
219239773|NCT00772902|DRUG|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
219239774|NCT03369457|BIOLOGICAL|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
219239775|NCT04704557|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
219239776|NCT01128322|DRUG|S-Amlodipine, Telmisartan|
219239777|NCT01128322|DRUG|S-Amlodipine|
219239778|NCT01128322|DRUG|Telmisartan|
219239779|NCT01128322|DRUG|Placebo|
219239780|NCT05596916|OTHER|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
219239781|NCT05596916|OTHER|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
219239782|NCT03824743|DRUG|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
219239783|NCT03824743|DRUG|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
219239784|NCT01848132|DRUG|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
219239785|NCT01848132|DRUG|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
219239786|NCT01848132|DRUG|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
219239787|NCT01848132|DRUG|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
219239788|NCT01848132|DRUG|Prednisone|Prednisone: oral, 100 mg, days 1-5
219239789|NCT01848132|DRUG|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
219239790|NCT04265235|OTHER|Home-based exercise program|see 'arm' section
219239791|NCT04086342|DRUG|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
219239792|NCT04086342|DRUG|Placebo|Placebo is a vehicle oil that will match CHI-902.
219239793|NCT05304676|OTHER|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
219239794|NCT05304676|OTHER|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
219239795|NCT05230394|DIAGNOSTIC_TEST|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
219239796|NCT05230394|DIAGNOSTIC_TEST|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
219239797|NCT02267109|BIOLOGICAL|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
219239798|NCT02267109|BIOLOGICAL|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
219239799|NCT03602807|DEVICE|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
219239800|NCT02256826|DRUG|BILR 355 BS|
219239801|NCT02256826|DRUG|Ritonavir (RTV)|NORVIR®
219170292|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
219170293|NCT06317064|DRUG|Ibuprofen and Aprepitant|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
219170294|NCT04821154|DEVICE|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
219170295|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
219170296|NCT04469036|OTHER|Virtual Pediatric Trauma Center|Telehealth
219170297|NCT05616026|BEHAVIORAL|Intervention|6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
219170298|NCT05616026|BEHAVIORAL|Attention Control|6 months of texts for general health promotion
219170299|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
219170300|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
219170301|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
219170302|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
219170303|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
219170304|NCT05935462|COMBINATION_PRODUCT|Digital Learning Aids|Recruitment is currently underway for special children undergoing outpatient early intervention. Among the recruited participants, five children between the ages of 6 and 9, who are receiving early intervention, were screened. After obtaining their consent to participate in this study, their basic information was recorded, including gender, age, education, diagnosis, Movement Assessment Battery for Children (MABC-2), Visual-Motor Integration (VMI) test, and Children's ABILHAND questionnaire for manual ability. Once the collection of basic information is completed, a trial of digital aids will be conducted, and a trial feedback questionnaire will be administered. The trial period will consist of a 20-minute session and 2-3 sessions (per week) of home (or therapy room) use.
219170305|NCT03393975|BIOLOGICAL|TAK-755|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg TAK-755 ORT during Period 1 and Period 2 and switch to TAK-755 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of TAK-755.
219170306|NCT03393975|BIOLOGICAL|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
219170307|NCT06508541|PROCEDURE|ICG Guided surgery|In ICG guided surgery group,Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
219170308|NCT06508541|PROCEDURE|conventional surgery|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose
219170309|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
219170310|NCT04902846|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
219170311|NCT04902846|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
219170312|NCT04501861|DRUG|Vasopressin|Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
219170313|NCT04501861|DRUG|Norepinephrine|Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
219239802|NCT02256826|DRUG|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
219239803|NCT05692245|DRUG|Ondansetron|Administered Medication
219239804|NCT05692245|DRUG|Dexamethasone|Administered Medication
219239805|NCT06192459|DEVICE|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
219239806|NCT06192459|OTHER|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
219170314|NCT00959140|DEVICE|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10\^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10\^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
219170315|NCT04807868|PROCEDURE|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
219170316|NCT04807868|OTHER|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
219170317|NCT04807868|OTHER|Biospecimen Collection|Blood and urine will be collected.
219170318|NCT05893173|BEHAVIORAL|Sleep Deprivation|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation.
219170319|NCT06173219|COMBINATION_PRODUCT|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
219170320|NCT00741728|OTHER|Spider flash ECG, high-precision carotid echo-tracking, step test|cardiac rhythm recorded during health check up, vascular aging parameters and baroreflex sensitivity recorded during carotid echotracking of the right common carotid artery , step test during 2 minutes
219170321|NCT04773457|OTHER|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
219170322|NCT06498973|DRUG|Azacitidine|Given IV
219170323|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219170324|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219170325|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219170326|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
219170327|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219170328|NCT06194721|PROCEDURE|Cold intrapulpal anesthesia|Intrapulpal cold local anesthesia at 4-5 c temperature
219170329|NCT06194721|PROCEDURE|Room temperature intrapulpal anesthesia|Intrapulpal cold local anesthesia at room temperature
219170330|NCT04031456|BIOLOGICAL|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
219170331|NCT04031456|BIOLOGICAL|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
219170332|NCT04597411|RADIATION|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
219170333|NCT04597411|RADIATION|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
219170334|NCT03221036|DRUG|Vedolizumab IV|Vedolizumab IV infusion
219170335|NCT03221036|DRUG|Placebo|Matching-placebo IV infusion
219170336|NCT05830721|DEVICE|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
219170337|NCT05830721|DEVICE|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
219239807|NCT00071188|DRUG|ZD6474|
219239808|NCT00071188|DRUG|Paclitaxel|
219239809|NCT00071188|DRUG|Carboplatin|
219239810|NCT02865109|DRUG|Nusinersen|Administered by intrathecal injection
219239811|NCT05893615|BEHAVIORAL|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
219170338|NCT05830721|OTHER|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
219170339|NCT01007591|DRUG|LEO 80190|Applied once daily
219170340|NCT01007591|DRUG|Hydrocortisone|Applied once daily
219170341|NCT04180397|DRUG|Furosemide|Furosemide 10 mg/ml for injection/infusion
219170342|NCT04180397|DRUG|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
219170343|NCT03333200|OTHER|Palliative Care|Collecting information about the natural progression of these diseases
219170344|NCT03333200|BIOLOGICAL|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
219170345|NCT02549339|DRUG|LEO 43204 gel|
219170346|NCT02549339|DRUG|Vehicle gel|
219170347|NCT06433050|DRUG|Sotagliflozin|Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
219170348|NCT03016169|DEVICE|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
219170349|NCT06024304|DEVICE|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
219170350|NCT06024304|DEVICE|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
219170351|NCT05669989|DRUG|Isatuximab intravenous (IV)|Route of administration: IV infusion; Pharmaceutical form: Vial
219170352|NCT05669989|DRUG|Cemiplimab (SAR439684)|Route of administration: IV infusion; Pharmaceutical form: Vial
219170353|NCT05669989|DRUG|Dexamethasone|Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial
219170354|NCT05669989|DRUG|Lenalidomide|Route of administration: Oral; Pharmaceutical form: Capsules
219170355|NCT05669989|DRUG|Pomalidomide|Route of administration: Oral; Pharmaceutical form: Hard capsules
219170356|NCT05669989|DRUG|Isatuximab subcutaneous (SC)|Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial
219170357|NCT05669989|DRUG|Carfilzomib|Route of administration: IV infusion; Pharmaceutical form: Vial
219170358|NCT05067166|DRUG|Ansuvimab|single infusion 50 mg/kg IV
219170359|NCT02605057|DRUG|LEO 80185 gel|
219170360|NCT02605057|DRUG|Dovobet(r) Ointment|
219170361|NCT04612192|DEVICE|Active luminette|receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
219239812|NCT02616926|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
219239813|NCT02616926|PROCEDURE|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
219239814|NCT02616926|PROCEDURE|RFA|RFA will be performed 1 week after TACE.
219239815|NCT05950607|BEHAVIORAL|TRAIN AD 2.0|"The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. ."
219239816|NCT06226116|PROCEDURE|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
219239817|NCT06226116|PROCEDURE|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
219239818|NCT06226116|PROCEDURE|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
219239819|NCT02610322|BEHAVIORAL|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
219170362|NCT04612192|DEVICE|Placebo luminette|receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
219170363|NCT03900468|DEVICE|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
219170364|NCT06489314|BEHAVIORAL|LEAD (Learn, Engage, Act, Dedicate)|LEAD is a 5-session behavioral activation (BA) intervention delivered by peer-father counselors. LEAD also incorporates motivational interviewing (MI) and masculinity discussion strategies. This is a task-shifted intervention meaning mental health service tasks are delegated to non-specialist providers, in this case peer-fathers, as opposed to a specialized workforce (e.g., psychiatrists, psychologists).
219170365|NCT02724878|DRUG|Bevacizumab|
219170366|NCT02724878|DRUG|Atezolizumab|
219170367|NCT04793685|DRUG|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
219170368|NCT04793685|BEHAVIORAL|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
219170369|NCT05978531|DRUG|Monomethyl Fumarate|95 mg oral capsule, 190 mg (2 x 95 mg) twice daily
219170370|NCT04301778|DRUG|Durvalumab|"1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV"
219170371|NCT04301778|DRUG|SNDX-6352|"1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV"
219170372|NCT06046573|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
219170373|NCT06046573|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
219170374|NCT06046573|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
219170375|NCT06046573|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
219170376|NCT06385028|BEHAVIORAL|Physical activity promotion|The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
219170377|NCT05164744|DIAGNOSTIC_TEST|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
219170378|NCT05164744|DIAGNOSTIC_TEST|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
219170379|NCT05164744|DIAGNOSTIC_TEST|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
219239820|NCT02610322|BEHAVIORAL|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
219239821|NCT02926313|OTHER|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
219170380|NCT05164744|DIAGNOSTIC_TEST|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
219170381|NCT04015765|PROCEDURE|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
219170382|NCT02104063|PROCEDURE|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
219170383|NCT06580418|OTHER|Additional biopsies and blood samples|During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
219170384|NCT04207346|DEVICE|TMS 1 hz|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
219170385|NCT04207346|DEVICE|Sham TMS|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
219170386|NCT04775602|DRUG|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
219170387|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
219170388|NCT04838262|OTHER|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
219170389|NCT04752319|DEVICE|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
219170390|NCT04752319|DEVICE|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
219170391|NCT06513299|DEVICE|low tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
219170392|NCT06513299|DEVICE|high tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
219170393|NCT06513299|DEVICE|low driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
219170394|NCT06513299|DEVICE|high driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
219239822|NCT00760877|DRUG|Nilotinib|Supplied in 200 mg capsules
219239823|NCT00760877|DRUG|Imatinib|Supplied in 100 mg and 400 mg capsules
219239824|NCT03829072|OTHER|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
219239825|NCT03829072|OTHER|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
219239826|NCT01605435|DRUG|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
219239827|NCT01605435|DRUG|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
219239828|NCT04284592|PROCEDURE|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
219239829|NCT03329547|DRUG|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
219239830|NCT03329547|DRUG|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
219239831|NCT04705883|DRUG|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
219239832|NCT03538223|OTHER|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
219239833|NCT03538223|RADIATION|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
219239834|NCT05379400|OTHER|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
219239835|NCT05379400|OTHER|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
219239836|NCT05480410|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
219239837|NCT05306613|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
219239838|NCT05306613|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
219239839|NCT04389996|OTHER|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
219239840|NCT05157464|DRUG|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
219239841|NCT01179659|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
219239842|NCT03763682|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
219239843|NCT02416102|DRUG|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
219239844|NCT02416102|DRUG|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
219239845|NCT06437327|PROCEDURE|Electrotherapy|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
219239846|NCT06437327|PROCEDURE|Active release technique|Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
219170395|NCT06062901|OTHER|Educational Intervention|Receive educational intervention
219239847|NCT06437327|PROCEDURE|Hold relax technique|This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
219239848|NCT04516980|OTHER|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
219239849|NCT03671356|OTHER|risk score|risk score
219170396|NCT06062901|OTHER|Interview|Participate in one-on-one interview
219170397|NCT06062901|OTHER|Survey Administration|Ancillary studies
219170398|NCT06388811|OTHER|Early Osteoarthritis Questionnaire|Self administered questionnaire
219170399|NCT05668754|DRUG|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
219170400|NCT05668754|OTHER|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
219239850|NCT04415580|OTHER|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
219239851|NCT04415580|OTHER|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
219239852|NCT00557518|DRUG|Alagebrium|200 mg bid
219239853|NCT00557518|DRUG|Placebo|bid
219239854|NCT01880359|DRUG|Cisplatin|
219239855|NCT01880359|RADIATION|Radiotherapy|
219239856|NCT01880359|DRUG|Placebo|
219239857|NCT01880359|DRUG|Nimorazole|
219239858|NCT01641848|DEVICE|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
219239859|NCT04780906|OTHER|Wrist taping|Wrist taping as used as standard in CrossFit practice
219239860|NCT04910399|DIETARY_SUPPLEMENT|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
219170401|NCT02406014|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
219170402|NCT02406014|DRUG|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
219170403|NCT04539574|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
219170404|NCT04539574|OTHER|Questionnaire Administration|Ancillary studies
219170405|NCT03175029|DRUG|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
219170406|NCT03175029|DRUG|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
219170407|NCT06521164|DEVICE|Haermonics Pure system|pericardial flushing with Haermonics Pure system
219170408|NCT06464341|OTHER|Observational study no intervention|Observational study no intervention
219170409|NCT06375200|OTHER|No intervention|Observational one-time questionnaire study without intervention
219170410|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
219170411|NCT04178252|OTHER|mask|investigators will add eye mask to standard treatment
219170412|NCT04178252|OTHER|headset|investigators will add headset to standard treatment
219170413|NCT04178252|OTHER|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
219170414|NCT06246422|DRUG|Tranexamic Acid 500 MG|Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
219170415|NCT06246422|DRUG|Normal saline|Local instillation of 20 ml normal saline in the gall bladder bed
219170416|NCT03169738|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219170417|NCT03169738|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
219170418|NCT03169738|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219170419|NCT03169738|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
219170420|NCT03169738|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219170421|NCT03169738|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219170422|NCT03169738|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
219170423|NCT03169738|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219170424|NCT03169738|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219170425|NCT03169738|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
219170426|NCT03169738|DRUG|Lovaza|Omega-3-acid ethyl esters
219170427|NCT03169738|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219170428|NCT03169738|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
219170429|NCT03169738|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
219170430|NCT03169738|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
219170431|NCT03169738|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
219170432|NCT03169738|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219170433|NCT03169738|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
219170434|NCT03169738|BIOLOGICAL|GI-4000|Ras yeast vaccine
219170435|NCT03169738|BIOLOGICAL|GI-6207|CEA yeast vaccine
219170436|NCT03169738|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219170437|NCT03169738|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
219170438|NCT04679376|DRUG|Atorvastatin|40 mg daily administered orally in tablet or capsule form
219170439|NCT04679376|DRUG|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
219170440|NCT04910724|OTHER|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
219170441|NCT05524233|DEVICE|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
219170442|NCT06411301|DRUG|225Ac-DOTATATE|Two intravenous infusions every 6 weeks (Q6W)
219170443|NCT04885959|BEHAVIORAL|Traditional Asian Diet|The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020). The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
219239861|NCT04910399|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
219239862|NCT00006428|DRUG|Amitriptyline|
219170444|NCT05826587|BEHAVIORAL|Home-based, m-Health Delivered Physical Function Training|An individualized home exercise physical function training will be prescribed. This would include 5 balance training exercises and 1-2 upper and lower-body muscular conditioning exercises (i.e., wall push-up and chair stand) prescribed 3 days/week over the course of a 6-week period. Subjects will be assigned exercises from 1 of 3 different levels of exercise progression based on performance during the baseline muscular fitness assessment (functional chair stand and static chest throw).
219170445|NCT05826587|BEHAVIORAL|Cardiac Rehabilitation & Exercise Prescription|Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
219170446|NCT05826587|OTHER|Connected mHealth mobile application|Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
219170447|NCT02506959|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
219170448|NCT02506959|DRUG|Busulfan|Given IV
219170449|NCT02506959|DRUG|Gemcitabine Hydrochloride|Given IV
219170450|NCT02506959|DRUG|Melphalan|Given IV
219170451|NCT02506959|DRUG|Panobinostat|Given PO
219170452|NCT02506959|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
219170453|NCT02506959|OTHER|Pharmacological Study|Correlative studies
219170454|NCT04736550|BEHAVIORAL|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
219170455|NCT04736550|BEHAVIORAL|Psychotherapy for Pain (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
219170456|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
219239863|NCT01680315|BEHAVIORAL|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
219239864|NCT01680315|BEHAVIORAL|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
219239865|NCT04694300|DRUG|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
219239866|NCT04694300|DRUG|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
219239867|NCT04694300|DRUG|Tramadol|50 mg by mouth every 6 hours as needed for pain
219239868|NCT03015961|DRUG|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
219239869|NCT03015961|DRUG|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
219239870|NCT03734588|GENETIC|SPK-8016|adeno-associated viral vector
219239871|NCT03337204|BEHAVIORAL|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
219239872|NCT03337204|BEHAVIORAL|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
219239873|NCT03792945|DRUG|local injection|In addition to the local injection, carpal tunnel brace will be given.
219239874|NCT03792945|DEVICE|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
219239875|NCT03602547|DRUG|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
219239876|NCT01263223|DRUG|LY2216684|Administered orally
219239877|NCT01263223|DRUG|Placebo|Administered orally
219239878|NCT00028509|PROCEDURE|management of therapy complications|
219239879|NCT01847599|OTHER|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
219239880|NCT06164119|OTHER|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
219170457|NCT03610490|DRUG|Cyclophosphamide|Given IV
219170458|NCT03610490|DRUG|Fludarabine|Given IV
219239881|NCT06164119|OTHER|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
219239882|NCT06164119|OTHER|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
219239883|NCT04605471|DRUG|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
219239884|NCT00212979|OTHER|non intervention study|
219239885|NCT05149976|DIAGNOSTIC_TEST|Voice recording before and after dietary intake|"* A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
219170459|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
219239886|NCT01322347|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
219239887|NCT01322347|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
219170460|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
219170461|NCT06310590|DRUG|NRT6003 Injection|Selective internal radiation therapy (SIRT) with TareSphere
219170462|NCT05443620|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
219170463|NCT05443620|DEVICE|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
219170464|NCT04382898|BIOLOGICAL|BNT112|Intravenous bolus injection
219170465|NCT04382898|DRUG|Cemiplimab|Intravenous infusion
219170466|NCT05229120|BEHAVIORAL|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
219170467|NCT05134350|DRUG|LOXO-305|LOXO-305 orally.
219170468|NCT05134350|DRUG|Omeprazole|Omeprazole Orally.
219170469|NCT03932682|BIOLOGICAL|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
219239888|NCT00494286|BEHAVIORAL|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
219239889|NCT00494286|BEHAVIORAL|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
219239890|NCT05413954|OTHER|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
219239891|NCT05413954|OTHER|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
219170470|NCT03932682|BIOLOGICAL|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (NeisVac-C)
219170471|NCT04884412|PROCEDURE|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO\_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
219170472|NCT04884412|PROCEDURE|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
219170473|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
219170474|NCT03836417|DIAGNOSTIC_TEST|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
219170475|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
219170476|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
219170477|NCT06419218|BEHAVIORAL|School meal messages|Messages focused on the benefits of children consuming school lunch and breakfast, using text and images developed based on parent interviews. Participants will view a total of 10 messages.
219170478|NCT06419218|BEHAVIORAL|Control (neutral) messages|Control messages approximately matched to the intervention messages on length and design, but discussing a neutral topic unrelated to school meals (reading). Participants will view a total of 10 messages.
219170479|NCT05665244|PROCEDURE|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
219170480|NCT05665244|DEVICE|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
219170481|NCT04804514|DRUG|KH001|The study drug is applied to teeth
219170482|NCT04804514|DRUG|Placebo|The placebo is applied to teeth
219239892|NCT02519270|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein.
219170483|NCT06639841|DEVICE|Virtual Reality Psychotherapy|"Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies."
219170484|NCT06639841|BEHAVIORAL|Yoga|"The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness."
219170485|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
219170486|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
219170487|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
219170488|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
219170489|NCT03763708|DEVICE|Spinal Cord Stimulation|Programming
219170490|NCT06281418|DRUG|Granisetron 1 Mg/mL Intravenous Solution|2mL intraperitoneal adminstration of granisetron (1 mg/mL)
219170491|NCT06281418|OTHER|Normal saline|2 ml IP normal saline (0.9% NaCl)
219170492|NCT05470400|BIOLOGICAL|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170493|NCT05470400|BIOLOGICAL|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170494|NCT05470400|BIOLOGICAL|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170495|NCT05470400|BIOLOGICAL|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170496|NCT05470400|BIOLOGICAL|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170497|NCT05470400|BIOLOGICAL|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
219170498|NCT06563609|BEHAVIORAL|Intensive physical Therapy|Tailored exercise programs supervised by trained physiotherapists, focusing on improving cardiorespiratory fitness, strength, and functional capacity.
219170499|NCT06563609|DIETARY_SUPPLEMENT|Probiotic treatment|Administration of probiotic yeast Saccharomyces boulardii twice daily
219170500|NCT06563609|BEHAVIORAL|Individualised Nutritional Support|Personalized nutritional plans guided by a dietitian, addressing malnutrition and caloric/protein deficiencies with daily caloric intake adjustments and supplements if necessary based on the EFFORT trial.
219170501|NCT06563609|OTHER|Standard hospital care|Patients will receive standard hospital care
219170502|NCT06584799|DRUG|Micronized purified flavonoid fraction|"Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months."
219170503|NCT06584799|DRUG|Diosmin 600|Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
219170504|NCT06584799|DRUG|Hesperidin+Diosmin combination 1000|"A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months"
219170505|NCT06427928|BEHAVIORAL|Explains the perioperative process with pictures|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
219170506|NCT06427928|BEHAVIORAL|The perioperative process is only explained|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
219170507|NCT05612048|OTHER|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
219170508|NCT05612048|OTHER|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
219170509|NCT05612048|OTHER|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
219170510|NCT06153563|OTHER|Data collection on patient history and intraoperative results.|Data collection on patient history and intraoperative results.
219239893|NCT05580302|OTHER|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
219239894|NCT00896389|PROCEDURE|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
219170511|NCT06755970|PROCEDURE|ICOUGH|"After the patient has recovered from postoperative anesthesia and their hemodynamic values have stabilized, the ICOUGH bundle applications mentioned above will be carried out. The patient's pain and nausea levels will be recorded for a period of 48 hours.~Postoperative pain and nausea will be assessed with the help of data collectors, using a numerical rating scale at 2, 4, 8, 12, 24, and 48 hours after surgery.~Considering that postoperative respiratory complications are relatively common and costly, various studies have been conducted to explore ways to reduce the risk of their occurrence. One of these protocols is the ICOUGH bundle, which stands for Incentive Spirometry, Coughing and Deep Breathing, Oral Care, Patient Understanding of the Interventions, Getting Out of Bed, and Head of Bed Elevation."
219170512|NCT05085496|BIOLOGICAL|Atezolizumab|Given IV
219170513|NCT05085496|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219170514|NCT05636943|BEHAVIORAL|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
219170515|NCT05636943|BEHAVIORAL|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
219170516|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
219170517|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
219170518|NCT03940963|DEVICE|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
219170519|NCT03940963|PROCEDURE|Standard Neurectomy|Surgical excision of symptomatic neuroma
219170520|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
219170521|NCT05677880|OTHER|Study Procedures|"Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw"
219170522|NCT05391906|OTHER|Diffusion-weighted magnetic resonance imaging|Diffusion-weighted magnetic resonance imaging
219170523|NCT02663219|BEHAVIORAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
219170524|NCT01809691|DRUG|TAK-700|300 mg, PO, twice daily
219170525|NCT01809691|DRUG|Bicalutamide|50 mg, PO, q daily
219170526|NCT06177873|OTHER|foot bath|On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
219170527|NCT05778266|DIETARY_SUPPLEMENT|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
219170528|NCT05778266|DIETARY_SUPPLEMENT|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
219170529|NCT05778266|OTHER|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
219170530|NCT04115371|BEHAVIORAL|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
219170531|NCT03574103|BEHAVIORAL|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
219170532|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
219170533|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
219170534|NCT04392401|BIOLOGICAL|Collection of blood samples in order to create a biocollection|Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
219170535|NCT05102591|DRUG|Ketorolac|Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
219170536|NCT05102591|DRUG|Metoclopramide|Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
219170537|NCT05102591|DEVICE|Active Remote Electrical Neuromodulation Device|The REN device is a battery-powered, wirelessly controlled neuromodulation device that attaches via armband to the upper arm. The REN device is controlled by a smartphone application and administers electrical stimulation to the local C and Aδ nociceptive sensory nerves of the upper arm. This stimulation is achieved using a symmetrical, biphasic, square pulse, modulated at a frequency between 100-120 Hz. Each pulse has a width of 400 µs and the user, via the smartphone application, can adjust the output current to apply a maximum of 40 mA. Each stimulation session occurs over 45 minutes and each device can administer up to 12 stimulation sessions.
219170538|NCT05102591|DRUG|Placebo|0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
219170539|NCT05102591|DEVICE|Sham Remote Electrical Neuromodulation Device|The sham REN device is identical to the active REN device but the stimulation parameters are different, administering a modulated symmetrical biphasic square electrical pulse, modulated frequency of \~0.083 Hz and a modulated pulse width of 40-550 µ. These sham parameters are designed to induce a sensation that will be perceptible to participants, similar to stimulation from the active REN device, but at a frequency that is low enough so as to not modulate the nociceptive sensory nerves.
219170540|NCT05455723|PROCEDURE|Inflation-deflation technique|Inflation-Deflation Technique: The tracheal tube cuff will be inflated with 15-20 ml of air (volume of air is depending on the level of larynx). Once the tip of ETT at the laryngeal inlet, the cuff of ETT will be deflated and advanced into the trachea.
219170541|NCT05455723|PROCEDURE|Magill forceps technique|The Magill forceps to guide the ETT tip to pass through the pharynx and glottis into the trachea.
219239895|NCT00896389|DRUG|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
219239896|NCT02612116|DRUG|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
219239897|NCT02612116|DRUG|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
219239898|NCT02612116|DRUG|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
219239899|NCT00205205|BEHAVIORAL|peer mentoring|
219239900|NCT01369147|DRUG|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
219239901|NCT01369147|DRUG|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
219239902|NCT01369147|DRUG|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
219239903|NCT01369147|DRUG|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
219239904|NCT01369147|DRUG|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
219170542|NCT06503809|BEHAVIORAL|Ketogenic Diet|Participants will consume a very-low-carbohydrate ketogenic diet for 12 weeks.
219170543|NCT06503809|BEHAVIORAL|Standard Diet|Participants will consume an American Diabetes Association-recommended standard diet for 12 weeks.
219170544|NCT05202678|DEVICE|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
219170545|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
219170546|NCT02281955|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
219170547|NCT02281955|DRUG|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
219170548|NCT02281955|PROCEDURE|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
219170549|NCT04768569|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
219170550|NCT04768569|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
219170551|NCT06118775|PROCEDURE|EaDyn Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.
219239905|NCT02351609|BEHAVIORAL|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
219239906|NCT02351609|OTHER|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
219239907|NCT02399982|OTHER|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
219239908|NCT02399982|OTHER|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
219239909|NCT04538534|DRUG|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
219239910|NCT03184519|DIAGNOSTIC_TEST|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
219239911|NCT01613573|DRUG|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
219239912|NCT01613573|DRUG|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
219239913|NCT02404012|DIETARY_SUPPLEMENT|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
219239914|NCT05417685|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
219239915|NCT05417685|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
219239916|NCT05417685|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
219170552|NCT06118775|PROCEDURE|PAM Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
219170553|NCT02958462|PROCEDURE|Biospecimen Collection|Undergo blood sample, hair follicle, and saliva collection
219239917|NCT04501354|DRUG|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
219239918|NCT06644235|OTHER|Cold Application|Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
219239919|NCT05395754|DEVICE|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
219239920|NCT06434571|BEHAVIORAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
219170554|NCT02958462|PROCEDURE|Bone Marrow Biopsy|Undergo a bone marrow biopsy
219170555|NCT02958462|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
219170556|NCT02958462|PROCEDURE|Buccal Swab|Undergo a saliva or buccal swab
219170557|NCT02958462|OTHER|Clinical Evaluation|Undergo clinical assessment
219170558|NCT02958462|OTHER|Genetic Counseling|Receive genetic counseling
219170559|NCT02958462|OTHER|Quality-of-Life Assessment|Ancillary studies
219170560|NCT02958462|OTHER|Electronic Health Record Review|Ancillary studies
219170561|NCT05148702|DRUG|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
219170562|NCT05148702|DRUG|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
219170563|NCT05396625|BEHAVIORAL|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
219170564|NCT05396625|BEHAVIORAL|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention, SAFE Children, which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children, such as, separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community. Each session lasts about one to one and a half hours and delivered by facilitator and co-facilitator at the SOS Child and Family Center.
219170565|NCT05396625|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
219170566|NCT05396625|OTHER|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
219170567|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1\. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
219170568|NCT05199909|DRUG|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
219170569|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
219170570|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
219170571|NCT04302493|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
219170572|NCT04302493|BEHAVIORAL|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
219170573|NCT05552105|OTHER|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
219170574|NCT06486311|PROCEDURE|satellite implant|Satellite implant is a additional holding component as a stabilizer to provide a polygonal support to distribute forces and moments on single-standing implants give the implant sufficient resistance to withstand masticatory forces or at least keep it in a stable position during an unloaded healing period to achieve stabilization and subsequent osseointegration of implants.
219170575|NCT04993859|DIAGNOSTIC_TEST|Non-invasive Urodynamic Test (niUDS)|A noninvasive urodynamics is a simple test used to evaluate urinary flow.
219170576|NCT04993859|DIAGNOSTIC_TEST|Urinary proteomic screen|Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
219170577|NCT04993859|OTHER|Dysfunctional Voiding Symptom Score Survey (DVSS)|The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
219170578|NCT06781697|DRUG|Ketamine|Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
219170579|NCT06781697|DEVICE|Oculus VR headset|Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
219170580|NCT03926624|DRUG|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
219170581|NCT03926624|DRUG|Cytarabine|cytosine arabinoside (ara-C)
219170582|NCT03926624|DRUG|Azacitidine|Azacitidine
219170583|NCT03926624|DRUG|Decitabine|Decitabine
219170584|NCT03926624|DRUG|Mitoxantrone|Mitoxantrone
219170585|NCT03926624|DRUG|Etoposide|Etoposide
219239921|NCT06434571|BEHAVIORAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
219239922|NCT06434571|BEHAVIORAL|Treatment as usual (TAU)|They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
219239923|NCT00156975|DRUG|Capecitabine|
219239924|NCT00156975|DRUG|Oxaliplatin|
219239925|NCT04010981|OTHER|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
219239926|NCT04010981|OTHER|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
219170586|NCT03926624|DRUG|Fludarabine|Fludarabine
219170587|NCT03926624|DRUG|Idarubicin|Idarubicin
219170588|NCT03926624|DRUG|Venetoclax|Venetoclax
219170589|NCT03926624|DRUG|Cladribine|Cladribine
219170590|NCT04945629|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
219170591|NCT04945629|DRUG|Blood clot and simple suture|Filling the alveolus with blood clot
219170592|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
219170593|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
219170594|NCT06781775|DRUG|Metformin + Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stay on metformin and add insulin.
219170595|NCT06781775|DRUG|Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stop on metformin and add insulin.
219170596|NCT05350722|RADIATION|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
219170597|NCT06140875|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
219170598|NCT05943626|BEHAVIORAL|Circadian Intervention|The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
219170599|NCT03892616|DRUG|BI 1358894 (B)|Tablet formulation 2 (TF2a), fed
219170600|NCT03892616|DRUG|BI 1358894 (C)|Tablet formulation 2 (TF2a), fasted
219170601|NCT03892616|DRUG|BI 1358894 (D)|Tablet formulation 2 (TF2b), fed
219170602|NCT03892616|DRUG|BI 1358894 (E)|Tablet formulation 2 (TF2b), fasted
219170603|NCT03892616|DRUG|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
219170604|NCT06475664|OTHER|Personalized legal care services|Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
219170605|NCT03785106|DRUG|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
219170606|NCT03785106|DRUG|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
219170607|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
219170608|NCT00378105|DRUG|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
219170609|NCT00378105|DRUG|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
219170610|NCT00378105|DRUG|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
219170611|NCT05874037|DRUG|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
219170612|NCT06255925|BEHAVIORAL|KF-STRIDE® Into Work!|Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
219170613|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
219170614|NCT06128174|DEVICE|Farawave PFA catheter|The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.
219170615|NCT02729467|DRUG|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
219170616|NCT02729467|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
219170617|NCT02729467|DRUG|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
219170618|NCT05192200|DRUG|Anti-Beta Interferon (PF-06823859)|IV infusion
219170619|NCT06341413|DEVICE|SmartSleep device|Device worn during sleep
219239927|NCT01092936|OTHER|Rating Scale administration|Movement Disorder Society\_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
219239928|NCT05329129|DEVICE|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
219239929|NCT02775175|BEHAVIORAL|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
219239930|NCT05972109|OTHER|Workplace SSB sales ban|Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.
219170620|NCT06389097|RADIATION|Radium-223|"Radium-223 will be given as per standard of care or other clinical trial. It is typically administered intravenously via slow injection once every 4 weeks with a dosage of 55 kBq/kg per cycle. Patients typically receive up to six cycles unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. These will be performed at 2-4 hr, 24 hr, and 48 hr after any cycle of Radium-223. Protocol preference is for imaging with 2 cycles, ideally cycle 1 and cycle 6, but imaging with any one or two cycle(s) is acceptable.~The imaging time at each time point is approximately 30 minutes per field of view with two fields of view (1 hr total) typically collected sequentially (i.e., without repositioning the patient on the imaging table)."
219170621|NCT06389097|RADIATION|177Lu-DOTATATE|"177Lu-DOTATATE to be given as Standard of Care (SOC) or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes with peptide co-infusion prior and during the infusion.~Patients will receive 4 cycles of 177Lu-DOTATATE administered approximately every 8 weeks. Treatment cycle is defined as 8 consecutive weeks (D1-D56) following a dose of 177Lu-DOTATATE. Patients receive up to four infusions of 7.4 GBq (200 mCi) every 8 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is \~ 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
219170622|NCT06389097|RADIATION|177Lu-PSMA-617|"177Lu-PSMA-617 will be given as per SOC or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes.~Up to 6 cycles of 177Lu- PSMA-617 will be administered approximately every 6 weeks. Treatment cycle is defined as 6 consecutive weeks (D1-D42) following a dose of 177Lu- PSMA-617. Patients will receive up to six infusions of 7.4 GBq (200 mCi) every 6 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is approximately 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
219170623|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
219170624|NCT05967273|OTHER|CirrhosisRx CDS|CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
219170625|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Low - Dose 435 mg/day)|Plant protein hydrolysate
219170626|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Mid - Dose 870 mg/day)|Plant protein hydrolysate
219170627|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (High - Dose 2610 mg/day)|Plant protein hydrolysate
219170628|NCT06440213|DIETARY_SUPPLEMENT|Placebo Microcrystalline Cellulose|Placebo MCC micro-crystalline cellulose
219170629|NCT01787383|DRUG|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
219239931|NCT05972109|BEHAVIORAL|Brief Intervention|Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
219239932|NCT04239911|BEHAVIORAL|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
219239933|NCT04239911|BEHAVIORAL|Virtual training course|Virtual training course on heart failure for home health aides.
219170630|NCT01787383|DRUG|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
219170631|NCT06414798|DRUG|Drug: ABBV-1088|• Oral Capsule
219170632|NCT06414798|DRUG|Drug: Placebo for ABBV-1088|• Oral Capsule
219170633|NCT06456359|DRUG|Signifor|Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
219170634|NCT03829631|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
219170635|NCT06303271|OTHER|Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Experimental group will received intervention of 30 minutes daily for 4 weeks (16 sessions). Assessment was done at the baseline, after 2 weeks and after 4 weeks. Intervention Group received non-invasive vagus nerve stimulation at left auricle (because of anatomy of vagus nerve as right VN innervate SA node which is regulating heartbeat and left VN innervates AV node which is responsible for controlling timing of heartbeat) of ear. VNS group received vagus nerve stimulation via Med Fit vagus nerve stimulator at auricle of left ear only as stimulation of right auricular branch of vagus nerve can result in bradycardia. Frequency of stimulation was kept between 15-30Hz. Intensity was gradually increased according to patient's tolerance. The participant was able to withdraw from the trial if he could not tolerate the stimulation
219170636|NCT06303271|OTHER|Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will intervention of 30 minutes daily for 4 weeks (16 sessions). Caw Thorne Cooksey exercises were carried out during the stimulation of vagus nerve. Although no adverse effects had been reported during the stimulation of left auricular branch of vagus nerve but a pulse oximeter was used during the stimulation to monitor the heart rate.
219170637|NCT05935748|DRUG|NKT2152|Oral HIF2a inhibitor
219170638|NCT05935748|DRUG|palbociclib|a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
219170639|NCT05935748|OTHER|sasanlimab|an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
219170640|NCT06513104|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
219239934|NCT05485441|OTHER|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
219239935|NCT00720161|DRUG|Metformin|daily 850 mg
219239936|NCT00720161|DRUG|Placebo|placebo
219239937|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (A) for oral administration
219239938|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (B) for oral administration
219239939|NCT03478306|DRUG|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
219239940|NCT02188745|DRUG|17B-estradiol|Anti-estrogen
219239941|NCT02188745|DRUG|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
219239942|NCT02188745|DRUG|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
219239943|NCT02188745|DRUG|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
219239944|NCT01927484|DRUG|25 mg/week oral methotrexate tablets|active oral methotrexate drug
219239945|NCT01927484|DRUG|25mg/week oral placebo tablets|placebo comparator oral drug
219239946|NCT03823794|OTHER|No intervention|Observational analysis of usual care only
219239947|NCT00680654|DRUG|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
219239948|NCT04285645|OTHER|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
219239949|NCT02869230|PROCEDURE|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
219239950|NCT02869230|PROCEDURE|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
219239951|NCT00584909|DRUG|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
219170641|NCT06513104|DRUG|Levonorgestrel + Ethinylestradiol|Levonorgestrel + Ethinylestradiol will be administered orally.
219170642|NCT06513104|DRUG|Paracetamol|Paracetamol will be administered orally.
219170643|NCT04533347|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
219239952|NCT05835856|DEVICE|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
219239953|NCT05835856|DEVICE|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
219239954|NCT05835856|DEVICE|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
219170644|NCT04533347|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
219170645|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
219170646|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
219170647|NCT03907397|BIOLOGICAL|Peanut Protein|up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
219170648|NCT03907397|OTHER|Continued peanut avoidance|Standard of care avoidance of peanut
219239955|NCT05835856|DEVICE|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
219239956|NCT05835856|OTHER|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
219170649|NCT05057624|OTHER|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
219170650|NCT05057624|OTHER|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
219170651|NCT05057624|OTHER|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
219170652|NCT06156202|OTHER|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
219170653|NCT06156202|OTHER|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
219170654|NCT06274112|DEVICE|TMS|TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.
219170655|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
219170656|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
219170657|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
219170658|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
219170659|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
219170660|NCT04061798|DRUG|ACT guided heparinization|"If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
219239957|NCT03345407|DRUG|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
219170661|NCT04061798|DRUG|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
219170662|NCT06017180|OTHER|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
219170663|NCT06017180|OTHER|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
219170664|NCT06106893|BIOLOGICAL|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
219170665|NCT06834776|DIAGNOSTIC_TEST|TOF (Train-of-Four) monitoring for depth of neuromuscular blockade.|General anesthesia with propofol and fentanyl induction followed by rocuronium for neuromuscular blockade; maintenance with desflurane and remifentanil.
219170666|NCT04973163|DRUG|BI 1823911|BI 1823911
219170667|NCT04973163|DRUG|BI 1701963|BI 1701963
219170668|NCT04973163|DRUG|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
219170669|NCT05878860|BIOLOGICAL|ATSN-201|AAV.SPR-hGRK1-hRS1syn
219170670|NCT06016621|BEHAVIORAL|Improvisational Music Therapy|The therapist engages with the child by playing and sharing musical instruments, and/or sings while being attuned to the child's behaviour and expression. Various improvisational techniques are employed to engage the child. There are opportunities for pulse, rhythmic, dynamic or melodic patterns, and timbre to be mirrored, reinforced, or complemented, which allows for moments of synchronization between the therapist and the child, giving the child's musical expressions a pragmatic meaning within this context. The therapist may also gently provoke the child by violating expectations or patterns that have been jointly developed in order to elicit specific social communication behaviours. Further, there are opportunities for the child to develop and enhance social communication skills such as joint attention, sharing affect, reciprocity, shared history, scaffolding, imitation and turn-taking. These have been shown to develop social competency and also resilience.
219170671|NCT06837948|DRUG|PM8002|Specified dose on specified days.
219170672|NCT06837948|DRUG|Sintilimab|Specified dose on specified days.
219170673|NCT06837948|DRUG|Nab-paclitaxel|Specified dose on specified days.
219170674|NCT06837948|DRUG|Carboplatin|Specified dose on specified days.
219170675|NCT06837948|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
219170676|NCT06509386|OTHER|Major Depressive Disorder without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
219170677|NCT06509386|OTHER|Major Depressive Disorder with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
219239958|NCT03345407|DRUG|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
219239959|NCT03345407|DRUG|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
219239960|NCT03345407|DRUG|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
219239961|NCT03345407|DRUG|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
219239962|NCT03345407|DRUG|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
219170678|NCT06509386|OTHER|Major Depressive Disorder without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
219170679|NCT06509386|OTHER|Major Depressive Disorder with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
219170680|NCT06509386|OTHER|Schizophrenia without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
219170681|NCT06509386|OTHER|Schizophrenia with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
219170682|NCT06509386|OTHER|Schizophrenia without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
219170683|NCT06509386|OTHER|Schizophrenia with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
219170684|NCT02457156|PROCEDURE|Blumgart Anastomosis|"1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
219170685|NCT02457156|PROCEDURE|Cattell-Warren Anastomosis|"1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
219170686|NCT02457156|DRUG|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
219170687|NCT04493034|BEHAVIORAL|Art Therapy|"The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health."
219170688|NCT04493034|BEHAVIORAL|Music Therapy|"Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study."
219170689|NCT06682572|DRUG|Avutometinib (VS-6766) + Defactinib (VS-6063)|combination therapy
219170690|NCT06837922|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
219170691|NCT06837363|DEVICE|Home-based Neofect Smart board|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart board, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
219170692|NCT06837363|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
219239963|NCT03345407|DRUG|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
219239964|NCT03345407|DRUG|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
219239965|NCT00065611|DRUG|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
219239966|NCT00545922|BEHAVIORAL|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
219239967|NCT00545922|BEHAVIORAL|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
219239968|NCT02385539|DRUG|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
219239969|NCT05007002|DEVICE|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
219239970|NCT00600366|DRUG|biphasic insulin aspart|
219239971|NCT02092909|DRUG|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
219239972|NCT06475690|OTHER|Psychological interventions|Psychological interventions is used for intervention group
219239973|NCT05721898|DIAGNOSTIC_TEST|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
219170693|NCT05555355|DEVICE|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
219170694|NCT05555355|PROCEDURE|Spine surgery|Patients will receive spine surgery
219170695|NCT05147155|BIOLOGICAL|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
219170696|NCT05503485|BEHAVIORAL|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
219170697|NCT05503485|BEHAVIORAL|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
219170698|NCT05497206|DEVICE|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
219239974|NCT03151109|DIAGNOSTIC_TEST|CT Scan|CT scan at minimum 1 year post op
219239975|NCT05924971|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
219239976|NCT01767025|DRUG|Oxytocin|
219239977|NCT01767025|DRUG|Sea water|
219239978|NCT02376062|OTHER|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
219239979|NCT04782570|DEVICE|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
219239980|NCT04782570|DEVICE|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
219239981|NCT04463485|PROCEDURE|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
219239982|NCT00083148|DRUG|capecitabine|
219239983|NCT00083148|DRUG|irinotecan hydrochloride|
219239984|NCT00118937|DRUG|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
219170699|NCT06208202|BEHAVIORAL|Behavioral Intervention|Receive and use flavored e-cigarettes (EC) as directed
219239985|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
219239986|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
219239987|NCT03969251|DEVICE|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
219239988|NCT03969251|DEVICE|Sham (SS)|repetitive sham rTMS
219239989|NCT03317509|PROCEDURE|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
219239990|NCT00161434|DRUG|valacyclovir|1 gram daily for 8 weeks
219239991|NCT00161434|DRUG|placebo|matching placebo for 8 weeks
219239992|NCT04626128|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
219239993|NCT04626128|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
219239994|NCT01182285|DRUG|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
219239995|NCT01182285|DRUG|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
219239996|NCT00741689|DRUG|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
219239997|NCT02122042|BIOLOGICAL|HBOT|
219239998|NCT02137603|OTHER|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
219239999|NCT05145088|BEHAVIORAL|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
219170700|NCT06208202|OTHER|Biospecimen Collection|Undergo biosample sample collection
219170701|NCT06208202|OTHER|Survey Administration|Complete surveys
219170702|NCT06432543|DEVICE|polyethylene|No intervention as this is an observational study
219170703|NCT06512259|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
219240000|NCT05055141|OTHER|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
219240001|NCT05146479|PROCEDURE|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
219240002|NCT02883985|RADIATION|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
219240003|NCT00379210|BEHAVIORAL|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
219240004|NCT00379210|BEHAVIORAL|Nutrition Education course|8-week course in nutrition
219240005|NCT03209492|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
219240006|NCT01292499|BEHAVIORAL|Psychotherapy|10 sessions (50 min)
219240007|NCT01292499|BEHAVIORAL|Psychoeducation|7 sessions + 7 phone calls
219240008|NCT01292499|BEHAVIORAL|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
219240009|NCT01762345|DEVICE|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
219240010|NCT01815255|DRUG|tenofovir (TDF)|
219240011|NCT01541176|OTHER|Absence of corticotherapy post-transplantation|No study treatment
219240012|NCT01541176|DRUG|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day."
219240013|NCT05072795|BEHAVIORAL|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
219170704|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
219170705|NCT06101862|PROCEDURE|CCTA|Participants will be examined with CCTA during admission.
219170706|NCT06101862|PROCEDURE|Conventional ICA|Patients will be examined with conventional standard-of-care ICA.
219170707|NCT06101862|OTHER|Team-based interventional triage|The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
219170708|NCT04984291|DEVICE|Alliance Glenoid|Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
219170709|NCT04984291|DEVICE|Identity Stem|Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
219170710|NCT06741475|BEHAVIORAL|Caregiver-Assist Strategy Training|CaST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing real-life limitations after stroke. During the intervention, the caregiver not only supervises the participant but also co-participates in the practice by instructing on when and how to be an assistant and facilitator when the stroke survivor executes their practice plan.
219170711|NCT06741475|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequela, and adaptive skills for impaired functions are provided.
219170712|NCT06822959|OTHER|Pharmacogenetics, TDM and MedReview|Patients will undergo pharmacogenetics, TDM and MedReview analyses according to the study protocol
219170713|NCT06835270|OTHER|Yoga Exercises|Yoga group practiced Iyengar yoga asanas, pranayama, and mental focusing components in a group exercise format for 45 minutes.The yoga group was advised to practice yoga exercises at home following their yoga sessions.
219170714|NCT06835270|DEVICE|Standard physiotherapy approaches|Standard physiotherapy approaches group ( standard physiotherapy approaches (therapeutic ultrasound, hotpack) and TENS (5x5 cm electrodes, applied to the thoracic 12 and sacral 1 regions). Four electrodes were applied for 20 minutes with a pulse width of 50-100 µs and a frequency of 60-120 Hz. This group was additionally recommended to perform home exercises
219170715|NCT06835270|OTHER|Kinesiology taping|In the kinesiology taping technique, tape was applied in an I-shape parallel to the m. quadratus lumborum muscle. Interventions were conducted three times a week for four weeks, totaling 12 sessions.This group was additionally recommended to perform home exercises
219170716|NCT06835270|BEHAVIORAL|Awareness training for low back pain|The educational training was based on the WHO's guidelines for back pain. This group was additionally recommended to perform home exercises.
219170717|NCT04765943|DEVICE|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
219170718|NCT03562377|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
219170719|NCT03562377|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
219170720|NCT03562377|BIOLOGICAL|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
219170721|NCT03562377|BIOLOGICAL|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
219170722|NCT05817838|BEHAVIORAL|Financial Incentives|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store
219170723|NCT05817838|BEHAVIORAL|Financial Incentives and Multilevel Multicomponent|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing
219170724|NCT05817838|OTHER|School Engagement|For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
219170725|NCT05499637|DRUG|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET/CT
219170726|NCT06837337|OTHER|Music intervention|Music intervention
219170727|NCT04431999|DRUG|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
219170728|NCT04431999|DRUG|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
219170729|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 1|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
219170730|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 2|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
219170731|NCT06557499|DEVICE|Natural Rubber Latex (NRL) male condom- Control condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
219170732|NCT06834542|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
219170733|NCT03737149|OTHER|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
219170734|NCT05254457|BIOLOGICAL|EN3835|Treatment or retreatment with EN3835
219170735|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
219170736|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
219170737|NCT06269146|DRUG|Pramipexole Pill|The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
219170738|NCT06269146|DRUG|Placebo Pill|Placebo will match the study drug in mode of administration, color, size, and taste.
219170739|NCT04595786|DRUG|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
219170740|NCT04595786|DRUG|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
219170741|NCT06490822|PROCEDURE|Skin biopsy|A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
219170742|NCT06844175|DRUG|Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol|The intervention group was given budigfovir once a day, the dose was 160ug/7.2ug/4.8ug by inhalation
219170743|NCT00287235|DEVICE|MARS|
219170744|NCT00287235|DRUG|Standard Medical Therapy|
219170745|NCT03972657|DRUG|REGN5678|Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration
219170746|NCT03972657|DRUG|Cemiplimab|Administered at the assigned DL by IV
219170747|NCT06221488|DIAGNOSTIC_TEST|TB infection testing|Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
219170748|NCT05981794|DEVICE|Electrical heating pad|A powered heating pad
219170749|NCT05981794|DEVICE|Sham heating pad|A heating pad that is not powered on
219737969|NCT03286075|DEVICE|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
219737970|NCT03286075|DEVICE|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
219737971|NCT00693732|DRUG|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
219737972|NCT00693732|BEHAVIORAL|Quantitative sensory testing|Rectal Distention Stimulation
219170750|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
219170751|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
219170752|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
219170753|NCT05736679|DEVICE|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
219170754|NCT06986369|DRUG|Rivaroxaban 2.5 MG Oral Tablet [Xarelto]|prospective, randomized, 3 months study to clarify the efficacy of rivaroxaban and aspirin versus aspirin in the alone the changes on the number of circulating endothelial cells and endothelial function, and systemic inflammation, platelet and coagulation activation in patients with stable atherosclerotic vascular diseases.
219170755|NCT06855186|BEHAVIORAL|Symptom-Targeted Approach to Rehabilitation for Concussion|This study is looking at a shortened version of a therapist-direct cognitive rehabilitation intervention, known as STAR-C. STAR-C is focused on strategy use, and for strategy use to become a habit the person must have the opportunity for high-dose spaced practice. Thus, in STAR-C each session includes opportunities for repeated practice and participants schedule practice times between sessions. Sometimes a new strategy requires learning new facts, in which case the clinician chooses ingredients such as self-quizzing or comparing and contrasting outcomes, which are effective for learning new facts and concepts.
219170756|NCT06866509|DRUG|Litorvazet Tablet 10/10mg|Ezetimibe 10 mg + Atorvastatin 10 mg
219170757|NCT06866509|DRUG|Litorvazet Tablet10/20mg|Ezetimibe 10 mg + Atorvastatin 20 mg
219170758|NCT06866509|DRUG|Litorvazet Tablet 10/40mg|Ezetimibe 10 mg + Atorvastatin 40 mg
219170759|NCT06676748|DRUG|Benzydamine Hydrochloride|The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
219170760|NCT04634019|BEHAVIORAL|Financially incentivized knowledge assessments|We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
219170761|NCT06718244|BIOLOGICAL|single dose of Inaticabtagene autoleucel|"Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.~If the quantity of CAR-T cells of the patient is sufficient, after the patient receives the first CAR-T transfusion 5\~6 months，they will receive a second CAR-T cell transfusion. The aim of the second transfusion is to prolong the duration of CAR-T in the patient's body and prolong the patient's DOR. The dose and procedures of the second transfusion are the same as those for the first transfusion. After the second infusion, the patient will receive evaluation based on the day of the second transfusion as Day0."
219170762|NCT06780709|BEHAVIORAL|Wellness Program and Behavioral Counseling|The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.
219170763|NCT06629766|DEVICE|Microfluidic sperm separation device|An aliquot of 850ul will be used for the Zymot sperm selection device. The sperm processing via Zymot will be per manufacturer's guidelines
219170764|NCT06629766|OTHER|Density grade centrifugation|5ul of the ejaculated sample will be assessed for DGC via Makler assessment. If the sample for DGC is adequate per lab standard operating procedures, then routine DGC sperm preparation and embryologist sperm selection for the ICSI procedure will occur.
219170765|NCT06835595|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|Paired stimulation protocols of TMS to collect SAI, SICI, ICF measures
219170766|NCT06927193|PROCEDURE|Regional anaesthesia|Regional anaesthesia
219170767|NCT06784778|DIAGNOSTIC_TEST|PBMC Kinase Activity Profile|Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments
219170768|NCT06840379|DRUG|Sertraline (Oral Antidepressant)|"* 25 mg/day sertraline, titrated up to 100 mg/day based on clinical response and tolerability.~* Administered orally once daily for 12 weeks.~* Used to assess its effects on C-reactive protein (CRP) levels and depressive symptoms in hemodialysis patients."
219170769|NCT06840379|DRUG|Placebo|"* Identical placebo tablet administered orally once daily for 12 weeks, following the same dosing schedule as the sertraline group.~* Used to compare the effects of sertraline vs. placebo on CRP levels and depression severity in hemodialysis patients."
219170770|NCT04858139|DRUG|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
219170771|NCT04858139|DRUG|Placebo|Intravenous injection (20 min)
219737973|NCT03256656|OTHER|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
219737974|NCT00890097|DRUG|AL-8309B Ophthalmic Solution|
219737975|NCT00890097|DRUG|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
219737976|NCT05858151|BEHAVIORAL|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
219737977|NCT01694771|DRUG|Tiotropium|Marketed dose
219737978|NCT01694771|DRUG|Placebo matching Olodaterol|One dose
219737979|NCT01694771|DRUG|Olodaterol|One dose
219737980|NCT01694771|DRUG|Tiotropium|Marketed dose
219737981|NCT04784871|BEHAVIORAL|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
219737982|NCT04784871|BEHAVIORAL|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
219737983|NCT04784871|BEHAVIORAL|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
219737984|NCT05672537|DRUG|Durvalumab|1500mg intravenous injection for 21d cycle
219737985|NCT05672537|PROCEDURE|Surgery|Surgery
219737986|NCT05672537|DRUG|Gemcitabine|gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
219737987|NCT05672537|DRUG|Cisplatin|cisplatin 25mg/m2, D1\&D8, 21d cycle.
219737988|NCT01950598|PROCEDURE|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
219737989|NCT01950598|PROCEDURE|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
219737990|NCT05151419|PROCEDURE|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
219737991|NCT03721367|OTHER|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
219737992|NCT06105892|DEVICE|Virtual Eye Rotation Vision Exercise (VERVE)|VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.
219737993|NCT06105892|DEVICE|Sham VR Therapy|VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
219170772|NCT06073743|OTHER|Conventional Physiotherapy|The conventional physiotherapy program will be applied 2 days a week, 60 minutes a day for 10 weeks and consist of weight bearing on the upper and lower extremities, strengthening, functional stretching exercises, walking training and balance exercises.
219170773|NCT06073743|OTHER|Video Game Based Exercise Training|In the Video Game Based Exercise Training program, in addition to the same conventional physiotherapy application for 30 minutes a day, 2 days a week for 10 weeks, 30 minutes of Microsoft Xbox Kinect video games such as reflex ridge and rallyball are used.
219737994|NCT04056429|COMBINATION_PRODUCT|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
219737995|NCT01163877|DIETARY_SUPPLEMENT|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
219737996|NCT03907956|OTHER|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
219737997|NCT00392509|PROCEDURE|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
219737998|NCT02037880|PROCEDURE|Lumbar puncture|
219737999|NCT02037880|DEVICE|Magnetic Resonance Imaging (MRI) of the brain|
219738000|NCT05792254|DRUG|Huaier granule|Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
219738001|NCT04249193|OTHER|Transfusion|pRBC and non-pRBC transfusions
219738002|NCT03059342|PROCEDURE|single event multilevel surgery|
219170774|NCT06630000|BEHAVIORAL|FACT|Two 90-minute FACT sessions led by a trained interventionist.
219170775|NCT06630000|BEHAVIORAL|Control|Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
219170776|NCT05395767|PROCEDURE|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
219170777|NCT06931613|DRUG|Nivolumab|Nivolumab with or without bendamustine is administered to children prior to auto-HSCT
219170778|NCT06932367|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
219170779|NCT06932367|COMBINATION_PRODUCT|Methylprednisolone (Corticosteroid)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
219170780|NCT06932289|DIETARY_SUPPLEMENT|Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF)|Participants will be randomized to either Mediterranean diet (MED), high-fat/low carb diet (HF/LC), or low-fat diet (LF).
219170781|NCT06932289|DEVICE|The integrated sweat sensor and vascular sensor (wearable)|The integrated sweat sensor and vascular sensor will be worn of each diet period.
219170782|NCT06932289|DEVICE|continuous glucose monitor (CGM)|A continuous glucose monitor (CGM) will be placed on the patients during each diet period.
219170783|NCT06931223|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of functional dyspepsia.
219170784|NCT06931223|DRUG|Lansoprazole|Placebo and Lansoprazole for functional dyspepsia.
219170785|NCT06932510|PROCEDURE|Manual Traction|Manual cervical traction will be administered by a trained physical therapist.
219170786|NCT06932510|DEVICE|Cervical Traction Collar|Cervical traction will be administered via Cervical Traction Collar.
219170787|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~4. The parameter setting of the equipment: the frequency is set to 2Hz, the pulse width is set to 500μs, continuous wave is used, and the current intensity is the maximum tolerance of the subject's small pain threshold for 30min."
219170788|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~(4)30 minutes of ineffective microcurrent stimulation."
219170789|NCT06932549|BEHAVIORAL|Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.|The TA is tailored to each congregation using the results of the implementation capacity survey completed by the congregation's team and materials from the EB Program selected by the congregation. The TA teams of two research staff are being trained and coached by Dr. Abe Wandersman, lead developer of Getting To Outcomes-TA (GTO-TA). TA sessions are audio-recorded and will be evaluated for fidelity to GTO-TA, and use of specific ERIC strategies.
219170790|NCT06931808|DRUG|Sintilimab plus Chemotherapy|All patients received standard long-term radiation therapy (LCRT) (50.0Gy/25f) and concurrent chemotherapy with capecitabine (825 mg/m2, bid, po) (Phase 1); Xelox scheme (Oxaliplatin 130 mg/m2, ivgtt ，d1； Capecitabine 1000 mg/m2, bid，d1-14) (Phase 2); . During the radiotherapy and chemotherapy period, they also received two cycles of immunotherapy with Sintilimab (200mg, ivgtt, d1, q3w).
219240014|NCT04301063|OTHER|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
219240015|NCT03925519|OTHER|Supervised aerobic exercise|
219240016|NCT03476525|DRUG|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
219240017|NCT01958346|OTHER|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
219170791|NCT06931808|DRUG|Intestinal microbiota capsules|During Phase 1, intestinal microbiota transplantation treatment, oral intestinal microbiota capsules are used for transplantation treatment, with a dose of 30 capsules/day (about 1U sediment microbiota, containing about 1 × 1013 bacteria). Transplantation is carried out continuously for 3 days starting from each week, for a total of 3 courses of treatment.
219170792|NCT06931808|RADIATION|Standard Long Course Radiotherapy|50.0Gy/25f
219170793|NCT06931808|PROCEDURE|Total mesorectal excision|6-8 weeks after the end of the first phase and combined with 5 cycles of Xelox regimen adjuvant chemotherapy.
219170794|NCT06931756|DEVICE|Neural Stimulator|Adjust the neural stimulator, with a stimulation duration of 0.1 ms, a stimulation frequency of 1Hz, and a stimulation current of 1.0mA. Under ultrasound guidance, the needle tip is used to touch the radial nerve, ulnar nerve, median nerve, and musculocutaneous nerve respectively, until a clear motor response is observed in the corresponding muscles. Thereafter, the minimum stimulation threshold current is verified by reducing the current until the distal motor response disappears. If no motor response is elicited, the current intensity is appropriately increased to achieve a motor response of the extensor tendon of the radial nerve, and the flexor tendon motor responses of the ulnar nerve, median nerve, and musculocutaneous nerve.
219170795|NCT06932159|DRUG|Empagliflozin + Linagliptin film-coated tablets|1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets
219170796|NCT06932159|DRUG|Glyxambi film-coated tablets|1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets
219170797|NCT06932913|OTHER|plyometric exercise|"Plyometric exercise procedures:~Patients in group (B) will receive Plyometric exercise :~Traditional physical therapy program for 20 to 30 minutes and 30 to 45 minutes of training program consisted of 6 lower extremity plyometric exercises for eight weeks .~Wall jumps : Knees slightly bent, arms raised overhead, bounce up and down off toes . Tuck jumps : From standing position, jump and bring both knees up to chest as high as possible Squat jumps : Standing jump raising both arms overhead, land in squatting position touching both hands to the floor Single leg jump distance : One-legged hop for distance .~Scissors jump : Start in stride position, jump and alternate position in midair .~Bounding in place : Jump from 1 leg to the other straight up and down."
219170798|NCT06932913|OTHER|Plyometric exercise procedures:|"The traditional physical therapy program will be in the form of (active knee range of motion exercise and stretching and strengthen exercise of hamstring) three times a week for eight successive weeks of treatment in 20 to 30 minutes to complete:-~Active range of motion exercises for knee joint:~This type of exercise was performed in the following manner:~Knee flexion :~From prone lying position. The child will asked to Slowly bend his knee by pulling heel to buttocks as far as he can . he should feel a gentle stretch in his thigh muscles and knee. Return to starting position.~Knee extension :~From sitting position at the edge of the plinth the child will asked to move his feet up word toward the ceiling as far as he can then return . he should feel gentle stretch on the hamstring muscle .~Hip and knee bend:"
219170799|NCT06931665|PROCEDURE|Animal Assisted Occupational Therapy|AAT is an ergotherapy including an animal. AAT is a specific type of Animal Assisted Intervention (AAI) with a therapeutic aim.
219170800|NCT06931314|PROCEDURE|Aromatherapy massage|Aromatherapy massage refers to a massage to be performed on the neck area with lavender oil.
219170801|NCT06931314|PROCEDURE|Muscle Energy Technique|Muscle Energy Technique is a form of manual therapy that uses active muscle contraction and relaxation to improve musculoskeletal mechanics and relieve pain.
219170802|NCT06932354|DEVICE|CGM|masked continuous glucose monitoring
219170803|NCT06932705|DRUG|PA-111|PA-111 1Tab., Per Oral
219170804|NCT06932705|DRUG|PA-111A|PA-111A 1Capsule., Per Oral
219170805|NCT06942585|DEVICE|Kinesiology Tape|An elastic therapeutic tape applied to the ankle and knee using standard kinesiology taping techniques. The tape is stretched to approximately 10-15% during application and is designed to mimic the properties of human skin. It aims to provide sensory stimulation, improve proprioceptive feedback, and support joint function without limiting range of motion. The application targets muscles and tendons surrounding the knee and ankle, commonly used in both preventive and rehabilitative physiotherapy.
219170806|NCT06942585|DEVICE|Dynamic tape|A biomechanical tape characterized by high elasticity (over 200%) and strong resistance, applied to the ankle and knee to assist movement and absorb load. The tape is applied in a shortened muscle position with maximal stretch across the joint, following the manufacturer's guidelines (GripIt ACTIVETAPE, 5 cm width). This taping method aims to provide both mechanical support and neurosensory input, facilitating muscle activation and improving joint stability during movement. It is used to address both biomechanical and proprioceptive components of lower limb control.
219170807|NCT06932887|BEHAVIORAL|Text Messaging|Weekly SMS messages sent to potential participants to inform them of the opportunity to participate in PA counseling for their arthritis. instructions also provided on how to request a referral.
219170808|NCT06932887|BEHAVIORAL|Motivational Messaging|The use of short motivational messages along with text messages inviting persons to participate in PA counseling. The messages are intended to enhance the motivation to participate in PA counseling.
219738003|NCT00398450|BIOLOGICAL|recombinant interferon alfa-2b|
219738004|NCT00398450|DRUG|azacitidine|
219738005|NCT01391871|DEVICE|OCT|Optical coherence tomography
219738006|NCT01391871|DEVICE|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
219738007|NCT03870971|OTHER|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
219738008|NCT04576221|DEVICE|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
219738009|NCT04576221|DEVICE|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
219170809|NCT06932887|BEHAVIORAL|Physical Activity Counseling and Self-Directed Walk with Ease|All persons consenting to PA counseling receive 6 weekly sessions provided in-person or remote with 2-way video or audio commu¬nication. All participants receive education to address negative psy-chological appraisals of OA, reassur¬ance that PA is safe and beneficial, and a PA program primarily focused on walk¬ing, although additional activities may be included. Additional components include exercises tai¬lored to the partici¬pant's needs and coping strategies such as mindful breathing to help manage stress.
219170810|NCT06932887|BEHAVIORAL|Enhanced Walk with Ease|Along with the portal registration participants in the Enhanced WWE group are also offered the opportunity to participate in virtual group WWE classes offered on a rolling basis in either English or Spanish.
219240018|NCT01958346|OTHER|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
219240019|NCT01958346|DEVICE|Fiberoptic Intubation|
219240020|NCT01130077|BIOLOGICAL|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
219170811|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
219170812|NCT06631677|DRUG|Dupilumab|Administered per protocol
219170813|NCT06477185|DRUG|Doxycycline|Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
219170814|NCT06477185|DRUG|Placebo|This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
219170815|NCT05449795|DEVICE|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
219170816|NCT05312892|DRUG|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
219170817|NCT05312892|DRUG|Moxonidine|Moxonidine
219170818|NCT05312892|DRUG|Placebo|Placebo
219170819|NCT05062369|DEVICE|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
219170820|NCT05062369|BEHAVIORAL|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
219170821|NCT04083235|DRUG|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
219170822|NCT04083235|DRUG|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
219170823|NCT04083235|DRUG|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
219170824|NCT04083235|DRUG|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
219170825|NCT04083235|DRUG|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
219170826|NCT04083235|DRUG|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
219240021|NCT01130077|BIOLOGICAL|Poly-ICLC|Vaccine given every 3 weeks
219240022|NCT02562521|BEHAVIORAL|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
219240023|NCT02562521|DRUG|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
219240024|NCT02562521|DRUG|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
219240025|NCT02562521|BEHAVIORAL|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
219240026|NCT00072670|DRUG|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
219240027|NCT05790317|PROCEDURE|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
219240028|NCT01259219|DRUG|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
219240029|NCT02845609|DRUG|Sialic Acid-Extended Release|Oral drug of Sialic acid
219170827|NCT04559334|DEVICE|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
219170828|NCT05101928|DRUG|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
219170829|NCT05101928|DRUG|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
219170830|NCT03887741|BIOLOGICAL|Plasmapheresis|Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma
219170831|NCT03887741|BIOLOGICAL|Plasma infusion|Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
219170832|NCT06310603|OTHER|Low-Processed Food Diet|Participants that receive intervention will be instructed to eat a diet rich in unprocessed/minimally-processed foods, as described by the NOVA food classification system
219240030|NCT02627794|DEVICE|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
219738010|NCT01783873|OTHER|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
219738011|NCT01941628|DRUG|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
219738012|NCT01941628|DRUG|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
219738013|NCT05515263|DIETARY_SUPPLEMENT|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
219738014|NCT05515263|DIETARY_SUPPLEMENT|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
219738015|NCT04920994|PROCEDURE|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
219738016|NCT04920994|PROCEDURE|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
219738017|NCT04920994|DRUG|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
219738018|NCT00289900|DRUG|MK-0524A|
219738019|NCT00289900|DRUG|Atorvastatin|
219738020|NCT00289900|DRUG|Simvastatin|
219738021|NCT04197323|DRUG|Alprostadil liposomes for injection|40ug,once a day,continuous administration for 2 weeks
219738022|NCT00859274|DRUG|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
219738023|NCT05777278|DRUG|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
219738024|NCT05777278|DRUG|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
219738025|NCT06209125|DEVICE|hybrid aesthetic functional appliance|treatment of class II division one malocclusion
219738026|NCT05740826|DEVICE|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
219738027|NCT01152385|DRUG|AZD1656|Oral tablet administered twice daily during 4 months
219738028|NCT01152385|DRUG|Placebo|administered twice daily during 4 months
219738029|NCT04029051|OTHER|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
219738030|NCT02999360|BEHAVIORAL|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
219738031|NCT02999360|BEHAVIORAL|Background Music|30 minutes background music only
219170833|NCT06425523|BEHAVIORAL|Home Gardening Intervention (HGI)|The Home Gardening Intervention (HGI) provides refugee participants with agricultural inputs and training (field prep., sowing, water management, pest control, weeding, etc.) through a participatory field school approach with a curriculum derived from best practices in agro-ecology. The program includes active monitoring during a 12-month period. The training involves nutrition education on cooking methods and the importance of dietary diversity using garden produce as well as guidance on surplus management and market support. The overall goal of the intervention is to enable climate-resilient farming for improved food security and dietary diversity that is sustainable long-term.
219170834|NCT06425523|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus (SH+) is a 5-session group intervention developed by the WHO and based on Acceptance and Commitment Therapy, delivered by trained local facilitators. It provides tools to manage stress and adversity through pre-recorded audio lessons and a self-help book. Sessions include individual exercises and group discussions.~SH+ aims to decrease psychological distress. It has shown effectiveness among refugees in Uganda and elsewhere."
219170835|NCT06425523|BEHAVIORAL|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
219170836|NCT03567096|DEVICE|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
219170837|NCT03567096|DEVICE|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
219170838|NCT06423196|OTHER|Experimental group|In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
219170839|NCT03958955|DRUG|Delgocitinib cream|Cream for topical application.
219170840|NCT03958955|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219170841|NCT06093334|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
219170842|NCT06093334|DIAGNOSTIC_TEST|Cardiopulmonary testing|Myocardial function (Strain-Analysis by echocardiography) and spiroergometry, capillary blood gases and lactate
219170843|NCT06093334|DIAGNOSTIC_TEST|Pulmonary testing|Lung function (VC%, FEV1%)
219170844|NCT06093334|DIAGNOSTIC_TEST|Blood sample|Standard procedures/parameters routinely available in follow-up care after oncological treatment
219170845|NCT05216068|DIAGNOSTIC_TEST|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
219170846|NCT05899998|BEHAVIORAL|Bright IDEAS|Bright IDEAS® (Identify, Define, Evaluate, Act, See) is a problem-solving skills training program that was originally developed to alleviate distress in caregivers of children recently diagnosed with cancer. Intervention materials include instructor and user manuals, a brochure, and worksheets to be completed by the parent caregiver, initially with the help of the interventionist and then with increasing independence.
219170847|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
219170848|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
219170849|NCT04975139|DEVICE|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
219170850|NCT05829902|OTHER|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
219170851|NCT05829902|OTHER|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
219170852|NCT05678998|DRUG|WTX-330|Investigation Product
219170853|NCT04638829|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
219170854|NCT04768322|DEVICE|HeartMate 3 TM Left Ventricular Assist System|The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
219170855|NCT04768322|OTHER|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
219170856|NCT05330975|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219170857|NCT05330975|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219170858|NCT05330975|BIOLOGICAL|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
219170859|NCT05330975|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219170860|NCT01368146|DEVICE|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
219240031|NCT02627794|DEVICE|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
219170861|NCT01368146|DEVICE|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
219240032|NCT03636958|DRUG|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
219170862|NCT01368146|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
219170863|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
219170864|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
219170865|NCT06408558|OTHER|Hypobaric|The effects of ambient pressure changes on glucose metabolism will be studied
219170866|NCT06408558|OTHER|Ground level|The effects of ambient pressure changes on glucose metabolism will be studied
219170867|NCT05415410|DRUG|Apraglutide|Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
219170868|NCT05477602|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
219170869|NCT05749627|DRUG|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
219170870|NCT05749627|DRUG|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
219170871|NCT06075784|OTHER|reiki|placebo reiki
219170872|NCT06296836|DRUG|Metformin|Continuation of home metformin
219170873|NCT05912478|OTHER|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
219170874|NCT05912478|OTHER|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
219170875|NCT03366272|DRUG|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
219170876|NCT03366272|DRUG|Rituximab|eight cycles of R-GemOx in 2-wk intervals
219170877|NCT03366272|DRUG|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
219170878|NCT03366272|DEVICE|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
219240033|NCT03636958|DRUG|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
219240034|NCT06285578|DIETARY_SUPPLEMENT|Probiotics supplementation|Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
219170879|NCT06188468|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
219170880|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
219170881|NCT06535971|OTHER|Manual therapy combined exercise|"1. Manual therapy included fascia release, progressive passive stretch, mobilization, etc.(depend on subject's current condition)~2. Exercise included muscle strengthening, trunk (spine) stabilization exercise. (depend on subject's current condition)"
219170882|NCT05617027|OTHER|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
219170883|NCT05617027|OTHER|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
219170884|NCT06142825|OTHER|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
219170885|NCT04742231|DEVICE|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
219170886|NCT06552689|DEVICE|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System|Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
219170887|NCT06046326|BEHAVIORAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
219170888|NCT05105802|BEHAVIORAL|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
219170889|NCT05105802|BEHAVIORAL|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
219170890|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
219170891|NCT05081622|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
219170892|NCT03652805|DRUG|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
219170893|NCT02927769|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
219170894|NCT02927769|BIOLOGICAL|brentuximab vedotin|Specified Dose on Specified Days
219170895|NCT02927769|BIOLOGICAL|bendamustine|Specified Dose on Specified Days
219170896|NCT06414122|OTHER|mid-frequency whole-body electromyostimulation (WB-EMS)|supervised group training sessions at least once and optionally twice a week, lasting 11-20 minutes, over 12 weeks, 12-24 training sessions in total
219170897|NCT06414122|OTHER|conventional exercise training|supervised group training at least once a week, optional additional home-based training once a week, lasting 40 minutes, over 12 weeks, 12-24 training sessions in total
219170898|NCT06414122|OTHER|nutritional therapy|conventional nutritional counselling with guidelines and digital nutritional coaching
219170899|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
219738032|NCT02999360|BEHAVIORAL|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
219738033|NCT06222736|OTHER|Rocabado Exercises|Patients trained by Rocabado Exercises
219738034|NCT06222736|OTHER|Servical Core Exercises|Servical Core Exercises
219738035|NCT06308926|DRUG|MRG-001 (Low-dose)|MRG-001 is subcutaneously administered.
219738036|NCT06308926|DRUG|MRG-001 (High-dose)|MRG-001 is subcutaneously administered.
219738037|NCT06308926|OTHER|Placebo|Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
219738038|NCT04200209|OTHER|Implementation of a quality indicator feedback mechanism|"1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
219738039|NCT05751811|DEVICE|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
219738040|NCT05751811|PROCEDURE|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
219738041|NCT05486065|DRUG|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
219738042|NCT05486065|DRUG|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
219738043|NCT02656173|DRUG|Mirabegron|Oral tablet
219738044|NCT02656173|DRUG|Placebo|Oral tablet
219738045|NCT02656173|DRUG|Tamsulosin|Oral tablet
219738046|NCT01064622|DRUG|Gemcitabine Hydrochloride|Given IV
219738047|NCT01064622|OTHER|Hydrocortisone/Placebo|Given PO
219738048|NCT01064622|DRUG|Vismodegib|Given PO
219240035|NCT06285578|BEHAVIORAL|HIIT training|HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
219240036|NCT06285578|DIETARY_SUPPLEMENT|Placebo supplementation|Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
219170900|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
219170901|NCT03113929|RADIATION|MRI|Research MRI
219170902|NCT05150860|BEHAVIORAL|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
219170903|NCT05150860|BEHAVIORAL|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
219170904|NCT05669846|DRUG|Healthy Donor Fecal Microbiota Transplant (hdFMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy, or, administered orally in the form of capsules. The FMT consists of introducing normal bacterial flora contained in the stool collected from a healthy donor into the small intestine. In this case, the hdFMT will be administered on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
219170905|NCT05669846|DRUG|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
219170906|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
219170907|NCT03747341|DRUG|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
219170908|NCT03747341|DRUG|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
219170909|NCT03747341|DRUG|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
219170910|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
219170911|NCT03747341|DRUG|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
219170912|NCT03747341|DRUG|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
219170913|NCT02807636|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
219170914|NCT02807636|DRUG|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
219170915|NCT02807636|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
219240037|NCT01026441|DEVICE|Vela100 (Aesthetic)|6 treatments once a week
219170916|NCT02807636|OTHER|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
219240038|NCT03218085|DRUG|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
219170917|NCT02807636|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
219170918|NCT06436053|DEVICE|LBBAP with SyncAV|Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.
219170919|NCT05082909|DRUG|Probenecid|Addition of 500mg QDS to oral penicillin.
219170920|NCT05531604|BEHAVIORAL|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
219170921|NCT04357574|OTHER|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
219170922|NCT04088630|DRUG|Fingolimod|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
219170923|NCT04088630|DRUG|Placebo|A single oral placebo pill within 24 hours of symptom onset
219170924|NCT04088630|DRUG|Open-label Fingolimod|A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
219170925|NCT05641623|DRUG|OSU6162|OSU6162
219170926|NCT05641623|DRUG|Placebo|Placebo
219170927|NCT05921448|BIOLOGICAL|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
219170928|NCT05921448|BIOLOGICAL|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
219170929|NCT03164980|DRUG|Trabectidin (Yondelis)|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
219170930|NCT04230499|DRUG|Encapsulated Rapamycin (eRapa)|eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
219170931|NCT04271709|BEHAVIORAL|Enhanced Intervention Using Patient Navigators|Enhanced support by patient navigators assisted with follow-up eye exam appointment scheduling and arranging transportation over a 1-year period.
219170932|NCT04271709|OTHER|Usual Care|Usual Care subjects who failed the screening and needed vision correction were given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects did not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
219170933|NCT05629156|OTHER|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
219170934|NCT05980000|DRUG|Ramucirumab|Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
219170935|NCT05980000|DRUG|Pembrolizumab|Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
219170936|NCT03315754|DRUG|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
219170937|NCT06123611|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
219170938|NCT06186336|OTHER|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
219240039|NCT03218085|DRUG|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
219240040|NCT00378456|DRUG|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
219170939|NCT04595435|PROCEDURE|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
219170940|NCT04595435|RADIATION|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
219240041|NCT00378456|DRUG|Folinic acid|
219240042|NCT00378456|DRUG|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
219240043|NCT00378456|DRUG|Placebo|
219240044|NCT05202444|PROCEDURE|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
219240045|NCT03610984|OTHER|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
219240046|NCT03000725|BEHAVIORAL|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
219240047|NCT03000725|BEHAVIORAL|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
219240048|NCT05590026|DRUG|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
219240049|NCT01448928|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
219240050|NCT01645241|DRUG|gonadotropins plus GnRH antagonists|
219240051|NCT01645241|DRUG|ganirelix|
219240052|NCT02296307|OTHER|Blood test: CA-125 biomarker|"* CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6."
219240053|NCT02296307|OTHER|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
219240054|NCT02296307|OTHER|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
219170941|NCT02954341|DEVICE|CardioMEMS HF System|
219240055|NCT05343936|OTHER|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
219240056|NCT01579955|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
219240057|NCT05224388|DRUG|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
219240058|NCT05224388|DRUG|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
219240059|NCT03379597|DRUG|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
219240060|NCT03379597|DIETARY_SUPPLEMENT|Dietary fiber|dietary fiber compound powder 30g bid
219240061|NCT01049815|DRUG|sevelamer hydrochloride|800-3200 mg with each meal
219240062|NCT01049815|DRUG|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
219240063|NCT04151030|PROCEDURE|PEG placement|Push PEG placement
219170942|NCT05520047|BEHAVIORAL|COVID19-severe Patient|Behavioral and social test assessment
219170943|NCT05520047|BEHAVIORAL|family of COVID19-severe Patient|Behavioral and social test assessment
219170944|NCT03381261|DRUG|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
219170945|NCT04421079|DIETARY_SUPPLEMENT|Trans-resveratrol|150mg, 300mg, 450mg
219170946|NCT04421079|DIETARY_SUPPLEMENT|Concord grape juice|8 oz, 16 oz, 24 oz
219170947|NCT04421079|DIETARY_SUPPLEMENT|Grape seed polyphenol extract|450mg, 900mg, 1200mg
219170948|NCT04421079|DRUG|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
219240064|NCT02754375|PROCEDURE|rTMS|
219240065|NCT02618876|DRUG|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
219240066|NCT02618876|DRUG|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
219240067|NCT00175253|DRUG|alemtuzumab|
219240068|NCT00175253|PROCEDURE|islet transplant|
219240069|NCT00882856|DRUG|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
219240070|NCT00882856|DRUG|Placebo|placebo
219240071|NCT01979211|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
219240072|NCT01979211|RADIATION|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
219240073|NCT03944889|DRUG|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
219240074|NCT03944889|DEVICE|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
219240075|NCT03944889|DEVICE|Cadwell Sierra Wave|Intramuscular EMG recording machinery
219240076|NCT03944889|DEVICE|Sonosite Ultrasound Machine|Ultrasound System
219240077|NCT03944889|DEVICE|Goniometer|A device to measure angular position
219240078|NCT05978089|DRUG|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
219170949|NCT05434819|PROCEDURE|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
219170950|NCT06297148|OTHER|Self-management|"Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast."
219170951|NCT06297148|OTHER|Usual care|Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
219240079|NCT05978089|DRUG|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
219240080|NCT02531061|DEVICE|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
219240081|NCT00579020|DRUG|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
219240082|NCT00579020|DRUG|Moxifloxacin ophthalmic solution 0.5%|
219240083|NCT00579020|DRUG|Dexamethasone phosphate solution, 0.1%|
219240084|NCT00509314|BEHAVIORAL|melanocyte self-assembly and functional analysis|
219240085|NCT03956771|BEHAVIORAL|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
219240086|NCT03956771|BEHAVIORAL|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
219240087|NCT00753896|DRUG|exenatide|subcutaneous injection, 2.0mcg, once weekly
219240088|NCT04347889|DRUG|Hydroxychloroquine|Oral loading dose followed by once weekly dosing
219240089|NCT04347889|OTHER|Vitamin C|Once daily vitamin C 1 gm
219240090|NCT00416585|DRUG|isotretinoin (Roaccutane)|
219240091|NCT00963105|DRUG|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
219240092|NCT02885610|BIOLOGICAL|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
219170952|NCT05634226|DEVICE|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
219170953|NCT05226351|DRUG|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
219170954|NCT05226351|DRUG|Placebo|single administration of placebo oral (oily solution)
219170955|NCT03945539|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
219170956|NCT03945539|DRUG|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
219170957|NCT03141424|DRUG|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
219170958|NCT06579872|OTHER|plantar pressure|foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases
219170959|NCT05227209|DRUG|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
219170960|NCT04848896|DEVICE|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
219170961|NCT04848896|PROCEDURE|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
219170962|NCT06202287|OTHER|Balance measurements using the HUR Smart balance device, balance tests, and other surveys.|50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
219170963|NCT05600348|DIETARY_SUPPLEMENT|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
219170964|NCT06089577|DRUG|Cangrelor 50 MG|Cangrelor will be administered during PCI
219170965|NCT06075758|OTHER|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
219170966|NCT06216548|OTHER|Usual Care and Enhanced Primary Care|"Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice."
219170967|NCT06216548|OTHER|Enhanced Primary Care|The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
219170968|NCT05331170|BIOLOGICAL|Research Grade RG-RV|Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
219170969|NCT06473233|DEVICE|TEG6S|Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician
219170970|NCT05464758|OTHER|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
219170971|NCT05329883|PROCEDURE|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
219170972|NCT05168605|OTHER|Home visit|Patients receiving home Visits
219170973|NCT06360419|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
219170974|NCT06360419|DRUG|Placebo|Placebo tablets, taken once daily
219170975|NCT05993845|OTHER|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video \& audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data \& other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- \& postoperative Standard axial hip x-rays pre- \& postoperative Western Ontario \& McMaster Universities Osteoarthritis Index \& Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
219170976|NCT05204589|BIOLOGICAL|Aerosolized Ad5-nCoV|Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
219170977|NCT05204589|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine|Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
219170978|NCT06470100|DRUG|0.9% Sodium Chloride Injection|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
219240093|NCT02885610|BIOLOGICAL|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
219170979|NCT06470100|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
219170980|NCT06470100|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
219170981|NCT03514329|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
219170982|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
219240094|NCT02885610|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
219240095|NCT02885610|BIOLOGICAL|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
219240096|NCT00458510|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
219240097|NCT05031052|DEVICE|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
219240098|NCT05031052|PROCEDURE|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
219240099|NCT00171652|DRUG|Diclofenac sodium gel 1%|
219240100|NCT05771272|DIAGNOSTIC_TEST|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
219240101|NCT05771272|DIAGNOSTIC_TEST|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
219240102|NCT01029925|DRUG|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
219240103|NCT03708744|DRUG|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
219240104|NCT03708744|DRUG|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
219240105|NCT03708744|DRUG|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
219240106|NCT03708744|DRUG|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
219240107|NCT00512265|DRUG|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
219240108|NCT00512265|DRUG|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
219240109|NCT05993247|COMBINATION_PRODUCT|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
219240110|NCT05993247|COMBINATION_PRODUCT|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
219240111|NCT03687554|DRUG|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
219240112|NCT03405480|OTHER|Rehabilitation|Rehabilitation
219240113|NCT01429168|DRUG|Etoricoxib|One 60-mg tablet orally daily
219240114|NCT01429168|DRUG|Placebo for etoricoxib|One 60-mg tablet orally daily
219240115|NCT06211751|DRUG|TQB3909 tablets|TQB3909 is a protein inhibitor.
219240116|NCT06211751|DRUG|TQB3702 tablets|TQB3702 is a kinase inhibitor.
219240117|NCT06179719|DRUG|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
219240118|NCT06179719|BEHAVIORAL|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
219240119|NCT03507452|DRUG|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
219240120|NCT03507452|DRUG|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
219240121|NCT01891006|DEVICE|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
219240122|NCT01891006|OTHER|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
219240123|NCT00183209|BEHAVIORAL|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
219240124|NCT01662804|DRUG|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
219240125|NCT05285592|OTHER|Fecal Transplantation|Fecal Transplantation
219240126|NCT05285592|DRUG|Standard Medical Treatment|Standard Medical Treatment
219240127|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
219170983|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
219170984|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
219170985|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
219170986|NCT04856176|DRUG|pemetrexed|500mg/m2
219170987|NCT04856176|DRUG|Paclitaxel|200mg/m2
219170988|NCT04856176|DRUG|Carboplatin|AUC 5/6
219170989|NCT04259580|PROCEDURE|Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures
219170990|NCT03042962|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
219170991|NCT03042962|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
219170992|NCT06024187|PROCEDURE|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
219240128|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
219240129|NCT04945616|DRUG|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
219240130|NCT04267549|DRUG|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
219240131|NCT04267549|DRUG|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
219240132|NCT04267549|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
219240133|NCT04267549|DRUG|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
219738049|NCT06663293|OTHER|Conventional Nasal Cannula|The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
219738050|NCT06663293|OTHER|High-flow nasal cannula|The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
219738051|NCT06663293|DRUG|midazolam, ketamine, propofol|Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
219738052|NCT06663293|DRUG|Propofol|Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
219738053|NCT04132427|COMBINATION_PRODUCT|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
219738054|NCT04132427|COMBINATION_PRODUCT|placebo vancomycin, real magnesium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
219738055|NCT06208631|BEHAVIORAL|Gait retraining|Changing muscle coordination while walking
219738056|NCT01426555|OTHER|FES-Rowing|FES- Rowing Exercise
219738057|NCT01426555|DRUG|Zoledronic acid|5 mg IV single dose
219738058|NCT03685435|OTHER|Bedside ultrasound|Checking for gastric content using bedside ultrasound
219738059|NCT05530707|OTHER|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
219738060|NCT03103308|OTHER|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
219738061|NCT03103308|OTHER|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
219170993|NCT06024187|PROCEDURE|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
219170994|NCT04470726|DRUG|AIV001|Intradermal/intratumoral
219170995|NCT04470726|DRUG|AIV001 suspension|AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
219170996|NCT04166266|OTHER|Blood draw for the laboratory assessment|Blood sampling for the biobank and, in addition, as sub-studies are planned on sub-groups of patients, additional blood samples are planned for the patients in these sub-studies.
219170997|NCT01705119|OTHER|Standing|
219170998|NCT03761537|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
219170999|NCT03761537|OTHER|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
219171000|NCT06111846|DRUG|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)
219171001|NCT06635915|DIAGNOSTIC_TEST|Postoperative ultrasound|Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.
219171002|NCT05226858|DIAGNOSTIC_TEST|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
219171003|NCT05359523|DEVICE|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
219171004|NCT05359523|OTHER|fascia injection|Under ultrasound guidance, a local anesthetic and steroid mixture will be injected into the fascia between the trapezius muscle and the rhomboid muscle.
219171005|NCT05795257|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
219171006|NCT06159634|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) will be the technique used to remove target lesions.
219171007|NCT06159634|DEVICE|Traction Device|Use of traction device to aid in removing target lesions
219171008|NCT05900700|BEHAVIORAL|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
219171009|NCT05493423|DEVICE|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
219171010|NCT04586959|DEVICE|Surgery with UM|The experimental group will have MIS with the placement of a uterine manipulator
219171011|NCT04586959|DEVICE|Surgery without UM|The control group will have MIS without the placement of a uterine manipulator
219171012|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
219171013|NCT04596189|DRUG|Dupilumab 300 MG in 2 ML Prefilled Syringe|"The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
219171014|NCT04596189|OTHER|Placebo|"The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
219171015|NCT04596189|DRUG|Mometasone Furoate nasal spray|On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert \& SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
219171016|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
219171017|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
219171018|NCT04632784|DEVICE|Artiflex Presbyopic (Artiplus) implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL (Artiplus)
219171019|NCT05086016|DEVICE|Catheterized Stenting|Catheterized stenting of vascular narrowings.
219171020|NCT05667701|DRUG|Soy isoflavone|Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
219171021|NCT05667701|DRUG|matching placebo|A matching placebo also administered twice daily.
219171022|NCT04709432|PROCEDURE|ECMO|ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
219171023|NCT06294613|DEVICE|vitreoretinal surgery|Patients undergoing vitreoretinal surgery
219171024|NCT06178861|DEVICE|Group wearing a radiotherapy bra|Group wearing a radiotherapy bra
219171025|NCT04234204|DRUG|Fezolinetant|Oral
219171026|NCT04234204|DRUG|Placebo|Oral
219240134|NCT04930263|BEHAVIORAL|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
219240135|NCT04930263|BEHAVIORAL|control group|control group received routine care and a manual on healthy living
219240136|NCT05656937|PROCEDURE|internal jugular venous cannulation|internal jugular venous cannulation
219240137|NCT04815135|OTHER|Observational study|Observational study, the study did not involve any interventions
219240138|NCT01628939|OTHER|MRI of the lumbar spine|standard protocol, approximately 30 minutes
219240139|NCT01628939|OTHER|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
219240140|NCT03684499|OTHER|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
219240141|NCT03684499|OTHER|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
219240142|NCT00732316|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
219240143|NCT00732316|PROCEDURE|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
219240144|NCT02649478|DRUG|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
219240145|NCT02649478|DRUG|Placebo|
219240146|NCT02649478|DRUG|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
219240147|NCT02011789|DIETARY_SUPPLEMENT|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
219240148|NCT02011789|DIETARY_SUPPLEMENT|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
219240149|NCT03528356|BEHAVIORAL|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
219240150|NCT00956527|BEHAVIORAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
219240151|NCT04364035|BIOLOGICAL|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
219240152|NCT04364035|BIOLOGICAL|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
219240153|NCT04364035|DRUG|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
219240154|NCT04364035|BIOLOGICAL|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
219240155|NCT04364035|DRUG|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
219240156|NCT04449445|DIETARY_SUPPLEMENT|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
219240157|NCT04449445|DIETARY_SUPPLEMENT|Nestle IMPACT AR|Dietary supplement
219240158|NCT04379310|DRUG|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
219240159|NCT02619045|OTHER|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
219240160|NCT03466645|DRUG|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
219240161|NCT03466645|DRUG|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
219738062|NCT06057337|BEHAVIORAL|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
219738063|NCT06600802|BIOLOGICAL|Blood samples|A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
219738064|NCT04822558|OTHER|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
219738065|NCT04822558|OTHER|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
219738066|NCT04822558|PROCEDURE|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
219738067|NCT04167436|OTHER|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
219171027|NCT05465551|COMBINATION_PRODUCT|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
219171028|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
219171029|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
219171030|NCT06316791|BIOLOGICAL|single dose of CNCT19|Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
219171031|NCT04245501|OTHER|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
219171032|NCT04245501|OTHER|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
219171033|NCT03940456|OTHER|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
219171034|NCT04097184|DEVICE|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
219171035|NCT05622448|OTHER|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
219171036|NCT05622448|OTHER|RPD with metallic framework|removable partial denture with cobalt chromium framework
219171037|NCT05711173|BIOLOGICAL|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
219171038|NCT04141020|PROCEDURE|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
219171039|NCT04141020|PROCEDURE|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
219738068|NCT04774146|PROCEDURE|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
219738069|NCT06674759|DRUG|Tongren-Dahuoluo Bolus|0.72g,2 times a day, oral, for 24 weeks.
219738070|NCT06674759|DRUG|Tongren-Dahuoluo Bolus Placebo|0.72g,2 times a day, oral, for 12 weeks.
219240162|NCT02163850|DEVICE|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
219240163|NCT02163850|DEVICE|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
219240164|NCT00337246|BIOLOGICAL|rituximab|
219171040|NCT04141020|DRUG|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
219171041|NCT01426425|DEVICE|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
219171042|NCT04147078|BIOLOGICAL|DC vaccine subcutaneous administration|subcutaneous administration
219171043|NCT05299138|BEHAVIORAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
219240165|NCT00337246|DRUG|cyclophosphamide|
219240166|NCT00337246|DRUG|fludarabine phosphate|
219240167|NCT00337246|DRUG|mitoxantrone hydrochloride|
219240168|NCT01368874|DEVICE|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
219240169|NCT01586494|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
219240170|NCT01586494|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
219240171|NCT02260726|PROCEDURE|Magnetic resonance imaging|
219240172|NCT02260726|PROCEDURE|Ultrasound|
219171044|NCT04773353|DRUG|Follitropin Delta (FE 999049)|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
219240173|NCT06475326|DRUG|Adebrelimab|Adebrelimab ,20mg/Kg per time, Q4W
219738071|NCT06673537|OTHER|Connective Tissue Massage (CTM)|"Connective Tissue Massage (CTM) was administered to the lumbar and abdominal regions by an experienced physiotherapist three times a week for 15 minutes over six weeks. The treatment started from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. Both short and long strokes were utilized during CTM. Each stroke was repeated three times, first on the right side and then on the left side, across all manipulated areas. During the manipulation, the tip of the middle finger remained in contact with the patient's skin. The finger was positioned at a 45° angle, with the distal interphalangeal joint in flexion, and was moved to create traction.~During the lumbar region treatment, participants were instructed to sit upright with their hips, knees, and ankles flexed at 90°, ensuring that their thighs and feet were fully supported. For the abdominal region treatment, participants lay supine with pillows placed under their head and knees."
219738072|NCT06673537|OTHER|Spinal Manipulation|Spinal manipulation was performed by an experienced physiotherapist on the intervention group three times a week following Connective Tissue Massage (CTM). Participants in this group were positioned laterally, ensuring their lower leg remained straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, allowing an unopposed force to be applied at the selected joint. Following CTM, manipulation was carried out with high-velocity, low-amplitude (HVLA) force applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, accompanied by an audible sound from one or more joints.
219738073|NCT06673537|OTHER|Sham Spinal Manipulation|Sham spinal manipulation was administered by an experienced physiotherapist to the Sham Manipulation group three times a week following Connective Tissue Massage (CTM). In this group, participants were positioned laterally with their lower legs straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, thereby allowing an unopposed force to be applied at the selected joint. Following CTM, low-amplitude force was applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, without creating an audible sound.
219738074|NCT06689579|DEVICE|Unipolar hemiarthroplasty|
219738075|NCT06689579|DEVICE|Bipolar hemiarthroplasty|
219738076|NCT02516111|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
219738077|NCT02516111|BIOLOGICAL|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
219738078|NCT02516111|DRUG|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
219738079|NCT02516111|DRUG|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
219738080|NCT05414747|DEVICE|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
219738081|NCT05414747|DEVICE|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
219738082|NCT02499536|DEVICE|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
219738083|NCT03289741|DRUG|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
219738084|NCT03289741|DRUG|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
219738085|NCT03289741|BEHAVIORAL|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
219738086|NCT06675305|DIETARY_SUPPLEMENT|Beetroot juice (James White, UK)|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
219738087|NCT06675305|DIETARY_SUPPLEMENT|Placebo acute supplementation (James White, UK)|One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
219738088|NCT06674369|DEVICE|Peli prism for hemianopia|Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
219738089|NCT06683924|PROCEDURE|Pulsed Radiofrequency Ablation|The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.
219738090|NCT06683924|DRUG|Steroid (dexamethasone) Injection|Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
219738091|NCT06688617|OTHER|Swedish Hand Massage|Swedish technique hand massage: Effleurage-petrissage-friction-tapotement,-vibration-effleurage
219171045|NCT04773353|DRUG|Follitropin Alfa (GONAL-F)|GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
219171046|NCT06052176|DRUG|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
219171047|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product A)|Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
219171048|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product B)|Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
219171049|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product C)|Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
219171050|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product D)|Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
219171051|NCT06093659|OTHER|Conventional Cigarette (Product E)|Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
219171052|NCT06631001|OTHER|Abdominal Massage|Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
219171053|NCT05736211|BEHAVIORAL|Organization-level Youth Engagement prevention strategy|Systematically incorporating Youth Engagement into prevention efforts in a community setting
219171054|NCT04558164|DEVICE|Active Theta Burst Stimulation|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
219171055|NCT04558164|DEVICE|Sham Theta Burst Stimulation|Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
219171056|NCT04268979|BEHAVIORAL|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
219171057|NCT04268979|BEHAVIORAL|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
219171058|NCT06394765|BEHAVIORAL|Mindful Mapping|Participants in the Mindful Mapping condition will receive a 5-minute, therapist-guided mindfulness intervention for chronic pain. During this training they will learn the 30-second Mindful Mapping technique, which they will be instructed to use each time they experience a painful sensation over the next 2 weeks. The Mindful Mapping technique consists of focusing on five basic characteristics (shape, weight, density, temperature, movement) of the most intense sensation in the body as it emerges in the present moment while remaining equanimous, i.e., preventing the learned reaction.
219171059|NCT06394765|BEHAVIORAL|Serial Sevens|"Participants in the control condition will receive a 5-minute, therapist-guided serial sevens intervention for chronic pain. During this training, participants will be instructed that each time they experience pain, they will count backwards in their heads by 7 from 100 for 30 second."
219171060|NCT05750212|DIAGNOSTIC_TEST|Tone|Tone is a binary measurement of the pelvic floor muscle on physical examination
219171061|NCT05750212|DIAGNOSTIC_TEST|Tenderness|Tenderness is a binary measurement of the pelvic floor muscle on physical examination
219171062|NCT05750212|DIAGNOSTIC_TEST|Contraction|Contraction is a binary measurement of the pelvic floor muscle on physical examination
219171063|NCT05750212|DIAGNOSTIC_TEST|Relaxation|Relaxation is a binary measurement of the pelvic floor muscle on physical examination
219171064|NCT05750212|DIAGNOSTIC_TEST|Electromyography|Electromyography is a measurement of the pelvic floor muscle in microvolts
219240174|NCT06475326|DRUG|Oxaliplatin 100 MG|Oxaliplatin: 60mg/m2, Q2W
219240175|NCT06475326|DRUG|Irinotecan liposome|Irinotecan Liposome: 50mg/m2, Q2W
219240176|NCT06475326|DRUG|Calcium Folinate|Calcium Folinate: 400mg/m2, Q2W
219240177|NCT06475326|DRUG|Fluorouracil|Fluorouracil: 2400mg/m2, Q2W
219240178|NCT00538499|DRUG|Fentanyl citrate|
219240179|NCT00538499|DRUG|Bupivacaine hydrocloride|
219240180|NCT00538499|PROCEDURE|videothoracoscopy|
219240181|NCT02648659|DRUG|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
219240182|NCT02648659|DRUG|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
219240183|NCT02648659|DRUG|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
219240184|NCT02648659|DRUG|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
219240185|NCT04112563|PROCEDURE|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
219240186|NCT04112563|PROCEDURE|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
219240187|NCT04550455|DRUG|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
219171065|NCT05750212|DIAGNOSTIC_TEST|Transperineal|Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
219171066|NCT05750212|DIAGNOSTIC_TEST|Pressure|Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
219171067|NCT05421325|BIOLOGICAL|QBKPN SSI|Site-Specific Immunomodulator
219171068|NCT05421325|OTHER|Normal Saline Placebo|Normal Saline
219171069|NCT06513897|OTHER|Acupressure|Acupressure will be applied to the foreheads of the babies in this group starting two minutes before the heel prick. Acupressure application will be finished when heel prick blood collection is finished.
219171070|NCT06513897|OTHER|Father's Lap|Infants in this group will be placed on the father's lap two minutes before heel prick blood collection. They will remain on the father's lap during the heel prick procedure.
219171071|NCT04178434|BEHAVIORAL|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
219171072|NCT02715284|BIOLOGICAL|Dostarlimab|Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
219171073|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
219171074|NCT01253824|DRUG|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
219171075|NCT01253824|DRUG|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
219171076|NCT00512070|DRUG|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
219171077|NCT05758415|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
219171078|NCT05758415|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
219171079|NCT05784012|DRUG|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
219171080|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
219171081|NCT05784012|DRUG|cisplatin plus radiotherapy|In the concurrent phase
219171082|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
219240188|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
219240189|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
219240190|NCT03012490|OTHER|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
219240191|NCT03012490|OTHER|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
219240192|NCT03012490|OTHER|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
219240193|NCT04791917|BEHAVIORAL|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
219240194|NCT04791917|BEHAVIORAL|Concentric Biceps Flexion|Muscle shortening biceps exercise
219240195|NCT01989156|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
219240196|NCT01989156|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
219240197|NCT01989156|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
219240198|NCT01942551|DRUG|Tadalafil|
219240199|NCT01942551|DRUG|Dutasteride|
219240200|NCT01899183|PROCEDURE|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
219240201|NCT06309771|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a random order (6 predetermined order). Each module will be composed on 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
219240202|NCT04237987|DRUG|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
219240203|NCT04237987|DRUG|ciclosporin and corticosteroid|ciclosporin and corticosteroid
219240204|NCT00606723|BIOLOGICAL|Hematopoietic stem cells from bone marrow or peripheral blood|\> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
219240205|NCT01643018|PROCEDURE|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
219240206|NCT01643018|PROCEDURE|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
219240207|NCT03296176|BIOLOGICAL|blood sample|blood sample for metabolome analyse
219240208|NCT03073122|DIAGNOSTIC_TEST|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
219240209|NCT00001280|DRUG|itraconazole|
219240210|NCT06412809|OTHER|Combined Land- and Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented both on land and in water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~Land-based exercise:~1. Plank exercise~2. Russian twist~3. Push-up~4. Goblet squat~5. Kettle bell swing~Water-based exercise:~1. Flutter kicks~2. Isometric core crunches~3. Jump lunges~4. Kicks~5. Resisted knee flexion"
219240211|NCT06412809|OTHER|Land-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented on land. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Plank exercise~2. Russian twist~3. Dead bug~4. Push-up~5. Goblet squat~6. Nordic hamstring curl~7. Lunges~8. Kettle bell swing~9. Calf raises~10. Bird dog"
219240212|NCT06412809|OTHER|Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented in the water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Core pulls~2. Flutter kicks~3. Water cycling~4. Isometric core crunches~5. Seated push-up~6. Jump squats~7. Jump lunges~8. Kicks~9. Ankle jumps~10. Resisted knee flexion"
219240213|NCT04794439|DRUG|Dentifrices|Dentifrice on plaque
219240214|NCT01323244|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
219738092|NCT02536339|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219738093|NCT02536339|DRUG|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
219738094|NCT04448912|PROCEDURE|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
219738095|NCT04448912|PROCEDURE|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
219738096|NCT06686277|OTHER|Gong's Mobilization Technique|The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.
219738097|NCT06686277|OTHER|Mulligan Mobilization Technique|Mulligan Mobilization Technique
219171083|NCT06417476|RADIATION|Short-course radiotherapy|The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
219171084|NCT06417476|DRUG|Irinotecan|150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
219171085|NCT06417476|DRUG|Oxaliplatin|85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
219171086|NCT06417476|DRUG|Calcium Formate|400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
219171087|NCT06417476|DRUG|Fluorouracil|2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
219171088|NCT06417476|RADIATION|Long-course chemoradiation|The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
219171089|NCT06417476|DRUG|Capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
219171090|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
219171091|NCT06296914|DEVICE|POTSapp|"Participants will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months. T"
219240215|NCT02835196|DEVICE|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
219240216|NCT02835196|OTHER|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
219240217|NCT04534699|DRUG|KBP-5074|KBP-5074 tablet
219240218|NCT02790788|DRUG|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
219240219|NCT02790788|DRUG|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
219240220|NCT03249805|DEVICE|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
219171092|NCT06296914|DEVICE|Waitlist Control|"Participants will receive educational information about online support for POTS via email. Starting at month 4, participants will receive equipment will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months."
219171093|NCT06266663|OTHER|Survey|A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.
219171094|NCT06087432|OTHER|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
219171095|NCT06087432|OTHER|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
219171096|NCT00961571|DRUG|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
219171097|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
219171098|NCT03779867|OTHER|Resting|Seated resting
219171099|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
219171100|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
219171101|NCT06446401|DRUG|ADT + NHT + Docetaxel|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives the triple therapy, i.e. ADT, NHT and Docetaxel.
219171102|NCT06446401|DRUG|ADT + NHT|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.
219171103|NCT03070184|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
219171104|NCT03070184|DIETARY_SUPPLEMENT|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
219171105|NCT03070184|OTHER|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
219171106|NCT03070184|DRUG|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
219171107|NCT05327101|OTHER|Patient Preference Survey|Patient preference survey on implantable cardiac pacemaker systems
219171108|NCT05641610|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
219171109|NCT03532360|OTHER|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
219171110|NCT06489522|BEHAVIORAL|THRIVE|THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
219171111|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
219171112|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
219171113|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
219738098|NCT06691633|DRUG|Preoperative Methadone|patient receives a one-time preoperative dose of 10 mg of methadone
219738099|NCT06691633|DRUG|Preoperative Oxycodone|patient receives a one-time preoperative dose of 10 mg of oral oxycodone
219738100|NCT03449147|DRUG|Placebo|Placebo tablet administered orally BID
219738101|NCT03449147|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
219738102|NCT03449147|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
219738103|NCT05924230|OTHER|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
219738104|NCT05924230|OTHER|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
219171114|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
219171115|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
219171116|NCT03441165|PROCEDURE|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
219171117|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
219171118|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
219171119|NCT06280976|DRUG|Statin|high intensity statin (eg atorvastatin 80 mg daily)
219171120|NCT06280976|DRUG|Aspirin tablet|aspirin 81 mg po qd
219171121|NCT06280976|DRUG|Nexlizet|bempedoic acid-ezetimibe 180-10 mg po qd
219171122|NCT06280976|DRUG|LEQVIO|inclisiran SQ as per product insert
219171123|NCT06280976|DRUG|Vascepa|icosapent ethyl 2g PO BID
219171124|NCT06280976|DRUG|Jardiance|empagliflozin 10 mg PO QD
219171125|NCT06280976|DRUG|Colchicine|Colchicine 0.5 MG po qd
219171126|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
219171127|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
219171128|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
219171129|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
219171130|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
219171131|NCT05676944|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
219171132|NCT04848337|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
219171133|NCT04848337|DRUG|Lenvatinib|Lenvatinib 20 mg orally daily.
219171134|NCT04652830|BEHAVIORAL|Naprapathy training|Active training aimed at strengthening the abdominal muscles
219171135|NCT04652830|OTHER|Control group|No change of daily routines in regard to training
219171136|NCT03775187|BIOLOGICAL|Burosumab|
219171137|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
219171138|NCT05358262|OTHER|Standard of Care|The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
219171139|NCT05312515|OTHER|Warm Application to Feet|Warm Application to Feet after Cesarean Section
219171140|NCT02945774|RADIATION|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
219171141|NCT06619015|DRUG|Pramlintide Acetate 1 MG/ML|Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.
219171142|NCT06619015|DRUG|Semaglutide Pen Injector|Semaglutide from 0,25mg/week to 2,4mg/week
219171143|NCT06619015|DRUG|Sodium Chloride 0.9% Inj|Placebo
219171144|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
219171145|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
219171146|NCT05192174|BIOLOGICAL|NIB101|NIB101
219171147|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
219171148|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
219171149|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
219171150|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
219171151|NCT05838651|DEVICE|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
219171152|NCT05838651|DEVICE|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
219171153|NCT04080531|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
219171154|NCT04080531|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
219171155|NCT03941132|DRUG|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
219171156|NCT03941132|DRUG|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
219171157|NCT06126822|DRUG|Zabdeno® booster|A single Zabdeno® booster vaccination
219171158|NCT06126822|DRUG|Ervebo® booster|A single Ervebo® booster vaccination
219171159|NCT06095154|RADIATION|CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma|CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
219171160|NCT06184256|BEHAVIORAL|BfedBwell - Core Curriculum|12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
219171161|NCT06184256|BEHAVIORAL|BfedBwell - 1:1 Counseling|Individual 1:1 counseling sessions with a registered dietitian
219171162|NCT06184256|BEHAVIORAL|BfedBwell - Behavioral Skills|Group-based behavioral skills development sessions
219171163|NCT06184256|BEHAVIORAL|BfedBwell - Group Support|Structured group support sessions
219171164|NCT06184256|BEHAVIORAL|Program delivery|Delivery and evaluation of one or more intervention components
219171165|NCT04441047|DRUG|AlloStim|Living, activated allogeneic Th1-like memory immune cells
219171166|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
219171167|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
219240221|NCT03249805|DEVICE|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
219240222|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
219240223|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
219240224|NCT05226728|DRUG|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
219240225|NCT00850993|DRUG|Stannsoporfin|Stannsoporfin administered as a single IM injection
219240226|NCT00850993|OTHER|Placebo|Placebo (sterile saline solution) administered as a single IM injection
219240227|NCT00850993|OTHER|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
219240228|NCT00521807|PROCEDURE|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
219240229|NCT03839355|DRUG|Apixaban|Dosage either 5mg or 2.5mg for 2 years
219240230|NCT03839355|DRUG|Warfarin|Dosage assessed by your treating physician for 2 years
219240231|NCT05321576|PROCEDURE|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
219240232|NCT04543032|OTHER|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
219240233|NCT00297089|DRUG|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
219240234|NCT00297089|DRUG|pemetrexed|Standard pemetrexed every 21 days
219240235|NCT00297089|DRUG|placebo|Placebo daily for 14 days every 21 days
219240236|NCT00349713|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
219240237|NCT00349713|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
219240238|NCT03652792|DRUG|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
219240239|NCT03652792|DRUG|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
219240240|NCT03573375|BEHAVIORAL|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
219240241|NCT00470990|DRUG|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
219240242|NCT00324571|DRUG|Sevelamer hydrochloride|
219240243|NCT00324571|DRUG|Calcium-based phosphate binder|
219240244|NCT05607147|DEVICE|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
219240245|NCT00082576|DRUG|Azithromycin/Chloroquine|
219240246|NCT00082576|DRUG|Mefloquine|
219240247|NCT00003778|DRUG|dolastatin 10|
219240248|NCT04566744|OTHER|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
219240249|NCT01589380|DRUG|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
219240250|NCT01589380|DRUG|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
219171168|NCT05111405|PROCEDURE|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
219171169|NCT02530671|DEVICE|Toothbrushing with manual toothbrush|
219171170|NCT02530671|DEVICE|Toothbrushing with power toothbrush|
219171171|NCT05448651|DRUG|UPB-101|Subcutaneous injection
219171172|NCT05448651|DRUG|Placebo|Subcutaneous injection
219171173|NCT03465865|DEVICE|optical coherence tomography|optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
219171174|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
219171175|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
219171176|NCT04528355|DRUG|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
219171177|NCT04390048|DEVICE|Anodal tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
219171178|NCT04390048|DEVICE|Sham tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
219171179|NCT02202356|DRUG|ALS-008176|
219171180|NCT02202356|DRUG|Placebo|
219171181|NCT05652296|DEVICE|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
219171182|NCT00294242|PROCEDURE|Membrane Sweep|Weekly Membrane Sweep
219171183|NCT00294242|PROCEDURE|No Membrane Sweep|No Membrane Sweep
219171184|NCT02361723|DRUG|BGB-290|
219171185|NCT02361723|DRUG|BGB-290|
219171186|NCT02361723|DRUG|BGB-290|
219171187|NCT02361723|DRUG|BGB-290|
219240251|NCT03959579|DIAGNOSTIC_TEST|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
219240252|NCT01738087|DRUG|NEXThaler 100/6 mcg DPI|
219240253|NCT01738087|DRUG|Flixotide Accuhaler 500 mcg|Active comparator
219240254|NCT01738087|DRUG|NEXThaler 200/6 mcg DPI|
219240255|NCT01738087|DRUG|NEXThaler placebo|Placebo comparator
219171188|NCT02361723|DRUG|BGB-290|
219171189|NCT05129969|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
219171190|NCT01415154|DEVICE|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
219171191|NCT05801913|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
219171192|NCT05801913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219171193|NCT05801913|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219171194|NCT05801913|PROCEDURE|Computed Tomography|Undergo CT
219171195|NCT05801913|PROCEDURE|Leukapheresis|Undergo leukapheresis per SOC
219171196|NCT05801913|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
219171197|NCT05801913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219171198|NCT05801913|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219171199|NCT05801913|PROCEDURE|Positron Emission Tomography|Undergo PET
219171200|NCT05801913|PROCEDURE|X-Ray Imaging|Undergo x-ray
219171201|NCT05629663|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
219171202|NCT04900363|DRUG|AK112|Subjects receive AK112 intravenously.
219171203|NCT03126019|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food
219171204|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
219171205|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
219171206|NCT04907929|BEHAVIORAL|targeted speech and cognitive therapy|One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
219171207|NCT06435468|GENETIC|Blood sample for genetic analysis|genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
219171208|NCT06435468|OTHER|Blood sample for immunological response assessments|Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
219171209|NCT06435468|OTHER|Blood sample to identify relevant biomarker of the disease|Research biomarkers for diagnosis, prognosis and monitoring of disease activity
219171210|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
219171211|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
219171212|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
219171213|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
219171214|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
219171215|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
219171216|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
219171217|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
219171218|NCT06368570|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery with neuraxial anesthetic
219171219|NCT04556656|DRUG|Pridopidine|Pridopidine hard gelatin capsule
219171220|NCT04556656|DRUG|Placebo|Pridopidine-matching placebo hard gelatin capsule
219171221|NCT06796400|OTHER|General exercises|4 general exercises were done by control group with 10 repetitions and 3 sets, 6 times per week, up to 8 weeks.These exercises are for lower trapzius and serratus anterior mucles strengthing.
219171222|NCT06796400|OTHER|Theraband exerises|5 Thera-band exercises were completed by experimental group with 3 sets and 10 repetitions, 6 times per week, up to 8 weeks. These exercises are for lower trapzius and serratus anterior mucles strengthing.
219171223|NCT05470894|BIOLOGICAL|Approved COVID-19 vaccine|Vaccination for COVI9-19
219171224|NCT04704037|OTHER|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
219171225|NCT04704037|OTHER|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
219171226|NCT05046314|BIOLOGICAL|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
219171227|NCT06638606|BEHAVIORAL|Sleep improvement techniques|Insomniac and hypersomniac individuals are given behavioral counselling to improve sleep.
219171228|NCT06286137|OTHER|Listening to music for 1 minute|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 19 minutes before the 1 minute music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
219171229|NCT06286137|OTHER|Listening to music for 5 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 15 minutes before the 5 minutes music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
219171230|NCT06286137|OTHER|Listening to music for 20 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 20 minutes through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels.
219171231|NCT06286137|OTHER|Not listening to music|Participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones), for a duration of 20 minutes.
219171232|NCT05118867|BEHAVIORAL|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
219171233|NCT05846451|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
219171234|NCT05846451|DRUG|Oxycodone|Immediate-release oral tablet, 10 mg
219171235|NCT05966714|DEVICE|aEEG|amplitude-integrated electroencephalography
219171236|NCT03498651|BEHAVIORAL|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
219171237|NCT03498651|BEHAVIORAL|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
219171238|NCT03498651|BEHAVIORAL|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
219171239|NCT05123300|DIAGNOSTIC_TEST|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
219171240|NCT05784857|OTHER|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
219171241|NCT06639269|OTHER|fertility health education program|"The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes."
219171242|NCT05159128|DRUG|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
219171243|NCT05159128|OTHER|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
219171244|NCT05737095|PROCEDURE|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
219171245|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
219171246|NCT05930821|BEHAVIORAL|Aerobic and Resistance Exercise Program (GEMS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
219171247|NCT05930821|BEHAVIORAL|Flexibility and Stretching Program (FLEX-MS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~* Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program."
219171248|NCT06636734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219171249|NCT06636734|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219171250|NCT06636734|DRUG|Lovastatin|Given PO
219171251|NCT06636734|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219171252|NCT06636734|BIOLOGICAL|Pembrolizumab|Given IV
219171253|NCT06636734|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219171254|NCT06643000|DRUG|furmonertinib|furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
219171255|NCT06121596|BEHAVIORAL|Breathing Exercise|A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
219171256|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
219171257|NCT06640361|DRUG|Olverembatinib|Oral administration with meal, QOD, every 28 days for a cycle.
219171258|NCT04647786|DEVICE|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
219171259|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
219171260|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
219171261|NCT06452446|DRUG|Selinexor|Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
219171262|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
219171263|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
219171264|NCT06479187|DRUG|18F-rhPSMA-7.3|radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.
219171265|NCT06479187|DEVICE|PET/CT|Diagnostic imaging test
219171266|NCT06641297|BEHAVIORAL|Music video game|The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
219171267|NCT02727972|BEHAVIORAL|Cognitive Testing|Verbal assessments as well as computer testing.
219240256|NCT02504034|PROCEDURE|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
219171268|NCT02727972|OTHER|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
219171269|NCT02727972|RADIATION|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
219171270|NCT06354049|OTHER|Reiki|Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
219171271|NCT06584539|BEHAVIORAL|Eco-Labels|"Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY."
219171272|NCT04918758|DEVICE|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
219171273|NCT04918758|DRUG|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
219171274|NCT04637152|DRUG|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
219171275|NCT05123014|OTHER|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
219171276|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
219240257|NCT02504034|DEVICE|6-French sheath|
219240258|NCT02504034|DEVICE|22-gauge chiba needle|
219240259|NCT02504034|DEVICE|260-cm-long stiff shaft wire|
219240260|NCT02504034|DEVICE|Balloon catheter|
219240261|NCT02504034|DEVICE|Bare metal stent|
219240262|NCT02504034|DEVICE|Covered stent|
219240263|NCT01596634|OTHER|questionnaire administration|Ancillary studies
219240264|NCT01596634|PROCEDURE|quality-of-life assessment|Ancillary studies
219240265|NCT01596634|OTHER|laboratory biomarker analysis|Correlative studies
219171277|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
219171278|NCT00580515|BEHAVIORAL|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
219171279|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
219171280|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
219171281|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
219171282|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
219171283|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
219171284|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
219171285|NCT04597372|DRUG|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
219171286|NCT04597372|DRUG|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
219171287|NCT06400342|PROCEDURE|TAVR-explant|Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.
219171288|NCT06400342|DEVICE|Redo-TAVR|Repeat transcatheter aortic valve implantation within a failed THV.
219171289|NCT06015542|DRUG|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
219171290|NCT06173258|DEVICE|Water exchange alone|During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
219171291|NCT06173258|DEVICE|Water exchange plus Artificial Intelligence (AI)|Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
219171292|NCT04815187|DRUG|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
219171293|NCT04815187|DRUG|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
219171294|NCT05200247|DRUG|spesolimab|solution for infusion
219171295|NCT06757322|PROCEDURE|Singel Needle Double Cannula TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991. The single needle technique was developed by Singh and Varghese and introduced in 2013. The single needle method is a more simplified modification of the first method.
219171296|NCT06757322|PROCEDURE|Double Needle TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991.
219171297|NCT06461689|DRUG|177Lu-PSMA-617|All patients treated with 177Lu-PSMA had a post-therapy 68Ga-PSMA PET scan and a post-therapy 177Lu-PSMA-617 SPECT/CT scan. These scans are available in the CHRU PACS, and patients are informed that their data may be used for research purposes, via posters in the nuclear medicine department or via the welcome booklet,
219171298|NCT03634930|BEHAVIORAL|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
219171299|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
219171300|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
219240266|NCT01596634|DIETARY_SUPPLEMENT|bovine lactoferrin|Given PO
219240267|NCT01320514|DRUG|Fibrin Sealant (Artiss)|
219240268|NCT02418286|OTHER|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
219240269|NCT02033343|RADIATION|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
219240270|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
219240271|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
219240272|NCT06058130|DRUG|Anticoagulant Oral|Anticoagulation alone
219240273|NCT06058130|DRUG|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
219240274|NCT02499497|DRUG|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
219240275|NCT02499497|DRUG|Placebo|The participants will receive pills containing no active drug.
219240276|NCT02471872|BEHAVIORAL|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
219240277|NCT02471872|OTHER|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
219240278|NCT01502839|OTHER|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
219240279|NCT02349802|DRUG|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
219240280|NCT02349802|DRUG|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
219240281|NCT05588297|DRUG|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
219738105|NCT01801969|OTHER|Rehabilitation service|"* Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
219738106|NCT02099591|DRUG|Naloxegol|Opioid Antagonist
219738107|NCT02286791|BEHAVIORAL|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
219738108|NCT02286791|BEHAVIORAL|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
219738109|NCT02037984|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
219738110|NCT02037984|BIOLOGICAL|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
219738111|NCT02037984|BIOLOGICAL|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
219240282|NCT05588297|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
219240283|NCT05588297|DRUG|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
219240284|NCT01709630|DRUG|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
219240285|NCT00860509|OTHER|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
219240286|NCT03542604|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
219240287|NCT03542604|BEHAVIORAL|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
219240288|NCT06277011|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
219240289|NCT01176409|DRUG|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
219240290|NCT01176409|DRUG|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
219240291|NCT01721109|DRUG|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
219240292|NCT00635323|DRUG|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
219240293|NCT03933241|BEHAVIORAL|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
219240294|NCT01171950|DEVICE|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
219738112|NCT02037984|BIOLOGICAL|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
219738113|NCT02037984|BIOLOGICAL|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
219738114|NCT02037984|BIOLOGICAL|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
219171301|NCT05323084|DIETARY_SUPPLEMENT|Dietary supplement|1 week of each intervention at bedtime with a 2-week washout period in between interventions
219171302|NCT04056897|BIOLOGICAL|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
219171303|NCT04056897|DRUG|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
219171304|NCT04056897|DRUG|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
219171305|NCT04056897|BIOLOGICAL|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
219738115|NCT03305211|OTHER|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
219738116|NCT02571855|DRUG|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
219738117|NCT02571855|DRUG|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
219171306|NCT06513559|DEVICE|Anatomic total shoulder replacement|Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
219738118|NCT02571855|DRUG|Placebo|Placebo capsules matching the ACT-541468 formulations
219240295|NCT05760417|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
219240296|NCT01145326|DRUG|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
219240297|NCT01145326|DRUG|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
219240298|NCT03563989|DEVICE|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
219240299|NCT01803945|DRUG|AVE8112|
219240300|NCT01803945|DRUG|Placebo|
219240301|NCT02472808|OTHER|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
219240302|NCT02472808|OTHER|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
219240303|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
219240304|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
219240305|NCT00928265|DEVICE|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
219738119|NCT03529149|COMBINATION_PRODUCT|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
219171307|NCT06513559|DEVICE|Reverse total shoulder replacement|Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
219240306|NCT01536795|DRUG|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
219240307|NCT01536795|DRUG|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
219240308|NCT00574301|PROCEDURE|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
219240309|NCT05266157|OTHER|Manual lymph drainage|Manual lymph drainage
219240310|NCT05266157|OTHER|Usual care|skin care, exercise and compression stocking
219240311|NCT04469517|OTHER|hypoxic induced factors|hypoxic induced factors analyzed in blood sample
219240312|NCT06426511|DRUG|Toripalimab+Chemotherapy|After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
219240313|NCT06426511|DRUG|Toripalimab+Chemotherapy followed by consolidation toripalimab|"After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians."
219240314|NCT05866887|BEHAVIORAL|Sleep ALL Night|Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
219240315|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
219171308|NCT03311503|BIOLOGICAL|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
219171309|NCT05780502|BEHAVIORAL|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
219171310|NCT05092139|DEVICE|endovascular treatment|all enrolled patients must receive endovascular treatment
219171311|NCT06261775|OTHER|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
219171312|NCT06261775|OTHER|No meat diet|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
219171313|NCT04382404|DRUG|Sofosbuvir-Velpatasvir Drug Combination|One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
219171314|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
219171315|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
219171316|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
219171317|NCT06251258|DIAGNOSTIC_TEST|Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)|Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)
219171318|NCT03587363|DRUG|Erdafitinib|Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
219171319|NCT05262296|PROCEDURE|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
219171320|NCT05262296|PROCEDURE|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
219171321|NCT06440317|DEVICE|Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)|The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.
219171322|NCT05102409|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
219171323|NCT05102409|DRUG|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
219171327|NCT04951492|DRUG|Olaparib|Given PO
219171328|NCT05691738|OTHER|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
219171329|NCT05691738|OTHER|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
219171330|NCT05279898|DEVICE|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
219171331|NCT05279898|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
219171332|NCT05279898|DRUG|Ketamine|Intraoperative infusion
219171333|NCT05279898|DRUG|Remifentanil|Intraoperative infusion
219171334|NCT05279898|DRUG|Dexmedetomidine|Intraoperative infusion
219171335|NCT05279898|DRUG|Rocuronium|Intraoperative intermittent bolus
219171336|NCT05279898|DRUG|Propofol|Intraoperative infusion
219171337|NCT05989035|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|"Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory."
219171338|NCT05687916|DRUG|Placebo|TAK-861 placebo matching tablets.
219171339|NCT05687916|DRUG|TAK-861 2 mg|TAK-861 2 mg tablets.
219171340|NCT05687916|DRUG|TAK-861 2 mg and 5 mg|TAK-861 2 mg and 5 mg tablets.
219171341|NCT05502861|BEHAVIORAL|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
219171342|NCT05502861|BEHAVIORAL|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
219171343|NCT05629182|OTHER|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
219171344|NCT06200259|RADIATION|Spot Delete planning for proton therapy|The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy
219240316|NCT04089748|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
219240317|NCT03198481|BEHAVIORAL|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
219240318|NCT03198481|BEHAVIORAL|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
219240319|NCT04546360|PROCEDURE|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
219240320|NCT03643770|COMBINATION_PRODUCT|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
219240321|NCT06139419|RADIATION|definitive radiotherapy|Participants were treated with definitive thoracic radiotherapy
219171345|NCT06200259|RADIATION|Traditional proton treatment planning system|In the control arm, the proton spots placed by the treatment planning system are not modified.
219171346|NCT01781338|OTHER|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
219171347|NCT06298136|BEHAVIORAL|mindfulness-based intervention|Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided
219171348|NCT06298136|BEHAVIORAL|child behavior management|worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
219240322|NCT06139419|DRUG|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
219240323|NCT06139419|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
219171349|NCT04614909|DRUG|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
219171350|NCT04614909|DRUG|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
219171351|NCT04614909|RADIATION|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
219171352|NCT04614909|DRUG|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
219171353|NCT03890263|BEHAVIORAL|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
219171354|NCT05830929|PROCEDURE|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
219171355|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
219171356|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
219171357|NCT05005442|BIOLOGICAL|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
219171358|NCT01261312|DRUG|Guadecitabine|Subcutaneous injection
219171359|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
219171360|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
219171361|NCT06380582|OTHER|Temperature and Airflow combination|23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
219171362|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
219171363|NCT05134636|OTHER|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
219171364|NCT05650723|DRUG|Zanubrutinib Pill|320 mg once per day by mouth
219171365|NCT05650723|DRUG|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
219171366|NCT05650723|DRUG|Obinutuzumab Injection|1000 mg IV given every 28 days
219171367|NCT05155007|DRUG|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
219171368|NCT05155007|DRUG|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
219171369|NCT01701843|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
219171370|NCT01701843|DRUG|Placebo|Twice daily topical treatment for 14 days
219171371|NCT04488133|DRUG|Nusinersen|Administered as specified in the treatment arm.
219171372|NCT04977024|BIOLOGICAL|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
219171373|NCT04977024|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219171374|NCT04977024|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
219171375|NCT05443737|BEHAVIORAL|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
219171376|NCT06082921|BEHAVIORAL|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
219171377|NCT06082921|BEHAVIORAL|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
219171378|NCT04682106|DRUG|LY3493269|Administered orally.
219171379|NCT04682106|DRUG|Placebo|Administered orally.
219171380|NCT04682106|DRUG|Salcaprozate Sodium|Administered orally.
219171381|NCT06582966|DRUG|Doxycyclin|Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
219171382|NCT01293383|DRUG|LEO 90105|Ointment
219171383|NCT05983185|BEHAVIORAL|Prism adaptation therapy|The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
219171384|NCT04528004|DRUG|Nicotinamide riboside|Nicotinamide riboside 250mg capsules
219171385|NCT04528004|OTHER|Placebo|Matching placebo 250mg capsules
219171386|NCT06417892|DRUG|PD-1inhibitor|PD-1 antibody was selected according to first-line drug use
219171387|NCT06417892|DRUG|Fruquintinib|a small molecular anti-tumor angiogensis drug
219171388|NCT06417892|DRUG|albumin paclitaxel|a kind of cytotoxic chemotherapy drug
219171389|NCT04757194|DIAGNOSTIC_TEST|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
219171390|NCT02685020|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
219171391|NCT02685020|BIOLOGICAL|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
219171392|NCT02685020|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
219171393|NCT04959487|OTHER|Food support|1\. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
219171394|NCT04959487|OTHER|Nutritional Counseling and education|2\. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
219171395|NCT05425992|OTHER|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
219171396|NCT04646460|BEHAVIORAL|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
219171397|NCT04646460|BEHAVIORAL|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
219171398|NCT04646460|BEHAVIORAL|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
219171399|NCT04646460|BEHAVIORAL|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
219171400|NCT06582160|OTHER|Risk-Based Pre-conception Screening|A long form questionnaire screening questionnaire administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
219171401|NCT06582160|OTHER|Patient-centered Pre-conception Screening|A short form, 2 question screening administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
219171402|NCT05938166|DEVICE|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
219171403|NCT05938166|OTHER|video-based oral hygiene education course|50-minute video-based oral hygiene education course
219171404|NCT06789718|DIETARY_SUPPLEMENT|GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose)|75 participants will be randomized into the study product group.
219171405|NCT06789718|OTHER|Placebo|75 participants will be randomized into the placebo group.
219171406|NCT06789718|DIAGNOSTIC_TEST|Optional Sub-Study: Neurotransmitter Urine Test|20 participants who opt-in to the sub-study will provide urine tests during baseline, day 2, day 4, day 7, day 14, day 28, and day 42 while simultaneously participating in the main-study.
219171407|NCT06790030|BEHAVIORAL|CBT-T|cognitive behavioral therapy-ten :
219171408|NCT06238531|DRUG|Gusacitinib|An orally active dual SYK/JAK kinase inhibitor
219171409|NCT06407284|OTHER|Produce Prescription Group|Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
219171410|NCT06407284|OTHER|Control Group|Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
219171411|NCT06311253|OTHER|Emoform Glic Toothpaste|Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
219171412|NCT06311253|OTHER|Emoform Glic Mouthwash|Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
219171413|NCT04665310|DRUG|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
219171414|NCT06397976|DEVICE|ANTERION investigational|Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
219171415|NCT05354024|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
219171416|NCT05354024|BIOLOGICAL|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
219171417|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
219171418|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
219171419|NCT04829604|DRUG|ARX788|The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
219171420|NCT04080180|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
219171421|NCT04080180|BEHAVIORAL|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
219171422|NCT05440734|DRUG|Melatonin|2 Mg Oral Tablet, slow release
219171423|NCT05440734|DRUG|Placebo|placebo pill identical to the treatment pill
219171424|NCT04782687|DRUG|Selinexor|oral drug that comes in 20 mg tablets
219171425|NCT04782687|DRUG|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.
219171426|NCT04782687|DRUG|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
219171427|NCT04782687|DRUG|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
219171428|NCT06800352|OTHER|Control|The degree of diaper dermatitis of the babies will be evaluated before and after the procedure (72 hours after the first procedure) by using the 'Uncomplicated Diaper Dermatitis Severity Rating Scale in Babies (UNDDCS)'. Mothers will be asked to diaper their babies with cotton wool soaked with clear water.
219171429|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
219171430|NCT02807805|DRUG|Abiraterone Acetate|Given PO
219171431|NCT02807805|DRUG|Niclosamide|Given PO
219171432|NCT02807805|DRUG|Prednisone|Given PO
219171433|NCT06541639|BIOLOGICAL|EVM16|cancer vaccine
219171434|NCT06541639|DRUG|Tislelizumab|Anti-PD1 antibody
219171435|NCT04954781|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219171436|NCT04954781|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
219171437|NCT02589275|DRUG|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
219171438|NCT05337215|BEHAVIORAL|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
219171439|NCT05264714|DRUG|Rimegepant|150 mg oral disintegrating tablet every other day for one week
219171440|NCT05776056|DRUG|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
219171441|NCT05776056|DRUG|Placebo|An inactive pill (placebo) will be taken twice daily.
219240324|NCT06139419|DRUG|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
219240325|NCT06139419|DRUG|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
219240326|NCT02215447|DRUG|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
219240327|NCT02215447|DRUG|Carboplatin|
219240328|NCT05656404|DEVICE|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
219240329|NCT01699178|DRUG|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
219240330|NCT01699178|DRUG|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
219240331|NCT06008080|DEVICE|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
219240332|NCT03448783|DRUG|Apixaban|Patients are tested for their normal prescription apixaban medication
219240333|NCT06494176|BEHAVIORAL|neVR Fear the Dentist|neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
219240334|NCT06646783|DRUG|[68Ga]Ga-NODAGA-SNA014|Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
219240335|NCT04928196|OTHER|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
219240336|NCT02086071|PROCEDURE|re biopsy|re biopsy depending on the location of the pathology
219240337|NCT06198452|PROCEDURE|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
219240338|NCT04407442|DRUG|Azacitidine|Given IV
219240339|NCT04407442|BIOLOGICAL|Daratumumab|Given SC
219240340|NCT04407442|DRUG|Dexamethasone|Given IV or PO
219240341|NCT00321555|DRUG|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
219240342|NCT00003245|DRUG|irinotecan hydrochloride|
219240343|NCT01107795|PROCEDURE|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
219240344|NCT04296409|OTHER|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
219240345|NCT01015794|DRUG|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
219240346|NCT01015794|DRUG|ephedrine hydrochloride|single dose of 1 mg/kg body weight
219240347|NCT03988855|DRUG|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
219240348|NCT02066389|DRUG|Placebo|Tablets for oral administration
219240349|NCT02066389|DRUG|Upadacitinib|Tablets for oral administration
219240350|NCT02907489|OTHER|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
219240351|NCT05724576|BIOLOGICAL|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
219240352|NCT01892982|BEHAVIORAL|Problem Solving Education tailored to NICU|
219171442|NCT02051218|DRUG|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
219171443|NCT02051218|DRUG|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
219171444|NCT04401800|DRUG|Lenvatinib|Capsules administered orally once daily
219171445|NCT04401800|DRUG|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
219171446|NCT06777251|OTHER|"analysis of predictive factors of IF in patients with Crohn's disease through the characterization of multiomics parameters"|"The study includes an initial evaluation in which faecal samples will be collected, a blood sample will be taken and an ileocolonoscopy with biopsies will be performed (additional biopsy in conjunction with a biopsy from clinical practice for study-specific analyses).~Patients will then be reevaluated nine months after the initial evaluation. In particular, fecal, blood and additional biopsy samples will be collected in conjunction with clinical practice biopsy and all treatment modifications will be recorded."
219171447|NCT06385938|DIAGNOSTIC_TEST|Ultrasound with quantitative vibro-acoustic assessment|Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
219240353|NCT06452888|BEHAVIORAL|Clinical decision support system.|The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.
219240354|NCT06452888|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
219240355|NCT06584877|OTHER|sample collection|Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
219240356|NCT06584877|OTHER|Seeking consent and assent|Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
219240357|NCT06585761|DRUG|SGLT2 inhibitor|patients with HF are subjected to regular dose of SGLT2I member according to patient status.
219240358|NCT06585761|DEVICE|echo cardiogram|the patients are subjected to ECHO to determine their EF prior to and post the study
219240359|NCT00762853|DRUG|Fluoride|Brush half mouth once with assigned study treatment
219240360|NCT00762853|DRUG|Fluoride and triclosan|Brush half mouth once with assigned study treatment
219240361|NCT06376006|BEHAVIORAL|EMR STAT - Survey|Surveys are completed before and after Advanced Fellow Training.
219240362|NCT00374673|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
219240363|NCT02114502|DRUG|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
219240364|NCT02114502|DRUG|SAHA|1,000 mg by mouth on Days -8 to -3.
219240365|NCT02114502|DRUG|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
219240366|NCT02114502|DRUG|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
219240367|NCT02114502|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
219240368|NCT02114502|PROCEDURE|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
219240369|NCT02114502|DRUG|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
219240370|NCT02114502|DRUG|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
219240371|NCT02114502|DRUG|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
219240372|NCT02114502|DRUG|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
219240373|NCT02114502|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
219240374|NCT02122822|BIOLOGICAL|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
219240375|NCT01783379|DRUG|micafungin|100mg/day infusion in 1 hour
219240376|NCT03639545|DRUG|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
219240377|NCT03639545|DRUG|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
219240378|NCT03639545|DRUG|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
219240379|NCT03639545|DRUG|Placebos|The patients receive for 12 weeks.
219240380|NCT00964756|GENETIC|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
219240381|NCT00964756|DRUG|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
219240382|NCT06407193|OTHER|MRI and scintigraphy|Gastric emptying measured with MRI and scintigraphy
219240383|NCT05757622|DRUG|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
219240384|NCT05757622|DRUG|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
219240385|NCT02659176|PROCEDURE|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
219240386|NCT02659176|PROCEDURE|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
219240387|NCT06079047|PROCEDURE|group Dexamethasone|Adductor canal block with dexamethasone
219240388|NCT06079047|PROCEDURE|group Controle|Adductor canal block with saline solution
219240389|NCT03612999|DEVICE|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
219240390|NCT03612999|DEVICE|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
219240391|NCT03612999|BEHAVIORAL|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
219240392|NCT03612999|BEHAVIORAL|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
219240393|NCT01755598|BIOLOGICAL|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
219240394|NCT01755598|BIOLOGICAL|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
219240395|NCT03671499|BEHAVIORAL|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
219240396|NCT00422786|DRUG|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
219240397|NCT02574910|DRUG|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
219240398|NCT02423447|DEVICE|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
219240399|NCT02423447|DEVICE|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
219240400|NCT04528875|DEVICE|Ultrasound imaging|Imaging of low back with ultrasound
219240401|NCT04443881|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
219240402|NCT05983991|OTHER|Biological samples (blood and bone marrow samples).|For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
219240403|NCT06559098|DEVICE|Vibrotactile coordinated reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
219240404|NCT06563310|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
219738120|NCT03338686|PROCEDURE|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
219738121|NCT03338686|PROCEDURE|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
219738122|NCT02842671|OTHER|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
219738123|NCT03556878|BEHAVIORAL|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
219738124|NCT01981993|BIOLOGICAL|Urinary proteomic analysis|
219738125|NCT00974233|DRUG|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
219738126|NCT00974233|DRUG|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
219738127|NCT00974233|DRUG|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
219738128|NCT01691092|DRUG|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
219738129|NCT05042687|DRUG|Tc99m sestamibi|Given by IV
219738130|NCT01539889|RADIATION|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
219738131|NCT01657942|DEVICE|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
219738132|NCT06891222|DIAGNOSTIC_TEST|AI-ECG (artificial intelligence-enabled electrocardiogram)|Participants will undergo electrocardiogram analysis using AI-ECG during the baseline visit
219738133|NCT06891222|DIAGNOSTIC_TEST|Focus Screening (focused cardiac ultrasonography)|Participants will undergo a focused cardiac ultrasound if the AI-ECG reflects a positive value
219738134|NCT06926361|BEHAVIORAL|Mindfulness for Life|Behavioral: Mindfulness for Life (MBCT-L) MBCT-L is an 8-week program consisting of mindfulness practices and cognitive-behavioral techniques with 8 sessions (2 hours and 15 minutes per session) and one-day retreat that can provide participants with an extended period to deepen their personal mindfulness practices.
219738135|NCT06926361|BEHAVIORAL|Positive education training|Positive Education program is an 8-week course consisting of theories and activities of positive psychology to enhance teachers' skills to support students' learning and wellbeing using a strength-based approach.
219738136|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
219738137|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
219738138|NCT05171205|DEVICE|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
219738139|NCT06932744|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d for 24 weeks
219738140|NCT06932744|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
219738141|NCT05529953|DIETARY_SUPPLEMENT|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
219738142|NCT05529953|DIETARY_SUPPLEMENT|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
219738143|NCT01529151|OTHER|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
219240405|NCT06563310|OTHER|fMRI with Sham-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
219240406|NCT06969612|DRUG|Tislelizumab|200 mg, intravenously on Day 1, every 3 weeks
219240407|NCT06969612|DRUG|Pemetrexed|administered via IV infusion
219240408|NCT06969612|DRUG|Cisplatin|administered via IV infusion
219240409|NCT06969612|DRUG|Carboplatin|administered via IV infusion
219240410|NCT06969612|DRUG|Paclitaxel|administered via IV infusion
219240411|NCT06969612|DRUG|Albumin Paclitaxel|administered via IV infusion
219240412|NCT06969612|DRUG|Golidocitinib|75mg, once a day orally
219240413|NCT02924051|BEHAVIORAL|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
219240414|NCT02924051|BEHAVIORAL|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
219240415|NCT05786911|OTHER|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
219240416|NCT00828178|DRUG|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
219240417|NCT00828178|DEVICE|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
219240418|NCT00828178|OTHER|corn starch|3 capsules qd for 12weeks
219240419|NCT03967197|DRUG|Saline spray|Physiologic saline spray
219240420|NCT03967197|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
219240421|NCT03234010|OTHER|FT21092|An electronic cigarette
219240422|NCT03234010|OTHER|FT21093|An electronic cigarette
219240423|NCT03234010|OTHER|FT21096|An electronic cigarette
219240424|NCT03234010|OTHER|FT21097|An electronic cigarette
219240425|NCT06153706|DRUG|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
219240426|NCT06153706|OTHER|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
219240427|NCT01596777|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
219240428|NCT01596777|DRUG|Loperamide placebo|200 ml apple juice
219240429|NCT01596777|DRUG|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
219240430|NCT01596777|DRUG|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
219240431|NCT01596777|DRUG|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
219240432|NCT01596777|DRUG|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
219240433|NCT01596777|DEVICE|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
219240434|NCT01596777|DRUG|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
219240435|NCT05307302|DIAGNOSTIC_TEST|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
219240436|NCT05307302|DIAGNOSTIC_TEST|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
219240437|NCT05307302|DIAGNOSTIC_TEST|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
219240438|NCT05307302|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
219240439|NCT05307302|DIAGNOSTIC_TEST|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
219240440|NCT05642663|DEVICE|Stapler|Stapling performed with ALTUS Powered Stapler
219240441|NCT03819647|DRUG|stiripentol (Diacomit)|Administration of stiripentol per os
219240442|NCT00690079|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
219240443|NCT00690079|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
219240444|NCT00317928|DRUG|Metformin|
219171448|NCT06221059|DRUG|HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo|Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
219171449|NCT04336436|BEHAVIORAL|Mindfulness training|Mindfulness training
219171450|NCT04336436|BEHAVIORAL|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
219240445|NCT05485025|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
219240446|NCT05485025|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
219240447|NCT00515892|DRUG|Immunotoxin therapy|
219240448|NCT00515892|DRUG|CAT-8015 Immunotoxin|
219240449|NCT00515892|PROCEDURE|Biological therapy|
219240450|NCT00515892|PROCEDURE|Antibody Therapy|
219240451|NCT00515892|PROCEDURE|Monoclonal Antibody Therapy|
219240452|NCT05396573|BIOLOGICAL|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
219240453|NCT05396573|BIOLOGICAL|Comirnaty|A single dose of 30 μg/0.3 mL
219240454|NCT04636515|DRUG|F520|200mg，Q3W
219240455|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
219240456|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
219240457|NCT03159494|OTHER|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
219240458|NCT06244394|RADIATION|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
219240459|NCT04093050|DRUG|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
219240460|NCT01664806|DEVICE|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
219240461|NCT01778842|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
219240462|NCT01778842|DRUG|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
219240463|NCT02363049|PROCEDURE|Colectomy|
219240464|NCT02363049|DRUG|Chemotherapy|
219240465|NCT02826954|OTHER|Upper airway assessment, including nasal biopsy|
219240466|NCT01446718|BIOLOGICAL|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
219240467|NCT03547167|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
219240468|NCT03547167|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
219240469|NCT03547167|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
219240470|NCT00312806|DRUG|Pantoprazole|Pantoprazole 40 mg o.d.
219240471|NCT04536766|BEHAVIORAL|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
219240472|NCT04536766|BEHAVIORAL|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
219240473|NCT03629366|BEHAVIORAL|Supported Employment (SE)|Supported Employment
219240474|NCT03629366|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual
219240475|NCT02502019|DEVICE|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
219240476|NCT05772338|DRUG|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
219240477|NCT05772338|OTHER|Placebo|Placebo. Up to six applications per day.
219240478|NCT01317966|DRUG|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
219240479|NCT02265120|BEHAVIORAL|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
219240480|NCT00753259|OTHER|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
219240481|NCT00753259|OTHER|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
219240482|NCT00000492|DRUG|propranolol|
219240483|NCT03102892|PROCEDURE|Scaling root planing|Treatment by scaling and root planing alone.
219240484|NCT03102892|PROCEDURE|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
219240485|NCT03138499|BIOLOGICAL|Nivolumab|Specified dose on specified days
219240486|NCT03138499|BIOLOGICAL|Brentuximab vedotin|Specified dose on specified days
219240487|NCT03180541|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
219240488|NCT05752370|DEVICE|High flow oxygen|Use of HFO
219240489|NCT05752370|OTHER|Usual care|Room air or normal flow oxygen
219240490|NCT00624637|OTHER|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
219240491|NCT01342497|DRUG|isoniazide|Tablets, dosing 3 times daily, 12 weeks
219240492|NCT01342497|DRUG|placebo|tablets, dosing 3 times daily, 12 weeks
219240493|NCT01014559|DRUG|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
219240494|NCT01014559|DRUG|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
219240495|NCT01156454|PROCEDURE|X-ray|surgical specimen taken to radiology and contents x-rayed
219240496|NCT00594282|DEVICE|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
219240497|NCT03226600|DEVICE|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
219240498|NCT03226600|DEVICE|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
219240499|NCT06358794|DIAGNOSTIC_TEST|Machine learning-based predictive model|The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
219240500|NCT02813304|BEHAVIORAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
219738144|NCT01529151|OTHER|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
219171451|NCT02421185|DRUG|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
219171452|NCT02682342|OTHER|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
219171453|NCT05334732|BEHAVIORAL|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
219171454|NCT06351839|BEHAVIORAL|Sleep-Well despite persistent pain|The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).
219171455|NCT06351839|BEHAVIORAL|TAU (treatment-as-usual)|The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
219171456|NCT05697198|DIAGNOSTIC_TEST|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
219171457|NCT02797275|DRUG|Albuterol|Beta agonist respiratory inhaler
219171458|NCT02797275|DRUG|Placebo|respiratory inhaler with no medication
219171459|NCT00974415|PROCEDURE|CO2|CO2 treatment delivered to randomized flank at each study visit
219171460|NCT00974415|PROCEDURE|Sham|Sham treatment to other flank at each study visit
219171461|NCT04094688|DRUG|Bevacizumab|Given IV
219171462|NCT04094688|DRUG|Oxaliplatin|Given IV
219171463|NCT04094688|DRUG|Leucovorin Calcium|Given IV
219171464|NCT04094688|DRUG|Fluorouracil|Given IV
219171465|NCT04094688|DRUG|Irinotecan Hydrochloride|Given IV
219171466|NCT04094688|DRUG|Irinotecan|Given IV
219171467|NCT04094688|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219171468|NCT04094688|OTHER|Quality-of-Life Assessment|Ancillary studies
219171469|NCT04094688|OTHER|Questionnaire Administration|Ancillary studies
219171470|NCT02651428|DRUG|Neutrolin|Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
219171471|NCT02651428|DRUG|Heparin|Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
219171472|NCT05670626|PROCEDURE|Refractive Surgery|Phakic implantable contact lens ( ICL)
219171473|NCT06064955|BEHAVIORAL|Peer Support|Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
219171474|NCT06105788|OTHER|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
219171475|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
219171476|NCT05629845|PROCEDURE|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
219171477|NCT05629845|PROCEDURE|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
219171478|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
219171479|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
219171480|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
219738145|NCT00851136|DRUG|bevacizumab|Intravenous repeating dose
219738146|NCT00851136|DRUG|FOLFOX|Intravenous repeating dose
219738147|NCT00851136|DRUG|PRO95780|Intravenous repeating dose
219738148|NCT05626608|DEVICE|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
219738149|NCT05626608|DEVICE|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
219743641|NCT06643520|DEVICE|22-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
219240501|NCT02813304|BEHAVIORAL|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
219240502|NCT00054197|DRUG|gemcitabine hydrochloride|
219240503|NCT00054197|DRUG|paclitaxel poliglumex|
219171481|NCT02732860|OTHER|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
219171482|NCT04785196|DRUG|APG-115|Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
219171483|NCT04785196|DRUG|Toripalimab|Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
219171484|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
219171485|NCT06252506|DRUG|N,N-dimethyltryptamine (DMT) + harmine|DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
219171486|NCT06252506|DRUG|Placebo|Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
219171487|NCT06233825|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Essential Amino Acids|Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
219171488|NCT06233825|DIETARY_SUPPLEMENT|Safflower Oil and Non-Essential Amino Acids|Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.
219171489|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
219171490|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
219171491|NCT03535272|DRUG|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
219171492|NCT03535272|DRUG|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
219171493|NCT04211025|OTHER|Modest|The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
219171494|NCT04211025|OTHER|Intensive|The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
219171495|NCT03843151|DRUG|BI 1358894|Oral administration of single dose of 10 milligram (mg) BI 1358894 (2 tablets of 5 mg) with 240 milliliter (mL) of water after an high-fat, high-calorie breakfast on Day 1 of Treatment Period 1.
219171496|NCT03843151|DRUG|Itraconazole|Oral administration of 200 mg itraconazole (20 mL of 10 mg/mL solution) with 240 mL of water after an overnight fast for at least 10 h once daily for 14 days on Days -3 to 11 combined with a single dose of 10 mg BI 1358894 (2 tablets of 5 mg) on Day 1 of Treatment Period 2, 1.5 hours after administration of itraconazole.
219240504|NCT00054197|DRUG|vinorelbine tartrate|
219240505|NCT05558748|PROCEDURE|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
219171497|NCT06836960|DRUG|Probiotic Therapy With Gegen Qinlian Tang|This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily) for 8 weeks. The combination therapy is designed specifically for the prevention and treatment of radiation enteritis, differentiating it from probiotics or herbal therapies used alone.
219171498|NCT06836999|PROCEDURE|deep sedation|The deep sedation was inducted using atropine 0.5 mg iv administered 15 min before the procedure to avoid aspiration. In the EP lab, anesthesia preparation is performed, including invasive arterial blood pressure monitoring via puncture of the radial artery or brachial artery. Noninvasive BP monitoring every 5 minutes is also permitted. Subsequently, midazolam 1-2mg or accompanied with propofol 0.3-0.5 mg/kg is administered intravenously at the start of the CA procedure (i.e., femoral vein puncture), and fentanyl 25 µg is administered intravenously. Then, continuous titrated infusion of propofol 0.2-0.5mg/kg/h for anesthesia maintenance throughout the CA procedure. An additional iv fentanyl (25-50 µg) is administrated at the beginning of RF applications. Further boluses or additional drugs are administrated as needed to maintain analgesia during the procedure. The anesthesiologist is responsible for administering anesthesia and administering medication.
219171499|NCT06836999|PROCEDURE|Conscious sedation|This protocol is aimed at analgesia, with local infiltration of lidocaine for femoral vein puncture followed by intravenous administration of fentanyl (1-2 ug/kg/h). The operator determines the dose of fentanyl and midazolam. A midazolam 1-5 mg bolus is administrated before electrical cardioversion is performed or when the patient is nervous.
219240506|NCT05558748|PROCEDURE|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
219240507|NCT01661972|DRUG|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
219240508|NCT03800368|OTHER|Exercise|Indoor cycling exercise intervention
219171500|NCT05947578|DRUG|CLZ-2002|Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
219171501|NCT06031688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219171502|NCT06031688|PROCEDURE|Computed Tomography|Undergo CT scan
219171503|NCT06031688|PROCEDURE|Lymphoscintigraphy|Undergo lymphoscintigraphy scan
219171504|NCT06031688|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219171505|NCT06031688|BIOLOGICAL|Ramucirumab|Given IV
219171506|NCT06031688|DRUG|Tepotinib|Given PO
219171507|NCT06828913|OTHER|Oral Health information on online platforms|oral health
219171508|NCT06251063|BEHAVIORAL|Web-based psychoeducational resource|"The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement"
219171509|NCT04457154|DEVICE|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
219171510|NCT05694156|OTHER|Music-based cognitive training|8-week music-based cognitive training
219171511|NCT05210322|PROCEDURE|Percutaneous cholangiopancreatoscopy|Per standard treatment protocol for percutaneous cholangiopancreatoscopy, access will be gained into the biliary system using the biliary tube or into the gallbladder using the cholecystostomy tube. After access has been secured, through a peel-away sheath a Spy Glass Discover Digital Catheter will be introduced. Next, either, the stones will then be removed from the biliary system or gallbladder using a combination of baskets, and lithotripsy equipment as required, or in case of biliary strictures, a clamshell biopsy will be taken from the stricture site as identified on endoscopic visualization and cross-sectional imaging. Further intervention maybe performed for the stricture based on operator preference. After the complete stone removal/ stricture management the cholecystostomy/ biliary tube will be removed after the patient passes a clinical capping trial.
219171512|NCT04755309|BEHAVIORAL|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
219171513|NCT04755309|BEHAVIORAL|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
219171514|NCT01804634|DRUG|Cyclophosphamide|preparative regimen
219171515|NCT01804634|DRUG|Fludarabine|
219171516|NCT01804634|RADIATION|low dose total body irradiation|
219171517|NCT01804634|DRUG|Melphalan|
219171518|NCT01804634|DRUG|Tacrolimus|
219171519|NCT05400369|DRUG|Sitafloxacin|Oral administration, 50 mg tablets
219171520|NCT05400369|DRUG|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
219171521|NCT03001414|BIOLOGICAL|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
219171522|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
219171523|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
219240509|NCT03800368|OTHER|Non-exercise|Psycho-education
219171524|NCT05917158|DRUG|RC48-ADC and JS001|Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
219171525|NCT05839041|DRUG|AVD-104|Intravitreal injection
219171526|NCT05839041|DRUG|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
219171527|NCT05660018|DEVICE|active rTMS first, then sham rTMS|Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
219171528|NCT05660018|DEVICE|sham rTMS first, then active rTMS|Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
219240510|NCT05466630|DIAGNOSTIC_TEST|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
219240511|NCT05466630|DIAGNOSTIC_TEST|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
219171529|NCT06270888|RADIATION|Radiation|Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
219171530|NCT03669367|DRUG|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
219171531|NCT03669367|DRUG|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
219171532|NCT05575128|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
219171533|NCT05575128|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
219171534|NCT05575128|OTHER|Care as usual|Care as usual, with written resources provided
219171535|NCT04983173|DRUG|Ovarian Stimulation with CC+rFSH|: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
219171536|NCT04983173|DRUG|Ovarian Stimulation with rFSH|rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
219171537|NCT05828719|PROCEDURE|Percutaneous coronary intervention|"Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
219171538|NCT04725695|DRUG|Viscous Lidocaine|The patients will be randomized to either viscous lidocaine or placebo
219171539|NCT03272373|DEVICE|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
219171540|NCT03272373|DEVICE|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
219171541|NCT04562766|DRUG|Rilzabrutinib|400mg Caplet
219171542|NCT04562766|DRUG|Placebo|400mg Caplet
219171543|NCT04831216|BEHAVIORAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
219171544|NCT05728697|DEVICE|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
219171545|NCT03818711|BEHAVIORAL|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
219171546|NCT03818711|BEHAVIORAL|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
219171547|NCT05605678|OTHER|No Intervention|This is a non-interventional study.
219171548|NCT05655065|PROCEDURE|increase of mean arterial pressure at 65-70 mmHg|Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)
219171549|NCT05655065|PROCEDURE|increase of mean arterial pressure at 80-85 mmHg|Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
219171550|NCT06850155|PROCEDURE|Sling release|The gluteal sling was released and left unrepaired at the end of the procedure
219171551|NCT06850155|PROCEDURE|Sling release and repair|The gluteal sling was released and then repaired at the end of the procedure
219171552|NCT06849024|DEVICE|Transcutaneous electrical neurostimulation|Transcutaneous electrical nerve stimulation or placebo during 30 minutes three times per week for 60 days.
219171553|NCT00891709|DRUG|LEO 29102|First-in-man. Healthy volunteers
219171554|NCT02670447|PROCEDURE|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
219171555|NCT06848985|BEHAVIORAL|Aerobic combined with Resistance exercise|Participants are required to perform aerobic and resistance exercises. Aerobic exercises included the use of treadmills and elliptical machines, with intensity maintained at 60%-70% of the maximum heart rate (calculated as 220 minus age), for a total of 40 minutes per session (5 minutes of warm-up, 30 minutes of main exercise, and 5 minutes of cool-down). Heart rate monitors were used to ensure the intensity was maintained; resistance exercises involved gym equipment and bodyweight exercises, including the use of a pec deck machine, lat pull-downs, chest presses, bicep curls, tricep extensions, leg curls, and leg presses. The intensity of resistance exercises was set at about 65%-70% of one repetition maximum (1RM), with each session consisting of three sets of 6-8 repetitions and lasting for 30 minutes.
219240512|NCT05466630|DIAGNOSTIC_TEST|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
219240513|NCT05466630|DIAGNOSTIC_TEST|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
219240514|NCT03500276|BEHAVIORAL|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
219240515|NCT03500276|BEHAVIORAL|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
219240516|NCT02894099|OTHER|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
219240517|NCT02894099|OTHER|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
219240518|NCT02894099|OTHER|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
219240519|NCT02894099|OTHER|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
219240520|NCT01111006|DEVICE|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
219240521|NCT03326037|GENETIC|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
219171556|NCT06850467|BEHAVIORAL|Sexual intercourse protocol|The study involved pregnant women who were randomly assigned to 2 groups. The protocol involved engaging in sexual intercourse and nipple stimulation 3 times per day for two consecutive weeks with the consecutive days of sexual intercourse and days of nipple stimulation being different. Patients documented their coital activities as well as the frequency of orgasms in their daily journal. There were no prohibitions regarding or promotions of sexual activities for the control group. The main outcome was the onset of labor, which was defined as the presence of effective uterine contraction with changes of the cervix (Bishop score \> 5) without using the induction treatments during protocol time or until 41 weeks of pregnancy.
219171557|NCT04146597|OTHER|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
219171558|NCT05868525|DRUG|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
219171559|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
219171560|NCT05918783|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
219171561|NCT06263595|DEVICE|gastric antral sonography|Participant will undergo gastric antrum ultrasound and be scanned in the supine position followed by the right lateral decubitus position. Qualitative and quantitative assessments will be completed.
219240522|NCT01171053|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
219240523|NCT01171053|BEHAVIORAL|Therapist support|Weekly therapist support without CBT-interventions
219240524|NCT03900988|DRUG|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
219240525|NCT03900988|DRUG|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
219240526|NCT04313985|DEVICE|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
219240527|NCT03542695|PROCEDURE|Computed Tomography|Undergo PET/CT
219240528|NCT03542695|DRUG|Copper Cu-64-DOTA-alendronate|Given IV
219240529|NCT03542695|OTHER|Pharmacokinetic Study|Correlative studies
219240530|NCT03542695|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219240531|NCT02159794|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
219240532|NCT03838575|DRUG|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
219240533|NCT03838575|DEVICE|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
219240534|NCT03838575|DEVICE|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
219240535|NCT03838575|OTHER|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
219240536|NCT01501825|DEVICE|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
219240537|NCT01501825|DEVICE|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
219240538|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
219240539|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
219240540|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
219240541|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
219240542|NCT02068053|DRUG|[14C] BMS-986020|
219240543|NCT06199011|DRUG|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
219240544|NCT06199011|DRUG|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
219240545|NCT04572165|DRUG|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219738150|NCT06942780|BEHAVIORAL|Exercise intervention|"The multi-component exercise mode is adopted, and the three-stage structured design of warm-up preparation - main training - finishing and relaxation is adopted, and the participants' heart rate is monitored in real time with the exercise bracelet throughout the whole process to ensure that the training intensity is reached. The movement process is guided synchronously by the video music teaching system, and the specific process is as follows:~1. Warm-up preparation (3 minutes) : Warm up the head and neck, shoulder joints, arms and wrists, waist and abdomen, thighs and ankles in turn, and perform 30 seconds for each movement.~2. Main training stage (60min) : aerobic exercise adopts basic steps of square dance or advanced step training; The resistance training module carries out compound resistance exercises of sitting posture, leg lift and arms forward lift.~3. Finishing and relaxing stage (12min) : select the traditional health exercise eight Duan Jin."
219738151|NCT06942780|BEHAVIORAL|Social intervention|"The duration of each intervention was 40min, mainly group social interaction, guided by professionals (medical social workers). Divided into three stages:~The first stage (3min) : The facilitator will go through small jokes, soothing music, etc.Create a relaxed atmosphere and briefly introduce the theme of the week.~The second stage (35min) : During the activity, participants began to chat around the theme, and the host guided them timely.~The third stage (2min) : Summarize the intervention and praise the participants."
219738152|NCT06942780|BEHAVIORAL|Dietary intervention|The researcher distributed the health education manual of the cognitive disorder diagnosis and treatment center, and conducted a 5-minute MIND diet health education, explaining relevant dietary requirements and focusing on the collocation of one type of food every week. The participants were then given homework that asked them to strictly follow the MIND diet in their daily diet. At the same time, the participants' caregivers are required to upload photos of their daily meals to the wechat group for supervision and feedback.
219738153|NCT06942780|BEHAVIORAL|Cognitive intervention|Cognitive digital therapy was adopted, and participants were supervised by their caregivers for 5 days a week and 30min each time for cloud-based home training (avoiding 2 hospital intervention days) for 8 weeks. The training covers core cognitive functions such as attention, memory and logical reasoning.
219240546|NCT04572165|DRUG|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219743642|NCT06644001|DIETARY_SUPPLEMENT|Bacillus coagulans GBI-30,6086 (BC GBI-30)|2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.
219743643|NCT06644001|DIETARY_SUPPLEMENT|Placebo|2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
219743644|NCT06643624|OTHER|Vision Training Program|Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
219743645|NCT06643624|OTHER|Routine Training Program|All athletes performed their routine training for wrestling 6 days a week.
219743646|NCT02914886|DRUG|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
219743647|NCT02914886|DRUG|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
219743648|NCT04287829|DRUG|Pembrolizumab|Infusion
219743649|NCT04287829|DRUG|Lenvatinib|Capsule
219743650|NCT04981145|DRUG|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
219743651|NCT04981145|DRUG|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
219743652|NCT01713829|OTHER|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
219743653|NCT01713829|OTHER|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
219171562|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
219171563|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
219171564|NCT05987371|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
219171565|NCT05987371|DRUG|TQC3721 matching placebo for inhalation|Placebo without active substance.
219171566|NCT05987371|DRUG|Salbutamol sulfate inhalation aerosol|Salbutamol is short-acting β2 receptor agonists.
219171567|NCT06538649|DRUG|Rosuvastatin|Rosuvastatin provided at 10 mg start; 5mg for Asians. Dose will be increased to 20 mg for those tolerating and without contraindication.
219171568|NCT06538649|OTHER|Placebo|Placebo tablet(s)
219171569|NCT03936218|DRUG|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
219171570|NCT03936218|DRUG|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
219171571|NCT06803888|PROCEDURE|Bariatric Surgery|Patients receive either RYGB or SG. The surgical risk, the differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
219171572|NCT06803888|DRUG|Semaglutide|"Semaglutide will be initiated at a dose of 0.25 mg once weekly and will be increased during the dose-escalation period to reach a maintenance dose of up to 2.4 mg once weekly by week 16. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Semaglutide is the FDA-approved dosing schedule.~The maintenance dose is 2.4 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 2.4 mg and may stay at the lower maintenance dose level (e.g., 1.7 mg once weekly), if needed."
219171573|NCT06803888|DRUG|Tirzepatide|"Tirzepatide will be initiated at a dose of 2.5 mg once weekly and will be increased by 2.5 mg every week during the dose-escalation period to reach a maintenance dose of up to 15 mg once weekly by week 20. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Tirzepatide is the FDA-approved dosing schedule.~The maintenance dose is 15 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 15 mg and may stay at the lower maintenance dose level (e.g., 10 mg once weekly), if needed."
219171574|NCT05518682|DEVICE|Lenire bimodal stimulation device|The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
219171575|NCT06290635|DIAGNOSTIC_TEST|Breathlessness Assessment Tool|Participants will complete a breathlessness assessment tool (questionnaire) at three timepoints over the study duration, among other validated questionnaires.
219171576|NCT04877041|BEHAVIORAL|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
219240547|NCT04572165|DRUG|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
219240548|NCT01204502|BIOLOGICAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
219171577|NCT06494930|OTHER|F-IMT|A core stabilization exercise protocol including functional respiratory muscle training will be applied to the F-IMT group. IMT will be provided with the red Powerbreath Plus MR exercise device. Initial training intensity will be set at 50% of the MIP value measured at the athlete's first evaluation. Every two weeks, the athlete will be re-evaluated the new MIP value will be measured, and the training intensity will be adjusted to 50% of the newly measured MIP value. After the nose clip is attached, the athlete will be asked to take the device's mouthpiece into his mouth, close his lips tightly, and take a deep, fast, and powerful breath, then exhale slowly and completely with minimal effort. While the athlete does breathing exercises with the device, he will also do core stabilization exercises. Athletes will be asked to train 30 minutes daily, five days a week, for six weeks.
219171578|NCT06494930|OTHER|Core Stabilization Exercise|Only the core stabilization exercise protocol will be applied to the control group. Athletes will be asked to train 30 minutes a day, five days a week, for six weeks.
219171579|NCT06570135|DIAGNOSTIC_TEST|Detecting Brain Activity with Functional Near Infrared Spectroscopy|Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
219171580|NCT06243211|PROCEDURE|DMED|Decompression of spinal cord with stabilization - posterior approach.
219171581|NCT06243211|PROCEDURE|ANGI|Implantation of nerve tissue following decompression ans stabilization.
219171582|NCT05422014|BEHAVIORAL|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group."
219171583|NCT03461991|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
219171584|NCT03931447|BIOLOGICAL|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
219171585|NCT03931447|BIOLOGICAL|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
219240549|NCT00397098|DRUG|SR58611A|
219240550|NCT05675748|DRUG|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
219240551|NCT02868983|OTHER|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
219240552|NCT02009865|DRUG|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
219240553|NCT02009865|DRUG|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
219240554|NCT01760876|DEVICE|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
219240555|NCT02290548|DEVICE|high flow nasal cannula|High flow nasal cannula used in postextubation patients
219171586|NCT03721913|OTHER|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
219171587|NCT03113422|DRUG|Induction Venetoclax|"1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
219171588|NCT03113422|DRUG|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
219171589|NCT06624176|DEVICE|Bionix ShotBlocker|This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.
219171590|NCT06624176|OTHER|Swaddling|Standard of care swaddling
219171591|NCT06624176|OTHER|Sucrose administration|Standard of care sucrose administration
219171592|NCT06624176|OTHER|Masimo Rad-97 Oximeter probe|Oximeter probe
219171593|NCT04594798|DRUG|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
219171594|NCT04594798|DRUG|Rituximab|IV 375 mg/m2 per cycle
219171595|NCT04594798|DRUG|Cyclophosphamide|IV 400 mg/m2 per cycle
219171596|NCT04594798|DRUG|Doxorubicin|IV 25 mg/m2 per cycle
219171597|NCT04594798|DRUG|Prednisone|PO 40 mg/m2 per cycle
219171598|NCT05827861|BEHAVIORAL|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
219171599|NCT05827861|BEHAVIORAL|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
219171600|NCT05827861|BEHAVIORAL|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
219171601|NCT03930342|BEHAVIORAL|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
219171602|NCT06967974|OTHER|Tai Chi + Sleep Hygiene Education|Conduct simplified training on the 24 style Tai Chi; Sleep hygiene education includes adjusting sleep time, maintaining regular lifestyle habits, optimizing bedroom environment, reducing nighttime stimulation, avoiding thinking when going to bed, adjusting alarm clock positions, and reducing daytime napping.
219171603|NCT06967974|OTHER|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
219171604|NCT06365320|OTHER|Single basketball training|Single basketball training session with fixed intensity and duration
219171605|NCT03209713|BEHAVIORAL|HPV Vaccine Education|A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
219171606|NCT03209713|BEHAVIORAL|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
219171607|NCT00152087|DEVICE|Brachytherapy|
219171608|NCT05000489|OTHER|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
219171609|NCT00912600|OTHER|Intensive Care Unit admission|Intensive Care Unit admission
219171610|NCT04788459|BIOLOGICAL|COVID-eVax|Plasmid DNA Vaccine for COVID-19
219171611|NCT04788459|DEVICE|Cliniporator® and EPSGun|IGEA Electroporation Device
219171612|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
219171613|NCT05824078|PROCEDURE|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
219171614|NCT05824078|PROCEDURE|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
219171615|NCT05523388|OTHER|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
219171616|NCT03859869|DRUG|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
219171617|NCT03859869|DRUG|Placebo|Placebo is administered orally as capsules with a meal or snack
219171618|NCT00558506|DRUG|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
219171619|NCT05857020|DEVICE|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
219171620|NCT06565429|BEHAVIORAL|5-Step Method Intervention|The 5-Step Method (5SM) intervention is delivered through a self-help handbook: There are writing prompts for the affected family member (AFM) in each step. The steps end with a summary, a space to reflect and a statement that the step is complete but can be reviewed as needed. The steps are: 1.Explore how the relative's drug and/or alcohol misuse is affecting the family member, causing stress and strain. 2.Determine the information the AFM needs to understand the situation using evidence-based websites in the handbook. 3.Reflect on coping styles, and which ones might be useful. 4.Determine who is a source of positive social support, and who could be one that the AFM has not used yet. 5.Review steps 1-4 and determine if the AFM is feeling less stress and strain, or if more help is needed and use websites to look for additional help. The activities should take about 1 hour per week.
219171621|NCT05374278|DRUG|[18F]RP-115 PET/MRI or PET/CT and MRI|An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
219171622|NCT04750707|DRUG|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
219738154|NCT06942780|BEHAVIORAL|Health Education Manual|Distribute health education handbooks to guide patients to establish a good awareness of a healthy lifestyle. The manual can popularize health knowledge, covering various aspects such as diet, exercise, and rest, enabling patients to understand the importance of a healthy lifestyle, encouraging them to actively improve their living habits, slow down the progression of the disease, and enhance their quality of life.
219738155|NCT06955962|OTHER|Mandala Art Therapy|Arm Description: The mandala art therapy for individuals in the intervention group is planned to be conducted in their home environments under suitable conditions. The therapy sessions will be accompanied by music of the participants' choosing and are scheduled to take place over a six-week period, at least three to four times per week, for a minimum of 30 minutes per session. Before the first mandala art therapy session, participants in the intervention group will receive a brief orientation by the researcher on the appropriate environment for the practice and an introduction to mandala art therapy. This orientation will include information on the definition and characteristics of mandala art therapy, the application setting and duration, and general guidelines to be followed during the sessions. At the end of the six-week mandala art therapy program, Post-tests ill be administered face-to-face, and the archived mandala folders will be collected
219738156|NCT05812495|PROCEDURE|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
219738157|NCT05812495|PROCEDURE|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
219738158|NCT03756935|PROCEDURE|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
219738159|NCT03971045|DRUG|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
219738160|NCT05405166|DRUG|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
219738161|NCT05405166|DRUG|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
219738162|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
219738163|NCT05405166|DRUG|Pomalidomide|Pharmaceutical form: hard capsules; Route of administration: Oral
219738164|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
219738165|NCT05405166|DRUG|Montelukast|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
219738166|NCT05405166|DRUG|Paracetamol / Acetaminophen|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
219738167|NCT05405166|DRUG|Diphenhydramine|Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
219171623|NCT06853548|OTHER|Assessment|Respiratory function, respiratory muscle strength, and core stability parameters will be assessed in children with hyperkyphosis.
219171624|NCT06654661|DEVICE|3D-Printed Mechanical Balancer|The 3D printed mechanical balancer is a surgeon-controlled handheld intraoperative tool used that provides a quantifiable measurement of force differences on the medial and lateral sides to guide achievement of a balanced knee. It will be used at one timepoint during scheduled TKA surgery while the patient is under anesthesia. Readings will be taken at 0, 45, and 90 degrees of flexion.
219171625|NCT06979778|DEVICE|See Yourself Differently (syd) mobile app|"The 'syd' mobile app is designed as an AI-powered Life Quality Mentor with the primary aim of enhancing users' quality of life. The app focuses on positive habit development, personalised feedback, and continuous support. It offers personalised guidance across various domains, including Physical health, Emotional health, Brain power, Self-awareness, Purpose, Career, Financial health, Social life and Environment. It utilizes an advanced AI platform and offers features like personalised recommendations, supportive interaction with an AI mentor, habit tracking tools, and integration with wearable technology."
219171626|NCT06602804|DEVICE|Trima Accel Auto RBC Collection|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.
219171627|NCT05752916|DRUG|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
219171628|NCT05752916|DRUG|Antiplatelet Agents|Aspirin (150-300mg) is offered to patients allocated in the control arm, unless contraindicated. According to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023, 150-300mg aspirin alone is recommended for acute stroke treatment in patients who are otherwise eligible for intravenous thrombolysis or EVT as soon as possible (Class 1 of recommendation, Level A of evidence). The aspirin dose can be changed to 50-300 mg/day after the acute phase. Clopidogrel is indicated as an alternative in case of aspirin intolerance (Class 2 of recommendation, Level C of evidence)
219171629|NCT06986473|OTHER|Questionnaire that measure the level of awareness of dermatologists|This study will be an observational cross-sectional analytical study that will recruit 165 dermatologists of both genders according to sample size calculation from different outpatient clinics in Cairo teaching hospitals. The aim of the study will be to develope a questionnaire to evaluate the awareness of Egyptian dermatologist towards the role of physical therapy in patients with various skin diseases
219171630|NCT06987396|DIETARY_SUPPLEMENT|1000 mg Betaglucans (daily)|Patients in the experimental group receive betaglucans supplement in capsule form, administered orally
219171631|NCT06986668|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
219171632|NCT06986668|OTHER|paraffin bath|It is an effective treatment for the treatment of patients' hands, arms and feet by applying the brushing method to different body parts, relieving pain and improving function, thus providing freedom of life.
219171633|NCT06986668|OTHER|home exersize|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
219171634|NCT06986395|DEVICE|Blood Flow Restriction Training (BFRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
219171635|NCT06986395|OTHER|Conventional Resistance Training (CRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
219171636|NCT06987149|DEVICE|CAD/CAM Zirconia Membrane|A prefabricated, non-resorbable zirconia membrane fabricated using CAD/CAM technology for guided bone regeneration in horizontal ridge deficiencies during simultaneous dental implant placement.
219171637|NCT06987149|PROCEDURE|Contour Augmentation|Traditional guided bone regeneration using particulate bone graft and a resorbable collagen membrane, placed concurrently with the dental implant to augment horizontal ridge deficiencies.
219171638|NCT06984913|OTHER|Ultrasound-guided sphenopalatine ganglion block|Patients will receive an ultrasound-guided sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
219171639|NCT06984913|OTHER|Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
219171640|NCT06984913|OTHER|Low dose Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (2 ml bupivacaine 0.25%) (low dose).
219171641|NCT06987630|DEVICE|monitor integrated pulmonary index（IPI） and take appropriate measures|When the IPI is ≤ 6, the patient's jaw is immediately lifted, the oxygen flow rate increases to 6L·min-1, and if the SpO2 continues to decrease by \<90%, the anesthesia mask is pressurized and ventilated.
219171642|NCT06987838|DRUG|Pharmacological treatment|All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3 menstrual cycles.
219171643|NCT06987838|OTHER|Virtual reality|The experimental group will receive virtual reality during the first 2 days of menstruation, for 3 menstrual cycles.
219171644|NCT06986915|OTHER|Aerobic exercise at moderate intensity level|"The intervention involved supervised aerobic activity sessions. Every session contained:~Warm-up (5-10 minutes): To get the body ready, do some light stretching and low-intensity exercises.~The primary aerobic activity (30-45 minutes) should consist of moderately intense exercises that aim to reach 60-75% of the participant's maximal heart rate.~Cool-down (5-10 minutes): Stretching and a gradual decrease in activity to aid in recuperation.~This intervention's objective was to evaluate how moderately intense aerobic exercise affected the anthropometric (body weight, BMI), biochemical (blood sugar, cholesterol), and psychological well-being indicators in obese adult women."
219171645|NCT06987747|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossei (FDI) muscle of the left motor cortex will be targeted using neuronavigation software. A series of 90 triplet pulses will be delivered at 100 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right FDI muscle. The delivery of rTMS requires \~ 15 minutes in total.
219171646|NCT03748342|DEVICE|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
219171647|NCT06303960|DEVICE|Bilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
219171648|NCT06303960|DEVICE|Unilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
219171649|NCT06303960|DEVICE|Vagus Nerve Stimulation|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
219171650|NCT06677450|OTHER|Pain neuoroscience education|Pain neurosicence education will be applied 1 day / 6 weeks at the beginning of one of the weekly exercise sessions in addition to the exercise program. The educations will include the definition and general characteristics of pain, pain physiology, peripheral neuropathic pain, the role of the brain in pain perception, tissue healing, peripheral and central sensitization, the effects of emotional, psychological and social factors on the pain process and pain coping strategies.
219171651|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
219171652|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
219171653|NCT05297864|DRUG|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
219171654|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
219171655|NCT03615690|OTHER|Regular Diet|Regular Diet
219171656|NCT06725615|OTHER|Regular Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
219171657|NCT06725615|OTHER|High Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
219171658|NCT06725615|OTHER|Low Umami exposure|This group will receive the basic diet without added MSG.
219171659|NCT06725615|OTHER|one-week run-in period|During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
219171660|NCT06926231|BEHAVIORAL|Protocolized medical hypnosis|Patients who will receive protocolized medical hypnosis before the SBT every day between inclusion and day 7. Medical hypnosis sessions will consist in the administration of a 5-min hypnotic text by a loudspeaker installed in the ICU room, after selection of a hypnotic theme (sea, mountain or animals) by the participant. The hypnosis session will involve an induction phase, a suggestion phase and an emergence phase, along with self-hypnosis tips. The hypnosis session will immediately precede the SBT (\<2h). The intervention is administered before the SBT daily from the randomization to day 7 or until extubation.
219171661|NCT06926231|BEHAVIORAL|Protocolized standard of care|The protocolized standard of care will consist in the description of authorized human/behavioral patient-nurse interactions and patient installation prior to the daily SBT.
219171662|NCT06752902|OTHER|Standard Care Arm|standard care combined with personalised prevention
219171663|NCT06752902|OTHER|standard care combined with personalised prevention|standard care combined with personalised prevention
219171664|NCT06793384|BEHAVIORAL|Virtual reality based Cognitive Stimulation Therapy (VR-CST)|In the VR-CST condition, participants wore a head-mounted display (HMD; model: DPVR P1 Pro Headset) for the themed activities in every session except sessions 1 and 14. In these two sessions, group physical activities (such as passing a ball from one participant to another) were conducted, so no HMDs were used. In other sessions, panoramic images (e.g., wet market) and videos (e.g., the neighborhood surroundings) prepared by the project team were mainly used, supplemented by 2-dimensional images /videos in which preparing panoramic images/videos was deemed impossible. Such a situation occurred in Session 5 (current affairs), in which news clips or captions from newspaper websites served as more appropriate content for discussion than self-created panoramic images/videos.
219171665|NCT06793384|BEHAVIORAL|Conventional Cognitive Stimulation Therapy (Conventional CST)|In the conventional CST group, 2-dimensional images/videos illustrating content identical to the VR-CST condition were displayed via tablet computers (see Table 2 for details) in which participants could manipulate the size of the image depicted or the pace of the videos with the help of the facilitator/therapy assistant.
219171666|NCT06840691|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
219171667|NCT06840691|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
219171668|NCT05180162|DRUG|68Ga-FAP-2286|A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
219171669|NCT05180162|PROCEDURE|Positron Emission Tomography (PET)|Imaging will begin 50-100 minutes after injection and last about 45 minutes.
219171670|NCT06794931|OTHER|Nutrition|The patient will be instructed to follow the modified Mediterranean diet or his usual diet based on the assigned treatment group.
219171671|NCT06794931|OTHER|Biological samples collection|Additional biological samples will also be collected.
219171672|NCT05674617|BEHAVIORAL|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
219171673|NCT05674617|BEHAVIORAL|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
219171674|NCT06464445|DEVICE|Monophasic iTBS|"iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
219171675|NCT06464445|DEVICE|Biphasic iTBS|"iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
219171676|NCT06464445|DEVICE|Monophasic-Long iTBS|"iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
219171677|NCT06324396|DRUG|Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)|A single oral dose of sildenafil will be administered to all study subjects.
219171678|NCT06324396|DRUG|Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)|A single oral dose of pravastatin will be administered to all study subjects.
219240556|NCT03609450|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
219171679|NCT05428618|OTHER|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
219171680|NCT05428618|OTHER|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
219171681|NCT06846164|OTHER|Supervised progressive strength training including elements of neuromuscular exercise intervention (SNG)|Participants will be randomized to SNG and will perform training sessions (60-70 minutes) twice weekly, over a duration of 12 weeks, commencing 8 exercises for the lower extremities in 3 sets of 10 repetitions with an intensity of 12 repetitions maximum. Individual progression, quality of exercise, number of sets, repetitions, and additional training weights will be monitored
219171682|NCT06846164|OTHER|home based low-intensity weight-bearing exercise protocol.|Participants allocated to CON will receive written and verbal instructions regarding 4 home-based (low intensity), weight-bearing exercises for the lower extremities, to be performed twice weekly. This intervention is designed to resemble usual care in cases where persistent knee muscle strength deficits would be discovered and considered a clinical issue.
219171683|NCT06844084|OTHER|Gardening Activity|In the project, gardening activities will be applied to the participants in the experimental group in the nursing home and greenhouse for 16 weeks (4 months), once a week for 60 minutes. During the implementation phase of horticulture activities, information meetings will be held in the meeting room of the nursing home in one group. In addition, 20 minutes break will be given during the activity in terms of the tolerance of the elderly to gardening activities.
219171684|NCT04747912|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
219171685|NCT04747912|DRUG|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
219171686|NCT04747912|DRUG|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
219171687|NCT04747912|DRUG|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
219171688|NCT04747912|DRUG|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
219738168|NCT05405166|DRUG|Methylprednisolone|Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
219738169|NCT05693935|DRUG|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
219738170|NCT05693935|DRUG|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
219738171|NCT05693935|DRUG|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
219738172|NCT05693935|DRUG|Placebo|In Period 1, 2 monthly injections (Period 1 only)
219738173|NCT04857281|DEVICE|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
219738174|NCT01569763|DEVICE|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
219738175|NCT01569763|DEVICE|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
219240557|NCT03609450|BEHAVIORAL|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
219240558|NCT04453930|DRUG|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
219240559|NCT04453930|DRUG|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
219240560|NCT04453930|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
219240561|NCT04453930|DRUG|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
219240562|NCT04979702|BEHAVIORAL|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
219240563|NCT04979702|BEHAVIORAL|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
219240564|NCT02135666|PROCEDURE|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
219240565|NCT01517282|BIOLOGICAL|MOR103|Anti-GM-CSF monoclonal antibody
219240566|NCT01517282|OTHER|Placebo|Placebo to anti-GM-CSF monoclonal antibody
219738176|NCT00148538|BEHAVIORAL|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
219738177|NCT00485342|DRUG|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
219738178|NCT00485342|DRUG|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
219738179|NCT06114472|DRUG|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
219738180|NCT03211858|DRUG|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
219738181|NCT03211858|DRUG|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
219738182|NCT03211858|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
219738183|NCT00002431|DRUG|Chlorhexidine gluconate|
219738184|NCT02795962|OTHER|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
219738185|NCT00963885|DRUG|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
219738186|NCT00963885|DRUG|Pegasys|180micrograms sc weekly for 24 or 48 weeks
219738187|NCT00963885|DRUG|Placebo|po for 12 weeks
219738188|NCT00963885|DRUG|Placebo|po for 24 weeks
219171689|NCT04747912|DRUG|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
219171690|NCT04747912|DRUG|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
219171691|NCT04747912|PROCEDURE|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
219171692|NCT06845878|OTHER|chatbot|"Participants will:~* Participate in a baseline session to complete an initial survey and get trained on using the chatbot~* Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback~* Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot~* Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context."
219171693|NCT05993078|DRUG|0.9% NaCl 2000ml|The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
219171694|NCT05993078|DRUG|0.9% NaCl 200-400ml|The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
219171695|NCT03948373|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
219171696|NCT03840421|DRUG|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
219171697|NCT03840421|DRUG|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
219171698|NCT03840421|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
219171699|NCT03840421|DRUG|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
219171700|NCT06245564|DRUG|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
219171701|NCT06245564|DRUG|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
219171702|NCT06245564|DRUG|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
219171703|NCT06245564|OTHER|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
219171704|NCT06245564|OTHER|Histamine|After the cream removal, itch will be induced using histamine in the first session
219171705|NCT06245564|OTHER|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
219240567|NCT00488969|DRUG|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
219240568|NCT00488969|DRUG|Placebo|
219171706|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
219171707|NCT04516616|DRUG|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
219171708|NCT06185296|DEVICE|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
219171709|NCT06185296|DEVICE|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
219171710|NCT04238364|DRUG|EI-1071|EI-1071 Tablet(s)
219171711|NCT04238364|DRUG|Placebo|Matching Placebo Tablet(s)
219171712|NCT06530446|OTHER|one group. observational study|observational study of this group
219171713|NCT06333964|DRUG|AST-001|AST-001, PO bid for 24weeks (dosage according to weight range)
219171714|NCT06333964|DRUG|Placebo of AST-001|Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
219171715|NCT04167761|DRUG|Ertugliflozin|Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
219171716|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
219240569|NCT00704548|DRUG|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
219240570|NCT00704548|DRUG|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
219240571|NCT03153423|PROCEDURE|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
219738189|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
219738190|NCT00963885|DRUG|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
219738191|NCT00963885|DRUG|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
219738192|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
219738193|NCT05476731|DIAGNOSTIC_TEST|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
219738194|NCT04636580|BEHAVIORAL|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
219738195|NCT00185614|PROCEDURE|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
219738196|NCT00185614|PROCEDURE|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
219738197|NCT00185614|DRUG|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
219240572|NCT02644980|DRUG|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
219240573|NCT02644980|DRUG|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
219240574|NCT02644980|DEVICE|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
219240575|NCT02644980|DRUG|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
219240576|NCT02644980|DRUG|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
219240577|NCT02644980|OTHER|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
219240578|NCT03886207|OTHER|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
219240579|NCT03886207|OTHER|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
219240580|NCT02275351|DRUG|SM04554|Topical solution, applied once a day
219240581|NCT02275351|DRUG|Vehicle|Topical solution, applied once a day
219240582|NCT04429672|BEHAVIORAL|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
219240583|NCT04429672|BEHAVIORAL|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
219240584|NCT00525915|DRUG|5-Fluorouracil|"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."
219240585|NCT00525915|DRUG|Oxaliplatin|"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"
219240586|NCT00525915|RADIATION|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
219240587|NCT00525915|PROCEDURE|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
219240588|NCT01328223|RADIATION|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
219240589|NCT05629806|DRUG|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
219240590|NCT05629806|DRUG|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
219240591|NCT04251845|DIETARY_SUPPLEMENT|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
219240592|NCT04251845|OTHER|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
219240593|NCT04305496|DRUG|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
219240594|NCT04305496|DRUG|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
219240595|NCT04305496|DRUG|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
219240596|NCT00253552|BIOLOGICAL|filgrastim|
219240597|NCT00253552|DRUG|busulfan|
219240598|NCT00253552|DRUG|cyclophosphamide|
219240599|NCT00253552|DRUG|cyclosporine|
219240600|NCT00253552|DRUG|etoposide|
219240601|NCT00253552|DRUG|methotrexate|
219240602|NCT00253552|PROCEDURE|allogeneic bone marrow transplantation|
219738198|NCT00185614|DRUG|Filgrastim|"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
219738199|NCT00185614|DRUG|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
219240603|NCT00253552|RADIATION|radiation therapy|
219240604|NCT05272202|DRUG|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
219738200|NCT00185614|RADIATION|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
219738201|NCT00185614|PROCEDURE|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
219738202|NCT00185614|DRUG|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
219171717|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
219171718|NCT06298396|DEVICE|Program using default MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
219171719|NCT06298396|DEVICE|Program using low-power 1 (LP1) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
219171720|NCT06298396|DEVICE|Program using low-power 2 (LP2) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
219171721|NCT06298396|DEVICE|Program using low-power 3 (LP3) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
219171722|NCT05817591|OTHER|Questionnaires|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
219171723|NCT06180837|BEHAVIORAL|Sleep Extension Intervention|Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
219240605|NCT05272202|DEVICE|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
219240606|NCT05272202|DEVICE|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
219240607|NCT01129375|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
219240608|NCT01129375|DRUG|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
219240609|NCT01129375|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
219240610|NCT03191097|DRUG|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
219240611|NCT03191097|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
219240612|NCT05751720|DRUG|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
219240613|NCT03368300|OTHER|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
219240614|NCT03657745|DEVICE|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
219240615|NCT04817293|OTHER|Questionnaire|Questionnaire SSD-12 and EQ5D5L
219240616|NCT04817293|OTHER|medical consultation|Medical consultation during the visit with data collection
219240617|NCT00453440|PROCEDURE|Cheek swab & blood test|Cheek swab \& blood test
219240618|NCT01045057|DEVICE|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
219240619|NCT04139486|PROCEDURE|combined EMBOTRAP II or III and Contact Aspiration|refer to title
219240620|NCT04139486|PROCEDURE|Contact Aspiration alone|refer to title
219240621|NCT01170936|DRUG|canakinumab|Single dose of canakinumab 300mg s.c. injection
219240622|NCT03677986|BEHAVIORAL|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
219240623|NCT03187249|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
219240624|NCT03187249|BEHAVIORAL|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
219738203|NCT01048359|BEHAVIORAL|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
219738204|NCT01048359|BEHAVIORAL|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
219738205|NCT01048359|BEHAVIORAL|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
219738206|NCT00536705|DRUG|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
219738207|NCT05856942|OTHER|Health service - home-based PrEP monitoring|Home-based PrEP care
219738208|NCT05818007|DRUG|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
219738209|NCT05818007|DRUG|Sodium bicarbonate|sodium bicarbonate solution
219738210|NCT03160573|DRUG|ClōSYS® Unflavored Rinse|
219738211|NCT03160573|DRUG|ClōSYS® Flavored Rinse|
219738212|NCT03160573|OTHER|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
219738213|NCT03160573|OTHER|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
219738214|NCT03638180|DRUG|BLU-5937|BLU-5937 oral tablet
219738215|NCT03638180|DRUG|Placebo|Matching placebo to BLU-5937
219738216|NCT01283945|DRUG|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
219738217|NCT05522400|BEHAVIORAL|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
219738218|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
219240625|NCT03187249|BEHAVIORAL|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
219240626|NCT04529200|OTHER|electrotherapy treatment|physical therapy management like EMS IFT
219240627|NCT02332889|BIOLOGICAL|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
219240628|NCT02332889|DRUG|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
219240629|NCT06812247|OTHER|Therapy dog visits|2-3 ten-minute visits by a trained therapy dog and the dog's handler
219240630|NCT06812247|OTHER|Dog handler visits|2-3 ten-minute visits by a dog handler
219240631|NCT05459584|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
219240632|NCT05283876|DEVICE|Excimer light|Excimer light sessions
219240633|NCT01647802|DEVICE|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
219240634|NCT01647802|DEVICE|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
219240635|NCT01647802|DEVICE|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
219240636|NCT05688605|DRUG|MRG003+HX008|Administered intravenously
219362376|NCT04406870|DRUG|propranolol|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
219171724|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
219171725|NCT04870112|DRUG|Durvalumab|Anti-PD-L1 antibody
219171726|NCT04870112|DRUG|Cisplatin|Chemotherapy
219171727|NCT04870112|DRUG|Carboplatin|Chemotherapy
219171728|NCT04870112|DRUG|Etoposide|Chemotherapy
219171729|NCT06077591|OTHER|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
219171730|NCT05078411|BEHAVIORAL|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
219171731|NCT05078411|BEHAVIORAL|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
219171732|NCT03606642|DRUG|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
219171733|NCT03606642|DEVICE|The Synergy® stent|IVUS guided stent
219171734|NCT06500975|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
219171735|NCT05021640|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
219171736|NCT05021640|DRUG|Placebo for DCR-AUD|0.9% saline for injection
219171737|NCT04737772|BEHAVIORAL|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
219171738|NCT04737772|BEHAVIORAL|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
219171739|NCT04911751|DRUG|KBL697|1 capsule BID of KBL697 or Placebo
219171740|NCT04911751|DRUG|KBL697|5 capsules BID of KBL697 or Placebo
219171741|NCT03763253|COMBINATION_PRODUCT|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
219171742|NCT03763253|PROCEDURE|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
219171743|NCT03763253|PROCEDURE|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
219362377|NCT02043925|DRUG|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
219362378|NCT03655834|DRUG|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
219362379|NCT00270608|PROCEDURE|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
219171744|NCT06504732|DRUG|IAH0968|Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
219171745|NCT05140148|DRUG|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
219171746|NCT05140148|DRUG|Placebo|placebo pills
219171747|NCT05041257|DRUG|Mirvetuximab soravtansine|Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
219171748|NCT05539352|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
219171749|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
219171750|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
219171751|NCT02206295|DRUG|selexipag|
219171752|NCT04537156|BIOLOGICAL|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219171753|NCT04537156|BIOLOGICAL|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
219171754|NCT06415422|BIOLOGICAL|Biological samples|Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
219171755|NCT05660746|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
219240637|NCT05127902|DIAGNOSTIC_TEST|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG\_max) for comparison with normalization signal processing program in Noraxon System."
219240638|NCT00424502|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
219240639|NCT00424502|DRUG|Methotrexate|10-25mg po/week
219240640|NCT06826326|DRUG|Escitalopram 10mg|oral administration of escitalopram 10 mg
219240641|NCT06826326|DRUG|Placebo|Placebo
219240642|NCT02010086|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
219240643|NCT02010086|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
219240644|NCT07008079|PROCEDURE|Flapless punch|use of flapless puch surgery to place dental implants
219240645|NCT07008079|PROCEDURE|Flapless mini-incision|Use of a flapless mini-incision to place a dental implant
219738219|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
219738220|NCT01872000|PROCEDURE|Cataract surgery|
219738221|NCT02163863|DEVICE|Femoropopliteal stenting|
219738222|NCT03066180|DEVICE|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
219738223|NCT00968630|OTHER|Laboratory Biomarker Analysis|Correlative studies
219738224|NCT00968630|PROCEDURE|Leukapheresis|Undergo leukapheresis
219738225|NCT05874011|OTHER|understanding of prosody|The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
219738226|NCT01728896|OTHER|Patient-controlled oral refeeding|
219738227|NCT03188380|DIAGNOSTIC_TEST|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
219738228|NCT03188380|DIAGNOSTIC_TEST|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
219738229|NCT04872647|BEHAVIORAL|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
219738230|NCT03397641|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
219738231|NCT03397641|OTHER|Placebo|Normal Saline
219738232|NCT01834378|BEHAVIORAL|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
219738233|NCT01834378|BEHAVIORAL|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
219738234|NCT06207019|DEVICE|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
219738235|NCT06569420|OTHER|Drug: Foritinib Succinate|SAF-189s: 160 mg QD, 21 days a cycle
219738236|NCT06569420|OTHER|Drug: Crizotinib|Crizotinib: 250 mg BID, 21 days a cycle
219738237|NCT06569966|BEHAVIORAL|preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
219738238|NCT06571318|OTHER|Destress and Perform Capsule-U001|Two Capsules in sequence daily after meal for 60 days.
219738239|NCT06571318|OTHER|Destress and Perform Capsule-I001|Two Capsules in sequence daily after meal for 60 days.
219738240|NCT06571318|OTHER|Placebo capsules 002|Two Capsules in sequence daily after meal for 60 days
219738241|NCT06569888|DEVICE|LIPUS stimulation|Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
219240646|NCT07008079|PROCEDURE|Conventional flap|Use of a conventional surgical flap to place a dental implant
219240647|NCT06870578|OTHER|Diet modification|In Study 2 only, children will be provided all meals for a 7-day period. Meals will consist of nutritious foods, calories provided will exceed the child's estimated daily caloric need, and children will be asked to consume meals ad libitum.
219240648|NCT04447586|OTHER|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
219240649|NCT04447586|OTHER|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
219240650|NCT05488002|BEHAVIORAL|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
219240651|NCT00711555|DRUG|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
219240652|NCT00466622|DRUG|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
219240653|NCT00466622|DRUG|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
219240654|NCT00470041|DRUG|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
219240655|NCT00801086|DRUG|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
219240656|NCT00801086|DRUG|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
219738242|NCT02155855|OTHER|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
219738243|NCT02155855|OTHER|Control|Routine care
219738244|NCT06570668|DRUG|CDD-2101|All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
219738245|NCT06571929|OTHER|INTERACT|INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
219738246|NCT06570837|DIETARY_SUPPLEMENT|Iron|observation effect of iron dificincy
219738247|NCT00283569|OTHER|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
219738248|NCT02402907|DEVICE|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
219738249|NCT02402907|DEVICE|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
219738250|NCT06570811|DRUG|Placebo|Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
219738251|NCT06570811|DRUG|Coenzyme Q10 200mg twice daily|400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
219738252|NCT04093882|DIAGNOSTIC_TEST|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
219738253|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
219738254|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
219738255|NCT02920294|DIETARY_SUPPLEMENT|Placebo|Acidified dairy drink without ferments
219738256|NCT03379493|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
219738257|NCT03570515|BEHAVIORAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
219240657|NCT04841811|DRUG|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
219240658|NCT04584359|OTHER|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
219240659|NCT04584359|OTHER|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
219240660|NCT04584359|OTHER|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
219240661|NCT06080919|DEVICE|Drug coated-balloon percutaneous coronary intervention.|Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.
219240662|NCT06080919|DEVICE|Angiography-derived coronary physiology (IMRangio)|Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
219240663|NCT01357447|DRUG|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
219240664|NCT01357447|DRUG|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
219240665|NCT00678132|DRUG|AZD 2281|
219240666|NCT00678132|DRUG|Cisplatin|
219240667|NCT00678132|DRUG|Gemcitabine|
219240668|NCT04049357|DEVICE|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
219240669|NCT03884075|DRUG|Semaglutide|Semaglutide injection once weekly
219240670|NCT06957496|OTHER|Allergenic extracts|In each subject, a drop of each of the 3 concentrations of the allergenic extract, in addition to the positive control (histamine) and the negative control, will be applied. The application will be duplicated on the subject's anterior forearm, with a distance of approximately 4 cm between each application to avoid overlapping reactions and false-positives results.
219240671|NCT06047080|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab
219240672|NCT06047080|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin in combination with R-CHP
219240673|NCT06047080|DRUG|Rituximab|Participants will receive IV rituximab
219240674|NCT06047080|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide as part of CHP chemotherapy
219240675|NCT06047080|DRUG|Doxorubicin|Participants will receive IV doxorubicin
219240676|NCT06047080|DRUG|Prednisone|Participants will receive oral prednisone as part of CHP chemotherapy
219240677|NCT06269640|DEVICE|Septal Scoring Along Midline Endocardium|Transcatheter ventricular myotomy called SEptal Scoring Along the Midline Endocardium (SESAME) that relies on intramyocardial guidewire navigation and transcatheter electrosurgery
219240678|NCT05878769|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W
219240679|NCT06052267|DRUG|TEV-56248|Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
219240680|NCT06052267|DRUG|Albuterol sulfate|Oral inhalation powder
219240681|NCT06830863|DRUG|ATR04-484|ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use
219240682|NCT06830863|DRUG|Vehicle|Topically applied vehicle.
219240683|NCT05588141|DRUG|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
219240684|NCT01234025|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
219240685|NCT01234025|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
219240686|NCT01234025|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
219240687|NCT01234025|DRUG|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
219240688|NCT01234025|DRUG|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
219362380|NCT00270608|PROCEDURE|MRI of the spine and the right knee|a single time 45 minutes procedure
219240689|NCT03803995|PROCEDURE|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
219240690|NCT03803995|PROCEDURE|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
219240691|NCT05058976|DRUG|Romosozumab|Monthly dose: 210 mg subcutaneous injection
219240692|NCT05058976|DRUG|Placebo|Monthly saline injection
219240693|NCT05058976|DRUG|Zoledronic acid|5 mg IV infusion at Month 12 Visit
219240694|NCT05058976|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
219240695|NCT05974410|DRUG|AVM0703|small molecule immunomodulatory drug
219240696|NCT05974410|DRUG|Hydrocortisone|physiologic circadian glucocorticoid
219240697|NCT05974410|DRUG|Proton pump inhibitor|
219240698|NCT05332236|DIAGNOSTIC_TEST|Parent-Adolescent Communication Scale (questionnaire)|Observational psychometric validation study
219240699|NCT04861259|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
219240700|NCT05593016|BEHAVIORAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
219240701|NCT05593016|BEHAVIORAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
219240702|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
219240703|NCT04914897|DRUG|THOR-707|Intravenous infusion: solution for infusion
219240704|NCT04914897|DRUG|Pembrolizumab|Intravenous infusion: solution for infusion
219240705|NCT05356130|BEHAVIORAL|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
219240706|NCT05356130|BEHAVIORAL|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
219240707|NCT05518903|PROCEDURE|Computed Tomography|Undergo CT
219240708|NCT05518903|DRUG|Gallium Ga 68 FAPi-46|Given IV
219240709|NCT05518903|PROCEDURE|Positron Emission Tomography|Undergo PET
219240710|NCT04705818|DRUG|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
219240711|NCT04705818|DRUG|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
219240712|NCT03141177|BIOLOGICAL|Nivolumab|Specified dose on specified day
219240713|NCT03141177|DRUG|Cabozantinib|Specified dose on specified days
219240714|NCT03141177|DRUG|Sunitinib|Specified dose on specified days.
219240715|NCT03141177|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219240716|NCT04098744|DRUG|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
219240717|NCT04098744|DRUG|Placebo vaginal insert|Placebo for artesunate vaginal inserts
219240718|NCT04798898|DEVICE|RFA (radiofrequency ablation)|Preoperative RFA-induced partial necrosis of the liver metastasis
219240719|NCT03178149|DRUG|ASP7317|subretinal injection
219240720|NCT03178149|DRUG|tacrolimus|oral
219240721|NCT03178149|DRUG|trimethoprim-sulfamethoxazole|oral
219240722|NCT03178149|DRUG|Acyclovir|oral
219240723|NCT03178149|DRUG|Nystatin|oral
219240724|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
219240725|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
219240726|NCT04630873|DRUG|Botulinum toxin|The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
219240727|NCT04630873|DIAGNOSTIC_TEST|gait analysis|The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
219240728|NCT03535376|DRUG|Valsartan|Patients are tested for their normal prescription valsartan medication
219240729|NCT06305416|DRUG|Ranibizumab 10mg/ml Injection|Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
219240730|NCT06305416|DRUG|Lucentis|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
219240731|NCT05569525|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
219240732|NCT04466345|BIOLOGICAL|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
219240733|NCT04466345|BIOLOGICAL|Placebo|Semaglutide placebo capsules
219240734|NCT05655715|RADIATION|Stereotactic body radiotherapy|8 Gray x 3
219738258|NCT03570515|BEHAVIORAL|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
219738259|NCT00449787|DRUG|Sumatriptan 100 mg|Sumatriptan 100mg tablet
219738260|NCT00449787|DRUG|Naproxen|Naproxen 500mg tablet
219240735|NCT05655715|DRUG|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
219240736|NCT05655715|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
219240737|NCT05655715|PROCEDURE|Biopsies|From soft tissue metastases.
219240738|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)
219240739|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
219240740|NCT02031055|DRUG|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
219240741|NCT05552326|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
219240742|NCT05552326|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
219240743|NCT06226545|DRUG|LASN01|Low dose of LASN01 will be administered intravenously.
219240744|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
219240745|NCT06226545|DRUG|Placebo|Placebo will be administered intravenously.
219240746|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
219240747|NCT05776979|DRUG|Isatuximab|Given by vein over about 75 minutes
219240748|NCT05776979|DRUG|lenalidomide|Given by PO
219240749|NCT02680314|DRUG|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
219738261|NCT00131742|DRUG|telbivudine|
219738262|NCT00131742|DRUG|lamivudine|
219738263|NCT03701074|DRUG|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
219738264|NCT03701074|DRUG|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
219738265|NCT00443014|DEVICE|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
219738266|NCT02852837|DRUG|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
219738267|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
219738268|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
219738269|NCT02317419|DRUG|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
219738270|NCT02317419|DRUG|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
219240750|NCT06720064|DEVICE|Chlorhexidine Dressing|Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
219240751|NCT06719908|DRUG|AFA-281 is a small molecule, orally available|This is a study to evaluate the interaction of AFA-281 with alcohol
219240752|NCT06719908|OTHER|Alcohol (Ethanol)|Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
219240753|NCT03020914|DEVICE|Audiovisual Distraction|watching a movie using video glasses and headphones
219240754|NCT03523897|PROCEDURE|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
219240755|NCT03523897|PROCEDURE|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
219738271|NCT00130390|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
219240756|NCT05066997|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
219240757|NCT05066997|DRUG|Vehicle|"Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
219240758|NCT06793722|PROCEDURE|Technological device in circumcision|Circumcision is performed by watching a video/playing a game during the procedure in children who are circumcised.
219738272|NCT00130390|OTHER|Placebo|One placebo tablet twice daily for 28 days
219738273|NCT03410745|BEHAVIORAL|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
219738274|NCT00019838|DRUG|7-hydroxystaurosporine|
219738275|NCT00019838|DRUG|fludarabine phosphate|
219738276|NCT03616093|OTHER|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
219738277|NCT03616093|OTHER|Placebo Beverage|Placebo supplement containing negligible nitrate
219738278|NCT02631785|OTHER|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
219240759|NCT05651607|DRUG|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
219240760|NCT04789096|DRUG|Tucatinib|Oral tablet
219240761|NCT04789096|DRUG|Pembrolizumab|Intravenous
219240762|NCT04789096|DRUG|Trastuzumab|Intravenous
219240763|NCT04789096|DRUG|Capecitabine|Oral tablet
219240764|NCT03188887|DRUG|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
219240765|NCT03188887|DRUG|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
219240766|NCT05349123|BEHAVIORAL|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
219240767|NCT05349123|BEHAVIORAL|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
219240768|NCT03968276|OTHER|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
219240769|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox]|
219240770|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
219240771|NCT04339543|OTHER|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
219240772|NCT01038206|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
219240773|NCT01671371|OTHER|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
219240774|NCT01364545|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
219240775|NCT01364545|DIETARY_SUPPLEMENT|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
219240776|NCT04127695|DRUG|ABBV-0805|ABBV-0805 administered by IV infusion.
219240777|NCT04127695|DRUG|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
219240778|NCT05644067|BIOLOGICAL|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
219240779|NCT05644067|BIOLOGICAL|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
219240780|NCT00409006|DRUG|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
219240781|NCT00409006|DRUG|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
219738279|NCT01423084|BIOLOGICAL|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
219738280|NCT01141764|PROCEDURE|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
219738281|NCT01141764|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
219738282|NCT01141764|OTHER|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
219240782|NCT00409006|DRUG|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
219240783|NCT01732055|BEHAVIORAL|Partner-Assisted Interpersonal Psychotherapy|
219240784|NCT01732055|OTHER|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
219240785|NCT00695149|PROCEDURE|Transplantation of bone marrow stromal cell|
219240786|NCT02652299|BIOLOGICAL|Synovial biopsy|Synovial tissue for analysis and biobank.
219240787|NCT01631318|PROCEDURE|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
219240788|NCT01631318|DEVICE|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
219240789|NCT01631318|DEVICE|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
219240790|NCT01631318|DRUG|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
219240791|NCT03533803|DRUG|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
219240792|NCT03533803|PROCEDURE|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
219240793|NCT04851444|DRUG|SI-F019|Single dose is administered IV.
219240794|NCT00228813|DRUG|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
219240795|NCT02615041|DRUG|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
219240796|NCT02615041|DRUG|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
219240797|NCT02615041|DRUG|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
219240798|NCT03769129|DRUG|Pembrolizumab|Pembrolizumab
219240799|NCT03769129|PROCEDURE|microwave ablation|microwave ablation
219240800|NCT02155218|OTHER|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
219240801|NCT02155218|OTHER|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
219240802|NCT02155218|OTHER|gadolinium contrast|
219240803|NCT01564134|BIOLOGICAL|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
219240804|NCT05450705|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
219362381|NCT00270608|PROCEDURE|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
219362382|NCT01133145|PROCEDURE|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
219362383|NCT02452333|PROCEDURE|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
219171756|NCT05660746|DRUG|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
219171757|NCT06489548|DRUG|Foralumab TZLS-401 50 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
219171758|NCT06489548|DRUG|Foralumab TZLS-401 100 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
219171759|NCT03289403|DRUG|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment."
219171760|NCT03289403|DRUG|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"
219171761|NCT03781128|DRUG|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
219171762|NCT03781128|DRUG|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
219240805|NCT03261713|DEVICE|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
219738283|NCT05497245|OTHER|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
219171763|NCT04696952|DRUG|TS-142|TS-142
219738284|NCT02695771|DRUG|Mitomycin C|Cancer chemotherapeutic agent
219738285|NCT02695771|DRUG|Gemcitabine|Cancer chemotherapeutic agent
219738286|NCT00656695|DRUG|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
219738287|NCT00656695|DRUG|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
219738288|NCT02758028|BEHAVIORAL|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
219738289|NCT00396370|BIOLOGICAL|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
219171764|NCT04696952|DRUG|Zopiclone|Zopiclone
219171765|NCT04696952|DRUG|Placebo|Placebo
219171766|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
219171767|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
219171768|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
219171769|NCT04974541|OTHER|Heart Health Yoga|Yoga-based digital intervention
219171770|NCT04974541|OTHER|Psychosocial education|Standard psychosocial education component
219171771|NCT04090736|DRUG|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
219171772|NCT04090736|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
219171773|NCT02207062|DRUG|Ibrutinib|Given PO
219171774|NCT02207062|OTHER|Laboratory Biomarker Analysis|Correlative studies
219171775|NCT04805333|DRUG|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
219171776|NCT04805333|DRUG|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
219171777|NCT04805333|DRUG|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
219171778|NCT04805333|DRUG|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
219171779|NCT04805333|DRUG|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
219171780|NCT04302168|DIETARY_SUPPLEMENT|Choline supplement|Choline 470mg twice daily for 8 weeks.
219171781|NCT04302168|DIETARY_SUPPLEMENT|Placebo|Placebo pill twice daily for 8 weeks
219240806|NCT03261713|DEVICE|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
219240807|NCT05693480|DEVICE|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
219240808|NCT02001389|DRUG|EVP-6308|Arms 1, 2, 3, 4
219240809|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
219240810|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
219240811|NCT02367664|BIOLOGICAL|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
219240812|NCT01246232|DRUG|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
219240813|NCT01246232|DRUG|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
219240814|NCT05618509|DEVICE|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
219240815|NCT05618509|OTHER|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
219240816|NCT05618509|OTHER|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
219240817|NCT05618509|DEVICE|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
219240818|NCT05995340|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
219240819|NCT05995340|OTHER|Saline Active Control|Intradermal Injections
219240820|NCT02162823|PROCEDURE|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
219240821|NCT05049174|BEHAVIORAL|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
219240822|NCT04102605|DEVICE|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
219240823|NCT04102605|DEVICE|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
219240824|NCT05001802|PROCEDURE|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
219240825|NCT05001802|PROCEDURE|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
219240826|NCT02518802|DRUG|Gefitinib|Gefitinib 250mg per day for 2 years.
219240827|NCT02518802|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
219240828|NCT00540800|DRUG|docetaxel|given in combination with epirubicin or capecitabine
219240829|NCT00540800|DRUG|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
219240830|NCT00540800|DRUG|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
219362384|NCT02452333|PROCEDURE|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
219240831|NCT00958971|DRUG|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
219240832|NCT00668746|DRUG|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
219240833|NCT03362294|DRUG|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
219240834|NCT03362294|DRUG|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
219240835|NCT02109172|DRUG|TD-4208|
219240836|NCT02109172|DRUG|Placebo|
219240837|NCT02011568|OTHER|Therapeutic Hypothermia|
219240838|NCT03539237|OTHER|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
219240839|NCT03591263|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
219240840|NCT05725447|OTHER|Validity and reliability study|Face-to-face questionnaire study
219240841|NCT01918852|DRUG|Capecitabine|
219240842|NCT01918852|DRUG|Teysuno|
219240843|NCT01918852|DRUG|Bevacizumab|
219240844|NCT03536637|DRUG|DMT310|Topical Powder
219240845|NCT03536637|DRUG|Hydrogen Peroxide|Liquid Diluent
219240846|NCT03536637|DRUG|Placebo|Placebo Topical Powder
219240847|NCT00368823|DEVICE|Electronic point-of-care delivery system|
219240848|NCT03867656|OTHER|GLP-2|GLP-2 injection
219240849|NCT03867656|OTHER|GIP|GIP injection
219240850|NCT03867656|OTHER|Placebo|Placebo injection
219240851|NCT01906073|DRUG|intranasal fentanyl spray|
219240852|NCT01906073|DRUG|slow release morphine|
219240853|NCT02232009|DEVICE|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
219240854|NCT04184609|OTHER|Control|In this condition, the participants will not receive any medications or drugs before exercise
219240855|NCT04184609|DRUG|Albuterol|180 mcg of Albuterol will be administered before exercise
219240856|NCT00164021|PROCEDURE|Physiotherapy, exercise, percutaneous gastrostomy feeds|
219240857|NCT00164021|DRUG|Anti-reflux pharmacotherapy|
219240858|NCT00674791|BIOLOGICAL|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
219240859|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
219240860|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
219240861|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
219240862|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
219240863|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
219240864|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
219240865|NCT01469442|PROCEDURE|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
219240866|NCT01107717|DRUG|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
219240867|NCT01107717|DRUG|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
219240868|NCT01242345|DEVICE|Capnography|Monitoring of the capnography curve for early detection of apnea
219240869|NCT02645578|DEVICE|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
219240870|NCT03696342|DRUG|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
219240871|NCT03696342|DRUG|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
219240872|NCT03131271|OTHER|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
219240873|NCT02962622|OTHER|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
219240874|NCT01125956|BEHAVIORAL|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
219240875|NCT01125956|BEHAVIORAL|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
219240876|NCT03875794|OTHER|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
219240877|NCT03371849|DRUG|montelukast and levocetirizine FDC|HCP1102
219240878|NCT03371849|DRUG|Singulair + xyzal|HGP0813 + HGP1408
219738290|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
219738291|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
219738292|NCT00396370|OTHER|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
219738293|NCT00396370|OTHER|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
219738294|NCT03602495|DRUG|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
219738295|NCT03602495|DRUG|Placebo|Matching placebo Bid orally, continuously.
219240879|NCT02187120|DRUG|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
219240880|NCT02187120|DRUG|Placebo|
219240881|NCT00310024|DRUG|bortezomib|Given IV
219240882|NCT00310024|DRUG|vorinostat|Given orally
219240883|NCT00310024|OTHER|laboratory biomarker analysis|Correlative studies
219240884|NCT00310024|OTHER|pharmacological study|Correlative studies
219240885|NCT02823171|DRUG|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
219240886|NCT02823171|DRUG|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
219738296|NCT00661687|DEVICE|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
219738297|NCT00661687|DEVICE|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
219738298|NCT05388968|BIOLOGICAL|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
219240887|NCT01461434|DEVICE|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
219240888|NCT05340426|DEVICE|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
219240889|NCT04726319|OTHER|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
219240890|NCT04077437|BEHAVIORAL|Therapy|Standardized non-directive therapy performed by therapist team.
219240891|NCT04077437|DRUG|Midomafetamine|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
219240892|NCT04077437|DRUG|Placebo|Administration of placebo with therapy during three experimental sessions
219240893|NCT05361304|DEVICE|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
219240894|NCT05361304|DEVICE|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
219240895|NCT00781209|PROCEDURE|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
219240896|NCT02877745|OTHER|Stratification, no intervention|
219240897|NCT03456830|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
219240898|NCT03456830|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
219240899|NCT03754686|DRUG|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
219240900|NCT03754686|DRUG|Paracetamol|Best medical care and oral paracetamol twice daily for five days
219240901|NCT01816165|DRUG|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
219240902|NCT01816165|DRUG|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
219240903|NCT05798754|PROCEDURE|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
219240904|NCT05798754|DEVICE|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
219240905|NCT02469493|DEVICE|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
219240906|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
219240907|NCT06049758|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
219240908|NCT06049758|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
219240909|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
219240910|NCT01746199|DRUG|cotrimoxazole daily prophylaxis|
219240911|NCT01746199|DRUG|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
219240912|NCT05716971|PROCEDURE|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
219240913|NCT05974371|OTHER|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
219240914|NCT02797795|DRUG|NEV801|Dose Escalation
219240915|NCT04914520|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
219240916|NCT04914520|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
219240917|NCT01560962|DRUG|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
219240918|NCT01560962|OTHER|No Intervention|
219240919|NCT01560962|DRUG|Azithromycin|
219240920|NCT01560962|DRUG|tobramycin-dexmethasone|
219240921|NCT01560962|OTHER|warm soaked eyelid wash|
219240922|NCT02898350|DEVICE|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
219240923|NCT02898350|DEVICE|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
219240924|NCT02898350|DEVICE|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
219240925|NCT02898350|DEVICE|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
219240926|NCT02956915|PROCEDURE|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
219240927|NCT00600223|BEHAVIORAL|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
219240928|NCT01469429|OTHER|placebo|Receive lozenge placebo PO
219240929|NCT01469429|OTHER|laboratory biomarker analysis|Correlative studies
219240930|NCT01469429|OTHER|questionnaire administration|Ancillary studies
219240931|NCT01469429|DRUG|chemoprevention|Receive LBR lozenge PO
219240932|NCT01469429|DRUG|chemoprevention|Receive LBR Saliva Substitute PO
219240933|NCT01469429|OTHER|placebo|Receive Saliva Substitute placebo PO
219240934|NCT04038723|BEHAVIORAL|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
219240935|NCT02409732|DRUG|aminolevulinic acid hydrochloride|
219240936|NCT02409732|PROCEDURE|Photodynamic therapy with blue light|
219240937|NCT03364556|OTHER|No intervention|
219240938|NCT04884282|DRUG|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
219240939|NCT04884282|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
219240940|NCT04884282|DRUG|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
219240941|NCT01233193|BEHAVIORAL|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
219240942|NCT05884671|DRUG|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
219240943|NCT05884671|DRUG|Placebo|All participants will receive placebo during one of the sessions.
219240944|NCT01167816|DRUG|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
219240945|NCT05234476|BEHAVIORAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
219240946|NCT05234476|BEHAVIORAL|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
219240947|NCT01982266|DEVICE|GRADION™ Hip Total Cartilage Replacement (TCR)™|
219240948|NCT01810640|PROCEDURE|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
219240949|NCT02099656|DRUG|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
219240950|NCT02099656|DRUG|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
219240951|NCT02099656|DRUG|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
219240952|NCT02099656|DRUG|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
219240953|NCT02478762|PROCEDURE|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
219240954|NCT02478762|PROCEDURE|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
219240955|NCT02829099|DRUG|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
219240956|NCT05285696|DRUG|CSB-111|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
219240957|NCT05579587|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
219240958|NCT00376259|DRUG|telbivudine|600mg/day oral tablet for 96 weeks
219240959|NCT00376259|DRUG|adefovir dipivoxil|10 mg of adefovir by mouth once daily
219240960|NCT05953818|DIAGNOSTIC_TEST|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
219240961|NCT00002401|DRUG|Indinavir sulfate|
219240962|NCT00002401|DRUG|Delavirdine mesylate|
219240963|NCT00002401|DRUG|Lamivudine|
219240964|NCT00002401|DRUG|Zidovudine|
219240965|NCT05423171|OTHER|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
219240966|NCT00841165|DEVICE|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
219240967|NCT00841165|DEVICE|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
219240968|NCT02376322|RADIATION|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
219240969|NCT01877720|DEVICE|noninvasive respiratory support with NAVA mode and PSV|
219240970|NCT02331771|DRUG|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
219240971|NCT02331771|DRUG|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
219240972|NCT04283396|COMBINATION_PRODUCT|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
219240973|NCT03331276|OTHER|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
219240974|NCT03331276|OTHER|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
219240975|NCT04667442|DIAGNOSTIC_TEST|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
219240976|NCT01084408|DEVICE|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
219240977|NCT01084408|DEVICE|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
219240978|NCT00447499|DRUG|Somatuline Autogel (lanreotide acetate)|Injections
219240979|NCT00447499|BEHAVIORAL|Home administration|Questionnaire
219240980|NCT01325519|OTHER|video decision aid|video
219240981|NCT01286870|DEVICE|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
219240982|NCT01286870|DEVICE|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
219240983|NCT02068352|DRUG|OPA-15406|OPA-15406 topical ointment
219240984|NCT02068352|DRUG|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
219240985|NCT05465499|PROCEDURE|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
219240986|NCT04891536|PROCEDURE|Salvage cryoablation of the prostate (SCAP)|Cryotherapy of the prostate through transperineal freeezing needles
219240987|NCT04967092|DRUG|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
219240988|NCT04967092|OTHER|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
219240989|NCT00079599|DRUG|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
219240990|NCT00079599|OTHER|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
219240991|NCT00841945|DRUG|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
219240992|NCT00841945|DRUG|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
219240993|NCT00841945|DRUG|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
219240994|NCT00841945|DRUG|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
219240995|NCT00841945|PROCEDURE|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
219240996|NCT06963281|DRUG|IBI3020|Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection
219240997|NCT03960437|DRUG|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
219240998|NCT01732419|BEHAVIORAL|Home-based training|Home-based exercise training for cardiac patients.
219240999|NCT01732419|BEHAVIORAL|Centre-based training|Usual exercise training in an outpatient setting.
219241000|NCT00249847|DRUG|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
219241001|NCT00249847|DRUG|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
219241002|NCT05893693|OTHER|Biological|CT0594CP
219241003|NCT00073788|PROCEDURE|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
219241004|NCT02332096|DEVICE|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
219241005|NCT02320045|DRUG|ITCA 650 (Exenatide in osmotic mini pump)|
219241006|NCT00473512|DRUG|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
219241007|NCT00473512|DRUG|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
219241008|NCT00473512|DRUG|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
219241009|NCT01598688|OTHER|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
219362385|NCT02452333|OTHER|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
219241010|NCT01598688|OTHER|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
219241011|NCT02551471|OTHER|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
219241012|NCT02551471|OTHER|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
219241013|NCT02551471|OTHER|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
219241014|NCT05280522|OTHER|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
219241015|NCT05280522|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
219241016|NCT05280522|DEVICE|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
219241017|NCT03809858|OTHER|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
219241018|NCT05686343|DIAGNOSTIC_TEST|Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy|Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
219241019|NCT03239171|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
219241020|NCT03239171|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
219241021|NCT02519829|PROCEDURE|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
219241022|NCT02519829|PROCEDURE|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
219241023|NCT02519829|PROCEDURE|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
219241024|NCT02519829|PROCEDURE|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
219241025|NCT06027424|OTHER||observational study, no intervention
219241026|NCT02665806|DRUG|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
219241027|NCT02665806|DRUG|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
219241028|NCT03924596|DRUG|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
219241029|NCT03924596|DRUG|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
219241030|NCT00267956|DRUG|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
219241031|NCT00267956|DRUG|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
219241032|NCT05121649|OTHER|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
219241033|NCT05569265|PROCEDURE|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
219241034|NCT00494416|OTHER|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
219241035|NCT01262794|BIOLOGICAL|CDP6038|100 mg/mL solution for injection, single dose
219241036|NCT01262794|BIOLOGICAL|Placebo|0.9% sodium chloride for injection Single-dose
219241037|NCT05082441|DRUG|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
219241038|NCT05082441|DRUG|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
219241039|NCT05906056|DEVICE|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
219241040|NCT05906056|OTHER|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
219241041|NCT05906056|DRUG|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
219241042|NCT01495754|OTHER|coffee|Comparison of different amounts of coffee
219241043|NCT00847847|PROCEDURE|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
219241044|NCT02705456|PROCEDURE|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
219241045|NCT02705456|PROCEDURE|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
219241046|NCT02637362|PROCEDURE|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
219241047|NCT02637362|PROCEDURE|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
219738299|NCT05388968|DIAGNOSTIC_TEST|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
219738300|NCT03574389|BIOLOGICAL|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
219738301|NCT03574389|BIOLOGICAL|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
219738302|NCT06316765|PROCEDURE|Intubation with stylet|The cohort of premature infants was intubated with stylet.
219738303|NCT00921544|OTHER|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
219738304|NCT00921544|OTHER|Sterile water|Sterile water administered 2 mins prior to eye exam
219738305|NCT04628052|PROCEDURE|Colonoscopy|Music vs. No-Music
219738306|NCT02715856|OTHER|Monitoring Device|Undergo surgical wound and physical activity monitoring
219738307|NCT02715856|OTHER|Physical Activity Measurement|Undergo physical activity measurement
219738308|NCT02715856|OTHER|Quality-of-Life Assessment|Ancillary studies
219738309|NCT02715856|OTHER|Questionnaire Administration|Ancillary studies
219241048|NCT02637362|PROCEDURE|Metatarsal block|A metatarsal block will be performed using a standardised technique
219241049|NCT02637362|PROCEDURE|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
219241050|NCT01844362|PROCEDURE|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
219241051|NCT02246647|DIAGNOSTIC_TEST|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
219241052|NCT02246647|PROCEDURE|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
219241053|NCT02246647|PROCEDURE|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
219241054|NCT00026078|DRUG|docetaxel|
219241055|NCT00026078|DRUG|ifosfamide|
219241056|NCT05807555|OTHER|Ambulatory ECG|24h ECG monitoring
219241057|NCT05807555|BIOLOGICAL|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
219241058|NCT03869411|BEHAVIORAL|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
219241059|NCT06537570|BEHAVIORAL|Guided Imagery Practice|"Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up."
219241060|NCT04597047|DIAGNOSTIC_TEST|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
219241061|NCT04597047|DIAGNOSTIC_TEST|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
219241062|NCT00195416|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
219241063|NCT01621087|OTHER|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
219241064|NCT06095752|OTHER|blood viscosity , albumin / fibrinogen ratio and red cell distribution|In multiple myeloma patients ,we get blood viscosity , albumin / fibrinogen ratio and red cell distribution directly after confirmed diagnosis to determine the prognosis of the disease in association with these tests results
219241065|NCT05667688|DRUG|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
219241066|NCT00005843|DRUG|tipifarnib|
219241067|NCT00095251|DRUG|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
219241068|NCT00095251|DRUG|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
219241069|NCT03144076|OTHER|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
219241070|NCT04983147|OTHER|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
219241071|NCT04983147|OTHER|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
219241072|NCT01012999|DRUG|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
219738310|NCT02715856|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
219738311|NCT02715856|OTHER|Survey Administration|Ancillary studies
219738312|NCT05227365|DEVICE|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
219738313|NCT02729012|DRUG|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
219738314|NCT02729012|OTHER|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
219738315|NCT06244823|DRUG|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
219241073|NCT01852851|BEHAVIORAL|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
219241074|NCT04712786|OTHER|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
219241075|NCT00648271|DRUG|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
219241076|NCT00648271|DRUG|Lopressor® Tablets 50 mg|1x50mg, single dose fed
219241077|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
219241078|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
219241079|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
219241080|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
219241081|NCT03557307|BIOLOGICAL|Benralizumab|Benralizumab subcutaneous injection
219241082|NCT01737034|OTHER|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
219241083|NCT03043950|DRUG|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
219241084|NCT03937076|PROCEDURE|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
219241085|NCT01037829|OTHER|Non-intervention observational study|Non-intervention observational study
219241086|NCT01509599|PROCEDURE|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
219241087|NCT01509599|PROCEDURE|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
219241088|NCT04158453|DRUG|AUT00201|Oral dose of AUT00201
219241089|NCT04158453|DRUG|Placebo|Oral dose of placebo
219241090|NCT03425045|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
219241091|NCT03425045|PROCEDURE|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
219241092|NCT03425045|DRUG|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
219241093|NCT06136325|PROCEDURE|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
219241094|NCT05229848|PROCEDURE|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
219241095|NCT05229848|PROCEDURE|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
219362386|NCT02452333|OTHER|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
219362387|NCT02441361|OTHER|Exercise training|Exercise training will comprise aerobic and strength exercises
219362388|NCT06412692|OTHER|The Motivational Interviewing Technique|Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
219738316|NCT04551586|DRUG|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
219738317|NCT04551586|DRUG|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
219738318|NCT01177306|DRUG|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
219738319|NCT02206438|DEVICE|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
219738320|NCT02206438|DEVICE|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
219241096|NCT02430935|BEHAVIORAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
219241097|NCT02430935|BEHAVIORAL|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
219241098|NCT04013347|PROCEDURE|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
219241099|NCT03852381|DEVICE|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
219241100|NCT05935683|OTHER|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
219241101|NCT03278808|DRUG|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
219241102|NCT03278808|DRUG|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
219241103|NCT03278808|DRUG|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
219241104|NCT00977340|BEHAVIORAL|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
219241105|NCT00977340|BEHAVIORAL|confrontation|Confrontation
219241106|NCT00977340|BEHAVIORAL|imagination|Imagination
219241107|NCT01665014|RADIATION|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
219241108|NCT00516178|DRUG|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
219241109|NCT00516178|DRUG|Saline|3 infusions, perioperative or post-PTCA
219241110|NCT00010322|DRUG|atamestane|
219241111|NCT00010322|DRUG|toremifene|
219241112|NCT03227432|DRUG|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
219241113|NCT03227432|DRUG|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
219241114|NCT03227432|DRUG|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
219241115|NCT03227432|DRUG|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
219241116|NCT02069366|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.
219241117|NCT02069366|DRUG|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
219241118|NCT01840696|DRUG|Regadenoson|Vasodilator stress testing
219241119|NCT00483171|DRUG|CP-945,598|CP-945,598
219241120|NCT00483171|BEHAVIORAL|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
219241121|NCT00483171|BEHAVIORAL|Low Calorie Diet|Low calorie diet
219241122|NCT04092699|DEVICE|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
219241123|NCT01378533|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
219241124|NCT06199050|OTHER|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
219241125|NCT06199050|OTHER|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
219241126|NCT06199050|OTHER|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
219241127|NCT06199050|OTHER|General questions|"* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline"
219241128|NCT06199050|OTHER|Clinical data collected|"Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
219362389|NCT00022074|DRUG|gabapentin|
219241129|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
219241130|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
219241131|NCT04624854|DRUG|Clopidogrel and aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
219241132|NCT04624854|DRUG|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
219241133|NCT06639074|PROCEDURE|Biopsy|Undergo biopsy
219241134|NCT06639074|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219241135|NCT06639074|PROCEDURE|Computed Tomography|Undergo CT
219241136|NCT06639074|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
219241137|NCT06639074|PROCEDURE|Leukapheresis|Undergo leukapheresis
219241138|NCT06639074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219241139|NCT06639074|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
219241140|NCT06639074|DRUG|Placebo Administration|Given ID
219241141|NCT06639074|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Given IM
219241142|NCT06460155|DEVICE|3 methods intervention|Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
219241143|NCT06281808|DEVICE|Photon Counting Detector CT|Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
219241144|NCT02256553|BIOLOGICAL|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
219241145|NCT02256553|BIOLOGICAL|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
219241146|NCT02256553|DRUG|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
219241147|NCT00003634|BIOLOGICAL|oregovomab|
219241148|NCT03436797|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
219241149|NCT02936609|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
219241150|NCT02955225|DEVICE|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
219241151|NCT02955225|DEVICE|Passive shoe insole|A deactivated insole measures shoe pressure only.
219241152|NCT00275418|DRUG|beta carotene from Dunaliella algae|
219241153|NCT00241475|DRUG|Gefitinib|
219241154|NCT05224596|DIAGNOSTIC_TEST|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
219241155|NCT03985228|DIETARY_SUPPLEMENT|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
219241156|NCT03985228|DIETARY_SUPPLEMENT|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
219738321|NCT01623427|PROCEDURE|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
219738322|NCT01623427|PROCEDURE|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
219738323|NCT01242384|DEVICE|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
219738324|NCT03379584|DRUG|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
219738325|NCT02462057|OTHER|Email message regarding the HealthyFood benefit|
219738326|NCT04582487|OTHER|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
219738327|NCT01682603|DRUG|Botulinum toxin A|BoNT-A (BOTOX 300U)
219738328|NCT02944045|DRUG|Methylprednisolone|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
219738329|NCT02944045|DRUG|Placebo|saline serum
219738330|NCT03382860|DIAGNOSTIC_TEST|Fundus videos|Recordings of fundus videos
219738331|NCT02336555|DRUG|MK-8291|MK-8291 oral tablets
219738332|NCT02336555|DRUG|Placebo|Placebo oral tablets
219738333|NCT00078195|BIOLOGICAL|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
219738334|NCT00078195|BIOLOGICAL|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
219738335|NCT00078195|BIOLOGICAL|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
219738336|NCT00078195|BIOLOGICAL|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
219738337|NCT00078195|BIOLOGICAL|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
219738338|NCT00078195|BIOLOGICAL|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
219241157|NCT01951105|DRUG|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
219241158|NCT01951105|DRUG|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
219241159|NCT01951105|DRUG|Placebo|Take two placebo capsules three times a day for 12 weeks.
219241160|NCT00427544|DRUG|PRA-027|
219241161|NCT05394727|DEVICE|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.
219241162|NCT05394727|DEVICE|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
219241163|NCT01601821|DRUG|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
219241164|NCT01601821|DRUG|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
219362390|NCT00022074|PROCEDURE|quality-of-life assessment|
219738339|NCT03333889|OTHER|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
219738340|NCT03333889|OTHER|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
219738341|NCT00993473|DRUG|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%."
219738342|NCT00993473|DRUG|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
219738343|NCT00993473|DRUG|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
219738344|NCT02363426|DEVICE|INVOcell Culture Device|INVOcell is a vaginal culture device
219738345|NCT02363426|DEVICE|IVF Incubation|IVF Incubator
219738346|NCT03258229|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
219738347|NCT03258229|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 weeks
219738348|NCT06323083|OTHER|Emotional Freedom Technique|Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
219738349|NCT01202357|BEHAVIORAL|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
219738350|NCT05752838|OTHER|No intervention|This is a survey study, and there were no intervention
219738351|NCT00900042|GENETIC|DNA ploidy analysis|
219738352|NCT00900042|GENETIC|DNA stability analysis|
219738353|NCT00900042|GENETIC|chromosomal translocation analysis|
219738354|NCT00900042|GENETIC|cytogenetic analysis|
219738355|NCT00900042|OTHER|flow cytometry|
219738356|NCT00900042|OTHER|laboratory biomarker analysis|
219738357|NCT05308459|BEHAVIORAL|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~1. A local health profile is conducted among all students~2. Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~3. A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~4. The activities are implemented~5. A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
219738358|NCT01235637|DRUG|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
219738359|NCT01235637|DRUG|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
219738360|NCT03609944|PROCEDURE|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
219738361|NCT03609944|PROCEDURE|EUS|Endoscopic ultrasound
219738362|NCT03863301|RADIATION|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
219738363|NCT01772693|DEVICE|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
219738364|NCT01772693|DEVICE|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
219241165|NCT05943379|DRUG|RC48-ADC in Combination with gemcitabine|RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
219241166|NCT02177058|OTHER|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
219241167|NCT02177058|OTHER|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
219241168|NCT05340439|DRUG|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
219241169|NCT04034602|OTHER|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
219241170|NCT04034602|OTHER|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
219241171|NCT06150222|OTHER|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
219241172|NCT00887471|PROCEDURE|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
219241173|NCT03322475|DEVICE|PiQo4 laser system|The PiQo4 laser system
219241174|NCT04391218|OTHER|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
219241175|NCT04130373|PROCEDURE|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
219241176|NCT04130373|PROCEDURE|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
219241177|NCT06351917|DRUG|PlexoZome® Levagen® topical spray solution|PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump
219241178|NCT06351917|DRUG|Placebo topical spray solution|Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
219241179|NCT00616395|DEVICE|No intervention|
219241180|NCT06435221|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
219241181|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
219241182|NCT06550024|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
219241183|NCT06550024|DRUG|Corticosteroid Injection|Corticosteroid injection in the knee
219241184|NCT02469155|DRUG|ITI-007|
219738365|NCT04872946|DIETARY_SUPPLEMENT|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
219738366|NCT04872946|OTHER|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
219743654|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
219241185|NCT02469155|DRUG|Risperidone|
219241186|NCT02469155|DRUG|Placebo|
219241187|NCT06451224|OTHER|Questionnaire|Online Questionnaire
219241188|NCT05780034|DRUG|AC676|AC676 will be given orally (PO) on a 28-day cycle.
219241189|NCT05755490|BEHAVIORAL|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
219241190|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
219241191|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
219241192|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
219241193|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
219241194|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
219241195|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
219241196|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
219241197|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
219241198|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
219241199|NCT06510374|DRUG|Nadofaragene Firadenovec|Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
219241200|NCT03490006|PROCEDURE|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
219241201|NCT03490006|PROCEDURE|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
219241202|NCT00442559|DRUG|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
219241203|NCT00442559|DRUG|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
219241204|NCT02267122|PROCEDURE|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
219241205|NCT02267122|PROCEDURE|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
219241206|NCT01318356|BEHAVIORAL|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
219241207|NCT01318356|DRUG|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
219241208|NCT01318356|DRUG|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
219241209|NCT05780957|OTHER|MCED|multi-cancer early detection (MCED) test
219241210|NCT02617459|DRUG|Levobetaxolol eye drops|one drop per time; twice daily
219241211|NCT02617459|DRUG|Betaxolol eye drops|one drop per time; twice daily
219241212|NCT02699619|DEVICE|Pinloc|3 hook pins interlocked in plate.
219241213|NCT02699619|DEVICE|2 Hansson pins|2 isolated hook pins.(Without plate)
219241214|NCT01597856|BEHAVIORAL|SBIRT|"SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback."
219241215|NCT01508117|DRUG|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
219241216|NCT01508117|RADIATION|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
219241217|NCT05270096|OTHER|Advice|non-interventional study
219241218|NCT00933634|PROCEDURE|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
219241219|NCT00933634|DRUG|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
219241220|NCT00731913|OTHER|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
219241221|NCT02846142|DRUG|PTI-428|
219241222|NCT02846142|OTHER|Placebo|
219241223|NCT02846142|DRUG|ethinyl estradiol and levonorgestrel|
219241224|NCT04463004|DRUG|Mavrilimumab|Treatment infusion
219241225|NCT04463004|DRUG|Placebos|Placebo infusion
219241226|NCT03677856|PROCEDURE|Paravertebral blockade|Type of anaesthesia
219241227|NCT03677856|PROCEDURE|Thoracic epidural block|Type of anaesthesia
219241228|NCT01912521|BEHAVIORAL|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
219241229|NCT02913898|BEHAVIORAL|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
219241230|NCT02913898|BEHAVIORAL|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
219241231|NCT01625494|DRUG|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
219241232|NCT01625494|DRUG|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
219241233|NCT01625494|DRUG|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
219241234|NCT01625494|DRUG|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
219241235|NCT00765791|PROCEDURE|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
219241236|NCT00765791|PROCEDURE|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
219241237|NCT04182451|DEVICE|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
219241238|NCT01474265|DRUG|Varenicline|0.5-2 mg per day, oral use
219241239|NCT01474265|DRUG|Placebo|1-2 tablets per day, oral use
219241240|NCT01474265|DRUG|Nicorette TX|10-15 mg per day, transdermal use (patches)
219241241|NCT03137732|DEVICE|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
219241242|NCT02604199|DRUG|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
219241243|NCT02604199|OTHER|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
219241244|NCT02604199|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
219241245|NCT02604199|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
219171782|NCT05145283|DRUG|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
219171783|NCT05145283|DRUG|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
219241246|NCT02604199|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
219241247|NCT00749840|BEHAVIORAL|Questionnaire|Questionnaire taking 60-90 minutes.
219241248|NCT05614141|DEVICE|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
219738367|NCT04872946|OTHER|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
219738368|NCT05572632|BEHAVIORAL|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (\~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
219738369|NCT05572632|BEHAVIORAL|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
219738370|NCT05572632|BEHAVIORAL|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
219738371|NCT01927848|DIETARY_SUPPLEMENT|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
219738372|NCT01927848|DIETARY_SUPPLEMENT|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
219738373|NCT02704377|OTHER|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
219738374|NCT02704377|PROCEDURE|Dual X-ray Absorptiometry|Undergo iDXA
219738375|NCT02704377|OTHER|Laboratory Biomarker Analysis|Correlative studies
219738376|NCT02704377|OTHER|Quality-of-Life Assessment|Ancillary studies
219738377|NCT02704377|OTHER|Questionnaire Administration|Ancillary studies
219738378|NCT02115971|OTHER|Jumping exercise|Total 120min exercise
219738379|NCT02115971|OTHER|Strength exercise|Total 120 min exercise
219738380|NCT01633112|DRUG|fingolimod|capsule
219738381|NCT01633112|DRUG|glatiramer acetate|subcutaneous injection
219738382|NCT01959919|DEVICE|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
219738383|NCT01908699|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
219738384|NCT01908699|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
219738385|NCT01816399|PROCEDURE|Routine coronary angiography|
219738386|NCT01697501|OTHER|Interleukin 28B testing|Blood sampling for IL28B genotyping
219738387|NCT01783808|OTHER|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
219738388|NCT02944331|PROCEDURE|Endovenous steam ablation|
219743655|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
219241249|NCT05614141|OTHER|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
219241250|NCT02812706|DRUG|Isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
219241251|NCT03834909|DRUG|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
219241252|NCT03834909|DRUG|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
219241253|NCT03500796|PROCEDURE|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
219241254|NCT03500796|PROCEDURE|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
219241255|NCT01276080|DRUG|Donepezil|10 mg tablets
219241256|NCT01315418|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
219241257|NCT01315418|OTHER|2-Non fermented dairy product (control)|
219241258|NCT03785041|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
219241259|NCT04150419|OTHER|Group 1|Attentional training to avoid threatening, negative or pain-related information.
219241260|NCT04150419|OTHER|Group 2|Attention training for vigilance for positive emotional information.
219241261|NCT04150419|OTHER|Group 3 (control group)|Neutral attentional training (control group).
219241262|NCT01532830|DEVICE|n-VNS|
219241263|NCT02961283|DRUG|ASN003 ascending doses|
219241264|NCT02961283|DRUG|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
219241265|NCT00101062|DRUG|celecoxib|
219241266|NCT00101062|DRUG|letrozole|
219241267|NCT04247256|DRUG|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
219241268|NCT04247256|DRUG|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
219241269|NCT02465632|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
219241270|NCT02465632|DRUG|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
219241271|NCT02465632|DRUG|Placebo|
219241272|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fed state
219241273|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fasted state
219241274|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as oral solution
219241275|NCT05989243|DEVICE|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
219241276|NCT05989243|DEVICE|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
219241277|NCT03014024|OTHER|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
219241278|NCT03014024|OTHER|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
219241279|NCT05428215|DRUG|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
219241280|NCT06646146|PROCEDURE|Fat grafting combine with hair transplantation|Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
219241281|NCT06646146|PROCEDURE|Hair transplantation|Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
219241282|NCT01648491|PROCEDURE|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
219241283|NCT01648491|BIOLOGICAL|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
219241284|NCT06155123|DRUG|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
219241285|NCT04135872|OTHER|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
219241286|NCT00481156|BEHAVIORAL|Cognitive Remediation|
219241287|NCT00481156|BEHAVIORAL|Cognitive Behavioral Social Skills Training|
219241288|NCT00481156|OTHER|Retest in Health Controls|Pre/Post test performance and neuroimaging only
219241289|NCT01403922|DRUG|TC-5214|Tablet oral bid days 1 to 7
219241290|NCT01403922|DRUG|TC-5214|Tablet oral bid days 8 to 14
219241291|NCT02299011|DEVICE|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
219241292|NCT02299011|DRUG|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
219241293|NCT00004578|DRUG|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
219241294|NCT00004578|DRUG|Lamivudine|150 mg, every 12 hours
219241295|NCT00004578|DRUG|Stavudine|40 mg every 12 hours
219241296|NCT00005971|DRUG|alvocidib|
219241297|NCT02784145|DIETARY_SUPPLEMENT|Resistant starch|
219241298|NCT02784145|OTHER|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
219241299|NCT06119802|DIAGNOSTIC_TEST|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
219241300|NCT06169878|DEVICE|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
219241301|NCT01349699|DRUG|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
219241302|NCT01349699|DRUG|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
219241303|NCT01349699|DRUG|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
219241304|NCT01349699|DRUG|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
219241305|NCT01116830|DRUG|Placebo|Orally daily for 6 weeks
219241306|NCT01116830|DRUG|RO4917838|10 mg daily orally for 6 weeks
219241307|NCT01116830|DRUG|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
219241308|NCT01717755|OTHER|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
219241309|NCT04485793|DIETARY_SUPPLEMENT|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
219241310|NCT04485793|OTHER|Placebo|Oral administration: 1 tablet/day at evening meal
219241311|NCT02042170|DRUG|human growth hormone self-injection|
219241312|NCT00687128|BEHAVIORAL|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
219241313|NCT00687128|BEHAVIORAL|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
219241314|NCT00687128|BEHAVIORAL|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
219241315|NCT02232958|OTHER|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
219241316|NCT05968898|DEVICE|Optellum Virtual Nodule Clinic|The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
219241317|NCT04362176|BIOLOGICAL|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
219241318|NCT04362176|BIOLOGICAL|Placebo|Lactated Ringer's solution with multivitamins
219241319|NCT06266494|DEVICE|Long-Acting silver dressings|Mepilex Transfer Ag
219241320|NCT06266494|OTHER|Aloe Vera|Dermaid Aloe Vera
219241321|NCT06266494|DRUG|Dalbavancin|1500mg IV dose
219241322|NCT00742560|BIOLOGICAL|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
219241323|NCT00742560|DRUG|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
219241324|NCT00742560|DRUG|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
219241325|NCT00742560|DRUG|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
219241326|NCT01426217|DEVICE|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
219241327|NCT03223935|OTHER|Corn nuts|Roasted corn nut snack
219241328|NCT03223935|OTHER|Chickpeas|Roasted chickpea snack
219241329|NCT03223935|OTHER|Yellow peas|Roasted yellow pea snack
219241330|NCT03223935|OTHER|Pinto beans|Roasted pinto bean snack
219241331|NCT03223935|OTHER|Soybeans|Roasted soybean snack
219241332|NCT03223935|OTHER|Almonds|Roasted almond snack
219241333|NCT04928235|DIAGNOSTIC_TEST|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
219241334|NCT06203717|DEVICE|Alpha-Stim AID cranial electrotherapy stimulation|Cranial electrotherapy stimulation using a modified square, bipolar waveform of 0.5 Hz at 100 μA to be used for four weeks on off-duty days.
219241335|NCT00768911|DRUG|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
219241336|NCT00768911|DRUG|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
219241337|NCT00768911|PROCEDURE|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
219241338|NCT04057677|BEHAVIORAL|Bed Rest Intervention|The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.
219241339|NCT04057677|BEHAVIORAL|Exercise Program|During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.
219241340|NCT00582985|DRUG|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
219241341|NCT01812837|DEVICE|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
219241342|NCT01812837|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
219241343|NCT01812837|RADIATION|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
219241344|NCT04889833|BEHAVIORAL|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
219241345|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
219241346|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
219241347|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
219241348|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
219241349|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
219241350|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
219241351|NCT05834829|DEVICE|Low-intensity focused ultrasound neuromodulation|ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.
219241352|NCT05834829|DEVICE|Sham Low-intensity focused ultrasound|sham application of ultrasound using blocking of the ultrasound waves of the transducer.
219241353|NCT05008224|BIOLOGICAL|Pembrolizumab|"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
219241354|NCT05008224|DRUG|Doxorubicin|"25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age)."
219241355|NCT05008224|DRUG|Vinblastine|6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
219241356|NCT05008224|DRUG|Dacarbazine|375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
219241357|NCT05008224|DRUG|Bleomycin|10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219241358|NCT05008224|DRUG|Etoposide|200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219241359|NCT05008224|DRUG|Cyclophosphamide|1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219241360|NCT05008224|DRUG|Vincristine|1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219738389|NCT04846946|BEHAVIORAL|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
219738390|NCT06154525|OTHER|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
219738391|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
219738392|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
219738393|NCT04635774|DRUG|Insulin|40 IU via four activations of an intranasal spray
219738394|NCT04635774|DRUG|Saline|Four activations of an intranasal spray containing placebo (normal saline).
219738395|NCT03439072|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
219738396|NCT03439072|DRUG|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
219738397|NCT02525432|BIOLOGICAL|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
219738398|NCT02525432|BIOLOGICAL|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
219738399|NCT02985944|PROCEDURE|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
219738400|NCT03497702|DRUG|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
219738401|NCT03497702|DRUG|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
219738402|NCT03497702|DRUG|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
219738403|NCT03497702|DRUG|Letrozole|2.5 mg once daily preoperably
219738404|NCT03497702|DRUG|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
219738405|NCT06232954|DEVICE|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
219738406|NCT06232954|DEVICE|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
219738407|NCT00253955|DRUG|Levofloxacin|
219738408|NCT00253955|DRUG|Piperacillin/Tazobactam|
219738409|NCT01951729|DRUG|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
219738410|NCT01951729|DRUG|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
219241361|NCT05008224|DRUG|Procarbazine|100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219241362|NCT05008224|DRUG|Prednisone|40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
219241363|NCT05302063|DEVICE|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
219241364|NCT05897450|OTHER|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
219241365|NCT05897450|OTHER|Local anesthetic infiltration|Local anesthetic infiltration was applied to the trocar sites with the same volume.
219241366|NCT04298125|BEHAVIORAL|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
219241367|NCT01303341|OTHER|Laboratory Biomarker Analysis|Correlative studies
219241368|NCT01303341|OTHER|Pharmacological Study|Correlative studies
219241369|NCT01303341|DRUG|Riluzole|Given PO
219241370|NCT01303341|DRUG|Sorafenib Tosylate|Given PO
219241371|NCT06443099|OTHER|Different methods used after intramuscular injection|Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
219241372|NCT05234632|DEVICE|PICO 14 single-use Negative Pressure Wound Therapy System|The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
219241373|NCT03347084|DEVICE|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
219241374|NCT03347084|DEVICE|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
219241375|NCT03970304|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
219241376|NCT05770570|BEHAVIORAL|Counseling|In-person individual diet and physical activity (PA) counseling
219241377|NCT05770570|BEHAVIORAL|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
219241378|NCT05770570|BEHAVIORAL|Phone calls|Weekly telephone support
219241379|NCT05770570|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools
219241380|NCT04889924|RADIATION|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
219241381|NCT04889924|PROCEDURE|Lymphadenectomy|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
219241382|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
219241383|NCT02262832|DRUG|Metreleptin|administered subcutaneously 1-2 times/day
219241384|NCT06286618|BEHAVIORAL|Psychosocial Intervention|Psychosocial intervention is an intensive behavioral therapy intervention to address dietary behaviors. Each intervention session is a one-on-one interaction that focuses on setting individualized dietary goals and following up on them and is delivered by trained personnel. Sessions are delivered in 3 modalities which include face-to-face, phone call, and telehealth delivery. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Face-to-face; Telehealth; Phone Call 2) Telehealth; Phone Call; Face-to-face 3) Phone call; Face-to-face; Telehealth.
219241385|NCT06286618|OTHER|Structural Intervention|The structural intervention is designed to supplement the diet with food resources via three modalities: voucher-based or F/V prescription, home meal delivery, or food bank box program. The voucher-based model includes a weekly $50 gift card with a prescription for having to eat more fruits and vegetables. The home meal delivery model includes a meal subscription that supplements the diet with two meals for two people each week (four total servings worth $65 including shipping). The food bank box program consists of participants picking up a box of food weekly from a food pantry located in the outpatient clinic. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Voucher; Meal Delivery; Food Box 2) Meal Delivery; Food Box; Voucher 3) Food Box; Voucher; Meal Delivery.
219241386|NCT06286618|OTHER|Traditional Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in a referral-based fashion in which participants will receive referral at enrollment visit.
219241387|NCT06286618|OTHER|Integrated Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in an integrated fashion in which participants will receive immediate onboard at enrollment visit.
219241388|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
219241389|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
219241390|NCT06312618|DRUG|Propofol|"After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) ."
219241391|NCT06312618|DRUG|Dexmedetomidine|After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
219241392|NCT00658632|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
219241393|NCT00658632|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
219241394|NCT06007430|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
219241395|NCT06007430|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
219241396|NCT06321302|DRUG|BI 764524|BI 764524
219241397|NCT06321302|DRUG|Sham comparator to BI 764524|Sham comparator to BI 764524
219241398|NCT06321302|DRUG|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
219241399|NCT06554223|BEHAVIORAL|SUSTAIN-DSD|"Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months."
219241400|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|"As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate."
219241401|NCT05712356|DRUG|certepetide|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
219241402|NCT05712356|DRUG|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
219241403|NCT05712356|DRUG|Cisplatin|cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
219241404|NCT05712356|DRUG|Gemcitabine|gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
219241405|NCT05712356|DRUG|FOLFOX regimen|"The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)"
219241406|NCT05712356|DRUG|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
219241407|NCT06349642|PROCEDURE|Biospecimen Collection|Undergo optional research blood sample.
219241408|NCT06349642|PROCEDURE|Tissue Collection|Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\&#39;t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.
219241409|NCT04501614|DRUG|Ponatinib|Ponatinib tablets.
219241410|NCT04501614|DRUG|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
219241411|NCT01524211|DEVICE|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
219241412|NCT01524211|DEVICE|Terumo Arch Branch|The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
219241413|NCT04610294|DEVICE|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
219241414|NCT04610294|DEVICE|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
219241415|NCT01202344|OTHER|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
219241416|NCT04623398|DRUG|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
219241417|NCT04623398|DRUG|Placebo|Placebo
219241418|NCT05269212|OTHER|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
219241419|NCT05269212|OTHER|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
219241420|NCT06963775|DEVICE|Delphi-MD device (QuantalX Neuroscience Ltd., Saba Israel)|"Delphi-MD utilizes the use of transcranial magnetic stimulation evoked electroencephalography (TMS-EEG) for diagnostic purposes in a wide range of neurological disorders. Delphi-MD includes a magnetic stimulator and coil, an EEG amplifier and electrode cap and software for the acquisition and analysis of the data.~Delphi-MD stimulation protocol includes low intensities (sub motor thresholds) and frequencies over six stimulation sites (bilateral primary motor cortex, and bilateral dorsolateral prefrontal cortex)."
219241421|NCT01293500|PROCEDURE|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
219241422|NCT05527405|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available through tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified structure and the Caregiver Training Program.~The MHS is a general wellness product. This functionality is not a regulated medical device."
219241423|NCT06671938|DRUG|exidavnemab|The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
219241424|NCT06671938|DRUG|Placebo Comparator|The trial medication will be administered as an intravenous (IV) infusion
219241425|NCT05555550|DRUG|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
219241426|NCT04877821|DRUG|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
219241427|NCT04877821|DRUG|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
219241428|NCT04877821|DRUG|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
219241429|NCT04877821|DRUG|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
219241430|NCT04877821|DRUG|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
219241431|NCT04877821|DRUG|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
219241432|NCT02534649|PROCEDURE|Newly obtained biopsy and Blood samples collection|"For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
219241433|NCT06229977|DRUG|Palmitoylethanolamide (PEA)|Participants will receive PEA at a dose of 600mg twice daily for 6 weeks.
219241434|NCT06229977|DRUG|Placebo|Participants will receive placebo (a tablet that contains no active ingredient) to be taken twice daily for 6 weeks
219241435|NCT06229977|DRUG|Treatment as Usual (TAU)|subjects will receive a mood stabilizer per usual care
219241436|NCT05487131|BEHAVIORAL|electrical stimulation|different types of weak electrical stimulation will be used
219241437|NCT06843564|OTHER|Remote Enhanced Assessment for Care at Home (REACH) Kit|"Families of 6 month old infants will receive tele-device kits that include thermometers, pulse oximeters, and tele-otoscopes and respiratory swab tests, which families will then have the option to use when they schedule telemedicine visits with their usual primary care practice.~Note that the investigators are not studying the devices themselves; the investigators are instead studying health care use and experiences when these devices are made available."
219241438|NCT06400511|DRUG|Pimecrolimus 0.3% Ophthalmic Ointment|Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
219241439|NCT06400511|DRUG|Placebo Ophthalmic Ointment|Placebo will be applied twice a day to both eyelid margins.
219241440|NCT05486819|DRUG|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
219241441|NCT06153355|DRUG|LY3839840|Administered orally.
219241442|NCT06153355|DRUG|Placebo|Administered orally.
219241443|NCT06153355|DRUG|Midazolam|Administered orally
219241444|NCT05361954|DRUG|STI-1386|Second generation oncolytic virus
219241445|NCT03800602|DRUG|Metformin|Given PO
219241446|NCT03800602|BIOLOGICAL|Nivolumab|Given IV
219241447|NCT02900937|DEVICE|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
219241448|NCT05904704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219241449|NCT05904704|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
219241450|NCT04819204|DRUG|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
219241451|NCT04819204|DRUG|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
219241452|NCT02264444|OTHER|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
219241453|NCT02991456|DRUG|Rolapitant|single 180 mg dose by mouth
219241454|NCT02991456|DRUG|Ondansetron|8 mg by mouth daily
219241455|NCT04420351|DRUG|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
219241456|NCT04420351|DRUG|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
219241457|NCT02255526|DEVICE|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
219241458|NCT06318364|OTHER|NO Intervention|NO Intervention
219241459|NCT06970366|OTHER|Cold pack application|Cold pack application
219241460|NCT06970366|OTHER|Cold spray application|Cold spray application
219241461|NCT03266419|DRUG|Deep NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
219241462|NCT03266419|DRUG|Moderate NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
219241463|NCT02327442|RADIATION|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
219738411|NCT01951729|DRUG|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
219738412|NCT01951729|DRUG|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
219738413|NCT01951729|DRUG|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
219738414|NCT01951729|DRUG|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
219738415|NCT01951729|DRUG|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
219738416|NCT01951729|DRUG|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
219738417|NCT05206045|OTHER|Standard of care|Standard of care for patients with Sezary Syndrome
219738418|NCT05853939|DEVICE|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
219738419|NCT04867629|DIETARY_SUPPLEMENT|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
219738420|NCT04867629|DIETARY_SUPPLEMENT|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
219738421|NCT01212692|BEHAVIORAL|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
219738422|NCT04248673|OTHER|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
219738423|NCT04248673|OTHER|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
219241464|NCT00980616|DRUG|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
219241465|NCT00738400|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
219241466|NCT00738400|DRUG|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
219241467|NCT00508144|DRUG|Alimta|500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
219241468|NCT04346784|BEHAVIORAL|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
219241469|NCT04346784|BEHAVIORAL|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
219241470|NCT04346784|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
219241471|NCT04346784|BEHAVIORAL|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
219241472|NCT06501053|RADIATION|Radiotherapy|45/50 Gy (1.8/2 Gy/fraction/5 weeks)
219241473|NCT06501053|RADIATION|Short-course radiotherapy|25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days
219241474|NCT06501053|RADIATION|Contact x-ray brachytherapy|90Gy/3 fractions/4 weeks
219241475|NCT06501053|DRUG|Chemotherapy|Capecitabine (900 mg/m2 bid, on radiation days)
219738424|NCT06222957|OTHER|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
219738425|NCT03992872|BIOLOGICAL|Chikungunya|Virus Like Particle
219738426|NCT01940744|PROCEDURE|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
219738427|NCT01940744|PROCEDURE|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
219738428|NCT05299320|DIAGNOSTIC_TEST|Neuromuscular fatigue and postural sway evaluation|Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
219738429|NCT04007679|OTHER|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
219738430|NCT00370084|DRUG|Itopride|oral, three times daily
219738431|NCT00370084|OTHER|Placebo|oral, three times daily
219738432|NCT06438731|OTHER|BREAST MILK|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
219738433|NCT06438731|OTHER|KNITTED OCTOPUS|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
219738434|NCT01033669|DEVICE|CRC-749|There is no drug being used. This is a device.
219738435|NCT01033669|DEVICE|Diskus|There is no drug being used. This is a device.
219738436|NCT01033669|DEVICE|Twisthaler|There is no drug being used. This is a device.
219241476|NCT04267523|BEHAVIORAL|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
219738437|NCT01033669|DEVICE|Miat Monohaler|There is no drug being used. This is a device.
219738438|NCT05580679|OTHER|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
219738439|NCT03707821|DEVICE|senofilcon A TEST Lens|JJVC Investigational Contact Lens
219738440|NCT03707821|DEVICE|senofilcon A CONTROL Lens|Acuvue Oasys
219241477|NCT04267523|BEHAVIORAL|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
219241478|NCT00552591|BEHAVIORAL|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
219241479|NCT00100009|DRUG|TAC-PF|
219241480|NCT00100009|DRUG|Triamcinolone Acetonide|
219241481|NCT01383785|OTHER|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
219241482|NCT01383785|OTHER|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
219241483|NCT01383785|OTHER|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
219241484|NCT05735379|DRUG|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
219241485|NCT05823714|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
219241486|NCT03270098|BEHAVIORAL|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
219241487|NCT03270098|BEHAVIORAL|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
219241488|NCT05777772|BEHAVIORAL|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
219241489|NCT02731950|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
219241490|NCT04115670|BEHAVIORAL|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
219241491|NCT04115670|BEHAVIORAL|Control group|The control group will follow its normal course of activity
219241492|NCT01074281|DRUG|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
219241493|NCT00255749|BIOLOGICAL|epoetin alfa|
219241494|NCT03155035|DRUG|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
219241495|NCT03155035|DIETARY_SUPPLEMENT|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
219241496|NCT04023266|DRUG|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
219241497|NCT02223078|BIOLOGICAL|G17DT|
219241498|NCT02223078|BIOLOGICAL|Placebo Comparator|
219241499|NCT05545891|DRUG|Placebo|A drug that contains no medicine
219241500|NCT05545891|DRUG|Aripiprazole|Atypical antipsychotic medication
219241501|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
219241502|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
219241503|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
219241504|NCT06135311|DEVICE|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
219241505|NCT06135311|DEVICE|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
219241506|NCT04748861|OTHER|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
219241507|NCT05691595|OTHER|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
219241508|NCT05413759|OTHER|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
219241509|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
219241510|NCT06185075|PROCEDURE|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
219241511|NCT05386888|DRUG|GFH018|Administered as oral
219241512|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
219241513|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
219241514|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
219241515|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
219241516|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
219241517|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
219241518|NCT05386888|DRUG|GFH018|Administered as an IV infusion
219241519|NCT06650254|OTHER|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed."
219241520|NCT06811909|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method, which, briefly includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C, and electron beam sterilization.
219241521|NCT06811909|OTHER|Standard Care|"Standard Care is defined as:~* Sharp debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and~* The UrgoK2™ dual compression system providing around 40 mmHg."
219241522|NCT06325709|DRUG|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
219241523|NCT06325709|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
219241524|NCT06325709|DRUG|Palifermin|Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
219241525|NCT06325709|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
219241526|NCT06325709|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.
219241527|NCT06325709|DRUG|Sirolimus|Immunomodulating agent: Daily oral dosing beginning Day -1 for approximately 3 to 6 months to prevent an immune response to the protein expressed by the BE HSPCs.
219241528|NCT04774718|DRUG|Alectinib|Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
219362391|NCT02058732|OTHER|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
219362392|NCT05293730|BEHAVIORAL|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
219362393|NCT05293730|OTHER|Usual Care|Routine treatment in primary care
219241529|NCT03357120|OTHER|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
219241530|NCT04007744|BIOLOGICAL|Pembrolizumab|Given IV
219241531|NCT04007744|DRUG|Sonidegib|Given PO
219241532|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
219241533|NCT05040815|RADIATION|chemo-radiation treatment|Radiotherapy (RT) with concurrent 5-fluorouracil and mitomycin-C (5FU/MMC) combination is the treatment of choice for non-metastatic locally advanced anal squam
219241534|NCT05198934|DRUG|Sotorasib|Sotorasib will be administered orally
219241535|NCT05198934|DRUG|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
219241536|NCT05198934|DRUG|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
219241537|NCT05198934|DRUG|Regorafenib|Regorafenib will be administered orally
219241538|NCT05796752|DRUG|Memantine|Cognition-enhancing medication
219241539|NCT05796752|BEHAVIORAL|ComB Behavioral Therapy|Therapy for BFRBs
219241540|NCT06440759|DEVICE|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared."
219241541|NCT06440759|DEVICE|M100 filter|Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
219241542|NCT06696534|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
219241543|NCT06696534|OTHER|Survey using a questionnaire.|Experience questionnaire into colorectal cancer screening programme
219241544|NCT05999552|OTHER|Eye exercises|The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
219241545|NCT04258137|GENETIC|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
219241546|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
219241547|NCT05385523|PROCEDURE|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
219241548|NCT05385523|PROCEDURE|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
219241549|NCT05385523|DRUG|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
219241550|NCT05385523|DRUG|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
219241551|NCT05385523|DRUG|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
219241552|NCT05531526|DRUG|AR1001|AR1001 Active Oral Tablet
219241553|NCT05531526|DRUG|Placebo|Placebo Oral Tablet
219241554|NCT05159466|PROCEDURE|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
219241555|NCT06010303|DRUG|LBL-007|LBL-007 will be administered at a standard dose intravenously.
219241556|NCT06010303|DRUG|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
219241557|NCT06010303|DRUG|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
219241558|NCT06789692|OTHER|tobacco smoking substitution products|Offer of preference-based smoking substitution menu, consisting of e-cigarettes or nicotine pouches or nicotine patches in addition to standard of care. This menu will be offered by the treating physician during the routine cohort visit and the participant can choose one product to test as an alternative to tobacco smoking. The products will be handed out directly after the consultation and are provided free of charge for 6 months.
219241559|NCT06786325|DRUG|Psilocybin|PEX010 is the Psilocybin produced by Filament
219738441|NCT00003455|DRUG|antineoplaston A10|
219241560|NCT06787287|PROCEDURE|Modified compression method|In the experimental group, an improved compression method was adopted. A thick gauze block of 9cm\*16cm\*8mm was folded three times and placed at the puncture site of the patient's radial artery, and a spiral radial artery hemostatic device was placed above it. The control group was treated with traditional compression method, and the spiral radial artery hemostat was applied directly at the radial artery puncture
219241561|NCT02836899|DRUG|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
219241562|NCT02836899|OTHER|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
219241563|NCT05422794|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219241564|NCT05422794|PROCEDURE|Biopsy Procedure|Undergo biopsy
219241565|NCT05422794|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219241566|NCT05422794|PROCEDURE|Computed Tomography|Undergo CT
219241567|NCT05422794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219241568|NCT05422794|DRUG|Nab-paclitaxel|Given IV
219241569|NCT05422794|BIOLOGICAL|Pembrolizumab|Given IV
219241570|NCT05953389|DRUG|Pitolisant|histamine H3 receptor antagonist/inverse agonist
219241571|NCT05953389|DRUG|Placebo|Matching placebo of pitolisant tablets
219241572|NCT06092749|OTHER|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
219241573|NCT06092749|OTHER|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
219241574|NCT06444724|COMBINATION_PRODUCT|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
219241575|NCT05064826|OTHER|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
219241576|NCT06539884|OTHER|Observational|Evaluating whether the 2005 SIRS - Sepsis diagnostic and grading criteria, pSOFA, PRISM III and PELOD scores are compatible and to compare their prognostic predictive power.
219241577|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
219241578|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
219241579|NCT05675449|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219241580|NCT05675449|DRUG|Carfilzomib|proteasome inhibitor
219241581|NCT05675449|DRUG|Maplirpacept|CD47-SIRP alpha-directed
219241582|NCT05413304|DRUG|pre-operative abemaciclib|pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
219241583|NCT05413304|DEVICE|Device for Cerebral Fluid Dialysate Collection|post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
219241584|NCT05413304|DEVICE|Ashion Analytics GEM ExTra|resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
219241585|NCT05413304|DRUG|abemaciclib + temozolomide|abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
219241586|NCT06679140|DRUG|ibuzatrelvir|ibuzatrelvir tablets
219241587|NCT06679140|DRUG|placebo|placebo tablets
219738442|NCT00003455|DRUG|antineoplaston AS2-1|
219738443|NCT00003455|PROCEDURE|alternative product therapy|
219738444|NCT00003455|PROCEDURE|biological therapy|
219241588|NCT05285111|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
219241589|NCT05285111|BEHAVIORAL|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
219241590|NCT04273243|GENETIC|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219241591|NCT04958265|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
219241592|NCT06044870|PROCEDURE|Modified laterally stretched technique with a connective tissue graft.|Modified laterally stretched technique with a connective tissue graft.
219738445|NCT00003455|PROCEDURE|biologically based therapies|
219738446|NCT00003455|PROCEDURE|cancer prevention intervention|
219738447|NCT00003455|PROCEDURE|complementary and alternative therapy|
219738448|NCT00003455|PROCEDURE|differentiation therapy|
219738449|NCT04585581|BEHAVIORAL|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
219738450|NCT04585581|BEHAVIORAL|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
219738451|NCT04585581|OTHER|Standard Care|Standard clinical care
219738452|NCT00916916|OTHER|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
219738453|NCT00889005|OTHER|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
219241593|NCT05205746|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
219241594|NCT05205746|BIOLOGICAL|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
219241595|NCT05498337|OTHER|calcium hydroxide|Dental pulp medicament material
219241596|NCT05498337|OTHER|MTA|Dental pulp medicament material
219241597|NCT05498337|DEVICE|Diode Laser|Device used in pulp therapy
219241598|NCT01861938|BIOLOGICAL|Melanoma vaccine modified to express HLA A2/4-1BB ligand|This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be effective against the residual tumor that may still be present in the body.
219241599|NCT01791842|DRUG|Tocilizumab|8 mg/kg/month
219241600|NCT01791842|DRUG|Placebo|
219241601|NCT06845202|DRUG|ALN-4324|ALN-4324 will be administered subcutaneously (SC)
219241602|NCT06845202|DRUG|Placebo|Placebo will be administered SC
219241603|NCT05295290|DIAGNOSTIC_TEST|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
219241604|NCT05156580|OTHER|No intervention|This is an observational study without any intervention
219241605|NCT05927753|DEVICE|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
219241606|NCT03118050|BEHAVIORAL|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
219241607|NCT03118050|BEHAVIORAL|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
219241608|NCT03118050|BEHAVIORAL|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
219241609|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
219241610|NCT05018780|OTHER|Muscle Energy Technique|"Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
219362394|NCT06193473|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
219362395|NCT03968419|DRUG|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
219241611|NCT05018780|OTHER|Sacral Manipulation|"* To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
219241612|NCT03615950|DIAGNOSTIC_TEST|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
219241613|NCT03615950|DIAGNOSTIC_TEST|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
219241614|NCT03615950|DIAGNOSTIC_TEST|Height measurement|Height will be measured at baseline and 12 months.
219241615|NCT03615950|OTHER|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
219241616|NCT05837325|PROCEDURE|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
219241617|NCT05837325|PROCEDURE|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
219241618|NCT05837325|PROCEDURE|ICSI|One oocyte injected at a time.
219241619|NCT05837325|PROCEDURE|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
219241620|NCT05837325|GENETIC|Biopsy|One embryo per culture drop.
219241621|NCT05837325|PROCEDURE|Vitrification|One embryo per vitrification straw.
219241622|NCT05837325|PROCEDURE|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
219241623|NCT05837325|PROCEDURE|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
219241624|NCT03569644|OTHER|qualitative study|Interviews
219241625|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including STRIDE (Single Tremelimumab Regular Interval Durvalumab), will be collected).
219241626|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including durvalumab + chemotherapy combinations (e.g., Durvalumab + GemCis etc.) will be collected.
219241627|NCT04250259|DRUG|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
219241628|NCT04250259|DRUG|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
219241629|NCT05475925|DRUG|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
219241630|NCT06260774|DRUG|TTX-MC138|The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
219241631|NCT05242692|DRUG|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
219241632|NCT05242692|DRUG|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
219241633|NCT05031026|DRUG|Dexmedetomidine|dexmedetomidine infusion rule in prevention of IRI
219241634|NCT05031026|DRUG|Normal Saline|normal saline infusion as a placebo
219241635|NCT03957707|PROCEDURE|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
219241636|NCT05195593|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
219241637|NCT06664151|BIOLOGICAL|Fluzone Trivalent|Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
219241638|NCT05061004|DEVICE|Cephea Mitral Valve System|Transcatheter mitral valve replacement
219241639|NCT04305613|OTHER|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
219241640|NCT06364163|DIETARY_SUPPLEMENT|Herring oil concentrate|Capsules containing herring oil concentrate, taken daily for 8 weeks.
219241641|NCT06364163|DIETARY_SUPPLEMENT|Control|Capsules containing control oil, taken daily for 8 weeks.
219241642|NCT02216162|OTHER|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
219241643|NCT02216162|OTHER|No intervention|Usual clinical follow-up
219241644|NCT02337894|DIETARY_SUPPLEMENT|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
219241645|NCT02337894|DIETARY_SUPPLEMENT|Placebo|Flavored drink without essential amino acids plus arginine.
219241646|NCT02738294|DEVICE|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
219241647|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 1 session of neuro-reinforcement.
219241648|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 3 sessions of neuro-reinforcement.
219241649|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 5 sessions of neuro-reinforcement.
219241650|NCT04788615|DRUG|Ofatumumab|20mg Subcutaneous injection
219241651|NCT04788615|DRUG|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
219241652|NCT05755360|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
219241653|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
219241654|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
219241655|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
219241656|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
219241657|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
219241658|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
219241659|NCT04043403|DEVICE|Open Loop DBS|Standard DBS therapy at a constant frequency and voltage
219241660|NCT04043403|DEVICE|Adaptive (Closed Loop) DBS|DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
219241661|NCT04043403|DEVICE|Intermittent Open Loop DBS|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
219241662|NCT01971892|OTHER|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
219241663|NCT01971892|OTHER|Standard oxygen therapy with facial mask|facial Venturi mask
219241664|NCT05768139|DRUG|STX-478|STX-478 is a mutant-selective PI3Kα inhibitor
219241665|NCT05768139|DRUG|Fulvestrant|Fulvestrant
219241666|NCT05768139|DRUG|Ribociclib|Ribociclib
219241667|NCT05768139|DRUG|Palbociclib|Palbociclib
219241668|NCT05768139|DRUG|Letrozole|Letrozole
219241669|NCT05768139|DRUG|Anastrozole|Anastrozole
219241670|NCT05768139|DRUG|Exemestane|Exemestane
219241671|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 and 3 will use the DV3407 pen injector.
219241672|NCT06563882|OTHER|Home-based exercise program|"The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly."
219241673|NCT06563882|OTHER|No intervention|No intervention
219241674|NCT05381948|DRUG|EYP-1901|Intravitreal Injection
219241675|NCT05381948|DRUG|Aflibercept 2mg/0.05mL Inj,Oph|Intravitreal Injection
219241676|NCT06639594|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
219241677|NCT06418711|DRUG|Clofazimine Inhalation Suspension|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
219241678|NCT06418711|DRUG|Placebo|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
219241679|NCT04198428|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
219241680|NCT04396860|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
219241681|NCT04396860|BIOLOGICAL|Ipilimumab|Given IV
219241682|NCT04396860|BIOLOGICAL|Nivolumab|Given IV
219241683|NCT04396860|DEVICE|NovoTTF-100A Device|Wear Optune device
219241684|NCT04396860|OTHER|Quality-of-Life Assessment|Ancillary studies
219241685|NCT04396860|OTHER|Questionnaire Administration|Ancillary studies
219241686|NCT04396860|RADIATION|Radiation Therapy|Undergo radiation therapy
219241687|NCT04396860|DRUG|Temozolomide|Given PO
219241688|NCT03239899|DRUG|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
219241689|NCT04557735|DRUG|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
219241690|NCT04557735|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
219241691|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
219241692|NCT05357482|RADIATION|TBI|300 cGy total body irradiation (TBI, day -2)
219241693|NCT05357482|DRUG|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
219241694|NCT05357482|BIOLOGICAL|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
219241695|NCT05357482|DRUG|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
219241696|NCT05357482|DRUG|Sirolimus|For immune suppression (day -1)
219241697|NCT05357482|BIOLOGICAL|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
219241698|NCT05357482|DRUG|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
219241699|NCT06439121|PROCEDURE|4-7-8 Breathing Technique|Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
219241700|NCT05168423|DRUG|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
219241701|NCT04588233|DIETARY_SUPPLEMENT|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
219241702|NCT04588233|OTHER|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
219241703|NCT06182709|BEHAVIORAL|online psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video online. This will be followed by a modeled exposure online. In this modeled exposure participants watch a film of an exposure treatment (about 45min) conducted with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
219241704|NCT06182709|BEHAVIORAL|live psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video. This will be followed by a live modeled exposure. In this modeled exposure participants watch an exposure treatment (about 45min) conducted live with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
219241705|NCT06182709|BEHAVIORAL|group exposure|Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
219241706|NCT06182709|BEHAVIORAL|mental retrieval cue|Before the group exposure, participants are asked to remember the modeled exposure they had observed the day before. Therefore, the participants are asked to recall the location where they have been during the modeled exposure and the reaction of the patient during the exposure (e.g., fear decline).
219241707|NCT05483738|DIAGNOSTIC_TEST|Clinical assessment, blood samples, bone marrow and bone biopsy|Assessment of blood samples, bone marrow and bone biopsy
219241708|NCT05932615|DEVICE|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
219241709|NCT05932615|DEVICE|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
219241710|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
219241711|NCT04913259|OTHER|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
219241712|NCT06090162|DIAGNOSTIC_TEST|ctDNA detection|ctDNA detection on CSF and blood
219241713|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
219241714|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
219241715|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
219241716|NCT05355701|DRUG|PF-07799933|Tablet
219241717|NCT05355701|DRUG|binimetinib|Tablet
219241718|NCT05355701|BIOLOGICAL|cetuximab|Injection for intravenous use
219362396|NCT03968419|DRUG|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
219362397|NCT04886271|DRUG|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
219362398|NCT02151513|DEVICE|Intrathecal Pump Placement|
219241719|NCT04863729|BEHAVIORAL|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
219241720|NCT04649359|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
219241721|NCT05080673|PROCEDURE|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
219241722|NCT05535582|DIAGNOSTIC_TEST|Investigation of clinical, laboratory and imaging profile|Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.
219241723|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
219241724|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intravenously)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
219241725|NCT04908579|DRUG|bupivacaine(intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
219241726|NCT06495229|BIOLOGICAL|CM310|Interleukin-4 receptor(IL-4Rα) monoclonal antibody
219241727|NCT03334305|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
219241728|NCT03334305|DRUG|Dose-intensified TMZ|After chemoradiation, subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
219241729|NCT03334305|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Prior to chemoradiation, enrolled subjects will undergo a mobilized leukapheresis for collection of PBSCs and PBMCs for generation of DCs. One group will receive recommended dose of \> 2 x 106 CD34+ HSCs/kg. Subjects enrolled in Group B will receive HSCs during TMZ Cycle 6 before receiving DC vaccine and T-cell infusion.
219241730|NCT03334305|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 6 and with DC vaccine #8, an infusion of T-cells will be administered to all subjects.
219241731|NCT03334305|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
219241732|NCT04071236|DRUG|Avelumab|Given IV
219241733|NCT04071236|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219241734|NCT04071236|PROCEDURE|Bone Scan|Undergo bone scan
219241735|NCT04071236|PROCEDURE|Computed Tomography|Undergo CT
219241736|NCT04071236|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219241737|NCT04071236|DRUG|Peposertib|Given PO
219241738|NCT04071236|OTHER|Questionnaire Administration|Ancillary studies
219241739|NCT04071236|RADIATION|Radium Ra 223 Dichloride|Given IV
219241740|NCT04776655|DRUG|Bevacizumab|"This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
219241741|NCT04776655|DRUG|Cetuximab|"This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
219241742|NCT04776655|DRUG|5-FU|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
219241743|NCT04776655|DRUG|Irinotecan|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
219241744|NCT04776655|DRUG|Calcium levofolinate|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
219241745|NCT06216301|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.
219241746|NCT06216301|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
219241747|NCT06216301|DRUG|Platinum based chemotherapy|Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
219241748|NCT04816994|DRUG|Single-dose of cannabis oil|Single-dose of cannabis oil in order to treat acute radicular pain
219241749|NCT04816994|DRUG|Control|Giving a sub-linguistic olive oil that is similar in appearance and taste to cannabis oil
219241750|NCT05856526|DRUG|Spesolimab - solution for infusion|Solution for infusion
219241751|NCT05856526|DRUG|Placebo matching to spesolimab - solution for infusion|Solution for infusion
219241752|NCT05856526|DRUG|Spesolimab - solution for injection|Solution for injection
219241753|NCT05856526|DRUG|Placebo matching to spesolimab - solution for injection|Solution for injection
219241754|NCT06588686|DRUG|Buloxibutid|Buloxibutid
219241755|NCT06588686|DRUG|Placebo|Placebo
219241756|NCT02221700|PROCEDURE|Massage Therapy|Undergo massage therapy
219241757|NCT02221700|OTHER|Quality-of-Life Assessment|Ancillary studies
219241758|NCT02221700|OTHER|Questionnaire Administration|Ancillary studies
219241759|NCT06708299|DRUG|CardiolRx|The intervention will be administered orally (via syringe) with food twice daily.
219241760|NCT05676931|DRUG|Domvanalimab|Administered as specified in the treatment arm
219241761|NCT05676931|DRUG|Quemliclustat|Administered as specified in the treatment arm
219241762|NCT05676931|DRUG|Zimberelimab|Administered as specified in the treatment arm
219241763|NCT05676931|DRUG|Docetaxel|Administered as specified in the treatment arm
219241764|NCT05676931|DRUG|Platinum-Based Doublet|Administered as specified in the treatment arm
219241765|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
219241766|NCT02968069|DEVICE|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
219241767|NCT02019706|RADIATION|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
219241768|NCT02019706|RADIATION|F-DOPA PET CT|68Ga-DOTATATE PET/CT
219241769|NCT02019706|RADIATION|CT scan|routine CT scan
219241770|NCT02019706|DIAGNOSTIC_TEST|Routine MRI scan|routine 1.5 or 3T MRI scan
219241771|NCT02019706|DIAGNOSTIC_TEST|Gated MRI scan|Cardiac gated MRI scan
219241772|NCT02019706|DRUG|68Ga-DOTATATE|68Ga-DOTATATE radioligand
219241773|NCT02019706|DRUG|18F-DOPA|18F-DOPA radioligand
219241774|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
219241776|NCT04567303|DRUG|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
219241777|NCT04567303|DRUG|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
219241778|NCT04567303|DEVICE|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
219241779|NCT05117840|DEVICE|Low-dose CT scan|Standard of care screening for individuals at high-risk of lung cancer
219241780|NCT06440616|DEVICE|Spectral CT images generated by a photon counting CT scanner|The reading radiologist will in the experimental arm have access to spectral CT images in the form of low virtual monoenergetic images, virtual non-contrast images, iodine maps and effective atomic number. In the non-interventional arms the reading radiologist will only have access to conventional CT images.
219241781|NCT05090800|DRUG|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
219241782|NCT05676970|BEHAVIORAL|Telehealth: Personalized Preventative Medicine Strategies|Individuals in this arm will complete a personalized telehealth interventions that focus on nutrition, work-life balance, medication compliance, herbals, exercise targets hyperlipidemia, diabetes and hypertension around individual risks for development of the disease state. All educations will be completed one-on-one as well as small group.
219241783|NCT05676970|BEHAVIORAL|TeleHealth: Preventative Medicine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension general education. All educations will be completed one-on-one as well as small group.
219241784|NCT06466486|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
219241785|NCT06466486|DRUG|FE999302|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
219241786|NCT06466486|DRUG|FE999302 Placebo|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
219241787|NCT05921331|DEVICE|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
219241788|NCT05921331|OTHER|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
219241789|NCT04763980|OTHER|Educational Intervention|Participate in educational session with health coach
219241790|NCT04763980|OTHER|Genetic Testing|Undergo genetic testing
219241791|NCT04763980|OTHER|Survey Administration|Complete surveys throughout course of study.
219241792|NCT04763980|OTHER|ProGene Artificial Intelligence (AI) Platform|AI Platform to be used by health coach during sessions
219241793|NCT04763980|OTHER|Interviews|Participant and provider interviews will be conducted by study staff.
219241794|NCT05834725|BEHAVIORAL|Promoting Resilience in Stress Management|Resilience coaching program.
219241795|NCT05834725|OTHER|Usual Care|Combination of physical therapy, occupational therapy, and psychological counseling as recommended by the treating provider.
219241796|NCT04978558|OTHER|Continuous assessment of cerebrovascular autoregulation with NIRS and TCD|Continuous monitoring of MAP, cerebral oxygenation, and cerebral blood flow velocity before, during, and after surgery to calculate two cerebrovascular autoregulation indices Cox and Mx.
219241797|NCT01316250|DRUG|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
219241798|NCT05493891|OTHER|Visual analogue scale (VAS)|VAS is a reliable and valid method for assessing the intensity of low back pain (LBP)
219241799|NCT05493891|DEVICE|Pressure Biofeedback Unit (PBU)|PBU is a valid and reliable instrument for measuring the maximal voluntary isometric contraction of both lumbar multifidus and transversus abdominis muscles (core muscle strength)
219241800|NCT06182631|DEVICE|Buzzy Bee|The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.
219241801|NCT06182631|DRUG|Vapocoolent|Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
219241802|NCT06182631|OTHER|Placebo|A band will be placed on the arm before IV insertion for placebo effect.
219241803|NCT06178822|OTHER|No intervention|There is no intervention
219241804|NCT05543460|PROCEDURE|MARPE with Corticopunctures|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
219241805|NCT05543460|DEVICE|MARPE|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
219241806|NCT04751929|DRUG|Abemaciclib|Taken orally 2x daily
219241807|NCT04751929|DRUG|Atezolizumab|Intravenously Day 1 of 21 day cycle
219241808|NCT01993251|DRUG|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
219241809|NCT01993251|DRUG|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
219241810|NCT01993251|DRUG|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
219241811|NCT01993251|DRUG|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
219241812|NCT06961344|DRUG|zagociguat 15mg|once daily oral tablets
219241813|NCT05087849|BIOLOGICAL|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
219241814|NCT05873127|BEHAVIORAL|web-based guided self-help Enhanced Cognitive Behavioral therapy|The subjects would learn and practice CBT-E course through the online learning platform for 12 times, and were required to complete the course once a week.
219241815|NCT05873127|BEHAVIORAL|online Enhanced Cognitive Behavioral therapy|A closed structured group would be established by online video conference for group CBT-E therapy. Each group would receive 12 group sessions, once a week for 120 minutes each time. Each group would be led by two CBT therapists, all of whom are nationally registered psychotherapists with systematic professional training.
219241816|NCT05936944|OTHER|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
219241817|NCT05692180|DRUG|Benralizumab|Benralizumab active solution will be administered SC to the patients.
219241818|NCT05692180|DRUG|Placebo|Placebo solution will be administered SC to the patients.
219241819|NCT02225600|DRUG|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
219241820|NCT02225600|DRUG|Placebo|Intranasal Placebo
219241821|NCT02225600|DRUG|24 IU intranasal Oxytocin|
219241822|NCT06152575|DRUG|Elranatamab|Elranatamab will be administered subcutaneously
219241823|NCT06152575|DRUG|Elotuzumab|Elotuzumab will be administered intravenously
219241824|NCT06152575|DRUG|Pomalidomide|Pomalidomide will be administered orally
219241825|NCT06152575|DRUG|Dexamethasone|Dexamethasone will be administered orally
219241826|NCT06152575|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
219241827|NCT06152575|DRUG|Carfilzomib|Carfilzomib will be administered intravenously
219241828|NCT04093570|DRUG|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
219241829|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219241830|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
219241831|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
219241832|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
219241833|NCT04374305|DRUG|Brigatinib|Oral daily per predetermined dosage per protocol.
219241834|NCT04374305|DRUG|Neratinib|Oral daily per predetermined dosage per protocol.
219241835|NCT05967689|DRUG|TAS6417|Oral tablets
219241836|NCT05967689|DRUG|CYP Cocktail|Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
219241837|NCT05967689|DRUG|Transporter Cocktail|Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.
219241838|NCT03880422|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet plan
219241839|NCT03880422|OTHER|Educational Intervention|Attend educational meeting
219241840|NCT03880422|BEHAVIORAL|Exercise Intervention|Complete exercise program
219241841|NCT03880422|OTHER|Quality-of-Life Assessment|Ancillary studies
219241842|NCT03880422|OTHER|Survey Administration|Ancillary studies
219241843|NCT06641076|DRUG|Sonelokimab|Randomized treatment, parallel-group
219241844|NCT06641076|DRUG|Placebo|Randomized treatment, parallel-group
219241845|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
219241846|NCT03077178|PROCEDURE|Geriatric assessment|Geriatric assessment, questionnaire assessment
219241847|NCT05630209|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
219241848|NCT05630209|DRUG|Doxorubicin|Doxorubicin infusion
219241849|NCT05609539|DEVICE|Endovascular Aortic Repair (EVAR)|"Techniques for delivery and deployment of the standard device have been well described by different papers, but for the prototype some attention is required.~Once the device was advanced at the level of the lowest RA the C-Arm has been moved to correct the parallax effect and positioned orthogonally to the origin of the artery. This procedure permits perfectly matching the scallop with the artery takeoff.~A selective angiogram was performed to assure the patency of the lower RA. After the deployment of the main body proper iliac extensions were delivered to completely exclude the aneurysm as standard practice."
219171784|NCT06023693|BEHAVIORAL|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
219171785|NCT06023693|BEHAVIORAL|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
219171786|NCT06531681|DEVICE|MR-Linac|Radiation therapy with the MR-Linac
219171787|NCT05980936|OTHER|Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
219171788|NCT05991310|OTHER|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
219241850|NCT06513806|DRUG|Granisetron 1 Mg/mL Intravenous Solution|will receive granisetron 3 mg iv bolus
219241851|NCT06513806|DRUG|Pethidin|will receive pethidine 25 mg iv bolus
219738454|NCT04105283|BIOLOGICAL|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
219738455|NCT03452345|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
219738456|NCT03452345|DRUG|Placebo|Placebo (Normal saline)
219738457|NCT05507047|DRUG|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
219738458|NCT04935593|OTHER|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
219738459|NCT03482232|DRUG|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
219738460|NCT03482232|DRUG|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
219738461|NCT03482232|DRUG|paracetamol|paracetamol 1g for more than 3 days
219738462|NCT03482232|DRUG|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
219738463|NCT03482232|DRUG|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
219738464|NCT03482232|DIAGNOSTIC_TEST|Prostate cancer|Screening for prostate cancer in asymptomatic patients
219738465|NCT03482232|RADIATION|Lumbago|image tests in non-specific lumbago
219738466|NCT03482232|DRUG|Antimicrobial agent|antibiotics for pharyngitis (infants)
219738467|NCT03482232|DRUG|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
219738468|NCT03482232|DRUG|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
219738469|NCT01950494|OTHER|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
219738470|NCT05929911|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
219171789|NCT05991310|OTHER|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
219171790|NCT05033392|DRUG|Toripalimab Injection|A domestic PD-1 antibody
219171791|NCT05309447|OTHER|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
219171792|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
219171793|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
219171794|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
219171795|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
219171796|NCT04862780|DRUG|BLU-945|Oral administration
219171797|NCT04862780|DRUG|osimertinib|Osimertinib tablets for oral administration
219171798|NCT03439488|DRUG|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
219171799|NCT03439488|DRUG|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
219171800|NCT06029647|OTHER|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
219171801|NCT06029647|OTHER|vanilla wafers|vanilla wafers
219171802|NCT06482034|DRUG|N-acetyl cysteine|N-acetyl cysteine sachets
219171803|NCT06482034|DRUG|Zinc sulfate|zinc sulfate capsules
219171804|NCT06482034|DRUG|saline mouth wash|saline mouth wash
219241852|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
219241853|NCT04945707|DRUG|Placebo|Normal saline
219241854|NCT05195580|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
219241855|NCT05992298|OTHER|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
219241856|NCT05710783|BIOLOGICAL|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
219241857|NCT05710783|BIOLOGICAL|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
219241858|NCT05538325|DEVICE|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion of the lumbar spine
219241859|NCT06236451|DRUG|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
219241860|NCT06236451|DRUG|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
219241861|NCT06317636|DRUG|Ketamine|0.5 mg/kg ketamine infused intravenously over 40 minutes
219241862|NCT06317636|DRUG|Normal saline|0.9% normal saline infused intravenously over 40 minutes
219241863|NCT06032546|DRUG|Budigalimab|Intravenous (IV) Infusion
219241864|NCT06032546|DRUG|Placebo for Budigalimab|IV Infusion
219241865|NCT06032546|DRUG|ABBV-382|IV Infusion
219241866|NCT06032546|DRUG|Placebo for ABBV-382|IV Infusion
219241867|NCT06032546|DRUG|Budigalimab|Subcutaneous (SC) Injection
219241868|NCT04458779|DEVICE|CPAP|CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
219241869|NCT03138005|OTHER|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
219241870|NCT03138005|OTHER|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
219241871|NCT05834452|PROCEDURE|The Epley Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotated 90° towards the unaffected side around the yaw axis~4. Rotate a further 90° toward the unaffected side around the yaw axis~5. Rotates back to an upright position with a 135° backward rotation around the pitch axis."
219241872|NCT05834452|PROCEDURE|The 360 Degree Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotate a further 90° backward around the pitch axis (total 225°)~4. Rotate a further 90° backward around the pitch axis (total 315°)~5. Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
219241873|NCT05834452|DEVICE|Mechanical rotational chair|TRV chair
219241874|NCT06636383|OTHER|No Intervention|No investigational/study product will be administered in this DMP.
219241875|NCT05177068|DRUG|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA\<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
219241876|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
219241877|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
219241878|NCT05156398|DRUG|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
219241879|NCT05156398|DRUG|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
219241880|NCT04743141|DRUG|Rimegepant (PF-07899801)|Rimegepant 75 mg, 50 mg or 35 mg ODT
219241881|NCT06496568|DRUG|Inavolisib|Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
219241882|NCT06496568|DRUG|Atezolizumab|Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
219241883|NCT04008238|DRUG|Trabectedin|\- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
219241884|NCT06524830|DRUG|VLS-01-203 BU|VLS-01 buccal transmucosal administration
219241885|NCT06524830|DRUG|VLS-01-BU Placebo|Placebo buccal transmucosal administration
219241886|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219241887|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
219241888|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
219241889|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
219241890|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219241891|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
219241892|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
219241893|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 4.1 Usage|Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.
219241894|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
219241895|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 5.1 Usage|Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.
219241896|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 7|Participants will use their Placebo Control Form 7 as directed for a period of 6 weeks.
219241897|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.1 as directed for a period of 6 weeks.
219241898|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.2|Participants will use their Placebo Control 7.2 as directed for a period of 6 weeks.
219241899|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.2.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
219241900|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.3.0|Participants will use their Placebo Control 7.3 as directed for a period of 6 weeks.
219241901|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.3.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.3.1 as directed for a period of 6 weeks.
219241902|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.4.0|Participants will use their Placebo Control 7.4 as directed for a period of 6 weeks.
219738471|NCT06015334|PROCEDURE|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
219738472|NCT00003151|DIETARY_SUPPLEMENT|bismuth subcitrate|
219738473|NCT00003151|DRUG|amoxicillin|
219738474|NCT00003151|DRUG|clarithromycin|
219738475|NCT00003151|DRUG|metronidazole hydrochloride|
219738476|NCT00003151|DRUG|omeprazole|
219738477|NCT00003151|DRUG|tetracycline hydrochloride|
219738478|NCT00128492|DRUG|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
219738479|NCT05145894|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
219738480|NCT00612768|BIOLOGICAL|TRUE Test allergens Fragrance Mix and Thimerosol|"* Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
219738481|NCT04334811|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
219738482|NCT04720170|PROCEDURE|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
219738483|NCT02166762|PROCEDURE|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
219738484|NCT05960123|PROCEDURE|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
219738485|NCT03148782|BEHAVIORAL|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
219738486|NCT02822690|OTHER|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
219738487|NCT03476252|DIAGNOSTIC_TEST|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
219738488|NCT04629157|DEVICE|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
219738489|NCT04394000|OTHER|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
219738490|NCT04394000|OTHER|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
219738491|NCT05209737|PROCEDURE|Trendelenburg position|A 10-degree head-down position will be used in this group
219738492|NCT05209737|PROCEDURE|Semirecumbent position|A 30-degree head-up position will be used in this group
219738493|NCT00989443|DRUG|Cidofovir gel|topical gel applied once a week for 3 weeks
219738494|NCT05788354|PROCEDURE|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
219738495|NCT00894010|DRUG|carbamazepine 400mg|
219738496|NCT00894010|DRUG|levetiracetam 1000mg|
219241903|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.4.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.4.1 as directed for a period of 6 weeks.
219241904|NCT05718063|BEHAVIORAL|MAP for Coaches - Complete Course|The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.
219241905|NCT05718063|BEHAVIORAL|Map for Coaches - Overview|This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
219241906|NCT05879926|DRUG|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
219241907|NCT05879926|DRUG|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
219241908|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
219241909|NCT04543591|OTHER|Placebo|Matching placebo
219241910|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
219241911|NCT05648266|DRUG|Continous SAPB (Ropivacain)|postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
219241912|NCT05648266|OTHER|institutional standard of care pain medication protocol|institutional standard of care pain medication protocol
219241913|NCT06800157|DRUG|Drug: LW402|Oral tablets administered BID
219241914|NCT06800157|DRUG|Other: placebo|Placebo to match LW402 administered BID
219241915|NCT06800157|DRUG|MTX|Background treatment with MTX once a week
219241916|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
219241917|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
219241918|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
219241919|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
219241920|NCT03805022|DRUG|At the discretion of the investigator|Drug at the discretion of the investigator.
219241921|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
219241922|NCT05783271|DIAGNOSTIC_TEST|Gadolinium|"All patients will be subjected to :~MRI examinations on a 1.5-T MRI system in the supine position by using a 16-channel pelvic phased-array coil. The MRI proto col includes the following sequences: unenhanced axial T1-WI, high-resolution three planes (axial, coronal, and sagittal) T2-WI, axial DWI with b values of 0, 800, and 1600 s/mm2, axial DCE T1-WI with three-dimensional (3D) high temporal resolution. In all sequences, the small field of view (FOV) was used with the scope of viewing the entire bladder, proximal urethra, distal ureteral orifices, and adjacent pelvic organs. Gadopentetate dimeglumine (Gadovist, 0.1 ml/kg body weight) is administered at a rate of 2 ml/s using a power injector."
219241923|NCT05609370|DRUG|LBL-007|Administered intravenously.
219241924|NCT05609370|DRUG|Tislelizumab|Administered intravenously.
219241925|NCT05609370|DRUG|Bevacizumab or Bevacizumab biosimilar|Administered intravenously
219241926|NCT05609370|DRUG|Capecitabine|Administered in accordance with relevant local guidelines and/or prescribing information
219241927|NCT05609370|DRUG|5-Fluorouracil|Administered in accordance with relevant local guidelines and/or prescribing information
219241928|NCT03356171|PROCEDURE|Cardiac Coherence|"* 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
219241929|NCT03356171|PROCEDURE|Adapted Physical Activity|\- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
219241930|NCT02062827|BIOLOGICAL|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
219241931|NCT04953897|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
219241932|NCT06217822|DRUG|225Ac-PSMA-Trillium (BAY3563254)|Intravenous slow injection on Day 1 of a 6 week treatment cycle.
219241933|NCT05733598|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
219241934|NCT05733598|BIOLOGICAL|Bevacizumab|Anti-VEGF therapy.
219241935|NCT05733598|BIOLOGICAL|Atezolizumab|Anti-PD-L1 monoclonal antibody.
219241936|NCT05733598|BIOLOGICAL|Durvalumab|Anti-PD-L1 monoclonal antibody
219241937|NCT05444959|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
219241938|NCT05444959|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
219241939|NCT02558504|PROCEDURE|Oesophagectomy|
219241940|NCT02558504|DEVICE|Radiofrequency ablation|
219241941|NCT05571189|BEHAVIORAL|Daily Activity Text|Participants will receive a text each day with instructions about the daily activity they should complete for that day.
219241942|NCT05571189|BEHAVIORAL|Control Text|"Participants will receive a text each day with no instructions about daily activity. It will have messages like have a nice day."
219241943|NCT04472338|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
219241944|NCT04472338|OTHER|Laboratory Biomarker Analysis|Correlative studies
219241945|NCT04472338|OTHER|Quality-of-Life Assessment|Ancillary studies
219241946|NCT04472338|OTHER|Questionnaire Administration|Ancillary studies
219241947|NCT02621944|DRUG|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
219241948|NCT02621944|OTHER|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
219241949|NCT02621944|OTHER|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
219241950|NCT02621944|BEHAVIORAL|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
219241951|NCT04649242|DRUG|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
219241952|NCT04649242|DRUG|Matching placebo|Matching 75 mg or 50 mg ODT placebo
219241953|NCT02453620|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219241954|NCT02453620|OTHER|Blood Sample|Undergo blood sample collection
219241955|NCT02453620|PROCEDURE|Bone Scan|Undergo bone scan
219241956|NCT02453620|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219241957|NCT02453620|DRUG|Entinostat|Given PO
219241958|NCT02453620|BIOLOGICAL|Ipilimumab|Given IV
219241959|NCT02453620|BIOLOGICAL|Nivolumab|Given IV
219241960|NCT02453620|OTHER|Pharmacogenomic Study|Correlative studies
219241961|NCT02453620|OTHER|Pharmacological Study|Correlative studies
219241962|NCT02453620|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219241963|NCT05587491|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
219241964|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
219241974|NCT06029296|DRUG|Diclofenac|100 mg
219241975|NCT06029296|DRUG|Placebo|Sugar pill
219241976|NCT00288353|DRUG|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
219241977|NCT00288353|DRUG|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
219241978|NCT05896826|DEVICE|Magnetometer|inspection equipment for magnetocardiography
219241979|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
219241980|NCT05648279|OTHER|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) Preoperative baseline cardiac index will be determined with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) (usually at least one day before surgery). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
219241981|NCT05739981|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV
219241982|NCT05739981|DRUG|Carboplatin|Carboplatin AUC 5-6 IV
219241983|NCT05739981|DRUG|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
219241984|NCT05739981|DRUG|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
219241985|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
219241986|NCT04059640|DEVICE|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
219241987|NCT06414993|BEHAVIORAL|Contingency Management for Emerging Adults (CM-EA)|After CM-EA is introduced, a contingency contract is developed between a parent and emerging adult (EA) that provides EAs with rewards for negative drug screens and completion of developmentally appropriate goals to build recovery capital, along with disincentives for positive screens or engaging in inappropriate behaviors. Concurrently, parents are taught to conduct random urine drug screens. Additionally, parents are trained to complete functional analyses in collaboration with their EA to identify the EA's triggers for poly-substance use and negative behaviors. Individualized triggers are targeted via self-management planning and drug refusal skills training. At the end of CM-EA, plans are made with the family for sustaining abstinence and improvements in other behaviors.
219362399|NCT02953717|RADIATION|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
219362400|NCT02953717|RADIATION|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
219362401|NCT05357456|BEHAVIORAL|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
219241988|NCT06414993|BEHAVIORAL|Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services|Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation, employment). After needs are identified, a peer worker addresses needs through informational resources and community referrals and engages clients in positive recreational activities offering advice, hope and empowerment to encourage steps toward a reduction in substance use and eventual abstinence. When desired, peer workers also link clients to a broader recovery peer community. In addition, the peer worker will dedicate time to increasing recovery capital via improving skills related to V/E advancement using a workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health Providers, for which peer workers will be trained.
219241989|NCT05581121|OTHER|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
219241990|NCT05581121|PROCEDURE|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy (by minimally invasive approach) followed by tailored chemo-radiotherapy and brachytherapy. Both traditional laparoscopy or robotically assisted laparoscopy approaches are accepted in the study.
219241991|NCT06343753|DRUG|Opioid free analgesia|o Group OFA: Opioid free anesthesia Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).
219241992|NCT06343753|DRUG|Opioid based Anesthesia|o Group TBA: Traditional balanced anesthesia Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)
219241993|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
219241994|NCT05519111|DRUG|Placebo|placebo equivalent
219241995|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
219241996|NCT05774535|OTHER|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~* informed consent;~* personal data and medical records;~* registration of medical therapy and post-procedural pharmacological protocol~* surgical check;~* supra-aortic trunks EchocolorDoppler;~* pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~* surgical checks;~* registration of drug therapy;~* recording of all adverse events that occurred during hospitalization~* supra-aortic trunks EchocolorDoppler and cIMT measurement;~* blood sampling."
219241997|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
219241998|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
219241999|NCT05946031|DRUG|Reat ETM|Exclusive cigarette smokers will be recruited and will be exposed to the real ETM condition in which tobacco purchases are real and they receive products from one randomly selected trial.
219242000|NCT05946031|DRUG|Hypothetical ETM|Exclusive cigarette smokers will be recruited and will be exposed to the hypothetical ETM condition in which tobacco purchases are hypothetical and they don't receive any products.
219242001|NCT06801145|OTHER|Education Video|48 hour before the surgery, patients were watched the training video.
219242002|NCT06801145|OTHER|Training video will not be watched group|No training was given about the intensive care process
219242003|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
219242004|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
219242005|NCT05691478|DRUG|Cisplatin|Given IV
219242006|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
219242007|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
219242008|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219242009|NCT05691478|DRUG|Methotrexate|Given IV
219242010|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
219242011|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
219242012|NCT06333951|DRUG|AMG 193|Administered PO
219242013|NCT06333951|DRUG|Carboplatin|Administered IV
219242014|NCT06333951|DRUG|Paclitaxel|Administered IV
219242015|NCT06333951|DRUG|Pembrolizumab|Administered IV
219242016|NCT06333951|DRUG|Pemetrexed|Administered IV
219242017|NCT06333951|DRUG|Sotorasib|Administered PO
219242018|NCT04967989|PROCEDURE|Low Energy SLT|SLT performed at low energy
219242019|NCT04967989|PROCEDURE|Standard Energy SLT|SLT performed at standard energy
219242020|NCT04662970|DEVICE|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
219242021|NCT01861106|PROCEDURE|Allogeneic HSCT|Stem cell transplant
219242022|NCT01861106|DRUG|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
219242023|NCT01861106|DRUG|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
219242024|NCT01861106|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
219242025|NCT01861106|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
219242026|NCT01861106|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
219242027|NCT01861106|DRUG|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
219242028|NCT01861106|DRUG|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
219242029|NCT01861106|BIOLOGICAL|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
219242030|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
219362402|NCT05357456|PROCEDURE|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
219242031|NCT05665504|DIAGNOSTIC_TEST|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
219242032|NCT06029127|DRUG|BGB-A445|Administered intravenously at protocol defined dose
219242033|NCT06029127|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) administered intravenously
219242034|NCT06029127|DRUG|Ramucirumab|10 mg/kg administered intravenously
219242035|NCT06029127|DRUG|BGB-15025|Administered orally at protocol defined dose
219242036|NCT04985604|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
219242037|NCT06575361|DIAGNOSTIC_TEST|Combination of targeted biopsy and systematic biopsy|Before prostate biopsy, the MR images of patients were independently reviewed by MRI-AI and urogenital radiologists. Then the images with suspicious lesions highlighted by MRI-AI and urogenital radiologists. Urologists conducted targeted biopsies for all suspicious lesions and systematic biopsies. Biopsies were performed under the guidance of transrectal ultrasound (TRUS) through the transrectal or transperineal route.
219242038|NCT05443971|BIOLOGICAL|Durvalumab|Given IV
219242039|NCT05443971|RADIATION|Radiation Therapy|Undergo grid therapy
219242040|NCT05443971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219242041|NCT01898039|BIOLOGICAL|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
219242042|NCT01898039|PROCEDURE|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
219242043|NCT01898039|DRUG|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
219242044|NCT05602766|DRUG|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
219242045|NCT02282761|DRUG|ITI-007|
219242046|NCT02282761|DRUG|Placebo|
219242047|NCT05018338|DEVICE|Brain shift monitoring|For use to monitor brain shift during craniotomy
219242048|NCT05249452|OTHER|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
219242049|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
219242050|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
219242051|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
219242052|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
219242053|NCT06475274|DRUG|RMC-035|Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
219242054|NCT06475274|DRUG|Placebo|Identical to RMC-035 intervention devoid of the active substance.
219242055|NCT05263492|DRUG|Lenvatinib|Lenvatinib once a day by mouth every day
219242056|NCT05263492|DRUG|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
219242057|NCT04483466|DRUG|Methotrexate|Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
219242058|NCT04483466|DRUG|Placebo|Placebo
219242059|NCT03680092|DRUG|Cyclophosphamide|Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
219242060|NCT03680092|DRUG|abatacept|Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
219242061|NCT03680092|DRUG|Methotrexate|standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
219242062|NCT03680092|DRUG|Tacrolimus|Tacrolimus per institutional guidelines
219242063|NCT05326035|DRUG|WJ05129|Twice daily (except for single dose), 12 hours apart, fixed time is recommended
219242064|NCT05326035|DRUG|Paclitaxel injection|80mg/m2 (The maximum dose is 80mg/m2 , and the dose can be adjusted according to the actual situation), The medication is administered on days 1, 8, and 15, and a 28-day period constitutes one cycle.
219242065|NCT06511791|DRUG|FE 999302|Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
219242066|NCT06511791|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
219242067|NCT06511791|DRUG|Placebo FE 999302|No active ingredient, subcutaneous injection.
219738497|NCT01287429|OTHER|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
219738498|NCT05657171|DRUG|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
219738499|NCT03823885|OTHER|e-cigarette|use e-cig for 30 minutes
219738500|NCT03823885|OTHER|empty (-cigarette sham control)|use empty e-cig (sham control)
219738501|NCT03956082|DEVICE|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
219738502|NCT03956082|DEVICE|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
219738503|NCT01079390|DEVICE|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
219242072|NCT05837312|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
219242073|NCT05699460|OTHER|This is an observational study.|This is an observational study.
219242074|NCT06238622|DRUG|BI 1015550|BI 1015550
219242075|NCT03345420|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219242076|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
219242077|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
219242078|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
219242079|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
219242080|NCT00722228|BIOLOGICAL|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
219242081|NCT06431204|OTHER|Obstetric comorbidity index|Obstetric comorbidity index score
219242082|NCT05614102|DRUG|BAY2965501|Daily oral application
219242083|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
219242084|NCT05614102|DRUG|Platinum-based Chemotherapy|Standard of care doses per tumor type will be administered.
219242085|NCT05216835|DRUG|Sabestomig (AZD7789)|Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
219242086|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
219242087|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
219242088|NCT06355154|OTHER|Nutritional intervention|The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
219242089|NCT06241313|DRUG|Atogepant|Oral Tablet
219242090|NCT06241313|DRUG|Placebo for Atogepant|Oral Tablet
219242091|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
219242092|NCT06965465|BIOLOGICAL|PF-07999415|Participants will receive single doses of PF-07999415.
219242093|NCT06965465|DRUG|Placebo|Participants will receive matching placebo.
219242094|NCT01842360|BIOLOGICAL|Placebo|The participants will receive daily dose of placebo during 12 months sublingually.
219242095|NCT01842360|BIOLOGICAL|MV130|The participants will receive daily dose of MV130 during 12 months sublingually.
219242096|NCT06127667|BEHAVIORAL|aerobic exercise|use of single bout of aerobic exercise
219242097|NCT06422507|DRUG|8 mg aflibercept (BAY 86-5321) (High Dose)|High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
219738504|NCT01197274|DEVICE|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
219738505|NCT00460915|DRUG|Lacidipine & Amlodipine|
219738506|NCT01201044|DRUG|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
219738507|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
219738508|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
219738509|NCT01201044|DRUG|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
219738510|NCT06168006|BEHAVIORAL|Exercise|The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
219738511|NCT06168006|BEHAVIORAL|Control|They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
219738512|NCT03479684|OTHER|Gene-directed dosage of warfarin|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
219738513|NCT03479684|OTHER|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
219738514|NCT00636337|BEHAVIORAL|Attention Training|Computer program training for attention difficulties.
219738515|NCT00636337|BEHAVIORAL|Placebo|Comparison computer program
219242098|NCT06422507|DRUG|2 mg aflibercept (EYLEA, BAY 86-5321)|"Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye."
219242099|NCT06422507|OTHER|Sham|"To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM)."
219242100|NCT05065216|DRUG|Recombinant human tissue kallikrein|DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21
219242101|NCT05065216|OTHER|Placebo for DM199 Solution for Injection|Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
219242102|NCT05227183|BEHAVIORAL|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
219242103|NCT06967155|DRUG|• Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU|"Irinotecan + Dabrafenib + Trametinib and Cetuximab or Panitumumab in the second line of therapy Dabrafenib 150 mg twice orally daily Trametinib 2 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Irinotecan 90 mg/m2 (90-minute IV infusion) weekly.~Second-line treatment is administered until disease progression or intolerable toxicity. It may be possible to switch to a regimen of dabrafenib, trametinib, cetuximab or panitumumab if irinotecan is intolerable."
219242104|NCT05438264|DRUG|Donepezil|acetylcholinesterase inhibitor
219242105|NCT05438264|DRUG|Placebo|placebo
219242106|NCT04551053|DRUG|parsaclisib|parsaclisib will be administered QD orally
219242107|NCT04551053|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
219242108|NCT04551053|DRUG|placebo|placebo will be administered QD orally
219242109|NCT06411197|OTHER|Hypertonic saline injection|Injection with hypertonic saline (7%)
219242110|NCT06411197|OTHER|Isotonic saline injection|Injection with isotonic saline (0.9%)
219242111|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
219242112|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
219242113|NCT06544772|DEVICE|Pivot cigarette smoking cessation program|The Pivot cigarette smoking cessation program comprises a mobile personal breath carbon monoxide sensor (Pivot Breath Sensor) and a smartphone app (Pivot app) with in-app asynchronous SMS text-based coaching with a certified human tobacco cessation coach.
219242114|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
219242115|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
219242116|NCT04256317|DRUG|Azacitidine|Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for SC administration.
219242117|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|FDC Capsules for oral administration.
219242118|NCT04256317|DRUG|Azacitidine|Powder for reconstitution to aqueous suspension for SC administration.
219242119|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|Tablets/Capsules for oral administration.
219242120|NCT04256317|DRUG|Cedazuridine|Tablets for oral administration.
219242121|NCT04256317|DRUG|Venetoclax|Oral tablets.
219242122|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) forced expiration technique and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
219242123|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
219242124|NCT03649503|OTHER|No intervention|
219242125|NCT06006299|DEVICE|transauricular Vagus Nerve Stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.
219738516|NCT05186298|DEVICE|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
219738517|NCT05186298|DEVICE|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
219738518|NCT05186298|PROCEDURE|Cataract Surgery|IOL implantation will be performed
219738519|NCT02088411|DRUG|Diclofenac|
219738520|NCT02088411|DIETARY_SUPPLEMENT|Wobenzym|
219738521|NCT02088411|OTHER|Placebo|
219738522|NCT01313325|OTHER|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
219738523|NCT05073731|OTHER|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
219738524|NCT05122143|DEVICE|Treatment A|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril"
219242126|NCT05169814|DRUG|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
219242127|NCT05169814|OTHER|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
219171805|NCT05774314|BEHAVIORAL|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
219738525|NCT05122143|DEVICE|Treatment B|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)"
219738526|NCT05122143|OTHER|Treatment C|No treatment
219738527|NCT05704699|BEHAVIORAL|eTRE|eating between 0800h and 1600h daily
219738528|NCT05704699|BEHAVIORAL|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
219738529|NCT00692237|DRUG|Sildenafil|100 mg daily (3 capsules/day)
219738530|NCT00692237|DRUG|Placebo|Placebo 100 mg (3 capsules/day)
219738531|NCT00359398|PROCEDURE|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
219738532|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
219738533|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
219738534|NCT05855096|OTHER|Google Form Questionnaire|Google form questionnaire is performed by responders.
219738535|NCT03854981|BEHAVIORAL|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
219738536|NCT03854981|PROCEDURE|Standard Care|Standard preoperative care of bariatric surgery
219738537|NCT03003065|DRUG|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
219738538|NCT02969226|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
219738539|NCT02969226|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
219738540|NCT02969226|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O
219738541|NCT02969226|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
219738542|NCT02475863|DEVICE|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
219738543|NCT02475863|OTHER|Standard Practice|Warfarin dose adjustments according to standard unit protocol
219738544|NCT04740346|DIAGNOSTIC_TEST|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
219738545|NCT01601561|DRUG|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
219738546|NCT04544605|OTHER|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
219738547|NCT01006486|OTHER|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
219738548|NCT01006486|OTHER|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
219738549|NCT02594072|RADIATION|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
219738550|NCT02594072|RADIATION|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
219738551|NCT02594072|DRUG|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
219171806|NCT04716140|PROCEDURE|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
219171807|NCT01804816|PROCEDURE|Acupuncture|Standardized acupuncture administration for 10 sessions.
219171808|NCT01804816|OTHER|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
219171809|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer FDG PET/CT Exam|"The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
219171810|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Cu64-DOTATATE PET/CT Exam|"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
219171811|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Ga68-DOTATATE PET/CT Exam|"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
219171812|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer PSMA PET/CT Exam|"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
219242128|NCT05169814|DRUG|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
219242129|NCT05169814|OTHER|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
219242130|NCT04976322|DRUG|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
219242131|NCT06617325|DRUG|DZP|Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
219242132|NCT06617325|OTHER|Placebo|Study participants will receive placebo at prespecified time-points.
219242133|NCT05943535|DRUG|Placebo|Placebo administered QID
219242134|NCT05943535|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
219242135|NCT05943535|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
219242136|NCT00739362|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Active tDCS (anodal left DLPFC)
219242137|NCT00739362|OTHER|Sham/no-stimulation|Sham tDCS
219242138|NCT06264557|DEVICE|SB-100|"Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
219242139|NCT06264557|OTHER|Educational book|Book of education on daily rules for preventing dementia
219242140|NCT06646822|OTHER|questionnaire|observational study
219242141|NCT05878184|DRUG|SC291|SC291 is an allogeneic CAR-T cell therapy
219242142|NCT04188912|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples
219242143|NCT04188912|PROCEDURE|Optical Coherence Tomography|Undergo optical coherence tomography
219242144|NCT04188912|PROCEDURE|Spirometry|Undergo portable spirometry
219242145|NCT04188912|OTHER|Survey Administration|Complete survey
219242146|NCT04188912|OTHER|Digital Photography|Undergo digital photography
219242147|NCT04188912|OTHER|Quality-of-Life Assessment|Ancillary studies
219242148|NCT04188912|OTHER|Medical Chart Review|Review of medical charts
219242149|NCT06252675|BIOLOGICAL|Obinutuzumab|Given intravenously (IV)
219242150|NCT06252675|BIOLOGICAL|Glofitamab|Given IV
219242151|NCT06252675|DRUG|Pirtobrutinib|Given Orally (PO)
219242152|NCT06252675|PROCEDURE|Tumor Imaging|Undergo regular care imaging/scans
219242153|NCT06252675|PROCEDURE|Biospecimen Collection|Blood and tissue samples
219242154|NCT06252675|DEVICE|ClonoSeq Assay|ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.
219242155|NCT06252675|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration.
219242156|NCT06350682|BEHAVIORAL|HealthMPowerment (HMP)|Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.
219242157|NCT06572579|PROCEDURE|Ultrasound-guided pharmacopuncture treatment|Pharmacopuncture treatment using ultrasound-guidance
219242158|NCT06172257|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
219242159|NCT06172257|DRUG|Vehicle|Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
219242160|NCT04897321|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
219242161|NCT04897321|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
219738552|NCT00964522|OTHER|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
219242162|NCT04897321|DRUG|MESNA|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
219242163|NCT04897321|DRUG|B7-H3 CAR T cells|The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
219242164|NCT05639647|DRUG|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
219242165|NCT05639647|DRUG|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
219242166|NCT06562192|DRUG|[68Ga]Ga-NNS309|Radioligand imaging agent
219242167|NCT06562192|DRUG|[177Lu]Lu-NNS309|Radioligand therapy
219242168|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
219242169|NCT06972966|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
219242170|NCT06972966|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
219242171|NCT04016415|BEHAVIORAL|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
219242172|NCT04016415|BEHAVIORAL|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
219242173|NCT05952804|BIOLOGICAL|Immune Globulin Infusion (Human), 10% Solution|Given IV
219242174|NCT05952804|BIOLOGICAL|Anti-CD19 CAR T Cells Preparation|Given CAR-T treatment
219242175|NCT05952804|OTHER|Saline|Given IV
219242176|NCT05952804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219242177|NCT05952804|OTHER|Survey Administration|Ancillary studies
219242178|NCT05952804|OTHER|Electronic Health Record Review|Ancillary studies
219242179|NCT03492671|DRUG|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
219242180|NCT03492671|DRUG|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
219242181|NCT03492671|RADIATION|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
219242182|NCT06504953|OTHER|Questionnaire|Questionnaires on contraception and sports activities
219738553|NCT04742023|DEVICE|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
219738554|NCT04742023|DIAGNOSTIC_TEST|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
219738555|NCT04742023|DRUG|Insulin|Insulin will be administered.
219738556|NCT04742023|DEVICE|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
219738557|NCT01358305|OTHER|Protein Blend|Single intake of approximately 20 grams of total protein
219738558|NCT02219451|OTHER|exercise training|exercise training
219738559|NCT00109668|DRUG|beclomethasone dipropionate (QVAR)|
219738560|NCT02934217|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
219738561|NCT02934217|DRUG|Placebo|One single intravenous bolus injection of Placebo
219738562|NCT02934217|PROCEDURE|Echocardiography|3 years after AMI
219738563|NCT03975179|PROCEDURE|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
219738564|NCT03975179|PROCEDURE|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
219738565|NCT01347086|DRUG|Matching placebo (low dose)|single dose of matching placebo
219738566|NCT01347086|DRUG|BI 207127 NA (medium dose)|Single does of BI 207127 NA
219242183|NCT06504953|OTHER|Beighton test|A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.
219738567|NCT01347086|DRUG|BI 207127 NA (low dose)|single dose of BI 207127 NA
219738568|NCT01347086|DRUG|Matching placebo (medium dose)|Single dose of matching placebo
219738569|NCT01347086|DRUG|BI 207127 NA (high dose)|Single dose of BI 207127 NA
219738570|NCT01347086|DRUG|Matching placebo (high dose)|Single dose of matching placebo
219738571|NCT01366274|OTHER|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
219738572|NCT01366274|OTHER|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
219738573|NCT03161496|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219738574|NCT05272605|BIOLOGICAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
219738575|NCT05272605|BIOLOGICAL|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
219738576|NCT05272605|OTHER|Normal Saline|Placebo comparator
219738577|NCT01424137|DEVICE|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
219738578|NCT01424137|DEVICE|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
219738579|NCT01424137|DEVICE|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
219738580|NCT03536858|BEHAVIORAL|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
219738581|NCT00395447|PROCEDURE|Straight-forward Device Replacement|
219738582|NCT00395447|PROCEDURE|Device Replacement with Upgrade|
219738583|NCT00019825|DRUG|decitabine|
219738584|NCT05818930|DIAGNOSTIC_TEST|REMI|Diagnostic monitoring
219738585|NCT03851952|DEVICE|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
219738586|NCT02090894|DEVICE|UV Light (Laser Genesis)|
219738587|NCT03678857|DIETARY_SUPPLEMENT|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
219738588|NCT05703295|PROCEDURE|Biopsy|Sentinel lymph node biopsy
219738589|NCT00111735|DRUG|Thyroxine|
219738590|NCT04582812|OTHER|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
219738591|NCT04582812|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
219738592|NCT02624687|BEHAVIORAL|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
219738593|NCT02624687|OTHER|No intervention|No contact control
219738594|NCT06500585|OTHER|Mill's Manipulation|"Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
219738595|NCT06500585|OTHER|Mill's Manipulation and Muscle Energy Technique|"Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
219738596|NCT03975946|PROCEDURE|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
219738597|NCT03975946|BIOLOGICAL|Blood Sample|Biological analysis
219738598|NCT03975946|PROCEDURE|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
219738599|NCT03111108|DRUG|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
219171813|NCT05894681|OTHER|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
219171814|NCT03400059|DEVICE|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
219738600|NCT06154850|OTHER|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
219738601|NCT06154850|OTHER|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
219738602|NCT00005038|BIOLOGICAL|aldesleukin|
219738603|NCT00005038|DRUG|histamine dihydrochloride|
219738604|NCT03307824|DEVICE|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
219738605|NCT03307824|PROCEDURE|Glue-Free Suture Technique|Suture Technique
219738606|NCT06110195|DRUG|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
219738607|NCT06110195|DRUG|Carboplatin|Given with radiation weekly for 7 doses.
219738608|NCT06110195|DRUG|Paclitaxel|Given with radiation weekly for 7 doses.
219738609|NCT06110195|RADIATION|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
219738610|NCT04475380|DEVICE|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
219738611|NCT02771145|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
219738612|NCT02771145|DEVICE|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
219171815|NCT03400059|DEVICE|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
219171816|NCT05989958|COMBINATION_PRODUCT|HepaCure|HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.
219171817|NCT05989958|DEVICE|DPMAS and LPE|Using DPMAS and LPE for extracorporeal dialysis treatment.
219171818|NCT04168385|DRUG|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"
219171819|NCT05659797|DEVICE|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
219171820|NCT05659797|DRUG|18F-FES|Radiolabelled fluoroestradiol for PET imaging
219171821|NCT06271187|DEVICE|Dynamic-orthosis|Engaging in motion training at home with the use of dynamic orthoses.
219171822|NCT06271187|OTHER|Traditional stroke occupational therapy training|Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.
219171823|NCT04421378|DRUG|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
219171824|NCT04421378|DRUG|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
219171825|NCT04421378|DRUG|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
219171826|NCT04421378|RADIATION|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
219171827|NCT04421378|DRUG|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
219171828|NCT04421378|DEVICE|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
219171829|NCT04421378|DRUG|Carmustine|Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
219171830|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional impression technique|surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit
219171831|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional digital technique|surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
219171832|NCT05683509|PROCEDURE|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
219171833|NCT05683509|PROCEDURE|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
219171834|NCT04545541|DRUG|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
219171835|NCT03020303|DRUG|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
219171836|NCT03020303|DRUG|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
219171837|NCT04049279|PROCEDURE|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
219171838|NCT04049279|PROCEDURE|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
219738613|NCT02771145|DEVICE|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
219738614|NCT00879372|DRUG|tianeptine|tianeptine 12,5mg TID
219738615|NCT00879372|DRUG|Placebo|Placebo 12.5 mg TID
219738616|NCT06328569|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
219738617|NCT06328569|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
219738618|NCT00168285|BEHAVIORAL|Pulmonary Rehabilitation|
219738619|NCT01414647|DIETARY_SUPPLEMENT|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
219738620|NCT01414647|DIETARY_SUPPLEMENT|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
219171839|NCT04049279|PROCEDURE|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
219242184|NCT06504953|OTHER|Lachman Test|"To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part."
219242185|NCT04979247|DRUG|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
219242186|NCT04087629|DEVICE|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
219242187|NCT06193200|DRUG|Dexamethasone sodium phosphate|Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
219242188|NCT06193200|OTHER|Placebo|Placebo encapsulated in autologous erythrocytes and administered via IV infusion
219242189|NCT06139393|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
219242190|NCT06139393|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
219242191|NCT06988358|DIAGNOSTIC_TEST|Group of children identified by the algorithm as having asthma|150 medical files of children identified by the algorithm as having asthma will be randomly selected for expert appraisal.
219242192|NCT06988358|DIAGNOSTIC_TEST|Group of children not identified by the algorithm as having asthma|150 medical files of children not identified by the algorithm as having asthma will be randomly selected for expert appraisal.
219242193|NCT02874885|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219242194|NCT06824077|DRUG|Dexmedetomidine|Dexmedetomidine will be prepared at a concentration of 4 mcg/ml by diluting 200 mcg/2 ml vials with 48 mL of 0.9% normal saline to a total volume of 50 ml. A maintenance infusion of 0.2-1.2 mcg/kg/hr will be initiated to sustain the sedative effect and promote sleep throughout the trial period. ICU nurses are experienced in titrating dexmedetomidine for both patients on high flow oxygen (Optiflow) and intubated patients with delirium as part of routine care. The ICU bedside nurse will be responsible for using the lowest effective dose to achieve a Richmond Agitation Sedation Scale (RASS) of -2, up to a maximum of 1.2 mcg/kg/hr, while monitoring for adverse events such as bradycardia and hypotension.
219242195|NCT06824077|OTHER|Control (placebo) group|The control group will receive an infusion of 0.9% saline at 5-45 ml/hr titrated to the lowest effective dose to achieve a RASS of -2 for two nights following randomization.
219242196|NCT05099770|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
219242197|NCT05099770|PROCEDURE|Sham Comparator|Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
219242198|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE001|P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
219738621|NCT01414647|OTHER|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
219738622|NCT02369939|RADIATION|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
219738623|NCT02369939|DRUG|Mitomycin C|MMC w1, w5
219738624|NCT02369939|DRUG|5-Fluorouracil|5-FU w1, w5
219738625|NCT02369939|PROCEDURE|Hyperthermia|6x deep regional hyperthermia
219738626|NCT05019963|BEHAVIORAL|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
219738627|NCT05019963|OTHER|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
219738628|NCT00160368|BEHAVIORAL|Potassium supplementation|
219738629|NCT02264821|DRUG|ropivacaine infiltration|wound infiltration
219171840|NCT05632614|DEVICE|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
219171841|NCT05632614|DEVICE|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
219171842|NCT05683041|DEVICE|Hyalobarrier|Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
219171843|NCT06518967|DIAGNOSTIC_TEST|analytical performance study|analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
219171844|NCT02662751|OTHER|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
219242199|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE002|P. vivax challenge agent derived from PvHMB-CCE002 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
219171845|NCT02662751|DEVICE|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
219171846|NCT05898516|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
219171847|NCT05831670|DRUG|KSP-0243|Oral administration
219171848|NCT05831670|DRUG|Placebo|Oral administration
219171849|NCT05042479|OTHER|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~* Application of a patch or anaesthetic cream 1 hour before the treatment~* Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~* Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~* Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~* The presence of the parents"
219171850|NCT05042479|OTHER|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
219171851|NCT05042479|OTHER|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
219171852|NCT04223024|DRUG|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
219171853|NCT04223024|DRUG|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
219242200|NCT03604991|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219242201|NCT03604991|DRUG|Carboplatin|Given IV
219242202|NCT03604991|PROCEDURE|Computed Tomography|Undergo CT scan
219242203|NCT03604991|BIOLOGICAL|Ipilimumab|Given IV
219242204|NCT03604991|BIOLOGICAL|Nivolumab|Given IV
219242205|NCT03604991|DRUG|Paclitaxel|Given IV
219242206|NCT03604991|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219242207|NCT03604991|RADIATION|Radiation Therapy|Undergo radiation therapy
219242208|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
219242209|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
219242210|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
219242211|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
219242212|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
219242213|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
219242214|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
219242215|NCT06598631|DRUG|Volenrelaxin|Administered SC
219242216|NCT06598631|DRUG|Placebo|Administered SC
219242217|NCT06594068|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE (Furie 2017). Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo (Furie 2019; Morand 2020). Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo (Furie 2017). These data resulted with applications to the FDA and the EMA, leading to approval by them in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
219171854|NCT04263311|BEHAVIORAL|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
219171855|NCT02966483|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
219171856|NCT02966483|PROCEDURE|LpTME|Conventional Laparoscopic Total Mesorectal Excision
219171857|NCT04614233|DIETARY_SUPPLEMENT|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
219171858|NCT04614233|DRUG|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
219171859|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
219171860|NCT01476371|BEHAVIORAL|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
219171861|NCT05264532|OTHER|Informational Intervention|Receive information-graphic video
219171862|NCT05264532|OTHER|Informational Intervention|Receive family letter
219171863|NCT05264532|OTHER|Survey Administration|Ancillary studies
219171864|NCT05664425|DEVICE|Ultrasonic debridement|Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)
219171865|NCT05890729|DRUG|XTMAB-16 or Placebo|Infusion
219242218|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 1|Participants will use their Radicle Spark Placebo Control Form 1 as directed for a period of 6 weeks.
219242219|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 1.1 Usage|Participants will use their Radicle Spark Active Study Product 1.1 as directed for a period of 6 weeks.
219242220|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 2|Participants will use their Radicle Spark Placebo Control Form 2 as directed for a period of 6 weeks.
219242221|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 2.1 Usage|Participants will use their Radicle Spark Active Study Product 2.1 as directed for a period of 6 weeks.
219242222|NCT06842355|DRUG|TYRA-300 0.125 mg/kg|Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
219242223|NCT06842355|DRUG|TYRA-300 0.25 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
219242224|NCT06842355|DRUG|TYRA-300 0.375 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
219242225|NCT06842355|DRUG|TYRA-300 0.50 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
219242226|NCT05847387|DIAGNOSTIC_TEST|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
219242227|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
219738630|NCT02264821|DRUG|intrathecal morphine|100 µg added to the spinal anaesthesia
219738631|NCT02264821|DRUG|placebo|placebo in spinal anaesthesia and in wound infiltration
219738632|NCT00527631|RADIATION|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
219738633|NCT02956148|RADIATION|Radioligand [18F]MNI-659|The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
219738634|NCT01943084|DRUG|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
219738635|NCT01943084|DRUG|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
219242228|NCT06610838|OTHER|Health Assessments|Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.
219242229|NCT02262806|DRUG|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
219242230|NCT06856577|GENETIC|Ixo-vec|Ixo-vec will be administered intravitreally.
219242231|NCT06856577|DRUG|Aflibercept|Aflibercept will be administered intravitreally.
219242232|NCT06989294|OTHER|Lean Leadership|Lean leadership was doing the right things to increase revenues, satisfying customers and reducing costs by eliminating all activities that do not add value to the product or service. It has five dimensions, namely: continuous improvement, self-development, qualification development, Gemba walk and Hoshin Kanri.
219242233|NCT06990477|DEVICE|EIT-guided PEEP|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to 6 every 2min.
219242234|NCT04095208|DRUG|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
219242235|NCT04095208|DRUG|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
219242236|NCT04576156|DRUG|Imetelstat|Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
219242237|NCT04576156|DRUG|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
219242238|NCT05548205|DEVICE|Continuous Glucose Monitor|Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.
219242239|NCT05548205|DEVICE|Blood Glucose Monitor|Self-administered according to investigator instruction.
219242240|NCT04661358|DRUG|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
219242241|NCT04661358|OTHER|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
219242242|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
219242243|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
219242244|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
219242245|NCT06990698|DRUG|FP008 for injection|FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.
219242246|NCT05192707|DIAGNOSTIC_TEST|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
219242247|NCT06672237|BIOLOGICAL|nexiguran ziclumeran|nexiguran ziclumeran 55 mg by single IV infusion
219242248|NCT06672237|DRUG|Normal Saline as Placebo|Normal saline (0.9% NaCl) by single IV infusion
219242249|NCT06859398|OTHER|Ocular Topography and Wavefront Aberrometry|Eyescan with Pentacam AXL Wave
219242250|NCT06672146|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219242251|NCT06672146|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219242252|NCT06672146|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219242253|NCT06672146|DRUG|Decitabine and Cedazuridine|Given PO
219242254|NCT06672146|DRUG|Enasidenib|Given PO
219242255|NCT06672146|DRUG|Venetoclax|Given PO
219242256|NCT06616194|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablets
219242257|NCT06616194|DRUG|Placebo|Matching placebo oral disintegrating tablets
219242258|NCT06664853|DRUG|Dexamethasone sodium phosphate|Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
219242259|NCT06673667|DRUG|KT-621|Oral drug
219242260|NCT06673667|DRUG|Placebo|Oral drug
219242261|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
219242262|NCT06997965|DRUG|Mirikizumab|Mirikizumab is an IL-23 antagonist.
219242263|NCT01532063|PROCEDURE|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
219242264|NCT06058793|DRUG|Brigimadlin|Brigimadlin
219738636|NCT06036524|DIAGNOSTIC_TEST|Multi-modal, multi-parametric, multiscale imaging of the myofascial unit|Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.
219738637|NCT05215561|OTHER|Cosentyx|There was no treatment allocation. Patients administered Cosentyx by prescription that had started before inclusion of the patient into the study were enrolled.
219738638|NCT05702489|DRUG|ZX-7101A|a drug to treatment influenza in Chinese adults
219738639|NCT05300607|OTHER|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
219738640|NCT05071027|OTHER|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
219738641|NCT05818943|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
219738642|NCT03287349|OTHER|Blood draw|Two 12.5 mL blood draws
219738643|NCT03287349|OTHER|Photograph|Photograph of severe reaction, will be anonymized
219738644|NCT03287349|DIAGNOSTIC_TEST|Autoimmune testing|Autoimmune testing in patients without prior testing
219738645|NCT06334211|DRUG|FP-020|MMP-12 inhibitor
219738646|NCT06334211|OTHER|placebo|placebo
219738647|NCT05804084|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
219738648|NCT05804084|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
219738649|NCT03136302|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
219738650|NCT06628960|BEHAVIORAL|Su Jok Therapy|Su Jok Therapy
219738651|NCT02522260|OTHER|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
219738652|NCT02522260|OTHER|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
219738653|NCT02522260|OTHER|Standard supportive care|Standard supportive care
219738654|NCT06344923|PROCEDURE|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
219738655|NCT06344923|PROCEDURE|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
219738656|NCT04656548|DEVICE|HydroPICC|PICC lines
219242265|NCT07002242|DRUG|Azvudine tablets(FNC) and Aluvia|FNC 3 mg each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.
219242266|NCT07002242|DRUG|Azvudine tablets(FNC)|FNC: 3 mg each time, 1 time a day, orally, for 5 consecutive days
219242267|NCT07002242|DRUG|Aluvia|Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.
219242268|NCT02751632|BEHAVIORAL|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
219242269|NCT02751632|BEHAVIORAL|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
219738657|NCT02314247|DRUG|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
219738658|NCT06082544|OTHER|mini-screw implant|JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
219738659|NCT06082544|DEVICE|removable partial denture|Acrylic removable partial denture
219738660|NCT03156452|DRUG|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
219738661|NCT03156452|DRUG|Prednisolone|5mg tablets for oral administration
219738662|NCT02965976|BIOLOGICAL|Botulinum Toxin Type A|Given IM
219738663|NCT02965976|PROCEDURE|Esophagectomy|Undergo esophagectomy
219738664|NCT02965976|OTHER|Quality-of-Life Assessment|Ancillary studies
219738665|NCT04420182|OTHER|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
219738666|NCT01687595|DRUG|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
219738667|NCT01687595|DRUG|Placebo|phosphate buffered saline
219738668|NCT00653705|OTHER|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
219738669|NCT00653705|OTHER|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
219738670|NCT01899378|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10\^8 CFU
219738671|NCT01899378|DIETARY_SUPPLEMENT|Bifidobacterium longum infantis|10\^9 CFU
219738672|NCT01307618|BIOLOGICAL|NA17.A2 Peptide Vaccine|Given SC or ID
219738673|NCT01307618|BIOLOGICAL|Recombinant MAGE-3.1 Antigen|Given SC or ID
219738674|NCT01307618|BIOLOGICAL|Recombinant Interleukin-12|Given SC or ID
219738675|NCT01307618|BIOLOGICAL|MART-1 Antigen|Given SC or ID
219738676|NCT01307618|OTHER|Laboratory Biomarker Analysis|Correlative studies
219738677|NCT05919212|DIAGNOSTIC_TEST|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
219738678|NCT02858661|OTHER|Nasopharyngeal swab|
219738679|NCT06300905|DRUG|test product|toothpaste containing 0.45% stannous fluoride
219738680|NCT06300905|DRUG|Control product|toothpaste containing 0.76% sodium monofluorophosphate
219738681|NCT00489359|DRUG|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
219738682|NCT00489359|DRUG|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
219738683|NCT00489359|DRUG|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
219738684|NCT00489359|DRUG|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
219738685|NCT04476485|OTHER|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
219738686|NCT03115515|DRUG|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
219738687|NCT04967001|DIAGNOSTIC_TEST|PSMA PET|68Ga-PSMA PET
219738688|NCT01872754|DRUG|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
219738689|NCT01872754|DRUG|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
219738690|NCT03905174|DEVICE|custom made device|surgical intervention to place custom made orthopaedic device
219738691|NCT01026428|DRUG|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
219738692|NCT01026428|OTHER|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
219242270|NCT02751632|DRUG|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
219242271|NCT02751632|DRUG|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
219242272|NCT02751632|BEHAVIORAL|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
219738693|NCT03719300|DRUG|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
219738694|NCT02442531|DRUG|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
219242273|NCT05134428|DEVICE|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
219738695|NCT05810116|DRUG|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
219738696|NCT05810116|DRUG|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
219171866|NCT04312802|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
219171867|NCT05773573|DEVICE|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
219171868|NCT05773573|DEVICE|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
219171869|NCT04847635|DEVICE|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
219171870|NCT04847635|DEVICE|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
219171871|NCT05671562|DIETARY_SUPPLEMENT|Lycopene|Capsule containing lycopene 7mg x 2 daily for 12 weeks
219171872|NCT05671562|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive substance 7mg x 2 daily for 12 weeks
219171873|NCT02592330|PROCEDURE|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
219171874|NCT02592330|BIOLOGICAL|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
219171875|NCT02592330|PROCEDURE|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
219171876|NCT05855941|DIAGNOSTIC_TEST|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
219171877|NCT05850247|DRUG|[18F]DPA-714 PET/MRI|"To assess the association between plasma ficolin-2 levels and plaque and brain inflammation assessed by \[18F\]DPA-714 PET/MRI in patients managed for transient ischaemic attack or ischaemic stroke related to carotid stenosis.~PET/MRI of the brain and carotid plaque with \[18F\]DPA-714 and gadolinium infusion will be performed at day 5."
219242274|NCT06591598|DRUG|Aflibercept (BAY86-5321, Eylea)|8 mg, intravitreal injection
219738697|NCT05587543|BEHAVIORAL|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
219738698|NCT05587543|DRUG|CAR|Target A positive subjects will receive CAR-T cell therapy.
219738699|NCT05587543|DRUG|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
219738700|NCT06542380|DEVICE|TAVI, pacemaker|Retrospective analysis of need for pacemaker implantation after TAVI
219738701|NCT04194619|OTHER|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
219738702|NCT05007860|BIOLOGICAL|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
219738703|NCT01903733|DRUG|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
219738704|NCT00192478|BIOLOGICAL|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
219738705|NCT04147169|BEHAVIORAL|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
219738706|NCT00043784|DRUG|enoxaparin|
219738707|NCT04878185|OTHER|Exercise|Preoperative exercise
219738708|NCT02281864|BEHAVIORAL|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
219738709|NCT02281864|OTHER|Control Group: Quitline|Referral to the Quitline
219738710|NCT02636335|DEVICE|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
219738711|NCT00551993|PROCEDURE|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
219738712|NCT00551993|PROCEDURE|Laparoscopic Sacral Colpopexy|Standard laparoscopy
219738713|NCT00318136|DRUG|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
219738714|NCT00318136|DRUG|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
219738715|NCT00318136|DRUG|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
219738716|NCT02487329|OTHER|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
219738717|NCT02487329|OTHER|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
219738718|NCT02487329|OTHER|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
219738719|NCT02487329|OTHER|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
219738720|NCT03599297|PROCEDURE|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
219738721|NCT06570057|BEHAVIORAL|Participatory, learning and Action (PLA) Based intervention|An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
219738722|NCT05245175|OTHER|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
219738723|NCT05245175|OTHER|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
219738724|NCT05245175|OTHER|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
219738725|NCT05245175|OTHER|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
219171878|NCT03090152|PROCEDURE|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
219171879|NCT03090152|PROCEDURE|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
219171880|NCT03090152|DRUG|Bupivacaine|EPCA: Bupivacaine 0.06%.
219171881|NCT03090152|DRUG|Placebo|EPCA: Saline.
219242275|NCT05588128|DRUG|18F-DCFpyL|Administered to Cohort.
219738726|NCT05245175|OTHER|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
219738727|NCT02449928|DRUG|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
219738728|NCT02449928|DRUG|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
219738729|NCT04151641|DIETARY_SUPPLEMENT|MNGDPF|Standardized mangosteen extract in dry powder form
219738730|NCT04151641|DIETARY_SUPPLEMENT|MNGEF|Standardized mangosteen extract in encapsulated form
219738731|NCT02631694|DRUG|Propranolol|Intake of propranolol pill (40 milligram)
219738732|NCT02631694|DRUG|Placebo|Intake of placebo pill (40 milligram)
219738733|NCT02631694|OTHER|Carbon dioxide|Inhalation of 35% carbon dioxide
219738734|NCT02631694|OTHER|Compressed air|Inhalation of air
219738735|NCT06455254|DRUG|Candonilimab (AK104)|Cadonilimab (AK104): 6mg/kg, i.v. q2w.
219738736|NCT06455254|DRUG|Regorafenib|Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
219738737|NCT01391494|BIOLOGICAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
219738738|NCT01391494|BIOLOGICAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
219171882|NCT06506604|BEHAVIORAL|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
219171883|NCT05759195|DIAGNOSTIC_TEST|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
219171884|NCT06219538|DEVICE|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery or D \& C,
219171885|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
219171886|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
219171887|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
219171888|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
219171889|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
219171890|NCT04278404|DRUG|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
219171891|NCT06580405|DEVICE|KNP-1000 Apheresis System|sFlt-1 is removed from the participants' plasma through treatment.
219171892|NCT03135106|DRUG|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
219171893|NCT03135106|DRUG|Fluconazole|A 400-mg fluconazole orally (4\*100 mg capsules) will be administered from Day 1 to Day 11.
219171894|NCT03135106|DRUG|Itraconazole|A 200-mg itraconazole orally (2\*100 mg capsules) will be administered from Day 1 to Day 11.
219171895|NCT03737045|OTHER|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
219171896|NCT06580912|DRUG|Krill oil|4 grams of krill oil per day
219171897|NCT06580912|DIETARY_SUPPLEMENT|Mixed vegetable oil|4 grams of mixed vegetable oil per day
219171898|NCT06314061|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A continuous glucose monitor which through a sensor in the skin registers glucose levels every 5 minutes. Glucose levels are shown by connecting the sensor to a mobile device or the Dexcom G7 Receiver where realtime alerts on deviating glucose levels will be sent.
219171899|NCT05932069|BEHAVIORAL|SPIN|Stationary cycling
219738739|NCT01391494|BIOLOGICAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
219738740|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
219738741|NCT01391494|BIOLOGICAL|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
219738742|NCT01391494|BIOLOGICAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
219738743|NCT01391494|BIOLOGICAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
219738744|NCT01391494|BIOLOGICAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
219738745|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
219738746|NCT01391494|BIOLOGICAL|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
219738747|NCT01391494|BIOLOGICAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
219738748|NCT01391494|BIOLOGICAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
219738749|NCT01391494|BIOLOGICAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
219171900|NCT05932069|BEHAVIORAL|Non-aerobic, stretching/balance intervention Control|Balance and stretching exercise
219171901|NCT05569174|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
219171902|NCT05569174|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
219171903|NCT05796297|DEVICE|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
219171904|NCT05006365|DEVICE|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
219171905|NCT05596162|OTHER|Blood Flow Restriction Therapy|Exercise with Blood Flow Restriction
219171906|NCT05596162|OTHER|Standard Physical Therapy|Exercise without Blood Flow Restriction
219171907|NCT06364189|BEHAVIORAL|Music|Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
219171908|NCT06364189|BEHAVIORAL|Exercise|"The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
219171909|NCT05738330|BEHAVIORAL|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
219171910|NCT05738330|BEHAVIORAL|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
219171911|NCT05859620|OTHER|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
219171912|NCT05964855|DEVICE|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
219171913|NCT05964855|DEVICE|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
219171914|NCT05964855|DEVICE|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
219171915|NCT05964855|DEVICE|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
219171916|NCT05964855|DEVICE|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
219171917|NCT00137540|DEVICE|RF ablation|
219171918|NCT00137540|DRUG|anti-arrhythmic drug therapy|
219242276|NCT06678789|BEHAVIORAL|High Nicotine Dose|Will receive a 5-week supply of 6 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
219242277|NCT06678789|BEHAVIORAL|Low Nicotine Dose|Will receive a 5-week supply of 3 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
219242278|NCT07131943|DEVICE|Radiofrequency|Radiofrequency (TECAR) therapy is a non-invasive, non-ablative treatment that uses electromagnetic energy to generate endogenous heat, promoting increased blood flow and tissue healing in both superficial and deep tissues. With a long wavelength and low frequency (300 KHz to 1 MHz), it can penetrate deeply into muscles, tendons, and bones, making it suitable even in acute conditions. TECAR operates in two modes: capacitive (targeting soft tissues rich in electrolytes) and resistive (targeting high-resistance tissues like bones and tendons). The therapy stimulates natural repair processes by inducing ion flow and micro-hyperemia, leading to the release of endorphins and cortisone, which help reduce pain, inflammation, and edema, while enhancing immune response and tissue regeneration.
219242279|NCT07131943|DEVICE|Ultrasound|The ultrasound waves accelerate healing, increasing local vascularity and improving several other characteristics, including energy absorption capacity and maximum rupture resistance tension, increased collagen synthesis, fibroblast proliferation, release of growth factors stimulated by mast cell degranulation and improved response of platelets and macrophages anticipating the proliferative and remodeling phase. 1-MHz continuous ultrasound, with a half-value depth of approximately 2.3 cm, is frequently used to treat deep tissues that are approximately 2.3 to 5 cm deep.
219242280|NCT07131943|OTHER|The designed physical therapy program|The designed physical therapy program focuses on improving upper limb mobility and stability through a structured set of exercises targeting the shoulder joint. It includes prolonged stretching performed in a seated position to extend the thumb, fingers, wrist, elbow, and shoulder, along with scapular mobilization in side-lying and stretching of internal rotators in a supine position. The stretching progression begins with external rotation at 45° abduction and advances to 90° abduction and full reach toward the ground if pain-free. Joint stabilization exercises involve resistance band movements in various shoulder and elbow positions, including controlled abduction, flexion, scapular movements, and external rotation, all aimed at enhancing joint control and muscular coordination.
219242281|NCT06675929|DRUG|BI 770371|BI 770371
219242282|NCT06675929|DRUG|Placebo for BI 770371|Placebo for BI 770371
219242283|NCT06679985|DRUG|Casdozokitug|Solution for infusion
219242284|NCT06679985|DRUG|Toripalimab|Solution for infusion
219242285|NCT06679985|DRUG|Bevacizumab|Solution for infusion
219242286|NCT07005752|DRUG|CnU cap. 250mg & Ursa placebo tab. 200mg|CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
219242287|NCT07005752|DRUG|Ursa tab. 200mg & CnU placebo cap. 250mg|Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
219242288|NCT06869785|BIOLOGICAL|Ofatumumab approved dose|Approved dosage
219242289|NCT06869785|BIOLOGICAL|Ofatumumab new dose|New dosage
219242290|NCT06869226|DRUG|Camrelizumab + Nab-paclitaxel + Cisplatin|Three cycles of neoadjuvant therapy with camrelizumab (200 mg/dose D1, IV, Q3W)+Nab-paclitaxel(260 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W); for patients with organ preservation intent entered into the watchful waiting strategy group and received radiotherapy (50.4 Gy/28 doses), with camrelizumab maintenance therapy for 4-12 weeks after the end of radiotherapy, and a total of up to one year of camrelizumab.
219242291|NCT06035588|OTHER|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
219242292|NCT06035588|OTHER|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
219242293|NCT06811272|DRUG|Epcoritamab|Bispecific IgG1 antibody
219242294|NCT06684314|DRUG|Efanesoctocog alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
219242295|NCT06687226|DIETARY_SUPPLEMENT|Reconstitutable food powder|During the intervention week, participants will be asked take one dose of a reconstitutable food powder provided in a ziplock bag. This powder will be a mix of Gatorade Zero Powder (1 serving) and 1 serving of commercially available powders of either one or all of the following: camu camu, kelp or maqui. The powder mix in the bag will be added to water and drunk by the participant as soon as possible after having a bowel movement (baseline stool sample). Food powders are sourced from reputable companies and are safe for consumption (Gatorade is a wellrecognized brand and available in grocery stores nationally, Navitas Organics provides certified organic, third-party tested plant food powders with fairtrade certification).
219242296|NCT05409846|DIAGNOSTIC_TEST|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
219242297|NCT07016269|DRUG|CnU capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
219242298|NCT07016269|DRUG|CnU placebo capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
219738750|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
219738751|NCT01391494|BIOLOGICAL|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
219738752|NCT03368521|OTHER|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
219738753|NCT03491085|DRUG|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
219738754|NCT02294019|DRUG|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
219738755|NCT02369159|DRUG|Peramivir|
219738756|NCT02369159|DRUG|Oseltamivir|
219171919|NCT05768295|DEVICE|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
219171920|NCT05725395|BEHAVIORAL|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
219171921|NCT05725395|BEHAVIORAL|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
219171922|NCT05962151|DRUG|NAL ER|Oral tablets
219171923|NCT05962151|DRUG|Placebo|Oral tablets
219171924|NCT04088370|OTHER|Blood Draw|Blood Draw Only
219171925|NCT05131321|PROCEDURE|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
219171926|NCT05131321|PROCEDURE|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
219171927|NCT05131321|PROCEDURE|Intramedullary Fibular Nailing (IMFN)|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
219171928|NCT06551922|COMBINATION_PRODUCT|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022)."
219171929|NCT06551922|COMBINATION_PRODUCT|Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022)."
219242299|NCT06869213|DRUG|Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin|All subjects were given 3 cycles of neoadjuvant therapy with adebrelimab (1200 mg D1, IV, Q3W)+Nab-paclitaxel(250 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W) preoperatively. Within 4-8 weeks of completion of neoadjuvant therapy, all subjects who were suitable for surgery underwent radical surgery, and patients who underwent radical esophageal cancer with R0 resection were given adebrelimab monotherapy postoperatively until disease recurrence or metastasis, toxicity intolerance, initiation of a new antitumor therapy, subject-initiated request to withdraw from the study, and subject's judgement that the subject needed to be withdrawn from the study. The maximum duration of adebrelimab in the adjuvant phase is 16 cycles.
219242300|NCT06424860|DIETARY_SUPPLEMENT|Fish oil|For 12 months
219242301|NCT06424860|DRUG|Metformin|12 months
219242302|NCT06424860|COMBINATION_PRODUCT|Fish Oil and Metformin|12 months
219242303|NCT07035769|DRUG|Debio 1453P|Powder for oral solution
219242304|NCT07035769|DRUG|Placebo|Oral solution
219242305|NCT06705335|OTHER|Blood sample|On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
219242306|NCT06887543|OTHER|Meal timing|Participants either eat all of their daily calories between 8 AM and 4 PM with 16 hours fasting for six days, or they eat the same meals ad lib daily for six days. After post-testing, they crossover to the other arm.
219242307|NCT06887543|OTHER|Time restricted eating|Eating restricted to 8 AM - 2 PM for 80% of caloric intake, the remaining 20% consumed by 4 PM, subsequent 16-hour fasting (4 PM-8 AM) each day for six days while on Time Restricted Arm.
219242308|NCT06887543|OTHER|Usual feeding pattern.|Participant consumes usual diet ad lib without enforced fasting period for six days while on Usual Feeding Pattern arm.
219242309|NCT06887010|DRUG|ABBV-101|Oral: Tablet
219242310|NCT06744660|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID Test|The Metrix COVID Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2 via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
219242311|NCT06743776|DRUG|MN-166|MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken.
219242312|NCT06744920|DRUG|Remibrutinib (Blinded)|Remibrutinib (Blinded) active treatment
219242313|NCT06744920|OTHER|Placebo|Placebo
219242314|NCT06744920|DRUG|Remibrutinib (Open Label)|Remibrutinib (Open Label) active treatment
219242315|NCT06741579|DEVICE|Peripheral Nerve Stimulation|This trial studies 2 FDA approved peripheral nerve stimulation devices that may reduce pain by sending electrical pulses to the nerve. The SPR SPRINT PNS System, a matchbox-sized, battery-powered wearable stimulator that uses a Mircrolead to deliver stimulation for pain relief. There is a small wireless hand-held remote that is used to activate/ adjust intensity of stimulation. Stimulation delivered by this device may interrupt pain signals and increase non-pain signals. The SPR SPRINT device is used for 60 days before the percutaneous Microlead(s) are removed. The Nalu PNS System, a dime-sized micro-implantable pulse generator (IPG) leveraging advanced microelectronics. The micro-IPG is powered by an externally worn therapy disc via radiofrequency worn over the IPG site with an adhesive clip applied to the skin or a relief belt. The device is remote-controlled by patients via an app.
219242316|NCT06741579|PROCEDURE|Conventional Care Regimen|CMM-Only participants will receive conventional medical management for the duration of their time in the study.
219242317|NCT05810038|DRUG|Rimegepant|Rimegepant
219242318|NCT05810038|DRUG|Placebo|matching placebo
219738757|NCT05214027|OTHER|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
219242319|NCT06636656|DRUG|BI 3032950 intravenous (Part A)|BI 3032950 intravenous (Part A)
219242320|NCT06636656|DRUG|BI 3032950 subcutaneous (Part B)|BI 3032950 subcutaneous (Part B)
219242321|NCT05937906|DRUG|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
219242322|NCT05937906|DRUG|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
219242323|NCT05937906|DRUG|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
219242324|NCT05937906|DRUG|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
219738758|NCT05214027|OTHER|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
219738759|NCT02975115|OTHER|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
219242325|NCT05937906|DRUG|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
219242326|NCT06897475|DRUG|LY3457263|Administered SC
219242327|NCT06897475|DRUG|Placebo|Administered SC
219242328|NCT06664619|DRUG|Fp/ABS|Inhalation powder
219242329|NCT06664619|DRUG|FP|Inhalation powder
219242330|NCT06664619|DRUG|ABS|Inhalation powder
219242331|NCT06664619|DRUG|Placebo|Inhalation powder
219242332|NCT05211570|DRUG|AB8939|Intravenous injection (from an initial dose of 0.9 mg/m²)
219242333|NCT05211570|DRUG|Venetoclax|the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.
219242334|NCT07138066|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
219738760|NCT00049946|DRUG|talnetant|
219738761|NCT00049946|DRUG|risperidone|
219242335|NCT07138066|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and 15 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
219242336|NCT07138066|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan.
219242337|NCT07138066|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program consists of a structured set of isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility. Exercises are performed in a supine, prone, or seated position, as appropriate, with 2 sets of 5-12 repetitions or sustained holds of 20-30 seconds, progressing gradually according to the rehabilitation plan. All movements are conducted within a pain-free range (not exceeding 4/10 on the VAS scale), with additional hourly ankle mobility work prescribed to reduce swelling and prevent thrombosis.
219242338|NCT07138066|DEVICE|Orthopedic shoes for use during rehabilitation period|Patients are provided with orthopedic shoes to be worn during the rehabilitation period (up to 6-10 weeks).
219242339|NCT06601946|OTHER|BLS Paper Based Cognitive App|BLS Paper Based Cognitive App
219242340|NCT06601946|OTHER|First Aid App|First Aid App
219242341|NCT06601946|OTHER|Corpatch App|Corpatch App
219242342|NCT05904080|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219242343|NCT05904080|DRUG|Cabozantinib S-malate|Given PO
219242344|NCT05904080|PROCEDURE|Computed Tomography|Undergo CT scan
219242345|NCT05904080|BIOLOGICAL|Ipilimumab|Given IV
219242346|NCT05904080|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219242347|NCT05904080|BIOLOGICAL|Nivolumab|Given IV
219242348|NCT06667830|OTHER|Physical exercise program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
219242349|NCT06667830|OTHER|Neural mobilization techniques|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
219242350|NCT07079969|DEVICE|Photobiomodulation therapy (PBM) device|FDA-cleared near-infrared PBM device delivering therapeutic light to the affected knee. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks (2-3 times per week).
219242351|NCT07079969|DEVICE|Sham PBM device|Identical in appearance to the active PBM device but emits no therapeutic light. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks.
219242352|NCT07079969|DRUG|Diclofenac Sodium 1 % Topical Cream|Topical nonsteroidal anti-inflammatory drug applied at a dose of 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks.
219242353|NCT07079969|DRUG|Placebo topical cream|Inert cream matching the appearance of diclofenac sodium 1% gel. Applied at 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks
219242354|NCT06760663|BEHAVIORAL|The load-velocity relationship: Neuromuscular adaptations to resistance training|Comparing the impact of adjusting training load based on movement velocity on hypertrophy and neural adaptations.
219242355|NCT07081087|DIAGNOSTIC_TEST|PERIBLOOD|In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology
219242356|NCT06891833|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219242357|NCT06891833|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
219242358|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Live Online|"Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes daily and increasing to 20 minutes daily using guided meditations. Attendance in the group sessions and home practice will be tracked to determine dose of the intervention received."
219242359|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Digital App|"The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine dose of the intervention received."
219242360|NCT06748222|BEHAVIORAL|Meditation Only Control Group|"Use of the meditations will be tracked to determine dose of the intervention received."
219242361|NCT06583759|PROCEDURE|Full coverage Crowns|The crown will be prepared accordingly. Try in of the best fitted crown will be done and cementation.
219242362|NCT06776783|COMBINATION_PRODUCT|APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)|Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.
219242363|NCT06776783|OTHER|Control|Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.
219242364|NCT05907746|DRUG|Mycophenolate Mofetil|15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)
219242365|NCT05907746|DRUG|Tacrolimus|0.02 mg/kg IV daily starting on day +5
219242366|NCT05907746|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg IV daily on days +3 and +4
219242367|NCT05907746|RADIATION|Total Body Irradiation|200cGy on day -1
219738762|NCT03969030|OTHER|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support"
219738763|NCT03038919|DRUG|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
219738764|NCT03038919|OTHER|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
219171930|NCT06236308|BIOLOGICAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
219738765|NCT04802005|OTHER|Aerobic Interval Training|The aerobic interval training group
219738766|NCT04292496|PROCEDURE|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
219738767|NCT02635672|DRUG|VIP152 (BAY 1251152)|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
219738768|NCT02635672|DRUG|VIP152 (BAY 1251152) 30 mg|30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
219738769|NCT02635672|DRUG|Keytruda|200 mg IV fixed dose once every 3 weeks of a 21 day cycle
219738770|NCT02635672|DRUG|VIP152 (BAY 1251152) 15 mg|The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
219738771|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
219738772|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
219738773|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
219171931|NCT06236308|BIOLOGICAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
219171932|NCT06236308|BIOLOGICAL|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
219171933|NCT02663193|OTHER|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
219171934|NCT06257810|DIAGNOSTIC_TEST|VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG|"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."
219171935|NCT06257810|OTHER|Standard of care practices|"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."
219171936|NCT02116335|DRUG|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
219171937|NCT02116335|DRUG|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
219171938|NCT05341986|OTHER|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
219171939|NCT06467487|OTHER|Traditional Letter|Patients receive a traditional letter.
219171940|NCT06467487|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
219171941|NCT06467487|OTHER|Optimized Letter|Patients receive an optimized letter.
219171942|NCT06467487|OTHER|Direct to Patient Message - Optimized|Patients receive an optimized direct to patient message via the portal.
219171943|NCT04536090|DRUG|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
219171944|NCT05935917|DRUG|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
219171945|NCT06165601|PROCEDURE|Follow-up at D14|A blood test and urinary test will be performed at D14.
219171946|NCT06165601|PROCEDURE|Follow-up at M1|A blood test and urinary test will be performed at M1.
219171947|NCT06326827|DEVICE|In'Oss™ (MBCP® Putty)|Use of In'Oss™ (MBCP® Putty) in surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia.
219171948|NCT05644483|DRUG|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
219171949|NCT05644483|DRUG|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
219242368|NCT05907746|PROCEDURE|Hematopoietic Cell Transplant|stem cell transplant on day 0
219242369|NCT05907746|DRUG|Briquilimab|Single 0.6 mg/kg IV infusion administered between days -13 and day -10
219242370|NCT05907746|DRUG|Cyclophosphamide|14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
219242371|NCT05907746|DRUG|Fludarabine|30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
219242372|NCT05327946|DRUG|BI 770371|BI 770371
219242373|NCT05327946|DRUG|ezabenlimab|ezabenlimab
219242374|NCT06598592|OTHER|Video-Emergency|Video Emergency Call using a webbased platform
219242375|NCT06598592|OTHER|Audio-Emergency Call|Audio Emergency Call
219242376|NCT07081841|OTHER|Observation|This is an observational study in which safety laboratories and non-invasive routine clinical assessments are conducted to gauge long term safety and efficacy.
219242377|NCT06903572|OTHER|the clinical pharmacists interventions about medication related information during transition of care|the intervention is the clinical pharmacists ' interventions regarding medication related information during transition of care .This includes reviewing medications regimen and treatment plan , documenting patients' drug history, drug related adverse events and detecting medication discrepancies.
219242378|NCT05891171|DRUG|AB598|Administered as specified in the treatment arm
219242379|NCT05891171|DRUG|Zimberelimab|Administered as specified in the treatment arm
219242380|NCT05891171|DRUG|Fluorouracil|Administered as specified in the treatment arm
219242381|NCT05891171|DRUG|Leucovorin|Administered as specified in the treatment arm
219242382|NCT05891171|DRUG|Oxaliplatin|Administered as specified in the treatment arm
219242383|NCT07085338|DRUG|Temozolomide|IV, Days 1-5
219242384|NCT07085338|DRUG|Irinotecan|IV, Days 1-5
219242385|NCT07085338|DRUG|hu14.18K322A|IV over 4 hours daily times 4 doses, Days 2-5.
219242386|NCT07085338|DRUG|N803|Subcutaneous (SC), Day 6.
219242387|NCT07085338|DRUG|Sargramostim|Subcutaneous injection (preferred) or IV, Days 7-13.
219242388|NCT06930651|DRUG|Dexamethasone|Given Orally
219242389|NCT06930651|DRUG|Cyclophosphamide|Given by IV
219242390|NCT06930651|DRUG|Fludarabine|Given by IV
219242391|NCT06930651|DRUG|Decitabine|Given by IV
219242392|NCT06930651|BIOLOGICAL|TGFBR2 KO CAR27/IL-15 NK cells|Given by Infusion
219242393|NCT06925477|DEVICE|DSLT treatment for Open-Angle Glaucoma|This intervention aims to determine the efficacy and safety of Direct Selective Laser Trabeculoplasty (DSLT) in reducing intraocular pressure in patients with open-angle glaucoma.
219242394|NCT06925477|DEVICE|SLT treatment for Open-Angle Glaucoma|To determine the efficacy and safety of using Selective Laser Trabeculoplasty for treatment of open-angle glaucoma.
219242395|NCT07085923|BEHAVIORAL|Lifestyle Intervention|The Lifestyle Program consists of monthly one-on-one dietary counselling sessions with a registered clinical dietitian, monthly group-based physical activity sessions led by an instructor, and support to follow a personalized exercise plan. The intervention focuses on cardioprotective dietary changes, weight reduction, and increasing physical activity at moderate-to-high intensity to meet recommended amount. Participants will receive dietary supplementation corresponding to a therapeutic dose of 1000 mg EPA+DHA per day from fish oil. During monthly visits with the dietitian, data will be collected to monitor progress and support adherence. Participants will be encouraged to monitor body weight at home between visits (bathroom scales are loaned as needed), and follow up is carried out biweekly via phone-calls. The intervention is designed to be feasible within routine mental health care and tailored to the needs of adults with severe mental illness.
219242396|NCT07086547|OTHER|AI-Based Fever Management Education|This intervention consists of a fever management education program developed using ChatGPT 4.0, a large language model by OpenAI. The educational content includes seven pages and eight visuals explaining how to manage fever in children. The content was reviewed by pediatric specialists and revised accordingly. It is delivered as a one-time structured session to mothers in the intervention group.
219242397|NCT05950464|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219242398|NCT05950464|PROCEDURE|Biopsy Procedure|Undergo biopsy
219242399|NCT05950464|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219242400|NCT05950464|PROCEDURE|Computed Tomography|Undergo CT
219242401|NCT05950464|PROCEDURE|Electrocardiography|Undergo ECG
219242402|NCT05950464|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219242403|NCT05950464|DRUG|Tuvusertib|Given PO
219242404|NCT05950464|PROCEDURE|X-Ray Imaging|Undergo x-ray
219242405|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219242406|NCT05348915|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
219242407|NCT06617845|DEVICE|Stimulation Set A and B|Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
219171950|NCT04010344|BEHAVIORAL|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools."
219242408|NCT06902545|DRUG|zolbetuximab|Intravenous
219242409|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
219738774|NCT02467881|BEHAVIORAL|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
219738775|NCT02467881|BEHAVIORAL|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
219738776|NCT02467881|OTHER|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
219738777|NCT01173926|DRUG|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
219738778|NCT01173926|DRUG|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
219171951|NCT04010344|OTHER|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
219242416|NCT07090499|DRUG|PF-08046876|Intravenous administration
219242417|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
219242418|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
219242419|NCT06004245|DRUG|RO7589831|RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
219738779|NCT01173926|DRUG|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
219738780|NCT03769116|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219738781|NCT03769116|GENETIC|placebo|Single IV infusion of matching placebo
219738782|NCT00932503|DEVICE|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
219738783|NCT06500871|DRUG|Diclofenac Potassium|NSAID
219738784|NCT04743206|DEVICE|Standard Airway Clearance device|Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.
219738785|NCT04743206|DEVICE|Portable Internal Airway Percussion device|Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
219738786|NCT04094090|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
219738787|NCT01821872|DRUG|Administration of paracetamol|Administration of 1g intravenous paracetamol
219738788|NCT06265610|PROCEDURE|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
219171952|NCT05259787|DRUG|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
219171953|NCT05259787|DRUG|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
219171954|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
219171955|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
219171956|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
219171957|NCT04428944|PROCEDURE|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
219171958|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
219171959|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
219171960|NCT06483477|OTHER|Standard skin care|From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
219171961|NCT06483477|DEVICE|Reminder App|In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
219171962|NCT04024813|DRUG|Seladelpar|Capsule(s) administered orally once daily
219171963|NCT04024813|DRUG|Placebo to match Seladelpar|Capsule(s) administered orally once daily
219171964|NCT05987033|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
219242420|NCT06004245|DRUG|Pembrolizumab|Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
219171965|NCT06258291|DEVICE|Hemosystem REBOOT|The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
219171966|NCT05747222|OTHER|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
219171967|NCT05747222|OTHER|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
219171968|NCT05008783|DRUG|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
219171969|NCT05008783|DRUG|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
219171970|NCT05515614|DIETARY_SUPPLEMENT|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
219171971|NCT05515614|DIETARY_SUPPLEMENT|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
219171972|NCT06088355|BEHAVIORAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
219171973|NCT06088355|BEHAVIORAL|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
219171974|NCT06088355|BEHAVIORAL|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
219171975|NCT04166331|DRUG|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
219171976|NCT04166331|DRUG|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
219171977|NCT05034952|DRUG|VX-548|Tablets for oral administration.
219171978|NCT05034952|DRUG|HB/APAP|Capsules for oral administration.
219171979|NCT05034952|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
219171980|NCT05034952|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
219171981|NCT04238949|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
219171982|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
219171983|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
219171984|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
219171985|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
219171986|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
219171987|NCT04770233|PROCEDURE|Early ACL reconstruction|ACL reconstruction followed by rehabilitation
219171988|NCT04770233|PROCEDURE|Active rehabilitation|Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
219171989|NCT04950660|DRUG|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
219171990|NCT04950660|DRUG|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
219171991|NCT06133829|BEHAVIORAL|upREACH Home Visitation Program|upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
219171992|NCT02111798|DRUG|Placebo|Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
219171993|NCT02111798|DRUG|Bupropion XL|Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
219171994|NCT02111798|BEHAVIORAL|Abstinence Initiation|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
219171995|NCT02111798|BEHAVIORAL|Relapse Prevention|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
219171996|NCT05459207|OTHER|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
219171997|NCT05459207|OTHER|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
219171998|NCT04786028|OTHER|Isatuximab|Brand name for interventional drug is Sarclisa
219171999|NCT04445168|BEHAVIORAL|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
219172000|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"* Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
219172001|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
219172002|NCT04107857|BEHAVIORAL|Data Driven Feedback reports|-Feedback reports will be based on data
219172003|NCT06546462|OTHER|Osteopathic Manipulative Treatment (OMT)|The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.
219172004|NCT06546462|OTHER|Sham Light touch arm|Sham arm will receive a light touch sham treatment.
219172005|NCT05891119|DIETARY_SUPPLEMENT|Caffeine|Oral liquid
219172006|NCT05891119|DRUG|Metoprolol|Oral tablet
219172007|NCT05891119|DRUG|Midazolam|Oral liquid
219172008|NCT05891119|DRUG|Warfarin|Oral tablet
219172009|NCT05891119|DIETARY_SUPPLEMENT|Vitamin K|Oral tablet
219172010|NCT05891119|DRUG|Omeprazole|Oral capsule
219172011|NCT05891119|DRUG|Rocatinlimab|Subcutaneous injection
219172012|NCT02437318|DRUG|Fulvestrant|500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
219172013|NCT02437318|DRUG|Alpelisib|300 mg of alpelisib tablets for oral use administered once daily
219172014|NCT02437318|DRUG|Placebo|300 mg of placebo tablets for oral use administered once daily
219172015|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.
219172016|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.
219172017|NCT05608187|BIOLOGICAL|Placebo|Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
219242421|NCT06816550|OTHER|Doing Interviews with the patients admitted to emergency department to detect whom are on chronic use of nonsteroidal anti inflammatory drugs|detection of patients on chronic use of nonsteroidal anti inflammatory drugs among total patients admitted to emergency department in Alexandria Main University Hospital
219242422|NCT07093619|DEVICE|FERTILE Plus|The FERTILE PLUS™ method is a standardized method with an easy-to-follow protocol that is far less dependent on the skill or experience of the embryologist than other methods, such as density gradients. The FERTILE PLUS™ (850 µL) Sperm Sorting Chip is a single-use, flow-free, dual chambered, microfluidic-based sperm sorting device. FERTILE PLUS™ was previously known as Zymot, prior to a name change by the manufacturer. The lower chamber contains a sample inlet and fluid channel separated from the upper collection chamber by a microporous membrane with 8-μm pores, demonstrated as the optimal size for selection of sperm with higher motility and normal morphology \[18\].
219242423|NCT07090122|PROCEDURE|Radiofrequency ablation and bone augmentation with radiotherapy|employs radiofrequency-generated heat to eradicate cancer cells, followed by the application of a bone-stabilizing agent
219242424|NCT07090122|PROCEDURE|Radiotherapy alone|High-energy radiation
219242425|NCT07092280|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method used to modulate cortical excitability, which produces facilitatory or inhibitory effects on behaviors. The anodal electrode will be positioned at F3 (using the international 10-20 EEG system) to target the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will undergo 20 active stimulation sessions, each lasting 20 minutes at a continuous 1.0 mA intensity.
219242426|NCT07092280|DEVICE|Sham (No Treatment)|The anodal electrode will be positioned at F3 (according to the international 10-20 EEG system), targeting the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will receive 20 sessions of sham stimulation, each 20 minutes long. At the start of each session, the current ramps up and remains active for 30 seconds. After 30 seconds, the current is DISCONTINUED (held at 0 mA) but the power indicator stays illuminated for the remainder of the 20-minute session to ensure effective blinding, as is standard in tDCS sham protocols
219242427|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219242428|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
219242429|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
219242430|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
219242431|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219242432|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
219738789|NCT02844075|DRUG|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
219738790|NCT05958225|BEHAVIORAL|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
219738791|NCT04530695|OTHER|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
219738792|NCT00003008|DRUG|indinavir sulfate|
219738793|NCT00003008|DRUG|nelfinavir mesylate|
219738794|NCT00003008|DRUG|paclitaxel|
219738795|NCT00003008|DRUG|ritonavir|
219738796|NCT00003008|DRUG|saquinavir mesylate|
219738797|NCT06566703|BEHAVIORAL|All Nations Snuff Out Smokeless|All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.
219738798|NCT06566703|BEHAVIORAL|Healthy Living|Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
219738799|NCT06125327|DRUG|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
219738800|NCT06125327|DRUG|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
219738801|NCT06530303|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
219738802|NCT06530303|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219738803|NCT06530303|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219738804|NCT06530303|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
219738805|NCT06530303|DRUG|Pembrolizumab|Intravenous (IV) infusion
219738806|NCT01908387|DRUG|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
219738807|NCT03540485|DRUG|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
219738808|NCT03540485|OTHER|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
219242433|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.2 Usage|Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
219242434|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
219738809|NCT06461273|BEHAVIORAL|Lifestyle Medicine Program|"Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM."
219738810|NCT06461273|BEHAVIORAL|Medically Tailored Groceries|"Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips."
219738811|NCT06006468|GENETIC|High genetic risk for type 1 diabetes|in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
219738812|NCT06006468|GENETIC|High gentic risk for Coeliac disease|in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
219738813|NCT02056951|PROCEDURE|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling."
219738814|NCT02056951|PROCEDURE|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations"
219738815|NCT00310141|BEHAVIORAL|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
219738816|NCT00310141|OTHER|Counseling intervention|In-person counseling (5 sessions)
219738817|NCT00310141|DRUG|Nicotine patch|6-week supply of the nicotine patch
219738818|NCT04980963|BEHAVIORAL|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
219738819|NCT01346917|DRUG|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
219738820|NCT01346917|DRUG|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
219738821|NCT01166698|DRUG|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
219738822|NCT01166698|DRUG|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
219738823|NCT01166698|DRUG|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
219738824|NCT01217515|DRUG|Diltiazem hydrochloride 4% cream|3 times daily
219738825|NCT01217515|DRUG|Diltiazem hydrochloride 2% cream|3 times daily
219738826|NCT01217515|OTHER|Placebo|3 times daily
219738827|NCT06275958|DRUG|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
219738828|NCT06275958|DRUG|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
219738829|NCT06275958|DRUG|Monotherapy, Standard Dose (100%)|\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
219738830|NCT06275958|DRUG|Monotherapy, Dose-reduced (75%)|"75% of:~\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
219738831|NCT05930067|DEVICE|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
219738832|NCT05930067|DEVICE|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
219738833|NCT03989674|DIETARY_SUPPLEMENT|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
219738834|NCT02344498|DRUG|Tenofovir disoproxil|
219242435|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
219242436|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
219242437|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
219242438|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
219242439|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 6|Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
219242440|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
219242441|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control 6.1.0|Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks.
219242442|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks.
219242443|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.2 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks.
219242444|NCT06910436|DIAGNOSTIC_TEST|Coronary Angiogram|Diagnostic/therapeutic procedure to reopen an occluded coronary artery by inflating a balloon and inserting a stent
219242445|NCT07136012|DRUG|Olpasiran|Olpasiran will be administered via SC injection.
219242446|NCT07136012|DRUG|Placebo|Placebo will be administered via SC injection.
219242447|NCT06813911|DRUG|Pelacarsen|Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.
219242448|NCT06813911|DRUG|Placebo|Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.
219242449|NCT06813911|DRUG|Inclisiran|All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.
219242450|NCT06762964|DRUG|Dapagliflozin tablet|Patient will take a 10mg tablet of Dapagliflozin once daily for 24 weeks
219738835|NCT01887600|DRUG|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
219738836|NCT01887600|DRUG|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
219738837|NCT03688139|BEHAVIORAL|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
219738838|NCT03688139|BEHAVIORAL|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
219738839|NCT02137278|DRUG|Vasoactive drug therapies|Continue current vasoactive therapy
219738840|NCT02137278|OTHER|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
219738841|NCT02380235|BIOLOGICAL|PEG-somatropin|0.20mg/kg/w
219738842|NCT02380235|BIOLOGICAL|PEG-somatropin|0.12mg/kg/w
219738843|NCT04545697|OTHER|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
219738844|NCT02470377|DEVICE|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
219738845|NCT01907646|DEVICE|bladder training|vescical catheter
219738846|NCT01907646|PROCEDURE|No bladder training|
219738847|NCT03274089|DEVICE|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices"
219738848|NCT03274661|DRUG|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
219738849|NCT02783859|DRUG|Amoxicillin-clavulanic Acid|
219738850|NCT02783859|DRUG|Placebo (for Amoxicillin-clavulanic Acid)|
219738851|NCT01083472|DEVICE|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
219738852|NCT01083472|PROCEDURE|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
219738853|NCT02451475|DRUG|Amitriptyline|Amitriptyline 25 mg/day
219738854|NCT02451475|DRUG|Venlafaxine|Venlafaxine 75 mg/day
219738855|NCT02451475|DRUG|Paroxetine|Paroxetine 25 mg/day
219738856|NCT01280500|BEHAVIORAL|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
219738857|NCT01280500|OTHER|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
219738858|NCT01280500|OTHER|usual care|No EMR
219738859|NCT01280500|OTHER|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
219242451|NCT06762964|DRUG|Placebo Tablet|Patient will take 10mg placebo tablet once daily for 24 weeks
219242452|NCT04451668|DRUG|FT218|once nightly sodium oxybate extended release
219242453|NCT07100483|PROCEDURE|Atrial Fibrillation Ablation|Ablation of the heart to reduce Afib Occurrence
219242454|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
219242455|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
219242456|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
219242457|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
219242458|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
219242459|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
219242460|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
219242461|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
219242462|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
219242463|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
219242464|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
219242465|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
219242466|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
219242467|NCT04250766|PROCEDURE|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
219242468|NCT07104500|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
219242469|NCT06915025|DRUG|IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)|100 mg/m2 IP given weekly during frontline treatment
219242470|NCT06915025|DRUG|Paclitaxel|175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment
219242471|NCT06915025|DRUG|Carboplatin|AUC 6 IV given every 21 days for 6 cycles during frontline treatment
219242472|NCT06915025|DRUG|Olaparib|Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
219242473|NCT06915025|DRUG|Niraparib|Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt.
219242474|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
219738860|NCT01280500|OTHER|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
219738861|NCT03093168|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
219738862|NCT03093168|DRUG|Fludarabine|dose: 25mg/m2/d
219738863|NCT03093168|DRUG|Cyclophosphamide|Dose: 40mg/kg
219738864|NCT05802849|DRUG|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
219738865|NCT01390584|DRUG|Doxorubicin|IV
219738866|NCT01390584|DRUG|Bleomycin|IV
219738867|NCT01390584|DRUG|Vinblastine|IV
219738868|NCT01390584|DIAGNOSTIC_TEST|PET|fludeoxyglucose F 18 Imaging exam
219242475|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
219738869|NCT01390584|RADIATION|INRT|selective external radiation therapy
219242476|NCT07104032|DRUG|Tirabrutinib|Administered orally.
219242477|NCT07104032|DRUG|Rituximab|Administered intravenously (IV).
219242478|NCT07104032|DRUG|Temozolomide|Administered orally.
219242479|NCT06029517|OTHER|Education Intervention|Receive Indigneous SIPin intervention
219242480|NCT06029517|OTHER|Interview|Complete interviews
219242481|NCT06029517|PROCEDURE|Discussion|Attend focus groups
219242482|NCT04143724|DRUG|ACE-536|Specified dose on specified days
219242483|NCT01036581|DEVICE|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
219738870|NCT01390584|DRUG|Dacarbazine|IV
219738871|NCT01390584|DRUG|Etoposide|IV
219738872|NCT01390584|DRUG|Cyclophosphamide|May be given orally, IV push, or by IV infusion
219738873|NCT01390584|DRUG|Vincristine|IV
219738874|NCT01390584|DRUG|Procarbazine|PO
219738875|NCT01390584|DRUG|Prednisone|PO
219738876|NCT00996177|DRUG|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
219738877|NCT00996177|DRUG|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
219738878|NCT01946100|GENETIC|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
219738879|NCT06438952|PROCEDURE|Transforaminal steroid injection combined with lumbar sympathetic blockade|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance Lumbar sympathetic blockade will be made with 5 ml 0.5% bupivacaine + 6 mg dexamethason + 10 ml NaCl
219738880|NCT06438952|PROCEDURE|Transforaminal steroid injection only|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance
219242484|NCT01036581|DEVICE|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
219242485|NCT01036581|DEVICE|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
219242486|NCT07107139|OTHER|Copenhagen group|Participants use product for up to 30 minutes
219242487|NCT07107139|OTHER|Snus group|Participants use product for up to 30 minutes
219242488|NCT05333471|DRUG|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
219242489|NCT05142345|OTHER|CONTINUUM Intervention|The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
219242490|NCT05142345|OTHER|Usual Care|Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
219242491|NCT06918990|BIOLOGICAL|Carfilzomib|Administered by intravenous infusion over 60 minutes.
219242492|NCT06918990|BIOLOGICAL|Belatacept|Administered by intravenous infusion over 30 minutes.
219242493|NCT07107321|BEHAVIORAL|WISE Words|WISE Words is a co-designed, multicomponent deimplementation strategy package including 6 discrete strategies. Of these, three are delivered in a standard fashion: (1) dynamic training driven by improvisation methods, (2) a peer learning collaborative, and (3) external facilitation. The additional three are tailored to each educator's preferences and goals: (4) reminders, (5) educational materials, and (6) audit and feedback. Educators are supported to set and achieve goals for one feeding practice they want to stop and one they want to start.
219242494|NCT07110376|OTHER|Nighttime Deep Brain Stimulation with Varying Amplitude Settings|Participants will undergo three different nighttime-only Deep Brain Stimulation (DBS) settings in a randomized crossover design: 0% amplitude (stimulation off), 50% amplitude of their optimal clinical DBS settings, and full clinical DBS settings (100%). Each setting is applied for two weeks during sleep, over a total six-week home monitoring period. The intervention is designed to assess how varying levels of subthalamic nucleus DBS influence sleep quality and neural oscillatory activity. Only nighttime DBS settings are modified; daytime settings remain unchanged.
219242495|NCT07104383|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
219242496|NCT07112690|OTHER|Electronic Health Record Review|Ancillary studies
219242497|NCT07112690|PROCEDURE|Fluoroscopy|Undergo fluoroscopy
219242498|NCT07112690|PROCEDURE|Ganglion Impar Neurolysis|Undergo ganglion impar neurolysis
219242499|NCT07112690|OTHER|Questionnaire Administration|Ancillary studies
219242500|NCT07115862|OTHER|pomegranate juice -> habitual diet|237 ml of pomegranate juice for the first 8 weeks -\> habitual diet for the second 8 weeks
219242501|NCT07115862|OTHER|habitual diet -> pomegranate juice|habitual diet for the first 8 weeks -\> 237 ml of pomegranate juice for the second 8 weeks
219242502|NCT06912854|OTHER|Sensory Adapted Dental Environment|"The SADE condition consists of physical adaptations (visual, auditory, tactile modifications) to the dental environment meant to create a less anxiety-provoking sensory experience. Direct overhead fluorescent lighting and the regular dental overhead lamp will be turned off and darkening curtains will cover the windows. Adapted lighting will include slow moving visual color effects (Snoezelen) shining on the ceiling in the child's visual field. The dentist will wear a surgical dental headlamp directed into the patient's mouth, reducing bright lights shining in the child's eyes. Auditory stimuli will be calming rhythmic music (Dan Gibson's Exploring Nature) projected via portable speakers. The tactile deep pressure stimulus will be a commercially available weighted blanket (10-15% of the child's weight) placed on the child to provide deep hugging pressure, which produces a calming effect."
219242503|NCT06912854|OTHER|Video-based Modeling|Participants will watch an approximately 5-minute video depicting a dental cleaning being performed on a sex and age-matched cooperative child, designed to expose the participant to the activities of the dental cleaning and thereby create a less anxiety-provoking dental experience.
219242504|NCT03342625|DEVICE|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
219242505|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
219242506|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
219242507|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
219242508|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
219242509|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
219242510|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
219242511|NCT06253663|DRUG|KTE-X19|A single infusion of chimeric antigen receptor (CAR) T cells
219242512|NCT06253663|DRUG|Cyclophosphamide|Administered intravenously
219242513|NCT06253663|DRUG|Fludarabine|Administered intravenously
219242514|NCT06923189|BEHAVIORAL|Family Planning Intervention|"This multilevel intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community. The intervention is paired with health system strengthening elements implemented with the intervention health clinics (provider training, strengthening skip the queue policies, linkage of family planning services directly to dialogues)."
219242515|NCT06923189|BEHAVIORAL|Water, Sanitation, and Hygiene (WASH) Intervention|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (handwashing, food preparation) following an intervention manual that was developed for community groups in East Africa and tailored to the local Uganda context."
219242516|NCT06922942|DEVICE|MSCopilot Flower mobile application|MSCopilot Flower includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Anxiety
219242517|NCT07118722|BEHAVIORAL|Quiet Focus|Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression
219242518|NCT07118722|BEHAVIORAL|Health Enhancement Program|Time- and dose-matched control for Quiet Focus.
219242519|NCT03323983|OTHER|data collection|data collection
219242520|NCT04428983|DIETARY_SUPPLEMENT|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
219242521|NCT01764204|DRUG|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
219242522|NCT05196256|PROCEDURE|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
219242523|NCT05196256|PROCEDURE|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
219242524|NCT05196256|PROCEDURE|Epidural analgesia|Epidural analgesia
219242525|NCT05196256|DRUG|Sufentanyl/Levobupivacaine|Epidural analgesia
219242526|NCT02101554|DRUG|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
219242527|NCT02101554|DRUG|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
219242528|NCT00437086|DRUG|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
219242529|NCT02236299|PROCEDURE|Right Coronary Artery Percutaneous Coronary Intervention|
219242530|NCT02236299|OTHER|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
219738881|NCT00025233|BIOLOGICAL|bevacizumab|Given IV
219738882|NCT00025233|OTHER|laboratory biomarker analysis|Correlative studies
219738883|NCT01522027|PROCEDURE|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
219738884|NCT06305546|DRUG|Chlorhexidine Gluconate|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
219738885|NCT06305546|DRUG|Metronidazole|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
219738886|NCT06305546|DRUG|combination gel (chlorhexidine and metronidazole)|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
219738887|NCT06305546|DRUG|Placebo|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
219738888|NCT00121953|DRUG|Rosiglitazone|
219738889|NCT05581888|DEVICE|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
219738890|NCT02382900|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
219738891|NCT01023464|OTHER|FID114657|artificial tears
219738892|NCT01023464|OTHER|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
219738893|NCT00452400|DRUG|BI 1744CL|
219738894|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
219738895|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
219738896|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
219738897|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
219738898|NCT01720602|DRUG|vorinostat|Given PO
219242531|NCT02236299|OTHER|GLP-1 Infusion|30 minute infusion GLP-1
219242532|NCT00003934|DRUG|tretinoin|Given orally
219242533|NCT00003934|DRUG|daunorubicin hydrochloride|Given IV
219242534|NCT00003934|DRUG|cytarabine|Given IV
219242535|NCT00003934|DRUG|mercaptopurine|Given IV
219242536|NCT00003934|DRUG|methotrexate|Given IV
219242537|NCT00003934|DRUG|arsenic trioxide|Given IV
219172018|NCT06364657|DIAGNOSTIC_TEST|Eye Exam|"* Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface"
219242538|NCT03624023|DRUG|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
219242539|NCT04061317|OTHER|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
219242540|NCT05465278|DRUG|Alirocumab|18 months treatment with alirocumab
219242541|NCT04565392|DRUG|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
219242542|NCT00092378|DRUG|MK0966, rofecoxib|
219242543|NCT00092378|DRUG|Comparator: diclofenac sodium, placebo|
219738899|NCT01720602|DRUG|anastrozole|Given PO
219738900|NCT01720602|DRUG|letrozole|Given PO
219738901|NCT01720602|DRUG|exemestane|Given PO
219738902|NCT01720602|PROCEDURE|positron emission tomography|Correlative studies
219738903|NCT01720602|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
219738904|NCT01720602|RADIATION|fludeoxyglucose F 18|Correlative studies
219738905|NCT01720602|OTHER|laboratory biomarker analysis|Correlative studies
219738906|NCT01399086|DRUG|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
219738907|NCT02423720|BEHAVIORAL|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
219738908|NCT02781701|DEVICE|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
219738909|NCT02767245|DRUG|Thiamine|Thiamine IV 100 mg/day
219738910|NCT02882984|DRUG|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
219738911|NCT02882984|RADIATION|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
219738912|NCT02882984|RADIATION|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
219738913|NCT05004168|OTHER|Day Gel-0120|Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
219738914|NCT05004168|OTHER|P5 Reference Standard (SPF 35 reference)|The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
219738915|NCT02580006|DRUG|EPORON|single dose administration subcutaneously
219738916|NCT02580006|DRUG|EPREX|single dose administration subcutaneously
219738917|NCT01714388|DRUG|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
219738918|NCT05013086|DRUG|1.48 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
219738919|NCT01835431|DRUG|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
219738920|NCT01835431|DRUG|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
219738921|NCT01835431|DRUG|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
219738922|NCT01835431|DRUG|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
219738923|NCT03977610|DRUG|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
219738924|NCT02609451|PROCEDURE|Ileostomy closure|Ileostomy closure at a different time point
219738925|NCT02978508|DRUG|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
219738926|NCT02978508|DRUG|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
219738927|NCT04633876|BEHAVIORAL|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
219738928|NCT04633876|BEHAVIORAL|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
219738929|NCT04633876|OTHER|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
219738930|NCT02846727|DEVICE|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
219172019|NCT03361826|DEVICE|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
219172020|NCT03361826|BEHAVIORAL|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
219172021|NCT06422403|DRUG|Extended Dosing Interval - A|Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
219172022|NCT06422403|DRUG|Extended Dosing Interval - B|Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
219172023|NCT06422403|DRUG|Extended Dosing Interval - C|Pembrolizumab 200mg 6 weekly (up to 2 years)
219172024|NCT06422403|DRUG|Standard of Care - A|Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
219172025|NCT06422403|DRUG|Standard of Care - B|Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
219172026|NCT06422403|DRUG|Standard of Care - C|Pembrolizumab 200mg 3 weekly (up to 2 years)
219172027|NCT03423953|DEVICE|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
219172028|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
219172029|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
219172030|NCT06120036|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
219172031|NCT06120036|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
219172032|NCT05153226|DRUG|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
219172033|NCT05153226|BIOLOGICAL|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
219172034|NCT05776641|DEVICE|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
219172035|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
219172036|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
219172037|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
219172038|NCT04570475|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
219172039|NCT04570475|DIETARY_SUPPLEMENT|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
219172040|NCT04570475|DIETARY_SUPPLEMENT|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
219172041|NCT05243017|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
219172042|NCT05097430|BEHAVIORAL|Alcohol-focused brief intervention|The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
219172043|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
219172044|NCT06378359|OTHER|Screening and decolonization for SA carriers with the 3 drug bundle|nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse and CHG soap showers x 5 days and non-SA carriers receive 2 CHG pre-op showers
219172045|NCT06378359|OTHER|No screening for SA|All receive the 3 drug bundle, Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash
219172046|NCT06378359|OTHER|no screening|giving pre-surgical patients the three drug decolonization bundle without screening
219172047|NCT06378359|OTHER|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
219172048|NCT06378359|OTHER|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
219172049|NCT03730922|PROCEDURE|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
219172050|NCT03730922|PROCEDURE|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
219738931|NCT01105832|DRUG|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
219738932|NCT03517293|BEHAVIORAL|Aerobic Exercise training|
219738933|NCT05383950|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
219172051|NCT05309655|DRUG|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
219172052|NCT05309655|DIAGNOSTIC_TEST|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
219172053|NCT05309655|DIAGNOSTIC_TEST|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
219172054|NCT05309655|OTHER|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
219172055|NCT05309655|BEHAVIORAL|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
219172056|NCT06308874|DRUG|Amg dose administration group|Orally, Amg tablet single administration
219172057|NCT06308874|DRUG|Amg dose administration group- Placebo|Orally, Placebo Amg tablet single administration
219172058|NCT06308874|DRUG|Bmg dose administration group|Orally, Bmg tablet single administration
219172059|NCT06308874|DRUG|Bmg dose administration group- Placebo|Orally, Placebo Bmg tablet single administration
219172060|NCT04321031|DRUG|Placebo|Tablet
219172061|NCT04321031|DRUG|PF-06865571|Tablet
219172062|NCT04321031|DRUG|PF-05221304|Tablet
219172063|NCT06223880|DRUG|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
219172064|NCT06223880|DRUG|Bupropion|Up to 26 weeks in double-blind period
219172065|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
219172066|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
219172067|NCT05366647|PROCEDURE|canaloplasty|canaloplasty ab interno with tensioning suture
219172068|NCT05366647|PROCEDURE|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
219172069|NCT05509153|DRUG|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
219172070|NCT05509153|DRUG|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
219172071|NCT02339922|DRUG|Ixazomib Citrate|Given PO
219172072|NCT02339922|OTHER|Laboratory Biomarker Analysis|Correlative studies
219172073|NCT02339922|BIOLOGICAL|Rituximab|Given IV
219172074|NCT05508165|DEVICE|Stream Dx|home uroflowmetry device
219172075|NCT05508165|DEVICE|DFree|at home wearable bladder scanner
219172076|NCT05508165|DEVICE|TestCard|mobile urinalysis reader
219172077|NCT04323774|BEHAVIORAL|AYA-RISE Adolescents and Young Adults Risk Information and Screening Education|A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.
219172078|NCT04323774|BEHAVIORAL|Standard clinical visit for genetic counseling|Standard clinical visit for genetic counseling and follow up
219172079|NCT05347472|OTHER|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
219172080|NCT05347472|OTHER|Sham Smartphone application|ham application that includes information and general advice about UI only
219172081|NCT05914155|DRUG|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
219172082|NCT05914155|DRUG|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
219172083|NCT05914155|DRUG|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
219172084|NCT03342079|DRUG|Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)|topical anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)
219172085|NCT03342079|DRUG|Placebos|placebo topical anesthetic
219172086|NCT06512025|BEHAVIORAL|WWWT psychoeducative intervention|"What Were We Thinking (WWWT) is a highly structured, interactive, gender-informed, couples-based, psycho-educational program for parents and a first newborn to promote confident parental caretaking, optimize functioning in the intimate partner relationship and improve infant care manageability.~The adaptation of the WWWT programme (Catalan and Spanish version) comprises 2 sessions, each lasting 2 hours, that will be designed for groups of 5-7 families - within the first 6 weeks postpartum -, each consisting of mother, partner (or other caregiver) and their infant(s)."
219172087|NCT05584124|DEVICE|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
219172088|NCT05584124|DEVICE|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
219738934|NCT01746069|BEHAVIORAL|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
219738935|NCT01746069|BEHAVIORAL|health advice|routine clinical practice
219242544|NCT04945356|OTHER|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
219242545|NCT02721628|PROCEDURE|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
219738936|NCT00562861|DRUG|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
219242546|NCT02721628|PROCEDURE|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
219242547|NCT02721628|DEVICE|Femtosecond laser|Use in the epic-keratoplasty surgery
219242548|NCT00155376|DRUG|morphine and glucagon|
219242549|NCT00717925|DRUG|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
219242550|NCT05219747|OTHER|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
219242551|NCT05219747|OTHER|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
219242552|NCT05221684|PROCEDURE|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
219738937|NCT00562861|DRUG|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
219738938|NCT00493558|DEVICE|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
219738939|NCT02080000|OTHER|Optimisation of V-V timing using R wave on surface ECG|
219242553|NCT02650453|PROCEDURE|Deep venous reconstruction|PTA \& stenting with/without endophlebectomy and/or arteriovenous fistula creation
219242554|NCT00612716|DRUG|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
219738940|NCT02080000|OTHER|Standard V-V timing settings|
219172089|NCT03982160|DRUG|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
219172090|NCT03982160|OTHER|Placebo|Saline
219172091|NCT05772130|OTHER|Best Practice|Receive family letter and genomic test report
219172092|NCT05772130|OTHER|Electronic Health Record Review|Ancillary studies
219172093|NCT05772130|BEHAVIORAL|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
219172094|NCT05772130|OTHER|Survey Administration|Ancillary studies
219172095|NCT04827875|DRUG|AIV001|Intradermal
219172096|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
219172097|NCT02736409|DRUG|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
219172098|NCT02736409|DRUG|Placebo|Matching Placebo dose
219172099|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
219172100|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
219172101|NCT06258889|BEHAVIORAL|reward-focused intervention|"Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session."
219172102|NCT06258889|BEHAVIORAL|cognitive flexibility intervention|"This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations."
219172103|NCT06258889|BEHAVIORAL|exposure|"All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions)."
219172104|NCT06258889|BEHAVIORAL|Psychoeducation|All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
219172105|NCT05410730|DRUG|SHR-1501|SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
219172106|NCT06205992|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
219172107|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
219172108|NCT06205992|DEVICE|2D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
219172109|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
219172110|NCT05351541|DRUG|Psilocybin therapy with Zolpidem and Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
219172111|NCT05351541|DRUG|Psilocybin therapy with Zolpidem|1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
219172112|NCT05351541|DRUG|Psilocybin therapy with Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
219172113|NCT05351541|DRUG|Psilocybin therapy with Placebo|1-30 mg (oral administration), and placebo (oral administration)
219172114|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
219172115|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
219172116|NCT04122235|OTHER|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
219738941|NCT01232582|DEVICE|Exablate treatment|MR guided Focused Ultrasound treatment
219738942|NCT00655356|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
219738943|NCT00655356|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
219738944|NCT04129333|OTHER|Hypnosis|"The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now"
219738945|NCT04129333|OTHER|No hypnosis|No hypnosis
219738946|NCT05324787|DEVICE|Grency venous stent system|Venous stent implantation during the index procedure
219738947|NCT05995418|OTHER|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
219738948|NCT06190379|OTHER|Essential oil blend|an aroma stick containing a blend of essential oils
219738949|NCT06190379|OTHER|Placebo|an aroma stick containing an inert blend of oils
219738950|NCT05023902|OTHER|Pilates|Pilates has been performed to all participants two times a week in order to compare the effects of NIA
219738951|NCT05023902|OTHER|Neuromuscular Integrative Action|NIA was the experimental group of this study.
219738952|NCT04349098|DRUG|Selinexor|Participants will receive 20 mg of selinexor.
219738953|NCT04349098|OTHER|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
219172117|NCT06797882|DRUG|Silver diamine fluoride- potassium iodide|SDF , Riva Star, SDI Limited., Australia
219738954|NCT05655988|DIAGNOSTIC_TEST|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
219738955|NCT00705276|DRUG|Lactic acid (Dermacyd Femina Delicata)|
219738956|NCT01703221|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
219738957|NCT01703221|DRUG|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
219738958|NCT01703221|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
219738959|NCT01703221|DRUG|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
219738960|NCT03505424|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
219172118|NCT06797882|DRUG|Fluoride varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd.
219172119|NCT06797882|OTHER|0.9 % saline|Standard oral hygiene instructions every 3 months and application of Normal Saline for every 6 months
219172120|NCT06798220|OTHER|Traditional Breakfast|In this intervention, participants are offered a traditional breakfast (consisting of unprocessed or minimally processed foods), and postprandial appetite regulation is evaluated. Traditional breakfast includes chicken egg (boiled), white cheese (full-fat), white bread, black and green olives, tomatoes, cucumbers, and freshly squeezed orange juice.
219172121|NCT06798220|OTHER|UPF Breakfast|In this intervention, participants are offered an ultra-processed breakfast, and postprandial appetite regulation is evaluated. Ultra-processed breakfast includes pan-fried beef sausage (without oil), packaged sandwich bread, tomato-based ketchup, and packaged orange juice.
219172122|NCT00709033|BIOLOGICAL|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
219172123|NCT04907695|DEVICE|I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700|All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
219172124|NCT05880979|BEHAVIORAL|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
219738961|NCT03505424|OTHER|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
219172125|NCT05880979|BEHAVIORAL|Regular well child care|Participants will receive their regularly scheduled well-child care
219172126|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
219172127|NCT05838183|DIAGNOSTIC_TEST|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
219172128|NCT05285618|DEVICE|Argus II|Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
219172129|NCT00170573|DRUG|Caelyx|40 mg/m² biweekly
219172130|NCT06789003|OTHER|Adapted exercises|"Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale."
219172131|NCT06789003|OTHER|No intervention|Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.
219172132|NCT06789003|BEHAVIORAL|Quality of Life questionnaire|QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
219172133|NCT06789003|BEHAVIORAL|Questionnaire of Fatigue|Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
219172134|NCT06789003|BEHAVIORAL|Physical activity questionnaire|Questionnaire (IPAQ) at baseline and after transplantation
219172135|NCT06789003|BEHAVIORAL|Physical condition|Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
219172136|NCT06487858|DRUG|BGB-R046|Intravenous administration
219172137|NCT06487858|DRUG|Tislelizumab|Intravenous administration
219172138|NCT04048304|DRUG|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
219172139|NCT05722704|PROCEDURE|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
219172140|NCT05722704|PROCEDURE|Occlusal reduction|Reduction of the functional and non-functional cusps
219172141|NCT06069713|BEHAVIORAL|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
219172142|NCT06792942|OTHER|nature view curtain group|During the fine needle biopsy, the patient will look at the nature view curtain on the ceiling.
219172143|NCT05536440|DRUG|PF-07261271|IV or SC
219172144|NCT05536440|DRUG|Placebo|IV or SC
219172145|NCT06283173|DEVICE|ColActive Plus Collagen Matrix Dressing|"Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article."
219172146|NCT06028113|BEHAVIORAL|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
219172147|NCT06799949|DIAGNOSTIC_TEST|ROTEM (TEM Innovations GmbH, Munich, Germany) assay|For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery, during the placement of the arterial line (Start ratio), and another one, at the end, during the completion of the surgical wound closure (Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specific empty coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.
219172148|NCT06798584|DIETARY_SUPPLEMENT|FeoSol Original Iron Supplement Tablets|325 mg of ferrous sulfate containing 65 mg of elemental iron
219172149|NCT06798584|DIETARY_SUPPLEMENT|21st Century Gelatin Capsules|600 mg
219172150|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
219172151|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
219172152|NCT03094663|DRUG|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
219172153|NCT03094663|DRUG|Methylprednisolone|40 mg/ml, 1 ml
219172154|NCT03094663|DRUG|Cefazolin|500 mg in 10 ml
219172155|NCT03094663|DEVICE|8 MHz. Chiba needle|22G/ 4 inches
219738962|NCT03505424|OTHER|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
219738963|NCT06608732|BIOLOGICAL|Inaticabtagene autoleucel|CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
219242555|NCT00612716|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
219242556|NCT00612716|BIOLOGICAL|Stem cell infusion|Infused on Day 0
219242557|NCT00612716|RADIATION|Total body irradiation|165 cGy morning and evening on days -4 through -1.
219172156|NCT03094663|DRUG|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
219172157|NCT03094663|DRUG|Bupivacaine 25cc|25 cc 0.25% bupivacaine
219172158|NCT03094663|DRUG|Bupivacaine 20cc|20cc 0.25% bupivacaine
219172159|NCT03094663|DRUG|Dexamethasone|2 mg IV dexamethasone.
219172160|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
219172161|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
219172162|NCT04519970|BEHAVIORAL|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
219172163|NCT05537766|BIOLOGICAL|Brexucabtagene Autoleucel|Administered intravenously
219172164|NCT05537766|DRUG|Cyclophosphamide|Administered intravenously
219172165|NCT05537766|DRUG|Fludarabine|Administered intravenously
219172166|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|1,330 mg curcumin
219172167|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|350 mg Epigallocatechin gallate (EGCG)
219172168|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
219172169|NCT06124521|BEHAVIORAL|ComBaT Glaucoma|ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
219172170|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
219172171|NCT05146440|DRUG|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
219172172|NCT03885713|BIOLOGICAL|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
219172173|NCT05253612|DIAGNOSTIC_TEST|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
219172174|NCT05253612|DIAGNOSTIC_TEST|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
219172175|NCT04119687|BIOLOGICAL|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
219172176|NCT05193786|PROCEDURE|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
219172177|NCT05077735|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219172178|NCT05077735|OTHER|Questionnaire Administration|Ancillary studies
219172179|NCT05077735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219172180|NCT05077735|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
219172181|NCT04164316|DEVICE|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
219172182|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
219172183|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
219172184|NCT06436560|OTHER|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
219172185|NCT06581627|DRUG|Etavopivat|2 tablets of Etavopivat will be administered in fasted state via oral route
219172186|NCT06156280|DRUG|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
219172187|NCT06156280|DRUG|Placebo injection|Placebo comparator
219172188|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
219172189|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
219242558|NCT05461092|DRUG|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
219242559|NCT05461092|DIAGNOSTIC_TEST|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
219242560|NCT05461092|OTHER|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
219242561|NCT05461092|OTHER|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
219242562|NCT05461092|OTHER|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
219242563|NCT05461092|OTHER|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
219242564|NCT05461092|OTHER|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
219242565|NCT05461092|OTHER|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
219242566|NCT05461092|OTHER|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
219242567|NCT05461092|OTHER|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
219242568|NCT05461092|OTHER|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
219242569|NCT05461092|OTHER|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
219242570|NCT05461092|OTHER|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
219738964|NCT01312077|DRUG|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
219738965|NCT01312077|DRUG|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
219738966|NCT03813251|DEVICE|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
219738967|NCT03073070|DRUG|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
219738968|NCT05177328|BIOLOGICAL|S. hominis A 9 Product|Commensal staph species, phosphate buffered saline, and glycerol.
219738969|NCT05177328|DRUG|Placebo|Phosphate buffered saline and glycerol
219242571|NCT05461092|OTHER|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
219242572|NCT05461092|OTHER|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
219242573|NCT05461092|OTHER|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
219242574|NCT05461092|OTHER|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
219242575|NCT05461092|OTHER|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
219242576|NCT02061215|OTHER|CMV viral load|
219242577|NCT04613219|DRUG|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
219242578|NCT06363409|OTHER|Cereal Bar as a recovery food snack|Cereal bar as a recovery snack food
219242579|NCT06363409|OTHER|Almond|Almond as a recovery snack food
219242580|NCT01521689|DRUG|Rituximab|Low doses of sub cutaneaous rituximab
219242581|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
219738970|NCT03927846|BEHAVIORAL|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
219738971|NCT05706376|BEHAVIORAL|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
219242582|NCT00535795|RADIATION|Radiation Therapy|Radiation Therapy
219242583|NCT05482295|BIOLOGICAL|In-House Recombinant Hepatitis B (Bio Farma) vaccine|3 doses of In-House Recombinant Hepatitis B (Bio Farma) vaccine
219242584|NCT05482295|BIOLOGICAL|Registered Hepatitis B vaccine recombinant (Engerix-B)|3 doses of Registered Hepatitis B vaccine recombinant (Engerix-B)
219242585|NCT04388917|PROCEDURE|Patial nephrectomy|Partial nephrectomy assisted with robot to remove kidney cancer
219242586|NCT03246256|OTHER|Group 1|
219242587|NCT01562587|DRUG|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
219242588|NCT01562587|DRUG|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
219242589|NCT04320810|OTHER|no intervention|It's only observational study. No interventions.
219242590|NCT00438230|DRUG|Warfarin|
219242591|NCT05016674|DEVICE|LipoLife system|Abdominal Laser-Assisted Liposuction
219242592|NCT01808898|PROCEDURE|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
219242593|NCT05893017|OTHER|Virtual Reality Exercises|Virtual Reality Exercises will be apply for muscle strengthening
219738972|NCT05706376|BEHAVIORAL|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
219738973|NCT03878069|BIOLOGICAL|elapegademase-lvlr|Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
219738974|NCT06671899|OTHER|Constraint-induced movement therapy (CIMT)|Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
219738975|NCT06521853|OTHER|PEEK With Autogenous Bone Graft|placement of PEEK With Autogenous Bone Graft
219738976|NCT06521853|OTHER|PEEK With Xenograft|placement of PEEK With xenograft
219172190|NCT05349487|DEVICE|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
219172191|NCT05349487|OTHER|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
219172192|NCT05349487|DEVICE|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
219172193|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
219172194|NCT06581497|DRUG|ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
219172195|NCT06581497|PROCEDURE|ICIs+MWA|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
219172196|NCT05324501|DRUG|MTX110|Soluble panobinostat
219172197|NCT05324501|DEVICE|Programmable pump and catheter system|To allow Convection-Enhanced Delivery (CED)
219172198|NCT03781141|PROCEDURE|Wound closure|Comparison of two wound closures
219172199|NCT05165108|DEVICE|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
219172200|NCT06582446|DRUG|Androgen Deprivation Therapy (ADT) - Goserelin|"The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.~* ADT will be applied for 24 months in total~* ADT must be given concurrently and adjuvant"
219172201|NCT06582446|RADIATION|High-Dose-Rate Interstitial Brachytherapy (HDR BRT)|HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)
219172202|NCT06582446|RADIATION|radiotherapy|EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction
219172203|NCT05951166|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
219172204|NCT02531126|DRUG|RPC1063|
219172205|NCT03669822|OTHER|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
219172206|NCT01580488|DRUG|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
219172207|NCT01580488|DRUG|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
219172208|NCT01580488|DRUG|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
219172209|NCT01580488|DRUG|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
219172210|NCT01580488|DRUG|Daivonex® ointment|once daily application, 3 weeks
219242594|NCT05893017|OTHER|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
219242595|NCT05893017|OTHER|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
219242596|NCT02896335|DRUG|Palbociclib|Administered orally once per day on days 1-21 of 28-day cycles.
219242597|NCT02896335|DRUG|Pembrolizumab|Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
219242598|NCT04815707|PROCEDURE|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
219242599|NCT05993832|OTHER|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
219242600|NCT01883297|BIOLOGICAL|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
219242601|NCT01883297|BIOLOGICAL|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
219242602|NCT01883297|DRUG|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
219242603|NCT05428839|DIAGNOSTIC_TEST|Pharyngeal width measurement|A simple, non-invasive measurement of the pharyngeal width inside each subjects mouth
219242604|NCT06415383|DRUG|Vitamin B6 100 MG|Vitamin B6 in for the form of pyridoxal phosphate (PLP)
219242605|NCT06415383|OTHER|Placebo|Placebo tablet containing microcrystalline cellulose
219242606|NCT05077072|OTHER|Best Practice|Receive SOC
219242607|NCT05077072|OTHER|Counseling|Participate in CHAT counseling intervention
219242608|NCT05077072|PROCEDURE|Electroencephalography|Undergo EEG
219242609|NCT05077072|BEHAVIORAL|Neurofeedback|Undergo NFB intervention
219242610|NCT05077072|OTHER|Questionnaire Administration|Ancillary studies
219242611|NCT06461065|DEVICE|AIDS|mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by Ypsomed, Dexcom blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)
219242612|NCT06461065|OTHER|Brain MRI|To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject
219242613|NCT06804655|DEVICE|Pharmacoscopy 1.0|The intervention is the submission of freshly obtained surgical material to ex vivo drug profiling which we term pharmacoscopy (PCY). The performance study is interventional as the test results shall influence patient management decisions and/or may be used to guide treatment.
219242614|NCT05615870|OTHER|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
219242615|NCT03750981|BEHAVIORAL|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
219242616|NCT03393884|BIOLOGICAL|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
219242617|NCT03393884|DRUG|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
219242618|NCT03393884|DRUG|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
219242619|NCT06019962|DEVICE|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
219242620|NCT05898464|BIOLOGICAL|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
219242621|NCT06647654|BIOLOGICAL|ABRYSVO|"Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026)."
219242622|NCT01915212|BIOLOGICAL|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
219242623|NCT01915212|OTHER|Placebo|Sodium Chloride 0.9%
219242624|NCT04852887|OTHER|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
219242625|NCT04852887|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
219242626|NCT06806852|DRUG|BI 770371|BI 770371
219172211|NCT01580488|DRUG|Daivonex® ointment vehicle|once daily application, 3 weeks
219172212|NCT04269213|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219172213|NCT05751382|DEVICE|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
219172214|NCT05751382|DEVICE|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
219172215|NCT01107340|DEVICE|AMIStem Hip System|
219172216|NCT06784544|OTHER|Operational Stressors|Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
219172217|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
219172218|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
219172219|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
219172220|NCT04931641|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
219172221|NCT04931641|OTHER|Maltodextrin|Maltodextrin (placebo)
219172222|NCT04931641|DIETARY_SUPPLEMENT|Ferrous fumarate|50 mg iron as ferrous fumarate
219172223|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
219172224|NCT03338790|BIOLOGICAL|nivolumab|Specified dose on specified days
219172225|NCT03338790|DRUG|docetaxel|Specified dose on specified days
219172226|NCT03338790|DRUG|enzalutamide|Specified dose on specified days
219172227|NCT03338790|DRUG|rucaparib|Specified dose on specified days
219172228|NCT03338790|DRUG|prednisone|Specified dose on specified days
219172229|NCT06781580|OTHER|Esports Ergonomic Protocol|"The Esports Ergonomic Protocol is a six-week intervention designed to reduce the risk of repetitive strain injuries and enhance gaming performance for esports athletes. It includes an educational session on ergonomics, focusing on proper posture, body mechanics, and workstation setup. The protocol also incorporates warm-up and cool-down exercises to prevent strain and improve flexibility, as well as a postural rehabilitation program targeting the upper extremities and core muscles.~Participants will attend four in-person sessions at specified intervals for ergonomic risk assessments (using REBA) and gaming performance evaluations (using Kovaaks). The intervention also features online resources, including exercise tutorials and ergonomic tips, to support adherence and long-term implementation. Feedback will be collected through post-intervention surveys and an optional focus group to refine the protocol for future use in the esports community."
219172230|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
219172231|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
219172232|NCT03921502|PROCEDURE|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
219172233|NCT06048757|DEVICE|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
219172234|NCT04106583|DEVICE|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
219172235|NCT05336721|DRUG|Chiauranib|25mg/35mg/50mg orally once daily
219172236|NCT05336721|DRUG|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
219242627|NCT06806852|DRUG|Pembrolizumab|Pembrolizumab
219242628|NCT06806852|DRUG|Cetuximab|Cetuximab
219242629|NCT05883436|DEVICE|DEXA-C Cervical Interbody System|The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
219242630|NCT06731296|OTHER|Presence of a risk factor|Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
219242631|NCT05170204|DRUG|Alectinib|Participants will receive oral alectinib twice daily with food.
219172237|NCT06063616|OTHER|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
219172238|NCT06063616|OTHER|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
219172239|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
219172240|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
219172241|NCT05067517|DRUG|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
219172242|NCT05067517|DRUG|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
219172243|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy for Couples|"Interpersonal Psychotherapy for Couples (IPT-C) consists of 8 weekly conjoint sessions. The clinical goals are to promote resolution of the role dispute via renegotiation of role relations between the marriage partners and improve common mental disorders in the woman. Like Interpersonal Psychotherapy, IPT-C has an initiation phase (Session 1-2), middle phase (Sessions 3-6), and termination phase (Sessions 7-8)."
219172244|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy (Individual)|Interpersonal Psychotherapy (IPT) is an evidence-based treatment to reduce depression and other common mental disorders. It focuses on helping patients resolve interpersonal problems of disagreements, loneliness, life changes, and grief, and/or change their orientation to the problem.
219172245|NCT06541431|OTHER|Abdominal Drainage Fluid Collection|Abdominal drainage fluid will be collected daily from the subjects until they are discharged from the hospital, or their abdominal/pelvic drain is removed, as determined by the treating surgeon.
219172246|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
219172247|NCT06125704|BEHAVIORAL|Moderate intensity walking or stepping|30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
219172248|NCT03850366|DRUG|Bortezomib|GVHD prophylaxis
219172249|NCT02380885|BEHAVIORAL|SCIT|psychosocial group intervention
219172250|NCT02380885|BEHAVIORAL|TAFT|psychosocial group intervention
219172251|NCT04588298|DRUG|AZD9833|AZD9833 tablets will be administered orally.
219172252|NCT01242917|DRUG|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
219172253|NCT01242917|DRUG|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
219172254|NCT01242917|DRUG|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
219172255|NCT04537988|OTHER|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
219172256|NCT04157231|OTHER|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
219172257|NCT03846505|DRUG|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
219172258|NCT03846505|OTHER|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
219172259|NCT06443892|PROCEDURE|Pericapsular Nerve Block (PENG)|Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
219172260|NCT06443892|PROCEDURE|Suprainguinal Fascia Iliaca Compartment Block (SFICB)|Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
219172261|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
219172262|NCT03091725|PROCEDURE|Roux-en-Y gastric bypass surgery|Roux-en-Y gastric bypass surgery will be performed with post-weight loss testing performed after \~16-18% weight loss is achieved.
219242632|NCT05170204|DRUG|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
219242633|NCT05170204|DRUG|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
219242634|NCT04388839|DRUG|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
219242635|NCT04388839|DRUG|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
219172263|NCT03091725|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose \~16-18% of their body weight.
219172264|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
219172265|NCT04774068|DRUG|Parsaclisib|Given PO
219172266|NCT04774068|DRUG|Romidepsin|Given IV
219172267|NCT05652322|DRUG|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
219172268|NCT05652322|DRUG|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
219172269|NCT05652322|DRUG|Furosemide Injection|change from intravenous to oral furosemide
219172270|NCT05238766|BEHAVIORAL|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
219172271|NCT02381535|DRUG|Cisplatin|Given IV
219172272|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219172273|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
219172274|NCT02381535|DRUG|Onalespib|Given IV
219172275|NCT02381535|OTHER|Pharmacological Study|Correlative studies
219172276|NCT06327646|DRUG|Multiple Micronutrient Supplement Blister|MMS in a blister pack along with related job aids, counselling during ANC, etc.
219172277|NCT06327646|DRUG|Multiple Micronutrient Supplement Bottle|MMS in bottles along with related job aids, counselling during ANC, etc.
219172278|NCT06327646|DRUG|Iron Folic Acid Blister|Standard of Care - IFA in a blister pack along with related job aids, counselling during ANC, etc.
219172279|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
219172280|NCT05922345|DRUG|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
219172281|NCT05922345|DRUG|TQB2450 placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
219172282|NCT05790889|BIOLOGICAL|Rabies vaccine|Vaccine
219172283|NCT05790889|BIOLOGICAL|RH5.1 10μg adjuvated with 50μg Matrix-M|Vaccine
219172284|NCT05790889|BIOLOGICAL|RH5.2 5μg adjuvated with 50μg Matrix-M|Vaccine
219172285|NCT05890768|DRUG|Lumateperone|FDA approved antipsychotic drug
219172286|NCT05890768|DRUG|Risperidone|FDA approved antipsychotic drug
219172287|NCT06162585|BIOLOGICAL|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
219172288|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
219242636|NCT04388839|DRUG|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
219242637|NCT04388839|DRUG|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
219242638|NCT04388839|DRUG|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
219242639|NCT06091930|DRUG|BI 765049|BI 765049
219242640|NCT06091930|DRUG|Ezabenlimab|Ezabenlimab
219242641|NCT05436041|BEHAVIORAL|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
219242642|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 500 ml alginate beverage per meal test
219242643|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 330 ml alginate beverage per meal test
219242644|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 500 ml placebo beverage per meal test
219242645|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 330 ml placebo beverage per meal test
219242646|NCT06425549|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
219242647|NCT06425549|DRUG|ustekinumab|Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
219242648|NCT06425549|DRUG|placebo|Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
219242649|NCT05346848|DRUG|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~\- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
219242650|NCT05346848|DRUG|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
219738977|NCT06212739|PROCEDURE|Laser|Diode laser used to effect closure of the anal fistula tract
219738978|NCT06212739|PROCEDURE|LIFT|The intersphincteric portion of the fistula is excised and ligated.
219738979|NCT06674512|BEHAVIORAL|Clinical Pharmacist-led Pharmaceutical Services|Pharmacists developed an intervention plan to reduce DRPs and improve patients' quality of life by assessing patients' medication knowledge, drug-related problems, and adherence problems in the intervention group in the order of urgency, importance, and priority to be addressed. The plan included a list of patients' medication or lifestyle-related problems, a list of programs based on the assessed problems, and other information.
219738980|NCT05787119|OTHER|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
219738981|NCT05787119|OTHER|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
219242651|NCT06285422|DRUG|SC262|SC262 is an allogeneic CAR -T cell therapy
219242652|NCT04077099|DRUG|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
219242653|NCT05240885|OTHER|Stable tracer infusion in a postabsorptive state|Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
219242654|NCT05727176|DRUG|TAS-120|TAS-120 is an oral FGFR inhibitor
219242655|NCT06101069|PROCEDURE|MRF in conjunction with IVIM MRI without contrast|MRF in conjunction with IVIM MRI scan, without contrast.
219242656|NCT05396352|DEVICE|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
219242657|NCT05920954|PROCEDURE|ERCP|Repeat ERCP
219242658|NCT06277765|BIOLOGICAL|CM310|Interleukin-4 receptor(IL-4Rα) monoclonal antibody
219242659|NCT06277765|OTHER|placebo|Placebo
219738982|NCT05787119|OTHER|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
219738983|NCT05787119|OTHER|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
219242660|NCT04343807|PROCEDURE|PECS Block|PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
219242661|NCT04343807|OTHER|Control Group|No nerve block will be performed and only intravenous nalbuphine will be given.
219242662|NCT04511130|DRUG|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
219242663|NCT03543189|DRUG|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
219242664|NCT03543189|RADIATION|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
219242665|NCT03543189|RADIATION|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
219242666|NCT03543189|DRUG|Androgen Deprivation Therapy|Standard of care.
219242667|NCT05351229|DRUG|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
219242668|NCT05351229|OTHER|Placebo|Sterile saline, placebo
219242669|NCT06011109|DRUG|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
219242670|NCT05230459|GENETIC|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
219242671|NCT05230459|GENETIC|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
219242672|NCT05230459|OTHER|Placebo|Single intravenous infusion of Placebo
219242673|NCT01584596|BEHAVIORAL|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
219242674|NCT01584596|BEHAVIORAL|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
219242675|NCT00070317|DRUG|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
219242676|NCT00070317|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping
219242677|NCT00070317|PROCEDURE|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
219242678|NCT00070317|DRUG|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
219242679|NCT00070317|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
219242680|NCT00070317|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
219242681|NCT00070317|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
219242682|NCT00070317|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical hysterectomy
219242683|NCT01885559|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
219242684|NCT01885559|DRUG|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
219242685|NCT01885559|DRUG|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
219242686|NCT05156281|DRUG|Remibrutinib|tablet taken orally
219242687|NCT05156281|DRUG|Teriflunomide|capsule taken orally
219242688|NCT00927849|PROCEDURE|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
219242689|NCT00927849|DRUG|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
219242690|NCT00927849|DRUG|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
219242691|NCT01549951|DRUG|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
219242692|NCT02843100|OTHER|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
219242693|NCT02843100|OTHER|Crohn's Disease Exclusion Diet|a limited whole food diet
219242694|NCT02843100|OTHER|Partial Enteral Nutrition|25-50% of Energy from formula
219242695|NCT02843100|OTHER|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
219242696|NCT02211872|DRUG|BI 2536 BS, intravenous|
219242697|NCT02312245|BIOLOGICAL|Bevacizumab|Given IV
219242698|NCT02312245|DRUG|Gemcitabine Hydrochloride|Given IV
219242699|NCT02312245|DRUG|Paclitaxel|Given IV
219242700|NCT02312245|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
219242701|NCT02312245|DRUG|Topotecan Hydrochloride|Given IV
219242702|NCT01399606|DRUG|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
219242703|NCT05654207|BEHAVIORAL|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
219242704|NCT06122064|OTHER|Best Practice|Receive standard of care
219242705|NCT06122064|OTHER|Communication Intervention|Use shared decision-making conversation tool
219242706|NCT06122064|OTHER|Electronic Health Record Review|Ancillary studies
219242707|NCT06122064|OTHER|Survey Administration|Ancillary studies
219242708|NCT06122064|OTHER|Video Recording|Ancillary studies
219242709|NCT06122064|OTHER|Audio Recording|Ancillary studies
219242710|NCT05169515|DRUG|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
219738984|NCT06688552|OTHER|Proprioception Measurements|Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.
219738985|NCT06688552|OTHER|Fatigue Measurement|Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.
219738986|NCT06541301|DEVICE|PICC-port|Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
219738987|NCT06541301|DEVICE|Chest-port|Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
219738988|NCT00834587|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
219738989|NCT00834587|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
219738990|NCT06679504|PROCEDURE|Fibrin glue fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation
219738991|NCT06679504|PROCEDURE|Tack fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
219738992|NCT06546735|DRUG|N0728|1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
219738993|NCT06546735|DRUG|Vesomni®|1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
219738994|NCT06543758|DEVICE|Wearable exoskeletal robot|Participants will wear a wearable exoskeletal robot for gait training and undergo 10 sessions of 30-minute gait training over 4 weeks at home or in nearby indoor spaces. Participants will participate in physical function assessments, including the 10-meter walk test, Timed Up and Go (TUG) test, and Berg Balance Scale, both before and after the intervention. Additionally, participants will complete quality of life and depression inventories before and after the intervention.
219172289|NCT05880381|DEVICE|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
219172290|NCT05880381|OTHER|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
219172291|NCT04485039|DRUG|Tecovirimat|oral antiviral
219172292|NCT04485039|DRUG|sevelamer carbonate oral tablet|phosphate binder
219172293|NCT04485039|DRUG|sucroferric oxyhydroxide chewable tablet|phosphate binder
219172294|NCT04485039|DRUG|calcium acetate oral tablet|phosphate binder
219172295|NCT04485039|DRUG|Lanthanum Carbonate Chewable Tablet|phosphate binder
219172296|NCT05481216|OTHER|COVID-19|Diagnosed with COVID-19 infection
219172297|NCT05481216|OTHER|HIV-1 infection|Diagnosed with HIV-1 infection
219172298|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
219172299|NCT06276127|DRUG|Oral Bisoprolol|Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
219172300|NCT06276127|DRUG|Intravenous Diltiazem|Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
219172301|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
219172302|NCT04005716|DRUG|Tislelizumab|200 mg administered intravenously on Day 1 of each 21-day cycle
219172303|NCT04005716|DRUG|Cisplatin|75 mg/m² was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of two hours. Treatment with cisplatin was discontinued starting in Cycle 5 and beyond.
219172304|NCT04005716|DRUG|Carboplatin|An area under the curve (AUC) of 5 mg/mL/min was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of 15 to 60 minutes. Treatment with carboplatin was discontinued starting in Cycle 5 and beyond.
219172305|NCT04005716|DRUG|Etoposide|100 mg/m² was administered intravenously from Day 1 to Day 3 of each 21-day cycle, infused over a duration of 60 minutes. Treatment with etoposide was discontinued starting in Cycle 5 and beyond.
219172306|NCT04005716|DRUG|Placebo|200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
219172307|NCT05786443|DRUG|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
219172308|NCT05786443|DRUG|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
219242711|NCT05169515|DRUG|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
219242712|NCT05169515|DRUG|Iberdomide|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
219242713|NCT05169515|DRUG|Golcadomide|Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
219242714|NCT05169515|DRUG|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
219242715|NCT05169515|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
219242716|NCT00442507|DRUG|Erlotinib|
219242717|NCT00442507|DRUG|Avastin|
219242718|NCT05813522|DRUG|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
219242719|NCT06034444|OTHER|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
219242720|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
219242721|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
219242722|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
219242723|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
219242724|NCT04429087|DRUG|BI 764532 - parenteral 1|BI 764532 - parenteral 1
219242725|NCT04429087|DRUG|BI 764532 - parenteral 2|BI 764532 - parenteral 2
219242726|NCT02827110|DEVICE|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
219242727|NCT02827110|DEVICE|pentax-airway scope|Tracheal intubation using pentax-AWS
219242728|NCT02827110|PROCEDURE|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
219242729|NCT00230269|PROCEDURE|PET-CT|
219242730|NCT05420584|PROCEDURE|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
219242731|NCT05420584|DRUG|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
219242732|NCT05420584|DRUG|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
219242733|NCT05420584|DIAGNOSTIC_TEST|Pelvic MRI|Pelvic MRI to evaluate efficacy
219242734|NCT05420584|PROCEDURE|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
219242735|NCT03902626|OTHER|Physiotherapy students|
219242736|NCT03902626|OTHER|Medical students|
219242737|NCT00003240|DRUG|cisplatin|
219242738|NCT00003240|DRUG|ifosfamide|
219242739|NCT00003240|DRUG|mitomycin C|
219242740|NCT00003240|DRUG|vinblastine sulfate|
219242741|NCT00003240|DRUG|vindesine|
219242742|NCT00003240|DRUG|vinorelbine tartrate|
219242743|NCT00003240|PROCEDURE|conventional surgery|
219242744|NCT00003240|RADIATION|radiation therapy|
219242745|NCT01123200|DEVICE|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
219242746|NCT06189898|DIAGNOSTIC_TEST|Re Staging FDG-PET|Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).
219242747|NCT05000359|BEHAVIORAL|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
219242748|NCT06466655|DRUG|MitoTempol|One intradermal microdialysis probes will be perfused with MitoTempol (0.5 mM) during a standard local skin heating protocol.
219242749|NCT06466655|DRUG|Lactated Ringer's (control)|One intradermal microdialysis probes will be perfused with lactated Ringer's (control) during a standard local skin heating protocol.
219242750|NCT04953910|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
219242751|NCT06570109|OTHER|Frailty|defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
219242752|NCT05726942|OTHER|Healthi|Healthi refers to the Healthi app, which is a mobile application for weight loss
219242753|NCT06344091|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
219242754|NCT06979232|DEVICE|Enhanced White Light Imaging|Use of E-WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
219242755|NCT06979232|DEVICE|White Light lmaging|Use of WLl for colon inspection during both insertion and withdrawal phase of colonoscopy
219242756|NCT07124221|DRUG|Cabergoline tablets|Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are made based on the serum PRL level.
219242757|NCT07124221|DRUG|Bromocriptine mesylate tablets|Bromocriptine mesylate tablets was administered for 14 weeks.The dose is 1.25 mg (0.5 tablet) QD to 7.5mg 3 tablets) QD. Dosage adjustments are made based on the serum PRL level.
219242758|NCT07127757|DEVICE|Wavelight Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
219242759|NCT07134257|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
219242760|NCT07134257|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 4 weeks, 8 weeks, and optionally at 12 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
219242761|NCT07134257|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
219242762|NCT07134257|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program includes isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent joint stiffness, reduce swelling, and improve circulation. All exercises are performed within a pain-free range (not exceeding 4/10 on the VAS scale) with gradual progression according to the rehabilitation plan.
219242763|NCT07132424|PROCEDURE|Assesment|Foot posture, toe muscle strength and balance assesment
219242764|NCT05619627|DRUG|Dexmedetomidine|Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
219242765|NCT05619627|DRUG|General Anesthesia (control group)|Participants will receive general anesthesia for their MRI
219242766|NCT06768177|DRUG|PRP injection|3 ML OF PRP
219242767|NCT06768177|DRUG|Alprostadil 20 micrograms|1 ML
219242768|NCT02929732|OTHER|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
219242769|NCT06654011|DRUG|IN10018|100 mg, orally, once daily
219242770|NCT06654011|DRUG|Nab-paclitaxel|260 mg/m², IV infusion, Q3W
219242771|NCT06654011|DRUG|Cadonilimab|10 mg/kg, IV infusion, Q3W
219242772|NCT06653985|DRUG|Hyaluronic and corticosteroid injection|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.
219242773|NCT06653985|OTHER|Physical Therapy|Patients will receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
219242774|NCT04063670|OTHER|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
219242775|NCT04063670|OTHER|Control|Routine, Standard-of-Care
219242776|NCT04640779|DRUG|Choline Salicylate|Given PO
219242777|NCT04640779|DRUG|Selinexor|Given PO
219242778|NCT05020236|DRUG|Elranatamab|subcutaneous
219242779|NCT05020236|DRUG|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
219242780|NCT05020236|DRUG|Pomalidomide|oral
219242781|NCT05020236|DRUG|Dexamethasone|oral
219242782|NCT06324357|DRUG|Zongertinib|Zongertinib
219242783|NCT06324357|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan
219242784|NCT06324357|DRUG|Trastuzumab emtansine|Trastuzumab emtansine
219242785|NCT06324357|DRUG|Trastuzumab|Herceptin®
219242786|NCT06324357|DRUG|Capecitabine|Xeloda®
219242787|NCT06465654|OTHER|Automated variable dose oxygen treatment|The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
219242788|NCT06465654|OTHER|Fixed dose oxygen treatment|The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
219242789|NCT05174169|DEVICE|Signatera test|Central ctDNA testing for all patients
219242790|NCT05174169|DRUG|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
219242791|NCT05174169|DRUG|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
219242792|NCT05174169|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
219242793|NCT05174169|DRUG|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
219242794|NCT05174169|DRUG|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
219242795|NCT06981702|OTHER|Exercise|. In our study, demographic information (age, gender, height, weight, education, marital status, occupation, where and with whom they live), additional diseases, medications used, whether they live in a rural or urban area, whether they have had any sleep problems before, and whether they have had any psychiatric diagnoses before will be recorded for all subjects. Before the exercise, students will fill out the Pittsburgh Sleep Quality Index to determine their sleep quality, the Morningness-Eveningness Scale to assess their chronotype, and the Beck Depression Inventory to measure their depressive symptom levels, and the results will be recorded. Students taking the body mechanics course will be asked to do aerobic exercises they learned in class, three days a week, including warm-up and cool-down, for a total of 60 minutes of exercise. The exercises will be performed on the same days and times each week. All exercises performed by the students for 8 weeks will be monitored by the resea
219242796|NCT06986122|BEHAVIORAL|Pain Threat Manipulation|Participants receive brief thermal pain stimuli in certain virtual environments to examine how threat influences perception and physiological responses.
219743656|NCT06276335|OTHER|Immediate implant placement and guided bone regeneration (Test)|In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.
219242797|NCT06986122|BEHAVIORAL|Pain Controllability Manipulation|In some contexts, participants can reduce or avoid pain using a button; in others, no action changes the outcome. This manipulation is used to study the effects of perceived control over pain.
219242798|NCT02201459|DRUG|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
219242799|NCT02201459|DRUG|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"* Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
219242800|NCT06681142|OTHER|Pharmacy-Physiotherapy Intervention|"Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials.~Participants will be offered either individual or group physiotherapy sessions at the a private clinic."
219242801|NCT06676228|BEHAVIORAL|Fear of cancer recurrence therapy (FORT)|"FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content"
219242802|NCT06676228|BEHAVIORAL|cognitive-behavioural therapy (CBT) group|"The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise"
219242807|NCT06263244|DRUG|Ziltivekimab|Monoclonal antibody targeting IL-6
219242808|NCT06263244|DRUG|Placebo|Placebo
219242809|NCT06682234|DRUG|obeldesivir|Tablets administered orally
219242810|NCT07014982|BEHAVIORAL|Guided Meditation|Participants who complete guided meditation will be asked to meditate for 5 minutes a day, five times a week for two 6-week periods.
219242811|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
219242812|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
219242813|NCT07013474|DRUG|ibuzatrelvir|tablet
219242814|NCT07013474|DRUG|remdesivir|injection, for intravenous use
219242815|NCT07013474|DRUG|placebo for ibuzatrelvir|tablet
219242816|NCT07013474|DRUG|placebo for remdesivir|injection, for intravenous use
219242817|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
219242818|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
219242819|NCT06624358|BEHAVIORAL|Increase Physical Activity|Behavioral interventions to improve physical activity
219242820|NCT07019922|DRUG|1mg elsunersen|24 weeks every 4 weeks intrathecally
219242821|NCT07019922|PROCEDURE|sham procedure|24 weeks of sham-procedure every 4 weeks
219242822|NCT07019922|DRUG|0.5mg elsunersen|24 weeks every 4 weeks intrathecally
219242823|NCT05399602|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)
219242824|NCT05399602|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement
219242825|NCT05399602|DIAGNOSTIC_TEST|Lumbar infusion test|Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
219242826|NCT05399602|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
219242827|NCT05399602|PROCEDURE|General Anesthesia|Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.
219242828|NCT05399602|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)
219242829|NCT05399602|PROCEDURE|Blood sampling #1|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
219242830|NCT05399602|PROCEDURE|Blood sampling #2|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery
219242831|NCT05399602|PROCEDURE|Blood sampling #3|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery
219242832|NCT05399602|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
219242833|NCT06683560|DEVICE|": photopolymer resin material graphy Tera Harz 85 will be used to print 3D printed aligners for NAM treatment"|3d printed NAM aligner is made from novel photopolymer resin as a novel device
219242834|NCT07018739|BIOLOGICAL|Wharton's jelly-derived mesenchymal stem cells|MSCs (1x10\^7 cells/kg) in 10 mL 0.9%normal saline administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
219242835|NCT07018739|DRUG|0.9 % Normal Saline|0.9% normal saline 10 mL administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
219242836|NCT05726591|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
219242837|NCT06630780|RADIATION|Head and Neck Cancers|All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
219242838|NCT05503030|DRUG|Nintedanib|Nintedanib
219242840|NCT06699836|DRUG|350 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
219242841|NCT06699836|DRUG|700 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
219242842|NCT03614949|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
219242843|NCT03614949|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
219242844|NCT04880382|DRUG|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
219242845|NCT04880382|DRUG|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
219242846|NCT06697236|OTHER|EPICES score|"EPICES score used to group participants as precarious and non precarious."
219242847|NCT06697236|OTHER|PICS evaluation|"* Assessment of physical symptoms using the Timed up and go test (TUG)~* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7 and screening for post-traumatic stress disorder using the IES-R~* Assessment of cognitive disorders using the MoCA"
219242848|NCT06697236|OTHER|PICS-F evaluation|"* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7~* Screening for post-traumatic stress disorder using the IES-R"
219242849|NCT06700343|DRUG|Ocrelizumab (US)|IV infusion
219242850|NCT06700343|DRUG|Ocrelizumab (EU)|IV infusion
219242851|NCT06700343|DRUG|ABP 692|IV infusion
219242852|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
219242853|NCT06877429|PROCEDURE|Time of OPU|OPU procedure either at 8 am or 8 pm
219242854|NCT05968534|BEHAVIORAL|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
219242855|NCT02819141|DRUG|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
219242856|NCT06716372|DEVICE|DSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
219242857|NCT06716372|DEVICE|Daily Silicone Hydrogel Contact Lenses (oB)|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
219242858|NCT07033416|BEHAVIORAL|Approach Bias Modification|ABM is a computerised training aiming to train the participants to avoid drug-related images (by pushing a joystick which causes the image to disappear) and approach positive images (by pulling a joystick which causes the image to expand). Each training session lasts 15 minutes and it takes place once per week for 4 weeks.
219242859|NCT07033416|BEHAVIORAL|Treatment as usual|Participants receiving TAU are not trained to avoid drug-related images and approach positive images.
219242860|NCT07039877|DRUG|Venetoclax low dose with itraconazole|The investigators will add venetoclax in low dose (100 mg) with itraconazole to the pediatric inspired regimen TACL to enchance the complete response rate
219242861|NCT07034794|DIETARY_SUPPLEMENT|Lysoveta|The Lysoveta capsules contain 500 mg of lysophosphatidylcholine-rich oil extract of Antarctic krill.
219242862|NCT07034794|OTHER|Placebo|The placebo capsules contain medium-chain triglyceride (MCT) oil, maize oil, olive oil, and palm kernel oil.
219242863|NCT06057402|DRUG|Elranatamab|Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
219242864|NCT06720038|BIOLOGICAL|0.5 mL of the low dose VAX-31|31 valent pneumococcal conjugate vaccine
219242865|NCT06720038|BIOLOGICAL|0.5 mL of the mid dose VAX-31|31 valent pneumococcal conjugate vaccine
219242866|NCT06720038|BIOLOGICAL|0.5 mL of the high dose VAX-31|31 valent pneumococcal conjugate vaccine
219242867|NCT06720038|BIOLOGICAL|0.5 mL dose of PCV20|20 valent pneumococcal conjugate vaccine
219242868|NCT06720038|BIOLOGICAL|0.5 mL of the High-PFS dose VAX-31|31 valent pneumococcal conjugate vaccine
219242869|NCT06879002|OTHER|Ovarian stimulation with menstruation or after ovulation|Ovarian stimulation with menstruation or after ovulation
219242870|NCT06881654|PROCEDURE|Bleaching teeth|Traditionally, home bleaching has been done with soft silicone trays. Patients now wear aligners, which are rigid trays used for orthodontic treatment. The use of rigid trays for home whitening has not been validated. The aim of this clinical trial is to analyse the effectiveness, comfort and sensitivity perceived by patients when whitening with 0.5 mm rigid aligners.
219738995|NCT06674057|PROCEDURE|KinesioTaping|"The experimental group will receive the following treatment for week 1-3 (3 days on alternate days):~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Kinesio tape 3 times per week. (Anchor opposed to effected compartment to provide facilitation and sustained stretch).~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of mediu"
219242871|NCT06884618|DRUG|RO7673396|RO7673396 will be administered as per the schedule specified in the protocol.
219242872|NCT06716385|DEVICE|MSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
219242873|NCT06716385|DEVICE|Monthly Silicone Hydrogel Contact Lenses (oA)|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
219242874|NCT06724978|DRUG|S-740792 Suspension|Participants will receive S-740792 as an oral suspension.
219738996|NCT06674057|PROCEDURE|Control|"The control group will receive the following treatment for week 1-3 on alternate days:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of medium resistance)."
219738997|NCT06673459|BIOLOGICAL|TBICy|The TBI-Cy group was administered 250 mg/m2/d oral Me-CCNU on day -8. A total of 12 Gy TBI was for each patient and fractionated dose was 2 Gy twice daily or 4Gy once daily on days -8 to -6. Occluding of the lung fields during TBI, the corresponding irradiation dose reduced to a total of 8 Gy. On day -5, the schedule was intravenous 2 g/m2 Ara-C every 12 hours. Then intravenous 1.8 g/m2 CTX once per day from days -4 to -3.
219738998|NCT06673459|BIOLOGICAL|BuCy|The BuCy group received oral Me-CCNU 250 mg/m2/d twice daily on day -8, intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7, intravenous Bu 3.2 mg/kg/d from days -6 to -4, and intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2. There were no patients accepted oral Bu.
219743384|NCT05250934|DEVICE|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
219242875|NCT06724978|DRUG|Midazolam|Participants will receive midazolam as a syrup.
219242876|NCT06724978|DRUG|Placebo|Participants will receive placebo as an oral suspension.
219242877|NCT06724978|DRUG|S-740792 Tablet|Participants will receive S-740792 as an oral tablet.
219242878|NCT06705764|DRUG|Tezepelumab|"Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90"
219242879|NCT06705764|DRUG|Placebo|Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
219242880|NCT06925529|BEHAVIORAL|Cardio-Oncology Rehabilitation and Exercise Programme|Participants randomised to the CORE programme will receive exercise training that is analogous to cardiac rehabilitation, but Exercise Physiologists will individualise each training program using the participants baseline CPET results to maximise adherence and improve the effectiveness of the training program beyond typical cardiac rehabilitation programs. An Exercise Physiologist will supervise two training sessions a week and monitor adherence to one other independent session at home each week for the first 12 weeks of the training program whilst exercise frequency, intensity, and time is progressively increased. Supervision of the exercise training will then be stepped down gradually after 12 weeks to a fortnightly check-in to encourage intervention adherence. Patients will be provided with a training calendar and objective tools for tracking physical activity (e.g. heart rate monitor and diary). Adherence will be monitored in real-time using a research web-based platform.
219242881|NCT06722157|DRUG|BI 771716|BI 771716
219242882|NCT06722157|DRUG|Pegcetacoplan|Pegcetacoplan
219242883|NCT06722157|DRUG|Sham comparator to BI 771716|Sham comparator to BI 771716
219242884|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
219242885|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
219242886|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
219242887|NCT07049575|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
219242888|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)|Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01
219242889|NCT06736379|DRUG|Pembrolizumab (KEYTRUDA®)|200mg twice 3 weeks apart IV
219242890|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)|Weekly IT injections of 3 x 10\^8 viral particles of VLPONC-01
219242891|NCT06712810|DRUG|Axl/Mer/CSF1R Inhibitor Q702|Given PO
219242892|NCT06712810|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219242893|NCT06712810|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219242894|NCT06712810|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219242895|NCT06712810|PROCEDURE|Computed Tomography|Undergo CT scan
219242896|NCT06712810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219242897|NCT06712810|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219242898|NCT06712810|OTHER|Survey Administration|Ancillary study
219242899|NCT07044362|DEVICE|HistoSonics Edison® System|Histotripsy is a novel, totally non-invasive, non-ionizing, and non-thermal ablation technique that mechanically disrupts tumors through precisely controlled acoustic cavitation. Histotripsy is administered via HistoSonics Edison® System.
219242900|NCT07044362|DRUG|Chemotherapy|Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).
219242901|NCT06734130|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) analog|The choice of the standard of care LHRH analog will be at the discretion of the treating physician.
219242902|NCT06734130|DRUG|Androgen Receptor Signal Inhibitor (ARSI)|The choice of the standard of care ARSI will be at the discretion of the treating physician.
219242903|NCT06734130|DRUG|Docetaxel|Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.
219242904|NCT06876480|OTHER|Keyboard|Day 0 : Collection of the general data required for the study, installation of the computer device including the LifeCompanion software with the different scanning keyboards configurations and organizations. Day 0 to Day 8 : write, in copy, a text using each of the virtual keyboard configurations. Day 8 : copying a text proposed by the investigator of identical difficulty for each condition, for a duration of 15 minutes, per experimental condition. This copying exercise, with the recording of measurements, will be done for each experimental condition. Day 8 to Day 16 : write a copy of a text of his/her choice for 10 minutes, using each of the virtual keyboard configurations. Day 16 : in a text-entry evaluation situation, copying a text proposed by the investigator, of identical difficulty for each condition.
219242905|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-HL|Participants will test continuous administration of investigational product for 16 weeks.
219242906|NCT06755892|DIETARY_SUPPLEMENT|Placebo syrup|Participants will test continuous administration of placebo product for 16 weeks.
219242907|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LH|Participants will test continuous administration of investigational product for 16 weeks.
219242908|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LL|Participants will test continuous administration of investigational product for 16 weeks.
219242909|NCT06755892|DIETARY_SUPPLEMENT|Col-L|Participants will test continuous administration of investigational product for 16 weeks.
219738999|NCT06675006|COMBINATION_PRODUCT|Medical Massage|This intervention refers to the application of therapeutic massage techniques aimed at alleviating pain and enhancing muscle relaxation in patients with nonspecific low back pain. The treatment focuses on manipulating soft tissues, including muscles, tendons, and fascia, to improve circulation, reduce muscle tension, and promote overall wellness. Medical massage is tailored to each patient's specific needs and can incorporate various techniques, including Swedish massage, Bowen Therapy, a gentle and non-invasive manual therapy, utilizes precise movements on specific points of the body to promote healing and restore balance. The therapist applies light pressure with the fingers, allowing the body to respond and relax. This technique aims to stimulate the body's innate healing mechanisms, encouraging improvements in pain levels and functional capacity. Sessions are typically structured to allow for periods of rest, giving the body time to process the treatment and enhancing its effects.
219739000|NCT04840875|BIOLOGICAL|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
219739001|NCT03810495|DRUG|naltrexone implant|1.8 g implant containing 60% naltrexone
219172309|NCT06103604|DIAGNOSTIC_TEST|latest generation tympanic thermometer|The patient whose core temperature is monitored during hospitalisation has his temperature at tympanic level taken once during the stay. The research nurse will record the core temperature from the monitor on the CRF and, within the next 5 minutes, take the peripheral temperature with the tympanic thermometer three times in a row, recording all three values on the CRF. Subsequently a second operator will always take the temperature 3 times within 5 minutes of the gold standard measurement. Only the first tympanic measurement will then be used to assess accuracy against the gold standard.
219172310|NCT06353321|DIAGNOSTIC_TEST|PET-CT imaging subsystem of the RefleXion X1 System Device|Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners
219172311|NCT06456853|OTHER|Pain assesment|We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
219172312|NCT06078514|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
219172313|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
219172314|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
219172315|NCT04830397|DRUG|QLS-101|Ophthalmic solution 1x daily
219172316|NCT04830397|DRUG|Timolol Maleate|Ophthalmic solution 1x daily
219172317|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
219172318|NCT05051098|OTHER|No intervention|No intervention
219172319|NCT06035679|DRUG|Pyrotinib and Trastuzumab|Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
219172320|NCT06295835|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingersticks.
219172321|NCT06788223|DEVICE|Parathyroidectomy|Parathyroidectomy under general anesthesia
219172322|NCT05200481|DRUG|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
219172323|NCT05200481|DRUG|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
219172324|NCT05200481|DRUG|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
219172325|NCT05845398|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
219172326|NCT05845398|DRUG|Placebo|0.9% saline for injection.
219172327|NCT06150040|DRUG|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
219172328|NCT06150040|DRUG|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
219172329|NCT06150040|DRUG|Venetoclax|Orally, 70 mg, every day on Days 1-28
219172330|NCT05754437|DEVICE|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
219172331|NCT05991284|DRUG|Sacubitril-valsartan|sacubitril-valsartan (target dose 97/103 mg twice daily)
219242910|NCT05650658|DEVICE|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
219739002|NCT06682975|DRUG|ZP9830|Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
219739003|NCT06682975|DRUG|Placebo|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
219172332|NCT05991284|DRUG|Standard of care|including SGLT-2 inhibitor and MRA
219172333|NCT05987657|DIAGNOSTIC_TEST|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
219172334|NCT04297683|DRUG|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
219172335|NCT04297683|DRUG|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
219739004|NCT03289195|PROCEDURE|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
219739005|NCT06691503|PROCEDURE|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
219242911|NCT05650658|DEVICE|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
219242912|NCT07058805|RADIATION|Compartmentalized Postoperative Radiotherapy|Pathology- and imaging-guided compartmentalized postoperative radiotherapy (PORT), with or without concurrent systemic treatment. Based on a predefined algorithm, PORT or specific anatomical volumes may be omitted. Dose prescription and volumes are risk-adapted.
219739006|NCT06691295|OTHER|Questionnaires|"This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort)."
219739007|NCT06691373|OTHER|Static Stretching|"Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip."
219739008|NCT06688812|OTHER|Perceptual Motor Training|"8 set of exercises~1. Balance training and related exercises~2. Tones of awareness training, body parts' role and related exercises~3. Space awareness training and related exercises~4. Perception of shape training and related exercises~5. Visual perception training and related exercise.~6. Kinesthetic-tactile perception training and related exercises~7. Auditory perception training and related exercises~8. Eye and hand coordination, ﬁne motor movements and related Exercises"
219739009|NCT06688812|OTHER|Repetitive Facilitation Exercises|"Eight set of exercises:~1. Shoulder Flexion with 90° Elbow Flexion (Supine).~2. Shoulder Horizontal Extension/Flexion with Elbow flexion (supine).~3. Complex Shoulder and Upper Limb Movements (Supine)~4. Shoulder Flexion/Abduction/External Rotation with Elbow and Forearm Supination (Supine)~5. Forearm Supination/Pronation with 90° Elbow Flexion (Sitting)~6. Wrist Extension and Forearm Pronation with Finger Extension (Supine)~7. Finger Extension with Wrist Flexion (Supine)~8. Finger Extension/Flexion with Wrist Flexion (Sitting) • Therapist facilitate the movement by rubbing, tapping and gentle stretching."
219739010|NCT06686004|DIETARY_SUPPLEMENT|Carrots|Detection of polyacetylene and carotenoids in human biofluids
219739011|NCT06686589|DIAGNOSTIC_TEST|Intestinal ultrasound|Intestinal ultrasound performed by hand held ultrasound devices
219739012|NCT06689982|DRUG|Tofacitinib tablets|All patients should be closely monitored for signs and symptoms of infection during and after treatment with tofacitinib tablets. If a patient develops a severe infection, opportunistic infection, or sepsis, medication should be discontinued. During treatment, patients with lymphocyte counts \< 500 cells/mm\^3 or ANC \< 500 cells/mm\^3 confirmed by repeated testing should be stopped. When 500≤ANC≤1000 cells/mm\^3, administration should be interrupted, and if ANC returns to more than 1000 cells/mm\^3, administration should be resumed. When hemoglobin \< 8 g/dL or decreases by more than 2 g/dL, administration should be interrupted until hemoglobin values return to normal.
219739013|NCT06691620|PROCEDURE|Nasal irrigation with isotonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of isotonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
219739014|NCT06691620|PROCEDURE|Nasal irrigation with hypertonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of hypertonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
219739015|NCT06691620|PROCEDURE|Nontraumatic nasopharyngeal aspiration|After nasal irrigation, the secretions and saline solution from the underlying nasal cavity were nontraumatically aspirated from the entrance of the nasal cavity after the irrigation. The infant was positioned on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
219739016|NCT06689865|DEVICE|HA-HCP|Prescription hearing aid fit by a hearing healthcare professional using audiology best practices.
219739017|NCT06689865|DEVICE|OTC-HCP|Over-the-counter hearing aids fit by a hearing care professional using audiology best practices.
219739018|NCT06689865|DEVICE|OTC-R|OTC fit to an individual using some best practices via remote consultation.
219739019|NCT06689865|DEVICE|OTC-SF|Self-fit OTC hearing aids without any clinical support from HCPs.
219739020|NCT06690580|OTHER|Motivational interviewing based on the knowledge motivation behavior skills model|Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
219739021|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule Placebo|Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
219739022|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
219172336|NCT06837831|OTHER|Control group|Give routine nursing measures. Symptom management: Participants were informed that the damage to the anal canal mucosa caused by radiotherapy was mainly manifested as anal pain, and diarrhea could aggravate the symptoms of anal pain. Therefore, the patient should be instructed to monitor the symptoms of diarrhea and anal pain and give timely feedback; Dietary guidance: eat high-protein, high-vitamin, low-slag, low-fiber food, do not eat spicy and irritating food; Medication guidance: Follow the doctor's advice to take the drug orally on time and according to the amount, cooperate with the retention enema, etc., observe the effect of medication; Psychological guidance: strengthen nurse-patient communication, give psychological counseling, and rationally vent anxiety and other emotions. Perianal skin care: Wear loose cotton underwear to keep the perianal area clean and dry.
219172337|NCT06837831|COMBINATION_PRODUCT|Experimental group|After the patient emptied urine and feces before going to bed (21:00), the patient was assisted to take the kneeling lateral position, and the anal canal was cleaned with 0.9%Nacl soaked cotton swab, and was fully left to dry. After 30min, the anal pain was relieved. The operator fully exposed the patient's anus and part of the anal canal mucosal lesions with his left thumb and index finger, and applied a 6cm\*6cm adhesive foam dressing on the injured mucosa with his right hand. With the help of a cotton swab, the patient was instructed to take a deep breath, send the foam dressing to 3cm of the anal canal, reveal 2cm, slowly release the left hand, withdraw the cotton swab at the same time the anus automatically retracted, which played a role in securing the dressing, and ask the patient to lie flat and rest, and take it out the next morning (06:00).
219172338|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
219172339|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
219172340|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
219172341|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
219172342|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
219172343|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
219172344|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
219172345|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
219739023|NCT06072261|OTHER|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
219739024|NCT06695793|PROCEDURE|Interrupted Sutures|The first layer of uterine incision will be closed using individual, separate sutures placed at regular intervals along the incision line. Each suture will be tied independently, ensuring adequate apposition of uterine tissue, followed by a second layer of running continuous sutures.
219739025|NCT06695793|PROCEDURE|Locked Sutures|The first layer of uterine incision will be closed using continuous sutures placed along the uterine incision, incorporating a locking technique at specified intervals to prevent unraveling. The knots will be securely tied to maintain tissue approximation, followed by a second layer of running continuous sutures.
219739026|NCT06695793|BIOLOGICAL|Running Continuous Sutures|Double layer closure of uterine incision using running continuous suture used to close the uterine incision without interruption, providing seamless tissue approximation throughout the incision length.
219739027|NCT06687499|DRUG|Bismuth-based susceptibility-guided treatment|The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
219739028|NCT06691399|OTHER|Oral care|Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)
219739029|NCT00879619|DRUG|sunitinib malate|Given PO
219739030|NCT00879619|DRUG|docetaxel|Given IV
219739031|NCT00879619|DRUG|prednisone|Given PO
219739032|NCT06695520|PROCEDURE|Caudal epidural block|Ultrasound Guidance: Using ultrasound improves the accuracy of the block by allowing real-time visualization of the anatomy and needle placement . injection: .5-1mg/kg of 25% bupivacaine according to the needed block level.
219739033|NCT06694610|PROCEDURE|non-pulmonary vein ablation group|In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
219739034|NCT06694610|PROCEDURE|only pulmonary vein ablation group|In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
219739035|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
219739036|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
219739037|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
219743385|NCT05067842|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
219743386|NCT00100893|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
219743387|NCT02364895|OTHER|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
219743388|NCT02364895|OTHER|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
219743389|NCT02364895|OTHER|Males Group 2: New letter with neutral gender content|Unisex letter
219743390|NCT02364895|OTHER|Males Group 3: New letter with male-specific content|New letter tailored for men
219743391|NCT02364895|OTHER|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
219172346|NCT05827926|BIOLOGICAL|Influenza Vaccine 1|quadrivalent seasonal influenza vaccine
219172347|NCT05827926|BIOLOGICAL|mRNA-1083.1|Sterile liquid for injection
219172348|NCT05827926|BIOLOGICAL|mRNA-1083.2|Sterile liquid for injection
219172349|NCT05827926|BIOLOGICAL|mRNA-1083.3|Sterile liquid for injection
219172350|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 1|Sterile liquid for injection
219172351|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 1|Sterile liquid for injection
219172352|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 1|Sterile liquid for injection
219172353|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 2|Sterile liquid for injection
219172354|NCT05827926|BIOLOGICAL|Influenza Vaccine 2|quadrivalent seasonal influenza vaccine
219172355|NCT05827926|BIOLOGICAL|mRNA-1083|Sterile liquid for injection
219172356|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 2|Sterile liquid for injection
219172357|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 2|Sterile liquid for injection
219172358|NCT06837389|BIOLOGICAL|JY306 universal NK cell injection|"3+3 dose escalation trial"
219172359|NCT04317677|OTHER|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
219172360|NCT05116709|DRUG|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
219172361|NCT06816667|DRUG|BMND08|Participants will receive a sublingual dose of 5-MeO-DMT once a week for four consecutive weeks. The intervention will be administered in the form of a sublingual tablet. The substance 5-MeO-DMT, a potent tryptamine, is known for its psychoactive properties but will be administered at a dose that does not induce a full psychedelic experience.
219172362|NCT06816667|PROCEDURE|Brain electrical activity monitor|EEG is a technique used to monitor brain electrical activity by recording brain waves through electrodes placed on the scalp. This procedure allows the assessment of brain waves such as delta, theta, alpha, and beta, specifically to evaluate the changes in brain activity following sublingual administration of 5-MeO-DMT.
219172363|NCT06816667|DIAGNOSTIC_TEST|Pharmacokinetic Study of Sublingually Administered Psychoactive Substance|For pharmacokinetic analysis, approximately 6 mL of EDTA blood will be collected to assess the pharmacokinetics of a sublingual dose of 5-MeO-DMT. Samples will be obtained at baseline (pre-dose, 0 minutes) and at the following time points post-dose: 5, 10, 20, 30, 40, 50, 60, and 120 minutes.
219172364|NCT06816667|DIAGNOSTIC_TEST|Biochemical determinations|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
219172365|NCT06816667|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
219172366|NCT06816667|DIAGNOSTIC_TEST|vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment
219172367|NCT06816667|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will undergo the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) for attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to assess any cognitive changes in response to the different doses of 5-MeO-DMT (6 mg, 9 mg, 12 mg) or placebo, helping to determine how the intervention may influence cognitive processing, memory, and attention.
219172368|NCT06816667|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
219172369|NCT04044859|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
219172370|NCT06838286|DRUG|SGLT2 inhibitor|SGLT2 inhibitor class of drugs
219172371|NCT06838286|DRUG|Thiazolidinedione|Thiazolidinedione class of drugs
219172372|NCT06838286|DRUG|DPP-4 inhibitor|DPP4 inhibitor class of drugs
219172373|NCT03467386|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
219172374|NCT03467386|DRUG|Cyclophosphamide|Given IV
219172375|NCT03467386|BIOLOGICAL|Filgrastim|Administer according to City of Hope standard operating procedures
219172376|NCT03467386|OTHER|Laboratory Biomarker Analysis|Correlative studies
219172377|NCT03467386|OTHER|Quality-of-Life Assessment|Ancillary studies
219172378|NCT03467386|OTHER|Questionnaire Administration|Ancillary studies
219172379|NCT03467386|DRUG|Tacrolimus|Given CIV
219172380|NCT03467386|RADIATION|Total Marrow Irradiation|Undergo TMLI
219172381|NCT06831786|BIOLOGICAL|Bivalent mRNA SARS-CoV-2 vaccine|Administering a booster dose of the bivalent mRNA vaccine BNT162b2
219172382|NCT06831786|BIOLOGICAL|Quardrivalent influenza vaccine|Administering a VaxigripTetra™
219172383|NCT04190953|OTHER|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
219172384|NCT04190953|OTHER|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
219172385|NCT06836310|BEHAVIORAL|Real Performance Task-Oriented Movement|Participants performed a task-oriented movement in a real environment by throwing balls into a physical pool for 10 minutes. The movement was designed to engage upper extremity function.
219172386|NCT06836310|BEHAVIORAL|Virtual Reality Task-Oriented Movement|Participants performed a task-oriented movement in a virtual environment using the Oculus Quest 2 VR system for 10 minutes. The task involved throwing virtual balls into a virtual pool with real-time feedback.
219172387|NCT06835010|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex, 100 µg/ml; Rewine Pharmaceutical; Varachha, Seurat, Gujarat) was administered before induction of anesthesia in the form of a 1 µg/kg; loading dose. The loading dose was diluted with 10 ml of normal saline and injected slowly for 10 minutes. IO infusion was prepared to provide 0.2-0.7 µg/kg/h, initially the lowest possible dose was infused and was increased gradually to control IO stress reflexes but with MAP, and HR monitoring to guard against IO hypotension and bradycardia. PO infusion was prepared to provide DXM in a dose of 0.15 µg/kg/h for 24-h. Placebo 0.9% saline solution was provided to patients of the SEVO group at a similar rate and duration.
219172388|NCT06835010|DRUG|Sevoflurane inhalant product|Anesthesia was induced by fentanyl 1 μg/kg/min, propofol 1.5-2 mg/kg and rocuronium 0.5 mg/kg, then tracheal intubation was aided by gentle tracheal pressure and an endotracheal tube of appropriate size was inserted with the aid of fiberoptic laryngoscopy and patients were mechanically ventilated to keep ETCO2 in the range of 30-35 mmHg. Anesthesia was maintained for patients of both groups by sevoflurane 2% in oxygen 100% and rocuronium (0.15 mg/ kg) according to the requirements.
219172389|NCT01687608|BIOLOGICAL|AskBio009|Single dose IV injection
219172390|NCT04922502|BEHAVIORAL|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
219172391|NCT04922502|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
219172392|NCT06827964|DIETARY_SUPPLEMENT|Soy-based Nutrition Package|Dry, vacuum-sealed sachets containing yellow powder, odorless, to be consumed with warm water. Each 12g sachet provides: 209 kJ energy, 3.1g protein, 1.7g fat, 4.6g carbohydrates, 3mg sodium, 200mg calcium, 7.5mg iron, 3mg zinc, 250μg RE vitamin A, 5μg vitamin D, 0.5mg vitamin B1, 0.5mg vitamin B2, 0.5μg vitamin B12, and 75μg folate. Intervention duration: 6 months, with 2 sachets per day. Produced by Tiantianai (Jiangsu) Biotechnology Co., Ltd., a certified supplier for maternal and child nutrition projects in China.The company has a Class D production workshop that meets the latest GMP standards for pharmaceuticals. The product has passed certifications for Food Safety Management System (ISO 22000) and Quality Management System (ISO 9001).
219172393|NCT06827964|DIETARY_SUPPLEMENT|Probiotics|Dry, vacuum-sealed sachets containing white powder, odorless. Each 2g sachet contains 500\*10\^9 CFU of Lactobacillus plantarum LLY-606 and Pediococcus pentosaceus JQI-7. Intervention duration: 6 months, with 1 sachet per day. Produced by Jiangsu Wecare Biotechnology Co., Ltd., compliant with international standards (cGMP, FSSC 22000, HACCP, ISO 22000, ISO 9001).
219172394|NCT06835543|PROCEDURE|Amnion membrane.|the amnion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material
219739038|NCT06695286|OTHER|Multimodal rehabilitation training at high intensity|"In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
219739039|NCT06695286|OTHER|Multimodal rehabilitation training at low intensity|"In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
219739040|NCT06686498|BEHAVIORAL|Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)|"Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments."
219739041|NCT04064671|OTHER|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
219739042|NCT05837247|OTHER|Game-based telerehabilitation exercises|online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.
219739043|NCT05837247|OTHER|Home exercises|The physiotherapist will evaluate the control group patients and monitor them using only a home exercise program.
219242913|NCT06752772|DEVICE|Smart watch|Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
219242914|NCT06752772|BEHAVIORAL|Dashboard with nudging system|Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
219242915|NCT06752772|DEVICE|Digital Health Coach (DHC)|Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
219242916|NCT07055477|DRUG|Cyclophosphamide|Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days
219242917|NCT07055477|DRUG|Fludarabine|Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days
219242918|NCT07055477|BIOLOGICAL|Autologous CCR4 CAR T cells|Day 0: Cells will be infused intravenously (IV) over 10-30 minutes
219242919|NCT06704672|DEVICE|Accu-Chek SmartGuide CGM Solution|The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.
219242920|NCT06704672|DEVICE|Accu-Chek SmartGuide Sensor and Blinded Apps|The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.
219242921|NCT06704672|DEVICE|SMBG Device|With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.
219242922|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for 7 days
219242923|NCT06641466|DRUG|Placebo Comparator|Matching placebo oral disintegrating tablets for 7 days
219242924|NCT06641466|DRUG|Standard of Care|Standard of care for acute treatment as needed
219242925|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for acute treatment as needed
219242926|NCT06892288|DRUG|GLM101 (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A
219242927|NCT06892288|DRUG|Placebo (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A
219172395|NCT06835543|PROCEDURE|Chorion membrane|chorion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 4-0 resorbable suture material.
219172396|NCT06838481|OTHER|Concentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Concentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
219172397|NCT06838481|OTHER|Eccentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Eccentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
219172398|NCT06838481|OTHER|Active Control|Walking
219172399|NCT06838234|OTHER|Arabic version QOL questionnaire|Arabic version QOL questionnaire The Wound-QoL is a wound-specific questionnaire containing 17 items from which one can derive three subscales and . The items 1-5, 6-10, and 11-16 belong to the subscale body, psyche, and everyday life, respectively
219172400|NCT05791968|PROCEDURE|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
219242928|NCT06892288|DRUG|GLM101 (Part B, Open-label)|IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants
219739044|NCT06184009|DRUG|ALL, High risk|"Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
219739045|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 1
219739046|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 2
219739047|NCT06540118|OTHER|15 Medically Tailored Meals (MTM) per week|15 heart-healthy medically tailored meals delivered to participants each week. Meals include breakfast, lunch, dinner, and snack to consume Monday-Friday.
219739048|NCT06540118|OTHER|14 Medically Tailored Meals (MTM) per week|14 heart-healthy medically tailored meals delivered to participants each week. Meals include lunch and dinner to consume Monday-Sunday.
219739049|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
219739050|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
219739051|NCT06053320|OTHER|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
219739052|NCT04548050|OTHER|Nurses training|"* Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation."
219739053|NCT03508440|PROCEDURE|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
219739054|NCT03508440|DRUG|Prednisone|Oral Steroid
219739055|NCT03242031|PROCEDURE|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
219739056|NCT03242031|PROCEDURE|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
219739057|NCT04070040|DRUG|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
219739058|NCT02881216|DEVICE|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
219739059|NCT02881216|DEVICE|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
219739060|NCT03557905|DEVICE|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
219739061|NCT03557905|DEVICE|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
219739062|NCT04869527|DEVICE|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
219739063|NCT06371378|PROCEDURE|PEEP 0|PEEP 0 CMH20 will be used During Surgery
219739064|NCT06371378|PROCEDURE|PEEP 4|PEEP 4 CMH20 will be used During Surgery
219739065|NCT06371378|PROCEDURE|PEEP 8|PEEP 8 CMH20 will be used During Surgery
219739066|NCT02730169|DRUG|BGS649|Capsules were taken weekly for a maximum of 24 weeks
219739067|NCT02730169|DRUG|Placebo|Capsules were taken weekly for a maximum of 24 weeks
219739068|NCT05522556|DRUG|Ritlecitinib|capsules
219739069|NCT01821846|DRUG|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
219172401|NCT06132035|DRUG|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
219242929|NCT07063420|OTHER|Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS)|Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS) PCM-DSS (n=12)
219172402|NCT06132035|DRUG|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
219172403|NCT06132035|DRUG|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
219172404|NCT06190275|BIOLOGICAL|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors
219172405|NCT06832475|DEVICE|clear aligners and elastics|"For the Fixed Appliance group, the straight wire treatment included an aligning and leveling phase, achieved by using Nickel-Titanium arches (0.016/0.019 × 0.025 arc sequence) and a phase with heavier stainless steel rectangular arches (0.019 × 0.025); during this last treatment phase patients were instructed to use Class II elastics for at least 16 h/day.~Pre- (T0) and post-treatment (T1) lateral cephalogram were collected from all selected patients. Treatment time was an average of 18 months (T1-T0=18 months)."
219242930|NCT07063420|OTHER|Continuous Glucose Monitor (CGM) + Usual Care|Continuous Glucose Monitor (CGM) + Usual Care (Physician)
219242931|NCT06898970|BIOLOGICAL|Vusolimogene Oderparepvec (VO)|Given intratumorally
219242932|NCT06898970|DRUG|Pembrolizumab|Given IV
219242933|NCT07069595|DRUG|Datopotamab deruxtecan|Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.
219743392|NCT02364895|OTHER|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
219743393|NCT02364895|OTHER|Females Group 2: New letter with neutral gender content|Unisex letter
219743394|NCT01713244|PROCEDURE|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
219743395|NCT01713244|PROCEDURE|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
219743396|NCT05267600|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
219743397|NCT05267600|OTHER|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
219743398|NCT05267600|DRUG|Prednisone|Oral Prednisone
219743399|NCT03026777|DRUG|intravenous crystalloid fluid, 500 mL|
219242934|NCT07069595|DIAGNOSTIC_TEST|Circulating tumor DNA (ctDNA) testing|Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.
219242935|NCT02755844|DRUG|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
219242936|NCT02755844|DRUG|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
219242937|NCT02755844|DRUG|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
219242938|NCT06916156|DRUG|ANT3310|ANT3310 will be administered in combination with Meropenem. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
219242939|NCT06916156|DRUG|Meropenem|Meropenem will be administered in combination with ANT3310. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
219242940|NCT04562129|DRUG|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
219242941|NCT04562129|DRUG|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
219242942|NCT04562129|DRUG|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
219242943|NCT06334016|PROCEDURE|Biospecimen Collection|Undergo blood collection
219242944|NCT06334016|DRUG|Cannabis sativa Extract|Vape THC
219242945|NCT06334016|DRUG|Nicotine|Vape active nicotine
219242946|NCT06334016|DRUG|Placebo Administration|Vape placebo nicotine
219242947|NCT06334016|OTHER|Questionnaire Administration|Ancillary studies
219242948|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
219242949|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
219242950|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
219242951|NCT07064473|DRUG|Vicadrostat|Vicadrostat
219242952|NCT07064473|DRUG|Empagliflozin|Empagliflozin
219242953|NCT07064473|DRUG|Placebo matching Vicadrostat|Placebo matching Vicadrostat
219242954|NCT06784947|PROCEDURE|Pre-Treatment Biopsy|The pre-treatment biopsy should be performed at least 3 days prior to C1D1 of treatment.
219242955|NCT06784947|PROCEDURE|On-Treatment Biopsy|While the acceptable window for the C3D1 biopsy is ±3 days, it is preferred that the biopsy occurs following all treatments on C3D1.
219172406|NCT06832475|DEVICE|class 2 elastics|"Class II malocclusion is the most common malocclusion, and it is one of the main reasons for people to undergo orthodontic treatment. This alteration is characterized by an improper relationship between the maxillary and mandibular arches because of skeletal or dental discrepancies or a combination of both . The treatment protocols may considerably vary depending on professional skills, malocclusion severity and patient compliance . Among all the well-known techniques, it is important to mention the Class II elastics , used to camouflage mild skeletal Class II or to treat mild to moderate Class II occlusal relationship.~During the correction of Class II malocclusions by means of inter-arch elastics, special attention should be paid to the position of the lower incisors."
219172407|NCT05514899|DRUG|THC|THC capsule
219242956|NCT06784947|DRUG|Tiragolumab|Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.
219172408|NCT05514899|DRUG|CBD|oral solution
219172409|NCT05225922|BEHAVIORAL|Communication Partner Training|This intervention aims to improve the language, communication, participation and overall quality of life of the Person with Aphasia.
219172410|NCT05225922|OTHER|Usual Speech and language Therapy|This group will receive usual speech and language therapy session.
219172411|NCT06833645|OTHER|molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)|The new imaging agents Aβ and TauPET/CT are molecular imaging, which have the advantage of earlier and more visual, and can study the mechanism of pathological changes and PET manifestations of Alzheimer's disease before symptoms appear from the molecular level.
219172412|NCT04062630|DEVICE|iFuse 3-D in Bedrock Configuration|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
219172413|NCT04062630|PROCEDURE|Multilevel Lumbar Fusion surgery|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
219242957|NCT06784947|DRUG|Atezolizumab|Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
219242958|NCT06784947|DRUG|Bevacizumab|Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.
219242959|NCT06118931|BEHAVIORAL|Early (7:00 - 16:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
219743400|NCT06472024|PROCEDURE|Verum Acupuncture|Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
219172414|NCT06830265|DEVICE|Novel needle biopsy catheter (test)|Tissue is collected from the prostate by introducing a needle into the prostate and cutting out a sample
219172415|NCT06769763|OTHER|My Journey with MS application|This is an Arabic application for MS patients that provides them with information about self-care like nutrition, exercise, mental health, and self-management, in addition to other features like symptom tracking and medication reminders.
219172416|NCT02986516|OTHER|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
219172417|NCT02986516|RADIATION|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
219172418|NCT06831682|DEVICE|Kinesiotaping (KT)|Kinesiotaping will be applied using muscle, lymphatic, and ligament taping techniques to promote healing, reduce swelling, and improve muscle function following total knee replacement surgery.
219172419|NCT06831682|OTHER|Standard Rehabilitation|Patients will receive standard postoperative rehabilitation, including physiotherapy, gait training, and medical exercises, without the application of Kinesiotaping.
219172420|NCT06836167|BEHAVIORAL|exercise promotion|a) Up to 10 weekly 1-hour group sessions of multicomponent exercise guided by a physiotherapist, incorporating resistance, endurance, balance, and flexibility. Supported by materials adapted for low literacy or cognitive impairment, it empowers participants to maintain physical activity. Vivifrail may be used to prevent frailty and falls.
219172421|NCT06836167|DRUG|review medication|d) Comprehensive medication review for optimization and deprescribing. Results show significant improvements in physical performance and intrinsic capacity at three and six months, sustained through empowerment and community resource connections.
219172422|NCT06836167|BEHAVIORAL|promoting healthy aging|b) Non-pharmacological interventions, including nutritional guidance for a Mediterranean diet, dysphagia and cognitive impairment screening, and sleep hygiene counselling.
219172423|NCT06836167|OTHER|against social isolation|Support against social isolation by activating community resources.
219172424|NCT05385718|OTHER|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
219172425|NCT06838546|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
219172426|NCT04639934|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
219172427|NCT05854329|BEHAVIORAL|Virtual Reality Exposure|Virtual Reality device using the immersive dental game.
219172428|NCT01141179|DRUG|LEO 27847|2 mL (0.1 mg) dose of oral solution
219172429|NCT06786988|DIAGNOSTIC_TEST|MRI|brain MRI scan: (1) one day before the procedure, (2) 24-36 hours after the procedure and (3) up to 1 year after the procedure
219172430|NCT06786689|DRUG|Azathioprine (AZA)|weekly single dose of tab azathioprine 300mg
219172431|NCT06786689|DRUG|Betamethasone|oral Betamethsone 5mg for 2 consecutive days weekly
219172432|NCT05250895|OTHER|18F-Fluoromisonidazole|Given IV
219172433|NCT05250895|PROCEDURE|Biopsy|Undergo biopsy
219172434|NCT05250895|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
219172435|NCT05250895|PROCEDURE|Positron Emission Tomography|Undergo PET
219242960|NCT06118931|BEHAVIORAL|Mid (9:30 - 18:30) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
219242961|NCT06118931|BEHAVIORAL|Late (12:00 - 21:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
219242962|NCT05844982|DRUG|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
219172436|NCT06838533|PROCEDURE|computer guided advancement genioplasty|PEEK vs Titanium patient specific plates
219172437|NCT02199054|OTHER|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
219172438|NCT02199054|OTHER|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
219172439|NCT02199054|OTHER|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
219172440|NCT06830551|DRUG|administration cord blood based eye drops, standardized to the deliver BDNF.|administration cord blood based eye drops customized to deliver epitelio tropic factors, incluiding EGF in EGFR blocked cells
219172441|NCT06058299|DRUG|TBAJ-876|tablet
219172442|NCT06058299|DRUG|Pretomanid|200 mg
219172443|NCT06058299|DRUG|Linezolid|600 mg
219172444|NCT06058299|DRUG|Bedaquiline|200 mg for 8 weeks followed by 100 mg for 18 weeks
219172445|NCT06058299|DRUG|HRZE|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
219172446|NCT06058299|DRUG|HR|Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
219172447|NCT06554444|PROCEDURE|Dental Implant Surgery|Dental implants will be placed in edentulous areas.
219739070|NCT03578172|DRUG|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
219739071|NCT03578172|DRUG|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
219172448|NCT03445988|BEHAVIORAL|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
219172449|NCT03445988|BEHAVIORAL|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
219172450|NCT03445988|OTHER|Taper Only|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
219172451|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using connective tissue graft|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. A connective tissue graft (CTG) will be harvested from the palatal mucosa using the De-epithelialized free gingival graft technique and tailored to the site dimensions. The graft will be carefully positioned under the elevated flap to augment the soft tissue. The palatal wound will be sutured with double-cross sutures.
219172452|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using xenogenic collagen matrix|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. The xenogenic collagen matrix, initially measuring 15 × 20 mm, is first moistened in saline for 10 minutes and slightly compressed to adapt its thickness to the defect. After a superficial incision to release any muscle tension, the XCM is accurately positioned and secured to the buccal mucosa using single sutures.
219172453|NCT06799715|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water
219172454|NCT06799715|DIETARY_SUPPLEMENT|Glucose|33.5g glucose dissolved in 300mL tap water
219172455|NCT06799715|DIETARY_SUPPLEMENT|Fructose|33.5g fructose dissolved in 300mL tap water
219172456|NCT06799715|DIETARY_SUPPLEMENT|Water|300mL water
219172457|NCT06478459|BIOLOGICAL|CAR-NK|Endoscopic ultrasound-guided intratumoral CAR-NK injection once at day 0, combined with intravenous CAR-NK infusion twice at day 4 and 5
219172458|NCT03988608|DRUG|Eltrombopag|Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.
219172459|NCT05424549|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
219172460|NCT05424549|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
219172461|NCT04034576|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
219172462|NCT04162626|OTHER|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
219172463|NCT04162626|OTHER|Treatment as usual|Follow up at the Child health center according to national regulations
219172464|NCT06064500|DRUG|Tarlatamab|Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
219172465|NCT05441579|BEHAVIORAL|Behavioral Economics (BE) recruitment strategies|Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.
219242963|NCT05844982|DRUG|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
219242964|NCT06780579|DRUG|Bulevirtide|10 mg BLV will be administered via subcutaneous injection
219242965|NCT07065214|DEVICE|APC|For the surgical procedure for ovarian endometrioma treatment APCapplicator will be used
219242966|NCT07065214|DEVICE|Lap bipolar forceps|For ovarian endometrioma treatment the standard of care treatment will be performed.
219242967|NCT07072650|DRUG|Dexmedetomidine|Studying combining a local anesthetic with dexmedetomidine (DEX) in a quadratus lumborum block (QLB) following a cesarean section (CS) in elective surgery in Bint Al-Huda Hospital.
219242968|NCT02363296|DEVICE|TMS|Paired associative stimulation and single pulse TMS
219739072|NCT01387867|PROCEDURE|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
219739073|NCT01387867|PROCEDURE|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
219739074|NCT01387867|PROCEDURE|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
219739075|NCT03190421|DIAGNOSTIC_TEST|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
219739076|NCT03190421|DIAGNOSTIC_TEST|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
219739077|NCT03741374|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
219739078|NCT06273163|OTHER|Medically tailored meals|Medically tailored meals are nutritious meals formulated for weight wellness.
219739079|NCT06273163|BEHAVIORAL|Noom®|Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.
219242977|NCT02998229|DEVICE|Artisse™ Intrasaccular Device|Intrasaccular Device
219242978|NCT07075367|OTHER|Proximal/distal protocol|The experimental group will receive a proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation.
219242979|NCT07075367|OTHER|Distal protocol|The control group will receive a distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises.
219242980|NCT06680427|DEVICE|Siegel Transcatheter Aortic Valve (TAVR)|Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.
219739080|NCT06273163|OTHER|Usual care|Care is provided at the discretion of the individual provider (e.g., usual care).
219242986|NCT05894239|DRUG|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
219242987|NCT05894239|DRUG|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
219242988|NCT05894239|DRUG|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
219242989|NCT05894239|DRUG|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
219242990|NCT05894239|DRUG|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
219242991|NCT06496490|DRUG|TQB2102 for injection|HER2 dual-antibody-drug Conjugate (ADC).
219242992|NCT06496490|DRUG|TQB2102 for injection combined with Benmelstobart injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
219242993|NCT07130513|DIETARY_SUPPLEMENT|Krill oil supplementation|Krill oil supplementation program providing 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks.
219242994|NCT07130513|DIETARY_SUPPLEMENT|Control|Vegetable oil supplementation (4 g/day)
219242995|NCT06924710|DRUG|Standard Therapy|For patients with negative EGFR/ALK mutation, adjuvant chemotherapy or adjuvant chemotherapy combined with immunotherapy was administered, for patients with positive EGFR/ALK mutation, targeted therapy was administered.
219242996|NCT06924710|OTHER|Adaptive Therapy|Patients will be under close MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
219242997|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
219242998|NCT06655246|DRUG|ziftomenib|menin inhibitor
219242999|NCT06655246|DRUG|imatinib mesylate|kinase inhibitor
219243000|NCT06927999|DRUG|Placebo|Placebo solution nasal spray containing no active drug
219243001|NCT06927999|DRUG|0.5 mg epinephrine|0.5 mg epinephrine per spray
219243002|NCT06927999|DRUG|1 mg epinephrine|1 mg epinephrine per spray
219243003|NCT06928142|BIOLOGICAL|Sibeprenlimab|400 mg administered SC Q4 weeks
219243004|NCT06928142|OTHER|Placebo|Administered SC Q4 weeks
219243005|NCT07136402|OTHER|Educating participants about healthcare resources|MA-CEAL team members, including the community health ambassador (CHA), will assist in connecting residents with healthcare resources.
219243006|NCT07136402|OTHER|Healthcare appointments|MA-CEAL team members, including the community health ambassador (CHA), will assist residents in making physician appointments.
219243007|NCT07136402|OTHER|Workshops|Trained CHAs will provide workshops with information about diabetes and hypertension and how to be screened and get care.
219243008|NCT06931509|DEVICE|Computerized mirror therapy (IVS3) + Tendon vibration (Vibramoov)|"Visit 1 : Followed by 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition.~Visit 2 : 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition."
219243009|NCT06926322|DRUG|Conventional double antibiotic paste of Metronidazole 500 mg plus Ciprofloxacin 500 mg mixed with propylene glycol|The studied medicament will be placed onto the floor of the pulp chamber.
219243010|NCT06926322|DRUG|Double antibiotic paste of Metronidazole and Ciprofloxacin loaded chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
219243011|NCT06926322|DRUG|chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
219243012|NCT06758505|BEHAVIORAL|Strategy Training Only|Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with an emphasis on START strategy, task-specific practice, and guided discovery to perform social participation activities. In session 1, participants will be guided to select 3 to 5 meaningful social activities and prioritize them. In sessions 2 - 9, participants will use structured START strategy worksheet to try the selected activity; assess execution (e.g., what went well, what did not); reflect on a plan with specific strategies and to address identified challenges; and try social participation activities again. The interventionist will use guided discovery to support START strategy application and to elicit problem solving skills. This process will be repeated iteratively across sessions. In session 10, participants will summarize lessons learned and generate an action plan for after the intervention.
219243013|NCT06758505|BEHAVIORAL|Strategy Training embedded with Acceptance and Commitment Therapy Principles|"Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with task-specific practice and an emphasis on psychological processes using ACT principles. In session 1, participants will clarify value-consistent social participation goals for engaging in 3-5 meaningful activities (Do What Matters). In sessions 2-9, participants will be guided applying ACT principles to cope with negative experiences and separate self from thoughts and feelings (Open Up) and practice mindfulness, stimulate awareness, recognize same person with different experiences, and build self-compassion (Be Present). This process (i.e., try an activity that aligns with values and committed actions; assess performance; and reflect on a plan) will be repeated iteratively. In session 10, participants reflect on lessons learned and generate an action plan for after the intervention."
219243014|NCT06930352|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219243015|NCT06930352|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
219243016|NCT06930352|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
219243017|NCT06930352|DRUG|Cytarabine|Given cytarabine
219243018|NCT06930352|PROCEDURE|Echocardiography Test|Undergo ECHO
219243019|NCT06930352|DRUG|Hydroxyurea|Given hydroxyurea
219243020|NCT06930352|PROCEDURE|Leukapheresis|Undergo leukapheresis
219243021|NCT06930352|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219243022|NCT06930352|OTHER|Questionnaire Administration|Ancillary studies
219243023|NCT06930352|DRUG|Ziftomenib|Given PO
219243024|NCT06937801|DIETARY_SUPPLEMENT|Collagen Peptide|10g Collagen Hydrolysate per sachet
219243025|NCT06937801|OTHER|Placebo|Placebo - active ingredients: N/A
219243026|NCT06940674|DRUG|Cannabidiol|1 capsule CBD 200mg
219243027|NCT06940674|DRUG|Placebo|Bovine Gel Placebo capsule
219739081|NCT06358144|BEHAVIORAL|Packaging imagery|Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
219739082|NCT06358144|BEHAVIORAL|No Imagery (Control)|Participants in the control condition will see the same four product packages, but without any added imagery.
219243028|NCT07115940|DEVICE|Endovascular Thrombectomy|EVT will be provided in addition to medical management and is a procedure to remove a thrombus in one of the brain arteries that is obstructing the blood flow and is responsible for the occurrence of stroke. Removing this occlusion results in restoration of blood flow to ischemic brain tissue and salvages the parts that are still viable, which is expected to improve functional outcomes. Endovascular thrombectomy procedure will be performed using stent retrievers, aspiration devices or combination approach at the discretion of the treating physician, using devices approved by the local regulatory authority. For patients treated in the United States of America, only US Food and Drug Administration-approved neurothrombectomy devices can be used.
219243029|NCT07115940|OTHER|Medical Management|Medical management comprises various measures to prevent further deterioration, enhance patients' outcomes and prevent occurrence of a secondary stroke in short and long term. This includes 1) evidence-based practices for blood pressure management 2) Neurocritical care monitoring with appropriate osmotic therapy and neurosurgical interventions such as hemicraniectomy for management of cerebral edema that occurs due to infracted brain tissue based on local institutional protocol, 3) stroke etiology identification by requisite neurology , cardiology, immunology evaluations and 4) short and long-term strategies for secondary stroke prevention, including anticoagulation, antiplatelet therapy, medical optimization and modification of stroke risk factors such as hypertension, hyperlipidemia, diabetes and other potential comorbidities.
219243030|NCT07144436|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
219739083|NCT04804709|DRUG|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).
219739084|NCT04804709|DEVICE|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
219739085|NCT02500966|DEVICE|DUDA device|Insertion DUDA device
219739086|NCT02500966|PROCEDURE|LEEP|Loop Electrosurgical Excision Procedure
219739087|NCT03087149|DIETARY_SUPPLEMENT|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
219739088|NCT03087149|DIETARY_SUPPLEMENT|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
219739089|NCT06002698|PROCEDURE|Root canal treatment (Control)|Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
219739090|NCT06002698|PROCEDURE|Full pulpotomy (Experimental)|Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
219739091|NCT02457546|BIOLOGICAL|EVICEL Fibrin Sealant|
219739092|NCT02457546|DEVICE|Hydrogel sealant|
219739093|NCT00273780|BEHAVIORAL|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
219739094|NCT00273780|DEVICE|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
219739095|NCT01215162|RADIATION|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
219172466|NCT05441579|OTHER|Biofeedback-based virtual reality (VR-BF)|Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
219172467|NCT05441579|OTHER|Manage My Pain|Commercially available and free app to track, analyze and monitor pain.
219172468|NCT04440254|DIAGNOSTIC_TEST|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
219172469|NCT01742143|BEHAVIORAL|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
219172470|NCT01742143|BEHAVIORAL|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
219172471|NCT02689284|BIOLOGICAL|Margetuximab 10 mg/kg|Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
219172472|NCT02689284|BIOLOGICAL|Margetuximab 15 mg|Margetuximab treatment is administered IV once every 21-day cycle
219172473|NCT02689284|BIOLOGICAL|Pembrolizumab|Pembrolizumab treatment is administered IV once every 21-day cycle
219172474|NCT05592418|DRUG|Rintatolimod|100 to 400 mg twice weekly
219172475|NCT05592418|OTHER|Placebo / Normal Saline|40 to 160 mL twice weekly
219172476|NCT06010329|DRUG|Sutetinib Maleate Capsule|Oral administration
219243031|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
219243032|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
219172477|NCT03662698|BEHAVIORAL|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
219172478|NCT03662698|OTHER|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
219172479|NCT04855747|DRUG|REL-1017|REL-1017 tablet
219172480|NCT04855747|DRUG|Placebo|Placebo tablet
219172481|NCT05855421|DEVICE|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
219172482|NCT04190589|DEVICE|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
219172483|NCT05425433|OTHER|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
219172484|NCT06057922|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.
219172485|NCT06652360|DEVICE|Chemical Debridement|The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.
219172486|NCT06652360|DEVICE|Curettage debridement|The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
219172487|NCT04816461|DRUG|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
219172488|NCT04816461|DRUG|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
219172489|NCT04816461|DIAGNOSTIC_TEST|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
219172490|NCT05172934|DRUG|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
219172491|NCT04339166|DIAGNOSTIC_TEST|Non-invasive chromosome screening（NICS）|NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
219172492|NCT06848582|BIOLOGICAL|umbilical cord blood NK cells|All subjects will receive Ex vivo Expanded and activated umbilical cord blood NK cells infusion.
219172493|NCT06220643|OTHER|resistance exercise|Progressive resistance exercise for 12 weeks
219172494|NCT06220643|DRUG|triamcinolone acetonide plus lidocaine|40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
219172495|NCT06444087|OTHER|secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
219172496|NCT06848517|OTHER|BSATP Group|"Participants and the therapist will communicate once weekly synchronously (e.g. through video calls with a 30 minute duration), regarding the proper execution of the PFM exercises, providing motivation etc. Additionally, participants will be advised to watch the educational videos (10 mins duration) asynchronously twice a week. In total, participants will follow a BSATP three times a week (for 12 weeks). The PFM exercise program will include endurance training (slow velocity contractions), speed training (quick contractions) and Knack maneuver training (pre-contraction before the increment of the intra-abdominal pressure).The PFM exercise program will be based on three assessments conducted by the therapist throughout the study (baseline, 6 weeks and 12 weeks). As a result, the PFM exercise program will be individualized to meet their needs and progressively increases in difficulty, with the exercise position being modified every two weeks (e.g. supine, side, prone ect)"
219172497|NCT06848517|OTHER|FtFS Group|Participants will attend one weekly face-to-face session with their therapist, to discuss the progress of their treatment and ensure its seamless continuation (intra-vaginal assessment, adjustments, motivation etc.). Each session will last approximately 30 minutes. Participants will also be advised to perform the PFM program twice a week on their own e.g. at home. In total, participants will follow a PFM program three times a week (for 12 weeks), once with their therapist and twice independently. The participants in the FtFS group will follow the same PFM exercise treatment program as the BSATP group, which will be an individualized program where the position will change every two weeks and include endurance training, speed training and 'Knack maneuver' training.
219243033|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
219243034|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
219243035|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
219243036|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
219243037|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
219243038|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
219243039|NCT05579769|DRUG|Bone marrow infusion|Day 0
219243040|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
219243041|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
219243042|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product Placebo Control|Participants will use their Menstrual Wellness Product Placebo Control as directed for a period of 12 weeks
219243043|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product 1|Participants will use their Menstrual Wellness Product 1 as directed for a period of 12 weeks
219243044|NCT07143305|OTHER|Multicomponent physical exercise programme|Participants engaged in a multicomponent physical exercise programme designed specifically for older adults. The programme was based on the latest evidence and international recommendations for sarcopenia and functional maintenance in ageing population.
219739096|NCT04680208|PROCEDURE|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
219739097|NCT03024411|OTHER|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
219739098|NCT04488887|DIAGNOSTIC_TEST|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
219739099|NCT00949065|BIOLOGICAL|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
219739100|NCT05533437|DEVICE|dry needling|the dry needle inserted to area of pain
219739101|NCT05533437|OTHER|kinesio taping|kinesio taping
219739102|NCT06313346|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
219739103|NCT06313346|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
219739104|NCT04575298|DIETARY_SUPPLEMENT|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
219739105|NCT06501248|DRUG|Triticum Aestivum|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
219739106|NCT06501248|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
219739107|NCT00926900|DRUG|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
219172498|NCT06848517|OTHER|Control Group (CG)|The participants will be advised to follow a PFM exercise treatment program at home, based on an educational home leaflet (with instructions and images about PFM exercises) that they received during their first assessment session (baseline). The participants of this group will follow a PFM exercise therapy program (through the leaflet) which will last 12 weeks and they will be advised to attend it three times a week. No face-to-face meetings or supervision will occur by the therapist during the treatment period. Similarly to the other two intervention groups, the provided PFM exercise treatment program will be individualized, will include endurance training, speed training, and 'Knack maneuver' training, and the participants will be encouraged to change their exercise position on their own every two weeks.
219243045|NCT06947122|BEHAVIORAL|Mindfulness based smartphone app|The Mindful Journey intervention includes (1) 14 foundational modules/lessons, (2) brief check-in surveys (3 times/day) via the app, (3) app-guided momentary mindfulness coaching (max 3 times/day), and (4) brief 5 to 10-minute phone-based check-in from a trained staff member, on a weekly basis. Occurring for approximately 8 weeks following enrollment visit
219243046|NCT07147933|OTHER|phusical therapy program|physical therapy program including stretching of the hamstrings and strengthening of the quadriceps only. The program will be delivered 3 times per week for 8 weeks under therapist supervisio
219739108|NCT00926900|DRUG|Placebo|Placebo
219739109|NCT03167658|BEHAVIORAL|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
219739110|NCT03614832|DRUG|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
219739111|NCT03614832|DRUG|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
219739112|NCT01883375|BEHAVIORAL|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
219739113|NCT01883375|BEHAVIORAL|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
219739114|NCT06160778|DRUG|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
219739115|NCT06160778|DRUG|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
219739116|NCT06160778|DRUG|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
219739117|NCT06160778|DRUG|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
219243047|NCT07147933|OTHER|physical therapy program|A targeted physical therapy program including correction of anterior pelvic tilt, strengthening of the soleus, core strengthening, stretching of the hamstrings, and strengthening of the quadriceps. The program will be delivered 3 times per week for 8 weeks under therapist supervision.
219243048|NCT07147803|OTHER|Pittsburgh Sleep Quality Index|PSQI (Arabic validated version) - main sleep measure; global score 0-21; PSQI \>5 = poor sleep quality.
219243049|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Placebo Control|Participants will use their Revive Product Form - Placebo Control as directed for a period of 12 weeks.
219243050|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Active|Participants will use their Revive Product Form - Active as directed for a period of 12 weeks.
219243051|NCT06954610|OTHER|No intervention|No intervention
219243052|NCT07142525|PROCEDURE|Hybrid Osteoplasty|Open rhinoplasty with dorsal hump reduction performed using a powered surgical burr under irrigation and direct visualization. Bone is contoured gradually to achieve a smooth dorsum while preserving the keystone area. No dorsal osteotomy is performed in this arm. Cartilaginous work and adjunctive steps (e.g., septoplasty or tip refinement) are performed as clinically indicated but are not part of the intervention being tested.
219243053|NCT07142525|PROCEDURE|Traditional Osteotomy and Rasping|Open rhinoplasty using the conventional technique for dorsal hump reduction. The bony hump is resected with a straight osteotome, followed by manual rasping to refine the nasal dorsum, with preservation of the keystone area. Powered burrs are not used for primary dorsal contouring in this arm. Cartilaginous work and adjunctive procedures may be performed as clinically indicated but are not part of the tested intervention.
219243054|NCT07153536|DEVICE|Spinal Cord Stimulator (Medtronic Inceptiv™ System)|The Medtronic Inceptiv™ spinal cord neurostimulation system is a rechargeable implantable pulse generator (IPG) designed to deliver electrical pulses to the spinal cord via implanted leads. The system is intended for use in patients with chronic pain.
219243055|NCT07153536|OTHER|Physical Therapy|The physical therapy intervention consists of two components: the Mind-Pod Dolphin system (targeting arm function) and the Hummingbird Hunt system (targeting hand function). Both systems use interactive gaming software that enables participants to engage in remote, game-based therapy. Each system offers multiple difficulty levels, allowing participants to progress as their skills improve.
219243056|NCT07155330|DEVICE|High-flow nasal cannula|Using high-flow nasal cannula oxygenation
219243057|NCT07153900|DEVICE|Treatment with BACK4 System|Use of combined RF and EMS therapy with BACK4 Device
219243058|NCT07160712|DIETARY_SUPPLEMENT|Relief Product Placebo Control|Participants will use their Relief Product Control as directed for a period of 6 weeks.
219243059|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 1|Participants will use their Relief Active Product 1 as directed for a period of 6 weeks.
219243060|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 2|Participants will use their Relief Active Product 2 as directed for a period of 6 weeks.
219243061|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 3|Participants will use their Relief Active Product 3 as directed for a period of 6 weeks.
219243062|NCT07160634|DRUG|SGT-003|Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)
219243063|NCT07160634|DRUG|Placebo|IV infusion
219243064|NCT05773274|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219243065|NCT05773274|DRUG|Cabozantinib|Given PO
219243066|NCT05773274|PROCEDURE|Computed Tomography|Undergo CT scan
219243067|NCT05773274|DRUG|Everolimus|Given PO
219243068|NCT05773274|DRUG|Lutetium Lu 177 Dotatate|Given IV
219243069|NCT05773274|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219243070|NCT05773274|OTHER|Quality-of-Life Assessment|Ancillary studies
219243071|NCT05773274|OTHER|Questionnaire Administration|Ancillary studies
219243072|NCT05773274|DRUG|Sunitinib|Given PO
219243073|NCT07162350|BEHAVIORAL|Food Navigation|"For those randomized to the FAME Intervention, it will begin with a Community Health Worker (CHW) Food Navigator consultation. The role of the Food Navigators is as follows:~1. Identify the top dietary and food needs of the participant and their family. The Food Navigator will perform a needs assessment to define food access, kitchen resources/capacity, and other social determinants of health.~2. Set realistic, participant and family-driven nutrition goals. The Food Navigator will utilize Motivational Interviewing (MI), an evidence-based method of counseling that promotes motivation for change.~3. Provide nutrition resources and referrals.~4. Support children and families for up to 12 months."
219243074|NCT07164040|DEVICE|The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG|When activating the GLOW800 mode, the white light illumination of the Leica microscope stand is extended to InfraRed (IR), to excite the fluorophore (ICG). The technology provides ergonomic advantages as the user can maintain an upright posture while observing the surgical field. To excite the fluorophore, ICG dye is illuminated with light at its excitation wavelength band around 750 - 800nm. GLOW800 utilizes a 400w xenon illumination light source integrated as a standard component within the compatible Surgical Operating Microscope (SOM) stand. Activation of the GLOW800 mode extends the white light illumination of the SOM to the infrared (IR) spectral range using a suitable filter placed in the compatible SOM's standard filter wheel for the excitation of the ICG. Each patient enrolled in this study will undergo standard of care for the surgical procedure. No deviations to the standard of care will occur in the execution of this study.
219243075|NCT07159308|BEHAVIORAL|Intrinsic Motivation Treatment|The Intrinsic Motivation treatment utilizes principles of Motivational Interviewing to help autistic young adults increase their desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
219172499|NCT05430035|DRUG|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
219743401|NCT06472024|PROCEDURE|Sham Acupuncture|Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
219743402|NCT02832531|DRUG|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
219172500|NCT06843733|OTHER|Mixed reality exergame|The participants will play the Balloon Popping game using Hololens2 (Mixed reality glasses) for one hour. The objective of this game will be to pop all the virtual balloons, focusing on training different executive functions such as inhibitory control and cognitive flexibility. When a participant raises a finger in the air, a virtual needle will appear. After that, the participant will move their finger towards a balloon. Successful contact with a balloon will be indicated by the sound of a pop and the visual effect of confetti.
219743403|NCT02832531|DRUG|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
219172501|NCT06843733|OTHER|Education|The participants will seat on a chair and watch video clip about MCI and dementia for one hour.
219172502|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
219172503|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
219172504|NCT06012929|DRUG|ONC201|ONC201 is an oral medication given once per week
219743404|NCT03615131|DIAGNOSTIC_TEST|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
219743405|NCT04255381|DEVICE|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC\_AP)
219743406|NCT03871504|OTHER|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
219743407|NCT05559047|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
219743408|NCT05559047|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
219743409|NCT00945880|DRUG|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
219743410|NCT00779610|PROCEDURE|Vibration with flexion|Vibration with forearm flexion (active contraction)
219743411|NCT00779610|PROCEDURE|Vibration without flexion|Vibration without forearm flexion (passive)
219743412|NCT03914833|OTHER|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
219743413|NCT03914833|OTHER|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
219743414|NCT00601445|BEHAVIORAL|Amount of sleep and wake|4 groups with different patterns of sleep and wake
219743415|NCT05985174|DIAGNOSTIC_TEST|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
219243076|NCT07159308|BEHAVIORAL|Extrinsic Motivation Treatment|The Extrinsic Motivation treatment utilizes behavioral principles to help autistic adolescents and young adults create reward schedules and behavioral tracking sheets to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
219243077|NCT07159308|BEHAVIORAL|Combined Intrinsic and Extrinsic Motivation Treatment|The Combined Intrinsic and Extrinsic Motivation treatment combines elements of both intrinsic and extrinsic motivation treatments to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60-90 minutes long. The goals of the treatment are to enhance motivation and behavior change.
219243078|NCT07166107|OTHER|EVOLV-Rx dashboard|Using the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. \[Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.\] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued.
219243079|NCT07164287|DRUG|Lysergic Acid Diethylamide (LSD) or psilocybin|Psychedelic-assisted psychotherapy with LSD or psilocybin as a part of a clinical routine in our department
219243080|NCT05655013|DRUG|Zoledronate|zoledronate 5 mg
219243081|NCT05655013|DRUG|Placebo|isotonic saline 100 mL
219243082|NCT07170397|DEVICE|Acupuncture Laser Therapy|Application of low-level laser therapy to patients with chronic kidney disease to evaluate its effects on pain, circulation, and functional outcomes
219243083|NCT07166523|DIETARY_SUPPLEMENT|Energy Product Placebo Control|Participants will use their Energy Product Placebo Control as directed for a period of 6 weeks
219243084|NCT07166523|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks
219243085|NCT07176572|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated + NS IV Infusion 100 ml
219243086|NCT07176572|DRUG|Dexketoprofen Trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution + Transcutaneous electrical nerve stimulation treatment will not be activated.
219243087|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243088|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243089|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243090|NCT07180342|BEHAVIORAL|Tourism-based intervention|Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.
219243091|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243092|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243093|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
219243094|NCT07184996|DRUG|Duvakitug|Pharmaceutical form:Solution for Injection-Route of administration:SC injection
219243095|NCT07184996|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
219243096|NCT07184931|DRUG|Duvakitug|Pharmaceutical form:Injection solution Route of administration:SC injection
219243097|NCT07184931|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration:SC injection
219243098|NCT07188818|DEVICE|Decoria Essence|Decoria® Essence is a hyaluronic acid based, BDDE-crosslinked dermal filler. Decoria® Essence dermal fillers are injected into dermal tissue to improve the volume and the contouring of the lips to desired level of correction by supporting the overlying tissue. Injection volume will be determined by the treating investigator according to the instructions for Use (IFU).
219743416|NCT06004583|DIAGNOSTIC_TEST|Biochemical blood analysis|Serum CRP and albumin levels
219743417|NCT05269797|BEHAVIORAL|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
219743418|NCT06228937|OTHER|analysis of a sample of stool|typing of the gut microbiota from a stool sample
219743419|NCT05645887|DRUG|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
219743420|NCT05645887|OTHER|Saline solution|Saline solution from day 0 to day 7.
219743421|NCT03999073|OTHER|Ultrasound measurement|Ultrasound measurement
219243099|NCT07190911|OTHER|Olfactory rehabilitation consists of smelling a series of spices every day for 2 months|"Olfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin.~This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8~Allergies to certain spices will be noted at the start of the study:~* in known allergy: change by another spice which belongs to the same chemical category.~* in case of allergies to several scents: patient is not included in the study.~* in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category.~* in case of allergies to several scents occuring during participation: patient is excluded from the study."
219243100|NCT07185009|DRUG|Duvakitug|Pharmaceutical form: Injection solution Route of administration: SC injection
219243101|NCT07185009|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
219243102|NCT07190079|DIAGNOSTIC_TEST|Saline contrast Electrical Impedance Tomography method|"This study will enroll patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who undergo electrical impedance tomography (EIT) with saline contrast within 24 hours before or after computed tomography pulmonary angiography (CTPA). The EIT procedure is performed as follows:~1. Breath-Hold Maneuver: (1)Spontaneous breathing patients: Supine position, instructed to hold expiration for ≥8 seconds. (2)Mechanically ventilated patients: Expiratory hold (\>8 sec) achieved via ventilator; deeper sedation will be applied when feasible to prolong breath-hold.~2. Venous Access: (1)Preferred: Central venous catheter (internal jugular or subclavian vein).(2)Alternative: Peripheral forearm vein (preferably the median cubital vein).~3. Contrast Administration:(1)Central venous route: 10 mL of 10% NaCl.(2)Peripheral venous route: 15 mL of 5% NaHCO₃."
219243103|NCT07190079|DIAGNOSTIC_TEST|Computed Tomography Pulmonary Angiography (CTPA)|Patients who meet the inclusion criteria will undergo CTPA examination using conventional clinical diagnostic methods.
219243104|NCT07189559|BEHAVIORAL|Digital Bodies|The Digital Bodies intervention consists of a one-hour interactive session. The core of the intervention involves the use of cognitive dissonance techniques and the development of critical literacy skills to encourage adolescents to critically reflect on appearance ideals, as well as to foster the skills needed to challenge such ideals.
219243105|NCT07191002|OTHER|placement depth of the double lumen tube|the anesthesiologist will select the appropriate DLT size and placement depth entirely at their discretion, as per routine practice, and confirm both using fiberoptic bronchoscopy (FOB). If malposition occurs, it will be corrected under FOB guidance, and the tube will be secured in the correct position
219243106|NCT07186387|DRUG|LW402|LW402 tablets
219243107|NCT07186387|DRUG|LW402 placebo|LW402 placebo tablets
219243108|NCT07192926|DRUG|Immune Checkpoint Inhibitors|Retrospective analysis of patients with metastatic non-small cell lung cancer (mNSCLC) who received standard-of-care immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors (e.g., nivolumab, pembrolizumab, atezolizumab, durvalumab). Patients received these agents as part of routine clinical practice; no experimental intervention was administered in this study.
219243109|NCT07193511|DRUG|AVZO-103|Specific dose in protocol specified schedule
219243110|NCT07193511|DRUG|Combination Agent|Per label based on combination agent used
219243111|NCT07194694|DRUG|Dexmedetomidine & Bupivacaine.|Group A (Dexmedetomidine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine + 1mcg/kg dexmedetomidine +normal saline.
219243112|NCT07194694|DRUG|ketamine and bupivacaine injection|Group K (ketamine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine+0.5 mg/kg ketamine + normal saline.
219243113|NCT07194694|DRUG|Bupivacaine|Group C (Control Group): Patients will receive 20 ml solution containing 1 mg/kg bupivacaine + normal saline.
219243114|NCT07184944|DRUG|Duvakitug|Pharmaceutical form:Injection solution-Route of administration:SC injection
219243115|NCT07184944|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
219243116|NCT07193940|PROCEDURE|Flexible Ureteroscopy|Flexible Ureterorenoscopy
219172505|NCT06850779|OTHER|Extracorporeal shock wave therapy (ESWT)|Radial ESWT (Vibrolith OrthoⓇ) was applied to the wrist as 1000 pulses with a frequency of 5 Hz and a power of 1.5 bar. The treatment was applied once a week for a total of 3 sessions.
219172506|NCT06850779|OTHER|Kinesio taping (KT)|KT was prepared as 2 pieces of 2.5 cm I band and 1 piece of 5 cm I band. It was applied with a maximum of 50% tension (without tension on the ends) while the wrist was in 30 degrees of extension, forearm supination and elbow extension. The treatment was applied once a week for a total of 3 sessions.
219172507|NCT06850779|OTHER|Exercise|Median nerve gliding exercises were given to the 4th group during the follow-up period. The same exercises were given to the other groups.
219243117|NCT07193940|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|extracorporeal shock wave lithotripsy (ESWL)
219243118|NCT07194148|BEHAVIORAL|Gamified Digital Education (ORNurse: Steril Setup 1.0)|A behavioral intervention utilizing a custom-developed 3D digital game designed to teach perioperative nurses or students the correct layout of surgical instrument tables in total hip arthroplasty. The game includes interactive modules, feedback mechanisms, and simulated scenarios based on a validated protocol.
219243119|NCT07194148|BEHAVIORAL|Traditional Training|A classroom-based lecture accompanied by printed materials covering the correct surgical instrument table setup for total hip replacement surgery.
219172508|NCT06850454|DRUG|olanzapine|olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
219172509|NCT06850454|DRUG|Placebo|placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
219172510|NCT06849128|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
219243120|NCT07192770|BIOLOGICAL|Granulocyte colony-stimulating factor (G-CSF)|Patients receive chemotherapy with prophylactic G-CSF (granulocyte colony-stimulating factor) as part of routine clinical care. Both short-acting (filgrastim) and long-acting formulations (pegfilgrastim, lipegfilgrastim) may be used according to standard oncology practice. The study does not assign the intervention but observes supportive care strategies and patient-reported outcomes related to G-CSF-induced bone pain.
219243121|NCT07192770|OTHER|Supportive Care (Analgesic and Non-Pharmacological Strategies)|Supportive care strategies including analgesic use (NSAIDs, opioids, antihistamines) and non-pharmacological interventions (rest, exercise, local heat/cold, relaxation techniques) will be recorded as part of routine practice. The study does not randomize or assign supportive care but documents their use and association with bone pain outcomes.
219243122|NCT07194044|DRUG|Vincristine|IV Push
219243123|NCT07194044|DRUG|Doxorubicin|IV
219243124|NCT07194044|DRUG|Cyclophosphamide|IV and Maintenance PO
219243125|NCT07194044|DRUG|Ifosfamide|IV
219243126|NCT07194044|DRUG|Actinomycin|IV
219243127|NCT07194044|DRUG|Irinotecan|IV
219243128|NCT07194044|DRUG|Cabozantinib|PO
219243129|NCT07194044|DRUG|Topotecan|IV
219243130|NCT07194044|DRUG|Temozolomide|IV
219243131|NCT07194044|DRUG|Etoposide|PO
219243132|NCT07194044|DRUG|Liposomal doxorubicin|IV
219243133|NCT07194564|BEHAVIORAL|Control Exercise|A standard exercise without self-correction, performed by all participants as the control condition.
219243134|NCT07194564|BEHAVIORAL|Self-corrective Exercise|A self-corrective exercise intervention targeting improved postural alignment and muscle activation.
219243135|NCT07195227|DRUG|Camizestrant|Next-generation oral SERD molecule that is intended for the treatment of women and men with ER+ breast cancer. In addition to degradation of ERα, camizestrant also acts as a pure ER antagonist
219243136|NCT07195227|DRUG|Ribociclib|Selective inhibitor of CDK 4 and 6, with 50% inhibition (IC50) values of 0.01 μM (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated by binding to D-cyclins and are crucial to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates the cell cycle by phosphorylating the retinoblastoma protein (pRb).
219243137|NCT07195929|OTHER|Allergenic Extract|In each subject, a drop of each of the 3 concentrations of the allergenic extract, in addition to the positive control (histamine) and the negative control, will be applied. The application will be duplicated on the subject's anterior forearm, with a distance of approximately 4 cm between each application to avoid overlapping reactions and false-positives results.
219243138|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+®|Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
219172511|NCT06849128|OTHER|Conventional cognitive training|A conventional cognitive training protocol involves structured, repetitive exercises designed to enhance specific cognitive functions, such as memory, attention, executive function, and processing speed. These training programs are delivered through paper-and-pencil tasks, computer-based exercises, and therapist-guided activities. Tasks used include working memory exercises (e.g., digit span recall), attention training (e.g., Stroop test, visual scanning), problem-solving activities (e.g., Tower of Hanoi), and language exercises (e.g., verbal fluency tasks), for 45 minutes per session, 3 times weekly, for 4 weeks.
219172512|NCT03737253|DRUG|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
219172513|NCT03737253|DRUG|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
219172514|NCT05491356|DRUG|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
219172515|NCT05491356|DRUG|Placebo|0.9% saline solution, intra-catheter administration, sterile
219243139|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+® with semaglutide|Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.
219172516|NCT04424407|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
219243140|NCT07179575|DRUG|LW231|LW231 tablets
219243141|NCT07179575|DRUG|LW231 placebo|LW231 placebo tablets
219243142|NCT07196683|PROCEDURE|Regenerative pulpotomy|Regenerative pulpotomy combines the use of hydraulic calcium silicate based cements; MTA, together with biodegradable scaffolds such as PRF.
219243143|NCT07201285|OTHER|Edge of laminar block|Patients will receive edge of laminar block using 20ml of bupivacaine 0.25%.
219243144|NCT07201285|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block using 20ml of bupivacaine 0.25%.
219243145|NCT07196085|BEHAVIORAL|Imagery Rescripting|"Four ImRs sessions over 2 weeks, targeting autobiographical criticism memory. Therapist-guided rescripting involved modifying the hotspot scene (critical interaction) with protective interventions addressing unmet needs."
219243146|NCT07196085|BEHAVIORAL|Sham Neutral Imagery|Four neutral imagery sessions over 2 weeks. Participants imagined neutral interpersonal interactions matched in structure and duration to ImRs but with rescription of neutral instead of criticism memories.
219243147|NCT07200544|DRUG|Meloxicam 7.5 mg|This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.
219243148|NCT07200544|DRUG|Meloxicam 15 mg|This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.
219243149|NCT07200544|DRUG|Acetaminophen 500mg|This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.
219243154|NCT07204080|DRUG|TNX-1500|This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.
219243155|NCT07204080|PROCEDURE|Kidney Transplant|Kidney Transplant
219243156|NCT07203950|OTHER|global postural reeducation with conventional therapy|"Global postural reeducation will include two postural positions aiming to improve alignment, flexibility and postural correction. Each session will be 35 minutes including each posture performed for 10 minutes each and 15 minutes for conventional therapy.~1. Coxofemoral Opening with Closed Arms Participants will begin in a supine position on a flat surface. The upper limbs will be 90° abducted, with palms facing to the ceiling. The lower limbs will be placed in hip and knee flexion, with soles of the feet together, heels close to the gluteal region, and hips in abduction between 30° and 45°.~2. Coxofemoral Closure with Closed Arms. In this posture, participants will again lie supine, with the arms abducted to 90° and palms facing upward. The hips and knees will be flexed, with the soles of the feet pressed together and placed against a wall.~   with Controlled and slow diaphragmatic breathing technique~3. Conventional therapy same as given to other group."
219243157|NCT07203950|OTHER|conventional therapy|"conventional therapy given to this group will be~* Hot pack for 15 minutes.~* Static stretching of rectus femoris and iliopsoas muscles (1 minute x 5 repetitions per session).~* Other exercises Pelvic tilt Straight leg raise Bridging Cat-camel exercise Knee-to-chest stretch Prescribed as 3 sets of 10 repetitions each, with rest in between."
219243158|NCT07204210|DEVICE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is a treatment using powerful acoustic pulses which is mostly used to treat kidney stones and in physical therapy and orthopedics. Extracorporeal shockwave therapy is used as a second line measure to treat tennis elbow, shoulder rotator cuff pain, Achilles tendinitis, plantar fasciitis, and greater trochanteric pain syndrome. The lithotripter attempts to break up the stone with minimal collateral damage by using an externally applied, focused, high-intensity acoustic pulse. The patient is usually sedated or anesthetized for the procedure in order to help them remain still and reduce possible discomfort.
219243159|NCT07204210|OTHER|myofascial release technique|"Myofascial release (MFR, self-myofascial release) is an alternative medicine therapy claimed to be useful for treating skeletal muscle immobility and pain by relaxing contracted muscles, improving blood and lymphatic circulation and stimulating the stretch reflex in muscles. Writing for Science-Based Medicine, Harriet Hall described myofascial release as an umbrella term for several types of physical manipulation, which might more simply be described as a kind of massage based on vaguely defined scientific notions. Reviews published in 2013 and 2015 evaluating evidence for MFR efficacy found that clinical trials that had been conducted varied in quality, technique, outcome measurements and had mixed outcomes; the 2015 review noted: it is time for scientific evidences on MFR to support its clinical use."
219243160|NCT07204210|OTHER|Placebo Control|Participants were not given any interventions that had proven effective for treatment. An appointment was made for 5 weeks later.
219243161|NCT07202702|DEVICE|tDCS|Applying tDCS to determine if it facilitates learning of a video game task
219243162|NCT07203586|PROCEDURE|Minimally invasive scoliosis surgery|Patients undergoing minimally invasive surgery have screws placed using the surgeon's preferred method: 3D navigation, robotic assistance, freehand, or combinations. A long incision of the skin is made without detaching the erector spinae muscles. Each screw is inserted through the musculature, and positioning is verified with intraoperative CT; misplaced screws are corrected. Rods are then shaped, placed, and deformity correction is performed. The surgeon may decorticate some or all facet joints using minimally invasive techniques before closing the wound.
219243163|NCT07203586|PROCEDURE|Traditional open scoliosis surgery group|In traditional open scoliosis surgery, the surgeon uses the preferred method for screw placement (3D navigation, robotic assistance, freehand, or combinations). A long incision is made, and the spinal musculature is detached to fully expose the posterior elements. All screws are inserted through this open area, and their positions are verified with intraoperative CT; misplacements are corrected if needed. Rods are shaped, placed, and deformity correction is performed. Decortication of facet joints, spinous processes, and laminae may be performed with a high-speed burr or similar technique. The wound is then closed.
219243164|NCT07202988|OTHER|vegetable combination 1|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
219243165|NCT07202988|OTHER|vegetable combination 2|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
219243166|NCT07202988|OTHER|vegetable combination 3|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
219243167|NCT07202988|OTHER|vegetable combination 4|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
219243168|NCT07202988|OTHER|vegetable combination 5|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
219243169|NCT07202546|DRUG|VH4524184|Oral tablet will be administered.
219243170|NCT07202546|DRUG|Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets|Oral table will be administered.
219243171|NCT07202546|DRUG|Dolutegravir / Lamivudine (DTG/3TC)|Oral tablets will be administered.
219243172|NCT07204509|DIAGNOSTIC_TEST|Conventional Karyotyping|Conventional chromosomal analysis was performed using karyotyping of peripheral blood lymphocytes. Standard cytogenetic techniques were applied to identify chromosomal abnormalities in pediatric patients with congenital heart disease. This diagnostic test was used solely for observational and genetic correlation purposes.
219243173|NCT07204223|DEVICE|Tulip Airway|In this study, patients scheduled for surgery under general anesthesia who meet the criteria for anticipated difficult mask ventilation will be included. Randomization will be performed to determine which device will be used first. If the Tulip airway is selected as the first device in the randomization process, mask ventilation will be initiated with the Tulip airway.
219243174|NCT07204223|DEVICE|Guedel Airway|In this study, patients scheduled for surgery under general anesthesia who meet the criteria for anticipated difficult mask ventilation will be included. Randomization will be performed to determine which device will be used first. If the Guedel airway is selected as the first device in the randomization process, mask ventilation will be initiated with the Guedel airway.
219243175|NCT07204873|OTHER|LUSHA digital app|Children with Attention Deficit Disorder with or without Hyperactivity (ADHD) and their parents will be asked to use LUSHA app during 3 months.
219243176|NCT07203612|BEHAVIORAL|SHS|Group-based and video-based intervention to teach caregivers of young children how to supervise their children more closely to prevent unintentional injuries.
219243177|NCT07203612|BEHAVIORAL|Parenting group|This intervention was designed to teach caregivers about evidence-based behavioral methods to manage common child behavior problems.
219243178|NCT07202611|BIOLOGICAL|In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer|The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use.
219243179|NCT07202572|DEVICE|TRIPP VR Meditation|Participants engage with the TRIPP virtual reality meditation program for 2 weeks. The TRIPP platform delivers guided mindfulness and breathing exercises through an immersive VR environment designed to promote relaxation and emotional regulation. Sessions are delivered via VR headset and used on a regular schedule (e.g., daily or as prescribed).
219243180|NCT07202572|BEHAVIORAL|Sham VR|Participants engage with a sham virtual reality experience for 2 weeks. The sham VR consists of non-therapeutic, visually engaging content without meditative, guided mindfulness, or relaxation components. It is designed to mimic the immersive nature of the TRIPP VR platform without delivering active therapeutic content.
219739118|NCT01946269|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
219739119|NCT01946269|OTHER|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
219243181|NCT07202559|DRUG|Indometacin suppository|Administration of a 100mg indometacin suppository rectally 30 minutes prior to ESWL
219739120|NCT06327165|OTHER|observation|The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
219739121|NCT05390320|PROCEDURE|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
219739122|NCT05390320|OTHER|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
219739123|NCT00000397|BEHAVIORAL|Behavioral insomnia therapy|
219739124|NCT02144337|BEHAVIORAL|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
219743422|NCT06549907|OTHER|Multi-omics testing|Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
219172517|NCT02919956|OTHER|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
219243182|NCT07202559|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
219739125|NCT03221335|DEVICE|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
219739126|NCT04973293|DRUG|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
219739127|NCT04973293|DRUG|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
219739128|NCT01013337|PROCEDURE|acupuncture therapy|
219739129|NCT01013337|PROCEDURE|sham intervention|Placebo acupuncture
219739130|NCT02743312|DEVICE|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
219172518|NCT02919956|OTHER|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
219739131|NCT02743312|DEVICE|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
219739132|NCT02743312|DEVICE|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
219739133|NCT01435642|OTHER|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
219739134|NCT01730729|DRUG|cabergoline|Given orally
219739135|NCT03752372|PROCEDURE|hematopoietic stem cell transplantation|"1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation"
219739136|NCT04127110|DRUG|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
219739137|NCT04053426|OTHER|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
219739138|NCT02584738|DRUG|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
219739139|NCT02584738|DRUG|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
219172519|NCT05435092|RADIATION|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
219172520|NCT03110315|DRUG|Suvorexant|See detailed information in associated Arm Description.
219172521|NCT03110315|DRUG|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
219172522|NCT01781468|DRUG|armodafinil 150 mg|given orally
219172523|NCT01781468|OTHER|Placebo|given orally
219172524|NCT01781468|DRUG|armodafinil 250 mg|given orally
219172525|NCT03365609|DRUG|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
219172526|NCT03365609|DRUG|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
219172527|NCT03365609|DRUG|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
219172528|NCT03365609|DRUG|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
219172529|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme1|15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol
219172530|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme 2|30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
219172531|NCT06203743|PROCEDURE|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
219172532|NCT06203743|PROCEDURE|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
219739140|NCT02584738|DRUG|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
219739141|NCT02584738|DRUG|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
219739142|NCT02584738|DRUG|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
219739143|NCT06570421|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
219739144|NCT01435980|PROCEDURE|Gastric Bypass|basal treatment and Gastric Bypass
219739145|NCT01435980|DRUG|Exenatide|basal treatment and Exenatide
219243183|NCT07202559|DRUG|Normal Saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h)
219743423|NCT06549907|OTHER|MRI|MRI will be conducted to investigate image characteristics during treatment
219172533|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
219172534|NCT04986917|DEVICE|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
219172535|NCT04986917|DIAGNOSTIC_TEST|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
219172536|NCT04986917|DIAGNOSTIC_TEST|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
219172537|NCT04986917|DIAGNOSTIC_TEST|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
219172538|NCT04986917|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
219172539|NCT04986917|DIAGNOSTIC_TEST|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
219172540|NCT04986917|OTHER|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
219172541|NCT04986917|OTHER|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
219172542|NCT04986917|DIAGNOSTIC_TEST|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity."
219172543|NCT04906382|PROCEDURE|Biopsy|Undergo biopsy
219172544|NCT04906382|DRUG|Carboplatin|Given IV
219172545|NCT04906382|DRUG|Paclitaxel|Given IV
219172546|NCT04906382|BIOLOGICAL|Tislelizumab|Given IV
219172547|NCT04373135|BEHAVIORAL|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
219172550|NCT06130683|OTHER|Single-cell sequencing|Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
219172551|NCT01083758|DRUG|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
219172552|NCT05416554|BEHAVIORAL|Neuropsychological testing|Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
219172553|NCT05294016|DEVICE|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
219172554|NCT02386371|PROCEDURE|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
219172555|NCT02386371|RADIATION|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
219172556|NCT03825965|DRUG|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
219172557|NCT03825965|DRUG|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
219172558|NCT04727554|DRUG|AMG 994|Administered as an intravenous (IV) infusion.
219172559|NCT04727554|DRUG|AMG 404|Administered as an intravenous (IV) infusion.
219172560|NCT03590821|DRUG|Aspirin 81 mg|timed administration of aspirin in the evening
219739146|NCT02532907|PROCEDURE|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
219172561|NCT03590821|DRUG|Celecoxib 200mg capsule|daily administration of celecoxib
219172562|NCT05966519|DEVICE|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
219172563|NCT02216838|DRUG|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
219172564|NCT02216838|OTHER|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
219172565|NCT05152368|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
219172566|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
219172567|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
219172568|NCT06931470|BEHAVIORAL|In-person supervised exercise sessions|Gold-standard, facility-based sessions (3 sessions/week) with an onsite trainer guidance with an exercise Intensity of 40-80% heart rate reserve (HRR) or Rate of Perceived Exertion (RPE) 12-16.
219172569|NCT06931470|BEHAVIORAL|Virtual classes (live-streamed sessions)|Live-streamed exercise classes (3 sessions/week) with a trainer providing real-time feedback.
219172570|NCT06931470|BEHAVIORAL|Self-directed aerobic exercise|Participants exercise independently and follow a weekly progression plan (3-5 sessions/week (depending on the specific progression)).
219172571|NCT06931470|DEVICE|Myzone mobile application|Training using the Myzone platform, with participants wearing the Myzone heart rate monitor and using the Myzone app to receive real-time feedback and guidance during exercise sessions (3 days per week). Myzone integrates with its proprietary wearable devices to monitor heart rate and other activity metrics, providing real-time data to users via the app.
219172572|NCT06931470|DEVICE|Map My Fitness mobile application|Participants will wear a Bluetooth-compatible heart rate monitor (e.g., apple watch/fitbit) that syncs with MapMyFitness. MapMyFitness automatically records workout sessions (duration, distance, heart rate, calories burned, and elevation gain where applicable).
219172573|NCT06931470|DEVICE|Centralized telemetry|Centralized telemetry monitors heart rates and provides immediate feedback for trainers to adjust exercise intensity.
219172574|NCT06931470|DEVICE|Myzone heart rate monitor|Wearable device (chest strap or armband) that monitors heart rate.
219172575|NCT06932445|DIAGNOSTIC_TEST|Shear Wave Elastography|Shear wave elastography will be used to measure liver and spleen stiffness in all participants. The procedure will be performed using standard ultrasound-based elastography protocols by a pediatric radiologist.
219172576|NCT06932497|OTHER|Standard of care|Standard of care according to national and international guideline or recommendations
219172577|NCT06932328|DRUG|Qinqiao Yanshu Granules|High - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Extremely low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Rescue medication: Paracetamol tablets. During the trial, if the subject's body temperature exceeds 38.5°C (including 38.5°C), rescue medication can be added. Use it according to the instructions and doctor's advice and record it truthfully.
219172578|NCT06932211|OTHER|Toothpaste containing proteins and enzymes|Toothpaste containing proteins, enzymes and 1450 ppm fluoride as sodium fluoride
219172579|NCT06932211|OTHER|Control fluoride toothpaste|Toothpaste containing sodium fluoride at 1450 ppm F
219172580|NCT06931275|OTHER|EMR-based BPA model|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based BPA implementation at six centers.
219172581|NCT06931275|BEHAVIORAL|Placebo (EMR-based without BPA model)|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based system without BPA at the implementation at six centers.
219172582|NCT06932393|BIOLOGICAL|exosomes|Each subject will receive 3 injections with an interval of one month.
219172583|NCT06932393|OTHER|saline|Each subject will receive 3 injections with an interval of one month.
219172584|NCT06931561|PROCEDURE|Whole Body MRI|Whole body MRI
219172585|NCT06931561|PROCEDURE|Whole Body Ultrasound|Whole Body Ultrasound
219172586|NCT06931561|DEVICE|MCD Assay|Cancer detection blood test
219172587|NCT06931561|OTHER|Occupational Exposure Questionnaire|Questionnaire
219739147|NCT06570330|DIETARY_SUPPLEMENT|SuperHMO|Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)
219739148|NCT06570330|DIETARY_SUPPLEMENT|Non-GMO corn Maltodextrin, Rapid Absorption|he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
219743424|NCT06286072|OTHER|Education and message|COPD general education content and fatigue-specific coping strategies. Messages sent to phones
219172588|NCT06782945|DIETARY_SUPPLEMENT|BIOHM FX Probiotic Blend|BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.
219172589|NCT04280445|OTHER|Psychological therapy|Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
219172590|NCT03752671|DEVICE|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
219172591|NCT03752671|PROCEDURE|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
219172592|NCT06085872|BEHAVIORAL|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
219172593|NCT06085872|BEHAVIORAL|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested."
219172594|NCT06085872|BEHAVIORAL|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
219172595|NCT06847035|DIETARY_SUPPLEMENT|Active Comparator|LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide)，once daily for 12 weeks
219172596|NCT06847035|DIETARY_SUPPLEMENT|Placebo Comparator|placebo solid beverage (Maltodextrin with edible flavor)，once daily for 12 weeks
219172597|NCT06211062|DRUG|Floradapt Intensive GI|one capsule daily for the eight week intervention
219172598|NCT06211062|OTHER|Placebo|one capsule daily for the eight week intervention
219172599|NCT05009394|PROCEDURE|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
219172600|NCT05009394|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
219172601|NCT05009394|PROCEDURE|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
219172602|NCT03238794|PROCEDURE|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
219172603|NCT03238794|OTHER|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
219172604|NCT06367283|DRUG|Metformin|Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
219172605|NCT06367283|DRUG|Placebo|Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
219172606|NCT06847932|OTHER|AF-predict AI-ECG alert system guided management|AF-predict AI-ECG alert system
219172607|NCT03057938|DRUG|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
219743425|NCT06296355|BEHAVIORAL|Health Warning Label|"Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes."
219743426|NCT06296355|BEHAVIORAL|Identity Warning Label|"Message displayed on warning label is: WARNING: Ultra-processed food."
219743427|NCT06296355|OTHER|Barcode Label|Barcode is displayed.
219743428|NCT03163329|PROCEDURE|TAVR|Transcatheter Aortic Valve Replacement
219743429|NCT03163329|PROCEDURE|SAVR|Surgical Aortic Valve Replacement
219743430|NCT05802836|OTHER|no interventions|no intervention, only 3 different patients groups
219243184|NCT07204496|BIOLOGICAL|Ex Vivo Expanded γδ T Cell Infusion|This study involves the use of γδ T cell infusion, a non-genetically modified adoptive cellular immunotherapy. The intervention utilizes autologous γδ T cells isolated from peripheral blood and expanded ex vivo using specific activators such as zoledronate and cytokines, without genetic engineering. Its mechanism of action relies on the inherent MHC-unrestricted tumor recognition capability of γδ T cells, activating both the NKG2D-NKG2DL axis and BTN3A1-CD277 pathway for dual antitumor activity. The manufacturing process follows GMP-compliant closed-system conditions, with final product release criteria requiring ≥80% purity for CD3+γδ TCR+ cells, along with sterility testing, endotoxin detection, and cytotoxicity assays. This approach fundamentally differs from genetically modified αβ T cell-based therapies like CAR-T or TCR-T, as well as non-specific immunotherapies such as CIK/DC-CIK, and demonstrates superior ex vivo expansion and tumor-targeting capabilities compared to TIL therap
219243185|NCT07204639|DRUG|RAP103 400mg single dose|RAP103 400mg single dose, orally 8 weeks
219243186|NCT07204639|DRUG|RAP103 200mg BID|RAP103 200mg BID, orally 8 weeks
219243187|NCT07204639|DRUG|Placebo for RAP400|Placebo for RAP400mg single dose for 8 weeks
219243188|NCT07204639|DRUG|Placebo for RAP200mg|Placebo for RAP400mg single dose for 8 weeks
219739149|NCT02688231|OTHER|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
219739150|NCT02688231|OTHER|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
219172608|NCT04675476|BEHAVIORAL|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
219172609|NCT06847009|OTHER|Acupressure application|Acupressure will be applied to hemodialysis patients within the first two hours of HD and three times a week for four weeks. This intervention aims to evaluate its effects on sleep quality.
219172610|NCT06847828|OTHER|QPL|The QPL is in the form of a structured list of questions that caregivers would like to ask. It includes 17 questions on concept communication and 20 questions on end-of-life care. You can check the questions you want to ask and then discuss them with the medical team.
219172611|NCT03378219|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
219172612|NCT06843928|DEVICE|Submucosal debridement|Participants will undergo non-surgical submucosal debridement alone (SD)
219172613|NCT06843928|DEVICE|Submucosal debridement + titanium brushes|Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
219172614|NCT05838131|DRUG|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
219172615|NCT05137899|COMBINATION_PRODUCT|Neoadjuvant|Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
219172616|NCT06846645|OTHER|No intervention|Patients will receive clinical treatment with no special intervention in this observational study. There is no difference in term of treatment of patients. It only involves one additional blood sampling early after admission.
219172617|NCT05610774|DRUG|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
219243189|NCT07203729|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan 4.8mg/kg, IV, Day 1, Q3W
219243190|NCT07203729|DRUG|Chemotherapy of Physician's Choice|Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine
219243191|NCT07203963|OTHER|Niel-Asher Technique + sleeper stretch|Niel-Asher Technique, Manual Soft Tissue releaser, Neuro-muscular release technique for adhesive capsulitis ( This manual technique will be applied for 3 days a week for 4 weeks).Sleeper stretch will be applied passively by investigator, pressure of the stretch will be held for 30 seconds (repeated twice with 30 seconds break for 3 days a week) Conventional PT including 1: shoulder anteroposterior, posteroanterior and inferior glides ( 3 times a week for 4 week) 2: active and active assisted ROM exercises of shoulder joint (frequency: 1 set of 10 repetitions twice a day). 3: Shoulder Isometric exercises, Codman's exercises and pulley and finger ladder exercises (frequency: 1 set of 10 repetitions twice a day), 4: trigger points will be released by applying ischemic pressure (90 seconds) on trigger points found in rotator cuff muscles.
219243192|NCT07203963|OTHER|sleeper stretch + Conventional Treatment|Sleeper stretch will be applied passively by investigator, pressure of the stretch will be held for 30 seconds (repeated twice with 30 seconds break for 3 days a week). Conventional PT including 1: shoulder anteroposterior, posteroanterior and inferior glides ( 3 times a week for 4 week) 2: active and active assisted ROM exercises of shoulder joint (frequency: 1 set of 10 repetitions twice a day). 3: Shoulder Isometric exercises, Codman's exercises and pulley and finger ladder exercises (frequency: 1 set of 10 repetitions twice a day) 4: ischemic compression (90seconds hold) on trigger points found in rotator cuff muscles
219243193|NCT07204327|OTHER|Atezo+Bev plus Locoregional Therapy|Patients received atezolizumab plus bevacizumab (Atezo+Bev) in combination with at least one locoregional therapy (transarterial chemoembolization \[TACE\], hepatic arterial infusion chemotherapy \[HAIC\], transarterial radioembolization \[TARE\], ablation, or radiotherapy) within ±2 months of systemic therapy initiation, in routine clinical practice.
219243194|NCT07204457|BIOLOGICAL|EG-MCV4|single intramuscular dose on Day 0
219243195|NCT07204457|BIOLOGICAL|Menveo|single intramuscular dose on Day 0
219243196|NCT07202689|DEVICE|Multimodal monitoring|Multimodal monitoring technology offers a novel approach to cerebral protection during the perioperative period of cardiac surgery by integrating hemodynamic parameters, autonomic nervous responses, cerebral oxygen saturation and indices, electroencephalographic activity, and cerebral blood flow velocity.
219243197|NCT07204132|PROCEDURE|TURBT combined with cryoablation-assisted postoperative immunotherapy|After successful anesthesia, the patient underwent TURBT. Other methods such as laser resection could also be used. The tumor should be completely removed and biopsy specimens taken as much as possible. Then, under the direct vision of the electrocautery scope, cryoablation was performed on the base of the tumor lesion. The freezing area was single lesion and at least 2 freezing cycles were carried out (the freezing start to the rewarming end constituted one cycle), with each cycle lasting 3-5 minutes. If the lesion area was large, 2 more freezing cycles could be added at different positions of the lesion to ensure coverage of the lesion area. After the operation, based on the pathological and immunohistochemical results, adjuvant immunotherapy was initiated, and concurrent adjuvant rhythm chemotherapy was also combined.
219243198|NCT07204132|PROCEDURE|The conventional surgery treatment group|According to the guidelines, a radical cystectomy should be performed, and at the same time, a urinary diversion procedure should be carried out based on the specific situation, such as bladder channeling, ileal bladder substitution, ureterocutaneous fistula, in situ neobladder surgery, etc. (open, laparoscopic or robot-assisted methods are all acceptable). The biopsy and resected specimens should be sent for pathological examination. The postoperative adjuvant treatment plan is determined by the attending physician based on the patient's condition as appropriate.
219243199|NCT07203287|DRUG|Rocuronium|Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
219243200|NCT07203287|DRUG|Cisatracurium|Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
219243201|NCT07204067|BEHAVIORAL|Mirror Therapy Conventional Physiotherapy|"Experimental: Mirror Therapy + Conventional Physiotherapy Mirror therapy performed 20 min/session, 2 sessions/week for 1 week. A mirror is placed midsagittal, reflecting the non-paretic limb while hiding the paretic limb. Patients perform bilateral movements (wrist, finger, elbow flex/extension; reaching/grasping) while focusing on the mirror image. This is followed by 20 min of conventional physiotherapy, including strengthening, functional tasks, theraputty squeezes, finger extension with rubber band, towel wringing, lifting small objects, overhead reaching, and ball toss.~Active Comparator: Conventional Physiotherapy Only Conventional physiotherapy 20 min/session, 2 sessions/week for 1 week. Exercises include upper limb strengthening, functional task practice, theraputty squeezes, finger extension with rubber band, towel wringing, lifting small objects, overhead reaching, and ball toss."
219243202|NCT07202806|BEHAVIORAL|Aromatherapy|1.Aromatherapy is made from self-made sachet of traditional Chinese medicine.Its components (albizzia, Angelica dahurica, cardamom, Polygala, Evodia, Magnolia, Acorus calamus) are 10g each. Place the pillow 1 hour in advance. It is forbidden to play with your mobile phone or turn off the lights before going to bed.
219243203|NCT07204613|BEHAVIORAL|Aquatic stimulation for child development|The intervention will be conducted in a heated pool located in the Physiotherapy building of the Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Minas Gerais, Brazil. A total of 24 twice-weekly, 45-minute aquatic stimulation sessions will be offered over a 13-week intervention period. The sessions will follow a previously tested and refined aquatic stimulation protocol for infants. The experimental group will consist of 15 dyads (infant + parent or guardian) and three supervisors. Two will be inside the pool offering support and encouragement to parents and infants, and one will be outside the pool providing overall supervision of the children and controlling the time of each activity. The activities included in the aquatic intervention plan involve stimulation of expressive language, cognitive development, gross motor skills, fine motor skills, and social interaction.
219243204|NCT04976335|DEVICE|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
219243205|NCT07203027|BEHAVIORAL|Behavioral Tasks with imaging|"Participants will complete the MDP task only during 3 separate fMRI scanning sessions.~After each session, they will complete one week of ambulatory assessment of real-world avoidance behavior (self-reported avoidance behavior) via Emory Qualtrics surveys. In a fourth scanning session, the brain signature of threat imminence constructed in the first set of participants (Aim 1) will be used to predict and modify avoidance behavior (on the task and in a further week of ambulatory assessment of avoidance) in these participants. During their last visit, the behavioral task will be modified to decrease the availability of avoidance choices; subsequent effects on EMA and passive sensing measures will be assessed."
219243206|NCT07202975|OTHER|Mixed realities rehabilitation program|"1. Two sessions at the hospital: one session with traditional exercise + one session with traditional exercise and training with XR system ( 2 weeks)~2. Four more sessions at home with therapist (L1 therapist and L1 patients) (4 weeks)~3. Former sessions (until 120 days) with L3 therapist and L1 and L3 patients. Usual care: Group rehabilitation sessions: 8 weeks"
219243207|NCT07202975|OTHER|Usual Care|Group rehabilitation sessions: 8 weeks
219739151|NCT06571825|DRUG|Venetoclax|The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
219739152|NCT06571825|DRUG|Allogeneic transplant|"The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity."
219243208|NCT07193173|OTHER|2 minute step test|The 2-Minute Step Test (2MST) is a simple, validated field test used to assess aerobic endurance and functional fitness, especially in older adults or people with chronic conditions (e.g., cardiopulmonary disease, neurological disorders).
219243209|NCT07204184|DEVICE|Multisite transspinal stimulation at rest|The intervention, combined cervical and lumbar transspinal stimulation, will be used for the first time to reconnect the spared neuronal pathways of the injured human spinal cord. The intervention will be administered while at rest lying on the back or during robotic gait training. Cervical and lumbar transspinal stimulation will be delivered via surface active electrodes placed on the back of the neck and on low back, and four returning electrodes placed on each clavicle and iliac crest.
219243210|NCT07204184|DEVICE|Multisite transspinal stimulation during robotic gait training|The intervention, combined cervical and lumbar transspinal stimulation, will be administered during robotic gait training. Cervical and lumbar transspinal stimulation will be delivered via surface active electrodes placed on the back of the neck and on low back, and four returning electrodes placed on each clavicle and iliac crest while participants step with the help of the Lokomat 6 Pro, a robotic device that helps the legs step. Locomotor training will depend on the ability of each participant to step without foot dragging. Over the training course, we will adjust the body weight support, ankle straps position, and leg guidance force. The tension of the ankle straps will be adjusted based on the right and left tibialis anterior muscle strength evaluated every 2 weeks. Body weight support and leg guidance force will be adjusted based on presence or absence of knee buckling during standing.
219243211|NCT07203365|BIOLOGICAL|This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65|The RSV vaccine (Arexvy) has demonstrated efficacy against LRTD over three RSV seasons in individuals aged 60 and older, with an acceptable safety and reactogenicity profile. However, data on vaccine responses in individuals aged 80 and older, including frail individuals, remains limited. This population is particularly affected by severe RSV infections, highlighting the need for further investigation to address these gaps.
219243212|NCT07203274|DRUG|Delgocitinib cream|Delgocitinib cream
219243213|NCT07203274|DRUG|lidocaine cream|Lidocaine cream
219243214|NCT07203274|COMBINATION_PRODUCT|Lidocaine+Delgocitinib|The two cream will me mixed togheter
219243215|NCT07203274|DRUG|Vehicle (placebo)|Vehicle Cream
219243216|NCT07203274|OTHER|Histamine Dihydrochloride (HDC)|One drop of histamine will be applied on the selected areas and pierced with a lancet
219172618|NCT05610774|DRUG|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
219172619|NCT06755359|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|Radioactive sources named Alpha DaRT sources: Ra - 224 coated onto titanium tubes inserted into the tumor.
219172620|NCT06217458|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
219172621|NCT06845722|OTHER|Balance training|"* The balance training will be given for 12 weeks (2 sessions/week, 30-35 in each) that included six balance exercises per training session.~* After 5-min warm-up program including general (e.g., neck rolls, shoulder circles, side bends, hip circles, marsh in place) and specific (e.g., two-/one-legged stance on unstable devices, forward/backward beam walking).~* Two sets per balance exercise will be performed for 30s each with a 60s rest period between sets and a 90 s break between exercises. Yet, both groups will execute the same training volume (i.e., number of exercises, number of sets per exercise, and duration per set of exercise).~* Progression during training will be achieved by means of increasing exercise duration (i.e., from 30s over 45s to 60 s), change of stance (i.e., two-legged stance, tandem. stance, one-legged stance) and walking (i.e., forward, backward) condition, manipulation of visual input (e.g., eyes opened vs. closed), and concurrent execution of cognitive"
219172622|NCT06845722|OTHER|Cognitive Rehabilitation:|"* The cognitive rehabilitation will be given for 12 weeks ( 2 sessions/week,30 min each session). The individual sessions for the CR approach will involve an individualized intervention focusing on a personally meaningful goal (e.g., maintaining attention while flipping cards and finding matching pairs, learning to use a cellular phone, remembering the names of people).~* The individual sessions will be consisted of practical strategies and aids, compensation strategies (e.g., using a memory notebook), and the techniques for stress management to improve performance and functioning in relation to goals. The group sessions of CR involved some tasks of cognitive training.~* The group sessions will be focused on practicing time-and-place orientation through paper-and pencil tasks provided by a therapist and use of a calendar and personal memory notebook or cellular phone at the start of each session. (30)~* The group sessions also involved matching faces and names and learning memory"
219243217|NCT07203274|OTHER|Cowhage (Mucuna Pruriens)|About 30 spicules will be applied on the selected areas and inserted manually
219243218|NCT07204340|DRUG|TLN-372|Specified dose on specified days
219243219|NCT07204340|DRUG|TLN-372 in combination with cetuximab|Specified dose on specified days
219243220|NCT07204340|DRUG|TLN-372 in combination with pembrolizumab|Specified dose on specified days
219243221|NCT07203833|BIOLOGICAL|blood sample|To assess whether circulating Vasn can become a potential diagnostic biomarker of septic shock, we will measure the concentrations of circulating Vasn
219243222|NCT07202767|DEVICE|Swept-Source Anterior Segment OCT|"Device: Swept-Source Anterior Segment OCT The CASIA-2 (Tomey, Japan) is a high-resolution swept-source anterior segment OCT with CE certification. The device allows for incomplete visualization of the lens, including the anterior and posterior lens curvature.~Device: AS-OCT + Placido disc corneal topography The MS-39 (CSO, Italy) is a non-invasive device that combines Placido topography with OCT-based anterior segment tomography.~Device: Wave-front abberomtery The OSIRIS aberrometer is a standard tool for examining corneal aberration and measuring the ocular wavefront.~Device: Swept-Source OCT The IOLMaster 700 (Carl Zeiss Meditec, Germany) is a standard swept-source OCT used for eye examinations.~Device: AS-OCT The ANTERION (Heidelberg Engineering, Germany) is an anterior segment swept-source OCT.~Diagnostic Test: Refraction Subjective Refraction evaluation using the cross-cylinder method"
219243223|NCT07202637|DRUG|Fluid bolus administration|Fluid infusion of 500 mL of a crystalloïd solution is performed for patients with signs of hypovolemia
219243224|NCT07204301|OTHER|Optimized Timing of Intravesical Lidocaine Gel|Procedural modification of intravesical anesthetic gel administration. Lidocaine gel is instilled before and after flexible cystoscopy or bladder instillation to optimize mucosal anesthesia. This differs from standard practice where timing is not standardized - usually just before flexible cystoscopy.
219243225|NCT07204301|BEHAVIORAL|Calming Music During Procedure|Participants listen to a standardized playlist of calming instrumental music delivered through headphones during the procedure. Intervention is intended to reduce procedural anxiety and discomfort.
219243226|NCT07204301|BEHAVIORAL|Visual Distraction with Screen Content|Participants watch standardized visual content (e.g., relaxing video) on a screen or tablet during cystoscopy or bladder instillation. Designed to distract attention and enhance comfort.
219243227|NCT07204301|OTHER|Calming Ambient Lighting|Flexible cystoscopy or intravesical instillation performed under standardized calming ambient lighting (blue-hue) instead of standard clinical lighting. Intervention aims to promote relaxation and reduce anxiety.
219243228|NCT07204301|BEHAVIORAL|Peak-End Modification of Procedure|"Modification of the procedural ending based on the psychological peak-end rule. The end of the cystoscopy or instillation is deliberately altered to reduce final discomfort, aiming to improve overall remembered patient experience."
219243229|NCT07203157|OTHER|Virtual Reiki Therapy|20-minute session once per week for 8 weeks via Webex. Each session will be delivered remotely by a Certified Reiki Practitioner Level II or higher.
219243230|NCT07203170|BEHAVIORAL|Readiness Supportive Leadership Training for the National Guard (RESULT-NG)|"RESULT-NG is a multi-level intervention where leaders receive the training intervention, with evaluation of effects at the subordinate, leader and spouse levels.~RESULT-NG consists of three distinct but related components: 1) a 60-minute, multimedia, interactive digital-learning training session, 2) a two-week behavior tracking exercise that takes less than 2 minutes/day after the digital learning to put what was learned into practice, and 3) a 60-minute facilitated session, either in person or virtual, with trained staff embedded within the National Guard."
219243231|NCT07204756|DIAGNOSTIC_TEST|2-Week Home Monitoring|Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.
219243232|NCT07204756|DIAGNOSTIC_TEST|6-Week Home Monitoring|HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.
219243233|NCT07204249|DRUG|Semaglutide|Semaglutide
219243234|NCT07202663|DRUG|BB-025|Reversal agent for BB-031
219243235|NCT07202663|DRUG|BB-031|RNA aptamer
219739153|NCT06289582|DRUG|[F-18]DPA714 administration IV|brain PET/MRI imaging after \[F-18\]DPA-714 administration
219739154|NCT03008096|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
219739155|NCT01121354|DRUG|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
219739156|NCT01121354|DRUG|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
219739157|NCT03240055|DRUG|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
219739158|NCT03240055|OTHER|etomidate|receive etomidate only
219739159|NCT03841474|DRUG|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
219739160|NCT03841474|DRUG|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
219739161|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
219739162|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
219739163|NCT03538821|DIETARY_SUPPLEMENT|Control|Control group receive tablet containing fillers
219739164|NCT03796975|DRUG|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
219739165|NCT03796975|DRUG|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
219739166|NCT01668199|DRUG|TZP-101|
219739167|NCT02167347|BEHAVIORAL|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
219739168|NCT03113188|DRUG|CBP501|CBP501, CDDP plus Nivolumab
219739169|NCT05020808|DIETARY_SUPPLEMENT|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
219243236|NCT07204379|DRUG|Novafen|Novafen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
219243237|NCT07204379|DRUG|Tramadol|Tramadol analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
219243238|NCT07204379|DRUG|Naproxen|naproxen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
219243239|NCT07204379|OTHER|No intervention?placebo|multivitamins to be administered in this group
219243240|NCT07204483|BEHAVIORAL|Educational Leaflet|Participants will receive an educational leaflet on lifestyle modification, which provides practical advice on diet, physical activity, and stress management. The leaflet will be distributed at baseline.
219243241|NCT07204483|DEVICE|Functional Shirt (Relive brand)|Participants will receive a functional shirt designed to support posture and physical comfort (Relive brand). They will be instructed to wear the shirt daily during the 8-week intervention period. Manufacturer: Relive Inc., Japan.
219243242|NCT07204483|BEHAVIORAL|Exercise Manual|Participants will receive a structured exercise manual and will be instructed to perform moderate-intensity exercise (e.g., brisk walking, light jogging, or calisthenics) for 30 minutes, three times per week, over 8 weeks. Weekly follow-up calls or messages will be provided to encourage adherence.
219243243|NCT07204730|BEHAVIORAL|Direct Social Skills Training|Participants attended six two-hour sessions led by a licensed psychologist. Sessions focused on social skills, including empathy, problem-solving, stress management, and strategies to prevent and counteract cyberbullying. Outcomes were measured at baseline and three months post-intervention.
219243244|NCT07204730|BEHAVIORAL|Peer-Led Social Skills Training|A volunteer group of students attended six two-hour sessions with a psychologist and then taught their peers the same curriculum. Weekly progress reports were submitted to the psychologist to ensure fidelity. Outcomes on emotional intelligence and cyberbullying were assessed at baseline and three months post-intervention.
219243245|NCT07204730|OTHER|Control No Training|Participants in the control group received no intervention during the study period. Outcomes were assessed at baseline and three months post-intervention to provide a comparison for the experimental groups.
219243246|NCT07204821|DEVICE|Inspiratory muscle functional electrical stimulation by Flexistem Digital electrical muscle stimulator|The electrical current is pulsed, biphasic, and symmetric, with the Frequency of 30 hertz, Phase width of 200µs, ON time 2s: OFF time 3s. Patients will be instructed to keep their RR constant and to coordinate their breathing with the pulsing of the electrical current. The intensity of the current is the minimum necessary to obtain diaphragm muscle contraction . Four silicone-carbon electrodes (4x4cm) were placed on the clean skin with gel. 2 electrodes each will be placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space Two sessions daily, each session will last for 30 minutes; the patients remained in the semi-Fowler position 30 º with the lower extremities extended and arms alongside the body
219243247|NCT07204821|DEVICE|Expiratory muscle functional electrical stimulation by Flexistem Digital electrical muscle stimulator|FES is applied for 30 min, 2 sessions daily, until patients are weaned from mechanical ventilation, but no longer than 6 weeks.Stimulation will be applied via surface electrodes on the abdominal wall Four pairs silicone-carbon electrodes (4x9cm) were placed on the clean skin with gel, and stimulation intensity will be titrated in order to activate the external oblique, internal oblique, transversus abdominis and Rectus abdominis muscles. The patient's tolerance of expiratory muscle FES is continuously monitored;Frequency 30 Hz, pulse width 352 µs and intensity set to cause strong muscle contraction, with a maximum intensity initially set at 60 mA (tolerated intensity in healthy volunteers). Then we amend the protocol to allow a maximum intensity of 100 mA .Strong muscle contraction will verify (visible and palpable) every ten minutes throughout each FES session, and if necessary, stimulation intensity was increased.
219243248|NCT07204821|DEVICE|Early rehabilitation program|"Rehabilitation therapy which consisted of six levels:~Level 0 turning over once every 2 h for unconscious patients with unstable vital signs level 1-2 in addition to turning over, maintaining joint range of motion to prevent muscle atrophy, and placing normal limb position for conscious patients who could sit up for at least 20 min, 2 times a day Level 3 similar to level 2, but sitting on the edge of the bed for patients who could perform upper-limb anti-gravity training Level 4 similar to level 3, but standing up or sitting in a chair for at least 20 min a day for patients who could perform lower-limb anti-gravity training Level 5 patients actively moved from the bed and walked bedside"
219243249|NCT07202741|OTHER|yoga group|"A total of 50 minutes of hatha yoga practice was performed three times a week for 12 weeks.~* In the first week, two days of face-to-face yoga practice with the researcher.~* During the eighth week, online yoga practices were held twice a week via Skype with the researcher and one yoga practice per week (a list was made for the group the researcher would create via WhatsApp).~The participants were supported with weekly motivation and follow-up information to continue practicing yoga at least twice a week for the next four weeks. All yoga sessions included a 10-minute warm-up and breathing session, 50 minutes of hatha yoga, 15 minutes of relaxation and separation, and 5 minutes of feedback. At the end of the session, the participants received support regarding correct yoga asanas, motivation, and consistency."
219739170|NCT05020808|DIETARY_SUPPLEMENT|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
219739171|NCT02149797|PROCEDURE|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
219739172|NCT02149797|PROCEDURE|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
219739173|NCT02149797|PROCEDURE|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
219739174|NCT05075473|OTHER|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
219739175|NCT05075473|OTHER|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
219739176|NCT02051387|DRUG|Cannabidiol CR|
219739177|NCT02051387|DRUG|Cannabidiol|
219739178|NCT02051387|DRUG|Amisulpride|
219739179|NCT02051387|DRUG|Olanzapine|
219739180|NCT02051387|DRUG|Quetiapine|
219739181|NCT02051387|DRUG|Risperidone|
219739182|NCT02051387|DRUG|Placebo|
219739183|NCT01832298|DRUG|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
219739184|NCT01661595|DRUG|Sildenafil|50 mg/day for 4 weeks
219739185|NCT01661595|DRUG|tadalafil|10 mg/day for 4 weeks.
219739186|NCT01661595|DRUG|Placebo|Placebo 1 capsule per day for four weeks.
219739187|NCT00615160|DRUG|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
219739188|NCT00615160|DRUG|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
219739189|NCT01952262|OTHER|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
219739190|NCT04578041|DEVICE|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
219739191|NCT04578041|OTHER|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
219739192|NCT04578041|OTHER|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
219739193|NCT01327729|DRUG|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
219739194|NCT02368873|PROCEDURE|Application of IPOM mesh|
219739195|NCT04808011|DEVICE|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
219739196|NCT00364195|DRUG|Tesmilifene (YMB1002)|
219739197|NCT01872182|DRUG|ALS-L1023|daily twice for 12 weeks
219739198|NCT01872182|DRUG|placebo|daily twice for 12 weeks
219739199|NCT03497286|BEHAVIORAL|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
219739200|NCT03497286|BEHAVIORAL|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
219739201|NCT00781664|OTHER|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
219739202|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
219739203|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
219739204|NCT00781664|OTHER|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
219739205|NCT00781664|DRUG|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
219243250|NCT07204444|BEHAVIORAL|standardized and manualized warm calls from providers trained in the BE training|Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration
219243251|NCT07204444|BEHAVIORAL|standardized and manualized warm calls from providers trained in the BE training + ASIST training|Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration
219243252|NCT07204899|OTHER|Play digital escape room game|In addition to traditional education, the intervention group will receive a digital escape room game developed with the Genially platform. Both groups' knowledge of Hypovolemic Shock and Nursing Management will be assessed using a fact sheet and satisfaction with the GAMEX scale.
219243253|NCT07204041|DRUG|Selinexor|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
219243254|NCT07204041|DRUG|Thalidomide (100mg)|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
219243255|NCT07204041|DRUG|Dexamethasone|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
219243256|NCT07204795|OTHER|Distilled water group|Group A participants will receive 400 mL of distilled water orally, two hours before surgery.
219243257|NCT07204795|OTHER|Carbohydrate Drink|Group A participants will receive 400 mL of a commercially available clear carbohydrate-rich drink orally, two hours before surgery.
219243258|NCT07203794|DRUG|Bupivacaine Infiltration|After removal of the gallbladder, 40 mL of 0.25% bupivacaine will be applied to the gallbladder bed with a sterile sponge for 10-15 minutes. At the end of the surgery, 15 mL of 0.25% bupivacaine will be infiltrated into trocar insertion sites (5 mL umbilical port, 5 mL epigastric port, 5 mL each auxiliary port).
219243259|NCT07203794|PROCEDURE|Erector Spinae Plane Block|Before induction of anesthesia, a bilateral ultrasound-guided erector spinae plane block will be performed at the T7 transverse process level. A total of 40 mL of 0.25% bupivacaine will be injected (20 mL per side) using an in-plane technique under ultrasound guidance.
219243260|NCT07203794|DRUG|Intrathecal Morphine|With the patient in the sitting position, a 27-gauge spinal needle will be inserted at the L3-L4 interspace. A dose of 100 mcg morphine will be administered intrathecally before induction of anesthesia.
219243261|NCT04913155|RADIATION|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
219243262|NCT07197190|PROCEDURE|Autologous augmentation mastopexy with subpectoral lipofilling and upper and medial pole fat grafting.|"The term 'internal bra' refers to a range of techniques that aim to stabilise the position of the breast and improve longevity of surgical results. In this study, the investigators address one of them which is dermal flap technique. Dermal flaps have two key advantages, the first of which is that they are low cost due to their autologous nature. The fact that they utilise the patient's own tissue also means they are not associated with an increased risk of infection or immunological reaction, which is their second main advantage, But it has some drawbacks on the long term, such as upper pole hollowness and lack of breast parenchymal tissue to give a good breast volume.~In this research, the investigators used the autogenous internal BRA mastopexy technique for correction of breast ptosis and sub pectoral lipofilling to help increase the breast volume and subcutaneous fat grafting to give the breast upper pole fullness."
219243263|NCT07204587|PROCEDURE|Autologous Semitendinosus Tendon Graft|Meniscal reconstruction will be performed using autologous semitendinosus tendon harvested from the ipsilateral leg. The graft diameter must be at least 6 mm. A two-tunnel fixation technique will be employed, securing the graft to the tibial plateau at the anatomic meniscal root sites. The graft will be shaped and positioned to mimic the native meniscal contour. Fibertape internal brace augmentation will be added to enhance fixation strength and graft stability. If concomitant anterior cruciate ligament reconstruction is indicated, the graft choice and ACL technique will be determined by the surgeon, without restriction. Postoperative rehabilitation will follow a standardized protocol across all centers.
219243264|NCT07204587|PROCEDURE|Meniscal Allograft Transplantation (MAT)|Meniscal allograft transplantation will use size-matched, fresh-frozen allograft menisci prepared according to institutional tissue bank standards. Grafts will be fixed using a two-tunnel bone plug technique, restoring the anatomic root insertions. The allograft will be centrally positioned within the tibiofemoral compartment, and centralization sutures may be added at the discretion of the operating surgeon. All procedures will be standardized across participating centers, and postoperative rehabilitation protocols will be identical to those used in the autologous graft arm.
219243265|NCT07202715|BEHAVIORAL|CBT Based C.A.T Project- Intervention for Anxious Adolescents.|The C.A.T Project is a structured, evidence-based intervention grounded in Cognitive Behavioral Therapy (CBT) principles, designed specifically for adolescents experiencing anxiety and related concerns. The core components includes: Psychoeducation, Cognitive Restructuring, Exposure Exercises, Coping Skills Training and Relapse Prevention. This age appropriate intervention will be delivered in Urdu language with culturally appropriate context.
219243266|NCT07204002|PROCEDURE|Treatment BPH|We compare 3 different types of BPH surgery - HoLEP vs. TURP vs. REZUM
219243267|NCT07203391|DRUG|roginolisib|Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)
219739206|NCT00781664|DRUG|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
219739207|NCT00781664|DRUG|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
219739208|NCT00781664|DRUG|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
219739209|NCT00781664|OTHER|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
219739210|NCT00912509|DRUG|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
219739211|NCT00912509|DEVICE|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
219243268|NCT07203716|BEHAVIORAL|Virtual Reality Orientation (Home+Booster)|Age-appropriate 360° VR module (\~8-10 min) showing MRI room, sounds, positioning, and the importance of keeping still; viewed at home 24-48 h pre-scan on a smartphone/VR viewer (or flat 360° if no headset), plus a brief booster view on site immediately before positioning (\~3-5 min refresher).
219243269|NCT07203716|BEHAVIORAL|Virtual Reality Orientation (Pre-Scan Only)|The same 360° VR module (\~8-10 min) viewed once on site in the MRI area immediately before positioning; no home exposure.
219243270|NCT07203716|OTHER|Usual Care (No VR)|Standard institutional pediatric MRI preparation (verbal explanation, hearing protection demo, child-friendly coaching) without VR.
219243271|NCT07203300|BEHAVIORAL|multicomponent, tiered intervention|"this intervention is a multi-level collaborative health management system-a digital health platform with four core modules: the Health Education Module, the Growth Monitoring Module, the Health Behavior Module, and the Home-School Partnership Module. The platform facilitates collaboration among schools, families, and hospitals as follows: Schools utilize the platform to manage tasks outlined in health policies, such as delivering educational content, monitoring student activity and diet, and recording monthly height/weight measurements via the Growth Monitoring Module.~Families access the platform to receive multi-format health education, set goals, and review personalized feedback. The Home-School Partnership Module also enables communication for motivational interviewing sessions conducted by professionals offline or by phone.~Hospitals leverage the platform to provide professional guidance and medical support, ensuring interventions are medically sound."
219243272|NCT07204353|PROCEDURE|Papilla-preserving incision (Control)|Standard papilla-preserving incision without additional flap modification or connective tissue grafting. This group serves as the control, receiving only routine surgical access for implant site management.
219243273|NCT07204353|PROCEDURE|Modified Labial Pedicle Papilla Flap (mLPPF)|Surgical reconstruction of the peri-implant papilla using the modified labial pedicle papilla flap technique. The flap is mobilized and sutured without adjunctive grafting procedures.
219243274|NCT07204353|PROCEDURE|Modified Labial Pedicle Papilla Flap with De-epithelialized Gingival Graft (mLPPF+dGG)|Surgical reconstruction of the peri-implant papilla combining the modified labial pedicle papilla flap with placement of a de-epithelialized gingival graft (dGG) at the papillary region to enhance soft tissue volume and stability.
219739212|NCT01218321|BIOLOGICAL|antiepileptic treatment|White blood cells from peripheral blood samples
219739213|NCT05299580|DRUG|dabrafenib|Dabrafenib 150 mg bid
219739214|NCT05299580|DRUG|Trametinib|Trametinib 2mg qd
219739215|NCT05001113|PROCEDURE|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
219739216|NCT05001113|PROCEDURE|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
219739217|NCT02923167|DEVICE|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
219739218|NCT06136299|OTHER|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
219739219|NCT04907955|PROCEDURE|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
219739220|NCT04932772|OTHER|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
219739221|NCT04932772|OTHER|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
219739222|NCT01537432|DRUG|secukinumab|secukinumab
219739223|NCT01537432|DRUG|placebo|placebo comparator
219739224|NCT00314977|DRUG|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
219739225|NCT00314977|DRUG|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
219739226|NCT00314977|DRUG|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
219739227|NCT01971918|BIOLOGICAL|anti drug antibodies dosage|anti drug antibodies dosage
219739228|NCT05166902|DEVICE|Lens A (comfilcon A lens)|1 month
219739229|NCT05166902|DEVICE|Lens B (lehfilcon A lens)|1 month
219243275|NCT07204197|OTHER|Virtual Reality-Assisted Physical Therapy|VR Assisted PT intervention, combines a standardized postoperative physical therapy program with an additional 20-minute immersive VR session. The VR component is relaxation-focused and interactive, making the total session length 60 minutes. The distinguishing feature is the integration of VR technology into early rehabilitation after lumbar disc surgery, which is not part of conventional therapy.
219243276|NCT07204197|OTHER|Conventional Physical Therapy|This intervention consists of the same standardized physical therapy program as the VR group, delivered for 60 minutes daily by increasing exercise repetitions and intensity. The distinguishing feature is that it does not include any VR component, allowing direct comparison of physical therapy alone versus VR-assisted therapy.
219243277|NCT07203196|BEHAVIORAL|Circadian Rhythm Optimization|Participants will follow a Mediterranean diet while consuming all calories within a personalized 8-10 hour daytime window. They will increase daytime light exposure to at least one hour per day, engage in a minimum of 150 minutes of moderate-intensity aerobic exercise each week (including at least two sessions lasting no less than 60 minutes), maintain a consistent 7-9 hour sleep schedule, and take supplements as recommended based on individual needs. Participants will also record all food and beverage intake, as well as exercise, using the myCircadianClock app.
219243278|NCT07202728|OTHER|No intervention|No intervention
219243279|NCT07203105|BEHAVIORAL|GAINS expert guiding technology to coach life skill teaching|GAINS expert guiding technology to coach life skill teaching
219243280|NCT07202819|DRUG|Neoadjuvant Chemotherapy|Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or gemcitabine and cisplatin. Administered prior to radical cystectomy to shrink the tumor and improve surgical outcomes. The post-treatment MRI findings will be analyzed for correlation with histopathological results after surgery.
219243281|NCT07202819|PROCEDURE|Radical Cystectomy|Surgical removal of the urinary bladder, typically performed in patients with muscle-invasive bladder cancer. In this study, participants in both arms will undergo radical cystectomy, either directly or following neoadjuvant chemotherapy. Histopathological examination of surgical specimens will be compared with MRI findings for staging accuracy assessment.
219243282|NCT07202624|DRUG|Dexmedetomidine (Precedex)|The ETT cuff will be filled with 4 mL of dexmedetomidine 4 mcg/mL
219243283|NCT07202624|DRUG|alkalinized lidocaine|lidocaine 2%, 2 ml will be initially injected into the cuff, and then a supplementary volume of 2 ml of sodium bicarbonate (NaHCO3) 8.4% will be added
219243284|NCT07203339|DEVICE|Transcranial direct current stimulation (tDCS) plus placebo.|Participants will be randomized to receive 28 sessions of active anodal tDCS (2 mA) or sham, with the anode over the left M1 and the cathode over the right supraorbital area, for 20 minutes, combined with pain neuroscience education and physical exercises. Sessions will be self-administered at home, daily for 4 weeks. Electrodes (35 cm²) will be placed using neoprene caps (sizes S to XL), adjusted according to head circumference. Monitoring: the device records session time, duration, and adherence, interrupting the session if impedance exceeds 1 mA (5-second interval) or if current varies \>10%. Developed in partnership with HCPA's Biomedical Engineering, the device is licensed by UFRGS/HCPA and registered with ANVISA (No. 80079190028).
219243285|NCT07203339|DRUG|Duloxetine (60 mg) once daily|"Duloxetine (30 mg and 60 mg) will be purchased from a commercial pharmacy and fractionated by a compounding pharmacy, which will also prepare the placebo. Capsules will be transferred into standardized jars based on dosing schedule:~* Jar 01 (white cap): 7 capsules of 30 mg~* Jar 02 (green cap): 16 capsules of 60 mg~* Jar 03 (green cap): 42 capsules of 60 mg~* Jar 04 (white cap): 7 capsules of 30 mg Placebo and duloxetine capsules will be identical in appearance. Kits will be labeled with CAEE number, participant ID (RedCap), pharmacist and PI names, and storage/use instructions. Kits will be stored at the HCPA Pharmacy Service under controlled conditions and dispensed during visits AV1 (Jars 1 and 2), AV2 (Jar 3), and AV3 (Jar 4)."
219243286|NCT07203339|DEVICE|Home-based transcranial direct current stimulaiton|Participants will be randomized to receive 28 sessions of active anodal tDCS (2 mA) anode over the left M1 and the cathode over the right supraorbital area, for 20 minutes
219739230|NCT05628571|COMBINATION_PRODUCT|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
219739231|NCT05628571|COMBINATION_PRODUCT|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
219739232|NCT01765413|BIOLOGICAL|Varicella-zoster virus|
219739233|NCT01765413|BIOLOGICAL|Yellow Fever Vaccine|
219739234|NCT01765413|BIOLOGICAL|Placebo|
219739235|NCT01269775|OTHER|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
219739236|NCT04843592|DEVICE|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
219739237|NCT05044481|PROCEDURE|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
219739238|NCT04984200|PROCEDURE|Retinal imaging|Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
219243287|NCT07203339|DRUG|Duloxetine 60 mg|"Duloxetine (30 mg and 60 mg) will be purchased from a commercial pharmacy and fractionated by a compounding pharmacy, which will also prepare the placebo. Capsules will be transferred into standardized jars based on dosing schedule:~* Jar 01 (white cap): 7 capsules of 30 mg~* Jar 02 (green cap): 16 capsules of 60 mg~* Jar 03 (green cap): 42 capsules of 60 mg~* Jar 04 (white cap): 7 capsules of 30 mg Placebo and duloxetine capsules will be identical in appearance. Kits will be labeled with CAEE number, participant ID (RedCap), pharmacist and PI names, and storage/use instructions. Kits will be stored at the HCPA Pharmacy Service under controlled conditions and dispensed during visits AV1 (Jars 1 and 2), AV2 (Jar 3), and AV3 (Jar 4)."
219243288|NCT07203599|DRUG|Human umbilical cord mesenchymal stem cell exosomes|Human umbilical cord mesenchymal stem cell exosomes are nanoscale vesicles released by mesenchymal stem cells from the umbilical cord. These exosomes act as natural carriers, transferring proteins, microRNAs (miRNAs), and other molecules to recipient cells. This communication helps the exosomes exert therapeutic effects, promoting tissue repair, reducing inflammation, and mediating cell-to-cell interactions in various disease models.
219243289|NCT07203599|DRUG|Minoxidil 5% Topical Solution|Topical minoxidil is a medicine used to help regrow the hair on your scalp. It works by increasing the blood flow to your hair and helps stimulate your hair follicles to grow.
219243290|NCT07204314|DRUG|Vortioxetine tablets|Vortioxetine tablets
219243291|NCT07204314|DRUG|Placebo tablets|Placebo tablets
219243292|NCT07203534|OTHER|Standard of Care|Standard of care for a bone marrow biopsy/bone marrow aspiration includes routine site-specific lidocaine anesthetic.
219243293|NCT07203534|OTHER|Virtual Reality intervention and Standard of Care|Participants will wear the VR headset (Quest 3 by Meta) during your bone marrow procedure.
219243294|NCT07204275|DRUG|Povetacicept|Solution for Subcutaneous Injection.
219243295|NCT07204275|DRUG|Tacrolimus|Tablets for Oral Administration.
219243296|NCT07203144|DRUG|selenium yeast supplementation|In this intervention, patients will receive adjunctive selenium yeast supplementation at a daily dose of 100-200 μg in addition to fluoxetine. Symptom rating scales, biospecimen collection, and brain MRI will be conducted at baseline, week 4, and week 8 to investigate the adjunctive role of selenium in fluoxetine treatment for depression.
219243297|NCT07203144|DRUG|Placebo yeast supplementation|In this intervention, patients will receive standard fluoxetine treatment combined with placebo yeast supplementation (100-200 μg/day), which is identical in appearance and odor to selenium yeast. The aim is to clarify the specific role of selenium in the treatment of depression.
219243298|NCT07203092|DEVICE|Active transcranial photobiomodulation|Active transcranial photobiomodulation to the forehead targeting prefrontal cortex involves administration of 1064-nm light delivered via laser with a 4 centimeter beam diameter and 250 mW/cm2 power density for 8 minutes per treatment.
219243299|NCT07203092|DEVICE|Sham transcranial photobiomodulation|Identical procedure as active group, but without 1064-nm light emitted by the device.
219243300|NCT07201922|DRUG|Nerandomilast|Nerandomilast
219243301|NCT07201922|DRUG|Placebo|Placebo
219243302|NCT07203846|DRUG|Rifaximin|Participants receiving a 7-day course of oral rifaximin 400 mg every 12 hours
219243303|NCT07204834|BEHAVIORAL|Physical Activity|"Participants will be encouraged to progressively increase the number of daily steps (volume) and the number of minutes per day spent at a higher cadence (intensity). To achieve these goals, the investigators will support participants in the intervention group through behavior change techniques. For example, wearable devices and an online platform will be used to monitor the behavior and track progress using simple graphs; participants will be provided with small, individualized goals which will be updated every two weeks based on the activity levels achieved the prior two weeks; standardized WhatsApp messages will be sent to prompt the behavior and face-to-face coaching sessions will be delivered throughout the intervention.~Participants in this group will also receive enhanced usual care, consisting of the usual care to manage heart failure plus an education pamphlet and in-depth evaluations and reports to measure the project outcomes."
219243304|NCT07204912|DEVICE|MIT Powered Leg|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
219243305|NCT07203859|PROCEDURE|Quadro-İliac Plane Block(QİPB)|40 mL of 0.25% bupivacaine
219243306|NCT07203807|OTHER|Voluntary movement and illusory movement of the right upper limb induced by TVS.|"The protocol comprises two different modalities: Voluntary movement and illusory movement of the right upper limb induced by TVS.~The experiment will begin and end with a one-minute rest period. Participants will be asked to open and close their right hand 20 times in 10 seconds. Similarly, they will experience 10 seconds of TVS-induced illusory movement 20 times. Each task epoch will be preceded by a 12-20 second resting period.~Both conditions will be randomized and counterbalanced. Participants can start with either the voluntary movement task or the illusory."
219243307|NCT07204535|OTHER|Prospective questionnaires|Post-traumatic stress disorder Checklist version DSM-5 (PCL-5) and quality of life questionnaires
219243308|NCT07203872|DEVICE|IsoDent Paro Strong (Isodent Ltd. Valtakatu 4 D, 96100 Rovaniemi, Finland) mouthwash|adjunctive anti-inflammatory mouthwash
219243309|NCT07203872|DEVICE|Placebo mouthwash|Contains all the inactive ingredients as the test mouthwash without the LXA4
219243310|NCT07203209|OTHER|thoracal mobility exercises|The exercise program given to the athletes in the mobility group will include 8 exercises specially designed for thoracic region mobility. The exercises will be practiced by the team trainer in every training session and otherwise at home twice a day.
219243311|NCT07203209|OTHER|regular training|This training program is composed of the teams daily practice exercises.
219243312|NCT07203014|BEHAVIORAL|Parent-Educator Action Response (PEAR)|PEAR is a novel adjunctive intervention aimed at improving teacher and family implementation of classroom-based interventions for child ADHD symptoms and disruptive behavior in preschool.
219243313|NCT07203014|BEHAVIORAL|Daily Report Card|The Daily Report Card is a behavioral intervention for children with challenging behaviors, and provides a structure for teachers and caregivers to support a child with reducing challenging behaviors and increasing positive behaviors. The DRC has been shown to be highly effective in reducing ADHD symptoms.
219243314|NCT07197359|OTHER|Looksmaxxing AI Facial Analysis|Participants' standardized frontal facial photographs will be analyzed using the Looksmaxxing AI application (versions 4o and 5) to determine the presence or absence of chin deviation relative to the facial midline.
219739239|NCT04984200|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
219243315|NCT07203040|DEVICE|Therapeutic Ultrasound|Continuous ultrasound applied to painful/stiff cervical muscles during a single clinic visit; frequency 1-3 MHz, intensity 1.0-1.5 W/cm²
219243316|NCT07203040|DEVICE|Sham Ultrasound|Single session mimicking active procedure; device displays appear normal but acoustic output is 0 W/cm²; \~10 minutes;
219243317|NCT07203742|OTHER|mandala painting|"After the child and parent agree to participate in the study and the child indicates that they wish to do the mandala exercise, the child will be seated in a comfortable position to paint. Thirty minutes before the start of the intrathecal chemotherapy procedure (children who will receive intrathecal chemotherapy at the clinic are identified and scheduled the day before), the child, their parent, and a nurse independent of the study will be assessed using the Child Anxiety Scale-State (ÇAS-D) and the Child Fear Scale. The mandala coloring activity will then continue until the child wishes to stop (the activity will be ensured to last at least 30 minutes). When the child is called to the procedure room for intrathecal chemotherapy, the scale assessments will be repeated. Thirty minutes after the intrathecal chemotherapy procedure is completed and the child has emerged from the effects of general anesthesia, the scales will be reassessed and recorded by the same i"
219243318|NCT07204054|OTHER|Medial longitudinal arch support taping using low dye tape|Low dye Taping which is applied by patient lying supine on treatment table. No tension is applied due to the characteristics of the tape and it is described in the following steps; placement of a strip in the area of the metatarsal heads, in the dorsal area placement of a strap on the back, forming a circle with the front strap and in the plantar area; a figure of eight was made, starting from the side of the fifth metatarsal, surrounding the heel and ending at the starting point, the same operation was performed as in point but starting from the hallux. The last part is different, as a strip at the main point of pain, that is, at the insertion towards the medial edge of the foot Ultrasound, stretching and strengthening exercises. Ultrasound will be applied for duration of 7 minutes at the plantar aspect of foot with 1.5 w/cm2 output and continuous mode of frequency of 1MHz. Stretching of gastrocnemius and soleus and towel curl exercise.
219243319|NCT07204054|OTHER|Fascia Stretch taping using KT tape|Fascia Taping which is applied in which In the first step, after the metatarsophalangeal joints were dorsiflexed, the first strap was adhered firmly to the posterior heel at its proximal end. The other end of the strap was cut into four slices of equal width. Each slice was applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap was applied following the same pattern and overlapped the first strap. In the third step, the last strap was applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot. Dashed arrows denote the direction of stretch Ultrasound, stretching and strengthening exercises. Ultrasound will be applied for duration of 7 minutes at the plantar aspect of foot with 1.5 w/cm2 output and continuous mode of frequency of 1MHz. Stretching (5reps with 10 sec hold each stretch) of gastrocnemius and Soleus and toe curl exercise
219243320|NCT07203755|BIOLOGICAL|Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
219243321|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
219243322|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
219243323|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
219243324|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
219243325|NCT07203755|BIOLOGICAL|Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)|3 doses of DTcP (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
219243326|NCT07203755|BIOLOGICAL|Haemophilus influenzae type b (Conjugate) (Hib)|3 doses of Hib (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
219243327|NCT07203755|BIOLOGICAL|Meningococcal Group ACYW135 (Conjugate) (MCV4)|3 doses of MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
219243328|NCT07203755|BIOLOGICAL|MCV4|3 doses of MCV4 (0.5ml) at 0, 1, and 2 months, followed by a booster dose at 12 months of age.
219243329|NCT07203755|BIOLOGICAL|MCV4|3 doses of MCV4 (0.5ml) at 0, 2, and 4 months.
219243330|NCT07203755|OTHER|Sodium Chloride Injection (0.9%) (Saline Solution) (NS)|3 doses of NS (0.5ml) at 0, 2, and 4 months.
219243331|NCT07203937|DEVICE|RoboGait® Robotic Gait Training|RoboGait® is a robotic lower limb orthosis system with adjustable dynamic body weight support, synchronized treadmill, and biofeedback software. Participants will receive robotic-assisted gait training 2 days per week for 6 weeks, in addition to conventional rehabilitation 5 days per week.
219243332|NCT07203937|DEVICE|Treadmill Walking Training|Participants will receive treadmill walking sessions 2 days per week for 6 weeks, combined with conventional rehabilitation 5 days per week. The treadmill sessions will be matched in duration and intensity to the robotic training sessions in the experimental arm.
219243333|NCT07203560|OTHER|Neurodynamic Mobilization|In the experimental group, neurodynamic mobilization was applied in addition to the conventional physiotherapy program. For the neurodynamic mobilization tibial nerve neural mobilization was performed. For neural mobilization of the tibial nerve, the patient was placed in the side-lying position with the hip in 90° flexion, knee flexion and ankle dorsi flexion. In this position, the ankle and hip positions were maintained, and knee extension was performed. When the symptoms were at a level that would not disturb the patient, it was held for 5 seconds, and knee flexion was performed by plantar flexion of the ankle. This practice was performed twice a week with 10 repetitions by a physiotherapist. The same neurodynamic mobilization exercise was recommended to the patients in the neuromobilization group as a home program with 10 repetitions twice a day.
219243334|NCT07203560|OTHER|Conventional Physiotherapy|All participants received hot pack therapy (20 minutes), conventional TENS (60 Hz, 60 msec, 20 minutes), therapeutic ultrasound (1.5 W/cm², 10 minutes), and a prescribed home exercise program, delivered 5 days per week for 4 weeks (20 sessions in total).
219243335|NCT07202897|DRUG|Anticoagulant treatment Rivaroxaban|Anticoagulant treatment Rivaroxaban in addition to best medical therapy
219243336|NCT07202897|OTHER|Best medical therapy|Best medical therapy alone
219243337|NCT07203443|OTHER|MRI|Anatomical and functional MRI
219243338|NCT07203443|OTHER|Psychological assessment|Inventories and clinical interviews
219243339|NCT07203443|BEHAVIORAL|Cognitive assessment|Attention and memory tests
219243340|NCT07203443|OTHER|Cortisol sample|Salivary test
219243341|NCT07203235|OTHER|evaluation|Participants will undergo a series of evaluations including core muscle function tests, endurance assessments, proprioceptive measurements, balance testing, and gait analysis. These assessments are non-invasive and observational, aimed at comparing functional performance between individuals with transtibial amputation and healthy controls. No interventions will be applied; only assessments will be conducted.
219243342|NCT07203417|BEHAVIORAL|STEP-T|Couples in the STEP-T group will meet online with a therapist for 120 minutes once a week over 8 weeks. Each meeting consists of a therapist-led session focused on the psychoeducational content from the STEP module. Sessions begin with a review of the homework completed during the previous week and end with the assignment of new sex therapy homework related to that day's session. After each session, the therapist will email the couple the module that includes the session's psychoeducational handouts and the sex therapy homework to be completed prior to the next session.
219243343|NCT07203417|BEHAVIORAL|STEP-NT|Couples in the STEP-NT group will receive STEP (i.e., one module per week for 8 weeks, including psychoeducational handouts and sex therapy homework), without the therapist-led online sessions. However, like couples in STEP-T, they will be allowed to contact the research team for clarifications related to the structure, instructions, or technical aspects of the exercises. This support will be limited to non-clinical guidance and will not involve any individualized feedback regarding participants' personal experiences or relationship dynamics.
219243344|NCT07203417|OTHER|Waitlist|While couples randomized to STEP-T and STEP-NT will complete one online baseline assessment battery before randomization, those assigned to the waitlist control condition will complete two baseline assessments online, spaced 10 weeks apart, before being randomized to one of the active treatment groups (i.e., STEP-T or STEP-NT). The 10-week waiting period was selected to match the time it takes couples to complete the 8 modules of STEP. This design allows us to determine that improvements in clinical outcomes are due to the STEP intervention rather than the mere passage of time. Following the post-waiting period assessment (i.e., the second baseline battery), waitlist participants will be randomized to STEP-T or STEP-NT.
219243345|NCT07202650|BEHAVIORAL|guided imagery|Guided imagery is a form of mind-body communication, defined as a flow of thoughts involving what we smell, taste, see, hear, and touch, or as the way the mind encodes, stores, and retrieves information. Guided imagery is based on the understanding that the mind and body are interconnected and that the mind can influence bodily functions. Stress and anxiety directly affect the brain and the immune system.
219243346|NCT07203404|DRUG|RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
219243347|NCT07202949|DRUG|Treatment dose antibiotic in combination with methenamine hippurate|"Arm A includes treatment with one of three treatment dose antibiotic options, selected by the treating clinician, in combination with methenamine hippurate. Participants allocated to this arm will receive combination therapy, consisting of one of the following antibiotics:~* Cefalexin (500mg four times daily), or~* Nitrofurantoin (100mg twice daily), or~* Trimethoprim (200mg twice daily) in combination with Methenamine Hippurate (1g twice daily) for 12 weeks."
219243348|NCT07202949|DRUG|Prophylactic dose antibiotic or methenamine hippurate monotherapy|"Arm B includes treatment with one of four prophylactic dose antibiotics or methenamine hippurate, but not both, selected by the treating clinician. Participants in this arm will receive monotherapy of one of the following:~* Amoxicillin (250mg once daily), or~* Cefalexin (125mg once daily), or~* Nitrofurantoin (50mg once daily), or~* Trimethoprim (100mg once daily), or~* Methenamine Hippurate (1g twice daily) for 12 weeks."
219243349|NCT07204886|OTHER|Multicomponent training and stability exercise|"The training program will span 14 weeks. Participants will engage in structured sessions twice a week (on Tuesdays and Thursdays), with each session lasting 60 minutes. The sessions will consist of aerobic, balance, Dynamic Neuromuscular Stabilization (DNS) and stability exercises, strength exercises (using body weight and the Swedish bar), and flexibility exercises.~Each training session will begin with a warm-up phase, including five minutes of dynamic stretching to prepare the body for the physical demands of the session. Following the warm-up, participants will perform 15 minutes of low-impact aerobic exercises, such as marching, knee lifts, leg curls, lunges, and kicks, incorporating coordinated arm movements.~Next, participants will complete 15 minutes of balance, DNS, and stability exercises. This will be followed by 20 minutes of strength training exercises. Each session will conclude with a 5-minute cooldown and flexibility segment to promote"
219243351|NCT07204769|DRUG|Antibiotic sensitivity|Molecular characterization of multidrug-resistance gene antibiotics.
219243352|NCT07203066|OTHER|observational only|observational only
219243353|NCT07203001|DRUG|MAS825|Experimental drug
219243354|NCT07202884|DRUG|Orforglipron|Administered orally
219243355|NCT07202884|DRUG|Placebo|Administered orally
219243356|NCT07204574|DRUG|HCB101|QW
219243357|NCT07204574|DRUG|Bevacizumab|5 mg/kg IV infusion, Day 1, Every 2 weeks
219243358|NCT07204574|DRUG|Cetuximab (Erbitux)|"* Initial dose: 400 mg/m² IV infusion, over \>2 hours, Day 1~* Maintenance dose: 250 mg/m² IV infusion, over 60 minutes, Day 1, weekly OR 500 mg/m² IV infusion, over \>2 hours, Day 1, every 2 weeks"
219243359|NCT07204574|DRUG|FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|Irinotecan: 180 mg/m² IV infusion over 30-90 minutes, Day 1, Every 2 weeks Folinic acid (Leucovorin): 400 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks 5-Fluorouracil (5-FU): 400 mg/m² IV bolus, Day 1; then 1200 mg/(m²·day) × 2 days continuous IV infusion (total 2400 mg/m² over 46-48 hours, Every 2 weeks
219739240|NCT01210781|PROCEDURE|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
219739241|NCT03462602|PROCEDURE|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
219243360|NCT07204574|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Folinic acid (Leucovorin): 400 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks 5-Fluorouracil (5-FU): 400 mg/m² IV bolus, Day 1; then 1200 mg/(m²·day) × 2 days continuous IV infusion (total 2400 mg/m² over 46-48 hours), Every 2 weeks Oxaliplatin: 85 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks
219243361|NCT07204093|DRUG|Drospirenone 4 mg orally|Daily oral administration of Drospirenone 4 mg + Transdermal estradiol; continuous administration for at least 6 months.
219243362|NCT07204093|DRUG|Dienogest 2 mg orally|Daily oral administration of Dienogest 2 mg + Transdermal estradiol; continuous administration for at least 6 months.
219243363|NCT07204418|DRUG|Xanomeline/ Trospium Chloride|Specified dose on specified days
219243364|NCT07203248|DRUG|CGRP R Inhibitor; CGRP Inhibitor|Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.
219243365|NCT07203248|DRUG|none-CGRP|Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.
219243366|NCT07204431|DEVICE|the PowerBreathe and PEP Therosold tools group|Initially, the following data were collected from each subject in addition to basic epidemiological data.
219243367|NCT07204548|DRUG|Ivonescimab|Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy
219243368|NCT07204145|DEVICE|Laser Acupuncture (808 nm laser pen)|Participants receive laser acupuncture using an 808 nm, 100 mW semiconductor laser pen applied at acupoints GV20, bilateral ST36, and bilateral PC6. Each acupoint is irradiated for 10 seconds, three times per week, for 12 weeks.
219243369|NCT07204145|DEVICE|Sham Laser Acupuncture|Participants receive the same procedure as the laser acupuncture group, using an 808 nm semiconductor laser pen applied at acupoints GV20, bilateral ST36, and bilateral PC6. The device is identical in appearance and produces lights and beeping sounds; however, it delivers no energy output. Each acupoint is contacted for 10 seconds, three times per week, for 12 weeks.
219243370|NCT07203911|DIAGNOSTIC_TEST|Ultrasound imaging|Ultrasound will be performed during surgery in two phases: 1) in-vivo and 2) ex-vivo. In the in-vivo phase surgeons will perform intraoral ultrasound with a small intraoral transducer in order to visualize size and boundaries of tumor. Then the surgeon begins the resection periodically pausing to obtain real-time images of the resection plane and determin if resection is performed at safe distance to the tumor. In the ex-vivo phase the resected tumor will undergo ultrasound by using a motorized mechanical arm designed to hold an ultrasound transducer. This ensures standardized and reproducible scans. The purpose of the ex-vivo scan is to measure the surgical margins at the operating theatre and allow for an immediate re-resection of necessary. Surgeons in the intervention group will also have the possibility of taking biopsies for frozen section analyses.
219243371|NCT07203911|OTHER|Standard Treatment|Standard surgical treatment of oral cancer
219243372|NCT07203664|COMBINATION_PRODUCT|steroids, tacrolimus and mTOR inhibitors|Patients receive immunosuppressive induction treatment with thymoglobulin (at least 1 dose and maximum of 5 doses) and immunosuppressive maintenance treatment with tacrolimus + mTOR inhibitors. Preemptive therapy will be administered as a preventive strategy, consisting of initiating antiviral treatment with valganciclovir (900 mg every 12 hours, adjusted according to renal function as per the technical data sheet) when CMV viral replication in blood exceeds 1,000 copies/ml. Treatment will be discontinued once viral load becomes undetectable in two consecutive tests.
219243373|NCT07203664|COMBINATION_PRODUCT|steroids, tacrolimus and mycophenolic acid.|Patients will receive immunosuppressive induction treatment with thymoglobulin (at least 1 dose and a maximum of 5 doses) and tacrolimus + mycophenolic acid following the guidelines of the technical file and the centre's usual protocols.
219243374|NCT07203898|BIOLOGICAL|IPM514|"2 primary immunization cycles: IPM514 will be administered once a week (QW) for 3 consecutive doses per cycle, there will be a 2-week interval between the two cycles.~Maintenance treatment: 6 doses administered every 3 weeks (Q3W), and 4 doses administered every 6 weeks (Q6W), if treatment continuously benefit the participant."
219739242|NCT03462602|PROCEDURE|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
219739243|NCT00779909|DRUG|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
219739244|NCT00779909|OTHER|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
219739245|NCT03523585|DRUG|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
219739246|NCT03523585|DRUG|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
219739247|NCT03523585|DRUG|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
219739248|NCT03523585|DRUG|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
219739249|NCT02171728|DRUG|BIBW 2992|
219739250|NCT02386072|DRUG|mirabegron|oral
219739251|NCT02386072|DRUG|antimuscarinic medication|oral
219743431|NCT01254214|BEHAVIORAL|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
219243375|NCT07203651|DRUG|Sterile Water Injection|WE will compare effectiveness of intradermal sterile water injection with intramuscular diclofenal
219243376|NCT07203651|DRUG|Diclofenac|comparing effectiveness of diclofenac with intradermal sterile water injection
219243377|NCT07203625|DRUG|Tenecteplase thrombolysis|Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.
219243378|NCT07204717|PROCEDURE|free gingival graft|standard free gingival technique
219243379|NCT07204717|PROCEDURE|ring free gingival greft|ring free gingival greft technique
219243380|NCT07204925|DEVICE|RISE guided personalization of prosthetic legs by tuning experts|The personalization procedure is conducted by tuning experts based on the recommendation of RISE system
219243381|NCT07204925|DEVICE|RISE guided personalization of prosthetic legs by prosthetists|The control parameters of the prosthetic leg prototype is decided by prosthetists without detailed knowledge about the prosthetic leg with the help of developed RISE system
219243382|NCT07204925|DEVICE|Manual personalization of the prosthetic leg by tuning experts|The control parameters of the prosthetic legs are decided by tuning experts based on their knowledge of the prosthetic leg prototypes and patients' response.
219739252|NCT05454982|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
219739253|NCT04614779|DRUG|CN128 Tablets|Iron chelator, oral tablets
219739254|NCT00000340|DRUG|Pemoline|
219739255|NCT01799902|DRUG|Solifenacin|Oral
219739256|NCT04870866|DRUG|Nicotinamide ribonucleoside|Two year intervention
219739257|NCT00005940|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
219739258|NCT00005940|DRUG|busulfan|Given PO
219739259|NCT00005940|DRUG|cyclophosphamide|Given IV
219739260|NCT00005940|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
219739261|NCT00005940|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
219739262|NCT00005940|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
219739263|NCT00005940|DRUG|cyclosporine|Given IV or PO
219739264|NCT00005940|DRUG|methotrexate|Given IV
219739265|NCT00005940|OTHER|laboratory biomarker analysis|Correlative studies
219739266|NCT02217007|DRUG|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
219739267|NCT03704922|BIOLOGICAL|Transfusion|Red cell units for transfusion
219739268|NCT04774562|BEHAVIORAL|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
219739269|NCT04774562|BEHAVIORAL|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
219739270|NCT04909411|OTHER|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
219739271|NCT04909411|OTHER|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
219739272|NCT05229367|OTHER|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
219739273|NCT05229367|OTHER|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
219739274|NCT02577380|BEHAVIORAL|IPV/GBV HTC|Participants will be interviewed after receiving their services.
219739275|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
219739276|NCT02977871|PROCEDURE|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
219739277|NCT01258699|DRUG|Thiocacid HR Tab 600mg|600mg for 1 day
219739278|NCT01258699|DRUG|BK-C-0701 320mg|320mg for 1 day
219739279|NCT01258699|DRUG|BK-C-0701 480mg|480mg for 1 day
219739280|NCT03599726|DRUG|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
219739281|NCT03599726|DRUG|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
219739282|NCT01690325|DRUG|Docetaxel|
219739283|NCT01690325|DRUG|Trastuzumab|
219739284|NCT01690325|DRUG|Bevacizumab|
219739285|NCT01690325|DRUG|Epirubicin|
219739286|NCT01690325|DRUG|Cyclophosphamid|
219739287|NCT01827189|OTHER|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
219739288|NCT06294899|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed to patients with suspected lower respiratory tract infections.
219739289|NCT06294899|DIAGNOSTIC_TEST|C-Reactive Protein Test|C-Reactive Protein Test will be performed to patients with suspected lower respiratory tract infections.
219739290|NCT03136094|BEHAVIORAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
219739291|NCT03136094|BEHAVIORAL|SBIRT+Usual Care|Patients receive usual SBIRT care
219739292|NCT02236897|OTHER|PET Scanning|
219739293|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
219739294|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young women|Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
219743432|NCT01254214|BEHAVIORAL|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
219243383|NCT07204470|OTHER|Breakfast cereal standardised to an isocaloric intake of approximately 350 kcal, consume entire portion within 15 minutes witnessed. No other food may be consumed during the 4 hour test period.|Cereal is in porridge form. One 350 ml bottle of water provided for the 4 hour test period 7:00-11:00 a.m.. Control dinner meal consumed the prior evening, then fast 10 hours overnight before visiting the test facility on four test days one week apart.
219243384|NCT07203989|BEHAVIORAL|family-supported care|Family video calling in the operating room
219243385|NCT07204171|DRUG|mitragynine|Mu opioid receptor partial agonist
219243386|NCT07204171|DRUG|Placebo|Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.
219243387|NCT07203638|DRUG|Beta Lactam Antibiotics|Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
219243388|NCT07203638|DRUG|Salin|Patient will receive .9 % saline (10ml /12h/2days)
219243389|NCT07203885|BEHAVIORAL|Unaided Review First, Then AI-Assisted Review|Readers first complete Block X (Unaided) on their assigned subset SX (up to 40 slides). They then complete Block Y (AI-Assisted) on two separate subsets: SY1 (up to 40 slides; AI as Double-Check) and SY2 (up to 40 slides; AI as First Look). Within Block Y, the order of Y1 and Y2 is randomized. For each reader, SX, SY1, and SY2 are disjoint and stratified by APL status.
219243390|NCT07203885|BEHAVIORAL|AI-Assisted Review First, Then Unaided Review|Readers first complete Block Y (AI-Assisted) on two assigned subsets: SY1 (up to 40 slides; AI as Double-Check) and SY2 (up to 40 slides; AI as First Look), with the order of Y1 and Y2 randomized. They then complete Block X (Unaided) on subset SX (up to 40 slides). For each reader, SX, SY1, and SY2 are disjoint and stratified by APL status.
219243391|NCT07203508|OTHER|Tongue-to-Palate Resistance Training|The Tongue-to-Palate Resistance Training (TPRT) is a home-based, device-free exercise program. Participants were instructed to press their tongue firmly against their hard palate and hold the contraction. The protocol consisted of 30 repetitions per session, performed five days a week for a duration of eight weeks. Adherence was supported through instructional videos, a caregiver, and a training logbook. The goal of the intervention is to strengthen the intrinsic and extrinsic tongue muscles and the suprahyoid muscle group to improve swallowing function.
219243392|NCT07203508|COMBINATION_PRODUCT|Standard Dysphagia Therapy|The active comparator consists of a conventional, multi-modal standard of care for oropharyngeal dysphagia. It includes in-clinic sessions twice a week featuring either Neuromuscular Electrical Stimulation (NMES), where electrodes are placed in the submental region to stimulate the swallowing muscles, or biofeedback swallowing therapy. Additionally, participants perform unsupervised Chin Tuck Against Resistance (CTAR) exercises at home. This arm represents the established clinical rehabilitation approach against which the experimental TPRT intervention is compared
219243393|NCT07203521|DRUG|RK-4 injection|take drug RK-4 (2mg/mL, 1mL) by transcranial bone marrow injection once daily for consecutive 3 days.
219243394|NCT07203521|OTHER|conventional treatment|conventional treatment of LHI other than RK-4
219243395|NCT07203703|DEVICE|Jaw Tracking Device|A jaw tracking device is a digital tool that records real-time jaw movements to accurately analyze occlusion and assist in virtual model mounting.
219243396|NCT07200895|DEVICE|Inspiratory Muscle Training (30% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 30% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following a standardized diaphragmatic-breathing warm-up.
219243397|NCT07200895|DEVICE|Inspiratory Muscle Training (60% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 60% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following the same standardized warm-up.
219243398|NCT07204236|DRUG|TVAX-008|TVAX-008
219243399|NCT07203469|BEHAVIORAL|Universal approach|In this intervention, the whole class participates in a 12-week nature-based experiential education program
219243400|NCT07203469|BEHAVIORAL|Selective approach|In this intervention, an intentional group of pupils with an identified need is recruited from different classes within the same school to participate in a 12-week nature-based experiential education program
219243401|NCT07203469|BEHAVIORAL|Outdoor therapy|This intervention is a 10-week outdoor therapy group treatment that takes place in nearby nature
219243402|NCT07203469|BEHAVIORAL|Climbing therapy|This intervention is a 10-week climbing therapy group treatment that takes place indoors in a climbing hall
219243403|NCT07204704|BEHAVIORAL|EUREKA Intervention|Participants will be asked to complete brief questionnaires about the child's sun protection up to six times daily throughout the study. During Week 2, participants will receive feedback and advice messages immediately after completing the questionnaires. During that week, participants will also be asked to collaboratively complete an action planning exercise (delivered to the child's phone) to plan sun protection for a selected outdoor activity that is likely to take place the next day.
219243404|NCT07201272|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 3.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
219243405|NCT07201272|DRUG|Morphine|Patients will receive spinal anesthesia (using 3 mL of hyperbaric bupivacaine 0.5%) + (75 µg morphine diluted in 0.5ml saline) with sham block at the end of surgery.
219243406|NCT07204561|OTHER|CeraVe Moisturizing Cream|During the 42-day maintenance phase, subjects must apply the CeraVe emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.
219243407|NCT07204561|OTHER|Galenico|During the 42-day maintenance phase, subjects must apply the emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.
219243408|NCT07204119|OTHER|Tissue Flossing Technique|Hot pack: 10 minutes, PNF (hold-relax with agonist contraction), CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice. 1 to 2 minutes for Tissue Flossing Technique Description: Active and passive movement with knee wrapped in a high-quality floss band (208×5×0.15 cm), Wrapped from upper gastrocnemius to lower quadriceps and hamstring muscles using a 50% overlapping pattern with a 25% elongation stretch, Series of active and passive exercises (knee flexion and extension) with 3 repetitions.
219243409|NCT07204119|OTHER|Graston Technique|"Hot pack: 10 minutes, PNF (hold-relax with agonist contraction), CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice.~2 minutes for Graston Technique Technique Description: Participant lies supine with hip and knee straight, Water-based gel used to reduce friction.~Superior and inferior longitudinal strokes delivered with GT-4 instrument at a 45° angle to soft tissues Sequence includes strokes from above patella to anterior inferior iliac spine (AIIS) and back, maintaining a 2-second cadence"
219243410|NCT07204119|OTHER|Control group|Hot pack: 10 minutes, PNF (hold-relax with agonist contraction): Gentle stretch of knee muscle for 10 seconds Isometric contraction for 6 seconds. Flex knee with therapist assistance. Hold position for 10 seconds, repeat 3 times, CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice
219243411|NCT07203820|BEHAVIORAL|Ready-Made Picture Template Painting Activity|The purpose of the study will be explained to the children and their parents before the painting process and verbal and written consent will be obtained from the parents who agree to participate in the study. The child will be asked to go to the child with the ready-made picture template and coloring pencils and color the given picture with the colors they want. Children's anxiety will be assessed using the Children's State Anxiety (CSA) and their fears will be assessed using the Children's Fear Scale (CFS) based on both mother's and child's reports before painting and after the painting process is completed (half an hour after the first measurement).
219243412|NCT07204678|DEVICE|PRECISE PRO Rx Nitinol Stent System|The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).
219243413|NCT07203430|OTHER|45-Degree Roman Chair Exercise|Participants in the intervention group will perform 3 sets of low back extension exercise on the Roman chair until volitional exhaustion. The three sets will be performed to volitional exhaustion or 20 repetitions, whichever comes first. If more than 20 repetitions can be completed after a set the investigator will add resistance according to the NSCA's guidelines (2.5-10% increase).
219243414|NCT07202871|DRUG|LY3537031|Administered SC
219243415|NCT07202871|DRUG|LY3537031|Administered IV
219243416|NCT07203781|OTHER|PEEP level changes|For each patient, six different PEEP levels (15-12-10-8-5-2 cmH2O) will be tested during a decremental PEEP trial. During each step, neural respiratory drive, inspiratory effort, expiratory muscle activity, lung inflation pattern through electrical impedance tomography, respiratory muscle geometry and function through ultrasound and surface EMG, gas exchange and hemodynamics data will be collected.
219743433|NCT05708690|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
219743434|NCT05708690|DRUG|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
219743435|NCT04505787|DRUG|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
219743436|NCT04505787|DRUG|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
219743437|NCT02264756|OTHER|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
219243417|NCT07204808|DEVICE|High velocity resistance training + Otago Exercise Program|"Participants who will be randomized to the HVRT will receive an exercise program targeting the lower limbs, to be performed twice a week for 8 weeks. Participants will be instructed to perform the exercises in a rapid and explosive manner such that all repetitions for each shortening phase will be performed as quickly as possible while the lengthening phase of the muscle will be controlled over 2-3 s The exercise will be done (bilateral leg press, step up, sit to stand, calf raise). The 8 weeks will be divided in three phases .~OEP consists of strengthening and balance exercises. Strengthening of ankle plantar and dorsiflexors, knee extensors and flexors, and hip abductors will be focused in this program. Ankle weight cuffs (1-3 kg) provide resistance for hip and knee exercises. The ankle plantar and dorsiflexors will be strengthened by performing heel and toe raise .~plantar and dorsiflexors will be strengthened by performing heel and toe"
219243418|NCT07203547|DRUG|Layla Tab.|Layla Tab., oral, twice daily, 8 weeks.
219243419|NCT07203547|DRUG|Laybon Tab.|Laybon Tab., oral, twice daily, 8 weeks.
219243420|NCT07203222|DEVICE|Low Dose Laser|Patients with subacromial-subdeltoid bursa, m. deltoideus, m. biceps longus, m. infraspinatus, and m. supraspinatus muscles (at the most painful point of the muscles) with a 13-diode Gallium-Aluminium-Arsenide laser device (Intelect Mobile Laser) with a wavelength of 850 nm and 50 mW, 4 Joules per day, 20 seconds, for a total of 15 laser sessions.
219243421|NCT07203222|DEVICE|TENS|TENS therapy will be administered using the TENS device (Intelect Advanced Therapy System) for a total of 15 sessions, 5 days a week, 20 minutes per day, at a dose of 20-40 mA.
219243422|NCT07203222|OTHER|Conventional physical therapy|Only conventional physiotherapy is planned to be administered to patients.
219243425|NCT07203378|OTHER|Whole-body resistance training and aerobic exercise|A 12-week individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise routine will be provided to each study participant.
219243426|NCT07203456|OTHER|Virtual Patient Based Learning (VPBL)|A digital platform featuring 20 virtual patients has been built to increase predoctoral student clinical exposure to patients with TMD signs and symptoms
219743438|NCT04802109|DEVICE|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
219743439|NCT04802109|DEVICE|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
219743440|NCT04802109|DEVICE|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
219743441|NCT06151418|DRUG|Novel hormonal therapy|As provided in real-world setting
219743442|NCT05704803|DIAGNOSTIC_TEST|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
219743443|NCT00302822|DRUG|enfuvirtide|from week 0 to 24
219743444|NCT00302822|DRUG|emtricitabine/tenofovir|1 pill/day
219743445|NCT00302822|DRUG|lopinavir or efavirenz|investigator choice
219743446|NCT00108563|DRUG|Citalopram or Placebo|
219743447|NCT06062485|DRUG|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
219743448|NCT01108874|DRUG|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
219743449|NCT02649309|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
219743450|NCT02649309|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
219743451|NCT02649309|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
219743452|NCT02649309|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
219743453|NCT00974597|DEVICE|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
219743454|NCT04535115|PROCEDURE|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
219743455|NCT04535115|PROCEDURE|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
219743456|NCT00273663|DEVICE|TCES|
219743457|NCT01573429|OTHER|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
219743458|NCT05529602|OTHER|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
219243427|NCT07203456|OTHER|Clinical exposure to patients with TMD|Participants in this arm will be exposed to patients with TMD signs and symptoms, to the history taking, interview, clinical examination, diagnostic process, and treatment plan under the supervision of an orofacial pain specialist
219243428|NCT07203456|OTHER|Clinical exposure to TMD + VPBL|Participants will be exposed to patients with TMD signs and symptoms (including history taking, interview, clinical exam, diagnostic process, and treatment plan) under the supervision of an orofacial pain specialist, and then will be exposed to the corresponding TMD patient on the VPBL, featuring virtual patients with TMD
219243429|NCT07204522|DRUG|Carbapenems|First-line empirical agent for febrile neutropenia complicating hematologic malignancies: carbapenem.
219243430|NCT07204522|DRUG|Anti-Gram-positive agent|Escalation to a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) is instituted if no defervescence occurs after 48h of first-line therapy; this combination is maintained for 3 days before further escalation in febrile-neutropenia patients with underlying hematologic malignancies.
219243431|NCT07204522|DRUG|Antifungal agent|If combination therapy with a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) remains ineffective after 72 h, empirical antifungal coverage is added while continuing antibacterial therapy for an additional 7 days; failure to defervesce thereafter mandates further therapeutic escalation in febrile-neutropenic patients with hematologic malignancies.
219243432|NCT07204522|DRUG|Ceftazidime-avibactam + Aztreonam|If the combination of a carbapenem and an anti-Gram-positive agent (vancomycin or linezolid) fails to achieve defervescence after 3 days of treatment, an antifungal agent is added while continuing the original antibacterial regimen for an additional 7 days. Should fever persist or recur with uncontrolled infection-related parameters after 12-14 days of empirical anti-infective therapy, the carbapenem/anti-Gram-positive combination is discontinued. Therapy is then switched to ceftazidime-avibactam plus aztreonam to cover multidrug-resistant pathogens, while concurrently maintaining antifungal treatment. This escalation strategy is indicated for febrile neutropenic patients with underlying hematologic malignancies.
219243433|NCT07202845|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging (mpMRI)|Multiparametric MRI (mpMRI) performed at three defined timepoints: prior to neoadjuvant chemotherapy (baseline), 24 hours after first cisplatin dose in the first NAC cycle, and after completing NAC but before radical cystectomy. Imaging protocols include T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Quantitative imaging biomarkers such as K\^trans\^, Ve, and ADC index are extracted and analyzed to evaluate early treatment response and predict pathological outcomes following chemotherapy.
219243434|NCT07204743|DRUG|Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy|Participants will receive dapagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor, administered once daily at a dose of 5-10 mg. The intervention is intended to reduce proteinuria and provide nephroprotection in pediatric patients with kidney disease. Patients will be followed monthly, with monitoring of renal function markers (serum creatinine, blood urea nitrogen, and estimated glomerular filtration rate) and 24-hour urinary protein excretion normalized to body surface area, in addition to safety outcomes such as hypoglycemia, dehydration, and urinary tract infections.
219243435|NCT07204652|DIAGNOSTIC_TEST|No Intervention: Observational Cohort|No Intervention: Observational Cohort
219243436|NCT07204106|DRUG|Dexmedetomidine Injection (nasal spray) + Propofol Injection + Sufentanil Injection|"1. Preoperative intervention：30 minutes before entering the operating room, 50-100μg of Dexmedetomidine Injection is administered via nasal spray in the anesthesia preparation room.~2. Induction phase：Intravenous injection of Sufentanil Injection (Yichang Renfu Pharmaceutical Co., Ltd.) at a dose of 0.1μg/kg, and Propofol Injection (Jiabo Pharmaceutical, Guangdong, China) at a dose of 1.5-2.0mg/kg (injection time \>30 seconds). During induction, the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/s) score is evaluated every 30±10 seconds; if MOAA/s \>1 after 2 minutes, an additional sedative dose (1/2 of the initial dose, injection time ≥10 seconds) is supplemented until MOAA/s ≤1.~3. Maintenance phase：Continuous intravenous infusion of Propofol Injection at a rate of 4-12mg/kg/h; the dose is adjusted according to Bispectral Index (BIS) to maintain BIS between 40-60. If the patient shows body movement, eye opening, speech or other signs of insufficient se"
219243437|NCT07204106|DRUG|Normal Saline (nasal spray) + Dexmedetomidine Injection (intravenous) + Propofol Injection + Sufentanil Injection|"1. Preoperative intervention：30 minutes before entering the operating room, normal saline is administered via nasal spray in the anesthesia preparation room; 10 minutes before induction, 0.5μg/kg of Dexmedetomidine Injection is given via intravenous injection.~2. Induction phase：Same as Experimental Group ① (intravenous Sufentanil 0.1μg/kg + Propofol 1.5-2.0mg/kg, with MOAA/s monitoring and supplementary dose rules).~3. Maintenance phase：Same as Experimental Group ① (continuous Propofol infusion at 4-12mg/kg/h, BIS-adjusted dose, and supplementary sedation rules for insufficient sedation)."
219243438|NCT07204106|DRUG|Regular sedation protocol|"Preoperative intervention：No dexmedetomidine or normal saline nasal spray; only routine preoperative preparation.~Induction phase：Same as Experimental Group ① (intravenous Sufentanil 0.1μg/kg + Propofol 1.5-2.0mg/kg, with MOAA/s monitoring and supplementary dose rules).~Maintenance phase：Same as Experimental Group ① (continuous Propofol infusion at 4-12mg/kg/h, BIS-adjusted dose, and supplementary sedation rules for insufficient sedation)."
219243439|NCT07202962|DRUG|medication review and deprescribing|"The study protocol includes the following assessments:~* T0: first data collection upon admission to the ward;~* T1 assessment: pharmacological review at discharge. Subjects who meet all study eligibility criteria will come consecutively enrolled in the study during admission to the department (T0).~By consulting the electronic health record, interviewing patients and family members and personal documentation, the following data will be collected:~* Remote and immediate pathological history;~* Family and social history;~* Home therapy;~* BRIEF-MPI. Home therapy and therapy suggested at discharge will be compared with the STOPPandSTART criteria to evaluate the prevalence of potential therapies inappropriate and to study possible interactions and contraindications pharmacological and for reporting possible adverse reactions to drugs. The prevalence and possible prevalence of each individual STOPPandSTART criterion will be assessed association with other variables of interest."
219243440|NCT07202832|DRUG|potassium citrate|Potassium citrate is a medication used to alkalinize the urine, providing symptomatic relief of dysuria in patients with urinary tract infections (UTIs). In this study, participants in Arm 1 will receive potassium citrate for a period of 7 days. The treatment is aimed at reducing discomfort related to UTIs, such as burning sensations during urination and suprapubic pain. In addition to symptomatic relief, the intervention may also enhance bacterial phagocytosis and bacterial killing in the urine. Participants will be monitored for any side effects or adverse events during the treatment period.
219243441|NCT07202832|DRUG|Nitrofurantoin|Nitrofurantoin is an antibiotic commonly used to treat uncomplicated urinary tract infections (UTIs). In this arm, participants will receive Nitrofurantoin for 7 days to treat their UTI. The primary objective is to evaluate its effectiveness in reducing UTI symptoms, such as dysuria, urgency, frequency, and suprapubic discomfort. This intervention will be compared with the urinary alkalinization therapy used in Arm 1. Researchers will also monitor changes in urine culture and any adverse events related to the antibiotic treatment.
219243442|NCT07203118|DRUG|HTS 20mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
219243443|NCT07203118|DRUG|HTS 30mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
219243444|NCT07203118|DRUG|HTS 40mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
219243445|NCT07203118|DRUG|TAF 25mg|Once daily, administered concomitantly with one HTS placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
219243446|NCT07203352|DRUG|targeted drug|Patients randomly assigned to the control group will receive standard chemotherapy treatment, but they cannot use targeted drugs in combination.The subjects randomly assigned to the experimental group received targeted drug treatment in addition to the chemotherapy regimen during the second course. Based on the results of bone marrow PCR, subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day; subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day.
219243447|NCT07203313|BEHAVIORAL|Digital PE teaching app|Pocket PE 3-5 is a digital app designed for 3rd - 5th grade teachers and students. It works across common platforms and devices, online and offline, and provides simple, easy to use, standards-based PE lesson activities tailored by time, instructional setting (classroom, gym, outside), grade, student skill level, and equipment resources. The app is low-cost and includes brief teacher and student skill demonstration videos for each activity, along with printable activity cards, music, and audio cues to signal transitions to assist teachers in class management with students in real time during PE. The program also includes embedded data tracking of PE minutes and completed instructional standards to assist with school and/or state mandated reporting.
219243448|NCT07203131|DIAGNOSTIC_TEST|Urine sample|5 mL of urine when the patient is admitted in intensive care To look for possible acute renal failure in the patient
219243449|NCT07203131|OTHER|Phone call at day 28|"It will allow the following information to be collected:~* Post-resuscitation monitoring and length of hospitalization,~* Vital status,~* Collection of adverse events,~* Concomitant treatments."
219243450|NCT07204691|DEVICE|DKL crosslinked sodium hyaluronate 20 mg/mL + Lidocaine 0.3% dermal filler|DKL crosslinked sodium hyaluronate 20 mg/mL + lidocaine 0.3% dermal filler is an injectable sterile, non-pyrogenic gel composed of crosslinked sodium hyaluronate of a non-animal origin and lidocaine in a phosphate-buffered saline solution.
219243451|NCT07204288|OTHER|Cat Scan, if applicable|Cat Scan is being used to assess fusion in previously implanted population
219243452|NCT07204262|COMBINATION_PRODUCT|Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)|Patients in this study received systemic therapy with molecular targeted agents, including tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies, and/or PD-(L)1 inhibitor immunotherapy. Some patients also received interventional therapies such as transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Treatment regimens, combinations, and sequencing were determined based on physician discretion and patient clinical status. This study focuses on the longitudinal monitoring of biomarkers during these therapies to evaluate their prognostic value and to develop a trajectory-based risk stratification model for advanced hepatocellular carcinoma (HCC).
219243453|NCT05966051|BEHAVIORAL|Educational interventions|The educational interventions will consist in:
219243454|NCT05296564|DRUG|CYCLOPHOSPHAMIDE and FLUDARABIN|1\. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
219243455|NCT05296564|DRUG|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
219243456|NCT05296564|BIOLOGICAL|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
219243457|NCT05296564|DRUG|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
219243458|NCT03556891|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
219243459|NCT01730118|BIOLOGICAL|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
219243460|NCT03707418|DRUG|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
219243461|NCT03707418|DRUG|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
219243462|NCT05545319|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
219243463|NCT05545319|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
219243464|NCT05545319|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
219243465|NCT00816621|BEHAVIORAL|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
219243466|NCT00816621|BEHAVIORAL|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
219243467|NCT04163185|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
219243468|NCT04163185|DRUG|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
219243469|NCT03154827|DRUG|BL-8040|Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
219243470|NCT03154827|DRUG|Atezolizumab|Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
219243471|NCT04208542|DRUG|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
219243472|NCT04212897|OTHER|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
219243473|NCT05624086|BEHAVIORAL|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
219243474|NCT00489489|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219243475|NCT00489489|DRUG|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
219243476|NCT00489489|DRUG|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
219243477|NCT06091982|PROCEDURE|Renal Replacement Therapy (RRT)|Renal Support therapy which consist of procedure of intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration/hemodialysis/hemodiafiltration (CVVH/CVVHD/CVVHDF)
219243478|NCT01886391|BEHAVIORAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
219243479|NCT03859700|BIOLOGICAL|DBV712 250 mcg|DBV712 250 mcg, once daily
219243480|NCT04553029|OTHER|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
219243481|NCT03698305|DRUG|ASP5354|Intravenous
219243482|NCT03698305|DRUG|Placebo|Intravenous
219243483|NCT04309006|PROCEDURE|CTG and customized healing abutment|screw- retained customized healing abutment
219243484|NCT04309006|PROCEDURE|CTG and conventional healing abutment|conventional healing abutment
219243485|NCT05583864|DEVICE|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
219243486|NCT05583864|DEVICE|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
219243487|NCT04851587|BEHAVIORAL|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
219243488|NCT06010368|DRUG|Tranexamic acid injection|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
219243489|NCT06010368|DRUG|Oxytocin|the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
219243490|NCT04588246|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219243491|NCT04588246|PROCEDURE|Computed Tomography|Undergo CT
219243492|NCT04588246|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219243493|NCT04588246|DRUG|Memantine|Given PO
219243494|NCT04588246|OTHER|Quality-of-Life Assessment|Ancillary studies
219243495|NCT04588246|OTHER|Questionnaire Administration|Ancillary studies
219243496|NCT04588246|RADIATION|Stereotactic Radiosurgery|Undergo SRS/fSRS
219243497|NCT04588246|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
219243498|NCT06721702|BEHAVIORAL|Motivational interviewing|Motivational interviews were administered as the intervention of the research. Motivational interviewing consists of two stages. In the first stage, the four principles of motivational interviewing (developing contradiction, showing empathy, supporting self-efficacy, and resolving resistance) are aimed at providing motivation in individuals. The second stage is strengthening the commitment to change.
219243499|NCT03697837|BEHAVIORAL|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
219243500|NCT01034683|DRUG|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
219243501|NCT04483791|COMBINATION_PRODUCT|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
219243502|NCT04701073|DEVICE|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
219243503|NCT04568304|BIOLOGICAL|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
219243504|NCT04568304|DRUG|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
219243505|NCT04568304|DRUG|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
219243506|NCT04568304|DRUG|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
219243507|NCT00324363|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
219243508|NCT00324363|DRUG|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
219243509|NCT01350102|DRUG|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
219243510|NCT01350102|DRUG|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
219243511|NCT01350102|DIETARY_SUPPLEMENT|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
219243512|NCT00158886|DRUG|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
219243513|NCT00158886|RADIATION|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
219243514|NCT05736445|BEHAVIORAL|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
219243515|NCT05809245|PROCEDURE|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
219243516|NCT06747637|OTHER|Skill-building classes|Unidos en el Cuidado is a manualized, multi-family group intervention provided at no cost vis-à-vis videoconferencing or on-site by trained facilitators Sessions are held weekly for 1.5 hours. Class components include caregiver role identity; skills-building; knowledge attainment; attitudinal changes; resource-sharing; practice/role-plays; homework; videos, handouts. Classes will be provided online with some classes offered in the community, if available
219243517|NCT06747637|OTHER|Wait list control group|The intervention is the same; the wait period is longer to receive the intervention described in Group A.
219243518|NCT02176512|DRUG|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
219243519|NCT02176512|DRUG|BIBR 277 SE|Treatment B - Monocomponent
219243520|NCT02176512|DRUG|HCTZ|Treatment B -Monocomponent
219243521|NCT03598803|OTHER|Survey|Urinary Incontinence Survey
219243522|NCT06458309|PROCEDURE|spine surgery|"AO Classification6 It classifies thoracolumbar fractures into 3 major groups, based on the mechanism of injury.and each of them subdivided to 3 subgroups.~A. Compression B. Distraction C. multi-directional with translation Thoracolumbar AO spine injury score"
219243523|NCT05610254|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
219243524|NCT00371696|DRUG|diclofenac|
219243525|NCT00371696|DRUG|paracetamol|
219243526|NCT00371696|DEVICE|heat retaining knee support|
219243527|NCT00371696|DEVICE|standard knee support|
219243528|NCT00589745|OTHER|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
219243529|NCT06549270|DRUG|MAbs|Monthly or quarterly mAbs administration
219243530|NCT04523571|BIOLOGICAL|BNT162b1|Intramuscular injection
219243531|NCT04523571|OTHER|Placebo|Intramuscular injection
219243532|NCT06584838|PROCEDURE|ACL reconstruction|Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
219243533|NCT01810328|OTHER|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
219243534|NCT01810328|OTHER|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
219243535|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
219243536|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
219243537|NCT03466775|DIAGNOSTIC_TEST|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
219243538|NCT03466775|DIAGNOSTIC_TEST|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
219243539|NCT03466775|OTHER|Allograft survival|
219243540|NCT03466775|OTHER|Allograft rejection appearance|
219243541|NCT06342635|DEVICE|Hydra Transcatheter Aortic Valve (THV) Series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
219243542|NCT05670678|DIETARY_SUPPLEMENT|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
219243543|NCT05670678|DIETARY_SUPPLEMENT|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
219243544|NCT02910336|OTHER|Quantitative Sensory Testing|sensory testing profile
219243545|NCT02201992|OTHER|Clinical Observation|Undergo observation
219243546|NCT02201992|DRUG|Crizotinib|Given PO
219243547|NCT02201992|OTHER|Laboratory Biomarker Analysis|Correlative studies
219243548|NCT00139308|DEVICE|high frequency stimulation|
219243549|NCT01837199|DRUG|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
219243550|NCT03782545|DEVICE|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
219243551|NCT00966888|PROCEDURE|standard follow-up care|No intervention
219243552|NCT00966888|RADIATION|radiation therapy|Chest wall radiotherapy
219243553|NCT00560209|DRUG|ONO-1101|placebo for 1 minute IV
219243554|NCT00560209|DRUG|ONO-1101|0.06 mg/kg for 1 minute IV
219243555|NCT00560209|DRUG|ONO-1101|0.125 mg/kg for 1 minute IV
219243556|NCT01581476|DRUG|Statin|10mg daily for a minimum period of 2 years
219243557|NCT01581476|DRUG|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
219243558|NCT01581476|DRUG|Placebo|Participants receive statin placebo and ACEI placebo
219243559|NCT01581476|DRUG|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
219243560|NCT03694210|DEVICE|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
219243561|NCT04107844|DIAGNOSTIC_TEST|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
219362403|NCT06958718|PROCEDURE|Ultrasound Guided erector spinae plane block (UB)|Ultrasound Guided erector spinae plane block (UB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine .. After the surgical incision is closed and before extubation, while the patient remains in the prone position. A linear high-frequency transducer (L6-12 linear array transducer (6-12 MHz) on GE Healthcare logiq p7, made in Korea) will be positioned in a sagittal orientation, 4 cm lateral to the L3 transverse process. A 22 G × 88 mm block needle will be inserted in the craniocaudal direction, with the needle tip placed beneath the erector spinae muscle and above the hyperechoic transverse process. The needle tip position will be confirmed via saline injection. Once correct needle placement is verified, 40 mL of 0.25% bupivacaine, combined with 0.5 μg/kg dexmedetomidine 15 will be administered divided on both sides.
219243562|NCT04916847|OTHER|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
219739295|NCT05306015|COMBINATION_PRODUCT|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
219739296|NCT05306015|COMBINATION_PRODUCT|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
219739297|NCT03232892|DRUG|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
219739298|NCT03373669|BIOLOGICAL|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
219739299|NCT03373669|BIOLOGICAL|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
219739300|NCT06003647|OTHER|Educational Intervention|Educational module and video
219739301|NCT05293002|DEVICE|Restorer Iliac Stent System|Not applicable (only one intervention)
219739302|NCT03766906|BEHAVIORAL|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
219739303|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
219739304|NCT03226665|DIAGNOSTIC_TEST|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
219739305|NCT04620980|DIAGNOSTIC_TEST|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
219739306|NCT06379620|DEVICE|Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)|Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
219739307|NCT05095441|BIOLOGICAL|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
219739308|NCT02035228|DEVICE|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
219739309|NCT02035228|DEVICE|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
219739310|NCT02035228|DEVICE|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
219739311|NCT02035228|DEVICE|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
219739312|NCT02035228|DEVICE|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
219739313|NCT02035228|DEVICE|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
219739314|NCT02035228|DEVICE|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
219243563|NCT04723784|OTHER|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
219243564|NCT04723784|OTHER|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
219243565|NCT04723784|OTHER|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
219243566|NCT00572299|DRUG|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
219243567|NCT03016364|DEVICE|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
219243568|NCT01347099|BEHAVIORAL|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
219243569|NCT01347099|BEHAVIORAL|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
219243570|NCT05418335|OTHER|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
219243571|NCT01404377|PROCEDURE|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
219243572|NCT02510404|BIOLOGICAL|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
219243573|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
219739315|NCT02035228|DEVICE|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
219739316|NCT02035228|DEVICE|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
219739317|NCT00860769|BEHAVIORAL|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
219739318|NCT00860769|BEHAVIORAL|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
219739319|NCT04555239|PROCEDURE|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
219739320|NCT04555239|OTHER|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral"
219739321|NCT05816161|DIAGNOSTIC_TEST|Integrated Neuromuscular Inhibition Technique|Exercises
219739322|NCT05816161|DIAGNOSTIC_TEST|Myofascial Release|Exercises
219739323|NCT03903341|OTHER|fMRI|bold signal in visual pathway
219739324|NCT05596812|OTHER|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
219739325|NCT03789370|DRUG|Propofol|Maintanance of general anaesthesia with propofol
219739326|NCT03789370|DRUG|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
219739327|NCT01830465|DRUG|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
219739328|NCT01830465|DRUG|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
219739329|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
219739330|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
219739331|NCT00983801|DRUG|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
219739332|NCT05600517|OTHER|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
219739333|NCT02189967|RADIATION|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
219739334|NCT02189967|RADIATION|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
219739335|NCT05545059|DRUG|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
219739336|NCT05545059|DRUG|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
219739337|NCT01251055|DRUG|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
219739338|NCT01251055|DRUG|Placebo|starch
219739339|NCT02150863|DEVICE|Ultrapulse Carbon Dioxide Laser|
219739340|NCT02150863|DEVICE|Cellutome epidermal harvesting system|
219739341|NCT05880784|OTHER|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
219739342|NCT05880784|OTHER|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
219739343|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
219739344|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
219739345|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
219739346|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
219739347|NCT01942369|DRUG|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
219739348|NCT01651208|BEHAVIORAL|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
219739349|NCT01651208|BEHAVIORAL|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
219739350|NCT06791538|PROCEDURE|Robotic Gastrectomy|"The intervention measures for robotic gastrectomy include:~Preoperative Preparation: Comprehensive preoperative examinations, including imaging studies, laboratory tests, and tumor marker assessments, to confirm the diagnosis and staging.~Surgical Procedure: Utilizing the da Vinci Surgical System, which provides a high-definition 3D view and flexible robotic arms for enhanced surgical precision.~Lymphadenectomy: Systematic D2 lymph node dissection according to oncological standards to ensure thorough removal of regional lymph nodes.~Gastrectomy and Reconstruction: Performing subtotal or total gastrectomy based on tumor location and extent, with intracorporeal reconstruction assisted by the robotic system.~Postoperative Management: Close monitoring of vital signs, pain management, and early mobilization to facilitate recovery, along with prevention and management of postoperative complications."
219739351|NCT06791538|PROCEDURE|Laparoscopic Gastrectomy|"Preoperative Preparation: Confirm diagnosis and staging through imaging and laboratory tests.~Surgical Procedure: Use standard laparoscopic instruments and 2D HD camera. Lymphadenectomy: Perform systematic D2 lymph node dissection. Gastrectomy and Reconstruction: Conduct subtotal or total gastrectomy and intracorporeal reconstruction.~Postoperative Management: Monitor vital signs, manage pain, and promote early mobilization."
219743459|NCT05529602|OTHER|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
219743460|NCT04162158|BIOLOGICAL|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
219243574|NCT03943771|OTHER|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
219243575|NCT04385849|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219243576|NCT04385849|OTHER|Saline|Sterile saline solution
219243577|NCT05530928|OTHER|Reproductive life plan counseling|The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
219243578|NCT05991947|OTHER|No intervention|No intervention measures are needed.
219243579|NCT06291220|DRUG|Obinutuzumab|Intravenous Infusion
219243580|NCT06291220|DRUG|ABBV-453|Oral; Tablet
219243581|NCT06837155|DRUG|TS-172 20 mg|oral administration of TS-172 20 mg
219243582|NCT06837155|DRUG|TS-172 90 mg|oral administration of TS-172 90 mg
219243583|NCT06837155|DRUG|Moxifloxacin|oral administration of moxifloxacin 400 mg
219243584|NCT06837155|DRUG|Placebo|oral administration of placebo
219243585|NCT01584999|BIOLOGICAL|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
219243586|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
219243587|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
219243588|NCT01375777|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219243589|NCT01375777|DRUG|Ezetimibe|Administered orally once a day
219243590|NCT01375777|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
219243591|NCT05878990|BEHAVIORAL|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
219243592|NCT05878990|BEHAVIORAL|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
219243593|NCT05878990|BEHAVIORAL|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
219243594|NCT05878990|BEHAVIORAL|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
219243595|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
219243596|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
219243597|NCT04807452|OTHER|Strength and balance training|Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.
219243598|NCT04807452|OTHER|Aerobics training|"After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down ."
219243599|NCT05500872|OTHER|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
219743461|NCT05327569|OTHER|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
219743462|NCT04046744|PROCEDURE|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
219743463|NCT04046744|PROCEDURE|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
219243600|NCT05500872|OTHER|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
219243601|NCT00512473|DRUG|Saline infusion|0.9 % NaCl
219243602|NCT00512473|DRUG|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
219243603|NCT00512473|DRUG|Pegvisomant|30 mg Somavert administered at t = - 36 hours
219243604|NCT05135845|DRUG|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
219243605|NCT05135845|DRUG|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
219243606|NCT05587907|DEVICE|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
219243607|NCT05163678|OTHER|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
219243608|NCT02334202|BEHAVIORAL|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
219243609|NCT02334202|OTHER|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
219243610|NCT05747872|BEHAVIORAL|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~1. The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~2. Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~3. Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
219243611|NCT05650437|DEVICE|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
219243612|NCT05650437|BEHAVIORAL|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
219243613|NCT05650437|DIETARY_SUPPLEMENT|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A\&B)
219243614|NCT00198666|DRUG|Zinc|Elemental Zinc
219243615|NCT02855892|OTHER|Placebo|
219243616|NCT02855892|DRUG|GV1001|
219243617|NCT02665624|DRUG|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
219243618|NCT02665624|DRUG|Senna alone|comparison of bowel cleansing and patient comfort.
219743464|NCT04046744|DRUG|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
219743465|NCT04046744|DRUG|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
219243619|NCT03598023|DEVICE|Cytal® Burn Matrix|Cytal® Burn Matrix
219243620|NCT03598023|DEVICE|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
219243621|NCT05851170|OTHER|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
219243622|NCT05851170|OTHER|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
219743466|NCT04046744|DRUG|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
219243623|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
219243624|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
219243625|NCT00000940|DRUG|Ritonavir|
219243626|NCT00000940|DRUG|Abacavir sulfate|
219243627|NCT00000940|DRUG|Amprenavir|
219243628|NCT00000940|DRUG|Lamivudine|
219243629|NCT00000940|DRUG|Stavudine|
219243630|NCT03886688|DRUG|HEC53856|oral administration
219243631|NCT03886688|DRUG|placebo|oral administration
219243632|NCT05554991|DIETARY_SUPPLEMENT|HMO|Composition comprising of HMO
219243633|NCT05554991|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
219243634|NCT05554991|BEHAVIORAL|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
219243635|NCT00042510|BIOLOGICAL|Treatment group|
219243636|NCT03635801|DEVICE|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
219243637|NCT04639752|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
219243638|NCT04639752|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
219243639|NCT04004663|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
219243640|NCT04357522|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
219243641|NCT04357522|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
219243642|NCT04871932|BIOLOGICAL|Recently Vaccination|
219243643|NCT04369547|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
219243644|NCT04369547|DRUG|Roflumilast|Roflumilast 250mcg
219243645|NCT04369547|DRUG|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
219243646|NCT01838499|BIOLOGICAL|MEDI8968|SC injection at baseline, Week 4 and Week 8
219243647|NCT01838499|BIOLOGICAL|Saline|SC injection at baseline, Week 4 and Week 8
219243648|NCT02246387|PROCEDURE|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
219243649|NCT00082784|DRUG|Bortezomib|Given IV
219243650|NCT00082784|DRUG|Alvocidib Hydrochloride|Given IV
219243651|NCT00082784|OTHER|Pharmacological Study|Correlative studies
219243652|NCT03068676|BEHAVIORAL|Space from Depression|internet-delivered CBT
219243653|NCT03068676|BEHAVIORAL|Space from Anxiety|internet-delivered CBT
219243654|NCT04143802|DRUG|LY3437943|Administered SC
219243655|NCT04143802|DRUG|Dulaglutide|Administered SC
219243656|NCT04143802|DRUG|Placebo|Administered SC
219243657|NCT04223661|DRUG|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
219243658|NCT04223661|DRUG|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
219172623|NCT06843629|DIAGNOSTIC_TEST|Specific positron imaging agents targeting MSLN|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using specific positron imaging agents targeting MSLN (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
219172624|NCT02694094|DIETARY_SUPPLEMENT|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
219172625|NCT03588481|DEVICE|DESyne X2|Novolimus-eluting stent
219172626|NCT05777031|DRUG|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
219172627|NCT06845189|OTHER|Modified Robbery Exercises|Prescribed set of Modified Robbery exercises will be applied
219172628|NCT06845189|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy Treatment for Frozen Shoulder
219172629|NCT06847594|DRUG|ringer lactate (20ml/kg)|ringer lactate 20 ml/kg over the first 90 to 120 minutes after induction intraoperatively
219172630|NCT06847594|DRUG|Dextrose 10%|Dextrose 10% 250 ml over 60 minutes
219172631|NCT06847672|DIAGNOSTIC_TEST|preoxygenation|The time required to reach EtO2 90% and the time until ORI drops below 0.55
219172632|NCT06845787|BEHAVIORAL|Live-music therapy|Children will be offered live-music therapy for 3 consecutive sessions, 30 minute sessions in which 10 to 20 minutes of music is provided by a trained music therapist in the presence of parents. In the sessions, the music therapist will make a tailored plan for each child to avoid overstimulation, which includes choosing the appropriate instrument, determining the child's behavioural state, and continuously monitoring the child (i.e., looking for signs of relaxation but also of overstimulation such as tension, crying movements, hiccups, yawning or frowning). The music therapist will collaborate with parents in constructing a program for the sessions. Parents will be actively involved in the sessions, to stimulate their role as caregiver and empower them. The contents of the live-music is thus constantly evaluated and adapted for the individual child.
219172633|NCT06847893|OTHER|rebozo technique|In accordance with the 'Rebozo Chart' developed by the researcher, the pregnant women in the experimental group were massaged with 4 different rebozo techniques (rebozo technique in hand-knee position, rebozo technique in knee-chest position, umbilical support with rebozo, rebozo technique applied with Pilates ball) in the active phase of labor. After the application, the duration, frequency and cervical dilatation of the pregnant woman were recorded in the chart.
219172634|NCT05085977|BIOLOGICAL|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
219172635|NCT05269160|DRUG|Dermaprazole 1%|Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
219172636|NCT05269160|DRUG|Dermaprazole 2%|Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
219172637|NCT03637400|DRUG|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
219172638|NCT03637400|DRUG|DOXY|DOXY will be administered over a period of 7 days.
219172639|NCT05964452|DRUG|Methimazole Tablets|Testing dosing algorithm for efficacy.
219172640|NCT05628415|PROCEDURE|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
219172641|NCT05628415|PROCEDURE|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
219243659|NCT04223661|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
219243660|NCT01136733|DRUG|Lenvatinib|taken orally, once a day
219243661|NCT01136733|DRUG|Everolimus|taken orally, once a day
219243662|NCT00113334|DRUG|ABT-510|100 mg subcutaneously twice daily
219172642|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
219243663|NCT01343147|OTHER|Microwave diathermy|Deep tissue heating via microwave diathermy
219172643|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
219172644|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
219172645|NCT05523401|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
219172646|NCT05523401|DRUG|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
219172647|NCT05523401|OTHER|Placebo|Placebo (Mannitol)
219243664|NCT01343147|OTHER|Superficial hyperthermia|Superficial heating via hot pack application
219243665|NCT00036309|DRUG|Duloxetine Hydrochloride|
219243666|NCT05267249|PROCEDURE|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
219243667|NCT03360071|DRUG|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
219243668|NCT03360071|DRUG|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
219243669|NCT03586739|PROCEDURE|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
219243670|NCT03586739|PROCEDURE|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
219243671|NCT03586739|DEVICE|Duplex-scan|a Duplex-scan will be performed during patient follow up.
219243672|NCT03586739|DEVICE|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
219243673|NCT03586739|DEVICE|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
219172648|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
219172649|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
219172650|NCT06007092|BIOLOGICAL|HPVDC injection level dose 1|patient receive 3 injections of vaccine at the same level dose
219172651|NCT06007092|BIOLOGICAL|placebo injection level dose 1|patient receive 3 injections of vaccine at the same level dose
219172652|NCT06007092|BIOLOGICAL|HPVDC injection level dose 2|patient receive 3 injections of vaccine at the same level dose
219172653|NCT06007092|BIOLOGICAL|placebo injection level dose 2|patient receive 3 injections of vaccine at the same level dose
219172654|NCT03270956|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
219172655|NCT05722964|DRUG|SHR-1906|Intravenous injection
219172656|NCT05722964|DRUG|SHR-1906|Intravenous injection
219172657|NCT05722964|DRUG|Placebo|Placebo，Intravenous injection
219172658|NCT06375005|DRUG|Telitacicept|Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
219172659|NCT06375005|DRUG|Mycophenolate Mofetil|All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
219172660|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
219172661|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
219172662|NCT06806696|OTHER|COVID-19 infection|COVID-19 diagnosis in the health database
219172663|NCT06237257|BIOLOGICAL|SHR-1316|SHR-1316（Adebrelimab Injection）
219172664|NCT06237257|DRUG|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
219172665|NCT06237257|RADIATION|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
219172666|NCT06237257|DRUG|Paclitaxel Injection|Paclitaxel Injection.
219172667|NCT05837221|DIAGNOSTIC_TEST|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
219172668|NCT05837221|DIAGNOSTIC_TEST|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
219172669|NCT04729907|DRUG|Nusinersen|Administered as specified in the treatment arm
219172670|NCT06486948|DEVICE|CT-156|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
219172671|NCT05579639|OTHER|Xylitol|Xylitol wipes
219172672|NCT05579639|OTHER|Placebo|Placebo wipes
219172673|NCT04150718|BEHAVIORAL|slow-wave disruption|A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
219172674|NCT04659343|OTHER|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
219172675|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
219172676|NCT04937868|OTHER|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
219172677|NCT05443165|BEHAVIORAL|The effectiveness of the online decision support system developed for symptom self-management|"The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area."
219243674|NCT03586739|OTHER|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
219243675|NCT01642888|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219243676|NCT01642888|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219243677|NCT03490942|DRUG|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
219243678|NCT03490942|DRUG|Placebo|The placebo solution is a non-active formulation containing excipients only.
219243679|NCT06011642|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter, digitale Version (Kinder-eDIPS)|The Kinder-eDIPS is a digital, structured interviews which assesses the most frequent psychological disorders. It exists in a parent and a child version. It can be delivered by trained clinicians and takes between 60 and 120 minutes.
219243680|NCT04114903|OTHER|Study A: Single use of cannabis flower product|Participants are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
219243681|NCT04114903|OTHER|Study B: Ad libitum cannabis use for four weeks or no cannabis use|Participants choose whether to use a cannabis flower product ad libitum for four weeks or to not use cannabis for four weeks. Participants who choose to use cannabis are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
219243682|NCT01189994|PROCEDURE|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
219243683|NCT01189994|BEHAVIORAL|Orientation|Orientation sessions focusing in fibromyalgia
219243684|NCT01525888|PROCEDURE|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
219243685|NCT03352570|DEVICE|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
219243686|NCT01373359|DRUG|Misoprostol|400 µg sublingual misoprostol
219243687|NCT01373359|DRUG|Oxytocin|10 IU IM
219243688|NCT05785975|OTHER|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
219243689|NCT03490188|BEHAVIORAL|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
219243690|NCT04692441|DIETARY_SUPPLEMENT|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
219243691|NCT06458296|OTHER|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
219743467|NCT05006040|DEVICE|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
219243692|NCT06458296|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
219243693|NCT02074709|DRUG|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
219243694|NCT02074709|DRUG|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
219243695|NCT04993976|OTHER|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs \[eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises\], one to three sets each) for 20-60 minutes five days a week.
219243696|NCT04993976|OTHER|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
219362404|NCT06958718|PROCEDURE|Surgical erector spinae plane block (SB)|Surgical erector spinae plane block (SB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine ..This volume will be divided into 8 injections, four 5 ml injections on each side. The surgeons will perform the block just before starting the wound closure stage. The surgical ESP block technique consists of injections at four bilateral levels, starting from one level above the operated vertebra and covering all surgical segments using a 22G × 88 mm needle. The needle will be inserted to contact the transverse process, and the injectate will be delivered between the erector spinae muscle and the transverse process at each level.
219362405|NCT06958718|DRUG|Dexmedetomidine|0.5 μg/kg dexmedetomidine added to block solution
219362406|NCT06958718|DRUG|Bupivacaine Hcl 0.5% Inj|40 ml Bupivacaine HCL
219243697|NCT04162977|BEHAVIORAL|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
219243698|NCT04175392|DRUG|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
219243699|NCT04175392|DRUG|Placebos|Placebos capsule 1 capsule Once daily
219243700|NCT02153697|DEVICE|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
219243701|NCT02153697|DRUG|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
219743468|NCT02999997|BEHAVIORAL|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
219743469|NCT05196529|OTHER|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
219243702|NCT03469089|DRUG|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
219243703|NCT03469089|DRUG|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
219243704|NCT03469089|DRUG|Modafinil|Modafinil tablet 100 mg placed in a capsule
219243705|NCT03469089|DRUG|Placebo for ketamine|0.9 % NaCl infusion solution
219243706|NCT03469089|DRUG|Placebo for modafinil|Placebo capsule for modafinil capsule
219243707|NCT02251405|BEHAVIORAL|One bag, stainless container|
219243708|NCT02727998|DRUG|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
219243709|NCT02727998|DRUG|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
219362407|NCT02395549|DRUG|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
219362408|NCT02395549|DRUG|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
219362409|NCT02395549|DRUG|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
219243710|NCT01289197|BEHAVIORAL|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
219243711|NCT01504178|DRUG|duloxetine|administration during 28 days
219243712|NCT01504178|DRUG|placebo of duloxetine|administration during 28 days
219243713|NCT01504178|DRUG|injection of apomorphine|injection performed at D28
219243714|NCT01504178|DRUG|injection of placebo of apomorphine|performed at D28
219243715|NCT01504178|DRUG|L-Dopa|performed at D28
219243716|NCT01504178|DRUG|injection of placebo of L-Dopa|performed at D28
219243717|NCT02072889|OTHER|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
219243718|NCT02105688|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
219243719|NCT02105688|DRUG|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
219243720|NCT03423537|DRUG|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
219243721|NCT03423537|DRUG|Placebo|100IU per day containing N/S 0.9% will be injected
219243722|NCT05237856|DEVICE|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
219243723|NCT00329771|OTHER|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
219243724|NCT03553459|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
219243725|NCT00308009|PROCEDURE|Vaginal Repair for prolapse, TVT procedure|"1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair"
219243726|NCT00308009|PROCEDURE|TVT and Prolapse surgery|"1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery"
219243727|NCT00942799|DRUG|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
219243728|NCT00942799|DRUG|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
219243729|NCT04994314|DRUG|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
219243730|NCT04994314|DRUG|Control primer|Conventional orthodontic primer
219243731|NCT00464932|DRUG|Vasoactive Intestinal Peptide (VIP)|
219362410|NCT02395549|DRUG|Vehicle Control Gel|
219739352|NCT06640803|BEHAVIORAL|Stepped-Care including Cognitive Behavioral Case Management|Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
219739353|NCT06642038|PROCEDURE|Transbronchial Endoscopic Thermal Vapor Ablation|Transbronchial Endoscopic Thermal Vapor Ablation
219739354|NCT06638138|DEVICE|Flexband|Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
219739355|NCT06640712|DIAGNOSTIC_TEST|Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|The same psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to all participants. Oral health examinations were performed by a trained dental student and a specialist dentist using a portable dental chair, artificial light, and a dental mirror. Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria. This index included the number of decayed, missing (due to caries, excluding 3rd molars), and filled teeth in the permanent dentition. The oral health examiners were blinded to each participant's substance use type and sociodemographic information.
219243732|NCT02010021|DRUG|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
219362411|NCT01825902|DRUG|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
219362412|NCT01825902|RADIATION|fludeoxyglucose F 18|Undergo 18F-FDG PET
219739356|NCT06640712|DIAGNOSTIC_TEST|Substance Use Disorder Diagnosis|This intervention involves a psychiatric evaluation conducted by a licensed psychiatrist to diagnose Substance Use Disorder according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The psychiatrist performs a comprehensive assessment of each participant's substance use history and related behaviors. This diagnosis step is essential for identifying participants with specific substance use disorders, such as Methamphetamine, Cannabis, or Polysubstance Use Disorders, before proceeding with the dental health examination.
219739357|NCT06442228|DIAGNOSTIC_TEST|spermiogram test|"Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported."
219739358|NCT04013854|DRUG|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
219739359|NCT04013854|DRUG|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
219739360|NCT06636825|OTHER|Graded hypercapnia|Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
219739361|NCT06636825|DRUG|Caffeine|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
219739362|NCT06636825|DRUG|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
219739363|NCT06637735|OTHER|education|pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
219739364|NCT03687671|OTHER|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
219739365|NCT03687671|OTHER|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
219739366|NCT00836901|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
219739367|NCT00836901|DRUG|Augmentin®|400 mg-57 mg chewable tablet
219739368|NCT05526157|DRUG|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
219739369|NCT05526157|DRUG|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
219739370|NCT05526157|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
219739371|NCT05526157|DRUG|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
219739372|NCT05526157|DRUG|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
219739373|NCT03760081|DRUG|ASP1650|Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
219739374|NCT00221221|DEVICE|Pedometer|
219739375|NCT00221221|DEVICE|Exercise guidebook|
219739376|NCT06357377|DRUG|NEO100|"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."
219739377|NCT02517918|DRUG|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
219739378|NCT05460169|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
219739379|NCT05336565|OTHER|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
219739380|NCT00771147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
219743470|NCT04628208|DIAGNOSTIC_TEST|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
219743471|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
219743472|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
219743473|NCT00803374|DRUG|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
219743474|NCT00803374|DRUG|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
219743475|NCT00803374|DRUG|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
219362413|NCT01825902|PROCEDURE|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
219743476|NCT00803374|DRUG|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
219743477|NCT00234793|BEHAVIORAL|Problem-Solving Skills Training|
219743478|NCT00267488|DRUG|topotecan|
219243733|NCT03456206|OTHER|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
219243734|NCT03456206|OTHER|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
219243736|NCT05080803|DRUG|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
219243737|NCT01551121|OTHER|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
219243738|NCT05469867|DEVICE|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
219243739|NCT03419754|DIETARY_SUPPLEMENT|Glucose|Glucose
219243740|NCT03419754|BEHAVIORAL|Fidgetting|low intensity physical activity (fidgetting)
219243741|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
219243742|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
219243743|NCT03166215|DRUG|TAK-935|TAK-935 tablets.
219243744|NCT03166215|DRUG|Placebo|TAK-935 placebo-matching tablets.
219243745|NCT00472368|DRUG|LBH589|
219243746|NCT00927316|BIOLOGICAL|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
219243747|NCT05903573|BEHAVIORAL|Cognitive Training|The intervention group will receive cognitive training that provides specific training tasks directed at essential cognitive domains tied to the project's aims and hypotheses (processing speed and working memory) that correspond with the neurocognitive and functional neuroimaging measures to be studied.
219243748|NCT05903573|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
219243749|NCT00208832|PROCEDURE|Graphic medication schedule (Pill card)|
219243750|NCT00208832|PROCEDURE|Refill reminder postcard|
219243751|NCT06451705|DRUG|PECS II block|Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
219243752|NCT06451705|DRUG|LIA|Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
219243753|NCT06585189|DRUG|Pembrolizumab|
219243754|NCT06585189|DRUG|Pemetrexed|
219243755|NCT06585189|DRUG|Cisplatin|
219243756|NCT06585189|DRUG|Carboplatin|
219243757|NCT06057870|OTHER|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
219243758|NCT05584761|DRUG|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
219243759|NCT03942276|OTHER|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
219243760|NCT03942276|OTHER|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
219243761|NCT03942276|OTHER|Control|Consist of performing no exercise training.
219243762|NCT04435821|DRUG|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
219243763|NCT04332367|DRUG|Carboplatin|Carboplatin IV
219243764|NCT04332367|DRUG|Paclitaxel|Paclitaxel IV
219243765|NCT04332367|DRUG|Ramucirumab|Ramucirumab IV
219243766|NCT03749837|DEVICE|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
219243767|NCT03749837|DEVICE|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
219243768|NCT01807845|DIETARY_SUPPLEMENT|enriched skimmilk with VD|enriched skimmilk with VD
219243769|NCT01807845|DIETARY_SUPPLEMENT|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
219243770|NCT01807845|DIETARY_SUPPLEMENT|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
219243771|NCT02632045|DRUG|LEE-011|600 mg capsule (3x 200 mg capsules)
219243772|NCT02632045|DRUG|Fulvestrant|500 mg injection
219243773|NCT02632045|DRUG|Placebo|600 mg capsule (3x 200 mg capsules)
219243774|NCT05878522|DRUG|sisunatovir|6 capsules administered Q12 hours for 5 doses
219243775|NCT05878522|DRUG|placebo|6 capsules administered Q12 hours for 5 doses
219243776|NCT05878522|DRUG|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
219243777|NCT05878522|DRUG|sisunatovir|7 capsules administered Q12 hours for 5 doses
219243778|NCT05122559|DRUG|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
219243779|NCT05122559|DRUG|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
219243780|NCT05272254|DRUG|10% povidone iodine + FV|applied to children's teeth
219243781|NCT05272254|OTHER|Placebo +FV|applied to children's teeth
219243782|NCT03147430|OTHER|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
219743479|NCT01557569|DRUG|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
219743480|NCT01557569|DRUG|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
219743481|NCT00055887|DRUG|carboplatin|
219743482|NCT00055887|DRUG|cisplatin|
219243783|NCT04707924|DEVICE|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
219243784|NCT05846932|BEHAVIORAL|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
219243785|NCT05846932|BEHAVIORAL|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
219243786|NCT04855708|OTHER|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
219243787|NCT04855708|OTHER|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
219243788|NCT04276142|BEHAVIORAL|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
219243789|NCT04276142|BEHAVIORAL|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
219243790|NCT02252172|DRUG|Daratumumab IV|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
219243791|NCT02252172|DRUG|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
219243792|NCT02252172|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
219243793|NCT02252172|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
219243794|NCT04441983|DIAGNOSTIC_TEST|7 Tesla MRI of the foot|7 Tesla MRI
219743483|NCT00055887|DRUG|efaproxiral|
219743484|NCT00055887|DRUG|gemcitabine hydrochloride|
219743485|NCT00055887|DRUG|paclitaxel|
219243795|NCT06084260|DIETARY_SUPPLEMENT|Diet group|Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
219243796|NCT06084260|BEHAVIORAL|Self-compassion group|Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
219243797|NCT03985020|OTHER|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
219243798|NCT03985020|OTHER|Water Intervention|Bottled Water
219243799|NCT03690011|GENETIC|CD7.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2"
219243800|NCT04563026|DRUG|DUR-928 30 mg|IV infusion
219243801|NCT04563026|DRUG|DUR-928 90 mg|IV infusion
219243802|NCT04563026|DRUG|Placebo+ Standard of Care (SOC)|IV infusion
219243803|NCT01483885|DEVICE|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
219243804|NCT01483885|DEVICE|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
219243805|NCT01483885|PROCEDURE|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
219243806|NCT00375388|DRUG|Metformin on top of intensive insulin therapy|
219243807|NCT00006229|DRUG|carboplatin|
219243808|NCT00006229|DRUG|paclitaxel|
219243809|NCT00006229|DRUG|rebimastat|
219243810|NCT05680597|OTHER|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
219243811|NCT06529809|RADIATION|Hypofractionated external beam radiation|Central pelvis (19.05 Gy in 15 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
219243812|NCT06529809|DRUG|Chemotherapy|Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
219243813|NCT06529809|RADIATION|Image-guided brachytherapy|HDR boost 7.3 Gy x 6 fractions
219243814|NCT03696147|DEVICE|Magnetic resonance imaging|Diffusion weighted sequence of MRI
219243815|NCT00629161|DRUG|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
219243816|NCT00629161|DRUG|placebo|12 months period of placebo plus 1 month period without placebo
219243817|NCT01482871|DRUG|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
219243818|NCT01482871|DRUG|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
219362414|NCT01825902|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
219243819|NCT01482871|DRUG|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
219243820|NCT01482871|DRUG|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
219243821|NCT05740371|DRUG|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
219243822|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
219243823|NCT05499117|DEVICE|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
219243824|NCT05499117|DEVICE|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
219243825|NCT04021277|DRUG|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
219243826|NCT04021277|DRUG|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
219243827|NCT04021277|DEVICE|Ultrasound|Ultrasound activation and enhancement
219243828|NCT04425837|BIOLOGICAL|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
219243829|NCT04425837|OTHER|Standard care|Standard care according to guidelines and national regulations
219243830|NCT05155553|DEVICE|QIAstat-Dx® Meningitis/Encephalitis (ME) Panel|The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.
219243831|NCT06416540|OTHER|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program|"Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient."
219243832|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Program|Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
219243833|NCT05766566|PROCEDURE|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
219243834|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
219243835|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
219243836|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
219243837|NCT05642702|OTHER|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
219243838|NCT05642702|OTHER|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
219243839|NCT06415825|BEHAVIORAL|Standard advice and Preliminary muscle contraction|The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.
219243840|NCT06415825|BEHAVIORAL|Standard advice|Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
219243841|NCT06080802|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
219243842|NCT04867044|OTHER|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
219243843|NCT04867044|OTHER|Control|healthy woman volunteers
219243844|NCT05534230|DRUG|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
219243845|NCT05534230|DRUG|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
219243846|NCT05860894|DEVICE|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
219243847|NCT04209322|PROCEDURE|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
219243848|NCT04209322|PROCEDURE|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
219243849|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|3 capsules daily.
219243850|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|2 capsules twice daily.
219243851|NCT04928937|PROCEDURE|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
219243852|NCT06032156|DIETARY_SUPPLEMENT|Low Dose β-OHB|Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
219243853|NCT06032156|DIETARY_SUPPLEMENT|High Dose β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
219243854|NCT06032156|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
219243855|NCT00777309|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
219243856|NCT00777309|DRUG|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
219243857|NCT00777309|DRUG|Placebo|The placebo is provided as a capsule
219243858|NCT01613599|DRUG|Rituximab|Participants received rituximab at the discretion of their treating physicians.
219243859|NCT02705729|DEVICE|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
219243860|NCT02705729|DEVICE|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
219243861|NCT02091102|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
219243862|NCT02003885|DRUG|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
219243863|NCT00228657|DRUG|4% Albumin / 0.9% Sodium Chloride|
219243864|NCT01049633|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
219243865|NCT01049633|DRUG|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
219243866|NCT01049633|BIOLOGICAL|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
219243867|NCT01049633|DRUG|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
219362415|NCT01825902|OTHER|laboratory biomarker analysis|Correlative studies
219243868|NCT01049633|DRUG|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
219243869|NCT01049633|DRUG|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
219243870|NCT01049633|DRUG|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
219243871|NCT01049633|DRUG|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
219243872|NCT01049633|DRUG|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
219243873|NCT01049633|DRUG|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
219243874|NCT01049633|DRUG|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
219243875|NCT01049633|DRUG|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
219243876|NCT04937309|DEVICE|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
219243877|NCT04937309|DRUG|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
219243878|NCT04937309|DEVICE|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
219243879|NCT06500169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219243880|NCT06500169|PROCEDURE|Discussion|Ancillary studies
219243881|NCT06500169|OTHER|Exercise Intervention|Complete golf related exercises
219243882|NCT06500169|OTHER|Interview|Ancillary studies
219243883|NCT06500169|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
219243884|NCT06500169|PROCEDURE|Physical Examination|Ancillary studies
219243885|NCT06500169|OTHER|Physical Performance Testing|Ancillary studies
219243886|NCT06500169|OTHER|Questionnaire Administration|Ancillary studies
219243887|NCT06500169|OTHER|Recreational Therapy|Participate in golf program
219243888|NCT01158716|OTHER|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
219243889|NCT00617708|BIOLOGICAL|cixutumumab|Given IV
219243890|NCT00617708|DRUG|erlotinib hydrochloride|Given PO
219243891|NCT00617708|DRUG|gemcitabine hydrochloride|Given IV
219243892|NCT00003049|DRUG|fluorouracil|
219243893|NCT00003049|DRUG|leucovorin calcium|
219243894|NCT00003049|PROCEDURE|conventional surgery|
219243895|NCT00003049|RADIATION|radiation therapy|
219243896|NCT01075815|DRUG|Recombinant human luteinizing hormone (rhLH)|
219243897|NCT01075815|DRUG|Recombinant follicle-stimulating hormone (rFSH)|
219243898|NCT02058992|DRUG|Ramelteon|Ramelteon 8 mg tablets
219243899|NCT03796585|BEHAVIORAL|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
219243900|NCT03796585|BEHAVIORAL|Informational flyer|Informational flyer with ImmPRINT contact information
219243901|NCT00021099|DRUG|ixabepilone|Given IV
219243902|NCT00002045|DRUG|Zidovudine|
219243903|NCT01794273|DRUG|ephedrine and phenylephrine|
219743486|NCT00055887|DRUG|vinorelbine ditartrate|
219743487|NCT00055887|PROCEDURE|radiation therapy|
219743488|NCT02256033|DRUG|Istradefylline|One 40 mg-tablet administered on Day 1
219743489|NCT00002171|DRUG|Nelfinavir mesylate|
219743490|NCT05222711|DEVICE|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
219743491|NCT03308773|OTHER|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
219743492|NCT03706066|DEVICE|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
219743493|NCT03706066|PROCEDURE|Cataract surgery|Per investigator's standard of care
219743494|NCT04369612|PROCEDURE|Standard follow-up|Standard post-transplant follow-up
219743495|NCT04369612|PROCEDURE|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
219743496|NCT00583531|DRUG|AST-120|Oral, 2 grams TID in sachets for 4 weeks
219743497|NCT04649749|DIAGNOSTIC_TEST|MRI|MRI scan
219743498|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
219243904|NCT02512315|DRUG|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
219243905|NCT02512315|DRUG|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
219243906|NCT02512315|RADIATION|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
219243907|NCT03503188|DEVICE|Littmann ®|electronic stethoscope
219243908|NCT05456061|DRUG|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
219243909|NCT05456061|PROCEDURE|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
219243910|NCT04485975|DEVICE|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
219243911|NCT03867396|DEVICE|CROS|Advanced Bionics CROS
219243912|NCT03867396|DEVICE|Hearing Aid|Advanced Bionics Naida hearing aid
219243913|NCT03867396|OTHER|Cochlear Implant Alone|No hearing device on contralateral ear
219243914|NCT06119256|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
219243915|NCT03868202|DRUG|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
219243916|NCT00046488|DRUG|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
219243917|NCT04172974|OTHER|eHealth intervention|Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
219243918|NCT04172974|OTHER|Usual Care|Treatment according to national clinical guideline (referral to GP)
219243919|NCT02391389|PROCEDURE|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
219243920|NCT00293085|DRUG|Docetaxel|
219243921|NCT00293085|DRUG|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
219243922|NCT04734236|DIAGNOSTIC_TEST|New technique vs Xpert|New technique vs Xpert
219243923|NCT03031223|RADIATION|low-level laser therapy|low-level laser therapy
219243924|NCT03747575|DRUG|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
219243925|NCT03747575|DRUG|Placebo|Participants will receive SC placebo
219243926|NCT03583034|PROCEDURE|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
219243927|NCT03522844|OTHER|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
219243928|NCT03522844|DRUG|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
219243929|NCT00658177|DRUG|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
219243930|NCT00658177|DRUG|Placebo|Matching placebo
219243931|NCT04878861|BEHAVIORAL|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
219243932|NCT06415695|BEHAVIORAL|Education sessions|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
219243933|NCT04430153|OTHER|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
219243934|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
219243935|NCT00003088|DRUG|cyclophosphamide|given IV
219243936|NCT00003088|DRUG|doxorubicin hydrochloride|given IV
219243937|NCT00003088|DRUG|paclitaxel|given IV
219243938|NCT02944981|DRUG|Gabapentin|Single oral dose
219243939|NCT02944981|DRUG|Placebo|Single oral dose
219243940|NCT02356874|BEHAVIORAL|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
219243941|NCT05811338|BEHAVIORAL|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
219243942|NCT05811338|BEHAVIORAL|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
219243943|NCT05811338|BEHAVIORAL|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
219243944|NCT04453982|OTHER|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
219243945|NCT01434732|PROCEDURE|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
219243946|NCT01434732|PROCEDURE|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
219243947|NCT03005106|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
219243948|NCT03005106|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
219243949|NCT02342652|DRUG|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
219243950|NCT02342652|DRUG|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
219243951|NCT01837368|OTHER|observational research|It is a observational research, no intervention are performed
219243952|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
219243953|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
219243954|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
219243955|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
219243956|NCT03163472|PROCEDURE|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
219243957|NCT03163472|PROCEDURE|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
219243958|NCT05716425|DRUG|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
219243959|NCT05716425|DRUG|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
219243960|NCT03288688|OTHER|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
219743499|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
219743500|NCT05634200|PROCEDURE|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
219739381|NCT01470820|OTHER|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
219739382|NCT04846699|PROCEDURE|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
219739383|NCT05261490|DRUG|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
219739384|NCT05261490|DRUG|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
219172678|NCT05443165|BEHAVIORAL|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
219172679|NCT05595486|OTHER|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
219172680|NCT06454539|OTHER|Functional Inspiratory Muscle Training|Functional IMT is an inspiratory muscle training that ensures core stabilization and maintains postural control. Rhythmic co-contractions of the core muscle areas (diaphragm, transversus abdominis, multifidus, pelvic floor) ensure the stability of the trunk and provide it with the feature of being the support point of movement. In the first stage, the person is given core stabilization training. Secondly, core stabilization is maintained and continued with strong trunk activation exercises. Postural exercises reinforce the other function of the breathing muscles, which is actually 'core' stabilization.
219172681|NCT06454539|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is one of the methods used to increase respiratory muscle strength. Different tools and methods (threshold resistive loading, normocapnic hyperpnea, and threshold pressure loading) have been developed for IMI. The most used method in the literature is the threshold pressure loading method. This method requires subjects to generate a negative pressure sufficient to overcome the load of the device and thus initiate inspiration. ICE is most commonly performed in a sitting position, with upper extremities supported and upper chest/shoulders relaxed. By placing the person in this position, the aim is for the respiratory muscles to focus only on the work of breathing.
219172682|NCT05640089|OTHER|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
219172683|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
219172684|NCT06529185|DEVICE|The BREATHER|The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
219172685|NCT06529185|DRUG|pharmacological treatment|patient will receive the usually pharmacological treatment.
219172686|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
219172687|NCT05875961|BIOLOGICAL|Intermediate dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
219172688|NCT05875961|BIOLOGICAL|High dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
219172689|NCT05875961|BIOLOGICAL|High dose A/H2N3c non-adjuvanted|Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
219172690|NCT05875961|BIOLOGICAL|Lowest dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
219172691|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
219172692|NCT04719156|DRUG|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
219172693|NCT04719156|DEVICE|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
219172694|NCT04869683|OTHER|description of MDS pzatient cohort|description of MDS patient cohort
219172695|NCT04341779|COMBINATION_PRODUCT|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
219172696|NCT06115954|OTHER|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
219172697|NCT05719220|BEHAVIORAL|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
219172698|NCT03948048|DEVICE|ECMO|ECMO is used to intervene septic shock and refractory septic shock
219243961|NCT01691404|DIETARY_SUPPLEMENT|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
219243962|NCT01691404|DIETARY_SUPPLEMENT|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
219243963|NCT01691404|DIETARY_SUPPLEMENT|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
219243964|NCT01636726|DRUG|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
219243965|NCT03310255|DIAGNOSTIC_TEST|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
219243966|NCT05836844|DEVICE|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
219243967|NCT00246350|PROCEDURE|massage|8 light massage treatments and hot pack
219243968|NCT00246350|PROCEDURE|massage|16 light massage treatments and hot packs
219243969|NCT00246350|PROCEDURE|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
219243970|NCT00246350|PROCEDURE|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
219243971|NCT03612388|PROCEDURE|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
219243972|NCT00512902|DRUG|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
219243973|NCT00512902|DRUG|Imatinib|Up to 600 mg QD PO for up to 1 year.
219243974|NCT04847180|PROCEDURE|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
219739385|NCT02732145|DIAGNOSTIC_TEST|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
219243975|NCT00227422|BIOLOGICAL|Mencevax ACWY|
219243976|NCT05414825|OTHER|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
219243977|NCT01151397|DRUG|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
219243978|NCT01151397|DRUG|Peg + Ribavirin|Peg+ Ribavirin for 6 months
219243979|NCT02502136|PROCEDURE|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
219243980|NCT02502136|PROCEDURE|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
219243981|NCT00272415|DRUG|INO-1001|Intravenous repeating dose
219243982|NCT00272415|DRUG|temozolomide|Oral repeating dose
219243983|NCT00523458|DRUG|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
219243984|NCT02877524|OTHER|Adaptive support ventilation|ASV during NIV
219243985|NCT02877524|OTHER|Pressure support ventilation|PSV during NIV
219739386|NCT02732145|PROCEDURE|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
219739387|NCT03979794|BEHAVIORAL|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
219739388|NCT03983070|OTHER|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
219739389|NCT03983070|OTHER|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
219739390|NCT03983070|OTHER|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
219243986|NCT06380959|OTHER|Art Based Activity|"Art Based Activity Module consists of 3 art-based activities under the titles My Life Journey, The Power Within Me and Letter to the Future. Each activity consists of three stages. In the first stage, the participants were made to practice breathing exercises. At this stage, the participant was expected to become aware of himself and his ideas. In the second stage, art activity was carried out. In the final stage, the revealed art object was concretized by the participants with a verbal expression. The materials used in the activities (dry paint, pastel paint, watercolor) are dermatologically tested and consist of anti-allergen products."
219243987|NCT01654198|RADIATION|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
219243988|NCT03019289|DRUG|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
219243989|NCT00388856|DRUG|Vitamin C 1000mg and E 400IU|
219243990|NCT06393855|PROCEDURE|single-step Trans-PRK|Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.
219243991|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
219243992|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
219243993|NCT01400997|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
219243994|NCT06505252|PROCEDURE|enoscopic Myringoplasty|"general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat"
219243995|NCT03473275|DIAGNOSTIC_TEST|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
219243996|NCT03473275|DIAGNOSTIC_TEST|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
219243997|NCT06337903|BEHAVIORAL|Self-compassion intervention (the Mindful Self-Compassion course)|An online 8-week mindful self-compassion course with weekly sessions.
219243998|NCT03258034|DRUG|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
219243999|NCT04168450|OTHER|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
219739391|NCT01722734|BEHAVIORAL|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
219739392|NCT01837550|BEHAVIORAL|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
219739393|NCT01837550|BEHAVIORAL|Control group|The control group only had access to reading material.
219244000|NCT04168450|OTHER|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
219244001|NCT06232005|DRUG|Mitomycin c|injection of antifibrotic drugs in urethral strictures after internal urethrotomy
219244002|NCT04896827|OTHER|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
219244003|NCT05667597|DIAGNOSTIC_TEST|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
219244004|NCT00474409|DRUG|Merislon|
219244005|NCT02076594|DRUG|Docetaxel|Powder for solution for infusion
219244006|NCT02076594|DRUG|Epirubicin|Solution for infusion
219244007|NCT02076594|DRUG|Oxaliplatin|Powder for solution for infusion
219244008|NCT02076594|DRUG|Capecitabine|Film coated tablets
219244009|NCT06124170|PROCEDURE|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
219244010|NCT06124170|PROCEDURE|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
219244011|NCT06124170|PROCEDURE|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
219244012|NCT01429285|DRUG|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
219244013|NCT01429285|DRUG|Usual care|Attending administers any IV opioid in any dose he chooses
219244014|NCT04780152|DEVICE|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
219244015|NCT04780152|DEVICE|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
219244016|NCT04780152|DRUG|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
219739394|NCT03594656|DRUG|Ganoderma|0.8g twice daily
219739395|NCT03594656|DRUG|Placebos|0.8g twice daily
219739396|NCT04425278|DEVICE|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
219739397|NCT04425278|DEVICE|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
219244017|NCT01991275|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
219244018|NCT01991275|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
219244019|NCT01540305|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
219739398|NCT04695626|PROCEDURE|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
219739399|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
219739400|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
219739401|NCT01971593|DRUG|Eplerenone|
219244020|NCT01540305|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
219244021|NCT03249857|BEHAVIORAL|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
219244022|NCT03249857|BEHAVIORAL|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
219362416|NCT06584409|DEVICE|Laser Pen|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
219172699|NCT05238792|BIOLOGICAL|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
219172700|NCT06300307|DRUG|ATX-01|Solution for infusion
219172701|NCT06300307|DRUG|Placebo|Solution for infusion
219244023|NCT05703412|BEHAVIORAL|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
219244024|NCT05703412|BEHAVIORAL|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
219244025|NCT04981431|DRUG|Elinzanetant (BAY3427080)|Oral administration
219244026|NCT04981431|DRUG|Placebo|Oral administration
219244027|NCT02452567|OTHER|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
219244028|NCT02680145|DEVICE|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
219244029|NCT04432415|DEVICE|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
219244030|NCT04432415|DEVICE|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
219244031|NCT04432415|DEVICE|Placebo|biannual application of artificial saliva
219244032|NCT02954783|BEHAVIORAL|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
219244033|NCT02954783|BEHAVIORAL|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
219244034|NCT03958526|DEVICE|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
219244035|NCT03958526|DEVICE|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
219244036|NCT03982797|BIOLOGICAL|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
219244037|NCT01768585|DRUG|Ivabradine|Please see description of Intervention Arm
219244038|NCT01768585|DRUG|Placebo|
219244039|NCT06519448|DRUG|Empagliflozin 10 miligrams (mg)|Use of empagliflozin 10 mg daily for 12 months.
219244040|NCT06506409|DEVICE|Smart-Video Based Game Therapy|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
219244041|NCT06506409|OTHER|Otago Based Structured Exercise|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
219739402|NCT02917538|PROCEDURE|RFA|Both groups will receive radiofrequency ablation treatment
219739403|NCT02452593|OTHER|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
219739404|NCT05103111|OTHER|No intervention|no intervention
219739405|NCT03374332|DRUG|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
219739406|NCT03374332|OTHER|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
219739407|NCT02316132|DRUG|Stress|Corticotropin-Releasing Hormone
219739408|NCT02316132|DRUG|Control|Saline 0.9%
219739409|NCT03497117|DEVICE|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
219172703|NCT06579001|DRUG|Nasal spray dexmedetomidine|Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment
219244042|NCT06506409|OTHER|No intervention|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
219244043|NCT03410680|BEHAVIORAL|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
219244044|NCT02034188|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
219244045|NCT06157684|BEHAVIORAL|Postprandial ambulation|See arm description
219244046|NCT01542502|DRUG|Anakinra|Anakinra 100 mg daily subcutaneous injection
219244047|NCT01542502|DRUG|Placebo|Placebo daily subcutaneous injection
219244048|NCT00193102|DRUG|Thalidomide|Thalidomide
219244049|NCT00193102|DRUG|Capecitabine|Capecitabine
219244050|NCT04971902|OTHER|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
219244051|NCT05972161|DEVICE|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
219244052|NCT04202822|OTHER|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
219244053|NCT00780988|BIOLOGICAL|Autologous tumor cell + CpG vaccine|
219244054|NCT00780988|PROCEDURE|Autologous hematopoietic and immune cell rescue (transplantation)|
219244055|NCT05497167|OTHER|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
219244056|NCT06261515|PROCEDURE|Active periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
219244057|NCT01234584|PROCEDURE|spk|implants using SPK Abutments
219244058|NCT01234584|PROCEDURE|CPK Abutments|implants using CPK Abutments
219244059|NCT02239614|BIOLOGICAL|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
219244060|NCT02239614|BIOLOGICAL|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
219244061|NCT06446726|DRUG|Tislelizumab|Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
219244062|NCT06446726|RADIATION|Low-dose radiotherapy|Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
219244063|NCT06446726|DRUG|Nab-paclitaxel|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
219244064|NCT06446726|DRUG|Cisplatin|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
219244065|NCT02168855|DRUG|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
219244066|NCT02168855|BEHAVIORAL|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
219244067|NCT04095897|PROCEDURE|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
219244068|NCT04490694|DRUG|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219244069|NCT04490694|PROCEDURE|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
219244070|NCT01217645|RADIATION|150 mg [14C] AZD6765|
219244071|NCT06473194|PROCEDURE|general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum|this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
219244072|NCT02411188|BEHAVIORAL|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
219244073|NCT02037009|OTHER|Health care organization (anesthetic surveillance)|
219244074|NCT01005563|OTHER|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
219244075|NCT01005563|OTHER|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
219244076|NCT03436537|OTHER|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
219172704|NCT06678672|BEHAVIORAL|Contingency Management (CM)|The participants will receive and be trained to use a CO monitor and iCO app to upload videos to verify smoking abstinence at a minimum of once per day, 5 times per week, over 5 weeks. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through remote CO monitoring. They will receive clinician feedback at the time of each CO reading, following the established VA CM protocol developed in the earlier phase of the project. Each CO reading during the weeks 2-5 will also be accompanied with a brief (5-minute) telephone or video feedback CM counseling session from the study clinician.
219172705|NCT06678672|BEHAVIORAL|Treatment as Usual (TAU)|Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (SFVAHCS), i.e., referral to Tobacco Cessation Clinic and the VA Telequit Quitline. The SFVAHCS Tobacco Cessation Clinic is a consult service that calls patients proactively 3 times to offer 1:1 behavioral counseling for smoking cessation. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for up to 5 sessions per NCI Quitline guidelines. The smoker initiates the first call, and subsequent calls will be proactively made by Quitline staff.
219172706|NCT06581068|DEVICE|AURA assisted ART treatment|The AURA device consists of five subsystems, which will operate in logical sequence to deliver comprehensive automation of the laboratory element of an ART cycle. The AURA treatment begins after ovarian stimulation, on the day of egg collection. A sperm sample is provided on the same day of egg collection. Sperm samples will be prepared by the C:SPERM subsystem. Follicular fluid obtained at egg collection will be processed by the C:EGG subsystem. 3 out of every 4 cumulus-oocyte complexes (COCs) recovered will be denuded by the C:EGG subsystem. These denuded eggs will be fertilized by the C:ICSI subsystem, incubated in the C:CULTURE subsystem and all resulting suitable embryos will be vitrified by the C:VIT subsystem. Thawed embryos may be used in conventional frozen embryo transfers.
219172707|NCT03226418|DRUG|Cytarabine|Given IV
219172708|NCT03226418|DRUG|Decitabine|Given IV
219172709|NCT03226418|DRUG|Idarubicin|Given IV
219172710|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
219172711|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219172712|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
219172713|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
219172714|NCT03226418|DRUG|Azacitidine|Given by infusion
219172715|NCT03226418|DRUG|Venetoclax|oral tablet
219172716|NCT03226418|DRUG|glasdegib|oral tablet
219172717|NCT06201728|OTHER|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
219172718|NCT04297280|DRUG|Sintilimab|a PD-1 immune check inhibitor
219172719|NCT04297280|COMBINATION_PRODUCT|TACE|TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
219172720|NCT06148519|DIAGNOSTIC_TEST|2WIN-S portable refractor|All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
219172721|NCT06316843|DRUG|Valacyclovir celecoxib dose 1|1500 mg valacyclovir 200 mg celecoxib taken two times a day
219172722|NCT06316843|DRUG|Valacyclovir celecoxib dose 2|750 mg valacyclovir 200 celecoxib mg taken two times a day
219172723|NCT06316843|DRUG|Placebo|Placebo capsules colored matched to investigational product taken two times a day
219172724|NCT06044987|PROCEDURE|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
219172725|NCT06044987|PROCEDURE|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
219172726|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
219172727|NCT06554587|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)|Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
219172728|NCT06237348|DEVICE|Simeox|Daily airway clearance therapy at home during 2 months
219172729|NCT06237348|COMBINATION_PRODUCT|Control|Daily airway clearance therapy at home during 2 months
219172730|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
219172731|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
219172732|NCT05445960|PROCEDURE|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
219172733|NCT05631262|DRUG|SKB264|Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
219172734|NCT05631262|DRUG|Docetaxel|Part II Control group will receive docetaxel monotherapy.
219172735|NCT06304831|BEHAVIORAL|Quality ratings of health care providers for children|Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
219172736|NCT05991414|DEVICE|Home blood pressure monitor|Participants provided home blood pressure monitor and instructions on use from pharmacist. They will measure home BP every 4-weeks for 7 days as per Hypertension Canada 7-day home BP protocol.
219244077|NCT04604899|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
219244078|NCT03689452|DEVICE|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
219244079|NCT03689452|DRUG|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
219244080|NCT03807947|PROCEDURE|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
219244081|NCT03807947|PROCEDURE|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
219244082|NCT04047303|DRUG|CC-90010|CC-90010
219244083|NCT05757063|OTHER|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
219244084|NCT05757063|OTHER|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
219244085|NCT01078051|PROCEDURE|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
219244086|NCT01078051|DRUG|optimal medical therapy|optimal medical therapy
219244087|NCT01383590|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
219739410|NCT03497117|DRUG|MRI with PFP|"* Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
219739411|NCT04213274|BIOLOGICAL|80 mg RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
219739412|NCT04213274|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
219739413|NCT05596240|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
219739414|NCT05596240|OTHER|Sham Dry Needling|Streitberger Placebo-needles (Asia-med, Las Vegas, NV) will be used to perform the intervention for participants in the sham DN group. These needles have been reported to be indistinguishable from real needles. The device consists of a plastic tube with a blunted tip needle that allows for the sensation of a prick without penetrating the skin. The sham needle produces a sensation, which causes the participant to feel as if the needle enters the skin, while maintaining similar patient-therapist contact time and total intervention time.
219172737|NCT05991414|PROCEDURE|Enhanced community pharmacist care|Pharmacist to follow up with participants every month to review home BP readings. Then the pharmacist will send home BP readings and recommendations for changes to antihypertensive medication regimen to participants prescribing clinician. Pharmacist will then advise participants to follow up with their prescribing clinician.
219172738|NCT05991414|PROCEDURE|Usual pharmacist care|Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
219172739|NCT06490796|BEHAVIORAL|Expanded diaphragm exercise|Individuals will be instructed in 360-degree expansive diaphragm exercises using the Ohmbelt device (Nilus Medical LLC, OHMBELT, Redwood City, CA, USA). Two Ohmbelt devices will be used in this study. The placement of the devices will be as described in the literature (14,23,24): The patient will be in a seated position with hips and knees flexed at 90 degrees, both feet supported on the ground, and sitting upright on a chair without back support. In this position, the Ohmbelt devices will be secured to the patient's body. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes
219172740|NCT06490796|BEHAVIORAL|Standard diaphragm exercise|Individuals in this group will be instructed in standard diaphragm exercises. They will be asked to lie on their backs with their heads and knees supported by pillows, and to close their eyes to focus before starting. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes.
219172741|NCT05708612|PROCEDURE|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
219172742|NCT04487847|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
219172743|NCT04990284|DRUG|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
219172744|NCT04990284|DRUG|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
219172745|NCT05448170|DRUG|Linerixibat|open label investigational product
219172746|NCT06190093|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
219172747|NCT06190093|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
219172748|NCT06096701|DEVICE|Blood pressure cuff|The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
219244088|NCT01964118|OTHER|Intermittent Fasting group|Intermittent fasting for 12 months
219172749|NCT05933265|DRUG|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
219172750|NCT05933265|DRUG|Spironolactone|A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.
219172751|NCT05933265|DRUG|Olaparib|A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.
219172752|NCT02729311|BEHAVIORAL|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
219172753|NCT02729311|BEHAVIORAL|Waitlist control|After engaging in usual activities for 12 weeks, the Waitlist control group participates in the Paired PLIÉ program.
219172754|NCT03842592|DIAGNOSTIC_TEST|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
219172755|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
219172756|NCT06194435|OTHER|Remote Monitoring of Participant Progress and Well-being via Video Calls|Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.
219172757|NCT06194435|OTHER|Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being|Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
219172758|NCT05450562|BIOLOGICAL|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
219172759|NCT05450562|BIOLOGICAL|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
219172760|NCT05177523|DIAGNOSTIC_TEST|MRI|Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
219172761|NCT05177523|OTHER|Neurocognitive examination for healthy subjects|Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
219172762|NCT05177523|OTHER|blood sampling|Each enrolled subject will undergo a blood sampling (10 ml) at baseline
219172763|NCT05493787|BEHAVIORAL|Reminder|Patient portal, SMS, email, and/or another modality
219172764|NCT06331403|BEHAVIORAL|Mind-Body Group Intervention|Weekly virtual group meetings with the study interventionist(s) and up to 9 other female cancer survivors over an approximately 6 week period. The group program includes topics related to coping with physical health changes, managing social factors relevant to sexual well-being, and managing thoughts and feelings related to sexual well-being changes.
219172765|NCT06679036|DRUG|HRS-2189|HRS-2189
219172766|NCT06679036|DRUG|Fluvustat|Fluvustat
219172767|NCT06679036|DRUG|HRS-8080|HRS-8080
219172768|NCT06679036|DRUG|HRS-6209|HRS-6209
219172769|NCT06679036|DRUG|HRS-1358|HRS-1358
219172770|NCT04783935|DRUG|Mavenclad®|No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
219172771|NCT01600222|DRUG|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
219172772|NCT04407338|DEVICE|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
219172773|NCT04407338|DEVICE|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
219172774|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (MDCK cells)|Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).
219172775|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (Chicken embryo)|Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).
219172776|NCT06342349|OTHER|Phosphate buffer solution|Phosphate buffer solution without vaccine antigen(0.5ml/dose).
219172777|NCT06636279|PROCEDURE|Gas bubble technique|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
219172778|NCT02639026|RADIATION|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
219172779|NCT02639026|DRUG|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
219172780|NCT02639026|DRUG|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
219172781|NCT05712746|DRUG|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
219172782|NCT06071065|BEHAVIORAL|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
219172783|NCT06678087|OTHER|motherhood preparation meditation training prepared with the thetahealing meditation method|"With Birth and Motherhood Preparation Meditation, all physiological and psychological reasons causing fear of birth will be addressed. How to do the meditation will be taught by the practitioner in the course.~The root belief analysis study for each topic is carried out with the questions of who, what, when, where, why and how. Then, the reprogramming work that allows the change of that belief, feeling, emotion will be done with methods specific to the technique.~The topics to be worked on during meditation each week are listed below. Each week, pregnant women will be given a 15-minute meditation homework per day until the next week regarding the topic worked on.~All meditations begin with relaxation and breathing exercises. In each meditation, the emotion and root-belief analysis related to the relevant topic will be done by the practitioner.~With this application, it is aimed to accelerate the change in the mind with positive language and regular repetition."
219244089|NCT01964118|OTHER|control group|usual diet for 6 months and intermittent fasting for other 6 months
219244090|NCT02704637|DEVICE|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
219244091|NCT05925751|DIAGNOSTIC_TEST|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
219244092|NCT00136851|DRUG|amlodipine besylate/benazepril hydrochloride|
219244093|NCT02676778|DRUG|E7777|
219244094|NCT04997408|DEVICE|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
219244095|NCT04997408|OTHER|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
219244096|NCT02879669|BIOLOGICAL|ONCOS-102|
219244097|NCT02879669|DRUG|Pemetrexed/cisplatin (carboplatin)|
219244098|NCT02879669|DRUG|Cyclophosphamide|
219244099|NCT03000829|OTHER|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
219244100|NCT03000829|OTHER|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
219244101|NCT02529735|OTHER|efficiency study|Blood pressure values measured for comparative lower limb and arm
219244102|NCT00732498|DRUG|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
219244103|NCT00732498|DRUG|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
219244104|NCT00732498|DRUG|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
219244105|NCT00732498|DRUG|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
219244106|NCT00732498|DRUG|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
219244107|NCT00732498|DRUG|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
219244108|NCT00732498|DRUG|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
219244109|NCT04904354|DEVICE|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
219244110|NCT04992494|BEHAVIORAL|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
219244111|NCT04992494|BEHAVIORAL|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
219244112|NCT04168437|OTHER|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
219244113|NCT01430299|DEVICE|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
219244114|NCT01430299|DEVICE|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
219244115|NCT03394508|DRUG|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
219244116|NCT03394508|DRUG|ALK diluent 0,3% human albumin|Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
219244117|NCT01288729|DEVICE|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
219244118|NCT01288729|DEVICE|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
219244119|NCT01107171|DRUG|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
219244120|NCT01107171|DRUG|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
219244121|NCT01107171|DRUG|Placebo|Tang-min-Ling pills analogue 6g,tid,po
219244122|NCT03214198|DRUG|Vonoprazan|Vonoprazan tablets
219244123|NCT03726528|DIAGNOSTIC_TEST|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
219244124|NCT06168994|DRUG|Eplerenone|Amiodarone vs eplerenone in AF
219739415|NCT04191733|DEVICE|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
219739416|NCT00288561|DRUG|ranibizumab|
219172784|NCT06678087|OTHER|pregnancy school,|"In the pregnancy school, an informational support training is provided to pregnant women and their families to ensure that the pre-pregnancy, pregnancy and birth process is passed in a healthy and conscious manner.~The training content includes:~Reproductive organs and development, Nutrition during pregnancy and puerperium, Common problems during pregnancy, Physiological changes, Non-formological methods, Breathing techniques during birth, Anesthetic methods, Birth methods and techniques, Postpartum and baby care, Newborn Care / Problems, Home-Bag-Hospital preparation, Breast milk - Its importance - Breastfeeding, Family planning topics are given five days a week for 2 hours."
219172785|NCT05728242|DIAGNOSTIC_TEST|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
219172786|NCT06321354|DRUG|The diprospan plus ropivacaine group|The local infiltration solution containing 0.5ml diprospan and 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
219172787|NCT06321354|DRUG|The ropivacaine group|The local infiltration solution containing 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
219172788|NCT04573725|DRUG|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
219172789|NCT04573725|DRUG|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
219172790|NCT04859725|DEVICE|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
219172791|NCT05275842|BEHAVIORAL|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
219172792|NCT05275842|BEHAVIORAL|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
219172793|NCT04419389|DRUG|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
219172794|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
219172795|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
219739417|NCT03308331|OTHER|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
219739418|NCT05579288|DRUG|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
219739419|NCT05579288|DRUG|Oxygen (O2)|Oxygen (O2) as placebo for control group
219739420|NCT02349477|DRUG|Gabapentin|gaba potentiating medication
219739421|NCT02349477|DRUG|Placebo|a pill that looks exactly like the active medication but does not contain medication
219739422|NCT00909688|DRUG|BLI-489|
219739423|NCT00909688|DRUG|placebo|
219172796|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT|APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
219172797|NCT04769206|DRUG|Galantamine|4mg daily titrating up to 8mg twice a day
219172798|NCT04769206|DRUG|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
219172799|NCT04769206|DEVICE|TENS 7000|The FDA-approved TENS 7000 device will be used for Trans-auricular vagus nerve stimulation (TaVNS) during a period of enhanced vascular oxidative stress. This device will be supplemented with ear clip electrodes. The site of the stimulation for such electrodes are the tragus or concha. The device will have built in safety controls to minimize additional risks to the subjects (as per FDA guidance on stimulators). We will use typical stimulation conditions (30 Hz, 300 µs) and amplitude dependent on perception threshold.
219172800|NCT06189066|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
219172801|NCT05020574|DRUG|Cephalexin|Given orally (PO)
219172802|NCT06074523|BEHAVIORAL|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
219172803|NCT02863718|DRUG|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
219172804|NCT02863718|DRUG|Placebo|Placebo 420mg daily
219172805|NCT05285826|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
219172806|NCT05285826|OTHER|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
219172807|NCT04829500|BEHAVIORAL|Montessori Approaches to Person-Centered Care (MAP-VA)|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities. Staff are also introduced to concrete strategies that improve dignity, control, and independence. MAP-VA is based on the work of Maria Montessori who demonstrated that a structured, supportive environment and meaningful, active roles in the classroom enabled children to fulfill their greatest potential physically, mentally, and emotionally. Montessori principles have been applied to dementia care for more than 20 years to promote functional independence, meaningful engagement, and dignity.
219172808|NCT04956861|BEHAVIORAL|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
219172809|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
219172810|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
219172811|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
219172812|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
219172813|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
219172814|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
219172815|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
219172816|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
219172817|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
219172818|NCT06822348|OTHER|Osteopathic treatment|Osteopathic manipulation
219172819|NCT06822348|BEHAVIORAL|Quality of life assessment|EORTC FA-12 questionnaire
219172820|NCT06822348|BEHAVIORAL|Anxiety assessment|STAI-Y-A and STAI-Y-B questionnaire assessment
219172821|NCT06822348|OTHER|Heart rate variability assessment|rMSSD (root mean square of successive R-R intervals), SDNN (standard deviation of all NN intervals), HF (high frequencies), LF (low frequencies), LF/HF ratio, Heart rate deceleration capacity, Heart rate acceleration capacity, Heart rate (bpm).
219172822|NCT06336304|DIAGNOSTIC_TEST|Urodynamic procedure|Urodynamic procedure
219172823|NCT04638309|DRUG|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
219244125|NCT02254200|OTHER|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
219739424|NCT04938843|DIETARY_SUPPLEMENT|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
219739425|NCT04938843|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
219739426|NCT02176759|OTHER|Administration of rice fortified with regular FePP|
219739427|NCT02176759|OTHER|Administration of rice fortified with regular FePP with citrate added during extrusion|
219739428|NCT02176759|OTHER|Administration of rice fortified with regular FePP and citrate added at consumption|
219739429|NCT02176759|OTHER|Administration of rice fortified with ferrous sulphate|
219739430|NCT03150641|PROCEDURE|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
219739431|NCT06499181|DRUG|Liposomal bupivacaine|The primary objective is to examine differences in post-operative opioid consumption between the two groups.
219739432|NCT06499181|DRUG|Bupivacain|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
219739433|NCT06499181|DRUG|Epinephrin|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
219739434|NCT01714063|DEVICE|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
219172824|NCT05337748|DEVICE|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
219244126|NCT02254200|OTHER|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
219244127|NCT02779972|OTHER|Echo stress test|Echo stress test
219244128|NCT02774876|DEVICE|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
219244129|NCT02774876|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
219739435|NCT01340534|DEVICE|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
219739436|NCT01340534|PROCEDURE|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
219739437|NCT02645370|DRUG|Danzhen|
219739438|NCT02645370|DRUG|Topiramate|
219739439|NCT02688166|OTHER|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
219739440|NCT02269774|PROCEDURE|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
219739441|NCT04964700|DRUG|Natalizumab|Monthly Infusions
219739442|NCT04090606|OTHER|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
219739443|NCT04090606|OTHER|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
219739444|NCT04090606|OTHER|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
219739445|NCT04411069|DRUG|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
219739446|NCT03660449|COMBINATION_PRODUCT|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
219739447|NCT00704834|OTHER|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
219739448|NCT01646216|BEHAVIORAL|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
219739449|NCT02587364|DRUG|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
219739450|NCT02587364|DRUG|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
219739451|NCT02587364|DRUG|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
219739452|NCT02587364|DRUG|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
219739453|NCT02587364|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
219739454|NCT02587364|DRUG|Placebo|Placebo once daily (QD)
219739455|NCT00773591|DRUG|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
219739456|NCT00461318|PROCEDURE|Individual placement and support (vocational rehabilitation)|
219739457|NCT02395627|DRUG|Tamoxifen|
219739458|NCT02395627|DRUG|Vorinostat|
219739459|NCT02395627|DRUG|Pembrolizumab|
219739460|NCT06311513|BIOLOGICAL|Concentrated Bone Marrow Aspirate Injection|Intraoperatively, bone marrow will be harvested from the iliac crest with a commercial kit, it will then be prepared via centrifugation and an injection of the resulting concentrated product (cBMA) will be administered in the operative knee. cBMA is an autologous biologic product.
219739461|NCT06311513|PROCEDURE|Sham Incision|A 2 mm sham incision will be made in the anatomical site where bone marrow would be harvested.
219739462|NCT06311513|PROCEDURE|Revision Anterior Cruciate Ligament Reconstruction|This is the standard-of-care surgical procedure.
219739463|NCT02492776|DRUG|Omeprazole|20 mg oral capsules administered once daily for 8 days
219739464|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
219739465|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
219739466|NCT06375772|DRUG|2-Deoxy-D-glucose|Intranasal administration
219739467|NCT06375772|OTHER|Placebo|Intranasal administration
219739468|NCT01903590|PROCEDURE|TVT surgery TOT surgery|
219172825|NCT05337748|DEVICE|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
219739469|NCT02953964|OTHER|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
219172826|NCT06426576|OTHER|Standard one-off instruction using a scale|"The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback."
219172827|NCT06426576|DEVICE|Plantar pressure insoles|The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
219172828|NCT04173637|BIOLOGICAL|AK101|an anti-IL-12/23p40 monoclonal antibody
219172829|NCT04173637|BIOLOGICAL|Placebo|matching placebo
219172830|NCT04148911|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
219172831|NCT04148911|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
219172832|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
219172833|NCT05918133|DRUG|PM8002|IV infusion
219172834|NCT05918133|DRUG|nab-paclitaxel|IV infusion
219172835|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
219172836|NCT06188286|OTHER|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
219172837|NCT06188286|OTHER|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
219172838|NCT05462613|OTHER|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
219172839|NCT05462613|PROCEDURE|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
219172840|NCT05462613|DRUG|Regorafenib|"\- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
219172841|NCT05462613|DRUG|Metronomic chemotherapies|"* Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months"
219172842|NCT05462613|DRUG|Aspirin|75 mg orally and daily during two months
219172843|NCT05462613|DRUG|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
219244130|NCT02774876|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
219362417|NCT06584409|OTHER|Observation|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
219172844|NCT05462613|DRUG|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
219172845|NCT06084338|RADIATION|stereotactic ablative radiotherapy|Metastasis directed
219172846|NCT06084338|DRUG|Pluvicto|PSMA targeted radiopharmaceutical therapy
219172847|NCT06084338|DRUG|topical testosterone|Topical testosterone 1.62% gel
219172848|NCT05390762|OTHER|Common phase|A common face to face day hospital combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.
219244131|NCT02774876|OTHER|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
219244132|NCT04552444|DRUG|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
219244133|NCT02966197|PROCEDURE|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
219244134|NCT02966197|DEVICE|Prophylactic internal iliac artery balloon|
219244135|NCT02966197|RADIATION|Radiology operation|
219244136|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
219244137|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
219244138|NCT00363090|BIOLOGICAL|alemtuzumab|
219244139|NCT00363090|DRUG|cyclophosphamide|
219244140|NCT00363090|DRUG|doxorubicin hydrochloride|
219244141|NCT00363090|DRUG|prednisone|
219244142|NCT00363090|DRUG|vincristine sulfate|
219244143|NCT00363090|OTHER|flow cytometry|
219244144|NCT00363090|OTHER|pharmacological study|
219244145|NCT03363009|DEVICE|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
219244146|NCT03363009|DEVICE|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
219244147|NCT03401099|PROCEDURE|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
219244148|NCT03401099|PROCEDURE|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
219244149|NCT02395406|DEVICE|Orotracheal intubation with Totaltrack|
219739470|NCT02953964|OTHER|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
219244150|NCT02395406|DEVICE|Orotracheal intubation with Airtraq|
219244151|NCT04650763|BIOLOGICAL|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
219244152|NCT04650763|DEVICE|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
219362418|NCT01097928|PROCEDURE|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
219362419|NCT05946772|DRUG|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
219244153|NCT06428799|DEVICE|Carebot AI MMG|"Carebot AI MMG is a software solution that utilizes artificial intelligence methods, specifically deep learning and computer vision algorithms, to evaluate and localize suspicious regions of potential lesions during the interpretation of digital breast x-rays as part of standard mammography screening procedures. The Carebot AI MMG medical device is not intended for use in diagnostic mammography. The Carebot AI MMG is intended for use in women over the age of 18.~The predictive outputs of the Carebot AI MMG medical device are intended to aid decision-making in screening clinical practice, always in conjunction with other relevant patient information and based on the professional judgment of the examining clinician. The Carebot AI MMG is specifically designed to provide a supporting layer of analysis that helps in evaluating or prioritizing mammography images with additional patient information and the professional judgment of the examining physician."
219244154|NCT04246099|OTHER|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
219244155|NCT02154893|DEVICE|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
219244156|NCT02154893|DEVICE|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
219244157|NCT02154893|DEVICE|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
219244158|NCT04295499|DEVICE|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
219244159|NCT03813602|DRUG|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
219244160|NCT05815459|DEVICE|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
219244161|NCT03122548|BIOLOGICAL|CRS-207|Administered by IV infusion over 1 hour.
219244162|NCT03122548|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over 30 minutes.
219244163|NCT03600207|OTHER|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
219244164|NCT03600207|OTHER|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
219244165|NCT02409407|DRUG|Misoprostol , Prostaglandins E1 analogue|
219244166|NCT06147115|OTHER|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
219244167|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
219739471|NCT02953964|OTHER|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
219739472|NCT06305858|PROCEDURE|Prosthetic Surgical Procedure|"The population consists of 48 patients divided into two groups:~24 patients Group A experimental group: partial denture surgical procedure~24 patients Group B control group: total denture surgical procedure with patellar resurfacing"
219739473|NCT04768478|DRUG|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
219739474|NCT04768478|DRUG|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
219739475|NCT04462250|DEVICE|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
219739476|NCT05615350|OTHER|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
219739477|NCT05615350|OTHER|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
219739478|NCT02633527|DRUG|Placebo|Placebo was administered once daily
219739479|NCT02633527|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
219739480|NCT02633527|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
219739481|NCT02633527|DRUG|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
219739482|NCT02633527|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
219739483|NCT01323543|DEVICE|Elaspine™|Implantation of device
219739484|NCT03615274|DEVICE|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
219739485|NCT03615274|OTHER|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
219244168|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
219244169|NCT06200818|PROCEDURE|Diode laser|
219244170|NCT06200818|PROCEDURE|Er:CrYSGG|
219739486|NCT03615274|DEVICE|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
219739487|NCT06475495|DRUG|KYV101|an autologous fully-human anti-CD19 CAR T-cell immunotherapy
219739488|NCT06475495|DRUG|Rituximab (active comparator)|anti CD20 monoclonal antibody
219739489|NCT05250557|DIAGNOSTIC_TEST|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
219739490|NCT01992081|DEVICE|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
219739491|NCT01992081|OTHER|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
219739492|NCT04254250|DIAGNOSTIC_TEST|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
219739493|NCT06125301|DEVICE|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
219739494|NCT01681849|DRUG|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
219739495|NCT01681849|DRUG|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
219739496|NCT01681849|OTHER|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
219739497|NCT04074837|DRUG|NNI-362|NNI-362 small molecule in liquid suspension.
219739498|NCT04074837|DRUG|Placebo|Placebo liquid suspension
219739499|NCT02957019|DRUG|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
219739500|NCT02957019|DRUG|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
219739501|NCT02957019|DRUG|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
219739502|NCT03948620|DRUG|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
219172849|NCT05390762|OTHER|Telecare rehabilitation|A Second phase of 5 weeks of telecare rehabilitation of the reconditioning type of 15 sessions.
219172850|NCT05390762|OTHER|Care in Face to Face|A Second phase of 5 weeks of care in face to face day hospital of the reconditioning type of 15 sessions.
219172851|NCT06071884|DEVICE|Bridge Percutaneous Nerve Field Stimulator|The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
219172852|NCT05672225|DRUG|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
219172853|NCT05672225|DRUG|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
219172854|NCT04806594|DEVICE|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
219172855|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
219172856|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
219172857|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
219172858|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219172859|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
219172860|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
219172861|NCT02312557|DRUG|Enzalutamide|Given PO
219172862|NCT02312557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219172863|NCT02312557|BIOLOGICAL|Pembrolizumab|Given IV
219172864|NCT02038569|DRUG|LEO 80185 gel|
219244171|NCT06200818|PROCEDURE|Formocresol|
219739503|NCT03948620|DRUG|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
219739504|NCT02852005|BIOLOGICAL|MVA/HIV62B vaccine|1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
219739505|NCT02852005|BIOLOGICAL|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
219739506|NCT02852005|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
219739507|NCT00962338|BEHAVIORAL|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
219172865|NCT06332352|BIOLOGICAL|PRP|Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
219172866|NCT05761756|BEHAVIORAL|Sleep Deprivation|24 hours sleep deprivation
219172867|NCT05761756|DRUG|Caffeine|Oral administration of caffeine
219172868|NCT05761756|DRUG|Methylphenidate|Oral administration of methylphenidate
219172869|NCT05761756|DRUG|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
219172870|NCT04418479|DRUG|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
219172871|NCT04418479|DRUG|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
219172872|NCT04876222|PROCEDURE|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
219172873|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
219172874|NCT05655325|OTHER|Attention control|Health education and stretching
219172875|NCT05886335|DRUG|Cyclophosphamide|Time of administration
219172876|NCT04747431|DRUG|PBFT02|PBFT02
219172877|NCT05919680|DRUG|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
219172878|NCT05919680|DRUG|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
219172879|NCT05919680|OTHER|Matched Placebo|Matched placebo for administration in Part A or Part B
219172880|NCT06123299|DEVICE|pHyph|vaginal tablet
219172881|NCT04882449|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
219172882|NCT06431295|DEVICE|FaceScan|"Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing."
219172883|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
219172884|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
219172885|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
219172886|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
219172887|NCT05607108|DRUG|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
219172888|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
219172889|NCT06161688|DRUG|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
219172890|NCT06161688|OTHER|Placebo|Matching placebo for Ensitrelvir
219172891|NCT04064086|OTHER|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
219244172|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
219244173|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
219244174|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
219244175|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
219244176|NCT01381198|PROCEDURE|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
219244177|NCT01946256|DRUG|Amoxicillin|
219244178|NCT01946256|DRUG|Erythromycin|
219244179|NCT02995447|OTHER|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
219244180|NCT02569294|BEHAVIORAL|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
219244181|NCT02569294|BEHAVIORAL|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
219244182|NCT02569294|BEHAVIORAL|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
219244183|NCT05977985|DRUG|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
219244184|NCT05977985|DRUG|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
219244185|NCT02871245|PROCEDURE|Laparoscopic Surgery|
219244186|NCT02871245|DEVICE|Acupuncture treatment|
219244187|NCT02815800|DIETARY_SUPPLEMENT|ETHNODYNE VISIO|
219739508|NCT06569511|DIAGNOSTIC_TEST|N-terminal pro-B-type natriuretic peptide (NT-proBNP)|In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
219739509|NCT06569511|DIAGNOSTIC_TEST|high sensitive cardiac troponin T (hs-cTnT)|In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
219739510|NCT06569849|OTHER|De-Stress and Focus capsule- U001|Two capsules in sequence daily after meal for 60 days.
219739511|NCT06569849|OTHER|De-Stress and Focus capsule - I001|Two capsules in sequence daily after meal for 60 days.
219739512|NCT06569849|OTHER|Placebo capsules 001|Two capsules in sequence daily after meal for 60 days.
219739513|NCT06113614|PROCEDURE|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
219739514|NCT06113614|DEVICE|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
219739515|NCT06113614|DEVICE|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
219739516|NCT03295786|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
219739517|NCT03295786|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
219172892|NCT04064086|OTHER|Provision of the freely available resources for Kidney Disease Education|freely available resources
219172893|NCT05309629|DRUG|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
219172894|NCT05309629|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
219172895|NCT05309629|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
219172896|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
219172897|NCT04791709|BEHAVIORAL|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
219172898|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
219172899|NCT04371913|RADIATION|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
219172900|NCT06582199|OTHER|Blood sample|Plasma, DNA, RNA and PBMC Sampling
219172901|NCT06582199|BEHAVIORAL|Neuropsychological battery tests|"* Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)"
219172902|NCT05932134|DIETARY_SUPPLEMENT|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
219172903|NCT05932134|BEHAVIORAL|UC + HP + core muscle rehabilitation|Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks
219172904|NCT05932134|DEVICE|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
219172905|NCT05618002|DRUG|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
219172906|NCT05142982|RADIATION|Radiotherapy|A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
219172907|NCT05816473|OTHER|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
219172908|NCT06225479|BEHAVIORAL|Exercise|"An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session)."
219244188|NCT05681611|DRUG|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
219244189|NCT06290453|DIAGNOSTIC_TEST|micro RNA 27- FLP1 gene expression|"From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined"
219244190|NCT06290453|DIAGNOSTIC_TEST|The Expanded Disability Status Scale (EDSS)|"The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients."
219244191|NCT06290453|DIAGNOSTIC_TEST|Electrophysiological assessment:|Electromyography and nerve conduction velocity will be performed for all MS patients.
219244192|NCT06290453|DIAGNOSTIC_TEST|MRI examination MRI brain:|will be done on all MS patients to detect the number, the site, and the enhancement of lesions
219244193|NCT06359483|OTHER|Meal Frequency Manipulation|The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
219244194|NCT03854032|BIOLOGICAL|Nivolumab|Given IV
219244195|NCT03854032|BIOLOGICAL|IDO1 Inhibitor BMS-986205|Given PO
219244196|NCT03854032|PROCEDURE|Therapeutic Conventional Surgery|Undergo Surgery
219244197|NCT03854032|OTHER|Questionnaire Administration|Ancillary studies
219244198|NCT06656663|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
219244199|NCT06656663|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
219244200|NCT06592664|DRUG|certepetide|certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
219244201|NCT06592664|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
219244202|NCT06592664|DRUG|gemcitabine|gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
219244203|NCT06592664|DRUG|placebo matching certepetide|placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
219244204|NCT06592664|DRUG|certepetide|certepetide given as two IV pushes over 1 minute when standard treatment(s) are given
219244205|NCT06592664|DRUG|placebo matching certepetide|placebo given as an IV infusion over 4 hours when standard treatment(s) are given
219244206|NCT06592664|DRUG|placebo matching certepetide|certepetide given as a slow IV push over 1 minute when standard treatment(s) are given
219244207|NCT06596915|DRUG|BA1302|BA1302 administered intravenously
219244208|NCT06600204|OTHER|lung scintigraphy|Use the SPECT/CT to predict pulmonary function
219244209|NCT05347849|DRUG|BPL-003|A single dose of BPL-003 will be administered intranasally
219244210|NCT05347849|OTHER|Placebo|A single dose of placebo will be administered intranasally
219244211|NCT06034145|OTHER|No intervention|No intervention
219244212|NCT00955097|DRUG|Definity®|Definity® injections given both pre-ablation and post-ablation
219244213|NCT05172648|OTHER|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
219244214|NCT05172648|OTHER|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
219362420|NCT05946772|DRUG|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
219362421|NCT02249741|DRUG|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
219172909|NCT06225479|OTHER|Calls and Newsletter|"A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications."
219172910|NCT05452304|BIOLOGICAL|AZD7798|Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
219172911|NCT05452304|BIOLOGICAL|Placebo|Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
219172912|NCT06581146|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
219172913|NCT06510868|RADIATION|Peptide receptor radionuclide therapy (PRRT)|Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
219172914|NCT06510868|DIAGNOSTIC_TEST|Blood collection|Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
219172915|NCT05950594|RADIATION|Radiotherapy|Standard of care pre-operative radiotherapy
219172916|NCT05950594|OTHER|Surgery|Standard of care definitive surgery
219172917|NCT05781243|DRUG|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
219172918|NCT05781243|DRUG|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
219172919|NCT04442763|DEVICE|Densah Burs|osseodensification method
219172920|NCT04442763|DEVICE|Standard drills|conventional drilling
219172921|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
219172922|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
219172923|NCT02240472|PROCEDURE|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
219172924|NCT03436745|DRUG|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr pharmacokinetic (PK) evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
219172925|NCT03436745|DIAGNOSTIC_TEST|ECG|Screening and baseline.
219172926|NCT05154487|DRUG|Alpelisib Pill|Kinase inhibitor
219172927|NCT05154487|DRUG|Fulvestrant injection|estrogen receptor agonist
219172928|NCT03947216|DRUG|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
219172929|NCT03947216|DRUG|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
219172930|NCT03947216|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
219172931|NCT03947216|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
219172932|NCT03947216|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
219172933|NCT03947216|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
219172934|NCT03947216|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
219172935|NCT03947216|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
219172936|NCT03947216|PROCEDURE|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
219172937|NCT03947216|PROCEDURE|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
219172938|NCT05145569|DRUG|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
219172939|NCT05145569|DRUG|HCW9218|HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
219172940|NCT03661840|BEHAVIORAL|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
219172941|NCT03661840|OTHER|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
219172942|NCT05754333|DRUG|pudexacianinium chloride|Intravenous
219172943|NCT04863430|DRUG|Apatinib|500mg oral qd
219172944|NCT04863430|DRUG|Oxaliplatin|130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
219172945|NCT04863430|DRUG|S1|According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
219172946|NCT05147519|BEHAVIORAL|Novel interventions to achieve HIV remission|To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
219172947|NCT06209203|DRUG|lowe-dose ZKY001 eye drops|eye drops
219172948|NCT06209203|DRUG|Medium-dose ZKY001 eye drops|eye drops
219172949|NCT06209203|DRUG|placebo|eye drops
219172950|NCT06133517|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
219739518|NCT04135443|BEHAVIORAL|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
219739519|NCT04135443|BEHAVIORAL|General Health Materials Website|The control group will receive access to a website containing general health promotion materials.
219739520|NCT05979818|DRUG|Propranolol hydrochloride|10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
219739521|NCT05979818|DRUG|Sintilimab|intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
219739522|NCT05979818|DRUG|Chemotherapy|"Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent."
219739523|NCT00070083|BIOLOGICAL|oblimersen sodium|
219739524|NCT00070083|BIOLOGICAL|rituximab|
219739525|NCT00070083|DRUG|cyclophosphamide|
219739526|NCT00070083|DRUG|doxorubicin hydrochloride|
219739527|NCT00070083|DRUG|prednisone|
219739528|NCT00070083|DRUG|vincristine sulfate|
219739529|NCT02420314|DRUG|Paclitaxel|"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
219739530|NCT02420314|DRUG|Carboplatin|"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
219739531|NCT02420314|DRUG|Ascorbic Acid|"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"
219739532|NCT04797884|DEVICE|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
219739533|NCT04797884|DEVICE|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
219739534|NCT04797884|DEVICE|Quality of Life Assessment|Ancillary services
219739535|NCT05584566|DEVICE|OSSIX Breeze|barrier membrane
219739536|NCT05584566|DEVICE|Jason membrane|barrier membrane
219739537|NCT05370209|DEVICE|Otinova® Ear Spray|Ear spray
219739538|NCT03760068|DRUG|MYL-1601D Product|(100 U/mL)
219739539|NCT03760068|DRUG|FlexPen NovoLog®|(100 U/mL)
219739540|NCT01057940|PROCEDURE|DBE PEJ placement|One time procedure with follow-up telephone call.
219739541|NCT03856177|BEHAVIORAL|Emotion Induction|Described in arm
219739542|NCT06195111|DRUG|Trifluridine/Tipiracil|This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
219739543|NCT04262427|DRUG|Cyclophosphamide 50mg|cytotoxic chemotherapy
219739544|NCT04262427|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
219739545|NCT05410795|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
219739546|NCT05062772|DIAGNOSTIC_TEST|Ultrasound|Intraoperative ultrasound imaging
219739547|NCT03172559|RADIATION|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
219739548|NCT00846482|DRUG|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
219739549|NCT02088580|PROCEDURE|Triple Chronotherapy|
219739550|NCT04037644|PROCEDURE|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
219739551|NCT04037644|PROCEDURE|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
219739552|NCT04913090|DRUG|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
219739553|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
219739554|NCT04913090|DRUG|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
219739555|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
219739556|NCT04913090|DRUG|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
219739557|NCT04913090|DRUG|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
219739558|NCT01906138|DEVICE|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
219172951|NCT06133517|DRUG|Zimberelimab|ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
219172952|NCT06133517|DRUG|Domvanalimab|DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
219172953|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
219172954|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
219172955|NCT06430021|BIOLOGICAL|blood sample|8 mL blood sample in EDTA tube
219172956|NCT06424483|BEHAVIORAL|Awareness, Courage, and Love Group Psychotherapy|Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
219172957|NCT06002789|DRUG|MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
219172958|NCT06002789|DRUG|All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy|For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
219172959|NCT04672889|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 1 months
219739559|NCT03460704|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
219739560|NCT03460704|OTHER|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
219739561|NCT01978301|DRUG|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
219739562|NCT01978301|DRUG|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
219739563|NCT02644057|DRUG|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
219739564|NCT02644057|DRUG|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
219739565|NCT05904379|DRUG|AK112|Subjects receive AK112 intravenously.
219739566|NCT05904379|DRUG|AK104|Subjects receive AK104 intravenously.
219739567|NCT05904379|DRUG|Carboplatin|Subjects receive carboplatin intravenously.
219739568|NCT05904379|DRUG|paclitaxel|Subjects receive paclitaxel intravenously.
219739569|NCT05904379|DRUG|pemetrexed|Subjects receive pemetrexed intravenously.
219739570|NCT05904379|DRUG|Docetaxel|Subjects receive docetaxel intravenously.
219739571|NCT00760305|BEHAVIORAL|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
219739572|NCT03888287|DEVICE|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
219739573|NCT03888287|OTHER|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
219739574|NCT05902975|DEVICE|Fiber reinforced composite resin space maintainer|Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
219739575|NCT04160598|DRUG|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
219739576|NCT04160598|DRUG|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
219739577|NCT02913326|DRUG|Dabigatran etexilate|
219739578|NCT02913326|DRUG|Warfarin|
219739579|NCT05600257|DEVICE|DBT|Image with digital breast tomosynthesis
219739580|NCT05600257|DEVICE|DM|Image with digital mammography
219739581|NCT00002515|BIOLOGICAL|filgrastim|
219739582|NCT00002515|DRUG|carboplatin|
219739583|NCT00002515|DRUG|thiotepa|
219739584|NCT00002515|DRUG|topotecan hydrochloride|
219739585|NCT00002515|PROCEDURE|autologous bone marrow transplantation|
219739586|NCT00002515|PROCEDURE|bone marrow ablation with stem cell support|
219739587|NCT00002515|PROCEDURE|in vitro-treated bone marrow transplantation|
219739588|NCT01767857|DRUG|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
219244215|NCT05746026|BEHAVIORAL|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~* Session 1: introduction and basic information about Climate Change~* Session 2: causes and factors that contribute to climate change by humans and nature~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
219244216|NCT02854982|PROCEDURE|therapeutic management of the prostate Cancer as usual|
219244217|NCT03346590|BEHAVIORAL|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
219244218|NCT04187378|DEVICE|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
219244219|NCT04187378|DEVICE|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
219244220|NCT00794274|DRUG|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
219244221|NCT02135445|DRUG|TAK-385|TAK-385 tablet
219244222|NCT02135445|DRUG|Degarelix|Degarelix injection
219244223|NCT06277206|DIAGNOSTIC_TEST|18F-FAPI PET/CT|Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.
219244224|NCT05816798|DEVICE|Photobiomodulation|PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.
219244225|NCT05816798|OTHER|Standard Physiotherapy Tretament|standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
219244226|NCT05816798|DEVICE|Photobiomodulation Placebo|The same interventions described of Photobiomodulation Group bu device will be turned off
219244227|NCT06985433|DEVICE|Vaginal light therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
219244228|NCT06985433|DEVICE|Vaginal Light Therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
219244229|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
219244230|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
219244231|NCT06232395|DIAGNOSTIC_TEST|DNA test|circulating DNA test
219244232|NCT06598774|OTHER|Assessment of head posture:|Head posture was assessed using photographic methods and craniovertebral angle
219244233|NCT06598774|OTHER|Assessment of Cervical Pain Pressure Threshold|The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
219244234|NCT06598774|OTHER|Assessment of general cervical mobility|Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
219244235|NCT06598774|OTHER|Assessment of upper cervical mobility|It will be assessed using the CROM device and the flexion-rotation test.
219244236|NCT06598774|OTHER|Assessment of Body Awareness|Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
219244237|NCT06037057|OTHER|no intervention name|no intervention description
219244238|NCT01533194|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219244239|NCT01533194|BIOLOGICAL|Wild-type Reovirus|Given IV
219244240|NCT00635609|DRUG|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
219244241|NCT00635609|DRUG|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
219244242|NCT03028961|OTHER|Stanford Letter|Receive and complete the Stanford Letter
219244243|NCT03028961|OTHER|Interview|Undergo semi-structured, research staff-led interview
219244244|NCT03028961|OTHER|Questionnaire Administration|Ancillary studies
219244245|NCT03028961|OTHER|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
219244246|NCT05771688|DEVICE|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
219244247|NCT02646098|PROCEDURE|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
219244248|NCT01795313|BIOLOGICAL|HLA-A2 restricted synthetic tumor antigen|
219739589|NCT01767857|DRUG|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
219244249|NCT01795313|DRUG|Imiquimod|
219739590|NCT02909257|DRUG|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
219244250|NCT01795313|OTHER|enzyme-linked immunosorbent assay|
219244251|NCT01795313|OTHER|flow cytometry|
219244252|NCT01795313|OTHER|immunohistochemistry staining method|
219739591|NCT02909257|DRUG|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
219244253|NCT01795313|OTHER|laboratory biomarker analysis|
219244254|NCT06989866|DRUG|Bupivacaine|Bupivicaine injection post operatively
219244255|NCT06989866|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline injected to control group
219739592|NCT00619398|DRUG|Prograf|Oral
219244256|NCT06598891|PROCEDURE|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
219244257|NCT06598891|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
219244258|NCT06913777|DRUG|Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib|The backbone is chemotherapy which will be used in the control group. The precision group will add targeted therapy agents which were determined according to SNF classification: the SNF2 subtype add adebrelimab combined with famitinib, the SNF3 subtype receives fluzoparib, and the SNF4 subtype receives apatinib.
219244259|NCT06913777|DRUG|Chemotherapy (wP-EC)|Chemotherapy : weely nab-P \* 12- EC \* 4
219244260|NCT00555932|PROCEDURE|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
219244261|NCT06994611|PROCEDURE|MOSE application|The length of the tissue strips was judged using the specimen table and photographed for record. If the MVC of the first needle sample was ≥10mm, the tissue strip was placed into bottle A formalin for fixation. A second needle of tissue strip was pushed directly into the B-bottle formalin. If the first needle sample MVC was \< 10mm, the puncture was continued until the total length of sample MVC was ≥10mm, and all samples were placed into bottle A formalin.
219244262|NCT06994611|PROCEDURE|Conventional processing|Two needles were punctured and all tissue strips were placed into bottle A formalin.
219244263|NCT05913609|DEVICE|Yaari Extractor|The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
219244264|NCT03991416|BEHAVIORAL|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
219244265|NCT03991416|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
219739593|NCT00619398|DRUG|FK506MR capsule|Oral
219739594|NCT02792946|DRUG|Acebrophylline|
219739595|NCT03138382|DEVICE|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
219739596|NCT03138382|DEVICE|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
219739597|NCT06468553|BEHAVIORAL|Prediabetes Care Program|Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
219739598|NCT03016702|OTHER|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
219739599|NCT03016702|OTHER|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
219739600|NCT00003680|DRUG|CMF regimen|
219739601|NCT00003680|DRUG|cyclophosphamide|
219739602|NCT00003680|DRUG|fluorouracil|
219739603|NCT00003680|DRUG|methotrexate|
219739604|NCT00003680|DRUG|tamoxifen citrate|
219739605|NCT00003680|DRUG|thiotepa|
219739606|NCT00003680|PROCEDURE|peripheral blood stem cell transplantation|
219739607|NCT00003680|RADIATION|radiation therapy|
219739608|NCT05208957|OTHER|No intervention|No intervention
219739609|NCT03184025|OTHER|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
219739610|NCT05438771|COMBINATION_PRODUCT|Ankaferd Blood Stopper|mouth wash
219739611|NCT05438771|OTHER|Bicarbonate|mouth wash
219739612|NCT03800901|OTHER|Continuing Medical Education|CME or ABIM MOC credits
219739613|NCT03800901|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
219739614|NCT04526457|OTHER|Standard of Care|Randomized to standard of care with lipid testing only.
219739615|NCT04526457|OTHER|Genetic Testing|Randomized to genetic testing.
219739616|NCT04938531|OTHER|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
219739617|NCT03635879|OTHER|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
219739618|NCT03635879|OTHER|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
219739619|NCT03635879|OTHER|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
219172960|NCT04672889|DIETARY_SUPPLEMENT|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
219172961|NCT01969539|DRUG|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
219244266|NCT01754389|DRUG|Tacrolimus|
219244267|NCT01754389|DRUG|Methotrexate|
219244268|NCT01754389|DRUG|Bortezomib|
219244269|NCT01754389|DRUG|Sirolimus|
219739620|NCT03635879|OTHER|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
219739621|NCT03635879|OTHER|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
219739622|NCT03635879|DRUG|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
219739623|NCT00214526|PROCEDURE|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
219739624|NCT00214526|DRUG|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
219739625|NCT03288259|PROCEDURE|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
219739626|NCT03288259|DRUG|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
219739627|NCT04681313|PROCEDURE|High-risk percutaneous coronary intervention|Percutaneous coronary interventions (PCI) deemed high risk based on patient-related risk features, hemodynamic criteria, clinical presentation and complexity of coronary anatomy.
219739628|NCT03784300|DRUG|50 mg PTI-125|PTI-125 50 mg Oral Solution
219739629|NCT03784300|DRUG|100 mg PTI-125|PTI-125 100 mg Oral Solution
219172962|NCT01969539|DRUG|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
219172963|NCT06777459|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Nitrate-rich beetroot juice, \~750 mg NO3- /d
219172964|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
219172965|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
219172966|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
219739630|NCT03784300|DRUG|200 mg PTI-125|PTI-125 200 mg Oral Solution
219739631|NCT06523816|DIAGNOSTIC_TEST|dermoscopy|Dermoscopy is a fast imaging technique that allows an excellent visualization of non-melanocytic skin tumors to diagnose them without invasive interventon.
219739632|NCT05196724|BEHAVIORAL|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family \[41\].
219172967|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
219172968|NCT05470517|DRUG|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
219172969|NCT05470517|PROCEDURE|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
219172970|NCT06776224|OTHER|Measurement of retinal vascular density and visual cognition|During the same visit, we will perform OCT-angiography (10 minutes) and evaluate visual cognition with an eye-tracker (20 minutes)
219739633|NCT05196724|BEHAVIORAL|Usual care|The control group will receive the usual care offered to foster families such as supervision
219739634|NCT06358703|DRUG|Caplacizumab|Early Caplacizumab use
219739635|NCT02739880|DEVICE|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
219739636|NCT04467853|BIOLOGICAL|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
219739637|NCT05756556|COMBINATION_PRODUCT|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
219739638|NCT03241420|DEVICE|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
219739639|NCT01162785|DRUG|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
219244270|NCT07004036|BEHAVIORAL|Occupation-based Self-Regulation Intervention Program|The intervention includes both group and individual applications. It has a large occupation/activity pool that can be selected in a person-centered manner. The activities are focused on supporting and developing the areas of influence in the sensory processing skills of individuals or the areas in executive functions, and providing occupations that will replace the screen and shape life in children for the screen abuse. It shapes the will, habits and routines necessary for the child to prefer alternative activities instead of the screen. For this purpose, an intervention program has been shaped to ensure that the child gains in the areas of daily life activities, productivity activities and leisure activities with the right developing skills, the child's wishes, the family's wishes, social expectations. As far as we know, it is the first flood regulation intervention program applied to children with screen addiction from an occupational therapy perspective.
219244271|NCT07004036|BEHAVIORAL|Family Awareness Training|Family awareness training on the harms of screen addiction and prolonged exposure to the screen, as a one-time event.
219244272|NCT04448561|DRUG|ASP8082|oral
219244273|NCT04448561|DRUG|morphine|oral
219244274|NCT04448561|DRUG|Placebo|oral
219244275|NCT07008729|DEVICE|Heart monitoring tools (data revision)|data collected by the devices will be reviewed by the treating physician in the intervention group
219244276|NCT07008729|OTHER|Control (Standard treatment)|Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations
219244277|NCT07008573|OTHER|probiotics in soybean concentrate|treatment with topical probiotics on DFU
219244278|NCT07008651|BEHAVIORAL|Digital parenting education|"Description: The digital parenting training to be given to mothers consists of 8 sessions of 20 minutes each. In the first week of the training process, a meeting will be held with the mothers in the experimental group and a brief introduction will be made to the subject. In the second week, information will be provided on the following topics: Definition and Roles of Digital Parenting, How Does the Use of Information Technologies Affect the Parent-Child Relationship?, How Does the Use of Information Technologies Affect Children's Behavior?, How Should Social Media Be Used Properly?, What are the Opportunities and Risks of Information Technologies for Parents and Children?, and What Should Parents Pay Attention to in the Use of Information Technologies? in the sixth week. In the eighth week, Question and Answer/Closing will be conducted to collect post-test data and end the training session."
219244279|NCT07008937|OTHER|Balneotherapy|"For balneotherapy, patients will be treated in a thermal pool for 15-20 minutes daily, with full-body immersion, for a total of 15 days.~For control, Volunteers in the control group will only receive a home exercise program. They will be called in for a check-up every five days to confirm that the home program is being followed correctly. In this way, the volunteers in the control group will not be left completely without treatment."
219244280|NCT07008937|OTHER|home exercise program|home exercise program
219244281|NCT07007754|PROCEDURE|Voice recording playback|Voice recordings were created from a text containing 12 standardised messages common to both the patient's relatives and the researcher and expert opinion was obtained in terms of the applicability of the created text. Before the intervention, the postoperative patient's suitability was determined by the patient's statement and the researcher's observations. No intervention was performed if the patient had nausea/vomiting, pain or agitation before the intervention. Kingboss 8 Gb+ 650 hours uninterrupted digital voice recorder and headphones were used for voice recording. When the voice recorder and headphones were to be used in a different patient, they were wiped with 70% alcohol and used after waiting for 2 minutes in accordance with the manufacturer's instructions. The voice of one of the family members was recorded for Intervention group-1 patients and the voice of one of the researchers was (nötr voice) recorded for intervention group-2.
219739640|NCT06268678|OTHER|Phase of the menstrual cycle|Follicular or luteal phase
219739641|NCT01433861|PROCEDURE|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
219739642|NCT05392751|DRUG|EA-2353|EA-2353 Ophthalmic Suspension
219739643|NCT05930444|DIAGNOSTIC_TEST|Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases|Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
219739644|NCT06563076|OTHER|Vestibular Rehabilitation|supervised vestibular rehabilitation program
219739645|NCT06563076|OTHER|Vestibular Electrical Stimulation|80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
219739646|NCT06144853|OTHER|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
219739647|NCT06132308|PROCEDURE|PENG Block with 0.25% bupivacaine|Peng block was performed.
219244282|NCT07008300|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
219244283|NCT07008833|PROCEDURE|Radiochemotherapy|Maximum TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m². After 2-6 weeks of neoadjuvant chemotherapy, patients will receive radiotherapy for 4 weeks, with concomitant cisplatin at a dose of 40 mg/m² weekly.
219244284|NCT07008833|PROCEDURE|Radical cystectomy|TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m², followed by radical cystectomy, bilateral pelvic lymphadenectomy, and reconstruction with either a Bricker procedure or a neobladder.
219244285|NCT07009054|BEHAVIORAL|Nutrition Education and Exercise|A 6-week intensive randomized controlled trial will be conducted with a total of 60 participants. Thirty participants will be assigned to the intervention group and thirty to the control group through simple randomization using a table of random numbers. The intervention group will receive one weekly theoretical-practical nutrition education session in Urdu and one physical activity session based on Nordic walking per week, for a total of six nutrition sessions and six physical activity sessions over the 6-week period.
219244286|NCT07009054|BEHAVIORAL|Usual Care Group|The control group will participate in 2 theoretical sessions of nutrition education and 2 of physical exercise.
219244287|NCT07008066|OTHER|Bicycle ergometer excercise|Patients will undergo a symptom-limited ergometer cycling test under medical supervision. If the atrial fibrillation is not converted to sinus rhythm during the exercise test, the patients will be electrically converted.
219244288|NCT07008066|PROCEDURE|Standard care with electrical cardioversion|Standard care with planned electrical cardioversion without exercise intervention.
219244289|NCT07009249|BEHAVIORAL|Pelvic floor muscle training|"Women in this group will undergo pelvic floor muscle training (PFMT) using the NeuroTrac MyoPlus 4 PRO EMG biofeedback device. Prior to the training, diaphragmatic breathing will be taught to all participants in this position to facilitate relaxation and prepare for PFMT. During the training, participants will perform pelvic floor muscle contractions while observing the real-time feedback of slow and fast contractions, as well as relaxation phases, on the computer screen connected to the device. Concurrently, the physiotherapist will guide the participants with verbal cues such as squeeze-lift-release. Participants will be instructed to avoid holding their breath, pulling in their abdomen, straining, contracting the thigh or gluteal muscles, or moving the pelvis during the exercises. The PFMT protocol will follow the principles of motor learning stages to ensure proper skill acquisition."
219244290|NCT07009249|BEHAVIORAL|Dynamic neuromuscular stabilization|Women in this group will be instructed in exercises based on the principles of Dynamic Neuromuscular Stabilization (DNS). Prior to the exercises, intra-abdominal pressure regulation through breathing techniques will be demonstrated. In this study, the Core 360 belt with OhmTrack sensors will be used. Both breathing exercises and DNS exercises will be taught with the belt in place. In a corrected posture, participants will be instructed to gently press the abdominal wall toward the sensors and to maintain expansion of the abdominal wall during both inspiration and expiration, while keeping the spine in a neutral position. The exercise program will begin with a preparatory training phase, which includes fascial mobilizations applied to the feet and hands. DNS exercises will start with the 4.5-month supine developmental position for sagittal stabilization. As the program progresses, exercises will be advanced according to developmental kinesiology positions.
219244291|NCT07008755|DRUG|Peginterferon α-2b injection|During the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 45 μg per administration, to be delivered on Day 1 and Day 3.
219244292|NCT07008755|DRUG|Peginterferon α-2b injection|CoDuring the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 90 μg per administration, to be delivered on Day 1 and Day 3.
219244293|NCT00997750|DRUG|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
219244294|NCT06700395|DRUG|TQB2029 injection|TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
219244295|NCT06719570|DRUG|MK-8591A|Fixed dose combination tablet
219244296|NCT06719570|DRUG|Islatravir|Oral capsule
219244297|NCT06719570|DRUG|Doravine|Oral tablet
219244298|NCT00826956|PROCEDURE|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
219244299|NCT01407302|OTHER|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
219244300|NCT05854056|PROCEDURE|Accelerated rehabilitation protocol|See Arms section
219244301|NCT05854056|PROCEDURE|Conservative rehabilitation protocol|See Arms section
219244302|NCT01748578|DRUG|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
219244303|NCT01748578|DRUG|EBI-005-1 Placebo|
219244304|NCT01709643|DIETARY_SUPPLEMENT|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
219244305|NCT01709643|DIETARY_SUPPLEMENT|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
219244306|NCT02178878|GENETIC|Progress, Pain|Progress, Pain
219244307|NCT06136507|DRUG|FRSW107|experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
219244308|NCT01252199|DRUG|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
219244309|NCT01252199|DRUG|Placebo|Placebo administered over 1 hour + standard of care
219244310|NCT02136797|BIOLOGICAL|CMVpp65 Specific T-cells|
219739648|NCT05544396|OTHER|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
219244311|NCT06520020|DEVICE|Transcutaneous Spinal Cord Stimulation (Tc-SCS)|This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.
219244312|NCT05017883|DRUG|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
219244313|NCT06552910|PROCEDURE|Nerve Block|Since this study was conducted retrospectively, the choice of anesthesia method was made based on our own experience. For every patient undergoing LEA under PNB, a popliteal sciatic nerve block was carried out. A saphenous nerve block was also carried out if the procedure was on a level that was close to the metatarsal bone. In some circumstances (distal surgery, such as the metatarsal bone), a sensory block on the surgical site was tried following the popliteal sciatic nerve block to demonstrate that the saphenous nerve's anatomic abnormalities required an additional saphenous nerve block. The related block was later carried out, if needed. Under ultrasound guidance, every PNB was finished.
219244314|NCT00040521|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|
219244315|NCT03162523|RADIATION|High-Dose Rate Brachytherapy|
219244316|NCT01903928|BIOLOGICAL|ASP0113|injection
219244317|NCT06584786|COMBINATION_PRODUCT|Jing Si herbal tea (JSHT)|JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
219244318|NCT06584786|OTHER|Placebo|Placebo of JSHT
219244319|NCT06313099|OTHER|Survey|Participants' musculoskeletal system disorders were assessed using the Cornell Musculoskeletal Disorders Questionnaire (CMDQ), fatigue levels were measured using the Fatigue Severity Scale (FSS), sleep quality was evaluated using the Visual Analog Scale (VAS), depression levels were assessed using the Beck Depression Inventory (BDI), and quality of life was measured with the Nottingham Health Profile (NHP). Google Forms was used to create the data collection tools, which were then sent to the participants' email addresses and collected online.
219244320|NCT04925245|OTHER|Clinical Reminder|Clinical reminder in the electronic medical record
219244321|NCT05669287|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
219244322|NCT02039297|OTHER|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
219244323|NCT06127485|PROCEDURE|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
219244324|NCT06127485|PROCEDURE|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
219244325|NCT02585752|DEVICE|Noninvasive ventilation|Expiratory pressure modulation
219244326|NCT02041845|RADIATION|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
219244327|NCT02041845|RADIATION|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
219244328|NCT03050372|DEVICE|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
219244329|NCT03050372|DEVICE|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
219244330|NCT00161954|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
219244331|NCT05727553|RADIATION|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
219244332|NCT05358184|DEVICE|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
219244333|NCT02904291|DRUG|Amlodipine|Patients are tested for their normal prescription amlodipine medication
219362422|NCT05855265|DEVICE|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
219244334|NCT05030467|BEHAVIORAL|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
219244335|NCT06047795|OTHER|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
219244336|NCT06047795|OTHER|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
219244337|NCT00799188|DRUG|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
219244338|NCT00211926|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
219244339|NCT00211926|BIOLOGICAL|placebo|single dose of placebo
219244340|NCT02181192|DEVICE|PET/CT|PET/CT
219244341|NCT02181192|RADIATION|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
219244342|NCT02181192|RADIATION|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
219244343|NCT00722514|BEHAVIORAL|patient education|"* complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* Patient education 6 x 90 Minutes"
219244344|NCT00722514|BEHAVIORAL|Standard Care|"* complex individual antiinflammatory rehabilitation program during inpatient~* complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
219244345|NCT01092585|DRUG|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
219244346|NCT02403414|DEVICE|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
219244347|NCT01133600|DRUG|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
219244348|NCT01133600|DRUG|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
219244349|NCT01648075|DIETARY_SUPPLEMENT|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
219362423|NCT01775631|BIOLOGICAL|Urelumab|
219362424|NCT01775631|BIOLOGICAL|Rituximab|
219362425|NCT00678145|DRUG|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
219739649|NCT06315894|DEVICE|SuperCAP Program|"Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome."
219739650|NCT06332339|BIOLOGICAL|16055 NFL delta Gly4 trimer|200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
219739651|NCT06332339|BIOLOGICAL|Trimer 4571|100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
219362426|NCT00678145|DIETARY_SUPPLEMENT|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
219739652|NCT06332339|BIOLOGICAL|Ad4-Env145NFL, 5 x 108 viral particles (vp)|to be administered intranasally (IN) (0.07 mL into 1 nostril)
219739653|NCT05787483|BEHAVIORAL|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
219739654|NCT05787483|BEHAVIORAL|active control group|business as usual; regular wellness or SEL classes
219739655|NCT02617212|PROCEDURE|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
219739656|NCT02617212|DEVICE|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
219739657|NCT02617212|DEVICE|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
219739658|NCT00141193|DRUG|Celecoxib|
219739659|NCT00742742|BEHAVIORAL|healthy life style education|healthy life style education
219739660|NCT06147869|DEVICE|phonophoresis|Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
219739661|NCT06147869|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
219739662|NCT03231735|DEVICE|Mid frequency ventilation|Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
219739663|NCT03231735|DEVICE|Standard frequency ventilation|Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
219739664|NCT04824066|DEVICE|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
219739665|NCT03192332|DEVICE|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
219739666|NCT03192332|DRUG|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
219739667|NCT06356350|OTHER|Conventional neuromuscular exercises|Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
219739668|NCT06356350|OTHER|Core based exercises|Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
219244350|NCT04231175|DIAGNOSTIC_TEST|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
219244351|NCT03205345|DRUG|Emricasan (25 mg)|25 mg emricasan
219244352|NCT03205345|DRUG|Emricasan (5 mg)|5 mg emricasan
219244353|NCT03205345|DRUG|Placebo|Matching Placebo
219244354|NCT03015415|PROCEDURE|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
219244355|NCT03015415|PROCEDURE|Non-surgical intervention|Rehabilitation with splinting protocols
219244356|NCT00647452|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
219244357|NCT05734235|DIETARY_SUPPLEMENT|Vitamin C|Two Vitamin C tablets daily for 8 days.
219244358|NCT05734235|DIETARY_SUPPLEMENT|Vitamin E|One Vitamin E tablet daily for 8 days.
219244359|NCT05444231|BEHAVIORAL|Brain Training A|Interventions may include education, exercises, and/or strategies to support brain health
219244360|NCT05444231|BEHAVIORAL|Brain Training B|Interventions may include education, exercises, and/or strategies to support brain health
219244361|NCT05444231|BEHAVIORAL|Brain Training C|Interventions may include education, exercises, and/or strategies to support brain health
219244362|NCT03672188|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
219244363|NCT03672188|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
219244364|NCT06561412|BEHAVIORAL|Produce Prescription|Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. These vouchers are sponsored by The Food Trust.
219244365|NCT00984334|DRUG|Naloxone SR 5 mg capsules|
219244366|NCT00984334|DRUG|Placebo|
219244367|NCT00984334|DRUG|Naloxone SR 10 mg capsules|
219244368|NCT00984334|DRUG|Naloxone SR 20mg capsules|
219244369|NCT00984334|DRUG|Naloxone SR 2.5 mg capsules|
219244370|NCT04006652|DRUG|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
219244371|NCT02169089|DRUG|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
219244372|NCT02169089|DRUG|Placebo|Placebo
219244373|NCT05911191|OTHER|Exercise based prehabilitation|A peripheral muscle strengthening program
219244374|NCT05791552|DIAGNOSTIC_TEST|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
219244375|NCT00001079|DRUG|Testosterone enanthate|
219244376|NCT00001079|DRUG|Megestrol acetate|
219244377|NCT00079235|DRUG|temsirolimus|Given IV
219244378|NCT00079235|OTHER|laboratory biomarker analysis|Correlative studies
219244379|NCT05599230|DRUG|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
219244380|NCT06090253|BEHAVIORAL|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
219244381|NCT06090253|BEHAVIORAL|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
219244382|NCT06090253|BEHAVIORAL|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
219244383|NCT06090253|BEHAVIORAL|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
219244384|NCT06090253|BEHAVIORAL|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
219244385|NCT03658018|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
219244386|NCT01810406|PROCEDURE|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
219244387|NCT01810406|PROCEDURE|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
219244388|NCT00317317|PROCEDURE|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
219244389|NCT03964545|BEHAVIORAL|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
219244390|NCT02367339|OTHER|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
219244391|NCT03320941|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
219244392|NCT03320941|DRUG|Placebo|Placebo will be supplied as tablets to be taken daily orally.
219244393|NCT03174470|DEVICE|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
219244394|NCT05829278|PROCEDURE|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
219244395|NCT00987155|DEVICE|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
219244396|NCT04260100|BEHAVIORAL|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
219244397|NCT00357747|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
219244398|NCT00357747|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
219244399|NCT00556296|DRUG|NRP104|NRP104 30mg capsule once daily in a.m.
219244400|NCT00556296|DRUG|NRP104|NRP104 50mg capsule once daily in a.m.
219244401|NCT00556296|DRUG|NRp104|NRP104 70mg capsule once daily in a.m.
219244402|NCT00556296|DRUG|Placebo|Placebo
219244403|NCT03234049|OTHER|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
219244404|NCT03236818|DRUG|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
219244405|NCT01125735|DEVICE|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
219244406|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
219244407|NCT02775123|DEVICE|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
219244408|NCT02183961|OTHER|Restech|
219244409|NCT02183961|OTHER|Peptest|
219244410|NCT02183961|OTHER|Detection of pepsin in adenoid specimen|
219244411|NCT00992654|DRUG|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
219244412|NCT04968314|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
219244413|NCT03336684|BEHAVIORAL|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
219244414|NCT03990909|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
219244415|NCT03990909|DIETARY_SUPPLEMENT|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
219244416|NCT03990909|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
219244417|NCT05364047|BIOLOGICAL|Low-dose of LVRNA009|25μg/person
219244418|NCT05364047|BIOLOGICAL|Middle-dose of LVRNA009|50μg/person
219244419|NCT05364047|BIOLOGICAL|High-dose of LVRNA009|100μg/person
219244420|NCT05364047|OTHER|Placebo|0.5ml/person
219244421|NCT01523678|DRUG|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
219244422|NCT01523678|DRUG|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
219244423|NCT01523678|DRUG|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
219244424|NCT03614923|BIOLOGICAL|Etokimab|Administered by subcutaneous injection
219244425|NCT03614923|BIOLOGICAL|Placebo|Administered by subcutaneous injection
219244426|NCT03614923|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
219244427|NCT03959930|DEVICE|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
219244428|NCT06505408|DIETARY_SUPPLEMENT|Multivitamin|4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks
219244429|NCT06505408|DIETARY_SUPPLEMENT|Placebo|4 placebo capsules consumed daily for 12 weeks
219244430|NCT04286893|DIAGNOSTIC_TEST|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
219244431|NCT04286893|DIAGNOSTIC_TEST|High resolution ECG|Measurement HRV using high resolution ECG
219244432|NCT04286893|DIAGNOSTIC_TEST|Blood withdrawal|Measurement of endothelial inflammation markers
219244433|NCT01107353|DRUG|Imipramine Pamoate|75 mg capsule
219244434|NCT00185848|RADIATION|[18F]FHBG|\< 7mCi and 2 ug, iv
219244435|NCT01943370|OTHER|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
219244436|NCT01943370|OTHER|Routine Irrigation|Routine initiation of saline irrigation
219244437|NCT00527696|PROCEDURE|transvaginal obturator tape|
219244438|NCT03321188|PROCEDURE|HIPEC|HIPEC with cisplatin
219244439|NCT03321188|DRUG|Carboplatin|Adjuvant IV chemotherapy
219244440|NCT03321188|DRUG|Paclitaxel|Adjuvant IV chemotherapy
219244441|NCT02988245|DRUG|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
219244442|NCT02988245|DRUG|JNC-8|Using JNC-8 guidelines to guide therapy
219244443|NCT02201368|DRUG|Triheptanoin (SpezialölÒ 107®)|"* Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
219244444|NCT02201368|DIETARY_SUPPLEMENT|MCT (Medium-Chain Triglycerides)|"* Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months"
219244445|NCT00128908|DRUG|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
219244446|NCT00128908|DRUG|Rapidly Cycled HAART|
219244447|NCT03364283|PROCEDURE|Surgical position|
219244448|NCT01193283|DRUG|Cyclophosphamide|30 my/kg for 4 days
219244449|NCT01193283|DRUG|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
219244450|NCT00125619|BEHAVIORAL|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
219244451|NCT02459132|BEHAVIORAL|High-intensity aerobic interval exercise|See arm/group description
219244452|NCT01931683|DRUG|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
219244453|NCT01931683|DEVICE|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
219244454|NCT03293329|OTHER|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
219244455|NCT03293329|OTHER|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
219244456|NCT03293329|OTHER|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
219244457|NCT01295788|DEVICE|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
219244458|NCT01295788|DEVICE|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
219362427|NCT00678145|BEHAVIORAL|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
219244459|NCT00788632|BEHAVIORAL|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
219244460|NCT00788632|BEHAVIORAL|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
219244461|NCT00788632|BEHAVIORAL|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
219244462|NCT04297423|DRUG|Plenvu|randomization 1:1
219244463|NCT00803335|DRUG|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
219244464|NCT00803335|DRUG|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
219244465|NCT01939483|DRUG|irinotecan hydrochloride|Given IV
219244466|NCT01939483|OTHER|laboratory biomarker analysis|Correlative studies
219244467|NCT02247141|BIOLOGICAL|Subgam® (Human Normal Immunoglobulin Solution)|
219244468|NCT02977468|DRUG|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
219244469|NCT02977468|RADIATION|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
219244470|NCT06228417|OTHER|Adaptive digital intervention|Participants received reminder for medication intake on daily basis. Also, short message regarding hypertension, medication and lifestyle changes
219244471|NCT02368691|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
219244472|NCT01502202|DRUG|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
219244473|NCT01502202|DRUG|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
219244474|NCT01502202|DRUG|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
219244475|NCT04513535|OTHER|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
219362428|NCT00678145|DRUG|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
219362429|NCT00678145|DRUG|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
219362430|NCT02000804|DRUG|darapladib 160mg|drug
219362670|NCT04543214|OTHER|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
219172971|NCT06776796|BEHAVIORAL|Online Personalized Normative Feedback Intervention Targeting Alcohol Misuse|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse. It is tailored by the identities chosen by participants including gender, race/ethnicity, and sexual orientation. The intervention is a modified version of an existing evidence-based program, the Brief Alcohol Screening and Intervention for College Students (BASICS) (Dimeff, et. al, 1999).
219172972|NCT06776796|BEHAVIORAL|Mental Health and Substance Use Resources|Participants were directed to a website where information regarding mental health and substance use may be found.
219172973|NCT02285816|BIOLOGICAL|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
219172974|NCT02285816|BIOLOGICAL|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
219172975|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
219172976|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
219172977|NCT02665507|DEVICE|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
219172978|NCT02665507|DEVICE|Sham|Hand held laser that emits no LLLI
219172979|NCT06782672|OTHER|Cardiovascular measurements|"Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.~These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.~Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.~cardiovascular values will be measured continuously:~* Each participant rested while watching a documentary for 8 minutes.~* During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.~The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort."
219172980|NCT06782672|OTHER|Experimental memory task|"First, a quiet period with the viewing of a documentary film (8min).~Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.~At the end of each difficulty level, self-report measures assessed by the following questions will be collected:~* How much effort did you exert during the task?;~* How difficult did you find the task?~* How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 (no effort at all, very easy, not at all motivated, respectively) to 7 (a lot of effort, very difficult, very motivated, respectively)."
219172981|NCT06782672|OTHER|Questionnaire and semi-structured psychological interview|"psychopathological measures collected using questionnaires:~* Beck Depression Inventory (BDI-II): mood~* State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety~* Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue~* General Self-Efficacy Scale (GSES): defeatist beliefs~* Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group"
219172982|NCT05959811|OTHER|yoga|60 minutes yoga practice ,twice a week for 8 weeks
219172983|NCT06357234|DRUG|Aprepitant|Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
219172984|NCT06357234|DRUG|Placebo|Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
219172985|NCT05456113|BIOLOGICAL|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
219172986|NCT05092841|DRUG|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
219172987|NCT05092841|DRUG|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
219172988|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
219172989|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
219172990|NCT05534893|DIETARY_SUPPLEMENT|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
219172991|NCT05534893|DIETARY_SUPPLEMENT|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
219172992|NCT06542796|PROCEDURE|Immunotherapy combined with targeted therapy|Immunotherapy combined with targeted therapy
219172993|NCT06542796|OTHER|Standard treatment plan|Standard treatment plan
219362671|NCT06073392|OTHER|Educational video|Educational video in animation mode
219362672|NCT06067880|OTHER|Cancer-related Unilateral|This group included patients who have used only contraction type LVs.
219362673|NCT06067880|OTHER|Normal + Ectasis LVs|This group included patients who had only non- contraction type LVs.
219362674|NCT00138697|DRUG|IVIG-L|
219362675|NCT02750787|OTHER|Nutritional Study Product|Two 220 ml servings per day
219362676|NCT00049088|DRUG|docetaxel|Given IV
219362677|NCT00049088|BIOLOGICAL|bevacizumab|Given IV
219244476|NCT04513535|OTHER|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
219244477|NCT04513535|OTHER|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
219244478|NCT04513535|OTHER|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
219244479|NCT00313963|DRUG|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
219244480|NCT00313963|DRUG|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
219244481|NCT02936193|PROCEDURE|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
219244482|NCT02936193|PROCEDURE|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
219244483|NCT01745718|OTHER|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
219244484|NCT04581772|DRUG|DNL343|Multiple oral doses
219244485|NCT04581772|DRUG|Placebo|Single oral dose
219244486|NCT04581772|DRUG|DNL343|Single oral dose
219244487|NCT01854164|DIETARY_SUPPLEMENT|HGE (hydrolyzed ginseng extract)|
219244488|NCT01854164|DIETARY_SUPPLEMENT|Placebo|
219244489|NCT00830284|PROCEDURE|Recruitment maneuver|"Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
219244490|NCT00675519|BEHAVIORAL|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
219244491|NCT03863184|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
219244492|NCT03863184|DRUG|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
219244493|NCT03863184|DRUG|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
219244494|NCT03863184|DRUG|Obinutuzumab|Obinutuzumab on days 1, 8, 15 of cycle 1, day 1 of cycles 2-6, then every 2 cycles
219244495|NCT05980325|BEHAVIORAL|Nordic Walking|A 12-week Nordic Walking exercise programme supervised twice weekly
219244496|NCT05980325|BEHAVIORAL|Aquatic Exercise|A 12-week water-based exercise training programme supervised twice weekly
219244497|NCT05980325|BEHAVIORAL|Functional Exercise Training|A 12-week circuit-based exercise training programme supervised twice weekly
219244498|NCT00895297|DRUG|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
219244499|NCT01459523|PROCEDURE|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
219244500|NCT01459523|PROCEDURE|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
219244501|NCT01459523|PROCEDURE|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
219244502|NCT01459523|PROCEDURE|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
219244503|NCT00550927|BIOLOGICAL|bevacizumab|
219244504|NCT00550927|DRUG|enzastaurin hydrochloride|
219244505|NCT00550927|OTHER|diagnostic laboratory biomarker analysis|
219244506|NCT00550927|OTHER|pharmacological study|
219244507|NCT00287183|DRUG|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
219244508|NCT00287183|OTHER|Placebo|Placebo
219244509|NCT02078947|BEHAVIORAL|High Intensity Exercise|
219244510|NCT02078947|BEHAVIORAL|Moderate Continuous Exercise|
219244511|NCT02078947|BEHAVIORAL|Usual Care|
219244512|NCT02266589|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
219244513|NCT05716152|DIAGNOSTIC_TEST|Morning blood sample and skin punch biopsy of 4 mm diameter.|"1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
219244514|NCT01330719|PROCEDURE|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
219244515|NCT01330719|PROCEDURE|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
219244516|NCT02281214|OTHER|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
219244517|NCT04950790|DRUG|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
219362678|NCT00049088|OTHER|laboratory biomarker analysis|Correlative studies
219244518|NCT04950790|DRUG|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
219244519|NCT04950790|DRUG|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
219244520|NCT03314233|PROCEDURE|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
219244521|NCT02029027|DEVICE|GYNEFFIK(R)|Vaginal electro-stimulation medical device
219244522|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
219244523|NCT03003832|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
219244524|NCT01585597|DEVICE|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
219244525|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
219244526|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
219244527|NCT00168805|DRUG|enoxaparin|40 mg once daily
219244528|NCT00168805|DRUG|dabigatran etexilate|150 mg once daily
219244529|NCT00168805|DRUG|dabigatran etexilate|220 mg once daily
219244530|NCT01114217|DRUG|Ferumoxytol|IV Ferumoxytol
219244531|NCT00302406|DRUG|methylphenidate hydrochloride|
219244532|NCT00302406|DRUG|OROS methylphenidate hydrochloride (CONCERTA)|
219244533|NCT03224689|DEVICE|PEEK-Optima Femoral Component|TKA Surgery
219244534|NCT01930877|DRUG|Lidocaine|Lidocaine iv bolus followed by infusion
219244535|NCT01930877|OTHER|Placebo (normal saline)|Normal saline bolus followed by infusion
219244536|NCT06642376|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
219244537|NCT05685511|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
219244538|NCT05685511|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
219244539|NCT05685511|OTHER|Usual care resources|List of resources that the patient can explore on their own
219244540|NCT01183013|DRUG|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
219244541|NCT01183013|DRUG|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
219244542|NCT01183013|DRUG|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
219244543|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
219244544|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
219244545|NCT01183013|DRUG|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
219244546|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
219244547|NCT06641128|DRUG|MTX SC or IM|IM or SC Methotrexate
219244548|NCT06641128|DRUG|Empagliflozin 25mg tab|Empa tablets 25 mg once daily for 3 months.
219244549|NCT03998423|BIOLOGICAL|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
219244550|NCT03379779|DIAGNOSTIC_TEST|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
219362679|NCT00049088|OTHER|pharmacological study|Correlative studies
219362680|NCT00553046|OTHER|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
219362681|NCT00152152|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
219172994|NCT01912651|DRUG|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
219172995|NCT06188936|DEVICE|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
219172996|NCT06188936|OTHER|Survey|Surveys will be completed on a hard copy or electronically.
219172997|NCT06782867|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
219172998|NCT04424745|OTHER|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
219172999|NCT06191731|OTHER|biological samples collection|Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
219173000|NCT05698459|BIOLOGICAL|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
219173001|NCT04126681|DRUG|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
219173002|NCT04126681|DRUG|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
219173003|NCT04126681|DRUG|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
219173004|NCT04126681|DRUG|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
219173005|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
219173006|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
219173007|NCT05045196|BEHAVIORAL|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
219173008|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
219173009|NCT05498896|DRUG|Atezolizumab|IV infusion
219173010|NCT05498896|DRUG|Ipatasertib|Oral
219173011|NCT05498896|DRUG|Paclitaxel|IV infusion
219173012|NCT05498896|DRUG|Doxorubicin|IV infusion
219173013|NCT05498896|DRUG|Cyclophosphamide|IV infusion
219173014|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
219173015|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
219173016|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
219173017|NCT04702529|DEVICE|Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)|Administration of 3 Rapid Acoustic Pulse (RAP) treatments
219173018|NCT03574727|PROCEDURE|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
219173019|NCT05601154|DRUG|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
219244551|NCT05114161|OTHER|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
219244552|NCT06571019|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
219244553|NCT03185910|BEHAVIORAL|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
219244554|NCT03185910|BEHAVIORAL|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
219244555|NCT00740298|OTHER|sucrose|sweet taste
219244556|NCT00740298|OTHER|warmth|warmth
219244557|NCT05317377|OTHER|Exercise Therapy|Structured exercises focused on hand functionality
219244558|NCT05317377|DEVICE|Leap Motion Based Exergame|Appropriate games from Leap Motion Based Exergame system focused on hand functionality
219244559|NCT06003868|OTHER|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
219244560|NCT06003868|OTHER|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
219244561|NCT05135741|DEVICE|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
219244562|NCT03897075|DRUG|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
219244563|NCT03897075|DRUG|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
219244564|NCT04503772|PROCEDURE|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
219244565|NCT01358201|DRUG|vINCRISTINE|
219244566|NCT01358201|DRUG|Dexamethasone|
219244567|NCT01358201|DRUG|Methotrexate|
219244568|NCT01358201|DRUG|Cytosine arabinoside|
219244569|NCT01952002|OTHER|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
219244570|NCT00004276|DRUG|thalidomide|
219244571|NCT02722278|DRUG|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
219244572|NCT02722278|DRUG|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
219244573|NCT05264506|DRUG|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
219244574|NCT01725087|DRUG|Matching Placebo|
219244575|NCT01725087|DRUG|Low Dose GRT6005|
219244576|NCT01725087|DRUG|Medium Dose GRT6005|
219244577|NCT01725087|DRUG|High Dose GRT6005|
219244578|NCT01725087|DRUG|Tapentadol|
219244579|NCT04734171|BEHAVIORAL|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
219244580|NCT04734171|BEHAVIORAL|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
219244581|NCT04734171|BEHAVIORAL|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
219244582|NCT00472199|DRUG|Pramipexole|
219244583|NCT00472199|DRUG|Placebo|
219244584|NCT01406899|BEHAVIORAL|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
219244585|NCT00731276|DRUG|irinotecan hydrochloride|
219244586|NCT00731276|OTHER|pharmacogenomic studies|
219244587|NCT00731276|OTHER|pharmacological study|
219244588|NCT00367445|DRUG|Inhaled Human Insulin (Exubera)|
219244589|NCT00367445|DRUG|Insulin Glargine (Lantus)|
219244590|NCT03635242|OTHER|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
219244591|NCT03635242|OTHER|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
219244592|NCT01540071|DRUG|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
219244593|NCT01370161|PROCEDURE|TIPS treatment|"1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
219244594|NCT01370161|DRUG|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
219244595|NCT04132388|OTHER|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
219244596|NCT04132388|DRUG|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
219244597|NCT03024593|BEHAVIORAL|Health- and illness-related internet use|
219244598|NCT00475436|DRUG|GSK573719|
219244599|NCT02357355|DEVICE|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
219244600|NCT02446912|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
219244601|NCT02446912|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
219244602|NCT00015171|DRUG|Buprenorphine/naloxone|
219244603|NCT01268488|DEVICE|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
219244604|NCT01670032|DRUG|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
219244605|NCT01670032|DRUG|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
219244606|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
219244607|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
219244608|NCT00517270|DRUG|Rabeprazole 20mg twice daily|
219244609|NCT03853642|OTHER|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
219244610|NCT01879488|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
219244611|NCT01879488|DEVICE|Vibrating-mesh nebulizer|
219244612|NCT01879488|OTHER|Gamma scintigraphy|
219244613|NCT01879488|OTHER|Preoperative spirometry|
219244614|NCT00266747|DRUG|SR58611A|
219244615|NCT00266136|DRUG|Cytarabine|see protocol
219244616|NCT00266136|DRUG|Thioguanine|see protocol
219244617|NCT00266136|DRUG|Daunorubicin|see protocol
219244618|NCT00266136|DRUG|Cyclophosphamide|see protocol
219244619|NCT00266136|DRUG|G-CSF|see protocol
219244620|NCT00266136|PROCEDURE|Autologous stem cell transplantation|for details see protocol
219244621|NCT00266136|PROCEDURE|Allogeneic stem cell transplantation|for details see protocol
219244622|NCT00537758|BEHAVIORAL|Cognitive Behavior Therapy|
219244623|NCT00537758|BEHAVIORAL|CBT and BWL|
219244624|NCT00537758|BEHAVIORAL|Behavioral Weight Loss Treatment|
219244625|NCT06575998|OTHER|Training|A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
219244626|NCT06575998|OTHER|Pro-active identification|Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
219244627|NCT04639076|BEHAVIORAL|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
219362682|NCT01438697|BEHAVIORAL|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
219362683|NCT01438697|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
219362684|NCT02373111|DIETARY_SUPPLEMENT|Isoflavone|
219362685|NCT02373111|DIETARY_SUPPLEMENT|Astaxanthin|
219244628|NCT04639076|BEHAVIORAL|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
219244629|NCT01757171|DRUG|Cabazitaxel|20mg IV over 1 hour every 3 weeks
219244630|NCT05858047|DRUG|Placebo|Administered orally, once daily (QD)
219244631|NCT05858047|DRUG|SYHX1901|Administered orally, once daily (QD)
219244632|NCT00103116|BIOLOGICAL|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
219244633|NCT02419664|DRUG|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
219244634|NCT05453292|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
219244635|NCT04264416|DEVICE|WB-EMS|16 weeks of WB-EMS
219244636|NCT04236622|OTHER|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
219244637|NCT03369652|BEHAVIORAL|Medication review|Conducted by the pharmacist and discussed with hospital physician
219244638|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
219244639|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
219362686|NCT02373111|DIETARY_SUPPLEMENT|Placebo|
219362687|NCT02597621|OTHER|no intervention|no intervention
219244640|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
219244641|NCT03771183|OTHER|Patients in long response during Halaven® treatment|Data collection
219244642|NCT00748488|OTHER|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
219244643|NCT00748488|OTHER|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
219244644|NCT06099119|DRUG|creon 35.000 Ph.U (R)|Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
219244645|NCT06099119|OTHER|Best Standarard of Care|Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
219244646|NCT00222209|BEHAVIORAL|Experimental heat pain model|
219244647|NCT01014013|DRUG|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
219244648|NCT01014013|DRUG|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
219244649|NCT04949113|DRUG|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
219244650|NCT04949113|DRUG|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
219244651|NCT03359187|OTHER|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
219244652|NCT03359187|OTHER|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
219244653|NCT03359187|OTHER|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
219244654|NCT04299698|BEHAVIORAL|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
219244655|NCT00316121|DEVICE|HEALOS and Leopard Cage|Placement in interbody space
219244656|NCT00316121|DEVICE|Leopard Cage and Autograft|Placement in the interbody space
219244657|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
219244658|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
219244659|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
219244660|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
219244661|NCT03324048|OTHER|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
219244662|NCT00547885|DRUG|Dihydrocodeine|"Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting"
219244663|NCT02305797|DRUG|Extended-release lorazepam|Extended-release lorazepam capsules
219244664|NCT02305797|DRUG|Placebo|Placebo capsules
219244665|NCT05274906|OTHER|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
219244666|NCT05404802|DEVICE|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
219244667|NCT05404802|DEVICE|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
219244668|NCT06337045|BEHAVIORAL|Complex prevention and rehabilitation intervention|The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
219244669|NCT03703999|DEVICE|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
219244670|NCT00003697|DRUG|vadimezan|
219244671|NCT01630239|PROCEDURE|Laser ablation|Laser ablation of hepatic tumors
219244672|NCT02720978|DRUG|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
219244673|NCT02720978|DRUG|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
219244674|NCT00038376|DRUG|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
219244675|NCT00038376|DRUG|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
219244676|NCT05048407|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
219244677|NCT03674476|DRUG|BMS-986036|Specified dose on specified days
219244678|NCT01115153|OTHER|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
219244679|NCT01115153|OTHER|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
219244680|NCT03075475|BEHAVIORAL|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
219244681|NCT04891263|PROCEDURE|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
219244682|NCT04891263|DEVICE|Surgical suture|Suture used for closure during septoplasty surgery.
219244683|NCT02100189|OTHER|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
219244684|NCT02100189|PROCEDURE|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
219244685|NCT02100189|OTHER|Laboratory Biomarker Analysis|Correlative studies
219244686|NCT00245505|DRUG|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
219244687|NCT01351597|DRUG|docetaxel/ oxaliplatin|"1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
219244688|NCT03148353|PROCEDURE|Subacromial injection|"1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection"
219244689|NCT01256814|BEHAVIORAL|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
219244690|NCT01894750|BEHAVIORAL|group-based skill building self-care program|
219244691|NCT06646068|OTHER|Philips 66 with CBL|Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
219244692|NCT03452735|OTHER|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
219244693|NCT00460577|DRUG|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
219244694|NCT00460577|DRUG|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
219244695|NCT01702688|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
219244696|NCT01702688|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
219244697|NCT02650661|BEHAVIORAL|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
219244698|NCT02650661|BEHAVIORAL|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
219244699|NCT02650661|BEHAVIORAL|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
219244700|NCT02650661|BEHAVIORAL|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
219244701|NCT06570954|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
219244702|NCT01628822|BEHAVIORAL|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
219244703|NCT01628822|BEHAVIORAL|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
219244704|NCT01306409|DRUG|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
219244705|NCT01306409|DRUG|ESA|Sequential application of three different ESA
219244706|NCT02469051|DEVICE|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
219244707|NCT02469051|DEVICE|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
219244708|NCT02469051|DEVICE|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
219244709|NCT04698499|OTHER|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
219244710|NCT02526199|DRUG|Bupivacaine|Sciatic nerve block
219244711|NCT02526199|DRUG|Epinephrine|Adjuvant to perinerual block
219244712|NCT02526199|DRUG|Dexamethasone|Adjuvant to perinerual block
219244713|NCT00441493|DRUG|fluvastatin|
219244714|NCT03316248|OTHER|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
219244715|NCT03316248|OTHER|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
219244716|NCT02213458|BEHAVIORAL|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
219244717|NCT02653066|OTHER|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
219244718|NCT02653066|OTHER|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
219244719|NCT00489151|DRUG|adefovir dipivoxil|
219244720|NCT00489151|DRUG|lamivudine|
219244721|NCT00910871|DRUG|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
219244722|NCT00910871|DRUG|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
219244723|NCT00787345|OTHER|simulation based training|simulation based training in aseptic techniques that included specified AT categories
219244724|NCT03759262|DRUG|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
219244725|NCT02606617|DRUG|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
219244726|NCT02606617|DRUG|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
219244727|NCT03343509|DRUG|Metronidazole Oral|Oral Metronidazole
219244728|NCT03343509|DRUG|Metronidazole Ointment|Metronidazole Ointment
219244729|NCT03343509|DRUG|Placebo Oral Tablet|Placebo Tablet
219244730|NCT03343509|DRUG|Placebo Ointment|Placebo Ointment
219244731|NCT01878253|DEVICE|Sidus Stem-Free Total Shoulder Arthroplasty System|
219244732|NCT03045549|DEVICE|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
219244733|NCT03045549|OTHER|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
219244734|NCT01224509|DRUG|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
219244735|NCT01224509|OTHER|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
219244736|NCT04043806|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219244737|NCT04043806|DRUG|IVA|Tablet for oral administration.
219244738|NCT04608006|DRUG|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
219244739|NCT00852345|DRUG|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
219244740|NCT03985826|OTHER|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
219244741|NCT01856647|PROCEDURE|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
219244742|NCT03327688|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
219244743|NCT02351388|DEVICE|Transcranial Direct Current Stimulation|
219244744|NCT02351388|OTHER|Sham Stimulation|
219244745|NCT02035345|DRUG|Carboplatin|
219244746|NCT04868734|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
219244747|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
219244748|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
219244749|NCT00881972|BEHAVIORAL|Exercise|walking/running/cycling
219244750|NCT02948686|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219244751|NCT02948686|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
219244752|NCT02948686|OTHER|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
219244753|NCT02948686|OTHER|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
219244754|NCT05165563|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
219244755|NCT04143100|OTHER|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
219244756|NCT06268600|RADIATION|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
219244757|NCT01095237|DEVICE|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
219244758|NCT06226896|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily plus RAS inhibitor
219244759|NCT06355271|PROCEDURE|Fentanyl 1|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl
219244760|NCT06355271|PROCEDURE|Fentanyl2|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl
219244761|NCT06355271|PROCEDURE|Fentanyl 3|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
219244762|NCT06124599|OTHER|Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
219173020|NCT05601154|DRUG|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
219173021|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
219173022|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
219173023|NCT05669430|BIOLOGICAL|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
219173024|NCT05669430|BIOLOGICAL|GV20-0251|GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
219173025|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
219173026|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
219173027|NCT03781700|DRUG|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
219173028|NCT03781700|DRUG|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
219173029|NCT03188146|DRUG|Ursodeoxycholic Acid|Standard care of PBC patients
219173030|NCT04551521|DRUG|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
219173031|NCT04551521|DRUG|Cobimetinib|60 mg once daily
219173032|NCT04551521|DRUG|Atezolizumab|840 mg every 2 weeks
219173033|NCT04551521|DRUG|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
219173034|NCT04551521|DRUG|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
219173035|NCT04551521|DRUG|Alectinib|600 mg twice daily
219173036|NCT04551521|DRUG|Ipatasertib|400 mg once daily
219173037|NCT04551521|DRUG|Atezolizumab|1200 mg every 3 weeks
219173038|NCT04551521|DRUG|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
219173039|NCT04551521|DRUG|Atezolizumab|1,200 mg every 3 weeks
219173040|NCT04551521|DRUG|Inavolisib|9 mg once daily
219173041|NCT03989947|DRUG|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
219173042|NCT06524687|DRUG|Imvotamab|Administered intravenously
219173043|NCT05766072|OTHER|EMOTION Kids coping with anxiety and depression (Mestrende barn in Norwegian)|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
219173044|NCT06251037|BEHAVIORAL|Youth Aware of Mental Health in Galicia|"The program follows a manualized protocol, comprising five interactive one-hour class sessions with adaptations to the Galician school population.~The Inaugural Session consists of an interactive slide presentation, an introduction of materials, the delivery of the manual, and the poster's display. The Second Session involves group discussions on real-life dilemmas. The Third and Fourth Sessions focus on crisis situations, depression, suicidal ideation, and help-seeking behaviors through role-playing games. The Closing Session includes a collective summary of topics and addresses dynamic aspects emerging during the group experience."
219173045|NCT06249841|DEVICE|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
219173046|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
219244763|NCT06124599|OTHER|Identification of symptoms of menstrual in control patient in the last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
219173047|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
219173048|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
219173049|NCT05153759|OTHER|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
219173050|NCT05494866|DRUG|Cobicistat Oral Tablet|Cobicistat Oral Tablet
219173051|NCT05494866|DRUG|Gemcitabin|Gemcitabin
219173052|NCT05494866|DRUG|Nab paclitaxel|nab-Paclitaxel
219173053|NCT04993885|DRUG|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
219173054|NCT02673424|PROCEDURE|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
219173055|NCT02673424|PROCEDURE|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)"
219173056|NCT03170453|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
219173057|NCT03170453|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
219173058|NCT04899011|OTHER|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
219173059|NCT06260514|DRUG|APR-1051|WEE1 Inhibitor
219244764|NCT03519893|DRUG|Losartan|Patients are tested for their normal prescription losartan medication
219244765|NCT04967521|DRUG|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
219173060|NCT03398876|DRUG|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
219173061|NCT03398876|DRUG|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
219173062|NCT03398876|OTHER|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
219173063|NCT06155669|DEVICE|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
219173064|NCT04531059|DRUG|Esomeprazole|Proton pump inhibitor
219173065|NCT04531059|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219173066|NCT04531059|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
219173067|NCT04531059|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
219173068|NCT06231810|BEHAVIORAL|Tactile stimulation|Tactile stimuli of differing magnitudes will be applied
219173069|NCT05480995|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
219173070|NCT06074666|BEHAVIORAL|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
219173071|NCT06074666|BEHAVIORAL|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
219173072|NCT03085108|OTHER|No Intervention|No Intervention
219173073|NCT01181375|OTHER|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
219173074|NCT04832295|OTHER|photo-supported conversations|"Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs."
219173075|NCT04832295|OTHER|Care as usual|Medication, psychological treatment
219173076|NCT05027958|DRUG|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
219173077|NCT05838274|OTHER|Alcohol vs. Placebo beverage conditions|Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.
219173078|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
219173079|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
219173080|NCT03443323|BEHAVIORAL|Organizational Skills Training - Tier 2 (OST-T2)|OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
219173081|NCT05432245|DEVICE|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
219173082|NCT06568471|DRUG|Lerodalcibep|PCSK9 inhibitor
219173083|NCT06568471|DRUG|matching placebo|placebo
219173084|NCT05391893|DRUG|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
219173085|NCT05391893|DRUG|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
219173086|NCT06541691|DRUG|Enteric-coated aspirin|Enteric-coated aspirin tablet 81 mg, once daily
219173087|NCT06541691|DRUG|Plain aspirin|Plain aspirin tablet 81 mg, once daily
219244766|NCT04967521|DRUG|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
219244767|NCT05004740|OTHER|Vaccinated Pregnant or Lactating persons|vaccinated lactating persons from Sinai Health System or the general public
219244768|NCT03623776|DRUG|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
219244769|NCT03623776|DRUG|Pemetrexed|Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
219244770|NCT03623776|DRUG|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
219244771|NCT03623776|PROCEDURE|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
219244772|NCT03476603|DRUG|Irbesartan|Patients are tested for their normal prescription irbesartan medication
219244773|NCT06471842|OTHER|MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire|The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
219244774|NCT04799587|OTHER|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
219244775|NCT04799587|OTHER|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
219244776|NCT04387916|DRUG|KC1036|Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
219244777|NCT04798833|DEVICE|Integrated Newborn Care Kit (iNCK)|"Contents of the integrated newborn care kit:~* Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~* 3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~* 4% CHX solution (15 mL)~* Sunflower oil emollient (50 mL)~* Temperature monitoring strip or sticker~* Fleece blanket for the newborn~* Click to heat warmer~* Pictorial guide that illustrates how and when to use each kit component~* Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit"
219244778|NCT05651347|OTHER|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
219244779|NCT05651347|DRUG|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
219244780|NCT05341960|BEHAVIORAL|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
219244781|NCT05341960|OTHER|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
219244782|NCT00515281|DRUG|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
219173088|NCT06541691|OTHER|Hybrid strategy|"A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days"
219173089|NCT06569121|BEHAVIORAL|Group Lifestyle Balance for People Post Stroke (GLB-CVA)|12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
219173090|NCT06392360|DIETARY_SUPPLEMENT|Betaine|White betaine powder
219173091|NCT06392360|DIETARY_SUPPLEMENT|Placebo|White placebo powder
219173092|NCT06465563|DRUG|SHR-8068|SHR-8068
219173093|NCT06465563|DRUG|Adebrelimab|Adebrelimab
219173094|NCT06465563|DRUG|Cisplatin|Cisplatin
219173095|NCT06465563|DRUG|Gemcitabine|Gemcitabine
219173096|NCT04857671|DRUG|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
219173097|NCT04857671|DRUG|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
219173098|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
219173099|NCT06472713|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection once every 3 weeks for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
219173100|NCT06472713|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
219173101|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
219173102|NCT05527392|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
219173103|NCT06292624|DEVICE|Intermittent vacuum therapy (Weyergans High Care® Medial, Germany)|The participants' lower limb will be placed in the vacuum chamber and sealed with a cuff. The maximum negative pressure applied in the experimental group would be -40mmHg (negative pressure/ambient pressure phase: 9s / 7s). The parameters are selected based on the manufacturer's recommendations.
219173104|NCT06292624|BEHAVIORAL|Cycling exercise|The participant will perform 20 minutes of cycling exercise. Aiming at reaching a moderate exercise intensity (50% - 70%) of maximal heart rate on a gym bike.
219173105|NCT05536336|DEVICE|Condom|Contraception
219173106|NCT05187182|DRUG|CA-4948|Provided by Curis, Inc.
219173107|NCT05187182|BIOLOGICAL|Nivolumab|240 mg IV on Day 1 of each cycle
219173108|NCT05187182|BIOLOGICAL|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
219173109|NCT05187182|DRUG|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
219173110|NCT05187182|DRUG|mFOLFOX7|Standard of care
219173111|NCT06021795|DEVICE|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
219173112|NCT06071806|OTHER|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
219173113|NCT03426748|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
219173114|NCT03426748|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
219173115|NCT06834165|DRUG|Neffy|Epinephrine nasal spray
219173116|NCT06834165|DRUG|Adrenaline|Epinephrine injection
219173117|NCT06836765|OTHER|the expression negative in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
219173118|NCT06836765|OTHER|the expression positive in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
219244783|NCT00515281|DRUG|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
219244784|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
219173119|NCT06829030|DRUG|5% dextrose prolotherapy|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection
219173120|NCT06829030|DRUG|Diclofenac 75mg/ml|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection (approximately 75 patients).
219173121|NCT04848870|OTHER|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
219173122|NCT04959201|DRUG|NMDAE plus AO|Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
219173123|NCT04959201|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator.
219173124|NCT06837272|DIAGNOSTIC_TEST|Multi-omics features extraction|Based on multi-omics features extracted from clinical data, gut microbiome, metabolomics, and multi-modal MRI, the diagnostic model of SCD due to preclinical AD will be established.
219173125|NCT05836168|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair|multispecies probiotic
219173126|NCT05836168|DIETARY_SUPPLEMENT|Placebo|Placebo
219173127|NCT03135548|DRUG|Spesolimab (low dose)|12 weeks treatment
219173128|NCT03135548|DRUG|Placebo|12 weeks treatment
219173129|NCT03135548|DRUG|Spesolimab (high dose)|12 weeks treatment
219173130|NCT04461236|DIETARY_SUPPLEMENT|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
219173131|NCT04461236|DIETARY_SUPPLEMENT|Placebo|Placebo
219173132|NCT06829810|OTHER|Modelisation of intraocular pressure profile|Modelisation of IOP profile of all surgical techniques and additional procedures during the follow-up
219173133|NCT05267808|PROCEDURE|Drug-induced sleep endoscopy|Endoscopy during drug-induced sleep
219173134|NCT06838195|BIOLOGICAL|S. Flexneri-S. Sonnei bivalent conjugate vaccine|Subjects receive two doses of the vaccine on the day of randomisation (day 0) and day 30.
219173135|NCT06838195|BIOLOGICAL|Placebo|Subjects receive two doses of the placebo on the day of randomisation (day 0) and day 30.
219173136|NCT06835335|BEHAVIORAL|opioid prescription|"The intervention consisted of a randomized questionnaire presenting a clinical case of a patient suffering from severe abdominal pain. The control case was As an emergency physician in an adult emergency department, you are presented with the following patient: The patient is a 39-year-old non-smoking male/female with a history of Meniere's disease and an allergy to Bactrim. He/she presents with abdominal pain that began abruptly 2 hours ago and has persisted despite taking NEFOPAM 45 minutes ago. This is his first episode. His/her vital signs are blood pressure 140/66, heart rate 91, pulse ox 97%, temperature 36.8°C. He/she rates his/her pain as 8/10 without any analgesic position. On clinical examination he/she presents with localized epigastric tenderness. The rest of the abdomen is soft, painless and depressed. There are hydro-aeriform noises. No diarrhea or vomiting. The rest of the clinical examination showed no abnormalities.. In the intervention case, patient had history of S"
219173137|NCT04103346|OTHER|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
219173138|NCT04103346|OTHER|sham|air purifier running with air filter removed
219173139|NCT06830330|BEHAVIORAL|Virtual reality|Patients in the experimental group were shown videos of natural landscapes with VR glasses in their beds. This application was used to distract patients who were experiencing negative emotions just before surgery. The video session begins with the introduction of the virtual reality glasses. A motionless virtual area is determined at the point where the patient's stretcher is located. The glasses are placed on the patient's head and both hands of the patient are trained to use the remote control. Video content is selected and started according to the patient's preference. Video sessions last approximately 10 minutes.
219173140|NCT04238676|DRUG|PP353|active administered by intradiscal injection
219173141|NCT04238676|OTHER|Placebo|Sham injection
219173142|NCT06342947|DRUG|ALG-055009|Softgel Capsule
219173143|NCT06342947|DRUG|Placebo|Softgel Capsule
219173144|NCT06830707|DEVICE|experimental group|The treatment comprised 5 robot-assisted gait training sessions over a 2-week period, followed by 10 lower limb Constraint Induced Movement Therapy(CIMT) sessions with a torque assisted exoskeleton.
219173145|NCT04475536|DEVICE|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
219173146|NCT05445479|DRUG|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
219173147|NCT04072406|OTHER|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
219173148|NCT04072406|OTHER|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
219244785|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
219244786|NCT04929236|DRUG|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
219244787|NCT03074097|DRUG|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
219244788|NCT02713776|DRUG|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
219244789|NCT02713776|DRUG|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
219244790|NCT01565031|PROCEDURE|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
219244791|NCT02288572|DIETARY_SUPPLEMENT|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
219244792|NCT02288572|DIETARY_SUPPLEMENT|Placebo|Taking dietary supplement on a daily basis for 3 months.
219173149|NCT06307470|BEHAVIORAL|EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)|"The intervention will be led by a registered nurse who holds certifications in sexuality counseling and sex education. The therapeutic, online environment will serve as a confidential, private space without judgement to encourage discussion to model safe sexuality communication for breast cancer survivors. The curriculum will include: i) psychoeducation: sexual body, mind-body connection, and sexual relationships; ii) physical-body education: physical response, safety, and navigating physical changes in survivorship; iii) solution-focused tools: tailored vaginal rehydration, lubrication, education; and iv) communication: internal, partnered, and patient-provider communication skills.~The solution-focused tools will include vaginal rehydration and dilation products with vaginal lubrication. Tools will be distributed via mail by Session 2."
219173150|NCT06541899|DEVICE|Polarys Cryolipolysis|The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.
219173151|NCT02738788|OTHER|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
219173152|NCT05443048|DEVICE|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
219173153|NCT03424941|DEVICE|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
219173154|NCT03424941|DEVICE|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
219173155|NCT05569252|DRUG|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
219173156|NCT05569252|OTHER|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
219173157|NCT03665597|BIOLOGICAL|Pembrolizumab Dose C|165 mg/mL administered to a final dose of 285 mg via subcutaneous injection
219173158|NCT03665597|BIOLOGICAL|Pembrolizumab Dose A|130 mg/mL administered to a final dose of 285 mg via subcutaneous injection
219173159|NCT03665597|BIOLOGICAL|Pembrolizumab Dose B|200 mg administered via intravenous infusion
219173160|NCT03665597|BIOLOGICAL|Pembrolizumab Dose D|400 mg administered via intravenous infusion
219739669|NCT04993911|OTHER|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
219173161|NCT04663087|DEVICE|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
219173162|NCT04663087|OTHER|Standard of Care|As currently provided by EMS services
219173163|NCT03951194|BIOLOGICAL|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
219173164|NCT03951194|OTHER|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
219173165|NCT04572152|BIOLOGICAL|AK119|Subjects will receive AK119 by intravenous administration.
219173166|NCT04572152|BIOLOGICAL|AK104|On the same day subjects will receive AK104 by intravenous administration.
219173167|NCT05504239|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
219173168|NCT05504239|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
219173169|NCT04861064|DRUG|Sirolimus|Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
219173170|NCT06242288|DRUG|ISOtretinoin 20 MG|Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
219173171|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
219173172|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
219173173|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
219173174|NCT02088645|DRUG|177Lu-PP-F11N|
219173175|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
219173176|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
219173177|NCT05593575|DRUG|SPH3127+valsartan matching placebo|4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
219173178|NCT05593575|DRUG|SPH3127 matching placebo+valsartan|4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
219173179|NCT06465498|PROCEDURE|LUS decongestive strategy|LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
219173180|NCT06465498|PROCEDURE|PE decongestive strategy|PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
219173181|NCT05371652|DRUG|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
219244793|NCT02672345|DRUG|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
219244794|NCT06247761|DEVICE|Skin closure at end of hand surgery|skin closure with vicryl rapide suture
219244795|NCT03722602|OTHER|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
219244796|NCT00872404|DRUG|CP-751,871|20mg/kg/3 weeks
219244797|NCT01287624|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
219244798|NCT01287624|DRUG|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
219244799|NCT01601925|OTHER|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
219244800|NCT02488733|PROCEDURE|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
219244801|NCT02488733|DRUG|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
219244802|NCT00745069|DRUG|tapentadol HCl|
219244803|NCT00441571|DRUG|177Lu-CYT-500|
219244804|NCT03109600|BIOLOGICAL|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
219244805|NCT03109600|BIOLOGICAL|Vi polysaccharide vaccine|Vi polysaccharide vaccine
219244806|NCT03109600|BIOLOGICAL|Influenzae vaccine|1 dose of Influenzae vaccine
219244807|NCT03109600|BIOLOGICAL|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
219244808|NCT03979144|BEHAVIORAL|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
219244809|NCT00336375|DRUG|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
219244810|NCT02241980|OTHER|Patient survey|
219244811|NCT02241980|OTHER|Physician survey|
219244812|NCT01292005|DRUG|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
219244813|NCT01292005|DRUG|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
219244814|NCT06585007|RADIATION|Radiotherapy|Progression-directed therapy (stereotactic body radiation therapy)
219244815|NCT06585007|PROCEDURE|metastasectomy|Progression-directed therapy (metastasectomy)
219244816|NCT03293147|OTHER|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
219244817|NCT03293147|OTHER|Standard care|Standard care for hypertensive patients
219244818|NCT01060163|DRUG|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
219244819|NCT01060163|DRUG|Saline|Saline served as placebo
219244820|NCT04140422|OTHER|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
219244821|NCT04140422|OTHER|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
219244822|NCT00347425|DRUG|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
219244823|NCT00347425|DRUG|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
219244824|NCT00347425|DRUG|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
219244825|NCT00347425|DRUG|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
219244826|NCT00347425|DRUG|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
219244827|NCT00347425|DRUG|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
219244828|NCT00347425|DRUG|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
219244829|NCT00347425|DRUG|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
219173182|NCT03699319|DRUG|CPI 613|"Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months"
219173183|NCT03699319|DRUG|Oxaliplatin|"Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
219173184|NCT03699319|DRUG|Irinotecan|"Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
219173185|NCT03699319|DRUG|5-flurouracil|"Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
219173186|NCT03699319|DRUG|Folinic acid|"Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
219173187|NCT06288919|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
219173188|NCT06288919|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
219173189|NCT05986136|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
219244830|NCT00347425|DRUG|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
219244831|NCT00347425|DRUG|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
219244832|NCT03831698|DRUG|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
219244833|NCT03010878|OTHER|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
219244834|NCT03010878|OTHER|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
219244835|NCT02444195|BEHAVIORAL|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
219244836|NCT00125723|OTHER|PI Discretion|PI Discretion
219244837|NCT05441293|PROCEDURE|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
219244838|NCT00138814|PROCEDURE|Radiotherapy (boost versus no boost)|
219244839|NCT05811000|DRUG|PM012|PM012 650 mg tablet drug
219244840|NCT05811000|DRUG|PM012 Placebo|PM012 tablet placebo
219244841|NCT05811000|DRUG|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
219244842|NCT05811000|DRUG|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
219244843|NCT00930319|OTHER|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
219244844|NCT06576037|DRUG|CBP-1019|Given by vein (IV)
219244845|NCT06576037|DRUG|Oxaliplatin|Given by vein (IV)
219244846|NCT06576037|DRUG|Leucovorin|Given by vein (IV)
219244847|NCT06576037|DRUG|5-FLUOROURACIL|Given by vein (IV)
219244848|NCT06576037|DRUG|Bevacizumab|Given by vein (IV)
219244849|NCT06576037|DRUG|Pembrolizumab|Given by vein (IV)
219244850|NCT06576037|DRUG|Enzalutamide|Given by mouth
219244851|NCT04682483|DRUG|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
219244852|NCT04682483|DRUG|Inotrope|Inotropes include dobutamine and milrinone.
219244853|NCT04682483|DEVICE|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
219244854|NCT02130401|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
219244855|NCT00176319|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
219244856|NCT01270906|DRUG|CHIR-258 (TKI258)|
219244857|NCT04594525|OTHER|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
219244858|NCT06509295|OTHER|Calcium Hypochlorite as Root Canal Irrigant|Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
219244859|NCT01731210|DEVICE|implantation of the new LV lead: NANO system.|
219244860|NCT05693428|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
219244861|NCT05693428|DRUG|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
219244862|NCT05693428|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
219244863|NCT01667159|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
219244864|NCT01667159|BEHAVIORAL|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
219244865|NCT00488267|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
219244866|NCT00488267|DRUG|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
219244867|NCT00488267|DRUG|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
219244868|NCT01829594|OTHER|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
219244869|NCT04019925|DEVICE|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
219244870|NCT05888285|PROCEDURE|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
219244871|NCT05888285|PROCEDURE|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
219244872|NCT01466556|OTHER|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
219244873|NCT01374152|OTHER|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
219244874|NCT00634998|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C capsules orally twice daily
219244875|NCT00634998|DIETARY_SUPPLEMENT|Placebo|1000mg Placebo capsules orally twice daily for 90 days
219244876|NCT02632188|PROCEDURE|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
219244877|NCT02632188|BIOLOGICAL|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
219244878|NCT03039556|BEHAVIORAL|Normal Daily Steps|Complete normal daily ambulation for one week
219244879|NCT03039556|BEHAVIORAL|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
219244880|NCT03039556|BEHAVIORAL|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
219244881|NCT05606796|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
219244882|NCT05410717|BIOLOGICAL|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
219244883|NCT04873544|PROCEDURE|ERAS protocols for TKA|ERAS protocols for TKA
219244884|NCT03147222|BEHAVIORAL|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
219244885|NCT00936065|DRUG|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
219244886|NCT00936065|DRUG|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
219244887|NCT00936065|DRUG|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
219739670|NCT04993911|OTHER|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
219739671|NCT02096965|DRUG|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
219739672|NCT02096965|DRUG|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
219739673|NCT03657407|DRUG|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
219739674|NCT03657407|DRUG|Glycerin Suppository|Glycerine rectal suppository
219739675|NCT06420076|BIOLOGICAL|CD5/CD7 CAR-T|"The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
219739676|NCT06087328|DRUG|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
219739677|NCT06087328|DRUG|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
219739678|NCT05956535|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
219739679|NCT05956535|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
219173190|NCT05986136|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
219173191|NCT04223141|PROCEDURE|SIA|As indicated by arm description
219173192|NCT02182245|DRUG|BIBF 1120|
219173193|NCT02182245|DRUG|Paclitaxel|
219173194|NCT02182245|DRUG|Carboplatin|
219173195|NCT05009004|BEHAVIORAL|text messages to support medication adherence|text messages to support medication adherence
219173196|NCT03555448|DRUG|Once daily immunosuppression regimen|Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
219173197|NCT03555448|DRUG|Twice daily immunosuppression regimen|This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
219173198|NCT04195568|DEVICE|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
219173199|NCT06205095|DRUG|Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII|Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
219173200|NCT06205095|OTHER|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
219173201|NCT06309745|PROCEDURE|retroperitoneal lymph node dissection|retroperitoneal lymph node dissection
219173202|NCT06309745|DRUG|Carboplatin AUC10|Carboplatin AUC10
219173203|NCT06445270|BEHAVIORAL|GDM Prevention Program|Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
219173204|NCT04036448|DRUG|REVLIMID®|REVLIMID®
219173205|NCT05509595|DRUG|Burosumab|Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
219173206|NCT05545956|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
219173207|NCT05545956|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
219173208|NCT06389656|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.
219173209|NCT06389656|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
219244888|NCT01002209|PROCEDURE|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
219739680|NCT05900830|OTHER|play therapy|A combined program based on physical and occupational therapy techniques within a play context
219739681|NCT05900830|OTHER|common educational methods|the child will receive his education in a passive manner
219244889|NCT01002209|PROCEDURE|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
219244890|NCT05832489|DRUG|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
219244891|NCT05832489|DRUG|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
219244892|NCT01285856|OTHER|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
219244893|NCT05832320|DRUG|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
219244894|NCT05832320|DRUG|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
219244895|NCT01779089|DRUG|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
219244896|NCT01779089|DRUG|placebo|
219244897|NCT04327349|BIOLOGICAL|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
219244898|NCT02389894|DEVICE|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
219244899|NCT02389894|DEVICE|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
219362688|NCT01361997|BIOLOGICAL|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
219739682|NCT02628145|BEHAVIORAL|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
219739683|NCT02628145|BEHAVIORAL|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
219739684|NCT05586685|OTHER|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
219739685|NCT00153933|DRUG|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
219739686|NCT00153933|DRUG|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
219739687|NCT00049283|DRUG|erlotinib hydrochloride|Given orally
219739688|NCT00049283|DRUG|docetaxel|Given IV
219739689|NCT00049283|RADIATION|radiation therapy|Undergo radiotherapy
219739690|NCT00049283|PROCEDURE|therapeutic conventional surgery|Undergo neck dissection
219739691|NCT00049283|OTHER|laboratory biomarker analysis|Correlative studies
219739692|NCT00049283|OTHER|pharmacological study|Correlative studies
219739693|NCT03186183|BEHAVIORAL|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
219739694|NCT02339675|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
219739695|NCT05668507|BEHAVIORAL|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours"
219739696|NCT05262673|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
219739697|NCT04098783|OTHER|Home visit, health education|
219739698|NCT05281458|PROCEDURE|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
219739699|NCT06121635|COMBINATION_PRODUCT|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
219739700|NCT06121635|COMBINATION_PRODUCT|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
219739701|NCT05530915|OTHER|Gel capsule|Single capsule per dose
219739702|NCT01460537|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
219739703|NCT01460537|DRUG|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
219739704|NCT01460537|DRUG|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
219739705|NCT01460537|DRUG|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
219739706|NCT01460537|DRUG|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
219173210|NCT06115070|DRUG|Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
219173211|NCT06487364|OTHER|Rehabilitation|A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
219173212|NCT05353140|DEVICE|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
219173213|NCT05353140|DRUG|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
219173214|NCT05353140|DRUG|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
219173215|NCT06156943|PROCEDURE|individualized goal-directed fluid therapy by Starling device|For patients in optimized group, fluids will be managed by Starling device during the lung resection surgery.
219739707|NCT05936138|DRUG|LY3502970|Administered orally.
219739708|NCT00167531|BEHAVIORAL|treadmill walking with partial weight support|
219739709|NCT00167531|BEHAVIORAL|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
219739710|NCT03976726|DEVICE|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
219739711|NCT02303483|DIETARY_SUPPLEMENT|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
219739712|NCT02303483|DIETARY_SUPPLEMENT|Placebo|
219739713|NCT05701631|DIAGNOSTIC_TEST|Radiomic model|Radiomic model for PCP diagnosis
219244900|NCT02440256|OTHER|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
219244901|NCT06222086|OTHER|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.
219244902|NCT06222086|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
219244903|NCT05618717|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
219244904|NCT00106405|DRUG|Memantine HCl|
219244905|NCT01034774|DRUG|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
219244906|NCT01034774|DRUG|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
219739714|NCT04180423|DEVICE|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
219739715|NCT04180423|DEVICE|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
219739716|NCT05625867|OTHER|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
219739717|NCT05625867|OTHER|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
219739718|NCT04409418|DEVICE|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
219739719|NCT06456684|DIAGNOSTIC_TEST|Fluoro[18F]promethazine|It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
219739720|NCT03066518|DRUG|Melatonin 5 mg|
219739721|NCT03066518|OTHER|Placebo|
219739722|NCT00307580|DRUG|Cathflo Activase (Alteplase)|
219739723|NCT04887805|DRUG|Lenvatinib Mesylate|Given PO
219739724|NCT04887805|BIOLOGICAL|Pembrolizumab|Given IV
219739725|NCT06643962|DRUG|Venetoclax|Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
219739726|NCT06643962|DRUG|Idarubincin|Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
219739727|NCT06643962|DRUG|Cytarabine|During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
219739728|NCT02926196|DRUG|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
219739729|NCT05996068|DEVICE|arterial line|insert arterial line for patients who meet major trauma criteria
219739730|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
219739731|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
219739732|NCT05510934|BEHAVIORAL|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
219739733|NCT06259812|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
219739734|NCT03153202|DRUG|Ibrutinib|once daily oral intake ibrutinib
219739735|NCT03153202|DRUG|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
219739736|NCT03201094|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
219739737|NCT03201094|DIETARY_SUPPLEMENT|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
219739738|NCT01540539|DRUG|REGN1154 or placebo|Participants will receive active drug or placebo
219739739|NCT03048825|DRUG|Colchicine|Colchicine 0.5 mg once daily
219739740|NCT03048825|DRUG|Spironolactone|Spironolactone 25 mg once daily
219739741|NCT03048825|DEVICE|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
219739742|NCT03048825|DRUG|Colchicine-Placebo|Matching Colchicine-placebo once daily
219739743|NCT03048825|DRUG|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
219739744|NCT00160875|DRUG|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
219739745|NCT00160875|DRUG|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
219739746|NCT00420056|DRUG|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
219739747|NCT00538265|DRUG|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
219739748|NCT00538265|DRUG|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
219739749|NCT00538265|DRUG|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
219739750|NCT02069184|DRUG|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
219739751|NCT02069184|OTHER|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
219739752|NCT05848843|DRUG|Durvalumab|Given by vein (IV)
219739753|NCT05848843|DRUG|Adagrasib|Given by PO
219739754|NCT00870155|DRUG|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
219739755|NCT01292538|DEVICE|Erchonia GLS|532 nm green diode low level laser light device
219739756|NCT01292538|DEVICE|Placebo laser|Sham light output with no therapeutic benefit
219739757|NCT00907088|OTHER|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
219739758|NCT00907088|OTHER|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
219739759|NCT00986895|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
219739760|NCT00029900|DRUG|ADI PEG|
219739761|NCT06254690|DRUG|Pyrotinib dose escalation|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
219739762|NCT06254690|DRUG|Pyrotinib dose normal|Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
219739763|NCT03179709|BEHAVIORAL|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
219739764|NCT03673722|OTHER|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
219739765|NCT03673722|OTHER|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
219173216|NCT06156943|PROCEDURE|group managed by standard of care|Patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols
219739766|NCT03673722|OTHER|Control|Participants will be given generic healthy eating advice based
219739767|NCT02301793|BEHAVIORAL|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
219173217|NCT05426005|DRUG|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
219173218|NCT05956028|PROCEDURE|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
219173219|NCT05956028|PROCEDURE|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
219173220|NCT04360928|DEVICE|Graymont X ERIS Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
219173221|NCT04360928|DEVICE|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
219173222|NCT04410042|DRUG|Tranexamic Acid|Given IV
219173223|NCT04410042|OTHER|0.9% sodium chloride|Given IV
219173224|NCT03898986|BIOLOGICAL|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
219173225|NCT03898986|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
219173226|NCT03374319|PROCEDURE|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
219173227|NCT05860751|PROCEDURE|Dry Needling with electrical stimulation|Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
219173228|NCT05971888|BEHAVIORAL|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
219173229|NCT03720795|BEHAVIORAL|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
219173230|NCT04401020|DRUG|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
219173231|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
219173232|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
219173233|NCT06418984|DEVICE|auxiliary|the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
219173234|NCT06022003|DRUG|AzaCITIDine Oral Tablet|AML study treatment
219173235|NCT06022003|DRUG|Xospata|R/R FLT3-mutated AML standard treatment
219173236|NCT06418425|BEHAVIORAL|counselling on home-based exercise program and dietary protein intake|Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
219739768|NCT02301793|BEHAVIORAL|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
219244907|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
219244908|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
219244909|NCT02790645|OTHER|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
219244910|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
219244911|NCT04453137|BIOLOGICAL|Adalimumab originator|Subcutaneous injection every other week
219244912|NCT04453137|BIOLOGICAL|Adalimumab biosimilar|Subcutaneous injection every other week
219244913|NCT04451720|DRUG|Risankizumab|Subcutaneous (SC) injection
219244914|NCT04451720|DRUG|Placebo|Subcutaneous (SC) injection
219244915|NCT01670942|OTHER|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
219244916|NCT02228889|PROCEDURE|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
219244917|NCT02228889|OTHER|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
219244918|NCT02228889|OTHER|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
219244919|NCT02228889|OTHER|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
219244920|NCT02228889|OTHER|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
219244921|NCT02228889|OTHER|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
219244922|NCT02228889|OTHER|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
219244923|NCT02228889|OTHER|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
219244924|NCT02228889|OTHER|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
219244925|NCT02228889|OTHER|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
219244926|NCT02228889|OTHER|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
219244927|NCT02228889|OTHER|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
219244928|NCT02228889|OTHER|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
219739769|NCT04281771|PROCEDURE|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
219739770|NCT02477046|BIOLOGICAL|tOPV|administered per protocol
219244929|NCT02228889|OTHER|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
219739771|NCT02477046|BIOLOGICAL|bOPV|administered per protocol
219739772|NCT02477046|BIOLOGICAL|IPV|administered per protocol
219739773|NCT01435746|BEHAVIORAL|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
219244930|NCT02228889|OTHER|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
219244931|NCT02228889|OTHER|Assess overall complications at 30 days postoperatively|
219244932|NCT02228889|OTHER|Assess overall complications at 1 year postoperatively|
219244933|NCT02228889|PROCEDURE|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
219244934|NCT02228889|DEVICE|Strattice|Strattice mesh
219244935|NCT02228889|DEVICE|XenMatrix|Xenmatrix mesh
219244936|NCT00145496|DRUG|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
219244937|NCT00145496|DRUG|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
219244938|NCT04912726|DRUG|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
219244939|NCT05536869|PROCEDURE|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
219244940|NCT05621902|OTHER|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
219244941|NCT00309439|PROCEDURE|ALA-rich diet|
219244942|NCT03120936|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
219244943|NCT03120936|BEHAVIORAL|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
219244944|NCT02791295|OTHER|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
219244945|NCT04732611|OTHER|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
219173237|NCT00179868|BEHAVIORAL|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~1. Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~2. Acute GVHD \> grade II defined according to the Seattle criteria~3. VOD- defined according to the modified Seattle criteria"
219739774|NCT04023474|PROCEDURE|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
219739775|NCT04978831|DEVICE|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
219739776|NCT04978831|OTHER|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
219739777|NCT01062295|DEVICE|Siesta-System|
219739778|NCT01062295|DEVICE|Standard headrest|
219739779|NCT02473263|DRUG|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
219739780|NCT02473263|DRUG|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
219739781|NCT02473263|DRUG|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
219739782|NCT02473263|DRUG|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
219739783|NCT05200780|DEVICE|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
219739784|NCT02838706|PROCEDURE|Surgery for hip fracture|
219739785|NCT01292993|DRUG|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
219739786|NCT01292993|DRUG|1000 mg metformin|1000 mg metformin given as a solid oral dose form
219739787|NCT01044459|DRUG|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
219739788|NCT01044459|DRUG|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
219739789|NCT05154929|BEHAVIORAL|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
219739790|NCT05154929|OTHER|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
219739791|NCT01029964|BEHAVIORAL|Individually and in groups|During three year in a clinical setting.
219173238|NCT04513626|DRUG|DORAVIRINE 100 MG [Pifeltro]|Immediate switch
219173239|NCT05134233|DEVICE|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
219739792|NCT01095965|BEHAVIORAL|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
219739793|NCT04195256|DRUG|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
219739794|NCT04195256|DRUG|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
219739795|NCT04195256|DRUG|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
219739796|NCT04195256|DRUG|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
219173240|NCT00367666|DEVICE|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
219173241|NCT06424977|DEVICE|Biomarker Targeted Stimulation (BTS)|Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
219173242|NCT03649659|DRUG|Silver Diamine Fluoride|SDF will be applied twice during the study
219173243|NCT03649659|DRUG|Placebo|This is being compared to the SDF and will also be applied twice
219173244|NCT05359276|DRUG|Olipudase alfa|GZ402665
219173245|NCT02104310|DRUG|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
219173246|NCT04764656|DRUG|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
219173247|NCT02302300|DEVICE|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
219173248|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
219173249|NCT04510974|OTHER|Spinal Cord Injury|Spinal Cord Injury
219173250|NCT04763265|BIOLOGICAL|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
219173251|NCT04763265|BIOLOGICAL|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
219173252|NCT04959318|OTHER|Professional nutrition counseling|Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.
219173253|NCT04959318|OTHER|No professional nutrition counseling|Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
219173254|NCT00397358|DRUG|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
219244946|NCT04732611|OTHER|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
219244947|NCT04373291|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
219244948|NCT04373291|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
219244949|NCT05503407|PROCEDURE|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
219244950|NCT05503407|PROCEDURE|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
219244951|NCT03382704|DIAGNOSTIC_TEST|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
219244952|NCT01443572|DRUG|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
219244953|NCT01443572|DRUG|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
219244954|NCT06510400|OTHER|OMNICHROMA|supra nano filled composite
219244955|NCT06510400|OTHER|Ceram. x spectra|nano hybrid composite resin
219244956|NCT05366478|DRUG|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
219244957|NCT02735005|OTHER|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
219244958|NCT06170125|OTHER|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
219244959|NCT02694107|OTHER|Proprioceptive exercises|
219244960|NCT02694107|OTHER|Control|
219739797|NCT05864716|BIOLOGICAL|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
219739798|NCT04131894|BIOLOGICAL|autogenous dentin graft|
219739799|NCT04131894|BIOLOGICAL|platelet rich fibrin (PRF)|
219739800|NCT02601365|DRUG|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
219739801|NCT02601365|DRUG|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
219739802|NCT02601365|DRUG|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
219739803|NCT01392066|BEHAVIORAL|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
219739804|NCT04634331|BEHAVIORAL|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
219739805|NCT04634331|BEHAVIORAL|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
219739806|NCT06644404|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
219739807|NCT06644404|DRUG|DWC202407 1,000mg|1 tablet, Orally, Twice daily
219739808|NCT06644404|DRUG|DWC202408 2mg|1 tablet, Orally, Once daily single dose
219739809|NCT06673199|DIETARY_SUPPLEMENT|Washoku diet|The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).
219739810|NCT06674772|DIAGNOSTIC_TEST|Saliva test|Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
219739811|NCT06673953|OTHER|Respiratory Muscle Training by (The Breather)|Patients are instructed to inhale deeply and forcefully (at non fatigable resistance) for 2-3 seconds, slight pause, and then exhale forcefully for 2-3 seconds for 10 repetitions with 2 sets.
219739812|NCT06673953|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )
219739813|NCT02171208|DRUG|dimethyl fumarate - Reference form|single dose 240 mg
219739814|NCT02171208|DRUG|dimethyl fumarate - Test form|single dose 240 mg
219739815|NCT06673680|DEVICE|Do colposcopy and cervical punch biopsy then compare between findings|The aim of this study is to correlate colposcopy and histopathological findings in early screening of suspicious cervix and cervical cancer. And to do a colposcopic evaluation of all cervical lesions and the early detection of all cervical precancer and invasive lesions of the cervix in symptomatic women.
219739816|NCT06675877|OTHER|virtual reality camera|The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
219173255|NCT04418466|COMBINATION_PRODUCT|Risperidone|Risperidone Implant
219173256|NCT06516341|PROCEDURE|CD patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
219173257|NCT06516341|PROCEDURE|UC patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
219173258|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
219173259|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
219173260|NCT04785820|DRUG|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
219173261|NCT04785820|DRUG|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
219173262|NCT04785820|DRUG|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
219173263|NCT03047837|DRUG|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
219173264|NCT03047837|DRUG|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
219173265|NCT03047837|OTHER|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
219173266|NCT06499090|DRUG|Mirtazapine 30 MG|patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
219244961|NCT04251455|PROCEDURE|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
219739817|NCT06674668|OTHER|Vibrotactile stimulation|The intervention includes traditional physiotherapy and 20 minutes of vibrotactile device use. As traditional physiotherapy, 30 seconds of 8 repetitions of passive wrist stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Afterwards, the Intellinetix Elbow Wearable Vibration Device providing vibration will be worn on the affected tissue. The patient will remain in a comfortable position on the treatment table with the affected extremity for 20 minutes (10 minutes × 2).
219739818|NCT06674668|OTHER|Traditional physiotherapy|For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Stretching exercises will be performed on the wrist flexor and extensor muscles for 30 seconds and 8 repetitions. Mill's manipulation, described by James Cyriax, will be applied once for radial head mobilization. The treatment will be completed with a 5-minute deep friction massage, affecting the wrist extensor muscle tendons and their ending points.
219739819|NCT06690203|COMBINATION_PRODUCT|NRICM102|A traditional Chinese medicine formula
219739820|NCT06687213|BEHAVIORAL|Smoking cessation counselling group|Case group will be counseled to cessate smoking and will be followed up with HbA1c
219739821|NCT06689137|OTHER|mini mental state assessment test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used. With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
219739822|NCT06689137|OTHER|mini-cog test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
219739823|NCT06691841|DRUG|Chlorhexidine Gluconate|oral wiping and oral care solution rinsing, oral care solution was 0.12% chlorhexidine gluconate, and the frequency of oral care was 3 times a day.
219739824|NCT06691841|OTHER|normal saline|oral wiping and oral care solution rinsing, oral care solution was 0.9% normal saline, and the frequency of oral care was 3 times a day.
219739825|NCT06689813|DIETARY_SUPPLEMENT|Vitamin D tablets|Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
219739826|NCT06689813|OTHER|Ispaghula husk|Ispaghula husk tablets were given to Group B participants
219739827|NCT06689683|DEVICE|Shock wave lithotripsy|SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
219739828|NCT06689293|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Self-collected sample from stool collected into testing kit
219739829|NCT06688877|DEVICE|headphones with activated noise cancelling|noise cancelling is new
219739830|NCT06688877|DEVICE|headphones with activated noise cancelling and soft 60 bpm musc|noise cancelling is new
219739831|NCT06688877|DEVICE|heart rate measurement|three times (before, during and after surgery)
219739832|NCT06688877|OTHER|Questionnaire|two times (before and after surgery)
219739833|NCT06683495|OTHER|Mirror Therapy|For mirror therapy, a 50×40 cm mirror will be used
219739834|NCT06685796|DRUG|BEBT-209 capsules|BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
219739835|NCT06685796|DRUG|Carboplatin injection|Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
219739836|NCT06685796|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
219173267|NCT06499090|DRUG|Placebo|patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
219173268|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
219173269|NCT06383676|OTHER|Functional reaction balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
219173270|NCT06383676|OTHER|Functional balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
219173271|NCT06092879|OTHER|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
219173272|NCT04958811|DRUG|Tiragolumab|600mg IV administered every 3 weeks.
219173273|NCT04958811|DRUG|Atezolizumab|1200mg IV administered every 3 weeks.
219173274|NCT04958811|DRUG|Bevacizumab|15mg/kg IV administered every 3 weeks.
219173275|NCT05477979|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
219244962|NCT02070640|DRUG|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
219244963|NCT02070640|DEVICE|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
219244964|NCT06459167|OTHER|The position adopted when patients undergoing procedure or surgery|For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
219244965|NCT01052714|BEHAVIORAL|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
219244966|NCT00631202|DRUG|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
219244967|NCT01389791|DRUG|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
219244968|NCT01389791|DRUG|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
219244969|NCT01389791|DRUG|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
219244970|NCT02168153|OTHER|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
219244971|NCT02168153|OTHER|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
219244972|NCT02991573|DEVICE|Prime & Bond Universal|Prime \& Bond Universal
219244973|NCT02991573|DEVICE|Ceram X|
219244974|NCT02991573|DEVICE|Prime & Bond XP|Control
219244975|NCT02991573|PROCEDURE|technique 1|
219244976|NCT02991573|PROCEDURE|technique 2|
219244977|NCT00121589|DRUG|Lutein|
219244978|NCT02492126|OTHER|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
219244979|NCT05871502|DEVICE|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
219244980|NCT03998956|PROCEDURE|CPVI|Circumferential PV isolation only
219244981|NCT03998956|PROCEDURE|CPVI+BOX|Circumferential PV and BOX isolation
219244982|NCT03998956|PROCEDURE|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
219244983|NCT01858909|DRUG|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
219244984|NCT01853904|PROCEDURE|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
219244985|NCT01853904|PROCEDURE|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
219244986|NCT00605605|DRUG|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
219244987|NCT01821222|DEVICE|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
219739837|NCT06695182|BEHAVIORAL|physical activity|
219739838|NCT06694870|DIAGNOSTIC_TEST|Transcutaneous CO2 monitoring|Transuctaneous CO2 monitoring
219739839|NCT06689345|DEVICE|taVNS - transauricular vagal nerve stimulation|30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
219739840|NCT06689345|DEVICE|rPMS - repetitive peripheric magnetic stimulation|Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
219739841|NCT06689345|DEVICE|rTMS - repetitive transcranial magnetic stimulation|rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
219739842|NCT06689345|DEVICE|taVNS sham|Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
219739843|NCT06694376|OTHER|No intervention|No intervention.
219244988|NCT05209256|DRUG|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
219244989|NCT05209256|DRUG|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
219244990|NCT05700656|DRUG|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
219244991|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
219244992|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
219244993|NCT02338505|DEVICE|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
219244994|NCT00021996|DRUG|valdecoxib|
219244995|NCT05799534|OTHER|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
219244996|NCT02521337|OTHER|observation|observation
219244997|NCT03662009|OTHER|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
219244998|NCT01748058|BEHAVIORAL|Exercise based on active video gaming|
219244999|NCT04158323|DEVICE|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
219245000|NCT00992693|DRUG|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1\) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
219245001|NCT03115619|DRUG|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
219245002|NCT03640078|OTHER|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
219245003|NCT01177644|DRUG|PDS 1.0|
219173276|NCT05925569|OTHER|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
219173277|NCT04903470|DRUG|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
219173278|NCT04903470|DRUG|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
219173279|NCT05869591|DRUG|Apixaban 5 MG [Eliquis]|Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
219173280|NCT05869591|DRUG|Edoxaban 60 MG [Lixiana]|Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
219173281|NCT03841318|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219173282|NCT03841318|BIOLOGICAL|biopsy of the labial salivary gland|Part of the biopsy of the labial salivary gland
219245004|NCT04119778|BEHAVIORAL|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
219245005|NCT00267865|DRUG|Methotrexate|6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
219245006|NCT00267865|DRUG|Rituximab|375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
219245007|NCT00267865|DRUG|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
219173283|NCT04055207|OTHER|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
219173284|NCT03730454|DEVICE|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
219173285|NCT03730454|OTHER|No Transanastomotic Tube|No transanastomotic tube used during repair
219173286|NCT05520710|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
219173287|NCT05520710|OTHER|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
219245008|NCT03556059|OTHER|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
219245009|NCT05866289|OTHER|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
219245010|NCT02973035|DRUG|Amlodipine|
219245011|NCT02973035|DRUG|Valsartan|
219245012|NCT03853525|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
219245013|NCT03853525|OTHER|Semisolid vaseline|Product is applied to one side of the inguinal region.
219245014|NCT06267326|PROCEDURE|debridment|resection of dead bone
219245015|NCT03603275|DRUG|New FVIII products|Kovaltry or Jivi prescribed by the treating Physician
219173288|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
219173289|NCT01963793|DRUG|Placebo|gel without active component
219245016|NCT00857909|DRUG|Amiloride|1 tablet twice a day
219245017|NCT00857909|DRUG|Spironolactone|1 tablet twice a day
219739844|NCT06687707|OTHER|Attitude Scale towards Physiotherapy Profession|It is a questionnaire that evaluates the attitudes of physiotherapists with 35 questions under 3 headings: professional satisfaction, qualifications required by the profession, and concerns about the profession. It was developed in 2018 by Begümhan Turhan. In this scale, which is a Likert-type questionnaire, each question is scored between 0 and 5 points. The minimum score that can be obtained from the scale is 35 and the maximum score is 175. A high score indicates that physiotherapists have a positive attitude towards their profession
219739845|NCT06687707|OTHER|Minnesota Job Satisfaction Scale|It is a 20-item Likert-type questionnaire. Scores less than 3 points indicate low job satisfaction. Turkish validity and reliability studies were conducted. The validity and reliability study in Turkey was conducted by Baycan and the Cronbach's alpha value of the scale was found to be 0.77. It is a tool consisting of 20 items with features that reveal internal and external job satisfaction factors. The neutral satisfaction score of the scale is 3. If the score obtained from the scale is less than 3, job satisfaction is considered low, and if it is greater than 3, job satisfaction is considered high.
219739846|NCT06687707|OTHER|Maslach Burnout Scale|The Burnout Inventory, which was developed by Maslach and Jackson (1981) and introduced to the literature under Maslach's name, is a seven-point Likert-type scale and consists of a total of 22 items and three subscales. Among these subscales, emotional exhaustion subscale consists of 9 items, depersonalisation subscale consists of 5 items and personal accomplishment subscale consists of 8 items. Scale items are scored as '1 never' and '7 always'. The Turkish validity and reliability of the questionnaire was conducted by Burhan Çapri. It is a 5-point Likert-type scale measured with 0: never 4: always options. High scores are expected
219173290|NCT05457738|OTHER|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
219173291|NCT05457738|OTHER|No E-REVA® app|No use smartphone
219173292|NCT04356612|OTHER|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
219173293|NCT06402721|DRUG|BAY3283142|Single oral dose.
219173294|NCT06595615|DEVICE|cardiovascular implantable electronic devices|Standard of care patients indicated for the devices
219245018|NCT00857909|DRUG|Placebo|Placebo
219245019|NCT00857909|DRUG|Placebo and spironolactone|5mg twice daily
219245020|NCT00857909|DRUG|Spironolactone|25mg twice daily
219245021|NCT01923935|DRUG|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
219245022|NCT01923935|DRUG|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
219245023|NCT02400372|DEVICE|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
219245024|NCT04546178|BEHAVIORAL|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
219245025|NCT04546178|OTHER|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
219245026|NCT03686176|OTHER|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
219245027|NCT00515879|DRUG|D-cycloserine|50 mg
219245028|NCT00515879|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
219245029|NCT00515879|DRUG|Placebo|Same dosage as active pill
219245030|NCT04882956|DRUG|intravitreal injection|Brolucizumab-Dbll intravitreal injection
219245031|NCT04882956|DRUG|intravitreal injection|Aflipercept intravitreal injection
219245032|NCT00391794|BEHAVIORAL|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
219245033|NCT00391794|BEHAVIORAL|Educational Seminar|4 hour education session led by trained facilitators
219245034|NCT01823458|BEHAVIORAL|Lottery Insurance|
219245035|NCT01823458|BEHAVIORAL|Standard Lottery|
219245036|NCT04880135|OTHER|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
219245037|NCT04880135|OTHER|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
219245038|NCT06181968|DIAGNOSTIC_TEST|Cardiothoracic ultrasound protocol|Combined echocardiography and lung ultrasound for guiding therapy
219245039|NCT02984787|PROCEDURE|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
219245040|NCT02984787|PROCEDURE|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
219173295|NCT01552473|BEHAVIORAL|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
219173296|NCT01552473|BEHAVIORAL|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
219173297|NCT05151237|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
219173298|NCT06800027|OTHER|SALSA group intervention: Going to lunch at the restaurant in a group and attending healthy eating workshops.|"The intervention group will dine at a selected and trained restaurant twice a week for 4 months (from March to June 2024). A facilitator will accompany the participants to the restaurant and supervise them. Once a month, a healthy habits and meal supplementation workshop will be held at the senior citizens' centre. Participants will not be required to pay for the meals at the restaurant or for participation in the workshops. The control group will receive standard care at their Primary Care Centre.~In order for the restaurant to provide appropriate services tailored to the users' needs, training will be conducted by professionals from the Alicia Foundation on how to manage the nutrition of elderly individuals and other participants in the study according to their dietary needs."
219173299|NCT05725941|DEVICE|TogRite stretch Strapping|it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
219173300|NCT05725941|OTHER|Traditional upper limb functional exercise training|The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
219173301|NCT02664805|DRUG|LEO 124249 ointment|Ointment
219173302|NCT02664805|DRUG|LEO 124249 ointment vehicle|Ointment vehicle
219173303|NCT03409133|DEVICE|Stimulating nerve electrodes and intramuscular recording electrodes|See Arm Description
219245041|NCT00642499|DRUG|Dronabinol|2.5 mg to 40 mg
219245042|NCT00642499|DRUG|Placebo|placebo
219245043|NCT00449917|DRUG|lutein|
219245044|NCT00449917|DRUG|DHA|
219245045|NCT00449917|DRUG|vitamins|
219245046|NCT03949699|OTHER|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
219739847|NCT04095936|DRUG|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
219739848|NCT00294567|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
219739849|NCT04951063|RADIATION|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
219245047|NCT05219409|DRUG|Sitagliptin|The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
219245048|NCT05219409|DEVICE|Professional CGM|The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
219245049|NCT04988958|PROCEDURE|hydatid cyst resection|radical resection of hydatic cyst
219245050|NCT02951416|OTHER|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
219245051|NCT04117256|DEVICE|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
219245052|NCT04117256|DEVICE|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
219245053|NCT00563433|DRUG|ofloxacin|400 mg twice a day for 14 days
219245054|NCT00563433|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
219245055|NCT01843699|DRUG|Topiramate flexible dosage|
219245056|NCT01843699|DRUG|Placebo matching tablets|
219245057|NCT01843699|BEHAVIORAL|4-session gambling cognitive restructuring|
219245058|NCT01441258|BEHAVIORAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
219173304|NCT04971343|DIAGNOSTIC_TEST|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
219173305|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
219173306|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
219245059|NCT01441258|BEHAVIORAL|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
219245060|NCT01441258|BEHAVIORAL|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
219245061|NCT01237509|DEVICE|Hypo device|
219245062|NCT01846988|DEVICE|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
219245063|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
219245064|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
219245065|NCT03663699|BEHAVIORAL|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
219245066|NCT05746676|DRUG|Insulin|in treatment of periodontal defects
219245067|NCT05746676|DRUG|Hyaluronic acid|in treatment of periodontal defects
219245068|NCT01033097|DRUG|DNK333 5 mg|5 mg oral
219245069|NCT01033097|DRUG|Placebo to 5 mg|5 mg placebo oral
219245070|NCT01033097|DRUG|DNK333 25 mg|25 mg oral
219245071|NCT01033097|DRUG|Placebo to 25 mg|25 mg placebo oral
219245072|NCT01033097|DRUG|DNK333 100 mg|100 mg oral
219245073|NCT01033097|DRUG|Placebo to 100 mg|100 mg placebo oral
219245074|NCT01033097|DRUG|Betamethasone 4 mg|4 mg oral
219245075|NCT01033097|DRUG|DNK333 1mg|1 mg oral
219245076|NCT01033097|DRUG|Placebo to 1mg|1 mg placebo oral
219245077|NCT03530345|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
219245078|NCT03530345|DRUG|Placebo|Glass vials with matching placebo.
219245079|NCT04652050|DRUG|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
219245080|NCT01095809|DRUG|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
219739850|NCT04951063|DRUG|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
219739851|NCT04951063|DRUG|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
219739852|NCT00527878|DRUG|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
219739853|NCT00527878|DRUG|Placebo|
219739854|NCT01177488|BEHAVIORAL|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
219739855|NCT04917939|OTHER|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
219739856|NCT01671774|DRUG|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
219739857|NCT01671774|DRUG|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
219739858|NCT01671774|DRUG|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
219739859|NCT01671774|DRUG|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
219739860|NCT04210115|BIOLOGICAL|pembrolizumab|IV infusion
219739861|NCT04210115|DRUG|placebo|IV infusion
219739862|NCT04210115|DRUG|cisplatin|IV infusion
219739863|NCT04210115|DRUG|5-FU|IV infusion
219739864|NCT04210115|RADIATION|radiotherapy|external radiation
219739865|NCT04210115|DRUG|leucovorin|IV infusion
219739866|NCT04210115|DRUG|levoleucovorin|IV infusion
219739867|NCT04210115|DRUG|oxaliplatin|IV infusion
219739868|NCT00188435|PROCEDURE|Minimum Dose CT|
219739869|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET|Prostate specific membrane antigen positron emission tomography
219739870|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
219739871|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
219739872|NCT01726608|PROCEDURE|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
219739873|NCT05770245|DEVICE|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
219739874|NCT02055339|DEVICE|Fisher & Paykel heated humidified high flow nasal cannula|
219739875|NCT02055339|DEVICE|InfantFlow/RAM nasal continuous positive airway pressure|
219739876|NCT01931826|PROCEDURE|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
219739877|NCT01931826|PROCEDURE|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
219739878|NCT06413069|DIETARY_SUPPLEMENT|Raw whole almonds|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
219739879|NCT02019173|BEHAVIORAL|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
219739880|NCT03348462|DRUG|ethosomal preparation of anthralin|once daily with short contact topical application
219739881|NCT03348462|DRUG|liposomal preparation of anthralin|once daily with short contact topical application
219739882|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
219739883|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
219739884|NCT04713046|BIOLOGICAL|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.
219739885|NCT04713046|BIOLOGICAL|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
219739886|NCT01905085|DEVICE|No intervention|
219739887|NCT02667561|DRUG|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
219739888|NCT02667561|DRUG|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
219173307|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
219245081|NCT01095809|DRUG|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
219245082|NCT03392688|OTHER|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
219245083|NCT03392688|DIAGNOSTIC_TEST|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
219245084|NCT03392688|OTHER|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
219173308|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
219173309|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
219173310|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
219173311|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
219173312|NCT05839951|DRUG|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
219173313|NCT05839951|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
219173314|NCT05839951|DRUG|Bevacizumab|VEGFR inhibitor
219173315|NCT04836195|DRUG|PCLX-001 - 20mg|20mg daily oral pills
219173316|NCT04836195|DRUG|PCLX-001 - 40mg|40mg daily oral pills
219173317|NCT04836195|DRUG|PCLX-001 - 70mg|70mg daily oral pills
219173318|NCT04836195|DRUG|PCLX-001 - 100mg|100mg daily oral pills
219173319|NCT04836195|DRUG|PCLX-001 - 140mg|140mg daily oral pills
219173320|NCT04836195|DRUG|PCLX-001 - 210mg|210mg daily oral pills
219173321|NCT04836195|DRUG|PCLX-001 - 280mg|280mg daily oral pills
219173322|NCT05609760|OTHER|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
219173323|NCT05609760|OTHER|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
219245085|NCT03282071|BEHAVIORAL|Joyful Parenting Intervention|"* Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
219245086|NCT01221532|BEHAVIORAL|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
219245087|NCT00212459|BEHAVIORAL|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
219173324|NCT06852833|BEHAVIORAL|One-day Mind Programme for women with breast cancer|This programme is theoretically founded on contextual behavioural therapies ( ACT and compassion-based interventions) and tailored for women with breast cancer. Its format comprises 1 session with the duration of 7 hours, that will be delivered by 2 psychologists through a secure video calling platform, in two subsequent days.
219173328|NCT04049643|DEVICE|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
219173329|NCT04049643|DEVICE|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
219173330|NCT04049643|DEVICE|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
219173331|NCT03814291|DRUG|IBI302|0.05mg/eye;Intraocular injection
219173332|NCT03814291|DRUG|IBI302|0.15mg/eye;Intraocular injection
219173333|NCT03814291|DRUG|IBI302|0.5mg/eye;Intraocular injection
219173334|NCT03814291|DRUG|IBI302|1mg/eye;Intraocular injection
219173335|NCT03814291|DRUG|IBI302|2mg/eye;Intraocular injection
219173336|NCT03814291|DRUG|IBI302|4mg/eye;Intraocular injection
219173337|NCT06434272|OTHER|Early exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 1-12 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Seated leg extension, standing knee flexion, and seated heel-rise performed at home as an adjunct to usual care treatment.~Each exercise is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~Pause in between sets is 30 seconds. Pause in between exercises are 120 seconds.~In weeks 13-24, patients in this arm follow usual care treatment."
219173338|NCT06434272|OTHER|Late exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 13-24 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Leg press in machine, heel-rise in machine, knee flexion in machine performed at training facilities as an adjunct to usual care treatment. If facilities are unavailable, three home-based exercises will be provided.~Each exercise, regardless of study arm, is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~In weeks 1-12, patients in this arm follow usual care treatment."
219173339|NCT06031038|OTHER|TECCU Software|patient monitoring by software application
219173340|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
219173341|NCT05089734|DRUG|Docetaxel|Administered intravenously
219173342|NCT03021031|OTHER|Observational|Observational study
219173343|NCT04387422|OTHER|Experimental hyperglycemia|Experimental hyperglycemia with MRI
219173344|NCT06134375|DRUG|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
219173345|NCT06134375|DRUG|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
219173346|NCT06134375|DRUG|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
219173347|NCT05062460|OTHER|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
219245088|NCT00212459|BEHAVIORAL|Control|No more contacts are made with control patients after the initial counseling session.
219245089|NCT04117386|DIAGNOSTIC_TEST|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
219245090|NCT04117386|DIAGNOSTIC_TEST|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
219245091|NCT01377545|PROCEDURE|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
219173348|NCT05062460|OTHER|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
219173349|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
219173350|NCT05821205|BEHAVIORAL|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
219173351|NCT05821205|BEHAVIORAL|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
219173352|NCT05821205|BEHAVIORAL|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
219173353|NCT05821205|BEHAVIORAL|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
219173354|NCT06043713|DRUG|Bendamustine|Receive IV
219173355|NCT06043713|PROCEDURE|Biopsy|Undergo tissue biopsy
219173356|NCT06043713|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219173357|NCT06043713|PROCEDURE|Computed Tomography|Undergo CT
219173358|NCT06043713|DRUG|Cyclophosphamide|Receive IV
219173359|NCT06043713|PROCEDURE|Echocardiography|Undergo ECHO
219173360|NCT06043713|DRUG|Fludarabine|Receive IV
219173361|NCT06043713|PROCEDURE|Leukapheresis|Undergo leukapheresis
219173362|NCT06043713|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219173363|NCT06043713|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219173364|NCT06043713|PROCEDURE|Positron Emission Tomography|Undergo PET
219173365|NCT06043713|BIOLOGICAL|T-cell Receptor-engineered T-cells|Receive FHA11KRASG12V-TCR IV
219245092|NCT01377545|PROCEDURE|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
219245093|NCT04889820|DRUG|Neoadjuvant chemotherapy|In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
219245094|NCT04889820|DRUG|Adjuvant chemotherapy|After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
219245095|NCT04889820|PROCEDURE|Curative resection|After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
219245096|NCT05190289|OTHER|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
219245097|NCT06471153|BEHAVIORAL|Empowerment Program Based on BASNEF Model|Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
219245098|NCT06471153|BEHAVIORAL|Routine Health Education|Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
219245099|NCT06490497|OTHER|Interview|individual interviews semi-directive
219245100|NCT01184755|BEHAVIORAL|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
219245101|NCT01184755|DEVICE|RESPeRate|
219245102|NCT00318591|DEVICE|SpeediCath|hydrophilic coated urinary intermittent catheter
219245103|NCT00318591|DEVICE|Conveen Uncoated|Uncoated urinary intermittent catheter
219245104|NCT04911322|DEVICE|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
219245105|NCT06976502|PROCEDURE|Blood Draw|Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.
219245106|NCT06976502|PROCEDURE|Tissue Collection|If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.
219245107|NCT06976502|PROCEDURE|DNA Collection|Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.
219245108|NCT06976502|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the participant's medical record.
219245109|NCT03507699|RADIATION|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
219245110|NCT03507699|DRUG|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
219173366|NCT05904548|DEVICE|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
219173367|NCT05494697|DRUG|Rintatolimod|Rintatolimod (poly I : poly C12U)
219173368|NCT02653755|DEVICE|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
219173369|NCT06854614|OTHER|Comprehensive weight loss|Shared Medical Appointments
219173370|NCT06854614|OTHER|Enhanced lifestyle changes|Subjects will also be referred to an exercise physiologist for a personalized physical activity program. Physical Activity and Exercise will be discussed during SMAs as well and individually as needed for exercise progression The participants exercise prescription will be individualized based on an initial assessment. Exercise duration and progression will be recommended at the discretion of staff and exercise physiologist. The exercise program will be structured but flexible, which means patients can substitute group exercises with individual exercise if necessary, following the FITT-VP format (frequency, intensity, time, type, volume and progression). Patients can reduce exercise frequency if the duration is prolonged, or intensity is increased. Investigators will encourage patients to use Cleveland Clinic gyms across the enterprise.
219173371|NCT06854614|DRUG|Phentermine-Topiramate|Medication for chronic weight management (Rx)
219173372|NCT06854614|DRUG|Naltrexone-Bupropion Combination|Medication for chronic weight management (Rx)
219173373|NCT06854614|DRUG|Orlistat|Medication for chronic weight management (Rx)
219173374|NCT06987305|DRUG|Intravenous rhTNK-tPA|Patients will received intravenous rhTNK-tPA
219173375|NCT06987305|DRUG|Intravenous placebo|Patients will received intravenous placebo
219173376|NCT06987305|PROCEDURE|Endovascular thrombectomy|Patients will received endovascular thrombectomy
219173377|NCT06987409|PROCEDURE|Continuous erector spinae plane block|The attending surgeon or fellow will place the erector spinae plane catheters in the operating room. Following decompression +/- fusion of the lumbar spine, catheters will be placed under direct vision. The tips of the catheters will be placed superficial to the transverse processes, instrumentation, and bone graft of the lumbar spine, as applicable to the procedure. These will be deep to the erector spinae muscles, which will be closed on top of the catheters.
219173378|NCT06692699|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
219173379|NCT06692699|DEVICE|A.R.R.E.S.T. spectacle film|A.R.R.E.S.T. spectacle film
219173380|NCT06921330|OTHER|white cover|A white cover will be covered over the incubator during phototherapy.
219173381|NCT06921330|OTHER|masaj|-Baby massage will be applied during phototherapy.
219173382|NCT05543798|DEVICE|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
219173383|NCT06845969|OTHER|Education: dry needling theory|Education relating to the theory of dry needling by physiotherapists
219173384|NCT06845969|OTHER|Education: Cadaver anatomy review|Educational instruction regarding the safe implementation of dry needling by physiotherapists using cadaver material.
219173385|NCT06925659|DRUG|QLM2011|QLM2011l by intravenous infusion.
219173386|NCT06925659|DRUG|Taxotere®|Taxotere® by intravenous infusion
219173387|NCT06931548|PROCEDURE|Implant-based breast reconstruction using polytetrafluoroethylene mesh|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with polytetrafluoroethylene (PTFE) mesh. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
219173388|NCT06931548|PROCEDURE|Implant-based breast reconstruction using Allogeneic dura mater graft|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with an allogeneic dura mater graft. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
219173389|NCT06932042|OTHER|PLADO|Low protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of \<4 g/day and \<3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance
219173390|NCT06932042|OTHER|Standard-of-care diet|Current standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences.
219173391|NCT06927544|PROCEDURE|Pars plana vitrectomy|All operations are performed in a similar fashion using the vitrectomy system with 23-gauge and 25-gauge vitrectomy probes. Surgical approach and technique include the use of tissue-staining dyes, choice of endotamponade, and postoperative face-down positioning regimen.
219173392|NCT06931847|OTHER|SUNRISE program|"The program will use several solutions, each focusing on different aspects of health promotion:~* SmartCoach, a mobile phone-based life-skills training program, focuses on self-management, social skills, and substance use resistance.~* Social robots and conversational assistants aim to engage students through interactive sessions on health topics like diet and physical activity.~* Educational and serious games enhance knowledge and resistance to unhealthy food marketing, providing an engaging way to learn about advertising tactics and healthy eating.~* The influencer campaign tackles nutritional misinformation by using content created by influencers to educate adolescents on detecting and critically evaluating misleading health information.~* Health and advertisement educational module aims to educate students on recognizing deceptive advertising and making informed choices about their health."
219173393|NCT06931366|PROCEDURE|Open reduction and internal fixation|plates and screws
219739889|NCT02667561|DRUG|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
219739890|NCT02667561|DRUG|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
219739891|NCT03236805|DRUG|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
219739892|NCT03236805|DRUG|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
219739893|NCT03150888|DRUG|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
219739894|NCT03150888|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
219739895|NCT01157494|OTHER|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
219739896|NCT05950997|DRUG|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
219739897|NCT05950997|DRUG|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
219739898|NCT04419987|GENETIC|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
219739899|NCT06310694|COMBINATION_PRODUCT|intervention group (Elastane circular dressing on sterile transparent dressing)|A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
219173394|NCT06931782|OTHER|AI|GPT-4o fine-tuned with the Lungdiag database
219739900|NCT03345810|DRUG|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
219739901|NCT03345810|DRUG|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
219739902|NCT03345810|DRUG|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
219739903|NCT03345810|DRUG|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
219739904|NCT03345810|DRUG|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
219739905|NCT06569472|BIOLOGICAL|CD19-targetd CAR-T|Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
219739906|NCT06571877|OTHER|Dietary intervention with manipulation of the energy density|Dietary intervention with manipulation of the energy density either during breakfast or during lunch
219739907|NCT06571617|PROCEDURE|Mini PCNL (mini percutaneous nephrolithotomy)|half of the cases will be treated using mini PCNL
219739908|NCT06571617|PROCEDURE|RIRS (retrograde intrarenal surgery/ flexible URS)|THE OTHER HALF WILL BE TRAETED USING Flexible URS
219739909|NCT06571097|DRUG|Levoﬂoxacin|0.5g/day for 2 weeks
219739910|NCT03854435|OTHER|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
219173395|NCT06931730|OTHER|Nutritional Intervention|Participants will receive comprehensive dietary education from the nutritionists of the research team, aimed at improving their baseline diet by incorporating nutritional recommendations based on the Mediterranean diet and the Italian dietary guidelines for healthy eating.
219173396|NCT06931730|OTHER|Physical Activity training|Participants will engage in a structured exercise program designed to improve motor competence and confidence. Tailored to each individual's baseline physical abilities and cardiorespiratory capacity, the program will focus on enhancing aerobic fitness, flexibility, and coordination.
219739911|NCT03854435|OTHER|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
219739912|NCT01793571|PROCEDURE|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
219173397|NCT06931730|OTHER|Cognitive training|Participants will undergo an online cognitive training program, with a particular focus on memory enhancement.
219245111|NCT03507699|DRUG|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
219739913|NCT01830101|DRUG|TMZ plus concurrent re-irradiation|
219739914|NCT01830101|DRUG|Temozolomide|low-dose temozolomide daily for one year
219739915|NCT02749461|PROCEDURE|heel stick|Consecutive routine blood sampling heel sticks
219739916|NCT02796482|DIETARY_SUPPLEMENT|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
219739917|NCT00203242|DRUG|Depacon IV and Depakote ER|
219739918|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 14 days before surgery|
219739919|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 72 hours before surgery|
219739920|NCT04304287|PROCEDURE|Without preoperative blood donation|
219739921|NCT06437457|RADIATION|ceus|MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
219739922|NCT00434811|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
219739923|NCT00434811|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
219739924|NCT00434811|DRUG|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
219739925|NCT00434811|DRUG|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
219739926|NCT00434811|BIOLOGICAL|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
219173398|NCT06931730|OTHER|Social Training|A peer interaction program within an ecological setting, meant as a natural context of daily life, will be offered to participants. The program aims to improve active listening skills, comprehension of various communication styles (passive, assertive, aggressive), and the efficient recognition and management of emotions.
219173399|NCT06931171|RADIATION|Patient-Applied Pelvic Lead Shielding|The intervention involves the application of a triple-layer lead apron to the patient's lower abdominal and pelvic region during transradial coronary procedures. The apron measures 75 cm × 45 cm and is composed of three layers of 0.25 mm Pb-equivalent material. This protective shield is placed on the patient in addition to standard operator radiation protection measures. The primary goal of this intervention is to reduce scatter radiation exposure to the operator, thereby improving occupational safety in the catheterization laboratory. This approach leverages existing radiation protection materials in a novel configuration.
219173400|NCT06386770|DRUG|Dexmedetomidine Injection [Precedex]|Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
219739927|NCT00434811|PROCEDURE|Islet Transplantation|Transplantation of pancreatic islet cell
219739928|NCT00434811|BIOLOGICAL|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
219739929|NCT00866775|DRUG|Eslicarbazepine acetate|1600 mg QD
219739930|NCT00866775|DRUG|Eslicarbazepine acetate|1200 mg QD
219739931|NCT02973022|OTHER|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
219739932|NCT05454007|BEHAVIORAL|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
219739933|NCT00569998|DEVICE|NovoPen™ 4|
219739934|NCT00569998|DEVICE|NovoPen® 3|
219739935|NCT01500135|DRUG|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
219739936|NCT01500135|DRUG|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
219739937|NCT03708510|DEVICE|Restorative materials- Filtek Silorane|Filtek Silorane
219739938|NCT03708510|DEVICE|Restorative materials-Kalore|Kalore
219739939|NCT03708510|DEVICE|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
219739940|NCT03708510|DEVICE|Preparation- Diamond Bur|Bur
219739941|NCT05175001|DRUG|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
219739942|NCT05175001|DRUG|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
219739943|NCT02073201|OTHER|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
219245112|NCT03507699|DRUG|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
219245113|NCT03577054|BEHAVIORAL|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
219245114|NCT03577054|BEHAVIORAL|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
219245115|NCT01613807|DRUG|Insulin LISPRO|Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
219245116|NCT01613807|DRUG|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
219245117|NCT04226651|DEVICE|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
219245118|NCT04226651|DEVICE|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
219245119|NCT01612221|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
219245120|NCT01612221|OTHER|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
219245121|NCT03015844|DRUG|131-I-meta-iodobenzylguanidine|
219245122|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
219739944|NCT02073201|OTHER|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
219739945|NCT02073201|OTHER|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
219739946|NCT03511287|OTHER|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
219739947|NCT02399566|DRUG|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
219739948|NCT03346746|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
219245123|NCT02661490|DRUG|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
219739949|NCT03346746|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
219739950|NCT00310843|DRUG|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
219739951|NCT03875443|OTHER|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
219245124|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
219245125|NCT00185796|PROCEDURE|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
219245126|NCT00185796|PROCEDURE|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
219245127|NCT03448354|PROCEDURE|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
219245128|NCT04999956|PROCEDURE|dynamic navigation surgery|immediate implant placement using dynamic navigation
219245129|NCT04999956|PROCEDURE|freehand surgery|immediate implant placement using freehand surgery
219245130|NCT00924599|BEHAVIORAL|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
219739952|NCT03875443|OTHER|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
219739953|NCT02115243|DRUG|Ipilimumab|
219739954|NCT01380132|PROCEDURE|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
219739955|NCT02674763|DRUG|IMGN779|
219739956|NCT03193138|DRUG|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
219739957|NCT01063569|DRUG|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
219173401|NCT06386770|DRUG|Bupivacaine Hydrochloride|.Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
219173402|NCT06386770|DRUG|Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
219173403|NCT06932003|DRUG|LT-002-158 Tablets|The subjects will orally administered LT-002-158 tablets once a day.
219173404|NCT06932718|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
219173405|NCT06932718|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions for 3 months consist of 2 parts. The first part includes regular messages via instant messages (IM). These messages will serve as probes for real-time chat-based support in which more details explanations and motivation to encourage quitting due to financial reasons. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using health economic principles on behavioral change to motivate smokers to quit. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
219173406|NCT06932718|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
219173407|NCT06932718|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (10 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
219173408|NCT06932718|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
219245131|NCT00924599|BEHAVIORAL|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
219739958|NCT01063569|DRUG|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
219739959|NCT02095457|BEHAVIORAL|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
219739960|NCT05513170|PROCEDURE|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
219739961|NCT05513170|PROCEDURE|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
219173409|NCT06932718|OTHER|Small incentive|Positive incentive was reported to be effective in reducing smoking. Participants in the intervention group will receive HK$ 100 at 3-month follow-up. HK$ 500 will be provided to successful quitters confirmed by biochemical validation at 6 months. A total of HK$ 600 maximum will be rewarded to the participants. The amount of the incentive is comparable to other community events on smoking cessation in Hong Kong. Of note, all smokers who reported quitting, completed and passed the biochemical validation of quitting had been offered HK$ 500 in the past rounds and will also be adopted in this round.
219173410|NCT06931990|DRUG|LT-002-158 tablets|The subjects will orally administered LT-002-158 tablets once a day.
219173411|NCT06807853|OTHER|Smartwatch|Smartwatch AppleWatch SE to track Mobility
219173412|NCT06932172|DEVICE|Artificial inteligence based decision support to detect skin cancer|When assessing skin lesions in patients seeking primary care, the primary care physician may use the device to be evaluated in the study (Dermalyser) as a complementary diagnostic doecision support to differentiate skin cancers from benign skin lesions. However, the decision on clinical management of the lesion remains with the physician.
219173413|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
219173414|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
219173415|NCT06933030|DEVICE|titanium mesh with bone graft with delayed implant placement.|titanium mesh with bone graft with delayed implant placement.
219173416|NCT06933030|DEVICE|zirconium mesh with bone graft with delayed implant placement.|zirconium mesh with bone graft with delayed implant placement.
219173417|NCT06931288|DEVICE|Blood pressure monitor|In the trial group, atrial fibrillation screening will be integrated into blood pressure measurements using the BP77A1T electronic blood pressure monitor (Omron Healthcare, Kyoto, Japan).
219173418|NCT06931288|DEVICE|Single-lead ECG|In the control group, a single-lead ECG will be recorded for 30s with a handheld ECG for atrial fibrillation detection. Each ECG rhythm strip will be reviewed and analyzed by a cardiologist from the research team.
219739962|NCT02542371|OTHER|Arterial Imaging|
219739963|NCT01933555|BEHAVIORAL|Empowerment Program|
219739964|NCT01582555|DRUG|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
219739965|NCT01582555|DRUG|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
219739966|NCT06564714|DRUG|Early baclofen Intervention|"Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic."
219739967|NCT06564714|DRUG|Usual routine care|"Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
219739968|NCT05665452|PROCEDURE|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
219739969|NCT02320071|OTHER|Examination of abdominal wall strength changes over time|
219739970|NCT04632862|DRUG|DWP16001|DWP16001 A mg
219739971|NCT05505786|BEHAVIORAL|Normal stance width|Normal self-selected stance width when performing squat exercises.
219739972|NCT05505786|BEHAVIORAL|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
219739973|NCT02133872|DRUG|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
219739974|NCT01520103|DRUG|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
219739975|NCT01520103|DRUG|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
219739976|NCT03590548|DIAGNOSTIC_TEST|gausher disease|lab investigation and radio logical
219739977|NCT01486329|BIOLOGICAL|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
219739978|NCT01486329|BIOLOGICAL|Placebo|Drink solution
219739979|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
219739980|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
219739981|NCT01998477|BIOLOGICAL|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
219739982|NCT01998477|BIOLOGICAL|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
219739983|NCT01532154|DRUG|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
219739984|NCT05129306|OTHER|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
219739985|NCT03878121|BIOLOGICAL|Ad4-Env145NFL|10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
219739986|NCT03878121|BIOLOGICAL|Ad4-Env150KN|10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
219739987|NCT03878121|BIOLOGICAL|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
219739988|NCT06546527|DRUG|[177Lu]Lu-PSMA-137|\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
219739989|NCT03940521|OTHER|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
219739990|NCT00003053|DRUG|cisplatin|
219739991|NCT00003053|DRUG|etoposide|
219739992|NCT00003053|PROCEDURE|adjuvant therapy|
219173419|NCT06931678|PROCEDURE|aPDT|This intervention involves the application of antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer, followed by activation with a light source at an appropriate wavelength. The protocol is applied after conventional root canal preparation and irrigation. The aPDT protocol is standardized and performed in both medically healthy patients and patients with Type 2 Diabetes Mellitus (T2DM), allowing comparison of microbiological and clinical outcomes between the two groups. This intervention aims to enhance root canal disinfection, particularly in anatomically complex areas that are difficult to reach with traditional methods.
219173420|NCT06404073|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
219173421|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
219173422|NCT05302596|DRUG|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
219173423|NCT04049539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219173424|NCT06843837|OTHER|Sweet orange essential oil aromatherapy|The sweet orange essential oil used in the study was prepared by the Food Engineering Department of Fırat University. To obtain the essential oil used for aromatherapy in this study, the peels of Citrus sinensis sweet oranges were utilized. The orange peels were cut into small pieces of approximately 3-5 mm in size, placed into a boiling flask, and distilled water was added. Based on the analysis results, the percentage composition of the total essential oil fatty acids was determined. The chemical composition analysis revealed that D-limonene was the major component, comprising 90% of the total oil. The oil is 100% pure essential oil, containing up to 90% D-limonene, along with citral and linalool. A cotton ball infused with three drops of sweet orange essential oil was held 4 to 5 cm away from the student's nose, and they were instructed to breathe slowly for five minutes. After this, the students were asked to perform IV cannulation on the patient.
219173425|NCT04520451|DRUG|rilzabrutinib|oral tablet
219173426|NCT04520451|DRUG|Glucocorticoids|oral tablet or capsule
219173427|NCT06196866|OTHER|Conventional Therapy|The control group will develop only conventional treatment for the whole trial (weeks 1-24), consisting of carrying out daily routine activities and/or 1 session/week of physiotherapy (which includes manual therapy, active exercises of repetition of functional movements, walking, stairs and stretching) with a time of 45 minutes/session.
219173428|NCT06196866|DEVICE|Nintendo Ring Fit Adventure + Conventional Therapy|"In the exergaming group 1, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Jogging: Begginia or Transient Temple.~Minigames: Squat Goals, Squattery Wheel, Gluting Gallery, Thigh Rider, Bank Balance or Dreadmill.~Lower Limbs Training: Knee Lift or Hip Lift.~Yoga: Tree Pose or Chair Pose."
219173429|NCT06196866|DEVICE|Nintendo Wii Fit + Conventional Therapy|"In the exergaming group 2, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Aerobics: Basic Run or Hula Hoop.~Strength Training: Rowing Squat, Single-Leg Extension, Sideways Leg Lift or Single-Leg Twist.~Balance Games: Ski Jump, Balance Bubble, Table Tilt or Penguin Slide.~Yoga: Chair or Standing Knee."
219739993|NCT05360225|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
219739994|NCT05406726|DIETARY_SUPPLEMENT|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
219739995|NCT05406726|DIETARY_SUPPLEMENT|Placebo|a capsule filled only with maltodextrin will be used as a placebo
219245132|NCT04891159|OTHER|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
219245133|NCT05381181|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
219245134|NCT05441371|OTHER|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
219245135|NCT04176926|DIAGNOSTIC_TEST|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
219245136|NCT02591914|DRUG|Fovista™|Anti-PDGF-B pegylated aptamer
219245137|NCT02591914|DRUG|Lucentis®|Anti-VEGF
219245138|NCT02591914|DRUG|Avastin®|Anti-VEGF
219245139|NCT02591914|DRUG|Eylea®|Anti-VEGF
219245140|NCT01755247|DRUG|Topical Gel Vehicle|
219245141|NCT01755247|DRUG|8% NVN1000 Topical Gel|
219245142|NCT01755247|DRUG|8% NVN1000 Topical Gel and moisturizer|
219245143|NCT00202306|DRUG|lithium carbonate|
219245144|NCT02243436|DRUG|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
219245145|NCT02243436|DRUG|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
219245146|NCT02243436|DRUG|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
219245147|NCT02243436|DRUG|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
219245148|NCT02243436|DRUG|Ara C|Intravenous use, 2g/m2, day 5
219245149|NCT00508859|DRUG|Sertraline|maintenance treatment with sertraline
219245150|NCT00508859|DRUG|placebo|placebo
219245151|NCT04617262|BEHAVIORAL|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
219245152|NCT00349648|PROCEDURE|acromioplasty|
219245153|NCT03460327|DRUG|Candesartan|Patients are tested for their normal prescription candesartan medication
219245154|NCT00468884|DRUG|Increasing doses of GLP-1|
219245155|NCT00468884|DRUG|PYY3-36|
219245156|NCT00644332|DRUG|Ranolazine|Oral dosage form.
219245157|NCT01863537|BEHAVIORAL|Multimedia Connect|
219245158|NCT01863537|BEHAVIORAL|Traditional Connect|
219245159|NCT01654445|DRUG|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
219245160|NCT02706834|DRUG|TAK-828|TAK-828 oral solution
219245161|NCT02706834|DRUG|Placebo|TAK-828 placebo-matching oral solution
219245162|NCT01896921|DRUG|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
219245163|NCT03519906|DRUG|Metoprolol|Patients are tested for their normal prescription metaprolol medication
219245164|NCT02132598|DRUG|cabozantinib|
219245165|NCT00627523|DRUG|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
219245166|NCT00627523|DRUG|Control-no treatment|Control-no treatment
219245167|NCT06386263|DRUG|Trastuzumab deruxtecan|This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.
219245168|NCT06538831|OTHER|Diet N-P-|Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)
219245169|NCT06538831|OTHER|Diet N+P-|Rich in SFAs, free sugar and sodium; Low in UPFs
219245170|NCT06538831|OTHER|Diet N-P+|Low in SFAs, free sugar and sodium; High in UPFs
219245171|NCT06538831|OTHER|Diet N+P+|Rich in SFAs, free sugar and sodium; High in UPFs
219245172|NCT03716947|PROCEDURE|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
219245173|NCT03716947|PROCEDURE|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
219245174|NCT03716947|PROCEDURE|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
219245175|NCT02344602|DRUG|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
219245176|NCT04607889|OTHER|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
219245177|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
219245178|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
219245179|NCT00734253|DRUG|Placebo|Placebo capsules taken twice a day for 1-year
219245180|NCT05399667|OTHER|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
219245181|NCT05399667|OTHER|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
219245182|NCT00266305|BEHAVIORAL|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
219245183|NCT01236963|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
219245184|NCT01236963|DEVICE|Dental Floss|
219245185|NCT03119051|BEHAVIORAL|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
219245186|NCT03119051|BEHAVIORAL|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
219245187|NCT00355784|OTHER|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
219245188|NCT00355784|DRUG|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
219245189|NCT04768491|DRUG|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
219245190|NCT02543294|DEVICE|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
219245191|NCT02543294|DEVICE|Electrocardiogram|Electrocardiogram performed at baseline.
219245192|NCT02543294|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
219245193|NCT02543294|BEHAVIORAL|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
219245194|NCT02794441|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
219245195|NCT02794441|OTHER|Placebo|Matched oral solution
219245196|NCT02181751|OTHER|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
219245197|NCT05681390|DRUG|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
219245198|NCT00406276|DRUG|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
219245199|NCT00406276|DRUG|Docetaxel|In combination with RAD001
219245200|NCT03258788|PROCEDURE|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
219245201|NCT03602053|BIOLOGICAL|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
219245202|NCT03602053|BIOLOGICAL|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
219245203|NCT03602053|BIOLOGICAL|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
219245204|NCT05206552|OTHER|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
219245205|NCT00575900|BEHAVIORAL|dietary intervention|12 weeks of dietary intervention
219245206|NCT00160537|DRUG|Levocetirizine|
219245207|NCT06375317|DRUG|PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets|"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."
219245208|NCT01038128|DRUG|Memantine|Drug: Memantine, 10-40 mg daily
219245209|NCT03622242|DEVICE|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
219245210|NCT03622242|DEVICE|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
219245211|NCT04851288|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
219245212|NCT04851288|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
219739996|NCT06401109|DEVICE|AquaPass|"The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety."
219245213|NCT01769352|DRUG|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
219245214|NCT05770193|OTHER|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
219739997|NCT03309475|BEHAVIORAL|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
219739998|NCT03309475|BEHAVIORAL|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
219739999|NCT03309475|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
219740000|NCT03309475|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
219740001|NCT06142591|DRUG|Oxycodone 10mg|10mg of oxycodone was added to Octenisept in the wound dressing.
219740002|NCT06142591|DRUG|Oxycodone 20mg|20mg of oxycodone was added to Octenisept in the wound dressing.
219740003|NCT00744419|DRUG|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
219245215|NCT05770193|OTHER|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
219245216|NCT05770193|OTHER|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
219362689|NCT01361997|BIOLOGICAL|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
219740004|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
219740005|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
219740006|NCT00635583|OTHER|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese"
219740007|NCT03920020|OTHER|the concentric isokinetic exercise group|concentric isokinetic exercises
219740008|NCT03920020|OTHER|the eccentric isokinetic exercise group|eccentric isokinetic exercises
219740009|NCT03920020|OTHER|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
219740010|NCT01132690|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
219740011|NCT00003327|DRUG|paclitaxel|
219740012|NCT03380988|OTHER|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
219740013|NCT03380988|OTHER|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
219740014|NCT00825448|PROCEDURE|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
219740015|NCT03495895|BEHAVIORAL|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
219740016|NCT03495895|BEHAVIORAL|Usual Care|Usual care condition
219740017|NCT03568786|PROCEDURE|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
219245217|NCT05770193|OTHER|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50\_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 \_75% tension and the tails will be applied toward the ribs."
219245218|NCT04554615|DRUG|Insulin|insulin infusion to control postoperative hyperglycemia
219245219|NCT01686256|DRUG|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
219245220|NCT00487253|DRUG|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
219245221|NCT00487253|DRUG|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
219245222|NCT03590067|OTHER|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
219245223|NCT00800917|DRUG|Temsirolimus|25 mg weekly IV
219245224|NCT00800917|DRUG|Bevacizumab|10 mg/kg every 2 weeks
219245225|NCT05744505|PROCEDURE|1565nm Non-ablative Fractional Laser|Every 3 weeks
219245226|NCT05744505|PROCEDURE|placebo|Every 3 weeks
219245227|NCT03292744|DRUG|Alfacalcidol|alfacalcidol 0,5 mcg
219740018|NCT03568786|PROCEDURE|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
219740019|NCT01795339|DRUG|AZD3293|Oral solution
219740020|NCT01795339|DRUG|Placebo|Oral solution
219740021|NCT02872142|BIOLOGICAL|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
219740022|NCT02872142|PROCEDURE|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
219740023|NCT05243316|PROCEDURE|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
219740024|NCT05243316|PROCEDURE|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
219740025|NCT06522932|DRUG|64Cu-GRIP B|Given IV
219740026|NCT06522932|PROCEDURE|Positron Emission Tomography (PET)|Undergo imaging procedure
219740027|NCT06522932|PROCEDURE|Optional tumor biopsy|Undergo optional tumor biopsy
219245228|NCT04958434|DRUG|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
219245229|NCT04403815|PROCEDURE|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
219245230|NCT04203225|DRUG|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
219245231|NCT05494099|PROCEDURE|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
219245232|NCT05494099|PROCEDURE|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
219245233|NCT05494099|PROCEDURE|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
219245234|NCT02791685|BEHAVIORAL|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
219245235|NCT02791685|BEHAVIORAL|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
219245236|NCT02791685|BEHAVIORAL|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
219245237|NCT01529853|DRUG|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219245238|NCT01529853|DRUG|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219245239|NCT05159037|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
219245240|NCT05159037|BEHAVIORAL|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
219245241|NCT00547716|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
219245242|NCT00547716|DRUG|Placebo comparator|
219245243|NCT03676400|OTHER|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
219245244|NCT03676400|OTHER|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
219245245|NCT04595110|OTHER|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
219245246|NCT02655536|DRUG|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
219245247|NCT02655536|DRUG|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
219245248|NCT00396409|DRUG|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
219245249|NCT00396409|DRUG|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
219245250|NCT00396409|DRUG|Placebo|Placebo given during the 2006 core study
219740028|NCT01903720|DRUG|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
219740029|NCT02002195|DRUG|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
219740030|NCT02002195|DRUG|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
219173430|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
219173431|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
219173432|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
219173433|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
219173434|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
219173435|NCT05284552|DRUG|Tinzaparin Injectable Solution|Subcutaneous injection
219173436|NCT05813275|DRUG|AD109|Oral administration at bedtime
219173437|NCT05813275|DRUG|Placebo|Oral administration at bedtime
219173438|NCT04927637|PROCEDURE|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
219173439|NCT04060355|BEHAVIORAL|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
219173440|NCT04060355|BEHAVIORAL|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
219173441|NCT03949387|OTHER|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
219173442|NCT03949387|OTHER|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
219173443|NCT01140880|DRUG|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
219173444|NCT06312813|DRUG|Imipramine|4% imipramine
219245251|NCT04399798|DRUG|Baricitinib|4 mg/day for 7 days
219245252|NCT02985476|OTHER|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
219245253|NCT01730261|BEHAVIORAL|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
219245254|NCT00071929|DRUG|oxaliplatin|
219362690|NCT03426020|OTHER|Oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before induction
219740031|NCT03199534|DRUG|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
219245255|NCT04564222|DIETARY_SUPPLEMENT|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
219245256|NCT04564222|DIETARY_SUPPLEMENT|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
219245257|NCT01763502|OTHER|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
219245258|NCT01763502|OTHER|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
219740032|NCT03199534|DRUG|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
219740033|NCT03199534|DRUG|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
219740034|NCT00952562|DIETARY_SUPPLEMENT|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
219245259|NCT06436612|RADIATION|Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy|stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
219245260|NCT00244426|DRUG|indobufen|Indobufen capsules 100 and 200mg
219245261|NCT00244426|DRUG|aspirin|Acetylsalicylic acid capsules 300mg
219245262|NCT00003116|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
219740035|NCT00952562|DIETARY_SUPPLEMENT|placebo|Empty capsules, 3 capsules per day for 16 weeks
219740036|NCT03470883|OTHER|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (\> 12 months)
219740037|NCT02416544|OTHER|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
219245263|NCT00003116|DRUG|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
219245264|NCT00003116|DRUG|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
219245265|NCT00003116|DRUG|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
219245266|NCT00003116|PROCEDURE|bone marrow ablation with stem cell support|
219245267|NCT00003116|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
219245268|NCT01309802|DRUG|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
219245269|NCT02161393|BEHAVIORAL|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
219362691|NCT03426020|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
219173445|NCT06312813|DRUG|Amitriptyline|4% amitriptyline
219173446|NCT06312813|DRUG|Vehicle|0.1ml propylene glycol
219173447|NCT04990232|DRUG|Anakinra or rhIFNγ|In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.
219173448|NCT04990232|DRUG|Placebo|20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
219173449|NCT01212029|BEHAVIORAL|Behavioral measures|Behavioral tasks/ questionnaires
219173450|NCT01212029|DEVICE|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
219173451|NCT01212029|OTHER|Physiological measures|A set of tasks.
219173452|NCT06357546|PROCEDURE|Spontaneous urination during the hour before caesarean section.|Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.
219173453|NCT06357546|PROCEDURE|Systematic bladder catherization during caesarean section.|After implementation of loco-regional analgesia by spinal anesthesia, the patient will be positioned, with a perineal toilet and installation of a bladder catheter type Foley ch. 16.
219173454|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
219173455|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
219173456|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
219173457|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
219173458|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
219173459|NCT04126200|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219173460|NCT04126200|DRUG|GSK3174998|GSK3174998 will be administered.
219173461|NCT04126200|DRUG|Feladilimab|feladilimab will be administered.
219173462|NCT04126200|DRUG|Nirogacestat|Nirogacestat will be administered.
219173463|NCT04126200|DRUG|Dostarlimab|Dostarlimab will be administered.
219173464|NCT04126200|DRUG|Isatuximab|Isatuximab will be administered.
219173465|NCT04126200|DRUG|Lenalidomide|Lenalidomide will be administered.
219173466|NCT04126200|DRUG|Dexamethasone|Dexamethasone will be administered.
219173467|NCT04126200|DRUG|Pomalidomide|Pomalidomide will be administered.
219173468|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
219245270|NCT02161393|BEHAVIORAL|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
219245271|NCT05179096|BEHAVIORAL|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
219245272|NCT02873442|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
219245273|NCT02873442|BIOLOGICAL|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~\+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
219245274|NCT01690871|DRUG|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
219245275|NCT04203199|DEVICE|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
219245276|NCT04203199|DEVICE|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
219245277|NCT02035488|DRUG|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
219245278|NCT03800745|DRUG|Colace 100Mg Capsule|Prescribed to Arm B
219245279|NCT03800745|DRUG|Miralax|Prescribed to Arm C
219245280|NCT03881267|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
219245281|NCT03881267|OTHER|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
219245282|NCT03881267|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
219245283|NCT01489163|BEHAVIORAL|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
219245284|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
219245285|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
219245286|NCT03083600|DIETARY_SUPPLEMENT|Placebo|Cellulose Placebo for 12-weeks
219245287|NCT06113822|DEVICE|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
219245288|NCT03967093|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
219245289|NCT00274976|BIOLOGICAL|alemtuzumab|
219245290|NCT01440699|BIOLOGICAL|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
219245291|NCT05865782|BEHAVIORAL|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
219245292|NCT02589678|BIOLOGICAL|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
219245293|NCT02589678|BIOLOGICAL|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
219245294|NCT04695249|BEHAVIORAL|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
219245295|NCT00391521|DRUG|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
219245296|NCT00391521|DRUG|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
219245297|NCT00391521|DRUG|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
219245298|NCT00819676|OTHER|analysis of exhaled breath by biosensors|
219245299|NCT00819676|OTHER|measurement of exhaled nitric oxide|
219245300|NCT00014235|DRUG|fludarabine phosphate|Given IV
219245301|NCT00014235|RADIATION|total-body irradiation|Undergo TBI
219245302|NCT00014235|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
219245303|NCT00014235|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
219245304|NCT00014235|DRUG|cyclosporine|Given PO or IV
219245305|NCT00014235|DRUG|mycophenolate mofetil|Given IV or PO
219245306|NCT00014235|OTHER|laboratory biomarker analysis|Correlative studies
219245307|NCT00301730|BIOLOGICAL|aldesleukin|
219245308|NCT00301730|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219245309|NCT00301730|BIOLOGICAL|trastuzumab|
219245310|NCT00301730|DRUG|paclitaxel|
219245311|NCT00301730|PROCEDURE|conventional surgery|
219245312|NCT04457245|PROCEDURE|Computed Tomography|Undergo whole body PET/CT
219245313|NCT04457245|OTHER|Fluorine F 18 DCFPyL|Given IV
219245314|NCT04457245|PROCEDURE|Positron Emission Tomography|Undergo whole body PET/CT
219245315|NCT04457245|RADIATION|Radiation Therapy|Undergo standard of care definitive radiation therapy
219245316|NCT06388876|OTHER|Exercise|Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
219245317|NCT06388876|OTHER|lifestyle advice|At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
219245318|NCT01745380|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
219245319|NCT01745380|DRUG|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
219245320|NCT01256645|OTHER|blood transfusion|application of single units of red blood cell transfusions
219245321|NCT05222178|DRUG|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
219245322|NCT01882088|DRUG|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
219245323|NCT03445507|OTHER|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
219245324|NCT03445507|OTHER|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
219173469|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
219173470|NCT03131648|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
219173471|NCT03131648|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
219173472|NCT06415370|BEHAVIORAL|Home Delivered Healthy Meals|In-person delivery of HDHM at least one time weekly for 12 weeks.
219173473|NCT06415370|BEHAVIORAL|"In-person friendly visits"|"Friendly visits last approximately 5-10 minutes and include brief wellness check questions such as, How are you doing today? Did you try \[HDHM recipe\] yesterday- how did it taste? Any suggestions for future flavors? What are some of the things you plan to do in the next few days? Is there anything else you want to share with me?"
219173474|NCT06415370|BEHAVIORAL|Student Companion calls|Student Companions call participants at least one time weekly to provide telephone reassurance- i.e., checking on the participant's well-being. These calls may also include referrals to appropriate resources such as NCCARE 360 (statewide network that connects individuals with complex health and social needs, to community resources and service)
219245325|NCT04226183|OTHER|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
219245326|NCT00574626|PROCEDURE|PBSCT|Peripheral Blood Stem Cell Transplant
219245327|NCT00574626|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant
219245328|NCT00210964|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
219245329|NCT00210964|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
219245330|NCT01655862|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
219245331|NCT04468633|DEVICE|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
219245332|NCT04468633|DEVICE|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
219245333|NCT00426218|DRUG|ACZ885|
219245334|NCT02592902|PROCEDURE|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
219245335|NCT02592902|PROCEDURE|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
219362692|NCT03426020|OTHER|Play game (PC fishing game)|Patients will be played a simple PC game (a fishing game) 20 minutes before induction
219245336|NCT01843920|DRUG|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
219245337|NCT01843920|DRUG|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
219245338|NCT01086514|PROCEDURE|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
219245339|NCT03398889|DIAGNOSTIC_TEST|Plasma levels of metabolites|plasma levels of metabolites
219245340|NCT03398889|BEHAVIORAL|Dietary questionnaire|Harvard food frequency questionnaire
219245341|NCT03398889|DIAGNOSTIC_TEST|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
219245342|NCT02216994|DRUG|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
219245343|NCT02216994|BEHAVIORAL|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
219245344|NCT02216994|DRUG|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
219245345|NCT00460434|DEVICE|TVT|Prophylactic TVT
219245346|NCT00460434|OTHER|Sham|Sham TVT
219245347|NCT05236218|OTHER|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
219245348|NCT05236218|OTHER|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
219245349|NCT04391439|DRUG|Intravenous Methylprednisolone|
219245350|NCT03426709|BEHAVIORAL|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
219740038|NCT00002656|DRUG|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
219740039|NCT01604798|OTHER|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
219740040|NCT02244957|DEVICE|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
219740041|NCT02244957|DRUG|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
219740042|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
219740043|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
219740044|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 24 weeks
219740045|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 48 weeks
219740046|NCT01482403|DRUG|boceprevir|800 mg three times a day for 24 weeks
219740047|NCT01482403|DRUG|boceprevir|800 mg three times a day for 48 weeks
219740048|NCT01482403|DRUG|mericitabine|1000 mg twice daily for 24 weeks
219740049|NCT01482403|DRUG|mericitabine placebo|mericitabine placebo
219740050|NCT01482403|DRUG|boceprevir placebo|boceprevir placebo
219740051|NCT01482403|DRUG|boceprevir|800 mg three times a day for 44 weeks
219740052|NCT02548819|OTHER|MRI|MR imaging of patients with implanted cardiac devices
219245351|NCT02292056|BEHAVIORAL|1-on-1 counseling|"1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
219245352|NCT01381185|DRUG|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
219740053|NCT03194932|DRUG|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
219740054|NCT03194932|DRUG|Cytarabine|Given intravenously (IV) or intrathecally (IT).
219740055|NCT03194932|DRUG|Idarubicin|Given IV.
219740056|NCT03194932|DRUG|Intrathecal Triple Therapy|Given IT.
219740057|NCT03194932|DRUG|Azacitidine|Given IV.
219740058|NCT05207839|DIETARY_SUPPLEMENT|Milk powder|one sachet per day dissolved in 200 ml of water
219740059|NCT01748656|DEVICE|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
219740060|NCT01748656|DEVICE|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
219740061|NCT06308211|OTHER|MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY|Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
219245353|NCT04232202|DEVICE|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
219245354|NCT04232202|PROCEDURE|Standard extraction|Standard extraction procedure
219245355|NCT01605084|DRUG|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
219245356|NCT01605084|DRUG|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
219245357|NCT01605084|DRUG|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
219245358|NCT01605084|DRUG|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~\- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine"
219245359|NCT00845286|BEHAVIORAL|Munich Marathon|42,195 km marathon run
219245360|NCT02782273|DRUG|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
219245361|NCT02782273|DRUG|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
219245362|NCT01090856|PROCEDURE|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
219245363|NCT05655689|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245364|NCT05655689|DRUG|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245365|NCT05655689|DRUG|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245366|NCT05655689|DRUG|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245367|NCT05655689|DRUG|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245368|NCT05655689|DRUG|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245369|NCT05655689|DRUG|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245370|NCT05655689|DRUG|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
219245371|NCT03363100|BEHAVIORAL|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
219245372|NCT05971199|DRUG|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
219245373|NCT05971199|DRUG|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
219245374|NCT05971199|DEVICE|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
219245375|NCT03249961|DEVICE|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
219245376|NCT03249961|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
219245377|NCT03249961|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
219245378|NCT01940913|DIETARY_SUPPLEMENT|Probiotic capsules|
219245379|NCT01940913|DIETARY_SUPPLEMENT|Placebo capsules|
219245380|NCT05438745|OTHER|Copenhagen Burnout Inventry|Questionnaire
219245381|NCT03460444|DIETARY_SUPPLEMENT|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
219245382|NCT05064475|DIAGNOSTIC_TEST|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
219245383|NCT06384859|DEVICE|ESWT|Receive ESWT once a week for 4 weeks
219245384|NCT06384859|BIOLOGICAL|PRP|Receive PRP injection at week 5
219245385|NCT02295293|DRUG|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
219245386|NCT02295293|DRUG|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
219245387|NCT02023099|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
219245388|NCT02023099|DRUG|Placebo|Tablet
219245389|NCT02607293|DRUG|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
219245390|NCT02607293|DRUG|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
219245391|NCT02607293|DRUG|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
219245392|NCT00967915|PROCEDURE|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
219245393|NCT00967915|OTHER|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
219245394|NCT05005338|DRUG|BIIB122 (DNL151)|Oral doses
219245395|NCT05005338|DRUG|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
219245396|NCT00935129|DEVICE|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
219245397|NCT00935129|DEVICE|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
219245398|NCT02093078|BEHAVIORAL|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
219245399|NCT00176969|DRUG|Capsaicin|
219245400|NCT02869308|DRUG|stannous pyrophosphate|Injection of 1ml Angiocis
219740062|NCT06308211|OTHER|MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY|"Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
219740063|NCT06641492|BEHAVIORAL|Chatbot-delivered interventions tailored to one's stage of changes|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
219740064|NCT06641492|BEHAVIORAL|Chatbot-delivered standard interventions|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
219740065|NCT04118920|DRUG|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
219740066|NCT04118920|DRUG|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
219740067|NCT04118920|DRUG|Artificial tears|N=3, 40 microliters per drop
219740068|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
219740069|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
219740070|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
219740071|NCT06636903|OTHER|Acupressure|Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
219740072|NCT06636903|OTHER|Acupressure|Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
219245401|NCT02869308|DRUG|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
219245402|NCT02869308|DEVICE|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
219245403|NCT02869308|DEVICE|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
219245404|NCT02274350|RADIATION|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
219245405|NCT01699802|OTHER|Inhaled anaesthetic agent|
219245406|NCT04554316|DEVICE|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
219245407|NCT04117711|DRUG|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
219245408|NCT04117711|DRUG|Placebo|Matching placebo will be administered once in the morning before breakfast
219245409|NCT01029418|DRUG|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
219245410|NCT04320433|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
219245411|NCT02878720|DEVICE|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
219245412|NCT02394171|BEHAVIORAL|Group Cohesion|See description in arm/group above
219245413|NCT02324088|DRUG|Docetaxel|
219245414|NCT02324088|DRUG|Cyclophosphamide|
219245415|NCT02324088|DRUG|Epirubicin|
219245416|NCT00682344|DRUG|Levobupivacaïne|1,75mg/kg
219245417|NCT00312871|DRUG|Epoetin alfa|
219245418|NCT02210949|DRUG|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
219245419|NCT00828542|DRUG|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
219245420|NCT00828542|DRUG|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
219245421|NCT00147745|DRUG|Colesevelam|Colesevelam 3.8g for 12 weeks
219245422|NCT00147745|DRUG|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
219245423|NCT00147745|DRUG|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
219245424|NCT02551926|BEHAVIORAL|mobile text messages|
219245425|NCT02551926|BEHAVIORAL|virtual community|
219245426|NCT02551926|BEHAVIORAL|brochures|
219245427|NCT02551926|OTHER|Usual care|
219245428|NCT02551926|DEVICE|mobile phone|
219245429|NCT02658032|BEHAVIORAL|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
219245430|NCT02658032|BEHAVIORAL|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
219245431|NCT02658032|OTHER|standard care|
219245432|NCT05430607|BEHAVIORAL|Running therapy|A 9-week running program.
219245433|NCT05223283|OTHER||
219245434|NCT04212559|OTHER|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
219245435|NCT00003057|DRUG|loperamide hydrochloride|
219245436|NCT00003057|DRUG|octreotide acetate|
219245437|NCT04257786|PROCEDURE|1ry cyto-reductive surgery|1ry surgery then chemotherapy
219245438|NCT04257786|COMBINATION_PRODUCT|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
219245439|NCT05903118|BIOLOGICAL|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
219245440|NCT05903118|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
219245441|NCT03151161|DRUG|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
219740073|NCT06638255|OTHER|Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.|"Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies."
219740074|NCT06638255|OTHER|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
219245442|NCT03151161|DRUG|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
219245443|NCT02829411|BEHAVIORAL|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
219245444|NCT02829411|BEHAVIORAL|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
219245445|NCT05966623|OTHER|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
219245446|NCT02409823|DRUG|Atypical Antipsychotics|any atypical antipsychotic
219245447|NCT05364541|DEVICE|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
219245448|NCT00912275|DRUG|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
219245449|NCT02504502|OTHER|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
219245450|NCT00796640|DRUG|ER Paliperidone|
219245451|NCT04388514|PROCEDURE|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
219245452|NCT01878188|DRUG|BC-819/PEI|Intravesical instillation
219245453|NCT01878188|DRUG|BCG Vaccine|intravesical instillations
219245454|NCT01509040|OTHER|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
219245455|NCT01509040|DEVICE|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
219245456|NCT01509040|DEVICE|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
219245457|NCT00658801|RADIATION|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~1. Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~2. Group 2: 5cm \<Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
219245458|NCT02739841|OTHER|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
219245459|NCT02739841|OTHER|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
219245460|NCT05256914|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
219245461|NCT05256914|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
219245462|NCT06379451|DRUG|NKG2D Chimeric Antigen Receptor NK Cell Injection|Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
219245463|NCT02461719|DRUG|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
219245464|NCT02461719|DRUG|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
219740075|NCT04709393|OTHER|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
219740076|NCT06551909|RADIATION|Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost|Patients with Glioblastoma will receive neoadjuvant stereotactic radiotherapy to Planning Target Volume (PTV) to 30 Gy in 5 fractions, and a Simultaneous Integrated Boost delivering 35-50 GY to GTV. Patients will be divided into groups of 5 and will receive (in the absence of 2 G4 toxicities per group), the following dose levels: 35-40-42.5-45-47.5 and 50 Gy. Standard Temozolomide chemotherapy will be prescribed after surgery.
219740077|NCT06564103|COMBINATION_PRODUCT||
219740078|NCT06639932|BEHAVIORAL|We-INtervention|The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
219740079|NCT06639932|BEHAVIORAL|Usual Care Group|The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
219173475|NCT03973320|OTHER|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
219173476|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
219173477|NCT04954664|BIOLOGICAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
219173478|NCT04954664|BIOLOGICAL|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
219173479|NCT04312308|OTHER|Sample collection|"1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3\. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
219173480|NCT05418699|DEVICE|closed-loop insulin pump|Follow up of patients with real-time closed-loop insulin delivery systems
219173481|NCT06067425|DRUG|SAR442501|Solution for injection; Subcutaneous injection
219173482|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
219173483|NCT03376321|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
219173484|NCT03376321|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
219173485|NCT03376321|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
219173486|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
219173487|NCT02496780|DRUG|levemir insulin|basal insulin once a day
219173488|NCT02496780|DRUG|placebo|once or 3x daily
219173489|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-High（Combined Vaccine）|
219173490|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-Low（Combined Vaccine）|
219173491|NCT02992925|BIOLOGICAL|Hib vaccine|
219173492|NCT02992925|BIOLOGICAL|DPT-IPV|
219245465|NCT03660254|BEHAVIORAL|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
219245466|NCT01580735|DRUG|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
219245467|NCT02725359|DRUG|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
219245468|NCT02725359|DRUG|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
219245469|NCT02725359|DRUG|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
219245470|NCT02725359|DRUG|Saline|USG guided SCPB with saline bilaterally 10 ml each side
219245471|NCT02389725|DEVICE|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
219245472|NCT02389725|DEVICE|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
219245473|NCT06446531|DRUG|Placebo|Oral tablet administered once daily
219245474|NCT06446531|DRUG|Rybelsus Tablet|Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
219245475|NCT06446531|DRUG|Jardiance 25Mg Tablet|Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
219245476|NCT06446531|DRUG|Metformin|Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
219245477|NCT06446531|DRUG|Actos|Oral tablet dosed at 15mg once daily
219245478|NCT05422859|OTHER|MobiDig|"The application will contain the following modules:~1. information and knowledge about heart failure;~2. vital sign diary, which can be sent to the certified HFU~3. pedometer (individualized step-goal), cardiac home training videos~4. frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
219245479|NCT04021927|DEVICE|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
219245480|NCT01799785|BEHAVIORAL|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
219245481|NCT01799785|OTHER|Usual Care|
219245482|NCT03741283|OTHER|Optimisation of nutrition and medication|"1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
219245483|NCT00420797|DRUG|10% Phenylephrine hydrochloride gel|
219245484|NCT02146300|BIOLOGICAL|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
219245485|NCT00427297|DRUG|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
219245486|NCT00427297|DRUG|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
219245487|NCT00427297|DRUG|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
219245488|NCT00427297|DRUG|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
219245489|NCT00427297|DRUG|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
219245490|NCT00427297|DRUG|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
219245491|NCT00427297|DRUG|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
219245492|NCT00724750|DEVICE|Gauze suction (G-SUC)|Negative pressure wound therapy
219245493|NCT00724750|DEVICE|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
219245494|NCT02230423|PROCEDURE|Nasal surgery|
219245495|NCT01890798|DRUG|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
219245496|NCT03410953|BIOLOGICAL|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
219245497|NCT01689285|DRUG|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
219245498|NCT01689285|DRUG|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
219173493|NCT05840250|OTHER|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
219173494|NCT05333185|BEHAVIORAL|DİABOT (mobile application robot )|"DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet."
219173495|NCT05426928|OTHER|Additional temperature monitoring/recording|All patients in this study will receive the same standard of care treatment for their HIPEC procedure. The only difference will be the use of additional temperature probes to collect more robust data regarding intraabdominal temperature, and the prospective collection of actual boundary conditions of the system.
219173496|NCT03779204|BEHAVIORAL|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
219173497|NCT03779204|BEHAVIORAL|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
219173498|NCT04641026|OTHER|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
219173499|NCT04641026|OTHER|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
219173500|NCT04641026|OTHER|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
219173501|NCT04641026|OTHER|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
219173502|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
219173503|NCT04258709|BEHAVIORAL|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
219173504|NCT04258709|BEHAVIORAL|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
219173505|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
219173506|NCT05972512|OTHER|Placebo|Mode of usage: Two times a day Route of administration: Oral
219173507|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
219173508|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
219245499|NCT01998997|BEHAVIORAL|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
219245500|NCT01860222|PROCEDURE|SR|
219245501|NCT01860222|PROCEDURE|PLAT|
219245502|NCT01827176|OTHER|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
219245503|NCT00639639|BIOLOGICAL|tetanus toxoid|Given by injection
219245504|NCT00639639|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
219173509|NCT05509192|DRUG|MTPI|Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
219173510|NCT05509192|DRUG|Classic Induction|Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
219173511|NCT04812366|DRUG|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
219173512|NCT04812366|DRUG|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
219173513|NCT04812366|DRUG|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
219173514|NCT04812366|DRUG|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
219173515|NCT04812366|DRUG|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
219173516|NCT04812366|DRUG|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
219173517|NCT02677025|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
219173518|NCT02677025|BEHAVIORAL|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
219173519|NCT05018494|OTHER|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
219173520|NCT05018494|OTHER|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
219173521|NCT04034251|DRUG|Paclitaxel|Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m\^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m\^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
219245505|NCT00639639|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
219173522|NCT04034251|DRUG|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
219173523|NCT04034251|DEVICE|BardPort Titanium Implanted Port with Peritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
219173524|NCT01105286|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
219173525|NCT04414280|DEVICE|Medtronic MiniMed 670G|The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
219173526|NCT04414280|DEVICE|Medtronic MiniMed 780G|The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.
219173527|NCT04414280|DEVICE|Tandem Control-IQ|The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
219173528|NCT06519279|DEVICE|Opals|Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
219173529|NCT06519279|DEVICE|Axivity|"At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering."
219173530|NCT06636539|DEVICE|CEM Exam in Investigational Device|All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
219173531|NCT04639206|BEHAVIORAL|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
219173532|NCT05273749|DRUG|TNX-102 SL Tablet, 5.6 mg|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
219173533|NCT05273749|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
219173534|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A standard dose will be administered on day 0 of the study.
219173535|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
219173536|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
219173537|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
219173538|NCT04203576|DEVICE|FIRE1 System|FIRE1 System
219173544|NCT06171269|RADIATION|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
219173545|NCT06171269|RADIATION|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
219173546|NCT06171269|OTHER|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
219173547|NCT05629143|PROCEDURE|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
219173548|NCT05629143|PROCEDURE|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
219173549|NCT05629143|DRUG|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
219173550|NCT04585477|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
219173551|NCT04585477|DRUG|Durvalumab|Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
219173552|NCT04585477|DRUG|Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy|Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
219173553|NCT06490900|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.
219173554|NCT06490900|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
219173555|NCT05290974|OTHER|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
219173556|NCT05290974|OTHER|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
219173557|NCT03378102|BIOLOGICAL|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
219173558|NCT03270111|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
219173559|NCT03270111|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
219173560|NCT03270111|BEHAVIORAL|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
219173561|NCT03270111|BEHAVIORAL|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
219173562|NCT05547984|DEVICE|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
219173563|NCT05547984|DEVICE|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
219173564|NCT06163547|RADIATION|MMA embolization|Middle meningeal artery embolization
219173565|NCT06015945|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study."
219173566|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
219173567|NCT05704621|DRUG|chemotherapy|six cycles of platinum-based chemotherapy +/- bevacizumab
219173568|NCT06796439|OTHER|Static stretching|"Participants will be divided into two groups with sample size of 52 participants in each group.~Group 1: Participants will perform static Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of static stretching exercises. After the general warm-up, participants would engage in a sequence of randomized static stretches including Lower back stretch, Quads stretch, Hams Stretch, Calf Stretch and Upper limb Stretches (biceps, Triceps, Arm across chest, Arm pull and head tilt, Side stretch, backward arm stretch, Pect. stretch and Towel Stretch). All stretches were done as 3 sets of 30 seconds for 20 minutes for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.~Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants wou"
219173569|NCT06796439|OTHER|Dynamic Stretching|Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants would engage in a sequence of randomized static stretches including Jumping Jacks, Lunges, Trunk Circles, arm swings and butt Kicks. All stretches were done as 3 sets of 30 seconds for 20mins for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.
219173570|NCT03364530|DRUG|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
219173571|NCT03364530|PROCEDURE|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
219173572|NCT03034811|DEVICE|Persona Partial Knee system|Fixed bearing partial knee
219173573|NCT02987530|DRUG|Dolutegravir|Oral use, 50mg/day
219173574|NCT02987530|DRUG|Darunavir-cobicistat|Oral use, 800-150mg/day
219173575|NCT02987530|DRUG|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
219173576|NCT06564701|DEVICE|Phonak Roger TouchScreen Microphone|Transmitter microphone system operating on the 2.4 GHz band, which allows for low-delay and reliable long-range broadcast to a compatible Roger receiver, designed to be used in educational settings. It features six microphones and adaptive technology in which speech signals are increased when background noise increases to ensure that the speech signal is always above the noise level.
219173577|NCT06564701|DEVICE|Phonak Partner Mic|Wireless microphone that uses Phonak proprietary AirStream technology to connect to Phonak hearing aids. It uses a fixed directional microphone, and is paired to the hearing aids such that the hearing aid microphones are attenuated at a fixed level when the microphone is in use.
219245506|NCT04390971|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
219245507|NCT03078699|RADIATION|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
219245508|NCT05255276|DRUG|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
219245509|NCT05255276|DRUG|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
219245510|NCT05255276|DRUG|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
219245511|NCT05255276|DRUG|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
219245512|NCT05055999|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
219245513|NCT02623101|DEVICE|Reflectance confocal microscopy|Non-invasive imaging of the lesion
219245514|NCT02623101|PROCEDURE|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
219245515|NCT02623101|PROCEDURE|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
219245516|NCT01047306|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
219245517|NCT05390697|OTHER|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
219245518|NCT01304953|DRUG|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
219245519|NCT01304953|DRUG|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
219245520|NCT01304953|DRUG|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
219245521|NCT01304953|DRUG|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
219245522|NCT01543009|OTHER|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
219245523|NCT00652496|DRUG|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
219245524|NCT00652496|DRUG|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
219245525|NCT00652496|DRUG|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
219245526|NCT00652496|DRUG|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
219245527|NCT00652496|DRUG|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
219245528|NCT03664271|BEHAVIORAL|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
219245529|NCT03664271|BEHAVIORAL|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
219245530|NCT01452204|OTHER|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
219245531|NCT03613571|DRUG|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
219245532|NCT05742256|DRUG|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
219245533|NCT05742256|DRUG|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
219245534|NCT05742256|DRUG|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
219245535|NCT02538055|BEHAVIORAL|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
219245536|NCT02538055|BEHAVIORAL|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
219245537|NCT04627259|OTHER|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
219245538|NCT01622088|DRUG|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
219245539|NCT04038034|DIETARY_SUPPLEMENT|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
219245540|NCT04038034|DIETARY_SUPPLEMENT|Placebo|Placebo
219245541|NCT04673071|OTHER|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
219245542|NCT04673071|OTHER|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
219245543|NCT00274846|BIOLOGICAL|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
219245544|NCT00274846|BIOLOGICAL|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
219245545|NCT00274846|DRUG|cyclophosphamide|Days -5 and -4: 60 mg/kg
219245546|NCT00274846|DRUG|fludarabine phosphate|Days -5 through -2: 25 mg/m\^2
219245547|NCT00274846|PROCEDURE|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
219245548|NCT00396721|DRUG|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
219245549|NCT00396721|DRUG|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
219245550|NCT03770299|BIOLOGICAL|Nivolumab|Specified dose on specified days
219245551|NCT03770299|DRUG|Vinorelbine|Specified dose on specified days
219245552|NCT03770299|DRUG|Gemcitabine|Specified dose on specified days
219245553|NCT03770299|DRUG|Docetaxel|Specified dose on specified days
219245554|NCT03770299|DRUG|Pemetrexed|Specified dose on specified days
219245555|NCT03770299|DRUG|Cisplatin|Specified dose on specified days
219245556|NCT03770299|DRUG|Carboplatin|Specified dose on specified days
219245557|NCT03770299|DRUG|Paclitaxel|Specified dose on specified days
219245558|NCT03770299|OTHER|Observation|Observation by the investigator
219245559|NCT05416970|BEHAVIORAL|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
219245560|NCT03027999|OTHER|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7"
219245561|NCT05168696|OTHER|Virtual Reality Glasses|Virtual Reality Glasses
219245562|NCT01670747|RADIATION|Chest computed tomography|
219245563|NCT02578628|OTHER|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
219245564|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
219245565|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
219245566|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
219245567|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
219173578|NCT04726501|OTHER|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
219173579|NCT00781690|DEVICE|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
219173580|NCT06317220|BIOLOGICAL|Vedolizumab|Administered over 30 minute infusion at MGH main campus
219173581|NCT04712851|BIOLOGICAL|Pembrolizumab|Given IV
219173582|NCT05152927|DEVICE|Parathyroid Eye (PTeye)|Intraoperative Tool
219173583|NCT05664841|BEHAVIORAL|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
219173584|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
219173585|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
219173586|NCT06637891|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
219173587|NCT05471414|BEHAVIORAL|Whole-food, Plant-Based Diet|Pre-packaged, freshly made plant-based meals (provided by either Plantable or CookUnity) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals with staff assistance available.
219173588|NCT05471414|BEHAVIORAL|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
219173589|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
219173590|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
219173591|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
219173592|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
219173593|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
219173594|NCT06427980|DRUG|Chinese Herbal formula HuoXue LiShui|The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
219173595|NCT06427980|DRUG|Chinese Herbal formula Placebo|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
219173596|NCT01416831|OTHER|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
219173597|NCT01416831|DRUG|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
219362693|NCT00927368|PROCEDURE|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
219740080|NCT06639152|DRUG|oil-based contrast medium|In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
219245568|NCT06035003|BEHAVIORAL|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219245569|NCT00812825|DRUG|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
219740081|NCT06639152|DRUG|water-based contrast medium|In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
219740082|NCT05694494|BEHAVIORAL|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
219740083|NCT05694494|BEHAVIORAL|upper limb exercise training|upper limb exercise training
219740084|NCT00830336|DRUG|Azithromycin|Oral Suspension
219740085|NCT00830336|DRUG|Zithromax®|Oral Suspension
219740086|NCT01565759|DRUG|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
219740087|NCT04138355|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
219740088|NCT04406454|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
219740089|NCT01127958|DEVICE|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
219740090|NCT01127958|DEVICE|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
219740091|NCT04873908|OTHER|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
219740092|NCT04873908|OTHER|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
219740093|NCT04873908|OTHER|conventional rehabilitation|Patients received conventional rehabilitation schedule
219740094|NCT02599831|DEVICE|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
219740095|NCT02599831|DEVICE|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
219740096|NCT02599831|DEVICE|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
219740097|NCT03376386|RADIATION|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
219740098|NCT00601731|BIOLOGICAL|MenACWY-CRM197|Blood test, 40-months and 60-months children
219740099|NCT00601731|BIOLOGICAL|Blood test|Blood test, 40-months and 60-months children
219740100|NCT01383876|BEHAVIORAL|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
219740101|NCT01383876|BEHAVIORAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
219740102|NCT05205863|BIOLOGICAL|Cofact|Human prothrombin complex concentrate
219740103|NCT06529627|PROCEDURE|Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection|pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
219740104|NCT06161181|DEVICE|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
219740105|NCT04388631|OTHER|Coronavirus Disease 2019|male patients who have developed COVID-19
219740106|NCT06501963|BIOLOGICAL|Live Attenuated Influenza Vaccine|The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
219740107|NCT01542944|DRUG|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
219740108|NCT05218707|OTHER|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
219740109|NCT02772302|DEVICE|mindBEAGLE EEG-based brain-computer interface|
219173598|NCT06507956|OTHER|Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis|Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive and/or hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
219173599|NCT05215314|BEHAVIORAL|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
219173600|NCT06107582|OTHER|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
219173601|NCT04974008|DRUG|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
219173602|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
219740110|NCT05821894|OTHER|Observational study|
219740111|NCT04702607|PROCEDURE|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
219740112|NCT00104884|DRUG|Depsipeptide|Given IV
219740113|NCT06184724|OTHER|Implementation Package for CGA|The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
219740114|NCT06184724|OTHER|Routine Clinical Care|Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
219740115|NCT03989908|OTHER|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
219740116|NCT03989908|OTHER|Control noodle|In this intervention arm, subjects will be served with normal noodle.
219740117|NCT05917964|DRUG|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
219740118|NCT05824728|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
219740119|NCT06160206|BIOLOGICAL|Bevacizumab|Given IV
219740120|NCT06160206|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219740121|NCT06160206|PROCEDURE|Computed Tomography|Undergo CT
219740122|NCT06160206|OTHER|Electronic Health Record Review|Ancillary studies
219740123|NCT06160206|RADIATION|Hypofractionated Radiation Therapy|Undergo radiation therapy
219740124|NCT06160206|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219740125|NCT06160206|BIOLOGICAL|Retifanlimab|Given IV
219740126|NCT03907891|BEHAVIORAL|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
219740127|NCT03907891|BEHAVIORAL|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
219740128|NCT03907891|BEHAVIORAL|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
219740129|NCT04503642|PROCEDURE|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
219740130|NCT03680508|DRUG|TSR-022 and TSR-042|immunotherapy
219740131|NCT06158477|DRUG|JYP0035 Experimental Drug Treatment|Single dose intervention
219740132|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
219740133|NCT03942653|DRUG|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
219740134|NCT03942653|DRUG|Pembrolizumab|Pembrolizumab, IV, Q3W
219740135|NCT03449485|DRUG|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
219740136|NCT04831346|OTHER|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
219740137|NCT04831346|DEVICE|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
219740138|NCT04893811|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
219740139|NCT05059626|DRUG|simvastatin 10mg|Simvastation acts as a systemic LOX inhibitor.
219740140|NCT05059626|DRUG|Bazedoxifene 20/Estrogens,Con 0.45Mg Tb|Duavee is a selective estrogen receptor modulator.
219740141|NCT04906187|OTHER|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
219245570|NCT00812825|DRUG|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
219245571|NCT00812825|DRUG|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
219245572|NCT00812825|DRUG|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
219245573|NCT00812825|DRUG|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
219245574|NCT02860858|BIOLOGICAL|Intravitreous aflibercept injection|
219245575|NCT05070637|PROCEDURE|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
219245576|NCT05070637|PROCEDURE|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
219245577|NCT05070637|PROCEDURE|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
219245578|NCT03653689|DIETARY_SUPPLEMENT|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
219245579|NCT03653689|DIETARY_SUPPLEMENT|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
219740142|NCT04906187|OTHER|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
219740143|NCT04140344|OTHER|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
219740144|NCT04970576|DRUG|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
219740145|NCT04970576|DRUG|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
219740146|NCT06463899|PROCEDURE|multi-perforated catheter|After skin closure, cardiac surgeons place multi-perforated catheters aseptically.
219740147|NCT06463899|PROCEDURE|Classic procedure|opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol
219173603|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
219740148|NCT03268499|PROCEDURE|Lipiodol-based transarterial chemoembolization|Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
219740149|NCT05991466|DRUG|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
219740150|NCT06224153|OTHER|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
219740151|NCT06224153|OTHER|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
219740152|NCT04526158|BEHAVIORAL|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
219173604|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
219173605|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
219173606|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
219173607|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
219173608|NCT06258005|DIAGNOSTIC_TEST|PocDoc|PocDoc is a digital rapid 5-marker lipid test
219173609|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
219173610|NCT02565069|DEVICE|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
219173611|NCT06822478|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30.
219173612|NCT06822478|DRUG|Meglumine antimoniate.|"Monotherapy with intralesional pentavalent antimonials is one of the treatments of care used for LC in Colombia and will be used as a comparator for safety evaluation.~Pentavalent antimonials: administered intralesionally. At a dose of 0.008 ml X mm of area of each lesion, maximum 15 ml in total, once a week for 5 weeks."
219173613|NCT05515198|OTHER|Patient Education|Patients will be provided educational opportunities.
219173614|NCT05515198|OTHER|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
219173615|NCT05515198|OTHER|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
219173616|NCT03181763|DRUG|Placebo|Participants will receive inactive placebo on their second visit.
219173617|NCT03181763|DRUG|Midomafetamine|Participants will receive 100 mg midomafetamine HCl on their second visit
219245580|NCT03653689|DIETARY_SUPPLEMENT|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
219245581|NCT03681002|BEHAVIORAL|structured lifestyle program|Intensive Lifestyle counseling during one year
219245582|NCT01463397|DRUG|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
219245583|NCT01463397|DRUG|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
219245584|NCT03710850|DIETARY_SUPPLEMENT|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
219245585|NCT02933996|DEVICE|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
219245586|NCT02933996|DEVICE|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
219245587|NCT05310058|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
219245588|NCT01357564|OTHER|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
219245589|NCT01357564|OTHER|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
219245590|NCT00346242|DRUG|Zoledronic Acid|
219245591|NCT06286592|BEHAVIORAL|Ultra-brief mindfulness intervention video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
219245592|NCT06286592|BEHAVIORAL|Forgiveness video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
219245593|NCT06286592|BEHAVIORAL|ACT values video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
219245594|NCT03778606|DIETARY_SUPPLEMENT|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
219245595|NCT03421600|DEVICE|blue laser imaging|blue laser imaging
219245596|NCT03421600|DEVICE|White light imaging|White light imaging
219245597|NCT04978688|DRUG|Relugolix|Administered as an oral tablet once daily.
219245598|NCT04978688|DRUG|E2/NETA|Administered as an oral tablet once daily.
219245599|NCT01648699|DRUG|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
219245600|NCT03521076|DEVICE|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
219245601|NCT03075111|DIAGNOSTIC_TEST|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
219245602|NCT02433392|PROCEDURE|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
219245603|NCT02267746|DRUG|Tazarotene (Fabior™)|
219245604|NCT02267746|DRUG|Tazarotene (Actavis)|
219245605|NCT02267746|DRUG|Vehicle foam|
219245606|NCT06336707|DRUG|HS-20089|Intravenous infusion
219245607|NCT06336707|DRUG|Adebrelimab|Intravenous infusion
219245608|NCT06336707|DRUG|Bevacizumab|Intravenous infusion
219245609|NCT06336707|DRUG|Cisplatin / carboplatin|Intravenous infusion
219245610|NCT03720717|DRUG|Baclofen 10mg|Baclofen administration pre-operatively
219245611|NCT03720717|OTHER|Placebo|Placebo administration
219245612|NCT06370572|OTHER|PAINAD EHR Prompt|Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain
219245613|NCT05078450|BEHAVIORAL|Mood Lifters|Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
219245614|NCT05095506|OTHER|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
219245615|NCT05095506|OTHER|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
219245616|NCT06329011|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219362694|NCT00927368|PROCEDURE|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
219173618|NCT03181763|BEHAVIORAL|Acoustic startle|Startle assessment
219173619|NCT03420833|DEVICE|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
219173620|NCT05389436|PROCEDURE|Ambulatory care|The surgery is performed in ambulatory setting
219173621|NCT05389436|PROCEDURE|Inpatient care|The surgery is performed during inpatient care
219173622|NCT05350527|OTHER|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
219173623|NCT03659760|OTHER|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
219173624|NCT05253664|BEHAVIORAL|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
219173625|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
219173626|NCT05376813|PROCEDURE|CT-Scan and MRI|CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
219173627|NCT03662607|BEHAVIORAL|Virtual reality experience|"* Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again."
219173628|NCT00569049|PROCEDURE|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
219173629|NCT05318066|DRUG|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
219173630|NCT06345170|OTHER|The DIR/Floortime™ Therapy Program|The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
219173631|NCT06345170|OTHER|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
219173632|NCT04294225|DRUG|Anastrozole|Given PO
219245617|NCT06329011|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219245618|NCT06329011|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
219245619|NCT06329011|BEHAVIORAL|Placebo Transcranial direct current stimulation|The Transcranial direct current stimulation will be performed without being turned on.
219245620|NCT03441750|DRUG|metformin|Metformin tablets will be administrated in the experimental arm.
219245621|NCT03441750|OTHER|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid."
219245622|NCT05923554|OTHER|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
219740153|NCT04526158|BEHAVIORAL|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
219740154|NCT03622905|DEVICE|DBS-f On|Deep Brain Stimulation of the fornix
219740155|NCT03622905|DEVICE|DBS Off|Deep Brain Stimulation of the fornix turned off
219740156|NCT03533491|BEHAVIORAL|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
219740157|NCT04002063|BEHAVIORAL|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
219740158|NCT04002063|BEHAVIORAL|CBT alone|CBT therapy individual
219740159|NCT06464913|RADIATION|With or without chest wall RT|Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
219173633|NCT04294225|DRUG|Letrozole|Given PO
219173634|NCT05927090|PROCEDURE|Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair|Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
219740160|NCT03164993|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
219740161|NCT03164993|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
219245623|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
219245624|NCT00348283|BIOLOGICAL|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
219245625|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
219245626|NCT05492721|DEVICE|2-Octylcyanoacrylate|Incisions on left will have one glue and on right will have the other glue
219245627|NCT05492721|DEVICE|N-butyl-2-cyanoacrylate|Incisions on left will have one glue and on right will have the other glue
219245628|NCT04453709|BEHAVIORAL|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~1. Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~2. Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~3. Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~4. Strengthening Social Support: Social skills session and practice exercise to identify social support.~5. Staying Well: Make a plan that helps to create supportive family environment."
219245629|NCT04453709|BEHAVIORAL|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
219245630|NCT05337722|BEHAVIORAL|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
219245631|NCT05337722|BEHAVIORAL|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
219245632|NCT01996098|DRUG|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
219245633|NCT01996098|DRUG|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
219245634|NCT03590847|BEHAVIORAL|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
219245635|NCT06233682|OTHER|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
219245636|NCT04374435|PROCEDURE|MKTP with Surgical blade|In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
219245637|NCT04374435|DEVICE|MKTP with Negative Pressure Instrument|In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
219245638|NCT04374435|DEVICE|Suction blister grafting without cell dissociation|In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
219245639|NCT05542004|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
219245640|NCT06408194|DRUG|CD22CART infusion|CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
219245641|NCT06408194|DRUG|Tisagenlecleucel|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
219245642|NCT05488678|DRUG|VNRX-7145|single oral dose
219245643|NCT05488678|DRUG|Ceftibuten|single oral dose
219245644|NCT03613363|DEVICE|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
219245645|NCT06312566|DRUG|brivaracetam (BRV) tablet|Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.
219245646|NCT06312566|DRUG|brivaracetam (BRV) dry syrup|Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
219245647|NCT05208255|OTHER|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
219245648|NCT06562244|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens (PLH)|The PLH program is the core intervention and will be delivered over 6 sessions with adolescents and caregivers, focusing on building positive parent-child relationships, problem-solving skills, stress management, effective limit-setting, and emotional regulation. There will also be a pre-program visit with the facilitator and families prior to the group sessions. Sessions will include both separate and joint activities between adolescents and caregivers. Engagement boosters will be provided during the PLH sessions and are part of the PLH intervention.
219245649|NCT06562244|BEHAVIORAL|Helping Adolescents Thrive comics|UNICEF's Helping Adolescents Thrive (HAT) comics will be used to guide adolescents through content on improving relationships, handling conflict, understanding emotions, and problem solving. These sessions will be group-based and cover the content in the HAT manual with the adolescents in an interactive format.
219245650|NCT06562244|BEHAVIORAL|I Support My Friends|"An adapted version of UNICEF's I Support My Friends program will be provided to adolescents by a facilitator in a group-based workshop format over the course of 1 day."
219245651|NCT05010031|RADIATION|Palliative radiotherapy|An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
219245652|NCT02430597|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
219245653|NCT02430597|DEVICE|NanoKnife|
219245654|NCT05039047|OTHER|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
219245655|NCT05977699|DRUG|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
219245656|NCT05977699|DRUG|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
219245657|NCT05977699|OTHER|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
219245658|NCT06281938|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
219245659|NCT06281938|OTHER|Standard care weight estimation|Standard care (unspecified) will be used to determine weight-based dosing and other management.
219245660|NCT04736472|DEVICE|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
219245661|NCT06435520|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.
219245662|NCT06435520|BEHAVIORAL|Structured Medication Tapering|A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
219245663|NCT04614558|DRUG|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
219245664|NCT02116582|DRUG|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
219245665|NCT06178471|DIAGNOSTIC_TEST|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
219245666|NCT01765439|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
219245667|NCT04476849|DRUG|fezolinetant|Oral
219245668|NCT04946656|PROCEDURE|sphenopalatine ganglion block|The sphenopalatine ganglion will be blocked with bupivacaine for this study
219245669|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
219245670|NCT04391803|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
219740162|NCT03164993|DRUG|Cyclophosphamide|Chemotherapy
219740163|NCT03164993|OTHER|Placebo|Placebo
219740164|NCT06397183|OTHER|Mulligan Strech with Traction (TSLR) Technique|The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.
219740165|NCT06397183|OTHER|Post-Isometric Relaxation Technique|Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
219740166|NCT04508530|BIOLOGICAL|Panzyga|Panzyga 10% IVIG
219740167|NCT04508530|OTHER|Placebo|Placebo
219740168|NCT05702047|BEHAVIORAL|Nose-only breathing|Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
219740169|NCT05702047|BEHAVIORAL|Mouth-only breathing|Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
219740170|NCT06148948|DRUG|BI 1584862|BI 1584862
219740171|NCT06148948|DRUG|Placebo|Placebo matching BI 1584862
219740172|NCT04324944|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
219740173|NCT04324944|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation around befriending. Each session is 60 minutes long.
219740174|NCT06175533|PROCEDURE|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
219740175|NCT03315026|DRUG|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
219740176|NCT03315026|BEHAVIORAL|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
219173635|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
219173636|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)|Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
219173637|NCT05927090|PROCEDURE|Extensive Root and Ascending Aorta Replacement with Total Arch Replacement|This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
219173638|NCT05927090|PROCEDURE|Thoracic Endovascular Aortic Repair|TEVAR patients have a higher incidence of complications and reintervention than open repair patients. TEVAR complications may include endoleak, retrograde type A aortic dissection, stent-graft migration, fracture or collapse, and increased size.
219173639|NCT05927090|PROCEDURE|Open Thoracic Aortic Descendig Repair|Surveillance imaging can detect complications of open repair, such as graft infection and anastomotic pseudoaneurysm. After open repair or TEVAR, patients may develop progressive aneurysmal dilatation of adjacent or remote aortic segments.
219173640|NCT02790502|DEVICE|Food Photography Application©|Group testing RFPM as method of recording plate waste
219173641|NCT06788457|DEVICE|Exhaled Breath Condensate|Measurement of hydrogen peroxide in exhaled breath
219173642|NCT04812535|DRUG|Vilobelimab|Vilobelimab Monotherapy
219173643|NCT04812535|DRUG|Vilobelimab + pembrolizumab combination therapy|Vilobelimab + pembrolizumab combination therapy
219173644|NCT04886531|DRUG|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.
219245671|NCT04060641|GENETIC|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
219173645|NCT04886531|DRUG|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*
219173646|NCT04886531|DRUG|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
219173647|NCT02560233|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
219173648|NCT02560233|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
219173649|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
219173650|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
219740177|NCT06121284|DRUG|D-Cycloserine|Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
219740178|NCT06121284|DEVICE|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
219740179|NCT06121284|DRUG|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
219740180|NCT01725282|DRUG|quetiapine extended release (XR)|Extended release tablets
219740181|NCT01725282|DRUG|Placebo|matching tablets
219740182|NCT04064567|BEHAVIORAL|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
219245672|NCT06012305|OTHER|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
219245673|NCT05626920|DRUG|Disulfiram 250 mg|Disulfiram treatment
219245674|NCT05626920|DRUG|Placebo|Placebo treatment
219245675|NCT01533896|BEHAVIORAL|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
219245676|NCT02978235|DRUG|TAS4464|Intravenous (IV) Infusion
219245677|NCT02465944|DRUG|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
219245678|NCT02465944|DRUG|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
219245679|NCT04895202|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
219245680|NCT03861078|OTHER|Own Brand Cigarette|Effects of own brand cigarette use.
219245681|NCT03861078|OTHER|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
219245682|NCT03861078|OTHER|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
219245683|NCT03861078|OTHER|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
219245684|NCT03861078|OTHER|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
219245685|NCT06315647|PROCEDURE|DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation|comparison between different technique in difficult CBD cannulation
219245686|NCT02950870|DRUG|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
219245687|NCT02950870|DRUG|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
219245688|NCT02950870|DRUG|Ribavirin|Patients will be treated with ribavirin if necessary.
219245689|NCT06339385|BEHAVIORAL|PADIS assessment|Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
219245690|NCT03627130|DRUG|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
219245691|NCT03627130|DRUG|Potassium Chloride|Potassium Chloride capsules for 5 days
219245692|NCT04050319|DIAGNOSTIC_TEST|Screening and diagnosis if injured|physical therapy
219245693|NCT00955565|PROCEDURE|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
219245694|NCT00955565|PROCEDURE|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
219245695|NCT02971683|DRUG|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
219245696|NCT02971683|DRUG|Placebo|Placebo of Abatacept subcutaneous
219245697|NCT02038114|BEHAVIORAL|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
219245698|NCT05692232|OTHER|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
219245699|NCT05692232|OTHER|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
219245700|NCT05692232|OTHER|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
219245701|NCT06169774|OTHER|Educational video|Watch the 17-minute educational video as many times as needed within a 12-month period.
219740183|NCT04064567|OTHER|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
219740184|NCT03984461|BIOLOGICAL|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
219740185|NCT05813093|DEVICE|rTMS|Accelerated iTBS treatment
219740186|NCT04624399|DRUG|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
219740187|NCT05263791|DEVICE|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
219173651|NCT03869736|DRUG|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
219173652|NCT03869736|DRUG|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
219245702|NCT04206501|DEVICE|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
219245703|NCT03408821|OTHER|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
219245704|NCT00067925|BEHAVIORAL|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
219173653|NCT06210971|DRUG|liposomal irinotecan|Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2
219173654|NCT06210971|DRUG|Capecitabine|Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
219173655|NCT06210971|RADIATION|Radiation threapy|50.4Gy/28 fractions
219173656|NCT03336333|DRUG|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
219173657|NCT03336333|DRUG|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
219173658|NCT03336333|DRUG|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
219173659|NCT03336333|DRUG|Venetoclax|400 mg tablets administered orally once daily.
219173660|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
219173661|NCT02664870|PROCEDURE|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
219245705|NCT02451553|DRUG|Afatinib Dimaleate|Given PO
219245706|NCT02451553|DRUG|Capecitabine|Given PO
219245707|NCT02451553|OTHER|Laboratory Biomarker Analysis|Correlative studies
219173662|NCT02664870|PROCEDURE|Arthroplasty|Total hip, shoulder, or knee arthroplasty
219173663|NCT03940911|OTHER|Measurement of aerobic exercise on cycloergometer|"The incremental effects tests will be performed in a service specialized in the exploration of the exercise (physiology or cardiology according to the centers) in a spacious and air-conditioned room, in the presence of a medical specialist. exercise and close to the resuscitation equipment.~Before the test, weight and height will be collected. Information on the conduct of the test will be given to the patient. A multi-derivation ECG recording will be detected throughout the duration of the test and followed by a physician experienced in the ECG effort.~O2 saturation by oximetry of hens will be recorded continuously. Blood pressure will be recorded at each level. The collection of expired gases in the face mask whose tightness will be verified to measure the fractions inspired and expired in O2 and CO2 (Sensor Medics Vmax229, Yorba Linda, CA, USA) and calculations VO2 max and VCO2.~Maximal power (W max) will be recorded. Patients will be encouraged during the test."
219173664|NCT05078086|OTHER|No intervention|No intervention
219173665|NCT04137913|BEHAVIORAL|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
219173666|NCT06213038|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
219173667|NCT04977310|DEVICE|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
219173668|NCT05318001|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
219173669|NCT05318001|OTHER|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
219245708|NCT02268526|BIOLOGICAL|CSJ148|CSJ148 IV q 4weeks
219245709|NCT02268526|DRUG|Placebo|Placebo IV q 4weeks
219245710|NCT00023621|DRUG|celecoxib|
219245711|NCT00596960|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
219245712|NCT00596960|BEHAVIORAL|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
219245713|NCT03147742|DRUG|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
219245714|NCT00801151|DRUG|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
219245715|NCT05689424|DRUG|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
219245716|NCT00231166|DRUG|HCD122|
219245717|NCT01305837|DRUG|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
219245718|NCT03874091|PROCEDURE|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
219245719|NCT03874091|PROCEDURE|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
219245720|NCT03874091|DRUG|Morphine PCA pump|Morphine given postoperatively.
219245721|NCT04258306|DIETARY_SUPPLEMENT|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
219245722|NCT04258306|DIETARY_SUPPLEMENT|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
219245723|NCT00916318|BEHAVIORAL|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
219245724|NCT01117532|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
219245725|NCT04201275|DRUG|HEC74647PA capsule|Capsule administered orally once daily
219245726|NCT04201275|DRUG|placebo|HEC74647PA capsule matching placebo administered orally once daily
219245727|NCT05945979|DIETARY_SUPPLEMENT|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
219245728|NCT02060071|OTHER|Blood test|Blood test
219245729|NCT03307993|DRUG|Idalopirdine|Idalopirdine 60-120 mg daily dose
219245730|NCT05910788|DEVICE|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
219245731|NCT00459433|PROCEDURE|Biopsychosocial intervention|Psychosocial versus usual care
219245732|NCT00327314|PROCEDURE|Transplantation|
219245733|NCT00327314|PROCEDURE|Hematopoietic cell transplantation|
219245734|NCT04400214|BEHAVIORAL|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
219740188|NCT04576481|BEHAVIORAL|Texting|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
219740189|NCT04576481|BEHAVIORAL|Regret|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
219740190|NCT04576481|BEHAVIORAL|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
219740191|NCT06402136|DRUG|83-0060|Oral MPro inhibitor
219740192|NCT06402136|DRUG|Placebo|Placebo
219740193|NCT04360681|DRUG|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
219740194|NCT04360681|DRUG|Placebo oral tablet|Placebo
219245735|NCT04400214|OTHER|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
219245736|NCT02303509|DRUG|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
219245737|NCT02303509|DRUG|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
219245738|NCT02303509|OTHER|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
219245739|NCT05404178|OTHER|Type 2 diabetes group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
219245740|NCT05360134|DRUG|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
219245741|NCT05360134|OTHER|Placebo|Placebo will be given in a similar manner
219245742|NCT02303613|OTHER|Mapping|Mapping of current triage situation regarding 30 days mortality
219245743|NCT03941769|BIOLOGICAL|Recombinant Interleukin-7|Given IM or SC
219245744|NCT06646757|BEHAVIORAL|APP|1\) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
219245745|NCT06646757|BEHAVIORAL|CBT|"2\) Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
219245746|NCT06646757|BEHAVIORAL|HELP|3\) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
219245747|NCT06646757|BEHAVIORAL|PEER|4\) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
219245748|NCT06646978|DRUG|Imatinib (STI571)|Imatinib-based regimen
219245749|NCT06646315|BEHAVIORAL|Early Intervention|The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
219245750|NCT03145909|DRUG|ABBV-176|Intravenous infusion
219245751|NCT01445379|DRUG|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
219245752|NCT00763919|BEHAVIORAL|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
219245753|NCT00763919|BEHAVIORAL|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
219245754|NCT00763919|BEHAVIORAL|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
219245755|NCT00763919|BEHAVIORAL|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
219173670|NCT05318001|OTHER|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
219173671|NCT05318001|OTHER|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
219173672|NCT03303586|OTHER|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
219173673|NCT03303586|OTHER|Control|Participants will not wearing compression stockings for two weeks.
219173674|NCT03992274|OTHER|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
219173675|NCT05336136|DEVICE|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
219173676|NCT05336136|DEVICE|Current commercial mask|Current commercial mask used for administration of non-invasive ventilation
219173677|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
219173678|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
219173679|NCT05274347|OTHER|Muti-faceted virtual, remote intervention|Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
219173680|NCT03673111|DRUG|Y14|Gut hormone analogue
219173681|NCT03673111|DRUG|Placebo|0.9% saline
219173682|NCT06036199|DEVICE|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
219173683|NCT04487249|OTHER|Vision Therapy|20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.
219173684|NCT06317350|DRUG|GNS-212-E1|Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.
219173685|NCT06317350|DRUG|GNS-212-E2|Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.
219173686|NCT06317350|DRUG|GNS-212-ER|Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
219173687|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
219173688|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
219245756|NCT05253066|DRUG|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
219173689|NCT03869996|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
219173690|NCT03869996|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
219173691|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
219173692|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
219173693|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
219173694|NCT05593510|BEHAVIORAL|No prep ready-to-eat meals|"Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference."
219173695|NCT05593510|BEHAVIORAL|Ingredient bundles (e.g. meal kits)|Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
219173696|NCT06502132|OTHER|Patient Education Group|Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
219173697|NCT06502132|OTHER|Therapeutic Touch Group|Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
219173698|NCT03942445|PROCEDURE|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
219173699|NCT06779968|DEVICE|Femoral Nerve Block|In the femoral nerve block (FNB) group, the femoral nerve was blocked distal to the inguinal ligament and lateral to the femoral artery. Under sterile conditions and ultrasound guidance using a short-axis out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the femoral nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
219173700|NCT06779968|DEVICE|Combined Sciatic and Femoral Nerve Block|In the combined sciatic and femoral nerve block (CS-FNB) group, the femoral nerve block was performed as described above. The sciatic nerve block was performed at either the gluteal region or popliteal fossa. Under sterile conditions and ultrasound guidance using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the sciatic nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
219245757|NCT05253066|DRUG|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
219173701|NCT06779968|DEVICE|Lumbar plexus block|In the lumbar plexus block (LPB) group, the lumbar plexus was blocked paraspinally within the psoas muscle. Under sterile conditions, ultrasound guidance, or with the assistance of a nerve stimulator, using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced within the psoas muscle adjacent to the lumbar plexus. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
219173702|NCT06779968|PROCEDURE|Epidural Analgesia|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine was administered followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hr. For pediatric patients, an initial bolus of 0.2% ropivacaine at 0.5-1 mg/kg was administered, not exceeding a maximum total dose of 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
219173703|NCT06779968|DRUG|Intravenous patient-controlled analgesia|For intravenous patient-controlled analgesia (PCA), fentanyl was administered at a dose of 2 mcg/kg, diluted in 100 mL of normal saline. The basal infusion rate was set at 2 mL/hr, with a PCA dose of 2 mL and a lockout interval of 15 minutes.
219173704|NCT06779968|DEVICE|General Aneasthesia|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
219173705|NCT06276764|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
219173706|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
219173707|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
219173708|NCT06782399|COMBINATION_PRODUCT|Microdevice|"Device: Microdevices~The microdevice is an investigational miniaturized implantable nanodose drug delivery device. It was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. The microdevice releases nanodoses of several approved drugs into the tumor, and is then excised minimally invasively several days later.~Other: Standard of care therapy~Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy"
219173709|NCT06780852|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
219173710|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
219173711|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
219245758|NCT02884622|OTHER|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
219245759|NCT02884622|OTHER|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
219245760|NCT06030999|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
219245761|NCT06030999|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
219245762|NCT06030999|DIETARY_SUPPLEMENT|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
219245763|NCT02816645|PROCEDURE|Magnetic Resonance Imaging (MRI)|
219245764|NCT03795792|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
219245765|NCT03795792|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Will be provided in capsules.
219245766|NCT00751088|PROCEDURE|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
219245767|NCT00751088|PROCEDURE|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
219245768|NCT00751088|PROCEDURE|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
219245769|NCT00751088|PROCEDURE|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
219245770|NCT02374476|DEVICE|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
219245771|NCT06585735|DIETARY_SUPPLEMENT|Proteolytic enzyme fortified protein supplement|Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
219173712|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
219173713|NCT02386553|DRUG|Nusinersen|Solution for intrathecal injection
219173714|NCT05557409|DRUG|AXS-05|AXS-05 tablets, taken twice daily
219173715|NCT05557409|DRUG|Placebo|Placebo tablets, taken twice daily
219173716|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
219173717|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
219173718|NCT05772169|DRUG|Mifepristone 300 MG [Korlym]|Mifepristone tablets for once daily oral dosing
219173719|NCT05772169|DRUG|Placebo for mifepristone|Placebo tablets for once daily oral dosing
219173720|NCT02051374|PROCEDURE|Decompression alone|
219173721|NCT02051374|PROCEDURE|Decompression followed by fusion with instrumentation|
219173722|NCT06545838|OTHER|Analysis of plasma renin concentration|The concentration of plasma renin in patients will be assessed using the immunochemiluminescent method
219173723|NCT06491732|DEVICE|Electrical Impedance Myography|EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
219173724|NCT02120456|DRUG|LEO 43204|
219173725|NCT02120456|DRUG|Placebo|
219173726|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
219173727|NCT05302934|DEVICE|Pheno4U|Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
219173728|NCT06515665|BEHAVIORAL|therapeutic foot orthosis|They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
219173729|NCT00606996|BEHAVIORAL|Group interpersonal psychotherapy (IPT-G)|
219173730|NCT00606996|BEHAVIORAL|Psychoeducation on co-occurring disorders (PSYCHOED)|
219173731|NCT03651076|DEVICE|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
219245772|NCT06545669|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
219245773|NCT06545669|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
219245774|NCT06545669|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
219245775|NCT06545669|OTHER|Lung Cancer Screening|After participating in shared decision-making, eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
219245776|NCT06584578|OTHER|Whole-Body Electromyostimulation|Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
219245777|NCT06584578|OTHER|Pilates|Pilates exercise twice weekly for 12 weeks
219245778|NCT06584578|OTHER|Tai Chi|Pilates exercise twice weekly for 12 weeks
219245779|NCT06584578|OTHER|Nutritional counseling|Nutritional counseling for 12 weeks
219245780|NCT06584994|OTHER|sample collection|Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
219245781|NCT04847284|RADIATION|Intraoperative radiotherapy|Intraoperative radiotherapy application immediately following resection of brain metastases.
219173732|NCT03623321|DRUG|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
219173733|NCT04690738|DIAGNOSTIC_TEST|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
219173734|NCT05790850|BEHAVIORAL|Pre-operative physical exercise|Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.
219245782|NCT03305458|BEHAVIORAL|TFCBT|treatment as usual
219245783|NCT03305458|BEHAVIORAL|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
219245784|NCT05431543|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
219245785|NCT05431543|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
219245786|NCT05431543|DRUG|Vehicle proprietary ophthalmic solution|Proprietary Vehicle ophthalmic solution
219245787|NCT00796497|DRUG|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
219173735|NCT05790850|BEHAVIORAL|Pre-operative mindfulness meditation practice|Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
219173736|NCT04128670|DEVICE|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
219173737|NCT03180996|DEVICE|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
219173738|NCT04511286|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
219173739|NCT04028687|DEVICE|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
219173740|NCT00211289|BEHAVIORAL|Education by community pharmacist|
219173741|NCT05692492|DRUG|ZSP1601|50mg BID
219173742|NCT05692492|DRUG|ZSP1601|100mg BID
219173743|NCT05692492|DRUG|Placebo|Placebo
219173744|NCT05192798|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
219173745|NCT05192798|DRUG|Apatinib Mesylate|Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
219173746|NCT05192798|DRUG|Bevacizumab|Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
219173747|NCT06109909|DEVICE|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
219173748|NCT05701059|PROCEDURE|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
219173749|NCT05701059|DEVICE|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
219173750|NCT05701059|DEVICE|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
219173751|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
219173752|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
219173753|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
219245788|NCT00440037|BIOLOGICAL|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
219245789|NCT00498797|DRUG|Zactima (vandetanib)|
219173754|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
219173755|NCT06029114|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
219173756|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
219173757|NCT03378570|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
219173758|NCT05627479|DRUG|GIK solution|Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
219173759|NCT05627479|DRUG|Isotonic Normal Saline Solution|Placebo injection - administered intravenously.
219173760|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
219173761|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
219173762|NCT06508294|BEHAVIORAL|8 week artificial intelligence based posture exercises|8 week artificial intelligence based posture exercises
219173763|NCT04495959|DRUG|68Ga-HTK03149|PET/MRI scan with radiotracer 68Ga-HTK03149
219173764|NCT05894694|DRUG|first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
219173765|NCT05894694|DRUG|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
219173766|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
219173767|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
219173768|NCT03001830|BIOLOGICAL|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
219173769|NCT03210688|DRUG|Prednisolone|Tablet prednisolone
219173770|NCT03210688|DRUG|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
219173771|NCT04180930|DIAGNOSTIC_TEST|CAPS-5|Clinician Administered PTSD Scale for DMS-5
219173772|NCT04180930|DIAGNOSTIC_TEST|PSSI-5|PTSD Symptom Scale Interview for DSM-5
219245790|NCT00498797|DRUG|Docetaxel|
219245791|NCT00498797|DRUG|Prednisolone|
219245792|NCT05840822|DRUG|Cannabidiol (CBD) Capsule 75mg|Cannabidiol (CBD) capsule containing 75mg CBD
219245793|NCT05840822|DRUG|Placebo|Placebo capsule without cannabidiol
219173773|NCT04180930|DIAGNOSTIC_TEST|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
219173774|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
219173775|NCT05657054|OTHER|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
219173776|NCT05657054|OTHER|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
219173777|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
219173778|NCT06567561|BEHAVIORAL|Whole Foods Plant-Based Diet|Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
219173779|NCT06567561|BEHAVIORAL|Usual Firehouse Diet|Usual firehouse meals.
219173780|NCT06567587|DRUG|Dexmedetomidine|Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
219173781|NCT06567587|DEVICE|BIPAP|Put exaggerated COPD patients on non invasive ventillation
219173782|NCT06566430|BEHAVIORAL|PrEP My Way intervention|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
219173783|NCT06566430|BEHAVIORAL|PrEP My Way intervention without STI testing|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
219173784|NCT06566430|BEHAVIORAL|Enhanced standard of care|These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
219173785|NCT06565715|DRUG|Remimazolam|Remimazolam is used for sedation during anesthetic induction and maintenance.
219173786|NCT06565715|DRUG|Propofol|propofol is used for sedation during anesthetic induction and maintenance.
219173787|NCT01785719|BEHAVIORAL|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
219173788|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
219245794|NCT02852499|OTHER|Urine sampling|
219245795|NCT02852499|OTHER|Carry a GPS and BET|
219245796|NCT02852499|OTHER|Carry pollution sensor|
219173789|NCT06040827|DEVICE|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
219173790|NCT03151616|OTHER|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
219173791|NCT05735600|BEHAVIORAL|AyuDa Virtual: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
219173792|NCT05735600|BEHAVIORAL|AyuDa Written: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
219173793|NCT05952453|DRUG|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
219173794|NCT05952453|DRUG|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
219173795|NCT05636293|DRUG|Ritlecitinib|200mg Ritlecitinib
219173796|NCT05636293|DRUG|Placebo|Placebo
219173797|NCT05636293|OTHER|Gluten|10g of gluten
219173798|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the DMPFC or left DLPFC
219173799|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the left DLPFC
219173800|NCT06305598|PROCEDURE|Biopsy|Undergo biopsy
219173801|NCT06305598|PROCEDURE|Bone Scan|Undergo bone scan
219173802|NCT06305598|PROCEDURE|Computed Tomography|Undergo CT scan
219173803|NCT06305598|DRUG|Leuprolide Acetate|Given SC
219173804|NCT06305598|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219173805|NCT06305598|OTHER|Survey Administration|Ancillary studies
219173806|NCT06305598|DRUG|Testosterone Cypionate|Given IM
219173807|NCT06273917|OTHER|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
219173808|NCT05090722|DEVICE|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
219173809|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219173810|NCT04750473|DRUG|Fluciclovine F18|Given IV
219173811|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
219173812|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219173813|NCT06568302|DRUG|SerpinPC|Administered as SC injection.
219173814|NCT05891496|DRUG|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
219173815|NCT05891496|DRUG|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
219173816|NCT00900575|DEVICE|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
219173817|NCT00900575|DEVICE|Portable Optical Spectrometer|This device is a portable optical spectrometer
219173818|NCT00900575|DEVICE|Transvaginal colposcope|
219173819|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
219173820|NCT05858593|BEHAVIORAL|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
219173821|NCT05858593|BEHAVIORAL|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
219173822|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
219173823|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
219173824|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
219173825|NCT05062031|DEVICE|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
219173826|NCT05062031|DRUG|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
219173827|NCT05062031|DEVICE|Monofocal lenses|Daily wear for 24 months
219173828|NCT04594486|OTHER|Medical treatment of acute appendicitis|All cases will be treated medically and will be followed for recurrences
219173829|NCT06568588|DRUG|S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745|250 mg three times a day for 4 months
219173830|NCT03511963|DRUG|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
219173831|NCT03511963|DRUG|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
219173832|NCT05559515|BEHAVIORAL|NDPP-Flex|NDPP + patient-centered goal setting
219173833|NCT05559515|BEHAVIORAL|NDPP|Usual care NDPP only
219173834|NCT06007391|DRUG|Nicotinamide|nicotinamide 3g per day
219173835|NCT04347161|DEVICE|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
219173836|NCT04347161|OTHER|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
219173837|NCT05188027|OTHER|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
219173838|NCT05188027|OTHER|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
219173839|NCT05188027|OTHER|No exercise|Participants will rest in a supine position for 30 minutes.
219173840|NCT02482376|RADIATION|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
219173841|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
219173842|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
219173843|NCT04169373|DRUG|Upadacitinib|Upadacitinib tablet administered orally
219173844|NCT04169373|DRUG|Placebo|Placebo for upadacitinib tablet administered orally
219245797|NCT02852499|OTHER|Sampling at the maternity|
219245798|NCT02852499|OTHER|Self-questionnaires|
219245799|NCT02852499|OTHER|Sampling in partum period|Meconium and a strand of hair.
219245800|NCT02531997|BEHAVIORAL|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
219245801|NCT02531997|BEHAVIORAL|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
219245802|NCT05386706|BEHAVIORAL|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
219245803|NCT05386706|DRUG|Metformin|Traditional metformin monotherapy.
219245804|NCT04677985|COMBINATION_PRODUCT|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
219245805|NCT04005248|DIAGNOSTIC_TEST|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
219245806|NCT06012214|PROCEDURE|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
219245807|NCT05431426|DRUG|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
219245808|NCT06036485|DEVICE|Kerecis Omega 3|Decellularized intact fish skin developed for the management of chronic wounds
219245809|NCT06036485|PROCEDURE|Surgical debridement|Superficial sharp surgical debridement technique
219245810|NCT03460366|DRUG|Enalapril|Patients are tested for their normal prescription enalapril medication
219245811|NCT00733174|DRUG|Rosiglitazone|tablet
219245812|NCT00733174|DRUG|Placebo|
219245813|NCT00561249|PROCEDURE|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
219245814|NCT00448344|BEHAVIORAL|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
219173845|NCT06221735|DIAGNOSTIC_TEST|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
219173846|NCT06221735|DIAGNOSTIC_TEST|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
219173847|NCT03974217|DRUG|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
219245815|NCT00448344|BEHAVIORAL|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
219245816|NCT00097409|DRUG|Ispinesib|
219245817|NCT00410150|DRUG|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
219245818|NCT00410150|DRUG|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
219245819|NCT05143099|DRUG|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
219245820|NCT00886548|PROCEDURE|Ultrasound performed|Nurse-driven ultrasound performed
219245821|NCT03478072|DEVICE|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
219245822|NCT04526132|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
219245823|NCT04526132|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
219245824|NCT00449254|DRUG|oleoyl-estrone (MP-101)|
219245825|NCT01644604|DEVICE|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
219245826|NCT06173167|DEVICE|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).
219245827|NCT06173167|DEVICE|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
219245828|NCT04281355|PROCEDURE|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
219245829|NCT04281355|RADIATION|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
219245830|NCT00079222|DRUG|itraconazole|
219740195|NCT06287853|DEVICE|Tapestry Biointegrative Implant|The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.
219245831|NCT00079222|DRUG|voriconazole|
219245832|NCT01720407|DRUG|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
219245833|NCT01720407|DRUG|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
219245834|NCT03455751|GENETIC|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
219245835|NCT02836184|DRUG|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
219245836|NCT02836184|DRUG|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
219245837|NCT04572425|OTHER|Guided imagery|10 minutes of guided imagery experience delivered on tablet
219245838|NCT04572425|OTHER|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
219245839|NCT01636778|DRUG|SB-497115-GR|TPO receptor agonist to increase platelet count
219245840|NCT03458416|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219245841|NCT01434355|OTHER|Laboratory Biomarker Analysis|Correlative studies
219173848|NCT03974217|DRUG|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
219173849|NCT05220709|DIAGNOSTIC_TEST|bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)|The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is \< 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
219173850|NCT04143711|DRUG|DF1001|Immunotherapy agent targeting NK cells.
219173851|NCT04143711|DRUG|Nivolumab|Anti-PD-1 immunotherapy agent
219173852|NCT04143711|DRUG|Nab paclitaxel|A chemotherapy treatment combining paclitaxel with albumin
219173853|NCT04143711|DRUG|Sacituzumab Govitecan-hziy|A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
219173854|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
219173855|NCT04610892|BIOLOGICAL|Placebo|Buffer
219173856|NCT05697146|OTHER|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
219173857|NCT01497405|BEHAVIORAL|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
219173858|NCT01497405|BIOLOGICAL|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
219173859|NCT05520190|BEHAVIORAL|Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)|"The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment."
219173860|NCT06491563|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
219173861|NCT06491563|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
219173862|NCT06491563|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
219173863|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
219173864|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
219173865|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
219173866|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219173867|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
219173868|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
219245842|NCT01434355|OTHER|Questionnaire Administration|Ancillary studies
219245843|NCT02131792|PROCEDURE|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
219245844|NCT06479499|OTHER|Pilates Exercises|Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
219740196|NCT04879563|OTHER|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
219173869|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
219740197|NCT05879302|BEHAVIORAL|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
219740198|NCT06642714|PROCEDURE|weaning by early non-invasive ventilation and progressive high flow oxygen therapy|"Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh"
219740199|NCT06641544|DRUG|Inetetamab|Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
219740200|NCT06640062|OTHER|Erector spinae plane block|Patients received ultrasound-guided erector spinae plane block.
219740201|NCT06640062|OTHER|Oblique subcostal transversus abdominis plane block|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
219740202|NCT05463952|DRUG|vepdegestrant|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
219740203|NCT06637007|DRUG|Chidamide Tablets combined with AK112|Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
219740204|NCT06637761|DRUG|NeoMTA2|Bio-active bio-ceramic mineral trioxide aggregate
219740205|NCT06637761|DRUG|WMTA|White Mineral trioxide aggregates
219740206|NCT06641947|PROCEDURE|Whipple procedure|Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
219740207|NCT06637033|BEHAVIORAL|Chewing Food|Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.
219740208|NCT06637033|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
219740209|NCT06637033|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219740210|NCT06639555|PROCEDURE|PRP( platelet rich plasma)|regenerative therapy with PRP for vertical bone defects
219740211|NCT06639555|PROCEDURE|EMD (Enamel Matrix Derivative)|regenerative therapy with EMD for vertical bone defects
219740212|NCT06639555|PROCEDURE|Guided Tissue Regeneration (barrier membrane)|guided tissue regeneration with barrier membrane alone for vertical bone defects
219740213|NCT06639555|PROCEDURE|Guided Tissue Regeneration(barrier membrane and PRP)|guided tissue regeneration with barrier membrane and PRP for vertical bone defects
219740214|NCT04652882|DRUG|Tasimelteon|oral capsule
219740215|NCT04652882|DRUG|Placebo|oral capsule
219740216|NCT06643819|DRUG|sacubitril/valsatran(dose maintenance)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
219740217|NCT06643819|DRUG|sacubitril/valsartan(dose increasing)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
219740218|NCT06643819|DRUG|Valsartan|During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
219173870|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
219173871|NCT05081583|DRUG|Midazolam Hcl 1Mg/Ml Inj|0.5 mL of an intravenous solution (1 mg/mL) will be administered.
219173872|NCT05081583|DIETARY_SUPPLEMENT|Goldenseal (Hydrastis canadensis)|Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.
219173873|NCT06537232|DIETARY_SUPPLEMENT|Greens-based Supplement|Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
219173874|NCT06285474|DEVICE|Low Intensity Focused Ultrasound Pulsation (LIFUP)|All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
219173875|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
219173876|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
219173877|NCT05949658|DRUG|Sirolimus|5mg, 10mg, or 15mg once weekly sirolimus
219173878|NCT05949658|DRUG|Everolimus|5mg, 10mg, or 15mg once weekly everolimus
219173879|NCT03507608|DRUG|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
219173880|NCT03507608|OTHER|Placebo|placebo prior to brachytherapy and prostatic biopsy
219173881|NCT04855526|DRUG|High THC/No CBD Marihuana|high THC (65 mg THC) and no CBD (0 mg CBD)
219173882|NCT04855526|DRUG|High THC/High CBD Marihuana|high THC (65 mg THC) and high CBD (50 mg CBD)
219173883|NCT04855526|DRUG|No THC/No CBD Marihuana|no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
219173884|NCT06277778|OTHER|Taekwondo training with music therapy|Taekwondo training with music therapy
219173885|NCT06277778|OTHER|Taekwondo training alone|Taekwondo training without music therapy
219173886|NCT05337943|BEHAVIORAL|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
219173887|NCT05337943|DEVICE|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
219173888|NCT06470763|DRUG|ANV600|ANV600 administered by intravenous (IV) infusion
219173889|NCT06470763|DRUG|ANV600 + pembrolizumab (KEYTRUDA®)|ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
219173890|NCT06219135|OTHER|no intervention - Contamination group|there is no intervention for this group of patients
219173891|NCT06219135|BIOLOGICAL|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
219740219|NCT01830387|DEVICE|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
219740220|NCT01830387|OTHER|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
219740221|NCT04816903|DIAGNOSTIC_TEST|Gyni|Vaginal discharge collection
219740222|NCT04880356|OTHER|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
219740223|NCT04715022|DRUG|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
219740224|NCT04715022|DRUG|Saline|Placebo (saline) will be administered
219740225|NCT03403790|DRUG|Quetiapine|Oral (extended-release tablet)
219740226|NCT03204747|OTHER|Observational study : gait speed|No intervention, only propose water and wait for need to void
219740227|NCT04355689|DRUG|NPI-001|oral tablet
219740228|NCT04355689|OTHER|Placebo|Placebo tablets
219740229|NCT05358782|DEVICE|Dental implant positioning|observational study of the effect of implant malposition
219740230|NCT05105971|DRUG|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
219740231|NCT02922712|DRUG|NISE|Nise 200mg Max per day in 2 divided doses
219740232|NCT01682720|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
219740233|NCT01682720|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219173892|NCT06219135|OTHER|no intervention - Emergency group|there is no intervention for this group of patients
219173893|NCT04799912|PROCEDURE|Elective labor induction|Elective labor induction at 39 weeks of gestation
219173894|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
219173895|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
219173896|NCT04059770|DRUG|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
219173897|NCT04059770|DRUG|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
219173898|NCT04059770|DRUG|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
219173899|NCT06438367|DRUG|[14C]TGRX-326|Healthy subjects will be given TGRX-326 60 mg orally on day 1.
219173900|NCT06397040|DEVICE|provider monitoring and feedback to remote data|provider monitoring of remote data and feedback to changes in remote data
219173901|NCT06397040|DEVICE|participant monitoring of remote data|participant monitoring of remote data, based upon post-operative instructions
219173902|NCT04896476|DEVICE|EchoMark / EchoSure|"The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.~The follow-up EchoSure scans will be conducted by the designated EchoSure user without the investigator and without the sonographer/RVT conducting the Duplex exam in the room, either during the routine work-up prior to the surgeon seeing the patient or after. The EchoSure results for flow, and vessel depth and diameter are shown as numerical values on the screen of the EchoSure device."
219173903|NCT06837662|BEHAVIORAL|"MOUD Plus Intervention (treatment as usual + coordinated counseling and referral to community based peer)"|"In addition to treatment as usual (clinic visits for primary care and MOUD), patients will meet with clinic based addictions counselor who provides 1) rapport building ; 2) brief counseling interventions (e.g. motivational interviewing, change talk/solutions based therapy, harm reduction counseling); 3) referral to community resources. Patients will also be referred to community based peer recovery services who are credentialed and trained to meet the person where they are in the community and provide advocacy and support for client directed goals."
219173904|NCT06837662|BEHAVIORAL|Treatment As Usual (primary care with low threshold MOUD prescribing)|Treatment as usual arm consists of primary care clinical appointments with prescribers who treat medical issues and are trained to diagnosis and treat OUD using low threshold prescribing approaches.
219173905|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
219173906|NCT03836911|OTHER|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
219173907|NCT03836911|OTHER|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
219173908|NCT03476187|DEVICE|µCor|Monitor with µCor
219173909|NCT05683548|DRUG|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
219173910|NCT05683548|DRUG|Tenofovir Disoproxil Fumarate|
219173911|NCT05683548|DRUG|Pegylated interferon alpha2a|
219173912|NCT05686499|OTHER|Didactic Lectures and demonstrations|"1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
219173913|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
219173914|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
219173915|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
219173916|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
219740234|NCT01682720|DRUG|Placebo to match SOF|Placebo to match SOF administered orally once daily
219740235|NCT01682720|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
219740236|NCT01396785|DRUG|33525|Daily for 14 days
219740237|NCT01396785|DRUG|Placebo|Daily for 14 days
219740238|NCT01091532|DRUG|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
219740239|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
219740240|NCT01091532|DRUG|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
219173917|NCT06837025|OTHER|Fascial manipulation|Fascial manipulation once a week
219173918|NCT06656286|DEVICE|Intra-Uterine suturing by X-TACK device and hysteroscope|"After general anesthesia and entering the abdomen with the laparoscope, Truclear hysteroscope with X-tack attached will be inserted to the uterine cavity. Insertion of normal saline to the cavity and applying 4 points suturing to the uterus. The procedure will be monitored by external laparoscopic camera located in the abdominal cavity. After the hysterectomy the uterus will be opened and the suture will be examine.~A preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure."
219173919|NCT03924986|DRUG|Tislelizumab|200 mg intravenously (IV) once every 3 weeks (Q3W)
219173920|NCT03924986|DRUG|Placebo|Placebo to match tislelizumab (administered intravenously Q3W)
219173921|NCT03924986|DRUG|Gemcitabine|1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
219173922|NCT03924986|DRUG|Cisplatin|80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
219173923|NCT04123847|OTHER|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
219173924|NCT04123847|DEVICE|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
219173925|NCT06829043|OTHER|clinical practice drug treatment|The study is observational, non-interventional and involves the review of the investigation18F-FDGPET/TC (performed according to the EANM guidelines) by two experts from the Nuclear Medicine Department.
219173926|NCT06836635|PROCEDURE|ESPB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
219173927|NCT06836635|PROCEDURE|TPVB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
219173928|NCT06160999|BEHAVIORAL|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
219173929|NCT06160999|BEHAVIORAL|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
219173930|NCT06574217|BEHAVIORAL|Stepping Stones (StSt)|StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.
219173931|NCT06574217|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
219740241|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
219740242|NCT01091532|DRUG|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
219740243|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
219245845|NCT06479499|OTHER|Aerobic Exercises|Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
219245846|NCT04288440|PROCEDURE|Surgery|Removal of epiretinal membrane and ILM
219245847|NCT04288440|DEVICE|Vitrectomy machine|Pars plana vitrectomy
219245848|NCT02286297|DEVICE|McGRATH® MAC|video-laryngoscopy-1
219245849|NCT02286297|DEVICE|AirTraq|video-laryngoscopy-2
219245850|NCT02286297|DEVICE|GlideScope|video-laryngoscopy-3
219245851|NCT02286297|DEVICE|Miller|Direct laryngoscopy
219245852|NCT02501876|OTHER|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
219245853|NCT02371278|DIETARY_SUPPLEMENT|Leucine|5 g leucine with sucrose and maltodextrin
219245854|NCT02371278|DIETARY_SUPPLEMENT|Placebo|5 g glycine with sucrose and maltodextrin
219245855|NCT02115945|OTHER|DN4 test|The DN4 test was used to evaluate neuropathic pain.
219245856|NCT02115945|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
219245857|NCT02115945|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
219245858|NCT02115945|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
219245859|NCT02115945|PROCEDURE|femoral block|
219740244|NCT01091532|DRUG|UK-396,082|"UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
219740245|NCT01091532|DRUG|placebo|given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
219245860|NCT02115945|PROCEDURE|epidural block|
219245861|NCT04081818|OTHER|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
219245862|NCT05910359|DIAGNOSTIC_TEST|Ultrasound|transabdominal and transperineal ultrasound by expert sonographers
219245863|NCT00991133|DRUG|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
219245864|NCT00329186|DRUG|desvenlafaxine SR|
219245865|NCT00329186|DRUG|venlafaxine ER|
219245866|NCT00083122|DRUG|cisplatin|Given IV
219245867|NCT00083122|DRUG|alvocidib|Given IV
219245868|NCT00083122|DRUG|cisplatin/flavopiridol|Given IV
219245869|NCT01154699|DEVICE|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
219245870|NCT01154699|OTHER|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
219245871|NCT01154699|OTHER|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
219245872|NCT00559195|BIOLOGICAL|epoetin beta|
219245873|NCT00559195|PROCEDURE|quality-of-life assessment|
219245874|NCT03875599|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
219740246|NCT04476680|DIETARY_SUPPLEMENT|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
219740247|NCT03370835|DRUG|Metoprolol succinate ER|Cardioselective beta-blocker
219740248|NCT03370835|DRUG|Carvedilol|Non-cardioselective beta-blocker
219245875|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
219245876|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
219245877|NCT03987698|BIOLOGICAL|SHR-1210|SHR-1210 injection
219245878|NCT03987698|BIOLOGICAL|CIK cells|CIK cells injection
219173932|NCT06836596|DEVICE|Peripheral sensory electrical stimulation via Elettronica Pagani Roland series model: ET 20 S/N: 1907 (Made in Italy)|Sensory electrical stimulation, Transcutaneous electrical nerve stimulation (TENS) involves delivering electrical current through electrodes placed on the skin to manage pain. It can be applied at different frequencies, ranging from low (50 Hz). The intensity can be adjusted from sensory to motor levels. Sensory intensity is when the patient experiences a strong yet comfortable sensation without triggering muscle contraction
219173933|NCT06836596|DEVICE|Alternating electromyogram (EMG) neuromuscular electrical stimulation via MyoTrac Infiniti device (T9800, Thought Technology Ltd. Montreal, Quebec, Canada)|the device detects the EMG threshold value (peak muscle torque) of the target muscle and activates stimulation to enhance the patient's voluntary activation of the targeted muscle groups. It is used to assess peak muscle torque and deliver alternating and EMG-triggered stimulation. Surface electrodes are employed to detect electromyography in the affected muscle and administer electrical stimulation to the targeted muscle during treatment. The device stimulates the targeted muscles, after which the patient attempts to replicate the same movement until reaching the preset EMG feedback level
219173934|NCT05523713|BIOLOGICAL|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
219245879|NCT03202056|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
219245880|NCT03202056|OTHER|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
219245881|NCT06456164|DEVICE|Cook Cervical Ripening Balloon|The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
219245882|NCT06993129|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
219245883|NCT06988540|OTHER|Personalized Health Planning Program Administration|The T2D PHP program is 8 hour-long sessions offered over 16 weeks. The program includes development of a personal health plan supported by a patient-provider health risk assessment; group session structure supplemented by educational, video sessions; lessons, discussions, and activities based on behavioral modification, health engagement, and diabetes distress; goal progress tracking; social support; mindful awareness practices and qualitative health evaluations via surveys and a one-on-one consultation with a personal health coach. Participants will be provided a group participant notebook that provides information discussed during the program. The T2D PHP program is a complement to routine care.
219245884|NCT06988540|OTHER|Usual Care|Patients will be encouraged to see their diabetes provider. Patients will not participate in the T2D PHP program but will complete laboratory tests and surveys as listed in the section on outcomes.
219245885|NCT06614582|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|"The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit."
219245886|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
219245887|NCT06999382|BEHAVIORAL|Active Dissemination and Implementation|This intervention is designed to accelerate the uptake of evidence-based interventions that help maximize the impact of the addition or renovation of public open spaces on their utilization for active recreation among community members, ultimately effective physical activity levels in communities. The intervention targets implementation partners: local stakeholders/decision makers and community leaders, to increase their awareness of these evidence-based approaches for place-activation, and their willingness to adopt and implement them in their neighborhood settings. Intervention components include capacity building workshops, newsletters, targeted messaging and access to a knowledge broker and implementation support for 1-year.
219245888|NCT06999382|BEHAVIORAL|Passive Dissemination|Delivery of booklet with menu of evidence-based interventions for place-activation; and of pamphlet summarizing importance of healthy lifestyle promotion.
219740249|NCT00663195|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
219740250|NCT05541328|OTHER|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
219740251|NCT04204902|DRUG|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
219740252|NCT04204902|DRUG|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
219740253|NCT03791424|DRUG|Midazolam|Administering premedication with sedative drug to relieve anxiety
219740254|NCT03101670|DRUG|filgotinib|one filgotinib oral tablet q.d.
219740255|NCT03101670|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
219173935|NCT02736500|DRUG|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
219173936|NCT02736500|DRUG|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
219173937|NCT06365918|DRUG|VG2025|Given by Intraperitoneal
219173938|NCT06158503|DEVICE|AID|Initiation of an automated insulin delivery system
219173939|NCT06097520|OTHER|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
219173940|NCT04406857|DRUG|Capecitabine|Given PO
219173941|NCT04406857|RADIATION|Radiation Therapy|Undergo radiation therapy
219173942|NCT04406857|DRUG|Ropidoxuridine|Given PO
219740256|NCT03876808|DEVICE|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
219740257|NCT03876808|DEVICE|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
219173943|NCT06836843|OTHER|Since this is an observational study rather than an interventional study, the exposure type refers to all potential factors influencing pregnancy both before and during pregnancy|"Since this is an observational study rather than an interventional study or clinical trial, the exposure type refers to all potential factors influencing pregnancy both before conception and during pregnancy. These exposures include:~Lifestyle habits: Such as obesity, smoking and alcohol use before and during pregnancy.~Sociodemographic factors: Such as age, residence, medical insurance. Medications: Any prescription, over-the-counter, or herbal medications used before or during pregnancy.~Past medical history: Pre-existing medical conditions or illnesses, such as hypertension, diabetes, or autoimmune diseases, that could affect pregnancy.~Past surgical history: Previous surgeries, especially those related to the reproductive system or any that may impact pregnancy outcomes.~Previous pregnancies: Information about past pregnancies, including the number of full-term and preterm births, complications, and outcomes.~Abortions: Any history of miscarriages"
219173944|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
219173945|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
219173946|NCT06467227|OTHER|exercise modality|exercise using legs and arms
219173947|NCT02649790|DRUG|KPT-8602|Participants will receive KPT-8602 oral tablets.
219173948|NCT02649790|DRUG|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
219173949|NCT02649790|DRUG|Dexamethasone|Participants will receive dexamethasone oral tablets.
219173950|NCT03699709|BEHAVIORAL|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
219173951|NCT06831006|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
219173952|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
219173953|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
219173954|NCT06837675|DEVICE|high tone power therapy|High tone Power therapy (HiToP191-H) device is a new electrotherapy technology. Its primary impact on the body is to provide energy to the body to activate cells and rebuild it. It can cause an oscillation or vibration that promotes metabolism, nand erve regeneration and relieves pain by dispersing pain and inflammation mediators, nutrients, and waste products
219173955|NCT06837675|OTHER|selected physical therapy program|selected physical therapy protocol for 45 minutes 3 times per week for 3 months in form of pelvic floor exercises and core stability exercise
219173956|NCT06838156|DRUG|Bupivacain|Suprainguinal Fascia Iliaca Compartment block was performed with a linear probe placed over the inguinal ligament using a portable ultrasound device. After visualization of the femoral nerve, 30 ml of 0.25% bupivacaine was injected into the fascia iliaca overlying the iliopsoas muscle using an appropriate needle.
219173957|NCT06838156|DRUG|Bupivacain|Quadratus Lumborum Type 3 block was performed using a portable ultrasound device with a linear probe placed between the costal margin and the iliac crest on the lateral abdominal wall. 30 ml of 0.25% bupivacaine was injected between the quadratus lumborum and psoas muscles using an appropriate needle.
219173958|NCT06828978|PROCEDURE|Full Pulpotomy|After control of bleeding in teeth allocated to the intervention group, the gel is to be placed into the pulp chamber to a level 3 mm below the cementoenamel junction (CEJ) over the root pulp stumps.
219173959|NCT06752915|BEHAVIORAL|acupressure application|Acupressure massage will be applied to LI4, HT7, LU1 and ST 36 acupuncture points for 2 minutes.
219173960|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
219173961|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
219173962|NCT06819293|BIOLOGICAL|IB-T101 injection|IB-T101 injection to treat advanced clear renal cell carcinoma
219173963|NCT06126809|DEVICE|Steep-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
219173964|NCT06126809|DEVICE|Flat-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
219173965|NCT06126809|DEVICE|Sham-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
219173966|NCT00390793|DRUG|Cyclophosphamide|Given IV
219173967|NCT00390793|DRUG|Cytarabine|Given IV or IT
219173968|NCT00390793|DRUG|Dasatinib|Given PO
219173969|NCT00390793|DRUG|Dexamethasone|Given IV or PO
219173970|NCT00390793|DRUG|Doxorubicin|Given IV
219173971|NCT00390793|DRUG|Methotrexate|Given IV or IT
219173972|NCT00390793|DRUG|Prednisone|Given PO
219173973|NCT00390793|DRUG|Vincristine|Given IV
219173974|NCT02945020|DRUG|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
219173975|NCT02945020|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
219173976|NCT02945020|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
219740258|NCT03139266|BEHAVIORAL|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
219740259|NCT03139266|BEHAVIORAL|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
219173977|NCT04344899|OTHER|Observational|Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
219173978|NCT06827405|DIETARY_SUPPLEMENT|Lactase enzyme|Patients were given 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, 5-30 minutes before feeding
219173979|NCT06827405|DIETARY_SUPPLEMENT|Lactose-free formula feed|Patients were advised lactose-free formula milk/diet.
219173980|NCT06832397|PROCEDURE|Diagnostic laparoscopy|Diagnostic laparoscopy with peritoneal biopsies
219173981|NCT06837597|DRUG|Jianzhong Qushi Formula|Jianzhong Qushi Formula (A Chinese traditional formula, approved by Chinese Patent, No. ZL202210097886.0)
219173982|NCT06837597|DRUG|Placebo|A simulated Chinese medicine placebo, with similar appearance and smell to Jianzhong Qushi Formula.
219740260|NCT04667559|DEVICE|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
219740261|NCT05129735|DIETARY_SUPPLEMENT|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
219740262|NCT05938569|DEVICE|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
219740263|NCT00247039|DIETARY_SUPPLEMENT|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
219740264|NCT00247039|OTHER|Placebo capsules|placebo capsules
219740265|NCT06047470|BEHAVIORAL|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
219740266|NCT06047470|BEHAVIORAL|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
219740267|NCT01724307|PROCEDURE|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
219740268|NCT00928720|DEVICE|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
219740269|NCT00928720|DEVICE|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
219740270|NCT06137092|DRUG|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
219740271|NCT02098486|DRUG|Moxifloxacin|
219740272|NCT02098486|DRUG|ceftriaxone|
219740273|NCT04170075|BEHAVIORAL|Whole Body Vibration|Undergo WBV
219740274|NCT03060265|DRUG|Paracetamol|Administrating Paracetamol IV pre-cesarean section
219740275|NCT03060265|DRUG|PLACEBO|Administrating SALINE IV pre-cesarean section
219740276|NCT06500156|OTHER|Fluid challenge|Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
219740277|NCT04167735|DEVICE|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
219740278|NCT04167735|DEVICE|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
219740279|NCT00237159|DRUG|Zoledronic acid|
219740280|NCT02680496|DEVICE|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
219740281|NCT02680496|OTHER|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
219740282|NCT02680496|OTHER|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
219740283|NCT06460662|OTHER|Routine Physical Therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
219740284|NCT01254929|DEVICE|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
219740285|NCT01254929|DEVICE|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
219245889|NCT06999447|OTHER|ChatGPT-Supported Case-Based AI Education (C-CASE)|In the intervention group (C-CASE), after informed consent and pretest completion (including a sociodemographic form and CDMNS), the case scenario was introduced by the course instructor. Students were divided into small groups, and each group selected a representative who accessed ChatGPT-4.0 Premium via credentials provided by the research team. Using a collaborative problem-solving format, each group worked through a structured case scenario involving pediatric surgical emergencies. Questions were distributed sequentially, with 5-minute intervals allocated per question. Students used ChatGPT to support reasoning and clinical decision-making within their group. After each interval, responses were submitted, and the next question was handed out. Sessions were proctored by research assistants, and the full implementation, including discussion, lasted approximately two hours. The intervention aimed to foster decision-making, teamwork, and AI literacy in a clinical nursing education.
219245890|NCT06999447|OTHER|Standard Education|In the control group (Standard Education), students followed the same structured case-based learning session as the intervention group, without access to AI tools. After providing informed consent and completing the pretest (sociodemographic form and CDMNS), the case scenario was introduced by the instructor. Students were divided into small groups and selected a representative to use a personal computer during the session. To ensure no access to AI-based tools, the Mobile Guardian app was installed to block websites such as ChatGPT. Students were allowed to use only academic databases and the university's online library. Each group answered a series of timed case questions (5 minutes per item), submitting responses before receiving the next question. Research assistants monitored the session in both classrooms to ensure standardization and prevent external support. The session concluded with a class-wide case discussion, led by the course instructor.
219245891|NCT03543982|DIETARY_SUPPLEMENT|Oral probiotic product|Once per day (QD), 28 days
219245892|NCT07009223|BEHAVIORAL|Mediterranean Diet|Participants will receive only the educational intervention about the Mediterranean diet. The program consists of 4-5 online sessions conducted by a nutritionist.
219245893|NCT07009223|BEHAVIORAL|Physical Activity|In addition to educational sessions on the Mediterranean diet, there will be 2-3 weekly personalized exercise sessions, followed by a dedicated personal trainer at a partner gym. The treatment will last 12 weeks.
219245894|NCT07009223|BEHAVIORAL|Cognitive Training|In addition to educational sessions on the Mediterranean diet, there will be one weekly cognitive training session in groups, supervised by qualified staff at the IRCCS FBF. The treatment will last for 12 weeks.
219245895|NCT07008053|DRUG|BR+OR|Patients who meet the inclusion criteria will enter the treatment period, which consists of an induction phase followed by a maintenance phase. During the induction treatment period, a combined treatment of 3 cycles of the BR regimen and 3 cycles of the OR regimen will be administered, every 28-day cycle for 6 cycles. After the induction treatment, the efficacy assessment will determine whether patients with CR or PR proceed to the maintenance treatment period. Orelabrutinib monotherapy will used as maintenance therapy, every 28-day cycle for up to 24 cycles, or until disease progression/recurrence, unacceptable toxicity, death or consent withdrawal.
219245896|NCT07007845|BEHAVIORAL|CVT Support intervention|The CVT Emergency Aid program focused on optimising the work on the diaphragm was conducted in 3 steps. Step 1 related to establishing diaphragmatic breathing by feeling expansion around lower ribs at inhalation. Step 2 related to establishing connection between pulmonary pressure and subtotal pressurisation by invoking inwards abdominal movements on controlled exhaled voiceless exercises (ssss-sound) Step 3 related to establishing dynamic control of subglottal pressure by performing fricative voice sounds (vvvf- and zzz-sounds) while contracting the abdominal wall inwards and thereby pressurising the pulmonary space leading to increased subglottal pressure on accents and extended pitch accents.
219245897|NCT07007845|PROCEDURE|Dooming Diaphragm|Osteopathic treatment: Dooming Diaphragm. The inferior costal margin was contacted with the hands, allowing the thumbs to rest just below the ribcage anteriorly. Care was taken to avoid contact with the xiphoid process, as this could cause discomfort for the patient. The patient was instructed to breathe deeply, and as they exhaled, gentle pressure was applied superiorly and laterally with the thumbs, rolling them underneath the ribcage as far as was comfortable. This process was repeated for 3-5 breath cycles or until no tension was felt in the thumbs during exhalation.
219245898|NCT07008872|BIOLOGICAL|CD7 CART|For intravenous infusion
219245899|NCT07007650|DRUG|High-concentration Ropivacaine|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
219245900|NCT07007650|DRUG|Low concentration ropivacaine group|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
219245901|NCT07008690|DIAGNOSTIC_TEST|MRI|This exploratory study will longitudinally image patients diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 18 months using 3T MRI.
219245902|NCT07008690|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|For comparison, this exploratory study will image patients that are not diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 4 weeks.
219245903|NCT04344236|DRUG|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
219245904|NCT04344236|DRUG|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
219173983|NCT06835998|OTHER|stress ball|"the stress ball intervention was initiated. Before starting, the researcher provided instructions and demonstrations on how to use the stress ball, allowing then the patients to practice. The stress ball intervention was administered during the second hour of the hemodialysis session when patients were most comfortable. Patients were instructed to squeeze the stress ball once, counting internally as 1-2-3 with each squeeze. The stress ball intervention was administered three times weekly during hemodialysis sessions for 15 minutes each session, totaling 12 sessions for a period of four weeks. Throughout the intervention, patients were observed by the same researcher."
219173984|NCT06837298|OTHER|Placebo control capsules|2.4 grams (g) daily
219173985|NCT06837298|OTHER|PeptiStrong® supplement capsules with same appearance as placebo capsules|2.4 g daily
219173986|NCT06837298|OTHER|PeptiStrong® supplement capsules following muscle damaging exercise on Day 14|2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
219173987|NCT04675567|BEHAVIORAL|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
219173988|NCT06325371|DEVICE|Visceral aneurysm stenting|Flow diverter stenting
219173989|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
219173990|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
219173991|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
219173992|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
219173993|NCT05331885|BIOLOGICAL|Suvratoxumab|Monoclonal antibody
219173994|NCT05331885|DRUG|Placebo|Placebo contains only excipients
219173995|NCT06377189|OTHER|Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings|"The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective."
219173996|NCT06377189|OTHER|Control Arm - Treatment As Usual (TAU)|PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
219173997|NCT06838377|DEVICE|standard Champy mini plate|the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments. Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone then mobilize the broken segment , Arch bar was made to achieve proper occlusion put the Champy 2.0 plate on the ventral surface of the external oblique of the mandible and remove it for further bending using plate pliers for further accommodation of the plate then fix it in place using mono cortical screws.
219173998|NCT06838377|DEVICE|computer guided screw holes locating guide and Patient Specific Champy plate|"the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments.~Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone to accommodate the screw holes locating guide and the custom-made Champy plate.~, Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made Champy plate and fix it with screw for passive reduction of the segments. Then suture the mucosa."
219173999|NCT06231108|OTHER|Kinesio Taping|"Three different taping applications will be applied, namely ankle correction, quadriceps facilitation, and gluteus maximus facilitation.~1. Taping: Functional correction technique will be used to facilitate dorsal flexion movement.~2. Taping: Quadriceps Femoris (QF) Facilitation Technique - In taping to activate the QF muscle and regulate muscle tone, the patient will be placed in a supine position with hips and knees in neutral.~3. Taping: Gluteus Maximus (GM) Facilitation Technique - For taping to facilitate the GM muscle, a double-band application will be performed."
219174000|NCT06833099|DIAGNOSTIC_TEST|VAS Point and Imaging Examination|"This intervention uses a machine learning model to predict the risk of recurrent lumbar disc herniation (rLDH) in patients who have had percutaneous endoscopic interlaminar discectomy (PEID) at the L5-S1 level. The model combines clinical data (e.g., BMI, disease duration, diabetes) and imaging metrics (e.g., posterior disc height index, spinal canal stenosis) to create a personalized risk score, unlike traditional methods that rely on clinical judgment or imaging alone.~Key Features:~Data-Driven Approach: Developed using data from 309 patients for real-world relevance.~Advanced Variable Selection: Identifies eight key predictors using LASSO regression.~Multiple Machine Learning Techniques: Uses algorithms like support vector machine, random forest, and extreme gradient boosting.~Optimized for Clinical Decision-Making: Assists surgeons in personalizing treatment plans to reduce recurrence risk."
219245905|NCT04344236|DRUG|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
219740286|NCT02136355|RADIATION|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
219245906|NCT07009314|BEHAVIORAL|Implementation package (training, facilitation, electronic health record nudge)|"Training will consist of an initial presentation on S.A.F.E. Firearm by the study team, informational resources to support program delivery, and recommendations for self-guided continuing medical education programs.~Facilitation will last 6 months at each site. It may involve 1) a readiness assessment for each clinic to identify implementation barriers and develop relationships with constituents; 2) kick-off meetings at trial launch, at which staff will identify how to implement S.A.F.E. Firearm in the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain the program for future years.~A clinician decision support (nudge), designed to align with best practices within each health system, will be deployed in the EHR workflow to remind clinicians to deliver S.A.F.E. Firearm and offer a cable lock."
219245907|NCT03167645|DRUG|Human albumin|Substitution according to pre-specified dosage
219245908|NCT00116233|DEVICE|REPEL-CV|
219245909|NCT02244775|DEVICE|SR™MCP|
219740287|NCT00069953|BIOLOGICAL|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
219740288|NCT00069953|BIOLOGICAL|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
219740289|NCT00069953|DRUG|cisplatin|During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
219740290|NCT00069953|DRUG|fluorouracil|During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
219740291|NCT00069953|DRUG|paclitaxel|During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
219740292|NCT00069953|PROCEDURE|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
219740293|NCT00069953|RADIATION|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
219740294|NCT00000373|DRUG|olanzapine + fluoxetine|
219740295|NCT00000373|DRUG|placebo + fluoxetine|
219740296|NCT02034565|DRUG|Apixaban|
219740297|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
219174001|NCT03505203|BEHAVIORAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
219174002|NCT03505203|BEHAVIORAL|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
219174003|NCT06835634|PROCEDURE|Self reported questionnaires|PROMs and psychological tests submission in patients affected by neurosurgical diseases
219740298|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
219740299|NCT04823052|DRUG|Placebo|Placebo Capsule
219740300|NCT04823052|DRUG|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
219740301|NCT05629572|DIAGNOSTIC_TEST|i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity|Paired whole blood and plasma samples collected at multiple time points.
219740302|NCT06416982|OTHER|Perineal massage|2 minutes of perineal massage as described in arm/group descriptions.
219740303|NCT06569628|COMBINATION_PRODUCT|Envita Stories Methodology in Long-term care Centres for old adults|Collaborative intervention program in long-term care Centres for old adults between professionals, old adults, families and volunteers that aims to foster person-centered care and promote meaningful relationships through the digitization of life stories and life project methodologies in a timeline.
219740304|NCT06569628|BEHAVIORAL|Contact Methodology in Long-term Care Centres for old adults|Professionals know and use Envita Stories Methodology but do not apply it directly with these people.
219740305|NCT05211960|BEHAVIORAL|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
219740306|NCT02842346|OTHER|ultrasonography|
219174004|NCT04562649|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
219174005|NCT04562649|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
219174006|NCT06822751|DRUG|Fosfomycun-trometamol|Study of the efficacy and safety of Fosfomycin trometamol as a 14-day treatment using a 3 g sachet every 2 days for 14 days for the treatment of male urinary tract infections in primary care: open-label, non-randomised, multicentre, inter-regional trial.
219174007|NCT06036004|DRUG|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
219174008|NCT06036004|OTHER|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
219174009|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
219174010|NCT00582231|OTHER|Questionnaires.|Questionnaires.
219740307|NCT05495230|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
219740308|NCT05495230|OTHER|Usual care|See arm description.
219740309|NCT00970710|BEHAVIORAL|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
219245910|NCT05838976|DIAGNOSTIC_TEST|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
219245911|NCT00569036|DRUG|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
219245912|NCT01613183|DRUG|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
219740310|NCT06446362|BEHAVIORAL|IMCHB-Based Breastfeeding Support Program|"This intervention includes a structured breastfeeding support program based on the Interaction Model of Client Health Behavior (IMCHB). It consists of:~Educational Sessions: Conducted during the last trimester of pregnancy to provide information and prepare mothers for breastfeeding.~Motivational Interviews: Conducted face-to-face at 1-3 days, 15 days, 30 days, 45 days, and 60 days postpartum to address individual challenges and provide personalized support.~Follow-Up Support: Two follow-up sessions via WhatsApp video calls at 4 and 5 months postpartum to reinforce the intervention and provide ongoing assistance."
219740311|NCT06446362|BEHAVIORAL|Standard Breastfeeding Education|Participants receive the standard care provided at Family Health Centers, which includes routine breastfeeding education and support typically offered to new mothers. This standard care does not include the additional structured support interventions provided in the IMCHB-Based Breastfeeding Support Program.
219740312|NCT04874961|DIETARY_SUPPLEMENT|Tensiofytol®|standardized olive extract
219740313|NCT04874961|OTHER|Placebo|contains excipients only
219740314|NCT02808884|GENETIC|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
219740315|NCT00113373|DRUG|lapatinib ditosylate|Given orally
219740316|NCT00113373|OTHER|laboratory biomarker analysis|Correlative studies
219740317|NCT05860244|DRUG|Salbutamol|Salbutamol for 6 months
219740318|NCT05860244|DRUG|Placebo|Placebo Syrup for 6 months
219740319|NCT05957523|DEVICE|Remote ischaemic preconditioning|The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
219740320|NCT00372320|GENETIC|Gene Transfer|
219740321|NCT00372320|DRUG|AdhAQP1|
219740322|NCT05112068|OTHER|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
219740323|NCT05112068|OTHER|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
219740324|NCT04657692|PROCEDURE|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
219740325|NCT01548885|DEVICE|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219740326|NCT01548885|DEVICE|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219740327|NCT01548885|DEVICE|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219740328|NCT01548885|DEVICE|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219245913|NCT01613183|OTHER|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
219245914|NCT00705614|BIOLOGICAL|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
219245915|NCT00742014|DRUG|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
219245916|NCT01044901|PROCEDURE|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
219245917|NCT05381077|OTHER|MRI|Whole body MRI (ZTE sequence)
219245918|NCT00676195|DRUG|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
219245919|NCT01676883|DEVICE|Bioelectric impedance|removal of calluses and corns by pedicure
219245920|NCT01676883|DEVICE|Air displacement plethysmography|
219245921|NCT00213226|DRUG|dexamethasone|
219245922|NCT00978783|DEVICE|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
219245923|NCT00978783|DEVICE|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
219740329|NCT01548885|DEVICE|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
219740330|NCT04231851|DRUG|Glasdegib|Given PO
219245924|NCT01414543|OTHER|Information Sheet|Providing the Participant with information regarding the aim of the experiment
219245925|NCT01414543|OTHER|Consent|Providing a consent form for participants. The participant is aware of his or her rights
219245926|NCT01414543|OTHER|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
219245927|NCT01414543|OTHER|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
219245928|NCT03787719|OTHER|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
219245929|NCT03498885|PROCEDURE|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
219245930|NCT03498885|PROCEDURE|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
219245931|NCT00019019|DRUG|carboxyamidotriazole|
219245932|NCT00019019|DRUG|paclitaxel|
219245933|NCT05918289|BEHAVIORAL|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
219245934|NCT02782598|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
219740331|NCT04231851|DRUG|CPX-351|Given IV
219740332|NCT05547854|BEHAVIORAL|Behavior Therapy Training Institute|In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
219740333|NCT05547854|BEHAVIORAL|CBIT-Trainer|In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
219740334|NCT00514397|DRUG|motexafin gadolinium|
219740335|NCT00514397|DRUG|temozolomide|
219740336|NCT00514397|PROCEDURE|adjuvant therapy|
219740337|NCT00514397|PROCEDURE|quality-of-life assessment|
219740338|NCT00514397|RADIATION|radiation therapy|
219740339|NCT06222333|BEHAVIORAL|Respiratory physiotherapy|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
219740340|NCT06222333|DRUG|Conservative Treatment|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
219740341|NCT04717479|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
219740342|NCT01414790|PROCEDURE|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
219740343|NCT02465112|DRUG|In111-Pentetréotide|
219740344|NCT02465112|OTHER|simple monitoring without active therapy|
219740345|NCT00236795|DRUG|norelgestromin + ethinyl estradiol; triphasil.|
219740346|NCT00003067|BIOLOGICAL|aldesleukin|
219740347|NCT00003067|BIOLOGICAL|lymphokine-activated killer cells|
219740348|NCT01950039|DRUG|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
219740349|NCT01950039|DRUG|Placebo|Placebo administered orally in divided doses over 3 months
219740350|NCT01974479|BIOLOGICAL|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
219245935|NCT02880969|BEHAVIORAL|answering questionnaires|
219245936|NCT05947708|DEVICE|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
219245937|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
219245938|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID DIET|2\. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
219245939|NCT02206087|DRUG|PER977|Reversal of heparin-induced anticoagulation
219245940|NCT02206087|DRUG|Placebo|Reversal of heparin-induced anticoagulation
219245941|NCT02206087|DRUG|Heparin Sodium|
219245942|NCT02646189|DRUG|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
219245943|NCT02646189|DRUG|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
219245944|NCT02646189|DRUG|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
219245945|NCT01064505|DRUG|QPI-1007 at various doses|Single Intravitreal Injection
219245946|NCT05530460|DEVICE|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
219245947|NCT05530460|DEVICE|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
219245948|NCT05608408|DEVICE|Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system|Stimulation of site with the Medtronic Percept PC system using low frequency stimulation at 0.5 Hz.
219245949|NCT05608408|DEVICE|Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system|Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system using standard of care high frequency stimulation parameters.
219245950|NCT04050722|DRUG|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
219245951|NCT04050722|DRUG|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
219245952|NCT01316809|DRUG|AZD8055|Patients will start at 120 mg once daily
219245953|NCT04245878|OTHER|gastric ultrasound|gastric ultrasound for measurement of the antral area
219245954|NCT00725036|DRUG|inhaled human insulin|
219245955|NCT00725036|DRUG|insulin aspart|
219245956|NCT00725036|DRUG|insulin NPH|
219740351|NCT06570239|PROCEDURE|intervention group|"Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks."
219740352|NCT05200338|DRUG|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
219740353|NCT04525183|BEHAVIORAL|Enhanced Usual Care (EOC)|Educational materials
219740354|NCT04525183|BEHAVIORAL|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
219740355|NCT06401733|OTHER|Intensive Aerobic and Resistance Exercise Program (IAREP)|"IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles."
219740356|NCT06571526|BEHAVIORAL|External focus|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
219740357|NCT06571526|BEHAVIORAL|Control|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
219740358|NCT05736887|DRUG|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
219740359|NCT05736887|DRUG|Placebo|Placebo in 600mg tablets
219740360|NCT02408029|OTHER|Observational study - no intervention|
219740361|NCT06101485|DEVICE|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
219740362|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
219740363|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
219740364|NCT00020007|DRUG|isolated perfusion|
219740365|NCT00020007|DRUG|paclitaxel|
219740366|NCT00020007|PROCEDURE|hyperthermia treatment|
219740367|NCT00178828|DRUG|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
219245957|NCT03353649|BEHAVIORAL|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
219245958|NCT03353649|DEVICE|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
219245959|NCT05641155|DEVICE|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
219245960|NCT03497143|DRUG|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
219245961|NCT01823926|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
219245962|NCT01823926|DEVICE|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
219245963|NCT01823926|DEVICE|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
219245964|NCT00155662|BEHAVIORAL|work-hardening program|
219245965|NCT04764864|PROCEDURE|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
219245966|NCT04764864|PROCEDURE|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
219245967|NCT03687918|OTHER|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~* To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
219245968|NCT04335695|BEHAVIORAL|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
219245969|NCT03759132|PROCEDURE|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
219245970|NCT00185783|DRUG|Hydrocortisone Administration (Standard of Care Therapy)|
219174011|NCT04942535|BEHAVIORAL|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
219174012|NCT04942535|BEHAVIORAL|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
219174013|NCT04942535|BEHAVIORAL|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
219174014|NCT04850274|BEHAVIORAL|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
219174015|NCT04850274|BEHAVIORAL|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
219174016|NCT06188026|DRUG|NNC0194-0499|Once a week for 5 weeks as an injection in dose of 30 mg. The injection will be given under the skin
219174017|NCT06188026|DRUG|ethinylestradiol/levonorgestrel|Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
219174018|NCT06513416|PROCEDURE|Elective upper abdominal surgery|The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
219174019|NCT06832527|OTHER|Rehabilitation treatment|ROM, strength, stretch and proprioception exercises
219174020|NCT06832527|OTHER|Virtual Reality games|Virtual Reality games using META QUEST PRO glasses
219174021|NCT05540639|BEHAVIORAL|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
219174022|NCT06835244|OTHER|68Ga-PSMA-11|All patients with non prostatic neoplasm expressing PSMA undergo 68\[Ga\]Ga-PSMA-11-PET/CT
219245971|NCT05811455|OTHER|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
219245972|NCT05811455|OTHER|Progressive muscle relaxation|progressive muscle relaxation exercises.
219245973|NCT01862614|DRUG|Articaine Hydrochloride + Epinephrine|
219245974|NCT01862614|DRUG|Buffered Articaine Hydrochloride + Epinephrine|
219740368|NCT00178828|DRUG|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
219740369|NCT04939103|DEVICE|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
219740370|NCT01782274|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
219740371|NCT01782274|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
219740372|NCT04499001|OTHER|Pharmacist's consultation|Information about bDMARDs management.
219740373|NCT01166646|DRUG|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
219740374|NCT01166646|DRUG|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
219740375|NCT05613946|DRUG|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
219740376|NCT05613946|DRUG|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
219740377|NCT05613946|DRUG|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
219740378|NCT05996445|BIOLOGICAL|XmAb662|Intravenous (IV) administration
219740379|NCT05996445|BIOLOGICAL|Keytruda® (pembrolizumab)|Intravenous (IV) administration
219740380|NCT01342042|BIOLOGICAL|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
219740381|NCT05216146|OTHER|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
219740382|NCT04265118|DEVICE|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
219740383|NCT04130971|OTHER|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
219174023|NCT05244889|BEHAVIORAL|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
219174024|NCT05244889|BEHAVIORAL|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
219174025|NCT05977114|BEHAVIORAL|family conflict intervention group|The family conflict preventive intervention includes the introduction to the occurrence of family conflicts, communication skills training, and role play to practice the skills.
219174026|NCT05977114|BEHAVIORAL|handicraft-making group|The group involves handicraft-making.
219174027|NCT06831708|BEHAVIORAL|Psychoanalytic Psychotherapy|This intervention involves short-term psychoanalytic therapy based on a standardized framework. Although not rigidly manualized, the treatment protocol includes core psychoanalytic concepts (such as transference, resistance, and the exploration of unconscious conflicts). Sessions will be conducted weekly (50 minutes each) for a total of 12 sessions. This intervention is delivered by two study authors who have undergone dedicated training and calibration to ensure consistent application of the framework.
219245975|NCT01792583|DRUG|Modafinil/armodafinil|
219245976|NCT02062281|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
219245977|NCT02062281|BIOLOGICAL|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
219245978|NCT02062281|BIOLOGICAL|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
219245979|NCT03932422|DIAGNOSTIC_TEST|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
219245980|NCT01319227|PROCEDURE|Hip replacement|Hip arthroplasty with uncemented components
219245981|NCT02603861|DRUG|LY3154207|LY3154207 administered orally.
219245982|NCT02603861|DRUG|Placebo|Placebo administered orally.
219245983|NCT02603861|DRUG|Modafinil|Modafinil administered orally.
219245984|NCT03451292|DRUG|Albutein 20%|Injectable solution
219245985|NCT03451292|OTHER|SMT|Participants received SMT according to institution standards for the management of decompensated cirrhosis.
219245986|NCT06373367|OTHER|Illustration based application|Illustrations regarding the cause, risks, and warning signs of preeclampsia
219245987|NCT06373367|OTHER|Text based application|Standard preeclampsia discharge instructions
219245988|NCT00702338|DRUG|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
219245989|NCT00702338|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
219245990|NCT00702338|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
219245991|NCT00702338|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
219245992|NCT06381297|DIAGNOSTIC_TEST|Hearing test|Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
219245993|NCT06381297|DIAGNOSTIC_TEST|Speech in noise discrimination test|Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
219245994|NCT06381297|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale|Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
219245995|NCT06381297|DIAGNOSTIC_TEST|Symbol Number Modalities Test (SDMT)|Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
219245996|NCT05051488|PROCEDURE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
219245997|NCT05051488|DEVICE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
219245998|NCT00936364|OTHER|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
219245999|NCT00936364|OTHER|Modified fast|Minimal caloric intake on days -2 and -1
219246000|NCT00936364|OTHER|Fasting|Day -1
219246001|NCT00936364|OTHER|Fasting|Days -2 and -1
219246002|NCT00936364|OTHER|Fasting|Days -3, -2, and -1
219246003|NCT00936364|OTHER|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
219246004|NCT02144116|OTHER|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
219246005|NCT02144116|OTHER|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
219246006|NCT01124656|DRUG|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
219246007|NCT05955222|DEVICE|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
219246008|NCT05955222|DEVICE|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
219246009|NCT05955222|DEVICE|Traditional|Participants receiving splints from vacuum forming system
219246010|NCT04769219|OTHER|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
219246011|NCT05129592|BEHAVIORAL|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
219246012|NCT05450939|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
219246013|NCT03321175|OTHER|subcutaneous saline irrigation|200 cc saline irrigation
219246014|NCT03003884|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
219246015|NCT03003884|DRUG|Propofol|Initial dose plus supplemental doses as necessary.
219246016|NCT02788305|DRUG|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
219246017|NCT06181019|DRUG|50 mg of mirabegron|Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
219246018|NCT06181019|COMBINATION_PRODUCT|acupuncture combined with mirabegron.|Patients in the treatment group were treated with acupuncture combined with mirabegron.
219246019|NCT06055478|PROCEDURE|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block|"Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline.~Low fixed dose patient controlled analgesia (PCA) were done in the two group."
219246020|NCT02871453|DEVICE|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
219246021|NCT02871453|OTHER|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
219246022|NCT00003541|BIOLOGICAL|filgrastim|
219246023|NCT00003541|DRUG|CHOP regimen|
219246024|NCT00003541|DRUG|carboplatin|
219246025|NCT00003541|DRUG|cyclophosphamide|
219246026|NCT00003541|DRUG|doxorubicin hydrochloride|
219246027|NCT00003541|DRUG|etoposide|
219246028|NCT00003541|DRUG|ifosfamide|
219246029|NCT00003541|DRUG|prednisone|
219246030|NCT00003541|DRUG|vincristine sulfate|
219246031|NCT00003541|PROCEDURE|peripheral blood stem cell transplantation|
219246032|NCT00003541|RADIATION|radiation therapy|
219246033|NCT05099068|BIOLOGICAL|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
219246034|NCT01572493|BIOLOGICAL|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
219246035|NCT01572493|BIOLOGICAL|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
219246036|NCT01234675|DRUG|Milnacipran|50 mg twice daily
219246037|NCT01234675|DRUG|Placebo|50 mg twice daily
219246038|NCT00609245|DRUG|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
219246039|NCT00609245|DRUG|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
219246040|NCT00454545|DRUG|Atorvastatin|
219246041|NCT05673421|OTHER|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
219246042|NCT05673421|OTHER|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
219246043|NCT04183803|PROCEDURE|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
219246044|NCT06422559|DEVICE|Transmagnetic stimulation|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
219246045|NCT06422559|DEVICE|TMS|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
219246046|NCT06275906|OTHER|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
219246047|NCT02746497|PROCEDURE|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
219246048|NCT02889809|DRUG|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
219246049|NCT02889809|DRUG|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
219246050|NCT02889809|DRUG|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
219246051|NCT02889809|DRUG|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
219246052|NCT04107688|OTHER|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
219246053|NCT04107688|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
219246054|NCT05065918|BEHAVIORAL|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
219740384|NCT02239042|PROCEDURE|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
219740385|NCT01130428|DEVICE|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
219740386|NCT02511769|BEHAVIORAL|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
219246055|NCT05065918|BEHAVIORAL|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
219246056|NCT03934944|DEVICE|Phone application|Weekly foot alerts and educational video
219246057|NCT03934944|OTHER|Usual care|Usual routine of diabetic foot education
219246058|NCT05707585|DIAGNOSTIC_TEST|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
219246059|NCT01634620|DEVICE|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
219246060|NCT03034772|DRUG|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
219246061|NCT03034772|OTHER|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
219246062|NCT00936195|DRUG|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
219246063|NCT00936195|DRUG|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
219246064|NCT00591188|DRUG|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
219246065|NCT04011995|BEHAVIORAL|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
219174028|NCT06831708|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention consists of a structured and manualized CBT program specifically tailored for individuals with Generalized Anxiety Disorder (GAD). The intervention includes defined session objectives, cognitive restructuring techniques, behavioral experiments, and homework assignments. Participants will receive 12 weekly sessions (50 minutes each), delivered by two study authors who are trained in CBT.
219174029|NCT05822557|OTHER|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
219174030|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
219174031|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
219174032|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
219174033|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
219174034|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
219174035|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
219174036|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
219174037|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
219174038|NCT05891236|OTHER|Control|No drug or placebo will be administered.
219174039|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
219174040|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
219174041|NCT05562791|DRUG|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
219174042|NCT05562791|DIAGNOSTIC_TEST|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
219174043|NCT06458894|BEHAVIORAL|Prerehabilitation|Home prerehabilitation was performed on the basis of routine preoperative preparation
219174044|NCT06836362|OTHER|Acupuncture treatment|"Children will receive 8 acupuncture sessions during 10 weeks (1 session per week during 6 weeks, followed by 1 session every other week during 4 weeks).~At each acupuncture session, the acupuncturist records the patient's bowel habits, gastrointestinal symptoms and the use of escape medication during the period between sessions. After 3, 6 and 8 acupuncture treatments respectively, patients will visit the research team after they receive acupuncture to evaluate adverse events.~After completion of these 10 weeks, an acupuncture-free follow-up period of 4 weeks commences. The follow-up period will be used to investigate if and how long effects of the intervention will persist. During the intervention period and the follow-up period, escape medication (bisacodyl or enemas) is allowed under the same conditions as during the run-in period."
219174045|NCT03861897|OTHER|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
219174046|NCT03861897|OTHER|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
219174047|NCT06065020|BEHAVIORAL|VIDACTIVA sessions|"Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)"
219174048|NCT06065020|BEHAVIORAL|Standard Care|Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
219174049|NCT06826391|DEVICE|Calcium hydroxylapatite|This intervention consists of calcium hydroxylapatite injections into the attached gingiva of a patient who has gingival recession to stabilize, grow and reverse gingival recession. These injections will also reduce tooth hypersensitivty in the affected teeth.
219174050|NCT06347874|DRUG|Cryoablation|an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
219174051|NCT06347874|DRUG|ESP Catheter|an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
219174052|NCT06010446|OTHER|No intervention, just retrospective analysis of data.|
219174053|NCT06198374|DIETARY_SUPPLEMENT|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
219174054|NCT06198374|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
219174055|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
219246066|NCT04011995|BEHAVIORAL|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
219174056|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
219174057|NCT05569382|DRUG|Verapamil|"1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
219174058|NCT05569382|DRUG|Bisoprolol|"1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
219174059|NCT05569382|DRUG|Placebo|"1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
219174060|NCT05893082|DEVICE|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
219174061|NCT06838182|DIAGNOSTIC_TEST|Salivary biomarkers tests|saliva samples are collected from participants
219174062|NCT03792282|BEHAVIORAL|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
219174063|NCT03792282|BEHAVIORAL|Usual care|Participants receive a general lifestyle counseling.
219174064|NCT03025698|DRUG|Eltrombopag|Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
219174065|NCT03025698|DRUG|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
219174066|NCT03025698|DRUG|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
219174067|NCT04864691|BIOLOGICAL|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
219174068|NCT05823740|OTHER|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174069|NCT05823740|OTHER|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174070|NCT05823740|OTHER|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174071|NCT05823740|OTHER|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174072|NCT05823740|OTHER|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174073|NCT05823740|OTHER|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
219174074|NCT05823740|OTHER|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
219174075|NCT05823740|OTHER|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
219174076|NCT06838260|OTHER|24°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 24°C for the T1 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
219174077|NCT06838260|OTHER|37°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 37°C for the T2 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
219174078|NCT06836557|DRUG|Tradipitant|BID
219174079|NCT04186520|BIOLOGICAL|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
219174080|NCT04186520|BIOLOGICAL|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
219174081|NCT04186520|BIOLOGICAL|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
219246067|NCT04011995|BEHAVIORAL|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
219246068|NCT02884921|DRUG|Paracetamol|Paracetamol
219246069|NCT02884921|DRUG|Paracetamol|Paracetamol
219246070|NCT02884921|DRUG|Placebo|Placebo
219246071|NCT03055819|DEVICE|Brow Lift|Minimally Invasive Brow Lift
219246072|NCT01116453|PROCEDURE|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
219246073|NCT01116453|PROCEDURE|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
219246074|NCT02503839|DRUG|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
219246075|NCT02503839|BIOLOGICAL|H56:IC31|Therapeutic and prophylactic TB vaccine
219246076|NCT00784771|BEHAVIORAL|Hypnotherapeutic Olfactory Conditioning (HOC)|
219246077|NCT01521221|OTHER|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
219246078|NCT00662415|DEVICE|mirror-box treatment|15 minutes daily for 4 weeks
219246079|NCT00662415|BEHAVIORAL|observation|observation
219246080|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 18%-protein diet|
219246081|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 35%-protein diet|
219246082|NCT02660034|BIOLOGICAL|Tislelizumab|
219246083|NCT02660034|DRUG|Pamiparib|
219246084|NCT02473588|DEVICE|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
219246085|NCT00952016|DRUG|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
219246086|NCT05990283|PROCEDURE|Socket shield technique|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
219246087|NCT05990283|PROCEDURE|Guided bone regeneration|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
219246088|NCT01065493|OTHER|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
219246089|NCT01065493|BEHAVIORAL|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
219246090|NCT04420897|PROCEDURE|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
219246091|NCT05394389|OTHER|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
219246092|NCT05394389|OTHER|social support|ten minutes of conversing.
219246093|NCT01838447|DIETARY_SUPPLEMENT|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
219174082|NCT05978986|DIAGNOSTIC_TEST|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
219174083|NCT05753189|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
219174084|NCT05753189|DRUG|Placebo|Placebo: Proprietary Vehicle Solution
219174085|NCT05753189|DRUG|Aceclidine Ophthalmic Solution|Aceclidine
219174086|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
219174087|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
219174088|NCT05817708|DRUG|CX-4945|"Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib"
219174089|NCT03605550|DRUG|PTC596|Oral tablets
219174090|NCT03605550|RADIATION|Radiotherapy|Cycle1
219174091|NCT04876742|OTHER|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
219174092|NCT04876742|OTHER|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
219174093|NCT06261450|DRUG|CBD Oral Solution (eCBD system Target)|Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
219174094|NCT06261450|DRUG|Placebo|Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
219174095|NCT05818696|BEHAVIORAL|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
219174096|NCT05818696|BEHAVIORAL|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
219174097|NCT03955510|OTHER|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
219174098|NCT03955510|OTHER|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
219174099|NCT03955510|PROCEDURE|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
219174100|NCT03955510|PROCEDURE|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
219174101|NCT03955510|OTHER|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
219174102|NCT02616445|DRUG|UE2343|"* UE2343~* 10mg, 20, 35mg~* twice daily for 9 days"
219174103|NCT02616445|DRUG|Placebo|"* 10mg, 20, 35mg~* twice daily for 9 days"
219246094|NCT05164133|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
219174104|NCT02616445|DRUG|Placebo|"* Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
219174105|NCT02616445|DRUG|UE2343|"* Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
219174106|NCT02616445|DRUG|UE2343|"* UE2343~* twice daily for 3 days~* single dose on day 4"
219174107|NCT05814874|DIETARY_SUPPLEMENT|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
219174108|NCT05814874|DIETARY_SUPPLEMENT|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
219174109|NCT05814874|OTHER|Placebo|Placebo pill
219174110|NCT06826157|DIAGNOSTIC_TEST|Electroencephalogram|EEGs will be acquired to explore progressive alteration of EEG patterns throughout the neuropathology progression.
219174111|NCT06826157|DIAGNOSTIC_TEST|3 Tesla MRI|MRI evaluations will be performed to investigate structural alterations and resting state functional MRI (RS-fMRI) connectivity in participants. Longitudinal measures of cortical/subcortical atrophy and RS-fMRI connectivity will be assessed and their relationship with EEG parameters will be explored.
219174112|NCT06826157|GENETIC|Apolipoprotein E genetic test|At baseline, a sample of blood will be collected to perform genetic analysis (APOE alleles) for all participants
219246095|NCT04747847|DRUG|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
219246096|NCT01394783|DEVICE|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
219246097|NCT01394783|DEVICE|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
219246098|NCT01493947|DRUG|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
219246099|NCT01493947|DRUG|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
219246100|NCT03204045|DRUG|fentanyl|2 mL mixture of fentanyl with isotonic saline
219246101|NCT03204045|DRUG|Oxycodone|2 mL mixture of oxycodone with isotonic saline
219246102|NCT03204045|DRUG|control|isotonic saline 2 mL
219246103|NCT03317678|DIETARY_SUPPLEMENT|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
219246104|NCT03317678|DIETARY_SUPPLEMENT|Non-fermented milk|A non-fermented milk drink.
219174113|NCT06830226|DIETARY_SUPPLEMENT|Test group|In this group the Miris Human Milk analyzer will be used, consisting of a real-time mid-infrared technology that directly measures the concentration of protein, fat and carbohydrate, and calculates the energy content based on direct measurements.
219174114|NCT06830226|DIETARY_SUPPLEMENT|Reference group|In this group the Kjeldahl method will be used to assess total nitrogen concentration, the Röse-Gottlib method to assess fat concentration, and energy and carbohydrate concentration will be calculated by differences. Kjeldahl and the Röse-Gottlib are considered reference methods
219174115|NCT06836986|DRUG|Norepinephrine Bolus|"Prophylactic norepinephrine bolus of 8 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of norepinephrine 4 micrograms will be administered in case of hypotension."
219174116|NCT06836986|DRUG|Phenylephrine bolus|"Prophylactic phenylephrine bolus of 100 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of phenylephrine 50 micrograms will be administered in case of hypotension."
219174117|NCT04354675|GENETIC|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
219174118|NCT04354675|GENETIC|Genetics counselor|Traditional in-person genetic counseling
219174119|NCT04354675|OTHER|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
219174120|NCT04354675|OTHER|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
219174121|NCT04354675|DEVICE|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
219174122|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
219174123|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
219174124|NCT06413641|OTHER|Follow up at general practice|As described before
219174125|NCT06413641|OTHER|Consultation|As described before
219174126|NCT06413641|OTHER|Visualization of CTA images|As described before
219174127|NCT06838338|DRUG|JAB-21822|Tablet, oral, 800 mg/QD, until PD or intolerable toxicity
219174128|NCT06838338|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by clinical practice
219174129|NCT06838338|DRUG|Bevacizumab|According to the assessment by investigator
219174130|NCT06164314|DRUG|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
219246105|NCT01533181|OTHER|Laboratory Biomarker Analysis|Correlative studies
219246106|NCT01533181|DRUG|Linsitinib|150 mg given orally (PO) twice a day (BID)
219246107|NCT01533181|OTHER|Pharmacological Study|Correlative studies
219246108|NCT01533181|DRUG|Topotecan Hydrochloride|1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
219246109|NCT01120561|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
219246110|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol Env A/B/C|1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
219246111|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol|5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
219246112|NCT02840175|DRUG|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
219174131|NCT06837350|OTHER|Music intervention|Listening to Turkish Music
219174132|NCT06787807|PROCEDURE|bariatric surgery|sleeve gastrectomy
219174133|NCT06786429|BIOLOGICAL|Gardasil 9 vaccine|Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
219174134|NCT06786429|BIOLOGICAL|Hepatitis B Virus Vaccine(HBV)|Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
219174135|NCT06786429|BEHAVIORAL|Cognitive Behavioral Therapy|Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
219174136|NCT04919109|BIOLOGICAL|CodaVax-RSV|live attenuated vaccine against RSV
219174137|NCT04919109|BIOLOGICAL|Normal Saline|Placebo comparator
219246113|NCT02840175|DRUG|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
219246114|NCT02840175|DRUG|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
219246115|NCT02840175|DRUG|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
219246116|NCT01074437|DRUG|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
219174138|NCT06783205|OTHER|Restriction of the Dominant Hand Due to Splint Use|This study aimed to assess whether the non-dominant hand function changes in patients using splints or casts on their dominant hand during the tissue healing period.
219174139|NCT06787495|PROCEDURE|Arterial repair|Arterial repair starting from simple repair or vein graft or synthetic graft
219174140|NCT03667196|PROCEDURE|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
219174141|NCT06485401|DRUG|ADC189|45 mg per tablet, oral administration, single dose.
219174142|NCT06833554|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|Dietary supplementation with Omega-3 Fatty Acids to study the effect on the immune system of breast milk
219174143|NCT06833554|DIETARY_SUPPLEMENT|Placebo|Inert dietary supplement, without activity in the activation of the immune system of breast milk
219174144|NCT03056040|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
219174145|NCT03056040|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
219246117|NCT01074437|DRUG|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
219246118|NCT01074437|DRUG|Placebo|Liquid placebo will be given during the two month treatment trial.
219174146|NCT04650087|DRUG|Apixaban 2.5 MG|Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
219174147|NCT04650087|DRUG|Placebo|Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
219174148|NCT05650970|OTHER|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
219174149|NCT05650970|OTHER|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
219174150|NCT03677999|DIAGNOSTIC_TEST|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
219174151|NCT06829342|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
219174152|NCT04317716|BEHAVIORAL|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
219174153|NCT04317716|OTHER|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
219174154|NCT06833242|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
219174155|NCT06475378|DEVICE|Moonbird|Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
219174156|NCT06475378|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
219174157|NCT04029688|DRUG|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
219174158|NCT04029688|DRUG|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
219174159|NCT04029688|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
219174160|NCT04029688|DRUG|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m\^2 as an IV infusion.
219174161|NCT04029688|DRUG|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m\^2 as an IV infusion.
219174162|NCT04029688|DRUG|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m\^2 as an IV infusion.
219174163|NCT04029688|DRUG|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
219174164|NCT05975450|DRUG|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~\- Abatacept 125 mg subcutaneous weekly"
219174165|NCT06493045|DRUG|IRL757|IRL757 capsule
219174166|NCT06493045|DRUG|Placebo|Placebo capsule
219174167|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
219174168|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
219174169|NCT03857061|DEVICE|smartphone, smartwatch, WearCOPDv2 application|"WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~1. Data collection service~2. Participant user interface"
219174170|NCT05731661|OTHER|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
219174171|NCT05731661|OTHER|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
219174172|NCT05731661|OTHER|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
219174173|NCT05157490|BEHAVIORAL|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
219174174|NCT06558071|DRUG|Galatonol 300 mg/Striatin 30 mg|1 film-coated caplet of Herba Asimor, twice daily
219246119|NCT00953342|BEHAVIORAL|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
219246120|NCT00953342|BEHAVIORAL|Usual care|Standard medical care
219246121|NCT03185845|DRUG|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
219246122|NCT02222844|OTHER|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
219246123|NCT06003738|PROCEDURE|fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected."
219246124|NCT06003738|PROCEDURE|pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
219246125|NCT06003738|PROCEDURE|palcebo fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected."
219246126|NCT06003738|PROCEDURE|palcebo pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
219246127|NCT00119756|DRUG|paliperidone palmitate|
219246128|NCT01837719|DRUG|Atazanavir|300-mg capsule
219246129|NCT01837719|DRUG|Cobicistat|150-mg tablet
219246130|NCT01837719|DRUG|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
219246131|NCT01475019|DRUG|Orlistat|Tablet, 120 mg, three times daily, for six months
219174175|NCT06558071|DRUG|Placebo|1 film-coated caplet of placebo Herba Asimor, twice daily
219174176|NCT06848998|BEHAVIORAL|aerobic exercise|"40 minutes of aerobic exercise, twice per week for six weeks.~Sessions comprised of the following: 10-minute warm-up, 40-minute conditioning period as a circuit, and 10-minute cool-down.~Aerobic exercises (for example, recumbent cycling, stepping, arm crank) commenced at an intensity of 40-50% heart rate reserve (HRR) and increased incrementally by 10% as tolerated, up to a maximum of 70-80%. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
219174177|NCT06848998|BEHAVIORAL|Resistance exercise|"4 x resistance exercises (3 sets of 6 repetitions), twice per week for six weeks.~Strengthening exercises (for example, resistance band work) were prescribed at an intensity that corresponded to 11-12 and incrementally increased to a maximum of 14-15, as tolerated, on the Borg Ratings of Perceived Exertion (RPE) 6-20 Scale. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
219174178|NCT04171661|BIOLOGICAL|SASS|SASS applied on chronic skin wounds as skin graft
219174179|NCT06845449|PROCEDURE|tenting screw combined with particulate autogenous|In Tenting screw cases, the screws will be placed in suitable positions and depths, blocks will be crushed into particulates which will then be mixed with equal amount of bovine particles. the mixture will be applied to the recipient site all around the tenting screws a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures.
219174180|NCT06845449|PROCEDURE|autogenous ring block grafts combined with xenogenic bone|In the non screw group, the blocks will be adapted to fit the recipient sites and secured to the alveolar bone using titanium bone fixation screws. Following the placement of the blocks, bovine particles will be applied over the graft and into any remaining gaps between the block and the recipient site, a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures
219174181|NCT06844942|DIAGNOSTIC_TEST|vessel Fractional Flow Reserve|Optical coherence tomography and vessel fractional flow reserve evaluation of coronary arteries with intermediate to severe stenosis.
219174182|NCT06848374|DRUG|40 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
219174183|NCT06848374|DRUG|80 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
219174184|NCT06848569|DRUG|Sintilimab in combination with AVD chemotherapy|Sintilimab in combination with AVD chemotherapy treating classical Hodgkin lymphoma
219174185|NCT06849817|OTHER|Diet - higher protein|Beef consumption 7 times per week (1 serving per day; 25 grams protein per serving (\~100 grams beef) as part of a higher protein diet (1.6 g protein/kg body weight)
219174186|NCT06849817|BEHAVIORAL|Physical activity and resistance training|150 minutes of physical activity including strength training 3 times per week
219174187|NCT06850064|PROCEDURE|Pulse Field Ablation (PFA)|The pulse field ablation group will undergo pulse field ablation of the mitral valve commissure.
219174188|NCT06850064|PROCEDURE|Radiofrequency ablation|In the radiofrequency ablation group, patients will undergo radiofrequency ablation targeted at the mitral valve commissure.
219174189|NCT06850285|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
219174190|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
219174191|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
219174192|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
219174193|NCT04978519|PROCEDURE|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
219174194|NCT05681520|BEHAVIORAL|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
219174195|NCT05763823|DRUG|Letermovir|Daily 240 mg or 480 mg oral tablets or IV dose
219174196|NCT06367829|PROCEDURE|Lubinus SPII hip stem 130mm|Shorter length of the SPII hip stem
219174197|NCT06367829|PROCEDURE|Lubinus SPII hip stem 150mm|Longer length of the SPII hip stem
219174198|NCT06262126|OTHER|Virtual Reality|Virtual Reality therapy
219174199|NCT03297151|DIETARY_SUPPLEMENT|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
219174200|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
219246132|NCT01475019|DRUG|Sibutramine|Tablet, 10 mg, once daily, for six months
219246133|NCT01475019|BEHAVIORAL|Diet and physical exercise|Hypocaloric diet and regular physical exercise
219246134|NCT04238559|OTHER|Self-report questionnaire|Fill in the SWAMECO questionnaire
219246135|NCT05286008|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219246136|NCT05286008|DRUG|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219246137|NCT05286008|DRUG|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
219246138|NCT04466397|DEVICE|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
219246139|NCT01703988|DRUG|Nusinersen|Single IT injection for each dose
219246140|NCT03199261|DRUG|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
219246141|NCT03199261|DRUG|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
219246142|NCT05194813|OTHER|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
219174201|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
219174202|NCT05628129|OTHER|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
219174203|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
219174204|NCT03778112|RADIATION|SBRT to whole prostate|Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate
219174205|NCT03778112|RADIATION|IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions|Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
219174206|NCT06367218|DRUG|opioid based strategy|Induction and maintenance of anesthesia with opioids
219174207|NCT06367218|DRUG|opioid-free strategy|Esketamine was used for induction and maintenance of anesthesia
219174208|NCT06367218|PROCEDURE|Laryngeal mask airway; Preserved spontaneous breathing|The patient used a laryngeal mask to maintain spontaneous breathing
219174209|NCT06367218|PROCEDURE|Double lumen tracheal tube; Mechanical ventilation|The patient was mechanically ventilated using a double-lumen tracheal catheter
219174210|NCT00906906|DEVICE|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
219174211|NCT06278961|OTHER|Observational|Observation of movement patterns through video recordings and neurodevelopmental battery of assessments.
219174212|NCT06553547|DRUG|Tenapanor|Tenapanor 5 mg/mL solution
219174213|NCT06553547|DRUG|Placebo|Matching Placebo solution
219174214|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
219174215|NCT01494662|DRUG|HKI-272|240 mg orally, once daily
219246143|NCT05194813|OTHER|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
219246144|NCT03750305|OTHER|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
219246145|NCT03750305|OTHER|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
219246146|NCT06247488|DRUG|Placebo|Participant will receive oral dose of placebo.
219246147|NCT06247488|DRUG|Oxycodone 20 mg|Participant will receive oral dose of oxycodone 20 mg.
219246148|NCT06247488|DRUG|GE-IR 200 mg|Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
219246149|NCT06247488|DRUG|GE-IR 450 mg|Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
219174216|NCT01494662|PROCEDURE|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
219174217|NCT01494662|DRUG|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
219174218|NCT01494662|DRUG|HKI-272|160 mg orally, once daily
219174219|NCT01494662|DRUG|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
219174220|NCT05311384|BEHAVIORAL|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
219174221|NCT04959123|OTHER|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
219174222|NCT05995535|DRUG|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
219174223|NCT05995535|DRUG|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
219174224|NCT05302921|PROCEDURE|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
219174225|NCT05302921|DRUG|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
219174226|NCT05302921|DRUG|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
219174227|NCT05640752|DIAGNOSTIC_TEST|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
219174228|NCT05640752|DIAGNOSTIC_TEST|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
219174229|NCT06545175|DRUG|Intracochlear application of VSF1.01|During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
219174230|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
219174231|NCT03799991|BEHAVIORAL|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
219174232|NCT03799991|BEHAVIORAL|Active control|Strength and flexibility exercises that do not involve head movements.
219246150|NCT05885841|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
219174233|NCT03302494|DEVICE|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
219174234|NCT03302494|DEVICE|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
219174235|NCT05403736|OTHER|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
219174236|NCT03386240|DRUG|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
219174237|NCT03386240|OTHER|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
219174238|NCT01573442|DRUG|testosterone|10.4 mg
219174239|NCT01573442|OTHER|placebo|
219174240|NCT05710107|OTHER|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
219174241|NCT05710107|OTHER|QL Block|Subjects randomized to this group will receive a QL Block
219174242|NCT04680663|DIAGNOSTIC_TEST|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
219174243|NCT04680663|DIAGNOSTIC_TEST|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
219174244|NCT03846167|DRUG|Imaging Drug FluorThanatrace (FTT)|\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
219174245|NCT04680741|BEHAVIORAL|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
219246151|NCT06640075|OTHER|Community co-produced action|"Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening."
219246152|NCT06640075|OTHER|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
219246153|NCT03743987|PROCEDURE|control group|a procedure used to prevent or resolves apical periodontitis.
219246154|NCT03743987|PROCEDURE|MTA group|a procedure used to prevent or resolves apical periodontitis.
219246155|NCT03743987|PROCEDURE|PRF group|a procedure that is used for wound healing
219246156|NCT03743987|PROCEDURE|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
219246157|NCT02749175|DEVICE|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
219246158|NCT02749175|DEVICE|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
219246159|NCT02995733|DRUG|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
219246160|NCT00790777|DRUG|Paliperidone ER|
219246161|NCT03802487|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
219246162|NCT03802487|DRUG|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
219246163|NCT03802487|DRUG|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
219246164|NCT04775173|DRUG|Sirolimus|Use of different doses of the same drug
219246165|NCT05550077|DIAGNOSTIC_TEST|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
219246166|NCT05550077|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
219246167|NCT01916447|DRUG|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219246168|NCT01916447|DRUG|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219246169|NCT01916447|DRUG|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
219246170|NCT04697641|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
219246171|NCT04697641|DRUG|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
219246172|NCT04697641|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
219246173|NCT04697641|DRUG|Levosulpiride|Levosulpiride 25 mg as and when required before meals
219246174|NCT04697641|DRUG|Acotiamide|Acotiamide 100mg as when required before meals
219246175|NCT04697641|DRUG|Itopride|Itopride 50mg as when required before meals
219246176|NCT05654558|DEVICE|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
219246177|NCT05654558|DEVICE|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
219246178|NCT00905814|DRUG|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
219246179|NCT00905814|DRUG|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
219246180|NCT06353919|OTHER|Yoga Nidra|"Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice."
219246181|NCT06353919|OTHER|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
219174246|NCT05999084|DRUG|Anti-amyloid Monoclonal Antibodies (mAbs)|Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
219174247|NCT05999084|COMBINATION_PRODUCT|Standard of Care|The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
219174248|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
219174249|NCT05044000|DEVICE|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
219174250|NCT03657771|OTHER|DED|DED: Diet eliminating dairy
219174251|NCT03657771|OTHER|FREE|FREE: Diet eliminating dairy and food additives
219246182|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)|0.25 mL per dose.
219246183|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)|0.5 mL per dose
219246184|NCT06642558|BIOLOGICAL|Placebo (Saline solution)|0.5 mL per dose
219246185|NCT00243633|PROCEDURE|Real-time contrast-enhanced ultrasound sonography|
219246186|NCT02844348|OTHER|Hypnosis session|
219246187|NCT05805033|OTHER|Mucointegration|Placement of abutment on a dental implant to study mucointegration
219246188|NCT05675839|OTHER|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI\_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
219246189|NCT04885764|BIOLOGICAL|Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart
219246190|NCT04885764|BIOLOGICAL|Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart
219246191|NCT02186587|DEVICE|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
219246192|NCT05942573|DRUG|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
219246193|NCT05942573|DRUG|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
219246194|NCT04157959|DRUG|SHR4640 dose1|Tablet,dose1,QD
219246195|NCT04157959|DRUG|Febuxostat dose2|Tablet,dose2,QD
219246196|NCT00000236|DRUG|Buprenorphine/naloxone|
219246197|NCT05023941|DRUG|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
219246198|NCT05023941|DEVICE|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
219246199|NCT05023941|DEVICE|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
219246200|NCT01910740|OTHER|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
219246201|NCT01910740|OTHER|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
219246202|NCT01910740|OTHER|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
219246203|NCT00001077|DIETARY_SUPPLEMENT|Multivitamin and mineral supplements|Oral tablets taken daily
219246204|NCT00001077|DIETARY_SUPPLEMENT|Peptamen|Solution received daily
219246205|NCT00001077|DIETARY_SUPPLEMENT|NuBasics|Solution or dietary bar received daily
219246206|NCT00316459|DRUG|ERB-041|
219246207|NCT00209222|DRUG|Rituximab|antibody
219246208|NCT00209222|DRUG|Cyclophosphamide|chemotherapy
219246209|NCT00209222|DRUG|Doxorubicin|chemotherapy
219246210|NCT00209222|DRUG|Vincristine|chemotherapy
219246211|NCT00209222|DRUG|Prednisone|corticosteroide
219246212|NCT00209222|DRUG|Cisplatinum|chemotherapy
219246213|NCT00209222|DRUG|Ara-C|chemotherapy
219246214|NCT00209222|DRUG|Dexamethasone|corticosteroide
219246215|NCT00209222|DRUG|BCNU|chemotherapy
219246216|NCT00209222|DRUG|Melphalan|chemotherapy
219246217|NCT00209222|DRUG|Etoposide|chemotherapy
219246218|NCT00209222|DRUG|G-CSF|growth factor
219246219|NCT00209222|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
219246220|NCT00209222|PROCEDURE|chemotherapy: R-DHAP|immuno-chemotherapy
219246221|NCT00209222|PROCEDURE|chemotherapy: Dexa-BEAM|chemotherapy
219246222|NCT00209222|PROCEDURE|stem cell harvest|procedure
219246223|NCT00209222|PROCEDURE|total body irradiation|radiation
219246224|NCT00209222|PROCEDURE|high-dose chemotherapy: Cyclophosphamide|chemotherapy
219246225|NCT00209222|PROCEDURE|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
219246226|NCT06027697|DEVICE|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
219246227|NCT03785210|DRUG|nivolumab|480 mg intravenous (IV) every 4 weeks
219246228|NCT03785210|DRUG|tadalafil|10 mg by mouth (PO) daily
219246229|NCT03785210|DRUG|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
219246230|NCT00067119|DRUG|Aggrenox|
219246231|NCT00067119|DRUG|Placebo|
219246232|NCT01189370|DRUG|sorafenib|"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."
219246233|NCT01599377|DRUG|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
219246234|NCT01599377|DRUG|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
219246235|NCT03952728|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
219246236|NCT03952728|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
219246237|NCT02615834|PROCEDURE|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
219246238|NCT01021202|PROCEDURE|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
219246239|NCT00161408|BEHAVIORAL|cognitive behavioural therapy|
219246240|NCT00161408|BEHAVIORAL|psychoeducation|
219246241|NCT02946450|DRUG|Other: Not applicable-observational study|
219246242|NCT04042259|DEVICE|Abthera|Negative Pressure Wound Therapy Device
219246243|NCT04042259|PROCEDURE|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
219246244|NCT05598138|BIOLOGICAL|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
219246245|NCT05354726|OTHER|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
219246246|NCT04636021|DIAGNOSTIC_TEST|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
219246247|NCT06306677|DIAGNOSTIC_TEST|AI-clincial-based hybrid system for radiographic image analysis|The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
219246248|NCT05303415|OTHER|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
219246249|NCT05804981|OTHER|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
219246250|NCT02879539|DEVICE|MP3000 sound coding strategy or ACE strategy with lower stimulation|
219246251|NCT02720198|DRUG|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
219246252|NCT02720198|DRUG|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
219246253|NCT06539325|DIAGNOSTIC_TEST|Diagnosis algorithm according to the delay between travel and consultation|Tests : RT-PCR for the most common arboviruses (Dengue, Zika, Chikungunya, and West Nile virus) and serology for dengue infection (NS1 antigen, and IgM and IgG), serologies for chronic viral infections (HIV, HBV and HCV) and schistosomiasis, Blood cultures and Innovativ Diagnostics : panel Dragonfly and two metagenomic analyses
219246254|NCT04879823|DRUG|Dexamethasone|IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
219246255|NCT04879823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219246256|NCT04879823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219246257|NCT04879823|DRUG|Placebo|An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
219246258|NCT05313178|DIETARY_SUPPLEMENT|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
219246259|NCT04047225|DEVICE|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
219246260|NCT05653050|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
219246261|NCT05653050|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Freestyle Libre 3 CGM
219246262|NCT00142532|PROCEDURE|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
219246263|NCT00142532|PROCEDURE|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
219246264|NCT05185089|DRUG|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
219246265|NCT05185089|DRUG|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
219246266|NCT01033123|DRUG|BSI-201|IV infusion, 5.6 mg/kg
219246267|NCT04344886|PROCEDURE|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
219246268|NCT04344886|PROCEDURE|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
219246269|NCT04344886|PROCEDURE|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
219246270|NCT04344886|PROCEDURE|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
219246271|NCT06398015|PROCEDURE|Surgical reconstruction of hip abductor tendon tear|"If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied."
219246272|NCT06398015|PROCEDURE|Sham surgery of hip abductor tendon tear|If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
219246273|NCT00289952|DRUG|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
219246274|NCT00289952|DRUG|HAART|As per standard of care.
219246275|NCT00003732|DRUG|carboplatin|
219246276|NCT00003732|DRUG|paclitaxel|
219246277|NCT00003732|DRUG|topotecan hydrochloride|
219246278|NCT00244556|DRUG|Methotrexate plus ENBREL or ENBREL alone|
219246279|NCT03593798|OTHER|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
219246280|NCT04653987|PROCEDURE|Percutaneous biliary drainage|
219246281|NCT00604344|DRUG|insulin detemir|
219246282|NCT00604344|DRUG|insulin NPH|
219246283|NCT00641797|DRUG|Meclizine|medication administration 25mg PO one time
219740387|NCT02511769|BEHAVIORAL|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
219246284|NCT00641797|OTHER|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
219246285|NCT00641797|DRUG|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
219246286|NCT00641797|DRUG|Diphenhydramine|25 - 50mg PO/IV once prn
219246287|NCT00641797|DRUG|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
219740388|NCT05168592|BEHAVIORAL|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
219740389|NCT05168592|BEHAVIORAL|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
219740390|NCT04043247|DEVICE|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
219740391|NCT04043247|DEVICE|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
219740392|NCT01406054|OTHER|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
219740393|NCT03019653|DRUG|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
219740394|NCT03019653|DRUG|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
219740395|NCT04286776|DEVICE|Direct electrical stimulation|Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
219740396|NCT03748212|DRUG|D935 Cap. 1T|single oral administration under fed condition
219740397|NCT03748212|DRUG|CKD-385 Tab. 1T|single oral administration under fed condition
219740398|NCT00967486|PROCEDURE|Carotid endarterectomy with routine shount|
219740399|NCT00967486|PROCEDURE|Carotid endarterectomy with selective shunt|
219740400|NCT00003192|DRUG|aminocamptothecin|
219740401|NCT00135876|DRUG|dalteparin|
219740402|NCT05814614|OTHER|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
219740403|NCT00274950|BIOLOGICAL|bleomycin sulfate|
219740404|NCT00274950|DRUG|carboplatin|
219740405|NCT00274950|DRUG|cisplatin|
219740406|NCT00274950|DRUG|etoposide|
219740407|NCT00274950|DRUG|ifosfamide|
219740408|NCT00274950|DRUG|vinblastine sulfate|
219740409|NCT00274950|PROCEDURE|adjuvant therapy|
219740410|NCT00274950|PROCEDURE|conventional surgery|
219740411|NCT02163356|DRUG|Fenretinide/LXS Oral Powder|Oral Powder
219740412|NCT02163356|DRUG|Ketoconazole|Oral Tablet
219740413|NCT02163356|DRUG|Vincristine|IV
219740414|NCT04063462|DRUG|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
219740415|NCT02858778|OTHER|Early order of palliative care consultation|
219740416|NCT00833729|DRUG|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
219740417|NCT01813227|DRUG|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
219740418|NCT01813227|DRUG|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
219740419|NCT01813227|DRUG|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
219740420|NCT03804255|OTHER|Survey Administration|Complete surveys
219740421|NCT06036264|OTHER|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
219740422|NCT06036264|OTHER|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
219740423|NCT06304896|DRUG|Carvedilol|Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
219740424|NCT06304896|DRUG|Ramipril|Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
219740425|NCT06304896|DRUG|Rosuvastatin|Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
219740426|NCT06304896|DRUG|Colchicine|Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
219740427|NCT06304896|DRUG|Placebo|Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
219740428|NCT04672616|BEHAVIORAL|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
219740429|NCT01335685|DRUG|Ixazomib|Ixazomib capsules
219740430|NCT01335685|DRUG|Melphalan|Melphalan tablets
219740431|NCT01335685|DRUG|Prednisone|Prednisone tablets
219740432|NCT04951843|DIETARY_SUPPLEMENT|Black soybean koji product|Black soybean koji product
219174252|NCT03485469|BEHAVIORAL|Hypnosis|"There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
219174253|NCT03485469|BEHAVIORAL|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
219174254|NCT05441501|DRUG|JNJ-80038114|JNJ-80038114 will be administered.
219174255|NCT04367883|DRUG|Antihistamine|No intervention is performed. We propose an observational study.
219174256|NCT04367883|DRUG|Amantadine|No intervention is performed. We propose an observational study
219174257|NCT04367883|DRUG|ACEI|No intervention is performed. We propose an observational study.
219740433|NCT00127478|DRUG|Atrasentan|
219740434|NCT03116178|OTHER|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
219740435|NCT03116178|OTHER|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
219740436|NCT05198661|BIOLOGICAL|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
219740437|NCT02732496|BEHAVIORAL|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
219740438|NCT02732496|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
219740439|NCT02214628|DRUG|Fovista® (anti-PDGF BB) plus anti-VEGF|
219740440|NCT01550887|OTHER|No intervention|No intervention will be performed on this study
219740441|NCT06391333|DEVICE|laryngeal mask airway and endotracheal tube|The two most commonly used devices for mechanical ventilation.
219740442|NCT03777020|BEHAVIORAL|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
219740443|NCT03777020|OTHER|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
219740444|NCT02274233|DRUG|SP-420|
219740445|NCT06020937|DIAGNOSTIC_TEST|TDI|Sniffin' Sticks Threshold and Identification Test
219740446|NCT06020937|DIAGNOSTIC_TEST|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
219740447|NCT06020937|DIAGNOSTIC_TEST|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
219740448|NCT06020937|DIAGNOSTIC_TEST|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
219740449|NCT06020937|DIAGNOSTIC_TEST|Visual Analogue Scale Ratings|"* Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
219740450|NCT06020937|DIAGNOSTIC_TEST|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
219740451|NCT06474962|BEHAVIORAL|Pause|7 days of no e-cigarette consumption
219740452|NCT00489476|DRUG|Staccato Loxapine|
219740453|NCT00489476|DRUG|Staccato Placebo|Placebo aerosol inhalation (0mg)
219740454|NCT03989479|BEHAVIORAL|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
219740455|NCT03989479|BEHAVIORAL|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
219740456|NCT00005839|DRUG|capecitabine|
219740457|NCT00005839|DRUG|oxaliplatin|
219740458|NCT04418154|DRUG|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
219740459|NCT04418154|DRUG|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
219740460|NCT04418154|DRUG|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
219740461|NCT04418154|DRUG|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
219740462|NCT02098473|DRUG|RPC4046|
219740463|NCT02098473|DRUG|Placebo|
219740464|NCT00002985|DRUG|daunorubicin hydrochloride|
219740465|NCT00002985|DRUG|pegylated liposomal doxorubicin hydrochloride|
219740466|NCT03485885|DIETARY_SUPPLEMENT|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
219174258|NCT04367883|DRUG|ARB|No intervention is performed. We propose an observational study.
219174259|NCT04367883|OTHER|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
219174260|NCT04055090|GENETIC|Long-Term Follow-Up of Patients who Received Engensis (VM202)|No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
219246288|NCT05481996|OTHER|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
219246289|NCT05481996|OTHER|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
219174261|NCT04055090|DRUG|Long-Term Follow-Up of Patients who Received Placebo|No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
219174262|NCT06318338|OTHER|Virtual Reality Program|Study participants will be provided a HTC or Pico VR head-mounted device (HTC Flow, HTC Focus or Pico Neo Pro) which will be fitted for comfort. Patients will remain seated for the entirety of the VR program. The program generally takes about ten minutes to complete but may last up to 11 minutes. The program displays a relaxing environmental setting with narration based in mindfulness meditation principles. Subjects will be prompted to practice breathing exercises designed to relax and reduce anxiety.
219174263|NCT05701306|DRUG|APG-115|Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
219174264|NCT05701306|DRUG|APG-2575|Orally once a day (QD) for 21 days, 21 days as a cycle.
219174265|NCT03673709|BEHAVIORAL|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
219174266|NCT03085147|DRUG|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
219174267|NCT05071807|DRUG|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
219174268|NCT05071807|OTHER|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
219174269|NCT05794412|OTHER|No intervention|No intervention
219174270|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
219174271|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
219174272|NCT05521776|PROCEDURE|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
219174273|NCT03888170|OTHER|No intervention|No intervention
219174274|NCT06259448|OTHER|urine self-sampling|urine self-sampling
219174275|NCT05551637|DIETARY_SUPPLEMENT|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
219174276|NCT05009264|PROCEDURE|OMT|OMT will be performed on identified areas of trapezius trigger points
219174277|NCT02878915|DEVICE|Ultrasound guided femoral puncture|
219246290|NCT03890692|PROCEDURE|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
219246291|NCT00490243|DRUG|budesonide and montelukast|
219246292|NCT00490243|DRUG|budesonide and formoterol|
219246293|NCT00490243|DRUG|montelukast|
219246294|NCT00490243|DRUG|budesonide|
219246295|NCT00490243|DRUG|placebo|
219246296|NCT02465866|DRUG|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
219246297|NCT02465866|DRUG|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
219246298|NCT02465866|DRUG|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
219246299|NCT02465866|DRUG|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
219246300|NCT05038319|PROCEDURE|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
219246301|NCT05591456|RADIATION|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
219246302|NCT03180086|OTHER|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
219246303|NCT01562288|GENETIC|DNA analysis|
219246304|NCT01562288|GENETIC|gene expression analysis|
219246305|NCT01562288|GENETIC|polymerase chain reaction|
219246306|NCT01562288|OTHER|enzyme-linked immunosorbent assay|
219246307|NCT01562288|OTHER|laboratory biomarker analysis|
219246308|NCT00203502|DRUG|Bevacizumab|IV 15mg/kg 21 days
219246309|NCT00203502|DRUG|Cyclophosphamide|500mg per meter squared, IV every 21 days
219246310|NCT00203502|DRUG|Docetaxel|60 mg per meter squared, IV every 21 days
219246311|NCT00597779|DEVICE|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
219246312|NCT02450279|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
219246313|NCT02450279|DEVICE|Vibrating-mesh nebulizer|
219246314|NCT02450279|DEVICE|Jet Nebulizer|
219246315|NCT02450279|OTHER|Planar scintigraphy|
219246316|NCT02450279|OTHER|Preoperative spirometry|
219246317|NCT02916524|BEHAVIORAL|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
219246318|NCT00801905|DRUG|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
219246319|NCT00801905|OTHER|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
219246320|NCT01071720|DRUG|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
219246321|NCT02699437|OTHER|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
219174278|NCT06241651|DEVICE|Conduction system pacing|Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
219174279|NCT06241651|DEVICE|Biventricular pacing|Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
219174280|NCT05184335|DRUG|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
219174281|NCT05184335|OTHER|Placebo|RP5063 matching Placebo
219174282|NCT06519968|DRUG|AZD4604|AZD4604 will be administered as Dry Powder Inhalation (DPI).
219174283|NCT06519968|DRUG|Placebo|Placebo will be administered as DPI.
219174284|NCT06304298|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride
219246322|NCT05147545|OTHER|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
219174285|NCT06304298|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine
219174286|NCT05982938|DRUG|Danicopan|Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
219174287|NCT05521672|DRUG|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
219174288|NCT04101903|DIAGNOSTIC_TEST|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
219174289|NCT02754882|DRUG|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
219174290|NCT02754882|DRUG|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
219174291|NCT02754882|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
219174292|NCT02754882|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
219174293|NCT05834608|BEHAVIORAL|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
219174294|NCT06204913|OTHER|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
219174295|NCT04648033|DRUG|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
219174296|NCT04648033|DRUG|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
219174297|NCT04648033|RADIATION|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
219174298|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
219246323|NCT05147545|OTHER|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
219246324|NCT05147545|OTHER|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
219246325|NCT05147545|DIAGNOSTIC_TEST|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
219246326|NCT01469819|DRUG|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
219246327|NCT01088347|DRUG|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
219246328|NCT01088347|DRUG|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
219246329|NCT01088347|RADIATION|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
219246330|NCT04284722|DRUG|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
219246331|NCT03597542|OTHER|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
219246332|NCT06431360|OTHER|hyperthermia|hyperthermia (using a heater, 44℃for 15 min)
219246333|NCT03856294|DRUG|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
219246334|NCT03856294|DRUG|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
219246335|NCT00049751|DRUG|Adalimumab|
219246336|NCT04714697|DRUG|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
219246337|NCT03366727|DEVICE|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
219246338|NCT03366727|DEVICE|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
219246339|NCT04501107|DRUG|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
219246340|NCT04501107|DRUG|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
219246341|NCT04501107|DRUG|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
219246342|NCT04501107|DRUG|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
219246343|NCT02686983|DRUG|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
219246344|NCT03992599|PROCEDURE|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
219246345|NCT04301947|OTHER|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
219246346|NCT04301947|OTHER|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
219246347|NCT02301871|DEVICE|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
219246348|NCT02301871|PROCEDURE|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
219246349|NCT02301871|PROCEDURE|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
219246350|NCT01403805|BIOLOGICAL|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
219246351|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
219246352|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
219246353|NCT01403805|OTHER|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
219246354|NCT03035149|OTHER|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
219246355|NCT03341754|BIOLOGICAL|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
219246356|NCT03341754|BIOLOGICAL|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
219246357|NCT03341754|OTHER|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
219246358|NCT02243488|DEVICE|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
219246359|NCT02250911|OTHER|webcasts|
219246360|NCT02250911|BEHAVIORAL|Assessments|
219246361|NCT02250911|OTHER|Usual care|
219246362|NCT05257434|BEHAVIORAL|inbody|Body fluid composition
219246363|NCT05697822|OTHER|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
219246364|NCT06086665|DRUG|Niraparib|Niraparib
219246365|NCT04057937|DRUG|Apremilast|Apremilast
219246366|NCT04057937|DRUG|Placebo|Placebo
219246367|NCT00862225|DRUG|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
219246368|NCT00862225|DRUG|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
219740467|NCT04795453|OTHER|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
219740468|NCT04795453|OTHER|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
219740469|NCT00474357|BEHAVIORAL|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
219740470|NCT01514422|DRUG|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
219740471|NCT02423954|DRUG|Temsirolimus|
219740472|NCT02423954|DRUG|Irinotecan|
219740473|NCT02423954|DRUG|Irinotecan + capecitabine|
219740474|NCT02423954|DRUG|nivolumab|
219740475|NCT04126174|DEVICE|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
219740476|NCT04126174|OTHER|Manual LRI|Manual LRI
219740477|NCT01942460|DRUG|Ferumoxytol|
219740478|NCT04511741|OTHER|no intervention, it is an observational study.|no intervention, it is an observational study.
219740479|NCT03563079|OTHER|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
219740480|NCT03563079|OTHER|Manual Myofascial Release|Myofascial Release Technique
219740481|NCT00004665|DRUG|dehydroepiandrosterone|
219740482|NCT03008980|OTHER|Diagnostic Test|
219740483|NCT03908294|DIAGNOSTIC_TEST|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
219740484|NCT01055119|DIETARY_SUPPLEMENT|Omega-3 fatty acids|duration: 4 month
219740485|NCT05812300|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
219740486|NCT06642688|OTHER|Sacroiliac Joint Manipulation|The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
219740487|NCT06642688|OTHER|Cervical Spine Manipulation|Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
219740488|NCT02244788|DEVICE|SR™ PIP|SR™ PIP
219740489|NCT05457140|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
219740490|NCT05457140|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
219740491|NCT05034887|DRUG|Trastuzumab Deruxtecan (T-DXd) monotherapy|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
219740492|NCT05034887|DRUG|T-DXd, Durvalumab and Capecitabine Combination|Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
219740493|NCT03978156|DRUG|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
219740494|NCT03978156|DRUG|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
219740495|NCT00378287|DRUG|rabeprazole sodium|
219740496|NCT05225012|OTHER|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
219740497|NCT05019807|OTHER|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
219246369|NCT00862225|DRUG|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
219246370|NCT06164041|BEHAVIORAL|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
219246371|NCT00428441|DRUG|Warfarin|tablets, based on INR levels, according to D-dimer levels
219246372|NCT03912298|OTHER|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
219246373|NCT03761134|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219246374|NCT03761134|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
219246375|NCT03761134|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
219246376|NCT03761134|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
219246377|NCT04340726|PROCEDURE|One time abutment|
219246378|NCT00692250|DRUG|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
219246379|NCT05269303|DEVICE|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
219246380|NCT00001436|DRUG|OncoLAR® (Registered Trademark)|
219246381|NCT00001436|DRUG|tamoxifen|
219246382|NCT05610943|PROCEDURE|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
219246383|NCT05610943|PROCEDURE|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
219246384|NCT00510783|DRUG|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
219246385|NCT00510783|DRUG|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
219246386|NCT00510783|DRUG|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
219246387|NCT05476770|DRUG|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
219246388|NCT05476770|DRUG|Fludarabine|"30 mg/m\^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
219246389|NCT05476770|DRUG|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
219740498|NCT05019807|OTHER|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
219740499|NCT05815784|DRUG|Atropine|0.05% atropine. One drop per eye per day for 2 years.
219740500|NCT05815784|DEVICE|MiSight contact lenses|Daily wear for 2 years.
219740501|NCT04722679|DRUG|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
219740502|NCT04983238|DRUG|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
219740503|NCT04983238|DRUG|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
219740504|NCT06500000|DIAGNOSTIC_TEST|liquid chromatography-mass spectrometry (LC/MS)|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
219740505|NCT02578537|DRUG|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
219740506|NCT02578537|DRUG|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
219740507|NCT03995511|PROCEDURE|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
219740508|NCT06517927|DIAGNOSTIC_TEST|Clinical and radiographic dental examination|complete clinical oral examination + intra-oral and panoramic x-rays
219246390|NCT05476770|DRUG|Dexamethasone|"* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~* Any oral formulation of dexamethasone is acceptable.~* IV may be given if oral formulation is not tolerated"
219246391|NCT05476770|DRUG|Vincristine|"* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~* Infusion will start 30 minutes after start of tagraxofusp on day 8."
219246392|NCT05476770|DRUG|Azacitidine|"* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
219246393|NCT05476770|DRUG|Methotrexate|"Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age"
219246394|NCT05476770|DRUG|Cytarabine IT|"Give intrathecally:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
219246395|NCT05476770|DRUG|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
219246396|NCT01285596|DRUG|Mirabegron|oral
219246397|NCT04044820|DRUG|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
219246398|NCT05990075|BEHAVIORAL|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
219246399|NCT05657418|DRUG|JS107|JS107, i.v., q3w
219246400|NCT05657418|COMBINATION_PRODUCT|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
219246401|NCT05099978|GENETIC|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
219246402|NCT05319756|DRUG|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
219246403|NCT05319756|DRUG|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
219246404|NCT05319756|DRUG|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
219174299|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
219246405|NCT05319756|DRUG|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
219246406|NCT05319756|DRUG|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
219246407|NCT05319756|DRUG|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
219246408|NCT00763087|BEHAVIORAL|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
219246409|NCT00763087|BEHAVIORAL|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
219246410|NCT00763087|BEHAVIORAL|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
219246411|NCT06399003|BIOLOGICAL|SIBP MMR Vaccine|This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.
219246412|NCT06399003|BIOLOGICAL|GSK MMR Vaccine (PRIORIX)|PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.
219246413|NCT06399003|BIOLOGICAL|Yellow Fever Vaccine (Stamaril)|This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
219246414|NCT00108407|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|
219246415|NCT00108407|BEHAVIORAL|Twelve Step Facilitation Therapy|
219246416|NCT02854657|BEHAVIORAL|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
219246417|NCT02237456|PROCEDURE|Comparison of OCT scans|
219246418|NCT02237456|PROCEDURE|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
219246419|NCT05574244|PROCEDURE|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
219174300|NCT04088851|DRUG|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
219174301|NCT04088851|DRUG|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
219174302|NCT05893498|DEVICE|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
219246420|NCT05574244|PROCEDURE|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
219246421|NCT00002792|DRUG|busulfan|
219246422|NCT00002792|DRUG|cyclophosphamide|
219246423|NCT00002792|DRUG|cyclosporine|
219246424|NCT00002792|DRUG|methotrexate|
219246425|NCT00002792|DRUG|tacrolimus|
219174303|NCT05893498|DEVICE|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
219174304|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
219174305|NCT04308174|DRUG|Durvalumab + Gem/Cis|Neoadjuvant Durvalumab + Gemcitabine/Cisplatin
219174306|NCT04308174|DRUG|Gem/Cis|Neoadjuvant Gemcitabine/Cisplatin
219174307|NCT03196011|OTHER|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
219174308|NCT03196011|OTHER|TKR with alternative alignment method|TKR implanted using alternative alignment methods
219174309|NCT06546982|DIAGNOSTIC_TEST|Surface-enhanced Raman Spectroscopy|The Raman spectra of patient samples will be measured in the presence of gold nanoparticles, which will enhance the spectroscopic characteristics of serum components via near-field enhancements.
219174310|NCT05322785|OTHER|Breath collection|Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
219174311|NCT05203341|DRUG|Placebo|Matching placebo tablets
219174312|NCT05203341|DRUG|NBI-1065845|NBI-1065845 tablets
219174313|NCT04833309|PROCEDURE|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
219174314|NCT04833309|PROCEDURE|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
219174315|NCT05076370|DRUG|CBD Day 1|CBD 400mg
219174316|NCT05076370|DRUG|CBD Day 2|CBD 800mg
219174317|NCT05076370|DRUG|CBD Day 3|CBD 1200mg
219174318|NCT04327557|BEHAVIORAL|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
219246426|NCT00002792|PROCEDURE|allogeneic bone marrow transplantation|
219246427|NCT00002792|PROCEDURE|peripheral blood stem cell transplantation|
219246428|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in plasma|
219246429|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in human albumin|
219246430|NCT02001207|OTHER|Salivary cortisol test|
219246431|NCT01803828|DRUG|Tadalafil|20 mg/die (1 capsule)
219246432|NCT01803828|DRUG|Placebo|Placebo 20 mg/die (1 capsule)
219246433|NCT00422162|DRUG|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
219246434|NCT00422162|DRUG|Placebo|placebo capsule by mouth
219246435|NCT05802498|DEVICE|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
219246436|NCT00393185|BIOLOGICAL|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
219246437|NCT03562702|OTHER|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
219246438|NCT03562702|OTHER|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
219246439|NCT01526486|PROCEDURE|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
219246440|NCT01526486|PROCEDURE|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
219246441|NCT02416297|PROCEDURE|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
219246442|NCT02896556|DEVICE|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
219246443|NCT05159726|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
219246444|NCT04816435|DIAGNOSTIC_TEST|Ultrasound test|Ultrasound evaluation of airway
219246445|NCT03508830|DRUG|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
219246446|NCT03508830|DRUG|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
219174319|NCT04327557|BEHAVIORAL|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
219174320|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
219174321|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
219174322|NCT05963425|OTHER|Physical activity|This physical activity program will be based only on the work of basic physical training, in which specifically and mainly the strength and resistance will be worked, but also flexibility
219174323|NCT05963425|OTHER|usual clinical practice|usual clinical practice
219174324|NCT05014984|BEHAVIORAL|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1). In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
219174325|NCT05014984|BEHAVIORAL|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
219174326|NCT05014984|BEHAVIORAL|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study. Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
219174327|NCT05014984|BEHAVIORAL|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies. To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
219174328|NCT04814446|BIOLOGICAL|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
219246447|NCT02064335|BEHAVIORAL|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
219246448|NCT00144937|DRUG|Stepwise therapy for dyslipidemia, hypertension and diabetes|
219246449|NCT00144937|BEHAVIORAL|Dietary recommendations|
219246450|NCT00144937|BEHAVIORAL|Increase in physical activity|
219246451|NCT00144937|BEHAVIORAL|Smoking cessation|
219246452|NCT00075699|DRUG|cisplatin|
219246453|NCT00075699|DRUG|mitomycin C|
219246454|NCT00075699|DRUG|vincristine sulfate|
219246455|NCT00075699|DRUG|vinorelbine tartrate|
219246456|NCT00075699|PROCEDURE|pain therapy|
219246457|NCT00075699|PROCEDURE|psychosocial assessment and care|
219246458|NCT00075699|PROCEDURE|quality-of-life assessment|
219246459|NCT05658445|OTHER|evacuation|after complete evacuation of uterus follow abortion
219246460|NCT02473549|DEVICE|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
219246461|NCT02473549|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
219246462|NCT02473549|DEVICE|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
219246463|NCT02473549|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
219246464|NCT00065247|BEHAVIORAL|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
219246465|NCT02522299|DRUG|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
219246466|NCT02522299|DRUG|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
219246467|NCT02522299|DEVICE|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
219246468|NCT02522299|DEVICE|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
219246469|NCT05487209|DIAGNOSTIC_TEST|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
219246470|NCT04975386|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram will be performed before the operation and at certain time intervals during the operation.
219246471|NCT02342275|DRUG|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
219246472|NCT02342275|DRUG|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
219740509|NCT02554838|OTHER|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
219740510|NCT02554838|OTHER|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
219740511|NCT02554838|BEHAVIORAL|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
219740512|NCT03324412|DRUG|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
219740513|NCT03324412|DRUG|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
219740514|NCT00544687|DRUG|CRx-191|topical (mometasone furoate + nortriptyline HCl)
219740515|NCT00544687|DRUG|mometasone furoate|topical mometasone furoate
219740516|NCT00544687|DRUG|nortriptyline HCl|topical nortriptyline HCl
219740517|NCT00544687|DRUG|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
219740518|NCT00544687|DRUG|Vehicle|topical (placebo)
219740519|NCT01885338|DRUG|N-acetylcysteine (NAC)|
219740520|NCT01885338|DRUG|Inactive placebo capsule|
219246473|NCT06037109|DEVICE|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
219246474|NCT04908800|DRUG|KRP-A218|KRP-A218 tablet
219246475|NCT04908800|DRUG|Placebo|Placebo tablet
219246476|NCT04908800|DRUG|itraconazole|10 mg/mL oral solution
219246477|NCT03639792|PROCEDURE|gastric cancer surgery|Gastric cancer surgery
219246478|NCT01979822|OTHER|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
219246479|NCT06249594|PROCEDURE|targeted sensory reinervation|targeted sensory reinnervation (TSR) in hand amputation by using and reactivation of existing nerves to treat and prevent phantom pain
219246480|NCT05153161|DEVICE|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
219246481|NCT05142553|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
219246482|NCT05142553|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
219246483|NCT05165303|DRUG|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
219246484|NCT01112163|DEVICE|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
219246485|NCT02468037|PROCEDURE|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
219246486|NCT03245996|DEVICE|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
219246487|NCT03245996|DEVICE|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
219246488|NCT03245996|DEVICE|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
219246489|NCT03245996|DRUG|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
219246490|NCT03245996|DRUG|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
219246491|NCT03245996|DRUG|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
219246492|NCT06647212|OTHER|introducing breathing exercises with the harmonica|In addition to regular breathing exercises, participants will perform harmonica exercises
219246493|NCT05082493|DRUG|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
219246494|NCT03873922|OTHER|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
219246495|NCT03287947|DRUG|nintedanib|Oral nintedanib, taken twice daily
219246496|NCT06472882|DEVICE|tDCS targeting DLPFC|The anodic electrode will be placed on the left DLPFC (area F3) and the cathode on the right orbitofrontal cortex (area Fp2). Participants will receive 20 minutes of tDCS at 2 mA while seated.
219246497|NCT06472882|DEVICE|tDCS targeting M1|The anodes will be placed over C3 and C4 (according to EEG 10-20 system), and the cathodes over the ipsilateral shoulders. Participants will receive 20 minutes of tDCS at 2 mA while seated.
219246498|NCT06472882|DEVICE|SHAM tDCS|The electrodes will be placed as in the other conditions, but the stimulation will be switched off after 30 seconds, providing an initial stinging sensation without continuous stimulation.
219246499|NCT05271799|DRUG|Gepotidacin|Gepotidacin will be administered
219246500|NCT04933188|DIAGNOSTIC_TEST|Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure|Baseline and follow-up examination of echocardiography is to be performed on study subjects.
219246501|NCT01436604|OTHER|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
219246502|NCT04074304|OTHER|I-HoME|A multi-component technology-based care intervention.
219246503|NCT04303598|DRUG|FNC|3mg, 1 tablet，QD
219246504|NCT04303598|DRUG|3TC|300mg, 1 tablet，QD
219246505|NCT04303598|DRUG|TDF|300mg, 1 tablet，QD
219246506|NCT04303598|DRUG|EFV|200mg, 1 tablet，QD
219246507|NCT04303598|DRUG|FNC placebo|1 tablet，QD
219246508|NCT04303598|DRUG|3TC placebo|1 tablet，QD
219246509|NCT01920399|DRUG|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
219246510|NCT01920399|DRUG|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
219246511|NCT06014788|DEVICE|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
219246512|NCT06014788|DEVICE|Conventional NPWT|Conventional NPWT
219246513|NCT02944526|DRUG|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
219246514|NCT02944526|DRUG|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
219246515|NCT03252899|OTHER|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
219246516|NCT03252899|OTHER|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
219246517|NCT04277273|OTHER|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
219246518|NCT06266065|DEVICE|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
219246519|NCT03606863|DRUG|Perioperative peripheral parenteral nutrition|
219246520|NCT04194671|BIOLOGICAL|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
219740521|NCT02472951|OTHER|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
219740522|NCT02472951|OTHER|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
219740523|NCT02261142|DEVICE|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
219246521|NCT04194671|OTHER|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
219246522|NCT04872465|DEVICE|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
219246523|NCT04872465|DEVICE|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
219246524|NCT01348763|DRUG|Maraviroc|Maraviroc 150 mg daily
219246525|NCT01348763|DRUG|Truvada|daily until 10. day then stop
219246526|NCT01348763|DRUG|Darunavir|daily until 10. day then stop
219246527|NCT05990309|DIAGNOSTIC_TEST|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
219246528|NCT03959735|OTHER|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
219246529|NCT03022747|DRUG|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
219246530|NCT03022747|DRUG|Standard treatment|Oral 6-mercaptopurine and methotrexate
219246531|NCT04004169|DEVICE|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
219246532|NCT04004169|DEVICE|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
219246533|NCT04004169|DEVICE|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
219246534|NCT03981120|PROCEDURE|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
219246535|NCT05199597|DRUG|0.01% atropine|0.01%, room temp, Lab A
219246536|NCT05199597|DRUG|0.05% atropine|0.05%, room temp, Lab A
219246537|NCT05199597|DRUG|0.05% atropine|0.05%, refrigerated, Lab A
219246538|NCT05199597|DRUG|0.05% atropine|0.05%, room temperature, Lab B
219740524|NCT06469580|OTHER|NPLUS (neonatologist performed lung ultrasound)|"NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists."
219740525|NCT06255340|DRUG|BI 3031185|BI 3031185
219246539|NCT00448786|DRUG|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
219246540|NCT00448786|DRUG|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
219246541|NCT00448786|DRUG|AMG 706|AMG 706 125 mg daily continuously (Arm A)
219246542|NCT00166361|DEVICE|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
219246543|NCT00166361|DEVICE|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
219246544|NCT03856424|PROCEDURE|Modality 1|Pressure support ventilation (PSV) modality
219246545|NCT03856424|PROCEDURE|Modality 2|T-Piece modality
219246546|NCT03856424|PROCEDURE|Modality 3|High-flow oxygen
219246547|NCT04007822|BEHAVIORAL|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
219246548|NCT02259296|PROCEDURE|Lower eGFR for AVF construction|Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
219246549|NCT02259296|PROCEDURE|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
219246550|NCT02053402|DRUG|Vitamin D|Vitamin D daily for six months
219246551|NCT05045638|DRUG|Rosuvastatin|Oral dose
219246552|NCT05045638|DRUG|Sotorasib|Oral dose
219246553|NCT00722488|DRUG|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
219740526|NCT06255340|DRUG|Placebo matching BI 3031185|Placebo
219740527|NCT01433003|PROCEDURE|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
219246554|NCT00730496|PROCEDURE|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
219246555|NCT03097458|BEHAVIORAL|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
219246556|NCT05570578|DEVICE|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
219246557|NCT00538616|DRUG|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
219246558|NCT00538616|DRUG|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
219246559|NCT04739293|DRUG|ON123300|ON 123300 hard gelatin capsules
219246560|NCT00187122|DRUG|Vincristine|See Detailed Description section for description of treatment plan.
219246561|NCT00187122|PROCEDURE|Radiation Therapy|See Detailed Description section for description of treatment plan.
219246562|NCT00187122|DRUG|Daunomycin|See Detailed Description section for description of treatment plan.
219246563|NCT00187122|DRUG|L-Asparaginase|See Detailed Description section for description of treatment plan.
219246564|NCT00187122|DRUG|Cytarabine|See Detailed Description section for description of treatment plan.
219740528|NCT01446510|OTHER|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
219740529|NCT05127785|PROCEDURE|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
219740530|NCT02856373|PROCEDURE|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
219740531|NCT04582643|BEHAVIORAL|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
219740532|NCT04105725|BEHAVIORAL|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
219740533|NCT04105725|OTHER|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
219740534|NCT01498380|DRUG|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease \>/= 20% or SBP/DBP/MAP decrease or increase \>/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
219740535|NCT02322931|PROCEDURE|Intra-operative C-arm CT imaging|"1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
219740536|NCT04879485|BIOLOGICAL|Blood products|Compare two different transfusion strategies against standard transfusion regimen
219740537|NCT06491576|DRUG|BGT-002|taking the study drug orally
219740538|NCT06491576|DRUG|Placebo|taking the placebo orally
219740539|NCT04190771|BEHAVIORAL|TAU + multicomponent treatment NAT-FM|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
219740540|NCT04190771|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
219740541|NCT00480025|BIOLOGICAL|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
219740542|NCT00480025|BIOLOGICAL|Placebo Control|Intramuscular administration, 13 doses
219740543|NCT03818971|OTHER|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
219740544|NCT01310114|BIOLOGICAL|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
219740545|NCT01310114|DRUG|Placebo|Thawed placebo
219740546|NCT04920825|DIETARY_SUPPLEMENT|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
219740547|NCT04920825|DIETARY_SUPPLEMENT|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
219740548|NCT05940649|PROCEDURE|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
219246565|NCT00187122|DRUG|Methotrexate|See Detailed Description section for description of treatment plan.
219246566|NCT00187122|DRUG|Mercaptopurine|See Detailed Description section for description of treatment plan.
219246567|NCT00187122|DRUG|Etoposide|See Detailed Description section for description of treatment plan.
219246568|NCT00187122|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
219246569|NCT00187122|DRUG|Prednisone|See Detailed Description section for description of treatment plan.
219246570|NCT00187122|DRUG|Dexamethasone|See Detailed Description section for description of treatment plan.
219246571|NCT02032420|BEHAVIORAL|STAR|
219246572|NCT02032420|BEHAVIORAL|ART|
219246573|NCT03451994|OTHER|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
219246574|NCT05788406|OTHER|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
219246575|NCT01001637|DIETARY_SUPPLEMENT|Curcumin Formulation|2000mg or 3000mg daily BID
219246576|NCT01001637|DIETARY_SUPPLEMENT|Placebo|Placebo
219246577|NCT03869541|OTHER|Mobilization|Physical rehabilitation
219246578|NCT02524951|DRUG|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
219246579|NCT01171885|DRUG|0.9% saline|20 ml of 0.9% saline
219246580|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.25%.
219246581|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.5%.
219246582|NCT05582421|DRUG|Diclofenac Sodium|intracanal medication
219246583|NCT03045302|DRUG|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
219246584|NCT01248663|PROCEDURE|antecolic reconstruction|see study arm description
219246585|NCT01248663|PROCEDURE|retrocolic reconstruction|see study arm description
219246586|NCT01995253|DEVICE|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
219246587|NCT01995253|DEVICE|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
219246588|NCT04409132|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
219246589|NCT02633345|DIETARY_SUPPLEMENT|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
219246590|NCT02633345|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219246591|NCT01063127|OTHER|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
219246592|NCT01063127|OTHER|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
219246593|NCT02971995|DEVICE|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
219246594|NCT02971995|DEVICE|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
219246595|NCT00737997|DRUG|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
219246596|NCT00737997|OTHER|Saline|10 ml saline alone
219246597|NCT05703477|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
219246598|NCT05287178|BEHAVIORAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
219246599|NCT01102985|BEHAVIORAL|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
219246600|NCT01102985|BEHAVIORAL|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
219246601|NCT01889277|DRUG|MT-3995-Low|
219246602|NCT01889277|DRUG|MT-3995-High|
219246603|NCT01889277|DRUG|Placebo|
219246604|NCT02037750|BEHAVIORAL|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
219246605|NCT00398749|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length
219246606|NCT02038803|DRUG|TOBIpodhaler|
219246607|NCT06369987|DEVICE|Deleficon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia.
219246608|NCT06369987|DEVICE|Senofilcon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia
219246609|NCT05073835|DRUG|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
219246610|NCT05073835|DRUG|Placebo|Placebo
219246611|NCT05419921|DIAGNOSTIC_TEST|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, \& did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
219740549|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
219740550|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
219740551|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
219246612|NCT05978947|DEVICE|ZyMōt Multi 850µL device|The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
219246613|NCT05978947|DEVICE|Density Gradient Centrifugation Method|Density gradient centrifugation is a laboratory technique used to separate and isolate different types of cells or particles based on their density. It is commonly used in various applications, including cell biology, immunology, and assisted reproductive technology (ART).
219246614|NCT02954276|DRUG|Omexa Sublingual Sumatriptan tablet|75 mg
219246615|NCT02954276|DRUG|Imitrex Oral Product|100 mg
219246616|NCT03658395|PROCEDURE|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
219246617|NCT03658395|PROCEDURE|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
219246618|NCT03312621|BEHAVIORAL|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
219246619|NCT01855399|BEHAVIORAL|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
219246620|NCT01855399|BEHAVIORAL|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
219246621|NCT01753674|DIETARY_SUPPLEMENT|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
219246622|NCT01753674|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
219246623|NCT03953079|DRUG|Drug: GB-102|Intravitreal injection of GB-102
219246624|NCT03953079|DRUG|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
219246625|NCT05550441|DRUG|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
219246626|NCT05550441|DRUG|Placebo|The Placebo group received placebo for 1 year.
219246627|NCT04394624|DRUG|SAR408701|Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
219246628|NCT04394624|DRUG|ramucirumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
219246629|NCT04394624|DRUG|pembrolizumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
219246630|NCT04306081|DRUG|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
219246631|NCT04306081|OTHER|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
219246632|NCT04004806|DEVICE|Hill Rom tracking device|Location tracking devices from Hill Rom company.
219246633|NCT01165944|DRUG|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
219246634|NCT06550674|GENETIC|Constitutional exome analysis|"For each patient included:~* A family tree is drawn up, reporting personal and family histories of cancer. The patient's anatomopathological reports, related to his or her tumor lesions, are retrieved, in order to confirm/clarify individual or family diagnoses.~* A blood sample and a jugal smear are taken to enable constitutional genetic exome analysis for research purposes."
219246635|NCT01026207|DEVICE|Polysomnography|Sleep study polysomnography compared with portable monitoring
219246636|NCT04617574|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
219246637|NCT04617574|DEVICE|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
219246638|NCT04236700|OTHER|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
219246639|NCT00254241|DRUG|Seroquel and Risperidone|
219246640|NCT00998517|DIETARY_SUPPLEMENT|Soy/peanut fortified spread|75kcal/kg/day
219246641|NCT00998517|DIETARY_SUPPLEMENT|Milk fortified corn/soy blend|75 kcal/kg/day
219246642|NCT00998517|DIETARY_SUPPLEMENT|Supplementary Plumpy®|75 kcal/kg/day
219246643|NCT06186349|GENETIC|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
219740552|NCT06480461|DRUG|VGN-R09b|This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
219246644|NCT03742882|DRUG|CC-90001|CC-90001
219246645|NCT01992276|BIOLOGICAL|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
219246646|NCT01992276|BIOLOGICAL|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
219246647|NCT01992276|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
219246648|NCT04439591|OTHER|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
219740553|NCT00966446|DRUG|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
219740554|NCT00966446|DRUG|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
219740555|NCT02189629|DRUG|CD5789 (trifarotene)|
219740556|NCT01043029|DRUG|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
219740557|NCT01043029|DRUG|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
219740558|NCT03726879|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
219740559|NCT03726879|DRUG|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
219740560|NCT03726879|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
219740561|NCT03726879|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
219740562|NCT03726879|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
219740563|NCT03726879|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
219740564|NCT03726879|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
219740565|NCT03726879|DRUG|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
219740566|NCT02766478|DRUG|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
219740567|NCT02766478|DRUG|Placebo|A placebo pill will be taken orally for 12 weeks.
219740568|NCT01093573|DRUG|midostaurin|Given orally
219740569|NCT01093573|DRUG|azacitidine|Given IV
219740570|NCT01093573|OTHER|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
219740571|NCT01093573|OTHER|mutation analysis|Correlative study
219740572|NCT01093573|OTHER|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
219740573|NCT02577575|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
219740574|NCT02577575|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
219740575|NCT05626686|DEVICE|CLINY catheter|Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
219740576|NCT05705804|DRUG|Pitavastatin|Pitavastatin 4 mg will be given.
219740577|NCT05705804|DRUG|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
219740578|NCT05705804|DRUG|Atorvastatin|Atorvastatin 40 mg will be given.
219740579|NCT00944840|DRUG|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
219740580|NCT00944840|DRUG|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
219740581|NCT06290037|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
219740582|NCT06290037|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
219740583|NCT06290037|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
219740584|NCT06290037|OTHER|Short Physical Performance Battery|Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
219740585|NCT06290037|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
219740586|NCT00023972|DRUG|exatecan mesylate|
219740587|NCT00023972|DRUG|gemcitabine hydrochloride|
219246649|NCT00372476|DRUG|Imatinib and Vinorelbine|
219246650|NCT02648555|BEHAVIORAL|Daily walking|Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.
219740588|NCT06354842|DIAGNOSTIC_TEST|pilocarpine iontopheresis|Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
219740589|NCT03708770|DEVICE|everlinQ endoAVF System|
219246651|NCT02648555|BEHAVIORAL|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
219246652|NCT00504205|DRUG|multitargeted receptor tyrosine kinase inhibitor MP470|
219246653|NCT00504205|OTHER|laboratory biomarker analysis|
219246654|NCT00504205|OTHER|pharmacological study|
219740590|NCT00901095|BEHAVIORAL|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
219740591|NCT05253326|OTHER|Progressive Muscle Relaxation Exercises|It is among the relaxation techniques that require the active participation of the individual.
219740592|NCT00098761|DRUG|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
219246655|NCT00504205|PROCEDURE|positron emission tomography|
219246656|NCT04728100|OTHER|LQT|Patients with LQT syndrome diagnosis.
219246657|NCT04806659|DRUG|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
219246658|NCT04413188|OTHER|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
219246659|NCT03471884|PROCEDURE|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
219246660|NCT03471884|PROCEDURE|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
219246661|NCT06272526|OTHER|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
219246662|NCT05953025|BEHAVIORAL|Questionnaire|No intervention on care- questionnaire to see effect of standard care treatment on symptoms
219246663|NCT03480815|DEVICE|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
219246664|NCT03480815|OTHER|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
219246665|NCT05080348|PROCEDURE|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
219246666|NCT05080348|PROCEDURE|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
219246667|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
219246668|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
219246669|NCT00141271|DRUG|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
219246670|NCT00816205|DRUG|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
219246671|NCT01249144|DEVICE|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
219246672|NCT00104442|DRUG|Rivastigmine|
219246673|NCT06176131|OTHER|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
219246674|NCT00990314|DRUG|Beraprost Sodium Modified Release|
219246675|NCT04749641|BIOLOGICAL|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
219246676|NCT03139045|BIOLOGICAL|Venous puncture in elderly patients|Venous puncture in elderly patients
219246677|NCT04623996|DRUG|TP-0184|Oral dose
219246678|NCT02355106|DEVICE|PolarStart System|Atrial flutter Ablation
219246679|NCT00380809|PROCEDURE|Rotational Atherectomy + PES|
219246680|NCT00380809|PROCEDURE|Standard Treatment (PES without Rotational Atherectomy)|
219740593|NCT04875845|BEHAVIORAL|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
219740594|NCT04444297|OTHER|3D Telemedicine|A consultation performed with a 3D form of telemedicine
219740595|NCT04444297|OTHER|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
219740596|NCT04924452|PROCEDURE|Laser conditioning and Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
219740597|NCT04924452|PROCEDURE|Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
219246681|NCT00587405|PROCEDURE|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
219246682|NCT00587405|PROCEDURE|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
219246683|NCT02704156|DEVICE|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
219246684|NCT02704156|DEVICE|Cyberknife plus Gemcitabine|Radiation therapy plus drug
219246685|NCT03584282|BEHAVIORAL|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
219246686|NCT03584282|BEHAVIORAL|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
219246687|NCT02978040|DRUG|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
219246688|NCT02978040|DRUG|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
219246689|NCT02978040|DRUG|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
219246690|NCT01798537|DRUG|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
219246691|NCT05111340|BEHAVIORAL|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
219246692|NCT03430362|DRUG|Hyoscine N Butylbromide|7\. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
219246693|NCT03430362|DRUG|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
219246694|NCT00255242|DRUG|Simvastatin treatment for 28 days|40 mg / day
219246695|NCT04834167|DEVICE|OneDoc Picopulse|Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
219246696|NCT00147394|DRUG|Risperidone|
219246697|NCT02995278|OTHER|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
219246698|NCT02932124|DEVICE|mechanical chest compression device|
219246699|NCT04578691|DEVICE|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
219246700|NCT04578691|DEVICE|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
219246701|NCT02195180|DRUG|ERY001|
219246702|NCT02195180|DRUG|Gemcitabine|
219246703|NCT02195180|DRUG|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
219246704|NCT04711018|DIAGNOSTIC_TEST|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
219246705|NCT05652985|BEHAVIORAL|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
219246706|NCT01217294|PROCEDURE|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
219246707|NCT01217294|PROCEDURE|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
219246708|NCT04472715|PROCEDURE|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
219174329|NCT05447689|BEHAVIORAL|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
219174330|NCT05633953|DRUG|Osilodrostat|oral administration
219174331|NCT06042387|GENETIC|Blood or saliva sample collection|Blood or saliva sample \& clinical data collection
219174332|NCT03839342|DRUG|Binimetinib|MEK inhibitor, 45mg oral tablet
219174333|NCT03839342|DRUG|Encorafenib|BRAF inhibitor, 450mg oral capsule
219174334|NCT05324124|DRUG|Selpercatinib|Administered orally.
219174335|NCT02026843|DRUG|Chorioretinal diseases|chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
219174336|NCT05585580|DRUG|Serplulimab|300mg d1 q3w
219174337|NCT05585580|DRUG|Lenvatinib|8mg po qd
219174338|NCT05585580|DRUG|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
219174339|NCT03643861|RADIATION|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
219174340|NCT05142059|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
219174341|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
219174342|NCT05935059|DRUG|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
219174343|NCT05935059|DRUG|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
219174344|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
219174345|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
219174346|NCT03706170|BEHAVIORAL|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
219174347|NCT03706170|BEHAVIORAL|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
219174348|NCT03410615|RADIATION|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
219174349|NCT03410615|DRUG|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
219174350|NCT03410615|DRUG|Durvalumab|Given in concurrent and adjuvant phase
219246709|NCT04229940|PROCEDURE|Peritoneal bridging|The defect is covered by peritoneal bridging
219174351|NCT03410615|DRUG|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
219174352|NCT03800550|DRUG|Bedaquiline|Bedaquiline tablet will be administered, orally.
219174353|NCT03800550|DRUG|Clarithromycin|Clarithromycin tablet will be administered, orally.
219174354|NCT05876858|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
219174355|NCT05876858|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
219174356|NCT04643379|DRUG|Olaparib|Supplied by Merck \& Co.
219174357|NCT04643379|DRUG|Pembrolizumab|Supplied by Merck \& Co.
219174358|NCT04643379|DRUG|Carboplatin|Commercially available
219174359|NCT04643379|PROCEDURE|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
219246710|NCT04229940|PROCEDURE|No peritoneal bridging|The defect is left without bridging
219246711|NCT00253851|DRUG|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
219246712|NCT05360771|DEVICE|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
219246713|NCT05360771|DEVICE|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
219246714|NCT04853394|BEHAVIORAL|MASLIHAT|peer educator intervention
219174360|NCT03818659|OTHER|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
219174361|NCT03818659|OTHER|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
219246715|NCT04853394|BEHAVIORAL|TANSIHAT|health education intervention
219246716|NCT04212299|DEVICE|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
219246717|NCT00943371|DRUG|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
219246718|NCT00943371|DRUG|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
219246719|NCT00715182|DRUG|TKI258|
219246720|NCT03754166|OTHER|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
219174362|NCT04969419|OTHER|Exposure of skin cancer of interest|Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.
219246721|NCT07008339|PROCEDURE|Areola Micropigmentation|Areola micropigmentation performed by trained nurses
219246722|NCT07008339|DEVICE|Hyaluronic Acid Filler Injection|Subcutaneous injection of cross-linked hyaluronic acid filler (Juvederm®) for nipple projection.
219246723|NCT07009574|DRUG|anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization|"All patients underwent one intravitreal injection at baseline (0.5 mg ranibizumab or 2.0 mg aflibercept); additional intravitreal injections were administered over the follow-up period based on the above-mentioned activity signs with a pro-re-nata (PRN) treatment protocol. The patients have been followed on a monthly or bimonthly basis. The number of visits and examinations in the 12-month study period will be collected.~Clinical and imaging data of the baseline examination as well as of the 12-month visit (M12) after the first intravitreal injection."
219246724|NCT07009652|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|Extracorporeal cardiopulmonary resuscitation (commonly known as ECPR) is a method of cardiopulmonary resuscitation (CPR) that passes the patient's blood through a machine in a process to oxygenate the blood supply.
219246725|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from reinforced resin|A comprehensive clinical examination with an understanding of patients' chief complaints and needs will be carried out. For each patient, two implants will be placed in the edentulous area, and the patient will receive a screw-retained bridge supported by both implants made of milled monolithic zirconia (Dental Direkt Zirconia, Germany). After 6 months, the zirconia restoration will be replaced with a milled resin-reinforced composite (Nanoska G Plus, USA), allowing the same patient to use the new restoration for another 6 months. Randomization will be performed to determine the sequence of bridge material for each participant. Accordingly, the two restorations will be sequentially delivered to each participant with no gap (wash-up period) between them. Consent will be signed by the selected participants after explaining the detailed information of the trial.
219246726|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia
219174363|NCT00200200|DRUG|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
219174364|NCT00200200|DRUG|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
219174365|NCT03772743|OTHER|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
219174366|NCT03772743|OTHER|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
219174367|NCT04363515|BEHAVIORAL|Social support network counseling intervention|Pilot social support counseling intervention for kidney transplant candidates along with their social support networks
219174368|NCT05091593|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
219174369|NCT05091593|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
219174370|NCT05247489|DRUG|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
219174371|NCT05247489|DEVICE|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
219174372|NCT03467360|DRUG|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
219174373|NCT03467360|DRUG|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
219174374|NCT03771898|DRUG|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
219174375|NCT05515367|DRUG|Desidustat|Oral tablet
219174376|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
219174377|NCT05257135|BIOLOGICAL|Biological collection|\- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
219174378|NCT05708833|DEVICE|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
219174379|NCT05708833|DEVICE|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
219174380|NCT05026541|BEHAVIORAL|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
219174381|NCT05026541|BEHAVIORAL|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
219174382|NCT05316740|OTHER|No intervention|Repeated clinical evaluation and sample collection
219174383|NCT04541706|DRUG|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
219174384|NCT06476002|OTHER|Questionnaire|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
219174385|NCT06495008|OTHER|no intervention, only questionnaires, saliva collection and taste/smell tests|no intervention, only questionnaires, saliva collection and taste/smell tests
219174386|NCT05534620|DRUG|Treosulfan|IV infusion
219174387|NCT05534620|DRUG|Fludarabine|IV infusion
219174388|NCT05563246|DRUG|LY3473329|Administered orally
219174389|NCT05563246|DRUG|Placebo|Administered orally
219174390|NCT05651399|DRUG|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
219174391|NCT05651399|DRUG|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
219174392|NCT02167867|DEVICE|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
219174393|NCT02167867|DEVICE|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
219174394|NCT06280989|OTHER|kinesio taping|"Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,."
219174395|NCT06280989|OTHER|myofascial release technique|"myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus."
219174396|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
219174397|NCT06639256|DRUG|Test Product HY07121|HY07121 should be administered intravenously at recommended dose.
219174398|NCT06641232|PROCEDURE|Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.|"The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block."
219174399|NCT05537727|DEVICE|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
219174400|NCT05537727|DEVICE|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
219174401|NCT05537727|DEVICE|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
219174402|NCT04913220|DRUG|THOR-707|Solution for infusion: intravenous infusion
219174403|NCT04913220|DRUG|Cemiplimab|Solution for infusion: intravenous infusion
219174404|NCT04927065|BIOLOGICAL|mRNA-1273.211|Sterile liquid for injection
219174405|NCT04927065|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219174406|NCT04927065|BIOLOGICAL|mRNA-1273.617.2|Sterile liquid for injection
219174407|NCT04927065|BIOLOGICAL|mRNA-1273.213|Sterile liquid for injection
219174408|NCT04927065|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
219174409|NCT04927065|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219174410|NCT04927065|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
219174411|NCT04927065|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
219174412|NCT04927065|BIOLOGICAL|mRNA-1273.231|Sterile liquid for injection
219174413|NCT03406871|DRUG|Regorafenib|One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.
219174414|NCT03406871|DRUG|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
219174415|NCT06130397|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~\- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1."
219174416|NCT06130397|OTHER|Ground truthing|Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
219174417|NCT01744782|DRUG|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
219174418|NCT01747863|OTHER|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
219174419|NCT06201078|RADIATION|Stereotactic Body Radiotherapy|"Salvage SBRT will be performed in three subgroups of patients with local recurrence:~Group A - after conventionally fractionated/moderately hypofractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT~Target volumes:~GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\*~\*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm.~Dose constrains:~The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed:~* Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%)~* Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%)~Dose-volume constrains:~Rectum:~• D30% \<15Gy~Bladder:~• D30% \< 15 Gy"
219174420|NCT06510764|OTHER|intradermal needles|Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosen for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.
219174421|NCT06510764|DRUG|Ziyinxiehuo Granules of traditional Chinese Medicine|Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
219174422|NCT05847595|OTHER|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
219174423|NCT05847595|OTHER|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
219174424|NCT05847595|OTHER|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
219174425|NCT04126018|DIAGNOSTIC_TEST|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
219174426|NCT04126018|DIAGNOSTIC_TEST|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
219174427|NCT06137937|BEHAVIORAL|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
219246727|NCT07008950|OTHER|The Self-Efficacy and Knowledge Trial|The intervention is composed on 8 sessions given over a period of 8 weeks covering topics of emotional regulation, communication, problem management, decision making, self-efficacy and others in relation to sexual reproductive health, family planning, and wellbeing. The intervention package will be delivered by trained non-specialists with at least 12 years of formal education. The package will be administered once a week for a duration of 90 minutes.
219246728|NCT07009405|DEVICE|non-invasive thermal infusion site monitoring NTISM device|Non-invasive thermal infusion site monitoring NTISM device for detecting extravasation and infiltration events using thermal anisotropy measurements
219246729|NCT07007871|OTHER|Tutoring and Counselling (1)|During the intervention, students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
219246730|NCT07007871|OTHER|Tutoring and Counselling (2)|Students assigned to the waitlist control group receive the program after the experimental group completes it. Students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
219246731|NCT07009613|DIAGNOSTIC_TEST|Parasitological tests|The primary outcome was reported based on the technicians' answers collected with a structured questionnaire. The individuals screened underwent testing with the tests detailed above
219246732|NCT07009613|OTHER|Questionnaire|The primary outcome was based on the technicians' evaluation, based on their answers collected in a questionnaire. The individuals screened were tested with assays used for the national control programmes
219246733|NCT07008040|OTHER|Silver dressing|Silver dressing will be applied to the sternotomy and donor site wounds for the CABG patients
219246734|NCT07008144|OTHER|Digoxin alarm|A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
219246735|NCT07009236|DEVICE|MIGS|Implant MINIject S+ in supraciliary space
219246736|NCT07008196|DRUG|Telitacicept|Telitacicept 160mg qw subcutaneous injection
219246737|NCT07008703|DRUG|Injection of humanized nerve growth factor (NGF) antibody|Subcutaneous injection, 20mg
219246738|NCT07008820|OTHER|Health-related quality of life questionnaires|"Questionnaires include:~EORTC-QLQ C30 FACT-An PGI-S EQ-5D-5L"
219246739|NCT07008820|OTHER|Qualitative interviews|For participants that meet eligibility criteria
219246740|NCT04702191|BEHAVIORAL|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, \& Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
219246741|NCT04702191|BEHAVIORAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
219246742|NCT07009158|DRUG|Ketamine Infusion|Ketamine hydrochloride (DIN: 02246795, 02246796) will be administered over 40-min intravenous (IV) infusion twice per week on non-consecutive days for the first two weeks of study treatment (four treatment sessions in total). We will use a standard dose of 0.5mg/kg which has demonstrated efficacy in safety in individuals with PTSD.
219362695|NCT00927368|PROCEDURE|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
219740598|NCT04924452|DEVICE|Er:YAG laser therapy|Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
219740599|NCT04924452|PROCEDURE|Conventional therapy|Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
219740600|NCT06189872|DEVICE|Attune Cementless|"* Attune AFFIXIUM Cementless Tibial Baseplate, Fixed Bearing~* Attune POROCOAT Cementless Femoral Component, Cruciate Retaining~* Attune AOX Antioxidant Polyethylene Tibial Insert, Cruciate Retaining~* Attune AOX Patellar Button, Domed or Medialized Dome, Cemented or Cementless (surgeon preference for resurfacing)"
219246743|NCT07009158|BEHAVIORAL|Mindfulness-based cognitive therapy|The Mindfulness-based cognitive therapy (MBCT) will be an 8-week group program adapted from a protocol developed to treat PTSD to include psychoeducation about chronic pain and mutual maintenance factors through which chronic pain and PTSD facilitate each other. The MBCT group will be delivered by trained professionals in weekly 2-hour sessions through Microsoft Teams. The 8-week program will include 1) mindfulness techniques; 2) psychoeducation regarding chronic pain, PTSD and stress responses; 3) psychoeducation on mutual maintenance factors that contribute to negative interactions between pain and PTSD symptoms, 4) promoting mindful awareness of these factors' impact on daily life and 5) feedback and supportive group discussion of exercises. Participants will be asked to complete daily mindfulness exercises between sessions to practice skills learned for a recommended minimum of 20 minutes per day.
219246744|NCT06634199|DRUG|Durvalumab|Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
219246745|NCT06721806|PROCEDURE|PRP & bone regeneration|PRP effect on bone healing
219246746|NCT06720129|DEVICE|the modified pressure-reducing fixation protective nasal strip|Materials Preparation consists of one foam dressing, one piece of 3M tape, and two pairs of scissors. 2. Manufacturing Procedure: step 1 Cut the foam dressing into two large rectangles and one little T-shape based on the patient's face shape and size as well as the width of the nasolabial fold. Attach these sections to the nasolabial fold region and both cheeks, respectively . Step 2: Based on the size of the oxygen cannula, set up small, medium, and large fixation patch models. Select the appropriate model according to the patient's condition and make the necessary cuts to properly secure the nasal prongs. Step 3: Check the tightness of the head strap, ensuring it is snug enough to fit one finger beneath it to avoid pressing on the skin around the ears. Ensure proper placement on the patient. See Figure 1 for detailed application.
219246747|NCT06720129|DEVICE|Standard care alone|standard care plus a hydrocolloid dressing for protection
219246748|NCT06703099|DIETARY_SUPPLEMENT|Magnesium Supplementation|Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning over 8 weeks.
219246749|NCT06720493|DEVICE|echocardiographic assessment of shocked patients to fluid administration|hemodynamic assessment of pediatric shocked patients using different modalities like echocardiography and electrical cardiometry
219246750|NCT03476538|DRUG|Gabapentin|Patients are tested for their normal prescription gabapentin medication
219246751|NCT06900140|DRUG|Methylene Blue|Continuous methylene blue infusion at a fixed dose of 0.50 mg/kg/hour (diluted in 500 mL of dextrose 5% in water) over 6 hours once daily, for a total of up to 3 doses.
219246752|NCT06900140|OTHER|Usual Care|Usual guideline-directed care for adult septic shock.
219246753|NCT03728803|DEVICE|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
219246754|NCT04728217|DRUG|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
219246755|NCT04414254|DRUG|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
219246756|NCT00657475|DRUG|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
219246757|NCT00657475|DRUG|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
219246758|NCT01414725|OTHER|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
219246759|NCT01414725|OTHER|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
219246760|NCT01414725|OTHER|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
219246761|NCT01239537|DRUG|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
219246762|NCT06309849|OTHER|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique)|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique) strengthening exercises for neck muscles, ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2.
219246763|NCT04389918|OTHER|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
219246764|NCT01151878|DIETARY_SUPPLEMENT|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
219246765|NCT01151878|DIETARY_SUPPLEMENT|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
219246766|NCT03950596|OTHER|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
219246767|NCT03950596|BEHAVIORAL|Background Questionnaire|Background questionnaire will be filled out by participants
219174428|NCT05401630|OTHER|Study Procedures|"All participants will answer a series of questionnaires that address several factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours before testing. Participants will also undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use.~A 3-day food recall diary, cognitive assessments via the NIH Toolbox, and a Sleep diary during home monitoring will be collected."
219174429|NCT05661552|DRUG|Evolocumab 140 MG/ML|Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe
219174430|NCT05661552|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg will be assigned to all participants
219174431|NCT05661552|DRUG|Ezetimibe 10mg|Ezetimibe 10mg will be assigned to all participants
219174432|NCT04294290|BIOLOGICAL|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
219174433|NCT06470971|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody|Receive anti-PD-L1 monoclonal antibody therapy
219174434|NCT06470971|BIOLOGICAL|Anti-PD1 Monoclonal Antibody|Receive anti-PD1 monoclonal antibody therapy
219174435|NCT06470971|PROCEDURE|Biopsy|Undergo biopsy
219174436|NCT06470971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219174437|NCT06470971|PROCEDURE|Bone Scan|Undergo bone scan
219174438|NCT06470971|PROCEDURE|Computed Tomography|Undergo CT
219174439|NCT06470971|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219174440|NCT06470971|OTHER|Quality-of-Life Assessment|Ancillary studies
219246768|NCT03950596|OTHER|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
219174441|NCT06470971|BIOLOGICAL|Siltuximab|Given IV
219174442|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
219174443|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
219246769|NCT03950596|GENETIC|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
219246770|NCT03950596|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
219246771|NCT03950596|DIAGNOSTIC_TEST|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
219246772|NCT00312364|DRUG|MRE0094|
219246773|NCT04693650|DEVICE|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
219246774|NCT05964270|DEVICE|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
219246775|NCT04809298|DEVICE|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
219246776|NCT04809298|DEVICE|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
219246777|NCT02878590|DEVICE|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
219246778|NCT01178281|DRUG|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
219246779|NCT01178281|DRUG|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
219246780|NCT01178281|DRUG|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
219362696|NCT01079481|DRUG|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
219362697|NCT02624492|DRUG|BI 836826|
219246781|NCT00541840|DRUG|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
219246782|NCT00329498|DRUG|L-Ascorbic Acid|
219246783|NCT05017688|PROCEDURE|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
219246784|NCT00826371|DRUG|ranibizumab 0.5 mg|
219246785|NCT02440646|RADIATION|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
219246786|NCT02440646|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
219246787|NCT04488978|DRUG|Irbesartan/Amlodipine|QID
219246788|NCT00549861|PROCEDURE|Cardiac Magnetic Resonance study|Cardiac MRI study
219174444|NCT05982015|DEVICE|Remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
219246789|NCT03586141|DIAGNOSTIC_TEST|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
219246790|NCT03292198|OTHER|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
219246791|NCT03292198|OTHER|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
219246792|NCT05451641|BEHAVIORAL|Blood flow restriction resistance training|The participants will receive a 2-week exercise training program (3 times per week). Each training session will consist of 3 resistance training exercises with two blood flow restriction devices (wide-rigid cuff and narrow-elastic band). For both arms, the participants will perform the same exercise with different BFR devices.
219246793|NCT03163836|PROCEDURE|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
219246794|NCT03163836|PROCEDURE|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
219246795|NCT00192322|BIOLOGICAL|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
219246796|NCT00192322|BIOLOGICAL|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T \<10\^5
219246797|NCT00192322|BIOLOGICAL|Placebo|a single intranasal 0.2 mL dose of placebo
219740601|NCT03224377|DIAGNOSTIC_TEST|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
219740602|NCT00072579|BIOLOGICAL|sargramostim|
219174445|NCT05982015|DEVICE|Sham remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
219174446|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy with a radiologist's guidance with map|All patients will undergo prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after mapping extracted by a single genitourinary radiologist in the Department of Radiology of our hospital.
219174447|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy without a radiologist's guidance with map|All patients will undergo cognitive prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after reported by a single genitourinary radiologist in the Department of Radiology of our hospital.
219174448|NCT06298487|OTHER|Patient questionnaires|Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
219174449|NCT04729686|DRUG|Pericapsular Nerve Block|Per Standard Institutional Practice
219174450|NCT04729686|DRUG|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
219174451|NCT05923385|DIAGNOSTIC_TEST|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
219174452|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
219174453|NCT04588896|DEVICE|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
219174454|NCT04588896|BEHAVIORAL|Lifestyle modification programme|Lifestyle modification programme
219174455|NCT06184373|DEVICE|Continuous glucose monitor|CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
219246798|NCT00192322|BIOLOGICAL|TIV|commercially available TIV injected intramuscularly
219362698|NCT02624492|DRUG|GemOx|
219740603|NCT06660030|OTHER|No intervention|No intervention
219740604|NCT04816292|PROCEDURE|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
219740605|NCT04816292|PROCEDURE|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
219740606|NCT05238220|DRUG|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
219740607|NCT04604093|DEVICE|SMBG Meter|Self Monitoring Blood Glucose Meter
219174456|NCT06184373|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
219174457|NCT06184373|DIAGNOSTIC_TEST|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
219174458|NCT05463887|BEHAVIORAL|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
219174459|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
219174460|NCT06515132|PROCEDURE|SCS Stimulation|Participants will accept the SCS stimulus for six months
219174461|NCT06515132|PROCEDURE|Sham Stimulation|Sham stimulation will be performed in the first three months after surgery, and SCS stimulation will be started in the fourth month after surgery
219246799|NCT01860495|PROCEDURE|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
219246800|NCT01860495|PROCEDURE|G2|tradetional occlusive collagen membrane
219246801|NCT01984853|OTHER|OBSERVATIONAL REGISTRY|
219246802|NCT00672672|BIOLOGICAL|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
219246803|NCT06047379|DRUG|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
219246804|NCT06047379|DRUG|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
219246805|NCT06047379|DRUG|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
219246806|NCT06047379|DRUG|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
219246807|NCT06047379|DRUG|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
219246808|NCT06047379|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
219246809|NCT06047379|DRUG|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
219246810|NCT06047379|DRUG|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
219362699|NCT02624492|DRUG|Rituximab|
219362700|NCT02624492|DRUG|GemOx|
219740608|NCT04604093|DEVICE|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
219740609|NCT06673797|OTHER|Effects of Swiss Ball exercises|"Effects of Swiss ball exercises along with stretching as baseline treatment.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times.~2. Swiss ball exercises. a.Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest. b.Sitting on the Swiss ball with trunk straight and arm by the sides. The therapist would assist the patient to engage the patient in shifting the body's weight to one side and the other side sideways as well as anterior and posterior and up and down alternatively. Start with 10 repetitions. c. Standing with gym ball in front. The therapist would stand behind the patient to provide support and ask the patient to lean forward on the gym ball with both hands via outstretched arms. Start with 10 repetitions d. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support. Start with 10 repetitions"
219740610|NCT06673797|OTHER|EFFECTS OF FRENKEL EXERCISES ON STATIC AND DYNAMIC BALANCE IN ATAXIC CHILDREN WITH CEREBRAL PALSY|"Frenkel Exercises along with stretching as baseline treatment. The second intervention group would participate in Frenkel Exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   a. Calf stretching. b. Hamstring stretches. c. Quads stretching~2. Frenkel\&#39;s lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice. (12)~   1. Supine lying~  2. While sitting~  3. Stride standing"
219740611|NCT06675981|OTHER|Real Acupuncture|Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
219740612|NCT06675981|OTHER|Non-acupuncture at real-acupoint|The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
219740613|NCT06675981|OTHER|Shallow acupuncture at real-acupoint|At the same acupoint in the acupuncture group, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
219740614|NCT06675981|OTHER|Shallow acupuncture at non-meridian and non-acupoint|At non-meridian and non-acupoint, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
219740615|NCT06535321|OTHER|vibration training|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
219740616|NCT06535321|OTHER|vibration training|For the vibration group, vibration training was performed immediately after DOMS modelling.
219740617|NCT06535321|OTHER|Y-shaped kinesio taping|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
219740618|NCT06535321|OTHER|Combined vibration training and Y-shaped kinesio taping|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
219740619|NCT00176254|RADIATION|Radiotherapy|80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
219246811|NCT06047379|DRUG|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
219246812|NCT02228083|DRUG|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
219246813|NCT00156377|DRUG|Mupirocin|
219246814|NCT03562897|DIETARY_SUPPLEMENT|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
219246815|NCT06164769|PROCEDURE|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
219246816|NCT04890483|DEVICE|Transcranial direct current stimulation|tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
219246817|NCT06529783|OTHER|Shockwave Therapy|The proposed model for radial shockwave therapy at Clínica Osteopática Dr. David Ponce is the DolorClast® by EMS, made in Nyon, Switzerland. Treatment parameters include 2500 impulses, 0.2 mJ/mm² energy density, and 15 pulses per second, using a 15 mm diameter applicator with ultrasound gel applied to the treatment area. The patient will be positioned laterally on the table with specific leg positions to ensure comfort and effectiveness.
219246818|NCT06529783|OTHER|Therapeutic Exercises|The exercise protocol was followed daily, with continuous physiotherapist supervision to ensure correct execution and avoid improper postures. The protocol includes four exercises: bilateral low-load supine abduction, unilateral isometric hip abduction in medial rotation, hip abduction with sliding, and bilateral supported glute bridge. A maximum of 4/10 on the VAS pain scale is allowed during exercise; exceeding this threshold means skipping exercises for that day.
219246819|NCT06529783|OTHER|Ultrasound-Guided Percutaneous Neuromodulation:|"This technique was applied only to the experimental group before shockwave therapy. An ultrasound-guided approach to the superior gluteal nerve used a 7-12 MHz linear probe from Esaote MyLab™Alpha and Physio Invasiva® equipment. The needle length varied with patient anatomy, with a typical safety reference from 0.30 x 60 to 0.35 x 70 mm. A biphasic current with 10 Hz frequency and 240 μs pulse width was used, with intensity adjusted for a visible but non-painful motor response, following the 10-10-10 protocol.~To locate the superior gluteal nerve, a longitudinal scan of the lateral iliac crest identified the nerve between the gluteus minimus and medius. The procedure used a short-axis approach at 80º to target the nerve's perineurium, with the area disinfected with chlorhexidine before needle insertion."
219246820|NCT06846463|DRUG|Zanubrutinib|Investigational Agent Administration. Zanubrutinib will be first administered on Cycle 2 Day 1 of rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP). It is up to the discretion of the treating physician how many cycles of R-CHOP the treatment would require, but it is not to exceed 6 cycles of R-CHOP and 5 cycles of zanubrutinib. The number of cycles of R-CHOP should be per standard of care, with the number of zanubrutinib cycles being 1 less than the number of total R-CHOP cycles.
219246821|NCT05335005|DRUG|MK-2060|MK-2060 administered via IV infusion
219246822|NCT04462653|DEVICE|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
219246823|NCT04462653|DEVICE|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
219246824|NCT01181206|PROCEDURE|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
219246825|NCT00527371|DEVICE|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
219246826|NCT00527371|PROCEDURE|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
219246827|NCT03194789|DEVICE|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
219246828|NCT03194789|OTHER|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
219246829|NCT05664711|DRUG|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
219246830|NCT02028234|DRUG|Pantoprazole,|os, 20 mg, once per day, for 30 days
219246831|NCT02028234|DRUG|Omeprazole|os, 20 mg, once per day, for 30 days
219246832|NCT01580462|OTHER|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
219246833|NCT06487897|DEVICE|Optimal laser keratoplasty|Laser
219246834|NCT02848885|OTHER|Active TDCS|Participants will receive active tDCS stimulation.
219246835|NCT02848885|OTHER|Sham TDCS|Participants will receive sham tDCS stimulation
219246836|NCT01602003|DRUG|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
219246837|NCT01602003|DRUG|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
219246838|NCT01602003|DRUG|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
219246839|NCT03684356|PROCEDURE|socket shield technique|immediate implant placement with buccal part of the root is retained
219246840|NCT03684356|PROCEDURE|xenograft|immediate implant placement with filling the buccal gap with xenograft
219246841|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
219246842|NCT05499247|OTHER|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
219246843|NCT01291043|OTHER|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
219246844|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
219246845|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
219246846|NCT04611048|DIAGNOSTIC_TEST|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
219740620|NCT00176254|DRUG|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
219740621|NCT00176254|DRUG|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
219740622|NCT06678997|DEVICE|Zinc-L carnosine/Polaprezinc|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
219740623|NCT06678997|OTHER|Thickened formula|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
219740624|NCT06678503|OTHER|balance exercise|Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).
219740625|NCT06678503|OTHER|Core stability exercises|"Core stability exercises are physical activities designed to improve the strength, endurance, and coordination of the muscles that support and stabilize the spine, pelvis, and torso. These exercises specifically target the muscles of the abdomen, lower back, hips, and pelvis, collectively referred to as the core. The goal is to enhance overall posture, prevent injury, and improve performance in daily activities or sports by increasing the body's ability to stabilize itself during movement."
219740626|NCT06618534|DRUG|Azithromycin|A standard dose of azithromycin (500 mg) will be delivered by oral route.
219174462|NCT05257850|DEVICE|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
219174463|NCT05257850|DEVICE|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
219174464|NCT01413100|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219174465|NCT01413100|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
219174466|NCT01413100|DRUG|Cyclophosphamide|Given IV
219174467|NCT01413100|BIOLOGICAL|Filgrastim|Given SC
219174468|NCT01413100|OTHER|Laboratory Biomarker Analysis|Correlative studies
219174469|NCT01413100|DRUG|Mycophenolate Mofetil|Given PO
219174470|NCT01413100|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
219174471|NCT01413100|DRUG|Plerixafor|Given SC
219174472|NCT01413100|OTHER|Quality-of-Life Assessment|Ancillary studies
219174473|NCT01413100|OTHER|Questionnaire Administration|Ancillary studies
219174474|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
219174475|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
219174476|NCT06310967|DRUG|IG3018|Oral administration
219174477|NCT06310967|OTHER|Placebo matching IG3018|Oral administration
219174478|NCT06437977|RADIATION|SBRT|SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
219174479|NCT06437977|DRUG|Toripalimab|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
219174480|NCT05369403|DRUG|Lebrikizumab|Administered SC
219174481|NCT04207814|BIOLOGICAL|biological sample|biological samples will be taken from the subjects included
219174482|NCT05402930|DIAGNOSTIC_TEST|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
219174483|NCT04750525|DEVICE|BreEStim|120 BreEStim stimuli will applied for about 10-30 minutes.
219174484|NCT04750525|DEVICE|EStim|120 EStim stimuli will applied for about 10-30 minutes.
219740627|NCT06674876|BEHAVIORAL|Blog writing|Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
219740628|NCT06623266|PROCEDURE|Neck management|"In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions."
219740629|NCT06679452|OTHER|Emotion-Focused Therapy|This feasibility protocol is a two-arm, parallel, double-blinded, RCT aimed at informing a future trial assessing the effectiveness of EFT in resolving emotional injuries in older adults in the context of interpersonal offenses.
219740630|NCT06691607|OTHER|Serum NGAL level|serum NGAL level
219740631|NCT06691347|BEHAVIORAL|Eye movement desensitization and reprocessing|Psychotherapy with EMDR. A therapist guides the client in recalling distressing events while simultaneously following a stimulus, like a moving light or tapping. The idea is that this bilateral stimulation helps reduce the intensity of the traumatic memory, allowing clients to gain perspective and lessen emotional distress associated with it. The standard treatment protocol includes up to 24 weekly sessions.
219740632|NCT06691347|BEHAVIORAL|Cognitive therapy for PTSD|"Psychotherapy with CT-PTSD. A therapist works with the client to understand how they interpret their trauma and identify distorted thinking patterns that fuel their PTSD symptoms. Through guided discussions, written exercises, and sometimes re-living the trauma in a controlled way, clients learn to reshape these beliefs, gain a more balanced perspective, and reduce symptoms like hypervigilance, flashbacks, and avoidance behaviors. The standard treatment protocol includes up to 24 weekly sessions."
219740633|NCT00941421|DEVICE|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
219740634|NCT06686823|BEHAVIORAL|Health Education Program|n informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
219174485|NCT05612971|BEHAVIORAL|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
219174486|NCT05612971|BEHAVIORAL|iAmHealthy|The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
219174487|NCT05744869|BEHAVIORAL|SBAT Implementation|Implementation of the SBAT Program
219174488|NCT05744869|BEHAVIORAL|Usual Care|Usual Care for children with asthma
219174489|NCT04516772|DEVICE|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
219174490|NCT06281119|BIOLOGICAL|Cervavac as three dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
219174491|NCT06281119|BIOLOGICAL|Cervavac as two dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
219174492|NCT06281119|BIOLOGICAL|Gardasil as three dose regimen|Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
219174493|NCT05521308|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
219174494|NCT05521308|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
219174495|NCT05521308|DEVICE|Hearing Aid - Variation #2|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
219174496|NCT05521308|DEVICE|Hearing Aid - Variation #3|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
219174497|NCT05521308|DEVICE|Hearing Aid - Variation #4|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
219174498|NCT04747496|DRUG|Edoxaban|This is a non-interventional, observational study.
219174499|NCT06836973|DRUG|Blinatumomab|Blinatumomab is used at its starting dose of 9 µg per day and administered as continuous infusion for 5 days (total dose of 38.5 µg). After a 1-week pause, the patients receive a second 5-day infusion with blinatumomab of total 38.5 µg of the drug.
219174500|NCT01458782|PROCEDURE|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
219174501|NCT06056518|OTHER|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
219174502|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
219174503|NCT05072340|BEHAVIORAL|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
219174504|NCT05729399|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
219174505|NCT06832956|PROCEDURE|robotic bronchoscopy system|cryobiopsy with the help of RBS
219174506|NCT00346788|PROCEDURE|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
219174507|NCT05570994|DRUG|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
219174508|NCT05570994|DRUG|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
219174509|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
219174510|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
219174511|NCT06829394|OTHER|Program Assignment|The intervention group will include People living with HIV who were assigned to the Arms Around You Program in the lottery.
219174512|NCT05430360|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
219174513|NCT05463874|BEHAVIORAL|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
219174514|NCT02791204|DEVICE|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
219174515|NCT02791204|DEVICE|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
219174516|NCT05368103|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
219174517|NCT05079256|DEVICE|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
219174518|NCT03675282|DRUG|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
219174519|NCT03675282|DRUG|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
219174520|NCT05056194|DRUG|Valiloxybate|XW10172 MR Granules for Oral Suspension
219174521|NCT05056194|OTHER|Placebo|Placebo Granules for Oral Suspension
219246847|NCT01243086|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
219246848|NCT01243086|DRUG|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
219246849|NCT01217723|BIOLOGICAL|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
219246850|NCT01217723|OTHER|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
219246851|NCT00084409|DRUG|iloprost|Given orally
219246852|NCT00084409|OTHER|placebo|Given orally
219246853|NCT02219529|DEVICE|MCE|
219246854|NCT02219529|DEVICE|Standard gastroscopy|
219246855|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
219246856|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
219246857|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
219246858|NCT01291524|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
219246859|NCT03639649|DIAGNOSTIC_TEST|STHLM3|
219246860|NCT04422509|BIOLOGICAL|lanadelumab|single dose, or two doses administered iv
219246861|NCT04422509|OTHER|regular care|no lanadelumab administration, treated according to regular care
219246862|NCT02339506|DRUG|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
219246863|NCT02339506|DRUG|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
219246864|NCT01257386|DRUG|Asacol®|400mg tablets
219246865|NCT01257386|DRUG|Mesalazine|400mg tablets
219246866|NCT00331799|DRUG|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
219246867|NCT00599599|BEHAVIORAL|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
219246868|NCT01062854|OTHER|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
219246869|NCT05208593|BEHAVIORAL|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
219174522|NCT06830213|OTHER|Questionnaire study|Questionnaire application
219174523|NCT06342011|BEHAVIORAL|Anti-inflammatory diet group|"Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later."
219174524|NCT06836206|DIETARY_SUPPLEMENT|Gum Arabic|Gum Arabic (Acacia seyal and Acacia senegal) 30g powdered GA in 100ml water, consumed daily.
219174525|NCT06836206|OTHER|Water|100ml water, consumed daily
219174526|NCT06838299|DEVICE|aerobic exercise + inspiratory muscle training|inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set. The resistance was adjusted every week to be 60% of the new maximum inspiratory pressure and if it remained the same, the subject continued to train at the level of the previous week Aerobic exercise: by bicycle ergomete 5-minute warm-up before exercise and a 5-minute cool-down following exercise at intensity (40-65%HR max) were carried out each time. In addition, the exercise was performed in the first half of the dialysis session over a 3 months period for 3 sessions a week
219246870|NCT05208593|BEHAVIORAL|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
219246871|NCT05208593|BEHAVIORAL|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
219246872|NCT05208593|BEHAVIORAL|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
219246873|NCT03149887|DRUG|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
219246874|NCT03149887|DRUG|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
219246875|NCT02502188|DRUG|CC-90005|
219246876|NCT02502188|DRUG|Placebo|
219246877|NCT05324527|OTHER|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
219246878|NCT01680302|BEHAVIORAL|High intensity exercise|
219246879|NCT01680302|BEHAVIORAL|Moderate intensity exercise|
219246880|NCT01680302|BEHAVIORAL|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
219246881|NCT01090076|DIETARY_SUPPLEMENT|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
219246882|NCT01323335|DRUG|IV Uric Acid|
219246883|NCT01323335|DRUG|IV Rasburicase|
219246884|NCT03104309|DEVICE|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
219246885|NCT03807271|DEVICE|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
219246886|NCT05527054|OTHER|Diuretics|Inpatients using diuretics
219246887|NCT00553800|DRUG|bevacizumab|
219246888|NCT00553800|DRUG|Erlotinib|
219246889|NCT00907699|GENETIC|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
219246890|NCT00907699|GENETIC|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246891|NCT00907699|GENETIC|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246892|NCT00907699|GENETIC|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246893|NCT00907699|GENETIC|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246894|NCT00907699|GENETIC|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219740635|NCT06686823|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
219740636|NCT06687486|BEHAVIORAL|relaxin|caregivers relaxing and care burden
219740637|NCT06687486|OTHER|kontrol|no intervention
219740638|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter|catheter ablation
219740639|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
219740640|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy|in experimental arm 1
219740641|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection|in experimental arm 2
219740642|NCT06689306|BEHAVIORAL|7E learning model|7E learning model7E learning cycle is a teaching model that encourages students to be active, to think about the findings they obtain, to interpret their findings according to their initial plans and to predict them in new situations. This model provides students with opportunities for discussion and interaction. The model is designed based on constructivist theory. The guiding concept of constructivism is that later learning is greatly influenced by previous knowledge; therefore, learning should be based on the interaction of old and new knowledge. 7E learning cycle model consists of seven steps: Reveal, Participate, Explore, Explain, Elaborate, Evaluate and Extend. According to past studies, 7E model is more effective in developing students than traditional learning models.
219740643|NCT06690619|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
219740644|NCT06690619|DIETARY_SUPPLEMENT|315 mg Alpha-GPC|350 mg of 90% pure alpha-GPC (315 mg)
219740645|NCT06690619|DIETARY_SUPPLEMENT|630 mg Alpha-GPC|700 mg of 90% pure alpha-GPC (630 mg)
219740646|NCT06691152|BIOLOGICAL|CD19 Universal CAR-T cells|Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
219740647|NCT06686719|OTHER|Post Facilitation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed to mid- range. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
219246895|NCT00907699|GENETIC|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246896|NCT00907699|OTHER|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
219246897|NCT03388021|PROCEDURE|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
219246898|NCT05576727|OTHER|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
219246899|NCT00721019|OTHER|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
219246900|NCT00721019|OTHER|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
219246901|NCT00501111|DRUG|AZD3480|3 oral doses
219246902|NCT00501111|DRUG|Donepezil|
219246903|NCT04096261|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
219246904|NCT01317771|PROCEDURE|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
219246905|NCT00319670|DRUG|MiraLax|
219246906|NCT00158236|DRUG|Buprenorphine|
219246907|NCT00158236|DRUG|Buprenorphine and Naloxone|
219246908|NCT00158236|DRUG|Hydromorphone|
219246909|NCT02332122|PROCEDURE|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
219246910|NCT02332122|PROCEDURE|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.
219246911|NCT02332122|OTHER|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
219246912|NCT05127122|DRUG|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
219246913|NCT05127122|OTHER|Saline|Placebo Saline
219246914|NCT02650388|BEHAVIORAL|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
219246915|NCT04905511|BIOLOGICAL|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
219246916|NCT05872984|DIAGNOSTIC_TEST|adjustment of dry weight based on absolute blood volume measurement|adjustment of dry weight based on absolute blood volume measurement
219246917|NCT01116440|DRUG|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
219246918|NCT01116440|DRUG|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
219246919|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
219246920|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
219246921|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
219246922|NCT02630147|OTHER|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
219740648|NCT06686719|OTHER|Post Isometric Relaxation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax.After relaxation, the therapist further extends the knee for 3 to 5 seconds.. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
219740649|NCT06686719|OTHER|Myofascial Release|"MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.~Stretching of the hip adductors, hip flexors and plantar flexors. Functional training includes kneeling, bridging and sit to stand."
219740650|NCT06687577|BEHAVIORAL|DBT-C|Tobacco cessation treatment adapted for high risk population.
219740651|NCT06687577|BEHAVIORAL|Treatment as usual|Standard behavioral tobacco cessation treatment.
219740652|NCT06633042|DRUG|Universal BCMA-CD19 CART|1.0-4.0×10\^6 CAR-T cells/kg
219740653|NCT06689904|DEVICE|Nanodropper|One eye is randomly selected to be dilated with the nanodropper
219740654|NCT06689904|DEVICE|Standard eye drop bottle|eye is dilated with the standard eye drop bottle
219740655|NCT06695234|BEHAVIORAL|Meditation Awareness Training|A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
219740656|NCT06687720|OTHER|MetBroma|Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
219740657|NCT06627595|DRUG|Immunotherapy|Patients will be treated in accordance with the guidelines for melanoma treatment.
219740658|NCT06690047|BIOLOGICAL|Ruconest|recombinant human C1-esterase inhibitor
219740659|NCT06687005|PROCEDURE|non-surgical periodontal therapy|non-surgical periodontal therapy
219740660|NCT06695559|OTHER|Labrida Bioclean|Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).
219740661|NCT06695559|COMBINATION_PRODUCT|Labrida Bioclean and tetracycline slurry|On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.
219740662|NCT06695468|DRUG|Levobupivacaine|40-ml mixture of 20 ml of 0.5% levobupivacaine diluted with 20 ml of 0.9% N.S. (20 ml to be injected on each side
219740663|NCT06695468|DRUG|Levobupivacaine + Dexmedetomidine|60 ml mixture of 1.5 mic/kg dexmedetomidine added to 30 ml of 0.5% levobupivacaine diluted with 30 ml of 0.9% N.S. (30 ml to be administered on each side, divided into 15 ml for the upper segment and 15 ml for the lower segment).
219740664|NCT02736812|BIOLOGICAL|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP"
219740665|NCT02736812|BIOLOGICAL|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution"
219740666|NCT01718106|DEVICE|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
219740667|NCT05561985|DRUG|Itacitinib|
219740668|NCT06055569|OTHER|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
219740669|NCT06055569|OTHER|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
219740670|NCT06055569|OTHER|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
219740671|NCT03668340|DRUG|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
219740672|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219740673|NCT04681885|DEVICE|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
219740674|NCT04681885|DEVICE|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
219740675|NCT04681885|DEVICE|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
219740676|NCT06003790|DEVICE|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
219740677|NCT05892393|DRUG|Zirconium Zr 89-DFO-YS5|Given IV
219740678|NCT05892393|PROCEDURE|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
219740679|NCT05892393|PROCEDURE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
219740680|NCT05892393|OTHER|Fludeoxyglucose F-18|Given IV
219740681|NCT01197300|DRUG|Zoledronic acid|intravenous infusion
219246923|NCT03591328|DIAGNOSTIC_TEST|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
219246924|NCT05279417|DRUG|ATI-450 50 mg oral tablet BID|Oral, small molecule MK2 inhibitor
219246925|NCT05279417|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
219246926|NCT05279417|DRUG|Methotrexate|15 mg to 25 mg weekly
219246927|NCT05279417|DRUG|ATI-450 20 mg oral tablet BID|Oral, small molecule MK2 inhibitor
219246928|NCT06963138|DEVICE|Visual Acuity|VA will be measured for near and distance vision with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
219246929|NCT06963138|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
219246930|NCT06963138|DEVICE|Standard Subjective refraction|Standard subjective refraction for distance vision will be performed with Vision-R™
219246931|NCT06963138|DEVICE|Near vision examination and determination of additions|"Near vision examination and determination of additions will be performed with Vision-R™. The following objective and subjective measurement methods will determine the values of the various additions:~1. Determination of addition using the retinoscopy method (Add\_OBJ)~2. Randomization and administration of addition determination tests: FCC; R/G; PRA-NRA"
219246932|NCT06963138|DEVICE|Binocular vision tests|"The following measurements will be taken in trial glasses equipped with the final addition:~1. Stereoscopic acuity measurement~2. Measurement of the Near Point of Accommodation (PPA)~3. Measurement of the Near Point of Convergence (PPC)~4. Measurement of fusion reserves~5. Measurement of prismatic rock~6. Subjective questionnaire on the different methods used"
219246933|NCT06963138|DEVICE|Extended trial of addition|"The following measurements will be performed using trial glasses equipped with the final addition:~1. Submission of the CISS questionnaire and distance adaptation~2. Initial measurements of accommodative positioning and phorias~3. Completion of three smartphone tasks: reading, memorization, and video viewing~4. Final measurements of accommodative positioning and phorias~5. Submission of the QoL questionnaire regarding visual discomfort during the trial."
219246934|NCT00119314|DRUG|capecitabine|
219246935|NCT00119314|DRUG|docetaxel|
219246936|NCT00119314|DRUG|gemcitabine hydrochloride|
219246937|NCT00119314|PROCEDURE|positron emission tomography|
219246938|NCT02245971|PROCEDURE|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
219246939|NCT02245971|PROCEDURE|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
219740682|NCT02498795|OTHER|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
219740683|NCT02498795|OTHER|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
219740684|NCT02498795|OTHER|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
219740685|NCT04775979|DRUG|diphenylcyclopropenone (DPCP)|Depigmenting agent
219740686|NCT05775042|BIOLOGICAL|CM338|CM338 injection
219740687|NCT06415240|OTHER|Facilitated Tucking|Facilitated Tucking is a position to be adopted for pain relief in neonates.
219740688|NCT06415240|OTHER|Gentle Human Touch|while gentle human touch is caressing on head for pain relief.
219740689|NCT02531451|DRUG|Ibuprofen|
219740690|NCT02531451|DRUG|Acetylsalicylic acid|
219740691|NCT05515575|DRUG|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
219740692|NCT06060444|OTHER|Telemedicine Consult|Neurological consultation completed remotely
219740693|NCT06060444|OTHER|In-person Consult|Neurological consultation completed in-person
219740694|NCT06479239|DRUG|EGFR FPBMC|Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
219740695|NCT04818177|DRUG|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
219740696|NCT00262613|DRUG|sodium pyruvate in 0.9% sodium chloride solution|
219740697|NCT03741855|DEVICE|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
219740698|NCT03741855|DEVICE|Cloud Dx Kit with remote-monitoring|"* Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals."
219740699|NCT02113878|DRUG|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
219740700|NCT02113878|DRUG|Cisplatin|Cisplatin is a chemotherapy drug
219174527|NCT06838299|DEVICE|resistance exercise + inspiratory muscle training|"Resistance exercise:~Dynamic closed- and open-chain resistance exercises performed by the patients quadriceps and hamstrings muscles . Patients started at 50% of their initial one-repetition maximum (1-RM) with 5 repetitions for each exercise and later progressed to three sets of 8 repetitions at 70% of their 1-RM according to the patient Borg scale of exertion; training loads were increased when patients could comfortably complete three sets with good form.~inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set."
219174528|NCT06838299|OTHER|control group|there is no exercise , patients do assessment pre and post 3 months and follow up
219174529|NCT05243342|DRUG|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
219740701|NCT02113878|RADIATION|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
219740702|NCT06303752|DRUG|ADRC injection|Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
219740703|NCT06303752|DRUG|ADRC001 injection|Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
219174530|NCT05243342|DRUG|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
219174531|NCT04977947|BEHAVIORAL|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
219174532|NCT05207085|DRUG|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
219174533|NCT05207085|OTHER|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
219174534|NCT05258422|RADIATION|stereotactic body radiotherapy, 20 Gy in 1 fraction|A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
219174535|NCT06837285|DEVICE|mandibular advancement device|Results of clinical trials on MADs are regularly published in the international literature but are generally very strongly controlled studies, still far away from being applied in routine daily clinical practice. The current retrospective study evaluates real-world data to determine the extent to which MAD improves both symptoms in patients with OSA. It is estimated that about 3% of newly diagnosed OSA patients are treated with MAD. In the light of new future treatment conventions, health government departments are increasingly demanding real-world data to stimulate knowledge of the relative effectiveness and value of treatments in the management of patients in routine clinical settings.
219174536|NCT06833515|OTHER|one flare+wave one gold glider+wave one gold|In this clinical study, the teeth will first undergo coronal shaping with the One Flare file. Then, the glide path and final shaping will be performed in reciprocal mode with reciprocal files.
219174537|NCT06833515|OTHER|wave one gold glider+wave one gold|In this group, only the glide path and final shaping will be performed using reciprocal files, without coronal shaping.
219174538|NCT06833515|OTHER|wave one gold|In this group, shaping will be performed using only a reciprocating file, without coronal shaping and glide path preparation.
219246940|NCT01100593|PROCEDURE|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
219246941|NCT06048471|OTHER|HiTop|High tone transcutaneous electrical stimulation
219740704|NCT02999659|DEVICE|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
219740705|NCT06090799|DRUG|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
219740706|NCT06090799|DRUG|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
219740707|NCT00581100|DRUG|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
219740708|NCT00834574|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
219740709|NCT00834574|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
219740710|NCT03058952|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
219740711|NCT03058952|BEHAVIORAL|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
219740712|NCT04744831|DRUG|DS-8201a 5.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
219740713|NCT04744831|DRUG|DS-8201a 6.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
219740714|NCT06105255|DRUG|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
219740715|NCT05210725|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
219740716|NCT03837509|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
219740717|NCT03837509|BIOLOGICAL|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
219740718|NCT02150746|PROCEDURE|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
219740719|NCT02150746|PROCEDURE|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
219740720|NCT05142319|BIOLOGICAL|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
219740721|NCT05142319|BIOLOGICAL|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
219740722|NCT05142319|BIOLOGICAL|COVAXIN|Single intradermal injection at 6ug (0.5ml) per dose.
219740723|NCT05142319|BIOLOGICAL|Nuvaxovid|Single intradermal injection at 5mcg (0.5mL) per dose.
219740724|NCT01627197|PROCEDURE|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
219740725|NCT05170061|DRUG|Nebivolol|Nebivolol 20 mg daily (1 week) followed by nebivolol 40 mg daily (3 weeks) followed by nebivolol 20 mg daily (1 week)
219740726|NCT05170061|DRUG|Valsartan|Valsartan 160 mg daily (1 week) followed by valsartan 320 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week).
219740727|NCT05170061|DRUG|Nebivolol/valsartan combination|Valsartan/Nebivolol, 160/20 mg daily (1 week) followed by valsartan/nebivolol 320/40 mg daily (3 weeks) followed by valsartan/nebivolol 160/20 mg daily (1 week)
219740728|NCT04901975|DRUG|Spironolactone|Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
219740729|NCT04392570|DIAGNOSTIC_TEST|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
219740730|NCT05931965|DIETARY_SUPPLEMENT|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
219740731|NCT05931965|DIETARY_SUPPLEMENT|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
219740732|NCT05931965|DIETARY_SUPPLEMENT|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
219740733|NCT02344472|DRUG|pertuzumab|HER2 targeted Therapy
219740734|NCT02344472|DRUG|Trastuzumab|HER2 targeted Therapy
219740735|NCT02344472|DRUG|Capecitabine|Chemotherapy
219740736|NCT02344472|DRUG|Paclitaxel|Chemotherapy
219740737|NCT02344472|DRUG|Vinorelbine|Chemotherapy
219740738|NCT02344472|DRUG|Docetaxel|Chemotherapy
219740739|NCT02344472|DRUG|Exemestane|endocrine therapy
219740740|NCT02344472|DRUG|Letrozole|endocrine therapy
219740741|NCT02344472|DRUG|Anastrozole|endocrine therapy
219740742|NCT02344472|DRUG|Fulvestrant|endocrine therapy
219740743|NCT02344472|DRUG|Ribociclib|CDK 4/6 inhibitor
219174539|NCT06833515|OTHER|15K-type stainless-steel hand file|The operator prepared the glide path using a #15K-type stainless-steel hand file with push-pull motion. On sensing resistance, the file was withdrawn, recapitulation was performed with a #10K-type stainless-steel file, and debris was removed by irrigating the canals with 5% NaOCl. The operator repeated this procedure until the #15K-file reached the complete working length
219174540|NCT06838598|OTHER|OCT-BIO-KTA cohort|Dynamic full-field optical coherence tomography (D-FF-OCT) analysis of arterial catheter sections before microbiological analysis of catheter biofilm
219174541|NCT06833307|DRUG|SHR-1314|SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3
219174542|NCT06835205|BEHAVIORAL|Tous Épanouis à l'École (TEAL Program)|The TEAL Program is a structured, five-session behavioral intervention targeting psychosocial skill development in children. Delivered by healthcare students in elementary school classrooms, the program includes interactive activities designed to improve communication, empathy, social proximity, and prosocial behaviors. The intervention aims to reduce bullying behaviors (victims and aggressors) and enhance classroom climate. Each session is guided by a detailed manual and includes active participation from students and their teachers.
219174543|NCT06835205|BEHAVIORAL|Standard Health Education Sessions|This intervention consists of five sessions on general health topics unrelated to bullying, such as nutrition, sleep hygiene, and physical activity. The sessions are facilitated by healthcare students as part of their Service Sanitaire training. These sessions provide a comparable structure and duration to the TEAL program but do not address bullying prevention.
219174544|NCT06837571|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
219246942|NCT00203788|BEHAVIORAL|Individual Placement and Support|Supported education/employment
219246943|NCT00203788|BEHAVIORAL|Workplace Fundamentals Module|Group skills training on job/school topics
219246944|NCT00203788|BEHAVIORAL|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
219246945|NCT00203788|DRUG|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
219174545|NCT06837571|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
219174546|NCT06837571|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
219174547|NCT05041023|OTHER|Relative section|"Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death."
219174548|NCT05041023|OTHER|Caregiver section|"Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist."
219246946|NCT00203788|BEHAVIORAL|Skills training group|Group social skills training that did not focus primarily on work situations
219246947|NCT01239225|DEVICE|Abdominal ultra-sound|
219246948|NCT01239225|PROCEDURE|Abdominal ultrasound|
219246949|NCT04809545|OTHER|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
219246950|NCT04809545|OTHER|Treatment as usual|Usual care provided on the Specialized Dementia Unit
219246951|NCT01604499|BEHAVIORAL|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
219246952|NCT01604499|BEHAVIORAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
219246953|NCT02894385|DRUG|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
219246954|NCT01870999|DRUG|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
219246955|NCT01870999|DRUG|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
219246956|NCT01518127|OTHER|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
219246957|NCT00940914|DRUG|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
219246958|NCT05939349|OTHER|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
219246959|NCT02064361|OTHER|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
219246960|NCT00148499|DRUG|Ambroxol hydrochloride (Mucoangin?)|
219246961|NCT00148499|DRUG|benzocaine|
219246962|NCT03491774|BEHAVIORAL|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
219246963|NCT00555334|PROCEDURE|RFA|radiofrequency ablation
219246964|NCT00555334|DRUG|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
219246965|NCT00582192|OTHER|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
219246966|NCT06003478|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
219246967|NCT01523028|OTHER|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter"
219246968|NCT01636258|BEHAVIORAL|Stress Management|Every other week
219246969|NCT01636258|BEHAVIORAL|Diet|Every other week
219246970|NCT01636258|BEHAVIORAL|Exercise|Every week
219246971|NCT01636258|BEHAVIORAL|Culinary education|Every other week
219246972|NCT01406171|DRUG|Isavuconazole|oral
219246973|NCT01406171|DRUG|Midazolam|Oral
219246974|NCT01763346|DRUG|Metformin|metformin 1000 mg bid
219246975|NCT01763346|DEVICE|gastric banding|LAP-BAND
219246976|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
219246977|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
219246978|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
219246979|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
219246980|NCT03416335|DRUG|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
219246981|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
219246982|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
219246983|NCT01418599|DRUG|Torrent's Alfuzosin Extended Release Tablet|
219246984|NCT00116584|DRUG|heliox|continuous heliox therapy
219246985|NCT00116584|DRUG|oxygen|continuous oxygen therapy
219740744|NCT02344472|DRUG|nab-Paclitaxel|chemotherapy
219740745|NCT02344472|DRUG|eribulin|chemotherapy
219740746|NCT02344472|DRUG|leuprorelin|endocrine therapy
219246986|NCT00411463|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
219174549|NCT06837428|OTHER|Peer comparison-based Risk Communication (PRICOM)|Based on the Health Belief Model, a risk communication intervention, Peer comparison-based Risk Communication (PRICOM), was developed for primary care physicians to counsel patients with T2DM on their glycaemic control and the complications that could arise, and to recommend ways to improve glycaemic control and prevent complications (or further complications). This will be supported by information from an AI (Artificial Intelligence) based diabetes tool. PRICOM aims to promote health actions in patients with T2DM by increasing their risk perceptions of diabetes complications.
219174550|NCT06832111|OTHER|Kinesio Taping 1|A specific Kinesio taping technique applied to the ankle to evaluate its effects on joint position sense and balance.
219174551|NCT06832111|OTHER|Kinesio Taping 2|A different Kinesio taping technique applied to the ankle to assess its impact on proprioception and postural stability.
219174552|NCT06832111|OTHER|Sham Kinesio Taping|A placebo taping application that mimics the real Kinesio tape placement but lacks therapeutic tension or functional support, serving as a control condition to evaluate the true effects of the experimental interventions.
219174553|NCT03452111|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
219174554|NCT06837545|OTHER|No Intervention (Observational Study)|"This study is an observational analysis of preoperative serum uric acid levels and their association with postoperative outcomes. No intervention was administered."
219174555|NCT06837883|PROCEDURE|Percutaneous nephrolithotomy through and through guiedwire|In the study group, a modification in percutaneous nephrolithotomy was carried out to have through-and-through guidewire.
219174556|NCT06837883|PROCEDURE|Standard percutaneous nephrolithotomy|Standard percutaneous nephrolithotomy without using through and through guide wire
219174557|NCT06833177|OTHER|Beautilink SA cement|"According to the manufacturer's instructions (BeautiLink SA - Shofu USA)~* To enhance the adhesion, adhesive bonding agent BeautiBond Xtreme, Shofu will be applied on the tooth and cured according to the manufacturer's instructions.~* Press the plunger of the auto-mix syringe of Beautilink SA to dispence the cement on the adhesive surface of the restoration.~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 1-2 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 5 minutes after light-curing to allow for chemical curing."
219174558|NCT06833177|OTHER|RelyX resin cement|"According to the manufacturer's instructions (Espe).~* To enhance the adhesion, adhesive bonding agent 3M™ Scotchbond™ Universal Plus Adhesive will be applied on the tooth and cured according to the manufacturer's instructions.~* Application of 3M™RelyX™ Universal Resin Cement into the cavity~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 2-3 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 6 minutes after light-curing to allow for chemical curing."
219174559|NCT04666571|DEVICE|TOKA|The device is a digitally planned (using individual CT scan measured anatomic data) personalised opening wedge high tibial osteotomy (HTO) procedure using a custom 3D printed surgical guide and plate.
219174560|NCT04666571|DEVICE|Tomofix or ActivMotion|The comparators, Tomofix and ActivMotion, are the most widely used devices for HTO procedures in the UK. Surgical procedures using the Tomofix and ActiveMotion are similar to TOKA, however, they are not patient specific and do not use custom-made plates.
219174561|NCT06054477|DRUG|ALE.C04|Q3W
219174562|NCT06054477|DRUG|Pembrolizumab|200mg Q3W
219174563|NCT05875142|BEHAVIORAL|Behavioral: Digital Tutorial Overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.
219174564|NCT05875142|BEHAVIORAL|Behavioral: Training Materials|10 weeks post-tutorial access to additional digital training materials.
219174565|NCT05875142|BEHAVIORAL|Behavioral: Feedback and Coaching|10 weeks post-tutorial access to additional digital training materials and systematic feedback and coaching.
219174566|NCT05664945|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
219740747|NCT02344472|DRUG|goserelin|endocrine therapy
219740748|NCT01460277|PROCEDURE|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
219246987|NCT00411463|DRUG|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
219246988|NCT05129371|OTHER|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
219246989|NCT05129371|OTHER|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
219246990|NCT05650580|DRUG|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
219246991|NCT02173249|DRUG|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
219246992|NCT05828602|OTHER|Conventional treatment|Conventional treatment
219246993|NCT05828602|OTHER|TeleRehabilitation|TeleRehabilitation
219246994|NCT03360227|DEVICE|implantation of cardiac devices|implantation of cardiac devices
219246995|NCT02798861|DEVICE|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
219246996|NCT05820542|OTHER|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
219246997|NCT05820542|OTHER|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
219246998|NCT05614843|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
219246999|NCT05614843|DEVICE|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
219247000|NCT01798238|DRUG|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
219247001|NCT01798238|DRUG|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
219740749|NCT01460277|PROCEDURE|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
219740750|NCT03966118|DRUG|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
219740751|NCT03966118|DRUG|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
219740752|NCT03966118|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
219740753|NCT02257138|DRUG|Decitabine|Given IV
219740754|NCT02257138|OTHER|Laboratory Biomarker Analysis|Correlative studies
219740755|NCT02257138|DRUG|Ruxolitinib Phosphate|Given PO
219740756|NCT04775758|BEHAVIORAL|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
219740757|NCT04775758|BEHAVIORAL|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
219740758|NCT00530257|DRUG|Placebo|Placebo (sugar pill)
219740759|NCT00530257|DRUG|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
219740760|NCT00385515|DRUG|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
219740761|NCT00385515|DRUG|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
219740762|NCT03676270|OTHER|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
219740763|NCT06184087|OTHER|Educational/Instructional|ICAP constructive-interactive engagement mode
219740764|NCT00000845|BIOLOGICAL|P3C541b Lipopeptide|
219740765|NCT03831776|DRUG|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
219740766|NCT03831776|DRUG|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
219740767|NCT06570460|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 6 months
219740768|NCT06570460|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 6 months
219247002|NCT02239666|OTHER|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
219247003|NCT02547025|DRUG|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
219247004|NCT02547025|DRUG|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
219247005|NCT02547025|DRUG|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
219247006|NCT01968083|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
219740769|NCT05670704|BIOLOGICAL|ARGX-119|Patients receiving ARGX-119 IV or SC
219740770|NCT05670704|OTHER|Placebo|Patients receiving Placebo IV or SC
219740771|NCT05603780|BEHAVIORAL|exploratory protocol|physiological and cognitive evaluations
219740772|NCT00467493|DRUG|Anastrozole|
219740773|NCT06365502|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
219247007|NCT01968083|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
219247008|NCT01785797|DEVICE|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
219247009|NCT02186015|DRUG|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
219247010|NCT00907517|DRUG|MK-8776|IV infusion
219247011|NCT00907517|DRUG|Cytarabine|IV infusion
219740774|NCT06365502|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
219740775|NCT03428347|BIOLOGICAL|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
219740776|NCT03457662|COMBINATION_PRODUCT|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
219740777|NCT03457662|COMBINATION_PRODUCT|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
219247012|NCT05952583|DIAGNOSTIC_TEST|Ultrasound|Additional ultrasound measurements during pregnancy
219247013|NCT00355602|DRUG|Cefuroxime|
219247014|NCT00355602|DRUG|Ciprofloxacin|
219247015|NCT00355602|DRUG|Clarithromycin|
219247016|NCT00355602|DRUG|Cotrimoxazole|
219247017|NCT00355602|DRUG|Coamoxiclav|
219247018|NCT00355602|DRUG|metronidazole|
219247019|NCT00355602|DRUG|neomycin|
219247020|NCT00355602|DRUG|rifaximin|
219247021|NCT00355602|DRUG|Vancomycin|
219247022|NCT00355602|DRUG|Doxycycline|
219740778|NCT05401409|DIETARY_SUPPLEMENT|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
219740779|NCT05401409|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
219740780|NCT04252664|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
219740781|NCT04252664|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
219740782|NCT02371889|DRUG|Topiramate|Max therapeutic dose of 200mg/day
219740783|NCT02371889|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
219740784|NCT02371889|DRUG|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
219247023|NCT00733551|DRUG|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
219247024|NCT00733551|DRUG|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
219247025|NCT03467802|BIOLOGICAL|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
219247026|NCT03467802|DEVICE|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
219247027|NCT02333071|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
219247028|NCT02333071|OTHER|Placebo|Placebo
219247029|NCT01048983|DRUG|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
219247030|NCT01048983|DRUG|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
219247031|NCT01048983|DRUG|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
219247032|NCT01048983|DRUG|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
219247033|NCT01048983|BEHAVIORAL|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
219247034|NCT04271514|DRUG|RPT193|Antagonist of the CCR4 chemokine receptor
219247035|NCT04271514|DRUG|Placebo|Matching placebo
219247036|NCT02396550|BEHAVIORAL|Positive Expectations|Give positive expectation of the treatment efficacy to patients
219247037|NCT02396550|PROCEDURE|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
219247038|NCT02325258|OTHER|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
219247039|NCT04348383|DRUG|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
219247040|NCT04348383|DRUG|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
219247041|NCT03377283|BIOLOGICAL|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
219247042|NCT03377283|OTHER|organ perfusion with saline|
219247043|NCT00201214|DRUG|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
219247044|NCT00571558|DRUG|aminolevulinic acid hydrochloride|Given PO
219247045|NCT00571558|DRUG|photodynamic therapy|Undergo photodynamic therapy
219247046|NCT00571558|OTHER|laboratory biomarker analysis|Correlative studies
219247047|NCT01537900|DRUG|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
219247048|NCT02133183|OTHER|Laboratory Biomarker Analysis|Correlative studies
219247049|NCT02133183|OTHER|Pharmacological Study|Correlative studies
219247050|NCT02133183|DRUG|Sapanisertib|Given PO
219247051|NCT02133183|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219247052|NCT04297436|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
219247053|NCT03800264|DRUG|Bisoprolol|PREVENTIVE DOUBLE BLINDED
219247054|NCT05453877|OTHER|No intervention will be applied.|This is an observational study.
219247055|NCT05304884|COMBINATION_PRODUCT|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
219247056|NCT01797705|DEVICE|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
219247057|NCT05181878|DEVICE|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
219247058|NCT00733577|DRUG|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
219247059|NCT00618384|DRUG|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
219247060|NCT05036499|BEHAVIORAL|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
219247061|NCT03340818|OTHER|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
219247062|NCT03340818|OTHER|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
219247063|NCT03919318|OTHER|Root Canal Filling Sealers|Root Canal Obturation
219247064|NCT02030847|BIOLOGICAL|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
219247065|NCT02030847|BIOLOGICAL|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
219247066|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
219247067|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
219247068|NCT01333137|DRUG|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
219740785|NCT00571714|DRUG|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
219740786|NCT00571714|DRUG|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
219740787|NCT06380907|DRUG|ZL-1102 1% w/w gel BID for 16 weeks|"ZL-1102~1% w/w gel BID for 16 weeks"
219740788|NCT06380907|DRUG|ZL-1102 3% w/w gel BID for 16 weeks|ZL-1102 3% w/w gel BID for 16 weeks
219740789|NCT06380907|DRUG|ZL-1102 3% w/w gel QD for 16 weeks|ZL-1102 3% w/w gel QD for 16 weeks
219740790|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel BID for 16 weeks|Vehicle 0% w/w gel BID for 16 weeks
219740791|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel QD for 16 weeks|Vehicle 0% w/w gel QD for 16 weeks
219740792|NCT06959121|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp
219740793|NCT06630689|OTHER|Dry Full Body Massage|Applying massage after phototherapy
219740794|NCT06630689|OTHER|Oil Full Body Massage|Oil Full Body Massage
219740795|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
219740796|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
219740797|NCT04904549|BIOLOGICAL|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
219740798|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
219740799|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
219740800|NCT05359718|OTHER|Questionnaire|Questionnaire
219740801|NCT06284278|OTHER|Diaphragmatic breathing retraining|8 weeks diaphragmatic breathing training
219740802|NCT06284278|OTHER|Pelvic stabilization exercise|8 weeks pelvic stabilization exercise training
219740803|NCT06284278|OTHER|pelvic anatomy education|pelvic anatomy education
219740804|NCT05272488|OTHER|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
219740805|NCT05272488|OTHER|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
219740806|NCT01521741|OTHER|Breast Cancer-Related Lymphedema Screening|All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
219740807|NCT03495232|DEVICE|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
219740808|NCT04951505|DRUG|cefepime-taniborbactam|IV infusion
219740809|NCT05822817|DRUG|sevoflurane|Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
219174567|NCT05664945|BEHAVIORAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
219174568|NCT05664945|BEHAVIORAL|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
219174569|NCT05501483|DRUG|Pioglitazone 45 mg|Starts with 45 mg
219174570|NCT05501483|DRUG|Empagliflozin 25 MG|Starts with 25 mg
219174571|NCT05501483|DRUG|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
219174572|NCT05784662|BEHAVIORAL|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
219174573|NCT02925871|BEHAVIORAL|Co-designed person-centred care transitions|The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
219740810|NCT05822817|DRUG|propofol|Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
219740811|NCT05520333|BEHAVIORAL|BIPAS Alcohol|Weekly text messages for three months.
219740812|NCT00614341|DEVICE|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
219740813|NCT04343833|PROCEDURE|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
219740814|NCT00071994|DRUG|gefitinib|Given orally
219740815|NCT00071994|OTHER|laboratory biomarker analysis|Correlative studies
219740816|NCT04859686|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
219740817|NCT04859686|PROCEDURE|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
219740818|NCT06548672|DRUG|BC3195|BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
219740819|NCT05513573|DRUG|HLX07|1500 mg, D1，Q3W
219740820|NCT05513573|DRUG|HLX10|300 mg, D1, up to 2 years,Q3W
219740821|NCT05513573|DRUG|placebo|1500 mg, D1，Q3W
219740822|NCT05513573|DRUG|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
219740823|NCT02579759|DRUG|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
219740824|NCT02579759|DRUG|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
219740825|NCT02579759|DRUG|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
219740826|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
219740827|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
219740828|NCT02735642|BEHAVIORAL|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
219740829|NCT02735642|BEHAVIORAL|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
219174574|NCT02925871|BEHAVIORAL|Current care transitions|Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
219174575|NCT03601728|BEHAVIORAL|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
219174576|NCT06642389|OTHER|Sonoanatomical Structure Identification|ChatGPT-4 will analyze the ultrasound images to identify key anatomical landmarks such as nerves, muscles, blood vessels, and fascial planes that are critical for successful regional anesthesia. These structures will be labeled and compared to the expert anesthesiologist's assessment to determine accuracy.
219174577|NCT06642389|OTHER|Block Type Prediction|Based on the ultrasound images and the position of the probe, ChatGPT-4 will predict the type of regional anesthesia block being performed (e.g., supraclavicular block, femoral nerve block). These predictions will be compared to the actual block performed to evaluate the AI's accuracy.
219174578|NCT06642389|OTHER|Block Success Assessment|After analyzing the ultrasound images from the block application, ChatGPT-4 will assess whether the block was successfully administered. This assessment will be based on the correct placement of the needle, the spread of the anesthetic, and proximity to target structures. The AI's evaluation of block success will be compared to the expert anesthesiologist's judgment.
219174579|NCT05912387|DRUG|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
219174580|NCT06283082|DIAGNOSTIC_TEST|Lithiasis assessment|Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.
219174581|NCT00583349|DRUG|Abraxane|"Abraxane is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Intravesically administered, dose escalation, 6 weekly instillations"
219174582|NCT06822036|PROCEDURE|Arm A - Application of 5g of ARISTA™ AH|Perioperative application of 5g of ARISTA™ AH to the prostate bed and neurovascular bundles during and at the end of the surgery to control bleeding and oozing in accordance with labelled directions; no other hemostyptic agent in aforementioned area
219174583|NCT05065658|DRUG|Posaconazole|Intravenous posaconazole prophylaxis
219174584|NCT06168721|OTHER|Expert survey|The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
219174585|NCT04755140|BEHAVIORAL|Questionnaires|The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.
219174586|NCT04755140|BEHAVIORAL|Interviews|Cognition and memory interviews will take place with the patient.
219174587|NCT04755140|DIAGNOSTIC_TEST|Blood Test|Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.
219174588|NCT04755140|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
219174589|NCT01570998|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
219174590|NCT01570998|OTHER|Laboratory Biomarker Analysis|Correlative studies
219174591|NCT03276832|DRUG|Imiquimod|Applied cutaneously
219174592|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
219174593|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
219174594|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219174595|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219174596|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219174597|NCT01851694|DRUG|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
219174598|NCT01851694|DRUG|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
219174599|NCT03210272|DRUG|Placebo|Tablet
219174600|NCT03210272|DRUG|BI 1358894|Tablet
219174601|NCT03210272|DRUG|BI 1358894 (Test)|Fasting state
219174602|NCT03210272|DRUG|BI 1358894 (Reference)|Fed state
219174603|NCT05397223|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219174604|NCT05397223|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
219174605|NCT05397223|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219174606|NCT05397223|BIOLOGICAL|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
219174607|NCT05397223|BIOLOGICAL|mRNA-1647|Sterile lyophilized product
219174608|NCT03039023|DIETARY_SUPPLEMENT|Choline Bitartrate|500mg choline bitartrate tablets
219174609|NCT03039023|OTHER|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
219247069|NCT01333137|DRUG|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
219247070|NCT00220441|BEHAVIORAL|Aerobic exercise|
219247071|NCT02908412|DRUG|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
219247072|NCT01099150|DIETARY_SUPPLEMENT|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
219247073|NCT01099150|DIETARY_SUPPLEMENT|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
219247074|NCT01099150|DIETARY_SUPPLEMENT|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
219247075|NCT02326740|DRUG|gevokizumab|
219247076|NCT02326740|DRUG|Placebo|
219247077|NCT02326740|DRUG|gevokizumab open-label|
219247078|NCT04193397|BEHAVIORAL|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
219247079|NCT02431832|DRUG|Augmentin tab|
219247080|NCT03730311|DRUG|Elpida|elsulfavirine, capsules
219247081|NCT03730311|DRUG|placebo|placebo
219247082|NCT04265911|BIOLOGICAL|ASP3772 (subcutaneous)|Subcutaneous injection
219247083|NCT04265911|BIOLOGICAL|ASP3772 (intramuscular)|Intramuscular injection
219247084|NCT04265911|BIOLOGICAL|PPSV23 (subcutaneous)|Subcutaneous injection
219247085|NCT04265911|BIOLOGICAL|PPSV23 (intramuscular)|Intramuscular injection
219247086|NCT00449202|DRUG|oleoyl-estrone (MP 101)|
219247087|NCT02213224|DRUG|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
219247088|NCT02213224|DRUG|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
219247089|NCT02213224|DRUG|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
219247090|NCT04542200|BIOLOGICAL|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
219247091|NCT02343978|DRUG|KWA-0711|
219740830|NCT02735642|BEHAVIORAL|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
219740831|NCT02735642|OTHER|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
219740832|NCT01117662|DRUG|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
219740833|NCT01117662|DRUG|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
219740834|NCT03939065|DEVICE|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
219740835|NCT03939065|DEVICE|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
219740836|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
219740837|NCT02465814|DRUG|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
219740838|NCT02465814|DRUG|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
219740839|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
219740840|NCT02465814|DRUG|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
219740841|NCT02465814|DRUG|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
219740842|NCT02465814|DRUG|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
219743501|NCT03269266|DIAGNOSTIC_TEST|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
219247092|NCT06545721|OTHER|Adjusting dietary structure + exercise + behavioral intervention|Adjusting to a healthy diet involves consuming low GI and low-fat foods, avoiding sugary drinks, increasing dietary fiber intake, reducing saturated fat while increasing omega-3 unsaturated fat intake, and limiting trans fat consumption. A weight loss program includes a high-protein diet, exercise, and behavioral intervention with daily total energy needs calculated based on ideal body weight (kg) x 15-20 kcal/kg/d; developing a daily meal plan with regular protein supplementation; limiting salt intake to ≤5 g/d; ensuring adequate water consumption at 2-3L/d; aiming for a dietary fiber intake of 25-30g/d; recommending micronutrient supplementation as needed; maintaining daily aerobic exercise (40 minutes at 70-80% HRmax) along with resistance training (20 minutes); establishing an early bedtime before 11pm and an early wake-up time.
219247093|NCT00352963|BIOLOGICAL|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
219247094|NCT00908193|DEVICE|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
219247095|NCT00908193|PROCEDURE|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
219247096|NCT02592434|DRUG|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg."
219247097|NCT02592434|OTHER|placebo|matching placebo tablet or solution for tofacitinib
219247098|NCT04061772|DRUG|Bortezomib|Bortezomib injection
219247099|NCT04061772|DRUG|Etoposide|Etoposide injection
219247100|NCT04061772|DRUG|Cyclophosphamide|Cyclophosphamide injection
219247101|NCT04061772|DRUG|Pharmorubicin|Pharmorubicin injection
219247102|NCT04061772|DRUG|Prednisone|Prednisone tablet
219247103|NCT06181123|OTHER|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
219247104|NCT00653419|DRUG|buspirone HCl|Tablets, 30 mg, single-dose
219247105|NCT00653419|DRUG|Buspar|Tablets, 30 mg, single-dose
219247106|NCT02668796|DRUG|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
219247107|NCT02668796|DRUG|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
219247108|NCT02668796|DRUG|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
219247109|NCT00219635|DRUG|UK-390,957|
219247110|NCT02366702|DEVICE|Lower Limb Powered Knee-Ankle Prosthesis|
219247111|NCT00993018|DRUG|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
219247112|NCT00993018|DRUG|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
219247113|NCT00993018|DRUG|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
219247114|NCT00993018|DRUG|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
219247115|NCT00291928|DRUG|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
219247116|NCT00291928|DRUG|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
219247117|NCT05382390|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
219247118|NCT05382390|DRUG|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
219247119|NCT02884219|DRUG|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
219247120|NCT02884219|OTHER|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
219247121|NCT02884219|DRUG|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
219247122|NCT00561678|DRUG|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
219247123|NCT00561678|DRUG|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
219247124|NCT03082196|DRUG|Test varnish|Topical application of test varnish to the teeth 4 times per year.
219247125|NCT03082196|DRUG|Standard varnish|Topical application of test varnish to the teeth 4 times per year
219247126|NCT04051190|DIETARY_SUPPLEMENT|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
219247127|NCT04051190|PROCEDURE|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
219247128|NCT04051190|PROCEDURE|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
219247129|NCT01103141|DEVICE|Micropuncture needle set|Groin access for vascular intervention
219247130|NCT01103141|DEVICE|Standard gauge-18 needle set|Groin access for vascular intervention
219247131|NCT01695993|DEVICE|Acupressure bands|Bilateral acupressure wrist bands
219247132|NCT01695993|OTHER|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
219247133|NCT01695993|BEHAVIORAL|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
219247134|NCT01695993|OTHER|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
219247135|NCT01695993|BEHAVIORAL|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
219247136|NCT01747616|DEVICE|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
219247137|NCT01747616|OTHER|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
219247138|NCT00718744|OTHER|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
219247139|NCT03263104|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
219247140|NCT03263104|DIETARY_SUPPLEMENT|Maltodextrin|
219247141|NCT00669149|DRUG|clopidogrel + aspirin|
219247142|NCT00669149|DRUG|heparin + clopidogrel + aspirin|
219247143|NCT00669149|DRUG|enoxaparin + clopidogrel + aspirin|
219247144|NCT00669149|DRUG|bivalirudin + clopidogrel + aspirin|
219247145|NCT00465699|DRUG|Topical B12 0.07%|
219247146|NCT02548052|DRUG|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
219247147|NCT02548052|DRUG|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
219247148|NCT02548052|DRUG|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
219247149|NCT02548052|DRUG|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
219247150|NCT02548052|DRUG|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
219247151|NCT02548052|DRUG|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
219247152|NCT00840918|DRUG|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
219247153|NCT00840918|OTHER|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
219247154|NCT03011554|DEVICE|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
219247155|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
219247156|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
219247157|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
219247158|NCT04301609|DIETARY_SUPPLEMENT|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
219247159|NCT04301609|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
219247160|NCT04479176|PROCEDURE|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
219174610|NCT03039023|OTHER|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
219247161|NCT02029521|DIETARY_SUPPLEMENT|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
219247162|NCT02029521|DIETARY_SUPPLEMENT|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
219247163|NCT02899676|OTHER|neuropsychological testing|
219174611|NCT03039023|DIETARY_SUPPLEMENT|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
219174612|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
219174613|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
219174614|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
219174615|NCT05847517|DRUG|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
219174616|NCT05847517|DRUG|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
219247164|NCT02899676|OTHER|functional magnetic resonance imaging|
219247165|NCT02899676|OTHER|simple arithmetic operations|
219247166|NCT02103816|DEVICE|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
219247167|NCT01072396|DRUG|Tiotropium|double blind randomized crossover
219247168|NCT01072396|DRUG|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
219247169|NCT03635047|BIOLOGICAL|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
219247170|NCT03635047|OTHER|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
219247171|NCT01007851|DRUG|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
219247172|NCT01007851|DRUG|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
219247173|NCT05584709|BIOLOGICAL|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
219174617|NCT06406881|OTHER|physical therapy|"Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
219174618|NCT06406881|OTHER|myofascial release therapy|"Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
219247174|NCT03748680|DRUG|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
219247175|NCT03748680|OTHER|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
219247176|NCT00340184|DRUG|paclitaxel, carboplatin|
219247177|NCT03779126|DEVICE|Electrical stimulation|1\) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
219174619|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)
219174620|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
219174621|NCT05789602|DRUG|BPI-460372|Subjects will receive BPI-460372 until disease progression
219174622|NCT06299748|BIOLOGICAL|Efgartigimod|Efgartigimod IV or SC
219174623|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
219174624|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
219174625|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
219174626|NCT05477407|DRUG|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
219174627|NCT06074900|OTHER|prospective cohort study|"This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient.~Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment."
219174628|NCT06540326|DRUG|irinotecan liposome (II)|irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
219174629|NCT06540326|DRUG|fluorouracil|fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
219174630|NCT06540326|DRUG|cetuximab|cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
219174631|NCT06540326|DRUG|bevacizumab|bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
219174632|NCT02914535|DRUG|Filgotinib|Tablet(s) administered orally once daily
219174633|NCT02914535|DRUG|Placebo|Tablet(s) administered orally once daily
219174634|NCT04339452|DEVICE|Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.5 with SmartAssist, followed by Impella-supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
219174635|NCT04939142|COMBINATION_PRODUCT|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
219247178|NCT05113212|DEVICE|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
219174636|NCT04939142|COMBINATION_PRODUCT|Vd (Bortezomib+dexamethasone)|Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
219174637|NCT03729518|RADIATION|Radiation Therapy (IMRT or IMPT)|"* Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
219247179|NCT05113212|DEVICE|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
219743502|NCT02640131|BEHAVIORAL|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
219743503|NCT02640131|BEHAVIORAL|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
219743504|NCT02640131|BEHAVIORAL|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
219743505|NCT02572648|OTHER|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
219743506|NCT02572648|OTHER|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
219743507|NCT04377776|OTHER|Practice details|Questionnaire
219743508|NCT01655446|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
219743509|NCT01655446|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
219743510|NCT01655446|BEHAVIORAL|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
219743511|NCT01655446|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
219743512|NCT01655446|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
219743513|NCT04098913|BEHAVIORAL|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
219743514|NCT03345082|BIOLOGICAL|OPT-302|Intravitreal injection
219743515|NCT03345082|BIOLOGICAL|ranibizumab|Intravitreal injection
219743516|NCT03345082|OTHER|sham intravitreal injection|Sham (mock) intravitreal injection
219743517|NCT04133038|OTHER|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
219743518|NCT05388825|DRUG|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
219743519|NCT05388825|DRUG|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
219743520|NCT05388825|DRUG|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
219743521|NCT05388825|DRUG|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
219743522|NCT05388825|DRUG|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
219743523|NCT01596023|DEVICE|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
219743524|NCT04096677|PROCEDURE|hysteroscpy|
219174638|NCT05936684|BEHAVIORAL|Breathing with prolonged exhalation (ProlEx) during risky decision-making|20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
219174639|NCT05936684|BEHAVIORAL|Normal breathing (Eupnea/Control) during risky decision-making|20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
219174640|NCT02424929|PROCEDURE|Sedation|Propofol anesthesia administered during entire surgery.
219174641|NCT02424929|PROCEDURE|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
219740843|NCT02674828|BEHAVIORAL|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
219740844|NCT02674828|OTHER|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
219740845|NCT00569075|OTHER|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
219740846|NCT02473302|OTHER|ham|160g per day during 4 days
219740847|NCT02473302|OTHER|ham + pomegranate extract|160g per day during 4 days
219740848|NCT02473302|OTHER|ham + tocopherol|160g per day during 4 days
219740849|NCT02473302|OTHER|rare sirloin steak|110g per day during 4 days
219740850|NCT02473302|OTHER|marinated rare sirloin steak|110g per day during 4 days
219740851|NCT02473302|OTHER|marinated cooked sirloin steak|110g per day during 4 days
219740852|NCT01897896|DRUG|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
219740853|NCT02002858|DRUG|Nicotine Patch|
219740854|NCT02002858|BEHAVIORAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
219740855|NCT02002858|BEHAVIORAL|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
219740856|NCT05708508|DRUG|ROVALCYTE|"Immuno-guided strategy arm"
219740857|NCT04519138|DEVICE|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
219740858|NCT04519138|DEVICE|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
219740859|NCT02056145|PROCEDURE|LFCNB|LFCNB - Normal Saline solution 10 cc
219740860|NCT02056145|PROCEDURE|FNB|FNB - Normal saline solution 10 cc
219740861|NCT02056145|PROCEDURE|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
219740862|NCT02056145|PROCEDURE|FNB|FNB - Chirocaine 0.25%, 20 cc
219740863|NCT00526851|OTHER|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
219740864|NCT00781898|DRUG|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
219740865|NCT00781898|OTHER|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
219740866|NCT01791179|BEHAVIORAL|Comprehensive substance abuse services|
219740867|NCT02090530|OTHER|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
219740868|NCT01266200|PROCEDURE|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
219740869|NCT01266200|PROCEDURE|XIA|Treatment of the fracture with Xia and conventional operation technique
219740870|NCT03151668|DRUG|Dexmedetomidine|
219740871|NCT01140932|DRUG|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
219740872|NCT01140932|BEHAVIORAL|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
219740873|NCT05315778|BIOLOGICAL|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
219740874|NCT03318627|DEVICE|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
219740875|NCT00698412|DEVICE|Cane|This group use the cane every day since the baseline
219740876|NCT00459550|DRUG|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
219740877|NCT00459550|DRUG|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
219740878|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
219740879|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
219247180|NCT06255899|BEHAVIORAL|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
219174642|NCT04021719|OTHER|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
219174643|NCT04021719|OTHER|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
219174644|NCT05340049|PROCEDURE|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
219174645|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (PCST, PMRT, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the cranial blocks and primitive reflexs therapies were expressed as block or normal and active or inactive, depending on what finds the physiotherapist in his evaluation"
219174646|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
219174647|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 old +/- 6 months to 18 years old +/- 6 months
219174648|NCT05260684|DRUG|Encorafenib|450 mg QD
219174649|NCT05260684|DRUG|Binimetinib|45 mg BID
219174650|NCT05260684|DRUG|Vemurafenib|960 mg BID for 28 days/cycle
219174651|NCT05260684|DRUG|Cobimetinib|60 mg QD for 21 days/cycle
219174652|NCT05260684|DRUG|Dabrafenib|150 mg BID
219174653|NCT05260684|DRUG|Trametinib|2 mg QD
219174654|NCT04386070|DRUG|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
219174655|NCT05953883|PROCEDURE|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
219174656|NCT06411639|DRUG|ianalumab|ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
219174657|NCT04739956|OTHER|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
219174658|NCT04739956|OTHER|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
219174659|NCT05770219|DRUG|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
219174660|NCT03167281|COMBINATION_PRODUCT|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
219174661|NCT04566991|DRUG|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
219174662|NCT04566991|DRUG|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
219174663|NCT03920111|BIOLOGICAL|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
219174664|NCT06848920|DRUG|Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment|Sinibolimab combined with Lenvatinib in neoadjuvant treatment
219174665|NCT06850012|BEHAVIORAL|Meleis' Transition Theory-Based Educational Program|This intervention is a 7-week online educational program based on Meleis' Transition Theory, aimed at helping immigrant nurses understand and cope with migration challenges, improve social integration, manage stress, and enhance professional self-efficacy. The program will be divided into three groups (12-12-11 participants), and it will include interactive sessions, group discussions, and practical activities such as breathing exercises to promote active participation and engagement.
219174666|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be navigated via Meta Quest II headset devices and will be used as an intervention.
219174667|NCT05858671|OTHER|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
219174668|NCT05858671|OTHER|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
219174669|NCT03372902|DEVICE|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
219174670|NCT03372902|DEVICE|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
219174671|NCT03372902|OTHER|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
219174672|NCT03372902|PROCEDURE|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
219174673|NCT03372902|BEHAVIORAL|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
219174674|NCT06850376|BEHAVIORAL|COVID Feel Good VR Self-Help Protocol|The intervention consists of a 7-day self-help protocol based on daily exposure to 'The Secret Garden' 360° VR video (10 minutes per day) available at www.covidfeelgood.com, combined with different daily cognitive and social exercises. Participants use a smartphone with VR headset compatible with the Cardboard format. Each day's exercise addresses different psychological aspects: fighting rumination, awakening self-esteem, autobiographical memory, sense of community, goals and dreams, empathy, and planning for change. Exercises are designed to be performed individually and then discussed with a partner.
219174675|NCT06850376|OTHER|Waiting Period|Participants in the control group initially undergo a 7-day waiting period before receiving the VR self-help protocol. During this period, they complete the same baseline assessments as the experimental group but do not receive any specific intervention.
219174676|NCT06531928|OTHER|chest tube withdrawal|The Effect of Chest Tube Withdrawal on Patients' Anxiety Levels in Thoracic Surgery Cases Performed with Video-Assisted Thoracoscopic Surgery
219174677|NCT04968119|OTHER|Exercise Intervention|Participate in telehealth exercise sessions
219174678|NCT04968119|OTHER|Quality-of-Life Assessment|Ancillary studies
219174679|NCT04968119|OTHER|Questionnaire Administration|Ancillary studies
219174680|NCT06848257|OTHER|Exercise|postural exercises
219174681|NCT06848972|OTHER|Structured musculoskeletal exercise programme|The module emphasizes specific exercises, strength training with and without weight, flexibility exercises and balancing exercises.
219174682|NCT06850649|OTHER|endocrowns|IPS Empress CAD Vita Enamic VarseoSmile Crown Plus
219174683|NCT02386722|DEVICE|Electronic Monitoring with audio reminders and additional support|"Automated reminder:~-Daily audio-reminder, generated by a smartphone.~Support calls (only patients with Smartinhaler):~* When the use of rescue medication doubles.~* When inhaled medication was not inhaled as prescribed for more than two consecutive days.~Feedback on adherence (only patients with POEMS):~-At every clinical visit (after 2, 4 and 6 months)."
219174684|NCT06849323|OTHER|Sujok therapy|The researchers will first detect the pain points in the hands by palpating them with a metal probe, then apply a clockwise massage to the painful point with the same metal probe, and finally complete the intervention by fixing the natural seed. The fixed seed should remain in the area where it is fixed for at least 4-8 hours, it should not come into contact with water or any liquid during this period, and the seed used should be used only once. There should be no wounds/cuts/scratches in the area where the massage and seed are applied, and the tissue integrity should be complete. According to the International Sujok Association (ISA), seeds similar to organs will be used in seed therapy, as well as neutral seeds (fenugreek, buckwheat and mung bean). Buckwheat seed, which is a powerful acupressure, will be applied. The effectiveness of the su jok treatment will be evaluated using the Bournemouth Neck Pain Question on the 11th day after all interventions and as a follow-up after 4 weeks
219174685|NCT06848608|PROCEDURE|traditional physiotherapy group|"* Resistance training: It is planned to give strengthening exercises for the upper and lower extremities (quadriceps, hamstrings, gluteus medius, gastrosoleus, deltoids, triceps and biceps brachii) with the resistive exercise band. The fatigue severity perceived by the patients during the exercises is aimed to be 4-6 according to the Modified Borg scale~* Pursed-lip breathing training (10 repetitions)~* Chest breathing exercise (10 repetitions)~* Diaphragmatic breathing exercise (10 repetitions)~* Thoracic expansion exercises (10 repetitions - apical expansion, unilateral basal expansion, bilateral basal expansion, posterior basal expansion)~Additionally In terms of aerobic training, free walking will be provided 3 days a week. (Based on distance determined by 6 DYT)"
219174686|NCT06848608|PROCEDURE|yoga program|"Pranayamic techniques:~Nadi Shodhana: 2 sets of nadi shodhana pranayama consisting of 8 breathing cycles will be applied.~Ujjai: Two sets of ujjayi technique consisting of 10 breathing cycles with an inhalation:exhalation ratio of 1:2 in each session will be applied with a 1-minute rest period between sets.~Bhramari: Two sets of bhramari pranayama consisting of 10 breathing cycles will be applied with a low respiratory rate with a 1-minute rest period between sets.~Sukha Pranayama : It will be applied 5:5 inhalation:exhalation ratio for 5 minutes.~Kapalabhati: 15 quick breaths in 10 seconds followed by a 20-second break (30 breaths per minute in total) will be practiced for 3 minutes~Asanas:~Sukhasana Bharadvajasana Marjaryasana- Bitilasana Bhujaganasana Kapotasana Hasta uttanasana Virabhadrasana I~In addition, free walking will be given 3 days a week in terms of aerobic training. (Based on distance determined by 6 DYT)"
219174687|NCT06849102|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
219174688|NCT06849102|OTHER|conventional physiotherapy interventions|Patients in this group will receive conventional physiotherapy interventions, including treadmill training, balance training, strengthening and stretching lower limb muscles, for 45 minutes per session, 3 times weekly, for 4 weeks.
219174689|NCT06849921|DRUG|Cellular Therapy|"This intervention involves the infusion of autologous or allogeneic CAR-T cells into patients with relapsed/refractory hematologic malignancies. CAR-T cells are modified to target specific antigens on the surface of cancerous cells. After the infusion, patients will be monitored for response and safety.~Administration: Intravenous infusion. Dosage: The maximum tolerated dose (MTD) will be determined as part of the study, with dose escalation used to identify the optimal and safest dose of CAR-T cells for treatment."
219174690|NCT06311760|DRUG|AZD0292|AZD0292 will be administered as single dose via IV infusion.
219174691|NCT06311760|DRUG|Placebo|Placebo will be administered as IV infusion.
219247181|NCT06255899|BEHAVIORAL|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
219247182|NCT01106586|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
219247183|NCT01106586|DRUG|ATV|Atazanavir 300 mg capsule administered orally once daily
219174692|NCT05205850|DRUG|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
219174693|NCT06848933|OTHER|Test meal|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
219174694|NCT06848933|DEVICE|Each participant will consume the test meal when on Medtronic Minimed 780G and will consume test meal on Medtronic Minimed 780G on manual mode|After the intervention, blood glucose values will be documented from continued glucose measurement system for postprandial 5 hours,and compared in manual mode and auto mode
219247184|NCT01106586|DRUG|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
219247185|NCT01106586|DRUG|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
219247186|NCT01106586|DRUG|Stribild Placebo|Placebo to match Stribild administered orally once daily
219247187|NCT01106586|DRUG|ATV Placebo|Placebo to match ATV administered orally once daily
219247188|NCT01106586|DRUG|RTV Placebo|Placebo to match RTV administered orally once daily
219247189|NCT01106586|DRUG|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
219247190|NCT01379521|DRUG|everolimus|
219247191|NCT01379521|DRUG|everolimus placebo|
219247192|NCT02502721|DRUG|DWC20151|
219247193|NCT02502721|DRUG|DWC20152|
219247194|NCT03894280|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
219247195|NCT03894280|DRUG|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
219247196|NCT03894280|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
219247197|NCT00938041|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
219247198|NCT04893902|DEVICE|medit intra oral scanner|ear scanning with intra oral scanner
219247199|NCT01714414|DRUG|FZD|
219247200|NCT01714414|DRUG|3TC|
219247201|NCT01714414|DRUG|EFV|
219247202|NCT01714414|DRUG|AZT|
219247203|NCT04464434|PROCEDURE|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
219247204|NCT03455569|BEHAVIORAL|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
219247205|NCT03455569|BEHAVIORAL|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
219247206|NCT01026103|DEVICE|Tri Staple Technology stapler|This is a single arm study.
219247207|NCT00105521|DRUG|Sarizotan|Sarizotan will be administered twice daily.
219247208|NCT00105521|DRUG|Placebo|Placebo matching to sarizotan will be administered twice daily.
219247209|NCT04723888|DIETARY_SUPPLEMENT|alpha-ketoglutarate|alpha-ketoglutarate supplements
219247210|NCT00281983|BIOLOGICAL|alemtuzumab|
219247211|NCT00281983|BIOLOGICAL|anti-thymocyte globulin|
219247212|NCT00281983|BIOLOGICAL|filgrastim|
219247213|NCT00281983|BIOLOGICAL|rituximab|
219247214|NCT00281983|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219247215|NCT00281983|DRUG|busulfan|
219247216|NCT00281983|DRUG|cyclophosphamide|
219247217|NCT00281983|DRUG|cyclosporine|
219247218|NCT00281983|DRUG|fludarabine phosphate|
219247219|NCT00281983|DRUG|methotrexate|
219247220|NCT00281983|DRUG|mycophenolate mofetil|
219247221|NCT00281983|PROCEDURE|peripheral blood stem cell transplantation|
219247222|NCT00281983|RADIATION|radiation therapy|
219247223|NCT06401447|RADIATION|Radiotherapy|Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
219247224|NCT03103178|OTHER|Quality of life questionnaire|Measurement of quality of life
219247225|NCT03999697|DRUG|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
219247226|NCT03698721|PROCEDURE|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
219247227|NCT03347773|DIETARY_SUPPLEMENT|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
219247228|NCT03053908|PROCEDURE|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
219247229|NCT03053908|PROCEDURE|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
219362701|NCT01043757|BEHAVIORAL|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
219362702|NCT03429946|DRUG|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
219247230|NCT05128539|DRUG|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
219247231|NCT00826527|DRUG|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
219247232|NCT02286427|DEVICE|Amniotic Membrane|
219247233|NCT00885859|DEVICE|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
219247234|NCT05051696|DRUG|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
219247235|NCT02686359|BIOLOGICAL|sample|
219247236|NCT05800483|BEHAVIORAL|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
219247237|NCT00482417|DRUG|MK0359|
219247238|NCT05202327|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
219247239|NCT05202327|DRUG|Placebo|The placebo contained corn starch.
219247240|NCT05876364|BIOLOGICAL|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
219174695|NCT06848933|DEVICE|Advanced hybrid closed loop system mode|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
219174696|NCT06850233|OTHER|No intervention|No intervention
219174697|NCT04163523|DRUG|Zanubrutinib|
219174698|NCT03519581|DEVICE|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
219174699|NCT03519581|DEVICE|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
219174700|NCT06389942|DRUG|9MW3011|Single dose intravenously on day 1
219174701|NCT06389942|DRUG|9MW3011 placebo|Single dose intravenously on day 1
219174702|NCT06850493|DIETARY_SUPPLEMENT|VLCKD (ketogenic diet)|diets prior to bariatric surgery
219174703|NCT06850493|DIETARY_SUPPLEMENT|VLCD (Very-low-calorie-diet)|diets prior to bariatric surgery
219174704|NCT06848309|PROCEDURE|Bronchoscopy|Some participants in all 5 groups may undergo an optional bronchoscopy procedure with bronchoalveolar lavage and endobronchial biopsy collection if they choose.
219174705|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
219174706|NCT06849609|BIOLOGICAL|VGN-R13|An adeno-associated viral vector 9 gene therapy product.
219174707|NCT06850597|DRUG|dimethyl fumarate|480 mg per day
219174708|NCT06848751|PROCEDURE|Non-intubated thoracoscopic surgery|Non-intubated thoracoscopic lung surgery for patients with impaired pulmonary function
219174709|NCT06848283|DIAGNOSTIC_TEST|Carotid ultrasonography|All examinations will be performed by a technician specialized in neurosonology, using the same technical protocol. For this purpose, a portable ultrasound device with a linear probe (L3-9 MHz) will be used. A quick screening will be conducted to check for the presence of atherosclerosis.
219174710|NCT02716012|DRUG|MTL-CEBPA|Intravenous administration
219174711|NCT02716012|DRUG|Sorafenib 200mg|Sorafenib tablets
219174712|NCT06843850|DEVICE|regenerative endodontics|The effect of different irrigation solutions on lesion healing in regenerative endodontics will be compared.
219174713|NCT06846840|DIETARY_SUPPLEMENT|Ketone ester|0.29 g per kilogram body mass per hour of ketone monoester (R)-3-hydroxybutyrate (R)-3-hydroxybutyl
219174714|NCT06846840|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides and bitter tastant (Bitrex)
219174715|NCT06848166|DEVICE|liquid embolic agent SQUID 12, liquid embolic agent SQUID 18|Total endovascular embolization of the frontal and parietal branches (less often the occipital branch) of the middle meningeal artery (MMA) with its complete devascularization. In the case of unilateral pain localization, ipsilateral MMA embolization will be performed; in the case of bilateral pain localization, total embolization of both MMA branches will be performed.
219174716|NCT04024917|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~\- The program cardiac coherence will be performed during 90 days after the surgery"
219174717|NCT04024917|OTHER|Standard care|Standard care
219174718|NCT06843616|PROCEDURE|Endoscopic surgery|Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma
219247241|NCT05876364|BIOLOGICAL|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
219247242|NCT05876364|BIOLOGICAL|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
219174719|NCT06846125|OTHER|GROUP A: Combined Mindfulness and Strength Training|"Week Exercises Reps x Sets 1-2 Mindfulness Training: Breathing exercises, body scans, and meditation. Strength Training: Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Mindfulness Training: Guided visualization and mindfulness integration during exercises.~Strength Training: Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Mindfulness Training: Focus on movement awareness and posture during high-intensity drills.~Strength Training: Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Mindfulness Training: Integration during advanced functional movements. Strength Training: Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4"
219174720|NCT06846125|OTHER|GROUP B: Strength Training Only|Week Exercises Reps x Sets 1-2 Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4
219174721|NCT05341167|DEVICE|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
219174722|NCT05341167|DRUG|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
219174723|NCT06844435|OTHER|continuous renal replacement therapy|continuous renal replacement therapy during OLT in surgery room
219174724|NCT05954143|DRUG|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
219174725|NCT05954143|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
219247243|NCT00495261|BEHAVIORAL|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
219247244|NCT00495261|BEHAVIORAL|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
219362703|NCT03429946|DRUG|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
219174726|NCT05118269|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
219174727|NCT05118269|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
219174728|NCT06846788|OTHER|Physical exercise|A traditional sensory relearning rehab session will be performed after our intervention consisting of 30 minutes of physical exercise.
219174729|NCT05591196|DEVICE|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
219174730|NCT05591196|OTHER|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
219174731|NCT06841315|DRUG|varegacestat|experimental intervention
219174732|NCT06841393|OTHER|Biometrological measurements|"Measurements will be taken from the face:~* For acne group: inflammatory lesional area and non-lesional area~* For control group: non-lesional area"
219174733|NCT06841393|OTHER|Biological sampling|"Samples will be taken from the face:~* For acne group: inflammatory lesional area, non-lesional area and retentional area~* For control group: non-lesional area"
219174734|NCT06841393|OTHER|Clinical assessments|Only for acne group: acne scores will be evaluated on the face by the investigator
219174735|NCT06841393|OTHER|Questionnaire|Only for acne group: consumers' perception
219174736|NCT06841861|GENETIC|Stem cell|Primary cell cultures of tissue cells will be established. Cell cultures will undergo genetic reprogramming to induce the long-term propagation of living cells.
219174737|NCT06841861|GENETIC|Genetic Screening|Serum samples are processed through RNA sequencing to reveal known and novel infertility-related biomarkers and genes.
219174738|NCT06841861|GENETIC|Genetic Reprogramming|Genes or gene products will be reinserted into cells to observe how the cells can be changed, or reprogrammed, into embryonic-like cells or into sperm precursor cells.
219174739|NCT06841861|GENETIC|Cell Maturation|Genetically unmodified and modified cells are placed in a laboratory-based testicular environment to promote spermatogenesis into maturity.
219174740|NCT06563245|DRUG|Brentuximab Vedotin for Injection|1.8mg/kg/dose (MAX 180 mg)
219174741|NCT06563245|RADIATION|response-adapted radiation|For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
219174742|NCT06563245|DRUG|Doxorubicin|25mg/m2/dose,
219174743|NCT06563245|DRUG|Etoposide|125 mg/m2/dose
219174744|NCT06563245|DRUG|Prednisone|20 mg/m2, BID, orally
219174745|NCT06563245|DRUG|Cyclophosphamide|600 mg/m2/dose
219174746|NCT06563245|DRUG|Dacarbazine|250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
219174747|NCT06563245|DRUG|Tislelizumab Injection|3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
219174748|NCT06563245|DRUG|Bedamustine|180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
219174749|NCT06843161|DEVICE|The jog or ground go no go task for retraining automatic bias|Recruited participants will be performing the JOGGNG Task on the Kinarm Endpoint Laboratory. This task requires participants to control a robotic handle to manipulate a virtual avatar that looks as if it is jogging across a field. During the jogging, a frisbee will appear and quickly move towards the avatar, eventually tilting clockwise or counterclockwise. Participants are required to either reach quickly to grab the frisbee from the air during clockwise tilts or to not move during counterclockwise tilts. This tilt/movement associated is reversed to control for a potential bias in tilt angle and movement. An image of physical activity or sedentary behaviour will appear inside of the frisbee but participants are not told that it is associated with any of the tilts. Each trial consists of one frisbee and participants will complete a total of 3 blocks of 360 trials each which will take approximately 30 minutes to complete.
219247245|NCT02578667|DEVICE|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
219247246|NCT00002471|DRUG|asparaginase|
219247247|NCT00002471|DRUG|cyclophosphamide|
219247248|NCT00002471|DRUG|cytarabine|
219247249|NCT00002471|DRUG|daunorubicin hydrochloride|
219247250|NCT00002471|DRUG|dexamethasone|
219247251|NCT00002471|DRUG|etoposide|
219247252|NCT00002471|DRUG|leucovorin calcium|
219247253|NCT00002471|DRUG|methotrexate|
219174750|NCT04342962|DRUG|tagraxofusp|Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
219174751|NCT06849180|COMBINATION_PRODUCT|Interventional therapies combined with or without systemic drugs|The study will include adult patients with histologically/cytologically confirmed unresectable CHC. Collect patient genomics, proteomics, immune microenvironment, pathology reports, medical images and clinical electronic medical records, etc., to form high-quality and deeply labeled data sets to support the subsequent development and application of AI large models. Based on multi-source heterogeneous data of CHC patients, a large model for comprehensive diagnosis and treatment was constructed. Firstly, multi-modal data of different stages of disease were integrated by using cross-modal multi-course fusion technology to achieve efficient fusion of complex data. Secondly, by fine-tuning the large model, tasks such as CHC classification, prognosis inference and treatment plan recommendation are accurately completed, and potential information in the diagnosis and treatment process is mined.
219247254|NCT00002471|DRUG|methylprednisolone|
219174752|NCT06850129|BEHAVIORAL|DIGITAL INTERVENTION|All patients received specific information about DM, treatments and po-tential complications. Then, patients were randomized to the digital interven-tion group or usual care. Those patients randomized to the intervention group were educated in the use of different social networks with access to infor-mation related to healthy lifestyle habits, dietary support, optimization of physi-cal activity, insulin titration, therapeutic targets, self-care, based on validated material from scientific societies and endorsed in diabetes education. Patients also had the valuable resource of a Digital Diabetes Coach: an online expert specializing in therapeutic education. This virtual guide provided patients with the flexibility to interact in both unidirectional and bidirectional ways, using methods such as chat boxes, audio messages, videos, and more. Through this digital medium, patients could seek guidance and have their questions re-solved.
219174753|NCT04691960|OTHER|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
219174754|NCT04691960|DRUG|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
219174755|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
219174756|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
219174757|NCT05048667|DEVICE|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
219174758|NCT05048667|DRUG|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
219174759|NCT05048667|OTHER|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
219174760|NCT05048667|OTHER|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
219174761|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
219174762|NCT06850181|BEHAVIORAL|game experience and learning motivation|game experience and learning motivation
219247255|NCT00002471|DRUG|therapeutic hydrocortisone|
219174763|NCT06848270|OTHER|Early palliative care integration|Early follow up by the palliative care team, from diagnosis
219174764|NCT04048278|DRUG|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
219174765|NCT04048278|DRUG|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
219174766|NCT03396926|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
219174767|NCT03396926|DRUG|Capecitabine|Given orally (PO)
219174768|NCT03396926|PROCEDURE|Specimen collection|For use in correlative studies
219174769|NCT03396926|BIOLOGICAL|Pembrolizumab|Given IV
219174770|NCT04266951|BEHAVIORAL|Singstrong:|Group singing and breathing control training
219174771|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
219174772|NCT04764448|OTHER|Placebo|Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
219174773|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
219174774|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
219174775|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
219174776|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
219174777|NCT06188754|BEHAVIORAL|Time restricted eating|Limiting food intake to 10 hours per day
219174778|NCT06188754|BEHAVIORAL|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
219174779|NCT06407830|OTHER|motor relearning programme|Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.
219174780|NCT06407830|OTHER|electrical muscle stimulations with motor relearning programme|"Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.~Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions for 8 weeks task specific training based on the motor relearning programme and 10 minutes of the EMS of each muscle during the session."
219174781|NCT05392192|DRUG|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
219174782|NCT05392192|DRUG|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
219174783|NCT04754945|DRUG|Bortezomib|Given SC
219174784|NCT04754945|DRUG|Cyclophosphamide|Given IV or PO
219174785|NCT04754945|DRUG|Dexamethasone|Given IV or PO
219174786|NCT04754945|BIOLOGICAL|Isatuximab|Given IV
219247256|NCT00002471|DRUG|thiotepa|
219247257|NCT00002471|DRUG|vincristine sulfate|
219247258|NCT01014663|BEHAVIORAL|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
219174787|NCT04529993|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
219174788|NCT03675815|DRUG|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
219174789|NCT03675815|DRUG|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
219174790|NCT03675815|DRUG|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
219247259|NCT01014663|BEHAVIORAL|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
219247260|NCT06170931|PROCEDURE|posterior cruciate ligament-retaining prostheses|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
219247261|NCT06170931|PROCEDURE|posterior cruciate ligament-substituting prostheses|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
219247262|NCT01504919|BEHAVIORAL|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
219247263|NCT01504919|BEHAVIORAL|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
219247264|NCT01504919|BEHAVIORAL|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
219247265|NCT01504919|DRUG|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
219247266|NCT04360642|OTHER|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
219247267|NCT02475733|DRUG|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
219247268|NCT02475733|DRUG|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
219247269|NCT02475733|DRUG|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
219247270|NCT06123819|DEVICE|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
219247271|NCT00404547|DRUG|Ciclesonide|Asthma Care with Alvesco
219247272|NCT00404547|DRUG|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
219247273|NCT00094497|DRUG|Etoposide|
219247274|NCT00094497|DRUG|Doxorubicin|
219247275|NCT00094497|DRUG|Cisplatin|
219247276|NCT00094497|DRUG|Streptozotocin|
219247277|NCT00094497|DRUG|Mitotane|
219247278|NCT00880152|BEHAVIORAL|Mindfulness-based stress reduction|An 8-week course in mindfulness training
219247279|NCT00917631|PROCEDURE|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
219247280|NCT03735641|PROCEDURE|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
219247281|NCT00415883|DRUG|Valsartan|
219247282|NCT03892122|DRUG|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
219247283|NCT03892122|DRUG|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
219247284|NCT05143437|BEHAVIORAL|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
219247285|NCT03047278|PROCEDURE|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
219174791|NCT03675815|DRUG|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
219174792|NCT03675815|DRUG|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
219174793|NCT03675815|DRUG|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
219174794|NCT03675815|DRUG|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
219174795|NCT05229146|BEHAVIORAL|Episodic Future Thinking|Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
219174796|NCT06104800|OTHER|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
219174797|NCT06104800|OTHER|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
219174798|NCT04226599|DEVICE|Dissolve AVF|Subjects in the test group will be treated with peripheral scoring drug balloon.
219174799|NCT04226599|DEVICE|Armada 35|Subjects in the test group will be treated with plain balloon catheter.
219174800|NCT03382977|BIOLOGICAL|VBI-1901|The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
219174801|NCT03382977|DRUG|Carmustine|Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
219174802|NCT03382977|DRUG|Lomustine|Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
219174803|NCT06276894|DEVICE|Motek C-Mill™ treadmill|We will enroll 10 to 15 participants to participate in a VR treadmill training session while wearing an fNIRS cap.
219174804|NCT06276894|OTHER|training session with and without VR wearing the fNIRS cap|training session with and without VR wearing the fNIRS cap
219174805|NCT05552547|DEVICE|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
219174806|NCT05552547|DEVICE|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
219174807|NCT05256706|DIAGNOSTIC_TEST|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
219174808|NCT05256706|OTHER|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
219174809|NCT01997840|DRUG|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
219174810|NCT04631094|OTHER|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
219174811|NCT04631094|OTHER|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
219174812|NCT04631094|OTHER|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
219174813|NCT04631094|OTHER|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
219174814|NCT06039865|BEHAVIORAL|Immediate Intervention|Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
219174815|NCT06039865|BEHAVIORAL|Waitlist control|Participants only receive usual care from the sleep center.
219174816|NCT04014673|BEHAVIORAL|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
219174817|NCT05304936|DRUG|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
219174818|NCT03850678|DEVICE|Hearing Aid|Hearing Aid
219174819|NCT06838611|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair of the tricuspid valve for the treatment of severe tricuspid valve regurgitation.
219174820|NCT05523154|PROCEDURE|Biospecimen Collection|Undergo collection of bile samples
219174821|NCT05523154|OTHER|Laboratory Procedure|Undergo routine laboratory testing
219174822|NCT05523154|DEVICE|Nanopore Sequencing|Undergo nanopore sequencing
219174823|NCT06849453|BEHAVIORAL|Exercise snacks group|Exercise snacks on the stairs for 8 weeks.
219174824|NCT06849453|BEHAVIORAL|Sprint interval training group|Sprint interval training on the stairs for 8 weeks.
219247286|NCT03047278|PROCEDURE|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
219247287|NCT03047278|DRUG|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
219174825|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
219174826|NCT06831201|DEVICE|Flow trigger sensitivity group|1\. Pressure support ventilation will be titrated at a level sufficient to achieve a respiratory rate of 20-30 breath/min and tidal volume 4-6 ml/kg. Pressure support will be reduced by 2 cm H2O every hour to reach pressure support 8 cm H2O. Two exercise sessions will be performed, at 9 AM and 5 PM. Training will be based on decreasing the trigger sensitivity gradually in order to increase muscle endurance. The trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training (In the first session), inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reach 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing trigger sensitivity by 10% of the initial MIP. Patients who could not tolerate IMT with 20% of MIP for 5 min were trained with 10% of MIP. Training consists of 5 to 6 sets of repetitions through the trainer.
219174827|NCT06831201|PROCEDURE|Active proprioceptive facilitation technique ( active PNF) technique|"1. patients in this group treated with the rhythmic initiation technique derived from the PNF concept. The RIT will be applied in four manual positions of the therapist's hands: The upper and lower chest wall, the sternum and below the rib cage, so that the patient can learn the correct breathing pattern. Verbal commands will be also used by the PT to reinforce the manual stimulation with each pattern/exercise being performed 10 times.~2. patients treated with the initial stretch technique ,This technique facilitates the initiation of inhalation. The IST was applied to help the patient to initiate the inhalation phase, increase the force developed by the inspiratory muscle, and to enhance the active range of motion of the chest wall and the diaphragm. At the final stage of exhalation, when inspiratory muscles will be elongated optimally, the stretch reflex will be initiated by applying a quick tap to elicit a strong and active inspiratory muscle contraction"
219178221|NCT06205420|DRUG|Injectable giomer restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
219247288|NCT03047278|DRUG|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
219247289|NCT01249599|PROCEDURE|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
219740880|NCT01458457|OTHER|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
219740881|NCT01458457|OTHER|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
219740882|NCT05314387|DEVICE|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
219174828|NCT06831201|PROCEDURE|Passive proprioceptive facilitation technique ( passive PNF) technique|"Perioral pressure is provided by applying pressure with the therapist's finger on the top lip between the nose and lip. The pressure is maintained for the length of time that the therapist wishes the patient to breathe in the activated pattern.~Intercostal stretch is provided by applying pressure to the upper border of a rib in order to stretch the intercostal muscle in a downward(not inward) direction. The stretch position is then maintained while the patient continues to breathe in his/her usual manner.~vertebral pressure high - manual pressure applied to thoracic vertebrae in the region T2 - T5.~vertebral pressure low - manual pressure applied to thoracic vertebrae in the region T9 - T10.~Co-contraction of the Abdomen Provided by the therapist by pressing adequate pressure on the lower ribs and pelvis on the same side, so that pressure is applied at right angles to the patient.~Moderate Manual Pressure of the open hand(s) is maintained over the area in which expansion is desired"
219174829|NCT04509102|DRUG|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
219740883|NCT05314387|DEVICE|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
219740884|NCT03816579|OTHER|PRO-A|30 g of beef protein will be consumed at each meal
219740885|NCT03816579|OTHER|PRO-B|30 g of complementary proteins will be consumed at each meal
219740886|NCT03816579|OTHER|PRO-C|30 g of complementary proteins will be consumed over 24 hours
219740887|NCT01879826|DEVICE|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
219740888|NCT01879826|DEVICE|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
219174830|NCT04509102|DRUG|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
219174831|NCT05355363|DIAGNOSTIC_TEST|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
219174832|NCT04022616|OTHER|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
219174833|NCT01492751|BEHAVIORAL|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
219174834|NCT01492751|PROCEDURE|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
219174835|NCT01492751|RADIATION|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
219174836|NCT01492751|RADIATION|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
219174837|NCT04415424|BIOLOGICAL|4CMenB vaccine|A four-component meningococcal B vaccine
219174838|NCT04415424|OTHER|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
219174839|NCT05321056|DEVICE|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
219174840|NCT04582825|OTHER|N/A - Observational Study|N/A - Observational Study
219174841|NCT05872477|DRUG|Ruxolitinib Topical|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
219362704|NCT03429946|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
219740889|NCT00292903|BEHAVIORAL|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
219740890|NCT00292903|BEHAVIORAL|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
219174842|NCT05872477|DRUG|Placebo|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
219174843|NCT06373562|OTHER|hypoxia|The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
219174844|NCT05849064|BEHAVIORAL|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
219174845|NCT05849064|BEHAVIORAL|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
219174846|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
219174847|NCT06422390|BIOLOGICAL|Platelet - Rich Plasma|Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
219174848|NCT04101474|DRUG|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
219174849|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
219174850|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
219174851|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
219174852|NCT04487145|DRUG|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
219174853|NCT06155266|DIAGNOSTIC_TEST|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
219174854|NCT06442059|OTHER|Kinesiophobia Level Due to Dyspnea|Kinesiophobia Level Due to Dyspnea
219174855|NCT03656549|DRUG|Pemetrexed + oral folinic acid rescue|3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
219174856|NCT06139042|DIAGNOSTIC_TEST|Blood drawing|The participants had their blood drawn.
219174857|NCT06543940|DRUG|Vancomycin|vancomycin dose is 7.5 to 10 mg/kg
219174858|NCT03767855|DRUG|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
219174859|NCT03767855|DRUG|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
219174860|NCT03767855|DRUG|CK-3773274 - Tablets|CK-3773274 formulated as tablets
219174861|NCT04322643|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
219174862|NCT04322643|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
219174863|NCT04322643|DRUG|Durvalumab|Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
219174864|NCT04322643|DRUG|Nivolumab|Nivolumab 480mg IV over 30 minutes every 4 weeks
219174865|NCT04322643|DRUG|Avelumab|Avelumab 800 mg IV over 60 minutes every 2 weeks
219174866|NCT04353804|OTHER|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
219174867|NCT04353804|OTHER|Active Control computer games|Active Control computer games
219174868|NCT04561232|BEHAVIORAL|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
219174869|NCT06304324|DRUG|0.9% Sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
219362705|NCT03429946|OTHER|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
219174870|NCT06304324|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
219174871|NCT06304324|DRUG|0.05ug/kg Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
219174872|NCT06798480|OTHER|Self-administered survey|An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.
219740891|NCT04431063|PROCEDURE|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
219740892|NCT04781842|OTHER|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
219740893|NCT00977444|DRUG|kondrium|intraarticular injections once month
219740894|NCT00977444|DRUG|kondrium f|intraarticular injections once month
219174873|NCT06288191|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
219174874|NCT02801812|DEVICE|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
219174875|NCT04704999|DRUG|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
219174876|NCT04704999|DRUG|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
219174877|NCT04704999|DRUG|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
219174878|NCT06346262|BEHAVIORAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
219174879|NCT06346262|DRUG|Valtoco Nasal Product|Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
219174880|NCT03584295|DEVICE|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
219174881|NCT03584295|OTHER|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
219174882|NCT03513614|PROCEDURE|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
219174883|NCT03513614|RADIATION|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
219174884|NCT03513614|RADIATION|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
219174885|NCT06007651|DRUG|LY3885125|Administered SC
219174886|NCT06007651|DRUG|Placebo|Administered SC
219174887|NCT06167343|PROCEDURE|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
219174888|NCT01524965|PROCEDURE|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
219740895|NCT00977444|DRUG|methyl prednisolone (corticosteroid)|intraarticular injections once month
219740896|NCT01630109|DRUG|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
219740897|NCT01630109|DRUG|Placebo|A placebo capsule made to look like the metoclopramide capsule.
219740898|NCT04714255|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
219174889|NCT01524965|PROCEDURE|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
219174890|NCT01524965|DEVICE|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
219174891|NCT05638620|DRUG|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
219174892|NCT03891667|DRUG|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
219174893|NCT03595293|DEVICE|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
219174894|NCT03595293|DEVICE|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
219362706|NCT03473561|DRUG|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to \< 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
219362707|NCT00276575|BIOLOGICAL|bevacizumab|
219362708|NCT00276575|DRUG|erlotinib hydrochloride|
219174895|NCT02698462|OTHER|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
219174896|NCT02515955|DRUG|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
219174897|NCT02515955|DRUG|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
219174898|NCT02515955|DRUG|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
219362709|NCT00276575|DRUG|everolimus|
219362710|NCT02876887|DRUG|Cocoa|
219362711|NCT02876887|DRUG|Placebo|
219740899|NCT04501822|DIAGNOSTIC_TEST|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
219740900|NCT04198649|DRUG|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
219740901|NCT04198649|OTHER|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
219740902|NCT05034081|PROCEDURE|body contouring|any post-bariatric body contouring surgery included
219740903|NCT06541132|OTHER|Observational study without human intervention|Observational study without human intervention
219740904|NCT04753359|OTHER|Med|Mediterranean diet
219740905|NCT04753359|OTHER|WL|Measuring change in weight
219740906|NCT05286112|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
219740907|NCT05286112|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
219740908|NCT00809588|BIOLOGICAL|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
219740909|NCT03692169|PROCEDURE|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
219740910|NCT03987685|DRUG|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
219740911|NCT04085731|PROCEDURE|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
219740912|NCT03594474|OTHER|Intravenous lipid emulsion|using higher dose of IV lipids after birth
219740913|NCT00859885|DRUG|Antithrombotic treatment|antiplatelets, anticoagulants
219740914|NCT00859885|DEVICE|percutaneous device closure of PFO|umbrella device for PFO closure
219740915|NCT05777863|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
219740916|NCT03822715|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
219740917|NCT03822715|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
219740918|NCT04386239|DRUG|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
219362712|NCT03972722|DRUG|GLS-010|Patients will be given 240mg GLS-010 every treatment.
219362713|NCT02755194|OTHER|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
219174899|NCT02515955|DRUG|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
219174900|NCT02515955|DRUG|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
219740919|NCT06440837|BEHAVIORAL|IMB stress self-management health education|The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
219740920|NCT01534221|DEVICE|Biomatrix drug eluting stent|Biomatrix drug eluting stent
219740921|NCT02125422|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
219740922|NCT02790736|DRUG|propranolol|active treatment
219740923|NCT02790736|DRUG|Placebo|inactive pill
219740924|NCT04306120|OTHER|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
219740925|NCT04545892|DRUG|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
219740926|NCT04854473|DEVICE|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
219740927|NCT01427673|PROCEDURE|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
219740928|NCT05412979|DRUG|ST-1891|ST-1891
219740929|NCT05412979|DRUG|Levothyroxine|Levothyroxine
219740930|NCT03484897|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
219740931|NCT01030809|OTHER|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
219740932|NCT02126891|PROCEDURE|Tests|Individual parameters of echocardiography and heart rate variability
219740933|NCT01839409|BEHAVIORAL|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
219740934|NCT02154230|DIETARY_SUPPLEMENT|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
219740935|NCT02154230|DIETARY_SUPPLEMENT|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
219740936|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
219740937|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
219740938|NCT00589524|DEVICE|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
219740939|NCT01993680|DRUG|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
219740940|NCT01993680|DRUG|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
219740941|NCT01246518|DRUG|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
219740942|NCT05131256|BEHAVIORAL|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
219740943|NCT04639791|OTHER|No intervention|Observation only, no intervention
219740944|NCT02192476|OTHER|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
219740945|NCT02192476|OTHER|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
219740946|NCT02003898|DEVICE|Medtronic MiniMed 530G Insulin Pump|
219740947|NCT03412591|DRUG|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
219740948|NCT03127163|DEVICE|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
219740949|NCT04952519|DRUG|Amantadine|Patients are treated with high doses of amantadine.
219740950|NCT06054308|OTHER|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
219740951|NCT03930511|PROCEDURE|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
219740952|NCT00273585|DEVICE|Personally-tailored educational software program|
219740953|NCT01484756|DIETARY_SUPPLEMENT|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
219740954|NCT01484756|DIETARY_SUPPLEMENT|Placebo|calcium carbonate 500 mg
219740955|NCT04586751|OTHER|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
219740956|NCT04586751|OTHER|no Pecs block|no regional block will be performed in this arm
219740957|NCT04949087|PROCEDURE|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
219740958|NCT01660373|DRUG|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
219740959|NCT01660373|DRUG|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
219740960|NCT05458531|OTHER|Questionnaire|A single questionnaire
219740961|NCT05458531|OTHER|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
219740962|NCT00663156|PROCEDURE|breast implants|patients will have breast augmentation using implants
219740963|NCT00663156|PROCEDURE|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
219740964|NCT05775939|OTHER|Fludeoxyglucose F-18|Given FDG
219740965|NCT05775939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219740966|NCT05775939|PROCEDURE|Computed Tomography|Undergo PET-CT
219740967|NCT05775939|OTHER|Questionnaire Administration|Ancillary studies
219740968|NCT02998307|PROCEDURE|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
219740969|NCT01582581|BEHAVIORAL|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
219740970|NCT01582581|BEHAVIORAL|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
219740971|NCT03064009|OTHER|Infection|This is an observational trial
219740972|NCT05277935|DEVICE|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
219174901|NCT05984069|OTHER|observational prospective data collection|Collection of data from medical records.
219740973|NCT00170820|DRUG|Everolimus|
219740974|NCT00944021|DRUG|PA-824|50mg
219740975|NCT00944021|DRUG|PA-824|100mg
219740976|NCT00944021|DRUG|PA-824|150 mg
219740977|NCT00944021|DRUG|Rifafour e-275 mg|275 mg
219740978|NCT00944021|DRUG|PA-824|200 mg
219740979|NCT00204581|DRUG|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
219740980|NCT00363363|BEHAVIORAL|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
219740981|NCT00363363|BEHAVIORAL|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
219174902|NCT05937321|BEHAVIORAL|Share plus intervention|"Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR"
219174903|NCT05937321|BEHAVIORAL|Control group|Diabetes self-management education materials
219247290|NCT04427397|OTHER|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
219247291|NCT05819983|DRUG|Ivermectin Tablets|Ivermectin 200µg/kg BW
219247292|NCT05819983|DRUG|Permethrin Cream|Permethrin cream 5%
219247293|NCT02744898|DRUG|Carboplatin AUC|
219174904|NCT05606705|DIETARY_SUPPLEMENT|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
219174905|NCT05980806|DRUG|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
219174906|NCT05980806|DRUG|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
219174907|NCT05980806|DRUG|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
219174908|NCT05980806|DRUG|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
219174909|NCT05980806|DRUG|Momelotinib|Participants will receive momelotinib 200 mg once daily.
219174910|NCT05226598|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
219174911|NCT05226598|DRUG|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
219174912|NCT05226598|DRUG|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
219174913|NCT05226598|DRUG|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
219247294|NCT02744898|DRUG|Abraxane|100mg/m2
219247295|NCT02411253|DRUG|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
219247296|NCT02411253|DRUG|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
219247297|NCT04075097|BEHAVIORAL|Aerobic exercise|1 session
219247298|NCT04075097|BEHAVIORAL|Iyengar yoga|1 session
219247299|NCT06214754|PROCEDURE|PCI|The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
219247300|NCT01973478|DEVICE|DBS|
219247301|NCT01973478|DEVICE|SHAM|
219247302|NCT03803488|DEVICE|DropSafe safety pen needle|
219247303|NCT00640354|DEVICE|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
219247304|NCT00640354|DEVICE|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
219247305|NCT05289778|OTHER|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
219247306|NCT00950430|DRUG|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
219247307|NCT00950430|DRUG|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
219247308|NCT00950430|DRUG|Tau (18-F-AV-1451)|"1. PIB PET scan, Tau PET scan and/or FDG PET scan~2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
219362714|NCT01499017|DRUG|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
219247309|NCT03158519|BEHAVIORAL|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
219247310|NCT06647368|OTHER|PET with 18-FDG|The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
219247311|NCT05680415|BIOLOGICAL|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
219247312|NCT04609579|DRUG|SNX281|SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
219740982|NCT05175729|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
219740983|NCT02534155|DEVICE|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
219740984|NCT02534155|PROCEDURE|Mitral valve Surgery|Repair or replace mitral valve
219740985|NCT02302326|DRUG|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
219740986|NCT02302326|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
219740987|NCT04801901|PROCEDURE|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
219740988|NCT04801901|PROCEDURE|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
219740989|NCT05770180|BIOLOGICAL|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
219740990|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (CHO cell)|control 1
219740991|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
219740992|NCT03177798|DRUG|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
219740993|NCT03177798|DRUG|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
219740994|NCT03662529|BEHAVIORAL|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
219740995|NCT03662529|BEHAVIORAL|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
219740996|NCT05600751|PROCEDURE|Radiosurgery of ganglion stellatum|Patients will undergo radiosurgery of ganglion stellatum (left one or both)
219247313|NCT04609579|DRUG|pembrolizumab|pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
219247314|NCT03779776|OTHER|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
219740997|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
219740998|NCT04072939|OTHER|Patients having had a lens surgery|Dilated fundus exam
219740999|NCT03713411|PROCEDURE|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
219741000|NCT02695186|PROCEDURE|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
219741001|NCT04309266|DEVICE|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
219741002|NCT04309266|BEHAVIORAL|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
219174914|NCT05226598|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
219174915|NCT05226598|DRUG|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
219174916|NCT05226598|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
219174917|NCT04145466|BEHAVIORAL|High-fat diet|"The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
219247315|NCT03779776|OTHER|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
219247316|NCT05797116|OTHER|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
219247317|NCT03538457|DRUG|Paracetamol|Patients are tested for their normal prescription paracetamol medication
219247318|NCT01973296|BEHAVIORAL|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
219247319|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
219247320|NCT03556345|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
219174918|NCT04145466|BEHAVIORAL|High-carbohydrate diet|"The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
219174919|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
219174920|NCT03563144|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
219174921|NCT03563144|DRUG|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
219174922|NCT03563144|DRUG|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
219247321|NCT01391533|DRUG|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
219247322|NCT00214162|BEHAVIORAL|Comprehensive Health Enhancement Support System|Full CHESS
219247323|NCT00214162|BEHAVIORAL|computer with internet|computer with internet use x 1 year
219247324|NCT04789616|DRUG|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
219247325|NCT04789616|BEHAVIORAL|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
219247326|NCT04789616|OTHER|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
219247327|NCT04789616|DEVICE|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
219247328|NCT04789616|BEHAVIORAL|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
219174923|NCT03563144|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
219174924|NCT03563144|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219174925|NCT03563144|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
219174926|NCT03563144|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
219174927|NCT03563144|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
219174928|NCT03563144|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
219174929|NCT03563144|BIOLOGICAL|GI-6207|CEA yeast vaccine
219174930|NCT03563144|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
219174931|NCT03563144|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
219174932|NCT03563144|DRUG|Avelumab|Avelumab
219174933|NCT03563144|DRUG|Bevacizumab|Bevacizumab
219174934|NCT03563144|DRUG|Capecitabine|Capecitabine
219174935|NCT03563144|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219174936|NCT03563144|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219174937|NCT03563144|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
219174938|NCT03563144|DRUG|Oxaliplatin|Oxaliplatin
219174939|NCT04774003|DRUG|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
219174940|NCT04774003|DRUG|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
219174941|NCT04774003|DRUG|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
219174942|NCT05603234|BEHAVIORAL|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
219174943|NCT06071312|BIOLOGICAL|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
219174944|NCT06071312|BIOLOGICAL|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
219174945|NCT04522375|DRUG|FP-045|activator of aldehyde dehydrogenase
219178222|NCT06635720|DRUG|Prednisone|This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.
219178223|NCT03513562|DRUG|Ibrutinib|Given PO
219178224|NCT03513562|OTHER|Laboratory Biomarker Analysis|Correlative studies
219178225|NCT03513562|DRUG|Venetoclax|Given PO
219174946|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
219174947|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
219174948|NCT00534469|BIOLOGICAL|aldesleukin|
219174949|NCT00534469|BIOLOGICAL|filgrastim|
219174950|NCT00534469|DRUG|busulfan|
219174951|NCT00534469|DRUG|cytarabine|
219174952|NCT00534469|DRUG|etoposide|
219174953|NCT00534469|DRUG|idarubicin|
219741003|NCT01720836|BIOLOGICAL|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
219741004|NCT00398879|DRUG|Perifosine|Perifosine 50 mg/d qd
219741005|NCT00398879|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
219741006|NCT00398879|OTHER|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
219741007|NCT05139095|DRUG|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
219741008|NCT05139095|DRUG|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
219741009|NCT06108609|OTHER|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~* Audiometry (as part of treatment)~* Clinical evaluation (as part of treatment)~* Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
219741010|NCT05599165|OTHER|signal processing on consonant recognition|Consonant recognition will be measured in noise without any signal processing.
219741011|NCT06642194|BEHAVIORAL|Education on sunnah of sleeping|The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
219743525|NCT02943499|BEHAVIORAL|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
219174954|NCT00534469|PROCEDURE|autologous hematopoietic stem cell transplantation|
219174955|NCT00534469|PROCEDURE|bone marrow transplantation|
219174956|NCT00534469|PROCEDURE|peripheral blood stem cell transplantation|
219174957|NCT00534469|RADIATION|total-body irradiation|
219174958|NCT04622943|BEHAVIORAL|firearms safety|interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety
219174959|NCT04622943|BEHAVIORAL|nutrition|interactive and engaging website with videos and educational games to teach children about nutrition and wellbeing
219174960|NCT02502435|OTHER|Observation|Observational study
219174961|NCT05896267|DEVICE|Masimo INVSENSOR00061|Masimo INVSENSOR00061 will be used to measure noninvasive SpO2 (Oxygen Saturation )
219174962|NCT05873504|DEVICE|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
219174963|NCT05873504|DEVICE|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
219174964|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
219174965|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
219174966|NCT05717907|DEVICE|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
219174967|NCT05845918|BEHAVIORAL|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
219174968|NCT05571878|DRUG|Humalog|All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
219174969|NCT05571878|DRUG|Saline nasal spray|All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
219174970|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
219174971|NCT05977270|DEVICE|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
219174972|NCT05038332|RADIATION|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
219174973|NCT05038332|RADIATION|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
219174974|NCT04166773|DRUG|Tirzepatide|Administered SC
219741012|NCT06637280|DEVICE|High - flow nasal cannula|"High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation."
219741013|NCT06637280|DEVICE|Standard nasal cannula|Standard method for supplementing oxygen during EBUS bronchoscopy
219741014|NCT03424343|OTHER|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
219741015|NCT03424343|OTHER|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
219741016|NCT05888922|DRUG|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
219741017|NCT05888922|DRUG|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
219741018|NCT05888922|DRUG|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
219741019|NCT05888922|DRUG|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
219741020|NCT03162211|OTHER|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
219741021|NCT06032923|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
219741022|NCT06059001|DRUG|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
219174975|NCT04166773|DRUG|Placebo|Administered SC
219247329|NCT06244888|BEHAVIORAL|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
219741023|NCT06059001|DRUG|Nab-Paclitaxel|IV infusion - Standard of Care
219741024|NCT06059001|DRUG|Gemcitabine|IV infusion - Standard of Care
219741025|NCT02081703|DRUG|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
219741026|NCT02081703|DRUG|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
219741027|NCT02081703|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
219741028|NCT02081703|DRUG|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
219741029|NCT01853280|DRUG|L-methylfolate|15mg/day L-methylfolate.
219741030|NCT01853280|DRUG|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
219741031|NCT01853280|DRUG|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
219741032|NCT05156112|DEVICE|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
219741033|NCT02735460|DEVICE|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
219741034|NCT03032484|DRUG|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
219741035|NCT03032484|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
219741036|NCT05501522|BIOLOGICAL|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
219741037|NCT05501522|OTHER|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
219741038|NCT04745806|DEVICE|ActiGraft|Whole blood clot (WBC) gel
219741039|NCT01229111|DRUG|cediranib maleate|Given PO
219741040|NCT01229111|DRUG|oxaliplatin|Given IV
219741041|NCT01229111|DRUG|leucovorin calcium|Given IV
219741042|NCT01229111|DRUG|fluorouracil|Given IV
219741043|NCT02383823|DRUG|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
219741044|NCT02383823|OTHER|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
219741045|NCT01689649|DRUG|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
219741046|NCT05796193|OTHER|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
219741047|NCT05796193|OTHER|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
219741048|NCT05796193|OTHER|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
219174976|NCT05858008|BEHAVIORAL|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
219174977|NCT06469398|DEVICE|Cutera Laser System|Subjects will receive up to 6 laser treatments
219174978|NCT06212440|DIAGNOSTIC_TEST|Radioactive Isotope (RI) Mapping|Administered via peritumoral or subareolar injection for sentinel lymph node detection.
219247330|NCT06244888|BEHAVIORAL|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
219362715|NCT01499017|DRUG|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
219741049|NCT05041699|COMBINATION_PRODUCT|IPM Ring-105|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
219741050|NCT05041699|COMBINATION_PRODUCT|IPM Ring-106|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
219741051|NCT06138158|PROCEDURE|Exercise and Education Group|Physical exercise and pain education
219741052|NCT03415048|OTHER|No Intervention|
219247331|NCT06244888|BEHAVIORAL|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
219247332|NCT06244888|BEHAVIORAL|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
219247333|NCT01825018|BEHAVIORAL|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
219741053|NCT04889950|DEVICE|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
219741054|NCT04889950|DEVICE|LipiFlow|LipiFlow
219741055|NCT05389150|DRUG|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
219741056|NCT05389150|DRUG|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
219741057|NCT05389150|DRUG|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
219741058|NCT06119321|OTHER|Pentacam, Corvis ST and Scansys|morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
219741059|NCT06241014|OTHER|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
219741060|NCT06241014|OTHER|Mulligan Mobilization|Mulligan Mobilization
219741061|NCT05662722|OTHER|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
219741062|NCT05662722|OTHER|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
219741063|NCT05662722|OTHER|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
219741064|NCT06215508|OTHER|Questionnaires|Questionnaires participants fill out at different study visits
219741065|NCT04724252|DRUG|Gabapentin|Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
219741066|NCT04724252|OTHER|Placebo|Control Arm
219741067|NCT03702738|DRUG|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
219741068|NCT03945253|DRUG|ASP8374|Intravenous
219741069|NCT05158699|DRUG|Bromfenac|Bromfenac topical eye drops (Yellox)
219741070|NCT05158699|DRUG|Dexamethasone|Dexamethasone topical eye drops
219741071|NCT05158699|DRUG|Triamcinolone Acetonide|0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
219741072|NCT05158699|DRUG|Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution|Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
219741073|NCT05531149|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
219741074|NCT05531149|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
219741075|NCT03100461|OTHER|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
219741076|NCT03100461|OTHER|Health Education|Standard of care approach that will provide basic information on CRC screening.
219741077|NCT05931718|BIOLOGICAL|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
219741078|NCT05931718|BIOLOGICAL|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
219741079|NCT05931718|BIOLOGICAL|Fecal microbiome|evaluation of fecal microbiome on fecal samples
219741080|NCT05931718|DRUG|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
219741081|NCT05931718|DRUG|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
219741082|NCT05931718|DRUG|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
219741083|NCT05931718|DRUG|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
219741084|NCT05201495|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
219741085|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
219741086|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
219247334|NCT01825018|BEHAVIORAL|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
219247335|NCT04241380|DRUG|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
219247336|NCT04241380|OTHER|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
219362716|NCT04992143|PROCEDURE|TACE|TACE first ,and more TACE could be performed when it is necessary.
219247337|NCT04241380|DRUG|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
219362717|NCT04992143|DRUG|Tilelizumab|Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
219362718|NCT04992143|DRUG|Sorafenib|Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
219741087|NCT04265768|PROCEDURE|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
219741088|NCT05995600|DRUG|Antiplatelet Drug|Clopidogrel ± other antiplatelet drug
219741089|NCT05995600|DRUG|Warfarin|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
219741090|NCT04914273|DRUG|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
219741091|NCT04914273|DRUG|Tablet|8 mg salbutamol administered per tablet for ingestion
219741094|NCT03042975|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
219741095|NCT03042975|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
219741096|NCT05999383|DRUG|Cannabis|Participants will vape marijuana in varying doses from the PAX device
219741097|NCT05999383|DRUG|Nicotine|Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
219741098|NCT05999383|DEVICE|Pax Loose Leaf Vaporizer|In all arms, participants will be using the PAX Loose Leave Vaporizer.
219741099|NCT05999383|OTHER|Placebo Marijuana|Participants will vape placebo marijuana from the PAX device
219741100|NCT03689179|BEHAVIORAL|Time for Living and Caring (TLC)|"Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?."
219741101|NCT03396861|DRUG|Aflibercept|Subconjunctival aflibercept
219741102|NCT06639243|DEVICE|QYM Technique|"The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out"
219247338|NCT01078571|BIOLOGICAL|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
219247339|NCT00574106|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
219247340|NCT05074004|OTHER|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
219247341|NCT00447356|DRUG|recombinant interferon alfa|
219247342|NCT05817864|DIAGNOSTIC_TEST|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level \> 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
219247343|NCT01592565|OTHER|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
219247344|NCT04979234|DEVICE|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
219247345|NCT04979234|BEHAVIORAL|Diet|Multidisciplinary follow up
219247346|NCT01107249|DEVICE|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
219247347|NCT04958629|OTHER|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
219247348|NCT00254722|DRUG|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
219362719|NCT00331409|DRUG|Everolimus|2.5 mg by mouth daily
219362720|NCT00331409|DRUG|imatinib mesylate|600 mg by mouth daily
219741103|NCT06637267|DIAGNOSTIC_TEST|Proclarix®|The aim of the study is the implementation of new biomarkers (Proclarix®) in order to increase the sensitivity and specificity of PSA-based Prostate cancer early detection avoiding unnecessary prostate biopsies thus decreasing the associated morbidity (infections, bleeding, urinary retention, etc.). PSA values, Proclarix and mpMRI findings will be correlated with the results of the prostate biopsy in order to improve patient selection for future biopsies in order to avoid unnecessary prostate biopsies, but still be able to detect relevant carcinomas at an early stage. The null hypothesis in our observational study is the lack of superiority in PCa early detection when using the Proclarix over PSA alone.
219741104|NCT06638983|OTHER|Non-extraction Orthodontic Treatment of Angle Class I Malocclusion|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
219741105|NCT06643689|DRUG|Tranilast|Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
219741106|NCT06643689|DRUG|Dexamethasone|Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
219741107|NCT06645405|BEHAVIORAL|AI algorithm|Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
219741108|NCT06527872|OTHER|None (Observational study)|Not Applicable since Observational Study
219741109|NCT05406453|OTHER|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
219741110|NCT00595075|DRUG|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
219741111|NCT00595075|DRUG|placebo|placebo identical in appearance to active experimental drug x 1 dose
219741112|NCT03495635|BEHAVIORAL|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
219741113|NCT01156467|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
219741114|NCT01156467|DEVICE|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
219741115|NCT04577703|DRUG|CT053PTSA|CT053PTSA will be administered daily in fasting state
219741116|NCT06571331|OTHER|De-Stress & Snooze Gummies-U001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
219741117|NCT06571331|OTHER|De-Stress & Snooze Gummies-I001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
219174979|NCT06212440|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG-F) Mapping|Administered via peritumoral or subareolar injection, detected using near-infrared fluorescence imaging.
219174980|NCT06212440|DIAGNOSTIC_TEST|Vital Dye Mapping|Administered via peritumoral or subareolar injection for intraoperative visualization of lymphatic drainage pathways.
219174981|NCT03952351|RADIATION|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
219174982|NCT06511752|BEHAVIORAL|Psychosocial educational, support group and implementation of strategies|Psychosocial educational, support group and implementation of strategies
219174983|NCT05076708|OTHER|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
219174984|NCT01544803|BEHAVIORAL|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
219174985|NCT01544803|BEHAVIORAL|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
219174986|NCT03159702|DRUG|Evomela|140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
219174987|NCT03159702|DRUG|Fludarabine|40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
219174988|NCT03159702|RADIATION|Total Body Irradiation|200 cGy on Day: -1
219174989|NCT05110443|OTHER|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
219178226|NCT04955470|DRUG|Ketamine Injectable Solution|A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
219178227|NCT04955470|DRUG|Midazolam Injectable Solution|A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
219178228|NCT04955470|DRUG|Normal Saline 0.9% Injectable Solution|A 0.9% normal saline solution will be infused over a 40 minute period.
219362721|NCT00783393|DRUG|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
219741118|NCT06571331|OTHER|Placebo Gummies 002|Two gummies daily in sequence 30-45 minutes before bed for 60 days
219741119|NCT01946880|DRUG|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
219741120|NCT01946880|DRUG|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
219741121|NCT01946880|DRUG|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
219741122|NCT04246944|PROCEDURE|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
219741123|NCT06225544|DRUG|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
219741124|NCT06225544|DRUG|0.9% Sodium Chloride (placebo)|Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
219741125|NCT04477837|DRUG|Apixaban 5 MG|frequency of heavy menstrual bleeding
219741126|NCT04477837|DRUG|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
219741127|NCT04477837|DRUG|Edoxaban 60 MG|frequency of heavy menstrual bleeding
219741128|NCT04477837|DRUG|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
219741129|NCT04543786|DEVICE|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
219741130|NCT04806399|OTHER|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
219741131|NCT01142570|OTHER|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
219741132|NCT01142570|OTHER|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
219741133|NCT01142570|DIETARY_SUPPLEMENT|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
219741134|NCT01142570|DIETARY_SUPPLEMENT|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
219741135|NCT01142570|DIETARY_SUPPLEMENT|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
219741136|NCT06063681|DRUG|SR-8541A|orally administered ENPP1 inhibitor
219741137|NCT06063681|DRUG|Immune checkpoint inhibitor (ICI)|The ICI will be either nivolumab or pembrolizumab.
219741138|NCT03864328|DRUG|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
219741139|NCT03864328|DRUG|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
219741140|NCT06484543|OTHER|Maslinic Acid|Consumption of Maslinic Acid for 12 weeks
219741141|NCT06484543|OTHER|Placebo|Consumption of Placebo for 12 weeks
219741142|NCT06547996|DEVICE|tES-tDCS group|2mA/20mins/session
219741143|NCT06547996|DEVICE|tES-tACS group|2mA/40Hz/20mins/session
219741144|NCT06547996|DEVICE|tES-sham group|0mA/20mins/session
219741145|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
219741146|NCT00720811|DRUG|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
219741147|NCT00720811|DRUG|paracetamol|paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
219741148|NCT00720811|DEVICE|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
219741149|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
219741150|NCT03197272|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
219741151|NCT04616235|DRUG|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
219741152|NCT04616235|OTHER|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
219741153|NCT06404554|OTHER|without any intervention|without any intervention
219741154|NCT06197516|OTHER|Integrated Neuromuscular Inhibition Technique|After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
219741155|NCT06197516|OTHER|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
219741156|NCT01766843|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
219741157|NCT01766843|DRUG|Seretide Diskus|2 inhalations as a single dose
219741158|NCT01766843|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
219741159|NCT01766843|DRUG|SF Easyhaler|2 inhalations as a single dose
219247349|NCT00802334|DRUG|generic lopinavir/ritonavir|"1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
219247350|NCT05859529|DRUG|JS002|The drug was administered by a single subcutaneous injection
219247351|NCT06802991|OTHER|ERAS 3.0 (Enhanced Recovery After Surgery)|Nutritional support at discharge and home visits which include comprehensive geriatric assessment, nutritional guidance by dietitian, and instructions on exercise and physical activity.
219247352|NCT01662661|DRUG|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
219247353|NCT01662661|DRUG|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
219247354|NCT02588027|DRUG|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
219247355|NCT02588027|DRUG|Placebo|Pharmacy formulated placebo
219247356|NCT05476601|BEHAVIORAL|CMAP Plus|The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
219247357|NCT05837650|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
219247358|NCT04372186|DRUG|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
219247359|NCT04372186|DRUG|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
219247360|NCT04848064|DRUG|Cyclophosphamide|Given IV
219247361|NCT04848064|DRUG|Fludarabine|Given IV
219247362|NCT04848064|BIOLOGICAL|Mogamulizumab|Given IV
219247363|NCT04848064|BIOLOGICAL|Natural Killer Cell Therapy|Given via infusion
219247364|NCT04848064|OTHER|Quality-of-Life Assessment|Ancillary studies
219247365|NCT04848064|OTHER|Questionnaire Administration|Ancillary studies
219247366|NCT03621683|PROCEDURE|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
219247367|NCT03621683|DIETARY_SUPPLEMENT|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
219247368|NCT06128330|DRUG|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
219247369|NCT06128330|DRUG|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
219247370|NCT06128330|DRUG|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
219247371|NCT06128330|DRUG|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
219247372|NCT05144854|DRUG|ONO-4538|Specified dose on specified days
219247373|NCT05144854|DRUG|Ipilimumab|Specified dose on specified days
219247374|NCT05144854|DRUG|Oxaliplatin|Specified dose on specified days
219247375|NCT05144854|DRUG|Capecitabine|Specified dose on specified days
219247376|NCT05144854|DRUG|S-1|Specified dose on specified days
219247377|NCT02261675|DRUG|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
219247378|NCT03219216|DRUG|Glecaprevir/Pibrentasvir|Film-coated tablet
219247379|NCT02332824|DRUG|TAK-272|TAK-272 tablets
219247380|NCT02332824|DRUG|TAK-272 Placebo|TAK-272 placebo-matching tablets
219247381|NCT02332824|DRUG|Candesartan cilexetil|Candesartan cilexetil tablets
219247382|NCT02332824|DRUG|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
219247383|NCT06585163|DRUG|Hydrocodone Bitartrate|Hydrocodone bitartrate oral suspension
219247384|NCT06585163|DRUG|Doxapram Hydrochloride|Doxapram hydrocholoride oral suspension
219247385|NCT06200480|OTHER|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
219247386|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
219247387|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
219247388|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
219247389|NCT00002405|DRUG|Amprenavir|
219247390|NCT04950010|BEHAVIORAL|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.
219741160|NCT04539431|GENETIC|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
219741161|NCT05900401|OTHER|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
219741162|NCT05900401|PROCEDURE|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
219741163|NCT05900401|DRUG|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
219741164|NCT05900401|DRUG|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
219741165|NCT05900401|DRUG|Rituximab|Rituximab on study day -6
219741166|NCT05900401|DRUG|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
219741167|NCT03098706|PROCEDURE|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
219741168|NCT03098706|PROCEDURE|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
219741169|NCT03165695|DRUG|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
219741170|NCT03165695|DRUG|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
219741171|NCT05187988|PROCEDURE|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
219741172|NCT05187988|PROCEDURE|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
219741173|NCT01545310|DRUG|SLV354|One dose of ABT-354
219741174|NCT02868931|BEHAVIORAL|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
219741175|NCT00154245|DRUG|Enteric-Coated Mycophenolate sodium (EC-MPS)|
219247391|NCT04950010|BEHAVIORAL|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
219247392|NCT04964297|DEVICE|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
219247393|NCT03840148|DRUG|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
219247394|NCT03840148|DRUG|Meropenem|Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
219741176|NCT00456365|DRUG|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
219741177|NCT00456365|DRUG|Placebo|Placebo daily
219741178|NCT00870324|DEVICE|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
219741179|NCT00870324|DEVICE|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
219741180|NCT02704000|BEHAVIORAL|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
219741181|NCT00706537|DRUG|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
219741182|NCT00706537|DRUG|Placebo|Placebo as two tablets once daily for three weeks
219741183|NCT04873193|DEVICE|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
219741184|NCT02124005|DRUG|Bupivacaine|
219741185|NCT04797390|DEVICE|Advanced Pneumatic Compression Device (APCD)|Once daily treatment with Flexitouch Plus.
219741186|NCT04797390|OTHER|Usual Care|Usual care consists of a two-phase CDT. Phase 1 includes consultation with a lymphedema therapist, patient education, MLD, compression garments or bandages, skin care techniques, and a program of exercises and postural recommendations. Phase 2 consists of ongoing self-care, where patients conduct a life-long program of disease management that mimics the program in phase 1.
219741187|NCT01930708|DRUG|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
219741188|NCT00347971|DRUG|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
219741189|NCT04634136|DIAGNOSTIC_TEST|Lab tests|CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
219741190|NCT04634136|DIAGNOSTIC_TEST|ECG|Electrocardiogram
219741191|NCT04634136|DIAGNOSTIC_TEST|Cannabinoid Levels|Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
219741192|NCT04634136|DRUG|Full-spectrum Medical Canabis Product (HemPhar)|Active substance
219741193|NCT04634136|DRUG|Placebo|Placebo
219741194|NCT04634136|DIAGNOSTIC_TEST|Spasticity level according to modified Ashworth scale (Bohannon)|"A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity)."
219741195|NCT04634136|DIAGNOSTIC_TEST|Gross Motor Function Measure|"A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75."
219741196|NCT04634136|DIAGNOSTIC_TEST|Borg rating of perceived exertion scale|Borg rating of perceived exertion scale
219741197|NCT04634136|DIAGNOSTIC_TEST|Edmonton symptom assessment system|Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
219741198|NCT02826785|BEHAVIORAL|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
219741199|NCT00832026|DEVICE|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
219741200|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.02%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
219741201|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.04%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
219741202|NCT05451329|DRUG|VVN539 Ophthalmic Solution Vehicle|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
219741203|NCT00133432|DRUG|Zinc|
219741204|NCT02714842|DRUG|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
219741205|NCT02714842|DRUG|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
219741206|NCT02714842|DRUG|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
219741207|NCT02714842|DRUG|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
219741208|NCT00020176|BIOLOGICAL|filgrastim|
219741209|NCT00020176|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219741210|NCT00020176|DRUG|cyclophosphamide|
219741211|NCT00020176|DRUG|cyclosporine|
219741212|NCT00020176|DRUG|fludarabine phosphate|
219741213|NCT00020176|PROCEDURE|peripheral blood stem cell transplantation|
219741214|NCT05152485|DRUG|BIIB104 Reference Formulation|Administered as specified in the treatment arm
219741215|NCT05152485|DRUG|BIIB104 Test Formulation|Administered as specified in the treatment arm
219741216|NCT03484195|DRUG|FOLFOXIRI|Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
219741217|NCT02202577|DRUG|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
219741218|NCT02202577|DRUG|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
219741219|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
219741220|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
219741221|NCT06569641|DEVICE|Neoneur Feeding System|The Neoneur Feeding System is placed between a nipple and a bottle, and used to measure feeding skill patterns.
219741222|NCT03442972|DRUG|Teduglutide|Teduglutide
219741223|NCT03442972|DRUG|Placebo|Placebo
219741224|NCT00829868|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg
219741225|NCT00829868|DRUG|SONATA® 10 mg capsules|1 x 10 mg
219741226|NCT05809154|DIAGNOSTIC_TEST|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
219741227|NCT05042466|DRUG|Trauma|0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
219741228|NCT00831155|DRUG|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
219247395|NCT02084615|DRUG|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
219247396|NCT06645522|DRUG|Edaravone dexborneol|Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
219247397|NCT06645522|DRUG|Placebo|Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
219741229|NCT06289283|OTHER|Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera|"Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for"
219741230|NCT00272805|DRUG|carvedilol|
219741231|NCT02029612|DRUG|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
219741232|NCT02029612|BEHAVIORAL|Phone Counseling|Each participant counseled on quitting smoking at baseline.
219741233|NCT02029612|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
219741234|NCT02029612|BEHAVIORAL|Breath Test|Breath test performed at 3 month and 6 month visit.
219741235|NCT02029612|BEHAVIORAL|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
219741236|NCT02029612|BEHAVIORAL|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
219741237|NCT02799043|PROCEDURE|Standard PVI|Standard PVI procedure without FIRMap.
219741238|NCT02799043|PROCEDURE|FIRM-Guided Procedure and PVI|
219741239|NCT00667979|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
219247398|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
219247399|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
219247400|NCT05876013|PROCEDURE|ACL reconstruction|Randomized between hamstring and patellar tendon graft
219247401|NCT04453969|OTHER|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
219247402|NCT01275911|DRUG|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
219741240|NCT00667979|DRUG|Placebo|Matching placebo
219741241|NCT05102461|DIETARY_SUPPLEMENT|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
219741242|NCT05102461|DIETARY_SUPPLEMENT|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
219741243|NCT04591587|PROCEDURE|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
219247403|NCT01275911|DRUG|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
219247404|NCT03133572|DEVICE|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
219247405|NCT03133572|DEVICE|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
219247406|NCT03784222|DRUG|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
219247407|NCT03784222|OTHER|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
219247408|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
219741244|NCT01326897|BEHAVIORAL|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
219741245|NCT01326897|BEHAVIORAL|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
219741246|NCT04142723|BIOLOGICAL|blood withdraw|venous blood sampling
219741247|NCT03981198|DEVICE|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
219741248|NCT01313533|DRUG|Polyarginine|Vein soak treated with polyarginine
219741249|NCT01313533|DRUG|Vein soak treated with Lactated Ringers Solution|Vein soak
219741250|NCT02665650|BIOLOGICAL|AFM13|
219741251|NCT02665650|BIOLOGICAL|Pembrolizumab|
219247409|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
219247410|NCT03455140|DRUG|PEG- BCT-100|PEGylated recombinant human arginase 1
219247411|NCT00105222|DRUG|Sodium Nitrite|
219741252|NCT03796221|BEHAVIORAL|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
219174990|NCT04115540|DEVICE|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
219247412|NCT04725552|BEHAVIORAL|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
219247413|NCT04927806|DEVICE|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli"
219247414|NCT05374967|BEHAVIORAL|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
219247415|NCT05374967|OTHER|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
219247416|NCT01794351|DIETARY_SUPPLEMENT|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
219247417|NCT01794351|OTHER|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
219741253|NCT03796221|BEHAVIORAL|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
219741254|NCT01674361|DRUG|Bitopertin|Bitopertin once daily orally.
219741255|NCT01674361|DRUG|Placebo|Placebo matched to bitopertin once daily orally.
219741256|NCT01674361|DRUG|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
219741257|NCT06091956|DRUG|Deucravacitinib|6 milligram (mg) orally administrated, twice daily
219741258|NCT05944393|DRUG|Ropivacaine 0.2% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine
219741259|NCT05944393|DRUG|Normal saline 0.9% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
219741260|NCT00896844|BEHAVIORAL|emotional disclosure|writing about emotional events from the past
219174991|NCT03395132|DRUG|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
219174992|NCT03395132|DRUG|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
219174993|NCT03395132|DRUG|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
219741261|NCT00896844|BEHAVIORAL|placebo writing|writing about how they spent their time the previous day
219741262|NCT02608086|BEHAVIORAL|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
219741263|NCT02608086|BEHAVIORAL|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
219741264|NCT01586897|DEVICE|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
219741265|NCT01586897|OTHER|Usual Care|
219741266|NCT02191995|BEHAVIORAL|yoga|
219741267|NCT04710303|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
219741268|NCT00801255|DRUG|RO5024048|500mg po bid/100mg po q8h for 7 days
219741269|NCT00801255|DRUG|danoprevir|500mg po bid/100mg po q8h for 14 days
219247418|NCT01959009|OTHER|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
219247419|NCT05022953|OTHER|Education, dijital storytelling|Digital story
219741270|NCT00801255|DRUG|danoprevir|1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
219741271|NCT00801255|DRUG|danoprevir|1000mg po bid/200mg po q8h for 14 days
219741272|NCT00801255|DRUG|danoprevir|1000mg/600mg po twice daily for 14 days
219741273|NCT00801255|DRUG|danoprevir|1000mg/900mg po twice daily for 14 days
219741274|NCT03154567|DRUG|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
219741275|NCT06307366|OTHER|No intervention will be used|This is a qualitative study, no intervention will be used
219741276|NCT03813121|DRUG|midazolam intravenous infusion|Participants will receive a single drug infusion
219741277|NCT03813121|DRUG|placebo intravenous infusion|Participants will receive a single placebo infusion
219741278|NCT03813121|DRUG|ketamine intravenous infusion|Participants will receive a single drug infusion
219741279|NCT06131112|DIAGNOSTIC_TEST|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
219741280|NCT00153790|DRUG|PhosphoLean|
219741281|NCT00196612|DRUG|emtricitabine, FTC (drug)|
219741282|NCT00196612|DRUG|didanosine, ddI (drug)|
219741283|NCT00196612|DRUG|efavirenz (drug)|
219741284|NCT01448304|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
219741285|NCT02890160|DEVICE|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
219741286|NCT02890160|DEVICE|XIENCE|Everolimus Eluting Coronary Stent System
219741287|NCT05282407|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
219741288|NCT05282407|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
219741289|NCT02429167|DEVICE|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
219741290|NCT02429167|DEVICE|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
219741291|NCT01641055|DIETARY_SUPPLEMENT|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
219741292|NCT01641055|DIETARY_SUPPLEMENT|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
219741293|NCT01641055|DIETARY_SUPPLEMENT|Cod protein|2.5g cod protein per day for 8wk.
219741294|NCT01641055|DIETARY_SUPPLEMENT|Milk protein|2.5g milk protein per day for 8wk.
219741295|NCT02542280|PROCEDURE|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
219741296|NCT02542280|PROCEDURE|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
219741297|NCT02542280|DRUG|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
219247420|NCT05568277|BEHAVIORAL|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
219247421|NCT04779463|DIAGNOSTIC_TEST|Parasternal intercostal muscles thickness ultrasound indicies|"Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration."
219247422|NCT04999722|BEHAVIORAL|Traditional mode of management|Traditional model management of Diabetes Mellitus patients
219247423|NCT04999722|BEHAVIORAL|Mobile APP management|Management of diabetic patients with mobile phone APP
219741298|NCT01396876|BEHAVIORAL|clown|a distraction technique is performed by a clown during venipuncture
219741299|NCT01588925|DEVICE|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
219741300|NCT01588925|DRUG|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
219741301|NCT01588925|DRUG|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
219741302|NCT04097665|DEVICE|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
219741303|NCT04054882|BIOLOGICAL|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
219741304|NCT04054882|BIOLOGICAL|Sabin-IPV|administration of Sabin-IPV only
219741305|NCT04054882|BIOLOGICAL|DTaP|administration of DTaP only
219741306|NCT01983670|OTHER|Temporal electrical stimulation|
219741307|NCT04096235|OTHER|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
219741308|NCT05626335|DIAGNOSTIC_TEST|Intraoral scan|On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
219741309|NCT01821014|OTHER|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
219741310|NCT01821014|OTHER|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
219741311|NCT01421459|DRUG|LY2963016|Administered subcutaneously
219741312|NCT01421459|DRUG|Lantus|Administered subcutaneously
219741313|NCT01421459|DRUG|OAMs|Administered orally
219741314|NCT00803049|DRUG|Teriflunomide (HMR1726)|Tablet, oral administration QD.
219741315|NCT01707446|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
219741316|NCT01707446|OTHER|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
219741317|NCT04203771|DIETARY_SUPPLEMENT|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
219741318|NCT04203771|OTHER|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
219741319|NCT04203771|PROCEDURE|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
219741320|NCT04203771|DRUG|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
219741321|NCT05045417|DIAGNOSTIC_TEST|Serum level of IL-17|"Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
219741322|NCT05181085|DRUG|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
219247424|NCT02408978|DRUG|OXP005|
219247425|NCT02408978|DRUG|Naproxen|
219247426|NCT01150305|BIOLOGICAL|blood sample|Peripheral whole blood sample, 5 ml
219741323|NCT05181085|DRUG|Placebo|inactive analogue
219741324|NCT02203279|OTHER|Rebase II Fast|It is going to be used a direct relining material
219741325|NCT02203279|OTHER|Flexacryl|This is going to be used as a second direct relining material
219741326|NCT02203279|OTHER|Vertex|This is going to be used as an indirect relining material
219741327|NCT01817946|OTHER|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
219741328|NCT01373411|DRUG|ticagrelor|ticagrelor 90 mg BID for 90 days
219247427|NCT01490047|DRUG|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
219247428|NCT01490047|DRUG|Liposomal doxorubicin|Infusion over 60 minutes
219247429|NCT01490047|DRUG|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
219741329|NCT01373411|DRUG|Placebo|Placebo 1 pill BID for 90 days
219741330|NCT05214508|DIAGNOSTIC_TEST|interleukin 6|assessment of serum IL-6 by ELISA
219741331|NCT03868280|PROCEDURE|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
219741332|NCT03868280|PROCEDURE|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
219741333|NCT03897881|DRUG|mRNA-4157|Individualized Neoantigen Therapy
219741334|NCT03897881|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219741335|NCT05980403|OTHER|no intervention|no intervention
219741336|NCT05656274|DRUG|JS1-1-01|Oral tables
219741337|NCT05656274|DRUG|Placebo|Oral tables
219741338|NCT06290323|PROCEDURE|Quadratus lumborum block|Posterior quadratus lumborum block
219741339|NCT06290323|PROCEDURE|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
219741340|NCT05700695|DRUG|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
219741341|NCT05700695|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
219741342|NCT04087655|BEHAVIORAL|Exercise|Eight weeks of interval exercise training
219741343|NCT05898334|DEVICE|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
219741344|NCT05898334|DEVICE|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
219741345|NCT02901561|DRUG|misoprostol 200|
219741346|NCT02901561|DRUG|misoprostol 400|
219741347|NCT01188993|COMBINATION_PRODUCT|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
219741348|NCT05117125|DIAGNOSTIC_TEST|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
219741349|NCT05117125|DIAGNOSTIC_TEST|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
219741350|NCT05117125|DIAGNOSTIC_TEST|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
219741351|NCT05117125|DIAGNOSTIC_TEST|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
219741352|NCT05117125|DIAGNOSTIC_TEST|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
219741353|NCT05673902|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
219741354|NCT01523431|DRUG|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
219741355|NCT01523431|DRUG|5-fluorouracil|The 5-FU dosage will remain the standard.
219741356|NCT01523431|DRUG|Leucovorin|The LV dosage will remain the standard.
219741359|NCT05444088|DRUG|Adebrelimab|intravenous infusion
219741360|NCT05444088|DRUG|Bevacizumab|intravenous infusion
219741361|NCT05444088|DRUG|SHR-8068|intravenous infusion
219741362|NCT04130867|PROCEDURE|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
219741363|NCT04130867|PROCEDURE|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
219741364|NCT05065671|DRUG|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
219741365|NCT05065671|DRUG|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
219741366|NCT01512251|DRUG|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
219741367|NCT04356378|OTHER|Data record|Data record
219247430|NCT01490047|DRUG|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
219247431|NCT03829566|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
219247432|NCT03829566|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
219247433|NCT03829566|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
219247434|NCT03829566|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
219247435|NCT03829566|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
219247436|NCT03829566|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
219247437|NCT03829566|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
219174994|NCT03395132|DRUG|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
219174995|NCT06282887|OTHER|Music therapy|The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
219174996|NCT04175847|DRUG|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
219247438|NCT03829566|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
219247439|NCT02313077|BIOLOGICAL|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
219247440|NCT02313077|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
219247441|NCT02313077|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
219247442|NCT00561275|BIOLOGICAL|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
219247443|NCT01844063|GENETIC|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
219247444|NCT01844063|GENETIC|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
219247445|NCT01844063|DRUG|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
219247446|NCT04126993|DRUG|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
219247447|NCT04126993|DRUG|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
219247448|NCT00604461|DRUG|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
219247449|NCT02097316|DEVICE|JewelPump|
219247450|NCT02097316|DEVICE|usual insulin pump|
219174997|NCT02524717|DRUG|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
219174998|NCT05759013|DEVICE|Breath synchronized abdominal FES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
219174999|NCT05759013|DEVICE|Sham breath synchronized abdominal FES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
219175000|NCT03790787|DRUG|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
219175001|NCT03790787|DRUG|Dorzagliatin|Glucokinase activator currently under development
219175002|NCT06214949|DEVICE|Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over 3-4 weeks. Specifically, the active or sham treatments will be conducted \~5 times a week during the treatment phase of the study. The treatment protocol parameters (stimulus location, frequency, duration, and intensity) will be derived from the PrTMS software algorithm which incorporates clinical inputs from neurocognitive surveys and quantitative EEG analysis. The mechanical parameters will adhere to the recommended PrTMS parameters for pain treatment: figure of 8 coil that produces biphasic stimulatory pulses to the central zone cortex, frontal zone cortex, Broca's area, and frontal pre-cortex areas at a stimulation depth of 2 cm. Treatment parameters will be unique to each participant but will remain within known ranges. The frequency will be between 8 and 13 Hz, at an amplitude of 20-30% (approximately 30-40% of RMT), and about 3200-7200 pulses per session. Since parameters are specific to each participant, treatment settings will vary.
219247451|NCT00504101|DRUG|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
219247452|NCT00504101|DRUG|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
219247453|NCT00504101|DRUG|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
219247454|NCT00504101|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
219247455|NCT06201000|DRUG|SGLT2 inhibitors (Dapagliflozin and Empagliflozin)|10 mg of dapagliflozin or empagliflozin
219362722|NCT03942315|OTHER|Data collection from standard follow-up after liver transplant|All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
219362723|NCT06549751|BIOLOGICAL|MT-601|Cellular Therapy
219247456|NCT02619578|OTHER|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
219247457|NCT02619578|OTHER|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
219247458|NCT02619578|DRUG|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
219247459|NCT02619578|OTHER|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
219247460|NCT05224245|DEVICE|ACURATE Prime XL Transfemoral Aortic Valve System|ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
219247461|NCT05125614|OTHER|No adjuvant chemotherapy|There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
219247462|NCT05928520|DRUG|Tramadol 5%|Topical tramadol 5%
219247463|NCT05928520|DRUG|Lidocaine 2%|Topical Lidocaine 2%
219247464|NCT05473468|DRUG|Famitinib|a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
219247465|NCT00065663|GENETIC|GAM501|
219741368|NCT05540184|DRUG|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
219741369|NCT05540184|DRUG|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
219741370|NCT05540184|DRUG|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
219741371|NCT01878474|DRUG|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
219741372|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
219741373|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
219741374|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
219741375|NCT01878474|DRUG|Placebo|Single ascending dose in Caucasian men
219741376|NCT01878474|DRUG|Placebo|Age-effect in Caucasian men
219741377|NCT01878474|DRUG|Placebo|Gender-effect in Caucasian women
219741378|NCT01878474|DRUG|Placebo|Single ascending dose in Japanese men
219741379|NCT06413875|OTHER|education|Education Specific to Menopause Symptoms
219741380|NCT06302985|PROCEDURE|atomized inhalation ICG before thoracoscope pneumonectomy|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed."
219741381|NCT01564030|OTHER|Empty|overnight fast
219741382|NCT01564030|OTHER|Fluid|250mL apple juice
219741383|NCT01564030|OTHER|Solid|breakfast
219741384|NCT06239753|BEHAVIORAL|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
219741385|NCT06239753|BEHAVIORAL|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
219741386|NCT03564067|DEVICE|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
219741387|NCT03564067|BEHAVIORAL|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
219741388|NCT06252987|OTHER|routine treatment|Routine medical treatment, basic rehabilitation training and individualized cognitive training
219741389|NCT06252987|OTHER|Non-invasive brain stimulation|tDCS\&rTMS
219741390|NCT06644027|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
219247466|NCT00389285|DRUG|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
219247467|NCT00389285|DRUG|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
219741391|NCT06644027|DEVICE|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
219175003|NCT06214949|DEVICE|Sham Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over the course of 3-4 weeks. More specifically, the active or sham treatments will be conducted roughly 5 times a week during the course of the treatment phase of the study. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
219175004|NCT06483503|DEVICE|EFOV Colonoscope|Routine colonoscopy using the EFOV lens in the colonoscope.
219175005|NCT01383512|DEVICE|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
219175006|NCT01383512|OTHER|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
219175007|NCT04869670|PROCEDURE|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
219247468|NCT00702871|DRUG|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
219741392|NCT04246749|DRUG|[14C]-CRN00808|Investigational drug
219741393|NCT04246749|DRUG|CRN00808|Investigational drug
219741394|NCT02598973|BEHAVIORAL|Exercise|Aerobic walking
219741395|NCT01790191|BEHAVIORAL|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
219741396|NCT01790191|BEHAVIORAL|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
219741397|NCT01790191|BEHAVIORAL|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
219741398|NCT05810467|OTHER|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
219741399|NCT03707392|OTHER|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
219741400|NCT03707392|OTHER|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
219743526|NCT02943499|BEHAVIORAL|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
219175008|NCT04869670|PROCEDURE|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
219175009|NCT05441969|OTHER|No intervention/expousure|No interventions/expousure since this is an observational study.
219175010|NCT05574946|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
219175011|NCT05517850|BEHAVIORAL|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
219175012|NCT05517850|BEHAVIORAL|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
219175013|NCT04063267|OTHER|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
219175014|NCT04063267|OTHER|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
219175015|NCT05774548|OTHER|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
219247469|NCT00702871|DRUG|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
219743527|NCT02943499|DEVICE|Smartphone|
219247470|NCT00593528|DEVICE|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
219247471|NCT00593528|DEVICE|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
219247472|NCT00593528|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
219247473|NCT05852379|DEVICE|active taVNS|Transcutaneous auricular vague nerve stimulation
219247474|NCT05852379|DEVICE|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
219247475|NCT05208021|BEHAVIORAL|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
219247476|NCT01766323|DRUG|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
219247477|NCT01766323|DRUG|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
219247478|NCT01844908|PROCEDURE|Electroacupuncture|
219247479|NCT05507372|DRUG|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
219247480|NCT00986661|DRUG|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
219247481|NCT02199171|DRUG|carboplatin|Given via HIPEC
219247482|NCT04363645|OTHER|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
219247483|NCT02135419|DRUG|imiquimod|Applied topically
219247484|NCT02135419|DRUG|fluorouracil|Applied topically
219247485|NCT02135419|DEVICE|infrared photocoagulation therapy|Undergo infrared coagulation
219247486|NCT02135419|DEVICE|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
219247487|NCT02135419|DEVICE|laser therapy|Undergo laser therapy
219247488|NCT02135419|OTHER|clinical observation|Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
219247489|NCT02135419|OTHER|laboratory biomarker analysis|Correlative studies
219247490|NCT05306223|DRUG|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
219247491|NCT05306223|DRUG|Levofloxacin|Levofloxacin filmcoated will be administered orally
219247492|NCT05306223|DRUG|Linezolid|Linezolid tablets will be administered orally
219247493|NCT05306223|DRUG|Cycloserine|Cycloserine capsules will be administered orally.
219247494|NCT05306223|DRUG|Clofazimine|Clofazimine capsules will be administered orally.
219247495|NCT05306223|DRUG|Pyrazinamide|Pyrazinamide tablets will be administered orally.
219247496|NCT05306223|DRUG|Protionamide|Protionamide enteric-coated tablets will be administered orally.
219247497|NCT00990821|DRUG|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
219247498|NCT00990821|DRUG|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
219247499|NCT00990821|DRUG|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
219247500|NCT00990821|DRUG|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
219741401|NCT04222504|BEHAVIORAL|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
219741402|NCT05607589|DRUG|DWP213388|immunosuppressant
219741403|NCT05607589|OTHER|Placebo|Placebo
219741404|NCT04003142|DRUG|Fezolinetant|Oral tablet
219741405|NCT04003142|DRUG|placebo|Oral Tablet
219741406|NCT05570318|DRUG|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
219741407|NCT05570318|DEVICE|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
219741408|NCT04042311|OTHER|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
219741409|NCT06535646|OTHER|Home exercise program using Physitrack exercise program and a smart watch|Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
219741410|NCT03434301|DEVICE|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
219741411|NCT03434301|DEVICE|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
219741412|NCT02725606|BIOLOGICAL|Pegylated Recombinant Human G-CSF|subcutaneous
219741413|NCT02725606|BIOLOGICAL|GW003|subcutaneous
219247501|NCT00990821|DRUG|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
219247502|NCT00990821|DRUG|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
219247503|NCT00990821|DRUG|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
219247504|NCT00990821|DRUG|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
219247505|NCT00990821|DRUG|Placebo|Placebo matching MK-0517
219247506|NCT00990821|DRUG|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
219247507|NCT00990821|DRUG|125 mg Aprepitant|Aprepitant oral tablet, single dose
219247508|NCT00990821|DRUG|2 mg Midazolam|Midazolam oral tablet, single dose
219362724|NCT04137783|OTHER|no intervention|there is no intervention in this study, only observation.
219362725|NCT02305693|DRUG|Letrozole|
219247509|NCT06311448|DRUG|Single target immunomodulation|Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
219247510|NCT06311448|DRUG|Standard of care|Standard of care during COVID-19 pandemic including steroids.
219247511|NCT00158561|DRUG|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
219247512|NCT03550014|PROCEDURE|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
219247513|NCT03550014|PROCEDURE|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
219247514|NCT05711017|DRUG|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
219247515|NCT05711017|DRUG|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
219247516|NCT02862158|DEVICE|FDT visual field|
219247517|NCT02862158|DEVICE|Standard HVF|
219247518|NCT05781984|PROCEDURE|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
219741414|NCT03182556|BEHAVIORAL|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
219741415|NCT03182556|BEHAVIORAL|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
219741416|NCT06567262|DEVICE|CAD/CAM metallic removable partial denture|"Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework."
219741417|NCT06567262|DEVICE|Conventional metallic removable partial denture|"Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally."
219741418|NCT06567301|COMBINATION_PRODUCT|Ultrasound therapy combined with Chitosan nanoparticles gel|Gymna - Belgian
219741419|NCT02370342|PROCEDURE|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
219741420|NCT02370342|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
219741421|NCT02370342|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
219741422|NCT02370342|DEVICE|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
219741423|NCT03382873|BEHAVIORAL|Group Lifestyle Balance (GLB)|The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
219741424|NCT03382873|BEHAVIORAL|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
219247519|NCT01631799|DEVICE|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
219247520|NCT01631799|DEVICE|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
219247521|NCT04150250|DRUG|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
219741425|NCT02592655|DEVICE|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
219741426|NCT02592655|DEVICE|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
219741427|NCT02592655|DEVICE|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
219741428|NCT02592655|DEVICE|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
219741429|NCT02592655|DEVICE|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
219741430|NCT00890656|DRUG|Cyclophosphamide (CTX)|300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
219741431|NCT00890656|DRUG|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
219741432|NCT00890656|DRUG|Doxorubicin|50 mg/m\^2 by vein (IV) over 24 hours
219741433|NCT00890656|DRUG|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
219741434|NCT00890656|DRUG|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
219741435|NCT00890656|DRUG|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
219741436|NCT00890656|DRUG|Ara-C|3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
219741437|NCT00890656|DRUG|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
219741438|NCT06308965|PROCEDURE|Vessel sparing technique|Vessel sparing
219741439|NCT06308965|PROCEDURE|Vessel ligation technique|Vessel ligation
219741440|NCT03436849|DRUG|ESN364|ESN364 will be administered orally.
219741441|NCT03436849|DRUG|Placebo|Placebo will be administered orally.
219741442|NCT03554330|OTHER|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
219741443|NCT03554330|OTHER|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
219741444|NCT06094855|OTHER|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
219741445|NCT06468930|DEVICE|Low-level light therapy (LLLT)|LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
219741446|NCT06468930|DEVICE|Intense pulsed light (IPL)|The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
219741447|NCT05857878|DRUG|BI 1815368|BI 1815368
219741448|NCT05857878|DRUG|Matching placebo|Matching placebo
219247522|NCT04150250|DRUG|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
219247523|NCT04150250|OTHER|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
219247524|NCT04150250|DRUG|Antibiotics|"Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
219247525|NCT04758156|DRUG|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
219247526|NCT04758156|DRUG|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
219362726|NCT02305693|PROCEDURE|Laparoscopic ovarian drilling|
219362727|NCT02103868|BEHAVIORAL|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
219741449|NCT05272579|OTHER|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
219741450|NCT05272579|OTHER|Placebo|Saline solution
219743528|NCT00853684|DRUG|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
219743529|NCT00853684|DRUG|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
219743530|NCT01076699|DRUG|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
219743531|NCT01076699|DRUG|0.125 mg RVX-100|This group is taking an average dose of RVX-100
219743532|NCT01076699|DRUG|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
219743533|NCT01076699|DRUG|placebo|This group is taking a placebo
219247527|NCT01112371|DRUG|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
219247528|NCT03468387|PROCEDURE|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
219247529|NCT03468387|PROCEDURE|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
219247530|NCT03885622|DEVICE|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
219247531|NCT02511847|DRUG|Afatinib|"1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
219247532|NCT01309633|DRUG|12.5mg sunitinib with Cisplatin and Gemcitabine|"1\) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
219741451|NCT05773352|DEVICE|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
219741452|NCT03228043|DRUG|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
219741453|NCT03228043|DRUG|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
219741454|NCT05378529|OTHER|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
219741455|NCT05306574|BIOLOGICAL|Telitacicept|Subcutaneous injection weekly for 52 weeks
219741456|NCT05306574|BIOLOGICAL|Placebo|Subcutaneous injection weekly for 52 weeks
219741457|NCT03717454|OTHER|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
219741458|NCT03717454|DRUG|Drug treatment|The medication will continue if DA causes tumors to shrink.
219741459|NCT06439927|DEVICE|Polycaprolactone nasal mesh|a 3-dimensional fabricated Polycaprolactone nasal mesh
219741460|NCT01924065|PROCEDURE|Cardioversion|Electrical cardioversion
219741461|NCT01924065|DRUG|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
219741462|NCT05838716|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219741463|NCT05838716|DIETARY_SUPPLEMENT|D Vitamin|Given PO
219741464|NCT05838716|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
219741465|NCT05838716|DRUG|Placebo Administration|Given PO
219741466|NCT05838716|OTHER|Quality-of-Life Assessment|Ancillary studies
219741467|NCT05838716|OTHER|Questionnaire Administration|Ancillary studies
219741468|NCT00112307|PROCEDURE|Brachytherapy|
219741469|NCT04012710|PROCEDURE|Laparoscopy|Conventional abdominal laparoscopy
219741470|NCT04012710|PROCEDURE|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
219741471|NCT03247673|DRUG|CT-P16|CT-P16 is a biosimilar product for Avastin
219741472|NCT03247673|DRUG|EU-approved Avastin|EU-approved Avastin
219741473|NCT03247673|DRUG|US-licensed Avastin|US-licensed Avastin
219741474|NCT02097225|DRUG|Dabrafenib|Given PO
219741475|NCT02097225|OTHER|Laboratory Biomarker Analysis|Correlative studies
219741476|NCT02097225|DRUG|Onalespib|Given IV
219741477|NCT02097225|OTHER|Pharmacological Study|Correlative studies
219741478|NCT02097225|DRUG|Trametinib|Given PO
219741479|NCT06357078|OTHER|Art Therapy|Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
219741480|NCT02074839|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
219741481|NCT04071535|DEVICE|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
219741482|NCT06037083|DEVICE|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
219741483|NCT06037083|DEVICE|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
219741484|NCT06037083|DEVICE|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)"
219741485|NCT05135754|DEVICE|Heylo|Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
219741486|NCT02685852|DRUG|Exenatide|Exenatide at a dose of 5 mcg
219741487|NCT02685852|DRUG|Acarbose|Acarbose at a dose of 25 mg
219741488|NCT02685852|DRUG|Exenatide Placebo|Placebo for Exenatide
219741489|NCT02685852|DRUG|Acarbose Placebo|Placebo for Acarbose
219741490|NCT02993666|DEVICE|Bair Hugger|forced air warming with Bair Hugger air warmer
219741491|NCT01764932|PROCEDURE|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
219741492|NCT00674063|DRUG|alefacept|IV
219741493|NCT00345280|PROCEDURE|impression cytology, obtain the tear fluid|Vitamin A
219741494|NCT00181545|PROCEDURE|escalation of dose (radiotherapy treatment)|
219741495|NCT01877057|DIETARY_SUPPLEMENT|Saturn|
219741496|NCT02757963|OTHER|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
219743534|NCT03889379|DRUG|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
219743535|NCT02510924|DEVICE|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
219743536|NCT03947463|PROCEDURE|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
219175016|NCT05774548|OTHER|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
219175017|NCT03695276|BEHAVIORAL|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
219175018|NCT03695276|BEHAVIORAL|Usual care|The standard of care, which usually means management within primary care.
219175019|NCT06475222|OTHER|Study 1: Facial serum with alpha albutin|Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
219175020|NCT06475222|OTHER|Study 1: Facial serum with Tubtim Chumpae rice extract|Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
219175021|NCT06475222|OTHER|Study 2: Facial mask with Hom Pathum rice extract|Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
219175022|NCT06475222|OTHER|Study 3: Control jelly|Consumption with control jelly as active comparator at 3.5 g/kg body weight.
219743537|NCT02538796|OTHER|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
219743538|NCT02538796|OTHER|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
219743539|NCT02538796|OTHER|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
219743540|NCT02538796|OTHER|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
219743541|NCT01737905|DRUG|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
219743542|NCT01737905|DRUG|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
219743543|NCT03009292|DRUG|lenvatinib|once daily continuous dosing
219743544|NCT04893525|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
219743545|NCT01817777|DRUG|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
219175023|NCT06475222|OTHER|Study 3: Jelly with Tubtim Chumpae rice|Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
219175024|NCT06475222|OTHER|Study 3: Jelly with Hom Pathum rice|Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
219175025|NCT05182242|OTHER|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
219175026|NCT05182242|BIOLOGICAL|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
219175027|NCT05182242|OTHER|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
219175028|NCT05182242|OTHER|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
219175029|NCT05182242|OTHER|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
219175030|NCT04644185|DRUG|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
219175031|NCT04644185|OTHER|Placebo|all SCTA01 excipients without active component+best supportive care
219175032|NCT05218447|DEVICE|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
219175033|NCT05218447|OTHER|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
219175034|NCT03641092|BEHAVIORAL|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
219175035|NCT03641092|BEHAVIORAL|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
219743546|NCT01817777|DRUG|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
219743547|NCT05517408|DRUG|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
219743548|NCT03538847|OTHER|Numerical rating scale|Measure of postoperative pain
219743549|NCT00756340|DRUG|Bevacizumab|"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"
219743550|NCT00756340|DRUG|Everolimus|"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"
219175036|NCT04336644|DEVICE|BodyGuardian Mini Plus|The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
219175037|NCT05490290|OTHER|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
219175038|NCT05590312|OTHER|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
219175039|NCT03269136|DRUG|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
219175040|NCT03269136|DRUG|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
219175041|NCT03269136|DRUG|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
219175042|NCT03269136|DRUG|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
219175043|NCT06439901|OTHER|Screening|A first step to identify and recruit people eligible for screening,
219175044|NCT06439901|OTHER|Inclusion|A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
219175045|NCT06439901|OTHER|Chest CTscan and follow-up|A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
219175046|NCT06193525|DRUG|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
219175047|NCT04717492|OTHER|Observational|Observational
219175048|NCT06550284|OTHER|Physical Therapy|The intervention will be physical therapy standard care.
219175049|NCT04456517|DRUG|Ranolazine|500 mg tablet
219175050|NCT04456517|DRUG|Placebo|Ranolazine-matched placebo tablet
219175051|NCT03543202|DRUG|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
219175052|NCT03543202|DRUG|local infiltration anesthesia|will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
219175053|NCT03543202|DRUG|Intravenous patient controlled analgesia|will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
219175054|NCT04376242|BEHAVIORAL|use of virtual reality|The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
219247533|NCT01309633|DRUG|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
219247534|NCT01309633|DRUG|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
219247535|NCT01309633|DRUG|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
219247536|NCT05200299|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
219247537|NCT05200299|DRUG|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
219247538|NCT01243658|DRUG|Oxytocin|Oxytocin
219247539|NCT01243658|OTHER|placebo|placebo
219362728|NCT01166451|DIETARY_SUPPLEMENT|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
219741497|NCT02757963|OTHER|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
219741498|NCT02505074|PROCEDURE|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
219741499|NCT02971137|BEHAVIORAL|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
219741500|NCT02971137|BEHAVIORAL|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
219741501|NCT05259098|DRUG|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
219741502|NCT05259098|DRUG|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
219741503|NCT00911157|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
219741504|NCT00911157|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
219741505|NCT02088086|BEHAVIORAL|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
219741506|NCT02088086|BEHAVIORAL|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
219741507|NCT02088086|BEHAVIORAL|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
219741508|NCT06577948|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
219741509|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 1|P.A.U.S.E. spectacle lens 1
219741510|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 2|P.A.U.S.E. spectacle lens 2
219741511|NCT06642948|OTHER|Motor rehabilitation based on ai visual recognition|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
219741512|NCT06637618|BEHAVIORAL|up front use of mineralocorticoid receptor antagonist|the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
219741513|NCT06644885|PROCEDURE|TIVAD implantation complications|Follow up and post operative outcome of patients with devices implantation
219741514|NCT06643104|PROCEDURE|Tuina|X-ray mapping guides three days of tailored exercises, including 3D therapy, breathing techniques, and spinal manipulation.
219741515|NCT06179004|DRUG|Liposomal bupivacaine|133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection
219741516|NCT06179004|DRUG|Bupivacaine Hydrochloride|20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
219741517|NCT06221813|BIOLOGICAL|PHV02|Nipah virus vaccine
219741518|NCT06221813|BIOLOGICAL|Lactated Ringer's|Placebo
219743551|NCT00557440|DRUG|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
219247540|NCT06269796|DIAGNOSTIC_TEST|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
219247541|NCT06269796|DIAGNOSTIC_TEST|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
219247542|NCT06072352|OTHER|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
219247543|NCT06072352|OTHER|Normal saline|Perineal cleansing using normal saline
219247544|NCT01786551|DRUG|Eplerenone|50 mg daily for 14 days
219247545|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
219247546|NCT03537014|BEHAVIORAL|Therapy|Non-directive therapy performed by therapist team
219247547|NCT03537014|DRUG|midomafetamine HCl|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions
219247548|NCT03537014|DRUG|Placebo|Administration of placebo during three experimental sessions
219247549|NCT04070521|OTHER|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
219247550|NCT02056925|OTHER|Echocardiography|
219247551|NCT03962127|OTHER|no intervention|no intervention
219247552|NCT01324011|BEHAVIORAL|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
219247553|NCT06819579|DRUG|1.5% Lidocaine|After successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose
219247554|NCT06819579|DRUG|1.0% Lidocaine|After successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose
219247555|NCT06819579|DRUG|0.5% Lidocaine|After successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose
219247556|NCT02442622|OTHER|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
219247557|NCT02442622|DEVICE|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
219247558|NCT03430440|DEVICE|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
219247559|NCT03430440|DEVICE|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
219247560|NCT01617889|OTHER|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
219247561|NCT01617889|OTHER|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
219247562|NCT02765867|DRUG|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
219741519|NCT02016599|OTHER|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
219741520|NCT06479863|COMBINATION_PRODUCT|Pozelimab/Cemdisiran|Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
219741521|NCT04650893|DRUG|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
219741522|NCT04650893|DRUG|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
219741523|NCT04650893|DRUG|Placebo|Control
219741524|NCT05919030|RADIATION|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
219741525|NCT05919030|DRUG|Tislelizumab|200 mg IV Q3W
219741526|NCT05919030|DRUG|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
219741527|NCT05919030|DRUG|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
219741528|NCT00298155|DRUG|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
219741529|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
219741530|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
219741531|NCT05487391|DRUG|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
219247563|NCT06987500|DRUG|XNW29016|Oral Medication. The study set 7 dose level cohorts in dose escalation part.
219247564|NCT06987500|DRUG|XNW29016|Oral Medication
219247565|NCT05836753|DRUG|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
219247566|NCT05836753|DRUG|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
219247567|NCT04890158|OTHER|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
219247568|NCT06993714|PROCEDURE|Breast restoration surgery based on 3D printed degradable biological implants|In the experimental group, the surgeon makes an incision on the skin and creates an electrosurgical free flap with a thickness of approximately 3mm. Based on the tumor size simulated by the computer and combined with real-time exploration during the operation, the tumor is resected. The incision margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the resected specimen. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are excluded from the clinical trial). Corresponding surgical treatment is provided. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The wound is soaked and rinsed, hemostasis is thoroughly achieved, the designed 3D printed filler is implanted, and sutured and fixed. After placing the drainage, the skin is sutured layer by layer. The corresponding operation time is recorde.
219247569|NCT06993714|PROCEDURE|Traditional breast-conserving surgery|In the control group undergoing traditional breast - saving surgery, tumor segment resection is performed according to the clinical routine. The resection margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the circumferential specimens after resection. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative resection margin. The volume of the resected part during the intraoperative section is replaced by autologous tissue. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The corresponding operation time is recorded.
219247570|NCT06993714|PROCEDURE|Traditional silicone prosthesis breast reconstruction|In the control group of traditional prosthesis reconstruction, subcutaneous gland resection with nipple and areola preservation combined with prosthesis for concurrent breast reconstruction is carried out according to the clinical routine. The incision method is selected by the surgeon. During the operation, the tissue behind the nipple is sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are considered out of the clinical trial and given corresponding surgical treatment), and the surgeon decides whether to use the patch in combination. The corresponding operation time is recorded.
219247571|NCT06999850|OTHER|Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps;
219247572|NCT06999850|OTHER|Walk Test|"Assessment of climbing and walking skills through test series:~Borg scale: An evaluation scale for measuring effort perception. The evaluation scale consists of answering some questions at the end of the exercise described above; 10-metre walk test (10MWT): Test to assess walking speed in metres per second over a short distance. Can be used to determine functional mobility, gait and vestibular function. The test consists of walking at a steady speed and safely for 10 metres; 30 second sit to stand test: test for the evaluation of strength and endurance of the legs in the elderly. The test consists in performing the movement of standing up and sitting down from a chair for 30 consecutive seconds; Timed Up \& Go test (TUG): test to assess the risk of falling and balance. During the test, patients wear normal footwear and may use a walking aid if necessary. The patient starts in a sitting position, gets up on the therapist's command, walks in a straight line for a distance of 3 m"
219247573|NCT06999850|OTHER|Repaeted Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps. In this case, the ascent and descent of the stairs must be repeated two times. Between the two trial the IMU units must be repositioned.
219175055|NCT04376242|BEHAVIORAL|use of standard technology|the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
219175056|NCT06096038|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
219175057|NCT06096038|DRUG|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
219175058|NCT06096038|BIOLOGICAL|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
219175059|NCT01477957|PROCEDURE|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
219247574|NCT07000305|DRUG|Cetuximabβ combined with Envolimab and mFOLFOX6|Envolimab, 200 mg, sc, day 1; Cetuximabβ 500 mg/m2 IV over 60- 120 min, day 1; chemotherapy mFOLFOX6; with the above regimen every 14 days for 1 treatment cycle. Then patients who did not experience disease progression within 8-12 cycles were entered into maintenance therapy, which consisted of a fluorouracil-based-chemotherapy with Cetuximabβ and Envolimab regimen until progression or unacceptable toxicity.
219247575|NCT07000253|DRUG|Chemotherapy|Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
219247576|NCT07000253|DRUG|Targeted Systemic Therapy|Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
219247577|NCT07000253|DRUG|Immunotherapy|Biomarker selected patients will recieve checkpoint inhibitors according to standard care
219247578|NCT07000253|PROCEDURE|Surgery|If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
219247579|NCT07000253|RADIATION|Radiotherapy|Metastases may be irradiated
219741532|NCT05487391|DRUG|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
219741533|NCT05487391|DRUG|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
219247580|NCT07002658|PROCEDURE|Harvesting of the saphenous vein graft|"Most existing studies on endoscopic saphenectomy have been conducted in CABG with cardiopulmonary bypass (CBP), whereas most CABG surgeries at the study center are performed without CBP.~The following outcomes will be identified:~* Days of admission or need for hospitalization~* Use of antibiotic therapy for saphenectomy wound infections~* Need for wound dressings due to necrosis and/or wound infection~* Need for analgesic treatment for wound pain"
219247581|NCT07001670|OTHER|Tele-Yoga Training|The Tele-yoga group will participate in real-time yoga sessions three times a week for eight weeks, including individual sessions for the first two weeks and small group sessions for the remaining six weeks, with all sessions supervised by a certified instructor. Each session will last approximately 45-60 minutes and include a 5-10 minute warm-up, 15-20 minutes of yoga postures, 15-20 minutes of yogic breathing exercises, and 5-10 minutes of relaxation and meditation.
219741534|NCT05487391|DRUG|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
219741535|NCT05487391|DRUG|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
219741536|NCT05487391|DRUG|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
219741537|NCT05487391|DRUG|Placebo|Placebo
219741538|NCT00250575|DRUG|Clozapine|
219741539|NCT00347087|DRUG|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
219741540|NCT05249400|PROCEDURE|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
219741541|NCT00804479|OTHER|No intervention.|
219741542|NCT00775086|DRUG|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
219741543|NCT03109769|BEHAVIORAL|Mobile phone application|
219741544|NCT03109769|BEHAVIORAL|Verbal oral hygiene instructions|
219247582|NCT07009392|DIAGNOSTIC_TEST|NGS Analysis|NGS (Next Generation Sequencing) analysis is performed on tissue from ACL
219247583|NCT07008625|DEVICE|virtual reality glasses|"Experimental Group (Those who applied virtual reality glasses):~1.Stage: The mothers who will be included in the experimental-application group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the"
219247584|NCT07008625|BEHAVIORAL|routine care|"1.Stage: The mothers who will be included in the control group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study, 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the control group were given 1 during the waiting for the next milking time. and 2. r"
219247585|NCT07008222|COMBINATION_PRODUCT|we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate|Either 3cc of unbuffered lidocaine (control) or 3cc of buffered 1% lidocaine (intervention) will be prepared and administered by the clinician. In a study investigating buffered lidocaine versus unbuffered lidocaine in intrauterine device insertion, investigators prepared 20cc of buffered lidocaine utilizing 18cc of 1% lidocaine (90%) and 2cc of 8.4% sodium bicarbonate (10%). 3 Thus, we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate.
219247586|NCT07008222|OTHER|Unbuffered lidocaine|For the control, 3cc of unbuffered lidocaine will be prepared and administered by the clinician.
219247587|NCT07009145|DRUG|QL1706|QL1706 (Iparomlimab and Tuvonralimab) is administered at a dose of 5 mg/kg via intravenous infusion on Day 1 of each 3-week cycle (Q3W).
219247588|NCT07009145|DRUG|Bevacizumab|Bevacizumab is administered at a dose of 7.5 mg/kg every 3 weeks (Q3W) via intravenous (iv) infusion.
219247589|NCT07008508|DRUG|Cyclin-dependent Kinase 4/6 Inhibitor|Planned new line of Cyclin-dependent Kinase 4/6 Inhibitor
219247590|NCT07007910|DRUG|HSK46575|co-administered with glucocorticoid and fludrocortisone, orally daily
219247591|NCT07008521|PROCEDURE|Universal exercise unit|universal exercise unit (UEU) for study groip (A)
219247592|NCT07008521|PROCEDURE|Rebound Therapy|rebound therpay for study group (B)
219247593|NCT07008521|PROCEDURE|Traditional physical therapy program|traditional physical therapy program for contrl group
219247594|NCT05022472|BEHAVIORAL|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
219247595|NCT05022472|BEHAVIORAL|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
219247596|NCT05022472|BEHAVIORAL|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
219362729|NCT01166451|DIETARY_SUPPLEMENT|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
219741545|NCT02034266|DIETARY_SUPPLEMENT|Omega-3 supplementation|5 mL twice daily, administered under the tongue
219741546|NCT02980185|PROCEDURE|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
219741547|NCT00648713|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
219741548|NCT00648713|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fed
219741549|NCT00185055|DRUG|Olmesartan medoxomil|
219741550|NCT00185055|DRUG|Irbesartan|
219741551|NCT00185055|DRUG|Valsartan|
219741552|NCT02714543|DRUG|aloevera juice|aloevera juice to drink twice daily for 3 months.
219741553|NCT02714543|DRUG|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
219741554|NCT02714543|DRUG|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
219247597|NCT05022472|BIOLOGICAL|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
219247598|NCT06720649|OTHER|isokinetic test|Bilateral strength will be measured using a Contrex ® dynamometer equipped with an exercise table. Each subject will perform isokinetic tests of the right and left knee extensors and flexors. Subjects will be stabilized by straps during testing and the joint rotation axis will be aligned with the input shaft of the dynamometer.
219247599|NCT06720649|OTHER|Ballistic test|ballistic squat jumps performed in the supine position on a frictionless sled at a resistance between 0% of body weight (BW)
219247600|NCT06720649|OTHER|K-STARTS test|"The K-STARTS (Knee Health Athletic Return To Sport) test brings together a set of 7 tests validated in the scientific literature to assess the control and neuromuscular capacities of the lower limb when performing dynamic movements as well as apprehension when resuming activity.~Test in 30 minutes with physical exercises and questionnaire."
219247601|NCT06720649|OTHER|Questionnaires|KOOS (Knee Injury and Osteoarthritis Outcome Score) Questionnaire
219247602|NCT04113187|DRUG|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
219247603|NCT04113187|DRUG|Placebo|per os, twice a day (morning and evening) during three months
219247604|NCT04233333|DEVICE|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
219247605|NCT06086522|DRUG|QN-302|Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
219247606|NCT01503437|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
219247607|NCT01802892|DRUG|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
219247608|NCT01802892|DRUG|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
219247609|NCT01802892|DRUG|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
219247610|NCT00874484|DRUG|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
219247611|NCT04983225|DRUG|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
219247612|NCT04983225|OTHER|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
219247613|NCT00439348|BEHAVIORAL|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
219247614|NCT00439348|BEHAVIORAL|Prescription|Patients receive a prescription for a specific over-the-counter medication.
219247615|NCT05990270|BEHAVIORAL|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
219247616|NCT05347121|DIAGNOSTIC_TEST|difficult airway|ultrasonography of airway
219247617|NCT04826419|OTHER|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
219247618|NCT00445861|BIOLOGICAL|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
219247619|NCT00445861|BIOLOGICAL|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
219247620|NCT00445861|BIOLOGICAL|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
219741555|NCT02714543|DRUG|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
219741556|NCT02714543|DRUG|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
219741557|NCT04712227|OTHER|intubation|intubation
219741558|NCT04712227|OTHER|mask ventilation|mask ventilation
219741559|NCT00313521|DRUG|thiotepa|
219741560|NCT00313521|PROCEDURE|adjuvant therapy|
219741561|NCT00313521|RADIATION|radiation therapy|
219741562|NCT04365270|DRUG|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
219741563|NCT04365270|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
219741564|NCT04365270|DRUG|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
219741565|NCT04365270|DRUG|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
219741566|NCT05346640|DEVICE|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
219247621|NCT00445861|PROCEDURE|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
219247622|NCT05490147|PROCEDURE|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.
219247623|NCT05490147|PROCEDURE|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
219247624|NCT06008106|DRUG|tunlametinib|12mg BID
219247625|NCT06008106|DRUG|paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin|according to investigators' suggestion
219247626|NCT03618927|BEHAVIORAL|Daily physical activity intervention|
219247627|NCT00598117|BEHAVIORAL|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS"
219247628|NCT00002519|DRUG|chemotherapy|
219247629|NCT00002519|DRUG|paclitaxel|
219247630|NCT00002519|RADIATION|radiation therapy|
219247631|NCT02872818|DRUG|17β estradiol hemihydrate|4mg/kg/day for 20 days
219247632|NCT02872818|DRUG|Metformin|50 mg/kg/day last 10 days
219247633|NCT02872818|DRUG|medroxyprogesterone acetate|1mg/kg/day last 10 days
219247634|NCT03945097|BEHAVIORAL|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
219247635|NCT00770640|DRUG|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
219247636|NCT00770640|DRUG|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
219247637|NCT00092365|DRUG|MK0966, rofecoxib|
219247638|NCT00092365|DRUG|Comparator: celecoxib, placebo|
219247639|NCT03219255|DRUG|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
219247640|NCT05242913|DIETARY_SUPPLEMENT|Resistant Potato Starch|Unmodified potato starch containing \>60% resistant starch Type 2
219247641|NCT05242913|DIETARY_SUPPLEMENT|Placebo|Fully digestible corn starch
219247642|NCT04346433|BEHAVIORAL|Restricted Sleep|During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
219247643|NCT04346433|BEHAVIORAL|Adequate Sleep|During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
219247644|NCT03322514|DIETARY_SUPPLEMENT|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
219247645|NCT03322514|DIETARY_SUPPLEMENT|Inulin|Inulin
219247646|NCT01184859|DRUG|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
219247647|NCT01184859|DRUG|Placebo|Placebo melt tablet for sublingual administration
219741567|NCT04831619|DRUG|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
219741568|NCT00103701|DRUG|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
219741569|NCT06694506|OTHER|Biological Sample|Clinical examination and blood test. The clinical examination and blood test are considered standard-of-care as they could be performed annually or bi-annually as part of an adult GHD follow-up. Subsequently, the data will be collected directly from the patient's chosen physician.
219741570|NCT06694064|PROCEDURE|Pulpotomy|Pulpotomy will be done for mta group
219741571|NCT06694064|PROCEDURE|extraction for histologic examination|after pulp therapy the teeth exrtracted for histologic examination
219741572|NCT03461120|DRUG|Experimental continuous peripheral nerve blocks|Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusions for 7 days via femoral and sciatic perineural catheters
219741573|NCT03461120|DRUG|Control continuous peripheral nerve blocks|Bupivacaine 0.1% \[or ropivacaine 0.2%\] infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
219741574|NCT03490994|DRUG|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
219741575|NCT03490994|DRUG|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
219741576|NCT05815199|OTHER|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
219741577|NCT05815199|OTHER|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
219741578|NCT05815199|BEHAVIORAL|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
219741579|NCT05815199|BEHAVIORAL|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
219741580|NCT05715320|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
219741581|NCT05584137|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
219741582|NCT05584137|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
219743552|NCT00557440|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
219247648|NCT04549142|OTHER|There is no intervention|There is no intervention
219247649|NCT03220659|DEVICE|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
219247650|NCT03220659|DEVICE|Standard settings|Normal bipolar LV pacing
219247651|NCT05607485|PROCEDURE|Randomized video numbers|See arm/group description
219247652|NCT00260676|PROCEDURE|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
219247653|NCT01827449|DEVICE|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
219247654|NCT00317850|DRUG|Gabapentin (Neurontin)|
219247655|NCT03022110|DEVICE|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
219247656|NCT05497037|DEVICE|PRF stimulation|One time 500 kHZ stimulation for 15 min
219247657|NCT05497037|DEVICE|Sham stimulation|Sham stimulation for 15 min
219247658|NCT04358614|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
219247659|NCT02016664|DRUG|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
219741583|NCT04208256|DIETARY_SUPPLEMENT|Energy Stimulus|Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
219741584|NCT03755401|OTHER|TFPP|Trauma-Focused Psychodynamic Psychotherapy
219741585|NCT03755401|OTHER|TAU|treatment as usual at the VA for PTSD
219741586|NCT06062472|DIETARY_SUPPLEMENT|Probiotics|Lactobacillus paracasei PS23 will be used in this study
219741587|NCT06062472|DIETARY_SUPPLEMENT|heat-treated of Lactobacillus paracasei HT-PS23|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
219741588|NCT06062472|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
219741589|NCT01251965|DRUG|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
219741590|NCT04540380|DRUG|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
219741591|NCT04540380|PROCEDURE|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
219741592|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 50,000 I.U of vitamin D weekly for 8 weeks
219741593|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks (totaling 8 weeks)
219741594|NCT02608385|RADIATION|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
219741595|NCT02608385|DRUG|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
219743553|NCT00557440|DRUG|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
219743554|NCT00557440|DRUG|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
219247660|NCT01537120|DRUG|Vildagliptin|
219247661|NCT01537120|DRUG|Placebo|
219247662|NCT05899621|DRUG|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
219247663|NCT05899621|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
219247664|NCT05899621|DRUG|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
219247665|NCT05899621|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
219247666|NCT05899621|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
219247667|NCT05899621|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
219247668|NCT05899621|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
219247669|NCT02657421|PROCEDURE|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
219247670|NCT03628183|OTHER|Hydrolysate Infant Formula 1|Feed ad lib
219247671|NCT03628183|OTHER|Hydrolysate Infant Formula 2|Feed ad lib
219247672|NCT05098756|OTHER|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
219247673|NCT00282828|DRUG|Sertraline|
219247674|NCT00282828|DRUG|Venlafaxine|
219247675|NCT00282828|DRUG|Placebo|
219247676|NCT00282828|DRUG|Clonazepam|
219247677|NCT05992662|BEHAVIORAL|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up"
219247678|NCT03695198|DRUG|LY3361237 - SC|LY3361237 administered SC
219247679|NCT03695198|DRUG|LY3361237 - IV|LY3361237 administered IV
219247680|NCT03695198|DRUG|Placebo - SC|Placebo administered SC
219247681|NCT03695198|DRUG|Placebo - IV|Placebo administered IV
219247682|NCT00945178|DRUG|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
219247683|NCT00945178|DRUG|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
219247684|NCT00945178|DRUG|Naproxen|Tablet, single oral dose, 500mg
219247685|NCT00945178|DRUG|Placebo for Naproxen|Tablet, single oral dose
219247686|NCT05698199|DRUG|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
219247687|NCT00944996|DRUG|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
219247688|NCT01503515|DRUG|Caspofungin Acetate|Given IV
219247689|NCT01503515|DRUG|Fluconazole|Given IV or PO
219741596|NCT00945542|OTHER|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
219741597|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
219741598|NCT02531386|DEVICE|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
219741599|NCT06633991|PROCEDURE|verbal instructions|verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
219741600|NCT06099366|DRUG|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
219741601|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
219741602|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
219741603|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
219741604|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
219741605|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
219741606|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
219741607|NCT06099366|DRUG|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
219741608|NCT03191734|DEVICE|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
219741609|NCT06439784|OTHER|whole body SPECT/CT|Patient will unergo a whole body SPECT/CT in treatment position
219741610|NCT04802590|DRUG|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
219741611|NCT04802590|DRUG|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
219741612|NCT04802590|DRUG|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
219741613|NCT04802590|DRUG|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
219741614|NCT02375711|BIOLOGICAL|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
219741615|NCT03261375|DEVICE|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
219741616|NCT03261375|DRUG|Antihypertensive Agents|Calcium channel blocker, Diuretic
219741617|NCT03261375|DEVICE|Sham Procedure|Catheterization without renal denervation
219741618|NCT00216385|DRUG|Gatifloxacin combined regimen|
219741619|NCT06057025|BIOLOGICAL|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
219741620|NCT05867888|OTHER|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
219741621|NCT05867888|OTHER|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
219741622|NCT05867888|OTHER|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
219741623|NCT04616196|DRUG|NKTR-255|NKTR-255 IV every 21 days
219247690|NCT01503515|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219247691|NCT01503515|DRUG|Voriconazole|Given IV or PO
219247692|NCT03690336|DRUG|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
219741624|NCT04616196|DRUG|Cetuximab|Cetuximab will be given at specified doses on specified days
219741625|NCT06062355|DRUG|HRS-9815 injection|HRS-9815 injection
219741626|NCT05463419|BIOLOGICAL|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
219247693|NCT01007617|DEVICE|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
219247694|NCT01563445|DRUG|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
219247695|NCT01563445|DRUG|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
219247696|NCT00231517|DRUG|topical opiod|
219247697|NCT00231517|DRUG|morphine sulphate in intrasite gel|
219247698|NCT01828593|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
219247699|NCT01828593|OTHER|Placebo|Matching placebo
219247700|NCT00515697|BIOLOGICAL|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
219247701|NCT04462497|OTHER|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
219247702|NCT02411695|DRUG|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
219247703|NCT06584643|DIAGNOSTIC_TEST|gasdermin d|evaluation of serum gasdermin d in vitligo patients and healthy controls
219247704|NCT05599516|BIOLOGICAL|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
219175060|NCT05706480|DIAGNOSTIC_TEST|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
219175061|NCT05706480|DIAGNOSTIC_TEST|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
219175062|NCT05706480|DIAGNOSTIC_TEST|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
219175063|NCT05485090|OTHER|Questionnaire : Adapted Safety Assessment Scale|Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
219175064|NCT05467943|DRUG|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
219175065|NCT06528743|RADIATION|RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.|Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
219175066|NCT06353841|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
219175067|NCT06295757|OTHER|Cigarettes|Participants will smoke their own usual brand cigarettes. Cigarette butts will be collected.
219175068|NCT06391125|DRUG|normal Saline|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
219175069|NCT06391125|DRUG|Lidocaine|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
219175070|NCT05751694|PROCEDURE|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
219175071|NCT05751694|PROCEDURE|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
219175072|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
219175073|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
219175074|NCT04909931|DRUG|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
219175075|NCT04909931|DRUG|Placebo|Second arm : add on placebo for 12 weeks
219175076|NCT04795843|OTHER|Exercise and patient education|Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
219175077|NCT04795843|OTHER|Usual Care|Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
219175078|NCT05735977|DIAGNOSTIC_TEST|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
219247705|NCT05599516|BIOLOGICAL|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
219247706|NCT05599516|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
219247707|NCT03087851|DRUG|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
219247708|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery
219247709|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
219175079|NCT05435495|PROCEDURE|Single-photon emission computed tomography|Imaging procedure
219175080|NCT05435495|PROCEDURE|Blood Draw|Blood draw for future research tests (45-60 mL).
219175081|NCT05435495|PROCEDURE|Tumor Biopsy|Guided biopsy of lesion
219175082|NCT04286490|OTHER|Prone position|Abdomen suspension in prone position
219175083|NCT04918823|DRUG|Restasis|Subject will use one drop of Restasis in the lens before insertion
219175084|NCT03144765|PROCEDURE|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
219175085|NCT02643498|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
219175086|NCT01659411|OTHER|Observational|Yearly clinical visits
219247710|NCT05341063|BEHAVIORAL|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
219247711|NCT05341063|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
219247712|NCT01742949|DEVICE|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
219247713|NCT01742949|DEVICE|No Humidification|Heated Humidification (ThermoSmart) Turn Off
219247714|NCT00443755|DRUG|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
219247715|NCT00443755|DRUG|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
219247716|NCT00443755|DRUG|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
219247717|NCT02515500|BEHAVIORAL|Gradual Cessation|
219247718|NCT02515500|BEHAVIORAL|Gradual Cessation w/ Quitbit|
219247719|NCT03520088|PROCEDURE|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
219247720|NCT03520088|PROCEDURE|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
219247721|NCT04225247|DRUG|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
219247722|NCT04225247|DRUG|Bifluorid 12|it is a fluoride varnish by VOCO.
219247723|NCT04225247|DRUG|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
219247724|NCT01588171|DRUG|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
219247725|NCT01588171|DRUG|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
219247726|NCT03637621|OTHER|ORIF|open reduction internal fixation of the distal humerus
219247727|NCT04739462|BEHAVIORAL|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
219247728|NCT06159933|PROCEDURE|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
219741627|NCT05463419|BIOLOGICAL|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
219741628|NCT02741050|BEHAVIORAL|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
219741629|NCT02741050|BEHAVIORAL|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
219741630|NCT05976633|OTHER|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
219741631|NCT05976633|OTHER|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
219741632|NCT05976633|OTHER|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
219741633|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
219741634|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
219743555|NCT01309061|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
219743556|NCT03524157|DRUG|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
219247729|NCT06159933|PROCEDURE|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
219247730|NCT06159933|PROCEDURE|Late pronation|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
219247731|NCT04782505|DRUG|DWJ1248|Camostat mesylate Tablet from Daewoong
219247732|NCT01695525|OTHER|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
219247733|NCT05849571|OTHER|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
219247734|NCT04441996|BIOLOGICAL|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
219247735|NCT04441996|OTHER|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
219247736|NCT00678899|DEVICE|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
219247737|NCT00159341|PROCEDURE|Nasal lavage|Nasal lavage was carried out at specified timepoints
219247738|NCT00159341|PROCEDURE|Nasal filter paper|Nasal filter paper was placed at specified timepoints
219247739|NCT00159341|PROCEDURE|Blood sampling|Blood sampling was performed as a routine safety check
219247740|NCT01543906|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
219247741|NCT05681845|DRUG|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
219247742|NCT06402123|DRUG|zagociguat 15mg|Once-daily oral tablets
219247743|NCT06402123|DRUG|zagociguat 30mg|Once-daily oral tablets
219247744|NCT06402123|DRUG|Placebo|Once-daily oral tablets
219247745|NCT05289375|DRUG|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
219743557|NCT03524157|DRUG|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
219743558|NCT03524157|DRUG|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
219743559|NCT05913167|PROCEDURE|laparoscopic nephrectomy|laparoscopic nephrectomy
219743560|NCT04815863|DIAGNOSTIC_TEST|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
219743561|NCT04815863|DIAGNOSTIC_TEST|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
219743562|NCT04815863|DIAGNOSTIC_TEST|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
219743563|NCT00520338|DRUG|celecoxib|"1. placebo~2. celecoxib 400 mg oral single dose"
219743564|NCT04629430|OTHER|Pre-biotic foods/drinks|2 servings per day
219743565|NCT05648708|PROCEDURE|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
219743566|NCT05648708|PROCEDURE|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
219743567|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
219743568|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
219743569|NCT00319189|DRUG|Nateglinide|
219743570|NCT03066375|DEVICE|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
219743571|NCT04826614|OTHER|optimized treatment|early adjust dose or change drug
219743572|NCT02695654|DRUG|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
219743573|NCT02695654|DRUG|Clonidine|Clonidine 100 mcg
219743574|NCT00850187|BIOLOGICAL|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
219743575|NCT02998099|DRUG|Rivipansel|A single dose of IV rivipansel over 20 minutes.
219743576|NCT01596426|DRUG|Sancuso|granisetron transdermal system
219743577|NCT01596426|DRUG|IV granisetron|IV granisetron
219743578|NCT01912235|OTHER|2-15N glutamine|Glutamine with N15 isotope tracer
219743579|NCT01912235|OTHER|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
219743580|NCT01912235|OTHER|1-13C glutamine|Glutamine carbon isotope tracer
219743581|NCT02256878|DRUG|BIRT 2584 XX|
219743582|NCT02256878|DRUG|Amitriptyline|
219743583|NCT03235492|DEVICE|SmartAlbu|"Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device"
219175087|NCT03114553|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
219175088|NCT06266260|DEVICE|EUS PPG measurement|Direct EUS PPG measurement
219247746|NCT05289375|DRUG|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
219247747|NCT02160496|BEHAVIORAL|Weight loss interventional study with 20% protein-diet|
219247748|NCT02160496|BEHAVIORAL|Weight loss interventional study with 27% protein-diet|
219247749|NCT02160496|BEHAVIORAL|Weight loss interventional study with 35% protein-diet|
219247750|NCT03932253|OTHER|FCN-159|Administered orally once a day
219247751|NCT01093976|DRUG|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
219247752|NCT00376935|DRUG|Palifermin|Keratinocyte growth factor administered via injection
219247753|NCT00376935|DRUG|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
219247754|NCT00840788|PROCEDURE|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
219247755|NCT00840788|PROCEDURE|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
219247756|NCT06141694|DEVICE|The LIBERTY® Robotic System|"The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures."
219741635|NCT05363930|DEVICE|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
219741636|NCT05363930|DEVICE|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
219741637|NCT02410200|DRUG|dimethyl fumarate|
219741638|NCT03517800|OTHER|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
219741639|NCT06548516|PROCEDURE|Control group (conventional scalpel surgery)|The patients in the control group will undergo frenectomy using conventional scalpel surgery.
219741640|NCT06548516|PROCEDURE|Diode laser group|The patients in the laser group will undergo frenectomy using a diode laser.
219741641|NCT04804436|GENETIC|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
219741642|NCT02510742|DEVICE|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
219741643|NCT02510742|DEVICE|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
219741644|NCT04722809|DRUG|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
219741645|NCT04722809|OTHER|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
219741646|NCT04722809|OTHER|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
219743584|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
219175089|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
219175090|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
219175091|NCT05282173|BEHAVIORAL|Siyakhana CHW Training|Please see arm description.
219175092|NCT06018454|OTHER|Handout on PGT-A|Educational handout on PGT-A
219175093|NCT06018454|OTHER|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
219175094|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
219175095|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
219175096|NCT05231837|BEHAVIORAL|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
219175097|NCT05231837|BEHAVIORAL|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
219175098|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
219175099|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
219247757|NCT04009902|BEHAVIORAL|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
219247758|NCT06344494|DEVICE|Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system|Novel ICE catheter and combined ultrasound system
219247759|NCT06344494|DEVICE|SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system|Commercially available devices
219247760|NCT02080143|DEVICE|Thermal Adhesion Patch|
219247761|NCT02080143|DEVICE|Thermal Adhesion Patch|
219247762|NCT03296423|BIOLOGICAL|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
219247763|NCT03296423|BIOLOGICAL|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
219247764|NCT05921929|DRUG|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
219741647|NCT04722809|OTHER|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
219741648|NCT04722809|OTHER|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
219741649|NCT04722809|OTHER|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
219741650|NCT05490056|OTHER|no intervention|the study will not apply on intervention
219741651|NCT05305573|BIOLOGICAL|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
219741652|NCT05305573|BIOLOGICAL|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
219741653|NCT04818710|PROCEDURE|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
219741654|NCT04818710|PROCEDURE|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
219741655|NCT02273427|DRUG|BIIL 284 BS|
219741656|NCT02273427|OTHER|high fat meal|
219741657|NCT02273427|OTHER|low fat meal|
219741658|NCT02801578|DRUG|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
219741659|NCT00668642|DRUG|Dutasteride|0.5 mg capsule given orally on daily basis
219741660|NCT00668642|DRUG|Placebo|Identical placebo
219741661|NCT05053685|DIAGNOSTIC_TEST|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
219741662|NCT06015009|OTHER|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
219741663|NCT02108808|DRUG|Ticagrelor|
219741664|NCT02108808|DRUG|Prasugrel or Clopidogrel|
219175100|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
219741665|NCT04166747|OTHER|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
219741666|NCT02458027|DIETARY_SUPPLEMENT|Hemp Shake|Hemp Protein
219741667|NCT02458027|DIETARY_SUPPLEMENT|Hemp|Hemp Protein Shake
219741668|NCT02458027|DIETARY_SUPPLEMENT|Soybean Shake|Soybean Protein
219741669|NCT02458027|DIETARY_SUPPLEMENT|Soybean|Soybean Protein Shake
219741670|NCT02458027|DIETARY_SUPPLEMENT|Control|Non-Protein Shake
219741671|NCT05115773|PROCEDURE|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
219741672|NCT05115773|PROCEDURE|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
219741673|NCT00960245|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
219741674|NCT00960245|DRUG|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
219741675|NCT01539031|DRUG|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
219741676|NCT01539031|DRUG|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
219741677|NCT01987999|DIETARY_SUPPLEMENT|Acetogenins|
219247765|NCT01763489|BEHAVIORAL|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
219247766|NCT00122707|DEVICE|catheters|
219247767|NCT03110640|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
219247768|NCT03110640|DRUG|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
219247769|NCT03110640|DRUG|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
219247770|NCT02112799|DRUG|NVR 3-778|
219247771|NCT02112799|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
219247772|NCT02112799|DRUG|Pegasys|
219247773|NCT03694249|DRUG|Ifetroban Sodium|Given by mouth
219247774|NCT03694249|OTHER|Placebo|Given by mouth
219247775|NCT02232919|DEVICE|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
219247776|NCT05166317|OTHER|This is an observational study|This is an observational study
219247777|NCT03997409|OTHER|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
219247778|NCT05834647|DRUG|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
219247779|NCT05834647|DRUG|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
219247780|NCT04463888|OTHER|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
219743585|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
219743586|NCT01592747|DRUG|Placebo capsules|Once daily, oral administration.
219743587|NCT02118415|OTHER|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
219743588|NCT01496859|DEVICE|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
219743589|NCT04503421|OTHER|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
219743590|NCT01740518|DRUG|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
219743591|NCT04695366|OTHER|No intervention|No intervention
219743592|NCT01275378|BEHAVIORAL|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
219743593|NCT01275378|BEHAVIORAL|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
219743594|NCT00832013|DRUG|Propofol|See detailed description
219743595|NCT00832013|DRUG|Propofol|See detailed description
219743596|NCT06639893|PROCEDURE|Telescopic overdenture|Telescopic overdenture with two dental implants in intraforaminal area for mandible.
219743597|NCT06638684|OTHER|Exercise|Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
219743598|NCT06565039|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
219247781|NCT02581826|DRUG|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
219247782|NCT02581826|DRUG|Placebo|No column specified.
219247783|NCT04975646|BEHAVIORAL|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
219247784|NCT01975259|DRUG|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
219743599|NCT06565013|DRUG|Cabenuva 600/900|Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
219743600|NCT06565013|OTHER|Self administered questionnaires|Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
219175101|NCT05945212|DEVICE|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
219175102|NCT05945212|DEVICE|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
219175103|NCT05945212|OTHER|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
219175104|NCT05945212|OTHER|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
219175105|NCT05945212|OTHER|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
219743601|NCT06565013|OTHER|Semi-directed interview|At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
219743602|NCT06560788|OTHER|collection of cerebrospinal fluid|CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
219743603|NCT02331303|OTHER|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
219743604|NCT01847014|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
219743605|NCT03730350|BEHAVIORAL|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
219175106|NCT05945212|OTHER|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
219175107|NCT05945212|OTHER|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
219175108|NCT05945212|OTHER|Barthel index|The Barthel index measure autonomy in daily life.
219175109|NCT05945212|OTHER|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
219175110|NCT05945212|OTHER|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
219175111|NCT05945212|OTHER|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
219175112|NCT05945212|OTHER|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
219175113|NCT05945212|OTHER|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
219175114|NCT05451940|DRUG|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
219175115|NCT05451940|DRUG|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
219175116|NCT05351554|DRUG|Namilumab|Specified dose on specified days
219175117|NCT06926335|PROCEDURE|Breast consevative surgery|plastic surgery principles within the context of sound oncological resection. Volume-reducing or volume- replacing methods are utilised to optimise postoperative appearances whilst prioritizing negative margin resection, supported by prompt adjuvant therapy
219175118|NCT06786247|BEHAVIORAL|ActivaTeen|"The ActivaTeen app is built on HIPAA-compliant instance of a popular messaging software. Participants in the treatment group can access the app at any time via desktop or mobile, where they can find features designed to enhance their receipt of BA therapy.~These features include: weekly BA skills and homework completion support, in-app messaging with their BA therapist, mood and activity tracking and data visualizations, chatbot check-ins on progress and guided problem-solving around barriers, and moderated peer support using the ActivaTeen app. The app will have a moderator, who is part of the study team, to manage peer-to-peer interactions within ActivaTeen."
219175119|NCT06786247|BEHAVIORAL|Behavioral Activation|Behavioral activation therapy involves individual weekly sessions with a trained therapist for 12 weeks. The sessions are completed either in-person or via telehealth. The treatment focuses on behavioral manifestations of depression such as isolating, and how these behaviors are interconnected with low mood and depressive emotions. BA helps patients find ways to engage in behaviors that are meaningful to them based on their values, priorities, and goals, with the aim of creating positive loops between doing meaningful activities and improved mood. The therapist provides structure and problem-solving for activating these behaviors and keeping track of changes over time.
219175120|NCT03774082|DRUG|INC424|"Ruxolitinib was taken orally based on age groups as follows:~Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid"
219175121|NCT05093829|BIOLOGICAL|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
219175122|NCT05093829|BIOLOGICAL|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
219175123|NCT05212610|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
219247785|NCT01975259|DRUG|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
219175124|NCT06790329|PROCEDURE|Endoscopic sleeve gastroplasty with fundal mucosal ablation|Mucosal ablation around the gastric fundus is initially performed using a hybrid argon plasma coagulation (H-APC) probe, following a submucosal saline injection, until ablation coagulum is visible. Subsequently, endoscopic sleeve gastroplasty (ESG) is performed using a full-thickness endoscopic suturing device (Overstitch, Apollo). This is done in a standard manner, employing 6-8 permanent full-thickness sutures along the greater curvature of the stomach in a running plication, starting from the angular incisura and extending proximally while sparing the fundus. Hemostasis is carefully checked and confirmed before the procedure is completed.
219175125|NCT06797765|DEVICE|OCTA|Optical Coherence Tomography Angiography
219175126|NCT06832163|DEVICE|Nitric Oxide Generation and Delivery System|"The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.~iNO devices with intelligent closed-loop offline function are required to meet the import and discharge standards. The initial concentration of NO withdrawal is 20ppm. In accordance with the withdrawal criteria outlined in the Chinese Guidelines, it is essential to conduct a comprehensive efficacy evaluation prior to initiating withdrawal. Furthermore, the process of inhaled nitric oxide (iNO) evacuation should commence only if specific conditions are satisfied."
219175127|NCT06923735|OTHER|Utilization of the Finnish Nutrition Navigator and the Finnish Nutrition Path|Participant fills in the food intake questionnaire of the Finnish Nutrition Navigator and receives an automated feedback on the diet before the visit to the occupational healthcare. At the visit, the information about the quality of diet can be utilized with the occupational healthcare professional. The client can utilize the self-care path (the Finnish Nutrition Path) for possible dietary changes independently or with the professional.
219175128|NCT06831396|BEHAVIORAL|Dose comparison (same intervention)|The intervention under investigation is a motor-phonetic approach to articulation therapy, enhanced with ultrasound visual biofeedback (UVBF). The treatment group will receive the intervention immediately, while the waitlist control group will receive treatment after the initial group completes the study. This design allows for comparative outcome assessments between both groups, ensuring that all participants ultimately receive treatment.
219175129|NCT04889755|BEHAVIORAL|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
219175130|NCT06837116|BIOLOGICAL|Vaccine|Subcutaneous route vs Intradermal route
219175131|NCT06845475|OTHER|Designed physical therapy program|Both groups will receive a designed physical therapy program, in the form of myofascial trigger points pressure release, stretching of the upper trapezius muscle, strengthening exercises, and infrared radiation for 4 weeks.
219175132|NCT06845475|OTHER|Extracorporeal shock wave therapy (ESWT)|Adolescents of the experimental group will receive Extracorporeal shock wave therapy with the following parameters; low-level energy radial extracorporeal shock wave by (STORZ MEDICAL Master Pulse MP200), each subject received 3 sessions per week for 4 weeks with 700 impulse/session 400 impulse was applied to tight band and 300 impulses will be applied surrounding the tight band, with frequency \[10HZ\], resulting in positive energy flux density \[EFD\] 0.056mJ/mm.
219175133|NCT06836583|OTHER|trans-nasal pterygopalatine Fossa block|Patients will be placed in 15-degree reverse Trendelenburg position, between the middle and inferior turbinates. This passage will be sterilized by an cotton-tipped applicator soaked with iodine solution. A 20-gauge/5-inch spinal needle will be used after bending 2-3 mm of its tip along the port side with a sterile needle holder to form a 45 angle. The needle will be lubricated with 5% lidocaine jelly, inserted into the nasal meatus and advanced with the bevel pointer facing laterally. Under endoscopic control (0\_ optics, 4 mm diameter), the needle will be inserted between middle and inferior turbinate. A total of 4 ml 0.25% bupivacaine will be injected after negative aspiration just behind and over middle turbinate tail, where the pterygopalatine fossa is deeply located.
219175134|NCT06836583|OTHER|US-guided infrazygomatic percutaneous pterygopalatine Fossa block|"US- guided percutaneous PPFB:~Patients will be placed in the lateral head position; the patient's mouth is slightly opened. Following standard sterile preparations, US linear probe covered with sterile sheath is positioned horizontally on the side of the face just below the zygomatic bone superior to the mandibular notch and anterior to the mandibular condyle to visualize the coronoid process, the lateral pterygoid muscle, the lateral pterygoid plate, and the maxillary bone, and the maxillary artery. Needle will be inserted in-plane parallel to the transducer probe and advanced from medial to lateral toward the pterygopalatine fossa. Following negative aspiration, the injectate is deposited deep to the lateral pterygoid muscle and plate. A total of 4 ml 0.25% bupivacaine will be injected."
219175135|NCT06462014|DRUG|Relugolix|relugolix
219175136|NCT06932419|OTHER|Ozone exposure|Participants' forearms were exposed to 200 ppb ozone for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
219175137|NCT06932419|OTHER|Clean air exposure|Participants' forearms were exposed to clean air for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
219175138|NCT06932029|BEHAVIORAL|SMBP with clinical pharmacist support|Self-measured blood pressure with clinical pharmacist support
219175139|NCT06931821|DEVICE|Isochronal Late Activation Mapping (ILAM)|an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters)
219175140|NCT06931821|DEVICE|High Density Voltage Mapping|high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV).
219175141|NCT06931496|OTHER|PROSTia test|questionnaire with 50 questions
219175142|NCT06932068|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.
219175143|NCT06932068|DRUG|Oxallplation|130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.
219175144|NCT06932068|DRUG|Capectitabine Tablets|1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.
219175145|NCT06931236|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) can noninvasively modulate cortical activity by delivering a sequence of magnetic pulses.
219175146|NCT06931236|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham tDCS was delivered using the same protocol and current intensity, but it is carried out as the coil is turned away from the skull at 90°.
219175147|NCT06931249|BEHAVIORAL|The observational study|This study is being conducted to create a Turkish version of the English version of the PAED scale, which did not exist before, and to determine its cultural suitability.
219175148|NCT06933004|DEVICE|Posterior Spinal Fixation System|Using spine implants SmartMIS Spinal Fixation System or ASA Spinal Fixation System.
219175149|NCT03310957|DRUG|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
219175150|NCT03310957|DRUG|Pembrolizumab|IV infusion every 3 weeks
219175151|NCT04793958|DRUG|MRTX849|28 Day Cycle
219175152|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
219175153|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
219175154|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
219175155|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
219175156|NCT02443857|DEVICE|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
219175157|NCT02443857|DEVICE|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
219175158|NCT02443857|DEVICE|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
219175159|NCT02443857|DEVICE|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
219247786|NCT01975259|DRUG|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
219247787|NCT01975259|DRUG|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
219247788|NCT01975259|DRUG|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
219247789|NCT01975259|DRUG|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
219247790|NCT01975259|OTHER|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
219247791|NCT01975259|OTHER|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
219247792|NCT01975259|OTHER|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
219247793|NCT01975259|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
219741678|NCT03446690|DRUG|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
219741679|NCT03446690|OTHER|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
219741680|NCT04787315|DEVICE|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
219741681|NCT04787315|BEHAVIORAL|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
219741682|NCT06240676|BEHAVIORAL|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
219741683|NCT00938626|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
219741684|NCT00938626|PROCEDURE|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
219741685|NCT00938626|PROCEDURE|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
219741686|NCT01266980|DRUG|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
219741687|NCT02738619|DRUG|Vitamin D3|1600 UI
219741688|NCT02738619|DRUG|placebo|placebo
219741689|NCT01751880|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
219175160|NCT02443857|DEVICE|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
219175161|NCT02443857|DEVICE|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
219175162|NCT04353661|DRUG|Azithromycin|Azithromycin will be administered orally.
219175163|NCT04353661|OTHER|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
219175164|NCT00667251|BIOLOGICAL|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
219175165|NCT00667251|DRUG|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
219175166|NCT00667251|DRUG|lapatinib ditosylate|1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
219175167|NCT00667251|DRUG|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
219175168|NCT06352567|OTHER|European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire|"It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively"
219175169|NCT02727699|DRUG|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
219175170|NCT02727699|DRUG|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
219175171|NCT04555512|OTHER|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
219175172|NCT04555512|OTHER|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
219175173|NCT06087601|DRUG|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
219175174|NCT06087601|DRUG|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
219175175|NCT06541951|OTHER|Services as usual|During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures
219175176|NCT06541951|OTHER|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
219175177|NCT05335967|BEHAVIORAL|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
219175178|NCT05335967|OTHER|Information package|The patients in this group will receive an information package on a healthy diet.
219175179|NCT03509116|OTHER|Observations, documents|Consultation observations, documentary analysis
219175180|NCT03509116|OTHER|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
219175181|NCT06146907|OTHER|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
219175182|NCT06146907|OTHER|exergaming|Nintendo switch games that involve physical activity by participants to complete
219743606|NCT03242447|BEHAVIORAL|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
219743607|NCT03242447|BEHAVIORAL|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
219175183|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle.
219175184|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
219175185|NCT06418555|BEHAVIORAL|A home rehabilitation program centered on exercise|Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
219175186|NCT06385925|DRUG|TSN1611|TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
219175187|NCT03047928|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
219175188|NCT03047928|BIOLOGICAL|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
219175189|NCT05543369|DRUG|Elafibranor|Oral Tablet
219175190|NCT04843722|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
219175191|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
219175192|NCT02182219|DRUG|BIBF 1120|
219175193|NCT05359939|DIAGNOSTIC_TEST|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
219175194|NCT06286514|OTHER|No intervention|This is an observational study
219175195|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
219175196|NCT03363711|OTHER|AYA STEPS|a mobile health application
219175197|NCT05625217|DIAGNOSTIC_TEST|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
219175198|NCT06405490|DRUG|Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab|Use the above medications on a regular basis
219175199|NCT06139211|BIOLOGICAL|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
219175200|NCT06139211|BIOLOGICAL|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
219175201|NCT06139211|BIOLOGICAL|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
219175202|NCT06139211|DRUG|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
219175203|NCT06139211|DRUG|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
219175204|NCT06139211|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
219741690|NCT05954884|OTHER|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~1. Community- and team-based model of hypertension care delivery~2. Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~3. Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~4. Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~5. Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~6. Community-based, multi-month prescription refills from CC~7. Training of clinic and research staff on BP measurement following standard techniques~8. Site monitoring and mentorship to ensure screening and patient enrollment/registration~9. Use of text messages to promote follow-up visits and medication adherence"
219741691|NCT04199390|PROCEDURE|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
219741692|NCT05941780|DIAGNOSTIC_TEST|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
219741693|NCT03682367|DRUG|Gabapentin|Use of Gabapentin peri- and post-operatively.
219741694|NCT03682367|DRUG|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
219741695|NCT06547320|BEHAVIORAL|Eat Less Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.
219741696|NCT06547320|BEHAVIORAL|Eat Slower Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
219741697|NCT02048007|DRUG|Azithromycin|Biannual mass oral azithromycin to children
219741698|NCT02048007|DRUG|Placebo|Biannual mass oral placebo to children
219741699|NCT02676037|DEVICE|foot pressure plate form|
219741700|NCT06044623|DRUG|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
219741701|NCT06044623|DRUG|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
219741702|NCT05755581|DRUG|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
219741703|NCT05755581|DRUG|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
219741704|NCT04595292|OTHER|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
219741705|NCT03295344|OTHER|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
219741706|NCT03295344|OTHER|Tissue Doppler|Determine the threshold value for diaphragm mobility
219741707|NCT05815264|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
219741708|NCT05815264|BIOLOGICAL|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
219741709|NCT00770679|DRUG|lipitor|80 mg everyday (QD) for 3 weeks
219741710|NCT05424588|DIAGNOSTIC_TEST|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
219741711|NCT06490666|DEVICE|femoral artery doppler|femoral artery pulse wave doppler to measure both pulsatility and resistive indices
219741712|NCT04840511|DRUG|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
219741713|NCT04840511|DRUG|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
219175205|NCT06139211|BIOLOGICAL|Bevacizumab|Bevacizumab of 5mg/kg will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or7.5mg/kg on day 1 every 21 day cycle, based on different combined chemotherapy.
219175206|NCT06139211|DRUG|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
219175207|NCT06139211|DRUG|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
219175208|NCT06139211|DRUG|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
219175209|NCT06139211|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
219175210|NCT04318548|COMBINATION_PRODUCT|Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)|1 dose of rMenB+OMV administered intramuscularly at day 1 and 61 to participants in MenB+MenACWY group and MenB group and as 1 dose at day 91 to participants in MenACWY group.
219175211|NCT04318548|BIOLOGICAL|Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)|1 dose of MenACWY administered intramuscularly at day 1 to participants in MenB+MenACWY group and MenACWY group, 1 dose at day 91 to participants for MenB group.
219175212|NCT04318548|COMBINATION_PRODUCT|Placebo|1 dose of Placebo administered intramuscularly at 1 to participants in MenB group and MenACWY group and as 1 dose at day 91 to participants in MenB+MenACWY group.
219175213|NCT05021419|OTHER|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
219175214|NCT05021419|OTHER|Standard Protocol|Current standard optimization protocol as per NICE and ESC
219175215|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root|This substance is extracted from the root of the plant.
219175216|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root and leaf|This substance is extracted from both the root and leaves of the plant.
219175217|NCT06793891|OTHER|placebo|The inert placebo does not contain any of the plant matter.
219247794|NCT05734976|DEVICE|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
219247795|NCT03300661|BEHAVIORAL|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
219247796|NCT01657071|DRUG|YH14659|YH14659 capsule by oral
219247797|NCT01657071|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
219247798|NCT02115542|DRUG|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
219247799|NCT03199170|DRUG|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
219247800|NCT03199170|DRUG|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
219741714|NCT03395093|DRUG|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
219741715|NCT03395093|DRUG|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
219741716|NCT03395093|DRUG|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
219741717|NCT03395093|DEVICE|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
219741718|NCT01577316|BIOLOGICAL|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus."
219741719|NCT06288893|DRUG|SHEN211 Tablets|SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
219741720|NCT06288893|PROCEDURE|Placebo for SHEN211 Tablets|Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
219741721|NCT04759287|DEVICE|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
219741722|NCT04759287|DEVICE|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
219741723|NCT00296712|DRUG|escitalopram + bupropion|same dosing as for monotherapy arms
219741724|NCT02494492|OTHER|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
219741725|NCT06220110|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
219741726|NCT06220110|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
219175218|NCT04330430|DRUG|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
219175219|NCT05879757|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
219175221|NCT04179500|DRUG|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
219175222|NCT04179500|DRUG|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
219175223|NCT04179500|DRUG|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
219175224|NCT04179500|DRUG|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
219175225|NCT04480918|DEVICE|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
219175226|NCT04480918|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
219175227|NCT04480918|DRUG|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
219175228|NCT04480918|DRUG|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
219175229|NCT04480918|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
219175230|NCT06581770|OTHER|Survey using a questionnaire.|It is a validity and reliability study that can evaluate digital health readiness.
219175231|NCT06581770|OTHER|Survey using a questionnaire.|This is a reliability and validity study.
219175232|NCT04854317|PROCEDURE|Endoscopic gastroplasty|Endoscopic Gastroplasty
219175233|NCT00009633|OTHER|No Intervention|No Intervention
219175234|NCT05171075|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
219175235|NCT05171075|DRUG|Dalteparin|Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
219175236|NCT04241068|DRUG|Aducanumab|Administered as specified in the treatment arm.
219247801|NCT03199170|DRUG|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
219175237|NCT02955784|DEVICE|Sinasprite Mobile App|Mobile App
219175238|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
219175239|NCT06566196|PROCEDURE|Cardiac Cath|Patient will undergo standard of care Cardiac Cath and in addition invasive CPET (Cardiopulmonary exercise testing) will be performed during the procedure.
219175240|NCT03317158|DRUG|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
219247802|NCT05959109|DRUG|Peresolimab|Administered SC
219175241|NCT03317158|RADIATION|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
219175242|NCT03317158|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
219175243|NCT03317158|DRUG|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
219175244|NCT03317158|DRUG|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
219175245|NCT03317158|BIOLOGICAL|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
219175246|NCT03317158|DRUG|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
219175247|NCT03317158|OTHER|To be determined|Other regimens to be determined
219175248|NCT03907904|DEVICE|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
219175249|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
219247803|NCT00788879|BEHAVIORAL|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
219175250|NCT04492007|BEHAVIORAL|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
219175251|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
219175252|NCT03463824|BEHAVIORAL|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
219175253|NCT03463824|BEHAVIORAL|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
219175254|NCT03169790|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
219175255|NCT03169790|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
219175256|NCT03169790|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
219175257|NCT03169790|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
219175258|NCT03169790|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
219175259|NCT03169790|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
219175260|NCT03169790|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
219175261|NCT03169790|DRUG|Lovaza|Omega-3-acid ethyl esters
219175262|NCT03169790|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
219175263|NCT03169790|DRUG|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
219175264|NCT03169790|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
219175265|NCT03169790|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
219175266|NCT03169790|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
219175267|NCT03169790|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
219175268|NCT04177823|DRUG|Belantamab mafodotin|Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
219175269|NCT05598203|BEHAVIORAL|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
219175270|NCT06404931|PROCEDURE|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
219175271|NCT06404931|PROCEDURE|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
219175272|NCT06404931|PROCEDURE|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
219175273|NCT03351504|OTHER|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
219175274|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
219175275|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
219175276|NCT05384119|DRUG|TTI-101|Oral tablet
219175277|NCT05384119|DRUG|Palbociclib|Oral capsule
219175278|NCT05384119|DRUG|Aromatase inhibitor (AI)|Oral tablet
219175279|NCT05384119|DRUG|fulvestrant|Oral tablet
219175280|NCT05384119|DRUG|ribociclib|Oral tablet
219741727|NCT00129974|DRUG|pemetrexed and gemcitabine|
219175281|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
219175282|NCT03457142|DRUG|Dexamethasone|Given PO
219175283|NCT03457142|DRUG|Ixazomib Citrate|Given PO
219175284|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
219175285|NCT05963711|OTHER|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
219741728|NCT05096130|BEHAVIORAL|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
219741729|NCT05848570|OTHER|Keeping it LITE|observational cohort only
219175286|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
219175287|NCT06031402|PROCEDURE|Endoscopy|Endoscopy
219175288|NCT06002932|PROCEDURE|Procedure: planed 2-stent strategy|Procedure: planed 2-stent strategy
219175289|NCT06002932|PROCEDURE|Procedure: provisional 1-stent plus DEB strategy|Procedure: provisional 1-stent plus DEB strategy
219175290|NCT06183892|DRUG|Tacrolimus Sustained-release Capsules|"Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)"
219175291|NCT04448002|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
219741730|NCT00266981|DEVICE|APOS - exercise component|
219741731|NCT04063202|OTHER|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
219741732|NCT01494857|DRUG|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
219741733|NCT03591536|OTHER|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
219741734|NCT03591536|OTHER|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
219741735|NCT04734392|PROCEDURE|TAVR|TAVR implantation in cusp overlay technique
219741736|NCT04633720|OTHER|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
219741737|NCT00414609|DRUG|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
219741738|NCT00414609|DRUG|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
219741739|NCT01665794|DRUG|Pomalidomide|Pomalidomide taken orally at assigned dose.
219741740|NCT01665794|DRUG|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
219741741|NCT01665794|DRUG|dexamethasone|Dexamethasone taken orally of given by IV infusion.
219741742|NCT01665794|DRUG|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
219741743|NCT00320320|DRUG|Irinotecan|
219741744|NCT03318393|DRUG|Bivalirudin|Continuous infusion
219741745|NCT03318393|DRUG|Unfractionated heparin|Continuous infusion
219741746|NCT06110871|OTHER|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
219741747|NCT06110871|OTHER|Working Group 2: Focusing|During IUD application
219741748|NCT06110871|OTHER|Working Group 3 music|for a total of 30 minutes
219741749|NCT00188032|PROCEDURE|Computer-Assisted diagnostic Decision Support|
219741750|NCT00188032|PROCEDURE|written diagnostic guidelines|
219741751|NCT00188032|PROCEDURE|electronic therapeutic reminders|
219741752|NCT03680521|DRUG|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
219741753|NCT03680521|DRUG|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
219741754|NCT00814983|PROCEDURE|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
219741755|NCT00814983|PROCEDURE|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
219741756|NCT00814983|DEVICE|Isolex device from Baxter|
219741757|NCT03627468|DRUG|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
219741758|NCT03627468|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
219741759|NCT02050399|OTHER|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
219741760|NCT00326014|DEVICE|iStent|Glaucoma Surgery
219743608|NCT03563001|DRUG|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
219175292|NCT04448002|BEHAVIORAL|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
219175293|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
219175294|NCT02446132|DRUG|AVP-786|
219175295|NCT05556473|DRUG|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
219175296|NCT03946111|DRUG|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
219175297|NCT03946111|OTHER|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
219175298|NCT05685927|DRUG|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
219175299|NCT05685927|PROCEDURE|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
219175300|NCT04784247|DRUG|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
219175301|NCT04784247|DRUG|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
219175302|NCT06537323|DRUG|Femoral nerve block with0.25% bupivacaine guided by ultrasound.|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
219175303|NCT06537323|DRUG|PENG block with0.25% bupivacaine guided by ultrasound.|PENG block with0.25% bupivacaine guided by ultrasound.
219175304|NCT06537323|DRUG|Preoperative IV fentanyl 100microgram|Preoperative IV fentanyl 100microgram
219175305|NCT04451044|DEVICE|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
219175306|NCT04451044|PROCEDURE|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
219175307|NCT04058743|DEVICE|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
219175308|NCT04058743|DEVICE|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
219175309|NCT05057429|DEVICE|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
219175310|NCT05057429|OTHER|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
219175311|NCT06064721|OTHER|Buerger-Allen Exercise|Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
219175312|NCT05150197|DEVICE|VisuALL|Virtual Reality Visual Field Device
219175313|NCT05150197|DEVICE|Humphrey Visual Field|Standard of care Visual Field test
219175314|NCT05624944|DRUG|TS-142 5 mg|Single-dose of 5 mg of TS-142
219175315|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous KR|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
219175316|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous PS|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous PS femoral component"
219175317|NCT04793841|OTHER|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
219175318|NCT03481881|DRUG|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
219175319|NCT04911452|DEVICE|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
219175320|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
219175321|NCT05939453|OTHER|Sham Light|Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
219175322|NCT05939453|OTHER|Bright Light Therapy|Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
219175323|NCT05454137|BEHAVIORAL|Shared medical appointment|Shared medical appointment
219175324|NCT04635098|DRUG|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
219175325|NCT04635098|DRUG|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
219743609|NCT03586921|BEHAVIORAL|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
219175326|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).
219175327|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
219175328|NCT06538961|OTHER|Blood samples: Main Study group|the collection of blood samples at specified time points.
219175329|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
219175330|NCT06538961|OTHER|Urine Sample- Main Study group|-Post-transplant monthly urine sample collection for 6 months in 10-18% of subjects
219175331|NCT06538961|OTHER|Urine sample- Sub-study group|\- Post-transplant monthly urine sample collection for 6 months in all subjects
219175332|NCT06538961|OTHER|Blood sample: Sub-study group|Monthly blood sample collection for 6 months
219175333|NCT04986605|DEVICE|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
219175334|NCT04986605|DRUG|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
219175335|NCT05294588|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
219175336|NCT05294588|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
219175337|NCT05294588|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
219175338|NCT05294588|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
219175339|NCT05294588|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
219175340|NCT05294588|BIOLOGICAL|Influenza Vaccine|All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
219175341|NCT05294588|BIOLOGICAL|Tetanus-diptheria Vaccine|All participants will receive the Td vaccine, 0.5 mL intramuscularly.
219175342|NCT05179655|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
219175343|NCT05179655|OTHER|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
219175344|NCT06206811|DRUG|OD-07656|innate immune modulator
219175345|NCT03310905|PROCEDURE|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
219175346|NCT03310905|PROCEDURE|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
219175347|NCT05387551|DEVICE|CGM|Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
219175348|NCT05514847|DRUG|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
219175349|NCT05514847|DRUG|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
219175350|NCT05260255|DRUG|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
219175351|NCT05260255|DRUG|Placebo|add on placebo ( 2 cap ) for 12 weeks
219175352|NCT05800366|DRUG|Glofitamab|human IgG1-bispecific antibody, via IV infusion
219175353|NCT05800366|DRUG|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
219175354|NCT05800366|DRUG|Rituximab|Per standard care, via IV infusion
219175355|NCT05800366|DRUG|Doxorubicin Hydrochloride|Per standard care, via IV infusion
219175356|NCT05800366|DRUG|Cyclophosphamide|Per standard care, via IV infusion
219175357|NCT05800366|DRUG|Prednisone|Per standard care, orally
219741761|NCT00812539|OTHER|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
219175358|NCT00579202|DEVICE|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
219175359|NCT04781543|DRUG|HZN-825 BID|300 mg oral tablets BID
219175360|NCT04781543|DRUG|Placebo|Placebo BID
219175361|NCT04781543|DRUG|HZN-825 QD|300 mg oral tablets QD
219175362|NCT05176951|DRUG|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
219175363|NCT05176951|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
219175364|NCT06836427|BIOLOGICAL|CMTS0929|CMTS0929 is defined as suspension from washed microbiota.
219175365|NCT06455631|PROCEDURE|Facilitated Tucking, Oral Breast Milk , Kangaroo Care|Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
219175366|NCT04195451|OTHER|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
219175367|NCT04195451|OTHER|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
219175368|NCT06836882|PROCEDURE|Selective caries removal|Selective caries removal followed by cavity disinfection with NaOCl \& CHX in each test group \& no cavity disinfection in control group.
219175369|NCT06836882|PROCEDURE|Selective caries removal with NaOCl|elective caries removal followed by cavity disinfection with NaOCl
219175370|NCT06836882|PROCEDURE|Selective caries removal with CHX|elective caries removal followed by cavity disinfection with CHX
219175371|NCT05920980|DRUG|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
219175372|NCT05920980|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
219175373|NCT05887609|DRUG|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
219175374|NCT05887609|DRUG|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
219175375|NCT01748448|DRUG|Vitamin D|"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"
219175376|NCT01748448|DRUG|Placebo: Oil|
219175377|NCT03561805|DEVICE|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
219175378|NCT05803811|DIETARY_SUPPLEMENT|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
219175379|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
219175380|NCT06209606|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
219175381|NCT06209606|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
219175382|NCT06209606|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
219175383|NCT06838624|DEVICE|Redcord|"Perticipants will perform exercises in different plank positions using RedCord® while applying local vibration in:~* Supine plank position~* Prone plank position~* Lateral prone plank position"
219175384|NCT06838624|OTHER|Control (Standard treatment)|"Participants will perform exercises in different plank positions:~Supine plank position Prone plank position Lateral prone plank position"
219175385|NCT06834841|DRUG|Dexmedetomidine|the preservative-free dexmedetomidine 100 μg/ml will be loaded into a 100-unit insulin syringe (1 μg/unit) and 5 units will be added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
219175386|NCT06834841|DRUG|Fentanyl|Fentanyl (Fentanyl Hameln® 0.1mg/2ml) 25 mcg will be given intrathecally added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
219175387|NCT06836713|PROCEDURE|Surgical Risk Stratification|Database implementation to formulate a regional risk score
219175388|NCT02907099|DRUG|CXCR4 Antagonist BL-8040|Given SC
219175389|NCT02907099|BIOLOGICAL|Pembrolizumab|Given IV
219175390|NCT02907099|OTHER|Pharmacological Study|Correlative studies
219175391|NCT06823778|DEVICE|Radiofrequency ablation|In this group of patients, epicardial radiofrequency left atrial posterior wall isolation will be performed with AtriCure Isolator Synergy OLL2 bipolar radiofrequency clamp without opening the left atrium.
219175392|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
219175393|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
219175394|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
219175395|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
219175396|NCT06837207|DEVICE|transcranial magnetic stimulation|Individualized transcranial magnetic stimulation of targets based on the association between the orbitofrontal cortex and the functional activity of the habenula .
219175397|NCT05597878|DRUG|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
219175398|NCT05597878|DRUG|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
219175399|NCT05597878|DRUG|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
219175400|NCT05597878|DRUG|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
219175401|NCT05597878|DRUG|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
219175402|NCT06836505|BIOLOGICAL|CART therapy|GD2/B7H3 CAR T-cell therapy
219175403|NCT06248398|PROCEDURE|Surgery with RobOtol®|Patient having cochlear implantation surgery with RobOtol®.
219741762|NCT00812539|OTHER|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
219741763|NCT00160563|DRUG|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
219741764|NCT00160563|OTHER|Placebo|Oral drops, bid for 18 months
219741765|NCT04157738|DRUG|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
219741766|NCT04157738|DRUG|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
219741767|NCT04205916|DRUG|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
219741768|NCT04205916|OTHER|Standard of care surgery|Standard method used for surgery and the use of post operative drops
219741769|NCT04325607|PROCEDURE|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
219741770|NCT04325607|PROCEDURE|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
219741771|NCT01730573|PROCEDURE|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
219741772|NCT01730573|PROCEDURE|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
219741773|NCT03721458|OTHER|Sequence|Potentially identifying genetic defects that could have clinical significance
219741774|NCT02118831|BIOLOGICAL|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
219741775|NCT02118831|DRUG|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
219741776|NCT02118831|DRUG|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
219741777|NCT02118831|DRUG|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
219741778|NCT04874597|DRUG|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
219741779|NCT04491110|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
219741780|NCT04491110|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
219741781|NCT03587090|DIAGNOSTIC_TEST|echocardiography|echocardiography by subcostal and transhepatic views
219741782|NCT03190876|PROCEDURE|Variable drain usage|Influence of drain usage on seroma formation rate
219741783|NCT03070834|DEVICE|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
219175404|NCT06248398|PROCEDURE|Conventional manual surgery|Patient having conventional manual cochlear implantation surgery
219175405|NCT06837753|OTHER|Exercise|It consist of traditional exercises.
219175406|NCT05432635|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
219175407|NCT05432635|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
219175408|NCT05432635|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219175409|NCT05432635|PROCEDURE|Myeloablative Conditioning|Given standard conditioning regimen
219175410|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
219175411|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
219175412|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
219175413|NCT01480206|OTHER|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
219175414|NCT06835192|OTHER|Experimental group|Initially, the first author presented a 25-minute lecture with a PowerPoint presentation to the nurses of the EG. Following this, each nurse received an IAD directive wheel chart. In the subsequent 25 minutes, the first author presented three clinical cases examples and relevant information, encouraging the nurses to utilize the IAD directive wheel chart in groups. To conclude the session, a 5-minute quiz was conducted, featuring five actual clinical photographs. After the course, the nurses were instructed to take the IAD directive wheel chart back to their clinics for review and use in health education and teaching.
219175415|NCT06835192|OTHER|Control Group|The first author conducted a 25-minute knowledge lecture for the nurses in the CG on the same topics covered in the EG. This lecture included an explanation of IAD, its causes, the latest global classification of IAD, as well as methods for skin prevention and IAD care. Following the lecture, the same three clinical examples presented in the EG were discussed for an additional 20 minutes, during which the nurses were divided into groups for case discussions. Finally, a 5-minute quiz competition was held, featuring the same five actual clinical photographs used in the EG.
219175416|NCT03349996|DEVICE|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
219175417|NCT05491382|PROCEDURE|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
219175418|NCT05491382|PROCEDURE|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
219175419|NCT05491382|PROCEDURE|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
219175420|NCT06829589|OTHER|Removal of economic incentives linked to 7 quality-of-care indicators|"The 7 intervened indicators will be the following:~* Blood pressure (BP) control in type-2 diabetes mellitus.~* BP control in ischemic cardiopathy/cerebrovascular accident.~* Hypertension: BP control in chronic renal insufficiency.~* Hypertension: BP control.~* Diagnostic adequacy of hypertension.~* Correct treatment of atrial fibrillation.~* Inhaler verification.~Professionals randomized to an arm with this intervention will no longer receive an economic reward for reaching a specific goal in the results of these 7 indicators.~The study guarantees no financial loss since the amount of money linked to these incentives will be automatically given to professionals under the concept of participating in the study."
219175421|NCT06829589|OTHER|Removal of information provision linked to 7 quality-of-care indicators|"The 7 indicators will be the same as the previous intervention.~Professionals randomized to an arm with this intervention will no longer see the following in the online platform:~* Numeric result of the indicator.~* Color coding to represent indicator result in relation to the yearly goal.~* 12-month evolution graph.~Next to the 7 indicator names, only the link to a list of patients that are not fulfilling the indicator criteria will be presented (identifying the patients missing a treatment, a control or any other intervention), since this is considered a tool to support clinical practice beyond informing on the result of an indicator."
219175422|NCT06838494|BEHAVIORAL|IVR-CST (Immersive Virtual Reality Cognitive Stimulation Therapy)|IVR-CST involves 14 sessions of cognitive stimulation therapy conducted twice a week in a virtual reality environment. Each session lasts approximately 45 minutes and utilizes head-mounted displays (HMDs) to immerse participants in engaging, themed activities. The therapy aims to enhance cognitive function and social interaction through interactive and stimulating virtual experiences tailored for individuals with mild cognitive impairment (MCI).
219741784|NCT05737680|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg daily
219741785|NCT05737680|DRUG|Colchicine|Colchicine continued
219741786|NCT00752219|DRUG|ceftazidime/NXL104 + metronidazole|IV TID
219741787|NCT00752219|DRUG|meropenem|IV TID
219741788|NCT05598515|BEHAVIORAL|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
219741789|NCT03604744|DRUG|LSD|LSD 0.1 mg per os, single dose
219741790|NCT03604744|DRUG|LSD|LSD 0.2 mg per os, single dose
219741791|NCT03604744|DRUG|Psilocybin|Psilocybin 15 mg per os, single dose
219741792|NCT03604744|DRUG|Psilocybin|Psilocybin 30 mg per os, single dose
219741793|NCT04211948|PROCEDURE|robotic surgery|Pancreatectomy with robotic assisted system
219741794|NCT04211948|PROCEDURE|open surgery|Traditional open pancreatectomy
219741795|NCT01514279|BEHAVIORAL|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
219741796|NCT01514279|BEHAVIORAL|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
219741797|NCT04383639|OTHER|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
219741798|NCT05149768|DRUG|Brentuximab vedotin|Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
219741799|NCT05801887|DEVICE|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
219741800|NCT05801887|DEVICE|No ESWT|the osteoblast like cells are not exposed to shockwaves
219741801|NCT06126172|DIAGNOSTIC_TEST|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
219741802|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
219741803|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
219741804|NCT06642961|OTHER|Placebo|The placebo will be administered SC.
219175423|NCT06838494|BEHAVIORAL|Intervention Name: Conventional CST (Cognitive Stimulation Therapy)|Conventional CST consists of 14 sessions of cognitive stimulation therapy conducted twice a week, each lasting about 45 minutes. In this arm, participants engage in group activities using physical materials, such as photos, pictures, and real objects, rather than virtual reality. The therapy focuses on providing cognitive stimulation through discussions and activities designed to improve cognitive function and social engagement among individuals with mild cognitive impairment (MCI).
219175424|NCT06835257|PROCEDURE|Acute normovolemic hemodilutions|Crystalloid infusion throughout the autologous blood collection (3 ml of crystalloid infusion for every 1 ml of blood)
219175425|NCT06835257|DRUG|Vasopressor infusion|Vasopressor infusion throughout the autologous blood collection (according to mean arterial pressure)
219175426|NCT05859191|BIOLOGICAL|Blood sample|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
219175427|NCT06788080|DRUG|BioRBC|Autologous biotin-labeled RBCs will be transfused to study participants
219175428|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
219175429|NCT04660955|OTHER|No Intervention - Observational study with MRI|90 minute MRI of the knees
219175430|NCT01639859|OTHER|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
219175431|NCT06838143|BIOLOGICAL|Ilaris|Prospective observational study. There is no treatment allocation.
219175432|NCT06834555|DIAGNOSTIC_TEST|Mobile phone thermal imaging|"The patient was supine, and the lower limb was naturally relaxed on a 20cm high stent to drain blood from the vein. The leg temperature was lowered with a cold towel at 2-6 ° C for five minutes. A tourniquet was applied to the upper 1/3 of the thigh and the level of the fibula of the lower leg with enough pressure to block the great saphenous vein and the small saphenous vein. The patient is then asked to stand. The smart phone and the supporting thermal imaging system were used to conduct continuous real-time imaging and take photos of the front, bilateral and rear of the thigh and lower leg. The hot spot of rapid rewarming of the lower limb was marked with a marker."
219175433|NCT06837012|DRUG|Duloxetine - low dose|Only patients who underwent single bilateral Total knee arthroplasty and WITHOUT central sensitisation were evaluated
219175434|NCT06837012|DRUG|Placebo|starch capsules identical in appearance and weight to the duloxetine capsules
219175435|NCT06248190|OTHER|ENHANCE intervention (health systems)|The intervention tools include a consolidated clinical decision support tool, health education posters, waiting room talks, medication list for treatment literacy and a patient health diary. Training session are delivered at all intervention sites and include 1 facility team session to introduce the ENHANCE study to the whole team; 3 clinical sessions for nurses and doctors; 2 sessions for community health workers and health promoters; Maintenance sessions to keep the ENHANCE intervention going for at least 12 months
219175436|NCT06782646|DRUG|Berberine|Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
219175437|NCT06782646|DRUG|Placebo|Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
219175438|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
219175439|NCT05773378|DEVICE|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 10-week period.
219175440|NCT05773378|DEVICE|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period.
219175441|NCT06832254|OTHER|Cryotherapy|The root canals were irrigated with 2 °C saline solution in final irrigation in cryotherapy group.
219175442|NCT06832254|DRUG|Dexamethasone|Each root canal was irrigated with 1 mL dexamethasone solution in final irrigation in dexamethasone group.
219175443|NCT04718675|DRUG|KB-0742|Oral capsules
219175444|NCT06830811|RADIATION|EOSedge imaging|Full body or full spine image
219175445|NCT06564493|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219175446|NCT06564493|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
219175447|NCT06564493|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
219175448|NCT06836271|DRUG|Isopropyl Alcohol|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 70% Isopropyl alcohol every time it came into contact with the rectal mucosa.
219175449|NCT06836271|DRUG|Povidine-iodine|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with povidine-iodine every time it came into contact with the rectal mucosa.
219175450|NCT06836271|COMBINATION_PRODUCT|formaldehit|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 10% formaldehit every time it came into contact with the rectal mucosa.
219175451|NCT06836271|PROCEDURE|Standard BP control|No disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy.
219741805|NCT03438032|DIAGNOSTIC_TEST|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
219741806|NCT00168376|DEVICE|Transcranial Magnetic Stimulation|
219741807|NCT03405350|PROCEDURE|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
219741808|NCT03405350|PROCEDURE|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
219741809|NCT03405350|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
219741810|NCT03405350|PROCEDURE|Terrain Therapy|walking, outdoors physical activities,
219175452|NCT06568029|OTHER|Questionnaire|In the study, the validity and responsiveness of EQ-5D-3L will be assessed. The EQ-5D-3L measures HRQoL and consists of two parts. The first part contains five questions about mobility, daily activities, self-care, pain/discomfort, and anxiety/depression (EuroQoL 1990, Brooks 1996). Each question can be answered with no problem (1), some/moderate problem (2) unable to perform certain activities/having extreme problems (3). The answers can be summarized in an index value based on an existing preference-based value set. In this study, the EQ-5D-3L value set by Dolan (Dolan 1997) will be used for the main analyses and a Swedish experience-based value set in a sensitivity analysis (Burström, Sun et al. 2014). For the EQ-5D-3L index, 1 represents full health and 0 represents a value equal to being dead. EQ VAS measures the persons health today on a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health) (EuroQoL 1990, Brooks 1996).
219175453|NCT05488847|DRUG|Celecoxib|preoperative pain medication given to all patients
219175454|NCT05488847|DRUG|Pregabalin|preoperative and discharge pain medication given to all patients
219175455|NCT05488847|DRUG|Tramadol|preoperative pain medication given to all patients
219175456|NCT05488847|DRUG|Dexamethasone|Intraoperative and discharge pain medication given to all patients
219175457|NCT05488847|DRUG|Acetaminophen|Intraoperative and discharge pain medication given to all patients
219175458|NCT05488847|DRUG|Ropivicaine|Intraoperative pain medication given to all patients
219175459|NCT05488847|DRUG|Epinephrine|Intraoperative pain medication given to all patients
219175460|NCT05488847|DRUG|Ketorolac|Intraoperative pain medication given to all patients
219175461|NCT05488847|DRUG|Tizanidine|Discharge pain medication given to all patients
219175462|NCT05488847|DRUG|Magnesium|Discharge pain medication given to all patients
219175463|NCT05488847|DRUG|Ibuprofen|Discharge pain medication given to all patients
219175464|NCT05488847|DRUG|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
219175465|NCT06497660|DRUG|Deoxyadrenaline|Deoxyadrenaline is a vasoactive drug
219175466|NCT06497660|DRUG|normal saline|Deoxyadrenaline is a vasoactive drug
219175467|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
219175468|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
219175469|NCT04274764|BEHAVIORAL|Personalized eHealth Education & Motivational Interviewing|This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web-based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
219175470|NCT00051532|DRUG|Seocalcitol|
219175471|NCT02810704|DRUG|Enteric Coated Aspirin|
219175472|NCT02810704|DRUG|Warfarin|
219175473|NCT02810704|DRUG|Rivaroxaban|
219175474|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
219175475|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
219175476|NCT03362736|DRUG|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to \[\<=\] 55 kilogram \[kg\] will receive 260 milligram \[mg\] ustekinumab; \> 55 kg to \<= 85 kg will receive 390 mg ustekinumab; and \> 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
219175477|NCT06044584|OTHER|No intervention|Observational study with no intervention - Monitoring
219175478|NCT06523413|BEHAVIORAL|Game activity|A game determined by the researcher will be played with the patients in the patient room.
219175479|NCT06523413|DEVICE|Stres Ball|Patients will use the stress ball for 15 minutes.
219175480|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
219741811|NCT03405350|PROCEDURE|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
219741812|NCT03405350|PROCEDURE|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
219741813|NCT03405350|PROCEDURE|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
219741814|NCT03405350|PROCEDURE|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
219741815|NCT03405350|PROCEDURE|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
219741816|NCT03405350|PROCEDURE|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
219741817|NCT03405350|PROCEDURE|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
219741818|NCT03007433|OTHER|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
219741819|NCT00651287|DRUG|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
219741820|NCT00651287|DRUG|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
219175481|NCT02677298|DRUG|Placebo|Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area
219175482|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
219175483|NCT04741542|DRUG|SP-420|This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
219175484|NCT03611621|DRUG|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
219175485|NCT04926766|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
219741821|NCT00651287|DRUG|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
219741822|NCT03893357|OTHER|Data extraction from medical files|Retrospective data extraction from the medical files
219741823|NCT06044792|OTHER|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
219741824|NCT00781261|DRUG|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
219741825|NCT00781261|DRUG|Placebo|Subjects in the control group will receive a placebo drug for a similar period
219741826|NCT05056857|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
219741827|NCT05056857|OTHER|Electronic Health Record Review|Medical charts are reviewed
219741828|NCT01047540|DRUG|AIC316|Oral administration
219741829|NCT01047540|DRUG|AIC316|Oral administration
219741830|NCT01047540|DRUG|AIC316|Oral administration
219741831|NCT01047540|DRUG|AIC316|Oral administration
219741832|NCT01047540|DRUG|Placebo|Oral administration
219741833|NCT05212909|BEHAVIORAL|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
219741834|NCT06320990|DRUG|Tamoxifen 20mg|Tamoxifen is a nonsteroidal antiestrogen for oral administration.
219741835|NCT06176586|OTHER|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
219741836|NCT00005980|DRUG|pegylated liposomal doxorubicin hydrochloride|
219741837|NCT03407950|BEHAVIORAL|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
219741838|NCT03407950|BEHAVIORAL|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
219175486|NCT03499821|DEVICE|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
219175487|NCT06478719|DRUG|Placebo|Placebo oral capsule
219175488|NCT06478719|DRUG|FB-1603|FB-1603 (165 mg/cap) oral capsule
219175489|NCT05737628|DRUG|BYON4228 + Rituximab|"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
219175490|NCT04890041|DRUG|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
219175491|NCT03369106|OTHER|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
219175492|NCT05273320|DRUG|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
219175493|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
219741839|NCT04098588|BEHAVIORAL|BEAST|See Arm Description
219741840|NCT04098588|BEHAVIORAL|Descriptive Feedback|See Arm Description
219741841|NCT04250207|DRUG|K-321 Solution|K-321 solution drops
219741842|NCT04250207|DRUG|Placebo Solution|Placebo solution drops for K-321
219741843|NCT02344355|DRUG|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
219741844|NCT02344355|RADIATION|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
219741845|NCT02344355|DRUG|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
219741846|NCT01437189|DRUG|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
219741847|NCT05603676|OTHER|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
219741848|NCT05603676|OTHER|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
219741849|NCT03308279|DIAGNOSTIC_TEST|Ultrasound|Ultrasound and Anthropometric meassures
219741850|NCT00347269|BEHAVIORAL|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
219741851|NCT00347269|DRUG|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
219741852|NCT00347269|BEHAVIORAL|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
219741853|NCT00376103|DRUG|temozolomide|75 mg/m2/day
219741854|NCT00376103|PROCEDURE|Brachytherapy|60 Gy to 1 cm
219741855|NCT00376103|PROCEDURE|External Beam Radiation Therapy|60 Gy
219741856|NCT01878448|DRUG|Anlotinib|
219741857|NCT06518369|OTHER|Prehabilitation|"Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight"
219741858|NCT06168968|BEHAVIORAL|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
219741859|NCT03654326|DRUG|Gefapixant|Gefapixant tablet 45 mg taken orally
219741860|NCT03654326|DRUG|Placebo|Placebo matching gefapixant tablet taken orally
219741861|NCT03654326|DRUG|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
219741862|NCT06399107|GENETIC|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan|An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
219175494|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
219175495|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
219175496|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
219175497|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
219175498|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
219175499|NCT03020212|DRUG|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
219175500|NCT04693598|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
219175501|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
219175502|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
219175503|NCT04066660|DIETARY_SUPPLEMENT|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
219175504|NCT04066660|DIETARY_SUPPLEMENT|Placebo|4.4 g placebo powder, oral, BID
219175505|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
219175506|NCT03232138|DRUG|Placebo|Inactive ingredients
219175507|NCT06057649|OTHER|Effleurage Abdominal Massage|perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
219175508|NCT06333392|PROCEDURE|Total underwater colonoscopy|one grooup will be randomized to receive a total underwater colonoscopy
219175509|NCT06333392|PROCEDURE|Conventional colonoscopy|one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
219175510|NCT03418818|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
219175511|NCT03418818|DRUG|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
219175512|NCT05529459|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
219175513|NCT04852328|DRUG|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
219175514|NCT04700527|DRUG|Short Chain Fatty Acid|Participants will take the supplement as prescribed to determine if it can help with GI toxicity
219175515|NCT04700527|DRUG|Tapioca Flour|Participants taking this will be used as a control group compared to those receiving the SCFA supplement
219175516|NCT06215313|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|In the EMDR condition, the Dutch version of the treatment protocol based on Shapiro's original work (2001) is followed. In the first session, the rationale of EMDR is explained. The patient describes the memory, and identifies the most aversive still image, the associated negative cognition, desired positive cognition, feelings, somatic sensations, and perceived tension, as measured by Subjective Unit of Distress (SUDs). Desensitization then begins by asking patients to focus on the still image while following the movement of a light bar or the therapist's fingers with their eyes (i.e., eye tracking task). Then, in the installation phase, the patient focuses on the positive cognition during the eye tracking task. When the validity of the positive cognition is 6 to 7 on a 7-point Likert scale, a body scan is performed to ensure that no unresolved traumatic material remains. Each session ends with a reflection and debriefing.
219175517|NCT06215313|BEHAVIORAL|Imagery Rescripting|The IR condition, following Arntz and Weertman's (1999) protocol, addresses traumatic or aversive memories by creating alternative scenarios. In the first session, the method is explained. The patient describes their memory in the present tense, from the first-person perspective, and describes associated feelings, thoughts, and emotional needs. The therapist then seeks permission to 'enter' the scene, guiding the patient to visualise an alternative, emotionally satisfying course of events. This may involve the therapist or patient intervening in the situation, ensuring the patient's emotional needs are met. The patient then relives the memory from the point of view of their younger self, with the adult-self intervening in the scene. The process continues until all emotional needs are fulfilled. Generally, one trauma memory is rescripted per session. The initial IR session involves therapist-led rescripting, with subsequent sessions encouraging patient-led rescripting whenever possible.
219175518|NCT00881920|BIOLOGICAL|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa"
219175519|NCT01440257|DRUG|Placebo|Placebo capsules once daily
219175520|NCT01440257|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
219175521|NCT04142788|DRUG|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
219175522|NCT05776836|DEVICE|Dermal filler|Subjects will be consecutively included to receive FASY F in nasolabial folds and cheeks and FASY P in periorbital areas.
219175523|NCT06188793|DEVICE|Virtual reality-directed BGBT|Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
219175524|NCT06493071|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
219175525|NCT06493071|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
219175526|NCT06324123|OTHER|Peacetil|Nutraceutical supplement Peacetil for a period of 2 months
219175527|NCT02515110|RADIATION|External Beam Radiation Therapy|Undergo hypofractionated RNI
219175528|NCT02515110|OTHER|Questionnaire Administration|Ancillary studies
219175529|NCT02515110|OTHER|Laboratory Biomarker Analysis|Correlative studies
219741863|NCT06404450|BEHAVIORAL|Digital CBT|The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
219741864|NCT05424315|DRUG|Dapagliflozin 10mg|10mg Tab once daily
219741865|NCT05424315|DRUG|Glucose Tab|Placebo Oral Tablet
219741866|NCT05872516|DEVICE|Chang Gung Atrial Fibrillation Detecting Software|This software is expected to be used in clinical testing to interpret the static 12-lead ECG of adults who are over 20 years old and suspected of having atrial fibrillation, detect whether there is a signal of atrial fibrillation, and output the results for clinicians Near-instant auxiliary diagnostic use.
219741867|NCT01628770|DRUG|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
219175530|NCT06211088|DRUG|famotidine plus10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine
219175531|NCT06211088|OTHER|10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo
219175532|NCT06845670|OTHER|Wurn technique|Wurn technique is a massage technique and PF relaxation exercises are to relax tighten pelvic floor muscles.
219175533|NCT06846151|DEVICE|retinal functional imaging|this is a proof of concept study
219175534|NCT06841211|PROCEDURE|Targeted and perilesional biopsy (TPLBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. For each predefined mpMRI suspicious lesion, two-core TBs are obtained within the ROI, followed by ring-distributed four cores within a 10-15 mm radius around the ROI. The location of these cores depends on the shape and location of the suspicious lesion.
219741868|NCT01628770|DRUG|Ferrous sulphate|200mg twice daily
219741869|NCT04472468|DEVICE|Percutaneous Balloon Pericardiotomy|"* Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
219741870|NCT04573478|DRUG|Atrasentan|Film-coated tablet
219741871|NCT04573478|DRUG|Placebo|Film-coated tablet
219741872|NCT00936650|DRUG|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
219741873|NCT00936650|DRUG|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
219741874|NCT04129021|DEVICE|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
219741875|NCT04129021|DEVICE|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
219741876|NCT05853406|DIAGNOSTIC_TEST|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
219741877|NCT05763303|OTHER|educational program|interventional program consists of educational part and training part in case of agreement of participants
219741878|NCT00281437|BEHAVIORAL|choice of exercise program|
219741879|NCT05181475|DRUG|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
219175535|NCT06841211|PROCEDURE|Combined targeted and systematic biopsy (CTSBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. Two-core TBs from the lesion were performed within each predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
219175536|NCT06841952|DRUG|ATRA+Venetoclax+Azacitidine|Participants will receive a standard dose of azacitidine (75mg/m²/day)，venetoclax (target dose, 400 mg)，ATRA 45mg/m²/day
219175537|NCT06841952|DRUG|Chemotherapy drug|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).
219175538|NCT06848322|BEHAVIORAL|resistance exercise|Participants will perform resistance exercise for 8 weeks
219175539|NCT06848322|BEHAVIORAL|aerobic exercise|Participants will perform aerobic exercise for 8 weeks
219175540|NCT06848322|OTHER|Control (placebo)|Participants will maintain their usual lifestyle for 8 weeks.
219175541|NCT03992339|DRUG|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
219175542|NCT03895567|DRUG|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
219175543|NCT03895567|DRUG|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"
219175544|NCT03895567|DRUG|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"
219175545|NCT06848777|BEHAVIORAL|Intervention group:|After a 50-meter walk while listening to the sounds of nature, the patient will walk 50 meters again to his/her room and then to his/her bed, where he/she will be seated. Then, the researcher nurse will remove the headphones from the patient's ears and ensure that the patient rests in a comfortable position.
219175546|NCT05694286|PROCEDURE|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
219175547|NCT04907136|OTHER|Preferred ENDS|Preferred ENDS without HWL on device
219175548|NCT04907136|OTHER|Preferred ENDS with HWL|Preferred ENDS with a HWL on device
219175549|NCT03853746|DRUG|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
219175550|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
219175551|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
219175552|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
219175553|NCT05737953|DIAGNOSTIC_TEST|cfDNA methylation sequencing and proteome analysis|Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples
219175554|NCT05873244|DRUG|Zabadinostat (CXD101) and Geptanolimab|"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
219175555|NCT05873244|DRUG|Lenvatinib and Sorafenib|"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
219175556|NCT03426579|DEVICE|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
219175557|NCT00999804|DRUG|Lapatinib|1000 mg of Lapatinib by mouth daily
219175558|NCT00999804|DRUG|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
219175559|NCT00999804|DRUG|Trastuzumab|6 mg/kg intravenously, every 3 weeks
219175560|NCT06191250|DRUG|Durvalumab|one dose of durvalumab (750 mg IV)
219175561|NCT06191250|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
219175562|NCT06379360|DRUG|Hypomethylating agent, Azacitidine or Decitabine|All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
219175563|NCT03751709|DRUG|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
219175564|NCT03751709|OTHER|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
219175565|NCT05023369|DRUG|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
219175566|NCT06455553|OTHER|Blood sample|A blood sample will be taken from all patients included in the study. This blood sampling is an added act of the study. It will be performed as soon as possible after inclusion in the study. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.
219175567|NCT05542238|BEHAVIORAL|One bout of moderate-intensity sub-maximal aerobic exercise|The intervention is a 20-min acute exercise using arm ergometer
219175568|NCT06639204|DEVICE|Electrical stimulation|A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
219175569|NCT06639204|PROCEDURE|Orthodontic treatment without acceleration|No additional appliances will be used. Only the traditional fixed appliances (braces).
219175570|NCT05820997|DRUG|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
219175571|NCT06093841|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
219175572|NCT06093841|DRUG|Fludarabine|Administered according to package insert
219175573|NCT06093841|DRUG|Cyclophosphamide|Administered according to package insert
219175574|NCT06248476|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation is non-invasive stimulation technique which modifies cortical excitability through forming magnetic field
219175575|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
219175576|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
219175577|NCT05602779|DEVICE|tVNS Program|Participants will use the Neuvana Xen device 30 minutes a day for 30 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
219175578|NCT05602779|OTHER|Phone App Program|Participants will have access to a specially designed phone app (MindTiles) in order to play a game designed for this study. Participants in the active intervention will be able to connect with a fellow participant who is matched as their peer for social support and they will complete a daily puzzle together and respond to a conversational prompt to encourage communication.
219175579|NCT05602779|COMBINATION_PRODUCT|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
219175580|NCT05602779|OTHER|Sham tNVS and Control App|Participants will have access to our program's phone app so the can complete the daily puzzle on their own. They will also engage in a sham tVNS session for 30min per day for 30 days during which no stimulation is provided.
219175581|NCT06405971|DRUG|Metformin|Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
219175582|NCT06262139|DRUG|MT218 injection|a targeted magnetic resonance imaging contrast agent
219175583|NCT04711551|COMBINATION_PRODUCT|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices
219175584|NCT06813807|DRUG|0.5% TM|From D1 to D10, each subject will receive one drop of 0.5% timolol maleate ophthalmic gel forming solution each in the left and right eyes once daily at the same time every day under fasted condition.
219175585|NCT05415124|DEVICE|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
219175586|NCT05415124|PROCEDURE|Endoscopy|Endoscopy is performed as scheduled.
219175587|NCT06155279|DRUG|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
219175588|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
219175589|NCT06797960|DEVICE|Ultra sound guided Injection of PRF intra articularly|Intra articular injection of PRF
219175590|NCT06797960|DRUG|Intra articular injection of HA|Intra articular injection of HA
219175591|NCT05353829|DRUG|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
219175592|NCT01901770|OTHER|educational intervention|Receive HPV vaccination educational materials
219175593|NCT01901770|OTHER|educational intervention|Receive influenza vaccination educational materials
219175594|NCT05079789|DRUG|Amiloride|Treatment with amiloride, start dose 5 mg
219175595|NCT05079789|DRUG|Furosemide|Treatment with furosemide, start dose 40 mg
219175596|NCT05329493|DEVICE|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
219175597|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Fixation|Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.
219175598|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Removal|Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
219175599|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
219175600|NCT04733950|OTHER|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
219175601|NCT04733950|OTHER|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
219175602|NCT06382727|OTHER|EN will be continued up to extubation (EN will not be withheld prior to extubation)|As per the arm/group descriptions.
219175603|NCT04474353|DEVICE|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
219175604|NCT04474353|DRUG|Gadolinium|Gadolinium contrast medium
219175605|NCT04474353|DRUG|Temozolomide|Chemotherapy agent
219175606|NCT04474353|RADIATION|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
219175607|NCT05345327|DRUG|Dapagliflozin|SGLT2 inhibitor
219175608|NCT05345327|DRUG|Metformin|Metformin
219175609|NCT03964727|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219175610|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
219175611|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
219175612|NCT05305235|DEVICE|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
219175613|NCT05305235|DEVICE|Relaxation Control|Guides users through relaxation techniques.
219175614|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
219175615|NCT05429125|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
219175616|NCT05429125|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
219175617|NCT06451809|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
219175618|NCT05697393|DEVICE|Shaker Pressure Band|
219175619|NCT05885360|DRUG|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
219175620|NCT04257097|DEVICE|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
219175621|NCT04257097|DEVICE|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
219175622|NCT03352258|RADIATION|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
219175623|NCT04256954|BEHAVIORAL|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
219175624|NCT04956432|DRUG|SHR4640|SHR4640 Dose 1 ,tablets, QD
219175625|NCT04956432|DRUG|Allopurinol|Allopurinol 300mg, tablets, QD
219175626|NCT05901519|DRUG|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
219362730|NCT06017154|OTHER|Motor-Cognitive Training Program|The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
219362731|NCT01654900|OTHER|No intervention in this study|
219175627|NCT05632575|BEHAVIORAL|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
219175628|NCT06550141|DRUG|Emapalumab|An interferon gamma (IFNγ) blocking antibody
219175629|NCT06550141|DRUG|Cyclophosphamide|Alkylating agent
219175630|NCT06550141|DRUG|Fludarabine Phosphate|Purine antagonist antimetabolite
219175631|NCT06550141|DRUG|Axicabtagene Ciloleucel|Autologous treatment
219175632|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
219175633|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
219175634|NCT06178354|OTHER|Survey Administration|Ancillary studies
219175635|NCT05342480|OTHER|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
219175636|NCT05765214|BEHAVIORAL|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
219175637|NCT04423185|DRUG|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
219362732|NCT03544073|DRUG|Saline Solution for Injection|Placebo arm will receive a saline injection
219175638|NCT04423185|DRUG|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
219175639|NCT04423185|DRUG|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
219175640|NCT04423185|DRUG|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
219175641|NCT04423185|DRUG|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
219175642|NCT04423185|DRUG|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
219175643|NCT04423185|DRUG|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
219175644|NCT04423185|DRUG|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
219175645|NCT04423185|DRUG|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
219175646|NCT04423185|DRUG|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
219175647|NCT04423185|DRUG|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
219175648|NCT05623007|DIETARY_SUPPLEMENT|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
219175649|NCT05623007|BEHAVIORAL|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
219175650|NCT05623007|DIETARY_SUPPLEMENT|Placebo probiotics|Maltodextrin
219175651|NCT06499740|BEHAVIORAL|Adapted SAFETY-A for PC|This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
219175652|NCT06499740|BEHAVIORAL|Treatment as Usual|Treatment as usual delivered in participating clinics.
219175653|NCT02378805|DRUG|ACE-inhibitor|observational study
219175654|NCT02378805|DRUG|Angiotensin-receptor blocker (ARB)|observational study
219175655|NCT02378805|DRUG|HMG-Coenzyme inhibitor (statin)|observational study
219175656|NCT02378805|DRUG|Spironolactone or Finerenone|observational study
219175657|NCT02378805|DRUG|Paricalcitol|observational study!
219175658|NCT02378805|DRUG|SGLT2 inhibitor|observational study
219175659|NCT04322370|PROCEDURE|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
219175660|NCT04322370|DEVICE|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
219175661|NCT05856591|BEHAVIORAL|Food Resources & Kitchen Skills (FoRKS)|Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
219175662|NCT05856591|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
219175663|NCT06206343|OTHER|TENS application, Tele-rehabilitation treatment program|Exercise training
219175664|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
219175665|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
219175666|NCT05145127|DRUG|PF-06741086|"For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria."
219175667|NCT04016818|DRUG|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
219175668|NCT04016818|DEVICE|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
219175669|NCT05326776|DRUG|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
219175670|NCT06038487|PROCEDURE|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
219175671|NCT06038487|PROCEDURE|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
219175672|NCT03834753|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
219175673|NCT03834753|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
219175674|NCT03927638|BEHAVIORAL|sit/stand|Subjects will be asked to both sit and stand during a single trial.
219175675|NCT05149872|OTHER|Muscle relaxation|Rocuronium will be used to induce partial paralysis
219175676|NCT05149872|OTHER|Reversal|Sugamamdex will be used to reverse muscle relaxation
219175677|NCT04557163|DRUG|TS-142|TS-142 will be given as 1 mg per capsule administered orally with water.
219175678|NCT04557163|DRUG|Itraconazole|Itraconazole will given as 50 mg per capsule administered orally with water.
219175679|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
219175680|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
219175681|NCT04302727|BEHAVIORAL|Med-South Weight Loss Intervention|Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.
219362733|NCT03544073|DRUG|Leuprolide Acetate|Treatment arm will receive a Leuprolide injection
219362734|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BNT162b2 subjects
219175682|NCT04302727|BEHAVIORAL|WW|If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
219175683|NCT02754765|DRUG|Bedaquiline|
219175684|NCT02754765|DRUG|Delamanid|
219175685|NCT02754765|DRUG|Clofazimine|
219175686|NCT02754765|DRUG|Levofloxacin|
219175687|NCT02754765|DRUG|Moxifloxacin|
219175688|NCT02754765|DRUG|Linezolid|
219175689|NCT02754765|DRUG|Pyrazinamide|
219175690|NCT02754765|DRUG|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
219175691|NCT04962672|DRUG|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
219175692|NCT04962672|DRUG|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
219175693|NCT05167968|OTHER|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~* Self-questioning of medication adherence: Girerd questionnaire~* Assessment of the Medication Possession Ratio~* Social and demographic data~* Comorbidities~* PH characteristics"
219175694|NCT04859283|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
219175695|NCT04859283|DRUG|Placebo|Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
219175696|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
219175697|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
219175698|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
219175699|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
219175700|NCT03981952|OTHER|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
219175701|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
219175702|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
219175703|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
219175704|NCT06442657|OTHER|Hydrocellular dressing|Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.
219175705|NCT06442657|OTHER|Hydrocolloids dressing|Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
219175706|NCT06014411|OTHER|Time to bathing (delayed)|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
219175707|NCT06014411|OTHER|Time to bathing (early)|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
219175708|NCT05618054|BEHAVIORAL|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
219362735|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BNT162b2 subjects
219362736|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
219362737|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
219362738|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
219741880|NCT04157465|OTHER|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
219741881|NCT05435859|BEHAVIORAL|Speech Tasks|Listen to 25-minutes of speech sounds in English.
219741882|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
219741883|NCT04424251|DRUG|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
219741884|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
219741885|NCT04424251|DRUG|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
219741886|NCT04424251|DRUG|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
219741887|NCT04424251|DRUG|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
219741888|NCT04424251|DRUG|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
219741889|NCT04102514|BEHAVIORAL|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
219741890|NCT04102514|BEHAVIORAL|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
219741891|NCT06432322|DRUG|Esketamine nasal spray|Nasal spray solution, 56mg (28mg per nostril), intranasal
219741892|NCT06432322|OTHER|Placebo|Nasal spray solution, 0.9% NaCl, intranasal
219741893|NCT03761641|OTHER|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics \& eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face \&cushion between the skin \& eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, \& dilation velocity. Total pupil dilation testing time is \< 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position \& movement velocity during these tests. Total saccade-tracking testing takes \< 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
219741894|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
219741895|NCT00835549|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
219741896|NCT00835549|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
219741897|NCT03298334|BIOLOGICAL|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
219741898|NCT03298334|OTHER|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
219741899|NCT05078710|DRUG|Telitacicept|160mg once a week for 24 weeks
219741900|NCT04360330|RADIATION|Stereotactic Ablative Breast Radiotherapy|"Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)"
219741901|NCT00835042|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
219741902|NCT00835042|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
219741903|NCT00619918|DRUG|Nebulized 3% saline|4 ml inhaled q8h
219741904|NCT00619918|DRUG|Nebulized 0.9% saline|normal saline
219741905|NCT06140420|DRUG|Naltrexone Oral Product|Generic, oral tablet.
219741906|NCT06140420|DRUG|Placebo|Oral Placebo
219175709|NCT05984511|PROCEDURE|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
219175710|NCT05984511|PROCEDURE|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
219175711|NCT05984511|DRUG|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
219175712|NCT04205110|DIAGNOSTIC_TEST|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
219175713|NCT03150810|DRUG|Pamiparib|Administered by mouth as a capsule twice daily
219175714|NCT03150810|DRUG|Temozolomide|TMZ at various doses administered by mouth as a capsule once daily.
219175715|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
219175716|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
219175717|NCT03884855|OTHER|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
219175718|NCT03884855|OTHER|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
219175719|NCT05381844|OTHER|Blood sampling|30 ml blood sampling for virological research
219175720|NCT05116787|DRUG|Placebo|Administered orally twice daily
219175721|NCT05116787|DRUG|BCX9930 monotherapy|Administered orally twice daily
219175722|NCT03841305|PROCEDURE|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
219175723|NCT05217420|BEHAVIORAL|Moving Well|Experimental arm
219175724|NCT05217420|BEHAVIORAL|Staying Well|Active comparator arm
219175725|NCT05159830|DRUG|Cannabidiol oral oil|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
219175726|NCT05159830|DRUG|Placebo oral oil|Placebo of similar cannabidiol galenic form
219175727|NCT04516564|DRUG|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
219175728|NCT04516564|DRUG|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
219175729|NCT03983018|DRUG|Rituximab|Infusion
219175730|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
219175731|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
219175732|NCT05090540|DEVICE|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
219175733|NCT05090540|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
219175734|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
219175735|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
219175736|NCT04325789|DEVICE|nanofiber scaffold|Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
219175737|NCT04712773|DEVICE|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
219175738|NCT04712773|DEVICE|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
219175739|NCT06757270|OTHER|Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis|Second arm : aleovera 3 times daily after brushing teeth
219175740|NCT04650256|OTHER|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
219175741|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
219175742|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
219175743|NCT06393088|DEVICE|IR REHAB|Participants undergo therapy sessions with active, dual frequency, low level laser therapy device
219175744|NCT06393088|DEVICE|Sham|Participants undergo therapy sessions with disabled device producing no laser energy
219175745|NCT01519154|DRUG|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
219175746|NCT01519154|DRUG|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
219362739|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
219741907|NCT04169009|BIOLOGICAL|Zostavax|Intradermal injection of Zostavax
219741908|NCT04169009|BIOLOGICAL|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
219741909|NCT03492385|DRUG|PB2452 Infusion|30 minute - 12 hour infusion
219741910|NCT03492385|DRUG|Placebo - Sodium Chloride|30 minute - 12 hour infusion
219741911|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
219741912|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
219741913|NCT03617939|PROCEDURE|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
219741914|NCT03617939|OTHER|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
219741915|NCT03617939|OTHER|Medical Chart Reviews|Data taken directly from the patients' medical charts.
219741916|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
219741917|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
219741918|NCT02891954|DRUG|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
219741919|NCT05700721|DRUG|Niraparib|Given by PO
219741920|NCT05700721|DRUG|Dostarlimab|Given by IV (vein)
219741921|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
219741922|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
219741923|NCT03920982|DIAGNOSTIC_TEST|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
219741924|NCT05829330|OTHER|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
219741925|NCT05829330|OTHER|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
219741926|NCT04989218|DRUG|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
219741927|NCT06076213|DRUG|Artesunate-amodiaquine|Tablets
219741928|NCT06076213|DRUG|Artemether-lumefantrine|Tablets
219741929|NCT06451458|BEHAVIORAL|ECHO program for DMMC|For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
219741930|NCT06451458|BEHAVIORAL|Usual care|The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
219741931|NCT06316999|DIAGNOSTIC_TEST|Intestinal Ultrasound|Transabdominal and trans perineal ultrasound of the pouch
219741932|NCT05632601|DIAGNOSTIC_TEST|PET scan|PET scan
219741933|NCT06449547|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
219741934|NCT03168529|DRUG|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
219741935|NCT03168529|DRUG|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
219741936|NCT04581629|DRUG|Encaleret|Tablets administered orally
219741937|NCT04522739|DRUG|Spironolactone|Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
219175747|NCT06302010|BEHAVIORAL|Stress Ball Intervention|The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
219175748|NCT06223035|OTHER|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
219175749|NCT04176965|DEVICE|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
219175750|NCT04176965|DEVICE|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
219175751|NCT05259072|DIAGNOSTIC_TEST|99m-technetium pyrophosphate scintigraphy|Imaging test
219741938|NCT04522739|DRUG|Placebo|A placebo to match spironolactone will be taken orally once per day for 12 months.
219741939|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219741940|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219741941|NCT04463914|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219741942|NCT06639308|PROCEDURE|Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles|The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
219741943|NCT06639308|PROCEDURE|Open Flexor Hallucis longus transfer to tendon achilles|The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
219741944|NCT06640504|DIAGNOSTIC_TEST|serum albumin|Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).
219741945|NCT06640504|DIAGNOSTIC_TEST|C-Reactive Protein|The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).
219741946|NCT06640504|DIAGNOSTIC_TEST|Serum procalcitonin|The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).
219741947|NCT06640504|DRUG|Blood Lactate|The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
219741948|NCT06637644|DEVICE|Right-sided ventricular assist device|Percutaneous device for right heart support
219741949|NCT05524948|OTHER|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
219741950|NCT05524948|OTHER|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
219741951|NCT05155085|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
219741952|NCT05155085|OTHER|Placebo|Placebo
219741953|NCT06639373|OTHER|Specialized clinical service access|A new model of addiction care that will offer comprehensive and coordinated service delivery
219741954|NCT06640686|OTHER|Exercise training|Inspiratory muscle training for increase strength of inspiratory muscle.
219741955|NCT06640348|OTHER|No intervention|No intervention
219741956|NCT06640205|PROCEDURE|pulpotomy|Removal of coronal pulp tissue and then placing pulpotomy agent
219741957|NCT06643078|DRUG|HL231 Solution for Inhalation|HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
219741958|NCT06643078|DRUG|Ultibro 110μg/50 μg|Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
219741959|NCT06640777|DRUG|LEAF-4L6715|LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
219741960|NCT06640777|DRUG|Supportive Care|Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
219175752|NCT03903146|BEHAVIORAL|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
219175753|NCT03861975|OTHER|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
219175754|NCT03808987|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
219175755|NCT03808987|BEHAVIORAL|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
219175756|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
219175757|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
219175758|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
219175759|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
219175760|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
219175761|NCT05394818|DRUG|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
219741961|NCT06638554|BEHAVIORAL|Active Choice|The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.
219741962|NCT06638554|BEHAVIORAL|Telehealth Only|The participant will be send a letter inviting them to complete a SDM visit via telehealth only.
219741963|NCT06638554|BEHAVIORAL|Low Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.
219741964|NCT06638554|BEHAVIORAL|High Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
219741965|NCT06642844|DRUG|Avastin, 25 Mg/mL Intravenous Solution|"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
219741966|NCT06637982|PROCEDURE|ridge splitting with the use of allograft and pericardium membrane|ridge splitting with the use of allograft and pericardium membrane
219741967|NCT06637982|PROCEDURE|ridge splitting with the use of extended platelet rich fibrin|ridge splitting with the use of extended platelet rich fibrin
219741968|NCT06638086|DRUG|Acetaminophen Suppositories|Per rectal suppositories
219741969|NCT06638086|DRUG|Acetaminophen Injection|Intra-venous injection
219741970|NCT06645392|DEVICE|visual transparent bladed trocar of|visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
219741971|NCT06645392|DEVICE|Ternamian bladeless trocar|Ternamian bladeless trocar of diameter 10 mm
219741972|NCT06644105|DRUG|cefditoren pivoxil tablets|took cefditoren pivoxil tablets 200mg after
219741973|NCT06643221|BEHAVIORAL|Exercise|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
219741974|NCT06643221|DRUG|Isoproterenol|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
219741975|NCT06643221|DRUG|Placebo|Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
219741976|NCT06643221|DRUG|Bisoprolol Fumarate Tablet 10 mg|Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
219741977|NCT06643221|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
219741978|NCT06643221|DRUG|Carvedilol 50 mg|Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
219741979|NCT06643221|DRUG|Roflumilast 500 Mcg Oral Tablet|Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
219741980|NCT06643182|OTHER|Back Support|When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
219741981|NCT06643806|BEHAVIORAL|CHAI dyad study|In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
219175762|NCT01874769|OTHER|Blood collection|"* 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
219175763|NCT01874769|OTHER|Skin biopsies|"* A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
219175764|NCT04427709|DRUG|Oxytocin|Intramuscular injection of Oxytocin (Pitocin®)
219175765|NCT04427709|DRUG|Placebo|Intramuscular placebo injection
219175766|NCT05614024|OTHER|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
219175767|NCT05614024|OTHER|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
219175768|NCT02919683|DRUG|Nivolumab|
219175769|NCT02919683|DRUG|Ipilimumab|
219175770|NCT02919683|PROCEDURE|Standard of Care Surgery|
219175771|NCT05911633|DEVICE|BioPearl™|TACE
219175772|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
219175773|NCT05854251|DRUG|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
219175774|NCT05854251|DRUG|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
219175775|NCT05456165|DRUG|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
219175776|NCT05456165|DRUG|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
219175777|NCT05456165|DRUG|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
219175778|NCT05456165|DRUG|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
219175779|NCT05456165|DRUG|Adjuvant chemotherapy|Administered according to standard of care.
219175780|NCT06052345|DEVICE|Garmin smartwatch|"* Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)"
219175781|NCT06052345|OTHER|REBECCA Mobile application|"* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
219175782|NCT06052345|OTHER|REBECCA PC plug-in|"* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
219175783|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
219175784|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
219175785|NCT05679154|BEHAVIORAL|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
219175786|NCT05679154|BEHAVIORAL|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
219175787|NCT05619900|OTHER|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
219175788|NCT05690581|DRUG|CM369|Specified dose on specified days.
219175789|NCT04187651|OTHER|platelet rich plasma|platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
219175790|NCT02742493|OTHER|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
219175791|NCT02742493|OTHER|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
219175792|NCT02742493|OTHER|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
219175793|NCT06771180|DRUG|Dara-CyBorD|Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
219175794|NCT04072380|DRUG|SUVN-G3031|SUVN-G3031 Tablets
219175795|NCT04072380|DRUG|Placebo|Placebo Tablets
219175796|NCT04512547|DRUG|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
219175797|NCT04783571|OTHER|Placebo|Auditory stimulation will not be delivered during the nap
219175798|NCT04783571|OTHER|Auditory Stimulation|Auditory stimulation will be delivered during the nap
219175799|NCT05722652|BEHAVIORAL|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
219175800|NCT04266080|OTHER|Fitbit Inspire HR|assessing step counts
219175801|NCT04266080|OTHER|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
219175802|NCT06223854|DIETARY_SUPPLEMENT|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
219175803|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
219175804|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
219175805|NCT05030155|DRUG|Mepolizumab|300 mg/month subcutaneous
219175806|NCT05030155|DRUG|cyclophosphamide/azathioprine|Patients with FFS≥1 will receive cyclophosphamide then azathioprine
219175807|NCT05030155|DRUG|Placebo|Patients with FFS=0 will receive placebo
219175808|NCT04721912|DRUG|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
219175809|NCT04740567|BEHAVIORAL|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
219175810|NCT04740567|BEHAVIORAL|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
219175811|NCT03339817|DIAGNOSTIC_TEST|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
219175812|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
219175813|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
219175814|NCT03033576|BIOLOGICAL|Ipilimumab|Given IV
219175815|NCT03033576|BIOLOGICAL|Nivolumab|Given IV
219175816|NCT05179837|DEVICE|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
219175817|NCT06237062|OTHER|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
219175818|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
219175819|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
219175820|NCT06453083|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 6-days.
219175821|NCT06453083|DRUG|Medrol|Medrol tablets will be dispensed to the participants for 6-days.
219175822|NCT05051124|BEHAVIORAL|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
219175823|NCT05051124|BEHAVIORAL|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
219175824|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
219175825|NCT06637787|OTHER|Pads|A specially desigend pad is used to collect information about leakage and body movement at night.
219175826|NCT05056129|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
219175827|NCT05056129|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
219175828|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
219175829|NCT05068648|OTHER|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
219175830|NCT06128200|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
219175831|NCT06128200|DEVICE|Sham NEUROMARK System|Sham ablation procedure using the NEUROMARK System
219175832|NCT06637592|OTHER|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
219362740|NCT03440359|DRUG|Progesterone Vaginal Gel 8%|progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
219175833|NCT06637592|OTHER|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
219175834|NCT06641635|COMBINATION_PRODUCT|Moderated hypofractionated online adaptive radiotherapy|"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
219175835|NCT06641635|COMBINATION_PRODUCT|Conventional radiotherapy|"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
219175836|NCT04422912|BIOLOGICAL|DSG3-CAART or CABA-201|"Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201."
219175837|NCT05694767|DRUG|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
219175838|NCT06008951|OTHER|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
219175839|NCT06008951|OTHER|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
219175840|NCT06449742|DIAGNOSTIC_TEST|AI software and automatic 3D reconstruction|Radiological medical evaluation with automatic 3D reconstruction of the thoracic and lumbar spine and through application of the AI software NanoxAIHealthVCF, NANO-X IMAGING LTD on abdomen-chest CT studies.
219175841|NCT05190471|DRUG|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
219175842|NCT05190471|DRUG|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
219362741|NCT03440359|DRUG|Letrozole Oral Tablet|letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
219175843|NCT05410509|PROCEDURE|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
219175844|NCT03642665|DRUG|Natural cycle|no medication
219175845|NCT03642665|DRUG|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
219175846|NCT03642665|DRUG|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
219175847|NCT06576622|OTHER|biological sampling|"As part of the health check-up oral, Will be taken:~* Salivary samples by sputum.~* Samples of subgingival plaque in the periodontal sulcus~* A collection of the history and disease risk factors will then be carried out.~* periodontal problems by a routine care interview, the clinical examination and radiological examination."
219175848|NCT05195151|DIETARY_SUPPLEMENT|Taking capsule containing probiotics or placebo|The probiotics capsule containing two strains of probiotics.
219175849|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
219175850|NCT06576817|OTHER|High intensity circuit exercise class - Lower and upper extremity|Exercises performed at high intensity effort in the circuit (8 total) will focus on both the lower extremity (4) and upper extremity (4)
219175851|NCT06576817|OTHER|High intensity circuit exercise class - Lower extremity alone|All exercises performed at high intensity effort in the circuit (8 total) will focus on the lower extremity alone
219175852|NCT06033001|DRUG|[Lu-177]-PNT2002|\[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
219175853|NCT05773326|DRUG|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
219175854|NCT05279690|DRUG|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
219175855|NCT05796583|DEVICE|Active Pulsed Shortwave Treatment|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
219175856|NCT05796583|DEVICE|Sham Treatment|Application of 8 days of a nonfunctional sham device
219175857|NCT05026320|DRUG|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
219175858|NCT05026320|DRUG|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
219175859|NCT05026320|DRUG|Placebo gel|bid for 5 days (final application on morning of Day 6)
219175860|NCT06299137|PROCEDURE|Serratus Anterior Plane Block|Patients who undergo randomization to the intervention arm will undergo the Serratus Anterior Plane Block.
219175861|NCT06299137|DRUG|Ropivacaine injection|For the Serratus Anterior Plane Block, Ropivacaine will be used as the anesthetic.
219175862|NCT04930822|OTHER|Table Top Visual Intervention|Table top visual interventions and exercises.
219175863|NCT04930822|DEVICE|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
219175864|NCT05666960|DRUG|R-3750|Probiotic
219175865|NCT06082063|DRUG|Aspirin tablet|Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
219362742|NCT03440359|DIAGNOSTIC_TEST|pelvic ultrasound|pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is \>17 mm in diameter
219362743|NCT03440359|DRUG|Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe|ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter
219175866|NCT06082063|DRUG|Semaglutide|GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
219175867|NCT06082063|DRUG|Sotagliflozin|SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
219175868|NCT06082063|DRUG|Finerenone|Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
219175869|NCT05478499|DRUG|Deucravacitinib|Specified dose on specified days
219175870|NCT05478499|OTHER|Placebo|Specified dose on specified days
219175871|NCT02962895|BIOLOGICAL|VAY736|VAY736
219175872|NCT02962895|OTHER|Placebo|Placebo control
219175873|NCT04252781|OTHER|Exhaustive exploration|"* clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index"
219175874|NCT06801067|BIOLOGICAL|SER-155|SER-155 (Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated) is an experimental designed ecology of 16 unique, human-commensal bacterial strains encapsulated for oral administration and will be provided by Seres as an investigational drug
219175875|NCT06191861|BEHAVIORAL|Most hoped for future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for future self for 20 minutes.
219175876|NCT06191861|BEHAVIORAL|Most feared future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most feared future self for 20 minutes.
219175877|NCT06191861|BEHAVIORAL|Control (trip to zoo)|Participants in this condition think and write about a future trip to the zoo
219362744|NCT03440359|OTHER|Intrauterine insemination or timed intercourse|Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
219175878|NCT06191861|BEHAVIORAL|Balanced future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for and feared future self for 20 minutes.
219175879|NCT06800807|OTHER|Observation of several factors involved in eating and nutrition disorders|Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.
219175880|NCT05582746|BEHAVIORAL|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
219175881|NCT06598930|OTHER|Routine follow-up|As recommended: a vascular doctor exclusively, face-to-face consultations.
219175882|NCT06598930|OTHER|Intensive follow-up|a vascular physician and an IPA, with alternating face-to-face and remote consultations.
219175883|NCT03530306|DEVICE|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
219175884|NCT03530306|DEVICE|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
219175885|NCT03530306|DEVICE|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
219175886|NCT03530306|DEVICE|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
219175887|NCT05252962|DIETARY_SUPPLEMENT|Collagen Peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
219175888|NCT05655078|RADIATION|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
219175889|NCT06013345|DRUG|Remimazolam|analgosedation without secured airway
219175890|NCT06013345|DRUG|Propofol|analgosedation with secured airway
219175891|NCT06013345|DRUG|Propofol|TIVA with secured airway
219175892|NCT04872790|DRUG|Dasatinib|Given PO
219175893|NCT04872790|DRUG|Methotrexate|Given IT
219175894|NCT04872790|DRUG|Prednisone|Given PO
219175895|NCT04872790|BIOLOGICAL|Rituximab|Given IV
219175896|NCT04872790|DRUG|Venetoclax|Given PO
219175897|NCT04872790|BIOLOGICAL|Blinatumomab|Given IV
219175898|NCT04872790|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219175899|NCT04872790|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219175900|NCT04872790|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219175901|NCT05891353|OTHER|Cold Water Immersion|Cold Water Immersion task of hand
219175902|NCT05891353|OTHER|Pain Inducing Stretch|Moderately painful stretch of the neck
219175903|NCT05891353|OTHER|Pain Free Stretch|Pain free stretch of the neck
219175904|NCT03364647|OTHER|Arm A - blood flow restriction training|Group receive standard of care plus blood flow restriction training
219175905|NCT03364647|OTHER|Arm B - standard of care|Group will receive standard of care plus a sham version of blood flow restriction training
219296217|NCT04059172|DRUG|Ibuprofen 200 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
219175906|NCT04842253|DEVICE|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
219175907|NCT03377361|BIOLOGICAL|Nivolumab|Specified dose on specified days
219175908|NCT03377361|DRUG|Trametinib|Specified dose on specified days
219175909|NCT03377361|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219175910|NCT03377361|DRUG|Regorafenib|Specified dose on specified days
219175911|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
219175912|NCT05184894|BEHAVIORAL|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
219175913|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
219175914|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
219175915|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
219175916|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
219175917|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
219175918|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
219175919|NCT06070194|BEHAVIORAL|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
219175920|NCT04263051|DRUG|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
219175921|NCT04263051|DRUG|standard chemotherapy|Second line chemotherapy at the choice of the investigator
219175922|NCT05119296|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
219362745|NCT03675880|DRUG|TAB014|TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
219175923|NCT06551090|OTHER|CAMERA (Context-Aware Multimodal Ecological Research and Assessment)|The CAMERA platform is a multimodal, hardware-software framework for measuring brain-behavior interactions in an unstructured environment and predict ecological states. CAMERA will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy. CAMERA consists of: Wristband sensors of autonomic physiologic signals, emphasizing heart rate metrics and electrodermal activity; Smartphone usage, emphasizing natural language processing of text input for linguistic features; Subject-tracking audiovisual array, emphasizing subject vocal activity; Intracranial neural recordings, emphasizing hippocampal theta power and high-frequency activity (\~70-200 Hz).
219175924|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
219175925|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
219175926|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
219175927|NCT02751762|OTHER|Observation Only|No Intervention
219175928|NCT06302946|OTHER|neuromuscular stimulation and mindfulness breathing|Receive neuromuscular stimulation and mindfulness breathing; the experimental group participants will receive neuromuscular electrical stimulation with Mindful breathing.
219175929|NCT06302946|OTHER|neuromuscular electrical stimulation|participants in the control group perceived neuromuscular electrical stimulation
219175930|NCT03476460|DRUG|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
219175931|NCT03476460|DRUG|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
219175932|NCT02766231|DEVICE|Physica CR|Cruciate retaining total knee replacement
219175933|NCT02766231|DEVICE|Physica PS|Posterior Stabilized total knee replacement
219175934|NCT06626672|BEHAVIORAL|Digital Health Intervention|Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
219175935|NCT05059041|DEVICE|Dilated Refraction|The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.
219175936|NCT05059041|DEVICE|Non-Dilated Refraction|The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
219175937|NCT05656794|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
219175938|NCT06249191|PROCEDURE|Biopsy|Undergo tumor biopsy
219175939|NCT06249191|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219175940|NCT06249191|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219175941|NCT06249191|PROCEDURE|Computed Tomography|Undergo CT scan
219175942|NCT06249191|DRUG|Cyclophosphamide|Given IV
219175943|NCT06249191|DRUG|Doxorubicin|Given IV
219175944|NCT06249191|PROCEDURE|Echocardiography|Undergo echocardiography
219175945|NCT06249191|DRUG|Etoposide|Given IV
219175946|NCT06249191|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219175947|NCT06249191|BIOLOGICAL|Mosunetuzumab|Given IV
219175948|NCT06249191|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219175949|NCT06249191|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219175950|NCT06249191|DRUG|Prednisone|Given PO
219175951|NCT06249191|DRUG|Vincristine|Given IV
219175952|NCT06389032|BEHAVIORAL|Peer Mentor Support and Caregiver Education|12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
219175953|NCT06389032|BEHAVIORAL|Caregiver Education|12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
219175954|NCT06225245|DEVICE|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
219175955|NCT05193149|BEHAVIORAL|Inspiratory muscle training|Training of respiratory muscles
219175956|NCT05193149|BEHAVIORAL|Exercise training|Supervised aerobic exercise intervention
219175957|NCT04123366|DRUG|Olaparib|Oral tablet
219175958|NCT04123366|BIOLOGICAL|Pembrolizumab|Intravenous infusion
219175959|NCT03984097|DRUG|TAK-079|TAK-079 subcutaneously.
219175960|NCT03984097|DRUG|Lenalidomide|Lenalidomide orally.
219175961|NCT03984097|DRUG|Dexamethasone|Dexamethasone orally.
219175962|NCT03984097|DRUG|Bortezomib|Bortezomib subcutaneously.
219175963|NCT03984097|DRUG|Pomalidomide|Pomalidomide orally.
219175964|NCT06190340|DRUG|TNP-2092 capsules|Administration orally.
219175965|NCT06190340|DRUG|Placebo|Administration orally.
219175966|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
219175967|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
219362746|NCT04873466|DIETARY_SUPPLEMENT|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
219741982|NCT06644313|DRUG|Vebreltinib|Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
219362747|NCT03850184|DIAGNOSTIC_TEST|The Exercise in Mental Illness Questionnaire (EMIQ)|Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
219362748|NCT05068609|BIOLOGICAL|Nivolumab|Participants in this study are being treated with nivolumab for SCCHN
219741983|NCT06560346|OTHER|Geneticlly confirmed disease causing FXN mutatuion|No intervention in this observational Natural History Study
219741984|NCT06560346|OTHER|Healthy Control|No intervention in this observational Natural History Study
219741985|NCT03060707|DRUG|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
219741986|NCT00607477|DRUG|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
219741987|NCT00607477|DRUG|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
219741988|NCT03318874|DEVICE|Blephasteam|Steam delivery goggles, once daily
219741989|NCT03318874|DEVICE|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
219741990|NCT03318874|DRUG|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
219741991|NCT03884920|DIETARY_SUPPLEMENT|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
219247804|NCT00788879|BEHAVIORAL|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
219175968|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
219175969|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
219175970|NCT06327945|DEVICE|Lung uDCD Protocol|The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
219175971|NCT05629286|DEVICE|McConnell taping|non-stretch rigid McConnell tape will be applied
219175972|NCT05629286|DEVICE|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
219175973|NCT04775719|OTHER|Patient-Specific Prediction of Functional Outcome|Information sheet that describes whether a patient is more likely to improve on or maintain their current preoperative function.
219175974|NCT04775719|OTHER|Standard Pre-Operative Total Knee Arthroplasty Information|Standard of care information that is routinely provided at patient preadmission appointments.
219247805|NCT06167915|BIOLOGICAL|30μg dose of LYB002V14|30μg dose of LYB002V14 vaccine IM, on day 0
219175975|NCT05583448|DEVICE|ExploR Radial Head|Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
219175976|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
219175977|NCT05421416|DRUG|Placebo|Placebo sugar pill
219175978|NCT05328635|DRUG|Candesartan|Multdisciplinary approach
219175979|NCT05828810|PROCEDURE|Chlorhexidne Gluconate-Alcohol Skin Preparation|"Participants will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using a wet chlorhexidine surgical scrub brush followed by immediate drying using towels. The definitive preparation will then be carried out using tinted chlorhexidine gluconate-alcohol sponges applied with forceps. The drying time and the minimum number of sponge packs used will comply with the product 'Instructions for Use'. The drapes can be applied as per the surgeon's usual approach and they will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
219175980|NCT05828810|PROCEDURE|Poviodine-iodine Skin Preparation|"Participants will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using iodine detergent soaked gauze pads followed by immediate drying using towels. The definitive preparation will then be carried out using povidone-iodine soaked gauze pads applied with forceps. The drapes can be applied as per the surgical team's usual approach and they otherwise will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
219175981|NCT01606215|DRUG|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
219175982|NCT01606215|DRUG|Placebo|Placebo
219175983|NCT04592549|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
219175984|NCT04592549|OTHER|Placebo|Placebo
219247806|NCT06167915|BIOLOGICAL|60μg dose of LYB002V14|60μg dose of LYB002V14 vaccine IM, on day 0
219247807|NCT06167915|BIOLOGICAL|placebo|placebo IM, on day 0
219247808|NCT04134221|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
219247809|NCT01189318|DRUG|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
219175985|NCT05184192|DRUG|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
219175986|NCT05184192|DRUG|Placebo|lactose monohydrate NF
219247810|NCT01498445|DRUG|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
219247811|NCT01498445|DRUG|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
219247812|NCT01498445|DRUG|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
219247813|NCT02305667|DEVICE|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
219175987|NCT03797716|DEVICE|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
219175988|NCT04610710|PROCEDURE|Operation|Operation for deep infiltrating endometriosis
219175989|NCT04610710|PROCEDURE|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
219175990|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
219175991|NCT04322357|DRUG|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
219175992|NCT04322357|BEHAVIORAL|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
219175993|NCT04322357|DRUG|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
219175994|NCT03042988|OTHER|Heating pad|Heat stress applied on the trunk for up to 8 hours
219175995|NCT03042988|OTHER|Sham control|heating pad turned off applied on the trunk for up to 8 hours
219175996|NCT04054596|BEHAVIORAL|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
219175997|NCT05565092|DRUG|ALXN1820|ALXN1820 will be administered subcutaneously.
219175998|NCT04823585|DRUG|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
219175999|NCT04823585|DRUG|Placebo|Solution. Subcutaneous.
219176000|NCT06793098|DIAGNOSTIC_TEST|Measurement of kisspeptin concentration|Measurement of kisspeptin concentration in fasting venous blood serum
219176001|NCT06793098|DIAGNOSTIC_TEST|Measurement of ghrelin concentration|Measurement of ghrelin concentration in fasting venous blood serum
219176002|NCT06793098|DIAGNOSTIC_TEST|Measurement of zonulin concentration|Measurement of zonulin concentration in fasting venous blood serum
219176003|NCT05558813|DIAGNOSTIC_TEST|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
219176004|NCT05558813|BIOLOGICAL|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
219176005|NCT03257215|DRUG|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
219176006|NCT03257215|DRUG|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
219176007|NCT03257215|DRUG|Stoss placebo|A single 1.5 mL dose administered on Day 1
219176008|NCT03257215|DRUG|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
219176009|NCT04860726|OTHER|Joint mobilization|Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
219247814|NCT02305667|DEVICE|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
219247815|NCT02305667|DEVICE|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
219247816|NCT02305667|DEVICE|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
219741992|NCT04067622|DEVICE|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
219741993|NCT02219100|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
219741994|NCT03288857|DEVICE|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
219741995|NCT04661839|BIOLOGICAL|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
219741996|NCT04661839|OTHER|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
219741997|NCT00248235|BEHAVIORAL|Exercise|
219741998|NCT03329131|DEVICE|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
219741999|NCT05504746|DRUG|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
219742000|NCT05504746|DRUG|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
219742001|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
219742002|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
219742003|NCT02758626|DRUG|ataluren|Powder formulation
219742004|NCT02758626|DRUG|Placebo|Powder formulation
219742005|NCT01462747|DEVICE|KULIST|Twice daily dosing for 8 weeks
219742006|NCT02928822|BEHAVIORAL|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
219742007|NCT02928822|BEHAVIORAL|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
219742008|NCT00610220|DEVICE|Fiberglass short arm cast|Cast will be applied for a 4-week period
219742009|NCT00610220|DEVICE|Prefabricated wrist splint|Splint will be applied for a 4-week period
219742010|NCT02489487|DRUG|VM-1500|VM-1500 40 mg
219742011|NCT02489487|DRUG|Darunavir|Darunavir 600 mg
219742012|NCT02489487|DRUG|Ritonavir|Ritonavir 100 mg
219742013|NCT02489487|DRUG|Raltegravir|400 mg Raltegravir
219742014|NCT05429411|OTHER|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
219742015|NCT04025957|DRUG|SHR-1501|Administered subcutaneously
219742016|NCT04833738|DRUG|Hyaluronic acid|
219742017|NCT04833738|DRUG|Corticosteroids Triamcinolone Acetonide|triamcinolone acetonide, 40 mg/ml, single dose
219742018|NCT04833738|OTHER|Electrotherapy|electrotherapy
219742019|NCT04850599|DRUG|Carfilzomib|Given IV
219742020|NCT04850599|BIOLOGICAL|Isatuximab|Given IV
219742021|NCT04850599|DRUG|Pomalidomide|Given PO
219742022|NCT05739162|DEVICE|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
219742023|NCT05739162|BEHAVIORAL|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
219742024|NCT05960201|DRUG|[18F]fluoroestradiol (FES)|F-18 FES 111\~222 MBq(megabecquerel) injection
219742025|NCT05617196|BEHAVIORAL|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
219176010|NCT04860726|OTHER|Myofascial Release|"Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes"
219176011|NCT04860726|OTHER|Joint mobilization & Myofascial Release|"Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min"
219176012|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
219176013|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
219176014|NCT06822777|BEHAVIORAL|RISE for Nurse Preceptors Program|Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
219176015|NCT03703492|DRUG|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
219176016|NCT03703492|DRUG|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
219176017|NCT06292975|OTHER|Supervised Vigorous intensity aerobic interval exercise|7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
219176018|NCT02348749|RADIATION|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
219176019|NCT02348749|DEVICE|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
219176020|NCT02348749|OTHER|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
219176021|NCT06781970|DRUG|Oral Vitamin C|Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
219176022|NCT06781970|DRUG|Placebo|Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
219176023|NCT06069843|DRUG|IV Ketamine|0.5 mg/kg IV Ketamine
219176024|NCT05794022|OTHER|MRI|1 MRI at 1 month with gadolinium injection
219176025|NCT05794022|BIOLOGICAL|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
219176026|NCT05794022|BEHAVIORAL|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
219176027|NCT05988515|BEHAVIORAL|Speech-Language Pathologist-led Speech Motor Chaining|Sessions begin with Pre-practice to elicit the /r/ sound. During Structured Practice, the same utterance is practiced several times in a row (with systematic increases in difficulty based on performance). Our web-based software manipulates the principles of motor learning, including feedback prompts for the clinician, the complexity of the utterance, and the variability in the practice trial; the software will analyze the clinician's rating to increase the difficulty of practice when the child is more accurate. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order. A trained speech-language pathologist is involved in all practice trials to provide feedback throughout the session.
219247817|NCT04596917|BEHAVIORAL|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
219176028|NCT05988515|BEHAVIORAL|Artificial Intelligence-led Speech Motor Chaining (CHAINING-AI)|Sessions include Structured Practice and Randomized Practice using our web-based software with an Artificial Intelligence clinician to address the /r/ sound. Within a practice session, participants speak into a microphone, and the audio file is sent to a server to be analyzed by a classifier, which returns a binary accurate/inaccurate rating of productions in a fashion similar to SLP judgment. Our web-based software manipulates the principles of motor learning, including feedback prompts, the complexity of the utterance, and the variability in the practice trial. The software will analyze the child's accuracy as determined by the classifier to increase the difficulty of practice when the child is more accurate.
219176029|NCT05544864|DEVICE|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
219176030|NCT05544864|DEVICE|Drug coated ballloon (DCB)|DCB angioplasty with any commercially available drug-coated balloon
219176031|NCT04855227|PROCEDURE|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
219176032|NCT01396655|DRUG|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
219176033|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
219176034|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
219176035|NCT06657703|DRUG|HC022|Administered as specified in the treatment arm
219176036|NCT06657703|DRUG|Placebo|Administered as specified in the treatment arm
219176037|NCT06312696|OTHER|SMT|"SMT will be provided by a licensed chiropractor with at least 5 years' experience.~Treatment will last 15 to 20 minutes each and include a brief history and examination of the cervical spine. SMT will consist of low velocity, variable amplitude spinal mobilization to the cervical spine - Maitland grades 3 or 4. Spinal segments will be determined by the chiropractor using manual palpation and the patients' response to care. Drop-table or instrument-assisted SMT will not be allowed."
219176038|NCT06312696|OTHER|Light Massage|Light Massage will be provided as a pseudo-sham intervention to control for time, attention, and touch by a licensed chiropractor with at least 5 years' experience to control for touch and is intended to be delivered gentler and shorter than recommended for therapeutic massage.
219176039|NCT06282016|OTHER|Case-control study (no intervention)|Observation of risk factors in cases and controls
219176040|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
219176041|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
219176042|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
219247818|NCT04596917|BEHAVIORAL|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
219247819|NCT00083473|DRUG|Pivanex|
219176043|NCT06779435|DRUG|Low intensity treatment options|"Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks"
219176044|NCT06779435|DRUG|Conventional immunochemotherapy regimen|"Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks"
219247820|NCT04441073|DRUG|Lignocaine|preoperative nebulization of lignocaine
219247821|NCT04441073|DRUG|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
219247822|NCT01526850|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
219176045|NCT06728696|PROCEDURE|Immediate implant with with dual zone technique using concentrated growth factor graft.|In the test group, pouch technique + CGFG will be used. The CGFG will be packed in the split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket. A convenient blood sample will be withdrawn from a peripheral venous blood from the patient using a specialized vacutaine. A standard, disposable, 10-ml non- anticoagulant tube and a matching centrifuge device was used. To prepare the CGFG, the centrifuge is accelerated for 30 seconds, then centrifuged at 2700 rpm for 2 minutes, 2400 rpm for 4 minutes, 2700 rpm for 4 minutes, and 3000 rpm for 3 minutes before being decelerated for 36 seconds to stop.
219176046|NCT06728696|PROCEDURE|Immediate implant with dual zone technique using connective tissue graft.|Patients assigned to the control group will receive pouch technique + CTG. Following implant placement, a split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket will be performed using 15c mini blade to allow for the placement of a CTG. The pouch preparation will be extended apical beyond the muco-gingival junction and to the neighboring teeth mesiodistally. The CTG will be harvested from the palate with a thickness of 1.5 mm using single-incision technique, which was done approximately 2-3 mm apical to the gingival margin of the maxillary teeth and parallel to the palatal long axis. A resorbable suture will be used to first pierce the labial mucosa along with the periosteum at an apical part, which then exits from the sulcus. Afterward, the CTG will be tucked in the pouch, labial to the suture, and held at a coronal area by using the needle to pierce it from its inner surface toward the labial soft tissue. The knot will then be se
219176047|NCT06911892|OTHER|Group Serratus Anterior Plane Block|Patients will receive a serratus anterior plane block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
219176048|NCT06911892|OTHER|Group Parasternal Block|Patients will receive a parasternal block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
219176049|NCT06911892|OTHER|Group Interpectoral+Pectoserratus Plane Block|"Patients will receive an interpectoral + pectoserratus plane block preoperatively under ultrasound guidance.~Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis."
219176050|NCT06913088|PROCEDURE|ultrasonication-mediated microbubbles dressing|The microbubble suspension is diluted with normal saline to a concentration of 2x10\^7 bubbles/mL, applied to a gauze cloth, and covered on the joint skin surface. The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan), and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
219247823|NCT01526850|DRUG|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
219247824|NCT00183235|DRUG|aripiprazole (up to 15 mg/day) for 8 days|
219176051|NCT06913088|PROCEDURE|ultrasonication using pure gel|The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan) with pure gel, and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
219176052|NCT06132867|DRUG|Brigatinib|Brigatinib oral solution
219176053|NCT06132867|DRUG|Brigatinib|Brigatinib tablet
219176054|NCT06931834|DRUG|Probucol|Probucol 250 mg tablets orally up to a daily dose of 1,000 mg
219176055|NCT05194514|DEVICE|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
219176056|NCT05194514|OTHER|Cold Storage|FDA-approved method for organ procurement
219176057|NCT02365623|DRUG|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
219176058|NCT02365623|DRUG|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
219176059|NCT06488222|DRUG|Docetaxel|Subjects will receive 40 mg docetaxel intravesically.
219176060|NCT06488222|DRUG|Gemcitabine|Subjects will receive 1 mg gemcitabine intravesically.
219176061|NCT05552534|OTHER|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
219176062|NCT02995434|DEVICE|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe\_Lucem\_\_Seize\_The\_Light\_VR/"
219176063|NCT02995434|OTHER|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
219176064|NCT05071729|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
219176065|NCT00740948|DRUG|Rituximab (mabthera) Injection|2 \* 1g of Rituximab at the 1st day and at the 14th day.
219176066|NCT00740948|DRUG|Placebo: NaCl 0.9% or Glucose 5%|2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
219176067|NCT05556174|OTHER|periodic lung recruitment maneuvers|lung recruitment maneuvers repeated every 30 minutes
219176068|NCT06089707|DRUG|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
219176069|NCT04873401|BEHAVIORAL|Chain-referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing. The peer recruiters are paid for each suvcessful and eligible recruit who enrolls to be tested. Those individuals are then themselves trained to recruit peers from their social networks to receive COVID-19 testing. This is repeated over a period of 4-6 months."
219176070|NCT04873401|BEHAVIORAL|Credible Messenger|In the credible messenger intervention, peers noted to be popular and socially influential individuals with lived experience will be trained to engage within community settings and areas to encourage community members to receive COVID-19 testing at the community partnering agencies. Peers will recruit community members over a period of 4-6 months.
219176071|NCT06524843|OTHER|Analysis|Analysis and review of imaging and clinical data
219247825|NCT01876719|DRUG|AR08|
219247826|NCT01876719|DRUG|Placebo|
219247827|NCT06376344|OTHER|myofascial release with tennis ball|Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
219247828|NCT05414435|BEHAVIORAL|Reading of informed consent form|Patients that adequately read informed consent forms
219247829|NCT04479137|DIAGNOSTIC_TEST|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
219247830|NCT02261519|DRUG|NaBen®|500 mg twice daily (1000 mg total)
219247831|NCT02261519|OTHER|Placebo|0 mg twice daily (0 mg total)
219247832|NCT05262218|DRUG|PBF-680 10mg|PBF-680 10mg administered orally once a day
219247833|NCT05262218|DRUG|Placebo|Placebo administered orally once a day
219247834|NCT06480851|PROCEDURE|Ecoguided Percutaneous Neuromodulation|Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
219247835|NCT03732950|BIOLOGICAL|Pembrolizumab|Given IV
219247836|NCT00411177|PROCEDURE|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
219247837|NCT00411177|PROCEDURE|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
219247838|NCT04171258|DRUG|Botulinum toxin type A injection|Experimental
219247839|NCT04171258|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
219247840|NCT03556540|OTHER|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
219247841|NCT06207084|BEHAVIORAL|asynchronous content only|Receives asynchronous exercise content and no live training
219247842|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
219247843|NCT06207084|BEHAVIORAL|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
219247844|NCT06207084|BEHAVIORAL|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
219247845|NCT06207084|BEHAVIORAL|asynchronous content and group training|receives asynchronous content and live group training
219247846|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
219247847|NCT03955341|DEVICE|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
219247848|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
219247849|NCT03437902|DIETARY_SUPPLEMENT|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
219247850|NCT03437902|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
219247851|NCT03543540|BIOLOGICAL|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
219247852|NCT03543540|BIOLOGICAL|Placebo|Placebo injections: 14 in total at twice weekly intervals
219247853|NCT02391714|PROCEDURE|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
219247854|NCT02391714|DRUG|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
219247855|NCT02391714|DRUG|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
219247856|NCT02391714|OTHER|Oxygen|100% oxygen via nasal mask.
219247857|NCT02391714|OTHER|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
219247858|NCT02350127|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
219247859|NCT02350127|BEHAVIORAL|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
219247860|NCT02701595|DRUG|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)
219247861|NCT02701595|PROCEDURE|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
219247862|NCT05324384|DRUG|Sirolimus|Use of different doses of the same drug
219247863|NCT06207747|DIAGNOSTIC_TEST|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
219247864|NCT02765347|DRUG|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
219247865|NCT02765347|DRUG|Insulin|For arm 2, just accept insulin for 24 weeks
219247866|NCT03906240|BEHAVIORAL|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
219247867|NCT06292247|BEHAVIORAL|Cognitive behavioral therapy|CBT aims to treat anxiety by restructuring unfavorable beliefs and controlling negative thoughts so as to reduce dental anxiety.
219247868|NCT06292247|BEHAVIORAL|Auricular plaster therapy|APT involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect (e.g. reduce anxiety)
219247869|NCT06292247|BEHAVIORAL|Tell Show Do|TSD is composed of 3 phases. The Tell phase involves an age-appropriate explanation of the procedure. The Show phase is used to demonstrate a procedure up to the point where the instrument is performed. The Do phase is then initiated, and the treatment is performed.
219247870|NCT02724423|DRUG|NRL-1|
219247871|NCT00720629|DRUG|Visilizumab|3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
219247872|NCT00720629|DRUG|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
219247873|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
219247874|NCT00720629|DRUG|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
219247875|NCT00720629|DRUG|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
219247876|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
219247877|NCT02080117|PROCEDURE|kidney transplantation, living or deceased donor|
219247878|NCT05624229|DRUG|Proton Pump Inhibitors|PPI infusion continued to use for 5 days in experimental group
219247879|NCT05624229|DRUG|No Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy.
219247880|NCT05223452|DEVICE|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
219247881|NCT02713698|DRUG|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
219247882|NCT03219788|DRUG|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
219742026|NCT05617196|BEHAVIORAL|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
219742027|NCT05830097|DRUG|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
219742028|NCT01204281|OTHER|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
219742029|NCT02626351|OTHER|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.
219742030|NCT02626351|OTHER|Baseline data collection (active comparator)|Endpoint data collection only
219742031|NCT05848232|DEVICE|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
219742032|NCT05848232|DEVICE|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
219742033|NCT05848232|DEVICE|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
219742034|NCT06253312|PROCEDURE|Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
219742035|NCT06253312|PROCEDURE|Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
219742036|NCT06253312|PROCEDURE|Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
219742037|NCT00408174|DRUG|Balsalazide disodium|
219742038|NCT03277872|DEVICE|Laryngoscopy with GlideScope (GVL) Blade|"1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
219742039|NCT03277872|DEVICE|Laryngoscopy with MacIntosh (MAC) Blade|"1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
219176072|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
219176073|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
219176074|NCT04898777|PROCEDURE|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
219247883|NCT03219788|DRUG|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
219247884|NCT03219788|DRUG|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
219247885|NCT03152409|DRUG|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
219247886|NCT03152409|DRUG|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
219247887|NCT00730392|DRUG|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
219247888|NCT00730392|DRUG|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
219247889|NCT01918943|DEVICE|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
219247890|NCT05085015|OTHER|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
219247891|NCT05085015|OTHER|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
219247892|NCT04737499|BEHAVIORAL|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
219247893|NCT05791305|BEHAVIORAL|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
219742040|NCT05902858|DEVICE|Conventional intubation with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo conventional intubation with hyperangulated videolaryngoscope
219742041|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope
219742042|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope
219742043|NCT04452370|DRUG|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
219742044|NCT00529815|DEVICE|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
219742045|NCT00529815|DEVICE|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
219742046|NCT03352180|PROCEDURE|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
219742047|NCT03352180|PROCEDURE|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
219742048|NCT05313958|DRUG|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
219742049|NCT05313958|DRUG|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
219742050|NCT05313958|DRUG|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
219742051|NCT05313958|DRUG|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
219742052|NCT05313958|DRUG|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
219742053|NCT05313958|DRUG|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
219742054|NCT05459779|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
219742055|NCT05459779|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
219742056|NCT05720351|PROCEDURE|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
219742057|NCT05720351|PROCEDURE|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
219247894|NCT04520620|DRUG|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
219247895|NCT04520620|DEVICE|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
219247896|NCT04405089|DEVICE|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
219247897|NCT04405089|DEVICE|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
219247898|NCT01745445|OTHER|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
219247899|NCT02217098|PROCEDURE|GIC Restorations|Restorations using Glass Ionomer Cement
219247900|NCT02217098|PROCEDURE|Carbomer Restorations|Restorations using Glass Carbomer
219247901|NCT02217098|PROCEDURE|Compomer Restorations|Restorations using Compomer
219247902|NCT00412802|DRUG|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
219247903|NCT00412802|DRUG|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
219247904|NCT01384916|BEHAVIORAL|Yoga|2x weekly
219247905|NCT01384916|BEHAVIORAL|Healthy Living Workshop|2x weekly
219247906|NCT04370392|PROCEDURE|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
219247907|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
219247908|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
219247909|NCT02845557|OTHER|OGTT and IVGTT tests|
219247910|NCT01532024|OTHER|Microdose of NAP|Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
219247911|NCT03987672|DIETARY_SUPPLEMENT|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
219362749|NCT03979326|PROCEDURE|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
219247912|NCT00764855|PROCEDURE|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
219247913|NCT03771573|OTHER|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
219247914|NCT03771573|OTHER|monitoring|the patients will be under monitoring to investigate the evolution of the disease
219247915|NCT04503889|DEVICE|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
219247916|NCT04503889|DEVICE|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
219247917|NCT06645990|DEVICE|Impella|LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
219247918|NCT06645990|DEVICE|IABP|LV unloading with IABP before or within 24 h of ECMO initiation
219247919|NCT06647355|OTHER|Effectiveness of physical exercise in preventing pain and improving plantar pressure distribution|At the beginning of the study, the participants underwent a baropodometric and photometric analysis. At the same time, anthropometric data and self-assessed body pain data were collected. For 12 continuous weeks, the participants completed a training programme that included specific exercises designed for each group. At the end, the baropodometry images were analysed again, which led to the final conclusion of the study.
219247920|NCT06647108|DIETARY_SUPPLEMENT|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium
219247921|NCT06647108|OTHER|Placebo|Placebo
219247922|NCT06646367|OTHER|Conventional therapy|All participants in the two groups will receive conventional therapy in the form of TENS and moist heat for 5 weeks.TENS will be applied 5 times a week for 5 weeks at a frequency of 80Hz with 10- to 30-mA intensity for 25 minutes. Four surface electrodes (5x5 cm each) were situated over the painful region in the neck (two electrodes will be placed in either side of the spine high on neck, just underneath the skull and the other two electrodes will be placed about 5cm underneath them) with intensity in the tactile sensation threshold. The hot packs will be applied for 30 minutes on the cervical area, 5 times per week for 5 weeks.
219247923|NCT06646367|OTHER|Alexander technique|Women in the experimental group will attend 10 Alexander Technique classes (60 minutes each, twice a week for 5 weeks). The Alexander Technique focuses on body awareness, reducing muscle tension, and improving coordination through three principles: enhanced awareness, purposeful inhibition, and mental imagery. Participants will learn to release habitual muscle tension and explore alternative movement patterns, covering biomechanics and ergonomics of the neck, spine, and limbs. The sessions involve hands-on guidance, verbal instruction, and group activities. Daily practice in a semi-supine position is encouraged to improve posture, coordination, and overall well-being.
219247924|NCT05815693|BEHAVIORAL|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
219247925|NCT03751280|DEVICE|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
219247926|NCT03751280|DEVICE|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
219247927|NCT06646393|OTHER|Skin to skin contact|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
219247928|NCT04002856|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
219247929|NCT06646744|BIOLOGICAL|mRNA COVID-19 vaccine|Children will be vaccinated according to standard local procedure
219247930|NCT05741866|DEVICE|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
219247931|NCT05741866|DEVICE|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
219247932|NCT00194961|DRUG|Recombinant Human Growth Hormone|
219247933|NCT02899481|OTHER|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
219247934|NCT05823051|OTHER|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
219247935|NCT02536729|DRUG|Oral Sodium Phosphate - Normal preparation|
219247936|NCT02536729|DRUG|Oral sodium phosphate - Modified Preparation|
219247937|NCT02536729|DRUG|polyethylene glycol + Electrolytes|
219247938|NCT02501616|DRUG|Metformin|
219247939|NCT02501616|DRUG|Dapagliflozin|
219247940|NCT00296504|DRUG|fosamprenavir (GW433908)|
219247941|NCT00296504|DRUG|ritonavir|
219247942|NCT02815709|DRUG|Oliceridine|
219247943|NCT02815709|DRUG|Placebo|
219247944|NCT02815709|DRUG|Morphine|
219247945|NCT01994135|OTHER|Reference food|Reference food will be used to which test food samples will be compared to.
219247946|NCT01994135|OTHER|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
219247947|NCT01994135|OTHER|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
219247948|NCT06493448|OTHER|observation|This is an observational study.
219247949|NCT02453971|OTHER|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
219247950|NCT02162771|BIOLOGICAL|Rituxan|
219247951|NCT02162771|BIOLOGICAL|CT-P10|
219247952|NCT02162771|DRUG|Cyclophosphamide|
219247953|NCT02162771|DRUG|Vincristine|
219247954|NCT02162771|DRUG|Prednisone|
219247955|NCT05118737|DRUG|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
219247956|NCT00685659|OTHER|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
219247957|NCT00685659|OTHER|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
219247958|NCT00685659|OTHER|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
219247959|NCT03044951|PROCEDURE|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
219247960|NCT03044951|PROCEDURE|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
219247961|NCT00223743|DRUG|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
219247962|NCT03154684|OTHER|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active"
219247963|NCT03154684|OTHER|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
219247964|NCT00004311|DRUG|leuprolide acetate|
219247965|NCT00004311|DRUG|spironolactone|
219247966|NCT03599934|OTHER|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
219247967|NCT03599934|OTHER|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
219247968|NCT03548272|PROCEDURE|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
219247969|NCT03317288|DEVICE|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
219247970|NCT03594266|DEVICE|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
219247971|NCT03594266|DEVICE|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
219247972|NCT02595593|DEVICE|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
219247973|NCT00029276|PROCEDURE|Prefrontal transcranial magnetic brain stimulation|
219247974|NCT01132378|PROCEDURE|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
219247975|NCT02956876|DRUG|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
219247976|NCT02956876|OTHER|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
219247977|NCT02956876|OTHER|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
219247978|NCT03647709|OTHER|opioids|dosage frequency and duration
219247979|NCT06154733|PROCEDURE|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
219247980|NCT06154733|PROCEDURE|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
219247981|NCT06154733|PROCEDURE|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
219247982|NCT05068687|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
219247983|NCT00449033|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
219247984|NCT00449033|DRUG|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
219247985|NCT00449033|DRUG|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
219247986|NCT00449033|DRUG|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m\^2 IV
219247987|NCT01818245|DRUG|LY2605541|
219247988|NCT05521555|PROCEDURE|Total knee arthroplasty|First intention total knee arthroplasty
219247989|NCT06021834|OTHER|rehabilitation|The subjects will be invited to attend the program three times per week.
219247990|NCT01257698|DRUG|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
219247991|NCT02959255|DRUG|Esomeprazole|dosage difference
219247992|NCT04018534|BEHAVIORAL|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
219247993|NCT04018534|BEHAVIORAL|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
219362750|NCT04882176|DRUG|LM-061|The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
219247994|NCT04018534|BEHAVIORAL|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
219247995|NCT04393779|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
219247996|NCT05915884|OTHER|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
219247997|NCT00666913|OTHER|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
219247998|NCT06340334|BIOLOGICAL|Tegoprazan-amoxicillin dual therapy|A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days. The eradication rate, adverse reactions, and compliance of the two groups were compared.
219247999|NCT03802513|OTHER|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
219248000|NCT02382913|BIOLOGICAL|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
219248001|NCT02382913|BIOLOGICAL|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
219248002|NCT02382913|BIOLOGICAL|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
219248003|NCT03623308|OTHER|Fiber cereal|Whole grain and bran cereal
219248004|NCT03788421|DEVICE|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
219248005|NCT03788421|PROCEDURE|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
219248006|NCT04727190|PROCEDURE|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
219248007|NCT04727190|PROCEDURE|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
219248008|NCT00000121|DEVICE|Prisms in Eyeglasses|
219248009|NCT06009770|DEVICE|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
219248010|NCT06009770|BEHAVIORAL|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
219248011|NCT01803789|DEVICE|Single Kirschner Wire|
219248012|NCT01803789|DEVICE|Double Kirschner Wire|
219362751|NCT04871503|DEVICE|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
219742058|NCT05249660|OTHER|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
219248013|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
219248014|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
219248015|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
219248016|NCT00006747|DRUG|carmustine|IV
219248017|NCT00006747|DRUG|melphalan|IV
219248018|NCT00006747|DRUG|etoposide|IV
219248019|NCT00006747|DRUG|cytarabine|IV
219248020|NCT00006747|DRUG|tacrolimus|IV
219248021|NCT00006747|DRUG|methotrexate|IV
219248022|NCT00006747|DRUG|sargramostim|IV
219248023|NCT00006747|PROCEDURE|transplant|
219248024|NCT01190228|BIOLOGICAL|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
219248025|NCT01190228|BIOLOGICAL|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
219742059|NCT05249660|OTHER|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
219742060|NCT01215331|DRUG|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
219742061|NCT01215331|DRUG|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
219742062|NCT04652297|DRUG|HS-10356|Single dose of HS-10356
219742063|NCT04652297|DRUG|Placebo|Single dose of Placebo
219742064|NCT04652297|DRUG|HS-10356|Multiple doses of HS-10356
219742065|NCT04652297|DRUG|Placebo|Multiple doses of Placebo
219742066|NCT06414031|DRUG|Tranexamic Acid|Intravenous administration
219742067|NCT06414031|DRUG|Placebo|Intravenous administration
219742068|NCT03071302|OTHER|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
219742069|NCT01071785|DIETARY_SUPPLEMENT|guar gum|guar gum 10g/day for six weeks
219742070|NCT01917370|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
219742071|NCT00389480|DRUG|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
219742072|NCT05769062|PROCEDURE|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
219742073|NCT03493893|DEVICE|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
219742074|NCT00855166|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
219742075|NCT00855166|DRUG|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
219742076|NCT00855166|DRUG|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
219742077|NCT00855166|DRUG|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
219742078|NCT03320993|OTHER|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
219248026|NCT04238299|DIAGNOSTIC_TEST|Multiparametric renal MRI|Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
219248027|NCT01567670|DRUG|Naloxone|2 mg x 1-2
219248028|NCT01567670|DRUG|naloxone placebo|h2o placebo spray
219248029|NCT02619279|OTHER|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
219176075|NCT01333969|PROCEDURE|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
219248030|NCT01516502|OTHER|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
219248031|NCT00024102|DRUG|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
219248032|NCT00024102|DRUG|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
219248033|NCT00974402|BEHAVIORAL|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
219248034|NCT04083690|DEVICE|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
219362752|NCT05885581|OTHER|Arm A Grow Well|"1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data."
219248035|NCT04187963|OTHER|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
219248036|NCT02488070|PROCEDURE|Computed Tomography|Part of PET/CT scan
219248037|NCT02488070|DRUG|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
219248038|NCT02488070|PROCEDURE|Magnetic Resonance Imaging|Part of PET/MRI scan
219248039|NCT02488070|PROCEDURE|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
219248040|NCT02445781|DEVICE|Glucose clamp|Different levels of hypoglycemia
219248041|NCT04789889|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
219248042|NCT04789889|RADIATION|postoperative radiotherapy|postoperative radiotherapy
219248043|NCT01876823|DRUG|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
219248044|NCT01876823|DRUG|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
219248045|NCT04290416|DIAGNOSTIC_TEST|Microwire electrodes|
219248046|NCT06646198|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
219248047|NCT06646198|DRUG|Donafenib|Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
219248048|NCT01770509|DEVICE|NMBM|Daily application of NMBM in addition to compression therapy
219248049|NCT01770509|OTHER|Compression garments|Compression garments
219248050|NCT01658176|DRUG|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
219248051|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
219248052|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
219248053|NCT03759405|BIOLOGICAL|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
219248054|NCT05888402|DRUG|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
219248055|NCT05888402|RADIATION|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
219248056|NCT00207935|BEHAVIORAL|Swallow instruction|
219248057|NCT04321915|OTHER|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
219248058|NCT04321915|OTHER|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
219248059|NCT03867123|DRUG|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
219248060|NCT03867123|RADIATION|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
219248061|NCT03867123|DRUG|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
219248062|NCT03615404|BIOLOGICAL|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
219248063|NCT03615404|BIOLOGICAL|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
219248064|NCT03370588|DRUG|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
219248065|NCT03370588|DRUG|Normal saline|Group B: Saline infusion during same time period.
219248066|NCT00455715|DRUG|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
219248067|NCT01774929|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
219248068|NCT05464082|OTHER|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
219248069|NCT00939211|DRUG|AZD9164|Solution for inhalation through nebulization, single dose
219248070|NCT00939211|DRUG|Tiotropium|Dry powder for inhalation, single dose
219248071|NCT00939211|DRUG|Placebo|Placebo
219248072|NCT01845337|DRUG|Teysuno|
219248073|NCT01845337|DRUG|Capecitabine|
219248074|NCT05959837|OTHER|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
219248075|NCT00603278|DRUG|GW685698X|GW685698X
219248076|NCT00603278|DRUG|placebo|placebo
219248077|NCT04943614|OTHER|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
219248078|NCT04943614|OTHER|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
219248079|NCT01855672|DEVICE|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
219248080|NCT04553627|DEVICE|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
219248081|NCT04617197|DEVICE|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
219248082|NCT00729170|DIETARY_SUPPLEMENT|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
219248083|NCT06509269|PROCEDURE|intraoral scanning|Intraoral Scanning of edentulous Jaw
219248084|NCT06509269|PROCEDURE|Desktop scanning|Desktop scanning of definitive impression
219248085|NCT04222400|DIAGNOSTIC_TEST|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
219248086|NCT00312546|DRUG|Enfuvirtide|90 mg subcutaneously twice daily
219248087|NCT00312546|DRUG|Valproic acid|500 to 750 mg, taken orally twice daily
219248088|NCT04937049|OTHER|EMAeHealth digital tool|eHealth intervention to support Maternal Education
219248089|NCT02406859|BEHAVIORAL|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
219248090|NCT02406859|BEHAVIORAL|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
219248091|NCT05384808|BEHAVIORAL|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
219248092|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
219248093|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
219248094|NCT01990183|DEVICE|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
219248095|NCT01990183|OTHER|Standard Care|Current care advices in the management of preterm infants in the first months of life
219362753|NCT05885581|OTHER|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
219742079|NCT02887794|OTHER|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
219742080|NCT03282994|DEVICE|Dermal Cooling System|Cryotherapy
219742081|NCT02407938|OTHER|Rice meal|
219742082|NCT02478749|PROCEDURE|arm retraction|gently pulling through the ipsilateral arm to the knee
219742083|NCT02702999|DEVICE|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
219742084|NCT02702999|DEVICE|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
219742085|NCT05391958|BEHAVIORAL|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.
219742086|NCT05391958|BEHAVIORAL|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.
219742087|NCT05391958|GENETIC|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
219742088|NCT05391958|GENETIC|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
219742089|NCT01848457|DRUG|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
219742090|NCT01848457|DRUG|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
219742091|NCT04314973|DEVICE|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
219742092|NCT04314973|OTHER|Walking exercises|Walking exercises without wearing the robotic device.
219742093|NCT06501352|DRUG|Dexmedetomidine|Additive to Local anesthetic mixture
219742094|NCT06501352|DRUG|Neostigmine|Additive to Local anesthetic mixture
219742095|NCT06501352|DRUG|Saline|Control
219742096|NCT01271231|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
219742097|NCT01271231|DRUG|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
219742098|NCT01271231|DRUG|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
219742099|NCT02825563|DRUG|Anlotinib|in the fasting state
219742100|NCT02825563|DRUG|Anlotinib|in the high fat diet
219742101|NCT01272219|DRUG|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
219742102|NCT01272219|DRUG|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
219742103|NCT01272219|DRUG|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
219742104|NCT01272219|DRUG|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
219742105|NCT03131479|DRUG|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
219742106|NCT06284122|DRUG|Mosunetuzumab|5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
219742107|NCT06284122|DRUG|Lenalidomide|20 mg/day Day 1 to Day 21 from C2 to C12
219742108|NCT06284122|DRUG|Rituximab|when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
219742109|NCT06284122|DRUG|Obinutuzumab|when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
219742110|NCT06284122|DRUG|Cyclophosphamide|750 mg/m2 Day 1 from C1 to C6
219742111|NCT06284122|DRUG|Doxorubicin|50 mg/m2 Day 1 from C1 to C6
219742112|NCT06284122|DRUG|Vincristin|1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
219742113|NCT06284122|DRUG|Prednisone|100 mg/day Day 1 to Day 5 from C1 to C6
219742114|NCT06284122|DRUG|Rituximab|when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
219742115|NCT06284122|DRUG|Obinutuzumab|when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
219742116|NCT06284122|DRUG|Bendamustin|90 mg/m2 Day 1 and Day 2 from C1 to C6
219742117|NCT01906320|BEHAVIORAL|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
219742118|NCT02009449|DRUG|Pegilodecakin|Daily subcutaneous injections of pegilodecakin up to 12 months
219742119|NCT02009449|DRUG|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
219742120|NCT02009449|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
219742121|NCT02009449|DRUG|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
219742122|NCT02009449|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
219742123|NCT02009449|DRUG|Pazopanib|Pazopanib will be administered orally daily continuously
219742124|NCT02009449|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
219742125|NCT02009449|DRUG|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
219742126|NCT02009449|DRUG|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
219742127|NCT02009449|DRUG|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
219742128|NCT04115254|RADIATION|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
219742129|NCT04243863|DRUG|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
219742130|NCT04243863|DRUG|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
219742131|NCT06087289|DRUG|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
219742132|NCT06087289|DRUG|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
219742133|NCT05408260|PROCEDURE|Ultrasonography|Undergo HHUS
219742134|NCT05408260|PROCEDURE|Automated Breast Ultrasound|Undergo ABUS
219742135|NCT04379271|DRUG|IMU-838|"Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube."
219742136|NCT04379271|OTHER|Placebo|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
219742137|NCT06190236|BEHAVIORAL|Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder|CBT4CBT is a 7-module web-delivered program based on CBT, an evidence-based behavioral treatment for alcohol use disorder (AUD).
219742138|NCT04439903|OTHER|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
219742139|NCT03917498|RADIATION|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
219742140|NCT03286569|DEVICE|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
219742141|NCT06522503|BEHAVIORAL|stress ball|The intervention group was provided with a stress ball to be held in both hands for a period of five minutes prior to the insertion of the port catheter needle. They were instructed to squeeze the ball in their hands at regular intervals until the conclusion of the procedure.
219742142|NCT02899754|BEHAVIORAL|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
219742143|NCT02899754|BEHAVIORAL|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
219742144|NCT01854762|DRUG|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
219742145|NCT01854762|DRUG|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
219742146|NCT04818229|DRUG|CBP-307|CBP-307 capsules oral administration.
219742147|NCT04818229|DRUG|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
219742148|NCT04818229|DRUG|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
219742149|NCT04818229|DRUG|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
219248096|NCT04374253|DRUG|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
219248097|NCT04374253|DRUG|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
219248098|NCT05024578|DEVICE|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
219248099|NCT05024578|DEVICE|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
219248100|NCT04716283|OTHER|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
219248101|NCT00959634|DRUG|ABT-126|Dose administered twice daily on Study Days 1-10
219248102|NCT00959634|DRUG|Placebo|Dose administered twice daily on Study Days 1-10
219742150|NCT04082364|BIOLOGICAL|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
219742151|NCT04082364|BIOLOGICAL|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
219742152|NCT04082364|BIOLOGICAL|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
219742153|NCT04082364|BIOLOGICAL|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
219742154|NCT04082364|OTHER|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
219742155|NCT02486770|BIOLOGICAL|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
219248103|NCT01207453|DRUG|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
219248104|NCT01207453|DRUG|Placebo|
219362754|NCT02239263|DEVICE|Nucleus 6 Sound Processor|
219362755|NCT03437551|OTHER|cross-sectional observation|cross-sectional ophthalmic examination
219362756|NCT02328898|DEVICE|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
219742156|NCT02486770|BIOLOGICAL|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
219742157|NCT02486770|BIOLOGICAL|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
219742158|NCT03186378|COMBINATION_PRODUCT|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
219742159|NCT06199999|PROCEDURE|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
219742160|NCT06199999|PROCEDURE|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
219742161|NCT00265642|DRUG|Irbesartan|one tablet of 150 mg/d during 2 years
219742162|NCT00265642|DRUG|placebo|one tablet per day during 2 years
219742163|NCT06229873|DEVICE|App-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
219742164|NCT06229873|DEVICE|Clinic-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
219742165|NCT02514746|BIOLOGICAL|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
219742166|NCT00045331|GENETIC|proteomic profiling|
219742167|NCT02181413|DRUG|Ixazomib Citrate|Ixazomib citrate capsules
219742168|NCT02181413|DRUG|Placebo|Ixazomib citrate placebo-matching capsules
219742169|NCT06048497|DEVICE|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
219742170|NCT04669093|BEHAVIORAL|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
219742171|NCT04669093|BEHAVIORAL|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
219742172|NCT04669093|BEHAVIORAL|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
219742173|NCT02365688|PROCEDURE|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
219362757|NCT02328898|DEVICE|Resolute Integrity stent|
219362758|NCT01906125|DRUG|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
219362759|NCT01906125|DRUG|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
219248105|NCT06212934|OTHER|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
219248106|NCT06212934|DRUG|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
219248107|NCT05959382|DEVICE|Dental Loupe|Magnification aid
219248108|NCT05959382|DEVICE|Dental Operation Microscope|Magnification aid
219248109|NCT00662883|DRUG|PMI-150 (intranasal ketamine HCl); mometasone furoate|"* 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15"
219248110|NCT05007600|OTHER|Online Interactive Courses|In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
219248111|NCT00266162|DRUG|Bosentan administration|
219248112|NCT02338310|DRUG|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
219742174|NCT04487821|OTHER|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
219742175|NCT00050011|DRUG|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
219742176|NCT00050011|DRUG|Letrozole|Participants received Letrozole 2.5 mg daily.
219742177|NCT05607472|OTHER|blood sampling|blood samples for bio collection
219742178|NCT05607472|OTHER|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
219742179|NCT03035097|OTHER|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
219742180|NCT01375140|DRUG|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
219742181|NCT01375140|DRUG|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
219742182|NCT01375140|DRUG|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
219742183|NCT05939544|DIETARY_SUPPLEMENT|Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient|Milk Fat Globule Membrane-enriched Powdered Ingredient
219742184|NCT05939544|DIETARY_SUPPLEMENT|Placebo Comparator: Control (Placebo) Powdered Ingredient|Placebo Comparator: Control (Placebo) Powdered Ingredient
219742185|NCT06362629|BEHAVIORAL|Artificial Intelligence assistant decision-making system (AIADMS) App|Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
219742186|NCT04806373|DRUG|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
219742187|NCT04806373|DRUG|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
219742188|NCT00423865|DRUG|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
219742189|NCT00423865|DRUG|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
219742190|NCT00423865|GENETIC|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
219742191|NCT00423865|OTHER|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
219742192|NCT00423865|OTHER|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
219742193|NCT00423865|OTHER|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
219742194|NCT00423865|PROCEDURE|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
219248113|NCT02020551|DRUG|Lidocaine Spray|
219248114|NCT02020551|DRUG|Placebo|
219248115|NCT03238599|BEHAVIORAL|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
219248116|NCT05432258|DEVICE|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
219248117|NCT05432258|DEVICE|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
219248118|NCT02363933|DRUG|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
219248119|NCT00797186|OTHER|Intensive risk factor management|Aggressive medical and lifestyle therapy.
219248120|NCT00365183|DRUG|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
219248121|NCT06212596|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
219362760|NCT01906125|DRUG|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
219362761|NCT01717469|DEVICE|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
219742195|NCT05513508|PROCEDURE|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
219742196|NCT05513508|PROCEDURE|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
219742197|NCT06566300|PROCEDURE|injection of autologous nanofat grafting|Injection of nanfat graft
219742198|NCT06566300|PROCEDURE|microneedling with autologus nanofat graft|delivery of nanofat graft with microneedling
219742199|NCT06568796|OTHER|randomize controlled study|eswt treatment
219742200|NCT02866331|DRUG|G-CSF (Leucostim)|
219742201|NCT02866331|BIOLOGICAL|CB (autologous cord blood)|
219742202|NCT02866331|DRUG|Placebo (Normal saline)|
219742203|NCT02214212|DEVICE|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
219742204|NCT02214212|DEVICE|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
219742205|NCT00772525|DRUG|Nerispirdine|"form: tablet~Route: oral"
219742206|NCT00772525|DRUG|Placebo|"form: tablet~Route: oral"
219742207|NCT06362889|COMBINATION_PRODUCT|Microneedling with CBD|Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
219742208|NCT05944237|DRUG|HTL0039732 Capsules|HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
219742209|NCT05944237|DRUG|HTL0039732 Capsules and atezolizumab infusion|HTL0039732 Capsules will be administered orally on a QD schedule to participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
219742210|NCT01285232|DRUG|Anakinra|150 mg sc once daily during four weeks
219742211|NCT06468865|DEVICE|Continuous glucose monitor (Dexcom® G7)|Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
219742212|NCT06171737|BEHAVIORAL|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
219742213|NCT06171737|BEHAVIORAL|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
219742214|NCT03223987|DIETARY_SUPPLEMENT|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
219742215|NCT02061085|DRUG|Eribulin|
219742216|NCT06047717|OTHER|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
219248122|NCT06212596|DRUG|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
219248123|NCT06212596|DRUG|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
219248124|NCT05189288|DRUG|D418 Tab.|1T
219248125|NCT05189288|DRUG|CKD-388 Tab.|1T
219248126|NCT04454671|OTHER|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
219248127|NCT04454671|OTHER|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
219248128|NCT00234299|DRUG|Aspirin|325mg, one tablet orally, six months
219248129|NCT00234299|DRUG|Placebo|325mg, one tablet orally every day, 6 months
219742217|NCT05861752|BEHAVIORAL|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
219742218|NCT06289062|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
219742219|NCT06289062|DRUG|Cisplatin|75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
219742220|NCT06289062|DRUG|Nab paclitaxel|260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
219742221|NCT06289062|PROCEDURE|biopsy|cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
219742222|NCT03503331|DRUG|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
219742223|NCT06645600|DIAGNOSTIC_TEST|Fracture risk|To calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the Fracture Risk Assessment Tool (FRAX®). The one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.
219742224|NCT03984578|DRUG|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
219742225|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
219742226|NCT03984578|DRUG|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
219742227|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
219742228|NCT03984578|DRUG|CAPEOX/Pembrolizumab|"* Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle."
219742229|NCT03984578|DRUG|Pembrolizumab alone|IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.
219742230|NCT03984578|PROCEDURE|Surgical resection|Performed after all medical intervention.
219248130|NCT01599221|DEVICE|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
219248131|NCT01126177|DRUG|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
219248132|NCT01126177|DRUG|Placebo|Placebo (excipients of the SNG001 solution only)
219248133|NCT01394263|DRUG|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
219248134|NCT01394263|DRUG|Zoladex goserelin implant|goserelin implant injection.
219248135|NCT00403299|PROCEDURE|MDCT of the coronary arteries.|
219362762|NCT01717469|DEVICE|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
219362763|NCT04926935|DIAGNOSTIC_TEST|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
219742231|NCT06308770|BEHAVIORAL|Standard Care|Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.
219742232|NCT06308770|BEHAVIORAL|4 week FMP|Participants attend 3 once weekly live online group interventions with a final intervention 8 weeks later.
219742233|NCT06308770|BEHAVIORAL|7 week FMP|Participants attend 6 once weekly live online group interventions with a final intervention 8 weeks later.
219742234|NCT03538808|DRUG|Varenicline|Participants will be provided varenicline medication
219742235|NCT03538808|OTHER|Placebo|Participants will be provided placebo medication
219248136|NCT05126199|OTHER|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
219248137|NCT05126199|OTHER|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
219248138|NCT05951556|DEVICE|Use of BCI|Clients will utilize BCI with training to communicate wants and needs
219248139|NCT02375607|DEVICE|Algometer|Algometer performed patients
219248140|NCT02985255|DRUG|Docetaxel|Neoadjuvant Arm
219248141|NCT02985255|DRUG|Cisplatin|Neoadjuvant Arm
219248142|NCT02985255|DRUG|5FU|Neoadjuvant Arm
219248143|NCT02985255|RADIATION|Radiotherapy|Neoadjuvant Arm
219248144|NCT02985255|PROCEDURE|Glossectomy|Neoadjuvant Arm
219248145|NCT03045289|BEHAVIORAL|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
219248146|NCT01114334|BEHAVIORAL|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
219248147|NCT01114334|BEHAVIORAL|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
219248148|NCT04747717|PROCEDURE|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
219248149|NCT01358643|OTHER|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
219248150|NCT03487302|OTHER|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
219248151|NCT03487302|OTHER|Neuropsychological test battery|"1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
219248152|NCT00998114|BEHAVIORAL|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
219248153|NCT02905877|OTHER|Behavioural study|reaching studies and other behavioural studies.
219248154|NCT04368533|DRUG|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
219248155|NCT04368533|DRUG|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
219248156|NCT05556070|OTHER|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
219248157|NCT05556070|OTHER|Arm 2|Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
219248158|NCT05556070|OTHER|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
219248159|NCT05556070|OTHER|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
219248160|NCT05531136|OTHER|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
219248161|NCT06330363|OTHER|Laser therapy|The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
219248162|NCT06330363|OTHER|Sham|The laser device has sham light option that will be used.
219248163|NCT04830163|COMBINATION_PRODUCT|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
219248164|NCT05542836|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
219248165|NCT05542836|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
219248166|NCT06291298|BEHAVIORAL|COGMUSE-AUT|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
219248167|NCT03256760|BIOLOGICAL|Endotoxin|Endotoxin
219248168|NCT03256760|BIOLOGICAL|Placebo|Placebo
219248169|NCT04758559|OTHER|myfood24|An app to support monitoring of food and nutrient intake using robust validated methodology.
219248170|NCT04758559|OTHER|usual care|Patients will receive standard advice as provided by the clinical team, this may or may not include nutrition.
219742236|NCT02118246|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
219742237|NCT02118246|DEVICE|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
219742238|NCT04903093|DRUG|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
219742239|NCT04903093|DRUG|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
219742240|NCT04903093|DRUG|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
219742241|NCT04903093|DRUG|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
219742242|NCT04903093|DRUG|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
219742243|NCT04903093|DRUG|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
219248171|NCT05065580|PROCEDURE|Osteopathic Manipulative Treatment|Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
219248172|NCT06646900|BEHAVIORAL|Culturally adapted CBT (CaCBT) based guided self-help manual|The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
219248173|NCT06646900|BEHAVIORAL|Standard CBT Manual|The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
219248174|NCT02737670|DRUG|Sulodexide|25 mg morning and evening for 40 days
219248175|NCT02737670|DRUG|Placebo|1 tablet morning and evening for 40 days
219248176|NCT03057197|PROCEDURE|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
219362764|NCT01243736|DRUG|Combination Prep|"combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
219742244|NCT04903093|DRUG|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
219742245|NCT04903093|DRUG|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
219742246|NCT03555994|DRUG|MEDI0382|MEDI0382 administered subcutaneously
219742247|NCT03555994|DRUG|Placebo|Placebo administered subcutaneously
219362765|NCT00822107|DRUG|Hydrochlorothiazide|50 mg one time
219742248|NCT03555994|DRUG|Liraglutide|Liraglutide administered subcutaneously
219742249|NCT05035628|OTHER|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
219742250|NCT06123468|DRUG|Sacituzumab govitecan|10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
219742251|NCT03724097|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
219742252|NCT03724097|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
219742253|NCT03724097|DRUG|target drug with the score above 0,1|target drug with the score above 0,1
219742254|NCT03724097|DRUG|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
219742255|NCT03724097|DRUG|non-target drug|non-target drug
219742256|NCT03724097|DRUG|palliative care|palliative care
219742257|NCT01097681|DRUG|ASP1941|oral
219742258|NCT05399433|OTHER|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
219742259|NCT01417988|DRUG|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
219742260|NCT01417988|DRUG|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
219742261|NCT05346809|DRUG|Isatuximab|Isatuximab in IV form 10 mg/kg doses
219742262|NCT05346809|OTHER|Standard Procedures|Standard procedures (standard of care) for transplant
219742263|NCT06541249|DRUG|Methotrexate (MTX)|MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
219742264|NCT05967455|BIOLOGICAL|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
219742265|NCT05967455|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
219742266|NCT04236154|OTHER|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
219742267|NCT04236154|OTHER|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
219742268|NCT04236154|OTHER|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
219742269|NCT03973489|BEHAVIORAL|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
219742270|NCT03973489|DRUG|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
219742271|NCT03973489|DRUG|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
219742272|NCT02113813|DRUG|naquotinib|oral
219742273|NCT02113813|DRUG|midazolam|oral
219742274|NCT06308237|OTHER|RESISTED EXERCISES|"Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions."
219742275|NCT06308237|OTHER|BALANCE EXERCISES|"Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes."
219742276|NCT05135260|BEHAVIORAL|Virtual reality therapy|Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.
219742277|NCT05135260|BEHAVIORAL|Questionnaires|Questionnaires will be completed regarding stress, pain and affect
219248177|NCT03740932|DIAGNOSTIC_TEST|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
219248178|NCT00131404|DRUG|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
219248179|NCT00131404|DRUG|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
219248180|NCT05054556|DIAGNOSTIC_TEST|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
219248181|NCT01615614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
219248182|NCT01615614|DRUG|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
219248183|NCT00546884|BEHAVIORAL|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
219248184|NCT00546884|BEHAVIORAL|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
219248185|NCT02263859|DEVICE|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
219248186|NCT02367248|DRUG|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
219248187|NCT02367248|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
219248188|NCT02367248|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
219248189|NCT01624532|BIOLOGICAL|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
219248190|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
219248191|NCT01346722|OTHER|Diet- CR|conventional rice-based diet
219248192|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
219248193|NCT01346722|OTHER|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
219248194|NCT02543307|PROCEDURE|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
219248195|NCT06107205|DRUG|TTYP01|1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
219248196|NCT06107205|DRUG|Radicava|1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
219248197|NCT06107205|DRUG|Radicava ORS|1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
219248198|NCT02495402|BEHAVIORAL|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
219248199|NCT02577315|DRUG|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
219248200|NCT02577315|DRUG|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
219248201|NCT02577315|DRUG|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
219248202|NCT02577315|DRUG|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
219248203|NCT05773599|OTHER|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
219248204|NCT01558245|DRUG|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
219248205|NCT03640793|DEVICE|Implantation|Implantation of 6 PPIS implants
219248206|NCT02703519|PROCEDURE|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
219248207|NCT01469884|DRUG|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
219248208|NCT01469884|DRUG|Cyclosporine|Trough level should be between 100 and 200ng/ml.
219248209|NCT01469884|DRUG|Tacrolimus|Trough level should be between 5 and 10ng/ml.
219248210|NCT01305551|DRUG|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
219248211|NCT01305551|DRUG|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
219248212|NCT01305551|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
219248213|NCT03994185|DEVICE|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
219362766|NCT01500356|BEHAVIORAL|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
219362767|NCT01500356|BEHAVIORAL|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
219248214|NCT02274116|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
219248215|NCT02274116|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
219248216|NCT04867499|OTHER|No intervention|Descriptive study. No intervention.
219248217|NCT03036722|OTHER|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
219248218|NCT03036722|OTHER|Placebo control porridge|control porridge matched for energy and fat content.
219248219|NCT01895868|OTHER|Simulation-based ultrasound training|
219248220|NCT05301725|OTHER|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
219248221|NCT05301725|OTHER|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
219248222|NCT03984734|PROCEDURE|Pancreatoduodenectomy with antrectomy|
219248223|NCT03984734|PROCEDURE|Pylorus-preserving pancreatoduodenectomy|
219248224|NCT03879252|DEVICE|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
219248225|NCT03879252|DRUG|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
219248226|NCT01425697|OTHER|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
219248227|NCT01425697|OTHER|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
219362768|NCT01500356|BEHAVIORAL|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
219362769|NCT04808856|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic Hormone Injection 25u qd iv \*3d
219248228|NCT02226029|OTHER|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions"
219248229|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
219248230|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
219248231|NCT04992884|DEVICE|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
219248232|NCT00417989|DEVICE|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
219248233|NCT06085859|DEVICE|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
219248234|NCT06085859|DEVICE|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
219248235|NCT06319924|DRUG|Simethicone combined with Macrogol 4000 (PEG)|bowel preparation product for colonoscopy as part of CRC screening
219248236|NCT05058547|DEVICE|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
219248237|NCT00683371|PROCEDURE|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
219248238|NCT00683371|PROCEDURE|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
219248239|NCT03761979|DIETARY_SUPPLEMENT|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
219248240|NCT05333133|DIETARY_SUPPLEMENT|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
219248241|NCT01432223|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
219248242|NCT01072734|DRUG|Vaccine|Influenza vaccine
219248243|NCT04661189|BEHAVIORAL|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
219248244|NCT04661189|BEHAVIORAL|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
219248245|NCT00782353|DRUG|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
219248246|NCT00782353|DRUG|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
219248247|NCT00782353|DRUG|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
219362770|NCT04808856|DRUG|Methylprednisolone Injection|Methylprednisolone Injection 40mg qd iv \*3d
219362771|NCT01835119|DRUG|gum|gum
219362772|NCT03671928|OTHER|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
219362773|NCT03671928|OTHER|additional blood sample|for le group control, another blood sample is taken outside the usual care.
219742278|NCT05135260|PROCEDURE|Measure heart rate|To be measured prior to starting treatment and halfway through the 11 minute Video
219742279|NCT05135260|BEHAVIORAL|Cyber sickness measurement|To be measured using the fast motion sickness scale
219742280|NCT05936736|RADIATION|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
219742281|NCT03774121|DEVICE|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
219742282|NCT03774121|OTHER|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
219742283|NCT03774121|DEVICE|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
219742284|NCT06168734|DRUG|Cefepime-taniborbactam|Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
219742285|NCT06168734|DRUG|Meropenem|Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
219742286|NCT06137807|DEVICE|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
219742287|NCT06472791|DIETARY_SUPPLEMENT|Centella Asiatica|Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
219742288|NCT06472791|DIETARY_SUPPLEMENT|Placebo Comparator|The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
219362774|NCT01207557|BEHAVIORAL|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
219362775|NCT01207557|BEHAVIORAL|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
219362776|NCT05781828|DIAGNOSTIC_TEST|Detailed abdominal ultrasound|size of the liver and architecture, size of the spleen, presence or absence of ascites
219248248|NCT02293278|BEHAVIORAL|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
219248249|NCT05076578|DEVICE|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
219248250|NCT04963998|DEVICE|Application of Wound Dressings with Copper Oxide|Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
219248251|NCT00469352|DRUG|Ranibizumab|Ranibizumab as needed
219248252|NCT05664061|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
219248253|NCT05664061|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
219248254|NCT05664061|DRUG|Placebo|twice daily inhalation throughout the treatment period
219248255|NCT01328483|PROCEDURE|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
219248256|NCT04342910|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
219248257|NCT04342910|DRUG|Apatinib Mesylate|250 mg qd
219248258|NCT04342910|DRUG|Paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
219248259|NCT04342910|DRUG|Irinotecan|180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
219248260|NCT03559296|DIAGNOSTIC_TEST|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
219248261|NCT04247906|DRUG|Narsoplimab|
219248262|NCT01945086|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
219248263|NCT01945086|DRUG|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
219248264|NCT01945086|OTHER|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
219248265|NCT03669965|DRUG|KRT-232|KRT-232, administered by mouth
219248266|NCT03669965|DRUG|Ruxolitinib|Ruxolitinib per approved prescribing label
219248267|NCT03576625|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
219248268|NCT03576625|DIETARY_SUPPLEMENT|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
219248269|NCT05588739|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
219248270|NCT04644692|OTHER|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
219248271|NCT00692757|DRUG|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
219248272|NCT00692757|DRUG|Iodopovidone|Iodopovidone
219248273|NCT00308113|DRUG|Prednisone|Prednisone 0/75 mg/kg/day.
219248274|NCT00308113|DIETARY_SUPPLEMENT|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
219248275|NCT01391234|RADIATION|STAT RT planning and delivery workflow|"* Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
219248276|NCT05563987|BEHAVIORAL|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
219248277|NCT05563987|BEHAVIORAL|DE|DE
219248278|NCT00507702|PROCEDURE|phlebotomy|Standard of care
219248279|NCT04018521|BEHAVIORAL|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
219248280|NCT04018521|BEHAVIORAL|CSC Usual Care|standard of care provided to youth following first episode of psychosis
219248281|NCT01019824|DRUG|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
219248282|NCT03852485|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
219248283|NCT04282863|PROCEDURE|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
219248284|NCT04282863|PROCEDURE|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
219248285|NCT05986799|DIETARY_SUPPLEMENT|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
219248286|NCT05986799|DIETARY_SUPPLEMENT|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
219248287|NCT03852771|DEVICE|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
219248288|NCT05280509|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
219248289|NCT05280509|DRUG|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
219248290|NCT05828654|BEHAVIORAL|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
219248291|NCT05828654|BEHAVIORAL|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
219248292|NCT01556087|BEHAVIORAL|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
219248293|NCT01556087|BEHAVIORAL|Health Education|7 individual sessions with didactic health education information
219248294|NCT00294879|PROCEDURE|pressure support ventilation at 0, 5, and 10% IRT|
219248295|NCT06416189|DEVICE|Fixed appliances|MBT Brackets 0.022 inch
219742289|NCT04105634|DRUG|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
219742290|NCT04105634|DRUG|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
219742291|NCT06381791|DRUG|Epidiolex|150mg of Epidiolex
219742292|NCT06381791|DRUG|Placebo oral solution|150mg of Placebo oral solution
219742293|NCT04046419|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants.~4. Second application of the scales to the participants.~5. Statistical analysis and scaling"
219742294|NCT03301415|DRUG|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
219742295|NCT01635530|DRUG|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
219742296|NCT01635530|DRUG|Ceftriaxone|2 g intravenous once a day, three weeks
219742297|NCT04912518|DRUG|Dexmedetomidine (DEX)|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
219742298|NCT04912518|DRUG|Placebo (Saline)|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
219742299|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
219742300|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
219742301|NCT00392288|DRUG|Placebo|Placebo MDI over twelve weeks
219742302|NCT01127204|DRUG|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
219742303|NCT01127204|DRUG|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
219742304|NCT02113280|PROCEDURE|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
219742305|NCT02113280|PROCEDURE|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
219742306|NCT02544763|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219742307|NCT02544763|DRUG|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
219742308|NCT01205412|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
219742309|NCT03940157|BEHAVIORAL|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
219742310|NCT01337310|DRUG|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
219742311|NCT00919360|PROCEDURE|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
219742312|NCT00919360|PROCEDURE|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
219742313|NCT00919360|PROCEDURE|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
219742314|NCT00919360|PROCEDURE|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
219742315|NCT01887197|OTHER|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
219742316|NCT01887197|DRUG|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
219742317|NCT01887197|DRUG|mannitol inhalation powder|mannitol inhalation powder
219742318|NCT05584631|DRUG|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
219742319|NCT05584631|DRUG|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
219742320|NCT05270031|DEVICE|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
219742321|NCT03233971|OTHER|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
219742322|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
219742323|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
219248296|NCT06301529|DRUG|Invokana Pill|100 mg and 150 mg doses, taken every day and every-other day, respectively.
219248297|NCT00170950|DRUG|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
219248298|NCT00170950|DRUG|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
219742324|NCT03434886|OTHER|CFView|Registry patient portal
219742325|NCT03434886|OTHER|CF educational videos|CF educational videos
219742326|NCT00299715|DRUG|Paliperidone extended-release|
219742327|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
219742328|NCT00656643|DRUG|Placebo|Two subconjunctival injections of placebo.
219742329|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
219742330|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
219742331|NCT02462629|DRUG|BLZ-100|
219742332|NCT01336699|OTHER|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
219742333|NCT01336699|BIOLOGICAL|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
219742334|NCT01336699|BIOLOGICAL|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
219742335|NCT04670315|DIAGNOSTIC_TEST|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
219742336|NCT05856760|DRUG|Sparsentan|Target dose of 400 mg daily
219742337|NCT03696693|DEVICE|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
219742338|NCT03689088|DEVICE|Goldfish|Goldfish will be placed in the eye for 24h monitoring
219742339|NCT03689088|DEVICE|Tonometry|Fellow eye will be measured by tonometry
219742340|NCT06554899|OTHER|Clinician-led intervention to address fear of cancer recurrence (CIFeR)|The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
219742341|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
219742342|NCT06641258|OTHER|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
219742343|NCT06535893|DRUG|TN|Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
219248299|NCT00170950|DRUG|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
219248300|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
219248301|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
219248302|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
219248303|NCT00748098|DRUG|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
219248304|NCT00748098|DRUG|Placebo|Placebo
219248305|NCT00488761|DRUG|Tigecycline|
219248306|NCT03136588|DEVICE|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
219248307|NCT06983808|OTHER|Digital Cardiac Prehabilitation|Digital Cardiac Prehabilitation - A combined telehealth and app-based preparation for cardiac surgery
219248308|NCT06983808|OTHER|Control (Standard treatment)|Standard preparation for surgery as per Melbourne Health hospital procedures and processes. This may include information sessions, pamphlets, and meetings with clinicians. This does not include a prehabilitation program.
219248309|NCT05351411|OTHER||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
219248310|NCT01307540|DEVICE|phototherapy|low level light therapy, broad band light wavelengths.
219248311|NCT03275467|OTHER|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
219248312|NCT05085678|DEVICE|Co'moon (online website to support women with AET)|"The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
219248313|NCT03771261|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
219248314|NCT03771261|DIETARY_SUPPLEMENT|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
219248315|NCT01946477|DRUG|Pomalidomide|
219248316|NCT01946477|DRUG|Dexamethasone|
219248317|NCT01946477|DRUG|Daratumumab|
219248318|NCT06993181|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
219248319|NCT06993181|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
219248320|NCT06993181|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
219248321|NCT06993181|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
219248322|NCT06860763|DRUG|Chinese herbal medicine|The general treatment strategy will follow principles of clearing excess and replenishing deficiency, regulating the internal organs, and balancing yin and yang. Based on the patient's specific syndrome in TCM.
219248323|NCT06860763|DEVICE|Acupuncture|The acupuncture needles used will be 0.25 mm in diameter and 25 mm in length, inserted quickly with even supplementation and reduction techniques.
219248324|NCT06859775|DRUG|SHR-A1811|SHR-A1811 injection.
219248325|NCT06859775|DRUG|Adebelimab injection|Adebelimab injection.
219248326|NCT06859775|DRUG|Bevacizumab injection|Bevacizumab injection.
219248327|NCT06859775|DRUG|SHR-8068|SHR-8068 injection.
219248328|NCT06859775|DRUG|Cisplatin injection|Cisplatin injection.
219248329|NCT06859775|DRUG|Carboplatin injection|Carboplatin injection.
219248330|NCT07003256|DRUG|Romiplostim|After transplantation + 6 days, the subcutaneous injection of roprastine 3ug/kg was started, and the number of platelets in the machine-taken platelet suspension was increased by 2 µg/kg per week, and the maximum dose was 10 μg/kg. Discontinued until platelets rose to 100 × 109/L. If platelets ≤ 20 X 109/L were used for + 20 days, roprastine combined with atropopa 25mg was given orally once a day. Patients were given 1 therapeutic dose of fresh machine-taken platelet suspension when platelets were ≤ 20 X 109/L, or when there was active bleeding at 21\~ 50 × 109/L. The number of platelets in the machine-taken platelet suspension per therapeutic dose was \> 2.5 × 1011. If not implanted at + 28 days after transplantation, re-transplantation is required, and roprastine is considered ineffective.
219248331|NCT07008547|BIOLOGICAL|Netakimab|Netakimab administered subcutaneously
219248332|NCT07008547|DRUG|Placebo|Placebo administered subcutaneously
219248333|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), stretching will be applied to the ankle joint as described by Tardieu: first at a velocity as slow as possible (V1) for 5 minutes, followed by stretching at the fastest possible velocity (V3), sufficient to elicit a catch, for 10 minutes. A 1-minute rest period will be provided between each stretch. This protocol will be conducted three times per week for four weeks under the supervision of a physiotherapist. Afterward, the exercise will be taught to the families and continued at home as a home-based program for up to six months, without velocity measurement.
219248334|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), standard stretching will be applied to the ankle joint three sessions per week. Stretching will be performed for a total of 15 minutes per leg in each session, consisting of 10 repetitions of 60 seconds with 30-second rest intervals. During the 4-week intervention period, the exercises will be taught to the families and continued at home as a home exercise program for up to six months
219742344|NCT06535893|DRUG|TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
219742345|NCT06019832|PROCEDURE|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
219742346|NCT06019832|DEVICE|Stemmed Tibial Implant|A stemmed tibial implant
219742347|NCT06019832|DEVICE|Non-stemmed tibial implant|non-stemmed tibial implants
219742348|NCT00622843|BIOLOGICAL|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
219742349|NCT00622843|BIOLOGICAL|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
219742350|NCT00842803|DRUG|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
219742351|NCT00586937|BEHAVIORAL|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
219742352|NCT02120248|OTHER|Telephone-based breastfeeding peer counseling|
219742353|NCT04825262|DRUG|Tacrolimus|Starting dose based on CYP3A5 genotype
219742354|NCT00057577|BEHAVIORAL|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
219248335|NCT07008846|DRUG|To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis|This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate
219248336|NCT07007975|BEHAVIORAL|Web based training|This group will receive information about healthy lifestyle behaviors and gynecological cancer awareness.
219248337|NCT07009275|OTHER|The game-based simulation application developed using 3D animation technology|The intervention group consisted of students using the game-based simulation application developed using 3D animation technology, while the control group consisted of students using traditional learning methods.
219248338|NCT07008092|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of C-reactive protein, white blood cell count and neutrophile count.
219248339|NCT07008092|DIAGNOSTIC_TEST|Urine collection|Urine sample collection for analysis of creatinine and prostaglandin E urinary metabolites
219248340|NCT07008183|OTHER|self-questionnaires|Patients who volunteer to take part in the research will complete self-questionnaires before their appointment with the psychiatrist.
219248341|NCT07007988|DRUG|SIM0388|Abdominal perfusion
219248342|NCT07007988|DRUG|SIM0388|Abdominal perfusion
219248343|NCT05183802|DRUG|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
219248344|NCT05843695|BEHAVIORAL|iTCBT-I|Individual format over 2 weeks
219248345|NCT05843695|BEHAVIORAL|iTCBT-G|Group format over 2 days
219248346|NCT05843695|BEHAVIORAL|TAU|Standard care
219248347|NCT07009028|COMBINATION_PRODUCT|Storigami figure|Combination Produc: The origami figure that will be formed as a result of the process will be used as a distraction method
219248348|NCT07007728|DRUG|Iparomlimab/Tuvonralimab|5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days). Duration: 3 or 6 cycles
219248349|NCT07007728|DRUG|Bevacizumab + CAPEOX|"Bevacizumab: 7.5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days).~Capecitabine: 1000 mg/m2 twice daily orally on Day 1-14 of each cycle (every 21 days).~Oxaliplatin: 130 mg/m2 intravenous infusion on Day 1 of each cycle (every 21 days).~Duration:~Conversion therapy phase: 3 or 6 cycles; Postoperative follow-up phase (for patients with successful conversion surgery ): 3 or 6 cycles (a total perioperative duration of 9 cycles); Maintenance phase (for patients without successful conversion surgery ): Continuous therapy until disease progression, intolerable adverse events, withdrawal of consent, loss to follow-up, death, or study termination."
219248350|NCT07007728|PROCEDURE|Surgical resection ± ablation or stereotactic radiotherapy (if applicable)|After 3 or 6 cycles of conversion therapy, surgical resection ± ablation or stereotactic radiotherapy will be provided if applicable.
219248351|NCT07007546|DRUG|ABSK061|A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.
219248352|NCT07007546|DRUG|ABSK061|A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.
219248353|NCT07007546|DRUG|ABSK061|Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).
219248354|NCT05827549|DRUG|Reinduction(4weeks)|Prednisolone 60 mg/m2/day tid days 1-28, Vincristine 1.5 mg/m2 on days 1, 8, 15, 22, L-asparaginase 6,000 IU/m2(days 2-4 start, total 9 doses for 3 weeks), Idarubicin 10 mg/m2 on days 1, 8, (15\~17), IT Ara-C on days 1, IT MTX on days 8, 29
219248355|NCT05827549|DRUG|Cosolodation 1st(3weeks)|Ifosfamide: 1.8 g/m2 (days 1, 2, 3, 4, 5), Etoposide: 100 mg/m2 (days 1, 2, 3, 4, 5), IT MTX on day 1
219248356|NCT05827549|DRUG|Consolidation 2nd(3weeks)|MTX: 500 mg/m2 over 30 min followed by 1,000 mg/m2 over 23.5 hr (day 1), Ara-C: 3,000 mg/m2/dose (day 2, 3), IT MTX on day 1
219248357|NCT05827549|DRUG|Blinatumomab 1st(High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), Dexamethasone 5 mg/m2/dose on Day 1, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
219248358|NCT05827549|DRUG|Blinatumomab 2nd (High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
219248359|NCT05827549|DRUG|Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks|Blinatumomab 9 mcg/day(Weight ≥ 45kg) or 5 mcg/m²/day(Weight \< 45kg) on 1-7 days, 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 8-28 days, Dexamethasone 5 mg/m2/dose on day 1 and day 8, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
219248360|NCT05827549|DRUG|Blinatumomab-Salvage 2nd (Very High Risk Group)_4 Weeks|Blinatumomab 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 1-28 days, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
219248361|NCT05827549|DRUG|Intensification course|"\<Intensification 1st(3 Weeks)\> Etoposide: 100 mg/m2 on day 1, 2, 3, Ifosfamide 3.4 g/m2 on day 1, 2, 3~\<Intensification 2nd(2 Weeks)\> Oral 6-mercaptopurine 50 mg/m2/day PO (days 1-14), Methotrexate: 25 mg/m2 on day 1, 8, TIT on day 1~\<Intensification 3rd(3 Weeks)\> Ara-C 1.0 g/m2 (days 1-3), Idarubicin: 5mg/m2 (days 1- 3)~\<Intensification 4th(2 Weeks)\> Dexamethasone 8 mg/m2/day on days 1-14, Vincristine 2 mg/m2 on days 1 and 8, L-asparaginase 10,000 IU/m2 on days 1 and 8"
219248362|NCT05827549|DRUG|Maintenance(12 Weeks/Cycle)|Prednisolone: 15 mg/m²/dose(Days 1-5, 29-33, 57-61), Vincristine: 1.5 mg/m²/dose(Day 1, 29, 57), Oral 6-mercaptopurine: 50 mg/m²/dose (Days 1-84), Methotrexate: 20 mg/m²/dose (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78), Intrathecal methotrexate (Day 1)
219248363|NCT05827549|PROCEDURE|Stem Cell Transplantation|All matters related to hematopoietic stem cell transplantation are subject to each institution's practice.
219248364|NCT02304289|DRUG|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
219248365|NCT06697431|DRUG|Anakinra|"Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase."
219248366|NCT06697431|DRUG|Intravenous Immunoglobulins, Human|see previous section
219248367|NCT04300478|BEHAVIORAL|REx Condition First|REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.
219248368|NCT04300478|BEHAVIORAL|Sedentary Control Condition First|Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
219248369|NCT06720519|DIAGNOSTIC_TEST|QIAstat-Dx®Meningitis/Encephalite Panel|"The analytical sensitivity of the test is assessed by comparing the results obtained with those known from routine diagnostic tests.~For viruses only, the semi-quantitative value of Ct is also evaluated with the viral load provided by qPCR."
219248370|NCT06721819|COMBINATION_PRODUCT|Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention|Preoperative Sleep Hygiene and Brain game followed by post operative IV acetaminophen administration
219248371|NCT06721819|DRUG|Control|Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
219742355|NCT00057577|DRUG|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
219742356|NCT00410436|BEHAVIORAL|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
219742357|NCT03094221|DEVICE|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
219742358|NCT04918914|DRUG|Dapsone 100 MG|Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID
219742359|NCT00233961|BIOLOGICAL|filgrastim|
219742360|NCT05530538|BEHAVIORAL|BrainWeighve App|46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
219742361|NCT06151665|PROCEDURE|single file rotary|Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars
219742362|NCT06151665|PROCEDURE|Conventional Manual K files|Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
219742363|NCT00189878|DRUG|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
219742364|NCT00189878|DRUG|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
219742365|NCT00761137|DRUG|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
219742366|NCT00761137|DRUG|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
219742367|NCT00761137|DRUG|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
219742368|NCT00761137|DRUG|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
219742369|NCT03468465|DRUG|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
219742370|NCT03468465|DEVICE|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
219742371|NCT01561612|BEHAVIORAL|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
219742372|NCT06085638|DRUG|Azacitidine|Given by SC (under the skin) or IV (vein)
219742373|NCT06085638|DRUG|Tamibarotene|Given by PO
219742374|NCT06085638|DRUG|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
219742375|NCT04548219|DRUG|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
219742376|NCT04107285|BEHAVIORAL|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
219742377|NCT04107285|DIAGNOSTIC_TEST|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
219742378|NCT04107285|OTHER|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
219742379|NCT00400088|DRUG|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
219248372|NCT06720116|OTHER|sustained natural apophysial glide|"The patients will be in the sitting position and asked to move their head in the direction that particularly produces their symptoms. As the participant moves their head, the physiotherapist gently glides the painful vertebra anteriorly and sustains the glide through the movement.~During the application of the glide, the participant should stay symptom free and is instructed to stop moving if any PAIN is produced. This movement was repeated for 10 times for 3 sets, The interval between the sets was 15 to 20 seconds.After mobilization subject had to perform same exercises as conventional group plus conventional physical therapy"
219248373|NCT06720116|OTHER|instrument assisted soft tissue mobilization|"The subject will be in comfortable sitting position leaning on a treatment table with the arm crossed to rest the head. After cleaning the skin of the subject and the blade with alcohol swabs, a lubricant (Vaseline) was applied, and a sweeping technique was used to apply a deep yet comfortable soft tissue mobilization on the upper trapezius from origin to insertion for approximately 3 min.~First, M2T blade will be utilized to locate the precise locations of limitation in the affected muscles. Second, the M2T blade was put at 45 degree angle by using convex surface to apply gentle strokes along the muscle. Subjects were instructed that slight hyperemia on the skin is a normal feeling and should subside before the next session."
219248374|NCT06720116|OTHER|conventional physical therapy|the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
219248375|NCT06721546|OTHER|Nursing interventions|"The data collection process took place between March and June 2024. The implementation process took place between July 9 and October 24, 2024. In this process, education, reminder messages and telephone counseling for individuals with type 2 diabetes continued for 12 weeks.~Introduction and Preliminary Preparation: Before randomization, both oral and written informed consent form and pretest forms (Personal Information Form, Nutrition Habits, Functional Foods Information Form, Functional Foods Consumption Form, Diabetes Self-Efficacy Scale, Healthy Lifestyle Behaviors II Scale Application) were administered by the researcher to individuals with type 2 diabetes who agreed to participate in the study between March and June 2024. After reaching the sample size (n=86), randomization was performed. Appointments were made for the intervention group for training at KEAH via telephone on Tuesday-Thursday of the week in groups."
219248376|NCT06721546|OTHER|reminder messages|Reminder messages: Address and telephone numbers of individuals with Type 2 diabetes in the intervention group were obtained after obtaining their informed consent at the first meeting. After the group training, the messages were sent to the groups (groups A, B, C and D) on Tuesdays and Thursdays during daylight hours every week on the 2nd (July 23-August 15) and 6th (August 20-September 12) weeks. The message was a reminder to the participants about healthy nutrition and consumption of functional foods.
219248377|NCT06721546|OTHER|Telephone counseling|Telephone counseling: After the group trainings applied to the intervention group, in the 4th (August 6-August 29) and 8th (September 3-September 26) weeks of each week on Tuesdays and Thursdays during daylight hours, individuals with diabetes mellitus were questioned about 'the obstacles they encounter during healthy eating and functional food consumption and whether they have the belief that they can overcome these obstacles and whether there is a change in their healthy eating and functional food consumption behaviors'. Reinforcement was made with reminder questions. In this process, the importance of functional food consumption was emphasized. The first telephone interview with 43 individuals with type 2 diabetes lasted 575 minutes in total and the second telephone interview lasted 495 minutes in total.
219248378|NCT05420701|PROCEDURE|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
219248379|NCT06721780|DEVICE|Participants randomised to wear AR headset|Participants will use an AR headset that employs a distraction game specifically designed for children and young adults undergoing painful procedures.
219248380|NCT06721780|DEVICE|Participants randomised to wear VR headset|Participants will utilise a VR headset, running a calming virtual environment or an interactive game during the dressing change.
219248381|NCT06717503|OTHER|data collection|data will be collected from data sheets of acute spinal cord injury patients (Patients' demographic and epidemiological ,Mode of trauma, Cause of injury, Method of arrival to hospital, Time passed between trauma and arrival at hospital,How to deal with the TSI patients from the time of the injury until arrival at hospital, Examination findings, Imaging findings, Type and level of the injury, Sequels, Hospital stay period and operations)
219742380|NCT00400088|DRUG|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
219742381|NCT04778709|DEVICE|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
219742382|NCT00005931|DRUG|SU5416|
219742383|NCT06311331|DEVICE|Total Talus Replacement (TTR)|The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
219742384|NCT03680131|DRUG|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
219742385|NCT03680131|DRUG|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
219742386|NCT03680131|DRUG|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
219742387|NCT03680131|DRUG|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
219742388|NCT06673641|DRUG|Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
219742389|NCT06673641|DRUG|CABTREO Topical Gel|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
219742390|NCT06673641|DRUG|Placebo Control|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
219742391|NCT05290298|DIETARY_SUPPLEMENT|NITRATE|Multi-component nutritional formula
219742392|NCT05290298|DIETARY_SUPPLEMENT|PLACEBO|Placebo
219742393|NCT03549507|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
219742394|NCT02613507|DRUG|Nivolumab|
219742395|NCT02613507|DRUG|Docetaxel|
219248382|NCT06719960|DRUG|Dexmedetomidine group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the dexmedetomidine group, in addition to propofol infusion at the same doses, dexmedetomidine 0.5 μg/kg-1 loading dose was administered within 10 minutes and then continued as infusion at a dose of 0.2-0.7 μg/kg/h.
219248383|NCT06719960|DRUG|Propofol group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the propofol group, propofol loading dose: 0.2-0.5mg/kg, maintenance infusion dose: 0.5-4mg/kg/h was continued.
219248384|NCT06720324|DRUG|Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
219248385|NCT04264884|DRUG|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
219248386|NCT06892587|BEHAVIORAL|An 8-week virtual group intervention designed to promote sustainable health behavior changes in participants|"The Healthy YOU Program is an 8-week virtual group intervention designed to help participants make lasting health behavior changes, focusing on diet and physical activity. Delivered via confidential Zoom sessions, it offers flexibility and support in a group setting. Participants engage in facilitated discussions, interactive activities, and expert guidance.~Participants receive a structured curriculum with a printed workbook, covering evidence-based topics like nutrition, exercise, and well-being. Learning methods include:~Weekly Newsletters: Provide health tips, resources, and reflections to support behavior change.~Facilitated Group Discussions: Live sessions to share experiences, ask questions, and support each other.~Applied Activities: Hands-on tasks like meal planning and goal-setting to build confidence.~Demonstrations: Live sessions on healthy cooking, home exercises, and overcoming barriers.~The program encourages goal setting, progress tracking, and self-regulation."
219742396|NCT03941093|DRUG|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
219742397|NCT03941093|DRUG|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
219742398|NCT06679660|OTHER|inferior alveolar nerve block with 4% articaine|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Inferior Alveolar Block anesthesia via the mandibular foramen.
219742399|NCT06679660|OTHER|Mental/Incisive Nerve Block (%4 Articaine)|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Mental or Incisive Nerve Block anesthesia via the mental foramen.
219248387|NCT06892587|BEHAVIORAL|Standard of care Nutritional Information|The standard of care will involve providing participants with 8 weeks of nutrition information through printed handouts. These handouts will be generic, similar to materials typically provided by healthcare providers or available on public-facing health/nutrition websites. While they will cover the same topics as the experimental group, the handouts will contain only basic, publicly available nutritional information and will not include guidance for application. These handouts are also included in the Healthy YOU curriculum as background material for weekly class preparation. Participants will be instructed to review and utilize the handout information in a self-paced manner over the 8-week period.
219248388|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
219248389|NCT06736600|BEHAVIORAL|Goal Attainment Scaling (GAS)|Goal-setting tele-coaching and the well-studied Patient Priorities Care framework will assist participants with bothersome CIPN identify their most important health goals and scale them into specific, measurable, achievable, relevant, and time-bound (SMART) goals
219248390|NCT06752577|DRUG|Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)|Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
219248391|NCT01819233|BEHAVIORAL|Behavioral dietary intervention|Receive caloric restricted dietary intervention
219248392|NCT01819233|PROCEDURE|Therapeutic conventional surgery|Undergo definitive lumpectomy
219248393|NCT01819233|RADIATION|Radiation therapy|Undergo radiation therapy
219248394|NCT01819233|OTHER|Counseling intervention|Receive dietary counseling
219248395|NCT01819233|PROCEDURE|Quality-of-life assessment|Ancillary studies
219248396|NCT05262244|DRUG|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
219248397|NCT06910241|DRUG|Lidocaine|Lidocaine local infiltration
219248398|NCT06910241|DRUG|Diphenhydramine|Diphenhydramine local infiltration
219248399|NCT02026583|DRUG|Simvastatin|
219248400|NCT01651650|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
219248401|NCT02630927|DRUG|AG-519|AG519 will be tested.
219248402|NCT02630927|DRUG|Placebo|Placebo will be tested.
219248403|NCT00747721|DRUG|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
219248404|NCT06244030|OTHER|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
219248405|NCT06347029|PROCEDURE|Urine sampling|Urine sampling
219248406|NCT06347029|PROCEDURE|Blood sampling|Blood sampling
219248407|NCT06347029|DEVICE|Flow mediated dilatation test|The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
219248408|NCT01913288|OTHER|Biological Maternal Sounds|
219248409|NCT05460429|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
219248410|NCT04041661|OTHER|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
219248411|NCT04041661|OTHER|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
219248412|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 30 grams|Roasted walnuts without salt or sugar.
219248413|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 60 grams|Roasted walnuts without salt or sugar.
219248414|NCT00961298|DRUG|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
219248415|NCT06414759|DRUG|Acetazolamide|"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."
219248416|NCT06414759|DRUG|Metolazone|"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."
219248417|NCT06414759|DRUG|IV Loop Diuretics|IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
219248418|NCT05144438|DIAGNOSTIC_TEST|Toxseek test|Hair taking
219248419|NCT03184142|BEHAVIORAL|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
219248420|NCT03184142|BEHAVIORAL|Video|Student watch a 15-minute intimidation video (see arm description).
219248421|NCT03184142|BEHAVIORAL|Control group|No intervention. The students suture for 70 minutes
219248422|NCT01232569|DRUG|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
219248423|NCT01232569|DRUG|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
219248424|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
219742400|NCT07009756|DIETARY_SUPPLEMENT|Cricket Powder|"The intervention product is each serving of cricket powder, which contains 21.5 grams of house cricket (Acheta domesticus) powder blended with pumpkin powder, packed in a sachet. The powder is prepared under sterile conditions and heat-treated to ensure microbiological safety, in compliance with Thai public health regulations.~Each serving of cricket powder will be consumed together with 32 grams of instant pork-flavored congee, serving as the food base.~This intervention is distinguished by its use of whole cricket powder as a natural, food-based source of protein, chitin, and bioactive compounds, rather than isolated nutrients or supplements. Unlike many clinical studies that use encapsulated insect protein, purified chitin, or insect extracts, this study utilizes a whole-food approach, incorporating cricket powder into a culturally relevant format, congee, to reflect real-life dietary practices."
219742401|NCT07009756|OTHER|Placebo|32 grams of instant pork-flavored congee that does not contain cricket powder
219742402|NCT06688669|OTHER|Fabrication of suitable complete or removable partial dentures for the patient|Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
219742403|NCT06689111|DEVICE|Left bundle branch pacing lead|Use of LBBp Vs the standard method of BiVp in resynchronization therapy
219742404|NCT06689111|DEVICE|CRT with the standard method through cs|standard CRT procedure
219742405|NCT06690021|DRUG|Dexmedetomidine|Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
219742406|NCT06690944|OTHER|Proprioceptive Neuromuscular Facilitation|The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.
219742407|NCT06690944|OTHER|Physical exercise without proprioceptive neuromuscular facilitation control group|The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
219742408|NCT06686043|DRUG|HPV vaccine, Imiquimod, and metformin combination therapy|Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.
219742409|NCT06686407|PROCEDURE|Open lumbar decompression ± fusion|"Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device"
219742410|NCT06686407|PROCEDURE|"Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device"|A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
219742411|NCT06141460|DRUG|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
219742412|NCT06693141|OTHER|ESP block|ESP block was applied to the patients.
219742413|NCT06693141|OTHER|ITM|ITM was applied to the patients.
219742414|NCT06694467|BEHAVIORAL|Education program|An official diabetes education program designed to provide people with diabetes and their families the information and abilities they need to manage their condition effectively. Diabetes kinds, blood sugar control, self-monitoring methods, nutrition, meal planning, physical activity recommendations, medication management, and problem-solving approaches are all included in these programs. Additionally, they offer psychological assistance to help people manage the emotional challenges of having diabetes.
219248425|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
219248426|NCT04044352|BIOLOGICAL|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
219248427|NCT00651937|DRUG|Melphalan|100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
219248428|NCT00651937|PROCEDURE|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0."
219248429|NCT00651937|BEHAVIORAL|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
219248430|NCT00651937|DRUG|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
219248431|NCT00651937|PROCEDURE|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
219248432|NCT05154539|DIAGNOSTIC_TEST|Remote digital assessment|Remote digital assessment of test group participants
219248433|NCT05154539|DIAGNOSTIC_TEST|Conventional physical assessment|Conventional physical assessment of control group participants
219248434|NCT06479330|OTHER|Milk Chocolate|Acute intake
219248435|NCT01778647|DIETARY_SUPPLEMENT|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
219248436|NCT01778647|DRUG|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
219248437|NCT02306213|DRUG|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
219248438|NCT02306213|OTHER|standard volume therapy|
219248439|NCT04282564|OTHER|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
219248440|NCT06399341|DEVICE|Papilocare vaginal gel|Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
219248441|NCT01517490|OTHER|Insulin pump|Insulin pump therapy
219248442|NCT01517490|OTHER|Multiple daily insulin injections|Multiple daily insulin injections
219248443|NCT01517490|PROCEDURE|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
219248444|NCT01517490|OTHER|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
219248445|NCT04125771|DIAGNOSTIC_TEST|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
219248446|NCT04125771|DIAGNOSTIC_TEST|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
219248447|NCT04591964|COMBINATION_PRODUCT|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
219248448|NCT05189171|DEVICE|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
219362777|NCT04658394|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
219742415|NCT06694116|DIAGNOSTIC_TEST|sentinel lymph node biopsy using carbon dye|Sterile Charcoal carbon dye peritumoral injection will be performed around vulvar tumor and inguinofemoral lymph node dissection will be done 20 min later (unilateral or bilateral)
219742416|NCT06695962|DRUG|Domperidone 10mg|30 mg per day for 21 days
219742417|NCT06695962|DRUG|Placebo|3 per day for 21 days
219742418|NCT06695962|DIAGNOSTIC_TEST|gastric emptying test|gastric emptying test
219742419|NCT06694909|DEVICE|tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
219176076|NCT06273241|OTHER|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
219176077|NCT03792256|DRUG|Palbociclib|Given PO (or via NG- tube)
219176078|NCT03792256|DRUG|Cytarabine|Given intrathecally (IT)
219176079|NCT03792256|DRUG|Methotrexate|Given intrathecally (IT)
219176080|NCT03792256|DRUG|Hydrocortisone|Given IT
219176081|NCT03792256|DRUG|Doxorubicin|Given intravenously (IV)
219176082|NCT03792256|DRUG|Prednisolone|Either prednisone or prednisolone is given PO
219176083|NCT03792256|DRUG|Vincristine|Given IV
219176084|NCT03792256|DRUG|Pegaspargase|Given IV
219176085|NCT03792256|DRUG|Hydrocortisone|Given intrathecally (IT)
219176086|NCT03792256|DRUG|Prednisone|Either prednisone or prednisolone is given PO
219176087|NCT05931289|BEHAVIORAL|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
219176088|NCT05931289|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
219176089|NCT04606069|DRUG|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
219176090|NCT04606069|OTHER|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
219176091|NCT05659264|DRUG|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
219176092|NCT05659264|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
219176093|NCT04760678|OTHER|Observational study|No intervention (observational study in human participants)
219176094|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
219176095|NCT02852694|DRUG|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
219176096|NCT02852694|DRUG|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
219176097|NCT02852694|DRUG|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
219176098|NCT03148678|BEHAVIORAL|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
219176099|NCT03148678|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
219176100|NCT03148678|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
219176101|NCT03148678|BEHAVIORAL|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
219176102|NCT06838520|OTHER|Bone health assessment|Assessments of physical function, DXA scan
219176103|NCT06836544|BEHAVIORAL|ALL YOU NEED IS LOVE syllabus|"1. Week 1: Introduction to the Kidneys~2. Week 2: Chronic Kidney Disease, Medication Management~3. Week 3: Making Healthy Choices~4. Week 4: Learning about Self-Care~5. Week 5: Becoming Independent~6. Week 6: Review and Self-assessment"
219176104|NCT06040957|BIOLOGICAL|Bone marrow aspirate concentrate injection|single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
219176105|NCT06040957|BIOLOGICAL|intra-articular injection of Minimally manipulated adipose tissue|single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
219248449|NCT04237519|BEHAVIORAL|SFL training|"The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
219248450|NCT04237519|BEHAVIORAL|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
219248451|NCT00235014|DRUG|trandolapril|2 mg QD
219248452|NCT00235014|DRUG|trandolapril/verapamil|180/2 mg QD
219248453|NCT00235014|DRUG|placebo|1 tablet QD
219248454|NCT00235014|DRUG|verapamil|SR 240 mg QD
219248455|NCT04266613|DIAGNOSTIC_TEST|TruGraf® Testing|5 mL collection PAXgene blood sample
219248456|NCT02589418|PROCEDURE|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
219248457|NCT02589418|PROCEDURE|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
219248458|NCT02589418|PROCEDURE|No Acupuncture|Control intervention: No needle insertion and manipulation
219248459|NCT01100268|DRUG|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
219248460|NCT06475027|OTHER|TBDESJS|Chinese herbal tea TBDESJS
219248461|NCT06475027|OTHER|Acupuncture|acupuncture GB20 or GB20 plus BL2
219362778|NCT00828282|DRUG|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
219362779|NCT04276207|DRUG|LY900014|Administered by CSII
219362780|NCT04276207|DRUG|Insulin Lispro|Administered by CSII
219742420|NCT06694909|DEVICE|sham tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
219742421|NCT06694909|DEVICE|tDCS + PNS without action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
219742422|NCT06694909|DEVICE|sham tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
219742423|NCT06694909|DEVICE|tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
219742424|NCT06695000|DEVICE|digital CBT-I|The intervention is a digital Cognitive Behavioral Therapy for Insomnia (CBT-I) program, delivered via a mobile application. The program includes structured, self-guided modules focusing on sleep hygiene education, cognitive restructuring, stimulus control, bed time restriction, and relaxation techniques. Each module offers interactive exercises and weekly assignments designed to support behavior change and improve sleep. Participants will receive app-based reminders to encourage regular engagement, with features for tracking progress and adherence throughout the 6 week program.
219742425|NCT06687512|OTHER|SaaTwae Bio-Natural Moisturizing Cream|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
219742426|NCT06687512|OTHER|Placebo|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
219742427|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
219742428|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
219742429|NCT06689709|OTHER|Serum Alkaline Phosphatase Levels|Venous blood was drawn from the patients
219742430|NCT06686095|PROCEDURE|Group Adductor canal block|Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.
219743610|NCT03586921|OTHER|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
219248462|NCT05264064|OTHER|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
219248463|NCT02217241|OTHER|Handoff Workshop|
219248464|NCT00962221|PROCEDURE|laboratory analysis|laboratory analysis
219248465|NCT01905371|DRUG|Dextroamphetamine|
219248466|NCT01905371|OTHER|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
219248467|NCT01905371|DRUG|Placebo|
219248468|NCT04059913|DRUG|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
219248469|NCT03632902|DEVICE|supraglottic device|airway management will be collected
219248470|NCT00814632|DRUG|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
219248471|NCT05657275|DIAGNOSTIC_TEST|CRP dosage|multimodal algorithm
219248472|NCT05657275|DIAGNOSTIC_TEST|multiplex PCR|multimodal algorithm
219248473|NCT05657275|DIAGNOSTIC_TEST|chest scan without injection|multimodal algorithm
219248474|NCT04991623|DEVICE|Kinesiology taping|We used kinesiology taping in abdominal muscles
219248475|NCT04991623|OTHER|Conventional physiotherapy|We used conventional physiotherapy to comparate
219248476|NCT03809650|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
219248477|NCT02946307|DEVICE|Restore DEB（dimeter>2.00 mm）|
219248478|NCT02946307|DEVICE|Resolute DES|
219248479|NCT02946307|DEVICE|Restore DEB（dimeter:2.00 mm）|
219248480|NCT05530382|OTHER|self-guided learning|video-based self-directed learning for medical device training
219362781|NCT01328795|OTHER|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
219362782|NCT02916940|DRUG|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
219176106|NCT06836726|DRUG|Evofosfamide|This study is evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.
219176107|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
219176108|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
219742431|NCT06686095|PROCEDURE|Group Genicular Nerve Block|Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
219742432|NCT06686095|PROCEDURE|Group IPACK Block|IPACK Block: Before the procedure, the patient is informed about the technique and written consent is obtained from the patient. The patient lies in the prone position. The linear USG probe is placed approximately 2-3 cm above the popliteal fossa and scanned distally to identify the femoral shaft and popliteal artery. If the femoral condyles are initially visualized, the probe is moved until the condyles disappear and the femoral shaft is identified as a straight line and hyperechoic. Color doppler can be used to identify the popliteal vessels. The peripheral block needle is advanced between the femoral shaft and the popliteal artery. After negative aspiration control, 15-20 mL of LA medication is injected here.
219742433|NCT06688591|OTHER|Intervention programme to optimise medication management and prevent MRPs|The intervention is based on a four-step patient empowerment process: 1) the patient understands their role; 2) the patient acquires sufficient knowledge to be able to engage with their healthcare professionals; 3) the patient improves their skills; and 4) there is a facilitating environment (30). Each older adult participant's plan will be unique and consider their preferences, medication literacy and treatment adherence.
219742434|NCT06685991|DRUG|Dexamethasone|Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
219742435|NCT06688825|BEHAVIORAL|Education regarding Weight loss|Per American Association of Clinical Endocrinology (AACE) guidelines
219742436|NCT06688825|BEHAVIORAL|Lifestyle tools for weight loss|Calorie App, Continuous GlucosWe Monitor (CGM), Weight Scale, Food Scale
219742437|NCT06688825|BIOLOGICAL|Blood draw|Per American Association of Clinical Endocrinology (AACE) guidelines
219742438|NCT06691139|PROCEDURE|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia
219742439|NCT06691139|OTHER|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft|Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
219742440|NCT06691139|PROCEDURE|Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years
219742441|NCT06691139|PROCEDURE|Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft|Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years
219742442|NCT06690645|OTHER|Exposure: psychological stress status|The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.
219742443|NCT03227575|BEHAVIORAL|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
219742444|NCT03454347|DIETARY_SUPPLEMENT|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
219742445|NCT03454347|OTHER|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
219742446|NCT01260831|OTHER|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
219742447|NCT01260831|OTHER|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
219742448|NCT06694818|BEHAVIORAL|trauma film paradigm|Use the trauma films as stressors to induce stress and evaluate how it affects sleep reactivity in healthy subjects with insomnia symptoms compared to healthy subjects without insomnia symptoms
219742449|NCT06694519|DEVICE|manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).|For this manometry the air probe, connected to the Phenix biofeedback system, covered by a latex probe cover lubricated with gel, will be used. In the procedure, the labia majora are opened with one hand and slowly rotated into the vagina while holding the back of the manometric probe with the other hand. Basal tone in g will be measured prior to pelvic floor muscles force measurements. The manometry probe will extract pelvic floor pressure signals by measuring both your basal tone and the maximum pressure held for 10 seconds in three measurements, the average of the three being calculated at the command, 'contract as hard as you can for as long as possible'.
219743611|NCT03622983|OTHER|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
219743612|NCT05597124|BEHAVIORAL|Cardio-Dance Fitness|This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
219743613|NCT05597124|BEHAVIORAL|Strength, Flexibility & Balance|This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
219743614|NCT04204616|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
219743615|NCT06352463|OTHER|Denken + Doen = Durven|DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
219743616|NCT06352463|OTHER|Supportive Parenting for Anxious Childhood Emotions|Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
219743617|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
219743618|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
219743619|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
219743620|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
219743621|NCT06038214|OTHER|core exercises|"1.5 minutes walking 2. Stretching exercise~* hallowing in supine and side lying position~* Bracing in supine and side lying position~* Bracing on the prone and forearms~* Bracing in the crawling position~* Bracing in laptop, half-lap and standing position~* Heel slide exercise~* Bridge building exercise~* Unilateral limb flexion exercise in crawling position~* Reciprocal heel slide exercise in supine position~* Bilateral lower extremity lifting exercise~* Unilateral lower extremity flexion in bridging position~* Side bridging exercise with knees extended~* Unilateral lower extremity extension in crawling position~* Contralateral lower and upper extremity lift in the crawling position~* Straight and oblique trunk flexion~* Straight and oblique trunk flexion with hip and knee flexed to 90°~* bracing on the ball~* squat~* bracing while walking"
219743622|NCT06038214|OTHER|home exercises|"Right and left rotation of the head~* lateral flexion of the head~* Flexion and extension of the head~* Stretching the neck extensors~* pectoral stretch~* Stretching the hip extensors~* Hamstrig stretching~* Stretching the lumbar extensors~* Abdominal strengthening~* bridging~* Hip abduction strengthening~* hip extension strengthening~* Upper extremity resistant flexion~* Upper extremity resistant abduction~* Upper extremity relaxation exercise~* Capsule stretching~* Stretching the hip flexors~* Stretching the lower extremity adductors~* relaxation exercise"
219743623|NCT05035927|DRUG|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
219743624|NCT05035927|BEHAVIORAL|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
219743625|NCT06644794|DRUG|Progesterone-modified natural cycle preparation for frozen embryo transfer|A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
219248481|NCT01319864|DRUG|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
219248482|NCT02493881|DEVICE|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
219248483|NCT00082511|DRUG|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
219248484|NCT05611489|PROCEDURE|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
219362783|NCT03253588|PROCEDURE|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
219362784|NCT04282005|PROCEDURE|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
219248485|NCT05611489|PROCEDURE|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
219248486|NCT02622464|OTHER|micro injection of SVF in vocal cords|
219248487|NCT02475005|BEHAVIORAL|pain self management app on smartphone|
219248488|NCT00420563|DRUG|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
219248489|NCT00420563|DRUG|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
219248490|NCT02073721|OTHER|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
219248491|NCT02073721|OTHER|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
219248492|NCT03540615|DRUG|BAY1830839|Dose escalation in healthy male subjects
219248493|NCT03540615|DRUG|Placebo|Matching placebo
219248494|NCT00664261|BEHAVIORAL|smoking cessation intervention|
219248495|NCT00664261|OTHER|cancer prevention|
219248496|NCT00664261|OTHER|counseling intervention|
219248497|NCT00664261|OTHER|educational intervention|
219248498|NCT00664261|OTHER|laboratory biomarker analysis|
219248499|NCT00664261|OTHER|questionnaire administration|
219248500|NCT00664261|OTHER|survey administration|
219248501|NCT00664261|PROCEDURE|study of high risk factors|
219248502|NCT05566353|OTHER|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
219248503|NCT03494621|BEHAVIORAL|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
219248504|NCT00003502|DRUG|antineoplaston A10|
219248505|NCT00003502|DRUG|antineoplaston AS2-1|
219248506|NCT00003502|PROCEDURE|alternative product therapy|
219248507|NCT00003502|PROCEDURE|biological therapy|
219248508|NCT00003502|PROCEDURE|biologically based therapies|
219248509|NCT00003502|PROCEDURE|cancer prevention intervention|
219248510|NCT00003502|PROCEDURE|complementary and alternative therapy|
219248511|NCT00003502|PROCEDURE|differentiation therapy|
219248512|NCT04231747|BIOLOGICAL|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
219248513|NCT00675038|PROCEDURE|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
219248514|NCT06127940|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
219248515|NCT06127940|DRUG|Temporary Stopping|Temporary stop of sotorasib during SBRT
219248516|NCT02652390|DRUG|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
219248517|NCT02652390|DRUG|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
219248518|NCT02652390|OTHER|Saline|2 mL saline + 1 mL lidocaine
219248519|NCT04387903|PROCEDURE|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
219248520|NCT01586533|DRUG|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
219248521|NCT01586533|DRUG|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
219248522|NCT03867552|PROCEDURE|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
219248523|NCT03867552|PROCEDURE|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
219248524|NCT01583738|DRUG|V0251|single dose
219248525|NCT01583738|DRUG|placebo|single dose
219248526|NCT00347737|DRUG|teriparatide|Teriparatide
219248527|NCT03583411|OTHER|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
219248528|NCT02712307|DRUG|Phenoxymethylpenicillin|
219362785|NCT04282005|OTHER|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
219362786|NCT03067909|OTHER|CIED surgery|
219362787|NCT06318845|DRUG|DHP2302R1|75 mg per dose, once daily
219248529|NCT00392704|DRUG|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
219248530|NCT00392704|DRUG|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
219248531|NCT00392704|DRUG|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
219248532|NCT00392704|DRUG|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
219248533|NCT00392704|RADIATION|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
219248534|NCT05854121|DIAGNOSTIC_TEST|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
219248535|NCT05854121|DIAGNOSTIC_TEST|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
219248536|NCT03390270|OTHER|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
219248537|NCT01532583|OTHER|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
219248538|NCT02985034|PROCEDURE|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
219248539|NCT04966936|OTHER|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
219248540|NCT04966936|OTHER|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
219248541|NCT04966936|OTHER|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
219248542|NCT03749148|DRUG|Dupilumab|anti-IL4-Receptor alpha
219248543|NCT03749148|DRUG|Placebo|Placebo
219248544|NCT03158935|DRUG|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
219248545|NCT03158935|DRUG|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
219248546|NCT03158935|PROCEDURE|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
219248547|NCT03158935|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
219248548|NCT03158935|BIOLOGICAL|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
219248549|NCT03590717|BEHAVIORAL|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
219362788|NCT06318845|DRUG|DHP2302R2|50 mg per dose, once daily
219362789|NCT01463098|DRUG|E2006 1.0 mg|E2006 1.0 mg capsule.
219248550|NCT03590717|OTHER|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
219248551|NCT03590717|OTHER|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
219248552|NCT03330171|BIOLOGICAL|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
219248553|NCT03330171|BIOLOGICAL|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
219248554|NCT03330171|BIOLOGICAL|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
219248555|NCT02514577|DRUG|IDP-122 Lotion|Topical lotion
219248556|NCT02514577|DRUG|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
219362790|NCT01463098|DRUG|E2006 2.5 mg|E2006 2.5 mg capsule.
219362791|NCT01463098|DRUG|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
219362792|NCT01463098|DRUG|E2006 10.0 mg|E2006 10.0 mg capsule.
219248557|NCT01585818|OTHER|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
219248558|NCT01585818|OTHER|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
219248559|NCT01730547|BIOLOGICAL|Autologous mesenchymal stem cells|
219248560|NCT00003162|PROCEDURE|pain therapy|
219248561|NCT00003162|RADIATION|radiation therapy|
219248562|NCT03756025|PROCEDURE|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
219248563|NCT06171503|BEHAVIORAL|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
219248564|NCT05692271|DRUG|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
219248565|NCT05692271|DRUG|Placebo|Matching placebo
219248566|NCT02533349|DRUG|Motilitone|30mg, 1 tablet, 3 times a day
219248567|NCT02533349|DRUG|Pantoprazole|40mg, 1 tablet, 1time a day
219248568|NCT02533349|DRUG|Placebo|30mg, 1 tablet, 3 times a day
219248569|NCT00229086|DEVICE|Gatekeeper Reflux Repari System (Device)|
219248570|NCT05033899|OTHER|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
219362793|NCT01463098|DRUG|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
219248571|NCT04680793|OTHER|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
219248572|NCT04200404|DRUG|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
219248573|NCT04200404|DRUG|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
219248574|NCT04467398|PROCEDURE|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
219248575|NCT04922645|DRUG|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
219248576|NCT04922645|DRUG|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
219248577|NCT02388932|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219248578|NCT02388932|DEVICE|Positron Emission Tomography|Undergo PET/CT
219248579|NCT02388932|DEVICE|Computed Tomography|Undergo PET/CT
219248580|NCT02388932|OTHER|Quality-of-Life Assessment|Ancillary studies
219248581|NCT05842915|BEHAVIORAL|Questionnaire|Baseline and 3 month questionnaire
219248582|NCT02490059|OTHER|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
219248583|NCT01486277|DRUG|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
219248584|NCT06041178|DRUG|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
219362794|NCT01463098|DRUG|E2006 50.0 mg|E2006 50.0 mg capsule.
219362795|NCT01463098|DRUG|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
219176109|NCT06838104|DRUG|Melatonin|Participants in this group will receive 6 mg of melatonin orally, administered as two 3 mg tablets 30 minutes before bedtime daily for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
219176110|NCT06838104|DRUG|Placebo|Participants in this group will receive placebo tablets identical in shape, size, smell, taste, and color to melatonin tablets, administered in the same manner (two tablets 30 minutes before bedtime) for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
219176111|NCT06438172|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
219176112|NCT06438172|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
219176113|NCT06438172|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
219176114|NCT06438172|DRUG|HPP2002-1|Placebo drug. Take it once daily for 8 weeks orally.
219176115|NCT06243588|OTHER|clinical records review|review the medical records, radiological imaging, and histological data of these patients
219176116|NCT06836817|OTHER|1-Laryngyscopic examination 2-Acoustic analysis|"1. History taking.~2. voice sample by recording (in sustained vowel \|a\| )~3. Auditory Perceptual Assessment (APA): (Kotby et al., 1986)~4. Laryngyscopic examination:~   Patients will taken to a room with a tower on which the 8.5 mm 70 rigid laryngoscope (KARL STORZ - endoscope) (Tele pack X LED).~5. Acoustic analysis: The voice sample will be subjected to computerized acoustic analysis using Multidimensional voice program software(MDVP)."
219176117|NCT06562634|PROCEDURE|erector spinea plane block|an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivicaine 0.25%, and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
219176118|NCT06562634|DRUG|Morphine Sulfate|intravenous morphine will be given in a dose of 0.1-0.2mg/kg to maintain intraoperative analgesia.
219176119|NCT06837519|DRUG|Lidocaine|Patients will receive lidocaine 0.3 mg/kg over 10 min loading, 0.3 mg/kg/h infusion after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of dexmedetomidine.
219176120|NCT06837519|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of lidocaine.
219176121|NCT06837519|DRUG|Lidocaine and Dexmedetomidine|Patients will receive lidocaine (0.3 mg/kg in 10 min loading, 0.3 mg/kg/h infusion) and dexmedetomidine infusions (0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h) till 10 min before the end of the operation.
219248585|NCT06041178|DRUG|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
219248586|NCT06041178|OTHER|Placebo|saline
219248587|NCT05054283|DIAGNOSTIC_TEST|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
219248588|NCT06442293|DIETARY_SUPPLEMENT|Treatment 1|A dietary supplement containing beet root extract, arginine and citrulline
219248589|NCT06442293|DIETARY_SUPPLEMENT|Treatment 2|A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
219248590|NCT06442293|DIETARY_SUPPLEMENT|Placebo|a placebo supplement that is similar in appearance to treatment 1
219248591|NCT00562926|PROCEDURE|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
219248592|NCT04730570|BEHAVIORAL|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
219248593|NCT05115721|OTHER|no intervention|It's only observational study. No interventions.
219248594|NCT04067206|OTHER|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
219362796|NCT01463098|DRUG|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
219362797|NCT01463098|DRUG|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
219248595|NCT04067206|OTHER|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
219248596|NCT04067206|OTHER|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
219248597|NCT01753323|DRUG|KAF156|KAF156 was supplied as tablets for oral use.
219248598|NCT01110161|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
219248599|NCT03558750|BIOLOGICAL|Nivolumab|Given by IV
219248600|NCT03558750|BIOLOGICAL|Rituximab|Given by IV
219248601|NCT03558750|DRUG|Lenalidomide|Given by mouth
219248602|NCT01103271|OTHER|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
219248603|NCT00224198|PROCEDURE|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
219248604|NCT04263558|BEHAVIORAL|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
219248605|NCT03568708|DRUG|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
219248606|NCT00511147|BIOLOGICAL|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
219248607|NCT00292305|PROCEDURE|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
219248608|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 10 mg
219248609|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 5 mg
219248610|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg
219248611|NCT00126555|DRUG|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
219248612|NCT00126555|RADIATION|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
219248613|NCT00126555|PROCEDURE|Conventional surgery|Undergo surgery
219248614|NCT00126555|OTHER|laboratory biomarker analysis|Correlative studies
219248615|NCT04514289|DRUG|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
219248616|NCT03973645|OTHER|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
219248617|NCT05309356|OTHER|ACCEPT Decision Intervention|The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
219248618|NCT05309356|OTHER|Comparator|The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
219248619|NCT02133066|PROCEDURE|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
219248620|NCT02133066|DEVICE|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
219248621|NCT02133066|PROCEDURE|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
219248622|NCT06299696|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration
219248623|NCT04798508|OTHER|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
219248624|NCT05087797|DRUG|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
219248625|NCT01399684|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
219248626|NCT01399684|DRUG|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
219248627|NCT01399684|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
219248628|NCT01399684|DRUG|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
219248629|NCT01399684|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
219248630|NCT01399684|DRUG|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
219248631|NCT05804526|DRUG|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
219248632|NCT05804526|DRUG|Sintilimab Injection|Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
219248633|NCT05982028|PROCEDURE|Minimally invasive pit-picking surgery|Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
219362798|NCT01463098|DRUG|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
219362799|NCT01463098|DRUG|E2006 Matched Placebo|E2006-matched placebo capsule.
219248634|NCT05982028|PROCEDURE|Radical surgical excision without suturing|Under the guidance of brilliant green, the cavity of the pilonidal cyst, along with the sinus tracts and fistulas, was marked. A symmetric elliptical incision was made to excise the pits and secondary fistula openings. The pilonidal cyst was removed from the healthy subcutaneous tissue and sacrococcygeal fascia using monopolar electrocautery. The wound was not sutured and was left open to heal by secondary intention. After haemostasis was achieved, the wound was covered with sterile gauze with 10 % povidone-iodine solution.
219248635|NCT01949649|BEHAVIORAL|Peer-Led Group Intervention|
219248636|NCT01949649|BEHAVIORAL|Internet-Based Intervention|
219248637|NCT01949649|BEHAVIORAL|Clinician-Led Group Intervention|
219248638|NCT01949649|BEHAVIORAL|Education Video|
219248639|NCT00647985|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fed
219248640|NCT00647985|DRUG|Allegra® Tablets 180 mg|180mg, single dose fed
219248641|NCT03792035|DRUG|Tongxinluo|tid, po.
219248642|NCT03792035|DRUG|Placebos|tid, po.
219248643|NCT05750017|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
219248644|NCT05750017|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
219248645|NCT05750017|DRUG|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
219248646|NCT04448925|OTHER|inertial-load exercise (ILE)|Length of time between exercise bouts
219248647|NCT00276783|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
219248648|NCT02411422|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube
219248649|NCT02411422|DEVICE|Reinforced endotracheal tube|Reinforced endotracheal tube
219248650|NCT03308383|OTHER|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
219248651|NCT03550183|BIOLOGICAL|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
219248652|NCT04614285|PROCEDURE|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
219248653|NCT02584075|DRUG|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
219248654|NCT02584075|DRUG|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
219248655|NCT02449837|OTHER|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
219248656|NCT02186496|DRUG|CKD-330 8/5mg|
219248657|NCT02186496|DRUG|Candesartan 8mg and Amlodipine 5mg|
219248658|NCT00168714|DRUG|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
219248659|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
219248660|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
219248661|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
219248662|NCT02571283|DRUG|Cocktail|Administered as a single dose injection.
219248663|NCT02571283|DRUG|Exparel|Administered 20 minutes+ before additional medications.
219248664|NCT02571283|DRUG|Marcaine|Administered 20 minutes or more after Exparel is administered.
219248665|NCT02150083|PROCEDURE|OR retrograde fill|
219248666|NCT01470664|DRUG|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
219248667|NCT01470664|DRUG|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
219248668|NCT01470664|DRUG|FST-100 Vehicle|FST-100 Vehicle
219248669|NCT01732588|DRUG|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
219248670|NCT01732588|DRUG|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
219248671|NCT01732588|DRUG|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
219248672|NCT01451697|BEHAVIORAL|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
219248673|NCT01451697|BEHAVIORAL|Control (Placebo)|The control condition will involve relaxation training.
219248674|NCT04875598|PROCEDURE|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
219248675|NCT03690921|DRUG|Cisplatin|Given IV
219248676|NCT03690921|DRUG|Fluorouracil|Given IV
219248677|NCT03690921|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
219248678|NCT03690921|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219248679|NCT03690921|OTHER|Questionnaire Administration|Ancillary studies
219248680|NCT02945007|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
219248681|NCT02183350|DRUG|BI 1356 BS - single rising dose|
219248682|NCT02183350|DRUG|Placebo|
219248683|NCT05171465|DEVICE|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
219248684|NCT04935918|DEVICE|ACT|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
219248685|NCT02737202|DRUG|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
219742450|NCT06694519|DIAGNOSTIC_TEST|PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)|This questionnaire allows assessment of the impact of urinary symptoms, colo-rectal-anal symptoms and genital prolapse symptoms. This questionnaire will also be used as an inclusion criterion, to homogenise the characteristics of the population in terms of pelvic dysfunction prior to the intervention, as indicated above.
219742451|NCT06694519|DIAGNOSTIC_TEST|ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)|a four-question self-administered questionnaire that identifies individuals with urinary incontinence by assessing frequency, severity and impact on quality of life. It is composed of five questions assessing frequency, severity and impact of UI, plus a set of eight self-diagnostic items related to UI situations experienced by patients. The maximum sum of the response values indicates a score of 21 points, referring to the high impact of UI on an individual's life.
219742452|NCT06694519|DIAGNOSTIC_TEST|Sandvik's test|It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.
219742453|NCT06694519|DIAGNOSTIC_TEST|vaginal health index (VHI)|this index consists of a graduated scale from 1 to 5 for each item (vaginal elasticity, fluid volume, pH, epithelial integrity and moisture).Vaginal elasticity ranges from 1 (no elasticity) to 5 (excellent elasticity), assessed by distension of the mucosa on palpation and speculum placement. The volume of fluid, assessed during inspection, varies between 1 (no discharge) and 5 (normal discharge) (white flocculent). The integrity of the epithelium varies between 1 (petechiae already detected on inspection) and 5 (non-friable tissue and normal mucosa). Moisture ranges from 1 (no moisture detected on inspection and presence of inflamed mucosa) to 5 (normal moisture). The pH will be quantified using a pH indicator strip between 0 and 14 (MColorpHast™-PH indicator strips) to be placed directly on the right lateral vaginal wall for one minute, giving 1 point for pH 6.1, 2 for pH 5.6-6.0, 3 for pH 5.1-5.5, 4 for pH 4.7-5.0 and 5 for pH ≤ 4.6. The sum of all items represents the vaginal health
219742454|NCT06694519|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|This scale allows the intensity of pain described by the patient to be measured with maximum reproducibility between observers. It consists of a horizontal line of 10 centimetres, at the ends of which are the extreme expressions of a symptom. At the left end is the absence or lowest intensity and at the right end the highest intensity. The patient is asked to mark on the line the point that indicates the intensity of the pain during sexual intercourse and it is measured with a millimetres ruler. The intensity is expressed in centimetres or millimetres. The rating will be: 1 Mild pain if the patient scores the pain as less than 3; 2 Moderate pain if the rating is between 4 and 7; 3 Severe pain if the rating is equal to or greater than 8.
219742455|NCT06694519|DIAGNOSTIC_TEST|Body Image Scale (S-BIS)|It consists of 10 items assessing various dimensions of body image in cancer patients, evaluating: affective, behavioural and cognitive. The items are scored on a four-point scale (0: not at all; 1: a little; 2: quite a lot; 3: a lot) with a maximum possible score of 3 points. The higher the score, the higher the body image problem. Its brevity facilitates rapid assessment in both clinical and research settings. It shows a stable factor structure between samples, and good psychometric properties with high reliability (Cronbach's alpha=0.93), suggesting that it is a suitable and useful measure for assessing body image in breast cancer patients.
219742456|NCT06694519|DIAGNOSTIC_TEST|Likert's scale questionnaire|five-point Likert scale for satisfaction with treatment to be classified as: 1 (very dissatisfied), 2 (dissatisfied), 3 (no change), 4 (satisfied), 5 (very satisfied). Women who miss any of the RF sessions and/or whose attendance at the face-to-face physiotherapy sessions (RF and/or PFMT) does not reach 80% will be considered as not complying with the study protocol and their participation will be terminated, although they will be included in the analysis (by intention to treat).
219742457|NCT06694519|DIAGNOSTIC_TEST|Oxford's Scale|It allows the contractile capacity of the pelvic floor muscles to be assessed. It scores from 0 to 5, as follows: if there is no contraction it is 0, if the contraction is very weak it is 1, if the contraction is weak it is 2, if the contraction is moderate/with tension/and maintained it is 3, if the contraction is good and maintains tension with resistance it is 4, and if the contraction is strong and maintains tension against a resistant force it is 5.
219742458|NCT06694519|DIAGNOSTIC_TEST|Sexual function and self-esteem|The Female Sexual Function Index (FSFI) questionnaire consists of 19 items that assess sexual function over the past 4 weeks and performance in six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. A cut-off point ≤ 26.5 is considered sexual dysfunction and an increase in score is considered an improvement.
219742459|NCT06691711|BEHAVIORAL|ASPIRE support package|The ASPIRE support package has a modular structure with core modules that all participating families are encouraged to complete initially, followed by optional modules which the family is supported to select from according to their strengths and needs. Core modules provide psychoeducation for the caregiver and optional modules contain information on the selected positive psychology topic together with instructions for suggested activities to be completed by the caregiver with their child to implement evidence-based positive psychology strategies. All resources can be accessed both electronically via an online portal or via the printed resource pack. Each caregiver is supported through the programme by a trained practitioner who offers regular support sessions (up to 8 in total) to provide information, advice and encouragement. Support sessions can take place face-to-face, by video call or over the phone according to participant preference.
219742460|NCT05004987|DRUG|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
219742461|NCT05004987|DRUG|Placebo|Daily dose of placebo will mimic that of ESC.
219742462|NCT06686069|DIETARY_SUPPLEMENT|bioarginina zero|treatment
219742463|NCT06686069|DIETARY_SUPPLEMENT|Placebo|absence of treatment
219742464|NCT01851226|PROCEDURE|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
219742465|NCT02841631|GENETIC|HPV status and typing of tissue|HPV status and typing of tissue
219248686|NCT05871190|OTHER|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
219742466|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
219742467|NCT00280488|BEHAVIORAL|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
219742468|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
219742469|NCT04017455|DRUG|Atezolizumab|3 cycles of atezolizumab 840 mg
219742470|NCT04017455|DRUG|Bevacizumab|3 cycles of bevacizumab 5mg/kg
219248687|NCT05871190|PROCEDURE|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
219248688|NCT01315197|OTHER|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
219742471|NCT05145387|BEHAVIORAL|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
219742472|NCT04507581|OTHER|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
219742473|NCT06438003|BEHAVIORAL|Special Services|Community members will complete data collection at the extension office or community partner location. Extension cooking classes and helping to make raised bed gardens along with other area happenings will be offered to participants throughout the year with check-ins and reminders. Data will be collected from study participants (regardless of the intervention decided) , at two time points, to include survey, dietary recall, and carotenoid scanner.
219742474|NCT06438003|OTHER|Services as Usual|Community members will receive extension services as usual with Data collection on participants at two time points to assess changes in rates of food insecurity, dietary quality, and overall health conditions.
219742475|NCT06538012|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
219742476|NCT06538012|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
219742477|NCT06538012|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
219742478|NCT06538012|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
219742479|NCT06538012|DRUG|Pembrolizumab|Intravenous (IV) infusion
219742480|NCT05597397|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
219742481|NCT05720091|DRUG|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
219742482|NCT03682744|BIOLOGICAL|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
219742483|NCT04021368|DRUG|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
219742484|NCT06334146|OTHER|Tap dance program|Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
219742485|NCT04679987|DIAGNOSTIC_TEST|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
219742486|NCT02811614|PROCEDURE|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
219742487|NCT02811614|PROCEDURE|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
219742488|NCT02811614|PROCEDURE|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
219248689|NCT05585671|DRUG|Belimumab|Lupus patients without previous involvement of kidney are enrolled, and receive 2-year of 10mg/kg belimumab intravenously on the background of standard of care (SOC). During follow-up, we observe whether these patients will develop new-onset lupus nephritis.
219248690|NCT02164136|PROCEDURE|L-PANP-TME|
219248691|NCT02164136|PROCEDURE|O-PANP-TME|
219248692|NCT06225986|BEHAVIORAL|LMH-4-DCP|Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
219248693|NCT06225986|BEHAVIORAL|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
219248694|NCT06318130|DEVICE|Fixed helix, lumenless pacing lead.|Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.
219248695|NCT06318130|DEVICE|Extendable helix, stylet-driven pacing lead.|Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
219248696|NCT00634426|PROCEDURE|Surgical excision of the metastatic process|Surgical excision of the metastatic process
219248697|NCT00634426|RADIATION|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
219248698|NCT02274051|DIETARY_SUPPLEMENT|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
219248699|NCT00645320|DRUG|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
219248700|NCT00319878|DRUG|Sirolimus|"Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
219248701|NCT00319878|DRUG|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
219248702|NCT06516562|DRUG|Optimal treatment|Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
219248703|NCT04240418|OTHER|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
219248704|NCT02912104|BIOLOGICAL|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
219248705|NCT00183599|BEHAVIORAL|5 Minutes of Simple Advice|
219248706|NCT00183599|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
219248707|NCT00183599|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219248708|NCT04636463|PROCEDURE|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
219248709|NCT04196517|OTHER|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
219248710|NCT04196517|OTHER|WebMD|WebMD is a widely used educational platform for health information.
219248711|NCT03199456|DEVICE|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
219248712|NCT03199456|DEVICE|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
219248713|NCT00113009|DRUG|VLTS-934|
219248714|NCT00605384|DRUG|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
219248715|NCT00605384|DRUG|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
219248716|NCT03599440|OTHER|Pressure line extensions|"Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line"
219248717|NCT00730925|DRUG|BIBW2992|tablet BIBW high dose
219248718|NCT00730925|DRUG|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
219248719|NCT01827800|BEHAVIORAL|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
219248720|NCT05071378|BEHAVIORAL|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
219248721|NCT01249378|OTHER|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
219248722|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
219248723|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
219248724|NCT01942538|DEVICE|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
219248725|NCT01942538|DEVICE|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
219248726|NCT05128227|BEHAVIORAL|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
219248727|NCT05128227|BEHAVIORAL|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
219248728|NCT02467049|DEVICE|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
219248729|NCT02467049|DEVICE|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
219248730|NCT02592044|PROCEDURE|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
219248731|NCT02592044|PROCEDURE|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
219248732|NCT02592044|PROCEDURE|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
219248733|NCT04872842|OTHER|Obervation|This study is an observational study without any intervention
219248734|NCT04086576|DEVICE|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
219248735|NCT04086576|DEVICE|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
219248736|NCT04086576|DEVICE|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
219248737|NCT04086576|DEVICE|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
219248738|NCT04086576|DEVICE|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
219248739|NCT04086576|DEVICE|Floome|Floome branded smartphone-paired breathalyzer
219248740|NCT04086576|DEVICE|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
219248741|NCT00005908|DRUG|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
219248742|NCT00005908|DRUG|Anastrozole|1 mg orally daily for five years
219248743|NCT00005908|DRUG|cyclophosphamide|600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
219248744|NCT00005908|DRUG|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
219248745|NCT00005908|DRUG|Doxorubicin hydrochloride|60 mg/m\^2 will be administered as a slow intravenous push on day 1
219248746|NCT00005908|DRUG|Tamoxifen Citrate|20 mg/day orally for five years
219248747|NCT00005908|DRUG|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
219248748|NCT00005908|DRUG|Capecitabine - Dose A|capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
219248749|NCT04557332|BEHAVIORAL|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
219248750|NCT04260282|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
219248751|NCT04260282|DIAGNOSTIC_TEST|Induced sputum microbiome|Microbiome in induced sputum
219248752|NCT01938209|OTHER|seated thoracic manipulation|seated general thoracic spine manipulation
219248753|NCT01938209|OTHER|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
219248754|NCT04562571|OTHER|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
219248755|NCT00475787|PROCEDURE|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
219248756|NCT00475787|PROCEDURE|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
219248757|NCT03092323|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
219248758|NCT05983328|DRUG|HUYPS-1 one tablet|After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
219248759|NCT05983328|DRUG|HUYPS-1 nine tablets|After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
219248760|NCT04736602|DRUG|Triptorelin pamoate 15mg|Intramuscular injection (IM)
219248761|NCT00578929|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
219248762|NCT00578929|DRUG|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
219248763|NCT03253783|BEHAVIORAL|Pulse|
219248764|NCT01827202|OTHER|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
219248765|NCT01827202|DRUG|Aliskiren|
219248766|NCT01827202|DRUG|Candesartan|
219248767|NCT01651416|DRUG|Artemether-lumefantrine combination|
219248768|NCT01651416|DRUG|Dihydroartemisinin Piperaquine combination|
219248769|NCT01651416|DRUG|Amodiaquine plus sulphadoxine-pyrimethamine combination|
219248770|NCT04745819|BEHAVIORAL|1. The Child Behavior Checklist (CBCL), parent form|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
219248771|NCT04299971|DRUG|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
219248772|NCT04299971|DRUG|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
219248773|NCT01481701|DRUG|Oxaliplatin|85 mg/m² / 14days
219248774|NCT01481701|DRUG|oxaliplatin|oxaliplatin
219248775|NCT05063292|PROCEDURE|Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation|Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
219248776|NCT00053391|BIOLOGICAL|recombinant CD40-ligand|
219248777|NCT00053391|BIOLOGICAL|therapeutic autologous dendritic cells|
219248778|NCT02690025|DRUG|ZP1848|
219248779|NCT00072826|DRUG|Oxypurinol|
219248780|NCT00072826|DRUG|L-NMMA|
219248781|NCT00072826|DRUG|Acetylcholine|
219248782|NCT05987839|PROCEDURE|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
219248783|NCT00317135|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
219248784|NCT00317135|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
219248785|NCT05312190|DRUG|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
219248786|NCT05312190|DRUG|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
219248787|NCT02884336|OTHER|No intervention|
219248788|NCT01468025|DRUG|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
219248789|NCT01468025|OTHER|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
219248790|NCT01468025|DRUG|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
219248791|NCT00765921|DRUG|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
219248792|NCT03223714|DRUG|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
219248793|NCT03223714|DRUG|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
219248794|NCT00957671|DRUG|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
219248795|NCT05107999|DRUG|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
219248796|NCT05107999|DRUG|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
219248797|NCT03681171|OTHER|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
219248798|NCT06477887|BIOLOGICAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin"
219248799|NCT06477887|BIOLOGICAL|Autogenous Partially Demineralized Dentine Matrix|"The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft."
219248800|NCT04364022|DRUG|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
219248801|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
219248802|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
219248803|NCT00530049|OTHER|questionnaire administration|
219248804|NCT00530049|PROCEDURE|assessment of therapy complications|
219248805|NCT00530049|PROCEDURE|psychosocial assessment and care|
219248806|NCT00530049|PROCEDURE|quality-of-life assessment|
219248807|NCT04973332|DEVICE|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
219248808|NCT00206609|PROCEDURE|Oxygen and air administration|
219248809|NCT00666991|DRUG|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
219248810|NCT02131155|DRUG|Placebo|Once daily
219248811|NCT02131155|DRUG|Afatinib|Once daily
219248812|NCT00452985|DRUG|Docetaxel|60-75 mg/m²
219248813|NCT00452985|DRUG|Carboplatin|AUC 5
219248814|NCT04147091|OTHER|ApaCare & Repair|Initial cariuos lesions were treated.
219248815|NCT01887418|DRUG|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
219248816|NCT01887418|DRUG|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
219248817|NCT01887418|DRUG|Delatestryl 200 mg IM Treatment C|Standard of care
219248818|NCT04770740|DIETARY_SUPPLEMENT|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
219248819|NCT04770740|DIETARY_SUPPLEMENT|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
219248820|NCT04787718|OTHER|Almond|2.0 oz of raw, shelled, unsalted almonds
219248821|NCT04787718|OTHER|Control group|an isocaloric amount of unsalted pretzels
219248822|NCT02238691|PROCEDURE|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
219248823|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
219248824|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
219248825|NCT01248078|DRUG|saline solution|100cc administered before skin incision
219248826|NCT02584218|PROCEDURE|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
219248827|NCT02584218|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
219248828|NCT00475735|DRUG|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
219248829|NCT00475735|DRUG|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
219248830|NCT00475735|DRUG|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
219248831|NCT03132753|BEHAVIORAL|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
219248832|NCT00125853|DRUG|Nebivolol|Nebivolol 2.5mg daily
219248833|NCT00125853|DRUG|Atenolol|Atenolol 25mg daily
219248834|NCT03255785|DEVICE|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
219248835|NCT00369239|DRUG|risperidone long acting injectable|
219248836|NCT01614899|DRUG|SM-13496 40mg|once daily orally
219248837|NCT01614899|DRUG|SM-13496 80mg|once daily orally
219248838|NCT01614899|DRUG|Placebo|once daily orally
219248839|NCT01000415|OTHER|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
219248840|NCT02521428|OTHER|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
219248841|NCT03547648|PROCEDURE|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
219248842|NCT02525497|DEVICE|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
219248843|NCT02525497|DEVICE|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
219248844|NCT02097056|DRUG|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
219248845|NCT01050699|DRUG|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
219248846|NCT01050699|DRUG|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
219248847|NCT01446042|DRUG|Testosterone|Intranasal testosterone
219248848|NCT01446042|DRUG|Testosterone|Intranasal testosterone
219248849|NCT00719056|DRUG|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
219248850|NCT00719056|DRUG|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
219248851|NCT01829685|DRUG|Entecavir, Adefovir|
219248852|NCT01871597|DEVICE|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
219248853|NCT03999398|PROCEDURE|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
219248854|NCT01400217|DRUG|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
219248855|NCT01400217|DRUG|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
219248856|NCT03575572|DRUG|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
219248857|NCT06153901|PROCEDURE|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
219248858|NCT03127475|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
219248859|NCT00179478|DRUG|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
219248860|NCT02328209|DRUG|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
219248861|NCT00843245|OTHER|No intervention|No intervention
219248862|NCT04028128|DIETARY_SUPPLEMENT|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
219248863|NCT04028128|DIETARY_SUPPLEMENT|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
219248864|NCT05174988|PROCEDURE|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
219248865|NCT04869046|DRUG|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
219248866|NCT04203368|DRUG|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
219248867|NCT04203368|DRUG|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
219248868|NCT00557154|DEVICE|ultrasound|ultrasound used to identify target vein
219248869|NCT00557154|DEVICE|standard technique for venipuncture|routine equipment
219362800|NCT05812664|OTHER|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
219248870|NCT00157209|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
219248871|NCT00157209|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
219248872|NCT00157209|OTHER|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
219248873|NCT00725127|DRUG|aspirin|100 mg/day upon awakening for five years
219248874|NCT00725127|DRUG|aspirin|100 mg/day at bedtime for five years
219248875|NCT06645691|DRUG|Hyperpolarized 13C-pyruvate|Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner
219248876|NCT02618200|DEVICE|3D prostate ultrasound|
219248877|NCT04536779|OTHER|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
219248878|NCT02521025|OTHER|Intermittent feeding pattern|Intermittent feeding
219248879|NCT02521025|OTHER|Continuous feeding pattern|Continuous feeding
219248880|NCT01979757|OTHER|Puregraft|
219248881|NCT01979757|OTHER|Centrifugation|
219248882|NCT04167150|DIETARY_SUPPLEMENT|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
219248883|NCT04842227|PROCEDURE|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
219248884|NCT00946010|BIOLOGICAL|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
219248885|NCT00210288|BIOLOGICAL|SC599|
219248886|NCT05812547|DEVICE|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
219248887|NCT05812547|OTHER|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
219248888|NCT04161872|DRUG|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
219248889|NCT04161872|DRUG|Placebo|Placebo
219248890|NCT05834972|DEVICE|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
219248891|NCT06090318|DRUG|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
219248892|NCT06090318|DRUG|Atezolizumab|1680mg administered every 4 weeks
219248893|NCT04837235|DRUG|Hemay005|oral
219248894|NCT04818918|DEVICE|Absolute coronary flow measurement|Absolute coronary flow will be measured.
219248895|NCT04818918|DEVICE|Microvascular resistance measurement|Microvascular resistance will be measured.
219248896|NCT04818918|OTHER|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
219248897|NCT05148247|BEHAVIORAL|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
219248898|NCT01385683|DRUG|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
219248899|NCT01385683|DRUG|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
219248900|NCT00176761|DRUG|Interleukin-2 (IL-2)|
219248901|NCT03684434|BEHAVIORAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
219248902|NCT03684434|BEHAVIORAL|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
219248903|NCT02137928|DRUG|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
219248904|NCT02137928|DRUG|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
219248905|NCT05961488|OTHER|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
219248906|NCT05033158|OTHER|Blood sampling|Blood sampling before and after COVID-19 vaccination
219248907|NCT02200016|PROCEDURE|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
219248908|NCT02200016|PROCEDURE|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
219248909|NCT02200016|DEVICE|B Braun Contiplex S catheter|
219248910|NCT06032702|PROCEDURE|tooth alignment|Alignment will be assessed by Little's Irregularity Index
219248911|NCT00310050|DRUG|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
219248912|NCT00310050|DEVICE|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
219248913|NCT02943109|OTHER|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
219248914|NCT02943109|OTHER|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
219248915|NCT02943109|OTHER|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
219248916|NCT02943109|OTHER|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
219248917|NCT04893993|DRUG|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
219248918|NCT04893993|DRUG|Placebo|Tablets. Same number of tablets as Thiamine
219248919|NCT03244202|OTHER|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
219248920|NCT03244202|OTHER|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
219248921|NCT05848102|DRUG|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
219248922|NCT04422210|DRUG|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
219248923|NCT04422210|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
219248924|NCT04422210|DRUG|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
219248925|NCT04422210|DRUG|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
219248926|NCT03937596|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
219248927|NCT03937596|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
219248928|NCT03937596|DRUG|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
219248929|NCT02732899|DRUG|Sirolimus|
219248930|NCT02732899|DRUG|EYLEA|
219248931|NCT01953406|DRUG|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
219248932|NCT01953406|DRUG|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
219248933|NCT02233504|DRUG|Exjade® (deferasirox, ICL670)|
219248934|NCT03264599|DEVICE|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
219248935|NCT06270849|OTHER|Questionnaire|The questionnaire to assess severity of LUTS in women.
219248936|NCT03126721|DRUG|midazolam|a single oral dose of 2 mg midazolam
219248937|NCT03126721|DRUG|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
219248938|NCT00570804|BEHAVIORAL|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
219248939|NCT00570804|BEHAVIORAL|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
219248940|NCT00092209|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium|
219248941|NCT00092209|DRUG|Comparator: placebo, losartan, hydrochlorothiazide|
219248942|NCT04773054|DIAGNOSTIC_TEST|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
219248943|NCT04773054|DIAGNOSTIC_TEST|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
219248944|NCT04773054|OTHER|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
219248945|NCT04773054|OTHER|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
219248946|NCT04773054|OTHER|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
219248947|NCT06381219|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE
219248948|NCT06381219|OTHER|Implementation of hen's egg in decreasingly heated forms|Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
219248949|NCT04647409|OTHER|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
219248950|NCT03023878|DRUG|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
219248951|NCT03023878|DRUG|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
219248952|NCT03023878|DRUG|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
219248953|NCT01198899|OTHER|blood sampling|Blood sampling will be used.
219248954|NCT04478799|DEVICE|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
219248955|NCT04478799|DEVICE|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
219248956|NCT04382183|BEHAVIORAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
219248957|NCT04382183|BEHAVIORAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
219248958|NCT05115136|DRUG|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
219248959|NCT05115136|DRUG|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
219248960|NCT04063345|PROCEDURE|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
219248961|NCT04063345|PROCEDURE|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
219248962|NCT06296797|BEHAVIORAL|Control arm: Existing educational website|Information about tubal sterilization currently provided on the Planned Parenthood website
219248963|NCT06296797|BEHAVIORAL|Advancing Access Website|A website comparing tubal sterilization to long-acting reversible contraceptives informed by recent patient centered outcomes research.
219248964|NCT04064840|DRUG|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
219248965|NCT04064840|DRUG|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
219248966|NCT04064840|DRUG|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
219248967|NCT04064840|DRUG|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
219248968|NCT05452005|DRUG|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
219248969|NCT05118308|PROCEDURE|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
219248970|NCT05118308|PROCEDURE|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
219248971|NCT06552897|PROCEDURE|Intervention 1: Adductor Canal Block (ACB)|"For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization."
219248972|NCT06552897|PROCEDURE|Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)|"Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption."
219248973|NCT00586807|OTHER|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
219248974|NCT01248143|DIETARY_SUPPLEMENT|Green tea|9 gram per day
219248975|NCT01248143|DIETARY_SUPPLEMENT|FPP|2 sachets twice daily
219248976|NCT04679597|DRUG|Capecitabine|comparison of two treatments
219248977|NCT06648707|OTHER|Dual-task training|Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.
219248978|NCT00649142|PROCEDURE|Open sutured mesh repair|Open sutured mesh repair
219248979|NCT00649142|PROCEDURE|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
219248980|NCT01247922|DRUG|Erlotinib|continuous oral Erlotinib 85 mg/m\^2 per day
219248981|NCT04281875|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
219248982|NCT06645106|DEVICE|Rapid Point of Care (POC) Syphilis testing|Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
219248983|NCT04788472|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
219248984|NCT02570815|DRUG|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
219248985|NCT04506359|OTHER|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
219248986|NCT00006578|DRUG|Ritonavir|
219248987|NCT00006578|DRUG|Abacavir sulfate|
219248988|NCT00006578|DRUG|Amprenavir|
219248989|NCT00006578|DRUG|Lamivudine|
219248990|NCT00006578|DRUG|Filgrastim|
219248991|NCT06545045|BEHAVIORAL|Metacognitive Strategy Training (MCST)|The MCST group will follow procedures for the Cognitive Orientation to daily Occupational Performance intervention. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, the therapist introduces the approach to the subject and teach a global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition. The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
219248992|NCT06545045|BEHAVIORAL|Inactive Control Group|Weekly contact will be made via telephone call to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce cognitive symptoms. The content of each of these meetings will be tracked in intervention notes.
219248993|NCT05174871|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
219248994|NCT05174871|BEHAVIORAL|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
219248995|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
219248996|NCT00577096|BEHAVIORAL|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
219248997|NCT00577096|BIOLOGICAL|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
219248998|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
219248999|NCT00577096|DRUG|Thalidomide|Fifty percent of the participants received 400 mg daily
219249000|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
219249001|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
219249002|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
219249003|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
219249004|NCT00577096|DRUG|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
219249005|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
219249006|NCT00577096|DRUG|Thalidomide|Fifty percent of participants received 400 mg daily
219249007|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
219249008|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
219249009|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
219249010|NCT02290197|PROCEDURE|Surgery|Surgical reconstruction of all injured ligaments.
219249011|NCT02290197|DEVICE|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
219249012|NCT02290197|DEVICE|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
219249013|NCT01956955|DRUG|enoxaparin ,alteplase, unfractionated heparin|
219249014|NCT05359705|DEVICE|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
219249015|NCT05359705|DEVICE|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
219249016|NCT05359705|DEVICE|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
219249017|NCT05359705|DEVICE|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
219249018|NCT01537263|DEVICE|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
219249019|NCT01849185|OTHER|Food supplement|
219249020|NCT04031534|DRUG|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
219249021|NCT03909334|DRUG|Osimertinib|Osimertinib 80 mg orally on Day 1
219249022|NCT03909334|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
219249023|NCT02518659|DIETARY_SUPPLEMENT|Inulin|This is the Intervention
219249024|NCT06360445|DRUG|Olaparib Tablet test formulation 100mg|A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.
219249025|NCT06360445|DRUG|Olaparib Tablet reference formulation 100mg|Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
219249026|NCT06360445|DRUG|Olaparib Tablet test formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
219249027|NCT06360445|DRUG|Olaparib Tablet reference formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
219249028|NCT05778799|OTHER|Balance test|10 second left- or right-leg stance with eyes open, and single 10 second left- or right-leg stance with eyes closed
219249029|NCT05185739|DRUG|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
219249030|NCT05185739|DRUG|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks
219249031|NCT05185739|DRUG|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
219249032|NCT05616312|BEHAVIORAL|Educational Teach Back|Patients will receive teach-back education while they fill out questionnaires.
219249033|NCT06584773|DRUG|Everolimus|mTORi added as the fourth maintenance immunosuppressive drug in recipients
219249034|NCT06584773|DRUG|standard maintenance immunosuppression|standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
219249035|NCT06584669|DIETARY_SUPPLEMENT|Krill oil|The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
219249036|NCT06584669|OTHER|Placebo|The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
219249037|NCT06584565|OTHER|microbiome; metabolomics; proteomics|post-stroke change of microbiome; metabolomics; proteomics
219249038|NCT03771378|DRUG|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
219249039|NCT03771378|DRUG|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
219249040|NCT02383121|DRUG|Midodrine|Not appliciable
219249041|NCT06385418|DRUG|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
219249042|NCT05028647|DEVICE|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
219249043|NCT05028647|DEVICE|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
219249044|NCT01370564|DRUG|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
219249045|NCT03143634|BEHAVIORAL|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
219249046|NCT03143634|BEHAVIORAL|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
219249047|NCT06390124|DRUG|Platelet Derived Growth Factor (PDGF)|Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
219249048|NCT01142154|DRUG|Prodarsan|Prodarsan TID, oral solution, 6-8 days
219249049|NCT02637466|DRUG|Vortioxetine|
219249050|NCT05967793|OTHER|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
219249051|NCT01595724|DRUG|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
219249052|NCT05774418|BIOLOGICAL|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
219249053|NCT02990299|BEHAVIORAL|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
219249054|NCT02181400|DEVICE|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
219249055|NCT01540877|PROCEDURE|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
219249056|NCT01540877|PROCEDURE|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
219249057|NCT01540877|PROCEDURE|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
219249058|NCT01540877|PROCEDURE|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
219249059|NCT00511459|DRUG|AMG 386 Placebo|AMG 386 Placebo \[blinded\]
219249060|NCT00511459|DRUG|AMG 386|AMG 386 3mg/kg IV QW \[blinded\]
219249061|NCT00511459|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
219249062|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[Open-Label\]
219249063|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[blinded\]
219249064|NCT00511459|DRUG|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
219249065|NCT04310800|PROCEDURE|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
219249066|NCT01626677|BIOLOGICAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
219249067|NCT01626677|PROCEDURE|Microfracture|Active control
219249068|NCT00719277|DEVICE|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
219249069|NCT06288347|DEVICE|GGON mobile app.|The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
219249070|NCT05621720|OTHER|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
219249071|NCT05621720|OTHER|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
219249072|NCT05899868|DEVICE|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
219249073|NCT06577376|DRUG|DP303c|DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
219176122|NCT06487741|OTHER|Home-based stretching exercises|The intervention comprises six weeks of daily static stretching exercises (six minutes a day) in accordance with the recommendation of the American College of Sports Medicine. The intervention is self-administered and consists of two bouts of 30-second bilateral static stretches of the knee flexors, hip abductors, and shoulder elevators.
219176123|NCT03337971|DIETARY_SUPPLEMENT|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
219176124|NCT03337971|DIETARY_SUPPLEMENT|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
219176125|NCT06364514|OTHER|Clinical Stability Assessment|Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
219176126|NCT06087471|DIETARY_SUPPLEMENT|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
219176127|NCT06087471|DIETARY_SUPPLEMENT|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
219176128|NCT06836778|DRUG|Carvedilol Tablets|Non-selective beta blocker (Carvedilol 3.125 mg BD for 3 days followed by 6.25 mg BD , maximum dose would be 12.5 mg BD , same shall be switch to maximum tolerable dose if Systolic BP\< 90 , H,R\<55)
219176129|NCT06836778|PROCEDURE|Endoscopic Variceal Ligation|EVL every 3 weeks till eradication of varices followed by every 3 months.
219176130|NCT06387108|OTHER|training course|Two-hour online training course for educational professionals at schools on depression and mental health in children and adolescents (including symptoms, causes, comorbidity, prevention) and practical tips for everyday school life to reduce stress.
219176131|NCT04278157|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
219249074|NCT06577376|DRUG|Simmitinib tablets|A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
219249075|NCT06577376|DRUG|Irinotecan liposomes|A chemotherapy
219249076|NCT06577376|DRUG|Paclitaxel or docetaxel or irinotecan|Paclitaxel or docetaxel or irinotecan is used as a control.
219249077|NCT06574503|DRUG|GP681 40mg|2X20mg tablets taken orally
219249078|NCT06574503|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
219249079|NCT03749538|OTHER|Transcranial direct current stimulation session.|Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
219249080|NCT03806218|DEVICE|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
219249081|NCT03806218|DEVICE|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
219249082|NCT03806218|DEVICE|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
219249083|NCT03806218|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
219249084|NCT06182800|DRUG|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
219249085|NCT00985621|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
219249086|NCT00985621|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
219249087|NCT00985621|DRUG|oxycodone|oxycodone CR, 10-40 mg q12h
219249088|NCT00985621|OTHER|placebo|placebo
219249089|NCT04153851|PROCEDURE|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
219249090|NCT01911819|PROCEDURE|Sinus augmentation|
219249091|NCT01911819|DRUG|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
219249092|NCT01911819|DRUG|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
219249093|NCT01911819|DRUG|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
219249094|NCT04008004|DRUG|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
219249095|NCT04008004|DRUG|Placebo|Placebo to match EDP-514
219249096|NCT01116700|DRUG|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
219249097|NCT03903185|DRUG|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
219249098|NCT05563961|DRUG|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
219249099|NCT05563961|DRUG|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
219249100|NCT05619991|OTHER|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
219249101|NCT05619991|OTHER|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
219249102|NCT03849300|OTHER|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
219249103|NCT03849300|OTHER|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
219249104|NCT03849300|OTHER|Land-based walking exercise group|12 week land-based walking exercise program
219249105|NCT05830422|OTHER|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
219249106|NCT00120952|DEVICE|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
219249107|NCT03529006|PROCEDURE|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
219249108|NCT03529006|PROCEDURE|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
219249109|NCT06212180|DEVICE|mask|patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation
219249110|NCT00874393|DRUG|Dopamine|Dopamine
219249111|NCT00874393|DRUG|Hydrocortisone|Hydrocortisone
219249112|NCT00874393|DRUG|Infusion Placebo|Dextrose (D5W)
219249113|NCT00874393|DRUG|Syringe Placebo|Normal saline
219249114|NCT05602961|DRUG|GLB-COV2-043|COVID-19 vaccine, administered as a booster
219249115|NCT05602961|DRUG|BNT162b2/COMIRNATY®|active control
219249116|NCT06450275|DRUG|Dolutegravir 50 MG Film Coated Tablet|1 tablet of Dolutegravir 50mg film-coated tablets
219249117|NCT06450275|DRUG|Tivicay 50mg, film-coated tablets|1 tablet of Dolutegravir 50mg film-coated tablets
219249118|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
219249119|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
219176132|NCT04278157|BEHAVIORAL|Treatment as Usual|Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
219249120|NCT00464737|OTHER|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
219249121|NCT02033668|DRUG|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
219249122|NCT02033668|DRUG|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
219249123|NCT02033668|DRUG|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
219249124|NCT02814279|PROCEDURE|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
219249125|NCT02814279|PROCEDURE|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
219249126|NCT02814279|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
219249127|NCT02814279|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
219249128|NCT00676663|DRUG|entinostat|Entinostat 5 mg tablet orally once per week
219249129|NCT00676663|DRUG|exemestane|Exemestane 25 mg tablet orally once daily
219249130|NCT00676663|DRUG|Placebo|Placebo-matching entinostat tablet orally once per week
219249131|NCT06190145|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
219249132|NCT05434533|DRUG|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
219249133|NCT00587899|PROCEDURE|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
219362801|NCT05812664|PROCEDURE|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
219176133|NCT06783153|DRUG|Rifaximin 550 MG|Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
219176134|NCT06783153|DRUG|Standard Care Chemoradiation|Patients will receive standard chemotherapy and/or radiation
219176135|NCT06778785|BEHAVIORAL|Digital Intervention|game-based digital intervention app
219176136|NCT06778785|BEHAVIORAL|Health Education|traditional health education app
219249134|NCT06185699|DIAGNOSTIC_TEST|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
219249135|NCT00023465|PROCEDURE|FDG-PET|
219249136|NCT00023465|PROCEDURE|spirometry|
219176137|NCT06778785|OTHER|Personalization Algorithm|a proprietary algorithm that adaptively adjust the treatment module and parameters to personalize the treatment regime
219176138|NCT05547347|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219176139|NCT05547347|PROCEDURE|Mammogram|Undergo a mammogram
219176140|NCT05547347|PROCEDURE|Ultrasound|Undergo a breast ultrasound
219176141|NCT05547347|PROCEDURE|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
219176142|NCT05547347|DEVICE|Twinkle marker|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
219176143|NCT03436290|BEHAVIORAL|Palliative Care Intervention|These patients will receive the palliative care intervention.
219176144|NCT06833021|OTHER|Transcriptomic Analysis|FFPE tissue blocks from patients diagnosed with CAC, including low- and high-grade dysplasia and adenocarcinoma, obtained from pathological archives will be used. RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results.
219176145|NCT06833021|OTHER|Transcriptomic Analysis|RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results. FFPE tissue blocks from CRC, diverticulitis, IC and CD without cancer patients will be utilized as controls.
219249137|NCT00023465|PROCEDURE|bronchoscopy with BAL|
219249138|NCT00354809|DRUG|GW679769|
219249139|NCT05842278|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219249140|NCT05842278|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219249141|NCT05842278|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219249142|NCT05842278|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
219249143|NCT05842278|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
219249144|NCT04117334|OTHER|Bracing|
219249145|NCT03814278|BEHAVIORAL|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
219249146|NCT03814278|BEHAVIORAL|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
219249147|NCT01249976|OTHER|blood culture|blood culture
219249148|NCT03721900|DRUG|SHX-001 Active low dose|ketamine transdermal patch
219249149|NCT03721900|DRUG|Placebo|transdermal patch
219249150|NCT03721900|DRUG|SHX-001 Active High dose|ketamine transdermal patch
219249151|NCT04357587|DRUG|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
219249152|NCT04357587|RADIATION|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
219249153|NCT04357587|DRUG|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
219249154|NCT02135588|DRUG|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
219249155|NCT02674555|DRUG|radio-labeled naquotinib|Oral administration
219249156|NCT02674555|DRUG|naquotinib|Oral administration
219249157|NCT01707498|PROCEDURE|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
219249158|NCT01707498|PROCEDURE|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
219249159|NCT02848586|OTHER|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
219249160|NCT02848586|BEHAVIORAL|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
219249161|NCT02848586|OTHER|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
219249162|NCT05665348|DRUG|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
219249163|NCT05665348|DRUG|Atezolizumab Injection|One of the standard treatment's product for HCC management
219249164|NCT05665348|DRUG|Bevacizumab|One of the standard treatment's product for HCC management
219249165|NCT05143580|BEHAVIORAL|Cognitive therapy|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
219249166|NCT05143580|BEHAVIORAL|Routine care|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
219249167|NCT01153997|DRUG|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
219249168|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
219249169|NCT01153997|DRUG|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
219176146|NCT05601752|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
219176147|NCT05601752|COMBINATION_PRODUCT|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
219176148|NCT05214092|BEHAVIORAL|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
219176149|NCT05516147|BEHAVIORAL|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
219176150|NCT03868592|PROCEDURE|Gastric sleeve/bariatric surgery|weight loss
219176151|NCT01728857|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219176152|NCT05027503|OTHER|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
219176153|NCT05027503|OTHER|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
219176154|NCT04947020|DRUG|Metformin|Metformin use before operation due to previously diagnosed diabetes.
219176155|NCT04497220|BEHAVIORAL|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
219249170|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
219176156|NCT04497220|BEHAVIORAL|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
219176157|NCT06561854|DRUG|Dexamethasone|"ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)"
219176158|NCT04383119|DRUG|Trabectedin|Trabectedin in monotherapy
219176159|NCT04383119|DRUG|Gemcitabine|Gemcitabine, control arm
219176160|NCT04383119|DRUG|No Intervention: Observational Cohort|Treatment according clinical practice
219176161|NCT06209801|BEHAVIORAL|Mirror therapy|60 seconds of intervention
219176162|NCT06209801|DEVICE|Neuromuscular electrical stimulation|60 seconds of intervention
219176163|NCT06209801|BEHAVIORAL|Motor imagery|60 seconds of intervention
219176164|NCT06227832|DRUG|KP-001|KP-001
219176165|NCT06227832|DRUG|Metformin|oral dose of 850 mg Metformin
219176166|NCT06227832|DRUG|Midazolam|oral dose of 2 mg Midazolam
219176167|NCT06227832|DRUG|Clarithromycin|oral doses of 1000 mg Clarithromycin
219176168|NCT05386758|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
219176169|NCT02984852|DRUG|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
219176170|NCT02984852|DRUG|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
219176171|NCT02984852|DRUG|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
219176172|NCT02984852|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
219176173|NCT06442631|BEHAVIORAL|MyStroke|MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
219176174|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 1)|Single dose of AZD3152 300 mg IM on Visit 2 Day 1
219176175|NCT05932641|BIOLOGICAL|Placebo (Cohort 1)|Single dose of Placebo IM on Visit 2 Day 1
219176176|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 2)|Single dose of AZD3152 600 mg IM on Visit 2 Day 1
219176177|NCT05932641|BIOLOGICAL|Placebo (Cohort 2)|Single dose of Placebo IM on Visit 2 Day 1
219176178|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 3)|Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
219176179|NCT05932641|BIOLOGICAL|Placebo (Cohort 3)|Single dose of Placebo IM on Visit 2 Day 1
219176180|NCT03432936|DEVICE|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
219176181|NCT04952909|DEVICE|ShortCut™|Splitting bioprosthetic aortic valve leaflets
219176182|NCT05634954|DRUG|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
219249171|NCT02397902|DIETARY_SUPPLEMENT|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
219249172|NCT02397902|DIETARY_SUPPLEMENT|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
219249173|NCT03945409|DEVICE|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
219249174|NCT01399905|DRUG|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
219249175|NCT00243568|DRUG|Vicriviroc|
219249176|NCT01898026|DIETARY_SUPPLEMENT|Bread|Samples of white bread, with or without the addition of PGX fibre blend
219249177|NCT01898026|DIETARY_SUPPLEMENT|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
219249178|NCT01898026|DIETARY_SUPPLEMENT|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
219249179|NCT01898026|DIETARY_SUPPLEMENT|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
219249180|NCT05512988|BIOLOGICAL|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person."
219742489|NCT06124924|DRUG|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
219743626|NCT06644794|DRUG|Hormone replacement therapy cycle preparation for frozen embryo transfer|A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
219743627|NCT04606290|DEVICE|O2matic HOT|Automated oxygen titration with O2matic HOT
219743628|NCT04606290|DEVICE|Oxygen concentrator|Fixed dose oxygen flow from concentrator
219743629|NCT06641167|PROCEDURE|Shoulder surgery|shoulder surgery by arthroscopic approach under locoregional anesthesia combining an interscalene block and a superficial cervical plexus block
219743630|NCT06642857|OTHER|Peripheral blood, tougue coating, saliva, and feces|Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
219743631|NCT06641206|DRUG|Triamcinolone Acetonide|1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
219743632|NCT06641206|DRUG|Bupivacaine Hydrochloride|20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
219743633|NCT06641206|DRUG|Dexmedetomidine|Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
219743634|NCT06636799|DEVICE|Microneedling only|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
219743635|NCT06636799|OTHER|Microneedling and actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
219743636|NCT06638047|PROCEDURE|robotic-assisted TKA|Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.
219743637|NCT06638047|PROCEDURE|CI-TKA|TKA operated with conventional instruments
219743638|NCT05014126|BEHAVIORAL|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
219743639|NCT06645067|BEHAVIORAL|Measuring energy balance|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA."
219743640|NCT06643520|DEVICE|19-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
219176183|NCT05634954|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
219176184|NCT05634954|DIAGNOSTIC_TEST|Static - PET/CT Scan|Group 2: Static whole-body scans
219176185|NCT06439147|PROCEDURE|U shaped capsular incision during capsulorrhaphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
219176186|NCT06439147|PROCEDURE|T-shaped capsular incision diuring capsulorraphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
219176187|NCT05886816|DRUG|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
219176188|NCT05886816|OTHER|Placebo|Placebo pills
219176189|NCT04191460|DRUG|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
219176190|NCT06315374|OTHER|Use soft mist inhaler|Only use soft mist inhaler
219176191|NCT06315374|DEVICE|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
219176192|NCT04898595|PROCEDURE|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
219176193|NCT03972930|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
219176194|NCT06355778|OTHER|Magnetic Resonance Imaging (MRI)|Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
219176195|NCT06355778|BEHAVIORAL|Computer Tasks|Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
219176196|NCT06266689|BEHAVIORAL|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
219176197|NCT02515773|DRUG|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
219176198|NCT02515773|BEHAVIORAL|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
219176199|NCT05391971|DRUG|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
219176200|NCT05391971|DRUG|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
219176201|NCT05280652|BEHAVIORAL|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
219176202|NCT05280652|BEHAVIORAL|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
219176203|NCT03836248|OTHER|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
219176204|NCT03836248|OTHER|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
219176205|NCT03836248|OTHER|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
219249181|NCT05512988|BIOLOGICAL|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
219249182|NCT03247985|DEVICE|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
219249183|NCT03247985|DEVICE|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
219249184|NCT00703365|DRUG|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
219249185|NCT05530434|OTHER|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
219249186|NCT05530434|OTHER|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
219249187|NCT01668992|BEHAVIORAL|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
219249188|NCT03063983|DRUG|Cyclophosphamide|Continuous oral cyclophosphamide
219249189|NCT03063983|DRUG|Methotrexate|Continuous oral methotrexate
219249190|NCT03074968|DRUG|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
219249191|NCT03074968|DRUG|Normal saline|normal saline application
219249192|NCT05588661|OTHER|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
219249193|NCT05588661|OTHER|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
219249194|NCT03750175|OTHER|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
219249195|NCT00104845|BIOLOGICAL|human gp100 plasmid DNA vaccine|
219249196|NCT00104845|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
219249197|NCT01245699|BEHAVIORAL|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
219249198|NCT05464199|OTHER|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
219249199|NCT04685434|OTHER|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
219249200|NCT04091945|DRUG|LT3001 Drug Product|Active comparator
219249201|NCT04091945|DRUG|Placebo|Placebo comparator
219249202|NCT01549171|DRUG|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
219249203|NCT01549171|OTHER|normal saline|Supplement with vehicle only no Iloprost.
219249204|NCT00672100|DRUG|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
219249205|NCT00672100|DRUG|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
219249206|NCT00672100|DRUG|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
219249207|NCT04640376|DRUG|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
219249208|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
219249209|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
219249210|NCT04640376|DRUG|Placebo|Dummy treatment
219249211|NCT03734172|DIAGNOSTIC_TEST|Sample collection|Specimen collection
219249212|NCT05406206|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
219249213|NCT05406206|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
219249214|NCT05534451|BEHAVIORAL|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
219249215|NCT05534451|BEHAVIORAL|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
219249216|NCT05534451|BEHAVIORAL|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
219249217|NCT05513222|PROCEDURE|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
219249218|NCT03038152|PROCEDURE|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
219249219|NCT03038152|PROCEDURE|Localization|Undergo axillary lymph node localization
219249220|NCT03038152|DEVICE|Medical Device|Receive Magseed via ultrasound guided injection
219249221|NCT05611476|BEHAVIORAL|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
219249222|NCT04892004|BEHAVIORAL|Symptom recognition|The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
219249223|NCT00401791|BEHAVIORAL|Exercise|"* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
219249224|NCT01436045|DRUG|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
219249225|NCT01436045|DRUG|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
219742490|NCT05581511|OTHER|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
219742491|NCT06640153|DIAGNOSTIC_TEST|mpMRI|Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
219249226|NCT00925288|BIOLOGICAL|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
219742492|NCT02988076|DEVICE|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
219249227|NCT04701970|PROCEDURE|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
219249228|NCT02847819|DEVICE|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
219249229|NCT00518583|DRUG|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
219249230|NCT03465085|DRUG|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
219249231|NCT03465085|DRUG|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
219249232|NCT02862652|OTHER|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
219249233|NCT00074178|BIOLOGICAL|filgrastim|
219249234|NCT00074178|BIOLOGICAL|pegfilgrastim|
219249235|NCT00074178|DRUG|cyclophosphamide|
219249236|NCT00074178|DRUG|cytarabine|
219249237|NCT00074178|DRUG|dexamethasone|
219249238|NCT00074178|DRUG|etoposide phosphate|
219249239|NCT00074178|DRUG|methotrexate|
219742493|NCT06402487|DIETARY_SUPPLEMENT|Propionic acid 1000 mg capsule|Patients will be assigned to propionic acid or placebo as add on MS treatment.
219742494|NCT06402487|DIETARY_SUPPLEMENT|Placebo|Patients will be assigned to propionic acid or placebo as add on MS treatment.
219742495|NCT02168699|OTHER|Ultrasound examination of the axilla|
219742496|NCT02686775|BEHAVIORAL|Patient coach|
219742497|NCT02686775|BEHAVIORAL|Standard care|
219742498|NCT06160167|DRUG|IMiD treatment|Participants with MM treated with IMiDs
219742499|NCT06160167|DRUG|No IMiD treatment|Participants with MM not treated with IMiDs
219742500|NCT06160167|DRUG|Systemic therapy|Participants with MM treated with systemic therapy
219742501|NCT06813378|BEHAVIORAL|(Neuro)Cognitive Remediation|(Neuro)Cognitive remediation is an intervention for people experiencing cognitive impairments that interfere with their daily functioning. Attention, memory, abstract reasoning, and processing speed are all examples of cognitive skills. By focusing on improving these underlying skills, the overall aim of cognitive remediation is to improve the client's daily satisfaction and success. Although cognitive remediation programs and strategies have been studied with other populations, it has not been sufficiently evaluated from a mental health trans-diagnostic perspective for military Veterans and police officers and retirees who this research will study.
219742502|NCT05633927|BIOLOGICAL|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
219742503|NCT00431379|DRUG|Tenecteplase|
219742504|NCT00297791|PROCEDURE|surgery|randomized to open or laparoscopic technique
219742505|NCT03850067|DRUG|CC-90011|CC-90011
219742506|NCT03850067|DRUG|Cisplatin|Cisplatin
219742507|NCT03850067|DRUG|Carboplatin|Carboplatin
219742508|NCT03850067|DRUG|Etoposide|Etoposide
219742509|NCT03850067|DRUG|Nivolumab|Nivolumab
219742510|NCT06274177|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
219742511|NCT00817609|DRUG|Angongniuhuang Pill|7 days of Angongniuhuang Pill
219742512|NCT00817609|DRUG|placebo|7 days of placebo
219742513|NCT04129398|DRUG|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
219742514|NCT04129398|DRUG|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
219742515|NCT05388487|DRUG|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
219742516|NCT05388487|DRUG|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
219742517|NCT05388487|DRUG|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
219742518|NCT05388487|DRUG|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
219742519|NCT05388487|DRUG|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
219742520|NCT00198900|BEHAVIORAL|survey of information|
219742521|NCT05711797|DRUG|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
219742522|NCT02376010|DRUG|rivaroxaban|
219742523|NCT02376010|DRUG|Warfarin|
219742524|NCT02256748|DRUG|BIRT 2584 XX|
219742525|NCT02256748|DRUG|Midazolam|
219742526|NCT01428635|DRUG|Eltrombopag Olamine|Given PO
219742527|NCT00590317|DRUG|Prochlorperazine|Patients receiving Prochlorperazine
219742528|NCT00590317|DRUG|Ondansetron|Patients receiving Ondansetron
219742529|NCT04473196|OTHER|weightbearing|immediate weightbearing
219742530|NCT01639690|GENETIC|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
219742531|NCT05615883|OTHER|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
219742532|NCT05615883|OTHER|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
219742533|NCT05186233|BEHAVIORAL|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
219742534|NCT04732806|BEHAVIORAL|Mightier video games|Biofeedback video game play in home
219742535|NCT06157983|OTHER|measurement of lipoprotein(a)|Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
219742536|NCT02363283|DRUG|Glembatumumab Vedotin|Given IV
219742537|NCT02363283|OTHER|Laboratory Biomarker Analysis|Correlative studies
219742538|NCT02363283|OTHER|Pharmacological Study|Correlative studies
219742539|NCT01965951|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
219742540|NCT01965951|OTHER|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
219249240|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
219249241|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
219249242|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
219249243|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
219249244|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
219742541|NCT02117271|DEVICE|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
219742542|NCT02117271|OTHER|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
219742543|NCT04850963|DEVICE|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
219249245|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
219742544|NCT04850963|DEVICE|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
219742545|NCT04850963|DEVICE|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
219742546|NCT00461890|DRUG|Injectable Naltrexone|
219742547|NCT04883203|DRUG|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
219742548|NCT04883203|DRUG|Physiological Irrigating Solution|ARM 2 : placebo
219742549|NCT04279769|DRUG|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
219742550|NCT04279769|DRUG|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
219742551|NCT03743519|DIETARY_SUPPLEMENT|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
219742552|NCT03743519|DIETARY_SUPPLEMENT|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
219742553|NCT02895984|BEHAVIORAL|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
219742554|NCT03362632|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
219742555|NCT04622267|DEVICE|Barbed suture|to close a C-section incision
219742556|NCT04622267|PROCEDURE|Standard antimicrobial suture|to close a C-section incision
219742557|NCT06571604|DIAGNOSTIC_TEST|Dislocation|One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
219742558|NCT06571604|DIAGNOSTIC_TEST|No dislocation|No experience of dislocation within two years post-surgery
219742559|NCT06570876|PROCEDURE|Surgery|The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
219742560|NCT06569225|DRUG|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
219742561|NCT06570226|DIETARY_SUPPLEMENT|hibiscus tea|Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
219742562|NCT06569732|OTHER|Homemade oral nutrition supplements|The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
219742563|NCT06569732|OTHER|Commercial oral nutrition supplements|The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
219742564|NCT06565676|DIETARY_SUPPLEMENT|Bread with whey protein powder added|Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
219742565|NCT06230913|DEVICE|Kinesiotape|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
219742566|NCT06230913|DEVICE|Pressure garment|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
219742567|NCT02174237|DRUG|LNP1892|Tablets of two strengths (5 and 25 mg)
219742568|NCT02174237|DRUG|Placebo|Matching placebo
219742569|NCT03829514|DRUG|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
219742570|NCT04174482|PROCEDURE|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
219742571|NCT01339091|DRUG|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
219742572|NCT01339091|DRUG|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
219742573|NCT00661180|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
219742574|NCT03923088|BEHAVIORAL|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
219742575|NCT03923088|BEHAVIORAL|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
219742576|NCT00844220|PROCEDURE|CT/MR|CT/MRI-directed clinical management strategy
219742577|NCT00844220|PROCEDURE|Catheterization|Standard clinical management directed by conventional coronary angiography
219742578|NCT02788292|DRUG|Acetylcysteine|See arm description
219742579|NCT03607110|DRUG|Ketamine|sedation drugs
219742580|NCT03607110|DRUG|fentanyl|sedation drugs
219742581|NCT03607110|DEVICE|patient control analgesia|patient control analgesia
219742582|NCT05051410|PROCEDURE|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
219742583|NCT05646173|DEVICE|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
219742584|NCT05646173|DEVICE|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
219742585|NCT05646173|OTHER|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
219742586|NCT01775345|PROCEDURE|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
219742587|NCT01775345|PROCEDURE|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
219742588|NCT01775345|PROCEDURE|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
219742589|NCT01775345|PROCEDURE|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
219742590|NCT04414943|DRUG|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
219742591|NCT04414943|DRUG|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
219742592|NCT02779231|OTHER|Bi-directional texting|
219742593|NCT05273736|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
219742594|NCT02593630|DEVICE|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
219742595|NCT00625105|BEHAVIORAL|Biofeedback|
219742596|NCT01321684|OTHER|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
219742597|NCT01321684|OTHER|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
219742598|NCT04437745|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
219742599|NCT00003907|DRUG|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
219742600|NCT00003907|DRUG|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
219742601|NCT00003907|DRUG|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
219742602|NCT00003907|PROCEDURE|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
219742603|NCT04520230|DRUG|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
219742604|NCT04520230|DRUG|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
219742605|NCT04520230|DRUG|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
219742606|NCT01517178|DEVICE|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
219742607|NCT01517178|DEVICE|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
219742608|NCT06502028|DEVICE|Video laryngeal mask airway|The airway is secured with a video laryngeal mask airway.
219742609|NCT06502028|DEVICE|Endotracheal tube|The participant is intubated with an endotracheal tube via direct laryngoscopy.
219742610|NCT05249855|BEHAVIORAL|Psychological measurement|Psychological assessment
219742611|NCT02553473|DRUG|Doxycycline|
219742612|NCT02553473|DRUG|Placebo|
219742613|NCT05663554|BEHAVIORAL|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
219742614|NCT05663554|OTHER|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
219742615|NCT04245605|PROCEDURE|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
219742616|NCT03895476|DIAGNOSTIC_TEST|palatal wound will be cover with collagen and sutures|after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
219249246|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
219249247|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
219249248|NCT00123435|DEVICE|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
219249249|NCT05572385|BEHAVIORAL|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
219249250|NCT03000647|PROCEDURE|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
219249251|NCT03000647|PROCEDURE|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
219249252|NCT05672498|DRUG|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
219249253|NCT05672498|OTHER|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
219249254|NCT01314898|DRUG|3 mg PF-03882845|3 mg PF-03882845, single oral dose
219249255|NCT01314898|DRUG|10 mg PF-03882845|10 mg PF-03882845, single oral dose
219249256|NCT01314898|DRUG|30 mg PF-03882845|30 mg PF-03882845, single oral dose
219249257|NCT01314898|DRUG|100 mg PF-03882845|100 mg PF-03882845, single oral dose
219249258|NCT01314898|DRUG|Spironolactone|100 mg spironolactone, single oral dose
219249259|NCT00104013|DRUG|xaliproden (SR57746A)|
219249260|NCT03698617|DRUG|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
219249261|NCT03698617|DRUG|Propofol|For induction of general anesthesia
219249262|NCT06096818|BEHAVIORAL|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
219249263|NCT06096818|BEHAVIORAL|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
219249264|NCT01488838|DRUG|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
219249265|NCT01488838|RADIATION|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
219249266|NCT04137978|DRUG|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
219249267|NCT04137978|DRUG|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
219249268|NCT02956122|BIOLOGICAL|GLASSIA|GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
219249269|NCT02956122|DRUG|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
219249270|NCT02956122|BIOLOGICAL|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
219249271|NCT02868619|OTHER|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
219742617|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
219249272|NCT02868619|OTHER|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
219249273|NCT02868619|OTHER|R-CMAS scale|Evaluate the anxiety
219742618|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
219742619|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
219742620|NCT06029166|DEVICE|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
219249274|NCT04882033|DRUG|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
219249275|NCT02004132|DRUG|Axiron|Solution administered topically using pump and applicator
219249276|NCT02364505|BEHAVIORAL|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
219742621|NCT04883047|OTHER|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
219249277|NCT02364505|BEHAVIORAL|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
219249278|NCT00635570|DRUG|Ortho Tri-cyclen Lo|Low dose oral contraceptive
219742622|NCT01050218|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
219742623|NCT06498180|OTHER|Periodontal initial treatment under local anesthesia|Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
219742624|NCT06498180|DRUG|Glucocorticoid Therapy|Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
219742625|NCT06498180|BEHAVIORAL|oral hygiene instruction|Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
219742626|NCT05510167|BEHAVIORAL|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
219742627|NCT06238973|OTHER|Group Low|In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
219742628|NCT06238973|OTHER|Group Middle|In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
219742629|NCT05231252|PROCEDURE|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
219742630|NCT01149460|DRUG|Valacyclovir|Test 1000 mg Tablet
219742631|NCT01149460|DRUG|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
219742632|NCT00433186|DRUG|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
219742633|NCT00077285|BIOLOGICAL|filgrastim|
219742634|NCT00077285|DRUG|carboplatin|
219742635|NCT00077285|DRUG|cyclophosphamide|
219742636|NCT00077285|DRUG|dexrazoxane hydrochloride|
219742637|NCT00077285|DRUG|doxorubicin hydrochloride|
219742638|NCT00077285|DRUG|etoposide|
219742639|NCT00077285|DRUG|ifosfamide|
219742640|NCT00077285|DRUG|irinotecan hydrochloride|
219742641|NCT00077285|DRUG|vincristine sulfate|
219742642|NCT00077285|PROCEDURE|conventional surgery|
219742643|NCT00077285|RADIATION|radiation therapy|
219742644|NCT02772120|DRUG|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
219742645|NCT02772120|DRUG|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
219742646|NCT05845892|OTHER|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
219742647|NCT01985282|BEHAVIORAL|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
219742648|NCT03673930|DIETARY_SUPPLEMENT|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
219742649|NCT03673930|DIETARY_SUPPLEMENT|Placebo|sunflower oil matched for appearance
219742650|NCT05059665|DIAGNOSTIC_TEST|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
219742651|NCT03020316|BEHAVIORAL|Peer Mentor|A volunteer with a similar disease as the subject
219742652|NCT03020316|BEHAVIORAL|Transcendental Meditation|A meditation technique
219742653|NCT06540014|OTHER|No intervention|No intervention is made, groups are formed just due to the races.
219742654|NCT03412552|DRUG|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
219742655|NCT05226052|DIETARY_SUPPLEMENT|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
219742656|NCT05226052|DIETARY_SUPPLEMENT|3 capsules of placebo|PGIC and PGIS assessment
219742657|NCT02869009|DRUG|clopidogrel|
219742658|NCT02869009|DRUG|Aspirin|
219742659|NCT05527769|PROCEDURE|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
219742660|NCT00353119|DRUG|Placebo comparator|Patients received placebo subcutaneously twice weekly
219742661|NCT00353119|DRUG|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
219742662|NCT02970058|OTHER|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
219742663|NCT02970058|OTHER|Control|The control group will receive saline as a placebo
219742664|NCT04359329|DRUG|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
219742665|NCT02771327|DEVICE|CPAP plus Gas|
219742666|NCT02771327|DEVICE|ventimask plus gas|
219742667|NCT00057798|DRUG|gemcitabine hydrochloride|
219742668|NCT00057798|DRUG|vinorelbine ditartrate|
219742669|NCT00057798|GENETIC|cytogenetic analysis|
219742670|NCT00057798|GENETIC|loss of heterozygosity analysis|
219742671|NCT00057798|GENETIC|microarray analysis|
219742672|NCT00057798|PROCEDURE|conventional surgery|
219742673|NCT00057798|PROCEDURE|neoadjuvant therapy|
219742674|NCT02512939|PROCEDURE|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
219742675|NCT03053232|DEVICE|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
219742676|NCT03053232|DEVICE|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
219742677|NCT02315950|OTHER|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
219742678|NCT05560113|OTHER|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
219742679|NCT05560113|OTHER|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
219742680|NCT00839930|DRUG|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
219742681|NCT00839930|DRUG|Pletal®|1 x 50 mg, single-dose tablet
219742682|NCT05313373|OTHER|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
219742683|NCT02500836|DRUG|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
219742684|NCT02500836|DRUG|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
219742685|NCT02500836|DRUG|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
219742686|NCT00228956|DRUG|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
219742687|NCT02475356|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
219742688|NCT05403866|DRUG|LT3001 Drug Product|Administered by intravenous infusion
219742689|NCT05403866|DRUG|Placebo|Administered by intravenous infusion
219742690|NCT00124358|DRUG|Buprenorphine|
219249279|NCT00635570|DEVICE|NuvaRing|Contraceptive vaginal ring
219249280|NCT01363336|DRUG|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
219249281|NCT05298293|DEVICE|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
219249282|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
219249283|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
219249284|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
219249285|NCT00729053|DRUG|IMO-2055|immunostimulatory oligonucleotide
219249286|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
219249287|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
219249288|NCT02303002|BIOLOGICAL|Botulinum Toxin Type A|Intramuscular injection (IM)
219249289|NCT02303002|BIOLOGICAL|Active Comparator botulinum toxin|IM injection
219249290|NCT02303002|BIOLOGICAL|Placebo Comparator|IM injection
219249291|NCT02760472|DRUG|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
219249292|NCT02760472|DRUG|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
219249293|NCT05114369|PROCEDURE|Curative surgery|
219249294|NCT00092313|DRUG|MK0966, rofecoxib|
219249295|NCT00092313|DRUG|Comparator: oxycodone and acetaminophen|
219249296|NCT03053115|DRUG|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
219249297|NCT03053115|DRUG|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
219249298|NCT03053115|DRUG|Placebos|Controls will take placebo two hours after dinner
219249299|NCT02907450|DEVICE|TwiCare®.|
219249300|NCT02552810|DEVICE|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
219249301|NCT02552810|DEVICE|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
219249302|NCT04816708|BEHAVIORAL|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
219249303|NCT05373225|DEVICE|Acetic acid shockwave phonophoresis therapy|This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
219249304|NCT05373225|DEVICE|Shock wave Therapy|This group composed of subjects and represented the control group who will receive shock wave therapy
219249305|NCT05373225|OTHER|conventional physical therapy program|"Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise"
219249306|NCT04794894|BEHAVIORAL|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
219249307|NCT04713176|DRUG|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
219249308|NCT04713176|DRUG|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
219249309|NCT04174222|OTHER|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
219249310|NCT04174222|OTHER|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
219249311|NCT04031196|PROCEDURE|QLB|QLB type 2 approach
219249312|NCT04031196|PROCEDURE|TAP block|classic TAP block approach
219249313|NCT00199160|DRUG|BAY 43-9006|
219249314|NCT02267564|PROCEDURE|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
219249315|NCT02267564|PROCEDURE|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
219742691|NCT00124358|BEHAVIORAL|Integrated HIV care and office-based opioid dependence treatment|
219742692|NCT02272985|OTHER|[15O]H2O PET-CT scan|All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
219742693|NCT02272985|OTHER|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
219742694|NCT02921867|OTHER|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
219742695|NCT03119129|BEHAVIORAL|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
219742696|NCT00497497|DRUG|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
219742697|NCT00497497|DRUG|cetuximab|Intravenous repeating dose
219249316|NCT04919330|BEHAVIORAL|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
219249317|NCT04919330|BEHAVIORAL|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
219249318|NCT04902196|OTHER|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
219249319|NCT04902196|OTHER|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
219249320|NCT03383029|BEHAVIORAL|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
219249321|NCT00462202|DRUG|sulodexide|
219249322|NCT02843542|DEVICE|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
219249323|NCT02843542|DEVICE|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
219249324|NCT01204593|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
219249325|NCT01204593|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
219249326|NCT02790047|DEVICE|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
219362802|NCT05812664|PROCEDURE|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
219742698|NCT00497497|DRUG|FOLFIRI regimen|Intravenous repeating dose
219742699|NCT00497497|DRUG|irinotecan|Intravenous repeating dose
219742700|NCT00497497|DRUG|PRO95780|Intravenous repeating dose
219742701|NCT02644304|DRUG|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
219742702|NCT02644304|DRUG|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
219742703|NCT02644304|OTHER|Placebo|placebo(half tablet) every 3 days (4 doses).
219742704|NCT02567903|DEVICE|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
219742705|NCT02567903|PROCEDURE|Knee arthroscopy|Knee arthroscopy
219742706|NCT00615888|PROCEDURE|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
219742707|NCT00615888|PROCEDURE|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
219742708|NCT01069757|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
219742709|NCT02463435|BEHAVIORAL|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
219742710|NCT02463435|OTHER|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
219249327|NCT02790047|OTHER|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
219249328|NCT02790047|OTHER|Health education|"Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD"
219249329|NCT02790047|OTHER|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing"
219249330|NCT02790047|DRUG|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
219249331|NCT04939883|DRUG|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
219249332|NCT04939883|DRUG|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
219249333|NCT05335239|OTHER|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
219249334|NCT04015128|DEVICE|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
219249335|NCT04402021|BEHAVIORAL|Outdoor Walking|Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
219249336|NCT04402021|OTHER|Quiet Rest|The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
219249337|NCT03229356|OTHER|Best Practices Advisory (BPA)|"1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
219249338|NCT03229356|OTHER|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
219249339|NCT00853203|BEHAVIORAL|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
219249340|NCT00853203|BEHAVIORAL|Questionnaires|Written survey taking about 1 hour.
219249341|NCT00853203|OTHER|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
219249342|NCT00853203|BEHAVIORAL|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
219249343|NCT00853203|BEHAVIORAL|Written Materials|Written educational materials plus community resource information.
219249344|NCT02194777|DRUG|BIBN 4096 BS - in single rising doses|
219249345|NCT02194777|DRUG|Placebo|
219249346|NCT05213559|OTHER|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
219249347|NCT05213559|OTHER|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
219249348|NCT03711825|DRUG|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
219249349|NCT03711825|PROCEDURE|Imaging Assessment (MRI)|Imaging assessments \[MRI\] will be performed on specified days according to protocol
219249350|NCT03711825|PROCEDURE|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
219249351|NCT04717362|DRUG|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
219249352|NCT01381614|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
219249353|NCT04520685|DRUG|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
219249354|NCT04520685|DRUG|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
219249355|NCT01247870|DRUG|Metformin|Metformin 1 g twice daily for 28-35 days
219249356|NCT01247870|DRUG|Placebo|Placebo
219249357|NCT01256372|DRUG|AP214|AP214
219249358|NCT01256372|DRUG|Placebo|Placebo; intravenous infusion
219249359|NCT05135156|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
219249360|NCT05135156|BEHAVIORAL|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
219249361|NCT01282749|BEHAVIORAL|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
219742711|NCT02463435|DIETARY_SUPPLEMENT|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
219249362|NCT01282749|BEHAVIORAL|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
219742712|NCT05158010|OTHER|HELIX's follow-up|"* Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
219742713|NCT04940078|DRUG|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
219742714|NCT04940078|DRUG|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
219742715|NCT04940078|DRUG|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
219249363|NCT03344913|BEHAVIORAL|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
219742716|NCT03709667|BEHAVIORAL|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
219742717|NCT03709667|BEHAVIORAL|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
219742718|NCT00441324|PROCEDURE|recombinant human LH|
219742719|NCT00380926|DRUG|polyunsatturated fatty acids (fish oil)|
219742720|NCT01988077|BIOLOGICAL|Adoptive cell transfer|Adoptive cell transfer
219249364|NCT04148716|PROCEDURE|additional biopsies|additional biopsies during a fibroscopy planned in the care
219249365|NCT04440514|PROCEDURE|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
219249366|NCT01724047|BEHAVIORAL|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
219249367|NCT01724047|BEHAVIORAL|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
219249368|NCT03284489|OTHER|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
219249369|NCT04741815|DEVICE|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
219249370|NCT04741815|DEVICE|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
219249371|NCT00059735|DRUG|E7070|
219249372|NCT02986659|DRUG|Metformin|
219249373|NCT02986659|DRUG|Placebo|
219249374|NCT01372826|DRUG|NKTR118 Group1|Oral dose, 25 mg
219249375|NCT01372826|DRUG|NKTR118 Group 2|Oral dose, 25 mg
219249376|NCT01372826|DRUG|NKTR118 Group3|Oral dose, 25 mg
219249377|NCT01372826|DRUG|NKTR118|Oral dose, 25 mg
219249378|NCT05814679|OTHER|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
219249379|NCT05814679|OTHER|Attention match|kidney function instruction
219249380|NCT00543634|DRUG|Premarin/MPA|0.625 mg/2.5 mg X4
219249381|NCT00543634|DRUG|Premarin/MPA|0.625 mg/5 mg X 2
219249382|NCT00543634|DRUG|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
219249383|NCT02445183|OTHER|None, N/A|
219742721|NCT01988077|DRUG|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
219742722|NCT01955551|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
219742723|NCT01955551|BEHAVIORAL|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
219742724|NCT00610038|DRUG|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
219742725|NCT01759641|DEVICE|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
219742726|NCT03735914|OTHER|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
219742727|NCT04877379|DRUG|VNRX-7145|β-lactamase inhibitor
219742728|NCT04877379|DRUG|VNRX-5024 (ceftibuten)|β-lactam antibiotic
219742729|NCT04877379|DRUG|Placebo|Placebo
219742730|NCT06264544|DIETARY_SUPPLEMENT|zinc, selenium, and L-tyrosine in SEPP1|zinc, selenium, and L-tyrosine in SEPP1 polymorphism
219249384|NCT01498523|OTHER|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
219249385|NCT01498523|OTHER|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
219249386|NCT01498523|OTHER|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
219249387|NCT01498523|OTHER|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
219249388|NCT02423252|BEHAVIORAL|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
219249389|NCT02423252|OTHER|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
219249390|NCT02650726|DIETARY_SUPPLEMENT|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
219249391|NCT02650726|OTHER|Placebo|placebo 320mg daily for 24 weeks
219249392|NCT01250847|DRUG|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
219249393|NCT00926952|DRUG|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
219249394|NCT00926952|DEVICE|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
219249395|NCT05600998|DRUG|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
219362803|NCT01417845|BEHAVIORAL|High Intensity Exercise Training|"* High intensity resistance and aerobic training~* Resistance training is performed 2 days per week for 3 months~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
219362804|NCT01417845|BEHAVIORAL|Moderate Intensity Exercise Training|"* Moderate intensity resistance and aerobic training~* Resistance training is performed on 2 days per week for 3 months.~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
219362805|NCT03648632|RADIATION|Stereotactic Radiotherapy|Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
219249396|NCT02883140|OTHER|Three-dimensional sialography CBCT and MRI sialography|"1. MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~2. 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
219249397|NCT03824353|BEHAVIORAL|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
219249398|NCT03824353|BEHAVIORAL|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
219249399|NCT03586752|OTHER|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
219249400|NCT03586752|OTHER|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
219249401|NCT00447629|DRUG|PPM-204|
219249402|NCT03669900|PROCEDURE|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
219249403|NCT04433949|OTHER|Best Practice|Receive standard of care
219249404|NCT04433949|RADIATION|Low Dose Radiation Therapy|Undergo LDRT
219249405|NCT02574897|OTHER|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
219249406|NCT02574897|OTHER|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
219249407|NCT03009877|DEVICE|Optiflow F&P 850™ System|"Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
219249408|NCT03009877|DEVICE|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
219249409|NCT03009877|DRUG|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
219249410|NCT03009877|DRUG|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
219249411|NCT03009877|DRUG|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
219249412|NCT03009877|DRUG|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
219249413|NCT03009877|DEVICE|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
219249414|NCT04595097|DEVICE|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
219249415|NCT02107729|PROCEDURE|Large needle gauge lidocaine injection|21 G
219249416|NCT02107729|PROCEDURE|Normal needle gauge lidocaine injection|23 G
219249417|NCT02107729|PROCEDURE|Small needle gauge lidocaine injection|27 G
219249418|NCT02931240|DEVICE|Revivent TC|Treatment of LV scar
219249419|NCT02915354|DRUG|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
219249420|NCT00647998|DRUG|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
219249421|NCT00647998|OTHER|Standard care|
219249422|NCT03704571|DRUG|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
219249423|NCT01939405|BEHAVIORAL|built environment use counseling|
219249424|NCT02449993|DEVICE|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
219249425|NCT00614536|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
219249426|NCT01960985|OTHER|Physicaltherapy|
219249427|NCT00308841|DRUG|Lidocaine (drug)|
219249428|NCT01259440|BEHAVIORAL|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
219249429|NCT01259440|BEHAVIORAL|Usual Care|Consists of one week telephone call and one month clinic visit
219249430|NCT01956071|DEVICE|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
219249431|NCT02924181|DEVICE|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
219249432|NCT06423859|DRUG|Articaine|supraclavicular brachial plexus block with articaine 2%
219249433|NCT06423859|DRUG|Dexmedetomidine|supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
219249434|NCT03326050|DRUG|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
219249435|NCT03326050|DRUG|Ciprofloxacin|cipro 750 tablet twice daily
219249436|NCT03326050|DRUG|Rifampicin|Rifampicin 150Mg Capsule twice daily
219249437|NCT02617433|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
219249438|NCT01862185|OTHER|semi-quantitative procalcitonin|
219249439|NCT02966600|OTHER|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
219249440|NCT02966600|OTHER|Physical Activity|The control group followed its usual weekly physical activity routine
219249441|NCT00981929|DRUG|Tramadol|50 mg single oral dose
219742731|NCT06264544|OTHER|Placebo|placebo comparator in SEPP1 polymorphism group
219742732|NCT06216262|OTHER|Control group|Brushing teeth twice a day for 8 weeks
219742733|NCT06216262|OTHER|Arginine|Brushing teeth twice a day for 8 weeks
219249442|NCT00981929|DRUG|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
219249443|NCT00981929|DRUG|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
219249444|NCT03058237|DRUG|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
219249445|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
219742734|NCT06216262|OTHER|Novamin|Brushing teeth twice a day for 8 weeks
219742735|NCT06216262|OTHER|Propolis|Brushing teeth twice a day for 8 weeks
219742736|NCT06216262|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate|Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks
219742737|NCT06216262|OTHER|Potassium Nitrate|Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
219742738|NCT04759170|OTHER|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
219742739|NCT00487630|DRUG|recombinant alpha-galactosidase A|
219249446|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
219249447|NCT03058237|DRUG|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
219249448|NCT01089387|BIOLOGICAL|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
219249449|NCT05269147|PROCEDURE|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
219249450|NCT03187041|OTHER|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
219249451|NCT04563247|DIAGNOSTIC_TEST|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
219249452|NCT04904237|DRUG|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
219249453|NCT02742792|OTHER|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
219249454|NCT02742792|OTHER|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
219249455|NCT01647152|DRUG|Ustekinumab|
219742740|NCT01819480|PROCEDURE|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
219742741|NCT04250792|DRUG|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
219742742|NCT00002480|RADIATION|radiation therapy|
219742743|NCT00266032|DRUG|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
219742744|NCT00266032|DRUG|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
219742745|NCT00266032|DRUG|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
219742746|NCT05736913|BIOLOGICAL|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
219742747|NCT05736913|BIOLOGICAL|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
219742748|NCT02796456|OTHER|blood sample|
219742749|NCT01991873|DRUG|Maintenance Chemotherapy|
219742750|NCT01991873|DRUG|Panitumumab (Within maintenance phase)|
219742751|NCT01991873|DRUG|mFOLFOX6 (Within re-induction phase)|
219742752|NCT01991873|DRUG|Panitumumab (Within re-induction phase)|
219742753|NCT01514357|DRUG|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
219742754|NCT01514357|DRUG|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
219742755|NCT04280380|DIAGNOSTIC_TEST|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
219742756|NCT05730660|DIETARY_SUPPLEMENT|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
219742757|NCT05730660|DIETARY_SUPPLEMENT|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
219249456|NCT03461211|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
219249457|NCT06395961|PROCEDURE|high ankle block|"The block position is in the middle and lower third of the calf, about 15cm above the inner or outer ankles. 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve. The water separation technique is used and 2ml of physiological saline is injected before blocking to clarify the position of the needle tip and avoid nerve damage. 20 minutes after, the effect was measured using acupuncture by visual analogue scale (VAS) score. If the VAS score is less than 3, the block is considered successful and surgery is immediately performed."
219249458|NCT06395961|PROCEDURE|general anesthesia|intravenous injection of midazolam 0.03-0.05 mg/kg, etomidate 0.15-0.20 mg/kg, cisatracurium 0.15-0.20 mg/kg, and sufentanil 0.3-0.5 μg/kg. Intraoperative anesthesia maintenance using intravenous infusion of remifentanil 0.1-0.3 μg/kg·min, propofol 4-6 mg/kg·h, maintain bispectral index (BIS) value of 40-60, maintain intraoperative blood pressure and heart rate fluctuations within ± 20% of the baseline value, intermittently inject cisatracurium intravenously as needed. After the surgery, the patient was transferred to post-anaesthesia care unit (PACU). After regaining consciousness and regaining autonomous breathing, the tracheal catheter was removed and transferred to the ward when the indications for transfer were met.
219249459|NCT03703349|DRUG|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
219249460|NCT03703349|DRUG|Placebo Oral Tablet|Placebo for Magnesium
219249461|NCT01284634|DRUG|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
219249462|NCT01284634|DRUG|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
219249463|NCT01284634|DRUG|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
219249464|NCT01284634|DRUG|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
219249465|NCT06408922|OTHER|prp injection|intraarticular prp
219249466|NCT04873297|DRUG|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
219249467|NCT04873297|DRUG|Placebo|Placebo 10 ml of plain water Via NG
219249468|NCT03294421|PROCEDURE|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
219249469|NCT03294421|PROCEDURE|standard closed tympanomastoidectomy|"1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0"
219249470|NCT01271153|DRUG|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
219249471|NCT01271153|DRUG|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
219249472|NCT04531371|DRUG|Dexmedetomidine injection|post surgical agitation prophylaxis
219249473|NCT02357719|DEVICE|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
219249474|NCT00220597|BEHAVIORAL|Trauma-focused group therapy|
219249475|NCT01059526|DRUG|ecallantide|30 mg SC
219249476|NCT02720081|DRUG|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
219249477|NCT02720081|DRUG|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
219249478|NCT02720081|DRUG|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
219249479|NCT02720081|DRUG|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
219249480|NCT01620398|BEHAVIORAL|BALANCE|
219249481|NCT01620398|BEHAVIORAL|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
219249482|NCT05790187|OTHER|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
219249483|NCT00743223|OTHER|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
219249484|NCT00356564|BIOLOGICAL|hepatitis B vaccine|
219249485|NCT03772041|DRUG|OPC-61815|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
219249486|NCT03772041|DRUG|Tolvaptan Tab 15 MG|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
219249487|NCT00219869|DRUG|Galantamine|
219249488|NCT05470881|DRUG|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
219249489|NCT05287698|OTHER|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
219249490|NCT02795819|DRUG|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
219249491|NCT02795819|DRUG|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
219249492|NCT00761410|DEVICE|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
219249493|NCT01193062|DRUG|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
219249494|NCT01193062|DRUG|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
219249495|NCT03964038|DRUG|gilteritinib|oral
219249496|NCT03964038|DRUG|gilteritinib mini tablet|oral
219249497|NCT02754310|OTHER|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
219249498|NCT02754310|OTHER|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
219249499|NCT05012397|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
219249500|NCT00003588|BIOLOGICAL|Ad5CMV-p53 gene|
219249501|NCT00003588|PROCEDURE|laparoscopic surgery|
219249502|NCT05362253|PROCEDURE|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
219362806|NCT02769624|DRUG|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
219362807|NCT02769624|DRUG|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
219362808|NCT04451330|DRUG|Trifarotene cream|Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
219362809|NCT04451330|DRUG|Doxycycline hyclate|Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
219249503|NCT05362253|PROCEDURE|Conventional Autologous Conjunctival Transplantation|"1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
219249504|NCT04676672|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
219249505|NCT01493388|DRUG|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
219249506|NCT05005572|OTHER|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
219249507|NCT03939871|DRUG|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
219249508|NCT04097314|DRUG|Zibotentan|10mg OD Zibotentan
219249509|NCT04097314|DRUG|Placebo oral tablet|Placebo
219249510|NCT03334747|DRUG|KAE609|Exploration of different doses of KAE609 to establish safety profile.
219249511|NCT03334747|DRUG|Coartem|Control Arm
219249512|NCT02567227|OTHER|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
219249513|NCT02567227|OTHER|Active Control|Computer, multimedia and group based health education programs.
219249514|NCT01961804|DRUG|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
219249515|NCT04748445|DIAGNOSTIC_TEST|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
219249516|NCT03570996|PROCEDURE|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
219249517|NCT03570996|PROCEDURE|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
219249518|NCT03570996|PROCEDURE|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
219249519|NCT01679457|BEHAVIORAL|ACT-Focused ERP|
219249520|NCT01679457|BEHAVIORAL|TAU-ERP|
219249521|NCT02831439|BEHAVIORAL|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
219362810|NCT04451330|DRUG|Trifarotene Vehicle|Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
219249522|NCT02831439|BEHAVIORAL|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
219362811|NCT04451330|DRUG|Doxycycline Placebo|Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
219742758|NCT04642209|DEVICE|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
219742759|NCT03751982|DEVICE|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
219742760|NCT02811419|DEVICE|i-scan|examination will be performed with i-scan digital enhancement
219742761|NCT02811419|DEVICE|standard high-definition white light|examination will be performed with high-definition white light
219742762|NCT03576651|BIOLOGICAL|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
219742763|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
219742764|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
219742765|NCT05263167|DRUG|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
219362812|NCT01443780|DIETARY_SUPPLEMENT|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
219362813|NCT05099640|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
219742766|NCT05263167|DRUG|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
219742767|NCT03058887|OTHER|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
219742768|NCT03058887|OTHER|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
219742769|NCT04691115|DRUG|AM1476|AM1476 Capsules
219742770|NCT04691115|DRUG|Placebo|Placebo Capsules
219742771|NCT06020079|OTHER|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
219742772|NCT00323245|BEHAVIORAL|Physiotherapy for urinary incontinence|See Detailed Description.
219742773|NCT06641674|DRUG|18F-LF13|18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
219742774|NCT05898178|OTHER|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
219742775|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
219742776|NCT05849246|DRUG|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
219742777|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
219249523|NCT02831439|BEHAVIORAL|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
219249524|NCT02604147|DEVICE|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
219249525|NCT02604147|DEVICE|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
219249526|NCT05307120|DEVICE|Diameter integrated in secondary diabetes care|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
219249527|NCT06210737|BIOLOGICAL|PCV13|3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
219249528|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13, and a booster dose
219249529|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13
219249530|NCT06210737|BIOLOGICAL|PCV13|single dose of PCV13
219249531|NCT03742232|DRUG|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
219249532|NCT03742232|DRUG|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
219249533|NCT01211717|DIETARY_SUPPLEMENT|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
219249534|NCT01211717|OTHER|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
219249535|NCT00301015|DEVICE|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
219249536|NCT00935649|DEVICE|PinPointe FootLaser|Medical laser
219362814|NCT05099640|DRUG|Placebo|Placebo matching to PTC923
219249537|NCT03291899|COMBINATION_PRODUCT|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
219249538|NCT04879875|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
219249539|NCT04879875|DEVICE|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
219249540|NCT02498418|DRUG|Rifaximin|Tablets, generic formulation of the brand product.
219249541|NCT02498418|DRUG|Xifaxan®|Tablets, brand product.
219249542|NCT02498418|DRUG|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
219249543|NCT00762502|DEVICE|senofilcon A toric contact lens|soft contact lens
219249544|NCT00762502|DEVICE|balafilcon A toric contact lens|soft contact lens
219249545|NCT00002347|DRUG|Saquinavir|
219249546|NCT00002347|DRUG|Nevirapine|
219249547|NCT00002347|DRUG|Zidovudine|
219249548|NCT00002347|DRUG|Zalcitabine|
219249549|NCT04596241|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
219249550|NCT03042559|DEVICE|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
219362815|NCT05135832|DEVICE|Electronic patient-reported outcomes regarding symptoms and health-related quality of life|"Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.~The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes."
219362816|NCT04844255|DIETARY_SUPPLEMENT|dietary salt|2 grams of dietary salt
219249551|NCT03042559|DEVICE|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
219249552|NCT05582135|DRUG|2 mg morphine sulfate|The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
219249553|NCT05582135|DRUG|0.25mg/kg esketamine|The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
219249554|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 2 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
219249555|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 1 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
219249556|NCT06057259|DEVICE|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
219249557|NCT01225705|DRUG|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
219249558|NCT01225705|DRUG|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
219249559|NCT01994538|OTHER|Longer therapy duration|14 days of antimicrobial treatment
219249560|NCT01994538|OTHER|Shorter therapy duration|7 days of antimicrobial treatment
219742778|NCT06451146|PROCEDURE|PCI Facilitated with Orbital Atherectomy Device|Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
219742779|NCT06638593|PROCEDURE|MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
219742780|NCT06638593|PROCEDURE|Standard open surgery|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
219742781|NCT06637228|BEHAVIORAL|Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines|"This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities."
219742782|NCT01220687|DRUG|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
219742783|NCT01220687|OTHER|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
219742784|NCT04694287|DIAGNOSTIC_TEST|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
219742785|NCT04878471|DRUG|Pudexacianinium chloride|Intravenous
219742786|NCT04878471|DRUG|Placebo|Intravenous
219742787|NCT02518698|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
219742788|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
219742789|NCT05109559|BIOLOGICAL|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
219742790|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
219742791|NCT02228330|PROCEDURE|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
219743657|NCT06276335|OTHER|Late implant placement and guided bone regeneration (Control)|A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
219249561|NCT02896439|DEVICE|Neurophysiological MONITORING|"The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention"
219249562|NCT02896218|OTHER|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
219249563|NCT03902145|OTHER|Egg|One egg per day for 6 months
219249564|NCT01550822|OTHER|HEALS|
219249565|NCT04545983|OTHER|Motion Analysis|Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
219249566|NCT01536535|DRUG|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
219249567|NCT01536535|DRUG|IV Corticosteroid|Treatment with IV Corticosteroid
219249568|NCT01536535|DRUG|Oral Corticosteroids|Treatment with oral corticosteroids
219249569|NCT01536535|OTHER|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
219249570|NCT01536535|PROCEDURE|Colectomy|Colectomy
219249571|NCT03315988|OTHER|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
219249572|NCT00392314|OTHER|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
219249573|NCT02788617|DEVICE|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
219249574|NCT03334773|BEHAVIORAL|Nutrition education|
219249575|NCT03703141|DIETARY_SUPPLEMENT|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
219249576|NCT04091919|DIAGNOSTIC_TEST|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
219249577|NCT06350370|PROCEDURE|Natural orifice specimen extraction|We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
219249578|NCT03866434|DRUG|SPD422|Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
219249579|NCT03866434|DRUG|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
219249580|NCT05452837|PROCEDURE|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
219249581|NCT05452837|PROCEDURE|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
219249582|NCT05738070|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
219249583|NCT00519714|DIETARY_SUPPLEMENT|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
219249584|NCT00519714|DIETARY_SUPPLEMENT|Placebo|Placebo
219249585|NCT01705951|OTHER|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
219249586|NCT01705951|BIOLOGICAL|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
219249587|NCT04139239|DIAGNOSTIC_TEST|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
219249588|NCT03623399|PROCEDURE|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
219249589|NCT00167323|BEHAVIORAL|Adherence therapy|
219249590|NCT00387907|DRUG|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
219249591|NCT00387907|DRUG|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
219249592|NCT00729885|DEVICE|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
219249593|NCT00729885|DEVICE|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
219249594|NCT02003664|DRUG|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
219249595|NCT02003664|DRUG|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
219249596|NCT05216952|DRUG|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
219249597|NCT05216952|DRUG|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
219249598|NCT02806596|DRUG|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
219249599|NCT00376207|BEHAVIORAL|Physical exercise|
219249600|NCT00385697|BIOLOGICAL|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
219249601|NCT00385697|DRUG|Placebo|Daily IV dosing for 14 days, repeated at Week 26
219249602|NCT04117906|BEHAVIORAL|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
219249603|NCT01485991|DRUG|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
219249604|NCT01485991|DRUG|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
219249605|NCT00815347|DRUG|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
219249606|NCT00815347|DRUG|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
219249607|NCT04715711|OTHER|Forearm coolng|forearm immersion will be performed for active cooling assessment
219249608|NCT04715711|OTHER|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
219249609|NCT04715711|OTHER|mist-fan|a mist-fan will be placed in front of the participant for active cooling
219249610|NCT04715711|OTHER|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
219249611|NCT01909947|OTHER|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
219249612|NCT01031186|DRUG|GSK356278|GSK356278
219249613|NCT01031186|DRUG|PLACEBO|PLACEBO
219249614|NCT02403284|DRUG|Liraglutide|Subcutaneous injection by patient
219249615|NCT02403284|DRUG|Sugar Pill|Subcutaneous injection daily
219249616|NCT03895892|BEHAVIORAL|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
219249617|NCT03895892|BEHAVIORAL|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
219249618|NCT03895892|DIETARY_SUPPLEMENT|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
219249619|NCT03895892|DIETARY_SUPPLEMENT|Ketone|Dietary supplement containing only ketone salts
219249620|NCT03895892|DIETARY_SUPPLEMENT|Water Placebo|Dietary supplement containing only water
219249621|NCT05621213|OTHER|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
219249622|NCT00877188|OTHER|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
219249623|NCT04313790|DRUG|Heparin Infusion|500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
219249624|NCT04313790|OTHER|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
219249625|NCT00386997|DRUG|liposomal amphotericin B (AmBisome®)|
219249626|NCT01136798|DRUG|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
219249627|NCT01136798|DRUG|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
219249628|NCT00919009|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
219249629|NCT03383809|DIETARY_SUPPLEMENT|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
219249630|NCT03383809|DIETARY_SUPPLEMENT|Strawberry Juice|Source of Polyphenols
219249631|NCT03383809|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
219249632|NCT02382406|DRUG|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
219249633|NCT02382406|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
219249634|NCT02382406|DRUG|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
219249635|NCT02382406|DRUG|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
219249636|NCT01625949|PROCEDURE|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
219249637|NCT01625949|PROCEDURE|coronary dilatation and stenting|coronary dilatation and stenting
219249638|NCT01093183|DRUG|lenalidomide|Given PO
219249639|NCT01093183|DRUG|cyclophosphamide|Given PO
219249640|NCT01093183|OTHER|laboratory biomarker analysis|Correlative studies
219249641|NCT01093183|OTHER|questionnaire administration|Ancillary studies
219249642|NCT01093183|OTHER|quality-of-life assessment|Ancillary studies
219249643|NCT01936298|DEVICE|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
219249644|NCT01936298|DEVICE|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
219249645|NCT03841006|DEVICE|MRI|dynamic MRI pelvis
219249646|NCT01436383|OTHER|Hypoxic exposure|Hypoxic exposure
219249647|NCT02360865|OTHER|Exercise|
219249648|NCT01445990|DEVICE|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
219249649|NCT01128777|BEHAVIORAL|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
219249650|NCT01128777|BEHAVIORAL|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
219249651|NCT06345924|BEHAVIORAL|MERAKI_PC|"The three music therapy sessions focus on helping the patient to adjust to their situation. The aim is to provide emotional support and encourage communication between family members through music. In addition, the therapy will help the patient to appreciate their remaining abilities and encourage their involvement in the rehabilitation process. The second session focuses on living in the present through re-identification. The session aims to improve the symptoms associated with the illness by focusing on the present situation and encouraging expression.~The main aim of the final session, 'The Journey of Life - Leaving a Mark', is to recapitulate and provide support.~Songs are used during the session, taking into account musical preferences."
219249652|NCT04543942|DRUG|Alcohol|Alcohol will be administered by IV infusion (60mg%).
219249653|NCT04543942|DRUG|Saline|Saline is administered as the placebo
219249654|NCT03840278|DEVICE|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
219249655|NCT03840278|DEVICE|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
219249656|NCT03840278|DRUG|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
219249657|NCT05707689|BEHAVIORAL|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
219249658|NCT03805698|DEVICE|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
219249659|NCT03805698|OTHER|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
219362817|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
219249660|NCT00926978|RADIATION|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
219249661|NCT05651334|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
219249662|NCT05651334|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
219249663|NCT06119386|DEVICE|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
219249664|NCT05881161|BEHAVIORAL|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
219249665|NCT05881161|BEHAVIORAL|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
219249666|NCT06647290|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
219249667|NCT02721420|DRUG|dihydroartemisinin-piperaquine|
219249668|NCT02721420|OTHER|message(SMS) reminder|
219249669|NCT02721420|OTHER|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
219249670|NCT02721420|OTHER|short message(SMS) reminder|
219249671|NCT03130127|DRUG|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
219249672|NCT06645587|DEVICE|Active HD-tDCS over pre-SMA|Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over Fz. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
219249673|NCT06645587|DEVICE|Active HD-tDCS over left DLPFC|Active cathodal HD-tDCS over left DLPFC cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over F3. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
219249674|NCT06645587|DEVICE|Sham HD-tDCS|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex for 10 days (3 sessions per week). The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. Each Sham session will last 20 minutes.
219249675|NCT00124137|DEVICE|Aquadex system|
219249676|NCT00124137|DRUG|IV diuretic|
219249677|NCT03604653|DEVICE|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
219249678|NCT03604653|DRUG|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
219249679|NCT03604653|DRUG|CDDP 50|50mg/m2@T0
219249680|NCT03604653|DRUG|CDDP 75|75mg/m2@T0
219249681|NCT03604653|DRUG|Doxorubicin|15mg/m2@T0
219249682|NCT06125639|BEHAVIORAL|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
219249683|NCT06645561|PROCEDURE|X-ray|defined radiographic semiological criteria to determine an analytical methodology to facilitate the dating of long bone fractures of infants under one year of age
219249684|NCT06645548|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
219249685|NCT06645730|DIAGNOSTIC_TEST|hypertension|diagnosed with hypertension
219249686|NCT06645730|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
219249687|NCT06645730|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver on CT
219249688|NCT00472056|DRUG|Carmustine|300 mg/m\^2 IV for 1 Day
219249689|NCT00472056|DRUG|Etoposide|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
219249690|NCT00472056|DRUG|Cytarabine|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
219249691|NCT00472056|DRUG|Melphalan|140 mg/m\^2 IV x 1 Day
219249692|NCT00472056|DRUG|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
219249693|NCT01421797|DRUG|Dexamethasone|1 mg PO
219249694|NCT01421797|DRUG|Cortrosyn|single IV bolus of 0.25 mg will be administered
219249695|NCT01209936|DEVICE|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
219249696|NCT03363542|DIETARY_SUPPLEMENT|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
219249697|NCT01109602|OTHER|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
219249698|NCT01258296|DRUG|Fentanyl|25 mcg/hr transdermal patch
219249699|NCT01258296|DRUG|Inactive patch|placebo patch (no drug)
219249700|NCT02572999|PROCEDURE|Not applicable (observational design)|
219249701|NCT00748358|DRUG|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
219743658|NCT06634771|DEVICE|10 Hz transcranial alternating current stimulation (tACS)|10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.
219743659|NCT06634771|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
219249702|NCT02511808|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
219249703|NCT02511808|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
219249704|NCT02511808|BEHAVIORAL|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
219249705|NCT03331848|DRUG|Placebo oral capsule|BID
219249706|NCT03331848|DRUG|PXT002331 - 20mg|Oral
219743660|NCT06628986|BEHAVIORAL|MBSR|20 minutes once a week for 8 weeks
219249707|NCT02894359|DEVICE|cone beam imagery of cervical spine|
219249708|NCT03630458|OTHER|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
219249709|NCT03630458|OTHER|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
219249710|NCT03630458|OTHER|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
219743661|NCT06628986|BEHAVIORAL|NLP|NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
219743662|NCT06628986|BEHAVIORAL|control|control group, no practice,
219743663|NCT04812483|DRUG|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
219743664|NCT04812483|DRUG|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
219249711|NCT03630458|OTHER|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
219249712|NCT03630458|OTHER|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
219249713|NCT05451056|DRUG|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
219249714|NCT06276751|PROCEDURE|End-tidal CO2 monitor|Throughout the study, measurements were taken at 2 and 4 hours after tube thoracostomy was applied to every patient undergoing the procedure.
219249715|NCT03672071|OTHER|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
219249716|NCT04833842|OTHER|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
219249717|NCT04833842|OTHER|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
219249718|NCT05240729|PROCEDURE|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
219249719|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
219249720|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
219249721|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
219249722|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
219249723|NCT01673100|BEHAVIORAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
219249724|NCT02843698|DRUG|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
219249725|NCT02843698|DRUG|Normal saline|Normal saline
219249726|NCT01531478|OTHER|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
219249727|NCT04707287|OTHER|No Intervention|No intervention used. This is observational study
219249728|NCT01642771|DRUG|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
219249729|NCT01642771|DRUG|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
219249730|NCT02332421|DEVICE|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
219249731|NCT00721708|DIETARY_SUPPLEMENT|pure carnosine|one time dose of pure carnosine (450 mg)
219249732|NCT00721708|OTHER|Beef|one time dose, 150 g of beef
219249733|NCT00721708|OTHER|Chicken|One time dose, 150g of chicken breast
219249734|NCT00721708|OTHER|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
219249735|NCT04031547|DEVICE|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
219249736|NCT05282316|DIETARY_SUPPLEMENT|EVOO polyphenols enriched|Addition of 40 ml daily of healthy polyphenols enriched EVOO to mediterranean diet for 6 months
219249737|NCT05282316|DIETARY_SUPPLEMENT|EVOO standard|Addition of 40 ml daily of standard EVOO to mediterranean diet for 6 months
219249738|NCT03686917|OTHER|CHAT-P|Survey
219249739|NCT00739024|DRUG|Ramelteon|8 mg tablet, oral, once daily
219249740|NCT00739024|DRUG|Placebo|Placebo tablet, oral, once daily
219249741|NCT04694859|DEVICE|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
219249742|NCT00832650|DRUG|fesoterodine fumarate|8 mg OD for 14 days
219249743|NCT00832650|DRUG|placebo|OD for 14 days
219249744|NCT00832650|DRUG|solifenacin|10 mg OD for 14 days
219249745|NCT06367426|DRUG|DDN-A-0101 (SAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
219249746|NCT06367426|DRUG|DDN-A-0101 (MAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
219249747|NCT06367426|DRUG|Placebo (SAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
219249748|NCT06367426|DRUG|Placebo (MAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
219249749|NCT02395224|OTHER|cancer treatment and follow-up according to current regional and national guidelines|
219249750|NCT05043428|BEHAVIORAL|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
219249751|NCT05555121|DRUG|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
219249752|NCT01881100|OTHER|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
219249753|NCT01881100|OTHER|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
219249754|NCT02078778|DEVICE|CPAP|3 months of CPAP treatment
219249755|NCT04419961|BEHAVIORAL|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
219249756|NCT00002099|DRUG|Lentinan|
219249757|NCT00002099|DRUG|Didanosine|
219249758|NCT03672383|DEVICE|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
219249759|NCT04290156|OTHER|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
219249760|NCT04593641|BIOLOGICAL|CT-P59|administered
219249761|NCT03074383|BEHAVIORAL|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
219249762|NCT03074383|BEHAVIORAL|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
219249763|NCT05958784|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
219249764|NCT04235894|DRUG|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
219249765|NCT06310330|DIAGNOSTIC_TEST|Comprehensive echocardiographic follow-up|Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
219249766|NCT06310330|DIAGNOSTIC_TEST|Simplified echocardiographic follow-up|Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
219249767|NCT03123224|BEHAVIORAL|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
219249768|NCT03123224|BEHAVIORAL|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
219249769|NCT01260259|PROCEDURE|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
219249770|NCT01260259|PROCEDURE|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
219249771|NCT04887597|DRUG|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
219249772|NCT01998334|OTHER|CVVH 6h|CVVH 6h for first three days
219249773|NCT01998334|OTHER|CVVH 10h|CVVH 10h for first three days
219249774|NCT01998334|OTHER|CVVHDF 6h|CVVHDF 6h for first three days
219249775|NCT05283642|DIETARY_SUPPLEMENT|DCI|Oral supplementation with D-chiro-inositol once daily
219249776|NCT05060406|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
219249777|NCT04681209|BEHAVIORAL|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
219249778|NCT04681209|BEHAVIORAL|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
219249779|NCT03473652|OTHER|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
219249780|NCT01341106|DRUG|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
219249781|NCT00794573|DRUG|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
219249782|NCT00794573|OTHER|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
219249783|NCT04433247|BEHAVIORAL|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
219249784|NCT02885376|DEVICE|Dentoxol|Mouthrinse
219249785|NCT02885376|DEVICE|Placebo|Mouthrinse
219249786|NCT05888272|BEHAVIORAL|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
219249787|NCT06454578|DRUG|Adebrelimab + Apatinib|"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"
219249788|NCT02109718|DRUG|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
219249789|NCT02109718|DRUG|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
219249790|NCT00490113|DRUG|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
219249791|NCT02985086|DRUG|Cefoxitin|
219249792|NCT02985086|DRUG|oxytocin/misoprostol|
219249793|NCT01884376|DEVICE|Neuromaix|
219249794|NCT03288480|DRUG|PT-112|This is a single arm study
219249795|NCT05620199|PROCEDURE|Upfront resection|Resection of the primary tumor
219249796|NCT05872906|DEVICE|Acupuncture|A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
219249797|NCT00848640|DRUG|Sorafenib|400 mg twice daily
219249798|NCT00524693|DRUG|Montelukast|4mg sachets
219249799|NCT00524693|DRUG|Placebo granules|
219249800|NCT05662878|OTHER|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
219249801|NCT00001623|PROCEDURE|Allogeneic Bone Marrow Transplant|
219249802|NCT03928821|BIOLOGICAL|PGT121|20 mg/kg administered intravenously
219249803|NCT03928821|BIOLOGICAL|PGDM1400|20 mg/kg administered intravenously
219249804|NCT03928821|BIOLOGICAL|10-1074|20 mg/kg administered intravenously
219249805|NCT03928821|BIOLOGICAL|VRC07-523LS|20 mg/kg administered intravenously
219249806|NCT05291962|OTHER|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
219176206|NCT06796387|BEHAVIORAL|Enhanced Implementation of SBAT|"For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~* Telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT school-based DOT of preventive asthma medications~* Follow-up telemedicine asthma control assessments~* Centralized case management support~* Care coordination"
219249807|NCT06585475|BEHAVIORAL|Structured training according to premenstrual syndrome symptom map|A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
219249808|NCT06584617|DEVICE|Berovenal®|Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
219249809|NCT06584617|DEVICE|NU-GEL Hydrogel with Alginate|Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
219249810|NCT01083537|DRUG|Cisplatin|"1\) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
219249811|NCT01083537|DRUG|Paclitaxel|"2\) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
219249812|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
219249813|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
219249814|NCT04260776|BEHAVIORAL|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
219249815|NCT04260776|BEHAVIORAL|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
219249816|NCT02646644|OTHER|Metastasized intestinal NET|This is an observational study
219249817|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
219249818|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
219249819|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
219249820|NCT00117650|OTHER|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
219249821|NCT04985071|PROCEDURE|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
219249822|NCT05156216|OTHER|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
219249823|NCT02784535|DRUG|Atomoxetine|norepinephrine transporter inhibitor
219249824|NCT02784535|DRUG|Placebo|placebo
219249825|NCT01796834|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
219249826|NCT06116266|OTHER|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
219249827|NCT06116266|OTHER|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
219249828|NCT06116266|OTHER|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
219249829|NCT06116266|OTHER|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
219249830|NCT06116266|OTHER|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
219249831|NCT04047680|DRUG|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
219249832|NCT04047680|DRUG|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
219249833|NCT04047680|DRUG|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
219249834|NCT04047680|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
219249835|NCT04047680|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
219249836|NCT04047680|DRUG|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
219249837|NCT05066178|BEHAVIORAL|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
219249838|NCT04655222|DRUG|Interferon Beta Therapy|Administered as specified in the treatment arm.
219249839|NCT03928171|OTHER|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
219249840|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
219249841|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
219249842|NCT01229527|DRUG|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
219249843|NCT06184295|DEVICE|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
219249844|NCT04453306|DRUG|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
219249845|NCT04453306|DRUG|Placebo|innocuous substance is coated in tablets in an independent laboratory
219249846|NCT00355732|PROCEDURE|Weaning from mechanical ventilation|
219249847|NCT02822040|OTHER|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
219249848|NCT02916745|DRUG|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
219249849|NCT02916745|DEVICE|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
219249850|NCT04749771|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
219249851|NCT04749771|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
219249852|NCT03588195|OTHER|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
219249853|NCT03588195|DEVICE|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
219249854|NCT02335242|DRUG|Sildenafil 20 mg tablets|
219249855|NCT02335242|OTHER|Placebo tablets (resembling Revatio)|
219249856|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after phage treatment.
219249857|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after standard infection treatment.
219249858|NCT02848898|DEVICE|Equistasi|
219249859|NCT02848898|OTHER|Placebo|
219249860|NCT04916340|BEHAVIORAL|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
219249861|NCT04916340|BEHAVIORAL|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
219249862|NCT06448390|BEHAVIORAL|Physical training|The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
219249863|NCT01637337|PROCEDURE|laparoscopic pyelolithotomy|laparoscopy
219249864|NCT01637337|PROCEDURE|percutaneous nephrolithotomy|percutaneous nephrolithotomy
219249865|NCT06059963|DEVICE|Signal-C™|Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
219249866|NCT02214017|DEVICE|A videotelephone, TandBerg E20,|
219249867|NCT02214017|BEHAVIORAL|Behavioral motivation|Optimization of medical care in diabetes
219249868|NCT00065234|PROCEDURE|Acupuncture|
219249869|NCT00433498|DRUG|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
219249870|NCT00433498|DRUG|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
219249871|NCT00433498|DRUG|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
219249872|NCT00433498|DRUG|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
219249873|NCT05550584|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
219249874|NCT05550584|DEVICE|LMA|Mechanical ventilation performed by a laringeal mask
219249875|NCT00296309|DRUG|Tacrolimus|Immunosuppression
219249876|NCT06385288|OTHER|Blood and tissue collection for immunological studies, advanced imaging.|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
219249877|NCT06385288|OTHER|neoadjuvant Therapy|neoadjuvant Therapy
219249878|NCT00257556|DRUG|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
219249879|NCT00257556|DRUG|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
219249880|NCT05351697|DRUG|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
219249881|NCT02225288|DRUG|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
219249882|NCT06026462|DIAGNOSTIC_TEST|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
219249883|NCT03760809|DRUG|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
219249884|NCT03760809|DRUG|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
219249885|NCT05324748|DRUG|Methylprednisolone|Injection with prednisolon
219249886|NCT05324748|DRUG|Saline solution|0,9%
219249887|NCT00905255|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
219249888|NCT00905255|DEVICE|Pen auto-injector|
219249889|NCT06383507|DRUG|CHT101|After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
219249890|NCT02506322|BEHAVIORAL|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management"
219249891|NCT02506322|BEHAVIORAL|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
219249892|NCT04178876|PROCEDURE|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
219249893|NCT04178876|PROCEDURE|stripping technique|Endometrioma laparoscopic cystectomy
219249894|NCT02240836|OTHER|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
219249895|NCT00807053|DRUG|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
219249896|NCT00807053|DRUG|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
219249897|NCT00807053|DRUG|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
219249898|NCT00807053|DRUG|Placebo|Placebo
219249899|NCT00383994|DRUG|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
219249900|NCT00383994|DRUG|Rituximab|375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
219249901|NCT00383994|BIOLOGICAL|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
219249902|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
219249903|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
219249904|NCT03479502|DRUG|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
219249905|NCT03479502|DRUG|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
219249906|NCT02716272|DRUG|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
219249907|NCT02716272|DRUG|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
219249908|NCT02297945|DRUG|metyrapone|Single arm study
219249909|NCT03826056|BEHAVIORAL|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
219249910|NCT03826056|BEHAVIORAL|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
219249911|NCT02821572|BIOLOGICAL|blood sample|
219249912|NCT02821572|PROCEDURE|spleen sample|
219249913|NCT05274490|PROCEDURE|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
219249914|NCT02400398|OTHER|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
219249915|NCT05357599|DIAGNOSTIC_TEST|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
219249916|NCT00966706|DRUG|capecitabine|Given systemically
219249917|NCT00966706|DRUG|cisplatin|Given systemically
219249918|NCT00966706|DRUG|docetaxel|Given systemically
219249919|NCT00966706|DRUG|epirubicin hydrochloride|Given systemically
219249920|NCT00966706|DRUG|gemcitabine hydrochloride|Given systemically
219249921|NCT06061588|DEVICE|Virtual Reality|The use of virtual reality as an adjunct to routine treatment.
219249922|NCT06367244|BEHAVIORAL|Transplant Wellness Program - Kidney and Liver|The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
219249923|NCT00163748|DRUG|gemcitabine, vinorelbine|
219249924|NCT01681394|DIETARY_SUPPLEMENT|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
219249925|NCT01681394|DIETARY_SUPPLEMENT|Chocolate cream|
219249926|NCT03031353|DRUG|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
219249927|NCT03031353|DRUG|Placebos|placebos tablet will be given before elective Cesarean sections
219249928|NCT04974021|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
219249929|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249930|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249931|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249932|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249933|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249934|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249935|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
219249936|NCT01428622|DRUG|Olodaterol|aqueous solution
219249937|NCT01428622|DRUG|Olodaterol|aqueous solution
219249938|NCT01428622|DRUG|Olodaterol|aqueous solution
219249939|NCT01428622|DRUG|Olodaterol|aqueous solution
219249940|NCT01428622|DRUG|Olodaterol|aqueous solution
219249941|NCT01428622|DRUG|Olodaterol|aqueous solution
219249942|NCT01428622|DRUG|Olodaterol|aqueous solution
219249943|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249944|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249945|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249946|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249947|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249948|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249949|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
219249950|NCT01428622|DRUG|BI54903|ethanolic solution
219249951|NCT01428622|DRUG|BI54903|ethanolic solution
219249952|NCT01428622|DRUG|BI54903|ethanolic solution
219249953|NCT01428622|DRUG|BI54903|ethanolic solution
219249954|NCT01428622|DRUG|BI54903|ethanolic solution
219249955|NCT01428622|DRUG|BI54903|ethanolic solution
219249956|NCT01428622|DRUG|BI54903|ethanolic solution
219249957|NCT02418819|DRUG|PF-06412562 3mg BID|PF-06412562
219249958|NCT02418819|DRUG|PF-06412562 9mg BID|PF-06412562
219249959|NCT02418819|DRUG|PF-06412562 45mg BID|PF-06412562
219249960|NCT02418819|OTHER|Placebo|Placebo
219249961|NCT05698888|DRUG|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
219249962|NCT01299324|DEVICE|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
219249963|NCT05776745|BEHAVIORAL|Speech|Patients read specific words and sentences
219249964|NCT05776745|DEVICE|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
219249965|NCT00386802|DRUG|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
219249966|NCT04743999|OTHER|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
219249967|NCT03191526|DRUG|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
219249968|NCT03191526|DRUG|Placebo (saline)|Intravenous injection every 12 weeks.
219249969|NCT02523417|PROCEDURE|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
219249970|NCT01597999|RADIATION|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
219249971|NCT01721759|DRUG|Nivolumab|
219249972|NCT00003731|DRUG|temozolomide|
219249973|NCT01400945|DRUG|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
219249974|NCT01786915|DRUG|Bendavia 10mg|
219249975|NCT01786915|DRUG|Bendavia 50mg|
219249976|NCT01786915|DRUG|Placebo|
219249977|NCT00040729|GENETIC|mutation analysis|
219249978|NCT04733989|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
219249979|NCT03094520|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
219249980|NCT03094520|DEVICE|sham-tDCS|sham stimulation
219249981|NCT05347524|OTHER|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
219249982|NCT06296888|PROCEDURE|Radiofrequency balloon catheter ablation|Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
219176207|NCT06796387|BEHAVIORAL|Usual Care|During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
219176208|NCT06343896|OTHER|monitorization reliability|evaluation of the use of the integral pulmonary index in the child patient group
219176209|NCT02587897|OTHER|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
219176210|NCT02587897|OTHER|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
219176211|NCT05991986|OTHER|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100\~500 ml of midstream urine, 20\~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
219249983|NCT03214471|BEHAVIORAL|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
219249984|NCT04475016|DRUG|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
219249985|NCT04475016|DRUG|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
219249986|NCT04475016|DRUG|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
219249987|NCT04475016|DRUG|Nimotuzumab|400 mg IV on Day 1
219249988|NCT04475016|DRUG|Triprilimab|240 mg IV on Day 1
219249989|NCT02544841|BEHAVIORAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
219249990|NCT02544841|BEHAVIORAL|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
219249991|NCT00580047|DRUG|Zoledronic Acid|4mg IV Annually
219249992|NCT00580047|COMBINATION_PRODUCT|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
219249993|NCT00580047|DRUG|Alendronate|70mg weekly
219249994|NCT04382053|DRUG|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
219249995|NCT04382053|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
219249996|NCT00924833|DRUG|placebo|placebo tablet BID
219249997|NCT00924833|DRUG|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
219249998|NCT00924833|DRUG|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
219249999|NCT04121949|DEVICE|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
219250000|NCT03042572|DRUG|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
219250001|NCT03042572|OTHER|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
219250002|NCT06197100|OTHER|Supportive care training|The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.
219250003|NCT06197100|OTHER|control grups|Mothers in this group will be given an educational brochure containing information about colic.
219250004|NCT01776749|DEVICE|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
219250005|NCT00390806|DRUG|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
219250006|NCT00390806|RADIATION|Radiation|Whole brain radiation
219250007|NCT01879735|DRUG|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
219250008|NCT01879735|DRUG|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
219250009|NCT02465606|DRUG|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
219250010|NCT02465606|DRUG|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
219250011|NCT00513292|DRUG|Cyclophosphamide|Given IV
219250012|NCT00513292|DRUG|Epirubicin Hydrochloride|Given IV
219250013|NCT00513292|OTHER|Laboratory Biomarker Analysis|Correlative studies
219250014|NCT00513292|DRUG|Paclitaxel|Given IV
219250015|NCT00513292|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219250016|NCT00513292|BIOLOGICAL|Trastuzumab|Given IV
219250017|NCT01630161|BEHAVIORAL|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
219250018|NCT01630161|BEHAVIORAL|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
219250019|NCT05833399|DRUG|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
219250020|NCT05480202|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
219250021|NCT05480202|OTHER|Designed chest physical therapy program|Percussion, vibration and postural drainage
219250022|NCT04910061|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
219250023|NCT01265914|BIOLOGICAL|FP-01.1|Ascending doses of FP-01.1 will be administered
219250024|NCT01265914|BIOLOGICAL|placebo|
219250025|NCT04532008|BEHAVIORAL|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
219250026|NCT02580981|OTHER|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
219250027|NCT00124644|DRUG|cytarabine|
219250028|NCT00124644|DRUG|daunorubicin hydrochloride|
219250029|NCT00124644|DRUG|etoposide|
219250030|NCT00124644|DRUG|tipifarnib|
219250031|NCT00124644|PROCEDURE|chemotherapy|
219250032|NCT00124644|PROCEDURE|enzyme inhibitor therapy|
219250033|NCT00124644|PROCEDURE|high-dose chemotherapy|
219250034|NCT02319304|DRUG|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
219250035|NCT02319304|RADIATION|Low dose fractionated radiation therapy (LDFRT)|see arm description
219250036|NCT04685759|OTHER|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
219250037|NCT04685759|OTHER|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
219250038|NCT01874470|DEVICE|renal denervation|
219250039|NCT01874470|OTHER|standard medication|
219250040|NCT04915456|DRUG|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
219250041|NCT04915456|OTHER|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
219250042|NCT02785900|DRUG|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
219250043|NCT02785900|DRUG|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
219250044|NCT02785900|DRUG|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
219250045|NCT02785900|DRUG|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
219250046|NCT05206916|PROCEDURE|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
219250047|NCT02077556|DRUG|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
219250048|NCT02077556|DRUG|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)
219250049|NCT02077556|DRUG|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
219250050|NCT02077556|DRUG|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
219250051|NCT02077556|DRUG|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
219250052|NCT01808144|DRUG|lesinurad|Tablets, 400 mg once daily (QD)
219250053|NCT01808144|DRUG|lesinurad|Tablets, 200 mg QD
219250054|NCT01808144|DRUG|febuxostat|Tabletsm 80 mg QD
219250055|NCT00409500|DRUG|AQW051|
219250056|NCT05493605|PROCEDURE|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
219250057|NCT06133569|BEHAVIORAL|ReDirection|Self help program based on principles for cognitive behavioral therapy
219250058|NCT04425070|COMBINATION_PRODUCT|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
219250059|NCT04425070|COMBINATION_PRODUCT|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
219250060|NCT04425070|COMBINATION_PRODUCT|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
219250061|NCT06088082|DRUG|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
219250062|NCT06647121|BEHAVIORAL|ACT Psychoeducational Workshop|The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
219250063|NCT06647121|BEHAVIORAL|ACTaide Mobile App|The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
219250064|NCT06647121|BEHAVIORAL|Reminders-only mobile app|This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
219250065|NCT02744105|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
219250066|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 1 Creatine HCl|Creatine hcl
219250067|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 2 Creatine HCl|Creatine hcl
219250068|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 3 Creatine Ethyl ester|Creatine ethyl ester
219250069|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 4 Placebo|Placebo
219250070|NCT06601504|DRUG|HMPL-760 planned dose 1|HMPL-760 planned dose 1 daily (QD) orally
219250071|NCT06601504|DRUG|R-GemOx|R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
219250072|NCT06601504|DRUG|HMPL-760 placebo planned dose 1|HMPL-760 placebo planned dose 1 daily (QD) orally
219250073|NCT06601504|DRUG|HMPL-760 planned dose 2|HMPL-760 planned dose 2 daily (QD) orally
219250074|NCT06601504|DRUG|HMPL-760 placebo planned dose 2|HMPL-760 placebo planned dose 2 daily (QD) orally
219250075|NCT03476551|DRUG|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
219250076|NCT06996327|OTHER|Evaluation of dietary consumption of UPFs|Evaluation of dietary consumption of ultraprocessed foods
219250077|NCT02697552|DRUG|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
219250078|NCT00383500|DEVICE|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
219250079|NCT00383500|DEVICE|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
219250080|NCT06519981|DRUG|HRS-9231or matching placebo|HRS-9231 injection or matching placebo will be administered through IV injection.
219250081|NCT07000097|DEVICE|PTA planning supported by 3D-printed model|Custom-made 3D-printed model as an additional tool to computed tomography angiography for planning Percutaneous Transluminal Angioplasty in aorto-iliac-femoral-popliteal artery disease
219250082|NCT07000097|DEVICE|PTA (Standard of Care)|Preoperative planning performed based on computed tomography angiography
219250083|NCT06324188|OTHER|Early atrial fibrillation ablation|Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
219250084|NCT06324188|OTHER|Usual Care|Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
219250085|NCT07000435|DEVICE|3D printed custom-made mouth guards|Participants in the first group will receive 3D printed custom-made mouth guards
219250086|NCT07000435|DEVICE|Traditional custom-made mouth guards|Participants in the active comparator arm will receive traditional custom-made mouth guards as an intervention
219362818|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
219250087|NCT07001228|BEHAVIORAL|SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~For SD rehabilitation, shoulder external rotation, push up plus, and shoulder rolls were performed. In the experimental group, rehabilitation for scapular dyskinesis will begin at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
219250088|NCT07001228|BEHAVIORAL|No SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~In the sham group, rehabilitation for scapular dyskinesis will not begun at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
219250089|NCT04907877|DIETARY_SUPPLEMENT|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
219250090|NCT04907877|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
219296218|NCT04059172|DRUG|Placebo oral tablet|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
219296219|NCT04865133|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219296220|NCT04865133|OTHER|Electronic Health Record Review|Medical record reviewed
219296221|NCT04972565|BEHAVIORAL|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
219296222|NCT02391753|DEVICE|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
219296223|NCT04595565|DRUG|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
219296224|NCT04595565|DRUG|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
219296225|NCT04595565|DRUG|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
219296226|NCT04595565|DRUG|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
219296227|NCT03642626|DRUG|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
219296228|NCT03642626|DRUG|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
219296229|NCT03642626|DRUG|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
219296230|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
219296231|NCT03642626|DRUG|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
219296232|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
219296233|NCT03642626|DRUG|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
219296234|NCT03642626|DRUG|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
219296235|NCT03642626|DRUG|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
219250091|NCT02176356|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
219250092|NCT02176356|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
219250093|NCT02176356|DEVICE|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
219250094|NCT02176356|DEVICE|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
219250095|NCT02176356|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
219250096|NCT03148483|OTHER|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
219250097|NCT03148483|OTHER|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
219296236|NCT03642626|DRUG|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
219296237|NCT03642626|DRUG|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
219743665|NCT06301815|DIAGNOSTIC_TEST|Scale for Contraversive Pushing|Lateropulsion will be assessed using the Scale for Contraversive Pushing (SCP). It involves observation of the posture of the participant in sitting and standing. Scores are assessed in sitting and standing giving a maximum score of 6.
219743666|NCT06301815|DIAGNOSTIC_TEST|Catherine Bergego Scale|Neglect will be assessed using the Catherine Bergego Scale. The scale is a 10-point scale with each item scored between 0 (no neglect) and 3 (severe neglect). It involves observation of a participant completing daily activities such as eating, dressing and walking.
219743667|NCT06301815|DIAGNOSTIC_TEST|Bucket Test|"The bucket test involves the patient being sat upright and looking into a translucent bucket with the bucket covering their complete field of vision. On the inside of the bucket on the bottom is a dark straight line. On the outside of the bottom of the bucket is a matching dark line, the bottom of the bucket is divided into degrees with the zero-degree line being equivalent to the line inside the bucket. For measurement the bucket will be randomly rotated right or left by the examiner to 45 degrees and then slowly rotated back to the zero-degree position. Patients will signal when they estimate the inside bottom line to be truly vertical by saying stop or by raising their non-paretic hand."
219743668|NCT04677361|COMBINATION_PRODUCT|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
219743669|NCT02372357|DRUG|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
219743670|NCT02372357|PROCEDURE|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
219743671|NCT01893099|DRUG|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
219743672|NCT01893099|DEVICE|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
219743673|NCT05318443|DRUG|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
219743674|NCT05318443|DRUG|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
219743675|NCT05318443|DRUG|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
219743676|NCT05318443|DRUG|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
219743677|NCT02951819|DRUG|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
219743678|NCT02951819|DRUG|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
219743679|NCT02951819|DRUG|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
219743680|NCT02951819|DRUG|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
219743681|NCT05273437|BEHAVIORAL|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
219743682|NCT03173378|OTHER|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
219743683|NCT02440165|BEHAVIORAL|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
219743684|NCT01800110|DIETARY_SUPPLEMENT|pomegranate juice|
219743685|NCT04877366|DIETARY_SUPPLEMENT|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
219743686|NCT04877366|OTHER|Reference control|A placebo matching to the test product will be used as control
219743687|NCT04877366|OTHER|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
219743688|NCT05032222|OTHER|Uroflowmetry|Diagnostic test
219743689|NCT05116345|DRUG|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
219743690|NCT05116345|DRUG|Topical Dexamethasone|topical dexamethasone drops
219743691|NCT05274698|BEHAVIORAL|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
219250098|NCT03148483|DIETARY_SUPPLEMENT|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
219250099|NCT03148483|DIETARY_SUPPLEMENT|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
219250100|NCT00174356|DRUG|CI 1033|
219250101|NCT00174356|DRUG|PACLITAXEL|
219250102|NCT00174356|DRUG|CARBOPLATIN|
219250103|NCT02591706|DEVICE|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
219250104|NCT02674048|OTHER|Metvix|
219250105|NCT03659890|DIETARY_SUPPLEMENT|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
219250106|NCT03659890|DIETARY_SUPPLEMENT|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
219250107|NCT03659890|DIETARY_SUPPLEMENT|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
219250108|NCT00996814|BEHAVIORAL|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
219250109|NCT05808062|PROCEDURE|Root canal obturation|Root canal dryness
219250110|NCT00332488|DRUG|Technosphere Insulin|Inhalation, 15U/30U, prandial
219250111|NCT00332488|DRUG|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
219250112|NCT00332488|DRUG|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
219250113|NCT00066378|DRUG|anastrozole|
219250114|NCT00066378|DRUG|gefitinib|
219250115|NCT00371462|BEHAVIORAL|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
219250116|NCT00371462|BEHAVIORAL|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
219250117|NCT05592769|DEVICE|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
219250118|NCT02983877|BEHAVIORAL|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
219250119|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
219250120|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
219250121|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
219250122|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
219250123|NCT02955706|DRUG|Acetyl-L-Carnitine|TID
219250124|NCT02955706|DRUG|Placebo of Acetyl-L-Carnitine|TID
219250125|NCT03721978|BIOLOGICAL|VGX-3100|1 milliliter (mL) VGX-3100 injected IM.
219250126|NCT03721978|BIOLOGICAL|Matched Placebo|1 mL of matched Placebo injected IM.
219250127|NCT03721978|DEVICE|CELLECTRA™-5PSP|CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
219250128|NCT01782729|DRUG|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
219250129|NCT05244226|DRUG|Fentanyl/Hydromorphone|Per routine care
219250130|NCT05244226|DRUG|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
219250131|NCT03767972|DEVICE|Energy-based device|Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
219250132|NCT02048683|DRUG|Short term sedation with sevoflurane in ICU|
219250133|NCT03453424|PROCEDURE|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
219250134|NCT03453424|PROCEDURE|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
219250135|NCT00605995|DRUG|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
219250136|NCT02459236|DRUG|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
219250137|NCT02459236|DRUG|Placebo|
219250138|NCT02841345|OTHER|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
219250139|NCT01165359|DRUG|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
219250140|NCT01165359|DRUG|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days."
219250141|NCT03038945|OTHER|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
219250142|NCT03038945|OTHER|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
219250143|NCT01801423|DRUG|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
219250144|NCT05163106|DRUG|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
219250145|NCT05163106|DRUG|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
219250146|NCT02507687|DRUG|Bimatoprost SR|Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
219250147|NCT02507687|DRUG|Sham Bimatoprost SR|Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
219250148|NCT02507687|PROCEDURE|Selective Laser Trabeculoplasty|"SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method."
219250149|NCT02507687|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
219250150|NCT06214598|DIETARY_SUPPLEMENT|Supplement|Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
219250151|NCT06214598|DIETARY_SUPPLEMENT|AI diet|diet rich in whole grains, healthy oils and polyphenols,
219250152|NCT06214598|DIETARY_SUPPLEMENT|Placebo|Placebo caps with standard diet
219250153|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
219250154|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
219250155|NCT03822195|PROCEDURE|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
219250156|NCT00733226|DRUG|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
219250157|NCT00733226|DRUG|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
219250158|NCT02397343|DRUG|Hyperbaric oxygen|
219250159|NCT03964181|OTHER|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
219250160|NCT04596605|OTHER|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
219250161|NCT04596605|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules daily for 12 weeks
219296238|NCT03642626|DRUG|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
219296239|NCT05929209|DIAGNOSTIC_TEST|Assessment of disease biomarkers|Assessment of serum, histological and radiological biomarkers
219250162|NCT02845310|PROCEDURE|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
219250163|NCT02845310|PROCEDURE|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
219250164|NCT01911923|PROCEDURE|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
219250165|NCT01911923|PROCEDURE|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
219250166|NCT05705336|DRUG|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
219250167|NCT05705336|DRUG|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
219250168|NCT03014817|PROCEDURE|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
219250169|NCT03014817|PROCEDURE|Electrocautery|Dissection with electrocautery
219250170|NCT03722485|DEVICE|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
219250171|NCT03722485|BIOLOGICAL|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
219250172|NCT03477409|OTHER|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
219250173|NCT00349622|DRUG|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
219250174|NCT00349622|OTHER|placebo|an inactive substance
219250175|NCT06478108|DEVICE|IRSW-MIM|IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
219250176|NCT06292559|DEVICE|Bilateral STN deep brain stimulation|patients with Meige syndrome underwent bilateral subthalamic stimulation
219250177|NCT06292559|DEVICE|Bilateral GPi deep brain stimulation|patients with Meige syndrome underwent bilateral pallidal stimulation
219250178|NCT04662736|OTHER|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
219250179|NCT01902381|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219250180|NCT00942513|OTHER|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
219250181|NCT00942513|OTHER|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
219250182|NCT00942513|OTHER|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
219296240|NCT06145438|DRUG|Dienogest|Drug is administered orally at the same time every day
219250183|NCT00942513|OTHER|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
219250184|NCT00942513|OTHER|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
219250185|NCT00942513|OTHER|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
219250186|NCT00942513|OTHER|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
219296241|NCT06145438|DRUG|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
219296242|NCT06145438|DRUG|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
219296243|NCT06145438|DRUG|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
219362819|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
219250187|NCT06170502|DEVICE|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
219250188|NCT05138432|BEHAVIORAL|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
219250189|NCT00755716|DRUG|Placebo (sugar pill)|patients receive
219250190|NCT00755716|DRUG|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
219250191|NCT00755716|DRUG|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
219250192|NCT02394509|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
219250193|NCT02762500|DRUG|LYC-30937-EC|
219250194|NCT02762500|DRUG|Placebo|
219250195|NCT02413099|DRUG|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
219250196|NCT00021021|BIOLOGICAL|anti-FLT-1 ribozyme|
219250197|NCT01565239|DEVICE|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
219250198|NCT02599077|DRUG|Dienogest|patients assigned to this treatment receive 2 milligrams per day
219250199|NCT02599077|DRUG|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
219250200|NCT01502787|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
219250201|NCT01502787|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
219250202|NCT01502787|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
219250203|NCT01502787|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
219250204|NCT01502787|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
219362820|NCT03342950|DRUG|Topical Solution|Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
219250205|NCT01502787|PROCEDURE|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
219250206|NCT01502787|DRUG|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
219250207|NCT00377312|DRUG|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
219250208|NCT02775214|DEVICE|Video Laryngoscopy|
219250209|NCT06227442|DIAGNOSTIC_TEST|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
219250210|NCT00192166|BIOLOGICAL|CAIV-T|
219250211|NCT03398434|DRUG|MAA868|3 MAA868 doses, single administration, subcutaneous,
219250212|NCT03398434|DRUG|Apixaban|Apixaban 5 mg b.i.d
219250213|NCT00762723|DEVICE|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
219250214|NCT02751645|PROCEDURE|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
219250215|NCT02145897|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
219250216|NCT02145897|BIOLOGICAL|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
219250217|NCT02145897|OTHER|Control|
219250218|NCT03279536|COMBINATION_PRODUCT|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
219250219|NCT03279536|COMBINATION_PRODUCT|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
219250220|NCT00045097|DRUG|ixabepilone|
219250221|NCT02779283|DRUG|Cyclophosphamide|Given IV
219250222|NCT02779283|DRUG|Cytarabine|Given IV
219250223|NCT02779283|DRUG|Dasatinib|Given PO
219250224|NCT02779283|DRUG|Dexamethasone|Given PO
219250225|NCT02779283|DRUG|Doxorubicin Hydrochloride|Given IV
219250226|NCT02779283|DRUG|Idarubicin|Given IV
219250227|NCT02779283|DRUG|Idelalisib|Given PO
219250228|NCT02779283|DEVICE|In Vitro Kinase Inhibitor Assay|Correlative studies
219250229|NCT02779283|DRUG|Leucovorin Calcium|Given IV
219250230|NCT02779283|DRUG|Methotrexate|Given IV
219250231|NCT02779283|DRUG|Methylprednisolone Sodium Succinate|Given IV
219250232|NCT02779283|DRUG|Ponatinib Hydrochloride|Given PO
219250233|NCT02779283|BIOLOGICAL|Rituximab|Given IV
219250234|NCT02779283|DRUG|Ruxolitinib Phosphate|Given PO
219250235|NCT02779283|DRUG|Sorafenib Tosylate|Given PO
219250236|NCT02779283|DRUG|Sunitinib Malate|Given PO
219250237|NCT02779283|DRUG|Vincristine Sulfate|Given IV
219250238|NCT05082662|DRUG|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|One Diclofenac tablet was administered orally.
219250239|NCT05082662|DRUG|Cataflam® 50 coated tablet|One Diclofenac tablet was administered orally.
219250240|NCT02185365|RADIATION|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
219250241|NCT01191697|DRUG|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
219250242|NCT01191697|DRUG|trastuzumab|Given intravenously on day 1 of each treatment cycle
219250243|NCT01191697|DRUG|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
219250244|NCT01191697|DRUG|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
219250245|NCT03939793|BEHAVIORAL|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
219250246|NCT03939793|BEHAVIORAL|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
219250247|NCT03939793|OTHER|Usual Care|Usual Care
219250248|NCT06154798|BEHAVIORAL|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
219250249|NCT04232488|PROCEDURE|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
219250250|NCT04232488|PROCEDURE|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
219250251|NCT00635011|BEHAVIORAL|psychotherapy|Cognitive Behavioral therapy
219250252|NCT01514630|DRUG|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
219250253|NCT01170871|DRUG|Ixabepilone|
219250254|NCT01170871|DRUG|Pemetrexed|
219250255|NCT03861429|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
219250256|NCT03942861|DRUG|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
219250257|NCT02338778|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
219250258|NCT02338778|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
219250259|NCT01447251|BEHAVIORAL|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
219250260|NCT04985747|OTHER|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
219250261|NCT04985747|OTHER|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
219250262|NCT04985747|OTHER|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
219250263|NCT03974451|DEVICE|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
219250264|NCT03974451|DEVICE|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
219296244|NCT05003609|OTHER|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
219250265|NCT06538727|OTHER|Osteopathic Manipulation Treatment - Scapular Release|First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
219250266|NCT01553578|OTHER|questionnaire administration|Ancillary studies
219250267|NCT01553578|PROCEDURE|therapeutic touch|Receive healing touch therapy
219250268|NCT01553578|BEHAVIORAL|management of therapy complications|Receive healing touch therapy
219250269|NCT01553578|BEHAVIORAL|management of therapy complications|Receive guided imagery audiotapes
219250270|NCT01553578|PROCEDURE|standard follow-up care|Receive standard care
219250271|NCT03661749|OTHER|clean catch|clean catch technique applied to collect urine for PR/CR ratio
219250272|NCT01842399|DIETARY_SUPPLEMENT|Resveratrol|Nutriceutical
219250273|NCT01842399|DRUG|Placebo|2x/day orally
219250274|NCT04330261|OTHER|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
219250275|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
219250276|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
219250277|NCT03266003|OTHER|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
219250278|NCT03266003|OTHER|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
219250279|NCT05240482|PROCEDURE|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
219250280|NCT03327051|DRUG|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
219250281|NCT03327051|DIETARY_SUPPLEMENT|VSL #3|Probiotics
219250282|NCT03327051|DRUG|Placebo|Placebo to match omeprazole
219250283|NCT01145859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
219250284|NCT00424723|DRUG|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
219250285|NCT05348642|DIETARY_SUPPLEMENT|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
219250286|NCT05348642|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
219250287|NCT06108752|OTHER|Scapular stabilization exercises|The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
219250288|NCT06108752|OTHER|Thoracic extension exercises|Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
219250289|NCT02271737|BEHAVIORAL|Training HC/VHSG, Health Education, and Supportive Supervision|1\. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
219250290|NCT05789927|PROCEDURE|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
219250291|NCT03086070|DRUG|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
219250292|NCT03086070|DRUG|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
219250293|NCT02635711|BEHAVIORAL|Adapted Taekwondo training|Adapted Taekwondo training for beginners
219250294|NCT02635711|BEHAVIORAL|Control|Daily jogging
219250295|NCT05946447|DEVICE|Ultrasound|The gastric antrum will be scanned using ultrasound.
219250296|NCT00393198|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
219250297|NCT00393198|DRUG|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
219250298|NCT00393198|DRUG|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
219250299|NCT00412828|DRUG|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
219250300|NCT02156999|DEVICE|Ibandronic acid, vitamin D|
219250301|NCT02608697|DRUG|CAT-2054|
219250302|NCT02608697|DRUG|Placebo|
219250303|NCT02608697|DRUG|Atorvastatin|
219250304|NCT02980198|BIOLOGICAL|IFN-Kinoid|IM administration
219250305|NCT02980198|OTHER|Placebo|IM administration
219250306|NCT02980198|OTHER|ISA 51|adjuvant
219250307|NCT01723332|BEHAVIORAL|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
219250308|NCT01723332|BEHAVIORAL|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
219250309|NCT03134976|DRUG|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
219250310|NCT02669888|DRUG|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
219250311|NCT02669888|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
219250312|NCT04949789|OTHER|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
219250313|NCT04949789|OTHER|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
219250314|NCT04949789|OTHER|IP I|2 Capsules to be taken 30 minutes before breakfast.
219250315|NCT04949789|OTHER|IP II|2 Capsules to be taken 30 minutes before breakfast.
219250316|NCT04949789|OTHER|IP III|2 Capsules to be taken 30 minutes before breakfast.
219250317|NCT04912102|DEVICE|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
219250318|NCT06330857|PROCEDURE|Laparoscopic vaginorectopexy|Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
219250319|NCT01661244|DRUG|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
219250320|NCT01661244|DRUG|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
219250321|NCT01661244|DRUG|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
219250322|NCT01661244|DRUG|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
219250323|NCT03440788|DRUG|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
219250324|NCT01846637|PROCEDURE|laparoscopic sleeve gastrectomy|
219250325|NCT02503306|DRUG|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
219250326|NCT02503306|DRUG|placebo|Pharmaceutical form:tablets Route of administration: oral
219250327|NCT00889733|DRUG|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
219250328|NCT00912054|DRUG|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
219250329|NCT00912054|DRUG|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
219362821|NCT03342950|DRUG|Placebos|Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
219362822|NCT00135460|DRUG|nucleoside analogue sparing HAART regimen|
219362823|NCT00179959|DRUG|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
219362824|NCT00179959|DRUG|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
219362825|NCT00179959|DRUG|Water|Water baths twice weekly for three months
219250330|NCT05372913|DEVICE|Woebot for Adolescents (W-GenZD) Mobile Application|"Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
219250331|NCT05372913|BEHAVIORAL|CBT-Lite Teletherapy Group|The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
219250332|NCT02842125|DRUG|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
219250333|NCT02842125|DRUG|Xeloda|Oral metronomic chemotherapeutic agent
219250334|NCT02842125|DRUG|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
219250335|NCT02842125|DRUG|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
219250336|NCT01137552|DRUG|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
219250337|NCT02810483|DRUG|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
219250338|NCT02810483|DRUG|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
219250339|NCT02149576|PROCEDURE|Low Dose Computed Tomography Imaging|
219250340|NCT02149576|PROCEDURE|Chest Radiograph Imaging|
219250341|NCT03275402|BIOLOGICAL|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
219250342|NCT06036797|DRUG|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
219250343|NCT06036797|DRUG|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
219250344|NCT06036797|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
219250345|NCT00199992|PROCEDURE|application of autologous platelet gel|
219250346|NCT02727647|DRUG|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
219250347|NCT02727647|DRUG|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
219250348|NCT00647283|PROCEDURE|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
219250349|NCT02835937|OTHER|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
219250350|NCT03968536|BEHAVIORAL|fall prevention|Training in physiotherapy sessions and ergonomic home development
219250351|NCT00694564|DRUG|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
219250352|NCT03378778|PROCEDURE|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
219250353|NCT02402465|DRUG|Placebo|Patients will be treated by placebo
219250354|NCT02402465|DRUG|Fluticasone propionate|Patients will receive fluticasone nasal spray
219250355|NCT02402465|DRUG|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
219362826|NCT00179959|DRUG|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
219362827|NCT00000704|DRUG|Zalcitabine|
219362828|NCT01592201|DRUG|Paliperdidone ER|Form = osmotic release oral system, route = oral
219250356|NCT02402465|PROCEDURE|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
219250357|NCT05004805|DRUG|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
219250358|NCT05004805|DRUG|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
219250359|NCT04392479|DRUG|Aflibercept-FOLFIRI|Aflibercept-FOLFIRI
219250360|NCT04392479|DRUG|Aflibercept-mFOLFIRI3|Aflibercept-mFOLFIRI3
219250361|NCT01763034|PROCEDURE|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
219250362|NCT05537519|BIOLOGICAL|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
219250363|NCT06031870|DEVICE|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
219250364|NCT06031870|BEHAVIORAL|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
219250365|NCT06031870|PROCEDURE|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
219250366|NCT01296178|DRUG|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
219250367|NCT01296178|DRUG|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
219250368|NCT03807700|DRUG|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
219250369|NCT00288379|DRUG|formoterol|
219250370|NCT00288379|DRUG|budesonide/formoterol|
219250371|NCT05021965|PROCEDURE|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
219250372|NCT03211897|DRUG|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
219250373|NCT03211897|DRUG|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
219250374|NCT03211897|DRUG|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
219250375|NCT03211897|DRUG|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
219250376|NCT04189341|DRUG|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219250377|NCT04189341|DRUG|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
219250378|NCT00785850|DRUG|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
219250379|NCT03630523|BIOLOGICAL|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
219250380|NCT02766010|DEVICE|TensorTip|Non Invasive screening of various physiological and hematological parameters.
219250381|NCT04632797|DEVICE|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
219250382|NCT01820221|PROCEDURE|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
219250383|NCT03738254|OTHER|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
219250384|NCT03738254|OTHER|Paper Survey|Paper version of daily survey
219250385|NCT03738254|OTHER|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
219250386|NCT00251290|PROCEDURE|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
219250387|NCT00570557|OTHER|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
219250388|NCT02005029|DRUG|Erythromycin|
219250389|NCT02005029|DRUG|placebo|
219250390|NCT00360750|DRUG|carboplatin|
219250391|NCT00360750|DRUG|cytarabine|
219250392|NCT00360750|DRUG|etoposide|
219250393|NCT00360750|DRUG|vincristine sulfate|
219250394|NCT00360750|OTHER|clinical observation|
219250395|NCT00360750|PROCEDURE|adjuvant therapy|
219250396|NCT00360750|RADIATION|radiation therapy|
219250397|NCT03191214|DEVICE|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
219250398|NCT03743129|DRUG|Anlotinib|Anlotinib 12mg p.o, qd
219250399|NCT01011127|DRUG|pravastatin, rosuvastatin|
219250400|NCT06120114|PROCEDURE|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
219250401|NCT02751801|OTHER|no intervention|
219250402|NCT03375840|BEHAVIORAL|Text-only PWL|Control condition
219250403|NCT03375840|BEHAVIORAL|Low-emot PWL|Pictorial warning
219250404|NCT03375840|BEHAVIORAL|High-emot PWL|Pictorial warning
219250405|NCT03375840|BEHAVIORAL|Immediate posttest|
219250406|NCT03375840|BEHAVIORAL|delay posttest|
219250407|NCT04811118|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
219250408|NCT04811118|DRUG|Taxotere|Taxotere
219250409|NCT02555488|DEVICE|diode laser|MB and diode
219250410|NCT02555488|DEVICE|diode laser|diode laser
219250411|NCT02555488|DRUG|Methylene blue|Methylene blue and diode laser was used
219250412|NCT06006832|DRUG|Steroid Drug|Maintaining low-dose oral steroids
219250413|NCT06006832|OTHER|Withdraw all immunosuppresants|Withdraw all immunosuppresants
219250414|NCT05450640|OTHER|satisfaction survey|1 eQuestionnaire per patient completed during study
219250415|NCT00001666|DEVICE|Cadwell High-Speed Magnetoelectric Stimulator|
219250416|NCT00001666|DEVICE|Magpro High-Speed Magnetoelectric Stimulator|
219250417|NCT02716857|DRUG|Oxycodone extended-release|
219250418|NCT02716857|DRUG|Placebo of oxycodone extended-release|
219250419|NCT03694119|DRUG|Phenelzine|Phenelzine
219250420|NCT03694119|DRUG|Tyramine|Tyramine
219250421|NCT03694119|DRUG|Phenelzine placebo|Phenelzine placebo
219250422|NCT03694119|DRUG|ozanimod placebo|ozanimod placebo
219250423|NCT03694119|DRUG|ozanimod|ozanimod
219362829|NCT01592201|DRUG|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
219250424|NCT04180306|OTHER|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
219250425|NCT04335370|OTHER|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion"
219250426|NCT03207698|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
219250427|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
219250428|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
219250429|NCT06215625|OTHER|Robot-assisted therapy|The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
219250430|NCT06215625|OTHER|Task-oriented training|The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.
219250431|NCT05127590|DRUG|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
219250432|NCT00683397|OTHER|Blood sampling|Screening of thrombophilia
219250433|NCT02599090|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
219250434|NCT02599090|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
219250435|NCT02599090|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
219250436|NCT02242799|DRUG|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
219250437|NCT02242799|DRUG|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
219250438|NCT02242799|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
219250439|NCT04717713|DRUG|steroid injection|steroid injection at surgical location
219250440|NCT04717713|DRUG|placebo|saline injection at surgical location
219250441|NCT02205723|BEHAVIORAL|Asthma teaching in ER|Asthma teaching
219250442|NCT02205723|BEHAVIORAL|Smartphone Asthma Control|Smartphone Asthma Control
219250443|NCT03739697|OTHER|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
219250444|NCT01370018|BIOLOGICAL|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
219250445|NCT03497780|PROCEDURE|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
219250446|NCT04056741|COMBINATION_PRODUCT|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
219250447|NCT03448289|BEHAVIORAL|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
219250448|NCT02125656|OTHER|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
219250449|NCT03386214|DRUG|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
219250450|NCT03386214|DRUG|Ruxolitinib|-Standard of care outside of protocol
219250451|NCT03386214|PROCEDURE|Peripheral blood draw|"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"
219250452|NCT03386214|PROCEDURE|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
219250453|NCT03809806|PROCEDURE|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
219250454|NCT03809806|DIAGNOSTIC_TEST|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
219250455|NCT03809806|DIAGNOSTIC_TEST|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
219250456|NCT03809806|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
219250457|NCT03809806|DIAGNOSTIC_TEST|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
219250458|NCT03809806|DIAGNOSTIC_TEST|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
219250459|NCT01525641|DRUG|Mirapex LA|Pramipexole Hydrochloride Hydrate
219250460|NCT04584216|OTHER|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
219250461|NCT04584216|OTHER|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
219250462|NCT01081119|BEHAVIORAL|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
219250463|NCT04213820|DEVICE|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
219250464|NCT04213820|BEHAVIORAL|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
219250465|NCT04213820|BEHAVIORAL|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
219250466|NCT00823446|DEVICE|Revera Wound Care|Revalesio Part Number MDW0060
219250467|NCT00823446|DEVICE|Normal Saline|Sodium Chloride for Irrigation
219250468|NCT01742650|PROCEDURE|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
219250469|NCT01742650|PROCEDURE|TightRope|TightRope transfixation of syndesmosis
219250470|NCT03255915|DRUG|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
219250471|NCT03255915|OTHER|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
219250472|NCT03643705|OTHER|Multi-component intervention|4 components as described
219250473|NCT03643705|OTHER|General prevention education|General education as described
219250474|NCT06054633|DIETARY_SUPPLEMENT|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
219250475|NCT06054633|DIETARY_SUPPLEMENT|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
219250476|NCT02552706|DIETARY_SUPPLEMENT|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
219250477|NCT02552706|DIETARY_SUPPLEMENT|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
219250478|NCT03279172|PROCEDURE|direct laryngoscope|procedure entubatıon
219250479|NCT03279172|PROCEDURE|videolaryngoscope|
219250480|NCT01016275|DEVICE|Misago (stent placement)|Misago iliac stent
219250481|NCT01123044|BIOLOGICAL|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
219250482|NCT01123044|PROCEDURE|Medical Therapy|Under usual care treatment
219250483|NCT04306445|DEVICE|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
219250484|NCT04306445|DIETARY_SUPPLEMENT|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
219250485|NCT04306445|PROCEDURE|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
219250486|NCT03417375|PROCEDURE|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
219362830|NCT04123158|DIAGNOSTIC_TEST|Ultrasound|"Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]"
219250487|NCT04051645|DEVICE|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
219250488|NCT00856453|BEHAVIORAL|Home yoga practice|training for and tracking of patient's practice of yoga at home
219250489|NCT00856453|BEHAVIORAL|yoga classes|organized out of home classes for yoga
219250490|NCT05557253|DRUG|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
219250491|NCT05557253|DRUG|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
219250492|NCT02231814|DIETARY_SUPPLEMENT|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
219250493|NCT02231814|OTHER|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
219250494|NCT03994900|DIAGNOSTIC_TEST|Blood sampling for HbNO assessment|Blood sampling
219250495|NCT01955720|DRUG|BI 655075|
219250496|NCT01955720|DRUG|BI 655075|
219250497|NCT01955720|DRUG|Placebo|
219250498|NCT01955720|DRUG|BI 655075|
219250499|NCT01955720|DRUG|Placebo|
219250500|NCT01955720|DRUG|Placebo|
219250501|NCT01955720|DRUG|Placebo|
219250502|NCT01955720|DRUG|BI 655075|
219250503|NCT05281419|OTHER|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
219250504|NCT05281419|OTHER|No intralesional triamcinolone injection|No intralesional triamcinolone injection
219250505|NCT02513810|DEVICE|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
219250506|NCT02513810|DEVICE|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
219250507|NCT01386411|GENETIC|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
219250508|NCT03005483|DRUG|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
219250509|NCT03005483|OTHER|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
219250510|NCT00191984|DRUG|pemetrexed|400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
219250511|NCT00191984|DRUG|irinotecan|180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
219250512|NCT04759599|PROCEDURE|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
219250513|NCT05112172|OTHER|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
219250514|NCT05422040|OTHER|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
219250515|NCT05422040|OTHER|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
219250516|NCT02137239|DRUG|Thymoglobulin|
219250517|NCT02137239|DRUG|Belatacept|
219250518|NCT02137239|DRUG|mycophenolate mofetil(MMF)|
219250519|NCT02137239|DRUG|Corticosteroids|
219250520|NCT02137239|DRUG|Everolimus(EVL)|
219250521|NCT02137239|DRUG|Tacrolimus(TAC)|
219250522|NCT04185142|COMBINATION_PRODUCT|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
219250523|NCT00100945|DRUG|gefitinib|
219250524|NCT06254079|PROCEDURE|video based education|The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
219250525|NCT05331716|PROCEDURE|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
219250526|NCT04362111|DRUG|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
219250527|NCT04362111|DRUG|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
219742792|NCT04025320|OTHER|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
219742793|NCT04025320|OTHER|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
219742794|NCT04373551|BEHAVIORAL|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
219742795|NCT04660682|OTHER|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
219742796|NCT04660682|OTHER|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
219742797|NCT04660682|OTHER|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
219742798|NCT06042491|BEHAVIORAL|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
219742799|NCT00718731|DRUG|GSI-136|
219742800|NCT00718731|OTHER|Placebo|
219742801|NCT00413712|DRUG|Calcium Channel Blocker & Adenosine|
219250528|NCT03595826|DRUG|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
219250529|NCT00019136|BIOLOGICAL|MOv-gamma chimeric receptor gene|
219250530|NCT00019136|BIOLOGICAL|aldesleukin|
219250531|NCT00019136|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219250532|NCT05682040|DIAGNOSTIC_TEST|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
219250533|NCT02042625|PROCEDURE|Nasopharyngeal|
219250534|NCT00786721|DEVICE|Diffuse Optical Spectroscopy|muscle properties scanning
219250535|NCT01861795|OTHER|Preterm Neonates|Preterm Neonates
219250536|NCT00850798|DRUG|Intensive glycemic control|Intensive glycemic control
219250537|NCT00850798|DRUG|Conservative glycemic control|OADs and insulin
219250538|NCT02581371|DRUG|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
219250539|NCT02581371|OTHER|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
219250540|NCT01855997|DRUG|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
219250541|NCT04854616|BEHAVIORAL|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
219250542|NCT03612453|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
219250543|NCT03612453|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
219250544|NCT03571347|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
219250545|NCT03571347|OTHER|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
219250546|NCT04134455|PROCEDURE|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
219250547|NCT04134455|PROCEDURE|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
219250548|NCT02212483|OTHER|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
219250549|NCT02212483|OTHER|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
219250550|NCT02212483|OTHER|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
219250551|NCT02538471|RADIATION|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
219250552|NCT02538471|DRUG|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
219250553|NCT05559164|DRUG|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
219250554|NCT01475370|DRUG|OCV-501|"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
219250555|NCT01365351|OTHER|Growth hormone|Drug given by prescription
219250556|NCT01243398|PROCEDURE|quality-of-life assessment|
219250557|NCT02429752|OTHER|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
219250558|NCT01388088|DRUG|Spironolactone|25 mg twice a day
219250559|NCT01388088|DRUG|Amiloride|5 mg twice a day
219250560|NCT01388088|DRUG|Placebo|twice a day
219250561|NCT05476978|DIAGNOSTIC_TEST|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
219250562|NCT03726125|DRUG|LY3374849 - SC|Administered SC
219250563|NCT03726125|DRUG|Insulin Degludec - SC|Administered SC
219250564|NCT03726125|DRUG|LY3374849 - IV|Administered IV
219250565|NCT03726125|DRUG|Insulin Degludec - IV|Administered IV
219250566|NCT04864236|DEVICE|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
219742802|NCT02524899|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
219742803|NCT02524899|DRUG|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
219742804|NCT02524899|DRUG|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
219742805|NCT01171079|DEVICE|application of oxidized regenerated cellulose|
219742806|NCT02096354|DRUG|RRx-001|
219742807|NCT02096354|DRUG|Regorafenib|
219742808|NCT02096354|DRUG|Irinotecan|To be dosed after RRx-001 or regorafenib
219742809|NCT00332566|BIOLOGICAL|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
219742810|NCT00332566|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
219742811|NCT03715829|DRUG|PF-06651600|Induction dose 1. Oral tablet taken QD
219742812|NCT03715829|DRUG|PF-06651600|Induction dose 2. Oral tablet taken QD
219742813|NCT03715829|DRUG|PF-06651600|Maintenance dose A. Oral tablet taken QD
219742814|NCT03715829|DRUG|PF-06651600|Maintenance Dose B. Oral tablet taken QD
219742815|NCT03715829|DRUG|PF-06651600|Maintenance Dose C. Oral tablet taken QD
219742816|NCT03715829|DRUG|placebo|placebo
219742817|NCT03715829|DRUG|PF06700841|Oral tablet taken QD
219742818|NCT03715829|DEVICE|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
219742819|NCT06538350|OTHER|Telemedicine Consultation|Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
219742820|NCT06538350|OTHER|Face-to-Face Consultation|Face-to-Face consultation according to the standard of care.
219742821|NCT00764426|DRUG|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
219742822|NCT00764426|DRUG|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
219742823|NCT04106635|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
219742824|NCT04106635|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
219742825|NCT01338597|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
219742826|NCT00001784|DRUG|Mexiletine|
219742827|NCT03422887|DRUG|Nalbuphine|Nalbuphine administration during surgery
219742828|NCT03422887|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
219742829|NCT03422887|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
219742830|NCT04903769|BEHAVIORAL|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
219742831|NCT02105480|DEVICE|Computer aided auscultation (CAA)|
219742832|NCT04593745|DEVICE|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
219742833|NCT03579719|DRUG|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
219742834|NCT03579719|DRUG|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
219742835|NCT00202241|PROCEDURE|testosterone injection|
219742836|NCT03747237|OTHER|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
219742837|NCT01173003|DRUG|Mifepristone, misoprostol|
219742838|NCT05295953|DEVICE|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
219742839|NCT05295953|DEVICE|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
219742840|NCT06569940|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
219742841|NCT01000116|PROCEDURE|Fibrin glue|Tissucol 2 ml
219742842|NCT01000116|PROCEDURE|Tacks|Protacks
219250567|NCT05056298|OTHER|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
219250568|NCT05056298|OTHER|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
219250569|NCT05056298|OTHER|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
219250570|NCT05056298|OTHER|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
219250571|NCT01675050|DRUG|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
219250572|NCT01675050|DRUG|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
219250573|NCT00988897|DRUG|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
219250574|NCT00988897|DRUG|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
219250575|NCT00988897|DRUG|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
219250576|NCT00988897|DRUG|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
219250577|NCT06321900|DIAGNOSTIC_TEST|Personalized risk model|WE will test the hypothesis that interpretable artificial intelligence models including clinical, bio-humoral, genetic, electrocardiography, echocardiography, cardiac magnetic resonance, and nuclear imaging data will predict the risk of SCD in patients with left ventricular dysfunction more accurately than NYHA class and LVEF, and this will translate in a more cost-effective use of ICDs compared to current clinical practice.
219250578|NCT01314638|OTHER|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
219250579|NCT02919397|DEVICE|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
219250580|NCT02919397|BEHAVIORAL|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
219250581|NCT02919397|BEHAVIORAL|Motivational messaging|Messages sent via smartphone application
219250582|NCT02216149|DRUG|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
219250583|NCT02216149|DRUG|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
219250584|NCT02216149|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
219250585|NCT01439997|DRUG|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
219250586|NCT00629551|DRUG|saredutant (SR48968)|oral administration,capsules
219250587|NCT00629551|DRUG|paroxetine|oral administration, capsules
219250588|NCT00629551|DRUG|placebo|oral administration, capsules
219250589|NCT00084747|DRUG|bortezomib|
219250590|NCT03665753|DRUG|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
219250591|NCT05478681|DEVICE|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
219250592|NCT03275441|DIAGNOSTIC_TEST|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
219250593|NCT00631098|PROCEDURE|venous cannulation|External jugular and cubital vein cannulation
219250594|NCT02157129|DEVICE|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
219250595|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
219250596|NCT01076322|DRUG|Meptin® Swinghaler|"Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)"
219250597|NCT01076322|DRUG|Ventolin® MDI|"Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)"
219250598|NCT01032746|OTHER|educational intervention|
219250599|NCT01032746|OTHER|internet-based intervention|
219250600|NCT01032746|PROCEDURE|evaluation of cancer risk factors|
219250601|NCT01032746|PROCEDURE|fecal occult blood test|
219250602|NCT01032746|PROCEDURE|screening colonoscopy|
219250603|NCT06645639|OTHER|Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)|"The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment)."
219250604|NCT04474691|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
219742843|NCT04957472|DEVICE|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
219742844|NCT04957472|OTHER|Manual Control|24 hours of manual control of FiO2
219742845|NCT00517114|DRUG|Rabeprazole 20mg twice daily|
219742846|NCT04598087|BEHAVIORAL|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
219742847|NCT02615613|OTHER|Low Acceptability Meal|
219742848|NCT02615613|OTHER|High acceptability meal|
219250605|NCT04474691|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
219250606|NCT00913562|DRUG|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
219250607|NCT00913562|DRUG|Placebo|one tablet a day for 12 weeks
219250608|NCT01309399|DRUG|Teriparatide|six weeks of teriparatide
219250609|NCT01309399|OTHER|placebo|placebo
219250610|NCT02819271|DRUG|CXL-1427 Ascending Dose|
219250611|NCT02819271|OTHER|Placebo|
219250612|NCT02819271|DRUG|CXL-1427 Descending Dose|
219250613|NCT01323309|BEHAVIORAL|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
219250614|NCT01323309|BEHAVIORAL|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
219250615|NCT01323309|BEHAVIORAL|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
219250616|NCT02970721|DRUG|Antipsychotic|Antipsychotic monotherapy
219250617|NCT02970721|DRUG|Antidepressant|Antidepressant monotherapy
219250618|NCT02970721|DRUG|Antipsychotic and Antidepressant|Polytherapy
219250619|NCT00437619|DRUG|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
219250620|NCT02961777|OTHER|implementation of care pathway|implementation of a care pathway
219250621|NCT06209905|PROCEDURE|Alveolar ridge augmentation|Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
219250622|NCT01341418|PROCEDURE|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
219250623|NCT01341418|PROCEDURE|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
219250624|NCT04728659|DRUG|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
219250625|NCT04728659|DRUG|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
219250626|NCT02794558|DEVICE|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
219250627|NCT03048058|DRUG|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
219250628|NCT03048058|DRUG|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
219250629|NCT00924209|DRUG|Gemcitabine|1250 mg/m\^2 dose for two doses on days 1 and 8
219250630|NCT00924209|DRUG|Cisplatin|80 mg/m\^2 on day 1
219250631|NCT00924209|DRUG|Bevacizumab|7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
219250632|NCT00924209|PROCEDURE|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
219250633|NCT00924209|DRUG|Etoposide|100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
219250634|NCT01654835|OTHER|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
219250635|NCT01654835|OTHER|standard of care|A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
219250636|NCT00333554|DIETARY_SUPPLEMENT|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
219250637|NCT00333554|DIETARY_SUPPLEMENT|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
219250638|NCT02625922|DRUG|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
219250639|NCT02625922|DRUG|Placebo|Matching placebo i.v infusion
219250640|NCT00966056|DRUG|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
219250641|NCT00966056|DEVICE|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
219250642|NCT03856645|DRUG|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
219250643|NCT04488809|OTHER|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
219250644|NCT06194786|BEHAVIORAL|Group D|Usual care
219250645|NCT02200029|DRUG|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
219250646|NCT02200029|DRUG|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
219250647|NCT01309555|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
219250648|NCT01110551|DRUG|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
219250649|NCT01110551|DRUG|Placebo (ID)|Phosphate buffered saline administered intradermally.
219250650|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
219250651|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
219250652|NCT02359552|DRUG|Rasagiline|
219250653|NCT02359552|DRUG|Placebo|
219250654|NCT02218671|DRUG|WE 941 OD tablets|
219250655|NCT01437384|DRUG|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
219250656|NCT06537219|OTHER|Assessment|Assessment of pain severity,pain thresold of the fascia, pain sensitivity
219250657|NCT03830515|DEVICE|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
219250658|NCT00161902|DRUG|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
219250659|NCT03100136|DRUG|[11C]PF-06809247|PET Tracer
219250660|NCT01395914|DRUG|Anamorelin HCl|
219250661|NCT01395914|DRUG|Placebo|
219250662|NCT01261455|PROCEDURE|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
219250663|NCT04136249|DIETARY_SUPPLEMENT|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
219250664|NCT06196073|OTHER|Osteopathic manual therapy|Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
219250665|NCT06196073|DIETARY_SUPPLEMENT|conservative treatment|Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
219250666|NCT03418701|BEHAVIORAL|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
219250667|NCT04998032|BIOLOGICAL|supaglutide injection+metformin|supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
219250668|NCT04998032|OTHER|placebo+metformin|placebo subcutaneous injection combined with metformin treatment
219250669|NCT06051721|DRUG|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
219250670|NCT06051721|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
219250671|NCT05908149|DEVICE|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
219250672|NCT04366648|DRUG|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
219250673|NCT04265742|RADIATION|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
219250674|NCT04265742|RADIATION|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
219250675|NCT04265742|DIAGNOSTIC_TEST|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
219250676|NCT04265742|OTHER|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
219250677|NCT04265742|OTHER|clinical tests|physical performance tests and grip strenght measurement
219250678|NCT00000521|BEHAVIORAL|diet, sodium-restricted|
219250679|NCT00000521|BEHAVIORAL|diet, potassium-supplemented|
219296245|NCT06348082|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|MBTI will be administered in 6 weekly sessions. Session 1 consists of introductions and an overview. Subsequent sessions consist of mindfulness concepts/practice and behavioral strategies for sleep. Each session will begin with guided formal meditation followed by discussion. Mindfulness practice (at home) expectations are 30-45 minutes of meditation/day at least 5 days during the period of the intervention, followed by 20 minutes/day until the final follow-up assessment (at 12 weeks). Mindfulness concepts: Overview of Mindfulness, Mindfulness of the Body, Obstacles to Mindfulness, Working with Difficult Emotions, Cultivating Positive Emotions, Working with Difficult Thoughts, Mindful Interactions.
219250680|NCT05204472|DEVICE|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -\> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
219250681|NCT05204472|DEVICE|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -\> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
219250682|NCT04542642|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
219250683|NCT04542642|DEVICE|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
219250684|NCT06394193|BEHAVIORAL|Community-based participatory research intervention|Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
219250685|NCT05609682|DRUG|Gabapentin|Scheduled gabapentin given for two weeks after surgery
219250686|NCT05609682|DRUG|Placebo|Placebo given for two weeks after surgery
219250687|NCT02987088|DRUG|Sodium Nitrite|
219250688|NCT05000593|OTHER|normal saline|Intra-articular injection of normal saline
219250689|NCT05000593|OTHER|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
219250690|NCT05343819|DRUG|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
219250691|NCT05343819|DRUG|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
219250692|NCT00131690|DRUG|Nescafé Gold Blend (exposed)|
219250693|NCT00131690|DRUG|Nescafé Decaffeinated (controls)|
219250694|NCT03772119|PROCEDURE|Surgical resection|Surgical resection of hemivertebra
219250695|NCT02849509|DRUG|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
219250696|NCT02849509|DRUG|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
219250697|NCT02735278|OTHER|different test paradigms|
219250698|NCT01261793|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
219250699|NCT01261793|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
219250700|NCT01261793|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
219250701|NCT00685347|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
219250702|NCT00685347|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
219250703|NCT00639236|OTHER|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
219250704|NCT00214071|BIOLOGICAL|Influenza vaccine|
219250705|NCT05300698|DEVICE|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
219250706|NCT00246389|DRUG|cyclobenzaprine hydrochloride|
219296246|NCT06420661|BEHAVIORAL|SPACE for T1D|school-partnered collaborative care model
219742849|NCT02800785|DRUG|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
219742850|NCT02800785|PROCEDURE|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
219742851|NCT01974947|OTHER|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
219742852|NCT00002759|DRUG|cyclosporine|
219742853|NCT00002759|DRUG|irinotecan hydrochloride|
219742854|NCT00002759|DRUG|phenobarbital|
219742855|NCT04753567|DEVICE|nCap pain relief patch|Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups
219742856|NCT04753567|DEVICE|Sham Patch|Sham patch will be worn for 3 weeks exactly like actual pain patch
219742857|NCT02446509|BEHAVIORAL|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
219742858|NCT02446509|BEHAVIORAL|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
219742859|NCT06198777|DEVICE|Magnetometer|Inspection equipment for magnetocardiography
219742860|NCT02261610|PROCEDURE|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
219742861|NCT03253627|BEHAVIORAL|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
219742862|NCT03253627|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
219742863|NCT03079778|PROCEDURE|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
219742864|NCT03079778|RADIATION|TACE plus RT|radiobiologically guided radiation
219742865|NCT00394225|DRUG|Oxygen|
219742866|NCT00394225|DRUG|Helium|
219742867|NCT06124300|DIETARY_SUPPLEMENT|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
219742868|NCT05187910|BEHAVIORAL|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
219742869|NCT05187910|BEHAVIORAL|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
219742870|NCT05187910|BEHAVIORAL|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
219742871|NCT01082458|DRUG|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
219742872|NCT00498966|DRUG|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
219742873|NCT05116644|OTHER|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
219742874|NCT00606099|DRUG|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
219742875|NCT00606099|DRUG|adefovir dipivoxil|Active Comparator
219742876|NCT00742157|DRUG|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
219742877|NCT03576820|DRUG|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
219742878|NCT03576820|DRUG|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
219742879|NCT03539640|OTHER|PEEP: 5 cmH2O|During second part of the study (MRI)
219742880|NCT03539640|OTHER|PEEP: 10 cmH2O|During second part of the study (MRI)
219742881|NCT03539640|OTHER|PEEP: 15 cmH2O|During second part of the study (MRI)
219742882|NCT06468943|DRUG|Polatuzumab Vedotin|1.8mg/kg/21d（d0） Intravenous infusion
219250707|NCT04528368|BIOLOGICAL|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
219250708|NCT00579475|DRUG|Mifegyne|tablets, 50 mg every other day
219250709|NCT00579475|DRUG|placebo|
219250710|NCT04964609|DEVICE|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
219250711|NCT04825210|BEHAVIORAL|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
219250712|NCT04825210|BEHAVIORAL|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
219250713|NCT05789199|DRUG|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
219250714|NCT03588676|OTHER|Melatonin|5mg Melatonin
219250715|NCT03588676|OTHER|Placebo|5mg Placebo capsule
219250716|NCT05457296|DRUG|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
219250717|NCT03771209|DIAGNOSTIC_TEST|ultrasound examination|ultrasound assessment
219250718|NCT05862779|DIETARY_SUPPLEMENT|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
219250719|NCT05862779|DIETARY_SUPPLEMENT|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
219250720|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
219250721|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
219250722|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
219250723|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
219250724|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
219250725|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
219250726|NCT02133131|DRUG|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
219250727|NCT02133131|DRUG|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
219296247|NCT06420661|BEHAVIORAL|Enhanced usual care|routine diabetes care with optional monthly insulin dose adjustment
219296248|NCT06457789|DRUG|[18F]F-AraG PET imaging|Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
219296249|NCT06457789|DRUG|[89Zr]Zr-Df-Crefmirlimab PET imaging|Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
219296250|NCT05858528|DIAGNOSTIC_TEST|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
219296251|NCT06576258|DIAGNOSTIC_TEST|cobas eplex multiplex PCR|Positive blood culture samples from the intervention group are subjected to cobas eplex multiplex PCR in addition to the SOC culture methods.
219250728|NCT06130904|BEHAVIORAL|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
219250729|NCT02144194|DRUG|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
219250730|NCT02144194|DRUG|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
219742883|NCT06468943|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
219742884|NCT06468943|DRUG|Rituximab|375mg/㎡/21d（d0） Intravenous infusion
219742885|NCT06468943|DRUG|Cyclophosphamide|750mg/㎡/21d（d1） Intravenous infusion
219742886|NCT06468943|DRUG|Doxorubicin|50mg/㎡/21d（d1） Intravenous infusion
219742887|NCT06468943|DRUG|Prednisone|100mg PO （d1-d5）/21d
219742888|NCT05043831|DEVICE|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
219742889|NCT04348630|OTHER|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
219742890|NCT01686321|DRUG|Bendamustine and subcutaneous rituximab|
219742891|NCT04005326|PROCEDURE|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
219742892|NCT04005326|PROCEDURE|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
219742893|NCT04005326|PROCEDURE|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
219742894|NCT03098927|BEHAVIORAL|Motor imagery training|Motor imagery training
219742895|NCT02644070|DEVICE|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
219742896|NCT02644070|DEVICE|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
219742897|NCT02644070|DEVICE|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
219742898|NCT03663023|PROCEDURE|Intestinal obstruction|
219742899|NCT02594943|DEVICE|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
219742900|NCT02594943|DEVICE|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
219742901|NCT04104477|OTHER|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
219742902|NCT04104477|OTHER|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
219742903|NCT02940223|DRUG|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
219742904|NCT02940223|BEHAVIORAL|Exercise Intervention|Complete resistance exercises and undergo walking program
219742905|NCT02940223|BEHAVIORAL|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
219742906|NCT02940223|OTHER|Laboratory Biomarker Analysis|Correlative studies
219742907|NCT02940223|OTHER|Placebo|Given PO
219742908|NCT02940223|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
219742909|NCT02940223|OTHER|Questionnaire Administration|Ancillary studies
219742910|NCT06497673|OTHER|sample collection|New collected samples, as well as surplus surgical and diagnostic samples.
219742911|NCT00245154|DRUG|carboplatin|Given IV
219742912|NCT00245154|DRUG|cediranib maleate|Given orally
219742913|NCT00245154|DRUG|paclitaxel|Given IV
219742914|NCT00245154|OTHER|placebo|Given orally
219742915|NCT01813357|DRUG|Rosuvastatin|encapsulated tablet 20mg daily
219742916|NCT01813357|OTHER|Placebo|Placebo arm included to maintain blinding
219742917|NCT05560880|BEHAVIORAL|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
219742918|NCT05560880|BEHAVIORAL|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
219742919|NCT03773562|DRUG|Erenumab|Erenumab will be used per label instructions.
219742920|NCT03317873|DIETARY_SUPPLEMENT|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
219742921|NCT03317873|DIETARY_SUPPLEMENT|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
219742922|NCT05449873|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
219742923|NCT05810597|DRUG|Tirzepatide|Administered SC
219742924|NCT05810597|DEVICE|Single Dose Pen|Used to administer tirzepatide SC
219742925|NCT05810597|DEVICE|Multi-use Prefilled Pen|Used to administer tirzepatide SC
219742926|NCT05899959|DEVICE|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
219742927|NCT03845166|DRUG|XL092|oral doses of XL092
219742928|NCT03845166|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
219742929|NCT03845166|DRUG|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
219742930|NCT02913846|OTHER|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
219742931|NCT02913846|OTHER|Muscular assessment|An assessment of muscular force will be performed once a week.
219742932|NCT02913846|OTHER|Pre-albumine dosage|Dosage performed once a month.
219742933|NCT06025708|DEVICE|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
219742934|NCT04354857|OTHER|olfactory and gustatory tests|"Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste"
219742935|NCT04065334|BEHAVIORAL|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
219742936|NCT04065334|BEHAVIORAL|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
219742937|NCT05021224|BEHAVIORAL|Caring Contacts|Non-demanding message sent from the care team
219742938|NCT05021224|BEHAVIORAL|Reminders|Appointment reminders sent electronically
219742939|NCT05021224|BEHAVIORAL|Informational Poster|An informational poster linking to an infographic
219742940|NCT05021224|BEHAVIORAL|Motivational Interviewing|Motivational interviewing training for intake coordinators
219742941|NCT03535987|DEVICE|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
219742942|NCT05966675|DEVICE|conduction system pacing|Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
219742943|NCT05966675|DEVICE|right ventricular or biventricular pacing|Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
219742944|NCT02392728|BEHAVIORAL|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
219742945|NCT02392728|BEHAVIORAL|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
219742946|NCT00515229|DRUG|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
219742947|NCT06026696|OTHER|follow-up|Long term follow-up
219742948|NCT01111552|DRUG|Escitalopram|Escitalopram oral capsules.
219742949|NCT01111552|DRUG|Aripiprazole|Aripiprazole oral capsules.
219742950|NCT01111552|DRUG|Placebo|Study drug matching placebo capsule.
219742951|NCT06230341|OTHER|Health Services Research|MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
219742952|NCT04990947|OTHER|lifestyle / RYGB|No intervention, just 2 different groups will be included
219742953|NCT06083571|DRUG|Ketorolac|Non-inferiority
219742954|NCT06083571|DRUG|Prochlorperazine|Adjunct
219742955|NCT06083571|DRUG|Diphenhydramine|Adjunct
219742956|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
219250731|NCT03209336|RADIATION|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
219250732|NCT06461949|DRUG|Dupilumab|Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
219250733|NCT02512107|DIETARY_SUPPLEMENT|Juice Plus+|Dried fruit and vegetable juice capsule.
219250734|NCT02512107|OTHER|Placebo|Placebo capsule
219742957|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
219742958|NCT04755231|DEVICE|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
219742959|NCT04755231|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
219742960|NCT04002934|DRUG|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
219742961|NCT05649540|DRUG|Vonoprazan|Potassium-competitive acid blocker
219742962|NCT05649540|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219742963|NCT04233385|OTHER|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
219742964|NCT04233385|OTHER|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
219742965|NCT05107271|DIAGNOSTIC_TEST|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
219742966|NCT01812941|OTHER|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
219742967|NCT01812941|OTHER|healthy volunteers: blood collection|blood collected at designated time intervals
219742968|NCT01812941|OTHER|Burn: blood collection|blood collected at designated time intervals
219742969|NCT00306098|DRUG|islets|Intraportal infusion of islets
219742970|NCT04418505|DEVICE|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
219742971|NCT00608790|DRUG|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
219742972|NCT00608790|DRUG|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
219742973|NCT02017834|PROCEDURE|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
219742974|NCT06375863|DIAGNOSTIC_TEST|QT and QTc interval|measuring of QT and QTc on ECG
219742975|NCT01407341|PROCEDURE|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
219742976|NCT01407341|PROCEDURE|bone graft|Receive beta tricalcium-phosphate bone graft
219742977|NCT01407341|PROCEDURE|quality-of-life assessment|Ancillary studies
219742978|NCT01407341|OTHER|questionnaire administration|Ancillary studies
219742979|NCT01515215|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
219742980|NCT05179915|OTHER|Therapeutic Touch focused on sacral region|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
219742981|NCT00236665|DRUG|topiramate|
219742982|NCT03487510|OTHER|NO interventions apply|does not apply
219742983|NCT06487286|OTHER|observational study|observational study
219742984|NCT04351672|BEHAVIORAL|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
219742985|NCT04351672|BEHAVIORAL|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
219742986|NCT05004298|OTHER|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
219742987|NCT05389371|BEHAVIORAL|Alberta Healthy Living Program|Weight management services
219742988|NCT05389371|BEHAVIORAL|Alberta Obesity Centre Program|Multi-disciplinary obesity management
219742989|NCT05389371|BEHAVIORAL|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
219742990|NCT05389371|BEHAVIORAL|Physiotherapy|GLA:D physiotherapy programs.
219742991|NCT02272010|OTHER|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
219742992|NCT02272010|OTHER|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
219742993|NCT03915756|PROCEDURE|Drainage of surgical wound|Introduction of a drain before full fascial closure
219250735|NCT06386575|OTHER|control group; Patients who received physiological saline|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
219250736|NCT06386575|OTHER|suprainguinal fascia block; Patients receiving local anesthetic|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
219250737|NCT01544153|BEHAVIORAL|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
219250738|NCT01544153|BEHAVIORAL|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
219250739|NCT01544153|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
219250740|NCT02070289|DRUG|PF-06372865|Tablets, 2.5 mg BID, 14 days
219250741|NCT02070289|DRUG|Placebo|Tablets, BID, 14 days
219250742|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
219250743|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
219250744|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
219250745|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
219250746|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
219250747|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
219250748|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
219250749|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
219250750|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
219250751|NCT02127892|BIOLOGICAL|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
219250752|NCT02127892|BIOLOGICAL|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
219250753|NCT02127892|BIOLOGICAL|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
219250754|NCT02127892|DEVICE|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
219250755|NCT03743597|DEVICE|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
219250756|NCT03743597|DEVICE|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
219742994|NCT03424980|COMBINATION_PRODUCT|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
219742995|NCT02577302|DEVICE|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
219742996|NCT02577302|DEVICE|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
219742997|NCT05983900|PROCEDURE|BRIX3000|chemo-mechanical caries removal agent
219742998|NCT05983900|PROCEDURE|papacarie|chemo-mechanical caries removal agent
219742999|NCT05983900|PROCEDURE|hand excavation|mechanical caries removal
219743000|NCT02416388|DRUG|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~\+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
219743001|NCT02416388|DRUG|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~\+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
219743002|NCT02416388|DRUG|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
219743003|NCT02416388|DRUG|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
219743004|NCT02416388|DRUG|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
219743005|NCT02416388|DRUG|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
219743006|NCT02416388|DRUG|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
219250757|NCT02249429|DRUG|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
219250758|NCT02074865|BIOLOGICAL|biological samples|
219250759|NCT02600988|DRUG|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
219250760|NCT02600988|DRUG|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
219250761|NCT00884793|DRUG|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
219250762|NCT00884793|DRUG|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
219250763|NCT00884793|DRUG|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
219250764|NCT06270004|OTHER|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
219250765|NCT01032200|DRUG|Armodafinil|Given orally
219250766|NCT01032200|OTHER|placebo|Given orally
219250767|NCT03145519|DEVICE|Vasofix Certo Catheter|Placement of IV-catheter
219250768|NCT03145519|DEVICE|OptiVein Catheter|Placement of IV-catheter
219250769|NCT00067808|DRUG|Decitabine|10 mg/m\^2 by vein over 1 hour daily for 10 days
219250770|NCT00067808|DRUG|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
219250771|NCT00067808|DRUG|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
219250772|NCT02278822|OTHER|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
219250773|NCT02278822|OTHER|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
219250774|NCT02338206|DRUG|Growth hormone|
219250775|NCT03188549|OTHER|AniosGel 85 NPC|Hand hygiene formula
219250776|NCT03188549|OTHER|Softa-Man (Braun)|Hand hygiene formula
219250777|NCT03188549|OTHER|Septol|alcohol-based hand rub
219250778|NCT06077695|OTHER|therapeutic education|The themes covered concern head trauma in the chronic phase.
219250779|NCT06077695|OTHER|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
219250780|NCT06077695|OTHER|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
219250781|NCT00665106|DRUG|"NOVA63035 Corticosteroid"|Single injection in the study eye
219250782|NCT05414656|DEVICE|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
219250783|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
219250784|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
219250785|NCT00714688|DRUG|Placebo|2xplacebo once daily for 13 weeks
219250786|NCT04542109|BEHAVIORAL|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
219250787|NCT04542109|BEHAVIORAL|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
219250788|NCT02391571|DRUG|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
219250789|NCT02391571|DRUG|Oxycodone|Oxycodone to be taken with stable dose of Methadone
219250790|NCT02391571|DRUG|Placebo|2 day placebo run in prior to test and active drug phase of study
219250791|NCT02931994|OTHER|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
219250792|NCT03314116|OTHER|Guidance on auditory protection|by video or medic
219250793|NCT02061189|OTHER|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
219250794|NCT06045364|DRUG|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
219250795|NCT06045364|DRUG|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
219250796|NCT00966641|DRUG|Naproxen|Single orally administered dose of 500 mg naproxen
219250797|NCT00966641|DRUG|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
219250798|NCT00370188|DRUG|Topiramate|
219250799|NCT04493307|DIAGNOSTIC_TEST|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
219250800|NCT04114279|PROCEDURE|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
219250801|NCT02316171|BIOLOGICAL|CVA21|CAVATAK is a purified preparation of CVA21
219250802|NCT02316171|DRUG|Mitomycin C|Chemotherapy
219250803|NCT03537534|DRUG|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
219250804|NCT03537534|DRUG|Placebos|Applying surgilube following endourologic procedure
219250805|NCT01524887|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
219250806|NCT01524887|BIOLOGICAL|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
219250807|NCT05663541|DIAGNOSTIC_TEST|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
219250808|NCT03373188|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
219250809|NCT03373188|BIOLOGICAL|Ipilimumab|Given IV
219250810|NCT03373188|BIOLOGICAL|Nivolumab|Given IV
219250811|NCT03373188|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
219250812|NCT06647147|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
219250813|NCT06647147|OTHER|Diaphragmatic breathing exercises|From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
219250814|NCT02779127|OTHER|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
219250815|NCT02779127|OTHER|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
219250816|NCT02779127|OTHER|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
219250817|NCT02779127|OTHER|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
219250818|NCT02779127|OTHER|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
219250819|NCT02249156|BEHAVIORAL|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
219250820|NCT03616314|DEVICE|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
219250821|NCT03616314|DEVICE|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
219250822|NCT03616314|OTHER|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
219250823|NCT06597435|OTHER|Nicotine pouch|Participants will self-administer an experimenter-provided nicotine pouch
219250824|NCT06242184|PROCEDURE|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
219250825|NCT06242184|PROCEDURE|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
219250826|NCT06261840|DRUG|Metronidazole 500 mg|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
219250827|NCT06261840|DRUG|Secnidazole 2000 MG|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
219250828|NCT06329544|DIETARY_SUPPLEMENT|Fructose|12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
219250829|NCT06329544|DIETARY_SUPPLEMENT|glucose|12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
219250830|NCT03993054|BEHAVIORAL|Culturally-tailored cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 10 weeks. This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
219250831|NCT03370861|BIOLOGICAL|Immunotherapy|Medications that increase the activity of the immune system.
219250832|NCT06672055|BIOLOGICAL|VXA-CoV2-3.1|Tablets for oral use.
219250833|NCT06672055|BIOLOGICAL|COMIRNATY®|Intramuscular (IM) injection.
219250834|NCT06672055|BIOLOGICAL|VXA-CoV2-3.3|Tablets for oral use.
219250835|NCT02648282|DRUG|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
219250836|NCT02648282|DRUG|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
219250837|NCT02648282|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
219250838|NCT02648282|RADIATION|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
219296252|NCT04524377|PROCEDURE|Deep Brain Stimulation|"Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain."
219250839|NCT06283693|OTHER|mindfulness-based stress reduction|Müdahale grubundaki kadınlara depresyon, anksiyete ve stres düzeylerini azaltmak için farkındalık temelli bir stres azaltma programı uygulanacaktır. Program, haftada bir seans olmak üzere haftada iki kez toplam 4 hafta boyunca 8 seanstan oluşacaktır. Müdahale grubu haftada 2 seans alacaktır. Her seans 80 dakika sürecektir. Çalışmadaki seanslar, katılımcıların iş yoğunluğu, hayattaki sorumlulukları ve 4 hafta boyunca düzenli olarak katılamama ihtimalleri göz önünde bulundurularak zoom programı üzerinden gerçekleştirilecektir. 4 hafta/8 oturumluk MBSR programı tamamlandıktan sonra müdahale grubundaki kadınlara veri toplama formları tekrar uygulanacak ve son test ölçümleri yapılacaktır. Son test ölçümlerinden sonra müdahale grubundaki kadınların takip ölçümleri ölçümlerden 8 hafta sonra yapılacaktır.
219250840|NCT07009067|BEHAVIORAL|Exercise-based Cardiac Rehabilitation|Participated will receive 36 individualized Exercise-based Cardiac Rehabilitation after enrollment in our Cardiac Rehabilitation Center.
219250841|NCT07009470|DRUG|Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar)|First, perform a single session of TACE. Followed by three cycles of neoadjuvant therapy with Finotonlimab combined with bevacizumab. Proceed with curative resection. Finally, initiate postoperative adjuvant targeted-immunotherapy . Finotonlimab: intravenously every three weeks ,200mg. bevacizumab：intravenously every three weeks , with a dosage based on body weight: 15 mg (≤60 kg) .
219250842|NCT07009470|PROCEDURE|TACE|Initial Perform a single session of TACE procedure.TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
219250843|NCT07009587|PROCEDURE|Endoscopy|endoscopic procedure
219250844|NCT07008157|OTHER|1. IFC|IFC therapy was applied while the patient lay in a supine position with the knees slightly apart. Each treatment session involved four electrodes enclosed in lint cloth covers. Two electrodes were positioned bilaterally on the lower abdomen, just below the anterior superior iliac spines (ASIS), while the remaining two were placed on the inner surfaces of both thighs. To maintain hygienic standards, the cloth covers were replaced for each participant at every session. The intervention was administered three times weekly over an eight-week period. A frequency range of 0-10 Hz was used, and the current intensity was carefully adjusted based on each patient's comfort and tolerance. Each IFC session lasted 15 minutes, with the aim of modulating pelvic region activity to support improved bladder function. This protocol was implemented three times per week over an eight-week period
219250845|NCT07008157|OTHER|2. Timed voiding.|The approach involved instructing participants to follow a fixed, scheduled voiding routine, typically every 3 hours, irrespective of the sensation to urinate. Additionally, patients were advised to adjust their toileting posture by sitting and leaning forward at an angle of approximately 45 degrees, allowing adequate time for complete bladder emptying. The technique also included practicing double voiding, where the individual would stand up and sit down again after the initial void to help ensure maximum bladder evacuation
219250846|NCT07008157|OTHER|motor imagery training|Prior to initiating MIT, participants watched a 10-minute instructional video in a quiet treatment space, illustrating proper PFM contractions through both visual and auditory cues. The therapist provided a detailed explanation, using a simple analogy of the bladder as a balloon filled with urine, connected by a tube (the urethra) to the outside, and controlled by the PFM. It was explained that contracting these muscles tightens the balloon, holding back urine, whereas weak or relaxed muscles may lead to leakage. Patients were then guided to mentally visualize contracting and holding these muscles until they reached a suitable time and place (the toilet), without physically performing the action. Following this explanation, patients were asked to sit comfortably with their eyes closed and spend 10 minutes visualizing the movement and control of their PFM while remaining physically relaxed. Throughout the session, the therapist used open-ended prompts to help maintain the patient's focu
219296253|NCT04988555|DRUG|Enzomenib|DSP-5336 orally
219296254|NCT04988555|DRUG|azoles|Posaconazole, Voriconazole, or Fluconazole
219296255|NCT04988555|DRUG|Venetoclax|Venetoclax orally
219296256|NCT04988555|DRUG|Gilteritinib|Gilteritinib orally
219296257|NCT04988555|DRUG|Azacitidine (AZA)|Azacitidine orally
219250847|NCT07008157|OTHER|pelvic floor muscles training|Before beginning each treatment session, participants were instructed to empty their bladders to promote comfort and relaxation during the exercises. All patients were taught a structured PFMT routine, to be performed daily in multiple positions such as lying, sitting, and standing. The program consisted of contracting the PFM for 10 seconds, followed by a 10-second relaxation period, with this sequence repeated 15 times in each session. To gradually enhance the endurance of the slow-twitch muscle fibers, both contraction and relaxation times were increased by one second each week. In addition, to activate and strengthen the fast-twitch muscle fibers, patients were directed to perform 20 quick, repetitive contractions and relaxations of the levator ani muscles - simulating the act of stopping urine flow, followed by a 10-second rest. This rapid contraction sequence was repeated for 2 to 4 sets in each session. This protocol was implemented three times per week over an eight-week period
219250848|NCT07008365|DRUG|Furosemide 20 Milligrams|Decongestive therapy with e.v. furosemide +/- hydrochlorothiazide will be adjusted by intraabdominal pressure and/or point of care ultrasound
219250849|NCT07008612|DIAGNOSTIC_TEST|Patients with a genetic syndrome linked to the MYT1L gene|"* Neuropsychological assessment by the neuropsychologist (lasting 1h30)~* Speech and language assessment (including language and prosody) by the speech therapist, lasting 1h30"
219250850|NCT07008612|DIAGNOSTIC_TEST|Patients with a neurodevelopmental disorder of genetic origin but not linked to MYT1L|Evaluation de la prosodie par l'orthophoniste (45 minutes)
219250851|NCT07009366|PROCEDURE|Sudden weaning of NCPAP|"NCPAP was taken off entirely when the neonate met the stability criteria and remained on oxygen or room air via a headbox or incubator with an aim to stay off NCPAP."
219250852|NCT07009366|PROCEDURE|Gradual weaning with increasing the time off NCPAP|The regimen adopted for this method was 1 hour off twice a day on the 1st day, then 2 hours off twice a day on the 2nd day, hence increasing the time off to 6 hours twice a day (or 12 hours per day), i.e., using a smaller period off. At this point, NCPAP was taken off completely.
219250853|NCT07009366|PROCEDURE|Pressure weaning of NCPAP|In this method the pressure was reduced in steps of 1 cm of H2O every 12 to 24 hours until 5 cm of H2O, and then if the child tolerated it well, NCPAP was removed, and the child was shifted to oxygen via incubator or room air according to the situation.
219250854|NCT07008326|BEHAVIORAL|High Intensity Circuit Training|HICT: 3x/week high intensity circuit training for 12 weeks
219250855|NCT07008326|BEHAVIORAL|Moderate Intensity Continuous Training|3x/week moderate intensity continuous training for 12 weeks
219250856|NCT07008443|DRUG|Bupivacaine + saline|25 ml of 0.5% bupivacaine combined with 5 ml of normal saline, administered via ultrasound-guided supraclavicular brachial plexus block as a control intervention
219250857|NCT07008443|DRUG|Bupivacaine + nalbuphine|25 ml of 0.5% bupivacaine combined with nalbuphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
219250858|NCT07008443|DRUG|Bupivacaine + morphine|25 ml of 0.5% bupivacaine combined with morphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
219250859|NCT07009106|OTHER|Educational video on postpartum care|Participants watched a short educational video on postpartum care during a regularly scheduled prenatal visit.
219250860|NCT07007715|OTHER|Flow of 40L/min|Setting flow rate at 40L/min
219250861|NCT07007715|OTHER|Peak tidal inspiratory flow (PTIF) guided|Setting HFNC flow at 5 L/min above the peak tidal inspiratory flow (PTIF), up to a maximum of 60 L/min.
219250862|NCT07007715|OTHER|PaO2/FiO2 ratio guided|Setting HFNC flow according to P/F ratio prior to extubation. Flow will be set at 60, 50 40 L/min if P/F ratio \<250 mmHg, 250-300 mmHg and \>300 mmHg, respectively.
219250863|NCT07007715|OTHER|Flow of 60L/min|Setting flow rate at 60L/min
219250864|NCT07007897|DEVICE|Optical Biometry|Biometric measurements of the eye used for surgical planning will be obtained.
219250865|NCT07007897|PROCEDURE|Cataract Surgery|A video recording of the surgical procedure will be obtained.
219250866|NCT07009678|DIAGNOSTIC_TEST|intravenous access in greater saphenous vein compared to upper extremity site.|Ultrasound access of greater saphenous vein with placement of midline 4French catheter and use of sphygmomanometer to regulate valsalva maneuver, imaging with and without valsalva and injection of agitated saline.
219250867|NCT03571100|DRUG|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
219250868|NCT03571100|DRUG|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
219250869|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
219296258|NCT05734638|BEHAVIORAL|MIM-DASH|Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.
219250870|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
219250871|NCT07008313|BEHAVIORAL|The enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) refers to a series of optimal management measures which are proved to be effective by evidence-based medical evidence in order to reduce patients' psychological and physiological traumatic stress reaction
219250872|NCT07008313|BEHAVIORAL|Traditional treatment methods.|Traditional treatment methods.
219250873|NCT07007741|OTHER|Software Group|"Download the Fatty Liver Data Analysis and Management Software, register and update your profile, connect to a scale, and associate with a researcher and dietitian. Upload meal charts and weight and body fat data every day, adjust recipes according to the patient's exercise and diet every week, and customise one-on-one Q\&A according to the patient's uploaded photos every day. After enrolment, w12 and w24 were required to follow-up to complete relevant examinations and scales and collect data."
219250874|NCT06285383|OTHER|Music listening|Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
219250875|NCT06285383|OTHER|classic physical therapy|classic physical therapy
219250876|NCT07006961|OTHER|Generative AI-based food chaining device|Our group has developed the only generative-AI tool that produces allergy-safe food-chaining recommendations, but it has not yet been clinically tested. This proposal builds on that proof of concept to evaluate its effectiveness in a broader pediatric ARFID population.
219250877|NCT07009327|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
219250878|NCT03586284|DRUG|Valganciclovir Hydrochloride|21 to 28 days of oral valganciclovir treatment
219250879|NCT03586284|DRUG|Ganciclovir Sodium|21 to 28 days of topical ganciclovir solution treatment
219250880|NCT03586284|DRUG|Placebo Oral Tablet|21 to 28 days of placebo pill treatment
219250881|NCT03586284|DRUG|Topical placebo|21 to 28 days of topical placebo treatment
219250882|NCT07009496|BEHAVIORAL|Tibialis Anterior Fatigue Protocol|Participants lie in a supine position with the ankle fixed at 100° dorsiflexion using a custom apparatus. They perform repeated isometric dorsiflexion contractions for 30 seconds followed by 15 seconds of rest. The protocol continues until a perceived exertion of ≥7 is reported on the Modified Borg Scale. Evaluations include joint position sense, balance, muscle elasticity, pain threshold, and performance metrics recorded at four time points: pre-, post-, 24h, and 48h.
219250883|NCT07009496|BEHAVIORAL|Gastrocnemius Fatigue Protocol|Participants lie in a prone position with their foot placed against a wall. They perform repeated isometric plantarflexion contractions for 30 seconds with 15 seconds of rest between repetitions. The exercise is continued until a Modified Borg score of ≥7 is reached. Measurements of neuromuscular and biomechanical parameters are conducted at the same four time points: before, immediately after, 24 hours, and 48 hours post-exercise.
219250884|NCT07009561|BEHAVIORAL|Motor Execution Typing Task|Participants will perform a 3-minute typing task using custom-designed text that emphasizes index finger use. This task is designed to actively engage the motor cortex and will be administered in a controlled environment using standard posture and equipment. The task aims to elicit changes in cortical excitability, which will be measured pre- and post-intervention using TMS.
219250885|NCT07009561|BEHAVIORAL|Action Observation of Typing Task|Participants will observe a 3-minute first-person video of an individual typing the standardized text. The video is designed to activate mirror neuron systems through visual engagement with a familiar motor task. It will be shown once in a controlled setting, and post-assessment of cortical excitability will follow immediately after.
219250886|NCT04142385|OTHER|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
219250887|NCT04142385|OTHER|Laboratory Biomarker Analysis|Correlative studies
219250888|NCT04142385|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
219250889|NCT04142385|PROCEDURE|Physical Examination|Undergo targeted physical exam
219250890|NCT04142385|PROCEDURE|Proctoscopy with Biopsy|Undergo HRA
219250891|NCT04142385|OTHER|Questionnaire Administration|Ancillary studies
219250892|NCT06095492|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
219250893|NCT06095492|DRUG|Linagliptin|linagliptin 5 mg once a day
219250894|NCT07008716|RADIATION|Radiation Therapy|Twice-daily (45 Gy/30 fractions) or once-daily (45 Gy/15 fractions) thoracic radiotherapy after 2-4 cycles of chemotherapy
219250895|NCT07008716|DRUG|Etoposide + carboplatin; Etoposide + cisplatin|Carboplatin IV (AUC=5) on day 1 combined with etoposide IV (100mg/m2) on days 1-3, or cisplatin IV (25mg/m2) on days 1-3 combined with etoposide IV (100mg/m2) on days 1-3. Treatment is repeated every 21 days for 4-6 cycles.
219250896|NCT07008716|RADIATION|Creating CTV for primary tumor|A margin of 0.8 cm beyond the gross target volume of primary tumor.
219250897|NCT07008716|RADIATION|prophylactic cranial irradiation (PCI)|Beginning 4-6 weeks after chemoradiotherapy completion, patients in both arms who achieve a complete or partial response without brain metastasis receive PCI at 25 Gy/10 fractions or 26 Gy/13 fractions, delivered once daily (5 days per week).
219250898|NCT06167330|OTHER|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
219250899|NCT06167330|OTHER|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
219250900|NCT06009861|DRUG|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
219250901|NCT06009861|DRUG|Albumin-Bound Paclitaxel|Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
219250902|NCT06009861|DRUG|Cisplatin|Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
219250903|NCT06134986|OTHER|Time restricted eating|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
219250904|NCT06134986|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
219250905|NCT06686888|DIETARY_SUPPLEMENT|SCFA|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
219250906|NCT06686888|DIETARY_SUPPLEMENT|microcristalline cellulose|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
219250907|NCT04387201|DRUG|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
219250908|NCT04387201|DRUG|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
219250909|NCT06698276|OTHER|Alveolar Ridge Reconstruction|It will be used a combination of two biomaterials for alveolar ridge preservation
219250910|NCT04341584|DRUG|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
219250911|NCT04320602|BIOLOGICAL|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
219250912|NCT04320602|BIOLOGICAL|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
219250913|NCT06309368|DRUG|Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|An elliptical transverse incision will be made extending 1-2 cm lateral and medial to the mucocutaneous junction. The mobilization, anastomosis and fascial closure will be performed as in the pursestring closure group. The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan. After one minute the wound will be suctioned dry. The subcutaneous fat will be mobilized and approximated with interrupted 2-0 Vicryl. The skin will be approximated with deep dermal 3-0 Vicryl and a running subcuticular 4-0 Monocryl suture and Dermabond will be applied.
219250914|NCT06309368|PROCEDURE|Pursestring Closure|A circular incision will be made at the mucocutaneous junction of the ileostomy. After complete mobilization of the ileal limbs off the fascia and a stapled side to side functional end to end anastomosis, the fascia including the external and posterior rectus sheath will be closed with two running #0 PDS (Polydioxanone) suture. The wound will then be irrigated with saline and partially closed in the subcuticular plane with a 2-0 Monocryl suture in a pursestring fashion and packed in the middle with plain packing.
219250915|NCT06879522|BEHAVIORAL|Maximizing Energy Intervention|A licensed occupational therapist will deliver the intervention. The Maximizing Energy program combines problem-solving therapy (PST) and energy conservation education. Participants will participate in 6 virtual once/week sessions for 30 minutes. The introductory session, they will track their fatigue and identify three key fatigue-related problems. In session 2, they will prioritize one problem and practice problem-solving steps. They then implement an action plan and review progress in the next session. If the solution is ineffective, the therapist helps modify it or create a new one. If successful, the participant moves to the next problem. A MAX workbook supports learning, covering intervention details, fatigue education, energy conservation strategies, and problem-solving worksheets. The goal is to help participants apply these strategies to improve daily life and return to work.
219250916|NCT06879522|BEHAVIORAL|Health Education|To control for the effects of interactions with an interventionist, participants in the attention control group will receive the Health Education intervention. The interventionists will review a workbook covering fatigue, energy conservation, healthy eating, exercise, and relaxation. Like the MAX intervention, Health Education will be delivered virtually in weekly 30-minute one-on-one sessions for six weeks. The interventionist provides education on breast cancer-related fatigue, diet, safe physical activities, and energy conservation strategies tailored to individual needs. A workbook will support learning.
219250917|NCT06721273|DIETARY_SUPPLEMENT|Iodine|In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
219250918|NCT06721273|DIETARY_SUPPLEMENT|Placebo|Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
219250919|NCT06720558|OTHER|Placebo probiotic|Three-week consumption of placebo probiotic capsules passed off as being actual probiotics
219250920|NCT06720558|OTHER|Open-Label Placebo probiotic|Participants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.
219250921|NCT06720558|OTHER|Control-no treatment|For the first three weeks, the Control group will not be exposed to any intervention.
219250922|NCT06719934|DRUG|Dienogest 2 mg orally|2 mg Dienogest orally
219250923|NCT06719934|PROCEDURE|UAE|under local anasthesia uterine artery embolizationwill be done
219743007|NCT02416388|DRUG|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
219743008|NCT02416388|DRUG|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
219743009|NCT02416388|DRUG|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)"
219743010|NCT03765021|DRUG|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
219743011|NCT03765021|DEVICE|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
219743012|NCT03307590|DRUG|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
219743013|NCT03307590|DRUG|Bupivacaine|Caudal block by bupivavaine alone
219743014|NCT02184442|DEVICE|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
219743015|NCT02184442|DEVICE|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
219743016|NCT05318560|DRUG|Lidocaine 2% Injectable Solution|for MPS
219743017|NCT05318560|DRUG|Ozone|for MPS
219743018|NCT05318560|OTHER|stretching exercise|for MPS
219743019|NCT03177915|DRUG|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
219743020|NCT03177915|DRUG|Saline|median nerve hydro-dissection using 10 cc saline injection
219743021|NCT01852214|DRUG|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
219743022|NCT01852214|DRUG|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
219250924|NCT06719687|DEVICE|Self-driving robotic-assisted bronchoscope|All procedures will be performed under general anesthesia with endotracheal intubation and mechanical ventilation. The self-driving robotic-assisted bronchoscope will automatically advance through airway to the target lesion according to the preoperative planning path under the guidance of electromagnetic navigation. After that, the bronchoscopist will use radial endobronchial ultrasound (rEBUS) to confirm the lesion localization. The choice of biopsy tools (eg. forceps, needles, brush, etc.) will be left to the discretion of the bronchoscopist.
219250925|NCT06720753|BEHAVIORAL|Opposite to emotion action|Participants will be taught the opposite action skill from Dialectical Behavior Therapy
219250926|NCT06720753|BEHAVIORAL|GIVE|Participants will be taught the GIVE skill from Dialectical Behavior Therapy
219250927|NCT06721832|PROCEDURE|Erector spina plane block (ESP)|"The block will be performed in prone position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) T1 transverse process will be approached with an 18 G Tuohy's needle in caudal-to-cranial direction. A total of 30 ml of 0.25% bupivacaine with 150 μg of clonidine and 8 mg dexamethasone was administered deep to erector spinae muscle (ESM) bilaterally."
219250928|NCT06720233|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
219250929|NCT06721377|PROCEDURE|Novaloc attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region \& will be loaded by Novaloc attachment.
219250930|NCT06721377|PROCEDURE|Equator attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region\& will be loaded by Equator attachment.
219250931|NCT06723587|OTHER|Instep weights use|"Players will perform their scheduled training sessions while wearing a 150-gram instep weight. The use of instep weights in the intervention group will be introduced progressively and gradually, increasing both the frequency of sessions and the duration of their use.~During weeks 1-2, instep weights will be used in one training session per week. During weeks 3-5, will be used in two training sessions per week.~And during weeks 6-8, will be used in three training sessions per week.~The duration of instep weight usage within each session will increase by 5% weekly, starting at 40% in Week 1 and reaching 75% by Week 8."
219250932|NCT06717113|DRUG|18F-FDG|Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
219250933|NCT06717113|DRUG|68Ga-BC1|The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
219250934|NCT06711458|BEHAVIORAL|AI-Generated Discharge Instructions|Patient-friendly hospital discharge instructions generated by GPT-4, an advanced natural language processing model.
219250935|NCT06711458|BEHAVIORAL|Standard of Care Discharge Instructions|Standard hospital discharge instructions.
219250936|NCT06721442|DRUG|Dapagliflozin (DAPA)|Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
219250937|NCT06887426|DRUG|Cladribine|To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
219250938|NCT06719557|DRUG|MK-1084|Oral Tablet
219250939|NCT06719557|DRUG|Itraconazole|Oral solution
219250940|NCT06719557|DRUG|Phenytoin|Oral capsule (extended)
219250941|NCT06721104|OTHER|Dual Task|"The dual-task abilities of individuals will be assessed by adding motor and cognitive tasks to the 10-Meter Walk Test. The tasks given to participants are as follows:~Single Motor Task (comfortable walking): The individual is asked to walk at a normal pace, and the time is recorded.~Motor-Motor Dual Task: The individual carries a half-filled water bottle in each hand while walking, and the time is recorded.~Motor-Cognitive Dual Task (mental): The individual counts backward from 10 in increments of one while walking, and the time is recorded.~Motor-Cognitive Dual Task (memory): The individual is asked to recall three previously mentioned words while walking, and the time is recorded."
219250942|NCT06721104|OTHER|Functional Balance|"Functional balance will be assessed using the Timed Up and Go (TUG) test. The TUG test measures the time it takes for an individual to stand up from a chair upon the ready, go signal, walk a distance of 3 meters, turn around, walk back to the chair, and sit down again. The TUG test is a reliable and sensitive measure of balance and functional mobility in children.~At the beginning of the test, participants will be seated on an armless chair with their hips and knees flexed at approximately 90 degrees and their feet flat on the ground. The children will be instructed to stand up from the chair, walk as quickly as possible, touch a target on the wall, walk back, and sit down again."
219250943|NCT06721104|OTHER|Social Adaptation Assessment|Adaptive behavior will be evaluated using the Vineland Adaptive Behavior Scales. This is a parent interview designed to assess functionality in daily life. Specifically, adaptive behavior is evaluated in four domains: Communication, Daily Living Skills, Socialization, and Motor Skills. The Vineland scales are known for their reliability and up-to-date validity. They have been reported to be sensitive to the challenges faced by children with Autism Spectrum Disorder (ASD).
219250944|NCT06721104|OTHER|Cervical Posture Assessment:|"Cervical posture will be evaluated using the Android-based PostureScreen Mobile application (version 8.5, developed by Posture Co. Inc., USA). This application assesses the static posture of individuals. After determining reference points, the application draws reference lines and records postural deviations. At least two photos of each participant will be taken for the assessment. Participants should not wear clothing items that cover the neck (e.g., scarves, shawls).~While the primary focus of the application is to assess postural deviations, it also includes a dental evaluation feature. The validity and reliability of the application have been established in previous studies. In addition to using the application, the posture of individuals will also be evaluated through observational analysis, and the findings will be documented."
219250945|NCT06721104|OTHER|Temporomandibular Joint (TMJ) Assessment|"The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population."
219250946|NCT06721182|DEVICE|REBOA|endovascular balloon occlusion of the aorta
219250947|NCT06721676|DEVICE|transcatheter aortic valve replacement in severe aortic stenosis|transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis
219250948|NCT06719739|DEVICE|Intraocular lens implantation|Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.
219250949|NCT06720025|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
219250950|NCT06720025|DRUG|rHuEPO injection|Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
219250951|NCT01193023|OTHER|Pressure Support|Ventilation under pressure support
219250952|NCT01193023|DEVICE|NAVA|Ventilation under NAVA
219250953|NCT03868735|DEVICE|CleanSweep Closed Suction System|Device with balloon sweeping technology
219250954|NCT01935193|DRUG|lysine acetylsalicylate|
219250955|NCT03549299|BIOLOGICAL|LSC2|Topical application of IMP on target eye
219250956|NCT00421122|DRUG|budesonide/formoterol (Symbicort)|inhalation therapy
219250957|NCT00421122|DRUG|budesonide (Pulmicort)|inhalation
219250958|NCT00421122|DRUG|terbutaline sulfate (Bricasol)|inhalation therapy
219250959|NCT03635437|DRUG|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
219250960|NCT03635437|DRUG|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
219250961|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
219250962|NCT01002547|DRUG|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
219250963|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
219250964|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
219250965|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
219250966|NCT01002547|DRUG|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
219250967|NCT01516606|DRUG|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
219250968|NCT03273283|BEHAVIORAL|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
219250969|NCT00710814|DRUG|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
219250970|NCT00710814|OTHER|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
219250971|NCT06023888|OTHER|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
219250972|NCT06023888|OTHER|Mapping strategy|PVI+ non-PV trigger
219250973|NCT05648448|DRUG|Oseltamivir|Oral oseltamivir 75mg BD for 5/7
219250974|NCT05648448|DRUG|Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
219250975|NCT05648448|DRUG|Zanamivir|Inhaled zanamivir 10mg BD for 5/7
219250976|NCT05648448|DRUG|Baloxavir|"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
219250977|NCT05648448|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5/7
219250978|NCT05648448|DRUG|Peramivir|Intravenous peramivir 600mg once only
219250979|NCT05648448|DRUG|Laninamivir|Inhaled laninamivir 40mg once only
219250980|NCT05648448|DRUG|Oseltamivir and Baloxavir|"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
219250981|NCT05648448|DRUG|Oseltamivir and Favipiravir|"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"
219250982|NCT05648448|DRUG|Favipiravir and Baloxavir|"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
219250983|NCT05823519|DEVICE|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
219743023|NCT00421408|DIETARY_SUPPLEMENT|Whey protein supplement|40-g whey protein supplement daily for 18 months
219743024|NCT00421408|DIETARY_SUPPLEMENT|Placebo|Placebo supplement daily for 18 months
219743025|NCT04091438|DRUG|TAK-925|TAK-925 IV infusion.
219743026|NCT04091438|DRUG|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
219743027|NCT05510973|OTHER|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
219743028|NCT00912873|DRUG|0.1% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
219743029|NCT00912873|DRUG|0.4% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
219743030|NCT01954511|OTHER|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
219250984|NCT00672763|DRUG|Colecalciferol D3 (Vigantol Oil)|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
219250985|NCT00672763|DRUG|Medium chain triglycerides|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)"
219250986|NCT04528537|OTHER|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
219250987|NCT02548754|DEVICE|Parasym device|
219250988|NCT00003212|DRUG|doxorubicin hydrochloride|
219250989|NCT00003212|DRUG|ifosfamide|
219250990|NCT04532983|PROCEDURE|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
219250991|NCT04532983|PROCEDURE|mesh placement without fixation|mesh placement in preperitoneal space without fixation
219250992|NCT02093897|BIOLOGICAL|rVIII-SingleChain|
219250993|NCT03429595|DRUG|ATx201|ATx201 GEL
219250994|NCT03429595|OTHER|ATx201 GEL Vehicle|Vehicle
219250995|NCT03377725|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
219250996|NCT03377725|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
219250997|NCT02264418|DRUG|ODM 203|ODM 203
219250998|NCT02264418|DRUG|ODM 203|ODM 203
219250999|NCT02596399|DRUG|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
219251000|NCT02596399|DRUG|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
219251001|NCT02629419|DRUG|Amphotericin B|Oral lipid nanocrystal formulation of amphotericin B
219251002|NCT02081196|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219251003|NCT02936492|DRUG|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
219251004|NCT02936492|DRUG|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
219251005|NCT02936492|DRUG|BAY1003803 0.01% ointment|Topical administration for 22 h per day
219251006|NCT02936492|DRUG|BAY1003803 0.1% ointment|Topical administration for 22 h per day
219251007|NCT02936492|DRUG|Lipophilic cream vehicle|Topical administration for 22 h per day
219251008|NCT02936492|DRUG|Ointment vehicle|Topical administration for 22 h per day
219251009|NCT02936492|DRUG|Clobetasol propionate|Topical administration for 22 h per day
219251010|NCT02055053|DRUG|0.5% Bupivicaine|Local anesthetic
219251011|NCT00399997|BEHAVIORAL|Exercise on Prescription|
219251012|NCT03018847|DEVICE|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
219251013|NCT03098797|DRUG|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
219251014|NCT03098797|DRUG|Placebo|daily subcutaneous injection for 12 weeks
219251015|NCT01176136|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
219251016|NCT04814615|DRUG|89Zr-daratumumab PET/CT|CD38-targeting imaging
219251017|NCT00985634|DEVICE|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
219251018|NCT00985634|DEVICE|Control|Vessel loops
219251019|NCT04568356|DIAGNOSTIC_TEST|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
219251020|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
219251021|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
219251022|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
219251023|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
219251024|NCT00434577|BIOLOGICAL|Placebo|Single intramuscular injection
219251025|NCT02821078|OTHER|4D flow imaging sequence|4D flow imaging sequence
219743031|NCT01954511|OTHER|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
219743032|NCT01954511|DEVICE|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
219743033|NCT02370693|DRUG|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
219743034|NCT02370693|DRUG|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
219743035|NCT02370693|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
219743036|NCT02142829|DRUG|EXPAREL|
219743037|NCT02142829|DRUG|On-Q Pain Ball|bupivacaine HCl 0.25%
219743038|NCT03075436|BEHAVIORAL|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
219743039|NCT03075436|BEHAVIORAL|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
219743040|NCT06234475|BEHAVIORAL|Mobile health support|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
219743041|NCT06234475|BEHAVIORAL|Financial incentive|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
219743042|NCT06234475|BEHAVIORAL|Combine intervention|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
219743043|NCT06234475|BEHAVIORAL|Control group|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
219743044|NCT02976688|OTHER|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
219743045|NCT00005880|DRUG|budesonide|
219743046|NCT03956108|DIAGNOSTIC_TEST|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
219743047|NCT03956108|DIAGNOSTIC_TEST|PSA + systematic biopsies|Systematic biopsies and PSA test
219743048|NCT02390999|PROCEDURE|48 hours of therapeutic hypothermia|
219743049|NCT03737890|OTHER|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
219743050|NCT03737890|OTHER|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
219743051|NCT05394051|BEHAVIORAL|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
219743052|NCT00373360|DRUG|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
219743053|NCT00677300|DRUG|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
219743054|NCT00677300|DRUG|Darunavir|800 mg P.O. (orally) once daily
219743055|NCT00677300|DRUG|Ritonavir|100mg once daily
219743056|NCT00677300|DRUG|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
219251026|NCT04826926|PROCEDURE|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
219251027|NCT01216059|PROCEDURE|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
219251028|NCT03982875|DEVICE|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
219251029|NCT05982080|DRUG|FP002 Injection|Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
219251030|NCT06050083|BEHAVIORAL|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
219251031|NCT03354897|DRUG|Torasemide 5Mg Tablet|16 weeks treatment
219251032|NCT04854278|OTHER|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
219251033|NCT03767400|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
219251034|NCT03767400|OTHER|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
219251035|NCT02924350|OTHER|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
219743057|NCT01955265|BEHAVIORAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
219743058|NCT01955265|BEHAVIORAL|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
219743059|NCT05297019|PROCEDURE|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
219743060|NCT02157337|DRUG|Atorvastatin|80 mg (PO) once daily for 6 days
219743061|NCT02157337|DRUG|placebo|80 mg (PO) once daily for 6 days
219743062|NCT01431547|DRUG|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
219743063|NCT01431547|DRUG|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
219743064|NCT01431547|DRUG|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
219743065|NCT00090675|DRUG|ZD1839|
219743066|NCT04309500|BEHAVIORAL|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
219743067|NCT00047580|DRUG|tizanidine hydrochloride capsule|
219743068|NCT04743063|DRUG|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
219743069|NCT04743063|DRUG|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
219743070|NCT06127901|PROCEDURE|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
219743071|NCT06366165|PROCEDURE|seemingly irrelevant funny videos and memes in teaching|linking funny videos and memes to special care dentistry curriculum lectures
219743072|NCT05648747|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
219743073|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
219743074|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
219743075|NCT05914129|OTHER|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
219743076|NCT05914129|OTHER|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
219743077|NCT05914129|OTHER|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
219251036|NCT02924350|OTHER|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
219251037|NCT00097708|DRUG|experimental anti-anxiety drug|
219251038|NCT04739488|DEVICE|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
219251039|NCT04739488|BEHAVIORAL|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
219251040|NCT01195740|BEHAVIORAL|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
219251041|NCT01195740|BEHAVIORAL|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
219251042|NCT06271083|BEHAVIORAL|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
219251043|NCT06271083|BEHAVIORAL|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
219251044|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
219251045|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
219251046|NCT03856398|DEVICE|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
219251047|NCT04605822|DEVICE|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
219251048|NCT04605822|DEVICE|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
219251049|NCT04605822|DEVICE|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
219251050|NCT04605822|OTHER|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
219251051|NCT04301700|BEHAVIORAL|mindfullness and relaxation|three arms: mindfullness and relaxation
219251052|NCT06363513|DRUG|Aescin in Horse Chestnut|Can aescin reduce bleeding in early hemorrhoid
219251053|NCT06363513|DRUG|Flavonoid|Can combine aescin and MPFF reduce bleeding in early hemorrhoid
219251054|NCT02514226|PROCEDURE|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
219251055|NCT02514226|PROCEDURE|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
219251056|NCT02514226|PROCEDURE|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
219251057|NCT02514226|OTHER|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
219251058|NCT01509937|DEVICE|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
219251059|NCT01509937|DEVICE|Device|participants in control arm will not receive BCM measurement.
219251060|NCT03966534|OTHER|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
219251061|NCT02615548|OTHER|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
219251062|NCT02615548|OTHER|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
219251063|NCT02096809|PROCEDURE|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
219251064|NCT02096809|DEVICE|Cochlear Baha BI300/BA400 Implant System|
219251065|NCT04744805|OTHER|face mask or not|long term face mask wear
219251066|NCT02077153|BEHAVIORAL|Reminiscence therapy|
219251067|NCT02077153|BEHAVIORAL|Active participation in group setting|
219251068|NCT00640185|DRUG|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
219251069|NCT00640185|DRUG|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
219251070|NCT00300963|DRUG|Talnetant|
219251071|NCT02358083|BEHAVIORAL|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
219251072|NCT01974453|RADIATION|Radiation dose|Radiation dose adsorbed by operators
219251073|NCT04082481|DRUG|TAK-988|TAK-988 tablets.
219251074|NCT04082481|DRUG|TAK-988 Placebo|TAK-988 placebo-matching tablets.
219251075|NCT03238456|BEHAVIORAL|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
219251076|NCT03157492|BEHAVIORAL|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
219251077|NCT03157492|BEHAVIORAL|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
219251078|NCT02580968|DEVICE|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
219251079|NCT02580968|DRUG|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
219251080|NCT00138918|BIOLOGICAL|OGX-011|See Detailed Description, Treatment Plan
219251081|NCT02854839|BIOLOGICAL|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
219251082|NCT06065709|BEHAVIORAL|Mindfulness breath awareness meditation|Mindfulness breath awareness meditation
219251083|NCT04279756|OTHER|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
219251084|NCT01319825|DRUG|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
219251085|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
219251086|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
219362831|NCT04123158|DIAGNOSTIC_TEST|MRI|"Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity \[relative to myometrium\] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI \[SItumour - SImyometrium / SImyometrium\]"
219251087|NCT01848262|PROCEDURE|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
219251088|NCT01848262|PROCEDURE|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
219251089|NCT01410084|DIETARY_SUPPLEMENT|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
219251090|NCT01410084|DIETARY_SUPPLEMENT|Vitamin E|400 IU vitamin E once monthly for 5 months
219251091|NCT00531063|DRUG|Everolimus (RAD001)|
219251092|NCT01249677|DRUG|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
219251093|NCT05964751|DIAGNOSTIC_TEST|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
219251094|NCT05964751|DIAGNOSTIC_TEST|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
219251095|NCT00383630|BIOLOGICAL|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
219251096|NCT00383630|BIOLOGICAL|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
219251097|NCT00383630|DEVICE|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
219251098|NCT01589523|DRUG|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
219251099|NCT00709540|BIOLOGICAL|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
219251100|NCT02245464|DRUG|Telmisartan|
219251101|NCT04039555|DEVICE|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
219251102|NCT04039555|DEVICE|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
219251103|NCT04039555|DEVICE|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
219251104|NCT05591170|DRUG|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
219251105|NCT06151847|PROCEDURE|Biospecimen Collection|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2
219251106|NCT06151847|DRUG|Cyclophosphamide|Given IV
219251107|NCT06151847|PROCEDURE|Echocardiography|Undergo echocardiography
219251108|NCT06151847|DRUG|Fludarabine|Given IV
219251109|NCT06151847|BIOLOGICAL|Interleukin-2|Given IV
219251110|NCT06151847|BIOLOGICAL|Lifileucel|Given IV
219251111|NCT06151847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219251112|NCT06151847|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219251113|NCT06151847|PROCEDURE|Tumor Resection|Undergo tumor resection
219251114|NCT00449436|DRUG|TRIZIVIR|TRIZIVIR
219251115|NCT00449436|DRUG|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
219251116|NCT00449436|DRUG|Boosted Protease Inhibitor|Boosted Protease Inhibitor
219251117|NCT03545178|BEHAVIORAL|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
219251118|NCT03545178|DIAGNOSTIC_TEST|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
219251119|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
219251120|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
219251121|NCT03844178|DRUG|installation of Tetracaine 1%|installation of Tetracaine 1%
219251122|NCT03844178|PROCEDURE|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
219251123|NCT00961896|DRUG|Vehicle|Placebo cream
219251124|NCT00961896|DRUG|LDE225 0.25%|
219251125|NCT00961896|DRUG|LDE225 0.75%|
219251126|NCT00506922|DRUG|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2"
219251127|NCT00506922|DRUG|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
219251128|NCT00506922|DRUG|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
219251129|NCT05584813|OTHER|Hypobaric Hypoxia|The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
219251130|NCT05283356|DRUG|Ticagrelor 60mg|Ticagrelor 60mg BID after TAVI
219251131|NCT02529371|DEVICE|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
219251132|NCT05684666|OTHER|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
219251133|NCT05684666|OTHER|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
219251134|NCT00298337|DRUG|Mixture of probiotic bacteria and prebiotic oligosaccharide|
219251135|NCT01304771|BIOLOGICAL|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
219251136|NCT00522470|DRUG|rosiglitazone|
219251137|NCT00046683|DRUG|alemtuzumab|
219251138|NCT00004097|DRUG|fluorouracil|
219251139|NCT00004097|DRUG|gemcitabine hydrochloride|
219251140|NCT00004097|DRUG|paclitaxel|
219251141|NCT00004097|RADIATION|radiation therapy|
219251142|NCT01623206|DRUG|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
219251143|NCT06442163|DEVICE|AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.|"After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours."
219251144|NCT01015378|PROCEDURE|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
219251145|NCT00175656|PROCEDURE|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
219251146|NCT05338112|DIAGNOSTIC_TEST|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
219251147|NCT04397614|OTHER|mHealth Assessments|Daily symptom tracker
219251148|NCT02490605|PROCEDURE|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
219251149|NCT02490605|PROCEDURE|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
219251150|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
219251151|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
219251152|NCT00555997|DRUG|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
219251153|NCT06260241|PROCEDURE|Traction Dressing|Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.
219251154|NCT06260241|OTHER|Without Traction Dressing|Without Traction Dressing
219251155|NCT02475018|DIETARY_SUPPLEMENT|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
219251156|NCT02475018|DIETARY_SUPPLEMENT|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
219251157|NCT00262249|DRUG|somatropin|
219251158|NCT03378947|OTHER|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
219362832|NCT05590520|PROCEDURE|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
219362833|NCT05590520|DRUG|GTN OINTMENT|0.2%GTN applied on anal canal.
219251159|NCT05285956|BEHAVIORAL|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
219251160|NCT02675998|DRUG|Tenapanor|
219251161|NCT02675998|DRUG|Placebo|
219251162|NCT00900406|GENETIC|gene expression analysis|blood collection
219251163|NCT00900406|GENETIC|microarray analysis|Blood collection
219251164|NCT00900406|GENETIC|polymorphism analysis|Blood collection
219251165|NCT00900406|GENETIC|proteomic profiling|Blood collection
219251166|NCT00900406|OTHER|flow cytometry|Blood collection
219251167|NCT00900406|OTHER|immunologic technique|Blood collection
219251168|NCT00900406|OTHER|laboratory biomarker analysis|Blood collection
219251169|NCT00900406|PROCEDURE|biopsy|Blood collection
219251170|NCT02867111|DEVICE|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
219251171|NCT02867111|OTHER|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
219251172|NCT02867111|PROCEDURE|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
219251173|NCT04981353|PROCEDURE|bilateral erector spinae plane block at T11|A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
219251174|NCT00022607|BIOLOGICAL|bevacizumab|
219251175|NCT00022607|DRUG|thalidomide|
219251176|NCT00848393|DRUG|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
219251177|NCT00848393|DRUG|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
219251178|NCT00848393|DRUG|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
219251179|NCT02534753|DRUG|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
219251180|NCT02475876|DRUG|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg."
219251181|NCT02475876|DRUG|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose = 4 mg/kg."
219251182|NCT01750086|DRUG|Teriparatide 40-mcg subcutaneous injection|
219251183|NCT01750086|DRUG|Denosumab Injection|One-time Denosumab injection
219251184|NCT01750086|DRUG|Alendronate Oral Tablet|weekly alendronate for 8 weeks
219251185|NCT03015597|BEHAVIORAL|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
219251186|NCT00003133|BIOLOGICAL|filgrastim|
219251187|NCT00003133|DRUG|cisplatin|
219251188|NCT00003133|DRUG|doxorubicin hydrochloride|
219251189|NCT00003133|DRUG|gemcitabine hydrochloride|
219251190|NCT00003133|DRUG|paclitaxel|
219251191|NCT06383429|OTHER|forward head posture by using mobile application. And patients will fill out headache disability index.|forward head posture by using mobile application. And patients will fill out headache disability index.
219251192|NCT01984749|DRUG|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8."
219251193|NCT04252300|DRUG|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
219251194|NCT04252300|DRUG|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
219251195|NCT02288364|DRUG|1% Lidocaine|
219251196|NCT02288364|DRUG|1% Lidocaine plus sodium bicarbonate|
219251197|NCT03555708|OTHER|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
219251198|NCT00043186|DRUG|Placebo|Placebo subcutaneous injection
219251199|NCT00043186|DRUG|Denosumab|Denosumab for subcutaneous injection
219251200|NCT00043186|DRUG|Alendronate|Alendronate 70 mg tablets
219251201|NCT04077385|BEHAVIORAL|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.
219251202|NCT04077385|BEHAVIORAL|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
219251203|NCT03181919|DRUG|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
219251204|NCT05668000|OTHER|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
219251205|NCT05668000|OTHER|Mobile application|The mobile application provide only self-management interventions.
219251206|NCT02246634|OTHER|Diffusion Weighted MRI scan|Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
219251207|NCT03032640|OTHER|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
219251208|NCT03032640|OTHER|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
219251209|NCT03032640|OTHER|Stool sampling|Subjects will provide a stool sample.
219251210|NCT03032640|OTHER|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
219251211|NCT03032640|OTHER|Placebo|Subjects in group 2 will be provided with placebo.
219251212|NCT03032640|OTHER|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
219251213|NCT00121446|DRUG|tenecteplase|
219251214|NCT00121446|DRUG|enoxaparin|
219251215|NCT00121446|DRUG|clopidogrel|
219251216|NCT00121446|PROCEDURE|percutaneous coronary intervention|
219251217|NCT01013688|PROCEDURE|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
219251218|NCT06201715|DRUG|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
219251219|NCT06632925|PROCEDURE|Catheter ablation|"The catheter ablation strategy is the same as the current treatment approach in patients with AF, according to the consensus of catheter ablation of AF. All procedures will be performed under local sedation or general anesthesia depending on the operator, and each patient will undergo an electrophysiological study and substrate mapping in the fasting state with adequate pre-ablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. All antiarrhythmic drugs except amiodarone will be discontinued for at least 5 half-lives before the procedure.~Step I: Substrate mapping before ablation, Step II: Pulmonary vein isolation (PVI), Step III: Post-ablation mapping in SR immediately after ablation, Step IV: Inducibility after ablation, Step V: Remmaping 30 minutes after ablation"
219362834|NCT06528275|OTHER|Health promotion intervention|Health promotion intervention with activites linked to nutrition, and distribution of baskets of fresh fruits and vegetables
219251220|NCT04100239|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
219251221|NCT02759887|PROCEDURE|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
219251222|NCT02759887|OTHER|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
219251223|NCT02759887|OTHER|caregiver questionnaire|
219251224|NCT02759887|PROCEDURE|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
219251225|NCT02759887|PROCEDURE|MRI|Magnetic resonance imaging of the head and brain.
219251226|NCT02759887|PROCEDURE|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
219251227|NCT02759887|PROCEDURE|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
219251228|NCT02759887|PROCEDURE|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
219251229|NCT00157690|DRUG|Alendronate|70 mg 1x weekly for 12 months
219251230|NCT00157690|DRUG|Placebo|70 mg 1 x weekly for 12 months
219251231|NCT00887185|OTHER|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
219251232|NCT05382910|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
219251233|NCT05382910|DRUG|Placebo|Placebo
219251234|NCT02977780|DRUG|Temozolomide|Temzolomide capsules
219251235|NCT02977780|DRUG|Neratinib|Neratinib tablets
219251236|NCT02977780|DRUG|QBS10072S|QBS10072S administered intravenously
219251237|NCT01341444|DEVICE|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
219251238|NCT01341444|OTHER|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
219251239|NCT05311774|DRUG|Duloxetine 30 mg|tablet
219251240|NCT05311774|DRUG|Tramadol|tablet
219251241|NCT05311774|DRUG|Placebo|tablet
219251242|NCT06268431|OTHER|Oxytocin rest|60-minute oxytocin rest
219251243|NCT05329649|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
219251244|NCT05082233|DRUG|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
219251245|NCT00038298|DRUG|Placebo|Placebo given 3 times weekly
219251246|NCT00038298|DRUG|AMG 719|50 mg 3 times weekly
219251247|NCT00038298|DRUG|AGM 719|200 mg 3 times weekly
219251248|NCT00038298|DRUG|AMG 719|400 mg 3 times weekly
219251249|NCT00038298|DRUG|placebo to AMG 719|Placebo dose given 3 times weekly
219251250|NCT02312609|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
219251251|NCT02229396|DRUG|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
219251252|NCT02229396|DRUG|Exentide|2 mg
219251253|NCT02229396|DRUG|Dapagliflozin|10 mg once daily Dapagliflozin
219251254|NCT04767802|DRUG|PTG-300|Hepcidin mimetic
219251255|NCT03460847|DRUG|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
219251256|NCT00429078|GENETIC|2nd Generation Designer T Cells|
219251257|NCT06479551|OTHER|high intensity-low volume resistance training|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
219251258|NCT06479551|OTHER|Moderate intensity-high volume resistance training|13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
219251259|NCT06235385|OTHER|Intervention not provided|This study is purely observational
219251260|NCT00823004|DRUG|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
219251261|NCT00823004|DRUG|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
219251262|NCT00823004|DRUG|GnRH agonist (buserelin)|50 µg SC twice daily
219251263|NCT00823004|DRUG|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
219251264|NCT00823004|DRUG|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
219251265|NCT02625129|OTHER|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
219251266|NCT04656860|DIETARY_SUPPLEMENT|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
219251267|NCT00397137|PROCEDURE|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
219251268|NCT00397137|PROCEDURE|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
219251269|NCT04517877|BEHAVIORAL|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
219251270|NCT04517877|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
219251271|NCT05142072|DRUG|Vitamin D3|intranasal film
219251272|NCT04703868|DRUG|Rabeprazole Sodium 10mg|Part A: 1 tablet administered before the breakfast during 7 days
219251273|NCT04703868|DRUG|Rabeprazole Sodium 20mg|Part B: 1 tablet administered before the breakfast during 7 days
219251274|NCT03245762|DRUG|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
219251275|NCT03245762|DRUG|Placebo|4 IU/day of placebo administered via nasal spray device each morning
219251276|NCT05056701|OTHER|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
219251277|NCT03498586|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
219251278|NCT03498586|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
219251279|NCT03168009|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
219251280|NCT02773407|DRUG|Azithromycin|
219251281|NCT02773407|DRUG|Co-trimoxazole|
219251282|NCT02384083|DRUG|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
219251283|NCT03474042|DRUG|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
219251284|NCT03474042|DRUG|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
219251285|NCT02657759|DIETARY_SUPPLEMENT|CARDICHOL|
219251286|NCT02657759|DIETARY_SUPPLEMENT|PLACEBO|
219251287|NCT04406142|DEVICE|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
219251288|NCT01304251|OTHER|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
219251289|NCT01304251|OTHER|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
219251290|NCT03681353|BEHAVIORAL|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
219251291|NCT00873561|DRUG|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
219251292|NCT00476918|DRUG|Intravitreal injection (triamcinolone acetonide)|
219251293|NCT01997749|DIETARY_SUPPLEMENT|Ketocal 4:1 (Nutricia)|
219251294|NCT01997749|DIETARY_SUPPLEMENT|Control diet: Regular diet offered at the hospitals|
219251295|NCT01997749|DIETARY_SUPPLEMENT|Ketogenic meals|
219251296|NCT03618212|DIAGNOSTIC_TEST|MRI|Skeletal MRI and pelvic and spinal MRI
219251297|NCT05384236|OTHER|kinesiology taping|To apply kinesiology taping in plantar fascia
219251298|NCT05384236|OTHER|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
219251299|NCT05117385|DIETARY_SUPPLEMENT|Botanical extract|1 capsule per day
219251300|NCT00613223|DRUG|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
219251301|NCT05515913|OTHER|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
219251302|NCT05515913|BEHAVIORAL|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
219251303|NCT05515913|OTHER|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
219251304|NCT05515913|OTHER|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
219251305|NCT05515913|OTHER|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
219251306|NCT05515913|OTHER|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
219251307|NCT06640998|DEVICE|Matrix Pro|Study subjects received up to three (3) study treatments with the Matrix Pro applicator
219251308|NCT01189617|DEVICE|Formula PD-F-7619|Off-White to Beige Lotion
219251309|NCT05389254|DEVICE|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
219251310|NCT05389254|DEVICE|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
219251311|NCT02640807|DRUG|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
219251312|NCT02640807|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
219251313|NCT02452125|DIETARY_SUPPLEMENT|Nicotine gum|Nicotine chewing gum
219251314|NCT04493983|PROCEDURE|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
219251315|NCT04493983|PROCEDURE|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
219251316|NCT01295775|DRUG|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
219251317|NCT00960284|DRUG|capecitabine|Given orally
219251318|NCT00960284|DRUG|cisplatin|Given IV
219251319|NCT00960284|DRUG|epirubicin hydrochloride|Given IV
219251320|NCT00960284|DRUG|fluorouracil|Given IV
219251321|NCT00960284|DRUG|gemcitabine hydrochloride|Given IV
219251322|NCT02358499|DRUG|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
219251323|NCT03113214|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
219251324|NCT03113214|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
219251325|NCT03113214|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
219251326|NCT03113214|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
219251327|NCT03113214|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
219251328|NCT03113214|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
219362835|NCT03942432|OTHER|Oral Glucose Tolerance Test (OGTT)|Blood samples at T0, T30min, T120min
219251329|NCT05092477|BEHAVIORAL|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response"
219251330|NCT05092477|BEHAVIORAL|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
219251331|NCT05439525|OTHER|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
219251332|NCT05439525|OTHER|conventional therapy|"1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness"
219251333|NCT03630783|BEHAVIORAL|Combined Cognitive Bias Modification|
219251334|NCT02456298|BEHAVIORAL|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
219251335|NCT02456298|BEHAVIORAL|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
219251336|NCT05135923|DIETARY_SUPPLEMENT|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
219251337|NCT02072798|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
219251338|NCT05415644|DRUG|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
219251339|NCT05415644|DRUG|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
219251340|NCT04105062|DRUG|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
219251341|NCT04105062|DEVICE|Cancer Vision Goggles|-Non-significant risk device
219251342|NCT01257412|DRUG|Dapagliflozin|5mg Oral dose od
219251343|NCT01257412|DRUG|Dapagliflozin|10 mg Oral dose od
219251344|NCT01257412|DRUG|placebo|5/10 mg Oral dose od
219251345|NCT02682004|OTHER|leptin, serotonin and adiponectin level|
219251346|NCT02682004|OTHER|leptin,serotonin, adiponectin level|
219251347|NCT00111839|DRUG|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
219251348|NCT00111839|DRUG|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
219251349|NCT04323111|PROCEDURE|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
219251350|NCT04768751|DIAGNOSTIC_TEST|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
219251351|NCT00626158|DRUG|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
219251352|NCT00626158|DRUG|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
219362836|NCT03942432|OTHER|Clinical exam|weight, length, waist measurement, cardiac frequency, blood pressure
219743078|NCT04868357|BEHAVIORAL|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
219743079|NCT04868357|BEHAVIORAL|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
219743080|NCT05039489|DRUG|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
219251353|NCT05971186|DRUG|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
219251354|NCT05971186|OTHER|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
219251355|NCT05971186|OTHER|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
219251356|NCT01532102|DRUG|AP611074|
219251357|NCT01532102|DRUG|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
219251358|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
219251359|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
219251360|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
219251361|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
219251362|NCT00478439|DIETARY_SUPPLEMENT|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
219251363|NCT00478439|DIETARY_SUPPLEMENT|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
219251364|NCT05319002|BEHAVIORAL|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
219251365|NCT01090232|OTHER|blood samples|
219251366|NCT01090232|OTHER|blood samples|
219251367|NCT06162637|DEVICE|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
219251368|NCT06162637|DEVICE|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
219251369|NCT03753750|DEVICE|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
219251370|NCT01347281|PROCEDURE|Injection of [18F]HX4|"Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position"
219251371|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
219251372|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
219251373|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
219251374|NCT05225285|BIOLOGICAL|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
219251375|NCT05225285|BIOLOGICAL|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
219251376|NCT02178397|DRUG|ERLOTINIB WITH CHEMOTHERAPY|
219251377|NCT02178397|DRUG|CHEMOTHERAPY ONLY|
219251378|NCT02312622|DRUG|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
219251379|NCT02361177|DRUG|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
219251380|NCT05475496|OTHER|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
219251381|NCT03358303|DEVICE|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
219743081|NCT05039489|DEVICE|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
219251382|NCT04589390|DRUG|Selexipag|treatment with selexipag
219251383|NCT04835233|DRUG|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
219251384|NCT05161143|DRUG|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
219251385|NCT00871143|BEHAVIORAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
219743082|NCT05039489|DEVICE|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
219743083|NCT05348122|DRUG|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
219743084|NCT05348122|DRUG|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
219743085|NCT05348122|DRUG|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
219743086|NCT05348122|DRUG|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
219743087|NCT05348122|DRUG|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
219743088|NCT06563830|OTHER|educational application|The content of the training to be applied to nurses will include: definition of MDRPI, etiology, prevalence and cost, staging, risk factors, nursing initiatives to be implemented to prevent MDRPI.
219743089|NCT03918408|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
219743090|NCT04948268|BEHAVIORAL|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
219743091|NCT04948268|BEHAVIORAL|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
219743092|NCT04948268|BEHAVIORAL|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
219743093|NCT04948268|BEHAVIORAL|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
219743094|NCT02414841|DRUG|Vonapanitase|
219743095|NCT02414841|DRUG|Placebo|
219743096|NCT02197988|DRUG|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
219743097|NCT02197988|DRUG|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
219743098|NCT06656221|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
219743099|NCT06656221|DRUG|Glofitamab|Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
219743100|NCT06656221|DRUG|Bortezomib|Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
219743101|NCT06656221|DRUG|Orelabrutinib|Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
219743102|NCT04846868|DRUG|Iclepertin|Iclepertin
219743103|NCT04846868|DRUG|Placebo|Placebo
219743104|NCT06609057|OTHER|Nutritional Intervention|Receive Cooking for Your Health in Southern New Mexico intervention
219743105|NCT06609057|OTHER|Questionnaire Administration|Ancillary studies
219743106|NCT06609057|OTHER|Survey Administration|Ancillary studies
219743107|NCT06609057|OTHER|Discussion|Ancillary studies
219743108|NCT03249558|DRUG|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
219743109|NCT03249558|DRUG|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
219743110|NCT03249558|DRUG|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
219743111|NCT06670521|DRUG|Methylprednisolone|50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
219743112|NCT06670521|DRUG|Normal Saline|Normal Saline placebo IV every 6 hours for 4 doses
219743113|NCT05032911|DIAGNOSTIC_TEST|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
219743114|NCT06675448|DEVICE|MitraClip|Participants will undergo the Mitraclip procedure according to current standards of practice
219743115|NCT06675448|OTHER|Moderate MR|Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
219251386|NCT00871143|BEHAVIORAL|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
219251387|NCT01150019|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
219251388|NCT05362513|DRUG|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
219251389|NCT05362513|DRUG|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
219251390|NCT02299856|OTHER|Cardiac magnetic resonance scan|
219251391|NCT05867550|DRUG|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
219251392|NCT05867550|DRUG|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
219251393|NCT05867550|DRUG|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
219251394|NCT05867550|DRUG|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
219251395|NCT03686241|PROCEDURE|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
219251396|NCT03686241|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
219251397|NCT05353621|BEHAVIORAL|VAS reported Stress|VAS reported Stress measurement during simulation
219251398|NCT03198936|DIETARY_SUPPLEMENT|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
219251399|NCT03198936|DIETARY_SUPPLEMENT|Placebo|2 capsules to be taken twice a day with meals with glassful of water
219251400|NCT00352053|DRUG|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
219251401|NCT00352053|DRUG|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
219362837|NCT03942432|BIOLOGICAL|Blood sample|Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
219362838|NCT03942432|DEVICE|MRI|3 Tesla abdominal MRI
219362839|NCT03942432|DEVICE|Bioimpedance|Measurement of body composition
219362840|NCT03942432|BEHAVIORAL|Questionnaires|Quality of life, physical activity, alcohol consumption and eating habits
219251402|NCT06478225|DRUG|BGT007H Cell Injection|"Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28)."
219251403|NCT02591797|PROCEDURE|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system."
219251404|NCT00520403|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
219251405|NCT00520403|DRUG|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
219251406|NCT00520403|DRUG|Vinblastine|0.1mg/kg iv every 3 weeks
219251407|NCT05871918|DRUG|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
219251408|NCT01145417|DRUG|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
219251409|NCT02671578|DRUG|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
219251410|NCT01921777|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
219251411|NCT01921777|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
219251412|NCT02435381|DRUG|Carisbamate|600mg Orally on days 2-4
219251413|NCT02435381|DRUG|Placebo|Placebo treatment only
219251414|NCT01828398|DEVICE|real-tDCS + UE robot-assisted therapy|
219251415|NCT01828398|DEVICE|sham-tDCS + UE robot-assisted therapy|
219251416|NCT04751461|OTHER|Product A|P0213420, a 1.8% nicotine ENDS product
219251417|NCT04751461|OTHER|Product B|P0213520, a 1.8% nicotine ENDS product
219251418|NCT04751461|OTHER|Product C|P0211220, a 1.8% nicotine ENDS product
219251419|NCT04751461|OTHER|Product D|P0211820, a 1.8% nicotine ENDS product
219251420|NCT04751461|OTHER|Product E|P0213417, a 2.4% nicotine ENDS product
219251421|NCT05635955|DRUG|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
219251422|NCT05635955|DRUG|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
219251423|NCT05635955|DRUG|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
219251424|NCT02969005|RADIATION|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
219251425|NCT03849521|DIAGNOSTIC_TEST|MRI|Enhanced carotid calcification presented by UTE MR.
219251426|NCT03227978|COMBINATION_PRODUCT|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
219251427|NCT01066897|DRUG|Pramipexole|Patients will received increasing dose of pramipexole
219251428|NCT02939859|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
219251429|NCT02939859|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
219251430|NCT02939859|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
219251431|NCT04113902|BEHAVIORAL|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
219251432|NCT06434545|BEHAVIORAL|Palliative Reasoning methodology|Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
219251433|NCT00529555|DRUG|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
219251434|NCT00529555|PROCEDURE|Scaling and root planing|scaling and root planing
219251435|NCT01372735|RADIATION|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
219251436|NCT01372735|RADIATION|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
219251437|NCT04881396|BIOLOGICAL|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
219251438|NCT04405856|DEVICE|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
219251439|NCT03857516|DEVICE|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
219251440|NCT02895854|RADIATION|Hypofractionated RT 5 x 7,25 Gy|
219251441|NCT02895854|RADIATION|LDR-brachytherapy with I125 seeds|
219251442|NCT05803902|DRUG|Experimental drug 9MW1911|Experimental drug administered with IV infusion
219251443|NCT05803902|DRUG|Placebo|Placebo administered with IV infusion
219251444|NCT03209050|DEVICE|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
219251445|NCT04323332|DRUG|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
219251446|NCT01974934|DRUG|Desvenlafaxine Succinate|
219251447|NCT04367363|BEHAVIORAL|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
219251448|NCT00293332|BIOLOGICAL|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
219251449|NCT00293332|DRUG|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
219251450|NCT00293332|DRUG|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
219251451|NCT00293332|PROCEDURE|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
219251452|NCT00162058|DRUG|Peflutren Lipid Microsphere Injectable Suspension|
219251453|NCT00139659|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
219251454|NCT00139659|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
219251455|NCT04232475|OTHER|1 minute of stair climbing and descending|1 minute of stair climbing and descending
219251456|NCT04232475|OTHER|3 minute of stair climbing and descending|3 minute of stair climbing and descending
219251457|NCT04232475|OTHER|10 minute of stair climbing and descending|10 minute of stair climbing and descending
219251458|NCT01591655|DRUG|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
219251459|NCT01591655|DRUG|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
219251460|NCT02391116|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
219251461|NCT05615896|DEVICE|Imaging Session|Various scans will be captured on both devices
219251462|NCT06454071|OTHER|Blood test|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
219251463|NCT05492123|DRUG|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
219251464|NCT05492123|DRUG|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
219251465|NCT05492123|RADIATION|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
219251466|NCT00399659|DRUG|Tegaserod|
219251467|NCT05261347|PROCEDURE|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
219251468|NCT05261347|PROCEDURE|sham|a lateral glide
219251469|NCT03451526|PROCEDURE|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
219251470|NCT02520414|DEVICE|Symphion® Bipolar Hysteroscopic Tissue Resection System|
219251471|NCT02580214|DIETARY_SUPPLEMENT|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
219251472|NCT04389944|OTHER|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
219362841|NCT01564836|BEHAVIORAL|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
219251473|NCT06073444|DEVICE|Picterus JP|Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
219251474|NCT02282917|DRUG|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
219251475|NCT01747629|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
219251476|NCT01747629|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
219251477|NCT00794911|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
219251478|NCT00794911|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
219251479|NCT06398171|OTHER|Exercise|Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
219251480|NCT05834361|DRUG|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
219251481|NCT05834361|DRUG|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
219251482|NCT05469763|OTHER|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week."
219251483|NCT04691336|BEHAVIORAL|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
219251484|NCT02260583|DEVICE|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
219251485|NCT05192226|BEHAVIORAL|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
219251486|NCT05440578|DRUG|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
219251487|NCT03081351|PROCEDURE|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
219251488|NCT03081351|PROCEDURE|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
219251489|NCT01940692|DRUG|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
219251490|NCT01940692|DRUG|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
219251491|NCT06293014|DRUG|TAS-102+bevacizumab|TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
219251492|NCT06293014|DRUG|Standard chemotherapy+bevacizumab|Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
219251493|NCT06263296|BEHAVIORAL|Self Management Education|Smartphone assisted self management education incorporated with the concept of motivational interviewing
219251494|NCT05183997|DIAGNOSTIC_TEST|complete blood count|laboratory test
219251495|NCT05183997|DIAGNOSTIC_TEST|prothrombin time|laboratory test
219251496|NCT05183997|DIAGNOSTIC_TEST|prothrombin concentration|laboratory test
219251497|NCT05183997|DRUG|Verapamil|drug will be add to prolong the effect of regional block
219251498|NCT02419040|PROCEDURE|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
219251499|NCT02419040|PROCEDURE|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
219251500|NCT02419040|PROCEDURE|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
219251501|NCT00400257|BEHAVIORAL|Early detection of heart failure|Early detection of heart failure
219251502|NCT02605772|DRUG|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
219251503|NCT02605772|DRUG|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
219251504|NCT02605772|DRUG|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
219251505|NCT00700518|DRUG|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
219251506|NCT00700518|DRUG|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
219251507|NCT00700518|DRUG|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
219251508|NCT00700518|DRUG|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
219251509|NCT00700518|DRUG|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
219251510|NCT01769729|BEHAVIORAL|PEPP|
219251511|NCT01769729|BEHAVIORAL|Care management|
219251512|NCT02802579|RADIATION|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
219251513|NCT02802579|RADIATION|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
219251514|NCT02802579|RADIATION|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
219251515|NCT02316145|BEHAVIORAL|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
219251516|NCT04414397|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC injectable gel
219251517|NCT04414397|OTHER|No-treatment control|Participants received no treatment for 3 months during the Control Period.
219251518|NCT02031445|DRUG|MRX-6|
219251519|NCT02031445|OTHER|Placebo|
219251520|NCT05439720|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
219251521|NCT05439720|DIETARY_SUPPLEMENT|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
219251522|NCT05439720|BEHAVIORAL|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
219251523|NCT02502487|PROCEDURE|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
219251524|NCT02502487|DRUG|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
219251525|NCT02502487|DRUG|Tetracaine|1% Tetracaine gel instilled into urethra
219251526|NCT01854372|DRUG|R-HCVAD and R-MC|
219251527|NCT06430151|DEVICE|CUE1|Sternal worn focused vibrotactile stimulation and cueing device
219251528|NCT01150500|DEVICE|MDT-4107 Zotarolimus-Eluting Coronary Stent|
219251529|NCT04350983|BEHAVIORAL|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
219251530|NCT01920178|DEVICE|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
219251531|NCT03944902|DRUG|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
219251532|NCT03944902|DRUG|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
219251533|NCT03962270|DEVICE|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
219251534|NCT04931199|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
219251535|NCT04931199|BEHAVIORAL|CBT+App|Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
219251536|NCT05880459|DRUG|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
219251537|NCT04764877|OTHER|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
219251538|NCT04341415|PROCEDURE|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
219251539|NCT04341415|PROCEDURE|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
219251540|NCT02798276|PROCEDURE|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
219251541|NCT02798276|OTHER|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
219251542|NCT02391545|DRUG|Duvelisib|PI3K Inhibitor
219251543|NCT02391545|DRUG|Rituximab|monoclonal antibody
219251544|NCT02391545|DRUG|Obinutuzumab|monoclonal antibody
219251545|NCT06485830|PROCEDURE|Neural mobilization of the lower limb|"Static neural mobilization techniques will be performed for the lower limb. Static procedures will consist of two sets of 10 repetitions, with one minute rest between sets. Next, dynamic neural mobilization techniques will be performed, with each exercise lasting 5 minutes per set, with one minute rest between them. Therefore, dynamic procedures will consist of 10 minutes per mobilization technique (with one minute rest between exercises).~At the end of all dynamic mobilization exercises, static mobilizations of the sciatic nerve will be performed again in the same order and with the same duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
219251546|NCT06485830|PROCEDURE|Conventional physical therapy|"The intervention will include a first part in which active mobilizations, active-assisted mobilizations, and active stretches will be performed, followed by activities aimed at improving physical training, mobility training, and strength training oriented towards specific tasks. After this second part, the first part will be repeated in the same order and duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
219251547|NCT04754594|BIOLOGICAL|BNT162b2|Intramuscular Injection
219251548|NCT04754594|OTHER|Placebo|Intramuscular Injection
219251549|NCT03386357|COMBINATION_PRODUCT|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
219251550|NCT03386357|DRUG|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
219251551|NCT05961228|OTHER|exercise|"Three different posture with and without correction according to the Schroth method"
219251552|NCT05820815|DEVICE|in-bed self-exercises based on EMG-sensor feedback intervention|It presents the exercise method and amount of exercise for self-exercise and performs self-exercise while receiving feedback from muscle activity during self-exercise.
219251553|NCT03467789|DRUG|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
219251554|NCT03467789|RADIATION|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
219251555|NCT03467789|DRUG|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
219251556|NCT05486871|PROCEDURE|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
219251557|NCT05789667|DRUG|Lenvatinib|Patients will be treated by lenvatinib as recommended by good clinical practice
219251558|NCT04896502|BEHAVIORAL|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
219251559|NCT04896502|OTHER|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
219251560|NCT05820256|DIETARY_SUPPLEMENT|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
219251561|NCT05820256|DIETARY_SUPPLEMENT|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
219251562|NCT06090487|DIAGNOSTIC_TEST|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
219251563|NCT02867371|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
219251564|NCT04473118|OTHER|Survey|An online-based questionnaire sent to participants via email
219251565|NCT00149071|DEVICE|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
219251566|NCT00149071|DEVICE|TMS|Transcraniel Magnetic Stimulation active and sham
219251567|NCT00149071|DEVICE|rTMS|active Transcranial Magnetic Stimulation
219251568|NCT00149071|DEVICE|rTMS|daily for three weeks
219251569|NCT04389983|DIETARY_SUPPLEMENT|Medium Chain Triglyceride oil|Bulletproof Braine Octane MCT oil
219251570|NCT00795977|BIOLOGICAL|dendritic cells, OK-432|Single Group Assignment
219251571|NCT06138834|DRUG|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
219251572|NCT06138834|DRUG|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
219251573|NCT06138834|DRUG|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
219251574|NCT06138834|DRUG|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
219251575|NCT06138834|DRUG|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
219251576|NCT01518517|DRUG|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
219251577|NCT01518517|DRUG|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
219251578|NCT03198416|DEVICE|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
219251579|NCT04374019|DRUG|Ivermectin|"Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)"
219251580|NCT04374019|DRUG|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
219251581|NCT04374019|DIETARY_SUPPLEMENT|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
219251582|NCT04374019|DRUG|Artesunate|Days 1-14:
219251583|NCT03899285|DRUG|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
219251584|NCT03071900|DIAGNOSTIC_TEST|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
219251585|NCT04198272|BEHAVIORAL|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
219251586|NCT04783272|DIAGNOSTIC_TEST|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
219251587|NCT03231579|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
219251588|NCT00690950|DRUG|Dutasteride|0.5mg capsule, taken once daily for 12 months
219251589|NCT03771534|DRUG|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
219251590|NCT03670199|OTHER|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
219251591|NCT03670199|OTHER|Physiotherapist intervention|Respiratory capacity Functional capacity
219251592|NCT03670199|OTHER|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
219251593|NCT03670199|OTHER|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
219251594|NCT05149716|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
219251595|NCT05149716|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
219251596|NCT03805685|PROCEDURE|Non-Cardiac Surgery|Non-cardiac surgery
219251597|NCT06606769|OTHER|Exercise|supervised exercise training; twice a week for 12 months
219251598|NCT07002320|DRUG|SX-682|SX-682 is supplied as 100mg film coated tablets.
219251599|NCT07002320|DRUG|Apalutamide|Apalutamide is supplied as 60mg film coated tablets.
219251600|NCT07000422|OTHER|Selected gait training program|All children in both groups will receive selected gait training (treadmill) sessions for five times per week over 6 successive months.
219251601|NCT07000422|OTHER|Eye movement exercise|All children in the experimental group will receive eye training exercises for five times per week over 6 successive months. The exercises include tasks to improve visual focus and tracking. Children search for a specific card among 20 while covering one eye, repeated 10 times. They follow a pencil moving vertically, horizontally, in circles, and in a figure 8, maintaining a 1m distance. Exercises include shifting gaze between two pencils, recognizing letters on a shaking card, and tracking a pencil from 5cm to 50cm. Tasks are done with each eye covered separately. Another task involves walking while focusing on a fixed target 1m away at eye level for 5 minutes.
219251602|NCT05667727|DRUG|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
219251603|NCT05667727|DRUG|Salbutamol|Patient will receive salbutamol as 4th nebulization.
219251604|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
219251605|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
219251606|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
219251607|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
219251608|NCT07007624|OTHER|Basketball training (Sport and diet)|The intervention program will last for 3 years, and each year will be divided into two periods: a preseason, beginning in early September and lasting for the first 6 weeks, followed immediately by a 32-week season (until the end of the school year). The preseason will include 5 training sessions per week, each lasting 2 hours (Monday to Friday). The following season will include 3 training sessions per week, each lasting 2 hours (after school), and one match on the weekend. Each session will be divided into 2 periods separated by a 10-minute break: the first period will focus on individual skills with moderate to high-intensity exercises (60-85% of heart rate), and the second period will focus on gameplay (tactics and strategy). The trainers had a high level of professional training, ensuring the quality of the sessions. Dietary recommendations based on the Mediterranean diet will be given to the subjects.
219251609|NCT07009041|OTHER|Strength training program|Strength training was implemented for eight weeks, including full-body, core, and leg exercises.
219251610|NCT07009041|OTHER|Stretching exercises program|Stretching exercises were performed after strength training for the entire eight-week period. The training was administered exclusively to participants in the experimental group, following a consistent schedule and sequence. The program was conducted three days a week for eight weeks, separate from regular football training.
219251611|NCT07009041|OTHER|Plyometric exercises program|Plyometric exercises were included only one day per week, and a minimum one-day rest period was maintained between training sessions.Since this program was originally 6 weeks long, it was implemented in the first 6 weeks of the study's implementation process.
219251612|NCT07009041|DIAGNOSTIC_TEST|Demographic tests|Demographic tests were applied to determine the height, weight and BMI values for the identification of the participants.
219251613|NCT07009041|DIAGNOSTIC_TEST|Jump tests|Jump tests (CMJ, CMJ Free, SJ, DJ, Horizontal Jump). Three different measurements were taken at three different times.(Before starting, end of week 4 and after completion of week 8).
219251614|NCT07009041|DIAGNOSTIC_TEST|Knee Valgus tests|It was conducted to determine the right and left knee valgus values of the participants.Three different measurements were taken at three different times. (Before starting, end of week 4 and after completion of week 8).
219251615|NCT07008274|PROCEDURE|surgery|laparoscopic sleeve gastrectomy
219251616|NCT07004465|DIETARY_SUPPLEMENT|cyanocobalamin|Group A will be given vitamin B12 tablets (1000 mcg) once daily.
219251617|NCT07004465|DEVICE|triamcinolone acetonide|Group B will be given Kenalog gel (triamcinolone acetonide 40 mg/ml). The other ingredients are benzyl alcohol, polysorbate 80, carmellose sodium, sodium chloride and water, by covering the area twice daily
219251618|NCT07008430|OTHER|No Intervention: Observational Cohort|There will be no intervention. Only archival data will be analyzed
219251619|NCT07009262|OTHER|Inapplicable|Inapplicable
219251620|NCT06701149|DRUG|Rademikibart injection|300 mg administered subcutaneously on the first day
219251621|NCT06701149|DRUG|CBP-201 injection|300 mg administered subcutaneously on the first day
219251622|NCT00497198|DRUG|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
219251623|NCT00497198|DRUG|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
219251624|NCT06702774|DIAGNOSTIC_TEST|Active case finding|Villagers will be informed through public announcements and social workers. Before the campaign, social workers and village doctors will recruit participants and obtain consent through door-to-door visits. A mobile van equipped with an AI-assisted digital radiography (DR) machine and a refrigerator will visit villages on agreed dates. Participants will complete a TB symptom questionnaire and undergo DR screening. Those with TB symptoms or abnormal DR results will provide on-site sputum samples and collect additional morning and night samples. Trained staff will ensure proper collection and offer nebulizer support if needed. Samples will be transported daily to hospitals for testing using smear, culture, and GeneXpert. Participants with negative bacteriological results but abnormal findings will be referred for further clinical assessment.
219251625|NCT06695988|BEHAVIORAL|Time Restricted Eating|The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
219251626|NCT06716970|DRUG|QR12000 75mg|QR12000 75mg QD
219251627|NCT06716970|DRUG|QR12000 75mg placebo|Matching placebo of QR12000 75mg QD
219251628|NCT06716970|DRUG|QR12000 150mg|QR12000 150mg QD
219251629|NCT06716970|DRUG|QR12000 150mg placebo|Matching placebo of QR12000 150mg QD
219251630|NCT06716970|DRUG|Sacubitril/valsartan 200mg|Sacubitril/valsartan 200mg QD
219251631|NCT06716970|DRUG|Sacubitril/valsartan 200mg placebo|Matching placebo of Sacubitril/valsartan 200mg QD
219251632|NCT06716281|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL
219251633|NCT06716281|BIOLOGICAL|Placebo|Sodium Chloride Injection
219251634|NCT06721923|DIETARY_SUPPLEMENT|Dietary protein|Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
219251635|NCT06719895|BEHAVIORAL|web based education|experimental
219251636|NCT06719999|DIETARY_SUPPLEMENT|B4HT Mediterranean Lunch box|lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)
219251637|NCT06720883|PROCEDURE|Major hepatectomy|All patients will undergo robotic major hepatectomy with S1 resection, hilar lymphadenectomy and biliary reconstruction
219251638|NCT06720766|DIAGNOSTIC_TEST|FibbroScan and biopsy|In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.
219251639|NCT06720792|OTHER|EscapeCovid|Online Escape Game with 4 players and a game guide. The players, in a group, must solve enigmas to win.
219251640|NCT06721286|DRUG|Teripalimab|240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
219251641|NCT06721286|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
219251642|NCT06721286|PROCEDURE|Surgery|Radical resection
219251643|NCT06720428|DEVICE|dry eye acupoint therapy instrument|The dry eye acupuncture point treatment device treat dry eye through stimulating acupuncture points by low pulse current.
219251644|NCT06720428|DRUG|Artificial tear|0.3% Ali eye drops
219251645|NCT06720194|DEVICE|Virtual therapy|Virtual therapy has been applied for four weeks, three times a week. We administered a total of twelve sessions with a duration of 30 minutes each. Prior to virtual therapy experimental group have received kinesitherapy for 15 minutes to improve and prevent muscle spasticity and joint contractures. Therapists recorded the order of the session and they have providen the same external aid to all patients. Two days a week the experimental group have received the conventional treatment for 45 minutes (kinesitherapy, strengthening exercises muscle, trunk control, transfers, standing and walking). In addition to physiotherapy treatment, participants have done occupational therapy 5 days a week (training to perform ADLs, tracking techniques and search, manipulation, reach and grasping of different utensils, etc.), for 30 minutes each session.
219251646|NCT06720194|OTHER|Usual treatment|Patients assigned to the control group have received the conventional treatment five days a week. They have done physiotherapy session and occupational therapy for 45 and 30 minutes a day each one.
219251647|NCT06721364|BEHAVIORAL|Suicide prevention treatment|"Intervention I:RAAHI RAAHI is a suicide literacy module that is specially designed to provide individuals with essential knowledge and skills by equipping them with tools to navigate the complexities of mental health and suicide prevention. This module aims to empower people to recognize signs of suicidal ideation, engage in empathetic communication through open discussion, combat stigma, and connect individuals in crisis with appropriate support and resources. The duration of the module will be of three hours.~Intervention II: safeTALK The \&#34;safeTalk\&#34; program is a psychoeducational initiative designed for suicide prevention among adolescents, consisting of a 4-hour workshop that incorporates presentations, videos, discussions, and questions.The workshop is designed according to the standard practices of safeTALK, to assist participants in (a) identifying warning signs of suicide; (b) Avoiding frequent impulses to overlook, dismiss, or avoid discussions about suicide."
219251648|NCT06721858|OTHER|Emotion Focused Therapy application|Participants in the intervention group will first be given face-to-face individual interviews to establish the therapeutic environment and relationship (Individual interviews are designed as orientation, diagnosis and planning stages, 30-minute interviews). Then, three intervention stages (40-minute, group therapy) will be applied and the last session will be both intervention (post-test application) and termination stage (completion of emotion-focused therapy application). After the individual interviews, individuals will be included in 3 intervention sessions as group training. It is planned that each group will have at least 4 and at most 6 people. If the specified number cannot be reached, the study will continue until the specified number is reached.
219251649|NCT06721858|OTHER|scale form|Emotion-focused therapy contributes to the treatment compliance and functionality of psychiatric patients.
219251650|NCT06721429|OTHER|dual task exercise group|Dual task exercise group Patients in the dual-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training. In addition, cognitive exercise training will be incorporated into each session, performed concurrently with the conventional physiotherapy. The cognitive exercises provided in this study are structured to target areas such as memory, verbal fluency, executive functions, calculation, and attentioN Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
219251651|NCT06721429|OTHER|single task group|Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
219251652|NCT05357066|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
219251653|NCT05357066|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
219251654|NCT03441659|PROCEDURE|ACL reconstruction|Surgical ACL reconstruction
219251655|NCT06720337|DRUG|bupivacaine 0.5%|patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique
219251656|NCT06720337|DRUG|Dexmedetomidine|patients will receive plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side
219251657|NCT06720337|DRUG|MgSO4|patients will receive plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
219251658|NCT06720402|BEHAVIORAL|Sun protection knowledge|To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.
219251659|NCT02475707|BIOLOGICAL|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
219251660|NCT06474546|OTHER|Diet intervention|"A diet based on the principles of the Mediterranean Diet (MedDiet): consists of an abundance of plant foods - unrefined cereals, fruit, vegetables, and extra-virgin olive oil - a moderate consumption of poultry, dairy products, eggs, and low consumption of sweets and red meats.~All subjects will be instructed to follow the MedDiet for 8 weeks by the study team. Families will be given the option to continue for 12 weeks if they wish to do so."
219251661|NCT06897982|BEHAVIORAL|One-arm feasibility pilot of a nutrition intervention to recruit, engage, and retain DPP participants in the safety-net setting in Los Angeles|This clinical trial incorporates a behavioral intervention as the primary outcome of Aim 3 is to assess the feasibility and acceptability of adding an educational intervention using nutritional demonstrations aligned with the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes. The purpose of this study is to assess if having a nutritional demonstration as part of the DPP would be accepted by clinic DPP patients and hear their perspectives about if this would help them in achieving DPP goals of achieving at least 5% weight loss and implementing sustainable lifestyle changes with healthy eating to reduce their risk of prediabetes. The intervention is designed to encourage healthier eating habits and encourage clinic DPP patients to incorporate this into their daily lives. This study will also determine if it is feasible to incorporate nutritional demonstrations to enhance the existing DPP curriculum
219251662|NCT04731428|BEHAVIORAL|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
219251663|NCT04269811|DRUG|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
219251664|NCT06868303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
219251665|NCT06868303|BEHAVIORAL|New Life Psychiatric Rehabilitation Association electronic clinic for psychological service|The eClinic treatment spans eight to fourteen week and is designed for individuals with moderate to severe mental health issues. The service is provided in a hybrid format, incorporating an in-person initial screening using the Patient Health Questionnaire-9 and General Anxiety Disorder-7, followed by online self-learning resources and sessions with a therapist. Pre- and post-treatment assessments as well as follow-ups will be used to keep track of service users' progress.
219251666|NCT06868303|BEHAVIORAL|Integrated Community Centres for Mental Wellness|Integrated Community Centres for Mental Wellness (ICCMWs) are the main community-based mental health services in Hong Kong. However, their reach among young people is limited, as their broad target age range primarily focuses on middle-aged individuals. ICCMW offers comprehensive, district-based community support and social rehabilitation services, from early prevention to risk management, for people in mental recovery, those with suspected mental health issues, their families and carers, and residents within the service area, all accessible through a single-entry point.
219251667|NCT06868303|OTHER|General Practitioner|Services provided by genersl practitioner
219251668|NCT06868303|BEHAVIORAL|Hub Casework|Services provided during hub casework sessions
219251669|NCT06898788|DRUG|Visbiome|"Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus.~Participants will be instructed to consume the powder mixed in water."
219251670|NCT06898788|DRUG|Placebo|Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).
219251671|NCT04957251|PROCEDURE|anterior approach to the hip|anterior hip hemiarthroplasty
219251672|NCT04957251|PROCEDURE|posterior approach to the hip|posterior hip hemiarthroplasty
219251673|NCT05223647|PROCEDURE|Thoracic radiotherapy|30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
219251674|NCT05223647|DRUG|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
219251675|NCT06313268|DRUG|Bevacizumab Biosimilar MB02|5 mg/kg to 15 mg/kg in combination with chemotherapy.
219251676|NCT06900998|DRUG|Nimodipine|Nimodipine will be administered orally beginning on the evening prior to the study lab session. 90mg doses will be administered at 6:00pm, 12:00am, 6:00am, and 12:00pm.
219251677|NCT06905561|DRUG|Diclofenac Sodium Gel|Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.
219251678|NCT06905561|OTHER|Placebo gel|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
219251679|NCT05344352|DIETARY_SUPPLEMENT|Multistrain Probiotic|8-week daily administration
219251680|NCT05344352|OTHER|Placebo|8-week daily administration
219251681|NCT06620809|DRUG|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）
219251682|NCT06620809|DRUG|A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles placebo(5×10\^9 particles）
219251683|NCT04639960|DRUG|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
219251684|NCT04639960|DRUG|Placebo|Twelve weeks of placebo treatment.
219251685|NCT05963854|OTHER|Survey Curbside|Observational. Waste will be collected on specific days for 2 consecutive weeks and surveys will be completed to coincide with the waste collections.
219251686|NCT04956094|DIAGNOSTIC_TEST|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
219251687|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
219251688|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
219251689|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
219251690|NCT06926153|OTHER|TABAPSY|"The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.~The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur"
219251691|NCT06926153|OTHER|Usual Care|Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)
219251692|NCT04990973|BEHAVIORAL|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
219251693|NCT04990973|BEHAVIORAL|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
219251694|NCT04822246|PROCEDURE|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
219251695|NCT04822246|PROCEDURE|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
219251696|NCT04822246|PROCEDURE|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
219251697|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
219251698|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
219251699|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
219251700|NCT02480283|PROCEDURE|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
219251701|NCT02480283|RADIATION|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
219251702|NCT02480283|PROCEDURE|Venipuncture|To collect blood cells and serum for analyses.
219251703|NCT02480283|PROCEDURE|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
219251704|NCT04800978|BIOLOGICAL|BAVC-C+Durvalumab|"* Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion"
219251705|NCT06923007|DEVICE|Vagus Nerve Stimulation|After randomization, VNS is performed for 6 months. The stimulation parameters will be 30 Hz and 250 μs, the maximum tolerable current is selected according to the patients' adverse reactions (dizziness, palpitations, abnormal sensations, local pain, etc.), and the recommended treatment intensity is 0.8 mA.
219251706|NCT06923007|DEVICE|Sham Vagus Nerve Stimulation|After randomization, sham vagus nerve stimulation VNS treatment is performed for 6 months. The stimulation parameters will be 30 Hz, 250 μs, and the treatment intensity will be 0 mA.
219251707|NCT00801749|BEHAVIORAL|sleep|
219251708|NCT04267393|DRUG|BMS-986263|Specified dose on specified days
219251709|NCT04267393|OTHER|Placebo|Specified dose on specified days
219251710|NCT02286245|OTHER|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
219251711|NCT02286245|OTHER|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
219251712|NCT00701597|DRUG|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
219251713|NCT06914349|PROCEDURE|Antecolic gastrojejunostomy|Gastrojejunostomy in front of the transverse colon
219251714|NCT06914349|PROCEDURE|Retrocolic gastrojejunostomy|Gastrojejunostomy through the transverse mesocolon
219251715|NCT04994418|DIETARY_SUPPLEMENT|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
219251716|NCT04994418|DIETARY_SUPPLEMENT|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
219251717|NCT04994418|DIETARY_SUPPLEMENT|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
219251718|NCT06941311|BEHAVIORAL|Cognitive Behavioral Therapy for Suicide Prevention (CBT-SP)|Clinicians will provide this specialized evidence-based mental health care. The study focuses on the acute phase of CBT-SP, which is 12 sessions. CBT-SP's goals are to reduce suicide risk factors, enhance coping, and prevent future suicidal behavior. Identifying the emotional, cognitive, behavioral, or familial processes that precede a suicide crisis is a major focus, which yields an individualized treatment plan. Each session lasts one hour and can be completed either in person or via a secure telehealth platform. Most youths will attend sessions on a weekly basis and therapists typically like to be in contact with parents as well.
219251719|NCT06941311|BEHAVIORAL|Youth-Nominated Support Team|Youth will nominate up to 4 trusted adults. Following parental approval, Support Persons will attend an orientation session with their assigned intervention specialist, learn about the youth's difficulties, treatment plan, and receive ideas for supporting the youth. Support Persons will be asked to have contact with the youth each week for up to three months to offer emotional support, encourage participation in treatment, and support the youth's healthy behaviors. Support Persons will have weekly check-ins with their intervention specialist every week for the 3 months of the study. During these calls, Support Persons have an opportunity to discuss any questions or concerns they may have about the youth and how best to support them.
219251720|NCT00586430|DRUG|lorazepam|single 2 mg dose of lorazepam
219251721|NCT00586430|DRUG|placebo|single dose of placebo
219251722|NCT01801813|OTHER|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
219251723|NCT04641234|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
219251724|NCT06951555|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction~Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency~1. Psychoeducational module and motivational interviewing.~2. Environmental planning~3. Beginning of training in emotional self-regulation techniques.~4. Cognitive errors and cognitive discussion.~5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources.~6. Self-esteem, stigma and life goals~7. Backpack of coping resources, mindfulness and slow breathing training for anxiety~8. Stress coping techniques~9. Lifestyle~10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues.~12\. Relapse prevention"
219251725|NCT03138629|DRUG|VAL-083|VAL-083 will be administered intravenously
219251726|NCT03723057|DRUG|AG-221|Oral AG-221 administered as directed by treating physician.
219251727|NCT03327025|BEHAVIORAL|Health education counseling|Health education counseling
219251728|NCT02475499|DRUG|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251729|NCT02475499|DRUG|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251730|NCT02475499|DRUG|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251731|NCT02475499|DRUG|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251732|NCT02475499|DRUG|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251733|NCT02475499|DRUG|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251734|NCT02475499|DRUG|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
219251735|NCT03542721|DRUG|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
219251736|NCT03542721|DRUG|Placebo of DA-5515|Placebo (three times a day)
219251737|NCT02799745|DRUG|Enzalutamide|Oral
219251738|NCT02799745|OTHER|Active Surveillance|
219251739|NCT04826744|OTHER|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
219251740|NCT05969119|DRUG|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
219251741|NCT05969119|DRUG|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
219251742|NCT05172557|BEHAVIORAL|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
219251743|NCT05172557|BEHAVIORAL|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
219251744|NCT06452043|OTHER|PARC program|Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
219251745|NCT00153374|BEHAVIORAL|Women's health|
219251746|NCT05982847|DIAGNOSTIC_TEST|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
219251747|NCT04853238|OTHER|Prospective observational cohort study|Prospective observational cohort study. No study treatment was administered in this study.
219251748|NCT04688554|DIAGNOSTIC_TEST|fMRI and DTI|Neurologic imaging correlates
219251749|NCT04688554|BEHAVIORAL|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
219251750|NCT04688554|BEHAVIORAL|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
219251751|NCT04688554|BEHAVIORAL|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
219251752|NCT06082856|DRUG|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
219251753|NCT06082856|DRUG|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
219251754|NCT05652387|BEHAVIORAL|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
219251755|NCT06212622|DRUG|Alfentanil|Subcutaneous injection
219251756|NCT06212622|DRUG|Oxycodone|Oral solution
219251757|NCT06493669|DIAGNOSTIC_TEST|Cognitive assessment|MoCA
219251758|NCT01557699|BIOLOGICAL|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
219251759|NCT01557699|BIOLOGICAL|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
219251760|NCT01557699|BIOLOGICAL|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
219251761|NCT01039259|DEVICE|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
219251762|NCT03394183|OTHER|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
219251763|NCT03159325|BEHAVIORAL|Healing Circles|See description in the arm description.
219251764|NCT02565888|DRUG|Daclatasvir|
219251765|NCT02565888|DRUG|Atazanavir|
219251766|NCT02565888|DRUG|Ritonavir|
219251767|NCT02565888|DRUG|Cobicistat|
219251768|NCT04792255|PROCEDURE|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
219251769|NCT04792255|PROCEDURE|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
219251770|NCT04792255|DIAGNOSTIC_TEST|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
219251771|NCT05277818|PROCEDURE|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
219251772|NCT00088452|DRUG|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
219251773|NCT00088452|DRUG|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
219251774|NCT00088452|DRUG|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
219251775|NCT02895698|DEVICE|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
219251776|NCT02895698|OTHER|Stretching exercises|"* The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds."
219251777|NCT02846935|DRUG|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
219251778|NCT02846935|DRUG|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
219251779|NCT02329223|BIOLOGICAL|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
219251780|NCT02329223|OTHER|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
219251781|NCT04526314|OTHER|observational|observational
219251782|NCT01921114|DEVICE|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
219251783|NCT01921114|DEVICE|Bard® Dual-Lumen PowerPICC SOLO2®|
219251784|NCT03614221|DRUG|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
219251785|NCT03614221|DRUG|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
219251786|NCT04005456|DIETARY_SUPPLEMENT|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
219251787|NCT04005456|BEHAVIORAL|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
219251788|NCT04005456|OTHER|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
219251789|NCT03380598|BEHAVIORAL|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
219251790|NCT03380598|BEHAVIORAL|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
219251791|NCT04675905|OTHER|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
219251792|NCT01101464|DRUG|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
219251793|NCT01101464|DRUG|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
219251794|NCT00306956|BEHAVIORAL|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
219251795|NCT06436495|OTHER|Hair Wash Shampoo|A standard marketed hair wash shampoo is to be used for the hair wash intervention post baseline evaluations of the scalp.
219251796|NCT05463926|BEHAVIORAL|PDA mobile application|"Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot."
219251797|NCT01083407|DRUG|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
219251798|NCT01083407|OTHER|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
219251799|NCT02189369|OTHER|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
219251800|NCT02189369|OTHER|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
219251801|NCT05851456|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
219251802|NCT03535077|OTHER|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
219251803|NCT01231464|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
219251804|NCT01231464|DRUG|placebo|placebo
219251805|NCT01580111|BIOLOGICAL|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
219251806|NCT03200236|BEHAVIORAL|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
219251807|NCT03200236|BEHAVIORAL|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
219251808|NCT06277518|PROCEDURE|Surgery for malignant tumors of the digestive system|Related treatment or palliative surgery under general anesthesia for digestive system malignancies
219251809|NCT01397188|DEVICE|PiCCO|transpulmonary thermodilution technique
219251810|NCT01397188|OTHER|sham, no intervention|no intervention
219251811|NCT02108197|DEVICE|Continuous positive airway pressure (S9, ResMed)|
219251812|NCT03045055|DEVICE|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
219251813|NCT03045055|PROCEDURE|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
219251814|NCT03045055|DEVICE|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
219251815|NCT02406274|OTHER|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
219251816|NCT02612805|OTHER|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
219251817|NCT02612805|OTHER|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
219251818|NCT02612805|OTHER|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
219251819|NCT00242164|DRUG|Dialysate Magnesium (Concentration)|
219251820|NCT00283777|DRUG|Chromium Picolinate|
219251821|NCT01916642|DRUG|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
219251822|NCT01916642|DRUG|Lidocaine 1.5mg/kg|same as other
219251823|NCT01916642|DRUG|Lidocaine 2mg/kg|same as other
219251824|NCT01916642|DRUG|Lidocaine 2.5mg/kg|same as other
219251825|NCT04513275|DRUG|non-medicine intervention|rating by MCCB only one time
219251826|NCT03948464|DRUG|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
219251827|NCT03948464|DRUG|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
219251828|NCT06395922|DEVICE|Blockbuster LMA|The LMA was inserted using the recommended technique, with the patient's head in the sniffing position. The appropriate size was selected based on body weight (size 3 for 30-50 kg, size 4 for 50-70 kg)
219251829|NCT06395922|DEVICE|Baska Mask|The BM was inserted by opening the mouth, avoiding the tongue, and negotiating the palatopharyngeal curve using the hand-tab.
219251830|NCT00272454|DRUG|Cilostazol|
219251831|NCT00272454|DRUG|Aspirin|
219251832|NCT04692376|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
219251833|NCT04692376|DRUG|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
219251834|NCT04692376|DRUG|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
219251835|NCT05611853|DRUG|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
219251836|NCT02304562|BIOLOGICAL|UCB Mesenchymal Stem Cells treatment|reduce skin injury
219251837|NCT04632212|BEHAVIORAL|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
219251838|NCT04632212|BEHAVIORAL|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~* Video: subjects will watch a video briefly explaining the food labels on the store.~* My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
219251839|NCT04632212|BEHAVIORAL|Ordering|To order food items by Nutri-Score (high to low).
219251840|NCT04632212|BEHAVIORAL|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
219251841|NCT05426447|OTHER|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
219251842|NCT05426447|OTHER|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
219251843|NCT00815022|DRUG|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
219251844|NCT01919346|DRUG|Eculizumab|
219251845|NCT01919346|DRUG|Normal Saline|
219251846|NCT01540578|OTHER|laboratory biomarker analysis|Correlative studies
219251847|NCT05336981|RADIATION|Low-Level Light Therapy|The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
219251848|NCT04210804|DIETARY_SUPPLEMENT|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
219251849|NCT02684955|DEVICE|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
219251850|NCT02684955|DEVICE|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
219251851|NCT03698630|DRUG|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
219251852|NCT03698630|DRUG|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone."
219251853|NCT02881021|OTHER|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
219251854|NCT02881021|DEVICE|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
219251855|NCT04164498|OTHER|music|exposure to music to investigate its effects on reducing noise adverse effects
219251856|NCT03065205|DEVICE|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
219251857|NCT06413277|DEVICE|Saluda Evoke Smart SCS System|Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation
219251858|NCT02182583|DRUG|Ba253MDI|
219251859|NCT02182583|DRUG|Ba253BINEB|
219251860|NCT02999932|OTHER|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
219251861|NCT04143737|BEHAVIORAL|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
219251862|NCT02480244|BEHAVIORAL|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
219251863|NCT02480244|OTHER|Control|Control arm receives no health-related behavioral intervention
219251864|NCT02763150|BEHAVIORAL|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
219251865|NCT02763150|OTHER|Health Promotion|The health promotion group will receive education on healthy eating and activity
219251866|NCT03334799|DEVICE|sacroiliac belt|standing and walking with the belt on and with the belt off
219251867|NCT02609035|BEHAVIORAL|Telephonic prompt|
219251868|NCT05278065|OTHER|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
219251869|NCT00550771|DRUG|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
219251870|NCT00550771|DRUG|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
219251871|NCT01701271|OTHER|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
219251872|NCT04598945|OTHER|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
219251873|NCT00349245|DRUG|Remifentanil|
219251874|NCT00349245|DRUG|Dexmedetomidine|
219251875|NCT00730847|BIOLOGICAL|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
219251876|NCT00333502|DRUG|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
219251877|NCT02733835|DRUG|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
219251878|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily.
219251879|NCT04655183|DRUG|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
219251880|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
219251881|NCT04655183|DRUG|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
219251882|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
219251883|NCT04655183|DRUG|Niraparib|Niraparib will be administered as single agent at the approved dose.
219251884|NCT04514796|DRUG|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
219251885|NCT01111136|BEHAVIORAL|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
219251886|NCT03022578|PROCEDURE|Laser Interstitial Thermal Therapy|Undergo LITT
219251887|NCT03022578|DRUG|Lomustine|Given PO
219251888|NCT03577756|OTHER|Neurodevelopmental assessments|Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
219251889|NCT02536885|PROCEDURE|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
219251890|NCT02536885|PROCEDURE|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
219251891|NCT01855178|DEVICE|Emfit Movement Monitor|Factory settings
219251892|NCT02160678|DRUG|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
219251893|NCT02160678|DRUG|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
219251894|NCT02160678|DRUG|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
219251895|NCT05428241|BEHAVIORAL|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
219251896|NCT02605278|OTHER|Clinical program for pain and depression|Already described
219251897|NCT02605278|OTHER|Control|Care as usual
219251898|NCT00003698|DRUG|fosbretabulin disodium|
219251899|NCT03666208|DEVICE|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
219251900|NCT02203045|OTHER|Total Knee Arthroplasty|
219251901|NCT04604951|DEVICE|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
219251902|NCT01502605|DRUG|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
219251903|NCT02136342|DRUG|chlorogenic acid|
219251904|NCT00206505|DRUG|Taxotere|
219251905|NCT06074445|OTHER|No intervention|No intervention
219251906|NCT01520077|DRUG|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
219251907|NCT04915079|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
219251908|NCT03935932|DEVICE|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
219251909|NCT04564859|DEVICE|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
219251910|NCT00002432|DRUG|Foscarnet sodium|
219251911|NCT03142828|DRUG|Chlorhexidine|Healing abutment with Clorhexidine
219251912|NCT03142828|OTHER|Placebo|Healing abutment without any antiseptic
219251913|NCT00560807|PROCEDURE|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
219251914|NCT04662606|BEHAVIORAL|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
219251915|NCT03581344|DIAGNOSTIC_TEST|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
219251916|NCT02660047|DRUG|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
219251917|NCT02660047|DRUG|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
219251918|NCT05065892|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
219251919|NCT06477237|BIOLOGICAL|HB0017 Q4W|HB0017 at W0,1,2,4,8+HB0017Q4W
219251920|NCT06477237|BIOLOGICAL|HB0017 Q8W|HB0017 at W0,1,2,4,8+HB0017Q8W
219251921|NCT06477237|BIOLOGICAL|placebo|placebo at W0,1,2,4,8+HB0017Q4W
219251922|NCT04113928|DIETARY_SUPPLEMENT|Broccoli & mustard seed soup|200ml acute feed
219251923|NCT04113928|DIETARY_SUPPLEMENT|Broccoli soup|200ml acute feed
219251924|NCT00982540|DRUG|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
219251925|NCT01928407|DRUG|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
219251926|NCT01928407|DRUG|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
219251927|NCT00726388|DRUG|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
219251928|NCT01924637|DRUG|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
219251929|NCT01924637|DRUG|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
219251930|NCT04070729|OTHER|Placebo gel|Localized subgingival application
219251931|NCT04070729|DRUG|Hyaluronic acid gel|Localized subgingival application
219251932|NCT04070729|BIOLOGICAL|Platelet rich fibrin|Localized subgingival application
219251933|NCT01628289|OTHER|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
219251934|NCT01628289|OTHER|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
219251935|NCT03207620|DIAGNOSTIC_TEST|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
219251936|NCT03207620|DIAGNOSTIC_TEST|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
219251937|NCT03152500|DEVICE|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
219251938|NCT03152500|DEVICE|Acrysof SN60WF IOL|IOL in the bag
219251939|NCT00069628|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
219251940|NCT00069628|DEVICE|Continuous Glucose Monitoring System (CGMS)|
219251941|NCT00002216|DRUG|Lamivudine/Zidovudine|
219251942|NCT00002216|DRUG|Abacavir sulfate|
219251943|NCT00002216|DRUG|Amprenavir|
219251944|NCT00002216|DRUG|Nelfinavir mesylate|
219251945|NCT02303847|DRUG|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
219251946|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
219251947|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
219251948|NCT05234645|OTHER|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
219251949|NCT00382408|BIOLOGICAL|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
219251950|NCT00382408|OTHER|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
219251951|NCT01717547|BEHAVIORAL|Yoga-based treatment|
219251952|NCT04165525|DEVICE|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
219251953|NCT05816577|DIETARY_SUPPLEMENT|EcN Colibactin knockout|E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin
219251954|NCT05816577|DIETARY_SUPPLEMENT|E Coli Nissle|E Coli wildtype strain
219251955|NCT00405912|DRUG|Placebo|Placebo (inactive drug) given 3 times per day
219251956|NCT00405912|DRUG|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
219251957|NCT00405912|DRUG|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
219251958|NCT06086405|DEVICE|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
219251959|NCT03372577|BEHAVIORAL|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
219251960|NCT03372577|OTHER|Treatment as usual|Routine discharge counseling
219251961|NCT03730662|DRUG|Tirzepatide|Administered SC.
219251962|NCT03730662|DRUG|Insulin Glargine|Administered SC
219251963|NCT03892928|DRUG|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
219251964|NCT06188312|OTHER|Health education program|"A pretest questionnaire will be filled out, asking the participants about their knowledge, attitudes, and practices toward chemical hazards and the use of personal protective equipment (PPE) then analysis of the obtained pre-test data will be done.~we will apply a health education program. Development phase: developing the message of the health education program and preparing the materials (slide presentation, brochures, and an educational video).Implementation phase: A group health education session through face-to-face, one hour long, interactive lecture combined with slide presentation will be carried out by the researcher. Evaluation phase: A post-test will be done, after 6 months of the first session, to assess the changes of their knowledge and attitude after the intervention."
219251965|NCT01309243|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
219251966|NCT01309243|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
219251967|NCT05329233|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
219251968|NCT02721433|DRUG|Pamidronate|Bone-targeted agent as standard of care
219251969|NCT02721433|DRUG|Denosumab|Bone-targeted agent as standard of care
219251970|NCT02721433|DRUG|Zoledronate|Bone-targeted agent as standard of care
219251971|NCT01458080|DRUG|eltrombopag|eltrombopag
219251972|NCT03930238|BEHAVIORAL|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
219251973|NCT03930238|BEHAVIORAL|Fitbit Only|Fitbit Only
219251974|NCT00632931|DRUG|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
219251975|NCT00632931|DRUG|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
219251976|NCT04332679|DEVICE|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
219251977|NCT04332679|DEVICE|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
219251978|NCT03009019|DRUG|DFN-15 Active|
219251979|NCT03009019|OTHER|DFN-15 Placebo|
219251980|NCT04705402|DRUG|Mannitol|"Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes."
219251981|NCT04705402|DRUG|Saline|Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
219251982|NCT04095598|DIAGNOSTIC_TEST|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
219251983|NCT01965145|DRUG|Gevokizumab|Sterile solution administered subcutaneously
219251984|NCT01965145|DRUG|Placebo|Sterile solution administered subcutaneously
219251985|NCT01441583|DEVICE|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
219251986|NCT01441583|DEVICE|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
219251987|NCT04517968|OTHER|immediate implant with customized healing abutment|"* All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant."
219251988|NCT00849745|PROCEDURE|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
219251989|NCT03014908|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
219251990|NCT00735228|DEVICE|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
219251991|NCT05291585|DEVICE|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
219251992|NCT05291585|DEVICE|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
219251993|NCT06375018|OTHER|Placebo Technique|In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.
219251994|NCT06375018|OTHER|Diaphragm Stretching|The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
219251995|NCT03341312|BIOLOGICAL|LY900014|Administered SC
219251996|NCT03341312|BIOLOGICAL|Insulin Lispro|Administered SC
219251997|NCT02640326|OTHER|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
219251998|NCT02640326|OTHER|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
219251999|NCT04712500|DRUG|AND017|AND017 oral capsule
219252000|NCT05692414|DIETARY_SUPPLEMENT|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
219362911|NCT05410288|DEVICE|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
219252001|NCT06448845|PROCEDURE|Arm intravenous regional anesthesia|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
219252002|NCT06448845|PROCEDURE|Forearm IVRA block|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
219252003|NCT00839306|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
219252004|NCT00839306|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
219252005|NCT03780699|PROCEDURE|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
219252006|NCT01812707|DRUG|Alirocumab|Two SC injections in the abdomen only
219252007|NCT01812707|DRUG|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
219252008|NCT01812707|DRUG|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
219252009|NCT05060237|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
219252010|NCT00965302|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
219252011|NCT00965302|BEHAVIORAL|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
219252012|NCT01819428|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
219252013|NCT00001848|DRUG|Raloxifene|
219252014|NCT06363877|DRUG|Povidone-Iodine|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline."
219252015|NCT06363877|DRUG|Normal Saline|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline."
219252016|NCT02007421|PROCEDURE|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
219252017|NCT02007421|PROCEDURE|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
219252018|NCT00218075|DRUG|Levodopa|
219252019|NCT00218075|DRUG|Carbidopa|
219252020|NCT00218075|BEHAVIORAL|Clinical Management|
219252021|NCT00218075|BEHAVIORAL|Relapse Prevention Therapy|
219252022|NCT00218075|BEHAVIORAL|Contingency Management|
219252023|NCT03221634|BIOLOGICAL|Pembrolizumab|IV infusion
219252024|NCT03221634|BIOLOGICAL|Daratumumab|IV infusion
219252025|NCT01697592|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
219252026|NCT01697592|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
219252027|NCT05733000|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219252028|NCT05733000|PROCEDURE|Computed Tomography|Undergo CT
219252029|NCT05733000|DRUG|Devimistat|Receive IV
219252030|NCT05733000|DRUG|Fluorouracil|Receive IV
219252031|NCT05733000|DRUG|Gemcitabine Hydrochloride|Receive IV
219252032|NCT05733000|DRUG|Hydroxychloroquine|Receive PO
219252033|NCT05733000|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219252034|NCT05315076|OTHER|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
219252035|NCT05315076|OTHER|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
219252036|NCT02396758|DEVICE|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
219252037|NCT02396758|BIOLOGICAL|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
219252038|NCT02312362|PROCEDURE|Combined sclerotomy ab interno and phaco|
219252039|NCT02312362|PROCEDURE|Phacoemulsification with IOL implantation|
219252040|NCT01132222|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
219252041|NCT00764010|DIETARY_SUPPLEMENT|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
219252042|NCT00764010|DIETARY_SUPPLEMENT|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
219252043|NCT00764010|DIETARY_SUPPLEMENT|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
219252044|NCT00111163|DRUG|sulfadoxine-pyrimethamine with artesunate|
219252045|NCT00111163|DRUG|amodiaquine with artesunate|
219252046|NCT00111163|DRUG|chlorproguanil-dapsone|
219252047|NCT00829647|DRUG|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
219252048|NCT06106789|DRUG|Tobramycin inhalation solution|"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."
219252049|NCT00485914|BEHAVIORAL|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
219252050|NCT00485914|BEHAVIORAL|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
219252051|NCT01095601|DRUG|Avanafil|"* Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
219252052|NCT05376735|BEHAVIORAL|Purrble intervention|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
219252053|NCT05376735|BEHAVIORAL|Single Session Intervention|"The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
219252054|NCT00265096|BIOLOGICAL|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
219252055|NCT00265096|BIOLOGICAL|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
219252056|NCT00265096|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
219252057|NCT05611658|OTHER|MR, PET CT|diagnostic method
219252058|NCT00774306|DRUG|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
219252059|NCT00774306|DRUG|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
219252060|NCT00774306|DRUG|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
219252061|NCT05325658|OTHER|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
219252062|NCT02269033|BEHAVIORAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
219252063|NCT02269033|BEHAVIORAL|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
219252064|NCT01862679|OTHER|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
219252065|NCT01862679|PROCEDURE|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
219252066|NCT05478200|BEHAVIORAL|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
219252067|NCT05478200|OTHER|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
219252068|NCT03126188|DRUG|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
219252069|NCT03126188|DRUG|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
219252070|NCT03126188|DRUG|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
219252071|NCT04927559|OTHER|Survey Administration|Complete survey
219252072|NCT01039597|DRUG|ORE1001|Oral capsules containing 300 mg of the active, study drug
219252073|NCT01039597|DRUG|Placebo|placebo capsules
219252074|NCT02261545|DIETARY_SUPPLEMENT|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
219252075|NCT02261545|DIETARY_SUPPLEMENT|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
219252076|NCT01024829|RADIATION|Radiotherapy|Radiotherapy
219252077|NCT00558220|PROCEDURE|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
219252078|NCT00558220|PROCEDURE|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
219252079|NCT00558220|PROCEDURE|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
219252080|NCT00558220|PROCEDURE|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
219252081|NCT00558220|PROCEDURE|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
219252082|NCT00558220|RADIATION|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
219252083|NCT03897049|BEHAVIORAL|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
219252084|NCT03897049|BEHAVIORAL|General Health App|The control group will download a mobile app that addresses COVID and provides COVID resources.
219252085|NCT00666835|DRUG|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
219252086|NCT00666835|DRUG|ERYPO®, Janssen-Cilag|Solution for i.v. injection
219252087|NCT01126879|DIETARY_SUPPLEMENT|genistein|Given orally
219252088|NCT01126879|OTHER|placebo|Given orally
219252089|NCT01126879|PROCEDURE|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
219252090|NCT03978299|DIAGNOSTIC_TEST|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
219252091|NCT04903912|DIAGNOSTIC_TEST|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
219252092|NCT04903912|DIAGNOSTIC_TEST|Laboratory tests|Metabolic profile and platelet reactivity
219252093|NCT04903912|DRUG|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
219252094|NCT04903912|PROCEDURE|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
219252095|NCT05295992|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
219252096|NCT04778683|PROCEDURE|Virtual Reality|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
219252097|NCT03254992|DEVICE|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
219252098|NCT03254992|DEVICE|ASD - Tangible task|Experimental group using Keyboard with more real activity.
219252099|NCT03254992|DEVICE|TD - Abstract task|Control group using Kinect with more virtual activity.
219252100|NCT03254992|DEVICE|TD - Tangible task|Control group using Keyboard with more real activity.
219252101|NCT00692445|DRUG|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
219252102|NCT00692445|DRUG|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
219252103|NCT01233492|DRUG|boron phenylalanine|
219252104|NCT01233492|DRUG|mannitol|
219252105|NCT01233492|OTHER|biologic sample preservation procedure|
219252106|NCT01233492|RADIATION|radiation therapy treatment planning/simulation|
219252107|NCT02024399|OTHER|Exercise|Strength training, aerobic exercise and core strengthening, running
219252108|NCT02336113|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
219252109|NCT02718053|OTHER|L-stiff|spasticity measurement with Lokomat
219252110|NCT02718053|OTHER|Ashworth|spasticity measurement with Ashworth scale
219252111|NCT04385628|BEHAVIORAL|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
219252112|NCT02801916|OTHER|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
219252113|NCT02801916|OTHER|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
219252114|NCT02801916|OTHER|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
219252115|NCT02801916|OTHER|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
219252116|NCT03319719|DEVICE|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
219252117|NCT03319719|DEVICE|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
219252118|NCT03715413|OTHER|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
219252119|NCT03715413|DRUG|Tamoxifen|received Tamoxifen 10 mg daily
219252120|NCT02429232|DRUG|Pioglitazone|Pioglitazone 30mg/tablet once daily
219252121|NCT02429232|DRUG|Linagliptin|Linagliptin 5mg/tablet once daily
219252122|NCT05221216|OTHER|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
219252123|NCT03139383|OTHER|dextrose solution|The patients received 5%D/N/2 during surgery
219252124|NCT03139383|OTHER|saline solution|The patients received NSS during surgery
219252125|NCT04086719|DRUG|BMS-986165|Oral administration of tablet BMS- 986165
219252126|NCT04086719|DRUG|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
219252127|NCT00220116|DRUG|Capecitabine, Oxaliplatin|
219252128|NCT02764788|OTHER|Specific auriculotherapy|Specific auriculotherapy with needles
219252129|NCT02764788|OTHER|non-specific auriculotherapy|non-specific auriculotherapy with needles
219252130|NCT02764788|OTHER|seed auriculotherapy|non-specific auriculotherapy with seeds
219252131|NCT04077775|DIAGNOSTIC_TEST|assesment|assesment
219252132|NCT00498433|DRUG|Aliskiren|300 mg tablet once daily
219252133|NCT00498433|DRUG|Amlodipine|5 mg capsule once daily
219252134|NCT00498433|DRUG|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
219252135|NCT00498433|DRUG|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
219252136|NCT00295048|BEHAVIORAL|Computer Assisted Cognitive Remediation (CACR)|
219252137|NCT06204614|DEVICE|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
219252138|NCT06204614|DRUG|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
219252139|NCT06204614|DRUG|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
219252140|NCT06204614|DRUG|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
219252141|NCT06204614|DRUG|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
219252142|NCT06204614|DRUG|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
219252143|NCT06204614|DRUG|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
219252144|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
219252145|NCT06204614|DRUG|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
219252146|NCT06204614|DRUG|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
219252147|NCT06204614|DRUG|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
219252148|NCT06204614|DRUG|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
219252149|NCT06204614|DRUG|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
219252150|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
219252151|NCT06204614|DRUG|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
219252152|NCT06204614|DRUG|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
219252153|NCT06204614|DRUG|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
219252154|NCT06204614|DRUG|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
219252155|NCT06204614|DRUG|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
219252156|NCT06204614|DRUG|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
219252157|NCT06204614|DRUG|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
219252158|NCT06457347|PROCEDURE|Ultra early (<24 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
219252159|NCT06457347|PROCEDURE|Early (24-72 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
219252160|NCT00744796|PROCEDURE|DSAEK|Endothelial Keratoplasty
219252161|NCT00744796|DIAGNOSTIC_TEST|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
219252162|NCT00744796|DIAGNOSTIC_TEST|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
219252163|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
219252164|NCT02537236|BEHAVIORAL|TLC nutritional intervention|nutritional orientation.
219252165|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
219252166|NCT03682237|DEVICE|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
219252167|NCT03682237|DEVICE|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
219252168|NCT01212952|DRUG|pomalidomide|Given orally
219252169|NCT01212952|DRUG|bortezomib|Given IV
219252170|NCT01212952|DRUG|dexamethasone|Given orally
219252171|NCT01212952|OTHER|laboratory biomarker analysis|Optional correlative studies
219252172|NCT01212952|OTHER|gene expression analysis|Optional correlative studies
219252173|NCT03134937|DEVICE|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
219252174|NCT05973357|PROCEDURE|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
219252175|NCT05973357|PROCEDURE|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
219252176|NCT00994396|DIETARY_SUPPLEMENT|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
219252177|NCT00994396|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
219252178|NCT01538901|OTHER|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
219252179|NCT01538901|DRUG|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
219252180|NCT01405521|BIOLOGICAL|Vaccine placebo (excipients only)|single oral dose,
219252181|NCT01405521|BIOLOGICAL|Ty21a|3 oral doses, alternate days
219252182|NCT01405521|BIOLOGICAL|M10ZH09 vaccine|single oral dose
219252183|NCT02117856|PROCEDURE|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
219252184|NCT02117856|PROCEDURE|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
219252185|NCT02117856|PROCEDURE|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
219252186|NCT02117856|DEVICE|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
219252187|NCT02117856|DEVICE|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
219252188|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
219252189|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
219252190|NCT03744741|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
219252191|NCT04208815|OTHER|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
219252192|NCT04208815|OTHER|Milk Fat|Effects of the addition of 20 g milk fat.
219252193|NCT00234221|BEHAVIORAL|Strengths Based Case Management|
219252194|NCT00234221|BEHAVIORAL|Motivational Enhancement Therapy|
219252195|NCT00234221|BEHAVIORAL|Brief Informational Feedback|
219252196|NCT03193216|DRUG|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
219252197|NCT02924532|BIOLOGICAL|immediate post operative bioassay of Parathyroid Hormone|
219252198|NCT02641106|OTHER|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
219252199|NCT02641106|OTHER|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
219252200|NCT04978012|DRUG|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
219252201|NCT05388864|BEHAVIORAL|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
219252202|NCT05217290|BEHAVIORAL|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
219252203|NCT06149052|OTHER|SMART TRAINING|Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
219252204|NCT06149052|OTHER|FIRE training|Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
219252205|NCT00212719|DRUG|ONO-5920|
219252206|NCT02846597|PROCEDURE|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
219252207|NCT02470611|DRUG|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel
219252208|NCT02470611|OTHER|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
219252209|NCT01414556|OTHER|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
219252210|NCT01414556|OTHER|saline|
219252211|NCT02316847|DRUG|diazepam nasal spray|
219252212|NCT00735462|DRUG|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
219252213|NCT00735462|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
219252214|NCT00735462|DRUG|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
219252215|NCT00607256|DRUG|[S,S]-reboxetine|S\_S reboxetine dosed daily.
219252216|NCT02236598|DRUG|K+ supplement|
219252217|NCT02236598|DRUG|Placebo|
219252218|NCT06123364|DRUG|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
219252219|NCT06123364|DEVICE|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
219252220|NCT06123364|DEVICE|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
219252221|NCT01484314|DRUG|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
219252222|NCT01264887|DRUG|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
219252223|NCT00443677|DRUG|COPPEBVCAD vs BEACOPP vs ABVD|
219252224|NCT05482256|DIAGNOSTIC_TEST|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
219252225|NCT05482256|OTHER|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
219252226|NCT05482256|DIAGNOSTIC_TEST|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
219252227|NCT00668512|BIOLOGICAL|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
219252228|NCT04613622|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
219252229|NCT03553849|DIETARY_SUPPLEMENT|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
219252230|NCT04915157|DEVICE|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
219252231|NCT01061775|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
219252232|NCT05812209|PROCEDURE|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
219252233|NCT04448821|DRUG|Metformin|Single administration of metformin
219252234|NCT04448821|DRUG|Metformin + Nilotinib|Coadministration of metformin and nilotinib
219252235|NCT04349124|DRUG|Nifedipine Extended-Release Tablets|Antihypertensive
219252236|NCT06379906|OTHER|Assessment|Baseline assessment
219252237|NCT01313299|BIOLOGICAL|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
219252238|NCT01313299|BIOLOGICAL|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
219252239|NCT01313299|DRUG|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
219252240|NCT02773121|BEHAVIORAL|Physical Activity|Trainer-guided at-home behavioral intervention
219252241|NCT01907022|DEVICE|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
219252242|NCT02176317|BIOLOGICAL|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
219252243|NCT01461343|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
219252244|NCT05021757|DEVICE|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
219252245|NCT04255173|DIAGNOSTIC_TEST|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
219252246|NCT04255173|DIAGNOSTIC_TEST|waist circumference|waist circumference is measured as cm
219252247|NCT04255173|DIAGNOSTIC_TEST|hip circumference|hip circumference is measured as cm
219252248|NCT04255173|DIAGNOSTIC_TEST|height|height is measured as cm
219252249|NCT04255173|DIAGNOSTIC_TEST|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
219252250|NCT04255173|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
219252251|NCT04255173|DIAGNOSTIC_TEST|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
219252252|NCT04255173|DIAGNOSTIC_TEST|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
219252253|NCT04255173|DIAGNOSTIC_TEST|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
219252254|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
219252255|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
219252256|NCT04893785|DRUG|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
219252257|NCT04089332|OTHER|Oral Glucose Tolerance Test (OGTT)|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
219252258|NCT04089332|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
219252259|NCT04089332|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
219252260|NCT04089332|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
219252261|NCT05984147|DRUG|AUR108|3 Days dosing, and 4 days no dose in a week
219252262|NCT01026883|OTHER|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
219252263|NCT05250492|PROCEDURE|Prosthetic hip surgery|"Total hip prosthesis performed by an anterior approach with intra-articular infiltration of an anesthetic product intraoperatively.~OR~\- Total hip prosthesis performed by an anterior approach with infiltration of the same anesthetic product by ultrasound-guided PENG block intraoperatively."
219252264|NCT01923870|DRUG|Androxal 25 mg|
219252265|NCT06217497|OTHER|Foot massage|Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
219252266|NCT04376255|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
219252267|NCT06015620|PROCEDURE|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
219252268|NCT05433129|PROCEDURE|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
219252269|NCT05433129|PROCEDURE|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
219252270|NCT05433129|PROCEDURE|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
219252271|NCT05433129|PROCEDURE|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
219252272|NCT05955365|DRUG|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
219252273|NCT05955365|DRUG|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
219252274|NCT05955365|DRUG|DOAC|The choice of DOAC is left at investigator's discretion.
219252275|NCT05383651|DEVICE|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
219252276|NCT05383651|DEVICE|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
219252277|NCT05657613|DRUG|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
219252278|NCT05657613|DRUG|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
219252279|NCT05657613|DRUG|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
219252280|NCT02720783|DRUG|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
219252281|NCT02720783|DRUG|Placebo plus Econazole nitrate 150 mg vaginal pessary|
219252282|NCT02720783|DRUG|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
219252283|NCT02720783|DRUG|Placebo vaginal pessary|
219252284|NCT06288451|DRUG|Oral calcitriol with cinacalcet rescue|Participants will receive in-center oral calcitriol at a fixed dose of 0.5 mcg three times weekly at their dialysis treatment sessions regardless of their parathyroid hormone (PTH) concentrations over the 12-month trial period. Only if their serum PTH exceeds 800 pg/mL over 2 consecutive measurements will they be started on cinacalcet at 30 mg/d in order to protect against severe unremitting hyperparathyroidism.
219252285|NCT06288451|DRUG|IV activated vitamin D|Participants will continue to receive intravenously-administered activated vitamin D per the Northwest Kidney Center treatment protocol, dose-titrated to monthly to quarterly parathyroid hormone concentrations.
219252286|NCT03340766|DRUG|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
219252287|NCT03340766|DRUG|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
219252288|NCT03443752|OTHER|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
219252289|NCT03443752|OTHER|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
219252290|NCT05057078|BEHAVIORAL|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
219252291|NCT03514745|DEVICE|GlideScope|Endobronchial intubation is performed using the GlideScope.
219252292|NCT03514745|DEVICE|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
219252293|NCT06415747|OTHER|Observational pain and motor function assessments, and also comorbidities assessments with x-ray.|There was no intervention in our study, only observational and quantitative clinical evaluations.
219252294|NCT03922295|PROCEDURE|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
219252295|NCT00581009|OTHER|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
219252296|NCT00581009|DRUG|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
219252297|NCT00581009|RADIATION|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
219252298|NCT05044078|OTHER|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
219252299|NCT05044078|OTHER|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
219252300|NCT03823261|BEHAVIORAL|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
219252301|NCT02256488|BIOLOGICAL|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
219252302|NCT02256488|BIOLOGICAL|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
219252303|NCT02256488|BIOLOGICAL|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
219252304|NCT02256488|BIOLOGICAL|TIVf|Single IM administration dose of 0.5 mL of TIVf
219252305|NCT00207298|PROCEDURE|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
219252306|NCT00449488|DRUG|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
219252307|NCT02108483|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
219252308|NCT02108483|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
219252309|NCT03847389|DRUG|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
219252310|NCT05739799|PROCEDURE|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
219252311|NCT05739799|PROCEDURE|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
219252312|NCT02019238|OTHER|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
219252313|NCT00975130|BIOLOGICAL|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
219252314|NCT00975130|BIOLOGICAL|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
219252315|NCT03204318|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
219252316|NCT03204318|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
219252317|NCT03204318|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
219252318|NCT03204318|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
219252319|NCT01018576|OTHER|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
219252320|NCT03792789|DEVICE|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
219252321|NCT03792789|DEVICE|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
219252322|NCT02599987|DEVICE|POWERbreathe® Classic Light|Inspiratory Muscle Training
219252323|NCT05603299|OTHER|Educational Materials on the Dawn test|Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
219252324|NCT05590845|OTHER|Survey|"Patients, 65 and above, scheduled for elective total hip replacement surgery, will be invited to participate in a survey (consisting of 15 questions) testing their knowledge regarding PND.~After completion of the survey, patients will receive a standard preoperative brochure on anaesthesia-related topics and delirium.~T-MOCA scores will be collected (22 = perfect score; \<18 = cutoff for cognitive impairment) (through a pre-operative telephone call).~Six weeks post-operatively patients will once again be called for T-moca scores.~Initially a feasibility study for 1/3 of sample size will be done."
219252325|NCT02815618|DEVICE|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
219252326|NCT02948205|PROCEDURE|3D group|infertility patient get TU-LESS by 3D Laparoscopy
219252327|NCT02948205|PROCEDURE|normal group|infertility patient get normal laparoscopic surgery
219252328|NCT00260702|DRUG|Omalizumab (Xolair)|
219252329|NCT00734851|DRUG|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
219252330|NCT00734851|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
219252331|NCT00734851|RADIATION|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
219252332|NCT06531811|DRUG|AZD8630 (test formulation) via test inhaler|Participants will receive AZD8630 via test inhaler.
219252333|NCT06531811|DRUG|AZD8630 (reference formulation) via Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
219252334|NCT06531811|DEVICE|Test inhaler|Participants will receive AZD8630 via test inhaler.
219252335|NCT06531811|DEVICE|Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
219252336|NCT00818519|DRUG|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
219252337|NCT00818519|DRUG|Placebo|Inert tablet
219252338|NCT01972373|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
219252339|NCT01972373|DEVICE|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
219252340|NCT03899844|OTHER|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
219252341|NCT02961816|DRUG|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
219252342|NCT02961816|DRUG|Panobinostat|20 mg by mouth daily from Day -9 to -2.
219252343|NCT02961816|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
219252344|NCT02961816|DRUG|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
219252345|NCT02961816|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
219252346|NCT02961816|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
219252347|NCT02961816|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
219252348|NCT02961816|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
219252349|NCT02961816|DRUG|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
219252350|NCT02961816|OTHER|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
219252351|NCT02961816|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
219252352|NCT02961816|BIOLOGICAL|Stem Cell Infusion|Stem cells administered by vein on Day 0.
219252353|NCT02961816|DRUG|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
219252354|NCT04306549|OTHER|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
219252355|NCT05584397|PROCEDURE|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
219252356|NCT05584397|PROCEDURE|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
219252357|NCT05584397|PROCEDURE|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
219252358|NCT05584397|PROCEDURE|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
219252359|NCT05584397|PROCEDURE|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
219252360|NCT03724695|OTHER|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
219252361|NCT05126537|OTHER|no intervention|prospective and observational study with no intervention
219252362|NCT04320472|OTHER|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
219252363|NCT03639194|DRUG|ABBV-011|Intravenous
219252364|NCT03639194|DRUG|Budigalimab|Intravenous
219252365|NCT03562117|DRUG|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
219252366|NCT05472883|PROCEDURE|blood samples|\- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
219252367|NCT05472883|PROCEDURE|collection of body tissues|removal of intra-abdominal fat and muscle tissue
219252368|NCT05472883|PROCEDURE|routine care procedure|"* Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens."
219252369|NCT02817685|OTHER|3 months|
219252370|NCT02817685|OTHER|6 months|
219252371|NCT02817685|OTHER|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
219252372|NCT05807542|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
219252373|NCT05807542|DRUG|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
219252374|NCT05807542|DRUG|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
219252375|NCT06149533|DRUG|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
219252376|NCT02804347|DEVICE|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
219252377|NCT02804347|DEVICE|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
219252378|NCT02804347|OTHER|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
219252379|NCT06135779|BEHAVIORAL|A Lust for Life|A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
219252380|NCT06135779|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life School programme.
219252381|NCT00829517|OTHER|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
219252382|NCT00829517|OTHER|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
219252383|NCT01294358|DRUG|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
219252384|NCT00104364|DRUG|MK0731|
219252385|NCT03356145|DRUG|12 mL paracervical block|Injection of 12 mL of lidocaine
219252386|NCT03356145|DRUG|20 mL paracervical block|Injection of 20 mL of lidocaine
219252387|NCT04885478|OTHER|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring"
219252388|NCT01511744|BIOLOGICAL|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
219252389|NCT02963922|DRUG|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
219252390|NCT02963922|DRUG|Placebo|Injected subcutaneously (s.c., under the skin) once daily
219252391|NCT02420938|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
219252392|NCT02420938|DRUG|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
219252393|NCT00702234|BIOLOGICAL|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
219252394|NCT00702234|BIOLOGICAL|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
219252395|NCT00702234|BIOLOGICAL|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
219252396|NCT00702234|BIOLOGICAL|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
219252397|NCT00702234|DRUG|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
219252398|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
219252399|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
219252400|NCT03554200|DRUG|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
219252401|NCT03554200|DRUG|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
219252402|NCT02684942|DRUG|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
219252403|NCT02684942|DRUG|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
219252404|NCT00659971|DRUG|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
219252405|NCT01239056|PROCEDURE|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
219252406|NCT03467997|BEHAVIORAL|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
219252407|NCT03467997|OTHER|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
219252408|NCT00655668|DRUG|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
219252409|NCT03740919|DRUG|LY900014|Administered SC
219252410|NCT03740919|DRUG|Insulin Lispro|Administered SC
219252411|NCT03740919|DRUG|Insulin Glargine|Administered SC
219252412|NCT03740919|DRUG|Insulin Degludec|Administered SC
219252413|NCT04763863|OTHER|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
219252414|NCT04763863|OTHER|Clinical usability evaluation of the Body Assessment Tool|"The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool."
219252415|NCT04477954|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
219252416|NCT06564246|DRUG|Vonoprazan 20 mg versus Pantoprazole 40 mg|Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
219252417|NCT01707914|DIETARY_SUPPLEMENT|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
219252418|NCT01707914|DIETARY_SUPPLEMENT|placebo|
219252419|NCT00004171|DRUG|busulfan|
219252420|NCT00004171|DRUG|cyclophosphamide|
219252421|NCT00004171|PROCEDURE|peripheral blood stem cell transplantation|
219252422|NCT03873038|DRUG|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
219252423|NCT03873038|DRUG|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
219252424|NCT02458274|OTHER|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
219252425|NCT02301104|DRUG|TAS-102|
219252426|NCT04222088|DRUG|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
219252427|NCT04222088|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
219252428|NCT04222088|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
219252429|NCT00595764|BEHAVIORAL|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
219252430|NCT00595764|BEHAVIORAL|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
219252431|NCT02467673|DRUG|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
219252432|NCT02467673|DRUG|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
219252433|NCT05749562|DEVICE|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
219252434|NCT02270125|PROCEDURE|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
219252435|NCT05385991|BIOLOGICAL|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
219252436|NCT05850858|DIAGNOSTIC_TEST|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
219252437|NCT03474978|DEVICE|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
219252438|NCT03735368|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
219252439|NCT03735368|DRUG|Placebo oral capsule|placebo oral capsules
219252440|NCT03735368|DRUG|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
219252441|NCT03735368|DRUG|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
219252442|NCT00471549|DRUG|Statin (simvastatin)|
219252443|NCT01657552|DRUG|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
219252444|NCT01657552|DRUG|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
219252445|NCT01657552|DRUG|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
219252446|NCT01332318|DRUG|XP13512|XP13512 once daily for 16 days
219252447|NCT01332318|DRUG|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
219252448|NCT01332318|DRUG|Placebo|XP13512 placebo once daily for 16 days
219252449|NCT05532319|COMBINATION_PRODUCT|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
219252450|NCT04741984|BIOLOGICAL|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
219252451|NCT01338051|BIOLOGICAL|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
219252452|NCT03229525|BEHAVIORAL|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
219252453|NCT03229525|BEHAVIORAL|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
219252454|NCT00789399|DRUG|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
219252455|NCT00789399|OTHER|Placebo|subcutaneous equivolume isotonic saline
219252456|NCT02820298|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
219252457|NCT00860522|DRUG|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
219252458|NCT00860522|DRUG|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
219252459|NCT01894256|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
219252460|NCT02599376|DEVICE|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
219252461|NCT03662854|BIOLOGICAL|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
219252462|NCT03662854|OTHER|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
219252463|NCT03261934|OTHER|No intervention|No intervention
219252464|NCT02750371|OTHER|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
219252465|NCT04793555|OTHER|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
219252466|NCT01780584|DRUG|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
219252467|NCT01780584|DRUG|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
219252468|NCT01780584|DRUG|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
219252469|NCT01464671|DRUG|Bivalirudin|Anticoagulation during percutaneous coronary intervention
219252470|NCT01464671|DRUG|Heparin|Anticoagulation during percutaneous coronary intervention
219252471|NCT04222335|OTHER|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
219252472|NCT01022671|DRUG|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
219252473|NCT03747159|DRUG|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
219252474|NCT02108496|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
219252475|NCT02108496|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
219252476|NCT02108496|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
219252477|NCT02108496|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
219252478|NCT00861354|DEVICE|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
219252479|NCT02691884|PROCEDURE|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
219252480|NCT03426332|OTHER|No intervention|No intervention
219252481|NCT03916159|PROCEDURE|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
219252482|NCT03916159|PROCEDURE|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
219252483|NCT01924468|DRUG|Oral methylphenidate and Oral haloperidol|
219252484|NCT00975078|PROCEDURE|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
219252485|NCT00975078|DRUG|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
219252486|NCT05939050|DEVICE|Powered toothbrush|Oral-B Powered toothbrush
219252487|NCT04783519|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
219252488|NCT04783519|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
219252489|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
219252490|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
219252491|NCT00727259|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
219252492|NCT00727259|DRUG|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
219252493|NCT01021683|DRUG|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
219252494|NCT03594786|DEVICE|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
219252495|NCT05566626|DEVICE|Hyperspectral retinal image|Hyperspectral image of both eyes
219252496|NCT05566626|DRUG|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
219252497|NCT01339156|DRUG|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
219252498|NCT01339156|DRUG|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
219252499|NCT00471562|BIOLOGICAL|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
219252500|NCT02579941|PROCEDURE|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
219252501|NCT02579941|PROCEDURE|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
219252502|NCT02926495|DEVICE|eCoin System|Median nerve neurostimulator.
219252503|NCT00500539|DRUG|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
219252504|NCT05160402|DRUG|IGM-6268|Active comparator
219252505|NCT05160402|DRUG|Placebo|Placebo comparator
219252506|NCT02921438|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
219252507|NCT00645099|DRUG|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
219252508|NCT00645099|DRUG|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
219252509|NCT06540248|DEVICE|Ialuadapter|minimally invasive syringe device for bladder catherization
219252510|NCT03785418|BEHAVIORAL|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
219252511|NCT01914302|DEVICE|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252512|NCT01914302|DEVICE|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252513|NCT01914302|DEVICE|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252514|NCT01914302|DEVICE|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252515|NCT01914302|DEVICE|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252516|NCT01914302|DEVICE|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252517|NCT01914302|DEVICE|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252518|NCT01914302|DEVICE|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
219252519|NCT06475092|OTHER|Tanita device|bioelectric impedance analysis
219252520|NCT06040138|DIAGNOSTIC_TEST|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
219252521|NCT06472960|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
219252522|NCT06472960|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
219252523|NCT06472960|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
219252524|NCT05234008|OTHER|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from \>3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
219252525|NCT06477562|OTHER|Endoscopy|surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
219252526|NCT03149432|PROCEDURE|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
219252527|NCT03149432|DRUG|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
219252528|NCT03149432|PROCEDURE|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
219252529|NCT03149432|OTHER|Local care|local care for directed healing of the stump.
219252530|NCT03037814|DEVICE|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
219252531|NCT03037814|DEVICE|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
219252532|NCT03037814|DEVICE|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
219252533|NCT03037814|DEVICE|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
219252534|NCT03920761|DEVICE|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
219252535|NCT03920761|DEVICE|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
219252536|NCT02095938|DRUG|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
219252537|NCT02076802|BEHAVIORAL|physical exercises|
219252538|NCT01121497|DRUG|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
219252539|NCT01685307|DIETARY_SUPPLEMENT|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
219252540|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
219252541|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
219252542|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
219252543|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
219252544|NCT00729508|BIOLOGICAL|Cat-PAD|Placebo
219252545|NCT05510102|DEVICE|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
219252546|NCT05510102|DEVICE|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
219252547|NCT01601639|DEVICE|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
219252548|NCT01601639|DEVICE|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
219252549|NCT04804228|OTHER|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
219252550|NCT04804228|OTHER|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
219252551|NCT02089984|BEHAVIORAL|Internet Based CBT Training|
219252552|NCT01863888|DRUG|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
219252553|NCT01863888|DRUG|cholestyramine|Pharmaceutical form:powder Route of administration: oral
219252554|NCT01863888|DRUG|charcoal|Pharmaceutical form:granule Route of administration: oral
219252555|NCT00415025|PROCEDURE|adjuvant therapy|
219252556|NCT00415025|PROCEDURE|management of therapy complications|
219252557|NCT00415025|PROCEDURE|quality-of-life assessment|
219252558|NCT00415025|RADIATION|intensity-modulated radiation therapy|
219252559|NCT03206489|DEVICE|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
219252560|NCT03206489|DEVICE|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
219252561|NCT01971424|DIETARY_SUPPLEMENT|Mg oxide|
219252562|NCT01971424|OTHER|healthy diet|
219252563|NCT01201915|DRUG|Vismodegib|Vismodegib was supplied in gelatin capsules.
219252564|NCT05734885|OTHER|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
219252565|NCT04354623|OTHER|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
219252566|NCT06653569|DRUG|Baloxavir Marboxil|"The antiviral baloxavir marboxil administered in one unique dose.~1 capsule (40 mg) if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg"
219252567|NCT06653569|DRUG|Placebo|Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.
219252568|NCT05024266|DRUG|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
219252569|NCT03406507|BIOLOGICAL|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
219252570|NCT00911014|OTHER|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
219252571|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
219252572|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
219252573|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
219252574|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
219252575|NCT01515202|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
219252576|NCT01282918|DEVICE|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
219252577|NCT01282918|DEVICE|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
219252578|NCT05248217|BEHAVIORAL|healthcare workers|healthcare
219252579|NCT00663923|PROCEDURE|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
219252580|NCT05799040|DEVICE|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
219252581|NCT05799040|DEVICE|Chartis detection system|The participants would evaluated by the Chartis detection system.
219252582|NCT05020886|BEHAVIORAL|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
219252583|NCT03071341|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
219252584|NCT02084589|OTHER|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
219252585|NCT02084589|OTHER|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
219252586|NCT00522678|DRUG|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
219252587|NCT00522678|DRUG|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
219252588|NCT01588379|BEHAVIORAL|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
219252589|NCT01588379|BEHAVIORAL|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
219252590|NCT01588379|OTHER|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
219252591|NCT05308342|PROCEDURE|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
219252592|NCT05308342|DRUG|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
219252593|NCT06585644|DRUG|Furmonertinib in combination with Anrotinib and chemotherapy|The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
219252594|NCT02832453|BEHAVIORAL|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
219252595|NCT02832453|BEHAVIORAL|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
219252596|NCT02832453|BEHAVIORAL|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
219252597|NCT03313544|DRUG|Nivolumab|NIVOLUMAB
219252598|NCT03313544|DEVICE|MRI|Cardiac MRI 6 MONTHS
219252599|NCT03313544|BIOLOGICAL|BLOOD SAMPLES|biological (BNP and troponin)
219252600|NCT03313544|DEVICE|trans-thoracic echocardiography|1, 3 and 6 months
219252601|NCT02039596|OTHER|Diet|
219252602|NCT02156089|OTHER|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
219252603|NCT00547300|DRUG|Metoprolol ER|Metoprolol ER once daily, oral administration
219252604|NCT00547300|DRUG|Nebivolol|Nebivolol once daily, oral administration
219252605|NCT00002371|DRUG|Indinavir sulfate|
219252606|NCT00002371|DRUG|Lamivudine|
219252607|NCT00002371|DRUG|Stavudine|
219252608|NCT00002371|DRUG|Zidovudine|
219252609|NCT01596699|DRUG|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
219252610|NCT01596699|DRUG|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
219252611|NCT01596699|DRUG|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
219252612|NCT01596699|DRUG|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
219252613|NCT05081778|BEHAVIORAL|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
219252614|NCT04380688|DRUG|Acalabrutinib|Acalabrutinib administered orally
219252615|NCT06602206|OTHER|Conventional Treatment|Hot pack,TENS, ultrasound and exercises
219252616|NCT06602206|OTHER|shoulder mobilization|In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
219252617|NCT06602206|OTHER|neck mobilization|Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.
219252618|NCT06574724|OTHER|Visiting a green space|Participants are asked to visit a green space for a defined time period
219252619|NCT02160548|DRUG|Standard care|Standard management for OP poisoning
219252620|NCT02160548|DRUG|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
219252621|NCT02160548|DRUG|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
219252622|NCT07008131|DEVICE|Double J stent|Extravesical ureteroneocystostomy with double J-catheter placement
219252623|NCT07008131|PROCEDURE|No Double J stent|Extravesical ureteroneocystostomy with no Double J stent colocation
219252624|NCT02275845|DRUG|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
219252625|NCT02275845|OTHER|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
219252626|NCT03130816|BIOLOGICAL|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
219252627|NCT00564564|DRUG|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
219252628|NCT00564564|DRUG|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
219252629|NCT04877132|DRUG|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
219252630|NCT00000133|PROCEDURE|Trans-scleral Cryotherapy|
219252631|NCT03146754|OTHER|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
219252632|NCT03838419|RADIATION|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
219252633|NCT03838419|RADIATION|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
219252634|NCT04306913|DRUG|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
219252635|NCT04306913|DRUG|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
219252636|NCT03561025|DIAGNOSTIC_TEST|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
219252637|NCT03561025|DIAGNOSTIC_TEST|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
219252638|NCT05087953|DIAGNOSTIC_TEST|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
219252639|NCT05087953|DIAGNOSTIC_TEST|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
219252640|NCT02476708|DIETARY_SUPPLEMENT|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
219252641|NCT02476708|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule
219252642|NCT03683914|DRUG|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
219252643|NCT03683914|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
219252644|NCT00888407|BEHAVIORAL|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
219252645|NCT00888407|BEHAVIORAL|Nutrition - Small group educational session|Small group session with diet \& nutrition focused, topic related resources provided.
219252646|NCT04734847|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
219252647|NCT04734847|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
219252648|NCT04258215|DEVICE|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
219252649|NCT04145323|DIAGNOSTIC_TEST|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
219252650|NCT05813535|DRUG|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
219252651|NCT05664399|OTHER|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
219252652|NCT05964556|OTHER|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
219252653|NCT05964556|OTHER|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
219252654|NCT04410315|OTHER|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
219252655|NCT04410315|OTHER|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
219252656|NCT01868516|DRUG|dexmecamylamine|
219252657|NCT01868516|DRUG|Placebo|
219252658|NCT02515656|DRUG|POLYGYNAX®|
219252659|NCT02515656|DRUG|GYNODAKTARIN®|
219252660|NCT02515656|DRUG|Placebo|
219252661|NCT03626311|DIETARY_SUPPLEMENT|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
219252662|NCT03626311|OTHER|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
219252663|NCT01967719|OTHER|mTHS 2.2|Single use of mTHS 2.2
219252664|NCT01967719|OTHER|mCC|Single use of subject's own mCC
219252665|NCT01967719|OTHER|NNS|Single administration of 1 mg of nicotine
219252666|NCT05037721|OTHER|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
219252667|NCT05037721|OTHER|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
219252668|NCT03626025|OTHER|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
219252669|NCT00761397|BEHAVIORAL|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
219252670|NCT00761397|BEHAVIORAL|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
219252671|NCT00761397|OTHER|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
219252672|NCT00761397|OTHER|Questionnaire|Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
219252673|NCT04196829|DRUG|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
219252674|NCT04196829|DRUG|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
219252675|NCT04314570|PROCEDURE|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
219252676|NCT04314570|PROCEDURE|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
219252677|NCT04759118|BEHAVIORAL|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
219252678|NCT03927677|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
219252679|NCT06058117|OTHER|No intervention|no intervention, this is an observational study
219252680|NCT06157619|PROCEDURE|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
219252681|NCT06144788|DRUG|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
219252682|NCT00189683|PROCEDURE|Monitoring|
219252683|NCT00189683|PROCEDURE|Xeloda|
219252684|NCT00174798|DRUG|SSR240600C|once daily
219252685|NCT00174798|DRUG|Placebo|oral
219252686|NCT00174798|DRUG|Tolterodine|once daily
219252687|NCT00286975|BEHAVIORAL|Leadership development program educational intervention|
219252688|NCT00796614|DRUG|tamsulosin hydrochloride|Oral
219252689|NCT00796614|DRUG|Placebo|Oral
219252690|NCT05182970|DRUG|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
219252691|NCT04103086|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
219252692|NCT04103086|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
219252693|NCT01865500|DRUG|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
219252694|NCT01865500|DRUG|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
219252695|NCT01865500|DRUG|Metil prednisolone|
219252696|NCT00381888|DRUG|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
219252697|NCT04162236|DIAGNOSTIC_TEST|Ecocardiographyc ultrasound|"* Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
219252698|NCT03308747|DIETARY_SUPPLEMENT|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
219252699|NCT00985283|BEHAVIORAL|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
219252700|NCT00985283|BEHAVIORAL|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
219252701|NCT00319813|BEHAVIORAL|Education|
219252702|NCT05654298|DRUG|Sumatriptan|Sumatriptan 100 mg
219252703|NCT05654298|DRUG|Ubrogepant|Ubrogepant 100 mg
219252704|NCT03449134|DRUG|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
219252705|NCT03449134|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
219252706|NCT02604706|DEVICE|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
219252707|NCT02604706|DEVICE|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
219252708|NCT02604706|BEHAVIORAL|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
219252709|NCT04120662|PROCEDURE|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
219252710|NCT04120662|DEVICE|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
219252711|NCT03055923|DEVICE|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
219252712|NCT01330992|OTHER|Ocular light or darkness exposure|Ocular light or darkness exposure
219252713|NCT01504009|OTHER|Muscle training|12 weeks of strength training 2-3 times/week
219252714|NCT00993798|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
219252715|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
219252716|NCT00993798|DRUG|Bupivacaine HCl Treatment 1c|20.0 ml
219252717|NCT00993798|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
219252718|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
219252719|NCT00993798|DRUG|Bupivacaine HCl Treatment 2c|20.0 ml
219252720|NCT03787238|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
219252721|NCT04280679|DEVICE|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
219252722|NCT01357109|DRUG|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
219252723|NCT01357109|DRUG|Placebo|Matched placebo bid
219252724|NCT04700475|DEVICE|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
219252725|NCT04700475|DRUG|citric acid solution|citric acid solution applied as a mouth rinse
219252726|NCT06289023|RADIATION|HA-WBRT-SIB|A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
219252727|NCT01997489|DRUG|Enzyme replacement|Observational study of current treatment and with no comparative groups
219252728|NCT03418181|PROCEDURE|Standard Haemodialysis|Thrice weekly dialysis.
219252729|NCT03418181|PROCEDURE|Incremental dialysis|Individualised dialysis dose according to native kidney function.
219252730|NCT04635085|BEHAVIORAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
219252731|NCT00854971|BIOLOGICAL|TKCell|Biological/Vaccine: TKCell
219252732|NCT06176053|OTHER|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
219252733|NCT06478576|DEVICE|multibranched stent graft system|To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)
219252734|NCT00957996|DRUG|Peramivir|300 mg twice daily
219252735|NCT00957996|DRUG|Peramivir|600 mg once daily
219252736|NCT02007811|BIOLOGICAL|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
219252737|NCT06319547|PROCEDURE|Thoracocentasis|patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
219252738|NCT02970357|OTHER|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline"
219252739|NCT02970357|BEHAVIORAL|WHO-5|5 item questionnaire of the World Health Organization about quality of life
219252740|NCT02542410|DRUG|Cabergoline|
219252741|NCT02542410|DRUG|Norethindrone acetate|
219252742|NCT00256685|DRUG|DVS-233 SR|
219252743|NCT00000897|DRUG|Zidovudine|
219252744|NCT01268124|DRUG|HTC-867|
219252745|NCT06229249|OTHER|Carpal ligament self-myofascial stretching|Carpal ligament self-myofascial stretching is a technique that involves applying pressure and stretching to the carpal ligaments and surrounding myofascial tissues of the wrist and hand. The objective is to release tension, improve flexibility, and alleviate discomfort or pain in the wrist and hand area.
219252746|NCT06229249|OTHER|Conventional physical therapy|In this technique, ultrasound therapy, nerve gliding exercise, tendon gliding exercise, and wrist splinting were performed.
219252747|NCT00547053|DRUG|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
219252748|NCT02072278|DRUG|Vortioxetine 10 mg|
219252749|NCT02072278|DRUG|Vortioxetine 20 mg|
219252750|NCT02072278|DRUG|Escitalopram 15 mg|
219252751|NCT02072278|DRUG|Placebo|
219252752|NCT00468507|DIETARY_SUPPLEMENT|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
219252753|NCT00020969|DRUG|arsenic trioxide|
219252754|NCT02503982|DRUG|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
219252755|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
219252756|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
219252757|NCT02383238|DRUG|Dapagliflozin|10 mg, oral for 6 weeks
219252758|NCT02383238|DRUG|Placebo|oral for 6 weeks
219252759|NCT04523298|PROCEDURE|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
219252760|NCT04523298|OTHER|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
219252761|NCT03209245|BIOLOGICAL|Purethal Mites|perennial allergren specific immunotherapy during 24 months
219252762|NCT03209245|OTHER|placebo injection|perrenial injection wich were administered in same protocol as Purethal
219252763|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
219252764|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
219252765|NCT01391676|PROCEDURE|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
219252766|NCT01805206|OTHER|Assessment of urinary iFABP|
219252767|NCT01805206|OTHER|Administration of enteral feedings|
219252768|NCT01538225|DRUG|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
219252769|NCT01538225|DRUG|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
219252770|NCT02123277|DEVICE|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
219252771|NCT01997437|DEVICE|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
219252772|NCT01502306|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
219252773|NCT01502306|DRUG|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
219252774|NCT01502306|BEHAVIORAL|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
219252775|NCT03385798|PROCEDURE|Endowrist|Anastomosis made by Endowrist
219252776|NCT03385798|PROCEDURE|Endo-GIA|Anastomosis made by Endo-GIA
219252777|NCT01960348|DRUG|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
219252778|NCT01960348|DRUG|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
219252779|NCT01019499|OTHER|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
219252780|NCT01019499|OTHER|control products|two portions daily
219252781|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
219252782|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
219252783|NCT06544421|OTHER|Assigned Interventions|Assigned Interventions
219252784|NCT04930003|BIOLOGICAL|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
219252785|NCT04930003|OTHER|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
219252786|NCT04934241|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
219252787|NCT01580995|DRUG|Valacyclovir|Valacyclovir 500 mg po bid
219252788|NCT01580995|DRUG|Placebo|Placebo tablet twice daily
219252789|NCT04274062|PROCEDURE|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
219252790|NCT01050361|PROCEDURE|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
219252791|NCT04996537|OTHER|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
219252792|NCT06250088|BIOLOGICAL|Emdogain (EMD) - test|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
219296259|NCT05734638|BEHAVIORAL|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice."
219252793|NCT06250088|PROCEDURE|Sham group|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
219252794|NCT02222883|GENETIC|Testing of BRCA status regarding germline and somatic mutation|
219252795|NCT06545110|DRUG|Baricitinib Oral Tablet|Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
219252796|NCT04917263|DIAGNOSTIC_TEST|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
219252797|NCT02510222|DIETARY_SUPPLEMENT|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
219252798|NCT02510222|OTHER|Placebo|
219252799|NCT05000411|DRUG|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
219252800|NCT05000411|DRUG|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
219252801|NCT04596098|OTHER|Blood sampling|During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
219252802|NCT02622256|BEHAVIORAL|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
219252803|NCT04143906|DRUG|Vinorelbine|injection
219252804|NCT04143906|DRUG|Gemcitabine|injection
219252805|NCT04143906|DRUG|Carboplatin|injection
219252806|NCT01324739|DRUG|human BNP-32|3pmol/kg/min infusion
219252807|NCT06255912|DRUG|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
219252808|NCT06255912|DRUG|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
219252809|NCT03511573|PROCEDURE|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
219252810|NCT00130910|DRUG|Albendazole|Albendazole 400mg x 3 first dose observed
219252811|NCT00130910|DRUG|Placebo|Albendazole Placebo 400mg x 3 first dose observed
219252812|NCT02197143|DRUG|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
219252813|NCT02197143|DRUG|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
219252814|NCT02197143|DRUG|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
219252815|NCT02916706|DRUG|Teneligliptin 20mg|
219252816|NCT02916706|DRUG|Placebo|
219252817|NCT00275301|DRUG|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
219252818|NCT04219878|BEHAVIORAL|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
219252819|NCT04219878|OTHER|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
219252820|NCT05688098|DRUG|Irbesartan/Amlodipine High FDC|Irbesartan/Amlodipine High FDC
219252821|NCT05688098|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine High
219252822|NCT05688098|DRUG|Amlodipine High|Co-administration of Irbesartan and Amlodipine High
219252823|NCT02097849|DRUG|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
219252824|NCT02097849|BIOLOGICAL|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
219252825|NCT02097849|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
219252826|NCT02097849|BIOLOGICAL|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
219252827|NCT02097849|DRUG|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
219252828|NCT05906901|OTHER|Cranial listening technique|5 minutes
219252829|NCT05906901|OTHER|Suboccipital muscles inhibition technique|6 minutes
219252830|NCT01939210|OTHER|Educational Intervention|Participate in breathing training sessions
219252831|NCT01939210|OTHER|Meditation Therapy|Participate in breathing training sessions
219252832|NCT01939210|OTHER|Questionnaire Administration|Ancillary studies
219252833|NCT02482532|BIOLOGICAL|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
219252834|NCT02424019|DRUG|ILUVIEN 0.19 MG|
219252835|NCT00361036|DEVICE|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
219252836|NCT00361036|DEVICE|Uterine fibroid embolization Embosphere®|Embosphere - control arm
219252837|NCT02137499|DEVICE|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
219252838|NCT01814436|DEVICE|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
219252839|NCT02874105|OTHER|Group C: physiotherapy protocol with Conventional physiotherapy.|
219252840|NCT02874105|OTHER|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
219252841|NCT02561078|DRUG|Human regular U-500 insulin (CSII)|Administered SC
219252842|NCT02561078|DRUG|Human regular U-500 insulin (MDI)|Administered SC
219252843|NCT00575367|DRUG|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
219252844|NCT00575367|DRUG|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
219252845|NCT00598871|DRUG|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
219252846|NCT00598871|OTHER|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
219252847|NCT01194271|DRUG|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
219252848|NCT01194271|DRUG|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
219252849|NCT01194271|PROCEDURE|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
219252850|NCT03376698|DRUG|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
219252851|NCT03376698|DRUG|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
219252852|NCT03376698|DRUG|Placebo|oral administration of Placebo once daily for 12 weeks
219252853|NCT01983462|DRUG|Clonidine|
219252854|NCT01983462|DRUG|Hydrochlorothiazide|
219252855|NCT01983462|DRUG|Placebo|
219252856|NCT00381797|BIOLOGICAL|Bevacizumab|Given IV
219252857|NCT00381797|RADIATION|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
219252858|NCT00381797|DRUG|Irinotecan Hydrochloride|Given IV
219252859|NCT02151630|DRUG|Pyruvic acid|
219252860|NCT02151630|DRUG|Salicylic Acid|
219252861|NCT01430117|BIOLOGICAL|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
219252862|NCT01828359|DRUG|Amosartan® tab|comparison of different combination of anti-hypertension drug
219252863|NCT01828359|DRUG|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
219252864|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
219252865|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 48 weeks
219252866|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
219252867|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 24 weeks
219252868|NCT00152399|DRUG|Somatostatin UCB (drug)|
219252869|NCT02763163|BEHAVIORAL|Sun exposure routine|
219252870|NCT03884062|DRUG|DAAs|lab, U/S, Fibroscan \& CT if needed
219252871|NCT00958711|DEVICE|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
219252872|NCT00958711|OTHER|Saline and Gauze|gauze moistened with sterile saline
219252873|NCT05965960|DEVICE|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
219252874|NCT05965960|DEVICE|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
219252875|NCT00949793|DEVICE|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
219252876|NCT01929577|DRUG|ASP015K|oral tablet
219252877|NCT02836041|BEHAVIORAL|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
219252878|NCT02836041|DEVICE|actigraph|This device reliably measures sleep by monitoring the child's motion.
219252879|NCT05137405|PROCEDURE|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
219252880|NCT00369603|DRUG|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
219252881|NCT00369603|DRUG|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
219252882|NCT02396446|OTHER|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
219252883|NCT02344017|DRUG|ODM-204|co-administered with prednisone, orally daily
219252884|NCT02344017|DRUG|Prednisone|ODM-204 is co-administered with oral prednisone
219252885|NCT04859218|PROCEDURE|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
219252886|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
219252887|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
219252888|NCT00695370|DRUG|Pegfilgrastim (drug)|
219252889|NCT00821119|DEVICE|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
219252890|NCT06240377|DEVICE|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
219252891|NCT06240377|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
219252892|NCT00243217|DRUG|SPM 936|
219252893|NCT04830761|BEHAVIORAL|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
219252894|NCT04830761|BEHAVIORAL|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
219252895|NCT04830761|BEHAVIORAL|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
219252896|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
219252897|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
219252898|NCT00555646|DRUG|Control|No treatment control.
219252899|NCT02645773|DEVICE|non-ablative laser|non-abaltive laser pre, immediate and post wounding
219252900|NCT05204316|OTHER|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
219252901|NCT02406040|OTHER|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
219252902|NCT00331851|DRUG|liraglutide|
219252903|NCT00331851|DRUG|insulin glargine|
219252904|NCT00331851|DRUG|metformin|
219252905|NCT00331851|DRUG|glimepiride|
219252906|NCT03135821|DIAGNOSTIC_TEST|TCM|
219252907|NCT02206464|BIOLOGICAL|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
219252908|NCT02206464|BIOLOGICAL|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
219252909|NCT01648985|OTHER|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
219252910|NCT00936754|DIETARY_SUPPLEMENT|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
219252911|NCT00936754|DIETARY_SUPPLEMENT|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
219252912|NCT02223507|DRUG|BIIR 561 CL|
219252913|NCT02223507|DRUG|Placebo|
219252914|NCT03535480|DRUG|G-CSF|G-CSF subcutaneously during five days
219252915|NCT03535480|COMBINATION_PRODUCT|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
219252916|NCT01807936|PROCEDURE|Lymphadenectomy|
219252917|NCT00024570|DRUG|IL13-PE38QQR|
219252918|NCT00024570|PROCEDURE|targeted fusion protein therapy|
219252919|NCT00024570|PROCEDURE|surgery|
219252920|NCT04420741|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
219252921|NCT04420741|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
219252922|NCT04239950|DRUG|Placebo|Placebo
219252923|NCT04239950|DRUG|Ethyl Icosapentate|Ethyl Icosapentate
219252924|NCT00153556|BIOLOGICAL|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
219252925|NCT02125097|DEVICE|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
219252926|NCT01065207|BIOLOGICAL|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
219252927|NCT02435797|DRUG|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
219252928|NCT02435797|DRUG|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
219252929|NCT01490359|BEHAVIORAL|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
219252930|NCT01490359|BEHAVIORAL|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
219252931|NCT00946634|DRUG|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
219252932|NCT00946634|DRUG|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
219252933|NCT00946634|DRUG|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
219252934|NCT04977297|BEHAVIORAL|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
219252935|NCT04977297|BEHAVIORAL|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
219252936|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
219252937|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions during fast
219252938|NCT03408223|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
219252939|NCT03408223|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
219252940|NCT04921748|PROCEDURE|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
219252941|NCT05173233|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
219252942|NCT01797562|DIAGNOSTIC_TEST|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
219252943|NCT00062686|DRUG|GW572016|
219252944|NCT03328845|DRUG|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
219252945|NCT03328845|DRUG|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
219252946|NCT03328845|DRUG|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
219252947|NCT03328845|DRUG|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
219252948|NCT03328845|DRUG|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
219252949|NCT03758794|OTHER|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
219252950|NCT03758794|OTHER|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
219252951|NCT02080390|PROCEDURE|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
219252952|NCT05846438|OTHER|Showering 48 hours after surgery|The main intervention is allowing patients to shower 48 hours after surgery
219252953|NCT02982070|BEHAVIORAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
219252954|NCT05698511|DRUG|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
219252955|NCT05999513|DRUG|casdatifan|Administered as specified in the treatment arm
219252956|NCT00692523|OTHER|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
219252957|NCT00692523|OTHER|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
219252958|NCT04845087|OTHER|Ozonized water|Irrigation of dental implants with ozonized water
219252959|NCT04845087|OTHER|Placebo|Irrigation of dental implants with water
219252960|NCT01631825|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
219252961|NCT02982096|DEVICE|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
219252962|NCT02982096|OTHER|Standard of Care|Acellular burn wound management
219252963|NCT06143488|PROCEDURE|Endovascular therapy|"Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
219252964|NCT06143488|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
219252965|NCT05109117|DRUG|CAP Unscented|Sunscreen lip balm.
219252966|NCT04481334|OTHER|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
219252967|NCT03362684|DRUG|Cetuximab|Cetuximab every 2 weeks
219252968|NCT03362684|DRUG|FOLFOX|FOLFOX-4 every 2 weeks
219252969|NCT03226353|DEVICE|somofilcon A|contact lens
219252970|NCT03226353|DEVICE|omafilcon A|contact lens
219252971|NCT03138616|DRUG|vitamin D|take 1600 units of vitamin D daily for nine months
219252972|NCT04244708|DRUG|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
219252973|NCT04244708|OTHER|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
219252974|NCT00215631|DRUG|tadalafil|
219252975|NCT04318587|DIAGNOSTIC_TEST|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
219252976|NCT03696732|OTHER|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
219252977|NCT03696732|OTHER|VAS questionnaire|verbal numerical scale (VNS) anxiety score
219252978|NCT01641289|DRUG|Paracetamol|\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
219252979|NCT01641289|DRUG|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
219252980|NCT01444547|DRUG|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
219252981|NCT02543697|RADIATION|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
219252982|NCT00425906|DRUG|nicotine|
219252983|NCT00425906|OTHER|Placebo|
219252984|NCT00425906|PROCEDURE|Quality of life|
219252985|NCT04092621|DRUG|Amiodarone in Parenteral Dosage Form|Amiodarone IV
219252986|NCT04092621|DRUG|Amiodarone Pill|Amiodarone tablet
219252987|NCT04092621|PROCEDURE|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
219252988|NCT04092621|DRUG|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
219252989|NCT03470103|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
219252990|NCT04024371|BEHAVIORAL|Self-rating Questionnaires|"* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)"
219252991|NCT04024371|BEHAVIORAL|Measures of Reward processing/reinforcement learning|"* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
219252992|NCT04024371|BEHAVIORAL|Additional Schizophrenia-specific Questionnaires and Interviews|"* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
219252993|NCT04498871|DRUG|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
219252994|NCT03342170|GENETIC|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
219252995|NCT01514864|DRUG|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
219252996|NCT04361916|OTHER|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
219252997|NCT05913583|DRUG|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
219252998|NCT03845335|DEVICE|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
219252999|NCT02373605|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
219253000|NCT02373605|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
219253001|NCT06158971|DEVICE|Flexible Bronchoscopic Microwave Ablation|The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
219253002|NCT00271466|DRUG|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
219253003|NCT02399683|BIOLOGICAL|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
219253004|NCT02223871|DRUG|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
219253005|NCT02223871|OTHER|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
219253006|NCT02223871|DRUG|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
219253007|NCT02223871|DRUG|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
219253008|NCT02253147|DEVICE|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
219253009|NCT00478322|DRUG|Placebo|Matching placebo of 100 mg BID
219253010|NCT00478322|DRUG|INCB013739|INCB013739 100 mg BID
219253011|NCT00004016|BIOLOGICAL|recombinant interferon gamma|
219253012|NCT03487341|OTHER|Cord drainage|Cord drainage
219253013|NCT03487341|OTHER|Cord clamping|Cord clamping
219253014|NCT04836338|DEVICE|orotracheal intubation|orotracheal intubation
219253015|NCT03965247|DRUG|Lithium|
219253016|NCT03965247|OTHER|Placebo - Rayotabs|
219253017|NCT03256370|PROCEDURE|milk collection|"* Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
219253018|NCT01873573|PROCEDURE|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
219253019|NCT01873573|OTHER|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
219253020|NCT01873573|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
219253021|NCT03348969|DRUG|Mitomycin c|Neoadjuvant Mitomycin C
219253022|NCT00131183|DRUG|Nebido|
219253023|NCT02210611|PROCEDURE|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
219253024|NCT02210611|PROCEDURE|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
219253025|NCT00371618|PROCEDURE|Fluoroscopy|
219253026|NCT04066400|OTHER|Nutritional Intervention|Dietary Counselling
219253027|NCT02054598|BEHAVIORAL|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
219253028|NCT00937456|PROCEDURE|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
219253029|NCT05915832|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
219253030|NCT05915832|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
219253031|NCT02254681|DRUG|Gemcitabine|
219253032|NCT02254681|DRUG|Cisplatin|
219253033|NCT02254681|RADIATION|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
219253034|NCT01181583|BEHAVIORAL|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
219253035|NCT01181583|BEHAVIORAL|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
219253036|NCT01181583|BEHAVIORAL|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
219253037|NCT02611375|OTHER|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
219253038|NCT02611375|OTHER|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
219253039|NCT02611375|OTHER|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
219253040|NCT04316221|DIETARY_SUPPLEMENT|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
219253041|NCT04316221|OTHER|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
219253042|NCT00207233|BEHAVIORAL|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
219253043|NCT00207233|BEHAVIORAL|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
219253044|NCT00207233|PROCEDURE|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
219253045|NCT00465907|DRUG|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
219253046|NCT02604485|DRUG|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
219253047|NCT02604485|DRUG|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
219253048|NCT02604485|DRUG|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
219253049|NCT02604485|DRUG|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
219253050|NCT05845840|DRUG|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
219253051|NCT05845840|DRUG|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
219253052|NCT00797511|BIOLOGICAL|TdcP-IPV vaccine|0.5 mL, Intramuscular
219253053|NCT01700114|DEVICE|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
219253054|NCT02880332|OTHER|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
219253055|NCT02880332|OTHER|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
219253056|NCT02880332|OTHER|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
219253057|NCT00979329|OTHER|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
219253058|NCT02762539|DRUG|omega-3 enriched SMOF lipid emusion|
219253059|NCT03471897|DIAGNOSTIC_TEST|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
219253060|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
219253061|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
219253062|NCT02959177|DRUG|Galcanezumab|Administered SC
219253063|NCT02959177|DRUG|Placebo|Administered SC
219253064|NCT04876768|PROCEDURE|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
219253065|NCT06236828|DEVICE|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
219253066|NCT04097691|DRUG|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
219253067|NCT03630692|DRUG|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
219253068|NCT01860807|DRUG|Ibudilast|
219253069|NCT01860807|DRUG|Placebo|
219253070|NCT02726035|DRUG|Naltrexone|oral naltrexone 50 mg daily
219253071|NCT02726035|OTHER|Placebo|oral placebo (appearing identical to naltrexone) once daily
219253072|NCT03146897|DIETARY_SUPPLEMENT|Supplementary Food|Supplementary food for treating MAM
219253073|NCT00129506|DRUG|methotrexate + misoprostol|
219253074|NCT00129506|DRUG|misoprostol|
219253075|NCT02805985|DEVICE|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
219253076|NCT00349388|DRUG|Asacol|Asacol is given once a day versus twice or three times a day
219253077|NCT04701528|DRUG|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
219253078|NCT04701528|DRUG|Tacrolimus|Comparator
219253079|NCT01947153|DRUG|Metformin|Free combination
219253080|NCT01947153|DRUG|Linagliptin|Fixed dose combination
219253081|NCT01947153|DRUG|Metformin|Combination
219253082|NCT01947153|DRUG|Linagliptin|Free combination
219253083|NCT00644956|DRUG|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
219253084|NCT00644956|DRUG|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
219253085|NCT00280020|BEHAVIORAL|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
219253086|NCT00280020|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
219253087|NCT00280020|BEHAVIORAL|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
219253088|NCT02353455|PROCEDURE|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
219253089|NCT04772313|BIOLOGICAL|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
219253090|NCT04772313|DRUG|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
219253091|NCT06504212|OTHER||
219253092|NCT01856010|OTHER|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
219253093|NCT01856010|OTHER|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
219253094|NCT05560945|DRUG|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
219253095|NCT05560945|DRUG|1.5% Arginine Dentifrice|Toothpaste
219253096|NCT05560945|DRUG|8.0% Arginine Dentifrice|Toothpaste
219253097|NCT01816100|OTHER|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
219253098|NCT01816100|BEHAVIORAL|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
219253099|NCT03303521|DRUG|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
219253100|NCT03303521|DRUG|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
219253101|NCT06233045|DRUG|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
219253102|NCT06233045|DRUG|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
219253103|NCT04194541|DEVICE|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
219253104|NCT04194541|DEVICE|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
219253105|NCT04194541|DEVICE|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
219253106|NCT02642159|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
219253107|NCT02642159|DRUG|Statins|Statins at stable dose without other LMT as clinically indicated.
219253108|NCT02642159|DRUG|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
219253109|NCT02642159|DRUG|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
219253110|NCT02642159|DRUG|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
219253111|NCT02642159|DRUG|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
219253112|NCT02642159|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
219253113|NCT02745184|BIOLOGICAL|Lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
219253114|NCT00237900|DRUG|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
219253115|NCT05645744|BIOLOGICAL|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
219253116|NCT05645744|BIOLOGICAL|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
219253117|NCT06023745|GENETIC|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
219253118|NCT00607737|DRUG|insulin detemir|3 cutaneous injections
219253119|NCT00607737|DRUG|saline|3 cutaneous injections
219253120|NCT04785742|DRUG|Almonertinib|Almonertinib
219253121|NCT03841227|DEVICE|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
219253122|NCT03841227|DEVICE|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
219253123|NCT00011778|DRUG|bortezomib|
219253124|NCT00011778|RADIATION|radiation therapy|
219253125|NCT03635775|DEVICE|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
219253126|NCT03635775|DEVICE|Sham tDCS|Sham-setting--no electrical current delivered.
219253127|NCT00240097|DRUG|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
219253128|NCT00240097|DRUG|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
219253129|NCT06585345|BIOLOGICAL|CD7 CAR-T cell|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
219253130|NCT06584981|PROCEDURE|pectoral nerve block (PECS II), parasternal and serratus plane blocks|These block applications are performed under sterile conditions under the guidance of ultrasonography
219253131|NCT06584981|OTHER|analgesic|Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
219253132|NCT05768321|DRUG|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
219253133|NCT03427177|BEHAVIORAL|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
219253134|NCT05248425|OTHER|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
219253135|NCT01446822|DEVICE|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
219253136|NCT01446822|DEVICE|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
219253137|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
219253138|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
219253139|NCT06046976|PROCEDURE|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
219253140|NCT06046976|PROCEDURE|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
219253141|NCT06585436|PROCEDURE|partial caries removal|removal of all cavity caries except last layer related to the pulp
219253142|NCT00523926|DRUG|TMC207|
219296260|NCT05734638|BEHAVIORAL|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
219253143|NCT06132906|PROCEDURE|Orthognathic surgery (lefort1)|"1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure"
219253144|NCT00908245|PROCEDURE|Control|Surgery without preconditioning surgery
219253145|NCT00908245|PROCEDURE|Preconditioning ischemia|Surgery with a preconditioning ischemia
219253146|NCT04106336|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
219253147|NCT06195878|DEVICE|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
219253148|NCT04053517|OTHER|Medical Chart Review|Medical chart is reviewed
219253149|NCT04053517|OTHER|Quality-of-Life Assessment|Ancillary studies
219253150|NCT04053517|OTHER|Questionnaire Administration|Ancillary studies
219253151|NCT04835493|OTHER|Intervention|In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
219253152|NCT04940780|OTHER|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
219253153|NCT04940780|OTHER|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
219253154|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate high dose|
219253155|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate low dose|
219253156|NCT03063346|DIETARY_SUPPLEMENT|Placebo|
219253157|NCT04035863|DEVICE|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
219253158|NCT01963858|PROCEDURE|Functional relaxation|Functional relaxation during colonoscopy
219253159|NCT01963858|PROCEDURE|No relaxation|No relaxation during colonoscopy
219253160|NCT06292832|PROCEDURE|Ultrasound-guided pain block|Ultrasound-guided pain block after cesarean section
219253161|NCT06292832|DEVICE|Ultrasound Machine|Ultrasound machine used to guide the nerve block.
219253162|NCT02832830|RADIATION|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
219253163|NCT02832830|RADIATION|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
219253164|NCT01074034|DEVICE|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
219253165|NCT03311997|PROCEDURE|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
219253166|NCT01071317|DRUG|Naproxen|Naproxen 500mg PO bid prn headache
219253167|NCT01071317|DRUG|Sumatriptan|100mg po q day prn headache
219253168|NCT01071317|BEHAVIORAL|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
219253169|NCT01071317|BEHAVIORAL|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
219253170|NCT01071317|OTHER|Typical care|Care to be determined by attending physician
219253171|NCT01865695|DRUG|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
219253172|NCT01865695|OTHER|Placebo|
219253173|NCT01159756|DRUG|Travacom|Travacom ophthalmic solution (1 drop per day)
219253174|NCT01748851|DRUG|XELOX|capecitabine 1000mg/m2 bid po D1-D14
219253175|NCT01748851|DRUG|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
219253176|NCT04301518|OTHER|Multimodal intervention strategy|"* Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
219253177|NCT03974308|OTHER|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
219253178|NCT03974308|OTHER|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
219253179|NCT03974308|OTHER|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
219253180|NCT06055400|DEVICE|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
219253181|NCT01555879|DRUG|Abatacept|As prescribed by a doctor for patient medical care.
219253182|NCT00585910|DRUG|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
219253183|NCT00814554|BEHAVIORAL|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
219253184|NCT00814554|BEHAVIORAL|Screening strategy|2\. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
219253185|NCT00814554|OTHER|Environmental strategy|3\. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
219253186|NCT00209053|PROCEDURE|Coronary Artery Bypass|
219253187|NCT04567745|DIAGNOSTIC_TEST|Retinal fundus photography|Fundus photographs
219253188|NCT00043368|DRUG|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
219253189|NCT02040532|DRUG|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
219253190|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
219253191|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
219253192|NCT03138356|DRUG|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
219253193|NCT03138356|DRUG|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
219253194|NCT03138356|DRUG|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
219253195|NCT03138356|DRUG|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
219253196|NCT03138356|DRUG|500 mg Glucophage XR®|Used in treatments C, F and I.
219253197|NCT02468882|DIETARY_SUPPLEMENT|Watercress|100g of watercress daily during radiation therapy
219253198|NCT03850847|OTHER|Step 1: Semi-structured Interviews|"1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
219253199|NCT03850847|OTHER|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
219253200|NCT00755924|DIETARY_SUPPLEMENT|Vinegar|Apple cider vinegar 2 TBlsp/day
219253201|NCT00755924|OTHER|Placebo|Water placebo colored with balsamic vinegar
219253202|NCT03956147|OTHER|Munich Shoulder Questionnaire|Validation and Reability study
219253203|NCT03973437|DEVICE|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
219253204|NCT03973437|DEVICE|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
219253205|NCT06372756|DIAGNOSTIC_TEST|Deep learning image reconstruction|Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
219253206|NCT02287571|DEVICE|Derotation splint|This group is the actual intervention group.
219253207|NCT02287571|DEVICE|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
219253208|NCT05985109|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
219253209|NCT05985109|DRUG|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
219253210|NCT01350388|DRUG|Febuxostat|80 mg/day of febuxostat for 24 weeks
219253211|NCT01350388|DRUG|Placebo|1 placebo tablet per day for 24 weeks
219253212|NCT01266499|DRUG|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
219253213|NCT01266499|DRUG|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
219253214|NCT01266499|DRUG|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
219253215|NCT01266499|DRUG|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
219253216|NCT00928876|DRUG|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
219253217|NCT00928876|DRUG|Placebo|placebo s/c daily for four weeks
219253218|NCT02767596|DRUG|Lixisenatide|
219253219|NCT02767596|DRUG|Basal insulins|patients are on basal insulin treatment
219253220|NCT02612363|DRUG|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose"
219253221|NCT05106023|DRUG|SHR-1701|SHR-1701 combined with temozolomide
219253222|NCT05106023|DRUG|Temozolomide|SHR-1701 combined with temozolomide
219253223|NCT01740999|PROCEDURE|silicone arthroplasty|silicone arthroplasty
219253224|NCT01740999|PROCEDURE|arthrodesis|arthrodesis
219253225|NCT03274206|BIOLOGICAL|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
219253226|NCT03274206|DRUG|Placebo|BLS-ILB-E710c-placebo
219253227|NCT05079958|BEHAVIORAL|cognitive-behavioral education|four-week cognitive-behavioral education course
219253228|NCT05079958|BEHAVIORAL|12-week brisk walking|12-week brisk walking
219253229|NCT04486742|BEHAVIORAL|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
219253230|NCT01039116|BEHAVIORAL|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
219253231|NCT01039116|BEHAVIORAL|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
219253232|NCT03441152|DEVICE|tDCS|Transcranial direct current stimulation
219253233|NCT02516371|OTHER|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
219253234|NCT04291716|DEVICE|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
219253235|NCT05887479|DRUG|Botulinum toxin type A|Toxin of Clostridium Botulinum
219253236|NCT05887479|DRUG|%0,9 NaCl|%0,9 NaCl
219253237|NCT03392779|DRUG|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
219253238|NCT03392779|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
219253239|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
219253240|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
219253241|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
219253242|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
219253243|NCT03392779|DRUG|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
219253244|NCT03392779|DRUG|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
219253245|NCT03392779|DRUG|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
219253246|NCT03392779|DRUG|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
219253247|NCT03392779|DRUG|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
219253248|NCT03392779|DRUG|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
219253249|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
219253250|NCT03392779|DRUG|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
219253251|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
219253252|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
219253253|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
219253254|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
219253255|NCT02330861|DEVICE|combowire and IVUS|
219253256|NCT03298347|DRUG|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
219253257|NCT03298347|DRUG|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
219253258|NCT01579461|DRUG|mirabegron|oral
219253259|NCT05194631|OTHER|Quadriceps microbiopsy using a Tru-Cut biopsy needle|During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
219253260|NCT03433378|DRUG|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
219253261|NCT03433378|DRUG|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
219253262|NCT03433378|DRUG|Vehicle of the test product|Vehicle of the test product
219253263|NCT05723029|OTHER|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
219253264|NCT05723029|OTHER|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
219253265|NCT04248049|OTHER|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
219253266|NCT02515526|DRUG|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
219253267|NCT02515526|DRUG|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
219253268|NCT05347602|DIETARY_SUPPLEMENT|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
219253269|NCT05347602|DIETARY_SUPPLEMENT|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
219253270|NCT03640754|BIOLOGICAL|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
219253271|NCT03640754|OTHER|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
219253272|NCT05729477|DEVICE|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
219253273|NCT05729477|DEVICE|Phaco Subject Cohort|Phaco Subject Cohort
219253274|NCT05075135|DEVICE|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
219253275|NCT05075135|DEVICE|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
219253276|NCT05329402|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
219253277|NCT05329402|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
219253278|NCT03249272|DRUG|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
219253279|NCT03249272|DRUG|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
219253280|NCT05858606|DIAGNOSTIC_TEST|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"1. pre-inclusion consultation~2. inclusion consultation~   * personal history~  * height, weight, cranial perimeters, and spans of both parents~  * clinical examination of the child~  * photographs of the child~  * additional X-rays"
219253281|NCT05858606|PROCEDURE|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~* either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~* or to the authentified idiopathic short stature group"
219253282|NCT05858606|GENETIC|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
219253283|NCT04314102|OTHER|No intervention will be made.|No intervention will be made. Only checks will be made
219253284|NCT00322764|DRUG|Uridine|
219253285|NCT00825513|DEVICE|Akreos Toric IOL|Lens implant following cataract surgery
219253286|NCT00825513|DEVICE|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
219253287|NCT00233207|DRUG|IC14|
219253288|NCT02458794|PROCEDURE|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
219253289|NCT02458794|DEVICE|LMA SupremeTM|
219253290|NCT02458794|DEVICE|Ambu-Aura GainTM|
219253291|NCT03638700|DEVICE|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
219253292|NCT03638700|DEVICE|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
219253293|NCT03638700|DEVICE|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
219253294|NCT03638700|DEVICE|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
219253295|NCT03157414|DRUG|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
219253296|NCT03157414|OTHER|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
219253297|NCT03734614|DRUG|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
219253298|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
219253299|NCT01679613|DRUG|Nintedanib|low dose oral administration
219253300|NCT01679613|DRUG|Ketoconazole|oral administration
219253301|NCT01679613|DRUG|Nintedanib|low dose oral administration
219253302|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
219253303|NCT01679613|DRUG|Ketoconazole|oral administration
219253304|NCT03169530|OTHER|Alcohol|\~15 gm daily of beer, wine, or spirits for \~6 years
219253305|NCT03087461|BEHAVIORAL|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
219253306|NCT04090788|DIETARY_SUPPLEMENT|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
219253307|NCT04090788|DIETARY_SUPPLEMENT|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
219253308|NCT03453177|DRUG|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
219253309|NCT03453177|PROCEDURE|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
219253310|NCT03453177|PROCEDURE|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
219253311|NCT05490368|DEVICE|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
219253312|NCT06269393|DRUG|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
219253313|NCT06269393|DRUG|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
219253314|NCT00355771|DRUG|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
219253315|NCT00355771|DRUG|Placebo|1 tablet OD in the morning for 8 weeks
219253316|NCT04753281|OTHER|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
219253317|NCT02154516|DEVICE|ODH Hip System|
219253318|NCT02173756|DRUG|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
219253319|NCT02173756|DRUG|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
219253320|NCT01540019|DRUG|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
219253321|NCT01991678|DRUG|145 mg/m2 NKTR 102|
219253322|NCT01991678|DRUG|120 mg/m2 NKTR 102|
219253323|NCT01991678|DRUG|50 mg/m2 NKTR 102|
219253324|NCT00000647|DRUG|CD4-IgG|
219253325|NCT00000647|DRUG|Zidovudine|
219253326|NCT00000647|DRUG|Interferon alfa-n1|
219253327|NCT00000647|PROCEDURE|Peripheral lymphocyte infusion|
219253328|NCT00000647|PROCEDURE|Bone marrow transplant|
219253329|NCT02827799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
219253330|NCT02827799|BEHAVIORAL|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
219253331|NCT02965599|DRUG|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
219253332|NCT02965599|DRUG|Placebo|Placebo is a white, opaque, gelatin capsule.
219253333|NCT04404699|DIAGNOSTIC_TEST|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
219253334|NCT00090558|DRUG|nitroglycerin|
219253335|NCT05762978|DEVICE|In-Check Dial|Patient will have their NIF measured with In-Check Dial
219253336|NCT05762978|DEVICE|Inhaler Device|Children will use inhaler per standard of care.
219253337|NCT06052683|RADIATION|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
219253338|NCT06052683|RADIATION|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
219253339|NCT04999683|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory diet for 14 days
219253340|NCT05401669|PROCEDURE|Trans-radial access|Cerebral angiography performed by trans-radial access
219253341|NCT05401669|PROCEDURE|Trans-femoral access|Cerebral angiography performed by trans-femoral access
219253342|NCT01693159|DEVICE|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
219253343|NCT01693159|OTHER|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
219253344|NCT00230971|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
219253345|NCT00230971|DRUG|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
219253346|NCT01919255|DRUG|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
219253347|NCT01919255|DRUG|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
219253348|NCT01398345|BEHAVIORAL|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
219253349|NCT02840812|DRUG|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
219253350|NCT02710578|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
219253351|NCT02710578|DRUG|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
219253352|NCT03216915|DRUG|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
219253353|NCT03166397|DRUG|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
219253354|NCT03166397|DRUG|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
219253355|NCT03166397|BIOLOGICAL|TIL|TIL administration
219253356|NCT03166397|DRUG|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
219253357|NCT03166397|DRUG|Nivolumab|Nivolumab 480 mg fixed dose
219253358|NCT03166397|DRUG|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
219253359|NCT03166397|DRUG|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
219253360|NCT05350514|DRUG|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
219253361|NCT00005088|DRUG|cisplatin|
219253362|NCT00005088|RADIATION|radiation therapy|
219253363|NCT02045745|BIOLOGICAL|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
219253364|NCT05243498|OTHER|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
219253365|NCT05243498|OTHER|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
219253366|NCT03941587|DRUG|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
219253367|NCT03941587|DRUG|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
219253368|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
219253369|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
219253370|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
219253371|NCT04614194|DRUG|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
219253372|NCT04614194|DRUG|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
219253373|NCT06646861|OTHER|Exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included.
219253374|NCT00689195|DIETARY_SUPPLEMENT|Curcumin powder|oral capsules containing the investigational agent
219253375|NCT00689195|DIETARY_SUPPLEMENT|Ashwagandha extract|4.5% extract of ashwagandha
219253376|NCT03254524|OTHER|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
219253377|NCT05186493|PROCEDURE|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
219253378|NCT06602128|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
219253379|NCT01818453|BEHAVIORAL|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
219253380|NCT01879085|DRUG|Docetaxel|75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
219253381|NCT01879085|DRUG|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
219253382|NCT01879085|DRUG|Vorinostat|given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
219253383|NCT01879085|DRUG|Pegfilgrastim|administered on day 9 subcutaneously at 6 mg
219253384|NCT01554345|DRUG|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
219253385|NCT01709071|DRUG|IPV|
219253386|NCT01709071|DRUG|Low dose Sabin-IPV|
219253387|NCT01709071|DRUG|Low dose adjuvanted Sabin-IPV|
219253388|NCT01709071|DRUG|Middle dose Sabin-IPV|
219253389|NCT01709071|DRUG|Middle dose adjuvanted Sabin-IPV|
219253390|NCT01709071|DRUG|High dose Sabin-IPV|
219253391|NCT01709071|DRUG|High dose adjuvanted Sabin-IPV|
219253392|NCT03285633|BEHAVIORAL|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
219253393|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
219253394|NCT04248881|BEHAVIORAL|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
219253395|NCT06517706|COMBINATION_PRODUCT|Combination of tDCS (device) with cognitive training (behavioral)|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
219253396|NCT06517706|BEHAVIORAL|Categorization Program|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
219253397|NCT03891433|DRUG|Meropenem|Carbapenems group intervention.
219253398|NCT03891433|DRUG|Ertapenem 1000 MG|Carbapenems group intervention.
219253399|NCT03891433|DRUG|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
219253400|NCT06607315|OTHER|physical properties of soft tissue|Using the Myoton Pro device, the physical properties such as elasticity and viscosity of the Achilles tendon, patellar tendon, gastrocnemius, quadriceps, and hamstring muscles will be measured.
219253401|NCT06607315|OTHER|Analysis of Running Form|High-speed camera systems will be used to analyze biomechanical parameters in detail, such as angular movements of the lower extremity joints (tibia, ankle, knee, hip), step length, and ground contact time during running. These analyses will allow us to objectively characterize different running forms.
219253402|NCT06377059|DEVICE|WARD|Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
219253403|NCT03741309|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
219253404|NCT03741309|OTHER|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
219253405|NCT03741309|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
219253406|NCT06673433|DIAGNOSTIC_TEST|obesity|Patients diagnosed with obesity (BMI ≥ 28kg/m2)
219253407|NCT06673433|DIAGNOSTIC_TEST|health|the health control group include paticipants with nomal BMI
219253408|NCT02676739|DRUG|Adderall XR|
219253409|NCT03019809|BIOLOGICAL|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
219253410|NCT03019809|BIOLOGICAL|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
219253411|NCT07007884|DEVICE|Active Transauricular Vagus Nerve Stimulation|Active taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left ear cymba choncae with a stimulator. Active taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform. In the sham group, stimulation was applied to the lobulus auriculae of the left ear (which is not innervated by the vagus nerve) using the same current intensity and duration as the active group.
219253412|NCT07007884|DEVICE|Sham Transauricular Vagus Nerve Stimulation|Sham taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left lobulus auriculae of the left ear (which is not innervated by the vagus nerve) with a stimulator. Sham taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform.
219253413|NCT07008794|DRUG|Atorvastatin 40 mg|Rosuvastatin 20 mg
219253414|NCT07008924|OTHER|No intervention is provided. We monitor natural recovery to full sleep.|Return to normal sleep observation.
219253415|NCT06721624|OTHER|Naturopathic medicine|Whole system naturopathic medicine
219253416|NCT06030440|RADIATION|Eliminating RT to the elective neck|Reduction of radiation volume by eliminating radiotherapy to the elective neck
219253417|NCT06030440|RADIATION|RT standard of care|postoperative radiotherapy of the head and neck region according to current standard including elective nodal irradiation
219253418|NCT06719830|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of the septal accessory pathway
219253419|NCT06721130|DIAGNOSTIC_TEST|FDG radiotracer|Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome
219253420|NCT06720740|DEVICE|RELIEF Ureteral Stent|The study intervention is placement of the RELIEF Ureteral Stent
219253421|NCT06720740|DEVICE|Standard of Care Ureteral Stent|The control product is the Ascerta stent by Boston Scientific.
219253422|NCT05505110|PROCEDURE|Vaginal Seeding|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
219253423|NCT05505110|PROCEDURE|Sterile Swab|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.
219253424|NCT06777589|DEVICE|Monitoring of anesthesia depth|During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
219253425|NCT06890923|DRUG|Foralumab TZLS-401 100 µg|Patients meeting the requirements of the dose escalation rules will receive nasal foralumab 100 µg three (3) days a week (Monday-Wednesday-Friday) for two weeks, followed by a one-week rest, comprising 3-week cycles.
219253426|NCT05368922|DEVICE|Virtual reality rehabilitation|"The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks."
219253427|NCT06919640|DRUG|Psilocybin|10mg oral psilocybin
219253428|NCT06192537|BEHAVIORAL|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
219253429|NCT04027491|BEHAVIORAL|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
219253430|NCT01722864|DRUG|COV155|COV155 tablets
219253431|NCT01520844|BIOLOGICAL|blood sampling|blood sampling
219253432|NCT03924128|DEVICE|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
219253433|NCT05172518|DRUG|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
219253434|NCT05172518|DRUG|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
219253435|NCT05172518|DRUG|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
219253436|NCT05172518|DRUG|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
219253437|NCT04695821|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
219253438|NCT02071680|OTHER|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
219253439|NCT04527783|OTHER|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
219253440|NCT04527783|OTHER|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
219253441|NCT01957592|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
219253442|NCT03105778|DIAGNOSTIC_TEST|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
219253443|NCT04419805|DEVICE|Single Palatal TAD|A single mini-screw inserted in the mid-palate
219253444|NCT04419805|DEVICE|Two buccal TADs|Two buccal TADs inserted in the upper jaw
219253445|NCT04240600|DIETARY_SUPPLEMENT|Experimental group|2 cans or bottles (200ml)per day, orally
219253446|NCT04240600|DIETARY_SUPPLEMENT|Control group|2 cans or bottles (200ml)per day, orally
219253447|NCT05937815|PROCEDURE|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
219253448|NCT00348868|BEHAVIORAL|enhanced behavioral motivation counseling|
219253449|NCT00348868|BEHAVIORAL|Motivational counseling|
219253450|NCT00348868|BEHAVIORAL|Standard counseling|
219253451|NCT04961242|DEVICE|Together for Wellness digital mental health website|The intervention is a digital mental health resources website that includes multiple, free resources for broad public use. Different categories of resources include information on COVID-19 from CDC, multi-language versions of the UCLA Mindfulness App and other meditation programs, resources for families and social connection, including addressing discrimination or equity, and resource links.
219253452|NCT01106365|DEVICE|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
219253453|NCT05005286|OTHER|Past history of vaginal Infections|With or without vaginal infection during pregnancy
219253454|NCT00684203|DRUG|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
219253455|NCT00684203|DRUG|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
219253456|NCT00684203|DRUG|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
219253457|NCT00684203|DRUG|Clopidogrel|100 mg two or three times daily for 60 days.
219253458|NCT05780216|DRUG|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
219253459|NCT05780216|DRUG|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
219253460|NCT02759237|DEVICE|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system"
219253461|NCT05493098|OTHER|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
219253462|NCT05493098|OTHER|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
219253463|NCT04257422|OTHER|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
219253464|NCT06483386|DRUG|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
219296261|NCT05394753|BEHAVIORAL|Unified Protocol for mood disorders|The group-based UP is structured and manualized and consists of 9 1.5 hours weekly sessions (90-min, 18 participants in each group). The group-based UP is a course consisting of components of psycho-education about mood disorders, cognitive and behavioural skills, and relapse prevention and is adapted for the non-clinical population in the current study. The UP will be led and delivered by trained therapists.
219296262|NCT00391859|PROCEDURE|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
219296263|NCT02880345|DRUG|PEMBROLIZUMAB|
219296264|NCT02880345|RADIATION|hypofractionated radiation|
219253465|NCT04338230|OTHER|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
219253466|NCT01699698|OTHER|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
219253467|NCT01628406|PROCEDURE|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
219253468|NCT05203809|DEVICE|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
219253469|NCT00485706|PROCEDURE|high calcium dialysate|
219253470|NCT00719212|BIOLOGICAL|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
219253471|NCT03837236|OTHER|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
219253472|NCT02106364|DRUG|Insulin Peglispro|Administered SQ
219253473|NCT02106364|DRUG|Insulin Glargine|Administered SQ
219253474|NCT00599833|BIOLOGICAL|cetuximab|
219253475|NCT00599833|RADIATION|3-dimensional conformal radiation therapy|
219253476|NCT06426147|DIETARY_SUPPLEMENT|L-citrulline|1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
219253477|NCT06426147|DIETARY_SUPPLEMENT|Placebo|1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
219253478|NCT00197119|BIOLOGICAL|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
219253479|NCT00197119|BIOLOGICAL|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
219253480|NCT02151643|DRUG|PT20|Modified ferric oxide adipate tablets
219253481|NCT02151643|DRUG|Placebo|Placebo tablets matched to each PT20 dose arm
219253482|NCT00383903|BIOLOGICAL|HRV vaccine|Two or three oral doses
219253483|NCT03619889|OTHER|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
219253484|NCT03619889|OTHER|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
219253485|NCT00508274|DRUG|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
219253486|NCT00508274|DRUG|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
219253487|NCT01179412|DRUG|2% povidone-iodine|apply 4 times a day for one week
219253488|NCT01179412|DRUG|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
219253489|NCT03296566|BEHAVIORAL|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
219253490|NCT02968823|OTHER|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
219253491|NCT02968823|OTHER|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
219253492|NCT06096376|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
219253493|NCT04276636|DRUG|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
219253494|NCT00791102|DRUG|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
219253495|NCT00791102|DRUG|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
219253496|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
219253497|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
219253498|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
219253499|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
219253500|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
219253501|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
219253502|NCT01742234|PROCEDURE|Organ Donation|People in this study will donate either a lung or kidney
219253503|NCT01187147|DIETARY_SUPPLEMENT|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
219253504|NCT01084239|RADIATION|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
219253505|NCT04163835|DRUG|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
219253506|NCT04163835|DRUG|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
219253507|NCT04163835|DRUG|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
219253508|NCT04163835|DRUG|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
219253509|NCT02889783|OTHER|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
219253510|NCT05501847|RADIATION|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
219253511|NCT05762081|PROCEDURE|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
219253512|NCT05762081|PROCEDURE|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
219253513|NCT03911362|BEHAVIORAL|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
219253514|NCT03911362|BEHAVIORAL|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
219253515|NCT02457442|DRUG|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
219253516|NCT02457442|DRUG|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
219253517|NCT02457442|DRUG|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
219253518|NCT02457442|DRUG|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
219253519|NCT02457442|DRUG|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
219253520|NCT02457442|DRUG|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
219253521|NCT03532269|DEVICE|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
219253522|NCT04038320|DRUG|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
219253523|NCT05598606|DRUG|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
219253524|NCT05598606|DRUG|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
219253525|NCT03987659|PROCEDURE|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
219253526|NCT03987659|PROCEDURE|Conventional Irrigation protocols|Conventional Irrigation protocols
219296265|NCT05638698|BIOLOGICAL|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
219296266|NCT05638698|DRUG|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
219296267|NCT05638698|DRUG|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
219296268|NCT00153270|DRUG|Sodium Valproate|
219253527|NCT04933838|DEVICE|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
219253528|NCT05579145|OTHER|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
219253529|NCT05579145|OTHER|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
219253530|NCT04715503|RADIATION|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
219253531|NCT04715503|RADIATION|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
219253532|NCT02679079|DRUG|NBI-98854|
219253533|NCT02679079|DRUG|Placebo|
219253534|NCT05283525|DIETARY_SUPPLEMENT|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
219253535|NCT05283525|DIETARY_SUPPLEMENT|Oxygen Saturation|0 - 90 Days of Treatment
219253536|NCT05283525|DIETARY_SUPPLEMENT|Total Blood Chemistry|0 and 90 Days of Treatment
219253537|NCT05283525|DIETARY_SUPPLEMENT|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
219253538|NCT05283525|DIETARY_SUPPLEMENT|Body Weight Monitoring|0 - 90 Days of Treatment
219253539|NCT05283525|DIETARY_SUPPLEMENT|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
219253540|NCT03361618|DIETARY_SUPPLEMENT|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
219253541|NCT00616486|DEVICE|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
219253542|NCT00616486|DEVICE|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
219253543|NCT01437813|DRUG|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
219296269|NCT05759481|DRUG|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
219296270|NCT05759481|OTHER|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
219296271|NCT05204355|DIAGNOSTIC_TEST|MRI|Patients will be imaged using MRI
219253544|NCT05655234|BEHAVIORAL|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
219253545|NCT05655234|BEHAVIORAL|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
219253546|NCT01395498|OTHER|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
219253547|NCT05199441|DRUG|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
219253548|NCT05199441|DRUG|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
219253549|NCT00787683|DEVICE|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
219253550|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
219253551|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
219253552|NCT04150341|DRUG|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
219253553|NCT04150341|DRUG|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
219253554|NCT05097898|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
219253555|NCT05097898|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
219253556|NCT05097898|PROCEDURE|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
219253557|NCT05097898|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
219253558|NCT05097898|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
219253559|NCT04482270|DRUG|fezolinetant|Oral
219253560|NCT00899379|DRUG|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
219253561|NCT00899379|DRUG|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
219253562|NCT02056600|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
219253563|NCT02056600|DRUG|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
219253564|NCT02821689|DRUG|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
219253565|NCT04297839|DRUG|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
219253566|NCT04297839|DRUG|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
219253567|NCT02536547|DEVICE|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
219253568|NCT03192202|DRUG|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
219253569|NCT02581189|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
219253570|NCT02581189|DRUG|Dasabuvir|Tablet
219253571|NCT02581189|DRUG|Ribavirin|Tablet
219253572|NCT00004740|DRUG|isoniazid|
219253573|NCT03402321|DRUG|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
219253574|NCT03402321|DRUG|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
219253575|NCT01615107|DEVICE|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
219253576|NCT01615107|DRUG|PITOCIN|: Oxytocin infusion alone (Standard Protocol
219253577|NCT01615107|OTHER|double balloonand oxytocin|balloonand oxytocin
219253578|NCT01615107|OTHER|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
219253579|NCT01615107|PROCEDURE|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
219253580|NCT02874248|DRUG|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
219253581|NCT02874248|DRUG|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
219253582|NCT02874248|DRUG|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
219253583|NCT02874248|DRUG|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
219253584|NCT02874248|DRUG|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
219253585|NCT00470171|DRUG|Ursodesoxycholic acid|
219253586|NCT05065164|DRUG|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
219253587|NCT00978497|DRUG|placebo|oral BID
219253588|NCT00978497|DRUG|ANA598|oral 200mg BID
219253589|NCT00978497|DRUG|ANA598|oral 400mg BID
219253590|NCT00978497|DRUG|Peginterferon|180 μg dose via subcutaneous injection weekly
219253591|NCT00978497|DRUG|Ribavirin|oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
219253592|NCT03551197|DRUG|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
219253593|NCT02666170|DRUG|Alpha-lipoic acid|
219253594|NCT00843115|OTHER|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
219253595|NCT02621047|DRUG|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
219253596|NCT04262778|DIAGNOSTIC_TEST|electrochemical skin conductance measurement|electrochemical skin conductance measurement
219253597|NCT06312995|DEVICE|T3DDY01|Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
219253598|NCT06312995|DEVICE|PLASTER|Standard treatment plaster for fractures.
219253599|NCT01002911|DRUG|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
219253600|NCT01002911|DRUG|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
219253601|NCT05765890|OTHER|No treatment given|No treatment given
219253602|NCT04621422|BIOLOGICAL|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
219253603|NCT00497692|DRUG|Lactoserum|
219253604|NCT00397020|DRUG|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
219253605|NCT00397020|DRUG|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
219253606|NCT02406495|DEVICE|filcon IV 1|contact lens
219253607|NCT02406495|DEVICE|ocufilcon D|contact lens
219253608|NCT01624597|BEHAVIORAL|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
219253609|NCT01624597|BEHAVIORAL|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
219253610|NCT04421313|DRUG|Dietary Fiber Supplementation|12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
219253611|NCT05546424|BEHAVIORAL|EMRESERVA|training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
219253612|NCT05110014|OTHER|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
219253613|NCT00582959|OTHER|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
219253614|NCT02271685|OTHER|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
219253615|NCT02271685|OTHER|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
219253616|NCT02271685|OTHER|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
219253617|NCT02271685|OTHER|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
219253618|NCT00703105|BIOLOGICAL|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
219253619|NCT05273177|OTHER|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
219253620|NCT00383747|DRUG|transdermal nicotine patch|14mg transdermal nicotine application
219253621|NCT00383747|DRUG|Transdermal Nicotine Patch|14mg transdermal nicotine application
219253622|NCT02204319|DEVICE|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
219253623|NCT02723305|OTHER|No intervention|
219253624|NCT02228135|DRUG|Dexamethasone|
219253625|NCT03371485|BIOLOGICAL|AST-VAC2|Allogeneic dendritic cell vaccine.
219253626|NCT03718819|OTHER|exercise|Pilates and aquaplyometric exercises will be done combinedly.
219253627|NCT05500898|DRUG|DWP16001|Tablets, Oral, multiple doses of DWP16001
219253628|NCT05500898|DRUG|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
219253629|NCT05500898|DRUG|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
219253630|NCT03228277|DRUG|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
219253631|NCT03121729|PROCEDURE|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
219296272|NCT05204355|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
219296273|NCT05204355|DIAGNOSTIC_TEST|HRCT|High Resolution Computer Tomography
219253632|NCT04675762|DRUG|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
219253633|NCT04675762|OTHER|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
219253634|NCT00153023|DRUG|Telmisartan|
219253635|NCT00153023|DRUG|Valsartan|
219253636|NCT01448382|DEVICE|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
219253637|NCT01746277|DRUG|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
219253638|NCT01746277|DRUG|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
219253639|NCT02046798|DRUG|ASP3652|oral
219253640|NCT05068271|BEHAVIORAL|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
219253641|NCT05068271|BEHAVIORAL|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
219253642|NCT04636957|DRUG|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
219253643|NCT04636957|DRUG|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
219253644|NCT05428592|BIOLOGICAL|LVRNA009|50μg /0.5 mL/Vial/person
219253645|NCT05428592|BIOLOGICAL|CoronaVac®|0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
219253646|NCT03140449|DRUG|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
219253647|NCT03140449|DRUG|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
219253648|NCT03140449|DRUG|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
219253649|NCT02099136|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
219253650|NCT02099136|OTHER|Placebo|Given PO
219253651|NCT02099136|DRUG|Celecoxib|Given PO
219253652|NCT02099136|PROCEDURE|Biopsy|Undergo skin biopsy
219253653|NCT02099136|OTHER|Imaging Biomarker Analysis|Correlative studies
219253654|NCT00866983|DRUG|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
219253655|NCT03783858|DEVICE|P200TE|OCT images
219253656|NCT06294483|DIAGNOSTIC_TEST|CBC|Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
219253657|NCT06294483|DIAGNOSTIC_TEST|Antinuclear Antibody tests (ANA)|To be tool in diagnosis of SLE
219253658|NCT06294483|DIAGNOSTIC_TEST|Rest of ANA profile|As tool of diagnosis of SLE
219253659|NCT06294483|DIAGNOSTIC_TEST|C3 and C4 complement level.|As method of detection of acute acivity of SLE
219253660|NCT06294483|DIAGNOSTIC_TEST|Anti phospholipid marker|To detect antiphospholipid syndrome if there is sign of thrombosis
219253661|NCT06294483|DIAGNOSTIC_TEST|Serum creatinine and Alb/create ratio|To detct complication of disease on kidney
219253662|NCT06294483|OTHER|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.|Is criteria of diagnosis of SLE
219253663|NCT06294483|OTHER|SLEDAI scores|Is score to detect the activity of disease
219296274|NCT04844814|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
219296275|NCT04844814|DRUG|Prednisone|Prednisone 30 mg/d
219296276|NCT04844814|DRUG|Placebo of Prednisone|Placebo of Prednisone
219296277|NCT04844814|DRUG|Placebo of Anakinra|Placebo of Anakinra
219253664|NCT02672397|BEHAVIORAL|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
219253665|NCT00700453|BEHAVIORAL|Control group with no video game play|Subjects will abstain from all video game play during study participation.
219253666|NCT00700453|BEHAVIORAL|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
219253667|NCT00700453|BEHAVIORAL|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
219253668|NCT00700453|BEHAVIORAL|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
219253669|NCT05923398|BEHAVIORAL|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
219253670|NCT00249730|DRUG|Sildenafil|
219253671|NCT05784077|DIAGNOSTIC_TEST|Polysomnography|Study of the sleep pattern
219253672|NCT05784077|BEHAVIORAL|Lifestyle counselling|Weight loss counselling
219253673|NCT01263990|DEVICE|NexFin|noninvasive finger cuff system
219253674|NCT06452927|PROCEDURE|Endoscopic enucleation of the prostate|"Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3"
219253675|NCT05306522|OTHER|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
219253676|NCT04009720|DEVICE|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] \<1.0 cm2 or AVA index \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
219253677|NCT04970381|DRUG|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
219253678|NCT03389451|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
219253679|NCT01327027|DRUG|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
219253680|NCT01327027|DRUG|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
219253681|NCT05246384|DRUG|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
219253682|NCT06024135|DEVICE|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
219253683|NCT02921139|RADIATION|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
219253684|NCT02921139|PROCEDURE|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
219253685|NCT01586429|OTHER|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
219253686|NCT02171130|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
219253687|NCT04531813|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
219253688|NCT04531813|DRUG|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
219253689|NCT04531813|OTHER|Negative Control|A blank patch was applied to the Negative Control test site.
219253690|NCT02853305|BIOLOGICAL|Pembrolizumab|IV infusion
219253691|NCT02853305|DRUG|Cisplatin|IV infusion
219253692|NCT02853305|DRUG|Carboplatin|IV infusion
219253693|NCT02853305|DRUG|Gemcitabine|IV infusion
219253694|NCT00858507|BEHAVIORAL|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
219253695|NCT00858507|BEHAVIORAL|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
219253696|NCT00781417|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
219253697|NCT00781417|OTHER|Placebo|Matching Placebo
219253698|NCT02981537|DEVICE|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
219253699|NCT02981537|DEVICE|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
219253700|NCT03836742|PROCEDURE|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
219253701|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
219253702|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
219253703|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
219253704|NCT05022290|PROCEDURE|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
219253705|NCT02510053|DRUG|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
219253706|NCT03883698|DRUG|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
219253707|NCT03883698|DRUG|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
219253708|NCT01340300|BEHAVIORAL|Exercise training|Two supervised exercise sessions per week
219253709|NCT01340300|DRUG|Metformin|Oral metformin QD for two weeks, then BID
219253710|NCT01340300|OTHER|Educational information|educational information
219253711|NCT05503693|DRUG|AP303 50 μg|AP303 tablet
219253712|NCT05503693|DRUG|AP303 150 μg|AP303 tablet
219253713|NCT05503693|DRUG|AP303 300 μg|AP303 tablet
219253714|NCT05503693|DRUG|AP303 600 μg|AP303 tablet
219253715|NCT05503693|DRUG|Placebo 50 μg|Placebo tablet
219253716|NCT05503693|DRUG|Placebo 150 μg|Placebo tablet
219253717|NCT05503693|DRUG|Placebo 300 μg|Placebo tablet
219253718|NCT05503693|DRUG|Placebo 600 μg|Placebo tablet
219253719|NCT02036255|DRUG|Taurolidine Urokinase|
219253720|NCT02036255|DRUG|Taurolidine Heparin|
219253721|NCT04757714|PROCEDURE|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
219253722|NCT04757714|PROCEDURE|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
219253723|NCT04757714|OTHER|Questionnaires|"* a physical activity questionnaire (PHAS instrument)~* a COPD quality of life questionnaire (St George Hospital)"
219253724|NCT04757714|OTHER|A search for sarcopenia by studying the strength of the grip (dynamometer)|A search for sarcopenia by studying the strength of the grip (dynamometer)
219253725|NCT03544229|DRUG|TAK-906 Maleate|TAK-906 maleate capsules.
219253726|NCT03544229|DRUG|Placebo|TAK-906 maleate placebo-matching capsules.
219253727|NCT04778787|DRUG|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
219253728|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
219253729|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
219253730|NCT00510263|DRUG|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
219253731|NCT00510263|DRUG|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
219253732|NCT00510263|DRUG|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
219253733|NCT00510263|DRUG|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
219253734|NCT01933659|DRUG|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
219253735|NCT02728947|DRUG|ROTIGOTINE|1 week at each dose
219253736|NCT04431739|DEVICE|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
219253737|NCT03472859|DEVICE|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
219253738|NCT03472859|DEVICE|KTP|This is the traditional green laser (KTP)
219253739|NCT03373500|OTHER|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
219253740|NCT02628613|DRUG|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
219253741|NCT02628613|DRUG|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
219253742|NCT00030745|DRUG|cisplatin|
219253743|NCT00030745|DRUG|gemcitabine hydrochloride|
219253744|NCT00030745|PROCEDURE|conventional surgery|
219253745|NCT01389609|DRUG|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
219253746|NCT01389609|DRUG|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
219253747|NCT01389609|DRUG|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
219253748|NCT03480945|DIAGNOSTIC_TEST|serotonin|Endothelium-dependent dilatation
219253749|NCT02683356|OTHER|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
219253750|NCT02683356|OTHER|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
219253751|NCT02949622|BEHAVIORAL|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
219253752|NCT02949622|OTHER|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
219253753|NCT01610622|DEVICE|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
219253754|NCT04796389|OTHER|Music|Preferred music of the participant administered using headphones.
219253755|NCT03512587|PROCEDURE|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
219253756|NCT03512587|PROCEDURE|Placebo|Headphones will be place in patients without playing quantum sonotherapy
219253757|NCT02840071|OTHER|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
219253758|NCT01779427|BEHAVIORAL|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
219253759|NCT00640523|DRUG|forodesine HCl|2 x 100mg capsules daily
219253760|NCT01951261|PROCEDURE|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
219253761|NCT02650934|PROCEDURE|Percutanous coronary intervention|
219253762|NCT03175835|DRUG|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
219253763|NCT03175835|DRUG|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
219253764|NCT03175835|DRUG|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
219253765|NCT04715919|DIAGNOSTIC_TEST|Chest Computed Tomography|Evaluation of Lung Structure
219253766|NCT04715919|DIAGNOSTIC_TEST|Pulmonary Function Tests|Respiratory Capacity
219253767|NCT04715919|OTHER|Six Minutes Walk Test|Exercise Capacity
219253768|NCT04715919|OTHER|Quality of Life|Physical disability assessment tool
219253769|NCT00043407|DRUG|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
219253770|NCT06338254|OTHER|percussion massage therapy|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks. Percussion massage was applied to both extremities at separate times for 5 minutes each with the Hypervolt device. (Fig. 2) Four muscles in total were focused on; These muscles are medial gastrocnemius, lateral gastrocnemius, peronus longus, and tibialis anterior. Percussion massage was applied in the longitudinal direction of the muscle, from distal to proximal and back to distal, going from posterior to anterior muscle groups. Percussion massage started on the medial side and ended on the lateral side for each muscle. Equal pressure and duration were applied to each muscle.
219253771|NCT05979402|OTHER|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
219253772|NCT05979402|OTHER|Control group|No intervention
219253773|NCT02730676|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
219253774|NCT02730676|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
219253775|NCT00309621|DRUG|alitretinoin|
219253776|NCT01138189|PROCEDURE|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
219253777|NCT01138189|PROCEDURE|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
219253778|NCT05436145|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
219253779|NCT05533645|OTHER|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
219253780|NCT01924806|DEVICE|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
219253781|NCT01924806|DEVICE|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
219253782|NCT02278133|DRUG|WNT974|
219253783|NCT02278133|DRUG|LGX818|
219253784|NCT02278133|BIOLOGICAL|Cetuximab|
219253785|NCT03284593|DRUG|intensive chemotherapy|
219253786|NCT03284593|DRUG|Azacitidine|
219253787|NCT01954771|BEHAVIORAL|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
219253788|NCT01954771|OTHER|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
219253789|NCT02025361|DRUG|intrarectal lidocaine gel|intrarectal local anesthetic application
219253790|NCT02025361|DRUG|periprostatic nerve blockade|periprostatic local anesthetic application
219253791|NCT05532683|BEHAVIORAL|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller \& Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
219253792|NCT00088075|DRUG|Risperidone|
219253793|NCT00184496|DRUG|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
219253794|NCT05171361|PROCEDURE|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
219253795|NCT02886234|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
219253796|NCT02886234|BEHAVIORAL|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
219253797|NCT00229190|PROCEDURE|Nasal lavage|
219253798|NCT00229190|PROCEDURE|Allergy skin testing|
219253799|NCT00229190|PROCEDURE|Peak nasal inspiratory flow|
219253800|NCT00229190|PROCEDURE|Acoustic rhinometry|
219253801|NCT00229190|PROCEDURE|Nasal examination|
219253802|NCT00229190|PROCEDURE|Quality of Life Questionnaire|
219253803|NCT00229190|PROCEDURE|Physical examination|
219253804|NCT03343288|DEVICE|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
219253805|NCT05106816|OTHER|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
219253806|NCT05106816|OTHER|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
219253807|NCT02937051|OTHER|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
219253808|NCT05542225|PROCEDURE|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
219253809|NCT05542225|PROCEDURE|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
219253810|NCT05542225|PROCEDURE|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
219253811|NCT00003359|DRUG|batabulin sodium|
219253812|NCT01007721|DRUG|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
219253813|NCT01007721|DRUG|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
219253814|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
219253815|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
219253816|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
219253817|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
219253818|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
219253819|NCT01007721|DRUG|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
219253820|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
219253821|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
219253822|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
219253823|NCT01007721|DRUG|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
219253824|NCT01007721|DRUG|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
219253825|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
219253826|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
219253827|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
219253828|NCT01007721|DRUG|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
219253829|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
219253830|NCT01007721|DRUG|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
219253831|NCT01007721|DRUG|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
219253832|NCT06223100|DRUG|Eravacycline|There is no other intervention.
219253833|NCT04783883|DEVICE|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
219253834|NCT00825214|DEVICE|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
219253835|NCT00825214|DEVICE|Inactivated zapperclick device|placebo
219253836|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"
219253837|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"
219253838|NCT01242033|DIETARY_SUPPLEMENT|red raspberries|single serving of one, two or four cups red raspberries
219253839|NCT01242033|DIETARY_SUPPLEMENT|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
219253840|NCT00262769|DRUG|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
219253841|NCT00262769|DRUG|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
219253842|NCT01990378|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
219253843|NCT01802476|DRUG|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
219253844|NCT01802476|DRUG|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
219253845|NCT04787900|DEVICE|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
219253846|NCT04787900|DEVICE|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
219253847|NCT05562583|BEHAVIORAL|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
219253848|NCT04034914|OTHER|Questionnaire administration|Ancillary studies
219253849|NCT05463835|DIETARY_SUPPLEMENT|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
219253850|NCT05463835|DIETARY_SUPPLEMENT|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
219253851|NCT05463835|DIETARY_SUPPLEMENT|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
219253852|NCT04331015|DIAGNOSTIC_TEST|Pure tone audiometry|pure tone audiometry
219253853|NCT02811393|OTHER|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
219253854|NCT00487513|PROCEDURE|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
219253855|NCT04098497|BEHAVIORAL|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
219253856|NCT03229096|DRUG|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
219253857|NCT01325818|DRUG|pravastatin, rosuvastatin|"1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
219253858|NCT04960436|PROCEDURE|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
219253859|NCT04960436|PROCEDURE|Meniscectomy|patients received surgery of Meniscectomy
219253860|NCT00162552|DRUG|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
219253861|NCT00162552|DRUG|PLACEBO|Patients with severe cirrhosis treated with a placebo
219253862|NCT00556764|DRUG|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
219253863|NCT00556764|DRUG|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
219253864|NCT06425094|DIETARY_SUPPLEMENT|Microalgae Extract Capsules|Tetrasol extract
219253865|NCT06425094|DIETARY_SUPPLEMENT|Placebo|maltodextrin \& vegetable magnesium stearate
219253866|NCT04957407|OTHER|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
219253867|NCT00212797|DRUG|Org 34517|low dose Org 34517
219253868|NCT00212797|DRUG|Org 34517|high dose Org 34517
219253869|NCT00212797|DRUG|Placebo|placebo
219253870|NCT04531878|DRUG|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
219253871|NCT00297778|DRUG|Pramipexole|Dopamine agonist
219253872|NCT00297778|OTHER|Placebo|
219253873|NCT01381458|DRUG|FSC|fluticasone propionate / salmeterol xinofoate combination
219253874|NCT01381458|DRUG|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
219253875|NCT00679549|DEVICE|CPAP Therapy|CPAP therapy is provided as an inpatient.
219253876|NCT04300322|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
219253877|NCT04300322|DRUG|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
219253878|NCT04700566|BIOLOGICAL|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
219253879|NCT01865578|DEVICE|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
219253880|NCT01865578|DEVICE|Sham Stimulation|no electrical stimulation
219253881|NCT03280108|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
219253882|NCT03280108|DEVICE|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
219253883|NCT06183905|DIAGNOSTIC_TEST|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
219253884|NCT06183905|PROCEDURE|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
219253885|NCT02957162|DRUG|Atorvastatin|
219253886|NCT02957162|OTHER|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
219253887|NCT01717170|DRUG|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
219253888|NCT04585568|OTHER|Biosensors|Measures of blood flow and preassures
219253889|NCT02511340|DRUG|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
219253890|NCT02996097|DEVICE|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
219253891|NCT02996097|DRUG|Intralesional Triamcinolone Acetonide|
219253892|NCT05050435|PROCEDURE|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
219253893|NCT02201771|DRUG|Aspirin|
219253894|NCT02201771|DRUG|Ticagrelor|
219253895|NCT02716753|BIOLOGICAL|seminal plasma|
219253896|NCT02716753|BIOLOGICAL|Physiological NaCL solution|
219253897|NCT01300078|DRUG|MF101|MF101 10 g/day MF101 15 g/day
219253898|NCT00218998|BEHAVIORAL|exercise training|
219253899|NCT05458830|BEHAVIORAL|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
219253900|NCT05458830|BEHAVIORAL|Plain advisory text|Care as usual
219253901|NCT01999543|DIETARY_SUPPLEMENT|plant-based dietary supplement|
219253902|NCT01999543|OTHER|Placebo|
219253903|NCT04719819|PROCEDURE|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
219253904|NCT01820637|DEVICE|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
219253905|NCT02852278|OTHER|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
219253906|NCT00583115|DRUG|Gleevec|260 mg/M2/day, given once daily by mouth
219253907|NCT00264498|DRUG|Gefitinib|oral tablet
219253908|NCT00264498|DRUG|Gemcitabine|intravenous injection
219253909|NCT00264498|DRUG|Carboplatin|intravenous injection
219253910|NCT03412513|DRUG|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
219253911|NCT03412513|DRUG|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
219253912|NCT05534464|OTHER|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
219253913|NCT05534464|OTHER|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
219253914|NCT05534464|OTHER|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
219253915|NCT01378598|OTHER|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
219253916|NCT05363605|DRUG|[225Ac]-FPI-1966|\[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
219253917|NCT05363605|DRUG|[111In]-FPI-1967|\[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
219253918|NCT05363605|BIOLOGICAL|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
219253919|NCT01767662|PROCEDURE|manipulation|home programme
219253920|NCT01767662|PROCEDURE|No intervention|observation
219253921|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg Ferrous sulfate
219253922|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg ferrous sulfate
219253923|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|6 mg ferrous sulfate
219253924|NCT01712295|DRUG|17% Salicylate with ethyl pyruvate|
219253925|NCT01712295|DRUG|Salicylates|
219253926|NCT04072666|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach \& Gysin-Maillart, 2017).
219253927|NCT04072666|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
219253928|NCT04072666|BEHAVIORAL|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
219253929|NCT04205136|DRUG|Spironolactone|If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is \>5.0 but less than 5.5 or creatinine \>4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
219253930|NCT04205136|DRUG|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
219253931|NCT01800539|BEHAVIORAL|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
219253932|NCT04692883|PROCEDURE|Percutaneous suturing|
219253933|NCT05153785|DRUG|Lidocaine|Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
219253934|NCT05153785|DRUG|Normal saline|Placebo
219253935|NCT02419209|OTHER|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
219253936|NCT02046447|DRUG|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
219253937|NCT02046447|OTHER|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
219253938|NCT02046447|OTHER|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
219253939|NCT02046447|OTHER|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
219253940|NCT04230668|BEHAVIORAL|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
219253941|NCT04230668|BEHAVIORAL|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
219253942|NCT04561167|OTHER|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
219253943|NCT04561167|OTHER|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
219253944|NCT03008304|DRUG|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219253945|NCT06550297|BEHAVIORAL|Medically Tailored Meals and Nutritional Counseling|God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
219253946|NCT06550297|BEHAVIORAL|Cardiovascular Health Promotion Educational Program|Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
219253947|NCT05204771|OTHER|Ultrasound exam|Ultrasound exam
219253948|NCT05204771|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
219253949|NCT05204771|OTHER|Pediatric Follow up|Pediatric Follow up
219253950|NCT01746628|PROCEDURE|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
219253951|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
219253952|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
219253953|NCT05029271|DEVICE|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
219253954|NCT04351100|DRUG|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
219253955|NCT03111849|OTHER|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
219253956|NCT00669292|BIOLOGICAL|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
219253957|NCT00360971|BIOLOGICAL|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
219253958|NCT00360971|DRUG|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
219253959|NCT00360971|OTHER|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
219253960|NCT00360971|PROCEDURE|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
219253961|NCT00360971|RADIATION|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
219253962|NCT02088723|BEHAVIORAL|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
219253963|NCT03868098|DRUG|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
219253964|NCT03868098|DRUG|Placebo ointment|Placebo ointment (vehicle)
219253965|NCT01425541|DRUG|estrace|0.5-1 mg once a day PO for 7 days
219253966|NCT01425541|DRUG|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
219253967|NCT05253547|BEHAVIORAL|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
219253968|NCT05253547|BEHAVIORAL|Healthy dietary guidelines|Personalised healthy dietary recommendations
219253969|NCT04533334|PROCEDURE|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
219253970|NCT02569944|PROCEDURE|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
219253971|NCT02569944|PROCEDURE|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
219253972|NCT05846048|OTHER|semi-structures questionaire|semi -structured questionnaire prepared by the researcher collect sociodemographic data , awareness ,attitudes about marital rape and health consequences
219253973|NCT04847908|OTHER|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
219253974|NCT02429037|DRUG|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
219253975|NCT02429037|RADIATION|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
219253976|NCT02429037|DRUG|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
219253977|NCT00000922|DRUG|Indinavir sulfate|
219253978|NCT00000922|DRUG|Abacavir sulfate|
219253979|NCT00000922|DRUG|Nelfinavir mesylate|
219253980|NCT00000922|DRUG|Efavirenz|
219253981|NCT00000922|DRUG|Nevirapine|
219253982|NCT00000922|DRUG|Lamivudine|
219253983|NCT00000922|DRUG|Stavudine|
219253984|NCT00000922|DRUG|Didanosine|
219253985|NCT02169245|OTHER|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
219253986|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
219253987|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
219253988|NCT02109107|DEVICE|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
219253989|NCT01643902|DRUG|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
219253990|NCT04184856|DIAGNOSTIC_TEST|fMRI|(Imaging while) performing reward related tasks.
219253991|NCT02811042|DEVICE|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
219253992|NCT02811042|DEVICE|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
219253993|NCT04714788|DEVICE|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
219253994|NCT04714788|OTHER|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
219253995|NCT05561296|PROCEDURE|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
219253996|NCT00741351|DRUG|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
219253997|NCT00741351|DRUG|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
219253998|NCT00741351|DRUG|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
219253999|NCT04260984|PROCEDURE|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
219254000|NCT04260984|PROCEDURE|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
219254001|NCT02526771|PROCEDURE|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
219254002|NCT02526771|PROCEDURE|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
219254003|NCT04159051|DEVICE|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
219254004|NCT03126214|DRUG|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
219254005|NCT01001130|DRUG|fluticasone furoate group|patients who are administered fluticasone furoate at least once
219254006|NCT03090893|DRUG|ATryn continuous infusion|replenish serum thrombin levels
219254007|NCT03164525|DIAGNOSTIC_TEST|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
219254008|NCT02745314|OTHER|Frailty measurement|Frailty measurement under Fried at el criteria
219254009|NCT02745314|OTHER|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
219254010|NCT03052478|DRUG|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
219254011|NCT04289714|DEVICE|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
219254012|NCT01630837|OTHER|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
219254013|NCT03525483|DIAGNOSTIC_TEST|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
219254014|NCT04868318|OTHER|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
219254015|NCT04868318|OTHER|Standard-high protein enteral formula|Peptamen® (16% protein)
219254016|NCT05846308|BEHAVIORAL|Structured synchronous physical training|"The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~1. Warm-up (10 minutes)~2. Social Game (10 minutes)~3. Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~4. Cool-down (10 minutes)"
219254017|NCT05846308|BEHAVIORAL|Structured non-synchronous physical training|The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
219254018|NCT02251197|DRUG|BIII 890 CL|
219254019|NCT02251197|DRUG|Placebo|
219254020|NCT02371161|DRUG|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
219254021|NCT05666063|DIAGNOSTIC_TEST|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
219254022|NCT04653207|OTHER|Glucose Solution 1|50g glucose dissolve in 300ml of water
219254023|NCT04653207|OTHER|Glucose Solution 2|50g glucose dissolve in 300ml of water
219254024|NCT04653207|OTHER|Glucose Solution 3|50g glucose dissolve in 300ml of water
219254025|NCT04653207|OTHER|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
219254026|NCT04653207|OTHER|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
219254027|NCT04653207|OTHER|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
219254028|NCT04653207|OTHER|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
219254029|NCT04653207|OTHER|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
219254030|NCT04653207|OTHER|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
219254031|NCT04390893|DEVICE|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
219254032|NCT04390893|DIAGNOSTIC_TEST|air leakage test|Anesthesiologist would use air leakage test to position the LMA
219254033|NCT04800133|BIOLOGICAL|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
219254034|NCT04800133|BIOLOGICAL|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
219254035|NCT04800133|BIOLOGICAL|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
219254036|NCT06280118|OTHER|Fatigue|Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
219254037|NCT02694198|OTHER|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
219254038|NCT00607789|DRUG|Duloxetine|30 mg/day - 120 mg/day
219254039|NCT00607789|DRUG|Placebo|identical to study drug
219254040|NCT03439397|DEVICE|Ballon Technique|Ballon Technique
219254041|NCT03439397|DEVICE|SOAI|SOAI
219254042|NCT02863913|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
219254043|NCT02863913|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
219254044|NCT02863913|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
219254045|NCT04832815|BEHAVIORAL|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
219254046|NCT04832815|BEHAVIORAL|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
219254047|NCT01406808|BEHAVIORAL|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
219254048|NCT00160979|PROCEDURE|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
219254049|NCT04786431|OTHER|Blood collection for lipid profiling by LC-MS|Blood withdrawal
219254050|NCT04512898|DRUG|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
219254051|NCT01130714|BEHAVIORAL|Exercise|Resistance training with resistance bands.
219254052|NCT00400959|PROCEDURE|cd133+cell intracoronary administration|
219254053|NCT02456675|DRUG|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
219254054|NCT02456675|DRUG|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
219254055|NCT02456675|DRUG|itacitinib|The dose of itacitinib will be given orally once daily (QD).
219254056|NCT05643443|OTHER|Gradual increase of force|steady force
219254057|NCT04402203|DRUG|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
219254058|NCT04402203|DRUG|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
219254059|NCT01137123|DRUG|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
219254060|NCT01137123|PROCEDURE|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
219254061|NCT01137123|PROCEDURE|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
219254062|NCT01137123|PROCEDURE|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
219254063|NCT01645358|DEVICE|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
219254064|NCT01645358|DEVICE|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
219254065|NCT00857298|BEHAVIORAL|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
219254066|NCT03269513|BEHAVIORAL|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
219254067|NCT02262390|PROCEDURE|Partner Notification Reminders|"For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
219254068|NCT03271918|DRUG|Cabergoline|
219254069|NCT02245750|DEVICE|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
219254070|NCT05654805|DIETARY_SUPPLEMENT|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
219254071|NCT03772600|DEVICE|Dexcom G6 CGM|Use of Dexcom G6
219254072|NCT03327077|OTHER|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
219254073|NCT04520581|OTHER|"group O"|"Endotracheal tube was made O shape by assistants."
219254074|NCT02506881|DRUG|Darbepoetin alfa|
219254075|NCT00984399|DRUG|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
219254076|NCT02369588|OTHER|Food portion size|
219254077|NCT05615480|OTHER|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
219254078|NCT06279299|PROCEDURE|lateral pelvic lymph node dissection|Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
219254079|NCT02774564|DRUG|BIA 3-202|Nebicapone tablets 50 mg, oral administration
219254080|NCT02774564|DRUG|Placebo|Nebicapone matching placebo tablets
219254081|NCT02774564|DRUG|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
219254082|NCT01919398|DRUG|LY2940680|Administered orally
219254083|NCT01359722|DRUG|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
219254084|NCT01359722|DRUG|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
219254085|NCT00887380|DRUG|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
219254086|NCT00887380|RADIATION|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
219254087|NCT00887380|DRUG|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
219254088|NCT01044836|BIOLOGICAL|HD203|Injectable form
219254089|NCT01766414|DRUG|C1-esterase inhibitor|intravenously
219254090|NCT01766414|DRUG|Endotoxin|intravenously
219254091|NCT00741468|DRUG|Proellex|2, 25 mg Proellex capsules administered daily
219254092|NCT00741468|DRUG|CYP1A2 probe|Caffeine (200 mg)
219254093|NCT00741468|DRUG|CYP2C9 probe|Tolbutamide (250 mg)
219254094|NCT00741468|DRUG|CYP2C19 probe|Omeprazole (20 mg)
219254095|NCT00741468|DRUG|CYP2D6 probe|Dextromethorphan (30 mg)
219254096|NCT00741468|DRUG|CYP3A4 probe|Midazolam (2mg)
219254097|NCT01975636|DRUG|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
219254098|NCT04834063|DIAGNOSTIC_TEST|Serum Zinc a level|Diagnostic test
219254099|NCT04834063|DIAGNOSTIC_TEST|serum selenium level|Diagnostic test
219254100|NCT04834063|DIAGNOSTIC_TEST|Fibroscan measurement|Diagnostic test
219254101|NCT02860299|DRUG|citrate 4%|
219254102|NCT02860299|DRUG|unfractionated heparin|
219254103|NCT02860299|BIOLOGICAL|blood sample|
219254104|NCT03997708|OTHER|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
219254105|NCT03997708|OTHER|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
219254106|NCT05438446|PROCEDURE|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
219254107|NCT01785771|DRUG|ITCA 650 (exenatide in DUROS)|
219254108|NCT01077011|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
219254109|NCT01077011|OTHER|GenTeal Gel|1 drop in each eye, one time
219254110|NCT05110651|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
219254111|NCT03887871|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
219254112|NCT03887871|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
219254113|NCT04509583|DIETARY_SUPPLEMENT|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
219254114|NCT04509583|OTHER|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
219254115|NCT02592928|OTHER|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
219254116|NCT03106337|DEVICE|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
219254117|NCT04865510|PROCEDURE|Regional citrate anticoagulation|"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."
219254118|NCT05026242|BEHAVIORAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
219254119|NCT05026242|BEHAVIORAL|Control|Participants will be provided with isocaloric snacks
219254120|NCT04923230|BEHAVIORAL|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
219254121|NCT05268822|OTHER|Home exercise|Movement control exercise with or without specific breathing techniques
219254122|NCT04056117|BIOLOGICAL|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
219254123|NCT04056117|BIOLOGICAL|MenACWY|Control vaccine administrated to adults and infants
219254124|NCT04056117|BIOLOGICAL|Rabies|Control vaccine administrated to children
219254125|NCT04056117|BIOLOGICAL|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
219254126|NCT04056117|BIOLOGICAL|Placebo|Control administrated to adults
219254127|NCT01888627|OTHER|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
219254128|NCT00596258|DRUG|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
219254129|NCT05042362|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
219254130|NCT05042362|DRUG|Placebo|Matching placebo orally once daily
219254131|NCT01372683|OTHER|Dietary Intervention|Comparison of oat based breakfast cereals
219254132|NCT04230993|OTHER|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
219254133|NCT03888261|BEHAVIORAL|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
219254134|NCT01683643|BEHAVIORAL|SBIRT|Screening, brief intervention, and referral to treatment.
219254135|NCT01683643|BEHAVIORAL|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
219254136|NCT05904288|DEVICE|Smartwatch Garmin Vivosmart [wearable sensor]|Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
219254137|NCT05904288|DEVICE|Soturi™ [digital mobile app]|Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
219254138|NCT05904288|OTHER|Clinical Assessment|Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
219254139|NCT05664230|OTHER|osteopathy|five osteopathy sessions
219254140|NCT00261625|DRUG|alendronate|
219254141|NCT00050167|DRUG|Paclitaxel|80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
219254142|NCT00050167|DRUG|Docetaxel|75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
219254143|NCT00050167|DRUG|Capecitabine|1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
219254144|NCT02085590|BIOLOGICAL|BCG vaccine|
219254145|NCT02085590|BIOLOGICAL|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
219254146|NCT06473272|OTHER|Cardiovascular and cerebrovascular diseases|Cardiovascular and cerebrovascular diseases
219254147|NCT06049433|BEHAVIORAL|Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
219254148|NCT06049433|BEHAVIORAL|On-Demand + Discussion board (DB)|Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
219254149|NCT06049433|BEHAVIORAL|Arm 2|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
219254150|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
219254151|NCT06049433|BEHAVIORAL|Arm 3|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
219254152|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
219254153|NCT04188119|DRUG|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
219254154|NCT04188119|DRUG|Aspirin|300mg tablets
219254155|NCT04188119|DRUG|Lansoprazole|30mg
219254156|NCT00743496|BIOLOGICAL|Anti-GD2 antibody|Anti-GD2 antibody
219254157|NCT01880944|OTHER|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
219254158|NCT05401149|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
219254159|NCT00495612|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
219254160|NCT00495612|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
219254161|NCT03974997|DIAGNOSTIC_TEST|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
219254162|NCT00006099|BIOLOGICAL|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
219254163|NCT00579657|OTHER|control diet, supported by dietary supplement twice daily|control diet, see above
219254164|NCT00579657|OTHER|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
219254165|NCT00579657|OTHER|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
219254166|NCT00579657|OTHER|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
219254167|NCT01489462|BEHAVIORAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
219254168|NCT01489462|BEHAVIORAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
219254169|NCT01489462|BEHAVIORAL|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
219254170|NCT02766764|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
219254171|NCT02766764|DRUG|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
219254172|NCT02766764|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
219254173|NCT02766764|DRUG|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
219254174|NCT06016127|DEVICE|iovera system|"The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The 190 Smart Tip will be used in this study."
219254175|NCT06016127|DEVICE|Radiofrequency ablation|The RFA system consists of a Cosman, G4 Generator. The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman. A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.
219254176|NCT05662215|DRUG|CK-3828136|CK-3828136
219254177|NCT05662215|DRUG|Placebo for CK-3828136|Placebo for CK-3828136
219254178|NCT05417555|DEVICE|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
219254179|NCT06091969|DIETARY_SUPPLEMENT|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
219254180|NCT06091969|DIETARY_SUPPLEMENT|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
219254181|NCT02103426|DRUG|ASP0113|intramuscular injection
219254182|NCT02103426|DRUG|Placebo|intramuscular injection
219254183|NCT02189122|DRUG|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
219254184|NCT02189122|DRUG|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
219254185|NCT02189122|DRUG|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
219254186|NCT02189122|DRUG|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
219254187|NCT02189122|DRUG|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
219254188|NCT02189122|DRUG|Placebo|Subjects will take matching placebo for five days.
219254189|NCT04593771|DRUG|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
219254190|NCT04026074|DRUG|Fentanyl|Weight adapted drug application
219254191|NCT04026074|DRUG|Remifentanil|Weight adapted drug application
219254192|NCT04026074|DRUG|Clonidine|Weight adapted drug application
219254193|NCT04026074|DRUG|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
219254194|NCT04026074|DRUG|Placebo iv|i.v. administration of 0,9% NaCl
219254195|NCT04026074|DRUG|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
219254196|NCT05572697|BEHAVIORAL|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
219254197|NCT05572697|BEHAVIORAL|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
219254198|NCT02264353|DRUG|Donepezil|Donepezil 10mg before sleep
219254199|NCT02264353|DRUG|placebo|One piece of placebo before sleep
219254200|NCT04461938|OTHER|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
219254201|NCT04475497|OTHER|Blood management|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
219254202|NCT04475497|OTHER|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
219254203|NCT02656745|DEVICE|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
219254204|NCT02574234|OTHER|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
219254205|NCT02574234|OTHER|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
219254206|NCT02574234|OTHER|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
219254207|NCT02574234|OTHER|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
219254208|NCT02574234|OTHER|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
219254209|NCT02864147|DRUG|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
219254210|NCT02864147|DRUG|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
219254211|NCT05364645|DRUG|Carboplatin|Given IV
219254212|NCT05364645|DRUG|Pemetrexed|Given IV
219254213|NCT05364645|DRUG|Selpercatinib|Given PO
219254214|NCT01351883|DIETARY_SUPPLEMENT|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
219254215|NCT06546566|OTHER|Video Game-Based Breathing Exercises|The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
219254216|NCT06546566|OTHER|Conventional Breathing Exercises|The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
219254217|NCT02269917|DRUG|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
219254218|NCT02269917|DRUG|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
219254219|NCT02269917|DRUG|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
219254220|NCT06105099|BEHAVIORAL|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
219254221|NCT06105099|BEHAVIORAL|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
219254222|NCT06105099|BEHAVIORAL|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
219254223|NCT05408156|OTHER|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
219254224|NCT02185586|PROCEDURE|laparoscopic cholecystectomy|
219254225|NCT00303017|DIETARY_SUPPLEMENT|flavocoxid|flavonoid mixture
219254226|NCT00303017|DRUG|Naproxen|non-steroidal anti-inflammatory drug
219254227|NCT01596894|DRUG|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
219254228|NCT01596894|DRUG|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
219254229|NCT02769390|DRUG|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
219254230|NCT02769390|DRUG|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
219254231|NCT02769390|DRUG|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
219254232|NCT02383927|DRUG|Tipifarnib|FTase inhibitor
219254233|NCT02973945|DEVICE|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
219254234|NCT02973945|DEVICE|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
219254235|NCT03093597|OTHER|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
219254236|NCT03093597|OTHER|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
219254237|NCT03093597|OTHER|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
219254238|NCT03093597|OTHER|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
219254239|NCT01334905|DRUG|YM178|oral
219254240|NCT02259569|OTHER|Pressure-controlled ventilation|
219254241|NCT02259569|OTHER|Volume-controlled ventilation|
219254242|NCT06645613|DEVICE|Transcranial Magnetic Stimulation Device|Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
219254243|NCT06646211|DRUG|Zanubrutinib , Thiotepa|"First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
219254244|NCT06646211|DRUG|Methotrexate , Thiotepa and Zanubrutinib|"Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
219254245|NCT06646211|DRUG|ASCT±Zanubrutinib|"Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)"
219254246|NCT06646705|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219254247|NCT04449133|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
219254248|NCT04449133|DRUG|Placebo|Oral administration of two capsules before sleep for 7 days.
219254249|NCT03600090|BIOLOGICAL|EOC202|EOC202 will be SC injection.
219254250|NCT03600090|DRUG|Paclitaxel|Paclitaxol will be IV injection
219254251|NCT03093233|OTHER|no intervention|only descriptive data analysis
219254252|NCT02671071|BEHAVIORAL|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
219254253|NCT04542551|PROCEDURE|Dilation 60-Fr non stricture|Dilation of patients with subjective dysphagia and normal endoscopy
219254254|NCT04542551|PROCEDURE|Sham|Sham dilator for patients with subjective dysphagia and normal endoscopy
219254255|NCT04542551|PROCEDURE|Non severe stricture - dilation with 60-Fr|Dilation of non severe stricture with 60-Fr dilator
219254256|NCT04542551|PROCEDURE|Non severe stricture - dilation with 46-Fr|Dilation of non severe stricture with 46-Fr dilator
219254257|NCT04542551|PROCEDURE|Severe stricture - dilation with 51-Fr|Dilation of a severe stricture with 51-Fr dilator
219254258|NCT04542551|PROCEDURE|Severe stricture - dilation with 42-Fr|Dilation of a severe stricture with 42-Fr dilator
219254259|NCT03876678|OTHER|Lactobacillus salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
219254260|NCT03876678|OTHER|Bifidobacterium animalis subspecies lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
219254261|NCT03876678|OTHER|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
219254262|NCT03071874|DRUG|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
219254263|NCT05888142|BEHAVIORAL|in clinic pain VR reduction exercises|"During the in clinic training phase, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality. But this group will not take a VR system home until after completing the in clinic training phase."
219254264|NCT05888142|BEHAVIORAL|In clinic VRpain reduction exercises + VR homeworks|"During the training phase, participants will use commercially available VR during in clinic physical therapy exercises, and during the training phase, they will also receive a VR system they take home and will begin VR homeworks during the traininng phase, to help reduce their pain and improve functionality."
219254265|NCT01754545|DRUG|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
219254266|NCT01754545|DRUG|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
219254267|NCT00282009|BEHAVIORAL|Basic Internet|Basic Internet control intervention
219254268|NCT00282009|BEHAVIORAL|Enhanced Internet|enhanced Internet cessation intervention
219254269|NCT00282009|BEHAVIORAL|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
219254270|NCT01995149|BEHAVIORAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
219254271|NCT00593983|BEHAVIORAL|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
219254272|NCT00593983|BEHAVIORAL|Time-matched health education|Health education and standard of care treatment
219254273|NCT05473221|BIOLOGICAL|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
219254274|NCT02942628|OTHER|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
219254275|NCT02502851|DEVICE|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
219254276|NCT02502851|DEVICE|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
219254277|NCT05966545|PROCEDURE|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
219254278|NCT05733793|OTHER|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
219254279|NCT01954758|OTHER|personalized Embryo Transfer (pET)|
219254280|NCT01954758|OTHER|Frozen Embryo Transfer (FET)|
219254281|NCT01954758|OTHER|Fresh Embryo Transfer (ET)|
219254282|NCT00337922|DRUG|Lamivudine / Abacavir Sulfate|
219254283|NCT03809871|BIOLOGICAL|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
219254284|NCT02865135|DRUG|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
219254285|NCT02865135|DRUG|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
219254286|NCT04337502|DIAGNOSTIC_TEST|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
219254287|NCT02772445|BEHAVIORAL|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
219254288|NCT01618578|PROCEDURE|rubber hand illusion|"There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
219254289|NCT00223561|DRUG|methylphenidate|
219254290|NCT01772147|DRUG|Umeclidinium bromide 62.5mcg|Inhalation powder
219254291|NCT01772147|DRUG|Umeclidinium bromide 125mcg|Inhalation powder
219254292|NCT01772147|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
219254293|NCT02748902|DRUG|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
219254294|NCT03415347|PROCEDURE|Abscess de-roofing and curettage|Abscess de-roofing and curettage
219254295|NCT03415347|PROCEDURE|Abscess wide local excision|Abscess wide local excision
219254296|NCT03386305|DRUG|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
219254297|NCT03386305|DRUG|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
219254298|NCT03025997|DIETARY_SUPPLEMENT|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
219254299|NCT03025997|DIETARY_SUPPLEMENT|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
219254300|NCT04382768|DRUG|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
219254301|NCT00787813|DRUG|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
219254302|NCT00787813|DRUG|Placebo|
219254303|NCT01630395|PROCEDURE|protective ventilation|low tidal volume and PEEP
219254304|NCT01630395|PROCEDURE|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
219254305|NCT04950387|OTHER|Breathing exercises|Based in yoga, common load
219254306|NCT02972242|RADIATION|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
219254307|NCT04572997|DRUG|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
219254308|NCT03795935|OTHER|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
219254309|NCT01628341|DRUG|insulin|Patients will be asked to complete 2 self-assessment questionnaires
219254310|NCT00435981|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
219254311|NCT06076798|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
219254312|NCT05235841|OTHER|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
219254313|NCT06309485|DRUG|WGI-0301 at MTD/RP2D dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
219254314|NCT06309485|DRUG|WGI-0301 at MTD/RP2D -1 dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
219254315|NCT06309485|DRUG|Sorafenib 400 mg PO, BID continuously|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
219254316|NCT06309485|DRUG|Sorafenib 400 mg PO, BID|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
219254317|NCT02956278|DRUG|Allopurinol|
219254318|NCT02956278|OTHER|Placebo|lactose placebo pill
219254319|NCT00018759|DRUG|paroxetine|
219254320|NCT00018759|BEHAVIORAL|ongoing psychological screening|
219254321|NCT04633213|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
219254322|NCT04633213|DRUG|Placebo|Ophthalmic Solution
219254323|NCT04588519|DEVICE|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
219254324|NCT00305097|DIETARY_SUPPLEMENT|Decaffeinated coffee|5 cups per day for 8 weeks
219254325|NCT00305097|DIETARY_SUPPLEMENT|Caffeinated coffee|5 cups per day for 8 weeks
219254326|NCT00305097|DIETARY_SUPPLEMENT|No coffee|
219254327|NCT03084198|PROCEDURE|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
219254328|NCT03084198|PROCEDURE|Standard care for ALF|A standard of care for subjects with acute liver failure.
219254329|NCT02782208|DRUG|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
219254330|NCT02782208|DRUG|Placebo|Placebo is administered 4 times previous to and during the investigation day.
219254331|NCT02782208|DRUG|GH substitution|GH substitution as usually
219254332|NCT02782208|OTHER|GH pause|GH substitution pause two days prior to the experimental day
219254333|NCT06479525|OTHER|Big Toe Flexor Strengthening Exercises|16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
219254334|NCT06479525|OTHER|Calf Strengthening Exercises|16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
219254335|NCT04755023|DRUG|Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide|Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
219254336|NCT01281215|BEHAVIORAL|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
219254337|NCT03067610|RADIATION|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
219254338|NCT03067610|DRUG|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
219254339|NCT02587013|PROCEDURE|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
219254340|NCT02587013|PROCEDURE|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
219254341|NCT01226485|DRUG|Taladegib|Administered IV
219254342|NCT04145609|BEHAVIORAL|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
219254343|NCT01795521|RADIATION|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
219254344|NCT00049335|DRUG|capecitabine|1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
219254345|NCT02125318|DRUG|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
219254346|NCT05063123|DRUG|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
219254347|NCT00509821|DRUG|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
219254348|NCT00509821|DRUG|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
219254349|NCT01165164|OTHER|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
219254350|NCT03436043|DEVICE|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
219254351|NCT03955354|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
219254352|NCT03955354|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
219254353|NCT05101083|DEVICE|New Receiver-in-Canal Device|Successor of previous device generation
219254354|NCT05101083|DEVICE|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
219254355|NCT01181219|PROCEDURE|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
219254356|NCT01181219|PROCEDURE|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
219254357|NCT00399503|PROCEDURE|Spectral T Wave Alternans|
219254358|NCT00399503|PROCEDURE|Modified Moving Average T Wave Alternans|
219254359|NCT00399503|PROCEDURE|Baroreceptor Sensitivity|
219254360|NCT00399503|PROCEDURE|Heart Rate Variability|
219254361|NCT00399503|PROCEDURE|Heart Rate Turbulence|
219254362|NCT00399503|PROCEDURE|Deceleration Capacity|
219254363|NCT00399503|PROCEDURE|Signal Averaged ECG|
219254364|NCT02967809|DEVICE|echography|cardiac and pulmonary echography
219254365|NCT01359683|DEVICE|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
219254366|NCT04438122|OTHER|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
219254367|NCT04438122|OTHER|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
219254368|NCT06171282|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
219254369|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
219254370|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
219254371|NCT03439098|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
219254372|NCT00932659|DEVICE|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
219254373|NCT03443063|DRUG|Lemborexant|oral tablet
219254374|NCT02827578|DRUG|Tamsulosin|Tamsulosin
219254375|NCT02827578|DRUG|Solifenacin|Solifenacin
219254376|NCT02827578|DRUG|Solifenacin placebo|Solifenacin placebo
219254377|NCT02239081|DRUG|CTP-730|
219254378|NCT02239081|DRUG|Placebo for CTP-730|
219254379|NCT04137302|DRUG|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
219362912|NCT05410288|OTHER|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
219254380|NCT05771597|OTHER|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
219362913|NCT05410288|OTHER|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
219254381|NCT05771597|OTHER|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
219254382|NCT03647202|DRUG|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
219254383|NCT03647202|DRUG|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
219254384|NCT03647202|DRUG|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
219254385|NCT04899401|DIETARY_SUPPLEMENT|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
219254386|NCT04899401|OTHER|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (\>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
219254387|NCT01816685|DEVICE|CPAP|
219254388|NCT01417702|DEVICE|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
219254389|NCT02720185|DRUG|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
219254390|NCT02720185|PROCEDURE|Conventional Surgery|Undergo surgery
219254391|NCT02720185|OTHER|Laboratory Biomarker Analysis|Correlative studies
219254392|NCT01157351|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
219254393|NCT01157351|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 15 months
219254394|NCT01157351|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
219254395|NCT01157351|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
219254396|NCT01157351|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
219254397|NCT01157351|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
219254398|NCT01157351|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
219254399|NCT01157351|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
219254400|NCT05188625|OTHER|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
219254401|NCT02990923|DEVICE|High-Flow Needleless Valve|
219254402|NCT02990923|DEVICE|DualCap Disinfection Devices|
219254403|NCT00513058|DRUG|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
219254404|NCT00513058|DRUG|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
219254405|NCT06133686|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
219254406|NCT06133686|DRUG|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
219254407|NCT03140566|DIAGNOSTIC_TEST|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index \>50% in addition to relief of symptoms and signs of congestion before discharge.
219254408|NCT03140566|DIAGNOSTIC_TEST|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
219254409|NCT03418493|DRUG|LY3316531 - IV|Administered IV.
219254410|NCT03418493|DRUG|LY3316531 - SC|Administered SC.
219254411|NCT03418493|DRUG|Placebo - IV|Administered IV.
219254412|NCT06063447|OTHER|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
219254413|NCT04847310|OTHER|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
219254414|NCT04847310|OTHER|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
219254415|NCT04847310|OTHER|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
219254416|NCT02454049|DIETARY_SUPPLEMENT|beetroot juice|6mmol nitrate
219254417|NCT02454049|DIETARY_SUPPLEMENT|sodium nitrate|6mmol sodium nitrate
219254418|NCT02454049|DIETARY_SUPPLEMENT|water|plain water
219254419|NCT05446714|DEVICE|CH 4 band|expansion of maxilla and observation improvement of the air way
219254420|NCT05446714|DEVICE|HH 2 bands|expansion of maxilla and observation improvement of the air way
219254421|NCT05446714|DEVICE|MSE 2 bands and 4|expansion of maxilla and observation improvement of the air way
219254422|NCT06412536|OTHER|Blood work|Blood work on some participants to review eligibility for future clinical trials
219254423|NCT03253120|OTHER|Water|Patient/ Healthy volunteer will drink 5dl of Water
219254424|NCT03499561|DIAGNOSTIC_TEST|urine analysis|Intervention is (urine analysis ): of a mid stream urine sample will be taken
219254425|NCT02742532|DRUG|Oxytocin|Intranasal oxytocin 40 IU
219254426|NCT02742532|DRUG|Placebo|Intranasal saline solution
219254427|NCT02392663|OTHER|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
219254428|NCT02392663|OTHER|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
219254429|NCT02392663|OTHER|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
219254430|NCT01335412|BIOLOGICAL|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
219254431|NCT01907945|BEHAVIORAL|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
219254432|NCT01907945|BEHAVIORAL|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
219254433|NCT06153030|OTHER|no intervention|No intervention
219254434|NCT04591262|DRUG|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
219254435|NCT04591262|DRUG|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
219254436|NCT04591262|DRUG|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
219254437|NCT00197106|DRUG|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
219254438|NCT00197106|DRUG|fluticasone propionate 2 x 100 mcg|comparator
219254439|NCT01881152|OTHER|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
219254440|NCT01881152|OTHER|Usual care|Information on stroke usually delivered at the community level.
219254441|NCT01709123|DRUG|chromium niacinate|200ug or 500ug supplementation in pill form
219254442|NCT01709123|DRUG|placebo|Placebo pill for chromium niacinate
219254443|NCT01878136|DRUG|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
219254444|NCT01990313|DEVICE|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
219254445|NCT00837096|DEVICE|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
219254446|NCT00837096|DEVICE|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
219254447|NCT01026116|DRUG|Epirubicin|75 mg/m2 every-3-week for four cycles
219254448|NCT01026116|DRUG|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
219254449|NCT01026116|DRUG|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
219254450|NCT01872156|OTHER|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
219254451|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
219254452|NCT01774461|OTHER|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
219254453|NCT02861625|BEHAVIORAL|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
219254454|NCT06190184|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
219254455|NCT06190184|OTHER|Control arm|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
219254456|NCT03025555|OTHER|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
219254457|NCT03025555|OTHER|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
219254458|NCT02637258|OTHER|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
219254459|NCT01536873|DRUG|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
219254460|NCT00170417|BEHAVIORAL|Cognitive Behaviour Therapy|
219254461|NCT05221437|OTHER|antibiotic prescription|
219254462|NCT00082641|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
219254463|NCT02335398|DRUG|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
219254464|NCT02396953|DRUG|Lanreotide PRF|
219254465|NCT05019313|DEVICE|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
219254466|NCT05748678|DEVICE|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
219254467|NCT03866980|BIOLOGICAL|AK105|IV infusion
219254468|NCT03866980|DRUG|carboplatin|IV infusion
219254469|NCT03866980|DRUG|pemetrexed|IV infusion
219254470|NCT03866980|DRUG|placebo|IV infusion
219254471|NCT03866980|DRUG|Anlotinib|PO
219254472|NCT03957408|DEVICE|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
219254473|NCT03018223|DRUG|Fludarabine|Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
219254474|NCT03018223|DRUG|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
219254475|NCT03018223|DRUG|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
219254476|NCT03018223|RADIATION|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
219254477|NCT03018223|PROCEDURE|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
219254478|NCT03018223|DRUG|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
219254479|NCT03018223|DRUG|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
219254480|NCT03018223|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is \> 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
219254481|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
219254482|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
219254483|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
219254484|NCT02786290|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
219254485|NCT00304668|DRUG|dapivirine (TMC120) vaginal gel|
219254486|NCT01530477|DEVICE|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
219254487|NCT01530477|DEVICE|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
219254488|NCT01530477|DEVICE|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
219254489|NCT06172998|DRUG|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
219254490|NCT06285227|BIOLOGICAL|CM313 injection|CM313
219254491|NCT00689520|DRUG|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
219254492|NCT00689520|DRUG|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
219254493|NCT01549249|DEVICE|optical coherence tomography|spectral-domain optical coherence tomography
219254494|NCT04312971|DRUG|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
219254495|NCT04312971|DRUG|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
219254496|NCT04312971|OTHER|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
219254497|NCT04312971|OTHER|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
219254498|NCT04735913|DRUG|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
219254499|NCT03962764|BEHAVIORAL|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
219254500|NCT02674009|DRUG|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
219254501|NCT00419419|DRUG|Topical AmphiMatrix with nitroglycerin (MQX-503)|
219254502|NCT01932983|DEVICE|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
219254503|NCT03713073|DEVICE|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
219254504|NCT03713073|DEVICE|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
219254505|NCT05648513|BEHAVIORAL|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
219254506|NCT01907113|DRUG|BI 10773|oral administration
219254507|NCT01907113|DRUG|BI 10773|oral administration
219254508|NCT01907113|DRUG|BI 10773|oral administration
219254509|NCT01907113|DRUG|BI 10773|oral administration
219254510|NCT01907113|DRUG|BI 10773|oral administration
219254511|NCT01646528|PROCEDURE|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
219254512|NCT02869815|PROCEDURE|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
219254513|NCT01179906|BEHAVIORAL|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
219254514|NCT01179906|BEHAVIORAL|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
219254515|NCT00833898|DEVICE|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
219254516|NCT00833898|BEHAVIORAL|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development \& application of various stress-mgmt techniques such as effective problem-solving, identifying \& challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support \& goal setting.
219254517|NCT06446271|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines."
219254518|NCT00805285|DRUG|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
219254519|NCT00917462|DRUG|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
219254520|NCT00917462|PROCEDURE|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
219254521|NCT01402063|DRUG|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
219254522|NCT01402063|DRUG|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
219254523|NCT03879083|OTHER|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
219254524|NCT03879083|OTHER|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
219254525|NCT00002878|DRUG|dexamethasone|
219254526|NCT00002878|DRUG|doxorubicin hydrochloride|
219254527|NCT00002878|DRUG|valspodar|
219254528|NCT00002878|DRUG|vincristine sulfate|
219254529|NCT00255515|DRUG|Quetiapine fumarate|oral
219254530|NCT00255515|DRUG|conventional treatment for schizophrenia|various standard therapies
219254531|NCT03378895|BEHAVIORAL|online questionnaire|Risk assessment identified by online questionnaire
219254532|NCT00825643|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
219254533|NCT02375932|BEHAVIORAL|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
219254534|NCT02375932|BEHAVIORAL|Usual Care Control|Patients continue to receive usual care from their primary care provider
219254535|NCT01535196|DRUG|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
219254536|NCT01057888|OTHER|Autodialer|Autodialer telephone calls
219254537|NCT01057888|OTHER|Letters|Mailed reminder letters
219254538|NCT03794128|PROCEDURE|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
219254539|NCT03794128|PROCEDURE|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
219254540|NCT00076063|BIOLOGICAL|ALVAC-HIV (vCP1452)|experimental vaccine
219254541|NCT00076063|BIOLOGICAL|LIPO-5|experimental vaccine
219254542|NCT05139576|DIAGNOSTIC_TEST|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
219254543|NCT02110225|DRUG|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
219254544|NCT02110225|DRUG|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
219254545|NCT02110225|DRUG|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
219254546|NCT01003379|DRUG|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
219254547|NCT01003379|DRUG|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
219254548|NCT02176018|DRUG|Dextromethorphan and quinidine|
219254549|NCT02176018|DRUG|Placebo|
219254550|NCT02157688|OTHER|no intervention : case control study|
219254551|NCT03967119|DEVICE|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
219254552|NCT03022045|DRUG|risankizumab|risankizumab administered by subcutaneous injection
219254553|NCT03436433|DRUG|Lacosamide|LCM 100mg twice a day.
219254554|NCT03436433|DRUG|Levetiracetam|LEV 1000mg twice a day.
219254555|NCT01653171|DRUG|Water (Placebo)|Water 100 mL
219254556|NCT01653171|DRUG|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
219254557|NCT01653171|DRUG|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
219254558|NCT01653171|DRUG|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
219254559|NCT02607345|DIETARY_SUPPLEMENT|Zusto|25gr
219254560|NCT02607345|DIETARY_SUPPLEMENT|Glucomedics®|25gr
219254561|NCT02499835|BIOLOGICAL|Pembrolizumab|Given IV
219254562|NCT02499835|BIOLOGICAL|pTVG-HP Plasmid DNA Vaccine|Given ID
219254563|NCT03972137|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
219254564|NCT03972137|BEHAVIORAL|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
219254565|NCT03972137|DRUG|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
219254566|NCT01751451|DRUG|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
219254567|NCT01751451|DRUG|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
219254568|NCT01751451|DRUG|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
219254569|NCT01906658|DRUG|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
219254570|NCT03865862|OTHER|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
219254571|NCT03865862|OTHER|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
219254572|NCT02127814|DIETARY_SUPPLEMENT|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
219254573|NCT03220776|DRUG|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
219254574|NCT03220776|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
219254575|NCT03220776|DRUG|Placebo Oral Tablet|5 day trial of matched placebo
219254576|NCT05939089|DIAGNOSTIC_TEST|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
219254577|NCT05723289|DEVICE|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
219254578|NCT05262439|DEVICE|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
219254579|NCT01608958|DRUG|Oxytocin|10 IU oxytocin in 500 ml infusion
219254580|NCT01608958|DRUG|Oxytocin|10 IU oxytocin IM injection
219254581|NCT06244706|COMBINATION_PRODUCT|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
219254582|NCT06537141|PROCEDURE|selective embolization of thyroid arteries (SETA)|selective embolization of thyroid arteries
219254583|NCT01797822|DRUG|Dexamethasone|
219254584|NCT01797822|DRUG|Artificial tear|
219254585|NCT03441789|DRUG|Enstilar|Enstilar foam applied to affected areas daily
219254586|NCT03441789|DRUG|Vehicle|vehicle foam applied to affected areas once daily
219254587|NCT03441789|DRUG|Otezla|Otezla 30mg
219254588|NCT01659177|DRUG|LY2140023|Administered orally
219254589|NCT01780545|DRUG|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
219254590|NCT01780545|DRUG|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
219254591|NCT01367613|DRUG|SC Methylnaltrexone|
219254592|NCT04872634|BIOLOGICAL|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
219254593|NCT04872634|DRUG|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
219254594|NCT04872634|BIOLOGICAL|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
219254595|NCT03825614|BEHAVIORAL|training|plates and therapeutic exercises applied on young adults
219254596|NCT01906645|OTHER|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
219254597|NCT00003926|DRUG|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
219254598|NCT00003926|DRUG|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
219254599|NCT00003926|DRUG|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
219254600|NCT00003926|DRUG|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
219254601|NCT00003926|DRUG|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
219254602|NCT00003926|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
219254603|NCT04233983|PROCEDURE|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
219254604|NCT00115986|BIOLOGICAL|Influenza A/H5N1 Vaccine|
219254605|NCT02892006|BEHAVIORAL|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
219254606|NCT03459521|BIOLOGICAL|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
219254607|NCT01591668|DRUG|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
219254608|NCT01591668|DRUG|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
219254609|NCT02814097|DRUG|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
219254610|NCT02814097|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
219254611|NCT04491006|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
219254612|NCT04491006|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
219254613|NCT01443546|DRUG|HCG|hCG Trigger
219254614|NCT01443546|DRUG|Lupron Trigger|leuprolide acetate 2 mg SQ
219254615|NCT01443546|DRUG|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
219254616|NCT03146325|DRUG|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
219254617|NCT03146325|DRUG|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
219254618|NCT00700947|DRUG|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
219254619|NCT01639014|DRUG|F2695|75 mg OD in 2 capsules
219254620|NCT01639014|DRUG|placebo|2 capsules
219254621|NCT03287375|DRUG|PIPAC|
219254622|NCT04838145|DRUG|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
219254623|NCT04838145|DRUG|Placebos|Randomized to treatment with placebo
219254624|NCT02302625|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
219254625|NCT00676429|DRUG|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
219254626|NCT00676429|DRUG|Placebo|Placebo as oral solution, individually titrated
219254627|NCT00639964|OTHER|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
219254628|NCT00639964|OTHER|diet questionnaire|questions about nutrition before and during pregnancy
219254629|NCT00639964|OTHER|umbilical cord blood collect|collected at the delivery
219254630|NCT00639964|OTHER|placenta collect|collected at the delivery
219254631|NCT04686370|OTHER|laser treated implant surface|Better marginal bone stability is expected for this type
219254632|NCT00414219|BEHAVIORAL|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
219254633|NCT01960114|DRUG|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
219254634|NCT01960114|DRUG|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
219254635|NCT04108975|PROCEDURE|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
219254636|NCT04108975|PROCEDURE|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
219254637|NCT01858064|DRUG|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
219254638|NCT03976778|OTHER|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
219254639|NCT01302301|PROCEDURE|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
219254640|NCT03052283|DIAGNOSTIC_TEST|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
219254641|NCT00572351|OTHER|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
219254642|NCT00572351|OTHER|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
219254643|NCT05753241|OTHER|no intervention|It's only observational study. No interventions.
219254644|NCT03650361|DRUG|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
219254645|NCT03650361|DRUG|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
219254646|NCT03650361|DRUG|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
219254647|NCT02639078|DRUG|TD-0714|One time dosing in capsule formulation
219254648|NCT02639078|DRUG|Placebo Comparator|One time dosing in capsule formulation
219254649|NCT03116672|DRUG|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
219254650|NCT03116672|DRUG|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
219254651|NCT03116672|DRUG|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
219254652|NCT03248713|DRUG|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
219254653|NCT03248713|DRUG|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
219254654|NCT02358213|PROCEDURE|Ultrasound|Ultrasound examinations are done 5 times
219254655|NCT02469077|BEHAVIORAL|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
219254656|NCT02469077|DRUG|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
219254657|NCT02469077|DRUG|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
219254658|NCT02469077|DRUG|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
219254659|NCT05212597|DRUG|Sacubitril-valsartan|50mg\~100mg twice daily
219254660|NCT05212597|DRUG|Amlodipine-losartan|amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
219254661|NCT00996359|BIOLOGICAL|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
219254662|NCT00996359|RADIATION|total-body irradiation|100 cGy TBI
219254663|NCT01040403|DRUG|olodaterol (BI 1744) low|olodaterol (BI 1744) low
219254664|NCT01040403|DRUG|low tiotropium bromide|low tiotropium bromide
219254665|NCT01040403|DRUG|olodaterol (BI 1744) high|olodaterol (BI 1744) high
219254666|NCT01040403|DRUG|medium tiotropium bromide|medium tiotropium bromide
219254667|NCT01040403|DRUG|high tiotropium bromide|high tiotropium bromide
219254668|NCT01040403|DRUG|Placebo|Placebo
219254669|NCT01040403|DEVICE|Respimat|Respimat inhaler
219254670|NCT03925662|DRUG|Folfox with avastin|Folfox with avastin only
219254671|NCT03925662|DRUG|Mebendazole|Folfox with avastin with mebendazole
219254672|NCT02017132|DIETARY_SUPPLEMENT|Pomegranate extract|
219254673|NCT03228953|OTHER|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
219254674|NCT05773027|BEHAVIORAL|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
219254675|NCT05773027|BEHAVIORAL|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
219254676|NCT01885936|DRUG|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
219254677|NCT01885936|DRUG|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
219254678|NCT01373333|DRUG|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
219254679|NCT03036150|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
219254680|NCT03036150|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
219254681|NCT02991703|DEVICE|pOpmètre®|the pOpmètre® uses saturation sensors,
219254682|NCT02991703|DEVICE|Sphygmocor|the Sphygmocor uses applanation tonometry
219254683|NCT01347177|PROCEDURE|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
219254684|NCT01347177|PROCEDURE|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
219254685|NCT00637832|BIOLOGICAL|rituximab|
219254686|NCT00637832|DRUG|cyclophosphamide|
219254687|NCT00637832|DRUG|doxorubicin hydrochloride|
219254688|NCT00637832|DRUG|prednisolone|
219254689|NCT00637832|DRUG|vincristine sulfate|
219254690|NCT00637832|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219254691|NCT00078234|DRUG|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
219254692|NCT05324813|BEHAVIORAL|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
219254693|NCT02554552|DRUG|YY1201 2ml|YY1201 2ml
219254694|NCT02554552|DRUG|Placebo 2ml|phosphate buffered saline 2ml
219254695|NCT02554552|DRUG|YY1201 3ml|YY1201 2ml
219254696|NCT02554552|DRUG|Placebo 3ml|phosphate buffered saline 3ml
219254697|NCT02455284|DEVICE|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
219254698|NCT03413540|OTHER|Jump|Drop jump from step
219254699|NCT03528109|BEHAVIORAL|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
219254700|NCT06353009|OTHER|NOVA4 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 4 - Ultra-processed foods. They are the ones that use many ingredients including food additives that improve palatability, processed raw materials (hydrogenated fats, modified starches, etc.) and ingredients that are rarely used in home cooking such as soy protein or mechanically separated meat. These foods are mainly of industrial origin and are characterized by a good pleasantness and the fact that they can be stored for a long time."
219254701|NCT06353009|OTHER|NOVA1-3 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 1 - Unprocessed or minimally processed foods (fruit, vegetables, eggs, meat, milk, etc.)~Group 2 - Foods processed in the kitchen with the aim of extending their shelf life. In practice, these are ingredients to be used in the kitchen such as fats, aromatic herbs, etc. to be kept in jars or in the refrigerator to be able to use them later.~Group 3 - Processed foods. These are the foods obtained by combining foods of groups 1 and 2 to obtain the many food products for domestic use (bread, jams, etc.) made up of a few ingredients"
219254702|NCT03646695|PROCEDURE|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
219254703|NCT03646695|PROCEDURE|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
219254704|NCT04719468|OTHER|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
219254705|NCT02935777|DIETARY_SUPPLEMENT|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
219254706|NCT02935777|DIETARY_SUPPLEMENT|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
219254707|NCT02845375|DRUG|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
219254708|NCT02845375|DRUG|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
219254709|NCT02845375|DRUG|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
219254710|NCT03679468|OTHER|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
219254711|NCT03679468|OTHER|Sham Exercise|Sets of balance and stretching exercises
219254712|NCT03679468|OTHER|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
219254713|NCT03679468|OTHER|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
219254714|NCT01265121|DEVICE|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
219254715|NCT01265121|OTHER|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
219254716|NCT04310527|DRUG|Enasidenib|Enasidenib
219254717|NCT06460181|DIETARY_SUPPLEMENT|Astaxanthin|Manufactured by AstaReal Inc
219254718|NCT06460181|DIETARY_SUPPLEMENT|Placebo|Manufactured by AstaReal Inc
219254719|NCT01593436|BEHAVIORAL|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
219254720|NCT01037413|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
219254721|NCT01037413|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
219254722|NCT02934542|DEVICE|AutoLap system|
219254723|NCT05215418|DRUG|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
219254724|NCT05215418|DRUG|Phentermine|Phentermine 30 mg capsule
219254725|NCT05215418|DRUG|Placebo|Inactive oral capsule
219254726|NCT02188277|DRUG|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
219254727|NCT02188277|DRUG|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
219254728|NCT01359878|DRUG|Fibrinogen Concentrate|2 gram intra venous
219254729|NCT01359878|DRUG|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
219254730|NCT04623359|DEVICE|High resolution manometry|High resolution manometry
219254731|NCT01218295|DEVICE|Spirotiger®|training session :10 minutes twice a day X 4 weeks
219254732|NCT00619983|DRUG|donepezil|Group 1: Will receive donepezil 5mg once a day
219254733|NCT00619983|DRUG|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
219254734|NCT00619983|DRUG|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
219254735|NCT00619983|DRUG|placebo|Group 4: Will receive placebo pills
219254736|NCT00619983|DRUG|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
219254737|NCT05730517|DIETARY_SUPPLEMENT|CP5HA|Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
219254738|NCT05730517|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
219254739|NCT05730517|DIETARY_SUPPLEMENT|CP5|Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
219254740|NCT02798913|DRUG|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
219254741|NCT02798913|DRUG|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
219254742|NCT04546659|OTHER|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
219254743|NCT04546659|OTHER|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
219254744|NCT05296252|BEHAVIORAL|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
219254745|NCT05296252|BEHAVIORAL|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
219254746|NCT02520596|OTHER|Bioavailability of Raspberry polyphenols|
219254747|NCT04326153|DRUG|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
219254748|NCT05334706|BIOLOGICAL|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
219254749|NCT01753596|DEVICE|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
219254750|NCT01753596|OTHER|Physiological Sodium Chloride solution (0,9%)|Placebo
219254751|NCT01177137|DEVICE|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
219254752|NCT01177137|DEVICE|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
219254753|NCT01177137|BEHAVIORAL|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
219254754|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
219254755|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
219254756|NCT05442073|OTHER|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
219254757|NCT05168709|BIOLOGICAL|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
219254758|NCT03044002|DEVICE|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
219254759|NCT03044002|DEVICE|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
219254760|NCT03600649|DRUG|Seclidemstat|Twice daily administration of seclidemstat
219254761|NCT03600649|DRUG|Cyclophosphamide|250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
219254762|NCT03600649|DRUG|Topotecan|0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
219254763|NCT02005068|DRUG|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
219254764|NCT02143310|DEVICE|EVP|
219254765|NCT01836198|DRUG|LY2409021|
219254766|NCT01836198|DRUG|Gemfibrozil|
219254767|NCT01836198|DRUG|Ketoconazole|
219254768|NCT01836198|DRUG|Clarithromycin|
219254769|NCT03187353|DRUG|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
219254770|NCT03187353|DRUG|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
219254771|NCT05183243|DRUG|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
219254772|NCT02215954|DRUG|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
219254773|NCT02215954|DRUG|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
219254774|NCT01656486|RADIATION|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
219254775|NCT06541340|PROCEDURE|Modified strategy|Modified preoperative biliary drainage strategy with prealbumin as the main indicator
219254776|NCT06541340|PROCEDURE|Traditional strategy|Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
219254777|NCT00203723|DRUG|Risperidone|
219254778|NCT01593865|PROCEDURE|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
219254779|NCT01593865|PROCEDURE|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
219254780|NCT05710198|DRUG|Citicoline eye drops 2%|Eye drops containing Citicoline 2%
219254781|NCT05710198|DRUG|Placebo|Eye drops containing placebo matching product
219254782|NCT05247476|DRUG|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
219254783|NCT05247476|DRUG|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
219254784|NCT04060732|DEVICE|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
219254785|NCT02683213|DRUG|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
219254786|NCT02683213|DRUG|Placebo|Matching placebo.
219254787|NCT02460562|DEVICE|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
219254788|NCT02460562|DEVICE|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
219254789|NCT03441919|RADIATION|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
219254790|NCT03441919|DIAGNOSTIC_TEST|Blood drawn|Blood drawn
219254791|NCT00888394|PROCEDURE|chiropody|basic procedure of chiropody in podiatry
219254792|NCT00888394|PROCEDURE|basic orthesis|individual basic orthesis of foot
219254793|NCT00888394|PROCEDURE|advantage orthesis|advantage orthesis of foot with special material and design
219254794|NCT00888394|PROCEDURE|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
219254795|NCT04451031|BEHAVIORAL|LiFT Program|
219254796|NCT04494243|DRUG|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
219254797|NCT04494243|DRUG|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
219254798|NCT01654289|OTHER|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
219254799|NCT01654289|OTHER|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
219254800|NCT04653571|OTHER|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
219254801|NCT00269126|DRUG|fluticasone propionate/salmeterol combination DISKUS|
219254802|NCT00269126|DRUG|salmeterol xinafoate|
219254803|NCT05615662|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
219254804|NCT05615662|BEHAVIORAL|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
219254805|NCT03746483|DRUG|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
219254806|NCT03746483|DRUG|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
219254807|NCT05712850|PROCEDURE|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
219254808|NCT00187135|DRUG|Fentanyl|"1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
219254809|NCT00187135|DRUG|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
219254810|NCT00187135|DRUG|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
219254811|NCT00187135|DRUG|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
219254812|NCT05937971|OTHER|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
219254813|NCT05937971|OTHER|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
219254814|NCT04101019|DRUG|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
219254815|NCT04101019|DRUG|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
219254816|NCT00694135|DRUG|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
219254817|NCT00694135|DRUG|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
219254818|NCT00694135|DRUG|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
219254819|NCT00694135|DRUG|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
219254820|NCT04364750|DIETARY_SUPPLEMENT|L-Histidine|1 capsule (0.6g) twice daily
219254821|NCT04364750|DIETARY_SUPPLEMENT|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
219254822|NCT04364750|DIETARY_SUPPLEMENT|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
219254823|NCT04364750|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
219254824|NCT04364750|OTHER|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
219254825|NCT03178318|PROCEDURE|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
219254826|NCT01823640|OTHER|placebo|
219254827|NCT01823640|OTHER|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
219254828|NCT00095017|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
219254829|NCT03807453|OTHER|Microbiota|The scalp microbiota
219254830|NCT00236483|DRUG|tramadol hydrochloride + acetaminophen|
219254831|NCT06406868|OTHER|American Cancer Society|"After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down"
219254832|NCT03336073|DRUG|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
219254833|NCT03336073|DRUG|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16
219254834|NCT03336073|DRUG|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
219254835|NCT03653377|OTHER|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
219254836|NCT02739490|PROCEDURE|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
219254837|NCT03128541|DIAGNOSTIC_TEST|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
219254838|NCT01018797|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
219254839|NCT01537406|RADIATION|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
219254840|NCT01644825|DRUG|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
219254841|NCT01644825|DRUG|pazopanib|orally, 800 mg orally daily
219254842|NCT02216578|DRUG|cabozantinib|Oral
219254843|NCT01905293|OTHER|Feeding Study|
219254844|NCT05544539|DRUG|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
219254845|NCT05544539|DRUG|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
219254846|NCT02277587|DRUG|Plenadren|Oral Tablets: 20-25-30 mg
219254847|NCT02277587|DRUG|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
219254848|NCT01287416|BEHAVIORAL|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
219254849|NCT01287416|BEHAVIORAL|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
219254850|NCT00010270|BIOLOGICAL|LMB-9 immunotoxin|
219254851|NCT00728832|DRUG|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
219254852|NCT00524810|DRUG|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
219254853|NCT00524810|DRUG|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
219254854|NCT02650206|DRUG|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
219254855|NCT02650206|OTHER|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
219254856|NCT00364221|DRUG|Rosiglitazone|
219254857|NCT02950688|BIOLOGICAL|Seasonal LAIV|10\^7.0 fluorescent focus units (FFU); administered by intranasal spray
219254858|NCT02950688|BIOLOGICAL|Placebo|Administered by intranasal spray
219254859|NCT02950688|BIOLOGICAL|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10\^6 TCID50; administered intranasally
219254860|NCT02494453|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
219254861|NCT02494453|PROCEDURE|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
219254862|NCT00181532|DRUG|Celecoxib|
219254863|NCT01708005|DRUG|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
219254864|NCT01708005|DRUG|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
219254865|NCT02689752|DRUG|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
219254866|NCT04817930|DEVICE|Polyetheretherketone patient specific implant|a customized peek patient specific implant is place to augment the chin
219254867|NCT04817930|DEVICE|Computer guided advancement genioplasty|advancement genioplasty using patient specific cutting and positioning surgical stents
219254868|NCT01270217|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
219254869|NCT05783154|BIOLOGICAL|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
219254870|NCT05721378|PROCEDURE|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
219254871|NCT05721378|PROCEDURE|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
219254872|NCT03277586|DRUG|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
219254873|NCT03277586|DRUG|Placebo|Identically formulated and packaged inactive substance
219254874|NCT05043688|DRUG|Camrelizumab|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
219254875|NCT05043688|RADIATION|radiotherapy|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
219254876|NCT00705042|DRUG|Etanercept|
219254877|NCT05889221|OTHER|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
219254878|NCT06543407|BEHAVIORAL|SWITCH IT|"Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6."
219254879|NCT06543407|OTHER|E-cig Provision Only|Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
219254880|NCT03915951|DRUG|encorafenib|self-administered orally
219254881|NCT03915951|DRUG|binimetinib|self-administered orally
219254882|NCT05631379|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
219254883|NCT05631379|DIAGNOSTIC_TEST|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
219254884|NCT05631379|DIAGNOSTIC_TEST|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
219254885|NCT05631379|DIAGNOSTIC_TEST|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
219254886|NCT05631379|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
219254887|NCT05631379|DIAGNOSTIC_TEST|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
219254888|NCT01948882|DEVICE|ESS505 (BAY1454033)|
219254889|NCT06241677|DRUG|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
219254890|NCT04760327|COMBINATION_PRODUCT|Electrochemotherapy with bleomycin or cisplatin|Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
219254891|NCT03928678|PROCEDURE|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
219254892|NCT00291863|DRUG|Simvastatin|
219254893|NCT00139971|DRUG|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
219254894|NCT00139971|DRUG|UFT 250mg/m2, daily for 1 year|
219254895|NCT01792206|DRUG|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
219254896|NCT01792206|DRUG|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
219254897|NCT02893371|DRUG|Lithium Carbonate|Exposure to all dosages and delivery forms.
219254898|NCT02893371|DRUG|Lamotrigine|Exposure to all dosages and delivery forms.
219254899|NCT02893371|DRUG|Valproic Acid|Exposure to all dosages and delivery forms.
219254900|NCT02893371|DRUG|Oxcarbazepine|Exposure to all dosages and delivery forms.
219254901|NCT02893371|DRUG|Carbamazepine|Exposure to all dosages and delivery forms.
219254902|NCT02893371|DRUG|Ziprasidone|Exposure to all dosages and delivery forms.
219254903|NCT02893371|DRUG|Risperidone|Exposure to all dosages and delivery forms.
219254904|NCT02893371|DRUG|Quetiapine|Exposure to all dosages and delivery forms.
219254905|NCT02893371|DRUG|Olanzapine|Exposure to all dosages and delivery forms.
219254906|NCT02893371|DRUG|Aripiprazole|Exposure to all dosages and delivery forms.
219254907|NCT02893371|DRUG|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
219254908|NCT02893371|DRUG|Haloperidol|Exposure to all dosages and delivery forms.
219254909|NCT02893371|DRUG|Perphenazine|Exposure to all dosages and delivery forms.
219254910|NCT02893371|DRUG|Clozapine|Exposure to all dosages and delivery forms.
219254911|NCT02893371|DRUG|Asenapine|Exposure to all dosages and delivery forms.
219254912|NCT02893371|DRUG|Lurasidone|Exposure to all dosages and delivery forms.
219254913|NCT02893371|DRUG|Paliperidone|Exposure to all dosages and delivery forms.
219254914|NCT02893371|DRUG|Mirtazapine|Exposure to all dosages and delivery forms.
219254915|NCT02893371|DRUG|Bupropion|Exposure to all dosages and delivery forms.
219254916|NCT02893371|DRUG|Desvenlafaxine|Exposure to all dosages and delivery forms.
219254917|NCT02893371|DRUG|Duloxetine|Exposure to all dosages and delivery forms.
219254918|NCT02893371|DRUG|Venlafaxine|Exposure to all dosages and delivery forms.
219254919|NCT02893371|DRUG|Citalopram|Exposure to all dosages and delivery forms.
219254920|NCT02893371|DRUG|Escitalopram|Exposure to all dosages and delivery forms.
219254921|NCT02893371|DRUG|Fluoxetine|Exposure to all dosages and delivery forms.
219254922|NCT02893371|DRUG|Fluvoxamine|Exposure to all dosages and delivery forms.
219254923|NCT02893371|DRUG|Paroxetine|Exposure to all dosages and delivery forms.
219254924|NCT02893371|DRUG|Sertraline|Exposure to all dosages and delivery forms.
219254925|NCT02893371|DRUG|Vilazodone|Exposure to all dosages and delivery forms.
219254926|NCT02893371|DRUG|Doxepin|Exposure to all dosages and delivery forms.
219254927|NCT02033499|BEHAVIORAL|SMBG|Blood glucose levels are tested once daily.
219254928|NCT04242342|RADIATION|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
219254929|NCT04313036|DRUG|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
219254930|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
219254931|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
219254932|NCT01562821|DRUG|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
219254933|NCT04935762|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
219254934|NCT03716583|DRUG|Melatonin|25 mg
219254935|NCT03716583|DRUG|Dimethyl Sulfoxide|150 mg
219254936|NCT03716583|DRUG|Placebos|1 g
219254937|NCT00456183|BIOLOGICAL|MVA 85A|
219254938|NCT06171919|OTHER|Organizational Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
219254939|NCT06171919|OTHER|HIV Continuum Care|Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
219254940|NCT01121185|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
219254941|NCT01121185|OTHER|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
219254942|NCT02991781|OTHER|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
219254943|NCT02991781|DRUG|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
219254944|NCT02991781|OTHER|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
219254945|NCT02991781|OTHER|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
219254946|NCT03835403|OTHER|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
219254947|NCT02880124|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
219254948|NCT02880124|BEHAVIORAL|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
219254949|NCT02880124|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
219254950|NCT02880124|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
219254951|NCT02880124|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
219254952|NCT02880124|OTHER|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
219254953|NCT02880124|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
219254954|NCT02880124|BEHAVIORAL|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
219254955|NCT03905213|DEVICE|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
219254956|NCT03905213|DEVICE|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
219254957|NCT03905213|DEVICE|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
219254958|NCT05999344|OTHER|commercially available cannabis administered prior to commercially available alcohol|Self administration of cannabis prior to researcher administered alcohol
219254959|NCT05999344|OTHER|commercially available alcohol administered prior to commercially available cannabis|Researcher administered alcohol prior to self-administration of cannabis
219254960|NCT03519477|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
219254961|NCT01196741|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
219254962|NCT01196741|DRUG|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
219254963|NCT01196741|DRUG|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
219254964|NCT00690534|DRUG|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
219254965|NCT00690534|DRUG|L-NMMA|variable rate for 3 hours
219254966|NCT00690534|DRUG|Sodium Nitroprusside|variable rate for 3 hours
219254967|NCT00690534|OTHER|mixed meal|mixed meal
219254968|NCT02851394|DRUG|Levobupivacaine|
219254969|NCT02851394|DRUG|levobupivacaine|
219254970|NCT02851394|DRUG|tramadol|
219254971|NCT05944133|OTHER|No intervention, observational retrospective study|No intervention
219254972|NCT05483192|DIETARY_SUPPLEMENT|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
219254973|NCT02465775|DEVICE|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
219254974|NCT01811823|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
219254975|NCT02150109|DEVICE|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
219254976|NCT02150109|DEVICE|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
219254977|NCT05076955|DRUG|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
219254978|NCT04938739|OTHER|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
219254979|NCT04938739|OTHER|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
219254980|NCT01442623|OTHER|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
219254981|NCT00984347|DRUG|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
219254982|NCT00984347|PROCEDURE|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
219254983|NCT06111183|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
219254984|NCT06111183|OTHER|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
219254985|NCT02825849|BIOLOGICAL|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
219254986|NCT05455554|DIAGNOSTIC_TEST|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
219254987|NCT05455554|DIAGNOSTIC_TEST|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
219254988|NCT02831751|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
219254989|NCT02831751|BIOLOGICAL|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
219254990|NCT02831751|BIOLOGICAL|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
219254991|NCT02831751|BIOLOGICAL|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
219254992|NCT05272787|OTHER|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
219254993|NCT05272787|OTHER|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
219254994|NCT05272787|OTHER|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
219254995|NCT05272787|OTHER|Sunscreen|Auxiliary product
219254996|NCT05272787|OTHER|Facial wash|Auxiliary product.
219254997|NCT00447239|PROCEDURE|glucontrol (insulin therapy)|
219254998|NCT05318716|DEVICE|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
219254999|NCT05318716|DEVICE|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
219255000|NCT03302871|DRUG|Botulinum toxin type A|
219255001|NCT03302871|DEVICE|transcranial direct current stimulation|
219255002|NCT03302871|OTHER|hybrid training model of CIMT and BIT|
219255003|NCT03302871|OTHER|usual care|
219255004|NCT06219902|DRUG|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
219255005|NCT06219902|DRUG|Placebo to elinzanetant|Oral administration
219255006|NCT06219902|DRUG|Zopiclone|Oral administration
219255007|NCT06219902|DRUG|Placebo to zopiclone|Oral administration
219255008|NCT05114902|DIAGNOSTIC_TEST|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
219255009|NCT01478256|DRUG|Erythromycin|Topical erythromycin ointment twice a day
219255010|NCT01478256|DRUG|Besifloxocin|Topical Besifloxocin twice a day
219255011|NCT03465670|DEVICE|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
219255012|NCT03465670|DEVICE|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
219255013|NCT05254288|OTHER|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
219255014|NCT05254288|OTHER|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
219255015|NCT01204775|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
219255016|NCT01204775|DRUG|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
219255017|NCT01204775|DRUG|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
219255018|NCT01204775|DRUG|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
219255019|NCT01204775|DRUG|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
219255020|NCT05270889|DRUG|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
219255021|NCT00860899|DRUG|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
219255022|NCT02008539|DRUG|MSC_apceth_101|
219255023|NCT02567786|PROCEDURE|Surgery with CPB|
219255024|NCT02567786|OTHER|Fresh Frozen Plasma|
219255025|NCT02567786|OTHER|Plasmalyte|
219255026|NCT04090216|DEVICE|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
219255027|NCT04135469|OTHER|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
219255028|NCT04135469|OTHER|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
219255029|NCT01427231|DIETARY_SUPPLEMENT|glucose|The effect of a glucose solution on cognitive performance will be measured.
219255030|NCT01427231|DIETARY_SUPPLEMENT|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
219255031|NCT01427231|DIETARY_SUPPLEMENT|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
219255032|NCT03148301|OTHER|Survey|Survey
219255033|NCT01690286|DRUG|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
219255034|NCT01690286|DRUG|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
219255035|NCT01690286|DRUG|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
219255036|NCT01690286|DRUG|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
219255037|NCT03165344|OTHER|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
219255038|NCT03165344|OTHER|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
219255039|NCT03165344|OTHER|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
219255040|NCT05938959|DRUG|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
219255041|NCT05938959|DRUG|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
219255042|NCT05466968|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
219255043|NCT05466968|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
219255044|NCT04021147|BEHAVIORAL|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
219255045|NCT04021147|BEHAVIORAL|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
219255046|NCT04021147|BEHAVIORAL|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
219255047|NCT04021147|BEHAVIORAL|Exercise|Orofacial exercises
219255048|NCT01702155|DRUG|DFP-10917|
219255049|NCT05793827|BEHAVIORAL|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
219255050|NCT05793827|BEHAVIORAL|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
219255051|NCT01138137|DRUG|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
219255052|NCT01138137|DRUG|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
219255053|NCT01138137|DRUG|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
219255054|NCT02273180|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
219255055|NCT02273180|DRUG|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
219255056|NCT02273180|DRUG|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
219255057|NCT05300217|OTHER|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
219255058|NCT05300217|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
219255059|NCT04266366|OTHER|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
219255060|NCT04266366|OTHER|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
219255061|NCT06128434|OTHER|zinc carbonate nano-hydroxyapatite toothpaste|Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.
219255062|NCT06128434|OTHER|8% arginine toothpaste|Participants will brush their teeth with 8% arginine toothpaste twice daily.
219255063|NCT06128434|OTHER|Fluoride toothpaste|Participants will brush their teeth with Fluoride toothpaste twice daily.
219255064|NCT06141772|OTHER|Measure of the circulating tumor DNA|Blood assessment to measure the kinetics au circulating tumor DNA
219255065|NCT05465486|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab."
219255066|NCT05465486|DEVICE|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab"
219255067|NCT02368366|BEHAVIORAL|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
219255068|NCT02368366|BEHAVIORAL|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
219255069|NCT02368366|BEHAVIORAL|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
219255070|NCT02297529|DRUG|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
219255071|NCT06410625|DIAGNOSTIC_TEST|FLT PET imaging|Evaluation of response to chemotherapy with FLT PET imaging
219255072|NCT00509925|DRUG|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
219255073|NCT00509925|DRUG|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
219255074|NCT00509925|DRUG|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
219255075|NCT02801747|BEHAVIORAL|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
219255076|NCT06069596|COMBINATION_PRODUCT|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
219255077|NCT04299724|BIOLOGICAL|Pathogen-specific aAPC|The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
219255078|NCT05056675|PROCEDURE|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
219255079|NCT05056675|PROCEDURE|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
219255080|NCT02722122|DRUG|AIR DNase™|
219255081|NCT00247117|DRUG|Metformin|
219255082|NCT05657132|DRUG|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
219255083|NCT05657132|DRUG|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
219255084|NCT00494208|DRUG|Testosterone|Testosterone ester
219255085|NCT06352034|BEHAVIORAL|Empathy Training|"The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique."
219255086|NCT02709798|DRUG|Shenfu Injection|
219255087|NCT02709798|DRUG|5% Glucose Injection|
219255088|NCT05173506|OTHER|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
219255089|NCT02946788|DRUG|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
219255090|NCT00275678|PROCEDURE|Blood stem cell versus bone marrow transplant|"1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
219255091|NCT03171389|DRUG|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
219255092|NCT06650137|DIAGNOSTIC_TEST|diaphragmatic ultrasound|"The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured."
219255093|NCT06658704|BEHAVIORAL|Supervised exercise in a group setting|Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.
219255094|NCT06658704|BEHAVIORAL|Usual care (Physical activity on Prescription)|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.
219255095|NCT02046057|PROCEDURE|PNB of SLN|Percutaneous biopsy of sentinel node
219255096|NCT06608459|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
219255097|NCT06608498|BEHAVIORAL|SPARK Coping|SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.
219255098|NCT06593275|PROCEDURE|Protection of the palatal donor area with flowable resin|Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days
219255099|NCT06593275|PROCEDURE|Protection of the palatal donor area with a self-adhesive dressing|Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
219255100|NCT03582917|DRUG|Alphacalcidol|Alphacalcidol 0,5mg tablet
219255101|NCT03749616|DRUG|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
219255102|NCT03749616|DRUG|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
219255103|NCT06600815|PROCEDURE|preemptive stepwise infiltration anaesthesia(PSIA)|For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
219255104|NCT06600815|PROCEDURE|postoperative local infiltration analgesia(PLIA)|Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
219255105|NCT04435522|DRUG|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
219255106|NCT05942183|DIAGNOSTIC_TEST|ONSD|ultrasound measurement of the optic nerve sheath diameter
219255107|NCT01874522|DRUG|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
219255108|NCT01874522|DRUG|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
219255109|NCT07009444|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
219255110|NCT07009444|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
219255111|NCT03925402|DRUG|Ertapenem|Ertapenem injection
219255112|NCT03925402|DRUG|Carbapenems|Other carbapenems injection
219255113|NCT05430074|DEVICE|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
219255114|NCT05430074|DEVICE|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
219255115|NCT06274892|OTHER|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
219255116|NCT06715787|BEHAVIORAL|FEAST Perinatal Support Program|The intervention will include the core perinatal support program (PSP) with $15 weekly grocery gift cards for healthful food (fruit, vegetables, whole grains), The PSP will be completed during weekly group sessions over 16 weeks. The core PSP includes the two primary behavior change techniques: group-based nutrition education based on current United States Department of Agriculture (USDA) national guidelines for pregnant individuals and guided group sharing and engagement.
219255117|NCT06720285|PROCEDURE|nerve block with 0.5% ropivacaine|Compared to active comparator arm, the experimental arm received the same procedure except in the analgesia maintenance which was performed by nerve block of the scalp using 0.5% ropivacaine. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
219255118|NCT06720285|DRUG|General anesthesia and opioids (fentanyl, propofol, rocuronium)|Compared to experimental arm, the active comparator arm received the same procedure except in the analgesia maintenance which was performed through continuous fentanyl infusion. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
219255119|NCT06719596|DRUG|Bifidobacterium Bifidum Oral Capsule|enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
219255120|NCT06721325|BEHAVIORAL|THERAPEUTIC EDUCATION IN PHYSIOTHERAPY|Educational program of physiotherapy for women survivors of sexual violence and female genital mutilation.
219255121|NCT06721325|BEHAVIORAL|Psychotherapy and legal advice|Usual psychological and legal advice therapy for this population
219255122|NCT06721039|DRUG|Bilateral QL block|sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes
219255123|NCT06721039|DRUG|Intraperitoneal and port sites infiltration|with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
219255124|NCT06728774|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD)|8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.
219255125|NCT06728774|BEHAVIORAL|Goal-focused Supportive Contact|8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.
219255126|NCT06724562|OTHER|Anti-IL1 Therapy|Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients
219255127|NCT06720506|DRUG|fentanyl|Fentanyl will be given intrathecal with dose 10-20ug
219255128|NCT06720506|DRUG|Nalbuphine|Nalbuphine will given IV as shot in Dose 1mg /kg
219255129|NCT06721117|OTHER|Grip strength assessment|Jamar hand dynamometer, recommended by the American Hand Therapists Association and accepted as the gold standard in many studies due to its high validity and reliability, will be used to measure hand grip strength. Pinchmeter (Baseline Mechanical Pinch Gauge) will be used to measure fine grip strength. Hand grip and finger grip strength measurements will be made in the recommended standard position of sitting, shoulder adduction and neutral rotation, elbow 90 degrees flexed, forearm in mid-rotation and supported, wrist in neutral. In the test procedure, 3 measurements will be taken for hand grip and finger grip strengths with one-minute intervals between each measurement and the averages will be recorded.
219255130|NCT06721117|OTHER|Forearm muscle strength assessment|Wrist isometric muscle strength assessment will be performed with a handheld dynamometer (Lafayette Instrument Company, Lafayette, Indiana, USA). Patients will be placed in the supine, prone and sitting positions using the positions required for the fine muscle test method defined by Lovett and will be performed without compensatory movements. Wrist flexor and extensor muscles will be assessed. The values obtained with isometric contraction will be recorded in kg. Muscle strength measurements will be assessed bilaterally, in three repetitions for 5 seconds. The average value of the three repetition results will be recorded.
219255131|NCT06721117|OTHER|Pain threshold assessment|"Pain sensitivity to pressure will be assessed with a pain measuring device called an algometer. The Baseline Dolorimeter brand algometer will be used in the assessment. 3 measurements will be taken from the midpoint of the upper trapezius muscle and C7 points between the lateral edge of the acromion and C7. The areas will be marked before the measurement. The algometer will be placed perpendicular to these points. The patients will be asked to report the moment they first felt the pain and 30 seconds of rest will be given between the measurements. The value on the display will be read and the pain threshold will be recorded in pounds (1kg=2.2 pounds)."
219255132|NCT06721117|OTHER|Anxiety level assessment|"The anxiety level will be determined with the Beck Anxiety Inventory. The Beck Anxiety Inventory is a scale developed by Aaron T. Beck (1988). This scale consists of 21 questions. For each item, the patient is asked to report how he/she has felt during the past week.~The items are scored as 0, 1, 2 or 3. The score range is between 0-63. For the total score, \< 21 is considered mild, 22-35 is considered moderate, and \> 36 is considered severe. The Turkish validity study of the Beck anxiety scale was conducted by Ulusoy et al (1996)."
219255133|NCT06719622|DRUG|budesonide|1 mg budesonide ampoule twice daily for patients weighing ≤35 kg or 2 mg twice daily for patients weighing \>35 kg
219255134|NCT06719622|DRUG|omeprazole (proton pump inhibitor)|omeprazole 10 mg twice daily for patients weighing ≤35 kg or 20 mg twice daily for patients weighing \>35 kg
219255135|NCT06525753|OTHER|Weaning off Parenteral Nutrition|pediatric intestinal failure patients who have been weaned off parenteral nutrition
219255136|NCT00767286|DRUG|flutamide|
219255137|NCT00767286|DRUG|goserelin acetate|
219255138|NCT00767286|RADIATION|low-LET cobalt-60 gamma ray therapy|
219255139|NCT00767286|RADIATION|low-LET photon therapy|
219255140|NCT00919061|DRUG|Gemcitabine|Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
219255141|NCT00919061|DRUG|Cisplatin|20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
219255142|NCT00919061|DRUG|Sorafenib|400 mg PO once a day continuously.
219255143|NCT05820451|DEVICE|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
219255144|NCT05820451|DEVICE|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
219255145|NCT02868788|DIETARY_SUPPLEMENT|dietary fiber|Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
219255146|NCT02868788|OTHER|HFHC meal|910 Calorie HFHC meal
219255147|NCT04769895|DRUG|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
219255148|NCT06317259|BEHAVIORAL|Hypoxic breathwork plus music and messaging|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
219255149|NCT06317259|BEHAVIORAL|Hypoxic breathwork only|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
219255150|NCT06317259|BEHAVIORAL|Music and messaging meditation|Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
219255151|NCT03127618|DRUG|Lorlatinib|
219255152|NCT04967677|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
219255153|NCT03658694|PROCEDURE|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
219255154|NCT03658694|PROCEDURE|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
219255155|NCT03658694|PROCEDURE|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
219255156|NCT03658694|PROCEDURE|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
219255157|NCT02270463|DRUG|Tagraxofusp-erzs|Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
219255158|NCT06374186|BEHAVIORAL|Behavioral Intervention with financial rewards and coaching|Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
219255159|NCT06374186|BEHAVIORAL|Control|Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
219255160|NCT03579680|BEHAVIORAL|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
219255161|NCT03579680|BEHAVIORAL|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
219255162|NCT05589584|DRUG|N acetyl cysteine with weight reduction|high dose 2400mg/day
219255163|NCT02896153|OTHER|Questionnaire|
219255164|NCT05294328|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
219255165|NCT05294328|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
219255166|NCT05294328|DRUG|Vehicle Proprietary Ophthalmic Solution|Proprietary Vehicle Ophthalmic Solution
219255167|NCT00442026|DRUG|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
219255168|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
219255169|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
219255170|NCT00647374|OTHER|this is an observational study|
219255171|NCT01319175|OTHER|Hip flexion strength training|
219255172|NCT05926232|DRUG|Repotrectinib|Repotrectinib
219255173|NCT04225234|OTHER|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
219255174|NCT02056873|DEVICE|Continuous DBS|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
219255175|NCT02056873|DEVICE|Responsive Brain Stimulation (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
219255176|NCT05327725|OTHER|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
219255177|NCT01765452|DRUG|Closone|75mg/100mg, 8weeks, PO
219255178|NCT01765452|DRUG|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
219255179|NCT04560777|OTHER|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
219255180|NCT00740597|GENETIC|gene expression analysis|
219255181|NCT00740597|GENETIC|polymerase chain reaction|
219255182|NCT00740597|GENETIC|western blotting|
219255183|NCT00740597|PROCEDURE|neoadjuvant therapy|
219255184|NCT00740597|PROCEDURE|therapeutic conventional surgery|
219255185|NCT00740597|RADIATION|intensity-modulated radiation therapy|
219255186|NCT04402983|OTHER|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
219255187|NCT00841607|PROCEDURE|pancreaticojejunostomy vs pancreaticogastrostomy|
219255188|NCT00413075|DRUG|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
219255189|NCT01304108|OTHER|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
219255190|NCT01304108|OTHER|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
219255191|NCT01304108|OTHER|Usual Care|No addition to the baseline system for care
219255192|NCT00552513|PROCEDURE|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
219255193|NCT00552513|PROCEDURE|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
219255194|NCT00990262|RADIATION|Cardiac Computed Tomography|"1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
219255195|NCT02825277|DEVICE|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
219255196|NCT00514475|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
219255197|NCT04316520|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet 2:1
219255198|NCT01827098|PROCEDURE|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
219255199|NCT05418686|BIOLOGICAL|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"* Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination."
219255200|NCT02867241|BEHAVIORAL|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
219255201|NCT02867241|BEHAVIORAL|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
219255202|NCT02711813|DRUG|TAB08|biologic
219255203|NCT02711813|OTHER|Placebo|
219255204|NCT03426553|BIOLOGICAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
219255205|NCT03426553|BIOLOGICAL|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
219255206|NCT06355128|OTHER|NOT|NOT
219255207|NCT05992636|PROCEDURE|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
219255208|NCT04732247|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
219255209|NCT04732247|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
219255210|NCT04249518|BEHAVIORAL|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
219255211|NCT00280683|DRUG|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
219255212|NCT00280683|DRUG|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
219255213|NCT06402578|DIAGNOSTIC_TEST|HbA1c testing|Bloods will be take pre and post 12 week intervention.
219255214|NCT02985047|OTHER|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
219255215|NCT05962515|PROCEDURE|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
219255216|NCT00000454|DRUG|nicotine replacement patch|
219255217|NCT02646735|DRUG|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
219255218|NCT02646735|DRUG|Exemestane 25 mg|Exemestane 25mg will be given once daily.
219255219|NCT01154465|PROCEDURE|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
219255220|NCT01154465|DEVICE|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~\- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
219255221|NCT00000137|PROCEDURE|Histocompatibility Matching|
219255222|NCT01565252|DIETARY_SUPPLEMENT|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
219255223|NCT00344539|BIOLOGICAL|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
219255224|NCT00344539|BIOLOGICAL|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
219255225|NCT02241278|DRUG|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
219255226|NCT02675803|BIOLOGICAL|VAY736|VAY736 treatment
219255227|NCT02675803|BIOLOGICAL|VAY736 placebo|VAY736 placebo
219255228|NCT05236140|DEVICE|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
219255229|NCT05367752|OTHER|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
219255230|NCT05367752|OTHER|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
219255231|NCT05367752|OTHER|Conventional TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
219255232|NCT05367752|OTHER|Sham TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
219255233|NCT00301041|OTHER|laboratory biomarker analysis|
219255234|NCT00301041|PROCEDURE|adjuvant therapy|
219255235|NCT00301041|RADIATION|radiation therapy|
219255236|NCT00318981|DRUG|Concerta|
219255237|NCT02191527|DEVICE|PIMA® for quantitative analysis of CD4-count|
219255238|NCT02191527|DEVICE|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
219255239|NCT02191527|DEVICE|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
219255240|NCT02483845|DRUG|Natalizumab|
219255241|NCT03068793|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
219255242|NCT05466188|DIAGNOSTIC_TEST|CPC|CPC
219255243|NCT02345915|OTHER|Blood sample|
219255244|NCT02345915|OTHER|Electrocardiogram|
219255245|NCT02335333|OTHER|No treatment|
219255246|NCT02209610|DEVICE|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
219255247|NCT02209610|DRUG|Intrathecal Fentanyl|Mu-opioid receptor agonist
219255248|NCT04547621|DEVICE|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
219255249|NCT04547621|DEVICE|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
219255250|NCT04547621|DRUG|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
219255251|NCT04475237|OTHER|CT-scan evaluation and segmentation|CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
219255252|NCT00414089|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|
219255253|NCT00899145|OTHER|Laboratory Biomarker Analysis|Correlative studies
219255254|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
219255255|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
219255256|NCT02932553|DEVICE|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
219255257|NCT06258954|OTHER|3D reconstruction|3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
219255258|NCT06258954|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and height.
219255259|NCT02020746|DRUG|EscharEx|
219255260|NCT02020746|DRUG|Gel Vehicle|
219255261|NCT01783158|PROCEDURE|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
219255262|NCT04393792|DRUG|Povidone-Iodine|0.23% three times daily (tds) for 3 days
219255263|NCT04393792|DRUG|Normal saline|0.9% three times daily (tds) for 3 days
219255264|NCT00387959|BIOLOGICAL|filgrastim|
219255265|NCT00387959|BIOLOGICAL|rituximab|
219255266|NCT00387959|DRUG|cyclophosphamide|
219255267|NCT00387959|DRUG|cyclosporine|
219255268|NCT00387959|DRUG|fludarabine phosphate|
219255269|NCT00387959|DRUG|mycophenolate mofetil|
219255270|NCT00387959|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219255271|NCT00387959|PROCEDURE|umbilical cord blood transplantation|
219255272|NCT00387959|RADIATION|total-body irradiation|
219255273|NCT03712449|DEVICE|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
219255274|NCT03712449|DRUG|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
219255275|NCT03712449|DRUG|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
219255276|NCT03712449|OTHER|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
219255277|NCT05432518|DRUG|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
219255278|NCT05432518|DRUG|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
219255279|NCT05432518|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
219255280|NCT05432518|DRUG|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
219255281|NCT05432518|DRUG|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
219255282|NCT02224183|BEHAVIORAL|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
219255283|NCT02224183|BEHAVIORAL|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
219255284|NCT00808145|DRUG|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
219255285|NCT00226993|DRUG|CPG 7909|
219255286|NCT01592396|BIOLOGICAL|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
219255287|NCT04849377|RADIATION|RT 50 Gy|Radiation Therapy (RT) 50 GY
219255288|NCT04849377|RADIATION|RT 54 GY|Radiation Therapy (RT) 54 GY
219255289|NCT04849377|RADIATION|RT 60 GY|Radiation Therapy (RT) 60 GY
219255290|NCT04849377|OTHER|Induction Therapy|Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
219255291|NCT04849377|DRUG|Carboplatin|Carboplatin AUC 9.0
219255292|NCT04849377|DRUG|Cisplatin 200|200 mg/m2
219255293|NCT04849377|DRUG|Cisplatin 240|240mg/m2
219255294|NCT04386993|RADIATION|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
219255295|NCT01984567|DIETARY_SUPPLEMENT|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
219255296|NCT01984567|DIETARY_SUPPLEMENT|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
219255297|NCT01984567|DIETARY_SUPPLEMENT|Control|Daily consumption of 3 placebo capsules
219255298|NCT03859817|OTHER|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
219255299|NCT05376787|DEVICE|Medline NE Grounding Pad|Split Universal Grounding Pads
219255300|NCT02115178|OTHER|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
219255301|NCT06279208|BIOLOGICAL|Blood sample|Recovery of plasma from the bottom of a blood collection tube.
219255302|NCT00666198|DRUG|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
219255303|NCT04156178|BIOLOGICAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
219255304|NCT05153499|BIOLOGICAL|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
219255305|NCT05153499|OTHER|Placebo|Placebo
219255306|NCT00793299|BEHAVIORAL|Video Illness Narrative|video
219255307|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
219255308|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
219255309|NCT01369706|DEVICE|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
219255310|NCT04528953|BEHAVIORAL|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
219255311|NCT02315079|OTHER|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
219255312|NCT02315079|OTHER|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
219255313|NCT04018547|DEVICE|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
219255314|NCT04461184|BEHAVIORAL|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
219255315|NCT03097302|PROCEDURE|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
219255316|NCT04127019|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
219255317|NCT04127019|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
219255318|NCT04127019|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
219255319|NCT04127019|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
219255320|NCT04127019|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
219255321|NCT06477757|PROCEDURE|Minimally Invasive Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
219255322|NCT06477757|PROCEDURE|Conventional Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
219255323|NCT05668442|BEHAVIORAL|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
219255324|NCT01046071|PROCEDURE|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
219255325|NCT01046071|PROCEDURE|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
219255326|NCT03317899|PROCEDURE|Hematopoietic Cell Transplantation|Undergo auto HSCT
219255327|NCT03317899|DRUG|Tbo-filgrastim|Given subcutaneously
219255328|NCT03317899|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219255329|NCT01091844|PROCEDURE|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
219255330|NCT01552668|DRUG|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
219255331|NCT01552668|DRUG|Placebo|Receive Placebo twice daily
219255332|NCT01292317|OTHER|application of intravenous volume|weight based intravenous application of volume
219255333|NCT01292317|OTHER|oral fluid application|oral fluid application
219255334|NCT02747121|BEHAVIORAL|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
219255335|NCT03168425|OTHER|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
219255336|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
219255337|NCT00003402|DRUG|carmustine|
219255338|NCT00003402|DRUG|cisplatin|
219255339|NCT00003402|DRUG|cyclophosphamide|
219255340|NCT00003402|DRUG|dexamethasone|
219255341|NCT00003402|DRUG|etoposide|
219255342|NCT00003402|DRUG|melphalan|
219255343|NCT00003402|DRUG|paclitaxel|
219255344|NCT00003402|PROCEDURE|bone marrow ablation with stem cell support|
219255345|NCT00003402|PROCEDURE|peripheral blood stem cell transplantation|
219255346|NCT03089502|OTHER|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
219255347|NCT05743114|DEVICE|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
219255348|NCT02599870|GENETIC|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
219255349|NCT00546702|DRUG|Insuline Glulisine|
219255350|NCT02084355|DRUG|oral oxycodone|
219255351|NCT02084355|DRUG|oral hydromorphone|
219255352|NCT02084355|DRUG|fentanyl patch|
219255353|NCT05563428|PROCEDURE|Free gingival graft|A free gingival graft will be carried out for recession treatment.
219255354|NCT05563428|PROCEDURE|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
219255355|NCT00042302|PROCEDURE|Chemotherapy|
219255356|NCT00042302|DRUG|tariquidar + paclitaxel/carboplatin|
219255357|NCT00042302|DRUG|placebo + paclitaxel/carboplatin|
219255358|NCT03029234|DRUG|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
219255359|NCT03029234|DRUG|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
219255360|NCT04073849|DRUG|EPOGEN® (epoetin alfa)|Active drug
219255361|NCT04073849|OTHER|Normal Saline|Placebo
219255362|NCT02694588|DRUG|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
219255363|NCT02694588|DRUG|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
219255364|NCT00996619|PROCEDURE|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
219255365|NCT05740969|DRUG|5Fluorouracil|Cream
219255366|NCT05740969|DRUG|Imiquimod|Cream
219255367|NCT05740969|DRUG|Melatonin|Cream
219255368|NCT03700463|OTHER|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
219255369|NCT02812628|PROCEDURE|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
219255370|NCT02812628|PROCEDURE|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
219255371|NCT03638401|PROCEDURE|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
219255372|NCT02166047|DRUG|Vesatolimod|Vesatolimod tablet administered orally
219255373|NCT02166047|DRUG|Placebo|Placebo to match vesatolimod tablet administered orally
219255374|NCT06407947|DRUG|Chimeric antigen receptor modified T cells Infusion|chimeric antigen receptor T cells
219255375|NCT03389321|DRUG|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
219255376|NCT03389321|DRUG|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
219255377|NCT02324309|DRUG|BIOD-531|
219255378|NCT02324309|DRUG|Humalog Mix 75/25|
219255379|NCT02324309|DRUG|Humulin R U-500|
219255380|NCT02324309|DRUG|BIOD-531|
219255381|NCT00598286|DRUG|[18F]FMPEP-d2|
219255382|NCT01359514|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
219255383|NCT01359514|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
219255384|NCT01730742|BEHAVIORAL|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
219255385|NCT01730742|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
219255386|NCT01730742|PROCEDURE|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
219255387|NCT03296007|BEHAVIORAL|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
219255388|NCT04562714|DEVICE|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
219255389|NCT04562714|OTHER|Diabetes self-management education|"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
219255390|NCT05141071|DRUG|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
219255391|NCT05141071|DRUG|Placebo|50 ml of saline will be administrated enterally
219255392|NCT01165502|DRUG|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
219255393|NCT01165502|DRUG|Placebo|Placebo for compound CM3.1-AC100 s.c.
219255394|NCT04995406|DIAGNOSTIC_TEST|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
219255395|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
219255396|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
219255397|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
219255398|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
219255399|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
219255400|NCT01649297|DRUG|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
219255401|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
219255402|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
219255403|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
219255404|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
219255405|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
219255406|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
219255407|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
219255408|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
219255409|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
219255410|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
219255411|NCT01649297|DRUG|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
219255412|NCT01649297|DRUG|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
219255413|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
219255414|NCT01649297|DRUG|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
219255415|NCT02413554|DRUG|Rivastigmine patch|acetylcholine esterase inhibitor
219255416|NCT03230110|DIAGNOSTIC_TEST|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
219255417|NCT05009147|OTHER|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
219255418|NCT00507975|DRUG|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
219255419|NCT01839383|OTHER|different dialysate calcium concentration|
219255420|NCT03228654|PROCEDURE|Unipolar Electrocautery sealing of vessels|"1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
219255421|NCT03228654|PROCEDURE|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
219255422|NCT00465478|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
219255423|NCT04509414|DRUG|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
219255424|NCT04509414|DRUG|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
219255425|NCT02538718|DRUG|MgSO4|
219255426|NCT02538718|DRUG|YTP(Ritodrine)|
219255427|NCT04059497|BEHAVIORAL|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
219255428|NCT04059497|BEHAVIORAL|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w\_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
219255429|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
219255430|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
219255431|NCT01176435|DRUG|Placebo|Solution taken orally three times a day.
219255432|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
219255433|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
219255434|NCT02636751|BEHAVIORAL|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
219255435|NCT02636751|DEVICE|Walking aid adjustment|Walking aid adjustment
219255436|NCT02636751|BEHAVIORAL|Information about pain control|General information about pain control, such as ice application and medication usage
219255437|NCT03313583|PROCEDURE|Transfusion of blood products|
219255438|NCT03722797|PROCEDURE|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
219255439|NCT02676440|OTHER|Treatment|F13/T38
219255440|NCT02676440|OTHER|Comparator|M26
219255441|NCT01940523|DRUG|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
219255442|NCT01940523|DRUG|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
219255443|NCT02490878|DRUG|bevacizumab|IV
219255444|NCT02490878|DRUG|corticosteroids|IV
219255445|NCT02490878|OTHER|placebo|IV
219255446|NCT05433311|OTHER|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
219255447|NCT04665778|OTHER|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
219255448|NCT02541942|OTHER|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
219255449|NCT01020942|PROCEDURE|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
219255450|NCT01020942|PROCEDURE|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
219255451|NCT03298633|OTHER|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
219255452|NCT03298633|OTHER|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
219255453|NCT05425173|OTHER|Conventional treatment|Chest Physical Therapy as required
219255454|NCT05425173|OTHER|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
219255455|NCT03962478|DEVICE|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
219255456|NCT03962478|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
219255457|NCT05195450|DRUG|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
219255458|NCT03122483|DIAGNOSTIC_TEST|blood biomarker|
219255459|NCT00451555|DRUG|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
219255460|NCT00451555|DRUG|placebo|oral, daily
219255461|NCT00451555|DRUG|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
219255462|NCT04017949|DRUG|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
219255463|NCT03460496|BEHAVIORAL|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
219362914|NCT05410288|OTHER|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
219255464|NCT03460496|BEHAVIORAL|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
219255465|NCT03460496|BEHAVIORAL|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
219255466|NCT03460496|BEHAVIORAL|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
219255467|NCT03460496|BEHAVIORAL|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
219255468|NCT03460496|BEHAVIORAL|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
219255469|NCT03460496|BEHAVIORAL|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
219255470|NCT03460496|BEHAVIORAL|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
219255471|NCT03460496|BEHAVIORAL|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
219255472|NCT03988478|BEHAVIORAL|Detoxification & psychotherapeutic support|
219255473|NCT03430050|DRUG|Progesterone|Progesterone capsule
219255474|NCT03430050|DRUG|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
219255475|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #1|Main Hairfinity formulation
219255476|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #2|Variation to main formulation
219255477|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #3|Variation to main formulation
219255478|NCT03106792|DIETARY_SUPPLEMENT|Placebo|No active ingredients
219255479|NCT06047613|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
219255480|NCT06047613|OTHER|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
219255481|NCT06047613|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
219255482|NCT05514197|DRUG|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
219255483|NCT05514197|DRUG|Control Rx|Intravenous loading 100ml normal saline
219255484|NCT00922441|DRUG|Fimasartan 60 mg group|Fimasartan 60 mg
219255485|NCT00922441|DRUG|Fimasartan 120 mg group|Fimasartan 120 mg
219255486|NCT00922441|DRUG|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
219255487|NCT06320327|OTHER|Cannabidiol cream|Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
219255488|NCT06320327|OTHER|Placebo cream|Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
219255489|NCT05592236|OTHER|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
219255490|NCT05592236|OTHER|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
219255491|NCT03606850|DEVICE|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
219255492|NCT03391583|OTHER|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
219255493|NCT05042713|OTHER|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
219255494|NCT02723383|DRUG|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
219255495|NCT02723383|DRUG|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
219255496|NCT00000398|BEHAVIORAL|Coping skills training|
219255497|NCT00000398|BEHAVIORAL|Physical exercise training|
219255498|NCT00000398|BEHAVIORAL|Coping skills training plus physical exercise training|
219255499|NCT04486079|DIETARY_SUPPLEMENT|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
219255500|NCT05404698|OTHER|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
219255501|NCT05404698|OTHER|Control|CONT: participants will receive hemodialysis treatment only (usual care)
219255502|NCT05255198|PROCEDURE|Anterior versus lateral approach to hip joint|
219255503|NCT00543101|DRUG|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
219255504|NCT00543101|DRUG|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
219255505|NCT00828529|DRUG|TMC207|
219255506|NCT04664985|DEVICE|Mucogyne® ovule|hyaluronic acid, vaginal ovule
219255507|NCT00196118|DEVICE|Günther Tulip Vena Cava Filter|
219362915|NCT03718845|BEHAVIORAL|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
219362916|NCT02899858|OTHER|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
219255508|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
219255509|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
219255510|NCT05764590|DRUG|AP-306|A blood phosphorus lowering drug with a novel mechanism
219255511|NCT05764590|DRUG|Sevelamer Carbonate|A phosphate binder
219255512|NCT01364441|DRUG|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
219255513|NCT01364441|DRUG|Placebo|Placebo dosed in the same manner as ONO-2952
219255514|NCT02973477|DRUG|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
219255515|NCT02973477|DRUG|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
219255516|NCT02654457|PROCEDURE|Women with Breast Cancer|IVD Study
219255517|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
219255518|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
219255519|NCT03500263|DRUG|PTI-808|Active
219255520|NCT03500263|DRUG|Placebo|Placebo
219255521|NCT03500263|DRUG|PTI-801|Active
219255522|NCT03500263|DRUG|PTI-428|Active
219255523|NCT03500263|DRUG|Placebo|Placebo
219255524|NCT06111443|DRUG|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
219255525|NCT02223013|DRUG|BIBV 308 SE solution|
219255526|NCT02223013|DRUG|BIBV 308 SE capsule L|
219255527|NCT02223013|DRUG|BIBV 308 SE capsule S|
219255528|NCT06400264|PROCEDURE|Biopsy|Undergo biopsy
219255529|NCT06400264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219255530|NCT06400264|PROCEDURE|Computed Tomography|Undergo CT scan
219255531|NCT06400264|PROCEDURE|Echocardiography|Undergo ECHO
219255532|NCT06400264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219255533|NCT06400264|BIOLOGICAL|Nivolumab|Given IV
219255534|NCT06400264|BIOLOGICAL|Relatlimab|Given IV
219362917|NCT02899858|OTHER|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
219255535|NCT04857775|BEHAVIORAL|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
219255536|NCT06208800|OTHER|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
219255537|NCT03109652|DRUG|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
219255538|NCT03322852|OTHER|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
219255539|NCT02619305|OTHER|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
219255540|NCT02690493|PROCEDURE|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
219255541|NCT02690493|OTHER|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
219255542|NCT02690493|OTHER|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
219255543|NCT01834768|DRUG|Eplerenone|
219255544|NCT00991029|DRUG|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
219255545|NCT00991029|DRUG|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
219255546|NCT01318538|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
219255547|NCT01318538|BEHAVIORAL|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
219255548|NCT00317603|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
219255549|NCT03758703|OTHER|Pre-recorded music intervention group|Refer to the arm/group descriptions.
219255550|NCT03758703|OTHER|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
219255551|NCT00256347|DRUG|intramuscular injections of morphine|
219255552|NCT02359578|DRUG|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
219255553|NCT00523549|DRUG|valsartan|160 mg or 320 mg tablets once a day
219255554|NCT00523549|DRUG|amlodipine|5 mg or 10 mg tablets once a day
219255555|NCT05262465|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
219255556|NCT05262465|DRUG|Azacitidine|azacytidine 50-75mg/m2
219255557|NCT05262465|DRUG|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
219255558|NCT02664025|PROCEDURE|vaginal examination simulator|
219255559|NCT02487251|BEHAVIORAL|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
219255560|NCT02487251|BEHAVIORAL|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
219255561|NCT03987490|BEHAVIORAL|Text Message|Vaccine reminder notification sent via text
219255562|NCT03987490|BEHAVIORAL|PostCard|Vaccine reminder notification sent via standard mail
219255563|NCT03987490|BEHAVIORAL|Standard of Care|No additional information given to parents
219255564|NCT03987490|BEHAVIORAL|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
219255565|NCT05183321|PROCEDURE|periodontal therapy|periodontal cleaning
219255566|NCT02747719|BEHAVIORAL|Light and exercise|Exposure to light and exercise
219255567|NCT06247618|DEVICE|visor|The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
219255568|NCT05641714|OTHER|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
219255569|NCT05641714|OTHER|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
219255570|NCT05641714|OTHER|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
219255571|NCT05641714|OTHER|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
219255572|NCT05641714|OTHER|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
219255573|NCT00427778|DEVICE|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
219255574|NCT00439647|DRUG|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
219255575|NCT00439647|DRUG|Placebo|Placebo intravenous (i.v.) once a year
219255576|NCT00053352|PROCEDURE|conventional surgery|
219255577|NCT00053352|DRUG|cisplatin|Given IV
219255578|NCT00053352|DRUG|etoposide|Given IV
219255579|NCT00053352|BIOLOGICAL|bleomycin sulfate|Given IV
219255580|NCT00053352|OTHER|laboratory biomarker analysis|Correlative studies
219255581|NCT03068221|OTHER|anaerobic exercise|assessing anaerobic exercise status
219255582|NCT02624505|DRUG|90 mcg Reference Product|Drug: 90 mcg Reference Product
219255583|NCT02624505|DRUG|180 mcg Reference Product|Drug: 180 mcg of Reference Product
219255584|NCT02624505|DRUG|90 mcg Test Product|Drug: 90 mcg of Test Product
219255585|NCT02624505|DRUG|Placebo|Placebo Product
219255586|NCT01408875|DEVICE|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
219255587|NCT04883021|DEVICE|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
219255588|NCT02822209|BEHAVIORAL|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
219255589|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
219255590|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
219255591|NCT02822209|BEHAVIORAL|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
219255592|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
219255593|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
219255594|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
219255595|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
219255596|NCT02621502|DIETARY_SUPPLEMENT|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
219255597|NCT03287778|DIETARY_SUPPLEMENT|Pyridoxine|Max dose of 400 mg QD PO
219255598|NCT03287778|DIETARY_SUPPLEMENT|Placebo|Matching placebos will be administered.
219255599|NCT04112875|DIETARY_SUPPLEMENT|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
219255600|NCT04112875|DIETARY_SUPPLEMENT|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
219255601|NCT02694796|BEHAVIORAL|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
219255602|NCT02127489|DRUG|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
219255603|NCT00003597|BIOLOGICAL|recombinant human thrombopoietin|
219255604|NCT00003597|DRUG|carboplatin|
219255605|NCT00003597|DRUG|etoposide|
219255606|NCT00003597|DRUG|ifosfamide|
219255607|NCT00003597|BIOLOGICAL|G-CSF|
219255608|NCT04304313|DRUG|Sildenafil citrate tablets|0.1g/day for 14 days
219255609|NCT02315053|OTHER|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
219255610|NCT01781013|OTHER|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
219255611|NCT00554944|PROCEDURE|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
219255612|NCT00586118|DRUG|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
219255613|NCT00586118|DRUG|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
219255614|NCT00570921|DRUG|Everolimus|Everolimus tablets, two-5 mg tablets a day
219255615|NCT00570921|DRUG|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
219255616|NCT04651556|DRUG|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
219255617|NCT04651556|DRUG|paracetamol & ketorolac|parenteral analgesics
219255618|NCT04683211|OTHER|Evaluation of iodine supplementation|survey of iodine supplementation
219255619|NCT03442140|OTHER|Harmonica playing|Patients will play the harmonica for up to 6 months
219255620|NCT02013895|DEVICE|99mTc-GSA|
219255621|NCT04168021|BEHAVIORAL|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
219255622|NCT00392886|DRUG|carboplatin|Given IV
219255623|NCT00392886|DRUG|cisplatin|Given IV
219255624|NCT00392886|DRUG|cyclophosphamide|Given IV
219255625|NCT00392886|DRUG|etoposide|Given IV and orally
219255626|NCT00392886|DRUG|methotrexate|Given IV
219255627|NCT00392886|DRUG|temozolomide|Given orally
219255628|NCT00392886|DRUG|thiotepa|Given IV
219255629|NCT00392886|DRUG|vincristine sulfate|Given IV
219255630|NCT00392886|PROCEDURE|autologous bone marrow transplantation|Given on day 0
219255631|NCT00392886|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
219255632|NCT00392886|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
219255633|NCT00392886|RADIATION|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
219255634|NCT03781947|DRUG|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
219255635|NCT01792596|OTHER|Pasta with protein|Pasta with Protein
219255636|NCT01792596|OTHER|Pasta with Fiber|Pasta with Fiber
219255637|NCT01792596|OTHER|Pasta|Pasta
219255638|NCT04673877|DRUG|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
219255639|NCT04673877|PROCEDURE|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
219255640|NCT04673877|DRUG|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
219255641|NCT05321771|OTHER|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
219255642|NCT03411928|DEVICE|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
219255643|NCT05524415|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
219255644|NCT02380638|DEVICE|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
219255645|NCT02314585|OTHER|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
219255646|NCT02314585|OTHER|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
219255647|NCT06187597|DRUG|S-1|Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
219255648|NCT06187597|DRUG|Toripalimab|Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
219255649|NCT06187597|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
219255650|NCT05573347|PROCEDURE|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
219255651|NCT05573347|PROCEDURE|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
219255652|NCT03686618|DRUG|Secretin|Drug to stimulate pancreatic secretion
219255653|NCT05001997|DIETARY_SUPPLEMENT|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
219255654|NCT00108498|DRUG|mirtazapine|
219255655|NCT03616236|DRUG|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
219255656|NCT03616236|OTHER|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
219255657|NCT02832284|DEVICE|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
219255658|NCT03493568|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
219255659|NCT03493568|DRUG|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
219255660|NCT05896111|PROCEDURE|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
219255661|NCT00280709|DEVICE|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
219255662|NCT04300153|PROCEDURE|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
219255663|NCT04300153|OTHER|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
219255664|NCT04300153|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
219255665|NCT02802150|DIETARY_SUPPLEMENT|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
219255666|NCT02802150|DIETARY_SUPPLEMENT|Soy Bean Oil;placebo(4g/day)|parallel design
219255667|NCT02513979|DRUG|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
219255668|NCT00784277|DRUG|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
219255669|NCT00784277|DRUG|oxycodone IR|10mg for 14 days
219255670|NCT00784277|DRUG|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
219255671|NCT00784277|DRUG|Tapentadol IR (CG5503)|50mg for 14 days
219255672|NCT00784277|DRUG|Tapentadol IR (CG5503)|75mg for 14 days
219255673|NCT00784277|DRUG|placebo|1 capsule for 14 days
219255674|NCT00784277|DRUG|placebo|Tablets and capsules 2 x a day for 28 days
219255675|NCT00598637|DEVICE|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
219255676|NCT00598637|DEVICE|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
219255677|NCT03857737|PROCEDURE|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
219255678|NCT03857737|PROCEDURE|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
219255679|NCT05315817|DEVICE|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
219255680|NCT01585688|DRUG|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
219255681|NCT02222337|BEHAVIORAL|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
219255682|NCT03198351|DRUG|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
219255683|NCT00375583|DRUG|DEC/Albendazole|
219255684|NCT04052932|DRUG|SHR4640 dose1|tablets，dose1，QD
219255685|NCT04052932|DRUG|SHR4640 dose2|tablets，dose2，QD
219255686|NCT04052932|DRUG|Placebo oral tablet|tablets，QD
219255687|NCT04052932|DRUG|Allopurinol 300 MG|tablets，300mg，QD
219255688|NCT03013725|OTHER|No intervention|No intervention
219255689|NCT04785586|BEHAVIORAL|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
219255690|NCT04785586|BEHAVIORAL|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
219255691|NCT04785586|BEHAVIORAL|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
219255692|NCT02702739|DRUG|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
219255693|NCT01202669|OTHER|No intervention planned, observational study only.|No intervention planned, observational study only.
219255694|NCT00789932|BEHAVIORAL|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
219255695|NCT00789932|BEHAVIORAL|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
219255696|NCT05558098|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
219255697|NCT05558098|OTHER|Standard of Care|Current standard of care for management of critically ill patients
219255698|NCT04968015|DRUG|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
219255699|NCT04968015|DRUG|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
219255700|NCT04171921|PROCEDURE|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
219255701|NCT04171921|PROCEDURE|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
219255702|NCT00999141|BIOLOGICAL|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
219255703|NCT02781077|PROCEDURE|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
219255704|NCT01641627|PROCEDURE|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
219255705|NCT02113150|DRUG|remifentanil|renal function
219255706|NCT02113150|DRUG|Ketamine|renal function
219255707|NCT01262118|DRUG|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
219255708|NCT02046941|BEHAVIORAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
219255709|NCT00087477|DRUG|Pivanex|
219255710|NCT03545321|BEHAVIORAL|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
219255711|NCT03595137|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
219255712|NCT03595137|DEVICE|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
219255713|NCT00404508|DRUG|Hydralazine and magnesium valproate|
219255714|NCT02414555|DRUG|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
219255715|NCT02414555|DRUG|fluid bolus|
219255716|NCT02414555|DEVICE|oesophagus doppler (CardioQ)|
219255717|NCT02414555|DRUG|Normal Saline|
219255718|NCT02414555|DEVICE|arterial cannulation|
219255719|NCT02414555|DEVICE|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
219255720|NCT02414555|DRUG|Elo-Mel Isoton (balanced acetat-based infusate)|
219255721|NCT03041701|DRUG|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
219255722|NCT03041701|DRUG|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
219255723|NCT03041701|DRUG|Ganitumab|Once every 2 weeks beginning on day 0.
219255724|NCT00123019|BEHAVIORAL|Exercise and diet|Advice and measurement only
219255725|NCT00123019|BEHAVIORAL|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
219255726|NCT00123019|BEHAVIORAL|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
219255727|NCT00123019|BEHAVIORAL|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
219255728|NCT03722498|DRUG|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219255729|NCT03722498|DRUG|Sorafenib|administration of Sorafenib
219255730|NCT03569475|DRUG|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
219255731|NCT03569475|DRUG|Fluoxetine|Fluoxetine oral capsules
219255732|NCT03569475|DRUG|Placebo|Matching placebo oral capsules
219255733|NCT06485648|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Treatment: G(glucocorticoid) + i.v. uc-MSC (1×106 cells/Kg)
219255734|NCT06485648|DRUG|Normal saline|Control: G(glucocorticoid) + i.v. Normal saline
219255735|NCT03638258|DRUG|Roflumilast Cream 0.3%|Applied once daily for 12 weeks
219255736|NCT03638258|DRUG|Roflumilast Cream 0.15%|Applied once daily for 12 weeks
219255737|NCT03638258|DRUG|Vehicle Cream|Applied once daily for 12 weeks
219255738|NCT04238533|OTHER|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
219255739|NCT04238533|OTHER|Conventional training|Conventional training with Myoboy has been the only training available to users.
219255740|NCT02630706|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
219255741|NCT02630706|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
219255742|NCT02630706|DRUG|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
219255743|NCT02630706|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
219255744|NCT02630706|DRUG|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
219255745|NCT05122078|DEVICE|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
219255746|NCT05122078|OTHER|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
219255747|NCT03134547|DRUG|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
219255748|NCT03134547|DRUG|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
219255749|NCT04410549|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|To perform OCT in pulmonary artery of patient with COVID-19
219255750|NCT00216788|DRUG|Esomeprazole (Nexium) 40 mg/day|
219255751|NCT01678898|DRUG|PRX-102|
219255752|NCT00221156|DRUG|Acarbose|
219255753|NCT00915460|DRUG|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
219255754|NCT03489837|DRUG|Levotuss|oral taken
219255755|NCT04934878|BIOLOGICAL|Referral information|first visit to our hospital/transfer from another hospital
219255756|NCT00752999|DRUG|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
219255757|NCT00752999|DRUG|Placebo|Placebo tablet, oral, twice-a-day
219255758|NCT06453304|DRUG|Calcium Hydroxide|Intracanal medication
219255759|NCT06453304|DRUG|Leddermix|Intracanal medication
219255760|NCT06453304|DRUG|Glycirrhizin|Intracanal medication
219255761|NCT01953471|OTHER|Allergic rhinitis|Questionnaire
219255762|NCT05888558|DEVICE|Body fluid diagnosis|miRNAs derived from exosomes in the serum
219255763|NCT00224809|DRUG|Angiotensin-Converting Enzyme Inhibitors|
219255764|NCT00224809|PROCEDURE|Coronary Artery Bypass Graft|
219255765|NCT00224809|DRUG|Angiotensin Receptor Blockers|
219255766|NCT00224809|DRUG|Spironolactone|
219255767|NCT00224809|DRUG|Aspirin|
219255768|NCT00224809|DRUG|Clopidogrel|
219255769|NCT00224809|PROCEDURE|Surgical Ventricular Restoration|
219255770|NCT00549042|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
219255771|NCT00549042|DRUG|Placebo|Placebo
219255772|NCT00144716|DEVICE|Insect Repellent plus Insecticide Treated Net|
219255773|NCT04471480|DRUG|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
219255774|NCT04521933|OTHER|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
219255775|NCT03535493|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
219255776|NCT03535493|BEHAVIORAL|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
219255777|NCT03535493|BEHAVIORAL|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
219255778|NCT04675671|OTHER|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
219255779|NCT00703599|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
219255780|NCT02631616|DRUG|Somatostatin|Monthly injections of Somatostatin
219255781|NCT00068835|BEHAVIORAL|Lindamood-Bell training for dyslexia|
219255782|NCT01527500|DRUG|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
219255783|NCT01527500|DRUG|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
219255784|NCT01527500|DRUG|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
219255785|NCT04782596|PROCEDURE|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
219255786|NCT00672347|DRUG|Clonidine|1 mcg/kg
219255787|NCT00672347|DRUG|Morphine|20 mcg/kg
219255788|NCT00672347|DRUG|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
219255789|NCT00672347|DRUG|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
219255790|NCT00003924|BIOLOGICAL|recombinant interferon alfa|
219255791|NCT03521206|BEHAVIORAL|ACP+ programme|Training program for nursing home staff.
219255792|NCT04355052|DRUG|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
219255793|NCT04355052|DRUG|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
219255794|NCT03039088|OTHER|Follow-up after 12 weeks after TNF alpha blockers initiation|
219255795|NCT03790878|BEHAVIORAL|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
219255796|NCT03790878|BEHAVIORAL|Habituation|An exposure procedure that reduces emotional distress through habituation
219255797|NCT03790878|BEHAVIORAL|Control|No emotion regulation intervention, placebo
219255798|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
219255799|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
219255800|NCT04851171|PROCEDURE|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
219255801|NCT04851171|PROCEDURE|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
219255802|NCT03657537|DRUG|Ketone infusion|β-hydroxybutyrate is infused intravenously.
219255803|NCT03657537|DRUG|Saline infusion|saline is infused intravenously.
219255804|NCT00895089|DRUG|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
219255805|NCT00895089|DRUG|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
219255806|NCT00655083|DRUG|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
219255807|NCT00655083|DRUG|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
219255808|NCT00484172|PROCEDURE|blood draws|
219255809|NCT02541799|PROCEDURE|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
219255810|NCT02541799|PROCEDURE|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
219255811|NCT03078751|DRUG|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
219255812|NCT03078751|DRUG|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
219255813|NCT03078751|DRUG|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
219255814|NCT05666271|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
219255815|NCT06117761|OTHER|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
219255816|NCT06117761|OTHER|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
219255817|NCT06117761|OTHER|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
219255818|NCT02093117|PROCEDURE|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
219255819|NCT02093117|PROCEDURE|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
219255820|NCT02960334|DEVICE|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
219255821|NCT00198198|DRUG|Aripiprazole|
219255822|NCT04934124|DRUG|ITI-333|ITI-333 oral solution
219255823|NCT04934124|OTHER|Placebo|Matching placebo
219255824|NCT02900222|PROCEDURE|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
219255825|NCT03212950|DRUG|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
219255826|NCT03212950|DRUG|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
219255827|NCT04848103|BEHAVIORAL|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
219255828|NCT01174485|PROCEDURE|exercise|combined resistance and aerobic training
219362918|NCT02899858|PROCEDURE|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
219255829|NCT02947581|DRUG|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
219255830|NCT02947581|DRUG|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
219255831|NCT02174159|DRUG|Ulonivirine|MK-8507 administered as a single oral dose
219255832|NCT01845311|DEVICE|ReZolve2 Scaffold|
219255833|NCT01209286|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
219255834|NCT05257252|BEHAVIORAL|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
219255835|NCT04903847|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
219255836|NCT04903847|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
219255837|NCT02496143|DRUG|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
219255838|NCT02496143|DRUG|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
219255839|NCT05132530|BEHAVIORAL|yoga|yoga practice will be done two days a week for 10 weeks.
219255840|NCT04865614|DRUG|Etomidate|Use of etomidate
219255841|NCT04865614|DRUG|Sevoflurane|Use of sevoflurane
219255842|NCT05093023|GENETIC|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
219255843|NCT04136964|OTHER|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
219255844|NCT06337240|OTHER|Pelvic floor on COPD patients|"Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months."
219255845|NCT06337240|OTHER|Pilates exercises on COPD patients|"Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months."
219255846|NCT04255654|OTHER|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
219255847|NCT02108847|DRUG|.2% Ropivacaine|
219255848|NCT02108847|DRUG|Saline|
219255849|NCT02108847|PROCEDURE|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
219255850|NCT05095714|OTHER|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
219255851|NCT05095714|OTHER|Liver ultrasound|Half-yearly liver ultrasound
219255852|NCT01068223|DRUG|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
219255853|NCT01068223|DRUG|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
219255854|NCT01068223|DRUG|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
219255855|NCT04271566|BEHAVIORAL|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
219255856|NCT01705314|DIETARY_SUPPLEMENT|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
219255857|NCT01705314|DIETARY_SUPPLEMENT|placebo|7mls of placebo drops per week for 8 months.
219362919|NCT02899858|OTHER|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
219362920|NCT02899858|OTHER|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
219362921|NCT02899858|OTHER|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
219362922|NCT04267211|OTHER|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
219362923|NCT04267211|OTHER|Standard Prenatal Consult|Standard prenatal consult
219255858|NCT05127018|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
219255859|NCT02199249|DEVICE|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
219255860|NCT02199249|DEVICE|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
219255861|NCT06478056|PROCEDURE|pancreatectomy|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
219255862|NCT05414006|DRUG|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
219255863|NCT00457171|DRUG|GI-270384|
219255864|NCT05014906|DRUG|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
219255865|NCT05014906|DRUG|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
219255866|NCT03121040|DIETARY_SUPPLEMENT|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
219255867|NCT05150002|DEVICE|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
219255868|NCT06105996|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
219255869|NCT05756348|DEVICE|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
219255870|NCT05845099|DEVICE|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
219255871|NCT05845099|DEVICE|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
219255872|NCT01363297|DRUG|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
219255873|NCT00000441|DRUG|lorazepam (Ativan)|
219255874|NCT00000441|DRUG|carbamazepine (Tegretol)|
219255875|NCT02515097|DRUG|IDP-122 Lotion|Medicated topical lotion
219255876|NCT02515097|DRUG|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
219255877|NCT01624012|DEVICE|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
219255878|NCT01624012|DEVICE|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
219255879|NCT05813132|DRUG|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
219255880|NCT05813132|DRUG|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
219255881|NCT05383053|DEVICE|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
219255882|NCT00985530|DRUG|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
219255883|NCT00985530|DRUG|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
219255884|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
219255885|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
219255886|NCT02453802|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
219255887|NCT02453802|DRUG|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
219255888|NCT02453802|DRUG|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
219255889|NCT01914458|PROCEDURE|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
219255890|NCT00613132|DRUG|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
219255891|NCT05621746|DRUG|Esperoct|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
219255892|NCT04751019|DEVICE|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
219255893|NCT02709447|BEHAVIORAL|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
219255894|NCT02709447|BEHAVIORAL|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
219255895|NCT03601949|DEVICE|SInergy Cooled Radiofrequency|ablation of low back pain
219255896|NCT03601949|OTHER|Medical Management|physical therapy, medications, lifestyle changes
219255897|NCT02411214|OTHER|survey|questionnaire survey sent by regular mail for 3 groups
219255898|NCT00025545|DRUG|cyclophosphamide|
219255899|NCT00025545|DRUG|methotrexate|
219255900|NCT00025545|PROCEDURE|peripheral blood stem cell transplantation|
219255901|NCT00025545|RADIATION|radiation therapy|
219255902|NCT01393314|DEVICE|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
219362924|NCT00760981|DRUG|Imatinib|The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
219255903|NCT06264661|BEHAVIORAL|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
219255904|NCT00574171|DRUG|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
219255905|NCT00574171|DRUG|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
219255906|NCT02269683|PROCEDURE|Robot-assisted distal pancreatectomy|
219255907|NCT02269683|PROCEDURE|Laparoscopic distal pancreatectomy|
219255908|NCT02026505|DRUG|Bortezomib|
219255909|NCT00404599|DRUG|atrorvastatin 10mg|Atorvastatin 10 mg once a day
219255910|NCT00404599|DRUG|simvastatin 40mg|simvastatin 40mg once a day
219255911|NCT00405002|PROCEDURE|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
219255912|NCT05240664|BEHAVIORAL|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
219255913|NCT05240664|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
219255914|NCT06140485|DIETARY_SUPPLEMENT|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
219255915|NCT06140485|DRUG|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
219255916|NCT06116942|DEVICE|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
219255917|NCT06116942|DEVICE|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
219255918|NCT03652870|DRUG|Nortriptyline|A medication used to treat conditions such as depression
219255919|NCT03652870|DRUG|Escitalopram|A medication used to treat conditions such as depression
219255920|NCT03652870|DRUG|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
219255921|NCT05765838|DIAGNOSTIC_TEST|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255922|NCT05765838|DIAGNOSTIC_TEST|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255923|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255924|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255925|NCT05765838|DIAGNOSTIC_TEST|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255926|NCT05765838|DIAGNOSTIC_TEST|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255927|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255928|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255929|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255930|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255931|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255932|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
219255933|NCT04407533|OTHER|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
219255934|NCT01547182|BEHAVIORAL|Caloric restriction|Caloric restriction
219255935|NCT01547182|BEHAVIORAL|Aerobic Training|Walking
219255936|NCT01547182|BEHAVIORAL|Resistance Training|Lifting weights
219255937|NCT03505918|OTHER|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
219255938|NCT03927742|BEHAVIORAL|Shade + app with messaging|Shade wearable device and application with UV messaging activated
219255939|NCT03927742|BEHAVIORAL|Shape + app without messaging|Shade wearable device and application without UV messaging activated
219255940|NCT04027673|BEHAVIORAL|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
219255941|NCT04238130|DIAGNOSTIC_TEST|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
219255942|NCT04340466|OTHER|No intervention|No intervention
219255943|NCT02611921|DRUG|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
219255944|NCT02611921|DRUG|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
219255945|NCT03456635|OTHER|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
219255946|NCT05404126|OTHER|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
219255947|NCT04713813|OTHER|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
219255948|NCT04713813|OTHER|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
219255949|NCT00005968|DRUG|irofulven|
219255950|NCT01169571|DRUG|Dexmedetomidine|
219255951|NCT06584747|DIAGNOSTIC_TEST|PET scan|18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
219255952|NCT05583734|DEVICE|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
219255953|NCT03291873|PROCEDURE|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
219255954|NCT00523133|DRUG|naltrexone|50 mg naltrexone daily for 3 months
219255955|NCT00523133|DRUG|naltrexone|50 mg of naltrexone daily for 6 months
219255956|NCT00523133|BEHAVIORAL|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
219255957|NCT00523133|BEHAVIORAL|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
219255958|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
219255959|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
219255960|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
219255961|NCT01180790|DRUG|Placebo|Powder in capsule once daily
219255962|NCT01180790|DRUG|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
219255963|NCT01180790|DRUG|Ribavirin|400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
219255964|NCT02789098|OTHER|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
219255965|NCT01885377|OTHER|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
219255966|NCT01885377|OTHER|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
219255967|NCT01628783|DRUG|escitalopram 10 mg|orally once daily
219255968|NCT01628783|DRUG|Placebo|once daily
219255969|NCT04263883|DEVICE|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
219255970|NCT02517476|DIETARY_SUPPLEMENT|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
219255971|NCT02332434|OTHER|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
219255972|NCT00263783|DRUG|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
219255973|NCT03379909|DRUG|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
219255974|NCT05905445|DRUG|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
219255975|NCT04560192|BEHAVIORAL|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU."
219255976|NCT04560192|OTHER|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
219255977|NCT01189136|DEVICE|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
219255978|NCT01189136|OTHER|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
219255979|NCT04950049|DRUG|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
219255980|NCT04950049|OTHER|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
219255981|NCT04950049|OTHER|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
219255982|NCT04950049|OTHER|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
219255983|NCT04273854|DEVICE|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
219255984|NCT00273650|DRUG|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
219255985|NCT00273650|OTHER|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
219255986|NCT01064856|BIOLOGICAL|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
219255987|NCT01064856|BIOLOGICAL|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
219255988|NCT04115956|DRUG|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
219255989|NCT04115956|DRUG|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
219255990|NCT03427606|PROCEDURE|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
219255991|NCT03323814|DEVICE|Slow-wave optimization|employing sensory stimulation to enhance slow waves
219255992|NCT04870814|DEVICE|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
219255993|NCT04870814|DIAGNOSTIC_TEST|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
219255994|NCT04870814|OTHER|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
219255995|NCT02223299|DIETARY_SUPPLEMENT|L-tyrosine|6g/d daily for 30 days
219255996|NCT02223299|DIETARY_SUPPLEMENT|L-Tryptophan|2g/d daily for 30 days
219255997|NCT02223299|DRUG|deplin|15mg daily for 30 days
219255998|NCT02223299|OTHER|Placebo A|a sugar-pill that looks like a real medication
219255999|NCT02223299|OTHER|Placebo B|a sugar-pill that looks like a real medication
219256000|NCT02062671|PROCEDURE|renal denervation|
219256001|NCT05532618|PROCEDURE|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
219256002|NCT05532618|DRUG|Levobupivacaine|Levobupivacaine
219256003|NCT05532618|DRUG|Placebo|10 ml of sodium chloride 0.9%
219256004|NCT05709886|DEVICE|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
219256005|NCT01379989|DRUG|Carboplatin|Carboplatin AUC 5
219256006|NCT01379989|DRUG|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
219256007|NCT01379989|DRUG|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
219256008|NCT02207322|OTHER|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
219256009|NCT07000318|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
219256010|NCT04457011|DRUG|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
219256011|NCT04457011|DRUG|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
219256012|NCT04457011|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
219256013|NCT07000344|DRUG|Cohort 1 (triple-drug group)|"Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle.~Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred."
219256014|NCT07000344|DRUG|Cohort 2 (dual-drug group)|Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred.
219256015|NCT02074878|DRUG|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
219256016|NCT02074878|DRUG|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
219256017|NCT02074878|DRUG|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
219256018|NCT03302559|OTHER|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
219256019|NCT03302559|OTHER|Facial cleanser|Facial cleanser in the morning and in the evening.
219256020|NCT03302559|OTHER|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
219256021|NCT03302559|OTHER|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
219256022|NCT03302559|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
219256023|NCT02661581|BEHAVIORAL|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
219256024|NCT03713437|DIAGNOSTIC_TEST|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
219256025|NCT07007767|DRUG|sintilimab|"Sintilimab (anti-PD-1 monoclonal antibody) Specification: 100 mg/10 mL (10 mg/mL concentrated solution)~Administration:~Dose: 200 mg (fixed dose) Route: Intravenous (IV) infusion over 30-60 minutes Schedule: Day 1 of each 21-day cycle (Q3W)"
219256026|NCT07007767|DRUG|Bevacizumab Biosimilar|"Bevacizumab biosimilar (anti-VEGF monoclonal antibody) Specification: 100 mg/4 mL (25 mg/mL concentrated solution)~Administration:~Dose: 7.5 mg/kg (body weight-adjusted) Route: IV infusion Schedule: Day 1 of each 21-day cycle (Q3W)"
219256027|NCT07007767|DRUG|Decitabine|"Decitabine (hypomethylating agent) Specification: 10 mg lyophilized powder per vial~Administration:~Dose: 10 mg/m²/day (body surface area-adjusted) Route: IV infusion over 1 hour Schedule: Days 1-5 of each 21-day cycle (Q3W)"
219256028|NCT06611657|DRUG|Antirotinib hydrochloride|Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
219256029|NCT03770338|DRUG|Teriparatide|20ug dosage daily injection, 1-month preoperative
219256030|NCT03386799|DEVICE|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
219256031|NCT06719648|DEVICE|Acellular dermal matrix + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
219256032|NCT06719648|PROCEDURE|Connective Tissue graft + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
219256033|NCT06721078|BEHAVIORAL|Peer navigation effectiveness|To determine the effectiveness of peer navigation on viral suppression and retention in care among adolescents living with HIV in South Africa.
219256034|NCT06719921|PROCEDURE|AF ablation|"The primary ablation strategy for both groups will be pulmonary vein isolation (PVI).~Other additional ablation, including but not limited to linear ablation, complex fractionated atrial electrogram (CFAE) ablation, or superior vena cava (SVC) isolation is not recommended unless necessitated by one of the following:~* Documented atrial flutter (AFL) or atrial tachycardia (AT) observed during the procedure, or~* Arrhythmias originating from the specific region requiring intervention."
219256035|NCT06719921|OTHER|AF ablation in a non-fluoroscopic EP lab|This procedure will take place in a non-fluoroscopic lab.
219256036|NCT06719921|OTHER|AF ablation in a fluoroscopic lab|This procedure will take place in a fluoroscopic lab.
219256037|NCT06720532|DIAGNOSTIC_TEST|characterization of renal function.|Blood and urine sample collection
219256038|NCT06720532|DIAGNOSTIC_TEST|Handgrip strength test|Assess the peak isometric strength of the hand and forearm muscles, as well as their susceptibility to fatigue.
219256039|NCT06720532|DIAGNOSTIC_TEST|Questionaires|The questionnaires evaluate quality of life, psychological distress, fear of progression, frailty, pain, decision regret and treatment expectations.
219256040|NCT06720480|DIAGNOSTIC_TEST|Homglobin Electrophoresis|To diagnose thalassaemia \&amp;best method to control disease progress
219256041|NCT06721052|DRUG|meta-Peng block|The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.
219256042|NCT06721052|DRUG|Postoperative analgesia management|We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
219256043|NCT06721650|OTHER|Perturbation-Based Balance Training|Perturbation-based balance training (PBT; or reactive balance training or perturbation training) is balance training that uses repeated, externally applied mechanical perturbations to trigger rapid reactions to regain postural stability in a safe and controlled environment
219256044|NCT06721650|OTHER|the selected physical therapy exercise program|trunk control therapeutic exercise, static and dynamic balance treaining exercises
219256045|NCT06719843|BEHAVIORAL|ACT-based intervention|"Participants in the intervention group will receive the face-to-face ACT-based intervention weekly for 4 weeks (each session lasting approximately 90 minutes), with each group consisting of 6-8 older adults. The intervention consists of 4 sessions:~Session 1 (acceptance and cognitive fusion) Session 2 (contact with the present moment and self-as-context) Session 3 (values) Session 3 (committed action)"
219256046|NCT06720779|OTHER|TRAK physio knee prosthesis protocol|The exercise protocol designed for knee conditions is carried out through TRAK, the digital rehabilitation tool.
219256047|NCT06720779|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
219256048|NCT06720805|DRUG|Pentabiocel|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
219362925|NCT04336098|DRUG|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
219362926|NCT04336098|DRUG|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
219256049|NCT06720805|DRUG|Placebo|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
219256050|NCT00951171|PROCEDURE|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
219256051|NCT00951171|PROCEDURE|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
219256052|NCT00989898|OTHER|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
219256053|NCT03747614|DRUG|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
219256054|NCT03747614|DEVICE|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
219256055|NCT00746785|DRUG|2.5 mg Olanzapine|2.5 mg
219256056|NCT00746785|DRUG|5mg Olanzapine|5 mg
219256057|NCT00746785|DRUG|placebo|placebo
219256058|NCT04243122|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
219256059|NCT04243122|DRUG|Aspirin 81 mg|81mg once per day for 6 months Then treated \& followed up as per standard of care
219256060|NCT02137395|DRUG|Dexamethasone|dexamethasone administration, intravenously
219256061|NCT02137395|DRUG|Placebo|saline administration intravenously
219256062|NCT04860856|DRUG|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
219256063|NCT04860856|DRUG|Normal Saline|20ml of normal saline
219256064|NCT06274450|COMBINATION_PRODUCT|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
219256065|NCT06274450|OTHER|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
219256066|NCT00566839|PROCEDURE|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
219256067|NCT00566839|PROCEDURE|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
219256068|NCT02752217|OTHER|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
219256069|NCT02752217|OTHER|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
219256070|NCT03876002|DRUG|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
219256071|NCT00196378|DRUG|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
219256072|NCT00196378|OTHER|Placebo|1 tablet daily
219256073|NCT02645539|DEVICE|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
219256074|NCT05849324|DEVICE|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
219256075|NCT05849324|DEVICE|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
219256076|NCT00120185|DRUG|Interleukin-2|
219256077|NCT03015870|BEHAVIORAL|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
219256078|NCT03015870|BEHAVIORAL|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
219256079|NCT02783053|DRUG|Metformin|Metformin vs no metformin
219256080|NCT01533558|DRUG|caspofungin|normal dosage for caspofungin, not adapted for the study
219256081|NCT05549336|DRUG|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
219256082|NCT00012636|PROCEDURE|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
219256083|NCT01145820|DIETARY_SUPPLEMENT|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
219256084|NCT00318786|DRUG|biphasic insulin aspart|
219256085|NCT00791297|DRUG|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
219256086|NCT01016223|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
219256087|NCT01016223|DRUG|placebo|Matched placebo swallowed two puffs twice daily
219256088|NCT01754532|BIOLOGICAL|Hair Sample|Analysis of hair cortisol levels
219256089|NCT04302649|DRUG|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
219256090|NCT00113269|DRUG|basiliximab|IV
219256091|NCT00113269|DRUG|rabbit anti-thymocyte globulin|IV
219256092|NCT00113269|DRUG|tacrolimus|oral
219256093|NCT00113269|DRUG|alemtuzumab|Intravenous (IV)
219256094|NCT00113269|DRUG|mycophenolate mofetil|oral
219256095|NCT00113269|DRUG|steroids|IV and/or oral
219256096|NCT05812586|BIOLOGICAL|SCB-2019/Clover|SCB-2019/Clover Vaccine
219256097|NCT05812586|BIOLOGICAL|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
219256098|NCT05812586|BIOLOGICAL|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
219256099|NCT01796223|BEHAVIORAL|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
219256100|NCT01796223|BEHAVIORAL|Control|
219256101|NCT04804059|DRUG|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
219256102|NCT04804059|DRUG|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
219256103|NCT00356993|DRUG|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
219256104|NCT00356993|BEHAVIORAL|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
219362927|NCT04336098|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
219362928|NCT04336098|DRUG|Pembrolizumab|Pembrolizumab as an IV infusion .
219256105|NCT04947826|PROCEDURE|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
219256106|NCT04947826|DRUG|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
219256107|NCT04947826|DRUG|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
219256108|NCT04947826|DRUG|Placebo|Placebo
219256109|NCT04813432|DIAGNOSTIC_TEST|Computed Tomography of the Abdomen|"Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.~Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.~Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.~Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase."
219256110|NCT04315129|DIAGNOSTIC_TEST|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
219256111|NCT04764201|DRUG|HIP2001|Test drug
219256112|NCT04764201|DRUG|HGP2001|Reference drug
219256113|NCT00461643|DRUG|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
219256114|NCT05827770|DRUG|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
219256115|NCT05651113|OTHER|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
219256116|NCT05076188|DIAGNOSTIC_TEST|Emergency radiography|The intervention is to determine how the radiographer classify emergency radiography.
219256117|NCT02028247|BEHAVIORAL|Personalized Cognitive-behavioral therapy|
219256118|NCT02028247|BEHAVIORAL|Standard Practice Cognitive-behavioral therapy|
219256119|NCT02028247|BEHAVIORAL|Treatment as Usual|
219256120|NCT05411874|DRUG|Chidamide|5mg po biw for 24 weeks
219256121|NCT05411874|DRUG|HD-DXM|40mg po qd for 4days
219256122|NCT00966979|DEVICE|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
219256123|NCT00092326|DRUG|MK0966, rofecoxib|
219256124|NCT00092326|DRUG|Comparator: oxycodone with acetaminophen, placebo|
219256125|NCT02993536|OTHER|Biospecimen Collection|
219256126|NCT04735783|DIETARY_SUPPLEMENT|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
219256127|NCT04735783|DIETARY_SUPPLEMENT|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
219256128|NCT04735783|DIETARY_SUPPLEMENT|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
219256129|NCT00636480|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
219256130|NCT00636480|DRUG|ChloraPrep One Step|Administer topically
219256131|NCT00636480|DRUG|Sterile saline|0.9% NaCl solution
219256132|NCT02718547|DRUG|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
219256133|NCT01542554|OTHER|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
219256134|NCT01542554|OTHER|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
219256135|NCT02024659|DRUG|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
219256136|NCT02024659|OTHER|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
219256137|NCT04140266|DRUG|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
219256138|NCT04140266|DRUG|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
219256139|NCT05431998|PROCEDURE|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement
219256140|NCT05431998|PROCEDURE|the use of autogenous bone graft in the jumping gap during immediate implant placement|the use of autogenous bone graft in the jumping gap during immediate implant placement
219256141|NCT01318317|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
219256142|NCT01318317|BIOLOGICAL|Filgrastim|Given IV
219256143|NCT01318317|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR
219256144|NCT01318317|OTHER|Laboratory Biomarker Analysis|Correlative studies
219256145|NCT01318317|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
219256146|NCT01318317|DRUG|Plerixafor|Given IV
219256147|NCT01318317|BIOLOGICAL|Rituximab|Given IV
219256148|NCT06308731|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Energy drink with 200 mg caffeine
219256149|NCT06308731|OTHER|Placebo|Placebo
219256150|NCT05484895|BEHAVIORAL|WeTest-WeLink|"WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST."
219256151|NCT05484895|BEHAVIORAL|Control condition|Contact information of local NGO for emergency referrals; free additional HST.
219256152|NCT04978428|DRUG|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
219362929|NCT05436548|OTHER|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
219256153|NCT05045950|DRUG|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
219256154|NCT05045950|RADIATION|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
219256155|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
219256156|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
219256157|NCT05645900|BIOLOGICAL|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
219256158|NCT06146790|PROCEDURE|endovascular treatment|For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
219256159|NCT06146790|OTHER|Standard medical management|Standard medical management
219256160|NCT01912183|BEHAVIORAL|Communication through PHR outside clinic|
219256161|NCT01912183|BEHAVIORAL|Monitoring device in PHR|
219256162|NCT01912183|DEVICE|Physical activity and sleep monitor|
219256163|NCT01912183|OTHER|PHR|Access to their PHR
219256164|NCT01859221|RADIATION|Stereotactic radiation|Stereotactic radiation
219256165|NCT04782700|OTHER|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
219256166|NCT01307917|DIETARY_SUPPLEMENT|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
219256167|NCT03738098|BEHAVIORAL|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
219256168|NCT03738098|BEHAVIORAL|GUÍA|GUÍA for the ROR1 visit.
219256169|NCT05259397|DRUG|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
219256170|NCT05259397|DRUG|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
219256171|NCT06168422|DEVICE|DES|drug eluting stent
219256172|NCT06168422|DEVICE|DCB|drug-coated balloon
219256173|NCT04018885|DRUG|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
219256174|NCT04018885|DRUG|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
219256175|NCT04018885|DRUG|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
219256176|NCT03511378|DRUG|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
219256177|NCT03511378|DRUG|Neulasta®|Administration of Neulasta®
219256178|NCT00522717|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
219256179|NCT00522717|BEHAVIORAL|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
219256180|NCT06311747|BEHAVIORAL|Oculo-motor exercises|Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
219362930|NCT05436548|OTHER|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
219256181|NCT06957353|PROCEDURE|oblique K-wire technique in controlling Calcaneal displacement during osteotomy in flatfoot correction|Under spinal Anaesthesia , patients will placed in lateral decubitus position. A standard lateral incision will be made over the calcaneus, and the osteotomy site will be exposed. An oblique K-wire will be inserted percutaneously into the posterior calcaneus under fluoroscopic guidance to facilitate the desired displacement. Cannulated screws will then be inserted across the osteotomy site to secure the calcaneal fragment. Post-operative care will include a non-weight bearing protocol for six weeks, followed by gradual weight bearing as tolerated.
219256182|NCT05249309|DRUG|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
219256183|NCT03293472|DRUG|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
219256184|NCT03293472|DRUG|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
219256185|NCT05251857|BEHAVIORAL|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
219256186|NCT02446379|DRUG|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
219256187|NCT02446379|DEVICE|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
219256188|NCT02446379|DEVICE|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
219256189|NCT01124214|PROCEDURE|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
219256190|NCT03433183|DRUG|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
219256191|NCT03433183|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
219256192|NCT00035802|DRUG|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
219256193|NCT00035802|DRUG|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
219256194|NCT03067363|DRUG|MOR107|MOR107 solution for injection
219256195|NCT03067363|DRUG|Placebo|Solution for injection manufactured to match MOR107 solution for injection
219256196|NCT03067363|OTHER|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
219256197|NCT00333281|DRUG|tadalafil|
219256198|NCT02921152|PROCEDURE|bone marrow aspiration /trephine biopsy|
219256199|NCT00866164|DEVICE|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
219256200|NCT05495919|OTHER|Control|No intervention was perfomed to reduce anxiety in control group
219256201|NCT05495919|OTHER|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
219256202|NCT05495919|OTHER|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
219256203|NCT01243411|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
219256204|NCT03299127|BEHAVIORAL|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
219256205|NCT06426095|BEHAVIORAL|Group A (instructional video),|Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars.
219256206|NCT06426095|BEHAVIORAL|Group B (live demonstration)|Participants in Group B were provided with live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique
219256207|NCT06426095|BEHAVIORAL|Group C (hybrid)|Group C received a dual approach, combining instructional video guidance with live demonstrations.
219256208|NCT03404050|OTHER|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
219256209|NCT00685425|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
219256210|NCT00685425|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
219256211|NCT02805036|DEVICE|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
219256212|NCT02805036|DEVICE|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
219256213|NCT06123949|DEVICE|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
219256214|NCT00510198|DEVICE|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
219256215|NCT00510198|DEVICE|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
219256216|NCT00245245|DRUG|recombinant porcine coagulation factor VIII (OBI-1)|
219256217|NCT00637247|DRUG|imexon in combination with gemcitabine|875 mg/m\^2 imexon IV + 1000 mg/m\^2 gemcitabine IV
219256218|NCT00637247|DRUG|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m\^2 gemcitabine IV
219256219|NCT02179853|DRUG|Anakinra|First two doses IV followed by SQ dosing
219256220|NCT00488319|DRUG|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
219256221|NCT00629317|OTHER|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
219256222|NCT00629317|DRUG|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
219256223|NCT04648111|DIAGNOSTIC_TEST|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
219256224|NCT04838964|DRUG|MRG003|Administrated intravenously
219256225|NCT02927899|OTHER|Survey Administration|Ancillary studies
219256226|NCT02927899|DIETARY_SUPPLEMENT|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
219256227|NCT00562185|DRUG|carboplatin|
219256228|NCT00562185|DRUG|doxorubicin hydrochloride|
219256229|NCT04372537|BEHAVIORAL|hypnosis|use of hypnosis.
219256230|NCT04372537|BEHAVIORAL|standard care|standard clinical procedure
219256231|NCT02762292|DEVICE|Measurement of work of breathing using indirect calorimeter|"1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
219256232|NCT00146198|DRUG|ALGRX 4975|
219256233|NCT03823274|DRUG|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
219256234|NCT05383105|PROCEDURE|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
219256235|NCT01649557|DRUG|OPC-34712|oral administered once daily
219256236|NCT04361968|OTHER|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
219256237|NCT04361968|OTHER|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
219256238|NCT04361968|OTHER|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
219256239|NCT04361968|OTHER|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
219362931|NCT06381661|DRUG|Tocilizumab|8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
219256240|NCT06370117|BEHAVIORAL|Buzzy|Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
219256241|NCT06370117|BEHAVIORAL|Music video listening|Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure.
219256242|NCT06370117|BEHAVIORAL|Buzzy+ Music video listening|60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool. 60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed midway between the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
219256243|NCT05501782|OTHER|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
219256244|NCT04016350|BEHAVIORAL|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
219256245|NCT04016350|BEHAVIORAL|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
219256246|NCT04700488|DIAGNOSTIC_TEST|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
219256247|NCT02444351|DRUG|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
219256248|NCT02444351|OTHER|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
219256249|NCT02958059|BIOLOGICAL|Pacetin® (cefoxitin)|1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
219256250|NCT02958059|BIOLOGICAL|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
219256251|NCT01763645|DRUG|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
219256252|NCT01763645|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
219256253|NCT01763645|DRUG|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
219256254|NCT01529541|DRUG|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
219256255|NCT01529541|DRUG|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
219256256|NCT02994264|RADIATION|adjuvant concurrent chemoradiation|
219256257|NCT02544113|DRUG|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
219256258|NCT02544113|DRUG|Placebo|Normal transplant immunosuppression
219256259|NCT01750177|BEHAVIORAL|Television Viewing before mealtime|
219256260|NCT01750177|BEHAVIORAL|Video Game Playing|
219256261|NCT01750177|BEHAVIORAL|Computer Use|
219256262|NCT01750177|BEHAVIORAL|Sitting quietly|
219256263|NCT06259513|PROCEDURE|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
219362932|NCT06381661|DRUG|Baricitinib|4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
219362933|NCT06381661|DRUG|Anakinra|100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
219362934|NCT06381661|DRUG|Hydrocortisone|50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
219256264|NCT02950714|OTHER|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
219256265|NCT02950714|OTHER|LIN_WAIT|Usual care for three months prior to access to the LIN
219256266|NCT01661530|DIETARY_SUPPLEMENT|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
219256267|NCT01661530|DIETARY_SUPPLEMENT|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
219256268|NCT02847637|DRUG|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
219256269|NCT02847637|DRUG|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
219256270|NCT01457833|DEVICE|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
219362935|NCT06381661|DRUG|Hydrocortisone and fludrocortisone|Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
219256271|NCT01457833|DEVICE|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
219256272|NCT04929054|DIAGNOSTIC_TEST|imaging|ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules
219256273|NCT04177628|BEHAVIORAL|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
219256274|NCT00026013|DRUG|hypericum perforatum|
219256275|NCT04232800|DRUG|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
219256276|NCT04232800|OTHER|Placebo|An inert, standard placebo in identical capsules to primary intervention.
219256277|NCT00563745|DEVICE|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
219256278|NCT06090019|BEHAVIORAL|Routine PICU nursing care for children on mechanical ventilator.|Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
219256279|NCT06090019|BEHAVIORAL|Self-instructional module for VAP care bundle prevention|Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
219256280|NCT04228900|DIETARY_SUPPLEMENT|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
219256281|NCT04228900|DRUG|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
219256282|NCT02845713|DRUG|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
219256283|NCT06339814|OTHER|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
219256284|NCT06339814|OTHER|Treatment As Usual|Treatment As Usual condition will receive only standard support.
219256285|NCT05282641|DIETARY_SUPPLEMENT|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
219256286|NCT05282641|DIETARY_SUPPLEMENT|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
219256287|NCT02494752|PROCEDURE|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
219256288|NCT02494752|PROCEDURE|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
219256289|NCT01388478|DRUG|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
219256290|NCT04150185|PROCEDURE|Donor hepatectomy|
219256291|NCT01990664|DEVICE|senofilcon A|
219256292|NCT01990664|DEVICE|senofilcon A for Astigmatism|
219256293|NCT04959461|BEHAVIORAL|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
219256294|NCT04959461|BEHAVIORAL|Usual Care|6 hours of driver education
219256295|NCT05767814|OTHER|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
219256296|NCT00221702|DRUG|PegIntron|100 mcg SC/week for 36 months
219256297|NCT00221702|DRUG|intron A|3mui TIWW SC for 18 months
219256298|NCT00931918|DRUG|Bortezomib|Bortezomib IV
219256299|NCT00931918|DRUG|Rituximab|Rituximab IV
219256300|NCT00931918|DRUG|Cyclophosphamide|Cyclophosphamide IV
219256301|NCT00931918|DRUG|Doxorubicin|Doxorubicin IV solution
219256302|NCT00931918|DRUG|Vincristine|Vincristine IV
219256303|NCT00931918|DRUG|Prednisone|Prednisone tablet
219256304|NCT03433209|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
219256305|NCT03433209|DEVICE|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
219256306|NCT03882996|DRUG|Ezetimibe|Ezetimibe 10 mg daily in the morning
219256307|NCT03882996|DRUG|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
219256308|NCT02764177|DIETARY_SUPPLEMENT|Protein drink|The protein drink was administered during this trial
219256309|NCT02764177|DIETARY_SUPPLEMENT|Carbohydrate drink|The carbohydrate drink was administered in this trial
219256310|NCT04724005|OTHER|No drug|No drug used
219256311|NCT00131898|PROCEDURE|Surgical Resection|
219256312|NCT00131898|PROCEDURE|Intensity Modulated Radiation Therapy (IMRT)|
219256313|NCT06118177|PROCEDURE|connective tissue harvesting|The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of canine and the mesial of first molar in the palate. Connective tissue dimensions were approximately 10 × 5 × 2 mm. Finally, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture
219256314|NCT06118177|DIAGNOSTIC_TEST|ultrasonography|A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the donor site in the palatal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit: Pulsality index (PI) = (Vmax-Vmin)/(Vmean) (Vmax is peak systolic flow velocity, Vmin is diastolic flow velocity and Vmean is mean flow velocity). The mean PI values of each patient were measured.
219256315|NCT06118177|OTHER|autolog platelet rich fibrin application|Leukocyte rich PRF (L-PRF) was obtained with the centrifugation of the two tubes at 2800 rpm for 12 minutes. After centrifugation, L-PRF clots were taken from the tubes using sterile tweezers, separated from the red blood cell base using scissors. Then L-PRF membrane was placed into the donor site.
219256316|NCT01019798|DRUG|sunitinib, docetaxel, cisplatin|"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"
219256317|NCT05887206|OTHER|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
219256318|NCT02388399|PROCEDURE|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)
219256319|NCT02388399|PROCEDURE|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
219256320|NCT00588341|DRUG|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
219256321|NCT03230071|DRUG|TMBCZG|0.1g per pill which contains 14mg TMBCZG
219256322|NCT03230071|OTHER|placebo|0.1g per pill which contains 0mg TMBCZG
219256323|NCT00543166|DRUG|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
219256324|NCT03435809|PROCEDURE|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
219256325|NCT00347802|DRUG|Bimatoprost 0.03%, Travoprost 0.004%|
219256326|NCT01039558|DRUG|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
219256327|NCT01039558|DRUG|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
219256328|NCT01039558|DRUG|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
219256329|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
219256330|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
219256331|NCT00983424|DRUG|Cyclosporins|dose escalation, administered orally twice a day
219256332|NCT00983424|DRUG|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
219256333|NCT03121599|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
219256334|NCT05245084|DRUG|CKD-386(3)|QD, PO
219256335|NCT05245084|DRUG|D013, D326, D337|QD, PO
219256336|NCT01372202|DRUG|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
219256337|NCT01372202|DRUG|Cisplatin|"Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29."
219256338|NCT01372202|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
219256339|NCT01372202|DRUG|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29."
219256340|NCT01372202|RADIATION|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
219256341|NCT01372202|PROCEDURE|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
219256342|NCT05662683|OTHER|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
219256343|NCT05662683|OTHER|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
219256344|NCT05662683|OTHER|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
219256345|NCT05924048|OTHER|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
219256346|NCT03504371|DEVICE|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
219256347|NCT03504371|DEVICE|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
219256348|NCT00658983|OTHER|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
219256349|NCT00658983|OTHER|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
219256350|NCT06277024|DRUG|Combination of Cardonizumab with Lenvatinib and SOX regimen|"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."
219256351|NCT04433286|OTHER|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
219256352|NCT03936075|BEHAVIORAL|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
219256353|NCT03936075|BEHAVIORAL|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
219256354|NCT00948103|DRUG|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
219256355|NCT00948103|DRUG|Oxygen|oxygen
219256356|NCT03305471|DRUG|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
219256357|NCT03305471|DRUG|Placebo|Placebo matching stock solution in bottle
219256358|NCT03305471|DRUG|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
219256359|NCT03305471|DRUG|DS-2330b Tablet|DS-2330b as tablet formulation
219256360|NCT01580007|DRUG|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
219256361|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
219256362|NCT01580007|DRUG|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
219256363|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
219256364|NCT02057302|DRUG|Xuezhikang capsule|
219362936|NCT06381661|DRUG|Heparin|Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
219362937|NCT06381661|DRUG|Low molecular weight heparin|Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
219256365|NCT05784649|OTHER|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
219362938|NCT06381661|DRUG|Recombinant humanThrombomodulin( rhTM)|Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
219362939|NCT06381661|DRUG|Sivelestat|0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)
219362940|NCT06381661|BIOLOGICAL|Fresh frozen plasma|12 ml/kg/day as long as INR remains \>1.4
219256366|NCT05784649|BEHAVIORAL|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
219256367|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
219256368|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
219256369|NCT04998097|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
219256370|NCT04998097|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
219256371|NCT01561885|OTHER|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
219256372|NCT02929316|DRUG|Vedolizumab|IV infusion week 0, 2 and 6
219256373|NCT03994341|DIAGNOSTIC_TEST|A FLIR Thermovision a320M thermal IR camera|"1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on."
219256374|NCT03719118|GENETIC|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
219256375|NCT03719118|OTHER|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
219256376|NCT06329271|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
219256377|NCT00913783|DRUG|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
219256378|NCT00913783|DRUG|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
219256379|NCT00033189|DRUG|Coenzyme Q10|
219256380|NCT02025985|DRUG|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
219256381|NCT05235776|OTHER|observation|observation
219256382|NCT02865759|BEHAVIORAL|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
219256383|NCT00585208|DRUG|Ramelteon|Ramelteon 8mg daily
219256384|NCT00585208|DRUG|Placebo|matching placebo for ramelteon 8mg daily
219256385|NCT00745121|DEVICE|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
219256386|NCT03628456|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
219256387|NCT03628456|DEVICE|Hill-Rom Monarch|High-frequency chest wall oscillation vest
219256388|NCT03709485|OTHER|rectal swab for microbial culture.|Rectal swab and culture.
219256389|NCT04961983|BEHAVIORAL|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months."
219256390|NCT03723915|BIOLOGICAL|Pembrolizumab|Given IV
219256391|NCT03723915|BIOLOGICAL|Wild-type Reovirus|Given pelareorep IV
219256392|NCT00989313|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
219256393|NCT01527903|DRUG|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
219256394|NCT01527903|DRUG|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
219256395|NCT05625568|DRUG|VYNT-0126|Liquid for oral administration once daily
219256396|NCT05625568|DRUG|Placebo|Liquid for oral administration once daily
219256397|NCT04577976|DEVICE|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
219256398|NCT00799136|DRUG|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
219256399|NCT04612478|BEHAVIORAL|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
219256400|NCT04612478|BEHAVIORAL|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
219256401|NCT03497221|BEHAVIORAL|Education intervention|The same description of arm Education intervention.
219256402|NCT03497221|BEHAVIORAL|Visual identity campaign|The same description of arm Visual identity campaign.
219256403|NCT03510377|OTHER|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
219256404|NCT03510377|OTHER|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
219256405|NCT03510377|OTHER|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
219256406|NCT01576913|OTHER|Music listening|Listening to tempo music while cycling in an exercise test
219256407|NCT05742659|OTHER|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
219256408|NCT01558778|PROCEDURE|management of therapy complications|Undergo mechanical stimulation
219256409|NCT01558778|PROCEDURE|musculoskeletal complications management/prevention|Undergo mechanical stimulation
219256410|NCT00873678|BIOLOGICAL|Whole blood sample|Whole blood sample (10 ml)
219256411|NCT02535962|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
219256412|NCT02535962|OTHER|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
219256413|NCT01744756|DRUG|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
219256414|NCT03756922|DRUG|FDL169|CFTR corrector
219256415|NCT03756922|DRUG|FDL176|CFTR potentiator
219256416|NCT05092776|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
219256417|NCT05092776|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
219256418|NCT01961921|DRUG|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
219256419|NCT01673295|DRUG|RTX infusions|RTX + Standard of Care
219256420|NCT01673295|OTHER|Standard of Care|Standard of Care only
219256421|NCT03023852|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
219362941|NCT06381661|OTHER|Usual care|Usual care
219362942|NCT00603135|DRUG|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
219256422|NCT03023852|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
219256423|NCT05143879|DIETARY_SUPPLEMENT|Citrulline|3 g/day during 9 weeks
219256424|NCT05143879|DIETARY_SUPPLEMENT|Nitrate|300 mg/day during 9 weeks
219256425|NCT05143879|DIETARY_SUPPLEMENT|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
219256426|NCT05143879|DIETARY_SUPPLEMENT|Placebo|3 g/day during 9 weeks
219256427|NCT04761341|DRUG|NUTROF TOTAL|1 per day over a course of 3 months
219256428|NCT00418418|PROCEDURE|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
219256429|NCT00418418|PROCEDURE|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
219256430|NCT00418418|BIOLOGICAL|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
219256431|NCT00418418|BIOLOGICAL|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
219256432|NCT05866341|DIETARY_SUPPLEMENT|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
219256433|NCT05866341|DIETARY_SUPPLEMENT|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
219256434|NCT00120822|DRUG|Folic acid|
219256435|NCT01650935|BEHAVIORAL|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
219256436|NCT01156402|BEHAVIORAL|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
219256437|NCT03598725|DRUG|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
219256438|NCT03598725|DRUG|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
219256439|NCT03598725|DRUG|Rituximab|375mg/Square meter for consecutive 4 months
219256440|NCT04967586|OTHER|No intervention, questioner only|questioner only
219256441|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
219256442|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
219256443|NCT03800485|DEVICE|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
219256444|NCT04723732|DRUG|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
219256445|NCT04723732|DRUG|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
219256446|NCT04723732|DRUG|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
219256447|NCT05024409|DEVICE|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
219256448|NCT05024409|OTHER|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
219256449|NCT00604513|OTHER|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
219256450|NCT00604513|OTHER|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
219256451|NCT01187407|DRUG|LY2216684|
219256452|NCT01187407|DRUG|Placebo|
219256453|NCT01187407|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
219256454|NCT03195049|DIAGNOSTIC_TEST|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
219256455|NCT02873325|OTHER|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
219256456|NCT04491084|DRUG|FLT3 Ligand (CDX-301)|Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.
219362943|NCT04478825|DRUG|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
219256457|NCT04491084|BIOLOGICAL|anti-CD40 antibody (CDX-1140)|CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
219256458|NCT04491084|RADIATION|SBRT|For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
219256459|NCT06245161|DEVICE|Quicksleeper5|intraosseous anesthesia for dental treatment
219256460|NCT06245161|DEVICE|conventional anesthesia|inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
219256461|NCT00003478|PROCEDURE|conventional surgery|
219256462|NCT00003478|RADIATION|iodine I 131 monoclonal antibody 81C6|
219256463|NCT00003478|RADIATION|radiation therapy|
219256464|NCT04878575|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
219256465|NCT04878575|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
219256466|NCT00238498|DRUG|vildagliptin|
219256467|NCT03951012|PROCEDURE|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
219256468|NCT05725733|OTHER|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
219256469|NCT06162065|DRUG|Oxybutynin Pill|pharmacological antimuscarinic treatment
219256470|NCT06162065|DIETARY_SUPPLEMENT|Boldo supplement|treatment supplemented with boldo
219256471|NCT02949076|BEHAVIORAL|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
219256472|NCT01713998|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
219256473|NCT03644706|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
219256474|NCT03644706|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
219256475|NCT04233502|DRUG|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
219256476|NCT04233502|DRUG|Placebo|Placebo melatonin
219256477|NCT04260399|OTHER|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
219256478|NCT04260399|OTHER|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
219256479|NCT04788966|DEVICE|the translation tool BabelDr|Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
219256480|NCT02101268|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
219256481|NCT02101268|DRUG|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
219256482|NCT02287740|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
219256483|NCT02287740|BEHAVIORAL|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
219256484|NCT02287740|BEHAVIORAL|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
219256485|NCT02719925|OTHER|Mg(+)|"* 1,5 L per day during 30 days~* No livestyle counseling"
219256486|NCT02719925|OTHER|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
219256487|NCT00740870|DEVICE|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
219256488|NCT02785445|DEVICE|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
219256489|NCT02785445|DEVICE|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
219256490|NCT02831998|DRUG|ZuraPrep|Apply topically.
219256491|NCT02831998|DRUG|ChloraPrep|Apply topically.
219256492|NCT02831998|DRUG|ZP Vehicle|Apply topically.
219256493|NCT01092988|DEVICE|Exablate 2100|MR guided focused ultrasound
219256494|NCT02222961|DRUG|BIIR 561 CL|
219256495|NCT02222961|DRUG|Placebo|
219256496|NCT01659047|DRUG|GS-1101|150 mg taken twice daily by mouth
219256497|NCT04970693|DRUG|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
219256498|NCT02028468|PROCEDURE|hemiarthroplasty|
219256499|NCT00177385|BEHAVIORAL|Modest sleep deprivation with sleep hygiene education|
219256500|NCT02892864|OTHER|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
219256501|NCT02892864|OTHER|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
219256502|NCT00488228|BEHAVIORAL|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
219256503|NCT05447728|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
219256504|NCT05447728|DIAGNOSTIC_TEST|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
219256505|NCT02109861|DRUG|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
219256506|NCT02109861|DRUG|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
219256507|NCT02109861|DRUG|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
219256508|NCT01677949|DRUG|Clofarabine|Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours
219256509|NCT01677949|DRUG|Etoposide|Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
219256510|NCT01677949|DRUG|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
219256511|NCT01677949|BIOLOGICAL|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
219256512|NCT05324007|OTHER|Basic Science|This is a basic science experiment to test whether infants' looking time to video stimuli differ according to the race of the individuals shown.
219256513|NCT02350855|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
219256514|NCT02350855|OTHER|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
219256515|NCT02350855|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
219256516|NCT06447298|OTHER|Satisfaction questionnaires|Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
219256517|NCT00839332|DRUG|LY2603618|
219256518|NCT00839332|DRUG|Gemcitabine|
219256519|NCT00433797|DIETARY_SUPPLEMENT|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
219256520|NCT01200485|DRUG|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
219256521|NCT01200485|DRUG|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
219256522|NCT06080438|DRUG|Botulinum toxin|15 units of botulinum toxin administered one time to the eye via eye drops
219256523|NCT02841176|OTHER|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
219256524|NCT02841176|BIOLOGICAL|Golimumab|Participants will start monthly Golimumab after their baseline visit
219256525|NCT00640042|DRUG|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
219256526|NCT01395706|PROCEDURE|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
219256527|NCT02264717|PROCEDURE|SPECT|Patients are randomized to either SPECT or Cardiac MRI
219256528|NCT02264717|PROCEDURE|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
219256529|NCT04748471|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccine
219256530|NCT00776984|DRUG|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
219256531|NCT00776984|DRUG|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
219256532|NCT00006137|DRUG|enalapril|
219256533|NCT02672137|BEHAVIORAL|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
219256534|NCT01971034|DRUG|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
219256535|NCT01971034|DRUG|Metformin|850mg, PO, every 8 hours, daily.
219256536|NCT04383834|DEVICE|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
219256537|NCT02686671|OTHER|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
219256538|NCT03852875|OTHER|Education|Same
219256539|NCT03852875|OTHER|Control|Same
219256540|NCT03524547|DEVICE|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
219256541|NCT03524547|DEVICE|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
219256542|NCT03644784|DIAGNOSTIC_TEST|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
219256543|NCT04369300|BEHAVIORAL|Registery Data Collection|Observational Data Collection
219256544|NCT03083093|DIAGNOSTIC_TEST|The initial CTPA will be reviewed|The initial CTPA will be reviewed
219256545|NCT01570621|PROCEDURE|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
219256546|NCT00806299|DRUG|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
219256547|NCT00806299|DRUG|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
219256548|NCT00806299|DRUG|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
219256549|NCT00009789|RADIATION|accelerated conformational radiotherapy|
219256550|NCT02311985|OTHER|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
219256551|NCT02311985|OTHER|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
219256552|NCT02311985|OTHER|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
219256553|NCT06039943|DEVICE|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
219256554|NCT04040283|PROCEDURE|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
219256555|NCT05687318|DEVICE|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
219256556|NCT01845558|DRUG|Wobenzym® plus|
219256557|NCT01845558|OTHER|Placebo|
219362944|NCT02525289|OTHER|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
219362945|NCT02525289|OTHER|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
219362946|NCT03514927|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219362947|NCT03514927|DEVICE|High-Intensity Focused Ultrasound|Under go HIFU
219362948|NCT03514927|OTHER|Laboratory Biomarker Analysis|Correlative studies
219362949|NCT03514927|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
219256558|NCT04559516|BEHAVIORAL|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
219256559|NCT04559516|BEHAVIORAL|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
219256560|NCT03298555|BEHAVIORAL|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
219256561|NCT01212484|DRUG|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
219256562|NCT01212484|DRUG|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
219256563|NCT01170923|DEVICE|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
219256564|NCT01170923|DEVICE|CT|CT performed after 3 cycles of chemotherapy
219362950|NCT03514927|PROCEDURE|Radical Prostatectomy|Undergo prostatectomy
219256565|NCT05895110|BIOLOGICAL|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
219256566|NCT04595526|PROCEDURE|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
219256567|NCT04595526|PROCEDURE|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
219256568|NCT04892602|DIAGNOSTIC_TEST|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
219256569|NCT02573883|DEVICE|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
219256570|NCT02573883|DRUG|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
219362951|NCT04908839|OTHER|spot-25 questionnaire|spot-25 questionnaire
219256571|NCT03697083|OTHER|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
219256572|NCT03697083|OTHER|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
219256573|NCT03697083|OTHER|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
219256574|NCT04919044|OTHER|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
219256575|NCT01544309|DRUG|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)"
219256576|NCT01544309|DRUG|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)"
219256577|NCT02410317|DRUG|Ropivacaine|
219256578|NCT02410317|DRUG|Morphine|
219256579|NCT05292170|OTHER|Heat acclimation|10 consecutive days of heat acclimation
219256580|NCT04959825|DRUG|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
219256581|NCT04959825|DRUG|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
219256582|NCT02671864|OTHER|1: incretin-based therapy|
219256583|NCT02671864|OTHER|2: other antidiabetic|
219256584|NCT01290783|DRUG|Irintoecan|"* Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment."
219256585|NCT01290783|DRUG|HA-Irinotecan solution for Infusion|"* HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment."
219256586|NCT04087070|DEVICE|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
219256587|NCT01990911|DEVICE|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
219256588|NCT01990911|DRUG|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
219256589|NCT04695314|DEVICE|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
219256590|NCT04695314|PROCEDURE|Experimental insert|Raised shoe insert, insert used for massage
219256591|NCT04695314|PROCEDURE|Sham insert|Flat shoe insert, insert used for massage
219256592|NCT01584271|DEVICE|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
219256593|NCT00118703|DRUG|GW685698X|
219256594|NCT01422083|PROCEDURE|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
219256595|NCT00087113|DRUG|pemetrexed disodium|
219256596|NCT03410095|DIAGNOSTIC_TEST|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
219256597|NCT05067543|DEVICE|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
219256598|NCT00953212|DRUG|beta blockers|metoprolol 25mg by mouth every 6 hours
219256599|NCT00953212|DRUG|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
219256600|NCT00953212|DRUG|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
219256601|NCT00115817|DRUG|Atorvastatin|
219256602|NCT04646135|DRUG|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
219256603|NCT00004090|DRUG|cisplatin|
219256604|NCT00004090|DRUG|gemcitabine hydrochloride|
219256605|NCT03688022|DRUG|MT-7117|MT-7117
219256606|NCT03688022|DRUG|PPI|Proton pump inhibitor
219256607|NCT03688022|DIETARY_SUPPLEMENT|Acidic beverage|Acidic beverage
219256608|NCT00067548|DRUG|EKB-569|
219256609|NCT05205252|DRUG|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
219256610|NCT05205252|DRUG|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
219256611|NCT05205252|DRUG|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
219256612|NCT05205252|DRUG|Acalabrutinib|Orally, 100 mg, twice daily.
219256613|NCT05205252|DRUG|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
219256614|NCT05205252|DRUG|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
219256615|NCT05205252|DRUG|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
219256616|NCT05205252|DRUG|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
219256617|NCT05205252|DRUG|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
219256618|NCT05205252|DRUG|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
219256619|NCT04514172|DEVICE|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
219256620|NCT04514172|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
219256621|NCT01933529|DRUG|ARA 290|ARA 290 is injected s.c. once daily during the study period
219256622|NCT01497340|OTHER|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
219256623|NCT01497340|OTHER|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
219256624|NCT00053768|BIOLOGICAL|filgrastim|
219256625|NCT00053768|DRUG|EPOCH regimen|
219256626|NCT00053768|DRUG|cyclophosphamide|
219256627|NCT00053768|DRUG|doxorubicin hydrochloride|
219256628|NCT00053768|DRUG|etoposide|
219256629|NCT00053768|DRUG|prednisone|
219256630|NCT00053768|DRUG|vincristine sulfate|
219256631|NCT00053768|RADIATION|radiation therapy|
219256632|NCT02218775|DRUG|LY2456302|Mood and Anxiety Disorders
219256633|NCT05861778|DRUG|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
219256634|NCT02970786|DRUG|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
219256635|NCT03796208|BEHAVIORAL|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
219256636|NCT03796208|BEHAVIORAL|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
219256637|NCT00953511|GENETIC|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
219256638|NCT00312234|BEHAVIORAL|Aerobic exercise|
219256639|NCT00312234|BEHAVIORAL|Qigong exercise|
219256640|NCT01808521|DRUG|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
219256641|NCT04469452|DEVICE|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
219256642|NCT00326703|PROCEDURE|Hypobaric hypoxia|
219256643|NCT02780739|BEHAVIORAL|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
219256644|NCT02780739|BEHAVIORAL|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
219256645|NCT02780739|BEHAVIORAL|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
219256646|NCT02780739|DEVICE|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
219256647|NCT02780739|DEVICE|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
219256648|NCT02780739|BEHAVIORAL|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
219256649|NCT01764698|BEHAVIORAL|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
219256650|NCT01764698|BEHAVIORAL|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
219256651|NCT01915992|OTHER|blood samples|
219256652|NCT00634218|BEHAVIORAL|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
219256653|NCT00634218|BEHAVIORAL|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
219256654|NCT00634218|BEHAVIORAL|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
219256655|NCT00634218|BEHAVIORAL|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
219256656|NCT05484713|DIAGNOSTIC_TEST|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
219256657|NCT05484713|DEVICE|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
219256658|NCT01707706|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
219256659|NCT04192539|DIAGNOSTIC_TEST|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
219256660|NCT02725008|DRUG|Dexamethasone|
219256661|NCT02725008|DRUG|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
219256662|NCT04303871|DIAGNOSTIC_TEST|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
219256663|NCT01837589|OTHER|QCT|
219256664|NCT01837589|OTHER|DXA|
219256665|NCT05456308|PROCEDURE|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
219256666|NCT06546761|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
219256667|NCT00519285|DRUG|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
219256668|NCT00519285|DRUG|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
219256669|NCT00519285|DRUG|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
219256670|NCT00519285|DRUG|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
219256671|NCT02175745|DRUG|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
219256672|NCT02175745|PROCEDURE|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
219256673|NCT02175745|PROCEDURE|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
219256674|NCT02175745|PROCEDURE|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
219256675|NCT04093466|DRUG|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
219256676|NCT04116242|OTHER|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
219256677|NCT04116242|OTHER|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
219256678|NCT04116242|OTHER|Health-related Questionnaires|Health-related Questionnaires (Questionnaire\_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
219256679|NCT04116242|OTHER|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
219256680|NCT05022927|DRUG|ERY974|ERY974 vial
219256681|NCT05022927|DRUG|Tocilicumab|Tocilizumab vial
219256682|NCT05022927|DRUG|Atezolizumab|Atezolizumab vial
219256683|NCT05022927|DRUG|Bevacizumab|Bevacizumab vial
219256684|NCT01090700|DRUG|TMC435|TMC435 150 mg daily for 7 days
219256685|NCT01090700|DRUG|Escitalopram|Escitalopram 10 mg daily for 7 days
219256686|NCT01090700|DRUG|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
219256687|NCT02292641|PROCEDURE|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
219256688|NCT00513461|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
219256689|NCT00513461|OTHER|placebo|Given PO
219256690|NCT00513461|OTHER|laboratory biomarker analysis|Correlative studies
219256691|NCT00513461|OTHER|immunoenzyme technique|Correlative studies
219256692|NCT00513461|OTHER|high performance liquid chromatography|Correlative studies
219256693|NCT02972814|DEVICE|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
219256694|NCT02972814|DEVICE|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
219256695|NCT02972814|DEVICE|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
219256696|NCT00317447|DRUG|Oral Prednisone|
219256697|NCT01536613|DRUG|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
219256698|NCT02201147|PROCEDURE|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
219256699|NCT02201147|PROCEDURE|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
219256700|NCT02201147|DEVICE|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
219256701|NCT02201147|DEVICE|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
219256702|NCT02814461|DRUG|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
219362952|NCT04823351|BEHAVIORAL|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
219362953|NCT02308683|DIETARY_SUPPLEMENT|Moringa oleifera|12 weeks supplementation
219256703|NCT02814461|RADIATION|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
219256704|NCT02580019|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
219256705|NCT03600922|PROCEDURE|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
219256706|NCT00981578|DEVICE|ExAblate 2100|Conformal Bone System
219256707|NCT03705988|DEVICE|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
219256708|NCT03705988|DEVICE|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
219256709|NCT03015181|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
219256710|NCT03711799|BEHAVIORAL|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
219256711|NCT04472442|PROCEDURE|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
219256712|NCT04472442|PROCEDURE|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
219256713|NCT04582864|DRUG|Flotetuzumab|Will be provided by MacroGenics Inc.
219256714|NCT04582864|PROCEDURE|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
219256715|NCT02657018|DEVICE|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
219256716|NCT02657018|OTHER|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
219256717|NCT02860559|BIOLOGICAL|TBX-1400|Hematopoietic stem cells transplantation
219256718|NCT01890499|DIETARY_SUPPLEMENT|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
219256719|NCT04177732|DIAGNOSTIC_TEST|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
219256720|NCT04177732|DIAGNOSTIC_TEST|Probing depth|Williams SE manual probe will be used to measure the probing depth
219256721|NCT04177732|DIAGNOSTIC_TEST|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
219256722|NCT04177732|DIAGNOSTIC_TEST|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
219256723|NCT04177732|DIAGNOSTIC_TEST|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
219256724|NCT03307083|OTHER|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
219256725|NCT01299441|DEVICE|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
219256726|NCT03314389|DEVICE|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
219256727|NCT01482819|DEVICE|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
219256728|NCT01482819|DEVICE|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
219256729|NCT01482819|DEVICE|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
219256730|NCT01482819|DEVICE|polymacon|contact lenses worn bilaterally for 8-12 hours
219256731|NCT01482819|OTHER|spectacles|habitual spectacles owned by subject, non-specific manufacturer
219256732|NCT05016778|DRUG|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
219256733|NCT06326281|PROCEDURE|unilateral external oblique intercostal plane block group|USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours
219256734|NCT06326281|PROCEDURE|unilateral oblique subcostal transversus abdomınıs plane block group|USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours
219256735|NCT06326281|PROCEDURE|Local anesthetic infiltration group|Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours
219256736|NCT06326281|DRUG|Control group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
219256737|NCT01958047|DRUG|ASP3652|Oral
219256738|NCT03440580|DEVICE|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
219256739|NCT01396733|DRUG|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
219256740|NCT03379311|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
219256741|NCT03594045|DRUG|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
219256742|NCT01297452|DRUG|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
219256743|NCT01297452|DRUG|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
219256744|NCT01297452|DRUG|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
219256745|NCT01297452|DRUG|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
219256746|NCT00562484|BIOLOGICAL|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
219256747|NCT00562484|BIOLOGICAL|Placebo|Placebo
219256748|NCT03427879|DRUG|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
219256749|NCT03427879|DRUG|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
219256750|NCT04685018|DEVICE|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
219256751|NCT04601883|DRUG|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
219256752|NCT04601883|DRUG|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
219256753|NCT02413502|BIOLOGICAL|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
219256754|NCT02811302|DEVICE|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
219256755|NCT05809726|OTHER|Manual lymph drainage|one session 20 minutes
219256756|NCT02826759|OTHER|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
219256757|NCT05744791|BEHAVIORAL|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
219256758|NCT04557865|DIAGNOSTIC_TEST|18F-PMPBB3 (APN-1607) PET imaging|"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"
219256759|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
219256760|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
219256761|NCT00702520|DRUG|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
219256762|NCT00702520|BIOLOGICAL|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
219256763|NCT00702520|BIOLOGICAL|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
219256764|NCT05119166|DIETARY_SUPPLEMENT|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
219256765|NCT05119166|BIOLOGICAL|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
219256766|NCT05119166|DIETARY_SUPPLEMENT|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
219256767|NCT06646588|DRUG|Fruquintinib|Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
219256768|NCT06646588|DRUG|Tislelizumab|Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
219256769|NCT06646588|RADIATION|Radiotherapy|Radiotherapy synchronised with drugs.
219256770|NCT03196622|DEVICE|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
219256771|NCT03597997|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
219256772|NCT03597997|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
219256773|NCT06290557|DRUG|HY_133|A recombinant chimeric bacteriophage endolysin HY-133
219256774|NCT06290557|DRUG|Placebo|Placebo
219256775|NCT06092684|DRUG|BT-KTM-I|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
219256776|NCT06092684|DRUG|Ketanest®S|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
219256777|NCT03460132|DEVICE|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
219256778|NCT05450822|DRUG|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
219362954|NCT01760161|DRUG|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
219256779|NCT05450822|DRUG|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
219256780|NCT05450822|DRUG|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
219256781|NCT00860301|OTHER|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
219256782|NCT04459949|DEVICE|Sharkskin|Use of Sharkskin ILM forceps
219256783|NCT04459949|DEVICE|Grieshaber|Use of Grieshaber ILM forceps
219256784|NCT02481934|PROCEDURE|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
219256785|NCT02481934|DRUG|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
219256786|NCT02481934|DRUG|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
219256787|NCT04547101|DRUG|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
219256788|NCT03044834|OTHER|PPB|Global current care
219256789|NCT05025553|DIETARY_SUPPLEMENT|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
219256790|NCT04907344|DRUG|Camrelizumab|IV infusion
219256791|NCT04907344|DRUG|Nab-Paclitaxel|IV infusion
219256792|NCT04907344|DRUG|Carboplatin|IV infusion
219256793|NCT03152474|DRUG|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
219256794|NCT03152474|DRUG|Vitamin A 100,000 IU|Dosed Intramuscular once daily
219256795|NCT03152474|OTHER|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
219256796|NCT00942188|DRUG|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
219256797|NCT00942188|DRUG|Placebo|Participants received 2 SC injections weekly for 12 weeks.
219256798|NCT04675086|DRUG|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
219256799|NCT04675086|DRUG|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
219256800|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
219256801|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
219256802|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
219256803|NCT00390936|DRUG|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
219256804|NCT04818047|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
219256805|NCT05181891|BEHAVIORAL|Contingency Management|Incentives for submitting negative-alcohol urine samples
219256806|NCT05181891|BEHAVIORAL|Non-contingent control|Incentives for submitting urine samples
219256807|NCT01378481|DRUG|Vorinostat|Given PO
219256808|NCT01378481|RADIATION|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
219256809|NCT01378481|OTHER|Laboratory Biomarker Analysis|Correlative studies
219256810|NCT01378481|OTHER|Pharmacological Study|Correlative studies
219256811|NCT01378481|PROCEDURE|Therapeutic Conventional Surgery|Undergo neurosurgery
219256812|NCT03735147|BIOLOGICAL|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
219256813|NCT05213117|BEHAVIORAL|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
219362955|NCT01760161|DRUG|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
219362956|NCT00244595|DRUG|candsartan cilexetil|
219362957|NCT00124111|DRUG|pegfilgrastim|
219362958|NCT00124111|DRUG|cyclophosphamide|
219362959|NCT00124111|DRUG|methotrexate|
219362960|NCT00124111|DRUG|5-fluorouracil|
219256814|NCT04127383|DEVICE|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
219256815|NCT00016237|BIOLOGICAL|tucotuzumab celmoleukin|
219256816|NCT00223132|DEVICE|Absorbable sutures|
219256817|NCT05980975|OTHER|Coffee|4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
219256818|NCT05980975|OTHER|Hot water|hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
219256819|NCT04577586|OTHER|oral contrast|negative oral contrast utilization in PET/CT studies
219256820|NCT05382871|BIOLOGICAL|BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
219256821|NCT05382871|BIOLOGICAL|WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
219256822|NCT05382871|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
219256823|NCT04946097|OTHER|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
219256824|NCT04946097|OTHER|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
219256825|NCT04946097|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
219256826|NCT00033462|DRUG|erlotinib hydrochloride|Given orally
219256827|NCT00033462|OTHER|laboratory biomarker analysis|Correlative studies
219256828|NCT02885883|DEVICE|MRI 3T|
219256829|NCT01182272|DRUG|sorafenib tosylate|
219256830|NCT01182272|OTHER|laboratory biomarker analysis|
219256831|NCT01182272|PROCEDURE|neoadjuvant therapy|
219256832|NCT01182272|PROCEDURE|therapeutic conventional surgery|
219256833|NCT00749671|DEVICE|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
219256834|NCT00749671|OTHER|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
219256835|NCT03973047|DRUG|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
219256836|NCT03973047|DRUG|Zofran|8 mg tablet (over-encapsulation in a capsule)
219256837|NCT03973047|DRUG|Placebo|capsule
219256838|NCT00068718|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
219256839|NCT05517577|BEHAVIORAL|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
219256840|NCT03572998|DRUG|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
219256841|NCT06589453|DEVICE|Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants|This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
219256842|NCT06589453|DEVICE|Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants|Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
219256843|NCT04601090|OTHER|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
219256844|NCT05085808|DRUG|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
219256845|NCT05085808|DRUG|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
219256846|NCT05085808|DRUG|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
219256847|NCT06620432|PROCEDURE|Low segment hysterotomy|A low segment hysterotomy is a surgical procedure in which an incision is made in the lower segment of the uterus, typically during a cesarean section or other uterine surgeries. This approach is preferred because the lower uterine segment is thinner and less vascular, reducing the risk of bleeding and complications during and after the procedure. The incision is typically horizontal.
219256848|NCT06620432|PROCEDURE|High segment hysterotomy|A high segment hysterotomy is a surgical procedure involving an incision in the upper segment of the uterus.
219256849|NCT06620432|PROCEDURE|Crossed hysterorrhaphy|Crossed hysterorrhaphy is a surgical technique used to close the uterine incision following a hysterotomy, particularly during cesarean sections. In this method, the sutures are placed in a crossed or X-shaped pattern, which helps to evenly distribute tension across the incision site.
219256850|NCT06620432|PROCEDURE|Non-Crossed hysterorrhaphy|Non-crossed hysterorrhaphy is a surgical technique used to close a uterine incision, typically after a hysterotomy, such as during a cesarean section. In this method, the sutures are placed in a linear, parallel fashion rather than in a crossed or X-shaped pattern
219256851|NCT01996397|PROCEDURE|Cardiac resynchronization therapy device implantation|
219256852|NCT06720571|DEVICE|Auricular vagal neuromodulation therapy (aVNT)|The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
219256853|NCT06720571|DEVICE|Sham Auricular vagal neuromodulation therapy (aVNT)|The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.
219256854|NCT06721195|DRUG|Remimazolam for Gastrointestinal Endoscopy Sedation|"This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction."
219256855|NCT06721533|DEVICE|Cerebellar rTMS|Cerebellar rTMS applied to pharyngeal area of right hemisphere
219256856|NCT01029678|DRUG|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
219256857|NCT01029678|DRUG|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
219256858|NCT01029678|RADIATION|Radiotherapy|66Gy, 33 fractions, 6 week
219256859|NCT06908486|BEHAVIORAL|Cognitive Bias Modification for Interpretation|"Cognitive Bias Modification involves administering the Ambiguous Scenarios paradigm. This is a series of ambiguous scenarios which could be resolved to be associated with pain. The task consists of 30 unique scenarios and an associated comprehension question (pertaining to the pain-relatedness of the scenario), which are presented in a random order to participants.~Each scenario presents an ambiguous sentence, ending with a word fragment which the participant must complete. The statement remains ambiguous until the completion of the word fragment, which resolves the statement as either pain-related or benign. For example, the statement You are bush walking. Suddenly, you trip over and fall onto your knees. Your knees feel all wet, and you look down to see... can be followed by le\_v\_s \[leaves\] for a benign resolution, or bl\_\_d \[blood\] for a pain-related resolution. In the intervention group, all 30 scenarios will be followed with the benign word fragment."
219256860|NCT06908486|BEHAVIORAL|Placebo|The Ambiguous Scenarios paradigm described previously will be used for the placebo intervention. The same 30 scenarios will be presented to participants, however 50% (15) trials will be followed by the benign word fragment, ad 50% (15) trials will be followed by the pain-related word fragment.
219256861|NCT04130061|BIOLOGICAL|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
219256862|NCT06096506|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
219256863|NCT00938288|DRUG|KW-3357|50IU/mL, IV single dose
219256864|NCT00202332|PROCEDURE|Coronary artery bypass|
219256865|NCT06090760|BEHAVIORAL|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
219256866|NCT01568112|DRUG|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
219256867|NCT01568112|DRUG|BG00012 placebo|Placebo matching BG00012
219256868|NCT01568112|DRUG|ASA|325 mg microcoated aspirin (ASA)
219256869|NCT01568112|DRUG|ASA placebo|Placebo matching aspirin
219256870|NCT06098443|OTHER|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.
219256871|NCT06098443|DEVICE|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
219256872|NCT06401096|PROCEDURE|Preoperative respiratory exercises|The Triflo Exerciser
219256873|NCT03390933|DRUG|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
219256874|NCT03371706|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
219256875|NCT03371706|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
219256876|NCT05862467|BEHAVIORAL|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
219256877|NCT03993561|OTHER|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
219256878|NCT05089981|DRUG|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
219256879|NCT05089981|DRUG|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
219256880|NCT02003690|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy
219256881|NCT02003690|BEHAVIORAL|Standard of Care Psychotherapy|Standard of Care Psychotherapy
219256882|NCT02003690|OTHER|Pharmacotherapy|Standard of Care Pharmacotherapy
219256883|NCT03480919|DEVICE|Shen Men acupuncture|20-minute acupuncture session
219256884|NCT03480919|PROCEDURE|Epidural injection|Epidural injection for the relief of back pain
219256885|NCT00832364|DRUG|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
219256886|NCT00832364|DRUG|Placebo|Placebo capsules
219256887|NCT00832364|BIOLOGICAL|Etanercept|Injectable Biologic
219256888|NCT02628964|DEVICE|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
219256889|NCT00560313|BIOLOGICAL|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
219256890|NCT00560313|BIOLOGICAL|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
219256891|NCT01704066|OTHER|Training and education|
219256892|NCT03140878|DIETARY_SUPPLEMENT|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
219256893|NCT03140878|DIETARY_SUPPLEMENT|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
219256894|NCT06250478|DIAGNOSTIC_TEST|Dynamic ultrasound of the calf muscles|Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
219256895|NCT04786483|OTHER|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
219256896|NCT05750342|DIETARY_SUPPLEMENT|Experimental Product Caqui|Supplement extracted from persimmon
219256897|NCT05750342|DIETARY_SUPPLEMENT|Control product placebo|Product with identical characteristics to the experimental product.
219256898|NCT00002721|DRUG|doxorubicin hydrochloride|
219256899|NCT00002721|DRUG|estramustine phosphate sodium|
219256900|NCT00002721|PROCEDURE|drug resistance inhibition treatment|
219256901|NCT02450617|BEHAVIORAL|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
219256902|NCT02450617|BEHAVIORAL|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
219256903|NCT02450617|BEHAVIORAL|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
219256904|NCT00344253|DRUG|Interferon beta|
219256905|NCT00344253|DRUG|Methotrexate|
219256906|NCT02282423|BEHAVIORAL|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
219256907|NCT02282423|PROCEDURE|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
219256908|NCT02282423|PROCEDURE|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
219256909|NCT02282423|PROCEDURE|VO2max.|VO2max.
219256910|NCT02282423|BEHAVIORAL|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
219256911|NCT02282423|PROCEDURE|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
219256912|NCT02602353|DRUG|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
219256913|NCT02602353|DRUG|Placebo Patch|One Placebo Patch applied daily for 3 days
219256914|NCT02602353|DRUG|No Treatment|No Treatment for 3 days
219256915|NCT02485314|OTHER|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
219256916|NCT00263484|DRUG|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
219256917|NCT00263484|DRUG|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
219256918|NCT00263484|DRUG|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
219256919|NCT00315666|DRUG|memantine|
219256920|NCT04085705|DIAGNOSTIC_TEST|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
219256921|NCT05052502|OTHER|Case Management and Follow-up|"Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions."
219256922|NCT05052502|OTHER|Reactive focal mass drug administration (rfMDA)|"Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants."
219256923|NCT04290611|DRUG|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
219256924|NCT03389425|BEHAVIORAL|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
219256925|NCT04668521|OTHER|OVA360|Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
219256926|NCT06462274|OTHER|body sample collection and imaging scan|
219256927|NCT06400797|OTHER|estimation of patient outcome by health care providers|On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
219256928|NCT04244149|OTHER|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
219256929|NCT05140707|OTHER|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
219256930|NCT04926441|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
219256931|NCT05817474|DRUG|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
219256932|NCT03090971|DRUG|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
219256933|NCT03090971|DRUG|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
219256934|NCT01317823|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
219256935|NCT01744743|PROCEDURE|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
219256936|NCT04289259|OTHER|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
219256937|NCT01821729|DRUG|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
219256938|NCT01821729|DRUG|Losartan|Taken orally every day during Phase I for all 8 cycles
219256939|NCT01821729|RADIATION|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
219256940|NCT04278495|DRUG|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
219256941|NCT04278495|DRUG|Placebo|Placebo
219256942|NCT06067022|OTHER|observation|Planned measurements and scales will be applied
219256943|NCT06201871|DRUG|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
219256944|NCT03441945|OTHER|magnetic steering|magnetic steering
219256945|NCT03120598|BEHAVIORAL|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
219256946|NCT03120598|BEHAVIORAL|ISF strategy|Implementation \& Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
219256947|NCT02517528|DRUG|ABT-450/r/ABT-267|Tablet
219256948|NCT02517528|DRUG|ABT-333|Tablet
219256949|NCT02517528|DRUG|ribavirin|Tablet
219256950|NCT02986750|DEVICE|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
219256951|NCT02986750|DEVICE|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
219256952|NCT02986750|DEVICE|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
219362961|NCT04497025|OTHER|Immersive Virtual-based vestibular rehabilitation|Vestibular rehabilitation based on virtual environment using a head mounted display
219256953|NCT00467298|BEHAVIORAL|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
219256954|NCT00467298|BEHAVIORAL|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
219256955|NCT00467298|BEHAVIORAL|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
219256956|NCT02361879|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
219256957|NCT02361879|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
219256958|NCT00668330|DRUG|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
219256959|NCT00668330|DRUG|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
219256960|NCT01672398|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
219256961|NCT01093599|BEHAVIORAL|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
219256962|NCT01093599|BEHAVIORAL|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
219256963|NCT01703845|DRUG|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
219256964|NCT01703845|DRUG|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
219256965|NCT01644188|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
219256966|NCT01644188|DRUG|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
219256967|NCT01644188|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
219256968|NCT01644188|DRUG|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
219256969|NCT01644188|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
219256970|NCT01087749|DRUG|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
219256971|NCT01087749|DRUG|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
219256972|NCT01087749|DRUG|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
219256973|NCT06546358|DRUG|Trazodone|Participants will be randomized to receive either quetiapine or trazodone.
219256974|NCT06546358|DRUG|Quetiapine|Participants will be randomized to receive either quetiapine or trazodone.
219256975|NCT04924088|BEHAVIORAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
219256976|NCT04924088|BEHAVIORAL|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
219256977|NCT04234945|DRUG|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
219256978|NCT04234945|DRUG|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
219256979|NCT06784310|BEHAVIORAL|Medically Tailored Meals|Dare to Care will provide meals each week for 12 weeks tailored for comorbidities. Meals will be provided to both the adult and the child(ren). Meals have been developed with a Registered Dietitian and have been approved through Food Is Medicine Coalition (FMIC). Meals are delivered via Door Dash each week.
219256980|NCT06784310|BEHAVIORAL|Grocery Prescription|Instacart Fresh Funds (for those that need delivery) or Kroger Grocery Rx cards will be issued to each participant per month to be spent on eligible healthy food items (lean protein, lean dairy, fruits, vegetables, eggs, and nuts). For each participating child in the household, they will receive additional funds/per child loaded on their grocery Rx card
219256981|NCT06784310|BEHAVIORAL|Medically Tailored Meals and Grocery Prescription|will receive both tailored MTM meals per week for adult and child(ren) and the GP monthly grocery funds
219256982|NCT06784310|BEHAVIORAL|Nutritional Counseling|30 minutes per week of nutrition counseling and assistance.
219256983|NCT03378037|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
219256984|NCT05835076|DIAGNOSTIC_TEST|Stool antigen test|Antigen test in the stool analysis
219256985|NCT01050387|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
219256986|NCT02750553|DRUG|SHR0534|
219256987|NCT02750553|DRUG|Placebo|
219256988|NCT06102798|DEVICE|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
219256989|NCT06102798|DEVICE|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
219256990|NCT02168621|PROCEDURE|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
219256991|NCT02168621|PROCEDURE|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
219256992|NCT05540418|OTHER|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
219256993|NCT05493228|DRUG|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
219256994|NCT05493228|DRUG|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
219256995|NCT03171532|PROCEDURE|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
219256996|NCT03119688|OTHER|Test Product|Micellar cleanser (0.09 ml)
219256997|NCT03119688|OTHER|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
219256998|NCT03119688|OTHER|Reference Product|Sterile Water (0.09 ml)
219256999|NCT03119688|OTHER|No Treatment|Unwashed area of the forearm
219257000|NCT00890539|DRUG|Methacholine challenge|Clinical and research test used in asthma
219257001|NCT01257399|DRUG|Asacol®|400 mg tablets
219257002|NCT01257399|DRUG|Mesalazine|400mg tablets
219257003|NCT03226106|BEHAVIORAL|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
219257004|NCT03226106|OTHER|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
219257005|NCT04349657|DEVICE|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
219257006|NCT04349657|PROCEDURE|Endarterectomy treatment group|Surgical treatment through endarterectomy
219257007|NCT03692689|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
219257008|NCT05188547|DEVICE|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
219257009|NCT00721214|DRUG|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
219257010|NCT02230293|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
219257011|NCT02230293|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
219257012|NCT00184197|DRUG|Botulinum toxin|
219257013|NCT00184197|DRUG|Placebos|
219257014|NCT05006417|DRUG|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
219257015|NCT00536081|DRUG|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
219257016|NCT04678713|DIETARY_SUPPLEMENT|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
219257017|NCT04678713|OTHER|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
219257018|NCT00038155|PROCEDURE|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
219257019|NCT00195884|BEHAVIORAL|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
219257020|NCT01830764|DRUG|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
219257021|NCT01058525|PROCEDURE|median nerve block|median nerve block performed using ultrasound guidance
219257022|NCT01058525|PROCEDURE|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
219362962|NCT04497025|OTHER|Conventional vestibular rehabilitation protocol|"Cawthorne-Cooksey vestibular rehabilitation exercises."
219257023|NCT04950036|DIAGNOSTIC_TEST|Diagnostic Test|The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.
219257024|NCT06454201|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
219257025|NCT06454201|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
219257026|NCT00883636|OTHER|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
219257027|NCT00883636|OTHER|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
219257028|NCT00883636|OTHER|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
219257029|NCT03553485|DEVICE|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
219257030|NCT03553485|DEVICE|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
219257031|NCT03553485|RADIATION|Radiotherapy|Standard treatment for included patients
219257032|NCT04047771|DRUG|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
219257033|NCT02041221|DRUG|SPARC1316 Dose 1|The subjects will receive SPARC1316.
219257034|NCT02041221|DRUG|Placebo|
219257035|NCT02041221|DRUG|SPARC1316 Dose 2|
219257036|NCT02041221|DRUG|SPARC1316 Dose 3|
219257037|NCT02041221|DRUG|SPARC1316 Dose 4|
219257038|NCT02041221|DRUG|SPARC1316 Dose 5|
219257039|NCT05220956|BEHAVIORAL|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
219257040|NCT05220956|BEHAVIORAL|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
219257041|NCT02716688|DRUG|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
219257042|NCT02716688|RADIATION|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
219257043|NCT02830009|OTHER|Urines samples|24-hour urines will be collected
219257044|NCT02830009|OTHER|Blood sample|
219257045|NCT00144378|DRUG|Irinotecan|
219257046|NCT01871168|PROCEDURE|TAP block|Infusion of 0.5-1% lidocaine
219257047|NCT01871168|PROCEDURE|Sham TAP block|Infusion of saline
219257048|NCT02344056|OTHER|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
219257049|NCT02344056|OTHER|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
219257050|NCT00255671|OTHER|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
219257051|NCT00875615|DRUG|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
219257052|NCT00875615|DRUG|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
219257053|NCT00875615|DRUG|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
219257054|NCT06478134|DRUG|Trimix tear substitutes|Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
219257055|NCT06478134|DRUG|Hyaluronic acid tear substitute|Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
219257056|NCT00002796|DRUG|fluorouracil|Given IV
219257057|NCT00002796|DRUG|sodium phenylbutyrate|Given IV
219257058|NCT00002796|DRUG|indomethacin|Given orally
219257059|NCT00002796|BIOLOGICAL|recombinant interferon gamma|Given subcutaneously
219257060|NCT00286962|DEVICE|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
219257061|NCT00286962|DEVICE|continuous subcutaneous insulin infusion (CSII) or MDI|
219257062|NCT00715637|DRUG|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
219257063|NCT00715637|DRUG|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
219257064|NCT00870532|DRUG|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
219257065|NCT00870532|DRUG|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
219257066|NCT01772823|BEHAVIORAL|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
219257067|NCT01772823|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
219257068|NCT01772823|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
219257069|NCT02176382|DRUG|denosumab|denosumab subcutaneous injection
219257070|NCT02176382|DRUG|teriparatide|teriparatide daily subcutaneous injection
219257071|NCT02176382|DRUG|Zoledronic acid|zoledronic acid infusion
219257072|NCT05786521|DRUG|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
219257073|NCT05786521|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
219257074|NCT05908578|OTHER|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
219257075|NCT05908578|OTHER|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
219257076|NCT00540384|DRUG|Placebo|Placebo
219257077|NCT00540384|DRUG|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
219257078|NCT02778334|OTHER|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
219257079|NCT04458987|BEHAVIORAL|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
219257080|NCT05452421|DIETARY_SUPPLEMENT|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
219257081|NCT05452421|DIETARY_SUPPLEMENT|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
219257082|NCT00282698|DRUG|Insulin infusion with a goal|
219257083|NCT06379555|PROCEDURE|Walanpoigne|Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
219257084|NCT00317759|BIOLOGICAL|therapeutic autologous lymphocytes|
219257085|NCT00317759|DRUG|fludarabine phosphate|
219257086|NCT04205214|BEHAVIORAL|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
219257087|NCT00902226|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
219257088|NCT02160561|OTHER|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
219257089|NCT04435405|OTHER|Observational|video footage analysis of group and individual behavioral processes.
219257090|NCT02648113|PROCEDURE|Restrictive transfusion|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
219257091|NCT02648113|PROCEDURE|Liberal transfusion|transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
219257092|NCT02648113|BIOLOGICAL|red blood transfusion|
219257093|NCT03742817|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
219257094|NCT05908305|DRUG|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
219257095|NCT06354192|BEHAVIORAL|Precision Nudging for Hypertension Management|The hypertension digital health intervention under study combines behavioral science theory with a type of machine learning called reinforcement learning to enable precision nudging: the selection, assembly, and delivery of behavioral science-based messages created to address barriers to, and promote, management of hypertension. The behavioral design process used for the hypertension DHI intentionally includes research on traditionally underserved populations, such as racial and ethnic minorities and people with lower incomes or educational attainment. By including the right ingredients to meet a diverse set of needs and by effectively personalizing the content each individual sees based on their own reactions, the intervention aims to improve health equity by matching each individual to the right behavioral approach.
219257096|NCT00104975|BIOLOGICAL|alemtuzumab|
219257097|NCT00104975|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219257098|NCT00104975|DRUG|fludarabine phosphate|
219257099|NCT00104975|DRUG|melphalan|
219257100|NCT00104975|DRUG|tacrolimus|
219257101|NCT00104975|DRUG|thiotepa|
219257102|NCT00104975|PROCEDURE|peripheral blood stem cell transplantation|
219257103|NCT06050018|OTHER|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
219257104|NCT06050018|OTHER|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
219257105|NCT04765553|DRUG|NI-0501|emapalumab single i.v infusion (1 mg/kg)
219257106|NCT04765553|DRUG|Saline|Saline single i.v infusion
219257107|NCT01746108|BIOLOGICAL|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
219257108|NCT04308642|OTHER|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
219257109|NCT04308642|OTHER|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
219257110|NCT03106298|DRUG|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
219257111|NCT01328808|DRUG|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
219257112|NCT00772655|DRUG|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
219257113|NCT00772655|DRUG|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
219257114|NCT02690415|PROCEDURE|Antibiotics Given|Patients who's treating physician prescribed antibiotics
219257115|NCT02690415|PROCEDURE|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
219257116|NCT02685007|OTHER|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
219257117|NCT01887990|DRUG|Ketamine|single dose IV 0.2 mg/kg ketamine
219257118|NCT01887990|DRUG|placebo|saline infusion
219257119|NCT00169585|DRUG|Levofloxacin oral tablets|
219257120|NCT04126122|DIAGNOSTIC_TEST|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
219257121|NCT04570254|DRUG|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
219257122|NCT04570254|DRUG|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
219257123|NCT04570254|DRUG|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
219257124|NCT04570254|DRUG|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
219257125|NCT04570254|DRUG|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
219257126|NCT06454318|DIAGNOSTIC_TEST|Wellue O2 ring|Wellue O2 ring wore when doing the polysomnography
219257127|NCT00005797|DRUG|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
219257128|NCT00005797|DRUG|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
219257129|NCT00005797|DRUG|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
219257130|NCT00005797|RADIATION|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
219257131|NCT00249119|DRUG|risperidone|
219257132|NCT02396498|DRUG|HIPEC|Using cisplatin in HIPEC plus oral S-1
219257133|NCT01486511|PROCEDURE|Liver resection|Hepatectomy including both minor and major.
219257134|NCT01486511|RADIATION|Computed Tomography|Computed Tomography +/- pulmonary angiography
219257135|NCT02274623|DRUG|CTAP101 Capsules|escalating doses
219257136|NCT01304628|DRUG|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
219257137|NCT02987322|DIETARY_SUPPLEMENT|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
219257138|NCT01829828|BEHAVIORAL|No intervention|This is an observational study with no investigational drug administered.
219257139|NCT04068285|OTHER|Aerobic Exercise|Participants will be making aerobic exercise
219257140|NCT06479226|DRUG|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|mouthrinse
219257141|NCT01396200|DRUG|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
219257142|NCT01396200|DRUG|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
219257143|NCT00932555|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
219257144|NCT04137718|OTHER|nonIntervention|nonIntervention
219257145|NCT04301115|OTHER|attachment|unilateral attachment from rehine 83
219257146|NCT04301115|OTHER|bridge|tooth implant supported bridge
219257147|NCT04301115|OTHER|CONVENTIONAL|conventional metalic partial denture
219257148|NCT05807425|PROCEDURE|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
219257149|NCT06146413|DRUG|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
219257150|NCT06146413|DRUG|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
219257151|NCT02741713|PROCEDURE|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
219257152|NCT02741713|PROCEDURE|Interscalene Block|An interscalene block will be performed on the subjects.
219257153|NCT02741713|PROCEDURE|Sham Block|
219257154|NCT02741713|DRUG|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
219257155|NCT02741713|DRUG|Solution for Injection in Sham Block|Lidocaine 1%
219257156|NCT02741713|DRUG|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
219257157|NCT04458181|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
219257158|NCT02081118|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
219257159|NCT02081118|DRUG|Placebo|Placebo for HM11260C
219257160|NCT04668534|DEVICE|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
219257161|NCT04668534|DEVICE|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
219257162|NCT04668534|DEVICE|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
219257163|NCT00003423|DRUG|asparaginase|
219257164|NCT00003423|DRUG|cyclophosphamide|
219257165|NCT00003423|DRUG|cytarabine|
219257166|NCT00003423|DRUG|daunorubicin hydrochloride|
219257167|NCT00003423|DRUG|dexamethasone|
219257168|NCT00003423|DRUG|etoposide|
219257169|NCT00003423|DRUG|mercaptopurine|
219257170|NCT00003423|DRUG|methotrexate|
219257171|NCT00003423|DRUG|prednisolone|
219257172|NCT00003423|DRUG|thioguanine|
219257173|NCT00003423|DRUG|vincristine sulfate|
219257174|NCT05047497|DIAGNOSTIC_TEST|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
219257175|NCT04011397|OTHER|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
219257176|NCT04011397|BEHAVIORAL|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
219257177|NCT06480253|DEVICE|Helmet Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
219257178|NCT06480253|DEVICE|Oronasal Mask Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
219257179|NCT00809341|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.
219257180|NCT00809341|DRUG|Cyclophosphamide|750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
219257181|NCT00809341|DRUG|Doxorubicin|50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
219257182|NCT00809341|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
219257183|NCT00809341|DRUG|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
219257184|NCT00809341|DRUG|Ifosfamide|2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
219257185|NCT00809341|DRUG|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
219257186|NCT00809341|DRUG|Etoposide|100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
219257187|NCT00809341|DRUG|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
219257188|NCT00809341|PROCEDURE|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
219257189|NCT02243761|OTHER|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
219257190|NCT02209727|DRUG|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
219257191|NCT01175564|DRUG|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
219257192|NCT01175564|DRUG|Placebo|Placebo tablet, single dose and 6 days repeated dose
219257193|NCT02273700|DRUG|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
219257194|NCT02629276|OTHER|neurodynamic testing|
219257195|NCT05524285|DEVICE|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
219257196|NCT05524285|DEVICE|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
219257197|NCT03503162|DEVICE|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
219257198|NCT02246218|DRUG|RAVICTI|
219257199|NCT04603833|DRUG|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
219257200|NCT04603833|DRUG|SHR3680|Participants will receive SHR3680
219257201|NCT04603833|DRUG|Docetaxel|Participants will receive Docetaxel
219257202|NCT04566198|OTHER|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
219257203|NCT00301561|PROCEDURE|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited"
219257204|NCT00301561|PROCEDURE|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed"
219257205|NCT03330717|PROCEDURE|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
219257206|NCT03330717|PROCEDURE|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
219257207|NCT03330717|PROCEDURE|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
219257208|NCT06544252|DIETARY_SUPPLEMENT|Low glycaemic index rice-based mixed meal (GI value = 47)|The mixed meal consisted of Basmati rice, chicken, and green-leafy vegetables. The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
219257209|NCT06544252|DIETARY_SUPPLEMENT|High glycaemic index rice-based mixed meal (GI value = 80)|The mixed meal consisted of fragrant rice, chicken, and green-leafy vegetables.The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
219257210|NCT02762305|OTHER|RSVP Bone Builders Group Exercise|
219257211|NCT06054919|DRUG|Cholecalciferol|vitamin D3
219257212|NCT03891641|BEHAVIORAL|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
219257213|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
219257214|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
219257215|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
219257216|NCT01093222|DRUG|Erlotinib Hydrochloride|Given PO
219257217|NCT01093222|DRUG|Sorafenib Tosylate|Given PO
219257218|NCT06051097|DIAGNOSTIC_TEST|sleep study|over-night polysomnography
219257219|NCT04696926|OTHER|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
219257220|NCT03941990|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
219257221|NCT03941990|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
219257222|NCT05527509|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
219257223|NCT05527509|BEHAVIORAL|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
219257224|NCT00836914|DRUG|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
219257225|NCT00836914|DRUG|Placebo|Placebo capsules administered orally BID for 7 days
219257226|NCT02696863|BEHAVIORAL|questionnaire|
219257227|NCT06298968|DRUG|combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab|"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."
219257228|NCT02825719|DRUG|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
219257229|NCT02825719|OTHER|Placebo pills|Placebo pills will be prescribed
219257230|NCT02825719|DRUG|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
219257231|NCT02825719|DRUG|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
219257232|NCT03277417|OTHER|Echocardiography|Imaging of fetal heart and amniotic fluid
219257233|NCT03986983|DEVICE|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
219257234|NCT03986983|OTHER|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
219257235|NCT00000701|DRUG|Zidovudine|
219257236|NCT03690284|DEVICE|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
219257237|NCT03690284|DEVICE|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
219257238|NCT02574949|RADIATION|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
219257239|NCT02574949|RADIATION|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
219257240|NCT02574949|RADIATION|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
219257241|NCT00841477|BIOLOGICAL|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
219257242|NCT00841477|BEHAVIORAL|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
219257243|NCT01880697|BIOLOGICAL|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
219257244|NCT05270473|PROCEDURE|uterine compressive sutures|uterine compression sutures comaprison
219257245|NCT06357936|PROCEDURE|nano-fat grafting in chronic limb ischaemia|The nano fat grafting procedure in the clinical trial involves the collection of adipose tissue under tumescent anesthesia, which is a technique to swell and firm the targeted area, through a separate puncture in the anterior abdominal wall. Following the collection, the adipose tissue undergoes a process of cannulation to prepare the nano fat. This prepared material is then injected into the tissues of the foot and leg using standard intramuscular injection needles. The injections are performed in various directions to ensure proper distribution of the nano fat. This method does not require additional drug therapy. It leverages the natural growth factors and stem cells present in adipose tissue, aiming to improve blood flow and tissue regeneration in limbs affected by critical ischemia. The unique aspect of this treatment is its focus on using autologous materials, minimizing the risk of rejection and side effects associated with foreign substances.
219362963|NCT01557166|DRUG|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
219257246|NCT06357936|PROCEDURE|sham comparator|For the clinical trial, a sham procedure would be designed to mimic the nano fat grafting without providing the actual therapeutic intervention. This involve the patient undergoing a similar process with tumescent anesthesia and making a puncture on the anterior abdominal wall. However, instead of harvesting adipose tissue and preparing nano fat, a placebo solution (such as saline) would be injected using the same intramuscular injection technique. The aim of this sham comparator is to assess the psychological and physiological effects of the nano fat grafting procedure itself, by eliminating the potential therapeutic benefits of the nano fat.
219257247|NCT04913623|PROCEDURE|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
219257248|NCT00865813|PROCEDURE|Punch Biopsy|"1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
219257249|NCT04677933|DRUG|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
219257250|NCT04677933|DRUG|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
219257251|NCT04677933|DRUG|C: Placebo|10 patients will receive Placebo BIW
219257252|NCT01311414|DRUG|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
219257253|NCT00941109|DRUG|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
219257254|NCT00941109|DRUG|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
219257255|NCT00941109|DRUG|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
219257256|NCT00941109|DRUG|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
219257257|NCT03557450|DEVICE|PET/CT Scan|PET/CT scanning with sodium fluoride
219257258|NCT00335374|DRUG|Pardoprunox|12 -42 mg
219257259|NCT06183827|PROCEDURE|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
219257260|NCT00614588|DEVICE|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
219257261|NCT03577925|DIAGNOSTIC_TEST|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
219257262|NCT00564252|DRUG|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
219257263|NCT05449847|BIOLOGICAL|Blood Sampling|Blood sampling under a complete aseptic conditions
219257264|NCT02362347|DEVICE|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
219257265|NCT02362347|OTHER|exercise|exercise
219257266|NCT00075283|DEVICE|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
219257267|NCT03416621|BEHAVIORAL|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
219257268|NCT03416621|BEHAVIORAL|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
219257269|NCT03416621|DRUG|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
219257270|NCT02388113|BEHAVIORAL|accumulated exercise|
219257271|NCT02388113|BEHAVIORAL|traditional exercise|
219257272|NCT03618836|OTHER|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
219257273|NCT01281917|DRUG|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
219257274|NCT01281917|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
219257275|NCT00096109|DRUG|tanespimycin|Given IV
219257276|NCT00096109|OTHER|laboratory biomarker analysis|Correlative studies
219257277|NCT04647318|BEHAVIORAL|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
219257278|NCT00646711|DRUG|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
219257279|NCT00646711|DRUG|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
219257280|NCT01801462|OTHER|Simulation-based training|
219257281|NCT05892822|OTHER|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
219257282|NCT04007146|DIAGNOSTIC_TEST|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
219257283|NCT02134613|OTHER|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
219257284|NCT02960126|DRUG|Aspirin|
219257285|NCT02960126|DRUG|Clopidogrel|
219362964|NCT01557166|DRUG|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
219257286|NCT00504413|DRUG|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
219257287|NCT00504413|DRUG|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
219257288|NCT00504413|DRUG|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
219257289|NCT01978236|DRUG|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
219257290|NCT01978236|DRUG|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
219257291|NCT04202016|PROCEDURE|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
219257292|NCT03153098|BEHAVIORAL|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
219257293|NCT02906696|DRUG|Bosutinib|Given PO
219257294|NCT02906696|OTHER|Laboratory Biomarker Analysis|Correlative studies
219257295|NCT02785276|DEVICE|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
219257296|NCT02785276|DRUG|Ropivacaine|Commonly used local anaesthetic drug
219257297|NCT02785276|OTHER|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
219257298|NCT02879799|OTHER|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
219257299|NCT01728688|OTHER|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
219257300|NCT01728688|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
219257301|NCT02643745|PROCEDURE|Nephrology Intervention|"1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction"
219257302|NCT02148653|OTHER|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
219257303|NCT02148653|OTHER|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
219257304|NCT00634920|DRUG|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
219257305|NCT00634920|DRUG|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
219257306|NCT00634920|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
219257307|NCT00634920|DRUG|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
219257308|NCT00634920|DRUG|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
219257309|NCT01068106|DEVICE|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
219257310|NCT01068106|DEVICE|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
219257311|NCT04082377|PROCEDURE|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
219362965|NCT00946309|DRUG|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
219362966|NCT00946309|DRUG|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
219362967|NCT00374244|DRUG|Pimozide|half of the subjects are randomized to the active drug group
219362968|NCT00374244|DRUG|placebo|half of the subjects are randomized to placebo group
219362969|NCT01698528|DEVICE|Tablet Computer|
219362970|NCT03976622|BIOLOGICAL|Blood samples|Blood samples: serum and PBMC
219257312|NCT04082377|PROCEDURE|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
219257313|NCT01299298|DRUG|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
219257314|NCT01299298|DRUG|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
219257315|NCT04037306|BEHAVIORAL|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
219257316|NCT04037306|BEHAVIORAL|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
219257317|NCT04885634|DRUG|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
219257318|NCT04885634|DRUG|Placebo|Subcutaneous injection of volume-matched placebo once weekly
219257319|NCT05091554|PROCEDURE|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
219257320|NCT00112710|DRUG|carboplatin|
219257321|NCT00112710|DRUG|cisplatin|
219257322|NCT00112710|DRUG|gemcitabine hydrochloride|
219257323|NCT00979745|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
219257324|NCT00979745|DRUG|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
219257325|NCT02870751|BIOLOGICAL|TW11681 or TW10722|
219257326|NCT02468310|OTHER|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
219257327|NCT00868764|DRUG|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
219257328|NCT04394312|OTHER|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
219257329|NCT04866706|DEVICE|Visiol|VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.
219257330|NCT02965053|DRUG|EOS789|
219257331|NCT02965053|DRUG|Placebo|
219257332|NCT02965053|DRUG|Renvela|
219257333|NCT00946205|PROCEDURE|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
219257334|NCT00946205|PROCEDURE|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
219257335|NCT01252056|DRUG|Probucol|250mg,Bid
219257336|NCT01252056|DRUG|Probucol and Cilostazol|50-100mg,Bid
219257337|NCT00414583|OTHER|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
219257338|NCT00607997|DRUG|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
219257339|NCT03247361|OTHER|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
219257340|NCT03247361|OTHER|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
219257341|NCT03247361|OTHER|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
219257342|NCT01606891|BEHAVIORAL|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
219257343|NCT03046381|DRUG|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
219257344|NCT05074771|DEVICE|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
219257345|NCT03975296|PROCEDURE|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
219257346|NCT03975296|PROCEDURE|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
219257347|NCT03975296|DRUG|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
219257348|NCT03558282|OTHER|Recession Observation|Soft tissue measurements
219257349|NCT03558282|DIAGNOSTIC_TEST|Crown Contour Observation|Ultrasound measures of implant crown contour.
219257350|NCT04350112|OTHER|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
219257351|NCT06083610|OTHER|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
219257352|NCT00576823|DRUG|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
219257353|NCT00409591|DRUG|Maternal and infant nevirapine|"* In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately"
219257354|NCT00409591|DRUG|Maternal placebo and infant nevirapine|"* In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
219257355|NCT00409591|DRUG|Maternal lopinavir+ritonavir|\- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
219257356|NCT00409591|DRUG|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
219257357|NCT00907946|PROCEDURE|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
219257358|NCT03360110|DEVICE|Phoebe test lens|Daily disposable contact lens
219257359|NCT03360110|DEVICE|stenfilcon A lens (control)|Daily disposable contact lens
219257360|NCT00510146|DRUG|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
219257361|NCT00510146|DRUG|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
219257362|NCT00005064|DRUG|bortezomib|Given IV
219257363|NCT03341858|OTHER|no intervention-strictly observational|
219257364|NCT00002388|DRUG|Abacavir sulfate|
219257365|NCT03029611|DRUG|Carboplatin|Given IV
219257366|NCT03029611|PROCEDURE|Gynecological Surgical Procedure|Undergo cytoreductive surgery
219257367|NCT03029611|OTHER|Laboratory Biomarker Analysis|Correlative studies
219257368|NCT03029611|DRUG|Paclitaxel|Given IV
219257369|NCT03029611|BIOLOGICAL|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
219257370|NCT06646601|OTHER|Intervention of prevention|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
219257371|NCT05104957|OTHER|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
219257372|NCT05104957|OTHER|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
219257373|NCT06647186|PROCEDURE|Non Incised Papillae Surgical Approach|Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.
219257374|NCT06647186|PROCEDURE|Conventional flap design|"Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures."
219257375|NCT06647199|PROCEDURE|the plaque index (PI)|Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
219257376|NCT06647199|PROCEDURE|the bleeding index (BI)|Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
219257377|NCT06647199|PROCEDURE|simpliﬁed gingival index(GI),|Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
219257378|NCT01073774|BEHAVIORAL|Side by side|
219257379|NCT01073774|BEHAVIORAL|couples control condition|
219257380|NCT06646809|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
219257381|NCT06646809|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
219257382|NCT06646809|OTHER|Standard care|Standard care
219257383|NCT00352391|OTHER|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
219257384|NCT05246618|DRUG|TUM012|Ex-vivo infusion
219257385|NCT05246618|DRUG|Placebo|Ex-vivo infusion
219362971|NCT03976622|BIOLOGICAL|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
219257386|NCT05278442|OTHER|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
219257387|NCT03235401|OTHER|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
219257388|NCT06646874|BEHAVIORAL|VR game|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
219257389|NCT06244693|OTHER|No intervention|No intervention
219257390|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
219257391|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
219257392|NCT04104724|OTHER|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
219257393|NCT00126061|DRUG|Tedisamil sesquifumarate|
219257394|NCT04713878|OTHER|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
219257395|NCT02134249|DRUG|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
219257396|NCT02134249|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
219257397|NCT02113540|DRUG|Atorvastatin|
219257398|NCT03240458|DEVICE|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
219257399|NCT03237598|OTHER||
219257400|NCT05753358|OTHER|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
219257401|NCT01424176|DRUG|Dexpramipexole (dose 1)|
219257402|NCT01424176|DRUG|Dexpramipexole (dose 2)|
219257403|NCT01841645|DIETARY_SUPPLEMENT|CLA depletion-repletion|
219257404|NCT03377959|OTHER|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
219257405|NCT03377959|OTHER|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
219257406|NCT00464217|DRUG|ARA-C|
219257407|NCT00464217|DRUG|Idarubicin|
219257408|NCT00464217|DRUG|Leucomax|
219257409|NCT05207449|OTHER|Questionnaire|"The questionnaire will include:~1. The demographic data of the patients~2. Chronic disease related questions~3. Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~4. Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~5. Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~6. Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~7. Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
219257410|NCT02284802|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
219257411|NCT02857309|DEVICE|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
219257412|NCT02857309|DRUG|Optimal medical therapy|OMT using standard heart failure (HF) drugs
219257413|NCT02134899|DRUG|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
219257414|NCT02134899|DRUG|Calcineurin inhibitors maintenance|Usual treatment
219257415|NCT01849679|OTHER|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
219257416|NCT00000904|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219257417|NCT00000904|BIOLOGICAL|gp160 MN/LAI-2|
219257418|NCT00000904|BIOLOGICAL|ALVAC(1)120(B,MN)GNP (vCP1433)|
219257419|NCT00000904|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219257420|NCT00000904|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219257421|NCT02146729|PROCEDURE|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
219257422|NCT02146729|PROCEDURE|Open Treatment|Midline posterior incision with instrumentation.
219257423|NCT04665349|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
219257424|NCT06205576|DEVICE|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
219257425|NCT01174498|DEVICE|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
219257426|NCT01174498|DEVICE|t-VNS Sham stimulation|t-VNS Sham stimulation
219257427|NCT03353155|BEHAVIORAL|Usual Care|
219257428|NCT03353155|BEHAVIORAL|CareHub|
219362972|NCT05149170|DRUG|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
219257429|NCT02864342|DEVICE|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
219257430|NCT02864342|DEVICE|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
219257431|NCT04615715|BEHAVIORAL|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
219257432|NCT04615715|BEHAVIORAL|Stress Reduction Messaging|Stress Reduction Messaging
219257433|NCT01309113|DRUG|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
219257434|NCT00661466|DRUG|Bupivacaine Collagen Sponge|
219257435|NCT00661466|DRUG|Placebo|placebo
219257436|NCT01192672|BEHAVIORAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
219257437|NCT01192672|BEHAVIORAL|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
219257438|NCT03609671|BEHAVIORAL|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
219257439|NCT03609671|OTHER|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
219257440|NCT03709316|DRUG|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
219257441|NCT03709316|DRUG|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
219257442|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
219257443|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
219257444|NCT00502983|BEHAVIORAL|Interview|Interview lasting approximately 50 minutes.
219257445|NCT02958813|BEHAVIORAL|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
219257446|NCT02958813|BEHAVIORAL|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
219257447|NCT00890214|DRUG|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
219257448|NCT00890214|DRUG|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
219257449|NCT05113485|BEHAVIORAL|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
219257450|NCT05113485|BEHAVIORAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
219257451|NCT01412632|DRUG|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
219257452|NCT02036606|BEHAVIORAL|questionary|
219257453|NCT01267058|BIOLOGICAL|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
219257454|NCT01267058|BIOLOGICAL|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
219257455|NCT01267058|BIOLOGICAL|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
219257456|NCT00183183|BEHAVIORAL|Screening and Brief Intervention|
219257457|NCT05734742|OTHER|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
219257458|NCT05857514|DRUG|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
219257459|NCT05857514|PROCEDURE|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
219257460|NCT05762471|DRUG|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
219257461|NCT05762471|DRUG|Placebo|Patients will receive GSBR-1290 or matching Placebo
219257462|NCT06396923|DIAGNOSTIC_TEST|Wingate test|Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
219257463|NCT03292497|PROCEDURE|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
219257464|NCT03292497|PROCEDURE|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
219257465|NCT02517125|DEVICE|Transoral robotic-assisted surgery with Da Vinci Xi|
219257466|NCT01246219|DRUG|GH treatment (Genotropin)|4 years treatment with GH
219257467|NCT01246219|DRUG|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
219257468|NCT02301364|DRUG|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
219257469|NCT02901483|DRUG|PEP503|PEP503 will be administered by intratumoral route as slow injection
219257470|NCT02901483|DRUG|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
219257471|NCT02901483|RADIATION|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
219257472|NCT00328380|DRUG|Rifaximin|
219257473|NCT00308919|DRUG|WST09|Treatment with WST09 Vascular Photodynamic therapy
219257474|NCT01612767|DEVICE|PRO-Kinetic Energy Stent|Coronary artery stent implant
219362973|NCT06501560|GENETIC|GWAS|In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.
219362974|NCT00004183|DRUG|capecitabine|
219257475|NCT02723513|OTHER|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
219257476|NCT06039592|DRUG|Captopril Tablets|0.3mg/kg, tid
219257477|NCT06039592|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
219257478|NCT06039592|DRUG|Spironolactone Tablets|2-4mg/kg, bid
219257479|NCT06039592|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
219257480|NCT06039592|DRUG|Potassium citrate powder|0.06g/kg, tid
219257481|NCT00287157|DRUG|Sublingual Tizanidine HCl|
219257482|NCT04717947|PROCEDURE|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
219257483|NCT00306878|DRUG|Abatacept|
219257484|NCT01560585|DRUG|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
219257485|NCT01240252|DRUG|Human insulin|U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
219257486|NCT04343859|DRUG|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
219257487|NCT02990364|DRUG|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
219257488|NCT02990364|DRUG|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
219257489|NCT02990364|DRUG|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
219257490|NCT04658654|DRUG|Roflumilast|chronic intervention (24 weeks): roflumilast capsule
219257491|NCT04658654|DRUG|Placebo oral tablet|Pill with inactive ingredients to mimic same appearance of roflumilast capsule
219257492|NCT04400799|DRUG|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
219257493|NCT01149876|OTHER|Nu Skin Product|Thin layer of Nu Skin product applied to face.
219257494|NCT01149876|OTHER|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
219257495|NCT01149876|DRUG|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
219257496|NCT01149876|OTHER|CeraVe moisturizer|Thin layer of CeraVe applied to face.
219257497|NCT03443011|RADIATION|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
219257498|NCT04890886|DIAGNOSTIC_TEST|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
219257499|NCT04890886|DIAGNOSTIC_TEST|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
219257500|NCT04890886|DIAGNOSTIC_TEST|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
219257501|NCT04890886|DIAGNOSTIC_TEST|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
219257502|NCT04890886|DIAGNOSTIC_TEST|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
219257503|NCT03447574|OTHER|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
219257504|NCT01438515|DRUG|Rifampin|600mg po once daily x 7 days
219257505|NCT01438515|DRUG|Doxycycline|100mg po twice daily x 7 days
219257506|NCT01438515|OTHER|2% mupirocin ointment|\~ 1cm applied to the anterior nares twice daily for 7 days
219257507|NCT01438515|OTHER|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
219257508|NCT04661514|DRUG|Psilocybin|Psilocybin-assisted psychotherapy
219257509|NCT01252511|PROCEDURE|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
219257510|NCT03284528|OTHER|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
219257511|NCT03529084|DRUG|EFG816|It will be administered orally daily.
219257512|NCT03529084|DRUG|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
219257513|NCT04987034|DEVICE|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
219257514|NCT03373955|DRUG|pembrolizumab|anti-programmed death 1 (PD-1) antibody
219257515|NCT02968121|DRUG|Brexpiprazole, OPDC-34712|
219257516|NCT06135675|DRUG|TNP-2092 capsules|Administration orally.
219257517|NCT06135675|DRUG|Placebo|Administration orally.
219257518|NCT04382807|BEHAVIORAL|Counseling|Online delivered group counseling session, providing insights into the tinnitus symptoms
219257519|NCT05632016|PROCEDURE|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
219257520|NCT04688086|DIAGNOSTIC_TEST|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
219257521|NCT03786003|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
219257522|NCT03786003|PROCEDURE|Thoracotomy|Standard thoracotomy
219257523|NCT02582034|RADIATION|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
219257524|NCT02582034|RADIATION|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
219257525|NCT06224335|DIAGNOSTIC_TEST|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
219257526|NCT05955547|OTHER|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
219257527|NCT00702273|DRUG|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
219257528|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
219257529|NCT00702273|DRUG|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
219257530|NCT00702273|DRUG|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
219257531|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
219257532|NCT00702273|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
219257533|NCT00702273|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
219257534|NCT00702273|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
219257535|NCT05683886|DRUG|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
219257536|NCT00853021|BIOLOGICAL|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
219257537|NCT00853021|BIOLOGICAL|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
219257538|NCT01329419|DRUG|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219257539|NCT05166798|BEHAVIORAL|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
219257540|NCT06199206|OTHER|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
219257541|NCT06348498|DRUG|Jia Shen Tablet|Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
219257542|NCT05370547|DRUG|Chidamide|"1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
219257543|NCT05370547|DRUG|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
219257544|NCT05370547|BIOLOGICAL|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
219257545|NCT02920021|DRUG|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
219257546|NCT02920021|DRUG|Placebo|Administered by intravenous infusion
219257547|NCT02824497|OTHER|No intervention. It's a description study|
219257548|NCT04522778|DEVICE|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
219257549|NCT04522778|OTHER|Traditional Securement Dressing|All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
219257550|NCT00688077|DRUG|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
219257551|NCT00688077|DRUG|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
219257552|NCT05258877|OTHER|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
219257553|NCT02010398|OTHER|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
219257554|NCT02010398|OTHER|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
219257555|NCT02010398|OTHER|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
219257556|NCT04786756|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
219257557|NCT04001998|DRUG|BLD-2660|Randomized to active product
219257558|NCT00316498|DRUG|OGT918|
219257559|NCT03974698|PROCEDURE|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
219257560|NCT02927652|OTHER|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
219257561|NCT04257942|PROCEDURE|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
219257562|NCT03630965|OTHER|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
219257563|NCT05400226|DRUG|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
219257564|NCT00930683|DRUG|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
219257565|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
219257566|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
219257567|NCT00930683|DRUG|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
219257568|NCT00930683|DRUG|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
219257569|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
219257570|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
219257571|NCT00930683|DRUG|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
219257572|NCT00930683|DRUG|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
219257573|NCT01145547|DEVICE|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
219257574|NCT04410354|DRUG|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
219257575|NCT04410354|DRUG|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
219257576|NCT04410354|DRUG|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
219257577|NCT05509283|BEHAVIORAL|Risk Reduction|Letter, patient portal, SMS and/or another modality
219257578|NCT02091297|DRUG|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
219257579|NCT02091297|DRUG|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
219257580|NCT02091297|DRUG|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
219257581|NCT02091297|DRUG|Morphine|
219257582|NCT06646497|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|"1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative)."
219257583|NCT04155333|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
219257584|NCT05765409|OTHER|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
219257585|NCT05765409|OTHER|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
219257586|NCT00806741|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
219257587|NCT00806741|DRUG|Phenylephrine|1μg/kg/min, infusion period 20 minutes
219257588|NCT00806741|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
219257589|NCT00806741|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
219257590|NCT00806741|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
219257591|NCT00806741|OTHER|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
219257592|NCT05130502|OTHER|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
219257593|NCT05130502|OTHER|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
219257594|NCT06369883|DIAGNOSTIC_TEST|Spine radiography|Posterior-anterior and lateral spine radiography
219257595|NCT02145195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
219257596|NCT04206384|DEVICE|Ultrasound|Ultimate Contour Body Sculpting Device
219257597|NCT00866502|DRUG|sNN0031|Continuous ICV infusion for two weeks
219257598|NCT00866502|DRUG|Placebo|Continous ICV infusion
219257599|NCT02212197|DRUG|leuprolide acetate FluidCrystal® injection depot|
219257600|NCT02212197|DRUG|leuprolide acetate|
219257601|NCT00321529|DEVICE|motion analysis by durometer|
219257602|NCT04030988|DRUG|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
219257603|NCT04030988|DRUG|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
219257604|NCT00346177|BIOLOGICAL|Autologous Stem Cells|Intramyocardial injections
219257605|NCT06454799|BEHAVIORAL|Akupressur|The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
219257606|NCT04641416|DIAGNOSTIC_TEST|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
219257607|NCT02551692|DRUG|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
219257608|NCT02551692|DRUG|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
219257609|NCT02551692|DRUG|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
219257610|NCT02551692|DRUG|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
219257611|NCT01091519|OTHER|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
219257612|NCT01091519|OTHER|Toviaz(fesoterodine) without educational materials|No educational materials
219257613|NCT00621946|DRUG|Placebo|Placebo Matching Escitalopram
219257614|NCT00621946|DRUG|Escitalopram|Active Escitalopram
219257615|NCT03030599|DRUG|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
219257616|NCT03030599|OTHER|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
219257617|NCT00598858|DRUG|Docetaxel|Given IV
219257618|NCT00598858|DRUG|Prednisone|Given PO
219257619|NCT01177228|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
219257620|NCT01177228|DRUG|Placebo|Placebo intravenous infusion
219257621|NCT05360342|DRUG|Vitamin K supplement|Single dose of vitamin K supplement
219257622|NCT02900313|OTHER|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
219257623|NCT03861585|OTHER|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
219257624|NCT03861585|OTHER|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
219257625|NCT06053047|DEVICE|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
219257626|NCT06288256|OTHER|No Intervention|No Intervention
219257627|NCT04292925|OTHER|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
219257628|NCT04292925|OTHER|Conventional therapy|conventional therapy
219257629|NCT05018949|PROCEDURE|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
219257630|NCT04975932|OTHER|TACE+ICIs|TACE plus ICIs ( with or without molecular targeted therapies)
219257631|NCT04975932|PROCEDURE|TACE|TACE without combination of ICIs ( with or without molecular targeted therapies)
219257632|NCT02618785|PROCEDURE|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
219257633|NCT04167085|DRUG|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
219257634|NCT04167085|OTHER|Placebo|Matching placebo, twice a day for 2 months
219257635|NCT05580783|OTHER|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
219257636|NCT05580783|OTHER|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
219257637|NCT05580783|OTHER|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
219257638|NCT01314014|DRUG|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
219257639|NCT00660764|DRUG|Rosuvastatin|Oral
219257640|NCT00006436|BIOLOGICAL|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
219257641|NCT00006436|BIOLOGICAL|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
219257642|NCT00006436|DRUG|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
219257643|NCT00316589|BIOLOGICAL|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
219257644|NCT01361789|DRUG|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
219257645|NCT01361789|DRUG|Dexamethasone|8 mg IV
219257646|NCT01361789|DRUG|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
219257647|NCT05306730|DEVICE|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
219257648|NCT06240403|DRUG|Digoxin 0.125 MG|One capsule containing digoxin per day for three months
219257649|NCT05876286|OTHER|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
219257650|NCT04671251|DRUG|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
219257651|NCT06310278|DIAGNOSTIC_TEST|Ossicular mobility measurement|Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
219257652|NCT03750500|DEVICE|Biofeedback device|12-week exercise program performed through the device
219257653|NCT03750500|BEHAVIORAL|Education on falls risk|Education on falls risk factors and how to minimize them
219257654|NCT03750500|OTHER|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
219257655|NCT03750500|DIAGNOSTIC_TEST|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
219257656|NCT06012877|BEHAVIORAL|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
219257657|NCT00276016|DRUG|phenylephrine|immediate-release 12 mg capsules for oral administration
219257658|NCT00276016|DRUG|pseudoephedrine|60 mg immediate-release tablets for oral administration
219257659|NCT00276016|DRUG|placebo|placebo capsules
219257660|NCT01507753|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
219257661|NCT01507753|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
219257662|NCT01507753|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
219257663|NCT05041439|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
219257664|NCT01552642|BEHAVIORAL|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
219257665|NCT03648684|BEHAVIORAL|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
219257666|NCT03648684|BEHAVIORAL|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
219257667|NCT01374971|DRUG|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
219257668|NCT01374971|PROCEDURE|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
219257669|NCT05803525|OTHER|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
219257670|NCT05878249|PROCEDURE|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
219257671|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
219257672|NCT05878249|PROCEDURE|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
219257673|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
219257674|NCT01431105|DRUG|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
219257675|NCT00960505|OTHER|Alternate day fasting|
219257676|NCT00960505|OTHER|Calorie restriction|
219257677|NCT00960505|OTHER|Control diet|
219257678|NCT06593288|OTHER|Pressure Support Ventilation|Conduct the Spontaneous breathing trial with pressure support
219257679|NCT06593288|OTHER|continuous positive airway pressure (CPAP)|Conduct the spontaneous breathing trial with CPAP
219257680|NCT05264649|DEVICE|acupuncture|"The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes De Qi reported by patients, needles were restimulated manually and removed after an additional 10 minutes."
219257681|NCT05264649|DRUG|Guizhi-Shaoyao-Zhimu decoction|The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
219257682|NCT06042270|DIETARY_SUPPLEMENT|Betaine|3 grams per day for \~4 weeks
219257683|NCT06042270|DIETARY_SUPPLEMENT|Placebo|3 grams per day for \~4 weeks
219257684|NCT07000266|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Standard PCI intervention
219257685|NCT07000266|DIAGNOSTIC_TEST|Diagnostic Imaging|Cardiac Magnetic Ressonance (CMR) and hospital discharge
219257686|NCT07000266|DEVICE|Device Treatment|SSO2 therapy
219257687|NCT07000266|PROCEDURE|Follow-up at 30 days|Remote (phone) follow-up at 30 days
219257688|NCT07000266|PROCEDURE|Follow-up at 60 days|In person follow-up at 60 days
219257689|NCT07000266|PROCEDURE|Follow-up at 12 months|Remote (phone) follow-up at 12 months
219257690|NCT01718613|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
219257691|NCT01718613|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
219257692|NCT05152706|OTHER|Aerobic training|Cycling at the aerobic intensity
219257693|NCT05152706|OTHER|Photobiomodulation|Photons therapy
219257694|NCT00153348|BEHAVIORAL|Women's health|
219257695|NCT05162196|RADIATION|SBRT|24Gy/3F
219257696|NCT05162196|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
219257697|NCT05162196|DRUG|Niraparib|200mg qd
219257698|NCT00747695|DRUG|Rabeprazole sodium|
219257699|NCT00835510|DRUG|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
219257700|NCT00835510|DRUG|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
219257701|NCT00835510|DRUG|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
219257702|NCT04578587|DEVICE|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
219257703|NCT03300609|BIOLOGICAL|Panitumumab|Given IV
219257704|NCT03300609|DRUG|Oxaliplatin|Given IV
219257705|NCT03300609|DRUG|Leucovorin Calcium|Given IV
219257706|NCT03300609|DRUG|Fluorouracil|Given IV
219257707|NCT03300609|DRUG|Capecitabine|Given PO
219257708|NCT03300609|OTHER|Quality-of-Life Assessment|Ancillary studies
219257709|NCT03300609|OTHER|Laboratory Biomarker Analysis|Correlative studies
219257710|NCT05238155|DRUG|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
219257711|NCT04166110|DRUG|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
219257712|NCT04166110|DRUG|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
219257713|NCT04083937|RADIATION|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
219257714|NCT04083937|RADIATION|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
219257715|NCT04083937|RADIATION|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
219257716|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
219257717|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
219257718|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
219257719|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
219257720|NCT01011699|DRUG|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
219257721|NCT01011699|DRUG|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
219257722|NCT01011699|DRUG|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
219257723|NCT03631303|DEVICE|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
219257724|NCT01130311|DRUG|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219257725|NCT01130311|DRUG|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
219257726|NCT01049386|OTHER|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
219257727|NCT01049386|PROCEDURE|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
219257728|NCT02807961|DRUG|ELX-02|Synthetic aminoglycoside
219257729|NCT02807961|DRUG|Placebo|Placebo comparator
219257730|NCT01028755|DRUG|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
219257731|NCT02572635|BIOLOGICAL|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
219257732|NCT02572635|BIOLOGICAL|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
219257733|NCT01055210|DEVICE|Optimisation of VV delay|Programmed VV delay altered on device
219257734|NCT04145388|OTHER|online cancer risk assessment|Electronic surveys to collect family cancer history information.
219257735|NCT04145388|OTHER|Usual care|Family cancer history captured by provider during a clinical encounter
219257736|NCT05726266|OTHER|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
219257737|NCT05726266|OTHER|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
219257738|NCT00970320|OTHER|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
219257739|NCT02311777|DRUG|Pregabalin|Pregabalin will be given orally during preoperative period
219257740|NCT02311777|DRUG|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
219257741|NCT02311777|DRUG|Placebo|Placebo will be given orally during preoperative period
219257742|NCT04721899|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
219257743|NCT02491710|DEVICE|Training on low-cost box trainer|
219257744|NCT02491710|DEVICE|Training on standard box trainer|
219257745|NCT03756168|DEVICE|1060nm Diode laser|"All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area."
219257746|NCT00936962|BIOLOGICAL|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
219257750|NCT01542398|BEHAVIORAL|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
219257751|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
219257752|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
219257753|NCT01605786|OTHER|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
219257754|NCT02960945|DRUG|CTP-543, 16 mg (2 x 8 mg tablet)|
219257755|NCT02960945|DRUG|Jakafi 15Mg Tablet|
219257756|NCT01692145|DRUG|KCT-0809|
219257757|NCT01692145|DRUG|Placebo|
219257758|NCT02743988|DRUG|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
219257759|NCT02257229|PROCEDURE|Surgical|Surgery only
219257760|NCT02257229|PROCEDURE|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
219257761|NCT02257229|PROCEDURE|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
219257762|NCT05382598|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
219257763|NCT01939561|DRUG|Lamotrigine|
219257764|NCT01939561|DRUG|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
219257765|NCT01966198|OTHER|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
219257766|NCT06701019|OTHER|Semi-structured interview/focus group discussion|"All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option."
219257767|NCT06122454|DRUG|Hepenofovir Fumarate Tablets|Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
219257768|NCT00141362|DRUG|Pregabalin|
219257769|NCT02139462|OTHER|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
219257770|NCT02139462|OTHER|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
219257771|NCT01662037|DRUG|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
219257772|NCT05955963|OTHER|Abdominal auscultation|spectral analysis of Bowel sounds
219257773|NCT00855725|OTHER|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
219257774|NCT00855725|OTHER|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
219257775|NCT00855725|OTHER|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
219257776|NCT00855725|OTHER|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
219257777|NCT01625676|OTHER|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
219257778|NCT01625676|OTHER|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
219257779|NCT04087564|OTHER|music intervention|"The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session"
219257780|NCT06031961|DRUG|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
219257781|NCT04458220|OTHER|photo and voice obtained|The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
219257782|NCT04795206|OTHER|No Intervention|Administered as specified in the treatment arm.
219257783|NCT03362034|DEVICE|double transfer trays|double trays one soft and one hard
219257784|NCT03362034|DEVICE|single transfer tray|single soft tray
219257785|NCT06957197|DRUG|Hydrogel with xenograft|vehicle to hold xenograft
219257786|NCT06957197|DRUG|Xenograft|to maintain the socket
219257787|NCT04742062|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
219257788|NCT04742062|OTHER|Placebo|100 mL 0.9% Sodium Chloride solution
219257789|NCT05931445|OTHER|e-PRO monitoring|"The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action."
219257790|NCT06238050|PROCEDURE|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
219257791|NCT00004316|DRUG|capsaicin|
219257792|NCT00004316|DRUG|Placebo|
219257793|NCT06951386|DIETARY_SUPPLEMENT|with short-chain fatty acids enriched drink|Oat-based drink enriched with 15 g/L short-chain fatty acids
219257794|NCT06951386|DIETARY_SUPPLEMENT|unenriched oat drink|Oat-based drink
219257795|NCT06956534|OTHER|Questionnaire and Physical Exam|online digital questionnaire
219257796|NCT06957717|COMBINATION_PRODUCT|cow's milk kefir|group given cow's milk kefir and blood supplement tablets (TTD)
219257797|NCT06957717|COMBINATION_PRODUCT|pasteurized cow's milk|group given pasteurized cow's milk and blood supplement tablets (TTD)
219257798|NCT00943618|DRUG|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
219257799|NCT00943618|DRUG|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
219257800|NCT00943618|OTHER|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
219257801|NCT00943618|BEHAVIORAL|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
219257802|NCT04584333|BEHAVIORAL|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
219257803|NCT03713281|DEVICE|Toric Multifocal etafilcon A with PVP|Investigational
219257804|NCT06509945|OTHER|allogeneic peripheral blood stem cell transplantation|Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
219257805|NCT02010983|OTHER|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
219257806|NCT03736278|OTHER|No intervention|We group the patients according to the outcome (survival vs mortality)
219257807|NCT00320814|DRUG|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
219257808|NCT04573556|DRUG|Lemborexant|Lemborexant oral tablets.
219257809|NCT00320398|DRUG|Fondaparinux|
219257810|NCT01355978|DEVICE|Noninvasive Open Ventilation System|Noninvasive ventilation system
219257811|NCT03206268|DEVICE|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
219257812|NCT03515447|OTHER|Non interventional study|
219257813|NCT00630552|OTHER|Placebo|Inactive dummy of AMG 655.
219257814|NCT00630552|DRUG|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
219257815|NCT00630552|DRUG|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
219257816|NCT04221958|DEVICE|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
219257817|NCT04150913|DRUG|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
219257818|NCT04150913|DRUG|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
219257819|NCT01245803|DRUG|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
219257820|NCT01245803|DRUG|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
219257821|NCT05124002|DRUG|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
219257822|NCT05124002|DRUG|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
219257823|NCT05633056|BEHAVIORAL|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
219257824|NCT03472976|OTHER|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
219257825|NCT03472976|DRUG|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
219257826|NCT03472976|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
219257827|NCT00799747|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
219257828|NCT00799747|DRUG|Placebo|placebo
219257829|NCT02546505|OTHER|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
219257830|NCT02546505|OTHER|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
219257831|NCT02428218|DRUG|dimethyl fumarate|enteric-coated microtablets
219257832|NCT02428218|DRUG|Placebo|enteric-coated microtablets
219257833|NCT06134583|PROCEDURE|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
219257834|NCT06134583|PROCEDURE|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
219257835|NCT00215722|DRUG|Cetuximab|
219257836|NCT01389414|DRUG|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
219257837|NCT01389414|DRUG|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
219257838|NCT04077697|DIAGNOSTIC_TEST|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
219257839|NCT01169636|DRUG|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
219257840|NCT01169636|DRUG|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
219257841|NCT01169636|DRUG|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
219257842|NCT01169636|DRUG|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
219257843|NCT01169636|DRUG|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
219257844|NCT01169636|DRUG|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
219257845|NCT03088098|DEVICE|LAAO|Left atrial appendage occlusion for stroke prevention
219257846|NCT00039117|BIOLOGICAL|oblimersen sodium|Given IV
219257847|NCT00039117|DRUG|cytarabine|Given IV
219257848|NCT00039117|DRUG|daunorubicin hydrochloride|Given IV
219257849|NCT00039117|OTHER|laboratory biomarker analysis|Correlative studies
219257850|NCT00039117|OTHER|pharmacological study|Correlative studies
219257851|NCT03745378|OTHER|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
219257852|NCT02705625|DRUG|MIV-711|MIV-711 administered orally once daily
219257853|NCT02705625|DRUG|Placebo|Placebo manufactured to mimic MIV-711 capsule.
219257854|NCT01284309|DRUG|Mirabegron|oral
219257855|NCT01284309|DRUG|Placebo|oral
219257856|NCT02719262|DEVICE|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
219257857|NCT02743299|DEVICE|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
219257858|NCT02168231|PROCEDURE|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
219257859|NCT01565317|OTHER|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
219257860|NCT04071509|DEVICE|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
219257861|NCT03680963|PROCEDURE|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
219257862|NCT03680963|PROCEDURE|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
219257863|NCT00494026|DRUG|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
219257864|NCT00494026|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
219257865|NCT00494026|PROCEDURE|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
219257866|NCT04366362|PROCEDURE|Individualised ACL reconstruction|ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
219257867|NCT04366362|PROCEDURE|Conventional ACL reconstruction|ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
219257868|NCT03423368|DEVICE|Libramed|Policaptil Gel Retard
219257869|NCT03423368|DEVICE|Placebo|Placebo-comparator
219257870|NCT00187499|DRUG|Inhaled fluticasone 500 ug BID for 8 weeks|
219257871|NCT00518856|OTHER|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
219257872|NCT00518856|OTHER|Standard of care|continued with current standard of care for birth attendants
219257873|NCT05972304|DEVICE|Nasal positive airway System by Vyaire Medical|Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor
219257874|NCT05557071|BEHAVIORAL|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
219257875|NCT00489645|DRUG|placebo|placebo SC during euglycemia
219257876|NCT00489645|DRUG|pramlintide|pramlintide SC during eglycemia
219257877|NCT00489645|DRUG|placebo|placebo during hyperglycemia
219257878|NCT00489645|DRUG|pramlintide|pramlintide SC during hyperglycemia
219257879|NCT06149143|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
219257880|NCT03238222|BEHAVIORAL|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
219257881|NCT00004039|BIOLOGICAL|recombinant interferon alfa|
219257882|NCT00004039|BIOLOGICAL|rituximab|
219257883|NCT00004039|DRUG|cyclophosphamide|
219257884|NCT00004039|DRUG|doxorubicin hydrochloride|
219257885|NCT00004039|DRUG|prednisone|
219257886|NCT00004039|DRUG|vincristine sulfate|
219257887|NCT01916798|DRUG|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
219257888|NCT02866071|DRUG|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
219257889|NCT02866071|DRUG|Placebo-Comparator|50mg IN Placebo
219257890|NCT06332300|DRUG|Adebelimumab+Famitinib + FOLFIRI+Ariely|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
219257891|NCT04296422|DRUG|NSAIDs or oral contraceptives treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
219257892|NCT04296422|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
219257893|NCT04296422|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
219257894|NCT04865783|PROCEDURE|Saline spray|The saline spray will be applied twice for 1-2 seconds.
219257895|NCT04865783|PROCEDURE|Cryospray|The cryospray will be applied twice for 1-2 seconds.
219257896|NCT03946098|BEHAVIORAL|iCBT|A newly developed iCBT protocol targeting problem gambling.
219257897|NCT04673799|DRUG|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
219257898|NCT04673799|DRUG|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
219257899|NCT05858801|DEVICE|PRIMUS|PRIMUS system
219257900|NCT03284125|OTHER|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
219257901|NCT04342598|OTHER|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
219257902|NCT04787289|DRUG|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
219257903|NCT03788122|OTHER|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
219257904|NCT00814411|BEHAVIORAL|group family planning counseling|group family planning counseling for gynecological patients with unmet need
219257905|NCT00814411|BEHAVIORAL|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
219257906|NCT05596747|DRUG|LY3209590|Administered SC.
219257907|NCT05596747|DRUG|Insulin Glargine|Administered SC.
219257908|NCT04615598|BEHAVIORAL|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
219257909|NCT04615598|BEHAVIORAL|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
219257910|NCT05097937|OTHER|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
219257911|NCT05097937|OTHER|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
219257912|NCT05097937|OTHER|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
219257913|NCT05479188|DEVICE|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
219257914|NCT05479188|DEVICE|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
219257915|NCT05479188|DEVICE|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
219257916|NCT05479188|DEVICE|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
219257917|NCT04231162|DIETARY_SUPPLEMENT|Active product|Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
219257918|NCT04231162|DIETARY_SUPPLEMENT|Control product|Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
219257919|NCT04731974|DRUG|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
219257920|NCT04731974|OTHER|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
219257921|NCT02815735|DEVICE|comfilcon A|contact lens
219257922|NCT02815735|DEVICE|lotrafilcon B|contact lens
219257923|NCT00334139|DRUG|Zoledronic Acid|every 4 weeks for 4 months
219257924|NCT02253745|DRUG|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
219257925|NCT02253745|DRUG|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
219257926|NCT04747821|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
219257927|NCT02476747|OTHER|EMR|performing EMR for patients with small polyp
219257928|NCT02476747|OTHER|CSP|performing CSP for patients with small polyp
219257929|NCT03182296|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
219257930|NCT01852188|OTHER|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
219257931|NCT02876848|OTHER|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~* Contact you over the phone or in person to provide medical advice on how to better take your pills,~* Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
219257932|NCT04287634|OTHER|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
219257933|NCT04287634|OTHER|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
219257934|NCT02064309|DEVICE|Beta-Air device for encapsulation of transplanted human islets|
219257935|NCT00132951|DRUG|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
219257936|NCT00132951|DRUG|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
219257937|NCT00676897|DRUG|Simvastatin|Simvastatin 40mg PO or NGT
219257938|NCT00676897|DRUG|Placebo|Corn Starch
219257939|NCT03552237|DIETARY_SUPPLEMENT|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
219257940|NCT02651883|BEHAVIORAL|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
219257941|NCT02651883|BEHAVIORAL|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
219257942|NCT04574661|OTHER|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
219257943|NCT04574661|OTHER|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
219257944|NCT00997932|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
219257945|NCT06008340|DEVICE|Dual chamber Pacemaker|Anti bradycardia device implanted in patients with complete heart block, the device has 2 leads, one in the RT atrium and the other in RV. The RV lead positioned either apical or septal
219257946|NCT00468858|OTHER|Placebo|"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
219257947|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
219257948|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
219257949|NCT05738447|BIOLOGICAL|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
219257950|NCT03645005|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
219257951|NCT03645005|BEHAVIORAL|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
219257952|NCT02497196|DEVICE|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
219257953|NCT02497196|DEVICE|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
219257954|NCT02497196|DEVICE|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
219257955|NCT02497196|DEVICE|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
219257956|NCT03022383|DEVICE|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
219257957|NCT00004403|DRUG|albendazole|
219257958|NCT00004403|DRUG|dexamethasone|
219257959|NCT00004403|DRUG|phenytoin|
219257960|NCT04853134|DRUG|Proxalutamide|200 mg q.d.
219257961|NCT04853134|OTHER|Standard of Care|Standard of care as determined by the PI
219257962|NCT05213325|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
219257963|NCT00581464|BEHAVIORAL|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
219257964|NCT00581464|BEHAVIORAL|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
219257965|NCT00321321|DRUG|Sulfonylurea|
219257966|NCT02154477|DRUG|intranasal insulin|insulin
219257967|NCT02154477|DRUG|placebo (intranasal saline)|saline
219257968|NCT01510002|PROCEDURE|Total thyroidectomy|Extracapsular total thyroidectomy
219257969|NCT01510002|PROCEDURE|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
219257970|NCT01228721|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
219257971|NCT04921878|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
219257972|NCT01086332|DRUG|Nelfinavir|1250 mg twice daily
219257973|NCT01086332|DRUG|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
219257974|NCT01709955|DIETARY_SUPPLEMENT|Glucomannan|750 MG of Glucomannan in capsule form
219257975|NCT01709955|OTHER|Placebo|750 mg of Cellulose powder in a capsule form
219257976|NCT00237614|DRUG|intravenous and oral N-acetylcysteine|
219257977|NCT01579110|DRUG|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
219257978|NCT01579110|DRUG|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
219257979|NCT05197114|OTHER|summerlunch+ At Home Food Skills Program|The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
219257980|NCT04311385|DIAGNOSTIC_TEST|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
219257981|NCT03694626|DEVICE|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
219257982|NCT03694626|DEVICE|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
219257983|NCT03694626|DEVICE|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
219257984|NCT03694626|DEVICE|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
219257985|NCT03694626|DEVICE|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
219257986|NCT05226247|PROCEDURE|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
219257987|NCT02954796|DRUG|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
219257988|NCT01219777|DRUG|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
219257989|NCT01219777|DRUG|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
219257990|NCT01219777|DRUG|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
219257991|NCT02678364|DIETARY_SUPPLEMENT|Control eggs|Control eggs containing no additional vitamin D beyond norm
219257992|NCT02678364|DIETARY_SUPPLEMENT|Vitamin D3 eggs|Vitamin D3-biofortified eggs
219257993|NCT02678364|DIETARY_SUPPLEMENT|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
219257994|NCT02106637|DRUG|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
219257995|NCT02106637|DRUG|placebo|placebo
219257996|NCT03937037|PROCEDURE|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
219257997|NCT02975297|DRUG|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
219257998|NCT02975297|DRUG|NRT|Nicotine Patch (21mg) / 24 hours.
219257999|NCT02975297|BEHAVIORAL|Counseling|Brief individual behavioral smoking cessation counseling.
219258000|NCT02975297|DRUG|Placebo|Normal saline.
219258001|NCT05864885|DRUG|Minoxidil|Topical formulation applied once a day.
219258002|NCT05501496|PROCEDURE|intramedullary nailing|Flexible intramedullary nailing using 2 nails
219258003|NCT05501496|PROCEDURE|casting|casting with long leg cast
219258004|NCT01655992|DRUG|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
219258005|NCT01655992|DRUG|S1 generic|40mg／m2 bid four weeks on two weeks off
219258006|NCT05291806|OTHER|Reference Product|This intervention is based on white rice.
219258007|NCT05291806|OTHER|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
219258008|NCT05291806|OTHER|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
219258009|NCT05291806|OTHER|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
219258010|NCT00225277|DRUG|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
219258011|NCT00225277|DRUG|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
219258012|NCT06468267|DRUG|Thiotepa|The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
219258013|NCT03432650|DRUG|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
219258014|NCT03432650|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
219258015|NCT00276900|DRUG|Sertraline|
219258016|NCT01961674|DIETARY_SUPPLEMENT|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
219258017|NCT03772509|OTHER|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
219258018|NCT00822666|DRUG|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
219258019|NCT02923609|BIOLOGICAL|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
219258020|NCT03220165|DRUG|MGL-3196|oral, 100 mg
219258021|NCT00711997|BIOLOGICAL|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
219258022|NCT00945763|DRUG|N1539|30 mg
219258023|NCT00945763|DRUG|placebo|tablets
219258024|NCT00945763|DRUG|N1539|15 mg
219258025|NCT00945763|DRUG|N1539|60 mg
219258026|NCT00945763|DRUG|Motrin|400 mg
219258027|NCT04731675|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
219258028|NCT00511186|DRUG|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
219258029|NCT00511186|DRUG|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
219258030|NCT02735356|DRUG|Itraconazole|Applied topically
219258031|NCT02735356|OTHER|Placebo|Applied topically
219258032|NCT04356638|DRUG|Midazolam|Oral Midazolam and intranasal placebo
219258033|NCT04356638|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
219258034|NCT04356638|OTHER|Placebo|Placebo orally and intranasally
219258035|NCT04582669|DRUG|Intralesional Triamcinolone 10 mg/mL|Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
219258036|NCT04582669|DRUG|Intralesional Triamcinolone 20 mg/mL|Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
219258037|NCT04582669|DRUG|Intralesional Triamcinolone 40 mg/mL|Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
219258038|NCT04582669|DRUG|Placebo|Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
219258039|NCT05700578|BEHAVIORAL|Safety Behavior Elimination for Traumatic Stress (SBETS)|This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
219258040|NCT05700578|BEHAVIORAL|Modifiable Behavior Intervention (MoBI)|The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
219258041|NCT04853407|DRUG|LY03005 extended-release tablet|orally once a day
219258042|NCT04853407|DRUG|Placebo|orally once a day
219258043|NCT04693845|BEHAVIORAL|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
219258044|NCT04693845|BEHAVIORAL|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
219258045|NCT04052035|PROCEDURE|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
219258046|NCT06511518|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
219258047|NCT00353093|PROCEDURE|Ultrasonography of the deep vein system of the legs|
219258048|NCT05277090|DRUG|2L of polyethyleneglycol|2L of polyethyleneglycol
219258049|NCT05277090|DIETARY_SUPPLEMENT|inulin|15g inulin per day
219258050|NCT05277090|COMBINATION_PRODUCT|probiotic combination product|"participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
219258051|NCT03544437|PROCEDURE|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
219258052|NCT01430078|DRUG|ASP015K|oral tablet
219258053|NCT01430078|DRUG|ASP015K|solution via oral capsule
219258054|NCT00591409|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
219258055|NCT00591409|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
219258056|NCT00677092|DRUG|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
219258057|NCT00502164|DRUG|AZD2171|
219258058|NCT05245305|OTHER|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
219258059|NCT04737005|PROCEDURE|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
219258060|NCT02716077|RADIATION|FDG PET/CT imaging|
219258061|NCT01795729|DEVICE|Stent|Coronary revascularization
219258062|NCT01795729|DRUG|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
219258063|NCT06371430|DEVICE|Dental Implant insertion and tooth extraction|"The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment."
219258064|NCT03401723|OTHER|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
219258065|NCT03401723|OTHER|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
219258066|NCT03401723|OTHER|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
219258067|NCT02554422|DEVICE|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
219258068|NCT05047653|DIAGNOSTIC_TEST|RALE score vs. severity score|RALE score vs. severity score and CORADS
219258069|NCT02673307|BEHAVIORAL|1 chewing gum over 45 minutes|
219258070|NCT06213519|DRUG|S-1, Oxaliplatin sintilimab HIPEC|"1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."
219258071|NCT02714699|DRUG|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
219258072|NCT02714699|DRUG|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
219258073|NCT02714699|DRUG|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
219258074|NCT02716298|DEVICE|fanfilcon A|contact lens
219258075|NCT02716298|DEVICE|lotrafilcon B|contact lens
219258076|NCT00550446|DRUG|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
219258077|NCT00550446|DRUG|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
219258078|NCT00550446|DRUG|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
219258079|NCT00550446|DRUG|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
219258080|NCT00550446|DRUG|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
219258081|NCT00550446|DRUG|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
219258082|NCT00550446|DRUG|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
219258083|NCT04052945|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 )."
219258084|NCT04052945|PROCEDURE|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6)."
219258085|NCT03230045|DEVICE|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
219258086|NCT03230045|DEVICE|no treatment|electrodes are attached, but no stimulation is given
219258087|NCT04134715|DRUG|PF-06826647|100 mg tablet
219258088|NCT04134715|DRUG|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
219258089|NCT04362098|BEHAVIORAL|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
219258090|NCT04952701|DEVICE|Control lenses|Control Multifocal lenses
219258091|NCT04952701|DEVICE|Test lenses|Test Multifocal lenses
219258092|NCT06295042|OTHER|BREAST-Q Questionnaire|Patient-reported outcome measure
219258093|NCT00818870|DRUG|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
219258094|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
219258095|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
219258096|NCT05132660|DRUG|Sinemet CR|25 mg carbidopa/100 mg levodopa
219258097|NCT05132660|DRUG|placebo|Placebo pill of similar size/shape
219258098|NCT05194475|OTHER|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
219258099|NCT05194475|OTHER|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
219258100|NCT02051985|OTHER|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
219258101|NCT02051985|OTHER|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
219258102|NCT01789619|DRUG|Extended release tacrolimus (Advagraf®)|
219258103|NCT01013064|DRUG|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
219258104|NCT00001359|DRUG|Penicillin or Placebo|
219258105|NCT05254717|OTHER|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
219258106|NCT04938622|OTHER|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
219258107|NCT04938622|OTHER|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
219258108|NCT04938622|OTHER|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
219258109|NCT04938622|OTHER|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
219258110|NCT04938622|OTHER|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
219258111|NCT04938622|OTHER|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
219258112|NCT03234842|RADIATION|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
219258113|NCT03234842|RADIATION|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
219258114|NCT03234842|DRUG|Chemotherapy|Concurrent weekly chemotherapy at standard doses
219258115|NCT03403556|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
219258116|NCT03403556|DRUG|Monorova|Rosuvastatin 20mg qd for 24 weeks
219258117|NCT02969629|DRUG|Apomorphine|
219258118|NCT02969629|DRUG|Normal Saline|
219258119|NCT05820321|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
219258120|NCT05820321|OTHER|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
219258121|NCT01033279|OTHER|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
219258122|NCT03578419|DEVICE|Small-Volume Blood Collection Tubes|Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
219258123|NCT03578419|DEVICE|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
219258124|NCT01670188|DEVICE|Pneumatic SCD - VenaFlow System (DJO Global)|
219258125|NCT00065819|BEHAVIORAL|HIV Symptom Education Program|
219258126|NCT00078858|DRUG|fludarabine phosphate|Given IV
219258127|NCT00078858|RADIATION|total-body irradiation|Undergo TBI
219258128|NCT00078858|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
219258129|NCT00078858|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
219258130|NCT00078858|DRUG|cyclosporine|Given PO
219258131|NCT00078858|DRUG|mycophenolate mofetil|Given PO or IV
219258132|NCT00078858|OTHER|laboratory biomarker analysis|Correlative studies
219258133|NCT02115334|BEHAVIORAL|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
219258134|NCT02115334|BEHAVIORAL|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
219258135|NCT02115334|BEHAVIORAL|health education|health education of the children with DD.
219258136|NCT01575483|DRUG|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
219258137|NCT01104064|DEVICE|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
219258138|NCT01104064|DEVICE|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
219258139|NCT06276101|BIOLOGICAL|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
219258140|NCT04499014|DEVICE|ultrasound|5 days a week, a total of 10 sessions
219258141|NCT02212301|DEVICE|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
219258142|NCT02212301|DEVICE|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
219258143|NCT05596149|OTHER|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
219258144|NCT05596149|OTHER|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
219258145|NCT05596149|OTHER|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
219258146|NCT05596149|OTHER|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
219258147|NCT03047902|OTHER|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
219258148|NCT03047902|OTHER|Group 2- Parents will not be present for the Questionnaire|
219258149|NCT04456049|DRUG|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
219258150|NCT03927222|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
219258151|NCT03927222|DRUG|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
219258152|NCT03927222|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
219258153|NCT03927222|BIOLOGICAL|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
219258154|NCT03927222|BIOLOGICAL|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
219258155|NCT06464614|DRUG|Adebrelimab|Adebrelimab 1200mg，d1，q3w, until disease progression or unacceptable toxicity
219258156|NCT06464614|DRUG|Apatinib|Apatinib 250mg，d1-21，q3w, until disease progression or unacceptable toxicity
219258157|NCT06464614|DRUG|Investigator chosen chemotherapy (ICC)|"Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.~Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or withdrawal due to other reasons; when synchronized with radiotherapy, 625mg/m2, bid, oral, d1-5, qw."
219258158|NCT06464614|RADIATION|Radiotherapy|Radiotherapy mode: IMRT for the primary lesion and SBRT for the metastasis; If the patient has symptoms of dysphagia, the radiation dose is 1.8 Gy×28 F or 2 Gy×25 F, d1-5 5 times a week; If oligometastatic lesions occur in the body: the radiation dose is 8 Gy×5F, d1-5; If oligometastatic lesions occur in the brain, the radiation dose is 7 Gy×5F, d1-5.
219258159|NCT06389929|BEHAVIORAL|Education|In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
219258160|NCT00273351|DRUG|[123I]B-CIT|Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
219258161|NCT01099683|DRUG|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
219258162|NCT01099683|DRUG|Placebo|All subjects will receive rectal suppository containing placebo
219258163|NCT00030303|BIOLOGICAL|recombinant 70-kD heat-shock protein|
219258164|NCT06011928|OTHER|MOPEX Exercise|"Exercises to be done in order:~1. Pelvic tilt in supine position~2. Bridge building~3. Pelvic stretching~4. Ball spin~5. Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
219258165|NCT06011928|OTHER|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
219258166|NCT06011928|OTHER|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
219258167|NCT03122405|DEVICE|RAM sensors|Noninvasive acoustic monitoring device
219258168|NCT00804414|DRUG|SBG|Solution for topical use
219258169|NCT00804414|DRUG|Placebo Comparator|Solutin for topical use
219258170|NCT00866827|OTHER|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
219258171|NCT00375778|DRUG|memantine (drug)|
219258172|NCT01929564|OTHER|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
219258173|NCT01929564|OTHER|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
219258174|NCT02997397|PROCEDURE|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
219258175|NCT02997397|PROCEDURE|tourniquet(-)|
219258176|NCT03231761|OTHER|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
219258177|NCT03231761|OTHER|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
219258178|NCT05240547|OTHER|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
219258179|NCT05240547|OTHER|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
219258180|NCT00001440|PROCEDURE|Autologous T cells|
219258181|NCT00001440|DRUG|Interleukin-2|
219258182|NCT04659200|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
219258183|NCT05062837|DRUG|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
219258184|NCT03455218|DRUG|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
219258185|NCT03455218|DRUG|Placebo|INOmax device connected to oxygenator, but no gas is delivered
219258186|NCT03455218|DEVICE|INOmax|All patients will have the INOmax device connected to the oxygenator
219258187|NCT01705223|BIOLOGICAL|DNA vaccine|4mg/dose, three doses at week 0,4,8
219258188|NCT01705223|BIOLOGICAL|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
219258189|NCT01705223|BIOLOGICAL|rTV boost|at week 16
219258190|NCT01705223|BIOLOGICAL|rTV boost|at week 24
219258191|NCT01705223|BIOLOGICAL|rTV boost|at week 32
219258192|NCT00204516|BIOLOGICAL|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
219258193|NCT00204516|DRUG|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
219258194|NCT00052325|DIETARY_SUPPLEMENT|mistletoe extract|
219258195|NCT06369857|PROCEDURE|Pectopexy|Suspension of apical organs
219258196|NCT00578318|BEHAVIORAL|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
219258197|NCT01340040|DRUG|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
219258198|NCT02486159|DRUG|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
219258199|NCT02486159|PROCEDURE|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
219258200|NCT04031118|DEVICE|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
219258201|NCT02053064|GENETIC|SAF-301|
219258202|NCT00866918|DRUG|Arsenic Trioxide|Given IV
219258203|NCT00866918|DRUG|Cytarabine|Given IT or IV
219258204|NCT00866918|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219258205|NCT00866918|DRUG|Idarubicin|Given IV
219258206|NCT00866918|DRUG|Mercaptopurine|Given orally
219258207|NCT00866918|DRUG|Methotrexate|Given orally
219258208|NCT00866918|DRUG|Mitoxantrone Hydrochloride|Given IV
219258209|NCT00866918|DRUG|Tretinoin|Given orally
219258210|NCT04611724|DRUG|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
219258211|NCT04069429|RADIATION|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
219258212|NCT04069429|RADIATION|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
219258213|NCT04069429|DRUG|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
219258214|NCT04069429|RADIATION|Planar Images|2 dimensional imaging - whole body planar scans
219258215|NCT04069429|PROCEDURE|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
219258216|NCT03775278|DRUG|PHP-303|Investigational drug
219258217|NCT03775278|OTHER|Placebo|Matching placebo
219258218|NCT00527514|DRUG|Amlodipine|Tablets
219258219|NCT00527514|DRUG|Olmesartan medoxomil plus amlodipine|Tablets
219258220|NCT00027963|DRUG|gabapentin|
219258221|NCT00027963|OTHER|placebo|
219258222|NCT05644236|OTHER|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
219258223|NCT01842919|OTHER|Kinesthetics tests|
219258224|NCT01842919|OTHER|Psychological questionnaires|
219258225|NCT01842919|OTHER|structural Magnetic ResonanceImaging (MRI)|
219258226|NCT04045522|DRUG|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
219258227|NCT05854771|OTHER|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
219258228|NCT05854771|OTHER|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
219258229|NCT01636830|DEVICE|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
219258230|NCT03230409|BEHAVIORAL|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
219258231|NCT03230409|BEHAVIORAL|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
219258232|NCT03230409|BIOLOGICAL|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
219258233|NCT03230409|BEHAVIORAL|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
219258234|NCT04850859|OTHER|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
219258235|NCT04850859|OTHER|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
219258236|NCT00812838|DRUG|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
219258237|NCT00812838|OTHER|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
219258238|NCT00812838|DRUG|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
219258239|NCT00141908|DRUG|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
219258240|NCT00141908|DRUG|Castor oil|weekly IM injections
219258241|NCT03106935|DRUG|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
219258242|NCT02643953|BEHAVIORAL|Incentives|1\) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
219258243|NCT02643953|BEHAVIORAL|Community|1\) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
219258244|NCT01562483|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
219258245|NCT01562483|DRUG|Placebo|Identical to the Namisol arm.
219258246|NCT04148521|BEHAVIORAL|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
219258247|NCT01539408|DRUG|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
219258248|NCT01539408|PROCEDURE|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
219258249|NCT06117202|OTHER|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
219258250|NCT05167513|DRUG|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
219258251|NCT01245335|DEVICE|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
219258252|NCT01245335|DEVICE|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
219258253|NCT04933162|DIETARY_SUPPLEMENT|High Protein and Low Fiber Diet|Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.
219258254|NCT04933162|DIETARY_SUPPLEMENT|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
219258255|NCT01793298|DRUG|ASM-024|Ascending doses of ASM-024
219258256|NCT01334762|DRUG|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
219258257|NCT01334762|DRUG|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
219258258|NCT04064723|DEVICE|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
219258259|NCT00557336|DRUG|somatropin|
219258260|NCT01530659|DRUG|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
219258261|NCT01530659|PROCEDURE|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
219258262|NCT00920699|DRUG|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
219258263|NCT00001941|BIOLOGICAL|daclizumab|
219258264|NCT00953862|DRUG|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
219258265|NCT01329185|DRUG|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
219258266|NCT01329185|DRUG|Placebo|1 capsule twice a day for 14 days prior to transplant date
219258267|NCT03696602|DIAGNOSTIC_TEST|bronchial provocation test|
219258268|NCT00632723|DRUG|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
219258269|NCT01723514|DRUG|Erenumab|Administered by subcutaneous injection once a month
219258270|NCT01723514|DRUG|Placebo|Administered by subcutaneous injection once a month
219258271|NCT04112277|DRUG|Cumulative morphine consumption|morphine equivalent \[mg\] 24 hours after the procedure
219258272|NCT01336387|DRUG|retinoid 9cUAB30|Given PO
219258273|NCT01336387|OTHER|placebo|Given PO
219258274|NCT01336387|OTHER|pharmacological study|Correlative studies
219258275|NCT01336387|OTHER|laboratory biomarker analysis|Correlative studies
219258276|NCT01336387|OTHER|cancer prevention|Disease prevention
219258277|NCT06124183|BEHAVIORAL|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
219258278|NCT02241161|OTHER|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
219258279|NCT02241161|OTHER|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
219258280|NCT02241161|OTHER|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
219258281|NCT05550714|DRUG|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
219258282|NCT05550714|DRUG|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
219258283|NCT00014222|BIOLOGICAL|epoetin alfa|40,000 IU
219258284|NCT00014222|BIOLOGICAL|filgrastim|5 mg/kg/d - days 2-13
219258285|NCT00014222|DRUG|cyclophosphamide|75, 600 and 830 mg/m2
219258286|NCT00014222|DRUG|doxorubicin hydrochloride|60 mg/m2
219258287|NCT00014222|DRUG|epirubicin hydrochloride|60 mg/m2
219258288|NCT00014222|DRUG|fluorouracil|500mg/m2
219258289|NCT00014222|DRUG|paclitaxel|175 mg/m2
219258290|NCT03964922|BIOLOGICAL|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
219258291|NCT03964922|BIOLOGICAL|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
219258292|NCT01723007|OTHER|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
219258293|NCT01222702|DRUG|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
219258294|NCT01222702|DRUG|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
219258295|NCT01222702|DRUG|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
219258296|NCT01222702|DRUG|Placebo-matching vancomycin|Placebo of vancomycin capsules
219258297|NCT05725044|DIETARY_SUPPLEMENT|Ginsengberry concentrate|Ginsengberry concentrate
219258298|NCT05725044|DIETARY_SUPPLEMENT|Placebo|Placebo
219258299|NCT00002621|BIOLOGICAL|recombinant interferon alfa|
219258300|NCT04322916|DEVICE|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
219258301|NCT02728375|OTHER|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
219258302|NCT02728375|OTHER|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
219258303|NCT03462498|DRUG|1-months DAPT|1-month DAPT followed by 59-month monotherapy
219258304|NCT03462498|DRUG|12-month DAPT|12-month DAPT followed by 48-month monotherapy
219258305|NCT04317001|DRUG|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
219258306|NCT04317001|DRUG|Placebo|placebo
219258307|NCT01547247|DEVICE|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
219258308|NCT01547247|PROCEDURE|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
219258309|NCT00626613|DRUG|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
219258310|NCT04266002|OTHER|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
219258311|NCT04054453|COMBINATION_PRODUCT|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
219258312|NCT01074697|DRUG|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
219258313|NCT01074697|DRUG|Placebo|Saline water
219258314|NCT06035185|PROCEDURE|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
219258315|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
219258316|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Pain (CBT-P)|
219258317|NCT04857047|DRUG|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
219258318|NCT04857047|DRUG|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
219258319|NCT05434715|PROCEDURE|Thyroidectomy|removal of the thyroid gland
219258320|NCT05867914|DEVICE|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
219258321|NCT01120288|DRUG|EZN-2968|
219258322|NCT05774171|OTHER|no intervention|no intervention
219258323|NCT00325546|DRUG|Rimonabant (SR141716)|
219258324|NCT00325546|DRUG|Placebo|
219258325|NCT04232878|DRUG|CVL-936|CVL-936
219258326|NCT04232878|DRUG|Matching Placebo|Placebo matching CVL-936
219258327|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
219258328|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
219258329|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
219258330|NCT00819013|BIOLOGICAL|Saline placebo|0.5 mL, Intramuscular
219258331|NCT03470792|DEVICE|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
219258332|NCT05101915|DRUG|RESP301|Inhaled IMP delivered via nebulisation
219258333|NCT03260803|DRUG|Oligopin|Oligopin ,150 mg ,once daily, 12 week
219258334|NCT03260803|DRUG|Placebo|Placebo,150 mg ,once daily, 12 week
219258335|NCT04189510|DEVICE|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
219258336|NCT04189510|OTHER|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
219258337|NCT03041298|PROCEDURE|MR mammography with Dotarem|
219258338|NCT00134147|DRUG|Inhaled Insulin|
219258339|NCT01930214|DEVICE|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
219258340|NCT04207645|DIAGNOSTIC_TEST|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
219258341|NCT00915577|DRUG|Interferon beta-1a|30mcg, IM once-a-week
219258342|NCT00915577|DEVICE|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
219258343|NCT02132117|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
219258344|NCT02132117|DRUG|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
219258345|NCT04075786|OTHER|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
219258346|NCT03589300|DEVICE|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
219258347|NCT01376297|DRUG|Netupitant and Palonosetron|
219258348|NCT01376297|DRUG|Aprepitant|
219258349|NCT01376297|DRUG|Palonosetron|
219258350|NCT01376297|DRUG|Dexamethasone|
219258351|NCT02569632|BIOLOGICAL|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
219258352|NCT04692090|OTHER|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
219258353|NCT04107597|OTHER|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
219258354|NCT04107597|OTHER|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
219258355|NCT04107597|OTHER|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
219258356|NCT04107597|OTHER|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
219258357|NCT02420405|PROCEDURE|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
219258358|NCT02420405|PROCEDURE|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
219258359|NCT03856814|DEVICE|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
219258360|NCT06570434|DRUG|budoprutug|monoclonal antibody
219258361|NCT00413855|PROCEDURE|laparoscopic appendectomy or not (surgery)|
219258362|NCT01213615|DEVICE|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
219258363|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
219258364|NCT04655742|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
219258365|NCT00466089|DRUG|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
219258366|NCT03352882|DIAGNOSTIC_TEST|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
219258367|NCT00142038|DRUG|Docetaxel|
219258368|NCT00142038|DRUG|Capecitabine|
219258369|NCT04622371|OTHER|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
219258370|NCT05652790|PROCEDURE|Enhanced Rehabilitation Programme|"The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
219258371|NCT05652790|PROCEDURE|Standard Care|Standard care received at usual NHS facility
219258372|NCT00006104|BIOLOGICAL|trastuzumab|
219258373|NCT00006104|DRUG|docetaxel|
219258374|NCT04573257|OTHER|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
219258375|NCT01545778|DRUG|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
219258376|NCT01545778|DRUG|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
219258377|NCT03612492|DRUG|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
219258378|NCT03612492|DRUG|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
219258379|NCT02447380|DRUG|AZD6094|AZD6094 600MG qd
219258380|NCT02447380|DRUG|Docetaxel|Docetaxel 60 mg/m2
219258381|NCT00264823|BEHAVIORAL|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
219258382|NCT05925062|BEHAVIORAL|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
219258383|NCT05640973|OTHER|Evaluation|Evaluation of ease of use
219258384|NCT00246610|DRUG|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
219258385|NCT06252090|OTHER|Short term mentalization-based treatment for adolescents (MBT-A)|The general framework of intervention corresponds to the Mentalization-Based Treatment model for adolescents (MBT-A). In this study, the model was adapted to a brief, time-limited format (12 sessions) aimed at both the adolescent and their family. The model retains the main characteristics of Mentalization-Based Therapy, such as the therapist's basic attitude toward actively promoting patients' mentalization, uncertainty of mental states, focus on the here and now, and the use of affect as a mechanism for change.
219258386|NCT03021278|OTHER|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
219258387|NCT03021278|OTHER|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
219258388|NCT04158973|OTHER|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
219258389|NCT04158973|OTHER|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
219258390|NCT00456417|DRUG|123-I MNI-187 Injection and Imaging Procedures|
219258391|NCT00686088|DRUG|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
219258392|NCT04915547|OTHER|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
219258393|NCT05750277|OTHER|Evening Time-Restricted Eating|Eating between 8am-6pm.
219258394|NCT05188898|OTHER|MINSD and Hyaluronic acid|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.
219258395|NCT05188898|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
219258396|NCT04631588|DRUG|Botox|Intradermal (ID) injection
219258397|NCT04631588|DRUG|Placebo|Intradermal (ID) injection
219258398|NCT02997683|DEVICE|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
219258399|NCT02997683|OTHER|exercises at home on the floor|exercises at home on the floor
219258400|NCT01020747|DRUG|Avastin® (bevacizumab)|Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
219258401|NCT01020747|DRUG|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
219258402|NCT01040923|DEVICE|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
219258403|NCT04206709|PROCEDURE|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
219258404|NCT04206709|OTHER|passive pedaling|20 minutes passive pedaling by upper limbs.
219258405|NCT01510132|DRUG|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
219258406|NCT01792778|DEVICE|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
219258407|NCT01792778|DEVICE|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
219258408|NCT01222078|BIOLOGICAL|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
219258409|NCT00136682|DRUG|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
219258410|NCT00136682|DRUG|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
219258411|NCT02576327|DRUG|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
219258412|NCT02576327|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
219258413|NCT02576327|DRUG|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
219258414|NCT02970305|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
219258415|NCT02970305|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
219258416|NCT03592823|DRUG|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
219258417|NCT06017336|OTHER|Inspiratory Muscle Training Group|Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
219258418|NCT06017336|OTHER|Control Group (breathing exercises)|Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
219258419|NCT02220777|DRUG|ASP8477|oral
219258420|NCT02220777|DRUG|omeprazole|oral
219258421|NCT02220777|DRUG|Placebo|oral
219258422|NCT00983892|BEHAVIORAL|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
219258423|NCT00006005|DRUG|thalidomide|
219258424|NCT00808899|DRUG|Temsirolimus|Temsirolimus
219258425|NCT00808899|DRUG|Irinotecan|Irinotecan
219258426|NCT00808899|PROCEDURE|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
219258427|NCT00808899|DRUG|Cyclophosphamide|Cyclophosphamide
219258428|NCT00808899|DRUG|Doxorubicin|Doxorubicin
219258429|NCT00808899|DRUG|Etoposide|Etoposide
219258430|NCT00808899|DRUG|Cisplatin|Cisplatin
219258431|NCT00808899|DRUG|Topotecan|Topotecan
219258432|NCT00808899|PROCEDURE|PBSC|Peripheral Blood Stem Cell Harvest
219258433|NCT00808899|RADIATION|Radiation Therapy|Radiation Therapy
219258434|NCT00808899|DRUG|13-cis-retinoic acid|13-cis-retinoic acid
219258435|NCT00450398|DRUG|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
219258436|NCT00450398|DRUG|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
219258437|NCT04615910|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
219258438|NCT04466410|BIOLOGICAL|XT-150|Single bolus intrathecal injection
219258439|NCT04466410|BIOLOGICAL|Placebo|Placebo is a sterile phosphate-buffered saline
219258440|NCT05459025|BEHAVIORAL|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
219258441|NCT05459025|BEHAVIORAL|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
219258442|NCT03509142|DEVICE|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
219258443|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
219258444|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
219258445|NCT03483597|OTHER|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
219258446|NCT01196247|DRUG|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
219258447|NCT01225159|DRUG|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
219258448|NCT01225159|DRUG|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
219258449|NCT05971017|DIETARY_SUPPLEMENT|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
219258450|NCT05971017|DIETARY_SUPPLEMENT|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
219258451|NCT05011617|DEVICE|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
219258452|NCT06646718|PROCEDURE|Close kinetic chain exercise group|●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
219258453|NCT06646718|PROCEDURE|Traditional physical therapy.|●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
219258454|NCT05950776|BIOLOGICAL|MVA-SARS-2-S|Vaccination with MVA-SARS-2-S
219258455|NCT05950776|OTHER|Placebo|Placebo
219258456|NCT03421171|OTHER|no intervention|Qualitative research through semi-structured interviews
219258457|NCT02946827|DIETARY_SUPPLEMENT|Balanced low FODMAPs /gluten free diet|
219258458|NCT02946827|DIETARY_SUPPLEMENT|Balanced gluten free diet|
219258459|NCT01911936|DRUG|LM716|
219258460|NCT02703402|OTHER|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
219258461|NCT02703402|OTHER|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
219258462|NCT04887701|DEVICE|Non-hormonal vaginal device therapy|Experimental Active Therapy
219258463|NCT04887701|DEVICE|Sham vaginal device therapy|Sham Comparator
219258464|NCT01592383|DRUG|erlotinib hydrochloride|Given PO
219258465|NCT01128140|BEHAVIORAL|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
219258466|NCT01128140|BEHAVIORAL|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
219258467|NCT05832944|DEVICE|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
219258468|NCT03462368|PROCEDURE|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
219258469|NCT03462368|PROCEDURE|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
219258470|NCT03462368|PROCEDURE|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
219258471|NCT06516692|DIAGNOSTIC_TEST|Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment|Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
219258472|NCT06561256|DRUG|Janus Kinase Inhibitor|Janus Kinase Inhibitor in combination with corticosteroids
219258473|NCT00115284|BEHAVIORAL|ABIM asthma practice improvement module|
219258474|NCT03955952|PROCEDURE|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
219258475|NCT02367742|BEHAVIORAL|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
219258476|NCT02367742|BEHAVIORAL|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
219258477|NCT00951574|DRUG|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
219258478|NCT00951574|DRUG|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
219258479|NCT03847220|DIAGNOSTIC_TEST|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
219258480|NCT05262504|DEVICE|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
219258481|NCT00328276|DRUG|Sarcosine|
219258482|NCT03650244|DEVICE|REMEEX implantation|Device implantation
219258483|NCT04365738|OTHER|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
219258484|NCT03761407|DRUG|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
219258485|NCT03761407|DRUG|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
219258486|NCT03761407|DRUG|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
219258487|NCT03761407|DRUG|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
219258488|NCT03761407|DRUG|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
219258489|NCT06310226|DEVICE|Epidural electrical spinal cord stimulator|Epidural electrical spinal cord stimulator turned on vs. turned off
219258490|NCT04807023|BIOLOGICAL|blood sampling|blood sampling
219258491|NCT05546736|BEHAVIORAL|iCanWork Intervention|Participants will receive RTW support from the VRC and OT.
219258492|NCT04322760|DRUG|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
219258493|NCT04322760|DRUG|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
219258494|NCT04417569|DRUG|hCG|human chorionic gonadotropin
219258495|NCT04417569|DIAGNOSTIC_TEST|Ultrasound|Endometrial thickness monitoring
219258496|NCT04417569|OTHER|Blood test|Progesterone, Luteinizing Hormone, Estradiol
219258497|NCT02809807|OTHER|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
219258498|NCT02809807|DEVICE|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
219258499|NCT01491542|DEVICE|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
219258500|NCT01491542|DEVICE|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
219258501|NCT06094335|DEVICE|Virtual reality rehabilitation|Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
219258502|NCT06094335|OTHER|Traditional physical therapy|Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
219362975|NCT03760497|PROCEDURE|Restorative treatment|For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
219258503|NCT02306447|DEVICE|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
219258504|NCT02236663|BEHAVIORAL|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
219258505|NCT02236663|BEHAVIORAL|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
219258506|NCT06413264|PROCEDURE|Ultrasonography guided Veress needle insertion for creating pneumoperitoneum|A real-time visualisation of the path of the Veress needle entry by the use of high frequency (13-6 MHz) probe ultrasonography.
219258507|NCT06413264|PROCEDURE|Veress needle will be inserted blindly as a closed technique for creating pneumoperitoneum|The Veress needle is inserted blindly and guided by the resistance of tissues and the click sounds of layers of abdominal wall.
219258508|NCT05248698|BEHAVIORAL|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
219258509|NCT05248698|OTHER|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
219258510|NCT01904136|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
219258511|NCT01904136|PROCEDURE|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
219258512|NCT01904136|DRUG|Cyclophosphamide|Given IV
219258513|NCT01904136|DRUG|Fludarabine|Given IV
219258514|NCT01904136|OTHER|Laboratory Biomarker Analysis|Correlative studies
219258515|NCT01904136|DRUG|Melphalan|Given IV
219258516|NCT01904136|DRUG|Mycophenolate Mofetil|Given PO
219258517|NCT01904136|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
219258518|NCT01904136|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
219258519|NCT01904136|DRUG|Tacrolimus|Given IV and PO
219258520|NCT01904136|RADIATION|Total-Body Irradiation|Undergo TBI
219258521|NCT01742845|OTHER|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
219258522|NCT01742845|OTHER|landmark based superfical ropivacaine 4.75 mg/ml injection|
219258523|NCT00370370|DRUG|bevacizumab|Injection of intravitreal bevacizumab
219258524|NCT00370370|DRUG|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
219258525|NCT00349739|DRUG|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
219258526|NCT00853372|DRUG|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
219258527|NCT00853372|DRUG|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
219258528|NCT04334447|OTHER|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
219258529|NCT04334447|OTHER|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
219258530|NCT04334447|OTHER|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
219258531|NCT04950062|OTHER|High Intensity Interval Training|"1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit."
219258532|NCT04950062|OTHER|Intermittent Fasting 16/8 Protocol|Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
219258533|NCT05218746|PROCEDURE|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
219258534|NCT05218746|PROCEDURE|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
219258535|NCT00489528|DRUG|Somatropin; Recombinant human growth hormone (r hGH)|
219258536|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
219258537|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
219258538|NCT03785626|PROCEDURE|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
219258539|NCT01346462|BEHAVIORAL|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
219258540|NCT05885269|DRUG|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
219258541|NCT05885269|DRUG|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
219258542|NCT02925234|DRUG|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
219258543|NCT02925234|DRUG|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
219258544|NCT02925234|DRUG|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
219258545|NCT02925234|DRUG|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
219258546|NCT02925234|DRUG|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
219258547|NCT02925234|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
219258548|NCT02925234|DRUG|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
219258549|NCT02925234|DRUG|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
219258550|NCT02925234|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
219258551|NCT02925234|DRUG|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
219258552|NCT02925234|DRUG|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
219258553|NCT02925234|DRUG|Afatinib|Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
219258554|NCT02925234|DRUG|Dabrafenib and trametinib|Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
219258555|NCT02925234|DRUG|Ribociclib|Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
219258556|NCT02925234|DRUG|Lenvatinib|Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
219258557|NCT02925234|DRUG|Pembrolizumab|Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
219258558|NCT02925234|DRUG|Durvalumab|Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
219258559|NCT02925234|DRUG|Rucaparib|Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
219258560|NCT02925234|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
219258561|NCT02925234|DRUG|Palbociclib|Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
219258562|NCT02925234|DRUG|Crizotinib|Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
219258563|NCT02925234|DRUG|Sunitinib|Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
219258564|NCT02925234|DRUG|Cabozantinib|Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
219258565|NCT02925234|DRUG|Abemaciclib|Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
219258566|NCT02925234|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
219258567|NCT02925234|DRUG|Atezolizumab and Bevacizumab|Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
219258568|NCT02925234|DRUG|Ipilimumab and nivolumab|Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
219258569|NCT02925234|DRUG|Entrectinib|Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
219258570|NCT02925234|DRUG|Talazoparib|Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
219258571|NCT02925234|DRUG|Dacomitinib|Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
219258572|NCT02925234|DRUG|Lorlatinib|Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
219258573|NCT02925234|DRUG|Erdafitinib|Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
219258574|NCT02925234|DRUG|Alpelisib|Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
219258575|NCT02925234|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
219258576|NCT02925234|DRUG|Pemigatinib|Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
219258577|NCT02925234|DRUG|Selpercatinib|Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
219258578|NCT02925234|DRUG|Tepotinib|Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
219258579|NCT02531399|DEVICE|FDOCT|Measurement of retinal blood velocities
219258580|NCT02531399|DEVICE|LDV|Measurement of retinal blood velocities
219258581|NCT02531399|DEVICE|DVA|Measurement of retinal vessel diameters
219258582|NCT02531399|DEVICE|LSFG|Imaging of retinal blood flow
219258583|NCT05096078|OTHER|Diet|Special diet program for gestational diabetes
219176212|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
219258584|NCT05096078|OTHER|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
219258585|NCT00033943|DRUG|deligoparin|
219258586|NCT00071877|DRUG|Replagal|
219258587|NCT04298099|DRUG|Ropivacaine|Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
219258588|NCT05348668|DRUG|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
219258589|NCT01268098|DRUG|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
219258590|NCT05439473|DIETARY_SUPPLEMENT|Curalin|Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
219258591|NCT00665132|DEVICE|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
219258592|NCT04311190|OTHER|Family engagement|Physical exercises and simple care tasks
219258593|NCT01727206|DRUG|Tocilizumab|
219258594|NCT04338906|DRUG|Camostat Mesilate|400 mg tid, d1-d7
219258595|NCT04338906|DRUG|Placebo|Instead of Camostat Mesilate, tid, d1-d7
219258596|NCT04338906|DRUG|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
219258597|NCT00000545|BEHAVIORAL|exercise|
219258598|NCT00000545|BEHAVIORAL|diet|
219258599|NCT04388696|BEHAVIORAL|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
219258600|NCT06037239|DRUG|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
219258601|NCT01584011|OTHER|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
219258602|NCT01584011|OTHER|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
219258603|NCT01584011|BEHAVIORAL|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
219258604|NCT01584011|OTHER|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
219258605|NCT06544447|DEVICE|taVNS|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
219258606|NCT06544447|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
219258607|NCT06385613|BEHAVIORAL|Mobile-based stoma care education group|Individuals included in the intervention group will be given mobile-based stoma care trainings before surgery, on the 3rd postoperative day, on the day of discharge, and on the 1st and 3rd months after discharge, and their effectiveness will be measured using data collection forms.
219258608|NCT00523068|DRUG|Tolterodine|
219258609|NCT00523068|PROCEDURE|tension free vaginal tape|
219258610|NCT03215342|BEHAVIORAL|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
219258611|NCT03215342|BEHAVIORAL|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
219258612|NCT00085878|DRUG|SB-485232|
219258613|NCT00228098|BEHAVIORAL|Smoking cessation|
219258614|NCT01059188|DRUG|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
219258615|NCT01059188|DRUG|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
219258616|NCT01059188|DRUG|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
219258617|NCT01059188|RADIATION|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
219258618|NCT01059188|PROCEDURE|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
219258619|NCT00687245|DRUG|esomeprazole magnesium|capsules, oral, qd, one day
219258620|NCT03345147|OTHER|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
219258621|NCT03345147|OTHER|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
219258622|NCT03587779|DRUG|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
219258623|NCT03587779|DRUG|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
219258624|NCT05995847|BEHAVIORAL|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
219258625|NCT05995847|BEHAVIORAL|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
219258626|NCT02376647|OTHER|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
219258627|NCT02376647|OTHER|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
219258628|NCT03921242|DRUG|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
219258629|NCT03921242|DRUG|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
219258630|NCT03921242|DRUG|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
219258631|NCT03921242|DRUG|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
219258632|NCT03921242|DRUG|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
219258633|NCT00206739|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
219258634|NCT02432170|DEVICE|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
219258635|NCT05507398|DRUG|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
219258636|NCT01347268|PROCEDURE|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
219258637|NCT01347268|PROCEDURE|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
219258638|NCT00093288|DRUG|bupropion XL|
219258639|NCT01929876|DRUG|Cobimetinib|10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
219258640|NCT01929876|DRUG|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
219258641|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
219258642|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
219258643|NCT02043834|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
219258644|NCT04037345|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
219258645|NCT04037345|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
219258646|NCT04037345|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
219258647|NCT05162898|DRUG|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
219258648|NCT05162898|DRUG|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day
219258649|NCT05162898|DEVICE|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
219258650|NCT01845649|DRUG|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
219258651|NCT01845649|DRUG|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
219258652|NCT05186896|OTHER|Risk perception questionnaire|A questionnaire for risk perception will be developed and administered
219258653|NCT00048503|DRUG|ZARNESTRA, tipifarnib, R115777|
219258654|NCT00148252|DRUG|Mycophenolate mofetil withdrawal|
219258655|NCT00148252|DRUG|Cyclosporione A withdrawal|
219258656|NCT01893853|OTHER|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
219258657|NCT04634955|PROCEDURE|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
219258658|NCT03988998|DRUG|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
219258659|NCT03988998|DRUG|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
219258660|NCT03991988|DRUG|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
219258661|NCT03991988|DRUG|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
219258662|NCT04224259|PROCEDURE|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
219258663|NCT04224259|PROCEDURE|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
219258664|NCT00248534|BIOLOGICAL|rituximab|given IV days 1,8, 15 and 22
219258665|NCT00248534|DRUG|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
219258666|NCT00248534|DRUG|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
219258667|NCT01222533|DRUG|Tiotropium medium|Tiotropium inhalation solution medium dose
219258668|NCT01222533|DRUG|Tiotropium low|Tiotropium inhalation solution low dose
219258669|NCT01222533|DRUG|Tiotropium high|Tiotropium inhalation solution high dose
219258670|NCT01222533|DRUG|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
219258671|NCT01222533|DRUG|Tiotropium placebo|Placebo inhalation solution
219258672|NCT05000099|OTHER|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
219258673|NCT05243615|BEHAVIORAL|Guided internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
219362976|NCT03607331|DEVICE|Auricular vagus nerve stimulation|Auricular vagus nerve stimulation is a typical representative of TCM modernization.
219362977|NCT03607331|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
219258674|NCT05243615|BEHAVIORAL|Stroke rehabilitation mental health education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
219258675|NCT01947517|DEVICE|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
219258676|NCT01947517|DEVICE|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
219258677|NCT04698798|PROCEDURE|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
219258678|NCT00238953|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
219258679|NCT02276638|DEVICE|Specular Microscope Nidek CEM-530|Nidek CEM-530
219258680|NCT02276638|DEVICE|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
219258681|NCT06957262|PROCEDURE|Surgical correction of nasal obstruction|Surgical intervention to correct anatomical nasal obstruction, specifically septal deviation, performed under general anesthesia. The procedure involved the repositioning and reshaping of the deviated nasal septum to improve nasal airflow. The surgery was conducted by an otolaryngologist with experience in nasal airway procedures. No additional medications or postoperative interventions beyond standard care (e.g., saline irrigation, analgesics) were administered. Postoperative assessments occurred 2-3 months after surgery, including evaluations of nasal patency, sleep quality, and aerobic performance using treadmill-based gas exchange measurements.
219258682|NCT06956378|BEHAVIORAL|Instruction Emphasis|The study team will emphasize the questionnaire instructions when asking the second time.
219258683|NCT06957015|DEVICE|EndoAIM|EndoAIM will be used during the withdrawal process of the colonoscopy
219258684|NCT06956326|BEHAVIORAL|Intensive rehab|Frequent moderate-to-high intensity physical therapy, provided by local physiotherapists.
219258685|NCT06956326|BEHAVIORAL|Usual care|Usual care physiotherapy
219258686|NCT06956248|OTHER|Off-label or non-standard systemic therapies|Off-label systemic treatments and/or relevant clinical trials recommended by the NCCS Molecular Tumour Board (MTB).
219258687|NCT06957613|PROCEDURE|Revascularization/Conservative management|Percutaneous Transluminal Angioplasty of Coronary Chronic Total Occlusions via Dedicated Drug Eluting Stents and/or Balloons.
219258688|NCT03629899|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
219258689|NCT00476112|DRUG|Vernakalant Injection 20 mg/mL|
219258690|NCT01630005|BEHAVIORAL|talk therapy|Psychotherapy
219258691|NCT05683912|DRUG|Aflibercept|Intravitreal aflibercept as used in the routice clinical practice
219258692|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 20mg
219258693|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 5 mg
219258694|NCT00600847|DRUG|placebo|single dose for 7 days, oral
219258695|NCT06084676|DRUG|Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
219258696|NCT00526097|DRUG|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
219258697|NCT00526097|DRUG|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
219258698|NCT00460564|DRUG|GSK1358820|botulinum toxin type A
219258699|NCT00460564|DRUG|Placebo|Placebo
219258700|NCT06951932|DIETARY_SUPPLEMENT|Mediterranean-type diet with MCT supplementation|The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)
219258701|NCT06951932|OTHER|Mediterranean-type food regimen using extra virgin olive oil|The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily
219258702|NCT06048133|DRUG|Gemcitabine|Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
219258703|NCT06048133|DRUG|Cisplatin|Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
219258704|NCT06048133|DRUG|Zimberelimab|Zimberelimab IV: Day 1 and 22 every 42 days
219258705|NCT06048133|DRUG|Quemliclustat|Quemliclustat IV: Day 1, 15, 29 every 42 days
219258706|NCT03919955|DRUG|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
219258707|NCT03919955|DRUG|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
219258708|NCT03919955|DRUG|Placebo|Placebo, per mouth, before bed.Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
219258709|NCT06142578|DEVICE|Dermal Filler Device|Injection of device by investigators according to the Instruction For Use (IFU)
219258710|NCT05986084|DRUG|Cabotegravir Injection [Apretude]|Injection
219258711|NCT05120596|DRUG|Pembrolizumab+T3P-Y058-739|intravenous infusion or intratumoural injection
219258712|NCT05120596|DRUG|T3P-Y058-739 (IV)|Intravenous infusion
219258713|NCT05120596|DRUG|T3P-Y058-739 (IT)|Intratumoral use
219258714|NCT06712693|DEVICE|Phonak Audeo Infinio Hearing Aid|Receiver-In-Canal hearing aid type that is coupled with either a custom earmold or a dome.
219258715|NCT06178718|DRUG|TNP-2092 capsules|Administered orally, 100 to 1200 mg
219258716|NCT06178718|DRUG|TNP-2092 placebo capsules|Administered orally
219258717|NCT04649671|BEHAVIORAL|Mobile health|"Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit"
219258718|NCT05566886|DEVICE|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
219258719|NCT01660919|DRUG|placebo|
219258720|NCT01660919|DRUG|rosuvastatin|
219258721|NCT02412111|DRUG|Ivacaftor|
219258722|NCT02412111|DRUG|Tezacaftor/Ivacaftor|
219258723|NCT00487552|DEVICE|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
219258724|NCT01543334|BIOLOGICAL|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
219258725|NCT02724293|DRUG|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
219258726|NCT02724293|DRUG|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
219258727|NCT02724293|DRUG|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
219258728|NCT02724293|DRUG|placebo|patients received placebo
219362978|NCT00330473|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
219362979|NCT00330473|DRUG|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
219362980|NCT03668509|DRUG|SHR1459|oral adminstration, single dose
219362981|NCT01469000|DRUG|Gefitinib|250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
219362982|NCT01469000|DRUG|Pemetrexed|500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
219362983|NCT03618056|BIOLOGICAL|AIDSVAX® B/E|Administered by intramuscular injection
219258729|NCT06064045|BEHAVIORAL|Simulation-based team training intervention|"Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~1. Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~2. Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~3. Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~4. Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period)."
219258730|NCT03371277|OTHER|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
219258731|NCT04038697|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
219258732|NCT04038697|PROCEDURE|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
219258733|NCT04038697|PROCEDURE|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
219258734|NCT00517842|DRUG|ViNeuro|
219258735|NCT00573456|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
219258736|NCT06316245|OTHER|DASI questionnaire|All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
219258737|NCT04349644|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.
219258738|NCT06845735|DEVICE|Non-Absorbable Sutures|Non-Absorbable Sutures
219258739|NCT06845735|DEVICE|Absorbable Suture|Absorbable suture
219258740|NCT04478838|DRUG|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
219258741|NCT04478838|DRUG|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
219258742|NCT04478838|DRUG|paliperidone|3 mg, 6 mg, 9 mg Tablets
219258743|NCT00522509|DRUG|Floxuridine FUDR|
219258744|NCT03170947|DEVICE|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
219258745|NCT03170947|DEVICE|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
219258746|NCT04826991|DEVICE|Active UV Device|Active water treatment system
219258747|NCT04826991|DEVICE|Inactive UV Device|Inactive water treatment system
219258748|NCT04669002|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
219258749|NCT04669002|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
219258750|NCT00983905|DRUG|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
219258751|NCT00983905|DRUG|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
219258752|NCT04488861|OTHER|Non-interventional cohort study|Non-interventional cohort study
219258753|NCT01114139|DRUG|Ferumoxytol|IV Ferumoxytol
219258754|NCT01114139|OTHER|Placebo|IV Placebo
219258755|NCT02250768|BIOLOGICAL|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
219258756|NCT03371537|PROCEDURE|Liver debit measure|Mesure of liver debit during hepatectomy
219258757|NCT04111900|BEHAVIORAL|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
219258758|NCT04834492|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty in Crowe type 4 developmental dysplasia of the hip.
219258759|NCT00002647|DRUG|verteporfin|
219258760|NCT00002647|PROCEDURE|conventional surgery|
219258761|NCT03507153|PROCEDURE|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
219258762|NCT03507153|PROCEDURE|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
219258763|NCT00364390|DRUG|Anginera, a human tissue replacement therapy|
219258764|NCT03298529|OTHER|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
219258765|NCT03298529|OTHER|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
219258766|NCT03298529|OTHER|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
219258767|NCT03298529|OTHER|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
219258768|NCT03298529|OTHER|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
219258769|NCT03298529|OTHER|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
219362984|NCT05406856|RADIATION|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
219258770|NCT05548413|BEHAVIORAL|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
219258771|NCT05548413|BEHAVIORAL|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
219258772|NCT06230133|BEHAVIORAL|MBSR intervention|In our study, it is the same to arm description.
219258773|NCT04937205|BEHAVIORAL|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
219258774|NCT03765515|DEVICE|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
219258775|NCT03765515|DEVICE|Q-Fix|Q-Fix
219258776|NCT01620307|DRUG|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
219258777|NCT02190552|DEVICE|EmboTrap® Revascularization Device|
219258778|NCT02413606|OTHER|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
219258779|NCT00784147|DRUG|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
219258780|NCT00784147|DRUG|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
219258781|NCT02637856|DRUG|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
219258782|NCT02637856|DRUG|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
219258783|NCT01057251|DRUG|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
219258784|NCT01057251|DRUG|Placebo|5 mg or 20 mg once daily, oral administration
219258785|NCT03677245|OTHER|Strider Balance Bike|Learning to ride a Strider balance bike
219258786|NCT03343210|DIAGNOSTIC_TEST|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
219258787|NCT00440388|DRUG|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
219258788|NCT00440388|DRUG|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
219258789|NCT00980577|DEVICE|NUUS|Sonosite Micro Maxx
219258790|NCT05722405|DRUG|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
219258791|NCT05722405|DRUG|Ixazomib|Ixazomib alone
219258792|NCT03049098|BEHAVIORAL|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
219258793|NCT00907192|BEHAVIORAL|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
219258794|NCT00907192|BEHAVIORAL|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
219258795|NCT01674920|BEHAVIORAL|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
219258796|NCT01982786|RADIATION|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
219258797|NCT01982786|RADIATION|Brachytherapy|Brachytherapy boost
219258798|NCT04544865|DEVICE|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
219258799|NCT04492137|PROCEDURE|Cannulation technique|"Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed"
219258800|NCT04358536|DEVICE|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
219258801|NCT02740205|OTHER|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
219258802|NCT03320642|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
219258803|NCT03320642|DRUG|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
219258804|NCT01501747|DRUG|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
219258805|NCT01501747|DRUG|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
219258806|NCT04608032|OTHER|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
219258807|NCT04608032|OTHER|Recovery-Oriented Therapy|The second group will have \[THoR\] Recovery-Oriented Therapy
219258808|NCT00610818|OTHER|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
219258809|NCT01297699|DRUG|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
219258810|NCT01297699|DRUG|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
219258811|NCT04841070|OTHER|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
219258812|NCT00064428|DRUG|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
219258813|NCT00064428|OTHER|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
219258814|NCT00064428|DRUG|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
219258815|NCT00064428|DRUG|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
219258816|NCT00005569|DRUG|SLPI (Secretory Leukocyte Protease Inhibitor)|
219258817|NCT05380102|DEVICE|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
219258818|NCT05380102|DEVICE|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
219258819|NCT05380102|DEVICE|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
219258820|NCT00048776|DRUG|Pletal|
219258821|NCT04485299|DRUG|Bifluorid 10 ,VOCO|NaF and CaF 10 %
219258822|NCT04485299|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
219258823|NCT06486675|OTHER|education|breastfeeding consultant training
219258824|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
219258825|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
219258826|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
219258827|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
219258828|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
219258829|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
219258830|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
219258831|NCT03740178|DRUG|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
219258832|NCT03740178|DRUG|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
219258833|NCT03740178|DRUG|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
219258834|NCT00935714|OTHER|Exercise|
219258835|NCT00935714|OTHER|Exercise|
219258836|NCT02601105|OTHER|Placebo Vehicle Cream|Lipoderm Cream alone
219258837|NCT02601105|OTHER|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
219258838|NCT03693040|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
219258839|NCT04551378|OTHER|Quality-of-Life Assessment|Ancillary studies
219258840|NCT04551378|OTHER|Survey Administration|Complete survey
219258841|NCT01732926|DRUG|Idelalisib|150 mg tablet administered orally twice daily
219258842|NCT01732926|DRUG|Rituximab|375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
219258843|NCT01732926|DRUG|Bendamustine|90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
219258844|NCT01732926|DRUG|Placebo|Tablet administered orally twice daily
219258845|NCT02018471|BEHAVIORAL|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
219258846|NCT05498077|PROCEDURE|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
219258847|NCT04868981|DRUG|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
219258848|NCT04868981|DRUG|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
219258849|NCT00583050|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
219258850|NCT06477991|DRUG|Tireilizumab（PD-1 inhibitor）|"Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed."
219258851|NCT02262364|BIOLOGICAL|APS|See above
219258852|NCT01049984|DRUG|Rasagiline|1mg tablet daily for 18 weeks
219258853|NCT01049984|DRUG|Placebo|one tablet daily for 18 weeks
219258854|NCT04658550|OTHER|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
219258855|NCT04658550|OTHER|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
219258856|NCT02753764|DRUG|AZD7624|
219258857|NCT02753764|DRUG|prednisone|oral prednisone 20 mg bid for one week
219258858|NCT02753764|DRUG|Placebo|
219258859|NCT02968654|PROCEDURE|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
219258860|NCT02968654|PROCEDURE|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
219258861|NCT03496337|OTHER|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
219258862|NCT00000578|DRUG|theophylline|
219258863|NCT00000578|DRUG|beclomethasone|
219258864|NCT02181998|DRUG|Full dose tenecteplase|
219258865|NCT02181998|DRUG|Unfractioned heparin|
219258866|NCT02181998|DRUG|Enoxaparin|
219258867|NCT03128788|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
219258868|NCT06435741|DIAGNOSTIC_TEST|99mTc-3PRGD2 Spect-CT scan|Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
219258869|NCT03523325|OTHER|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
219258870|NCT02730000|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
219258871|NCT02730000|PROCEDURE|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
219258872|NCT02801500|DEVICE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
219258873|NCT02801500|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
219258874|NCT04550286|BEHAVIORAL|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
219258875|NCT04550286|BEHAVIORAL|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
219258876|NCT06347770|DRUG|Probiotic Blend Oral Tablet|In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
219258877|NCT01650727|DRUG|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
219258878|NCT01650727|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
219258879|NCT01681199|DRUG|Fluvastatin extended release tablet|
219258880|NCT04510610|DRUG|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
219258881|NCT01743521|DRUG|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
219258882|NCT05154240|DRUG|INS018_055|INS018\_055 is a small molecule compound. INS018\_055 has good solubility in water and was chemically and physically stable at different temperatures.
219258883|NCT05154240|DRUG|Placebo|Placebo
219258884|NCT00382798|DRUG|RO5024048|
219258885|NCT02282306|BEHAVIORAL|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
219258886|NCT05090475|BEHAVIORAL|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
219258887|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
219258888|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
219258889|NCT01209741|DRUG|telcagepant potassium|\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
219258890|NCT01209741|DRUG|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
219258891|NCT01209741|DRUG|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
219258892|NCT02287883|OTHER|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
219258893|NCT06222775|BEHAVIORAL|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
219258894|NCT06222775|BEHAVIORAL|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
219258895|NCT06222775|BEHAVIORAL|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
219258896|NCT06222775|BEHAVIORAL|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
219258897|NCT06222775|BEHAVIORAL|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
219258898|NCT06222775|BEHAVIORAL|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
219258899|NCT06222775|BEHAVIORAL|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
219258900|NCT06222775|BEHAVIORAL|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
219258901|NCT06222775|BEHAVIORAL|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
219258902|NCT06222775|BEHAVIORAL|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
219258903|NCT06222775|BEHAVIORAL|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
219258904|NCT06222775|BEHAVIORAL|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
219258905|NCT05089604|DRUG|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
219258906|NCT05089604|DRUG|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
219258907|NCT03144778|BIOLOGICAL|Durvalumab|Given IV
219258908|NCT03144778|BIOLOGICAL|Tremelimumab|Given IV
219258909|NCT05648136|BIOLOGICAL|blood sample|"Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation"
219258910|NCT01476124|DRUG|morphine Placebo|Morphine Placebo
219258911|NCT01476124|DRUG|GEn 600 mg|Gabapentin enacarbil 600 mg
219258912|NCT01476124|DRUG|Morphine|morphine extended release 60 mg
219258913|NCT01476124|DRUG|GEn Placebo|Gabapentin enacarbil placebo
219258914|NCT03436030|OTHER|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
219258915|NCT02234635|OTHER|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
219258916|NCT00402584|DRUG|sibutramine|
219258917|NCT00802438|BIOLOGICAL|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
219258918|NCT00245440|DRUG|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
219258919|NCT00245440|DRUG|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
219258920|NCT03705364|OTHER|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
219258921|NCT06308185|OTHER|observational study|Observational retrospective study on infants with neonatal seizures
219258922|NCT03175198|DRUG|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
219258923|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
219258924|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
219258925|NCT01512914|DRUG|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
219258926|NCT01512914|DRUG|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
219258927|NCT03903523|DEVICE|Lumen apposing metal stent (LAMS)|Stent positioning
219258928|NCT00302497|DRUG|basiliximab|
219258929|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
219258930|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
219258931|NCT05191836|OTHER|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
219258932|NCT03382288|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
219258933|NCT03367910|DRUG|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
219258934|NCT00275145|BEHAVIORAL|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
219258935|NCT00275145|BEHAVIORAL|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
219258936|NCT00275145|BEHAVIORAL|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
219258937|NCT00275145|BEHAVIORAL|Continued Sedentary lifestyle|No changes
219258938|NCT01603771|OTHER|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
219258939|NCT03331432|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
219258940|NCT03331432|DIETARY_SUPPLEMENT|Placebo|Taking daily placebo capsules for 4 weeks.
219258941|NCT05993520|OTHER|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
219258942|NCT00363649|BIOLOGICAL|GM-K562 cell vaccine|Given by injection
219258943|NCT00363649|BIOLOGICAL|Interferon alfa|Given by injection
219258944|NCT00363649|BIOLOGICAL|Sargramostim|Given by injection
219258945|NCT06350708|OTHER|Virtual reality (VR) tracheostomy educational tool|This is an unsupervised VR training packaged designed to train healthcare professionals and their students the management of the paediatric tracheostomy emergency.
219258946|NCT01432522|DRUG|Epinephrine|"1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray"
219258947|NCT03290222|OTHER|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
219258948|NCT00067093|DRUG|SanOrg34006|
219258949|NCT00067093|DRUG|LMW heparin|
219258950|NCT00067093|DRUG|Unfractionated heparin|
219258951|NCT00067093|DRUG|Vitamin K antagonist (VKA)|
219258952|NCT02790112|OTHER|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
219258953|NCT04183244|PROCEDURE|Erector spinae block|A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
219258954|NCT04183244|PROCEDURE|Infraclavicular subomohyoid (ISO) block|Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
219258955|NCT04114097|DRUG|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
219258956|NCT04114097|DRUG|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
219258957|NCT05051215|OTHER||
219258958|NCT01913626|BEHAVIORAL|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
219258959|NCT00166881|DRUG|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
219258960|NCT03188536|OTHER|No Intervention|As it was an observational study, no intervention was administered in this study.
219258961|NCT06201637|OTHER|Performance Test|Performance Test
219258962|NCT04311047|DIAGNOSTIC_TEST|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
219258963|NCT02550912|DRUG|Vitamin D3|vitamin D drops for paediatrics
219258964|NCT02550912|OTHER|Placebo|glucose syrup with same taste and color to vitamin D3 drops
219258965|NCT02885792|OTHER|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
219258966|NCT02885792|OTHER|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
219258967|NCT02885792|OTHER|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
219258968|NCT02885792|PROCEDURE|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
219258969|NCT04869150|PROCEDURE|radial access coronary angiography|The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
219258970|NCT00673127|DRUG|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
219258971|NCT02548676|DEVICE|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
219258972|NCT03719378|OTHER|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
219258973|NCT03779321|OTHER|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
219258974|NCT02161185|DRUG|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
219258975|NCT06646380|BEHAVIORAL|Multicomponent Training|The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
219258976|NCT06646380|OTHER|Maintenance|Participants were instructed to maintain daily life activities regarding physical activity.
219258977|NCT04655014|OTHER|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
219258978|NCT00372255|BIOLOGICAL|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
219258979|NCT04461314|BEHAVIORAL|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
219258980|NCT00086021|PROCEDURE|Acupuncture|
219258981|NCT04602039|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (Neovite)
219258982|NCT01940783|RADIATION|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
219258983|NCT01940783|DEVICE|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
219258984|NCT00944892|DRUG|REGN475|2 Administrations of REGN475 within 24 weeks.
219258985|NCT00944892|OTHER|Placebo|Placebo to match REGN475 doses
219258986|NCT02149732|BIOLOGICAL|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
219258987|NCT02341599|DRUG|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
219258988|NCT05211453|PROCEDURE|atrioventricular node ablation|atrioventricular node ablation
219258989|NCT02638233|DRUG|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
219258990|NCT02360813|BEHAVIORAL|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
219258991|NCT02360813|OTHER|Treatment as usual|Keep getting usual care.
219258992|NCT05727488|OTHER|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
219258993|NCT01540812|DRUG|Vincristine in induction|
219258994|NCT01540812|DRUG|Daunorubicin in induction|
219258995|NCT01540812|DRUG|Prednisone in induction|
219258996|NCT01540812|DRUG|Metotrexato in induction|
219258997|NCT01540812|DRUG|Cytarabine in induction|
219258998|NCT01540812|DRUG|Hydrocortisone in induction|
219258999|NCT01540812|DRUG|Idarubicin in induction-2|
219259000|NCT01540812|DRUG|Fludarabine in induction-2|
219259001|NCT01540812|DRUG|Ara-C in induction-2|
219259002|NCT01540812|DRUG|G-CSF in induction-2|
219259003|NCT01540812|DRUG|Dexamethasone in consolidation-1|
219259004|NCT01540812|DRUG|Vincristrine in consolidation-1|
219259005|NCT01540812|DRUG|Metotrexato in consolidation-1|
219259006|NCT01540812|DRUG|PEG-ASP in consolidation-1|
219259007|NCT01540812|DRUG|Dexamethasone in consolidation-2|
219259008|NCT01540812|DRUG|ARA-C in consolidation-2|
219259009|NCT01540812|DRUG|PEG-ASP in consolidation-2|
219259010|NCT01540812|DRUG|Dexamethasone in consolidation-3|
219259011|NCT01540812|DRUG|Vincristine in consolidation-3|
219259012|NCT01540812|DRUG|Metotrexato in consolidation-3|
219259013|NCT01540812|DRUG|PEG-ASP in consolidation-3|
219259014|NCT01540812|PROCEDURE|allogeneic HSCT|
219259015|NCT01540812|PROCEDURE|Allo HSCT with reduced-intensity conditioning|
219259016|NCT04885426|DRUG|low-dose metformin|Metformin Pill 250mg/day
219259017|NCT04885426|DRUG|high-dose metformin|Metformin Pill 500mg/day
219259018|NCT04885426|DRUG|Placebo|Placebo
219259019|NCT04777097|OTHER|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
219259020|NCT01729923|DRUG|Capecitabine|Given PO
219259021|NCT01729923|DRUG|Celecoxib|Given PO
219259022|NCT01729923|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219259023|NCT01729923|OTHER|Laboratory Biomarker Analysis|Correlative studies
219259024|NCT01729923|OTHER|Quality-of-Life Assessment|Ancillary studies
219259025|NCT01729923|RADIATION|Radiation Therapy|Undergo radiation therapy
219259026|NCT01729923|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
219259027|NCT01729923|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219259028|NCT04338347|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
219259029|NCT02894905|DRUG|AL-335|Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
219259030|NCT05335343|OTHER|no intervention|no intervention
219259031|NCT04124016|DIETARY_SUPPLEMENT|Inulin|Powder of inulin fractions dissolved into 250 ml of water
219259032|NCT04124016|DIETARY_SUPPLEMENT|green tea extract|Powder of green tea extract dissolved into 200 ml of water
219259033|NCT04124016|DIETARY_SUPPLEMENT|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
219259034|NCT04124016|DIETARY_SUPPLEMENT|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
219259035|NCT03120949|DRUG|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
219259036|NCT03120949|DRUG|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
219259037|NCT03120949|DRUG|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
219259038|NCT03466229|DIETARY_SUPPLEMENT|Androferti|
219259039|NCT03466229|DIETARY_SUPPLEMENT|Placebo|
219259040|NCT00988117|DRUG|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
219259041|NCT02996318|DEVICE|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
219259042|NCT02996318|DEVICE|Sirolimus coated balloon|Sirolimus coated balloon
219259043|NCT00312845|DRUG|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
219259044|NCT00312845|DRUG|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
219259045|NCT02659384|DRUG|Bevacizumab|
219259046|NCT02659384|DRUG|atezolizumab|
219259047|NCT02659384|DRUG|acetylsalicylic acid|
219259048|NCT02659384|DRUG|placebo|
219259049|NCT00453934|DEVICE|h-Patch|
219259050|NCT06646770|PROCEDURE|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
219259051|NCT06646770|PROCEDURE|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
219259052|NCT01220856|DRUG|Reparixin|Reparixin + immunosuppression
219259053|NCT04088500|BIOLOGICAL|Nivolumab|Specific dose on specific days
219259054|NCT04088500|BIOLOGICAL|Ipilimumab|Specific dose on specific days
219259055|NCT00688051|OTHER|My Life with CF game|Play the game My Life with CF
219259056|NCT03953378|OTHER|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
219259057|NCT05317299|OTHER|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
219259058|NCT02274519|OTHER|Tai Chi|Arm 1
219259059|NCT02274519|OTHER|Education|Arm 2
219259060|NCT05310344|COMBINATION_PRODUCT|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
219259061|NCT00148616|DRUG|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
219259062|NCT00148616|DRUG|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
219259063|NCT05218421|DIAGNOSTIC_TEST|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
219259064|NCT05218421|OTHER|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
219259065|NCT05218421|OTHER|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
219259066|NCT03726983|OTHER|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
219259067|NCT01355471|DRUG|CD07805/47 Gel|applied topically once daily
219259068|NCT01355471|DRUG|Placebo|applied topically once daily
219259069|NCT01600235|DRUG|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
219259070|NCT01102387|DRUG|LAS41003|Once daily, topically
219259071|NCT01102387|DRUG|LAS189962|Once daily, topically
219259072|NCT01102387|DRUG|LAS189961|Once daily, topically
219259073|NCT02345707|DRUG|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
219259074|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
219259075|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
219259076|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
219259077|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
219259078|NCT01208870|BEHAVIORAL|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
219259079|NCT01208870|BEHAVIORAL|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
219259080|NCT05402618|OTHER|No intervention|This is an observational study without any intervention.
219259081|NCT01133925|DEVICE|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
219259082|NCT01133925|DEVICE|Sirolimus Eluting Stent|Cypher stents implanted in overlap
219259083|NCT01133925|DEVICE|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
219259084|NCT01133925|DEVICE|Zotarolimus eluting stent|Endeavor stents implanted in overlap
219259085|NCT01086878|DRUG|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
219259086|NCT06034964|DRUG|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
219259087|NCT06028399|OTHER|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
219259088|NCT06028399|OTHER|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
219259089|NCT05645809|DEVICE|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
219259090|NCT05645809|DEVICE|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
219259091|NCT04976283|DRUG|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
219259092|NCT04976283|DRUG|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
219259093|NCT04976283|DRUG|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
219259094|NCT05787171|DEVICE|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
219259095|NCT05787171|DEVICE|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
219259096|NCT05787171|DEVICE|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
219259097|NCT00402636|DEVICE|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
219259098|NCT00402636|DEVICE|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
219259099|NCT06032273|BEHAVIORAL|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
219259100|NCT02872519|DRUG|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
219259101|NCT02872519|PROCEDURE|Positron Emission Tomography|Undergo scan
219259102|NCT02872519|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
219259103|NCT03069014|DRUG|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
219259104|NCT03069014|DRUG|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
219259105|NCT03069014|DRUG|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
219259106|NCT05157568|BEHAVIORAL|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
219259107|NCT05157568|BEHAVIORAL|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
219259108|NCT05157568|BEHAVIORAL|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
219259109|NCT06158178|DIAGNOSTIC_TEST|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
219259110|NCT00747045|OTHER|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
219259111|NCT00733564|DRUG|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
219259112|NCT00733564|DRUG|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
219259113|NCT00733564|DRUG|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
219259114|NCT00496834|DRUG|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
219259115|NCT00496834|DRUG|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
219259116|NCT00496834|DRUG|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
219259117|NCT00496834|DRUG|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
219259118|NCT00721825|DRUG|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
219259119|NCT00721825|DRUG|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
219259120|NCT06291584|OTHER|Exercise|In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
219259121|NCT02112578|DRUG|Meclizine|25 mg, 3 times per day up to 30 days
219259122|NCT02112578|DRUG|Dimenhydrinate|50 mg, 3 times per day up to 30 days
219259123|NCT03030105|DRUG|BPN14770|investigational drug
219259124|NCT03030105|DRUG|BPN14770 placebo|placebo
219259125|NCT03030105|DRUG|Donepezil|comparator
219259126|NCT03030105|DRUG|Donepezil placebo|placebo
219259127|NCT03030105|DRUG|Scopolamine 0.6 MG/ML|cognition impairment
219259128|NCT03030105|DRUG|Scopolamine placebo|placebo
219259129|NCT05253079|OTHER|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
219362985|NCT05406856|RADIATION|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
219259130|NCT05253079|OTHER|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
219259131|NCT01227928|DRUG|Pazopanib|Pazopanib 800 mg daily for 24 months
219259132|NCT01227928|DRUG|Placebo comparator|Placebo 800 mg daily for 24 months
219259133|NCT04785573|DIETARY_SUPPLEMENT|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
219259134|NCT01042145|DRUG|Prednisone|2 mgs/kg for 3 days
219259135|NCT01042145|DRUG|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
219259136|NCT01993628|OTHER|Rey figure test|
219259137|NCT01993628|OTHER|MRI|
219259138|NCT04721405|DEVICE|Observational Study: No intervention|Observational Study: No intervention
219259139|NCT03065439|DIAGNOSTIC_TEST|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
219259140|NCT06543550|DRUG|Implantable gestrinone|1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
219259141|NCT06543550|DRUG|Oral Dienogest|Administered orally at 2 mg daily
219259142|NCT00016978|DRUG|FOLFOX regimen|
219259143|NCT00016978|DRUG|fluorouracil|
219259144|NCT00016978|DRUG|leucovorin calcium|
219259145|NCT00016978|DRUG|oxaliplatin|
219259146|NCT06585319|DRUG|Collagen-polyvinylpyrrolidone|2 ml intramuscular q24 h
219259147|NCT06585319|DRUG|Pirfenidone 1200 mg|1,200 mg of oral q12 h
219259148|NCT05613504|OTHER|Acupuncture treatment|"Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
219259149|NCT05613504|OTHER|Sham acupuncture treatment|"Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
219259150|NCT04743453|DRUG|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
219259151|NCT04743453|DRUG|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
219259152|NCT02722759|OTHER|hemoglobin measurement|
219259153|NCT04501978|BIOLOGICAL|LY3819253|Participants are no longer being randomized to this intervention.
219259154|NCT04501978|DRUG|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
219259155|NCT04501978|BIOLOGICAL|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
219259156|NCT04501978|BIOLOGICAL|VIR-7831|Participants are no longer being randomized to this intervention.
219259157|NCT04501978|BIOLOGICAL|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
219259158|NCT04501978|BIOLOGICAL|AZD7442|Participants are no longer being randomized to this intervention.
219259159|NCT04501978|DRUG|MP0420|Participants are no longer being randomized to this intervention.
219259160|NCT04501978|DRUG|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
219362986|NCT05406856|DRUG|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
219259161|NCT05699967|OTHER|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
219259162|NCT00768209|DRUG|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
219259163|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
219259164|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
219259165|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
219259166|NCT03614286|DIAGNOSTIC_TEST|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
219259167|NCT04159805|DRUG|TAK-079|TAK-079 subcutaneous injection
219259168|NCT04159805|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
219259169|NCT02044341|DRUG|AR01|drops administered an needed for pain
219259170|NCT02044341|DRUG|Glycerin ear drops|placebo drops administered for ear pain
219259171|NCT03819842|DIAGNOSTIC_TEST|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
219259172|NCT03328910|DEVICE|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
219259173|NCT05708976|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
219259174|NCT05708976|DEVICE|Active Whole-Body Hyperthermia (Active WBH)|Active whole-body hyperthermia (active WBH) will be administered by trained research assistants. Preparation for the active WBH session, the active WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 38.5 C.
219259175|NCT05708976|DEVICE|Sham Whole-Body Hyperthermia (Sham WBH)|Sham whole-body hyperthermia (sham WBH) will be administered by trained research assistants. Preparation for the sham WBH session, the sham WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the sham WBH session will minimally impact core body temperature.
219259176|NCT01919177|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
219259177|NCT01919177|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
219259178|NCT04636879|OTHER|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
219259179|NCT04636879|OTHER|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
219259180|NCT04636879|OTHER|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
219259181|NCT05335577|DIAGNOSTIC_TEST|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
219259182|NCT05335577|DIAGNOSTIC_TEST|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
219259183|NCT05335577|DIAGNOSTIC_TEST|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
219259184|NCT01393613|DRUG|OPC-34712|Higher dose tablet, once daily, for six weeks,
219259185|NCT01393613|DRUG|OPC-34712|Middle dose tablet, once daily, for six weeks
219259186|NCT01393613|DRUG|OPC-34712|Lower dose tablet, once daily, for six weeks
219259187|NCT01393613|DRUG|Placebo|Placebo, once daily, for six weeks
219259188|NCT03821064|OTHER|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
219259189|NCT01618227|DEVICE|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
219259190|NCT01618227|PROCEDURE|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
219259191|NCT03945851|PROCEDURE|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
219259192|NCT03209297|OTHER|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
219259193|NCT02187445|DRUG|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
219259194|NCT02489721|DEVICE|PICC and Midline|Peripherally inserted central venous catheter
219259195|NCT00110955|DRUG|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
219259196|NCT00110955|DRUG|Placebo|Q3W dosing of placebo
219259197|NCT06574633|BEHAVIORAL|In-person therapy|Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
219259198|NCT06574633|BEHAVIORAL|Telehealth therapy|Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
219259199|NCT01794650|DIETARY_SUPPLEMENT|Meal composition|
219259200|NCT00525200|DRUG|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
219259201|NCT00525200|DRUG|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
219259202|NCT06212765|DRUG|L-citrulline|to take 1 pod a day for 45 days
219259203|NCT02592486|BIOLOGICAL|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
219259204|NCT02592486|BIOLOGICAL|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
219259205|NCT02978846|OTHER|Clinical Observation|Undergo side effects evaluation using cards
219259206|NCT06453161|OTHER|Post-operative acute kidney injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
219259207|NCT03002233|DRUG|TRK-820|
219259208|NCT02511171|OTHER|Cranial osteopathic manipulative therapy|
219259209|NCT01283971|DRUG|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
219259210|NCT01283971|DRUG|adalimumab|Adalimumab 40 mg SC every 2 weeks.
219259211|NCT01283971|DRUG|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
219259212|NCT01283971|DRUG|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
219259213|NCT01283971|DRUG|methotrexate|Methotrexate 10-25 mg weekly.
219259214|NCT01283971|DRUG|folate|Folate at least 5 mg weekly.
219259215|NCT02617667|DRUG|Cyclosporine A|topical ocular, eye drops
219259216|NCT02617667|DRUG|Placebo|topical ocular, eye drops
219259217|NCT00427245|DRUG|cyclophosphamide|
219259218|NCT00427245|DRUG|goserelin acetate|
219259219|NCT00427245|PROCEDURE|adjuvant therapy|
219259220|NCT00427245|PROCEDURE|fertility assessment and management|
219259221|NCT00427245|PROCEDURE|neoadjuvant therapy|
219259222|NCT01108484|BEHAVIORAL|Exercise|Supervised exercise: Three 90-minutes sessions per week.
219259223|NCT01108484|BEHAVIORAL|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
219259224|NCT01108484|BEHAVIORAL|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
219259225|NCT02791126|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
219259226|NCT02791126|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
219259227|NCT03777553|BEHAVIORAL|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
219259228|NCT02552693|OTHER|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
219259229|NCT06196229|OTHER|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
219259230|NCT06196229|OTHER|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
219259231|NCT06045871|PROCEDURE|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
219259232|NCT02864199|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
219259233|NCT02864199|DRUG|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
219259234|NCT01554371|DRUG|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
219259235|NCT01554371|DRUG|Cyclophosphamide|Given IV
219259236|NCT04421118|OTHER|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
219259237|NCT03216252|BIOLOGICAL|samples|Blood samples, oral smear and urine
219259238|NCT02598934|DRUG|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
219259239|NCT02672514|DEVICE|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
219259240|NCT02672514|DEVICE|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
219259241|NCT03441737|BEHAVIORAL|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
219259242|NCT03441737|BEHAVIORAL|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
219259243|NCT01618071|DIETARY_SUPPLEMENT|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
219259244|NCT00002855|DRUG|Bicalutamide|
219259245|NCT00002855|DRUG|Doxorubicin hydrochloride|
219259246|NCT00002855|DRUG|Estramustine Phosphate Sodium|
219259247|NCT00002855|DRUG|Flutamide|
219259248|NCT00002855|DRUG|Ketoconazole|
219259249|NCT00002855|DRUG|Nilutamide|
219259250|NCT00002855|DRUG|Therapeutic Hydrocortisone|
219259251|NCT00002855|DRUG|Vinblastine|
219259252|NCT00002855|PROCEDURE|Conventional Surgery|Surgical castration
219259253|NCT02409121|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
219259254|NCT03212183|BEHAVIORAL|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
219259255|NCT03212183|OTHER|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
219259256|NCT02456259|PROCEDURE|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
219259257|NCT05313815|RADIATION|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
219259258|NCT02579278|OTHER|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
219259259|NCT02579278|OTHER|Blood sample (mrEMVI negative patient)|
219259260|NCT03325608|OTHER|POISED Care|Program of dementia care management.
219259261|NCT03352661|OTHER|Collect retrospectively data|Collect retrospectively data
219259262|NCT03600519|DEVICE|NOTAL OCT V2.5|AMD Patients
219259263|NCT02154347|DRUG|KAD-1229|
219259264|NCT02154347|DRUG|Placebo|
219259265|NCT02154347|DRUG|Insulin|
219259266|NCT04205500|OTHER|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
219259267|NCT02188784|DRUG|Polysaccharide Iron Complex 150 mg|Oral Iron
219259268|NCT02188784|DRUG|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
219259269|NCT05634083|DIETARY_SUPPLEMENT|Uremic pateints with itching|Activated charcoal
219259270|NCT00884884|DRUG|Double Placebo|1 capsule daily
219259271|NCT00884884|DRUG|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
219259272|NCT00884884|DRUG|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
219259273|NCT00884884|DRUG|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
219259274|NCT00884884|DRUG|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
219259275|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
219259276|NCT00884884|DRUG|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
219259277|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
219259278|NCT00884884|DRUG|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
219259279|NCT00884884|DRUG|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
219259280|NCT01356121|DRUG|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
219259281|NCT01356121|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
219259282|NCT04643496|PROCEDURE|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
219259283|NCT02473913|DRUG|Milk Thistle|
219259284|NCT02473913|DRUG|Placebo|
219259285|NCT01568021|OTHER|No Intervention|No intervention was administered in this study.
219259286|NCT04160000|DEVICE|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
219259287|NCT04160000|DRUG|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
219259288|NCT04160000|DEVICE|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
219259289|NCT04160000|DRUG|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
219259290|NCT01789229|OTHER|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
219259291|NCT01789229|OTHER|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
219259292|NCT01789229|OTHER|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
219259293|NCT01789229|OTHER|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
219259294|NCT01789229|OTHER|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
219259295|NCT01789229|OTHER|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
219259296|NCT01789229|OTHER|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
219259297|NCT00204100|DEVICE|Surface Functional Electrical Stimulation|
219259298|NCT02503488|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
219259299|NCT02503488|BEHAVIORAL|Treatment as Usual|See arm description
219259300|NCT03527758|DEVICE|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
219259301|NCT01889771|DRUG|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
219259302|NCT01772381|DRUG|Dexamethasone|Long acting corticosteroid
219259303|NCT01497951|OTHER|Aminolaevulinic acid|Photodynamic therapy
219259304|NCT01497951|OTHER|Methylcellulose Placebo|Methylcellulose
219259305|NCT02177435|DRUG|Telmisartan|
219259306|NCT02177435|DRUG|Telmisartan/Hydrochlorothiazide|
219259307|NCT02177435|DRUG|Placebo|
219259308|NCT04145089|DEVICE|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
219259309|NCT03614351|DIETARY_SUPPLEMENT|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
219259310|NCT03614351|OTHER|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
219259311|NCT05051683|PROCEDURE|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
219259312|NCT04531852|OTHER|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
219259313|NCT04531852|BEHAVIORAL|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
219259314|NCT05116865|BIOLOGICAL|HH-120 Dose 1|Dose level 1 of HH-120
219259315|NCT05116865|BIOLOGICAL|HH-120 Dose 2|Dose level 2 of HH-120
219259316|NCT05116865|BIOLOGICAL|HH-120 Dose 3|Dose level 3 of HH-120
219259317|NCT05116865|DRUG|Placebo|Placebo to match
219259318|NCT06291597|OTHER|Vaping|Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
219259319|NCT00871455|DRUG|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
219259320|NCT00038961|DRUG|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
219259321|NCT00038961|OTHER|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
219259322|NCT06283563|OTHER|Physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
219259323|NCT06283563|OTHER|No physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
219259324|NCT01399502|BEHAVIORAL|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
219259325|NCT00035061|DRUG|pemetrexed|
219259326|NCT02094547|DIETARY_SUPPLEMENT|New infant formula|New infant formula
219259327|NCT02094547|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
219259328|NCT02094547|DIETARY_SUPPLEMENT|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
219259329|NCT05753319|OTHER|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
219259330|NCT04939324|BIOLOGICAL|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
219259331|NCT06538519|PROCEDURE|total hip replacement using lateral approach|In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
219259332|NCT06538519|PROCEDURE|total hip replacement using anterior approach|the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
219259333|NCT06538519|DEVICE|gait analysis at 6wks, 3 months and 18 months|gait analysis done in the gait lab at the mentioned postoperative periods
219259334|NCT00938132|DRUG|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
219259335|NCT06415071|OTHER|No intervention|Exposures of interest would be clearly defined according to a specific research question and identified from the database
219259336|NCT05399082|DEVICE|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
219259337|NCT05399082|PROCEDURE|Forceps biopsy|Biopsy forceps used to collect tissue
219259338|NCT03188809|PROCEDURE|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
219259339|NCT03188809|PROCEDURE|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
219259340|NCT01190449|BIOLOGICAL|ofatumumab|Given IV
219259341|NCT02724163|DRUG|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
219259342|NCT02724163|DRUG|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
219259343|NCT02724163|DRUG|Mitoxantrone|DNA-reactive agent
219259344|NCT02724163|DRUG|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
219259345|NCT02724163|DRUG|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
219259346|NCT02724163|DRUG|Busulfan|Alkylsulfonate
219259347|NCT02724163|DRUG|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
219259348|NCT03216941|DRUG|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
219259349|NCT05187000|DEVICE|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
219259350|NCT05187000|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
219259351|NCT00601133|OTHER|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
219259352|NCT00601133|OTHER|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
219259353|NCT00601133|BEHAVIORAL|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
219259354|NCT00601133|BEHAVIORAL|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
219259355|NCT02209688|DRUG|ESR 1150 CL|
219259356|NCT02209688|DRUG|Placebo|
219259357|NCT05442593|OTHER|Plyometric training|Participants will perform: 8 sets of 10 maximal countermovement jumps
219259358|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
219259359|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
219259360|NCT02127983|BEHAVIORAL|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
219259361|NCT02127983|BEHAVIORAL|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
219259362|NCT05992519|DIAGNOSTIC_TEST|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
219259363|NCT05335668|PROCEDURE|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
219259364|NCT06632340|PROCEDURE|TUR-BT|Transurethral resection of bladder tumor
219259365|NCT04944784|DRUG|Reldesemtiv|Reldesemtiv Oral Tablet
219259366|NCT04944784|DRUG|Placebo|Placebo Oral Tablet
219259367|NCT05831995|DRUG|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
219259368|NCT01601717|DRUG|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
219259369|NCT01601717|DRUG|Placebo|Matching placebo pill administered once per day for 10 days.
219259370|NCT03836170|PROCEDURE|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
219259371|NCT06014970|BEHAVIORAL|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
219259372|NCT03717077|PROCEDURE|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
219259373|NCT04596176|OTHER|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
219259374|NCT04596176|OTHER|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
219259375|NCT02210208|DEVICE|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
219259376|NCT02210208|DEVICE|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
219259377|NCT00004478|DRUG|droxidopa|
219259378|NCT01718431|OTHER|test meal|
219259379|NCT01718431|OTHER|reference meal|
219259380|NCT01171183|DRUG|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
219259381|NCT01171183|DRUG|Placebo|Placebo
219259382|NCT03840356|OTHER|Postoperative|No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
219259383|NCT03371121|OTHER|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
219259384|NCT03416569|DRUG|Placebo|placebo skin patch + placebo capsule
219259385|NCT03416569|DRUG|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
219259386|NCT03416569|DRUG|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
219259387|NCT03416569|DRUG|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
219259388|NCT00817245|DRUG|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
219259389|NCT03602248|OTHER|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
219259390|NCT03602248|OTHER|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
219259391|NCT00607178|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
219259392|NCT00607178|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
219259393|NCT05280743|DRUG|Oxycodone|exposure to opioids after Cesarean Section
219259394|NCT06302595|DEVICE|MRI-guided prostate biopsy using the needle holder frame.|A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
219259395|NCT04333732|DRUG|MR or M-M-R II ® vaccine|Education and surveillance plus MR or M-M-R II ® vaccine
219259396|NCT04333732|DRUG|Placebo|Placebo injection
219259397|NCT01310712|DRUG|Oxybutynin|5 mg every 12 hours for 6 weeks
219259398|NCT01310712|DRUG|placebo|placebo twice a day for 42 days.
219259399|NCT04865055|OTHER|cyclic merocyanine|long-UVA absorber
219259400|NCT04865055|OTHER|placebo|placebo
219259401|NCT03238807|DRUG|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
219259402|NCT04827589|DRUG|Tirabrutinib|Tablets administered orally
219259403|NCT04827589|DRUG|Placebo|Tablets administered orally
219259404|NCT02418845|DRUG|SYM-1219|
219259405|NCT02418845|DRUG|Placebo|
219259406|NCT00003693|DRUG|Dolastatin 10|IV bolus once every 3 weeks.
219259407|NCT01489917|OTHER|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
219259408|NCT06385847|DRUG|Zoladex|Patients received 3.6 mg subcutaneous Zoladex
219259409|NCT06385847|DRUG|LY01005|Patients received 3.6 mg intramuscular LY01005
219259410|NCT06957561|DRUG|Disitamab Vedotin Injection|Participants will receive Disitamab Vedotin at a dose of 2.0 mg/kg. In the neoadjuvant phase, it will be administered every 2 weeks for 6 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 4 cycles, starting 4-8 weeks after surgery.
219259411|NCT06957561|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Participants will receive Ivonescimab at a dose of 20 mg/kg. In the neoadjuvant phase, it will be administered every 3 weeks for 4 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 9 cycles, starting 4-8 weeks after surgery.
219259412|NCT06957561|PROCEDURE|Radical Cystectomy with Pelvic Lymph Node Dissection|Participants will undergo radical cystectomy with pelvic lymph node dissection 4-6 weeks after the last dose of neoadjuvant treatment.
219259413|NCT01540604|DRUG|CRD007|
219259414|NCT05500781|BEHAVIORAL|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
219259415|NCT05611541|BEHAVIORAL|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
219259416|NCT05611541|BEHAVIORAL|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
219259417|NCT00884559|OTHER|instruction|Debriefing
219259418|NCT04984239|BEHAVIORAL|Acceptance and Commitment Therapy for aphasia|The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
219259419|NCT03166046|DEVICE|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
219259420|NCT03166046|DEVICE|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
219259421|NCT02083601|BEHAVIORAL|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
219259422|NCT02083601|BEHAVIORAL|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
219259423|NCT00460018|BEHAVIORAL|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
219259424|NCT06956716|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
219259425|NCT06956716|DRUG|Gemcitabine + cisplatin (GP)|As standard chemotherapy (D1, D8 gemcitabine 1000mg/m², intravenous drip for 30 minutes, cisplatin 25mg/m², intravenous drip), once every 3 weeks
219259426|NCT06956716|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion
219259427|NCT03902509|DRUG|Pirfenidone|pirfenidone capsule made in China
219259428|NCT03902509|DRUG|basic treatment|glucocorticoid and expectant treatment etc.
219259429|NCT06045000|DRUG|DC-806|Oral tablets
219259430|NCT06045000|DRUG|[14C]-DC-806|Oral capsules
219259431|NCT04578288|PROCEDURE|INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION|The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
219259432|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
219259433|NCT05213429|OTHER|non interventional study|non interventional
219259434|NCT04190225|BEHAVIORAL|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
219259435|NCT05145439|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
219259436|NCT06439641|OTHER|Ulcerative colitis Disease Activity Index|QUESTIONNAIRE - Score between 0 to 12, the higher is the worse
219259437|NCT04294524|OTHER|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
219259438|NCT06028217|OTHER|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
219259439|NCT05671978|PROCEDURE|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
219259440|NCT05671978|PROCEDURE|neutral position|The patient was then placed in the netural position
219259441|NCT03728959|OTHER|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
219259442|NCT03728959|OTHER|GIP|Subcutaneous injected GIP
219259443|NCT03728959|OTHER|GLP-2|Subcutaneous injected GLP-2
219259444|NCT03728959|OTHER|Placebo (saline)|Subcutaneous injected Placebo (saline)
219259445|NCT00963443|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
219259446|NCT00963443|DRUG|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
219259447|NCT00963443|DRUG|Placebo|Matching Placebo
219259448|NCT05471804|DIETARY_SUPPLEMENT|Sceletium tortuosum|Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
219259449|NCT02813213|PROCEDURE|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
219259450|NCT02813213|PROCEDURE|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
219259451|NCT00771095|BEHAVIORAL|podcasting|
219259452|NCT01275768|PROCEDURE|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
219259453|NCT00632385|DRUG|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
219259454|NCT05707715|DEVICE|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
219259455|NCT06371469|BEHAVIORAL|PHeBAC|Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
219259456|NCT06371469|BEHAVIORAL|Control Group|Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
219259457|NCT03367598|GENETIC|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.
219259458|NCT00389688|DRUG|cisplatin|
219259459|NCT00389688|DRUG|pemetrexed disodium|
219259460|NCT00389688|PROCEDURE|adjuvant therapy|
219259461|NCT00389688|PROCEDURE|conventional surgery|
219259462|NCT00389688|PROCEDURE|neoadjuvant therapy|
219259463|NCT03669198|DIAGNOSTIC_TEST|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
219259464|NCT02603705|DRUG|Oxycodone extended-release|
219259465|NCT02994784|DRUG|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
219259466|NCT05282238|DIAGNOSTIC_TEST|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
219259467|NCT00805597|RADIATION|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
219259468|NCT00805597|RADIATION|no radiation|no radiotherapy
219259469|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
219259470|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
219259471|NCT05803083|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
219259472|NCT02363998|DRUG|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
219259473|NCT04248907|OTHER|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
219259474|NCT04248907|OTHER|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
219259475|NCT04248907|OTHER|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
219259476|NCT02466243|DRUG|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
219259477|NCT02466243|DRUG|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
219259478|NCT04106570|OTHER|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
219259479|NCT03347266|DRUG|VVZ-149 injections|•VVZ-149 injection
219259480|NCT03347266|DRUG|Placebo|water for injection
219259481|NCT02803671|DEVICE|TFU-NIRS|
219259482|NCT02803671|DEVICE|NIRS|
219259483|NCT02803671|DEVICE|EEG|
219259484|NCT00477464|DRUG|Lapatinib|1250mg once daily
219259485|NCT00477464|DRUG|capecitabine|2000mg/m\^2 twice daily (14 days out of 21 days)
219259486|NCT03664206|DIAGNOSTIC_TEST|MRS, conventional TMS and treshold tracking TMS|"Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
219259487|NCT04952779|DRUG|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
219259488|NCT01921907|DRUG|AD17137 topical treatment|
219259489|NCT01921907|DRUG|Placebo|
219259490|NCT04329546|OTHER|NA (no intervention)|NA (no intervention)
219259491|NCT03647384|DRUG|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
219259492|NCT03647384|DRUG|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
219259493|NCT00639769|DRUG|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
219259494|NCT00639769|DRUG|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
219259495|NCT00072683|DRUG|tolvaptan|
219259496|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
219259497|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
219259498|NCT00863798|DRUG|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
219259499|NCT02418715|OTHER|Water Aerobics Training|
219259500|NCT04238520|BEHAVIORAL|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
219259501|NCT04238520|BEHAVIORAL|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
219259502|NCT01470599|DRUG|CP-690,550|ORAL TABLET, TWICE DAILY
219259503|NCT01470599|DRUG|CP-690,550|ORAL TABLETS, TWICE DAILY
219259504|NCT00195442|DRUG|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219259505|NCT01917006|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
219259506|NCT01917006|DRUG|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
219259507|NCT00624013|DRUG|sertraline|50 mg up to 100 mg daily for 6 months
219259508|NCT00624013|DRUG|Placebo|50 mg up to 100 mg daily for 6 months
219259509|NCT00847132|BEHAVIORAL|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
219259510|NCT00847132|BEHAVIORAL|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
219259511|NCT04651309|OTHER|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
219259512|NCT03596242|OTHER|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
219259513|NCT03596242|BEHAVIORAL|blood pressure control education|standard blood pressure control education given during visits
219259514|NCT02509312|DRUG|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
219259515|NCT02509312|DRUG|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
219259516|NCT01733589|DRUG|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
219259517|NCT01733589|DRUG|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
219259518|NCT01733589|DRUG|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
219259519|NCT01733589|OTHER|laboratory biomarker analysis|
219259520|NCT01733589|OTHER|CT perfusion imaging|
219259521|NCT03616860|DEVICE|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
219259522|NCT01705405|DEVICE|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
219259523|NCT05419310|OTHER|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
219259524|NCT05419310|OTHER|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
219259525|NCT05419310|OTHER|Elastic taping application|Application of elastic taping
219259526|NCT02162017|OTHER|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
219259527|NCT02162017|OTHER|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
219259528|NCT01939951|DIETARY_SUPPLEMENT|Activation Energy Serum|7 drops or 21 drops twice daily
219259529|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
219259530|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
219259531|NCT04912700|BIOLOGICAL|COVID-19 vaccine|Full or partial reception of vaccine
219259532|NCT01508832|DRUG|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
219259533|NCT01508832|DRUG|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
219259534|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
219259535|NCT02306083|DRUG|Placebo three times a day|
219259536|NCT02306083|DRUG|glucosamine sulfate 1500 mg three times a day|
219259537|NCT03820570|PROCEDURE|hernia repair|inguinal hernia repair
219259538|NCT00397202|DEVICE|Diva Cup TM|See Detailed Description.
219259539|NCT03412578|PROCEDURE|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
219259540|NCT02221999|DRUG|Paclitaxel|
219259541|NCT02221999|DRUG|Cisplatin|
219259542|NCT02221999|DRUG|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
219259543|NCT02221999|DRUG|Letrozole|
219259544|NCT03357471|DRUG|e-Device|"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"
219259545|NCT02973802|BIOLOGICAL|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
219259546|NCT05131711|COMBINATION_PRODUCT|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
219259547|NCT02668627|PROCEDURE|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
219259548|NCT03046797|DEVICE|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
219259549|NCT03046797|DEVICE|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
219259550|NCT03457974|OTHER|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
219259551|NCT04418180|DRUG|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
219259552|NCT04418180|DRUG|Placebo|oral distilled water
219259553|NCT04561583|DEVICE|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
219259554|NCT04561583|DEVICE|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
219259555|NCT02906995|DRUG|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
219259556|NCT04832581|BEHAVIORAL|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
219259557|NCT00706914|DRUG|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
219259558|NCT00706914|DRUG|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
219259559|NCT00706914|DRUG|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
219259560|NCT00706914|DRUG|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
219259561|NCT04771962|DRUG|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
219259562|NCT00087997|DRUG|STA-4783|
219259563|NCT04214275|OTHER|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
219259564|NCT04010383|DIAGNOSTIC_TEST|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
219259565|NCT02025478|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
219259566|NCT06220812|DEVICE|low level laser ,pulsed electromagnetic field .|"LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage."
219259567|NCT05338541|DRUG|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
219259568|NCT02122549|DEVICE|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
219259569|NCT03505255|DRUG|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
219259570|NCT03505255|OTHER|Normal saline|Normal saline 0.9 % is given in the control group
219259571|NCT00392535|RADIATION|conventional radiotherapy 74 Gy delivered in 37 fractions|
219259572|NCT00392535|RADIATION|hypofractionated radiation therapy 60 Gy in 20 fractions|
219259573|NCT00392535|RADIATION|hypofractionated radiation therapy 57 Gy in 19 fractions|
219259574|NCT03364478|PROCEDURE|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
219259575|NCT03364478|PROCEDURE|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
219259576|NCT02609152|DRUG|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
219259577|NCT02609152|DRUG|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
219259578|NCT01159483|DRUG|PF-04958242|Administered as specified in the treatment arm
219259579|NCT01159483|DRUG|Placebo|Administered as specified in the treatment arm
219259580|NCT05187247|DEVICE|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
219259581|NCT02352077|BIOLOGICAL|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
219259582|NCT03017313|DRUG|LHRH analogues|3-or 6-month formulations
219259583|NCT01903083|DRUG|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
219259584|NCT01903083|DRUG|Gemcitabine|Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
219259585|NCT01903083|RADIATION|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
219259586|NCT01903083|PROCEDURE|Pancreaticoduodenectomy|Surgical resection.
219259587|NCT05987644|DRUG|Alectinib|600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)
219259588|NCT05987644|RADIATION|Stereotactic Radiosurgery|SRS dose varies by brain met size and location
219259589|NCT03669328|PROCEDURE|locoregional anesthesia|Both groups received locoregional anesthesias
219259590|NCT04241809|DIAGNOSTIC_TEST|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
219259591|NCT02932085|DEVICE|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
219259592|NCT05897983|OTHER|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
219259593|NCT01751165|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
219259594|NCT02200978|DRUG|ATO|Given IV
219259595|NCT02200978|DRUG|RIF|Given orally
219259596|NCT02200978|DRUG|ATRA|Given orally
219259597|NCT02200978|DRUG|mitoxantrone|Given IV
219259598|NCT02200978|DRUG|Ara-C|Given IV
219259599|NCT02200978|DRUG|MTX|Given orally
219259600|NCT02200978|DRUG|6MP|Given orally
219259601|NCT02200978|OTHER|intrathecal injection|Ara-C and dexamethasone
219259602|NCT02652195|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
219259603|NCT02652195|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
219259604|NCT02830048|DRUG|Glibenclamide|
219259605|NCT05663164|DRUG|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
219259606|NCT05663164|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
219259607|NCT04026399|OTHER|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
219259608|NCT04026399|BEHAVIORAL|therapy|practice of daily living tasks
219259609|NCT03626077|OTHER|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
219259610|NCT03626077|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
219259611|NCT03626077|COMBINATION_PRODUCT|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
219259612|NCT00239096|DRUG|losartan (drug)|
219259613|NCT06202911|DRUG|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
219259614|NCT06202911|OTHER|placebo|the control group will receive placebo
219259615|NCT00511277|DRUG|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
219259616|NCT02431455|DEVICE|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
219259617|NCT02431455|DEVICE|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
219259618|NCT00988533|DRUG|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
219259619|NCT00675792|DRUG|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
219259620|NCT00675792|DRUG|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
219259621|NCT00675792|DRUG|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
219259622|NCT05105568|BEHAVIORAL|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
219259623|NCT05413863|BIOLOGICAL|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
219259624|NCT05413863|BIOLOGICAL|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
219259625|NCT02573649|DEVICE|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
219259626|NCT02573649|DEVICE|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
219259627|NCT05219578|DRUG|RTX-224|RTX-224 monotherapy
219259628|NCT00943722|BIOLOGICAL|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
219259629|NCT03613636|DIAGNOSTIC_TEST|Enzyme-linked immunospot (ELISpot) assay [Blood]|The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
219259630|NCT03993457|DRUG|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
219259631|NCT03993457|DRUG|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
219259632|NCT00828893|DEVICE|navigation station|navigation station for gestures (carried out under CT) guidance
219362987|NCT05406856|RADIATION|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2\_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
219362988|NCT00504764|DRUG|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
219362989|NCT00504764|PROCEDURE|Autologous Transplantation|Autologous Transplantation
219259633|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
219259634|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
219259635|NCT00037115|DRUG|interferon beta 1a|
219259636|NCT00037115|DRUG|methotrexate|
219259637|NCT00037115|DRUG|methylprednisolone|
219259638|NCT04240028|OTHER|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
219259639|NCT04640818|DRUG|Cladribine Oral Tablet|Treatment according to the label and medical prescription
219259640|NCT04640818|DRUG|Rituximab|Treatment according to the label and medical prescription
219259641|NCT04640818|DRUG|Ocrelizumab|Treatment according to the label and medical prescription
219259642|NCT01117129|DRUG|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
219259643|NCT01117129|DRUG|placebo|i.v. infusion on day 1 and 15
219259644|NCT01117129|DRUG|methotrexate|10-25 mg weekly
219259645|NCT01117129|DRUG|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
219259646|NCT04410809|BIOLOGICAL|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
219259647|NCT04410809|OTHER|Placebo|The same composition as the active medication but without the active substance TA-46
219259648|NCT02580175|PROCEDURE|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
219259649|NCT02580175|PROCEDURE|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
219259650|NCT01036165|DEVICE|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
219259651|NCT03100955|DRUG|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
219259652|NCT03100955|DRUG|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
219259653|NCT02378636|DEVICE|600S|Monofocal Aspheric Intraocular Lens (IOL)
219259654|NCT04330378|OTHER|Hospital-at-home|As per experimental arm
219259655|NCT04330378|OTHER|Usual in-hospital care|As per control arm
219259656|NCT01840449|DRUG|Somatuline Autogel® 60, 90 or 120 mg|
219259657|NCT06125899|BEHAVIORAL|emhGAP-Age|"* Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources."
219259658|NCT04423172|DEVICE|the new tissue containment system|Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
219259659|NCT04434118|DRUG|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
219259660|NCT02656849|DRUG|BAY 1000394|
219259661|NCT01276613|DRUG|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
219259662|NCT01276613|DRUG|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
219259663|NCT03468179|DIETARY_SUPPLEMENT|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
219259664|NCT03701633|DIAGNOSTIC_TEST|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
219259665|NCT02958241|OTHER|MRI|Supine and weight bearing MRI
219259666|NCT05423431|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
219259667|NCT01339624|DRUG|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
219259668|NCT01339624|DRUG|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
219259669|NCT03543605|BEHAVIORAL|PROA Experimental|PROA Control plus clinical advice
219259670|NCT03543605|OTHER|PROA Control|PROA Control
219259671|NCT03752242|DRUG|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
219259672|NCT04456647|OTHER|Parenteral nutrition|Parenteral nutrition treatment in palliative care
219259673|NCT03082898|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
219259674|NCT01387815|BIOLOGICAL|Adalimumab|Adalimumab administered by subcutaneous injection.
219259675|NCT02389322|BIOLOGICAL|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
219362990|NCT00504764|PROCEDURE|Allogenic Transplantation|Allogenic Transplantation
219362991|NCT00504764|DRUG|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
219259676|NCT02389322|BIOLOGICAL|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
219259677|NCT02389322|BIOLOGICAL|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
219362992|NCT03122431|DRUG|Thalidomide|Thalidomide 100 mg/day
219362993|NCT03122431|DRUG|Hydroxychloroquine reduced|Hydroxychloroquine 2.5 mg/kg/day
219362994|NCT03122431|DRUG|standard dose of HCQ|Hydroxychloroquine 5.0 mg/kg/day
219259678|NCT02389322|BIOLOGICAL|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
219259679|NCT06164808|DEVICE|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
219259680|NCT00916305|OTHER|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
219259681|NCT00916305|OTHER|Unmodified audio video|An audio video with unaltered music
219259682|NCT03177109|DRUG|5% fluoride varnish|Applied topically as a coating at single point in time
219259683|NCT03177109|DRUG|8% arginine containing paste|Applied topically as a coating at single point in time
219259684|NCT03177109|DRUG|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
219259685|NCT00307164|DRUG|NucleomaxX|36 g sachet taken orally three times daily
219259686|NCT00307164|DRUG|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
219259687|NCT01416935|OTHER|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
219259688|NCT00583271|DRUG|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
219259689|NCT00583271|DRUG|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
219259690|NCT02325362|DRUG|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
219259691|NCT02325362|DRUG|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
219259692|NCT00000677|DRUG|SCH 39304|
219259693|NCT04067843|PROCEDURE|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
219259694|NCT05710237|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
219259695|NCT05710237|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
219259696|NCT05710237|DRUG|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
219259697|NCT05936008|BEHAVIORAL|Exercise MICT|Standard of care, exercise recommendations for people with stroke
219259698|NCT05936008|BEHAVIORAL|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
219259699|NCT06224400|DRUG|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
219259700|NCT06224400|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
219259701|NCT06224400|DRUG|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
219259702|NCT06224400|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
219259703|NCT03729427|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
219259704|NCT05098015|BEHAVIORAL|Game Changers|8-session group intervention that uses didactic instruction, role plays and experience sharing to empower participants to engage in HIV prevention advocacy.
219259705|NCT04183023|GENETIC|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
219259706|NCT03803943|BEHAVIORAL|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
219259707|NCT03803943|OTHER|No Intervention - Business-as-usual control|Does not receive PICT internvention
219259708|NCT05286242|BIOLOGICAL|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
219259709|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
219259710|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
219259711|NCT04151706|DRUG|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
219259712|NCT04151706|DRUG|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
219259713|NCT04151706|DRUG|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
219259714|NCT04151706|RADIATION|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
219259715|NCT04151706|DRUG|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
219259716|NCT04151706|DRUG|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
219259717|NCT04672499|DRUG|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
219259718|NCT04672499|DRUG|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
219259719|NCT04672499|DRUG|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
219259720|NCT01963442|RADIATION|Chest X-ray|at Day 0, Day 30 and relapse
219259721|NCT01963442|BIOLOGICAL|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
219259722|NCT01963442|DRUG|Augmentin|2 tablets 3 times a day for 5 days from Day 3
219259723|NCT01963442|DRUG|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
219259724|NCT01963442|DRUG|Beta-Lactams|administered from Day 0 to Day 3
219259725|NCT02298855|BEHAVIORAL|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
219259726|NCT02648711|DRUG|CRLX101|infusion CRLX101 weekly
219259727|NCT02648711|DRUG|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
219259728|NCT02648711|DRUG|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
219259729|NCT02652715|OTHER|Laboratory Biomarker Analysis|Correlative studies
219259730|NCT02652715|OTHER|Quality-of-Life Assessment|Ancillary studies
219259731|NCT02652715|OTHER|Questionnaire Administration|Ancillary studies
219259732|NCT02652715|DIETARY_SUPPLEMENT|Salvia hispanica Seed|Given PO
219259733|NCT00742898|OTHER|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
219259734|NCT00384098|DRUG|CTA018 cream|
219362995|NCT04323904|OTHER|Retrospective data collection|Retrospective data collection from patients with hantavirus infection and matching control group patients.
219259735|NCT02434523|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
219259736|NCT02434523|OTHER|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
219259737|NCT03487653|BIOLOGICAL|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
219259738|NCT03565302|DRUG|Formoterol|Subjects are treated with daily inhalation of formoterol
219259739|NCT03565302|DRUG|Terbutaline|Subjects are treated with daily inhalation of terbutaline
219259740|NCT03565302|OTHER|Placebo|Subjects are treated with placebo
219259741|NCT00212277|DRUG|Norethindrone,Ethinyl Estradiol|
219259742|NCT03510806|DIETARY_SUPPLEMENT|Supplement|dietary supplement contain protein from milk and fruit extract
219259743|NCT03510806|OTHER|Placebo|color, taste, and calorie-matched placebo
219259744|NCT03060213|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
219259745|NCT03016949|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
219259746|NCT03016949|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
219259747|NCT00664183|DRUG|Vitreosolve|Intravitreal injection
219259748|NCT04761692|BEHAVIORAL|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
219259749|NCT04761692|BEHAVIORAL|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
219259750|NCT04761692|BEHAVIORAL|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
219259751|NCT04191148|DRUG|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
219259752|NCT04191148|DRUG|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
219259753|NCT01637285|BIOLOGICAL|PF-04856883|Dose A
219259754|NCT01637285|BIOLOGICAL|PF-04856883|Dose B
219259755|NCT01637285|BIOLOGICAL|PF-04856883|Dose C
219259756|NCT01637285|BIOLOGICAL|PF-04856883|Dose D
219259757|NCT03696888|BEHAVIORAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
219259758|NCT03696888|BEHAVIORAL|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
219259759|NCT05410119|BEHAVIORAL|8-week Resilience Group Psychotherapy|Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
219259760|NCT05410119|OTHER|Usual care|Usual care means treating as usual, such as regular home visit.
219259761|NCT00016445|DRUG|growth hormone|
219259762|NCT02090998|PROCEDURE|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
219176213|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
219176214|NCT03468218|DRUG|Cabozantinib|Given PO
219176215|NCT03468218|BIOLOGICAL|Pembrolizumab|Given IV
219259763|NCT02090998|DRUG|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
219259764|NCT06546514|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
219259765|NCT00085111|BIOLOGICAL|bevacizumab|Given IV
219259766|NCT04156347|DRUG|Episcleral Topotecan|Transscleral Topotecan
219259767|NCT01148498|DRUG|solanezumab|400mg administered once intravenously
219259768|NCT06416332|OTHER|group A: in face to face live therapeutic exercise|"In group A: in face to face live therapeutic exercise the program and its progressivity will be determined and performed for life according to the progress of the patient, with a frequency of sessions twice a week, session duration 45 minutes, following the recommended dosage of exercise according to clinical guidelines, while the total duration of the intervention will be eight weeks. You will be instructed to perform the program at home, 3 times a week. The standardized exercise program to be followed by this group will include :~1. Exercises to strengthen the hip and knee muscles through isometric contractions and resistance exercises using elastic bands.~2. Balance and neuromuscular coordination exercises."
219259769|NCT06416332|OTHER|group B: telerehabilitation program|In group B: telerehabilitation program, the therapeutic exercise program will follow the same structure, which was mentioned above. The differentiation in the intervention of this group will be that the explanation of the exercises, their presentation, monitoring and information of the participants will be done through the telerehabilitation platform and special data processing software. The intervention time remains the same, with the physical therapist during these 45 minutes of the session , to evaluate the data on the patients progress by receiving the information through the software and to inform the patient of any changes in the progressivity of the exercise program. The other parameters of the intervention remain the same, as in person exercise.
219259770|NCT01799109|DRUG|Magnesium Sulfate & albuterol|
219259771|NCT01799109|DRUG|albuterol|
219259772|NCT01799109|DRUG|magnesium|
219259773|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
219259774|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
219259775|NCT01274559|DRUG|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
219259776|NCT01274559|DRUG|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
219259777|NCT03757078|DRUG|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
219259778|NCT03757078|DRUG|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
219259779|NCT01013506|DRUG|IGF-1R inhibitor OSI-906|Given orally
219259780|NCT01013506|DRUG|erlotinib hydrochloride|Given orally
219259781|NCT01013506|DRUG|goserelin|Given subcutaneously
219259782|NCT01013506|DRUG|letrozole|Given orally
219259783|NCT04267471|BEHAVIORAL|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
219259784|NCT04267471|BEHAVIORAL|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
219259785|NCT03623477|BEHAVIORAL|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
219259786|NCT03623477|BEHAVIORAL|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
219259787|NCT04683328|BIOLOGICAL|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
219259788|NCT04683328|BIOLOGICAL|SCTA01 Placebo|The excipients of SCTA01
219259789|NCT00069381|BEHAVIORAL|Psychotherapy treatment|
219259790|NCT00678977|DRUG|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
219259791|NCT00678977|DRUG|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
219259792|NCT00678977|DRUG|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
219259793|NCT01003145|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
219259794|NCT03478046|OTHER|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
219259795|NCT04167228|DRUG|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with ceftazidime-avibactam.
219259796|NCT04167228|DRUG|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
219259797|NCT05416411|BEHAVIORAL|Inspiratory muscle training|Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
219259798|NCT02560389|DRUG|Placebo|Sugar pill packaged to resemble levodopa
219259799|NCT02560389|DRUG|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
219259800|NCT01217619|DRUG|erlotinib|erlotinib 150mg/d continuously for 56 days
219259801|NCT01401114|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
219259802|NCT06325345|BEHAVIORAL|Gut-directed hypnotherapy|Eight session gut-directed hypnotherapy for IBS symptoms adapted from the evidence-based Manchester protocol for treatment of IBS.
219259803|NCT06325345|OTHER|Standard Medical Therapy|Standard medical treatment will be administered by board certified gastroenterologists
219259804|NCT04703257|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
219259805|NCT04703257|DRUG|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
219259806|NCT06101472|DEVICE|ASQELIO Toric Biaspheric Monofocal Lens|Intraocular lens implantation in cataract surgery
219259807|NCT03359226|PROCEDURE|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
219259808|NCT03774212|DEVICE|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
219259809|NCT03700372|DEVICE|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
219259810|NCT00030537|DRUG|erlotinib hydrochloride|
219259811|NCT03409731|DEVICE|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
219259812|NCT04171947|DEVICE|Matuzalem ovule|vaginal ovule with 2 mg tea extract
219259813|NCT04171947|DEVICE|Vehicle ovule|polyethylene glycol vaginal ovule
219259814|NCT02205541|DRUG|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
219259815|NCT02205541|DRUG|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
219259816|NCT04933799|DRUG|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
219259817|NCT04933799|DRUG|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
219259818|NCT00892944|DRUG|AZD2516|Fractionated single oral dose
219259819|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
219259820|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
219259821|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
219259822|NCT04074343|DRUG|TAS-102|Given PO
219259823|NCT04074343|DRUG|Irinotecan|Given IV
219259824|NCT01537185|OTHER|Placebo|3 cohorts of normal saline injection
219259825|NCT01537185|BIOLOGICAL|SPWCV+Alum 100 mcg|3 injections 28 days apart
219259826|NCT01537185|BIOLOGICAL|SPWCV+Alum 600 mcg|3 injections 28 days apart
219259827|NCT01537185|BIOLOGICAL|SPWCV+Alum 300 mcg|3 injections 28 days apart
219259828|NCT00687947|DRUG|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
219259829|NCT01211444|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
219259830|NCT00484601|DRUG|Ifosfamide|
219259831|NCT00484601|DRUG|Doxorubicin|
219259832|NCT06157528|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients were treated with abarelix prior to the examination
219259833|NCT00784745|DRUG|Dexamethasone|2mg morning and night for 5 days.
219259834|NCT05018897|BEHAVIORAL|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
219259835|NCT05018897|BEHAVIORAL|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
219259836|NCT03131349|DIAGNOSTIC_TEST|serum zinc and iron|history ,examination,investigations
219259837|NCT00965120|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
219259838|NCT00965120|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
219259839|NCT00965120|DRUG|Placebo (saline)|Systemic infusion of placebo (saline).
219259840|NCT03052712|BEHAVIORAL|social cognition|battery of tests of social cognition
219259841|NCT05117879|PROCEDURE|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
219259842|NCT05549999|DIAGNOSTIC_TEST|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
219259843|NCT00251888|DRUG|campto (irinotecan)|
219259844|NCT00251888|DRUG|cisplatin (cisplatyl)|
219259845|NCT04016402|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
219259846|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
219259847|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
219259848|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 0
219259849|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
219259850|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
219259851|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 4
219259852|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
219259853|NCT01264445|BIOLOGICAL|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
219176216|NCT01814501|BIOLOGICAL|panitumumab|Each vial of panitumumab will contain 20 mL of a sterile protein solution containing a 20-mg/mL solution of panitumumab. The vial will contain approximately 400mg of panitumumab and is for single dose use only.
219176217|NCT01814501|DRUG|irinotecan hydrochloride|Diluted with 5% dextrose (D5W) to a total volume of 500 mL and infused intravenously over 90 minutes. Nothing else should be added to the bag. Patients will be given a dose of 180 mg/M2 by intravenous infusion.
219176218|NCT01814501|DRUG|fluorouracil|Administered intravenously. A bolus of 400 mg/m2 to be followed by a continuous infusion over 46 hrs at a dose of 2400mg/m2.
219176219|NCT01814501|DRUG|leucovorin calcium|Leucovorin will be administered at a dose of 200 mg/m2 over 120 minutes prior to the 5-FU bolus. Leucovorin may be run simultaneously with irinotecan infusion via y-site connection.
219176220|NCT05404958|OTHER|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
219176221|NCT03075254|DEVICE|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
219176222|NCT03075254|DEVICE|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
219176223|NCT03075254|DEVICE|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
219176224|NCT05936281|DRUG|Genakumab for injection|150 mg/1ml/ vial
219176225|NCT05936281|DRUG|Colchicine|0.5 mg/table
219176226|NCT05851378|DRUG|Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)|Given intravenously at time of imaging
219176227|NCT05851378|PROCEDURE|Magnetic Resonance Image (MRI)|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
219176228|NCT04605809|DEVICE|combined motor and cognitive training|The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.
219176229|NCT04605809|DEVICE|motor training alone|The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
219176230|NCT04605809|DEVICE|cognitive training alone|The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
219259854|NCT00005946|BIOLOGICAL|filgrastim|
219259855|NCT00005946|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219259856|NCT00005946|DRUG|cyclophosphamide|
219259857|NCT00005946|DRUG|etoposide|
219259858|NCT04617236|BEHAVIORAL|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
219259859|NCT06278337|GENETIC|genetic restrospective study|it is not an interventional study but observational
219259860|NCT05891652|PROCEDURE|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
219259861|NCT02938897|BEHAVIORAL|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
219259862|NCT02938897|BEHAVIORAL|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
219259863|NCT02938897|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
219259864|NCT02151578|OTHER|home/community case management|
219259865|NCT00479843|BEHAVIORAL|Nutritional programme|
219259866|NCT00414258|PROCEDURE|breastfeeding|See detailed description.
219259867|NCT04912154|PROCEDURE|Rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture
219259868|NCT03980132|DRUG|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
219259869|NCT02767518|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
219259870|NCT05624697|PROCEDURE|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
219259871|NCT05243537|OTHER|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
219259872|NCT03828877|OTHER|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
219259873|NCT04440930|OTHER|White tea|Mouthwash with white tea five to six times a day for nine weeks
219259874|NCT04440930|OTHER|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
219259875|NCT01811628|BEHAVIORAL|Questionnaire|Questionnaire completion taking about 10-15 minutes.
219259876|NCT01811628|BEHAVIORAL|Interview|Audio-recorded interview that will last about 1 hour.
219259877|NCT00591604|DRUG|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
219259878|NCT05077241|DEVICE|Inspiratory muscle training|Individuals will be instructed to perform a rapid contraction of the inspiratory muscles against a load and sustain it for 2 seconds in each maneuver.
219259879|NCT02110511|OTHER|blended lentils|blended lentils burritto breakfast
219259880|NCT02110511|OTHER|whole lentils|whole lentils breakfast burritto
219259881|NCT02110511|OTHER|no lentils|No lentils control breakfast burritto
219259882|NCT00372177|RADIATION|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
219259883|NCT02568878|DRUG|Creatine monohydrate|
219259884|NCT00151697|DRUG|Novomix 30|
219259885|NCT00151697|DRUG|Novorapid and Amaryl|
219259886|NCT00151697|DRUG|Lantus|
219259887|NCT02833623|BEHAVIORAL|Short-message-based Re-education|
219259888|NCT02833623|BEHAVIORAL|conventional education|
219259889|NCT04016805|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion"
219259890|NCT04016805|DRUG|Umbralisib|"* Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis"
219259891|NCT04016805|DRUG|Ibrutinib|"* Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis"
219259892|NCT04016805|DRUG|Venetoclax|"* BCL-2 inhibitor~* Tablet form, to be taken orally"
219259893|NCT04016805|DRUG|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
219259894|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
219259895|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
219259896|NCT03092245|DRUG|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
219259897|NCT03092245|DRUG|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
219259898|NCT01540903|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
219259899|NCT01540903|BIOLOGICAL|Saline|Saline
219259900|NCT03722693|DEVICE|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
219259901|NCT02765386|DEVICE|Hybrid fittings for cochlear implant recipients|
219259902|NCT05632718|OTHER|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
219259903|NCT04863638|BIOLOGICAL|3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 42
219259904|NCT04863638|BIOLOGICAL|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 111
219259905|NCT04863638|BIOLOGICAL|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 171
219259906|NCT04863638|BIOLOGICAL|2 doses of vaccine|the schedule of Day 0, 21
219259907|NCT01800578|DEVICE|monitor for depth of hypnosis|"evaluation of depth of hypnosis~\--------------------------------------------------------------------------------"
219259908|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
219259909|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
219259910|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
219259911|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
219259912|NCT01193218|DRUG|BI 10773|BI 10773 tablets low dose once a day
219259913|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
219259914|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
219259915|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
219259916|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-high dose once a day
219259917|NCT01193218|DRUG|BI 10773|BI 10773 tablets high dose once a day
219259918|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
219259919|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
219259920|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
219259921|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
219259922|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-low dose once a day
219259923|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
219259924|NCT03168698|DRUG|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
219259925|NCT03168698|DRUG|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
219259926|NCT04124783|DEVICE|Cooling Bolero|A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
219259927|NCT01271023|DEVICE|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
219259928|NCT02940210|DEVICE|Mediclore® (adhesion barrier)|
219259929|NCT02725398|DRUG|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
219259930|NCT02725398|DRUG|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
219259931|NCT02725398|DRUG|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
219259932|NCT03781245|OTHER|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
219259933|NCT04164862|DEVICE|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
219259934|NCT05655039|OTHER|Rehabilitation|Stroke Rehabilitation Program
219259935|NCT00006010|DRUG|docetaxel|
219259936|NCT00006010|DRUG|gemcitabine hydrochloride|
219259937|NCT04610632|DIAGNOSTIC_TEST|home pregnancy test|use of home pregnancy test
219259938|NCT00187343|DEVICE|Breast IMRT|
219259939|NCT03811834|DRUG|Mobocertinib|Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
219259940|NCT01138761|BEHAVIORAL|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
219259941|NCT04444219|OTHER|Breakfast meals|Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
219259942|NCT03183180|DIAGNOSTIC_TEST|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
219259943|NCT02620956|OTHER|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
219259944|NCT04991688|DRUG|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
219259945|NCT01108042|DRUG|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
219259946|NCT01748045|DRUG|inhaled nitric oxide|
219259947|NCT01748045|DRUG|Placebo Comparator - nitrogen gas|
219259948|NCT04947436|DEVICE|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
219259949|NCT04947436|DEVICE|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
219259950|NCT05268185|BEHAVIORAL|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
219259951|NCT05268185|BEHAVIORAL|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
219259952|NCT00359385|DRUG|Alendronate 70mg weekly|70mg weekly
219259953|NCT00169949|DRUG|aripiprazole|
219259954|NCT02681445|DEVICE|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
219259955|NCT06647329|BIOLOGICAL|CAR-T Therapy|CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
219259956|NCT05153642|PROCEDURE|Microsurgical intervention|The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
219259957|NCT03389997|DIAGNOSTIC_TEST|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
219259958|NCT02661503|DRUG|Bleomycin|
219259959|NCT02661503|DRUG|Etoposide|
219259960|NCT02661503|DRUG|Doxorubicin|
219259961|NCT02661503|DRUG|Cyclophosphamide|
219259962|NCT02661503|DRUG|Vincristine|
219259963|NCT02661503|DRUG|Procarbazine|
219259964|NCT02661503|DRUG|Prednisone|
219259965|NCT02661503|DRUG|Brentuximab Vedotin|
219259966|NCT02661503|DRUG|Dacarbazine|
219259967|NCT02661503|DRUG|Dexamethasone|
219259968|NCT00107081|DRUG|ciprofloxacin and amoxicillin|
219259969|NCT00107081|PROCEDURE|Outpatient management|
219259970|NCT00107081|DRUG|i.v. antibiotics|
219259971|NCT00107081|PROCEDURE|inpatient management|
219259972|NCT04248036|BEHAVIORAL|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
219259973|NCT03987464|BEHAVIORAL|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
219259974|NCT03987464|BEHAVIORAL|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
219259975|NCT03987464|BEHAVIORAL|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
219259976|NCT03987464|BEHAVIORAL|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
219259977|NCT03987464|BEHAVIORAL|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
219259978|NCT00131547|BEHAVIORAL|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
219259979|NCT01692132|DRUG|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
219259980|NCT03752489|DIAGNOSTIC_TEST|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
219259981|NCT03752489|DIAGNOSTIC_TEST|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
219259982|NCT04012099|DRUG|BMT101|Intradermal injection to each of 3 dose-groups.
219259983|NCT05499143|OTHER|Online questionnaire|Online questionnaire impact for DCD - Belgian version
219259984|NCT05930002|DRUG|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
219259985|NCT05930002|DRUG|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
219259986|NCT05930002|DRUG|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
219259987|NCT00281502|DRUG|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
219259988|NCT05207631|OTHER|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
219259989|NCT05300997|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
219259990|NCT00961610|BEHAVIORAL|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
219259991|NCT01215032|DRUG|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
219259992|NCT02041312|OTHER|No intervention|No intervention will be needed.
219259993|NCT03002922|DRUG|BAY987517|Sunscreen formula Y65-158
219259994|NCT03420898|OTHER|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
219259995|NCT01818609|BEHAVIORAL|Step reduction|taking less than 1500 steps/d
219259996|NCT03156205|BEHAVIORAL|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
219259997|NCT03156205|BEHAVIORAL|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
219259998|NCT03156205|BEHAVIORAL|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
219259999|NCT06180863|DRUG|oral azacitidine (CC-486)|Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
219260000|NCT03087331|OTHER|medication reviews, assessment, recommendations, education.|
219260001|NCT06342245|RADIATION|Radiofrequency coblation micro-tenotomy|Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed.
219260002|NCT04477356|PROCEDURE|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
219260003|NCT04477356|PROCEDURE|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
219260004|NCT02886169|OTHER|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
219260005|NCT02886169|OTHER|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
219260006|NCT02643511|RADIATION|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
219260007|NCT05934656|OTHER|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
219260008|NCT02924558|OTHER|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
219260009|NCT02924558|OTHER|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
219260010|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
219260011|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
219260012|NCT01474421|DRUG|Placebo|Patients will receive placebo once daily orally for 28 days.
219260013|NCT00357318|DRUG|sunitinib malate|Given PO
219260014|NCT00357318|BIOLOGICAL|bevacizumab|Given IV
219260015|NCT00357318|OTHER|pharmacological study|Correlative studies
219260016|NCT00357318|OTHER|laboratory biomarker analysis|Correlative studies
219260017|NCT03524950|DRUG|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
219260018|NCT04270656|PROCEDURE|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
219260019|NCT04270656|PROCEDURE|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
219260020|NCT01424189|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
219260021|NCT01424189|DEVICE|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
219260022|NCT00269841|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
219260023|NCT00269841|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
219260024|NCT00269841|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
219260025|NCT06197113|DEVICE|Magstim Rapid2 Magnetic Stimulator|For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
219260026|NCT05201170|DRUG|Vehicle Ophthalmic Solution|Ophthalmic Solution
219260027|NCT05201170|DRUG|PL9643 Ophthalmic Solution|Ophthalmic Solution
219260028|NCT05959018|DEVICE|Arrow Three-Lumen Central Venous Catheter|Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
219260029|NCT05959018|DEVICE|Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
219260030|NCT00308399|DRUG|Itopride|
219260031|NCT00221481|DRUG|divalproex or olanzapine|
219260032|NCT04682340|DIAGNOSTIC_TEST|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
219260033|NCT05288504|DRUG|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
219260034|NCT05288504|DRUG|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
219260035|NCT05455684|DRUG|Aticaprant|Aticaprant will be administered orally as tablets.
219260036|NCT05455684|OTHER|Placebo|Placebo will be administered orally as tablets.
219260037|NCT03937232|BEHAVIORAL|Cross-Education|Home exercise program + usual care
219260038|NCT03937232|BEHAVIORAL|Mirror Visual Feedback|Home exercise program + usual care
219260039|NCT03937232|OTHER|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
219260040|NCT03955861|BIOLOGICAL|adalimumab|Subcutaneous injection
219260041|NCT03955861|BIOLOGICAL|Certolizumab|Subcutaneous injection
219260042|NCT03955861|BIOLOGICAL|Etanercept|Subcutaneous injection
219260043|NCT03955861|BIOLOGICAL|Golimumab|Subcutaneous injection
219260044|NCT03955861|BIOLOGICAL|Secukinumab|Subcutaneous injection
219260045|NCT01203956|DEVICE|SmartFlex|Device used with smartflex engaged.
219260046|NCT01203956|DEVICE|Standard|
219260047|NCT06015685|OTHER|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
219260048|NCT06015685|OTHER|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
219260049|NCT04092959|BEHAVIORAL|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
219260050|NCT04092959|BEHAVIORAL|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
219260051|NCT04092959|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
219260052|NCT06465615|DEVICE|Self-education with dichoptic reading on tablet|"Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books."
219362996|NCT05751356|DRUG|TR128|TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
219362997|NCT00686647|DEVICE|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
219260053|NCT06465615|PROCEDURE|Conventional orthoptic rehabilitation|Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
219260054|NCT06048939|OTHER|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
219260055|NCT06048939|OTHER|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
219260056|NCT00069277|DRUG|E7389|
219260057|NCT00175370|DRUG|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
219260058|NCT02933307|DEVICE|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
219260059|NCT02933307|DEVICE|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
219260060|NCT02230306|DRUG|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
219260061|NCT02230306|DRUG|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
219260062|NCT03127878|OTHER|Exercise|
219260063|NCT04150471|OTHER|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
219260064|NCT00002061|DRUG|Inosine pranobex|
219260065|NCT02442245|DIETARY_SUPPLEMENT|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
219260066|NCT02442245|OTHER|Placebo: Microcrystalline Cellulose|
219260067|NCT02442245|OTHER|Control: No supplementation|
219260068|NCT03010345|DEVICE|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
219260069|NCT03010345|OTHER|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
219260070|NCT02657954|BEHAVIORAL|CCT|10-week Compensatory Cognitive Training
219260071|NCT02657954|BEHAVIORAL|HCE|10-week Holistic Cognitive Education
219260072|NCT01006447|BEHAVIORAL|Instructor contact|
219260073|NCT01006447|BEHAVIORAL|Instructor contact|
219260074|NCT00136175|DRUG|Paclitaxel|
219260075|NCT00136175|DRUG|Carboplatin|
219260076|NCT00136175|DRUG|Gemcitabine|
219362998|NCT00686647|DEVICE|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
219362999|NCT02385279|DEVICE|MiStent|Percutaneous Coronary Intervention
219260077|NCT04801784|PROCEDURE|Increased net ultrafiltration with advanced hemodynamic monitoring|A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.
219260078|NCT04801784|PROCEDURE|Zero or near-zero net ultrafiltration|The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
219260079|NCT06353802|DIAGNOSTIC_TEST|Chronic non-specific neck pain and lumbar reposition sense|"In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times."
219260080|NCT04345783|DRUG|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
219260081|NCT03704649|BEHAVIORAL|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
219260082|NCT03795402|DEVICE|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
219260083|NCT01770314|BEHAVIORAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
219260084|NCT04373356|DEVICE|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
219260085|NCT04373356|DEVICE|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
219260086|NCT06385314|OTHER|Collecting data with oral health related quality of life, dental anxiety and state anxiety|Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
219260087|NCT00801450|DRUG|Triamcinolone acetonide|4 mg
219260088|NCT00801450|DRUG|Triamcinolone acetonide|40 mg
219260089|NCT06129045|BEHAVIORAL|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
219260090|NCT06129045|BEHAVIORAL|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
219363000|NCT02385279|DEVICE|XIENCE EES|Percutaneous Coronary Intervention
219260091|NCT03185585|OTHER|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
219260092|NCT03185585|OTHER|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
219260093|NCT03582150|DEVICE|Remote Monitoring with Ambulatory Detox|"* Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
219260094|NCT06647316|OTHER|Physiotherapy|The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
219260095|NCT00361842|DRUG|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
219260096|NCT01172899|PROCEDURE|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
219260097|NCT01172899|BEHAVIORAL|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
219260098|NCT03581253|OTHER|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
219260099|NCT03581253|OTHER|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
219260100|NCT03512288|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
219260101|NCT03512288|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
219260102|NCT06585748|DRUG|Lidocaine spray|4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
219260103|NCT06585748|OTHER|Placebo|No medication/application will be administered as placebo.
219260104|NCT04814992|BEHAVIORAL|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
219260105|NCT00601471|OTHER|proximal tibiofibular manipulation|proximal tibiofibular manipulation
219260106|NCT00601471|OTHER|distal tibiofibular manipulation|distal tibiofibular manipulation
219260107|NCT00601471|OTHER|no intervention|no intervention / control
219260108|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram on visit 5 single dose
219260109|NCT01257048|DRUG|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
219260110|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
219260111|NCT03910296|BEHAVIORAL|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
219260112|NCT02108418|DRUG|TG-2349 as the original formulation|single oral dose under fed condition
219260113|NCT02108418|DRUG|TG-2349 as a new capsule formulation|single oral dose under fed condition
219260114|NCT01594697|DRUG|Metformin|
219260115|NCT05680285|DEVICE|diode lazer|diode laser was applied during the pulpotomy procedure
219260116|NCT05680285|DEVICE|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
219260117|NCT06176378|OTHER|traditional pulpotomy|After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
219260118|NCT06176378|DEVICE|diode laser pulpotomy|after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
219260119|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260120|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260121|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260122|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260123|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260124|NCT00945698|DIETARY_SUPPLEMENT|Maize-soy flour|"* No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
219260125|NCT03526471|DEVICE|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
219260126|NCT01077622|DRUG|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
219260127|NCT02966418|PROCEDURE|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
219260128|NCT02966418|PROCEDURE|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
219260129|NCT05764577|PROCEDURE|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
219260130|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
219363001|NCT00632853|RADIATION|Standard Radiation Dose Therapy|45 Gy
219363002|NCT00632853|DRUG|cisplatin|IV
219176231|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
219176232|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
219176233|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
219176234|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
219176235|NCT04641897|PROCEDURE|Respiratory rate modification|"During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate)."
219176236|NCT06180135|OTHER|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
219176237|NCT06180135|OTHER|FENNEL TEA DRINK|FENNEL TEA DRINK
219176238|NCT06274307|PROCEDURE|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
219176239|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
219176240|NCT04537312|OTHER|Survey Administration|ancillary correlative
219176241|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
219176242|NCT03829410|DRUG|Onvansertib|Onvansertib orally.
219176243|NCT03829410|BIOLOGICAL|Bevacizumab|Bevacizumab intravenously.
219176244|NCT03829410|DRUG|FOLFIRI|FOLFIRI intravenously.
219176245|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
219176246|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
219176247|NCT03668977|DIETARY_SUPPLEMENT|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
219260131|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
219260132|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
219260133|NCT00424177|DRUG|eltrombopag|experimental
219260134|NCT01123512|DEVICE|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
219260135|NCT05712655|OTHER|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
219260136|NCT04022603|DEVICE|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
219260137|NCT06479252|OTHER|Sit-to-Stand Test (STS)|The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
219260138|NCT00816153|OTHER|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
219260139|NCT03822377|DRUG|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
219260140|NCT03822377|DRUG|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
219260141|NCT03792893|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
219260142|NCT03792893|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
219260143|NCT00691678|DRUG|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
219260144|NCT00691678|DRUG|Glucosamine|500mg glucosamine TID for twenty-four weeks
219260145|NCT01058083|DRUG|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
219260146|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
219260147|NCT01058083|DRUG|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
219260148|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
219260149|NCT01058083|DRUG|Placebo|Placebo, Oral, 0 mg, daily, 28 days
219260150|NCT03161223|DRUG|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
219260151|NCT03161223|DRUG|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
219363003|NCT00632853|DRUG|etoposide|IV
219363004|NCT00632853|RADIATION|High Radiation Dose Therapy|70 Gy
219363005|NCT00632853|DRUG|carboplatin|IV
219176248|NCT04290221|OTHER|Ultrasound-guided percutaneous electrolysis in the lumbar nerve root|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 6 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
219176249|NCT04290221|OTHER|Electrical Dry Needling in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
219176250|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
219176251|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
219176252|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
219176253|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
219176254|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
219260152|NCT03161223|DRUG|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
219260153|NCT03161223|DRUG|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
219260154|NCT05772481|OTHER|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
219260155|NCT02930837|DRUG|alteplase|
219260156|NCT05463445|OTHER|Only observation|No intervention is needed.
219260157|NCT01831726|DRUG|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
219260158|NCT05159778|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
219260159|NCT05159778|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
219260160|NCT01379261|PROCEDURE|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
219260161|NCT01716923|BIOLOGICAL|S-303 Red Blood Cells (RBCs) - Test|
219260162|NCT01716923|BIOLOGICAL|Conventional, untreated red blood cells (RBCs) - Control|
219260163|NCT00654615|DEVICE|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
219260164|NCT00654615|PROCEDURE|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
219260165|NCT02623686|OTHER|Aroma Therapy Massage and Inhalation Patch|
219260166|NCT00701506|DEVICE|Patterned Electrical Neuromuscular Stimulation|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings"
219260167|NCT00701506|DEVICE|Placebo PENS|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
219260168|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
219260169|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
219260170|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
219260171|NCT01502371|DRUG|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
219260172|NCT01502371|DRUG|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
219260173|NCT01502371|DRUG|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
219260174|NCT02007759|DEVICE|VitalStim|This group will receive active VitalStim treatment.
219260175|NCT02007759|DEVICE|Sham VitalStim|This group will receive a sham VitalStim intervention.
219260176|NCT00005058|PROCEDURE|ultrasound imaging|
219260177|NCT04106453|PROCEDURE|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
219260178|NCT04106453|PROCEDURE|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
219260179|NCT04438330|OTHER|Nickel sulfate hexahydrate|Patch test
219260180|NCT03754764|BIOLOGICAL|Specificity CD38 CAR-T Cells|1\) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
219260181|NCT01531907|OTHER|Study visit procedures|"Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
219260182|NCT00605566|DRUG|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
219260183|NCT00605566|DRUG|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
219260184|NCT06107049|DIETARY_SUPPLEMENT|BLa80|During the experiment, the subjects took a packet of probiotics every day, and the sleep condition, anxiety level and memory level of the subjects were evaluated by questionnaires and ability tests. The questionnaire included PSQI Pittsburgh Sleep Quality Index scale, ISI Insomnia Severity Index Scale and GSRS gastrointestinal symptom Score scale.
219260185|NCT00945113|BEHAVIORAL|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
219260186|NCT04185038|BIOLOGICAL|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
219260187|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
219260188|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
219260189|NCT04502043|OTHER|Exercise therapy|"* Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises"
219260190|NCT05955677|DRUG|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
219260191|NCT05955677|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
219260192|NCT05787145|BEHAVIORAL|Let's Discuss Health Group|Use of the Let's Discuss Health website to prepare four medical encounters with the radiation oncologist throughout the radiation care trajectory.
219260193|NCT00207402|DRUG|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
219260194|NCT04156399|OTHER|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
219260195|NCT03440047|DEVICE|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
219260196|NCT01181609|DRUG|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
219260197|NCT04813497|DIAGNOSTIC_TEST|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
219260198|NCT01338974|GENETIC|gene expression analysis|
219260199|NCT01338974|GENETIC|proteomic profiling|
219260200|NCT01338974|OTHER|flow cytometry|
219260201|NCT01338974|OTHER|laboratory biomarker analysis|
219260202|NCT06957132|DEVICE|Audiogram|"Either the patient can be proposed to perform the audiogram during their long-term consultation, or they will be contacted by the physician to come especially for the project and realize the audiogram.~iAudiogram is an Artificial Intelligence (AI) - automated audiometry platform (https://iaudiogram.com/), certified CE (European conformity).~This examination will be performed once within the study."
219260203|NCT06956352|BEHAVIORAL|Adapted Collaborative Care Model (CCM)|Person-centered, recovery supports.
219260204|NCT06956352|BEHAVIORAL|Usual Care Group|Usual care, referral-based.
219260205|NCT06956885|DRUG|Discontibuation of oral ULT|Patients will stop the ULT at D0. They will have an US scan to look for urate deposits at each visit.
219260206|NCT06956885|DRUG|Maintenance of ULT|Patients will continue their ULT according to the recommendations of the Eular and French Society of Rheumatology, to maintain their SUA levels below 60 mg/l.
219260207|NCT03479125|DIAGNOSTIC_TEST|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
219260208|NCT05397366|DIAGNOSTIC_TEST|Task Specific Training|"Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side."
219260209|NCT05397366|DIAGNOSTIC_TEST|Neurodevelopmental Training|"Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways."
219260210|NCT00478647|BIOLOGICAL|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
219260211|NCT04378647|DRUG|Induction with Brentuximab vedotin (BV)|3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
219260212|NCT04378647|DRUG|Induction without Brentuximab Vedotin|3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
219260213|NCT04378647|DRUG|Consolidation with Brentuximab Vedotin|Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
219260214|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract|207 mg curcumin
219260215|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
219260216|NCT03530436|DIETARY_SUPPLEMENT|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
219260217|NCT03530436|DIETARY_SUPPLEMENT|Cyclodextrin complex of curcuminoids|207 mg curcumin
219260218|NCT03530436|DIETARY_SUPPLEMENT|Turmeric oleoresin|207 mg curcumin
219260219|NCT03530436|DIETARY_SUPPLEMENT|Liposomal curcumin|207 mg curcumin
219260220|NCT03530436|DIETARY_SUPPLEMENT|Phytosomal curcumin|207 mg curcumin
219260221|NCT03530436|DIETARY_SUPPLEMENT|Micellar turmeric extract|207 mg curcumin
219260222|NCT05758987|BEHAVIORAL|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
219260223|NCT05758987|BEHAVIORAL|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
219260224|NCT06956261|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
219260225|NCT06956261|DRUG|Drug: NW-301D|TCR-T T cell targeting KRAS G12D mutation
219260226|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
219260227|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
219260228|NCT03176901|BEHAVIORAL|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
219260229|NCT03176901|BEHAVIORAL|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
219260230|NCT00511836|DRUG|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
219260231|NCT00511836|DRUG|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
219260232|NCT03003598|OTHER|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
219260233|NCT03003598|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
219260234|NCT00721812|DRUG|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
219260235|NCT05650541|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
219260236|NCT01936324|DRUG|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
219260237|NCT01936324|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
219260238|NCT05359055|DRUG|SPH3127 tablet|100mg once daily on Day 1 and Day 8
219260239|NCT05359055|DRUG|Itraconazole|200mg once daily from Day 3 to Day10.
219260240|NCT05359055|DRUG|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
219260241|NCT05359055|DRUG|Rifampin|600mg once daily from Day 3 to Day13.
219260242|NCT02187367|BIOLOGICAL|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
219260243|NCT04957329|DRUG|Xalatan|Eye drop
219260244|NCT04957329|DRUG|Monoprost|Eye drop
219260245|NCT01674517|DRUG|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
219260246|NCT03061604|DEVICE|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
219260247|NCT03061604|DRUG|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
219260248|NCT03061604|BIOLOGICAL|Blood transfusion|Blood transfusion will be administered to all patients if needed
219260249|NCT03061604|DRUG|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
219260250|NCT05142930|OTHER|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
219260251|NCT05142930|OTHER|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
219260252|NCT03851380|BEHAVIORAL|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
219260253|NCT03851380|OTHER|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
219260254|NCT03851380|DEVICE|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
219260255|NCT03851380|DEVICE|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
219260256|NCT05880225|BEHAVIORAL|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
219260257|NCT05880225|BEHAVIORAL|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
219260258|NCT06956222|OTHER|Hybrid Tele-rehabilitation|"In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under the physiotherapist's supervision, including watching and correcting exercise techniques.~Video session: participants attend video session via Zoom platform (Zoom Video Communications, inc., USA), an accessible internet-based platform from any laptop or mobile device that offers a real-time video and audio communications. Participants will receive a Zoom link with a unique password. During the video session, the physiotherapist accesses from the clinic using a laptop, while participants are based at their home. Participants will receive exercises (attached in the study protocol document) with real time instructions from the physiotherapist. Instructions on downloading and accessing Zoom platform will be given to the participants in the first in-person session to ensure their readiness to access the Zoom platform."
219260259|NCT06956222|OTHER|Standard Rehabilitation|In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under physiotherapist's supervision, including watching and correcting exercise techniques.
219260260|NCT06735807|BEHAVIORAL|Generated AI-based intervention (Emohaa)|Participants will complete the intervention process by interacting with the Wechat applet. Participants will be required to complete a 6-week self-help therapy. Participants will be required to have a 30-minute dialogue including input and reflection time with Emohaa each week simultaneously with group ACT. Participants are free to dialogue with Emohaa for the rest of the week. An independent research assistant will monitor the intervention process from the platform. If the corresponding dialogue is not completed on time each week, the participant will be reminded via WeChat to complete this session before the start of the next session in the following week.
219260261|NCT06735807|BEHAVIORAL|group ACT|A 6-week group ACT intervention. Each group has 6-10 participants. Each session is one hour.
219260262|NCT06735807|BEHAVIORAL|wailist (delayed intervenion)|During the intervention period, participants in the WLG were only required to complete the appropriate assessments without receiving any intervention. Upon completion of the 15-day follow-up assessment, participants in the WLG could be free to choose to receive one of the two interventions. The intervention will be the same as the corresponding experimental group.
219260263|NCT04695886|OTHER|Community-delivered Integrated Malaria Elimination (CIME) intervention model|"Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral."
219260264|NCT05417347|OTHER|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
219260265|NCT05417347|OTHER|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
219260266|NCT00969969|DEVICE|Arthrodesis|arthrodesis using screws and/or a plate
219260267|NCT00969969|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
219260268|NCT05987098|DIAGNOSTIC_TEST|BBPA PET examination|A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
219260269|NCT06521424|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
219260270|NCT06521424|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219260271|NCT04868253|DRUG|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
219260272|NCT02943707|PROCEDURE|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
219260273|NCT02943707|DRUG|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
219260274|NCT01721174|PROCEDURE|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
219260275|NCT01721174|PROCEDURE|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
219260276|NCT00702650|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
219260277|NCT02156388|BIOLOGICAL|GW003|freeze-dried powder；single SC injection
219260278|NCT02787811|DEVICE|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
219260279|NCT03954223|BEHAVIORAL|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)
219260280|NCT03954223|BEHAVIORAL|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
219260281|NCT03954223|DEVICE|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
219260282|NCT01850823|DRUG|placebo|
219260283|NCT01850823|DRUG|Mometasone Nasal Spray|
219260284|NCT01850823|DRUG|Mometasone nasal spray|
219260285|NCT04601597|DEVICE|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
219260286|NCT05184777|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
219260287|NCT02888223|BIOLOGICAL|SCT800|
219260288|NCT02888223|BIOLOGICAL|Xyntha|
219260289|NCT05865171|DRUG|IXP|Tablets for oral administration.
219260290|NCT04592497|PROCEDURE|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
219260291|NCT03293836|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
219260292|NCT03293836|PROCEDURE|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
219260293|NCT01752764|OTHER|Test product: Salad with a high dosage fat|
219260294|NCT01752764|OTHER|Control product: Salad with low dosage fat|
219260295|NCT02470923|DRUG|Nicotine replacement therapy|
219260296|NCT02470923|BEHAVIORAL|Intensive counseling|
219260297|NCT02470923|BEHAVIORAL|Medical advice|
219260298|NCT00072605|DRUG|VRC-EBODNA012-00-VP|
219260299|NCT05803148|PROCEDURE|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
219260300|NCT05803148|DRUG|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
219260301|NCT05616598|DRUG|Sofosbuvir +daclatasvir+ simeprevir+Ribavirin|Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
219260302|NCT00913523|DEVICE|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
219260303|NCT00913523|DEVICE|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
219260304|NCT00483353|PROCEDURE|Intra-nasal allergen challenge with Phleum pratense.|
219260305|NCT00483353|PROCEDURE|Collection of nasal effluent using filter paper.|
219260306|NCT00483353|PROCEDURE|Measurement of nasal congestion using acoustic rhinometry.|
219260307|NCT02895360|DRUG|BAL101553|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
219260308|NCT02895360|DRUG|BAL101553 at MTD|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
219260309|NCT01844726|DRUG|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
219260310|NCT01844726|DRUG|Placebo|Single injection of placebo (saline)
219260311|NCT02717741|DRUG|tafetinib|
219260312|NCT05781165|OTHER|Augmented reality|Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
219260313|NCT02149524|DRUG|Herceptin (trastuzuamb)|Intravenous administration
219260314|NCT02149524|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
219260315|NCT01688817|OTHER|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
219260316|NCT01688817|OTHER|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
219260317|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
219260318|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
219260319|NCT05656612|OTHER|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
219260320|NCT00777998|PROCEDURE|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> 2 months later: Melphalan plus allogeneic PBSCT~* -\> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~* -\> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10\^6 (MRD) or 5 x 10\^5 (MUD) CD3+ cells per kg BW)~* -\> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Further DLI depending on MRD-measurement"
219260321|NCT00777998|PROCEDURE|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~* -\> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
219260322|NCT01457274|OTHER|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80)."
219260323|NCT04264546|BIOLOGICAL|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
219260324|NCT00190099|DEVICE|Dexamethasone-Eluting Stent|
219260325|NCT05574751|OTHER|Titanium tacker|Mesh fixation with Titanium tacker
219260326|NCT05574751|OTHER|Polypropylene 0|Mesh was sutured and fixed with polypropylene 0
219260327|NCT02520700|DEVICE|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
219260328|NCT03219177|BEHAVIORAL|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
219260329|NCT03219177|OTHER|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
219260330|NCT02171884|OTHER|Sample of cord blood|
219260331|NCT02171884|OTHER|Sample of placenta|
219260332|NCT00005997|DRUG|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
219260333|NCT02518347|DIETARY_SUPPLEMENT|FDS-Strawberry|Natural frozen and dried strawberries
219260334|NCT02518347|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
219260335|NCT05758103|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)|Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
219260336|NCT01475461|DRUG|Placebo|double-dummy placebo tablets administered once-daily for 84-days
219260337|NCT01475461|DRUG|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
219260338|NCT01475461|DRUG|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
219260339|NCT01475461|DRUG|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
219260340|NCT01475461|DRUG|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
219260341|NCT01475461|DRUG|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
219260342|NCT04676633|DRUG|STP705|Investigational Product
219260343|NCT03911908|COMBINATION_PRODUCT|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
219260344|NCT01271036|DEVICE|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
219260345|NCT01093170|DRUG|RNA-144101|Intravitreous administration of RNA-144101
219260346|NCT02512861|DRUG|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs"
219260347|NCT02512861|DRUG|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs"
219260348|NCT01269255|DRUG|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy"
219260349|NCT05286086|BEHAVIORAL|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
219260350|NCT02347969|DIETARY_SUPPLEMENT|X34|Dietary supplement named X34
219260351|NCT01362283|OTHER|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
219260352|NCT03180554|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
219260353|NCT03180554|OTHER|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
219260354|NCT02107547|PROCEDURE|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
219260355|NCT02107547|PROCEDURE|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
219260356|NCT05146661|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
219260357|NCT03891498|DRUG|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
219260358|NCT03206476|BEHAVIORAL|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
219260359|NCT03206476|BEHAVIORAL|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
219260360|NCT04774783|DEVICE|Low-Level Laser Therapy|The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
219260361|NCT03104777|BEHAVIORAL|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
219260362|NCT02883179|DRUG|lidocaine injection|anhydrous solution
219260363|NCT02883179|DRUG|lidocaine-prilocaine cream|topical cream
219260364|NCT02179710|BEHAVIORAL|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
219363006|NCT04763070|DRUG|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
219260365|NCT06642363|DRUG|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"
219260366|NCT06642363|DRUG|Placebo|The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
219260367|NCT05985083|DRUG|IMM47|IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
219260368|NCT00694733|DRUG|Placebo injection|Normal saline injection IM monthly for 4 months
219260369|NCT00694733|DRUG|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
219260370|NCT00694733|DRUG|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
219260371|NCT00694733|DRUG|placebo|Placebo Cream 1ml applied twice daily for four months
219260372|NCT00694733|DRUG|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
219260373|NCT03214250|DRUG|APX005M|Administer intravenously once every 28-day Cycle
219260374|NCT03214250|DRUG|Nivolumab|Administer intravenously twice every 28-day cycle
219260375|NCT03214250|DRUG|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
219260376|NCT03214250|DRUG|Gemcitabine|Administer intravenously 3 times every 28-day cycle
219260377|NCT04503837|PROCEDURE|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
219260378|NCT00848068|OTHER|FID 114657|artificial tears
219260379|NCT00848068|OTHER|OPTIVE Lubricant Eye Drops|artificial tears
219260380|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
219260381|NCT02264964|PROCEDURE|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
219260382|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
219260383|NCT02264964|PROCEDURE|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
219260384|NCT03065478|DIETARY_SUPPLEMENT|OnLife|Daily dosing of dietary supplement OnLife
219260385|NCT02428816|OTHER|MRI acquisition|MRI acquisitions
219260386|NCT02428816|BEHAVIORAL|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
219260387|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
219260388|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
219260389|NCT00616577|DRUG|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
219260390|NCT03801681|DIAGNOSTIC_TEST|ECG holter monitoring|patients will be monitored using ECG-holter
219260391|NCT00292981|DRUG|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
219260392|NCT05755217|DIETARY_SUPPLEMENT|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
219260393|NCT05755217|DIETARY_SUPPLEMENT|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
219260394|NCT00594178|DEVICE|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
219260395|NCT00496626|BIOLOGICAL|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
219260396|NCT00496626|BIOLOGICAL|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
219260397|NCT03080662|DEVICE|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
219260398|NCT03080662|DEVICE|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
219260399|NCT02541045|DRUG|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
219260400|NCT02541045|OTHER|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
219260401|NCT03738306|OTHER|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
219260402|NCT03738306|OTHER|Conventional Physiotherapy|therapeutic exercise; physical agents
219260403|NCT00727415|DRUG|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
219260404|NCT00727415|DRUG|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
219260405|NCT00727415|DRUG|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
219260406|NCT02005393|DEVICE|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
219260407|NCT00374088|DRUG|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
219260408|NCT00374088|DRUG|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
219260409|NCT03535805|BEHAVIORAL|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (\>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
219260410|NCT03535805|BEHAVIORAL|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
219260411|NCT00429442|DRUG|Simvastatin|80 mg once daily
219260412|NCT00429442|DRUG|placebo|calcium tablets once daily
219260413|NCT04223128|PROCEDURE|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
219260414|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
219260415|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
219260416|NCT04031573|DRUG|Placebo|Placebo will be administered via the enteral route, every 12 hours.
219260417|NCT00171418|DRUG|Tegaserod|
219260418|NCT05554783|DIAGNOSTIC_TEST|Trendelenburg position|Positioning the patient with head 15 degrees down
219260419|NCT04262609|RADIATION|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
219260420|NCT05629247|DIAGNOSTIC_TEST|Systematic screening of immune deficiency|Systematic screening of immune deficiency with blood tests
219260421|NCT00721032|PROCEDURE|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
219260422|NCT00721032|DRUG|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD"
219260423|NCT02971228|DRUG|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
219260424|NCT02971228|DRUG|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
219260425|NCT02971228|DRUG|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
219260426|NCT02971228|DEVICE|iPhone-based bionic pancreas|An experimental device.
219260427|NCT02971228|DEVICE|iLet-based bionic pancreas|An experimental device.
219260428|NCT02066610|OTHER|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
219260429|NCT02066610|OTHER|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
219260430|NCT02066610|OTHER|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
219260431|NCT02066610|OTHER|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
219260432|NCT03315234|GENETIC|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
219260433|NCT06215287|OTHER|Physician survey|Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
219260434|NCT03354234|OTHER|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
219260435|NCT03354234|OTHER|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
219260436|NCT03354234|OTHER|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
219260437|NCT03354234|DEVICE|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
219260438|NCT03354234|DEVICE|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
219260439|NCT01940406|PROCEDURE|Stimulation procedure|Device
219260440|NCT01584323|DIETARY_SUPPLEMENT|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
219260441|NCT01584323|DIETARY_SUPPLEMENT|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
219260442|NCT05913986|DIETARY_SUPPLEMENT|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
219260443|NCT05913986|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
219260444|NCT01167192|DRUG|Cisplatin|
219260445|NCT01167192|DRUG|Carboplatin|
219260446|NCT01167192|RADIATION|Radiation therapy|
219260447|NCT01167192|PROCEDURE|Mastectomy (recommended but not mandatory)|
219260448|NCT00498615|DRUG|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
219260449|NCT00220909|DRUG|Lansoprazole|
219260450|NCT04226937|OTHER|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
219260451|NCT02856490|DEVICE|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
219260452|NCT02856490|DEVICE|InTone|A genital device using electric muscle stimulation to treat incontinence.
219260453|NCT03039881|DEVICE|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
219260454|NCT02934945|DRUG|budesonide 160μg/formoterol 4.5μg|SMART regimen
219260455|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
219260456|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
219260457|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
219260458|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
219260459|NCT00480155|BIOLOGICAL|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
219260460|NCT00480155|OTHER|Placebo|
219260461|NCT00827775|DRUG|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
219260462|NCT00663273|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
219260463|NCT05425225|OTHER|Low level LASER therapy|Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
219260464|NCT05425225|OTHER|Conventional physical therapy|Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
219260465|NCT00000725|DRUG|Interferon alfa-2a|
219260466|NCT00000725|DRUG|Zidovudine|
219260467|NCT00000725|DRUG|Interferon alfa-n1|
219260468|NCT02806817|DRUG|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
219260469|NCT02806817|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
219260470|NCT02806817|OTHER|Normal saline|Use saline as placebo
219260471|NCT00241969|BEHAVIORAL|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
219260472|NCT00241969|BEHAVIORAL|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
219260473|NCT02600585|BIOLOGICAL|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
219260474|NCT02600585|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
219260475|NCT05896540|BEHAVIORAL|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
219260476|NCT03989583|OTHER|Infrared thermography|Temperature observation in foot and footwear in healthy children
219260477|NCT00854152|DRUG|GDC-0980|Escalating repeating dose
219260478|NCT03847922|DRUG|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
219260479|NCT03847922|DRUG|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
219260480|NCT03847922|OTHER|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
219260481|NCT02679547|OTHER|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
219260482|NCT03696641|OTHER|glazed lithium disilicate crowns|glazing of IPS e.max crowns
219260483|NCT03696641|OTHER|polished lithium disilicate crowns|polishing of IPS e.max crowns
219260484|NCT04080063|OTHER|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
219260485|NCT05188313|DRUG|Trastuzumab|Intravenous administration of study drug
219260486|NCT05188313|DRUG|Pertuzumab|Intravenous administration of study drug
219260487|NCT05188313|DRUG|Paclitaxel|Intravenous administration of study drug
219260488|NCT05188313|DRUG|Carboplatin|Intravenous administration of study drug
219260489|NCT02384278|BEHAVIORAL|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
219260490|NCT02114983|OTHER|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
219260491|NCT03240497|BEHAVIORAL|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\]."
219260492|NCT03240497|BEHAVIORAL|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
219260493|NCT06310798|BEHAVIORAL|Inter-professional team test|"Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff."
219260494|NCT05184621|OTHER|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
219260495|NCT00545571|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
219260496|NCT05999019|PROCEDURE|robotic surgery|robotic surgery
219260497|NCT01491763|DRUG|Imatinib|600 mg p.o. from day 1 until consolidation
219260498|NCT04255121|DRUG|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
219260499|NCT04255121|DRUG|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
219260500|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
219260501|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
219260502|NCT04692298|OTHER|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
219260503|NCT01684618|PROCEDURE|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
219260504|NCT06112522|DRUG|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
219260505|NCT02599493|DRUG|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
219260506|NCT06480435|OTHER|Chest physical Therapy|Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful
219260507|NCT06480435|OTHER|Lungs squeezing technique|"It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase"
219260508|NCT04578899|DEVICE|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
219260509|NCT00177684|DRUG|Amphotericin B|
219260510|NCT00037895|PROCEDURE|Ambulation training|
219260511|NCT05088538|OTHER|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
219260512|NCT04071093|OTHER|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
219260513|NCT02869906|OTHER|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
219260514|NCT02830828|OTHER|Investigation of precision pinch grip control|
219260515|NCT06104579|OTHER|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
219260516|NCT00238719|DRUG|Venlafaxine ER|
219260517|NCT00796393|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
219260518|NCT00796393|DIETARY_SUPPLEMENT|Starch of potato|1 pill per day for 12 weeks
219260519|NCT01013740|DRUG|Vinorelbine|Vinorelbine
219260520|NCT01013740|DRUG|Lapatinib|Lapatinib
219260521|NCT01013740|DRUG|Capecitabine|Capecitabine
219260522|NCT03159078|DRUG|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
219260523|NCT01137747|DRUG|Carfilzomib|
219260524|NCT02950181|DEVICE|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
219260525|NCT04773730|PROCEDURE|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
219260526|NCT04773730|PROCEDURE|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
219260527|NCT00338949|DRUG|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
219260528|NCT00338949|DRUG|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
219260529|NCT04733898|OTHER|SamenSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to elicit personal interaction.
219260530|NCT04733898|OTHER|FijnSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to not elicit personal interaction.
219260531|NCT05527743|OTHER|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
219260532|NCT05527743|OTHER|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
219260533|NCT03232034|DIETARY_SUPPLEMENT|Calcium Citrate|1000 mg calcium as calcium citrate
219260534|NCT03232034|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
219260535|NCT03232034|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
219260536|NCT00251264|PROCEDURE|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
219260537|NCT00251264|PROCEDURE|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
219260538|NCT05168137|DRUG|Low-dose colchicine|prescribed colchicine 0.6 mg/day
219260539|NCT05168137|DRUG|Placebo|Placebo of colchicine
219260540|NCT03302442|OTHER|Non interventional study|Not applicable - Non interventional Study
219260541|NCT05417464|OTHER|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
219260542|NCT02819219|DIETARY_SUPPLEMENT|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
219260543|NCT02819219|OTHER|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
219260544|NCT03643757|PROCEDURE|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
219260545|NCT03643757|DRUG|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
219260546|NCT01944449|DIETARY_SUPPLEMENT|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
219260547|NCT01944449|DIETARY_SUPPLEMENT|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
219260548|NCT01944449|DIETARY_SUPPLEMENT|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
219260549|NCT01419938|DEVICE|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
219260550|NCT01419938|DEVICE|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
219260551|NCT04785716|DRUG|Niraparib|Niraparib provided through the patient access program
219260552|NCT04550559|PROCEDURE|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
219260553|NCT01230762|DRUG|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
219260554|NCT06189989|BEHAVIORAL|The group to which a care package was applied in addition to the clinical routine care protocol)|"Intervention Group:~* Immediately after the newborn's admission to the intensive care unit, mechanical ventilation mode, physiological parameters, blood gas results and descriptive characteristics of the baby were recorded in the Data Collection and Daily Monitoring Form.~* In addition to the routine care practices of the clinic (every 3 hours / 8 times a day), the newborn's temporary tachypnea care package was applied. Postural drainage, percussion and vibration were applied 4 times a day for an average of 10-15 minutes.~* Mechanical ventilation mode and physiological parameters were recorded one hour after 4 daily maintenance applications.~* Blood gas parameters were evaluated immediately before and 1 hour after the newborn was separated from mechanical ventilation.~* Physiological parameters were recorded again 1 hour after the first routine nursing care after the newborn was separated from mechanical ventilation."
219260555|NCT01242371|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
219260556|NCT01242371|DIETARY_SUPPLEMENT|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
219260557|NCT00947141|DRUG|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR \>200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
219260558|NCT00947141|OTHER|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
219260559|NCT00947141|DRUG|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
219260560|NCT00947141|OTHER|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
219363007|NCT01715584|OTHER|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
219260561|NCT02382523|DRUG|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
219260562|NCT01491906|BEHAVIORAL|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
219260563|NCT00025662|DRUG|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
219260564|NCT00025662|DRUG|Isolex system|CD34 selection/ T cell depletion used this system
219260565|NCT01686490|BEHAVIORAL|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
219260566|NCT01686490|BEHAVIORAL|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
219260567|NCT05097183|PROCEDURE|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
219260568|NCT05052749|OTHER|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
219260569|NCT05052749|OTHER|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
219260570|NCT04518761|PROCEDURE|Elective surgery|Any patient who needs to undergo an elective surgery.
219260571|NCT01043198|GENETIC|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~* Standardized screening with :~* radiological (hands, feet, spine ; and renal ultrasonography)~* biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
219260572|NCT06647251|PROCEDURE|Q-MODE : radiofrequency ablation up to 50W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W."
219260573|NCT06647251|PROCEDURE|Q-MODE+ : radiofrequency up to 90W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W."
219260574|NCT06647251|PROCEDURE|Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part."
219260575|NCT06646081|PROCEDURE|Greater Occipital Nerve Block|The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
219260576|NCT06646081|PROCEDURE|Stellate Ganglion Block|The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
219260577|NCT02068196|PROCEDURE|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
219260578|NCT02068196|DRUG|Ipilimumab|
219260579|NCT02934815|OTHER|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
219260580|NCT00478998|DRUG|Tamsulosin|
219260581|NCT01113164|DRUG|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
219260582|NCT00525018|DEVICE|contact heat evoked potential stimulator|
219260583|NCT00582114|DRUG|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
219363008|NCT03961711|PROCEDURE|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
219363009|NCT03961711|PROCEDURE|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
219260584|NCT00582114|DRUG|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
219260585|NCT02640222|DRUG|VKA|
219260586|NCT02640222|DRUG|Apixaban|
219260587|NCT02640222|DRUG|dabigatran|
219260588|NCT02640222|DRUG|rivaroxaban|
219260589|NCT06140914|DIAGNOSTIC_TEST|Proteomics, miRNA studies and studies of blood cells from blood samples|This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
219260590|NCT05388097|OTHER|Managed Services|coordination of care and assistance with community resources (food, transportation)
219260591|NCT05848453|DRUG|BAP5191|Placebo
219260592|NCT06088797|OTHER|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
219260593|NCT06088797|OTHER|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
219260594|NCT06088797|OTHER|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
219260595|NCT06088797|OTHER|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
219260596|NCT06088797|OTHER|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
219260597|NCT06088797|OTHER|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
219260598|NCT06088797|OTHER|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
219260599|NCT05643313|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
219260600|NCT02604342|DRUG|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
219260601|NCT02604342|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
219260602|NCT02604342|DRUG|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
219260603|NCT00130728|DRUG|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
219260604|NCT00130728|DRUG|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
219260605|NCT00130728|DRUG|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
219260606|NCT06213064|BEHAVIORAL|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
219260607|NCT05230030|BEHAVIORAL|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
219260608|NCT05457322|BEHAVIORAL|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
219260609|NCT05457322|BEHAVIORAL|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
219260610|NCT01398644|OTHER|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
219260611|NCT04225000|OTHER|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
219260612|NCT04225000|OTHER|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
219260613|NCT01027663|DIETARY_SUPPLEMENT|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
219260614|NCT01561456|DRUG|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
219260615|NCT01561456|DRUG|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
219260616|NCT01349036|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
219260617|NCT04830878|DRUG|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
219260618|NCT05582590|DRUG|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
219260619|NCT05582590|DRUG|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
219260620|NCT05582590|BIOLOGICAL|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
219260621|NCT00600301|DRUG|Triamcinolone Acetonide and Bevacizumab|
219260622|NCT04218552|DRUG|AD209|PO, Once daily(QD), 8weeks
219260623|NCT04218552|DRUG|Amlodipine low|PO, Once daily(QD), 8weeks
219260624|NCT04218552|DRUG|Amlodipine high|PO, Once daily(QD), 8weeks
219260625|NCT04218552|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
219260626|NCT04003961|OTHER|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
219260627|NCT02787759|OTHER|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
219260628|NCT02787759|OTHER|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
219260629|NCT01582412|DRUG|Isavuconazole|oral
219260630|NCT01582412|DRUG|digoxin|oral
219260631|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
219260632|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
219260633|NCT05729204|OTHER|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
219260634|NCT00119795|BEHAVIORAL|Exercise|Increase Physical Activity to 150 min/wk
219260635|NCT00119795|BEHAVIORAL|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
219260636|NCT00119795|BEHAVIORAL|Health Education Control|Lectures on information relevant to successful aging
219260637|NCT00383591|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
219260638|NCT00383591|BIOLOGICAL|Engerix-B|
219260639|NCT00032747|DRUG|Vasopressin V2 Receptor Antagonist|
219260640|NCT01449747|DRUG|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
219260641|NCT02196168|DRUG|Cisplatin|Given IV
219260642|NCT02196168|OTHER|Laboratory Biomarker Analysis|Correlative studies
219260643|NCT02196168|OTHER|Pharmacological Study|Correlative studies
219260644|NCT02196168|OTHER|Placebo|Given PO
219260645|NCT02196168|DRUG|WEE1 Inhibitor AZD1775|Given PO
219260646|NCT02896101|DRUG|Pimecrolimus Cream, 1%|
219260647|NCT02896101|DRUG|Elidel® (pimecrolimus) Cream|
219260648|NCT02896101|DRUG|Placebo of Pimecrolimus Cream, 1%|
219260649|NCT06002321|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.
219260650|NCT06002321|DIAGNOSTIC_TEST|Laboratory Test|BNP, NT-proBNP and renal function.
219260651|NCT01125566|DRUG|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
219260652|NCT01125566|DRUG|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
219260653|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
219260654|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
219260655|NCT01825317|DEVICE|NeuroAD|synchronized TMS+COGNITIVE TRAINING
219260656|NCT01825317|DEVICE|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
219260657|NCT00511498|DRUG|Sildenafil|50 mg daily at bedtime
219260658|NCT00053378|DRUG|paricalcitol injection (Zemplar)|
219260659|NCT00053378|BEHAVIORAL|Effects on calcium regulation|
219260660|NCT00053378|BEHAVIORAL|Administration of elemental Ca during hypocalcemic ICU pts.|
219260661|NCT03703843|DEVICE|ARTUS MONO|Temporarily implant and activation of the medical device
219260662|NCT04538222|OTHER|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
219260663|NCT03779477|BEHAVIORAL|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
219260664|NCT05768737|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
219260665|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
219260666|NCT00640198|BEHAVIORAL|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
219260667|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
219260668|NCT00640198|DRUG|placebo|Placebo
219260669|NCT03618706|RADIATION|Involved-field radiotherapy|After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
219260670|NCT00739076|BEHAVIORAL|Virtual Reality|Using Virtual Reality for pain control
219260671|NCT04303546|DEVICE|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
219260672|NCT04886817|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
219260673|NCT03998501|BEHAVIORAL|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
219260674|NCT02881047|DEVICE|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
219260675|NCT02881047|RADIATION|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
219260676|NCT02881047|DIAGNOSTIC_TEST|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
219260677|NCT01454232|OTHER|stools sampling|stools sampling at baseline, 1, 3 and 12 months
219260678|NCT01454232|OTHER|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
219260679|NCT02595606|DRUG|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
219260680|NCT01810276|OTHER|Saline|400 mL of Saline will be given intravenously over 2 hours once
219260681|NCT01810276|OTHER|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
219260682|NCT01687868|DRUG|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
219260683|NCT03936764|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing."
219260684|NCT02895321|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
219260685|NCT02895321|OTHER|Colgate, Protection Caries|a fluorine-based toothpaste gels
219260686|NCT02895321|OTHER|Placebo gel|a glycerin and water gel
219260687|NCT03028012|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
219260688|NCT03028012|DRUG|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
219260689|NCT03028012|DRUG|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
219260690|NCT00099203|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
219260691|NCT00099203|DRUG|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
219260692|NCT03181282|BEHAVIORAL|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
219260693|NCT00270647|DIETARY_SUPPLEMENT|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
219260694|NCT00270647|DIETARY_SUPPLEMENT|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
219260695|NCT00270647|DIETARY_SUPPLEMENT|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
219260696|NCT00270647|DIETARY_SUPPLEMENT|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
219260697|NCT03020056|DRUG|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
219260698|NCT03020056|PROCEDURE|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
219260699|NCT02606097|DRUG|regorafenib|
219260700|NCT02624375|DRUG|Zoster Vaccine Live|
219260701|NCT04897685|BEHAVIORAL|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
219260702|NCT00569010|DRUG|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days
219260703|NCT00569010|DRUG|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)"
219260704|NCT04525456|DIETARY_SUPPLEMENT|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
219260705|NCT06194812|OTHER|Pain Catastrophizing scale|"Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked."
219260706|NCT00331708|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
219260707|NCT02508597|OTHER|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
219260708|NCT03745586|DRUG|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
219260709|NCT03745586|DRUG|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
219260710|NCT00148135|DRUG|Carboplatin|
219260711|NCT00148135|DRUG|Gemcitabine|
219260712|NCT00148135|DRUG|Capecitabine|
219260713|NCT02484547|DRUG|Aducanumab (BIIB037)|Low dose
219260714|NCT02484547|DRUG|Aducanumab (BIIB037)|High dose
219260715|NCT02484547|DRUG|Placebo|Placebo
219260716|NCT04287140|OTHER|Bolus fluid administration|1000 ml of 0.9% normal saline bolus over one hour
219260717|NCT00001123|DRUG|Ribavirin|
219260718|NCT01813305|DRUG|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
219260719|NCT01813305|DRUG|CSTC1 Matched vehicle|
219260720|NCT01515722|BEHAVIORAL|Health education intervention (HEI)|"* \<Part 1\> Understanding OAB~* \<Part 2\> Behavioral/lifestyle modification~* \<Part 3\> Bladder training~* \<Part 4\> Understanding antimuscarinics"
219260721|NCT02736955|DRUG|Valbenazine|
219260722|NCT05337488|OTHER|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
219260723|NCT05050526|BEHAVIORAL|Real-time videoconference-based Exercise program|12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
219260724|NCT02286687|OTHER|Laboratory Biomarker Analysis|Correlative studies
219260725|NCT02286687|OTHER|Pharmacological Study|Correlative studies
219260726|NCT02286687|DRUG|Talazoparib|Given PO
219260727|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
219260728|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
219260729|NCT03953209|DRUG|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
219260730|NCT03953209|DRUG|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
219260731|NCT03953209|DRUG|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
219260732|NCT00949221|DEVICE|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"* group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
219260733|NCT01665599|DRUG|Testosterone gel (FE 999303)|
219260734|NCT03705533|DRUG|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
219260735|NCT03705533|DRUG|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
219260736|NCT04548297|OTHER|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
219260737|NCT03878290|BEHAVIORAL|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
219260738|NCT00897754|GENETIC|gene expression analysis|
219260739|NCT00897754|GENETIC|protein expression analysis|
219260740|NCT00897754|GENETIC|reverse transcriptase-polymerase chain reaction|
219260741|NCT00897754|OTHER|immunoenzyme technique|
219260742|NCT00897754|OTHER|immunohistochemistry staining method|
219260743|NCT00897754|OTHER|immunologic technique|
219260744|NCT02876003|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
219260745|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
219260746|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
219260747|NCT01262742|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219260748|NCT01262742|DRUG|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219260749|NCT01262742|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219260750|NCT01262742|DRUG|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219260751|NCT01262742|DRUG|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219260752|NCT06500858|OTHER|Exercise Intervention|Receive a welcome package with exercise equipment
219260753|NCT06500858|OTHER|Exercise Intervention|Participate in virtual-exercise sessions
219260754|NCT06500858|OTHER|Exercise Intervention|Receive access to optional drop-in classes
219260755|NCT06500858|OTHER|Health Promotion and Education|Receive monthly newsletters
219260756|NCT06500858|OTHER|Internet-Based Intervention|Receive access to online fitness buddy matching program
219260757|NCT06500858|OTHER|Physical Activity|Participate in a walking program
219260758|NCT06500858|OTHER|Questionnaire Administration|Ancillary studies
219260759|NCT06448104|OTHER|Dry needling and immersive virtual reality|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~The procedure will be carried out simultaneously with the use of immersive virtual reality distraction software, applied through MetaQuest 2 virtual reality glasses. This procedure consists of immersive visualization (video and sound images that represent scenes related to relaxation).~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
219260760|NCT06448104|OTHER|Dry needling|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
219260761|NCT01993576|DRUG|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
219260762|NCT04547166|DRUG|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
219260763|NCT04547166|DRUG|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
219260764|NCT06009445|DIAGNOSTIC_TEST|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity \_ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
219260765|NCT01705145|DRUG|Ivacaftor|
219260766|NCT05745181|BIOLOGICAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
219260767|NCT05253911|DRUG|TUKYSA®|tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
219260768|NCT01664897|DRUG|Erlotinib Hydrochloride|Given PO
219260769|NCT01664897|OTHER|Laboratory Biomarker Analysis|Correlative studies
219260770|NCT02480777|BIOLOGICAL|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
219260771|NCT03011905|DRUG|Dexamethasone|4 ml DexaGalen 4 mg/ml
219260772|NCT03011905|DRUG|NaCl (Control)|4 ml NaCl 9 mg/ml
219260773|NCT03011905|DRUG|Paracetamol|Premedication and as needed after operation
219260774|NCT03011905|DRUG|EtoriCoxib|Premedication and first 2 postoperative days.
219260775|NCT03011905|DRUG|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
219260776|NCT03011905|DRUG|Ropivacaine|In brachial plexus block
219260777|NCT04209998|DIAGNOSTIC_TEST|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
219260778|NCT02026245|DEVICE|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove"
219260779|NCT00626015|BIOLOGICAL|PEP-3-KLH conjugate vaccine|Given intradermally
219260780|NCT00626015|BIOLOGICAL|daclizumab|Given IV
219260781|NCT00626015|DRUG|temozolomide|Given by mouth.
219260782|NCT00626015|OTHER|placebo|Given IV
219260783|NCT00626015|BIOLOGICAL|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
219260784|NCT04854902|PROCEDURE|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
219260785|NCT04854902|PROCEDURE|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
219260786|NCT04854902|PROCEDURE|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
219260787|NCT00953199|DRUG|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
219260788|NCT00953199|DRUG|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
219260789|NCT00004758|DRUG|carbamazepine|
219260790|NCT00004758|DRUG|corticotropin|
219260791|NCT00004758|DRUG|nitrazepam|
219260792|NCT00004758|DRUG|pyridoxine|
219260793|NCT00004758|DRUG|valproic acid|
219260794|NCT00004758|PROCEDURE|Surgery|
219260795|NCT00051103|DRUG|Investigational Cancer Drug|
219260796|NCT02214771|DRUG|Fidaxomicin|oral
219260797|NCT02214771|DRUG|Treatment for CDI other than fidaxomicin Type|Oral
219260798|NCT06646133|DIAGNOSTIC_TEST|3D camera weight estimate|Weight estimation using 3D camera system
219260799|NCT06646133|DIAGNOSTIC_TEST|Standard methods of weight estimation|Standard methods of weight estimation will be used
219260800|NCT04528290|DRUG|Ozanimod|Ozanimod capsule formulation of 0.92mg
219260801|NCT04528290|DRUG|Ozanimod|Ozanimod, granule formulation of 0.92mg
219260802|NCT02542085|PROCEDURE|Laparoscopic repair|operative method
219260803|NCT02542085|PROCEDURE|Hybrid repair|operative method
219260804|NCT00113997|DRUG|REG1|
219260805|NCT04815785|DEVICE|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
219260806|NCT06086119|DIAGNOSTIC_TEST|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
219260807|NCT04520841|DEVICE|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
219260808|NCT04520841|DEVICE|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
219260809|NCT05699369|OTHER|Digital health interventions|Described in arm descriptions.
219260810|NCT00468065|DEVICE|VeinViewer|Veinveiwer is used to view veins subQ
219260811|NCT00468065|DEVICE|Veinviewer|near infrared light reveals veins subcutaneously
219260812|NCT02618863|DEVICE|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
219260813|NCT05819775|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
219260814|NCT02928809|DEVICE|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
219260815|NCT02928809|OTHER|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
219260816|NCT06219161|DIETARY_SUPPLEMENT|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
219260817|NCT00554086|DRUG|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
219260818|NCT01012596|BEHAVIORAL|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
219260819|NCT00618917|GENETIC|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
219260820|NCT00618917|DRUG|carboplatin|Chemotherapy to stop the growth of tumor cells.
219260821|NCT00618917|DRUG|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
219260822|NCT00618917|RADIATION|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
219260823|NCT00528710|DIETARY_SUPPLEMENT|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
219260824|NCT01458964|DRUG|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
219260825|NCT04882748|OTHER|ADAMO|Physical therapy provided with or without the help of a robot
219260826|NCT05481398|OTHER|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
219260827|NCT01503164|DEVICE|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
219260828|NCT01503164|BEHAVIORAL|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
219260829|NCT05404217|OTHER|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
219260830|NCT05404217|OTHER|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
219260831|NCT02277067|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
219260832|NCT02277067|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
219260833|NCT02348372|DRUG|GSK1278863A Placebo|Matching size, shape and color
219260834|NCT02348372|DRUG|GSK1278863A|A round, biconvex, white film coated tablet
219260835|NCT01462825|DIETARY_SUPPLEMENT|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
219260836|NCT01462825|DIETARY_SUPPLEMENT|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
219260837|NCT00472069|PROCEDURE|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
219260838|NCT01211223|DRUG|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
219260839|NCT01308047|DRUG|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
219260840|NCT06348745|DEVICE|ultrasound|5\. Transthoracic ultrasound for both right and left diaphragm during inspiration and expiration.
219260841|NCT00547183|DRUG|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
219260842|NCT00547183|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
219260843|NCT00547183|DRUG|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
219260844|NCT04168996|BEHAVIORAL|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
219260845|NCT03591432|DEVICE|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
219260846|NCT03591432|DEVICE|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
219260847|NCT02279992|DRUG|Vardenafil|
219260848|NCT02279992|DRUG|Carboplatin|
219260849|NCT05173259|BEHAVIORAL|F|The participant will be asked to chew the two-coloured chewing gum naturally.
219260850|NCT05173259|BEHAVIORAL|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
219260851|NCT05173259|BEHAVIORAL|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
219260852|NCT05173259|BEHAVIORAL|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
219260853|NCT05173259|BEHAVIORAL|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
219260854|NCT05173259|BEHAVIORAL|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
219260855|NCT02480751|DRUG|Beraprost|
219260856|NCT02480751|DRUG|Placebo|
219260857|NCT05372471|OTHER|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
219260858|NCT05372471|OTHER|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
219260859|NCT03463538|PROCEDURE|arthroscopic capsular release|surgical release of shoulder joint capsule
219260860|NCT03463538|PROCEDURE|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
219260861|NCT03074045|DRUG|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
219260862|NCT03074045|DRUG|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
219260863|NCT05087329|BEHAVIORAL|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
219260864|NCT03049306|DRUG|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
219260865|NCT03049306|DRUG|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
219260866|NCT02001467|OTHER|Simulation-based training|
219260867|NCT00282061|DRUG|Melatonin|
219260868|NCT05363098|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
219260869|NCT01607099|PROCEDURE|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
219260870|NCT00584376|DRUG|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
219260871|NCT00584376|DRUG|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
219260872|NCT01199445|DIETARY_SUPPLEMENT|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
219260873|NCT03159065|OTHER|Bilberry|Fruit beverage with bilberry and fermented oatmeal
219260874|NCT03159065|OTHER|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
219260875|NCT03159065|OTHER|Mango|Fruit beverage with mango and fermented oatmeal
219260876|NCT03159065|OTHER|Beetroot|Fruit beverage with beetroot and fermented oatmeal
219260877|NCT03159065|OTHER|Rose hip|Fruit beverage with rose hip and fermented oatmeal
219260878|NCT03159065|OTHER|Glucose drink|A reference glucose drink
219260879|NCT01420900|DEVICE|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
219260880|NCT01420900|DEVICE|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
219260881|NCT06140576|DRUG|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
219260882|NCT06140576|DRUG|Nab-paclitaxel|Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
219260883|NCT06140576|DRUG|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
219260884|NCT03151551|DRUG|Ixekizumab|Administered SC
219260885|NCT03151551|DRUG|Adalimumab|Administered SC
219260886|NCT01669720|DRUG|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
219260887|NCT04458012|DIAGNOSTIC_TEST|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
219260888|NCT04013932|BEHAVIORAL|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
219260889|NCT02934893|OTHER|Medication Management Clinic|referral to medication management clinic from primary care
219260890|NCT02934893|OTHER|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
219260891|NCT00356213|PROCEDURE|sleeve gastrectomy|laparoscopic sleeve gastrectomy
219260892|NCT00356213|PROCEDURE|Roux-Y-gastric bypass|laparoscopic gastric bypass
219260893|NCT05859009|PROCEDURE|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
219260894|NCT05859009|DRUG|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
219260895|NCT00730210|DRUG|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
219260896|NCT00730210|DRUG|b:placebo|100 microgram placebo subcutaneous a day for 6 months
219260897|NCT04739189|BEHAVIORAL|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
219260898|NCT04739189|BEHAVIORAL|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
219260899|NCT04739189|BEHAVIORAL|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
219260900|NCT04131699|DEVICE|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
219363010|NCT03752645|DEVICE|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
219363011|NCT04161287|PROCEDURE|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
219363012|NCT02137967|PROCEDURE|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
219260901|NCT04337034|BEHAVIORAL|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
219260902|NCT04337034|PROCEDURE|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
219260903|NCT03604289|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
219260904|NCT03604289|DRUG|Saline|Saline will be used as the placebo comparator
219260905|NCT02785575|OTHER|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
219260906|NCT00514813|DRUG|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
219260907|NCT03043170|DEVICE|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
219260908|NCT02979613|DRUG|TAF|25 mg tablet administered orally once daily
219260909|NCT02979613|DRUG|TDF|300 mg tablet administered orally once daily
219260910|NCT02979613|DRUG|TAF Placebo|Tablet administered orally once daily
219260911|NCT02979613|DRUG|TDF Placebo|Tablet administered orally once daily
219260912|NCT02923817|BIOLOGICAL|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
219260913|NCT05590806|OTHER|Direct composite build-ups|Direct composite build-ups application
219260914|NCT01202383|BEHAVIORAL|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
219260915|NCT01202383|BEHAVIORAL|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
219260916|NCT02626689|OTHER|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
219260917|NCT02626689|OTHER|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
219260918|NCT03369314|DRUG|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
219260919|NCT05773209|DEVICE|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
219260920|NCT05795309|DEVICE|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
219260921|NCT02746237|DRUG|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
219260922|NCT02746237|DRUG|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
219260923|NCT01550783|OTHER|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
219260924|NCT01550783|OTHER|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
219260925|NCT01550783|OTHER|Questionnaire Administration|Ancillary studies
219260926|NCT01550783|PROCEDURE|Screening Method|Undergo standard of care Pap test screening
219260927|NCT01550783|PROCEDURE|Screening Method|Undergo home-based HPV screening
219260928|NCT01138098|BIOLOGICAL|Engerix™-B|Intramuscular, single dose
219260929|NCT04186884|OTHER|Quality-of-Life Assessment|Ancillary studies
219260930|NCT04186884|OTHER|Questionnaire Administration|Complete questionnaires
219260931|NCT04029792|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
219260932|NCT04029792|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
219260933|NCT00655369|DRUG|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
219260934|NCT00655369|DRUG|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
219260935|NCT00655369|DRUG|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
219260936|NCT00655369|DRUG|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
219260937|NCT00655369|DRUG|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
219260938|NCT00655369|DRUG|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
219260939|NCT03282799|DRUG|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
219260940|NCT03194945|DRUG|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
219260941|NCT03194945|DRUG|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
219260942|NCT03194945|DRUG|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
219260943|NCT03194945|DRUG|CSII alone|No OHA is given after short-term intensive CSII
219260944|NCT03501888|BEHAVIORAL|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
219260945|NCT03501888|BEHAVIORAL|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
219260946|NCT00637325|DRUG|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
219260947|NCT02585141|DEVICE|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
219260948|NCT02585141|PROCEDURE|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
219260949|NCT02585141|DRUG|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
219260950|NCT04438369|PROCEDURE|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
219260951|NCT02546778|DEVICE|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
219260952|NCT03379428|DRUG|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
219260953|NCT03379428|DRUG|Ibrutinib 560 mg|560 mg by mouth daily
219260954|NCT03379428|DRUG|Ibrutinib 840 mg|840 mg by mouth daily
219260955|NCT03379428|DRUG|Ibrutinib 420 mg|420 mg by mouth daily
219260956|NCT06591767|DIETARY_SUPPLEMENT|Quercetin|200 mg supplemental Quercefit®
219260957|NCT06591767|COMBINATION_PRODUCT|Berberol K®|"Berberine Phytosome® 730 mg~\+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"
219260958|NCT04229706|DRUG|High dose Xiang Ju Ru Pi Ning capsule|xingjurupining capsule,8 capsule,tid,3 months.
219260959|NCT04229706|DRUG|Low dose Xiang Ju Ru Pi Ning capsule|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
219260960|NCT04229706|DRUG|Xiang Ju Ru Pi Ning capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
219260961|NCT04981184|DEVICE|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
219260962|NCT03972397|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
219260963|NCT03972397|DRUG|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
219260964|NCT03972397|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
219260965|NCT05079906|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
219260966|NCT05079906|DEVICE|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
219260967|NCT02169778|BEHAVIORAL|Intermittent energy restricted diet|
219260968|NCT02169778|BEHAVIORAL|Continuous energy restricted diet|
219260969|NCT01649037|DRUG|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h."
219260970|NCT01649037|DRUG|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
219260971|NCT00788047|DRUG|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
219260972|NCT00788047|DRUG|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
219260973|NCT05908539|BEHAVIORAL|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
219260974|NCT05908539|BEHAVIORAL|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
219363013|NCT02137967|PROCEDURE|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
219260975|NCT05908539|BEHAVIORAL|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
219260976|NCT05908539|BEHAVIORAL|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
219260977|NCT04633785|OTHER|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
219260978|NCT06355037|DRUG|Quercetin|quercetin 1000mg d1-d3, qw
219260979|NCT06355037|DRUG|Dasatinib|Dasatinib 50mg d1-d3, qw
219260980|NCT06355037|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
219260981|NCT05264142|DRUG|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
219260982|NCT05264142|DRUG|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
219260983|NCT05264142|DRUG|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
219260984|NCT06625645|COMBINATION_PRODUCT|Modified triple antibiotic paste (TAP) mixed with chlorehexidine|M-TAP with CHX 2%
219260985|NCT06625645|COMBINATION_PRODUCT|Modified Triple Antibiotic Paste mixed with saline|M-TAP mixed with saline
219260986|NCT06625645|COMBINATION_PRODUCT|Calcium Hydroxide mixed with chlorohexidine Intracanal medication|calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
219260987|NCT06625645|COMBINATION_PRODUCT|calcium hydroxide mixed with saline as intracanal medication|calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
219260988|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
219260989|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
219260990|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
219260991|NCT06632834|DRUG|simvastatin therapy|Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
219260992|NCT06332391|DEVICE|Exercise-similar cardiac pacing|Cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
219260993|NCT06332391|DEVICE|Sham cardiac pacing|Simulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
219260994|NCT05958147|BIOLOGICAL|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
219260995|NCT00143598|DEVICE|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
219260996|NCT00143598|DEVICE|Knee-length, placebo stocking|Worn daily for two years
219260997|NCT05576012|BIOLOGICAL|SOL-116|Participants will receive SC injection in a double-blind manner
219260998|NCT05576012|BIOLOGICAL|Placebo|Participants will receive SC injection in a double-blind manner
219260999|NCT00610805|OTHER|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
219261000|NCT00610805|OTHER|Usual Care|Participants will receive usual care per their primary care physician.
219261001|NCT00420147|DEVICE|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
219261002|NCT00420147|DEVICE|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
219261003|NCT00771238|DEVICE|P500 Mattress|Study mattress
219261004|NCT05241197|OTHER|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
219261005|NCT05241197|OTHER|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
219261006|NCT04817657|BIOLOGICAL|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.
219261007|NCT04260464|DRUG|PF-06700841|A single dose of 30 mg PF-06700841 will be administered on Day 1
219261008|NCT05390996|OTHER|dental implant placement|dental implant placement by using a different drilling techniques
219261009|NCT04390412|RADIATION|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
219261010|NCT03384147|DIETARY_SUPPLEMENT|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
219261011|NCT03384147|OTHER|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
219261012|NCT04724096|DIAGNOSTIC_TEST|Oxygen Enhanced MRI scan|Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.
219261013|NCT01395849|DRUG|Salmeterol and Fluticasone|
219261014|NCT00695136|DRUG|Donepezil hydrochloride|
219261015|NCT00695136|BEHAVIORAL|Increase REM sleep percentage|
219261016|NCT03469492|DRUG|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
219261017|NCT03469492|BEHAVIORAL|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
219261018|NCT03469492|DIETARY_SUPPLEMENT|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
219261019|NCT01726049|DRUG|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
219261020|NCT01726049|DRUG|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
219261021|NCT02925936|OTHER|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
219261022|NCT02925936|OTHER|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
219261023|NCT04410939|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
219261024|NCT02331810|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219261025|NCT02331810|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219261026|NCT04249050|DIETARY_SUPPLEMENT|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
219261027|NCT01811498|DRUG|Bevacizumab|
219261028|NCT00008320|DRUG|ceramide|
219261029|NCT00349570|DEVICE|Xtract Aspiration Catheter|
219261030|NCT03887247|BEHAVIORAL|E-mail Alert|Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
219363014|NCT02137967|DRUG|2.5% NaOCl|
219363015|NCT02137967|DRUG|20% Formocresol|
219261031|NCT05528822|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
219261032|NCT05528822|PROCEDURE|ultrasound-guided pericapsular nerve group (PENG) block|A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
219261033|NCT03320395|DEVICE|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
219261034|NCT06114134|DIETARY_SUPPLEMENT|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
219261035|NCT06114134|DIETARY_SUPPLEMENT|Placebo|Placebo
219261036|NCT02806505|DRUG|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
219261037|NCT06410339|DIAGNOSTIC_TEST|Ultrasound|ultrasound of flexor tendons on hands
219261038|NCT04334668|DIETARY_SUPPLEMENT|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
219261039|NCT04334668|OTHER|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
219261040|NCT02416713|DEVICE|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
219261041|NCT02416713|OTHER|Education Only|No active intervention, educational materials will be provided
219261042|NCT04853498|DRUG|TQB3720|This is an androgen receptor antagonists.
219261043|NCT00034853|DRUG|meloxicam oral suspension|
219261044|NCT00034853|DRUG|naproxen oral suspension|
219261045|NCT06049069|DIAGNOSTIC_TEST|physical activity in stroke|physical activity in stroke
219261046|NCT01722045|DRUG|Intravitreal Aflibercept Injection (IAI)|
219261047|NCT04332432|DRUG|belapectin|intravenous
219261048|NCT02219698|DRUG|Ibuprofen|
219261049|NCT02219698|DRUG|Paracetamol|
219261050|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
219261051|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
219261052|NCT01333111|DRUG|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
219261053|NCT06103643|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency breech birth.
219261054|NCT01339299|DRUG|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
219261055|NCT01339299|DRUG|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
219261056|NCT02471456|OTHER|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
219261057|NCT02471456|OTHER|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
219261058|NCT04732871|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
219261059|NCT03339271|BEHAVIORAL|Technology-Enhanced Support|The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.
219261060|NCT03339271|BEHAVIORAL|Usual Care Support|The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.
219261061|NCT02267265|OTHER|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
219261062|NCT02267265|OTHER|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
219261063|NCT00002492|DRUG|cisplatin|
219261064|NCT00002492|DRUG|doxorubicin hydrochloride|
219261065|NCT00002492|DRUG|isolated limb perfusion|
219261066|NCT00002492|PROCEDURE|conventional surgery|
219261067|NCT00002492|RADIATION|brachytherapy|
219261068|NCT00002492|RADIATION|radiation therapy|
219261069|NCT05649189|DIAGNOSTIC_TEST|telomere length measure|length of telomere between two groups
219261070|NCT04256369|COMBINATION_PRODUCT|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
219261071|NCT02697838|DRUG|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
219261072|NCT02697838|DRUG|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens"
219261073|NCT02594046|OTHER|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
219261074|NCT00384865|DRUG|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
219261075|NCT00384865|DRUG|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
219261076|NCT00384865|DRUG|Placebo|Placebo, taken orally, once a day for 6 months
219261077|NCT00327353|DRUG|formoterol (TURBOHALER)|
219261078|NCT00327353|DRUG|Salmeterol (DISKUS)|
219261079|NCT02727257|PROCEDURE|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
219261080|NCT02582398|OTHER|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
219261081|NCT02582398|OTHER|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
219261082|NCT00485550|DRUG|Atomoxetine Hydrochloride|
219261083|NCT00485550|DRUG|Methylphenidate Hydrochloride|
219261084|NCT00485550|DRUG|Placebo|
219261085|NCT00006145|DRUG|Valganciclovir|
219261086|NCT03990142|DIAGNOSTIC_TEST|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
219261087|NCT02854371|DRUG|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
219261088|NCT02854371|DRUG|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
219261089|NCT06018688|DRUG|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
219261090|NCT06018688|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
219261091|NCT03089736|BEHAVIORAL|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
219261092|NCT03089736|BEHAVIORAL|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
219261093|NCT03089736|OTHER|Treatment as usual (TAU)|pharmacological treatment + advices
219261094|NCT00482898|DRUG|MK0359|
219261095|NCT01572298|DEVICE|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
219261096|NCT01572298|DEVICE|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
219261097|NCT00640744|DRUG|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
219261098|NCT01935596|DRUG|ropivacaïne|spinal anesthesia.
219261099|NCT01935596|DRUG|lévobupivacaïne|
219261100|NCT04467346|DRUG|Ped-TMZ|Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
219261101|NCT00077597|DRUG|epoetin|3 times a week iv, as prescribed.
219261102|NCT00077597|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
219261103|NCT03893006|DEVICE|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
219261104|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
219261105|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
219261106|NCT05328310|DRUG|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
219261107|NCT01937195|DEVICE|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
219261108|NCT05354713|DRUG|NVP-1805|NVP-1805 (80/10/20.8mg)
219261109|NCT05354713|DRUG|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
219261110|NCT05594004|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
219261111|NCT05594004|DEVICE|Sonic electric toothbrush|Sonic electric toothbrush used twice daily
219261112|NCT05594004|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
219261113|NCT03834623|DRUG|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
219261114|NCT03834623|DRUG|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
219261115|NCT05316909|OTHER|Breastfeeding Simulation|In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.
219261116|NCT00867178|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
219261117|NCT00867178|DRUG|Carboplatin|Given IV
219261118|NCT00867178|DRUG|Cisplatin|Given IV
219261119|NCT00867178|DRUG|Cyclophosphamide|Given IV
219261120|NCT00867178|DRUG|Etoposide Phosphate|Given IV
219261121|NCT00867178|DRUG|Isotretinoin|Given PO
219261122|NCT00867178|OTHER|Laboratory Biomarker Analysis|Correlative studies
219261123|NCT00867178|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
219261124|NCT00867178|DRUG|Thiotepa|Given IV
219261125|NCT00867178|DRUG|Vincristine Sulfate|Given IV
219261126|NCT00867178|DRUG|Vorinostat|Given PO
219261127|NCT00384605|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
219261128|NCT00384605|DRUG|placebo|Placebo capsule once daily. Treatment for 52 weeks.
219261129|NCT06787482|DIETARY_SUPPLEMENT|ACE Retino|1 ml sublingually self administer / 4 times/day for 6 months
219261130|NCT06957067|BEHAVIORAL|CPT Skills|CPT trainings recommend that if an individual is experiencing challenges with the CPT protocol (e.g., ambivalence about continuing treatment or struggling with completing homework), the provider can apply the skills of CPT to that particular problem. Those skills include problem solving and cognitive restructuring to identify and alter maladaptive underlying beliefs. The purpose of this work is to address the individual's underlying problem or problematic beliefs to improve the individual's attitudes about CPT and/or improve the individual's compliance with treatment activities. The therapist's end-goal is to keep the individual moving forward in the CPT protocol.
219363016|NCT05420389|OTHER|breast massage|Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
219261131|NCT06957067|BEHAVIORAL|Cognitive Processing Therapy|"CPT is a 12-session, cognitive-behavioral treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to prior trauma. The goal is to build a new understanding of prior trauma in order to limit the negative influence trauma and it's reminders have on individuals' daily lives. The treatment involves education about PTSD and skill building to identify and challenge maladaptive, trauma-related thinking through Socratic questioning and worksheets that teach individuals to challenge this thinking themselves. Later sessions focus on specific themes that are difficult for individuals with PTSD and can keep individuals stuck in their symptoms. Themes include safety, trust, control, self-esteem, and intimacy.~Although the skills utilized in CPT may be used to respond to challenges individuals have with participating in CPT, the effectiveness of these strategies has not been explicitly tested."
219261132|NCT06957067|BEHAVIORAL|Present Centered Therapy|"PCT was developed as a comparator for active TFT, so protocol length typically matches the comparator. PCT focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to life difficulties and stress, and emotional support and validation. Its hypothesized mechanisms are increased interpersonal connection and mastery in managing life stressors. Therapist skills include validation, support, and reflective listening. The first 2 sessions provide an overview and rationale for PCT. Subsequent sessions focus on topics participants choose and are less structured. Participants use a daily diary to record any concerning problems or issues they experience during the week. These diaries are used to select session topics."
219261133|NCT06957067|BEHAVIORAL|Shared Decision Making|Shared decision making (SDM) is widely considered the best model for achieving patient-provider agreement on treatment plans and an ethical imperative for decision making. SDM is a communicative process in which patients and their provider personalize treatment approaches to the individual, their situation, and the problems that they are experiencing. Providers and patients engage in a shared deliberation of meaningful treatment alternatives, including pros and cons, how choices align or misalign with values, and patients' abilities to complete the plans under consideration.
219261134|NCT06957067|BEHAVIORAL|Measurement Based Care|"Investigators will compare methods of identifying individuals experiencing challenges in CPT. Investigators will use self-report measures administered each week during treatment to identify individuals who may be struggling in during CPT and compare two approaches to cut scores on these measures to classify individuals as in need of intervention. Investigators will also use behavioral indices to determine if veterans are in need of intervention, including homework compliance and session attendance. One approach will liberally classify many individuals as in need of intervention (Catchall), while the other will take a more targeted approach (Targeted)."
219261135|NCT06957340|DEVICE|Low-Intensity Transcranial Ultrasound Stimulation|"LITUS is conducted using the UE880C model from RuAo Medical Technology Co., Ltd. (Beijing). The parameters are set as follows:Frequency: 800(1+10%) kHz,Pulse repetition period: 25 ms,Duty cycle: 50%,Output power: 1.2 W,Maximum output power duration: 0.6 W,Effective sound intensity: 0.4 W/cm².During treatment, the patient is placed in a quiet room and asked to relax in a seated position. Three ultrasound probes are coated with a coupling agent and positioned on the patient's forehead.The total treatment duration is 20 minutes.~The upper limb rehabilitation virtual training is used by the EM-BURT02-01 model from Eston.The affected limb is fixed to the robotic arm. Each treatment session consists of two virtual games (such as Airplane Battle, Mosquito Smasher, and other motion-based games).Each game lasts for 10 minutes, totaling 20 minutes of treatment. Treatment is administered 5 times a week."
219261136|NCT06957340|DEVICE|sham TUS|In the sham group, the machine only operates for 30 seconds, then stopping. Due to the physical characteristics of ultrasound, this stimulation cannot be perceived.Treatment is administered 5 times a week.
219261137|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM)|The tPBM-2.0 device consists of a therapeutic laser console (that produces laser energy as NIR), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap). tPBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead at the standard scalp location \~12 minutes per day, 3 days per week, for 6 weeks (18 total sessions).
219261138|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM) in sham mode|The tPBM-2.0 device consists of a therapeutic laser console (which will be in sham mode, which does not produce laser energy), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap).
219261139|NCT06957288|OTHER|Mindfulness-based psychoeducation|The aim of psychoeducation is to reduce the death anxiety of nurses and to increase their awareness of death by providing them with information about the death experience they are secondarily exposed to (1- Death process and death anxiety, 2- Effects of the death process on the individual and family, 3- Coping with the death process, 4- Effects of the death process on caregiving nurses, 5- Awareness of death, 6- Nursing care and emotional competence during the death process). Therefore, it will be evaluated whether the implemented psychoeducation program reduces the intended death anxiety and creates awareness about death. This study will be conducted to examine the effect of a 6-week, 12-session mindfulness-based group psychoeducation program given to nurses on death anxiety and death awareness levels.
219261140|NCT03447275|OTHER|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
219261141|NCT05119634|OTHER|whole body vibration training|participants will receive whole body vibration training 3 days in a week and for 8 weeks
219261142|NCT05119634|OTHER|home based exercises|participants will receive a home based exercise program for 8 weeks
219261143|NCT04363619|DIAGNOSTIC_TEST|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
219261144|NCT01045863|DRUG|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
219261145|NCT01045863|DRUG|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
219261146|NCT01045863|DRUG|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
219261147|NCT01045863|DRUG|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
219261148|NCT01045863|DRUG|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
219261149|NCT03046368|BEHAVIORAL|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
219261150|NCT05634798|OTHER|no intervention|There is no intervention in this study.
219261151|NCT06142981|BIOLOGICAL|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
219261152|NCT06546540|DRUG|Telitacicept|160mg，once weekly
219261153|NCT01522703|DRUG|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
219261154|NCT01522703|DRUG|Placebo|Alfalfa Sprouts
219261155|NCT02525081|DRUG|Ramipril (ACE-inhibitor)|up to 10 mg
219261156|NCT02525081|DRUG|placebo|up to 10 mg
219261157|NCT01755546|DRUG|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
219261158|NCT04127071|PROCEDURE|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
219261159|NCT04127071|PROCEDURE|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
219261160|NCT04820647|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
219261161|NCT06830772|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
219261162|NCT06830772|OTHER|Active comparator|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
219261163|NCT06957184|PROCEDURE|bladder dissection in placenta accreta spectrum|"All caesarean sections will be performed by a surgeon who has experience in performing caesarean hysterectomy in both groups.~* Scrubbing the abdomen as usual.~* Subumblical midline skin incision versus Pfannenstiel incision will be chosen according to site of the placenta and previous surgeries.~* In group A careful bladder dissection will be done before uterine incision with ensuring hemostasis, uterine incision will be done above the placenta, after delivering the baby awaiting for placental separation if not proceeding for caesarean hysterectomy.~* In group B uterine incision will be done above the placenta and after delivering the baby awaiting for placental separation if not proceeding to caesarean hysterectomy and dissecting bladder just before clamping uterine artery."
219261164|NCT06328140|DRUG|Lurasidone|Daily medication treatment
219261165|NCT06328140|DRUG|FDA Approved antidepressant treatment|Daily treatment with an FDA approved antidepressant
219261166|NCT06091839|OTHER|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
219261167|NCT00974389|BIOLOGICAL|bevacizumab|
219261168|NCT00974389|DRUG|tegafur-gimeracil-oteracil potassium|
219261169|NCT03376555|DIETARY_SUPPLEMENT|Low sodium no cheese|Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese 8 days
219261170|NCT03376555|DIETARY_SUPPLEMENT|Low sodium cheese|Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
219261171|NCT03376555|DIETARY_SUPPLEMENT|High sodium no cheese|Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese 8 days
219261172|NCT03376555|DIETARY_SUPPLEMENT|High sodium cheese|Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
219261173|NCT03660397|PROCEDURE|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
219261174|NCT03660397|DRUG|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
219261175|NCT01435707|OTHER|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
219261176|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
219261177|NCT01435707|OTHER|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
219261178|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
219261179|NCT03801187|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
219261180|NCT03801187|PROCEDURE|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
219261181|NCT03801187|PROCEDURE|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
219261182|NCT03637647|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
219261183|NCT04867707|DRUG|Zanamivir|5 days of treatment with 10mg zanamivir inhaler BID
219261184|NCT02142634|DRUG|Budesonide granules 9 mg|per day
219261185|NCT02142634|DRUG|Placebo granules|per day
219261186|NCT05231278|DEVICE|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
219261187|NCT05815823|OTHER|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
219261188|NCT05815823|OTHER|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
219261189|NCT04797598|OTHER|Virtual reality group|This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment
219261190|NCT04797598|OTHER|Cyclic training group|This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
219261191|NCT04871347|DRUG|TWP-101|IV infusion
219261192|NCT06788691|DRUG|Luspatercept|Administered at 1 mg/kg once every 3 weeks
219261193|NCT03373851|DEVICE|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
219261194|NCT04441827|OTHER|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
219261195|NCT04308213|DEVICE|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
219261196|NCT03294941|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
219261197|NCT02732002|PROCEDURE|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
219261198|NCT05051423|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
219261199|NCT03927690|DRUG|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
219261200|NCT03927690|DRUG|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
219261201|NCT03248141|DRUG|Hemophilia B standard half-life|Benefix
219261202|NCT03248141|DRUG|Hemophilia B extended half-life|Alprolix
219261203|NCT03248141|DRUG|Hemophilia A standard half-life|Xyntha and other standard half-life agents
219261204|NCT03248141|DRUG|Hemophilia A extended half-life|Eloctate and Adynovate
219261205|NCT05469412|DEVICE|iPad®|Use of Technology.
219261206|NCT05469412|DRUG|Midazolam|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
219261207|NCT03871621|DRUG|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
219261208|NCT03871621|DRUG|Dapagliflozin|Dapagliflozin tablet (10 mg)
219261209|NCT00661544|DRUG|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
219261210|NCT00661544|DRUG|Melphalan|Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
219261211|NCT00661544|DRUG|Ascorbic Acid|Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
219261212|NCT01605656|BEHAVIORAL|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
219261213|NCT01605656|BEHAVIORAL|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
219261214|NCT01605656|BEHAVIORAL|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
219261215|NCT05463731|DRUG|Remternetug (IV)|Administered IV
219261216|NCT05463731|DRUG|Remternetug (SC)|Administered SC
219261217|NCT05463731|DRUG|Placebo|Administered IV or SC
219261218|NCT01617798|DRUG|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
219261219|NCT01617798|DRUG|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
219261220|NCT04184349|DRUG|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
219261221|NCT04184349|DRUG|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
219261222|NCT04051242|DEVICE|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
219261223|NCT01848067|DRUG|Alisertib|Given PO
219261224|NCT01848067|DRUG|Abiraterone acetate|Given PO
219261225|NCT01848067|DRUG|Prednisone|Given PO
219261226|NCT00000770|DRUG|Nevirapine|
219261227|NCT00000770|DRUG|Zidovudine|
219261228|NCT00000770|DRUG|Didanosine|
219261229|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
219261230|NCT06315426|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
219261231|NCT06315426|BIOLOGICAL|Placebo|Placebo
219261232|NCT05259358|OTHER|exercise|exercises that increase muscular endurance
219261233|NCT01522677|DRUG|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
219261234|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
219261235|NCT00093132|DRUG|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
219261236|NCT05917548|DEVICE|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
219261237|NCT05917548|BEHAVIORAL|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
219261238|NCT05781997|DIAGNOSTIC_TEST|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by \>0.50D.
219261239|NCT01061853|DRUG|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
219261240|NCT01061853|DRUG|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
219261241|NCT00141713|DRUG|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
219261242|NCT03194854|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
219261243|NCT00176475|BIOLOGICAL|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
219261244|NCT00176475|BIOLOGICAL|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
219261245|NCT00337285|DRUG|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
219261246|NCT04008056|OTHER|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
219261247|NCT01774019|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
219261248|NCT01115283|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
219261249|NCT01115283|BEHAVIORAL|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
219261250|NCT01115283|BEHAVIORAL|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
219261251|NCT06443424|DEVICE|ultrasound device|usage of ultrasound device in pediatric airway asessment
219261252|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
219261253|NCT02160470|BEHAVIORAL|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
219261254|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
219261255|NCT02160470|BEHAVIORAL|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
219261256|NCT00448773|BEHAVIORAL|Online education|
219261257|NCT00003185|BIOLOGICAL|autologous tumor cell vaccine|
219261258|NCT00003185|BIOLOGICAL|sargramostim|
219261259|NCT00003185|BIOLOGICAL|tumor-draining lymph node lymphocyte therapy|
219261260|NCT00003185|DRUG|cyclophosphamide|
219261261|NCT00003185|PROCEDURE|conventional surgery|
219261262|NCT02949856|DEVICE|Mallinckrodt, COVIDIEN|
219261263|NCT02949856|DEVICE|Endotracheal tube, Unomedica|
219261264|NCT04567797|DEVICE|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
219261265|NCT04567797|DEVICE|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
219261266|NCT04567797|DEVICE|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
219261267|NCT04567797|DEVICE|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
219261268|NCT01004185|DRUG|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM
219261269|NCT01004185|DRUG|Asacol 400 mg|17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
219261270|NCT00574483|DRUG|quinacrine|100 mg day
219261271|NCT03503487|OTHER|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
219261272|NCT00508534|DRUG|SB-751689|
219261273|NCT04747210|BEHAVIORAL|contextual one-on-one coaching|Training workshop and coaching one-on-one
219261274|NCT04747210|BEHAVIORAL|Trainig workshop|Ten-hour training workshop.
219261275|NCT05923502|DRUG|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
219261276|NCT04157023|DEVICE|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
219261277|NCT03643497|DRUG|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
219261278|NCT02217488|DRUG|DG3173|
219261279|NCT02217488|DRUG|Placebo|
219261280|NCT00931008|DRUG|SID530, Taxotere|75mg/m2
219261281|NCT05203224|DRUG|Dornase Alfa|Intravenous Dornase alfa
219261282|NCT03396211|DRUG|Apatinib|Apatinib tablets
219261283|NCT03396211|DRUG|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
219261284|NCT02239861|BIOLOGICAL|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
219261285|NCT02292485|BEHAVIORAL|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
219261286|NCT02652377|DRUG|EDP-494|10, 100 and 200 mg capsules
219261287|NCT02652377|DRUG|Placebo|placebo to match EDP-494
219261288|NCT04932226|DEVICE|cloth mask|Buff bandana double layer worn over nose and mouth
219261289|NCT04932226|DEVICE|surgical mask|standard surgical mask
219261290|NCT04932226|DEVICE|FFP2 respirator|filtering facepiece 2 respirator
219261291|NCT01376050|DEVICE|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
219261292|NCT01376050|DEVICE|Placebo Laser|Placebo Laser has no therapeutic output emitted.
219261293|NCT02296203|DRUG|cetuximab|
219261294|NCT02296203|DRUG|irinotecan|
219261295|NCT03526978|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
219261296|NCT03526978|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
219261297|NCT01553227|DEVICE|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
219261298|NCT03481556|DRUG|Melphalan flufenamide (Melflufen)|Intravenous infusion
219261299|NCT03481556|DRUG|Dexamethasone|Oral tablets
219261300|NCT03481556|DRUG|Bortezomib|Subcutaneous administration
219261301|NCT03481556|DRUG|Daratumumab|Intravenous infusion
219261302|NCT03463577|OTHER|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
219261303|NCT05694533|DRUG|INDV-2000|Capsules administered orally twice a day
219261304|NCT05694533|DRUG|Midazolam|Midazolam syrup administered orally on Days 1 and 15
219261305|NCT00188825|OTHER|placebo|
219261306|NCT00188825|DRUG|basiliximab|
219261307|NCT01797133|PROCEDURE|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
219261308|NCT01797133|PROCEDURE|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
219261309|NCT05008263|DIAGNOSTIC_TEST|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
219261310|NCT05008263|DIAGNOSTIC_TEST|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
219261311|NCT02073253|OTHER|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
219261312|NCT01101997|DEVICE|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
219261313|NCT03334877|DIAGNOSTIC_TEST|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
219261314|NCT04709978|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
219261315|NCT04709978|DIAGNOSTIC_TEST|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
219261316|NCT04709978|DIAGNOSTIC_TEST|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
219261317|NCT04709978|DIAGNOSTIC_TEST|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
219261318|NCT04709978|DIAGNOSTIC_TEST|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
219261319|NCT04709978|DIAGNOSTIC_TEST|Lung Ultrasound|To image the lungs (ED participants only)
219261320|NCT04709978|DIAGNOSTIC_TEST|Respiratory Function Tests|To measure respiratory pressures.
219261321|NCT00610025|PROCEDURE|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
219261322|NCT06042023|DEVICE|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
219261323|NCT05041725|DRUG|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
219261324|NCT03588819|RADIATION|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
219261325|NCT04427878|PROCEDURE|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
219261326|NCT02943642|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
219261327|NCT02943642|DRUG|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
219261328|NCT01272323|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
219261329|NCT01272323|BIOLOGICAL|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
219261330|NCT01272323|BIOLOGICAL|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
219261331|NCT00070343|BIOLOGICAL|oblimersen sodium|
219261332|NCT00070343|DRUG|dacarbazine|
219261333|NCT03110263|OTHER|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
219261334|NCT03110263|OTHER|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
219261335|NCT05469113|DRUG|Repaglinide|Administered orally.
219261336|NCT05469113|DRUG|Selpercatinib|Administered orally.
219261337|NCT00495872|DRUG|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
219261338|NCT00495872|DRUG|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
219261339|NCT00495872|DRUG|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
219261340|NCT00495872|DRUG|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
219261341|NCT00495872|DRUG|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
219261342|NCT00495872|DRUG|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
219261343|NCT00495872|DRUG|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
219261344|NCT04745377|DIAGNOSTIC_TEST|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
219261345|NCT02172950|BIOLOGICAL|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
219261346|NCT01196585|PROCEDURE|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
219261347|NCT01196585|PROCEDURE|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
219261348|NCT00269997|DRUG|epoetin alfa|
219261349|NCT00503217|DRUG|Tryptorelin|
219261350|NCT04379817|DIAGNOSTIC_TEST|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
219261351|NCT05560750|PROCEDURE|Frenotomy|Releasing the tongue-tie with scissors
219261352|NCT05560750|PROCEDURE|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
219261353|NCT02163798|BEHAVIORAL|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
219261354|NCT02163798|BEHAVIORAL|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
219261355|NCT02795715|DEVICE|tDCS|
219261356|NCT02795715|BEHAVIORAL|training|
219261357|NCT02606383|DRUG|Dapaconazole|
219261358|NCT02606383|DRUG|Ketoconazole|
219261359|NCT00611715|DRUG|erlotinib hydrochloride|OSI-774 150 mg/day
219261360|NCT00611715|DRUG|letrozole|Letrozole 2.5 mg/day
219261361|NCT00611715|GENETIC|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
219261362|NCT00611715|OTHER|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
219261363|NCT00611715|OTHER|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
219261364|NCT00000850|DRUG|Indinavir sulfate|
219261365|NCT00000850|DRUG|Sargramostim|
219261366|NCT03752255|OTHER|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
219261367|NCT00291239|BEHAVIORAL|partial sleep deprivation|
219261368|NCT00107978|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
219261369|NCT00107978|DRUG|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
219261370|NCT02003378|DEVICE|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
219261371|NCT02003378|DEVICE|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
219261372|NCT01016418|DIETARY_SUPPLEMENT|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
219261373|NCT04731142|DEVICE|Huma|Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
219261374|NCT04731142|BEHAVIORAL|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals."
219261375|NCT04731142|BEHAVIORAL|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
219261376|NCT04731142|OTHER|Standard of care|Normal primary care service provided to matched control group.
219261377|NCT00611299|DIETARY_SUPPLEMENT|BB-12 and CRL 431|
219261378|NCT04864717|DRUG|Doxycycline 100mg po once daily x 6 months|active intervention
219261379|NCT04864717|DRUG|Isotretinoin 40 mg po once daily x 6 months|active intervention
219261380|NCT03892551|OTHER|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
219261381|NCT03892551|OTHER|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
219261382|NCT03892551|OTHER|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
219261383|NCT03892551|DIAGNOSTIC_TEST|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
219261384|NCT03892551|OTHER|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
219261385|NCT03892551|OTHER|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
219261386|NCT03892551|OTHER|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
219261387|NCT05371145|BIOLOGICAL|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
219261388|NCT01391429|BEHAVIORAL|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
219261389|NCT00878293|DRUG|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
219261390|NCT00878293|DRUG|MS Continus®|60 mg, capsule, once daily
219261391|NCT00878293|DRUG|Placebo|liquid formulation and capsule, once daily
219261392|NCT04716218|PROCEDURE|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
219261393|NCT03135613|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
219261394|NCT00704171|PROCEDURE|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
219261395|NCT00704171|DEVICE|PleuraSeal Lung Sealant System|
219261396|NCT06386445|OTHER|Serum metabolomics sequencing|Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
219261397|NCT01874665|DRUG|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
219261398|NCT00237354|DRUG|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
219261399|NCT05763654|DEVICE|Linovera emulsion|Apply Linovera emulsion in clinical routine
219261400|NCT00078728|BEHAVIORAL|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
219261401|NCT00078728|BEHAVIORAL|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
219261402|NCT00350298|BIOLOGICAL|GS-CDA1/MDX-1388|One Intravenous dose
219261403|NCT00350298|BIOLOGICAL|normal saline|One Intravenous dose
219261404|NCT03277885|OTHER|chronic pain|work related chronic pain
219261405|NCT06133868|DRUG|Lavender and Chamomile Essential Oils|essential oils
219261406|NCT00233389|DRUG|Rebamipide|
219261407|NCT00607061|PROCEDURE|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
219261408|NCT03740477|DIAGNOSTIC_TEST|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
219261409|NCT04963946|DRUG|Stop ACA|discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
219261410|NCT04963946|DRUG|ACA Continuation|continuation of acalabrutinib at the same dose
219261411|NCT04622475|BIOLOGICAL|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
219261412|NCT03948399|DEVICE|Duplex scanning of carotid arteries|Measurement of carotid arteries
219261413|NCT03948399|DEVICE|ABI measurement|ankle brachial index (ABI) assessment
219261414|NCT05333575|BEHAVIORAL|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
219261415|NCT05333575|BEHAVIORAL|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
219261416|NCT02780102|OTHER|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
219261417|NCT02780102|DRUG|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
219261418|NCT02780102|OTHER|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
219261419|NCT04021225|DEVICE|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
219261420|NCT04021225|DEVICE|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
219261421|NCT04021225|DEVICE|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
219261422|NCT03019198|DRUG|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
219261423|NCT03019198|DRUG|Placebo - Concentrate|
219261424|NCT03463434|DEVICE|Air Fluidized Therapy|AFT bed used for pressure injury treatment
219261425|NCT03463434|DEVICE|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
219261426|NCT01380288|DRUG|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
219261427|NCT02471482|OTHER|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
219261428|NCT05225207|OTHER|Non-interventional|No intervention will be administered.
219261429|NCT05238363|DRUG|HLX07|HLX07 1500mg ivgtt Q3W
219261430|NCT04269434|OTHER|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
219261431|NCT03548493|DRUG|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
219261432|NCT03548493|DRUG|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
219261433|NCT03548493|DRUG|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
219261434|NCT05098691|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
219261435|NCT04485754|OTHER|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
219261436|NCT04485754|OTHER|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
219261437|NCT00277199|DRUG|Abatacept|
219261438|NCT01685125|DRUG|abiraterone acetate|Given PO
219261439|NCT01685125|DRUG|dasatinib|Given PO
219261440|NCT01685125|DRUG|prednisone|Given PO
219261441|NCT04962698|BEHAVIORAL|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
219261442|NCT04962698|BEHAVIORAL|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
219261443|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
219261444|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
219261445|NCT04962698|BEHAVIORAL|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
219261446|NCT04962698|BEHAVIORAL|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
219261447|NCT04962698|BEHAVIORAL|Rest|Subjects will rest without a task.
219261448|NCT00165334|DRUG|Cetuximab|
219261449|NCT00165334|DRUG|Vinorelbine (Navelbine)|
219261450|NCT05660330|BEHAVIORAL|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
219261451|NCT02906280|DEVICE|EBUS-TBNA needle|tissue sampling
219261452|NCT00853229|DRUG|pregabalin|pregabalin 150mg twice daily for 4 weeks
219261453|NCT04477993|DRUG|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
219261454|NCT04477993|OTHER|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
219261455|NCT00264563|BEHAVIORAL|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
219261456|NCT00264563|BEHAVIORAL|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
219261457|NCT00466713|DRUG|Rosiglitazone therapy|
219261458|NCT02361398|OTHER|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
219261459|NCT01006499|DRUG|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
219261460|NCT01700322|PROCEDURE|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
219261461|NCT01700322|DRUG|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
219261462|NCT01700322|DRUG|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
219261463|NCT01700322|DRUG|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
219261464|NCT02208037|DRUG|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
219261465|NCT02208037|DRUG|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
219261466|NCT02208037|DRUG|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
219261467|NCT02208037|DRUG|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
219261468|NCT02208037|DRUG|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
219261469|NCT02208037|DRUG|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
219261470|NCT02208037|DRUG|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
219261471|NCT02208037|DRUG|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
219261472|NCT03201900|DRUG|E2007|Oral tablet
219261473|NCT05953831|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
219261474|NCT05953831|DRUG|Placebo|Placebo to CDR132L
219261475|NCT02790775|DRUG|Anti-VEGF in quadrant 1|
219261476|NCT02790775|DRUG|Anti-VEGF in quadrant 2|
219261477|NCT02790775|DRUG|Anti-VEGF in quadrant 3|
219261478|NCT02790775|DRUG|Anti-VEGF in quadrant 4|
219261479|NCT04752033|DRUG|Morphine|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
219261480|NCT04752033|DRUG|Hydromorphone|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
219261481|NCT05352971|OTHER|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
219261482|NCT02673554|DRUG|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
219261483|NCT02673554|DRUG|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
219261484|NCT02673554|PROCEDURE|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
219261485|NCT02673554|PROCEDURE|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
219261486|NCT01043445|DIETARY_SUPPLEMENT|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
219261487|NCT01043445|DIETARY_SUPPLEMENT|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
219261488|NCT01043445|DIETARY_SUPPLEMENT|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
219261489|NCT00375765|DRUG|Dutasteride|
219261490|NCT03634306|DEVICE|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
219261491|NCT03634306|PROCEDURE|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
219261492|NCT05326698|PROCEDURE|Medtronic NIM Eclipse for evoked potentials recording|Recording of somesthetic and motor evoked potentials during endoscopic posterior cervical foraminotomy.
219261493|NCT01292577|BEHAVIORAL|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
219261494|NCT01292577|BEHAVIORAL|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
219261495|NCT04185987|OTHER|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
219261496|NCT04185987|OTHER|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
219261497|NCT04185987|OTHER|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
219261498|NCT04185987|OTHER|AO twisted ended ligature wire|AO twisted ended ligature wire application
219261499|NCT00119938|BEHAVIORAL|Access to online patient portal|
219261500|NCT03104283|DRUG|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
219261501|NCT02909309|DEVICE|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
219261502|NCT00776659|OTHER|Aromasin|Non-Interventional study design.
219261503|NCT04889859|PROCEDURE|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
219261504|NCT04889859|PROCEDURE|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
219261505|NCT05090605|GENETIC|DNA analysis|GWAS
219261506|NCT05498454|BEHAVIORAL|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
219261507|NCT00995384|PROCEDURE|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
219261508|NCT04863820|DIAGNOSTIC_TEST|cutaneous silent period|form of Nerve conduction studies
219261509|NCT01667172|DEVICE|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
219261510|NCT01339962|OTHER|Non-interventional|Non-interventional (retrospective chart reviews)
219261511|NCT02192723|DRUG|Typical antipsychotic|Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
219261512|NCT02192723|DRUG|Risperidone|2\~6mg/day, twice per day, 8 weeks
219261513|NCT02192723|DRUG|Olanzapine|Olanzapine, 400\~750mg/day, twice per day, 8 weeks
219261514|NCT02192723|DRUG|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
219261515|NCT02192723|DEVICE|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
219261516|NCT02192723|DRUG|Ziprasidone|Ziprasidone 80\~160mg/day, twice per day, 8 weeks
219261517|NCT01903369|DEVICE|Shear Wave Elastography|Shear wave elastography
219261518|NCT06287086|DRUG|BRL-101 autologous hematopoietic stem and progenitor cells injection|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
219261519|NCT02602795|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
219261520|NCT02602795|BEHAVIORAL|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
219261521|NCT03409562|BEHAVIORAL|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
219261522|NCT03409562|BEHAVIORAL|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
219261523|NCT01664923|DRUG|Enzalutamide|160 mg, daily, by mouth.
219261524|NCT01664923|DRUG|Bicalutamide|50 mg, daily, by mouth
219261525|NCT00117897|DRUG|pegfilgrastim|
219261526|NCT00117897|DRUG|Filgrastim|
219261527|NCT05260554|DRUG|Fosfomycin|In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
219261528|NCT05260554|DIETARY_SUPPLEMENT|Cranberry|In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
219261529|NCT06258733|BEHAVIORAL|Lay-led FL workshops|Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.
219261530|NCT06258733|BEHAVIORAL|Expert-led workshops|Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
219261531|NCT01233999|DRUG|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
219261532|NCT04588675|DIAGNOSTIC_TEST|MRI|the patients will underwent dobutamine stress cardiac MRI
219261533|NCT05350124|DRUG|Ascorbic acid|vitamin C (200 mg) capsule
219261534|NCT05350124|DRUG|Tocopherol|vitamin E (400 IU) capsule
219261535|NCT05350124|DRUG|Placebo capsule|Placebo one pill only
219261536|NCT05350124|DRUG|Placebo capsule|Placebo two pills only
219261537|NCT03895502|DRUG|12-month Edoxaban|Prescription of Edoxaban for 12 months
219261538|NCT03895502|DRUG|3-month Edoxaban|Prescription of Edoxaban for 3 months
219261539|NCT01721083|PROCEDURE|Procedure: Z-track|Subject received immunization by z-track
219261540|NCT01721083|PROCEDURE|Procedure: Bunch|Subject receives immunization by bunch method.
219261541|NCT00024323|DRUG|cisplatin|
219261542|NCT00024323|DRUG|triapine|
219261543|NCT00889837|DRUG|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
219261544|NCT00889837|DRUG|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
219261545|NCT01977183|DIETARY_SUPPLEMENT|MSPrebiotic|Potato Resistant Starch
219261546|NCT01977183|DIETARY_SUPPLEMENT|Placebo|Placebo - Corn Starch
219261547|NCT03771222|BIOLOGICAL|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
219261548|NCT00047177|DRUG|Oxaliplatin|
219261549|NCT01001962|DRUG|empagliflozin|ACTIVE TREATMENT FOR DIABETES
219261550|NCT01001962|DRUG|Metformin|ACTIVE TREATMENT FOR DIABETES
219261551|NCT03231969|DRUG|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
219261552|NCT03231969|DRUG|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
219261553|NCT03231969|DRUG|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
219261554|NCT03231969|DRUG|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
219261555|NCT03109509|BEHAVIORAL|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
219261556|NCT03109509|BEHAVIORAL|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
219261557|NCT03247738|DRUG|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
219261558|NCT03247738|OTHER|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
219261559|NCT06392893|COMBINATION_PRODUCT|Meat product without additives and allergens|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of meat products without additives and allergens (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
219261560|NCT06392893|COMBINATION_PRODUCT|Commercial meat product|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of commercial meat products (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
219261561|NCT03184506|OTHER|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
219261562|NCT03184506|OTHER|no warming|patients were covered only with two layers of cotton blanket
219261563|NCT02314104|DRUG|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
219261564|NCT03613324|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
219261565|NCT00129649|BEHAVIORAL|Telephone reminder call|
219261566|NCT02670499|DEVICE|CPM|Used to aid in recovery from TKR
219261567|NCT02670499|DEVICE|GAPFLEX|Used to aid in the recovery of TKR
219261568|NCT06499688|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219261569|NCT06499688|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219261570|NCT06499688|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
219261571|NCT04875897|DEVICE|keepMED PAP device|The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).
219261572|NCT03569605|BEHAVIORAL|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
219261573|NCT03569605|BEHAVIORAL|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
219261574|NCT02080377|DRUG|Glibenclamide|
219261575|NCT02080377|DRUG|Insulin|
219261576|NCT04540562|OTHER|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
219261577|NCT03632005|DEVICE|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
219261578|NCT03632005|OTHER|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
219261579|NCT05566392|DIAGNOSTIC_TEST|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
219261580|NCT05840562|DRUG|Capsaicin|Application of capsaicin patches 179 mg
219261581|NCT05840562|DRUG|Duloxetine|Administration of duloxetine
219261582|NCT01321723|DRUG|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
219261583|NCT01321723|DRUG|Placebo|
219261584|NCT01321723|DRUG|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
219261585|NCT00025506|OTHER|Laboratory Biomarker Analysis|Correlative studies
219261586|NCT00025506|DRUG|Thalidomide|Given orally
219261587|NCT02250690|DEVICE|experimental group - tDCS|
219261588|NCT02250690|DEVICE|Control group (tDCS sham)|
219261589|NCT05223972|OTHER|Schroth Treatment|Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise
219261590|NCT05623371|BEHAVIORAL|Training leaders in leading well-being and the psychosocial working environment|"The intervention comprises five training modules with practice in small groups in between. Training will take place over 5 months. The training will be received in groups of 20 and the training will be facilitated by 2 facilitators. Central themes of the training are:~1. Self-care and well-being of the manager and how to cope with stress as a manager.~2. Employee well-being and reducing risk-factors in the psychosocial working environment of employee mental health problems~3. Enhancing protective factors social social support and a healthy team climate~4. Responding to employees at risk and how to handle difficult conversations and procedures on return to work~5. Managing well-being in employees during organizational change and final reflections~The training will comprise video material and in person training of competencies and behaviors in group settings.~The waitlist control group will receive an offer of a webinar and written information."
219261591|NCT05623371|BEHAVIORAL|The offer of a webinar and written material|The offer of a webinar plus written material
219261592|NCT03331926|DRUG|Xiapex|Follow-up of effect of treatment
219261593|NCT02947841|OTHER|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
219261594|NCT02947841|OTHER|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
219261595|NCT04310683|OTHER|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
219261596|NCT04310683|OTHER|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
219261597|NCT02011217|OTHER|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
219261598|NCT02011217|OTHER|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
219261599|NCT02011217|OTHER|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
219261600|NCT03551431|DIAGNOSTIC_TEST|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
219261601|NCT05623813|OTHER|Postoperative education|provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
219261602|NCT00713206|DEVICE|Dental Implant (Osseotite)|Root form titanium dental implant
219261603|NCT02182232|DRUG|BIBF 1120|
219261604|NCT02182232|DRUG|Paclitaxel|
219261605|NCT02182232|DRUG|Carboplatin|
219261606|NCT00276666|DRUG|cisplatin|
219261607|NCT00276666|DRUG|lomustine|
219261608|NCT00276666|DRUG|vincristine sulfate|
219261609|NCT00276666|PROCEDURE|adjuvant therapy|
219261610|NCT00276666|RADIATION|radiation therapy|
219261611|NCT01838486|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
219261612|NCT05336617|PROCEDURE|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
219261613|NCT00347399|DRUG|bevacizumab intravitreal injection|
219261614|NCT00347399|PROCEDURE|verteporfin photodynamic therapy|
219261615|NCT05158023|DRUG|Placebo Comparator|Sterile solution for subcutaneous injection
219261616|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
219261617|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
219261618|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
219261619|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
219261620|NCT02737111|BEHAVIORAL|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
219261621|NCT02737111|BEHAVIORAL|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
219261622|NCT02737111|BEHAVIORAL|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
219261623|NCT02737111|BEHAVIORAL|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
219261624|NCT02737111|BEHAVIORAL|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
219261625|NCT01377168|DRUG|oral naltrexone|
219261626|NCT01377168|DRUG|Placebo pill|
219261627|NCT02901236|PROCEDURE|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
219261628|NCT02901236|DRUG|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
219261629|NCT02901236|DRUG|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
219261630|NCT06040047|OTHER|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
219261631|NCT06040047|OTHER|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
219261632|NCT03516045|DRUG|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
219261633|NCT05075512|DRUG|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
219261634|NCT02561806|DRUG|Ixekizumab|Administered SC
219261635|NCT02561806|DRUG|Ustekinumab|Administered SC
219261636|NCT02561806|DRUG|Placebo|Administered SC
219261637|NCT04314388|OTHER|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
219261638|NCT04314388|OTHER|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
219261639|NCT05887141|BEHAVIORAL|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
219261640|NCT05887141|BEHAVIORAL|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
219261641|NCT02062112|OTHER|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
219261642|NCT04038749|DRUG|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
219261643|NCT04038749|DRUG|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
219261644|NCT04038749|OTHER|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
219261645|NCT00941642|DRUG|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
219261646|NCT00941642|DRUG|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
219261647|NCT02547441|DRUG|CLS001 (Omiganan)|Topical gel
219261648|NCT02547441|DRUG|Vehicle|Vehicle Gel
219261649|NCT01427049|DEVICE|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
219261650|NCT04128800|DRUG|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
219261651|NCT01859611|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
219261652|NCT00229710|DRUG|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
219261653|NCT05739110|BEHAVIORAL|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
219261654|NCT04169451|DRUG|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
219261655|NCT01322009|DRUG|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
219261656|NCT01322009|DRUG|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
219261657|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
219261658|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
219261659|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
219261660|NCT01241006|DRUG|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
219261661|NCT01241006|DRUG|Prednisone|Prednisone 60mg PO q day for 5 days
219261662|NCT00905034|DRUG|Methotrexate|200 mg/m\^2 by vein on days 1 and 15.
219261663|NCT00905034|DRUG|Vincristine|1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
219261664|NCT00905034|DRUG|PEG-l-asparaginase|2500 International units/m\^2 by vein on days 2 and 16
219261665|NCT00905034|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
219261666|NCT00905034|DRUG|Rituximab|Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
219261667|NCT00004265|DRUG|paclitaxel|
219261668|NCT00394589|DRUG|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
219261669|NCT00394589|DRUG|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
219261670|NCT00394589|DRUG|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
219261671|NCT03707847|DRUG|Crizotinib|250mg, BID, PO
219261672|NCT03707847|DRUG|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
219261673|NCT03707847|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
219261674|NCT04081389|DRUG|Celecoxib|Given PO
219261675|NCT04081389|DRUG|Cyclophosphamide|Given IV
219261676|NCT04081389|DRUG|Doxorubicin|Given IV
219261677|NCT04081389|DRUG|Doxorubicin Hydrochloride|Given IV
219261678|NCT04081389|DRUG|Paclitaxel|Given IV
219261679|NCT04081389|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
219261680|NCT04081389|DRUG|Rintatolimod|Given IV
219261681|NCT02134366|DRUG|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
219261682|NCT02134366|DRUG|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
219261683|NCT02134366|DRUG|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
219261684|NCT01089309|DRUG|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
219261685|NCT02582385|OTHER|in-situ cytokine expression|
219261686|NCT02173145|DRUG|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
219261687|NCT02173145|DRUG|placebo|Placebo will be given 3 times a wek over a period of 3 months.
219261688|NCT04191876|OTHER|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
219261689|NCT05914415|OTHER|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
219261690|NCT03411993|DIAGNOSTIC_TEST|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
219261691|NCT01710800|DRUG|Esomeprazole|
219261692|NCT01710800|DRUG|placebo|
219261693|NCT00144846|DRUG|albuterol sulfate inhalation aerosol|
219261694|NCT00900783|DRUG|valacyclovir|1 gram, three times a day for seven days
219261695|NCT00900783|DRUG|FV-100|400 mg, once daily, for seven days
219261696|NCT00900783|DRUG|FV-100|200 mg, once daily, for seven days
219261697|NCT00900783|DRUG|Valacyclovir placebo|three times a day, for seven days
219261698|NCT00900783|DRUG|FV-100 placebo|once daily, for seven days
219261699|NCT00498095|PROCEDURE|Renal biopsy|
219261700|NCT02780505|DRUG|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
219261701|NCT02780505|DRUG|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
219261702|NCT03818243|BEHAVIORAL|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
219261703|NCT00830609|DRUG|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)
219261704|NCT00830609|DRUG|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks
219261705|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 24 weeks
219261706|NCT00830609|DRUG|ribavirin|ribavirin 800 mg/day for 24 weeks
219261707|NCT00830609|DRUG|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
219261708|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
219261709|NCT02108626|DRUG|Nicotine|E-Cigarette with nicotine cartridge
219261710|NCT02108626|DRUG|Placebo|E-Cigarette with 0mg nicotine cartridge
219261711|NCT02025855|DRUG|Methadone|
219261712|NCT02025855|DRUG|Placebo|
219261713|NCT01388062|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
219261714|NCT04777825|OTHER|Heart rate variability biofeedback training (Symbiocenter)|12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training
219261715|NCT04777825|OTHER|psychoeducation session|Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
219261716|NCT04982627|BEHAVIORAL|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
219261717|NCT04982627|BEHAVIORAL|OUD Education & Treatment Resources|The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
219261718|NCT00992719|BIOLOGICAL|Inactivated H1N1 Vaccine|H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
219261719|NCT05903677|OTHER|magnesium levels|Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
219261720|NCT04241783|OTHER|descriptive|correlation
219261721|NCT00257764|BEHAVIORAL|behavioral swallowing exercises/ strategies|
219261722|NCT00383864|DRUG|Pegylated interferon and ribavirin|
219261723|NCT02604797|DRUG|Nalbuphine|patient-controlled intravenous analgesia
219261724|NCT02604797|DRUG|Sufentanil|patient-controlled intravenous analgesia
219261725|NCT02604797|DRUG|flurbiprofen axetil|patient-controlled intravenous analgesia
219261726|NCT02604797|DRUG|ramosetron|patient-controlled intravenous analgesia
219261727|NCT02427958|DRUG|Leuprorelin|Suspension for injection.
219261728|NCT05863013|OTHER|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
219261729|NCT00322140|DRUG|CDDO|
219261730|NCT00001383|DRUG|PSC 833|
219261731|NCT00001383|DRUG|paclitaxel|
219261732|NCT00511797|DRUG|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
219261733|NCT00511797|DRUG|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
219261734|NCT00511797|DRUG|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
219261735|NCT00511797|DRUG|Placebo|Placebo
219261736|NCT00056329|DRUG|Vitamin E|1,000 international units twice daily for three years
219261737|NCT00056329|DRUG|multivitamin|once daily for three years
219261738|NCT00056329|DRUG|Placebo|Placebo twice daily for three years
219261739|NCT03974100|BIOLOGICAL|GP2411|60 mg /mL subcutaneous injection every 6 months
219261740|NCT03974100|BIOLOGICAL|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
219261741|NCT02941419|BIOLOGICAL|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
219261742|NCT01401036|DEVICE|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
219261743|NCT01401036|PROCEDURE|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
219261744|NCT04758546|DIAGNOSTIC_TEST|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
219261745|NCT00373022|BEHAVIORAL|exercise intervention|
219261746|NCT00373022|OTHER|flow cytometry|
219261747|NCT00373022|OTHER|laboratory biomarker analysis|
219261748|NCT00373022|PROCEDURE|management of therapy complications|
219261749|NCT00373022|PROCEDURE|psychosocial assessment and care|
219261750|NCT00373022|PROCEDURE|quality-of-life assessment|
219261751|NCT02236702|OTHER|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
219261752|NCT01009138|BEHAVIORAL|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement"
219261753|NCT01009138|BEHAVIORAL|Standard Diabetes Education|"Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
219261754|NCT04973514|PROCEDURE|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
219261755|NCT05557149|DEVICE|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
219261756|NCT05557149|BEHAVIORAL|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
219261757|NCT05557149|DEVICE|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
219261758|NCT04356625|DIAGNOSTIC_TEST|MEPic|"* patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
219261759|NCT01560871|BEHAVIORAL|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
219261760|NCT01560871|BEHAVIORAL|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
219261761|NCT05853692|DEVICE|Zinc Gluconate|Three times a day (spray)
219261762|NCT05853692|DEVICE|Sodium Bicarbonate|Five times a day (rinse)
219261763|NCT01010997|DEVICE|Foresee Home|using the Foresee home device
219261764|NCT00548002|DRUG|trovafloxacin and levofloxacin|Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
219261765|NCT00616330|DRUG|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
219261766|NCT00616330|DRUG|clindamycin phosphate|semi solid, single dose
219261767|NCT00616330|DRUG|butoconazole nitrate|semi solid, single dose
219261768|NCT03108976|OTHER|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
219261769|NCT03108976|OTHER|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
219261770|NCT03108976|OTHER|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
219261771|NCT05377645|OTHER|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
219261772|NCT03245177|BIOLOGICAL|Pembrolizumab|Anti-PD-1 antibody
219261773|NCT03245177|RADIATION|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
219261774|NCT04281693|DIAGNOSTIC_TEST|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
219261775|NCT04281693|DIAGNOSTIC_TEST|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
219261776|NCT01501227|DEVICE|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
219261777|NCT01501227|OTHER|Conventional endotracheal tube|Sham Comparator
219261778|NCT05217355|DRUG|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
219261779|NCT05217355|DRUG|Placebo|Placebo will be injected into the Glabellar line
219261780|NCT02958475|BEHAVIORAL|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
219261781|NCT02958475|BEHAVIORAL|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
219261782|NCT02958475|BEHAVIORAL|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
219261783|NCT05432700|OTHER|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
219261784|NCT03053635|DRUG|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
219261785|NCT02024750|BEHAVIORAL|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
219261786|NCT04807283|DEVICE|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
219261787|NCT00000636|DRUG|Isoniazid|
219261788|NCT00000636|DRUG|Pyrazinamide|
219261789|NCT00000636|DRUG|Pyridoxine hydrochloride|
219261790|NCT00000636|DRUG|Rifampin|
219261791|NCT03075098|DEVICE|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
219261792|NCT00998829|OTHER|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
219261793|NCT00702546|DRUG|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
219261794|NCT00702546|BIOLOGICAL|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
219261795|NCT00702546|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
219261796|NCT00702546|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
219261797|NCT00702546|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
219261798|NCT00702546|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
219261799|NCT00702546|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
219261800|NCT00702546|BIOLOGICAL|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
219261801|NCT03714542|OTHER|Pre- and postoperative MRI|
219261802|NCT02914171|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
219261803|NCT02914171|DEVICE|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
219261804|NCT01574014|BEHAVIORAL|CBGT|Cognitive-behavioral group therapy
219261805|NCT01574014|DRUG|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
219261806|NCT01574014|DRUG|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
219261807|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
219261808|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
219261809|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
219261810|NCT02083679|DRUG|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
219261811|NCT00159549|BEHAVIORAL|education and training program|
219261812|NCT00592735|PROCEDURE|laparoscopic gastric banding|standard surgical procedure
219261813|NCT00248079|DEVICE|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
219261814|NCT06170229|BEHAVIORAL|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
219261815|NCT06170229|BEHAVIORAL|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
219261816|NCT01849913|OTHER|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
219261817|NCT01849913|OTHER|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
219261818|NCT05980819|OTHER|Sustainability lecture and opportunity to create a project|Pure education
219261819|NCT02277392|BIOLOGICAL|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
219261820|NCT02277392|BIOLOGICAL|SB---485232 (Human recombinant Interleukin---18)|
219261821|NCT00934700|OTHER|Xenon gas|30% Xenon gas inhaled for 24 hours
219261822|NCT05027880|BEHAVIORAL|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
219261823|NCT00566345|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
219261824|NCT00566345|OTHER|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
219261825|NCT05182671|OTHER|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
219261826|NCT04133259|DRUG|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
219261827|NCT04133259|DRUG|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
219261828|NCT04364503|DEVICE|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
219261829|NCT03799354|OTHER|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
219261830|NCT03799354|OTHER|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
219261831|NCT02130271|DRUG|Radioactive dye|The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
219261832|NCT02130271|RADIATION|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
219261833|NCT02130271|OTHER|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
219261834|NCT04634812|DRUG|KBP-5074|a single oral dose of \[14C\]-KBP-5074
219261835|NCT06289855|OTHER|MDS-UPDRS|"Movement disorder society- unified Parkinson disease rating scale (MDS-UPDRS) for Parkinson's disease.~Movement disorder society- non motor rating scale (MDS-NMS) Cognitive assessment using Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog)~Using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale:~Timed up and go: originally aimed to clinically evaluate dynamic balance in elderly people during the performance of a task MR imaging of the brain will be performed with a 1.5T MR imaging scanner Assessment of Cortical excitability and unhibition by NIHON KOHDEN- neuropack2"
219261836|NCT02756299|OTHER|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
219261837|NCT02756299|OTHER|Standard Support|General information about OSA and PAP treatment at baseline
219261838|NCT06304597|DRUG|Imfinzi|Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
219261839|NCT06304597|DRUG|Opdivo|Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
219261840|NCT05320861|DRUG|[14C]SJP-0008|Single oral dose of \[14C\]SJP-0008
219261841|NCT03096977|DIAGNOSTIC_TEST|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
219261842|NCT03096977|DEVICE|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
219261843|NCT03096977|DEVICE|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
219261844|NCT03096977|DEVICE|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
219261845|NCT03096977|DEVICE|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
219261846|NCT04599387|OTHER|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
219261847|NCT04599387|OTHER|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
219261848|NCT02453477|GENETIC|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
219261849|NCT00498758|DEVICE|APOS System - biomechanical wedge shoe|
219261850|NCT06055972|OTHER|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~1. Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~2. Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~3. For patients with CAC\>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~4. Links to American Heart Association (AHA) and phone number for study research coordinator."
219261851|NCT03900715|DRUG|Luspatercept|Luspatercept
219261852|NCT02960256|DEVICE|ekocardiogram test|ekocardiogram test
219261853|NCT00092521|BIOLOGICAL|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
219261854|NCT00092521|BIOLOGICAL|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
219261855|NCT00092521|BIOLOGICAL|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
219261856|NCT03464383|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
219261857|NCT03464383|OTHER|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
219261858|NCT03464383|OTHER|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
219261859|NCT03304613|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
219261860|NCT03304613|BEHAVIORAL|Promoting Resilience through Innovative Self-Management|Already noted.
219261861|NCT06090175|OTHER|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
219261862|NCT06090175|OTHER|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
219261863|NCT04505345|BEHAVIORAL|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
219261864|NCT04505345|BEHAVIORAL|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
219261865|NCT05308277|DEVICE|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
219261866|NCT01921361|DRUG|Levobupivacaine|Intrathecal 3ml (15 mg)
219261867|NCT01921361|DRUG|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
219261868|NCT01921361|DRUG|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
219261869|NCT01921361|DRUG|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
219261870|NCT04361383|OTHER|control group|the patient will receive general anesthesia
219261871|NCT04361383|PROCEDURE|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
219261872|NCT04361383|PROCEDURE|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
219261873|NCT02332304|PROCEDURE|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
219261874|NCT00837590|DRUG|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
219261875|NCT00837590|DRUG|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
219261876|NCT05470270|DRUG|Hydroxycarbamide|Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
219261877|NCT01709396|RADIATION|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
219261878|NCT06465992|DRUG|Exparel 266 MG Per 20 ML Injection|20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
219261879|NCT06465992|DRUG|Bupivacaine Hcl 0.75% Inj|10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
219261880|NCT06465992|DRUG|Dexamethasone|1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
219261881|NCT03344016|OTHER|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
219261882|NCT06310083|PROCEDURE|Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy|The study's Participants Were Randomly classified in two groups Interventional Group, applied for Submucosal Resection Turbinoplasty and the controlled group who were applied for Partial Inferior Turbinectomy
219261883|NCT02895243|OTHER|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
219261884|NCT03353142|OTHER|Equal Breathing|"* Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
219261885|NCT03901443|OTHER|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
219261886|NCT06351462|OTHER|Spermogram|Spermogram will be proposed to men
219261887|NCT06351462|OTHER|Hospital Anxiety and Depression Scale (HADS)|Anxiety and depression will be evaluated 10 years after HSCT
219261888|NCT06351462|OTHER|SF36 Quality of life questionnaire|Quality of life will be evaluated 10 years after HSCT
219261889|NCT06351462|OTHER|Psychologist interview|During a follow-up visit
219261890|NCT06351462|OTHER|Optional sera banking|One in the study
219261891|NCT06351462|OTHER|Optional DNA banking|Once in the study
219261892|NCT03607617|OTHER|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
219261893|NCT03912974|DRUG|Escitalopram|see 'arm description'
219261894|NCT03912974|DRUG|Placebo oral capsule|see 'arm description'
219261895|NCT06198699|DIETARY_SUPPLEMENT|Jing Si Herbal Tea|Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water
219261896|NCT06198699|DIETARY_SUPPLEMENT|Barley Tea|Consuming Barley Tea for three months; twice per day with each time 600 ml barley tea consumption
219261897|NCT04710186|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
219261898|NCT00542932|OTHER|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
219261899|NCT02135822|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
219261900|NCT02135822|DRUG|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
219261901|NCT04317534|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
219261902|NCT04470843|DRUG|Acetazolamide|Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
219261903|NCT04470843|OTHER|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
219261904|NCT03953456|DRUG|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
219261905|NCT03953456|DRUG|Placebo|Placebo is a coated tablet for oral administration, once daily
219261906|NCT03550053|DEVICE|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
219261907|NCT05720377|DEVICE|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
219261908|NCT05158283|DEVICE|chocolate balloon|chocolate balloon dilatation
219261909|NCT05158283|DEVICE|plain balloon|plain balloon dilatation
219261910|NCT03080818|DIETARY_SUPPLEMENT|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
219261911|NCT03080818|OTHER|Placebo|2 placebo capsules per day for 90 days
219261912|NCT02161406|DRUG|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
219261913|NCT02161406|DRUG|Placebo|125 mg of Placebo
219261914|NCT01875341|DEVICE|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
219261915|NCT01875341|DEVICE|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
219261916|NCT05155891|DEVICE|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
219261917|NCT05155891|PROCEDURE|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
219261918|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
219261919|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
219261920|NCT02607202|DRUG|nab-paclitaxel|
219261921|NCT02607202|DRUG|Carboplatin|
219261922|NCT02607202|DRUG|Gemcitabine|
219261923|NCT01095159|DEVICE|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
219261924|NCT01095159|DEVICE|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
219261925|NCT05380128|GENETIC|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
219261926|NCT00097838|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
219261927|NCT00097838|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
219261928|NCT03271749|OTHER|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
219261929|NCT03458728|DRUG|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
219261930|NCT02077205|BEHAVIORAL|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
219261931|NCT00816647|PROCEDURE|Patellofemoral stabilizing surgery|Comparison of surgical techniques
219261932|NCT06547385|DRUG|ONO-4578|Specified dose on specified days
219261933|NCT06547385|DRUG|ONO-4538|Specified dose on specified days
219261934|NCT06547385|DRUG|Capecitabine|Specified dose on specified days
219261935|NCT06547385|DRUG|Oxaliplatin|Specified dose on specified days
219261936|NCT06547385|DRUG|Fluorouracil|Specified dose on specified days
219261937|NCT06547385|DRUG|Calcium Levofolinate Hydrateb|Specified dose on specified days
219261938|NCT06547385|DRUG|Bevacizumab|Specified dose on specified days
219261939|NCT03787420|OTHER|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
219261940|NCT00908349|DRUG|Oxcarbazepine XR|Open Label Study
219261941|NCT02459405|PROCEDURE|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
219261942|NCT02459405|DEVICE|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
219261943|NCT01097499|DEVICE|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
219261944|NCT03617068|DRUG|Cocos Nucifera Whole|Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
219261945|NCT03617068|DRUG|Cocos Nucifera Whole|For dermatopharmacokinetic evaluation using tape/ skin stripping
219261946|NCT00458354|DEVICE|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
219261947|NCT00458354|PROCEDURE|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
219261948|NCT02813083|OTHER|No intervention (observational)|No intervention (observational)
219261949|NCT04028817|DEVICE|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
219261950|NCT04028817|DEVICE|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
219261951|NCT06424730|OTHER|Feasibility Interview|One audio-recorded interview with the participants lasting about 30-minutes
219261952|NCT06424730|BEHAVIORAL|Team Based Equity Conscious Telemedicine Hypertension Intervention|Will provide blood pressure monitor connected to a telehealth application. Patients will be asked to measure home blood pressure once daily. Will intensify medications as needed based on blood pressure measurement. Trained nurses or pharmacists will provide 4 self-management telephone calls (up to 30 minutes per call) to patients to address hypertension knowledge, medication adherence, healthy eating, physical activity, weight management, stress management, tobacco and alcohol use, and sleep apnea (with referrals if needed). Will support needs relevant in blood pressure control using locally available resources via community health worker and social workers.
219261953|NCT06424730|BEHAVIORAL|Usual Care|Usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
219261954|NCT06956820|DEVICE|Medication Management Center|The MMC that provides patient centred information on drug-drug interactions and pharmaco-genetics affecting personal polytherapy. The MMC will show a selection of high quality publicly available information such as details on different types of medications, including their uses, side effects and instructions for use, in the language of the patient. This information is targeted at an individual patient's medication profile to inform patients to better understand and deal with their personal health information, with regard to drug therapy. Patients in the Netherlands, Slovenia and Greece also will receive their PGx profile to further personalise the MMC experience.
219261955|NCT06956196|BIOLOGICAL|Stapokibatrt|Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)
219261956|NCT06956196|OTHER|Placebo|Placebo of matching volume，Subcutaneous injection(SC)
219261957|NCT06957470|PROCEDURE|Total Intravenous Anesthesia|It is a general anesthesia technique performed through a combination of intravenous agents administered intravenously by various methods.
219261958|NCT03099408|DRUG|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
219261959|NCT03099408|DRUG|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
219261960|NCT01741389|DRUG|"Melatonin (Circadin)"|
219261961|NCT01452737|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
219261962|NCT01452737|DRUG|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
219261963|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
219261964|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
219261965|NCT03448705|BIOLOGICAL|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
219261966|NCT06957093|OTHER|artificial intelligence|The platform will also monitor the medical and lifestyle data of the patients every two weeks,offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform.
219261967|NCT06957093|OTHER|Routine diagnosis and treatment group for diabetes|There is no limit to the number of outpatient visits for the control group; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team (endocrinologist and nutritionist) objectively conducttheir diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.
219261968|NCT00362375|BEHAVIORAL|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
219261969|NCT00362375|BEHAVIORAL|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
219261970|NCT06469567|OTHER|Patient Counselling|Doctor's counselling using Culturally-responsive pamphlet
219261971|NCT06956898|OTHER|Mindfulness Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
219261972|NCT06956898|OTHER|Haptonomy Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
219261973|NCT06399991|BEHAVIORAL|Champion strategy|The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
219261974|NCT06399991|BEHAVIORAL|Adapted LOCI leadership and climate alignment strategy plus champion strategy|The LOCI strategy involves engaging with district health leadership through data and feedback, leadership development trainings, coaching, and alignment strategy activities to align leadership and climate in support of implementing the evidence-based mental health package. The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
219261975|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
219261976|NCT02948569|DRUG|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
219261977|NCT04668365|DRUG|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
219261978|NCT04668365|DRUG|Zanubrutinib|160mg twice daily continuous oral administration.
219261979|NCT04668365|DRUG|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219261980|NCT04668365|DRUG|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219261981|NCT04668365|DRUG|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219261982|NCT04668365|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
219261983|NCT01009762|BIOLOGICAL|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
219261984|NCT00244907|DIETARY_SUPPLEMENT|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
219261985|NCT02995382|PROCEDURE|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
219261986|NCT02624869|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219261987|NCT02341586|OTHER|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
219261988|NCT02341586|DIETARY_SUPPLEMENT|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
219261989|NCT02341586|OTHER|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
219261990|NCT01620970|DRUG|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
219261991|NCT05305677|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
219261992|NCT05305677|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
219261993|NCT00812721|OTHER|Preservative Free Saline|One drop will be instilled into each eye once
219261994|NCT00812721|OTHER|Optive|One drop will be instilled into each eye once
219261995|NCT00812721|OTHER|Refresh Moderate/Severe|One drop will be instilled into each eye once
219261996|NCT00812721|OTHER|Systane|One drop will be instilled into each eye once
219261997|NCT00812721|OTHER|Systane Ultra|One drop will be instilled into each eye once
219261998|NCT00163007|PROCEDURE|Nutritional support|
219261999|NCT03917537|GENETIC|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
219262000|NCT00514800|BEHAVIORAL|Intervention - a validated home BP monitor and support from the specialist nurse|
219262001|NCT00514800|BEHAVIORAL|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
219262002|NCT06114485|BEHAVIORAL|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
219262003|NCT06114485|BEHAVIORAL|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
219262004|NCT03204500|COMBINATION_PRODUCT|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
219262005|NCT03204500|DRUG|Placebos|Administered orally under the same conditions
219262006|NCT01626729|BEHAVIORAL|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
219262007|NCT01626729|BEHAVIORAL|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
219262008|NCT01626729|BEHAVIORAL|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
219262009|NCT01626729|BEHAVIORAL|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
219262010|NCT01626729|BEHAVIORAL|No label control group|No label control group
219262011|NCT02703753|BEHAVIORAL|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
219262012|NCT03277677|DRUG|Normal saline|for resuscitation in sepsis patients
219262013|NCT03277677|DRUG|Ringer's Acetate|for resuscitation in sepsis patients
219262014|NCT06553807|OTHER|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
219262015|NCT05264272|OTHER|Prospective serological assays|"1. Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~2. BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
219262016|NCT05264272|OTHER|Retrospective serological assays|"1. Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~2. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
219262017|NCT05897528|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
219262018|NCT01913899|OTHER|Occupational/ physical therapy|
219262019|NCT01913899|OTHER|Mirror therapy|\- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
219262020|NCT00694798|BIOLOGICAL|Mycobacterium w|Immunomodulator
219262021|NCT04949854|DEVICE|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
219262022|NCT04949854|DEVICE|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
219262023|NCT04331132|DRUG|Tolvaptan 15 MG|vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
219262024|NCT01377792|DRUG|Hypertonic saline|comparison of different dosages of drug
219262025|NCT04291209|DRUG|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
219262026|NCT02148510|DEVICE|Monobloc|Construction fitted to upper and lower jaw
219262027|NCT02148510|DEVICE|Bibloc|Biblock construction
219262028|NCT03234998|DEVICE|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
219262029|NCT03234998|DEVICE|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
219262030|NCT01520337|DEVICE|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
219262031|NCT05328024|DRUG|Immunotherapy|anti-PD1
219262032|NCT01354249|DIETARY_SUPPLEMENT|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
219262033|NCT02582268|DEVICE|intrauterine device TCu 380A|
219262034|NCT02582268|RADIATION|Trans-abdominal sonography|
219262035|NCT04582305|DRUG|Bleomycin|Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
219262036|NCT04582305|DRUG|Normal saline|Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
219262037|NCT04208347|DRUG|Apatinib 250mg|Apatinib 250mg
219262038|NCT04208347|DRUG|Camrelizumab|Camrelizumab 200mg
219262039|NCT04208347|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
219262040|NCT04208347|DRUG|Apatinib 500mg|Apatinib 500mg
219262041|NCT02226497|DEVICE|Health Telemonitoring|Use home telemonitoring device
219262042|NCT02226497|OTHER|Quality-of-Life Assessment|Ancillary studies
219262043|NCT02226497|OTHER|Questionnaire Administration|Ancillary studies
219262044|NCT02226497|PROCEDURE|Supportive Care|Receive standard outpatient supportive care
219262045|NCT03962517|DEVICE|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
219262046|NCT03962517|OTHER|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
219262047|NCT01649505|DRUG|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
219262048|NCT01649505|PROCEDURE|breast reconstruction|Undergo sharp dissection technique
219262049|NCT01649505|PROCEDURE|breast reconstruction|Undergo electrocoagulation dissection technique
219262050|NCT06235853|DIAGNOSTIC_TEST|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
219262051|NCT06235853|DIAGNOSTIC_TEST|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
219262052|NCT02440737|OTHER|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
219262053|NCT02440737|OTHER|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
219262054|NCT02440737|PROCEDURE|Psychosocial Assessment and Care|Undergo the NEST intervention
219262055|NCT02440737|OTHER|Questionnaire Administration|Ancillary studies
219262056|NCT00171366|DRUG|amlodipine/benazepril|
219262057|NCT06483685|DRUG|Radiopharmaceuticals drugs|radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
219262058|NCT05470959|OTHER|ACTIVA bioactive|bioactive ionic resin composite
219262059|NCT05470959|OTHER|Riva LC|resin-modified glass ionomer
219262060|NCT01085812|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
219262061|NCT01085812|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily.
219262062|NCT02953028|DEVICE|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
219262063|NCT02953028|DEVICE|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
219262064|NCT01172639|DRUG|Methotrexate|Methotrexate tablet
219262065|NCT01172639|DRUG|Sulfasalazine|Sulfasalazine tablet
219262066|NCT01172639|DRUG|Leflunomide|Leflunomide tablet
219262067|NCT01172639|DRUG|Prednisone|Prednisone tablet
219262068|NCT01516853|DEVICE|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
219262069|NCT03500666|DEVICE|Robot|Robot lateral neck lymph node dissection
219262070|NCT03500666|DEVICE|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
219262071|NCT00469456|DRUG|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
219262072|NCT00469456|DRUG|placebo|Placebo oral administration twice daily for 12 weeks
219262073|NCT04367077|BIOLOGICAL|MultiStem|intravenous infusion
219262074|NCT04367077|BIOLOGICAL|Placebo|intravenous infusion
219262075|NCT03565692|BIOLOGICAL|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR"
219262076|NCT03565692|BIOLOGICAL|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
219262077|NCT01136447|PROCEDURE|Ultrasound|Block catheter will be introduced using ultraosound
219262078|NCT03453203|OTHER|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
219262079|NCT05307263|PROCEDURE|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
219262080|NCT05307263|PROCEDURE|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
219262081|NCT03336697|DIAGNOSTIC_TEST|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
219262082|NCT02316288|BEHAVIORAL|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
219262083|NCT02316288|BEHAVIORAL|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
219262084|NCT00791739|DRUG|trazodone, pregabalin|"* phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
219262085|NCT00910325|PROCEDURE|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
219262086|NCT04988399|OTHER|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
219262087|NCT01113671|DRUG|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
219262088|NCT01113671|DRUG|Placebo|includes inactive Ingredients
219262089|NCT03634839|DRUG|Flavoring Agents|Flavor of e-liquid - sweet or tobacco
219262090|NCT03634839|DRUG|Nicotine|Nicotine level (36 mg/ml)
219262091|NCT05969405|PROCEDURE|Laparoscopic staging|Laparoscopic staging
219262092|NCT05969405|PROCEDURE|Robotic staging|Robotic staging
219262093|NCT05969405|PROCEDURE|Laparotomic staging|Laparotomic staging
219262094|NCT02571998|DRUG|Omiganan (CLS001) Topical Gel|
219262095|NCT02571998|DRUG|Vehicle Topical Gel|
219262096|NCT04198948|DRUG|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
219262097|NCT04198948|DRUG|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
219262098|NCT04198948|DRUG|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
219262099|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
219262100|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
219262101|NCT02447432|BIOLOGICAL|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
219262102|NCT00913068|PROCEDURE|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
219262103|NCT00913068|PROCEDURE|standard post op pain control|opiates
219262104|NCT00302159|PROCEDURE|adjuvant therapy|
219262105|NCT00302159|DRUG|Temozolomide|Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
219262106|NCT00302159|DRUG|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
219262107|NCT00302159|RADIATION|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
219262108|NCT02794714|DRUG|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
219262109|NCT02794714|DRUG|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
219262110|NCT02928471|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
219262111|NCT02815059|DRUG|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
219262112|NCT02815059|DRUG|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
219262113|NCT02815059|DRUG|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
219262114|NCT02125136|DRUG|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
219262115|NCT02125136|DRUG|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
219262116|NCT05195892|DRUG|Treatment A|Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
219262117|NCT05195892|DRUG|Treatment B|Single oral dose of alpelisib granule at 50 mg in fed state
219262118|NCT05195892|DRUG|Treatment C|Single oral dose of alpelisib granule at 50 mg in fasted state
219262119|NCT03413215|BEHAVIORAL|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
219262120|NCT00470405|DRUG|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
219262121|NCT00470405|DRUG|pemetrexed disodium|a novel antifolate with multiple targets.
219262122|NCT03789812|DEVICE|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
219262123|NCT03789812|DEVICE|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
219262124|NCT03789812|DEVICE|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
219262125|NCT03789812|DEVICE|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
219262126|NCT06456086|BIOLOGICAL|stimulation with EB virus|stimulation with EB virus
219262127|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
219262128|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
219262129|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
219262130|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
219262131|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
219262132|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
219262133|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
219262134|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
219262135|NCT03626831|DRUG|Evolocumab Prefilled Syringe|Injection of study drug
219262136|NCT03626831|DRUG|Placebos|Injection of placebo
219262137|NCT00726713|OTHER|Metanx (a medical food)|Metanx one tablet twice a day
219262138|NCT00726713|OTHER|Metanx placebo|Metanx placebo one tablet twice a day
219262139|NCT02367105|DRUG|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
219262140|NCT02367105|OTHER|Lifestyle Therapy|Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
219262141|NCT02367105|DRUG|Placebo|Placebo gel for testosterone
219262142|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
219262143|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
219262144|NCT02684799|DRUG|Cenicriviroc|
219262145|NCT02684799|DRUG|Omeprazole|
219262146|NCT02684799|DRUG|Famotidine|
219262147|NCT03840109|BEHAVIORAL|Questionnaire 1a|Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262148|NCT03840109|BEHAVIORAL|Questionnaire 1b|Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262149|NCT03840109|BEHAVIORAL|Questionnaire 2a|Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262150|NCT03840109|BEHAVIORAL|Questionnaire 2b|Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262151|NCT03840109|BEHAVIORAL|Questionnaire 3a|Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262152|NCT03840109|BEHAVIORAL|Questionnaire 3b|Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262153|NCT03840109|BEHAVIORAL|Questionnaire 4a|Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262154|NCT03840109|BEHAVIORAL|Questionnaire 4b|Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
219262155|NCT01743105|PROCEDURE|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
219262156|NCT01743105|PROCEDURE|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
219262157|NCT06015906|DEVICE|Plenum® Guide|Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.
219262158|NCT06015906|DEVICE|Plenum® Oss|Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.
219262159|NCT06015906|PROCEDURE|Tooth extraction|Tooth extraction and subsequent surgical procedure of guided bone regeneration.
219262160|NCT03961997|DRUG|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
219262161|NCT03961997|DRUG|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
219262162|NCT03961997|DRUG|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
219262163|NCT06511375|OTHER|sprint training|sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
219262164|NCT06511375|OTHER|Power Training|"GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week."
219262165|NCT04811898|BIOLOGICAL|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
219262166|NCT05073549|BEHAVIORAL|Collaborative Antimicrobial Stewardship Program (ASP)|"The collaborative ASP interventions will be implemented from October 1st, 2021 to September 30th, 2023 in all participating NICUs.~The collaborative ASP interventions include two levels of interventions that will be delivered at the NICU level: the NICU-targeted ASP program and collaborative quality improvement interventions to facilitate implementation of the ASP.~The core elements of the NICU-targeted ASP program include the establishment of ú ASP leader and team, development of the facility-specific antibiotic guidelines, checklist-led audit and feedback, and staff education.~The collaborative quality improvement interventions include data feedback and benchmarking, a potential 'better practice' list on neonatal antibiotic use, implementation using Plan-Do-Study-Act cycles and collaborative learning."
219262167|NCT05477303|OTHER|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
219262168|NCT02835092|OTHER|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
219262169|NCT02835092|OTHER|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
219262170|NCT02835092|OTHER|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
219262171|NCT03530462|DRUG|rituximab|375 mg/m2 weekly for 4 weeks
219262172|NCT03530462|DRUG|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
219262173|NCT03530462|DRUG|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
219262174|NCT03530462|DRUG|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
219262175|NCT04312412|PROCEDURE|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
219262176|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
219262177|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
219262178|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
219262179|NCT01582503|DRUG|placebo|Subcutaneous repeating dose
219262180|NCT05603065|DRUG|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m\^2D1 + paclitaxel 150mg/m\^2D1 Q3W 3 cycles
219262181|NCT05603065|DRUG|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
219262182|NCT03197077|PROCEDURE|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
219262183|NCT03197077|PROCEDURE|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
219262184|NCT03197077|PROCEDURE|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
219262185|NCT03197077|DRUG|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
219262186|NCT03197077|DRUG|Follitropin beta|Daily injection (three days) of follitropin beta
219262187|NCT03197077|DRUG|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
219262188|NCT05383625|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
219262189|NCT05383625|DRUG|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
219262190|NCT05383625|DRUG|Saline|intralesional into the largest warts every two weeks
219262191|NCT00047749|DRUG|Prialt (ziconotide)|
219262192|NCT03630263|OTHER|Raw Corn Starch|Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
219262193|NCT03630263|OTHER|No Raw Corn Starch|200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
219262194|NCT04805047|BEHAVIORAL|education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
219262195|NCT02767609|DEVICE|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
219262196|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
219262197|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
219262198|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
219262199|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
219262200|NCT06311643|OTHER|Postpartum back massage in study group|Effleurage massage from shoulders toward lower back
219262201|NCT04055415|BIOLOGICAL|adipose derived mesenchymal stem cells|The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
219262202|NCT04055415|DRUG|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
219262203|NCT03449862|OTHER|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
219262204|NCT05765747|DRUG|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
219262205|NCT05765747|DRUG|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
219262206|NCT00458146|DRUG|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
219262207|NCT02671214|OTHER|Control|100 g high fibre flour
219262208|NCT02671214|OTHER|Active 2|98 g high fibre flour + 2 g guar gum
219262209|NCT02671214|OTHER|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
219262210|NCT02671214|OTHER|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
219262211|NCT02671214|OTHER|Active 5|96 g high fibre flour + 4 g guar gum
219262212|NCT02671214|OTHER|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
219262213|NCT02671214|OTHER|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
219262214|NCT02671214|OTHER|Active 8|94 g high fibre flour + 6 g guar gum
219262215|NCT02671214|OTHER|Active 9|98 g high fibre flour + 2 g konjac mannan
219262216|NCT02671214|OTHER|Active 10|96 g high fibre flour + 4 g konjac mannan
219262217|NCT02671214|OTHER|Active 11|100 g low fibre flour
219262218|NCT02671214|OTHER|Active 1|85 g high fibre flour + 15 g legume flour
219262219|NCT02735590|DRUG|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
219262220|NCT02735590|DRUG|Rifapentine|Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
219262221|NCT05573100|DRUG|CU06-1004|CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
219262222|NCT01657877|DRUG|Calcium sodium phosphosilicate|CSP high percentage weight by weight
219262223|NCT01657877|DRUG|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
219262224|NCT01657877|DRUG|Placebo|No CSP and no fluoride
219262225|NCT01532635|RADIATION|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
219262226|NCT01532635|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
219262227|NCT01532635|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
219262228|NCT01532635|DRUG|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
219262229|NCT01532635|DRUG|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
219262230|NCT01532635|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
219262231|NCT06428877|OTHER|analyzed on the post-operative scanner|analyzed on the post-operative scanner
219262232|NCT05209724|BEHAVIORAL|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
219262233|NCT01114672|DRUG|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
219262234|NCT01114672|DRUG|Placebo|oral placebo once weekly
219262235|NCT04693910|OTHER|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
219262236|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
219262237|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
219262238|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
219262239|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
219262240|NCT03371745|PROCEDURE|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
219262241|NCT03371745|PROCEDURE|Cryopreservation|Rapid freezing using vitrification
219262242|NCT03371745|PROCEDURE|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
219262243|NCT01135082|BIOLOGICAL|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
219262244|NCT06226298|DEVICE|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
219262245|NCT06226298|BEHAVIORAL|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
219262246|NCT03304756|DRUG|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
219262247|NCT03091582|BEHAVIORAL|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
219262248|NCT03091582|BEHAVIORAL|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
219262249|NCT03091582|BEHAVIORAL|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
219262250|NCT00934414|DRUG|Technosphere Insulin Inhalation Powder|30U
219262251|NCT00341471|PROCEDURE|Risk Behavior Prevention Intervention Program|
219262252|NCT04520074|DRUG|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
219262253|NCT01672593|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
219262254|NCT01672593|DRUG|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
219262255|NCT01672593|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
219262256|NCT01672593|PROCEDURE|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
219262257|NCT04240236|PROCEDURE|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
219262258|NCT04240236|OTHER|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
219262259|NCT04745936|OTHER|Style curve similar to natural curvature of endotracheal tube|Stylet curvature is made similar to the natural curvature of endotracheal tube for intubation using C-MAC videolaryngoscope.
219262260|NCT04745936|OTHER|Style curve similar to hockey stick shape|Stylet curvature is made similar to hockey stick shape for intubation using C-MAC videolaryngoscope.
219262261|NCT00696553|OTHER|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
219262262|NCT00696553|BEHAVIORAL|Nutrition plus Exercise|Nutrition plus Exercise
219262263|NCT04383145|DEVICE|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
219262264|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-PreF-A vaccine|B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
219262265|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-F-B365 vaccine|B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
219262266|NCT06546423|DRUG|Placebo|Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
219262267|NCT05143112|BIOLOGICAL|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
219262268|NCT00639899|PROCEDURE|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
219262269|NCT01756144|DEVICE|rhBMP-2|
219262270|NCT00329563|DRUG|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
219262271|NCT03451409|OTHER|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
219262272|NCT03451409|OTHER|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
219262273|NCT04216485|BEHAVIORAL|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
219262274|NCT04216485|BEHAVIORAL|Standard Care|Standard prenatal care on diet, nutrition and physical activity
219262275|NCT00196534|DRUG|Human Thrombin|
219262276|NCT00196534|DRUG|Bovine Thrombin|
219262277|NCT01423708|DRUG|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
219262278|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
219262279|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
219262280|NCT04770909|BEHAVIORAL|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
219262281|NCT04721288|OTHER|Active communication through Reboot application|Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
219262282|NCT04721288|OTHER|Generic communication through Reboot application|Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
219262283|NCT03094962|OTHER|Motion capture|Capture kinematics of finger movements
219262284|NCT03094962|DIAGNOSTIC_TEST|MR scan|Capture MR images of hand and fingers in three postures
219262285|NCT03094962|DIAGNOSTIC_TEST|CT scan|Capture CT images of hand and fingers in three postures
219262286|NCT05072262|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml
219262287|NCT05072262|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex)
219262288|NCT04400344|OTHER|No intervention|No intervention
219262289|NCT05132855|BIOLOGICAL|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
219262290|NCT05132855|BIOLOGICAL|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
219262291|NCT05132855|BIOLOGICAL|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
219262292|NCT04131010|DEVICE|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
219262293|NCT04707456|OTHER|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
219262294|NCT06115239|OTHER|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
219262295|NCT06072963|DRUG|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
219262296|NCT06072963|DRUG|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
219262297|NCT06072963|OTHER|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
219262298|NCT06072963|OTHER|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
219262299|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
219262300|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
219262301|NCT04545476|OTHER|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
219262302|NCT04545476|OTHER|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
219262303|NCT03143296|OTHER|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
219262304|NCT04161547|DRUG|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
219262305|NCT04161547|DRUG|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
219262306|NCT04161547|DRUG|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
219262307|NCT04161547|DRUG|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
219262308|NCT03904875|OTHER|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
219262309|NCT06478810|OTHER|Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy|For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
219262310|NCT04620031|DRUG|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
219262311|NCT04620031|DRUG|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
219262312|NCT06479200|BEHAVIORAL|VR-guided mindfulness|The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.
219262313|NCT06479200|OTHER|Sham VR|The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
219262314|NCT04827186|PROCEDURE|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
219262315|NCT02186314|DEVICE|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
219262316|NCT02186314|DEVICE|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
219262317|NCT02206945|BEHAVIORAL|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
219262318|NCT02206945|BEHAVIORAL|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
219262319|NCT02768077|DRUG|Melatonin(Circadin®)|
219262320|NCT02768077|DRUG|Placebo|
219262321|NCT04024514|OTHER|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
219262322|NCT04024514|OTHER|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
219262323|NCT05297253|DEVICE|telescopic overdenture|fixed implant retained prostheses
219262324|NCT04237714|BEHAVIORAL|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
219262325|NCT01980524|DRUG|acipimox|
219262326|NCT01980524|DRUG|Placebo Oral Capsule|
219262327|NCT00114543|PROCEDURE|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
219262328|NCT00114543|PROCEDURE|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
219262329|NCT00114543|PROCEDURE|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
219262330|NCT00114543|PROCEDURE|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
219262331|NCT02878421|DEVICE|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
219262332|NCT02878421|OTHER|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
219262333|NCT02878421|OTHER|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
219262334|NCT03440983|DEVICE|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
219262335|NCT00680147|BEHAVIORAL|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
219262336|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
219262337|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
219262338|NCT02169921|DEVICE|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
219262339|NCT00690378|DRUG|NXL104/ceftazidime|125mg/500mg TID
219262340|NCT00690378|DRUG|Imipenem/Cilastatin|4 x daily
219262341|NCT02044614|OTHER|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
219262342|NCT02019641|OTHER|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
219262343|NCT02019641|OTHER|Education|Weekly education
219262344|NCT03318783|DRUG|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
219262345|NCT03318783|DRUG|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
219262346|NCT02238964|DEVICE|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
219262347|NCT02238964|PROCEDURE|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
219262348|NCT01246050|OTHER|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
219262349|NCT01246050|OTHER|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
219262350|NCT00001677|DRUG|Methotrexate|
219262351|NCT00001677|DRUG|Fludarabine|
219262352|NCT04019249|BEHAVIORAL|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
219262353|NCT02949232|DRUG|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
219262354|NCT02949232|DRUG|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
219262355|NCT01355822|DRUG|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
219262356|NCT01355822|DRUG|Placebo control|orally, twice daily
219262357|NCT01335321|DRUG|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
219262358|NCT01335321|DRUG|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
219262359|NCT04560023|OTHER|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
219262360|NCT03271177|DEVICE|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
219262361|NCT03271177|DEVICE|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
219262362|NCT01051102|DRUG|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
219262363|NCT01051102|DRUG|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
219262364|NCT03410108|DRUG|Brigatinib|Brigatinib tablet
219262365|NCT05426161|DRUG|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
219262366|NCT00216957|PROCEDURE|Coronary bypass surgery without cardiopulmonary bypass|
219262367|NCT03398421|DRUG|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
219262368|NCT03398421|DRUG|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
219262369|NCT01154270|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
219262370|NCT06173232|DEVICE|Camera Imaging|Camera Imaging
219262371|NCT05644535|DIAGNOSTIC_TEST|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
219262372|NCT05644535|DIAGNOSTIC_TEST|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
219262373|NCT05644535|DIAGNOSTIC_TEST|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
219262374|NCT05269927|DIAGNOSTIC_TEST|EEG|resting state EEG
219262375|NCT05269927|DIAGNOSTIC_TEST|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
219262376|NCT05269927|DIAGNOSTIC_TEST|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
219262377|NCT05269927|OTHER|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
219262378|NCT02878460|OTHER|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
219262379|NCT02878460|OTHER|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
219262380|NCT01463514|PROCEDURE|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
219262381|NCT01463514|PROCEDURE|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
219262382|NCT03770052|DRUG|duvie|take the intervention drug once daily according to the randomized groups
219262383|NCT02801409|DRUG|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
219262384|NCT02801409|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
219262385|NCT05689281|BEHAVIORAL|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
219262386|NCT04006236|OTHER|Experimental Infant Formula|Feed Ad Libitum
219262387|NCT04006236|OTHER|Control Infant Formula|Feed Ad Libitum
219262388|NCT04593706|DRUG|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
219262389|NCT04593706|DRUG|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
219262390|NCT04593706|DRUG|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
219262391|NCT04593706|DRUG|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
219262392|NCT06406998|OTHER|Pre-existing atherosclerotic cardiovascular disease|Presence of pre-existing atherosclerotic cardiovascular disease
219262393|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
219262394|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
219262395|NCT04650659|DIAGNOSTIC_TEST|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
219262396|NCT04650659|DIAGNOSTIC_TEST|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
219262397|NCT04650659|DIAGNOSTIC_TEST|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
219262398|NCT04650659|DIAGNOSTIC_TEST|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
219262399|NCT04650659|DIAGNOSTIC_TEST|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
219262400|NCT04650659|DIAGNOSTIC_TEST|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
219262401|NCT03420261|BIOLOGICAL|0.9% saline|Fluid administration
219262402|NCT03420261|BIOLOGICAL|HES 130/0.4|Fluid administration
219262403|NCT04647305|OTHER|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
219262404|NCT04647305|OTHER|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
219262405|NCT03100864|DRUG|Spesolimab|12 weeks treatment
219262406|NCT02415283|DEVICE|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
219262407|NCT05808855|PROCEDURE|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
219262408|NCT05808855|PROCEDURE|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
219262409|NCT02101658|OTHER|clinic-based weight measurements|
219262410|NCT05810441|OTHER|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
219262411|NCT01648036|DRUG|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
219262412|NCT01648036|DRUG|Dalteparin|Dose 5000 IU, subcutaneous, daily
219262413|NCT04469062|DRUG|Mirikizumab IV|Administered IV
219262414|NCT04469062|DRUG|Mirikizumab SC|Administered SC
219262415|NCT04469062|DRUG|Vedolizumab IV|Administered IV
219262416|NCT04469062|DRUG|Placebo IV|Administered IV
219262417|NCT04469062|DRUG|Placebo SC|Administered SC
219262418|NCT02277197|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
219262419|NCT02277197|DRUG|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
219262420|NCT02749136|DRUG|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
219262421|NCT06471907|PROCEDURE|erector spinae plane block|fascial plane injection using ultrasound
219262422|NCT05612841|OTHER|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
219262423|NCT04035577|BEHAVIORAL|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
219262424|NCT00639314|PROCEDURE|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
219262425|NCT00639314|PROCEDURE|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
219262426|NCT01233414|BEHAVIORAL|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
219262427|NCT01233414|OTHER|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
219262428|NCT02056002|OTHER|Usual Care|\- Standard CPAP educational training
219262429|NCT02056002|OTHER|Peer-Buddy System|"* Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~\- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy"
219262430|NCT02056002|OTHER|Usual Care|\- Educational Brochures
219262431|NCT02056002|OTHER|Usual Care|\- Educational DVD videos mailed to participant
219262432|NCT03269695|DRUG|PF-06687234|SC QW
219262433|NCT03269695|DRUG|Placebo|SC QW
219262434|NCT05413837|DIAGNOSTIC_TEST|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
219262435|NCT05413837|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
219262436|NCT02591862|DRUG|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
219262437|NCT00705562|OTHER|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
219262438|NCT00104637|DRUG|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
219262439|NCT00104637|DRUG|Placebo|25 mg po tid
219262440|NCT01313624|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
219262441|NCT01313624|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
219262442|NCT00505414|DRUG|Tapentadol in the Titration Phase|
219262443|NCT00505414|DRUG|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
219262444|NCT00505414|DRUG|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
219262445|NCT00505414|DRUG|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
219262446|NCT00505414|DRUG|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
219262447|NCT04660578|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
219262448|NCT01619462|BIOLOGICAL|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
219262449|NCT02715427|OTHER|Conventional care|
219262450|NCT02715427|OTHER|Enhanced recovery|
219262451|NCT03411798|DRUG|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
219262452|NCT02931578|OTHER|Glucose100|
219262453|NCT02931578|OTHER|Glucose50|
219262454|NCT02931578|OTHER|Glucose42|
219262455|NCT02931578|OTHER|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
219262456|NCT04012658|OTHER|No intervention|No intervention
219262457|NCT00846768|DRUG|BI 1744 CL|
219262458|NCT00527150|DRUG|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
219262459|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
219262460|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
219262461|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
219262462|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
219262463|NCT05060835|OTHER|Virtual assistants offering medical recommendations to health care profesionals|the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
219262464|NCT05318235|OTHER|No intervention|No intervention
219262465|NCT00746109|PROCEDURE|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
219262466|NCT00746109|PROCEDURE|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
219262467|NCT04158271|DEVICE|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
219262468|NCT04158271|DEVICE|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
219262469|NCT04158271|DEVICE|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
219262470|NCT02187289|DEVICE|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
219262471|NCT02187289|DEVICE|Compression Sleeve, daytime wear|
219262472|NCT02187289|DEVICE|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
219262473|NCT01003262|OTHER|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
219262474|NCT01003262|OTHER|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
219262475|NCT03591627|DIAGNOSTIC_TEST|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
219262476|NCT00644878|DRUG|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
219262477|NCT01328210|PROCEDURE|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
219262478|NCT00630136|BEHAVIORAL|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
219262479|NCT02625753|DRUG|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
219262480|NCT02625753|DRUG|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
219262481|NCT02625753|DRUG|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
219262482|NCT05879562|DIAGNOSTIC_TEST|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
219262483|NCT04389346|PROCEDURE|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
219262484|NCT04389346|PROCEDURE|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
219262485|NCT00948610|DRUG|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
219262486|NCT05549167|DRUG|Sirolimus|Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
219262487|NCT04310176|DRUG|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
219262488|NCT04310176|DRUG|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
219262489|NCT04310176|DRUG|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
219262490|NCT04310176|DRUG|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
219262491|NCT04310176|DRUG|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
219262492|NCT04310176|DRUG|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
219262493|NCT01395511|DEVICE|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
219262494|NCT02649361|DRUG|Anlotinib|Anlotinib p.o. qd
219262495|NCT02649361|DRUG|Placebo|Placebo p.o. qd
219262496|NCT03121612|DEVICE|CPAP|CPAP therapy
219262497|NCT03889054|BEHAVIORAL|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
219262498|NCT00591591|DEVICE|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
219262499|NCT00579449|BEHAVIORAL|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
219262500|NCT00579449|BEHAVIORAL|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
219262501|NCT05028946|DRUG|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
219262502|NCT02085902|DRUG|Ropivacaine|
219262503|NCT01270698|DRUG|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
219262504|NCT04455685|OTHER|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
219262505|NCT03530488|DRUG|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
219262506|NCT03530488|PROCEDURE|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
219262507|NCT03949712|DEVICE|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
219262508|NCT03949712|DEVICE|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
219262509|NCT01419977|DRUG|Placebo|Normal saline solution, administered by nursing staff once daily
219262510|NCT01419977|DRUG|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
219262511|NCT02447276|DRUG|REGN475|
219262512|NCT02447276|DRUG|Placebo|
219262513|NCT03040830|DRUG|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
219262514|NCT00137020|DRUG|ziprasidone|
219262515|NCT04011423|OTHER|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
219262516|NCT04011423|OTHER|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
219262517|NCT05564546|PROCEDURE|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
219262518|NCT05564546|PROCEDURE|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
219262519|NCT05564546|OTHER|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* …"
219262520|NCT05564546|OTHER|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
219262521|NCT05082844|RADIATION|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
219262522|NCT05674292|DEVICE|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
219262523|NCT03399838|DRUG|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
219262524|NCT03399838|DRUG|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
219262525|NCT04324658|DEVICE|Lactiplus|capsules containing L. gasseri LA806
219262526|NCT01841112|DRUG|Placebo|Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
219262527|NCT01841112|DRUG|BI-409306 25 milligram (mg) SD|Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
219262528|NCT01841112|DRUG|BI-409306 50 mg SD|Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
219262529|NCT01841112|DRUG|BI-409306 100 mg SD|Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
219262530|NCT01841112|DRUG|BI-409306 100 mg MD|Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
219262531|NCT00177762|BEHAVIORAL|behavior weight loss|
219262532|NCT04247269|OTHER|Enteral Tube Feeding|Enteral tube feeding
219262533|NCT04114812|OTHER|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
219262534|NCT04114812|OTHER|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
219262535|NCT06319651|OTHER|Lower Limb Resistance Band Exercises|"* Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening"
219262536|NCT06319651|OTHER|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
219262537|NCT03219671|DRUG|Nivolumab|nivolumab 240mg every 2 weeks
219262538|NCT03219671|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
219262539|NCT03981718|PROCEDURE|Fat grafting|Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
219262540|NCT02680197|DRUG|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
219262541|NCT05851664|DEVICE|intubation by direct laryngoscopy|intubation using a direct laryngoscopy type macintosh
219262542|NCT05851664|DEVICE|Intubation by videolaryngoscopy|Intubation using a videolaryngoscope type McGrath
219262543|NCT00878553|DRUG|placebo|tablet at bedtime
219262544|NCT00878553|DRUG|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
219262545|NCT00912223|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
219262546|NCT03980197|OTHER|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
219262547|NCT03980197|OTHER|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
219262548|NCT05784766|DIAGNOSTIC_TEST|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
219262549|NCT05784766|OTHER|routine care|medical review
219262550|NCT00592462|PROCEDURE|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
219262551|NCT03253068|DRUG|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
219262552|NCT05009381|DEVICE|Stylage XXL at enrollment|Injection in the chin at enrollment
219262553|NCT05009381|DEVICE|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
219262554|NCT03866447|DRUG|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
219262555|NCT03866447|DRUG|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
219262556|NCT02504749|PROCEDURE|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
219262557|NCT01226836|OTHER|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
219262558|NCT05792761|DRUG|Peginterferon alfa-2b combined and ETV|"Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks."
219262559|NCT03288077|OTHER|Tryptophan|Beverage including tryptophan
219262560|NCT03625453|DRUG|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
219262561|NCT03625453|DRUG|Placebo|Part 1: 8 weeks with daily administration
219262562|NCT01341847|PROCEDURE|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
219262563|NCT01341847|PROCEDURE|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
219262564|NCT04276298|DRUG|Metronidazole cream|10% metronidazole applied rectally
219262565|NCT04276298|DRUG|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
219262566|NCT04276298|DRUG|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
219262567|NCT04276298|DRUG|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
219262568|NCT03739333|OTHER|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
219262569|NCT03834207|DEVICE|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
219262570|NCT00461123|DRUG|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
219262571|NCT00461123|DRUG|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
219262572|NCT04377412|OTHER|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
219262573|NCT02692287|DEVICE|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
219262574|NCT01100918|DEVICE|BiV ICD|Biventricular ICD
219262575|NCT01100918|DEVICE|ICD|Implantable Defibrillator
219262576|NCT05955755|OTHER|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
219262577|NCT00177372|DRUG|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
219262578|NCT00927901|DRUG|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
219262579|NCT00927901|DRUG|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
219262580|NCT00927901|DRUG|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
219262581|NCT00927901|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
219262582|NCT03299413|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
219262583|NCT00483080|DRUG|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
219262584|NCT05012943|BIOLOGICAL|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
219262585|NCT05012943|OTHER|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
219262586|NCT05012943|BIOLOGICAL|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
219262587|NCT04252170|DEVICE|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
219262588|NCT01306006|BIOLOGICAL|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
219262589|NCT03989921|OTHER|no intervention. observational study|no intervention. observational study
219262590|NCT02882841|OTHER|Biopsies, stool and blood collection|
219262591|NCT03739255|DEVICE|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
219262592|NCT03739255|DEVICE|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
219262593|NCT00040820|DRUG|oxaliplatin|
219262594|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
219262595|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
219262596|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
219262597|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
219262598|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
219262599|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
219262600|NCT05804682|PROCEDURE|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
219262601|NCT05804682|PROCEDURE|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
219262602|NCT03029819|BEHAVIORAL|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
219262603|NCT03029819|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
219262604|NCT03029819|BEHAVIORAL|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
219262605|NCT03029819|DRUG|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
219262606|NCT05436210|OTHER|foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test|Patients will be evaluated only observationally without intervention by foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test
219262607|NCT01989923|OTHER|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
219262608|NCT01989923|DEVICE|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
219262609|NCT03536702|OTHER|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
219262610|NCT03536702|OTHER|Independent Writing - Control Group|This group will receive a book for a self writing session.
219262611|NCT05818995|DRUG|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
219262612|NCT04344665|OTHER|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
219262613|NCT02998619|RADIATION|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
219262614|NCT03605368|BEHAVIORAL|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
219262615|NCT03605368|BEHAVIORAL|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
219262616|NCT03605368|BEHAVIORAL|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
219262617|NCT05046106|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
219262618|NCT05046106|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
219262619|NCT02690337|DRUG|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
219262620|NCT03559829|DEVICE|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
219262621|NCT00698555|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
219262622|NCT00698555|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
219262623|NCT05694962|RADIATION|Low-Dose Radiation Therapy|1.5Gy single treatment of whole-lung radiation therapy
219262624|NCT01982175|BIOLOGICAL|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~\--------------------------------------------------------------------------------"
219262625|NCT05639998|BIOLOGICAL|COVAXIN(BBV152)|COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
219262626|NCT05639998|BIOLOGICAL|BBV154 Intranasal Vaccine|BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
219262627|NCT00876499|BEHAVIORAL|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
219262628|NCT05566509|PROCEDURE|Breast excision|some patient had minimal excision, some had maximal excision.
219262629|NCT01962311|PROCEDURE|lumbar puncture|lumbar puncture at enrollment in study
219262630|NCT01475422|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
219262631|NCT01475422|BEHAVIORAL|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
219262632|NCT04234503|BEHAVIORAL|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
219262633|NCT02675218|OTHER|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
219262634|NCT00037661|DRUG|INS365 Ophthalmic Solution|
219262635|NCT02483598|DRUG|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
219262636|NCT02483598|DRUG|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
219262637|NCT00249171|DRUG|risperidone|
219262638|NCT02650466|DEVICE|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
219262639|NCT03633864|BIOLOGICAL|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
219262640|NCT02741258|DEVICE|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
219262641|NCT02741258|DRUG|skin cream|cream to treat skin erythema due to radiotherapy
219262642|NCT05886946|OTHER|ABG|ABG
219262643|NCT04972539|DRUG|AJU-A51 Tab.|Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
219262644|NCT04972539|DRUG|A51R1 Tab. and A51R2 Tab.|Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
219262645|NCT02547597|DRUG|Carvedilol|
219262646|NCT02547597|DRUG|Atenolol|
219262647|NCT03682198|DEVICE|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
219262648|NCT03682198|DRUG|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
219262649|NCT03682198|DRUG|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
219262650|NCT05160571|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
219262651|NCT02843425|OTHER|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
219262652|NCT02843425|OTHER|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
219262653|NCT00927550|DRUG|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
219262654|NCT00927550|DRUG|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
219262655|NCT01837797|DRUG|Placebo|Once daily, tablets, orally
219262656|NCT01837797|DRUG|Brexpiprazole 1 mg|once daily dose, tablets, orally
219262657|NCT01837797|DRUG|Brexpiprazole 3 mg|once daily dose, tablets, orally
219262658|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
219262659|NCT04700397|DIAGNOSTIC_TEST|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
219262660|NCT02176837|DRUG|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
219262661|NCT05971277|DEVICE|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
219262662|NCT02053740|DRUG|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
219262663|NCT02053740|DRUG|Routine western medicine|
219262664|NCT04766047|DRUG|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
219262665|NCT01684111|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
219262666|NCT01684111|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
219262667|NCT04017637|BEHAVIORAL|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
219262668|NCT04088136|BEHAVIORAL|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
219262669|NCT04088136|BEHAVIORAL|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
219262670|NCT05577663|OTHER|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
219262671|NCT05577663|PROCEDURE|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
219262672|NCT05577663|PROCEDURE|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
219262673|NCT05105425|DIETARY_SUPPLEMENT|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
219262674|NCT05105425|DIETARY_SUPPLEMENT|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
219262675|NCT03129971|PROCEDURE|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
219262676|NCT03129971|PROCEDURE|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
219262677|NCT05095233|BEHAVIORAL|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
219262678|NCT05095233|DEVICE|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
219262679|NCT02224352|DEVICE|Functional neuromuscular electrical stimulation|
219262680|NCT00609323|DRUG|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
219262681|NCT00609323|DRUG|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
219262682|NCT03134274|DEVICE|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
219262683|NCT00169962|DRUG|rhDNAse (pulmozyme)|
219262684|NCT01075100|DRUG|Ixabepilone|20 mg/m2 on Days 1 and 8
219262685|NCT01075100|DRUG|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
219262686|NCT05308199|OTHER|thoracic manipulation|thoracic manipulation for unlocking of facet joints
219262687|NCT05308199|OTHER|muscle enegy technique|to release muscle spasm of cervical musces
219262688|NCT02250183|DEVICE|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
219262689|NCT02250183|DEVICE|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
219262690|NCT01497678|DEVICE|Extracellular Matrix|Extracellular Matrix
219262691|NCT03862105|OTHER|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
219262692|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat|
219262693|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
219262694|NCT01811329|DIETARY_SUPPLEMENT|Palm fat|
219262695|NCT01811329|DIETARY_SUPPLEMENT|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
219262696|NCT01068405|DRUG|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
219262697|NCT01068405|DRUG|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
219262698|NCT05088733|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
219262699|NCT05088733|OTHER|Routine medical care|Routine medical care
219262700|NCT05970783|DRUG|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
219262701|NCT05970783|OTHER|Placebo|Placebo 0.2g tid p.o.
219262702|NCT05797883|DRUG|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
219262703|NCT06817993|BEHAVIORAL|Rejection and Acceptance Feedback|Participants will be administered cues of peer acceptance and rejection from virtual peers during an fMRI task. In the CHAT-I task, they will be chosen or not chosen to discuss various topics with a virtual peer. In the TBO Task, they will receive a high or low number of likes relative to the other photos displayed of peers. They will also view comments on their posts from peers, which may have positive, negative, or neutral content.
219262704|NCT03769077|DEVICE|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
219262705|NCT05896696|DEVICE|BeShape One|Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
219262706|NCT00406406|DRUG|SKI-606|
219262707|NCT03751553|DRUG|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
219262708|NCT01878383|DEVICE|Genexpert assay|
219262709|NCT05588947|OTHER|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
219262710|NCT05588947|OTHER|Active Control|Life After Stroke educational video
219262711|NCT05706636|DRUG|oral mini pulse|5mg / week oral dexamethasone
219262712|NCT05706636|DRUG|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
219262713|NCT05706636|DEVICE|targeted phototherapy|twice weekly targeted excimer light sessions
219262714|NCT02185677|OTHER|Clinical evaluation|
219262715|NCT02185677|OTHER|neuropsychological battery test|
219262716|NCT02185677|OTHER|MRI|
219262717|NCT02185677|OTHER|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
219262718|NCT03475056|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
219262719|NCT04396847|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
219262720|NCT04396847|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
219262721|NCT04415827|DIAGNOSTIC_TEST|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
219262722|NCT01988298|DRUG|Ibuprofen|Ibuprofen 400 mg each 8 hours
219262723|NCT01988298|DRUG|Acetaminophen|Control group
219262724|NCT04678908|DRUG|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
219262725|NCT01833208|OTHER|Laboratory Biomarker Analysis|Correlative studies
219262726|NCT01833208|RADIATION|Radiation Therapy|Undergo single-fraction radiation therapy
219262727|NCT04214327|BEHAVIORAL|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
219262728|NCT04214327|BEHAVIORAL|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
219262729|NCT04214327|BEHAVIORAL|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
219262730|NCT02331199|DEVICE|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
219262731|NCT02331199|DEVICE|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
219262732|NCT01699737|DRUG|JTT-851|
219262733|NCT01699737|DRUG|Glimepiride|Encapsulated Glimepiride tablets
219262734|NCT01699737|DRUG|Placebo for Active|
219262735|NCT01699737|DRUG|Placebo for comparator|
219262736|NCT01932762|DRUG|Grazoprevir|100 mg every day (QD) orally
219262737|NCT01932762|DRUG|Elbasvir|50 mg QD orally
219262738|NCT01932762|DRUG|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
219262739|NCT00390078|BIOLOGICAL|MVA-mBN32|3 immunizations: 1x 10E8\_TCID50 MVA-mBN32
219262740|NCT00390078|BIOLOGICAL|IMVAMUNE|3 immunizations: 1x 10E8\_TCID50 IMVAMUNE
219262741|NCT04597970|DRUG|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
219262742|NCT03795168|DEVICE|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
219262743|NCT03795168|DEVICE|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
219262744|NCT02861196|PROCEDURE|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
219262745|NCT02851849|DRUG|LGD-6972-5 mg|5 mg LGD-6972 QD
219262746|NCT02851849|DRUG|LGD-6972-10 mg|10 mg LGD-6972 QD
219262747|NCT02851849|DRUG|LGD-6972-15 mg|15 mg LGD-6972 QD
219262748|NCT02851849|OTHER|Placebo|Placebo QD
219262749|NCT02250599|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
219262750|NCT02250599|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
219262751|NCT02250599|DRUG|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
219262752|NCT01101334|DRUG|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
219262753|NCT01101334|DRUG|erlotinib|Erlotinib; One 150mg tablet administered once daily
219262754|NCT05550597|DRUG|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
219262755|NCT05550597|DRUG|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
219262756|NCT00940654|OTHER|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
219262757|NCT01384383|DRUG|GS-5885|GS-5885 30 mg tablet administered orally once daily
219262758|NCT01384383|DRUG|GS-9451|GS-9451 200 mg tablet administered orally once daily
219262759|NCT01384383|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219262760|NCT01384383|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
219262761|NCT01004029|DRUG|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
219262762|NCT01004029|DRUG|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
219262763|NCT05084599|DRUG|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
219262764|NCT05084599|DRUG|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
219262765|NCT03864341|BEHAVIORAL|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
219262766|NCT03864341|BEHAVIORAL|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
219262767|NCT03864341|BEHAVIORAL|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
219262768|NCT04069533|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
219262769|NCT00154427|DRUG|activated recombinant human factor VII|
219262770|NCT00514488|DRUG|STI571 (400 mg/day; or 800 mg/day)|
219262771|NCT05279534|DIETARY_SUPPLEMENT|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
219262772|NCT05279534|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
219262773|NCT01338805|DRUG|BGG492|
219262774|NCT04325009|DRUG|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
219262775|NCT04325009|DRUG|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
219262776|NCT04780984|DRUG|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
219262777|NCT04780984|DRUG|Placebo|Placebo comparator
219262778|NCT00127400|BEHAVIORAL|anger management therapy|
219262779|NCT04067349|OTHER|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
219262780|NCT03184597|DIAGNOSTIC_TEST|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
219262781|NCT01597583|BEHAVIORAL|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
219262782|NCT05064644|OTHER|Product that contains plant stanol ester|Product with active ingredient
219262783|NCT05064644|OTHER|Placebo product|Product without active ingredient
219262784|NCT04927962|OTHER|Questionnaires|For youth: self-reported questionnaires (on oral quality of life, bullying and cyberbullying, dental anxiety) and routine clinical examination for adolescents. For one parent: self-reported questionnaires (on perceived oral quality of life of their child and on their own dental anxiety).
219262785|NCT01138371|PROCEDURE|LDL Apheresis|LDL Apheresis
219262786|NCT00143026|DRUG|carbidopa, levodopa, entacapone|
219262787|NCT04595942|DRUG|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
219262788|NCT04595942|DRUG|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
219262789|NCT04595942|BEHAVIORAL|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
219262790|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
219262791|NCT02654899|OTHER|Placebo|Placebo
219262792|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
219262793|NCT01688453|BEHAVIORAL|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
219262794|NCT01688453|BEHAVIORAL|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
219262795|NCT02668198|DEVICE|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
219262796|NCT02668198|DEVICE|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
219262797|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
219262798|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
219262799|NCT02668198|PROCEDURE|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
219262800|NCT02826798|DRUG|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
219262801|NCT02826798|DRUG|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
219262802|NCT02826798|DRUG|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
219262803|NCT02826798|DRUG|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
219262804|NCT02826798|DRUG|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
219262805|NCT05932706|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219262806|NCT05932706|DEVICE|sham high definition transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
219262807|NCT04387045|BEHAVIORAL|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
219262808|NCT02377323|OTHER|MACFIMS|Cognitive evaluation of 50 participants
219262809|NCT02377323|OTHER|MSQoL-54|Quality of life questionnaires
219262810|NCT06338436|DEVICE|Proton Radiation Therapy System (ProBeam)|All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
219262811|NCT01361958|DRUG|NOMAC|
219262812|NCT01798862|PROCEDURE|Endometrial injury by hysteroscopy or pipelle sampling|
219262813|NCT01798862|PROCEDURE|Proceed to COH directly|
219262814|NCT02979171|DEVICE|Laryngeal Mask Airway Classic|
219262815|NCT00997711|DEVICE|Cypher|Sirolimus-eluting stents
219262816|NCT04831047|DRUG|Oxymetazoline hydrochloride 0.1% ophthalmic solution|One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
219262817|NCT04831047|DRUG|Placebo|One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
219262818|NCT05141227|PROCEDURE|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates \& screws
219262819|NCT05141227|PROCEDURE|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov \& minimal fixation of the articular surface using cannulated screws through mini open approaches
219262820|NCT01955759|DRUG|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
219262821|NCT01955759|DRUG|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
219262822|NCT01955759|DRUG|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
219262823|NCT04531306|OTHER|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
219262824|NCT05747612|OTHER|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
219262825|NCT03888222|DRUG|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
219262826|NCT03888222|DRUG|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
219262827|NCT01612247|DRUG|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
219262828|NCT01969045|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
219262829|NCT01969045|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
219262830|NCT00263211|DRUG|Plavix|
219262831|NCT00263211|DRUG|Aspirin|
219262832|NCT06134947|OTHER|Echocardiographic examination|"Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~* Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE \<-2 Z Score is considered abnormal .~* Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler \<-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś)."
219262833|NCT00760513|DRUG|OMACOR|4 grammes daily, oral capsule
219262834|NCT00760513|DRUG|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
219262835|NCT01042249|OTHER|Pelvic Floor Muscle training|12 week training program including home exercises
219262836|NCT03379545|DIAGNOSTIC_TEST|3-dimensional (3D) magnetic resonance (MR) imaging|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
219262837|NCT03379545|DIAGNOSTIC_TEST|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
219262838|NCT01445795|DRUG|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
219262839|NCT01445795|DRUG|Placebo QD Fasted|Placebo capsule QD fasted x7 days
219262840|NCT01445795|DRUG|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
219262841|NCT01445795|DRUG|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
219262842|NCT01445795|DRUG|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
219262843|NCT01445795|DRUG|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
219262844|NCT01445795|DRUG|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
219262845|NCT01445795|DRUG|Placebo BID Fasted|Placebo BID fasted x7 days
219262846|NCT01445795|DRUG|ribavirin|
219262847|NCT04224454|OTHER|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
219262848|NCT00263497|DEVICE|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
219262849|NCT04453163|PROCEDURE|Vertebroplasty|Patient will undergo a surgery in percutaneous vertebroplasty
219262850|NCT02999737|BIOLOGICAL|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
219262851|NCT02999737|BIOLOGICAL|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
219262852|NCT05451797|DEVICE|Implant of WiSE-CRT with intracardiac pacemaker|Implant of two cardiac devices
219262853|NCT01122875|DRUG|MFGR1877S|Intravenous repeating dose
219262854|NCT01333553|DEVICE|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
219262855|NCT01468077|DRUG|Tocilizumab|8 mg/kg infusion
219262856|NCT00345709|BEHAVIORAL|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
219262857|NCT05327036|OTHER|collect information about all participants|collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
219262858|NCT03921489|PROCEDURE|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
219262859|NCT03189147|PROCEDURE|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
219262860|NCT03189147|PROCEDURE|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
219262861|NCT03008109|DRUG|EGFR-TK Inhibitor|
219262862|NCT00525928|DRUG|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
219262863|NCT03421977|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
219262864|NCT06789965|PROCEDURE|SADI-S|In the case of SADI-S, the complete dissection of the antrum and the first portion of the duodenum is performed up to the limit of the gastroduodenal artery. The right gastric artery is dissected, clipped, and sectioned at its root. A vertical gastrectomy is created using a 38F Foucher tube with staplers. Next, the duodenum is sectioned with a stapler, and the resection of the greater gastric curvature is completed. Then, from the left side of the patient, 250 cm is measured from the ileocecal valve, where the duodenoileal anastomosis will be performed. This anastomosis is carried out with the surgeon positioned again between the patient's legs. A manual end-to-side anastomosis with two layers of monofilament is performed. Finally, the vertical gastrectomy and the duodenoileal anastomosis are verified using intraoperative endoscopy or a methylene blue and air test. The gastrectomy specimen is removed through the left pararectal trocar incision. A drain will only be placed in cases of s
219262865|NCT06789965|PROCEDURE|RY-GBP|In the case of RY-GBP, first, the lesser gastric curvature is dissected between the cardia and the angular incisura, accessing the gastric transcavity. A horizontal gastric transection is performed using the first firing of a stapler. A gastric reservoir is created through successive firings with a 38F Foucher tube stapler. Next, 100 cm of the biliopancreatic limb is measured, where the manual or semi-mechanical gastrojejunostomy will be performed, with an end-to-side anastomosis using a stapler and manual closure of the loop. Then, 150 cm of the alimentary limb is measured, and a side-to-side jejunojejunostomy is created. A section is made between the two anastomoses. The mesenteric opening and the Petersen space are closed with a continuous non-absorbable suture. The anastomosis is verified using intraoperative endoscopy or a methylene blue and air test. A drain will only be placed in cases of special technical difficulty or intraoperative complications.
219262866|NCT03362541|BEHAVIORAL|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
219262867|NCT03362541|BEHAVIORAL|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
219262868|NCT06956911|DEVICE|traditional cardiac rehabilitation with early low resisted exercise with blood flow restriction|Traditional cardiac rehabilitation and early low resisted exercise with 0.5 kilogram in form of bilateral upper limb exercise (elbow flexion and extension,wrist flexion and extension ) with external pressure applied with pressure cuff which determined by 40% of systolic blood pressure which applied on the proximal part of the arm,the frequency of exercise is once per day for 14 consecutive day and intensity determined by rate of perceived exertion scale
219262869|NCT06956911|DEVICE|traditional cardiac rehabilitation|Diaphragmatic and costal breathing exercise, active assisted to active range of motion,percussion,splinted cough,early mobility, upper limb exercise with breathing and incentive spirometer
219262870|NCT06957678|DIAGNOSTIC_TEST|Artificial Intelligence-Based Predictive Model for Lymph Node Metastasis|The intervention is an artificial intelligence-based predictive model developed using preoperative multimodal data, including contrast-enhanced CT images, preoperative histopathological findings, and clinical features. The model is designed to predict (1) the presence or absence of lymph node metastasis, (2) the specific lymph node stations involved, and (3) the individual lymph nodes involved. Each lymph node's metastatic status is confirmed by serial pathological sectioning of surgically retrieved nodes, ensuring a highly accurate reference standard for model training and validation. This distinguishes the intervention from traditional imaging-based assessments and from other AI models that do not use individually validated lymph node pathology.
219262871|NCT04553445|BEHAVIORAL|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
219262872|NCT04553445|BEHAVIORAL|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
219262873|NCT00303927|DRUG|capecitabine|
219262874|NCT06956365|PROCEDURE|Group-C|100 iu carbetosin administered to carbetocin group
219262875|NCT06956365|PROCEDURE|Group-O|In cesarean surgery, 5 IU of oxytocin will be administered after the baby delivered.
219262876|NCT06956872|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
219262877|NCT06956872|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
219262878|NCT06956872|OTHER|Printed Nutrition Pamphlet|After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose. Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions.
219262879|NCT05869045|OTHER|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
219262880|NCT05764551|DIAGNOSTIC_TEST|Serum DNA methylation|Serum DNA methylation
219262881|NCT05559879|DRUG|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
219262882|NCT01951378|DEVICE|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
219262883|NCT01951378|DEVICE|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
219262884|NCT01951378|DRUG|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
219262885|NCT00487318|DRUG|standard of care|peginterferon/RBV
219262886|NCT00487318|DRUG|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
219262887|NCT00021047|DRUG|capecitabine|
219262888|NCT00021047|DRUG|carboplatin|
219262889|NCT00021047|DRUG|epirubicin hydrochloride|
219262890|NCT06624839|BIOLOGICAL|Human papillomavirus (HPV) vaccine, 9-valent|0.5 ml intramuscular injection
219262891|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
219262892|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
219262893|NCT01134471|DEVICE|Ostene|applied to sternal surface
219262894|NCT01134471|DEVICE|Bonewax|applied to sternal surface
219262895|NCT05444036|DRUG|Ketamine|compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
219262896|NCT06190288|OTHER|Transitional care model|A newly developed care model to support frail older adults during their transition from hospital to home.
219262897|NCT06301347|BEHAVIORAL|Learning through Play Plus|Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
219262898|NCT06418399|OTHER|cancer patients|Patients aged between 18 and 80 years with cancer-related pain lasting for more than 3 months will be included.
219262899|NCT03437941|DRUG|CORT125281|CORT125281 is supplied as capsules for oral dosing
219262900|NCT03437941|DRUG|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
219262901|NCT03437941|DRUG|Placebo|Placebo capsules to match the appearance of the CORT125281
219262902|NCT04759846|DRUG|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
219262903|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
219262904|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
219262905|NCT05907317|DEVICE|Cerebral oximetry monitoring device|Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.
219262906|NCT05907317|OTHER|Usual care|Treatment as usual
219262907|NCT03239418|DEVICE|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
219262908|NCT03239418|DEVICE|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
219262909|NCT06456606|PROCEDURE|before prone position|It was evaluated with transesophageal echocardiography
219262910|NCT06456606|PROCEDURE|the first hour of prone position|It was evaluated with transesophageal echocardiography
219262911|NCT06456606|PROCEDURE|the first hour of returning to the supine position|It was evaluated with transesophageal echocardiography
219262912|NCT03563625|PROCEDURE|Caudal block|Caudal block/bupivacaine 0.25%
219262913|NCT03563625|PROCEDURE|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
219262914|NCT03563625|DRUG|Bupivacaine|bupivacaine
219262915|NCT04340765|DRUG|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
219262916|NCT04674254|DRUG|Bevacizumab Injection|Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
219262917|NCT04674254|PROCEDURE|Targeted retinal photocoagulation|Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
219262918|NCT04674254|PROCEDURE|Standard pan-retinal photocoagulation|Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
219262919|NCT02367430|BEHAVIORAL|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
219262920|NCT03234712|DRUG|ABBV-321|Intravenous infusion
219262921|NCT01759147|PROCEDURE|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
219262922|NCT04285047|OTHER|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
219262923|NCT02904785|DEVICE|Extracorporeal Shock Waves|
219262924|NCT02904785|DEVICE|Sham Extracorporeal Shock Waves|
219262925|NCT02904785|OTHER|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
219262926|NCT05876169|PROCEDURE|Orthognathic surgery|Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
219262927|NCT01851707|DRUG|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
219262928|NCT01851707|DRUG|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
219262929|NCT00002716|DRUG|dexamethasone|
219262930|NCT00002716|DRUG|floxuridine|
219262931|NCT00002716|DRUG|fluorouracil|
219262932|NCT00002716|DRUG|leucovorin calcium|
219262933|NCT00002716|PROCEDURE|laparotomy|
219262934|NCT00002716|PROCEDURE|conventional surgery|
219262935|NCT04692805|DEVICE|coils|EUS-guided injection of coils
219262936|NCT04692805|DRUG|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
219262937|NCT05421156|PROCEDURE|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
219262938|NCT05421156|PROCEDURE|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
219262939|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
219262940|NCT01038453|OTHER|placebo tablet|placebo 2 tablet, once a day,
219262941|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
219262942|NCT03491215|DRUG|Ruxolitinib|All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
219262943|NCT01855347|DEVICE|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
219262944|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
219262945|NCT01984762|PROCEDURE|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
219262946|NCT01984762|PROCEDURE|sleeve gastrectomy|SG = sleeve gastrectomy
219262947|NCT06512220|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
219262948|NCT06512220|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
219262949|NCT00058942|DEVICE|home drinking water treatment device|
219262950|NCT00541671|DRUG|Saline|10 c of saline
219262951|NCT00541671|DRUG|Phenergan|Physician ordered dose
219262952|NCT05031468|BIOLOGICAL|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
219262953|NCT03993496|DIAGNOSTIC_TEST|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation"
219262954|NCT01202409|DRUG|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
219262955|NCT03171116|OTHER|none intervention|it is not an interventional study; it is an observational study
219262956|NCT05648318|DRUG|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
219262957|NCT05648318|DRUG|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
219262958|NCT05375383|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219262959|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219262960|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219262961|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
219262962|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
219262963|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
219262964|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
219262965|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
219262966|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219262967|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219262968|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219262969|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
219262970|NCT00500981|PROCEDURE|Volume challenge|
219262971|NCT00500981|PROCEDURE|Ultrasound evaluation of internal jugular vein|
219262972|NCT00210678|BEHAVIORAL|No intervention|No treatment is given to the patients as this is an observational study.
219262973|NCT00553605|DRUG|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
219262974|NCT00553605|DRUG|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
219262975|NCT05671744|OTHER|Cell-based non-invasive prenatal testing|Blood sampling
219262976|NCT00145483|DRUG|Sildenafil|
219262977|NCT02788526|PROCEDURE|Adjuvant TACE|1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
219262978|NCT02788526|PROCEDURE|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
219262979|NCT06407583|BEHAVIORAL|ProMIO2.0 program|"ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)"
219262980|NCT04067908|OTHER|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
219262981|NCT04546022|DRUG|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
219262982|NCT02153190|DEVICE|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
219262983|NCT02153190|DEVICE|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
219262984|NCT01046591|PROCEDURE|Polysomnography|Overnight sleep studies will be performed on all children.
219262985|NCT00002971|DRUG|O6-benzylguanine|
219262986|NCT04604470|OTHER|Decision tool|no intervention.
219262987|NCT00509457|BIOLOGICAL|GV 1001 Telomerase peptide|
219262988|NCT00126139|DRUG|Abciximab|
219262989|NCT05708300|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
219262990|NCT02176564|DRUG|inhaled bronchodilator|
219262991|NCT02880683|DEVICE|NeuroTronik CANS Therapy System|
219262992|NCT05789550|DIAGNOSTIC_TEST|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"1. Full clinical history with detailed history about T2DM (its duration and treatment).~2. Full medical examination, including BMI using the formula: weight (kg)/height (m2).~3. Laboratory investigation, including the following:~   1. Complete blood picture.~  2. Fasting blood sugar (FBS).~  3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~  4. HbA1c.~  5. Kidney function tests (serum creatinine and blood urea).~  6. Liver function tests (serum albumin, ALT, and AST).~  7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
219262993|NCT05130346|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
219262994|NCT05139823|PROCEDURE|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
219262995|NCT01487902|DRUG|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
219262996|NCT01487902|DRUG|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
219262997|NCT05964361|BIOLOGICAL|IL15-transpresenting WT1-targeted Dendritic Cell Vaccine|IL15/IL15Ra/WT1 DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered every 2 weeks (+- 3 days) for a total of 6 administrations.
219262998|NCT06007105|BEHAVIORAL|SUCCEED Community-Based Intervention|"The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach."
219262999|NCT01035047|OTHER|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
219263000|NCT04061863|DRUG|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
219263001|NCT02669407|PROCEDURE|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
219263002|NCT02669407|DRUG|regional nerve block with a local anesthetic (Lidocaine)|
219263003|NCT05538416|PROCEDURE|Posterior Lumbar Interbody Fusion (PLIF)|Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
219263004|NCT01168245|DEVICE|Sham-NICE-System|sham TMS and sham cognitive training
219263005|NCT01168245|DEVICE|NICE-System|TMS combined with cognitive training
219263006|NCT05512078|PROCEDURE|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
219263007|NCT02785731|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
219263008|NCT02785731|PROCEDURE|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
219263009|NCT02785731|PROCEDURE|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
219263010|NCT00595647|DEVICE|Drug eluting stent|Implantation of stent
219263011|NCT00595647|DEVICE|Bare metal stent|Implantation of stent
219263012|NCT01624298|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
219263013|NCT02840916|PROCEDURE|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
219263014|NCT02840916|PROCEDURE|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
219263015|NCT02259062|OTHER|Music with brief mindfulness intervention|Music listening with mindfulness therapy
219263016|NCT02259062|OTHER|Music listening alone|
219263017|NCT02259062|OTHER|Audiobook listening|
219263018|NCT02121743|DEVICE|strattice|use of a strattice
219263019|NCT02121743|PROCEDURE|No strattice|no use of a strattice
219263020|NCT01168336|DRUG|Betahistine standard formulation|betahistine 24 mg tablets
219263021|NCT01168336|DRUG|Betahistine Extended Release formulation|betahistine 32 mg tablets
219263022|NCT01168336|DRUG|Placebo|matching placebo
219263023|NCT00739609|DRUG|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
219263024|NCT00345800|DRUG|Sodium Oxybate (Xyrem)|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
219263025|NCT01832454|OTHER|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
219263026|NCT03807817|OTHER|Alcohol administration|Amount of alcohol to be administered.
219263027|NCT03807817|OTHER|Placebo|Placebo Alcohol
219263028|NCT03807817|OTHER|No Alcohol|No Alcohol
219263029|NCT00142545|DRUG|apomorphine HCl injection|
219263030|NCT00135577|DRUG|alvimopan|
219263031|NCT00135577|DRUG|placebo|
219263032|NCT00408798|DRUG|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
219263033|NCT06215417|PROCEDURE|Rotator cuff repair|Arthroscopic rotator cuff repair augmented with graft.
219263034|NCT04409522|DRUG|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
219263035|NCT04409522|DRUG|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
219263036|NCT04678765|PROCEDURE|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
219263037|NCT04678765|PROCEDURE|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
219263038|NCT00639977|OTHER|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
219263039|NCT00639977|OTHER|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
219263040|NCT02647788|DRUG|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
219263041|NCT02647788|DRUG|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
219263042|NCT06224010|OTHER|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
219263043|NCT06438692|PROCEDURE|VOM ethanol chemical ablation and 2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
219263044|NCT06438692|PROCEDURE|2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
219263045|NCT03723122|BEHAVIORAL|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
219263046|NCT04961632|DRUG|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
219263047|NCT04961632|DRUG|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
219263048|NCT00130078|DRUG|1.0% C31G SAVVY vaginal gel|
219263049|NCT03862209|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
219263050|NCT02107742|PROCEDURE|Normal speed lidocaine injection|30 seconds
219263051|NCT02107742|PROCEDURE|Slow lidocaine injection|speed 45 seconds
219263052|NCT02107742|PROCEDURE|Fast lidocaine injection|speed 15 seconds
219263053|NCT01127321|OTHER|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
219263054|NCT01127321|BIOLOGICAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
219263055|NCT01127321|BIOLOGICAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
219263056|NCT01127321|BIOLOGICAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
219263057|NCT01127321|BIOLOGICAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
219263058|NCT02800447|DRUG|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14
219263059|NCT02800447|DRUG|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
219263060|NCT00003912|DRUG|carboplatin|
219263061|NCT00003912|DRUG|cisplatin|
219263062|NCT00003912|DRUG|doxorubicin hydrochloride|
219263063|NCT00003912|PROCEDURE|conventional surgery|
219263064|NCT02874573|DRUG|Tocilizumab|Investigational agent
219263065|NCT02874573|DRUG|Normal saline|Placebo
219263066|NCT01849445|PROCEDURE|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
219263067|NCT01849445|OTHER|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
219263068|NCT00719043|BIOLOGICAL|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
219263069|NCT00719043|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
219263070|NCT00719043|BIOLOGICAL|Placebo|Administered as an intramuscular (IM) injection
219263071|NCT01588366|DRUG|Placebo|Administered orally
219263072|NCT01588366|DRUG|LY2409021|Administered orally
219263073|NCT06344806|BEHAVIORAL|Gamified Breastfeeding Education|Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
219263074|NCT03520062|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for \~6 weeks
219263075|NCT04991636|PROCEDURE|Angioscan|"La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen."
219263076|NCT06009744|DRUG|Low-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
219263077|NCT06009744|DRUG|High-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
219263078|NCT02754336|BEHAVIORAL|Cogmed Robomemo, working memory training|
219263079|NCT02754336|BEHAVIORAL|Othmer, neurofeedback|
219263080|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
219263081|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
219263082|NCT04077814|DEVICE|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
219263083|NCT04077814|DEVICE|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
219263084|NCT00000447|DRUG|naltrexone (Revia)|
219263085|NCT00000447|DRUG|nicotine replacement patch|
219263086|NCT06009172|OTHER|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
219263087|NCT04758676|OTHER|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
219263088|NCT04758676|OTHER|Standard of care|Study subjects will receive the current standard of care.
219263089|NCT03245619|DRUG|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
219263090|NCT03245619|DRUG|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
219263091|NCT04212975|OTHER|joint lavage with dextrose|joint lavage with dextrose
219263092|NCT03202485|DEVICE|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
219263093|NCT03202485|DEVICE|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
219263094|NCT05595811|OTHER|outcome following surgery|
219263095|NCT03635840|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
219263096|NCT05082623|OTHER|Music|Music medicine
219263097|NCT05082623|OTHER|Earplug|Earplug with noise cancelling
219263098|NCT04339023|DRUG|Open-Label Placebo|in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
219263099|NCT04339023|OTHER|treatment as usual|usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
219263100|NCT01411449|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
219263101|NCT05159986|PROCEDURE|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
219263102|NCT05159986|OTHER|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
219263103|NCT02414347|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
219263104|NCT04991350|DRUG|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
219263105|NCT04991350|DRUG|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
219263106|NCT01558323|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
219263107|NCT02869945|GENETIC|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
219263108|NCT02869945|OTHER|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
219263109|NCT02869945|OTHER|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
219263110|NCT00766402|DRUG|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
219263111|NCT00766402|DRUG|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
219263112|NCT04205656|BIOLOGICAL|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
219263113|NCT04205656|BIOLOGICAL|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
219263114|NCT04205656|OTHER|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
219263115|NCT03619798|DEVICE|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
219263116|NCT03984175|PROCEDURE|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
219263117|NCT01007006|DEVICE|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
219263118|NCT01238393|DRUG|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
219263119|NCT05605561|OTHER|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
219263120|NCT05370729|DRUG|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
219263121|NCT05975632|DEVICE|Device: Self testing Potassium device|"Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test"
219263122|NCT01336205|DRUG|NKTR-118|25 mg oral tablet once daily
219263123|NCT01336205|DRUG|Usual care|As prescribed by the investigator
219263124|NCT03629470|OTHER|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
219263125|NCT03629470|OTHER|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
219263126|NCT00462111|DRUG|Indometacin|
219263127|NCT01006616|DRUG|Navarixin|Navarixin 10 mg and 30 mg capsules
219263128|NCT01006616|DRUG|Placebo|Placebo to navarixin capsules
219263129|NCT01006616|DRUG|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
219263130|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
219263131|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
219263132|NCT01008163|DRUG|YY-351|comparison of different dosages of drug
219263133|NCT01008163|DRUG|Placebo|comparison of different dosages of drug
219263134|NCT03943836|BEHAVIORAL|Music|Patients in the music group will listen to classical music during their dental procedure.
219263135|NCT02049112|DEVICE|Salivary equivalent|14-day treatment with salivary equivalent sticks
219263136|NCT02049112|DEVICE|Aequasyal|14-day treatment with Aequasyal oral spray
219263137|NCT02049112|DEVICE|Biotene|14-day treatment with Biotene oral spray
219263138|NCT06284434|DRUG|Liposomal Bupivacaine|Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
219263139|NCT06284434|DRUG|Bupivacain|Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
219263140|NCT06284434|DRUG|Epinephrine|Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
219263141|NCT03672175|DRUG|SAGE-217|SAGE-217 hard gelatin capsules.
219263142|NCT03672175|DRUG|Placebo|SAGE-217 matched placebo hard gelatin capsules.
219263143|NCT01061190|DRUG|Propranolol|oral application of 160 mg Propranolol for 30 days
219263144|NCT03675412|DIETARY_SUPPLEMENT|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
219263145|NCT00089830|DRUG|MSI-1256F (Squalamine Lactate)|
219263146|NCT02482935|DRUG|Abemaciclib|Administered orally
219263147|NCT01337375|DRUG|peginterferon alfa 2a [Pegasys]|sc weekly
219263148|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv weekly
219263149|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|sc twice weekly
219263150|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv twice weekly
219263151|NCT02813993|OTHER|Health educational video|
219263152|NCT03414047|DRUG|Prexasertib|Administered IV
219263153|NCT00438139|DRUG|Dronabinol|
219263154|NCT00270036|DRUG|epoetin alfa|
219263155|NCT00510939|DRUG|Tipifarnib plus Bortezomib|
219263156|NCT04360798|OTHER|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
219263157|NCT04360798|OTHER|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
219263158|NCT03712592|OTHER|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
219263159|NCT00197223|BIOLOGICAL|Influenza vaccine|
219263160|NCT03421405|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
219263161|NCT02897089|DEVICE|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
219263162|NCT02053883|DRUG|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
219263163|NCT02053883|DRUG|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
219263164|NCT01163955|OTHER|Time to fatigue|5 minutes while playing video games
219263165|NCT04672798|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
219263166|NCT04672798|BEHAVIORAL|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
219263167|NCT02550483|OTHER|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
219263168|NCT02550483|OTHER|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
219263169|NCT02550483|OTHER|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
219263170|NCT04472988|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
219263171|NCT04472988|OTHER|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
219263172|NCT04472988|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
219263173|NCT01636622|DRUG|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
219263174|NCT01636622|DRUG|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
219263175|NCT01636622|DRUG|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
219263176|NCT00019695|DRUG|alendronate sodium|
219263177|NCT00019695|DRUG|ketoconazole|
219263178|NCT01963715|DRUG|IMGN289|
219263179|NCT03040609|BEHAVIORAL|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
219263180|NCT03040609|BEHAVIORAL|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
219263181|NCT03040609|BEHAVIORAL|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
219263182|NCT06486727|DEVICE|Redtouch|675-nm laser
219263183|NCT02146092|PROCEDURE|Incentive spirometry|
219263184|NCT02146092|OTHER|Physiotherapy|Standard of care exercise training and supervision
219263185|NCT02000128|DEVICE|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
219263186|NCT02000128|OTHER|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
219263187|NCT03854019|DRUG|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
219263188|NCT03854019|DRUG|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
219263189|NCT00060437|DRUG|perifosine|
219263190|NCT06538467|OTHER|Hip extension exercise with inertial load|Hip extension exercise with inertial load
219263191|NCT06538467|OTHER|Hip extension exercise with gravitational load|Hip extension exercise with gravitational load
219263192|NCT02586415|PROCEDURE|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
219263193|NCT02586415|DEVICE|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
219263194|NCT02586415|DEVICE|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
219263195|NCT02586415|DEVICE|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System \[026, 032, 041\] Penumbra System Separator Flex \[026, 032, 041, 054\] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 \& ACE68"
219263196|NCT02586415|DEVICE|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
219263197|NCT00229762|BEHAVIORAL|phone call from nurses - informational only|
219263198|NCT04811326|RADIATION|NB-UVB|radiation
219263199|NCT04811326|DRUG|Latanoprost|eye drops
219263200|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
219263201|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
219263202|NCT00561899|DRUG|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
219263203|NCT00561899|DRUG|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
219263204|NCT00561899|DRUG|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
219263205|NCT00429897|DRUG|Bendroflumethiazide 2.5mg - 5mg|
219263206|NCT00429897|DRUG|Amiloride 20-40mg|
219263207|NCT00429897|DRUG|Spironolactone 50-100mg|
219263208|NCT00429897|DRUG|Frusemide 20-40mg|
219263209|NCT00429897|DRUG|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
219263210|NCT00000349|DRUG|Flupenthixol|
219263211|NCT01189422|DRUG|teplizumab or placebo|infusion or injection
219263212|NCT04056793|OTHER|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
219263213|NCT03708705|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
219263214|NCT01037062|DRUG|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
219263215|NCT02872311|BIOLOGICAL|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
219263216|NCT02872311|BIOLOGICAL|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
219263217|NCT02872311|BIOLOGICAL|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
219263218|NCT02872311|BIOLOGICAL|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
219263219|NCT03913169|OTHER|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
219263220|NCT04718233|DRUG|Sildenafil 25Mg Tablet|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
219263221|NCT04718233|DRUG|Placebo Oral Tablet|placebo will be administered orally in patients with recurrent pregnancy loss
219263222|NCT03385577|BEHAVIORAL|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
219263223|NCT04662437|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
219263224|NCT03521518|DIAGNOSTIC_TEST|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
219263225|NCT03579238|PROCEDURE|CV4|The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
219263226|NCT03579238|PROCEDURE|touching|the clinician allows the participant's head to rest quietly upon his open palms on a table.
219263227|NCT03171935|DEVICE|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
219263228|NCT03171935|DEVICE|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 \>92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 \>96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
219263229|NCT03171935|DEVICE|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
219263230|NCT03991598|OTHER|Exercise program|Exercise program in communities / Exercise program at home
219263231|NCT00316368|DEVICE|Ethicon TPW32 60 cm (pacing wires x 2)|
219263232|NCT01341249|DRUG|Experimental DW224aa|DW224aa tablet, single dose
219263233|NCT01341249|DRUG|Experimental DW224a|DW224a capsule, single dose
219263234|NCT03562429|DRUG|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
219263235|NCT03562429|DRUG|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
219263236|NCT01187745|OTHER|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
219263237|NCT00156923|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
219263238|NCT00156923|DRUG|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
219263239|NCT01585298|DRUG|FTY720|
219263240|NCT06064370|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy for pheochromocytoma
219263241|NCT05294718|PROCEDURE|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
219263242|NCT05294718|PROCEDURE|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
219263243|NCT04699097|DRUG|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
219263244|NCT00757978|DRUG|memantine|memantine 10mg twice a day
219263245|NCT00757978|DRUG|placebo|1 capsule of placebo twice a day
219263246|NCT02625571|BEHAVIORAL|Phase-based treatment of sexual behavior problems of children|
219263247|NCT02777242|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
219263248|NCT00519064|BIOLOGICAL|Adjuvanted influenza vaccine|
219263249|NCT02508779|BEHAVIORAL|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
219263250|NCT02508779|OTHER|Routine Care|Participants will continue to receive care from their clinician.
219263251|NCT03306693|BEHAVIORAL|Emotional skills|2-hour 3 group sessions
219263252|NCT03306693|BEHAVIORAL|Relaxation and talking group|2-hour 3 group sessions
219263253|NCT05029349|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
219263254|NCT03262155|BIOLOGICAL|Blood test|
219263255|NCT01898442|DRUG|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
219263256|NCT01898442|DRUG|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
219263257|NCT01898442|DRUG|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
219263258|NCT05178979|BEHAVIORAL|Training for HIV care providers (effect on provider outcomes)|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
219263259|NCT00611728|DRUG|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 \& 1/2 hrs on 1st day of each cycle \& then again on days 14 \& 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 \& continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height \& weight. Irinotecan will be given intravenously over 90 min on days 1, 14 \& 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, \& then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, \& then within 1 week prior to completion of every other cycle."
219263260|NCT03788954|OTHER|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
219263261|NCT03124550|BEHAVIORAL|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
219263262|NCT05394883|BEHAVIORAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
219263263|NCT05394883|BEHAVIORAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
219263264|NCT05168514|OTHER|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
219263265|NCT03671239|BEHAVIORAL|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
219263266|NCT03671239|BEHAVIORAL|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
219263267|NCT03671239|BEHAVIORAL|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
219263268|NCT05717517|DEVICE|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
219263269|NCT05167032|BEHAVIORAL|Cognitive Multisensory Rehabilitation (CMR)|The goal of CMR is to restore proprioception (i.e., sense of joint position and movement), body awareness, and awareness of the paralyzed limbs and trunk in space, in order to improve sensory and motor function. For example, CMR tasks will have the participant solve exercises related to: (i) where the legs are situated in space; where the legs are in relation to the pelvis and the upper part of the body (ii) the dimensions and length of the legs, the dimension of the pelvis, and sensation of the pelvis as a central body reference. (iii) the relationship between the left and right side of the body, and the relationship between the pelvis and the feet. Further, improvements in touch and pressure sensation are obtained with (v) texture discrimination tasks, and (vi) discrimination of sponges with varying resistance. Given the importance of sensory feedback for movement, sensory improvements create the opportunity for motor recovery to occur.
219263270|NCT05167032|BEHAVIORAL|Adaptive fitness|The Courage Kenny Rehabilitation Institute centers provide access to state-of- the-art adaptive gym equipment in their fitness center to promote fitness and recreation. Equipment includes treadmills, elliptical, NuSteps, SciFit upper body ergometers, Ski Erg and Rowing Machine, Upright and recumbent stationary bicycles, chest press, rear row, leg extension, leg curl, leg press, uppertone, free weights, and kettlebells. The equipment is spaced to allow for movement and is accessible for use from a wheelchair. They allow for transfers and caregiver assistance.
219263271|NCT03713697|BEHAVIORAL|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
219263272|NCT03713697|BEHAVIORAL|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
219263273|NCT03713697|BEHAVIORAL|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
219263274|NCT02368899|OTHER|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
219263275|NCT02368899|OTHER|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
219263276|NCT02115919|DRUG|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
219263277|NCT02115919|DRUG|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
219263278|NCT01344499|PROCEDURE|Carbon dioxide|standard pneumoperitoneum with 100% CO2
219263279|NCT01344499|PROCEDURE|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
219263280|NCT01344499|DRUG|Adept|instillation of 1 liter of fluid at the end of laparoscopy
219263281|NCT01344499|DRUG|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
219263282|NCT05066919|PROCEDURE|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
219263283|NCT05066919|OTHER|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
219263284|NCT03849768|DRUG|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219263285|NCT03849768|DRUG|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
219263286|NCT01293799|BEHAVIORAL|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
219263287|NCT03467698|DEVICE|Active tDCS|Real stimulation
219263288|NCT03467698|DEVICE|Sham tDCS|Sham stimulation
219263289|NCT02138656|OTHER|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
219263290|NCT02138656|OTHER|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
219263291|NCT01099579|DRUG|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
219263292|NCT01099579|DRUG|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
219263293|NCT01099579|DRUG|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
219263294|NCT01099579|DRUG|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
219263295|NCT01991145|PROCEDURE|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
219263296|NCT01991145|BIOLOGICAL|Erythropoietin alfa|
219263297|NCT01991145|OTHER|Rehabilitation|Active rehabilitation
219263298|NCT01991145|PROCEDURE|Placebo UCB|
219263299|NCT01991145|BIOLOGICAL|Placebo EPO|
219263300|NCT00909532|DRUG|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
219263301|NCT00909532|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
219263302|NCT01020214|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
219263303|NCT01020214|DRUG|Benicar HCT® Tablets 40 mg/25 mg|
219263304|NCT01912989|BEHAVIORAL|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
219263305|NCT01398462|DRUG|CWP232291|IV Infusion
219263306|NCT04500028|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.
219263307|NCT04500028|DRUG|Placebo Comparator|3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
219263308|NCT04186052|BIOLOGICAL|BCMA-CART cells|Target BCMA chimeric antigen receptor T cell infusion
219263309|NCT06401785|DIETARY_SUPPLEMENT|Hydrogen capsules|In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
219263310|NCT01430208|PROCEDURE|resectoscopy|hysteroscopy for myomas G0 and/or polyps
219263311|NCT04583462|DRUG|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
219263312|NCT04583462|DRUG|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
219263313|NCT00904709|DRUG|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
219263314|NCT05851040|OTHER|Observation study|Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
219263315|NCT01536197|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
219263316|NCT01536197|PROCEDURE|Gastric banding|Laparoscopic adjustable gastric banding
219263317|NCT01536197|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy surgery
219263318|NCT04507633|BEHAVIORAL|ROMA therapy(reminiacence therpy, orientation, music, and art)|An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
219263319|NCT03478410|PROCEDURE|Epicardial fat biopsy|A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
219263320|NCT04522206|DRUG|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
219263321|NCT00520871|DRUG|Blueberry juice|
219263322|NCT03180008|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
219263323|NCT03180008|BEHAVIORAL|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
219263324|NCT05760911|BEHAVIORAL|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
219263325|NCT00890890|DRUG|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
219263326|NCT00890890|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
219263327|NCT01726517|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
219263328|NCT01726517|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219263329|NCT01588210|OTHER|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
219263330|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
219263331|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
219263332|NCT00573651|OTHER|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
219263333|NCT01695447|PROCEDURE|duct-to-mucosa|
219263334|NCT01695447|PROCEDURE|invagination|
219263335|NCT01695447|DEVICE|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
219263336|NCT04149587|DRUG|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
219263337|NCT05266625|BEHAVIORAL|BT-001|"Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
219263338|NCT05266625|OTHER|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
219263339|NCT01495676|OTHER|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~* In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~* In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
219263340|NCT01495676|OTHER|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
219263341|NCT04137861|OTHER|Bioceramics|root repair material
219263342|NCT03747627|DIAGNOSTIC_TEST|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
219263343|NCT05338151|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
219263344|NCT05338151|BEHAVIORAL|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
219263345|NCT05338151|BEHAVIORAL|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
219263346|NCT05275023|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously.
219263347|NCT05275023|DRUG|PD-1 inhibitor|PD-1 inhibitor will be administered as IV infusion.
219263348|NCT05275023|DRUG|Tenofovir Disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
219263349|NCT05275023|DRUG|Tenofovir Alafenamide|TAF film-coated tablets will be administered orally.
219263350|NCT05275023|DRUG|Entecavir|ETV film-coated tablets will be administered orally.
219263351|NCT00812123|DRUG|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
219263352|NCT00812123|DRUG|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
219263353|NCT00812123|DRUG|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
219263354|NCT00812123|DRUG|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
219263355|NCT00812123|PROCEDURE|Protocol biopsies|protocol kidney biopsies at month one and three
219263356|NCT01820910|DRUG|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
219263357|NCT04562896|DEVICE|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
219263358|NCT06188624|DRUG|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
219263359|NCT04689828|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
219263360|NCT04689828|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
219263361|NCT04689828|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
219263362|NCT04689828|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
219263363|NCT03797989|BIOLOGICAL|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
219263364|NCT01653249|BIOLOGICAL|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
219263365|NCT04052997|DRUG|Camidanlumab Tesirine|Intravenous Infusion
219263366|NCT02852811|OTHER|Group education|Intervention involving two education session with topics common in menopause transition.
219263367|NCT04958941|BEHAVIORAL|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
219263368|NCT00287547|DRUG|CTLA4Ig / Abatacept|
219263369|NCT06416319|DEVICE|Daily Activity Goal and Feedback|The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.
219263370|NCT04652011|PROCEDURE|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
219263371|NCT04652011|PROCEDURE|osteopathic manipulative treatment|Osteopathic manipulative treatment
219263372|NCT04652011|DRUG|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
219263373|NCT00968006|DRUG|Sitagliptin|100 mg once daily for 4 weeks
219263374|NCT05971628|PROCEDURE|RAPID procedure|RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma
219263375|NCT05959161|PROCEDURE|DBS|We observed the prognostic changes of patients after DBS surgery
219263376|NCT05212311|DEVICE|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
219263377|NCT05212311|DEVICE|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
219263378|NCT05212311|DEVICE|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
219263379|NCT05212311|OTHER|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
219263380|NCT03560414|PROCEDURE|simple plasma exchange|simple plasma exchange treatment
219263381|NCT03560414|PROCEDURE|conventional PDF treatment group|conventional PDF treatment group
219263382|NCT03560414|PROCEDURE|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
219263383|NCT03769298|DRUG|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
219263384|NCT02942368|DEVICE|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
219263385|NCT02453516|PROCEDURE|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
219263386|NCT02453516|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
219263387|NCT02453516|DRUG|ropivacaine|Drug indicated for regional anesthesia
219263388|NCT02453516|DRUG|epinephrine|Drug indicated to prolong the action of regional anesthesia
219263389|NCT02453516|OTHER|sterile saline|Neutral injection (no drug involved)
219263390|NCT00644735|DRUG|Esomeprazole|
219263391|NCT00644735|DRUG|Lansoprazole|
219263392|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
219263393|NCT00396214|DRUG|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
219263394|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
219263395|NCT01939821|BEHAVIORAL|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
219263396|NCT01939821|BEHAVIORAL|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
219263397|NCT01024036|DRUG|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
219263398|NCT01024036|DRUG|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
219263399|NCT01024036|DRUG|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
219263400|NCT06584825|DEVICE|Enhanced Vitals Monitoring|"For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first)."
219263401|NCT04032119|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
219263402|NCT04032119|DRUG|Epinephrine|Epinephrine
219263403|NCT03459612|DRUG|Lasmiditan|Administered orally
219263404|NCT03459612|DRUG|Placebo|Administered orally
219263405|NCT03459612|DRUG|Diphenhydramine|Administered orally
219263406|NCT05930132|PROCEDURE|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
219263407|NCT05930132|PROCEDURE|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
219263408|NCT03979547|BEHAVIORAL|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
219263409|NCT05230095|BEHAVIORAL|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
219263410|NCT05230095|BEHAVIORAL|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
219263411|NCT03628690|DEVICE|BandGrip|Topical skin closure device
219263412|NCT03628690|DEVICE|Suture|Wound closure
219263413|NCT05511558|DRUG|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
219263414|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
219263415|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
219263416|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
219263417|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
219263418|NCT03246399|DRUG|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
219263419|NCT04017897|DRUG|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
219263420|NCT03282578|DEVICE|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
219263421|NCT03282578|DEVICE|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
219263422|NCT05261230|BEHAVIORAL|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
219263423|NCT05261230|BEHAVIORAL|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
219263424|NCT04318314|DIAGNOSTIC_TEST|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
219263425|NCT02570256|BEHAVIORAL|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
219263426|NCT02570256|BEHAVIORAL|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
219263427|NCT02570256|BEHAVIORAL|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
219263428|NCT03965221|BEHAVIORAL|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
219263429|NCT03965221|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
219263430|NCT03397316|PROCEDURE|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
219263431|NCT04130581|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
219263432|NCT04344756|DRUG|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
219263433|NCT01032356|DEVICE|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
219263434|NCT00604188|DRUG|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
219263435|NCT00604188|DRUG|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
219263436|NCT04440059|DRUG|ICP-022|ICP-022 at a dose of 150mg PO QD
219263437|NCT04360434|DRUG|NI006|NI006 will be administered intravenously
219263438|NCT04360434|DRUG|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
219263439|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
219263440|NCT05940831|BEHAVIORAL|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
219263441|NCT05940831|BEHAVIORAL|Control|Routine care/ information giving
219263442|NCT06254300|BEHAVIORAL|Exercise Training|The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
219263443|NCT04452409|DEVICE|low level laser|The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
219263444|NCT04452409|OTHER|Mediterranean diet|recommend healthy diet component evaluated periodically by 24 hour recall
219263445|NCT00857740|BEHAVIORAL|Education|Education about the neurophysiology of pain
219263446|NCT01218425|DRUG|Methylphenidate 40 mg|Oral dose 40 mg
219263447|NCT01218425|DRUG|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
219263448|NCT01218425|DRUG|Domperidon 10 mg|Domperidon 10 mg
219263449|NCT01214681|DIETARY_SUPPLEMENT|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
219263450|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
219263451|NCT01214681|DIETARY_SUPPLEMENT|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
219263452|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
219263453|NCT03167047|PROCEDURE|Caudal block|Caudal epidural
219263454|NCT03167047|PROCEDURE|Nerve Block|Peripheral nerve block
219263455|NCT03167047|DRUG|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
219263456|NCT02291809|BIOLOGICAL|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
219263457|NCT04956614|DEVICE|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
219263458|NCT02850718|DRUG|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
219263459|NCT02850718|DRUG|Oral Sildenafil|50 mg oral sildenafil (Viagra)
219263460|NCT05850182|BEHAVIORAL|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
219263461|NCT06153498|DRUG|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
219263462|NCT04498988|OTHER|Observational study without interventions|
219263463|NCT01817712|BEHAVIORAL|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
219263464|NCT01817712|BEHAVIORAL|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
219263465|NCT05571306|OTHER|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
219263466|NCT05904756|DEVICE|framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone|evaluation of patient satisfaction and oral healty related quality of life
219263467|NCT04666376|OTHER|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
219263468|NCT05822128|OTHER|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
219263469|NCT02111720|BEHAVIORAL|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
219263470|NCT02111720|BEHAVIORAL|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
219263471|NCT03094455|OTHER|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
219263472|NCT03674762|DEVICE|Microgrooved dental implants|Dental Implant placement
219263473|NCT05226039|BEHAVIORAL|Moderate intensity acute exercise bout|The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
219263474|NCT05554926|DRUG|AEF0117|2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
219263475|NCT00281047|DRUG|FP-10|
219263476|NCT01260207|OTHER|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
219263477|NCT04643093|DRUG|Pitavastatin|Pitavastatin, QD
219263478|NCT04643093|DRUG|Ezetimibe|Ezetimibe, QD
219263479|NCT04643093|DRUG|1PC111|1PC111, QD
219263480|NCT00356759|DRUG|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
219263481|NCT03750526|BEHAVIORAL|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
219263482|NCT03750526|BEHAVIORAL|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
219263483|NCT03750526|BEHAVIORAL|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
219263484|NCT03750526|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
219263485|NCT05648604|BEHAVIORAL|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardening mentor twice monthly, and attending a gardening informational workshop once monthly.
219263486|NCT04702399|DEVICE|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
219263487|NCT01965041|DRUG|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
219263488|NCT01134718|DRUG|TMC435 (G006)|one morning dose of 150 mg
219263489|NCT01134718|DRUG|TMC435 (F021)|one morning dose of 150 mg
219263490|NCT01134718|DRUG|TMC435 (G007)|one morning dose of 150 mg
219263491|NCT04236245|DEVICE|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
219263492|NCT00474383|DRUG|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
219263493|NCT00474383|DRUG|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
219263494|NCT04151771|OTHER|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
219263495|NCT04151771|OTHER|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
219263496|NCT00926302|DRUG|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
219263497|NCT00926302|DRUG|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
219263498|NCT02998918|DIETARY_SUPPLEMENT|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
219263499|NCT02998918|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
219263500|NCT05910697|OTHER|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
219263501|NCT03393065|OTHER|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
219263502|NCT03642288|DRUG|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
219263503|NCT00443599|DRUG|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
219263504|NCT00443599|OTHER|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
219263505|NCT03110692|BEHAVIORAL|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
219263506|NCT00220571|DEVICE|Coronary Angioplasty (PTCA)|
219263507|NCT05655624|OTHER|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
219263508|NCT05655624|OTHER|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
219263509|NCT04836234|OTHER|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
219263510|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
219263511|NCT05901155|DEVICE|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
219263512|NCT03455205|DRUG|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
219263513|NCT03455205|DRUG|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
219263514|NCT02080403|DRUG|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
219263515|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
219263516|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
219263517|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
219263518|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
219263519|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
219263520|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
219263521|NCT06105762|OTHER|Ketogenic Diet|The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
219263522|NCT03533777|PROCEDURE|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
219263523|NCT03533777|OTHER|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
219263524|NCT03533777|DEVICE|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
219263525|NCT03533777|DRUG|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
219263526|NCT00103532|BEHAVIORAL|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
219263527|NCT00103532|BEHAVIORAL|Standard care|Participants will receive standard care plus referrals at three months post-baseline
219263528|NCT02202109|BEHAVIORAL|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
219263529|NCT02202109|BEHAVIORAL|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
219263530|NCT00803777|DEVICE|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
219263531|NCT04634370|BIOLOGICAL|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
219263532|NCT00002463|DRUG|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
219263533|NCT00002463|DRUG|Leucovorin Calcium|
219263534|NCT00002463|DRUG|Mechlorethamine Hydrochloride|
219263535|NCT00002463|DRUG|Methotrexate|
219263536|NCT00002463|DRUG|Prednisone|
219263537|NCT00002463|DRUG|Procarbazine Hydrochloride|
219263538|NCT00002463|DRUG|Vincristine Sulfate|
219263539|NCT00002463|PROCEDURE|Conventional Surgery|
219263540|NCT03163706|BEHAVIORAL|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
219263541|NCT01861639|DEVICE|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
219263542|NCT01861639|DEVICE|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
219263543|NCT01861639|DEVICE|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
219263544|NCT01861639|DEVICE|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
219263545|NCT01861639|DEVICE|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
219263546|NCT01861639|DEVICE|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
219263547|NCT04460729|DRUG|Capmatinib|400 mg administered orally twice daily
219263548|NCT02369861|DRUG|ST266|Topical ocular application 4 times per day
219263549|NCT02369861|DRUG|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
219263550|NCT04431245|DRUG|Entecavir|Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.
219263551|NCT00902798|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
219263552|NCT00902798|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
219263553|NCT05731505|BEHAVIORAL|theory-based education-consulting|Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
219263554|NCT04505475|PROCEDURE|Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)|single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
219263555|NCT00612352|DRUG|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
219263556|NCT01986114|DRUG|SM-13496|
219263557|NCT00846508|DRUG|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
219263558|NCT00438178|DRUG|Obatoclax mesylate (GX15-070MS)|
219263559|NCT01979289|OTHER|computerized cognitive remediation|
219263560|NCT01979289|OTHER|computerized cognitive remediation:Control|
219263561|NCT02450890|DRUG|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
219263562|NCT02450890|DRUG|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
219263563|NCT00664105|DRUG|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
219263564|NCT00664105|DRUG|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
219263565|NCT00664105|RADIATION|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
219263566|NCT06240429|DIETARY_SUPPLEMENT|Collagen|Daily doses of 10 g collagen peptide supplementation
219263567|NCT06080360|OTHER|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
219263568|NCT00683059|DRUG|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
219263569|NCT05068921|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
219263570|NCT04171245|OTHER|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
219263571|NCT04171245|DEVICE|Sleep tracking equipment|Tracking sleep using equipment
219263572|NCT00220545|PROCEDURE|Laparoscopic ovarian diathermy|
219263573|NCT02034162|DRUG|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
219263574|NCT02034162|DRUG|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
219263575|NCT02450695|DEVICE|rTMS|
219263576|NCT03624387|OTHER|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
219263577|NCT03969576|PROCEDURE|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
219263578|NCT03969576|PROCEDURE|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
219263579|NCT04556409|DEVICE|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
219263580|NCT04556409|DEVICE|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
219263581|NCT04556409|OTHER|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
219263582|NCT05828849|BEHAVIORAL|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
219263583|NCT06118242|OTHER|Use of oral care solutions|Oral care solutions to be used: Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid
219263584|NCT00571077|DEVICE|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
219263585|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
219263586|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
219263587|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
219263588|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
219263589|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
219263590|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
219263591|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
219263592|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
219263593|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
219263594|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
219263595|NCT04729842|PROCEDURE|Axillary Brachial plexus block|Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
219263596|NCT01501292|OTHER|Fixation and staining|Fixation and staining by MitiTracker Green FM
219263597|NCT01501292|OTHER|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
219263598|NCT01042717|DRUG|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
219263599|NCT01788475|DRUG|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
219263600|NCT02619214|DRUG|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
219263601|NCT02619214|DRUG|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
219263602|NCT00564148|DRUG|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
219263603|NCT00749242|OTHER|orthopedic brace|antalgic drugs and orthopedic brace
219263604|NCT00749242|DEVICE|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
219263605|NCT01508637|OTHER|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
219263606|NCT01508637|OTHER|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
219263607|NCT01508637|DRUG|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
219263608|NCT01508637|DRUG|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
219263609|NCT00761956|DEVICE|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
219263610|NCT00761956|DEVICE|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
219263611|NCT03437135|DIAGNOSTIC_TEST|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
219263612|NCT03234361|DIETARY_SUPPLEMENT|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
219263613|NCT03234361|DIETARY_SUPPLEMENT|Low Phosphate Phase|2 capsules of sodium chloride.
219263614|NCT06956313|DEVICE|Hydraulic Pressure Lifting Technique|Hydraulic Pressure Lifting Technique
219263615|NCT06956313|DEVICE|Piezo-Surgical Lifting Technique|Piezo-Surgical Lifting Technique
219263616|NCT03024996|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
219263617|NCT03024996|OTHER|Placebo|Placebo matching to atezolizumab q3w
219263618|NCT00372346|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
219263619|NCT01885923|DEVICE|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
219263620|NCT03060382|DEVICE|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
219263621|NCT03060382|BIOLOGICAL|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
219263622|NCT02263040|BIOLOGICAL|Fluzone High-Dose|Influenza vaccine
219263623|NCT02263040|BIOLOGICAL|Fluzone (standard dose)|Influenza vaccine
219263624|NCT02828345|OTHER|Specimen Collection|
219263625|NCT02106195|DRUG|Belumosudil|
219263626|NCT04157192|OTHER|Real acupuncture|The patient will be treated for migraine with real acupuncture.
219263627|NCT04157192|OTHER|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
219263628|NCT04027959|DIETARY_SUPPLEMENT|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
219263629|NCT04182633|COMBINATION_PRODUCT|vancomycin, Miralax, intestinal microbiota|vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
219263630|NCT04182633|COMBINATION_PRODUCT|placebo vancomycin, Miralax, placebo intestinal microbiota|placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
219263631|NCT04581408|DRUG|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
219263632|NCT05097209|DRUG|Camrelizumab|Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
219263633|NCT05097209|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
219263634|NCT05097209|DRUG|Induction Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
219263635|NCT05097209|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
219263636|NCT05097209|DRUG|Concurrent cisplatin|Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219263637|NCT04633954|DRUG|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
219263638|NCT04472845|RADIATION|1 week RT|RT will be delivered over 1 week
219263639|NCT04472845|RADIATION|2 week RT|RT will be delivered over 2 week
219263640|NCT05013515|DRUG|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
219263641|NCT02988297|DRUG|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
219263642|NCT02988297|DRUG|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
219263643|NCT05611749|DRUG|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
219263644|NCT05611749|OTHER|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
219263645|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
219263646|NCT04469465|DRUG|Danicopan|Oral tablet
219263647|NCT04469465|DRUG|Placebo|Oral tablet
219263648|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
219263649|NCT00522743|DRUG|growth hormone and gonadotropin-releasing hormone agonist|GH \& GNRHa treatment
219263650|NCT00522743|DRUG|growth hormone|GH treatment
219263651|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
219263652|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
219263653|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
219263654|NCT03212677|OTHER|Placebo|Cornstarch
219263655|NCT06573346|OTHER|Cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
219263656|NCT06255626|DRUG|CD40.RBDv vaccin (SARS-Cov2 Vaccin)|1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
219263657|NCT06548217|DRUG|ONO-4538HSC|ONO-4538HSC will be administered subcutaneously once every 4 weeks.
219263658|NCT03480295|DEVICE|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
219263659|NCT03480295|DEVICE|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
219263660|NCT06130059|DRUG|Low Dose Colchicine|Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
219263661|NCT06130059|DRUG|Placebo|Placebo
219263662|NCT00314418|PROCEDURE|Colonoscopy in the prone position|
219263663|NCT04214613|PROCEDURE|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
219263664|NCT03163043|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
219263665|NCT01854736|DRUG|Grazax|GRAZAX
219263666|NCT01854736|OTHER|Placebo|Placebo
219263667|NCT06177899|PROCEDURE|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
219263668|NCT00385099|DRUG|GW876008|
219263669|NCT05735743|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
219263670|NCT02585297|OTHER|no intervention|
219263671|NCT06078566|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
219263672|NCT01122563|DRUG|Solifenacin|oral
219263673|NCT03568812|DRUG|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
219263674|NCT03568812|OTHER|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
219263675|NCT05032404|DEVICE|BNT103|BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.
219263676|NCT03194867|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219263677|NCT03194867|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219263678|NCT04943354|BEHAVIORAL|Taking a person's venous blood|Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
219263679|NCT00464945|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
219263680|NCT03831854|DRUG|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).
219263681|NCT03831854|DRUG|Placebo|300 mg of oral Placebo
219263682|NCT03831854|DRUG|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
219263683|NCT01828086|BIOLOGICAL|CJM112|Monoclonal antibody
219263684|NCT01828086|BIOLOGICAL|Secukinumab|Monoclonal antibody
219263685|NCT01828086|OTHER|Placebo|Liquid for subcutaneous injection without active drug.
219263686|NCT01642953|DIETARY_SUPPLEMENT|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
219263687|NCT05253859|OTHER|No intervention|Registry study: No intervention
219263688|NCT04654962|PROCEDURE|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
219263689|NCT03067545|OTHER|Step rate increase|increase the step rate during running by 10% steps per minute
219263690|NCT04293952|OTHER|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
219263691|NCT04293952|OTHER|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
219263692|NCT03305809|DRUG|LY3154207|Administered orally.
219263693|NCT03305809|DRUG|Placebo|Administered orally.
219263694|NCT02851875|OTHER|Registry|
219263695|NCT01124071|BEHAVIORAL|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
219263696|NCT01124071|BEHAVIORAL|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
219263697|NCT03065933|DRUG|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
219263698|NCT02536742|DRUG|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
219263699|NCT02536742|DRUG|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
219263700|NCT03559790|DRUG|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
219263701|NCT06488638|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days|commercially available beetroot juice dietary nitrate supplement
219263702|NCT04173702|DIAGNOSTIC_TEST|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
219263703|NCT04629443|DRUG|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
219263704|NCT01547117|RADIATION|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
219263705|NCT01547117|RADIATION|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
219263706|NCT01547117|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
219263707|NCT01547117|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
219263708|NCT00258362|DRUG|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
219263709|NCT00258362|DRUG|docetaxel|75 mg/m\^2 on Day 1 of each course
219263710|NCT00258362|RADIATION|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
219263711|NCT01265043|OTHER|Oral hygiene intervention|Oral health promotion intervention
219263712|NCT04481646|DIAGNOSTIC_TEST|Face mask sampling|Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
219263713|NCT06322147|DRUG|Doublet or triplet chemotherapy combined with cetuximab|"chemotherapy+cetuximab combination therapy，chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h)."
219263714|NCT02024295|DRUG|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
219263715|NCT02024295|DRUG|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
219263716|NCT02024295|DRUG|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
219263717|NCT00568698|DRUG|Hydroxyurea|
219263718|NCT00568698|DRUG|Placebo to match hydroxyurea|
219263719|NCT05648396|OTHER|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
219263720|NCT01660256|DRUG|OPC-12759|Instillation, 4 times/day for 4 weeks
219263721|NCT01660256|DRUG|Placebo|
219263722|NCT06027229|BIOLOGICAL|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
219263723|NCT05407987|DRUG|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
219263724|NCT05407987|DRUG|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
219263725|NCT04456244|OTHER|Evaluation of the static posture|Photographing from the back, front and side with ADIBAS posturography in standing position
219263726|NCT04585737|DRUG|Dolutegravir / Lamivudine Pill|Experimental
219263727|NCT04585737|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
219263728|NCT00551135|DRUG|Pregabalin|150 mg BID
219263729|NCT00551135|DRUG|placebo|Placebo
219263730|NCT00551135|DRUG|Pregabalin|75 mg BID
219263731|NCT00551135|DRUG|Pregabalin|25 mg BID
219263732|NCT00858247|DIETARY_SUPPLEMENT|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
219263733|NCT03096197|DEVICE|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
219263734|NCT03096197|DEVICE|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
219263735|NCT02913170|DIETARY_SUPPLEMENT|Nattokinase|
219263736|NCT02913170|DIETARY_SUPPLEMENT|Placebo|
219263737|NCT06433440|BIOLOGICAL|PVRV|Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
219263738|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
219263739|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
219263740|NCT03596463|OTHER|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
219263741|NCT04129047|DRUG|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
219263742|NCT04129047|DRUG|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
219263743|NCT04674878|OTHER|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
219263744|NCT04674878|OTHER|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
219263745|NCT01154062|DRUG|Pazopanib|Pazopanib tablet
219263746|NCT02627898|DRUG|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
219263747|NCT02627898|DRUG|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
219263748|NCT00585975|DRUG|bromfenac ophthalmic solution|sterile opthalmic solution
219263749|NCT00120575|PROCEDURE|hemofiltration|
219263750|NCT06547671|OTHER|Employment of a confort room to help in anxiety and agitation moments.|Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
219263751|NCT04456712|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
219263752|NCT04456712|DRUG|Levofloxacin 750 MG|antibiotic
219263753|NCT00247702|DRUG|warfarin|
219263754|NCT02735798|DRUG|MM-302|
219263755|NCT02735798|DRUG|Trastuzumab|
219263756|NCT04627441|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
219263757|NCT04627441|DEVICE|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
219263758|NCT01747837|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
219263759|NCT04157218|DEVICE|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
219263760|NCT04157218|DEVICE|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
219263761|NCT05579665|BIOLOGICAL|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
219263762|NCT05579665|BIOLOGICAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
219263763|NCT05579665|DRUG|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
219263764|NCT01728207|DRUG|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
219263765|NCT03184818|OTHER|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
219263766|NCT04730076|PROCEDURE|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
219263767|NCT04730076|PROCEDURE|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
219263768|NCT02836054|PROCEDURE|lumbar puncture (LP)|
219263769|NCT02836054|PROCEDURE|brain MRI|
219263770|NCT02338427|OTHER|Immunohistochemistry|
219263771|NCT02338427|OTHER|Proteomic analysis|
219263772|NCT01171300|OTHER|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
219263773|NCT01171300|OTHER|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
219263774|NCT00155883|DRUG|Taxteral|
219263775|NCT00155883|DRUG|5-Fluorouracil|
219263776|NCT00155883|DRUG|Leucovorin|
219263777|NCT00010842|DRUG|Ginkgo biloba|
219263778|NCT00010842|DRUG|Alpha-lipoic acid|
219263779|NCT00010842|DRUG|Vitamin E/Selenium|
219263780|NCT00010842|DRUG|Essential fatty acids|
219263781|NCT04207697|BIOLOGICAL|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
219263782|NCT01253447|DRUG|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
219263783|NCT01253447|OTHER|laboratory biomarker analysis|Correlative studies
219263784|NCT01435798|DRUG|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
219263785|NCT02299427|BEHAVIORAL|dog safety|use of dog safety website at home for about 2 weeks
219263786|NCT02299427|BEHAVIORAL|transportation safety|use of transportation safety website at home for about 2 weeks
219263787|NCT04187430|BEHAVIORAL|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
219263788|NCT04187430|BEHAVIORAL|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
219263789|NCT01554293|DRUG|Matching placebo|Matching Placebo, single dose
219263790|NCT01554293|DRUG|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
219263791|NCT02032108|BEHAVIORAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
219263792|NCT03035318|DEVICE|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
219263793|NCT03035318|DEVICE|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
219263794|NCT03035318|DEVICE|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
219263795|NCT03035318|DEVICE|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
219263796|NCT03035318|DEVICE|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
219263797|NCT01603342|DRUG|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
219263798|NCT01603342|DRUG|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
219263799|NCT01095913|DRUG|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
219263800|NCT05241054|DRUG|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
219263801|NCT05241054|DRUG|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
219263802|NCT05241054|DRUG|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
219263803|NCT05241054|DRUG|Fentanyl|fentanyl 1 microgram.kg
219263804|NCT05241054|DRUG|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
219263805|NCT05241054|PROCEDURE|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
219263806|NCT05241054|DRUG|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
219263807|NCT05241054|DRUG|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
219263808|NCT05241054|OTHER|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
219263809|NCT05241054|DRUG|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
219263810|NCT01481519|DRUG|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
219263811|NCT01481519|DRUG|Artificial Tears|artificial tears 1 drop, 4 times per day
219263812|NCT03311269|DEVICE|ClariVein RES|ClariVein system
219263813|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
219263814|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
219263815|NCT02929706|GENETIC|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
219263816|NCT04760197|OTHER|no intervention|no intervention
219263817|NCT04826497|DRUG|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
219263818|NCT04826497|DRUG|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
219263819|NCT03756064|DRUG|Pyrotinib|Pyrotinib: 400mg orally daily
219263820|NCT03756064|DRUG|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
219263821|NCT03756064|DRUG|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
219263822|NCT03756064|DRUG|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
219263823|NCT03756064|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
219263824|NCT03758456|BIOLOGICAL|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
219263825|NCT00000232|DRUG|Buprenorphine|
219263826|NCT00143741|DRUG|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
219263827|NCT04307641|BEHAVIORAL|2 Page Information Sheet|2 page information sheet about medication abortion
219263828|NCT04152395|OTHER|EVAR|Patients undergoing EVAR
219263829|NCT06478732|OTHER|health services|Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
219263830|NCT04522583|DIAGNOSTIC_TEST|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
219263831|NCT06192719|OTHER|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
219263832|NCT04244422|OTHER|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
219263833|NCT04237675|PROCEDURE|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
219263834|NCT04964778|DEVICE|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
219263835|NCT02830256|OTHER|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
219263836|NCT02283021|OTHER|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
219263837|NCT02757313|DRUG|Low dose THC marijuana|
219263838|NCT02757313|DRUG|High dose THC marijuana|
219263839|NCT02757313|DRUG|Placebo marijuana|
219263840|NCT02987998|DRUG|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
219263841|NCT02987998|DRUG|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
219263842|NCT02987998|DRUG|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
219263843|NCT02987998|DRUG|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
219263844|NCT01627470|DEVICE|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
219263845|NCT03990298|DIAGNOSTIC_TEST|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
219263846|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation I
219263847|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation II
219263848|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation III
219263849|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation IV
219263850|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation V
219263851|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation VI
219263852|NCT00937521|BIOLOGICAL|Control|Control
219263853|NCT00937521|BIOLOGICAL|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
219263854|NCT00487526|PROCEDURE|duodenal jejunal bypass|
219263855|NCT00198302|DRUG|Aurexis®|
219263856|NCT01732341|DEVICE|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
219263857|NCT01732341|DEVICE|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~\--------------------------------------------------------------------------------"
219263858|NCT05771025|PROCEDURE|Hepatectomy|Patients in the hepatectomy group receive liver resection.
219263859|NCT05181397|DRUG|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
219263860|NCT02828163|OTHER|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
219263861|NCT02828163|DRUG|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
219263862|NCT02945371|BEHAVIORAL|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
219263863|NCT02945371|BEHAVIORAL|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
219263864|NCT02792647|DRUG|Placebo|Administered orally
219263865|NCT02792647|DRUG|IX-01|Administered orally
219263866|NCT03503383|BEHAVIORAL|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
219263867|NCT03503383|BEHAVIORAL|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
219263868|NCT06234813|OTHER|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
219263869|NCT06234813|OTHER|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
219263870|NCT06234813|OTHER|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
219263871|NCT06234813|OTHER|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
219263872|NCT06234813|OTHER|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
219263873|NCT05609799|OTHER|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
219263874|NCT04116281|OTHER|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
219263875|NCT02261298|DRUG|ONO-4538|
219263876|NCT01317706|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
219263877|NCT02276209|DRUG|Dasotraline|Dasotraline 4 mg once daily
219263878|NCT02276209|DRUG|Dasotraline|Dasotraline 6 mg once daily
219263879|NCT02276209|OTHER|Placebo|Placebo once daily
219263880|NCT00506272|PROCEDURE|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
219263881|NCT00506272|PROCEDURE|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
219263882|NCT06192030|OTHER|Prediction model|We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
219263883|NCT01721746|BIOLOGICAL|BMS-936558|
219263884|NCT01721746|DRUG|Dacarbazine|
219263885|NCT01721746|DRUG|Carboplatin|
219263886|NCT01721746|DRUG|Paclitaxel|
219263887|NCT05428111|DIAGNOSTIC_TEST|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
219263888|NCT04358068|DRUG|Hydroxychloroquine (HCQ)|Administered orally
219263889|NCT04358068|DRUG|Azithromycin (Azithro)|Administered orally
219263890|NCT04358068|DRUG|Placebo for Hydroxychloroquine|Administered orally
219263891|NCT04358068|DRUG|Placebo for Azithromycin|Administered orally
219263892|NCT00237211|DRUG|Letrozole|
219263893|NCT01438762|BEHAVIORAL|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
219263894|NCT01438762|OTHER|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
219263895|NCT03887169|DRUG|Methionine|Administration of methionine from D1 to D60
219263896|NCT03887169|DRUG|Vitamin B12, B9, B6, C supplementation|In case of hyperhomocysteinemia
219263897|NCT03887169|DIAGNOSTIC_TEST|Methionine/homocysteine Dosage|Plasma concentration control of methionine and homocysteine from D0 to D75
219263898|NCT03887169|DIAGNOSTIC_TEST|Thoracic CT scan|At D60
219263899|NCT03887169|DIAGNOSTIC_TEST|Abdominal and liver ultrasound.|At D60
219263900|NCT03887169|DIAGNOSTIC_TEST|Brain MRI|In case of abnormal neurological examination
219263901|NCT02411708|DRUG|SANGUINATE|Single two-hour infusion of SANGUINATE
219263902|NCT02411708|DRUG|Placebo|Single two-hour infusion of placebo
219263903|NCT05605288|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
219263904|NCT02781298|DIETARY_SUPPLEMENT|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
219263905|NCT02781298|DIETARY_SUPPLEMENT|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
219263906|NCT03133078|OTHER|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
219263907|NCT03133078|OTHER|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
219263908|NCT06382571|DRUG|Renin-Angiotensin System Inhibitor|
219263909|NCT00774423|DRUG|Riluzole|50 mg per day during 24 months
219263910|NCT00831012|BIOLOGICAL|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
219263911|NCT05005325|OTHER|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
219263912|NCT05005325|OTHER|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
219263913|NCT00945399|PROCEDURE|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
219263914|NCT00945399|PROCEDURE|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
219263915|NCT00239681|DRUG|Rosuvastatin|Oral
219263916|NCT00239681|OTHER|Placebo|Oral
219263917|NCT04055610|DEVICE|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
219263918|NCT02447718|BIOLOGICAL|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
219263919|NCT02447718|BIOLOGICAL|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
219263920|NCT02447718|BIOLOGICAL|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
219263921|NCT00716547|DRUG|ketoprofen in Diractin®|50 mg (b.i.d.)
219263922|NCT00716547|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
219263923|NCT00716547|DRUG|Placebo|b.i.d.
219263924|NCT00716547|DRUG|celecoxib|100 mg (b.i.d.)
219263925|NCT03599622|DRUG|BMS-986165|Specified dose on specified days
219263926|NCT03599622|OTHER|Placebo|Specified dose on specified days
219263927|NCT00770588|DRUG|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
219263928|NCT00770588|DRUG|Placebo|To match Gefitinib
219263929|NCT00142688|BEHAVIORAL|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
219263930|NCT00142688|BEHAVIORAL|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
219263931|NCT01114308|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
219263932|NCT01114308|DRUG|placebo implant|Implant contains ethylene vinyl acetate
219263933|NCT01114308|DRUG|Buprenorphine|sublingual buprenorphine/naloxone tablets
219263934|NCT06176898|DEVICE|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
219263935|NCT04620369|DRUG|Placebo Administration|Instill isotonic nasal saline intranasally
219263936|NCT04620369|OTHER|Questionnaire Administration|Ancillary studies
219263937|NCT04620369|DRUG|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
219263938|NCT05294406|DRUG|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
219263939|NCT01711346|BIOLOGICAL|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
219263940|NCT01711346|BIOLOGICAL|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
219263941|NCT00516828|DRUG|cytarabine|subcutaneously twice daily from Day 1 to 10
219263942|NCT05809336|DRUG|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
219263943|NCT05809336|DRUG|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
219263944|NCT04891471|RADIATION|Stereotactic RadioTherapy|To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).
219263945|NCT04891471|RADIATION|Whole Brain Irradiation|To irradiate the entire brain, site of at least 5 parenchymal metastasis.
219263946|NCT03712384|OTHER|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
219263947|NCT01003171|DRUG|MCS-2 soft-gel capsule|MCS-2 30 mg/day
219263948|NCT04502836|BEHAVIORAL|Preliminary psychological intervention|psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
219263949|NCT00332826|DRUG|Technosphere Insulin|
219263950|NCT02812875|DRUG|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
219263951|NCT05874778|DRUG|6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy|All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
219263952|NCT05874778|RADIATION|Radiotherapy beyond standard R-CHOP Chemotherapy|Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
219263953|NCT03579433|DEVICE|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
219263954|NCT03579433|OTHER|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
219263955|NCT03579433|DEVICE|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
219263956|NCT00468130|DRUG|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
219263957|NCT00468130|DRUG|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
219263958|NCT00436956|PROCEDURE|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
219263959|NCT00436956|DRUG|AZD2171|20 mg oral daily for 28 days
219263960|NCT00436956|DRUG|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
219263961|NCT05330052|DEVICE|Agilik|The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
219263962|NCT02782572|OTHER|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
219263963|NCT00103636|PROCEDURE|Extending peripheral intravenous (IV) cannula dwell times|
219263964|NCT06014047|PROCEDURE|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
219263965|NCT06014047|PROCEDURE|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
219263966|NCT02460536|BEHAVIORAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
219263967|NCT02460536|BEHAVIORAL|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
219263968|NCT02460536|BEHAVIORAL|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
219263969|NCT02460536|BEHAVIORAL|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
219263970|NCT01316965|BEHAVIORAL|Multifaceted prevention program HELP(Hospital Elder Life Program)|"* A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
219263971|NCT02038998|DEVICE|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
219263972|NCT00000902|DRUG|Ritonavir|
219263973|NCT00000902|DRUG|Nelfinavir mesylate|
219263974|NCT00000902|DRUG|Nevirapine|
219263975|NCT00000902|DRUG|Lamivudine|
219263976|NCT00000902|DRUG|Stavudine|
219263977|NCT00000902|DRUG|Zidovudine|
219263978|NCT00000902|DRUG|Zalcitabine|
219263979|NCT00000902|DRUG|Didanosine|
219263980|NCT05336513|OTHER|Diet Control|Diet following mediterranean principles, for 15 weeks
219263981|NCT05336513|OTHER|Diet anti-inflammatory|Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
219263982|NCT00406900|PROCEDURE|Treatment of metastatic disease|
219263983|NCT02542423|OTHER|Endocan blood test samples|
219263984|NCT04683341|DRUG|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.
219263985|NCT03827850|DRUG|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
219263986|NCT01177995|BEHAVIORAL|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
219263987|NCT01006889|DRUG|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
219263988|NCT04128462|DRUG|MNK-6105|L-Ornithine Phenylacetate for IV infusion
219263989|NCT04128462|DRUG|Placebo|Matching placebo for IV infusion
219263990|NCT04128462|DRUG|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
219263991|NCT02838576|DRUG|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
219263992|NCT02838576|DRUG|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
219263993|NCT04228406|DRUG|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
219263994|NCT02174614|BEHAVIORAL|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
219263995|NCT02174614|BEHAVIORAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
219263996|NCT02174614|BEHAVIORAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
219263997|NCT03595423|PROCEDURE|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
219263998|NCT05809102|PROCEDURE|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
219263999|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
219264000|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
219264001|NCT02455999|DRUG|Placebo|Placebo eye drops administration for 10 consecutive days
219264002|NCT01642095|OTHER|Laboratory Biomarker Analysis|Correlative studies
219264003|NCT03384771|BEHAVIORAL|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
219264004|NCT05267678|OTHER|No intervention|This is an observational study without any intervention
219264005|NCT01036243|DIETARY_SUPPLEMENT|test formula 1|hydrolyzed formula with probiotics
219264006|NCT01036243|DIETARY_SUPPLEMENT|test formula 2|acidified hydrolyzed formula
219264007|NCT01036243|DIETARY_SUPPLEMENT|test formula 3|hydrolyzed formula without probiotics
219264008|NCT01036243|DIETARY_SUPPLEMENT|reference formula|standard infant formula
219264009|NCT00238992|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219264010|NCT03494465|PROCEDURE|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
219264011|NCT03494465|DRUG|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
219264012|NCT01095133|DRUG|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
219264013|NCT01095133|DRUG|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
219264014|NCT02143063|BEHAVIORAL|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
219264015|NCT02143063|BEHAVIORAL|prize contingency management on a variable interval schedule for cocaine abstinence|
219264016|NCT02143063|BEHAVIORAL|standard care|
219264017|NCT02206932|DRUG|Sofosbuvir + Simeprevir|
219264018|NCT02509988|DIETARY_SUPPLEMENT|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
219264019|NCT02509988|DIETARY_SUPPLEMENT|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
219264020|NCT03245463|OTHER|Educational handout|The educational handout will include information on self-management strategies.
219264021|NCT03245463|OTHER|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
219264022|NCT03245463|DRUG|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
219264023|NCT04482192|COMBINATION_PRODUCT|Thoracic paravertebral block|After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
219264024|NCT04482192|DRUG|Systemic analgesia|Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
219264025|NCT03582345|PROCEDURE|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1\. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
219264026|NCT02782611|BEHAVIORAL|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
219264027|NCT06029985|DIAGNOSTIC_TEST|Hysteroscopic Follow Up|Office hysteroscopy was carried out to detect the scar site, performed with a 4-mm, continuous-flow operative hysteroscope by vaginoscopic approach, without analgesia or anesthesia. Distension of the uterus was obtained using a normal solution as distension medium, dispensed by an electronic suction/irrigation pump. This can maintain a constant intrauterine pressure of around 30-40 mmHg, balancing an irrigation flow of 200 mL/min with a vacuum of 0.2 bars, necessary to avoid overdistension of the muscle fibers and patient discomfort. The use of this distension medium allows blood or mucus to be washed out from the pouch if necessary.
219264028|NCT00623363|DRUG|piclozotan|piclozotan, intravenous (IV) infusion
219264029|NCT00623363|DRUG|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
219264030|NCT02332083|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
219264031|NCT02332083|DEVICE|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
219264032|NCT02332083|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
219264033|NCT02332083|DEVICE|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
219264034|NCT05172986|BEHAVIORAL|Follow-up patient program|An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
219264035|NCT05343208|DIAGNOSTIC_TEST|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
219264036|NCT04581252|DEVICE|Non-invasive cardiac system|Non-invasive cardiac system
219264037|NCT04848376|DEVICE|(1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L|As long as there are patients using the above device, conduct questionnaire interview.
219264038|NCT01140282|OTHER|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
219264039|NCT01140282|PROCEDURE|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
219264040|NCT01140282|PROCEDURE|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
219264041|NCT01140282|BEHAVIORAL|exercise intervention|12 week exercise intervention
219264042|NCT01473615|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
219264043|NCT06402214|OTHER|Lombard test|In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
219264044|NCT04751136|DRUG|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
219264045|NCT03499262|BEHAVIORAL|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
219264046|NCT03962322|OTHER|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
219264047|NCT04115852|BEHAVIORAL|fmri|functional magnetic resonance imaging
219264048|NCT04919733|DEVICE|Fluoroscopy reduction|To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
219264049|NCT00718471|DRUG|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
219264050|NCT00718471|DRUG|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
219264051|NCT04120142|OTHER|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
219264052|NCT04120142|OTHER|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
219264053|NCT05655455|BEHAVIORAL|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
219264054|NCT05655455|BEHAVIORAL|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
219264055|NCT00869271|PROCEDURE|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
219264056|NCT00869271|PROCEDURE|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
219264057|NCT02584036|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
219264058|NCT02584036|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
219264059|NCT02584036|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
219264060|NCT06263439|DIAGNOSTIC_TEST|Throat/buccal swab sample|The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
219264061|NCT01719588|DRUG|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
219264062|NCT03065998|DRUG|Opipramol|PO
219264063|NCT03065998|DRUG|Baclofen|PO
219264064|NCT00001509|DRUG|IFN-alpha with retinoic acid|
219264065|NCT02669615|DRUG|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
219264066|NCT03903497|DEVICE|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
219264067|NCT02505477|DRUG|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
219264068|NCT02505477|OTHER|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
219264069|NCT04188756|OTHER|Exercise|High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
219264070|NCT04243642|DEVICE|IntelliSpace Cognition|Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.
219264071|NCT01130168|DRUG|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
219264072|NCT01130168|DRUG|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
219264073|NCT01130168|DRUG|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
219264074|NCT05252936|OTHER|COVID-19 vaccine social media campaign exposure|A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
219264075|NCT03715868|OTHER|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
219264076|NCT00220480|DRUG|escitalopram|10 to 30 mg / day
219264077|NCT00750451|DRUG|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
219264078|NCT00750451|DRUG|crinone 8% gel|routine luteal phase support with progesterone gel
219264079|NCT01711398|DRUG|Drug|
219264080|NCT00932295|OTHER|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
219264081|NCT00932295|OTHER|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
219264082|NCT00932295|OTHER|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
219264083|NCT00932295|OTHER|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
219264084|NCT00430742|DRUG|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
219264085|NCT00430742|DRUG|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
219264086|NCT00859976|DEVICE|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
219264087|NCT00859976|DEVICE|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
219264088|NCT00192426|BIOLOGICAL|CAIV-T|
219264089|NCT06078098|OTHER|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
219264090|NCT00603083|DRUG|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
219264091|NCT00603083|DRUG|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
219264092|NCT01791777|BEHAVIORAL|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
219264093|NCT03428464|DRUG|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
219264094|NCT03428464|OTHER|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
219264095|NCT01157377|DRUG|AGN-214868|AGN-214868 injected into the bladder.
219264096|NCT01157377|DRUG|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
219264097|NCT03935061|OTHER|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
219264098|NCT03220997|DIETARY_SUPPLEMENT|Vitaflow Preload|Carbohydrate loading drink
219264099|NCT04959500|DRUG|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
219264100|NCT04959500|DRUG|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
219264101|NCT04959500|RADIATION|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
219264102|NCT04959500|DRUG|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
219264103|NCT01228305|OTHER|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
219264104|NCT00080041|DRUG|Motexafin Gadolinium Injection|
219264105|NCT02261285|DRUG|ONO-4538|
219264106|NCT02760485|DRUG|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
219264107|NCT02760485|DRUG|ibrutinib|
219264108|NCT05427019|PROCEDURE|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
219264109|NCT05427019|PROCEDURE|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
219264110|NCT05157737|OTHER|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
219264111|NCT05157737|OTHER|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
219264112|NCT05157737|OTHER|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
219264113|NCT01702519|DRUG|nicotine|nicotine transdermal patch
219264114|NCT04530877|BIOLOGICAL|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
219264115|NCT04530877|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
219264116|NCT03738397|BIOLOGICAL|Upadacitinib|Extended release tablet
219264117|NCT03738397|BIOLOGICAL|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
219264118|NCT03738397|DRUG|Placebo to dupilumab|Placebo administered as a subcutaneous injection
219264119|NCT03738397|DRUG|Placebo to upadacitinib|Tablet
219264120|NCT01795859|DRUG|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
219264121|NCT01795859|DRUG|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
219264122|NCT00904722|DRUG|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
219264123|NCT00904722|DRUG|Rituximab|Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
219264124|NCT01748123|DRUG|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
219264125|NCT01748123|DRUG|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
219264126|NCT03862261|OTHER|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services."
219264127|NCT02592681|PROCEDURE|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
219264128|NCT02592681|PROCEDURE|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
219264129|NCT02592681|PROCEDURE|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
219264130|NCT00855322|OTHER|Gym exercise group intervention|Gym based circuit class
219264131|NCT00855322|OTHER|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
219264132|NCT00855322|OTHER|Control group|No intervention
219264133|NCT04759950|BEHAVIORAL|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
219264134|NCT04759950|BEHAVIORAL|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
219264135|NCT04759950|BEHAVIORAL|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
219264136|NCT04241887|PROCEDURE|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
219264137|NCT04241887|PROCEDURE|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
219264138|NCT00296023|BIOLOGICAL|anti-thymocyte globulin|
219264139|NCT00296023|BIOLOGICAL|filgrastim|
219264140|NCT00296023|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219264141|NCT00296023|DRUG|busulfan|
219264142|NCT00296023|DRUG|fludarabine phosphate|
219264143|NCT00296023|DRUG|methotrexate|
219264144|NCT00296023|DRUG|tacrolimus|
219264145|NCT00296023|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
219264146|NCT00296023|PROCEDURE|peripheral blood stem cell transplantation|
219264147|NCT04360083|OTHER|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
219264148|NCT04360083|OTHER|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
219264149|NCT02251340|BEHAVIORAL|Eczema Care Plan|
219264150|NCT01413022|DRUG|Oxaliplatin|
219264151|NCT01413022|DRUG|Irinotecan|
219264152|NCT01413022|DRUG|Leucovorin|
219264153|NCT01413022|DRUG|Fluorouracil|
219264154|NCT01413022|OTHER|laboratory biomarker analysis|Correlative studies
219264155|NCT01413022|OTHER|flow cytometry|Correlative studies
219264156|NCT01413022|OTHER|immunohistochemistry staining method|Correlative studies
219264157|NCT01413022|OTHER|pharmacological study|Correlative studies
219264158|NCT01413022|DRUG|PF-04136309|
219264159|NCT01187810|DRUG|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
219264160|NCT01187810|DRUG|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
219264161|NCT01187810|DRUG|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
219264162|NCT03880825|DRUG|Metformin 500 mg Oral Tablet|single dose
219264163|NCT03880825|DRUG|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
219264164|NCT00567983|DRUG|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
219264165|NCT00567983|DRUG|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
219264166|NCT05980962|PROCEDURE|Inferior oblique anteriorization|symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
219264167|NCT05980962|PROCEDURE|Inferior oblique anteriorization together with unliateral resction|asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
219264168|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
219264169|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
219264170|NCT00334971|PROCEDURE|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
219264171|NCT00631397|DEVICE|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
219264172|NCT01087814|DRUG|Efavirenz|Subject will take efavirenz for 5 days.
219264173|NCT01087814|DRUG|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
219264174|NCT04319614|DRUG|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
219264175|NCT04319614|DRUG|Placebos|100 ml of saline will be administered in the beginning of the procedure.
219264176|NCT02050698|PROCEDURE|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
219264177|NCT02050698|PROCEDURE|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
219264178|NCT04842526|DRUG|Anlotinib and irinotecan combined with temozolomide|Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
219264179|NCT05685953|BIOLOGICAL|DNA vaccine OC-007|Plasmid DNA vaccine
219264180|NCT05685953|OTHER|Placebo|0.9% NaCl solution
219264181|NCT05665413|DEVICE|TENS|strocking technique, HOT PACK and Ergon instrument
219264182|NCT01891656|BEHAVIORAL|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
219264183|NCT01891656|BEHAVIORAL|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
219264184|NCT01891890|DRUG|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
219264185|NCT01891890|DRUG|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
219264186|NCT01891890|DRUG|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
219264187|NCT04429035|DIETARY_SUPPLEMENT|Vitamin K2|Administration of 300 μg Vitamin K2 (MQ7) daily p.o
219264188|NCT04429035|DIETARY_SUPPLEMENT|Placebo|Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
219264189|NCT05656963|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
219264190|NCT06480877|DIAGNOSTIC_TEST|Taking a swab from periodontal pockets or gingival sulci|Swabs for next generation sequencing were taken with paper points as described earlier.
219264191|NCT00279877|PROCEDURE|Kyphoplasty|kyphoplasty
219264192|NCT02383407|DEVICE|Medtronic Deep Brain Stimulation|
219264193|NCT01938898|OTHER|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project"
219264194|NCT03515200|DRUG|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
219264195|NCT03515200|DRUG|Intrathecal Triple Therapy|Given intrathecally (IT).
219264196|NCT03515200|DRUG|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
219264197|NCT03515200|DRUG|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
219264198|NCT03515200|DRUG|Dasatinib|Given orally or nasogastrically (NG).
219264199|NCT03515200|DRUG|Doxorubicin|Given intravenously (IV).
219264200|NCT03515200|DRUG|Ruxolitinib|Given orally or nasogastrically (NG).
219264201|NCT01143883|OTHER|Silverlon|Silverlon dressings are gauze impregnated with silver ions
219264202|NCT01143883|OTHER|Standard of Care Dressing|Standard dry gauze dressing
219264203|NCT00984698|BEHAVIORAL|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
219264204|NCT00984698|BEHAVIORAL|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
219264205|NCT06076824|DRUG|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
219264206|NCT06076824|OTHER|Placebo|Saline solution
219264207|NCT01263925|DRUG|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
219264208|NCT01263925|DRUG|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
219264209|NCT01263925|DRUG|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
219264210|NCT01263925|DRUG|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
219264211|NCT05076136|OTHER|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
219264212|NCT05076136|OTHER|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
219264213|NCT01137877|OTHER|Milk based infant formula powder|milk based infant formula ad lib
219264214|NCT01137877|OTHER|Investigational Infant Formula #1|Milk based infant formula ad lib
219264215|NCT01137877|OTHER|Investigational Infant Formula #2|Milk based infant formula powder ad lib
219264216|NCT01137877|OTHER|Human Milk|Human milk ad lib
219264217|NCT04833244|BEHAVIORAL|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
219264218|NCT04833244|BEHAVIORAL|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
219264219|NCT05021822|PROCEDURE|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
219264220|NCT03185702|GENETIC|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
219264221|NCT05799521|DRUG|Optate|Alkaline Buffer
219264222|NCT05799521|DRUG|Placebo|Normal Saline
219264223|NCT05865925|DRUG|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
219264224|NCT03539133|OTHER|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
219264225|NCT00806598|DRUG|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients \>55 years receive 2.5 mg/kg/day for 5 days"
219264226|NCT00806598|DRUG|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
219264227|NCT00806598|DRUG|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
219264228|NCT00806598|DRUG|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
219264229|NCT03540290|PROCEDURE|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
219264230|NCT04896684|BIOLOGICAL|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
219264231|NCT03055546|DRUG|Oxytocin|intranasal administration of oxytocin
219264232|NCT03055546|DRUG|Placebo|intranasal administration of placebo
219264233|NCT02188394|DRUG|Anesthetic blockades with bupivacaine|
219264234|NCT02188394|DRUG|Isotonic saline injection|
219264235|NCT05200325|OTHER|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
219264236|NCT04665362|DRUG|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
219264237|NCT01729845|DRUG|Cytarabine|Given IV
219264238|NCT01729845|DRUG|Decitabine|Given IV
219264239|NCT01729845|DRUG|Etoposide|Given IV
219264240|NCT01729845|OTHER|Laboratory Biomarker Analysis|Correlative studies
219264241|NCT01729845|DRUG|Mitoxantrone Hydrochloride|Given IV
219264242|NCT01576198|GENETIC|DNA analysis|
219264243|NCT01576198|GENETIC|nucleic acid amplification|
219264244|NCT01576198|OTHER|diagnostic laboratory biomarker analysis|
219264245|NCT01576198|OTHER|medical chart review|
219264246|NCT02294097|PROCEDURE|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
219264247|NCT02759926|DRUG|Denatonium benzoate|
219264248|NCT02759926|DRUG|Quinine hydrochloride|
219264249|NCT02759926|DRUG|Tap water|
219264250|NCT00398723|DEVICE|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
219264251|NCT01674803|DEVICE|Orsiro|biodegradable polymer sirolimus eluting stent
219264252|NCT01674803|DEVICE|Synergy|biodegradable polymer everolimus eluting stent
219264253|NCT01674803|DEVICE|Resolute Integrity|durable polymer zotarolimus-eluting stent
219264254|NCT03455777|DRUG|AKCEA-ANGPTL3-LRX|Single open-label cohort
219264255|NCT03051893|DRUG|Chronocort|Modified formulation of hydrocortisone
219264256|NCT03765164|DIAGNOSTIC_TEST|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
219264257|NCT03765164|OTHER|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
219264258|NCT03843398|PROCEDURE|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
219264259|NCT03843398|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
219264260|NCT05168098|OTHER|board game comparison|The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
219264261|NCT05168098|OTHER|olfactory stimulation intervention|The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
219264262|NCT05115292|BIOLOGICAL|BJ-005|dosed with intravenous infusion
219264263|NCT05630378|BEHAVIORAL|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
219264264|NCT05630378|OTHER|waiting group|Patients receive no intervention
219264265|NCT01029236|OTHER|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
219264266|NCT01351337|PROCEDURE|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
219264267|NCT03448536|DRUG|Naproxen Sodium, (Aleve, BAY117031)|220 mg \*2 tablets, orally, single dose
219264268|NCT03448536|DRUG|Acetaminophen (Tylenol Extra Strength)|500 mg \*2 caplets, orally, single dose
219264269|NCT00592189|PROCEDURE|blood draw|blood collection
219264270|NCT05476510|DRUG|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
219264271|NCT05006222|DRUG|Enzyme Replacement Agent|Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
219264272|NCT04016116|DRUG|Pembrolizumab|Pembrolizumab IV every 3 weeks
219264273|NCT04016116|DRUG|Ruxolitinib|Ruxolitinib po days 1-21
219264274|NCT03421639|DRUG|GnRH analog (11.25mg Leuprolide acetate)|11.25 Leuprolide acetate only one administration
219264275|NCT03421639|DRUG|Aromatase inhibitor and GnRH analog|1mg/day of Anastrazole for 3 months
219264276|NCT03421639|DRUG|Aromatase and GnRH analog (11.25mg Leuprolide acetate)|Leuprolide acetate 11.25mg only one
219264277|NCT02528851|PROCEDURE|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
219264278|NCT01191554|DRUG|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
219264279|NCT03783546|DEVICE|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
219264280|NCT03783546|OTHER|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
219264281|NCT05128734|DRUG|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
219264282|NCT05128734|DRUG|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
219264283|NCT05107752|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
219264284|NCT05107752|DRUG|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
219264285|NCT04500847|DRUG|Emtriva Capsule|200mg daily oral dose
219264286|NCT04500847|DRUG|Placebo|200mg daily oral dose
219264287|NCT03909282|PROCEDURE|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
219264288|NCT03909282|RADIATION|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
219264289|NCT04243798|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
219264290|NCT04243798|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
219264291|NCT05103098|DRUG|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219264292|NCT05103098|DRUG|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219264293|NCT03900429|DRUG|MGL-3196|Tablet
219264294|NCT03900429|DRUG|Placebo|Matching Tablets
219264295|NCT03900429|PROCEDURE|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
219264296|NCT00557349|DRUG|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
219264297|NCT00557349|DRUG|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
219264298|NCT04303442|PROCEDURE|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
219264299|NCT03524768|DIAGNOSTIC_TEST|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
219264300|NCT03111797|DRUG|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
219264301|NCT03111797|OTHER|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
219264302|NCT05988034|DRUG|Avacopan|Administered orally.
219264303|NCT05988034|DRUG|Moxifloxacin|Administered orally.
219264304|NCT05988034|DRUG|Placebo for avacopan|Administered orally.
219264305|NCT05988034|DRUG|Placebo for moxifloxacin|Administered orally.
219264306|NCT01190722|DRUG|etoricoxib|120 mg once daily for the 1st 6 postoperative days
219264307|NCT01190722|DRUG|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
219264308|NCT00352378|DRUG|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
219264309|NCT00102271|DRUG|Oxypurinol|
219264310|NCT00102271|DRUG|Sodium Nitrite|
219264311|NCT01752010|OTHER|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
219264312|NCT01752010|DEVICE|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
219264313|NCT01752010|DEVICE|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
219264314|NCT03269747|DRUG|Prednisone|2 tablets of Prednisone 20 Mg in the morning
219264315|NCT03269747|DRUG|Placebo|2 Placebo tablets in the morning
219264316|NCT03115229|BEHAVIORAL|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
219264317|NCT02316392|DRUG|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
219264318|NCT06010550|RADIATION|Magnetic resonance imaging|Brain magnetic resonance imaging
219264319|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
219264320|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
219264321|NCT04817033|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
219264322|NCT04817033|DRUG|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
219264323|NCT06320847|DIAGNOSTIC_TEST|rPPG|A pulse oximeter and blood pressure cuff will be applied on the study patient by the study team member (research coordinators). At the same time, vital signs from Nervotec's rPPG technology will be recorded via the laptop and webcam. Synchronous measurement process of heart rate, respiration rate, pulse oximetry, heart rate variability and blood pressure estimates using Nervotec rPPG technology will take place for a duration of 3 minutes.
219264324|NCT00977795|DRUG|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
219264325|NCT03500835|BEHAVIORAL|App|"1. 6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~2. Daily Weigh In~3. App based reminders~4. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months."
219264326|NCT03500835|BEHAVIORAL|Coaching|"1. 6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~2. Daily Weighing~3. Daily Text messages from Coach~4. Weekly 15 minute phone meetings with Coach~5. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent"
219264327|NCT03500835|BEHAVIORAL|Clinic: Modified KidsNFitness|"1. 6 month in-clinic, evidence-based, multi-disciplinary intervention~2. 90 minute sessions, in clinic that occur every month for 6 months~3. Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months."
219264328|NCT02364609|DRUG|Afatinib Dimaleate|Given PO
219264329|NCT02364609|BIOLOGICAL|Pembrolizumab|Given IV
219264330|NCT00487799|DRUG|Ularitide|
219264331|NCT01952106|OTHER|play computer game|
219264332|NCT00615355|RADIATION|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
219264333|NCT00615355|DEVICE|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
219264334|NCT06336941|DEVICE|Ultrasound|Ultrasonographic scan with a 70 MHz probe
219264335|NCT01119534|DRUG|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
219264336|NCT01119534|DRUG|guaiacol suppository|2 times per day
219264337|NCT01119534|DRUG|Guaifenesin syrup|4.19 mL - 4 in 4 hours
219264338|NCT03594578|BEHAVIORAL|Episodic future thinking|Prospective thinking intervention
219264339|NCT03594578|BEHAVIORAL|Episodic recent thinking|Sham episodic thinking
219264340|NCT01974661|BIOLOGICAL|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
219264341|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
219264342|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale|"Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line"
219264343|NCT01286376|DIETARY_SUPPLEMENT|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
219264344|NCT01286376|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
219264345|NCT05197153|BIOLOGICAL|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
219264346|NCT05197153|BIOLOGICAL|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
219264347|NCT05197153|BIOLOGICAL|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
219264348|NCT05197153|BIOLOGICAL|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
219264349|NCT02540343|OTHER|questionnaires|fill out all questionnaires twice
219264350|NCT00833183|DRUG|MAL|80 mg/g cream one administration with incubation for 90 minutes
219264351|NCT00057044|BEHAVIORAL|education and reminder|
219264352|NCT04811339|DRUG|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
219264353|NCT04811339|OTHER|Placebo oral tablet without BSS|Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
219264354|NCT04228354|DRUG|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
219264355|NCT05928858|DRUG|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
219264356|NCT05928858|DRUG|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
219264357|NCT01517607|OTHER|Mesalazine|Patient's treated with oral Mesalazine
219264358|NCT02827032|DEVICE|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
219264359|NCT04544592|DRUG|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF-19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
219264360|NCT06187064|OTHER|Mobile Van Clinic|The investigators will implement a pilot clinic one evening per week, with the primary goal of measuring a community-based extension of SHE Clinic's impact on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). The clinic will be dispatched with a driver, nurse, physician, and research assistant. The van clinic will be outfitted with space to obtain a confidential history and physical exam and include a space for sample collection. In addition to standard of care, the investigators will provide participants with rapid point-of-care HIV and STI testing, and HIV PrEP and MOUD counseling and prescriptions.
219264361|NCT04551222|DRUG|probenecid|1 gr. orally of probenecid twice daily for 180 days
219264362|NCT04551222|DRUG|Placebo|identical tablets to probenecid
219264363|NCT01547221|DRUG|clotrimazole|single application of 1%clotrimazole ear drop
219264364|NCT01547221|DRUG|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
219264365|NCT05834023|DRUG|Bupivacaine-Lidocaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
219264366|NCT05834023|DRUG|Bupivacaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
219264367|NCT04055259|BEHAVIORAL|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
219264368|NCT04055259|BEHAVIORAL|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
219264369|NCT02336256|PROCEDURE|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
219264370|NCT06782217|BIOLOGICAL|VENOX|Treatment with allergy vaccine againts Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
219264371|NCT04360785|DRUG|Methotrexate|Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
219264372|NCT00930956|DIETARY_SUPPLEMENT|Resistant Starch|30 g of carbohydrate per Arm
219264373|NCT05258591|DEVICE|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
219264374|NCT05068947|DRUG|GV101|GV101 administered once orally.
219264375|NCT05068947|DRUG|Placebo|Matched placebo
219264376|NCT02444780|PROCEDURE|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
219264377|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
219264378|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
219264379|NCT06251999|DRUG|fospropofol sedation|Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
219264380|NCT06251999|DRUG|Propofol|propofol
219264381|NCT06391437|DIAGNOSTIC_TEST|Extraction of blood sample|Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.
219264382|NCT03755973|DRUG|CFA|Long-acting exogenous ovarian stimulation
219264383|NCT03755973|DRUG|rFSH|Daily rFSH
219264384|NCT03755973|PROCEDURE|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
219264385|NCT03755973|PROCEDURE|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
219264386|NCT01749267|PROCEDURE|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
219264387|NCT00497874|BEHAVIORAL|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
219264388|NCT03020953|OTHER|Exercise + Estrogen|12 weeks resistance training and estrogen patches
219264389|NCT03020953|OTHER|Exercise + Placebo|12 weeks resistance training and placebo patches
219264390|NCT05475847|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
219264391|NCT02382562|BEHAVIORAL|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
219264392|NCT00014287|DRUG|gemcitabine hydrochloride|
219264393|NCT00548756|PROCEDURE|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
219264394|NCT00548756|OTHER|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
219264395|NCT00548756|BEHAVIORAL|Questionnaire|Questionnaire taking 40 minutes to complete.
219264396|NCT04759430|OTHER|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
219264397|NCT04759430|OTHER|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
219264398|NCT05606198|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
219264399|NCT02435576|RADIATION|Radiotherapy (primary or postoperative)|
219264400|NCT00927524|DRUG|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
219264401|NCT00927524|DRUG|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
219264402|NCT02330276|DRUG|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
219264403|NCT04486976|DEVICE|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
219264404|NCT04486976|DEVICE|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
219264405|NCT01256671|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
219264406|NCT04212780|DEVICE|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
219264407|NCT04212780|PROCEDURE|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
219264408|NCT04212780|PROCEDURE|standard ET DBS|Single Lead VIM
219264409|NCT04212780|PROCEDURE|ipsilateral VO|second lead in the ipsilateral VO
219264410|NCT05175469|DIAGNOSTIC_TEST|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
219264411|NCT03718377|PROCEDURE|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
219264412|NCT03718377|PROCEDURE|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
219264413|NCT06085053|DRUG|TQA3038 injection|TQA3038 is an injection.
219264414|NCT06085053|DRUG|TQA3038 injection matching placebo|Placebo injection contains no active substance.
219264415|NCT02185105|DEVICE|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
219264416|NCT02185105|DEVICE|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
219264417|NCT03132662|DIETARY_SUPPLEMENT|Omega-3|3 gr/day of Omega-3
219264418|NCT03132662|DIETARY_SUPPLEMENT|Very Low Calorie Diet|4 servings/day Optifast
219264419|NCT01789840|DEVICE|Embosphere Microspheres|
219264420|NCT01789840|PROCEDURE|TURP|
219264421|NCT04199468|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
219264422|NCT04199468|DRUG|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
219264423|NCT04199468|DRUG|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
219264424|NCT04199468|DRUG|Placebo Ketamine|A placebo dose given intravenously (IV)
219264425|NCT03006185|DEVICE|Ablative Fractional Carbon Dioxide (CO2) Laser|One 50 cm2 test area was randomized to pretreatment using a fractional 2940 nm Er:YAG laser (Joule®; Sciton Inc., Palo Alto, CA, USA). To remove hyperkeratosis, a fully-ablative 4 mm handpiece was optionally applied, followed by a single pass of a fractional Profrax 430 handpiece for all AKs. Subsequent field treatment consisted of a single pass of the Profrax 430 handpiece over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
219264426|NCT03006185|DEVICE|Microdermabrasion|Another adjacent 50 cm2 test area was exposed to microdermabrasion using an MD pad with 58.5 µm-diameter particles (Ambu® Skin Prep Pads 2121M; Ambu A/S, Ballerup, Denmark). Lesion-directed treatment consisted of an increasing number of swipes concentrated to AK lesions. During field treatment, multiple swipes were applied in perpendicular directions over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
219264427|NCT01306539|PROCEDURE|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
219264428|NCT02828397|DRUG|REGN2222|
219264429|NCT03984513|BEHAVIORAL|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
219264430|NCT03984513|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
219264431|NCT00883974|BEHAVIORAL|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
219264432|NCT02169557|DRUG|Fexinidazole|
219264433|NCT02234947|PROCEDURE|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
219264434|NCT04843579|DRUG|Selinexor|Given as 60 mg oral capsule
219264435|NCT04843579|DRUG|Clarithromycin|Given as 500 mg oral capsule
219264436|NCT04843579|DRUG|Pomalidomide|Given as 4 mg oral capsule
219264437|NCT04843579|DRUG|Dexamethasone|Given as 40 mg oral capsule
219264438|NCT01755910|OTHER|Left thoracic paravertebral block|
219264439|NCT01755910|OTHER|Right thoracic paravertebral block|
219264440|NCT04009629|BEHAVIORAL|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
219264441|NCT02825186|DRUG|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
219264442|NCT02825186|DRUG|Dexamethasone 0.1%|
219264443|NCT00004146|RADIATION|radiation therapy|Undergo radiotherapy
219264444|NCT00004146|DRUG|carboxyamidotriazole|Given orally
219264445|NCT00004146|OTHER|pharmacological study|Correlative studies
219264446|NCT02808975|DRUG|Placebo|Subcutaneous injections administered as described in arm description
219264447|NCT02808975|DRUG|Adalimumab|Subcutaneous injections administered as described in arm description
219264448|NCT01672138|PROCEDURE|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
219264449|NCT01672138|PROCEDURE|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
219264450|NCT01672138|PROCEDURE|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
219264451|NCT06956729|PROCEDURE|Proximal Femoral Guided Growth.|"Proximal Femoral Guided Growth (PFGG) is performed under general anesthesia with the patient in a supine position on a radiolucent table. The surgical field is prepared from the abdomen to the feet. Anatomical landmarks on the femur and femoral neck are marked to guide the procedure.~A smooth guidewire (4.0-7.0 mm) is introduced parallel to the table and advanced to the lateral quarter of the femoral neck.~A 1-2 cm incision is made along the lateral femur, allowing access to the vastus lateralis muscle.~Fluoroscopic control is used to ensure precise guidewire placement in the proximal femoral epiphysis in both anteroposterior (AP) and lateral views.~The lateral cortex is drilled, and a fully threaded cannulated screw is inserted, ensuring at least three threads reach the epiphysis for effective growth modulation.~Final fluoroscopic verification is performed to confirm proper screw placement and rule out joint penetration. Continuous fluoroscopy is used if necessary.~The guidewire is r"
219264452|NCT06956729|PROCEDURE|Standard prophylactic treatment for Hips at Risk of Dislocation.|"Both groups will receive standard prophylactic treatment for HRD, which consists of soft tissue release procedures based on clinical indication and functional level (GMFCS classification):~Adductor Tenotomy - Percutaneous or open technique, depending on contracture severity.~Psoas Tenotomy - Intrapelvic approach for GMFCS levels I-III and IV (ambulatory). Lesser trochanter approach for GMFCS levels IV-V (non-ambulatory). Additional tenotomies may be performed as needed, targeting muscles contributing to hip displacement and contractures.~Botulinum toxin type A may be administered to specific muscle groups if clinically indicated.~Postoperative immobilization includes:~Hip abduction wedge Knee immobilizers in extension Ankle-foot orthoses (AFOs), based on individual patient needs~The goal of this intervention is to reduce spastic muscle imbalance, improve hip stability, and delay or prevent hip dislocation in children with spastic CP and HRD."
219264453|NCT06957704|DRUG|ketamine|Ketamine will be administered as adjunctive therapy at an initial dose of 0.5 mg/kg via subcutaneous injection, twice weekly for four weeks, under double-blind conditions. Dose adjustments between 0.5 and 1.0 mg/kg will be based on depressive symptoms, efficacy, and tolerability. All procedures will occur at the Ketamine Clinic of Federal University of São Paulo.
219264454|NCT06957704|DRUG|Midazolam|Midazolam will be administered subcutaneously twice weekly for four consecutive weeks, also under double-blind conditions. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
219264455|NCT06956807|COMBINATION_PRODUCT|VB-C01 cellularised patch|surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure
219264456|NCT04996368|DRUG|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
219264457|NCT05258955|OTHER|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
219264458|NCT05258955|DRUG|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
219264459|NCT03602586|DRUG|Epacadostat|Given PO
219264460|NCT03602586|BIOLOGICAL|Pembrolizumab|Given IV
219264461|NCT03292445|PROCEDURE|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
219264462|NCT03292445|DRUG|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover \>10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
219264463|NCT02371720|BEHAVIORAL|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
219264464|NCT03372590|OTHER|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
219264465|NCT03372590|OTHER|Standard of care|Standard NICU care
219264466|NCT04721782|OTHER|smoking|to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
219264467|NCT02713971|DEVICE|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
219264468|NCT02713971|OTHER|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
219264469|NCT03819751|PROCEDURE|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
219264470|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
219264471|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
219264472|NCT01792388|DIETARY_SUPPLEMENT|Vitamin D|Capsule Form
219264473|NCT01792388|DIETARY_SUPPLEMENT|Soya Bean oil|Capsule form
219264474|NCT01382498|DRUG|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
219264475|NCT01382498|DRUG|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
219264476|NCT02627768|DRUG|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
219264477|NCT03232710|DRUG|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
219264478|NCT03232710|DRUG|abilify|Aripiprazol orodispersible tablets 10mg
219264479|NCT04564521|DRUG|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
219264480|NCT04564521|DRUG|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
219264481|NCT01479270|DRUG|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
219264482|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate.|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF
219264483|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
219264484|NCT03570151|OTHER|no intervention|no intervention will be done
219264485|NCT00030823|BIOLOGICAL|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
219264486|NCT00030823|BIOLOGICAL|QS21|
219264487|NCT01488955|DRUG|Ibuprofen|400 mg oral once a day from day 0 for 3 days
219264488|NCT01488955|DRUG|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
219264489|NCT03102489|DRUG|BP101|Nasal spray
219264490|NCT03102489|DRUG|Placebo|Nasal spray
219264491|NCT05019170|BEHAVIORAL|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
219264492|NCT05019170|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
219264493|NCT00706771|DRUG|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
219264494|NCT00706771|DRUG|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
219264495|NCT03513744|DIETARY_SUPPLEMENT|human milk oligosaccharides|mixture of five different human milk oligosaccharides
219264496|NCT06456476|DIAGNOSTIC_TEST|ERCP|ERCP used only if needed in some patients
219264497|NCT01509261|DRUG|Ilaprazole|20mg/Tap, QD
219264498|NCT01509261|DRUG|Lansoprazole|30mg/Tap, QD
219264499|NCT00269932|DRUG|levofloxacin|
219264500|NCT01083199|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
219264501|NCT01830062|OTHER|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
219264502|NCT01830062|OTHER|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
219264503|NCT04415645|DRUG|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
219264504|NCT04333147|BIOLOGICAL|Otilimab (GSK3196165)|GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
219264505|NCT04333147|DRUG|csDMARD(s)|Stable dose of csDMARD(s) as standard of care (SoC).
219264506|NCT05498922|PROCEDURE|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9\_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
219264507|NCT03215953|DEVICE|cast shoe|ankle-high, custom-made, well-moulded cast shoe
219264508|NCT03215953|DEVICE|removable walker|Prefabricated especially designed for relieving load on the foot
219264509|NCT06957522|OTHER|face to face rehabilitation|"The face-to-face rehabilitation program will be delivered in a clinical setting to infants aged 0-6 months with congenital muscular torticollis (CMT). It is based on neurodevelopmental treatment (NDT) principles and consists of:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities to promote the development of symmetrical movement~Environmental modification suggestions for the home setting~Parent/caregiver education and training~Sessions will be conducted twice per week, 30 minutes per session, over a total of 8 weeks.~In addition, an individualized home exercise program will be prescribed for each infant based on their specific needs. Frequency and duration of the home exercises may vary accordingly."
219264510|NCT06957522|OTHER|telerehabilitation|"The telerehabilitation program provides the same therapeutic content as the face-to-face rehabilitation group but will be delivered remotely via the Zoom video conferencing platform. The program will be applied to infants aged 0-6 months with congenital muscular torticollis (CMT) and is based on neurodevelopmental treatment (NDT) principles, including:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities for symmetrical movement development~Environmental modification suggestions~Parent/caregiver education and guidance~Sessions will be conducted via live video calls, twice per week, 30 minutes per session, for 8 weeks.~Each family will also receive an individualized home exercise program, with its frequency and duration adapted to the infant's needs."
219264511|NCT06957041|PROCEDURE|Intertransverse process block|The patient(s) will receive a pre-induction Intertransverse process block as pilot study
219264512|NCT06957054|OTHER|Any|Any
219264513|NCT06529718|DRUG|Ivonescimab|20 mg/kg IV infusion every 3 weeks
219264514|NCT06529718|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks
219264515|NCT06633757|DRUG|RCT1100|mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
219264516|NCT03939182|DRUG|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
219264517|NCT03939182|DRUG|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
219264518|NCT04743934|DRUG|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
219264519|NCT04743934|DRUG|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
219264520|NCT04743934|DRUG|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
219264521|NCT02849405|DEVICE|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
219264522|NCT03062449|DRUG|L-Serine|Gummy containing L serine dose
219264523|NCT03062449|OTHER|Placebo Gummy|Gummy with no dosing of L Serine
219264524|NCT03765398|BEHAVIORAL|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
219264525|NCT02168283|COMBINATION_PRODUCT|treatment arm|Hypertonic peritoneal dialysis cycles
219264526|NCT02168283|BEHAVIORAL|Control arm|Dietary counseling
219264527|NCT02578888|OTHER|Palliative Therapy|Palliative Therapy
219264528|NCT02578888|OTHER|Palliative Therapy + idiographic|Ancillary studies
219264529|NCT04702893|DRUG|Nintedanib|150 or 100 milligrams (mg) of nintedanib, when 150 mg is not tolerated, twice daily, administered 12 hours apart, according to the approved label.
219264530|NCT05900180|BEHAVIORAL|Speech Therapy|Delivery of speech therapy services
219264531|NCT06140901|DIAGNOSTIC_TEST|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
219264532|NCT06013865|DRUG|Empagliflozin|SGLT2 Inhibitor
219264533|NCT06956183|OTHER|Control (Standard treatment)|In control group participants will take one hour conventional physiotherapy including stretching, strengthening, balance and gait exercises in each session.
219264534|NCT06956183|OTHER|Vestibular exercise|In vestibular group (study group) participant will take 40 minutes conventional physiotherapy including stretching, strengthening, balance and gait exercises, and 20 minutes vestibular exercises including head and gaze stabilization, occulomotor, head turning and balance exercises in different postures.
219264535|NCT06956846|DRUG|insulin eye drops|Use of topical insulin eye drops following a standard excimer laser photo-refractive keratecotmy in myopic/astigmatic patients, in order to examine its efficacy in promoting corneal epithelial healing and patient comfort
219264536|NCT06956846|DRUG|Artificial tears eye-drops|The other arm receiving only artificial tears
219264537|NCT06956924|DIAGNOSTIC_TEST|CCTA|The data acquisition protocol was tailored to each patient's heart rate and rhythm. Specifically, a prospectively ECG-triggered volume scan was used to account for heart rates and rhythms, capturing predefined scanning areas during R-R intervals, especially in instances of frequent ectopic beats or irregular heart rates noted during pre-scan ECG monitoring. Imaging system parameters included a gantry rotation time of 0.275 seconds, collimation of 0.5 mm, tube voltage settings ranging from 100 kV to 120 kV, and a tube current-time product between 200 mAs and 450 mAs, with adjustments based on the patient's BMI.
219264538|NCT05854667|DRUG|Treatment as Usual plus Placebo|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
219264539|NCT05854667|DRUG|Treatment as Usual plus Placebo plus Contingency Management|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
219264540|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01)|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15)."
219264541|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13."
219264542|NCT06630624|DRUG|IP-001|Intra-tumoral injection of IP-001 following ablation (MWA or IRE).
219264543|NCT00408928|DRUG|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
219264544|NCT06309576|BEHAVIORAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
219264545|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
219264546|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
219264547|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
219264548|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
219264549|NCT02976168|OTHER|12° head down tilt|supine head down tilt
219264550|NCT05435989|DIAGNOSTIC_TEST|Reduced extended high-frequency audibility|This study examines the effects of low-pass filtering speech on speech perception.
219264551|NCT01547624|OTHER|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
219264552|NCT03813732|PROCEDURE|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
219264553|NCT02161198|DIETARY_SUPPLEMENT|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
219264554|NCT02161198|DIETARY_SUPPLEMENT|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
219264555|NCT02941848|DRUG|HGP0816|
219264556|NCT02941848|DRUG|HGP1404|
219264557|NCT02941848|DRUG|HCP1306|
219264558|NCT01863797|OTHER|Early induction|
219264559|NCT01863797|OTHER|Expectant mamagement|
219264560|NCT04014790|DRUG|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
219264561|NCT04014790|DRUG|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
219264562|NCT00816556|DRUG|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
219264563|NCT00816556|DRUG|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
219264564|NCT00816556|DRUG|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
219264565|NCT03546816|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
219264566|NCT03546816|DRUG|Placebo Tablets|Placebo Tablets
219264567|NCT02438371|DRUG|Nifedipine|
219264568|NCT02438371|DRUG|Indomethacin|
219264569|NCT04847245|DRUG|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
219264570|NCT04847245|DRUG|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
219264571|NCT04847245|DRUG|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
219264572|NCT04847245|DRUG|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
219264573|NCT01161446|BEHAVIORAL|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
219264574|NCT01161446|DEVICE|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
219264575|NCT01411098|RADIATION|3-dimensional conformal radiation therapy|Undergo 3D-CRT
219264576|NCT01411098|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
219264577|NCT01411098|DRUG|cisplatin|Given IV
219264578|NCT01411098|DRUG|etoposide|Given IV
219264579|NCT04183010|BEHAVIORAL|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise"
219264580|NCT06468189|DEVICE|transcranial direct stimulation|Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
219264581|NCT06468189|DEVICE|Sham treatment|The same device used for stimulation will be used, but no stimulation will be given.
219264582|NCT02878369|PROCEDURE|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
219264583|NCT04959578|DRUG|Recombinant human erythropoietin|Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
219264584|NCT04959578|DRUG|Darbepoetin Alfa|Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
219264585|NCT00360477|PROCEDURE|Floseal|Bioglue that seals the kidney
219264586|NCT00360477|PROCEDURE|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
219264587|NCT00360477|PROCEDURE|Fascial Stitch|Stitch that closes the kidney
219264588|NCT03916822|DIAGNOSTIC_TEST|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
219264589|NCT05952947|BIOLOGICAL|HRYZ-T101 Injection|On day 1, the TCR-T cells will be administered intravenously.
219264590|NCT05952947|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
219264591|NCT04751682|BIOLOGICAL|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.
219264592|NCT04751682|BIOLOGICAL|Placebo|Placebo
219264593|NCT03450668|DEVICE|mOm incubator|24 hour usage of test incubator
219264594|NCT03450668|DEVICE|standard incubator|standard incubator
219264595|NCT05933889|GENETIC|Molecular Analysis|Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples
219264596|NCT05933889|OTHER|Radiomic/ Morphological analysis|Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
219264597|NCT04338789|OTHER|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
219264598|NCT01656213|DEVICE|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
219264599|NCT00844337|DRUG|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
219264600|NCT00844337|DRUG|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
219264601|NCT00844337|DRUG|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
219264602|NCT04301570|DEVICE|Ultrasound device|"The measurement of bone age is performed via ultrasound with the Ultrasound System for Bone Age Assessment (BAUS) from Sonic Bone (SonicBone Medical Ltd., Rishon Lezion, Israel)."
219264603|NCT04301570|RADIATION|XR|The measurement of bone age is performed via imaging procedure via X-ray (Röntgengerät, Stadler SE 4600, Littau, CH) of the left hand.
219264604|NCT05719402|PROCEDURE|non-interventional prospective cross-sectional observational study|to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD
219264605|NCT02330562|DRUG|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
219264606|NCT02330562|DRUG|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
219264607|NCT02412449|DRUG|AKB-6548 tablet, reference formulation given in the fasted state|
219264608|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fasted state.|
219264609|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fed state|
219264610|NCT01777126|OTHER|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
219264611|NCT01777126|OTHER|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
219264612|NCT00765154|DRUG|darunavir|two 400mg tablets (800mg) once daily
219264613|NCT00765154|DRUG|ritonavir|one 100mg capsule once daily
219264614|NCT03042364|OTHER|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
219264615|NCT02751047|OTHER|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
219264616|NCT02751047|OTHER|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
219264617|NCT00565266|DRUG|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
219264618|NCT00565266|DRUG|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
219264619|NCT00565266|DRUG|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
219264620|NCT02977247|OTHER|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
219264621|NCT02977247|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
219264622|NCT05601427|PROCEDURE|aACB|The patient will undergo a pre-operative single-shot, ultrasound-guided ACB performed by an anaesthesiologist skilled in regional anaesthesia techniques. The ACB will be performed in a dedicated block room, immediately prior to administration of a spinal anaesthetic.
219264623|NCT05601427|PROCEDURE|sACB|The patient will undergo an intraoperative single-shot ACB performed by the treating surgeon following placement of the TKA components.
219264624|NCT01184885|DRUG|Hyper-CVAD|"* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
219264625|NCT01184885|DRUG|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
219264626|NCT06374082|OTHER|WhatsApp message|"Participants in the intervention group will receive 3 WhatsApp messages per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205). These messages are about the core content of the course, including (1) Knowledge Themes: harmfulness of smoking and benefits of quitting, the fundamentals of nicotine addiction, smoking cessation counselling with the 5A model, and pharmacotherapy for smoking cessation; (2) Attitude Themes: nurses' role in smoking cessation and the importance of smoking cessation; and (3) Practice Themes: practical advice on counseling techniques, communication skills by motivational interviewing, local smoking cessation resources for referral.~Participants in the control group will receive 3 WhatsApp messages about generic mental health information per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205)."
219264627|NCT01162135|DRUG|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
219264628|NCT02088554|DEVICE|Model 400 aortic valve bioprosthesis|
219264629|NCT06331104|GENETIC|gene expression levels|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
219264630|NCT01896180|DRUG|ALZ-1101|ALZ-1101 Ophthalmic Solution
219264631|NCT01896180|DRUG|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
219264632|NCT02002962|PROCEDURE|radiofrequency ablation|
219264633|NCT02002962|DRUG|Botulinum Toxin Type A injection|
219264634|NCT04411134|BIOLOGICAL|E7 TCR|Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
219264635|NCT05204069|DRUG|Instillation of cyclopentolate|Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
219264636|NCT04205955|OTHER|Best Practice|Receive healthy living education via phone call
219264637|NCT04205955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet modification coaching via phone call
219264638|NCT04205955|OTHER|Message|Receive motivational messages via email and/or text message
219264639|NCT04205955|OTHER|Quality-of-Life Assessment|Ancillary studies
219264640|NCT04205955|OTHER|Questionnaire Administration|Ancillary studies
219264641|NCT03898960|DEVICE|NIMBUS Device|NIMBUS Geometric Clot Extractor
219264642|NCT01325597|OTHER|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
219264643|NCT01325597|OTHER|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
219264644|NCT01325597|OTHER|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
219264645|NCT01325597|OTHER|Control group|No intervention
219264646|NCT00548847|BIOLOGICAL|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
219264647|NCT00548847|BIOLOGICAL|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
219264648|NCT04866433|PROCEDURE|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
219264649|NCT04866433|PROCEDURE|Music|Play the same music in both ears through headphones during sedation
219264650|NCT04866433|PROCEDURE|Control|Just wear headphones during sedation
219264651|NCT04059887|DRUG|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
219264652|NCT02271659|RADIATION|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
219264653|NCT02271659|RADIATION|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
219264654|NCT04199455|DRUG|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
219264655|NCT04199455|DRUG|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
219264656|NCT04347785|PROCEDURE|carotid endarterectomy|shunt
219264657|NCT02902653|DRUG|Oral misoprostol|hourly titrated misoprostol
219264658|NCT02902653|DRUG|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
219264659|NCT02902653|DRUG|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
219264660|NCT05054465|DRUG|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
219264661|NCT05054465|DRUG|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
219264662|NCT00252018|BEHAVIORAL|Daily intake of broccoli sprouts|
219264663|NCT00237861|DRUG|risperidone|
219264664|NCT00237861|DRUG|olanzapine|
219264665|NCT00237861|DRUG|quetiapine|
219264666|NCT00151905|DRUG|3 % hypertonic saline|
219264667|NCT05225636|PROCEDURE|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
219264668|NCT02142998|OTHER|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
219264669|NCT02142998|OTHER|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
219264670|NCT01316887|DRUG|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
219264671|NCT01316887|DRUG|125mcg once-daily GSK573719|GSK573719
219264672|NCT01316887|DRUG|Placebo once-daily|inactive
219264673|NCT00720369|DRUG|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
219264674|NCT03121495|DIAGNOSTIC_TEST|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
219264675|NCT04092049|OTHER|lollipop|chewing lollipop for 10 minutes
219264676|NCT00813098|DRUG|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
219264677|NCT00813098|DRUG|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
219264678|NCT00813098|DRUG|Placebo|Matching placebo dosing with daily oral intake
219264679|NCT03732976|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
219264680|NCT03732976|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
219264681|NCT04517383|PROCEDURE|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
219264682|NCT04517383|PROCEDURE|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
219264683|NCT03564834|PROCEDURE|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
219264684|NCT03564834|PROCEDURE|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
219264685|NCT01809899|BEHAVIORAL|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
219264686|NCT01809899|BEHAVIORAL|Consent as Usual|Routine informed consent procedures
219264687|NCT02089412|DRUG|E2006|
219264688|NCT02462343|OTHER|walk tests|
219264689|NCT01068288|PROCEDURE|Laparoscopic or open appendectomy|
219264690|NCT01068288|PROCEDURE|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
219264691|NCT03361098|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
219264692|NCT03361098|DRUG|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
219264693|NCT03361098|OTHER|placebo exenatide|placebo b.i.d. exenatide
219264694|NCT03361098|OTHER|placebo dapagliflozin|placebo tablets dapagliflozin
219264695|NCT02298049|OTHER|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
219264696|NCT02298049|DEVICE|MRI|
219264697|NCT05155488|OTHER|No Intervention|This is a non-interventional study.
219264698|NCT01143545|BIOLOGICAL|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
219264699|NCT01143545|DRUG|Celecoxib|400 g po bid
219264700|NCT01143545|DRUG|cyclophosphamide|50 mg po bid
219264701|NCT01301703|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
219264702|NCT03354910|BEHAVIORAL|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
219264703|NCT03354910|BEHAVIORAL|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
219264704|NCT03470545|DRUG|mavacamten|mavacamten capsules
219264705|NCT03470545|DRUG|Placebo|placebo oral capsule
219264706|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
219264707|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
219264708|NCT00002547|DRUG|busulfan|
219264709|NCT00002547|DRUG|cyclophosphamide|
219264710|NCT00002547|DRUG|cyclosporine|
219264711|NCT00002547|DRUG|cytarabine|
219264712|NCT00002547|DRUG|methotrexate|
219264713|NCT00002547|PROCEDURE|allogeneic bone marrow transplantation|
219264714|NCT00002547|PROCEDURE|syngeneic bone marrow transplantation|
219264715|NCT05142839|PROCEDURE|EUS-CD|EUS-guided choledochoduodenostomy
219264716|NCT05142839|PROCEDURE|EUS-GEA|EUS-guided gastroenterostomy
219264717|NCT04380428|OTHER|No Intervention. Observational study.|No Intervention. Observational study.
219264718|NCT01192776|PROCEDURE|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
219264719|NCT04374383|DRUG|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
219264720|NCT04374383|DRUG|LASER assisted SRP|LASER assisted SRP will be carried
219264721|NCT03107507|DRUG|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
219264722|NCT03107507|DRUG|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
219264723|NCT02181907|DRUG|UH-AC 62 XX tablet|
219264724|NCT02181907|DRUG|UH-AC 62 XX capsule|
219264725|NCT04974723|DRUG|Abaloparatide|Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
219264726|NCT04974723|DRUG|Teriparatide|Teriparatide subcutaneous (TPTD; Forteo®)
219264727|NCT04614571|DIETARY_SUPPLEMENT|Gluten Powder|Administered orally daily for 14 days
219264728|NCT05138250|DRUG|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
219264729|NCT00000983|DRUG|Zidovudine|
219264730|NCT03251612|DRUG|Based on sensitivity analysis|"* 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin"
219264731|NCT02877732|DEVICE|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
219264732|NCT02877732|OTHER|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
219264733|NCT02877732|OTHER|DEM|Participant will be asked to read list of numbers out loud from a card
219264734|NCT02877732|OTHER|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
219264735|NCT02877732|OTHER|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
219264736|NCT02567305|OTHER|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
219264737|NCT02719041|OTHER|Immunohistochemistry staining method|
219264738|NCT01938313|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem."
219264739|NCT01938313|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed"
219264740|NCT03225976|DEVICE|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
219264741|NCT03225976|DEVICE|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
219264742|NCT06019065|DRUG|AJA001|AJA001
219264743|NCT06019065|OTHER|Placebo|Placebo
219264744|NCT06254755|DEVICE|mechanical thrombectomy|mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
219264745|NCT00451828|DRUG|Simvastatin|40mg/day
219264746|NCT03683550|PROCEDURE|SLNE with preoperative hybrid SPECT/CT|Single-photon emission computed tomography/computed tomography (SPECT/CT) provides complementary functional and anatomical information and has been shown to be superior to planar imaging in a number of indications. It can provide valuable information before sentinel lymph node biopsy and advocate its use in a range of tumors such as truncal and head and neck melanomas.
219264747|NCT03683550|PROCEDURE|Standard SLNE|"The current gold standard for detection and targeted extirpation of the sentinel lymph node (SLN) is preoperative lymphoscintigraphy.~Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy."
219264748|NCT01804010|DRUG|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
219264749|NCT02250534|OTHER|Very low nicotine content cigarettes|
219264750|NCT03716388|BIOLOGICAL|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
219264751|NCT03716388|DRUG|Mesalamine Granules|Mesalamine granules 4 grams a day
219264752|NCT03716388|OTHER|Placebo infusion|Water with food grade colour to resemble fecal slurry
219264753|NCT03716388|OTHER|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
219264754|NCT03197025|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
219264755|NCT03197025|BIOLOGICAL|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
219264756|NCT04576845|OTHER|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
219264757|NCT04044703|DRUG|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
219264758|NCT00217022|OTHER|Placebo|Placebo, 3 tablets daily
219264759|NCT00217022|DRUG|Budesonide|9 mg daily (three tablets)
219264760|NCT02804451|DEVICE|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
219264761|NCT02804451|DEVICE|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
219264762|NCT02804451|DEVICE|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
219264763|NCT02804451|DEVICE|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
219264764|NCT01854307|PROCEDURE|Pneumoperitoneum and SVV/PPV|
219264765|NCT03527498|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
219264766|NCT03527498|BEHAVIORAL|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
219264767|NCT01806935|DEVICE|DC086|
219264768|NCT01806935|DEVICE|Placebo|
219264769|NCT02305745|OTHER|Observational|
219264770|NCT00832000|DRUG|Mexiletine|200 mg three times a day; in pill form
219264771|NCT00832000|DRUG|Placebo|Placebo three times a day; in pill form
219264772|NCT03045809|DIAGNOSTIC_TEST|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
219264773|NCT02505893|BIOLOGICAL|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
219264774|NCT02505893|DRUG|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
219264775|NCT02505893|DRUG|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
219264776|NCT02505893|DRUG|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
219264777|NCT05780905|DRUG|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
219264778|NCT05780905|OTHER|Placebo|Placebo
219264779|NCT01383239|OTHER|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
219264780|NCT01383239|OTHER|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
219264781|NCT04295018|DRUG|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
219264782|NCT01689467|DIETARY_SUPPLEMENT|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
219264783|NCT01689467|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
219264784|NCT02929719|DRUG|Test.|gel
219264785|NCT02929719|DRUG|Aczone Gel 5%|gel
219264786|NCT02929719|DRUG|Placebo|gel
219264787|NCT00001234|GENETIC|human glucocerebrosidase cDNA|
219264788|NCT04626271|DEVICE|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
219264789|NCT04626271|DEVICE|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
219264790|NCT05431725|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
219264791|NCT05431725|BIOLOGICAL|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
219264792|NCT04597099|DRUG|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
219264793|NCT04597099|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
219264794|NCT04597099|DRUG|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
219264795|NCT04597099|DRUG|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
219264796|NCT03877952|DRUG|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
219264797|NCT00751634|DEVICE|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
219264798|NCT00001083|DRUG|Indinavir sulfate|
219264799|NCT00001083|DRUG|Ritonavir|
219264800|NCT00001083|DRUG|Nevirapine|
219264801|NCT00001083|DRUG|Lamivudine|
219264802|NCT00001083|DRUG|Stavudine|
219264803|NCT00001083|DRUG|Zidovudine|
219264804|NCT02815137|OTHER|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
219264805|NCT02189577|DRUG|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
219264806|NCT02189577|DRUG|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
219264807|NCT02162914|DRUG|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
219264808|NCT02162914|DRUG|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
219264809|NCT05674383|PROCEDURE|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
219264810|NCT05674383|PROCEDURE|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
219264811|NCT04048798|OTHER|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
219264812|NCT04048798|OTHER|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
219264813|NCT03450148|OTHER|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
219264814|NCT03450148|OTHER|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
219264815|NCT00817336|DRUG|D Serine|60 mg/kg/day
219264816|NCT00817336|DRUG|Placebo|oral
219264817|NCT02449083|PROCEDURE|MRI|MRI
219264818|NCT02449083|PROCEDURE|coronary angiography|coronary angiography
219264819|NCT03123419|BEHAVIORAL|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
219264820|NCT02108652|DRUG|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
219264821|NCT04151823|DRUG|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
219264822|NCT04151823|DRUG|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
219264823|NCT04151823|OTHER|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
219264824|NCT04151823|OTHER|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
219264825|NCT01182181|DRUG|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
219264826|NCT01182181|DRUG|Anastrozole (Arimidex®)|1 mg Tablets
219264827|NCT05756049|OTHER|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
219264828|NCT01940289|DEVICE|Algometric meter readings for perception of pain|
219264829|NCT01280383|DEVICE|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
219264830|NCT06128213|DRUG|NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
219264831|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
219264832|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
219264833|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
219264834|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
219264835|NCT01086618|DRUG|systemic chemotherapy|
219264836|NCT01086618|PROCEDURE|adjuvant therapy|
219264837|NCT01086618|PROCEDURE|quality-of-life assessment|
219264838|NCT01086618|PROCEDURE|therapeutic conventional surgery|
219264839|NCT05065697|OTHER|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
219264840|NCT05940714|BEHAVIORAL|Video participants|Showing a video of oral hygiene intructions
219264841|NCT04815473|PROCEDURE|Valvulotomy|Valvulotomy of the venous valves
219264842|NCT03028259|OTHER|lab results|Comparison of lab results
219264843|NCT02597036|DRUG|LY3127804|Administered IV
219264844|NCT02597036|DRUG|Ramucirumab|Administered IV
219264845|NCT02597036|DRUG|Paclitaxel|Administered IV
219264846|NCT00938990|DRUG|Etomidate|
219264847|NCT00938990|DRUG|Midazolam|
219264848|NCT03101033|DEVICE|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
219264849|NCT03101033|DRUG|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
219264850|NCT03101033|DRUG|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
219264851|NCT03101033|DRUG|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
219264852|NCT02767102|OTHER|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
219264853|NCT02767102|OTHER|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
219264854|NCT02564718|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
219264855|NCT05458154|OTHER|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
219264856|NCT03845075|DRUG|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
219264857|NCT03845075|DRUG|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
219264858|NCT02654613|OTHER|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
219264859|NCT00935259|DRUG|Simvastatin|40 mg once daily for 2 weeks
219264860|NCT00935259|DRUG|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
219264861|NCT04795583|DRUG|Prednisone|Prednisone 25 mg capsules
219264862|NCT04795583|DEVICE|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
219264863|NCT00904683|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
219264864|NCT00904683|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
219264865|NCT03585283|OTHER|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
219264866|NCT03585283|OTHER|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
219264867|NCT02089438|DRUG|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
219264868|NCT02089438|DRUG|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
219264869|NCT02089438|DRUG|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
219264870|NCT03322241|OTHER|overall wellness|Wellness lab testing
219264871|NCT03494855|DEVICE|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
219264872|NCT05234775|DRUG|lerodalcibep|300 mg of each drug given SC as single dose
219264873|NCT04346485|PROCEDURE|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
219264874|NCT04346485|PROCEDURE|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
219264875|NCT04346485|PROCEDURE|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
219264876|NCT05918393|BEHAVIORAL|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
219264877|NCT01017263|DRUG|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
219264878|NCT05177783|BEHAVIORAL|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
219264879|NCT05177783|BEHAVIORAL|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
219264880|NCT03949465|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
219264881|NCT01675310|DRUG|medical nutrition therapy + metformin|
219264882|NCT01675310|BEHAVIORAL|Medical nutrition therapy|medical nutrition therapy
219264883|NCT02004106|DRUG|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
219264884|NCT02980705|DRUG|SUNPG1622 I dose|Injection
219264885|NCT02980705|DRUG|Placebo dose|Injection
219264886|NCT01005368|GENETIC|fluorescence in situ hybridization|
219264887|NCT01005368|GENETIC|mutation analysis|
219264888|NCT01005368|GENETIC|nucleic acid sequencing|
219264889|NCT01005368|GENETIC|polymerase chain reaction|
219264890|NCT01005368|GENETIC|western blotting|
219264891|NCT01005368|OTHER|flow cytometry|
219264892|NCT01005368|OTHER|laboratory biomarker analysis|
219264893|NCT01659671|PROCEDURE|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
219264894|NCT05803642|DRUG|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
219264895|NCT05803642|DRUG|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
219264896|NCT06301971|DRUG|Emraclidine|Oral solution/suspension
219264897|NCT04515628|DRUG|Rosuvastatin|Specified dose on specified days
219264898|NCT04515628|DRUG|Branebrutinib|Specified dose on specified days
219264899|NCT04353817|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
219264900|NCT04353817|DRUG|IVA|Tablet for oral administration qd in the evening.
219264901|NCT04353817|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
219264902|NCT04353817|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
219264903|NCT05474898|OTHER|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
219264904|NCT05474898|OTHER|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
219264905|NCT05474898|OTHER|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
219264906|NCT02032264|OTHER|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
219264907|NCT02032264|OTHER|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
219264908|NCT02868372|DRUG|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
219264909|NCT02886598|DRUG|degarelix|
219264910|NCT04226898|BIOLOGICAL|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
219264911|NCT04226898|BIOLOGICAL|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
219264912|NCT01518088|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to study foods
219264913|NCT00012662|BEHAVIORAL|Diabetes Self Management Education|
219264914|NCT06545578|OTHER|low-level laser therapy|The Low-level laser (LLL) pain-relief instrument RG-300IB (code E22), manufactured in China, was utilized for low-level laser therapy (LLLT) in Group A . The therapy employed a wavelength of 830 nm (near infrared) and involved careful skin contact hygiene at specified positions, 2.5 and 3.5 cm laterally from the spinous process (L4, L5, or S1) and one distal level segment. The laser operated at a repetition rate of 5,000, with a power density of 300 mW/cm2 and a power output of 10 mW. Each point received 3 J of energy, resulting in a density of 3 J/cm2, with four points. The spot size was 1 cm, and each point received a 30-second treatment. The energy was administered three times per week for four weeks
219264915|NCT06545578|OTHER|TENS|TENS Intelect Advanced device (Chattanooga, Mouguerre, France). The parameters for TENS stimulation included a frequency range of 60-80 Hz, a pulse width of 50-80 ms, and an intensity of 10-30 mA. Before commencing therapy, patients were provided information regarding the therapeutic approach and any potential adverse effects. During the procedure, two channels (four electrodes) were employed, with one set placed on the right and one on the left paraspinal muscles at the level of L2-L4. Active electrodes from the other channels were affixed 1.5 cm laterally to the spine, while passive electrodes were positioned 3 cm away. TENS therapy was utilized for 30 minutes in Group B, and the intensity of the pain and discomfort was adjusted to the patient's tolerance level.
219264916|NCT06545578|OTHER|motor control exercises|Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.
219264917|NCT00002597|DRUG|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
219264918|NCT00002597|DRUG|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
219264919|NCT00002597|DRUG|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
219264920|NCT00002597|RADIATION|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
219264921|NCT01682746|DRUG|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
219264922|NCT02654132|DRUG|Elotuzumab|
219264923|NCT02654132|DRUG|Pomalidomide|
219264924|NCT02654132|DRUG|Dexamethasone|
219264925|NCT03201536|DEVICE|conventional Suture|Sutures
219264926|NCT03201536|DEVICE|Zip3|wound closure device
219264927|NCT01494545|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
219264928|NCT01447199|BEHAVIORAL|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
219264929|NCT04933981|DIAGNOSTIC_TEST|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
219264930|NCT02485899|BIOLOGICAL|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
219264931|NCT02485899|DEVICE|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
219264932|NCT01918371|DRUG|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
219264933|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219264934|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219264935|NCT05238649|BIOLOGICAL|SARS-Cov-2 Vaccine Inactivated|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
219264936|NCT02219399|DIETARY_SUPPLEMENT|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
219264937|NCT02219399|DIETARY_SUPPLEMENT|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
219264938|NCT02219399|DIETARY_SUPPLEMENT|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
219264939|NCT03415399|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
219264940|NCT05752045|DEVICE|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
219264941|NCT06105112|DEVICE|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
219264942|NCT06105112|DEVICE|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
219264943|NCT00511771|DRUG|Tegaserod|Tegaserod maleate
219264944|NCT03272529|OTHER|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
219264945|NCT03272529|OTHER|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
219264946|NCT03272529|OTHER|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
219264947|NCT04711486|DRUG|Contraloid acetate|Oral administration of drug substance capsules
219264948|NCT04711486|DRUG|Placebo|Oral administration of placebo without any exipients.
219264949|NCT05376904|DRUG|HR18034|HR18034 low dose
219264950|NCT05376904|DRUG|HR18034|HR18034 midium dose
219264951|NCT05376904|DRUG|HR18034|HR18034 high dose
219264952|NCT05376904|DRUG|ropivacaine HCl.|ropivacaine HCl.
219264953|NCT00179257|DRUG|sertraline (Zoloft)|
219264954|NCT00460668|BEHAVIORAL|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
219264955|NCT02572115|BEHAVIORAL|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
219264956|NCT02572115|BEHAVIORAL|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
219264957|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
219264958|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
219264959|NCT01069328|DRUG|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
219264960|NCT01069328|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenously
219264961|NCT01069328|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
219264962|NCT01069328|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenously
219264963|NCT01069328|DRUG|Paclitaxel|Paclitaxel 200 mg/m² intravenously
219264964|NCT01069328|DRUG|Carboplatin|Carboplatin AUC 6 intravenously
219264965|NCT03654768|DRUG|Bosutinib|Given PO
219264966|NCT03654768|DRUG|Dasatinib|Given PO
219264967|NCT03654768|OTHER|Laboratory Biomarker Analysis|Correlative studies
219264968|NCT03654768|DRUG|Nilotinib|Given PO
219264969|NCT03654768|DRUG|Ruxolitinib|Given PO
219264970|NCT03654768|DRUG|Imatinib|Given PO
219264971|NCT04215315|OTHER|Retrospective observation|Case note and imaging review
219264972|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
219264973|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
219264974|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
219264975|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
219264976|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
219264977|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
219264978|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
219264979|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
219264980|NCT04470570|OTHER|Cross-Education|1\) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
219264981|NCT04470570|OTHER|Blood-Flow Restriction Training|1\) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
219264982|NCT02867098|DRUG|XmAb5871|
219264983|NCT00087945|DRUG|Abacavir sulfate|
219264984|NCT00087945|DRUG|Abacavir sulfate, lamivudine, and zidovudine|
219264985|NCT02801864|DEVICE|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
219264986|NCT02801864|DEVICE|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
219264987|NCT02801864|OTHER|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
219264988|NCT01880437|DRUG|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
219264989|NCT01880437|DRUG|vismodegib|Cohorts 1 and 2: 150 mg orally daily
219264990|NCT04967183|DIAGNOSTIC_TEST|Annual FIT|"Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas)."
219264991|NCT04967183|PROCEDURE|Endoscopic surveillance.|First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
219264992|NCT00823836|DRUG|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
219264993|NCT00823836|DRUG|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
219264994|NCT01492621|DRUG|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
219264995|NCT00530998|PROCEDURE|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
219264996|NCT00530998|PROCEDURE|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
219264997|NCT02109666|DRUG|Abatacept|
219264998|NCT04421339|DIETARY_SUPPLEMENT|Melatonin|Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
219264999|NCT04421339|OTHER|Placebo|Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
219265000|NCT04065126|BEHAVIORAL|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
219265001|NCT04065126|BEHAVIORAL|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
219265002|NCT02271230|DRUG|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
219265003|NCT02271230|DIETARY_SUPPLEMENT|Fish oil (EPA/DHA) alone|1 g/d fish oil
219265004|NCT02271230|DRUG|Vitamin D alone|2000 IU vitamin D
219265005|NCT02271230|OTHER|Placebo|Vitamin D placebo and fish oil placebo
219265006|NCT01551069|DRUG|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
219265007|NCT01551069|DRUG|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
219265008|NCT04022577|BEHAVIORAL|Adherence Therapy|Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
219265009|NCT04022577|BEHAVIORAL|control group|The control group received routine care
219265010|NCT02168322|DEVICE|collagen membrane|bovine collagen membrane used for selective tissue regeneration
219265011|NCT02168322|DEVICE|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
219265012|NCT06102564|BEHAVIORAL|Group schematherapy|Brief group schematherapy for mothers with young children (age 0-5) focused on attachment relations between mother and child
219265013|NCT00066846|BIOLOGICAL|bevacizumab|
219265014|NCT00066846|DRUG|fluorouracil|
219265015|NCT00066846|DRUG|leucovorin calcium|
219265016|NCT02121327|OTHER|disease management|disease management program include self management education
219265017|NCT02121327|OTHER|usual care|usual care group receive regular outpatient treatment
219265018|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)
219265019|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
219265020|NCT03672799|BEHAVIORAL|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
219265021|NCT03672799|OTHER|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
219265022|NCT01477736|DRUG|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
219265023|NCT01477736|DRUG|Botulinum toxin A|300 U intradetrusor injection
219265024|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
219265025|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
219265026|NCT03537235|DEVICE|Libramed|
219265027|NCT03537235|DEVICE|Placebo|
219265028|NCT04354168|BEHAVIORAL|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
219265029|NCT03042299|DRUG|TAK-536|TAK-536 granules.
219265030|NCT03042299|DRUG|TAK-536|TAK-536 tablet.
219265031|NCT02461862|BEHAVIORAL|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
219265032|NCT02461862|PROCEDURE|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
219265033|NCT02461862|PROCEDURE|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
219265034|NCT01582373|BEHAVIORAL|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
219265035|NCT00607464|DEVICE|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
219265036|NCT01438840|DRUG|Avatrombopag|
219265037|NCT01438840|DRUG|Placebo|
219265038|NCT01438840|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
219265039|NCT05401383|DEVICE|Lumevis (IIa class)|intake of Lumevis 30 minutes before EGDS
219265040|NCT03062345|OTHER|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
219265041|NCT03062345|OTHER|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
219265042|NCT02594410|DEVICE|stent|patients receiving renal artery stenting for renal artery atherosclerosis
219265043|NCT02594410|DRUG|Aspirine|100mg Qd
219265044|NCT02594410|DRUG|Clopidogrel|75mg Qd
219265045|NCT02594410|DRUG|Lercanidipine|10-20mg Qd
219265046|NCT03004586|DEVICE|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
219265047|NCT03004586|DEVICE|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
219265048|NCT03004586|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
219265049|NCT02942342|PROCEDURE|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
219265050|NCT02062645|DRUG|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
219265051|NCT02804399|DRUG|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
219265052|NCT02804399|DRUG|rifampin|600 mg QD from day 1 to day 12 in period 2.
219265053|NCT02912754|DRUG|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
219265054|NCT02912754|DRUG|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
219265055|NCT01362647|PROCEDURE|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
219265056|NCT01362647|PROCEDURE|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
219265057|NCT02970097|DRUG|20ml bolus of 0.5% ropivicaine|local anesthetic
219265058|NCT02970097|DRUG|10 ml of 0.5% ropivicaine|local anesthetic
219265059|NCT02970097|DRUG|Midazolam|1-2 mg of medication given intravenously before nerve block
219265060|NCT02970097|DRUG|Fentanyl|50-100 mcg of medication given intravenously before nerve block
219265061|NCT03763149|BIOLOGICAL|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
219265062|NCT01372007|DRUG|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
219265063|NCT01372007|DRUG|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
219265064|NCT05247697|DRUG|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
219265065|NCT05247697|DRUG|Placebo oral tablet once daily at bedtime|Matching placebo
219265066|NCT05549947|DRUG|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
219265067|NCT05549947|DRUG|Placebo|Treatment group D：placebo
219265068|NCT03679897|DRUG|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
219265069|NCT03679897|DRUG|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
219265070|NCT03553290|DEVICE|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
219265071|NCT03553290|PROCEDURE|Control|Mechanical debridement alone
219265072|NCT03201237|OTHER|Action observation training|Each child observed a task video and then performed a task
219265073|NCT01774305|DRUG|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
219265074|NCT01774305|DRUG|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
219265075|NCT04797117|DIAGNOSTIC_TEST|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
219265076|NCT04211389|DRUG|ARQ-151 0.3% cream|ARQ-151 0.3% cream
219265077|NCT04211389|DRUG|ARQ-151 vehicle cream|ARQ-151 vehicle cream
219265078|NCT04627454|PROCEDURE|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
219265079|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid|
219265080|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid formulation|
219265081|NCT02209103|DIETARY_SUPPLEMENT|Identical looking placebo|
219265082|NCT00692458|DRUG|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
219265083|NCT00692458|DRUG|Comparator: placebo|placebo; oral, once daily for approximately 60 months
219265084|NCT02001142|OTHER|Exercise|single session of exercise
219265085|NCT04246853|DEVICE|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
219265086|NCT00953316|OTHER|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
219265087|NCT00333190|DEVICE|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
219265088|NCT05608031|OTHER|Pittsburgh sleep quality index (PSQI) scale|Pittsburgh Sleep Quality Index (PSQI) (6), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), was used to evaluate sleep quality over the last month.
219265089|NCT02394249|BEHAVIORAL|Physical activity regime|Information already included in arm descriptions
219265090|NCT04042025|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
219265091|NCT06540885|DRUG|Palonosetron (Group P)|Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia
219265092|NCT06540885|DRUG|Granisetron (Group G)|Group G participants will receive IV Granisetron 1mg at the start of wound closure
219265093|NCT00840671|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
219265094|NCT00840671|DRUG|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
219265095|NCT00456378|DEVICE|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
219265096|NCT00456378|PROCEDURE|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
219265097|NCT02964546|OTHER|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
219265098|NCT04009109|DRUG|Lenalidomide|Induction and Maintenance
219265099|NCT04009109|DRUG|Ixazomib|Induction and Only Maintenance Arm B
219265100|NCT04009109|DRUG|Daratumumab Injection|Induction and Only Maintenance Arm B
219265101|NCT04009109|DRUG|Dexamethasone|Induction and Only Maintenance Arm B
219265102|NCT02357264|DEVICE|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
219265103|NCT05528263|DEVICE|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
219265104|NCT05528263|OTHER|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
219265105|NCT03623373|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
219265106|NCT03623373|DRUG|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m\^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
219265107|NCT03623373|DRUG|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
219265108|NCT03623373|DRUG|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
219265109|NCT03623373|PROCEDURE|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
219265110|NCT03623373|PROCEDURE|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
219265111|NCT03623373|PROCEDURE|Oral rinse|-Baseline
219265112|NCT03623373|PROCEDURE|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
219265113|NCT03793322|DRUG|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
219265114|NCT00020709|DRUG|cisplatin|Given IV
219265115|NCT00020709|DRUG|docetaxel|Given IV
219265116|NCT00020709|DRUG|etoposide|Given IV
219265117|NCT00020709|DRUG|gefitinib|Given orally
219265118|NCT00020709|RADIATION|radiation therapy|Undergo radiation therapy
219265119|NCT00020709|OTHER|placebo|Given orally
219265120|NCT04797520|DEVICE|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
219265121|NCT04797520|DEVICE|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
219265122|NCT02856061|BEHAVIORAL|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
219265123|NCT05833776|PROCEDURE|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
219265124|NCT00193596|DRUG|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
219265125|NCT00193596|DRUG|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
219265126|NCT00193596|DRUG|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
219265127|NCT00193596|DRUG|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
219265128|NCT00193596|DRUG|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
219265129|NCT05226988|DEVICE|robot-assisted|Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
219265130|NCT05226988|DEVICE|Conventional rehabilitation intervention|Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
219265131|NCT00620633|BIOLOGICAL|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
219265132|NCT01062971|DRUG|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
219265133|NCT04823364|OTHER|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
219265134|NCT01759238|DRUG|Capecitabine|825mg/m2 per os bid
219265135|NCT01759238|DRUG|Bevacizumab|7.5 mg/kg
219265136|NCT01759238|RADIATION|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
219265137|NCT01530087|DEVICE|CASTLE barrier|Prototype barrier to be used in place of current two piece device
219265138|NCT00230945|BEHAVIORAL|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
219265139|NCT00641836|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
219265140|NCT01949883|DRUG|CPI-0610|
219265141|NCT02702336|BEHAVIORAL|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
219265142|NCT01182207|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
219265143|NCT01182207|DRUG|YAZ®|3 mg/0.02 mg Tablets
219265144|NCT05819047|DEVICE|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
219265145|NCT00503607|DRUG|BLI-800|
219265146|NCT00503607|DRUG|Polyethylene glycol 3350 based bowel preparation|
219265147|NCT00250978|DRUG|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
219265148|NCT01458847|DRUG|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
219265149|NCT01458847|DRUG|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
219265150|NCT01458847|DRUG|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
219265151|NCT05563090|OTHER|Questionnaires+Tongue diagnosis+Pulse diagnosis|Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
219265152|NCT00383409|DRUG|multivitamins|
219265153|NCT00383409|DRUG|placebo|
219265154|NCT01779453|DRUG|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
219265155|NCT01779453|DRUG|Placebo|Placebo once daily for 8 weeks
219265156|NCT01779453|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
219265157|NCT03242668|PROCEDURE|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
219265158|NCT03242668|PROCEDURE|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
219265159|NCT03242668|DRUG|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
219265160|NCT05176691|DRUG|HMPL-760|Administered orally QD for 28-day cycles
219265161|NCT05154032|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
219265162|NCT05376371|OTHER|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
219265163|NCT04680637|DRUG|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
219265164|NCT04680637|DRUG|Placebo|Administered as a subcutaneous (SC) injection.
219265165|NCT04680637|OTHER|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
219265166|NCT03427008|OTHER|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
219265167|NCT06276517|OTHER|questionnaire|self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
219265168|NCT06276517|OTHER|SS-QoL|49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
219265169|NCT06276517|OTHER|SF-36|multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
219265170|NCT06276517|OTHER|CIQ-R|16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
219265171|NCT06276517|DIAGNOSTIC_TEST|BREFF|rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
219265172|NCT06276517|DIAGNOSTIC_TEST|MoCA|MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
219265173|NCT06276517|OTHER|IADL|8 questions rated from 0 to 1 to assess functional outcome
219265174|NCT06276517|OTHER|mMRS|mMRS score from 0 to 4 to assess functional outcome
219265175|NCT06276517|OTHER|PCL-5|To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
219265176|NCT06276517|OTHER|Brief-Cope|28-question self-questionnaires to study patients' coping strategies
219265177|NCT03477825|DIETARY_SUPPLEMENT|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
219265178|NCT03477825|DIETARY_SUPPLEMENT|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
219265179|NCT03477825|DIETARY_SUPPLEMENT|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
219265180|NCT03277560|OTHER|No Intervention as it is an observational study|No Intervention as it is an observational study
219265181|NCT01822145|DEVICE|ICD|
219265182|NCT02530398|DRUG|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
219265183|NCT00097669|DRUG|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo|multivitamin
219265184|NCT00097669|OTHER|Placebo|
219265185|NCT02037256|DRUG|bortezomib|Given IV
219265186|NCT02037256|BIOLOGICAL|filgrastim|Given SC
219265187|NCT02037256|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
219265188|NCT05250960|DEVICE|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
219265189|NCT00951678|OTHER|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
219265190|NCT01837498|DRUG|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
219265191|NCT01837498|DRUG|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
219265192|NCT01828385|DRUG|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
219265193|NCT01828385|DRUG|Saline|Saline + rocuronium + sugammadex
219265194|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
219265195|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
219265196|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
219265197|NCT03700905|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
219265198|NCT03700905|RADIATION|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
219265199|NCT03700905|DRUG|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
219265200|NCT03700905|DRUG|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
219265201|NCT03700905|DRUG|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
219265202|NCT03061058|DRUG|Docetaxel|intraperitoneal and/or intravenous
219265203|NCT03061058|DRUG|Oxaliplatin|intravenous
219265204|NCT03061058|DRUG|Cisplatin|intraperitoneal
219265205|NCT03061058|DRUG|Irinotecan|intraperitoneal and/or intravenous
219265206|NCT03061058|DRUG|Pemetrexed|intraperitoneal and/or intravenous
219265207|NCT03061058|DRUG|S1|oral
219265208|NCT02246881|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
219265209|NCT02295176|DIETARY_SUPPLEMENT|Armolipid Plus|
219265210|NCT02295176|DIETARY_SUPPLEMENT|Placebo|
219265211|NCT04154800|DRUG|BMS-986209|Specified Dose on Specified Days
219265212|NCT04154800|OTHER|BMS-986209 Placebo|Specified Dose on Specified Days
219265213|NCT04154800|DRUG|Itraconazole|Specified Dose on Specified Days
219265214|NCT04154800|DRUG|Diltiazem|Specified Dose on Specified Days
219265215|NCT04587986|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
219265216|NCT05879003|DEVICE|novel brace with neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on scapular muscles and adductor muscle
219265217|NCT05879003|BEHAVIORAL|scapular and adductor exercise|The symptomatic rotator cuff tear subjects conduct scapular and adductor exercise
219265218|NCT04398368|DRUG|Gemcitabine Hydrochloride|Given intravesically
219265219|NCT02421549|DEVICE|Unpaired remote monitoring transmitter|
219265220|NCT06957301|PROCEDURE|Intrathecal Fentanyl Group (F)|Group fentanyl (F), an injection of bupivacaine 0.5% (3.5 ml) + fentanyl 0.5 ml (25 μg) will be administered intrathecally.
219265221|NCT06957301|PROCEDURE|intrathecal dexmedetomidine group(D)|Group dexmedetomidine( D), dexmedetomidine will be first diluted in normal saline to obtain a dose of 5 μg in 0.5 ml. Then, an injection of bupivacaine 0.5% (3.5 ml) + dexmedetomidine 0.5 ml (5 μg) will be administered intrathecally. Drug will be administered over 10 seconds (s) using 5 cc syringes with cephalad orientation of the spinal needle bevel.
219265222|NCT03257098|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
219265223|NCT03691545|BEHAVIORAL|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
219265224|NCT04427176|DEVICE|ARFC mask|Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
219265225|NCT00682227|BIOLOGICAL|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
219265226|NCT01459146|DRUG|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
219265227|NCT01459146|DRUG|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
219265228|NCT01459146|DRUG|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
219265229|NCT02646709|DRUG|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
219265230|NCT02646709|DRUG|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
219265231|NCT02646709|DRUG|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
219265232|NCT02646709|DRUG|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
219265233|NCT00848510|BIOLOGICAL|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
219265234|NCT01399762|DEVICE|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
219265235|NCT00891046|DRUG|Canakinumab|Canakinumab
219265236|NCT05828758|DRUG|Amoxicillin|Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
219265237|NCT05828758|OTHER|Placebo|Distilled water 0.2 ml/kg by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
219265238|NCT04525599|BIOLOGICAL|ASP3772|Intramuscular (IM) injection
219265239|NCT04525599|BIOLOGICAL|PCV13|Intramuscular injection
219265240|NCT05337098|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
219265241|NCT02034019|DRUG|Dexamethasone|
219265242|NCT02034019|DRUG|Punctum Plug|
219265243|NCT04523207|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
219265244|NCT04523207|DRUG|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
219265245|NCT04523207|DRUG|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
219265246|NCT06956976|PROCEDURE|Dissection of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), and dissecting the lymph nodes at the root of the inferior mesenteric artery (IMA).
219265247|NCT06956976|PROCEDURE|Preservation of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), but preserving the lymph nodes at the root of the inferior mesenteric artery (IMA).
219265248|NCT06954194|BEHAVIORAL|Explicit intervention (Shape Coding+syntactic priming)|For explicit intervention, a syntactic priming task will be preceded by explicit teaching of the target structure using the Shape Coding scheme adapted to be age- and language (Cantonese)-appropriate. A different set of 10 sentences will be used for teaching in each explicit intervention session, with five sentences used as exemplars for the experimenter to explain the target structure, and the remaining five sentences for children to practice. The syntactic priming session will be presented as a game to sustain the children's interest and to disguise the purpose of the study. Each intervention session will contain 40 pairs of prime-target pictures, 40 pairs of control-target pictures, and 20 pairs of filler pictures, randomly presented to the experimenter and child and controlled by the experimenter. In total, there are 500 doses of SRC-O sentences (50 sentences x10 sessions).
219265249|NCT06954194|BEHAVIORAL|Implicit intervention (syntactic priming only)|For implicit intervention, the same 10 sessions of syntactic priming will be provided to the children without explicit instruction of the SRC-O structure using the Shape Coding System. Nonetheless, to make the exposure and dosage as comparable as possible between the two groups, children in the implicit intervention group will also receive 10 listening sessions before the syntactic priming sessions. During the listening sessions, the same sets of sentences used in the explicit instruction sessions will be presented and the children will be instructed to listen closely as the tutor reads aloud the SRC-O sentence. Each listening session will be followed by a syntactic priming session that is identical to that of the explicit intervention group. In total, there are also 500 doses of SRC-O sentences (50 sentences x10 sessions).
219265250|NCT06956573|OTHER|aorta imaging|Retrospective analysis of imaging data (echocardiography and/or cardiac MRI) in adult patients with Fabry disease to assess ascending aortic diameters.
219265251|NCT06956599|DRUG|test toothpaste|A commercially available fluoride toothpaste
219265252|NCT06956599|DRUG|Control toothpaste|A commercially available fluoride toothpaste
219265253|NCT03113383|DEVICE|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
219265254|NCT02122172|DRUG|afatinib dimaleate|Given PO
219265255|NCT02122172|OTHER|laboratory biomarker analysis|Correlative studies
219265256|NCT02738957|BEHAVIORAL|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
219265257|NCT06640296|DRUG|Liposomal Amphotericin B (LAmB)|collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
219265258|NCT05624788|OTHER|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
219265259|NCT05418413|DEVICE|CTB|conventional Twin-block (CTB) will be comprised of maxillary and mandibular removable appliances having the labial bows, adam's clasps, and with no incisal capping.
219265260|NCT05418413|DEVICE|ETB|will be comprised of maxillary and mandibular removable 1.5-mm biocryl sheet will be adapted separately on maxillary and mandibular casts with help of vacuum machine, and Acrylic bite blocks with the inclined plane will be fabricated on biocryl sheets sim
219265261|NCT06242938|PROCEDURE|Early intensive antihypertensive treatment|"1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.)."
219265262|NCT02720211|DEVICE|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
219265263|NCT02720211|DEVICE|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
219265264|NCT00207818|DEVICE|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
219265265|NCT05061199|PROCEDURE|approach of anastomosis|The approach of anastomosis
219265266|NCT02349945|DRUG|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
219265267|NCT04849689|BEHAVIORAL|Whole-food, plant-based lifestyle|"The WFPB lifestyle program included:~1. Nutrition/plant-based food (energy intake: at least 90% of whole-food, plant-based diet and ≤ 10% of energy intake from plant-based meal replacements (PBMR) and dietary supplements (e.g., vitamin B12, D, and EPA and DHA omega-3 fatty acids).~2. Physical activity (habitual; organized and other).~3. Support system (lectures, workshops and individual nutrition counselling, grocery shopping assistance, cooking classes, regular measurements body composition, food logging, regular medical monitoring)."
219265268|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
219265269|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
219265270|NCT01010204|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
219265271|NCT01010204|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
219265272|NCT05875454|DIAGNOSTIC_TEST|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
219265273|NCT01519778|DRUG|TR701 FA|1 tablet 200 mg once daily
219265274|NCT01603433|DEVICE|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
219265275|NCT01704443|BEHAVIORAL|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
219265276|NCT01704443|OTHER|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
219265277|NCT04476836|OTHER|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
219265278|NCT01657799|DRUG|Veliparib|Veliparib capsules for oral administration
219265279|NCT01657799|DRUG|Placebo|Placebo to veliparib capsules for oral administration
219265280|NCT01657799|RADIATION|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
219265281|NCT00051038|DRUG|Entecavir|
219265282|NCT06011278|OTHER|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
219265283|NCT05963009|DRUG|baxdrostat (formerly CIN-107) oral solution|5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
219265284|NCT02449057|OTHER|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
219265285|NCT00882076|DRUG|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
219265286|NCT00882076|DRUG|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
219265287|NCT00882076|DRUG|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
219265288|NCT03021551|DEVICE|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
219265289|NCT00947232|BEHAVIORAL|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
219265290|NCT00947232|BEHAVIORAL|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
219265291|NCT02543099|DRUG|policosanol|Patients will receive policosanol 20mg Qd
219265292|NCT02543099|DRUG|placebo|Patients will receive placebo 20mg Qd;
219265293|NCT01765738|DEVICE|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
219265294|NCT02871583|PROCEDURE|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
219265295|NCT02871583|PROCEDURE|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
219265296|NCT05147337|DRUG|E2511|E2511 tablets.
219265297|NCT05147337|DRUG|Placebo|E2511 matched placebo tablets.
219265298|NCT06487143|DRUG|Triptorelin pamoate（15mg）|Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
219265299|NCT06487143|DRUG|Triptorelin acetate （3.75mg）|Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
219265300|NCT00412880|DRUG|BI 2536|Intravenous Infusion
219265301|NCT02131727|BEHAVIORAL|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
219265302|NCT02131727|BEHAVIORAL|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
219265303|NCT06296004|DEVICE|Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S|"Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US"
219265304|NCT03265015|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
219265305|NCT03265015|OTHER|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas.
219265306|NCT06001151|DRUG|Cadonilimab|Patients receive cadonilimab (10mg/kg) every 3 weeks.
219265307|NCT06001151|DRUG|Pemetrexed|Patients receive pemetrexed (500mg/m2) every 3 weeks.
219265308|NCT06001151|DRUG|Carboplatin|Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
219265309|NCT03017937|DEVICE|Q-collar|capture ultrasound images at each pressure point
219265310|NCT01821105|PROCEDURE|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
219265311|NCT01821105|PROCEDURE|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
219265312|NCT01821105|RADIATION|fludeoxyglucose F 18|Given IV
219265313|NCT01821105|PROCEDURE|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
219265314|NCT02978677|RADIATION|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
219265315|NCT02978677|RADIATION|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
219265316|NCT02978677|RADIATION|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
219265317|NCT04700059|BEHAVIORAL|Virtual perinatal home visiting|10 perinatal home visits
219265318|NCT04883060|DEVICE|midline localizer|a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
219265319|NCT03539068|BEHAVIORAL|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive::~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider)."
219265320|NCT05888844|DRUG|INCB099280|Administered as specified in the treatment arm description.
219265321|NCT03672019|BEHAVIORAL|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
219265322|NCT04488666|DEVICE|npSIMS|incisional NPWT
219265323|NCT00520624|DEVICE|inspiratory muscle strength training|
219265324|NCT00520624|PROCEDURE|Surgery|
219265325|NCT03546387|OTHER|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
219265326|NCT03546387|OTHER|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
219265327|NCT03546387|OTHER|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
219265328|NCT03546387|OTHER|Grooved Pegboard Test|Measures dexterity
219265329|NCT03546387|OTHER|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
219265330|NCT04398901|OTHER|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
219265331|NCT03359564|PROCEDURE|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
219265332|NCT05896189|BEHAVIORAL|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.
219265333|NCT05896189|BEHAVIORAL|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
219265334|NCT06214624|BEHAVIORAL|Two types of exercise interventions|"* HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
219265335|NCT06962020|DRUG|first-line biologic：IFX|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
219265336|NCT06962020|DRUG|first-line biologic:VDZ|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
219265337|NCT06531304|DEVICE|Lokomat Robot Assisted Gait Training|Patients will underwent 12 RAGT training sessions (3 times/week for 4 consecutive weeks, 45 min each including the time for wearing the harness and the exoskeleton) with the Lokomat device as add-on to conventional regimen (5 times/week, 80 min each). The Lokomat is a technologically advanced robot-assisted gait training device. Patients are supported in a harness above a treadmill while the robotic device assists the movements of their legs to provide physiological gait. As treatment progresses, weight bearing is increased and assistance from the robotic legs is reduced, requiring the patient to gradually assume greater responsibility for movements needed during walking.
219265338|NCT04599855|DRUG|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
219265339|NCT04599855|DRUG|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
219265340|NCT04599855|DRUG|Placebo|Matching placebo will be self administered as nasal spray.
219265341|NCT06134622|DRUG|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
219265342|NCT06134622|DRUG|Intravenous thrombolysis plus placebo|placebo (saline)
219265343|NCT00951964|DRUG|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
219265344|NCT00951964|DRUG|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
219265345|NCT02165397|DRUG|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
219265346|NCT02165397|DRUG|Placebo|Participants will receive placebo capsules orally.
219265347|NCT02165397|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV.
219265348|NCT03297398|DRUG|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
219265349|NCT03297398|DRUG|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
219265350|NCT03297398|OTHER|Placebo|Placebo
219265351|NCT06555770|BEHAVIORAL|müzik müdahalesi|One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
219265352|NCT00424554|DRUG|temozolomide|"Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
219265353|NCT02772718|DRUG|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
219265354|NCT02772718|DRUG|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
219265355|NCT02772718|DRUG|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
219265356|NCT02772718|DRUG|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
219265357|NCT02956083|OTHER|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
219265358|NCT02956083|OTHER|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
219265359|NCT02956083|OTHER|saline|Saline - no brand name
219265360|NCT04431752|RADIATION|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
219265361|NCT03587519|PROCEDURE|Early|Early ileostomy closure
219265362|NCT03587519|PROCEDURE|Late|Late ileostomy closure
219265363|NCT03431480|BIOLOGICAL|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
219265364|NCT00236184|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
219265365|NCT00236184|OTHER|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
219265366|NCT06380647|DRUG|Intravenous Acyclovir|Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
219265367|NCT01397500|DRUG|Genotropin|Genotropin administered sc once a day by patient or caregiver.
219265368|NCT01397500|DRUG|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
219265369|NCT04768868|DRUG|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
219265370|NCT01579721|PROCEDURE|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
219265371|NCT03211585|DEVICE|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
219265372|NCT02394964|OTHER|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
219265373|NCT03689439|DIAGNOSTIC_TEST|bone scintigraphy|bone scintigraphy
219265374|NCT00250640|DRUG|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
219265375|NCT00643435|BEHAVIORAL|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
219265376|NCT00643435|BEHAVIORAL|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
219265377|NCT01984671|BEHAVIORAL|Mobile Pain Coping Skills Training|
219265378|NCT05580198|DIAGNOSTIC_TEST|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
219265379|NCT00000319|DRUG|Buprenorphine|
219265380|NCT04874623|OTHER|Collection of peripheral blood mononuclear cells|Analysis of specific memory B cells in CDI patients
219265381|NCT04696133|OTHER|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
219265382|NCT04696133|OTHER|sensory integration|"* Tactile stimulation~* Proprioceptive stimulation"
219265383|NCT01470729|OTHER|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
219265384|NCT02876029|OTHER|Reference|the reference product used
219265385|NCT02876029|OTHER|Test product|The test Product used
219265386|NCT04049370|OTHER|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
219265387|NCT02584881|OTHER|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
219265388|NCT02875002|DRUG|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.
219265389|NCT02875002|DRUG|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
219265390|NCT00133055|BEHAVIORAL|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
219265391|NCT00133055|BEHAVIORAL|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
219265392|NCT02312206|DRUG|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
219265393|NCT02312206|OTHER|Placebo|Placebo
219265394|NCT00507156|PROCEDURE|Standard primary PCI|Acute re-opening of the occluded coronary artery
219265395|NCT00507156|PROCEDURE|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
219265396|NCT03082612|BEHAVIORAL|Faith-Based African American Cancer Survivorship Storytelling Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
219265397|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
219265398|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
219265399|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
219265400|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
219265401|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
219265402|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
219265403|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
219265404|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
219265405|NCT02333266|OTHER|Candidemia|
219265406|NCT03157908|DEVICE|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
219265407|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
219265408|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
219265409|NCT00336817|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
219265410|NCT00336817|DRUG|CellCept|CellCept 500mg or 1000mg BID for 90 days
219265411|NCT01846403|DEVICE|Semi-quantitative urine pregnancy test|
219265412|NCT01028612|RADIATION|thermal ablation with external beam radiation|thermal ablation with external beam radiation
219265413|NCT04668703|PROCEDURE|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
219265414|NCT05921487|BEHAVIORAL|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
219265415|NCT01772563|DRUG|volasertib|Solution for infusion
219265416|NCT01772563|DRUG|itraconazole|capsules
219265417|NCT04068051|DRUG|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
219265418|NCT02542098|DRUG|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
219265419|NCT01946555|DRUG|Morphine|
219265420|NCT01946555|DRUG|Fentanyl|
219265421|NCT01946555|DRUG|Methadone|
219265422|NCT01946555|DRUG|Buprenorphine|
219265423|NCT01946555|DRUG|Oxycodone|
219265424|NCT01946555|DRUG|Hydromorphone|
219265425|NCT01946555|DRUG|Tapentadol|
219265426|NCT03003806|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
219265427|NCT03003806|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
219265428|NCT05779917|BIOLOGICAL|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
219265429|NCT04817605|OTHER|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
219265430|NCT00026182|BIOLOGICAL|rituximab|Given IV
219265431|NCT00026182|BIOLOGICAL|recombinant interleukin-12|Given SC
219265432|NCT00026182|OTHER|laboratory biomarker analysis|Correlative studies
219265433|NCT00026182|OTHER|questionnaire administration|Ancillary studies
219265434|NCT00026182|PROCEDURE|quality-of-life assessment|Ancillary studies
219265435|NCT00736125|DEVICE|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
219265436|NCT00736125|DEVICE|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
219265437|NCT05793307|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
219265438|NCT02905409|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
219265439|NCT03757871|DEVICE|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
219265440|NCT00353886|PROCEDURE|TONI-3|
219265441|NCT00353886|PROCEDURE|WRAT-3|
219265442|NCT00353886|PROCEDURE|Connor's Rating Scales PRS & TRS|
219265443|NCT00353886|PROCEDURE|Peabody Picture Vocabulary Test|
219265444|NCT00353886|PROCEDURE|Children's Memory Scale|
219265445|NCT00353886|PROCEDURE|WISC-3|
219265446|NCT00353886|PROCEDURE|Behavioral Assessment System for Children PRS & TRS|
219265447|NCT06194682|PROCEDURE|Anterior cruciate ligament reconstruction|Anterior cruciate ligament arthroscopic reconstruction
219265448|NCT03292523|OTHER|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
219265449|NCT03790904|OTHER|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
219265450|NCT03790904|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
219265451|NCT03790904|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
219265452|NCT03231332|OTHER|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
219265453|NCT01927107|DIETARY_SUPPLEMENT|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
219265454|NCT02119949|BEHAVIORAL|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
219265455|NCT02119949|BEHAVIORAL|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
219265456|NCT04919070|BEHAVIORAL|Connect for Caregivers|The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.
219265457|NCT03815864|DIAGNOSTIC_TEST|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
219265458|NCT03666195|COMBINATION_PRODUCT|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
219265459|NCT01896453|PROCEDURE|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
219265460|NCT01896453|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
219265461|NCT01648595|DRUG|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
219265462|NCT01550432|DIETARY_SUPPLEMENT|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
219265463|NCT01550432|DIETARY_SUPPLEMENT|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
219265464|NCT01550432|OTHER|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
219265465|NCT02493465|DRUG|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
219265466|NCT00890799|DEVICE|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
219265467|NCT00890799|PROCEDURE|surgery|Patient in this group received open surgical repair of pmVSD.
219265468|NCT02466698|PROCEDURE|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
219265469|NCT02466698|DRUG|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
219265470|NCT02466698|DRUG|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
219265471|NCT02466698|DRUG|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
219265472|NCT01196819|DEVICE|Firehawk|Implantation of Firehawk drug eluting stent
219265473|NCT01196819|DEVICE|Xience V|Implantation of Xience V drug eluting stent
219265474|NCT05350488|OTHER|Informational Interview|Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.
219265475|NCT05350488|OTHER|Focus Group|Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
219265476|NCT06356623|OTHER|1|this is not an intervention study
219265477|NCT01086384|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
219265478|NCT01086384|DRUG|Fluticasone furoate|Inhaled corticosteroid
219265479|NCT00380965|DRUG|Cesamet™ (nabilone)|
219265480|NCT02077725|OTHER|interdisciplinary polypharmacy clinic visit|
219265481|NCT03211728|DRUG|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
219265482|NCT03211728|DRUG|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
219265483|NCT01694888|OTHER|lecture|Teaching documentation skill using lecture method
219265484|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
219265485|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
219265486|NCT02244268|DRUG|ALNA®|
219265487|NCT06062615|PROCEDURE|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
219265488|NCT06062615|PROCEDURE|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
219265489|NCT06062615|DEVICE|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
219265490|NCT02632812|DRUG|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
219265491|NCT02632812|DRUG|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
219265492|NCT02632812|DRUG|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
219265493|NCT01998971|DRUG|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
219265494|NCT01998971|DRUG|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
219265495|NCT01998971|DRUG|Pomalidomide|Administered orally in accordance with product labeling and local standards.
219265496|NCT01998971|DRUG|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
219265497|NCT01998971|DRUG|Melphalan|Administered orally in accordance with product labeling and local standards.
219265498|NCT01998971|DRUG|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
219265499|NCT01998971|DRUG|Thalidomide|Administered orally in accordance with product labeling and local standards.
219265500|NCT01998971|DRUG|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
219265501|NCT01998971|DRUG|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
219265502|NCT01998971|DRUG|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
219265503|NCT01998971|DRUG|Lenalidomide|Administered orally in accordance with product labeling and local standards.
219265504|NCT01998971|DRUG|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
219265505|NCT04988776|OTHER|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
219265506|NCT04988776|OTHER|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
219265507|NCT03416413|PROCEDURE|Ambulatory phlebectomy|Minor surgery to remove varicose vein tributaries
219265508|NCT03416413|DRUG|Foam sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
219265509|NCT01776359|DIETARY_SUPPLEMENT|High Protein|2.4g/kg of protein
219265510|NCT01776359|DIETARY_SUPPLEMENT|Low Protein|1.2g/kg of protein
219265511|NCT03732820|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
219265512|NCT03732820|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
219265513|NCT03381469|PROCEDURE|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs \> 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
219265514|NCT03381469|PROCEDURE|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
219265515|NCT00590525|PROCEDURE|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
219265516|NCT06317402|OTHER|malnutrition questionary|At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
219265517|NCT00992992|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
219265518|NCT01130649|DEVICE|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
219265519|NCT05399368|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
219265520|NCT05399368|OTHER|Placebo|Nonactive placebo tablet
219265521|NCT02398045|OTHER|Computerised CBT for OCD|Computerised CBT for OCD
219265522|NCT03840265|PROCEDURE|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
219265523|NCT04236232|DIAGNOSTIC_TEST|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
219265524|NCT00850486|DEVICE|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
219265525|NCT05730998|DIETARY_SUPPLEMENT|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
219265526|NCT05730998|DIETARY_SUPPLEMENT|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
219265527|NCT02725567|DRUG|IVA|Granules in sachet for oral administration.
219265528|NCT02592499|DEVICE|HM III|
219265529|NCT02592499|OTHER|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
219265530|NCT02198261|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
219265531|NCT00115947|DRUG|Terlipressin|
219265532|NCT04397146|DIETARY_SUPPLEMENT|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
219265533|NCT03974789|DIAGNOSTIC_TEST|Blood test|Plasma cortisol level test
219265534|NCT03974789|DIAGNOSTIC_TEST|24-hour Urine test|Urinary free cortisol test
219265535|NCT03974789|DIAGNOSTIC_TEST|Saliva swab|salivette® for salivary cortisol quantification
219265536|NCT03974789|DIAGNOSTIC_TEST|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
219265537|NCT00945451|DEVICE|CK|Cyberknife Irradiation
219265538|NCT00255944|BEHAVIORAL|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
219265539|NCT00255944|BEHAVIORAL|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
219265540|NCT01129115|BEHAVIORAL|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
219265541|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
219265542|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
219265543|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
219265544|NCT05951621|OTHER|Qigong|An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
219265545|NCT05951621|BEHAVIORAL|guidance of nutrition and exercise|Provide health promotion and guidance to participants on diet and physical exercise
219265546|NCT00005845|DRUG|tipifarnib|Given PO
219265547|NCT00005845|OTHER|laboratory biomarker analysis|Correlative studies
219265548|NCT00005845|OTHER|pharmacological study|Correlative studies
219265549|NCT03120299|DRUG|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
219265550|NCT03120299|DRUG|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
219265551|NCT01963572|OTHER|SG will be screened every time when they visit the clinics.|
219265552|NCT01768741|PROCEDURE|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
219265553|NCT01768741|PROCEDURE|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
219265554|NCT01797978|DRUG|Intravenous methylene blue administration|Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
219265555|NCT01797978|DRUG|Placebo|
219265556|NCT06240546|DRUG|LPM6690176|Administered orally
219265557|NCT02610621|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
219265558|NCT04679740|DEVICE|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
219265559|NCT05393622|DEVICE|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
219265560|NCT05278013|OTHER|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
219265561|NCT02400814|DRUG|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
219265562|NCT02400814|RADIATION|Stereotactic Body Radiation Therapy|Undergo SAR
219265563|NCT02539238|OTHER|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
219265564|NCT00992121|DRUG|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
219265565|NCT00992121|DRUG|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
219265566|NCT00992121|DRUG|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
219265567|NCT05531890|DRUG|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
219265568|NCT05531890|DRUG|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
219265569|NCT05531890|DRUG|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
219265570|NCT05531890|DRUG|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
219265571|NCT05531890|DRUG|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
219265572|NCT05531890|DRUG|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
219265573|NCT04582513|OTHER|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
219265574|NCT02877264|DRUG|vapendavir 132 mg capsule|
219265575|NCT02877264|DRUG|vapendavir 264 mg tablet|
219265576|NCT02877264|DRUG|vapendavir 24 mg/mL oral suspension|
219265577|NCT02798692|BIOLOGICAL|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
219265578|NCT02798692|BIOLOGICAL|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
219265579|NCT02798692|BIOLOGICAL|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
219265580|NCT02798692|BIOLOGICAL|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
219265581|NCT02951169|OTHER|No intervention|No intervention. Treatment are accordance with clinical practice.
219265582|NCT05354310|COMBINATION_PRODUCT|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
219265583|NCT06801171|OTHER|cognitive stimulation|12 sessions (one per week for 12 weeks) in group of cognitive stimulation
219265584|NCT06801171|OTHER|mixed intervention|12 sessions (one per week for 12 weeks) in group of mixte stimulation (yoga, cognitive behavioral therapy, mindfullness meditation, positive psychology)
219265585|NCT02605096|PROCEDURE|MRI|Magnetic Resonance Imaging Scan
219265586|NCT02605096|PROCEDURE|X-ray|X-ray exam (conventional radiography)
219265587|NCT01860547|DIETARY_SUPPLEMENT|Bilberries|Frozen bilberries, 100 g/d
219265588|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
219265589|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
219265590|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
219265591|NCT03856047|DRUG|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
219265592|NCT03856047|DRUG|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
219265593|NCT03856047|DRUG|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
219265594|NCT03856047|DRUG|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
219265595|NCT00673556|DRUG|alefacept|Intramuscular (IM)
219265596|NCT00673556|DRUG|placebo|Intramuscular (IM)
219265597|NCT00000370|BEHAVIORAL|Cognitive behavior therapy|
219265598|NCT00000370|BEHAVIORAL|Performance-based exposure therapy|
219265599|NCT00000370|BEHAVIORAL|Psychosocial intervention|
219265600|NCT03599336|PROCEDURE|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
219265601|NCT03599336|OTHER|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
219265602|NCT02734186|DRUG|Praziquantel|Anthelminthic
219265603|NCT02205099|DRUG|SKL15508|
219265604|NCT02205099|DRUG|Placebo|
219265605|NCT02713737|DEVICE|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.
219265606|NCT02713737|DEVICE|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
219265607|NCT00171795|DRUG|Rivastigmine|
219265608|NCT02419963|PROCEDURE|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
219265609|NCT02419963|OTHER|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
219265610|NCT02419963|OTHER|Stool Sample|Stool sample to evaluate microbiome fingerprint.
219265611|NCT02609802|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
219265612|NCT02609802|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
219265613|NCT03177681|OTHER|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
219265614|NCT03177681|OTHER|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
219265615|NCT03177681|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
219265616|NCT03177681|DEVICE|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
219265617|NCT03177681|OTHER|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
219265618|NCT01135030|PROCEDURE|Total knee|Primary Total knee
219265619|NCT02023905|DRUG|Everolimus|everolimus at 10 mg daily continuously
219265620|NCT02023905|DRUG|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
219265621|NCT02878759|DEVICE|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
219265622|NCT02377011|BEHAVIORAL|Problem solving cognitive behaviour therapy (PS CBT)|
219265623|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
219265624|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
219265625|NCT04842409|RADIATION|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
219265626|NCT00874497|DRUG|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
219265627|NCT00874497|DRUG|placebo|Placebo for 104 weeks (2 years)
219265628|NCT03235362|DRUG|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
219265629|NCT03235362|DRUG|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
219265630|NCT03235362|DRUG|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
219265631|NCT00176410|DRUG|fluvastatin|40mg fluvastatin daily
219265632|NCT05192564|OTHER|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
219265633|NCT05192564|OTHER|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
219265634|NCT06330987|DEVICE|electrocardiograph|Ten standard derivation electrodes were used to acquired FANTE registrations. The peripheral electrodes (Left (L), Right (R) and Foot (F)) were placed on the maternal abdomen in a triangle around the navel (orange) with lower apex, while the precordial ones (C1, C2, C3, C4, C5, C6) were put on an external circle. The Neutral electrode was on the right side of the patient abdomen. The software was configured so that the system acquired and wrote on disk 8 signals (2 bipolar and 6 referenced to the centroid of the three L, R and F leads) at 1000 sps with a resolution of 0.763uV. This high resolution is needed to resolve the very small voltage changes related to fetal cardiac activity.
219265635|NCT02420041|PROCEDURE|Active comparator: Fluoroscopic Guided SIJ injection|"* Needle entry point is in the lower one-third of the SIJ~* Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~* Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~* 1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~* Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~* Patient observed in recovery bay for 20 minutes and then discharged home"
219265636|NCT02420041|PROCEDURE|Ultrasound Guided Sacroiliac Joint Injection|"* Sterile preparation (with chlorhexidine) and drape~* Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~* 3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~* Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~* After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~* Patient observed in recovery bay for 20 minutes and then discharged home"
219265637|NCT02420041|DEVICE|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
219265638|NCT02420041|DEVICE|SonoSite S-nerve|
219265639|NCT02420041|DEVICE|iohexol|
219265640|NCT02420041|DRUG|triamcinolone/lidocaine|
219265641|NCT00103272|DRUG|tanespimycin|Given IV
219265642|NCT00103272|DRUG|bortezomib|Given IV
219265643|NCT00665223|DRUG|ACR16|Capsules will be swallowed whole with water.
219265644|NCT00665223|DRUG|Placebo|Capsules will be swallowed whole with water.
219265645|NCT00040898|DIETARY_SUPPLEMENT|Sho-saiko-to|
219265646|NCT04195932|OTHER|Exercise training|
219265647|NCT01657643|DIETARY_SUPPLEMENT|Probiotics|
219265648|NCT01657643|DIETARY_SUPPLEMENT|placebo|
219265649|NCT05188872|DIAGNOSTIC_TEST|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
219265650|NCT00905359|PROCEDURE|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
219265651|NCT00905359|PROCEDURE|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
219265652|NCT02138253|DRUG|IDN-6556|
219265653|NCT02138253|DRUG|Placebo|Placebo control
219265654|NCT02136771|DIETARY_SUPPLEMENT|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
219265655|NCT02136771|DIETARY_SUPPLEMENT|Placebo|
219265656|NCT00239447|DRUG|Tiotropium|
219265657|NCT00239447|DEVICE|HandiHaler|
219265658|NCT00239447|DEVICE|Respimat SMI|
219265659|NCT00146510|BEHAVIORAL|HealtheLifestyle Program|
219265660|NCT00146510|BEHAVIORAL|step counters with monthly feedback on logs|
219265661|NCT05665322|PROCEDURE|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
219265662|NCT05665322|PROCEDURE|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
219265663|NCT01073319|OTHER|Placebo|Administration of placebo pill
219265664|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
219265665|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
219265666|NCT00027976|DRUG|celecoxib|
219265667|NCT00027976|DRUG|Placebo|
219265668|NCT01682798|DIETARY_SUPPLEMENT|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
219265669|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
219265670|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
219265671|NCT02572440|PROCEDURE|Sorin XTRA/Sorin Group,|
219265672|NCT02739776|DEVICE|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
219265673|NCT06270277|DIAGNOSTIC_TEST|Pediatric Quality of Life Inventory (PedsQL)|Questionnaire
219265674|NCT06270277|DIAGNOSTIC_TEST|Strengths and Difficulties Questionnaire (SDQ)|Questionnaire
219265675|NCT00894998|BIOLOGICAL|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
219265676|NCT00894998|BIOLOGICAL|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
219265677|NCT00083330|DRUG|VRC-HIVADV014-00-VP|
219265678|NCT05612451|PROCEDURE|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
219265679|NCT05612451|OTHER|non-setting calcium hydroxide|non-setting calcium hydroxide
219265680|NCT05612451|OTHER|modified triple antibiotic paste|modified triple antibiotic paste
219265681|NCT05441098|OTHER|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
219265682|NCT01031849|DRUG|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
219265683|NCT06210061|DRUG|Propofol-Fentanyl|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
219265684|NCT06210061|DRUG|Propofol-Fentanyl-Dexmedetomidine|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
219265685|NCT06210061|DRUG|Propofol-Fentanyl-Sevoflurane|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
219265686|NCT00741832|DEVICE|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
219265687|NCT00741832|OTHER|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
219265688|NCT04855357|BEHAVIORAL|Resident counselling|One hour, one-on-one counseling for residents
219265689|NCT04855357|BEHAVIORAL|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
219265690|NCT01728623|DRUG|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
219265691|NCT01382862|OTHER|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
219265692|NCT04783103|DEVICE|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
219265693|NCT00243022|DRUG|Boswellia serrata extract|given orally
219265694|NCT00243022|DIETARY_SUPPLEMENT|cyanocobalamin|given orally
219265695|NCT02957695|DEVICE|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
219265696|NCT02957695|DEVICE|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
219265697|NCT03297476|DIAGNOSTIC_TEST|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
219265698|NCT00479219|DRUG|GSI-953|
219265699|NCT00479219|OTHER|Placebo|
219265700|NCT01380977|BEHAVIORAL|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
219265701|NCT06307067|DIAGNOSTIC_TEST|Urine dipstick|Urine dipstick is a point of care test that can be performed on the urine in the public health center.
219265702|NCT04901845|OTHER|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
219265703|NCT03517111|BEHAVIORAL|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
219265704|NCT03517111|BEHAVIORAL|Substance use prevention only|Parenting program focusing only on substance use prevention
219265705|NCT03517111|BEHAVIORAL|Academic success program|Program focusing on academic success and college acceptance
219265706|NCT02001909|DRUG|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
219265707|NCT02001909|DRUG|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
219265708|NCT06171035|OTHER|3D-printed high-fidelity craniofacial manikin model education|Slide-based presention plus 3D printed model
219265709|NCT06171035|OTHER|Traditional model education|Slide-based presention plus traditional model
219265710|NCT00853736|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
219265711|NCT00853736|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
219265712|NCT01514955|RADIATION|Gold seeds insertion to detect movements at pelvis|
219265713|NCT01514955|RADIATION|Image guided MRI based RT (IMRT+Brachytherapy)|
219265714|NCT06302725|PROCEDURE|Vaginal self sampling detecting HPV|IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
219265715|NCT02944396|DRUG|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
219265716|NCT02944396|DRUG|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
219265717|NCT02944396|DRUG|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
219265718|NCT02944396|DRUG|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
219265719|NCT02944396|DRUG|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
219265720|NCT03592004|OTHER|neoadjuvant chemotherapy|neoadjuvant chemotherapy
219265721|NCT00621192|DRUG|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
219265722|NCT04769375|OTHER|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
219265723|NCT04769375|OTHER|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
219265724|NCT04769375|OTHER|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
219265725|NCT05445063|BIOLOGICAL|Autologous iPSC-derived RPE|Autologous transplantation of iPSC-derived RPE
219265726|NCT04426435|DRUG|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
219265727|NCT06401837|BEHAVIORAL|Circadian based acupressure application|Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
219265728|NCT01580683|DRUG|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
219265729|NCT01580683|OTHER|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
219265730|NCT04706793|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
219265731|NCT04706793|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
219265732|NCT04416932|PROCEDURE|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
219265733|NCT00499928|DRUG|SB-751689|
219265734|NCT02844530|DRUG|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
219265735|NCT02844530|DRUG|chemotherapy/ immunotherapy|
219265736|NCT04438382|BIOLOGICAL|Infliximab|Given IV
219265737|NCT04438382|BIOLOGICAL|Intravenous Immunoglobulin Therapy|Given IV
219265738|NCT04438382|DRUG|Prednisone|Given IV or PO
219265739|NCT04438382|DRUG|Methylprednisolone|Given IV or PO
219265740|NCT01398098|DRUG|Sodium phosphate|32 tablets
219265741|NCT03713320|DRUG|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
219265742|NCT03713320|DRUG|Vorinostat|Daily doses of vorinostat throughout study treatment period
219265743|NCT04454099|DIAGNOSTIC_TEST|4 kind of FOBT and colonoscopy with pathological examination|Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
219265744|NCT00503503|DRUG|Enbrel (etanercept)|
219265745|NCT05513183|PROCEDURE|Intraoperative blood and peritoneal fluid samplings during HIPEC|"\- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
219265746|NCT00004922|DRUG|irinotecan hydrochloride|
219265747|NCT06345326|OTHER|Greater occipital nerve block|The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
219265748|NCT04063046|DRUG|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
219265749|NCT04063046|DRUG|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
219265750|NCT02238106|DRUG|Salmeterol medium dose|
219265751|NCT02238106|DRUG|Salmeterol low dose|
219265752|NCT02238106|DRUG|Salmeterol high dose|
219265753|NCT02238106|DRUG|Serevent® Diskus®|
219265754|NCT02238106|DRUG|Placebo HandiHaler®|
219265755|NCT02238106|DRUG|Placebo Diskus®|
219265756|NCT02418962|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
219265757|NCT02418962|OTHER|Normal Saline|0.9% Sodium chloride solution for injection
219265758|NCT04181489|DRUG|Sintilimab|Sintilimab 200mg d0
219265759|NCT04181489|DRUG|Rituximab|Rituximab 375 mg/m2 d0
219265760|NCT04181489|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
219265761|NCT04181489|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
219265762|NCT04181489|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
219265763|NCT04181489|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
219265764|NCT03874936|DRUG|Dexamethasone 24mg Solution for Injection|Administrated i.v.
219265765|NCT03874936|DRUG|Saline Solution for Injection|administrated i.v.
219265766|NCT05395923|PROCEDURE|Suture|The pressure application will be applied before the incision on the palate.
219265767|NCT05395923|PROCEDURE|No Suture CTG -Control|A graft will be taken from the palate before the procedure is applied.
219265768|NCT03260933|OTHER|No intervention given. This is a qualitative interview study|This is a qualitative interview study
219265769|NCT02087215|DRUG|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
219265770|NCT02087215|DRUG|Placebo|
219265771|NCT00336336|DRUG|n-3 PUFA|1 g die per os
219265772|NCT00336336|DRUG|Rosuvastatin|10 mg die per os
219265773|NCT00336336|DRUG|Placebo|1 gram c. per os
219265774|NCT00336336|DRUG|Placebo|10 mg c. per os
219265775|NCT03191071|DIAGNOSTIC_TEST|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
219265776|NCT03191071|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
219265777|NCT03191071|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
219265778|NCT03191071|DIAGNOSTIC_TEST|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
219265779|NCT04370535|DEVICE|cellulose|The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks.
219265780|NCT04370535|DEVICE|PMA-zeolite|The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks.
219265781|NCT04909671|DEVICE|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
219265782|NCT04909671|OTHER|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
219265783|NCT02868671|OTHER|acupuncture|
219265784|NCT02868671|OTHER|sham acupuncture|
219265785|NCT05367206|DRUG|Albumin-Bound Paclitaxel|260mg/m2 q3w \*2 circles
219265786|NCT05367206|DRUG|Carboplatin|AUC 5-6 q3w \* 2 circles
219265787|NCT04850235|DRUG|Nab paclitaxel|Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
219265788|NCT04767334|DEVICE|Anti-Gravity Treadmill|"Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
219265789|NCT02725528|DRUG|collagenase injection|injection
219265790|NCT02725528|PROCEDURE|limited palmar fasciectomy|surgery
219265791|NCT05438134|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
219265792|NCT05442346|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
219265793|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
219265794|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
219265795|NCT02569957|DRUG|Acetylcysteine|Given IV and PO
219265796|NCT00177021|DRUG|Aldara Cream 5%|
219265797|NCT03990636|DRUG|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
219265798|NCT02960971|PROCEDURE|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
219265799|NCT03276390|BEHAVIORAL|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
219265800|NCT02864823|PROCEDURE|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
219265801|NCT02900235|DRUG|MT-3995|
219265802|NCT01410864|DEVICE|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
219265803|NCT01410864|OTHER|Control|Devices or drugs used to seal the dura (other than DuraSeal)
219265804|NCT02893098|DRUG|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
219265805|NCT02893098|DRUG|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
219265806|NCT01283022|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
219265807|NCT04839055|DRUG|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
219265808|NCT04839055|DRUG|Abiraterone|Abiraterone
219265809|NCT04226092|DEVICE|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
219265810|NCT04226092|DEVICE|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
219265811|NCT00444262|PROCEDURE|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
219265812|NCT00444262|DRUG|VOLUVEN and others solute|VOLUVEN and others solute
219265813|NCT02468908|DRUG|Molgramostim|
219265814|NCT02468908|DRUG|Placebo|
219265815|NCT01993277|DEVICE|Nexalin Brain Stimulator|
219265816|NCT01993277|DEVICE|Fischer Wallace Stimulator|
219265817|NCT01993277|DEVICE|David Delight Stimulator|
219265818|NCT01993277|BEHAVIORAL|Relaxation Therapy|
219265819|NCT02530788|DRUG|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
219265820|NCT02530788|DRUG|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
219265821|NCT01781832|DEVICE|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
219265822|NCT02920255|OTHER|Diagnostic|Measurement of spinal tilt
219265823|NCT05820113|DEVICE|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
219265824|NCT05710289|BIOLOGICAL|Immune Responses|To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510\_004 study.
219265825|NCT02719743|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
219265826|NCT03062085|OTHER|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
219265827|NCT01971281|DEVICE|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
219265828|NCT01971281|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
219265829|NCT01971281|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
219265830|NCT01209598|DRUG|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
219265831|NCT01209598|DRUG|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
219265832|NCT01440010|RADIATION|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
219265833|NCT04606147|PROCEDURE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
219265834|NCT04606147|PROCEDURE|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
219265835|NCT02846493|DRUG|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
219265836|NCT02846493|DRUG|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
219265837|NCT01085383|DRUG|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
219265838|NCT01874509|BEHAVIORAL|Check Your Drinking|
219265839|NCT01874509|BEHAVIORAL|Alcohol Help Centre|
219265840|NCT04686292|DIAGNOSTIC_TEST|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
219265841|NCT02601209|DRUG|Pazopanib|Given PO
219265842|NCT02601209|DRUG|Pazopanib Hydrochloride|Given PO
219265843|NCT02601209|DRUG|Sapanisertib|Given PO
219265844|NCT03439618|OTHER|time-restricted feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
219265845|NCT03439618|OTHER|continuous feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
219265846|NCT02599922|BIOLOGICAL|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
219265847|NCT01390142|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
219265848|NCT01390142|PROCEDURE|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
219265849|NCT01390142|PROCEDURE|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
219265850|NCT05995093|OTHER|no intervention|no intervention
219265851|NCT01314599|DRUG|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
219265852|NCT03636373|DRUG|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
219265853|NCT03636373|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
219265854|NCT02150395|OTHER|music therapy|
219265855|NCT01313169|OTHER|EMR Reminder|EMR reminders displayed
219265856|NCT01313169|OTHER|EMR Reminder + Panel management|EMR Reminder + Panel management
219265857|NCT06148402|DRUG|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
219265858|NCT00572533|OTHER|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
219265859|NCT00572533|OTHER|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
219265860|NCT05889962|PROCEDURE|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
219265861|NCT05889962|PROCEDURE|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
219265862|NCT02830529|BEHAVIORAL|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
219265863|NCT02830529|BEHAVIORAL|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
219265864|NCT04228198|PROCEDURE|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
219265865|NCT00557531|DEVICE|BL-1040|2 mL of BL-1040
219265866|NCT04196543|OTHER|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra\_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
219265867|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
219265868|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
219265869|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
219265870|NCT02313337|OTHER|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
219265871|NCT02313337|OTHER|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
219265872|NCT02313337|OTHER|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
219265873|NCT02313337|OTHER|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
219265874|NCT02313337|DRUG|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
219265875|NCT02313337|PROCEDURE|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
219265876|NCT02313337|DRUG|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
219265877|NCT04810897|OTHER|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
219265878|NCT03720223|DRUG|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
219265879|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
219265880|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
219265881|NCT05825222|DIETARY_SUPPLEMENT|Placebo|One Capsule to be consumed twice a day
219265882|NCT02807610|DRUG|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
219265883|NCT02807610|DRUG|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
219265884|NCT02807610|DRUG|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
219265885|NCT03873454|DEVICE|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
219265886|NCT03873454|DEVICE|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
219265887|NCT03873454|OTHER|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
219265888|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
219265889|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
219265890|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
219265891|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
219265892|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
219265893|NCT00322686|DRUG|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
219265894|NCT00322686|DRUG|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
219265895|NCT02961478|DRUG|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
219265896|NCT05928949|OTHER|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
219265897|NCT03850275|DIETARY_SUPPLEMENT|Intervention/treatment|Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
219265898|NCT04999605|DRUG|AK112 low dose|AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
219265899|NCT04999605|DRUG|AK112 medium dose|AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
219265900|NCT04999605|DRUG|AK112 high dose|AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
219265901|NCT01773876|DRUG|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
219265902|NCT01773876|DRUG|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
219265903|NCT04089072|DRUG|Methylene Blue|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
219265904|NCT04089072|DRUG|Phenylephrine|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
219265905|NCT01560195|DRUG|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
219265906|NCT01560195|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
219265907|NCT01560195|DRUG|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
219265908|NCT05160311|DRUG|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
219265909|NCT05160311|DEVICE|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
219265910|NCT05551936|DRUG|Bendamustine|90 mg/m\^2 IV Days 1-2, Cycles 1-3
219265911|NCT05551936|DRUG|Rituximab|375 mg/m\^2 IV Day 1 Cycles 1-6
219265912|NCT05551936|DRUG|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
219265913|NCT04882189|DIAGNOSTIC_TEST|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
219265914|NCT03896074|DRUG|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
219265915|NCT03896074|DRUG|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
219265916|NCT04201704|OTHER|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
219265917|NCT04201704|OTHER|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
219265918|NCT04201704|OTHER|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
219265919|NCT04201704|OTHER|Platelets volume|For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
219265920|NCT01161628|DRUG|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
219265921|NCT04089839|OTHER|Non-Interventional|Non-Interventional
219265922|NCT03436550|PROCEDURE|mpMRI|Multiparametric MRI
219265923|NCT03436550|PROCEDURE|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
219265924|NCT06413017|DRUG|Nimotuzumab|Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
219265925|NCT06413017|DRUG|ICIs(Immune checkpoint inhibitors)|Use it as it is describe in the instructions from the specification
219265926|NCT05832619|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
219265927|NCT05832619|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
219265928|NCT05832619|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
219265929|NCT04605744|BEHAVIORAL|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
219265930|NCT02778906|DRUG|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
219265931|NCT02778906|DRUG|Placebo|Administration of the comparator s.c. weekly in comparable to verum
219265932|NCT01589549|BIOLOGICAL|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
219265933|NCT06172114|PROCEDURE|Alveolar ridge preservation using sticky bone|In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
219265934|NCT04363710|OTHER|Low Calorie Diet|800-1000 Kcal/day
219265935|NCT04641117|OTHER|Exercise|Walking and Power Training
219265936|NCT01232400|DRUG|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached."
219265937|NCT06360952|DEVICE|Tasso+ CBC|Novel blood collection device
219265938|NCT00865137|DRUG|Tacrolimus, modified release|Oral
219265939|NCT00321490|DRUG|Quetiapine fumarate|
219265940|NCT00321490|DRUG|Duloxetine|
219265941|NCT02240797|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
219265942|NCT03906604|PROCEDURE|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
219265943|NCT00523952|DRUG|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
219265944|NCT03482947|DRUG|ultrasonography-guided TAP block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
219265945|NCT03482947|DRUG|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
219265946|NCT04629937|OTHER|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
219265947|NCT02081937|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|
219265948|NCT01977027|OTHER|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
219265949|NCT04459221|DRUG|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
219265950|NCT03339947|OTHER|Questionnaire|
219265951|NCT02391077|OTHER|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
219265952|NCT02391077|OTHER|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
219265953|NCT02391077|OTHER|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
219265954|NCT01463228|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
219265955|NCT01463228|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
219265956|NCT00080522|BEHAVIORAL|Monitoring by HIV-trained primary care nurses|
219265957|NCT00080522|BEHAVIORAL|Community-based directly observed therapy (DOT)|
219265958|NCT00080522|DRUG|stavudine|
219265959|NCT00080522|DRUG|lamivudine|
219265960|NCT00080522|DRUG|efavirenz|
219265961|NCT00080522|DRUG|zidovudine|
219265962|NCT00080522|DRUG|didanosine|
219265963|NCT00080522|DRUG|lopinavir/ritonavir|
219265964|NCT03226301|DRUG|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
219265965|NCT03226301|DRUG|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
219265966|NCT03226301|DRUG|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
219265967|NCT00715117|DRUG|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
219265968|NCT00715117|OTHER|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
219265969|NCT04966559|DRUG|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
219265970|NCT04966559|DRUG|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
219265971|NCT03954288|DIAGNOSTIC_TEST|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
219265972|NCT01652859|DRUG|Liposomal Amphotericin B|
219265973|NCT01652859|DRUG|AmBisome|
219265974|NCT06546059|DEVICE|narrow band ultraviolet-B|vitiligo patients will recevie twice sessions per week
219265975|NCT04292080|DRUG|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
219265976|NCT04292080|OTHER|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
219265977|NCT01338376|BEHAVIORAL|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration"
219265978|NCT01338376|BEHAVIORAL|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration"
219265979|NCT01338376|DRUG|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
219265980|NCT05028036|OTHER|Personalized lifestyle treatment program|"The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program."
219265981|NCT02332200|OTHER|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
219265982|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
219265983|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (monthly)|
219265984|NCT00471172|BEHAVIORAL|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
219265985|NCT00471172|BEHAVIORAL|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
219265986|NCT00471172|BEHAVIORAL|Self help|
219265987|NCT01454388|OTHER|breakfast|
219265988|NCT00169845|DIETARY_SUPPLEMENT|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
219265989|NCT00169845|DIETARY_SUPPLEMENT|Placebo|Provided by Roche Vitamins Inc
219265990|NCT00176059|DRUG|intravenous immunoglobulins (IVIG)|
219265991|NCT00176059|PROCEDURE|kidney transplantation|
219265992|NCT01482429|OTHER|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
219265993|NCT03747809|DEVICE|CIEDs Remote Monitoring System|Cardiac device remote monitoring system
219265994|NCT02759796|PROCEDURE|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
219265995|NCT02759796|PROCEDURE|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
219265996|NCT04567810|DRUG|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
219265997|NCT04567810|DRUG|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
219265998|NCT05032846|PROCEDURE|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
219265999|NCT05032846|OTHER|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
219266000|NCT04286763|DIAGNOSTIC_TEST|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
219266001|NCT02311088|DRUG|Caffeine|
219266002|NCT02311088|DRUG|Placebo|
219266003|NCT05739539|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
219266004|NCT05739539|DIAGNOSTIC_TEST|spectral domain optical coherence tomography|optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
219266005|NCT02399397|PROCEDURE|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
219266006|NCT02399397|PROCEDURE|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
219266007|NCT02399397|PROCEDURE|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
219266008|NCT02399397|DRUG|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
219266009|NCT02399397|PROCEDURE|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
219266010|NCT06394609|OTHER|double loaded knotted suture anchor|arthroscopic bankart repair by using double loaded knotted suture anchor
219266011|NCT06394609|OTHER|double grand knot|arthroscopic bankart repair by using double grand knot
219266012|NCT05079594|OTHER|Mother voice|"Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale."
219266013|NCT05079594|OTHER|White noise|"Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed."
219266014|NCT05714423|PROCEDURE|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
219266015|NCT05714423|PROCEDURE|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
219266016|NCT06939413|DEVICE|Continuous glucose monitor (CGM)|The glucose data from the CGM will help participants to understand the effect of lifestyle and medications on their glucose levels. The glucose levels from the CGM will be remotely monitored. Outreach will be made to participants not reaching glycemic goals. Appropriate adjustments in treatment regimen will be made based on the glucose data obtained from CGM and RPM
219266017|NCT06944236|OTHER|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
219266018|NCT06945588|BEHAVIORAL|Music listening|Happy music group listened to happy music (major mode with a tempo of \>120 beats per minute).
219266019|NCT06945588|BEHAVIORAL|Music listening|Sad music group listened to sad music (minor mode with a tempo of \<80 beats per minute).
219266020|NCT06944652|OTHER|Stretching|Stretching of the plantar flexors or the shoulder joint
219266021|NCT06944301|DIAGNOSTIC_TEST|blood sampling|measuring troponine preoperative and postoperative first and second day
219266022|NCT06945705|DRUG|furmonertinib combined with anlotinib|furmonertinib: 160 mg po qd Anlotinib: 8 mg per day, orally administered.The treatment cycle is every 3 weeks, with each cycle lasting 21 days. Anlotinib are taken on Days 1-14 of each cycle.
219266023|NCT06945510|DEVICE|PCT detection|Clinicians will prescribe PCT tests every day for enrolled patients, with assigning a dedicated person monitoring the daily PCT results. Once the PCT \<0.5 ng/ml or ΔPCT (drop from the peak value) \>80%, the clinicians will receive a notification and will strictly adhere to guidelines and PCT values to adjust antibiotic prescriptions.
219266024|NCT02893488|DRUG|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
219266025|NCT02893488|DRUG|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
219266026|NCT02893488|DRUG|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
219266027|NCT04287283|OTHER|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
219266028|NCT02371772|OTHER|Training|Patients were trained to monitor INR and dose warfarin
219266029|NCT02209844|DRUG|BI 44847|
219266030|NCT02209844|DRUG|Placebo|
219266031|NCT05099289|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
219266032|NCT03414528|DIAGNOSTIC_TEST|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
219266033|NCT06957665|DEVICE|T-scan Assisted Occlusal Adjustment with Stabilization Splint|Participants were treated with a custom-fabricated stabilization splint (Michigan-type) whose occlusion was adjusted using the T-scan system (Tekscan, Norwood, MA, USA) to measure and optimize occlusal force distribution. The T-scan system was used in conjunction with articulating paper to guide occlusal refinement until bilateral force balance was achieved.
219266034|NCT06957652|DEVICE|DBMM-C plus Resorbable collagen membrane|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, followed by coverage with a resorbable collagen membrane. The flaps will then be coronally advanced and stabilized over the biomaterials.
219266035|NCT06957652|DEVICE|DBMM-C|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, and then the flaps will be coronally advanced and stabilized over the graft material.
219266036|NCT06401278|DEVICE|Transcutaneous electrical acupoint stimulation|"It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)"
219266037|NCT06401278|DEVICE|Transcutaneous electrical nerve stimulation (group b):|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
219266038|NCT03305887|DEVICE|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
219266039|NCT03305887|DEVICE|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
219266040|NCT03305887|DEVICE|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
219266041|NCT03305887|DEVICE|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
219266042|NCT03142347|PROCEDURE|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
219266043|NCT03142347|PROCEDURE|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
219266044|NCT05395364|BEHAVIORAL|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
219266045|NCT00416598|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
219266046|NCT00416598|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
219266047|NCT00416598|DRUG|Busulfan|Given IV
219266048|NCT00416598|DRUG|Cytarabine|Given IV
219266049|NCT00416598|DRUG|Daunorubicin Hydrochloride|Given IV
219266050|NCT00416598|DRUG|Decitabine|Given IV
219266051|NCT00416598|DRUG|Etoposide|Given IV
219266052|NCT00416598|BIOLOGICAL|Filgrastim|Given SC
219266053|NCT00416598|OTHER|Laboratory Biomarker Analysis|Correlative studies
219266054|NCT00416598|OTHER|Pharmacological Study|Correlative studies
219266055|NCT01266746|PROCEDURE|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
219266056|NCT00848796|DRUG|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
219266057|NCT01226732|DRUG|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
219266058|NCT01226732|DRUG|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
219266059|NCT01347372|BEHAVIORAL|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
219266060|NCT06421077|DEVICE|transauricular auricular vagus nerve stimulation|transauricular auricular vagus nerve stimulation
219266061|NCT02166970|DEVICE|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
219266062|NCT06072040|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
219266063|NCT02166476|DRUG|Meropenem-Vaborbactam|Meropenem-vaborbactam
219266064|NCT02166476|DRUG|Piperacillin-Tazobactam|Piperacillin-tazobactam
219266065|NCT02166476|DRUG|Levofloxacin|Levofloxacin
219266066|NCT02166476|DRUG|Saline|Saline
219266067|NCT00004060|DRUG|exatecan mesylate|
219266068|NCT05869695|OTHER|OSPRO-ROS Questionnaire|Completion of questionnaires
219266069|NCT05869695|OTHER|OSPRO-YF Questionnaire|Completion of questionnaires
219266070|NCT01618370|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
219266071|NCT01076244|PROCEDURE|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
219266072|NCT01561677|DEVICE|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
219266073|NCT01561677|DEVICE|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
219266074|NCT03024892|PROCEDURE|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
219266075|NCT03024892|PROCEDURE|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
219266076|NCT03024892|PROCEDURE|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
219266077|NCT03024892|PROCEDURE|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
219266078|NCT00524186|DRUG|fluorouracil|Given IV
219266079|NCT00524186|DRUG|irinotecan hydrochloride|Given IV
219266080|NCT00524186|DRUG|leucovorin calcium|Given IV
219266081|NCT00524186|DRUG|sunitinib malate|Taken Orally
219266082|NCT00524186|OTHER|flow cytometry|Correlative Study
219266083|NCT00524186|OTHER|pharmacological study|Correlative Study
219266084|NCT02939846|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
219266085|NCT01808131|DRUG|Lesinurad|Tablets, 200 mg QD
219266086|NCT01808131|DRUG|Lesinurad|Tablets, 400 mg QD
219266087|NCT05262010|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
219266088|NCT05262010|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
219266089|NCT06956274|OTHER|Preoperative Telehealth|Conduct a preoperative telehealth consultation with a Certified Wound, Ostomy, and Continence Nurse (WOCN) to provide patient education on post-surgical care expectations.
219266090|NCT06956274|OTHER|Measure Ostomy Output|Patients will be sent home with a measuring container (graduated container) and will measure their ostomy output every 12 hours and record it in a pad that will be provided to them.
219266091|NCT06145789|OTHER|standing powered wheelchair evaluation|standing powered wheelchair evaluation
219266092|NCT02989571|DRUG|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
219266093|NCT02989571|DRUG|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
219266094|NCT05688683|OTHER|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
219266095|NCT03463551|DRUG|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
219266096|NCT03463551|OTHER|0.9% NaCl|Placebo
219266097|NCT03863132|DEVICE|TAVR|Repair of defective aortic valve by microsurgical Intervention.
219266098|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
219266099|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
219266100|NCT06381648|DIAGNOSTIC_TEST|LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)|A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
219266101|NCT05317559|BEHAVIORAL|room light|The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
219266102|NCT01178307|BEHAVIORAL|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
219266103|NCT01178307|BEHAVIORAL|Interview|Each interview will take approximately 30 minutes.
219266104|NCT01178307|BEHAVIORAL|MDASI-GIST Questionnaire|Every 4 weeks for one year
219266105|NCT00636662|OTHER|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
219266106|NCT01347671|DRUG|GRT6005|25µg/day once daily
219266107|NCT01347671|DRUG|GRT6005|75 µg/day once daily
219266108|NCT01347671|DRUG|GRT6005|200 µg/day once daily
219266109|NCT01347671|DRUG|Matching Placebo|Once daily
219266110|NCT02178930|OTHER|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
219266111|NCT02429908|DEVICE|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
219266112|NCT03051425|DIETARY_SUPPLEMENT|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
219266113|NCT03051425|DIETARY_SUPPLEMENT|Placebo|120 mL of low-fat milk
219266114|NCT00459914|DEVICE|cpap treatment during sleep|CPAP
219266115|NCT00252083|BEHAVIORAL|Popular Opinion Leader|
219266116|NCT02053610|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
219266117|NCT02053610|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
219266118|NCT02053610|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
219266119|NCT00197795|BIOLOGICAL|"Meningococcal outer membrane vesicle vaccine MenBVac"|
219266120|NCT06367634|DEVICE|injection in NLF|TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin
219266121|NCT05286294|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
219266122|NCT01798979|DRUG|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
219266123|NCT01798979|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
219266124|NCT04297592|DRUG|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
219266125|NCT04297592|DRUG|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
219266126|NCT04297592|DRUG|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
219266127|NCT00698282|DRUG|AZD1981|Oral tablet, 250 mg single dose
219266128|NCT00698282|DRUG|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
219266129|NCT00698282|DRUG|Placebo|
219266130|NCT00429143|RADIATION|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
219266131|NCT00429143|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
219266132|NCT00429143|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
219266133|NCT00429143|DRUG|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
219266134|NCT00429143|DRUG|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
219266135|NCT00429143|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
219266136|NCT05602623|DEVICE|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
219266137|NCT06086041|PROCEDURE|cochlear implant|cochlear implant
219266138|NCT03427060|DRUG|Coversin|Coversin - 22.5mg followed by 45mg for 6 months.
219266140|NCT02617979|OTHER|SAFECARE at Home customized lessons|
219266141|NCT01296763|DRUG|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
219266142|NCT01296763|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
219266143|NCT01296763|DRUG|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
219266144|NCT01296763|DRUG|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
219266145|NCT01296763|DRUG|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
219266146|NCT05508269|GENETIC|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
219266147|NCT05508269|PROCEDURE|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
219266148|NCT02866396|DRUG|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
219266149|NCT02866396|OTHER|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
219266150|NCT03462043|COMBINATION_PRODUCT|ND0612|s.c. infused
219266151|NCT03462043|COMBINATION_PRODUCT|CLES|Carbidopa-Levodopa Enteral Suspension.
219266152|NCT04921137|OTHER|No endocrine therapy|No endocrine therapy given
219266153|NCT04921137|OTHER|Endocrine therapy|Endocrine therapy given for at least 5 years
219266154|NCT04461769|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
219266155|NCT01869114|DRUG|Sirolimus|Given PO
219266156|NCT01869114|DRUG|Azacitidine|Given IV
219266157|NCT05808127|BEHAVIORAL|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
219266158|NCT05673733|OTHER|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
219266159|NCT05673733|OTHER|exergaming training|Group B will receive only exergaming training
219266160|NCT00543062|DRUG|Inhaled placebo|Inhaled Staccato placebo (0 mg)
219266161|NCT00543062|DRUG|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
219266162|NCT00543062|DRUG|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
219266163|NCT00543062|DRUG|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
219266164|NCT00543062|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
219266165|NCT03703726|DIETARY_SUPPLEMENT|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
219266166|NCT03703726|DIETARY_SUPPLEMENT|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
219266167|NCT03703726|DIETARY_SUPPLEMENT|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
219266168|NCT03703726|DIETARY_SUPPLEMENT|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
219266169|NCT03703726|DIETARY_SUPPLEMENT|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
219266170|NCT03703726|DIETARY_SUPPLEMENT|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
219266171|NCT03703726|DIETARY_SUPPLEMENT|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
219266172|NCT02075619|DRUG|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
219266173|NCT02075619|DRUG|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
219266174|NCT02075619|DRUG|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
219266175|NCT01439854|DRUG|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
219266176|NCT01439854|DRUG|Placebo|Patients are treated with placebo
219266177|NCT05095428|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
219266178|NCT05095428|BEHAVIORAL|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
219266179|NCT03020030|DRUG|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
219266180|NCT03020030|DRUG|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
219266181|NCT03020030|DRUG|Cyclophosphamide|Standard of Care
219266182|NCT03020030|DRUG|CYTARABINE|Standard of Care
219266183|NCT03020030|DRUG|DASATINIB|Standard of Care
219266184|NCT03020030|DRUG|DEXAMETHASONE|Standard of Care
219266185|NCT03020030|DRUG|Dexrazoxane|Standard of Care
219266186|NCT03020030|DRUG|Doxorubicin|Standard of Care
219266187|NCT03020030|DRUG|ETOPOSIDE|Standard of Care
219266188|NCT03020030|DRUG|HYDROCORTISONE|Standard of Care
219266189|NCT03020030|DRUG|LEUCOVORIN CALCIUM|Standard of Care
219266190|NCT03020030|DRUG|MERCAPTOPURINE|Standard of Care
219266191|NCT03020030|DRUG|METHOTREXATE|Standard of Care
219266192|NCT03020030|DRUG|NELARABINE|Standard of Care
219266193|NCT03020030|DRUG|Vincristine|Standard of Care
219266194|NCT05429255|BEHAVIORAL|Aerobic Exercise|Bicycle training
219266195|NCT05429255|BEHAVIORAL|Exergame Training|Nintendo Wii
219266196|NCT00328562|DRUG|ZD1839 (Iressa)|
219266197|NCT00328562|RADIATION|Thoracic Radiotherapy|
219266198|NCT06298708|BIOLOGICAL|Mevac-A vaccine|"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."
219266199|NCT06298708|BIOLOGICAL|Havrix 720 Junior|"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."
219266200|NCT03509961|DIAGNOSTIC_TEST|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
219266201|NCT03509961|DRUG|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
219266202|NCT04608136|BEHAVIORAL|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
219266203|NCT05080205|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
219266204|NCT05070832|PROCEDURE|Deep Hyperthermia|Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
219266205|NCT05311553|PROCEDURE|Zona pellucida thinning|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
219266206|NCT05311553|PROCEDURE|Zona pellucida drilling|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
219266207|NCT04648826|DEVICE|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
219266208|NCT04648826|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
219266209|NCT04648826|DRUG|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
219266210|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
219266211|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
219266212|NCT05203861|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
219266213|NCT05203861|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
219266214|NCT03360578|DEVICE|Garmin|A commercial grade health wearable
219266215|NCT01240889|DRUG|Fluticasone|nasal spray
219266216|NCT01240889|DRUG|Fluticason|2 sprays per day in each nostril
219266217|NCT01610960|DEVICE|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
219266218|NCT01610960|DEVICE|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
219266219|NCT00976690|DRUG|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
219266220|NCT01793636|DRUG|AZD2014|AZD2014 vs Everolimus
219266221|NCT01793636|DRUG|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
219266222|NCT00424788|PROCEDURE|Plasma exchange|
219266223|NCT00424788|DRUG|natalizumab treatment|
219266224|NCT01513330|DEVICE|SenSura Mio|Ostomy product - 1 piece closed bag
219266225|NCT01513330|DEVICE|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
219266226|NCT00207753|DRUG|albendazole vs. combined albendazole/ivermectin treatment|
219266227|NCT00703183|DRUG|ACU-4429|administered as a single dose, orally
219266228|NCT00703183|DRUG|matching placebo|administered as a single dose, orally
219266229|NCT01592812|DEVICE|electrical muscle stimulation|Duration of the stimulation 20 minutes
219266230|NCT01858051|DIETARY_SUPPLEMENT|Cholecalciferol|
219266231|NCT01858051|DIETARY_SUPPLEMENT|Placebo|
219266232|NCT04136600|DRUG|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
219266233|NCT04136600|DRUG|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
219266234|NCT04178447|DRUG|Glepaglutide|Single dose of Glepaglutide 10 mg
219266235|NCT04486313|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
219266236|NCT04486313|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
219266237|NCT04486313|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
219266238|NCT04719715|DIAGNOSTIC_TEST|Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays|Measurement and evaluation of the ANCA testing
219266239|NCT04815343|DEVICE|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
219266240|NCT04636645|OTHER|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
219266241|NCT04636645|OTHER|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
219266242|NCT04636645|OTHER|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
219266243|NCT05029011|DEVICE|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
219266244|NCT03236610|DRUG|tenofovir monotherapy|switching to tenofovir monotherapy
219266245|NCT03236610|DRUG|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
219266246|NCT02561208|OTHER|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
219266247|NCT06064747|DEVICE|LF-rTMS|"LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);"
219266248|NCT06064747|DEVICE|Sham stimulation|Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
219266249|NCT01159951|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
219266250|NCT03002142|DEVICE|Hearing aids|Phonak Audéo B-R (Target V 5.0)
219266251|NCT03002142|DEVICE|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
219266252|NCT01041989|BEHAVIORAL|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
219266253|NCT01041989|BEHAVIORAL|Exercise|Guided muscle strength training and aerobic exercise.
219266254|NCT01041989|BEHAVIORAL|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
219266255|NCT01041989|OTHER|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
219266256|NCT01409005|DRUG|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1\~21~Interval: every 4 weeks"
219266257|NCT04176289|DIAGNOSTIC_TEST|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI\> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
219266258|NCT04752800|DEVICE|Direct Current Transcranial Stimulation - tDCS|Intervenção Ativa
219266259|NCT04752800|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham Intervention
219266260|NCT03922152|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
219266261|NCT00981708|DRUG|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
219266262|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
219266263|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
219266264|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
219266265|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
219266266|NCT05142579|OTHER|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
219266267|NCT05142579|OTHER|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
219266268|NCT04597346|DEVICE|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
219266269|NCT03084276|OTHER|High-fat meal|High-fat meal
219266270|NCT03084276|OTHER|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
219266271|NCT05928468|BIOLOGICAL|LYB002V14|Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.
219266272|NCT05928468|BIOLOGICAL|LYB002V14A|Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.
219266273|NCT05928468|BIOLOGICAL|LYB002CA|Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
219266274|NCT04212754|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
219266275|NCT05995652|PROCEDURE|elastography|elastography
219266276|NCT00589537|OTHER|questionnaire administration|
219266277|NCT00589537|PROCEDURE|computed tomography|
219266278|NCT00589537|PROCEDURE|magnetic resonance imaging|
219266279|NCT00589537|PROCEDURE|quality-of-life assessment|
219266280|NCT01496365|DRUG|DS-5565 tablet|5mg and 10mg tablets
219266281|NCT01496365|DRUG|pregabalin capsule|75mg and 150mg over-encapsulated
219266282|NCT01496365|DRUG|Placebo tablet|
219266283|NCT01496365|DRUG|placebo capsule|
219266284|NCT01288209|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
219266285|NCT01288209|DRUG|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
219266286|NCT01288209|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
219266287|NCT01015677|DRUG|MK-6913|
219266288|NCT01015677|DRUG|17-β estradiol|
219266289|NCT01015677|DRUG|Placebo to MK-6913|
219266290|NCT01015677|DRUG|Placebo to 17-β estradiol|
219266291|NCT01015677|DRUG|MK-6913 25 mg|
219266292|NCT06464952|DIETARY_SUPPLEMENT|Resistant potato starch|Prebiotic
219266293|NCT06464952|DIETARY_SUPPLEMENT|Powdered cellulose|Active comparator
219266294|NCT00293345|DRUG|gemcitabine hydrochloride|
219266295|NCT00293345|DRUG|triapine|
219266296|NCT01755676|DRUG|Orlistat 60 mg|1 tablet 3 times a day
219266297|NCT01755676|OTHER|Placebo|1 tablet 3 times a day
219266298|NCT02232399|DRUG|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
219266299|NCT02232399|DRUG|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
219266300|NCT02830542|DRUG|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
219266301|NCT02830542|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
219266302|NCT00814008|DRUG|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
219266303|NCT00814008|DRUG|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
219266304|NCT04623762|OTHER|Yoga|yoga application
219266305|NCT00751322|OTHER|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
219266306|NCT00751322|OTHER|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
219266307|NCT03064152|DEVICE|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
219266308|NCT05317455|DRUG|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
219266309|NCT05429047|BIOLOGICAL|Tozinameran|Tozinameran during pregnancy
219266310|NCT05429047|OTHER|COVID-19|SARS-CoV-2 infection during pregnancy
219266311|NCT05429047|OTHER|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
219266312|NCT00601432|DRUG|levofloxacin oral solution|
219266313|NCT00209664|DRUG|irinotecan|
219266314|NCT00209664|DRUG|S-1|
219266315|NCT04083924|OTHER|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
219266316|NCT01986296|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
219266317|NCT05759286|BEHAVIORAL|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
219266318|NCT05759286|BEHAVIORAL|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
219266319|NCT05759286|BEHAVIORAL|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
219266320|NCT05558436|DIAGNOSTIC_TEST|Genome-wide methylation profiling|Detection for colorectal tumor-specific ctDNA methylation biomarkers
219266321|NCT04487353|OTHER|Labor mechanism application developed with virtual reality technology (VRT-LMA)|"In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups."
219266322|NCT05471440|DRUG|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
219266323|NCT05471440|DRUG|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
219266324|NCT05471440|DRUG|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
219266325|NCT05471440|DRUG|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
219266326|NCT01646385|DRUG|etanercept|use as per routine clinical practice
219266327|NCT01646385|DRUG|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
219266328|NCT01843777|BEHAVIORAL|Standard-of-Care|the standard of care in audiologic practice
219266329|NCT01843777|BEHAVIORAL|Treatment|motivational interviewing
219266330|NCT04324190|BEHAVIORAL|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
219266331|NCT04324190|BEHAVIORAL|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
219266332|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
219266333|NCT06838169|BEHAVIORAL|Virtual reality glasses|virtual reality glasses application
219266334|NCT06838169|BEHAVIORAL|breathing exercise|breathing exercise app
219266335|NCT04977115|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
219266336|NCT04977115|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
219266337|NCT02846064|PROCEDURE|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
219266338|NCT01124968|OTHER|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
219266339|NCT01146977|OTHER|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
219266340|NCT01146977|OTHER|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
219266341|NCT01777334|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
219266342|NCT01777334|DRUG|Tiotropium 18 mcg|Inhalation Powder
219266343|NCT05216042|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
219266344|NCT05216042|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
219266345|NCT05216042|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
219266346|NCT05216042|OTHER|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
219266347|NCT05500833|OTHER|Multidimentional observation scale (MDP)|Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later
219266348|NCT05948423|OTHER|Tisue Flossing Technique|"Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted."
219266349|NCT04740723|DEVICE|iRF System Renal Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery
219266350|NCT00491621|PROCEDURE|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
219266351|NCT06332898|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
219266352|NCT06332898|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219266353|NCT03322553|DEVICE|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
219266354|NCT04070768|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
219266355|NCT04070768|DRUG|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
219266356|NCT04685447|PROCEDURE|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
219266357|NCT04685447|PROCEDURE|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
219266358|NCT03915769|DRUG|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
219266359|NCT03915769|OTHER|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
219266360|NCT01836016|DRUG|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
219266361|NCT01836016|DRUG|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
219266362|NCT01836016|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
219266363|NCT01836016|DRUG|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
219266364|NCT01836016|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
219266365|NCT01836016|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
219266366|NCT01836016|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
219266367|NCT01836016|DRUG|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
219266368|NCT04058236|OTHER|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
219266369|NCT04058236|OTHER|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
219266370|NCT04799418|DEVICE|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
219266371|NCT01855477|PROCEDURE|Histological biopsy procedure|
219266372|NCT05387837|DRUG|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
219266373|NCT04921553|OTHER|Data collection and quality of life questionnaire|"* Data collection from the medical file~* Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
219266374|NCT04106713|BEHAVIORAL|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
219266375|NCT04106713|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
219266376|NCT04106713|BEHAVIORAL|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
219266377|NCT02988349|OTHER|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
219266378|NCT04335747|OTHER|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
219266379|NCT02895334|BEHAVIORAL|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
219266380|NCT00000177|DRUG|Estrogen|
219266381|NCT05965739|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
219266382|NCT05965739|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
219266383|NCT05965739|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
219266384|NCT05965739|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
219266385|NCT05965739|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
219266386|NCT06105931|BIOLOGICAL|Hyperinsulinemic-euglycemic clamp|Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.
219266387|NCT06105931|OTHER|High Fat Mixed Meal Tolerance Test|After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.
219266388|NCT05185297|OTHER|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
219266389|NCT04493697|DEVICE|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
219266390|NCT04493697|DEVICE|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
219266391|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
219266392|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
219266393|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
219266394|NCT01476813|DRUG|Comparator|comparison of different dosages of drug versus comparator
219266395|NCT02492698|DIETARY_SUPPLEMENT|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
219266396|NCT02492698|DIETARY_SUPPLEMENT|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
219266397|NCT05911178|RADIATION|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesicle density."
219266398|NCT05911178|RADIATION|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
219266399|NCT05911178|RADIATION|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topography of tau deposition."
219266400|NCT05911178|RADIATION|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
219266401|NCT01973062|BIOLOGICAL|rituximab|Given IV
219266402|NCT01973062|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219266403|NCT04288206|DRUG|Cefazolin|intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
219266404|NCT04288206|DRUG|normal saline|intravenous normal saline placebo
219266405|NCT03889873|BEHAVIORAL|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
219266406|NCT02113410|BEHAVIORAL|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
219266407|NCT02113410|BEHAVIORAL|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
219266408|NCT02205775|DRUG|Atorvastatin|80 + 40 mg pre PCI
219266409|NCT02205775|DRUG|Rosuvastatin|40 + 40 mg before PCI
219266410|NCT02205775|DRUG|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
219266411|NCT02205775|DRUG|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
219266412|NCT02205775|DRUG|placebo|twice before PCI
219266413|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
219266414|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
219266415|NCT04915131|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
219266416|NCT02196805|DRUG|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
219266417|NCT02196805|DRUG|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
219266418|NCT00364377|DRUG|Sitagliptin|100 mg once daily
219266419|NCT00364377|OTHER|Placebo|once daily for duration of the study
219266420|NCT03286309|DEVICE|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
219266421|NCT02193659|DIETARY_SUPPLEMENT|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
219266422|NCT02906475|OTHER|standardized skin care regimen|"Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed"
219266423|NCT00926380|DRUG|denosumab|denosumab: 60 mg SC every 6 months
219266424|NCT00926380|DRUG|teriparatide|teriparatide: 20 mcg SC QD
219266425|NCT00565838|PROCEDURE|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
219266426|NCT00244647|DRUG|RESTEN-MP|
219266427|NCT00136110|DRUG|Sodium Valproate|
219266428|NCT05109000|DRUG|Sodium Chloride 0.9% Inj|10 mL subcutaneous injection into one randomized anterior thigh of subject
219266429|NCT05109000|DRUG|Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)|10 mL subcutaneous injection into the contralateral anterior thigh of subject
219266430|NCT01601912|DRUG|Atomoxetine|40 mg, 1 application
219266431|NCT01601912|DRUG|Citalopram|20 mg, 1 application
219266432|NCT03349411|DIAGNOSTIC_TEST|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
219266433|NCT03349411|DIAGNOSTIC_TEST|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
219266434|NCT03349411|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
219266435|NCT03349411|DIAGNOSTIC_TEST|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
219266436|NCT03349411|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
219266437|NCT03349411|DIAGNOSTIC_TEST|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
219266438|NCT03349411|DIAGNOSTIC_TEST|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
219266439|NCT03533205|DIAGNOSTIC_TEST|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
219266440|NCT06404983|OTHER|Opioid Free Anaesthesia (OFA)|Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
219266441|NCT06404983|OTHER|Conventional General Anaesthesia (CGA)|Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
219266442|NCT02045290|DRUG|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
219266443|NCT02045290|DRUG|Placebo|
219266444|NCT00632021|BEHAVIORAL|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
219266445|NCT04624945|DIAGNOSTIC_TEST|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
219266446|NCT04394195|OTHER|measurement of circulating sFlt1 concentration|blood circulating sFlt1 concentration will be determined
219266447|NCT03563313|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.
219266448|NCT03563313|DEVICE|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
219266449|NCT00952848|OTHER|questionnaire administration|Pain Rating Score
219266450|NCT00952848|OTHER|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
219266451|NCT00952848|OTHER|Quality of Life instrument|Uniscale 0-100 scale global quality of life
219266452|NCT00952848|DEVICE|MC5-A Scrambler device|Electrical stimulation for 60 minutes
219266453|NCT00458393|DRUG|daily TDF/FTC|daily oral medication
219266454|NCT00458393|DRUG|Placebo|daily oral medication
219266455|NCT02486419|OTHER|Outdoor weather|Seasonal changes in temperature
219266456|NCT00788164|BIOLOGICAL|TA-HPV|Given intramuscularly
219266457|NCT00788164|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
219266458|NCT00788164|DRUG|imiquimod|Given topically
219266459|NCT01690923|DEVICE|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
219266460|NCT01690923|DEVICE|Pillows mask|Nasal pillows mask (Swift FX)
219266461|NCT04315116|DRUG|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 \& day10 .
219266462|NCT04315116|DRUG|Loperamide|Loperamide 4 mg bid from day 7 to day 13
219266463|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
219266464|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
219266465|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
219266466|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
219266467|NCT04148118|BIOLOGICAL|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
219266468|NCT04148118|BIOLOGICAL|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
219266469|NCT04148118|BIOLOGICAL|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
219266470|NCT04035330|COMBINATION_PRODUCT|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
219266471|NCT04035330|COMBINATION_PRODUCT|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
219266472|NCT05313906|DRUG|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
219266473|NCT05526456|PROCEDURE|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
219266474|NCT04846855|DRUG|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
219266475|NCT00521443|PROCEDURE|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
219266476|NCT06164015|DIAGNOSTIC_TEST|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
219266477|NCT02937896|DRUG|Desmopressin|40 micrograms Nasal Desmopressin.
219266478|NCT02937896|DRUG|Ketorolac|30mg intravenous Ketorolac.
219266479|NCT02937896|DRUG|Normal Saline|1cc intravenous Normal Saline.
219266480|NCT02937896|DRUG|Normal Saline|4 puffs nasal Normal Saline.
219266481|NCT06102226|DIAGNOSTIC_TEST|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
219266482|NCT02615678|DEVICE|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
219266483|NCT05585177|DRUG|Growth hormone|3 months of growth hormone treatment (2 units daily)
219266484|NCT06315101|DRUG|Chinese Herbal Medicine|Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
219266485|NCT05506215|DEVICE|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
219266486|NCT05506215|DEVICE|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
219266487|NCT00227123|DRUG|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
219266488|NCT05736731|BIOLOGICAL|A2B530|Autologous logic-gated Tmod CAR T-cells
219266489|NCT05736731|DIAGNOSTIC_TEST|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
219266490|NCT00455845|DEVICE|Levonorgestrel IUD|levonorgestrel IUD
219266491|NCT04419363|DRUG|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
219266492|NCT00857233|DRUG|Memantine|20 mg oral tablets once daily
219266493|NCT06488885|BEHAVIORAL|Elderly care training|The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
219266494|NCT05997459|DRUG|Pemigatinib|Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
219266495|NCT05052710|DRUG|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
219266496|NCT05052710|DRUG|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
219266497|NCT04517942|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
219266498|NCT04517942|OTHER|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
219266499|NCT03820869|OTHER|Family Training|Family Training
219266500|NCT03820869|OTHER|Occupational Therapy|Occupational Therapy
219266501|NCT01447862|DRUG|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
219266502|NCT01447862|DRUG|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
219266503|NCT01587118|DRUG|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
219266504|NCT00263575|DRUG|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
219266505|NCT00224978|DRUG|Chloroquine|
219266506|NCT04560062|OTHER|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
219266507|NCT03655665|DRUG|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
219266508|NCT04749498|OTHER|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
219266509|NCT04749498|OTHER|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
219266510|NCT04749498|OTHER|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
219266511|NCT04749498|OTHER|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
219266512|NCT00574600|BIOLOGICAL|SAAVI DNA-C2 vaccine|DNA vaccine
219266513|NCT00574600|BIOLOGICAL|SAAVI MVA-C vaccine|Boost vaccine
219266514|NCT00574600|BIOLOGICAL|Placebo|Placebo vaccine
219266515|NCT00537329|DRUG|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
219266516|NCT04340856|PROCEDURE|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
219266517|NCT04340856|DRUG|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
219266518|NCT06108453|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
219266519|NCT06108453|DRUG|Rifampicin|Co-administration of methotrexate and rifampicin
219266520|NCT00984438|DRUG|BCNU Wafer|Implantable during surgical resection into the tumor bed
219266521|NCT00984438|DRUG|Irinotecan|IV every 2 weeks for up to one year
219266522|NCT00984438|DRUG|Bevacizumab|IV every 2 weeks for up to one year
219266523|NCT01200927|OTHER|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
219266524|NCT03324971|OTHER|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
219266525|NCT05946122|DRUG|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
219266526|NCT05946122|DRUG|placebo drug|tablet resembles atorvastatin
219266527|NCT01658956|DRUG|GCSF administration on days 8 and 12 after chemotherapy|
219266528|NCT01818427|BIOLOGICAL|infusion of 2 units of plasma|infusion of 2 units of plasma
219266529|NCT04011293|BIOLOGICAL|CNCT19|0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
219266530|NCT01902498|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
219266531|NCT01902498|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
219266532|NCT01902498|DRUG|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
219266533|NCT02660268|OTHER|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
219266534|NCT03049345|PROCEDURE|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
219266535|NCT03049345|DRUG|Radioactive Tracers|see above
219266536|NCT03049345|DRUG|Methylene Blue 20 MG/ML|see above
219266537|NCT02622711|BEHAVIORAL|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
219266538|NCT02622711|BEHAVIORAL|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
219266539|NCT02622711|BEHAVIORAL|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
219266540|NCT02622711|BEHAVIORAL|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
219266541|NCT01278615|OTHER|Laboratory Biomarker Analysis|Correlative studies
219266542|NCT01278615|DRUG|Selumetinib|Given PO
219266543|NCT04587583|BEHAVIORAL|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
219266544|NCT03118245|DEVICE|AuraGain|After anesthetic induction, AuraGain is inserted in children
219266545|NCT03118245|DEVICE|I-gel|After anesthetic induction, I-gel is inserted in children
219266546|NCT04117815|DEVICE|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
219266547|NCT04117815|OTHER|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
219266548|NCT01792843|BEHAVIORAL|data|"* comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features"
219266549|NCT03602222|BEHAVIORAL|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
219266550|NCT03602222|BEHAVIORAL|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
219266551|NCT00749359|DRUG|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
219266552|NCT03967912|BEHAVIORAL|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
219266553|NCT01426113|DRUG|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
219266554|NCT01426113|DRUG|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
219266555|NCT01426113|DRUG|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
219266556|NCT01152476|DRUG|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
219266557|NCT01152476|DRUG|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
219266558|NCT06454305|OTHER|Active cycle of breathing technique|Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing. Secretions are moved into the central airways during the forceful expiratory exercise that follows The three stages of ACBT
219266559|NCT06454305|OTHER|Blow Bottle Technique|A 1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly, Breath in through nose and out through mouth, Blowing enough water is bubbled, Short Breaks for 2 to 3 mints, When mucus rises up get out of it by coughing or huffing
219266560|NCT00809913|DRUG|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
219266561|NCT00157898|DRUG|MK0826; ertapenem sodium|
219266562|NCT00157898|DRUG|Comparator: ceftriaxone + metronidazole|
219266563|NCT03379558|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
219266564|NCT04758052|OTHER|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
219266565|NCT05715736|DRUG|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
219266566|NCT05715736|DRUG|Placebo|0.90% Normal Saline only
219266567|NCT02872012|DEVICE|Cryoanesthesia device|The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
219266568|NCT02872012|DRUG|Lidocaine|Lidocaine applied to the non-cryoanesthesia eye.
219266569|NCT01749163|BIOLOGICAL|Saline|
219266570|NCT01749163|BIOLOGICAL|GIP|
219266571|NCT01749163|BIOLOGICAL|GLP-1|
219266572|NCT05331976|DIAGNOSTIC_TEST|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
219266573|NCT03842631|DRUG|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
219266574|NCT05559632|PROCEDURE|osteotomy for implant placement|preparing the bone for implant placement
219266575|NCT00672282|DRUG|Bicalutamide|150mg p.o. daily
219266576|NCT00672282|DRUG|Placebo|
219266577|NCT02787447|DRUG|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
219266578|NCT02787447|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
219266579|NCT02787447|DRUG|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
219266580|NCT03336099|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique"
219266581|NCT02085473|BIOLOGICAL|Tralokinumab 300 mg|Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
219266582|NCT01390441|BIOLOGICAL|MK-8808|MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
219266583|NCT01390441|BIOLOGICAL|MabThera® (rituximab)|MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
219266584|NCT01390441|DRUG|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
219266585|NCT01390441|BIOLOGICAL|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
219266586|NCT01390441|DRUG|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
219266587|NCT01390441|DRUG|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
219266588|NCT01390441|DRUG|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
219266589|NCT00272350|DRUG|Steroids|
219266590|NCT00272350|DRUG|ZD6474|
219266591|NCT02573545|DEVICE|Planning@IFE and Standard@IFE Software|
219266592|NCT02573545|DEVICE|MR Syngo (Numaris/4) software|
219266593|NCT00088647|DRUG|MST-997|
219266594|NCT00887029|DRUG|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
219266595|NCT00887029|DRUG|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
219266596|NCT00435955|PROCEDURE|High dose chemotherapy with autologous transplantation|
219266597|NCT00435955|DRUG|Rituximab|
219266598|NCT02039544|DRUG|Xuebi formula|
219266599|NCT02039544|DRUG|placebo|
219266600|NCT00004072|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
219266601|NCT00004072|DRUG|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
219266602|NCT03833362|DRUG|Narlaprevir|yellow film-coated 100 mg. tablets
219266603|NCT03833362|DRUG|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
219266604|NCT03833362|DRUG|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
219266605|NCT03833362|DRUG|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
219266606|NCT03833362|DRUG|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
219266607|NCT03833362|DRUG|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b"
219266608|NCT04731350|DEVICE|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
219266609|NCT04731350|DEVICE|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
219266610|NCT04731350|OTHER|Exercise|strengthening exercise
219266611|NCT02754193|OTHER|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
219266612|NCT05457166|DEVICE|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
219266613|NCT02484989|OTHER|Surviellance card|
219266614|NCT02489409|DRUG|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
219266615|NCT02489409|DRUG|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
219266616|NCT02489409|DRUG|Navelbine|40 mg/d, iv, d1, 8
219266617|NCT02489409|DRUG|Platinum|30 mg/m2, iv 3h, d1-3
219266618|NCT02489409|DRUG|Xeloda Tablets:|2 000 mg/m2, po, d1-14
219266619|NCT00020722|BIOLOGICAL|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
219266620|NCT00020722|DRUG|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
219266621|NCT00020722|DRUG|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
219266622|NCT00020722|PROCEDURE|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
219266623|NCT00020722|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
219266624|NCT00027703|DRUG|gemcitabine hydrochloride|Given IV
219266625|NCT00027703|DRUG|cisplatin|Given IV
219266626|NCT00027703|BIOLOGICAL|bevacizumab|Given IV
219266627|NCT00027703|OTHER|placebo|Given IV
219266628|NCT00027703|OTHER|laboratory biomarker analysis|Correlative studies
219266629|NCT01284712|BIOLOGICAL|blood sample|blood sample coming from therapeutic bleeding in hospital
219266630|NCT06497790|DIAGNOSTIC_TEST|BJH-SDS Screenint Test|The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)
219266631|NCT06497790|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists
219266632|NCT05213442|DIAGNOSTIC_TEST|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
219266633|NCT04642547|DRUG|Lenvatinib and Gefitinib|"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral."
219266634|NCT02287233|DRUG|Venetoclax|Venetoclax will be taken orally once daily.
219266635|NCT02287233|DRUG|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
219266636|NCT02925845|DEVICE|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
219266637|NCT01280604|DRUG|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
219266638|NCT02888379|DRUG|TOP1288|
219266639|NCT02888379|DRUG|Placebo (for TOP1288)|
219266640|NCT01126320|DEVICE|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
219266641|NCT01126320|DEVICE|routine mechanical ventilator|routine mechanical ventilation
219266642|NCT03432390|DEVICE|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
219266643|NCT03432390|DEVICE|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
219266644|NCT01472614|DRUG|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
219266645|NCT03144297|OTHER|Lumbar puncture|diagnostic lumbar puncture
219266646|NCT03144297|OTHER|BOD POD (air-displacement plethysmography)|Assessment of body fat
219266647|NCT00835185|BIOLOGICAL|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
219266648|NCT00835185|DRUG|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
219266649|NCT00835185|DRUG|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
219266650|NCT00835185|DRUG|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
219266651|NCT05429593|DRUG|Semaglutide|Tablet given orally
219266652|NCT05429593|DRUG|Dapagliflozin|Tablet given orally
219266653|NCT05429593|DRUG|Semaglutide/dapagliflozin|Tablet given orally
219266654|NCT01844713|BEHAVIORAL|Workbook|Subjects will read a workbook about sun protection
219266655|NCT02717182|OTHER|interviews|interviews
219266656|NCT00375531|BEHAVIORAL|Mindfulness Meditation (MfM)|
219266657|NCT02168478|DRUG|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
219266658|NCT02168478|OTHER|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
219266659|NCT02168478|OTHER|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
219266660|NCT03168399|DIETARY_SUPPLEMENT|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
219266661|NCT01324700|DRUG|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
219266662|NCT01324700|DRUG|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
219266663|NCT01324700|DRUG|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
219266664|NCT01324700|DRUG|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
219266665|NCT05122741|DRUG|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
219266666|NCT05122741|DRUG|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
219266667|NCT05194228|BEHAVIORAL|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
219266668|NCT00000959|DRUG|Isoniazid|
219266669|NCT00000959|DRUG|Pyridoxine hydrochloride|
219266670|NCT05479747|DRUG|post operative analgesics|post-operative pain killer
219266671|NCT03618810|DRUG|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
219266672|NCT03618810|DRUG|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
219266673|NCT05432505|OTHER|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
219266674|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
219266675|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
219266676|NCT03108638|BEHAVIORAL|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
219266677|NCT04061070|OTHER|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
219266678|NCT04061070|OTHER|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
219266679|NCT05696223|OTHER|Ultrasound|Doppler mesure
219266680|NCT05698862|DIETARY_SUPPLEMENT|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
219266681|NCT05698862|DIETARY_SUPPLEMENT|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
219266682|NCT02220218|DRUG|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
219266683|NCT02220218|DRUG|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
219266684|NCT02220218|DRUG|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
219266685|NCT00661713|BIOLOGICAL|rMenB+OMV NZ|
219266686|NCT00661713|BIOLOGICAL|Placebo|
219266687|NCT06183671|DRUG|JX09 or placebo SAD|For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
219266688|NCT06183671|DRUG|JX09 or placebo MAD|For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
219266689|NCT06183671|DRUG|JX09|For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
219266690|NCT04103502|DEVICE|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
219266691|NCT04103502|DEVICE|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
219266692|NCT05193747|OTHER|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
219266693|NCT00571337|DRUG|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
219266694|NCT03310398|BEHAVIORAL|NeuroImaging|standard anatomical and functional imaging
219266695|NCT03310398|BEHAVIORAL|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
219266696|NCT05124821|DEVICE|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
219266697|NCT03462537|DEVICE|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
219266698|NCT03462537|DEVICE|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
219266699|NCT03462537|DEVICE|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
219266700|NCT05585736|DRUG|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
219266701|NCT01743976|DRUG|Donepezil|donepezil 5 mg once daily for 6 weeks
219266702|NCT01743976|DRUG|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
219266703|NCT01985646|PROCEDURE|surgery treatment|one staged pull-through left-colectomy
219266704|NCT01985646|BEHAVIORAL|anal dilation|anal dilation
219266705|NCT01985646|BEHAVIORAL|colonic lavage|colonic lavage
219266706|NCT01985646|DRUG|oral probiotic|oral probiotic
219266707|NCT02072421|PROCEDURE|PCI|
219266708|NCT05019703|BIOLOGICAL|Atezolizumab|Given IV
219266709|NCT05019703|DRUG|Cabozantinib|Given PO
219266710|NCT02302703|OTHER|low FODMAP diet vs Gluten free diet|
219266711|NCT00420225|DEVICE|Low-weight prolypropylene mesh|
219266712|NCT02918292|DRUG|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
219266713|NCT02918292|DRUG|Fludarabine|Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.
219266714|NCT02918292|DRUG|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
219266715|NCT02918292|RADIATION|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
219266716|NCT02918292|PROCEDURE|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
219266717|NCT02918292|DRUG|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
219266718|NCT02918292|DRUG|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
219266719|NCT02918292|DRUG|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.
219266720|NCT02915562|OTHER|exercise|
219266721|NCT01801982|OTHER|non-interventional|non-interventional
219266722|NCT00476528|BEHAVIORAL|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
219266723|NCT00476528|BEHAVIORAL|Reality Orientation|A quasiexperimental study
219266724|NCT03772093|DEVICE|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
219266725|NCT03772093|OTHER|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
219266726|NCT00002406|DRUG|Indinavir sulfate|
219266727|NCT01185171|DRUG|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
219266728|NCT03518242|DRUG|Cyclophosphamide|Given PO
219266729|NCT03518242|DRUG|Methotrexate|Given PO
219266730|NCT03518242|DRUG|Capecitabine|Given PO
219266731|NCT03518242|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
219266732|NCT01493999|DRUG|Clopidogrel reloading|Up to three times 600 mg clopidogrel
219266733|NCT01493999|DRUG|Prasugrel|60 mg prasugrel in patients with HPR
219266734|NCT01869140|DEVICE|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
219266735|NCT00282945|DRUG|Rosiglitazone|
219266736|NCT00282945|DRUG|Metformin|
219266737|NCT00727506|DRUG|BIBW 2992|BIBW 2992 once daily
219266738|NCT00727506|DRUG|TMZ|TMZ 21/28
219266739|NCT00727506|DRUG|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
219266740|NCT00223210|DRUG|Quetiapine|Active Quetiapine
219266741|NCT00223210|DRUG|PLacebo|Placebo
219266742|NCT05716776|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
219266743|NCT00302926|PROCEDURE|energy restriction and maintenance|
219266744|NCT01555398|DIETARY_SUPPLEMENT|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
219266745|NCT00149617|DRUG|Buspirone|
219266746|NCT02394522|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
219266747|NCT02394522|DEVICE|Active Ingredient|Transfluthrin (Active ingredient)
219266748|NCT02394522|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
219266749|NCT04373837|BEHAVIORAL|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
219266750|NCT04373837|OTHER|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
219266751|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
219266752|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
219266753|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
219266754|NCT01440413|BIOLOGICAL|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
219266755|NCT02450097|OTHER|Caloric restriction|
219266756|NCT04414631|DRUG|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
219266757|NCT04322812|DEVICE|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index \[WPI\] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
219266758|NCT04322812|DEVICE|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
219266759|NCT03492710|BIOLOGICAL|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
219266760|NCT01089296|OTHER|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
219266761|NCT02207036|BEHAVIORAL|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
219266762|NCT02207036|BEHAVIORAL|Smokefree.gov|referral to the NCI Smokefree.gov website
219266763|NCT01692093|DIETARY_SUPPLEMENT|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
219266764|NCT01692093|DIETARY_SUPPLEMENT|Placebo|Placebo
219266765|NCT03561597|BEHAVIORAL|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
219266766|NCT02460055|DEVICE|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
219266767|NCT02460055|DRUG|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
219266768|NCT02460055|DRUG|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
219266769|NCT02460055|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
219266770|NCT02460055|DRUG|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
219266771|NCT02460055|DRUG|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
219266772|NCT00940862|BIOLOGICAL|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
219266773|NCT00940862|DEVICE|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
219266774|NCT00940862|OTHER|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
219266775|NCT03545412|DEVICE|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
219266776|NCT03783689|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
219266777|NCT04996940|DEVICE|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette"
219266778|NCT01931982|DRUG|Victoza|
219266779|NCT03975842|OTHER|Sinonasal and otologic evaluation|"At onset, each participant had:~* sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~* otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
219266780|NCT04399343|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
219266781|NCT04399343|DRUG|Normal saline|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
219266782|NCT04182347|OTHER|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
219266783|NCT05167084|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
219266784|NCT05167084|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
219266785|NCT05167084|DRUG|Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg
219266786|NCT05167084|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8
219266787|NCT03616483|OTHER|This is a non-interventional trial|This is a non-interventional trial
219266788|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
219266789|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
219266790|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
219266791|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
219266792|NCT05355129|DRUG|TT-00920|Tablets
219266793|NCT05355129|DRUG|TT-00920 Placebo|Tablets
219266794|NCT01539577|DRUG|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
219266795|NCT01437488|DRUG|Cabazitaxel|"* Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
219266796|NCT01437488|DRUG|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
219266797|NCT01437488|PROCEDURE|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
219266798|NCT01437488|BIOLOGICAL|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
219266799|NCT05392491|OTHER|No intervention|No intervention. It is an observational study
219266800|NCT05063331|PROCEDURE|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
219266801|NCT05063331|PROCEDURE|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
219266802|NCT00669734|BIOLOGICAL|Falimarev|Given intratumorally or SC
219266803|NCT00669734|BIOLOGICAL|Inalimarev|Given SC
219266804|NCT00669734|OTHER|Laboratory Biomarker Analysis|Correlative studies
219266805|NCT00669734|BIOLOGICAL|Sargramostim|Given SC
219266806|NCT01717586|DRUG|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
219266807|NCT01717586|DRUG|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
219266808|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
219266809|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
219266810|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
219266811|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
219266812|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
219266813|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
219266814|NCT04356807|PROCEDURE|Reflex Locomotion Therapy|The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
219266815|NCT04356807|PROCEDURE|Passive Joint Mobilizations|Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
219266816|NCT04356807|PROCEDURE|Massage|Soft massage with soft pressures in limbs, tactile stimulation and no motion.
219266817|NCT06391398|BEHAVIORAL|Stoma care education with the Stoma Care Training Belt|Stoma care education
219266818|NCT06339463|BEHAVIORAL|Self-Distancing Intervention|"In the Self Distancing Intervention condition, participants will be instructed to describe the exposure task from a self-distanced perspective (e.g., Emily is going to touch the spider)."
219266819|NCT06339463|BEHAVIORAL|First-person self-talk|"Youth will be randomized to a BAT with a control condition. In this arm, participants will be instructed to describe the exposure task from a self-immersed perspective (e.g., I'm going to touch the spider)"
219266820|NCT05213234|BEHAVIORAL|Chronotherapy|Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
219266821|NCT06014827|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219266822|NCT06014827|PROCEDURE|Computed Tomography|Undergo CT or PET/CT scan
219266823|NCT06014827|DRUG|Osimertinib|Given PO
219266824|NCT06014827|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219266825|NCT06014827|RADIATION|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
219266826|NCT06014827|OTHER|Survey Administration|Ancillary study
219266827|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
219266828|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
219266829|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
219266830|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
219266831|NCT04284397|DRUG|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
219266832|NCT04284397|OTHER|Control|All participants will be tested with no treatment.
219266833|NCT05505084|PROCEDURE|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
219266834|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
219266835|NCT04560712|OTHER|Best Practice|Undergo usual care
219266836|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
219266837|NCT03947918|BEHAVIORAL|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
219266838|NCT03947918|BEHAVIORAL|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
219266839|NCT05289908|DRUG|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
219266840|NCT05289908|DRUG|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
219266841|NCT05289908|DRUG|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
219266842|NCT05289908|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
219266843|NCT05289908|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
219266844|NCT06124131|BEHAVIORAL|Financial incentive for colorectal cancer screening|$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
219266845|NCT06124131|BEHAVIORAL|Financial incentive for flu shot|$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
219266846|NCT06124131|BEHAVIORAL|Financial incentive for COVID-19 shot|$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
219266847|NCT03783871|DEVICE|Microwave ablation|Subjects will be treated with microwave ablation.
219266848|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
219266849|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
219266850|NCT05663528|PROCEDURE|orotracheal intubation|Clinical and laboratory data will be collected from patients who are intubated after 48 hours of admission to the intensive care unit
219266851|NCT05916235|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
219266852|NCT04797767|DRUG|Cladribine|Given IV
219266853|NCT04797767|DRUG|Cytarabine|Given IV
219266854|NCT04797767|DRUG|Mitoxantrone|Given IV
219266855|NCT04797767|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
219266856|NCT04797767|DRUG|Venetoclax|Given PO
219266857|NCT04797767|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219266858|NCT04797767|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219266859|NCT04797767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219266860|NCT06369363|DRUG|Placebo|Subjects will be assigned to 1 week of transdermal placebo patch.
219266861|NCT06369363|DRUG|Estradiol|Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
219266862|NCT06131203|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
219266863|NCT05443880|BEHAVIORAL|Exercise|The exercise intervention will focus on working the core muscles, starting with low-intensity isometric contraction of the core muscles that stabilize the trunk; increasing intensity by performing functional tasks (phase 1: independent isometric contraction of transversus-abdominis and multifidus, phase 2: co-contraction and functional tasks of the deep trunk muscles; phase 3: functional task with load; phase 4: functional task with unstable surface)
219266864|NCT05443880|BEHAVIORAL|Exercise + mindfulness|The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group (using appreciative inquiry) and a Mindfulness practice. Participants will be provided with workbooks, audios with guided meditations, and instructions for practice at home. In addition, the Exercise + mindfulness intervention will include the exercise program described in the exercise intervention.
219266865|NCT05443880|OTHER|Control group|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks.
219266866|NCT01898715|DRUG|ATR-101|
219266867|NCT04670770|DRUG|Drug - SHR1459|Oral Tablets taken once daily for 52 weeks
219266868|NCT04594733|DRUG|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
219266869|NCT04594733|DRUG|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
219266870|NCT06646224|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
219266871|NCT06646796|OTHER|Yoga|Yoga with certified teacher, 3 times a week during 3 months.
219266872|NCT00277342|PROCEDURE|measurement of lipid-induced hepatic insulin resistance|
219266873|NCT00885326|DRUG|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
219266874|NCT00885326|DRUG|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
219266875|NCT00885326|DRUG|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
219266876|NCT00796627|GENETIC|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
219266877|NCT00796627|OTHER|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
219266878|NCT02055456|DRUG|Nandrolone Decanoate|
219266879|NCT01804998|PROCEDURE|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
219266880|NCT01804998|PROCEDURE|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
219266881|NCT03588598|DRUG|SHC014748M|a selective PI3Kδ inhibitor
219266882|NCT02647645|DEVICE|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
219266883|NCT02647645|PROCEDURE|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
219266884|NCT02647645|DEVICE|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
219266885|NCT01832662|OTHER|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
219266886|NCT01832662|OTHER|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
219266887|NCT01832662|OTHER|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
219266888|NCT00507806|DRUG|perflutren lipid microsphere|
219266889|NCT00801411|DRUG|cyclophosphamide|Given IV
219266890|NCT00801411|DRUG|docetaxel|Given IV
219266891|NCT00801411|DRUG|doxorubicin hydrochloride|Given IV
219266892|NCT00658840|DRUG|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
219266893|NCT00658840|RADIATION|Localization, simulation and immobilization|"Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
219266894|NCT00169975|DEVICE|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
219266895|NCT04626986|PROCEDURE|microwave ablation|Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
219266896|NCT04626986|PROCEDURE|breast conserving surgery|The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
219266897|NCT04584879|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
219266898|NCT04584879|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
219266899|NCT04584879|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
219266900|NCT02230462|OTHER|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
219266901|NCT05484232|PROCEDURE|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
219266902|NCT00356811|DRUG|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
219266903|NCT00356811|DRUG|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
219266904|NCT00503724|DRUG|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
219266905|NCT02386839|DRUG|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
219266906|NCT02101983|DRUG|Cytosine Arabinoside|
219266907|NCT03190629|DEVICE|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
219266908|NCT03190629|DEVICE|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
219266909|NCT04251546|DIAGNOSTIC_TEST|p2PSA|p2PSA test(for calculation of PHI)
219266910|NCT04251546|DIAGNOSTIC_TEST|Ultrasonic parameters|Ultrasonic parameters(TPV)
219266911|NCT04251546|DIAGNOSTIC_TEST|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
219266912|NCT04038671|DEVICE|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
219266913|NCT04038671|DEVICE|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
219266914|NCT04038671|DEVICE|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
219266915|NCT04840498|BEHAVIORAL|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
219266916|NCT05756179|DRUG|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
219266917|NCT04783987|OTHER|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
219266918|NCT06862011|BEHAVIORAL|control group|Only surveys will be filled out.
219266919|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
219266920|NCT06738316|BEHAVIORAL|Simulation|Simulation of a patient safety incident in practice. The simulation closely replicates the workplace experience.
219266921|NCT04314492|PROCEDURE|Tonsillectomy|Intracapsular removal of tonsillar tissue (\>90%) with coblation
219266922|NCT01803347|DRUG|◦Drug: ASCs. + fibrin glue|Experimental group
219266923|NCT01803347|DRUG|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
219266924|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
219266925|NCT06945289|BEHAVIORAL|Let's Know!|This intervention is modified from a whole-classroom intervention by LARRC, 2018 and modified by Hogan et al. used in a larger NIH R01 investigation. We are examining the efficacy of the first two units used by Hogan et al.
219266926|NCT06944834|DEVICE|Implant|Implantation of the device and follow-up
219266927|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
219266928|NCT03865290|DRUG|Placebo|Oral matched placebo
219266929|NCT05824169|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
219266930|NCT02425345|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
219266931|NCT05532735|BIOLOGICAL|ANXV|ANXV (Human recombinant Annexin A5 protein)
219266932|NCT04761367|OTHER|Physical activity. Physical Activity program is performed in a group in a gym|The intervention groups will be trained in a gyms under the direct supervision of a graduate trainer. All subjects will be requested to choose an additional third day of the week to carry out at least one of the following activities: walking, cycling or swimming
219266933|NCT02275013|DRUG|Levosimendan|
219266934|NCT00826228|DRUG|teriparatide|teriparatide 20ug daily sc for 6 months
219266935|NCT00826228|OTHER|weight-bearing|device assisted walking
219266936|NCT04099485|OTHER|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
219266937|NCT00206856|DEVICE|Triage® B-Type Natriuretic Peptide (BNP) Test|
219266938|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
219266939|NCT04845490|DRUG|Mitomycin|Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
219266940|NCT04845490|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
219266941|NCT04385758|OTHER|Diabetes-REM Program|A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
219266942|NCT05999890|DRUG|Tapentadol Hydrochloride|Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
219266943|NCT00698347|DEVICE|M2a-Magnum™ Hip System|
219266944|NCT00297804|DEVICE|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
219266945|NCT00297804|DEVICE|Control stent|control stent
219266946|NCT02764099|BEHAVIORAL|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
219266947|NCT00717548|BEHAVIORAL|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
219266948|NCT00823537|PROCEDURE|therapeutic electrical stimulation|
219266949|NCT02336100|DEVICE|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
219266950|NCT01606423|DRUG|Placebo|Administered orally, single dose
219266951|NCT01606423|DRUG|LY2409021|Administered orally, single dose
219266952|NCT01593930|OTHER|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
219266953|NCT01593930|OTHER|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
219266954|NCT01593930|OTHER|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
219266955|NCT01593930|OTHER|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
219266956|NCT04169191|DRUG|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
219266957|NCT03614676|PROCEDURE|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
219266958|NCT03614676|PROCEDURE|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
219266959|NCT03614676|OTHER|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
219266960|NCT03614676|PROCEDURE|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
219266961|NCT03614676|OTHER|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
219266962|NCT02807974|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
219266963|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
219266964|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
219266965|NCT00296738|DEVICE|SPECT/CT|GE INFINIA HAWKEYE
219266966|NCT00903760|DRUG|Decitabine|Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
219266967|NCT00903760|DRUG|Clofarabine|Clofarabine 10 mg/m\^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
219266968|NCT01718951|DRUG|golimumab|golimumab
219266969|NCT01718951|DRUG|Pamidronate|pamidronate
219266970|NCT06173011|DRUG|QL2107|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
219266971|NCT06173011|DRUG|Keytruda®(china)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
219266972|NCT06173011|DRUG|Keytruda®(US)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
219266973|NCT05366543|DIAGNOSTIC_TEST|Visual acuity measurement|Visual acuity will be measured using autorefractometer after cycloplegic eye drops 3 times and glasses will be prescribed for those who are needed.
219266974|NCT02711319|DEVICE|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
219266975|NCT02711319|DEVICE|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
219266976|NCT01115686|DRUG|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
219266977|NCT01115686|DRUG|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
219266978|NCT03774290|DRUG|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
219266979|NCT03774290|DRUG|Placebo oral capsule|Oral gelatine capsule
219266980|NCT02388347|DRUG|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
219266981|NCT02388347|BIOLOGICAL|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
219266982|NCT02388347|BIOLOGICAL|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
219266983|NCT02388347|BIOLOGICAL|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
219266984|NCT02388347|BIOLOGICAL|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
219266985|NCT05089747|BIOLOGICAL|Blood sampling for biomarker analysis (microRNA, circulating DNA…)|From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
219266986|NCT05440604|OTHER|Fortified milk|Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
219266987|NCT00986596|DIETARY_SUPPLEMENT|vitamin D3|4000 IU once daily by mouth for 4 months
219266988|NCT00986596|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
219266989|NCT01177956|BIOLOGICAL|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
219266990|NCT01177956|DRUG|Cisplatin|Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
219266991|NCT01177956|DRUG|5-Fluorouracil|Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
219266992|NCT03423810|DRUG|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
219266993|NCT04775147|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
219266994|NCT04239599|RADIATION|Hypofractionated IMRT Radiation treatment|
219266995|NCT04935216|PROCEDURE|Laparoscopic|Laparoscopic resection of the pancreas has become widely accepted in the treatment of lesions which are benign or of low-grade malignancy
219266996|NCT00733395|DIETARY_SUPPLEMENT|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
219266997|NCT00733395|DIETARY_SUPPLEMENT|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
219266998|NCT00609856|DRUG|pioglitazone|tablet, 30 mg, once daily, 26 weeks
219266999|NCT00609856|DRUG|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
219267000|NCT02825251|DRUG|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
219267001|NCT02825251|DRUG|insulin aspart|Injected s.c. /subcutaneously (under the skin)
219267002|NCT00260247|DRUG|carbamazepine oxcarbazepine|
219267003|NCT00959777|DRUG|DA-3031|
219267004|NCT00959777|DRUG|Filgrastim|
219267005|NCT02089139|DEVICE|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
219267006|NCT02089139|OTHER|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks"
219267007|NCT03662269|DRUG|indomethacin|indomethacin (75mg, bid, po, 14days)
219267008|NCT03662269|DRUG|Placebo|placebo (75mg, bid, po, 14days)
219267009|NCT03662269|DRUG|Omeprazole|placebo (20mg, qd, po, 14days)
219267010|NCT04923490|BEHAVIORAL|state and trait anxiety scale levels|"While the STAI-I anxiety level is scored as (1) never, (2) somewhat, (3) frequently, and (4) almost always, the scoring options in STAI-II are (1) almost never, (2) sometimes, (3) most of the time, and (4) almost always."
219267011|NCT02475304|DRUG|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
219267012|NCT02475304|DRUG|Placebo|
219267013|NCT05588544|PROCEDURE|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
219267014|NCT01845805|DRUG|oral azacitidine|
219267015|NCT01845805|OTHER|Observation|
219267016|NCT03815383|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
219267017|NCT02549417|DRUG|KHK7580|Oral administration
219267018|NCT00277368|OTHER|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
219267019|NCT03852108|OTHER|Comfort Care|Face, Hand and body care for 15 to 45 minutes
219267020|NCT02531867|BIOLOGICAL|Asfotase Alfa|
219267021|NCT02977299|DRUG|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
219267022|NCT02977299|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
219267023|NCT02977299|DRUG|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
219267024|NCT01674322|DRUG|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
219267025|NCT00130845|DRUG|Octreotide Acetate in Microspheres|
219267026|NCT00130845|DRUG|Placebo|
219267027|NCT06544850|OTHER|experimental group|Oswestry Low Back Pain Questionnaire will be used to assess functional limitations in daily life activities of patients with low back pain. Recognize mobile application will be used to assess lateralization performance. Evaluation will be made with hand, foot and back modules of this application. Reaction time and accuracy given at the end of the application will be recorded. The most accurate response instruction will be given in the shortest possible time. Visual Analog Scale (VAS) will be used to measure general pain status of patients. Tampa Kinesiophobia Scale will be used to assess fear of movement. Pain catastrophizing level will be assessed with Pain Catastrophizing Scale. Two-point discrimination device will be used to assess two-point discrimination. Central Sensitization Inventory will be used for central sensitization findings.
219267028|NCT06544850|OTHER|control group|Healthy volunteer participants who meet the inclusion criteria will be evaluated with the tests applied to the experimental group
219267029|NCT06484374|PROCEDURE|Robot-assisted minimally invasive treatment|An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
219267030|NCT02419768|OTHER|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
219267031|NCT02738905|DRUG|Rifaximin|One 550 mg tablet taken orally two times a day.
219267032|NCT06326879|OTHER|No intervention|Questionnaires compilation and sample collection
219267033|NCT05815615|DEVICE|Plasmapheresis|Plasma donation at different frequencies
219267034|NCT04080713|DRUG|Budesonide|Budesonide 9 mg prolonged release tablet
219267035|NCT02820597|DEVICE|ClariFix device|
219267036|NCT00575042|DRUG|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
219267037|NCT00960609|PROCEDURE|Ultrasound guided liver resection|
219267038|NCT05383638|OTHER|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
219267039|NCT00273286|BEHAVIORAL|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
219267040|NCT04718311|DRUG|Oral lichen clinical Healing evaluation|Treatments were topically applied for 5 days
219267041|NCT04795336|DRUG|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
219267042|NCT04795336|OTHER|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
219267043|NCT00008281|DRUG|FOLFOX regimen|
219267044|NCT00008281|DRUG|fluorouracil|
219267045|NCT00008281|DRUG|leucovorin calcium|
219267046|NCT00008281|DRUG|oxaliplatin|
219267047|NCT00619268|DRUG|Temsirolimus|25 mg once per week administered intravenously
219267048|NCT00619268|DRUG|Bevacizumab|10 mg/kg \* 1 time /2 weeks administered intravenously
219267049|NCT00619268|DRUG|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
219267050|NCT00619268|DRUG|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
219267051|NCT03544645|OTHER|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
219267052|NCT03544645|OTHER|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
219267053|NCT04901832|OTHER|Intradialytic stretching exercises|Exercises performed actively and passively to reduce or prevent muscle cramps during hemodialysis procedure.
219267054|NCT02112890|OTHER|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
219267055|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
219267056|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
219267057|NCT04432545|BIOLOGICAL|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
219267058|NCT02472002|BIOLOGICAL|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~* Registry Type: autologous~* Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~* Route of administration: endomyocardial injection~* Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
219267059|NCT00478283|OTHER|survey administration|
219267060|NCT01928693|DRUG|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
219267061|NCT01928693|DRUG|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
219267062|NCT01928693|DRUG|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
219267063|NCT00954005|DRUG|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
219267064|NCT03596398|GENETIC|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
219267065|NCT02515006|OTHER|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
219267066|NCT06330935|DRUG|Tranexamic Acid (TXA)|30 patients will be randomized to A arm and 30 patients to B arm
219267067|NCT06330935|DRUG|Normal saline|30 patients will be randomized this arm C
219267068|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
219267069|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
219267070|NCT01699464|DRUG|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
219267071|NCT06957457|BEHAVIORAL|Exercise|The exercise program lasts 32 minutes in total. The first 6 (six) minutes of this program consists of warm-up exercises. Active exercise time is 21 (twenty-one) minutes. Relaxation exercises consist of 5 (five) minutes of relaxation exercises. exercise was accompanied by music. it consists of warm-up exercise and relaxation sections.
219267072|NCT06957457|BEHAVIORAL|Control (Standard treatment)|do nothing
219267073|NCT03553381|OTHER|hypocaloric balanced diet|
219267074|NCT05276271|DIAGNOSTIC_TEST|the blood sample test results|Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.
219267075|NCT00166946|PROCEDURE|foreskin from healthy adults for organotypic culture|
219267076|NCT04351698|DRUG|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
219267077|NCT04351698|OTHER|Oral Placebo|Inert chewable tablet with no therapeutic value
219267078|NCT00253331|DRUG|topical organogel with nitroglycerin|
219267079|NCT00419302|DRUG|Technosphere/Insulin|
219267080|NCT03832972|OTHER|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
219267081|NCT04385576|DEVICE|Aerosol Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
219267082|NCT04385576|DEVICE|Intubation Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
219267083|NCT06956482|DRUG|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine for five days (day 1 to day 5) at a daily dose of 300mg/Kg
219267084|NCT06956482|DRUG|Prednisolone|prednisolone 40 mg/day for a total of 30 days
219267085|NCT06956482|DRUG|Placebo of N-acetylcysteine|Placebo of N-acetylcysteine for five days (day 1 to day 5)
219267086|NCT06956482|DRUG|Placebo of Prednisolone|Placebo of prednisolone for 30 additional days
219267087|NCT06956482|DRUG|Prednisolone|prednisolone (tapering dose) for 30 additional days
219267088|NCT05833841|DIAGNOSTIC_TEST|Surface Electromyography and Video fluoroscopy|Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
219267089|NCT04692545|DIETARY_SUPPLEMENT|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
219267090|NCT01335906|OTHER|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
219267091|NCT02608736|DRUG|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
219267092|NCT02608736|DRUG|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
219267093|NCT06564285|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
219267094|NCT06564285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219267095|NCT02379143|OTHER|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
219267096|NCT03790709|DRUG|High dose ANAVEX2-73|Oral capsule
219267097|NCT03790709|DRUG|Mid dose ANAVEX2-73|Oral capsule
219267098|NCT03790709|DRUG|Placebo oral capsule|Oral capsule
219267099|NCT06120647|DIETARY_SUPPLEMENT|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
219267100|NCT04907279|DRUG|Aripiprazole Once-Monthly (AOM)|Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.
219267101|NCT03082937|DRUG|3 mg [14C]-A4250 capsule|Each subject will receive a single administration of 3 mg \[14C\]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
219267102|NCT05567107|OTHER|massage|Classical foot massage was applied by the researcher with efflorescence, superficial friction and petrissage techniques for 10 minutes on each foot.
219267103|NCT00216047|DRUG|PTK787|PTK787 daily
219267104|NCT00216047|DRUG|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*
219267105|NCT02922205|DEVICE|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
219267106|NCT00631345|BEHAVIORAL|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
219267107|NCT00631345|OTHER|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
219267108|NCT00631345|BEHAVIORAL|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
219267109|NCT00631345|BEHAVIORAL|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
219267110|NCT02579824|DRUG|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
219267111|NCT01403870|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
219267112|NCT06016699|OTHER|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
219267113|NCT05923346|OTHER|GLUTLEARN|"The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management."
219267114|NCT03085199|PROCEDURE|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
219267115|NCT03113747|BIOLOGICAL|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
219267116|NCT05967182|DRUG|Pembrolizumab|Given by IV (vein)
219267117|NCT05967182|DRUG|Gemcitabine|Given by IV (vein)
219267118|NCT05967182|DRUG|Cisplatin|Given by IV (vein)
219267119|NCT00240214|DRUG|sirolimus|Tablet, dosage is determined by trough level
219267120|NCT02409095|BIOLOGICAL|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
219267121|NCT02409095|DEVICE|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
219267122|NCT02409095|OTHER|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
219267123|NCT00712647|DRUG|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard \& Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
219267124|NCT00712647|OTHER|Placebo|Two placebos, one each/day
219267125|NCT06566261|BIOLOGICAL|ABA-101|ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
219267126|NCT04200898|DEVICE|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
219267127|NCT00839566|PROCEDURE|Ablation|AV-node ablation
219267128|NCT00839566|OTHER|Rate Control|Rate control by drug
219267129|NCT01176318|DRUG|Erdosteine|capsule 300mg twice daily for 10 days
219267130|NCT01176318|DRUG|Placebo|placebo capsule, twice daily for 10 days
219267131|NCT04213677|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
219267132|NCT04213677|DRUG|Placebo|Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
219267133|NCT05146115|OTHER|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
219267134|NCT05921097|DIAGNOSTIC_TEST|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
219267135|NCT05921097|DIAGNOSTIC_TEST|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
219267136|NCT05921097|DIAGNOSTIC_TEST|2-point discrimination tasks|2-point discrimination tasks
219267137|NCT05921097|DIAGNOSTIC_TEST|NC-Stat DPNCheck|NC-Stat DPNCheck
219267138|NCT05921097|DIAGNOSTIC_TEST|QST|QST
219267139|NCT05921097|DIAGNOSTIC_TEST|Biothesiometry|Biothesiometry
219267140|NCT00810342|BEHAVIORAL|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
219267141|NCT00810342|BEHAVIORAL|physical activity standard|standard print and website information on how to become more active
219267142|NCT04144647|OTHER|Single testing session|"All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off."
219267143|NCT03932578|DRUG|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
219267144|NCT03932578|DRUG|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
219267145|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
219267146|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
219267147|NCT02674269|DRUG|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
219267148|NCT02674269|DRUG|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
219267149|NCT02674269|DEVICE|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
219267150|NCT04451447|PROCEDURE|The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
219267151|NCT04451447|PROCEDURE|Saline test (routine test)|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
219267152|NCT00040287|BEHAVIORAL|smoking cessation program|
219267153|NCT00040287|BEHAVIORAL|weight control program|
219267154|NCT04676789|DRUG|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
219267155|NCT04676789|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
219267156|NCT04676789|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
219267157|NCT04513353|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
219267158|NCT04513353|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
219267159|NCT03186586|DRUG|Ulipristal acetate|5mg/day/five days
219267160|NCT03186586|DRUG|Placebo|Placebo one pill a day for 5 days at the bleeding episode
219267161|NCT04030689|OTHER|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
219267162|NCT02007200|OTHER|Laboratory Biomarker Analysis|Correlative studies
219267163|NCT02007200|DRUG|Soy Isoflavones|Given PO
219267164|NCT02007200|OTHER|Survey Administration|Ancillary studies
219267165|NCT01921647|DRUG|YH4808|
219267166|NCT01921647|DRUG|Nexium|
219267167|NCT01921647|DRUG|Amoxicillin|
219267168|NCT01921647|DRUG|clarithromycin|
219267169|NCT02429479|BEHAVIORAL|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
219267170|NCT02429479|BEHAVIORAL|Standard advance care planning|This is a online simple living will form.
219267171|NCT04339660|BIOLOGICAL|UC-MSCs|1\*10E6 UC-MSCs /kg body weight suspended in 100mL saline
219267172|NCT04339660|OTHER|Placebo|100mL saline intravenously
219267173|NCT04218474|PROCEDURE|Evaluation Of Cross Mental Nerve Transfer In Restoration Of Chin &Lip Sensation Post Inferior Alveolar Nerve Injury|-sural nerve harvest ,and use it as conduit between injured mental nerve and the normal one
219267174|NCT00890578|PROCEDURE|adhesive to suture|surgical closure
219267175|NCT00648687|BEHAVIORAL|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
219267176|NCT02911194|DIETARY_SUPPLEMENT|a2 milk|replace all milk with a2 milk
219267177|NCT02911194|DIETARY_SUPPLEMENT|a1 containing milk|use a1 containing milk
219267178|NCT04040049|GENETIC|FLT190|Gene Therapy product.
219267179|NCT03310671|PROCEDURE|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm"
219267180|NCT02865551|DEVICE|Foley catheter|Extended bladder catheterization after epidural anesthesia.
219267181|NCT02865551|DEVICE|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
219267182|NCT02865551|DRUG|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
219267183|NCT03253432|OTHER|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
219267184|NCT06008223|DRUG|vitamin B6|The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
219267185|NCT06008223|DRUG|0.9% sodium chloride solution|That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
219267186|NCT00534053|OTHER|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
219267187|NCT06074692|COMBINATION_PRODUCT|Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)|Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
219267188|NCT00297843|PROCEDURE|allergen challenge (grass pollen), nasal lavage|
219267189|NCT03560570|BIOLOGICAL|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
219267190|NCT03560570|OTHER|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
219267191|NCT03851081|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219267192|NCT03851081|OTHER|Quality-of-Life Assessment|Ancillary studies
219267193|NCT03851081|DRUG|Vincristine Sulfate Liposome|Given IV
219267194|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
219267195|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
219267196|NCT04182113|DEVICE|1 Hz rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
219267197|NCT04182113|DEVICE|Sham rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
219267198|NCT01526837|DRUG|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
219267199|NCT04563598|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
219267200|NCT04563598|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
219267201|NCT05282836|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
219267202|NCT01186731|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
219267203|NCT05194163|DRUG|MW150|oral-delivered capsule of study drug
219267204|NCT05194163|DRUG|Placebo|oral delivered capsule matched to study drug capsule
219267205|NCT06269159|OTHER|Concept mapping: brainstorm|"Group health care providers:~* Duration: 1.5 hour for HCP via zoom session~* Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~* Duration: online survey (REDCAP) of approx. 10 minutes~* Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?"
219267206|NCT06269159|OTHER|Concept mapping: clustering and rating|"The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~* Duration: flexible use of the online tool (available for two weeks)~* The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~* Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks."
219267207|NCT02634047|DEVICE|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
219267208|NCT02634047|DEVICE|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
219267209|NCT01667406|DRUG|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
219267210|NCT01667406|DRUG|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
219267211|NCT01667406|DRUG|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
219267212|NCT01667406|DRUG|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
219267213|NCT01667406|DRUG|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
219267214|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
219267215|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
219267216|NCT02229578|DRUG|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
219267217|NCT02229578|DRUG|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
219267218|NCT03792347|DRUG|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
219267219|NCT00943787|PROCEDURE|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
219267220|NCT03306004|OTHER|Questionare|
219267221|NCT05213546|OTHER|Aerobic exercise training|bicycle ergometer exercise training
219267222|NCT03091322|DEVICE|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
219267223|NCT00206297|DRUG|Pramlintide|
219267224|NCT02706951|DRUG|Methotrexate|Capsule; Oral
219267225|NCT02706951|DRUG|Upadacitinib|Tablet; Oral
219267226|NCT02706951|DRUG|Placebo Upadacitinib|Tablet; Oral
219267227|NCT02706951|DRUG|Placebo Methotrexate|Capsule; Oral
219267228|NCT00289575|DEVICE|MBCP|
219267229|NCT04338412|DEVICE|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
219267230|NCT04719299|BEHAVIORAL|Tell-Play-Do|Using smart phone application
219267231|NCT04719299|BEHAVIORAL|Tell-Show-Do|Using traditional behavior management technique
219267232|NCT06956677|DEVICE|Novel UE rehabilitation device training|The novel UE rehabilitation device training includes the single-joint exercise and dual-joint exercise, each performed 20 repetitions per set, for a total of 5 sets with 30-second rest intervals between sets.
219267233|NCT06956677|OTHER|The UE functional training|The UE functional training focuses on the affected arm, incorporating exercises such as push-pull boxes (standing or seated), alternating push-pull boxes, and hand-crank exercises.
219267234|NCT06956677|OTHER|Conventional occupational therapy|Conventional occupational therapy
219267235|NCT01834612|DEVICE|CM1500|blood volume monitor
219267236|NCT00508495|DRUG|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
219267237|NCT00508495|DRUG|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
219267238|NCT00508495|DRUG|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
219267239|NCT01495351|DRUG|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
219267240|NCT03193242|OTHER|Electronic Asthma Management System: eAMS|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
219267241|NCT01300442|OTHER|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
219267242|NCT01300442|OTHER|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
219267243|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
219267244|NCT05361811|BEHAVIORAL|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
219267245|NCT05361811|BEHAVIORAL|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
219267246|NCT04627051|DEVICE|Atherectomy and balloon angioplasty|Atherectomy and balloon angioplasty of arterial-venous graft stenosis
219267247|NCT05758805|DEVICE|mini-invasive esophagoscopy|mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
219267248|NCT05758805|DEVICE|HP-SD AF ablation by a CF sensing catheter|AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
219267249|NCT01076790|DRUG|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
219267250|NCT01076790|DRUG|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
219267251|NCT05264779|OTHER|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
219267252|NCT03895528|DRUG|Lonafarnib|Farnesyl transferase inhibitor
219267253|NCT01112436|DRUG|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
219267254|NCT01112436|DRUG|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
219267255|NCT01435148|PROCEDURE|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
219267256|NCT05306444|DRUG|CLN-418|Intravenous (IV) administration
219267257|NCT04266444|DEVICE|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
219267258|NCT04294667|DRUG|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
219267259|NCT04294667|OTHER|Placebo|Subjects will receive placebo at prespecified time-points.
219267260|NCT02599688|OTHER|Observation only|No intervention in this study.
219267261|NCT01841697|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
219267262|NCT01841697|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
219267263|NCT01841697|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
219267264|NCT01841697|DRUG|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
219267265|NCT01841697|DRUG|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
219267266|NCT01841697|DRUG|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
219267267|NCT06801717|DEVICE|KTP Laser Therapy|Participants will receive full face treatments with 532 nm KTP laser for 3 sessions at 8-12 weeks apart. Laser therapy will be conducted in person. Each laser treatment session will last up to 10 minutes.
219267268|NCT06801717|DEVICE|Radiofrequency microneedling|Participants will receive unilateral facial treatments with radiofrequency microneedling device for 3 sessions at 8-12 weeks apart. Radiofrequency microneedling will be conducted in person. Each treatment session will last up to 1 hour.
219267269|NCT06026475|PROCEDURE|Goal directed Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining SVV below 11
219267270|NCT06026475|PROCEDURE|Conventional Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining CVP between 8-12 cms H20
219267271|NCT00756457|DEVICE|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
219267272|NCT00756457|OTHER|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
219267273|NCT00756457|OTHER|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
219267274|NCT03019081|DRUG|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
219267275|NCT03019081|OTHER|placebo|placebo
219267276|NCT04682561|BEHAVIORAL|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
219267277|NCT03919409|DRUG|TS-161|TS-161 capsules
219267278|NCT03919409|DRUG|TS-161 Placebo|TS-161 matching placebo capsules
219267279|NCT05040945|PROCEDURE|Traditional corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
219267280|NCT05040945|PROCEDURE|Flapless corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
219267281|NCT05264701|OTHER|Physiotherapist supervised exercise training|Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.
219267282|NCT05264701|OTHER|Exercise training via phone app|Exercise training for 12 weeks will be given over the developed phone application.
219267283|NCT05264701|OTHER|Physical activity recommendations|The program will be consist of 12 weeks of physical activity recommendations.
219267284|NCT05514171|PROCEDURE|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
219267285|NCT06183411|BEHAVIORAL|Assessment|"* Observations using two valid, observational instruments (MABC-2 and ToM test-R) that each child completes once at random.~* A demographic and developmental questionnaire is completed once by the parent/guardian at recruitment.~* Standardized questionnaires (Coordination Questionnaire For Parents (CVO), Social Responsiveness Scale second edition (SRS-2), Strengths and Difficulties Questionnaire (SDQ) and Theory of Mind Behavior Checklist (ToMBC)) are also questioned once to parent/guardian for data collection."
219267286|NCT03043482|DRUG|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
219267287|NCT03043482|DRUG|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
219267288|NCT03043482|DRUG|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
219267289|NCT04486599|DEVICE|Electromagnetic Navigation|The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
219267290|NCT04690478|DEVICE|Electronic remote blood pressure monitor|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
219267291|NCT04690478|DEVICE|Ordinary household electronic sphygmomanometer|One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
219267292|NCT04690478|DEVICE|Office electronic sphygmomanometer|One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
219267293|NCT04192864|PROCEDURE|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
219267294|NCT04192864|PROCEDURE|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
219267295|NCT04703400|OTHER|anonymous survey|anonymous survey with 25 mandatory questions
219267296|NCT01727661|BEHAVIORAL|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
219267297|NCT01727661|BEHAVIORAL|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
219267298|NCT01727661|BEHAVIORAL|quality of life|assessing quality of life using short-forum 36 (questionnaire)
219267299|NCT04776902|BEHAVIORAL|Survey|Patients will fill a questionary with 8 questions.
219267300|NCT01613963|DRUG|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
219267301|NCT02698306|DRUG|Dexamethasone|Dexamethasone
219267302|NCT02698306|DRUG|Diclofenac Sodium|Diclofenac Sodium
219267303|NCT02386878|BEHAVIORAL|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
219267304|NCT02386878|BEHAVIORAL|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
219267305|NCT01764308|DIETARY_SUPPLEMENT|Omega-3|1200mg twice a day for 24 weeks
219267306|NCT01764308|DIETARY_SUPPLEMENT|Placebo|4 tablets twice a day for 24 weeks
219267307|NCT01544504|DRUG|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
219267308|NCT00827398|BIOLOGICAL|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
219267309|NCT02635386|DRUG|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
219267310|NCT02635386|DRUG|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
219267311|NCT02635386|DRUG|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
219267312|NCT02635386|DRUG|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
219267313|NCT02635386|DRUG|Phentermine /Topiramate (PHEN/ TPM) ER|PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
219267314|NCT01982409|BIOLOGICAL|Live Attenuated Varicella Vaccine|
219267315|NCT02446613|OTHER|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
219267316|NCT00715689|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219267317|NCT00715689|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219267318|NCT00715689|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219267319|NCT00715689|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
219267320|NCT00715689|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219267321|NCT00715689|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219267322|NCT00715689|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219267323|NCT00715689|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
219267324|NCT02063581|DRUG|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
219267325|NCT02063581|DRUG|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
219267326|NCT06422442|BEHAVIORAL|Threat-related stimulus exposure|Participants will view threat-related stimuli (words or faces) paired with nonthreat matches in three related experimental paradigms.
219267327|NCT02612506|DRUG|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
219267328|NCT02612506|DRUG|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
219267329|NCT01062269|DRUG|Cholestyramine|Cholestyramine 4 grams one time dose
219267330|NCT01062269|DRUG|Cholestyramine|Cholestyramine 12 grams one dose, one day
219267331|NCT01062269|DRUG|Tang|Tang one dose one day
219267332|NCT05742048|DIAGNOSTIC_TEST|traumatic patient suspect to have long bone fracture between 18 - 65 years old|Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
219267333|NCT00085566|DRUG|everolimus|
219267334|NCT00085566|DRUG|gefitinib|
219267335|NCT04805450|PROCEDURE|ES before fully covered SEMS placement|
219267336|NCT04805450|PROCEDURE|no ES before fully covered SEMS placement|
219267337|NCT04113057|OTHER|Remote Coaching|In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
219267338|NCT04553588|OTHER|Disposal pouch|Medication Disposal Pouch
219267339|NCT06454045|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
219267340|NCT05891145|DRUG|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
219267341|NCT05891145|DRUG|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
219267342|NCT04592081|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
219267343|NCT05701241|DRUG|Somatostatin analog|Somatostatin analog treatment every 4 weeks
219267344|NCT05500079|DEVICE|Wrist splint|A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.
219267345|NCT05500079|OTHER|Pulsed radiofrequency current|Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
219267346|NCT04730674|DRUG|tetracycline mixed with xylocaine|10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
219267347|NCT02775305|BEHAVIORAL|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
219267348|NCT03174782|DRUG|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
219267349|NCT03174782|DRUG|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
219267350|NCT00424567|PROCEDURE|Fracture surgery|
219267351|NCT00424567|DRUG|Cultured Bone Marrow Tissue|
219267352|NCT04378374|OTHER|Food-1|Baked food made of lentil flour
219267353|NCT04378374|OTHER|Food-2|Baked food made of lentil flour and wheat flour
219267354|NCT04378374|OTHER|Food-3|Baked food made of wheat flour
219267355|NCT04378374|OTHER|Food-4|Potable water (energy and carbohydrate-free control)
219267356|NCT06140342|BEHAVIORAL|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
219267357|NCT03754790|DRUG|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
219267358|NCT03178045|OTHER|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
219267359|NCT03178045|OTHER|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
219267360|NCT01163474|OTHER|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
219267361|NCT00450138|DRUG|ZD6474 (vandetanib)|once daily oral dose
219267362|NCT00450138|DRUG|Cisplatin|intravenous infusion
219267363|NCT00450138|RADIATION|Radiation|radiation of head and neck
219267364|NCT02991586|BEHAVIORAL|Dialectical Behaviour Therapy|Group of families
219267365|NCT04802304|OTHER|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
219267366|NCT04086238|DRUG|Decitabine|Capsules containing a combination of decitabine and THU
219267367|NCT02757820|DEVICE|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
219267368|NCT02757820|DEVICE|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
219267369|NCT02757820|DEVICE|Air-Q|Patients will be anesthetized using Air-Q\_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
219267370|NCT05907642|OTHER|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
219267371|NCT01586481|DEVICE|SANIDIAB|off-loading shoe
219267372|NCT01586481|DEVICE|BAROUK|old shoe
219267373|NCT02119338|DRUG|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
219267374|NCT01078922|DRUG|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
219267375|NCT04021082|DRUG|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
219267376|NCT04721964|DIETARY_SUPPLEMENT|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
219267377|NCT03382769|DEVICE|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
219267378|NCT04429802|DRUG|Prucalopride|Orally administered
219267379|NCT04429802|DRUG|Placebo|Orally administered
219267380|NCT02706847|DRUG|Placebo|Tablet; Oral
219267381|NCT02706847|DRUG|Upadacitinib|Tablet; Oral
219267382|NCT00645580|DRUG|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
219267383|NCT02297685|DEVICE|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
219267384|NCT02297685|DEVICE|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
219267385|NCT02297685|DEVICE|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
219267386|NCT05702541|DEVICE|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
219267387|NCT05702541|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
219267388|NCT05702541|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
219267389|NCT02519946|OTHER|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
219267390|NCT04718636|DRUG|Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)|Daily
219267391|NCT04718636|DRUG|CC-99677|Daily
219267392|NCT05302297|DRUG|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
219267393|NCT05260593|DEVICE|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
219267394|NCT05260593|DEVICE|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
219267395|NCT05260593|DEVICE|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
219267396|NCT05260593|OTHER|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
219267397|NCT00136370|DRUG|Chlorhexidine|
219267398|NCT00136370|PROCEDURE|Birth canal wipe|
219267399|NCT00136370|PROCEDURE|sterile water external genital wipe|
219267400|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
219267401|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
219267402|NCT01408745|DEVICE|Sternumfix|sternotomy closure with Sternumfix
219267403|NCT01408745|PROCEDURE|steel wire|sternotomy closure with steel wire
219267404|NCT00299923|DRUG|Peginterferon alfa-2a, Ribavirin, Amantadine|
219267405|NCT00980590|DEVICE|Airway Scope|Tracheal intubation by Airway Scope
219267406|NCT00980590|DEVICE|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
219267407|NCT00136279|BEHAVIORAL|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
219267408|NCT03062696|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
219267409|NCT04921579|PROCEDURE|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
219267410|NCT04921579|PROCEDURE|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
219267411|NCT04816864|DIAGNOSTIC_TEST|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
219267412|NCT00672451|DIETARY_SUPPLEMENT|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
219267413|NCT00672451|DIETARY_SUPPLEMENT|placebo|placebo titrated up to 6 pills daily as patient tolerates
219267414|NCT03478137|BEHAVIORAL|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
219267415|NCT05422989|DIAGNOSTIC_TEST|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
219267416|NCT00484692|DRUG|sustained-release bupropion (Zyban(R))|
219267417|NCT00484692|BEHAVIORAL|Psychodynamic Model Training (R) = PDM(R)|
219267418|NCT02689453|BIOLOGICAL|IL-15 plus|Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
219267419|NCT02689453|BIOLOGICAL|alemtuzumab|Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
219267420|NCT01425177|PROCEDURE|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
219267421|NCT05222100|DIAGNOSTIC_TEST|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
219267422|NCT00661843|OTHER|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
219267423|NCT04211077|OTHER|Date collection|Data collection from national SNIIRAM and PMSI database
219267424|NCT01337206|DEVICE|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
219267425|NCT01337206|PROCEDURE|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
219267426|NCT04206085|DEVICE|Viveve - Active|Radiofrequency and Cryogen-Cooling
219267427|NCT04206085|DEVICE|Viveve - Cryogen-Alone|Cryogen-Cooling
219267428|NCT04206085|DEVICE|Viveve - Sham|Sham
219267429|NCT00763451|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219267430|NCT00763451|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219267431|NCT00763451|DEVICE|Pen auto-injector|
219267432|NCT00763451|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
219267433|NCT03165578|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
219267434|NCT03165578|OTHER|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
219267435|NCT00453024|PROCEDURE|Pericardial graft & tissue glue|
219267436|NCT00453024|PROCEDURE|scleral flap & sutures|
219267437|NCT04258657|DRUG|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
219267438|NCT04135508|DRUG|BAT1406|40mg/0.8ml
219267439|NCT04135508|DRUG|Humira|40mg/0.8ml
219267440|NCT06021587|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
219267441|NCT06021587|DRUG|No Levosimendan|Without Levosimendan Infusion
219267442|NCT04741737|PROCEDURE|reSLNB arm|Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
219267443|NCT01473992|DEVICE|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
219267444|NCT01473992|DEVICE|Otto Bock Genium|Study knee.
219267445|NCT02673411|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
219267446|NCT00003428|DRUG|arzoxifene hydrochloride|
219267447|NCT00725543|BIOLOGICAL|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
219267448|NCT06336798|DRUG|Pioglitazone 30mg|Study participants will take Pioglitazone 30 mg PO daily
219267449|NCT06336798|DRUG|Placebo|Study participants will take a placebo PO daily
219267450|NCT06336798|DIAGNOSTIC_TEST|Labs|Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
219267451|NCT05594589|DRUG|Lemborexant|Lemborexant oral tablet.
219267452|NCT05594589|OTHER|PBO|Lemborexant-matched PBO tablet.
219267453|NCT04741854|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
219267454|NCT03200444|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
219267455|NCT03200444|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
219267456|NCT03200444|OTHER|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
219267457|NCT03200444|OTHER|P-4|Newly developed adhesive P-4
219267458|NCT03200444|OTHER|P-15|Newly developed adhesive P-14
219267459|NCT03200444|OTHER|P-16|Newly developed adhesive P-8
219267460|NCT05949567|OTHER|urodynamic exam in sitting and lying position|Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
219267461|NCT05347212|DRUG|Nivolumab|Given by IV
219267462|NCT05347212|DRUG|Relatlimab|Given by IV
219267463|NCT05787249|BEHAVIORAL|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
219267464|NCT05787249|BEHAVIORAL|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
219267465|NCT03688997|OTHER|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
219267466|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
219267467|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
219267468|NCT00087555|DRUG|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
219267469|NCT04219917|OTHER|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
219267470|NCT01233271|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
219267471|NCT04793581|DEVICE|Atherectomy|Directional atherectomy of lesions below the knee.
219267472|NCT00723918|DRUG|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
219267473|NCT00723918|DRUG|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
219267474|NCT00723918|DRUG|SAB placebo|an inactive substance
219267475|NCT00723918|DRUG|Methadone placebo|Methadone placebo
219267476|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 1 application|
219267477|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 2 applications|
219267478|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 1 application|
219267479|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 2 applications|
219267480|NCT06414005|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)
219267481|NCT06414005|OTHER|Placebo (Saline)|Ultrasound-guided intratendinous placebo injection
219267482|NCT01691547|DRUG|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
219267483|NCT01691547|DRUG|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
219267484|NCT01691547|DRUG|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
219267485|NCT01691547|DRUG|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
219267486|NCT03845023|DRUG|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
219267487|NCT03845023|DRUG|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
219267488|NCT03845023|DRUG|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
219267489|NCT03845023|DRUG|Placebo|Placebo oral capsule administered before sleep
219267490|NCT02478385|OTHER|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
219267491|NCT03772613|DRUG|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
219267492|NCT03243500|DRUG|Atracurium|5mg in 1 ml normal saline
219267493|NCT03243500|DRUG|Lidocaine 2%|
219267494|NCT03243500|DRUG|Bupivacaine 0.5%|
219267495|NCT03243500|DRUG|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
219267496|NCT03243500|PROCEDURE|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
219267497|NCT02640170|OTHER|Registry|
219267498|NCT04422977|DIAGNOSTIC_TEST|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
219267499|NCT01427738|DRUG|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
219267500|NCT01427738|DRUG|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
219267501|NCT04185922|DEVICE|Hemopatch|As stated in Hemopatch arm description
219267502|NCT00371995|DRUG|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
219267503|NCT02731456|OTHER|altitude exposure|altitude exposure
219267504|NCT05314374|DIETARY_SUPPLEMENT|Ileocolonic-release conjugated bile acid|500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
219267505|NCT05314374|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient. 500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
219267506|NCT06003699|BEHAVIORAL|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
219267507|NCT04250688|DEVICE|Ekso Training with FES|
219267508|NCT02658175|DRUG|Volanesorsen|300 mg volanesorsen administered via SC injection.
219267509|NCT02351336|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. \- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. \- CL measurement using 2D ultrasound ( in cm)"
219267510|NCT00895388|BEHAVIORAL|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
219267511|NCT03691142|OTHER|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
219267512|NCT02151071|DEVICE|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
219267513|NCT02151071|DEVICE|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
219267514|NCT05111743|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
219267515|NCT00847158|PROCEDURE|phacoemulsification alone|phacoemulsification alone
219267516|NCT00847158|DEVICE|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
219267517|NCT03096756|DRUG|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
219267518|NCT03096756|DRUG|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
219267519|NCT03096756|OTHER|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
219267520|NCT03096756|OTHER|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
219267521|NCT03096756|OTHER|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
219267522|NCT03096756|OTHER|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
219267523|NCT03096756|OTHER|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
219267524|NCT03096756|DRUG|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
219267525|NCT02719756|DRUG|Metformin|Metformin tablets 1000 mg
219267526|NCT02719756|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets
219267527|NCT02719756|DRUG|Metformin up-titration|
219267528|NCT02554383|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
219267529|NCT02554383|DRUG|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
219267530|NCT04580498|DRUG|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
219267531|NCT04580498|DRUG|SHR-1701|Drug: SHR-1701 30mg/kg
219267532|NCT01965106|DRUG|QPI-1007 Injection|1.5 mg QPI-1007 Injection
219267533|NCT01965106|DRUG|(including placebo)|Sham injection procedure
219267534|NCT00827736|PROCEDURE|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
219267535|NCT00827736|DRUG|ISDN ointment|application of ISDN 1% ointment 6 times a day
219267536|NCT00827736|DRUG|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
219267537|NCT06140394|OTHER|diode laser|low level diode therapy
219267538|NCT06140394|OTHER|non surgical scaling|non surgical scaling using ultrasonic
219267539|NCT01966978|DRUG|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
219267540|NCT01966978|DRUG|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
219267541|NCT01966978|DRUG|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
219267542|NCT01966978|DRUG|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
219267543|NCT05399615|DIAGNOSTIC_TEST|VOX|Breath biopsy
219267544|NCT01126697|DRUG|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
219267545|NCT04574232|DRUG|knee intra-articular infiltration with Triamcinolone acetonide|knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
219267546|NCT05936918|OTHER|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
219267547|NCT05936918|OTHER|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
219267548|NCT00002722|DRUG|cisplatin|
219267549|NCT00002722|DRUG|fluorouracil|
219267550|NCT00002722|DRUG|leucovorin calcium|
219267551|NCT05802771|PROCEDURE|surgical resection|surgical resection of the lung cancer
219267552|NCT04805957|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
219267553|NCT04342312|PROCEDURE|Pulmonary vein isolation|Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.
219267554|NCT01594645|PROCEDURE|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
219267555|NCT01214421|DRUG|Tolvaptan|Tablets of 15 or 30 mg
219267556|NCT04297072|DRUG|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
219267557|NCT04297072|DRUG|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
219267558|NCT02744339|DRUG|Riociguat|Adempas up-titrated to max. 1.5mg TID
219267559|NCT02744339|DRUG|Placebo|Placebo sham-titrated TID
219267560|NCT00542412|DRUG|Riluzole|
219267561|NCT06457685|DEVICE|Pulse Intravascular Lithotripsy (Pulse IVL)|The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
219267562|NCT03391856|DRUG|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
219267563|NCT03391856|OTHER|supportive therapy|prophylactic platelet transfusion was given when platelet count \<20000/ul
219267564|NCT00985270|DRUG|Rifampicin|
219267565|NCT00985270|DRUG|Placebo|
219267566|NCT05888610|BEHAVIORAL|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
219267567|NCT03928392|BEHAVIORAL|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
219267568|NCT03928392|BEHAVIORAL|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
219267569|NCT00509405|DRUG|potassium citrate|6 times 10 mEq per day, oral for 24 months
219267570|NCT06266598|DRUG|Metformin|Only obese children with insulin resistance were treated with metformin.
219267571|NCT06202768|OTHER|data collection|data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
219267572|NCT05874310|GENETIC|FT-002|Comparison of different dosages of FT-002
219267573|NCT05784922|OTHER|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
219267574|NCT04191408|PROCEDURE|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
219267575|NCT04749407|GENETIC|biomarker detection|PBMC and ctDNA analysis
219267576|NCT03465943|DRUG|Ringer|1L of Ringer's solution as a preload in one group.
219267577|NCT03465943|DRUG|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
219267578|NCT01621789|OTHER|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
219267579|NCT00104767|DRUG|celecoxib|
219267580|NCT00550212|DRUG|neratinib|HKI-272, Single-dose capsule and solution
219267581|NCT05768399|DIAGNOSTIC_TEST|The level of biomarkers in Peripheral blood|All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
219267582|NCT02900898|OTHER|Dynamic exercise and Mediterranean diet|DE, MD
219267583|NCT02900898|OTHER|Dynamic exercise|DE
219267584|NCT02900898|OTHER|Mediterranean diet|MD
219267585|NCT02900898|OTHER|Control|Control
219267586|NCT01493037|DEVICE|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
219267587|NCT05144399|OTHER|Accelerated antibiotic treatment|"E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
219267588|NCT05144399|OTHER|Standard treatment length|"E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
219267589|NCT02321267|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
219267590|NCT02581059|DRUG|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
219267591|NCT02581059|DIETARY_SUPPLEMENT|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
219267592|NCT02392104|DRUG|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
219267593|NCT04115189|DRUG|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
219267594|NCT01582698|BIOLOGICAL|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
219267595|NCT03239327|DRUG|Misoprostol|
219267596|NCT04887506|DRUG|TAVT-45|250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
219267597|NCT04887506|DRUG|Zytiga|500 mg tablet, two tablets administered once daily
219267598|NCT04887506|DRUG|Prednisone|mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
219267599|NCT01999777|DRUG|USL261|
219267600|NCT01999777|DRUG|Placebo|
219267601|NCT04460833|DEVICE|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
219267602|NCT04238013|OTHER|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
219267603|NCT04238013|OTHER|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
219267604|NCT03666806|BIOLOGICAL|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
219267605|NCT02394665|RADIATION|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
219267606|NCT02394665|DRUG|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle."
219267607|NCT02394665|BEHAVIORAL|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
219267608|NCT02394665|RADIATION|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
219267609|NCT02394665|RADIATION|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
219267610|NCT02394665|DEVICE|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
219267611|NCT06445088|DIAGNOSTIC_TEST|VCA-IgA, EBNA1-IgA, and EBV-DNA|Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
219267612|NCT06445088|DIAGNOSTIC_TEST|EBV C Promoter Methylation Detection in nasopharyngeal swab samples|Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
219267613|NCT02906722|DRUG|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
219267614|NCT02906722|DRUG|Intravenous placebo|administration once, twice or 3 times per day according to renal function
219267615|NCT02906722|DRUG|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
219267616|NCT02906722|DRUG|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
219267617|NCT03170843|DEVICE|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
219267618|NCT01774136|BEHAVIORAL|Enhanced HIV and MCH training for CHW|
219267619|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
219267620|NCT01805245|BEHAVIORAL|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
219267621|NCT06019364|OTHER|Whole blood transfusion|Transfusion of whole blood in a situation with acute bleeding according to routine practice.
219267622|NCT04669769|OTHER|interview|telephone interview
219267623|NCT05473936|BEHAVIORAL|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
219267624|NCT01957540|DRUG|Ticagrelor|
219267625|NCT01957540|DRUG|Prasugrel|
219267626|NCT05161741|DRUG|Insulin|Human rDNA Insulin (Insuget, local brand of Getz Pharma)
219267627|NCT06050447|PROCEDURE|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
219267628|NCT06050447|PROCEDURE|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
219267629|NCT06050447|PROCEDURE|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
219267630|NCT06050447|PROCEDURE|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
219267631|NCT06050447|PROCEDURE|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
219267632|NCT06050447|PROCEDURE|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
219267633|NCT06050447|PROCEDURE|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
219267634|NCT03860090|DEVICE|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
219267635|NCT03860090|DEVICE|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
219267636|NCT03860090|PROCEDURE|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
219267637|NCT03860090|PROCEDURE|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
219267638|NCT02227797|DRUG|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
219267639|NCT05421767|PROCEDURE|nerve stimulation guided renal denervation procedure|RNS-in
219267640|NCT05692219|BEHAVIORAL|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
219267641|NCT05692219|BEHAVIORAL|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
219267642|NCT05849623|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
219267643|NCT05849623|PROCEDURE|Cold Endoscopic Mucosal Resection (C-EMR)|C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
219267644|NCT05849623|PROCEDURE|Underwater Endoscopic Mucosal Resection (U-EMR)|U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
219267645|NCT01386723|DRUG|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
219267646|NCT03411785|OTHER|CPC+ model|CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
219267647|NCT01280851|PROCEDURE|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
219267648|NCT01255761|BIOLOGICAL|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
219267649|NCT03506347|DRUG|Vancomycin|Antibiotic
219267650|NCT01255956|DEVICE|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
219267651|NCT01255956|DEVICE|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
219267652|NCT05613088|DRUG|MORAb-202|Specified dose on specified days
219267653|NCT05613088|DRUG|Paclitaxel|Specified dose on specified days
219267654|NCT05613088|DRUG|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
219267655|NCT05613088|DRUG|Topotecan|Specified dose on specified days
219267656|NCT06163651|BEHAVIORAL|Parent-Child Assistance Program - One-Year Version|Case managers work closely with parents over the course of one year, meeting them in their own homes when possible, to help them set goals and take advantage of available resources.
219267657|NCT03127839|PROCEDURE|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
219267658|NCT03127839|PROCEDURE|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
219267659|NCT03127839|BEHAVIORAL|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
219267660|NCT03912532|BIOLOGICAL|NGM282|NGM282
219267661|NCT03912532|OTHER|Placebo|Placebo for NGM282
219267662|NCT05424003|DRUG|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
219267663|NCT05424003|DRUG|Placebo|Placebo solution injected weekly for 72 weeks
219267664|NCT04068649|RADIATION|Palliative Radiation Therapy|Undergo palliative RT
219267665|NCT04068649|OTHER|Quality-of-Life Assessment|Ancillary studies
219267666|NCT04068649|OTHER|Questionnaire Administration|Ancillary studies
219267667|NCT04068649|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219267668|NCT05357092|DEVICE|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
219267669|NCT01628640|OTHER|Laboratory Biomarker Analysis|Correlative studies
219267670|NCT01628640|OTHER|Pharmacological Study|Correlative studies
219267671|NCT01628640|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
219267672|NCT06636942|DEVICE|Intermittent pneumatic compression|Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
219267673|NCT05824910|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
219267674|NCT03569891|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
219267675|NCT03569891|BIOLOGICAL|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
219267676|NCT01315015|OTHER|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
219267677|NCT06538298|OTHER|Multimodal Exercise Program with Gamification|A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
219267678|NCT04178811|DEVICE|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
219267679|NCT06802081|DRUG|Tirzepatide|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
219267680|NCT06802081|DRUG|Placebo|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
219267681|NCT05575063|DEVICE|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
219267682|NCT05575063|DEVICE|Control Healon EndoCoat|Ophthalmic Viscoelastic device
219267683|NCT06266442|OTHER|Whole genome sequencing testing|Whole genome sequencing
219267684|NCT03965780|OTHER|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
219267685|NCT00175591|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
219267686|NCT03134261|DIAGNOSTIC_TEST|WB-MRI|scanning methods
219267687|NCT03134261|DIAGNOSTIC_TEST|SPECT-CT|scanning methods
219267688|NCT03134261|DIAGNOSTIC_TEST|Cholin-PET-CT|scanning methods
219267689|NCT03134261|DIAGNOSTIC_TEST|PSMA-PET-CT|
219267690|NCT04795076|DIETARY_SUPPLEMENT|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
219267691|NCT00758823|DEVICE|Paranix|pediculicide product
219267692|NCT02360800|PROCEDURE|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
219267693|NCT02360800|PROCEDURE|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
219267694|NCT04417400|BEHAVIORAL|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
219267695|NCT01198847|BEHAVIORAL|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
219267696|NCT05047978|OTHER|Cow's milk protein infant formula|A routine cow's milk-based infant formula
219267697|NCT05047978|OTHER|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
219267698|NCT03406650|DRUG|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
219267699|NCT03220685|BIOLOGICAL|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
219267700|NCT04198922|DRUG|Acalabrutinib|Given PO
219267701|NCT04198922|OTHER|Questionnaire Administration|Ancillary studies
219267702|NCT05523414|BEHAVIORAL|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
219267703|NCT06223841|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q3w
219267704|NCT01716091|PROCEDURE|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
219267705|NCT05098652|BEHAVIORAL|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
219267706|NCT06831929|BEHAVIORAL|Intervention Arm|Within the intervention clinics, parents of patients between the ages of 10-12 (who are eligible for the HPV vaccine) will receive a culturally tailored customized HPV vaccine message and testimonial video from a patient/survivor of an HPV associated cancer (e.g., oropharyngeal, or cervical) via the MyChart patient portal. Parents will also receive a personal call from the research coordinator to remind them that their child is due for the HPV vaccine. If the parent is interested in scheduling the HPV vaccine appointment during this call, the research coordinator will transfer the parent to UC Davis appointment call center to schedule the appointment. Also, primary care team members will receive a semi-annual learn at lunch workshop focused on strategies to introduce the HPV vaccine to parents and how to address concerns from vaccine hesitant parents. Workshop content will be tailored/adapted to include patient/parent cultural considerations.
219267707|NCT06933628|PROCEDURE|Patient-Specific Titanium Plates|Custom 3D-printed titanium fixation plates and cutting guides
219267708|NCT06933628|PROCEDURE|3D-Printed Intermediate Splint|CAD/CAM-fabricated occlusal splint for maxillary positioning
219267709|NCT06936683|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy|"Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy~1. Site selection: For patients with limited lesions, the lesion segment was chosen; For patients with diffuse lesions, the right middle lobe or left upper lobe tongue should be severed.~2. Injecting physiological saline: After the top of the bronchoscope is embedded in the target bronchial segment or subsegment opening, 37 ℃ or room temperature physiological saline is rapidly injected through the operating channel, with a total volume of 60-120ml, injected in batches (20-50ml each time).~3. Negative pressure suction: After injecting physiological saline, immediately use appropriate negative pressure (generally recommended below 100mmHg) to suction and obtain BALF, with a total recovery rate of ≥ 30%.~4. BALF collection: Specimens used for pathogen analysis need to be collected in sterile containers; Cytological analysis requires the selection of plastic containers or siliconized glass containers to reduce cell adhesion."
219267710|NCT06936683|DIAGNOSTIC_TEST|throat Swab|"A throat swab is a diagnostic sampling technique used to collect microbial specimens from the oropharynx and tonsillar areas. The standardized procedure involves:~1. Positioning the patient with their head tilted slightly backward;~2. Using a sterile, synthetic-fiber swab with a plastic shaft (avoiding calcium alginate or wooden shafts);~3. Vigorously rubbing the swab over both tonsillar pillars and the posterior pharyngeal wall while avoiding contact with the tongue, teeth, or uvula;~4. Immediately placing the swab into appropriate transport media viral/bacterial);~5. Maintaining cold chain (2-8°C) for specimen transport if required."
219267711|NCT06943001|BEHAVIORAL|Fit24+|This is a digital diabetes prevention program for adolescents that leverages a Fitbit device, rule-based chatbot, and eLearning platform to deliver a comprehensive nutrition and physical activity lifestyle intervention to Hispanic adolescents with obesity.
219267712|NCT06945874|DIAGNOSTIC_TEST|Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french version|"The RCSQ questionnaire translated into French (RCSQ-F) will be distributed to intensive care patients who meet the inclusion and non-inclusion criteria and who have given their informed consent to participate in the study.~The questionnaire will be distributed on two occasions: at the first visit and on the day of discharge from intensive care for survivors, or at the latest on the 14th day of hospitalisation.~Patients' use of the questionnaire will enable internal validation (primary objective) by exploratory factor analysis."
219267713|NCT06944275|PROCEDURE|Blood draw for thromboelastography - admission|Two blood samples will be collected at admission for thromboelastography using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
219267714|NCT06944275|PROCEDURE|Blood draw for thromboelastography - follow-up|Two blood samples will be collected 3 - 7 days after initial thromboelastography for follow-up analysis using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
219267715|NCT06944275|PROCEDURE|Blood draw for transcriptomic analysis|One blood sample will be collected at admission for transcriptomic analysis. Blood sample will be collected into a PAXgene® RNA tube and analysed using nanopore sequencing to characterise the viral and host transcriptome.
219267716|NCT06944275|OTHER|Data collection - clinical/demographic/epidemiological data|Routine clinical/demographic/epidemiological data will be collected at admission and throughout hospitalisation. This will relate to clinical presentation (day of illness at presentation, presenting symptoms); demographics and epidemiology (age, gender, site of infection); clinical course during hospitalisation (maximum level of care, dialysis use, blood product use, survival outcome).
219267717|NCT06944275|OTHER|Data collection - routine laboratory parameters|Data on routine laboratory parameters will be collected throughout hospitalisation. These will relate to laboratory clotting parameters (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer); liver function tests (aspartate aminotransferase, alanine aminotransferase); laboratory haematology parameters (haemoglobin, white cell count, blood film); laboratory biochemistry parameters (urea, creatinine); viral load.
219267718|NCT06944275|OTHER|Severity score calculation|A severity score will be assigned to each patient based on clinical and laboratory data at admission according to a pre-defined scoring system.
219267719|NCT06944990|BEHAVIORAL|Meta self-efficacy internet intervention|The meta self-efficacy intervention is a three-week program comprised of activities designed to enhance meta self-efficacy (the ability to leverage self-efficacy sources). The intervention is contextualized to young employees.
219267720|NCT06944990|BEHAVIORAL|Placebo|The placebo condition contains educational material delivered with the same modality as in the experimental condition.
219267721|NCT06945601|DRUG|ICI monotherapy or combinations of chemo- immunotherapy|ICI monotherapy or combinations of chemo- immunotherapy
219267722|NCT06944873|BIOLOGICAL|Blood test 4 EDTA tubes|Blood test 4 EDTA tubes for biological check-up
219267723|NCT06944782|DIAGNOSTIC_TEST|Electromyography (EMG) of the Oropharynx|The transmembranous electromyography (tmEMG) probe is a disposable single-use bipolar recording device with the sensor configured with two electrodes located at the distal end of the probe in a parallel orientation. Unlike conventional EMG probes that are designed to be inserted into the muscle, the tmEMG probe is placed on the surface of the muscle similar to a surface electrode; the tip of the probe is approximately the size of a ball point pen, which allows us to record from the smaller muscles inside the mouth. Recordings will be taken from the genioglossus and palatoglossus in the mouth bilaterally. Recordings will be taken while the subject performs various maneuvers such as shallow breathing, deep breathing, and pressing their tongue against the side of their mouth.
219267724|NCT06944392|DIETARY_SUPPLEMENT|Pumpkin Seed Extract|This is the only intervention
219267725|NCT06940986|BEHAVIORAL|Empowered Relief|ER is provided in a single, 2-hour session delivered remotely by trained instructors. ER has two main components: didactics and skills acquisition as outlined below. The ER class is administered virtually. The class includes the didactic and skill acquisition content. At the end of the class participants receive tangible items including the self-crafted, personalized catastrophizing cessation plan, a guided relaxation response audio file, and an electronic copy of the didactic class content.
219267726|NCT06940986|BEHAVIORAL|Move to Health|The M2H intervention is delivered virtually by trained health coaches using a 6-step process. The administration of M2H begins with an initial session with follow-up sessions scheduled every 1-2 weeks for up to 8 weeks or until the participant is ready to transition to self-management.
219267727|NCT06940986|OTHER|Usual Care as determined by primary care provider|Patients will receive care as determined by their primary care provider, with no input or control by the research team.
219267728|NCT06945146|DRUG|Ponatinib|Ponatinib treatment will be initiated per usual treatment procedure at 45 mg once daily p.o., which will be gradually decreased to 30 mg and 15 mg according to the predefined criteria based on responsiveness to treatment and AEs in the course of the treatment.
219267729|NCT06944249|DRUG|NaCl (placebo)|During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.
219267730|NCT06944249|DRUG|Verteporfin Injection|During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.
219267731|NCT01321983|OTHER|Inspiratory muscular training - IMT|
219267732|NCT06945614|DRUG|Xenon gas inhalation|Administration of xenon gas in the mixture with oxygen for the period of time via inhalation
219267733|NCT00873262|DRUG|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
219267734|NCT00873262|DRUG|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
219267735|NCT02531854|DRUG|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
219267736|NCT02531854|DRUG|Pemetrexed|Chemotherapy
219267737|NCT04650698|DRUG|Tranexamic acid (TXA) injection|IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
219267738|NCT03527641|BEHAVIORAL|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
219267739|NCT03527641|BEHAVIORAL|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
219267740|NCT03527641|BEHAVIORAL|Physical Activity|Physical fitness activities for teens
219267741|NCT03527641|BEHAVIORAL|Health Education|Health knowledge curriculum for adolescents
219267742|NCT03527641|BEHAVIORAL|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
219267743|NCT03527641|BEHAVIORAL|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
219267744|NCT02559401|OTHER|MRI|
219267745|NCT02559401|OTHER|Neurocognitive battery|
219267746|NCT02069197|OTHER|Ketogenic diet|ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.
219267747|NCT02069197|DRUG|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
219267748|NCT02069197|OTHER|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
219267749|NCT02149238|DIETARY_SUPPLEMENT|flavanol|
219267750|NCT02149238|DIETARY_SUPPLEMENT|methylxanthine|
219267751|NCT02149238|DIETARY_SUPPLEMENT|flavanol + methylxanthine|
219267752|NCT01144390|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
219267753|NCT01144390|DRUG|methadone maintenance treatment|methadone maintenance treatment
219267754|NCT03778294|PROCEDURE|Computed Tomography|Undergo PET/CT
219267755|NCT03778294|OTHER|Fluorodopa F 18|Given IV
219267756|NCT03778294|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219267757|NCT03778294|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
219267758|NCT03778294|RADIATION|Proton Beam Radiation Therapy|Receive proton beam RT
219267759|NCT03778294|OTHER|Quality-of-Life Assessment|Ancillary studies
219267760|NCT03778294|OTHER|Questionnaire Administration|Ancillary studies
219267761|NCT03778294|DRUG|Temozolomide|Drug
219267762|NCT04259697|OTHER|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
219267763|NCT04259697|OTHER|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
219267764|NCT01641653|OTHER|Normal saline|Normal saline 2cc. one dose prior to OR
219267765|NCT01641653|DRUG|Midazolam|1-2.5 mg
219267766|NCT01511497|BIOLOGICAL|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
219267767|NCT01511497|OTHER|Normal saline|Intravenous, normal saline
219267768|NCT01197612|DRUG|pulmicort|applied to nasal packing after surgery
219267769|NCT02723097|BEHAVIORAL|3 RP|
219267770|NCT06141200|DRUG|NW Roselle|NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
219267771|NCT06141200|DRUG|Captopril 25Mg Tab|Active Comparator
219267772|NCT02812992|DRUG|Nab-paclitaxel|
219267773|NCT02812992|DRUG|Gemcitabine|
219267774|NCT02812992|OTHER|Best Supportive Care|
219267775|NCT01792531|BEHAVIORAL|Parent training group|The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
219267776|NCT01792531|BEHAVIORAL|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
219267777|NCT01792531|BEHAVIORAL|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
219267778|NCT01176461|BIOLOGICAL|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
219267779|NCT01176461|BIOLOGICAL|NY-ESO-1|NY-ESO-1 peptide vaccine
219267780|NCT01176461|BIOLOGICAL|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
219267781|NCT01176461|BIOLOGICAL|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
219267782|NCT01176461|DRUG|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
219267783|NCT01176461|BIOLOGICAL|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
219267784|NCT01992367|DRUG|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
219267785|NCT00009906|DRUG|Imatinib Mesylate|Given orally
219267786|NCT03484494|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
219267787|NCT00512616|DRUG|Ceftriaxone|
219267788|NCT03550079|PROCEDURE|fixation|treated with different fixation method
219267789|NCT00122486|DRUG|Tenofovir Disoproxil Fumarate|
219267790|NCT00487825|DRUG|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
219267791|NCT00487825|DRUG|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
219267792|NCT00487825|DRUG|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
219267793|NCT00671710|DRUG|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
219267794|NCT02192593|BEHAVIORAL|Computer CBT|
219267795|NCT01993771|PROCEDURE|Surgery with general anaesthesia.|
219267796|NCT01993771|PROCEDURE|Raw EEG|
219267797|NCT05113797|DIAGNOSTIC_TEST|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
219267798|NCT05113797|BEHAVIORAL|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
219267799|NCT04669743|OTHER|Ozone exposure|Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
219267800|NCT02779348|DRUG|BIA 3-202|Nebicapone tablets 200 mg
219267801|NCT02779348|DRUG|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
219267802|NCT00249782|DRUG|Vehicle control, 2x/day|
219267803|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 2x/day|
219267804|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day|
219267805|NCT00249782|DRUG|MetroGel® (metronidazole gel), 1.0% 1x/day|
219267806|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
219267807|NCT01473745|PROCEDURE|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
219267808|NCT01473745|PROCEDURE|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
219267809|NCT02230722|BEHAVIORAL|Motivational Interviewing|
219267810|NCT02230722|BEHAVIORAL|Attention Control|
219267811|NCT03225898|OTHER|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
219267812|NCT03225898|OTHER|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
219267813|NCT05895708|OTHER|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
219267814|NCT05895708|OTHER|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
219267815|NCT01639742|DEVICE|New texture round breast implants|Breast implant surgery
219267816|NCT01295203|BEHAVIORAL|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
219267817|NCT03082755|DRUG|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
219267818|NCT03082755|DRUG|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
219267819|NCT00673608|DRUG|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
219267820|NCT04515407|OTHER|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
219267821|NCT04515407|OTHER|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
219267822|NCT04515407|OTHER|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
219267823|NCT04864366|DRUG|Tenofovir Alafenamide 25 MG [Vemlidy]|TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
219267824|NCT01509443|OTHER|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
219267825|NCT03996265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219267826|NCT03996265|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
219267827|NCT03996265|OTHER|Placebo Administration|Given PO
219267828|NCT03996265|OTHER|Quality-of-Life Assessment|Ancillary studies
219267829|NCT03996265|OTHER|Questionnaire Administration|Ancillary studies
219267830|NCT05221138|DRUG|VV116|VV116 oral tablets, 400mg
219267831|NCT01190644|DRUG|Sotatercept|single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
219267832|NCT01452568|DRUG|Aspirin|150mg/daily for three months, starting day after surgery
219267833|NCT01452568|DRUG|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
219267834|NCT02366143|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
219267835|NCT02366143|DRUG|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
219267836|NCT02366143|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
219267837|NCT02366143|DRUG|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
219267838|NCT00373919|DRUG|intravenous (IV) administration of erythromycin|
219267839|NCT00807703|PROCEDURE|Select Stim|Select Stim: see summary
219267840|NCT04411186|PROCEDURE|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
219267841|NCT04411186|PROCEDURE|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 \>94%"
219267842|NCT04912310|DEVICE|Argon laser peripheral iridoplasty|Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
219267843|NCT02244138|BEHAVIORAL|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
219267844|NCT03376035|OTHER|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
219267845|NCT04945447|OTHER|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
219267846|NCT00167154|DRUG|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
219267847|NCT04992754|BEHAVIORAL|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
219267848|NCT04339712|DRUG|Anakinra|In case of diagnosis of MAS treatment with anakinra
219267849|NCT04339712|DRUG|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
219267850|NCT03480113|BEHAVIORAL|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
219267851|NCT03480113|BEHAVIORAL|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
219267852|NCT06146192|DRUG|Colchicine|colchicine 1-2 mg/day
219267853|NCT00171236|DRUG|Fluvastatin|
219267854|NCT03985436|BEHAVIORAL|Trek for Surgical Success|Cognitive behavioral therapy for pain
219267855|NCT05571826|BEHAVIORAL|telerehabilitation|No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
219267856|NCT01026298|OTHER|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
219267857|NCT01053247|DRUG|0416|Topical 0416 test product applied twice daily for 2 weeks
219267858|NCT01053247|DRUG|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
219267859|NCT01053247|DRUG|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
219267860|NCT03038269|BEHAVIORAL|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
219267861|NCT01240538|BIOLOGICAL|wild-type reovirus|Given IV
219267862|NCT01240538|DRUG|cyclophosphamide|Given PO
219267863|NCT01240538|OTHER|laboratory biomarker analysis|Correlative studies
219267864|NCT01240538|OTHER|pharmacological study|Correlative studies
219267865|NCT03118167|DIETARY_SUPPLEMENT|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
219267866|NCT03118167|DIETARY_SUPPLEMENT|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
219267867|NCT03118167|OTHER|Placebo|Edible starches 0.35g, edible capsule
219267868|NCT03118167|OTHER|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
219267869|NCT03575949|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
219267870|NCT03575949|OTHER|Fludeoxyglucose F-18|Given IV
219267871|NCT03575949|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
219267872|NCT00566813|DRUG|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
219267873|NCT00566813|DRUG|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
219267874|NCT01863628|OTHER|aerobic exercise|
219267875|NCT01863628|OTHER|psychoeducation|
219267876|NCT05633498|OTHER|Book|Self-help book describing advice to cope with shift work
219267877|NCT05633498|OTHER|Sleep hygiene|Basic sleep hygiene advice on a piece of paper
219267878|NCT03927898|DRUG|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
219267879|NCT03927898|RADIATION|Stereotactic Body Radiotherapy|Participants receive SBRT (BED\>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
219267880|NCT05616377|OTHER|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
219267881|NCT05616377|OTHER|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
219267882|NCT06547463|OTHER|nasal oxygenation device|Use of the nasal oxygenation device on one of the two nights during which polysomnography will be performed.
219267883|NCT05783713|OTHER|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
219267884|NCT00726271|DIETARY_SUPPLEMENT|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
219267885|NCT01663558|DRUG|imiquimod|
219267886|NCT01663558|PROCEDURE|ablative|
219267887|NCT00319800|DRUG|Gefitinib|
219267888|NCT00319800|DRUG|Irinotecan|
219267889|NCT01278147|BEHAVIORAL|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
219267890|NCT01636908|DRUG|Sunitinib|50 mg once daily, oral use, 14 days
219267891|NCT01636908|DRUG|Sorafenib|400 mg, twice daily, oral use, 14 days
219267892|NCT01636908|DRUG|Erlotinib|150 mg once daily, oral use, 14 days
219267893|NCT01636908|DRUG|Everolimus|10 mg once daily, oral use, 14 days
219267894|NCT01636908|DRUG|Lapatinib|1250 mg once daily, oral use, 14 days
219267895|NCT01636908|DRUG|Dasatinib|100 mg once daily, oral use, 14 days
219267896|NCT01636908|DRUG|Pazopanib|800 mg once daily, oral use, 14 days
219267897|NCT01636908|DRUG|Vemurafenib|960 mg twice daily, oral use, 15-21 days
219267898|NCT01636908|PROCEDURE|tumor biopsy|
219267899|NCT01636908|PROCEDURE|skin biopsy (optional)|
219267900|NCT02857075|OTHER|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
219267901|NCT06304467|BEHAVIORAL|Contingency Management|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
219267902|NCT06330493|DEVICE|PCB|Paclitaxel coated PTA balloon catheter
219267903|NCT06330493|DEVICE|PTA|Non-coated FDA cleared (US) or CE-marked (EU) standard percutaneous transluminal angioplasty balloon catheter
219267904|NCT01229774|DRUG|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
219267905|NCT01229774|DRUG|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
219267906|NCT04800939|OTHER|Acupressure|The experimental group will start with HT7 points and continue with SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
219267907|NCT04800939|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the HT7 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
219267908|NCT02772328|BEHAVIORAL|Peer Mentor|comparison of communication training to equal attention control
219267909|NCT04303507|DRUG|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
219267910|NCT04303507|DRUG|Placebo|Placebo
219267911|NCT03898700|BEHAVIORAL|strength based coaching|strength based and solution focused coaching
219267912|NCT04692701|DEVICE|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
219267913|NCT00701909|DRUG|Morphine plus Ketamine|Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV
219267914|NCT00701909|DRUG|Morphine plus Saline (placebo)|Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
219267915|NCT03637413|DIETARY_SUPPLEMENT|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
219267916|NCT00663975|DRUG|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
219267917|NCT00158197|BEHAVIORAL|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
219267918|NCT03023722|DRUG|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
219267919|NCT01629212|DRUG|Tiropramide HCl 100mg|
219267920|NCT01629212|DRUG|Octylonium bromide 20mg|
219267921|NCT02666664|DRUG|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
219267922|NCT02666664|DRUG|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
219267923|NCT02061878|DRUG|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
219267924|NCT02061878|DRUG|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
219267925|NCT00720564|DRUG|arsenic trioxide|
219267926|NCT00720564|DRUG|temozolomide|
219267927|NCT00720564|PROCEDURE|adjuvant therapy|
219267928|NCT00720564|RADIATION|intensity-modulated radiation therapy|
219267929|NCT00720564|RADIATION|radiation therapy|
219267930|NCT00582725|DRUG|R-CHOP+GM-CSF|addition of GM-CSF
219267931|NCT00068432|DRUG|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
219267932|NCT00068432|DRUG|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
219267933|NCT05000632|BEHAVIORAL|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
219267934|NCT05000632|BEHAVIORAL|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
219267935|NCT01053481|DIETARY_SUPPLEMENT|vitamin D|Vitamin D supplement
219267936|NCT01053481|BEHAVIORAL|exercise program (rebounding on a trampoline)|40 days at 30 min/d
219267937|NCT03616964|DRUG|Baricitinib|Administered orally.
219267938|NCT03616964|DRUG|Placebo|Administered orally
219267939|NCT02836288|DRUG|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
219267940|NCT02836288|OTHER|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
219267941|NCT03126071|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
219267942|NCT03126071|DRUG|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
219267943|NCT03126071|DRUG|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
219267944|NCT03126071|DRUG|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
219267945|NCT02867683|OTHER|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
219267946|NCT00971997|DRUG|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
219267947|NCT02425540|DEVICE|Pelvic MRI|
219267948|NCT01385748|DRUG|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
219267949|NCT01385748|DRUG|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
219267950|NCT01385748|DRUG|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
219267951|NCT04520568|COMBINATION_PRODUCT|High flow nasal cannula|using sedation with the HFNC F\&P AIRVOTM 2 to maintain oxygenation
219267952|NCT04520568|COMBINATION_PRODUCT|CONTROL|using general anaesthesia with one lung ventilation (OLV) technique
219267953|NCT00568841|DRUG|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
219267954|NCT00568841|PROCEDURE|FDG-/FLT-PET|
219267955|NCT01450293|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
219267956|NCT01450293|BIOLOGICAL|AdCH63 ME-TRAP, MVA ME-TRAP|5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
219267957|NCT00656201|DRUG|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
219267958|NCT00656201|DRUG|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
219267959|NCT00850122|DRUG|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
219267960|NCT03243240|DIAGNOSTIC_TEST|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
219267961|NCT02022111|BEHAVIORAL|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
219267962|NCT02022111|BEHAVIORAL|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
219267963|NCT02022111|OTHER|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
219267964|NCT02022111|OTHER|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
219267965|NCT02022111|OTHER|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
219267966|NCT01193998|OTHER|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
219267967|NCT01193998|OTHER|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
219267968|NCT02551211|PROCEDURE|blood drawn|blood drawn
219267969|NCT02551211|PROCEDURE|surgical resection of cancer|
219267970|NCT06199154|DRUG|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
219267971|NCT05543239|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes."
219267972|NCT05543239|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)|"Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes."
219267973|NCT01118559|DRUG|YM150|oral
219267974|NCT04644211|DRUG|Ruxolitinib|Pill taken by mouth.
219267975|NCT05875649|COMBINATION_PRODUCT|CLAG|Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
219267976|NCT02434757|DRUG|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
219267977|NCT02147847|BEHAVIORAL|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
219267978|NCT02147847|BEHAVIORAL|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
219267979|NCT05250765|DEVICE|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
219267980|NCT05250765|DEVICE|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
219267981|NCT01266018|DRUG|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
219267982|NCT04183998|OTHER|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
219267983|NCT05801445|BEHAVIORAL|Occupation-based activity|Painting large-scale canvas
219267984|NCT05801445|BEHAVIORAL|Body-Weight Exercise|Body-weight exercises designed for older adults
219267985|NCT03167151|DRUG|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
219267986|NCT06197659|OTHER|Liberal Fluid Grubu|Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
219267987|NCT06197659|OTHER|Restrictive Fluid Group|Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
219267988|NCT00560157|DIETARY_SUPPLEMENT|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
219267989|NCT02165410|PROCEDURE|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
219267990|NCT02165410|PROCEDURE|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
219267991|NCT02165410|PROCEDURE|Resting state MRI|This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.
219267992|NCT02165410|PROCEDURE|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
219267993|NCT02165410|PROCEDURE|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
219267994|NCT02098447|DEVICE|PrimeStim|
219267995|NCT03145012|DRUG|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
219267996|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
219267997|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
219267998|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
219267999|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
219268000|NCT01081847|OTHER|Placebo|PLacebo: Isotonic saline solution
219268001|NCT04955977|OTHER|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
219268002|NCT04955977|OTHER|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
219268003|NCT00709501|BEHAVIORAL|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
219268004|NCT00709501|BEHAVIORAL|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
219268005|NCT02470689|DRUG|Diacerin cream|Diacerin tablet solubule in ultraphil cream
219268006|NCT06957028|OTHER|Diabetes Treatment|"Management will include an unblinded CGM sensor worn 24/7, GDM specific nutrition information, training on using CGM in daily glucose management to achieve euglycemia (maximizing time 63-140 mg/dL \[3.5-7.8 mmol/L\]).~Visits (which could be telehealth) per usual obstetrical care for glycemia management (expected to be about every 4 weeks for most participants) and weekly glycemic management with review of CGM data by site and by central CGM Resource Center for flagged cases.~Participants not receiving glucose lowering medication by 24-28 weeks will undergo OGTT per usual obstetrical management and those with positive OGTT will be treated for GDM per usual clinic routine and continue to wear an unblinded CGM."
219268007|NCT06957028|OTHER|Usual Care Group|"The control group will receive usual obstetrical care at the clinical center. A general pregnancy nutrition information handout will be provided to each participant and a blinded CGM sensor will be placed at routine obstetrical care visits and worn for 10-14 days each time throughout the pregnancy beginning between 18-22 weeks' gestation.~At 18-22 weeks, blinded CGM data will be reviewed to assess if participant has ≥25% time \>140 mg/dL to determine if an early OGTT or glycemic management is required. Site clinicians will be unblinded to the masked CGM data for participants with CGM data ≥25% time \>140 mg/dL and those participants may be treated as those with a positive OGTT.~An OGTT will be performed at \~24-28 weeks per the clinic's usual routine and those with positive OGTT will be treated for GDM per usual clinic routine. If real-time CGM is to be used, then unblinded study CGM sensors can be used instead of blinded sensors for the duration of the study."
219268008|NCT06957691|DRUG|fezolinetant - reference formulation|Daily oral administration of fezolinetant at a dose of 45 mg
219268009|NCT06957691|DRUG|Placebo|Daily oral administration of placebo
219268010|NCT00950196|DRUG|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
219268011|NCT01439386|PROCEDURE|Catheter ablation|PVAI with or without CTI ablation
219268012|NCT01439386|PROCEDURE|Catheter ablation|CTI ablation only
219268013|NCT03984877|DIAGNOSTIC_TEST|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
219268014|NCT02023359|DRUG|Everolimus and exemestane|
219268015|NCT01021709|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
219268016|NCT03037047|DRUG|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
219268017|NCT03037047|DRUG|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
219268018|NCT06776172|PROCEDURE|Extended Pelvic Lymph Node Dissection|Extended pelvic lymph node dissection during radical prostatectomy
219268019|NCT05744102|DIAGNOSTIC_TEST|MRI Image|MRI sequences
219268020|NCT01458522|DRUG|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
219268021|NCT01458522|DRUG|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
219268022|NCT05526365|OTHER|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
219268023|NCT04194047|OTHER|Transfusion|RBC transfusion (1 unit)
219268024|NCT04194047|OTHER|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
219268025|NCT00656032|OTHER|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
219268026|NCT00656032|OTHER|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
219268027|NCT05775159|DRUG|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
219268028|NCT05775159|DRUG|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
219268029|NCT05775159|DRUG|Lenvatinib|Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
219268030|NCT05775159|DRUG|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
219268031|NCT05775159|DRUG|Gemcitabine|1000 mg/m2, IV infusion
219268032|NCT05775159|DRUG|Cisplatin|25 mg/m2, IV infusion
219268033|NCT02684123|DRUG|Apremilast|Subjects will get drug or placebo
219268034|NCT02684123|DRUG|Placebo|
219268035|NCT00513201|DRUG|lyspro|
219268036|NCT00513201|DRUG|regular insulin|
219268037|NCT00516139|DRUG|Lamotrigine|Open-label
219268038|NCT00466609|DRUG|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
219268039|NCT00466609|DRUG|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
219268040|NCT00466609|DRUG|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
219268041|NCT02638688|OTHER|ultrasound|
219268042|NCT02755701|DRUG|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
219268043|NCT02755701|DRUG|Placebo|Placebo will be administered in the same way
219268044|NCT04770870|DEVICE|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
219268045|NCT01052363|DRUG|Bevacizumab, CA4P|
219268046|NCT00517036|DIETARY_SUPPLEMENT|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
219268047|NCT00517036|DIETARY_SUPPLEMENT|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
219268048|NCT00517036|DIETARY_SUPPLEMENT|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
219268049|NCT00990951|DRUG|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
219268050|NCT00676104|DEVICE|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
219268051|NCT00942747|DRUG|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
219268052|NCT02594449|DRUG|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
219268053|NCT04840342|DRUG|Eplerenone|Dose escalations of eplerenone 50, 100, or 200mg
219268054|NCT04840342|DRUG|Amlodipine|Dose escalations of amlodipine 2.5, 5, or 10mg
219268055|NCT06164535|DRUG|Control group|35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
219268056|NCT06164535|DRUG|DPP-4 inhibitor group|35 T2DM patients will be given DPP-4 I once or twice daily
219268057|NCT06164535|DRUG|DPP-4 inhibitor + metformin group|35 T2DM patients will be given DPP-4 I + metformin once or twice daily
219268058|NCT00286988|DRUG|Topiramate|
219268059|NCT04367480|DEVICE|Placebo Administration|Wear placebo TENS device
219268060|NCT04367480|OTHER|Questionnaire Administration|Ancillary studies
219268061|NCT04367480|DEVICE|Transcutaneous Electrical Nerve Stimulation|Wear active TENS device
219268062|NCT03687008|BEHAVIORAL|Cognitive Computer Based Intervention|25 sessions \[each 30-45 minutes, 5 days a week / for 5 weeks\], supervised by trained coaches
219268063|NCT01156740|DRUG|Penicillin G, Benzathine|IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg)
219268064|NCT01156740|DRUG|Amoxicillin|750 mg/QD
219268065|NCT03034850|PROCEDURE|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size \> 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
219268066|NCT03503929|DEVICE|LaparoGuard System|Adjunctive safety system for laparoscopic surgery
219268067|NCT03651557|DRUG|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
219268068|NCT03651557|DRUG|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
219268069|NCT03651557|DRUG|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
219268070|NCT00068172|DRUG|PI-88|
219268071|NCT00749697|OTHER|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
219268072|NCT03549091|DIAGNOSTIC_TEST|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
219268073|NCT03549091|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
219268074|NCT06956859|BEHAVIORAL|Paternal Skin to skin applicated to newborns|Paternal Skin to skin applicated to newbornsin the intervention group for 45 minutes. Routine care will be applied to the newborns in the control group. Father Descriptive Information Form, Newborn Descriptive Information Form, Skin-to-Skin Contact Monitoring Form (Newborn/Father), Newborn Comfort
219268075|NCT04290377|DEVICE|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
219268076|NCT04290377|OTHER|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
219268077|NCT06391736|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
219268078|NCT02731911|DRUG|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
219268079|NCT01458925|DEVICE|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
219268080|NCT05728190|OTHER|steril/salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose. Green food coloring was added (one drop of food coloring to 5 ml of sterile/saline water) to make sterile/saline water similar to lavender oil.
219268081|NCT05728190|OTHER|Lavender essential oil|Five days seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
219268082|NCT01954433|PROCEDURE|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
219268083|NCT01954433|PROCEDURE|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
219268084|NCT01954433|PROCEDURE|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~1. RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~2. RISA with FCR-Ligament modified according to Weilby~3. RISA with APL-Ligament (abductor pollicis longus ligament)~4. RISA with Graftjacket modified according to Weilby~5. Resection arthroplasty"
219268085|NCT05921669|BEHAVIORAL|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
219268086|NCT04697953|DRUG|brolucizumab|Pre-filled Syringes for intravitreal injection
219268087|NCT00420875|DEVICE|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
219268088|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
219268089|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
219268090|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
219268091|NCT01648153|OTHER|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
219268092|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
219268093|NCT03419676|DEVICE|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
219268094|NCT04799769|DEVICE|Percutaneous arterial closure device|Large hole percutaneous arterial closure device
219268095|NCT05425407|DIETARY_SUPPLEMENT|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
219268096|NCT05425407|DIETARY_SUPPLEMENT|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
219268097|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
219268098|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
219268099|NCT03963427|PROCEDURE|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
219268100|NCT00915083|DRUG|Amrubicin|40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
219268101|NCT01642147|DEVICE|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
219268102|NCT01642147|PROCEDURE|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
219268103|NCT01642147|PROCEDURE|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
219268104|NCT01642147|PROCEDURE|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
219268105|NCT01642147|PROCEDURE|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
219268106|NCT00579709|BIOLOGICAL|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell \>4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
219268107|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
219268108|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
219268109|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
219268110|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
219268111|NCT05492968|DRUG|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
219268112|NCT05492968|DRUG|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
219268113|NCT05492968|DRUG|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
219268114|NCT01636583|DEVICE|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
219268115|NCT01636583|DEVICE|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
219268116|NCT01636583|OTHER|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
219268117|NCT03040245|BEHAVIORAL|Whiplash book|
219268118|NCT01542346|PROCEDURE|subcutaneous adaption|
219268119|NCT01852032|RADIATION|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
219268120|NCT01852032|RADIATION|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
219268121|NCT05036954|DEVICE|EyeBrid Excel hybrid lenses|new lenses
219268122|NCT05679999|DIAGNOSTIC_TEST|CIMT (Carotid artery intima media thickness measurement)|Carotid artery intima media thickness measurement with ultrasound
219268123|NCT04962451|DRUG|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
219268124|NCT04962451|DRUG|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
219268125|NCT01275599|DRUG|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
219268126|NCT01275599|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
219268127|NCT01979263|OTHER|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
219268128|NCT01979263|OTHER|Placebo Computer Task|Computer task that does not actively modify attention bias
219268129|NCT04540445|OTHER|Pupillary Assessment|Pupillary assessment with handheld pupillometer
219268130|NCT06450236|DRUG|Perampanel 10 MG|1 tablet of Perampanel Tablets 10mg
219268131|NCT06450236|DRUG|Fycompa 10Mg Tablet|1 tablet of Perampanel Tablets 10mg
219268132|NCT04351269|DEVICE|CanGaroo Envelope|CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
219268133|NCT04351269|DEVICE|TYRX Envelope|TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
219268134|NCT05452551|OTHER|Myotonometric measurement|MyotonPRO is a non-invasive myotonometer used to evaluate the viscoelastic properties of soft tissues. Data collection will be carried out by three researchers experienced in the use of myotonometer. Before the evaluations, participant and repeated measurement information for both researchers will be recorded on the device. All assessments will be made bilaterally. The first researcher will perform two measurements 30 minutes apart from the measurement point standardized with MyotonPRO to evaluate the plantar mechanical properties. Then, the second researcher will take two measurements with MyotonPRO from the same point with 30 minutes intervals. One day later, the first researcher will measure again from the same reference point once.
219268135|NCT02838537|DRUG|Exposure to Triptan|
219268136|NCT02838537|DRUG|Exposure to Ergot|
219268137|NCT05141396|OTHER|Telehealth- enabled support for SAT/SBT adherence|Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
219268138|NCT05141396|OTHER|Usual audit and feedback for SAT/SBT adherence|Usual audit and feedback
219268139|NCT00535938|OTHER|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
219268140|NCT04154969|OTHER|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
219268141|NCT04154969|OTHER|conventional Physiotherapy|conventional Physiotherapy
219268142|NCT03598699|DRUG|AXR-159|AXR-159 Ophthalmic Solution
219268143|NCT03598699|DRUG|Vehicle|AXR-159 Ophthalmic Solution Vehicle
219268144|NCT00393653|PROCEDURE|N-of-1 prescription method|
219268145|NCT04412083|BEHAVIORAL|PPA Tele-Savvy Pilot Intervention|We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
219268146|NCT05802927|OTHER|DSF|Diabetes-specific formula
219268147|NCT05802927|OTHER|Breakfast 1|Noodle Soup
219268148|NCT05802927|OTHER|Breakfast 2|Glutinous rice
219268149|NCT05893589|OTHER|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
219268150|NCT02422732|OTHER|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
219268151|NCT02422732|RADIATION|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
219268152|NCT02422732|GENETIC|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
219268153|NCT01543022|DEVICE|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
219268154|NCT01543022|PROCEDURE|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
219268155|NCT00912210|DIETARY_SUPPLEMENT|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
219268156|NCT00912210|DIETARY_SUPPLEMENT|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
219268157|NCT04812743|BEHAVIORAL|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
219268158|NCT04061135|PROCEDURE|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
219268159|NCT01216072|DRUG|Fingolimod|0.5 mg/day oral capsule
219268160|NCT01216072|DRUG|Standard MS DMTs|
219268161|NCT04175561|OTHER|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
219268162|NCT02440334|DRUG|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
219268163|NCT05856136|DRUG|Fentanyl Injection|Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
219268164|NCT05567757|BIOLOGICAL|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
219268165|NCT05289661|DRUG|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
219268166|NCT05289661|DRUG|Topical Placebo|topical Placebo
219268167|NCT05425264|OTHER|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
219268168|NCT02357602|DRUG|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
219268169|NCT05411263|DIAGNOSTIC_TEST|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
219268170|NCT01785147|DRUG|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
219268171|NCT01785147|DRUG|Placebo|
219268172|NCT04611347|DRUG|CBD|Topical CBD application for thumb basal joint osteoarthritis.
219268173|NCT04611347|DRUG|Shea Butter|Placebo Shae Butter for comparison
219268174|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
219268175|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
219268176|NCT01184534|BEHAVIORAL|Video|5 minute multimedia presentation (video)
219268177|NCT01184534|BEHAVIORAL|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
219268178|NCT06043453|OTHER|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
219268179|NCT05860569|GENETIC|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
219268180|NCT03656276|BEHAVIORAL|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
219268181|NCT05398549|OTHER|Conventional Physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise
219268182|NCT05398549|OTHER|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
219268183|NCT01028872|DEVICE|Intraocular lens|
219268184|NCT01028872|DEVICE|Intraocular lens|
219268185|NCT01028872|DEVICE|Intraocular lens|
219268186|NCT01612273|DRUG|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
219268187|NCT01612273|DRUG|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
219268188|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
219268189|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
219268190|NCT01309477|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
219268191|NCT02518815|DEVICE|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
219268192|NCT00251056|DRUG|mannitol|120mg BD
219268193|NCT00251056|DRUG|mannitol|40 mg BD
219268194|NCT00251056|DRUG|mannitol|240mg BD
219268195|NCT00251056|DRUG|mannitol|400mg BD
219268196|NCT01910883|DRUG|Finafloxacin i.v. solution 200 mg|
219268197|NCT01910883|DRUG|Finafloxacin i.v. solution 400 mg|
219268198|NCT01910883|DRUG|Finafloxacin i.v. solution 600 mg|
219268199|NCT01910883|DRUG|Finafloxacin i.v. solution 800 mg|
219268200|NCT01910883|DRUG|Finafloxacin i.v. solution 1000 mg|
219268201|NCT01910883|DRUG|Placebo i.v. solution|
219268202|NCT00822770|DRUG|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
219268203|NCT00822770|DRUG|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
219268204|NCT00822770|DRUG|Fludarabine|Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
219268205|NCT00822770|DRUG|Busulfan|Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.
219268206|NCT00822770|PROCEDURE|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
219268207|NCT00822770|DRUG|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
219268208|NCT00930345|DRUG|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
219268209|NCT00051623|DRUG|Infliximab|
219268210|NCT01975298|DRUG|Laquinimod|Oral Administration
219268211|NCT01975298|DRUG|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
219268212|NCT05140083|DRUG|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
219268213|NCT02818998|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
219268214|NCT06499662|OTHER|Vagus Nerve Neurodynamics|This intervention involves passive cervical movements designed to enhance vagus nerve functionality.
219268215|NCT06499662|OTHER|Guided Breathing|This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.
219268216|NCT06499662|OTHER|Manual Therapy|This intervention includes suboccipital inhibition techniques applied during the session.
219268217|NCT04787432|BEHAVIORAL|Salutogenic Frailty Prevention Program|"Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources."
219268218|NCT05069298|DIETARY_SUPPLEMENT|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
219268219|NCT02444468|DEVICE|Flowtron ACS800|Flowtron ACS800 and bandage
219268220|NCT02444468|OTHER|Bandage|Bandage only
219268221|NCT04560478|DEVICE|Pro Seal Sealant|Sealant was reapplied every 3 months
219268222|NCT04560478|DEVICE|MI Varnish|Fluoride varnish was applied every 4-6 weeks
219268223|NCT00480064|DRUG|Lomustine, intermediate dose cytarabine|
219268224|NCT00004254|DRUG|raltitrexed|
219268225|NCT01101061|DRUG|Romosozumab|Administered by subcutaneous injection
219268226|NCT01101061|DRUG|Placebo|Administered by subcutaneous injection
219268227|NCT06478901|DEVICE|Echocardiography|Echocardiography assited by Artificial intelligence
219268228|NCT05043883|DEVICE|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
219268229|NCT03181906|OTHER|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
219268230|NCT01041768|PROCEDURE|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
219268231|NCT02033473|DRUG|Apelin|An apelin clamp in which an apelin infusion will be administered
219268232|NCT02033473|DRUG|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
219268233|NCT03598881|OTHER|Treatment|
219268234|NCT05002530|DRUG|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219268235|NCT05002530|DRUG|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
219268236|NCT05002530|OTHER|Standard therapy|Standard therapy
219268237|NCT04532762|DEVICE|nasal spray|Application of a nasal spray
219268238|NCT00299598|DEVICE|alkylated polyethylenimine nanoparticles antibacterial evaluation|
219268239|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
219268240|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
219268241|NCT05744583|OTHER|Packed red cell transfusion|Type O RhD negative packed red cell transfusion during prehospital emergency care
219268242|NCT05744583|OTHER|Whole blood transfusion|Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
219268243|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
219268244|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
219268245|NCT03886597|OTHER|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
219268246|NCT02164006|DRUG|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
219268247|NCT01530386|DRUG|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
219268248|NCT02425241|BIOLOGICAL|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
219268249|NCT02425241|BIOLOGICAL|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
219268250|NCT02425241|BIOLOGICAL|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10\^8 pfu at week 20
219268251|NCT02425241|DRUG|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
219268252|NCT02425241|OTHER|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
219268253|NCT02049515|DRUG|IPI-145|PI3K Inhibitor
219268254|NCT02049515|DRUG|Ofatumumab|Monoclonal antibody
219268255|NCT02100683|DEVICE|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
219268256|NCT06248112|DRUG|Sacubitril and Valsartan-Test product|Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
219268257|NCT06248112|DRUG|Sacubitril and Valsartan-Reference product|Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
219268258|NCT01308268|DRUG|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (\>= 2 years old) single dose, PO
219268259|NCT01363310|DRUG|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
219268260|NCT01363310|DRUG|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
219268261|NCT05394090|DIAGNOSTIC_TEST|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
219268262|NCT01640171|PROCEDURE|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
219268263|NCT01640171|DRUG|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
219268264|NCT01640171|DRUG|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
219268265|NCT01640171|DRUG|Acuvail|Anti-inflammatory drop given after treatment
219268266|NCT01640171|DRUG|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
219268267|NCT02577588|BIOLOGICAL|re-activated T cells|autologous reactivated T cells against p53
219268268|NCT02444728|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
219268269|NCT02444728|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
219268270|NCT02444728|DRUG|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
219268271|NCT02444728|DRUG|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
219268272|NCT05575570|DEVICE|EVAR|EVAR stent graft and embolization material CE marked.
219268273|NCT01586975|DRUG|Clopidogrel|Clopidogrel 75 mg QD
219268274|NCT01586975|DRUG|Aspirin 81 mg|Aspirin 81mg QD
219268275|NCT01586975|DRUG|Aspirin >300 mg|Aspirin \>300 mg QD
219268276|NCT05749861|DRUG|CKD-348(5)|QD, PO
219268277|NCT05749861|DRUG|CKD-828, D097, D337|QD, PO
219268278|NCT05482490|PROCEDURE|Maintenance protocol for the hygiene of implant supported prosthesis|Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
219268279|NCT04376112|OTHER|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
219268280|NCT04376112|OTHER|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
219268281|NCT04648098|OTHER|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
219268282|NCT00754598|DEVICE|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
219268283|NCT00224029|DRUG|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
219268284|NCT03357978|DIAGNOSTIC_TEST|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
219268285|NCT03357978|DIAGNOSTIC_TEST|blood draw|Blood samples are taken from sober patients
219268286|NCT03357978|DIAGNOSTIC_TEST|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
219268287|NCT03357978|DIAGNOSTIC_TEST|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
219268288|NCT03357978|DIAGNOSTIC_TEST|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
219268289|NCT01793077|DRUG|Depo-Eligard®|Subcutaneous
219268290|NCT02051569|DIETARY_SUPPLEMENT|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
219268291|NCT02316262|PROCEDURE|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
219268292|NCT04295330|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
219268293|NCT04295330|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
219268294|NCT05364034|OTHER|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
219268295|NCT05480462|BIOLOGICAL|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
219268296|NCT05480462|BIOLOGICAL|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
219268297|NCT04470869|OTHER|Phone call|The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
219268298|NCT05088109|DIAGNOSTIC_TEST|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
219268299|NCT04539067|DRUG|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
219268300|NCT00394420|BEHAVIORAL|Telephone Quitline|
219268301|NCT05414383|DEVICE|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
219268302|NCT02276534|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention.
219268303|NCT02276534|BEHAVIORAL|Delayed Intervention|
219268304|NCT06061380|OTHER|no intervation taken|
219268305|NCT05703152|OTHER|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
219268306|NCT00532246|DRUG|raloxifene|
219268307|NCT00532246|DRUG|Placebo|
219268308|NCT04799847|DRUG|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
219268309|NCT00752245|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
219268310|NCT00752245|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
219268311|NCT00752245|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
219268312|NCT04964895|OTHER|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
219268313|NCT01210378|DRUG|Nitroglycerin patch|Nitroglycerin patch
219268314|NCT05005299|DRUG|Venetoclax|Venetoclax is administered as an oral tablet once daily.
219268315|NCT05005299|DRUG|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
219268316|NCT05005299|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
219268317|NCT01498562|DRUG|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
219268318|NCT01498562|DRUG|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
219268319|NCT06314139|DEVICE|continuous theta-burst stimulation (cTBS)|Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
219268320|NCT04912713|OTHER|Stress group|This group will perform the MAST stress protocol
219268321|NCT04912713|OTHER|Control group|This group will perform the MAST control protocol
219268322|NCT01407276|DRUG|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
219268323|NCT06420050|BEHAVIORAL|Instagram Intervention|The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
219268324|NCT03035110|BEHAVIORAL|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
219268325|NCT04171349|DRUG|Articaine|Vial
219268326|NCT04171349|DRUG|Dexmedetomidine|Vial
219268327|NCT04302129|PROCEDURE|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
219268328|NCT04302129|DRUG|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
219268329|NCT04695704|DRUG|Montelukast|10 mg oral montelukast once daily for 28 days
219268330|NCT04695704|OTHER|placebo|10 mg oral placebo once daily for 28 days
219268331|NCT00296010|DRUG|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
219268332|NCT00296010|DRUG|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
219268333|NCT00296010|DRUG|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
219268334|NCT00296010|PROCEDURE|adjuvant therapy|
219268335|NCT00296010|RADIATION|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
219268336|NCT04073797|DRUG|Inclisiran|Inclisiran 284 mg, one injection
219268337|NCT04073797|DIAGNOSTIC_TEST|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
219268338|NCT04073797|DRUG|Colchicine|Colchicine 500 mcg tablet once daily
219268339|NCT04762303|OTHER|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
219268340|NCT05979428|DRUG|NNC0491-6075|NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
219268341|NCT05979428|DRUG|Placebo|Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
219268342|NCT00184379|BEHAVIORAL|Psychoeducation|Structured disorder-related educational program for relatives
219268343|NCT00778921|DRUG|Amlodipine 10 mg|Amlodipine 10 mg
219268344|NCT00778921|DRUG|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
219268345|NCT00778921|DRUG|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
219268346|NCT04805073|DRUG|Promethazine|1cc 25mg/ml Promethazine (study medication)
219268347|NCT04805073|DRUG|Placebo|1cc 0.9% Sodium Chloride (placebo)
219268348|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).
219268349|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).
219268350|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
219268351|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
219268352|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
219268353|NCT00133575|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
219268354|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
219268355|NCT04583644|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
219268356|NCT04434001|DRUG|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
219268357|NCT04434001|DRUG|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
219268358|NCT04434001|BIOLOGICAL|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
219268359|NCT05260099|DEVICE|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
219268360|NCT01174264|OTHER|Pharmacological Study|Correlative studies
219268361|NCT01174264|DRUG|Vismodegib|Given PO
219268362|NCT00675584|DRUG|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
219268363|NCT00675584|DRUG|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
219268364|NCT02872389|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
219268365|NCT02872389|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
219268366|NCT01298882|DRUG|Diacerein|
219268367|NCT01298882|OTHER|Placebo|
219268368|NCT00541905|DRUG|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
219268369|NCT00358007|DEVICE|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
219268370|NCT04237285|OTHER|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
219268371|NCT03376750|BEHAVIORAL|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
219268372|NCT00470028|DEVICE|Transcranial Magnetic Stimulation|
219268373|NCT02058836|DRUG|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
219268374|NCT02058836|PROCEDURE|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
219268375|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
219268376|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
219268377|NCT02903303|OTHER|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
219268378|NCT04902469|BEHAVIORAL|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
219268379|NCT04902469|BEHAVIORAL|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
219268380|NCT02802397|OTHER|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
219268381|NCT01508338|DIETARY_SUPPLEMENT|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
219268382|NCT01508338|DIETARY_SUPPLEMENT|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
219268383|NCT01508338|DIETARY_SUPPLEMENT|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
219268384|NCT01508338|DIETARY_SUPPLEMENT|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
219268385|NCT01115608|OTHER|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
219268386|NCT00843427|BEHAVIORAL|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
219268387|NCT04201899|DIETARY_SUPPLEMENT|No intervention - pure observation|Phosphate administration (yes or no)
219268388|NCT04767724|DEVICE|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
219268389|NCT03798873|DEVICE|FeelWell™ Compression garment|"Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back."
219268390|NCT03798873|BEHAVIORAL|Increase Mobility|Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
219268391|NCT00547534|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4, 8, 11
219268392|NCT00547534|DRUG|bendamustine|90 mg/m\^2 days 1 and 4
219268393|NCT00547534|DRUG|rituximab|375 mg/m\^2 day 1
219268394|NCT04330651|PROCEDURE|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
219268395|NCT03747887|BEHAVIORAL|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
219268396|NCT03747887|OTHER|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
219268397|NCT05668299|DEVICE|TrachFlush|See detailed description previously entered.
219268398|NCT00164268|BEHAVIORAL|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
219268399|NCT01303250|DRUG|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
219268400|NCT01303250|DRUG|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
219268401|NCT01348152|DRUG|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
219268402|NCT01348152|DRUG|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
219268403|NCT02286453|DRUG|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
219268404|NCT02286453|DRUG|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
219268405|NCT00861822|OTHER|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
219268406|NCT02891642|DEVICE|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
219268407|NCT02111863|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
219268408|NCT02111863|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
219268409|NCT02111863|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
219268410|NCT02111863|BIOLOGICAL|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
219268411|NCT04402697|OTHER|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
219268412|NCT00569543|OTHER|high performance liquid chromatography|urine analysis
219268413|NCT00569543|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
219268414|NCT00569543|OTHER|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
219268415|NCT00569543|OTHER|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
219268416|NCT05515783|DRUG|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
219268417|NCT05515783|DRUG|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
219268418|NCT03879174|DRUG|Pembrolizumab + Tamoxifen|"The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage."
219268419|NCT04121780|BIOLOGICAL|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
219268420|NCT04121780|OTHER|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
219268421|NCT01044992|RADIATION|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
219268422|NCT01044992|DRUG|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
219268423|NCT05295394|DRUG|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
219268424|NCT01807429|DRUG|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
219268425|NCT01807429|DRUG|Morphine|morphine 0.05 mg/kg
219268426|NCT02737423|DRUG|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
219268427|NCT04321122|PROCEDURE|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
219268428|NCT02688530|DRUG|IV Saline|
219268429|NCT02688530|DRUG|IV Dexamethasone 4mg|
219268430|NCT02688530|DRUG|IV Dexamethasone 6mg|
219268431|NCT02688530|DRUG|IV Dexamethasone 8mg|
219268432|NCT01919515|DEVICE|ZR Crown|This is an esthetic primary molar crown.
219268433|NCT01919515|DEVICE|Stainless Steel Crown|This is a conventional stainless steel crown.
219268434|NCT00001107|DRUG|Fluconazole|
219268435|NCT00001107|DRUG|AmBisome|
219268436|NCT02897999|BIOLOGICAL|QBKPN|QBKPN Site Specific Immunomodulators
219268437|NCT02897999|OTHER|Placebo|Placebo
219268438|NCT06430671|DRUG|CLS12311 low|Peptide-coupled Red Blood Cells (RBCs)
219268439|NCT06430671|DRUG|CLS12311 medium|Peptide-coupled Red Blood Cells (RBCs)
219268440|NCT06430671|DRUG|CLS12311 high|Peptide-coupled Red Blood Cells (RBCs)
219268441|NCT06430671|DRUG|uncoupled RBCs|autologous Red Blood Cells (RBCs)
219268442|NCT04364685|OTHER|Walking on soft-sand|The participants are required to walking on sand for 30 minutes. Walking is self-paced.
219268443|NCT04364685|OTHER|Walking on Levelled Surface|The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
219268444|NCT05470361|PROCEDURE|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
219268445|NCT02621554|DIETARY_SUPPLEMENT|resveratrol supplementation|6 months of resveratrol supplementation
219268446|NCT02621554|DIETARY_SUPPLEMENT|Placebo|6 months of placebo intake
219268447|NCT01867970|DEVICE|Tool|"The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
219268448|NCT01867970|BEHAVIORAL|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
219268449|NCT00571896|DRUG|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
219268450|NCT00571896|DRUG|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
219268451|NCT00115336|DRUG|Intravenous Ketorolac|Intravenous ketorolac
219268452|NCT00115336|DRUG|Ibuprofen|Ibuprofen, taken orally
219268453|NCT02526186|DEVICE|Battlefield Auricular Acupuncture|
219268454|NCT04115267|RADIATION|Radiotherapy|Combined modality
219268455|NCT00841230|DRUG|Deanxit|Deanxit 1x/day
219268456|NCT00841230|DRUG|Lactose placebo|Lactose used as placebo
219268457|NCT01696786|PROCEDURE|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
219268458|NCT04877613|DRUG|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
219268459|NCT04877613|DRUG|Fludarabine|Lymphodepletion
219268460|NCT04877613|DRUG|Cyclophosphamide|Lymphodepletion
219268461|NCT03960853|PROCEDURE|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
219268462|NCT03960853|PROCEDURE|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
219268463|NCT03851835|DRUG|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
219268464|NCT03851835|DRUG|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24-hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
219268465|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
219268466|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
219268467|NCT03059004|BEHAVIORAL|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
219268468|NCT03059004|BEHAVIORAL|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
219268469|NCT03059004|BEHAVIORAL|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
219268470|NCT03059004|BEHAVIORAL|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
219268471|NCT05901987|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
219268472|NCT04199052|BEHAVIORAL|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
219268473|NCT06944886|OTHER|Active Static Stretching Exercise Combined with Breathing Exercise (Experimental Group)|"Participants in the intervention group performed active static stretching exercises using a pictorial exercise booklet. The booklet contained a series of self-directed stretching postures targeting major muscle groups. Each stretch was held in a static position without external assistance, encouraging the participant to engage and maintain the stretch voluntarily.~Each stretch was held for 30 seconds and repeated 3 times per muscle group. The targeted areas included the hamstrings, quadriceps, calves, hip flexors, and shoulders."
219268474|NCT02689947|DEVICE|Restylane Silk|
219268475|NCT04959526|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
219268476|NCT06839196|OTHER|VR and first aid training|"Intervention Stages:~Stage 1: Descriptive Information Form and the Home Accident Awareness Questionnaire for Parents of Children with Special Needs will be administered to the parents as pre-tests.~Stage 2: A total of 100 parents will participate in the virtual reality simulation scenarios, organized into four separate groups of 25 for implementation.~Stage 3: Balance assessments for children will be conducted using the Children's Balance Assessment Form, the Tinetti Balance and Gait Assessment, and the Nintendo Wii Fit Balance Board.~Stage 4: Each group of 25 participants will receive hands-on training at three different stations focusing on basic first aid and home accidents, delivered by nurses, and transfer training provided by physiotherapists.~Stage 5: Post-tests will be administered to the parents using the Home Accident Awareness Questionnaire for Parents of Children with Special Needs."
219268477|NCT00815919|DRUG|bortezomib|Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
219268478|NCT00815919|DRUG|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
219268479|NCT05520723|DRUG|Sacituzumab govitecan|"Upon meeting all selection criteria, patients enrolled in the single-arm study will receive the combination of: sacituzumab govitecan and prophylaxis (loperamide and G-CSF).~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle . This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision."
219268480|NCT05520723|DRUG|Loperamide|Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
219268481|NCT05520723|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
219268482|NCT03833804|OTHER|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
219268483|NCT02854397|OTHER|blood sample|
219268484|NCT01951521|RADIATION|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
219268485|NCT01700283|BEHAVIORAL|exercise education and walking program|12-week moderate intensity walking program
219268486|NCT00910260|PROCEDURE|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
219268487|NCT01527162|DEVICE|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
219268488|NCT01527162|OTHER|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
219268489|NCT01287845|DRUG|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
219268490|NCT01287845|DRUG|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
219268491|NCT04147559|DEVICE|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
219268492|NCT00231764|DRUG|daclizumab|
219268493|NCT03542162|BIOLOGICAL|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
219268494|NCT04599907|DEVICE|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
219268495|NCT04599907|DEVICE|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
219268496|NCT04599907|DEVICE|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
219268497|NCT06547047|BEHAVIORAL|Speed, Agility, and Quickness (SAQ) Training|The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.
219268498|NCT06547047|BEHAVIORAL|Regular Training|Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
219268499|NCT03635736|OTHER|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
219268500|NCT04585100|DRUG|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
219268501|NCT04585100|DRUG|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
219268502|NCT04585100|DRUG|Placebo|Placebo BID for 28 days
219268503|NCT04585100|DRUG|FM101 150 mg|FM101 (150 mg) BID for 28 days
219268504|NCT04585100|DRUG|FM101 300 mg|FM101 (300 mg) BID for 28 days
219268505|NCT00370643|DRUG|human regular insulin|
219268506|NCT03192969|DRUG|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
219268507|NCT03192969|OTHER|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
219268508|NCT03192969|DRUG|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
219268509|NCT05196880|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
219268510|NCT05774041|DEVICE|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
219268511|NCT04431219|BIOLOGICAL|LIS1|LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
219268512|NCT03780010|DRUG|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
219268513|NCT01466790|DRUG|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
219268514|NCT01466790|DRUG|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
219268515|NCT01466790|DRUG|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
219268516|NCT00311246|DRUG|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
219268517|NCT03557242|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
219268518|NCT03557242|OTHER|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
219268519|NCT03557242|OTHER|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
219268520|NCT00495092|DRUG|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
219268521|NCT00495092|DRUG|Biperiden|Biperiden 2-4 mg/d p.o.
219268522|NCT00495092|DRUG|Placebo|Placebo + Placebo
219268523|NCT04172012|BIOLOGICAL|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
219268524|NCT04172012|OTHER|Placebo|Placebo mixture
219268525|NCT01888809|BEHAVIORAL|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
219268526|NCT01888809|BEHAVIORAL|Screening and referral|
219268527|NCT03638921|DRUG|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
219268528|NCT03753243|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
219268529|NCT03753243|DRUG|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
219268530|NCT01251887|DIETARY_SUPPLEMENT|Linoleic Acid|
219268531|NCT01251887|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|
219268532|NCT01251887|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|
219268533|NCT05858398|BIOLOGICAL|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
219268534|NCT02275299|DRUG|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
219268535|NCT02275299|DRUG|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
219268536|NCT02275299|DRUG|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
219268537|NCT02324478|PROCEDURE|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
219268538|NCT06577649|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)
219268539|NCT06577649|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
219268540|NCT05488119|BEHAVIORAL|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
219268541|NCT00915785|DRUG|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
219268542|NCT04823117|OTHER|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
219268543|NCT06297031|OTHER|heat application|• Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
219268544|NCT03668223|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
219268545|NCT01103232|PROCEDURE|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
219268546|NCT01103232|PROCEDURE|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
219268547|NCT05742568|DRUG|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
219268548|NCT05742568|DRUG|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
219268549|NCT05742568|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
219268550|NCT05742568|DRUG|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
219268551|NCT05742568|DRUG|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
219268552|NCT05742568|DRUG|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
219268553|NCT04938934|BEHAVIORAL|Lipids infusion|Lipids infusion via intestinal tube
219268554|NCT04938934|BEHAVIORAL|Sham infusion|Sham infusion via intestinal tube
219268555|NCT03115671|DIETARY_SUPPLEMENT|Vayarin|Vayarin capsule
219268556|NCT04156893|BIOLOGICAL|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
219268557|NCT05900986|DRUG|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
219268558|NCT05900986|DRUG|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
219268559|NCT05900986|DRUG|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
219268560|NCT05900986|DRUG|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
219268561|NCT04498754|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
219268562|NCT04498754|BEHAVIORAL|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
219268563|NCT01793662|PROCEDURE|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
219268564|NCT06022055|OTHER|Blood and tissue collection|"Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research."
219268565|NCT03371147|OTHER|CancerLife|CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
219268568|NCT03243097|DEVICE|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
219268569|NCT03243097|DEVICE|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
219268570|NCT03243097|DEVICE|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
219268571|NCT00616824|PROCEDURE|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
219268572|NCT00616824|PROCEDURE|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
219268573|NCT00979186|DEVICE|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
219268574|NCT00307047|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219268575|NCT00307047|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219268576|NCT00855790|OTHER|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
219268577|NCT04445298|DIAGNOSTIC_TEST|Transepidermal water loss|We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
219268578|NCT04445298|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
219268579|NCT04445298|DIAGNOSTIC_TEST|Blood draw|We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
219268580|NCT04445298|DIAGNOSTIC_TEST|Bacterial PCR swab|Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
219268581|NCT06282211|DRUG|Ondansetron Oral Soluble Pellicles|patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.
219268582|NCT01726569|BEHAVIORAL|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
219268583|NCT01726569|OTHER|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
219268584|NCT02104505|DRUG|Gamma Tocopherol 700 mg capsules,|2 capsules daily
219268585|NCT02104505|DRUG|Placebo|Safflower oil capsules
219268586|NCT00170274|DEVICE|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
219268587|NCT00170274|DEVICE|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
219268588|NCT02665585|PROCEDURE|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
219268589|NCT02448498|BEHAVIORAL|Exercise Intervention|
219268590|NCT04928807|COMBINATION_PRODUCT|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
219268591|NCT02155049|DRUG|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
219268592|NCT04470661|DIAGNOSTIC_TEST|Ultrasonography|"Point-of-care ultrasound:~1. Kidney length and echogenity,~2. Bladder scanning~3. VCI measures~4. Lung B lines and effusion~5. Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
219268593|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
219268594|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
219268595|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
219268596|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
219268597|NCT05203705|DRUG|Enoxaparin|Enoxaparin, for 12 days
219268598|NCT04066517|PROCEDURE|SBRT|Multimodal-imaging guided SBRT for VT ablation.
219268599|NCT04533009|PROCEDURE|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
219268600|NCT05244369|OTHER|Only TENS|Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump
219268601|NCT05244369|PROCEDURE|Acupuncture+TENS|acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
219268602|NCT06252012|BEHAVIORAL|Mobile application|The mobile application will be designed as a health assistant for women aged between 30-65 to encourage healthy choices and positively develop their behaviors regarding the prevention of cancer. Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study
219268603|NCT03752177|DRUG|LY3415244|Administered IV
219268604|NCT00589303|DRUG|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone"
219268605|NCT00589303|DEVICE|AV Node ablation and device implant|"Pacing Systems:~* Enpusle Premarket Approval Number (PMA#) P980035~* EnRhythm PMA# P980035~* Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~\- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~* EnTrust PMA# P980016~* Virtuoso PMA# P980016~ICD CRT Pacing Systems:~* InSync Maximo PMA# P980016~* InSync Sentry PMA# P890003~* Concerto PMA# P980016"
219268606|NCT06292390|OTHER|Pet Therapy|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy.
219268607|NCT05015582|DEVICE|Pre op upper body forced air warming (32˚C)|Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
219268608|NCT05015582|DEVICE|Pre op lower body forced air warming (32˚C)|lower body forced air warming at ambient (32˚C) for at least 30 minutes
219268609|NCT05015582|DEVICE|Pre op fluids (45˚C)|fluids from warmed cabinet set at 45˚C
219268610|NCT05015582|DEVICE|Intra op upper body forced air warming (32˚C)|Use of upper body forced air warming intra-operative at ambient (32˚C)
219268611|NCT05015582|DEVICE|Intra op fluids at room temperature|IV fluids at room temperature
219268612|NCT05015582|DEVICE|Intra op upper body forced air warming at (32˚C)|upper body forced air warming intra-operative at ambient (32˚C)
219268613|NCT05015582|DEVICE|Intra op upper body forced air warming at (42˚C)|upper body forced air warming intra-operative at ambient (42˚C)
219268614|NCT05015582|DEVICE|Intra op lower body forced air warming at (32˚C)|Lower body forced air warming intra-operative at ambient (32˚C)
219268615|NCT05015582|DEVICE|Intra op lower body forced air warming at (42˚C)|Lower body forced air warming intra-operative at ambient (42˚C)
219268616|NCT05015582|DEVICE|Intra op fluid (42˚C)|IV fluids with hotline fluid warmer set at 42˚C
219268617|NCT00529477|OTHER|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
219268618|NCT00529477|OTHER|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
219268619|NCT00529477|OTHER|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
219268620|NCT03049670|DEVICE|latent available chlorine (LAC)|local application on the necrotic infected tissue
219268621|NCT03038035|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
219268622|NCT03038035|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
219268623|NCT00304382|BIOLOGICAL|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
219268624|NCT00304382|BIOLOGICAL|Pneumovax|0.5 ml IM one time
219268625|NCT02931422|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
219268626|NCT01780454|DRUG|MEDI-507|T-Cell Depleting Agent
219268627|NCT01780454|DRUG|Rituximab|B-Cell Depleting Agent
219268628|NCT01780454|RADIATION|Total Body Irradiation|Bone Marrow Depletion
219268629|NCT01780454|RADIATION|Thymic Irradiation|
219268630|NCT01421212|BIOLOGICAL|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
219268631|NCT05055947|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
219268632|NCT03121820|DRUG|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
219268633|NCT03121820|DRUG|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
219268634|NCT00672685|DIETARY_SUPPLEMENT|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
219268635|NCT00672685|BEHAVIORAL|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
219268636|NCT00672685|DRUG|Placebo|OMEGA-3 placebo
219268637|NCT02805478|OTHER|There is no intervention|This is a prospective observational cohort study without any intervention
219268638|NCT03088540|DRUG|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
219268639|NCT03088540|DRUG|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
219268640|NCT03088540|DRUG|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
219268641|NCT03088540|DRUG|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
219268642|NCT03088540|DRUG|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
219268643|NCT03088540|DRUG|cemiplimab|Patients will be administered cemiplimab as per protocol.
219268644|NCT06360926|DEVICE|SuperSonic® Ultrasound System|SuperSonic® Ultrasound System equipped with new software iterations used with a new probe and CE marked probes. The new software and probe are the new study investigational device not CE marked
219268645|NCT05427526|PROCEDURE|intraocular lens implantation|Lens surgery during or before vitrectomy surgery.
219268646|NCT00730015|DRUG|Matching Placebo|Oral, once daily
219268647|NCT00730015|DRUG|Linaclotide|Oral, once daily
219268648|NCT00330356|BEHAVIORAL|Low Salt Diet versus High salt diet|
219268649|NCT03740243|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone tablet or film
219268650|NCT03740243|DRUG|Buprenorphine|Buprenorphine tablet
219268651|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
219268652|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
219268653|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
219268654|NCT05724199|OTHER|Placebo|SC injection
219268655|NCT04120376|BEHAVIORAL|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
219268656|NCT03270800|BIOLOGICAL|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
219268657|NCT03270800|BIOLOGICAL|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
219268658|NCT02641587|OTHER|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
219268659|NCT02641587|OTHER|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
219268660|NCT01114451|PROCEDURE|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
219268661|NCT01165177|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
219268662|NCT01165177|BIOLOGICAL|Placebo|Intramuscular injection
219268663|NCT06546085|BEHAVIORAL|Exercise|Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.
219268664|NCT00610909|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
219268665|NCT00610909|DRUG|Placebo|Placebo
219268666|NCT05864677|DRUG|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
219268667|NCT00867737|DRUG|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
219268668|NCT00867737|DRUG|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
219268669|NCT02411617|DEVICE|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
219268670|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
219268671|NCT04626804|OTHER|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
219268672|NCT02488083|DEVICE|Ultrashape|circumference reduction
219268673|NCT03562390|DRUG|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
219268674|NCT03210519|DIETARY_SUPPLEMENT|Eleutherococcus senticosus|taken orally once/day for 90 days
219268675|NCT03210519|OTHER|Placebo|taken orally once/day for 90 days
219268676|NCT02342990|OTHER|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
219268677|NCT02342990|OTHER|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
219268678|NCT04387877|DEVICE|Graston|"Graston technique will be applied on the lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~For the first 2 weeks; dorsolumbar stabilization, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
219268679|NCT04387877|OTHER|Sham|"Sham graston technique will be applied on lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied by partially touching the skin overlying the muscle or fascia region via ultrasound gel with the flat part of the Graston instrument so as not to provide any activity of the fascia) For the first 2 weeks; dorsolumbar stabilization, counting on spot, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
219268680|NCT00284232|BEHAVIORAL|Use and interpretation of blood glucose results|
219268681|NCT00284232|DRUG|Insulin dosing based on SMBG chart and education|
219268682|NCT00000490|PROCEDURE|jejunoileal bypass|
219268683|NCT00000490|BEHAVIORAL|diet, fat-restricted|
219268684|NCT02270671|BEHAVIORAL|ABMT|Attention Bias Modification Training
219268685|NCT02270671|OTHER|Placebo|Placebo Training
219268686|NCT02713399|DEVICE|Optical Coherence Tomography|
219268687|NCT00476242|DRUG|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
219268688|NCT00476242|DRUG|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
219268689|NCT00916708|PROCEDURE|Intensive/Low-Risk follow up (IA G1; IA G2)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months~\* clinical visit with gynecological exploration"
219268690|NCT00916708|PROCEDURE|Intensive/High-Risk follow up (≥ IA G3)|"\- First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~\- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~\* clinical visit with gynecological exploration"
219268691|NCT00916708|PROCEDURE|Minimalist/Low-Risk follow up (IA G1; IA G2)|"\- First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
219268692|NCT00916708|PROCEDURE|Minimalist/High-Risk follow up (≥ IA G3)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
219268693|NCT02070770|DIETARY_SUPPLEMENT|Very low calorie diet|
219268694|NCT02070770|OTHER|Standard weight loss diet|
219268695|NCT02693704|DEVICE|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
219268696|NCT03624153|BEHAVIORAL|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
219268697|NCT03624153|BEHAVIORAL|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
219268698|NCT06474065|PROCEDURE|Myomectomy|Patients submitted to operation of fibroids removal
219268699|NCT01472029|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
219268700|NCT01472029|DRUG|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
219268701|NCT01306123|DRUG|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
219268702|NCT01306123|DRUG|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
219268703|NCT01819142|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
219268704|NCT02700854|OTHER|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE \> -5 mmol/L in arterial blood gas samples
219268705|NCT02689570|OTHER|observational|no interventions; observational study
219268706|NCT04283708|PROCEDURE|Submental liposuction|Advancement Genioplasty With Submental Liposuction
219268707|NCT03144544|PROCEDURE|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
219268708|NCT00399841|DEVICE|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
219268709|NCT01578213|DRUG|Imatinib mesylate|"* Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use"
219268710|NCT05063695|OTHER|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
219268711|NCT01383811|OTHER|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
219268712|NCT01383811|OTHER|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
219268713|NCT02356796|OTHER|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
219268714|NCT02356796|OTHER|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
219268715|NCT05469724|OTHER|Role of ct pulmonary angiography in diagnosis of pulmonary embolism|Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery
219268716|NCT00639327|DRUG|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
219268717|NCT00639327|DRUG|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
219268718|NCT06060483|DEVICE|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
219268719|NCT01585441|DRUG|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
219268720|NCT01585441|DRUG|Placebo|Capsule with no active ingredients to mimic finasteride
219268721|NCT01448369|DEVICE|Blephasteam|10 minute treatment twice daily
219268722|NCT01448369|DEVICE|EyeGiene|10 minute treatment, twice daily
219268723|NCT01448369|DEVICE|Hot compresses|10 minute treatment, twice daily
219268724|NCT05352945|DEVICE|HyPNOS self-hypnosis mask from DREAMINZZ|"The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections"
219268725|NCT05221177|BEHAVIORAL|TR-30|Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
219268726|NCT05221177|BEHAVIORAL|TR-45|Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
219268727|NCT03043430|DRUG|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
219268728|NCT03043430|DRUG|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
219268729|NCT01803334|OTHER|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
219268730|NCT03792490|DRUG|Fasudil|Fasudil hydrochloride hydrate IV solution
219268731|NCT03792490|DRUG|Placebo|Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
219268732|NCT03486483|OTHER|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
219268733|NCT03487198|DRUG|Brexpiprazole|Brexpiprazole 2-3mg/day
219268734|NCT03487198|DRUG|Placebo|Placebo 2-3 mg/day
219268735|NCT02140736|DRUG|Epoetin biosimilar|
219268736|NCT00311415|BIOLOGICAL|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
219268737|NCT01054378|PROCEDURE|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
219268738|NCT05525507|COMBINATION_PRODUCT|Conditioning and Stem cell infusion|Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
219268739|NCT00174447|DRUG|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
219268740|NCT01437423|BIOLOGICAL|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
219268741|NCT00907764|DRUG|regadenoson|400 ug, IV
219268742|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
219268743|NCT04695652|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
219268744|NCT04695652|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
219268745|NCT05282251|DRUG|Intrapleural bupivacine nebulization|Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
219268746|NCT05282251|DRUG|Intravenous paracetamol and ketorolac|Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
219268747|NCT00497666|DRUG|Rosiglitasone (retrospective observation)|
219268748|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
219268749|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
219268750|NCT04739410|DRUG|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
219268751|NCT02695147|PROCEDURE|TAVI|
219268752|NCT02639806|DRUG|Sevoflurane|
219268753|NCT02639806|DRUG|Lidocaine|
219268754|NCT06484868|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
219268755|NCT02114762|PROCEDURE|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
219268756|NCT01409122|DRUG|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
219268757|NCT01409122|DRUG|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
219268758|NCT01409122|DRUG|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
219268759|NCT01409122|DRUG|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
219268760|NCT01409122|DRUG|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
219268761|NCT03839810|OTHER|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
219268762|NCT00633945|DRUG|Lenalidomide|
219268763|NCT01579643|PROCEDURE|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~2. The host cornea bed will be prepared with an excimer laser.~3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
219268764|NCT01579643|PROCEDURE|Penetrating Keratoplasty (KP)|"1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~2. The donor cornea is then sutured where the patient's cornea was."
219268765|NCT01928667|OTHER|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
219268766|NCT01487187|PROCEDURE|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
219268767|NCT01487187|PROCEDURE|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
219268768|NCT01861977|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
219268769|NCT01861977|BEHAVIORAL|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
219268770|NCT03865953|DRUG|LAT8881|LAT8881 oral capsule
219268771|NCT03865953|DRUG|Placebo|Placebo oral capsule
219268772|NCT00882115|DRUG|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
219268773|NCT01514851|DRUG|Lanthanum carbonate (BAY77-1931)|
219268774|NCT01514851|DRUG|Calcium carbonate|
219268775|NCT05828836|DRUG|Allopurinol Tablet|allopurinol300mg once daily
219268776|NCT05828836|DRUG|Placebo|placebo once daily
219268777|NCT04737837|DRUG|lacosamide|lacosamide as first add on therapy
219268778|NCT01545947|DRUG|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
219268779|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
219268780|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
219268781|NCT04513743|DIAGNOSTIC_TEST|24/7 EEG™ SubQ|24/7 EEG™ SubQ device will be worn by each subject for 365 nights
219268782|NCT04181112|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT using retention enema
219268783|NCT03502577|BIOLOGICAL|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
219268784|NCT03502577|DRUG|Cyclophosphamide|Given IV
219268785|NCT03502577|DRUG|Fludarabine|Given IV
219268786|NCT03502577|DRUG|Gamma-Secretase Inhibitor LY3039478|Given PO
219268787|NCT03502577|OTHER|Laboratory Biomarker Analysis|Correlative studies
219268788|NCT03502577|OTHER|Pharmacokinetic Study|Correlative studies
219268789|NCT03673995|DIETARY_SUPPLEMENT|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
219268790|NCT01093443|DRUG|ovarian stimulation|rFSH with GnRH antagonists
219268791|NCT01093443|DRUG|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
219268792|NCT05297344|PROCEDURE|direct pulp capping|direct pulp capping
219268793|NCT05297344|PROCEDURE|pulpotomy|pulpotomy
219268794|NCT05833659|PROCEDURE|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
219268795|NCT01080326|DEVICE|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
219268796|NCT01296555|DRUG|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
219268797|NCT01296555|DRUG|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
219268798|NCT01296555|DRUG|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
219268799|NCT01296555|DRUG|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
219268800|NCT05762419|DRUG|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
219268801|NCT05762419|DEVICE|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
219268802|NCT02008071|BEHAVIORAL|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
219268803|NCT02008071|BEHAVIORAL|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
219268804|NCT03998722|DEVICE|Vagivital|Vagivital once Daily for 12 weeks
219268805|NCT03735953|DIAGNOSTIC_TEST|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
219268806|NCT03115398|BEHAVIORAL|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
219268807|NCT04457817|DEVICE|CRI|Monitoring via CRI
219268808|NCT03531554|DIETARY_SUPPLEMENT|ketone ester drink|395 mg of ketone ester/kg
219268809|NCT03531554|BEHAVIORAL|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
219268810|NCT03531554|PROCEDURE|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
219268811|NCT03531554|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
219268812|NCT06333977|DRUG|LC542019|oral dose, once daily
219268813|NCT06333977|DRUG|Placebo|matching placebo
219268814|NCT01617499|BEHAVIORAL|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
219268815|NCT01183442|DRUG|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
219268816|NCT05759377|DEVICE|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
219268817|NCT03817723|RADIATION|c-arm cholangiography|
219268818|NCT05964959|OTHER|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
219268819|NCT05964959|OTHER|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
219268820|NCT05643898|BEHAVIORAL|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
219268821|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
219268822|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
219268823|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
219268824|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
219268825|NCT01046422|DRUG|Placebo|Capsule, Oral, 0mg, Daily, 28 days
219268826|NCT01046422|DRUG|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
219268827|NCT01052389|DRUG|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
219268828|NCT01052389|DRUG|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
219268829|NCT01052389|DRUG|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
219268830|NCT00677768|OTHER|No intervention|Sample collection
219268831|NCT05281289|OTHER|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
219268832|NCT05281289|OTHER|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
219268833|NCT05281289|OTHER|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
219268834|NCT01989949|DRUG|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
219268835|NCT03980990|DRUG|Metformin|Continuation of Metformin
219268836|NCT00966030|DRUG|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
219268837|NCT00966030|DRUG|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
219268838|NCT04756206|DRUG|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
219268839|NCT04756206|DRUG|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
219268840|NCT04040998|BEHAVIORAL|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
219268841|NCT04053569|DIETARY_SUPPLEMENT|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
219268842|NCT03380364|DEVICE|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
219268843|NCT05967078|DEVICE|ExerG|"The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training."
219268844|NCT04657562|DRUG|Tacrolimus|Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
219268845|NCT04657562|DIAGNOSTIC_TEST|Unbound tacrolimus measurement|Unbound tacrolimus measurement in plasma ultrafiltrate.
219268846|NCT04657562|DIAGNOSTIC_TEST|CYP3A4 and CYP3A5 genotyping|DNA purification and genotyping
219268847|NCT04533828|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
219268848|NCT03970499|PROCEDURE|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
219268849|NCT02163707|DRUG|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
219268850|NCT05156515|DIAGNOSTIC_TEST|68Ga-THP-APN09|APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
219268851|NCT03000348|DRUG|Cysteamine|Oral Cysteamine Capsule
219268852|NCT03000348|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
219268853|NCT06034899|DRUG|BMS-986196|Specified dose on specified days
219268854|NCT00741208|DIETARY_SUPPLEMENT|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
219268855|NCT02429986|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
219268856|NCT04042077|DRUG|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
219268857|NCT04042077|DRUG|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
219268858|NCT04042077|DRUG|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
219268859|NCT04042077|DRUG|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
219268860|NCT04042077|DRUG|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
219268861|NCT02661633|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
219268862|NCT02661633|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
219268863|NCT00696488|DRUG|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
219268864|NCT01758744|DRUG|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
219268865|NCT01159522|DRUG|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
219268866|NCT00745498|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
219268867|NCT03672942|BEHAVIORAL|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
219268868|NCT03672942|BEHAVIORAL|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
219268869|NCT03672942|BEHAVIORAL|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
219268870|NCT00079755|DRUG|SGN-30 (anti-CD30 mAb)|
219268871|NCT03159351|DEVICE|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
219268872|NCT03159351|DEVICE|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
219268873|NCT00298675|DRUG|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
219268874|NCT00298675|DRUG|irinotecan|Irinotecan administered weekly, IV.
219268875|NCT00299806|DRUG|Aliskiren|
219268876|NCT04502797|BEHAVIORAL|Electronic Patient Visit Assessment (ePVA)|The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
219268877|NCT05196451|BEHAVIORAL|Rehabilitation based on CBT principles|Cf. arm description
219268878|NCT05597423|OTHER|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
219268879|NCT05597423|OTHER|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
219268880|NCT02442193|OTHER|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
219268881|NCT02188537|DRUG|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
219268882|NCT02188537|DRUG|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
219268883|NCT02188537|DRUG|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
219268884|NCT00005599|DRUG|bryostatin 1|
219268885|NCT00005599|DRUG|paclitaxel|
219268886|NCT02409446|DIETARY_SUPPLEMENT|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
219268887|NCT05578430|DRUG|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
219268888|NCT05578430|PROCEDURE|TACE|TACE will be performed per institutional standard of care.
219268889|NCT05578430|PROCEDURE|Surgery|Surgery will be performed per institutional standard of care.
219268890|NCT02365103|OTHER|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
219268891|NCT02365103|OTHER|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
219268892|NCT02365103|OTHER|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
219268893|NCT02365103|OTHER|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
219268894|NCT00943046|DEVICE|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
219268895|NCT01084226|DIETARY_SUPPLEMENT|Rye-2008|
219268896|NCT00827554|DRUG|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
219268897|NCT00827554|PROCEDURE|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
219268898|NCT06260488|PROCEDURE|Endovascular surgery|routine endovascular surgery and FPAS harvesting from amputated limbs to evaluate the technical feasibility of histological segmentation by the FPAS algorithm from CT
219268899|NCT02271022|OTHER|Non-Interventional Study|Non-Interventional Study
219268900|NCT02595320|DRUG|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
219268901|NCT02191904|OTHER|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
219268902|NCT03639727|DIAGNOSTIC_TEST|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
219268903|NCT03639727|DIAGNOSTIC_TEST|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
219268904|NCT00884897|DRUG|Oxytocin|Oxytocin given as 20 IU BID
219268905|NCT00884897|DRUG|Placebo|Placebo given as 20 IU BID
219268906|NCT00085397|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
219268907|NCT00085397|BIOLOGICAL|gp100 antigen|Given IV
219268908|NCT00085397|BIOLOGICAL|therapeutic autologous dendritic cells|Given IV
219268909|NCT04679155|BEHAVIORAL|Eating Time Restriction|early vs late time of day restriction
219268910|NCT01510353|DEVICE|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
219268911|NCT05923645|DEVICE|Transcranial magnetic stimulation (Hf rTMS)|"TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
219268912|NCT02806843|DEVICE|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
219268913|NCT01980004|DIETARY_SUPPLEMENT|Potassium Citrate Supplementation|20 mEq taken twice daily
219268914|NCT01980004|OTHER|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
219268915|NCT01096576|DRUG|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
219268916|NCT01096576|DRUG|placebo|orally twice daily for 5 days
219268917|NCT04088929|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
219268918|NCT04452136|DRUG|68GA PSMA-HBED-CC|Given IV
219268919|NCT00358982|DRUG|MGCD0103|MGCD0103 administered orally three times per wek
219268920|NCT02609542|OTHER|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
219268921|NCT05196971|DRUG|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
219268922|NCT05196971|DRUG|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
219268923|NCT02830282|OTHER|Blood Collection|
219268924|NCT00501683|DRUG|Radiolabelled GSK189075|
219268925|NCT05735665|DIAGNOSTIC_TEST|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
219268926|NCT05735665|DIAGNOSTIC_TEST|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
219268927|NCT06234553|PROCEDURE|surgery of pituitary adenomas|evaluate pathological type and treatment effect after treatment
219268928|NCT02853487|DEVICE|Actigraphy|An actigraph from Philips
219268929|NCT02853487|OTHER|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
219268930|NCT04530578|DRUG|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
219268931|NCT04530578|DRUG|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
219268932|NCT02031536|DRUG|everolimus|Given PO
219268933|NCT02031536|OTHER|placebo|Given PO
219268934|NCT06370442|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 100mcg
219268935|NCT06370442|DRUG|Lorazepam|0.5mg IV
219268936|NCT06370442|DRUG|Haloperidol|0.5mg IV
219268937|NCT06028490|BIOLOGICAL|GR1802 injection-1|subcutaneous，dose\*1
219268938|NCT06028490|BIOLOGICAL|GR1802 injection-2|subcutaneous，dose\*2
219268939|NCT06028490|BIOLOGICAL|Placebo|subcutaneous，dose\*2
219268940|NCT04449237|OTHER|music therapy|music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
219268941|NCT00905047|DRUG|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
219268942|NCT00905047|DRUG|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
219268943|NCT04201145|DRUG|Pembrolizumab|IV, predetermined dosage, twice per cycle
219268944|NCT04201145|DRUG|Defactinib|Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
219268945|NCT04678778|BEHAVIORAL|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
219268946|NCT00799955|PROCEDURE|Placebo block|100 micrograms of spinal morphine
219268947|NCT00799955|PROCEDURE|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
219268948|NCT03180944|DRUG|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
219268949|NCT03180944|DRUG|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
219268950|NCT03180944|DRUG|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
219268951|NCT03180944|DRUG|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
219268952|NCT03180944|DRUG|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
219268953|NCT04530604|DRUG|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (\>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
219268954|NCT06360211|DRUG|BAY2927088|Oral administration
219268955|NCT06360211|DRUG|Midazolam|Oral administration
219268956|NCT05442450|DRUG|oral semaglutide|Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
219268957|NCT01282515|DRUG|clobetasol propionate 0,05% ointment|continuously daily treatment for 6 weeks
219268958|NCT01282515|DRUG|hexaminolevulinate|one PDT treatment
219268959|NCT00304772|DRUG|Fluconazole|400mg/day
219268960|NCT00304772|DRUG|Micafungin|150mg/day
219268961|NCT02718222|DEVICE|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
219268962|NCT03045913|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
219268963|NCT00561106|DRUG|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
219268964|NCT00561106|DRUG|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
219268965|NCT01658020|DRUG|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
219268966|NCT01658020|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
219268967|NCT00364364|DRUG|Radiolabeled humanized PAM4 IgG|
219268968|NCT02353871|BIOLOGICAL|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
219268969|NCT02353871|DRUG|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
219268970|NCT00001649|DRUG|Valaciclovir|
219268971|NCT04093388|DIAGNOSTIC_TEST|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
219268972|NCT04093388|DIAGNOSTIC_TEST|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
219268973|NCT02128698|DIETARY_SUPPLEMENT|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
219268974|NCT02128698|DIETARY_SUPPLEMENT|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
219268975|NCT02128698|BEHAVIORAL|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
219268976|NCT02128698|BEHAVIORAL|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
219268977|NCT00762645|DRUG|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
219268978|NCT00762645|DRUG|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
219268979|NCT02998398|OTHER|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
219268980|NCT00095043|DRUG|MK0928, gaboxadol|
219268981|NCT00095043|DRUG|Comparator: placebo|
219268982|NCT03634722|DEVICE|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
219268983|NCT00002498|DRUG|CMF regimen|
219268984|NCT00002498|DRUG|cyclophosphamide|
219268985|NCT00002498|DRUG|fluorouracil|
219268986|NCT00002498|DRUG|methotrexate|
219268987|NCT00002498|DRUG|mitoxantrone hydrochloride|
219268988|NCT03581669|DEVICE|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
219268989|NCT05434585|BIOLOGICAL|ABO1009-DP|Vaccine
219268990|NCT05434585|BIOLOGICAL|ABO-CoV.617.2|Vaccine
219268991|NCT05434585|OTHER|Placebo|Placebo
219268992|NCT04786613|OTHER|Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
219268993|NCT04786613|OTHER|Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
219268994|NCT04786613|OTHER|Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection|"Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
219268995|NCT01545557|DEVICE|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
219268996|NCT00487032|DRUG|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
219268997|NCT00487032|DRUG|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
219268998|NCT00487032|DRUG|Prazosin hydrochloride|Prazosin 1mg one dose only
219268999|NCT00487032|DRUG|Placebo to Prazosin|Placebo 1 tablet one dose only
219269000|NCT06152679|OTHER|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
219269001|NCT02326259|OTHER|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
219269002|NCT03434028|DRUG|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
219269003|NCT03434028|OTHER|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
219269004|NCT02712970|PROCEDURE|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
219269005|NCT02712970|PROCEDURE|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
219269006|NCT02712970|PROCEDURE|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
219269007|NCT02712970|PROCEDURE|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
219269008|NCT05928663|OTHER|double surgical gloves|In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
219269009|NCT05928663|OTHER|single surgical gloves|MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
219269010|NCT03729713|OTHER|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
219269011|NCT03729713|OTHER|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
219269012|NCT05115708|PROCEDURE|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
219269013|NCT05115708|PROCEDURE|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
219269014|NCT01702870|PROCEDURE|Magnetic Resonance Imaging|
219269015|NCT04753944|DIETARY_SUPPLEMENT|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
219269016|NCT04753944|DIETARY_SUPPLEMENT|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
219269017|NCT02037776|DRUG|Rikkunshito|\- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
219269018|NCT02037776|DRUG|Rikkunshito placebo|\- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
219269019|NCT02578498|DIETARY_SUPPLEMENT|High carbohydrate intake|Carbohydrate intake \< 50 gram
219269020|NCT02578498|DIETARY_SUPPLEMENT|Low carbohydrate intake|Carbohydrate intake \> 250 gram
219269021|NCT00763594|BEHAVIORAL|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
219269022|NCT00763594|BEHAVIORAL|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
219269023|NCT04131764|DIAGNOSTIC_TEST|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
219269024|NCT04032912|DIAGNOSTIC_TEST|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
219269025|NCT00332969|DRUG|Octreotide|
219269026|NCT01368237|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
219269027|NCT03230825|DRUG|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
219269028|NCT03230825|OTHER|Expectant management|No intervention and a follow up visit a wewk later
219269029|NCT03575676|DRUG|SOM3355 100mg BID|Oral
219269030|NCT03575676|DRUG|SOM3355 200mg BID|Oral
219269031|NCT03575676|DRUG|Placebo BID|Oral
219269032|NCT00552864|DRUG|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
219269033|NCT00552864|DRUG|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
219269034|NCT02626247|DIETARY_SUPPLEMENT|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
219269035|NCT02626247|OTHER|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
219269036|NCT01850537|DEVICE|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
219269037|NCT01568385|DRUG|TAK-438|
219269038|NCT04975503|OTHER|Observing cardiovascular risk factors|Documenting the presence or absence of CVD risk factors in each participant.
219269039|NCT01963169|BEHAVIORAL|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
219269040|NCT01963169|BEHAVIORAL|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
219269041|NCT02832349|OTHER|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
219269042|NCT05678686|OTHER|Active Comparator: Routine Exercise Group|Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.
219269043|NCT05678686|OTHER|Experimental: PNF Exercise|In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.
219269044|NCT05678686|OTHER|Experimental: CTAR Exercise|In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
219269045|NCT03892005|PROCEDURE|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
219269046|NCT01279837|BEHAVIORAL|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
219269047|NCT05803681|DEVICE|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
219269048|NCT05803681|OTHER|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
219269049|NCT05354882|BEHAVIORAL|Physical activity program|The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing
219269050|NCT00873327|DRUG|piperacillin-tazobactam|"6 doses intravenously at the following doses:~Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6"
219269051|NCT02780895|DRUG|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
219269052|NCT01554722|PROCEDURE|Needle placement|In plane versus out of plane needle placement techniques
219269053|NCT01486381|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
219269054|NCT01191008|DRUG|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
219269055|NCT03060018|DEVICE|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
219269056|NCT03786744|BIOLOGICAL|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
219269057|NCT03786744|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
219269058|NCT05906706|DRUG|dupilumab|Subcutaneous (SC) administration
219269059|NCT04741594|DEVICE|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
219269060|NCT04905849|BEHAVIORAL|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=\> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=\> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=\> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
219269061|NCT04905849|BEHAVIORAL|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
219269062|NCT05404555|OTHER|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
219269063|NCT04430257|OTHER|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
219269064|NCT04430257|BEHAVIORAL|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
219269065|NCT04430257|BEHAVIORAL|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
219269066|NCT04430257|BEHAVIORAL|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
219269067|NCT04430257|OTHER|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
219269068|NCT04430257|OTHER|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
219269069|NCT06464315|PROCEDURE|Functional Substrate-Only Mapping without VT Induction|In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
219269070|NCT06464315|PROCEDURE|Standard-of-Care Mapping/Imaging|Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
219269071|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
219269072|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
219269073|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
219269074|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
219269075|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
219269076|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
219269077|NCT05010850|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
219269078|NCT05010850|PROCEDURE|Stoma Creation|Protective ileostomy
219269079|NCT06316700|DIETARY_SUPPLEMENT|Nutritional supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
219269080|NCT06316700|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
219269081|NCT02810873|DEVICE|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
219269082|NCT02810873|DEVICE|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
219269083|NCT02810873|RADIATION|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
219269084|NCT02810873|DRUG|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
219269085|NCT00838929|DRUG|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
219269086|NCT00838929|RADIATION|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
219269087|NCT06181474|OTHER|ESAS|Observation of symptoms
219269088|NCT05362344|PROCEDURE|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
219269089|NCT04683510|OTHER|Navigation - Study Specific - Researcher Voice|The intervention is delivered over the telephone
219269090|NCT04683510|OTHER|Navigation - Study Specific - Cancer Survivor Voice|The intervention is delivered over the telephone
219269091|NCT04683510|OTHER|Navigation - Research General - Researcher Voice|The intervention is delivered over the telephone
219269092|NCT04683510|OTHER|Navigation - Research General - Cancer Survivor Voice|The intervention is delivered over the telephone
219269093|NCT04683510|OTHER|Brochure - Study Specific - Researcher Voice|The invention is mailed to the participant in a brochure.
219269094|NCT04683510|OTHER|Brochure - Study Specific - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
219269095|NCT04683510|OTHER|Brochure - Research General - Researcher Voice|The invention is mailed to the participant in a brochure.
219269096|NCT04683510|OTHER|Brochure - Research General - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
219269097|NCT04101565|BEHAVIORAL|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
219269098|NCT06267911|OTHER|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
219269099|NCT04461158|BEHAVIORAL|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
219269100|NCT05365178|DRUG|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
219269101|NCT05365178|DRUG|Placebo|It is a placebo
219269102|NCT05365178|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
219269103|NCT06114277|OTHER|ETCO2 levels|Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in group 1.
219269104|NCT06114277|OTHER|Patients with high ETCO2 levels|Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
219269105|NCT02023775|DEVICE|Melody valve implantation|
219269106|NCT04942158|PROCEDURE|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
219269107|NCT04942158|PROCEDURE|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
219269108|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
219269109|NCT04913948|OTHER|No intervention|No intervention
219269110|NCT03652571|DRUG|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
219269111|NCT03652571|DRUG|Placebo|Placebo
219269112|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
219269113|NCT00170261|DEVICE|Use of an Implantable Loop Recorder|
219269114|NCT01068210|BEHAVIORAL|Aerobic Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
219269115|NCT01068210|BEHAVIORAL|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
219269116|NCT01068210|BEHAVIORAL|Resistance Training|The ultimate goal for resistance training alone is 3 resistance training session/week at an intensity above 50% to 85% of 1-RM for 30-60 minutes/session. Resistance trainings will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Participants will be progressively trained to perform two to three sets of 75-85% of maximal strength.
219269117|NCT01068210|BEHAVIORAL|Aerobic and Resistance Training|The ultimate goal will be three combined exercise sessions per week at an intensity above 50% VO2speak and above 50% 1-RM for aerobic and resistance training, respectively for 30-90 minutes/session.
219269118|NCT04925258|BEHAVIORAL|SPACE Parenting Program|The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online \~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
219269119|NCT05549609|BIOLOGICAL|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
219269120|NCT05549609|OTHER|Vehicle|CryoStor CS10 cryomedium
219269121|NCT06279728|DRUG|Datopotamab deruxtecan|6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
219269122|NCT02591719|DEVICE|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
219269123|NCT02591719|DEVICE|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
219269124|NCT02591719|DEVICE|MagPro magnetic stimulator (LF rTMS)|"Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session"
219269125|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
219269126|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
219269127|NCT05255380|BEHAVIORAL|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
219269128|NCT05255380|BEHAVIORAL|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
219269129|NCT06188559|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
219269130|NCT01076998|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
219269131|NCT01076998|OTHER|Refresh PM Ointment|1 drop in each eye, one time
219269132|NCT03764033|BEHAVIORAL|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
219269133|NCT03764033|BEHAVIORAL|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
219269134|NCT03522389|PROCEDURE|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
219269135|NCT03522389|PROCEDURE|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
219269136|NCT03522389|OTHER|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
219269137|NCT05368350|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
219269138|NCT05118854|DRUG|AMG 510|Given by IV
219269139|NCT05118854|DRUG|Cisplatin|Given by IV
219269140|NCT05118854|DRUG|Carboplatin|Given by IV
219269141|NCT05118854|DRUG|Pemetrexed|Given by IV
219269142|NCT00814645|DRUG|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
219269143|NCT00814645|DRUG|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
219269144|NCT02257918|DRUG|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
219269145|NCT02257918|DRUG|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
219269146|NCT05082207|OTHER|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
219269147|NCT05082207|OTHER|sham group|a deflated cuff placed on the upper arm for 30 min
219269148|NCT01674452|BEHAVIORAL|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
219269149|NCT01674452|BEHAVIORAL|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
219269150|NCT02422225|DEVICE|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention\]~* Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~* Stimulation site \<Experimental group\>~  * Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~ * Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~ * Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit \<Control group\> Sham stimulation"
219269151|NCT02422225|DEVICE|Sham Eldith DC-STIMULATOR|
219269152|NCT06215859|DRUG|MR-107A-02|tablet
219269153|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
219269154|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
219269155|NCT04170491|DIAGNOSTIC_TEST|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
219269156|NCT05432921|BEHAVIORAL|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
219269157|NCT00695825|DIETARY_SUPPLEMENT|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
219269158|NCT00695825|DIETARY_SUPPLEMENT|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
219269159|NCT04403906|DIAGNOSTIC_TEST|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
219269160|NCT05612646|PROCEDURE|Acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
219269161|NCT05612646|PROCEDURE|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
219269162|NCT02121912|DEVICE|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
219269163|NCT02121912|DEVICE|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
219269164|NCT04266847|DEVICE|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
219269165|NCT02842983|DRUG|Esmolol|conventional management plus esmolol infusion
219269166|NCT05783999|DEVICE|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
219269167|NCT03667937|COMBINATION_PRODUCT|CUTIMED|Hydrophobic Dressing
219269168|NCT03667937|OTHER|AQUACEL silver|Silver Dressing
219269169|NCT05696925|OTHER|Motor Imagery|Motor imagery (MI) is a cognitive process that involves the ability to perform an action mentally, without the need to perform the movement itself. The perspective that the person uses to imagine can be: internal perspective (first person - imagines himself/herself), which relates to the person's view of the content of the images or to his/her kinesthetic sensation - the person imagines the movement being performed, as if feeling the movement of the action; or external perspective (third person - imagines another person), which relates to the visual imagination of scenes outside the person.
219269170|NCT05696925|OTHER|Action Observation|Action observation consists of watching another person acting, or doing a motor task, on video or in real-time.
219269171|NCT05696925|OTHER|Exoskeletons|The term Brain-Machine Interface (BMI) refers to systems that capture brain activity signals, translating them into computer commands to control external devices, with the robotic exoskeletons. The electrodes are positioned on the skull cap.
219269172|NCT05696925|OTHER|Execution of the Action|In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
219269173|NCT02930252|DEVICE|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
219269174|NCT02930252|DEVICE|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
219269175|NCT02635178|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
219269176|NCT02635178|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
219269177|NCT01633476|DRUG|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
219269178|NCT00002740|BIOLOGICAL|filgrastim|
219269179|NCT00002740|DRUG|carboplatin|
219269180|NCT00002740|DRUG|cyclophosphamide|
219269181|NCT00002740|DRUG|doxorubicin hydrochloride|
219269182|NCT00002740|DRUG|etoposide|
219269183|NCT00002740|DRUG|mesna|
219269184|NCT00002740|DRUG|vincristine sulfate|
219269185|NCT00002740|PROCEDURE|conventional surgery|
219269186|NCT00002740|PROCEDURE|peripheral blood stem cell transplantation|
219269187|NCT00002740|RADIATION|low-LET cobalt-60 gamma ray therapy|
219269188|NCT00002740|RADIATION|low-LET photon therapy|
219269189|NCT00220623|DRUG|antidepressant medications, flexible drug choice|
219269190|NCT00220623|BEHAVIORAL|CBT, Psychodynamic or Supportive Psychotherapy|
219269191|NCT02145169|DRUG|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
219269192|NCT02923193|DEVICE|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
219269193|NCT02923193|DRUG|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
219269194|NCT01670071|DRUG|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
219269195|NCT01670071|DRUG|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
219269196|NCT01812798|OTHER|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
219269197|NCT02328586|OTHER|Group Acupuncture|
219269198|NCT06061224|BEHAVIORAL|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
219269199|NCT04708483|DEVICE|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
219269200|NCT03616795|DRUG|LY3154207|Administered orally
219269201|NCT03616795|DRUG|[14C]-LY3154207|Administered orally
219269202|NCT01263054|DEVICE|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
219269203|NCT01263054|OTHER|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
219269204|NCT06110065|DRUG|CT-guided Pudendal Nerve Cryoneurolysis|CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
219269205|NCT06110065|DRUG|Percutaneous image-guided cryoneurolysis|Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
219269206|NCT02242643|BIOLOGICAL|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
219269207|NCT02242643|BIOLOGICAL|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
219269208|NCT00449345|PROCEDURE|Blood test for Quantiferon-GOLD assay|
219269209|NCT00003495|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219269210|NCT04342988|DRUG|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
219269211|NCT00668785|DRUG|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
219269212|NCT02634814|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
219269213|NCT02634814|OTHER|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
219269214|NCT02634814|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
219269215|NCT05587452|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is performed to identify whether the patient has colorectal adenoma or cancer
219269216|NCT05587452|DIAGNOSTIC_TEST|Test of ctDNA methylation|A specified panel is used to detect the site of methylation of ctDNA in plasma
219269217|NCT05587452|DIAGNOSTIC_TEST|Test of characteristics of ctDNA fragment|Low pass whole genome sequencing is used to detect the characteristics of ctDNA fragment
219269218|NCT00078143|BEHAVIORAL|Behavior Therapy|
219269219|NCT04001738|OTHER|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
219269220|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA."
219269221|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
219269222|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
219269223|NCT03766373|COMBINATION_PRODUCT|Drug: OP0201 20mg|OP0201
219269224|NCT03766373|COMBINATION_PRODUCT|Drug: Placebo 0mg|Placebo
219269225|NCT02351713|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
219269226|NCT03750253|OTHER|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
219269227|NCT03298269|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
219269228|NCT03298269|BEHAVIORAL|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
219269229|NCT04516005|PROCEDURE|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
219269230|NCT06976424|DRUG|Eflornithine Topical|Eflornithine cream will be applied to the face of group B female patients
219269231|NCT06976424|RADIATION|Instense pulsed light|Intense pulse light will be applied to the face of patient of Group A on areas having increase hair. Patient will be called for a followup every month for next session.
219269232|NCT06976424|DRUG|Eflornithine Topical|Eflornithine will be given to group A patient along with intense pulsed light and results will be compared to group B who recieved only Eflornithine cream
219269233|NCT03313895|BEHAVIORAL|Aerobic & Cognitive Training (ACT)|ACT stands for combined aerobic exercise and cognitive training.
219269234|NCT03313895|BEHAVIORAL|Cycling Only|Cycling on a recumbent stationary cycle
219269235|NCT03313895|BEHAVIORAL|Cognitive Training Only|Engage in cognitive training on a computer
219269236|NCT03313895|BEHAVIORAL|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
219269237|NCT02282059|DRUG|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
219269238|NCT05708313|BEHAVIORAL|lifestyle modification|Participants will undergo an exercise program designed by AHH
219269239|NCT04979156|PROCEDURE|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
219269240|NCT06334640|DIAGNOSTIC_TEST|Three questionaires|Berlin, Pittsburgh and Epworth tests administered during study visit
219269241|NCT05093504|DEVICE|Sham comparator|Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit
219269242|NCT05093504|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
219269243|NCT02574351|BIOLOGICAL|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
219269244|NCT00439361|DRUG|Bortezomib|1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
219269245|NCT00439361|DRUG|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
219269246|NCT00439361|DRUG|Etoposide|100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
219269247|NCT00439361|DRUG|Ifosfamide|5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
219269248|NCT00439361|DRUG|Mesna|5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
219269249|NCT04592809|DRUG|Ketamine Hydrochloride|infused over a 40 minute period
219269250|NCT04592809|DRUG|Midazolam Hydrochloride|infused over a 40 minute period
219269251|NCT02272244|BEHAVIORAL|Decision Support & Navigation|
219269252|NCT02272244|BEHAVIORAL|Standard|
219269253|NCT03430661|DRUG|ACT-246475|Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
219269254|NCT03430661|DRUG|Clopidogrel|Tablet for oral administration (300 or 600 mg)
219269255|NCT03430661|DRUG|Prasugrel|Tablet for oral administration (60 mg)
219269256|NCT03430661|DRUG|Placebo|Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
219269257|NCT03430661|DRUG|Ticagrelor|Tablet for oral administration (180 mg)
219269258|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
219269259|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
219269260|NCT04919382|BIOLOGICAL|Atezolizumab|Given IV
219269261|NCT04919382|DRUG|Temozolomide|Given PO
219269262|NCT00702598|BEHAVIORAL|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
219269263|NCT00702598|BEHAVIORAL|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
219269264|NCT00212992|PROCEDURE|Fixed lower-energy defibrillation|Every shock administered at 150 J
219269265|NCT00212992|PROCEDURE|Escalating higher-energy defibrillation|First shock administered at 200 J, second shock at 300 J, all subsequent shocks at 360 J
219269266|NCT05945615|DRUG|Oxymetazoline 0.1% (Pf) Oph Soln Ud|"Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis."
219269267|NCT05945615|OTHER|Preservative free lubricating drops|Over the counter ophthalmic lubricating drop.
219269268|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
219269269|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
219269270|NCT00578578|DIETARY_SUPPLEMENT|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
219269271|NCT05954182|BEHAVIORAL|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
219269272|NCT05660031|PROCEDURE|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
219269273|NCT05660031|PROCEDURE|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
219269274|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
219269275|NCT02774668|OTHER|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
219269276|NCT02774668|OTHER|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
219269277|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
219269278|NCT03906032|DEVICE|TFNA IM Nail|IM nail
219269279|NCT03906032|DEVICE|Sliding hip screw|SHS surgical fixation
219269280|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
219269281|NCT06860971|DRUG|AL2846 Capsules|AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET).
219269282|NCT06860971|DRUG|AL2846 Placebo|AL2846 Placebo without drug substance.
219269283|NCT06242925|DEVICE|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
219269284|NCT06371586|DRUG|Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy|Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
219269285|NCT06518720|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
219269286|NCT05347485|DRUG|Cilta-cel|Cilta-cel will be administered as an IV infusion.
219269287|NCT05347485|DRUG|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
219269288|NCT06615284|DRUG|Atorvo+™ (Arm1)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
219269289|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 2)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
219269290|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 3)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
219269291|NCT05423041|DIAGNOSTIC_TEST|BOSS Imaging|Biomechanical Imaging of Cornea and Lens
219269292|NCT05414019|OTHER|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
219269293|NCT05414019|OTHER|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
219269294|NCT05414019|OTHER|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
219269295|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
219269296|NCT06619210|DRUG|HL231 Dose 1/2/3/4|HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
219269297|NCT04886518|DRUG|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
219269298|NCT04886518|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
219269299|NCT06611696|DRUG|Avacopan, prednisolone and rituximab|Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.
219269300|NCT06611696|DRUG|Prednisolone and rituximab|Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
219269301|NCT03034096|DRUG|Propofol|Maintenance of general anesthesia with propofol infusion
219269302|NCT03034096|DRUG|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
219269303|NCT06626711|DRUG|Propofol|Propofol as a part of total venous anesthesia
219269304|NCT06626711|DRUG|Sevoflurane|Sevoflurane as a part of intravenous anesthesia
219269305|NCT06694155|DIETARY_SUPPLEMENT|Whey Protein Isolate Crossover|This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
219269306|NCT06694155|DIETARY_SUPPLEMENT|Placebo|1 week of Non-whey protein Placebo supplement
219269307|NCT01729715|BEHAVIORAL|Internet|
219269308|NCT01729715|BEHAVIORAL|DVD|
219269309|NCT00610571|DRUG|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
219269310|NCT06707883|DRUG|TQC2731 injection|TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)
219269311|NCT06707883|DRUG|TQC2731 Placebo|TQC2731 Placebo without drug substance.
219269312|NCT06888427|OTHER|Questionnaires|With the help of a questionnaires, determination of postoperative sleep quality
219269313|NCT06724510|DEVICE|HIFU treatment with ULTRAFOMER MPT|The high-intensity focused ultrasound (HIFU) treatment, which is the primary intervention being evaluated for efficacy and safety in eyebrow lifting.
219269314|NCT06765902|DRUG|N-803|A subcutaneous injection of an IL-15 superagonist.
219269315|NCT06765902|DRUG|ETBX-071|A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.
219269316|NCT06765902|DRUG|M-CENK|An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
219269317|NCT06326554|BEHAVIORAL|Virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2)|Study nurse will offer a palliative care clinic visit referral alongside usual cancer care to participants who report moderate to high symptom burden.
219269318|NCT06893406|DIAGNOSTIC_TEST|Cervical MRI|Participants whose history and physical exam indicate signs or symptoms of cervical myelopathy will be scheduled for a cervical MRI.
219269319|NCT06893406|OTHER|History & Physical Exam|A history and physical exam to evaluate for specific signs and symptoms of cervical myelopathy will be performed.
219269320|NCT06773000|DIETARY_SUPPLEMENT|XR™ Recovery Supplement|Participants will receive a total daily dosage of 59.2 grams of XR™ Recovery Supplement orally, divided into two doses of 29.6 grams each (or two pouches). The dosing regimen will begin upon hospital admission and continue for three weeks post-operatively.
219269321|NCT06773000|DIETARY_SUPPLEMENT|XR Carbohydrate Loading Supplement|2 packets of XR Carbohydrate Loading will be administered the evening before surgery and one packet on the day of surgery up to 2 hours prior to the scheduled operating time. The powder will be mixed with 14 oz of room temperature water only until dissolved then may be served over ice for desired temperature of consumption by the participant.
219269322|NCT05501665|PROCEDURE|Biospecimen Collection|Correlative studies
219269323|NCT05501665|DRUG|Carboplatin|Given carboplatin
219269324|NCT05501665|PROCEDURE|Computed Tomography|Undergo PET/CT
219269325|NCT05501665|OTHER|Fludeoxyglucose F-18|Given IV
219269326|NCT05501665|DRUG|Nab-paclitaxel|Given nab-paclitaxel
219269327|NCT05501665|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
219269328|NCT05501665|DRUG|Pemetrexed|Given pemetrexed
219269329|NCT05501665|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219269330|NCT05501665|RADIATION|Radiation Therapy|Undergo radiation therapy
219269331|NCT05501665|OTHER|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
219269332|NCT05501665|BIOLOGICAL|Ipilimumab|Given Ipilimumab
219269333|NCT05501665|BIOLOGICAL|Nivolumab|Given Nivolumab
219269334|NCT05501665|BIOLOGICAL|Cemiplimab|Given Cemiplimab
219269335|NCT05501665|BIOLOGICAL|Atezolizumab|Given Atezolizumab
219269336|NCT06761781|OTHER|Augmented Reality|"Each participant will receive a standard trial consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Each session will consist of 2-10 exercises selected by the trainer from a pool of 46 exercises. The selected exercises will be tailored based on the participant's condition and progress. The exercise pool will be designed as comprehensively as possible to cover the upper limb (22 exercises and lower limb (7 exercises) motor functions, balance ability (11 exercises), or/and coordination (6 exercises).~Each exercise with a duration ranging from 3 to 23 min, and will be determined by a set of parameters that can be adjusted to the individuals dynamically according to the participant's performance."
219269337|NCT06761781|OTHER|Traditional Training|Each participant will receive a Traditional training based on Task oriented training consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Exercises will be tailored based on the participant's condition and progress. The exercises will cover the upper limb, lower limb, motor functions, balance ability and coordination.
219269338|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
219269339|NCT06775730|DRUG|Ensitrelvir|Ensitrelvir will be administered per schedule specified in the arm description.
219269340|NCT06899711|DEVICE|External Cranial Prosthesis|The external cranial prosthesis is a 3D printed external plate that approximates patients' post-craniectomy skull defect. The prosthesis is made from the same material used in other external Craniofacial prostheses. Patients will be counseled on securing it properly and comfortably on their scalp. Patients will be asked to wear this prosthesis as much as possible until Cranioplasty takes place. After Cranioplasty, the participant will be asked to stop wearing the prosthesis.
219269341|NCT06494904|DRUG|Buprenorphine|All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
219269342|NCT06320717|OTHER|Blood sample|To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
219269343|NCT03733899|DIAGNOSTIC_TEST|Local Anesthesia|Minims Proxymetacaine hydrochloride Eye Drops
219269344|NCT03733899|DIAGNOSTIC_TEST|Placebo|Sodium Chloride Solution
219269345|NCT03716765|DIETARY_SUPPLEMENT|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
219269346|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
219269347|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
219269348|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
219269349|NCT06525636|DRUG|KK8123|Subcutaneous administration
219269350|NCT06857474|PROCEDURE|Bristle Brush Polishing|After ultrasonic scaling, teeth will be polished using a bristle brush attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
219269351|NCT06857474|PROCEDURE|Rubber Cup Polishing|After ultrasonic scaling, teeth will be polished using a rubber cup attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
219269352|NCT06857474|PROCEDURE|Air Polishing|After ultrasonic scaling, teeth will be polished using sodium bicarbonate air polishing with an air polishing device in a circular motion for 10 seconds.
219269353|NCT06857474|PROCEDURE|Ultrasonic Scaling|Teeth in the control group will undergo ultrasonic scaling only, with no additional polishing procedures.
219269354|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
219269355|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
219269356|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
219269357|NCT06907628|DRUG|SHR-3792 Injection|SHR-3792 injection.
219269358|NCT06829836|BEHAVIORAL|Hight intensity interval training|Participants assigned to this intervention group will complete 6 supervised HIIT sessions over 2 weeks.
219269359|NCT06829836|BEHAVIORAL|Cyclic Hyperventilation with Retention|Participants of this intervention group will complete a total of 10 remote guided breathing sessions on Zoom over 2 weeks.
219269360|NCT06044649|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
219269361|NCT06044649|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
219269362|NCT06044649|BEHAVIORAL|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
219269363|NCT06044649|OTHER|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
219269364|NCT06933901|PROCEDURE|Oocyte retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
219269365|NCT06945770|BEHAVIORAL|POLSIS|web based smoking cessation psycho-education
219269366|NCT06945770|DRUG|routine service delivery(Nicotine Replacement Theraphy, Cytisine)|routine smoking cessation service delivery
219269367|NCT06944366|OTHER|Imagery intervention|Imagery rescripting or imaginal exposure
219269368|NCT06945445|DRUG|SLN12140|SLN12140 for sc injection or IV infusion
219269369|NCT06945445|OTHER|Placebo|Placebo for sc injection or IV infusion
219269370|NCT01390597|GENETIC|DNA analysis|
219269371|NCT01390597|GENETIC|cytogenetic analysis|
219269372|NCT01390597|GENETIC|gene mapping|
219269373|NCT01390597|GENETIC|mutation analysis|
219269374|NCT01390597|GENETIC|polymerase chain reaction|
219269375|NCT01390597|OTHER|laboratory biomarker analysis|
219269376|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
219269377|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine (TIVc)|
219269378|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
219269379|NCT05202873|DIAGNOSTIC_TEST|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.
219269380|NCT04474444|OTHER|attendance by ambulance crew|hear, attendance, convey
219269381|NCT06486142|DRUG|Afatinib/Dacomitinib|Second-generation EGFR-inhibitors
219269382|NCT06486142|DRUG|Osimertinib|Third-generation EGFR-inhibitor
219269383|NCT00616590|OTHER|medical chart review|
219269384|NCT00616590|OTHER|questionnaire administration|
219269385|NCT00616590|PROCEDURE|fatigue assessment and management|
219269386|NCT00616590|PROCEDURE|quality-of-life assessment|
219269387|NCT01530581|PROCEDURE|G-PB Transplant|G-PB Transplant
219269388|NCT01530581|PROCEDURE|G-BM Transplant|G-BM Transplant
219269389|NCT05987020|OTHER|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
219269390|NCT02672449|RADIATION|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
219269391|NCT00585871|DRUG|clonidine|0.1 mg tid
219269392|NCT00585871|DRUG|metoprolol|25 mg tid
219269393|NCT04814602|DRUG|Proglumide|CCK receptor antagonist
219269394|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active episodic thinking task
219269395|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active future thinking priming task
219269396|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control episodic future thinking task
219269397|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control future thinking priming task
219269398|NCT04297332|OTHER|Informational Intervention|Provided with Forever Free relapse prevention booklet
219269399|NCT04297332|DRUG|Nicotine Replacement|Receive nicotine patches, gum, or lozenges
219269400|NCT04297332|OTHER|Telephone-Based Intervention|Receive coaching call
219269401|NCT02209753|DRUG|BIRB 796 BS, low dose|
219269402|NCT02209753|DRUG|BIRB 796 BS, medium dose 1|
219269403|NCT02209753|DRUG|BIRB 796 BS, medium dose 2|
219269404|NCT02209753|DRUG|BIRB 796 BS, high dose|
219269405|NCT02209753|DRUG|Placebo|
219269406|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
219269407|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
219269408|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
219269409|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
219269410|NCT01181245|DRUG|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
219269411|NCT03422861|DRUG|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
219269412|NCT03422861|DRUG|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
219269413|NCT00379769|DRUG|Rosiglitazone|Rosiglitazone maximum 8 mg per day
219269414|NCT00379769|DRUG|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
219269415|NCT00379769|DRUG|Metformin|Metformin maximum permitted daily dose .
219269416|NCT00406614|BEHAVIORAL|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
219269417|NCT05249647|OTHER|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
219269418|NCT05249647|OTHER|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
219269419|NCT04446806|DRUG|Ruxolitinib|Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore
219269420|NCT04420039|DEVICE|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
219269421|NCT04560751|DRUG|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
219269422|NCT04560751|PROCEDURE|TACE|TACE will be performed as needed.
219269423|NCT03890198|BIOLOGICAL|LCAR-C182A cells|Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
219269424|NCT04476212|OTHER|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
219269425|NCT02859077|DRUG|EGFR-TKI|EGFR-TKI (gefitinib)
219269426|NCT02859077|DRUG|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
219269427|NCT02859077|DRUG|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
219269428|NCT06119347|DRUG|AntiVEGF|anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
219269429|NCT06119347|DRUG|ICIs|immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
219269430|NCT00234598|PROCEDURE|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
219269431|NCT00234598|PROCEDURE|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
219269432|NCT00234598|PROCEDURE|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
219269433|NCT02852356|DEVICE|MIRI-TL Incubator|MIRI-TL Timelapse incubator
219269434|NCT01689363|DRUG|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
219269435|NCT01689363|DRUG|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
219269436|NCT01689363|DRUG|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
219269437|NCT02859064|DRUG|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
219269438|NCT02859064|DEVICE|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
219269439|NCT00404885|DRUG|Placebo|PO BID
219269440|NCT00404885|DRUG|LX211|0.2 mg/kg, twice a day (BID)
219269441|NCT00404885|DRUG|LX211|0.4 mg/kg, twice a day (BID)
219269442|NCT00404885|DRUG|LX211|0.6 mg/kg, twice a day (BID)
219269443|NCT02414009|DRUG|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
219269444|NCT02414009|DRUG|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
219269445|NCT02414009|DRUG|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
219269446|NCT02414009|DRUG|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
219269447|NCT02414009|DRUG|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
219269448|NCT00321685|BIOLOGICAL|Bevacizumab|Given IV
219269449|NCT00321685|DRUG|Capecitabine|Given PO
219269450|NCT00321685|DRUG|Fluorouracil|Given IV
219269451|NCT00321685|DRUG|Leucovorin Calcium|Given IV
219269452|NCT00321685|DRUG|Oxaliplatin|Given IV
219269453|NCT00321685|RADIATION|Radiation Therapy|Undergo radiotherapy
219269454|NCT00321685|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219269455|NCT05286463|COMBINATION_PRODUCT|bee venom gel phonophoresis|a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
219269456|NCT05286463|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
219269457|NCT05815537|OTHER|Low-Reverberation|The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.
219269458|NCT05815537|OTHER|High-Reverberation|The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
219269459|NCT02573272|DRUG|eslicarbacepine|
219269460|NCT02619526|DRUG|Nebivolol|Nebivolol 10mg, once a day
219269461|NCT02619526|DRUG|Carvedilol|Carvedilol 25mg, twice a day
219269462|NCT00172939|PROCEDURE|foreskin from healthy adults|
219269463|NCT01019239|PROCEDURE|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
219269464|NCT01019239|PROCEDURE|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
219269465|NCT00127842|DRUG|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
219269466|NCT01589926|DEVICE|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
219269467|NCT01589926|DEVICE|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
219269468|NCT01898780|PROCEDURE|pancreaticojejunostomy with horizontal mattress suture|
219269469|NCT01898780|PROCEDURE|pancreaticojejunostomy with interrupted suture|
219269470|NCT04253938|OTHER|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
219269471|NCT01289132|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
219269472|NCT01289132|DRUG|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
219269473|NCT01289132|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
219269474|NCT01289132|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
219269475|NCT01289132|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
219269476|NCT01289132|DRUG|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
219269477|NCT01289132|DRUG|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
219269478|NCT00000469|DRUG|aspirin|
219269479|NCT00000469|DRUG|lovastatin|
219269480|NCT03436303|DRUG|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
219269481|NCT03436303|DRUG|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
219269482|NCT03436303|DRUG|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
219269483|NCT02364596|BIOLOGICAL|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
219269484|NCT02364596|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
219269485|NCT01638390|DEVICE|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
219269486|NCT01536587|DRUG|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
219269487|NCT04435964|DRUG|Immunotherapy|Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
219269488|NCT00551850|DRUG|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
219269489|NCT00143104|DRUG|Inhaled insulin|
219269490|NCT05858255|BEHAVIORAL|Exergaming|Please see Arms description.
219269491|NCT04397211|PROCEDURE|Angiography-derived FFR|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~\*Criteria for revascularization: Angiography-derived FFR ≤ 0.80"
219269492|NCT04397211|PROCEDURE|IVUS|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3\< MLA ≤ 4mm2 \& Plaque burden \> 70%"
219269493|NCT02354651|OTHER|Diaphragm conditioning via phrenic nerve stimulation|Diaphragm pacing will be prescribed by the patient's clinical team.
219269494|NCT05996367|RADIATION|Single-dose involved-site radiotherapy|Single-dose of 8 Gy at involved-site radiotherapy
219269495|NCT01377389|DRUG|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
219269496|NCT01377389|DRUG|Leuprolide|7.5 mg intramuscular once a month for 8 months
219269497|NCT01377389|DRUG|Goserelin|3.6 mg subcutaneous once a month for 8 months
219269498|NCT01377389|DRUG|Degarelix|80 mg subcutaneous once a month for 8 months
219269499|NCT05708547|BIOLOGICAL|Blood samples|at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1
219269500|NCT05708547|PROCEDURE|myocardial tissue samples|use of usually harvested right auricular tissue
219269501|NCT05708547|OTHER|Data collection|pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital
219269502|NCT00645177|DRUG|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
219269503|NCT00645177|DRUG|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
219269504|NCT00645177|DRUG|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
219269505|NCT03430544|DRUG|Cariprazine Oral Capsule [Vraylar]|Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
219269506|NCT03430544|DRUG|Placebo oral capsule|PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
219269507|NCT00577070|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
219269508|NCT02882997|BEHAVIORAL|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
218987444|NCT04362982|OTHER|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
219269509|NCT02882997|BEHAVIORAL|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
219269510|NCT04682782|DRUG|Esketamine|Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .
219269511|NCT04682782|DRUG|Saline|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
219269512|NCT05519553|OTHER|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
219269513|NCT06957379|DRUG|Letrozole|Oral administration at a dose of 2.5 mg once daily for a 4-week cycle
219269514|NCT06957379|DRUG|Anastrozole|Oral administration at a dose of 1 mg once daily for a 4-week cycle
218987445|NCT06964061|COMBINATION_PRODUCT|PA5436 Ocular Implant, 115mcg|The PA5346 Ocular Implant is supplied preloaded into the needle of a single use Administration Device ready for use.
218987446|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
218987447|NCT00254904|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
218987448|NCT00254904|DRUG|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
218987449|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
218987450|NCT00254904|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
219269515|NCT06957379|DRUG|Exemestane|Oral administration at a dose of 25 mg once daily with a meal every 4 weeks
219269516|NCT06957379|DRUG|Fulvestrant|Fulvestrant: IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
218987451|NCT02637284|DRUG|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
218987452|NCT02637284|DRUG|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
218987453|NCT01594281|DRUG|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
218987454|NCT01594281|PROCEDURE|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
218987455|NCT05115903|DRUG|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
219269517|NCT06957379|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
219269518|NCT04334616|DEVICE|Video Laryngocope|VDL used for VDL arm
219269519|NCT04334616|DEVICE|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
219269520|NCT01615172|PROCEDURE|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
219269521|NCT00628277|BEHAVIORAL|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
219269522|NCT00628277|BEHAVIORAL|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
219269523|NCT05184270|DEVICE|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
219269524|NCT00709397|OTHER|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
219269525|NCT04885348|BEHAVIORAL|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
219269526|NCT04885348|BEHAVIORAL|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
219269527|NCT02375451|OTHER|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
219269528|NCT04003766|DIAGNOSTIC_TEST|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
219269529|NCT04872023|OTHER|Blood and bone marrow sampling|Blood and bone marrow sampling
218987456|NCT05115903|DRUG|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
218987457|NCT04032860|DRUG|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
218987458|NCT04032860|DRUG|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
219269530|NCT00807105|DEVICE|H-coil dTMS|treatment with deep TMS stimulation.
219269531|NCT00421629|BEHAVIORAL|After-sales service and supportive supervision (AfterSS)|
219269532|NCT00421629|BEHAVIORAL|Prospective reimbursement (PR)|
219269533|NCT00421629|BEHAVIORAL|Both (AfterSS and PR)|
219269534|NCT06790082|DRUG|[68Ga]Ga-FAPI-46 PET/CT|"Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment."
219269535|NCT01419340|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
219269536|NCT03382561|DRUG|Carboplatin|Given IV
219269537|NCT03382561|DRUG|Cisplatin|Given IV
219269538|NCT03382561|DRUG|Etoposide|Given IV
219269539|NCT03382561|BIOLOGICAL|Nivolumab|Given IV
219269540|NCT01131104|DRUG|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
218987459|NCT05392296|OTHER|Power ball|experimental group getting the power ball training with conventional treatment.
218987460|NCT05392296|OTHER|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
219269541|NCT01282528|BIOLOGICAL|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
218987461|NCT02373852|DEVICE|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
218987462|NCT02971397|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
218987463|NCT02971397|DRUG|Cytarabine|Given IV
219269542|NCT05496153|BEHAVIORAL|Adaptive posture-balance cardiac rehabilitation exercise|The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
219269543|NCT04681053|DRUG|Ivermectin Powder|\- Administration through inhalation (6mg) BID for 3 days
219269544|NCT04985578|OTHER|Dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
218987464|NCT02971397|DRUG|Daunorubicin Hydrochloride|Given IV
218987465|NCT02971397|OTHER|Laboratory Biomarker Analysis|Correlative studies
219269545|NCT04985578|OTHER|Sham dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
219269546|NCT04889469|PROCEDURE|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
219269547|NCT01003119|BEHAVIORAL|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
219269548|NCT00334542|DRUG|simvastatin|24-28 weeks of simvastatin
219269549|NCT03095170|BEHAVIORAL|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
219269550|NCT03095170|BEHAVIORAL|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
218987466|NCT02449655|DRUG|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
218987467|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
219269551|NCT03095170|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
219269552|NCT03095170|BEHAVIORAL|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
218987468|NCT02449655|DRUG|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
218987469|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
218987470|NCT04664062|BEHAVIORAL|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
218987471|NCT03695250|DRUG|IDO1 Inhibitor BMS-986205|Given PO
218987472|NCT03695250|BIOLOGICAL|Nivolumab|Given IV
218987473|NCT06805253|OTHER|Not applicable - observational study|observation only
219269553|NCT03095170|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
219269554|NCT02370251|DRUG|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB \<2 mg/dL) occurs.
218987474|NCT03243071|BEHAVIORAL|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
218987475|NCT03243071|BEHAVIORAL|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
218987476|NCT03268902|DRUG|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
218987477|NCT03268902|DRUG|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
218987478|NCT03268902|DIETARY_SUPPLEMENT|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
218987479|NCT03268902|DRUG|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
218987480|NCT03097094|DIAGNOSTIC_TEST|Male dog|Male dog extract
218987481|NCT03097094|DIAGNOSTIC_TEST|Female dog|Female dog extract
218987482|NCT01871532|DRUG|Gonal-f®|
219269555|NCT05643040|OTHER|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
219269556|NCT05643040|OTHER|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
219269557|NCT05643040|OTHER|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
218987483|NCT00289471|OTHER|No intervention delivered.|No intervention delivered.
218987484|NCT05777590|DRUG|Indocyanine Green Angiogram|Angiogram using ICG dye the occurs directly after conventional angiogram in assessment of frostbite patients undergoing thrombolysis
218987485|NCT06063824|OTHER|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
218987486|NCT02339272|OTHER|non interventional|
218987487|NCT05693558|BIOLOGICAL|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
218987488|NCT02256852|BIOLOGICAL|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
219269558|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
219269559|NCT06108206|OTHER|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)"
219269560|NCT03012529|DRUG|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
219269561|NCT03012529|DRUG|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
219269562|NCT06261957|DRUG|Salbutamol HFA-134a|100 microgram (μg) (ex-valve) at 30-second intervals per actuation
219269563|NCT06261957|DRUG|Salbutamol HFA-152a|100 μg (ex-valve) at 30-second intervals per actuation
218987489|NCT06103123|DIAGNOSTIC_TEST|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
218987490|NCT06103123|OTHER|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
218987491|NCT04945954|OTHER|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
219269564|NCT06348134|DRUG|Trastuzumab emtansine|A chemotherapy drug.
218987492|NCT03069807|OTHER|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
218987493|NCT03069807|OTHER|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
219269565|NCT06348134|DRUG|Pertuzumab Injection|A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
219269566|NCT06348134|DRUG|Docetaxel|A chemotherapy drug.
218987494|NCT04066049|BEHAVIORAL|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
218987495|NCT04706676|BEHAVIORAL|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
218987496|NCT04706676|BEHAVIORAL|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
218987497|NCT04706676|BEHAVIORAL|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
218987498|NCT05834374|OTHER|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
218987499|NCT05834374|OTHER|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
218987500|NCT04345042|OTHER|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
218987501|NCT00379093|BEHAVIORAL|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~* A personalized risk report;~* An educational booklet titled Healthy Drinking as You Age;~* A drinking diary;~* Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
218987502|NCT04503785|DIAGNOSTIC_TEST|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
218987503|NCT02502578|DRUG|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
219269567|NCT06348134|DRUG|Tamoxifen|A medication used to treat breast cancer.
219269568|NCT06348134|DRUG|Letrozole|A medication used to treat breast cancer.
219269569|NCT06348134|DRUG|Goserelin|A hormone therapy drug.
219269570|NCT06011200|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
219269571|NCT06011200|BIOLOGICAL|MSPV4|1 dose of MSPV4 on Day 0
219269572|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
218987504|NCT02195583|DRUG|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
218987505|NCT02195583|DRUG|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
218987506|NCT02195583|DRUG|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
218987507|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
218987508|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
218987509|NCT02195583|DRUG|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
219269573|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
219269574|NCT02453061|DRUG|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
218987510|NCT00294437|DRUG|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
218987511|NCT01182987|BEHAVIORAL|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
218987512|NCT02349087|DEVICE|Acute EEG with fast applicable EEG electrode|
218987513|NCT03478202|DIETARY_SUPPLEMENT|GOLO RELEASE|GOLO RELEASE plus Diet
218987514|NCT04177797|DRUG|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
218987515|NCT03801291|PROCEDURE|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
219269575|NCT02453061|DRUG|Placebo|Safflower oil orally administered at 1g/kg/day
219269576|NCT01985815|DEVICE|VC/VS stimulation|
219269577|NCT00151398|DRUG|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
219269578|NCT00151398|DRUG|Donepezil|10 mg donepezil QD dosed up to 40 weeks
219269579|NCT04546802|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
219269580|NCT02738528|OTHER|Mental practice and brushing guidance in patients with Parkinson Disease|
219269581|NCT05627869|PROCEDURE|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
218987516|NCT03801291|PROCEDURE|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
218987517|NCT01818232|DRUG|[14C]-LX4211|
218987518|NCT01709513|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets.
218987519|NCT01709513|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet.
218987520|NCT01709513|DRUG|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
218987521|NCT01709513|DRUG|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
218987522|NCT00081068|BIOLOGICAL|alemtuzumab|
218987523|NCT04218695|DRUG|Ceftriaxone|Antibiotic
218987524|NCT04218695|DRUG|Normal saline|50cc intravenous once daily
218987525|NCT00752180|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
219269582|NCT05627869|PROCEDURE|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
218987526|NCT00752180|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
218987527|NCT06256965|DIAGNOSTIC_TEST|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
218987528|NCT00983437|DRUG|Armodafinil|
218987529|NCT01543958|DRUG|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
218987530|NCT01543958|DEVICE|Sevelamer carbonate|
218987531|NCT04019288|DRUG|Batiraxcept|Given IV
218987532|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
218987533|NCT04538430|DEVICE|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
218987534|NCT01945281|DRUG|Caspofungin|
218987535|NCT01945281|DRUG|Amphotericin B Deoxycholate|
218987536|NCT00691314|DEVICE|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
218987537|NCT00691314|DRUG|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
218987538|NCT01728909|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
218987539|NCT01728909|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
218987540|NCT04401423|DRUG|TXA127|0.5 mg/kg per day
218987541|NCT04401423|DRUG|Placebo|0.5 mg/kg per day
218987542|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
218987543|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
218987544|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
219269583|NCT03003377|DEVICE|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
219269584|NCT03003377|DEVICE|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
219269585|NCT05252845|BIOLOGICAL|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
219269586|NCT05252845|DRUG|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
218987545|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
218987546|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
219269587|NCT05252845|DRUG|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
219269588|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
218987547|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
218987548|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
218987549|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
218987550|NCT04639167|BEHAVIORAL|Paths to everyday life (PEER)|The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
218987551|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
218987552|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
219269589|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
219269590|NCT04698915|DRUG|Drug GC4711|15 Minute IV Infusion
219269591|NCT04698915|DRUG|Placebo|15 Minute IV Infusion
219269592|NCT02992847|OTHER|Unenhanced MRI|
218987553|NCT06267105|PROCEDURE|Longitudinal incision|Incision performed longitudinally
219269593|NCT02379962|OTHER|no intervention|
219269594|NCT00236262|DEVICE|ventilatory strategies with pressure|
219269595|NCT01150045|DRUG|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
219269596|NCT01150045|DRUG|5-fluorouracil|Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.
219269597|NCT01150045|OTHER|placebo|Patients receive placebo administered by mouth, once daily.
219269598|NCT01150045|DRUG|oxaliplatin|Patients receive 85 mg/m\^2 intravenous over two hours.
219269599|NCT01150045|DRUG|leucovorin|Patients receive 400 mg/m\^2 intravenous over two hours.
219269600|NCT00002430|DRUG|Indinavir sulfate|
219269601|NCT00002430|DRUG|Nelfinavir mesylate|
219269602|NCT00002430|DRUG|Lamivudine|
219269603|NCT00002430|DRUG|Stavudine|
219269604|NCT03124693|DEVICE|Rainbow DCI pulse oximeter sensor|
218987554|NCT06267105|PROCEDURE|Transverse incision|Incision performed transversally
218987555|NCT01112358|DRUG|r-FSH|r-FSH will be administered as specified in the arm description.
218987556|NCT01112358|DRUG|r-hLH|r-hLH will be administered as specified in the arm description.
219269605|NCT02407210|DRUG|azilsartan|
219269606|NCT02407210|DRUG|Olmesartan medoxomil|
219269607|NCT03234946|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
219269608|NCT04855942|DEVICE|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
219269609|NCT04855942|DEVICE|physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
219269610|NCT02431052|DRUG|Olumacostat Glasaretil|
219269611|NCT02431052|OTHER|Vehicle|
218987557|NCT01112358|DRUG|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
219269612|NCT02094898|DRUG|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
218987558|NCT01112358|DRUG|r-hCG|r-hCG will be administered as specified in the arm description.
218987559|NCT01112358|DRUG|Progesterone|Progesterone will be administered as specified in the arm description.
218987560|NCT04389853|PROCEDURE|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
218987561|NCT04389853|PROCEDURE|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
218987562|NCT00000409|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
218987563|NCT00000409|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
218987564|NCT00000409|PROCEDURE|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
218987565|NCT00000409|PROCEDURE|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
218987566|NCT01136148|BEHAVIORAL|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
218987567|NCT02621697|OTHER|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
218987568|NCT02621697|OTHER|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
218987569|NCT01337700|DRUG|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
218987570|NCT01337700|DRUG|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
218987571|NCT00799383|DRUG|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
218987572|NCT00799383|OTHER|Placebo|
218987573|NCT00791960|DRUG|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
218987574|NCT00791960|OTHER|Placebo|single dose, 10 mL normal saline, IV
218987575|NCT06557564|GENETIC|TruGraf liver gene expression|Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
218987576|NCT01140893|DRUG|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
218987577|NCT01140893|DRUG|Placebo|Placebo
219269613|NCT04029805|COMBINATION_PRODUCT|Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
219269614|NCT04029805|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
219269615|NCT05455372|DRUG|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
219269616|NCT02875145|PROCEDURE|Cataract surgery|
219269617|NCT03520075|DRUG|ASTX029|PiB
219269618|NCT03520075|DRUG|ASTX029|Tablet
218987578|NCT03208205|PROCEDURE|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
218987579|NCT06127680|BEHAVIORAL|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
218987580|NCT00726986|DRUG|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
218987581|NCT00726986|DRUG|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
218987582|NCT00726986|DRUG|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
218987583|NCT01313793|DRUG|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
218987584|NCT01313793|DRUG|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
219269619|NCT00073398|BIOLOGICAL|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
218987585|NCT05667844|BEHAVIORAL|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
218987586|NCT06505304|PROCEDURE|Colonoscopy|"The colonoscopy will be performed at 3 or 6 months after surgery according to FC:~* In patients with FCP \>=150µg/g at around 3 months after surgery, a colonoscopy will be immediately performed~* In patients with FCP \<150µg/g at around 3 months after surgery, the colonoscopy will be organized at 6 months after surgery~Colonoscopy will be performed using high definition white-light endoscopy (HD-WLE) followed by virtual chromoendoscopy (VCE). The neoterminal ileum, ileocolic anastomosis and right colon will be assessed.~A follow-up colonoscopy will be performed within 18 months after index colonoscopy, as standard of care."
218987587|NCT06505304|PROCEDURE|Intestinal biopsies|During index colonoscopy, at least 2 biopsies from each of the segments will be taken as standard of practice to assess inflammation in post-operative CD. Only in Irish sites, twelve biopsies - four in the area of ileocolonic anastomosis, four in the neo-terminal ileum and four in the colon just distal to the anastomosis- will be taken for research purposes, in addition to standard-of-care biopsies.
219269620|NCT01432626|DRUG|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
218987588|NCT06505304|PROCEDURE|Confocal laser endomicroscopy|pCLE with fluorescein injection will be performed during index colonoscopy, in centres where is available, to assess early alteration of the barrier function.
218987589|NCT06505304|PROCEDURE|Intestinal ultrasound|All patients will undergo a cross-sectional imaging test as part of their standard of care at 3 and 6 months after surgery. A follow-up IUS will be performed within 18 months after index colonoscopy, as standard of care.
218987590|NCT06505304|DIAGNOSTIC_TEST|Stool|Stool samples will be collected at 3 and 6 months after surgery and used for faecal calprotectin analysis. Research stool will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for metagenomics (only in Irish sites).
218987591|NCT06505304|DIAGNOSTIC_TEST|Blood|Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
218987592|NCT06505304|DIAGNOSTIC_TEST|Saliva|Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)
218987593|NCT06505304|OTHER|Clinical follow-up|Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
218987594|NCT01178957|OTHER|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
218987595|NCT00768157|DRUG|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
218987596|NCT00768157|PROCEDURE|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
218987597|NCT06241833|DRUG|PPI|use of PPI concomitant with DAPT
219269621|NCT05382039|DEVICE|Transcutaneous Electrical Nerve Stimulation|High frequency sensory transcutaneous electrical nerve stimulation
218987598|NCT01101503|DRUG|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
218987599|NCT01101503|DRUG|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
218987600|NCT02119364|OTHER|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
218987601|NCT03119831|DRUG|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
218987602|NCT03119831|DRUG|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
218987603|NCT03119831|DRUG|C31G|Rinsing with 15ml for one minute twice daily for 14 days
218987604|NCT03598283|DEVICE|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
218987605|NCT00000869|DRUG|Nevirapine|
218987606|NCT01497158|OTHER|Self-help brochure|Self help brochure given at baseline visit.
218987607|NCT01497158|OTHER|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
218987608|NCT02456441|OTHER|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
218987609|NCT02456441|OTHER|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
218987610|NCT02767843|DEVICE|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
218987611|NCT03454711|DEVICE|fMRI|Brain MRI
218987612|NCT03454711|DEVICE|Indirect calorimetry|Resting energy expenditure
218987613|NCT03454711|DEVICE|Bioimpedance|Measurement of body composition
218987614|NCT03454711|BIOLOGICAL|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
218987615|NCT03454711|BEHAVIORAL|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
218987616|NCT03475368|OTHER|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
218987617|NCT03475368|OTHER|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
218987618|NCT03475368|OTHER|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
218987619|NCT01270516|DRUG|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
218987620|NCT01270516|DRUG|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
218987621|NCT01270516|DRUG|Saline|Control
218987622|NCT02265068|DRUG|Ticagrelor|Treatment of ACS patients with Ticagrelor
218987623|NCT01861964|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
218987624|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
218987625|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
218987626|NCT01785693|DRUG|levobupivacaine, clonidine|
218987627|NCT03772691|PROCEDURE|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
218987628|NCT03772691|PROCEDURE|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
218987629|NCT03393637|BEHAVIORAL|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
219269622|NCT01276769|DRUG|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
218987630|NCT03399721|DEVICE|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
218987631|NCT03399721|DEVICE|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
218987632|NCT01587820|DRUG|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
218987633|NCT01587820|DRUG|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
218987634|NCT05801276|DIAGNOSTIC_TEST|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
218987635|NCT05256953|PROCEDURE|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
219269623|NCT01276769|DRUG|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
219269624|NCT00932971|DRUG|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
218987636|NCT05256953|PROCEDURE|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
218987637|NCT05911516|DIETARY_SUPPLEMENT|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
218987638|NCT05911516|DIETARY_SUPPLEMENT|Placebo|Placebo
218987639|NCT05278208|DRUG|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
218987640|NCT00612040|DRUG|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
218987641|NCT00612040|DRUG|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
219269625|NCT00932971|DRUG|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
218987642|NCT00612040|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
218987643|NCT00612040|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
218987644|NCT06959368|DRUG|Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg|Participants will receive the respective drug regimens twice daily. The Vonoprazan triple therapy arm will administer Vonoprazan 20 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily. The Standard triple therapy arm will administer Esomeprazole 40 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily.
218987645|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
218987646|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
218987647|NCT05303857|DRUG|Semaglutide Pen Injector|Injection of the semaglutide once weekly
218987648|NCT05303857|DRUG|Placebo|Injection of placebo once weekly
218987649|NCT04717791|DEVICE|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
218987650|NCT03449108|BIOLOGICAL|Aldesleukin|Given IV
218987651|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
218987652|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Given IV
218987653|NCT03449108|DRUG|Cyclophosphamide|Given IV
218987654|NCT03449108|DRUG|Fludarabine|Given IV
218987655|NCT03449108|BIOLOGICAL|Ipilimumab|Given IV
218987656|NCT03449108|BIOLOGICAL|Nivolumab|Given IV
218987657|NCT03449108|OTHER|Quality-of-Life Assessment|Ancillary studies
218987658|NCT03449108|OTHER|Questionnaire Administration|Ancillary studies
218987659|NCT06846996|DRUG|Trastuzumab deruxtecan (T-DXd)|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd (starting dose 6.4 mg/kg IV Q3W) will be enrolled in this study as part of clinical routine or the clinical judgement of physician.
218987660|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
218987661|NCT05705596|OTHER|Sucrose|10% sucrose corresponding to a regular soft drink
218987662|NCT05705596|DRUG|Hesperetin|increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
218987663|NCT04673617|DRUG|AB-101|NK cell therapy
218987664|NCT04673617|DRUG|Rituximab|Anti-CD20 antibody therapy
218987665|NCT04673617|DRUG|Interleukin-2|Immune cytokine
218987666|NCT04673617|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
218987667|NCT04673617|DRUG|Fludarabine|Lymphodepleting chemotherapy
218987668|NCT04673617|DRUG|Bendamustine|Chemoimmunotherapy
218987669|NCT01342302|BEHAVIORAL|Psychosocial Intervention for Couples|Intervention delivered on line
218987670|NCT05672836|DRUG|Enavogliflozin|0.3 mg 1 tablet once daily
218987671|NCT05672836|DRUG|Standard-of-Care|Standard-of-Care medical therapy plus Enavogliflozin matching placebo
218987672|NCT05320757|DRUG|Olaparib|a PARP inhibitor
218987673|NCT06149546|DIETARY_SUPPLEMENT|Control|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Four scheduled appointments with a dietitian"
218987674|NCT06149546|DIETARY_SUPPLEMENT|Intervention|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Seven scheduled appointments with a dietitian~* Six scheduled appointments with a physiotherapist"
218987675|NCT00639431|BEHAVIORAL|direct observation|direct observation of another person's foot moving
218987676|NCT00639431|BEHAVIORAL|mental visualization|mentally imagining moving one's phantom foot/feet
218987677|NCT02004483|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
218987678|NCT01458236|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
218987679|NCT01458236|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
218987680|NCT03890081|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
218987681|NCT06210503|PROCEDURE|Pericapcelar group nerve block|In the supine position, a high-frequency linear sensor is placed in the anterior superior iliac spine and then aligned with the ramus of the pubis by rotating the probe counterclockwise approximately 45 degrees. The iliopsoas muscle and tendon, femoral artery, and pectineus muscle were observed in this view.The iliopsoas muscle and its tendon are visualized, as well as the vascular and nerve bundle: femoral artery, vein, and nerve. The needle is inserted laterally to medially in a planar approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the ramus pubis posteriorly. After negative aspiration, local anesthetic will be gradually injected aspirating every 3 mL.
218987682|NCT06210503|PROCEDURE|Fascia iliaca compartment block|In the supine position, a high-frequency linear sensor is placed in the inguinal fold. Scan starting lateral to the femoral artery and the nerve in the inguinal crease to identify the sartorius muscle, tracing the muscle to its origin to the anterior superior iliac spine. A shadow of the iliac crest bone and iliacus muscle will be visible, with the end point of injection being deep in the fascia iliaca and above the iliacus muscle at the lateral aspect of the iliacus muscle. After negative aspiration, local anesthetic will be gradually injected under the fascial plane, aspirating every 3 mL.
218987683|NCT05671705|DIAGNOSTIC_TEST|DEXA Scan|Fu of diagnostic tests
218987684|NCT06273085|BEHAVIORAL|Patient education|3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
218987685|NCT03800329|DEVICE|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
218987686|NCT03800329|OTHER|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
218987687|NCT02785120|DRUG|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
218987688|NCT04147702|OTHER|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
219269626|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
218987689|NCT02673138|DRUG|canagliflozin|basal interruption with canagliflozin
218987690|NCT02673138|OTHER|basal interruption without canagliflozin|basal interruption
218987691|NCT01502930|BEHAVIORAL|IRT|Internet-based IRT with therapist support during 6 weeks
218987692|NCT01502930|BEHAVIORAL|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
218987693|NCT03226483|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
218987694|NCT00885846|OTHER|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
218987695|NCT00885846|OTHER|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
218987696|NCT05841485|DIAGNOSTIC_TEST|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
218987697|NCT04213417|OTHER|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
218987698|NCT04213417|OTHER|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
218987699|NCT04609371|BEHAVIORAL|self-care tools|self-care tools only
218987700|NCT04609371|BEHAVIORAL|lay telephone coaching|coaching
218987701|NCT03719612|DRUG|DEFINITY®|All subjects will receive a single dose of DEFINITY®
218987702|NCT00985023|PROCEDURE|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
218987703|NCT00985023|PROCEDURE|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
218987704|NCT01953107|OTHER|Oral Ferrous Fumarate|
218987705|NCT01953107|OTHER|Placebo|
218987706|NCT05091047|DEVICE|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
218987707|NCT00727636|BIOLOGICAL|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
218987708|NCT00695409|BIOLOGICAL|rituximab|Given IV
218987709|NCT00695409|DRUG|carmustine|Given IV
218987710|NCT00695409|DRUG|cytarabine|Given IV
218987711|NCT00695409|DRUG|etoposide|Given IV
218987712|NCT00695409|DRUG|melphalan|Given IV
218987713|NCT00695409|PROCEDURE|ASCT|Undergo autologous peripheral blood stem cell transplant
218987714|NCT00695409|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
219269627|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
219269628|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
219269629|NCT01958242|OTHER|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
219269630|NCT00371059|DRUG|Memantine|Memantine 10mg BD
218987715|NCT00900237|DRUG|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
218987716|NCT00900237|DRUG|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
218987717|NCT05253638|DIAGNOSTIC_TEST|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
218987718|NCT05111873|OTHER|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
218987719|NCT02639767|DRUG|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
219269631|NCT00371059|DRUG|Placebo|Placebo 10 mgs BD
218987720|NCT02639767|RADIATION|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
218987721|NCT02639767|DEVICE|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
218987722|NCT05314751|BEHAVIORAL|Questionnaire and interview|An online survey and an in-depth interview.
218987723|NCT02365831|OTHER|Observation of treatment management|Group/cohort
218987724|NCT01218373|DEVICE|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
218987725|NCT01218373|DEVICE|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
218987726|NCT02437266|OTHER|Scapular mobilization|
218987727|NCT04646837|DRUG|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
218987728|NCT04646837|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
219269632|NCT02557126|DRUG|URC102|
219269633|NCT02557126|DRUG|Placebo|
218987729|NCT04646837|DRUG|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
218987730|NCT01251237|DRUG|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
218987731|NCT00427843|BEHAVIORAL|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
218987732|NCT00123396|BEHAVIORAL|BioCASES and BioTESTS|
218987733|NCT06455176|PROCEDURE|alveolar cleft Grafting from the symphysis|grafting using particulate bone from the symphysis
218987734|NCT06455176|PROCEDURE|alveolar cleft Grafting from the iliac cancellous bone|grafting using iliac cancellous bone
218987735|NCT00268788|DRUG|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
218987736|NCT00268788|DRUG|Intravenous immunoglobulin|Individual dose and frequency
219269634|NCT01234883|DRUG|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
218987737|NCT02834260|DRUG|Dexamethasone implant OZURDEX|
218987738|NCT05596760|BEHAVIORAL|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
218987739|NCT05123729|BEHAVIORAL|Crowdsourced campaign package|Disease prevention intervention developed using a crowdsourcing process.
218987740|NCT05123729|BEHAVIORAL|Rapid Response Teams|Pilot a new hybrid training focused on contact tracing and case investigation.
218987741|NCT02230553|DRUG|Lapatinib|
219269635|NCT01234883|DRUG|saline|IV solutions dosed as clinically indicated for rehydration
219269636|NCT00919945|OTHER|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
219269637|NCT00919945|OTHER|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
219269638|NCT01970254|OTHER|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
218987742|NCT02230553|DRUG|trametinib|
218987743|NCT01554683|DRUG|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
218987744|NCT02424760|DEVICE|Shoulder hemi-arthroplasty|
218987745|NCT01685944|DIETARY_SUPPLEMENT|Live Pediococcus pentosaceus LP28|
218987746|NCT01685944|DIETARY_SUPPLEMENT|Heat-killed Pediococcus pentosaceus LP28|
219269639|NCT01970254|OTHER|Survey Administration|Ancillary studies
218987747|NCT01685944|DIETARY_SUPPLEMENT|Placebo|
218987748|NCT01116115|OTHER|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
218987749|NCT01116115|OTHER|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
218987750|NCT03330288|DRUG|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
218987751|NCT04764773|OTHER|No intervention|No intervention
218987752|NCT02581787|BIOLOGICAL|Fresolimumab|Given IV
218987753|NCT02581787|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
219269640|NCT03042403|OTHER|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
219269641|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
219269642|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
219269643|NCT01179776|DRUG|Ilomedin|Ilomedin
219269644|NCT01179776|DRUG|Placebo|i.v saline
219269645|NCT01179776|DRUG|Ilomedin|
219269646|NCT01179776|DRUG|Ilomedin and standard low dose treatment|
218987754|NCT00891592|BIOLOGICAL|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg"
218987755|NCT00891592|OTHER|Observation Arm|Single infusion of Cord Blood Cells
218987756|NCT06458192|BEHAVIORAL|Adaptive Messaging Intervention|The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
218987757|NCT06458192|BEHAVIORAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
218987758|NCT06458192|BEHAVIORAL|Psychoeducation-Only Control|An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
218987759|NCT04068870|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
218987760|NCT01719783|BIOLOGICAL|LAIV H5N2|2 doses provided intranasally
218987761|NCT01719783|OTHER|Placebo|2 doses of placebo provided intranasally
218987762|NCT05923983|OTHER|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
218987763|NCT05923983|OTHER|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
218987764|NCT06107400|GENETIC|RM-004|Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
218987765|NCT02504710|DEVICE|Kinematic Real Time Feedback|
219269647|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
218987766|NCT02504710|OTHER|Traditional systems of manual therapy teaching|
218987767|NCT06396325|OTHER|Tales from the Magic Keep™|Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services
218987768|NCT06396325|OTHER|Usual Care|Continue with regularly accessed physical activities and rehabilitation services
218987769|NCT04971707|OTHER|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
218987770|NCT04971707|OTHER|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
218987771|NCT06480773|DRUG|standard of care chemotherapy|intravenous Paclitaxel or the combination of Bleomycin and Vincristine.
218987772|NCT00563355|DRUG|erythropoietin|
218987773|NCT03890315|DIAGNOSTIC_TEST|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
219269648|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
219269649|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
219269650|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
219269651|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
219269652|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
219269653|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
219269654|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
219269655|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
219269656|NCT02593383|DRUG|Placebo|
218987774|NCT00671333|PROCEDURE|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
218987775|NCT00671333|PROCEDURE|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
218987776|NCT03020173|OTHER|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
218987777|NCT04197531|OTHER|Irrigation Method|Irrigation Method
218987778|NCT00004307|BEHAVIORAL|Protein and calorie controlled diet|
218987779|NCT00004307|GENETIC|Ornithine transcarbamylase vector|
218987780|NCT05613400|DRUG|Simvastatin 10mg|One simvastatin 10mg-tablet
219269657|NCT01481688|OTHER|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
218987781|NCT05613400|DRUG|Ezetimibe 10mg|One ezetimibe 10mg-tablet
219269658|NCT01481688|OTHER|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
219269659|NCT05577325|BEHAVIORAL|control group will be followed without health education|After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
218987782|NCT02758704|OTHER|High stress|Generation of a stressful environment during a neonatal intubation procedure.
218987783|NCT02758704|OTHER|Low stress|Absence of stressful stimuli during neonatal intubation procedure
219269660|NCT06375486|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)
218987784|NCT02758704|OTHER|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
218987785|NCT04736082|OTHER|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
218987786|NCT04736082|OTHER|Control Group: Infant Formula with intact protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
218987787|NCT04859673|DEVICE|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
218987788|NCT02218749|OTHER|Initially triaged to physiotherapist|
218987789|NCT02218749|OTHER|Initially triaged to physician|
218987790|NCT04328766|DRUG|DWC202005, alone|DWC202005, as a single dose
218987791|NCT04328766|DRUG|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
219269661|NCT03405077|BEHAVIORAL|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
219269662|NCT01535001|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
219269663|NCT01535001|BEHAVIORAL|Information|"Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet."
219269664|NCT01535001|DRUG|Paracetamol|1 g x 4/day
219269665|NCT01535001|DRUG|Burana|400 mg x 3/day for three weeks
219269666|NCT01535001|DRUG|Pantoprazole|20mg x 1/day for three weeks
219269667|NCT01535001|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
219269668|NCT01535001|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
219269669|NCT01535001|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
219269670|NCT02775838|DRUG|Indocyanine green|perioperative application of Indocyanine green (ICG)
219269671|NCT02274077|DRUG|EXPAREL|
219269672|NCT02274077|DRUG|Normal Saline|
219269673|NCT00126659|PROCEDURE|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
219269674|NCT00126659|DRUG|sorafenib tosylate|Given orally
219269675|NCT00126659|OTHER|laboratory biomarker analysis|Correlative studies
219269676|NCT02367352|DRUG|Alisertib|Alisertib tablets
219269677|NCT02367352|DRUG|Paclitaxel|Paclitaxel intravenous solution
219269678|NCT05021445|COMBINATION_PRODUCT|plates based exercises|12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
219269679|NCT05021445|COMBINATION_PRODUCT|conventional exercises|12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
219269680|NCT02272361|OTHER|laparoscopic sacrocolpopexy|
219269681|NCT02272361|OTHER|vaginal mesh surgery|
219269682|NCT06547567|BEHAVIORAL|Motivational Interviewing|In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
219269683|NCT04400968|PROCEDURE|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen \[FT2\], uterus \[FT5\], sympathetic \[HI4\], kidney \[CS6\], heart \[CI4\], endocrine \[IT2\] and thalamus \[PC2\].
219269684|NCT04400968|PROCEDURE|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
219269685|NCT04400968|PROCEDURE|Auricular therapy Placebo group|Sham auricular therapy
219269686|NCT04400968|PROCEDURE|kinesio tape Placebo group|Sham kinesio tape
218987792|NCT04328766|DRUG|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
218987793|NCT06043726|DIAGNOSTIC_TEST|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
218987794|NCT02434978|DEVICE|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
218987795|NCT02434978|DRUG|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
218987796|NCT02434978|OTHER|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
218987797|NCT06557915|PROCEDURE|screening|screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
219269687|NCT03796078|PROCEDURE|Maxillomandibular advancement|Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
219269688|NCT03796078|PROCEDURE|monomaxillary surgery (isolated MaxS)|Monomaxillary surgery (Isolated MaxS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
219269689|NCT03796078|PROCEDURE|monomandibullary surgery (MandS)|Monomandibullary surgery (Isolated MandS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
218987798|NCT06557993|OTHER|Serratus Posterior Superior Intercostal Plane Block|The serratus posterior superior muscle is located deep to the rhomboid major and minor. Ligamentum nuchae starts from the processus spinosus of C7-T3 vertebrae and extends to the 2nd-5th. In the ribs, the angulus ends at the upper edge of the rib. Serratus posterior superior -intercostal plane block (SPSİPB) is a newly defined block, and C7-T7 spread has been shown in cadaver studies
218987799|NCT04925908|DIAGNOSTIC_TEST|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
218987800|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
218987801|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
218987802|NCT04089475|DEVICE|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
218987803|NCT00795847|DRUG|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
219269690|NCT02097186|PROCEDURE|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
219269691|NCT02164019|PROCEDURE|long-stem cemented hemiarthroplasty (LSCH)|
219269692|NCT02164019|PROCEDURE|intramedullary nailing (IMN)|
219269693|NCT02164019|BEHAVIORAL|questionnaires|
219269694|NCT02296749|DRUG|Sirolimus|Sirolimus tablets 2 mg
219269695|NCT00232219|DRUG|Fish oil|
219269696|NCT01375751|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219269697|NCT01375751|BIOLOGICAL|Placebo|d by subcutaneous injection
219269698|NCT02980523|DRUG|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
219269699|NCT02980523|DRUG|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
218987804|NCT02364622|DEVICE|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
218987805|NCT02364622|DEVICE|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
218987806|NCT02364622|DEVICE|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
218987807|NCT03041987|OTHER|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
218987808|NCT04853030|DRUG|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
218987809|NCT04853030|DRUG|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
219269700|NCT02980523|DRUG|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
219269701|NCT02980523|DRUG|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
219269702|NCT01383447|DRUG|entinostat|Given PO
219269703|NCT01383447|DRUG|imatinib mesylate|Given PO
219269704|NCT01383447|OTHER|laboratory biomarker analysis|Correlative studies
219269705|NCT01383447|OTHER|pharmacological study|Correlative studies
219269706|NCT01383447|GENETIC|western blotting|Correlative studies
219269707|NCT01383447|OTHER|immunohistochemistry staining method|Correlative studies
219269708|NCT01383447|OTHER|flow cytometry|Correlative studies
219269709|NCT01383447|GENETIC|polymerase chain reaction|Correlative studies
219269710|NCT01383447|OTHER|high performance liquid chromatography|Correlative studies
219269711|NCT01383447|OTHER|mass spectrometry|Correlative studies
218987810|NCT02645097|PROCEDURE|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
218987811|NCT00886561|BEHAVIORAL|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
218987812|NCT03882112|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
218987813|NCT05583565|OTHER|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
219269712|NCT02738645|OTHER|pneumonia|
218987814|NCT05583565|OTHER|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2\) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
218987815|NCT03395392|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
218987816|NCT03395392|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
218987817|NCT00736424|DEVICE|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
218987818|NCT05534685|OTHER|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
218987819|NCT05534685|OTHER|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
218987820|NCT01050283|PROCEDURE|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
218987821|NCT06114225|COMBINATION_PRODUCT|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
219269713|NCT04142099|BEHAVIORAL|skin to skin contact 60 min group|Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
219269714|NCT04142099|BEHAVIORAL|skin to skin contact 20min group|Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
219269715|NCT00254969|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
219269716|NCT04515056|DRUG|Papain 10 µg|The area will be exposed to 10 µg of papain.
219269717|NCT04515056|DRUG|Papain 50 µg|The area will be exposed to 50 µg of papain.
219269718|NCT04515056|DRUG|Papain 100 µg|The area will be exposed to 100 µg of papain.
219269719|NCT04515056|OTHER|Vehicle|The area will be exposed to vehicle
219269720|NCT04515056|DRUG|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
219269721|NCT04515056|DRUG|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
218987822|NCT00627185|BEHAVIORAL|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
218987823|NCT00627185|OTHER|No intervention arm|
218987824|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
219269722|NCT04515056|DRUG|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
219269723|NCT04515056|OTHER|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
219269724|NCT04908345|DRUG|Methadone|Used at induction and during surgery
219269725|NCT04908345|DRUG|Fentanyl|Used at induction and during surgery
219269726|NCT01192789|DRUG|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
219269727|NCT01192789|OTHER|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
219269728|NCT06545318|DEVICE|Density Gradient Centrifugation|Sperm separation with density gradients
219269729|NCT06545318|DEVICE|CA0 chamber|Sperm separation with a novel device
219269730|NCT04528823|OTHER|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
219269731|NCT04528823|OTHER|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
218987825|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
218987826|NCT00003962|BIOLOGICAL|aldesleukin|
218987827|NCT00092157|DRUG|MK0733, simvastatin|
219269732|NCT02392754|DEVICE|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
218987828|NCT00092157|DRUG|Comparator: simvastatin|
218987829|NCT02386631|DEVICE|Custom Made Orthotic|Provides longitudinal arch support
218987830|NCT05446896|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
218987831|NCT01252147|OTHER|No treatment|No treatment (intervention) will be provided in this study
218987832|NCT05732246|OTHER|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
218987833|NCT03023462|DRUG|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
218987834|NCT03023462|DRUG|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
218987835|NCT03023462|DRUG|Ropivacaine|Local anesthetic for the block
218987836|NCT02800343|PROCEDURE|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
218987837|NCT00940160|DRUG|QAX576|
218987838|NCT00940160|DRUG|QAX576|
218987839|NCT00940160|DRUG|QAX576|
219269733|NCT03936842|BEHAVIORAL|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
218987840|NCT00940160|DRUG|Placebo|
218987841|NCT03315546|RADIATION|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
218987842|NCT01254331|DRUG|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
218987843|NCT02494674|BEHAVIORAL|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
218987844|NCT00002532|BIOLOGICAL|filgrastim|
218987845|NCT00002532|DRUG|asparaginase|
218987846|NCT00002532|DRUG|cytarabine|
219269734|NCT03936842|BEHAVIORAL|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
219269735|NCT01271504|DRUG|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
219269736|NCT01271504|DRUG|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
219269737|NCT02028286|DRUG|CLS001|
219269738|NCT04467645|OTHER|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
218987847|NCT00002532|DRUG|daunorubicin hydrochloride|
218987848|NCT00002532|DRUG|dexamethasone|
218987849|NCT00002532|DRUG|etoposide|
218987850|NCT00002532|DRUG|idarubicin|
218987851|NCT00002532|DRUG|ifosfamide|
218987852|NCT00002532|DRUG|leucovorin calcium|
218987853|NCT00002532|DRUG|methotrexate|
218987854|NCT00002532|DRUG|prednisolone|
218987855|NCT00002532|DRUG|vindesine|
218987856|NCT01500889|PROCEDURE|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
218987857|NCT01500889|PROCEDURE|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
218987858|NCT01500889|PROCEDURE|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
219269739|NCT02375347|OTHER|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
219269740|NCT02552147|DRUG|Transdermal nicotine|
219269741|NCT02552147|OTHER|Transdermal placebo|
218987859|NCT05642767|DIAGNOSTIC_TEST|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
218987860|NCT05642767|DIAGNOSTIC_TEST|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
218987861|NCT05642767|DIAGNOSTIC_TEST|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
219269742|NCT04412525|DEVICE|vitrectomy (27G gauge or larger needle)|vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
219269743|NCT04699045|OTHER|No active intervention|
219269744|NCT06442696|OTHER|Health Education: Healthy Choices Program|Six session for students and school personel
219269745|NCT00730613|BIOLOGICAL|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
219269746|NCT00730613|GENETIC|gene expression analysis|At the time of excess pathology samples documenting response/relapse
219269747|NCT00730613|OTHER|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
219269748|NCT00114296|DIETARY_SUPPLEMENT|omega-3 fatty acid|
219269749|NCT02034097|DRUG|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
218987862|NCT05642767|DIAGNOSTIC_TEST|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
218987863|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
218987864|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
218987865|NCT01471678|DRUG|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
218987866|NCT01471678|DRUG|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
218987867|NCT01471678|DRUG|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
218987868|NCT06327009|BEHAVIORAL|fasting month of ramadan|100 patients with glomerulonephritis who decided to fast month of ramadan
218987869|NCT02910115|OTHER|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
219269750|NCT02034097|DRUG|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
219269751|NCT03469726|DIAGNOSTIC_TEST|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
219269752|NCT02968706|DEVICE|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
219269753|NCT02968706|DEVICE|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
219269754|NCT02968706|OTHER|Patient satisfaction questionnaire|Questionnaire
219269755|NCT04575181|DRUG|NNC0268-0965|For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
219269756|NCT04575181|DRUG|Insulin glargine|For s.c. injection once daily for 26 weeks
219269757|NCT04575181|DRUG|Placebo (NNC0268-0965)|For s.c. injection once daily for 26 weeks
219269758|NCT04575181|DRUG|Placebo (insulin glargine)|For s.c. injection once daily for 26 weeks
219269759|NCT01943682|DRUG|CPX-351|Comparison of Different doses of drug
219269760|NCT03888599|BEHAVIORAL|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
218987870|NCT02910115|DRUG|Pitocin|Pitocin is administered intravenously according to the usual protocol.
218987871|NCT00406965|DRUG|HAE1 (PRO98498)|
218987872|NCT04392752|OTHER|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
218987873|NCT01014000|DEVICE|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
218987874|NCT01014000|DEVICE|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
219269761|NCT01547598|DRUG|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
219269762|NCT01547598|DRUG|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
219269763|NCT01547598|DRUG|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
219269764|NCT00590226|DRUG|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
219269765|NCT00590226|DRUG|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
218987875|NCT02211222|DRUG|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
218987876|NCT04971421|DIAGNOSTIC_TEST|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
218987877|NCT04971421|DIAGNOSTIC_TEST|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
219269766|NCT03815253|OTHER|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
218987878|NCT03890406|DRUG|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
219269767|NCT00635401|DRUG|Varenicline|0.5 mg BID for 7 weeks
219269768|NCT02423889|RADIATION|Radiotherapy|
219269769|NCT01349452|DRUG|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
218987879|NCT03890406|DRUG|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
218987880|NCT03985059|OTHER|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
218987881|NCT06322069|OTHER|Self-compassion intervention group|Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
218987882|NCT04710602|PROCEDURE|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
218987883|NCT04710602|PROCEDURE|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
218987884|NCT03254979|BEHAVIORAL|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
219269770|NCT01349452|DRUG|Artificial tear|Artificial tear 5 times per day
219269771|NCT02229227|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
219269772|NCT02229227|DRUG|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
219269773|NCT05383339|OTHER|Blood collection|\- 56mL blood collected additionally to routine care
219269774|NCT06428864|DEVICE|Plaster cast|Wearing a Garchois brace produced after a plaster cast
219269775|NCT06428864|DEVICE|3D Scanning|Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
219269776|NCT05775783|PROCEDURE|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
218987885|NCT05943028|DRUG|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
218987886|NCT01993706|DRUG|VRC-HIVMAB060-00-AB|
218987887|NCT02683720|DIETARY_SUPPLEMENT|ONS|randomized clinical trial involving different ONS strategies
218987888|NCT06136078|OTHER|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
218987889|NCT01612858|DRUG|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
218987890|NCT01612858|DRUG|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
218987891|NCT03181035|RADIATION|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
218987892|NCT03181035|DRUG|Pimonidazole|oral pimonidazole hypoxia labeling
218987893|NCT01706978|PROCEDURE|Bone Trephination|
218987894|NCT01706978|PROCEDURE|Soft Tissue Trephination|
218987895|NCT01626430|DIETARY_SUPPLEMENT|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
218987896|NCT01626430|DIETARY_SUPPLEMENT|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
218987897|NCT02233114|OTHER|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
218987898|NCT02233114|OTHER|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
218987899|NCT02206074|DIETARY_SUPPLEMENT|Beetroot|
218987900|NCT05431660|OTHER|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
218987901|NCT05431660|OTHER|control group|diabetic foot school information booklet and weekly video conference meeting
218987902|NCT03631875|DRUG|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
218987903|NCT02204956|BEHAVIORAL|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
219269777|NCT04071301|DEVICE|TENA SmartCare Change Indicator|"Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
219269778|NCT06475794|OTHER|Patients with osteoporosis group|Pain, Q angle, muscle strength and foot posture will be evaluated.
219269779|NCT06475794|OTHER|Patients with osteoarthritis group|Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
219269780|NCT01114347|DIETARY_SUPPLEMENT|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
218987904|NCT02204956|BEHAVIORAL|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
218987905|NCT02326792|OTHER|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
218987906|NCT03757156|OTHER|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
218987907|NCT06071208|DRUG|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
219269781|NCT01114347|DIETARY_SUPPLEMENT|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
218987908|NCT02173808|BIOLOGICAL|levonorgestrel butanoate|
218987909|NCT06558292|OTHER|Virtual Reality Group|Students will experience the operating room environment with virtual reality glasses before clinical practice.
219269782|NCT03917745|BEHAVIORAL|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
219269783|NCT00548743|BEHAVIORAL|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
219269784|NCT00548743|BEHAVIORAL|Usual care|usual care for identification and management of postpartum depression
219269785|NCT00419289|BEHAVIORAL|follow-up rehabilitation of participants with COPD|
219269786|NCT02480699|BIOLOGICAL|Recurring blood sample|
218987910|NCT01204554|DRUG|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
218987911|NCT00746083|BEHAVIORAL|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
218987912|NCT00249860|DRUG|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
218987913|NCT00249860|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
218987914|NCT00249860|DRUG|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
218987915|NCT04456257|DEVICE|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
218987916|NCT02236403|DRUG|Ivermectin 0.1% Metronidazole 1%|
218987917|NCT02236403|OTHER|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
218987918|NCT01768286|DRUG|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
218987919|NCT01768286|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
218987920|NCT04520412|DRUG|GV-971|Administered PO
218987921|NCT04520412|DRUG|Placebo|Administered PO
218987922|NCT00929383|DEVICE|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
218987923|NCT05345977|DEVICE|eMotiph|Mobile application for patients with schizophrenia.
218987924|NCT04276571|DEVICE|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
218987925|NCT05615168|DIAGNOSTIC_TEST|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
218987926|NCT05615168|DIAGNOSTIC_TEST|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
218987927|NCT05552521|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
219269787|NCT02480699|OTHER|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
219269788|NCT05186311|DEVICE|Capillary Blood Collection System|Test Blood Sample Collection
218987928|NCT02699593|DEVICE|Test Contact Lens|
218987929|NCT02699593|DEVICE|Control Contact Lens|
218987930|NCT03344796|BEHAVIORAL|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
218987931|NCT05481892|DEVICE|Cellular Home blood pressure (BP) monitoring|Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
218987932|NCT05108285|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
218987933|NCT01199965|DRUG|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
218987934|NCT01199965|DRUG|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
218987935|NCT04749706|BEHAVIORAL|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
218987936|NCT04749706|BEHAVIORAL|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
218987937|NCT03805269|DRUG|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
218987938|NCT03805269|DRUG|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
218987939|NCT04275531|DRUG|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
218987940|NCT02179489|PROCEDURE|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
218987941|NCT01920321|PROCEDURE|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
218987942|NCT04035798|DRUG|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
218987943|NCT04594343|DRUG|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
218987944|NCT04594343|DRUG|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
218987945|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
219269789|NCT04072705|DRUG|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
218987946|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
218987947|NCT05656495|DRUG|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
218987948|NCT03593603|DEVICE|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
218987949|NCT00662246|RADIATION|respiratory gated proton beam radiotherapy|\- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
218987950|NCT03914482|DEVICE|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
218987951|NCT01443871|OTHER|Aromatherapy|Subject will assigned inhale aromatherapy
218987952|NCT01443871|OTHER|Pure water|Subject will assigned inhale Pure water
218987953|NCT02124525|DRUG|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
219269790|NCT00883298|DRUG|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 \& 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 \& 5 every 28-day cycle
219269791|NCT04901923|DRUG|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
218987954|NCT00032123|DRUG|erlotinib hydrochloride|
218987955|NCT01710969|BEHAVIORAL|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
218987956|NCT01710969|BEHAVIORAL|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
218987957|NCT00417508|DIETARY_SUPPLEMENT|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
218987958|NCT00417508|DIETARY_SUPPLEMENT|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
218987959|NCT05020782|DRUG|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
218987960|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
218987961|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
218987962|NCT01049100|PROCEDURE|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
218987963|NCT01049100|OTHER|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
218987964|NCT03298867|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
218987965|NCT03298867|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
218987966|NCT02746796|DRUG|ONO-4538|
218987967|NCT02746796|DRUG|Oxaliplatin|
218987968|NCT02746796|DRUG|Tegafur- Gimeracil-Oteracil potassium|
218987969|NCT02746796|DRUG|Capecitabine|
218987970|NCT02746796|DRUG|Placebo|
218987971|NCT04875663|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
218987972|NCT04742998|OTHER|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
218987973|NCT04614922|BEHAVIORAL|Acceptance and Commitment Therapy|ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.
218987974|NCT04452240|DEVICE|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
218987975|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation|
218987976|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
218987977|NCT07044349|DRUG|Utidelone capsule 75mg/m2/d QD|75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
218987978|NCT07044349|DRUG|Utidelone capsule 40mg/m2/d BID|40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
218987979|NCT07044349|DRUG|Utidelone capsule 50mg/m2/d BID|50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
218987980|NCT07044349|DRUG|Utidelone capsule 35mg/m2/d BID|35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
218987981|NCT06729242|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
218987982|NCT06729242|OTHER|HIIT session|The HIIT exercise will consist of strength exercises with elastic bands.
218987983|NCT06733129|DRUG|direct IV injection|direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation
218987984|NCT06733129|DRUG|combination of Ketamine and Propofol|combination of Ketamine and Propofol described above: consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg (adjusted body weight if BMI \> 30). Dilution are not necessary.
218987985|NCT07050784|DEVICE|Hydrogel electrodes|Neurostimulation using standard self-adhesive hydrogel electrodes
218987986|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion A|Neurostimulation with dry polymer-textile electrodes using Skin Lotion A
218987987|NCT07050784|DEVICE|Dry textile electrodes with gel pads attached to the electrode|Neurostimulation with dry textile electrodes with gel pads attached to the electrode
218987988|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion B|Neurostimulation with dry polymer-textile electrodes with Skin Lotion B
218987989|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion C|Neurostimulation with dry polymer-textile electrodes using Skin Lotion C
218987990|NCT07049159|BIOLOGICAL|ShigETEC vaccine|The ShigETEC vaccine will be administered orally 4 times at 3-day intervals as a bacterial suspension in a volume of 30 mL per dose (target to contain 5x10\^10 CFU)
218987991|NCT07049159|OTHER|Placebo|Eligible participants will be randomly assigned in a 1:1 ratio to receive either ShigETEC 5x10\^10 colony forming units (CFU) or placebo. Participants will receive their assigned treatment on Days 1, 4, 7, and 10.
218987992|NCT07049159|BIOLOGICAL|Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU|In the challenge stage all participants will receive 1 oral dose of Shigella flexneri 2457T at a dose of 1.5x10\^3 CFU.
219269792|NCT04901923|DRUG|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
219269793|NCT01355276|DRUG|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
219269794|NCT01355276|DRUG|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
219269795|NCT05646147|DEVICE|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
219269796|NCT02125279|DRUG|Calcitriol|
219269797|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
219269798|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
219269799|NCT01537692|DRUG|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
219269800|NCT03178344|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
219269801|NCT03178344|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
219269802|NCT01948674|BEHAVIORAL|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
219269803|NCT01126034|OTHER|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record"
219269804|NCT00567840|DRUG|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
219269805|NCT01850589|OTHER|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~* Chantix (varenicline) GlaxoSmithKline,~* Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
219269806|NCT00823953|DRUG|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
219269807|NCT00823953|OTHER|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
219269808|NCT00111995|DRUG|Aranesp®|
219269809|NCT01392703|DRUG|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
219269810|NCT01392703|DRUG|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
219269811|NCT01392703|DRUG|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
218987993|NCT07049315|DEVICE|Mandibular Advancement Device|A custom-made intraoral appliance designed to reposition the mandible forward during sleep. The device increases the upper airway space by maintaining the lower jaw in a protruded position, aiming to reduce airway collapse and decrease nocturnal gastroesophageal reflux. It is fabricated from heat-cured acrylic based on individual dental impressions and bite registrations taken in a protruded mandibular position.
218987994|NCT07049315|DEVICE|Lower Oral Device Without Mandibular Advancement|A lower jaw oral appliance made of heat-cured acrylic, fabricated from standard dental impressions and bite registration in habitual occlusion. This device does not reposition the mandible but provides posterior dental disocclusion. It is also used in patients with obstructive sleep apnea and serves as an active comparator to evaluate the specific impact of mandibular advancement on nocturnal gastroesophageal reflux.
218987995|NCT06705868|OTHER|Diet-Time-restricted eating (TRE)|Ad libitum time-restricted scheme with a further time-restriction on fruit and vegetable consumption in participants with MASLD
218987996|NCT06705868|OTHER|Lifestyle Management|The SoC intervention refers to an adaptation of a healthier lifestyle in elements that have to do with weight management, adopting healthier dietary habits, alcohol intake reduction, increase physical activity levels, in people diagnosed with MASLD.
218987997|NCT07045077|BEHAVIORAL|AI Chatbot-Assisted Case-Based Learning|Participants in this intervention used a conversational AI chatbot integrated into a case-based learning activity focused on Parkinson's disease. The chatbot simulated a virtual client and responded to student questions in natural language. Students used the chatbot to gather occupational history, clarify symptoms, and explore intervention planning options during a structured 90-minute session.
218987998|NCT07045077|BEHAVIORAL|Traditional Case-Based Learning with Standard Materials|Participants in this intervention completed the same Parkinson's disease case analysis using only traditional educational materials, such as lecture notes, textbooks, and class handouts. No digital or AI-based tool was used. The session was instructor-guided and lasted 90 minutes, during which students worked collaboratively to assess the case and develop intervention plans.
219269812|NCT06058715|PROCEDURE|Transverse Abdominal Plan block (TAP block)|Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane and after placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, 20 ml of ropivacaine 0.25% is injected bilaterally. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.
219269813|NCT04468230|DRUG|Nicotine Transdermal Patch|Nicotine Treatment Condition
218987999|NCT07047794|OTHER|Assessment|Children with thoracic hyperkyphosis between the ages of 7 and 14 who meet the inclusion criteria will be included in this study, which was conducted to examine the scapular position and its relationships with upper extremity joint range of motion, strength and performance in children with thoracic hyperkyphosis.
218988000|NCT07049627|OTHER|Total Neoadjuvant Therapy (TNT)|Patients included in this retrospective cohort received total neoadjuvant therapy (TNT), consisting of systemic chemotherapy and radiotherapy, followed by curative-intent surgery. No experimental interventions were applied. The analysis focused on evaluating clinical, inflammatory, nutritional, and sarcopenia-based predictors of pathological response.
218988001|NCT07052565|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-6.0 x10\^5 CART cells/kg）
218988002|NCT07053748|RADIATION|Trimodality Bladder-preserving Therapy|High-risk NMIBC patients who have a strong desire to preserve their bladder actively choose to receive Trimodality Bladder-preserving Therapy instead of radical resection.
218988003|NCT07055126|OTHER|Individualised dietary counselling, coaching and resource provision around healthy eating for young children|Study participants randomised to receive the intervention will receive nutrition education support, through individualised dietary counselling, coaching and resource provision around healthy eating, with a particular focus on incorporating fresh meat and vegetables into a healthy, sustainable and safe diet for young children. Those in the control group will not receive this individualised nutrition education and supports.
219269814|NCT06319157|DEVICE|minimal access breast reconstruction with a latissimus dorsi muscle flap|minimal access breast reconstruction with a latissimus dorsi muscle flap
219269815|NCT06319157|DEVICE|conventional breast reconstruction with a latissimus dorsi muscle flap|conventional breast reconstruction with a latissimus dorsi muscle flap
219269816|NCT03714659|DEVICE|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
219269817|NCT00417053|BIOLOGICAL|filgrastim|
218988004|NCT07054957|OTHER|Handheld fan|Group using hand fans
218988005|NCT07054957|OTHER|Control Group|pre-test, mid-test and post-test will be administered.
218988006|NCT07054762|DIETARY_SUPPLEMENT|omega-3 supplements in female athletes|Participants in the experimental group were given four capsules of omega-3 fatty acids with breakfast every day for 8 weeks. Each capsule contains 150 mg of omega-3 fatty acids and has a ratio of 60% EPA and 40% DHA. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end. In addition, anthropometric measurements, simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
218988007|NCT07054762|DIETARY_SUPPLEMENT|Placebo Group|Participants in the control group were given a placebo containing maltodextrin with breakfast every day for 8 weeks. Each capsule contains 250 mg maltodextrin. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end of the study. Additionally, anthropometric measurements, a simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
218988008|NCT07055035|DEVICE|Bachmann Bundle Pacing|Implantation of a permanent pacemaker system. The atrial lead (Medtronic 3830 active electrode) is surgically positioned and fixed in the Bachmann bundle region, located at the angle between the superior vena cava and the atrium in the mid-posterior position of the high atrial septum. Successful placement is confirmed by achieving a P-wave width shortening of at least 30ms compared to the preoperative P-wave. The ventricular lead is positioned in the mid-to-lower portion of the ventricular septum. Pacing parameters are measured and confirmed to be good.
218988009|NCT07055035|DEVICE|Right Atrial Appendage Pacing|Implantation of a permanent pacemaker system using the conventional technique. The atrial active electrode is surgically positioned and fixed in the right atrial appendage. The ventricular lead is placed in the mid-to-lower portion of the ventricular septum. Pacing parameters (sensing \> 2.0mV; impedance between 300 to 1000Ω; threshold \< 1.5mV) are confirmed to be good.
218988010|NCT07055386|DRUG|GZR102|Administered SC
218988011|NCT07055386|DRUG|GZR18|Administered SC
218988012|NCT07054034|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|MG-ZG122 Humanized Monoclonal Antibody Injection
218988013|NCT07054034|OTHER|Placebo|MG-ZG122 Humanized Monoclonal Antibody Injection Placebo
218988014|NCT07054164|OTHER|dual-task aerobic exercise|In addition to aerobic training during treadmill walks, participants were given some cognitive tasks and were asked to continue these tasks throughout the exercise.
218988015|NCT07054164|OTHER|aerobic exercise|Aerobic training with a treadmill at medium-high intensity, 3 days a week, for 8 weeks, accompanied by a physiotherapist
218988016|NCT07054424|OTHER|Conventional occupation therapy|Standard occupational therapy focused on improving daily functional skills through task-specific training and adaptive techniques.
218988017|NCT07054424|OTHER|stretching exercise|Techniques involving passive or active stretching of muscles to enhance flexibility, reduce spasticity, and prevent contractures.
219269818|NCT00417053|DRUG|busulfan|
219269819|NCT00417053|DRUG|carboplatin|
219269820|NCT00417053|DRUG|cyclophosphamide|
218988018|NCT07054424|OTHER|rTMS|Non-invasive brain stimulation method using magnetic pulses to modulate cortical excitability and promote neural plasticity.
218988019|NCT07054424|DEVICE|bimanual therapy|A training approach that involves simultaneous use of both hands to enhance coordination and functional hand movements through guided exercises, including device-assisted and robot-assisted therapy
219269821|NCT00417053|DRUG|doxorubicin hydrochloride|
219269822|NCT00417053|DRUG|etoposide phosphate|
219269823|NCT00417053|DRUG|melphalan|
218988020|NCT07055412|DRUG|Y-3 for injection（40mg）|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
218988021|NCT07052994|DRUG|Revumenib|Given by IV
219269824|NCT00417053|DRUG|vincristine sulfate|
218988022|NCT07052994|DRUG|Cytrabine|Given by IV
219269825|NCT00417053|PROCEDURE|autologous bone marrow transplantation|
218988023|NCT07052994|DRUG|Daunorubicin|Given by IV
218988024|NCT07053553|OTHER|Education|It was planned to provide bed bath training to inpatients because 90.5% of the caregivers of the patients in the experimental group wanted to receive bed bath training.
218988025|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Women|HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test
219269826|NCT00417053|PROCEDURE|bone marrow ablation with stem cell support|
219269827|NCT00417053|PROCEDURE|conventional surgery|
219269828|NCT00417053|PROCEDURE|peripheral blood stem cell transplantation|
219269829|NCT00417053|RADIATION|radiation therapy|
219269830|NCT00839384|DEVICE|Advisa IPG|Implantable Pulse Generator will be implanted
219269831|NCT03090750|DRUG|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
219269832|NCT03090750|DRUG|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
219269833|NCT03090750|OTHER|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
219269834|NCT03091816|DEVICE|Computed Tomography Perfusion Imaging|Undergo DPCT
219269835|NCT03091816|OTHER|Laboratory Biomarker Analysis|Correlative studies
219269836|NCT03091816|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219269837|NCT02503098|BEHAVIORAL|Recovery Record adaptive smartphone application|
219269838|NCT02503098|BEHAVIORAL|Recovery Record standard smartphone application|
219269839|NCT02691988|OTHER|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
219269840|NCT02691988|OTHER|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
218988026|NCT07054359|DRUG|Treatment by TDF if HBcrAg RDT positive|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
218988027|NCT07054359|DRUG|Treatment by TDF|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
218988028|NCT07054359|OTHER|Social sciences component|"The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study.~A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers"
219269841|NCT02454504|DRUG|sugammadex|
219269842|NCT02454504|DRUG|Neostigmine|
219269843|NCT00415701|DRUG|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
219269844|NCT00415701|DRUG|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
219269845|NCT00415701|DRUG|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
219269846|NCT00415701|DRUG|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
219269847|NCT00415701|OTHER|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
219269848|NCT05860621|BEHAVIORAL|Brief Physical Activity Counselling|The brief physical activity counselling program will comprise 8 sessions (120 minutes each), every fifteen days, addressing the following themes: reasons to change, an introduction to the PAC-WOMAN program and principles, types of physical activity and their benefits, strategies on how to become more active and less sedentary, how to safely practice exercise at home, the importance of social support for doing more physical activity, barriers and facilitators for becoming more active, development of coping plans and strategies to overcome those barriers, establishing SMART goals, self-monitoring, medical aspects related to symptom management in breast cancer survivors, body image and self-acceptance, sharing experiences with role models, and re-evaluating action plans. It will be delivered in a need-supportive interpersonal climate, according to Self-Determination Theory principles.
219269849|NCT05860621|BEHAVIORAL|Structured Exercise Program|The structured exercise program was informed by the most recent guidelines for exercise prescription and safe practice in cancer populations. A supervised program of 32 sessions (over 4 months), lasting 90 min each, and taking place twice a week, was developed. The program combines aerobic, strength and mobility exercises, and is organized in four mesocycles, with progressive intensity, always adapted according to participants' initial assessments and evolution throughout the weeks. Once every 15 days, a thematic group class will be offered to participants, so that they can experiment and discover new physical activities, and more easily maintain regular practice in the future.
219269850|NCT04381923|DEVICE|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (Sp02) remains \< 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
219269851|NCT04381923|DEVICE|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (SpO2) remains \< 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
219269852|NCT05933785|PROCEDURE|transanal endoscopic ISR|perform ISR using laparoscopy through transanal port
218988029|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Infants|At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.
218988030|NCT07054905|DEVICE|HiCardi wearable ECG|A chest-attached, single-lead wearable ECG device used to collect real-time ECG data from hemodialysis patients. The device records ECG waveforms during dialysis sessions and transmits the data to a secure cloud platform. This non-invasive tool is used to analyze T-wave morphology for early detection of hyperkalemia in patients with chronic kidney disease.
218988031|NCT07054398|DRUG|Isotretinoin|"* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons.~* Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris."
219269853|NCT01560845|PROCEDURE|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
219269854|NCT01560845|PROCEDURE|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
219269855|NCT04202445|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
218988032|NCT07053215|DEVICE|Argon-Helium Cryoablation|Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.
218988033|NCT07053215|DRUG|Camrelizumab|200 mg intravenously every 3 weeks for 4 cycles.
218988034|NCT07053215|DRUG|Platinum-based doublet chemotherapy|"* Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Administered for 4 cycles."
218988035|NCT07053241|DEVICE|Game-App-KNEE|"* In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria.~* The mobile-compatible web-based gamified application created for individuals included in the intervention group will be downloaded to patients' phones in the outpatient clinic phase and information will be provided on how to use the application, and the training will be repeated if they have questions.~* Individuals in the intervention group will be able to access both the education module in PDF format and the game module containing the gamified education program for three months in the application.~* In-app reminder messages will be sent to individuals to actively use the application. (We missed you today, warrior, where are you, let's finish this job, etc.)~* Whether the application is actively logged in, how long it is in the application, and the level of success in the game will be monitored by the researcher from the administrator panel."
218988036|NCT07053241|OTHER|Control group (standart care)|Description: In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria. -An application will be installed on the phones of individuals included in the control group during the outpatient clinic phase. -In the first information phase, individuals will be registered to the system with their username and password by the researcher via their smartphones or tablets and will be allowed to enter the application. Considering that the participant may forget their username and password, a 'forgot my password' button will be added. -Individuals in the control group will only be able to access the training module in PDF format for three months.
218988037|NCT07054541|PROCEDURE|Ultrasound-guided intervention with assistance of specialized instruments|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under pure ultrasound guidance in the entire process with assistance of specialized instruments
218988038|NCT07054541|PROCEDURE|fluoroscopy-guided intervention|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under fluoroscopic guidance in the entire process
218988039|NCT07054307|DRUG|MRG003|MRG003 (2.3 mg/kg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
218988040|NCT07054307|DRUG|HX008|HX008 (200 mg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
218988041|NCT07054788|OTHER|Flexibility Exercise|"Participants will perform calf muscle stretching exercises. The participant will be asked to keep the knee of the stretched leg straight with the heel flat on the ground, slightly bend the front knee, and push the hips toward a wall.~The exercise will be done in 2 sets of 3 repetitions, every repetition for 30 seconds and a ten-second rest, with a one-minute rest between sets"
218988042|NCT07054788|OTHER|Mulligan mobilization with movement|The Mulligan mobilization techniques involve talar glide and fibular glide. Talar glide involves manually stabilizing the patient's talus and leg with anteroposterior direction pressure, while fibular glide involves a pain-free sustained anterior to posterior, slightly superior, and lateral glide of the distal fibula. The patient is then asked to plantar-flex, invert the foot, and perform overpressure. The technique is performed during ankle dorsiflexion in a closed kinetic chain.
218988043|NCT07054788|OTHER|Kinesiology Taping|"The length of tape is calculated using a formula: B = A + (XA ∗ 0.35), where A is the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails. Fibular taping is applied immediately after the MWM to improve positional alignment, wrapping around the distal tibia and applying Mueller tape in the same direction. Talar taping involves wrapping Mueller tape from the talus downward and posterior to the calcaneus while holding the ankle in slight dorsiflexion."
218988044|NCT07054788|OTHER|Placebo tape|"The formula for cutting tape length is B = A + (XA ∗ 0.35), where A represents the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails' length. The tape application involves two steps: from below the medial calcaneus to the medial aspect of the lower leg, and from below the lateral malleolus to the lateral aspect."
218988045|NCT07055061|BEHAVIORAL|ISO Principle Music Intervention|Participants will receive music playlists designed according to the ISO principle, which involves matching the participant's current emotional state and gradually transitioning to music reflecting a desired mood. The intervention aims to reduce stress and support emotional regulation by guiding affective resonance through music progression.
218988046|NCT07055061|BEHAVIORAL|Compensation Principle Music Intervention|Participants will receive music playlists based on the compensation principle, where the music contrasts the participant's current emotional state by directly presenting tracks aligned with the desired emotional outcome (e.g., calm music for stressed mood). This approach seeks to counteract stress and shift affective states through musical contrast.
218988047|NCT07053761|DRUG|five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths|Experimental group: If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll take five - flavor sophora flavescens enteric - coated capsules (4 capsules thrice daily for 8 weeks), plus glutamine and warm - water sitz baths.
218988048|NCT07053761|DRUG|glutamine and warm - water sitz baths|If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll use only glutamine and warm - water sitz baths.
218988049|NCT07054827|OTHER|Hemodialysis|The participants receive hemodialysis for 4 hours, 3 times per week
218988050|NCT07054827|OTHER|Intradialytic resistive exercise|"The participants will receive intradialytic resistive exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session in a recumbent position or seated position.~Time of session: The program starts with a warm-up phase which is 3:5 minutes in the form of light aerobic and stretching exercises for big muscles and ends with a cooling down phase which is 3:5 in the form of light aerobic exercise.~The resistance exercises include exercises for the big muscles of only the Lower Limbs (LL) muscles of single and multiple-joint which are:1- Knee extensors, 2- Knee flexors, 3- Hip flexors, 4- Hip abductors and adductors. using sandbags of different weights. Sandbag weights are placed on the distal third of the tibia for LL exercises.~Intensity: On the Borg's Scale of Perceived Exertion, which will be measured every 5 minutes during exercise."
219269856|NCT02839005|OTHER|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
219269857|NCT02839005|OTHER|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
219269858|NCT02735304|OTHER|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
219269859|NCT01371422|OTHER|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
219269860|NCT01371422|OTHER|Saline|Ultrasonography and local infiltration of saline will only be performed
219269861|NCT04560374|DEVICE|crochet octopus|Delivering crochet octopus to the hands of the neonates
219269862|NCT02274090|DRUG|Placebo gel|Placebo gel consist of drug without the active component.
219269863|NCT02274090|DRUG|1% Metformin gel|Metformin gel consist of active component.
219269864|NCT03721705|DEVICE|Renew NCP-5|Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
218988051|NCT07054827|OTHER|Intradialytic aerobic exercise|"Patients with chronic kidney disease will receive an intradialytic aerobic exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session using a stationary bicycle ergometer in a supine position or seated position.~Time of session: The warming up and the cooling down phase consists of 5:10 minutes of slow Pedaling. the main exercise phase consisted of 20 minutes of cycling.~Intensity: The use of the Borg's Scale of Perceived Exertion (RPE) scale enables the intensity of the exercise to be adapted According to the tolerance of each patient.~The use of the RPE scale enables the intensity of the exercise to be adapted According to the tolerance of each patient, the aim was to obtain between 11 light And 14 somewhat hard."
218988052|NCT07054476|OTHER|Intermittent Enteral Nutrition|"Intermittent Enteral Nutrition (IE):~The intervention involves intermittent enteral nutrition using a diabetic-specific enteral formula, administered in 5 separate sessions daily with scheduled breaks between feedings. Each feeding session is followed by a break (1-2 hours). Energy needs are calculated based on the ESPEN guideline (25 kcal/kg/day). This protocol is designed to assess the effects of intermittent feeding in critically ill diabetic patients."
219269865|NCT01790295|DRUG|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
219269866|NCT05783609|DRUG|Epcoritamab|T-cell bispecific antibody, via subcutaneous injection
219269867|NCT05783609|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, via IV infusion
219269868|NCT03105063|DIAGNOSTIC_TEST|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
219269869|NCT04471545|PROCEDURE|Pectoral nerve block type II|A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided
219269870|NCT05194670|DEVICE|enhanced depth of focus IOL|Acunex Vario AN6V, enhanced depth of focus IOL
219269871|NCT05194670|DEVICE|monofocal IOL|Acunex AN6, monofocal IOL
219269872|NCT06291064|DRUG|Cyclophosphamide|Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
219269873|NCT06291064|DRUG|Epirubicin|Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
219269874|NCT06291064|DRUG|Docetaxel|Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
218988053|NCT07054476|OTHER|Continuous Enteral Nutrition (CE)|Continuous Enteral Nutrition (CE): The intervention involves continuous enteral nutrition provided via a diabetic-specific enteral formula, administered 24 hours a day with 1-hour breaks between feeding sessions. The feeding rate starts at 40cc per hour and is gradually increased based on tolerance. Energy needs are calculated using the ESPEN guideline (25 kcal/kg/day).
218988054|NCT07052890|DIETARY_SUPPLEMENT|Curcumin, vitamin d and green tea extract|"A combination of the following ingrediants per 4 capsules:~CurcuWin® 1000mg - of which 200mg Curcuminoids~Green Tea Extract 400mg - (0.1-0.5% caffeine)~Vitamin D₃ 50 µg 2000IU"
218988055|NCT07052890|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert color matched power
218988056|NCT07053995|PROCEDURE|Vaginal cleaning|Before giving incision for C-section surgery, vaginal cleaning was done with 50cc diluted antiseptic solution as a single push.
218988057|NCT07053995|OTHER|Non vaginal cleansing|Routine abdominal scrubbing was carried out before incision. No vaginal cleaning was done before incision.
218988058|NCT06321757|DEVICE|Percutaneous Coronary Intervention with DCB and DAPT|"* Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT)~* Patients with PCI (DCB) + short DAPT"
218988059|NCT07052955|OTHER|The Normal Riddles Book|"The distribution of the participating children to the experimental and control groups will be carried out by simple random sampling method. Children included in the Normal Riddle Book group will be introduced to a book containing general, entertaining riddles that are not related to health during the pre-circumcision period.~The book will be given to the children approximately 1 hour before the circumcision operation and the children will be allowed to read the puzzles, solve them or interact with the researcher/nurse. The application period is planned as approximately 20-30 minutes.~The children's fear, anxiety and pain levels will be measured before and after the application. During the application process, the children's attention level, interest in the book and general behavior will be observed and recorded."
218988060|NCT07052955|OTHER|Health Riddles Group|"The children included in this group will be presented with the Health Riddles Book, which contains health information and is prepared to reduce fear and anxiety before the circumcision.~The book will be given to the children approximately 1 hour before the circumcision procedure and the children will be allowed to read the riddles or interact with the researcher/nurse. The application time is planned to be 20-30 minutes. Before and after the application, the children's fear, anxiety and pain levels will be measured with the Introductory Information Form, Child Fear Scale, Child Anxiety Scale-State and Wong-Baker Face Pain Scale.~The data obtained from the health riddles group will be compared with the data obtained from the normal riddle and control groups and the unique effect of the riddles containing health information on fear, anxiety and pain will be analyzed."
218988061|NCT07055347|OTHER|Comprehensive Home-based Cardiac Rehabilitation Program for Postoperative Congenital Heart Disease Patients and Their Caregivers|Intervention Description: For children, provide age-appropriate rehab manuals with pictures and texts to encourage participation. Include gentle physical activities, breathing and stretching exercises. For caregivers, offer detailed manuals and checklists. Organize training. Manage drugs with personalized guidance. Provide health education for both via manuals and video consultations. Focus on mental and physical health with support and activities. Regular phone follow-ups ensure nursing continuity. Multidisciplinary team offers professional support through video consultations and referrals.
218988062|NCT06615895|BEHAVIORAL|Telehealth home activity|Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
218988063|NCT07055087|DRUG|Prasinezumab|Prasinezumab 1500 mg monthly infusion
218988064|NCT07055087|DRUG|Sodium Chloride|Saline infusion (0,9 % sodium chloride) monthly infusion
218988065|NCT07053033|PROCEDURE|Surgery|Participants will initially undergo craniotomy and surgical resection of lesions or LITT
218988066|NCT07053033|PROCEDURE|LITT|Participants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.
219269875|NCT06291064|DRUG|Carboplatin|Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
219269876|NCT06291064|PROCEDURE|Breast Surgery|Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
219269877|NCT06291064|DRUG|Capecitabine|Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
219269878|NCT06046833|DEVICE|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
219269879|NCT06046833|OTHER|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
219269880|NCT05139290|BEHAVIORAL|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
218988067|NCT07054736|DRUG|XKH001 Injection|"100 mg quaque 4 weeks dose group: Subjects will receive 1 mL (1 vial) of XKH001 injection (100 mg) and 5 mL (5 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~300 mg quaque 4 weeks dose group: Subjects will receive 3 mL (3 vials) of XKH001 injection (300 mg) and 3 mL (3 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~600 mg quaque 4 weeks dose group: Subjects will receive 6 mL (6 vials) of XKH001 injection (600 mg) subcutaneously each time, once every 4 weeks, for a total of 5 times."
218988068|NCT07054736|DRUG|XKH001 Placebo Injection|Subjects will receive 6 mL (6 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.
218988069|NCT07054671|DIETARY_SUPPLEMENT|Elderberry-Based Functional Beverage|A polyphenol- and anthocyanin-rich beverage derived from Sambucus nigra L., administered once daily for 12 weeks as a dietary supplement.
218988070|NCT07054671|DIETARY_SUPPLEMENT|Placebo Beverage|A placebo beverage that mimics the elderberry drink in color and flavor but contains no polyphenols or bioactive compounds. Consumed once daily for 12 weeks.
218988071|NCT07054437|OTHER|Gross Motor Development Screening Tool|"This intervention is an automated gross motor development screening tool specifically designed for independently walking children aged one to six years old in Taiwan. What sets it apart is its use of artificial intelligence (AI) algorithms to analyze motion data, enabling early identification of potential gross motor developmental delays.~Unlike traditional methods that rely on manual, visual observation and subjective recording by healthcare professionals, this tool aims to significantly reduce assessment time and human resource costs. Furthermore, its automated nature makes it uniquely suited for telemedicine applications, allowing for remote screenings and overcoming geographical barriers to access early intervention services. The tool will be developed and validated against established developmental norms relevant to the Taiwanese population."
219269881|NCT05868941|DEVICE|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
218988072|NCT07055178|DEVICE|Virtual reality (VR) guided meditation therapy|Participants will engage in the TRIPP relaxation app on the MetaQuest 3 VR headset.
218988073|NCT07055178|OTHER|Treatment as usual|Participants undergo a standard vasectomy.
219269882|NCT03908892|DRUG|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
219269883|NCT03908892|DRUG|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
219269884|NCT05698251|BEHAVIORAL|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
219269885|NCT01441219|DEVICE|Colon 2|Ingest one colon 2 capsule
218988074|NCT07052968|DEVICE|Echocardiography|Echocardiography is the non invasvive interventional assessment and the RHC is the invasive international assessment of the hemodynamics in PH patients with ckd.
218988075|NCT07053878|PROCEDURE|Non-Surgical Periodontal Therapy (Step 1 & 2)|Comprehensive supra- and sub-gingival instrumentation (scaling, root planing, ultrasonic and manual instruments), following EFP step-1 and step-2 protocols. Includes individualized oral-hygiene instruction and motivation.
218988076|NCT07053878|PROCEDURE|Supragingival Plaque Removal and Polishing|Professional supragingival scaling with ultrasonic tips plus rubber-cup polishing in a single session. Includes the same individualized oral-hygiene instruction and motivation provided to the experimental group.
218988077|NCT07053735|DRUG|Nimotuzumab and Radiotherapy|"1. nimotuzumab: 200mg, iv, qw, used for 5 weeks.~2. radiotherapy: radiotherapy is performed according to clinical routine;"
218988078|NCT07055022|PROCEDURE|LLLT|Patients in the LLLT group will receive 3 sessions of LLLT treatment with Eye-light device (Espansione Group S.p.A., Bologna, Italy) 7 days before phacoemulsification (D-7), 7 days after phacoemulsification (D+7), and 30 days after phacoemulsification (D+30). Each session will consist of 15 minutes of light treatment using a wavelength of 625±40 nm and maximum power of 10 W (maximal total fluence of 32 J/cm2 ± 20% per session) applied on the periorbital region. The patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
219269886|NCT00389272|DRUG|Ibuprofen, acetaminophen|
219269887|NCT00181506|PROCEDURE|dose escalation (radiotherapy treatment schedule)|
218988079|NCT07055022|PROCEDURE|IPL|Patients in the IPL group will receive 3 sessions of IPL treatment with OptiClear device (Alma Lasers GmbH, Nuremberg, Germany) at D-7, D+7, and D+30. Each session will comprise 90 homogenously spaced pulses of light (wavelength of 550-650 nm, pulse time 10,12 or 15 ms, pulse repetition rate 1-2 Hz) using an energy density of 8-12 J/cm2 adjusted to Fitzpatrick skin type according to the manufacturer's recommendations. The treatment will be applied to the lower eyelid region. Ultrasound gel, as well as protective eye patches will be used, and the patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
218988080|NCT07055139|BEHAVIORAL|Digital Aftercare|A structured, app-based digital aftercare program designed for patients recovering from distal radius or clavicle fractures. The 12-week program includes weekly video-guided physiotherapy exercises, educational content on fracture healing, pain management guidance, and milestone-based progression. The program replaces in-person physiotherapy and standard clinic follow-up, with patients instructed to follow the app independently. Medical contact is initiated only in case of uncertainty or complications.
218988081|NCT07055139|BEHAVIORAL|Traditional Aftercare|Standard postoperative follow-up care for patients with distal radius or clavicle fractures, consisting of scheduled clinical visits and in-person physiotherapy sessions according to institutional protocols. The treatment includes individual exercise instruction, physiotherapy, and physician-led follow-up at defined intervals during the 12-week rehabilitation period.
218988082|NCT07053722|RADIATION|NA-TMT|After neoadjuvant therapy, patients choose trimodality therapy (TMT) for bladder preservation over radical cystectomy.
218988083|NCT07055295|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|Receiving three doses of rabies vaccine rabies vaccine manufactured by Sinovac using a three-dose PrEP schedule
218988084|NCT07055295|BIOLOGICAL|Verorab®|Receiving three doses of marketed rabies vaccine manufactured by Sanofi using the three-dose PrEP schedule
218988085|NCT07054450|COMBINATION_PRODUCT|All patients in the study will be included in rehabilitation program|A total of 110 consecutive participants with previous diagnosed CR lasting more than 3 months will be enrolled in this study. After initial assessment, participants without surgical recommendation, will be included into two groups: Study Group will be received 10 sessions of rehabilitation program and nutraceutical product daily, 3 months, and Control Group will be received 10 sessions of rehabilitation program. The rehabilitation program include physical therapy (electrical muscle stimulation of the neck muscle and upper limb muscles , low-Level Laser Therapy and ultrasound) and kinetic training.
218988086|NCT07054450|DIETARY_SUPPLEMENT|Study Group will receive a nutraceutical product daily, 3 months.|Study Group will receive a nutraceutical product daily, 3 months in addition to the rehabilitation program.
218988087|NCT07053176|DRUG|0.5% Lidocaine|0.5% lidocaine injection will be administered in the paravertebral intramuscular region with 12 mm, 30 G needle from C2 to C7 bilaterally
219269888|NCT02489734|DRUG|sevoflurane|extubation when end-tidal concentration of sevoflurane \< 0.5%
219269889|NCT02489734|DRUG|Sevoflurane|extubation when end-tidal concentration of sevoflurane \>= 0.5%
218988088|NCT07053176|DRUG|Saline Solution (NaCl 0,9%)|saline solution will be administered bilaterally in the paravertebral intamuscular region from C2 to C7 with 12 mm 30 G needle
219269890|NCT03597373|OTHER|reintubation|Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
219269891|NCT01746147|OTHER|No intervention and study treatment|
218988089|NCT06603623|DRUG|BHV-2100|BHV-2100 75mg
218988090|NCT06603623|DRUG|BHV-2100|BHV-2100 150 mg
219269892|NCT03721172|DRUG|Apremilast|Apremilast, oral, twice daily
218988091|NCT06603623|DRUG|Placebo|matching placebo
218988092|NCT06753214|OTHER|Telemedicine-Based Education|Intervention through telemedicine
218988093|NCT06753214|OTHER|Standard Care (in control arm)|Sham comparator through telemedicine
219269893|NCT03721172|OTHER|Placebo|Placebo, oral, twice daily
219269894|NCT03204162|OTHER|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
218988094|NCT01453361|BIOLOGICAL|Vigil™ Vaccine|
218988095|NCT06649604|DEVICE|Vibration Anesthesia Device|The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
218988096|NCT06649604|PROCEDURE|Panretinal Photocoagulation|Laser treatment for diabetic retinopathy done in a standard fashion
218988097|NCT06810141|BIOLOGICAL|rMBCG|1-19.2e8 colony-forming units (CFU) of rMBCG
219269895|NCT04594837|DEVICE|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
219269896|NCT04594837|OTHER|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
218988098|NCT06809608|DRUG|RO7795081|A single dose will be administered orally per study period (see arm descriptions).
218988099|NCT06809608|DRUG|Itraconazole|Administered orally (see arm description).
218988100|NCT06809608|DRUG|Gemfibrozil|Administered orally (see arm description).
218988101|NCT06809608|DRUG|Cyclosporine|A single dose will be administered orally per study period (see arm descriptions).
219269897|NCT04594837|DEVICE|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
218988102|NCT06897735|DRUG|Afatinib Dimaleat|printed capsule containing 40 mg afatinib dimaleate
218988103|NCT06897735|BIOLOGICAL|inhalation of afatinib dimaleate|inhalation stable form of afatinib dimaleate at an equivalent therapeutic dose in a single-use maintenance-free ultrasonic inhaler with controlled frequency and number of inhalations
218988104|NCT04175483|OTHER|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
218988105|NCT06926608|BEHAVIORAL|Actívatexto|Actívatexto is a mobile intervention that promotes both smoking cessation and physical activity. Actívatexto integrates four components: 1) a text messaging program that promotes both smoking cessation and physical activity, 2) wearable devices to monitor physical activity, 3) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 4) an online dashboard where the research team manages participants' incoming and outgoing data from both the text messaging program and wearable devices.
218988106|NCT06926608|BEHAVIORAL|Decídetexto|Decídetexto is a mobile intervention that solely promotes smoking cessation. Decídetexto integrates three components: 1) a text messaging program that solely promotes smoking cessation, 2) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 3) an online dashboard where the research team manages participants' incoming and outgoing data from the text messaging program.
218988107|NCT04560998|DRUG|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
218988108|NCT04560998|DRUG|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
218988109|NCT06907329|DIETARY_SUPPLEMENT|NMN|NMN SR tablets(1000mg/tablets) , 1 tablet daily before breakfast
218988110|NCT06907329|DIETARY_SUPPLEMENT|Placebo|Matching Placebo (tablets) once daily before breakfast
218988111|NCT05794230|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
218988112|NCT05794230|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
218988113|NCT05794230|BIOLOGICAL|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
218988114|NCT05794230|BIOLOGICAL|Pneumoccocal Vaccine|Suspension for injection - intramuscular
218988115|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
218988116|NCT05794230|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
219269898|NCT04594837|DEVICE|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
219269899|NCT01914081|OTHER|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
218988117|NCT05794230|BIOLOGICAL|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
218988118|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Lyophilized powder for injection - subcutaneous
218988119|NCT05794230|BIOLOGICAL|Rotavirus vaccine|Oral solution - oral
218988120|NCT05794230|BIOLOGICAL|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
218988121|NCT05794230|BIOLOGICAL|Measles vaccine|Freeze-dried powder for reconstitution and injection - subcutaneous
218988122|NCT05794230|BIOLOGICAL|Varicella vaccine live|Sterile powder and diluent for injection - subcutaneous
218988123|NCT05794230|BIOLOGICAL|Varicella vaccine live|Lyophilized powder for injection - subcutaneous
218988124|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
218988125|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Suspension for injection - intramuscular
218988126|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given a mouth rinse.
218988127|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given mouth rinse.
218988128|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
218988129|NCT04659928|DRUG|Placebo|Subjects will be given a placebo (plain water) mouth rinse
218988130|NCT06065228|OTHER|AlgometRx Nociometer|Physiologic characterization of disease activity
218988131|NCT06911866|DRUG|RC1416|there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
218988132|NCT06911866|DRUG|RC1416 Placebo|Each subjects will receive the placebo once by subcutaneous injection.
218988133|NCT04589728|DRUG|Venetoclax plus HMA|patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.
218988134|NCT06937827|BEHAVIORAL|HF Kit and Follow-ups|"These patients will receive TOCC intervention, which includes: pre-discharge introduction to the program; watching educational videos about heart failure via Mytonomy; receiving the American Heart Association's Get With The Guidelines (GWTG) booklet and a heart failure (HF) kit. These patients will receive a follow-up phone call days 1 to 3 days post discharge from the pharmacist and nurse practitioner to review discharge instructions, provide medication education, and assess clinical status; a second follow-up call will be conducted days 21 to 24 post discharge. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate"
218988135|NCT06951100|DIAGNOSTIC_TEST|CT coronary angiography|To assess the presence of obstructive coronary artery disease, participants will either have coronary angiography as part of their routine care or they will return for a research CT scan of their heart (CT Coronary Angiogram)
218988136|NCT05960799|DEVICE|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
218988137|NCT05960799|DEVICE|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
218988138|NCT03980041|DRUG|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
218988139|NCT03980041|DRUG|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
218988140|NCT03980041|DRUG|Placebos|Placebo administered orally in 28-day cycles
218988141|NCT02055716|DRUG|Sulforadex|
218988142|NCT02055716|DRUG|alpha-cyclodextrin|
218988143|NCT04918433|PROCEDURE|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
218988144|NCT01410032|PROCEDURE|Plate fixation|Reconstruction plate
218988145|NCT01410032|PROCEDURE|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
218988146|NCT03552315|DIETARY_SUPPLEMENT|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
218988147|NCT03552315|DIETARY_SUPPLEMENT|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
218988148|NCT01338766|PROCEDURE|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
219269900|NCT01914081|OTHER|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
219269901|NCT04589299|BIOLOGICAL|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
219269902|NCT01951768|DRUG|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
219269903|NCT01951768|DRUG|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
219269904|NCT05534932|DEVICE|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
219269905|NCT02509520|DIETARY_SUPPLEMENT|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
218988149|NCT03558776|DIETARY_SUPPLEMENT|linseed oil|linseed oil and defined background diet
218988150|NCT02338141|DEVICE|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
218988151|NCT02338141|DEVICE|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
218988152|NCT01827605|OTHER|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
218988153|NCT01827605|DRUG|BEAM|"BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc"
218988154|NCT04360629|DRUG|Tranexamic Acid|Tranexamic Acid will be given through central vein
218988155|NCT04360629|DRUG|normal saline|normal saline will be given through central vein
218988156|NCT04214769|DIAGNOSTIC_TEST|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
218988157|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|This is dose level 0 (de-escalation).
218988158|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|This is dose level 1, the starting dose.
218988159|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|This is dose level 2.
218988160|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|This is dose level 3.
219269906|NCT00951470|OTHER|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
219269907|NCT00951470|OTHER|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
218988161|NCT05976555|BIOLOGICAL|Maximum tolerated dose|The maximum tolerated dose is yet to be determined.
218988162|NCT04091854|DRUG|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
218988163|NCT00764283|DEVICE|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
218988164|NCT00764283|DEVICE|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
218988165|NCT00764283|DEVICE|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
218988166|NCT00530244|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
218988167|NCT00530244|DIETARY_SUPPLEMENT|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
218988168|NCT05497154|BEHAVIORAL|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
218988169|NCT04602988|DEVICE|EEG|EEG monitoring of brain rhythms
218988170|NCT00969917|DRUG|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
218988171|NCT01912365|PROCEDURE|Above Elbow Cast|
218988172|NCT01912365|PROCEDURE|Long Arm Splint|
218988173|NCT06164977|PROCEDURE|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
218988174|NCT00653744|DRUG|Rosuvastatin|
219269908|NCT00951470|OTHER|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
219269909|NCT01968889|OTHER|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
218988175|NCT00653744|DRUG|Atorvastatin|
218988176|NCT02314702|DEVICE|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
218988177|NCT00289445|DRUG|Mitomycin C|
219269910|NCT00745771|DRUG|Diractin|
218988178|NCT00289445|DRUG|5-FU|
218988179|NCT00289445|DRUG|Folinic acid|
218988180|NCT00401596|DRUG|Xolair (omalizumab)|
218988181|NCT00522197|DIETARY_SUPPLEMENT|multi-herbal agent ACAPHA|
218988182|NCT00522197|DIETARY_SUPPLEMENT|Sugar Pill|
218988183|NCT00036452|DRUG|lopinavir/ritonavir|
218988184|NCT00036452|DRUG|emtricitabine|
218988185|NCT00036452|DRUG|stavudine|
218988186|NCT00036452|DRUG|tenofovir DF|
218988187|NCT05092724|PROCEDURE|fetal blood transfusion|transfusion of fetal blood
218988188|NCT00325728|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
218988189|NCT00325728|DRUG|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
218988190|NCT02066805|DRUG|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
218988191|NCT06959030|OTHER|No Intervention: Observational Cohort|Observation study
218988192|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
218988193|NCT04525378|OTHER|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
218988194|NCT01748669|DIETARY_SUPPLEMENT|Garlic oil|Oral administration
218988195|NCT04678661|DEVICE|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
218988196|NCT04678661|BEHAVIORAL|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
218988197|NCT00019097|DRUG|autologous tumor cell vaccine|
218988198|NCT00019097|DRUG|keyhole limpet hemocyanin|
219269911|NCT00745771|DRUG|Diractin|
218988199|NCT00019097|DRUG|melphalan|
218988200|NCT00019097|DRUG|sargramostim|
218988201|NCT00000308|DRUG|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
219269912|NCT05036525|DEVICE|HANBIO BarriGel|an anti-adhesive product
219269913|NCT00996502|DRUG|Docetaxel|"Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
219269914|NCT00996502|DRUG|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
219269915|NCT00996502|DRUG|Erlotinib|200 mg of Erlotinib PO daily days 2-16
219269916|NCT00996502|DRUG|Prednisone|5 mg of Prednisone PO bid
218988202|NCT00000308|DRUG|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
218988203|NCT00000308|DRUG|placebo|placebo
218988204|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
218988205|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
218988206|NCT05048290|OTHER|Communication Skills Training|Participate in communication workshops
218988207|NCT05048290|OTHER|Communication Skills Training|Participate in generic communication skills workshops
218988208|NCT05048290|OTHER|Educational Intervention|Develop a video
218988209|NCT05048290|OTHER|Survey Administration|Complete surveys
218988210|NCT06536751|RADIATION|Photobiomodulation|LED photobiomodulation therapy, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). PBM will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght.
218988211|NCT06536751|OTHER|Institution's Standard Physiotherapy|Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
219269917|NCT01198483|PROCEDURE|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
219269918|NCT01198483|PROCEDURE|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
219269919|NCT06477861|OTHER|calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity|calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)
219269920|NCT01013545|BEHAVIORAL|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
218988212|NCT06536751|RADIATION|Photobiomodulation Placebo|The same procedures of PBM group but device will be turned off
218988213|NCT05393804|BIOLOGICAL|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
218988214|NCT01397890|DRUG|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
218988215|NCT01397890|DRUG|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
218988216|NCT00156052|RADIATION|Conventional whole breast radiation schedule|
218988217|NCT00156052|RADIATION|Hypofractionated whole breast radiation schedule|
218988218|NCT00462618|DRUG|Quetiapine|
219269921|NCT00037713|BIOLOGICAL|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.
218988219|NCT00462618|BEHAVIORAL|Cogntive behavioral therapy|
218988220|NCT01603498|DRUG|Dexamethasone|Dexamethasone 8mg
218988221|NCT01603498|DRUG|Methylprednisolone|Methylprednisolone 40mg
218988222|NCT06231732|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
218988223|NCT06231732|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
218988224|NCT00002651|DRUG|bicalutamide|Given orally
218988225|NCT00002651|DRUG|goserelin acetate|Given subcutaneously
219269922|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
219269923|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
218988226|NCT00002651|OTHER|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
218988227|NCT00659048|DRUG|Ciclesonide|Ciclesonide 200µg versus Placebo
218988228|NCT00659048|DRUG|Placebo|placebo
218988229|NCT03296098|DRUG|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
218988230|NCT05666076|PROCEDURE|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
218988231|NCT05666076|PROCEDURE|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
218988232|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
218988233|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
218988234|NCT04797078|PROCEDURE|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
218988235|NCT04797078|PROCEDURE|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
218988236|NCT00187200|DEVICE|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
218988237|NCT00187200|DEVICE|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
218988238|NCT03829839|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
218988239|NCT03829839|DRUG|Lorazepam 1 mg|Oral administration of 1mg lorazepam
218988240|NCT03829839|DRUG|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
218988241|NCT03829839|DRUG|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
218988242|NCT00841919|DRUG|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
218988243|NCT00841919|DRUG|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
218988244|NCT00841919|DRUG|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
218988245|NCT00006426|PROCEDURE|Achilles tendon-lengthening surgery|
218988246|NCT06558396|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
218988247|NCT05267847|OTHER|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
218988248|NCT05267847|OTHER|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
218988249|NCT00487708|DRUG|canakinumab|
218988250|NCT03493620|PROCEDURE|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
218988251|NCT03493620|PROCEDURE|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
219269924|NCT04706689|BEHAVIORAL|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
219269925|NCT04706689|BEHAVIORAL|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
219269926|NCT00621205|BEHAVIORAL|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
219269927|NCT00025909|PROCEDURE|Leukapheresis|
218988252|NCT00638482|DRUG|Hydrochlorothiazide|Hydrochlorothiazide
218988253|NCT00182884|DRUG|Donepezil|
218988254|NCT04736693|DRUG|Raloxifene|Raloxifene dispensing claim is used as the reference group.
218988255|NCT04736693|DRUG|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
218988256|NCT05954975|COMBINATION_PRODUCT|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
218988257|NCT03928119|BEHAVIORAL|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
218988258|NCT03260309|PROCEDURE|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
218988259|NCT03260309|PROCEDURE|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
218988260|NCT03757325|DRUG|DNL747|DNL747
218988261|NCT03757325|DRUG|Placebo|Placebo
218988262|NCT04811885|OTHER|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
219269928|NCT02402322|BEHAVIORAL|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
218988263|NCT03070028|PROCEDURE|crystallised phenol|crystallised phenol will be applied to sinus cavity
218988264|NCT03070028|PROCEDURE|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
219269929|NCT02402322|BEHAVIORAL|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
219269930|NCT06035536|DEVICE|Symphony™ plus Off-loading|Application of Symphony™
218988265|NCT05231057|OTHER|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
218988266|NCT05231057|OTHER|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
218988267|NCT00030290|PROCEDURE|high-intensity focused ultrasound ablation|
219269931|NCT06035536|DEVICE|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
219269932|NCT04593823|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
219269933|NCT00530582|DRUG|progesterone|300mg progesterone /placebo each for 21 days
219269934|NCT04442347|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
219269935|NCT04442347|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
219269936|NCT01408810|DRUG|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
218988268|NCT04946747|DEVICE|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
218988269|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
218988270|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
218988271|NCT02717520|DEVICE|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
218988272|NCT00318448|DRUG|Zolpidem (SL800750)|
218988273|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
218988274|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
218988275|NCT06556368|DRUG|Aflibercept|Intravitreal injection
218988276|NCT05737589|RADIATION|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
218988277|NCT05010057|DIETARY_SUPPLEMENT|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
218988278|NCT05010057|DIETARY_SUPPLEMENT|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
218988279|NCT03593096|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219269937|NCT03511690|BEHAVIORAL|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
219269938|NCT01061099|BIOLOGICAL|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
218988280|NCT03593096|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
218988281|NCT03741062|DEVICE|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
218988282|NCT03741062|DEVICE|Control|Sham treatment with laser unit turned off
218988283|NCT00304746|DRUG|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
218988284|NCT00304746|DRUG|Placebo|Placebo
218988285|NCT05070195|DRUG|SKLB1028|SKLB1028, capsule, oral
218988286|NCT05070195|DRUG|Midazolam|Midazolam Maleate, tablet, oral
218988287|NCT06535386|DRUG|Dexmedetomidine 0.004 MG/ML|Incidence of polyuria during the intraoperative period, associated with dexmedetomidine .
218988288|NCT01198678|DIETARY_SUPPLEMENT|Boost Nutritional Supplement|Boost- Nutritional Supplement
218988289|NCT02261896|DRUG|Placebo|Evaluate usefullness of antibiotic prophylaxis
218988290|NCT02261896|DRUG|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
218988291|NCT06095583|DRUG|Tifcemalimab injection|200mg once every 3weeks
218988292|NCT06095583|DRUG|toripalimab injection|240mg once every 3 weeks
218988293|NCT06095583|DRUG|Placebo for Tifcemalimab|every 3weeks
218988294|NCT06095583|DRUG|Placebo for toripalimab|every 3weeks
218988295|NCT00541593|PROCEDURE|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
218988296|NCT00460096|DRUG|Kamada-API|
218988297|NCT06469593|DEVICE|Automated insuling delivery system|Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
218988298|NCT05434000|DRUG|Hydroxyurea|Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
218988299|NCT01497431|DIETARY_SUPPLEMENT|Selenium|Given PO
218988300|NCT01497431|OTHER|Placebo|Given PO
218988301|NCT01497431|OTHER|Laboratory Biomarker Analysis|Correlative studies
218988302|NCT01497431|OTHER|Pharmacological Study|Correlative studies
218988303|NCT01497431|DRUG|Methylselenocysteine|Given PO
218988304|NCT00531271|DRUG|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
218988305|NCT03605589|DRUG|Blinatumomab|Continuous IV infusion
218988306|NCT03605589|DRUG|Pembrolizumab|IV infusion
218988307|NCT00145782|BEHAVIORAL|Life style|
218988308|NCT03417219|BEHAVIORAL|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
218988309|NCT03417219|BEHAVIORAL|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
218988310|NCT03702985|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
219269939|NCT02472145|DRUG|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/\[m\^2\]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
219269940|NCT02472145|DRUG|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
219269941|NCT02602483|DRUG|Ibuprofen|
218988311|NCT03702985|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
218988312|NCT03702985|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
218988313|NCT03702985|DRUG|Amifostine|400mg/m2 per week
218988314|NCT05831631|DIAGNOSTIC_TEST|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
218988315|NCT05831631|DIAGNOSTIC_TEST|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
219269942|NCT02602483|DRUG|Magnesium|
219269943|NCT02602483|DRUG|Ascorbic Acid|
219269944|NCT02602483|DRUG|Placebo|
218988316|NCT00776204|DEVICE|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
218988317|NCT00776204|DEVICE|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
218988318|NCT00776204|DEVICE|Taxus Libertè|Taxus Libertè stent placed in coronary artery
218988319|NCT00747331|DRUG|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
218988320|NCT00747331|DRUG|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
218988321|NCT00261807|DRUG|Daptomycin 6mg/kg/day|
218988322|NCT01602159|PROCEDURE|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
219269945|NCT01200498|DRUG|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
218988323|NCT01602159|PROCEDURE|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
218988324|NCT01550731|BEHAVIORAL|PREPARE website|Advance care planning website and materials plus an advance directive.
218988325|NCT01550731|BEHAVIORAL|Advance directive|The control group will only receive an advance directive.
218988326|NCT01004965|OTHER|laboratory biomarker analysis|
218988327|NCT00092989|DRUG|montelukast sodium|Duration of Treatment: 1 dose
218988328|NCT00092989|DRUG|placebo|Duration of Treatment: 1 dose
218988329|NCT05116475|DRUG|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
218988330|NCT05116475|DRUG|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
218988331|NCT00000315|DRUG|Cocaine|
218988332|NCT01036893|DRUG|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
218988333|NCT04105582|BIOLOGICAL|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
218988334|NCT01478880|PROCEDURE|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
218988335|NCT01478880|PROCEDURE|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
218988336|NCT03466567|DRUG|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
218988337|NCT03466567|DRUG|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
218988338|NCT03466567|DRUG|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
218988339|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
218988340|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
218988341|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
218988342|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
218988343|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
218988344|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
218988345|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
218988346|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
218988347|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
218988348|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
218988349|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
218988350|NCT02023281|BEHAVIORAL|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
218988351|NCT02654834|OTHER|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
218988352|NCT00362310|DRUG|indinavir|
219269946|NCT03375736|DEVICE|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
218988353|NCT02100514|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
218988354|NCT02100514|OTHER|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
218988355|NCT01669226|DRUG|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
218988356|NCT01669226|DRUG|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
219269947|NCT01502592|PROCEDURE|Cryoablation|"OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*"
219269948|NCT01502592|BIOLOGICAL|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
219269949|NCT01236352|DRUG|BMS-911543|
219269950|NCT02768350|PROCEDURE|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
218988357|NCT06300931|OTHER|educational lecture|An Educational lecture about SDF
218988358|NCT06008821|PROCEDURE|Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine|60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)
218988359|NCT06008821|PROCEDURE|Bilateral sham block with normal saline|10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
218988360|NCT04017078|OTHER|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
218988361|NCT02273778|PROCEDURE|MRI Scan|
218988362|NCT02273778|PROCEDURE|PET-CT Scan|
218988363|NCT02273778|OTHER|No intervention|
218988364|NCT04551755|DRUG|Ivermectin and Doxycycline|"1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
218988365|NCT04551755|OTHER|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
218988366|NCT02021331|DEVICE|immediate implant placement without provisionalization|
218988367|NCT02021331|DEVICE|immediate implant placement with immediate provisionalization|
218988368|NCT02222740|DRUG|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
218988369|NCT02222740|DRUG|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
218988370|NCT03804697|DRUG|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
218988371|NCT00005814|BIOLOGICAL|cetuximab|
218988372|NCT00005814|DRUG|cisplatin|
218988373|NCT00005814|RADIATION|radiation therapy|
218988374|NCT00487877|DEVICE|SenseWear Pro3 Armband|
218988375|NCT00487877|DEVICE|i-button DS2191 H|
218988376|NCT04665700|DRUG|BI 764198|BI 764198
218988377|NCT04665700|DRUG|Placebo|Placebo
218988378|NCT00465036|DIETARY_SUPPLEMENT|Whole flaxseeds, flaxseed mucilage, glucomannan|
218988379|NCT04944251|BEHAVIORAL|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
218988380|NCT04165200|DIAGNOSTIC_TEST|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
218988381|NCT04391647|OTHER|First-void urine collection|"* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)"
218988382|NCT04391647|OTHER|Blood draw|\- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
218988383|NCT00762229|DRUG|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
218988384|NCT00762229|DRUG|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
218988385|NCT06457880|PROCEDURE|PENG BLOCK|Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
218988386|NCT06457880|PROCEDURE|Femoral Nerve Block|Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
219269951|NCT02768350|PROCEDURE|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
219269952|NCT05834868|DRUG|THDB0206 Injection|Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.
218988387|NCT06457880|PROCEDURE|Obturator Nerve Block|Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
218988388|NCT02218320|DRUG|Raltegravir|
218988389|NCT02218320|DRUG|Dolutegravir|
218988390|NCT02218320|PROCEDURE|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
218988391|NCT02459210|BEHAVIORAL|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
218988392|NCT02459210|BEHAVIORAL|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
218988393|NCT06304129|DIAGNOSTIC_TEST|Blood ponction|Blood ponction
219269953|NCT05834868|DRUG|Insulin Lispro Injection|Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
218988394|NCT03681431|DRUG|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
218988395|NCT03681431|DRUG|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
218988396|NCT03122769|RADIATION|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
218988397|NCT06505174|OTHER|Hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
218988398|NCT01628133|PROCEDURE|ultrasound|sonographic evaluation of intestinal blood flow
218988399|NCT02702154|DEVICE|High-frequency rTMS|20 Hz active stimulation, twice daily
218988400|NCT02702154|DEVICE|Low-frequency rTMS|1 Hz active stimulation, twice daily
218988401|NCT02702154|DEVICE|Sham rTMS|Sham stimulation, twice daily
218988402|NCT02661659|BIOLOGICAL|Multipeptide vaccine S-588210|
218988403|NCT00253227|DRUG|galantamine hydrobromide|
219269954|NCT06119152|BEHAVIORAL|DESA|Intervention group is monitored via remote bp monitoring and telehealth device.
219269955|NCT04623606|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
219269956|NCT04198389|PROCEDURE|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
219269957|NCT01031498|DRUG|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
218988404|NCT00303732|DRUG|RAD001 (everolimus)|
218988405|NCT00303732|DRUG|PTK787 (vatalanib)|
218988406|NCT00999089|PROCEDURE|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
218988407|NCT00999089|PROCEDURE|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
218988408|NCT00999089|PROCEDURE|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
218988409|NCT04457635|BEHAVIORAL|Psychotherapy|
218988410|NCT03256097|DEVICE|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
218988411|NCT03256097|DEVICE|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
218988412|NCT03256097|DEVICE|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
218988413|NCT03256097|DEVICE|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
218988414|NCT03256097|DEVICE|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
218988415|NCT03256097|DEVICE|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
219269958|NCT01031498|DRUG|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
218988416|NCT03256097|DEVICE|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
218988417|NCT03256097|DEVICE|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
218988418|NCT00319553|BIOLOGICAL|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
218988419|NCT00319553|BIOLOGICAL|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
218988420|NCT06264375|BEHAVIORAL|Physical exercise|see group description
218988421|NCT01896102|GENETIC|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
218988422|NCT00204230|DRUG|mycophenolate mofetil (drug)|
218988423|NCT03795454|BEHAVIORAL|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
219269959|NCT00631267|PROCEDURE|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
219269960|NCT00631267|PROCEDURE|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
218988424|NCT03166007|BEHAVIORAL|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
219269961|NCT02825342|DRUG|Citalopram|
219269962|NCT02471989|DIETARY_SUPPLEMENT|Low-FODMAP diet|
219269963|NCT02471989|DIETARY_SUPPLEMENT|GERD diet|
218988425|NCT03166007|BEHAVIORAL|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
218988426|NCT06341075|DEVICE|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
218988427|NCT01725503|DIETARY_SUPPLEMENT|Creatine and Amino Acid supplement|
218988428|NCT03732157|PROCEDURE|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
218988429|NCT03732157|PROCEDURE|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
218988430|NCT01409330|DIETARY_SUPPLEMENT|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
219269964|NCT01827046|DRUG|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
219269965|NCT03143738|PROCEDURE|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
219269966|NCT03143738|PROCEDURE|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
219269967|NCT03143738|PROCEDURE|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
218988431|NCT04253444|BEHAVIORAL|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
218988432|NCT04253444|BEHAVIORAL|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
218988433|NCT03415568|DIETARY_SUPPLEMENT|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
218988434|NCT03415568|DIETARY_SUPPLEMENT|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
218988435|NCT01439633|DEVICE|MGH OFDI marking|Imaging of esophagus with OFDI system
218988436|NCT02940912|DRUG|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
218988437|NCT02940912|DRUG|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
218988438|NCT00194948|DRUG|escitalopram|
218988439|NCT00194948|BEHAVIORAL|interpersonal psychotherapy|
219269968|NCT04454034|PROCEDURE|arthroscopic synovectomy|arthroscopic synovectomy
219269969|NCT02734004|DRUG|Olaparib|Olaparib
219269970|NCT02734004|DRUG|MEDI4736|MEDI4736
219269971|NCT02734004|DRUG|Bevacizumab|Bevacizumab
219269972|NCT03153813|DRUG|capsaicin 8% patches (Qutenza)|
219269973|NCT03153813|OTHER|Placebo patches|
219269974|NCT04796675|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
219269975|NCT01294436|DRUG|Dapagliflozin|Oral Dose 5 or 10 mg
219269976|NCT00889967|DRUG|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
219269977|NCT00889967|DRUG|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
218988440|NCT06338371|BEHAVIORAL|Pelvic Floor exercise training|The level of sexual function was determined by implementing FSFI for all individuals included in the sample. The participants were divided into two groups, control and training groups, using the randomization program on the computer. Pelvic floor exercise training was given to one group. Trainings were conducted online on different days. Each training lasted 120 minutes. After training was completed, women in the training group were instructed to perform three sets of 8-12 repetitive pelvic floor muscle contractions per day and to use an exercise diary to record their practice. Women in the training group were also given a booklet and the recording of the training video was shared. the training, a brochure explaining how to perform the pelvic floor muscle exercises, which was included in the training content, was prepared and delivered to the training group on the first day of each week. After the training, FSFI was applied to both groups 3 times, in the 1st, 2nd, and 3rd months.
218988441|NCT04878497|DRUG|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
218988442|NCT04878497|DRUG|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
218988443|NCT04878497|DRUG|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
218988444|NCT04878497|DRUG|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
218988445|NCT04878497|DRUG|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
218988446|NCT03889106|DRUG|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
218988447|NCT02231944|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
218988448|NCT04152473|DRUG|Proglumide|oral CCK receptor antagonist
219269978|NCT00889967|DRUG|Placebo|Placebo once daily by inhalation for 28 days
218988449|NCT01496248|DIETARY_SUPPLEMENT|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
218988450|NCT05866900|DEVICE|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
219269979|NCT05946694|OTHER|intubation in manikin|Evaluation of 3 videolaryngoscopes under simulated out-of-hospital conditions by people without clinical experience on a manikin model
219269980|NCT02595775|OTHER|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
219269981|NCT02595775|OTHER|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
219269982|NCT02595775|OTHER|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
219269983|NCT02595775|OTHER|A/F report alone|
219269984|NCT02343289|DRUG|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
219269985|NCT02343289|DRUG|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
219269986|NCT00822146|DEVICE|CRT|classified
219269987|NCT03272711|DRUG|Vortioxetine 10 mg|
218988451|NCT04158492|DIAGNOSTIC_TEST|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
218988452|NCT04158492|DIAGNOSTIC_TEST|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
218988453|NCT01267760|DEVICE|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
218988454|NCT05662150|DIAGNOSTIC_TEST|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
218988455|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
218988456|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
218988457|NCT00444912|BIOLOGICAL|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
218988458|NCT01281865|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
218988459|NCT01281865|DRUG|everolimus|Given PO
218988460|NCT01281865|DRUG|imatinib mesylate|Given PO
218988461|NCT02747875|DRUG|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
219269988|NCT03272711|BEHAVIORAL|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
219269989|NCT06056271|DEVICE|AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation
219269990|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
219269991|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
219269992|NCT04488042|OTHER|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
219269993|NCT04488042|OTHER|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
219269994|NCT02149706|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
219269995|NCT02149706|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
218988462|NCT02747875|DRUG|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
218988463|NCT01977742|OTHER|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
218988464|NCT01977742|OTHER|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
218988465|NCT03339908|DEVICE|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
218988466|NCT03132818|OTHER|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
218988467|NCT03069300|DRUG|N-acetyl cysteine (NAC)|
218988468|NCT00884169|DRUG|M518101|Proper quantity twice a day
218988469|NCT00884169|DRUG|placebo|Proper quantity twice a day
218988470|NCT02008760|DIETARY_SUPPLEMENT|Omega Krill with D3|
218988471|NCT03758001|DRUG|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
218988472|NCT03758001|DRUG|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
218988473|NCT03758001|DRUG|Sintilimab|200mg iv infusion day 1 of every 21 days
218988474|NCT03478657|DRUG|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
218988475|NCT03478657|DEVICE|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
218988476|NCT03478657|OTHER|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
218988477|NCT02226146|BIOLOGICAL|Bertilimumab|
218988478|NCT01698372|DEVICE|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
218988479|NCT00386659|DRUG|tenofovir + abacavir + lopinavir/ritonavir|
218988480|NCT00386659|DRUG|tenofovir + abacavir + efavirenz|
218988481|NCT05523752|DEVICE|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
218988482|NCT05523752|DEVICE|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
218988483|NCT05523752|DEVICE|I-gel|insertion of I-gel
218988484|NCT05523752|DEVICE|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
218988485|NCT04530916|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day wild blueberry powder
218988486|NCT04530916|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder
218988487|NCT02590003|DRUG|Carboplatin|
218988488|NCT02590003|DRUG|Nab-paclitaxel|
219269996|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
218988489|NCT00310167|RADIATION|radiation therapy|
219269997|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
219269998|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
219269999|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
218988490|NCT00459225|DRUG|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
218988491|NCT01120002|DRUG|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
218988492|NCT01120002|DRUG|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
218988493|NCT00483639|OTHER|Medical chart review|medical chart review
218988494|NCT00483639|OTHER|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
218988495|NCT00483639|PROCEDURE|management of therapy complications|management of therapy complications
218988496|NCT00483639|PROCEDURE|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
219270000|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
219270001|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
219270002|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
218988497|NCT00483639|OTHER|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
218988498|NCT02292797|OTHER|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
218988499|NCT00544518|DRUG|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
218988500|NCT00544518|DRUG|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
218988501|NCT02012101|DEVICE|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
218988502|NCT02012101|DEVICE|oxygen therapy|
218988503|NCT02983825|DEVICE|Continuous positive airway pressure (CPAP); level changes|as per arm description
218988504|NCT04561466|DRUG|Béfizal|600 mf befizal a day for one year
218988505|NCT01702805|PROCEDURE|Liberal Cell Transfusion|
218988506|NCT01702805|PROCEDURE|Restricted red cell transfusion|
218988507|NCT03573739|PROCEDURE|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
218988508|NCT03573739|PROCEDURE|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
218988509|NCT03813069|OTHER|IR3535|The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
218988510|NCT03813069|OTHER|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
218988511|NCT03813069|OTHER|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
218988512|NCT03964623|DIAGNOSTIC_TEST|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
218988513|NCT04329403|DRUG|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
218988514|NCT04329403|DRUG|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
218988515|NCT04329403|OTHER|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
219270003|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
219270004|NCT03547245|BIOLOGICAL|DPBS Sucrose|Placebo
218988516|NCT05197556|DRUG|HSG4112|Once-daily oral administration
218988517|NCT05197556|DRUG|Placebo|Once-daily oral administration
218988518|NCT00197639|DRUG|Ritonavir-boosted indinavir|
218988519|NCT05113758|DIAGNOSTIC_TEST|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
218988520|NCT03131778|PROCEDURE|Liver resection|liver resections for colorectal liver metastases
218988521|NCT00900965|DEVICE|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
218988522|NCT00900965|DEVICE|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
218988523|NCT00935363|DRUG|glyburide|single oral dose
218988524|NCT00935363|DRUG|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
218988525|NCT00935363|DRUG|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
218988526|NCT00935363|DRUG|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
219270005|NCT01018732|BIOLOGICAL|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
219270006|NCT01536171|OTHER|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
219270007|NCT00585078|DRUG|Capecitabine|
219270008|NCT00585078|DRUG|Oxaliplatin|
219270009|NCT04198571|DRUG|Zinforo (ceftaroline fosamil)|IV Solution
218988527|NCT00198939|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
218988528|NCT00198939|OTHER|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
218988529|NCT04973137|DRUG|Birtamimab|Intravenous administration of 24 mg/kg birtamimab every 28 days
218988530|NCT04973137|OTHER|Placebo|Intravenous 0.9% Saline administration as a placebo every 28 days
218988531|NCT04973137|DRUG|Standard of Care Chemotherapy|Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care
218988532|NCT04803058|BIOLOGICAL|TCD601|Investigational Product
218988533|NCT02018185|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
218988534|NCT02018185|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
218988535|NCT03500354|DIETARY_SUPPLEMENT|Nutrient drink|High calorie drink with therapeutic supplements
218988536|NCT04461210|DIAGNOSTIC_TEST|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
219270010|NCT02874599|PROCEDURE|Dental restoration|Damaged teeth will be restored
219270011|NCT00288951|DRUG|Travoprost 0.004% with and without BAK|
218988537|NCT06321393|OTHER|7-week Core stabilization exercise with abdominal drawing-in maneuver technique|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consists of 2 stages, including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-minute sessions with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly video call with the main researcher as a telerehabilitation program.
218988538|NCT04464759|DRUG|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
219270012|NCT05474547|BEHAVIORAL|Meditation|Students will meditate for 30 min every day for 10 days
219270013|NCT00160082|DRUG|Xepol|
218988539|NCT04464759|DRUG|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
218988540|NCT04464759|DRUG|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
218988541|NCT06114667|DEVICE|Ventilatory support via nasal high flow|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
218988542|NCT06114667|DEVICE|Ventilatory support via NIV|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
218988543|NCT03908177|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
219270014|NCT01335945|PROCEDURE|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
219270015|NCT02119247|DEVICE|CHF 6001 dry powder for inhalation via NEXThaler®|
219270016|NCT02119247|DEVICE|CHF 6001 DPI capsules for inhalation via Aerolizer|
219270017|NCT02788071|DIETARY_SUPPLEMENT|FMT capsules|25 capsules per day for 12 days
219270018|NCT02788071|DIETARY_SUPPLEMENT|FMT placebo|25 capsules per day for 12 days
219270019|NCT01002716|BIOLOGICAL|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
219270020|NCT01056263|DRUG|axitinib: observational study|Non-interventional observational study
219270021|NCT06338085|OTHER|emotional liberation technique|In this intervention, with the technique taught by the researcher, women will self-administer the practice of lightly touching certain points 5 days and 1 time per week for 8 weeks. A whatsup group will be created by the researcher. A reminder message will be sent from this group to do the practice 1 time every day.
219270022|NCT03612076|OTHER|Global cost of management of PJI|estimation of the global cost to manage PJI with 2-step exchange over 3 years
219270023|NCT05026489|GENETIC|G6PD gene deficiency|we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
218988544|NCT03908177|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
218988545|NCT04893707|BIOLOGICAL|CM310|"adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
218988546|NCT04457336|DRUG|Tildacerfont/Placebo|Tablet, administered daily
218988547|NCT02100904|PROCEDURE|Radiofrequency ablation of fibroids|
219270024|NCT06194331|BEHAVIORAL|iCHART/cASAP|When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.
219270025|NCT06194331|BEHAVIORAL|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
218988548|NCT02100904|PROCEDURE|Myomectomy of fibroids|
218988549|NCT05023629|OTHER|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
218988550|NCT04633733|DRUG|HL237 tablet|HL237 400mg will be administered orally twice a day.
218988551|NCT04633733|DRUG|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
218988552|NCT01972100|DEVICE|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
218988553|NCT01972100|OTHER|isokinetic exercise|
218988554|NCT01972100|DEVICE|Placebo low-level laser therapy|
218988555|NCT00479193|DRUG|bacitracin/xeroform|single layer, change every 3 days
218988556|NCT00479193|DRUG|Polymem|single layer of Polymen, change every 3 days
218988557|NCT00163839|BEHAVIORAL|Dietary Therapy|
218988558|NCT01517620|DRUG|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
218988559|NCT00714441|BEHAVIORAL|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
218988560|NCT00714441|BEHAVIORAL|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
219270026|NCT00170300|DEVICE|Implantable Cardiac Resynchronisation (pacing) device|
218988561|NCT00714441|BEHAVIORAL|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
218988562|NCT02284516|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
219270027|NCT05446584|DEVICE|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
219270028|NCT01476163|DRUG|migalastat HCl 150 mg|150 mg capsule
218988563|NCT02284516|DRUG|Placebo|Placebo to match active treatment, BID for 84 days
218988564|NCT02693119|DRUG|elamipretide (MTP-131) 1% topical ophthalmic solution|
218988565|NCT02693119|DRUG|Vehicle topical ophthalmic solution|
218988566|NCT05478369|BEHAVIORAL|storybook|anxiety and fear during operative
218988567|NCT01350492|BEHAVIORAL|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
218988568|NCT04058730|PROCEDURE|Laparoscopic Roux en Y Gastric by pass surgery|
218988569|NCT04058730|PROCEDURE|Laparoscopic Sleeve Surgery|
218988570|NCT04058730|OTHER|Standard Medical Management|
218988571|NCT06309732|DRUG|Pegfilgrastim|6mg at each cycle
218988572|NCT06309732|DRUG|Dactinomycin|1mg/m2
218988573|NCT06309732|DRUG|Methotrexate|Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
218988574|NCT06309732|DRUG|Etoposide|90mg/m2 injection for infusion
218988575|NCT06309732|DRUG|Cisplatin|50mg/m2
218988576|NCT06309732|DRUG|Epirubicin|37.5mg/m2
218988577|NCT05174377|DIAGNOSTIC_TEST|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
218988578|NCT01979965|DRUG|Ranolazine (Active drug)|Ranolazine therapy for three months
218988579|NCT01979965|DRUG|Placebo|Placebo therapy for three months
218988580|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
218988581|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
218988582|NCT04574973|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
218988583|NCT04574973|BEHAVIORAL|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
218988584|NCT03539146|OTHER|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
218988585|NCT03539146|OTHER|Control yogurt|Control yogurt
218988586|NCT02654847|DRUG|Norepinephrine|
218988587|NCT02654847|DRUG|Normal Saline|0.9% sodium chloride solution, used as a diluent.
218988588|NCT04569656|DRUG|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
219270029|NCT01476163|DRUG|migalastat HCl 20 mg|20 mg dispersible tablets; dosing will be based on body weight
218988589|NCT01199172|BEHAVIORAL|voice hygiene|subjects will receive voice hygiene training
218988590|NCT01199172|BEHAVIORAL|VH + VP|subjects will be trained in voice hygiene and voice production training
218988591|NCT04945577|DIAGNOSTIC_TEST|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
219270030|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
219270031|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
218988592|NCT04945577|OTHER|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
218988593|NCT06287190|OTHER|Dental interns|Assessing self-assessment
218988594|NCT00238888|PROCEDURE|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
218988595|NCT00238888|PROCEDURE|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
218988596|NCT01706796|DRUG|PF-06273340|Oral solution, single dose, fasted
218988597|NCT01706796|DRUG|PF-06273340|Immediate Release Tablet, single dose, fasted
218988598|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
218988599|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
218988600|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
218988601|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
218988602|NCT05132634|OTHER|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
218988603|NCT03944031|DRUG|LY3372689|Administered orally.
218988604|NCT03944031|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered IV.
218988605|NCT02295410|BEHAVIORAL|CPT|
218988606|NCT00222560|BEHAVIORAL|Intensive physical activity counselling by an integrated physical activity counsellor|
218988607|NCT02502318|PROCEDURE|Video-thoracoscopy|
218988608|NCT02502318|PROCEDURE|thoracotomy|
218988609|NCT00645749|BIOLOGICAL|Helminth ova|2500 ova per dose (liquid form)
218988610|NCT04203498|DRUG|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
218988611|NCT04203498|DRUG|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
218988612|NCT06556771|OTHER|Gongs mobilization + conventional physical therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
218988613|NCT06556771|OTHER|Kaltenborn mobilization along with traction + conventional therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
218988614|NCT04044495|OTHER|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
218988615|NCT04044495|OTHER|Actimetry|7 days actimetry
218988616|NCT04044495|OTHER|Sleep Diary|7 days Record of sleep and wake cycle
218988617|NCT04261868|DEVICE|Virtual Reality|New treatment for amblyopia therapy using playing games
218988618|NCT04261868|OTHER|Patching|Patching
218988619|NCT06412224|DRUG|RRG001|Administered by subretinal injection. Dosage form: injection.
218988620|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
218988621|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
218988622|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
218988623|NCT01474083|DRUG|Placebo|Dose-matched placebo. Oral administration.
219270032|NCT05842928|BEHAVIORAL|PARTNER intervention|"The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)"
219270033|NCT05842928|BEHAVIORAL|Control intervention|The control intervention only comprises a pharmacy visit with brown bag review.
219270034|NCT06853340|BIOLOGICAL|blood sampling|Patients with septic shock will have three differents times of blood sampling and of clinical and biological statements. Healthy volunteers will have a unique visit to collect clinical data and blood samples.
219270035|NCT05304208|BIOLOGICAL|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
218988624|NCT06503055|OTHER|Questionnaire|"A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles."
218988625|NCT05128318|PROCEDURE|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
218988626|NCT01536470|OTHER|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
218988627|NCT01536470|OTHER|Ephedryne chorydrate|
218988628|NCT00939640|BEHAVIORAL|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
218988629|NCT05954702|PROCEDURE|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
218988630|NCT05954702|PROCEDURE|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
218988631|NCT05745012|PROCEDURE|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
218988632|NCT05745012|PROCEDURE|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
218988633|NCT04205981|OTHER|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
218988634|NCT01513096|DRUG|itopride|itopride, 10mg, twice per day, for 1 day
218988635|NCT02433457|DRUG|CC-292|
219270036|NCT05365802|DRUG|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
219270037|NCT05365802|PROCEDURE|Computed Tomography|As part of PET/CT scan
219270038|NCT05365802|PROCEDURE|Positron Emission Tomography|As part of PET/CT scan
218988636|NCT02433457|DRUG|Oral Omeprazole (OMP)|
218988637|NCT01743183|DEVICE|Threshold|The load adjustment was done weekly by a single examiner.
218988638|NCT00789490|DIETARY_SUPPLEMENT|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
218988639|NCT00789490|DIETARY_SUPPLEMENT|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
218988640|NCT00023946|DRUG|ixabepilone|Given IV
218988641|NCT00023946|OTHER|laboratory biomarker analysis|Correlative studies
218988642|NCT05089279|DRUG|D113|QD, PO
218988643|NCT05089279|DRUG|CKD-349|QD, PO
218988644|NCT03142178|DRUG|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
219270039|NCT05365802|PROCEDURE|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
219270040|NCT06028438|DRUG|Placebo|Placebo will be administered intravenously.
219270041|NCT06028438|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
219270042|NCT06028438|DRUG|Certolizumab|Certolizumab will be administered subcutaneously.
218988645|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
218988646|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
218988647|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
218988648|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
218988649|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
218988650|NCT03730675|PROCEDURE|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
218988651|NCT03730675|PROCEDURE|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
218988652|NCT03730675|DRUG|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
218988653|NCT06371443|BEHAVIORAL|Sucking and swallowing exercises|Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
218988654|NCT06150625|OTHER|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
218988655|NCT06150625|OTHER|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
218988656|NCT06150625|OTHER|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
218988657|NCT06150625|OTHER|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
218988658|NCT05763095|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
218988659|NCT02169479|DRUG|BIA 9-1067|OPC, Opicapone
218988660|NCT02169479|DRUG|Placebo|PLC, Placebo
218988661|NCT02169479|DRUG|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
218988662|NCT04634383|DEVICE|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
218988663|NCT00431769|DRUG|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
218988664|NCT05656508|BIOLOGICAL|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
218988665|NCT02645201|DIETARY_SUPPLEMENT|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
218988666|NCT02645201|OTHER|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
218988667|NCT06372301|DIAGNOSTIC_TEST|Dobutamine stress echocardiography|Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
218988668|NCT05992181|OTHER|NEORTHO|early orofacial stimulation
218988669|NCT00344708|PROCEDURE|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
218988670|NCT02258425|BEHAVIORAL|FEM-CARE|
218988671|NCT02258425|BEHAVIORAL|Health Promotion|
218988672|NCT01076920|GENETIC|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
218988673|NCT06284031|PROCEDURE|3 fractions HDR brachytherapy|"The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days"
218988674|NCT01443182|BEHAVIORAL|STAIR|Skills Training in Affective and Interpersonal Regulation
218988675|NCT01443182|BEHAVIORAL|MPE|Modified prolonged exposure (MPE)
218988676|NCT01443182|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing
219270043|NCT00699842|DRUG|Lenalidomide|"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"
219270044|NCT06356610|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
219270045|NCT06356610|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
219270046|NCT06356610|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
219270047|NCT06356610|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
219270048|NCT06356610|OTHER|Reference Product E|Use of Reference Product E in controlled use and ad libitum use sessions
219270049|NCT06356610|OTHER|Reference Product F|Use of Reference Product F in controlled use and ad libitum use sessions
218988677|NCT01235689|BIOLOGICAL|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
218988678|NCT01235689|DRUG|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
218988679|NCT01235689|DRUG|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
218988680|NCT01443078|DRUG|pemetrexed|
218988681|NCT01443078|DRUG|cisplatin|
218988682|NCT01443078|DRUG|Carboplatin|
218988683|NCT01443078|DRUG|Gemcitabine Hydrochloride|
218988684|NCT01443078|DRUG|Vinorelbine Tartrate|
218988685|NCT01443078|DRUG|Docetaxel|
218988686|NCT03700593|DEVICE|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
218988687|NCT00039078|RADIATION|yttrium Y 90 glass microspheres|
218988688|NCT04257734|OTHER|observation|different serum antibodies status
218988689|NCT00163878|PROCEDURE|Sensory Stimulation|
218988690|NCT00163878|DEVICE|Sesnory Modality Assessment and Rehabilitation Technique|
218988691|NCT05915221|PROCEDURE|SMS|Receive SMS
218988692|NCT01809106|DRUG|Morphine|60 mg /24 ore
218988693|NCT01809106|DRUG|Fentanyl|25 microg/h
218988694|NCT01809106|DRUG|Buprenorphine|35 microg/h
218988695|NCT01809106|DRUG|Oxycodone|40 mg /24 ore
218988696|NCT05616975|OTHER|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
218988697|NCT05616975|OTHER|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
218988698|NCT05616975|OTHER|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
218988699|NCT02399371|BIOLOGICAL|Pembrolizumab|Given IV
218988700|NCT02399371|OTHER|Laboratory Biomarker Analysis|Correlative studies
218988701|NCT02399371|OTHER|Pharmacogenomic Study|Correlative studies
218988702|NCT05123170|DRUG|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
218988703|NCT05123170|DRUG|Lidocaine IV|Intravenous regional anaesthesia
218988704|NCT00508365|DRUG|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
218988705|NCT00508365|DRUG|Placebo|Placebo capsules to match each dose level will be provided.
218988706|NCT00508365|DRUG|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
218988707|NCT02467075|DRUG|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
218988708|NCT02467075|DRUG|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
218988709|NCT02106975|DRUG|Ascorbic Acid|Intervention
218988710|NCT02106975|DRUG|Placebo: 5% Dextrose in water|Placebo
218988711|NCT01272973|DRUG|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
218988712|NCT01272973|DRUG|placebo|Placebo (oral) administered once daily for 10 weeks.
218988713|NCT01272973|DRUG|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
218988714|NCT02168127|DRUG|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
218988715|NCT02168127|DRUG|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
218988716|NCT00834223|DEVICE|Aquashunt|A shunt which is implanted into the suprachoroidal space.
218988717|NCT05594056|PROCEDURE|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
219270050|NCT06531538|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine.
219270051|NCT06531538|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
219270052|NCT05939570|OTHER|Interview|Prospective, semi-structured, qualitative interview.
219270053|NCT05709327|OTHER|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
219270054|NCT06402006|PROCEDURE|PENG block|pericapsular nerve group block
219270055|NCT06402006|PROCEDURE|LFCN block|Lateral femoral cutaneous nerve block
219270056|NCT06402006|PROCEDURE|ESP block|Erector spinae plane block
219270057|NCT03789084|BEHAVIORAL|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
219270058|NCT03789084|BEHAVIORAL|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
219270059|NCT03423160|OTHER|None--observational|Observational study of behavior and electrical brain activity
218988718|NCT03951155|BEHAVIORAL|Muscle Relaxation|"* Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise."
218988719|NCT01469312|OTHER|modified pasta|50 grams carbohydrate as a single breakfast meal
218988720|NCT00005044|DRUG|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
218988721|NCT00005044|DRUG|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
218988722|NCT00005044|DRUG|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
218988723|NCT00005044|RADIATION|radiation therapy|\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
218988724|NCT00141843|GENETIC|ReFacto AF|
218988725|NCT00141843|GENETIC|B-Domain deleted Recombinant Factor VIII|
218988726|NCT00141843|GENETIC|BDDrFVIII|
218988727|NCT03988088|DRUG|Lasmiditan|Administered orally.
218988728|NCT04431453|DRUG|Remdesivir|Administered as an intravenous infusion
218988729|NCT05847361|DIAGNOSTIC_TEST|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
218988730|NCT03574831|DEVICE|Stretta|Stretta
218988731|NCT03823456|OTHER|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
218988732|NCT03823456|OTHER|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
218988733|NCT02256657|BEHAVIORAL|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
219270060|NCT05834907|BEHAVIORAL|Circle of Security Parenting|"COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs."
218988734|NCT01881074|DRUG|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
218988735|NCT01881074|DRUG|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
218988736|NCT04314934|DRUG|ANAVEX2-73|Oral capsules
218988737|NCT05175508|DRUG|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
218988738|NCT05175508|DRUG|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
218988739|NCT02962388|DRUG|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
218988740|NCT02962388|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
218988741|NCT02962388|DRUG|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
218988742|NCT01354457|DRUG|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
218988743|NCT03580993|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
218988744|NCT02563171|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
218988745|NCT02563171|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
218988746|NCT01206348|DRUG|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
218988747|NCT02583126|BEHAVIORAL|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
218988748|NCT01332370|DRUG|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
218988749|NCT01332370|DRUG|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
218988750|NCT03241875|DRUG|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
218988751|NCT03241875|DRUG|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
218988752|NCT03241875|DRUG|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
218988753|NCT05675176|DRUG|BCG|Intravesical Instillation
218988754|NCT03622073|OTHER|Misoprostol treatment by Midwife|Medical management of incomplete abortion
218988755|NCT03622073|OTHER|Misoprostol treatment by Doctor|Medical management of incomplete abortion
218988756|NCT03546062|OTHER|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
218988757|NCT05840783|DEVICE|Open ended needle irrigation|irrigation during root canal shaping and cleaning using an open-ended needle
218988758|NCT05840783|DEVICE|side vented needle irrigation|irrigation during root canal shaping and cleaning using a 30-guage side-vented needle
218988759|NCT05840783|DEVICE|Sonic activation|Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
218988760|NCT01703325|DRUG|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group"
218988761|NCT03410329|OTHER|Resistance training|Physical activity
218988762|NCT05719376|DRUG|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
218988763|NCT05719376|DRUG|control group|Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
218988764|NCT00099541|DRUG|zoledronic acid|
218988765|NCT00353795|PROCEDURE|MR Imaging of the Coronary Arteries|
219270061|NCT05834907|BEHAVIORAL|Little Talks|Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
219270062|NCT05990387|DRUG|Mirabegron|Dose-response effect on thermogenesis
218988766|NCT05216783|BEHAVIORAL|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
218988767|NCT06081712|DRUG|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
218988768|NCT06081712|DRUG|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
218988769|NCT00285233|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
218988770|NCT06132516|OTHER|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
218988771|NCT06132516|OTHER|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
218988772|NCT00003710|DRUG|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
218988773|NCT00003710|DRUG|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
218988774|NCT02416570|DRUG|Clarithromycin|
218988775|NCT02416570|DRUG|Placebo|
218988776|NCT01723345|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
218988777|NCT01095211|DRUG|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
218988778|NCT02083965|BIOLOGICAL|rFVIIIFc|Administered as specified in the treatment arm.
219270063|NCT05990387|DRUG|Placebo|Placebo control condition
218988779|NCT05203432|DEVICE|Red Light Intervention|Repeated Low-Level Red-Light Therapy
218988780|NCT05203432|DRUG|Atropine|0.01% atropine
218988781|NCT02568774|OTHER|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
219270064|NCT05840510|DRUG|Adagrasib|KRAS G12C inhibitor
218988782|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
218988783|NCT03137420|DIAGNOSTIC_TEST|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
218988784|NCT02539446|BEHAVIORAL|stable condition|
218988785|NCT02539446|BEHAVIORAL|unstable condition|
218988786|NCT02539446|BEHAVIORAL|attentional focus|
218988787|NCT04516330|GENETIC|miRNA|miRNA's expressed in breast cancer
218988788|NCT01870284|DRUG|Ixekizumab|Administered SC
218988789|NCT01870284|DRUG|Placebo|Administered SC
218988790|NCT01870284|DRUG|Adalimumab|Administered SC
218988791|NCT02481908|DEVICE|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
218988792|NCT00028782|DRUG|etanidazole|Given IV
218988793|NCT00028782|PROCEDURE|therapeutic conventional surgery|Undergo surgery
218988794|NCT00028782|OTHER|laboratory biomarker analysis|Correlative studies
219270065|NCT05840510|DRUG|nab-Sirolimus|mTOR inhibitor
219270066|NCT04750577|DRUG|Placebo matching BI 685509|film-coated tablet
219270067|NCT04750577|DRUG|BI 685509|film-coated tablet
219270068|NCT04934605|PROCEDURE|Cochlear implantation|Cochlear implantation
219270069|NCT04980378|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
219270070|NCT00056810|DRUG|4-aminopyridine (4-AP)|
219270071|NCT00428025|DRUG|diclofenac|100 mg diclofenac rectal suppository
218988795|NCT02718157|DEVICE|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
218988796|NCT00651352|DRUG|4 mg nicotine lozenge|marketed formulation
218988797|NCT00651352|DRUG|2 mg nicotine lozenge|marketed formulation
218988798|NCT00651352|DRUG|2 mg nicotine prototype|2 mg
218988799|NCT00651352|DRUG|4 mg nicotine prototype|4 mg
218988800|NCT02956239|PROCEDURE|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
219270072|NCT00428025|DRUG|placebo|similar shape and size suppository
219270073|NCT02496598|PROCEDURE|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
219270074|NCT02496598|DRUG|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
219270075|NCT02337452|OTHER|Questionnaire Administration|Ancillary studies
219270076|NCT02337452|BEHAVIORAL|Web Site|Communicate via family outreach program website
219270077|NCT03445117|OTHER|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
219270078|NCT05256810|DRUG|ALN-XDH|ALN-XDH administered by SC injection
219270079|NCT05256810|DRUG|Placebo|Placebo administered by SC injection
218988801|NCT02956239|PROCEDURE|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
218988802|NCT02956239|PROCEDURE|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
218988803|NCT04502433|DRUG|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
218988804|NCT02935842|OTHER|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
218988805|NCT02935842|OTHER|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
218988806|NCT00911547|DRUG|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
218988807|NCT00911547|DRUG|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
218988808|NCT00911547|DRUG|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
219270080|NCT05092698|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
219270081|NCT05092698|DIETARY_SUPPLEMENT|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
219270082|NCT01084993|DRUG|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
219270083|NCT01084993|DRUG|Heparin|70 U/kg
218988809|NCT00911547|DRUG|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
218988810|NCT05281679|OTHER|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
218988811|NCT05281679|OTHER|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
218988812|NCT01072422|BEHAVIORAL|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
218988813|NCT04544397|PROCEDURE|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
218988814|NCT04530526|PROCEDURE|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
218988815|NCT05412303|OTHER|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
218988816|NCT00034541|BIOLOGICAL|cetuximab|400 mg/m2 i.v. over 120 minutes
218988817|NCT00034541|DRUG|paclitaxel|225 mg/m2, infusion
218988818|NCT00034541|DRUG|carboplatin|30-minute AUC = 6, infusion.
218988819|NCT05230420|OTHER|Clamping|Clamping of chest tube
218988820|NCT05230420|OTHER|Urine bag|Attachment of a urine bag to chest tube
218988821|NCT01374841|DRUG|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
218988822|NCT01374841|OTHER|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
218988823|NCT00808990|DIETARY_SUPPLEMENT|BioFemale|BioFemale 6 months.
218988824|NCT02615314|PROCEDURE|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
218988825|NCT00113503|DRUG|Azathioprine weight-based dose|
218988826|NCT00113503|DRUG|Azathioprine individualised dose|
218988827|NCT00324610|DRUG|capecitabine|
218988828|NCT03691181|DEVICE|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
218988829|NCT00004762|DRUG|cladribine|
218988830|NCT00076843|DRUG|Hu MiK-Beta-1|
218988831|NCT05489744|DRUG|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
218988832|NCT01201785|DRUG|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
218988833|NCT03947801|OTHER|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
218988834|NCT03947801|OTHER|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
218988835|NCT03531931|DRUG|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
218988836|NCT02116946|BIOLOGICAL|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
218988837|NCT02116946|OTHER|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
218988838|NCT04903444|DEVICE|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
218988839|NCT02774954|BEHAVIORAL|Change the Cycle|See previous response
218988840|NCT02902432|DRUG|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
218988841|NCT05228171|BEHAVIORAL|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
218988842|NCT04545385|DRUG|TEV-48574|subcutaneous infusion
218988843|NCT04545385|DRUG|Placebo|Matching Placebo
218988844|NCT04710173|PROCEDURE|ECMO|VV-ECMO
218988845|NCT04629807|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
218988846|NCT00915278|DRUG|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
218988847|NCT05843045|DEVICE|Indoor Air Quality Mitigation|Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
218988848|NCT04872582|DRUG|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
218988849|NCT00001381|DRUG|suramin|
218988850|NCT04719286|DEVICE|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
218988851|NCT02649595|OTHER|Red Cross Respite care|See detailed description.
218988852|NCT04074031|DEVICE|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
218988853|NCT02721485|OTHER|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
218988854|NCT02721485|OTHER|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
218988855|NCT02449252|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
218988856|NCT02449252|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
218988857|NCT02449252|DRUG|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
218988858|NCT02449252|DRUG|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
218988859|NCT02449252|DRUG|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
218988860|NCT02449252|DRUG|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
218988861|NCT01995110|OTHER|high-fat meal A|
219270084|NCT01688310|PROCEDURE|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
218988862|NCT01995110|OTHER|high-fat meal B|
218988863|NCT01995110|OTHER|high-fat meal C|
218988864|NCT02045810|DRUG|Levobupivacaine|
218988865|NCT02045810|DRUG|Saline|
218988866|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
218988867|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
218988868|NCT01468883|PROCEDURE|M|Modified radical mastectomy
218988869|NCT01468883|RADIATION|X|Excisional biopsy plus radiation
219270085|NCT01688310|PROCEDURE|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
218988870|NCT02264561|OTHER|Food|Active group
218988871|NCT02264561|OTHER|Food|Control group
219270086|NCT01071837|DRUG|APG101|400mg weekly as intravenous infusion
219270087|NCT01071837|PROCEDURE|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
219270088|NCT00284193|DRUG|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
218988872|NCT00335361|DEVICE|Intra Vas Device (IVD)|
218988873|NCT03221283|BEHAVIORAL|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
218988874|NCT02552875|OTHER|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
218988875|NCT02552875|OTHER|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
218988876|NCT00241943|PROCEDURE|Hepatitis C educational video|
218988877|NCT04601415|DIAGNOSTIC_TEST|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
218988880|NCT04586907|DRUG|LY3537021|Administered SC.
218988881|NCT04586907|DRUG|Placebo|Administered SC.
219270089|NCT00284193|DRUG|FEIBA- Activated Prothrombin Complexes|
218988882|NCT04431180|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
218988883|NCT02168361|DRUG|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
218988884|NCT02168361|DRUG|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
218988885|NCT02168361|DRUG|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
218988886|NCT02168361|DRUG|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
218988887|NCT01593657|OTHER|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
218988888|NCT01593657|OTHER|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
218988889|NCT01593657|PROCEDURE|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
218988890|NCT01593657|PROCEDURE|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
218988891|NCT05822661|DIETARY_SUPPLEMENT|Black Seed Oil|Dietary supplement
218988892|NCT05822661|DIETARY_SUPPLEMENT|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
218988893|NCT02428517|PROCEDURE|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
218988894|NCT02428517|PROCEDURE|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
218988895|NCT02428517|PROCEDURE|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
219270090|NCT03668171|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
218988896|NCT02428517|PROCEDURE|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
218988897|NCT05492214|PROCEDURE|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
218988898|NCT05492214|PROCEDURE|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
218988899|NCT05492214|PROCEDURE|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
218988900|NCT00048321|DRUG|ISIS 104838|
218988901|NCT02543580|OTHER|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
218988902|NCT02543580|OTHER|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
218988903|NCT02706184|DRUG|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
218988904|NCT02706184|DRUG|Placebo|Placebo
218988905|NCT05693389|BEHAVIORAL|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
218988906|NCT05693389|OTHER|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
218988907|NCT02951065|OTHER|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
218988908|NCT02951065|OTHER|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
218988909|NCT00032409|BEHAVIORAL|Music therapy-based relaxation/stress reduction|
218988910|NCT01334164|BEHAVIORAL|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
218988911|NCT01334164|OTHER|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
218988912|NCT00491816|DRUG|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
218988913|NCT06217341|OTHER|In the study, bispectral index monitoring and follow-up will be applied to both groups.|Perioperative Bispectral Index Monitoring (BIS) monitor and Bispectral Index suppression Rate (BIS-SR) monitoring will be applied. The duration and magnitude of BIS-SR values will be examined together with BIS values in terms of recovery agitation.
218988914|NCT00965315|DRUG|Rosuvastatin,SFC fenofibrate|"1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
218988915|NCT04510584|DRUG|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
218988916|NCT04510584|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
218988917|NCT06188533|OTHER|Urinary activin A in AKI|Urinary activin A in AKI patient
218988918|NCT03093883|DRUG|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
219270091|NCT04865692|OTHER|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
219270092|NCT04865692|OTHER|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
219270093|NCT05205564|OTHER|This is a cross-sectional research design.|No intervention will be involved in the study.
218988919|NCT03093883|DRUG|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
218988920|NCT03844880|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
218988921|NCT03844880|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
218988922|NCT00925041|DEVICE|Vedera KXS|one treatment with the Vedera KXS
218988923|NCT00939770|DRUG|Crizotinib|Given PO
218988924|NCT00939770|OTHER|Laboratory Biomarker Analysis|Correlative studies
218988925|NCT00939770|OTHER|Pharmacological Study|Correlative studies
218988926|NCT00939770|OTHER|Questionnaire Administration|Ancillary studies
218988927|NCT05076292|DRUG|GlucaGen|150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
218988928|NCT05076292|DRUG|Saline|Saline will be used as placebo before and after exercise.
218988929|NCT02178371|PROCEDURE|mCIMT|affected upper limb use with constraint of the healthy hand
218988930|NCT02178371|PROCEDURE|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
218988931|NCT00758836|DRUG|placebo|
218988932|NCT00758836|DRUG|ibuprofen|
218988933|NCT00758836|DRUG|acetominophen|
218988934|NCT00758836|DRUG|telcagepant|
218988935|NCT00958100|DRUG|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
218988936|NCT00958100|DRUG|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
218988937|NCT00958100|DRUG|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
218988938|NCT03306563|DIAGNOSTIC_TEST|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
219270094|NCT05947266|BEHAVIORAL|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
218988939|NCT01817530|OTHER|Elagolix placebo|oral coated tablet
218988940|NCT01817530|DRUG|Elagolix|oral coated tablet
218988941|NCT01817530|DRUG|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
218988942|NCT01817530|DRUG|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
218988943|NCT01817530|DRUG|E2/NETA placebo|oral hard capsule
218988944|NCT03824314|DRUG|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
218988945|NCT03824314|DRUG|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
218988946|NCT05160493|DRUG|S-ketamine and pregabalin|"S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
218988947|NCT05160493|DRUG|Normal saline and placebo capsule|Normal saline and placebo capsule
218988948|NCT03838952|DRUG|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
218988949|NCT05262608|DRUG|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
218988950|NCT05147025|OTHER|Revascularization|Regain pulp vascularity for young permenant teeth
218988951|NCT02236975|DEVICE|BuMA Supreme Biodegradable drug coating coronary stent system|
218988952|NCT02236975|DEVICE|Resolute Integrity durable polymer stent system|
218988953|NCT02106260|DRUG|CLS003|
218988954|NCT04827381|OTHER|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
218988955|NCT04827381|OTHER|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
218988956|NCT05865028|DRUG|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
218988957|NCT06724328|BEHAVIORAL|Gentle Human Touch|the trained NICU nurse will place one hand's fingertips on the baby's forehead along the brow line, while the other hand will be placed around the baby's lower abdomen
218988958|NCT06724328|BEHAVIORAL|Maternal Heartbeat and Gentle Human Touch|maternal heartbeat will be played and GHT steps will be applied simultaneously at the designated times
218988959|NCT06724328|BEHAVIORAL|Maternal Heartbeat|The recording of the mother's heartbeat will be done when the mother's mood is stable and the environment is quiet. A Doppler fetal heart monitor will be used to detect the mother's heartbeat. After ensuring a regular and stable heart rate, the mother's heartbeat will be recorded for 15 minutes using a recording device
218988960|NCT01798004|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
218988961|NCT01798004|DRUG|Busulfan|Given IV
218988962|NCT01798004|DRUG|Cisplatin|Given IV
218988963|NCT01798004|DRUG|Cyclophosphamide|Given IV
218988964|NCT01798004|DRUG|Doxorubicin Hydrochloride|Given IV
218988965|NCT01798004|DRUG|Etoposide|Given IV
218988966|NCT01798004|RADIATION|External Beam Radiation Therapy|Undergo EBRT
218988967|NCT01798004|BIOLOGICAL|Filgrastim|Given SC or IV
218988968|NCT01798004|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
218988969|NCT01798004|DRUG|Melphalan|Given IV
218988970|NCT01798004|DRUG|Mesna|Given IV
218988971|NCT01798004|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
218988972|NCT01798004|OTHER|Pharmacological Study|Correlative studies
218988973|NCT01798004|DRUG|Topotecan Hydrochloride|Given IV
218988974|NCT01798004|DRUG|Vincristine Sulfate|Given IV
218988975|NCT01488929|DRUG|TC-5619|
218988976|NCT01488929|DRUG|Placebo|
218988977|NCT00666029|DRUG|atorvastatin|40 m.g. o.d. tablets for 6 months
218988978|NCT00666029|DRUG|placebo|Placebo
218988979|NCT06131697|OTHER|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
218988980|NCT06131697|OTHER|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
218988981|NCT03623815|OTHER|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
218988982|NCT01853761|DEVICE|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
218988983|NCT01853761|DEVICE|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
218988984|NCT01853761|DEVICE|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
218988985|NCT01853761|DEVICE|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
218988986|NCT01853761|DEVICE|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
218988987|NCT01853761|DEVICE|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
218988988|NCT02847156|OTHER|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
218988989|NCT01534871|BEHAVIORAL|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
218988990|NCT03940612|DIETARY_SUPPLEMENT|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
218988991|NCT03940612|DIETARY_SUPPLEMENT|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
218988992|NCT03608098|DEVICE|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
218988993|NCT03608098|DEVICE|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
218988994|NCT02823431|DRUG|lidocaine gel|
218988995|NCT02823431|OTHER|Plain aqueous gel|
218988996|NCT00544466|DRUG|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
219270095|NCT03371823|OTHER|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
218988997|NCT00544466|DRUG|melphalan|140 mg/m2 day -2 prior to transplant
218988998|NCT00544466|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
219270096|NCT03371823|DRUG|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
218988999|NCT00544466|RADIATION|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
218989000|NCT04412408|DRUG|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
219270097|NCT01876615|DRUG|YH4808|experimental drug
219270098|NCT01876615|DRUG|Diclofenac|Depain tablet 25mg
219270099|NCT01876615|DRUG|YH4808+Diclofenac|
218989001|NCT03281577|DRUG|TAK-954|TAK-954 IV infusion.
218989002|NCT03281577|DRUG|Placebo|TAK-954 placebo-matching IV infusion.
218989003|NCT02323113|DRUG|TAK-659|TAK-659 tablets.
218989004|NCT05061732|DRUG|Rabeprazole|20mg bid
218989005|NCT05061732|DRUG|Bismuth potassium citrate|0.6g bid
218989006|NCT05061732|DRUG|Metronidazole|0.4g qid
218989007|NCT05061732|DRUG|Clarithromycin|0.5g bid
218989008|NCT05061732|DRUG|Levofloxacin|0.5g qd
218989009|NCT05061732|DRUG|Amoxicillin|1g tid
218989010|NCT05061732|DRUG|Metronidazole|0.4g tid
218989011|NCT05061732|DRUG|Doxycycline|0.1g bid
218989012|NCT05061732|DRUG|Tetracycline|0.5g qid
218989013|NCT06366932|DRUG|Second-line systemic treatment|Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
218989014|NCT06366932|OTHER|Folllow-up of second-line systemic treatment already started|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
218989015|NCT02541682|OTHER|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
218989016|NCT04091594|DEVICE|Flexible orthotic|Participants will receive the SIAFO to wear
218989017|NCT04091594|DEVICE|Standard orthotic|Participants will received the standard AFO to wear
218989018|NCT01324843|DRUG|EMLA Cream|
218989019|NCT01324843|DRUG|Aveeno Daily Moist|
218989020|NCT01324843|DEVICE|Derma Vax|
218989021|NCT01324843|PROCEDURE|Intradermal Electroporation|
218989022|NCT01324843|PROCEDURE|Visual Analogue Scale|
218989023|NCT01324843|PROCEDURE|Present Pain Intensity|
218989024|NCT01324843|PROCEDURE|McGill Pain Questionnaire|
218989025|NCT01324843|PROCEDURE|Skin Assessment|
218989026|NCT00443261|DRUG|Azacitidine|SC azacitidine
218989027|NCT00443261|DRUG|Cisplatin|cisplatin 75 mg/m\^2 day 8 every 28 days
218989028|NCT02079220|DRUG|Arm A|"* Capecitabine~* Oxaliplatin~* Ziv-aflibercept"
218989029|NCT02079220|DRUG|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
218989030|NCT03315624|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
218989031|NCT02968901|DRUG|macitentan|used in open label
218989032|NCT02968901|DRUG|tadalafil|used in open label
218989033|NCT03947320|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
218989034|NCT02320383|BIOLOGICAL|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
218989035|NCT02320383|DRUG|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
218989036|NCT02387398|PROCEDURE|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
218989037|NCT01663532|DRUG|Aripiprazole IM Depot|
218989038|NCT01663532|DRUG|Placebo|Matching Placebo
218989039|NCT05731778|DRUG|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
218989040|NCT05731778|DRUG|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
218989041|NCT00117481|DRUG|DR-2001a|DR-2001a administered vaginally each month
218989042|NCT00117481|DRUG|DR-2001b|DR-2001b administered vaginally each month
218989043|NCT00117481|OTHER|Placebo|Placebo administered vaginally each month
218989044|NCT02421432|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
218989045|NCT03848117|OTHER|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
218989046|NCT03848117|OTHER|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
219270100|NCT03330964|OTHER|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
218989047|NCT00025493|DRUG|docetaxel|
218989048|NCT05968391|RADIATION|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
218989049|NCT02622308|DEVICE|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
218989050|NCT00393393|DRUG|intra-articular injection of Hylan G-F 20|
218989051|NCT01481727|DEVICE|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.
218989052|NCT01481727|DEVICE|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
218989053|NCT05239923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
218989054|NCT02785432|DEVICE|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
218989055|NCT02785432|DEVICE|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
218989056|NCT01633853|DRUG|Vitamin D2|Treatment with Vit D2.
218989057|NCT01633853|DRUG|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
218989058|NCT05855252|OTHER|No intervention|No intervention
218989059|NCT00517816|DRUG|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
218989060|NCT01002027|BEHAVIORAL|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
219270101|NCT02675049|DRUG|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
219270102|NCT02675049|DRUG|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
218989061|NCT00583609|DRUG|PEG3350|PEG3350
218989062|NCT03159767|DEVICE|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
219270103|NCT02675049|DRUG|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
219270104|NCT02675049|DRUG|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
218989063|NCT00030121|DRUG|recombinant human atrial natriuretic polypeptide|
218989064|NCT05677659|DRUG|VGL101|Solution administered via Intravenous Infusion (IV)
218989065|NCT00656383|OTHER|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
218989066|NCT00656383|OTHER|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
218989067|NCT03570073|OTHER|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
218989068|NCT03570073|OTHER|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
218989069|NCT01101087|DEVICE|Taurolock|
218989070|NCT01101087|OTHER|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
218989071|NCT00897260|DRUG|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
218989072|NCT00897260|RADIATION|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
218989073|NCT00897260|PROCEDURE|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
218989074|NCT05578391|BIOLOGICAL|Convalescent plasma|Admistration of one unit of convalescent plasma
219270105|NCT06021938|DEVICE|Immersive virtual reality (IVR) & Music therapy|The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
219270106|NCT01902186|DRUG|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
219270107|NCT01902186|DRUG|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
219270108|NCT03259399|GENETIC|detection of genotype|detection of genotype by next generation sequencing
219270109|NCT03843294|BIOLOGICAL|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
219270110|NCT03843294|DRUG|Nivolumab|Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
219270111|NCT03796000|PROCEDURE|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
219270112|NCT02180347|DEVICE|Contact lenses|
218989075|NCT00756756|DRUG|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
218989076|NCT00756756|DRUG|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
218989077|NCT01955096|PROCEDURE|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
218989078|NCT01955096|PROCEDURE|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
218989079|NCT01032005|OTHER|double fortified salt|Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
218989080|NCT01433991|DRUG|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
218989081|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
218989082|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
218989083|NCT04915144|DRUG|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
218989084|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
218989085|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
218989086|NCT02619552|DRUG|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
218989087|NCT00769470|BIOLOGICAL|trastuzumab|Given IV
218989088|NCT00769470|DRUG|carboplatin|Given IV
218989089|NCT00769470|DRUG|docetaxel|Given IV
219270113|NCT05087836|DEVICE|Sensor at forehead area|NIRS sensor attached at forehead area.
219270114|NCT05087836|DEVICE|Sensor at temporal area|NIRS sensor attached at temporal area.
219270115|NCT06382389|DRUG|EMONO|Exposure of Emono via facial mask
219270116|NCT06382389|DRUG|Medical air|exposure to Medical Air
219270117|NCT05120154|OTHER|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
219270118|NCT05120154|BEHAVIORAL|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
219270119|NCT00556647|PROCEDURE|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
218989090|NCT00769470|DRUG|lapatinib ditosylate|Given orally
219270120|NCT00556647|PROCEDURE|conventional diagnosis|out-patient diagnosis
219270121|NCT00554645|BEHAVIORAL|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
219270122|NCT00554645|OTHER|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
219270123|NCT02398032|DEVICE|CPAP nasal|During the night
219270124|NCT02398032|DEVICE|sham CPAP nasal|During the night
219270125|NCT01310699|DEVICE|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
219270126|NCT05436015|OTHER|Virtual nature-based intervention|"Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor"
219270127|NCT03293069|DRUG|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
219270128|NCT03293069|DRUG|Placebo Oral Tablet|the placebo twice daily morning and evening.
219270129|NCT05074199|PROCEDURE|W-plasty/Linear closure|"The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material."
218989091|NCT03486548|DRUG|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
218989092|NCT03486548|DRUG|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
218989093|NCT03486548|DEVICE|Ultrasound|ultrasound
218989094|NCT00871260|DRUG|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
219270130|NCT00936598|DRUG|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or \> 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
219270131|NCT00936598|DRUG|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
219270132|NCT01158989|DEVICE|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
219270133|NCT00127361|BEHAVIORAL|doula training|
218989095|NCT03275012|DRUG|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
218989096|NCT03275012|DRUG|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
218989097|NCT03539081|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
218989098|NCT03539081|OTHER|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
218989099|NCT03539081|OTHER|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
218989100|NCT03539081|OTHER|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
218989101|NCT03539081|OTHER|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
218989102|NCT03539081|OTHER|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
218989103|NCT03539081|OTHER|Anthropometric Measurements|Height and weight will be obtained.
218989104|NCT03539081|BEHAVIORAL|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
218989105|NCT03539081|BEHAVIORAL|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
218989106|NCT04170816|DEVICE|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
218989107|NCT00542555|DRUG|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
218989108|NCT00542555|DRUG|Naproxcinod 375 mg|
218989109|NCT00542555|DRUG|Naproxen|
218989110|NCT00542555|DRUG|Naproxcinod 750 mg|
218989111|NCT03579732|DRUG|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. \< 150 mg daily
218989112|NCT03579732|OTHER|No drug|Non-consumers
218989113|NCT06803914|PROCEDURE|Biomechanical analysis|Biomechanical assessment is performed using a set of sensors (Qualisys Sports Marker Set - functional assessment, already in use at the Clinique du Sport) as well as 3D optoelectronic cameras and force and pressure platforms. These sensors are placed at various points on both lower limbs (hip, knee, ankle) and provide data in different planes (sagittal, frontal, transverse), as well as a comparison of both sides.
218989114|NCT00258401|DIETARY_SUPPLEMENT|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
218989115|NCT00258401|PROCEDURE|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
218989116|NCT00258401|PROCEDURE|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
218989117|NCT01776892|DRUG|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
218989118|NCT01776892|PROCEDURE|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
218989119|NCT06256016|OTHER|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
218989120|NCT06256016|OTHER|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
218989121|NCT03542474|BEHAVIORAL|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
219270134|NCT02413814|BEHAVIORAL|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
218989122|NCT02474459|DEVICE|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
218989123|NCT02474459|OTHER|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
218989124|NCT00987220|DRUG|Placebo|Oral
219270135|NCT02413814|BEHAVIORAL|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
219270136|NCT03278743|OTHER|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
219270137|NCT02405897|DEVICE|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
218989125|NCT00987220|DRUG|donepezil (Aricept)|5mg oral
218989126|NCT00990236|DRUG|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
218989127|NCT00990236|DRUG|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
218989128|NCT01673867|BIOLOGICAL|Nivolumab|
218989129|NCT01673867|DRUG|Docetaxel|
218989130|NCT03075540|BEHAVIORAL|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
218989131|NCT02259868|DRUG|BILR 355 BS /1B, current low dose formulation|
218989132|NCT02259868|DRUG|BILR 355 BS /1B, current high dose formulation|
218989133|NCT02259868|DRUG|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
218989134|NCT02259868|DRUG|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
218989135|NCT02259868|DRUG|BILR 355 BS - Suspension low dose|
218989136|NCT02259868|DRUG|BILR 355 BS - Suspension high dose|
218989137|NCT02259868|DRUG|Ritonavir|
218989138|NCT05021991|DRUG|100 mg PRAX-944|Once daily oral treatment with titration
218989139|NCT05021991|DRUG|60 mg PRAX-944|Once daily oral treatment with titration
218989140|NCT05021991|DRUG|Placebo|Once daily oral treatment
218989141|NCT05021991|DRUG|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
218989142|NCT03340701|DRUG|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
218989143|NCT00479609|DRUG|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
218989144|NCT00479609|DRUG|Placebo|Placebo gel
218989145|NCT04043260|DEVICE|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
218989146|NCT00186030|BEHAVIORAL|HIV Skills-based Prevention|
218989147|NCT02048891|DRUG|GnRH agonist trigger|
218989148|NCT02048891|DRUG|hCG trigger|
218989149|NCT02957877|DRUG|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
218989150|NCT02957877|DRUG|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
218989151|NCT01045720|DRUG|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
218989152|NCT01045720|DRUG|Placebo|Placebo (starch)
218989153|NCT01084746|BEHAVIORAL|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
218989154|NCT01084746|BEHAVIORAL|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
218989155|NCT05169749|PROCEDURE|Control-Service Nurse Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
218989156|NCT05169749|PROCEDURE|Nursing Visiting Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
218989157|NCT02550106|DRUG|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
218989158|NCT02172924|BIOLOGICAL|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
218989159|NCT02172924|BIOLOGICAL|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
218989160|NCT02345681|DRUG|Furosemide|
218989161|NCT05132920|DRUG|Dexamethasone|3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
218989162|NCT05132920|DRUG|Placebo|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
218989163|NCT05226715|OTHER|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
219270138|NCT02405897|DEVICE|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
219270139|NCT06018038|DIAGNOSTIC_TEST|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
219270140|NCT05761340|PROCEDURE|Helfer skin tap injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~2. After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~3. After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~4. During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~5. After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~6. After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke"
218989164|NCT01897844|DRUG|ITF2984 (100, 2000, 3000 mcg bid)|
218989165|NCT01897844|DRUG|Placebo|
218989166|NCT04261348|OTHER|No intervention|There is no intervention
218989167|NCT06143813|DIAGNOSTIC_TEST|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
218989168|NCT01405248|DRUG|Butylphthalide|20 mg/time per os three times a day. 180days
218989169|NCT01405248|DRUG|Placebo|20 mg/time per os three times a day. 180days
218989170|NCT02628652|DIETARY_SUPPLEMENT|GOS|
218989171|NCT02628652|DIETARY_SUPPLEMENT|GLOS|
218989172|NCT02628652|DIETARY_SUPPLEMENT|FOS|
218989173|NCT04870593|BEHAVIORAL|Information|Elder informed about vaccination.
218989174|NCT04870593|BEHAVIORAL|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
218989175|NCT04870593|BEHAVIORAL|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
218989176|NCT04870593|BEHAVIORAL|Information assigned in community|Information intervention assigned for other elders in community.
218989177|NCT04870593|BEHAVIORAL|Buddy assigned in community|Buddy intervention assigned for other elders in community.
218989178|NCT05657912|DEVICE|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
218989179|NCT03807518|BEHAVIORAL|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
218989180|NCT00957554|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
218989181|NCT00957554|DRUG|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
218989182|NCT00354744|BIOLOGICAL|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
218989183|NCT00354744|DRUG|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
218989184|NCT00354744|DRUG|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
218989185|NCT00354744|DRUG|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
218989186|NCT00354744|DRUG|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
218989187|NCT00354744|DRUG|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
218989188|NCT00354744|DRUG|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
218989189|NCT00354744|PROCEDURE|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
218989190|NCT00354744|RADIATION|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
218989191|NCT00354744|BIOLOGICAL|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
218989192|NCT00109122|BIOLOGICAL|zoster vaccine live (Oka/Merck)|
218989193|NCT00109122|BIOLOGICAL|Comparator: placebo (unspecified)|
218989194|NCT01193530|OTHER|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
218989195|NCT01193530|OTHER|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
219270141|NCT05761340|PROCEDURE|Standard Injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~2. After determining the injection site, prepare the skin with alcohol.~3. Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~4. After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~5. Remove the syringe needle 10 seconds after the drug is consumed"
218989196|NCT01193530|BEHAVIORAL|Questionnaires|Weekly
218989197|NCT01193530|BEHAVIORAL|Study Diaries|Daily logs
218989198|NCT01193530|DEVICE|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
218989199|NCT01193530|DEVICE|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
218989200|NCT03539328|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
218989201|NCT03539328|DRUG|Gemcitabine|Chemotherapy medication
218989202|NCT03539328|DRUG|Paclitaxel|Chemotherapy medication
219270142|NCT00926575|DRUG|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
218989203|NCT03539328|DRUG|Liposomal Doxorubicin|Chemotherapy medication
219270143|NCT00926575|DRUG|Placebo|Two tablets QID for 50 days
219270144|NCT01179503|DIETARY_SUPPLEMENT|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
219270145|NCT01179503|DIETARY_SUPPLEMENT|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
218989204|NCT05998044|OTHER|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch"
218989205|NCT05998044|OTHER|control|They will be asked not to participate in any regular exercise for 8 weeks.
219270146|NCT06201546|PROCEDURE|TAP block group|TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
219270147|NCT06201546|PROCEDURE|m-TAPA block group|m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
219270148|NCT00004448|DRUG|omega-3 fatty acids|
218989206|NCT01544283|DRUG|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
219270149|NCT00004448|DRUG|prednisone|
219270150|NCT00004448|DRUG|Placebo|
219270151|NCT02183077|DRUG|Meloxicam gel|
219270152|NCT02183077|DRUG|Meloxicam tablet|
219270153|NCT04243512|BEHAVIORAL|Time-restricted eating|Restrict food and beverage intake (except water) to a 10-hour window
218989207|NCT01544283|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
218989208|NCT03489148|BEHAVIORAL|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
218989209|NCT03489148|BEHAVIORAL|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
218989210|NCT00936156|DRUG|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
218989211|NCT05545709|PROCEDURE|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
219270154|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
218989212|NCT00002734|BIOLOGICAL|recombinant interferon alfa|
218989213|NCT00002734|DRUG|chemotherapy|
218989214|NCT00002734|DRUG|paclitaxel|
218989215|NCT00002734|DRUG|topotecan hydrochloride|
219270155|NCT02633397|DRUG|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
219270156|NCT02633397|DRUG|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
218989216|NCT00002734|RADIATION|lutetium Lu 177 monoclonal antibody CC49|
218989217|NCT00002734|RADIATION|yttrium Y 90 monoclonal antibody CC49|
218989218|NCT04284358|OTHER|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
219270157|NCT03595878|RADIATION|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
219270158|NCT03595878|RADIATION|Standard WBRT|Standard Whole Brain Radiation Therapy
218989219|NCT04714957|OTHER|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
218989220|NCT00455078|PROCEDURE|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
218989221|NCT00455078|OTHER|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
219270159|NCT04673357|DRUG|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
219270160|NCT04673357|DRUG|Placebo|Matching placebo will be administered as SC injection.
219270161|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
219270162|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
218989222|NCT00455078|PROCEDURE|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
219270163|NCT05441982|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
218989223|NCT00455078|PROCEDURE|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
218989224|NCT00455078|PROCEDURE|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
218989225|NCT05219305|DEVICE|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
218989226|NCT05882942|DIETARY_SUPPLEMENT|Matcha green tea|This is the condition with the Matcha green tea
218989227|NCT05882942|DIETARY_SUPPLEMENT|Placebo|This is the condition with the placebo
218989228|NCT02282579|DRUG|Pazopanib|Non interventional study
218989229|NCT00312559|BEHAVIORAL|Yoga Training|
218989230|NCT03963037|OTHER|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
218989231|NCT00917566|DEVICE|Airtraq|intubation with airtraq
218989232|NCT00917566|DEVICE|Macintoch|use Macintoch laryngoscope for intubation
218989233|NCT02782728|BEHAVIORAL|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
219270164|NCT05131789|PROCEDURE|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
219270165|NCT03494985|DEVICE|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
218989234|NCT02782728|BEHAVIORAL|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
218989235|NCT00266734|DEVICE|RPS Adeno Detector|
218989236|NCT04263077|OTHER|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
219270166|NCT03494985|DEVICE|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
219270167|NCT03494985|DEVICE|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
219270168|NCT03494985|OTHER|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
219270169|NCT00581841|OTHER|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
218989237|NCT04263077|OTHER|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
218989238|NCT04263077|OTHER|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
218989239|NCT04263077|OTHER|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
218989240|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
218989241|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
219270170|NCT06028594|DRUG|Pozelimab|Subcutaneous (SC) administration
218989242|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
218989243|NCT00787384|DRUG|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
218989244|NCT00993200|GENETIC|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
218989245|NCT00993200|DRUG|Warfarin|Usual care warfarin dosing
219270171|NCT06028594|DRUG|Cemdisiran|Subcutaneous (SC) administration
219270172|NCT00244686|DRUG|Mepolizumab|open label investigational product
218989246|NCT00926328|DRUG|Triclosan, fluoride|Six Month study, brush twice daily
218989247|NCT00926328|DRUG|Fluoride|twice daily usage
218989248|NCT00289133|DEVICE|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
218989249|NCT00289133|DEVICE|total knee arthroplasty|cross-linked polyethylene tibial insert
219270173|NCT06194032|DRUG|Baxdrostat|Participants will receive baxdrostat as two separate doses.
219270174|NCT06194032|DRUG|Placebo|Participants will receive baxdrostat matching placebo.
219270175|NCT06194032|DRUG|Moxifloxacin|Participants will receive a single dose moxifloxacin
218989250|NCT00795860|BEHAVIORAL|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
218989251|NCT00795860|BEHAVIORAL|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
218989252|NCT02644642|OTHER|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
218989253|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
218989254|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
218989255|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
218989256|NCT05051371|DEVICE|Train of four monitoring|Train of four monitoring in postoperative care unit
218989257|NCT01227434|DRUG|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
218989258|NCT01227434|DRUG|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
218989259|NCT01227434|PROCEDURE|Resection as clinical care|Indicated, intended, surgical resection as clinical care
218989260|NCT01783262|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
218989261|NCT01783262|DEVICE|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
218989262|NCT02803255|DEVICE|MAHI Exo-II|
218989263|NCT04029831|DRUG|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
218989264|NCT03546660|DEVICE|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
218989265|NCT04365296|OTHER|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
218989266|NCT02034669|DEVICE|Laminectomy|surgical laminectomy with glial scar resection
219270176|NCT05424094|BEHAVIORAL|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
219270177|NCT03036124|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
219270178|NCT03036124|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
219270179|NCT04359264|OTHER|Cash transfer|Cash transfer of $1000
219270180|NCT04274699|DIAGNOSTIC_TEST|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
219270181|NCT06632236|DRUG|Amivantamab|Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
218989267|NCT02034669|DEVICE|Intradural space|ADSCs injection into Intradural space at damage site
218989268|NCT02034669|DEVICE|Intrathecal|ADSCs Intrathecal into lumbar puncture
218989269|NCT02034669|DEVICE|Intravenous|ADSCs intravenous
218989270|NCT05475132|OTHER|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
219270182|NCT02908984|BEHAVIORAL|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
219270183|NCT02908984|OTHER|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
219270184|NCT03863860|DRUG|Fluzoparib capsules|Fluzoparib capsules
219270185|NCT03863860|DRUG|Placebo capsules|Placebo capsule
219270186|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
219270187|NCT04906954|OTHER|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
219270188|NCT05619822|BEHAVIORAL|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES\_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
219270189|NCT05619822|BEHAVIORAL|TAU|Treatment as usual
219270190|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
219270191|NCT05274100|DRUG|Risankizumab|Intravenous Infusion
219270192|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
219270193|NCT06276114|DEVICE|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
219270194|NCT04684771|DIETARY_SUPPLEMENT|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
219270195|NCT04684771|DIETARY_SUPPLEMENT|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
219270196|NCT02394925|DEVICE|Multifocal Test Contact lens|Used in a daily wear modality
219270197|NCT02134847|OTHER|SCS intervention schedule|
219270198|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
219270199|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
219270200|NCT00151827|DRUG|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
219270201|NCT00151827|DRUG|Losartan|Medications are taken once daily before breakfast with water.
219270202|NCT00151827|DRUG|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
219270203|NCT03670277|DEVICE|etafilcon A|Test Soft Contact Lens
219270204|NCT03670277|DEVICE|Habitual Orthokeratology Lenses|CONTROL
219270205|NCT02660112|DRUG|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
219270206|NCT04339374|DEVICE|Photoacoustic imaging, photoacoustic microscopy|-Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise -The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers -The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)
219270207|NCT04339374|DEVICE|Endorectal photoacoustic imaging probe|-An endorectal imaging device using coregistered photoacoustic and ultrasound imaging has been constructed. This probe is used to perform in vivo imaging among patients with rectal pathology intraoperatively.
219270208|NCT04339374|OTHER|Reader Performance|After initial training, the study surgeon will grade the lesion as either PAM/US non-cCR or PAM/US cCR at the time of PAM/US imaging. The study radiologist, blinded from the surgeon's read, will also grade the lesion based on MRI. PAM/US-CNNs provide a real-time imaging tool to assist the reader team in diagnosis. The pathological outcomes of the patients will be assessed based on Tumor Regression Score by standard pathologic evaluation. The study will evaluate the effect of the assistance of PAM/US-CNNs for trained readers on their performance i.e. sensitivity and specificity of their diagnosis of rectal cancers from images obtained from the testing cohort of (Group 2) patients.
219270209|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
219270210|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
219270211|NCT04762069|DRUG|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
219270212|NCT04762069|DRUG|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
218989271|NCT05475132|OTHER|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
218989272|NCT01513343|BEHAVIORAL|Parent and child groups focused on self-regulation of eating|
218989273|NCT02632981|OTHER|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
218989274|NCT02632981|OTHER|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
219270213|NCT06816498|DRUG|nL-LMNB1-001|Personalized antisense oligonucleotide
219270214|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
219270215|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
219270216|NCT04322955|DRUG|Cabozantinib|2 x 20 mg capsules taken orally daily
219270217|NCT04322955|DRUG|Nivolumab|480mg IV on first day of each 28-day cycle
219270218|NCT04322955|PROCEDURE|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
219270219|NCT00541151|DEVICE|MiniArc|sling system
218989275|NCT03438669|OTHER|no intervention|no intervention
218989276|NCT02840097|DRUG|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
219270220|NCT06735482|BEHAVIORAL|Therapeutic play program|Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
219270221|NCT05896644|OTHER|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
219270222|NCT06944470|DRUG|Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma|"Carboplatin Injection:~One dose of carboplatin AUC 5 IV on Day 1 of each 3-week cycle.~Cisplatin injection:~Cisplatin 75 mg/m2 IV on Day 1 of every 3-week cycle.~Paclitaxel injection:~175 mg/m2 IV on Day 1 of each 3-week cycle.~Pemetrexed Injection:~Pemetrexed 500 mg/m2 IV on Day 1 of each 3-week cycle."
219270223|NCT06944470|PROCEDURE|surgery|Subjects with surgical indications will undergo radical surgery for NSCLC，within 4-6 weeks after the last dose of neoadjuvant therapy.
218989277|NCT02840097|DRUG|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
218989278|NCT00920283|DEVICE|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
218989279|NCT00920283|DEVICE|Driver Cobalt Alloy Coronary Stent|
218989280|NCT01758562|DEVICE|Caphosol|
218989281|NCT02665520|PROCEDURE|liposuction for retrieval of own stem cells from fat cells|
218989282|NCT05831020|OTHER|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
218989283|NCT02161081|PROCEDURE|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
218989284|NCT05751460|OTHER|Straight leg raise|Diagnostic test, tool for \*g\*
218989285|NCT04736407|OTHER|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
218989286|NCT02794038|DEVICE|Soberlink Cellular Device|BAC breath analyzer
218989287|NCT02794038|DEVICE|BACtrack S80 Pro|BAC breath analyzer
218989288|NCT02165215|DRUG|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
218989289|NCT02165215|DRUG|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
218989290|NCT02576002|DRUG|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
218989291|NCT06218693|BEHAVIORAL|VIA Family|A family-based, multi-component, individual-tailored intervention based on case-management.
218989292|NCT06218693|BEHAVIORAL|Treatment As Usual (TAU)|care as usual
218989293|NCT00855569|DEVICE|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
218989294|NCT03222336|BEHAVIORAL|Family pedigree and data collection|"1. Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~2. Collect and analyze medical history, genetic and biochemical assessment data"
218989295|NCT06312605|PROCEDURE|Injectable applied vitamin C|Surgical gingival depigmentation is done for all participants, after then they receive injectable vitamin C
218989296|NCT06312605|PROCEDURE|Topical applied Vitamin C|Surgical gingival depigmentation is done for all participants, after then they are instructed to apply topical vitamin C
218989297|NCT06312605|PROCEDURE|Surgical depigmentation only|Surgical gingival depigmentation only without any drug
218989298|NCT01224860|DRUG|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
218989299|NCT01224860|DRUG|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
218989300|NCT01631981|DRUG|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
218989301|NCT01631981|DRUG|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
218989302|NCT01816282|DRUG|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
218989303|NCT04645875|OTHER|Sit regimen|See Sit regimen arm description
218989304|NCT04645875|OTHER|SitLess regimen|See SitLess regimen arm description
218989305|NCT01560364|OTHER|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
218989306|NCT05453604|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
218989307|NCT00064337|BIOLOGICAL|filgrastim|
218989308|NCT00064337|DRUG|cyclophosphamide|
218989309|NCT00064337|DRUG|dexamethasone|
218989310|NCT00064337|DRUG|melphalan|
218989311|NCT00064337|DRUG|thalidomide|
218989312|NCT00064337|PROCEDURE|peripheral blood stem cell transplantation|
219270224|NCT06944470|RADIATION|Radiochemotherapy|If radical surgery is not suitable after MDT evaluation, the subjects will receive comprehensive treatment mainly based on radiotherapy.
219270225|NCT06944470|DRUG|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days.
218989313|NCT06504095|OTHER|intervention group (Flipped Teaching Method Group)|"Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students."
218989314|NCT05060302|OTHER|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
218989315|NCT04700709|DRUG|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
218989316|NCT04700709|DRUG|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
218989317|NCT01784978|DRUG|Sunitinib|50 mg pd
219270226|NCT02604563|OTHER|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
219270227|NCT02604563|OTHER|Activities of Daily Living Questionnaire|"* 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
218989318|NCT01784978|DRUG|Everolimus|10 mg pd
218989319|NCT04112056|DIETARY_SUPPLEMENT|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
218989320|NCT01506713|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
218989321|NCT01165437|DEVICE|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
218989322|NCT00385983|DEVICE|Harmonic Scalpel|
218989323|NCT04773860|OTHER|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
218989324|NCT05529303|BEHAVIORAL|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
218989325|NCT05733780|DRUG|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
218989326|NCT02279420|DEVICE|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
218989327|NCT03423381|OTHER|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
219270228|NCT02604563|OTHER|Instrumental Activities of Daily Living, subscale of the OARS|"* 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
218989328|NCT03423381|OTHER|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
218989329|NCT03423381|OTHER|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
218989330|NCT03423381|OTHER|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
218989331|NCT03423381|OTHER|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
218989332|NCT03423381|OTHER|Control product|A cereal based product with low concentrations of df
218989333|NCT01948947|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
218989334|NCT01948947|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
218989335|NCT01874613|DEVICE|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
218989336|NCT01874613|DEVICE|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
218989337|NCT06959641|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
218989338|NCT06959641|PROCEDURE|Computed Tomography|Undergo CT scan
218989339|NCT06959641|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218989340|NCT06959641|OTHER|Survey Administration|Ancillary studies
218989341|NCT06959641|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
218989342|NCT06959641|DRUG|Zanzalintinib|Given PO
218989343|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
218989344|NCT00565786|DEVICE|ArCom® Polyethylene|Argon packaged compression molded polyethylene
218989345|NCT00565786|DEVICE|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
218989346|NCT04178564|BEHAVIORAL|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
218989347|NCT01619696|PROCEDURE|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
219270229|NCT02604563|OTHER|Karnofsky Self-reported Performance Rating Scale|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
218989348|NCT02069717|OTHER|Not applicable-observational study|
218989349|NCT05096221|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
218989350|NCT05096221|GENETIC|placebo|Single IV infusion of matching placebo.
218989351|NCT00236587|DRUG|risperidone|
218989352|NCT04096729|OTHER|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
218989353|NCT00002946|DRUG|penclomedine|
218989354|NCT00779701|DRUG|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
218989355|NCT04655378|OTHER|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
218989356|NCT02733432|DRUG|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
218989357|NCT02733432|DRUG|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
218989358|NCT02733432|DRUG|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
219270230|NCT02604563|OTHER|Number of Falls|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
218989359|NCT02733432|DRUG|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
218989360|NCT02733432|DRUG|Fluconazole|oral fluconazole (150mg) on Day 1
219270231|NCT02604563|OTHER|Physical Health Section, subscale of the OARS|"* 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death"
219270232|NCT02604563|OTHER|MOS Social Activity Survey|"* 4 items about social activity~* Baseline and no more frequently than every 6 months until death"
219270233|NCT02604563|OTHER|Unintentional Weight Loss|"* 2 items about nutrition~* Baseline and no more frequently than every 6 months until death"
219270234|NCT02604563|GENETIC|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
218989361|NCT04394117|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
219270235|NCT02604563|GENETIC|Buccal Swab|"* Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death"
218989362|NCT04394117|OTHER|Placebo|Placebo
218989363|NCT06382051|DIAGNOSTIC_TEST|PEST Screening group|PEST Screening group
218989364|NCT04810078|BIOLOGICAL|Nivolumab and rHuPH20|Specified dose on specified days
218989365|NCT04810078|BIOLOGICAL|Nivolumab|Specified dose on specified days
218989366|NCT06281223|OTHER|intraoperative neuroelectrophysiological monitoring|"The procedure involves intraoperative neuroelectrophysiological monitoring. The aim is to record the electrical activity of the central and peripheral nervous system at several levels during a neurosurgical procedure.~The equipment used comes from INOMED and consists of :~* a recording station (ISIS)~* scalp corkscrew electrodes (2 to 4 electrodes)~* a 4-pin FSR spinal cord electrode (Ad-Tech)~* hook electrodes for roots/radicles (X2)~* needle electrodes for muscles (X18)~Electrode placement and recording take place in the operating room while the patient is under general anaesthetic (intubated and sedated)."
218989367|NCT04200950|DEVICE|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
218989368|NCT03821883|DRUG|Aspirin Tablet|Aspirin 100mg qd
218989369|NCT03821883|DRUG|Placebo|Placebo qd
218989370|NCT04483141|DIAGNOSTIC_TEST|Abbey Pain Scale|Hetero-assessment of pain
218989371|NCT04146233|OTHER|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
218989372|NCT03094169|DRUG|AVID100 IV|AVID100 is administered once every 3 weeks
218989373|NCT04645953|COMBINATION_PRODUCT|3mg AZ-010|Subjects who received a single inhaled dose (3mg)
218989374|NCT04645953|COMBINATION_PRODUCT|1mg AZ010|Subjects who received a single inhaled dose (1mg)
218989375|NCT04645953|COMBINATION_PRODUCT|Staccato Placebo|Subject who received a single inhaled dose (Staccato Placebo)
218989376|NCT04613375|DIAGNOSTIC_TEST|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
218989377|NCT04613375|DIAGNOSTIC_TEST|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
218989378|NCT03800134|DRUG|Durvalumab|1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
219270236|NCT02604563|OTHER|Heart Health and Smoking History from BRFSS questionnaire|"* 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death"
219270237|NCT02604563|OTHER|Gait Speed|"* Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death"
219270238|NCT02604563|OTHER|Grip Strength|"* Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death"
219270239|NCT02604563|OTHER|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
219270240|NCT02604563|OTHER|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
219270241|NCT02604563|PROCEDURE|Optional bone marrow biopsy|-1 optional bone marrow biopsy
219270242|NCT02604563|PROCEDURE|Blood draw for trauma measurements|-For Arm E only
219270243|NCT05535413|DRUG|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
218989379|NCT03800134|OTHER|Placebo|Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
218989380|NCT03800134|DRUG|Carboplatin|Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
218989381|NCT03800134|DRUG|Cisplatin|75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
218989382|NCT03800134|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
218989383|NCT03800134|DRUG|Paclitaxel|200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
218989384|NCT03800134|DRUG|Gemcitabine|1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
218989385|NCT03800134|PROCEDURE|Surgery|Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
218989386|NCT06285279|DRUG|FKC288|"The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion."
218989387|NCT04993521|PROCEDURE|Block type|Regular block type
218989388|NCT02737098|OTHER|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
218989389|NCT02737098|OTHER|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
218989390|NCT04718298|DEVICE|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
218989391|NCT00899054|DRUG|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
218989392|NCT00899054|RADIATION|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
218989393|NCT03311633|PROCEDURE|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
218989394|NCT06414889|DRUG|G-CSF (filgrastim or biosimilar)|Given by IV or SC
218989395|NCT06414889|PROCEDURE|Apheresis|Given by procedure
218989396|NCT06414889|DRUG|Plerixafor|Given by IV
218989397|NCT05845450|DRUG|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
218989398|NCT05845450|DRUG|Durvalumab|durvalumab 1500 mg IV on day 1
218989399|NCT05845450|DRUG|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
218989400|NCT05845450|DRUG|Botensilimab|botensilimab 1 mg/kg on day 1
218989401|NCT05845450|DRUG|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
219270244|NCT01515943|OTHER|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
218989402|NCT05845450|DRUG|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
218989403|NCT05845450|DRUG|Vorbipiprant|vorbipiprant 90 mg orally bid from day 1 to 28
218989404|NCT05845450|DRUG|Nivolumab|240 mg IV on days 1 and 15
218989405|NCT01964859|BIOLOGICAL|autologous skin fibroblasts|
218989406|NCT05219721|DRUG|CAR-T (CAR-GPRC5D)|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
218989407|NCT03346018|DIAGNOSTIC_TEST|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
218989408|NCT06960564|DEVICE|Hyaluronic Acid injections|Intra-articular hyaluronic acid will be administered to 30 selected patients. Blood and synovial fluid samples will be collected before HA injection and 1 week after 3 sessions of HA injection with one week interval. Home exercise programme will be given.
219270245|NCT01515943|PROCEDURE|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
219270246|NCT01515943|OTHER|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
219270247|NCT01515943|PROCEDURE|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~* Weeks 1-4: View the target through prism flippers~* Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~* Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
218989409|NCT06960564|OTHER|Saline -- placebo comparator|Intra-articular saline (SF) will be administered to 20 selected patients. Blood and synovial fluid samples will be collected before and 1 week after 3 session of salin injection with one week interval. Home exercise programme will be given.
218989410|NCT03191188|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
218989411|NCT03191188|DRUG|Placebo Oral Tablet|Placebo
218989412|NCT04203654|BEHAVIORAL|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
218989413|NCT04203654|BEHAVIORAL|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
218989414|NCT01921387|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
218989415|NCT01921387|DRUG|Carmustine|Given IV
218989416|NCT01921387|DRUG|Cytarabine|Given IV
218989417|NCT01921387|DRUG|Etoposide|Given IV
218989418|NCT01921387|OTHER|Laboratory Biomarker Analysis|Correlative studies
218989419|NCT01921387|DRUG|Melphalan|Given IV
218989420|NCT01921387|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
218989421|NCT01921387|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
218989422|NCT02537119|PROCEDURE|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
218989423|NCT02537119|PROCEDURE|Massage therapy|Rubbing on hamstrings
218989424|NCT01998776|DRUG|Misoprostol|Misoprostol 200ug four times daily
218989425|NCT01998776|DRUG|Placebo|Placebo Starch four times daily
218989426|NCT00135096|DRUG|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
218989427|NCT00135096|DRUG|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
218989428|NCT06142071|BEHAVIORAL|Telephone questionnaire|Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial
218989429|NCT06264414|DRUG|DTT106|oral route
218989430|NCT06264414|DRUG|Dutasteride-Tamsulosin|oral route
218989431|NCT03828175|PROCEDURE|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
218989432|NCT02051504|BEHAVIORAL|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
218989433|NCT02051504|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
218989434|NCT02051504|PROCEDURE|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
219270248|NCT01535651|BEHAVIORAL|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
219270249|NCT05572749|DIETARY_SUPPLEMENT|Crocus Kozanis|In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.
219270250|NCT05572749|DIETARY_SUPPLEMENT|Placebo of Crocus Kozanis|Placebo of Crocus Kozanis
219270251|NCT05572749|DRUG|Metformin|Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
218989435|NCT02051504|PROCEDURE|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
218989436|NCT02051504|PROCEDURE|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
218989437|NCT02051504|PROCEDURE|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
218989438|NCT02051504|OTHER|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
218989439|NCT00510497|BIOLOGICAL|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
218989440|NCT01706146|DRUG|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
218989441|NCT04459728|BEHAVIORAL|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
218989442|NCT04459728|BEHAVIORAL|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
218989443|NCT04459728|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
218989444|NCT04459728|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
218989445|NCT04459728|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
218989446|NCT04459728|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
219270252|NCT03930329|BEHAVIORAL|MBRP group|same as arm description
219270253|NCT02204020|DRUG|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
218989447|NCT04459728|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
218989448|NCT01597531|DRUG|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
218989449|NCT01597531|DRUG|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
219270254|NCT05163795|PROCEDURE|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
219270255|NCT01951404|DRUG|Allopurinol|
219270256|NCT01951404|DRUG|Placebo (for allopurinol)|
219270257|NCT04684667|DRUG|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
219270258|NCT03236532|DIETARY_SUPPLEMENT|Glutamine and exercise|
218989450|NCT01597531|DRUG|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
218989451|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
218989452|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
218989453|NCT03499977|BEHAVIORAL|Sitting|10 min bouts
218989454|NCT03499977|BEHAVIORAL|Light-Intensity Cycling|10min bout
218989455|NCT03499977|BEHAVIORAL|Moderate-Intensity Cycling|10 min bout
218989456|NCT03499977|BEHAVIORAL|High-Intensity Cycling|10 min bout
218989457|NCT00675948|DRUG|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
218989458|NCT00675948|DRUG|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
218989459|NCT05146310|DEVICE|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
218989460|NCT02582983|DRUG|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
218989461|NCT01528475|BEHAVIORAL|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
218989462|NCT00742430|PROCEDURE|PCI|percutaneous coronary intervention in stable coronary artery disease
218989463|NCT05428046|BEHAVIORAL|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
218989464|NCT05428046|BEHAVIORAL|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
218989465|NCT03461913|PROCEDURE|Cesarean section|Lower segment elective Cesarean section
219270259|NCT03236532|DIETARY_SUPPLEMENT|Maltodextrin and exercise|
219270260|NCT04435444|OTHER|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
219270261|NCT04435444|OTHER|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
219270262|NCT05224843|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
218989466|NCT00528463|PROCEDURE|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
218989467|NCT04044378|DRUG|Famitinib|famitinib with RP2D orally daily
218989468|NCT04044378|DRUG|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
218989469|NCT04044378|DRUG|Camrelizumab|camrelizumab 200mg infusion once Q2W
218989470|NCT04449081|BEHAVIORAL|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
218989471|NCT01476956|OTHER|Observational study|RA patients on standard DMARD therapy
218989472|NCT01317654|OTHER|Observation|Collection of mortality data at 5 years post trial
218989473|NCT03597880|OTHER|obese patients|underwent bariatric surgery
218989474|NCT05970185|DRUG|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
218989475|NCT05970185|DRUG|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
218989476|NCT05124314|DRUG|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
218989477|NCT05124314|DRUG|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
218989478|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
218989479|NCT02527161|DEVICE|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
218989480|NCT05209360|DEVICE|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
218989481|NCT05209360|DEVICE|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
218989482|NCT03155971|DEVICE|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
218989483|NCT03021941|DRUG|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
218989484|NCT02329912|DEVICE|SmartPill|Application of the SmartPill at the end of surgery
218989485|NCT02459301|DRUG|IPH2201|
218989486|NCT04456608|DRUG|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
218989487|NCT01951274|DRUG|VPD-737|NK1 Receptor Antagonist
218989488|NCT01951274|DRUG|Placebo|
218989489|NCT05198999|OTHER|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
218989490|NCT05198999|OTHER|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
218989491|NCT00724932|DRUG|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
219270263|NCT05834192|OTHER|Backward treadmill walking|Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
219270264|NCT05834192|OTHER|Lower extremity cross training|"For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down."
219270265|NCT03684876|PROCEDURE|diuretic use|use of diuretic
219270266|NCT02422680|PROCEDURE|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
219270267|NCT02294747|DEVICE|Sliding Hip Screw with Trochanteric Stabilization Plate|
219270268|NCT02294747|DEVICE|Sliding Hip Screw without Trochanteric Stabilization Plate|
219270269|NCT05058053|OTHER|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
218989492|NCT00724932|DRUG|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
218989493|NCT00724932|DRUG|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
218989494|NCT00724932|DRUG|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
218989495|NCT04922970|OTHER|Strength training|The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
218989496|NCT03885258|DRUG|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
218989497|NCT05648383|BEHAVIORAL|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
219270270|NCT03415243|DRUG|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters \[mcL\]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel \[MBq\] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
218989498|NCT05648383|BEHAVIORAL|Standard care|Participants will receive standard care, including lifestyle recommendations.
218989499|NCT04289662|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
218989500|NCT04289662|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
218989501|NCT02425371|OTHER|Screening and treatment of comorbidities|Screening and treatment of comorbidities
218989502|NCT02425371|OTHER|Placebo Comparator|No screening of comorbidities
218989503|NCT04843137|DEVICE|Cervical Transcutaneous Electrical Spinal Cord Stimulation|Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
218989504|NCT04302896|DRUG|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
218989505|NCT04302896|DRUG|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
218989506|NCT04302896|DRUG|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
218989507|NCT04302896|DRUG|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
218989508|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
218989509|NCT03236285|BEHAVIORAL|Continous exercise training in the fed state|Continous exercise training in the fed state
218989510|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
219270271|NCT03415243|DRUG|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi\[4MBq\]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
219270272|NCT03258320|DRUG|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
219270273|NCT01245140|DRUG|alitretinoin|to receive verum (20 patients)
219270274|NCT01245140|DRUG|Placebo|to receive placebo (10 patients)
219270275|NCT05863767|OTHER|Baduanjin sequential therapy|Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.
219270276|NCT05863767|OTHER|Conventional Therapy|Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
218989511|NCT03236285|BEHAVIORAL|Continous exercise training in the fasting state|Continous exercise training in the fasting state
218989512|NCT05251987|BIOLOGICAL|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
218989513|NCT02477150|BIOLOGICAL|Zostavax|Vaccination of a zoster vaccine (Zostavax)
218989514|NCT02477150|BIOLOGICAL|placebo|placebo administration
218989515|NCT04946383|DRUG|Dasatinib plus Quercetin|Dasatinib plus Quercetin
218989516|NCT02259881|DRUG|Low dose of BIBT 986 CL, per i.v. infusion|
218989517|NCT02259881|DRUG|Medium dose of BIBT 986 CL, per i.v. infusion|
218989518|NCT02259881|DRUG|High dose of BIBT 986 CL, per i.v. infusion|
219270277|NCT02766127|OTHER|Veritise Flow|Self-adhering composite
219270278|NCT02766127|OTHER|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
218989519|NCT02259881|DRUG|Placebo|
218989520|NCT02259881|DRUG|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
218989521|NCT04655638|DEVICE|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
218989522|NCT04655638|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
218989523|NCT06072846|BEHAVIORAL|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
218989524|NCT05617469|OTHER|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
218989525|NCT05310890|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
218989526|NCT05310890|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
218989527|NCT00469274|DRUG|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
218989528|NCT00469274|DRUG|Antibiotic PEP|TMP-SMX DS po BID for 14 days
218989529|NCT01059591|DRUG|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
218989530|NCT01059591|DRUG|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
218989531|NCT01059591|RADIATION|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
218989532|NCT01081678|DRUG|Placebo|Administered by subcutaneous (under the skin) injection
218989533|NCT01081678|DRUG|Romosozumab|Administered by subcutaneous injection
218989534|NCT03728920|OTHER|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
218989535|NCT04824352|DRUG|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
218989536|NCT00158574|DRUG|sulphadoxine-pyrimethamine|
218989537|NCT00158574|DRUG|mefloquine|
218989538|NCT00158574|DRUG|Chlorproguanil-dapsone|
218989539|NCT00158574|DRUG|Placebo|Placebo
219270279|NCT02766127|OTHER|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
218989540|NCT00158574|DRUG|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
218989541|NCT00158574|DRUG|IPTi mefloquine|IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
218989542|NCT00158574|DRUG|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
219270280|NCT02766127|OTHER|Flor-Opal® Varnish|fluoride-based varnish
219270281|NCT04526093|OTHER|Medical Cannabis|Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
219270282|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
218989543|NCT02326532|OTHER|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
218989544|NCT02326532|OTHER|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
218989545|NCT01507012|DIETARY_SUPPLEMENT|Berry Polyphenols|
218989546|NCT01507012|DIETARY_SUPPLEMENT|Placebo|Placebo control containing sugar and artificial flavouring.
218989547|NCT03998930|OTHER|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
218989548|NCT02900339|DEVICE|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
218989549|NCT02508181|DEVICE|I-gel|supraglottic airway device without cuff
218989550|NCT02508181|DEVICE|LMA Supreme|supraglottic airway device with cuff
218989551|NCT00149162|DRUG|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
218989552|NCT02295384|OTHER|Retrospective Audit|Retrospective Audit
219270283|NCT06492603|DEVICE|Ultrasonography|Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).
219270284|NCT06492603|DEVICE|The MyotonPRO Device|The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues
218989553|NCT04326556|OTHER|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
218989554|NCT01517711|DRUG|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
218989555|NCT01517711|DRUG|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
219270285|NCT04836559|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
218989556|NCT01466335|DRUG|Ronacaleret (100mg tablet)|100mg tablet
219270286|NCT04836559|DRUG|Placebo|Placebo will be administered orally.
218989557|NCT01466335|DRUG|Placebo|matching placebo tablet
218989558|NCT02376231|DEVICE|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
218989559|NCT02560597|PROCEDURE|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
218989560|NCT03800797|DRUG|Loxoprofen sodium hydrogel patch|100 mg per day
218989561|NCT03800797|DRUG|Loxoprofen sodium tablet|60 mg t.i.d.
218989562|NCT04157491|DRUG|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
218989563|NCT00318422|DRUG|liraglutide|
218989564|NCT00318422|DRUG|rosiglitazone|
218989565|NCT00318422|DRUG|glimepiride|
218989566|NCT04218630|OTHER|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
219270287|NCT05230537|DRUG|Iptacopan (LNP023)|oral capsules
219270288|NCT05230537|DRUG|Placebo|oral capsules
219270289|NCT03807609|OTHER|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
218989567|NCT04218630|OTHER|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
218989568|NCT03415334|BEHAVIORAL|behavioral development for change|"1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
218989569|NCT01906398|OTHER|ketogenic diet|KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
218989570|NCT01007812|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
218989571|NCT01007812|DEVICE|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
218989572|NCT01091974|DRUG|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
218989573|NCT01091974|DRUG|Placebo Comparator|Placebo for 47 days
218989574|NCT01091974|BEHAVIORAL|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
218989575|NCT04556513|OTHER|Paraclinical examination|Respiratory functional tests
218989576|NCT04556513|OTHER|Clinical Examination|Clinical Examination
218989577|NCT04556513|OTHER|Semi-directive interview|By phone
218989578|NCT04556513|OTHER|quality of life questionnaires|SF36, VSRQ, IESR, HADS
218989579|NCT04524910|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
218989580|NCT04511169|BEHAVIORAL|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
219270290|NCT03807609|OTHER|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
218989581|NCT02325960|DRUG|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
218989582|NCT02325960|DRUG|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
218989583|NCT02499783|BIOLOGICAL|adalimumab|subcutaneous injections of adalimumab
218989584|NCT02499783|OTHER|placebo|subcutaneous injections of placebo
218989585|NCT03873844|BEHAVIORAL|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
218989586|NCT03873844|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
218989587|NCT05090059|DEVICE|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
218989588|NCT04387032|OTHER|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
218989589|NCT04387032|OTHER|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
218989590|NCT00597181|PROCEDURE|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
218989591|NCT00597181|PROCEDURE|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
218989592|NCT01866293|DRUG|Cabozantinib (XL184)|
218989593|NCT00002378|DRUG|Ritonavir|
218989594|NCT00002378|DRUG|Nelfinavir mesylate|
218989595|NCT00002378|DRUG|Saquinavir|
218989596|NCT00002378|DRUG|Delavirdine mesylate|
218989597|NCT00002378|DRUG|Lamivudine|
218989598|NCT00002378|DRUG|Stavudine|
218989599|NCT00002378|DRUG|Zidovudine|
219270291|NCT03807609|OTHER|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219270292|NCT05364580|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
219270293|NCT05364580|BIOLOGICAL|Botox®|Botulinum toxin Type A
218989600|NCT02652754|DRUG|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
218989601|NCT03050554|DRUG|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
218989602|NCT03050554|RADIATION|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
218989603|NCT06263205|PROCEDURE|Non-Dressing of Surgical Wound|In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.
219270294|NCT06373796|DEVICE|Echographic scan|Liver ultrasound exam
219270295|NCT04264715|DEVICE|405nm light|In this room, surgeries will be performed under ambient light including the wavelength 405nm
219270296|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
219270297|NCT04573660|DEVICE|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
218989604|NCT06263205|PROCEDURE|Regular Dressing Change of Surgical Wound|This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
218989605|NCT00415805|DRUG|Multihance|0.5 Molar, single injection at 0.2 mL/kg
218989606|NCT00415805|DRUG|vasovist|0.25 molar single injection 0.03 ml/kg
218989607|NCT00555971|DRUG|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
218989608|NCT00555971|DRUG|placebo|Subjects randomized to Placebo prior to aspirin desensitization
218989609|NCT03183076|OTHER|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
218989610|NCT03183076|DRUG|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
218989611|NCT04985864|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
218989612|NCT04985864|DEVICE|Treadmill gait training|Lokomat robot training was applied to stroke patients.
218989613|NCT06440096|DIAGNOSTIC_TEST|hemogram|hemogram
218989614|NCT01815216|PROCEDURE|Bariatric surgery|Gastric bypass surgery
218989615|NCT01815216|BEHAVIORAL|Brain activity in resting state|Measure of activity in brain networks during resting state
218989616|NCT01815216|BEHAVIORAL|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
218989617|NCT03916120|GENETIC|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
219270298|NCT04573660|DEVICE|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
219270299|NCT04573660|DEVICE|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
218989618|NCT01525810|DRUG|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
218989619|NCT06238583|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
218989620|NCT03497208|PROCEDURE|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
218989621|NCT03497208|PROCEDURE|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
218989622|NCT03497208|RADIATION|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
218989623|NCT06096753|DEVICE|Bruxoff gnathological function analysis|The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
218989624|NCT03528772|DRUG|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
218989625|NCT03528772|DRUG|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
218989626|NCT06131801|OTHER|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
218989627|NCT05051072|PROCEDURE|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
219270300|NCT04573660|DEVICE|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
219270301|NCT04573660|DEVICE|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
219270302|NCT04573660|DEVICE|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
218989628|NCT02335866|PROCEDURE|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
218989629|NCT02335866|PROCEDURE|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
218989630|NCT05539794|BEHAVIORAL|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
218989631|NCT05081609|DRUG|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
218989632|NCT05081609|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
218989633|NCT05081609|DRUG|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
218989634|NCT05081609|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
218989635|NCT05081609|PROCEDURE|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
218989636|NCT05081609|DRUG|Trastuzumab|Trastuzumab will be administered as an intravenous (IV) infusion
218989637|NCT05081609|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
218989638|NCT03972306|DRUG|Ocrelizumab|Administered by subcutaneous Injection
218989639|NCT03972306|DRUG|Ocrelizumab|Administered by Intravenous (IV) Injection
218989640|NCT03972306|DRUG|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
218989641|NCT06492967|BEHAVIORAL|Systematic Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
218989642|NCT06492967|BEHAVIORAL|Flexible Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
218989643|NCT00868985|DRUG|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
218989644|NCT00868985|DRUG|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
218989645|NCT03963375|DRUG|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
218989646|NCT01274078|BIOLOGICAL|Blueberries|150 grams of frozen blueberries on the same day as exercise
219270303|NCT04573660|DEVICE|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
219270304|NCT04573660|DEVICE|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
218989647|NCT05410483|DRUG|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
219270305|NCT04573660|DEVICE|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
219270306|NCT05574296|DRUG|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
219270307|NCT05574296|OTHER|Usual care|Usual care post-ECPR event, including targeted temperature management.
219270308|NCT05867017|OTHER|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
218989648|NCT00518284|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
218989649|NCT04619927|GENETIC|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
218989650|NCT04619927|GENETIC|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
218989651|NCT04619927|DRUG|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
218989652|NCT04619927|DRUG|Intermediate metabolisers|Clopidogrel 75mg twice daily
218989653|NCT04619927|DRUG|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
218989654|NCT00307177|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
218989655|NCT00307177|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
218989656|NCT03128879|DRUG|Ibrutinib|Given PO
218989657|NCT03128879|DRUG|Venetoclax|Given PO
218989658|NCT03128879|DRUG|Acalabrutinib|Given BID
218989659|NCT05752292|BEHAVIORAL|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
218989660|NCT05752292|BEHAVIORAL|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
218989661|NCT05752292|BEHAVIORAL|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
218989662|NCT05752292|BEHAVIORAL|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
218989663|NCT05752292|BEHAVIORAL|Action planning (AP)|Interactive prompts to problem solve challenges
218989664|NCT03294759|OTHER|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
218989665|NCT03294759|OTHER|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
218989666|NCT02571777|DRUG|QVM149 150/50/160|
218989667|NCT02571777|DRUG|QVM149 150/50/80|
218989668|NCT02571777|DRUG|QMF149 150/320|
218989669|NCT02571777|DRUG|QMF149 150/160|
218989670|NCT02571777|DRUG|salmeterol/fluticasone|
218989671|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
218989672|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
218989673|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
218989674|NCT02192138|PROCEDURE|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
218989675|NCT02192138|DEVICE|Pleural catheter|
218989676|NCT02192138|DEVICE|Pleural manometer|
218989677|NCT01299740|BEHAVIORAL|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
218989678|NCT01299740|OTHER|Control Group|Treatment as usual
218989679|NCT00801632|PROCEDURE|Kidney Transplantation|Surgical transplantation of donor kidney
218989680|NCT00801632|PROCEDURE|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
218989681|NCT00801632|BIOLOGICAL|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
218989682|NCT00801632|DRUG|cyclophosphamide|60 mg/kg infusion on days -5, -4
219270309|NCT05582772|OTHER|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
219270310|NCT05582772|OTHER|RSM intervention|Telephone-based, symptom management of patients with cancer
219270311|NCT05582772|OTHER|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
219270312|NCT04796220|DEVICE|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
219270313|NCT04796220|OTHER|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
218989683|NCT00801632|BIOLOGICAL|rituximab|375 mg/m\^2 infusion on days -7, -2, 5, and 12
218989684|NCT00801632|DRUG|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
219270314|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
218989685|NCT00801632|DRUG|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
218989686|NCT00801632|RADIATION|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
218989687|NCT03678298|OTHER|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
218989688|NCT06770842|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa 2b is administered subcutaneously once every 2 weeks. The dosing will be 250mcg at Week 0, 350mcg at Week 2, 500mcg at Week 4, and 500mcg every 2 weeks thereafter
218989689|NCT05012982|DEVICE|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
218989690|NCT05012982|DEVICE|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
218989691|NCT01028144|BEHAVIORAL|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
218989692|NCT01028144|BEHAVIORAL|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
218989693|NCT05852145|DRUG|Stevioside|"250 ml of natural water added with 0.1 gr. of stevioside should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
219270315|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
218989694|NCT05852145|DRUG|Sucrose|"250 ml of natural water added with 25 gr of sucrose should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
218989695|NCT05852145|OTHER|Natural water|"250 ml of natural water should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
218989696|NCT05076500|PROCEDURE|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
218989697|NCT06263361|DIAGNOSTIC_TEST|MRI imaging|To characterize the peritumoral area in PCNLs through the use of advanced MRI sequences.
219270316|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
219270317|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
218989698|NCT06263361|DIAGNOSTIC_TEST|Cerebral biopsy|To evaluate the predictive value of sodium fluorescence to confirm ex-vivo the diagnostic tumor tissue prior to histopathological examination.
218989699|NCT03961568|DRUG|Cenobamate|active drug
218989700|NCT00626964|PROCEDURE|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
218989701|NCT00626964|BEHAVIORAL|Conservative Treatment:|Intensive Lifestyle Intervention Program
218989702|NCT06448286|PROCEDURE|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|Undergo CEST MRI
219270318|NCT06151899|OTHER|Kinesio taping with angle and tension|Kinesio taping by applying angle and tension to back muscle
219270319|NCT05634876|BIOLOGICAL|UB-312 Injection|UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.
219270320|NCT05634876|BIOLOGICAL|Placebo Injection|Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
219270321|NCT06062212|PROCEDURE|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
219270322|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
219270323|NCT03593278|DRUG|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
219270324|NCT05844930|DRUG|Corticosteroid|Triamcinolone 20 mg (1cc)
219270325|NCT05844930|OTHER|ActiveMatrix|1cc ActiveMatrix (Skye Biologics, Inc.)
219270326|NCT05844930|DRUG|Lidocaine|Lidocaine 10 mg/mL (5cc)
219270327|NCT06001008|OTHER|PQA|PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
219270328|NCT02078726|DRUG|Glucagon|glucagon (hormone produced by the body) administered through IV
219270329|NCT04400292|OTHER|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
218989703|NCT06448286|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
218989704|NCT06448286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
218989705|NCT06448286|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
218989706|NCT06448286|PROCEDURE|Surgical Procedure|Undergo surgical resection
218989707|NCT06448286|DRUG|Temozolomide|Given PO
218989708|NCT00850590|DRUG|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
218989709|NCT03018600|BEHAVIORAL|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
218989710|NCT06011044|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
218989711|NCT01375244|DRUG|Lisinopril|Tablets, 10 mg, single dose
218989712|NCT01375244|DRUG|Zestril|Tablets, 10 mg, single dose
218989713|NCT02294955|DEVICE|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
218989714|NCT02294955|DRUG|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
219270330|NCT04400292|DEVICE|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
219270331|NCT04400292|PROCEDURE|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
219270332|NCT02130245|PROCEDURE|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
219270333|NCT02130245|PROCEDURE|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
219270334|NCT02383992|DRUG|3% H2O2 solution|
219270335|NCT02383992|DRUG|0.9% normal saline|
219270336|NCT06182345|PROCEDURE|spray skin|autologous skin cell suspension combined with skin graft
219270337|NCT06182345|PROCEDURE|skin graft|skin graft
218989715|NCT02294955|DRUG|Sotalol|Dosage orally 80-160 mg twice daily
219270338|NCT02484378|DRUG|CER-001|Engineered pre-beta HDL particle
219270339|NCT02484378|DRUG|Placebo|Normal saline
219270340|NCT02605486|DRUG|Palbociclib|
219270341|NCT02605486|DRUG|Bicalutamide|
218989716|NCT02294955|DRUG|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
219270342|NCT05765435|OTHER|12-week exercise and walking program|The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.
219270343|NCT05765435|DEVICE|NMES|Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.
219270344|NCT05765435|DEVICE|FES|Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
218989717|NCT02294955|DRUG|Propafenone|Dosage orally 300 mg twice daily
218989718|NCT02294955|DRUG|Disopyramide|Dosage orally 250-375 mg twice Daily
218989719|NCT02294955|DRUG|Dronedarone|Dosage orally 400 mg twice daily
218989720|NCT01959074|DRUG|Naftopidil|Naftopidil 75mg 1T qd hs
218989721|NCT01959074|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
219270345|NCT03836573|BEHAVIORAL|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
218989722|NCT01959074|DRUG|Standard treatment|aceclofenac 100mg on demand
219270346|NCT02761798|DEVICE|Automated Mobile Interactive Audiometer|iPad game
219270347|NCT00333905|PROCEDURE|Ischemic exercise training|
219270348|NCT03834389|BEHAVIORAL|Case- based Learning|critical thinking, self efficacy, focus group interview
219270349|NCT01467310|DRUG|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
219270350|NCT05172492|DEVICE|Endocare|Endocare will be administred through a virtual reality headseat used one to twice a day.
219270351|NCT05172492|DEVICE|Digital control|Digital control will be administred through a virtual reality headseat used one to twice a day.
218989723|NCT00651560|DRUG|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
218989724|NCT00740571|DRUG|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
219270352|NCT04377854|OTHER|Observation. No intervention per se.|Observation. No intervention (no collection of blood).
219270353|NCT04377854|OTHER|2) Observation and collection and of blood sample|All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
218989725|NCT00740571|DRUG|pregabalin|Strategy in which patient starts with pregabalin
218989726|NCT03824730|DEVICE|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
218989727|NCT03136354|PROCEDURE|Endoscopic Submucosal Dissection|
218989728|NCT03136354|PROCEDURE|Laparoscopic assisted Gastrectomy|
218989729|NCT00037141|DRUG|dehydrated alcohol|
218989730|NCT02694965|OTHER|observational|
218989731|NCT02369016|DRUG|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
218989732|NCT06326385|OTHER|no intervention|no intervention
218989733|NCT01702961|DRUG|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
218989734|NCT01702961|DRUG|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
218989735|NCT01702961|DRUG|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
218989736|NCT01702961|DRUG|BCNU|BCNU 300 mg/m2 IV given on Day -6
218989737|NCT01702961|DRUG|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
218989738|NCT01702961|DRUG|Stem Cells|Stem cells given on Day 0
219270354|NCT02701062|DEVICE|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
219270355|NCT02701062|DRUG|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
218989739|NCT02229383|DRUG|Exenatide|2 mg weekly suspension injection
218989740|NCT02229383|DRUG|Exenatide matching placebo|Once weekly Placebo injection
219270356|NCT00166062|PROCEDURE|Screening patients for IPV|
219270357|NCT01597843|OTHER|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
219270358|NCT00517049|DRUG|PRO95780|Intravenous repeating dose
218989741|NCT03954665|BEHAVIORAL|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
218989742|NCT03954665|BEHAVIORAL|30s Wingate|30s all-out test to measure peak power output
218989743|NCT03954665|DIETARY_SUPPLEMENT|Ketone|Supplement containing exogenous ketone salts
218989744|NCT03954665|BEHAVIORAL|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
218989745|NCT03954665|BEHAVIORAL|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
218989746|NCT04803071|DIETARY_SUPPLEMENT|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
218989747|NCT04803071|DIETARY_SUPPLEMENT|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
218989748|NCT04803071|DIETARY_SUPPLEMENT|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
218989749|NCT04589806|PROCEDURE|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
218989750|NCT02849041|DEVICE|medical imaging|Low-dose CT-scanner
218989751|NCT02849041|BIOLOGICAL|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
218989752|NCT02849041|PROCEDURE|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
218989753|NCT06557902|DRUG|Lumateperone 10.5 mg capsule|Lumateperone 10.5 mg capsule, oral administration
218989754|NCT06557902|DRUG|Lumateperone 21 mg capsule|Lumateperone 21 mg capsule, oral administration
218989755|NCT06557902|DRUG|Lumateperone 5 mg ODT|Lumateperone 5 mg ODT, oral administration
218989756|NCT06557902|DRUG|Lumateperone 10.5 mg ODT|Lumateperone 10.5 mg ODT, oral administration
219270359|NCT00517049|DRUG|rituximab|Intravenous repeating dose
219270360|NCT03363347|DRUG|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
219270361|NCT02677077|DRUG|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
219270362|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from animal sources.|Diet was prescribed to the participant and menus and recipes were also provided.
218989757|NCT06557902|DRUG|Lumateperone 15.5 mg ODT|Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
218989758|NCT06557902|DRUG|Lumateperone 21 mg ODT|Lumateperone 21 mg ODT, oral administration
218989759|NCT03207477|DIAGNOSTIC_TEST|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
218989760|NCT00307645|DRUG|Cyclophosphamide|
218989761|NCT00307645|DRUG|Mycophenolate mofetil|
218989762|NCT00307645|DRUG|Azathioprine|
218989763|NCT00307645|DRUG|Prednisone (and methylprednisolone)|
218989764|NCT04594811|DRUG|NT-I7|Administered by intramuscular (IM) injection.
218989765|NCT04594811|DRUG|Nivolumab|Administered by intravenous (IV) injection.
218989766|NCT00108173|DRUG|Zyban|
218989767|NCT03488732|DEVICE|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
218989768|NCT05890885|PROCEDURE|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
219270363|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from plant sources.|Diet was prescribed to the participant and menus and recipes were also provided.
219270364|NCT03823144|DEVICE|Diagnostic Microscopy|Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
219270365|NCT03823144|DRUG|Fluorescein Sodium Injection|Given IV as part of IVM procedure
219270366|NCT00121121|BIOLOGICAL|Lipopeptides LIPO-4|
219270367|NCT04952363|DEVICE|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
219270368|NCT04952363|DEVICE|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
219270369|NCT00337753|BEHAVIORAL|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
218989769|NCT05890885|PROCEDURE|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
218989770|NCT00674362|BIOLOGICAL|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
218989771|NCT00674362|BIOLOGICAL|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
218989772|NCT00919425|OTHER|biologic sample preservation procedure|
218989773|NCT02188108|OTHER|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
218989774|NCT06239766|DIAGNOSTIC_TEST|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
218989775|NCT00084383|BIOLOGICAL|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
219270370|NCT00337753|BEHAVIORAL|Wait-list|subjects assigned to wait-list condition for six-weeks
219270371|NCT05988242|OTHER|Primrose oil|group A will take primrose oil
219270372|NCT05988242|OTHER|Lavender oil|group B will take lavender oil
219270373|NCT05988242|OTHER|placcebo|this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
219270374|NCT00697398|OTHER|Transcranial stimulation|Stimulation to white
218989776|NCT03857048|OTHER|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
218989777|NCT03857048|OTHER|Exercise training|16-wk supervised endurance exercise training program
218989778|NCT03857048|OTHER|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
218989779|NCT01201850|DRUG|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
218989780|NCT03816384|DEVICE|Standard of Care|Standard of care urinary drainage system.
218989781|NCT03816384|DEVICE|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
218989782|NCT03816384|DEVICE|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
218989783|NCT01045525|PROCEDURE|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
218989784|NCT01045525|BEHAVIORAL|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
218989785|NCT05856071|DEVICE|goniometer|to measure the range of motion
218989786|NCT05856071|OTHER|clamshells exercises|clamshells exercises
218989787|NCT05856071|OTHER|traditional physical therapy|traditional physical therapy
218989788|NCT00191139|DRUG|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
218989789|NCT00191139|DRUG|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
219270375|NCT00697398|OTHER|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
218989790|NCT00191139|DRUG|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
218989791|NCT00191139|DRUG|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
218989792|NCT00191139|RADIATION|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
218989793|NCT02419105|DRUG|Testosterone|transdermal gel, 75 mg daily
218989794|NCT02419105|DRUG|Colecalciferol|drink solution, 24000 IU once per month
219270376|NCT01973140|DRUG|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
219270377|NCT01973140|DRUG|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
218989795|NCT02419105|DRUG|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
218989796|NCT02419105|DRUG|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
218989797|NCT03846804|DIAGNOSTIC_TEST|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
218989798|NCT00002989|DRUG|busulfan|
218989799|NCT00002989|DRUG|cyclophosphamide|
218989800|NCT00002989|DRUG|idarubicin|
218989801|NCT00002989|DRUG|melphalan|
218989802|NCT00002989|RADIATION|radiation therapy|
218989803|NCT05658120|DRUG|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
218989804|NCT00259337|BIOLOGICAL|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
218989805|NCT05134675|DIETARY_SUPPLEMENT|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
218989806|NCT00404235|DRUG|carboplatin|
218989807|NCT00404235|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
218989808|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
218989809|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
218989810|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
218989811|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
218989812|NCT02211079|DRUG|JNJ-54861911|JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
218989813|NCT02211079|DRUG|Caffeine|Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
218989814|NCT02211079|DRUG|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
218989815|NCT02211079|DRUG|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
218989816|NCT02937675|DRUG|Tomivosertib (eFT-508)|eFT508
218989817|NCT00608660|OTHER|acupuncture|staging acupuncture
218989818|NCT00608660|OTHER|acupuncture and moxibustion|staging acupuncture and moxibustion
218989819|NCT00608660|OTHER|electroacupuncture|staging electroacupuncture
218989820|NCT00608660|OTHER|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
218989821|NCT00608660|OTHER|acupuncture|non-staging acupuncture
218989822|NCT00273546|DRUG|XRP6976 (Docetaxel/Taxotere)|
218989823|NCT01841788|DEVICE|Thermal Adhesion Patch|
218989824|NCT01841788|DEVICE|Marketed Thermal Adhesion Patch|
218989825|NCT01841788|DEVICE|Placebo Patch|
218989826|NCT02308605|DEVICE|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
218989827|NCT03456050|BEHAVIORAL|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
218989828|NCT03456050|BEHAVIORAL|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
218989829|NCT02123888|RADIATION|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
218989830|NCT02562534|DEVICE|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
218989831|NCT01482845|DRUG|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
218989832|NCT01482845|DRUG|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
218989833|NCT03245515|DRUG|BMS-986195|specified dose on specified days
218989834|NCT05309408|DIAGNOSTIC_TEST|Venipuncture|Venipuncture
218989835|NCT05309408|DIAGNOSTIC_TEST|Lumbar Puncture|Lumbar Puncture
218989836|NCT00345839|DRUG|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
218989837|NCT00345839|DRUG|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
219270378|NCT05600140|BEHAVIORAL|Viewing strategy training|Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.
219270379|NCT02162498|BEHAVIORAL|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
219270380|NCT04434248|DRUG|Favipiravir|200 mg coated tablets
219270381|NCT04434248|DRUG|Standard of Care|Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
219270382|NCT05633069|OTHER|Datas analysed by medical records|"Datas analysed by medical records : pupillary parameters: pupillary diameter and pupillary diameter variation. heart rate, the blood pressure, the Behavioral Pain Scale (BPS) pain score before and during painful procedures.~The pupillary parameters were recorded with the AlgiScan® pupillometer (iDMed, Marseille, France), which allows the recording of Pupillary Diameter (PD) variations at the patient's bed at a sampling frequency of 67 hertz."
218989838|NCT01960400|DEVICE|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
218989839|NCT01960400|DEVICE|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
218989840|NCT03321266|DEVICE|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
218989841|NCT00743483|DRUG|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
218989842|NCT04119921|DRUG|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
218989843|NCT04119921|DRUG|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
218989844|NCT04119921|DRUG|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
218989845|NCT04119921|DRUG|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
218989846|NCT04375371|PROCEDURE|Bariatric surgery|Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
218989847|NCT01881360|OTHER|Gluten-free diet|A diet that is free of the gluten component
218989848|NCT01881360|OTHER|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
219270383|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
219270384|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 1)
219270385|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 15)
219270386|NCT02061059|OTHER|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
219270387|NCT02061059|OTHER|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
219270388|NCT02061059|OTHER|standard|patient wears shoes produced with standard method
219270389|NCT02061059|OTHER|with measurements|patient wears shoes produced with plantar pressure measurements
218989849|NCT01109797|BEHAVIORAL|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
218989850|NCT01109797|BEHAVIORAL|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
218989851|NCT01410201|DRUG|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
218989852|NCT04838483|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
218989853|NCT02085122|OTHER|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
218989854|NCT04649320|OTHER|questionnaire|"1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30"
218989855|NCT06400862|COMBINATION_PRODUCT|eOCT implantation|eOCT is regarded as an Advanced Therapy Product (ATP).
218989856|NCT02276001|DRUG|K-877|
219270390|NCT06022068|DRUG|Sirolimus|7 mg taken once per week during 26 weeks.
219270391|NCT06474299|DRUG|Varenicline|0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
218989857|NCT02276001|DRUG|Cyclosporine|
218989858|NCT01466153|DRUG|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
218989859|NCT01466153|DRUG|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
218989860|NCT01466153|DRUG|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
218989861|NCT03105791|OTHER|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
218989862|NCT03708016|DEVICE|Robot gait training|Lokomat robot training was applied to stroke patients.
218989863|NCT03708016|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
218989864|NCT05250778|BEHAVIORAL|Nudge|Room intervention
219270392|NCT06474299|DRUG|Nicotine patch|Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
218989865|NCT01213329|DRUG|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
218989866|NCT06504680|PROCEDURE|Repair of flexor tendon injury zone ll using 8- strand|Repair cut flexor zone ll using 8-strand with and without splinting the wrist
218989867|NCT01684956|PROCEDURE|Intradermal injection|
218989868|NCT01684956|PROCEDURE|Subcutaneous injection|
218989869|NCT00150748|DRUG|Levetiracetam 166 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use"
218989870|NCT00150748|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use"
218989871|NCT00150748|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use"
218989872|NCT04138238|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
219270393|NCT06474299|BEHAVIORAL|Dual Focused Cessation Counseling|Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
219270394|NCT06474299|BEHAVIORAL|Smoking Focused Cessation Counseling|Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
218989873|NCT03483740|BEHAVIORAL|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
218989874|NCT03483740|BEHAVIORAL|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
218989875|NCT07053904|DRUG|Sequential use of P1101 and P1801|Sequential use of ropeginterferon alfa-2b and P1801 (anti PD-1 antibody drug)
218989876|NCT07055191|PROCEDURE|Transoral Endoscopic Thyroidectomy by Vestibular Approach|Transoral Endoscopic Thyroidectomy by Vestibular Approach
218989877|NCT07055191|PROCEDURE|Anterior Cervical thyroidectomy|Anterior Cervical thyroidectomy
218989878|NCT07055373|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular VNS will be administered using the Parasym aVNT (auricular vagal neuromodulation therapy) Device (Nurosym, London, UK). The Parasym aVNT Device delivers non-invasive neuromodulation targeting the auricular branch of the vagus nerve via the tragus of the outer ear. All participants will receive four weeks of twice daily (morning and evening) 45-minute sessions of taVNS (frequency ≥ 25Hz; pulse width =250µs (Fig). The safety and tolerability of taVNS has been demonstrated in seven studies with a total of 205 (116 active, 121 sham) cardiovascular patients. Stimulation protocols ranged from 43 min to 8 hrs daily, for 1 day to 6 months. There were no device-related serious adverse events. Three patients (1.5%) experienced minor adverse events, i.e., dermal paresthesias (light tingling at the ear). No differences in tolerability were observed between active and sham taVNS \[21\].
218989879|NCT07053280|DEVICE|Teleaudiological tests|Initially, the FPT, DPT, RGDT, and SSWT were administered face-to-face; one month later, the same tests were repeated via teleaudiology, with the audiologist and participant in separate rooms using identical laptops and headphones, without visual or auditory contact.
218989880|NCT07053189|DEVICE|Clear Aligner treatment|Interproximal enamel reduction and attachment impact
218989881|NCT06903195|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
218989882|NCT06903195|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
218989883|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
218989884|NCT06939504|DRUG|HRS-9813 Capsule|HRS-9813 capsule.
218989885|NCT06939504|DRUG|HRS-9813 Tablet|HRS-9813 tablet.
218989886|NCT01153347|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
218989887|NCT01153347|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
218989888|NCT03169556|DEVICE|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
218989889|NCT03169556|DEVICE|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
218989890|NCT00297830|DRUG|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
218989891|NCT00297830|DRUG|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
218989892|NCT00297830|OTHER|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
218989893|NCT00297830|OTHER|Placebo Alendronate|Placebo alendronate 70 mg once weekly
218989894|NCT06064422|BEHAVIORAL|BeatIt-MV|BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
218989895|NCT01651377|DRUG|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
218989896|NCT01651377|DRUG|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
218989897|NCT01548651|DRUG|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
218989898|NCT01548651|DRUG|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
218989899|NCT03632200|OTHER|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
218989900|NCT04433403|OTHER|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
218989901|NCT02430012|BEHAVIORAL|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
218989902|NCT05777850|PROCEDURE|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
218989903|NCT05777850|PROCEDURE|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
218989904|NCT03391180|DRUG|ICON Remineralization|A material used for the Remineralization of white spot lesions.
218989905|NCT03391180|DRUG|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
218989906|NCT06568614|DRUG|BG-89894|Administered orally
218989907|NCT05307055|DEVICE|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
218989908|NCT05307055|DEVICE|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
218989909|NCT06360536|BEHAVIORAL|Resistance Training|A home-based resistance training condition that is delivered through a web-based platform.
218989910|NCT05799586|BEHAVIORAL|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
218989911|NCT05799586|BEHAVIORAL|Waitlist control group|Usual care
218989912|NCT06013397|DIETARY_SUPPLEMENT|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
218989913|NCT05944887|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
218989914|NCT05944887|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
218989915|NCT05944887|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
218989916|NCT05944887|PROCEDURE|gastroscopy|esogastroduodenoscopy
218989917|NCT05046093|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|"When the lung nodule is visualized by thin bronchoscope (4mm) with R-EBUS, cryobiopsy is performed. If not visualized, ultrathin (3mm) bronchoscope is used.~Cryobiopsy is performed with 1.1mm cryo-probe."
218989918|NCT06066164|DEVICE|Transcranial magnetic stimulation (TMS)|Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability
219270395|NCT06474299|OTHER|Counseling Intensity: 1 Session|Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).
219270396|NCT06474299|OTHER|Counseling Intensity: 4 Sessions|Participants assigned to intensive counseling will have four, 15-20-minute sessions.
218989919|NCT00327275|BEHAVIORAL|strength training|
218989920|NCT02241629|DRUG|placebo|placebo of levo phencynonate hydrochloride
218989921|NCT02241629|DRUG|levo phencynonate hydrochloride|levo phencynonate hydrochloride
219270397|NCT00781937|DRUG|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
219270398|NCT00781937|DRUG|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
219270399|NCT01263249|PROCEDURE|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
219270400|NCT01263249|PROCEDURE|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
219270401|NCT04920747|DRUG|Taxane|docetaxel or paclitaxel
219270402|NCT02967276|DRUG|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
218989922|NCT03206775|BEHAVIORAL|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice"
218989923|NCT03206775|BEHAVIORAL|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey"
218989924|NCT03206775|BEHAVIORAL|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment"
218989925|NCT03206775|BEHAVIORAL|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey"
218989926|NCT03831399|DIETARY_SUPPLEMENT|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
218989927|NCT03831399|DIETARY_SUPPLEMENT|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
218989928|NCT04568044|PROCEDURE|Blood sample|Peripheral blood sample will be obtained.
219270403|NCT02967276|DRUG|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
219270404|NCT00013611|DRUG|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
219270405|NCT03964051|DRUG|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
219270406|NCT00298688|DRUG|Gefitinib|
219270407|NCT00234897|DRUG|adalimumab|
218989929|NCT02128971|DIETARY_SUPPLEMENT|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
219270408|NCT03167853|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
219270409|NCT00791193|DRUG|Paliperidone ER|
219270410|NCT01430637|GENETIC|DNA analysis|
219270411|NCT01430637|GENETIC|RNA analysis|
219270412|NCT01430637|GENETIC|gene expression analysis|
219270413|NCT01430637|GENETIC|mutation analysis|
219270414|NCT01430637|GENETIC|nucleic acid sequencing|
218989930|NCT02128971|DIETARY_SUPPLEMENT|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
218989931|NCT02128971|DIETARY_SUPPLEMENT|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
218989932|NCT02128971|DIETARY_SUPPLEMENT|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
218989933|NCT02128971|DIETARY_SUPPLEMENT|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
218989934|NCT02128971|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
219270415|NCT01430637|GENETIC|polymerase chain reaction|
219270416|NCT01430637|OTHER|laboratory biomarker analysis|
219270417|NCT01430637|OTHER|pharmacogenomic studies|
219270418|NCT02838784|OTHER|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
219270419|NCT02838784|PROCEDURE|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
219270420|NCT00370110|DRUG|Itopride 100 mg|100 mg three times daily
219270421|NCT00370110|OTHER|Placebo|
219270422|NCT00370110|DRUG|Itopride 200 mg|200 mg three times daily
219270423|NCT06109597|OTHER|75 g glucose tolerance test|Pregnant patient who visited obstetric clinic , who did 75 g glucose tolerance test
219270424|NCT06277180|PROCEDURE|Surgery|Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.
219270425|NCT06277180|PROCEDURE|Surgery|68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.
219270426|NCT03435146|COMBINATION_PRODUCT|3HP plus DTG +2NRTIs|"* HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~* LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)"
218989935|NCT00932100|DRUG|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
218989936|NCT00932100|DRUG|Heparin|IV dose per standard of care at the local institution
218989937|NCT03857893|DEVICE|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
218989938|NCT03857893|DRUG|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
218989939|NCT03026660|DIETARY_SUPPLEMENT|Moringa Oleifera|
218989940|NCT03026660|DIETARY_SUPPLEMENT|Cabbage Placebo|
218989941|NCT05178771|OTHER|Platelet rich fibrin|"1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
218989942|NCT03280901|OTHER|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
218989943|NCT02275858|DEVICE|Stiffening wire|Stiffening wire
218989944|NCT02275858|DEVICE|Placebo wire|Placebo wire
218989945|NCT03747588|PROCEDURE|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
218989946|NCT03747588|OTHER|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
218989947|NCT02050516|OTHER|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
218989948|NCT03391037|DIAGNOSTIC_TEST|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
218989949|NCT06201364|PROCEDURE|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
218989950|NCT06201364|PROCEDURE|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
218989951|NCT06022744|DRUG|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
218989952|NCT03981770|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
218989953|NCT01322269|DRUG|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
218989954|NCT03385460|OTHER|ESWL BOTOX|ESWL after intrravesical BOTOX
218989955|NCT06260852|DIAGNOSTIC_TEST|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
218989956|NCT00870883|DRUG|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
218989957|NCT03084770|DIAGNOSTIC_TEST|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
218989958|NCT03084770|OTHER|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
218989959|NCT03342365|DIAGNOSTIC_TEST|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
218989960|NCT00004132|BIOLOGICAL|filgrastim|
218989961|NCT00004132|BIOLOGICAL|palifermin|
218989962|NCT00004132|DRUG|cyclophosphamide|
218989963|NCT00004132|DRUG|etoposide|
218989964|NCT00004132|DRUG|ifosfamide|
218989965|NCT00004132|PROCEDURE|quality-of-life assessment|
219270427|NCT04025268|BEHAVIORAL|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
219270428|NCT04025268|BEHAVIORAL|Standard of Care|Standard of prenatal care
219270429|NCT04253847|PROCEDURE|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
218989966|NCT00004132|RADIATION|radiation therapy|
218989967|NCT00210405|DIETARY_SUPPLEMENT|"Sprinkles containing mulitple micronutrients"|
218989968|NCT00210405|BEHAVIORAL|Education/communication on use of micronutrient sprinkles|
218989969|NCT00210405|DIETARY_SUPPLEMENT|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
218989970|NCT00560456|OTHER|Chronic sleep restriction and driving simulator|"* One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator"
218989971|NCT05911529|BEHAVIORAL|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
218989972|NCT05911529|BEHAVIORAL|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
218989973|NCT04978961|BEHAVIORAL|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
218989974|NCT04978961|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
218989975|NCT05306275|DRUG|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
218989976|NCT00349531|DRUG|Pramipexole|
218989977|NCT05561049|DRUG|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
218989978|NCT02892578|OTHER|electrocardiogram|
218989979|NCT05690373|DIETARY_SUPPLEMENT|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
218989980|NCT02933723|PROCEDURE|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
218989981|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
218989982|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
218989983|NCT06028139|BEHAVIORAL|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
218989984|NCT06028139|BEHAVIORAL|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
218989985|NCT04406376|DRUG|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
218989986|NCT03699605|OTHER|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
218989987|NCT03699605|OTHER|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
218989988|NCT06091631|PROCEDURE|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
218989989|NCT02616406|DEVICE|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
218989990|NCT05253729|DEVICE|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
218989991|NCT05253729|BEHAVIORAL|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
218989992|NCT00078182|DRUG|Tenofovir DF|
218989993|NCT05604352|DEVICE|DiaSole|Diabetic ulcer offloading insole
218989994|NCT02114216|PROCEDURE|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
218989995|NCT04444102|PROCEDURE|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
218989996|NCT01850628|DRUG|Paclitaxel|
218989997|NCT01850628|BIOLOGICAL|trastuzumab|
218989998|NCT01850628|BIOLOGICAL|pertuzumab|
218989999|NCT02118883|OTHER|Essentia Water|
218990000|NCT02118883|OTHER|Bottled water|
218990001|NCT04574011|DIAGNOSTIC_TEST|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
218990002|NCT01934023|DRUG|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
218990003|NCT01934023|DRUG|Placebo|
218990004|NCT01610570|DRUG|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
218990005|NCT04957004|DEVICE|CPAP|CPAP ventilator was worn at nigh
218990006|NCT04282785|DIAGNOSTIC_TEST|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
218990007|NCT05310695|OTHER|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
218990008|NCT05310695|OTHER|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
218990009|NCT05310695|OTHER|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
218990010|NCT05286437|DRUG|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
219270430|NCT04253847|PROCEDURE|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
219270431|NCT04312932|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
219270432|NCT04312932|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
219270433|NCT01714167|GENETIC|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
219270434|NCT01947712|DIETARY_SUPPLEMENT|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
219270435|NCT01947712|DIETARY_SUPPLEMENT|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
219270436|NCT03895697|DRUG|dasiglucagon|Glucagon analogue
219270437|NCT00981539|PROCEDURE|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
219270438|NCT00316433|DRUG|Irinotecan (CPT-11)|
219270439|NCT00316433|DRUG|Oxaliplatin (Eloxatin)|
219270440|NCT01601613|DRUG|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
219270441|NCT01601613|DRUG|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
219270442|NCT00979693|DRUG|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
219270443|NCT00979693|DRUG|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
219270444|NCT05889949|DRUG|Sorafenib|oral sorafenib
219270445|NCT05889949|DRUG|Lenvatinib|oral lenvatinib
219270446|NCT03182998|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
219270447|NCT03182998|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
218990011|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
218990012|NCT05500222|DRUG|Resmetirom|Randomized 80 mg
218990013|NCT05500222|DRUG|Placebo|randomized matching placebo
218990014|NCT04339686|DIAGNOSTIC_TEST|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
218990015|NCT04480008|BEHAVIORAL|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
218990016|NCT04249531|DRUG|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
218990017|NCT04249531|DRUG|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
218990018|NCT00753571|DRUG|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2"
218990019|NCT03155282|PROCEDURE|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
218990020|NCT05185193|DEVICE|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
218990021|NCT05185193|DEVICE|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
219270448|NCT03182998|OTHER|Best Practice|Undergo usual care
219270449|NCT03182998|OTHER|Quality-of-Life Assessment|Ancillary studies
219270450|NCT03182998|OTHER|Questionnaire Administration|Ancillary studies
219270451|NCT03182998|OTHER|Survey Administration|Ancillary studies
219270452|NCT03182998|OTHER|Laboratory Biomarker Analysis|Correlative studies
219270453|NCT01907932|DEVICE|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
219270454|NCT01013961|BIOLOGICAL|alemtuzumab|Given IV
219270455|NCT01013961|BIOLOGICAL|rituximab|Given IV
219270456|NCT01006525|DRUG|zolpidem|placebo or zolpidem (10mg)daily for one year
219270457|NCT02866669|BEHAVIORAL|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
219270458|NCT02866669|BEHAVIORAL|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
218990022|NCT02358174|PROCEDURE|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
218990023|NCT02358174|OTHER|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
218990024|NCT02358174|OTHER|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
218990025|NCT05279339|OTHER|Exercise|Upper limb exercises using an elastic band.
219270459|NCT02866669|BEHAVIORAL|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
218990026|NCT06175455|DEVICE|dynamic chest radiography|A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
218990027|NCT02330237|DRUG|natural gels|whole fruits and vegetables
218990028|NCT02330237|DRUG|Placebo|
218990029|NCT02541019|DRUG|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
218990030|NCT02541019|DRUG|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
218990031|NCT00828997|BIOLOGICAL|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
218990032|NCT05894408|OTHER|this is no intervention|this is no intervention
218990033|NCT04255108|DEVICE|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
218990034|NCT04806997|DIAGNOSTIC_TEST|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
218990035|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation|"Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
218990036|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena|"In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
219270460|NCT04658563|OTHER|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
219270461|NCT00540943|DRUG|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
219270462|NCT00540943|DRUG|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
219270463|NCT00540943|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
219270464|NCT00132197|BEHAVIORAL|Cognitive Behavioral Therapy|1\. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
219270465|NCT00132197|PROCEDURE|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
219270466|NCT04789343|OTHER|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
219270467|NCT00131963|DRUG|cyclophosphamide|Given IV
218990037|NCT02981420|BEHAVIORAL|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
218990038|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
218990039|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
219270468|NCT00131963|DRUG|doxorubicin|Given IV
219270469|NCT00131963|DRUG|paclitaxel|Given IV
218990040|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
218990041|NCT00244010|DEVICE|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
219270470|NCT00037206|DRUG|Anidulafungin, VER002|
218990042|NCT04850937|DRUG|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
218990043|NCT04850937|DRUG|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
218990044|NCT03937297|BEHAVIORAL|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
218990045|NCT03937297|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
218990046|NCT03937297|BEHAVIORAL|Usual Care|usual dementia care provided by participating center
218990047|NCT00717691|DEVICE|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
218990048|NCT00717691|OTHER|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
218990049|NCT06499311|OTHER|Foot Reflexology|Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.
218990050|NCT06499311|OTHER|Acupressure|Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
218990051|NCT03220178|DRUG|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
218990052|NCT03220178|DRUG|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
218990053|NCT03220178|DRUG|Anastrozole|1mg per day
218990054|NCT03220178|DRUG|Letrozole|2,5mg/day
218990055|NCT03220178|DRUG|Exemestane|25mg/day
218990056|NCT02016573|DEVICE|Renal Denervation|Renal Denervation Catheter
218990057|NCT03830632|OTHER|Plyometric Training|
218990058|NCT03830632|OTHER|Traditional Training|
219270471|NCT02884037|DRUG|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
219270472|NCT05241132|DRUG|Tislelizumab plus chemotherapy|"1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
219270473|NCT01202799|DRUG|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
218990059|NCT03095612|DRUG|Selinexor|Selinexor once weekly oral or twice weekly oral
219270474|NCT01202799|DRUG|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
219270475|NCT01202799|DRUG|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
218990060|NCT03095612|DRUG|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
218990061|NCT04425512|DIAGNOSTIC_TEST|Complete Blood Count|Complete Blood Count samples
218990062|NCT04600375|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
218990063|NCT04600375|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
218990064|NCT06139107|DRUG|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
219270476|NCT02412579|OTHER|None - Standard of Care|
218990065|NCT06139107|DRUG|Letrozole|Letrozole 2.5mg daily
219270477|NCT01114490|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
219270478|NCT05472103|BEHAVIORAL|ergonomics surgical workshop|ergonomics surgical workshop
219270479|NCT00959010|DIETARY_SUPPLEMENT|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
219270480|NCT00959010|DIETARY_SUPPLEMENT|Placebo|capsules containing middle chain triglycerides
219270481|NCT02743897|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
219270482|NCT02743897|DRUG|Mavyret|Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
218990066|NCT01238510|PROCEDURE|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
218990067|NCT01238510|PROCEDURE|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
219270483|NCT00371176|BEHAVIORAL|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
219270484|NCT00371176|DRUG|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
218990068|NCT04868175|DRUG|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
218990069|NCT04868175|DRUG|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
218990070|NCT04868175|DRUG|Hypromellose|Placebo eye drop, lubricant
218990071|NCT04076397|PROCEDURE|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
218990072|NCT04076397|OTHER|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
218990073|NCT05518019|DIETARY_SUPPLEMENT|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
218990074|NCT05679323|OTHER|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
219270485|NCT00371176|OTHER|Placebo pill|
219270486|NCT01573949|DRUG|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
219270487|NCT00777634|OTHER|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
219270488|NCT05052918|BEHAVIORAL|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
219270489|NCT04225741|BEHAVIORAL|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
219270490|NCT05215691|PROCEDURE|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
218990075|NCT04447794|BEHAVIORAL|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
218990076|NCT04447794|BEHAVIORAL|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
218990077|NCT00798980|DRUG|Mirena (BAY86-5028)|Nulliparous Women
218990078|NCT04167579|DEVICE|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
218990079|NCT04208633|PROCEDURE|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
218990080|NCT04208633|PROCEDURE|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
218990081|NCT03771820|DRUG|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
218990082|NCT03771820|DRUG|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
218990083|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
218990084|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
218990085|NCT06557837|DIAGNOSTIC_TEST|Questionnaires and pain assessment|Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
218990086|NCT06557837|DIAGNOSTIC_TEST|Standing sagittal whole spine X-ray|Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
219270491|NCT05215691|PROCEDURE|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
218990087|NCT06557837|DIAGNOSTIC_TEST|Dynamic test|With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
218990088|NCT06557837|DIAGNOSTIC_TEST|Muscle strength and body composition measurement|Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
218990089|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
218990090|NCT05062356|DRUG|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
218990091|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
218990092|NCT05062356|DRUG|Ketorolac|15mg
218990093|NCT04672993|DEVICE|Urine collection device for men|Use of urine collection device for men
218990094|NCT03990454|DRUG|SLC-391|SLC-391 is an AXL inhibitor
219270492|NCT06516679|DRUG|Consolidation #4(without daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
218990095|NCT01387932|DEVICE|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
218990096|NCT01387932|PROCEDURE|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
218990097|NCT00740389|DRUG|TMC125|
218990098|NCT03959553|DRUG|GV1001|Lyophilized peptide from hTERT
218990099|NCT03959553|DRUG|Normal saline|0.9% normal saline
218990100|NCT03661671|DIAGNOSTIC_TEST|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
218990101|NCT00005639|DRUG|Azacitidine Injection|subcutaneous injection (SC)
218990102|NCT00005639|DRUG|sodium phenylbutyrate|continuous intravenous (CIV)
218990103|NCT00762060|DEVICE|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
218990104|NCT00762060|DRUG|Patient controlled analgesia|IV opioids delivered via PCA
218990105|NCT05142163|OTHER|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
218990106|NCT05142163|OTHER|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
218990107|NCT06475586|DRUG|Semaglutide|0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
218990108|NCT04070885|PROCEDURE|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
218990109|NCT04070885|PROCEDURE|Urine sample|The urine will be taken from three 15 ml tubes.
218990110|NCT02571075|OTHER|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
218990111|NCT00000371|DRUG|D-cycloserine|50 mg/daily by mouth
219270493|NCT06516679|DRUG|Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
219270494|NCT06516679|DRUG|Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation"
219270495|NCT01908751|PROCEDURE|Sliding Hip Screw|
219270496|NCT01908751|PROCEDURE|Cancellous Screws|
218990112|NCT00000371|DRUG|Placebo|50 mg/day of placebo by mouth
218990113|NCT05871775|BEHAVIORAL|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
218990114|NCT05871775|BEHAVIORAL|Stabilization exercise|Neck stabilization exercise and sensorimotor program
218990115|NCT05871775|BEHAVIORAL|General exercise|General mobility exercise and strength exercise program
218990116|NCT03916991|OTHER|Exercise|Hip focused Neuromuscular Activation Exercise
218990117|NCT06162936|DIAGNOSTIC_TEST|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
218990118|NCT06162936|DIAGNOSTIC_TEST|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
218990119|NCT06162936|DIAGNOSTIC_TEST|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
218990120|NCT03266536|BEHAVIORAL|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
218990121|NCT01343420|BIOLOGICAL|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
218990122|NCT02237131|DRUG|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
218990123|NCT02237131|DRUG|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
218990124|NCT03795623|OTHER|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
219270497|NCT01908751|DRUG|Vitamin D|
218990125|NCT03795623|OTHER|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
219270498|NCT01908751|DRUG|Vitamin D Placebo|
219270499|NCT00179738|DRUG|CC5013|
219270500|NCT00092183|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
219270501|NCT00092183|DRUG|Comparator: ondansetron / Duration of Treatment: 3 days|
219270502|NCT00092053|DRUG|Placebo|tablets
219270503|NCT00092053|DRUG|ibandronate|50 mg tablets
219270504|NCT02719288|OTHER|CLARIX® CORD 1K graft|
219270505|NCT00420784|DRUG|Telaprevir|tablet
219270506|NCT00420784|DRUG|Ribavirin|tablet
219270507|NCT00420784|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
218990126|NCT04092439|DIETARY_SUPPLEMENT|Watermelon Juice|100% Watermelon Juice
218990127|NCT00963937|DRUG|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
218990128|NCT00963937|DRUG|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
218990129|NCT00963937|DRUG|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
218990130|NCT02800681|OTHER|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
218990131|NCT02800681|OTHER|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
218990132|NCT02800681|OTHER|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
219270508|NCT00420784|DRUG|Matching Placebo|Tablet
218990133|NCT02800681|OTHER|Other general interviewer ratings|1\. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
218990134|NCT02433730|DRUG|Testosterone|intramuscular injection
218990135|NCT02433730|DRUG|placebo|intramuscular injection
219270509|NCT06441864|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Partners will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.
219270510|NCT00002838|BIOLOGICAL|Filgrastim (G-CSF)|
219270511|NCT00002838|DRUG|Cyclophosphamide|
219270512|NCT00002838|DRUG|Fludarabine Phosphate|
219270513|NCT00002838|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
219270514|NCT06183541|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
219270515|NCT00157794|DEVICE|Search AV+ algorithm|
219270516|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
219270517|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
219270518|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
219270519|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
219270520|NCT00148668|DRUG|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
219270521|NCT00148668|DRUG|Navelbine|Weekly injections given starting week 3 and ending week 14
219270522|NCT00148668|DRUG|Taxotere|Given every three weeks starting week 3 and ending on week 14
219270523|NCT00148668|DRUG|Carboplatin|Given every three weeks starting week 3 and ending on week 14
219270524|NCT03052660|DRUG|Midazolam|Oral administration preoperatively
219270525|NCT03052660|DRUG|Placebo oral capsule|Oral administration preoperatively
219270526|NCT00148408|DRUG|Montelukast|
219270527|NCT00148408|BEHAVIORAL|Education|
219270528|NCT02322086|DRUG|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
219270529|NCT04884919|DEVICE|Regular Gauze|Regular gauze
219270530|NCT04884919|DEVICE|Chitosan Dressing|Dressing made of chitosan material
219270531|NCT05487235|DRUG|GDC-1971|Capsule or tablet administered orally.
219270532|NCT05487235|DRUG|Atezolizumab|Administered as IV infusion.
219270533|NCT05487235|DRUG|Omeprazole|Administered orally as tablet or capsule in the acid-reducing agent assessment.
218990136|NCT01306903|DEVICE|MECC|Minimized extracorporeal circulation
218990137|NCT01306903|DEVICE|MOPS|Modified and optimized perfusion system Frankfurt
218990138|NCT01306903|DEVICE|Super MOPS|Super modified and optimized perfusion system Frankfurt
218990139|NCT03756844|BEHAVIORAL|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
219270534|NCT03845270|DRUG|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
219270535|NCT03005990|OTHER|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
219270536|NCT02417441|DEVICE|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
218990140|NCT03147261|OTHER|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
218990141|NCT01352104|BEHAVIORAL|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
218990142|NCT02740881|OTHER|Counselor Training Methods|
218990143|NCT03912168|OTHER|Question Prompt List|Question prompt list for common orthopaedic conditions
219270537|NCT05679804|OTHER|validity and realibility of scale|Turkish validity and realibility of Bipolar Recovery Questionnare
218990144|NCT03912168|OTHER|3 questions list|3 questions from the AskShareKnow model
218990145|NCT03253276|DRUG|Obeticholic acid|Placebo-controlled
218990146|NCT03253276|DRUG|Placebos|
218990147|NCT00205881|DEVICE|HiRes 90K Bionic Ear System|Cochlear implant system
218990148|NCT05902520|BIOLOGICAL|DP CD8 TIL|intravenous infusion of T cell suspension
218990149|NCT05902520|BIOLOGICAL|DP CD8 TIL KD|intravenous infusion of T cell suspension
218990150|NCT05902520|BIOLOGICAL|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
218990151|NCT05913492|BEHAVIORAL|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
218990152|NCT01634724|DRUG|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
218990153|NCT04960501|PROCEDURE|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
218990154|NCT05963594|DIETARY_SUPPLEMENT|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
218990155|NCT05963594|DIETARY_SUPPLEMENT|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
218990156|NCT01889004|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
218990157|NCT01889004|DRUG|Propofol|Escalating concentrations until loss of responsiveness
218990158|NCT04173988|GENETIC|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."
218990159|NCT04173988|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
218990160|NCT04173988|DRUG|Fludarabine|Chemotherapy for lymphodepletion
218990161|NCT06273410|OTHER|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
218990162|NCT06273410|OTHER|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
218990163|NCT06273410|OTHER|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
218990164|NCT00714649|DRUG|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
218990165|NCT05192967|BEHAVIORAL|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
218990166|NCT05192967|BEHAVIORAL|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
218990167|NCT03403075|BEHAVIORAL|ETAF|Therapeutic education and Physical activity
218990168|NCT03403075|BEHAVIORAL|Usual care|Usual care
218990169|NCT03530358|DEVICE|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
218990170|NCT03530358|BEHAVIORAL|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
218990171|NCT01310153|PROCEDURE|prone positioning|newborn babies in prone positioning
218990172|NCT01310153|PROCEDURE|Supine|newborn babies in supine positioning
218990173|NCT06429137|DRUG|BI 3731579|BI 3731579
218990174|NCT06429137|DRUG|Matching placebo to BI 3731579|Matching placebo to BI 3731579
218990175|NCT01928069|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
218990176|NCT02048969|DRUG|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
218990177|NCT02048969|DRUG|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
218990178|NCT01395667|OTHER|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
219270538|NCT01180504|RADIATION|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
219270539|NCT04081077|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
218990179|NCT05051618|BEHAVIORAL|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
218990180|NCT05051618|BEHAVIORAL|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
218990181|NCT03867188|DRUG|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
218990182|NCT01015599|BEHAVIORAL|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
219270540|NCT04081077|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
218990183|NCT04946968|DRUG|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
218990184|NCT03463512|DRUG|Racecadotril plus ORS|Racecadotril plus ORS
218990185|NCT03463512|DRUG|ORS|ORS
219270541|NCT04081077|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
218990186|NCT01423578|BEHAVIORAL|Hatha Yoga (HY)|3 Sessions of yoga instruction
218990187|NCT01423578|BEHAVIORAL|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
218990188|NCT01423578|BEHAVIORAL|Smoking Cessation Counseling|4 smoking cessation counseling visits.
218990189|NCT04442412|DRUG|Vitamin D3 (Cholecalciferol)|patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
218990190|NCT04442412|DRUG|RCHOP o R-miniCHOP at standard doses|"Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses"
218990191|NCT01627483|OTHER|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
218990192|NCT06212154|BIOLOGICAL|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
218990193|NCT01293773|DEVICE|Taxus Element stent|paclitaxel-eluting stent
218990194|NCT01293773|DEVICE|Integrity Resolute stent|ABT 578-eluting stent
218990195|NCT01293773|DEVICE|Xience Prime stent|Everolimus-eluting stent
218990196|NCT05934578|OTHER|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
218990197|NCT04641858|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
218990198|NCT04641858|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
218990199|NCT05642988|DEVICE|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
218990200|NCT01022749|DRUG|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
218990201|NCT01022749|BIOLOGICAL|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
219270542|NCT04081077|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
219270543|NCT04081077|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
219270544|NCT06331455|DRUG|Durvalumab|Two doses of durvalumab (1500 mg IV)
219270545|NCT06331455|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
219270546|NCT04709653|OTHER|Occupation-based nursing program|"First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille."
219270547|NCT04709653|OTHER|Control Group|Routine nursing care
219270548|NCT03748862|OTHER|Taper Plan|Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
219270549|NCT05053880|DRUG|ACT001|Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
219270550|NCT05053880|DRUG|ACT001 + Pembrolizumab|Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
219270551|NCT03080142|DRUG|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
219270552|NCT03080142|DRUG|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
219270553|NCT03567044|DIAGNOSTIC_TEST|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
219270554|NCT06544356|OTHER|No intervention, questionnaire filled out|Mother introductory information form, Health Literacy Scale, Knowledge and Attitude Scale about Newborn Screenings were completed.
219270555|NCT02328079|DRUG|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
219270556|NCT04205357|DRUG|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
219270557|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
219270558|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
219270559|NCT00983853|BIOLOGICAL|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
219270560|NCT00983853|DRUG|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
219270561|NCT00983853|DRUG|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
219270562|NCT03946202|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
219270563|NCT02346929|OTHER|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
219270564|NCT01632189|DRUG|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
219270565|NCT04345380|OTHER|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
219270566|NCT04345380|OTHER|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
219270567|NCT04345380|OTHER|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
218990202|NCT04789499|DRUG|Theophylline Powder|Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
219270568|NCT03603639|DRUG|Placebo|Participants will receive E2730-matched placebo capsule, orally.
218990203|NCT04789499|DRUG|Placebo Comparator|Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
219270569|NCT03603639|DRUG|E2730|Participants will receive E2730 capsule, orally.
219270570|NCT02934204|DRUG|methotrexate|
219270571|NCT02934204|DRUG|temozolomide|
219270572|NCT00607672|DRUG|Placebo|Placebo
219270573|NCT00607672|DRUG|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
218990204|NCT00519454|OTHER|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
218990205|NCT04805762|OTHER|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
219270574|NCT00607672|DRUG|Candesartan|Candesartan 16mg/d
218990206|NCT00005118|DRUG|Indinavir sulfate|
218990207|NCT00005118|DRUG|Ritonavir|
218990208|NCT04326829|DRUG|QL1604|QL1604, IV infusion
218990209|NCT04016233|DRUG|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
218990210|NCT00644657|DRUG|Clopidogrel|All subjects will receive a 300 mg loading dose
218990211|NCT05626062|DEVICE|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
218990212|NCT05243355|DRUG|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
218990213|NCT00513656|DRUG|Oxycodone|
218990214|NCT00513656|DRUG|Oxycodone/Naloxone|
218990215|NCT01407822|DRUG|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
218990216|NCT01407822|DRUG|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
218990217|NCT04121975|RADIATION|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
218990218|NCT04121975|DRUG|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
218990219|NCT04121975|DRUG|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
218990220|NCT01210469|OTHER|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
218990221|NCT01210469|OTHER|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
219270575|NCT03496077|OTHER|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
219270576|NCT00485953|DRUG|risedronate|risedronate 35 mg per week
219270577|NCT04944667|DIAGNOSTIC_TEST|TAVR planning|TAVR planning without VR vs after VR
219270578|NCT02900950|PROCEDURE|Multicolour inking specimens|
219270579|NCT02900950|PROCEDURE|Monocolour inking specimens|
219270580|NCT01436747|DRUG|Paricalcitol|2 micrograms daily, peroral, 24 weeks
219270581|NCT01436747|DRUG|Placebo|2 micrograms daily, peroral, 24 weeks
219270582|NCT01673789|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
219270583|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
219270584|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/kg every three days.
219270585|NCT04817423|OTHER|No intervention|No intervention
219270586|NCT03736538|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
218990222|NCT01581775|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
218990223|NCT04010695|DIAGNOSTIC_TEST|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
218990224|NCT04010695|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
218990225|NCT04010695|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
218990226|NCT01686308|PROCEDURE|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
218990227|NCT01686308|PROCEDURE|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
219270587|NCT03736538|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
218990228|NCT03531359|DEVICE|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
219270588|NCT05034939|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
218990229|NCT03531359|DRUG|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
218990230|NCT05113290|DRUG|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
218990231|NCT05113290|DRUG|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
219270589|NCT05034939|DEVICE|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
218990232|NCT02362581|OTHER|prophylaxis treatment, on demand treatment|
219270590|NCT04576793|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
218990233|NCT05760560|DRUG|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
218990234|NCT05269433|BEHAVIORAL|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
218990235|NCT05269433|BEHAVIORAL|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
219270591|NCT04576793|DRUG|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
218990236|NCT05269433|OTHER|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
218990237|NCT05269433|OTHER|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
218990238|NCT04965727|PROCEDURE|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
218990239|NCT00389597|DEVICE|Cervical Artificial Disc|Cervical artificial disc mechanical device
218990240|NCT01182142|DRUG|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
218990241|NCT01663025|BEHAVIORAL|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
218990242|NCT00352339|DRUG|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
218990243|NCT00352339|DRUG|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
219270592|NCT04576793|DRUG|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
219270593|NCT04576793|PROCEDURE|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
219270594|NCT04714463|PROCEDURE|Implant-based breast reconstruction|All types of implant based breast reconstructions
219270595|NCT04714463|PROCEDURE|Autologous breast reconstruction|All types of autologous breast reconstructions
219270596|NCT04714463|PROCEDURE|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
219270597|NCT06003881|DRUG|Pozelimab|Subcutaneous (SC) administration
218990244|NCT00352339|DRUG|Abilify|Start with abilify and keep it through the end of study
218990245|NCT05116618|DIAGNOSTIC_TEST|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
218990246|NCT06361433|DRUG|HUFF-01|autologous MSC combined with scaffold
218990247|NCT05728021|BEHAVIORAL|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
218990248|NCT05728021|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
218990249|NCT00781274|DRUG|MP-424|750 mg every 8 hours for 12 weeks
218990250|NCT00781274|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
218990251|NCT00781274|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
218990252|NCT04953754|DIETARY_SUPPLEMENT|Melatonin|The melatonin group will receive 5mg melatonin nightly
218990253|NCT04953754|DEVICE|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
218990254|NCT03406767|OTHER|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
219270598|NCT00489801|OTHER|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
219270599|NCT05681273|DRUG|Chiglitazar|Chiglitazar 48mg
219270600|NCT05681273|DRUG|Empagliflozin|Empagliflozin 10mg
219270601|NCT05681273|DRUG|Atorvastatin|Atorvastatin 20mg
219270602|NCT05681273|DRUG|Valsartan|Valsartan 160mg
219270603|NCT00532168|DRUG|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
219270604|NCT00532168|DRUG|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
219270605|NCT00532168|DRUG|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
219270606|NCT00551499|DEVICE|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
218990255|NCT03406767|OTHER|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
218990256|NCT06098092|OTHER|Long-term non-invasive Blood pressure monitoring|All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
218990257|NCT04794842|DRUG|Tetracaine 5% drops|same as information in the arm/group description
218990258|NCT04794842|DRUG|Phenol 90% concentration|same as information in the arm/group description
218990259|NCT01147523|DRUG|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
218990260|NCT02532088|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
218990261|NCT02532088|DIETARY_SUPPLEMENT|Placebo|Placebo
218990262|NCT01950975|BIOLOGICAL|Peripheral blood samples in EDTA tubes|
218990263|NCT01950975|PROCEDURE|Skin biopsies|
218990264|NCT02021773|DRUG|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
218990265|NCT02021773|DRUG|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
219270607|NCT03910777|DIAGNOSTIC_TEST|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
218990266|NCT02021773|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
218990267|NCT03691259|OTHER|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
218990268|NCT03993795|OTHER|A19010-W|A snus product
218990269|NCT03993795|OTHER|B19010-F|A snus product
218990270|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
218990271|NCT00768183|DRUG|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
218990272|NCT00768183|DRUG|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
218990273|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
218990274|NCT04456530|DRUG|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
218990275|NCT04456530|OTHER|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
218990276|NCT06097286|PROCEDURE|external oblique intercostal plane block|o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
218990277|NCT06097286|PROCEDURE|erector spinae plane block|o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
218990278|NCT01388738|DRUG|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
218990279|NCT01388738|DRUG|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
218990280|NCT01388738|DRUG|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
218990281|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
218990282|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
218990283|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
218990284|NCT01534962|DRUG|Placebo|Oral administration, BID; for a maximum of 112 days.
218990285|NCT01760460|DRUG|Anacetrapib|
218990286|NCT01760460|DRUG|Placebo for anacetrapib|
218990287|NCT01041833|DRUG|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
218990288|NCT01041833|DRUG|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
218990289|NCT05241743|OTHER|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
218990290|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
218990291|NCT00087607|DRUG|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
218990292|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
218990293|NCT00087607|DRUG|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
218990294|NCT00190671|DRUG|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
218990295|NCT00190671|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
219270608|NCT04267055|DEVICE|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
219270609|NCT05465759|OTHER|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
219270610|NCT03515304|DRUG|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
218990296|NCT00190671|DRUG|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
218990297|NCT04903275|PROCEDURE|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS\_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
218990298|NCT04903275|PROCEDURE|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
218990299|NCT02911714|DRUG|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
219270611|NCT03515304|DRUG|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
219270612|NCT04042818|DIAGNOSTIC_TEST|Rehabilitative Ultrasound|Ultrasound imagining
218990300|NCT02836730|PROCEDURE|Low back pain surgery|
218990301|NCT01460004|DEVICE|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
218990302|NCT03697473|OTHER|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
218990303|NCT03697473|OTHER|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
218990304|NCT00191269|DRUG|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
218990305|NCT00191269|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
218990306|NCT01583491|PROCEDURE|autologous platlet rich fibrin|one dose immediate after surgery
218990307|NCT01583491|PROCEDURE|one side in control group|control group insert any things after surgery
218990308|NCT01551992|PROCEDURE|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
218990309|NCT01741974|DIETARY_SUPPLEMENT|Karinat|
218990310|NCT01741974|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
218990311|NCT01745133|DRUG|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
218990312|NCT01745133|DRUG|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
218990313|NCT01745133|DRUG|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
218990314|NCT03021070|OTHER|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
219270613|NCT00483028|DRUG|donezepil (Aricept)|
219270614|NCT00301483|DRUG|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
219270615|NCT00301483|OTHER|Standard of Care|Standard Therapy
219270616|NCT02137577|PROCEDURE|DEB catheter|DEB catheter (trade name: Litos/Tulip)
219270617|NCT02137577|PROCEDURE|common PTA balloon catheter|common PTA balloon catheter
219270618|NCT06086678|OTHER|Conventional physical therapy|"1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise."
219270619|NCT06086678|OTHER|Hydrotherapy|"1. Water walking exercise.~2. Forward lunges exercise.~3. Single leg balance exercise.~4. Side stepping exercise.~5. Push ups exercise.~6. Standing knee lifts exercise."
219270620|NCT06086678|OTHER|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
219270621|NCT00678483|DRUG|rimonabant (SR141716)|once daily
219270622|NCT03016598|DRUG|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
219270623|NCT03016598|DRUG|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
219270624|NCT01980602|PROCEDURE|Supervised Exercise program|
219270625|NCT06566183|PROCEDURE|Guideline-directed medical therapy (GDMT)|Participants receive guideline-directed medical therapy (GDMT).
219270626|NCT06566183|PROCEDURE|Coronary artery bypass grafting (CABG)|Participants receive coronary artery bypass grafting (CABG).
219270627|NCT06566183|PROCEDURE|Percutaneous coronary intervention (PCI).|Participants receive percutaneous coronary intervention (PCI).
219270628|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
219270629|NCT05980416|DRUG|Ramucirumab (CYRAMZA®)|VEGFR2 inhibitor
219270630|NCT05980416|DRUG|Dostarlimab|anti-PD-1 antibody
219270631|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
219270632|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
219270633|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
219270634|NCT01954225|OTHER|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
219270635|NCT02952196|DRUG|drug administration|administering drug to patient with amphetamine addiction
219270636|NCT04051918|BEHAVIORAL|Piano Training|Cognitive training via music learning
219270637|NCT04924049|OTHER|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
219270638|NCT03913559|DRUG|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
219270639|NCT03913559|DRUG|Methotrexate|Intrathecal (IT) therapy
219270640|NCT03913559|DRUG|Hydrocortisone|Intrathecal (IT) therapy
219270641|NCT03913559|DRUG|Cytarabine|Intrathecal (IT) therapy
219270642|NCT03913559|DRUG|Diphenhydramine|1 mg/kg (max 50 mg) IV
219270643|NCT03913559|DRUG|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
219270644|NCT03913559|DRUG|Methylprednisolone|1 mg/kg IV x 1
219270645|NCT06213324|DRUG|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
219270646|NCT06213324|DRUG|Placebo|Normal saline delivered intravenously
219270647|NCT03200652|DIETARY_SUPPLEMENT|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
219270648|NCT04162002|DRUG|Restylane® Lyft|Filler Injection
218990315|NCT03031197|COMBINATION_PRODUCT|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
218990316|NCT05516394|PROCEDURE|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
218990317|NCT02412995|OTHER|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
218990318|NCT02412995|OTHER|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
218990319|NCT02412995|OTHER|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
218990320|NCT02412995|OTHER|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
218990321|NCT02412995|OTHER|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
219270649|NCT02167919|DEVICE|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
219270650|NCT01873326|DRUG|Paclitaxel|
219270651|NCT01873326|DRUG|Ifosfamide|
219270652|NCT01873326|DRUG|Cisplatin|
219270653|NCT01873326|DRUG|Mesna|
219270654|NCT01873326|DRUG|Bleomycin|
219270655|NCT01873326|DRUG|Etoposide|
219270656|NCT05986045|OTHER|Quality of Life|ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
219270657|NCT00119652|DRUG|quetiapine fumarate (Seroquel)|
219270658|NCT00119652|DRUG|paroxetine|
219270659|NCT00119652|BEHAVIORAL|mood stabilizing activity|
219270660|NCT03662646|OTHER|no intervention performed- observational only|no intervention performed- observational only
219270661|NCT00549978|DRUG|Cilostazol|cilostazol, then cilostazol/probucol
219270662|NCT00549978|DRUG|Probucol|Probucol probucol/ cilostazol
219270663|NCT03943017|OTHER|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
219270664|NCT05488288|PROCEDURE|Mesh repair|Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
219270665|NCT05488288|PROCEDURE|Suture repair|The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
219270666|NCT00022815|DEVICE|Tissue ultrafiltration|
219270667|NCT02927015|OTHER|Purple Majesty potato chips|Purple Majesty potato chips
219270668|NCT02927015|OTHER|Mountain Rose potato chips|Mountain Rose potato chips
219270669|NCT02927015|OTHER|White potato chips|White potato chips
219270670|NCT02927015|OTHER|Crackers|Crackers
219270671|NCT03848884|BEHAVIORAL|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
219270672|NCT02947100|DRUG|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
219270673|NCT05400837|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
219270674|NCT00742326|DRUG|Pioglitazone|45 mg/daily
219270675|NCT00742326|DRUG|Placebo|one capsule daily
219270676|NCT03567642|DRUG|Osimertinib|Osimertinib 80mg daily
219270677|NCT03567642|DRUG|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
219270678|NCT03567642|DRUG|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
219270679|NCT01828866|BEHAVIORAL|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
219270680|NCT01828866|BEHAVIORAL|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring"
219270681|NCT05100810|OTHER|Natural History Study|Longitudinal assessment of disease progression of Angelman syndrome in patients
219270682|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
219270683|NCT00922688|DRUG|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
219270684|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
219270685|NCT04097847|DRUG|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
219270686|NCT04189055|DRUG|Cetuximab|Cetuximab 500mg/m² IV, day 1
219270687|NCT04189055|DRUG|Irinotecan|Irinotecan 180mg/m² IV, day 1
219270688|NCT06002646|DRUG|Formocresol|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
219270689|NCT06002646|DRUG|Sodium Hypochlorite Solution|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
219270690|NCT06002646|DEVICE|Diode laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.
219270691|NCT06002646|DEVICE|Er,Cr:YSGG laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
219270692|NCT00074295|BIOLOGICAL|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
219270693|NCT00385307|DRUG|amibegron (SR58611A)|
219270694|NCT00828555|OTHER|Vaccination Program|Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis
219270695|NCT00034554|BIOLOGICAL|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5\* patient safely completing the 2nd vaccination at the lower dose level.
219270696|NCT03218566|DEVICE|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
219270697|NCT04443478|PROCEDURE|Radical gastrectomy with dissection of lower mediastinal lymph node|Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
219270698|NCT03569215|BEHAVIORAL|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
219270699|NCT00573547|DRUG|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
219270700|NCT05861765|DRUG|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
219270701|NCT05861765|DRUG|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
219270702|NCT00443209|DRUG|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
219270703|NCT00443209|DRUG|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
219270704|NCT00443209|DRUG|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
219270705|NCT00443209|DRUG|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
219270706|NCT00443209|DRUG|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
219270707|NCT00443209|DRUG|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
219270708|NCT04522661|PROCEDURE|Vitrectomy|Vitrectomy within 48 hours of randomisation
219270709|NCT04522661|PROCEDURE|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
219270710|NCT03219762|DRUG|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
219270711|NCT05564481|BEHAVIORAL|diabetes education and parent coaching support|Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
218990322|NCT02412995|OTHER|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
218990323|NCT02151110|BIOLOGICAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
218990324|NCT02151110|BIOLOGICAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
218990325|NCT02151110|BIOLOGICAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
218990326|NCT02151110|BIOLOGICAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
218990327|NCT02151110|BIOLOGICAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
218990328|NCT02151110|BIOLOGICAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
218990329|NCT02151110|BIOLOGICAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
218990330|NCT02151110|OTHER|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
218990331|NCT03801486|OTHER|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
218990332|NCT03801486|OTHER|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
218990333|NCT03290872|DEVICE|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
218990334|NCT03290872|DEVICE|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
218990335|NCT01651247|PROCEDURE|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
218990336|NCT06236672|DRUG|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
218990337|NCT06236672|DRUG|basal insulin|basal insulin initiated between January 2019 and December 2022
218990338|NCT00785694|DRUG|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
219270712|NCT03452683|BEHAVIORAL|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
219270713|NCT05489562|DEVICE|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
218990339|NCT04493073|PROCEDURE|Trabectulectomy|decrease IOP
218990340|NCT04493073|DRUG|Mitomycin|Decrease bleb failure
218990341|NCT04493073|DEVICE|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
218990342|NCT04493073|DEVICE|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
218990343|NCT03652597|DEVICE|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
218990344|NCT06385951|DIAGNOSTIC_TEST|Procedure for patients|We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
218990345|NCT06385951|DIAGNOSTIC_TEST|Procedure for healthy controls|Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
218990346|NCT02015754|DRUG|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
218990347|NCT02015754|DEVICE|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
218990348|NCT02015754|PROCEDURE|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
218990349|NCT01546805|DRUG|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
218990350|NCT01546805|DRUG|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
218990351|NCT00375648|DRUG|Zoledronic acid|
218990352|NCT05498012|COMBINATION_PRODUCT|placebo dental gel, placebo toothpaste|"* Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
218990353|NCT05498012|COMBINATION_PRODUCT|Cannabidiol dental gel, Cannabidiol toothpaste|"* Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
218990354|NCT05498012|COMBINATION_PRODUCT|Placebo toothpaste, Corsodyl dental gel|"* Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
218990355|NCT01086761|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye.
218990356|NCT04600141|DRUG|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
218990357|NCT04600141|DRUG|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
218990358|NCT04600141|DRUG|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
219270714|NCT03427983|PROCEDURE|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
219270715|NCT03427983|PROCEDURE|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
218990359|NCT04528732|BEHAVIORAL|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
218990360|NCT04528732|BEHAVIORAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
218990361|NCT03482544|DRUG|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
218990362|NCT03482544|OTHER|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
219270716|NCT03922607|DRUG|ABBV-157|ABBV-157 will be administered orally as capsule
218990363|NCT03375606|BIOLOGICAL|CSL730|Solution for IV infusion
218990364|NCT03375606|OTHER|Placebo|Saline solution for IV infusion
218990365|NCT01262911|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
218990366|NCT01262911|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
218990367|NCT02888301|PROCEDURE|Computed Tomography|Undergo 18F-clofarabine PET/CT
218990368|NCT02888301|RADIATION|Fluorine F 18 Clofarabine|Given IV
218990369|NCT02888301|PROCEDURE|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
218990370|NCT05399641|DRUG|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
218990371|NCT02094677|DEVICE|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
218990372|NCT02094677|DEVICE|etafilcon A|Participants were randomized to wear etafilcon A control lens.
218990373|NCT02094677|DEVICE|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
219270717|NCT03922607|DRUG|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
219270718|NCT06300983|BEHAVIORAL|Psychoeducative|The intervention consiste of 5 sessions (Table 1), with each lasting 100 minutes and delivered on a weekly basis. Individual meetings will be conducted with each participant prior to starting the group work. These were considered pre-intervention sessions, during which patients provided informed consent to participate in the study and the first assessment tests were administered.
218990374|NCT00003165|DRUG|doxorubicin-HPMA conjugate|
218990375|NCT05987228|DIETARY_SUPPLEMENT|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
218990376|NCT03566160|DEVICE|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
218990377|NCT01300650|DRUG|Anakinra|Anakinra 100 mg subcutaneous injection daily
218990378|NCT03805399|DRUG|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
218990379|NCT03805399|DRUG|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
218990380|NCT03805399|DRUG|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
218990381|NCT03805399|DRUG|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
218990382|NCT03805399|DRUG|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
218990383|NCT03805399|DRUG|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
218990384|NCT03805399|DRUG|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
218990385|NCT00672932|DRUG|raltegravir|400 mg two times daily for three months
218990386|NCT03127410|OTHER|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
218990387|NCT02041884|BEHAVIORAL|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
218990388|NCT02041884|BEHAVIORAL|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
219270719|NCT06300983|BEHAVIORAL|Placebo|The control group, which do not receive any psychoeducative intervention
219270720|NCT05426993|OTHER|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
219270721|NCT01151514|OTHER|Nephrologist referral|Nephrologist specialty, renal replacement therapy
219270722|NCT01486368|DRUG|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
218990389|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
219270723|NCT01628692|DRUG|Daclatasvir|Tablets, oral, 30 mg, once daily
219270724|NCT01628692|DRUG|Simeprevir|Capsule, oral, 150 mg, once daily
219270725|NCT01628692|DRUG|Ribavirin|Tablets, oral, 500-600 mg, twice daily
219270726|NCT04563299|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
218990390|NCT01804465|DRUG|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
219270727|NCT04563299|DRUG|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
219270728|NCT05760521|OTHER|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
219270729|NCT03959852|DRUG|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
219270730|NCT03959852|COMBINATION_PRODUCT|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
219270731|NCT03959852|DRUG|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
219270732|NCT05502822|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219270733|NCT05502822|DEVICE|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
219270734|NCT01355640|OTHER|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
219270735|NCT01355640|OTHER|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
219270736|NCT03640247|DRUG|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
219270737|NCT03640247|DRUG|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
219270738|NCT01651533|BEHAVIORAL|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
219270739|NCT01651533|BEHAVIORAL|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
219270740|NCT05554042|DIAGNOSTIC_TEST|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
219270741|NCT05175300|DEVICE|Prosthesis with CoPXE couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
219270742|NCT05175300|DEVICE|Prosthesis with CoC torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
219270743|NCT05976230|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
219270744|NCT03212755|DIAGNOSTIC_TEST|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
219270745|NCT04288414|DIAGNOSTIC_TEST|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
218990391|NCT01804465|DRUG|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
218990392|NCT00255125|DRUG|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
218990393|NCT00255125|DRUG|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
218990394|NCT04489628|DRUG|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
218990395|NCT04489628|DEVICE|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
218990396|NCT06376292|DRUG|Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
219270746|NCT04452591|BIOLOGICAL|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
218990397|NCT05960552|DIAGNOSTIC_TEST|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
219270747|NCT04452591|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
219270748|NCT00047541|DRUG|Alcon Investigational Agent|
219270749|NCT05856578|DRUG|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
219270750|NCT05856578|DRUG|Canagliflozin|Canagliflozin 100mg po qd
219270751|NCT01607931|BEHAVIORAL|Exercise|1 hour of cycling at 50% of maximum power output
219270752|NCT04263805|OTHER|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
219270753|NCT03536078|OTHER|home phototherapy|
219270754|NCT04657601|DEVICE|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
219270755|NCT00409409|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219270756|NCT00409409|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
219270757|NCT04012723|DEVICE|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
219270758|NCT04296045|DIETARY_SUPPLEMENT|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
219270759|NCT04296045|DIETARY_SUPPLEMENT|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
219270760|NCT02247843|BIOLOGICAL|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
218990398|NCT05960552|DIAGNOSTIC_TEST|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
218990399|NCT02834039|PROCEDURE|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
219270761|NCT03585686|DRUG|Vemurafenib|vemurafenib 20 mg/kg/day
219270762|NCT03585686|DRUG|Cytarabine|100 mg/m2/12 h, days 1-5
219270763|NCT03585686|DRUG|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
219270764|NCT01087515|OTHER|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
219270765|NCT02716363|DEVICE|Rotational Atherectomy by Rotablator|
219270766|NCT01607528|DIETARY_SUPPLEMENT|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
218990400|NCT02834039|PROCEDURE|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
218990401|NCT01939808|OTHER|Splint Neutral|
218990402|NCT01939808|OTHER|Splint Extended|
218990403|NCT03180073|DIAGNOSTIC_TEST|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
218990404|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
219270767|NCT01607528|DIETARY_SUPPLEMENT|Placebo|A similar looking and tasting powder with no active substances
219270768|NCT00643318|RADIATION|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being \> 2 cms from the carina and \> 2 cms from the right and left mainstem bronchus and/or \> 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
218990405|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
218990406|NCT05364190|DRUG|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
219270769|NCT02472054|DRUG|Alemtuzumab|
219270770|NCT02472054|DRUG|Methyl Prednisolone (MP)|
218990407|NCT05364190|DRUG|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
218990408|NCT05142111|BEHAVIORAL|Therapy|Discussion with therapist
218990409|NCT02653183|DEVICE|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
219270771|NCT02472054|DRUG|Cyclosporin A (CSA)|
218990410|NCT02653183|DEVICE|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
218990411|NCT06474702|DEVICE|'Fitbit charge 4' 'smart-watch'-|smartwatch device that collects physiological measures
218990412|NCT05235048|PROCEDURE|Tooth extraction|Atraumatic tooth extraction without flap elevation
218990413|NCT05235048|PROCEDURE|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
218990414|NCT05235048|PROCEDURE|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
219270772|NCT05277077|OTHER|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
219270773|NCT05277077|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
218990415|NCT05235048|PROCEDURE|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
218990416|NCT01908283|BIOLOGICAL|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
218990417|NCT05739188|BIOLOGICAL|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."
218990418|NCT00668707|DIETARY_SUPPLEMENT|melatonin|20 mgs ingested nightly
218990419|NCT00668707|DIETARY_SUPPLEMENT|placebo|similar to experimental in all ways except for lack of active ingredient
218990420|NCT00004771|DRUG|leuprolide|
218990421|NCT00004771|DRUG|testosterone|
218990422|NCT00923156|DRUG|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
218990423|NCT00923156|DRUG|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
218990424|NCT00923156|DRUG|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
218990425|NCT00923156|DRUG|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
219270774|NCT00820664|DRUG|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
219270775|NCT00820664|DRUG|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
218990426|NCT01404858|BEHAVIORAL|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
218990427|NCT00057278|DRUG|gabapentin|
218990428|NCT03274128|RADIATION|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
218990429|NCT03274128|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
218990430|NCT01170858|DRUG|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
218990431|NCT01170858|DRUG|glucose solutions|
218990432|NCT00317005|DRUG|folate treatment|
219270776|NCT00820664|DRUG|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
219270777|NCT03137706|PROCEDURE|Biospecimen Collection|Undergo fresh tumor tissue collection
219270778|NCT03137706|OTHER|Laboratory Biomarker Analysis|Correlative studies
219270779|NCT03137706|OTHER|Laboratory Procedure|Tissue stiffness and cell viability analysis
219270780|NCT03635086|BIOLOGICAL|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
219270781|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
219270782|NCT03635086|BIOLOGICAL|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
218990433|NCT01646723|BEHAVIORAL|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
218990434|NCT00399750|DRUG|oxaliplatin|
218990435|NCT00399750|DRUG|fluoropyrimidine|
219270783|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.
219270784|NCT03635086|OTHER|Placebo|Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
218990436|NCT00399750|DRUG|bevacizumab|
218990437|NCT01899261|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
218990438|NCT03893370|DEVICE|RejuvenAir System|RejuvenAir Metered CryoSpray
218990439|NCT03893370|DEVICE|Sham Control Procedure|Sham Control Procedure
218990440|NCT03931161|DRUG|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
218990441|NCT03931161|DRUG|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
218990442|NCT03656432|DRUG|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
218990443|NCT00831025|BIOLOGICAL|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
218990444|NCT00831025|BIOLOGICAL|Placebo|Placebo for subcutaneous monthly administration
218990445|NCT06040931|PROCEDURE|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
218990446|NCT00489138|DRUG|Ertapenem|1g a day by drip of 30 min
218990447|NCT03659500|DIAGNOSTIC_TEST|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
218990448|NCT03659500|DIAGNOSTIC_TEST|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
218990449|NCT03137537|DRUG|Ivabradine|lower heart rate in heart failure patients.
218990450|NCT03137537|DRUG|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
218990451|NCT01552993|DRUG|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
218990452|NCT01552993|DRUG|sucrose|pacifier and sucrose
218990453|NCT04066023|DRUG|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
218990454|NCT04066023|DRUG|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
218990455|NCT02212795|DRUG|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
218990456|NCT02212795|DRUG|Levofloxacin 250mg|Levofloxacin 250mg single dose
218990457|NCT02212795|DRUG|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
218990458|NCT04368676|OTHER|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
218990459|NCT04368676|OTHER|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
218990460|NCT05468060|DRUG|PA1010|Placebo as control
218990461|NCT05476471|BEHAVIORAL|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
219270785|NCT00080860|GENETIC|microarray analysis|
219270786|NCT00080860|OTHER|immunohistochemistry staining method|
219270787|NCT00080860|PROCEDURE|conventional surgery|
219270788|NCT00080860|PROCEDURE|lymphangiography|
219270789|NCT00080860|PROCEDURE|radionuclide imaging|
219270790|NCT00080860|PROCEDURE|sentinel lymph node biopsy|
219270791|NCT00080860|RADIATION|technetium Tc 99m sulfur colloid|
219270792|NCT02126462|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|
219270793|NCT02126462|BIOLOGICAL|Na-GST-1/Alhydrogel®|
218990462|NCT05058820|OTHER|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
219270794|NCT02126462|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
219270795|NCT02196077|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
219270796|NCT02196077|DRUG|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
219270797|NCT02196077|DRUG|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
219270798|NCT02196077|DRUG|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
219270799|NCT02196077|DRUG|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
219270800|NCT05592977|DEVICE|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
218990463|NCT05058820|OTHER|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
218990464|NCT03214939|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
218990465|NCT04524546|DIAGNOSTIC_TEST|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
218990466|NCT01211470|DRUG|Daptomycin|Active Comparator: Daptomycin.
218990467|NCT01211470|DRUG|PMX-30063-investigational drug|Experimental: PMX-30063
218990468|NCT03442205|PROCEDURE|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
218990469|NCT03442205|PROCEDURE|ERCP technique + LC|ERCP technique + LC
219270801|NCT04353206|BIOLOGICAL|Multiple Doses of Anti-SARS-CoV-2 convalescent plasma|Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
219270802|NCT03316807|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
219270803|NCT03316807|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
219270804|NCT00458588|OTHER|physiologic testing|
219270805|NCT00458588|OTHER|questionnaire administration|
218990470|NCT03442205|PROCEDURE|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
218990471|NCT05534737|OTHER|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
218990472|NCT05534737|OTHER|Control|usual care of social services
218990473|NCT01193699|DRUG|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
219270806|NCT00458588|PROCEDURE|breast imaging study|
219270807|NCT00458588|PROCEDURE|dual x-ray absorptometry|
219270808|NCT00458588|PROCEDURE|evaluation of cancer risk factors|
219270809|NCT00458588|PROCEDURE|magnetic resonance imaging|
219270810|NCT05713162|BEHAVIORAL|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
219270811|NCT00387699|BIOLOGICAL|bevacizumab|
219270812|NCT00387699|DRUG|cisplatin|
219270813|NCT00387699|DRUG|etoposide|
219270814|NCT00387699|RADIATION|radiation therapy|
218990474|NCT00807729|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
218990475|NCT00807729|PROCEDURE|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
218990476|NCT05840367|BEHAVIORAL|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
218990477|NCT02352129|OTHER|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
218990478|NCT03386448|DRUG|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
218990479|NCT03386448|DRUG|placebo arm|participants will receive placebo medications
218990480|NCT01211730|DRUG|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
218990481|NCT06440720|OTHER|ELDOA ,UPPER THORACIC MOBILIZATION AND MOBILITY EXERCISE|Already mentioned
219270815|NCT06191081|PROCEDURE|lymphaticovenous anastomosis|lymphaticovenous anastomosis
219270816|NCT02046512|DIETARY_SUPPLEMENT|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
219270817|NCT02046512|OTHER|Placebo|Sugar pill
218990482|NCT03338010|DRUG|LY2963016|Administered SC
219270818|NCT06544681|PROCEDURE|Coronary stenting with planned drug eluting stent (DES).|Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.
219270819|NCT01367444|DRUG|SAR422459|"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
219270820|NCT03995342|DIETARY_SUPPLEMENT|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
219270821|NCT03995342|DIETARY_SUPPLEMENT|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
218990483|NCT03338010|DRUG|Lantus®|Administered SC
219270822|NCT01932268|DRUG|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
219270823|NCT00513747|BIOLOGICAL|rituximab|Given IV over 4 hours
219270824|NCT00513747|DRUG|fludarabine phosphate|Given IV over 30 minutes
219270825|NCT01198106|DRUG|scopolamine|0.6 mg
219270826|NCT01198106|DRUG|cinnarizine|50 mg
219270827|NCT03180567|DIAGNOSTIC_TEST|Genetic Mutations|By next generation sequencing
219270828|NCT04510181|DIETARY_SUPPLEMENT|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
219270829|NCT02181153|OTHER|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
219270830|NCT02952521|PROCEDURE|Blood Draw|CA125 and ctDNA
219270831|NCT02952521|PROCEDURE|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
219270832|NCT02499523|PROCEDURE|THR with conventional technique|THR with conventional technique.
219270833|NCT02499523|PROCEDURE|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
218990484|NCT04667871|PROCEDURE|cataract surgery|Eyes for cataract surgery
218990485|NCT01146665|BEHAVIORAL|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
218990486|NCT01146665|BEHAVIORAL|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
219270834|NCT03701048|PROCEDURE|Cesarean Section|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
219270835|NCT00505154|DRUG|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
219270836|NCT00505154|DRUG|placebo|placebo
219270837|NCT01267240|DRUG|Capecitabine|Given PO
219270838|NCT01267240|DRUG|Vorinostat|Given PO
219270839|NCT02638103|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
218990487|NCT01752361|DEVICE|Motilis-3D transit|
218990488|NCT01601730|DRUG|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
219270840|NCT02638103|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
219270841|NCT01731964|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
218990489|NCT01601730|DRUG|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
218990490|NCT01601730|DRUG|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
218990491|NCT01601730|DRUG|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
218990492|NCT03801343|DIETARY_SUPPLEMENT|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
219270842|NCT01731964|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
219270843|NCT01770795|DRUG|Genexol-PM/Gemcitabine|
219270844|NCT00214747|DRUG|Vehicle gel formulations|
219270845|NCT05864404|DRUG|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
219270846|NCT05864404|DRUG|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
218990493|NCT02696460|PROCEDURE|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
218990494|NCT02696460|PROCEDURE|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
218990495|NCT02465515|BIOLOGICAL|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
218990496|NCT02465515|BIOLOGICAL|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
218990497|NCT02465515|BIOLOGICAL|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
218990498|NCT04211883|BEHAVIORAL|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
218990499|NCT06062134|PROCEDURE|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
218990500|NCT06062134|DRUG|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
219270847|NCT05520853|RADIATION|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
219270848|NCT02292472|DRUG|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
219270849|NCT02292472|DRUG|Placebos|Inject intramuscularly once in visit 2
219270850|NCT02037620|DEVICE|5-6-5 Specify electrode|
219270851|NCT02037620|DEVICE|Restore Advance Pulse Generator|
218990501|NCT05091359|DEVICE|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
218990502|NCT01848730|DRUG|CNV2197944|
218990503|NCT01848730|DRUG|Placebo|
218990504|NCT00536185|DIETARY_SUPPLEMENT|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
218990505|NCT00536185|DIETARY_SUPPLEMENT|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
218990506|NCT01631344|OTHER|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
218990507|NCT00036517|DRUG|PHY906|
218990508|NCT00293033|DRUG|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
218990509|NCT00293033|DRUG|Placebo|
218990510|NCT00816595|BIOLOGICAL|bevacizumab|Given IV
218990511|NCT00816595|BIOLOGICAL|pegfilgrastim|Given subcutaneously
218990512|NCT00816595|BIOLOGICAL|rituximab|Given IV
219270852|NCT02933086|OTHER|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
219270853|NCT02933086|OTHER|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
219270854|NCT01005797|DRUG|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
219270855|NCT00171912|DRUG|imatinib mesylate|
219270856|NCT01810523|BEHAVIORAL|Narrative|Narrative form as described above.
219270857|NCT01810523|BEHAVIORAL|Control|Blank piece of paper
219270858|NCT04737265|OTHER|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
218990513|NCT00816595|DRUG|cyclophosphamide|Given IV
218990514|NCT00816595|DRUG|pentostatin|Given IV
218990515|NCT02685410|OTHER|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
218990516|NCT05494931|PROCEDURE|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
218990517|NCT03840798|OTHER|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets"
218990518|NCT06557655|DIETARY_SUPPLEMENT|caffeinate chewing gum|participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
218990519|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
218990520|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
218990521|NCT03583697|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
218990522|NCT03583697|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
218990523|NCT04449601|OTHER|clinical assesment|Comparison of Hypertensive group and normotensive group
218990524|NCT06557746|OTHER|Coca-Cola|100 ml Coca-Cola every 30 minutes during the operation
218990525|NCT06557746|OTHER|Supplemental oxygen|Continuous supply of oxygen (2 L/min) during the operation
218990526|NCT06555536|OTHER|Tele OI|A data collection and Telemedicine tool translated into an APP.
218990527|NCT05378178|DRUG|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
218990528|NCT03158025|DRUG|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
218990529|NCT03158025|DRUG|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
219270859|NCT00535093|DEVICE|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
219270860|NCT01379456|PROCEDURE|physiotherapy|exercises, 20 sessions over 10 weeks
218990530|NCT03158025|DRUG|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
218990531|NCT03158025|DRUG|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
218990532|NCT03158025|DRUG|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
218990533|NCT03158025|DRUG|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
218990534|NCT04889807|OTHER|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
218990535|NCT01586065|DEVICE|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
219270861|NCT00105105|DRUG|Mifepristone|
218990536|NCT06426810|DEVICE|Electrosurgical bipolar system (LigaSure)|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
218990537|NCT01122771|DRUG|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
218990538|NCT01122771|DRUG|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
218990539|NCT01122771|DRUG|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
218990540|NCT01122771|DRUG|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
218990541|NCT04395404|DIAGNOSTIC_TEST|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
218990542|NCT00981370|DRUG|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
218990543|NCT03708081|PROCEDURE|ProTaper Next|Root canal instrument
218990544|NCT03708081|PROCEDURE|TF Adaptive|Root canal instrument
218990545|NCT01826877|BIOLOGICAL|AdGMCAIX-transduced autologous dendritic cells|Given ID
218990546|NCT01826877|BIOLOGICAL|therapeutic autologous dendritic cells|Given ID
218990547|NCT01826877|OTHER|laboratory biomarker analysis|Correlative studies
218990548|NCT04184713|DIETARY_SUPPLEMENT|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
218990549|NCT04184713|DIETARY_SUPPLEMENT|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
219270862|NCT04565262|DRUG|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
218990550|NCT04851080|DEVICE|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
218990551|NCT04851080|DEVICE|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
218990552|NCT04851080|BEHAVIORAL|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
218990553|NCT06556732|DRUG|Eplereone|Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
218990554|NCT02325037|DRUG|GLPG1837 single ascending doses|Single dose, oral suspension
218990555|NCT02325037|DRUG|Placebo single dose|Single dose, oral suspension matching placebo
218990556|NCT02325037|DRUG|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
218990557|NCT02325037|DRUG|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
218990558|NCT05096793|DIETARY_SUPPLEMENT|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
218990559|NCT00679432|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
218990560|NCT00679432|DRUG|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
218990561|NCT00679432|DRUG|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
218990562|NCT00679432|DRUG|Placebo|Placebo
218990563|NCT00679432|DRUG|Asacol® 400 mg|2400 mg/day, 400 mg tablets
218990564|NCT00192569|DRUG|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
218990565|NCT00192569|DRUG|Ribavirin (HIV conifected patients only)|"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
218990566|NCT05610683|DEVICE|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
218990567|NCT04638257|BIOLOGICAL|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
218990568|NCT04638257|OTHER|Placebo|Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
218990569|NCT01040975|BEHAVIORAL|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
218990570|NCT01699360|DRUG|Cyclosporine A, Tacrolimus, Sirolimus|
218990571|NCT02369432|DRUG|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
218990572|NCT04753983|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|Diagnostic imaging measuring the metabolic changes that occur within the brain used for measuring and mapping brain activity
218990573|NCT05442814|PROCEDURE|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
218990574|NCT05442814|PROCEDURE|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
218990575|NCT03704467|DRUG|M6620|Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
218990576|NCT03704467|DRUG|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
218990577|NCT03704467|DRUG|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
218990578|NCT00002554|DRUG|busulfan|
218990579|NCT00002554|DRUG|cyclophosphamide|
218990580|NCT00002554|DRUG|methotrexate|
218990581|NCT00002554|PROCEDURE|allogeneic bone marrow transplantation|
218990582|NCT00002554|RADIATION|radioimmunotherapy|
218990583|NCT03928353|DRUG|PB2452 Infusion|30 minute - 24 hour infusion
219270863|NCT06542406|DEVICE|Endotracheal intubation|The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
219270864|NCT02745639|RADIATION|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
219270865|NCT02745639|DRUG|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
219270866|NCT02781311|DRUG|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
219270867|NCT02781311|DRUG|Placebo|Placebo tablets, orally, BID for 24 weeks.
219270868|NCT02781311|DRUG|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
219270869|NCT00597142|DEVICE|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~* Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~* Lesion length ≤15mm~* Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~* RVD 4.0-7.0mm"
218990584|NCT03928353|DRUG|Placebo - Sodium Chloride|30 minute - 24 hour infusion
218990585|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
218990586|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
219270870|NCT01299142|DRUG|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
218990587|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
218990588|NCT03928353|DRUG|PB2452 Infusion|30 minute - 16 hour infusion
218990589|NCT03928353|DRUG|Placebo - Sodium Chloride|Placebo - Sodium Chloride
218990590|NCT02339584|DRUG|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
218990591|NCT02339584|DRUG|Brinzolamide 10 mg/mL eye drops, suspension|
218990592|NCT02339584|DRUG|Brimonidine 2 mg/mL eye drops, solution|
218990593|NCT02339584|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
219270871|NCT02562898|DRUG|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
219270872|NCT02562898|DRUG|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
219270873|NCT02562898|DRUG|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
218990594|NCT02695225|BEHAVIORAL|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
218990595|NCT02695225|BEHAVIORAL|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
218990596|NCT00260481|DRUG|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
218990597|NCT00260481|DRUG|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
218990598|NCT05544734|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
219270874|NCT01262092|DRUG|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
219270875|NCT00891553|PROCEDURE|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
219270876|NCT02400775|DRUG|Azilsartan|Azilsartan tablets
219270877|NCT02694042|BEHAVIORAL|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
218990599|NCT05544734|DRUG|Acetaminophen 1000mg|1000 mg tablet
218990600|NCT05544734|DRUG|Ibuprofen 400 mg|400 mg tablet
218990601|NCT05866406|BEHAVIORAL|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
218990602|NCT05866406|BEHAVIORAL|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
218990603|NCT05866406|BEHAVIORAL|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
218990604|NCT01084083|BIOLOGICAL|cetuximab|Given IV
218990605|NCT01084083|RADIATION|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
218990606|NCT01084083|DRUG|Paclitaxel|Given IV, 90 mg/m\^2 on days 1, 8 and 15
218990607|NCT01084083|DRUG|Cisplatin|Given IV, 75 mg/m\^2 on day 1
218990608|NCT04670198|BEHAVIORAL|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
218990609|NCT04670198|BEHAVIORAL|Waiting-list control|Usual care for 6 months, followed by the YES programme.
218990610|NCT05875363|OTHER|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
218990611|NCT02914119|DRUG|Rocuronium|
219270878|NCT00328575|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
218990612|NCT02914119|DRUG|Succinylcholine|
218990613|NCT02914119|DRUG|Cisatracurium|
218990614|NCT02914119|DRUG|Mivacurium|
218990615|NCT02914119|DEVICE|Objective neuromuscular monitoring (acceleromyography)|
218990616|NCT02914119|DRUG|Sugammadex|
218990617|NCT02914119|DRUG|Neostigmine|
218990618|NCT04573712|OTHER|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
218990619|NCT00873912|BIOLOGICAL|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
219270879|NCT05638347|DRUG|HRS-7085 tablets|Single oral administration
219270880|NCT05638347|DRUG|Placebo tablet|Single oral administration
219270881|NCT04413422|DRUG|type of hypnotic used for induction of general anesthesia|
218990620|NCT00873912|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
218990621|NCT00713856|PROCEDURE|Custom PRK with iris registration|PRK
218990622|NCT00713856|PROCEDURE|Conventional PRK|PRK
218990623|NCT03915821|DEVICE|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
218990624|NCT05827380|BEHAVIORAL|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
218990625|NCT04742985|DIETARY_SUPPLEMENT|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
218990626|NCT04742985|DIETARY_SUPPLEMENT|Placebo group|Placebo 320 mg/day during 8 weeks
218990627|NCT03144960|PROCEDURE|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
218990628|NCT05774678|RADIATION|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
218990629|NCT05774678|OTHER|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
218990630|NCT05566743|DRUG|Capecitabine|maintenance capecitabine after 4 months of FOLFRINOX
218990631|NCT05566743|OTHER|follow up|follow up after 4 months of FOLFRINOX
218990632|NCT05497609|OTHER|no intervention. Care as ususal|No intervention
219270882|NCT04147858|DRUG|NYX-2925|NYX-2925 administered orally
219270883|NCT04147858|DRUG|Placebo|Placebo administered orally
218990633|NCT06149832|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
218990634|NCT04859361|DRUG|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
218990635|NCT04859361|PROCEDURE|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
218990636|NCT03145974|DEVICE|mechanical ventilation|ventilatory support
218990637|NCT05433493|BEHAVIORAL|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
218990638|NCT06180772|BEHAVIORAL|FIT FIRST|High intensity sports drills and games
218990639|NCT01088997|DRUG|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
219270884|NCT03573193|OTHER|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
219270885|NCT00751660|OTHER|laboratory biomarker analysis|
219270886|NCT00751660|OTHER|screening questionnaire administration|
219270887|NCT00751660|PROCEDURE|bronchoscopic and lung imaging studies|
219270888|NCT00751660|PROCEDURE|computed tomography|
219270889|NCT00751660|PROCEDURE|endoscopic biopsy|
219270890|NCT00751660|PROCEDURE|quality-of-life assessment|
219270891|NCT03439358|DRUG|Magnesium Sulfate|Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
218990640|NCT01797744|OTHER|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
219270892|NCT03439358|OTHER|Normal Saline|Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
219270893|NCT00006462|DRUG|gemcitabine hydrochloride|
218990641|NCT00004211|BIOLOGICAL|PSA RNA-pulsed dendritic cell vaccine|
218990642|NCT02383498|OTHER|Placebo|Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
219270894|NCT03543553|OTHER|This is not an intervention study|This is not an intervention study
219270895|NCT04312542|PROCEDURE|Measurement of Biomarkers|Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.
219270896|NCT04217772|DEVICE|Optical Coherence Tomography Angiography|A device testing the vascular density in the retina
219270897|NCT05884489|BEHAVIORAL|A gamified smartphone app-based eating behaviour intervention|All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
219270898|NCT01885169|BIOLOGICAL|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
218990643|NCT02383498|BIOLOGICAL|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
218990644|NCT02383498|RADIATION|Radiotherapy|Standard of care
218990645|NCT02383498|DEVICE|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
218990646|NCT04676074|DEVICE|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
218990647|NCT02022852|DRUG|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
218990648|NCT02022852|DRUG|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
219270899|NCT06601140|DEVICE|EMOCARE software|Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
219270900|NCT04929184|BEHAVIORAL|Speech and non-speech tasks|Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
219270901|NCT03814200|DRUG|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
219270902|NCT03814200|DRUG|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
219270903|NCT03814200|DRUG|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
219270904|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
218990649|NCT01675791|BIOLOGICAL|ALK tree AIT 0.5 DU|
218990650|NCT01675791|BIOLOGICAL|ALK tree AIT 1 DU|
218990651|NCT01675791|BIOLOGICAL|ALK tree AIT 2 DU|
218990652|NCT01675791|BIOLOGICAL|ALK tree AIT 4 DU|
218990653|NCT01675791|BIOLOGICAL|ALK tree AIT 7 DU|
218990654|NCT01675791|BIOLOGICAL|ALK tree AIT 12 DU|
218990655|NCT01675791|BIOLOGICAL|ALK tree AIT Placebo|
218990656|NCT03859505|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
218990657|NCT03859505|DEVICE|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
218990658|NCT03225885|OTHER|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
218990659|NCT03225885|OTHER|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
219270905|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
219270906|NCT05422144|DEVICE|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
218990660|NCT05871645|PROCEDURE|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
218990661|NCT05871645|PROCEDURE|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
218990662|NCT04137705|OTHER|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
218990663|NCT02100085|BIOLOGICAL|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
218990664|NCT03913312|BIOLOGICAL|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
218990665|NCT05425134|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
218990666|NCT06537817|DRUG|HT-4253|HT-4253 Single or Multiple doses administered orally as a tablet
218990667|NCT06537817|DRUG|Placebo|Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
218990668|NCT06337877|PROCEDURE|Depth of sedation monitoring|In the study, group rates of patient state index (PSI) \[(below 25); (25-50); (51-75); (above 75)\] will be determined within a 24-hour timeframe in patients undergoing therapeutic paralysis. The concordance between PSI rates\* determined at baseline (time zero) and Richmond Agitation-Sedation Scale (RASS) \[(between -4 and -5); (between -3 and -2); (equal to or greater than -1)\] rates will be assessed. Suppression rate (SR) and electromyography (EMG) values will be obtained from patients, and significant differences among PSI groups \[(below 25); (25-50); (51-75); (above 75)\] in terms of these data will be examined. Additionally, changes in Propofol (mg/hour), Midazolam (mg/hour), Fentanyl (mg/hour), and Rocuronium (mg/hour) values will be analyzed for each time interval.
218990669|NCT04280133|BEHAVIORAL|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
218990670|NCT03261973|DEVICE|DV8|DV8 esophageal deviation tool
218990671|NCT01006174|OTHER|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
218990672|NCT01006174|OTHER|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
218990673|NCT01006174|OTHER|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
218990674|NCT05695209|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
218990675|NCT06976853|DRUG|Tirzepatide|Addition of tirzepatide to current biological therapy
218990676|NCT06976853|DRUG|Standard of care treatment|Intervention will be to change patient's current therapy to a 3rd or later advanced biologic patient have never been exposed to
219270907|NCT05422144|DEVICE|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
219270908|NCT05688852|DRUG|VTX958|Dose A VTX958
218990677|NCT06387459|DEVICE|Fabric-Type Knee Extensor Muscle-Mimicking Orthosis|The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
218990678|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
218990679|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
218990680|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
218990681|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
218990682|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
219270909|NCT05688852|DRUG|VTX958|Dose B VTX958
219270910|NCT05688852|DRUG|VTX958 Placebo|Placebo
219270911|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
219270912|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
219270913|NCT01908777|OTHER|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
219270914|NCT04511234|DEVICE|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
219270915|NCT04511234|DEVICE|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
218990683|NCT07001826|PROCEDURE|Virtual Surgical Planning (VSP) with Patient-Specific Plates (PSPs)|Patients will undergo orthognathic surgery using Virtual Surgical Planning (VSP) combined with custom-fabricated Patient-Specific Plates (PSPs). High-resolution CT scans will be used to create 3D models of each patient's craniofacial structure. Surgical plans will be developed using specialized CAD software, and PSPs will be designed and manufactured using 3D printing and milling techniques. During surgery, these custom plates and accompanying cutting guides will be used to accurately reposition the maxilla, ensuring precise correction of maxillary cant. This approach aims to improve surgical accuracy, reduce operating time, and enhance postoperative outcomes.
218990684|NCT06677021|BEHAVIORAL|Exercise|Physical activity promotion and engagement
218990685|NCT07004777|OTHER|Isocaloric diet including chia and pumpkin seeds|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of pumpkin and chia seeds."
218990686|NCT07004777|DIETARY_SUPPLEMENT|Isocaloric diet plus fish oil|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates EPA + DHA supplement (fish oil) to the diet."
218990687|NCT07004777|OTHER|Isocaloric diet including salmon|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of salmon."
218990688|NCT07000383|DEVICE|Gelsectan|Gelsectan is a medical device containing xyloglucan, pea protein, and tannins, administered orally. Dosage: 2 capsules BID during Month 1, followed by 1 capsule BID during Month 2.
218990689|NCT07000383|DRUG|Antispasmodic Agent|An oral antispasmodic medication, prescribed according to standard clinical practice for IBS-D.
218990690|NCT06679699|DEVICE|Trunk control exercises combined with patient education program|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces. In addition, the experimental group provided a patient education program which focuses on the importance of trunk control and benefits of trunk control exercises during the rehabilitation process. Further, caregivers and family members were also explained about the patient education program and adherence with treatment protocol during and after the interventions.
218990691|NCT06679699|DEVICE|Trunk control exercises|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces.
218990692|NCT06865989|DEVICE|Omnipod 5 SmartAdjust 2.0 System|Omnipod 5 System with changes
218990693|NCT06865989|DEVICE|Omnipod 5 System|Cleared device as comparator
218990694|NCT06868381|DRUG|Baricitinib (LY3009104) 4 mg|baricitinib 4 mg tablet taken orally once daily
218990695|NCT06614868|BEHAVIORAL|Acceptance and Commitment Therapy|Up to 16 session of unstructured counseling therapy informed by Acceptance and Commitment Therapy tradition.
218990696|NCT06614868|BEHAVIORAL|Treatment as Usual (TAU)|Unstructured counseling
218990697|NCT07007936|DRUG|SSS17 Capsule (6 Dose Levels)|Arm1 ： This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly
218990698|NCT07007936|DRUG|Placebo Drug|Arm2：placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).
218990699|NCT06681779|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
218990700|NCT06681779|OTHER|Standard of Care (SOC)|Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
218990701|NCT06680544|DRUG|Voriconazole high dose|Oral voriconazole 200mg once a day for a maximum of 28 days
218990702|NCT06680544|DRUG|Voriconazole low dose|Oral voriconazole 200mg twice a day for a maximum of 28 days
218990703|NCT06680804|OTHER|chance for vaginal delivery.|chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy
218990704|NCT07055321|DRUG|ETH47|Dose level 1; single intranasal administration
218990705|NCT07055321|DRUG|ETH47|Dose level 2; single intranasal administration
218990706|NCT07055321|DRUG|ETH47|Dose level 3; single intranasal administration
218990707|NCT07055321|DRUG|ETH47|Dose level 4; single intranasal administration
218990708|NCT07055321|DRUG|ETH47|Dose level 5; single intranasal administration
218990709|NCT07055321|DRUG|ETH47|Dose level 1; single inhaled administration
218990710|NCT07055321|DRUG|ETH47|Dose level 2; single inhaled administration
218990711|NCT07055321|DRUG|ETH47|Dose level 3; single inhaled administration
218990712|NCT07055321|DRUG|ETH47|Dose level 4; single inhaled administration
218990713|NCT07053475|DRUG|Ferric Carboxymaltose|Intravenous infusion of 1 gram FCM during index hospital stay, followed by a second dose at Week 6 (1,000 mg if \> 70 kg or 500 mg if ≤ 70 kg).
218990714|NCT07053475|DRUG|Ferrous Sulfate|Oral administration of one 150 mg capsule every 48 hours for 12 weeks.
218990715|NCT07054775|DRUG|Morphine Sulfate|intrathecal administered morphine
218990716|NCT07053319|DRUG|Empagliflozin 25 MG plus Pioglitazone placebo|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
218990717|NCT07053319|DRUG|Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo|Placebo-Inert tablet
218990718|NCT07053319|DRUG|Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)|Pioglitazone, a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
218990719|NCT07053319|DRUG|Pioglitazone placebo + Empagliflozin placebo|Placebo-Inert tablet
218990720|NCT07055217|BEHAVIORAL|Mindfulness Training|"A single 45-minute mindfulness training will be provided to all at-risk participants at visit 2. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
218990721|NCT07055217|BEHAVIORAL|Mindfulness-based Neurofeedback (Real mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label, with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. All participants will be trained until they feel competent to use mental noting in the scanner. Study clinicians will show 85% fidelity on the mindfulness training assessment before working with participants and sessions will be recorded and 10% of sessions will be assessed quarterly for fidelity. During active mbNF (6 runs, 2.5 mins each), participants will use mental noting with the aim of controlling the visual feedback; specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
218990722|NCT07055217|BEHAVIORAL|Sham mindfulness-based neurofeedback (Sham mbNF)|During sham mbNF condition, participants will undergo similar MRI scan procedures. The primary difference in scan procedures is that rather than receiving mbNF, participants will view a visual display (i.e., white dot, red and blue circles) extracted from a previously acquired mbNF session. Thus, the visual display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures that participants across groups are viewing equivalent stimuli for the same amount of overall time.
218990723|NCT07054970|BIOLOGICAL|CT-P55|150 mg in 1.0 mL, administered as a single SC injection via PFS
218990724|NCT07054970|BIOLOGICAL|US-licensed Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
219270916|NCT03641456|DRUG|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
219270917|NCT03641456|DRUG|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
218990725|NCT07054970|BIOLOGICAL|EU-approved Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
218990726|NCT07053982|PROCEDURE|Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery|This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.
218990727|NCT07053631|DEVICE|venous occlusion pressure Measurement|non-invasive venous occlusion pressure of a targeted periorbital vein is measured in parallel to clinical standard CSF dyanmic testing including standard CSF infusiontest
218990728|NCT07053527|BEHAVIORAL|PrEP Awareness and Uptake Educational Program|This intervention targets African American college students aged 18-26 using a tailored, community participatory approach. It is delivered by trained peer educators and focuses on increasing PrEP awareness, access, and uptake through interactive, behaviorally focused sessions. Developed with input from focus groups to ensure relevance, the program includes a 6-month follow-up to assess sustained impact, distinguishing it from general PrEP education efforts.
218990729|NCT06004128|DRUG|VYD222|Monoclonal antibody
218990730|NCT05628883|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
218990731|NCT05628883|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
219270918|NCT03641456|DRUG|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
219270919|NCT04800783|DIAGNOSTIC_TEST|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
219270920|NCT00280865|DRUG|Tesaglitazar|
219270921|NCT00280865|DRUG|Pioglitazone|
219270922|NCT00280865|BEHAVIORAL|Dietary and Lifestyle Modification Counseling|
219270923|NCT06972212|DRUG|suzetrigine 100mg|Suzetrigine is an inhibitor of the NaV1.8 voltage-gated sodium channel and FDA approved for the treatment of moderate-to-severe acute pain in adults
218990732|NCT05628883|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
218990733|NCT05628883|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
219270924|NCT06972212|OTHER|Placebo|biologically inactive placebo comparator
219270925|NCT03512197|DRUG|Midostaurin|Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
219176255|NCT05364879|BEHAVIORAL|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
219176256|NCT04119544|OTHER|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
219176257|NCT04119544|DEVICE|Intensive Visual Simulation|"* First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
219176258|NCT02008045|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
219176259|NCT02008045|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
219176260|NCT05674539|DRUG|Fludarabine and Busulfan|Fludarabine with total dose of 150 mg/m\^2 in combination with Busulfan with total dose of 6.4 mg/kg
219176261|NCT05674539|DRUG|Fludarabine and Melphalan|Fludarabine with total dose of 150 mg/m\^2 in combination with Melphalan with total dose of 140 mg/m\^2
219176262|NCT06636708|COMBINATION_PRODUCT|Nanodropper and Proparacaine HCl 0.5%|The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
219176263|NCT06636708|COMBINATION_PRODUCT|Standard Eye Drop Bottle with Proparacaine HCl 0.5%|This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
219176264|NCT06637904|DIAGNOSTIC_TEST|TriVerity Test|Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
219176265|NCT03719443|BIOLOGICAL|VIS649|Single IV dose of study product on Day 1 of study
219176266|NCT03719443|BIOLOGICAL|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
219270926|NCT03512197|DRUG|Placebo|Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
219270927|NCT03512197|DRUG|Chemotherapy|Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
219270928|NCT03842436|DEVICE|Digital pill|Digital pills over encapsulating Truvada
219270929|NCT03842436|DRUG|Truvada|Truvada prescribed with digital pills for PrEP
219270930|NCT01155076|DIETARY_SUPPLEMENT|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
219270931|NCT01155076|DIETARY_SUPPLEMENT|Placebo|Placebo taken twice a day for 8 weeks
219176267|NCT06315959|PROCEDURE|Bilateral ultrasound guided erector spinae plane block|"Bilateral ultrasound-guided ESP(total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS).~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
219176268|NCT06315959|DRUG|morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
219176269|NCT06315959|OTHER|Control group|"Patients in this group will not be performed plane blocks. Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS) .~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
219176270|NCT06315959|DRUG|morphine PCA|V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
219176271|NCT06638229|DEVICE|The StimaWELL 120MTRS system|A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
219176272|NCT06365125|BEHAVIORAL|eCHECKUP TO GO|Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
219176273|NCT06365125|BEHAVIORAL|Text messaging boosters|Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
219176274|NCT05586516|DRUG|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
219270932|NCT06038851|PROCEDURE|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~* The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~* The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~* In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
219176275|NCT05647369|DIETARY_SUPPLEMENT|Mastic mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
219176276|NCT05647369|DIETARY_SUPPLEMENT|Placebo mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
219176277|NCT05080842|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
219270933|NCT06038851|PROCEDURE|Femoral Triangle Block (FTB)|"* The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
219270934|NCT06038851|PROCEDURE|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
219176278|NCT06643052|OTHER|No intervention|No intervention
219176279|NCT05845476|OTHER|Patient SOGI Self-Report|"EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record."
219176280|NCT05845476|OTHER|SOGI Resource for Clinical Care Education (SORCE)|SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
219176281|NCT05845476|OTHER|Cancer Center Care Environment|At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
219270935|NCT03514381|DRUG|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)"
219270936|NCT03893110|PROCEDURE|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
219176282|NCT06638866|DIAGNOSTIC_TEST|PDAC|Participants with algorithm-identified PDAC will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
219176283|NCT06638866|DIAGNOSTIC_TEST|Pancreatic precursor lesions|Participants with algorithm-identified pancreatic precursor lesions will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
219176284|NCT06642428|DRUG|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
219176285|NCT06642428|DRUG|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
219176286|NCT06638853|BEHAVIORAL|Distress Tolerance Skills Training|"These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions."
219270937|NCT05026268|PROCEDURE|intracorporeal anastomosis|"intracorporeal stapled side-to-side isoperistaltic anastomosis"
219270938|NCT01939301|DRUG|Inhaled Nitric Oxide|Nitric Oxide + oxygen
219270939|NCT01939301|DRUG|Sham|Nitrogen + Oxygen
219176287|NCT06637254|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
219176288|NCT06637254|DRUG|Placebo|the placebo comparator of study
219176289|NCT06641284|DRUG|Spironolactone|All patients will receive Spironolactone as a part of their GDMT for Heart Failure
219176290|NCT06556394|DRUG|RAG-17|RAG-17 is a therapeutic small interfering RNA (siRNA).
219176291|NCT06556394|DRUG|Placebo|Placebo will be administered via intrathecal injection
219176292|NCT06556940|BIOLOGICAL|LMN-401|Orally delivered tablets and capsules
219176293|NCT04924660|DRUG|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
219176294|NCT04924660|DRUG|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
219176295|NCT04924660|DRUG|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
219270940|NCT02201901|DRUG|SOF/VEL|400/100 mg tablets administered orally once daily
219270941|NCT02201901|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219176296|NCT04924660|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
219176297|NCT04769765|OTHER|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
219176298|NCT05275855|DRUG|EDI048|Oral Liquid
219176299|NCT05275855|OTHER|Placebo|Oral Liquid
219176300|NCT05957536|BIOLOGICAL|D3L-001|Intravenous administration
219270942|NCT00490698|DRUG|Zoledronate|4 mg IV Once Every 4 Weeks
219270943|NCT00490698|DRUG|Atorvastatin|20 mg PO Daily
219176301|NCT03707691|BEHAVIORAL|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
219176302|NCT03707691|BEHAVIORAL|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
219176303|NCT03707691|BEHAVIORAL|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
219176304|NCT05712564|OTHER|Questionnaire|Questionnaire for fatigue assessment
219176305|NCT06643195|OTHER|ImmediateAllogeneic Hematopoietic Stem Cell Transplantation|patients proceeded to allogeneic HSCT as soon as possible. Patients were allowed to receive low-dose chemotherapy that is not intended for the purpose of achieving a second remission.
219176306|NCT06643195|OTHER|Retreatment|Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
219176307|NCT06082739|OTHER|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
219176308|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
219176309|NCT06643494|DIETARY_SUPPLEMENT|N-111|A combination of Acetogenins
219176310|NCT06643494|OTHER|Placebo|Placebo
219176311|NCT05596630|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
219176312|NCT05165407|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
219176313|NCT05165407|DRUG|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
219176314|NCT05165407|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
219176315|NCT06557577|OTHER|No intervention group.|There is no intervention group.
219176316|NCT05818332|OTHER|Observational study|No intervention, observational only
219176317|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
219176318|NCT06576765|DRUG|AZD0780|Dose 1
219270944|NCT01654068|RADIATION|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
219270945|NCT00611169|DRUG|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
219270946|NCT05137925|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
219270947|NCT05137925|BEHAVIORAL|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
219270948|NCT01431950|DRUG|fluticasone furoate|Inhaled corticosteroid
219270949|NCT01431950|DRUG|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
219176319|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
219176320|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
219270950|NCT03210649|DRUG|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14
219270951|NCT03210649|DRUG|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
219176321|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
219176322|NCT03557697|BEHAVIORAL|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
219176323|NCT03557697|BEHAVIORAL|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
219270952|NCT00101998|DRUG|alvimopan|
219270953|NCT00101998|DRUG|placebo|
219176324|NCT05052723|DRUG|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
219176325|NCT05052723|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
219176326|NCT05402202|OTHER|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
219176327|NCT05402202|OTHER|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
219176328|NCT04572399|DEVICE|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
219176329|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
219176330|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
219176331|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
219176332|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
219176333|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
219176334|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
219176335|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
219176336|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219176337|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219176338|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219176339|NCT06576882|DRUG|Vonoprazan|Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
219176340|NCT06576882|DRUG|Amoxicillin|Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
219176341|NCT06576882|DRUG|Clarithromycin|Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
219176342|NCT05270733|DRUG|Ustekinumab|Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
219270954|NCT00129142|DRUG|Toremifene Citrate|
219270955|NCT04588766|OTHER|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
219176343|NCT04711278|DEVICE|Mask-wearing hypnosis|"Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient."
219176344|NCT04711278|OTHER|Without hypnosis|No hypnosis during surgery of Hallux valgus.
219270956|NCT04588766|OTHER|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
219270957|NCT00895726|DRUG|APD209|Oral tablets twice per day for 56 days
219270958|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
219176345|NCT06576596|OTHER|apnoeic Oxygenation|One approach to preventing adverse respiratory events due to hypoxaemia during paediatric anaesthesia is the use of apnoeic oxygenation. The principle is to deliver oxygen to the airways of anaesthetised patients via a conventional nasal cannula. As less carbon dioxide is produced than oxygen is consumed during apnoea, the supply of oxygen to the upper airways leads to an 'inward diffusion' of oxygen, which may prolongs the time until desaturation and hypoxaemia occur.
219176346|NCT05932485|PROCEDURE|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
219176347|NCT06263101|OTHER|Biochemical testing of abdominal drainage fluid|Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).
219176348|NCT06263101|OTHER|Cytological examination of abdominal drainage fluid|Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)
219176349|NCT06263101|OTHER|Peripheral blood cytology tests|Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
219176350|NCT06528964|DIAGNOSTIC_TEST|Immunohistochemistry and immunofluorescence|Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
219176351|NCT05662631|DEVICE|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
219176352|NCT05048706|DEVICE|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
219176353|NCT05048706|DEVICE|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
219176354|NCT03153527|DRUG|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
219176355|NCT03153527|OTHER|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
219176356|NCT05743673|DEVICE|Shape II|cardiopulmonary exercise testing apparatus
219176357|NCT03189641|DEVICE|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
219176358|NCT04458883|PROCEDURE|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
219176359|NCT04458883|PROCEDURE|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
219176360|NCT04458883|PROCEDURE|Electrocardiogram|Electrocardiogram
219176361|NCT04458883|PROCEDURE|Echocardiogram|Echocardiogram
219176362|NCT04749615|DRUG|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
219270959|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
219270960|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
219270961|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
219270962|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
219270963|NCT05455203|BEHAVIORAL|ADAPT-ITT|ADAPT-ITT is an implementation framework that guides adaptation of evidence-based interventions (EBI) for specific settings/populations. It will be used to adapt target interventions with a Family and Community Advisory Board. It has 8 phases: (1) Assess the risk profile of Black families in Paterson and East Orange, (2) Adopt or adapt an EBI, (3) Administer novel methods with families and children to facilitate the adaptation process, (4) Plan on what aspects of the EBI need to be adapted/how best to evaluate the adapted EBI, (5) Identify additional experts to assist in the adaptation process, (6) Integrate material from experts to adapt the EBI, (7) Train staff to implement the adapted intervention, and (8) Test the adapted intervention. Given time and financial constraints, five phases will be completed at the end of the pilot study. Qualitative data collected from individual dyad interviews will be used to inform the data.
219270964|NCT06590675|DRUG|Chlorhexidine Gluconate (CHG)|A locally-prepared CHG formulation as a 1% or 2% solution
219270965|NCT05275972|DRUG|Ripasudil|Topical Ripasudil 0.4%
219270966|NCT05275972|DRUG|Placebo|Topical Placebo
219270967|NCT07043777|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|Bilateral modified catheter antegrade cerebral perfusion technique applied during acute type A aortic dissection repair; avoids additional right-axillary incision while providing continuous cerebral flow.
219270968|NCT07043777|PROCEDURE|Conventional Brain Perfusion|Conventional cerebral perfusion strategy (e.g., standard bilateral antegrade cerebral perfusion) used during arch repair according to surgeon preference.
219176363|NCT04749615|DRUG|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
219176364|NCT06220071|OTHER|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
219176365|NCT05686590|BEHAVIORAL|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
219176366|NCT05363631|DRUG|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
219176367|NCT05363631|DRUG|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
219176368|NCT05363631|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy
219176369|NCT06491758|DEVICE|ML1101 Stimulus Isolator|Electrical stimulation electrodes will be placed on the ear with the intensity of the current being increased by 10 percent every 60 seconds, the subject will grade the intensity of the current on a scale of 0-10. Increasing of the current will occur until the subject reports a comfortable level. Once the target level has been achieved the stimulation will be delivered for 2 minutes.
219176370|NCT06491758|PROCEDURE|Vagal Maneuver|"Subjects will undergo the following procedures to stimulate the vagus nerve.~* Cough: 6 to 8 forceful coughs~* Cold stimulus: a washcloth soaked in ice water will be placed on the face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor will be inserted for 10 seconds into the mouth touching the back of the mouth.~* Valsalva maneuver: subjects will will be asked to bear down as if they were having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a machine that measures how hard they are blowing.~* Eating: Subjects will be asked to drink water ( 8oz or 1 cup) or/ and Ensure Original ( 8 oz or 1 cup) that has 220 calories after fasting overnight to see that effect on vagal activity during eating."
219176371|NCT04121858|OTHER|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
219176372|NCT04121858|OTHER|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
219176373|NCT03611491|DEVICE|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
219176374|NCT06445556|BEHAVIORAL|NatureUplift|a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.
219176375|NCT06445556|BEHAVIORAL|NatureUplift+Active|NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
219176376|NCT03810287|DRUG|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
219176377|NCT05499897|PROCEDURE|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
219176378|NCT05499897|PROCEDURE|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
219176379|NCT03769415|DEVICE|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
219176380|NCT04676022|DEVICE|WaveWriter|To receive Spinal Cord Stimulation programming
219176381|NCT04676022|OTHER|Conventional Medical Managament|To receive conventional medical management
219176382|NCT03736720|DRUG|Fluorouracil|Given IV
219176383|NCT03736720|DRUG|Leucovorin|Given IV
219176384|NCT03736720|DRUG|Liposomal Irinotecan|Given IV
219176385|NCT03736720|PROCEDURE|Quality-of-Life Assessment|Correlative studies
219176386|NCT05620342|BIOLOGICAL|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
219176387|NCT06513936|PROCEDURE|The skin care Bundle|S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown
219176388|NCT06513936|PROCEDURE|Routine care|Routine care delivered in the unit
219176389|NCT04188470|BEHAVIORAL|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
219176390|NCT06425198|DRUG|BMS-986278|Specified dose on specified days
219270969|NCT06717815|DRUG|IPG11406|"Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed."
219270970|NCT06721494|DRUG|Methamphetamine|Methamphetamine HCl for intravenous administration
219176391|NCT02914951|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
219176392|NCT02914951|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
219176393|NCT03373071|BIOLOGICAL|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
219176394|NCT06050109|DRUG|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
219176395|NCT06050109|DIAGNOSTIC_TEST|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
219176396|NCT02235909|DRUG|Azilsartan Medoxomil Low-dose|Azilsartan medoxomil low-dose (AZM-L) 10 mg
219176397|NCT02235909|DRUG|Losartan|
219270971|NCT06721494|DRUG|Sterile Saline|Sterile Saline for intravenous administration
219176398|NCT02235909|DRUG|Placebo for Azilsartan Medoxomil|
219176399|NCT02235909|DRUG|Placebo for Losartan|
219176400|NCT02235909|DRUG|Azilsartan Medoxomil Medium-dose (20 mg)|Azilsartan medoxomil medium-dose (AZM-M) 20 mg
219176401|NCT02235909|DRUG|Azilsartan Medoxomil High-dose (40 mg)|Azilsartan medoxomil high-dose (AZM-L) 40 mg
219176402|NCT02235623|PROCEDURE|Single-stage Fowler-Stephens orchidopexy (FSO)|
219270972|NCT06721494|DRUG|CS-1103|CS-1103 for intravenous administration
219270973|NCT07050134|DRUG|DR10624 Injection；|"The experimental group(Trial Drug)~* Name: DR10624 Injection (referred to as DR10624)~* Specification: 60mg (1mL)/vial~* Active Ingredient: DR10624~* Route of Administration: Subcutaneous injection~* Packaging: Vial~* Expiry Date: See the drug label~* Storage Conditions: 2\~8℃, protected from light~* Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd.~* Supplier: Zhejiang Daor Biotechnology Co., Ltd."
219176403|NCT02235623|PROCEDURE|Two-stage Fowler-Stephens orchidopexy (FSO)|
219176404|NCT06435299|DRUG|Cannabis oil|Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
219176405|NCT06435299|DRUG|Placebo|Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
219176406|NCT05538533|RADIATION|46 Gy Radiation Therapy|Dose per fraction of 4.6.
219176407|NCT05538533|RADIATION|40 Gy Radiation Therapy|Dose per fraction 5.7.
219176408|NCT05538533|RADIATION|35 Gy Radiation Therapy|Dose per fraction 7.0.
219270974|NCT07050134|DRUG|DR10624 Injection Placebo (referred to as placebo)|(The control group)Placebo: Name: DR10624 Injection Placebo (referred to as placebo) Specification: 0mg (1mL)/vial (no active ingredient) Main Component: Normal saline Route of Administration: Subcutaneous injection Packaging: Vial Expiry Date: See the drug label Storage Conditions: 2\~8℃, protected from light Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. Supplier: Zhejiang Daor Biotechnology Co., Ltd.
219270975|NCT07050524|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Participants assigned to the experimental group will receive Omega-3 fatty acids supplementation as part of their treatment regimen. The Omega-3 supplementation will consist of high-quality fish oil capsules, providing a daily dose of \[specific dosage, e.g., 2000 mg of EPA and DHA combined\], taken orally. This supplementation will commence concurrently with the initiation of neoadjuvant immunotherapy and will continue throughout the treatment period.
219270976|NCT07050524|DRUG|Neoadjuvant Immunotherapy|"Participants in both the experimental and control groups will receive neoadjuvant immunotherapy designed to stimulate the body's immune response against locally advanced gastric and gastroesophageal junction adenocarcinomas. The specific regimen will involve administration of \[specific immunotherapeutic agents, e.g., pembrolizumab, nivolumab, etc.\] in accordance with established clinical protocols.~The neoadjuvant immunotherapy will be administered through intravenous infusion, typically starting \[specify timeline, e.g., 4-6 weeks\] prior to surgical resection of the tumor. Treatment cycles will be scheduled every \[specify interval, e.g., 2 or 3 weeks\], depending on the specific agent used and participant response."
219176409|NCT05065970|DRUG|Felzartamab|anti-CD38+ monoclonal antibody
219270977|NCT07051135|DEVICE|"HablaRÉ: Emotional Reasoning bias correction training"|"The HablaRÉ bias correction training for Emotional Reasoning consists of ten online, self-administered sessions that last no more than 30 minutes each. These courses include practice tasks in addition to textual and audio-visual content. The explanation of ER bias, motivation to change, emotional psychoeducation, and the distinction between emotionally biassed and objective information are all addressed."
219270978|NCT07050849|BEHAVIORAL|Slackline Training|This intervention consisted of a six-week supervised slackline training program designed to improve core stability, physical performance, and dynamic balance. Participants in the intervention group performed 18 sessions (3 sessions per week, 45 minutes each) using a Gibbon-brand slackline (12.5 meters in length, 50 mm wide). The training protocol included a structured progression of 11 exercises, ranging from assisted standing to unassisted long walks and dynamic movements on the slackline. All sessions were conducted under the supervision of a licensed physiotherapist to ensure participant safety and training fidelity. Exercises were adapted weekly to increase difficulty, challenge motor control, and stimulate neuromuscular adaptation.
219270979|NCT07049302|COMBINATION_PRODUCT|Conventional Risk Factor Assessment|Participants in Group 1 will undergo evaluation for conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS
219176410|NCT05065970|OTHER|Placebo|Placebo comparator
219176411|NCT03547869|DEVICE|Active tDCS|Active tDCS will be adminestered
219176412|NCT03547869|DEVICE|Sham tDCS|Sham tDCS will be administered
219176413|NCT05591144|DRUG|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
219176414|NCT05591144|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
219176415|NCT06072105|OTHER|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
219176416|NCT06072105|OTHER|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
219176417|NCT05595239|DEVICE|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
219176418|NCT05595239|DEVICE|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
219176419|NCT05595239|DEVICE|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
219270980|NCT07049302|COMBINATION_PRODUCT|Non-Conventional Risk Factor|Participants in Group 2 will be assessed for non-conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS).
219176420|NCT05757596|DRUG|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
219176421|NCT05757596|DRUG|Placebo|0.9% Saline, volume matched
219176422|NCT06178198|PROCEDURE|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
219176423|NCT04266210|DEVICE|Fuji Bulk|Restorative system
219176424|NCT04266210|DEVICE|G-ænial Posterior|Restorative system
219176425|NCT05559671|BIOLOGICAL|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
219176426|NCT05559671|BIOLOGICAL|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
219176427|NCT04585035|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
219176428|NCT04585035|DRUG|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
219176429|NCT03194217|DRUG|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
219176430|NCT03194217|DRUG|Placebo|Placebo
219176431|NCT06666517|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Routine surgery after neoadjuvant chemotherapy for breast cancer according to current guidelines.
219176432|NCT06666517|OTHER|Immunohistochemistry Analysis|Determination of breast cancer subtypes through immunohistochemical analysis, and selection of Luminal B, HER2-positive, and triple-negative groups.
219176433|NCT06666517|PROCEDURE|Second Biopsy|Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
219176434|NCT06484309|BEHAVIORAL|Reflexology Group|"* In the 3rd stage of labor, local anesthesia (5 ml lidocaine 2%) will be applied and episiotomy repair will begin.~* Reflexology application will be started at the same time,~* Reflexology application will continue for at least 20-30 minutes during the episiotomy repair until the episiotomy repair is completed,~* Pain will be evaluated with VAS to determine the pain level four times in total: just before suturing, during perineal suturing (internal), during skin suturing and immediately after suturing is completed,~* Approximately 15-20 minutes after the end of the episiotomy repair, a face-to-face interview will be held and the McGill Pain Questionnaire will be filled out."
219270981|NCT07050901|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Kolcaba's Nursing Care Applications Based on Comfort Theory were carried out individually; each application was planned for one and a half hours, one day a week and for 8 weeks, and each session was carried out for each individual through home visits. The topics of Nursing Care Based on Kolcaba's Comfort Theory were; Physical Care Practices (2 weeks), Psychospiritual Care Practices (2 weeks), Environmental Care Practices (2 weeks) and Sociocultural Care Practices (2 weeks).
219176435|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
219176436|NCT06045936|DRUG|Placebo|Saline injection
219270982|NCT07049718|DEVICE|whole body vibration|Whole-body vibration (WBV) is a training method that uses mechanical vibration and external resistance loading to stimulate the body, causing muscle vibration and increasing central nervous system adaptations (Rittweger, 2010).
219270983|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
219176437|NCT03784248|OTHER|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
219176438|NCT06801431|DEVICE|Transcutaneous spinal cord stimulation|Individuals will receive a 10-day course of daily, 30-minute sessions of transcutaneous spinal cord stimulation to the thoracolumbar spine cord using the Chattanooga Mobile 2 Stim Device. These sessions will be conducted in the morning before bowel care and therapy. Cathode pads will be placed between the T10 and T11 spinous processes and the T12 and L1 spinous processes. Anode pads will be placed over the iliac crests. Stimulation will consist of 1 millisecond duration, biphasic pulses, at 30 Hertz frequency. The intensity of the current, will be adjusted to be suprasensory and sub-motor, and no more than 140 milli-amperes.
219176439|NCT06801691|OTHER|Experimental: Intervention group|Educational materials: Iodine Feedback Tool, lecture on the topic of iodine and health, booklet, exercises, group assignments and a webpage This is a pre/post intervention with no control group.
219176440|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
219270984|NCT06934694|DEVICE|Instrument-Assisted Soft Tissue Mobilization|Participants will receive a single session of instrument-assisted soft tissue mobilization (IASTM) applied to the gastrocnemius muscle using a stainless-steel instrument. The treatment consists of longitudinal and transverse strokes targeting both the medial and lateral heads of the muscle. The procedure will be performed by a trained clinician, following a standardized protocol lasting approximately 5 minutes. The goal is to induce mechanical and neuromodulatory effects on muscle tissue. This intervention is designed to assess acute changes in muscle stiffness (via shear-wave elastography) and ankle dorsiflexion range of motion (via the weight-bearing lunge test).
219270985|NCT06944327|PROCEDURE|MANAGEMENT CARE|Administration of the sealing element after canalization and initial treatment of the device, prior to fixation with a suture system and a 7-day vs. 14-day cadence test.
219176441|NCT06800690|DIAGNOSTIC_TEST|Urinary Estrogen Level|Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.
219176442|NCT06800495|BEHAVIORAL|THALEA (Thalassemia Education and Awareness) Kit|"By using the opinions obtained by the experts, THALEA's content will then be designed using the Theory of Planned Behaviour (TPB) by Ajzen and Fishbein.~Development of THALEA:~• Language: Malay and English.~• Contents of the THALEA kit: i. PowerPoint or Canva presentations with discussion prompts (softcopy form) ii. Links/joining codes to free educational game platforms such as Kahoot or Quizziz iii. Videos - convey messages on thalassemia awareness and screening importance.~iv. Illustrated guides/brochures - to provide step-by-step tutorials on how to get thalassemia screening in both the public and private healthcare.~• Developer would be the main researcher with aid from: i. Illustrator ii. Video graphic designer iii. Influencers~• Delivery of THALEA to students by: i. Medical personnel"
219176443|NCT06800495|BEHAVIORAL|Basic thalassemia and family health education|They are basic family health education in which it is the usual family health education given by the MOH, usually delivered by a medical officer, to fourth form students at government schools prior to the thalassemia screening programme. It will consist of a delivery of a PowerPoint presentation and videos, that will be obtained from government public health clinics in Klang Valley.
219176444|NCT06570655|DRUG|Huperzine A injection|intramuscular
219270986|NCT06944327|OTHER|traditional care|Traditional cure administration with sutureless device fixation every 7 days
219270987|NCT06944613|DEVICE|Augmented reality-based programme/Microsoft Hololens version 2|Participants play two exergames, the aim of this process is to engage cognitive double tasks
219270988|NCT06945679|DRUG|CPLE|It will be a double-blind study,CPLE and Placebo will be marked as either Group A or Group B.Half of the patients will receive Group A and other half will receive Group B drug along with standard treatment according to national guideline,Each participant will receive either CPLE or Placebo,500 mg 2 capsules three times daily for 5 days and will be followed up daily upto study day 5.
219176445|NCT06570655|DRUG|Huperzine A injection|intravenous bolus
219176446|NCT06801119|DRUG|HN2301 injection|Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
219176447|NCT06800924|OTHER|Postural and mobility analysis|Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)
219176448|NCT05003739|PROCEDURE|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
219176449|NCT06429436|BEHAVIORAL|VENDY|At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
219176450|NCT06801613|OTHER|Intervention Group|Group/Cohort Description: Participants with Upper Cross Syndrome (UCS) who undergo the prescribed exercise or treatment protocol.
219176451|NCT05581745|PROCEDURE|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
219176452|NCT05965609|BEHAVIORAL|CBTI|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
219176453|NCT05965609|BEHAVIORAL|MRTI|Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
219176454|NCT06800742|OTHER|Collection of anthropometric and biochemical parameters|Collection of anthropometric parameters biochemical parameters basal metabolic rate body composition questionnaires
219176455|NCT05481320|BEHAVIORAL|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
219176456|NCT05481320|BEHAVIORAL|Enhanced Control|A single phone session providing education about dementia.
219176457|NCT05894577|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
219176458|NCT05894577|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
219176459|NCT05784584|PROCEDURE|Blood samples collection|The study population will take blood samples for virological and immunological measurements.
219176460|NCT05876598|DRUG|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
219176461|NCT06323408|DIAGNOSTIC_TEST|Tissue, blood, cerebrospinal-spinal fluid|Processing, analysis
219176462|NCT05093478|DRUG|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
219176463|NCT05093478|DRUG|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
219176464|NCT06800937|OTHER|Determination of sphingolipidomic profile|The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.
219176465|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
219176466|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
219176467|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
219176468|NCT06297434|DRUG|Placebo|Orally, once daily before meals
219176469|NCT04509674|DRUG|Empagliflozin|Empagliflozin
219176470|NCT04509674|DRUG|Placebo|Placebo
219176471|NCT04636229|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
219270989|NCT06945679|DRUG|Placebo|"The patients will be assigned to visually matched placebo 2 capsule t.i.d for 5 days The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR). On receipt, the medications will be stored in a secure area at room temperature. Enrolled patients will receive CPLE or placebo for 5 days.~Clinical data will be captured on structured case report forms."
219176472|NCT04636229|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
219176473|NCT06800612|DRUG|Oncologic drugs administered for treatment of breast cancer|Data on oncologic drugs administered for treatment of breast cancer will be recorded
219176474|NCT06800612|DRUG|Oncologic drug administered for treatment of gynecologic cancer|Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
219176475|NCT06801990|PROCEDURE|S1 transforaminal epidural steroid(dexamethasone) injection|"The designed study will examine the effect of oblique entry angles on contrast distribution patterns and treatment outcomes. Therefore, it aims to compare the smallest and largest angles that can be achieved under co-axial imaging at the S1 foramen. For this purpose, patients will be divided into two groups through randomization using a computer program. In the first group, after angling cranially and visualizing the foramen, the needle entry point will be determined. In the second group, after achieving optimal imaging by cranially angling the C-arm fluoroscope, an additional ipsilateral oblique angle will be applied to the fluoroscope.~In this context, Plastaras et al. reported that an angle of 5° ± 5° is the most suitable range for the S1 foramen. Additionally, another study examining dorsal and ventral S1 foramen via tomography images found that the average angle providing the widest view of the dorsal foramen was 26.6° ± 3°. In the current study, no oblique angle will be applied"
219176476|NCT02972801|PROCEDURE|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
219176477|NCT06801132|BEHAVIORAL|Online self-delivered death anxiety intervention|"The online self-guided death anxiety intervention developed in this study is based on the Death Education and CBT framework. It took approximately two hours to complete the full intervention. The main content includes:~1. Emotional reactions and behavioral manifestations about death, fear management theories, and Chinese cultural attitudes toward death;~2. Imagine what you would like to say to yourself at the end of your life, and learn about various attitudes towards death through numerous examples;~3. Expressive writing, with moderate emotional exposure to stimulate reflection, accompanied by breathing exercises and positive thinking about death, to improve tolerance and control of death anxiety, and finally to correct biased perceptions by examining bad beliefs about death;~4. Prioritize the importance of things and make a practical action plan to enrich your life."
219176478|NCT06801132|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked not to use our death anxiety intervention or seek additional help related to death anxiety during the 1-week intervention period. After the one-month follow-up of the experimental group, the WL group will receive the same intervention for death anxiety. WL participants will also be given contact information to use in case of increasing distress.
219176479|NCT06800911|OTHER|Questionnaires|Metacognition Questionnaire Penn State Worry Questionnaire Ruminative Response Scale Anger Rumination scale Difficulties in Emotion Regulation Scale Emotional Eating subscale of the Dutch Eating Behavior Questionnaire
219176480|NCT06800677|PROCEDURE|Hysterectomy|Elective hysterectomy
219270990|NCT06944184|DEVICE|Intraarticular microdialysis|The intervention decive is placed during the routine surgery to remove the infected knee prosthesis and implantation of the static cement spacer. A microdialysis catheter is implemented to generate continious intra-articular samples of the knee joint. To ensure complete removal and no damage of the membrane it is inserted via a regular drainage tube. The catheter membrane is placed intra-articularly next to the spacer and continious to an outlet tube for sample collection.
219270991|NCT06945315|PROCEDURE|RALP (Robotic-assisted radical prostatectomy)|Robotic-assisted radical prostatectomy (RALP) is a standard surgical procedure for managing localized prostate cancer that focuses on prostate anatomy and surrounding structures to enable personalized surgeries. The procedure incorporates nerve-sparing techniques through careful dissection of the neurovascular bundle and can use a thermal and traction-free dissection to improve functional outcomes, particularly erectile function.
219176481|NCT06800898|OTHER|Blood samples and Questionnaires|"Blood samples for methylation of the promoter of the OX-A and OX-B genes and questionnaires:~Eating Disorder Examination Q Eating Disorder Inventory 3 Major Depression Inventory Symptom Checklist-revised ESS - Epworth Sleepiness Scale Pittsburgh Sleep Quality Index Horne \& Ostberg questionnaire"
219176482|NCT06457945|BEHAVIORAL|ASRT|The task involves the presentation of a visual stimulus in one of four horizontal locations on the screen, and participants are instructed to indicate the location of the target stimulus by pressing the corresponding key on the keyboard. In case of correct response, the target stimulus disappears, and after a 120 ms interstimulus interval, the next stimulus appears. In case of an incorrect response, the target stimulus remains in place until the first correct response. The stimuli follow a probabilistic eight-element sequence, with pattern and random elements alternating with each other. Each participant will be assigned to one of 24 possible sequences throughout the task. The ASRT task will be composed of 25 blocks, with each block containing ten repetitions of the eight-element sequence. After each block, participants will have to take a short break and answer the thought probes before continuing. All patients will perform the task one time.
219176483|NCT06457945|BEHAVIORAL|Questionnaires|"All patients will have to fill questionnaire at the beginning of the study~* Spontaneous and Deliberate Mind Wandering Scales (SDMWS)~* Epworth Sleepiness Scale~* Narcolepsy Severity Index~* Idiopathic Hypersomnia Severity Scale~* Hospital Anxiety and Depression scale~* Horne \& Ostberg questionnaire~* Attention Deficit Hyperactivity Disorder (ADHD) auto-evaluation~* Pittsburgh Sleep Quality Index~* Insomnia Severity Index~* Psychotic-like experiences scale"
219176484|NCT06457945|DEVICE|Electrophysiological recordings|A subset of patients in each arm will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT
219176485|NCT04336228|DRUG|Escitalopram|20mg daily for 3-4 weeks.
219176486|NCT04336228|DRUG|Placebo oral tablet|20mg placebo tablet daily for 3-4 weeks.
219176487|NCT05620771|DRUG|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
219176488|NCT05620771|DRUG|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
219176489|NCT02474862|BEHAVIORAL|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
219176490|NCT02474862|BEHAVIORAL|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
219176491|NCT01214616|DRUG|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
219176492|NCT01214616|DRUG|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
219270992|NCT06945315|DRUG|SAFE (Saline assisted fascial engorgement)|SAFE (Saline assisted fascial engorgement) an innovative technique to achieve enhanced nerve-sparing outcomes among patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). Essentially a new method of hydro dissection, SAFE involves an injection of 30 cc of normal saline solution between the layers of the periprostatic fascia after early release of the neurovascular bundle. This injection effectively pushes the nerves away from the prostate, enabling a dissection of the prostate that is atraumatic vis a vis the neural hammock.
219270993|NCT06944288|PROCEDURE|total knee replacement|The Orthopedic Surgeon will remove the damaged cartilage and bone then implant the new metal and plastic knee to restore the alignment and function of your knee. The surgical procedure takes about 1-2 hours on average. While in case of infection, an antibiotic cement is inserted, which will be removed with the subsequent prosthetic implant surgery. Finally, prosthetic components can be more filling, depending on the amount of bone that is previously removed.
219270994|NCT06945185|PROCEDURE|Intervention Group A Conventional Physical Therapy|"Active Range of Motion Exercises: (5-10 reps with 2 sets) Finger bends, finger spreads, finger to thumb opposition, thumb to palm stretches, palm up and down, wrist rotation, wrist bends, elbow bends, shoulder shrugging and shoulder rotation.~Strengthening Exercises: (10-15 reps 2 sets weight 500 ml to 1L water bottle). Finger pinch, power grip, finger spread, pushing movement, wrist curls, roll and squeeze, bicep curls, side arm raise, lifting objects to a height, pulling resistance band.~Coordination Exercises: (10-15 reps 2 sets) finger to finger, finger to doctor's finger, finger to nose, holding and lifting coins, buttoning, holding and lifting coins, alternate hand movement, closing and opening hand."
219270995|NCT06945185|PROCEDURE|Intervention Group B Motor Imagery with Conventional Physical Therapy|"1. Subjects will be asked to sit comfortably on a chair with a backrest. A Quiet environment is ensured for proper concentration of subject .Take deep breaths for 2-3 min to relax.~2. Subjects will be asked to close their eyes and imagine the training scene for each task for 5 min while listening to the therapist 's voice describing the motion.~3. The non-paralysis part of the body's movement was imagined first and then the movement of the paralysis part was imagined.~4. Upon completion of the mental practice for the first activity, the subject will be given a comfortable break.~Motor Imagery Training:~Week 1-2: Approaching and holding a cup, turning book pages and grasping pencil to write.~Week 3-4: wiping desk, turning door handle and drinking water from cup. Week 5-6: pressing light switch on and off, turning faucet and putting card in wallet.~Week 7-8: folding towel, brushing teeth and brushing hair. Imagine for 30 sec 2-3 repetitions."
219270996|NCT06943911|BEHAVIORAL|AI Chatbot for Breast Cancer Patient Education and Empowerment|The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.
219176493|NCT01214616|DRUG|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
219176494|NCT03721952|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
219176495|NCT04461405|BEHAVIORAL|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
219176496|NCT03367533|DRUG|Ketamine|Intravenous ketamine
219270997|NCT06944028|PROCEDURE|Selective excavation|Partial removal of carious dentine, soft carious tissue is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, and a permanent restoration is placed on the tooth.
219176497|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
219176498|NCT03367533|DRUG|Placebo|Oral placebo
219176499|NCT05699928|DIAGNOSTIC_TEST|General pediatrician autism diagnostic assessment|General pediatricians will assess children for possible autism spectrum disorder diagnosis as they usually would (i.e. no specific tests will be required).
219176500|NCT05699928|DIAGNOSTIC_TEST|Multidisciplinary team diagnostic assessment|The multidisciplinary team will assess children for possible autism spectrum disorder diagnosis. The team consists of a developmental pediatrician, a psychologist, and a psychometrist. Administered tests include the Autism Diagnostic Interview - Revised (ADI-R; a developmental history will be substituted for children with a developmental age of \<18 months), the Autism Diagnostic Observation Schedule (ADOS), and the Mullen Scales of Early Learning. When needed and available, the team will call a preschool or school teacher to gather more information about the child.
219176501|NCT05699928|DIAGNOSTIC_TEST|Autism Assessment for Preschoolers with Language Element Sequence|The AAPLES was developed at the Glenrose/Holland Bloorview and is designed for children who have flexible phrase speech. The assessment will be conducted virtually over Zoom Health by a trained clinician. This tool involves coaching the caregiver to interact with the child in specific ways to allow a trained professional to observe for features of ASD while watching remotely. It should take about 30-45 minutes. The individual who conducts the assessment will be blinded to the results of the other assessments. This virtual assessment will occur after the other assessments have been completed so as to not delay the child receiving a potential diagnosis.
219176502|NCT06801470|DRUG|CD-001|CD-001 administered as an intravenous (IV) infusion.
219176503|NCT02893267|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
219176504|NCT02893267|OTHER|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
219176505|NCT02893267|OTHER|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
219176506|NCT02893267|DEVICE|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
219176507|NCT05505916|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
219176508|NCT05505916|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg
219176509|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
219176510|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
219176511|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
219176512|NCT05640765|OTHER|Best Practice|Receive standard of care services
219176513|NCT05640765|OTHER|Educational Intervention|Receive additional educational and supportive material
219176514|NCT05640765|OTHER|Health Promotion and Education|Participate in BeWell360-CG Care Model sessions
219176515|NCT05640765|OTHER|Questionnaire Administration|Ancillary studies
219176516|NCT06129344|OTHER|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
219270998|NCT06944028|PROCEDURE|Stepwise excavation|Partial removal of carious dentine is performed, soft dentine is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, application of a provisional restoration. After approximately 3-5 months, the provisional restoration is removed, and any remaining carious dentine is further removed until firm dentine is reached. A permanent restoration is then applied.
219270999|NCT06944561|DIAGNOSTIC_TEST|Culture and identify Mycobacterium tuberculosis from patient faeces|When faecal samples have been identified only by a pseudo-anonymised label they will be transferred to the designated secure collection point (Vaccine Institute). Professor Tim Bull will then be informed of their availability and will collect and transport to the research laboratory, located in the same building, making a log of all samples received. All samples will then be processed by the research laboratory as defined in the sample processing protocol. Culture result data will be obtained and stored on a secure password protected PC Excel file for collation and archiving by the chief analyst.
219271000|NCT06945211|PROCEDURE|LOW INTENSITY TASK ORIENTED MIRROR THERAPY|"Group A Low Intensity Task Oriented Mirror Therapy will be administered for 2 and half hour per week for 30 min a day, 10 rep five times a week for 8 weeks.~Task-oriented Activities for Group A:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 30 min with 10 reps per day for 8 consecutive weeks."
219271001|NCT06945211|PROCEDURE|High Intensity Task Oriented Mirror Therapy|"Group B High Intensity Task Oriented Mirror Therapy will be administered for 5 hours per week for 60 min a day, 20 rep five times a week for 8 weeeks. The mode of mirror therapy will be unilateral as subjects will perform movement only on unaffected arm.~Task-oriented Activities for Group B:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 60 min with 20 reps per day for 8 consecutive weeks"
219271002|NCT06945393|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
219271003|NCT06944691|OTHER|Major depressive disorder scale|Pass HDRS to patient taking PrEP to study prevalence of Major Depressive Disorder
219176517|NCT06129344|OTHER|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
219176518|NCT06514677|PROCEDURE|Ultrasonic Carbon Tip|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
219176519|NCT06514677|PROCEDURE|Titanium Curette|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
219176520|NCT05292365|BEHAVIORAL|RE-PACT Intervention|"* Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching"
219176521|NCT06033898|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1000 steps. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
219176522|NCT06033898|BEHAVIORAL|24 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 24 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
219271004|NCT03439475|BIOLOGICAL|AMG 714|
219271005|NCT06940895|DRUG|Sirolimus 0.2%|sirolimus 0.2% gel
219176523|NCT06033898|BEHAVIORAL|36 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 36 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
219176524|NCT05299931|DRUG|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
219176525|NCT06398886|BEHAVIORAL|Ericksonian Hypnosis|The Ericksonian hypnosis intervention was designed to create a nurturing and therapeutic setting, specifically tailored to the unique challenges of prolonged grief faced by university students. This approach focused on accessing the subconscious, using symbolic and imaginative techniques to facilitate change. The goal was to alleviate the emotional pain associated with prolonged grief and to empower students to adapt more effectively to their loss. This intervention highlighted the transformative potential of Ericksonian methods in addressing deep-seated emotional issues through gentle and indirect therapeutic modalities.
219176526|NCT06398886|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention aimed to provide a supportive and healing environment, addressing the specific challenges of prolonged grief within a university student population. The focus was on developing concrete skills to manage the cognitive and behavioral aspects of grief. This approach sought to mitigate the pain of prolonged grief and empower students to adapt more healthily to their loss, emphasizing practical strategies for change and coping. Participants were encouraged to actively engage in exercises that challenged their thought patterns and promoted behavioral adjustments tailored to their individual needs.
219176527|NCT05315999|DRUG|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
219176528|NCT05315999|DRUG|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
219176529|NCT06208215|DRUG|RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
219176530|NCT06208215|DRUG|RZ358 (10 mg/kg) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
219176531|NCT06208215|DRUG|RZ358 (5-10 mg/kg) + SOC|Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
219271006|NCT06944756|OTHER|Global Postural Reeducation|"Two stretching postures were maintained for 10 minutes each.~* In order to stretch the posterior muscle chain(the supine posture with hip ﬂexion, which stretches the posterior muscle chain) the patient lay in the supine position with the occipital, lumbar, and sacral spine stabilized, with the lower limbs at 90° hip flexion, and performed gradual knee extensions, and dorsiﬂexion of the ankle.~* In order to stretch the anterior muscle chain (the supine posture with leg extension, which progressively stretches the anterior muscle chain) the patient lay in the supine position with the upper limbs abducted at 30° and the forearms supine.. Hips were flexed, abducted, and laterally rotated, with the soles of the feet touching each other. Gradually, respecting the patient's limits, the lower limbs were extended as much as possible and adduction of the upper limbs."
219271007|NCT06944756|OTHER|Scapular Stabilization Exercises|"1\) Push up plus and 2) press up, were selected in reference to a study for scapular stabilization.~During the 5-week intervention training, sets of repetitions were increased progressively. In the ﬁrst week participants performed 3 sets of each exercise (10 repetitions × 10-second duration each) and worked up to a maximum of 5 sets of 10 repetitions in the last weeks of the intervention."
219176532|NCT04818060|OTHER|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
219176533|NCT04818060|DIAGNOSTIC_TEST|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
219176534|NCT04818060|DIAGNOSTIC_TEST|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
219176535|NCT05077618|OTHER|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
219176536|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
219176537|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
219176538|NCT06481475|BIOLOGICAL|YY003|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
219176539|NCT06481475|BIOLOGICAL|Vehicle Control|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
219176540|NCT02496754|DRUG|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
219271008|NCT06944574|BEHAVIORAL|Guided online intervention|"The intervention combines a one-hour in-person workshop with a four-week app-based program tailored to elite athletes. The workshop focuses on sleep education and individual motivation setting. Athletes then complete seven self-paced audio modules via the 7-Schläfer app, covering strategies to improve sleep quality. Weekly reminder emails reinforce motivation. Unlike other interventions, this program is fully integrated into the elite sport context, emphasizes behavioral change through personalized goal-setting, and includes no therapist contact, ensuring scalability. No control group is included in this one-arm pre-post design."
219271009|NCT06945367|BEHAVIORAL|Active Learning-Based Research Methods Course|A four-month educational intervention based on active learning strategies, delivered as part of a Research Methods course for fourth-year undergraduate students in physiotherapy. The intervention included weekly group activities focused on literature retrieval, critical appraisal, oral presentations, peer feedback, and structured formative assessments using rubrics. The aim was to improve beliefs, attitudes, perceived skills, and frequency of use of evidence-based practice.
219176541|NCT02496754|DRUG|GnRH-anta|In control group, patients use GnRH-antagonist. Patients' serum or follicle fluid will be collected if needed.
219176542|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
219176543|NCT05858515|DRUG|Placebo|Placebo
219176544|NCT05998226|OTHER|Virtual Antimicrobial stewardship Team (VAT)|The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
219176545|NCT06330116|DEVICE|IQoro|Please refer to arm/group description for information
219176546|NCT06330116|DEVICE|eXciteosa|Please refer to arm/group description for information
219176547|NCT06330116|BEHAVIORAL|Grouptraining|Please refer to arm/group description for information
219176548|NCT04619069|RADIATION|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
219176549|NCT04619069|DRUG|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
219176550|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
219176551|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
219176552|NCT04495894|DRUG|Preoperative Ketorolac|30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
219176553|NCT06799637|DRUG|XNW28012|Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
219271010|NCT06945692|PROCEDURE|patient specific reconstruction plates|Use of patient specific reconstruction plates on the 3-D virtually-generated defect using Artificial Intelligence.
219271011|NCT06945055|BEHAVIORAL|FAMES|225 dyads (family member/support persons and individuals receiving services for psychosis) will be recruited over a period of 30 months. Family member/support persons will be connected to a family peer for a period of 12 weeks who will use the cultural formulated interview to develop rapport and identify unique cultural needs which can inform treatment and resource identification. Participants will receive brief contact, family psychoeducation, and be connected to an online family resource group where they can receive additional support from certified peers and other family member/support persons.
219271012|NCT06945055|BEHAVIORAL|Control|participants will receive 12 weeks of automated communication which contain positive messaging, appointment reminders, links to community resources, and coping skills.
219271013|NCT06944457|DRUG|MPD-1|It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.
219271014|NCT06945757|OTHER|Physical Exercise|"Patients will participate in the routine rehabilitation program for 12 weeks, consisting of two 1h30 one-to-one sessions per week of physical activity administered by experienced physical therapist. Both sessions of the week are tailored to the need of the individual participant and are typically structured as follow:~* 10 minutes of warming up by light exercises~* 20 minutes of coordination exercises~* 20 minutes of strengths exercises~* 20 minutes of mobility exercises~* 10-15 minutes of cool down and stretching~Patients will further benefit during the 12-weeks program of several individual encounters with a psycho-oncologist, a nurse specialized in cognitive support and a nutritionist. Furthermore, a dietician will conduct an introductory evaluation, several intermediate evaluations and a final evaluation on nutritional status and habits of the patients."
219271015|NCT06944054|OTHER|Group 1|Every 2 hours, the heat probes were replaced. Hypoallergenic patches were removed with a silicone-based spray used in the clinic. The application continued for 24 hours. In total, 12 heat probe displacements were made to different points in the abdominal, chest or lower extremity region. Heat probe stabilising tapes were attached to different points in a clockwise direction. At the end of 24 hours, the skin conditions of the newborns were re-evaluated with scales and recorded. This application continued for 3 days.
219271016|NCT06944132|PROCEDURE|Excision of the pterygium|The surgical procedure involved excision of the pterygium, including the fibrovascular head and associated conjunctival tissue, followed by bare sclera closure using an autologous conjunctival graft harvested from the superior bulbar conjunctiva. The graft was secured in place using either fibrin glue or 8-0 absorbable sutures. In Group B, 0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
219271017|NCT06944132|DRUG|Post-operative application of CsA|Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.
219271018|NCT06944132|DRUG|Intra-operative application of MMC|0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
219271019|NCT06944769|OTHER|Group A myofascial technique|"Group A with MET (latissimus dorsi), myofascial release (thoracolumbar fascia) and posterior oblique sling strengthening it will be a six-week protocol, with sessions conducted five times a week for 30-40 minutes, focusing on posterior oblique sling activation. Week 1: Myofascial release (thoracolumbar fascia, 60-90 sec), MET (latissimus dorsi, 7-10 sec isometric + 30-sec stretch, 5 reps), glute max strengthening (prone hip extensions, 10-sec holds ×5; bilateral bridges, 5-sec holds ×5).~Week 2: Prone hip extension (3-kg resistance), arm extension (1-kg dumbbell, 5-sec holds ×5), bird-dog (5-sec holds ×10, 1 set).~Weeks 3-4: Prone hip extensions (5-sec holds ×10), single-leg bridges (5-sec holds ×10), twice daily.~Weeks 5-6: Increased intensity to 10-sec holds ×10 reps"
219271020|NCT06944769|OTHER|Group B posterior sling exercises|A six-week conservative protocol, was conducted five times weekly for 30-40 minutes, focuses on core stability exercises. Week 1 includes static stretching of the latissimus dorsi (30-second hold, 3 reps) and prone hip extensions with knee flexed at 90° (5-second hold, 10 reps). By Week 2, bird-dog exercises are introduced (5-second hold, 10 reps per side). In Weeks 3-6, these exercises are maintained to provide a stable baseline for comparison with Group A's more intensive protocol. The latissimus dorsi stretch is performed 2-3 times daily for improved flexibility.
219271021|NCT06944977|BEHAVIORAL|Anticipatory guidance and postnatal home visits|Anticipatory guidance to pregnant women, followed by scheduled home visits at 6, 12, and 18 months
219271022|NCT06944977|BEHAVIORAL|Anticipatory guidance|Postnatal anticipatory guidance
219271023|NCT06944210|OTHER|'Rosy Red Valencia' sweet orange|The participants consume 2 'Rosy Red Valencia' sweet oranges daily for 4 weeks
219271024|NCT06944210|OTHER|'Olinda Valencia' sweet oranges|The participants consume 2 'Olinda Valencia' sweet oranges daily for 4 weeks
219271025|NCT06945133|OTHER|Clinical testing|"Intervention includes :~* Surface EMG to measure inhibition of the VM and the rectus femoris (RF) on the injured and non-injured sides during attempts at voluntary contractions of the knee extensor muscles.~* Myotonometry to measure the stiffness of the semimembranosus and biceps femoris (long head) on the injured and non-injured sides under resting conditions"
219271026|NCT06945003|BEHAVIORAL|Exercise Intervention|Those assigned to the intervention group will be invited to attend one of three group activity sessions with their parent/guardian that will occur at one of Ulster University's sport centres. Three group activity sessions will be delivered separately for each cohort (i.e Primary, Post-Primary and those with an Intellectual Disability) and their respective parent/guardian.) Parents/guardians and their child will then meet one-to-one with Professor Frank Casey, a paediatric cardiologist, will discuss with them, their child's results from their cardiopulmonary exercise test and from wearing their activity monitor. Using these results, alongside their age and diagnosis and likes and dislikes, Professor Casey will provide an individualised physical activity recommendation plan for each child that will be safe and beneficial to them, to be implemented at home over 12-weeks.
219271027|NCT06945835|BEHAVIORAL|Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.|Partticipants will be performing supported and unsupported walking, free weights, rowing, cycling, resistance bands, adaptive bikes and body weight exercises.
219271028|NCT06944808|OTHER|Sham-BFR + EMS|Daily passive sham-BFR with a fixed pressure of 20mmHg in combination with electrical stimulation of the m. vastus lateralis and mediales
219271029|NCT06944808|OTHER|BFR + EMS|Daily passive BFR with an individual pressure of 80% of the limb occlusion pressure in combination with electrical stimulation of the m. vastus lateralis and mediales
219271030|NCT06944496|BIOLOGICAL|Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine|Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W
219271031|NCT06944496|BIOLOGICAL|Tislelizumab+Oxaliplatin+Capecitabine|Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 130 mg/m², IV, D1, Q3W; Capecitabine: 1000 mg/m², po, BID, D1-D14, Q3W
219176554|NCT05661669|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
219176555|NCT05661669|DRUG|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
219271032|NCT06945562|DEVICE|collagen cone (resorbable material used for socket sealing )|The test group include those sites enrolled for placement of immediate dental implant (N=8) with application of collagen cone
219271033|NCT06945562|PROCEDURE|Placement of Immediate Dental Implant Only|Participants will receive placement of an immediate dental implant without any additional material (N=8).
219271034|NCT06945029|DEVICE|Ambu Aura Gain|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric population.
219271035|NCT06945029|DEVICE|Laryseal Pro|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric
219271036|NCT06938269|DRUG|MWN109 tablet|Strength: 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.
219176556|NCT05682937|DEVICE|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5.
219176557|NCT05650775|DRUG|Concerta|3-week trial of oral methylphenidate extended release
219176558|NCT05650775|DRUG|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
219176559|NCT06279221|DRUG|LITFULO|as provided in real world practice
219176560|NCT05865561|OTHER|VOC sampling|"* Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~* Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
219176561|NCT06058949|BEHAVIORAL|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
219176562|NCT06058949|BEHAVIORAL|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
219176563|NCT06204094|RADIATION|node-sparing short-course radiotherapy|5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
219176564|NCT06204094|DRUG|Sintilimab|200mg intravenous infusion d1 of each cycle\*8cycles
219176565|NCT06204094|DRUG|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
219271037|NCT06938269|DRUG|Placebo|Administration: Oral.
219176566|NCT06204094|DRUG|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle\*8cycles
219176567|NCT06204094|PROCEDURE|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
219176568|NCT06204094|PROCEDURE|watch and wait|WW for cCR patients
219176569|NCT04535271|DRUG|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
219176570|NCT06242405|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Umbilical cord mesenchymal stem cells injected through peripheral veins
219271038|NCT06950840|DRUG|Acetaminophen|Acetaminophen 1 g IV once
219271039|NCT06950840|DRUG|dipyrone|Dipyrone IV 1 g once
219271040|NCT06948227|OTHER|Daily Living Activities (ADL) Training Program|After the 1st assessment, activities that the investigators frequently use in daily life such as eating and brushing our teeth and activities that are appropriate for the age group of the participants and that affect their participation such as throwing a ball or playing games will be implemented with the therapist for 6 weeks. During the session, the therapist will provide practical training so that the participants can do the activities correctly and will provide a demonstration of the activity, observe whether the child compensates while performing the movements during all these activity steps and will make corrections for the movements that he/she compensates for. At the same time, the therapist will give reinforcing verbal affect for the activity skills that the participants do correctly in order to increase their motivation during the session. The 2nd Assessment will be made at the end of the 6th week in order to analyze the change during the 6-week period.
219176571|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
219176572|NCT05579899|DRUG|EVO101|Topical Cream
219176573|NCT03937128|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
219176574|NCT03937128|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
219176575|NCT06224790|DRUG|Pirfenidone|Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
219176576|NCT06224790|OTHER|Placebo|2 Capsules 3 times a day for 3 months
219176577|NCT05750680|DRUG|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
219176578|NCT06506084|DRUG|Ropeginterferon alfa-2b|"Data will be collected at each visit during the observational study (total duration: 24 months). In accordance with routine clinical practice in this patient population, visits are expected to take place every 6 months.~Patients who discontinue ropeginterferon alfa-2b treatment at any time will no longer be followed up."
219176579|NCT06537622|OTHER|Implementation group|Implementation strategies to increase uptake of the clinical practice guidelines for earlier diagnosis of cerebral palsy
219176580|NCT06537622|OTHER|Standard of care|No active implementation strategies
219176581|NCT05604391|PROCEDURE|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
219176582|NCT05604391|PROCEDURE|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
219176583|NCT04172038|BEHAVIORAL|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
219176584|NCT04172038|BEHAVIORAL|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
219176585|NCT04172038|BEHAVIORAL|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences"
219176586|NCT02951845|DRUG|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
219176587|NCT02951845|DRUG|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
219176588|NCT02951845|DRUG|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
219176589|NCT03224858|OTHER|SUMMIT intervention|See description in experimental arm.
219176590|NCT03224858|OTHER|Enhanced usual care|See description in active comparator arm.
219176591|NCT05373862|DEVICE|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
219176592|NCT06179407|DRUG|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
219176593|NCT06179407|DRUG|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
219176594|NCT01000961|DRUG|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
219176595|NCT01000961|DRUG|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
219176596|NCT01701817|OTHER|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
219176597|NCT05156983|DRUG|TAK-330|Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
219176598|NCT05156983|DRUG|SOC 4F-PCC|Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
219176599|NCT06177457|DRUG|PF-07293893|PF-07293893 will be administered as tablets every day (QD) over 14 days
219176600|NCT06177457|DRUG|Placebo|Placebo will be administered as tablets; QD over 14 days
219176601|NCT06177457|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
219176602|NCT05780372|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
219176603|NCT05780372|DRUG|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
219176604|NCT02222155|DRUG|CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
219176605|NCT02222155|DRUG|CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids|
219176606|NCT02222155|OTHER|Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
219176607|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
219176608|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
219176609|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
219176610|NCT05991882|BEHAVIORAL|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
219271041|NCT06948227|OTHER|Social Robot Application|The basic daily life activities that the Social Robot can perform, such as eating and brushing teeth, and the ball throwing activity that affects their participation, will be coded into the robot by engineers. 1. The evaluations will be applied as in the other group, and occupational therapy sessions for upper extremity skills will be applied with the Social Robot Nao accompanied by a therapist for 6 weeks. In this group, the robot will show the selected activities to the children according to the activity application steps during the session and then ask the child to apply them. The verbal feedback that the Social Robot Nao will use will be determined and applied by the therapist. At the end of the 6th week, the second evaluations will be made and the 6-week developments of the participants in this group will be analyzed. Each session will be applied once a week for 40 minutes.
219271042|NCT06950944|DEVICE|Theranova 500|Participants will dialysis by Theranova 500 dialyzer during study period, the dialyzer will reprocessing with standard hospital protocol and dialyzer will check before use in dialysis session.
219271043|NCT06950502|PROCEDURE|transversus abdominis plane block|Transversus abdominis plane block was performed with the patient lying in the supine position via an oblique subcostal approach from the anterior abdominal wall. After skin asepsis of the anterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the linear ultrasound probe was placed parallel to the subcostal border at the level of the xiphoid bone and the subcutaneous fat tissue, rectus abdominis muscle and transversus abdominis muscle were visualized, respectively. A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
219176611|NCT05991882|BEHAVIORAL|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
219176612|NCT05991882|BEHAVIORAL|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
219176613|NCT05991882|BEHAVIORAL|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
219176614|NCT05991882|BEHAVIORAL|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
219176615|NCT05991882|BEHAVIORAL|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
219176616|NCT05991882|BEHAVIORAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
219296278|NCT06412354|DEVICE|EasyCross™ first-in human|"At T0 the patient will undergo the TAVR procedure including the investigational procedure with the VIVHEART EasyCross™ catheter.~The interventional cardiologist will introduce the VIVHEART EasyCross™ catheter through the femoral artery with a percutaneous access according to the clinical practice through a vascular introducer on an already positioned guidewire. An operator in the procedure room will start a chronometer at this point to measure the investigational device crossing procedure duration.~The VIVHEART EasyCross™ catheter will be progressed into the aorta and up to the aortic valve.~At that time the external part of the VIVHEART EasyCross™ catheter will be opened to allow the self-centering of the catheter on the aortic valve. The guidewire will be introduced and once having crossed the valve the VIVHEART EasyCross™ catheter will be retracted by the physician and removed from the patient's body."
219176617|NCT05991882|BEHAVIORAL|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
219176618|NCT05601596|DIAGNOSTIC_TEST|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
219176619|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
219176620|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
219176621|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
219176622|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
219176623|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
219176624|NCT06631391|BIOLOGICAL|umbilical cord blood NK cells|This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells) and other therapy.
219176625|NCT06262932|DRUG|Amiodarone|Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
219176626|NCT06609889|GENETIC|ION283|Anti-sense Oligonucleotide therapy that includes intrathecal (IT) injections by lumbar puncture (LP) with dose level of 15 mg.
219176627|NCT04881032|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
219176628|NCT04881032|RADIATION|radiotherapy|60 Gy in 6 weeks
219176629|NCT04881032|DRUG|Temozolomide|"Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
219176630|NCT04185298|BEHAVIORAL|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
219176631|NCT04185298|BEHAVIORAL|Activity monitoring|Participants will have activity monitored (via Fitbit)
219176632|NCT03993171|DRUG|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
219176633|NCT05389202|OTHER|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
219271044|NCT06950502|PROCEDURE|Quadratus Lumborum Block (QLB)|Quadratus lumborum block; after the patient was lying in the lateral decubitus position and skin asepsis of the posterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the ultrasound probe was moved from the level of the iliac crest to the 4th lumbar vertebra and the quadratus lumborum muscle was visualized on the transverse process of the 4th lumbar vertebra at the point where the anterior abdominal wall muscles end. The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
219271045|NCT06950502|DRUG|quadratus lumborum block using bupivacaine|The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
219271046|NCT06950502|DRUG|transversus abdominis plane block using bupivacaine|A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
219176634|NCT06283238|DRUG|Immune checkpoint inhibitor (ICI) or chemotherapy alone|Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone
219176635|NCT05976672|OTHER|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
219176636|NCT05207202|DEVICE|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
219176637|NCT06480448|OTHER|Traditional physical herapy|core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.
219176638|NCT06480448|OTHER|Treadmill training|Treadmill training for 20 minutes three time a week.
219271047|NCT06949982|COMBINATION_PRODUCT|experimental group x-MAP|hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.
219271048|NCT06949982|DRUG|Regorafenib (BAY 73-4506)|Regorafenib 160 mg PO daily on days 1-21, every 28 days OR 1st cycle: Regorafenib 80 mg PO daily on days 1-7, followed by 120 mg PO daily on days 8-14, followed by 160 mg PO daily on days 15-21, every 28 days, 2nd and subsequent cycles: Regorafenib 160 mg PO daily on days 1-21, every 28 days
219271049|NCT06947512|DEVICE|Seleggo Test|Seleggo Test is a computerized procedure to identify the personalized visual and auditory parameters facilitating reading and writing for each participant. By applying these parameters to the visualization and to the TTS software during reading of school texts, the participants are expected to be facilitated in reading and understanding the text.
219176639|NCT05545761|OTHER|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
219176640|NCT05538754|DEVICE|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
219176641|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
219176642|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
219176643|NCT06543732|OTHER|Return to work program|The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
219176644|NCT06068686|DRUG|Vildagliptin 50 MG|vildagliptin plus their metformin.
219176645|NCT06068686|DRUG|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
219176646|NCT04471038|BIOLOGICAL|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
219271050|NCT06546137|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing of genomic DNA extracted from buccal swab
219271051|NCT06245213|DRUG|ANAVEX3-71 oral capsules|ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
219271052|NCT06245213|DRUG|Placebo oral capsules|The placebo comparator for the study.
219176647|NCT04471038|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
219176648|NCT06126198|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
219176649|NCT05480124|DEVICE|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
219176650|NCT05480124|DEVICE|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
219296279|NCT05695586|BEHAVIORAL|Mindful Self-Compassion (MSC) training|8-week Mindful Self-Compassion (MSC) intervention protocol, developed by Germer and Neff (2013, 2019). After the training, participants will enter a 12-month phase of regular MSC-based supervised practice.
219271053|NCT06432972|OTHER|Pulmonary Rehab|Prehab will include 2, one-hour sequential sessions of PR per day as is standard, however this intervention will increase the frequency from 2 days to 4 days per week, for 2 weeks, thus completing 16 sessions of PR prior to surgery. An exercise prescription will be written by the medical director based on initial 6MWD, age, height, weight, and co-morbidities, as is standard of care. Prior to each session, patients are evaluated for symptoms and vital signs are measured. Exercise will include 30 minutes of warm-up and upper and lower extremity resistance training, either against gravity or with resistance bands as appropriate. Exercise will then move to the open gym, where patients utilize endurance equipment of their choosing, such as a treadmill or recumbent bicycle. As with traditional PR, participants will be given online education videos regarding lung health to complete at home, with a supplementary video on breathing techniques to reduce atelectasis from pain.
219271054|NCT06184659|DRUG|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
219176651|NCT02405858|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
219176652|NCT02405858|DRUG|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
219176653|NCT03576248|DEVICE|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
219176654|NCT03576248|DEVICE|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
219176655|NCT03576248|DEVICE|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
219176656|NCT03576248|DEVICE|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
219176657|NCT06821334|BIOLOGICAL|MK-6194|Subcutaneous Administration
219176658|NCT06821334|BIOLOGICAL|Placebo|Subcutaneous administration
219176659|NCT06807294|BEHAVIORAL|Tai Chi Program|12-week virtual Tai Chi program with experienced Tai Chi instructor. Sessions will be conducted via the HIPPA-compliant teleconference platform, Zoom.
219176660|NCT05000684|DRUG|JS004 in combination with toripalimab|Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks
219176661|NCT06807567|OTHER|Receipt of healthcare for long-term conditions|The patient participants are people who are already receiving healthcare for CKD and/or hypertension, diabetes, HIV, heart failure and/or stroke at one of the named study sites, for at least 6 months prior to recruitment into this qualitative study. The caregiver participants are caregivers for patients meeting these criteria.
219176662|NCT06807567|OTHER|Provision of healthcare|The healthcare worker participants are all providing care to patients with long-tem conditions, at one of the names study sites
219176663|NCT06807567|OTHER|Policy making|The policy makers recruited to this study will be individuals involved in policy making for long-term conditions in Malawi
219176664|NCT06014593|DEVICE|expirogram|Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
219271055|NCT06184659|DRUG|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
219176665|NCT06210633|OTHER|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
219176666|NCT06210633|OTHER|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
219176667|NCT05732428|DRUG|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
219271056|NCT02070679|DRUG|Vitamin E|
219271057|NCT00966264|DRUG|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
219271058|NCT00966264|PROCEDURE|Hysterectomy|operation
219271059|NCT01246999|BIOLOGICAL|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
219176668|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
219176669|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars.
219176670|NCT04550468|OTHER|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
219176671|NCT04550468|OTHER|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
219271060|NCT01246999|BIOLOGICAL|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
219271061|NCT01246999|BIOLOGICAL|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
219176672|NCT06484569|OTHER|Control|The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.
219176673|NCT06484569|OTHER|exercise and cranio sacral therapy|Posture exercises Stretching exercises Strengthening Exercises In addition, deep tissue massage will be applied to increase blood circulation and cranio-sacral therapy will be applied to increase cerebrospinal fluid circulation.
219176674|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
219176675|NCT04015167|DEVICE|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
219176676|NCT03640312|DRUG|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
219176677|NCT03640312|DRUG|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
219176678|NCT06168253|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
219176679|NCT06168253|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
219176680|NCT05192863|OTHER|No Intervention|This is a non-interventional study.
219176681|NCT03382652|DEVICE|Metal-on-Metal Articulation|\<Metal-on-Metal Articulation\>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component\>:Continuum Acetabular Shell, \<Femoral Component\>: Zimmer® M/L Taper Hip Stem
219176682|NCT06169254|DEVICE|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
219271062|NCT01246999|BIOLOGICAL|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
219176683|NCT06482528|OTHER|Motor Imagery|"After the measurement devices are connected to the individuals, they will be seated in a comfortable chair.~After the calibration of the devices, individuals will undergo a 2-minute relaxation session. During the relaxation session, individuals will be asked to focus on their breathing and relax as much as possible.~Then, heart rate variability, electrodermal activities and respiratory frequencies of the individuals will be measured in a sitting position for 5 minutes. In case of rest, after taking the variables, individuals will be kept to rest for 10 minutes.~After 10 minutes, the devices will be placed on the individuals again and a 2-minute relaxation session will be held.~Then, individuals will be asked to imagine running through kinesthetic imagery for 5 minutes.~Feedback will be given to individuals throughout the entire session. These feedbacks will be given verbally with an audio recording prepared by the physiotherapist."
219271063|NCT03811990|BEHAVIORAL|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
219271064|NCT01867047|DRUG|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
219271065|NCT01867047|DRUG|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
219176684|NCT05925855|OTHER|US with fastum|apply fastum on trigger point with US
219176685|NCT05925855|OTHER|US with reparil|apply reparil on trigger point with US
219176686|NCT05925855|OTHER|US with plain gel|apply gel on trigger point with US
219176687|NCT05003258|DEVICE|Intravitreal injection of Dexamethasone implant|Intravitreal injection of Dexamethasone implant
219176688|NCT03866109|DRUG|Temferon|Genetically modified HSPCs
219176689|NCT06419712|DRUG|vitamin D (cholecalciferol) supplementation|This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
219176690|NCT03885518|OTHER|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
219176691|NCT05225584|DRUG|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
219176692|NCT06141187|PROCEDURE|Vertebroplasty|PVP
219176693|NCT06141187|PROCEDURE|Sham Vertebroplasty|Sham PVP
219176694|NCT04709783|OTHER|3-Step Workout for Life|Participants will receive the modified 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and/or lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life exercise, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
219176695|NCT04542161|DRUG|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
219176696|NCT04542161|DRUG|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
219176697|NCT04542161|DRUG|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
219176698|NCT04810650|OTHER|Mobility Dynamic Treatment Intervention|"1\) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
219176699|NCT04810650|OTHER|Health Living Intervention for Heavy Alcohol Users|1\) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
219176700|NCT04810650|OTHER|Hypertension Linkage|1\) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
219176701|NCT04810650|OTHER|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
219271066|NCT00746629|BEHAVIORAL|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
219271067|NCT04309695|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
219271068|NCT04702516|DRUG|Ozempic|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
219271069|NCT04702516|DRUG|Placebo|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
219271070|NCT03249870|DRUG|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~* First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~* Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
219271071|NCT06378697|DRUG|AK111|Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.
219271072|NCT06378697|DRUG|Placebo+AK111|Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
219271073|NCT04350099|OTHER|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
219271074|NCT02895919|OTHER|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
219271075|NCT01918592|DEVICE|MRI/acetate-PET imaging|
219271076|NCT00113815|DRUG|topiramate|15 mg/kg/day
219271077|NCT00113815|DRUG|topiramate|5 mg/kg/day
219271078|NCT00113815|DRUG|topiramate|25 mg/kg/day
219271079|NCT00113815|DRUG|placebo|placebo
219271080|NCT02517814|DIETARY_SUPPLEMENT|Vitamin D|
219271081|NCT00003622|DRUG|paclitaxel|
219271082|NCT00003622|DRUG|vinorelbine tartrate|
219271083|NCT03089996|PROCEDURE|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
219271084|NCT03089996|PROCEDURE|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
219271085|NCT03089996|DEVICE|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
219271086|NCT03089996|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
219271087|NCT04536389|PROCEDURE|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
219176702|NCT04810650|OTHER|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
219176703|NCT04810650|OTHER|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
219176704|NCT04810650|OTHER|Standard of Care|Local country standard of care protocols
219176705|NCT04810650|OTHER|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
219176706|NCT05868902|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
219176707|NCT06360757|DIAGNOSTIC_TEST|NeuMoDx SARS-CoV-2 Assay|The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
219176708|NCT03682250|DEVICE|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
219176709|NCT03682250|DEVICE|Holter monitor|A Holter monitor will be used to measure heart's activity
219176710|NCT03763604|DRUG|Abemaciclib|Administered orally.
219176711|NCT06357013|PROCEDURE|Bilateral Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.
219176712|NCT06357013|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
219176713|NCT05794243|DRUG|LY3493269|Administered orally.
219176714|NCT05794243|DRUG|Sodium Caprate (C10)|Administered orally.
219176715|NCT05794243|DRUG|Salcaprozate Sodium (SNAC)|Administered orally.
219271088|NCT00349466|DRUG|CF101|Orally CF101 1mg
219271089|NCT00349466|DRUG|Placebo|Orally matching Placebo
219271090|NCT04608747|OTHER|Tahini|Fifty grams of tahini were consumed by 20 healthy males
219271091|NCT06137612|DIAGNOSTIC_TEST|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
219271092|NCT03153150|DRUG|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219176716|NCT05935527|DRUG|POLAT-001|Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
219176717|NCT05935527|DRUG|Placebo|Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
219271093|NCT03153150|DRUG|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271094|NCT03153150|DRUG|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271095|NCT03153150|DRUG|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271096|NCT03153150|DRUG|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271097|NCT03153150|DRUG|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271098|NCT03153150|DRUG|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
219271099|NCT01076764|DRUG|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271100|NCT01076764|DRUG|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271101|NCT01076764|DRUG|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271102|NCT01076764|DRUG|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271103|NCT01076764|DRUG|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271104|NCT01076764|DRUG|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
219271105|NCT04142411|DRUG|Insulin|Ultrasound guided perineural injection therapy (PIT)
219271106|NCT04142411|DRUG|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
219271107|NCT04142411|DEVICE|Ultrasound|Philips Neuromuscular Ultrasound
219271108|NCT02185547|DRUG|Zoloft|Sertraline treatment 25 mg
219271109|NCT02185547|BEHAVIORAL|ICBT|Internet behavioral cognitive therapy only
219271110|NCT03554720|DEVICE|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
219271111|NCT03554720|DEVICE|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
219271112|NCT03055169|GENETIC|genetic analysis|
219271113|NCT03055169|BIOLOGICAL|blood and stools samples|
219271114|NCT04661943|DRUG|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
219271115|NCT04698746|PROCEDURE|Pericapsular nerve group block|PENG block will be made with 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml NaCl under US-guidance
219271116|NCT04698746|PROCEDURE|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
219271117|NCT03058380|OTHER|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
219271118|NCT04930497|PROCEDURE|vestibular socket technique with bone grafting|a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral
219271119|NCT04930497|PROCEDURE|vestibular socket technique without bone grafting|the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
219271120|NCT06096584|PROCEDURE|Triple Injection Perisartorius block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata"
219271121|NCT06096584|PROCEDURE|Dual sub sartorial block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB."
219271122|NCT06096584|PROCEDURE|Femoral triangle block|Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.
219271123|NCT06096584|PROCEDURE|Distal adductor canal block|Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.
219271124|NCT06096584|PROCEDURE|Suprasartorial plane block|Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
219271125|NCT04707950|DRUG|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
219271126|NCT04707950|DRUG|Oxytocin|both groups will be given oxytocin as a standard management
219271127|NCT05311254|DRUG|Fosfomycin Calcium|Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.
219271128|NCT02555553|BEHAVIORAL|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
219271129|NCT05574283|PROCEDURE|Erector spinae plane block and transmuscular quadratus lumborum block|"All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side"
219271130|NCT04012619|DRUG|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
219271131|NCT05614440|DRUG|Local anesthetic + tramadol hydrochloride|Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block
219271132|NCT05614440|DRUG|Only local anesthetic|Using articain HCL for inferior alveolar nerve block
219271133|NCT03880253|DRUG|CTP-692|Placebo or CTP-692
219271134|NCT01060397|BEHAVIORAL|Extended Brief Intervention|Frames motivational interviewing approach
219271135|NCT01060397|BEHAVIORAL|Control|Usual care
219271136|NCT04596995|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
219271137|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
219271138|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
219271139|NCT02517177|OTHER|Parabolic flight|
219271140|NCT02517177|OTHER|Cardiovascular parameters measurements|
219271141|NCT06432114|BEHAVIORAL|Sensory Awareness Program (SAP)|SAP is a new rehabilitation program for people with severe mental health problems. SAP aims to help the target group manage anxiety outburst and live an active life through sensory modulation techniques.
219271142|NCT06432114|OTHER|Treatment as usual (TAU)|Treatment as usual is standard psychiatric care for the target group.
219271143|NCT00233662|DRUG|Alefacept|
219271144|NCT02701998|BEHAVIORAL|mHealth-Enhance Physical Activity Intervention|
219271145|NCT02701998|OTHER|Physical Activity Intervention|
219271146|NCT04058470|DRUG|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
219271147|NCT04058470|DRUG|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
219271148|NCT01377298|DRUG|Pazopanib|200mg/tablet, 800mg/day PO.
219271149|NCT00590564|DRUG|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
219271150|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
219271151|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
219271152|NCT05369949|DRUG|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
219271153|NCT05369949|OTHER|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
219271154|NCT01791998|PROCEDURE|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
219271155|NCT01791998|PROCEDURE|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
219271156|NCT02611453|OTHER|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
219271157|NCT02986191|PROCEDURE|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
219271158|NCT02986191|PROCEDURE|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
219271159|NCT02344875|DRUG|FYU-981, (Oral single dosing)|
219271160|NCT04696393|DRUG|Mitapivat tablet|Oral tablets
219271161|NCT00194324|DRUG|Miconazole nitrate|
219271162|NCT00194324|PROCEDURE|Magnetic resonance imaging|
219271163|NCT00194324|BEHAVIORAL|Moderate levels of exercise|
219271164|NCT03051399|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
219271165|NCT03051399|DIETARY_SUPPLEMENT|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
219271166|NCT00925392|DRUG|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
219271167|NCT00925392|DRUG|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
219271168|NCT05657756|DEVICE|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
219271169|NCT01964846|DIETARY_SUPPLEMENT|Resveratrol, curcumin|
219271170|NCT01964846|DIETARY_SUPPLEMENT|Placebo|
219271171|NCT01434680|BIOLOGICAL|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
219271172|NCT01434680|BIOLOGICAL|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
219271173|NCT01434680|BIOLOGICAL|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
219271174|NCT04819061|OTHER|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
219271175|NCT04819061|OTHER|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
219271176|NCT05161793|DEVICE|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
219271177|NCT03947008|OTHER|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
219271178|NCT00214253|DRUG|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
219271179|NCT02939339|DEVICE|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
219271180|NCT02939339|DEVICE|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
219176718|NCT06688448|DEVICE|Dafodil prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
219176719|NCT06688448|DEVICE|Aortic Valve Replacement - Inspires Resilia prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
219176720|NCT03099499|DRUG|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
219176721|NCT03942419|DRUG|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered with a microdose dispenser
219176722|NCT03942419|DRUG|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered with a microdose dispenser
219176723|NCT03942419|DRUG|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered with a microdose dispenser
219176724|NCT05733975|OTHER|Decision Making Guide|The tool includes a brief introduction to the tool and decision-making, a values clarification exercise, and a question prompt list.
219176725|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
219176726|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 100mcg
219176727|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
219176728|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 500mcg
219176729|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
219176730|NCT05999565|OTHER|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
219271181|NCT04617249|PROCEDURE|median anesthesia|giving median anesthesia
219271182|NCT04617249|PROCEDURE|paramedian anesthesia|giving paramedian anesthesia
219271183|NCT03020069|DEVICE|CGMS Device|
219271184|NCT03020069|OTHER|No Device|
219271185|NCT02655289|DEVICE|Modulated TENS|"* Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
219271186|NCT02655289|DEVICE|Placebo TENS|"* Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
219271187|NCT05163223|BIOLOGICAL|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
219271188|NCT05163223|DRUG|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
219271189|NCT05163223|DRUG|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
219271190|NCT05163223|DRUG|Pembrolizumab|Q3W; IV infusion
219271191|NCT05163223|DRUG|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
219271192|NCT01142167|PROCEDURE|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
219271193|NCT01142167|PROCEDURE|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
219271194|NCT02788266|PROCEDURE|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
219271195|NCT02788266|PROCEDURE|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
219271196|NCT02788266|PROCEDURE|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
219271197|NCT04082351|DIETARY_SUPPLEMENT|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
219271198|NCT04082351|DIETARY_SUPPLEMENT|ordinary water|Ordinary bottled water
219271199|NCT05730114|DRUG|Antiplatelet Drug|anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
219271200|NCT06956456|OTHER|Supervised Multicomponent Training Protocol|"Supervised Multicomponent Training Protocol~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
219271201|NCT06956456|OTHER|Non-Supervised Home-Based Multicomponent Training Protocol|"Participant will receive a personalized exercise plan tailored to their fitness level.~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
219271202|NCT02997332|DRUG|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
219271203|NCT02997332|DRUG|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
219271204|NCT02997332|DRUG|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
219271205|NCT02997332|DRUG|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
219271206|NCT00467415|BEHAVIORAL|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
219271207|NCT00467415|BEHAVIORAL|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
219271208|NCT01439867|DRUG|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
219271209|NCT01439867|DRUG|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
219271210|NCT02806492|OTHER|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
219271211|NCT02806492|OTHER|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
219271212|NCT02806492|OTHER|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
219271213|NCT02806492|OTHER|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
219271214|NCT02806492|OTHER|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
219176731|NCT05999565|OTHER|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
219176732|NCT05328687|DIAGNOSTIC_TEST|Shear wave elastography|or measuring the muscle stiffness, we use a linear 9 MHz ultrasound probe (9L) and the Logic E9 scanner, both from GE Healthcare (Chalfont St Giles, UK). All measurements are performed with the probe parallel to the muscle fibers. We will measure the stiffness of the trapezius muscle in the middle botulinum toxin A injection side (G1) according to the PREEMPT protocol. All data are saved as images by the observer and subsequently analyzed by a blinded observer.
219176733|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (face-to-face care)|A Program structured in 28 visits (in group and individual) and 21 contacts (through phone calls or video calls) to guide the improvement of diet quality, self-care, and regular practice of physical activity
219176734|NCT06426277|BEHAVIORAL|Diet|Hypocaloric diet prescription
219176735|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (remote care)|A Program structured in 49 contacts delivered through telehealth (through phone calls or video calls between professional and participant) to guide the improvement of diet quality, self-care, and regular practice of physical activity
219176736|NCT05729945|BEHAVIORAL|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
219176737|NCT06473961|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
219176738|NCT01093547|PROCEDURE|Blood samples|Samples taken monthly
219176739|NCT01093547|PROCEDURE|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
219176740|NCT06697717|OTHER|Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., \>0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen."
219176741|NCT06697717|OTHER|EIT-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes."
219176742|NCT02369770|DEVICE|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
219176743|NCT05221671|OTHER|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
219176744|NCT02848040|OTHER|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
219176745|NCT05407129|BEHAVIORAL|Family safety reporting intervention|Family safety reporting intervention for patients/families
219176746|NCT06801327|DEVICE|Simeox|The Investigators chose to evaluate this device for respiratory physiotherapy in our patients because it is the only one that offers innovative technology, as, unlike other commercially available devices, it does not require the patient to perform forced breathing. Instead, the patient can exhale calmly at tidal volume. This is expected to reduce the patient's effort and improve compliance with treatment. Furthermore, the vibratory signal with small, rapid, and sequential depressions within the airways could be more effective in mobilizing mucus from the airways, preventing collapse.
219176747|NCT06802120|OTHER|osteopathy real|treatment with real osteopathy 2 times a week for 8 weeks
219176748|NCT06802120|OTHER|sham osteopathy|treatment with sham osteopathy 2 times a week for 8 weeks
219176749|NCT03891576|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
219176750|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
219271215|NCT03422445|DRUG|Apatinib|Apatinib：500mg/d，qd，po，d1-28
219271216|NCT03422445|DRUG|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
219271217|NCT06830850|DRUG|HRS-5041 Single dose of HRS-5041 orally administered|HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.
219271218|NCT04663477|DIAGNOSTIC_TEST|patient-completed Caprini Risk Score|The participants will be asked to complete patient-completed Caprini Risk Score
219271219|NCT00540462|PROCEDURE|gastric bypass|
219271220|NCT00540462|PROCEDURE|sleeve gastrectomy|
219271221|NCT03597984|RADIATION|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~\- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
219271222|NCT00157781|DEVICE|Medtronic AT500|
219271223|NCT01135654|OTHER|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
219271224|NCT00322244|PROCEDURE|Massage Therapy|
219271225|NCT05360498|BEHAVIORAL|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
219271226|NCT05360498|BEHAVIORAL|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
219271227|NCT02616159|OTHER|Oatmeal|
219271228|NCT06960980|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. During phase 1 of each training session, on a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During phase 2 of each training session, teens will complete five 5-minute simulated drives using a fixed-base driving simulator. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
219296280|NCT05695586|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) training|8-week Mindfulness Based Stress Reduction (MBSR) intervention protocol, as developed by Stahl \& Goldstein (2010). After the training, participants will enter a 12-month phase of regular MBSR-based supervised practice.
219296281|NCT04039971|PROCEDURE|ACL Reconstruction|Surgical techniques
219176751|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
219176752|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
219176753|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
219176754|NCT05455086|PROCEDURE|Computed Tomography|Undergo PET/CT
219176755|NCT05455086|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219176756|NCT05455086|OTHER|Questionnaire Administration|Ancillary studies
219176757|NCT05764863|RADIATION|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
219176758|NCT06802341|OTHER|Normal protein diet|Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids
219176759|NCT06802341|OTHER|Animal protein diet|Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
219176760|NCT06802341|OTHER|Plant based diet|Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
219176761|NCT06803095|BEHAVIORAL|free walking with dog and diet restriction|the total participants of tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet.. this diet will be applied for 12 weeks.. during this period the study, this group will receive free walking (30 min) with dog three timmes weekly.
219176762|NCT06803095|BEHAVIORAL|diet restriction|the total participants with tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet only .. this diet will be applied for 12 weeks..
219176763|NCT06451848|DRUG|Genakumab Injection (T, Solution for injection)|A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
219271229|NCT06960980|BEHAVIORAL|VR-FOCAL+|Weekly for 5 weeks, teens complete a training program designed to train teens to limit the length of glances away from the roadway. The training has two phases, each of which will be administered using immersive virtual reality. The first phase will have teens switch between the upper half of a virtual reality screen which will play a simulated video drive while the bottom half contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During the second phase of each session, teens will complete five 5-minute simulated drives in a virtual reality environment where teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
219176764|NCT06451848|DRUG|Genakumab for Injection (R, Powder for solution for injection)|A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
219176765|NCT06802250|BEHAVIORAL|RINEW intervention|The intervention included behavioral recommendations and guidance on the topics of Nutrition, WASH, Lead exposure prevention, Mental Health, and child stimulation. The intervention also included the provision of nutritional supplements based on age and nutritional status, low-cost picture books and toys, and soapy water bottles.
219176766|NCT02761057|PROCEDURE|Biospecimen Collection|Undergo collection of plasma and serum samples
219176767|NCT02761057|PROCEDURE|Bone Scan|Undergo bone scan
219176768|NCT02761057|DRUG|Cabozantinib S-malate|Given PO
219176769|NCT02761057|PROCEDURE|Computed Tomography|Undergo CT
219176770|NCT02761057|DRUG|Crizotinib|Given PO
219176771|NCT02761057|DRUG|Savolitinib|Given PO
219176772|NCT02761057|DRUG|Sunitinib Malate|Given PO
219176773|NCT06227182|DIAGNOSTIC_TEST|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
219176774|NCT06227182|DIAGNOSTIC_TEST|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
219176775|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
219176776|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone|20ml 0.2% Ropivacaine + 4mg Dexamethasone
219271230|NCT01632826|DRUG|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
219176777|NCT05926934|DEVICE|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
219176778|NCT05926934|DEVICE|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
219176779|NCT05926934|DEVICE|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
219176780|NCT04499053|DRUG|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
219176781|NCT04499053|DRUG|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
219176782|NCT06105060|DRUG|Rosuvastatin 20mg|to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
219176783|NCT01898754|OTHER|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
219176784|NCT02921581|RADIATION|FDG-PET guided dose painting|
219176785|NCT06037369|BEHAVIORAL|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
219176786|NCT03041805|PROCEDURE|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
219176787|NCT03041805|PROCEDURE|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
219176788|NCT03041805|PROCEDURE|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
219176789|NCT03041805|PROCEDURE|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
219176790|NCT03041805|PROCEDURE|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
219176791|NCT03041805|PROCEDURE|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
219176792|NCT03041805|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
219176793|NCT03041805|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
219176794|NCT03411083|PROCEDURE|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
219176795|NCT03993509|DEVICE|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
219176796|NCT03937050|BEHAVIORAL|Intervention|"Three film-based components:~1. Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~2. Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~3. Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices."
219176797|NCT04605679|PROCEDURE|Kidney Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
219176798|NCT05724264|DIAGNOSTIC_TEST|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
219271231|NCT02635360|DRUG|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
219271232|NCT02635360|RADIATION|Brachytherapy|Radiation is done for standard clinical care purposes.
219271233|NCT02635360|DRUG|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
219271234|NCT04602377|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
219271235|NCT05413005|COMBINATION_PRODUCT|ECP regular-intensity arm|"* Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
219271236|NCT05413005|COMBINATION_PRODUCT|ECP accelerated-intensity arm|"* Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks"
219271237|NCT05413005|BIOLOGICAL|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
219271238|NCT04516369|GENETIC|voretigene neparvovec|Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
219271239|NCT04978350|BEHAVIORAL|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
219271240|NCT02165553|DIETARY_SUPPLEMENT|Hibiscus sabdariffa calyces extract as a cold drink|
219271241|NCT03366532|OTHER|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
219176799|NCT05757310|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219176800|NCT05757310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219176801|NCT05757310|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
219176802|NCT05757310|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219176803|NCT05757310|DRUG|Cyclophosphamide|Given PO and IV
219176804|NCT05757310|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
219176805|NCT05757310|DRUG|Pentostatin|Given IV
219176806|NCT05757310|OTHER|Questionnaire Administration|Ancillary studies
219176807|NCT06465225|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of developing pressure injury, without pressure injury, up during the day and lying between 15 and 20 hours per day will ly a on a R'GO Soins overlay mattress
219176808|NCT05930353|OTHER|COHORT|this evaluation includes a brief interview with perma profiler scale
219176809|NCT04946734|DEVICE|PFO closure device|Device PFO closure.
219176810|NCT04946734|DRUG|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
219176811|NCT04946734|DRUG|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
219176812|NCT03958474|DRUG|Oxycodone|Participants receive oxycodone or placebo.
219176813|NCT03958474|DRUG|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
219176814|NCT04876118|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
219176815|NCT01703806|PROCEDURE|Early Surgery|MItral valve surgery
219176816|NCT01703806|PROCEDURE|Watchful Observation|Watchful observation
219176817|NCT02986698|BIOLOGICAL|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
219176818|NCT06109753|PROCEDURE|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
219271242|NCT03743779|BEHAVIORAL|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q\&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
219271243|NCT04360720|DRUG|Antiplatelet Monotherapy|"All subjects randomized to the Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to the Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12."
219271244|NCT01673022|DRUG|IC Green|IC Green
219271247|NCT04843410|OTHER|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
219271248|NCT04843410|OTHER|The routine care|Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
219271249|NCT02778672|OTHER|Thermal imaging of infant's chest with a mobile phone|
219271250|NCT02833805|DRUG|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
219271251|NCT02833805|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
219271252|NCT02833805|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
219271253|NCT02833805|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
219271254|NCT02833805|DRUG|Tacrolimus|Start on Day 5 through Day 365
219271255|NCT02833805|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
219271256|NCT00983749|DEVICE|Full-pressure ECP|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
219271257|NCT00983749|DEVICE|Sham-pressure ECP|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
219271258|NCT05267795|BEHAVIORAL|Experimentally-induced pain|Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
219271259|NCT02552017|DEVICE|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
219271260|NCT02656550|PROCEDURE|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
219271261|NCT05439330|DEVICE|MRI of teeth and surrounding structures|included above
219271262|NCT02975063|BEHAVIORAL|A&T IYCF intervention|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
219271263|NCT03587766|DRUG|Fexinidazole|Drug: fexinidazole (FEXI)
219271264|NCT03587766|DRUG|Placebo Oral Tablet|Drug: fexinidazole
219271265|NCT01296009|DRUG|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
219271266|NCT01177761|PROCEDURE|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
219176819|NCT06109753|PROCEDURE|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
219176820|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
219271267|NCT01952847|OTHER|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
219271268|NCT01952847|DRUG|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
219176821|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
219176822|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
219176823|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
219176824|NCT04113642|OTHER|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
219176825|NCT05992220|RADIATION|Atezolizumab plus bevacizumab, combined EBRT to vascular invasion|"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
219176826|NCT05992220|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab q3w
219176827|NCT05948267|DRUG|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
219176828|NCT05948267|DRUG|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
219176829|NCT01052467|DRUG|Xamiol® Gel|Once daily application for about 4 weeks
219271269|NCT01952847|BEHAVIORAL|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
219271270|NCT06242769|DRUG|Stannous Fluoride Toothpaste (SnF)|test
219176830|NCT06178887|DIAGNOSTIC_TEST|imaging|cardiac angioMR
219176831|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
219176832|NCT05545150|PROCEDURE|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
219176833|NCT05545150|DEVICE|Lumpectomy|Per standard of care (SOC)
219176834|NCT06298318|OTHER|Vodka|BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.
219176835|NCT06298318|OTHER|water|equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
219271271|NCT06242769|DRUG|Colgate Fluoride Toothpaste (CDC)|negative control
219271272|NCT01598103|DRUG|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
219271273|NCT01598103|DRUG|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
219271274|NCT02015988|DRUG|Fenofibrate|
219271275|NCT02015988|DRUG|Simvastatin|
219271276|NCT03908567|DRUG|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
219271277|NCT03908567|DRUG|Oral Tablet|Oral dosing with tablets 3 times a day
219271278|NCT03908567|OTHER|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
219271279|NCT05227781|DIETARY_SUPPLEMENT|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
219271280|NCT05227781|DIETARY_SUPPLEMENT|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
219271281|NCT01907906|DEVICE|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
219271282|NCT06352073|DRUG|Dupilumab|300mg weekly subcutaneous injection
219271283|NCT04451811|DRUG|OPL-002|Spray dried dispersion and tablet formulation
219271284|NCT00708851|OTHER|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
219271285|NCT00708851|DEVICE|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
219271286|NCT00448006|DEVICE|Allium Biliary Stent|device
219271287|NCT00448006|DEVICE|allium biliary stent|allium biliary stent
219271288|NCT00490945|DRUG|VEC-162|
219271289|NCT03263247|BEHAVIORAL|Memory Training|
219271290|NCT03263247|BEHAVIORAL|Psychoeducation|
219271291|NCT03263247|BEHAVIORAL|Alphabet search|
219271292|NCT01882153|BEHAVIORAL|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, \& Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
219271293|NCT01882153|BEHAVIORAL|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
219271294|NCT01882153|BEHAVIORAL|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
219271295|NCT03334253|DRUG|Atropine|Daily 0.01% atropine eyedrops
219271296|NCT03334253|OTHER|Placebo Eyedrops|Daily placebo eyedrops
219271297|NCT02324777|DRUG|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
219271298|NCT02324777|DEVICE|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
219271299|NCT01359839|BEHAVIORAL|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
219271300|NCT00203047|DRUG|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
219271301|NCT00203047|DRUG|Placebo|Placebo for prednisone given daily
219271302|NCT00203047|DRUG|Prednisone|Prednisone 1250 mg taken daily
219271303|NCT01580904|BEHAVIORAL|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
219271304|NCT01446146|BEHAVIORAL|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
219271305|NCT01446146|BEHAVIORAL|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
219271306|NCT00340704|DRUG|tamsulosin hydrochloride|oral
219271307|NCT04197167|PROCEDURE|Hysteroscopy|Diagnostic procedure
219271308|NCT04197167|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
219271309|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
219271310|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
219271311|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
219271312|NCT00121667|DRUG|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
219271313|NCT00121667|DRUG|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
219271314|NCT02214511|BEHAVIORAL|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
219271315|NCT02214511|BEHAVIORAL|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
219271316|NCT01453023|DRUG|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
219271317|NCT01453023|DRUG|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
219271318|NCT00890292|DRUG|JNJ-31001074|
219271319|NCT02879383|PROCEDURE|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
219271320|NCT02879383|PROCEDURE|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
219271321|NCT00312585|PROCEDURE|Acupuncture|
219271322|NCT00312585|PROCEDURE|Sham comparator|
219271323|NCT00637468|DRUG|Intravenous injection of heparin|
219271324|NCT00637468|DRUG|Intravenous injection of acetazolamide|
219271325|NCT00637468|PROCEDURE|Local intra-arterial fibrinolysis|
219271326|NCT00637468|PROCEDURE|Globe massage|
219271327|NCT00637468|DRUG|Topical use of beta-blocker|
219271328|NCT00637468|DRUG|Isovolaemic haemodilution|
219271329|NCT00637468|DRUG|Acetylsalicylic acid|
219271330|NCT05332678|DRUG|SLS-005 - Once Weekly|Please see Arm description.
219271331|NCT05332678|DRUG|SLS-005 - Twice Weekly|Please see Arm description.
219271332|NCT04829123|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
219271333|NCT04829123|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
219271334|NCT02480647|DRUG|Levonorgestrel|20μg/day.
219271335|NCT02480647|DRUG|Etonogestrel|20μg/day.
219271336|NCT01721889|RADIATION|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
219271337|NCT00980642|DEVICE|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
219271338|NCT00980642|DEVICE|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
219271339|NCT00980642|DEVICE|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
219271340|NCT05104255|PROCEDURE|Spinal anesthesia|Twins delivered under under spinal anesthesia
219271341|NCT05104255|PROCEDURE|General anesthesia|Twins delivered under general anesthesia
219271342|NCT01953445|DRUG|paclitaxel|
219271343|NCT01953445|DRUG|BKM120|
219271344|NCT04577131|BEHAVIORAL|Weekly check-in|Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
219271345|NCT01627262|DRUG|Mesalamine|3x1000mg mesalamine granules per day
219271346|NCT01627262|DRUG|Placebo|3x1000mg placebo granules per day
219271347|NCT01338753|OTHER|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
219271348|NCT02018653|DRUG|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
219271349|NCT02018653|OTHER|Placebo|1 by mouth every 6 hours for up to 6 days.
219271350|NCT02018653|BEHAVIORAL|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
219271351|NCT03699189|BEHAVIORAL|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
219271352|NCT00349414|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|
219271353|NCT00349414|PROCEDURE|Conventional Transscleral Cyclophotocoagulation|
219271354|NCT00195377|DRUG|Etanercept|
219271355|NCT06311370|OTHER|Observation|Observed by trained staff and wearing a sensor watch
219271356|NCT02677870|DRUG|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
219271357|NCT02677870|OTHER|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
219271358|NCT02710227|OTHER|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
219271359|NCT04889027|DIAGNOSTIC_TEST|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
219271360|NCT00648999|DRUG|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
219271361|NCT05518695|DRUG|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
219271362|NCT00015080|DRUG|Naltrexone|
219271363|NCT04375267|DRUG|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
219271364|NCT01893047|BEHAVIORAL|live music|live harp music
219271365|NCT01893047|BEHAVIORAL|recorded music|recorded harp music
219271366|NCT03188367|DIAGNOSTIC_TEST|Gluten or placebo capsules|Administration of gluten or placebo capsules
219271367|NCT03343093|BEHAVIORAL|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
219271368|NCT03343093|BEHAVIORAL|Control|usual care, surveys every 3 months
219271369|NCT03042832|BEHAVIORAL|LOCI|Leadership development with coaching and organizational change support
219271370|NCT03042832|BEHAVIORAL|Internet Based Webinar Leadership Training|Internet Based Webinar Leadership Training
219271371|NCT01108315|OTHER|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
219271372|NCT05950451|OTHER|No intervention|No intervention is led during this descriptive study
219271373|NCT01139359|DRUG|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
219271374|NCT01139359|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
219271375|NCT04990778|DRUG|Eprenetapopt|Given IV
219271376|NCT04990778|DRUG|Venetoclax|Given PO
219271377|NCT03833791|BEHAVIORAL|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
219271378|NCT03833791|BEHAVIORAL|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
219271379|NCT02664597|PROCEDURE|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
219271380|NCT02664597|OTHER|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
219271381|NCT04918004|BEHAVIORAL|Sleep Hygiene|"1. One-to-one sleep hygiene training, the content of which was created by the researchers,~2. A brochure containing 10 lifestyle changes related to sleep hygiene"
219271382|NCT03055962|DRUG|E2609|tablet
219271383|NCT03055962|DRUG|Placebo|tablet
219271384|NCT02610075|DRUG|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
219271385|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
219271386|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
219271387|NCT04652388|BEHAVIORAL|Nutritional counseling|Nutritional counseling about mediterranean diet
219271388|NCT04510480|OTHER|Observational study without specific intervention|Observational study with standard cardiac arrest approach
219271389|NCT05641779|DEVICE|pigtail|pigtail catheter insertion in chest in the pleural cavity
219271390|NCT00506805|DRUG|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
219271391|NCT05948969|OTHER|Decision support|"This implementation strategy will include the clinician education of the previous arm and apply audit and feedback of prior care to inform recommendations for future care. These suggestions will encompass 5 different domains based on eligibility and potential opportunity for an SGLT2i, GLP-1RA, angiotensin converting enzyme inhibitors (ACEi)/angiotensin-receptor blockers (ARB), antiplatelet or antithrombotic therapy, and statin therapy. The incorporation of clinical decision support technology will be utilized to identify tailored opportunities for each CV risk reduction based on guideline recommendations for individual patients. Clinicians will be presented prompts with patient-specific recommendation(s) for further optimization of cardioprotective agents. These prompts will be conveyed by a Study Coordinator to responsible clinicians. The follow-up clinical prompts will be based on auditing of updated clinical parameters and medication use."
219296282|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
219296283|NCT05367271|DRUG|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
219176836|NCT03854214|DEVICE|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 revolutions per minute (RPM). Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
219176837|NCT03854214|DEVICE|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
219176838|NCT04354480|BIOLOGICAL|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
219176839|NCT04354480|OTHER|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
219176840|NCT04263467|OTHER|Exercise intervention|The exercise intervention will consist a intermediate to high aerobic exercise training program.
219176841|NCT04263467|OTHER|Standard oncological treatments|Standard oncological treatments
219176842|NCT04255615|OTHER|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
219176843|NCT06407713|OTHER|Intrinsic foot muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with intrinsic foot muscle training
219176844|NCT06407713|OTHER|Hip abductor muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with hip abductor muscle training
219176845|NCT06492239|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
219176846|NCT06492239|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
219296284|NCT05367271|DRUG|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
219176847|NCT04857164|DRUG|Pembrolizumab combined with Chemotherapy|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
219176848|NCT05056727|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~\- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water."
219176849|NCT05056727|DRUG|Placebo|"Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~\- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water."
219271392|NCT05948969|OTHER|Facilitated referral to a cardiometabolic team-based center|Each site will have access to clinicians caring for patients in structured, multidisciplinary cardiometabolic centers. Clinicians caring for patients randomized to this intervention strategy will receive a facilitated referral via the EHR together). If the clinician approves the referral, the patient will be referred to this local team-based comprehensive risk factor management clinic. All patients randomized to this group will be considered in this group whether or not a visit to the cardiometabolic center is completed.
219176850|NCT05056727|DRUG|Lisinopril|Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
219176851|NCT05056727|DRUG|Valsartan|Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
219176852|NCT05056727|DRUG|Irbesartan|"Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved."
219176853|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
219176854|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
219176855|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
219176856|NCT04420676|DIETARY_SUPPLEMENT|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
219176857|NCT04420676|DIETARY_SUPPLEMENT|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
219176858|NCT05846620|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
219176859|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
219176860|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
219176861|NCT05972655|RADIATION|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
219176862|NCT05972655|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
219176863|NCT05972655|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
219176864|NCT05972655|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
219176865|NCT03428763|DEVICE|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~* Joint score by the patient~* Patient global disease activity measured on a 0-100 mm visual analogue scale.~* CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
219271393|NCT00003704|DRUG|capecitabine|
219271394|NCT00003704|RADIATION|radiation therapy|
219271395|NCT05428280|OTHER|Physiotherapy|Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise
219271396|NCT05428280|OTHER|Muscle Energy technique|Muscle Energy Technique (MET) is a technique that was developed in 1948 by Fred Mitchell, Sr, D.O\[1\]. It is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.
219176866|NCT03428763|OTHER|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
219176867|NCT02534272|OTHER|Stool sampling and sequencing of gut microbiota.|
219176868|NCT06143306|DRUG|bupivacaine.|an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
219176869|NCT06143306|DRUG|Saline|an ultrasound guided pectoserratus block with 25 mL of saline
219176870|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
219271397|NCT05428280|OTHER|Myofacial mobilization|It is a type of gentle, constant massage that releases tightness and pain throughout your myofascial tissues
219271398|NCT06846775|DIAGNOSTIC_TEST|DNA-methylation testing in patient-collected urine and vaginal samples|DNA-methylation testing of methylation markers CDO1, GHSR and ZIC1 for patient-collected vaginal samples and GHSR, CDH13 and SST for patient-collected urine samples.
219271399|NCT02003677|DRUG|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
219271400|NCT02003677|DRUG|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
219271401|NCT00448526|BEHAVIORAL|low protein diet|
219271402|NCT05508815|DRUG|Modified Zhiwang Decoction Combined with methotrexate|Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
219271403|NCT05508815|DRUG|Methotrexate|Methotrexate(7.5-15mg, once a week) for 12 weeks.
219271404|NCT00292344|DRUG|Rifaximin and loperamide|
219271405|NCT01821768|PROCEDURE|Sentinel Lymph Node Biopsy|
219271406|NCT04413370|DIAGNOSTIC_TEST|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
219271407|NCT00325598|RADIATION|Partial Breast Irradiation (PBI)|
219176871|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
219176872|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
219176873|NCT06267014|BEHAVIORAL|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
219176874|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
219176875|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
219176876|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
219176877|NCT06173206|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
219176878|NCT06173206|DRUG|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
219176879|NCT06173206|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
219176880|NCT02377999|DRUG|Picato|
219176881|NCT04338061|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.
219176882|NCT04338061|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
219176883|NCT06205368|BEHAVIORAL|Combine mobile app|"* HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~* Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~* Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~* Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~* Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
219176884|NCT06205368|BEHAVIORAL|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
219271408|NCT00502502|BEHAVIORAL|Questionnaire|Weekly questionnaires lasting about 30 minutes.
219271409|NCT04723290|DIAGNOSTIC_TEST|Serological tests for SARS Cov-2|Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
219271410|NCT05288829|DRUG|ALXN1210 SC|All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
219271411|NCT05288829|DRUG|ALXN1210 IV|All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
219176885|NCT06205368|BEHAVIORAL|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
219271412|NCT05288829|DRUG|Placebo|All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
219271413|NCT06144593|OTHER|Dietary macronutrient composition|Intermittent carbohydrate restriction
219271414|NCT04874558|DIAGNOSTIC_TEST|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
219271415|NCT06023251|OTHER|Clinical Nutrition|"Nutritional care plan implementation, including~* A step-up and step-down nutritional protocol guided by caloric and protein ratio~* Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~* Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~* Dedicated and specialized dietician and nurse involvement~* Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition."
219271416|NCT02520583|DIETARY_SUPPLEMENT|Lactic acid bacteria and bifidobacteria|
219271417|NCT02520583|OTHER|Placebo|
219271418|NCT05046925|PROCEDURE|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
219271419|NCT05046925|PROCEDURE|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
219271420|NCT01375998|DRUG|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
219271421|NCT04382235|DEVICE|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
219271422|NCT03567135|DRUG|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
219271423|NCT03567135|DRUG|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
219271424|NCT04958720|PROCEDURE|Surgery|Surgery
219271425|NCT04958720|DRUG|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
219271426|NCT04958720|RADIATION|Radiotherapy|Radiotherapy
219271427|NCT00519545|BEHAVIORAL|Prayer|Data collection on physiological biomarkers
219271428|NCT05666817|OTHER|breastfeeding education|"Mothers in the intervention group will be given breastfeeding training after the pre-test application. The content of breastfeeding education is as follows;~* General information about breastfeeding,~* General information about breast milk and the benefits of breast milk,~* Benefits of breastfeeding for mother and baby,~* How the baby should be held during breastfeeding, the baby's position,~* Effective breastfeeding positions for the mother,~* Ensuring that the baby holds the breast correctly,~* Providing the correct breastfeeding technique,~* Breast milking and storage conditions,~* The necessity and benefits of continuing breastfeeding."
219271429|NCT06320002|BEHAVIORAL|Communication Intervention for fecal ostomy surgery|This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
219271430|NCT00819702|OTHER|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
219271431|NCT00272259|PROCEDURE|Participants will interact with up to two small robots and a visual display|
219271432|NCT02474043|BEHAVIORAL|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
219271433|NCT02474043|BEHAVIORAL|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
219271434|NCT00508989|DRUG|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
219271435|NCT00508989|DRUG|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
219271436|NCT00508989|DRUG|L-NMMA|
219271437|NCT00508989|DRUG|Acetylcholine|
219271438|NCT02640105|OTHER|Neurological clinical examination|Diagnostic and description of cluster headache
219176886|NCT05895149|OTHER|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
219176887|NCT05895149|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
219176888|NCT06110975|OTHER|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
219271439|NCT02640105|OTHER|Psychological clinical examination|Scale and questionnaires
219271440|NCT02640105|OTHER|Questionnaires|Psychopathological and cognitive questionnaires
219176889|NCT06543953|DEVICE|HearCare MED-EL App|The main task of the HearCare MED-EL App is to perform technical checks on both implants and audio processors and create backups of audio processor configurations so that these configurations can be written on to an empty audio processor of the same type.
219176890|NCT05485376|DEVICE|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
219176891|NCT05158101|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
219176892|NCT04703166|DEVICE|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
219176893|NCT05202990|DRUG|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
219176894|NCT05202990|DRUG|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
219176895|NCT06450782|OTHER|Post-isometric Relaxation Technique|"Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier."
219176896|NCT06450782|OTHER|Myofascial Release Technique|"Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times."
219176897|NCT06450782|OTHER|Control|Participants will rest for thirty minutes.
219176898|NCT03486067|DRUG|CC-93269|Specified dose on specified days
219271441|NCT02640105|OTHER|Blood sample|Blood sample for DNA collection
219271442|NCT02640105|OTHER|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
219271443|NCT03945643|DRUG|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
219271444|NCT03945643|OTHER|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
219271445|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
219271446|NCT02413593|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
219271447|NCT02413593|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219271448|NCT04696783|DRUG|Esomeprazole Magnesium Enteric-coated Tablets|Nexium taken once every 2 days plus lifestyle adjustment
219271449|NCT04696783|BEHAVIORAL|Lifestyle adjustment|Lifestyle adjustment
219176899|NCT06884761|BEHAVIORAL|Maximal Rest|Participants in this group are instructed to follow maximal rest protocols. They are advised to avoid strenuous activities, including prolonged standing, lifting heavy objects, or engaging in physically demanding tasks. This group represents the traditional bed rest approach to managing pregnancies with a short cervix.
219176900|NCT05081037|DEVICE|Wearable Care Group|"Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels."
219176901|NCT06128863|DRUG|Pembrolizumab, Eftilagimod alpha|Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
219176902|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
219271450|NCT05828563|DIAGNOSTIC_TEST|Blood sample test|Blood sample will be taken to determine immunological indices
219176903|NCT05359848|OTHER|Diet|Using dietary interventions as an adjuvant tool may represent an effective step toward advancing the treatment options of cancer. Dietary modifications can impact the growth and proliferation of tumors via multiple mechanisms
219176904|NCT03365882|BIOLOGICAL|Cetuximab|Given IV
219176905|NCT03365882|DRUG|Irinotecan Hydrochloride|Given IV
219176906|NCT03365882|OTHER|Laboratory Biomarker Analysis|Correlative studies
219176907|NCT03365882|BIOLOGICAL|Pertuzumab|Given IV
219176908|NCT03365882|BIOLOGICAL|Trastuzumab|Given IV
219176909|NCT03365882|DEVICE|HER-2 testing|Central testing of HER-2 for eligibility
219176910|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
219176911|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
219176912|NCT06377631|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219176913|NCT06377631|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
219176914|NCT06825273|OTHER|space maintainer|3-D printed partial denture space maintainer will designed for each child patient who has premature loss of primary teeth after doing intraoral scanning
219271451|NCT05542121|DEVICE|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
219176915|NCT06825273|OTHER|space maintainer|a conventional impression will be done for a child patient with premature loss of his primary teeth, then a plaster model will gained. A conventional acrylic partial denture will be designed and delivered to the patient.
219176916|NCT06917768|PROCEDURE|Adenotonsillectomy|Children undergoing adenoidectomy and intracapsular tonsillectomy using Coblation™, by the same surgeon at HDF.
219176917|NCT06917768|DRUG|Prednisolone|The second Group includes children whose parents have refused surgery despite informed understanding of the therapeutic algorithm of OSA. They received medical treatment consisting of a 1-month treatment with intranasal corticosteroids, coupled with a 5-day course of oral corticosteroids (prednisolone) at a safe dose of 1mg/kg.
219176918|NCT06916819|DIAGNOSTIC_TEST|Home-Based Food Challenge|Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels.
219176919|NCT06916819|DIAGNOSTIC_TEST|In-Clinic Food Challenge|Standard of care - Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels.
219176920|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
219176921|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
219176922|NCT06786455|DRUG|SHR-1905 Injection|SHR-1905 Injection,medium dose, administered by subcutaneous injection;
219176923|NCT00587314|OTHER|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
219271452|NCT05542121|OTHER|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
219271453|NCT02319863|PROCEDURE|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
219176924|NCT06848946|COMBINATION_PRODUCT|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
219176925|NCT06848946|PROCEDURE|Sham procedure in conjunction with cataract surgery|Sham procedure in conjunction with cataract surgery
219271454|NCT02319863|PROCEDURE|hepatectomy (rapid ligating)|
219271455|NCT04666363|OTHER|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
219271456|NCT01125462|OTHER|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
219271457|NCT00723125|DRUG|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
219271458|NCT00723125|DRUG|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
219271459|NCT00723125|DRUG|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
219271460|NCT00134771|DRUG|Nutrient enriched infant formula|
219271461|NCT05290012|OTHER|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
219271462|NCT02676609|DEVICE|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
219271463|NCT06487663|PROCEDURE|TACE with ICI|Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
219271464|NCT05359692|BIOLOGICAL|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
219271465|NCT05359692|BIOLOGICAL|retifanlimab|retifanlimab will be administered via IV Q4W
219176926|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
219176927|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
219176928|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
219176929|NCT05361317|DEVICE|Nexis® PECA Bunion device|Hallux valgus correction with percutaneous chevron and Akin osteotomy.
219176930|NCT06212752|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
219271466|NCT01587482|PROCEDURE|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
219271467|NCT00003477|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
219176931|NCT06212752|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
219176932|NCT06212752|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
219176933|NCT06212752|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
219176934|NCT06212752|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
219176935|NCT06212752|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
219176936|NCT06212752|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
219176937|NCT06212752|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
219176938|NCT06212752|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
219176939|NCT01105234|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
219176940|NCT02710734|DRUG|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
219176941|NCT02710734|DRUG|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
219176942|NCT02710734|DRUG|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
219271468|NCT04610411|DEVICE|surgical navigation|surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software
219271469|NCT04610411|OTHER|standard surgical method|standard surgical method established at the institution
219271470|NCT02580747|BIOLOGICAL|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
219271471|NCT05671497|DRUG|Cilostazol 100 MG|An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
219271472|NCT05671497|DRUG|conventional synthetic antirheumatic drugs|methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
219271473|NCT05575297|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
219271474|NCT05575297|DRUG|Rifampicin Sodium|Co-administration of methotrexate and rifampicin
219271475|NCT05575297|DRUG|Febuxostat Tablets|Co-administration of methotrexate and febuxostat
219271476|NCT01575873|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months
219271477|NCT01575873|DRUG|Placebo for risendronate|Administered orally once a day
219271478|NCT01575873|DRUG|Risendronate|Administered orally once a day
219271479|NCT01575873|DRUG|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
219271480|NCT04625010|OTHER|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
219271481|NCT04625010|OTHER|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
219271482|NCT00820261|OTHER|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
219271483|NCT02777645|OTHER|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
219271484|NCT03235206|OTHER|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
219271485|NCT04910633|OTHER|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~* Age~* Gender~* Cancer type~* Cancer Stage~* Cancer Treatment~* COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~* Living Status~* Attribution of Mortality to COVID status~* Comorbidities"
219271486|NCT01680081|OTHER|Adenosine stress dynamic CT perfusion|
219271487|NCT00463853|PROCEDURE|Autologous stem cell therapy|
219271488|NCT00463853|PROCEDURE|CABG|
219271489|NCT00463853|RADIATION|CMRI|
219271490|NCT02920840|DEVICE|Intermittent theta-burst stimulation|see associated arm/group description
219271491|NCT02920840|DEVICE|Negative-peak-triggered-TMS|see associated arm/group description
219271492|NCT02920840|DEVICE|Open-loop replay TMS|see associated arm/group description
219271493|NCT01407055|BEHAVIORAL|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
219296285|NCT04834635|PROCEDURE|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
219296286|NCT04834635|PROCEDURE|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
219176943|NCT02710734|DRUG|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
219176944|NCT02710734|RADIATION|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
219176945|NCT02710734|PROCEDURE|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
219176946|NCT02710734|DRUG|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
219176947|NCT02710734|DRUG|Mitomycin C|Intravenous on day 1 with radiation treatment
219176948|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
219176949|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
219176950|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
219176951|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
219271494|NCT01407055|BEHAVIORAL|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
219271495|NCT02931305|DRUG|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
219176952|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
219176953|NCT04229992|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
219176954|NCT04229992|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
219271496|NCT02931305|DRUG|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
219176955|NCT03770273|BIOLOGICAL|sarilumab|Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.
219176956|NCT03770273|OTHER|Placebo|Placebo
219176957|NCT04060654|DRUG|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
219176958|NCT02753777|OTHER|Questionnaires|
219176959|NCT03572985|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
219176960|NCT03572985|OTHER|Car-following test|Driving with simulator program for DCV measurement
219176961|NCT03572985|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
219176962|NCT05823363|DRUG|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
219176963|NCT05823363|DRUG|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
219176964|NCT03332940|DRUG|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
219176965|NCT03332940|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
219176966|NCT05439759|BEHAVIORAL|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
219271497|NCT05006118|DRUG|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of \[12C\]-rodatristat ethyl and \[14C\]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
219176967|NCT05439759|BEHAVIORAL|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
219176968|NCT05439759|BEHAVIORAL|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
219176969|NCT05439759|BEHAVIORAL|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
219176970|NCT06567821|DEVICE|RELIEVA SPINPLUS® NAV Balloon Sinusplasty System|The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
219176971|NCT06656013|BEHAVIORAL|Motivational Interview|After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
219176972|NCT06074419|DEVICE|Occulus quest 2 virtual reality glasses|Patients will be shown nature videos via the specified virtual reality connection.
219271498|NCT04678739|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
219176973|NCT03725878|PROCEDURE|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
219271499|NCT04678739|DRUG|Tocilizumab|Actemra IV Infusion
219271500|NCT05253768|BIOLOGICAL|Fecal microbiota transplant (FMT)|"Patients will randomized to a fecal microbiota transplantation by using a nasointestinal tube for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
219176974|NCT03725878|PROCEDURE|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration \>400 ng/ml before pregnancy is recommended.
219176975|NCT03725878|PROCEDURE|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
219176976|NCT06410391|RADIATION|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
219176977|NCT02203552|DRUG|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
219176978|NCT02203552|OTHER|placebo|Placebo given by mouth for 9 weeks
219176979|NCT02203552|OTHER|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
219176980|NCT02203552|OTHER|Questionnaire administration|The CES-D and STAI will be administrated weekly.
219176981|NCT03208062|OTHER|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
219176982|NCT06295965|OTHER|Non-Interventional Study|Non-interventional study
219176983|NCT06829082|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Antiretroviral therapy (ART) has advanced with the introduction of integrase strand transfer inhibitors (INSTIs), such as the fixed-dose combination of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC), known as Biktarvy®. This regimen is preferred for its high genetic barrier to resistance, minimal drug interactions, and once-daily, single-tablet formulation, which enhances adherence and long-term treatment outcomes. While clinical trials have demonstrated its efficacy, real-world data specific to Colombia are lacking.
219176984|NCT02921230|DEVICE|Peripheral stenting|stent implantation during the index procedure
219176985|NCT04691297|OTHER|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
219176986|NCT04691297|OTHER|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
219176987|NCT06089980|BEHAVIORAL|Effects from acute kratom exposure|Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.
219176988|NCT06232902|DRUG|QL1101|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
219176989|NCT06232902|DRUG|Avastin®|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
219296287|NCT04548544|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
219296288|NCT06545500|DRUG|Glycopyrrolate (85 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
219176990|NCT06636721|BEHAVIORAL|LuCA Behavioral Intervention|The intervention will integrate aspects of Cognitive Behavioral Therapy (identifying and challenging automatic thoughts, engaging in behavioral activation) and Acceptance and Commitment Therapy (integrating one's values, distancing skills). The intervention will include skills such as problem-solving, communicating with close others and the medical team, and breathing techniques to improve shortness of breath related to lung cancer.
219176991|NCT01926496|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
219176992|NCT01926496|DRUG|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
219176993|NCT03427580|BEHAVIORAL|MERIT|Metacognitive Reflection and Insight Therapy
219176994|NCT06165978|BEHAVIORAL|Self-monitoring|pedometer/activity band provided to each participant
219271501|NCT05253768|OTHER|normal saline and glycerin/food coloring|"Patients will receive an equivalent volume of normal saline and glycerin/food coloring via a nasointestinal tube (sham transplantation) for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of placebo FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
219176995|NCT06165978|BEHAVIORAL|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
219176996|NCT06165978|BEHAVIORAL|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
219176997|NCT06165978|BEHAVIORAL|Feedback|Daily or weekly feedback for patients (emotional/social support)
219271502|NCT05784610|DEVICE|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
219176998|NCT06165978|BEHAVIORAL|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
219176999|NCT06165978|BEHAVIORAL|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
219177000|NCT06165978|BEHAVIORAL|Report|Daily or weekly reporting for therapists (messages)
219177001|NCT06165978|BEHAVIORAL|Social support|Support meetings (in-person), parallel to educational sessions
219177002|NCT06165978|BEHAVIORAL|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
219177003|NCT06165978|BEHAVIORAL|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
219177004|NCT06348160|BEHAVIORAL|iHERO Toolkit Resource|iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
219271503|NCT05784610|DEVICE|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
219271504|NCT05005702|OTHER|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
219271505|NCT00965497|DRUG|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
219177005|NCT06529250|DRUG|HAD|"Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
219271506|NCT01258621|PROCEDURE|Laparoscopy|Laparoscopic distal pancreatectomy
219271507|NCT02266342|DEVICE|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
219177006|NCT06529250|DRUG|Daunorubicin+Cytarabine|"Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
219177007|NCT05276973|PROCEDURE|Biopsy|Undergo biopsy
219177008|NCT05276973|DRUG|Carboplatin|Given IV
219177009|NCT05276973|DRUG|Ipatasertib|Given PO
219177010|NCT05276973|DRUG|Paclitaxel|Given IV
219271508|NCT00001905|DRUG|Interferon gamma|
219271509|NCT02799641|DRUG|Diazepam|5 mg Diazepam
219271510|NCT02799641|DRUG|Lidocaine|2 ml of 2% lidocaine
219271511|NCT02799641|OTHER|Placebo pill|Placebo pill
219271512|NCT02799641|OTHER|Placebo injection|Placebo injection
219177011|NCT05773820|DRUG|WJB001|"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
219177012|NCT05953155|OTHER|Control|Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
219177013|NCT05953155|OTHER|Yoga|Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
219177014|NCT03064217|DEVICE|Making impression at surgery|Making impression at surgery
219296289|NCT06545500|DRUG|Glycopyrrolate (42.5 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
219177015|NCT05044793|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
219177016|NCT03270020|DRUG|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
219177017|NCT05688111|DRUG|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
219177018|NCT05688111|OTHER|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
219177019|NCT06847243|DIAGNOSTIC_TEST|Nutrigenetic diet according the genetic test|Subjects within the nutrigenetic intervention group will be provided with a dietary plan according to nutrient intake characteristics by alghoritm genetic afinity.
219177020|NCT06847243|OTHER|Control intervention group|Subjects within the control intervention group will be provided with a dietary plan according to general nutrient recommendation by the AHA (American Hearth association) and national cholesterol education program
219177021|NCT06816992|DRUG|ORIC-114 Dose 1 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
219177022|NCT06816992|DRUG|ORIC-114 Dose 2 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
219177023|NCT06816992|DRUG|ORIC-114 Dose 3 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
219177024|NCT06322407|PROCEDURE|Stellate Ganglion Block (SGB)|All SGB procedures will be performed by the same experienced physicians. Patients will be positioned in a supine position with the neck slightly hyperextended and receive a SGB procedure using the B-ultrasound visualization technique (Aurora A5 Ultrasound, Risco Tech Co., Ltd.). 1% lidocaine 5mL (Shanxi Jinxin Shuanghe Pharm Co., Ltd.) will be injected below the prevertebral fascia on the surface of longus colli muscle
219177025|NCT06322407|DRUG|standardized drug treatment|Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
219177026|NCT06202118|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
219177027|NCT06152003|BEHAVIORAL|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
219177028|NCT06848738|PROCEDURE|FNB|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the 3rd generation FNB needle
219177029|NCT06848738|PROCEDURE|FNA|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the standard FNA needle
219177030|NCT06849908|DRUG|Baricitinib|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.
219177031|NCT06849908|DRUG|Adalimumab|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.
219177032|NCT06850675|OTHER|Clinical performance|Supraglottic airway devices were evaluated for ease of insertion, time of insertion, success rate at first attempt, number of attempts, ease of gastric tube insertion, oropharyngeal leak pressure, and intraoperative and postoperative complications
219177033|NCT04612309|DRUG|Immunotherapy|patient treated with at least 1 immunotherapy administration
219177034|NCT03338933|BEHAVIORAL|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
219177035|NCT06174272|BEHAVIORAL|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
219177036|NCT04843683|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
219177037|NCT06295796|DRUG|MK-8527|Oral Capsule
219177038|NCT04771195|BEHAVIORAL|Examination of students' naturally occurring social ties|In this observational study, features of students' social lives, such as the number of quality of relationships they form, and their subjective loneliness, will be used to predict their mental health and well being at later time points.
219271513|NCT05034068|DRUG|0.15% bezaydamine hydrochloride.|0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
219177039|NCT02777879|PROCEDURE|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
219177040|NCT03784014|DRUG|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219271514|NCT05034068|DEVICE|low power laser with a wavelength of 870 nm|the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
219271515|NCT00178347|RADIATION|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
219271516|NCT05146089|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
219177041|NCT03784014|DRUG|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177042|NCT03784014|DRUG|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177043|NCT03784014|DRUG|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177044|NCT03784014|DRUG|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177045|NCT03784014|COMBINATION_PRODUCT|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
219177046|NCT03784014|COMBINATION_PRODUCT|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177047|NCT03784014|DRUG|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
219177048|NCT03784014|DRUG|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
219177049|NCT03784014|DRUG|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
219177050|NCT03784014|OTHER|Next Generation sequencing exome|Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
219177051|NCT06158529|DEVICE|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
219177052|NCT06158529|DEVICE|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
219177053|NCT01084876|DRUG|CT-P6|Administered every 3 weeks
219177054|NCT01084876|DRUG|Herceptin|Administered every 3 weeks
219177055|NCT01084876|DRUG|Paclitaxel|Administered every 3 weeks
219177056|NCT04927741|OTHER|Sweet Marjoram Essential Oil|"Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
219177057|NCT04927741|OTHER|Grapeseed Oil|"Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
219177058|NCT03981705|RADIATION|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
219177059|NCT06338826|DRUG|TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI|"The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir"
219177060|NCT06338826|DRUG|Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)|dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
219177061|NCT02020720|PROCEDURE|Biopsy|Undergo image-guided biopsy
219271517|NCT05146089|OTHER|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
219177062|NCT02020720|PROCEDURE|Computed Tomography|Undergo 18F-DOPA-PET/CT
219177063|NCT02020720|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
219177064|NCT02020720|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
219177065|NCT02020720|OTHER|Laboratory Biomarker Analysis|Correlative studies
219177066|NCT02020720|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
219271518|NCT05146089|DRUG|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
219271519|NCT05146089|OTHER|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
219271520|NCT02965105|DEVICE|Coloplast Test Catheter|This is a newly developed intermittent catheter
219271521|NCT02965105|DEVICE|Speedicath|This is a marketed Catheter which is used as comparator
219271522|NCT02214953|DRUG|BI 11634 ER formulation A|
219271523|NCT02214953|DRUG|BI 11634 ER formulation B|
219177067|NCT02020720|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
219177068|NCT02020720|PROCEDURE|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
219177069|NCT05530070|OTHER|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
219177070|NCT05530070|OTHER|Standard of care|Patients will receive standard of care and baseline dietary education.
219177071|NCT05530070|DIAGNOSTIC_TEST|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
219177072|NCT06069778|DRUG|BNT321 Dose Level 1|Intravenous infusion
219177073|NCT06069778|DRUG|BNT321 Dose Level 2|Intravenous infusion
219177074|NCT06069778|DRUG|mFOLFIRINOX|Intravenous infusion
219177075|NCT06069778|DRUG|BNT321 RP2D|Intravenous infusion
219177076|NCT04423029|DRUG|DF6002|Specified dose on specified days
219177077|NCT04423029|DRUG|Nivolumab|Specified dose on specified days
219177078|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
219271524|NCT02214953|DRUG|BI 11634 ER formulation M|
219271525|NCT02214953|DRUG|BI 11634 ER formulation C|
219271526|NCT02214953|DRUG|BI 11634 IR tablet|
219271527|NCT04545333|DIAGNOSTIC_TEST|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
219271528|NCT03981939|OTHER|No intervention|This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.
219177079|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
219271529|NCT06031831|OTHER|airway anomalies|with or without airway anomalies
219271530|NCT02847481|PROCEDURE|fecal microbiota transplantation|fecal microbiota transplantation
219271531|NCT02847481|DRUG|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
219271532|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
219271533|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
219271534|NCT04833413|DRUG|Continuous intensive insulin therapy|After initial intensive insulin therapy in hospital, patients were grouped according to different treatment regimens within 6 months of discharge
219271535|NCT00246090|DRUG|E7389|E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
219271536|NCT03867162|BIOLOGICAL|Live Attenuated Tularemia Vaccine|Subjects will be vaccinated with a bifurcated needle; approximately 0.06 mL of the reconstituted vaccine will be placed on the volar surface of the forearm and applied by multiple puncture.
219271537|NCT03402074|BEHAVIORAL|Group hypnosis|5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
219271538|NCT05427227|DEVICE|EV-array detection|Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
219271539|NCT01896622|DRUG|Ritonavir|Impact on dabigatran PK/PD
219271540|NCT01896622|DRUG|Cobicistat|Impact on dabigatran PK/PD
219271541|NCT01098916|RADIATION|Home X-rays|X-rays examinations performed at home
219271542|NCT01098916|RADIATION|X-rays in hospital|
219271543|NCT04633850|DRUG|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
219271544|NCT04633850|DRUG|Bupivacain|"Bupivacaine dose according to weight. \<60 kg: Total dose 100mg 60-90kg: Total dose 150mg \>90kg: Total dose 200mg~Given once at the end of surgery."
219177080|NCT05602571|OTHER|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
219177081|NCT05602571|PROCEDURE|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
219177082|NCT05602571|PROCEDURE|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
219177083|NCT05615558|OTHER|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
219177084|NCT06127225|DRUG|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
219177085|NCT06127225|DRUG|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
219177086|NCT04259632|BEHAVIORAL|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
219177087|NCT04259632|BEHAVIORAL|Caloric Restriction (CR)|15% daily caloric deficient
219177088|NCT06581575|BIOLOGICAL|JCXH-105|IM injection
219177089|NCT06581575|BIOLOGICAL|Shingrix|IM injection
219177090|NCT05868213|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
219177091|NCT06552507|PROCEDURE|Duroplasty|The investigators open the dura from midline and repaired with fish mouth for dura augmentation
219177092|NCT03249181|DRUG|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
219177093|NCT03249181|DRUG|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
219177094|NCT03368963|DRUG|Nanoliposomal Irinotecan|Given IV
219177095|NCT03368963|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219177096|NCT06409169|OTHER|DBS TaT|Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
219177097|NCT06409169|OTHER|Usual Care|Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
219177098|NCT05482711|OTHER|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
219271545|NCT05312346|DIAGNOSTIC_TEST|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
219271546|NCT02275208|PROCEDURE|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
219177099|NCT06549803|DEVICE|skin bond|"In the skin bond group, fascia closure is performed for incision sites of 10 mm or more, and skin bond is sufficiently applied after subcuticular suture.~For incision sites less than 10 mm, subcuticular closure is performed without closing the fascia, and then skin bond is applied."
219177100|NCT06549803|DEVICE|skin stapler|"In the skin stapler group, fascia closure is performed on incision sites larger than 10 mm, and the skin is closed at 2-3 mm intervals using a stapler.~For incision sites less than 10 mm, skin closure is performed using a skin stapler without closing the fascia."
219177101|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
219177102|NCT00885716|BEHAVIORAL|patient training in shared decision making|
219177103|NCT00885716|BEHAVIORAL|cognitive training|
219177104|NCT02487056|BEHAVIORAL|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of HF patients|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of patients were recorded.
219271547|NCT04527484|DRUG|SHR-1314|each group subjects will be given different formulations of SHR-1314
219271548|NCT00270192|BEHAVIORAL|individual lactation counseling and educational material|
219271549|NCT00270192|BEHAVIORAL|educational material alone|
219271550|NCT00270192|BEHAVIORAL|routine antenatal care without educational intervention|
219271551|NCT05334043|DRUG|CuminUP30|7 capsules, 500 mg / capsule
219177105|NCT05363852|DIAGNOSTIC_TEST|Standard set of visual word and picture stimuli|Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
219177106|NCT06300320|DRUG|TQ05105 tablets|Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
219177107|NCT04904601|DIETARY_SUPPLEMENT|Kale supplement|Kale (blanched freeze-dried Kale) group1
219271552|NCT05334043|DRUG|Curcumin capsules|5 capsules, 450 mg / capsule
219271553|NCT05639608|PROCEDURE|SCALING|SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
219177108|NCT04904601|DIETARY_SUPPLEMENT|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
219177109|NCT03444064|BIOLOGICAL|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
219177110|NCT05455281|DEVICE|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
219177111|NCT06488313|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
219177112|NCT03195699|DRUG|TTI-101|Oral capsule
219177113|NCT03195699|DRUG|TTI-101|Oral tablet
219177114|NCT06256003|DEVICE|UC-A|Mobile app digital therapy
219177115|NCT06256003|DEVICE|UC-N|Mobile app digital therapy
219271554|NCT03132675|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
219271555|NCT03132675|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
219177116|NCT06522516|BEHAVIORAL|Evidence-based caregiving training|This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.
219177117|NCT06522516|BEHAVIORAL|family resilience intervention|The intervention will be developed based on the Maccubbin Family Resilience Theory, and Delphi methods. The content will contain 8 topics and be incorporated into caregiving training manual.
219177118|NCT06522516|BEHAVIORAL|usual service|This means the usual service provided by the local community health center from nurses during bi-weekly home visit.
219177119|NCT06270173|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
219177120|NCT02924272|DRUG|Ixazomib|Ixazomib Capsules
219177121|NCT05546749|DEVICE|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
219177122|NCT05546749|DEVICE|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
219177123|NCT06392373|DIETARY_SUPPLEMENT|CHO+PRO|0.9 g CHO/kg/hr + 0.3 g PRO/kg/hr
219177124|NCT06392373|DIETARY_SUPPLEMENT|CHO|1.2 g CHO/kg/hr
219177125|NCT05621811|DRUG|Naronapride|Naronapride is a 5HT-4 agonist
219271556|NCT03132675|DEVICE|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
219271557|NCT05350046|DEVICE|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
219271558|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
219271559|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
219271560|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
219271561|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
219177126|NCT05621811|DRUG|Placebo|Placebo
219271562|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
219271563|NCT02817061|DEVICE|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
219177127|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
219177128|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
219177129|NCT04069624|OTHER|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
219177130|NCT06213194|OTHER|MindZone|The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
219177131|NCT04975399|DRUG|CC-92328|CC-92328
219177132|NCT06508697|DIAGNOSTIC_TEST|invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital
219177133|NCT05506319|OTHER|Norepinephrine|The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).
219177134|NCT05506319|OTHER|Vasopressin|The patients will be randomized for the initial suspension of vasopressin (vasopressin group).
219271564|NCT05973123|BEHAVIORAL|Group Nature Outings|A 6 week nature-based intervention for pediatric anxiety. Every other week group outings for families in nature, alternating with every other week nature-based goals for families at home.
219271565|NCT05973123|BEHAVIORAL|Family Outings|6 weeks of weekly outings into nature. These will be supported by the research team through a weekly text message and written materials on skill building and activities to do outdoors.
219271566|NCT05037253|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
219271567|NCT02482610|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
219271568|NCT02482610|OTHER|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
219271569|NCT02482610|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
219271570|NCT02928211|DEVICE|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
219271571|NCT02928211|DRUG|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
219271572|NCT02928211|RADIATION|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
219271573|NCT02296892|DRUG|Remimazolam|For induction and maintenance of sedation
219177135|NCT02100813|DRUG|LEO 43204|
219177136|NCT02100813|DRUG|Placebo|
219177137|NCT04028674|DEVICE|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
219177138|NCT06507462|PROCEDURE|prostate biopsy|All patients were required to underwent transperineal prostate biopsy and have corresponding pathological diagnosis results.
219177139|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
219177140|NCT06210958|OTHER|Intertransverse process block|The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
219177141|NCT06112002|OTHER|Educational Intervention|Attend an educational session
219177142|NCT06112002|BEHAVIORAL|Health Education|Receive educational materials
219177143|NCT06112002|OTHER|Survey Administration|Ancillary studies
219177144|NCT04496947|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being."
219177145|NCT04701047|DEVICE|vaginal pessary|insertion and follow up of a vaginal pessary
219271574|NCT02296892|DRUG|Placebo|Inactive control arm
219271575|NCT02296892|DRUG|Midazolam|For induction and maintenance of sedation
219271576|NCT04253119|DRUG|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
219271577|NCT02653209|DRUG|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
219177146|NCT04701047|PROCEDURE|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
219177147|NCT05703490|DIAGNOSTIC_TEST|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
219177148|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
219177149|NCT03729999|DEVICE|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
219177150|NCT06071871|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant)."
219177151|NCT06071871|DRUG|Polatuzumab vedotin|Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
219177152|NCT06071871|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
219177153|NCT03903120|BEHAVIORAL|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
219177154|NCT05231993|PROCEDURE|Conization|A cone biopsy to remove abnormal tissue.
219177155|NCT05231993|PROCEDURE|Colposcopy|"1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
219177156|NCT06538675|OTHER|Psychotherapy|Patients are assigned to a therapist and will receive psychotherapy
219177157|NCT06537063|OTHER|G4 DNAm test|Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
219177158|NCT03933735|DRUG|TNB-383B|Intravenous (IV) Injection
219177159|NCT06546293|OTHER|core stabilization exercises|The program consists of lumbo-pelvic/core strength and stability exercises. The program will be implemented individually under the supervision of a physiotherapist twice a week for 12 weeks.
219177160|NCT06546293|OTHER|daily physical activity program|The program consists of a daily physical activity program established and monitored for participation through weekly exercise tracking chart. The program will be implemented through weekly physiotherapist's control of the exercise tracking chart for 12 weeks.
219177161|NCT03002207|DEVICE|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
219177162|NCT03002207|PROCEDURE|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
219177163|NCT05182827|OTHER|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
219177164|NCT06438705|DIAGNOSTIC_TEST|SPECT-CT imaging|The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
219177165|NCT03991481|BIOLOGICAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
219177166|NCT03991481|BIOLOGICAL|Liquid-stored platelets|Liquid-stored platelets as per standard practice
219177167|NCT04378439|BEHAVIORAL|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
219177168|NCT04378439|BEHAVIORAL|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
219177169|NCT05308004|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
219177170|NCT06507345|OTHER|Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]|In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.
219177171|NCT06507345|OTHER|Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]|Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
219271578|NCT02653209|DRUG|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
219271579|NCT02653209|DRUG|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
219271580|NCT04268056|DIAGNOSTIC_TEST|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
219271581|NCT06543563|DRUG|esketamine|After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
219271582|NCT06543563|DRUG|normal Saline|After the craniotomy, a continuous infusion of normal saline at a rate of 0.3 ml/kg/h is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
219271583|NCT02165826|DRUG|Roflumilast|Roflumilast tablets
219177172|NCT06129825|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
219177173|NCT03575897|DIAGNOSTIC_TEST|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
219271584|NCT02165826|DRUG|Roflumilast Placebo|Roflumilast placebo-matching tablets
219177174|NCT03525964|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
219177175|NCT03525964|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
219177176|NCT03525964|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
219177177|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
219177178|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
219177179|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
219177180|NCT05827809|BEHAVIORAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
219177181|NCT05483283|OTHER|Empowerment and Navigation|Empowerment and Navigation
219177182|NCT05483283|OTHER|SOC|SOC
219177183|NCT06107738|DRUG|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
219177184|NCT06107738|DRUG|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
219177185|NCT03206671|DRUG|Rituximab window|Rituximab window (375 mg/m²)
219177186|NCT03206671|DRUG|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
219177187|NCT03206671|DRUG|Cyclophosphamide|see detailed protocol description
219177188|NCT03206671|DRUG|Cytarabine|see detailed protocol description
219177189|NCT03206671|DRUG|Dexamethasone|see detailed protocol description
219177190|NCT03206671|DRUG|Doxorubicin hydrochloride|see detailed protocol description
219177191|NCT03206671|DRUG|Vindesine Sulfate|see detailed protocol description
219177192|NCT03206671|DRUG|Etoposide|see detailed protocol description
219177193|NCT03206671|DRUG|Ifosfamide|see detailed protocol description
219177194|NCT03206671|DRUG|Methotrexate|see detailed protocol description
219177195|NCT03206671|DRUG|Prednisolone|see detailed protocol description
219177196|NCT03206671|DRUG|Vincristine|see detailed protocol description
219177197|NCT02285140|DRUG|Cefazolin|administration as outlined
219177198|NCT02285140|DRUG|Vancomycin|administration as outlined
219177199|NCT02503709|DRUG|CDK Inhibitor AT7519|Given IV
219177200|NCT02503709|OTHER|Laboratory Biomarker Analysis|Correlative studies
219177201|NCT02503709|DRUG|Onalespib|Given IV
219177202|NCT02503709|OTHER|Pharmacological Study|Correlative studies
219177203|NCT03455582|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
219177204|NCT03455582|OTHER|Ecological evaluation|Virtual reality task and Actual reality
219177205|NCT03455582|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
219177206|NCT03455582|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
219177207|NCT03455582|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
219177208|NCT05642715|BEHAVIORAL|EX+|All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
219177209|NCT05642715|DRUG|Varenicline|All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
219177210|NCT05642715|BEHAVIORAL|HR|Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
219177211|NCT05642715|BEHAVIORAL|TAU|Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
219177212|NCT05287568|DRUG|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
219177213|NCT05287568|DRUG|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
219177214|NCT05723601|DRUG|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
219177215|NCT05723601|DRUG|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
219177216|NCT05936099|BEHAVIORAL|E-cigarette & Tobacco Use Treatment Intervention|The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
219177217|NCT05406817|DRUG|Revumenib|Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
219177218|NCT04359108|DEVICE|Navigation system mode: Argus Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Argus mode~* Haptics: none~* Audio: none Since this mode only provides the standard Argus vision, it is equivalent to using the base Argus II system without the navigational aid."
219177219|NCT04359108|DEVICE|Navigation system mode: Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: none~* Audio: none"
219177220|NCT04359108|DEVICE|Navigation system mode: Depth Vision with Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: yes~* Audio: yes"
219177221|NCT04359108|DEVICE|Navigation system mode: Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: none~* Haptics: yes~* Audio: yes Since this mode does not provide any visual feedback, it is equivalent to using navigational aid completely blind without a visual prosthesis."
219177222|NCT04359108|DEVICE|Navigation system mode: High Field-of-View Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: High Field-of-View Depth mode (at twice the Argus II resolution and field-of-view along each dimension)~* Haptics: none~* Audio: none"
219177223|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: Low"
219177224|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: High"
219177225|NCT04359108|DEVICE|Distance test vision mode: High Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: Low"
219177226|NCT04359108|DEVICE|Distance test vision mode: High Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: High"
219177227|NCT05340270|DRUG|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
219177228|NCT05340270|DRUG|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
219177229|NCT04087707|DRUG|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
219177230|NCT04087707|DRUG|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
219177231|NCT04087707|DRUG|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
219177232|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
219177233|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
219177234|NCT04851145|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
219177235|NCT06196801|DRUG|Triple-combination therapy|phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
219177236|NCT05413018|DRUG|CC-486|Specified dose on specified days
219177237|NCT05413018|OTHER|Placebo|Specified dose on specified days
219177238|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
219177239|NCT03652688|BEHAVIORAL|Nightlife Safety Plans (NSP)|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
219177240|NCT03652688|BEHAVIORAL|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
219271585|NCT02165826|DRUG|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
219271586|NCT00005964|BIOLOGICAL|filgrastim|
219271587|NCT00005964|DRUG|cyclophosphamide|
219271588|NCT00005964|DRUG|doxorubicin hydrochloride|
219177241|NCT05487248|OTHER|Blood Sample Collection|"For subjects receiving treatments with a 2- or 4-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 2 weeks after treatment start (day 15)~Plasma :~* Before the treatment start (day 1)~* 4 weeks after treatment start (day 29)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1~For subjects receiving treatments with a 3-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 3 weeks after treatment start (day 22)~Plasma :~* Before treatment start (day 1)~* 6 weeks after treatment start (day 43)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1"
219271589|NCT00005964|DRUG|etoposide|
219271590|NCT00005964|DRUG|prednisone|
219271591|NCT00005964|DRUG|vincristine sulfate|
219177242|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
219177243|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
219177244|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
219177245|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
219177246|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
219177247|NCT02050802|DRUG|Moxifloxacin 400 mg|
219177248|NCT02050802|DRUG|Macitentan 10 mg|
219177249|NCT02050802|DRUG|Macitentan 30 mg|
219177250|NCT02050802|OTHER|Placebo|
219177251|NCT06158412|DRUG|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."
219177252|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
219177253|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
219177254|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
219177255|NCT04234685|DEVICE|High Intensity Physio Light Therapy (HIPL Therapy™)|HIPL Therapy™ is an advanced phototherapy method that utilizes an emission wavelength spectrum that has been optimized for treatment of musculoskeletal disorders (MSD) such as OA.
219177256|NCT04234685|BEHAVIORAL|Education|Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
219177257|NCT04234685|BEHAVIORAL|Aerobic Exercise|Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
219177258|NCT04234685|BEHAVIORAL|Resistance Exercise|Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
219177259|NCT04234685|DEVICE|Placebo Physio Light Therapy (HIPL Therapy™)|Phototherapy delivered at an intensity of 5 mW/cm2, a dosage at which there is no therapeutic benefit expected, but the light will still be visible to the participant.
219177260|NCT06643156|DRUG|GP681 10mg/20mg/40mg|0.5/1/2×20mg power for oral suspension taken orally
219177261|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
219177262|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
219177263|NCT05504057|DRUG|Antihistamine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
219177264|NCT05504057|DRUG|Amantadine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
219177265|NCT02737878|BEHAVIORAL|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
219177266|NCT02737878|BEHAVIORAL|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
219177267|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
219271592|NCT01936467|DEVICE|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
219177268|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
219177269|NCT04416815|OTHER|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
219177270|NCT05746494|DEVICE|tDCS|active anodal tDCS and sham tDCS
219177271|NCT06027554|DRUG|Mitoquinone Mesylate|MitoQ given 20 mg per day for 12 weeks.
219177272|NCT06027554|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule taken every day for 12 weeks.
219177273|NCT05899036|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
219177274|NCT05724875|DEVICE|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
219177275|NCT05724875|DEVICE|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
219177276|NCT03168854|BIOLOGICAL|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
219271593|NCT01936467|DEVICE|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
219271594|NCT05810805|OTHER|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
219271595|NCT06212089|DRUG|TR-012001|A single dose of TR-012001 will be administered.
219271596|NCT06212089|OTHER|Placebo|A single dose of placebo will be administered.
219177277|NCT03168854|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
219177278|NCT06554158|RADIATION|Radiation Therapy|De-escalation of Adjuvant Radiotherapy
219177279|NCT03762291|BIOLOGICAL|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
219177280|NCT05147649|DIAGNOSTIC_TEST|functional magnetic resonance imaging|functional magnetic resonance imaging
219177281|NCT04526782|DRUG|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
219177282|NCT04526782|DRUG|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
219177283|NCT06443125|OTHER|Natural psychotherapy|Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
219177284|NCT05409183|DRUG|CRD-740|Tablets administered orally.
219177285|NCT05409183|DRUG|Placebo|Tablets administered orally.
219177286|NCT02274662|BIOLOGICAL|Cultured Thymus Tissue|"Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection."
219177287|NCT02274662|PROCEDURE|Blood Draw|
219177288|NCT02274662|DRUG|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
219177289|NCT02692105|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
219177290|NCT02692105|RADIATION|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
219177291|NCT05931484|DRUG|Gemfibrozil|Oral Solution
219177292|NCT05931484|DRUG|Placebo|Daily dose of Placebo
219271597|NCT01774045|DRUG|PDC-1421|
219271598|NCT01774045|DRUG|Placebo|
219271599|NCT04034849|RADIATION|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
219271600|NCT04034849|RADIATION|Placebo|Device turned off
219271601|NCT00315679|DRUG|Pentoxifylline (also known as oxpentifylline)|
219177293|NCT03709758|DRUG|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
219177294|NCT03709758|DRUG|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
219177295|NCT03709758|DRUG|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
219177296|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
219177297|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
219177298|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
219177299|NCT03469362|PROCEDURE|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
219177300|NCT03469362|PROCEDURE|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
219177301|NCT03472807|OTHER|Collection of blood sample or saliva|at Inclusion
219177302|NCT03472807|OTHER|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
219177303|NCT03472807|OTHER|Collection of blood sample if tumor sample is not available|at Inclusion
219177304|NCT05255224|OTHER|Not applicable as observational study|Not applicable as observational study
219177305|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
219177306|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
219177307|NCT06800326|DIAGNOSTIC_TEST|Ultrasound|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
219177308|NCT06800326|DIAGNOSTIC_TEST|MRE Scan|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
219177309|NCT05356195|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
219177310|NCT02936752|DRUG|Entinostat|Given PO
219177311|NCT02936752|BIOLOGICAL|Pembrolizumab|Given IV
219177312|NCT06801769|DIAGNOSTIC_TEST|C-peptide|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT).
219177313|NCT04197765|DEVICE|accelerated Thetaburst stimulation|"We will administer 20-30 treatment sessions over the course of the study. The study technician will place the coil over the Fp2 electrode of a 10-20 International EEG system hair net, to approximate stimulation of the R-OFC). For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays. We estimate all study-related treatments will be complete in 5-6 weekdays."
219177314|NCT04197765|DEVICE|Sham Comparator|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
219177315|NCT04605549|DRUG|CIN-107 2 mg dosing|One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
219177316|NCT04605549|DRUG|CIN-107 4 mg dosing|Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
219177317|NCT04605549|DRUG|CIN-107 8 mg dosing|Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
219177318|NCT06801938|PROCEDURE|Perioperative Cystoscopy and Methylene Blue Test|The ability of perioperative methylene blue and cystoscopy versus postoperative cystoscopy to detect complications will be compared in patients.
219177319|NCT04489771|DRUG|Belzutifan|Oral administration
219177320|NCT03659734|BEHAVIORAL|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
219177321|NCT03659734|BEHAVIORAL|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
219177322|NCT06800950|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
219177323|NCT06800950|BIOLOGICAL|QIV Control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
219177324|NCT06801652|OTHER|Sperm morphology indexes|We analyzed all sperm morphology indexes in all groups.
219177325|NCT06147622|DRUG|Prazosin + cyproheptadine|Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.
219177326|NCT06147622|DRUG|KT110|Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.
219177327|NCT04776330|BIOLOGICAL|BCMA targeted prime CAR-T cells|BCMA targeted prime CAR-T cell therapy
219177328|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
219177329|NCT05899452|BEHAVIORAL|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
219271602|NCT04547023|BEHAVIORAL|Fasting before gestational diabetes screen|Fasting for at least 6 hours before 1-hour gestational diabetes screen.
219177330|NCT05899452|BEHAVIORAL|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
219177331|NCT03241459|DEVICE|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
219177332|NCT03241459|DEVICE|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
219177333|NCT05971563|DIETARY_SUPPLEMENT|Casein|Natural protein
219177334|NCT05971563|DIETARY_SUPPLEMENT|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
219271603|NCT04547023|BEHAVIORAL|Per oral intake of food and drink|Per oral intake of food and drink within 2 hours of gestational diabetes screen
219271604|NCT00250432|DRUG|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
219271605|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
219271606|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
219271607|NCT04319146|PROCEDURE|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
219271608|NCT04214353|DIAGNOSTIC_TEST|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
219271609|NCT04214353|DIAGNOSTIC_TEST|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
219177335|NCT05971563|DIETARY_SUPPLEMENT|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
219177336|NCT06789237|OTHER|weighted blanket|Participants will be covered with a weighted blanket for 30 minutes
219271610|NCT00830687|DEVICE|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
219271611|NCT03764995|OTHER|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
219177337|NCT06789237|OTHER|non-weighted blanket|Participants will be covered with a sham non-weighted blanket for 30 minute
219177338|NCT06795633|OTHER|Holistic Care Program for High-Risk Pregnancies|High-risk pregnant women admitted to the perinatology clinic participated in the Holistic Care Program for High-Risk Pregnancies in addition to the midwifery care provided in the clinic.
219177339|NCT03476746|DRUG|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
219177340|NCT03476746|DRUG|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
219177341|NCT06800573|OTHER|Conventional physical therapy|including strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior, (2 sets of 10 repetitions per day) and stretching exercises for pectoralis muscles (20seconds hold, 5 repetition.
219177342|NCT06800573|OTHER|lying posture with progression|"Exercise 1, the lying posture with leg extension progression, was aimed to stretch the anterior muscle chain (diaphragm, pectoralis minor, scalene, sternocleidomastoid, intercostalis, iliopsoas, arm, forearm, and hand flexors)(Bonetti et al., 2010).~Exercise 2, the lying posture with flexion of the thighs, was intended to stretch the posterior chain (upper trapezius, levator scapulae, suboccipital, erector spinae, gluteus maximus, ischiotibial, triceps surae, and foot intrinsic muscles)."
219177343|NCT06800573|OTHER|smartphone app exercises|about 50 min a day, 4 days a week for an 8-week period also, performed exercises which were reminded by a smartphone app at predetermined times.
219177344|NCT06546384|DRUG|Semaglutide|"Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d."
219177345|NCT06546384|BEHAVIORAL|Weight reduction recommendations (nutritional and exercise)|Participants will receive nutritional and exercise recommendations and 2 telephone consultations
219177346|NCT06801730|DRUG|Irinotecan liposome combined with bevacizumab|Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
219271612|NCT03764995|OTHER|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
219271613|NCT03764995|OTHER|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
219177347|NCT05100251|DRUG|WBC100 QOD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 7 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QOD. The second dose group is 1mg QOD. The third dose group is 1.5 mg QOD. The fourth dose group is 2.0 mg QOD. The fifth dose group is 2.5 mg QOD. The sixth dose group is 3.0 mg QOD. The seven dose group is 3.5 mg QOD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
219271614|NCT02760901|DRUG|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
219271615|NCT02760901|DRUG|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
219271616|NCT02760901|DRUG|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
219271617|NCT02760901|DRUG|saline|saline hydration 2500 ml before cisplatin therapy
219271618|NCT02760901|DRUG|Cisplatin|patients with tumours already prescribed cisplatin
219271619|NCT01663038|DRUG|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
219271620|NCT01663038|DRUG|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
219271621|NCT01663038|DRUG|Aspirin|
219177348|NCT05100251|DRUG|WBC100 QD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
219177349|NCT05100251|DRUG|WBC100 BID|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
219177350|NCT03793972|OTHER|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
219177351|NCT03793972|OTHER|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
219177352|NCT05558501|OTHER|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
219177353|NCT05558501|OTHER|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
219177354|NCT06560112|DRUG|AK104|ivgtt
219177355|NCT06560112|DRUG|AK112|ivgtt
219177356|NCT06560112|DRUG|Chemotherapy|ivgtt
219271622|NCT05226676|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
219271623|NCT00627354|DRUG|etoposide|
219271624|NCT00627354|DRUG|mitoxantrone hydrochloride|
219271625|NCT00627354|DRUG|prednisone|
219271626|NCT00627354|DRUG|vinorelbine tartrate|
219271627|NCT02039895|RADIATION|HITS|Helical irradiation of the total skin by helical tomotherapy
219271628|NCT03981497|PROCEDURE|Microwave ablation (MWA)|Thermal ablation
219271629|NCT05438836|RADIATION|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
219271630|NCT03525470|BIOLOGICAL|Water|150 mil of water was drunk on two occasions
219271631|NCT03525470|OTHER|No drink|Although body weight lost no drink consumed
219271632|NCT00855855|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
219271633|NCT04518904|OTHER||
219271634|NCT01655303|DRUG|Propranolol|
219271635|NCT01655303|DRUG|Metoprolol|
219271636|NCT01655303|DRUG|Verapamil|
219271637|NCT01655303|DRUG|Diltiazem|
219271638|NCT00652509|BEHAVIORAL|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
219271639|NCT00652509|BEHAVIORAL|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
219271640|NCT03784820|BEHAVIORAL|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
219271641|NCT03784820|BEHAVIORAL|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
219271642|NCT00736411|PROCEDURE|acupuncture|16 treatments over 8 weeks
219271643|NCT00736411|PROCEDURE|IVF|one 4 week IVF cycle
219177357|NCT04943497|OTHER|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
219177358|NCT04943497|OTHER|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
219177359|NCT04943497|OTHER|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
219177360|NCT04943497|OTHER|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
219177361|NCT05480384|DRUG|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
219177362|NCT05480384|DRUG|Trastuzumab deruxtecan|Given in combination with Nivolumab.
219177363|NCT06801028|BIOLOGICAL|injection Sekucinumab|All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.
219177364|NCT05597345|DRUG|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
219177365|NCT03197662|DRUG|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
219177366|NCT03197662|DRUG|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
219177367|NCT06453551|DRUG|TRN501 - Dose 1|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177368|NCT06453551|DRUG|TRN501 - Dose 2|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177369|NCT06453551|DRUG|TRN501 - Dose 3|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177370|NCT06453551|DRUG|TRN501 - Dose 4|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177371|NCT06453551|DRUG|TRN501 - Dose 5|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219271644|NCT04501393|OTHER|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
219177372|NCT06453551|DRUG|TRN501 - Dose 6|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177373|NCT06453551|DRUG|TRN501 - Dose 7|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177374|NCT06453551|DRUG|TRN501 - Dose 8|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
219177375|NCT04757519|BEHAVIORAL|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
219271645|NCT04539223|DRUG|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
219271646|NCT05321199|DRUG|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
219271647|NCT06067607|OTHER|eye gaze technology|eye gaze technology and software activities
219271648|NCT05536206|DEVICE|Wireless and continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
219271649|NCT05652439|OTHER|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
219271650|NCT00794170|BEHAVIORAL|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
219271651|NCT00658606|DRUG|alefacept|IM
219271652|NCT00658606|PROCEDURE|Narrow Band UVB Phototherapy|UVB Phototherapy
219271653|NCT04831879|DEVICE|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
219271654|NCT05097391|BEHAVIORAL|Warm-up (5 minutes)|Participants will benefit from passive stretches of hamstrings, calf muscles including a range of motion (ROM) exercise to the lower limbs as mat exercises.
219177376|NCT04757519|BEHAVIORAL|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
219177377|NCT03318406|DEVICE|Bronchoscopic Thermal Vapor Ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
219177378|NCT05565534|BEHAVIORAL|Nurse-practitioner led intervention|"* Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
219177379|NCT05918328|DRUG|Albumin paclitaxel+trastuzumab+pyrrolitinib|albumin paclitaxel （260mg/㎡ every 3 weeks or 125mg/㎡ weekly）+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg, once every 3 weeks)+pyrrolitinib (320mg, QD), 3 weeks as one cycle.
219177380|NCT05918328|DRUG|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
219177381|NCT05381597|DRUG|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
219177382|NCT05381597|DRUG|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
219177383|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
219177384|NCT01463423|RADIATION|iSABR, 25 Gray in 1 fraction for small peripheral tumors|Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
219177385|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium peripheral tumors|Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
219177386|NCT01463423|RADIATION|iSABR, 54 Gray in 3 fractions for large peripheral tumors|Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
219177387|NCT01463423|RADIATION|iSABR, 40 Gray in 4 fractions for small central tumors|Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
219271655|NCT05097391|BEHAVIORAL|Conventional physiotherapy exercise (15 minutes)|The conventional treatments will be active-assisted and free active exercises to the lower limbs on the mat for five (5) minutes. This will be followed by strength training such as sit-to-stand exercises for five (5) minutes and squatting exercises for five (5) minutes prior to the over-ground training.
219177388|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium central tumors|Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.
219177389|NCT01463423|RADIATION|iSABR, 60 Gray in 8 fractions for large central tumors|Radiotherapy procedure for participants with large central tumors \> 30 cc.
219177390|NCT04702581|DRUG|PCV chemotherapy|"1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given."
219177391|NCT04702581|DRUG|Radiotherapy and PCV chemotherapy|"Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally"
219177392|NCT04920812|GENETIC|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
219177393|NCT05792280|DEVICE|AI system|Patients will undergo EUS examination with the assistance of AI system.
219177394|NCT05730231|OTHER|Effects of calorie restriction and time-restricted eating on human health|Calorie restriction plan will be prepared for each participant. After nutritional data collection at baseline, all participant will attend educational sessions about healthy diet and beneficial effects of time-restricted eating. To estimate total energy needs, individuals' RMR will be measured from indirect calorimeter and multiplied by the appropriate factor of physical activity (from 1.3 to 1.6), and then a reduction of 200-500 kcal will be made. Macronutrient composition of the diet will be approximately 45-55% of carbohydrate, 30-35% of fat, and 15-20% of protein. 30% of daily energy intake will be consumed by breakfast, 40% by lunch and 30% by dinner. During posting participants will be allowed to consume only water and herbal infusions without added sugars or sweeteners. Dietary intake of participants will be followed during the study using a 24-h recall. Dietary data will be analysed using the Open Platform for Clinical Nutrition accessible through the website http://opkp.si/.
219177395|NCT06107634|PROCEDURE|Gastropexy|"In the intervention group, a three-point gastropexy is added to the repair. First, the right fundus flap is adapted posteriorly to the crural portion of the diaphragm with a 2-3 cm long running non-absorbable suture (posterior gastropexy). Second, the left fundus flap is adapted to the diaphragm anterolateral to the hiatus with a 2-3 cm long running non-absorbable suture (left anterolateral gastropexy). Finally, the minor curvature of the anterior stomach wall is adapted during reduced intraabdominal pressure to the anterior abdominal wall with a 2-3 cm long running non-absorbable suture (anterior gastropexy)."
219296290|NCT06545500|DRUG|Glycopyrrolate (14 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
219296291|NCT06545500|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
219296292|NCT05618106|OTHER|Low FODMAP DIET = Diet with Low polyol, FOS and GOS|Low Polyol diet
219177396|NCT06107634|PROCEDURE|Paraesophageal hernia repair|Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
219177397|NCT06021197|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of CIAS
219177398|NCT06021197|DRUG|Placebo Cap|Use of placebo as a comparator
219177399|NCT05033314|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
219177400|NCT05033314|DRUG|Placebo|matching placebo daily
219177401|NCT04541147|DRUG|Dexamethasone|dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
219177402|NCT04541147|DRUG|Analgesics|"standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)"
219177403|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
219177404|NCT01030328|DRUG|Placebo|2 sugar pills by mouth once a day.
219177405|NCT01030328|DRUG|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
219271656|NCT05097391|BEHAVIORAL|Over-ground training with lower limb loading (15-25 minutes)|"Participants will perform the over-ground training exercise with an external 1.5kg load on the paretic lower limb placed 2cm above the ankle joint. Before commencing the over-ground training, all the participants will observe a pre-exercise rest period of about two (2) minutes during which their heart rate and blood pressure measurements will be recorded.~The over-ground training will involve the patients walking within a demarcated path. Each participant will be instructed to stand and walk 15meters to and fro for five (5) minutes after which they will be asked to stop and rest for two (2) minutes. The over ground training exercise will be repeated 3 times in the first 2 weeks of the training (15 minutes); 4 times in weeks 3-4 of the training (20 minutes); and 5 times in weeks 5-8 of the training (25 minutes)."
219271657|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
219271658|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
219271659|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
219271660|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
219271661|NCT05520528|BEHAVIORAL|Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia|The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
219271662|NCT05673967|OTHER|Non-Interventional|No study treatment will be administered on this study.
219271663|NCT04112186|BEHAVIORAL|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
219271664|NCT04112186|BEHAVIORAL|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
219177406|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
219177407|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
219271665|NCT03025308|DRUG|Filgotinib|Tablet(s) administered orally once daily
219271666|NCT03025308|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
219271667|NCT06267092|OTHER|No treatment given|Participants will not get any medicine during this study.
219177408|NCT04064164|BEHAVIORAL|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
219177409|NCT06332430|DRUG|CAN2109|CAN2109 IT injection (once every 3 weeks)
219177410|NCT06176664|DEVICE|Low flow oxygen|Standard nasal cannula oxygen up to 2 liters/minute
219177411|NCT06176664|DEVICE|High-flow nasal cannula oxygen|High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
219177412|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
219177413|NCT06160908|DEVICE|sham NirsCure|Non near-infrared light irradiation；only the equipment appearance is consistent with the test device；Once a day, once for 30 minutes, 6 times a week
219177414|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
219177415|NCT06455059|DRUG|Vosoritide|Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
219271668|NCT06267092|DRUG|Cagrilintide and Semaglutide|Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
219177416|NCT06455059|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
219177417|NCT04724447|DRUG|Valganciclovir|2 x 450mg VGCV tablets
219177418|NCT04724447|DRUG|Placebo|Placebo equivalent of 900mg/day VGCV
219177419|NCT05736133|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
219177420|NCT05736133|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
219177421|NCT05179187|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
219177422|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
219177423|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
219177424|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
219177425|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
219177426|NCT06072768|DRUG|15-day taper prednisone|The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
219177427|NCT06072768|DRUG|150-day taper prednisone|The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
219177428|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
219177429|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
219177430|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
219177431|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
219177432|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
219271669|NCT06267092|DRUG|Placebo|Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
219271670|NCT06132828|DRUG|DR30206|Subjects receive DR30206 intravenously
219177433|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
219177434|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
219177435|NCT05183204|DRUG|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
219177436|NCT05183204|DRUG|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
219271671|NCT03355976|DRUG|Nivolumab|240mg flat dose every 2 weeks
219271672|NCT03355976|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
219177437|NCT05183204|OTHER|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
219177438|NCT05470088|OTHER|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
219177439|NCT06371300|DEVICE|Red LLLT|Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
219177440|NCT06371300|DEVICE|Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
219177441|NCT06371300|DEVICE|Sham Red LLLT|Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
219177442|NCT06371300|DEVICE|Sham Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
219177443|NCT05227248|DIETARY_SUPPLEMENT|Dark chocolate|Patients were administered 20 grams of dark chocolate
219177444|NCT05227248|DIETARY_SUPPLEMENT|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
219271673|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
219271674|NCT06314438|BEHAVIORAL|Family Care Project|Caregivers will be administered the Family Care Project workbook.
219271675|NCT06191042|DRUG|si-544|Subcutaneous injection in the abdomen
219271676|NCT06191042|DRUG|Placebo|Subcutaneous injection in the abdomen
219271677|NCT04253262|DRUG|Rucaparib|Rucaparib (PO twice daily continuous)
219271678|NCT04253262|DRUG|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
219271679|NCT04468607|DRUG|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
219271680|NCT04734015|BEHAVIORAL|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
219271681|NCT01972945|PROCEDURE|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
219271682|NCT01972945|PROCEDURE|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
219177445|NCT06254313|OTHER|Additional tubes and LBA|4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
219177446|NCT04897256|BEHAVIORAL|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
219177447|NCT06092671|OTHER|Family-centred perioperative care for anaesthesia|The patient in intervention group and parent will receive the Family-centred perioperative care for anaesthesia, including video education, anaesthesia mask practice, electronic pamphlet, distraction strategies and parental presence. The patient will not receive sedatives before surgery. During the anesthesia induction period, it is recommended that the parent be instructed by the anesthesiologist to complete the induction of inhalation of the anesthesia mask, and the patient will be accompanied by the parent during the awakening period.
219177448|NCT02949362|DRUG|Teduglutide|0.05mg/kg
219177449|NCT02949362|OTHER|SOC|Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
219177450|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
219177451|NCT03986697|DRUG|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
219177452|NCT06165146|DRUG|Repaglinide|Administered orally.
219177453|NCT06165146|DRUG|Pirtobrutinib|Administered orally.
219177454|NCT03390322|DEVICE|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
219177455|NCT06784076|DRUG|Anifrolumab|Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
219177456|NCT05817357|DEVICE|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
219271683|NCT00365547|BIOLOGICAL|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
219271684|NCT00365547|DRUG|topotecan hydrochloride|Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
219177457|NCT04633122|DRUG|Ripretinib|Oral kinase inhibitor
219177458|NCT04633122|DRUG|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
219177459|NCT05260957|DRUG|Mosunetuzumab|"Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77."
219177460|NCT05260957|DRUG|Polatuzumab|"Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77."
219177461|NCT05260957|BIOLOGICAL|CAR-T Cell Therapy|Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
219177462|NCT04380558|OTHER|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
219177463|NCT03307343|BEHAVIORAL|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
219177464|NCT05564273|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
219177465|NCT05564273|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
219177466|NCT05385367|OTHER|Regional anesthetic|Patient having just the nerve block for surgery
219177467|NCT05385367|OTHER|General anesthetic|Patient having just general anesthetic ie. 'go completely under' for surgery
219271685|NCT00198003|BEHAVIORAL|Educational program to address patients' expectations|
219177468|NCT05385367|OTHER|Combined general anesthetic and regional anesthetic|Patient having a combination of a nerve block and general anesthetic for surgery
219177469|NCT05088876|DRUG|Placebo|Blinded withdrawal of regular co-medication with paracetamol
219177470|NCT05088876|DRUG|Paracetamol|Paracetamol in the dose already used
219177471|NCT05831566|DRUG|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
219177472|NCT06636006|BEHAVIORAL|Aerobic Exercise|50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
219271686|NCT00728000|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
219271687|NCT00728000|DRUG|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
219177473|NCT06636006|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
219177474|NCT06261437|OTHER|CCAR|The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.
219177475|NCT06261437|OTHER|FSR|The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
219177476|NCT06541145|DRUG|Mupirocin|Participants will place a pea-sized amount (or approximately 1cm ribbon) of 2% mupirocin ointment (Duke formulary) on a cotton swab and gently massage it into the anterior nares twice daily for 5 days.
219177477|NCT06541145|DRUG|Chlorhexidine baths|Participants will be instructed to use pre-packaged chlorhexidine cloths. Each cloth will be used to wipe designated body areas (i.e., arms, legs, chest and neck, back and perineum) once a day for 5 days. These are inexpensive cloths that are easy to use and have been shown to be effective at eradicating Staph aureus carriage. Ideally, participants will be instructed not to rinse off immediately after using the cloths. Baths should be performed on the same 5 days as they apply the intranasal mupirocin.
219177478|NCT04630899|OTHER|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
219177479|NCT04630899|OTHER|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
219177480|NCT05364515|DRUG|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
219177481|NCT05364515|DRUG|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
219177482|NCT04848740|DEVICE|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
219177483|NCT03686345|DRUG|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
219177484|NCT04979130|DRUG|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
219177485|NCT04979130|DRUG|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
219177486|NCT00144261|DRUG|nevirapine|
219271688|NCT00728000|DRUG|Erlotinib|100mg/day PO on days 1-14 and 15-28
219271689|NCT01258647|DIETARY_SUPPLEMENT|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
219271690|NCT00546247|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
219271691|NCT01287728|DRUG|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
219177487|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
219177488|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
219177489|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
219177490|NCT05738148|DRUG|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
219177491|NCT05738148|DRUG|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC."
219177492|NCT03847636|DEVICE|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
219177493|NCT01798498|DEVICE|Princess® VOLUME|
219177494|NCT03896789|OTHER|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
219177495|NCT06360237|DRUG|Olezarsen|Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
219177496|NCT05206422|DEVICE|Doraya Catheter|The Doraya Catheter is a temporary intravenous flow regulator, positioned in the inferior vena cava below the level of the renal veins
219177497|NCT05367414|OTHER|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
219177498|NCT05367414|OTHER|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
219177499|NCT04227769|DRUG|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
219177500|NCT05495490|PROCEDURE|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
219177501|NCT05495490|PROCEDURE|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
219177502|NCT03447470|DRUG|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
219177503|NCT03447470|DRUG|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
219177504|NCT06798870|DEVICE|removable appliances|removable appliances; clear aligner and removable inclined plane, for correcting anterior crossbite vin mixed dentition patient
219177505|NCT06147726|OTHER|Upper extremity position matching exercises in virtual reality|In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
219177506|NCT06147726|OTHER|Conventional physiotherapy|proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
219177507|NCT06806462|GENETIC|Biomolecular profile of bone metastases|Describe the biomolecular profile of bone metastases
219177508|NCT06224530|DRUG|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
219177509|NCT06224530|DRUG|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
219177510|NCT05901246|DIETARY_SUPPLEMENT|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
219177511|NCT05901246|OTHER|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
219177512|NCT06806605|OTHER|3d analisys|To analyze the orthodontic-surgical set-up carried out as part of the normal care pathway of patients operated since January 2015 and who completed treatment on May 30, 2020 in the Orthodontic First patient.
219177513|NCT06528145|OTHER|Evalation|Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
219271692|NCT05435911|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
219177514|NCT04722848|DRUG|Ponatinib + Blinatumomab|"Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation"
219177515|NCT04722848|DRUG|Chemotherapy + Imatinib|patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
219271693|NCT05435911|DRUG|Flumazenil|Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
219271694|NCT05435911|DRUG|Propofol|Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
219177516|NCT05349500|BEHAVIORAL|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
219177517|NCT05349500|BEHAVIORAL|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
219177518|NCT06137963|OTHER|Transform10 Diabetes Prevention Program|"The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation."
219271695|NCT04444934|OTHER|histological examination|Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
219271696|NCT02693951|DRUG|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
219177519|NCT06300528|DRUG|Pemigatinib|Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
219177520|NCT04750200|PROCEDURE|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
219177521|NCT05782582|DIAGNOSTIC_TEST|Package investigation|Investigations performed on a single visit, according to arm description
219177522|NCT05782582|DEVICE|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
219271697|NCT00196352|DRUG|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
219271698|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
219271699|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
219271700|NCT02033447|OTHER|Magnetic Nanoparticle Injection|
219177523|NCT05782582|DIAGNOSTIC_TEST|Standard investigation|Sequential investigations according to arm description
219177524|NCT05780437|BIOLOGICAL|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
219177525|NCT05780437|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
219177526|NCT05780437|BIOLOGICAL|Remdesivir|Antiviral agent
219271701|NCT06545461|OTHER|Fruits and Vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups daily of F+V provided in weekly allotments. Amount provided will be that calculated for the participant multiplied times number of household members to assure participants eat the prescribed amount and do not share with household members.
219271702|NCT06545461|OTHER|Sodium Bicarbonate (NaHCO3)|Participants will receive 0.3 mEq/kg bw/day NaHCO3 tablets to match the alkali provided by F+V given to F+V participants. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in two divided oral doses.
219271703|NCT06545461|OTHER|Usual Care|Participants will receive standard medical care but no additional alkali (F+V nor NaHCO3).
219271704|NCT00000951|DRUG|Fluconazole|
219271705|NCT06851806|DRUG|Palivizumab 15 mg/kg|Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection
219271706|NCT04827745|DRUG|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
219271707|NCT04447833|DRUG|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
219271708|NCT06646653|DEVICE|Alma System|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
219271709|NCT06646913|DEVICE|Transcutaneous Electrical Nerve Stimulation|Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
219271710|NCT05924386|PROCEDURE|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
219271711|NCT05924386|PROCEDURE|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
219271712|NCT03170518|DRUG|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
219271713|NCT03170518|DRUG|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
219271714|NCT03170518|DRUG|Placebo|Matching placebo tablet will be administered orally once-daily.
219271715|NCT04428476|BIOLOGICAL|Deramiocel (CAP-1002)|Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months
219271716|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
219271717|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
219271718|NCT00546078|BIOLOGICAL|Cervarix™|Intramuscular injection, one or three doses
219271719|NCT04637516|DEVICE|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
219271720|NCT00135785|DRUG|Bupropion|
219271721|NCT00135785|DRUG|Placebo|
219177527|NCT06584812|DRUG|Tiprogrel|Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
219177528|NCT06584812|DRUG|Tiprogrel|Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
219177529|NCT06584812|DRUG|Clopidogrel|Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.
219177530|NCT06584812|DRUG|Ticagrelor|Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.
219177531|NCT03198702|DRUG|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
219271722|NCT02068378|DEVICE|CMPE Optical Sensor Device|Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
219177532|NCT03198702|OTHER|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
219177533|NCT03452579|DRUG|Nivolumab|240mg
219177534|NCT03452579|DRUG|Standard Dose Bevacizumab|10mg/kg
219177535|NCT03452579|DRUG|Low Dose Bevacizumab|3mg/kg
219177536|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
219177537|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
219271723|NCT04455607|BEHAVIORAL|perturbation training|A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
219177538|NCT06772480|DRUG|Thalidomide|Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
219177539|NCT06772480|PROCEDURE|Argon Plasma Coagulation|Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
219177540|NCT04487054|OTHER|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
219177541|NCT06502327|OTHER|Instructions A|"Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
219177542|NCT06502327|OTHER|Instructions B|"Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
219177543|NCT05965440|DRUG|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
219177544|NCT05538247|DRUG|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
219177545|NCT05538247|DIETARY_SUPPLEMENT|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
219177546|NCT05538247|DRUG|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
219177547|NCT04474613|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
219177548|NCT06132503|DRUG|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
219177549|NCT06461832|PROCEDURE|Group 1|In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.
219177550|NCT06461832|PROCEDURE|Group 2|In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
219271724|NCT02325830|DEVICE|Carillon Mitral Contour System|Percutaneous mitral valve repair
219271725|NCT03454659|PROCEDURE|Craniotomy|Extracting the part of the sculpt
219177551|NCT04345250|OTHER|Energy restriction|A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
219177552|NCT06800443|OTHER|Silica-based fluoride toothpaste containing clay, charcoal, blue covarine and green covarine|Silica-based toothpaste containing charcoal, clay, blue covarine, green covarine and fluoride as sodium fluoride
219177553|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing lower level of blue covarine and fluoride as sodium monofluorophosphate
219177554|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing higher level blue covarine and fluoride as sodium monofluorophosphate
219177555|NCT06800443|OTHER|Control silica-based fluoride toothpaste|Control silica-based toothpaste containing fluoride as sodium fluoride
219271726|NCT02854618|OTHER|additional blood sample|
219271727|NCT03023423|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
219177556|NCT01597388|DRUG|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
219177557|NCT01597388|DRUG|Fulvestrant|IM monthly after loading dose
219177558|NCT06798987|OTHER|Meteorological conditions and air pollution|Climate change e.g. global surface temperature rise; extreme weather events e.g. heat waves, floods
219177559|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
219271728|NCT03023423|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
219271729|NCT03001622|BIOLOGICAL|IFX-1|chimeric, monoclonal antibody
219177560|NCT05377242|DIETARY_SUPPLEMENT|Curcumin|"Curcumin (chemical C21H20O6) is derived from turmeric (Curcuma longa) root extract, standardized to contain 95% curcuminoids. The greatest obstacle with curcumin is its poor natural bioavailability. To help circumvent that issue, a piperazine is included as black pepper 5.3mg (Piper nigrum) fruit extract standardized to 95% piperine. The botanical we are using is provided by Pure Encapsulations. Curcumin being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive curcumin. Participants will receive placebo, low-dose (500 mg/day), medium-dose (1000 mg/day), and/or high dose (2000 mg/day) curcumin in a randomized order."
219271730|NCT02335645|OTHER|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
219177561|NCT05377242|DIETARY_SUPPLEMENT|Resveratrol|"Resveratrol (chemical C14H12O3) is provided as 99% Pure Trans-Resveratrol (MegaResveratrol) from polygonum cuspidatum root). Resveratrol being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive resveratrol. Participants will receive placebo, low-dose (250 mg/day), medium-dose (500mg/day), and/or high dose (1000mg/day) resveratrol in a randomized order."
219177562|NCT05377242|DIETARY_SUPPLEMENT|Stinging Nettle|"Stinging nettle is derived from nettle (Urtica spp) leaf. The botanical we are using is provided by Pure Encapsulations. Stinging Nettle being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive stinging nettle. Participants will receive placebo, low-dose (435mg/day), medium-dose (870mg/day), and/or high dose (2610mg/day) stinging nettle in a randomized order."
219177563|NCT05352074|PROCEDURE|Total colectomy with ileorectal anastomosis|Following complete colonic mobilization without preservation of the ileocolic vascular pedicle, the surgical specimen was extracted by extending the right lower quadrant trocar incision to approximately 4-5 cm. A resection of ileum, 2-3 cm proximal to the ileocecal junction, will be conducted by stapler. The anvil of a 29-mm circular stapler was inserted into the proximal ileal lumen and repositioned intra-abdominally. Ileorectal anastomosis was performed by transanal insertion of the circular stapler, aiming to achieve a tension-free, contamination-minimized reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in layers.
219177564|NCT05352074|PROCEDURE|Subtotal colectomy with cecal-rectal anastomosis|Following complete colonic mobilization with preservation of the ileocolic vascular pedicle and its branches, the surgical specimen was extracted by extending the right lower quadrant trocar incision to 4-5 cm. After insertion of the anvil from a 29-mm circular stapler through the ascending colon resection margin, a resection about 3 cm distal to the ileocecal junction will be conducted. The cecum was then positioned in the pelvis without rotational torsion, and an antiperistaltic cecorectal anastomosis was created between cecal fundus (after appendectomy) and the rectal stump. The anastomosis was performed via transanal insertion of the circular stapler to ensure tension-free, contamination-controlled reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in a layered fashion.
219177565|NCT05390918|BEHAVIORAL|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
219177566|NCT05390918|OTHER|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
219271731|NCT01498783|DRUG|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
219271732|NCT03214536|PROCEDURE|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
219271733|NCT03214536|DRUG|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
219271734|NCT03214536|PROCEDURE|Spine surgery|Surgery of lumbar spine
219271735|NCT03214536|PROCEDURE|anesthesia|general anesthesia
219271736|NCT05568368|OTHER|No intervention|no intervention
219271737|NCT05716529|OTHER|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
219271738|NCT00273208|BEHAVIORAL|10 week behavioral intervention program|
219271739|NCT01267669|DRUG|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
219271740|NCT01267669|DRUG|Placebo|Emergency EVL plus placebo infusion for 5 days
219271741|NCT00333255|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|
219271742|NCT01907269|BEHAVIORAL|Video-based Intervention|Video clips delivered by DVD and Internet
219271743|NCT03358238|BEHAVIORAL|Weekly review|Each week in the study, an interviewer will review manic and depressive symptoms self-reported by a participant and patterns of activity, sleep, and heart rate collected by the participant's activity tracker.
219271744|NCT03358238|OTHER|No weekly review|An interviewer will not review self-report symptoms and patterns collected from an activity tracker.
219177567|NCT06802510|PROCEDURE|Microwave Ablation|The MWA group followed a similar resection procedure as the control group. The area of ablation was evaluated strictly by radiologists and surgeons according to the following criteria: 1) Areas of tumor response, progression, or suspicious invasion (intermediate-high signal and edema range in T2) were assessed. Wide margins of at least 2-3 cm or more were obtained over the normal tissue around the tumor. Ablation margins were covered using a microwave ablation array with antennas (Microwave Ablation System BD-GT, Baird Medical LLC), aimed at completely inactivating the tumor in situ. Ablation needles were strategically arranged to form a matrix covering the target zone. The ablation time and power were determined based on the extent of the lesion, ensuring the temperature of the ablation area remained between 70-80°C. A 50 ml syringe was used to continuously drip and spray ice-cold saline to keep surrounding tissue temperatures below 40-43°C.
219177568|NCT05227664|DRUG|AK117|Intravenous (IV) infusion
219177569|NCT05227664|DRUG|AK112|Intravenous (IV) infusion
219271745|NCT04618380|DIAGNOSTIC_TEST|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
219271746|NCT01227616|DRUG|Ferumoxytol|IV Ferumoxytol
219177570|NCT05227664|DRUG|Nab paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
219177571|NCT05227664|DRUG|paclitaxel|Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
219177572|NCT06803459|OTHER|Baduanjin|36 times.
219177573|NCT06803459|OTHER|PNF|36 times.
219177574|NCT06803875|BIOLOGICAL|Autologous hALK.CAR T cells|Autologous chimeric antigen receptor T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor
219177575|NCT06802796|DIAGNOSTIC_TEST|Plasma NGAL test|Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.
219177576|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
219177577|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
219177578|NCT06082804|OTHER|APN and medical management|Patients are followed by the advanced practice nurse and the hematologist.
219177579|NCT06082804|OTHER|Medical management|Patients are followed by the hematologist only (standard of care).
219177580|NCT06082804|BEHAVIORAL|Quality of life assessment|EORTC-QLQ-C30 questionnaire
219177581|NCT06082804|BEHAVIORAL|Treatment compliance assessment|GIRERD questionnaire
219177582|NCT05261282|BEHAVIORAL|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
219177583|NCT05828680|OTHER|Observation|No intervention
219177584|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
219177585|NCT06306612|DRUG|Systemic Chemohormonal Therapy|Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
219177586|NCT06306612|DRUG|Systemic Hormonal Therapy|Under continuous ADT, oral darolutamide 600mg twice per day
219177587|NCT06306612|PROCEDURE|Cytoreductive Prostatectomy|Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
219177588|NCT06306612|PROCEDURE|Postoperative Adjuvant Radiotherapy|Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
219177589|NCT04788511|DRUG|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
219177590|NCT04788511|DRUG|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
219177591|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
219177592|NCT06441422|OTHER|Blood flow restriction training|Participants randomized to blood flow restriction training will complete low load resistance training exercises while the limb is occluded at 80% arterial occlusion pressure.
219177593|NCT06441422|OTHER|No blood flow restriction training|Participants randomized to no blood flow restriction training will complete low load resistance without occlusion.
219271747|NCT01227616|DRUG|Iron Sucrose|IV Iron Sucrose
219271748|NCT03128528|DRUG|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
219177594|NCT05918263|BEHAVIORAL|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
219177595|NCT03737734|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
219177596|NCT05828459|DRUG|OT-A201|OT-A201 IV infusion qw or q2w
219177597|NCT05828459|DRUG|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
219177598|NCT05828459|DRUG|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
219177599|NCT05828459|DRUG|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
219177600|NCT05828459|DRUG|TBD Compound|Combination regimen for hematological malignancy
219177601|NCT04250116|DRUG|NOAC monotherapy|Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
219271749|NCT03128528|DRUG|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
219271750|NCT04749355|DRUG|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
219271751|NCT03297762|BEHAVIORAL|gamification|incentives/rewards and contact between standard visits
219271752|NCT03297762|BEHAVIORAL|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
219271753|NCT05688163|OTHER|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
219177602|NCT04250116|DRUG|Dual antithrombotic therapy with NOAC and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
219177603|NCT06645483|OTHER|ChatGPT-assisted instruction|"ChatGPT will interactively support students by answering questions, initiating discussions, and providing customized learning materials in line with the course objectives. It will be supervised by the instructor to ensure guidance and prevent misinformation.~Duration: ChatGPT-assisted learning for the first two weeks, followed by traditional teaching for the next two weeks."
219177604|NCT06645483|OTHER|Traditional lecture-based instruction|"Students will learn through a traditional teaching format, where the instructor delivers the course content through lectures and presentations.~Duration: Traditional teaching for the first two weeks, followed by ChatGPT-assisted learning for the next two weeks."
219177605|NCT05185947|DRUG|Paclitaxel|Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.
219177606|NCT05185947|DRUG|Nilotinib|Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
219177607|NCT06153810|DEVICE|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
219177608|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
219177609|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
219177610|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
219177611|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
219177612|NCT06510062|DRUG|2.5% Diclofenac Patches|Topical pain relief gel worn via SAM patch.
219177613|NCT04837248|OTHER|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
219271754|NCT05688163|OTHER|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
219271755|NCT01611961|DRUG|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
219271756|NCT01611961|DRUG|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
219271757|NCT06171022|OTHER|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
219271758|NCT06171022|OTHER|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
219271759|NCT02387697|DEVICE|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
219271760|NCT06294197|OTHER|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
219271761|NCT03772769|DIAGNOSTIC_TEST|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
219271762|NCT03772769|DIAGNOSTIC_TEST|Microbial culture|Standard diagnosis by microbial culture.
219271763|NCT00583947|DRUG|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
219271764|NCT00583947|DRUG|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
219271765|NCT06024915|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
219271766|NCT06024915|DRUG|Itraconazole capsule|Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
219271767|NCT06024915|DRUG|Rifampicin Capsule|Rifampicin is a strong inducer of CYP3A.
219271768|NCT02314689|DRUG|Intravenous (IV) citrulline|
219271769|NCT00958542|PROCEDURE|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
219271770|NCT00788242|DRUG|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
219271771|NCT00788242|DRUG|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
219271772|NCT01855711|DRUG|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
219271773|NCT05405699|BEHAVIORAL|digitalized group psychoeducation|"Problem Solving Approach based problem solving skills psychoeducation's session topics of eight weeks are as follows:~1. Introduction and warm-up,~2. Problem orientation-identifying the problem,~3. Identifying prior problems-Which do I want to start from?~4. Recognizing the losses caused by problems and complaints,~5. Setting reachable and realistic goals,~6. Generating alternatives -What can I do?~7. Regulating emotions,~8. Experimenting and exploring. The main outcomes of each session were determined, and sessions were completed in approximately one hour as a semi-structured interactive group training according to group dynamics.~Three days a week for eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. Participants were connected to the live broadcast of the research team and interacted via text messages."
219271774|NCT03534583|OTHER|Sudarshan Kriya Yoga|Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
219271775|NCT03534583|OTHER|Health Enhancement Program|Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
219271776|NCT04246398|OTHER|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
219271777|NCT04246398|OTHER|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
219271778|NCT01815853|RADIATION|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy \[Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle (non-concurrent); Oxaliplatin 100 mg/m² IV on Day 1 + Capecitabine 825 mg/m² orally BID on Days 1-14 of a 21-day cycle (concurrent chemoradiotherapy)\]
219271779|NCT01815853|DRUG|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
219271780|NCT01815853|PROCEDURE|R0 D2 Gastrectomy|
219177614|NCT04837248|OTHER|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
219177615|NCT05682157|OTHER|Paula Method of muscle exercises|12 weekly sessions of Paula Method of exercise
219177616|NCT03637660|DRUG|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
219177617|NCT03618199|DEVICE|Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing|"Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testing stimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified."
219177618|NCT05733910|RADIATION|simultaneous integrated boost of carbon ions radiation therapy|"CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB).~The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion)."
219177619|NCT05304481|BIOLOGICAL|ATL administration|Subjects have ATL administration using intravenous infusion
219177620|NCT04929951|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
219177621|NCT04929951|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
219177622|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
219177623|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
219177624|NCT05948306|OTHER|Critical Patient-Centered Skin Care Protocol|"A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added."
219177625|NCT05846867|DRUG|AK119|AK119 IV every 2 weeks.intravenous infusion
219177626|NCT05846867|DRUG|AK112|AK112 IV every 2 weeks.intravenous infusion
219177627|NCT05846867|DRUG|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
219177628|NCT05846867|DRUG|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
219177629|NCT05846867|DRUG|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
219177630|NCT05846867|DRUG|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
219177631|NCT05955066|DRUG|Baricitinib 4 MG|1 capsule (4mg) daily for 24 weeks
219177632|NCT05955066|DRUG|Placebo|1 capsule daily
219177633|NCT04507568|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
219177634|NCT05465616|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
219177635|NCT06408597|PROCEDURE|Nitroglycerin Infusion|"Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU."
219177636|NCT06408597|PROCEDURE|Mannitol Infusion|"Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes."
219177637|NCT06408597|PROCEDURE|Fluid Regimen|"Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status."
219177638|NCT06570447|DRUG|Glofitamab|For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.
219177639|NCT06570447|DRUG|Chidamide|Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.
219271781|NCT01815853|DRUG|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
219271782|NCT01740154|PROCEDURE|transcranial magnetic stimulation|Undergo TMS
219271783|NCT01740154|PROCEDURE|electromyography|Undergo EMG
219271784|NCT01740154|OTHER|survey administration|Ancillary studies
219271785|NCT01740154|DRUG|sunitinib malate|Given PO
219271786|NCT06282640|DRUG|Vitamin D|Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
219177640|NCT06067139|OTHER|SHUTi|"Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like."
219177641|NCT06067139|OTHER|Patient Education|The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
219271787|NCT03070704|DRUG|insulin degludec/liraglutide|Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
219177642|NCT06579599|OTHER|an integrated working group nursing|(1) Establishment of an integrated team in the operating room; (2) Development of a nursing plan; (3) Nursing safety training and reflection in the operating room; (4) Designate a person to manage instruments and equipment in the operating room and establish protocols (5) Nurses should also participate in the development of the patient's individualized surgical plan communicate with the surgeon about the preparation of items needed for surgery to ensure seamless coordination. Assist anesthesiologists and surgeons and oversee the implementation of aseptic procedures.
219177643|NCT06161337|DIETARY_SUPPLEMENT|Meals|"Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition."
219177644|NCT05841212|OTHER|DBT for ADHD|See information included in arm/group description.
219177645|NCT05603143|DRUG|Obeldesivir|Tablets administered orally without regard to food.
219177646|NCT05603143|DRUG|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
219177647|NCT04209465|DRUG|BDTX-189|Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.
219177648|NCT05783102|BEHAVIORAL|Knowledge and Interpersonal Skills to Develop Exemplary Relationships|During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
219177649|NCT04759794|DIAGNOSTIC_TEST|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
219177650|NCT06381700|OTHER|MySmile app|"The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders"
219271788|NCT06049368|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
219177651|NCT06381700|OTHER|Control|"This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained."
219177652|NCT05492318|DRUG|Givinostat 10 mg/mL|10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.
219177653|NCT05492318|DRUG|Midazolam 1mg/ml IV|Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
219271789|NCT00141999|BIOLOGICAL|hepatitis B vaccine|
219271790|NCT04134884|DRUG|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
219271791|NCT04134884|DRUG|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
219271792|NCT02132871|DEVICE|Impedance cardiography Physioflow ®|
219271793|NCT00469859|DRUG|cytarabine|given IV
219271794|NCT00469859|DRUG|idarubicin|Given IV
219271795|NCT00469859|DRUG|lestaurtinib|Given orally
219271796|NCT02214680|DRUG|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
219271797|NCT02214680|DRUG|Timolol|0.5% eye drop
219271798|NCT05172752|OTHER|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
219177654|NCT05492318|DRUG|Midazolam 2.5 mg oromucosal solution|"Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration.~Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose.~Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
219271799|NCT05172752|OTHER|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
219271800|NCT04323046|BIOLOGICAL|Nivolumab|Given IV
219177655|NCT05492318|DRUG|Dabigatran etexilate 75 mg oral hard capsules|"Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration.~Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
219271801|NCT04323046|OTHER|Quality-of-Life Assessment|Ancillary studies, given in person or online
219271802|NCT04323046|OTHER|Questionnaire Administration|Ancillary studies, given in person or online
219271803|NCT02884492|DRUG|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
219177661|NCT01892137|DRUG|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
219177662|NCT05008835|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
219177663|NCT05008835|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
219177664|NCT05008835|DRUG|Placebo|Placebo
219177665|NCT04171999|OTHER|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
219271804|NCT02884492|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
219271805|NCT06682650|BEHAVIORAL|NPT-PLA|"NPT-PLA was developed and initially tested in 5 European countries in the EU-funded RESTORE study. PLA Participatory Learning in Action is a set of participatory research techniques in which participants use democratic processes to identify key actions needed to achieve a specific goal e.g. implementation of a tested decision making tool such as I2; and prioritize which of these need to be acted upon first and subsequently (in which order). Normalization Process Theory (NPT) is combined with PLA to help implementation teams using PLA to assess organization capacity and readiness to enact the selected action steps vis-a-vis NPT constructs, iteratively. These are coherence does everyone understand what needs to be done?; Cognitive participation Does everyone who needs to act 'buy in' to take action; collective action Is everyone who needs to act taking steps to make the change?'; and reflexive monitoring After the step has been taken, has it had the desired impact on the goal?"
219271806|NCT06682650|BEHAVIORAL|Usual Quality Improvement|Usual quality improvement includes principles of continuous quality improvement, such as Plan-Do-Study-Act cycles, to implement a specific goal. In this study, 'usual QI' methods already in use in 'active comparator' arm will be documented during the baseline assessment of clinical workflows in clinics assigned to that arm; and will be provided with a 'preset protocol' to implement the study shared decision-making tool (I2). Processes that implementation teams in these clinics use to achieve implementation will be documented.
219271807|NCT06882720|BEHAVIORAL|Exercise|Cardiorespiratory exercises include walking at a normal pace for 30 minutes three times a week, or three 10-minute sessions. The resistance exercises involve five leg muscle strengthening exercises, including knee extensors, knee flexors, hip adductors, ankle plantar flexors, and ankle dorsolflexors, performed 8-10 times, 1-2 sets, 3 times a week, with 1 day intervals in between. Balance training includes 12 exercises such as kneeling, walking backwards, walking and turning, walking sideways, tandem standing (heel-toe standing), tandem walking (heel-toe walking), standing on one leg, walking on the heel, and walking on the tip of the foot. Only 1 set of 1 exercise, 3 times a week, 1 day interval in between. Add 4 upper body strength exercises and 4 lower body strength exercises to the OEP, using water bottles and elastic bands as AIDS. Each movement is completed 8-12 times, 1-3 sets, 3 times a week, 1 day apart.
219271808|NCT06728787|DEVICE|Robot-Assisted Gait Training|15 sessions of robot-assisted gait training(LOKOMAT)+ 15 session of usual treatment for a total of 30 sessions in three weeks. 45 minutes for each session.
219271809|NCT07049835|DRUG|Ilioinguinal/iliohypogastric Nerve Block|15cc 0.25% of Bupivacaine + Dexamethasone 8 mg 2cc
219271810|NCT07049835|OTHER|Ilioinguinal/iliohypogastric with Placebo Block|17 cc of Placebo
219271811|NCT07050602|BEHAVIORAL|Health Belief Model Nursing Intervention|Participants received a one-year health belief model nursing intervention. This included: comprehensive assessment and psychological interventions (Perceived Susceptibility); education on OSAHS risks and consequences (Perceived Severity); weekly weight/blood pressure monitoring, dietary/exercise guidance, sleep posture correction aids, and a daily health diary (Perceived Benefits); and regular phone follow-ups (2-3 times/week for 0-8 weeks post-discharge, bi-weekly up to 1 year) for support and addressing difficulties (Perceived Barriers).
219271812|NCT07050602|BEHAVIORAL|Routine Care|Participants received routine postoperative care for OSAHS for one year, including general education, dietary and exercise guidance. Post-discharge monitoring was conducted via monthly phone calls.
219271813|NCT07050043|DRUG|Nivolumab 40mg|Nivolumab is an immunotherapy medicine used to treat several cancers, including lung cancer.
219271814|NCT07050043|DRUG|Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel|Cisplatin, carboplatin, pemetrexed, paclitaxel, Gemcitabine, and docetaxel are chemotherapy drugs used to treat various types of cancer, including non-small cell lung cancer.
219271815|NCT07049913|DEVICE|Gore® TAG® Thoracic Aortic Branch Stent Graft System|Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance.
219271816|NCT06743321|BEHAVIORAL|Speech-to-speech Voice-Cloning Care (SVCC)|After patients in the intervention group were transferred to the ICU, the SVCC intervention was initiated. It is administered three times daily: in the morning, at noon, and in the evening. The SVCC intervention includes three types of activities: awakening, reassurance, and preparatory exercises for the removal of the endotracheal tube (ETT). Before each intervention is carried out, the clinical status of the participants must be assessed to determine whether they are suitable for SVCC and to decide on the specific content of the intervention. Once the removal of the ETT is implemented, the SVCC intervention will no longer be carried out.
219271817|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,500 participants. There is no medication or non-medication treatment or intervention provided by this study.
219271818|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered by intravenous drip, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
219271819|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered via intravenous drip at a fixed frequency and cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study occurs. The dose for each administration will be calculated based on the body weight measured prior to administration. The dosing regimen (dosing frequency and interval) for subsequent studies may be adjusted based on prior data. The intravenous drip duration should be ≥ 90 minutes for the first dose and may be adjusted to ≥ 30 minutes for subsequent doses if the first dose is well tolerated.
219271820|NCT06939907|DEVICE|Nexpowder™|Nexpowder™ hemostatic powder
219271821|NCT06944015|OTHER|normal saline|After completion of surgery, Study Group patients underwent intraperitoneal irrigation with 30 mL/kg of normal saline at 37C infused under the right hemidiaphragm. Patients were placed in Trendelenburg position and reverse Trendelenburg position, to allow contact between the liquid and all abdominal structures, including the diaphragm and surgical wounds. At the end of the procedure, all the introduced liquid was carefully removed.
219271822|NCT06950008|OTHER|Educational Intervention|Receive links to informational websites
219271823|NCT06950008|BEHAVIORAL|Patient Navigation|Receive patient navigator phone calls
219271824|NCT06950008|OTHER|Survey Administration|Ancillary studies
219271825|NCT06950008|BEHAVIORAL|Telephone-Based Intervention|Receive patient navigator phone calls
219271826|NCT00233753|DEVICE|Cordis Neurovascular Self-Expanding Stent|
219271827|NCT03728985|DEVICE|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
219177666|NCT05795842|DEVICE|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
219177667|NCT05795842|OTHER|Samsung Galaxy Watch 6|"The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development."
219177668|NCT05795842|DEVICE|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
219177669|NCT05668780|BEHAVIORAL|NIATx Coaching|"The intervention will consist of:~1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD~2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD~3. training for primary care providers"
219177670|NCT05302089|OTHER|Pain management and shoulder bandage|All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
219177671|NCT05302089|OTHER|One-time physiotherapy instruction|Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
219271828|NCT05992922|DRUG|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice a day
219271829|NCT05992922|DRUG|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice a day
219271830|NCT03778502|DRUG|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
219271831|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
219271832|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
219271833|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
219271834|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
219271835|NCT06476938|OTHER|Gene PilotLX|eHealth decision making tool regarding tumor genomic profiling
219271836|NCT01882413|OTHER|No intervention|No intervention
219271837|NCT00551746|DIETARY_SUPPLEMENT|Purple Grape Juice|Grape Juice
219271838|NCT00243906|DRUG|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
219271839|NCT00243906|PROCEDURE|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS \>/= 10) treated within 3 hours of symptoms onset.
219271840|NCT00269906|DRUG|Abciximab|
219271841|NCT00269906|DRUG|Placebo|
219271842|NCT06051110|DEVICE|Combined risk score|Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
219271843|NCT06051110|OTHER|Usual care|Prehospital risk stratification by EMS protocols
219271844|NCT06051110|DEVICE|point-of-care troponin|Prehospital risk stratification by the use of a POC-troponin
219271845|NCT01895790|DEVICE|Pancreatic Duct Stent Placement|
219271846|NCT01442922|OTHER|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
219271847|NCT01442922|OTHER|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
219271848|NCT03514316|PROCEDURE|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
219271849|NCT03514316|PROCEDURE|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
219271850|NCT03514316|PROCEDURE|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
219271851|NCT04161651|DEVICE|eversense|eversense CGM
219271852|NCT00554996|DEVICE|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
219271853|NCT01606371|DRUG|Placebo|Administered orally
219271854|NCT01606371|DRUG|LY2409021|Administered orally
219177672|NCT05302089|OTHER|Usual rehabilitation care|At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
219177673|NCT05452889|DIAGNOSTIC_TEST|18F-FGLN PET Imaging|PET/CT Imaging: The study visit will take around 3-4 hours, the duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Participants will be retained in the PET facility following the PET scan to promote urination to increase elimination of the radiotracer.
219177674|NCT05452889|DRUG|(18F)FPGLU|\[F-18\]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
219177675|NCT05048056|DRUG|Placebo|Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
219271855|NCT06044246|BIOLOGICAL|PRF membrane|Placing implant with PRF membrane treatment
219271856|NCT02796768|OTHER|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
219271857|NCT02796768|OTHER|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
219177676|NCT05048056|DRUG|AK120|AK120 Regimen 1- subcutaneous injection every 2 weeks.
219177677|NCT05048056|DRUG|AK120|AK120 Regimen 2- subcutaneous injection every 2 weeks
219177678|NCT03973853|BEHAVIORAL|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
219177679|NCT03973853|BEHAVIORAL|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
219177680|NCT06269978|PROCEDURE|Biopsy|Undergo biopsy
219177681|NCT06269978|PROCEDURE|Biospecimen Collection|Undergo collection of blood and IP fluid samples
219177682|NCT06269978|PROCEDURE|Computed Tomography|Undergo CT
219177683|NCT06269978|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
219177684|NCT06269978|DRUG|Fluorouracil|Given via IP infusion
219271858|NCT00785837|OTHER|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
219271859|NCT02560753|DRUG|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
219271860|NCT00000416|OTHER|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
219271861|NCT01893489|OTHER|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
219271862|NCT03795857|BEHAVIORAL|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
219271863|NCT03944642|BEHAVIORAL|Breastfeeding support|Breastfeeding self-efficacy enhancing through professional support
219271864|NCT02881372|OTHER|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
219271865|NCT03267810|DEVICE|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
219271866|NCT03267810|OTHER|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
219271867|NCT04371237|DEVICE|Compression sleeve|From foot to hip/groin on both legs with only 1 leg connected to pneumatic pump for 1 hour
219271868|NCT04371237|DEVICE|Heat therapy|Custom leg garment with one leg heated by circulating hot water approx 40 degrees C, the other leg approx 32 degrees C (thermoneutral) for 1 hour
219177685|NCT06269978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219177686|NCT06269978|DRUG|Oxaliplatin|Given via IP infusion
219177687|NCT06269978|PROCEDURE|Surgical Procedure|Undergo placement of indwelling IP port
219177688|NCT04079686|DRUG|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
219271869|NCT04371237|OTHER|Glycogen-depleting exercise session|Prolonged intermittent high intensity running (LIST protocol)
219177689|NCT04079686|OTHER|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
219177690|NCT05476913|DEVICE|geko™ device|Neuromuscular electrical stimulation of the peroneal nerve
219177691|NCT04505904|DRUG|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
219177692|NCT04505904|DRUG|Placebo|Placebo spray with no active ingredient.
219177693|NCT03629990|BEHAVIORAL|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
219177694|NCT03629990|BEHAVIORAL|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
219177695|NCT03629990|BEHAVIORAL|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
219177696|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
219177697|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
219177698|NCT04277442|DRUG|Decitabine|Given IV
219177699|NCT04277442|BIOLOGICAL|Nivolumab|Given IV
219177700|NCT04277442|DRUG|Venetoclax|Given PO
219177701|NCT04118660|OTHER|Tissue Banking|Blood, tissue, and fluid collection
219177702|NCT03544281|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as an infusion.
219177703|NCT03544281|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
219177704|NCT03544281|DRUG|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
219177705|NCT03544281|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
219177706|NCT05235750|BEHAVIORAL|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
219177707|NCT05922176|OTHER|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
219177708|NCT05922176|OTHER|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
219177709|NCT04809311|DRUG|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
219177710|NCT04809311|DRUG|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
219177711|NCT04809311|DRUG|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
219177712|NCT06333808|DRUG|Bictegravir|Tablets administered orally without regard to food
219177713|NCT06333808|DRUG|Lenacapavir|Tablets administered orally without regard to food
219177714|NCT06333808|DRUG|B/F/TAF|Tablets administered orally without regard to food
219177715|NCT06333808|DRUG|Placebo to match B/F/TAF|Tablets administered orally without regard to food
219177716|NCT06333808|DRUG|Placebo to match BIC/LEN|Tablets administered orally without regard to food
219177717|NCT06227221|DRUG|Sorafenib|Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
219177718|NCT06227221|DRUG|Placebo|Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
219271870|NCT04371237|OTHER|Nutrient Intake (beverage)|Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher
219271871|NCT04371237|PROCEDURE|Skeletal muscle biopsy|Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
219271872|NCT02820545|OTHER|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
219271873|NCT02820545|OTHER|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
219271874|NCT01775293|DEVICE|Non-absorbable polypropylene mesh|"2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
219177719|NCT06105684|DRUG|Capecitabine Pill|Will be given once per day by mouth
219177720|NCT05970367|OTHER|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
219177721|NCT06354010|GENETIC|Genotyping|Genotyping to determine if patients present mutations to the gene GJB2.
219177722|NCT06354010|OTHER|Audiological assessments|Audiological assessments
219177723|NCT06240325|BEHAVIORAL|SPP|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
219177724|NCT06240325|BEHAVIORAL|Sleep Psychoeducation|Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
219177725|NCT06456671|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219177726|NCT06456671|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177727|NCT06456671|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177728|NCT06456671|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177729|NCT01693263|OTHER|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
219177730|NCT03092518|PROCEDURE|Surgery|Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
219177731|NCT03092518|DRUG|Cisplatin|Cisplatin (90 mg/m\^2) will be administered via circuit to the peritoneal cavity
219177732|NCT03092518|DRUG|Mitomycin C|Mitomycin C 10 mg/m\^2 will be administered via circuit to the peritoneal cavity
219177733|NCT03092518|DRUG|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
219177734|NCT03092518|PROCEDURE|Tumor Biopsy|At screening, baseline (if not done at screening) and operation (as clinically indicated).
219177735|NCT03092518|DIAGNOSTIC_TEST|CT C/A/P|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
219177736|NCT03092518|DIAGNOSTIC_TEST|PET-CT|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
219177737|NCT03092518|DIAGNOSTIC_TEST|MRI|If computed tomography (CT) contraindicated.
219177738|NCT03092518|DIAGNOSTIC_TEST|EKG|At screening and baseline (if not done at screening).
219177739|NCT02301910|DRUG|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
219177740|NCT02301910|DRUG|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml"
219271875|NCT00624910|DRUG|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
219177741|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
219177742|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
219177743|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
219177744|NCT02845882|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
219177745|NCT02845882|DRUG|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
219271876|NCT00624910|DRUG|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
219271877|NCT06171555|DEVICE|CTM|decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
219271878|NCT06171555|DRUG|Celestone|standard of care
219177746|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
219177747|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
219177748|NCT02845882|DRUG|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
219271879|NCT01947322|DRUG|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
219271880|NCT05989594|BEHAVIORAL|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
219271881|NCT05989594|BEHAVIORAL|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
219271882|NCT00778245|DRUG|cefprozil 500mg tablets|
219271883|NCT05792098|PROCEDURE|percutaneous dilatational tracheostomy (PDTS)|Tracheostomy made by percutaneous dilatational technique
219271884|NCT05792098|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound verification of guidewire position
219271885|NCT05792098|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopic control of guidewire position
219271886|NCT01149122|DRUG|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
219177749|NCT02845882|DRUG|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
219177750|NCT02845882|DRUG|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
219177751|NCT06000059|BEHAVIORAL|Radio Drama|An hour long radio drama adapted from from a previous community-led theater intervention
219271887|NCT01149122|DRUG|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
219271888|NCT02172911|BIOLOGICAL|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
219177752|NCT03160612|BEHAVIORAL|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
219177753|NCT04747613|DRUG|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
219177754|NCT02547987|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
219177755|NCT02547987|DRUG|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
219177756|NCT06547866|DRUG|zanubrutinib + BGB-11417|"The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose"
219177757|NCT05589194|BEHAVIORAL|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
219177758|NCT04925986|DRUG|Sitravatinib|Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
219177759|NCT04925986|DRUG|Pembrolizumab|All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
219177760|NCT04861571|DIETARY_SUPPLEMENT|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
219177761|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
219271889|NCT02172911|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
219177762|NCT06181760|DRUG|Fenretinide|Ascending single doses of oral fenretinide
219177763|NCT06181760|DRUG|Placebo|Single oral dose of matching placebo capsules
219177764|NCT05965765|DIAGNOSTIC_TEST|Total knee arthroplasty|who got total knee arthroplasty because of osteoarthritis
219177765|NCT05965765|DIAGNOSTIC_TEST|osteoarthritis without surgery|who has osteoarthritis and didn't get any surgery
219177766|NCT05965765|DIAGNOSTIC_TEST|control group|healthy people
219271890|NCT04669379|BEHAVIORAL|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
219271891|NCT05472064|OTHER|Persona: Primary care doctor|The chatbot persona is a Black woman who is a primary care doctor.
219177767|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
219177768|NCT06450522|OTHER|Usual care|Usual care
219177769|NCT04770532|DRUG|Insulin degludec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
219177770|NCT04770532|DRUG|Insulin Icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
219177771|NCT04938492|BEHAVIORAL|Cognitive Behavioral Therapy for loneliness (CBT-L)|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
219271892|NCT05472064|OTHER|Persona: Breast cancer survivor|The chatbot persona is a Black woman who is a breast cancer survivor.
219271893|NCT05472064|OTHER|Communication Style: Direct|The chatbot messages are characterized by commands and direct addresses (''you'').
219271894|NCT05472064|OTHER|Communication Style: Indirect|"The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's)."
219271895|NCT05831137|PROCEDURE|shorter cryoanalgesia|duration time of cryoanalgesia
219271896|NCT05641116|OTHER|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
219271897|NCT05641116|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
219271898|NCT03328377|DIAGNOSTIC_TEST|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
219271899|NCT00043069|DIETARY_SUPPLEMENT|calcium carbonate|
219271900|NCT00043069|DIETARY_SUPPLEMENT|cholecalciferol|
219271901|NCT00043069|DRUG|Estrogen Antagonists|
219271902|NCT00043069|DRUG|risedronate sodium|
219271903|NCT00043069|OTHER|placebo|
219271904|NCT01227291|DRUG|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
219271905|NCT03349619|DRUG|Resveratrol plus Carboxymethyl-β-Glucan|Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
219271906|NCT03349619|DRUG|Placebo|Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
219271907|NCT02737826|DRUG|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
219271908|NCT02737826|DRUG|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
219271909|NCT02737826|DRUG|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
219271910|NCT02737826|DRUG|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
219271911|NCT05838963|DIAGNOSTIC_TEST|CTQ-SSS scores|"The CTQ-SSS is a self-reported questionnaire that measures the severity of symptoms related to carpal tunnel syndrome, including pain, numbness, tingling, and weakness in the hand and wrist.~Participants in this study will complete the CTQ-SSS and other functional measures that include:~1. demographic information~2. hand dominance~3. Boston Carpal Tunnel Questionnaire (BCTQ)~4. nerve conduction studies (NCS) to measure median nerve conduction velocity (NCV), distal motor latency (DML), and sensory nerve action potential (SNAP) amplitude, Compound muscle action potential (CMAP) amplitude.~5. Hand grip strength~Outcomes will be measured at baseline, 3 months, 6 months, and 12 months.~The primary outcome will be progression to carpal tunnel release surgery, and logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for this outcome, adjusted for potential confounding factors such as age, sex, and baseline symptom severity."
219177772|NCT04938492|BEHAVIORAL|Physical Health Education Training (PHET)|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
219177773|NCT04982237|BIOLOGICAL|AK104|IV infusion
219177774|NCT04982237|DRUG|paclitaxel|IV infusion
219177775|NCT04982237|DRUG|carboplatin|iv infusion
219177776|NCT04982237|DRUG|cisplatin|iv infusion
219177777|NCT04982237|DRUG|bevacizumab|iv infusion
219177778|NCT04982237|DRUG|Placebo|iv infusion
219177779|NCT04841148|DRUG|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
219177780|NCT04841148|DRUG|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
219177781|NCT04841148|DRUG|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
219177782|NCT05866562|DRUG|Dupilumab|Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;
219177783|NCT05866562|DRUG|Placebo|Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
219177784|NCT05897710|OTHER|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
219177785|NCT05897710|OTHER|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
219177786|NCT04899141|DEVICE|Percutaneous Coronary Intervention|stenting with the ihtDEStiny® sirolimus eluting stent
219177787|NCT05739279|DIAGNOSTIC_TEST|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
219177788|NCT05739279|DIAGNOSTIC_TEST|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
219177789|NCT05739279|DIAGNOSTIC_TEST|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
219177790|NCT05739279|DIAGNOSTIC_TEST|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
219177791|NCT05555199|RADIATION|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
219177792|NCT05555199|DRUG|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
219177793|NCT06296498|PROCEDURE|Leukocyte Platelet-rich fibrin|Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis
219177794|NCT06296498|OTHER|Standard of care OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
219177795|NCT06351306|DRUG|Thioguanine (Tabloid ®)|60-80mg/m\^2 oral tablet
219177796|NCT06351306|DRUG|DecitabineCedazuridine (Inqovi ®)|35 mg decitabine and 100 mg cedazuridine oral tablet
219177797|NCT06459726|OTHER|shi style mobilization|Step 1 soothing tendon stepTherapist will aerate patient's neck 3 to 6 times.Step 2 moblization step Therapist will apply low velocity small amplitude oscillatory movement without thrust. Head will be in 45 degrees of flexion or extension. Repeat this for 3 to 6 times. Then distraction force is applied to the cervical. Step 3 dredging collateral step Therapist holds thenar and hypothenar muscles of patient's hand on affected side and gently shook the upper limb ebb and flow with small shaking and high frequency. Repeat the procedure 3 times 6 sesions over 2 weeks for 20minutes
219271912|NCT01973153|BEHAVIORAL|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
219271913|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
219271914|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
219271915|NCT01378806|BEHAVIORAL|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
219271916|NCT04349007|DIETARY_SUPPLEMENT|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
219271917|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
219271918|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use plus Milk|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
219271919|NCT06541769|DEVICE|Limb hypothermia|Limb hypothermia with special gel-gloves
219271920|NCT06541769|DEVICE|Limb compression|compression with sterile one way Latex gloves. Size measured for every Patient individually
219271921|NCT04239131|OTHER|Skin prick test|a Skin prick test is planned in all patients
219271922|NCT02509949|DRUG|Dexmedetomidine|
219271923|NCT02509949|DRUG|Saline|
219271924|NCT03215147|DIAGNOSTIC_TEST|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6\~8 weeks later.
219271925|NCT03428308|OTHER|Screening|Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
219271926|NCT03428308|OTHER|Treatment|Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
219271927|NCT04432792|OTHER|Questionnaire|Study survey participants will be administered 3 online surveys.
219271928|NCT01613690|DRUG|NVA237|NVA237 is administered via a BREEZHALER device
219271929|NCT01949181|PROCEDURE|Lung surgery|
219271930|NCT02856516|OTHER|Boost Glucose Control (A)|Oral nutrition supplement
219271931|NCT02856516|OTHER|Boost Glucose Control (B)|Oral nutrition supplement
219271932|NCT02856516|OTHER|Boost Original|Oral nutrition supplement
219271933|NCT00487955|PROCEDURE|Resting Energy Expenditure examination|
219271934|NCT03289559|DRUG|GnRH antagonist|
219271935|NCT03289559|DRUG|Aromatase Inhibitors|
219271936|NCT03289559|DRUG|Testosterone gel|
219271937|NCT05308394|OTHER|No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.|Each participant will provide a blood and fecal sample.
219271938|NCT02056626|DRUG|carvedilol|
219271939|NCT02834767|DEVICE|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
219271940|NCT02834767|DEVICE|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
219271941|NCT02622555|DRUG|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
219271942|NCT00863512|DRUG|cisplatin|Given IV
219271943|NCT00863512|DRUG|docetaxel|Given IV
219271944|NCT00863512|DRUG|gemcitabine hydrochloride|Given IV
219271945|NCT00863512|DRUG|pemetrexed disodium|Given IV
219271946|NCT00863512|DRUG|vinorelbine tartrate|Given IV
219271947|NCT00863512|PROCEDURE|standard follow-up care|Standard care
219271948|NCT02259660|DEVICE|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
219271949|NCT02259660|DEVICE|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
219271950|NCT05153928|DRUG|Norethisterone acetate|Norethisterone acetate for 5 months
219271951|NCT03527797|OTHER|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
219271952|NCT02015507|DRUG|ivacaftor|
219271953|NCT02015507|DRUG|VX-661|
219271954|NCT02015507|DRUG|ciprofloxacin|
219271955|NCT00642525|PROCEDURE|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
219271956|NCT00640770|DEVICE|balloon angioplasty|balloon angioplasty
219271957|NCT00640770|DEVICE|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
219271958|NCT02037477|DRUG|Vonoprazan|Vonoprazan tablets
219271959|NCT02037477|DRUG|Esomeprazole|Esomeprazole capsules
219271960|NCT02037477|DRUG|Rabeprazole sodium|Rabeprazole sodium tablets
219271961|NCT00633269|DRUG|AZD2281|100mg Oral Dose
219271962|NCT01211301|BEHAVIORAL|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
219271963|NCT01211301|OTHER|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 \& 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean \& Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are \>70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 \& 1 Plan. The Medifast 5 \& 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean \& Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 \& 1 Plan.
219271964|NCT02511444|OTHER|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
219271965|NCT04110925|GENETIC|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
219271966|NCT04110925|OTHER|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
219271967|NCT04110925|OTHER|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease \[ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents\], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
219271968|NCT02961257|DRUG|cabazitaxel|"* Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used"
219271969|NCT02961257|DRUG|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
219271970|NCT02961257|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
219271971|NCT00463905|PROCEDURE|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
219271972|NCT02963675|OTHER||external unexposed reference group
219271973|NCT01955187|DRUG|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
219271974|NCT01955187|DRUG|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
219271975|NCT01955187|DRUG|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
219271976|NCT01955187|DRUG|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
219271977|NCT01454739|DRUG|rFVIIIFc|Administered as specified in the treatment arm.
219271978|NCT03564197|OTHER|18F-PD-L1|18F-PD-L1 PET/CT scan
219271979|NCT00326053|DRUG|Budesonide/formoterol|
219271980|NCT04621253|DRUG|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
219271981|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
219271982|NCT05146206|OTHER|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
219271983|NCT04344210|BEHAVIORAL|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
219177798|NCT06459726|OTHER|SNAGS|Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced. the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patientsNumber of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10second
219271984|NCT04964245|DEVICE|accelometer|the respiration parameters are measured using an accelometer.
219271985|NCT04964245|DEVICE|thermographic camera|the respiration parameters are measured using an thermographic camera.
219271986|NCT04964245|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
219271987|NCT04964245|DEVICE|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
219177799|NCT06408688|DRUG|Immune checkpoint inhibitors plus Iscador® Qu.|Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
219177800|NCT06408688|DRUG|Immune Checkpoint Inhibitors|Standard cancer treatment.
219271988|NCT06407609|DIETARY_SUPPLEMENT|Curcuma and boswellia extracts plus low fodmap diet|Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability
219271989|NCT06407609|OTHER|Low Foodmap diet|such as lactose or gluten free diet in the last 6 months
219271990|NCT04482153|DEVICE|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
219271991|NCT04484389|OTHER|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
219271992|NCT04484389|OTHER|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
219271993|NCT06489275|BEHAVIORAL|Building Financial Wellness|In addition to receiving services as usual, subjects attend financial literacy classes and booster sessions.
219271994|NCT06489275|OTHER|Services as Usual|Subjects continue to receive services as usual.
219271995|NCT02039648|OTHER|Rumex acetosa L. extract|
219271996|NCT02039648|OTHER|Placebo|
219177801|NCT02774746|OTHER|35-week delivery|Induction at 35 weeks gestational age
219271997|NCT02577003|DRUG|Ipragliflozin|50 mg tablet administered orally
219271998|NCT02577003|DRUG|Placebo|Placebo to ipragliflozin tablet administered orally
219271999|NCT02577003|DRUG|Sitagliptin|Background medication; 50 mg tablet administered orally
219272000|NCT02786004|DEVICE|Full Field Digital Mammography|
219272001|NCT02786004|DEVICE|Digital Breast Tomosynthesis|
219272002|NCT02185898|OTHER|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
219272003|NCT02185898|OTHER|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
219272004|NCT02185898|OTHER|Electronic cigarette #1|Electronic cigarette
219272005|NCT02185898|OTHER|Electronic cigarette #2|Electronic cigarette
219272006|NCT02185898|OTHER|Electronic cigarette #3|Electronic cigarette
219272007|NCT02185898|OTHER|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
219177802|NCT02774746|OTHER|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
219177803|NCT05084508|BIOLOGICAL|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously.
219177804|NCT05084508|BIOLOGICAL|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.
219177805|NCT05084508|BIOLOGICAL|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously.
219177806|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 1|1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.
219177807|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 2|1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.
219177808|NCT05084508|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.
219177809|NCT05084508|BIOLOGICAL|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly.
219177810|NCT05084508|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.
219177811|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
219177812|NCT05606887|OTHER|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~1. Completion of brief text-message based surveys 2-3 times per week~2. Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~3. Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
219177813|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
219177814|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
219177815|NCT02213731|OTHER|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
219177816|NCT03506867|BEHAVIORAL|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
219177817|NCT03506867|BEHAVIORAL|Standard Care|Usual care will receive information on locally available services.
219177818|NCT02733328|PROCEDURE|CPB Surgery|
219177819|NCT06054776|DRUG|Acalabrutinib|Given PO
219177820|NCT06054776|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219177821|NCT06054776|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsies
219177822|NCT06054776|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219177823|NCT06054776|PROCEDURE|Echocardiography|Undergo ECHO
219177824|NCT06054776|BIOLOGICAL|Glofitamab|Given IV
219177825|NCT06054776|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219177826|NCT06054776|BIOLOGICAL|Obinutuzumab|Given IV
219177827|NCT06054776|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219177828|NCT04616469|PROCEDURE|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
219177829|NCT04616469|PROCEDURE|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
219177830|NCT06253130|DRUG|IMP1734|PARP1 selective inhibitor
219177831|NCT06183216|BIOLOGICAL|Sinovac PCV13|0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
219177832|NCT06183216|BIOLOGICAL|PREVNAR 13|0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
219177833|NCT04624906|DRUG|Acalabrutinib|100 mg oral capsules twice daily for 1 year
219177834|NCT04624906|DRUG|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
219177835|NCT04624906|DRUG|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
219177836|NCT05123118|BEHAVIORAL|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
219177837|NCT05123118|BEHAVIORAL|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
219177838|NCT03301506|DRUG|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
219177839|NCT03301506|DRUG|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
219272008|NCT01833689|DIETARY_SUPPLEMENT|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
219272009|NCT01502046|DRUG|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
219272010|NCT01502046|DRUG|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
219272011|NCT05671354|DEVICE|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
219272012|NCT02835027|PROCEDURE|Open versus endovascular surgery|Treatment for acute ischemia
219272013|NCT05878912|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
219272014|NCT01517997|PROCEDURE|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
219272015|NCT01517997|PROCEDURE|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
219272016|NCT01677299|DRUG|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
219272017|NCT01677299|DRUG|EFB0026 (metformin immediate-release)|Active comparator
219272018|NCT04860440|DEVICE|GeneActiv wrist worn accelerometer|Wrist worn device worn for 7 days
219272019|NCT03723577|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
219272020|NCT03931993|BIOLOGICAL|Placebo comparator|
219272021|NCT03931993|BIOLOGICAL|Grass MATA MPL|
219272022|NCT03835962|DEVICE|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
219272023|NCT00737828|OTHER|Perioperative care pathway guided by CPX results|"* AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
219272024|NCT02813902|DRUG|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
219272025|NCT02813902|OTHER|Sugar Pill|A pill that appears similar to the supplement
219272026|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
219272027|NCT00676845|DRUG|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
219272028|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
219272029|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
219272030|NCT06486337|DRUG|CMOP±R|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
219272031|NCT00193479|DRUG|Cyclophosphamide|Cyclophosphamide
219272032|NCT00193479|DRUG|Mitoxantrone|Mitoxantrone
219272033|NCT00193479|DRUG|Vincristine|Vincristine
219272034|NCT00193479|DRUG|Prednisone|Prednisone
219272035|NCT00193479|DRUG|Rituximab|Rituximab
219272036|NCT01862497|DRUG|Carvedilol vs. Prazosin|
219272037|NCT00787072|DRUG|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
219272038|NCT00787072|DRUG|Placebo|Oral suspension
219272039|NCT05625347|DRUG|single dose (100 mg) of ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
219272040|NCT05625347|DRUG|single dose (162 mg) of non-enteric-coated chewable aspirin tablets|orally administered
219272041|NCT00559377|OTHER|18F-fluoromisonidazole|Undergo \^18F FMISO PET scan
219272042|NCT00559377|RADIATION|fluorodeoxyglucose F 18|Undergo \^18F FDG PET scan
219272043|NCT00559377|PROCEDURE|positron emission tomography|Undergo \^18F-FMISO and \^18F FDG PET scan
219272044|NCT00559377|OTHER|tissue oxygen measurement|Undergo \^18 F FMISO PET and \^18F FDG PET
219272045|NCT04312256|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
219272046|NCT00940875|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
219272047|NCT00940875|DRUG|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
219272048|NCT00940875|DRUG|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
219272049|NCT04830189|DEVICE|shoulder sling|Patients were used shoulder slings
219272050|NCT04830189|DEVICE|forearm sling|Patients were used forearm slings
219272051|NCT03685682|BIOLOGICAL|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
219272052|NCT04976647|DRUG|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
219272053|NCT04976647|DRUG|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
219272054|NCT04976647|DRUG|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
219272055|NCT00867698|DRUG|AST-120|AST-120
219272056|NCT05857254|OTHER|Patient with chronic intestinal failure|"The negociation component will be assessed during an office visit with the help of forms, by the difference between  ideal  parenteral nutrition prescription proposed by prescriber and the  final  prescription, that the patient ultimately receives at the end of the office visit.~The compliance component will be assessed by a telephone interview, 8 weeks after the office visit."
219272057|NCT04541368|DRUG|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
219272058|NCT03667118|DIETARY_SUPPLEMENT|Food Supplement|A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
219272059|NCT04329572|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
219272060|NCT04329572|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
219272061|NCT06072976|DIETARY_SUPPLEMENT|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
219272062|NCT06072976|DIETARY_SUPPLEMENT|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
219272063|NCT04266353|DIETARY_SUPPLEMENT|Resveratrol (RSV)|Participants will receive Resveratrol at 150 mg daily for 6 weeks.
219272064|NCT01615549|PROCEDURE|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
219272065|NCT00297947|DRUG|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
219272066|NCT00297947|DRUG|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
219272067|NCT00872001|DRUG|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
219272068|NCT00872001|DRUG|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
219272069|NCT02768883|BEHAVIORAL|Respira Sano|The intervention is all three components: clinic + home + community.
219272070|NCT02603692|OTHER|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
219272071|NCT03471377|OTHER|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
219272072|NCT03471377|OTHER|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
219272073|NCT00047723|DRUG|minocycline|
219272074|NCT06106867|PROCEDURE|External pressure to the palm|During the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages of the labor process, palm external pressure was applied to the pregnant women in the experimental group.
219272075|NCT00016224|DRUG|thalidomide|
219272076|NCT04211090|DRUG|Camrelizumab|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
219272077|NCT04211090|DRUG|Pemetrexed|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
219272078|NCT04211090|DRUG|Carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
219272079|NCT06186297|DIETARY_SUPPLEMENT|Cranberry extract|polyphenol PAC-1
219272080|NCT02030002|DEVICE|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
219272081|NCT02030002|DEVICE|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
219272082|NCT00512486|BIOLOGICAL|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~* 0.03 mg/kg intravenous injection~* 0.1 mg/kg intravenous injection~* 0.3 mg/kg intravenous injection~* 1.0 mg/kg intravenous injection~* 3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
219272083|NCT03504722|BEHAVIORAL|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
219272084|NCT03504722|BEHAVIORAL|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
219272085|NCT05256212|OTHER|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
219272086|NCT03935256|DRUG|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 \& Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 \& Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 \& 7 concurrent with radiotherapy
219272087|NCT03935256|RADIATION|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
219272088|NCT05020145|BIOLOGICAL|BNT162b2 (Tozinameran)|Covid-19 Vaccine
219272089|NCT00220064|DRUG|Irinotecan, 5-Fluorouracil, Leucovorin|
219272090|NCT00167232|DRUG|Naltrexone|
219272091|NCT00376415|DRUG|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
219272092|NCT00376415|DRUG|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
219272093|NCT03313141|DIAGNOSTIC_TEST|Ultrasound|Volitional and non volitional respiratory tasks
219272094|NCT00531726|DEVICE|DBS of Cg25|
219272095|NCT04970290|DEVICE|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
219272096|NCT00494468|DRUG|Zolpidem|
219272097|NCT00564616|DEVICE|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
219272098|NCT03333161|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
219272099|NCT03653923|BEHAVIORAL|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
219272100|NCT02239744|BEHAVIORAL|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
219272101|NCT03618004|OTHER|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
219272102|NCT03618004|OTHER|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
219272103|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
219272104|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
219272105|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
219272106|NCT05252832|PROCEDURE|Superficial Cervical Plexus Block|Location of injection for block.
219272107|NCT05252832|PROCEDURE|Local Infiltrate|Local infiltration location.
219272108|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
219272109|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
219272110|NCT03922789|DIAGNOSTIC_TEST|6 minute walking test|change of 6MWT pre to post pulmonary rehabilitation
219272111|NCT04653428|DEVICE|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
219272112|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic RFA assisted TE|
219272113|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic partial nephrectomy|
219272114|NCT06509360|DEVICE|Feelee app|Adolescents uses the Feelee app for 4-weeks in addition to treatment as usual in the forensic outpatient setting. The use of Feelee involves: submitting one emoji every day and allow the Feelee app to read the following passive data from the health app on the smartphone: number of steps and number of hours of sleep. The collected Feelee data will be presented in a dashboard in the Feelee app itself which will be discussed by the clinician in the weekly treatment session (in case the adolescents agreed to show the Feelee data to the clinician).
219272115|NCT06007196|DEVICE|non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)|Intraoperative cardiac output will be measured using the non-invasive device (Task Force CORE(R) and Task Force CARDIO(R) and will be compared with the invasive thermodilution method (PiCCO).
219272116|NCT02844452|DEVICE|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
219272117|NCT02844452|DEVICE|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
219272118|NCT02792595|OTHER|Negative Control|Untreated area
219272119|NCT02792595|OTHER|Positive Control|High SPF Standard P3/SPF 15
219272120|NCT02792595|OTHER|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
219272121|NCT02792595|OTHER|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
219272122|NCT02792595|OTHER|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
219272123|NCT02792595|OTHER|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
219272124|NCT02792595|OTHER|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
219272125|NCT02792595|OTHER|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
219272126|NCT02792595|OTHER|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
219272127|NCT02792595|OTHER|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
219272128|NCT05521711|OTHER|Food|Commercially available powders or liquids
219272129|NCT02410005|DIETARY_SUPPLEMENT|Calcitriol|
219272130|NCT02410005|DRUG|Losartan|
219272131|NCT04955899|DEVICE|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
219272132|NCT06405412|OTHER|MUST malnutrition score|MUST malnutrition score
219272133|NCT03453047|DIAGNOSTIC_TEST|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
219272134|NCT03424070|OTHER|Shoulder Roll|The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.
219272135|NCT03424070|OTHER|No shoulder roll (placebo)|Placebo
219272136|NCT03453723|PROCEDURE|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
219272137|NCT03453723|DRUG|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
219272138|NCT05101512|BEHAVIORAL|Questionnaires on quality of life after surgery|Patient has to answer different questionnaire about quality of life, pain, functional scores
219272139|NCT04197076|DRUG|anti-PD-1 or anti-PD-L1|immunotherapy anti-PD-1 or anti-PD-L1
219272140|NCT04197076|DRUG|EGFR-TKI, ALK inhibitor, ROS1 inhibitor|targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
219272141|NCT04197076|DRUG|investigator decided|chemotherapy
219272142|NCT02562157|RADIATION|HYALURONIQUE ACIDE|Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
219272143|NCT01598077|DRUG|LJM716|
219272144|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
219272145|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
219272146|NCT02669134|OTHER|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
219272147|NCT03968068|PROCEDURE|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
219272148|NCT03968068|PROCEDURE|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
219272149|NCT03344406|OTHER|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
219272150|NCT03344406|OTHER|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
219272151|NCT03344406|OTHER|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
219272152|NCT03344406|OTHER|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
219272153|NCT03344406|OTHER|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
219272154|NCT03344406|OTHER|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
219272155|NCT05530330|DIAGNOSTIC_TEST|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
219272156|NCT05174598|DRUG|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
219272157|NCT05174598|DRUG|Calcipotriol Ointment 50 micrograms/g|Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
219272158|NCT05174598|OTHER|Placebo|Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
219272159|NCT05815706|DEVICE|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
219272160|NCT00080990|DRUG|alvocidib|Given IV
219272161|NCT00080990|DRUG|fluorouracil|Given IV
219272162|NCT00080990|DRUG|oxaliplatin|Given IV
219272163|NCT00080990|DRUG|leucovorin calcium|Given IV
219272164|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
219272165|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
219272166|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
219272167|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
219177840|NCT06597305|BEHAVIORAL|Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)|Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.
219177841|NCT04598230|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
219177842|NCT04598230|DRUG|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
219177843|NCT05771545|OTHER|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
219177844|NCT06791265|DEVICE|Guided Eminectomy|The patients will be subjected to computer-guided osteotomy utilizing a virtually preplanned cutting guide
219177845|NCT06791265|PROCEDURE|Free hand Eminectomy|The patients will be subjected to a free-hand Eminectomy utilizing the routine surgical technique
219177846|NCT06830018|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
219177847|NCT06830018|COMBINATION_PRODUCT|Standard Treatment|Standard Treatment，First-line treatment (chemotherapy + immunotherapy/targeted therapy)
219177848|NCT06793839|DEVICE|Transcranial Enhanced Ultrasonography localizing microscopy|3 bilateral transcranial enhanced (with Sonovue) ultrasonography per patient to visualize cranial arteries of the anterior circulation of the brain
219177849|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
219177850|NCT06845306|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.
219177851|NCT06845306|OTHER|Conventional Bowel Anastomosis group|conventional perfusion assessment
219177852|NCT04437615|PROCEDURE|Colonoscopy|Standard of care colonoscopy, with added use of CDSD as an adjunctive tool
219177853|NCT04437615|DEVICE|Clinical Decision Support Device|The investigational device consists of software residing on a dedicated computer enabling display of predicted diminutive polyp histology during colonoscopy.
219177854|NCT06915363|DEVICE|BioPoly|partial resurfacing knee replacement
219177855|NCT06915363|PROCEDURE|surgical standard of care (SSOC)|either microfracture or debridement
219272168|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
219272169|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
219272170|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
219272171|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
219272172|NCT02726477|DRUG|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
219272173|NCT02726477|DRUG|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
219272174|NCT03112447|PROCEDURE|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
219272175|NCT03112447|PROCEDURE|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
219272176|NCT00501956|DRUG|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
219272177|NCT05783687|DIAGNOSTIC_TEST|NCC-Sp Assay|Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.
219272178|NCT02839785|DRUG|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
219272179|NCT02839785|DRUG|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
219272180|NCT04969809|DIAGNOSTIC_TEST|Ultrasound of the jugular veins|Ultrasound of the jugular veins to assess the thickness of the carotid intima media
219272181|NCT04969809|DIETARY_SUPPLEMENT|addition of phenylalanine-free protein substitutes|addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
219272182|NCT02880839|DEVICE|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
219272183|NCT02880839|DEVICE|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
219272184|NCT02880839|DEVICE|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
219272185|NCT03497715|DRUG|Ibuprofen lysine|Test 1
219272186|NCT03497715|DRUG|Ibuprofen Sodium|Test 2
219272187|NCT03497715|DRUG|Ibuprofen|Test 3
219272188|NCT03497715|DRUG|Ibuprofen (Nurofen)|Reference 1
219272189|NCT03497715|DRUG|Ibuprofen (Wockhardt)|Reference 2
219272190|NCT03446638|DRUG|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
219272191|NCT03446638|DRUG|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count \> 500/ microliter for 3 days.
219272192|NCT03446638|DRUG|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
219272193|NCT03446638|DRUG|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
219272194|NCT03446638|OTHER|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
219272195|NCT03446638|DEVICE|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
219272196|NCT04867109|OTHER|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
219272197|NCT04867109|DIAGNOSTIC_TEST|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
219272198|NCT05247008|OTHER|Thyme honey|"* Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
219272199|NCT04537598|PROCEDURE|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
219272200|NCT04537598|PROCEDURE|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
219272201|NCT03258671|DRUG|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
219177856|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
219177857|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
219177858|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with low-dose adjuvant|Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
219177859|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with high-dose adjuvant|Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
219177860|NCT06932523|BIOLOGICAL|Low-dose adjuvant|Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
219177861|NCT06932523|BIOLOGICAL|High-dose adjuvant|Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
219177862|NCT06932523|BIOLOGICAL|Shingrix (GSK)|Positive control, Intramuscular injection, 0, 2 months schedule
219177863|NCT06932523|BIOLOGICAL|Normal Saline|Placebo control, Intramuscular injection, 0, 2 months schedule
219177864|NCT06835777|COMBINATION_PRODUCT|Positive Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance enhancing neurostimulant,. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance enhancing qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
219177865|NCT06835777|COMBINATION_PRODUCT|Negative Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance inhibiting neuro-depressant. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance inhibiting qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
219177866|NCT06835777|OTHER|Control|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about EEG research and set ups and give general information about isometric strength testing. They will be shown neutral adjectives unrelated to performance instead of implicit adjectives related to performance (experimental groups). EEG set up and strength testing remains the same as the experimental groups.
219177867|NCT05772845|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
219177868|NCT05772845|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
219177869|NCT00418886|DRUG|Vandetanib|oral once daily tablet
219177870|NCT00418886|DRUG|Pemetrexed|intravenous infusion
219177871|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
219177872|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
219177873|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
219177874|NCT03906695|DRUG|ASTX727|oral decitabine 20mg + cedazuridine
219177875|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
219177876|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
219177877|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
219177878|NCT04887129|DIAGNOSTIC_TEST|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
219177879|NCT04887129|OTHER|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
219177880|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
219272202|NCT03258671|RADIATION|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
219272203|NCT06544369|BIOLOGICAL|COVID-19 vaccin|injection
219272204|NCT01512797|DRUG|Sitagliptin phosphate|100 mg/day orally
219272205|NCT01512797|OTHER|Placebo|1 Placebo Pill per day
219272206|NCT02119897|DEVICE|Low Level Light Therapy|
219272207|NCT05972798|OTHER|Omega-3 fatty acids|2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
219272208|NCT05972798|OTHER|Soybean oil|Soybean oil in patients with LLD
219272209|NCT04582747|DIAGNOSTIC_TEST|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
219272210|NCT00433875|DRUG|AMG 714|
219272211|NCT05950100|DEVICE|Virtual reality group|"It is composed of the physiotherapeutic procedures usually used in the hospital applied by the institution's physiotherapist, and the immersive virtual reality therapy that will be conducted by a third researcher (blind to the sampling and evaluations). Physiotherapeutic consultations will have the conventional duration offered by the Institution and therapy with virtual reality will last 10 minutes, using the game Aviãozinho. Both interventions will have a frequency of 2x a day (morning and afternoon shifts), during the period of 4 days."
219272212|NCT01895036|DRUG|Naltrexone|
219272213|NCT00776022|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
219272214|NCT01945398|OTHER|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
219272215|NCT01945398|OTHER|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
219272216|NCT02552459|DRUG|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
219272217|NCT02552459|DRUG|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
219272218|NCT02552459|DRUG|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
219272219|NCT02552459|DRUG|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
219272220|NCT05750836|OTHER|Specific nursing support|"* 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
219272221|NCT05750836|OTHER|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
219272222|NCT03482752|DRUG|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
219272223|NCT01080300|DRUG|Gabapentin Extended Release|Gabapentin ER 1800mg daily
219272224|NCT01080300|DRUG|Placebo|Sugar pill
219272225|NCT04947514|DRUG|Tranexamic acid|Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
219272226|NCT04947514|OTHER|Placebo (topical saline)|The untreated breast will receive topical saline.
219272227|NCT01807182|BIOLOGICAL|Aldesleukin|Given IV
219272228|NCT01807182|DRUG|Cyclophosphamide|Given IV
219272229|NCT01807182|DRUG|Fludarabine Phosphate|Given IV
219272230|NCT01807182|OTHER|Laboratory Biomarker Analysis|Correlative studies
219272231|NCT01807182|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
219272232|NCT00924222|DRUG|Sevoflurane|Sedation with sevoflurane
219272233|NCT00924222|DRUG|Propofol|Sedation on intensive care unit with propofol
219272234|NCT00369096|DRUG|bemiparin 3500 IU/day|
219272235|NCT01991847|BEHAVIORAL|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
219177881|NCT06084572|OTHER|Questionnaires|FSSG \& BEDQ
219177882|NCT06158399|DRUG|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
219177883|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
219177884|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
219177885|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
219177886|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
219177887|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
219177888|NCT04266275|DRUG|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
219177889|NCT04266275|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
219177890|NCT06849193|DRUG|Systemic chemotherapy combined with immunotherapy|The electronic medical record system was used to collect patients' basic information and treatment plan information, including treatment plan, administration cycle, administration date, administration dose, frequency, number of cycles, efficacy, adverse reactions, etc.
219177891|NCT06844266|PROCEDURE|Administration of the ACT + PA-R questionnaires|"The ACT + PA-R questionnaires will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
219177892|NCT06844266|PROCEDURE|ACT questionnaire|"The ACT questionnaire will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
219177893|NCT06562946|DRUG|Pimicotinib|Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
219177894|NCT05177848|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
219177895|NCT05177848|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177896|NCT05177848|OTHER|Nicotine vaping products at 2x market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177897|NCT05177848|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177898|NCT05177848|OTHER|Heated tobacco products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177899|NCT05177848|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177900|NCT05177848|OTHER|Nicotine pouch products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
219177901|NCT06561971|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219177902|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
219177903|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
219177904|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
219177905|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
219177906|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
219177907|NCT06849375|PROCEDURE|phakic IOL implantation|specular microscopy examination to assess endothelial cells before and after phakic IOL implantation
219177908|NCT06848764|DRUG|Lidocaine|Patients will receive lidocaine (1.5 mg/kg loading then 1mg/kg/h infusion) just after induction of anesthesia induction and continued until the end of the operation.
219177909|NCT06848764|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg/kg/h just after induction of anesthesia induction and continued until the end of the operation.
219177910|NCT06848556|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
219177911|NCT06848556|PROCEDURE|Transarterial Embolization|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
219177912|NCT06848556|PROCEDURE|TACE|Patients received standard Transarterial Chemoembolization (TACE) with intra-arterial injection of a mixture of epirubicin and iodized oil at a personalized dose, followed by embolization completed by injecting a suspension of gelatin sponge and contrast agent.
219177913|NCT06843707|OTHER|Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.|This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.
219177914|NCT06849856|DEVICE|non-surgical peri-implantitis therapy with airflow device|Airflow device with erythritol powder will be used in the treatment of non-surgical peri-implantitis
219177915|NCT06849856|PROCEDURE|non-surgical peri-implantitis therapy with titanium curette|Titanium curette will be used for non-surgical treatment of peri-implantitis
219177916|NCT06846307|DRUG|Mannitol|mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
219177917|NCT05041647|DRUG|25:1 CBD/THC|"* 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC"
219177918|NCT05041647|DRUG|5:1 CBD/THC|"* 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC"
219177919|NCT05041647|OTHER|Placebo|"* 1 dose (1 mL) of PLACEBO~* No active ingredients"
219177920|NCT05634109|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
219177921|NCT02035787|DRUG|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
219177922|NCT04581590|OTHER|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
219177923|NCT02978456|DEVICE|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).
219177924|NCT02978456|DEVICE|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
219177925|NCT06414213|BEHAVIORAL|Motor Imagery (MI)|Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
219177926|NCT06414213|DEVICE|Active tDCS|"The participants received a 20-minute active session of tDCS at a 2-milliamp current."
219177927|NCT06414213|DEVICE|Sham tDCS|"The participants received a 20-minute session of sham tDCS."
219177928|NCT06178900|DIAGNOSTIC_TEST|Assisted by the AI-Gatekeeper software group|The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
219177929|NCT06849947|DRUG|Ribociclib with fulvestrant|"▪ Ribociclib group~\- Ribociclib (600 mg orally once daily on days 1 to 21 in a 28 day cycle) + Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day 15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
219272236|NCT04636762|PROCEDURE|Radiation Therapy|Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions\>3:whole brain radiotherapy PTV:30Gy/10F.
219272237|NCT04467892|DRUG|methylprednisolone|received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
219272238|NCT04467892|DRUG|Methyl Prednisolonate|received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
219272239|NCT04467892|DEVICE|ventilators|all patients in both groups will be ventilated with CMV for 2 weeks
219272240|NCT05191147|DIETARY_SUPPLEMENT|Dietary supplement|We will study dietary supplement consumption among pregnant women
219272241|NCT04210843|DRUG|Ligelizumab|"For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.~Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.~The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period."
219272242|NCT00791375|BEHAVIORAL|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
219272243|NCT03444740|OTHER|ICIQ-FLUTS, ADMN-20|Questionnaire
219272244|NCT03614806|DIAGNOSTIC_TEST|Simultaneous Transcutaneous and End-tidal CO2 measurements|Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement
219272245|NCT01776008|DRUG|Akt Inhibitor MK2206|Given PO
219272246|NCT01776008|DRUG|Anastrozole|Given PO
219272247|NCT01776008|DRUG|Goserelin Acetate|Given SC
219272248|NCT01776008|OTHER|Laboratory Biomarker Analysis|Correlative studies
219272249|NCT01776008|PROCEDURE|Neoadjuvant Therapy|Given before standard-care surgery
219272250|NCT01776008|OTHER|Pharmacological Study|Correlative studies
219272251|NCT01776008|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard-care surgery
219272252|NCT03026647|PROCEDURE|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
219272253|NCT00813982|DEVICE|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
219272254|NCT00813982|DEVICE|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
219272255|NCT04458818|PROCEDURE|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
219272256|NCT04444843|DRUG|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
219272257|NCT02999243|BEHAVIORAL|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
219272258|NCT02999243|BEHAVIORAL|Harm reduction education|Both arms will receive harm reduction education
219272259|NCT00926081|BEHAVIORAL|Supervised exercise training|A standardized supervised exercise training program
219272260|NCT02799355|DRUG|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
219272261|NCT00663637|DEVICE|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
219272262|NCT03513068|DEVICE|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
219272263|NCT00478205|DRUG|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
219272264|NCT00478205|DRUG|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
219272265|NCT04748536|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
219272266|NCT04748536|DRUG|Placebo|Matching placebo for IRL201104
219272267|NCT03214445|PROCEDURE|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
219272268|NCT03214445|PROCEDURE|Sealing margins with seal|Seal the margin of restoration with sealant without filler
219272269|NCT01808183|DEVICE|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
219272270|NCT00947323|DRUG|Simvastatin|simvastatin 20 daily for six months.
219272271|NCT00947323|DRUG|Placebo|
219272272|NCT03993275|DEVICE|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
219272273|NCT04003194|OTHER|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
219272274|NCT04003194|OTHER|Green Beans - control|The control was 1/2 cup of green beans each day.
219272275|NCT03451708|DEVICE|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
219272276|NCT04810468|OTHER|Anthropometric measurment|Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
219272277|NCT01012947|BEHAVIORAL|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
219272278|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
219272279|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
219272280|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
219272281|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
219272282|NCT01078961|DRUG|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
219272283|NCT01078961|DRUG|sorafenib|400mg taken orally twice a day
219272284|NCT00382447|DEVICE|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
219272285|NCT00382447|DEVICE|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
219272286|NCT01791413|DRUG|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
219272287|NCT06129032|PROCEDURE|Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation|"a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision"
219272288|NCT06129032|PROCEDURE|Group QUADRATUS LUMBORUM BLOCK (QLB)|quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
219272289|NCT01010087|DRUG|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
219272290|NCT05837299|DRUG|IMC008|allowing 10% dose error
219272291|NCT02682940|DEVICE|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
219272292|NCT01566097|DEVICE|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~1. Information on the risk of continued smoking and benefits of cessation~2. Messages that address common misbeliefs regarding smoking cessation services and medications~3. Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~1. Behavioral only~2. Nicotine replacement therapy~3. Bupropion~4. Varenicline"
219272293|NCT00175747|DRUG|Inhaled Budesonide 800 µg twice daily|
219272294|NCT00405938|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
219272295|NCT00405938|DRUG|Anastrozole|anastrozole (1 mg orally daily)
219272296|NCT00405938|DRUG|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
219272297|NCT00825305|BIOLOGICAL|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
219272298|NCT00825305|BIOLOGICAL|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
219272299|NCT04016272|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
219272300|NCT04016272|DEVICE|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
219272301|NCT03617289|DRUG|Magnesium Sulfate|
219272302|NCT03617289|DRUG|D5W|
219272303|NCT03190512|OTHER|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
219272304|NCT02264782|OTHER|Computer-Assisted Intervention|Complete PreView
219272305|NCT02264782|OTHER|Computer-Assisted Intervention|Watch an educational video
219272306|NCT02264782|OTHER|Questionnaire Administration|Ancillary studies
219272307|NCT00435747|DRUG|PARECOXIB SODIUM|
219272308|NCT01854606|DRUG|AEB071|a Protein Kinase C Inhibitor
219272309|NCT01854606|DRUG|Everolimus|mTOR inhibitor
219272310|NCT03272737|PROCEDURE|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study \[37\]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
219272311|NCT03272737|PROCEDURE|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of \< 0.,9 m/s (Guralnik, 1994).
219272312|NCT03272737|DEVICE|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
219272313|NCT03272737|DEVICE|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity \[33\]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ \* distance travelled by the pulse wave (m) / transit time(s)."
219272314|NCT03272737|DEVICE|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
219272315|NCT03272737|DEVICE|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
219272316|NCT03272737|DEVICE|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
219272317|NCT03272737|DIAGNOSTIC_TEST|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
219272318|NCT03272737|OTHER|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
219272319|NCT01915797|OTHER|blood and tumor samples|all tumor pathology associated with anomaly of development
219272320|NCT03473210|DRUG|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
219272321|NCT03473210|DRUG|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
219272322|NCT03473210|PROCEDURE|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
219272323|NCT03783676|DRUG|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
219272324|NCT03783676|DRUG|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
219272325|NCT04684433|OTHER|Data extraction from medical files|Data extraction from medical files
219272326|NCT01850030|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
219272327|NCT01850030|DRUG|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
219272328|NCT01850030|DRUG|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
219272329|NCT01850030|DRUG|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
219272330|NCT05620615|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
219272331|NCT05567042|OTHER|No intervention|No intervention
219272332|NCT02263807|PROCEDURE|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
219272333|NCT02263807|PROCEDURE|Control|Arthroscopy followed by active rehabilitation
219272334|NCT00279188|PROCEDURE|Guiding therapy by bronchial hyperrsponsiveness|
219272335|NCT04107753|BEHAVIORAL|Brief counseling based on the 5As model|"It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~1. ASK: every patient should be asked whether he/she is or is not a smoker;~2. ADVICE: the patient is advised to quit in a strong, clear and personalized way;~3. ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~4. ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~5. ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses."
219272336|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
219272337|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
219272338|NCT00762476|DRUG|3804-250A|"* topical product~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
219272339|NCT00762476|DRUG|3804-291|"* topical~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
219272340|NCT00992342|DRUG|PF-03893787|oral solution, 5 mg, QD for 14 days
219272341|NCT00992342|DRUG|PF-03893787|oral solution, 15 mg, QD for 14 days
219272342|NCT00992342|DRUG|PF-03893787|oral solution, 50 mg, QD for 14 days
219272343|NCT02116569|DRUG|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
219272344|NCT05444946|DRUG|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
219272345|NCT05444946|DRUG|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
219272346|NCT06517238|OTHER|There is no intervention|Observal Study.There is no intervention
219272347|NCT05072652|OTHER|Neuromuscular Electrical Stimulation|Participants in this group will perform twice daily neuromuscular electrical stimulation training sessions of the quadriceps muscles (specifically, the vastus lateralis and rectus femoris) or the immobilized left leg.
219272348|NCT05072652|OTHER|Action Observation + Mental Imagery|Participants in this group will perform daily action observation + mental imagery training via video and audio recordings.
219272349|NCT02708381|OTHER|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
219272350|NCT06017908|DEVICE|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
219272351|NCT05323019|BEHAVIORAL|Psychotherapy|Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.
219272352|NCT05323019|BEHAVIORAL|Treatment as Usual|Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
219272353|NCT05323019|DRUG|Intranasal Ketamine (esketamine)|Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
219272354|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
219272355|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
219272356|NCT03931759|DIAGNOSTIC_TEST|laparoscopic surgery|patients with diabetes mellitus in laparoscopic surgery
219272357|NCT02878603|BIOLOGICAL|Caplacizumab|
219272358|NCT02878603|OTHER|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
219272359|NCT02892643|PROCEDURE|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
219272360|NCT02892643|PROCEDURE|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
219272361|NCT00866489|PROCEDURE|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
219272362|NCT01551368|DRUG|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
219272363|NCT01551368|DRUG|Placebo|Identical inactive tablets.
219272364|NCT03620097|DIETARY_SUPPLEMENT|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
219272365|NCT03620097|OTHER|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
219272366|NCT03127670|DRUG|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
219272367|NCT01357642|DRUG|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
219272368|NCT01357642|DRUG|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
219272369|NCT01357642|DRUG|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
219272370|NCT04674189|BIOLOGICAL|CVnCoV Vaccine|Intramuscular injection
219272371|NCT04674189|DRUG|Placebo|Intramuscular injection
219272372|NCT02838134|OTHER|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
219272373|NCT02838134|OTHER|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
219272374|NCT06502392|OTHER|Assessment of creatine phosphokinase|Assessment will be done through collecting a blood sample.
219272375|NCT06502392|OTHER|Assessment of pelvic floor muscle strength|Assessment will be done by a biofeedback.
219272376|NCT00111267|BEHAVIORAL|vitamin B12 supplementation|
219272377|NCT00111267|BEHAVIORAL|vitamin B12 + folic acid combined supplementation|
219272378|NCT01564277|DRUG|rasburicase|Given IV
219272379|NCT01564277|DRUG|allopurinol|Given PO
219272380|NCT01889576|DIETARY_SUPPLEMENT|Magnesium Oxide|
219272381|NCT04240249|BEHAVIORAL|Constructive self-assertiveness program via the internet|"Participants will get one chapter a week to work with. All chapters are presented on web pages and include information and exercises and end with homework assignments."
219272382|NCT05403931|DEVICE|Low level laser therapy|Omega XP is the particular device producing low level laser therapy and has been in use for therapeutic purposes to treat different musculoskeletal conditions.
219272383|NCT04489108|DRUG|Tranexamic acid|Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
219272384|NCT04489108|OTHER|Standard Medical Treatment|Standard Medical Treatment
219272385|NCT04489108|OTHER|Placebo|isotonic solution (saline)
219272386|NCT01637077|DRUG|pregabalin|Given PO
219272387|NCT01637077|DRUG|placebo|Given PO
219272388|NCT01637077|OTHER|questionnaire administration|Ancillary studies
219272389|NCT04796311|DIAGNOSTIC_TEST|blood samples|T cells, B cells and cytokines testing
219272390|NCT04091035|OTHER|To describe the incidence of disease and evaluate risk factors|Se above
219272391|NCT03979534|OTHER|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
219272392|NCT03731923|DIAGNOSTIC_TEST|Biannual ultrasonography|Biannual liver ultrasonography for HCC surveillance, without contrast agent.
219272393|NCT03731923|DIAGNOSTIC_TEST|Annual abbreviated liver MRI|Abbreviated liver MRI using standard dose of extracellular contrast agent (Dotarem, Guerbet, France) on weight-based dosing. Table time targets 10 minutes.
219272394|NCT00515788|DRUG|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
219272395|NCT00515788|DRUG|Temozolomide|100 mg/m\^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
219272396|NCT02842437|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
219272397|NCT02842437|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
219272398|NCT02595372|DRUG|Omeprazole|
219272399|NCT02320513|OTHER|Wearing activty monitoring device (Fitbit Flex)|
219272400|NCT02320513|DEVICE|Fitbit Flex|
219272401|NCT00500344|DRUG|Lucentis (ranibizumab)|intravitreal injection
219272402|NCT04937322|PROCEDURE|Interventional Endoscopy procedures|• All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
219272403|NCT00794924|DIETARY_SUPPLEMENT|VSL#3|one sachet per day, for 45 consecutive days
219272404|NCT00794924|DIETARY_SUPPLEMENT|placebo|one sachet per day, for 45 consecutive days
219272405|NCT01552759|PROCEDURE|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
219272406|NCT01552759|BEHAVIORAL|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
219272407|NCT01552759|BEHAVIORAL|Test meal|Subjects are presented with an ad libitum buffet meal.
219272408|NCT01594970|DRUG|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
219272409|NCT00953615|DRUG|Thalidomide|Titrate to 400 mg daily for 6 months
219272410|NCT04794153|DIETARY_SUPPLEMENT|whole food sources|Foods selected are naturally high in protein and consumed by the general population as part of a meal.
219272411|NCT02016378|BEHAVIORAL|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
219272412|NCT02016378|BEHAVIORAL|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
219272413|NCT01018108|PROCEDURE|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
219272414|NCT01018108|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
219272415|NCT01018108|OTHER|Questionnaire Administration|Ancillary study
219272416|NCT01018108|OTHER|Laboratory Biomarker Analysis|Correlative Study
219272417|NCT02802358|PROCEDURE|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
219272418|NCT02876952|OTHER|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
219272419|NCT02876952|OTHER|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
219272420|NCT02876952|OTHER|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
219272421|NCT02876952|OTHER|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
219272422|NCT04129476|BEHAVIORAL|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
219272423|NCT04041973|DRUG|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
219272424|NCT04041973|DIETARY_SUPPLEMENT|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
219272425|NCT02568670|OTHER|clinical signs|to remove the peripheral venous catheter according clinical signs
219272426|NCT04517240|OTHER|endoscopy|upper and lower endoscopy and fecal calprotectin test
219272427|NCT03554031|DRUG|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
219272428|NCT05393089|DRUG|AGN-190584|Eye drops
219272429|NCT05393089|DRUG|Vehicle|Eye drops
219272430|NCT06430229|PROCEDURE|Volume controlled ventilation (VCV) mode|"Patients to be ventilated with VCV mode were placed on respiratory support (Dräger Primus) with a breathing rate that would provide 8 ml/kg tidal volume, 5 cmH2O PEEP, and 30-35 mmHg end-tidal carbon dioxide concentration (etCO2) level.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
219272431|NCT06430229|PROCEDURE|Pressure controlled ventilation (PCV) mode|"Appropriate peak inspiratory pressure was set to create a tidal volume of 8 ml/kg in patients who would be ventilated with PCV mode. The number of breaths (Dräger Primus) was adjusted to provide an end-tidal carbon dioxide concentration (etCO2) level of 30-35 mmHg. PEEP was set to 5 cmH2O.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
219272432|NCT06426602|DEVICE|mindBEAGLE daily device use|If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
219272433|NCT03491267|DRUG|Retinoic acid|The study team will treat skin with topical retinoic acid
219272434|NCT03491267|DEVICE|Laser|The study team treat skin with a surface laser.
219272435|NCT03491267|DRUG|Sham treatment|No drug will be given
219272436|NCT03491267|DEVICE|Sham treatment|No laser treatment will be given
219272437|NCT06166056|DRUG|CHF6333|CHF6333 Part I SAD; CHF6333 Part II MD.
219272438|NCT06166056|DRUG|CHF6333 Placebo|Placebo Part I SAD; Placebo Part II MD.
219272439|NCT03751501|PROCEDURE|Indocyanine green-Guided Targeted Laser photocoagulation|Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
219272440|NCT03751501|PROCEDURE|Sham laser|Therapeutic procedure used in ophthalmology
219272441|NCT00205647|DRUG|Oral N-acetycystein (NAC)|
219272442|NCT03189173|DEVICE|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
219272443|NCT03189173|DRUG|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
219272444|NCT03189173|OTHER|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
219272445|NCT03189173|OTHER|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
219272446|NCT00428337|BIOLOGICAL|EP-1233|DNA-HIV-recombinant vaccine
219272447|NCT00428337|BIOLOGICAL|MVA-mBN32|HIV-recombinant viral vaccine
219272448|NCT04277507|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
219272449|NCT05996978|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
219272450|NCT02559310|DRUG|lefamulin|antibacterial agent
219272451|NCT02559310|DRUG|Moxifloxacin|antibacterial agent
219272452|NCT02559310|DRUG|Linezolid|antibacterial agent
219272453|NCT03472989|DEVICE|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
219272454|NCT03472989|DEVICE|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
219272455|NCT03472989|BEHAVIORAL|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
219272456|NCT03472989|BEHAVIORAL|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
219272457|NCT05224661|OTHER|Prospective determination of the clinical utility of measurable residual disease (MRD) testing|Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
219272458|NCT01972997|DEVICE|SENSIMED Triggerfish|
219272459|NCT04511247|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
219272460|NCT04511247|DEVICE|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
219272461|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
219272462|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
219272463|NCT04092660|BEHAVIORAL|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits"
219272464|NCT04092660|DEVICE|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
219272465|NCT01607541|BEHAVIORAL|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
219272466|NCT01607541|BEHAVIORAL|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
219272467|NCT03358472|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
219272468|NCT03358472|DRUG|Epacadostat|Epacadostat administered orally twice daily.
219272469|NCT03358472|DRUG|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
219272470|NCT03358472|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
219272471|NCT03358472|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
219272472|NCT03358472|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
219272473|NCT05789433|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
219272474|NCT05789433|BEHAVIORAL|Progressive stretching|Statistic stretching of eight major muscle groups
219272475|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
219272476|NCT06823947|DRUG|Placebo|Placebo is administered single dose or multiple dose by SC injection.
219272477|NCT06823947|DRUG|KK3910|KK3910 is administered single dose or multiple dose by SC injection.
219272478|NCT04402840|PROCEDURE|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
219272479|NCT03732677|DRUG|Durvalumab|Anti- PD-L1 Antibody
219272480|NCT03732677|DRUG|Cisplatin|Chemotherapy Agent
219272481|NCT03732677|DRUG|Gemcitabine|Chemotherapy agent
219272482|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
219272483|NCT05767177|OTHER|Glucemia following Mixed Meal Test|On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.
219272484|NCT05767177|OTHER|Enteroscopy - mucosal ketogenic activity as well as glucose transport|On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
219272485|NCT03780647|OTHER|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
219272486|NCT04286854|DIAGNOSTIC_TEST|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
219272487|NCT05237869|DEVICE|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
219272488|NCT05237869|OTHER|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
219272489|NCT04557280|COMBINATION_PRODUCT|Selatogrel|A single subcutaneous injection of 16 mg.
219272490|NCT04557280|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
219272491|NCT05928533|OTHER|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
219272492|NCT05647109|OTHER|No intervention|No intervention
219272493|NCT01991925|OTHER|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
219272494|NCT04500600|OTHER|Quality-of-Life Assessment|Ancillary studies
219272495|NCT04500600|OTHER|Questionnaire Administration|Complete questionnaire
219272496|NCT04554212|DEVICE|Blood Flow Restriction Training|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
219272497|NCT04554212|DEVICE|Sham Blood Flow Restriction Training|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
219272498|NCT05902897|DEVICE|Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.|Heart Valve Replacement
219272499|NCT05216198|OTHER|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
219272500|NCT01965509|DRUG|PEX168 or placebo|injection has to administered subcutaneously weekly
219272501|NCT02520310|DEVICE|AVJ-514|Patients receiving AVJ-514 device
219272502|NCT01340014|DRUG|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
219272503|NCT01340014|DRUG|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
219272504|NCT02270307|DRUG|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
219272505|NCT02270307|BIOLOGICAL|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
219272506|NCT00809679|DRUG|T-62 Dose 1|Capsule dosage form 100 mg bid
219272507|NCT00809679|DRUG|T-62 Dose 2|Capsule dosage form 200 mg bid
219272508|NCT00809679|OTHER|Placebo|Capsule dosage form placebo bid
219272509|NCT01237847|BEHAVIORAL|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
219272510|NCT01237847|BEHAVIORAL|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
219272511|NCT01237847|BEHAVIORAL|Wait list comparison group|Wait list comparison group to receive intervention at later point.
219272512|NCT01769430|OTHER|Observational Study of influenza aerosol shedding -- No Intervention|No intervention -- observational study only
219272513|NCT01864460|BEHAVIORAL|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
219272514|NCT00257114|DRUG|bortezomib|
219272515|NCT06380179|DEVICE|THOR3 training + Photobiomodulation Therapy (PBMT)|"PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball."
219272516|NCT06380179|DEVICE|THOR3 training + sham PBMT|Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
219272517|NCT06903312|PROCEDURE|Deferred Cytoreductive Nephrectomy + medical treatment|Patients randomized to Deferred Cytoreductive Nephrectomy can be treated with one among radical nephrectomy; partial nephrectomy or lumpectomy. Patients will continue to receive the ongoing medical treatment before the randomization.
219272518|NCT06903312|RADIATION|Radiotherapy + medical treatment|Patients randomized to RT should be treated with single shot of 25 Gy (or with multiple fractions with equivalent biological dose). Patients will continue to receive the ongoing medical treatment before the randomization.
219272519|NCT06903312|DRUG|Medical therapy|Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab.
219272520|NCT06587958|DIETARY_SUPPLEMENT|Fermented plant-based foods|Participants will daily consume five different types of fermented plant-based foods, in addition to their habitual diet.
219272521|NCT06587958|DIETARY_SUPPLEMENT|Non-fermented plant-based foods|Participants will daily consume five different types of non-fermented plant-based foods, in addition to their habitual diet.
219272522|NCT06587958|OTHER|Habitual diet|Participants will follow their habitual diet.
219272523|NCT00155532|PROCEDURE|3 mm-punch biopsies of the skin|
219272524|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
219272525|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
219272526|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
219272527|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
219272528|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
219272529|NCT04529811|DRUG|Rifaximin Novel Formulation|Rifaximin Novel Formulation
219272530|NCT04529811|DRUG|Placebo|Placebo
219272531|NCT01754987|DRUG|Ascorbic Acid + Sorafenib|
219272532|NCT01754987|DRUG|Sorafenib|
219272533|NCT06590558|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
219272534|NCT06590558|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219272535|NCT06590558|PROCEDURE|Computed Tomography|Undergo CT
219272536|NCT06590558|DRUG|Eribulin Mesylate|Given IV
219272537|NCT06590558|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219272538|NCT06590558|DRUG|Tolinapant|Given PO
219272539|NCT06590558|PROCEDURE|X-Ray Imaging|Undergo chest X-ray
219272540|NCT03746509|DEVICE|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
219272541|NCT03746509|DEVICE|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
219272542|NCT06005675|DEVICE|Intervention|No study treatments will be administered during this study.
219272543|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
219272544|NCT05131477|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219272545|NCT05131477|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
219272546|NCT06590168|PROCEDURE|Socket Preservation by vestibular socket therapy|Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
219272547|NCT06590168|PROCEDURE|Socket Preservation by icecream cone technique|Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
219272548|NCT06595368|PROCEDURE|Vimala massage|The massage will be given three times per day, each lasting 15 minutes and planned one hour after the first feeding of each shift.
219272549|NCT06595368|PROCEDURE|Hydrotherapy|Hydrotherapy will be applied two times per day before feeding, each lasting 5-10 min.
219272550|NCT06267807|DIAGNOSTIC_TEST|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
219272551|NCT05009199|DRUG|[18F]MNI-444|Subjects will undergo PET imaging using \[18F\]MNI-444.
219272552|NCT02194829|DRUG|AZD1775|Given PO
219272553|NCT02194829|DRUG|Gemcitabine|Given IV
219272554|NCT02194829|DRUG|Nab-paclitaxel|Given IV
219272555|NCT06336512|DIAGNOSTIC_TEST|ELISA|Estimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy .
219272556|NCT06819098|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
219272557|NCT06819098|OTHER|Isometric Multicomponent Training|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Isometric training: Gradual progression of 8 isometric exercises targeting major muscle groups, such as wall squats, isometric bicep curls, lateral raises, and rows (1-3 sets, 30 seconds per exercise, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
219272558|NCT00730821|DRUG|BIBW 2992|
219272559|NCT00730821|DRUG|BIBF 1120|
219272560|NCT03539029|PROCEDURE|Surgery|Surgical fracture fixation
219272561|NCT03539029|PROCEDURE|Conservative treatment|immobilisation with plaster cast
219272562|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Active|Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
219272563|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Sham|Wearable device programmed to deliver sham stimulation.
219272564|NCT02536495|DRUG|Docetaxel|Given IV
219272565|NCT02536495|OTHER|Laboratory Biomarker Analysis|Correlative studies
219272566|NCT02536495|OTHER|Pharmacological Study|Correlative studies
219272567|NCT02536495|DRUG|Selinexor|Given PO
219272568|NCT02706249|DRUG|Enoxaparin|
219272569|NCT06819904|BEHAVIORAL|Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE)|Participants will receive the ACT treatment. It is comprised of three processes: Open Up, Be Present, and Do What Matters. Each of these is further sub-divided, for a total of six core processes. These processes include, but are not limited to, present moment awareness, de-fusion, and committed action. This group will also receive targeted vestibular therapy and standardized behavioral management strategies (physical activity, sleep, hydration, and nutrition prescription). Participants will also receive usual care at the discretion of each site's treating providers. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
219272570|NCT06819904|BEHAVIORAL|Usual Care Vestibular Rehabilitation|Participants will receive usual care at the discretion of each site's treating providers, excluding any components associated with ACT. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
219272571|NCT05101993|DEVICE|AtriClip|Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
219272572|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
219272573|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
219272574|NCT03920176|DIAGNOSTIC_TEST|Computed tomography coronary angiography|CTCA \>64 detector row scanner
219272575|NCT03920176|OTHER|ASSIGN Score|ASSIGN Cardiovascular Risk Score
219272576|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1, 5, 9, and 13 months.
219272577|NCT06030986|DIAGNOSTIC_TEST|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
219272578|NCT04577573|DEVICE|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
219272579|NCT04577573|DEVICE|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
219272580|NCT05706844|DRUG|Spinal anesthesia|plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal
219272581|NCT05706844|DRUG|General anaesthesia|Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously
219272582|NCT05176626|BEHAVIORAL|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
219272583|NCT05176626|DRUG|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
219272584|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
219272585|NCT06608966|BEHAVIORAL|Epilepsy Journey web-based modules|Participants assigned to Epilepsy Journey modules will independently review web-based EJ modules focused on executive functioning skills. The modules cover 10 topic areas: Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Participants will complete 10 modules (\~15-30 minutes each session) within a 14-week time frame. The goal is to complete one module per week.
219272586|NCT06608966|BEHAVIORAL|Telehealth with a therapist|Therapist will cover 10 areas of executive functioning during telehealth sessions, including Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Telehealth sessions with a therapist will occur via HIPAA-compliant videoconference (e.g. Microsoft Teams) each week ideally over the course of 14 weeks.
219272587|NCT06820528|BEHAVIORAL|Occupational Therapy|Formal therapy with a certified hand therapist, weekly for 6 weeks
219272588|NCT06820528|BEHAVIORAL|Home Exercise Program|A booklet on hand exercises to complete following surgery, including range of motion and strengthening exercises
219272589|NCT06600373|BEHAVIORAL|Mindful Walking meditation|Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.
219272590|NCT06600373|BEHAVIORAL|physical education group class|120 minutes physical education group class about volleyball.
219272591|NCT06600607|DRUG|pregabalin 300 mg|pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain
219272592|NCT06600607|OTHER|Placebo|biologically inactive placebo comparator
219272593|NCT01124838|DRUG|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
219272594|NCT01124838|DRUG|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
219272595|NCT01124838|DRUG|Placebo|Administered by subcutaneous injection
219272596|NCT03708796|DIAGNOSTIC_TEST|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
219272597|NCT06857929|BEHAVIORAL|energy reduced Mediterranean diet (25% caloric restriction) plus physical activity program|An intensive multifactorial lifestyle intervention involving monthly individual and group sessions during 6 months. Participants will be asked to follow a Mediterranean diet with a 25% reduction in energy and a physical activity program based on WHO recommendations to achieve a moderate physical activity level.
219272598|NCT06857929|BEHAVIORAL|Usual Care|Participants in the control group will be asked to follow general recommendations to adhere to a healthy lifestyle, as indicated in the clinical guidelines of general practitioners and nurses for adults with metabolic syndrome
219272599|NCT06859138|OTHER|Manual Therapy|Manual therapy techniques including massage, trigger point pressure, muscle stretching and joint mobilization.
219272600|NCT06859138|OTHER|Splint therapy|Dental splint used for temotoromandibular disorders treatment
219272601|NCT06670768|DIAGNOSTIC_TEST|Stress Dynamic MPI SPECT|BMI standardized radiopharmaceutical injection in pharmacological stress (dipyridamole or adenosine) is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
219272602|NCT06670768|DIAGNOSTIC_TEST|Stress Static MPI SPECT|30-60 minutes after stress dynamic SPECT imaging is performed, an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
219272603|NCT06670768|DIAGNOSTIC_TEST|Rest Dynamic MPI SPECT|3 hours after the stress phase, the rest phase is also recorded. A radiopharmaceutical injection with a three-fold dose at rest is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
219272604|NCT06670768|DIAGNOSTIC_TEST|Rest Static MPI SPECT|30-60 minutes after rest, dynamic SPECT imaging is performed, and an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
219272605|NCT06670768|DIAGNOSTIC_TEST|Cardiac CT|Within 30 days of MPI SPECT imaging, a cardiac CT is performed for every patient, including a native calcium-scoring scan and a coronary CT angiography as a reference standard. A photon-counting detector CT is used.
219272606|NCT00000505|DRUG|tissue plasminogen activator|
219272607|NCT00000505|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
219272608|NCT04182997|DRUG|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
219272609|NCT04182997|DRUG|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
219272610|NCT06989541|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous immune globulin replacement
219272611|NCT06989541|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous immune globulin replacement
219272612|NCT04297618|DRUG|Xiidra|Xiidra (lifitegrast 5% ophthalmic solution)
219272613|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
219272614|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
219272615|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
219272616|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
219272617|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
219272618|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
219272619|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
219272620|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
219272621|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
219272622|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
219272623|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
219272624|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
219272625|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
219272626|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
219272627|NCT06719986|DRUG|Nalmefene HCl injection|Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
219272628|NCT06719986|DRUG|Naloxone HCl intranasal|Naloxone 4 mg for intranasal (IN) administration
219272629|NCT06726408|OTHER|Neuromonitoring with 10 electrodes|"In case of no parental objection, the clinician may begin neuromonitoring according to standard indications. The number of electrodes applied to the child's skull will be 10 electrodes (8 recording electrodes, 1 reference electrode, and 1 ground electrode) instead of the current 5.~The intensivist will analyze the quantitative EEG trace as they currently do but will also have access to additional tools for seizure detection support (CDSA and seizure detection software) and targeted review of part of the recording by a neurophysiologist in case of doubt. Access to the neurophysiologist will be available during current working hours on weekdays. Data will be collected in 12-hour periods."
219296293|NCT04367285|OTHER|Sensor-based Training|Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
219272630|NCT06915285|DIAGNOSTIC_TEST|Automated software for malarial retinopathy detection|"ASPIRE mobile application (App) software is intended to perform computer-aided detection of malarial retinopathy (MR) in digital retinal images of clinically diagnosed cerebral malaria (CM) patients under 21 years of age, to be used by a healthcare provider (user) with basic training, in primary care settings such as healthcare clinics and hospitals. The mobile Application hosts a software module developed using Deep-Learning algorithms to analyze digital retinal images of diagnosed CM patients for features suggestive of malarial retinopathy. ASPIRE requires at least four adequate quality retinal images (as determined by the image quality analysis software) captured from a patient to process it for MR detection. ASPIRE outputs a screening result of Malarial retinopathy detected or Malarial retinopathy not detected to the user. ASPIRE software is designed and validated to perform at clinically acceptable sensitivity and specificity in the detection of MR."
219272631|NCT06921213|DRUG|Linezolid (LZD)|Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
219272632|NCT06921213|DRUG|Amoxicillin|Ten day course. Oral Linezolid dosed at 50mg/kg twice a day.
219272633|NCT06921213|DRUG|Benzathine Penicillin G|Single IM dose 50,000iu/kg
219272634|NCT07050316|DRUG|CBT101|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
219272635|NCT07050316|DRUG|Placebo|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
219272636|NCT07049224|OTHER|Meat diet|Participants will be subjected to a 10-day diet containing meat and animal products. During the interventional period participants will perform unilateral lower limb resistance exercise.
219272637|NCT07049224|OTHER|Plant diet|Participants will be subjected to a 10-day diet containing plant products. During the interventional period participants will perform unilateral lower limb resistance exercise.
219272638|NCT07049666|DEVICE|Bag-valve mask|A BVM equipped with an oxygen reservoir, coupled with a correctly fitted oronasal mask was used.
219272639|NCT07049666|DEVICE|Noninvasive mechanical ventilation|Preoxygenation was conducted over a three-minute period using NIMV employing a properly fitted oronasal mask. This was facilitated by a mechanical ventilator operating in pressure support mode. The preoxygenation protocol entailed the administration of 100% FiO2, applying Positive End-Expiratory Pressure set at 5 cmH2O, delivering breaths at a frequency of 15 per minute, and providing a tidal volume ranging between 6 to 8 ml/kg of body weight.
219272640|NCT07050446|DRUG|Vizol S DIGI EYE eye drops|1 drop 4 times a day
219272641|NCT07050446|DRUG|0,9% saline solution, eye drops|1 drop 4 times a day
219272642|NCT07049146|PROCEDURE|EUS-guided tissue glue/coil injection|Under linear array endoscopic ultrasound (EUS), puncture GVs with a 19G/22G needle, deploy coils, and inject 1-2ml tissue glue until blood flow in GVs disappears (or inject glue directly if coils are unsuitable). Treat moderate-to-severe esophageal varices (EVs) with band ligation during or after the procedure.
219272643|NCT07049146|PROCEDURE|BRTO|Establish vascular access via the femoral or internal jugular vein, occlude gastrorenal shunts with a balloon catheter, and inject sclerosant foam. Treat moderate-to-severe EVs with band ligation within 5 days post-procedure.
219272644|NCT07049601|OTHER|Insulin Therapy|The effect of this intervention on HbA1c leading to either tight glycemic control HbA1c less than 7% or less tight glycemic control HbA1c less than 7.5%
219272645|NCT07049601|OTHER|Antidiabetic therapy, lifestyle modification|Individualized adjustments in antidiabetic therapy, lifestyle modification, and monthly clinical follow-up.
219272646|NCT07049549|BIOLOGICAL|Injectable PRF|Autologous injectable platelet-rich fibrin (i-PRF) will be prepared from venous blood using low-speed centrifugation and administered subgingivally to the test quadrants following full-mouth scaling and root planing.
219272647|NCT07049549|OTHER|Plasebo (Sterile Saline)|sterile saline solution will be administered subgingivally to the control quadrants following full-mouth scaling and root planing (SRP).
219272648|NCT06741280|DEVICE|Profilm Mouth Sores|Daily applications of the product as soon as a mouth sore appears, until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
219272649|NCT07050277|DRUG|Intrathecal Morphine|Intrathecal morphine
219272650|NCT07050277|DRUG|No Intrathecal Morphine|No Intrathecal Morphine
219272651|NCT06903741|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-acetyl-aspartyl-glutamate
219272652|NCT06906783|PROCEDURE|Transtibial Pull Out Method|The Transtibial Pull-Out Repair is a surgical technique used to fix posterior root tears of the meniscus, particularly in the medial meniscus. This method restores the hoop stress mechanism of the meniscus, which is essential for knee stability and function.
219272653|NCT06906783|PROCEDURE|Suture Anchor Method|The Suture Anchor Technique is an alternative to the Transtibial Pull-Out Method for repairing posterior meniscal root tears, especially in the medial meniscus. Instead of using a tibial tunnel, this technique fixes the meniscal root directly to the native footprint using suture anchors.
219272654|NCT06817967|DEVICE|PSNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
219272655|NCT06817967|DEVICE|ISNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
219272656|NCT06914050|DRUG|Adebrelimab|Induction therapy：Adebrelimab, 1200mg, d1, q3w, 2 cycles; Maintenance therapy：Adebrelimab, 1200mg, d1, q3w, until disease progression or unbearable toxicity.
219272657|NCT06914050|DRUG|EC/EP|Chemotherapy: standard chemotherapy EC/EP
219272658|NCT06914050|RADIATION|SBRT|8Gy\*3
219272659|NCT06914050|RADIATION|Chest radiotherapy|Chest radiotherapy: conventional fractionation mode 2Gy QD total dose 60Gy or 1.5Gy BID total dose 45Gy, according to the patient's physical condition, concurrent EP or EC chemotherapy can be considered
219272660|NCT03506672|OTHER|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
219272661|NCT03506672|OTHER|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
219272662|NCT06931535|DEVICE|remote ischemic conditioning|The cuff of the remote ischemic conditioning device was placed on both upper arms (at the same position as blood pressure measurement) and inflated to 200 mmHg. The treatment protocol consisted of 5 cycles of 5-minute inflation followed by 5-minute deflation, performed twice daily. The treatment duration was 8-12 consecutive days.
219272663|NCT06938568|OTHER|Personalized back exercises|"The study intervention is a 12-week personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
219272664|NCT06938568|OTHER|Non-personalized back exercises|"The active control intervention is a 12-week non-personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
219272665|NCT06941506|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has three phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
219272666|NCT06941506|OTHER|Control|Participants maintain their routine activities.
219272667|NCT06941714|OTHER|Perturbation|Jack is attached to force plates and it is used to give perturbation when participants are standing on force platform. Balance is assessed after perturbation and readings will be taken through HRV and GSR.
219272668|NCT06941714|OTHER|Working Memory Task|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants are asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher. while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
219272669|NCT06941714|OTHER|Visual and Verbal Fluency Task|Modified Stroop test or Stroop color word test: Participants are asked to name the color of ink that each word is printed. The test will appear on screen while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
219272670|NCT06940843|BEHAVIORAL|Hopeful and Healthy Living (HHL)|The HHL intervention is a 16-week long, manualized group intervention. Classes will be held weekly for 90 minutes. The class covers 15 topics centered on building social connections, developing healthy lifestyle routines around eating, exercise, and sleep. Each class will target one social skill (i.e. starting conversations) and one cognitive self-management strategy (i.e. memory tips), which will be taught and practiced in class. Each class also includes a facilitated exercise component and individually tailored take home application activity.
219272671|NCT06945666|DRUG|Combined therapy of Iguratimod and tofacitinib|This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.
219272672|NCT06945068|BIOLOGICAL|GB261|GB261 will be dosed according to the assigned group.
219272673|NCT06945302|DIETARY_SUPPLEMENT|Intervention Group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
219272674|NCT06945302|DIETARY_SUPPLEMENT|Control group (placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
219272675|NCT06944418|OTHER|observation|observation
219272676|NCT06944093|BEHAVIORAL|audio book|Listen to a audio book
219272677|NCT06945471|BEHAVIORAL|1) Face-to-face, and 2) Computer-mediated motivational type interviews|
219272678|NCT06944405|DEVICE|Mechanocardiography|Using mechanocardiography for the detection of signs of heart failure.
219272679|NCT06937463|BEHAVIORAL|Rehabilitation|This is a study on the recovery of physical function in bed patients through a digital rehabilitation exercise system
219272680|NCT06944431|DEVICE|Continuous Passive Motion (CPM)|Continuous passive motion was applied to the left ankle joint for 60 minutes per day using a motorized CPM device. The therapy was initiated within 48 ho
219272681|NCT06945731|DEVICE|TMS|20 sessions 10 Hz rTMS
219272682|NCT06945731|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS
219272683|NCT06945848|DRUG|Acetazolamide|Acetazolamide will be maintained and weight loss will be recommended
219272684|NCT06945848|DEVICE|Stent (Tentos 4F or Precise ProRX)|Transverse venous sinus will be stented by neuroradiological intervention
219272685|NCT06944730|BEHAVIORAL|Structural Exercise|Multi-joint limb movement with force vector through the spine. The spine is held at neutral position
219272686|NCT06944730|BEHAVIORAL|Isolated Trunk Exercise|Holding the spine in neutral position with no limb movement, with static loading through the spine
219272687|NCT06944730|BEHAVIORAL|Back school|Patient education that has been proven to not be effective and has been used as control in past low back pain intervention studies
219272688|NCT06944665|DEVICE|Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture theory|Based on the theory of wrist and ankle needles, transcutaneous electrical nerve stimulation is a kind of analgesic treatment device that combines wrist and ankle needles with transcutaneous electrical nerve stimulation, and can be worn on the human wrist and ankle. Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture Theory uses low-frequency electronic pulses to stimulate the entry point of the wrist-ankle needle, which has the advantages of easy to wear, concentration of the treatment site, safety of the treatment, and no needles.
219272689|NCT06945822|OTHER|Blood sample|"For febrile patients with confirmed (group 1) or refuted (group 2) diagnosis of leptospirosis:~\- At D0, D1, D3 and D15 a 20-ml blood sample~For healthy patients (group 3):~\- At D0 and D15: a 20-ml blood sample"
219272690|NCT06945822|OTHER|Urine Sample|For all participants, a 5-ml urine sample at D0
219272691|NCT06945497|BEHAVIORAL|Art Therapy|The art therapy program will include different weekly experientials to explore mindfulness, establish safety, cultivate relaxation, find strength, honor self-identity, and cultivate community. Art media will include markers, colored pencils, fabrics, watercolors, collage, and yarn.
219272692|NCT06945497|BEHAVIORAL|Yoga/Mindfulness|The yoga/mindfulness curriculum will explore consciousness (awareness of self and others), compassion, confidence, courage, and community. Each week, new movement and breathing exercises will be learned.
219272693|NCT06944847|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
219272694|NCT06944847|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
219272695|NCT06944938|PROCEDURE|Non-Surgical Periodontal Treatment|Participants in this arm received standard non-surgical periodontal treatment, including scaling and root planing, without any additional supplementation or dietary modification.
219272696|NCT06944938|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants in this arm received standard periodontal treatment along with a daily probiotic supplement (1 capsule/day, containing 10⁹ CFU of Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis) for six consecutive weeks.
219272697|NCT06944938|OTHER|Probiotic Supplementation + Personalized Diet|Participants in this arm received standard periodontal treatment, the same probiotic protocol as the probiotic group, and a personalized anti-inflammatory diet. The diet was developed by a clinical dietitian and emphasized high-fiber, antioxidant-rich, and prebiotic foods. Consumption of refined carbohydrates, added sugars, and trans fats was restricted.
219272698|NCT06944743|PROCEDURE|Transurtheral Resection of prostate ( TURP)|"TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones).~The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria."
219272699|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
219272700|NCT02726945|OTHER|Placebo|Placebo Control
219272701|NCT00903071|BEHAVIORAL|Real PPL|See above arm description
219272702|NCT00903071|BEHAVIORAL|Sim PPL|See above arm description
219272703|NCT06261619|DEVICE|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
219272704|NCT05363189|PROCEDURE|Venous augmentation|Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
219272705|NCT05363189|PROCEDURE|Traditional ERAS (enhanced recovery after surgery) protocol|Pre-, peri-, and post-operative care as described in the ERAS protocol
219272706|NCT05363189|PROCEDURE|Sahlgrenska recovery protocol|Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
219272707|NCT05363189|PROCEDURE|No venous augmentation|Traditional deep inferior epigastric artery perforator flap (DIEP)
219272708|NCT06388317|BEHAVIORAL|Adaptive Step Goal (Intervention)|Receiving automated personalized daily step goals,
219272709|NCT06388317|BEHAVIORAL|Static Step Goal (Control)|Receiving personalized static daily step goals.
219272710|NCT05389553|OTHER|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
219272711|NCT04200469|DIAGNOSTIC_TEST|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
219272712|NCT05835271|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
219272713|NCT05442268|PROCEDURE|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
219272714|NCT05442268|PROCEDURE|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
219272715|NCT00140374|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
219272716|NCT05654623|DRUG|ARV-471|orally, once daily on a 28-day continuous dosing schedule
219272717|NCT05654623|DRUG|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
219272718|NCT03501810|DEVICE|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
219272719|NCT01682551|DRUG|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
219272720|NCT01682551|DRUG|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
219272721|NCT05230719|PROCEDURE|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
219272722|NCT01340248|DRUG|Dilatrend 64mg capsule|"1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
219272723|NCT03430622|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
219272724|NCT03430622|OTHER|TAU|This group will be on their routine care and will not be given any intervention
219272725|NCT02432664|DRUG|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
219272726|NCT02432664|DRUG|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
219272727|NCT02432664|DRUG|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
219272728|NCT02432664|DRUG|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
219272729|NCT02432664|DRUG|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
219272730|NCT02432664|DRUG|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
219272731|NCT02790697|OTHER|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
219272732|NCT02369471|DRUG|GWP42006|
219272733|NCT02369471|DRUG|Placebo|
219272734|NCT00919451|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
219272735|NCT02539849|DIETARY_SUPPLEMENT|FOS|
219272736|NCT02539849|DRUG|Adalimumab|
219272737|NCT00129935|DRUG|Docetaxel|
219272738|NCT00129935|DRUG|Capecitabine|
219272739|NCT00129935|DRUG|Epirubicin|
219272740|NCT00129935|DRUG|Cyclophosphamide|
219272741|NCT04055428|DRUG|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
219272742|NCT04055428|DRUG|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
219272743|NCT04055428|OTHER|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
219272744|NCT04055428|DIETARY_SUPPLEMENT|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
219272745|NCT04055428|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
219272746|NCT02047162|DRUG|Bismuth subsalicylate|
219272747|NCT02047162|OTHER|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
219272748|NCT02783573|DRUG|Lanabecestat|Administered orally
219272749|NCT02783573|DRUG|Placebo|Administered orally
219272750|NCT00581893|DRUG|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
219272751|NCT00581893|DRUG|Placebo oral capsule|Placebo
219272752|NCT00233480|DRUG|atorvastatin|atorvastatin 10mg PO QD
219272753|NCT00233480|DRUG|placebo|matched placebo Qd x 3 months
219272754|NCT01896765|BEHAVIORAL|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
219272755|NCT01896765|OTHER|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
219272756|NCT05656755|OTHER|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
219272757|NCT05656755|OTHER|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
219272758|NCT03514615|PROCEDURE|Incision|A skin incision will be made on the medial aspect of the upper arm.
219272759|NCT03514615|DRUG|Active gel|The incision site on one arm will be dosed with the active gel.
219272760|NCT03514615|DRUG|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
219272761|NCT03112915|PROCEDURE|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
219272762|NCT03112915|PROCEDURE|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
219272763|NCT05157945|DRUG|ALTO-300 PO Tablet|One tablet daily
219272764|NCT02503826|DRUG|Sufentanil|low dose
219272765|NCT02503826|DRUG|Sufentanil|moderate dose
219272766|NCT02503826|DRUG|Sufentanil|high dose
219272767|NCT02503826|DRUG|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
219272768|NCT02503826|DRUG|propofol|
219272769|NCT02503826|DRUG|cisatracurium|
219272770|NCT02760563|DRUG|BAY 987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
219272771|NCT04204382|DRUG|Levofloxacin Injection|Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
219272772|NCT04204382|DRUG|Compound Kushen Injection（CKI）|CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
219272773|NCT00159263|DRUG|Placebos|Dry powder inhaler
219272774|NCT00159263|DRUG|Formoterol Inhalant Powder|12ug
219272775|NCT00159263|DRUG|Budesonide Powder|Inhaler
219272776|NCT00159263|DRUG|Budesonide and Formoterol Product|Combination Inhaler, Symbicort
219272777|NCT04834713|OTHER|clinical classification of HFRS|Based upon clinical classification of HFRS , the patients were classified into four types
219272778|NCT01375413|BEHAVIORAL|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
219272779|NCT02858453|DRUG|AQX-1125 100 mg|Synthetic SHIP1 activator
219272780|NCT02858453|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
219272781|NCT02858453|DRUG|Placebo|Appearance and weight matched placebo tablets
219272782|NCT02989090|OTHER|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
219272783|NCT02989090|OTHER|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
219272784|NCT04519593|PROCEDURE|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
219272785|NCT04519593|PROCEDURE|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
219272786|NCT00372736|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
219272787|NCT00372736|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
219272788|NCT00372736|GENETIC|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs \> 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs \> 5 x ULN1
219272789|NCT00372736|GENETIC|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
219272790|NCT00372736|OTHER|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
219272791|NCT00372736|OTHER|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
219272792|NCT00372736|OTHER|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
219272793|NCT00372736|OTHER|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
219272794|NCT01012245|OTHER|no intervention|
219272795|NCT06814197|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy for Procrastination|This intervention incorporates Motivational Interviewing (e.g., open-ended questions, affirmations, reflective listening, summarising) and Cognitive Behavioural Therapy (e.g., cognitive restructuring) techniques in natural conversations instead of having a fully manualised programme. This approach resembles coaching instead of traditional therapy to build therapeutic relationships naturally and keep clients engaged with genuine human connection.
219272796|NCT00174694|DRUG|Telithromycin|
219272797|NCT04429282|DRUG|ibuprofen|Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
219272798|NCT04429282|DRUG|Placebo|Placebo
219272799|NCT00158067|DEVICE|external Responsive Neurostimulator (eRNS) System|
219272800|NCT02797522|DRUG|ARC-521 Injection|
219272801|NCT02797522|OTHER|Placebo|0.9% normal saline
219272802|NCT02797522|DRUG|antihistamine|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
219272803|NCT02797522|DRUG|acetaminophen|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
219272804|NCT02797522|DRUG|entecavir|Participants take entecavir OR tenofovir daily throughout the study.
219272805|NCT02797522|DRUG|tenofovir|Participants take entecavir OR tenofovir daily throughout the study.
219272806|NCT00004940|DRUG|cysteine hydrochloride|
219272807|NCT04398329|DRUG|HTX-034|HTX-034, low dose
219272808|NCT04398329|DRUG|HTX-034|HTX-034, high dose
219272809|NCT04398329|DEVICE|Luer lock applicator|Applicator for instillation
219272810|NCT04398329|DRUG|Bupivacaine HCl|Bupivacaine HCl, 50 mg
219272811|NCT00725712|DRUG|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
219272812|NCT05799469|DRUG|Envafolimab|SC
219272813|NCT05799469|DRUG|Cisplatin|IV infusion
219272814|NCT05799469|RADIATION|External Beam Radiotherapy (EBRT)|45-50.4Gy
219272815|NCT05799469|RADIATION|Brachytherapy (BT)|Performed according to clinically required dose
219272816|NCT01605682|DIETARY_SUPPLEMENT|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
219272817|NCT01475305|DRUG|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
219272818|NCT01475305|DRUG|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
219272819|NCT04826276|OTHER|smoking abstinence|participants will be asked to not smoke for at least 12 hours
219272820|NCT04826276|OTHER|smoking satiety|participants will be asked to smoke as usual
219272821|NCT01561482|DRUG|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
219272822|NCT01561482|DRUG|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
219272823|NCT01872481|DEVICE|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
219272824|NCT01872481|DEVICE|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
219272825|NCT00757224|BEHAVIORAL|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
219272826|NCT00132678|DRUG|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
219272827|NCT00132678|DRUG|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
219272828|NCT03318029|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
219272829|NCT03318029|DIETARY_SUPPLEMENT|Placebo|rice flour with no vitamin D
219272830|NCT03815370|DEVICE|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
219272831|NCT03815370|DEVICE|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
219272832|NCT01758679|BIOLOGICAL|Licartin and CIK|Licartin and CIK
219272833|NCT05711277|DIETARY_SUPPLEMENT|Standard milkshake ONS (Fortisip Compact Protein)|Two 125ml bottles of standard ONS administered a day for two days
219272834|NCT05711277|DIETARY_SUPPLEMENT|High protein, fortified, ice cream|Two 80g servings of N-ICE CREAM administered a day for two days
219272835|NCT01367847|BEHAVIORAL|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon \& Forehand) for parents of 3 to 8 y.o. children with externalizing problems
219272836|NCT01367847|BEHAVIORAL|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
219272837|NCT06277505|COMBINATION_PRODUCT|Take prebiotics and probiotics|Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
219272838|NCT06277505|BEHAVIORAL|lifestyle guidance|lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
219272839|NCT04511624|DRUG|IBI112 dose1|Drug: IBI112 SC dose1 Drug:placebo
219272840|NCT04511624|DRUG|IBI112 dose2|Drug: IBI112 SC dose2 Drug:placebo
219272841|NCT04511624|DRUG|IBI112 dose3|Drug: IBI112 SC dose3 Drug:placebo
219272842|NCT04511624|DRUG|IBI112 dose4|Drug: IBI112 SC dose4 Drug:placebo
219272843|NCT04511624|DRUG|IBI112 dose5|Drug: IBI112 IV dose5 Drug:placebo
219272844|NCT04511624|DRUG|IBI112 dose6|Drug: IBI112 SC dose6 Drug:placebo
219272845|NCT04511624|DRUG|IBI112 dose7|Drug: IBI112 IV dose7 Drug:placebo
219272846|NCT06957314|OTHER|Hospital-at-Home/HAH|After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence
219272847|NCT04665609|DRUG|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
219272848|NCT04665609|DRUG|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
219272849|NCT01949636|OTHER|Functional Magnetic Resonance Imaging|
219272850|NCT02781805|DRUG|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
219272851|NCT00174837|DRUG|Tirapazamine|in combination with cisplatin and concomitant radiation
219272852|NCT00174837|DRUG|Cisplatin|with concomitant radiation
219272853|NCT05205070|BIOLOGICAL|Rosnilimab|humanized monoclonal antibody
219272854|NCT05205070|BIOLOGICAL|Placebo|Placebo solution
219272855|NCT03148522|DRUG|Escitalopram|receive escitalopram
219272856|NCT03148522|DRUG|Duloxetine|receive duloxetine
219272857|NCT03148522|DRUG|Mirtazapine|receive mirtazapine
219272858|NCT05665569|DEVICE|Flourish HEC, which contains BioNourish|The Flourish HEC vaginal hygiene system comprises Balance intimate wash used daily, BioNourish vaginal moisturizing gel used daily, and BiopHresh homeopathic vaginal suppository containing probiotics, used once every 3 days. In addition, for all therapy requiring insertion in the clinic or at home, or for sex if desired, BioNude personal lubricant will be used. These four products are intended to allow the vaginal microbiome to self-correct by supporting the vaginal environment in terms of providing pH, osmolality, and lactic acid levels that match those in a healthy vagina.
219272859|NCT05665569|OTHER|Routine pelvic physical therapy|Routine pelvic physical therapy may include external and internal manual techniques, exercises, diaphragmatic breathing exercises, and other modalities.
219272860|NCT02276105|OTHER|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
219272861|NCT03659162|DRUG|Azole Antifungal|oral gel \& injections
219272862|NCT04047277|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
219272863|NCT00756041|DRUG|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
219272864|NCT02292862|PROCEDURE|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant."
219272865|NCT04264377|PROCEDURE|Bronchoscopy|Bronchoscopy for retrieval of airway cells
219272866|NCT03602300|DRUG|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
219272867|NCT03602300|DRUG|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
219272868|NCT05495321|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
219272869|NCT04591379|DRUG|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
219272870|NCT01235000|BIOLOGICAL|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
219272871|NCT06314971|OTHER|Tw1CE|A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
219272872|NCT00592293|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
219272873|NCT02559427|OTHER|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
219272874|NCT02559427|OTHER|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
219272875|NCT02022722|DRUG|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
219272876|NCT02022722|PROCEDURE|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
219272877|NCT06305442|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
219272878|NCT06305442|DIETARY_SUPPLEMENT|Ready-to-Use Supplementary Food|RUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above.
219272879|NCT00421655|DRUG|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
219272880|NCT05692869|DRUG|Propranolol|Administered orally.
219272881|NCT05692869|DRUG|Pseudoephedrine|Administered orally.
219272882|NCT05692869|DEVICE|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
219272883|NCT05692869|OTHER|No Intervention|No intervention during this period (Control Period)
219272884|NCT00218608|DRUG|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
219272885|NCT01449786|DRUG|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
219272886|NCT01449786|DRUG|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
219272887|NCT01449786|OTHER|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
219272888|NCT06378723|OTHER|Balance Tests|With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured
219272889|NCT05639452|OTHER|Data collection for developing an algorithm for an Early Warning Score|Data collection of patient parameters (heart rate, respiratory rate, clinical outcomes (death, transfer to intensive care unit, adverse events like sepsis, infection, heart attack))
219272890|NCT01384812|DRUG|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
219272891|NCT01384812|DRUG|isoton sodium chloride|intravenous injection for 25 min
219272892|NCT03504345|DRUG|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
219272893|NCT05330988|DEVICE|anodal transcranial direct current stimulation (a-tDCS)|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
219272894|NCT05330988|DEVICE|sham stimulation|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
219272895|NCT05371366|DEVICE|ASD closure with the novel occluder (ReAces)|Transcatheter closure atrial septal defect with the novel occluder (ReAces)
219272896|NCT05371366|DEVICE|ASD closure with normal occluder|Transcatheter closure atrial septal defect with normal occluder
219272897|NCT00258752|BEHAVIORAL|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
219272898|NCT00258752|OTHER|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
219272899|NCT00258752|OTHER|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
219272900|NCT05820399|DIETARY_SUPPLEMENT|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
219272901|NCT05820399|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
219272902|NCT01543997|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
219272903|NCT01543997|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
219272904|NCT05724238|DIETARY_SUPPLEMENT|Traditional Herbal Supplements (Kuan Sin Yin)|Astragalus-based Kuan Sin Yin
219272905|NCT05724238|DIETARY_SUPPLEMENT|Placebo|Placebo starch powder with 10% Kuan Sin Yin
219272906|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
219272907|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
219272908|NCT04803747|DRUG|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
219272909|NCT04803747|DRUG|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
219272910|NCT05688553|DEVICE|Flexi-bar|two groups, experimental group intervention Flexi-bar with balance and strength training
219272911|NCT05688553|OTHER|balance and strength training|the control group intervention only balance and strength training
219272912|NCT01784523|DRUG|Hydroxychloroquine|
219272913|NCT02926222|DRUG|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
219272914|NCT02926222|DRUG|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
219272915|NCT01898377|DRUG|Imatinib mesylate, Mycophenolate mofetil|
219272916|NCT00241488|DRUG|Rosuvastatin|
219272917|NCT06271876|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
219296294|NCT04367285|OTHER|Upper limb motor training|Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
219272918|NCT01173276|OTHER|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
219272919|NCT01720576|DRUG|REGN1033 (SAR391786)|
219272920|NCT01720576|DRUG|Placebo|
219272921|NCT01609426|GENETIC|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
219272922|NCT00960362|DRUG|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
219272923|NCT00960362|DRUG|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
219272924|NCT05903157|BEHAVIORAL|Control Group: Delivery of a health literacy flyer|"A health literacy flyer was delivered, by e-mail, in the first week of the intervention (the flyer contained its original source - the European Centre for Disease Prevention and Control). Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and follow-up moments (3 and 6 months after the intervention)."
219272925|NCT05903157|BEHAVIORAL|Experimental Group: Weekly group sessions for weight management|"The eHealth intervention was designed based on: i) the Health Action Process Approach determinants, ii) the Health Belief Model constructs, and iii) behaviour change techniques (BCT, Taxonomy v1, by Michie et al., 2013) to implement healthy behaviours.~The intervention consists of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, are led by the psychologist responsible for the study. Whatsapp groups were created, to share experiences, knowledge, doubts, fears...~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and in follow-up moments (3 and 6 months after the intervention)."
219272926|NCT04340947|OTHER|Very low nicotine cigarette: menthol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
219272927|NCT04340947|OTHER|Very low nicotine cigarette: non-mentol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
219272928|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Ketamine
219272929|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Normal Saline
219272930|NCT05478382|DRUG|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
219272931|NCT05478382|DRUG|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
219272932|NCT02092532|DRUG|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
219272933|NCT02092532|PROCEDURE|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
219272934|NCT04127903|OTHER|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
219272935|NCT03181347|PROCEDURE|RYGB|Roux-en-Y Gastric Bypass
219272936|NCT03181347|PROCEDURE|SG|Sleeve Gastrectomy
219272937|NCT03181347|BEHAVIORAL|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
219272938|NCT03293459|PROCEDURE|Shunt Occlusion|Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
219272939|NCT03293459|DIETARY_SUPPLEMENT|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
219272940|NCT03608059|DRUG|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
219272941|NCT03608059|DRUG|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
219272942|NCT03608059|DRUG|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
219272943|NCT02484664|DRUG|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
219272944|NCT04646369|BEHAVIORAL|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
219272945|NCT04646369|BEHAVIORAL|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
219272946|NCT04646369|BEHAVIORAL|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
219272947|NCT01782521|PROCEDURE|No primer|Primer not used when bonding orthodontic brackets
219272948|NCT01124097|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
219272949|NCT01124097|DRUG|Placebo|Tablets will be used.
219272950|NCT00620269|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
219272951|NCT00620269|DRUG|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
219272952|NCT00620269|DRUG|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 \& 8 every 3 weeks X 2 cycles
219272953|NCT00620269|RADIATION|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
219272954|NCT01748305|BEHAVIORAL|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
219272955|NCT01754415|DEVICE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
219272956|NCT01821937|DRUG|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
219272957|NCT01821937|DRUG|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
219272958|NCT03258736|PROCEDURE|inguinal hernia surgery|repair of inguinal hernia
219272959|NCT04787237|OTHER|VST and immediate implants|One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
219272960|NCT04787237|OTHER|Buser technique and early implants placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
219272961|NCT03193463|DRUG|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
219272962|NCT03193463|DRUG|Topotecan (>8cc)|In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
219272963|NCT03193463|DEVICE|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
219272964|NCT03193463|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
219272965|NCT03193463|DRUG|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
219272966|NCT01139788|DRUG|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
219272967|NCT05772143|PROCEDURE|Percutaneous discectomies under CT|Percutaneous discectomies under CT guidance to treat lumbar disc herniations resistant to conservative treatment and nerve root infiltrations.
219272968|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
219272969|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
219272970|NCT02238249|DRUG|Alesion®|Dry Syrup
219272971|NCT04250779|DEVICE|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
219272972|NCT04250779|BEHAVIORAL|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
219272973|NCT04455022|OTHER|Bedside blood culture bottles weighing combined with educational interventions.|Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
219272974|NCT06470477|DRUG|Guideline-based treatment|Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
219272975|NCT04118413|OTHER|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
219272976|NCT01717079|PROCEDURE|Sham rTMS|120 pulses 0.2Hz
219272977|NCT01717079|PROCEDURE|rTMS|120 pulses 0.2Hz
219272978|NCT02784743|DRUG|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
219272979|NCT05090189|OTHER|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
219272980|NCT03768622|PROCEDURE|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
219272981|NCT03768622|PROCEDURE|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
219272982|NCT04079205|DEVICE|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
219272983|NCT04079205|BEHAVIORAL|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
219272984|NCT06427733|BIOLOGICAL|Placebo comparator|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
219272985|NCT06427733|BIOLOGICAL|Active Comparator|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
219272986|NCT00470197|DRUG|alvocidib|Given IV
219272987|NCT00470197|DRUG|cytarabine|Given IV
219272988|NCT00470197|DRUG|mitoxantrone hydrochloride|Given IV
219272989|NCT00470197|OTHER|pharmacological study|Correlative study
219272990|NCT03396068|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
219272991|NCT03396068|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
219272992|NCT04315805|OTHER|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
219272993|NCT02388152|DRUG|Lu AF20513, low dose|
219272994|NCT02388152|DRUG|Lu AF20513, medium dose|
219272995|NCT02388152|DRUG|Lu AF20513, high dose|
219272996|NCT02388152|DRUG|Lu AF20513, double high dose|
219272997|NCT05201053|DIAGNOSTIC_TEST|Exploratory for different markers|Test biomarkers for development of mild, moderate or severe disease
219272998|NCT04966026|OTHER|No inervention|No inervention
219272999|NCT04249570|OTHER|Povidone iodine|
219273000|NCT03849703|BEHAVIORAL|Full Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
219273001|NCT03849703|BEHAVIORAL|Full Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
219273002|NCT03849703|BEHAVIORAL|Partial Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
219273003|NCT03849703|BEHAVIORAL|Partial Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
219273004|NCT01070576|OTHER|no intervention|no intervention
219273005|NCT00830323|DRUG|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
219273006|NCT00830323|DRUG|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
219273007|NCT00830323|DRUG|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
219273008|NCT04853615|DRUG|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
219273009|NCT00675532|BEHAVIORAL|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
219273010|NCT00675532|BEHAVIORAL|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
219273011|NCT01749852|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
219273012|NCT01749852|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
219273013|NCT06146478|DRUG|Thalidomide|Thalidomide given at an average dose of 1.5mg/kg/day
219273014|NCT02868840|BEHAVIORAL|Tai Chi exercise|exercise twice a week each for one hour
219273015|NCT02868840|BEHAVIORAL|symptom management|sending text message weekly to manage symptoms related to stroke
219273016|NCT00737503|BIOLOGICAL|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
219273017|NCT00887770|DRUG|AZD5672|12 x 50mg tablet, oral, single dose
219273018|NCT00887770|DRUG|Moxifloxacin|1 x 400mg capsule, oral, single dose
219273019|NCT00887770|DRUG|placebo|12 x matched to AZD5672 50 mg tablet
219273020|NCT00887770|DRUG|AZD5672|3 x 50mg tablet, oral. single dose
219273021|NCT00887770|DRUG|placebo|9 x matched to AZD5672 50mg tablet
219273022|NCT00887770|DRUG|placebo|1 x matched to Moxifloxacin capsule
219273023|NCT02361086|DRUG|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
219273024|NCT00609947|DEVICE|Endeavor Zotarolimus-Eluting Coronary Stent|
219273025|NCT03088774|OTHER|Information material|Online web-application developed together with patients with low back pain
219273026|NCT02478437|PROCEDURE|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
219273027|NCT02478437|PROCEDURE|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
219273028|NCT03863145|DRUG|CB-03-10|CB-03-10, 100 mg capsule for oral use
219273029|NCT05492305|DRUG|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
219273030|NCT02406248|DRUG|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
219273031|NCT02675257|BEHAVIORAL|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
219273032|NCT02675257|BEHAVIORAL|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
219273033|NCT02675257|BEHAVIORAL|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
219273034|NCT02675257|BEHAVIORAL|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
219273035|NCT02675257|BEHAVIORAL|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
219273036|NCT02675257|BEHAVIORAL|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
219273037|NCT02675257|BEHAVIORAL|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
219273038|NCT02675257|BEHAVIORAL|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
219273039|NCT02675257|BEHAVIORAL|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
219273040|NCT02675257|BEHAVIORAL|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
219273041|NCT02675257|BEHAVIORAL|Sports, activities and exercise|Education on sports, activities and exercise
219273042|NCT02675257|BEHAVIORAL|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
219273043|NCT02675257|BEHAVIORAL|Diabetes complications|Education on diabetes complications
219273044|NCT02675257|BEHAVIORAL|Social aspects of living with diabetes|Education on social aspects of living with diabetes
219177930|NCT06849947|DRUG|Physician's choice treatments group|"▪Fulvestrant or exemestane group~1. Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or periomenopausal women) OR,~2. Exemestane (25 mg orally once daily on day 1 to 28 in a 28 day cycle) + Everolimus (10 mg orally once daily on day 1 to 28 in a 28 day cycle) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
219273045|NCT04701723|OTHER|cardiac coherence|standard care associated to cardiac coherence training during 3 months
219273046|NCT04046458|BEHAVIORAL|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
219273047|NCT04046458|OTHER|No EHR alert|No change to EHR function; no alert visible to providers
219273048|NCT02257476|DRUG|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
219273049|NCT02257476|DRUG|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
219273050|NCT00569114|DRUG|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
219273051|NCT00657735|DEVICE|H-Coil deep TMS|20 daily deep rTMS treatments
219273052|NCT00657735|DEVICE|sham|inactive treatment
219273053|NCT06544603|DEVICE|Multiwave Locked System (MLS) laser|Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)
219273054|NCT03102866|OTHER|Best Practice|Receive usual care
219273055|NCT03102866|BEHAVIORAL|Exercise Intervention|Undergo aerobic and strength training exercise
219273056|NCT03102866|OTHER|Quality-of-Life Assessment|Ancillary studies
219273057|NCT03102866|OTHER|Questionnaire Administration|Ancillary studies
219273058|NCT01304498|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
219273059|NCT01304498|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
219273060|NCT04484584|OTHER|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
219273061|NCT05054569|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
219273062|NCT00894504|DRUG|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
219273063|NCT00894504|DRUG|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
219273064|NCT00894504|DRUG|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
219273065|NCT04706858|DIETARY_SUPPLEMENT|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
219273066|NCT01834586|DRUG|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
219273067|NCT00219245|DRUG|Rivastigmine|
219273068|NCT00168493|DRUG|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
219273069|NCT00440245|DRUG|salbutamol|200 micrograms salbutamol from MDI
219273070|NCT02722811|DRUG|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
219273071|NCT02722811|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
219273072|NCT04041830|BEHAVIORAL|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
219273073|NCT04041830|BEHAVIORAL|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
219273074|NCT01667549|OTHER|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
219273075|NCT00375622|DRUG|Tamoxifen|
219273076|NCT04155970|OTHER|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
219273077|NCT04155970|OTHER|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
219273078|NCT02637102|OTHER|Not applicable - observational study|
219273079|NCT01883284|OTHER|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
219273080|NCT03174665|OTHER|No intervention|
219273081|NCT05790525|DRUG|Standard bismuth quadruple|Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
219273082|NCT02844777|DRUG|Placebo|200 mg applied once-daily for 28 days
219273083|NCT02844777|DRUG|5% VDA-1102|200 mg applied once-daily for 28 days
219273084|NCT02844777|DRUG|10% VDA-1102|200 mg applied once-daily for 28 days
219273085|NCT01749098|DRUG|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
219273086|NCT01749098|DRUG|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
219273087|NCT01749098|DRUG|Placebo|Placebo capsule orally administered on Days 1 - 5
219273088|NCT01749098|DRUG|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
219273089|NCT03758495|OTHER|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
219273090|NCT00150618|DRUG|SPD503 (1 mg)|
219273091|NCT00150618|DRUG|SPD503 (2 mg)|
219273092|NCT00150618|DRUG|SPD503 (3 mg)|
219273093|NCT00150618|DRUG|SPD503 (4 mg)|
219273094|NCT00150618|DRUG|Placebo|
219273095|NCT00609401|DRUG|Nexavar (Sorafenib)|400 mg bid
219273096|NCT00609401|DRUG|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
219273097|NCT01132469|PROCEDURE|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
219273098|NCT05336175|DRUG|Angiotensin 1-7|"A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
219273099|NCT05336175|DRUG|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
219273100|NCT04344951|DRUG|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
219273101|NCT04711083|DIAGNOSTIC_TEST|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of \> 4%), the percentage of oximetry sleep time spent with a SpO2 of \< 90%, and the total oximetry time. Recordings were classified as normal (\< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (\> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
219273102|NCT05693077|BIOLOGICAL|10E4 NTCD spores|in capsule for oral ingestion.
219273103|NCT05693077|BIOLOGICAL|10E7 NTCD spores|in capsule for oral ingestion.
219273104|NCT05693077|OTHER|placebo|in capsule for oral ingestion.
219273105|NCT05693077|DRUG|Vancomycin Oral Capsule|4 times a day 250mg
219273106|NCT03294824|OTHER|blood sample|peripheral blood samples are collected
219273107|NCT00004251|DRUG|letrozole|2.5 mg of letrozole per day
219273108|NCT05143164|DEVICE|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
219273109|NCT05143164|DRUG|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
219273110|NCT02493946|BIOLOGICAL|Botulinum toxin type A|
219273111|NCT02493946|DRUG|Placebo|
219273112|NCT00003664|BIOLOGICAL|aldesleukin|
219273113|NCT00003664|BIOLOGICAL|recombinant interferon alfa|
219273114|NCT00003664|DRUG|fluorouracil|
219273115|NCT00003664|DRUG|gemcitabine hydrochloride|
219273116|NCT01239784|BEHAVIORAL|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
219273117|NCT01244165|DEVICE|Cytrix|
219273118|NCT01244165|OTHER|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
219273119|NCT03747406|PROCEDURE|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
219273120|NCT03747406|PROCEDURE|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
219273121|NCT00431613|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
219273122|NCT00431613|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
219273123|NCT00431613|DRUG|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
219273124|NCT00431613|RADIATION|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
219273125|NCT00431613|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
219273126|NCT03135990|BEHAVIORAL|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
219273127|NCT05000047|DEVICE|3D ear scanner|A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.
219273128|NCT05000047|OTHER|Conventional silicon ear impressions|A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
219273129|NCT05776290|BIOLOGICAL|Hyaluronic Acid|This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
219273130|NCT04855045|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
219273131|NCT02445651|DIETARY_SUPPLEMENT|Intravenous and Oral n-acetyl cysteine|
219273132|NCT05329168|DRUG|Tonabacase (LSVT-1701)|4.5 or 6.0 mg/kg IV once daily for 4 days
219273133|NCT01583504|PROCEDURE|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
219273134|NCT01583504|PROCEDURE|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
219273135|NCT01583504|BEHAVIORAL|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
219273136|NCT03452215|BEHAVIORAL|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
219273137|NCT03452215|BEHAVIORAL|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
219273138|NCT00508209|DRUG|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
219273139|NCT05822492|PROCEDURE|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
219273140|NCT05822492|PROCEDURE|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
219273141|NCT05822492|OTHER|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
219273142|NCT01727505|DEVICE|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
219273143|NCT01727505|DEVICE|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
219273144|NCT02847390|OTHER|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
219273145|NCT01543542|RADIATION|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
219273146|NCT05845203|DIAGNOSTIC_TEST|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
219273147|NCT04154852|DRUG|Adalimumab|
219273148|NCT04154852|DRUG|Methotrexate|
219273149|NCT04154852|DRUG|Placebo|Placebo to replace adalimumab
219273150|NCT04154852|DRUG|Folic Acid|
219273151|NCT00246935|DRUG|Roflumilast|
219273152|NCT06146764|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Integrated scoring method and up-and-down scoring method
219273153|NCT00599274|DRUG|Interferon beta-1a|injection once a week
219273154|NCT00599274|DRUG|Interferon beta-1a|injection three times a week
219273155|NCT01081275|BEHAVIORAL|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
219273156|NCT01081275|BEHAVIORAL|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
219273157|NCT03889847|DEVICE|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
219273158|NCT03889847|DEVICE|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
219273159|NCT03643549|DRUG|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
219273160|NCT03643549|DRUG|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
219273161|NCT03306420|DRUG|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
219273162|NCT01893476|OTHER|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
219273163|NCT05320510|DIETARY_SUPPLEMENT|Se-yeast|The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219273164|NCT05320510|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
219273165|NCT00452140|BIOLOGICAL|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
219273166|NCT04351308|DRUG|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)"
219273167|NCT04351308|DRUG|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
219273168|NCT04351308|DRUG|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
219273169|NCT00536653|DRUG|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
219273170|NCT00536653|DRUG|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
219273171|NCT00536653|DRUG|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
219273172|NCT01540942|DIETARY_SUPPLEMENT|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;\[W=weight（Kg）；H=height（cm）；A=age（year）\]
219273173|NCT01540942|OTHER|surgery|bowel resection
219273174|NCT00763464|PROCEDURE|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
219273175|NCT00763464|PROCEDURE|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
219273176|NCT04792177|BEHAVIORAL|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
219273177|NCT02694445|OTHER|observation|The study is non-interventional.
219273178|NCT04196634|OTHER|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
219273179|NCT00115518|DRUG|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
219273180|NCT02389764|DRUG|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
219273181|NCT02389764|BEHAVIORAL|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
219273182|NCT04518046|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
219273183|NCT04518046|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
219273184|NCT04518046|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
219273185|NCT05167890|DIETARY_SUPPLEMENT|Coffee|Coffee 3 times per day
219273186|NCT05167890|DIETARY_SUPPLEMENT|Orange juice|Orange juice 3 times per day
219273187|NCT06121804|DRUG|Immunosuppressive Agents|Prescribing immunosuppressive agents
219273188|NCT00953732|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
219273189|NCT01500993|DRUG|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
219273190|NCT01500993|DRUG|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
219273191|NCT00806637|PROCEDURE|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
219273192|NCT00806637|PROCEDURE|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
219273193|NCT01814072|BEHAVIORAL|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
219273194|NCT01814072|BEHAVIORAL|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
219273195|NCT01814072|BEHAVIORAL|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
219273196|NCT01814072|BEHAVIORAL|Text Messages|Participants will receive regular text messages
219273197|NCT01814072|BEHAVIORAL|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
219273198|NCT01814072|BEHAVIORAL|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
219273199|NCT06406699|BEHAVIORAL|Pain Reprocessing Therapy (PRT)|PRT is a psychological intervention for chronic pain patients with a primary nociplastic component. PRT aims to help patients reconceptualize their pain as a non-dangerous signal that is not indicative of tissue pathology or structural abnormality. Through decreasing the threat level of their chronic pain, the pain itself can also resolve.
219273200|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
219273201|NCT01011868|DRUG|BI 10773 low dose|BI 10773 low dose
219273202|NCT01011868|DRUG|BI 10773 high dose|BI 10773 high dose
219273203|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
219273204|NCT03833895|DRUG|Norepinephrine|0.05ug/kg/min Norepinephrine during Cesarean Section Operation
219273205|NCT03833895|DRUG|Phenylephrine|0.25ug/kg/min phenylephrine during Cesarean Section Operation
219273206|NCT03833895|DRUG|Ringer's Solution|3 ml/kg/min of LR was administrated according to standard weight.
219273207|NCT04049981|DEVICE|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
219273208|NCT02336425|DRUG|QGE031|QGE031 120 mg per 1 mL liquid in vial
219273209|NCT02336425|DRUG|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
219273210|NCT04499612|PROCEDURE|Cardiac implantable electronic device implantation.|Patients who have indications will receive cardiac implantable electronic device implantation.
219273211|NCT04499612|PROCEDURE|Cardiac implantable electronic device replace.|Patients who have indications will receive cardiac implantable electronic device replace.
219273212|NCT04499612|DIAGNOSTIC_TEST|Duplex ultrasound.|Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
219273213|NCT04499612|DIAGNOSTIC_TEST|Echocardiography.|Patients will undergo an ultrasound examination of the heart.
219273214|NCT04499612|DIAGNOSTIC_TEST|Blood sampling.|Patients will be taken venous blood to determine the studied markers of hemostasis system.
219273215|NCT01836172|DRUG|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
219273216|NCT00978562|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
219273217|NCT00978562|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
219273218|NCT00978562|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
219273219|NCT00978562|DRUG|Gadolinium|Given IV
219273220|NCT02250053|OTHER|Exercise|
219273221|NCT00175539|BEHAVIORAL|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
219273222|NCT06479928|OTHER|delivery mode|Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.
219273223|NCT03230604|DEVICE|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
219273224|NCT03230604|DEVICE|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
219273225|NCT06311305|PROCEDURE|Early Laparoscopic cholecystectomy|laparoscopic cholecystectomy early after ERCP with assessing the risks and complications
219273226|NCT01782690|DRUG|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
219273227|NCT01782690|DRUG|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
219273228|NCT04121897|OTHER|Therapist Education and Massage for Parents of Extremely Preterm Infants|"TEMPO includes these components:~* Early Parent Education Session~* Weekly Parent Education Sessions~* Infant Massage Parent Education Sessions~* Discharge Parent Education Session~* Parent Education Post-Discharge~* Bi-weekly emails (or texts)~* 2 Month Follow-up Massage Review Session"
219273229|NCT04614168|PROCEDURE|Stepped hyperinsulinaemic-hypoglycaemic clamp study|Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
219273230|NCT04614168|DEVICE|Insulin pump|Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
219273231|NCT04614168|DEVICE|Continuous glucose monitor|Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
219273232|NCT04614168|OTHER|Low carbohydrate diet|30-40g of carbohydrate per main meal portion.
219273233|NCT04614168|DEVICE|Blinded continuous glucose monitor|Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
219273234|NCT04614168|PROCEDURE|Stable isotope studies- D2 Glucose and D5 Glycerol|These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
219273235|NCT06123689|DEVICE|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine."
219273236|NCT06123689|DEVICE|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
219273237|NCT06074562|DRUG|LY3556050|Administered orally.
219273238|NCT06074562|DRUG|Placebo|Administered orally.
219273239|NCT05763342|DEVICE|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
219273240|NCT04946942|BEHAVIORAL|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
219273241|NCT04946942|BEHAVIORAL|Usual Care|Attendance at primary care appointments as usual.
219273242|NCT04907357|DEVICE|rTMS|Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
219273243|NCT04907357|DEVICE|Sham (Placebo)|Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
219273244|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
219273245|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
219273246|NCT04216888|DRUG|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
219273247|NCT04505436|DRUG|HM15211|A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes
219273248|NCT04505436|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
219273249|NCT06054009|BEHAVIORAL|Brief CBT|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
219273250|NCT06457191|DRUG|Roflumilast|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
219273251|NCT06457191|DRUG|Placebo|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
219273252|NCT06457191|DEVICE|Intermittent theta-burst stimulation transcranial magnetic stimulation|Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.
219273253|NCT06457191|DEVICE|Continuous theta-burst stimulation transcranial magnetic stimulation|Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.
219273254|NCT05368155|BEHAVIORAL|Brief ACT for Pelvic Pain|The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
219273255|NCT00040495|DRUG|Pantoprazole|
219273256|NCT05035797|PROCEDURE|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
219273257|NCT05035797|PROCEDURE|Usual care|Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
219273258|NCT01948076|DEVICE|resident with GE vscan|resident with GE vscan
219273259|NCT04896788|BIOLOGICAL|Monitoring of the immune response|Blood sample at 3,6,12,18 and 24 months in order to assess the blood level of anti-S1 / RBD anticoprs
219273260|NCT01745276|DEVICE|Biphosfonate|External pins coated by biphosfonate.
219273261|NCT01745276|DEVICE|Hydroxylapatit|External pins coated by Hydroxylapatit.
219273262|NCT00521859|DRUG|Cloretazine|800 mg/m\^2 by vein daily
219273263|NCT00521859|DRUG|Fludarabine|25 mg/m\^2 by vein daily x 5 Days
219273264|NCT03995225|BEHAVIORAL|Smartband automatic smoking detection combined with brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
219273265|NCT04264975|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
219273266|NCT03799419|BEHAVIORAL|Cognitive bias modification for interpretation bias|Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
219273267|NCT03799419|BEHAVIORAL|Psychoeducation|Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
219273268|NCT03799419|BEHAVIORAL|Approach avoidance training|Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, \& Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).
219273269|NCT03799419|BEHAVIORAL|Inactive sham approach avoidance training|Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
219273270|NCT05663905|DRUG|Ambroxol Hydrochloride|IV ambroxol hydrochloride 30mg TDS as adjunct therapy to standard therapy for severe pneumonia in ICU for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour.
219273271|NCT05663905|OTHER|Standard Therapy|Standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC). This includes antibiotics stewardship and supportive therapy.
219273272|NCT04443959|BEHAVIORAL|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
219273273|NCT05592184|OTHER|Exercise|The experimental protocol begins with the assessment of self-perceived pain intensity and perceived exertion when using different intensities of elastic resistance, during wrist flexion and extension, at a controlled speed of 1.5sec/ phase. To assess the intensity at which they will work, participants will perform 2 repetitions and will be allowed a rest of 60s between sets until they obtain a score of 3 on the Borg CR10 scale. Exercises should be performed with the subject's available ROM. Participants are asked to move their body and trunk as little as possible and to perform the exercise smoothly, without stopping or accelerating. The exercise will be performed in a seated position, with the back supported by the backrest and the forearm resting on a table, with the shoulders and elbows bent at 90o, leaving the wrist free, with the elastic bands held under the feet (stepping on them).
219273274|NCT01044927|OTHER|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
219273275|NCT01044927|OTHER|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
219273276|NCT01390350|DRUG|Canakinumab|150mg subcutaneous injections on day 0
219273277|NCT01390350|DRUG|Placebo|150mg subcutaneous injections on day 0
219273278|NCT05261841|OTHER|Standard care for T2D patients, Smartwatch|No intervention, observational study
219273279|NCT04306146|DRUG|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
219273280|NCT04306146|DRUG|Placebos|Capsules
219273281|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
219273282|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
219273283|NCT04673045|DEVICE|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
219273284|NCT04673045|DEVICE|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
219273285|NCT02565550|DIETARY_SUPPLEMENT|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
219273286|NCT02975791|OTHER|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
219273287|NCT02975791|PROCEDURE|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
219273288|NCT05680324|PROCEDURE|Monsplasty|liposuction assisted monsplasty
219273289|NCT05015725|DIAGNOSTIC_TEST|Quality of life assessment, biochemical measures|"Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to \~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels."
219273290|NCT04765410|DIAGNOSTIC_TEST|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
219273291|NCT00569192|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
219273292|NCT00569192|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
219273293|NCT00569192|DRUG|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
219273294|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
219273295|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
219273296|NCT06544564|DEVICE|Membrane Wrap™|Membrane Wrap™
219273297|NCT06544564|OTHER|Standard of Care|SOC treatment will be defined as: 1) debridement of non-viable, necrotic tissue, 2) application of Biologic as the primary, wound covering, 3) application of a dressing over Biologic that maintains moisture balance, 4) application of a Class 3 high compression system, and 5) wrapping with a covering dressing
219273298|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing every 2 weeks~* Intravenous injection"
219273299|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing weekly~* Intravenous injection"
219273300|NCT00691600|DRUG|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
219273301|NCT00691600|DRUG|Placebo|Placebo caps or suspension every 12 hours for 10 days
219273302|NCT02910843|DRUG|Regorafenib|"* Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
219273303|NCT02910843|DRUG|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
219273304|NCT02910843|RADIATION|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
219273305|NCT02910843|PROCEDURE|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
219273306|NCT05365399|DEVICE|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
219273307|NCT00723385|DIETARY_SUPPLEMENT|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
219273308|NCT00723385|OTHER|Placebo|Administration of placebo for 12 weeks with repeated D measurements
219273309|NCT06770972|BEHAVIORAL|Family Foundations|The FF intervention is 9 sessions, 5 in the prenatal period and 4 in the postpartum period.
219273310|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
219273311|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
219273312|NCT02643147|DRUG|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
219273313|NCT04687098|DRUG|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
219273314|NCT04687098|DRUG|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~\- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
219273315|NCT04687098|DRUG|G-CSF|"* Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7."
219273316|NCT04687098|PROCEDURE|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
219273317|NCT04687098|PROCEDURE|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
219273318|NCT04687098|PROCEDURE|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
219273319|NCT02600078|DEVICE|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
219273320|NCT02600078|OTHER|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
219273321|NCT02600078|OTHER|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
219273322|NCT02600078|OTHER|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
219273323|NCT02737813|DRUG|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
219273324|NCT02737813|DRUG|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
219273325|NCT00405119|DRUG|AH23844 (lavoltidine)|
219273326|NCT00405119|DRUG|NEXIUM (esomeprazole)|
219273327|NCT00405119|DRUG|ZANTAC (ranitidine)|
219273328|NCT03169998|DEVICE|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
219273329|NCT06559839|OTHER|Vestibulocortical Stimulation|50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
219273330|NCT05238753|DEVICE|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
219273331|NCT00161265|PROCEDURE|tissue procurement|tissue procurement
219273332|NCT05511337|OTHER|Caloric restriction and control oxalate and citrate foods|Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.
219273333|NCT05511337|OTHER|Caloric restriction|Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan
219273334|NCT05511337|OTHER|Real-life intervention with control oxalate and citrate foods|Decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.
219273335|NCT03866096|OTHER|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
219273336|NCT03866096|OTHER|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
219273337|NCT00869947|DEVICE|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
219273338|NCT00869947|OTHER|No device|
219273339|NCT04833478|BEHAVIORAL|Anxiety|Techniques used to reduce anxiety in paediatric patients.
219273340|NCT00486252|OTHER|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
219273341|NCT03019419|DRUG|Perampanel|4mg/d or 8mg/d
219273342|NCT03019419|DRUG|placebo|placebo
219273343|NCT01210651|BEHAVIORAL|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
219273344|NCT01210651|BEHAVIORAL|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
219273345|NCT01261247|DRUG|panobinostat|Given orally
219273346|NCT01261247|OTHER|laboratory biomarker analysis|Correlative studies
219273347|NCT01261247|GENETIC|western blotting|Correlative studies
219273348|NCT01261247|GENETIC|DNA analysis|Correlative studies
219273349|NCT01261247|OTHER|flow cytometry|Correlative studies
219273350|NCT01261247|OTHER|pharmacological study|Correlative studies
219273351|NCT01261247|OTHER|immunohistochemistry staining method|Optional correlative studies
219273352|NCT02314351|DRUG|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
219273353|NCT02314351|DRUG|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
219273354|NCT02314351|DRUG|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
219273355|NCT01976572|DRUG|colestilan|
219273356|NCT01976572|DRUG|candesartan|
219273357|NCT00382525|DEVICE|Cardiac Rhythm Management device|
219273358|NCT02592707|DRUG|Satoreotide tetraxetan|Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
219273359|NCT02592707|OTHER|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
219273360|NCT02592707|OTHER|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
219273361|NCT03358368|DEVICE|Vitalscan|Vitalscan is a magnetocardiograph device
219273362|NCT05615688|PROCEDURE|Pain Intensity following Placement of Orthodontic Separators|Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
219273363|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
219273364|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
219273365|NCT00721929|PROCEDURE|MRI|Magnetic Resonance Imaging
219273366|NCT04404166|BEHAVIORAL|PINGS 2|Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
219273367|NCT06195865|PROCEDURE|DIEP-flap|Breast reconstruction with a deep inferior epigastric perforator flap
219273368|NCT06195865|PROCEDURE|Implant|Breast reconstruction with an implant-based technique
219273369|NCT04124471|BEHAVIORAL|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
219296295|NCT06478511|PROCEDURE|Classic Immediate implant|The teeth will be extracted gently using periotomes to preserve facial and lingual bone plates. All walls of the socket will be inspected and checked for the presence of fenestration or dehiscence defects in bone. The length and width of extracted roots will be measured to determine the length and diameter of implants placed. The osteotomy sites will be prepared and the drills will be used in proper sequence according to manufacturer's instructions, with maximum use of bone apical to the extraction sockets. The drills will extend 3 to 5 mm beyond the apex of the socket to ensure primary stability after placement, taking care of the anatomical boundaries. The implants will be placed.
219273370|NCT04560621|BEHAVIORAL|Managed Problem Solving (MAPS)|MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
219273371|NCT05261412|OTHER|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
219273372|NCT05261412|OTHER|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
219273373|NCT02132715|BEHAVIORAL|Resistance Exercise|
219273374|NCT02132715|BEHAVIORAL|KAATSU exercise|
219273375|NCT06434116|DEVICE|Immersive virtual reality|"The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection."
219273376|NCT02574325|DRUG|Placebo|Control
219273377|NCT02574325|DRUG|ARI-3037MO|Treatment
219273378|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
219273379|NCT04855734|BEHAVIORAL|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
219273380|NCT03701581|DRUG|4-Aminopyridine|FDA-approved tablets.
219273381|NCT03701581|OTHER|Placebo|Placebo will be tooled to look similar to the study drug.
219273382|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
219273383|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
219273384|NCT06015256|BIOLOGICAL|blood sample|Blood sample (56mL) taken in a heparin tube
219273385|NCT04577209|DEVICE|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
219273386|NCT05260320|OTHER|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
219273387|NCT05954286|DRUG|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
219273388|NCT05954286|DRUG|Placebo (PO)|Oral Capsules
219273389|NCT04013971|OTHER|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
219273390|NCT04013971|OTHER|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
219273391|NCT04013971|OTHER|Control Condition|Participants will complete a control walk with out feedback.
219273392|NCT05853900|DEVICE|ReMMi-D Digital Therapeutic|Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
219273393|NCT05263960|BIOLOGICAL|CM350 group1|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
219273394|NCT05263960|BIOLOGICAL|CM350 group2|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
219273395|NCT05263960|BIOLOGICAL|CM350 group3|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
219273396|NCT02538198|DRUG|Lenalidomide|
219273397|NCT05194033|DIETARY_SUPPLEMENT|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
219273398|NCT05194033|DIETARY_SUPPLEMENT|Placebo daily|Placebo 1 time/day for 7 consecutive days
219273399|NCT05129410|DRUG|Mycophenolate Mofetil|"1. Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. MMF1.5g-2.0g/d"
219273400|NCT03040947|OTHER|Cardiovascular Magnetic Resonance|
219273401|NCT06521268|OTHER|Inspiratory muscle training|Inspiratory muscle training
219273402|NCT06521268|OTHER|Decongestive treatment|Decongestive treatment
219273403|NCT04157036|DRUG|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
219273404|NCT04157036|DRUG|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
219273405|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D
219273406|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
219273407|NCT06655649|DIETARY_SUPPLEMENT|Ketone-IQ (1,3 Butanediol)|Ketone-IQ (1,3 Butanediol) 20 or 40 g will be ingested (open-label) before bedtime.
219273408|NCT06547788|OTHER|Mitral valve repair with creation of an 8 mm inter-atrial shunt|Mitral valve repair with creation of an 8 mm inter-atrial shunt
219273409|NCT03429166|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation|A non-trauma-focused treatment
219273410|NCT03429166|BEHAVIORAL|Present Centered Therapy|A non-trauma-focused treatment
219273411|NCT00344032|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
219273412|NCT00344032|BIOLOGICAL|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
219273413|NCT02000778|DRUG|EC17|
219273414|NCT00755456|DRUG|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
219273415|NCT00755456|DRUG|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
219273416|NCT06056128|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
219273417|NCT04513977|OTHER|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
219273418|NCT02390661|DEVICE|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
219273419|NCT06658873|OTHER|Proximal arterial cannulation|Radial arterial cannulation from the proximal part of the artery 5 cm proximal to the level of the styloid process.
219273420|NCT06658873|OTHER|Distal arterial cannulation|Radial arterial cannulation from the distal part of the artery at the styloid process.
219273421|NCT06856863|BEHAVIORAL|Test of personality : questionnary|The questionnary Temperament and Character Inventory (TCI) describes personality through temperament traits governed by the individual's neurobiological systems and predetermined by heredity; and character traits shaped by social and cognitive experience
219273422|NCT06872684|DEVICE|Surpass Elite with Guardian Flow Diverter System|The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeter (mm) and ≤ 6.0 mm and located on the Internal Carotid Artery (ICA) or its branches.
219273423|NCT06858540|BEHAVIORAL|Unified protocol for transdiagnostic treatment of emotional disorders in adolescents|The blended UP-A includes 8 weekly modules, 6 of which (Module 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (module 8), each with an expected duration of 90 minutes.
219273424|NCT06604754|OTHER|Assigned Intervention for VR Training|In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.
219273425|NCT06604754|OTHER|Assigned Intervention for Traditional Physical Therapy Training|In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.
219273426|NCT07002294|OTHER|Transfer to specialty care|Interfacility transport and treatment at the specialty care hospital
219273427|NCT07002294|OTHER|Usual care|Hospitalization and treatment at the closest appropriate facility
219273428|NCT06669975|DRUG|AP402 (Part 1 Dose esclation)|Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
219273429|NCT06669975|DRUG|AP402 (Part 2 Dose Expansion)|After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
219273430|NCT04466566|OTHER|Saline|Saline will serve as the control
219273431|NCT04466566|BIOLOGICAL|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
219273432|NCT06546150|BIOLOGICAL|RE002 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
219273433|NCT06998667|BEHAVIORAL|Standard Heat Illness Prevention Measures|Standard CAL-OSHA workplace heat illness prevention interventions, which require availability of cool, potable water; availability of shade when temperatures exceed 80F; and encouragement of rest for cool down breaks
219273434|NCT06998667|OTHER|Cooling bandana|Cooling bandana embedded with a polymer to slow evaporation
219273435|NCT06998667|OTHER|Cooling glove|Cooling glove with ability to circulate cool water interface with palmar skin
219273436|NCT03534011|PROCEDURE|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
219273437|NCT03534011|DEVICE|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
219273438|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
219273439|NCT07009548|DRUG|Cytogam|CytoGam 150 mg/kg intravenously (IV) administered as a single dose
219273440|NCT06869824|DIETARY_SUPPLEMENT|Minayo Iron-rich Nutritional Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
219273441|NCT06869824|DIETARY_SUPPLEMENT|Common Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
219273442|NCT05388435|DRUG|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
219273443|NCT01688011|DRUG|Luspatercept|Prescribed by treating physician as per product label.
219273444|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
219273445|NCT06627335|DRUG|TCS|Topical corticosteroid
219273446|NCT07014852|OTHER|Traditional Country Foods|Participants will receive weekly distributions of traditional foods, including caribou and fish. Guided conversations will explore changes in dietary habits, emotional well-being, and cultural connections
219273447|NCT07014852|BEHAVIORAL|Cultural Workshops|Weekly workshops led by Elders will focus on traditional country food, food preparation, and sharing practices, enhancing cultural identity and community bonds. Participants will also engage in cultural camps where they will be led by Elders in land based teachings on country food.
219273448|NCT05890963|DRUG|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
219273449|NCT05890963|DRUG|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
219273450|NCT05890963|DRUG|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
219273451|NCT05419388|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
219273452|NCT02325583|DRUG|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
219273453|NCT02325583|DRUG|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
219273454|NCT06875154|PROCEDURE|Valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy or minitoracothomy Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium or from peripheral access. Left ventricle was vented through the right superior pulmonary vein.~In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion.. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
219273455|NCT07017478|DRUG|LSD|The serotonin 2A receptor agonist LSD
219273456|NCT07017478|DRUG|Placebo|Distilled water
219273457|NCT03687593|DEVICE|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
219273458|NCT07024160|DRUG|MT1011|MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.
219273459|NCT07024160|DRUG|Placebo|This intervention contains no active ingredients
219273460|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
219273461|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
219273462|NCT07031180|OTHER|educational video|"The experimental educational intervention will consist of professional video recordings that will cover the following topics:~1. Disease knowledge (VLU)~2. Medication management~3. The importance of compression therapy~4. Diet and physical activity The video recordings' contents will result from a review of the literature and guidelines, which will be later reviewed by a panel of experts in VLU. The video will be recorded by experienced video-maker and by a group of volunteers who will be the actors."
219273463|NCT07031180|OTHER|educational pamphlet (standard educational intervention)|The educational brochure is an educational intervention already in use at the setting involved in the study.
219273464|NCT07030218|PROCEDURE|Office hysteroscopy|In office hysteroscopy will utilize 1.9-2.9 mm hysteroscopes (primarily Bettocchi) by the technique of vaginoscopy, without anesthesia or up to level 3a analgesia, in accordance with International Consensus Statement for Recommended Terminology Describing Hysteroscopic Procedures. The choice of distension medium and hysteroscope is left to the operator's discretion. A nurse positioned at the head of the patient will record signs and symptoms of VVR/VVS.
219273465|NCT07031544|DEVICE|deep brain stimulation|Deep Brain Stimulation (DBS) involves the use of stereotactic techniques to implant microelectrodes into specific target nuclei within the brain through minimally invasive surgery. These electrodes are connected via leads to a subcutaneously implanted pulse generator, typically placed beneath the clavicle. By delivering low-intensity electrical pulses, DBS suppresses abnormal intracranial neural activity, thereby alleviating symptoms. Long-term stimulation can also induce neuroplastic changes in neural networks and neurotransmitter systems, contributing to the restoration of neurological function.
219273466|NCT07033572|PROCEDURE|Endoscopic Hemithyroidectomy with Central-Neck Dissection|Gas-less axillo-breast approach (trans-axillary + peri-areolar), carbon-dioxide-free working space, removing dominant thyroid lobe plus level VI lymph nodes; intra-operative neuromonitoring used throughout.
219273467|NCT07033572|PROCEDURE|Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule|17-gauge internally-cooled electrode, 0.7 cm active tip, power 40 W; moving-shot technique under real-time ultrasound until hyperechoic halo fully covers ≤ 7 mm papillary microcarcinoma ≥ 2 mm from posterior capsule; same anesthesia session as surgery.
219273468|NCT06710899|DRUG|Methenamine Hippurate 1g BD|Methenamine Hippurate 1g BD for 6 months
219273469|NCT06710899|DRUG|Methenamine Hippurate 1g BD + Vitamin C 1g BD|Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
219273470|NCT07037589|PROCEDURE|investigation setting (cystoscopy + CTU + cytology)|Observational study. All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for acute macroscopic hematuria.
219273471|NCT07037589|PROCEDURE|Cystoscopy - CTU - cytology (if needed)|All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for atypical or chronic presentations of macroscopic hematuria.
219273472|NCT06880406|OTHER|MMSE and blood draw|Each patient will be evaluated by Mini-Mental State Examination (MMSE) and will have a blood draw
219273473|NCT06881264|DRUG|HR17031 injection|HR17031 injection
219273474|NCT06881264|DRUG|insulin glargine|insulin glargine
219273475|NCT07044466|BEHAVIORAL|CBT4CBT-Buprenorphine|CBT4CBT-Buprenorphine is an evidence-based, Internet-delivered cognitive behavioral therapy program for individuals prescribed buprenorphine by a medical provider. It includes eight 30-minute modules.
219273476|NCT07045428|DRUG|68Ga-GP-01 Injection|A certain mass dose of 68Ga-GP-01 will be used in this study, and the radiation dose will be no more than, enabling all participants will receive a radiation dose of 5±2 mCi in the study.
219273477|NCT07048990|BEHAVIORAL|Empowerment Group Therapy|Empowerment is a manualized, culturally sensitive treatment program. The treatment is based on a modular principle that transdiagnostically targets major symptom domains (e.g. stress, depression, anxiety), and can be flexibly adapted to individual mental health conditions of clients who participate in this program. The intervention is designed as a psychological group intervention for resource-limited settings and scalable for different formats (i.e. in-person, online, hybrid) to be feasible under the unstable conditions of war (e.g. missile attacks, power outrages). Key therapeutic elements are psychoeducation, emotion regulation strategies, problem solving and building coping skills. The activation of individual and culture-specific resources as well as building self-help skills are at focus of the treatment.
219273478|NCT06727799|DIAGNOSTIC_TEST|Docking Assessment / Observation|One eye of each subject will have corneal marks placed and will be docked at the study visit.
219273479|NCT07049237|BEHAVIORAL|Evidence-Based Nursing Under Quantitative Assessment Strategy (EB-NQAS)|A multifaceted nursing program using the Edmonton Symptom Assessment Scale (ESAS) for quantitative symptom assessment to guide personalized, evidence-based care plans. Interventions included tailored strategies for pain management (graded, music therapy, heat, opioids), fatigue (supervised walking, sleep optimization), nausea/vomiting prevention (prophylactic antiemetics, ginger, dietary advice), and psychological support (cognitive-behavioral therapy). Care plans were dynamically monitored and adjusted.
219273480|NCT07049237|BEHAVIORAL|Routine Nursing Care|Standard hospital oncology nursing care including health education, general psychological support (weekly 15-minute sessions), dietary guidance based on nutritional risk screening, and verbal instructions for managing common adverse effects.
219273481|NCT07049393|DIAGNOSTIC_TEST|Road traffic accident (RTA) victims(SAQ)|"Road traffic accident (RTA) victims present with respiratory and/or cardiac complications. a self-administered questionnaire.~Patients transported to healthcare facilities in District Karak using emergency transport systems.Road traffic accident (RTA) victims presenting with respiratory and/or cardiac complications."
219273482|NCT07045792|PROCEDURE|Body Awareness Therapy|Individuals trained for body awareness therapy.
219273483|NCT07050394|DRUG|CD-GA-102|CD-GA-102 will be administered intravenously at 50 μg per dose, with dosing scheduled at 2 weeks (±3 days) and 4 weeks (±3 days) after the initial dose, followed by maintenance therapy every 3 weeks (±3 days). Dosing intervals may be adjusted based on participant tolerability and safety. After receiving at least two doses of CD-GA-102 monotherapy and completing safety assessments, participants may be offered combination therapies, as determined by the investigator.
219273484|NCT05775523|DRUG|No intervention|No intervention
219273485|NCT07050953|OTHER|focused cardiac ultrasound|A focused cardiac ultrasound will be performed to measure the dimensions of ascending aorta
219273486|NCT07050914|DEVICE|McGrath Video Laryngoscope|A video laryngoscope.
219273487|NCT07050914|DEVICE|Macintosh Laryngoscope|A classic laryngoscope.
219273488|NCT07049055|DRUG|E-EDV-D682|"E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptors via single chain bispecific antibodies (BsAb).~E-EDV-D682 packages a chemotherapeutic payload PNU159682 into the EDV which targets the epidermal growth factor (EGFR) on cancer cells via a BsAb."
219273489|NCT07049055|DRUG|EDV-GC|EDV-GC is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different drugs. EDV-GC packages the immunomodulatory adjuvant aplha-galactosyl ceramide (GC) into the EDV and is designed to recruit anti-tumor immune cells.
219273490|NCT07049055|DRUG|Gemcitabine|Gemcitabine in combination with nab-paclitaxel is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
219273491|NCT07049055|DRUG|Nab paclitaxel.|Nab-paclitaxel in combination with gemcitabine is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
219273492|NCT07050147|DEVICE|Nasal high flow|3 sonographic measurements after use of 30 minutes
219273493|NCT07050147|DEVICE|NIV|3 sonographic measurements after 30 minutes use
219273494|NCT07050199|PROCEDURE|Emergency laparotomy|Emergency laparotomy
219273495|NCT07049458|DRUG|CHO-A04|CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.
219273496|NCT07048977|PROCEDURE|Needle-Knife Precut Papillotomy over Pancreatic Stent|If the papilla was treated with three unintended MPD cannulations, a needle-knife precut papillotomy with a small incision over a pancreatic stent (NKP-SIPS)
219273497|NCT07048977|PROCEDURE|Transpancreatic Sphincterotomy|TPS was performed as Goff reported; in short, after cannulation of the pancreatic duct was achieved, a pull-sphincterotome on a guidewire was used to cut the septum between the bile and pancreatic ducts along the direction from 11 o'clock to 12 o'clock. After that, the pancreatic stent is placed first, and the sphincterotomy is extended to expose the biliary lumen, and the biliary duct can be cannulated.
219273498|NCT06421155|OTHER|MRF with neurocognative studies|Magnetic Resonance Imaging is used to assess the risk of neurocognitive side effects in pediatric and AYA patients with acute leukemia receiving chemotherapy and participants will also be asked to complete a neurocognitive battery designed by Cogstate and administered on iPad in a simple gaming format
219273499|NCT06861712|RADIATION|SBRT|The experimental group will first receive SBRT (Stereotactic Body Radiotherapy) for the primary tumor and positive lymph nodes (prescribed dose: 6 Gy × 3 fractions, once every other day).
219273500|NCT06861712|DRUG|Docetaxel, Cisplatin, Toripalimab|Toripalimab 240mg (free medicine) + Docetaxel 75mg/m2 + Cisplatin 75mg/m2, q3w for 3 courses
219273501|NCT06861712|PROCEDURE|Radical resection surgery|Radical resection surgery
219273502|NCT06861712|RADIATION|IMRT ± chemotherapy/toripalimab|According to the preoperative staging and postoperative pathological characteristics, all patients will receive postoperative radiotherapy with or without cisplatin-based chemotherapy. Additionally, patients can choose whether to continue maintenance therapy with toripalimab after surgery.
219273503|NCT03835273|OTHER|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
219273504|NCT03835273|OTHER|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
219273505|NCT03835273|OTHER|Questionnaires|Three validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and LASORS questionnaire.
219273506|NCT04447131|OTHER|venipuncture in peripheral vein|single vacuum venipuncture in peripheral vein
219273507|NCT06753331|COMBINATION_PRODUCT|DSP-1083 implantation|DSP-1083 subjects will receive 2.7M viable cells per hemisphere; 5.4M total cell dose as implants.
219273508|NCT06753331|PROCEDURE|Sham surgery treatment|Sham surgery subjects will undergo a partial thickness burr hole surgical procedure on each side of the skull with no DSP-1083 administration.
219273509|NCT06715371|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE)|"Transthoracic echocardiography (TTE) is a non-invasive imaging technique performed by placing an ultrasound transducer on the chest to obtain detailed heart images. TTE is conducted preoperatively on awake patients within two weeks prior to cardiac surgery, following ASE chamber quantification guidelines.~Transesophageal echocardiography (TEE) is an invasive imaging technique where an ultrasound transducer is placed in the esophagus, providing closer and clearer images of the heart. TEE is performed intraoperatively under general anesthesia as part of routine care."
219273510|NCT06751407|PROCEDURE|Single level SPSIPB|The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.
219273511|NCT06751407|PROCEDURE|Two-level SPSIPB|In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
219273512|NCT04165746|OTHER|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
219273513|NCT04165746|BEHAVIORAL|Caregiving Intervention|During AVI an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. During that meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. AVI is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. The AVI methodology was selected to be used as a method of caregiving intervention with the study participants due to its demonstrated results in its use with children in contexts of social vulnerability, as well as families included in the child protection system. This will be the first time that AVI is being used in foster and institutional care in Brazil.
219273514|NCT02600897|DRUG|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
219273515|NCT02600897|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
219273516|NCT02600897|DRUG|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
219273517|NCT02600897|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
219273518|NCT01945814|DRUG|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
219273519|NCT01945814|DRUG|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
219273520|NCT00157846|DEVICE|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
219273521|NCT06892327|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
219273522|NCT06830733|GENETIC|ARI0002h|"* Treatment with ARI0002h cells~* Other names: CARTBCMA\_J22.9-h:CD8TM:4-1BB:CD3. Adult differentiated autologous T cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory domain and the CD3z signalling domain that has been humanized."
219273523|NCT06837103|DEVICE|Intermittently Scanned Continuous Glucose Monitor|intervention used by the isCGM and isCGM+Coaching groups
219273524|NCT05203471|OTHER|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
219273525|NCT06804213|BEHAVIORAL|Mobile health app with positive psychological activities|Mobile health app with step tracking, sleep tracking, and positive psychological activities
219273526|NCT03377517|RADIATION|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
219273527|NCT06823765|OTHER|Large Language Model Clinical Decision Support|A Large Language Model (LLM) integrated into the clinic's Electronic Medical Record system provides real-time feedback on patient assessments. Community Health Extension Workers first create a standard SOAP note, submit it to the LLM, and receive detailed feedback and key recommendations. They can then update their assessment based on this feedback. All final treatment decisions are made by Medical Officers who independently evaluate patients.
219273528|NCT06898476|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
219273529|NCT06898476|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
219273530|NCT06840769|DRUG|Fosnetupitant 235 mg solution|Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration
219273531|NCT06840769|DRUG|Akynzeo solution|235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution
219273532|NCT05780177|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|Participants in this arm will receive 4 sessions (30-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
219273533|NCT05780177|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|Participants in this arm will receive 4 sessions (30-60 minutes) of progressive muscle relaxation training called PMRT.
219273534|NCT04550676|BEHAVIORAL|HIIT (intervention)|Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
219273535|NCT04550676|BEHAVIORAL|CME (active control)|Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
219273536|NCT06816264|DRUG|HRS-5346|HRS-5346
219273537|NCT06816264|DRUG|Placebo|Placebo
219273538|NCT04802161|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219273539|NCT04802161|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
219273540|NCT04802161|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219273541|NCT04802161|DRUG|Pomalidomide|Given PO
219273542|NCT06753110|DEVICE|OPRA transhumeral|Skeletal anchorage of amputation prostheses.
219273543|NCT06910059|OTHER|Observational|It is a observational study and patients with pacing indications who plan to receive Micra AV implantation will be recruited. No intervention procedure will be performed.
219273544|NCT06913140|DRUG|Erector Spinae plane Block|Patients received (20ml) plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath at the level of the second thoracic segment (T2)
219273545|NCT06913140|DRUG|Costoclavicular block|Patients received (20ml) plain bupivacaine 0.25% injected in the costoclavicular space lateral to axillary artery.
219273546|NCT06913140|DRUG|Control group|Patients received sham block
219273547|NCT06918158|OTHER|Mobilization with Movement|"Mobilization with Movement~* The proximal row of carpals glides passively radially.~* Active thumb and wrist movements superimposed on the glide.~Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction"
219273548|NCT06918158|OTHER|Joint Specific Manipulation|"Joint Specific Manipulation~* High-velocity, low-amplitude thrust to the first carpometacarpal joint~* Radiocarpal wrist mobilization .Grade III-IV applied at end range. 2. Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction Ergonomics modifications"
219273549|NCT06844903|OTHER|Pulsed ultrasound at acupuncture points|The experimental group will receive pulsed ultrasound at bilateral acupuncture points of St29, Sp6 and unilateral acupuncture points on Ren4 and Ren5 in addition to standard care program for 12 weeks.
219273550|NCT06844903|OTHER|Placebo ultrasound at acupuncture points|The placebo group will receive the same but in Placebo manner for 12 weeks.
219273551|NCT06844903|OTHER|Standard care program|All participants in both groups will be given an info brochure, that included advice on a healthy diet as a low-carbohydrate and high-protein diet, high dietary fiber, and less saturated fat in addition to engagement in aerobic exercise, fast walking for at least 30 - 45 min, 3 days a week for 12 weeks.
219273552|NCT06848335|BEHAVIORAL|Remote Physical Activity Intervention|The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6, with maintenance doses in months 8 and 10. Mailings include motivation-matched physical activity manuals, tip sheets (on stretching, boredom, places to be active, etc.) and computer expert system-tailored PA feedback reports which draw from a bank of over 330 messages addressing psychosocial and environmental factors affecting PA. Participants receive one interactive text message on PA (goal setting and tips for increasing PA) daily for the first 6 months and weekly for months 7-12.
219273553|NCT06848335|BEHAVIORAL|Mindfulness Enhanced Remote Physical Activity Intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Attention Matched Enhanced Remote PA intervention or Mindfulness enhanced remote Physical Activity intervention. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals. For the Mindfulness enhanced remote Physical Activity intervention participants will receive additional messaging and support to manage their stress through incorporating evidence based MBSR and mindful movement into their daily routine.
219273554|NCT06848335|BEHAVIORAL|Attention Matched Enhanced Remote PA intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Mindfulness enhanced remote Physical Activity intervention or the Attention Matched Enhanced Remote PA intervention as described here. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals.
219273555|NCT06944587|DRUG|Chemotherapy|The choice of chemotherapy regimen follows national guidelines, preferably mFOLFIRINOX or gemcitabine-nab-paclitaxel.
219273556|NCT06944587|DIAGNOSTIC_TEST|Radiology|PET/CT is optional. PET/CT will be offered as a part of the diagnostic work up at baseline and one additional scan after a minimum of two months of chemotherapy.
219273557|NCT06944587|PROCEDURE|Pancreatectomy|Surgery is scheduled within 4 weeks after the last neoadjuvant infusion. Resection will be performed as a standard or pylorus-preserving pancreatoduodenectomy (PD), distal pancreatectomy (DP) with splenectomy, or total pancreatectomy (TP) with splenectomy, and with or without venous or arterial resection and reconstruction.
219273558|NCT06944587|PROCEDURE|Endoscopy|Endoscopic ultrasound fine-needle biopsy to establish the diagnosis with histopathology and to obtain an adequate sample for molecular pathology (KRAS status (mutation or wild type), microsatellite instability (MSI)).
219273559|NCT04330690|DRUG|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
219273560|NCT04330690|DRUG|Imatinib|400 mg enterally daily for 14 days plus standard of care
219273561|NCT04330690|DRUG|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
219273562|NCT04330690|DRUG|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
219273563|NCT04330690|DRUG|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
219273564|NCT04946578|DIETARY_SUPPLEMENT|Prebiotic|6 weeks of prebiotic supplementation twice a day
219273565|NCT04946578|OTHER|Placebo|6 weeks of maltodextrin supplementation twice a day
219273566|NCT02288169|BEHAVIORAL|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
219273567|NCT02288169|BEHAVIORAL|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
219273568|NCT03427697|DEVICE|Virtual reality and accommodation relax techniques in combination|The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
219273569|NCT02356627|OTHER|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
219273570|NCT03192462|BIOLOGICAL|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
219273571|NCT00294411|PROCEDURE|elective cesarean section|
219273572|NCT00279253|DRUG|clonidine (drug) intravenously|
219273573|NCT01030393|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
219273574|NCT05925257|OTHER|ePRO application and proactive clinical care with nurses.|The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
219273575|NCT04358432|DRUG|AK102|Administered by subcutaneous injection
219273576|NCT04358432|DRUG|Placebos|Administered by subcutaneous injection
219273577|NCT04358432|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
219273578|NCT03587337|OTHER|POEM|Pt. are going to submit a POEM procedure.
219273579|NCT02344589|DRUG|Lidocaine|used for the active blocks
219273580|NCT02344589|DRUG|Saline|used for the placebo-block
219273581|NCT00502268|DRUG|Doxercalciferol administration|Doxercalciferol administration
219273582|NCT00502268|DRUG|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
219273583|NCT02419417|DRUG|BMS-986158|Specified dose on specified days
219273584|NCT02419417|BIOLOGICAL|Nivolumab|Specified dose on specified days
219273585|NCT04879212|OTHER|PCIA +Acupuncture group:|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6)
219273586|NCT05995509|PROCEDURE|Micro-osteo-perforations|small perforations drilled in Alveolar bone, adjacent to site of tooth movement.
219273587|NCT02567851|DRUG|Brentuximab Vedotin|Monoclonal antibody drug conjugate
219273588|NCT03313492|BEHAVIORAL|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~1. A mobile version of the site~2. Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~3. Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
219273589|NCT03313492|BEHAVIORAL|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
219273590|NCT03313492|BEHAVIORAL|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
219273591|NCT03640572|DIAGNOSTIC_TEST|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
219273592|NCT04376151|OTHER|Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'|The intervention has been described in the arm/group descriptions.
219273593|NCT00078377|DRUG|Armodafinil|Armodafinil 250 mg once daily in the morning
219273594|NCT00078377|DRUG|Armodafinil|Armodafinil 150 mg once daily in the morning
219273595|NCT00078377|DRUG|Placebo|Matching placebo tablets once daily
219273596|NCT01820520|DRUG|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
219273597|NCT03231124|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
219273598|NCT03231124|DRUG|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
219273599|NCT04697134|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
219273600|NCT03437889|OTHER|Cold Stimulus (Ice)|The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
219273601|NCT02960503|DRUG|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
219273602|NCT02960503|OTHER|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
219273603|NCT00953147|DRUG|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
219273604|NCT00953147|DRUG|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
219273605|NCT00953147|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
219273606|NCT06216652|OTHER|downhill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
219273607|NCT06216652|OTHER|uphill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
219273608|NCT06216652|OTHER|walking with no incline|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
219273609|NCT01913145|DEVICE|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
219273610|NCT00498472|PROCEDURE|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is \>3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
219273611|NCT00004139|DRUG|docetaxel|
219273612|NCT00004139|DRUG|gemcitabine hydrochloride|
219273613|NCT00004139|DRUG|irinotecan hydrochloride|
219273614|NCT00790400|DRUG|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
219273615|NCT00790400|DRUG|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
219273616|NCT00000877|DRUG|Indinavir sulfate|
219273617|NCT00000877|DRUG|Rifabutin|
219273618|NCT00078338|DRUG|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
219273619|NCT00078338|DRUG|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
219273620|NCT02614378|PROCEDURE|air insufflation|modulated air insufflation of the ear canal
219273621|NCT02614378|PROCEDURE|placebo|no air will be introduced in the ear canal
219273622|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Wonderlab Product|Chew two tablets of Wonderlab Product for phase 1 (day 1)
219273623|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Placebo|Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
219273624|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Placebo|Chew two tablets of placebo for phase 1 (day 1)
219273625|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Wonderlab Product|Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
219273626|NCT00218231|DRUG|300 mg/day bupropion-sr|300 mg/day for 1 week
219273627|NCT00218231|DRUG|0 mg/day bupropion-sr|0 mg/day bupropion-sr
219273628|NCT00005977|BIOLOGICAL|filgrastim|Given IV
219273629|NCT00005977|DRUG|cyclophosphamide|Given IV
219273630|NCT00005977|DRUG|cytarabine|Given IV
219273631|NCT00005977|DRUG|dexamethasone|Given IV
219273632|NCT00005977|DRUG|doxorubicin hydrochloride|Given IV
219273633|NCT00005977|DRUG|etoposide|Given IV
219273634|NCT00005977|DRUG|ifosfamide|Given IV
219273635|NCT00005977|DRUG|leucovorin calcium|Given IV
219273636|NCT00005977|DRUG|methotrexate|Given IV
219273637|NCT00005977|DRUG|vincristine sulfate|Given IV
219273638|NCT05026021|BIOLOGICAL|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion), M6 visit (6 months after inclusion) and M12 visit (12 months after inclusion).
219273639|NCT03176264|DRUG|PDR001|400 mg every 4 weeks
219273640|NCT03176264|DRUG|bevacizumab|5 mg/kg every 2 weeks
219273641|NCT03176264|DRUG|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
219273642|NCT06055504|OTHER|Control Strategy|ICDs will be implanted in all patients according to current recommendations
219273643|NCT06055504|OTHER|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
219273644|NCT00010153|DRUG|fulvestrant|
219273645|NCT00010153|PROCEDURE|conventional surgery|
219273646|NCT04184453|DRUG|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
219273647|NCT04219995|DRUG|methylprednisolone sodium succinate|Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
219273648|NCT04219995|OTHER|Placebo|The placebo used in this study will be simple syrup.
219273649|NCT04149938|DRUG|Lidocaine topical system 1.8%|
219273650|NCT04149938|DRUG|Lidocaine patch 5%|
219273651|NCT05378334|DRUG|ICI|PD-1 inhibitors selected by clinicians based on patients' condition
219273652|NCT05378334|DRUG|Chemotherapy|AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
219273653|NCT05378334|DRUG|Placebo|The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
219273654|NCT05378334|DRUG|Bone-protecting and Mass-dispersesing Decoction|Chinese Herbal Formula,also named as HGXJT
219273655|NCT03258723|BEHAVIORAL|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
219273656|NCT03258723|DRUG|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
219273657|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
219273658|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
219273659|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
219273660|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
219273661|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
219273662|NCT04211311|OTHER|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
219273663|NCT02622399|BEHAVIORAL|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
219273664|NCT02693197|DRUG|T-817MA|A single oral dose of 448 mg
219273665|NCT05214547|DEVICE|Focal VibrationTherapy|Myovolt delivers oscillatory mechanical vibration of focussed frequency and low amplitude to stimulate physiological benefits in soft tissues. Myovolt is non-aggressive and gentle to the body so can be safely targeted. Digitally tuned to transmit a discrete vibration frequency range between 30 - 100Hz for effective neuromuscular stimulation.
219273666|NCT06177951|OTHER|NICU Discharge Passport|"The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns."
219273667|NCT06177951|OTHER|NICU Infant Care Class|The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
219273668|NCT04765878|DEVICE|RespirAq Humidification|Humidifier
219273669|NCT01614353|OTHER|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
219273670|NCT01614353|OTHER|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
219273671|NCT05454345|DRUG|Sitafloxacin|In our Intervention group, sitafloxacin replace the ethambutol, 200mg/d
219273672|NCT05454345|DRUG|SMZ/TMP|In our The three-month Rifapentine\&Isoniazid\&Pyrazinamide\&Sitafloxacin\&SMZ/TMP-containing regimen, Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin, SMZ 80mg/kg/d, TMP16mg/kg/d
219273673|NCT05454345|DRUG|Rifampin|Rifampin is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, Rifampin 600mg (8-12mg/kg/d)
219273674|NCT05454345|DRUG|Pyrazinamide|Pyrazinamide is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 2000mg (20-30mg/kg/d)
219273675|NCT05454345|DRUG|Rifapentine|In our Intervention group, rifapentine replace rifampin, 600mg/d
219273676|NCT05454345|DRUG|Isoniazid|Isoniazid is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 300mg (4-6mg/kg/d)
219273677|NCT05454345|DRUG|Ethambutol|Ethambutol is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 1200mg (15-25mg/kg/d)
219273678|NCT05454345|DRUG|Moxifloxacin|Moxifloxacin is a fourth-generation fluoroquinolone with potent activity against M. tuberculosis in vitro and in vivo, 400mg (7.5-10mg/kg/d)
219273679|NCT02979106|OTHER|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
219273680|NCT00157768|DEVICE|Implantable cardioverter defibrillator|
219273681|NCT01037426|OTHER|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information"
219273682|NCT06958848|DEVICE|16 F chest tube|Insertion of 16F chest tube
219273683|NCT06958848|DEVICE|24 F chest tube|Insertion of 24F chest tube
219273684|NCT06958848|PROCEDURE|Early removal|Removal 2-6h after end of skin closure
219273685|NCT06958848|PROCEDURE|Standard removal|Removal 1day postoperative
219273686|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
219273687|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
219273688|NCT06145750|DIAGNOSTIC_TEST|Ability to order FirstLook™|FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
219273689|NCT06145750|OTHER|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
219273690|NCT05992896|DRUG|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
219273691|NCT05992896|DRUG|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
219273692|NCT04488250|OTHER|Robot Therapy|Robot Therapy
219273693|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
219273694|NCT05323630|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
219273695|NCT00943345|DRUG|indometacin|"* capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
219273696|NCT05989828|BIOLOGICAL|Aldesleukin|Given IV
219273697|NCT05989828|BIOLOGICAL|Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|Given IV
219273698|NCT05989828|PROCEDURE|Biopsy|Undergo biopsy of breast tumor
219273699|NCT05989828|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219273700|NCT05989828|PROCEDURE|Computed Tomography|Undergo CT scan
219273701|NCT05989828|DRUG|Cyclophosphamide|Given IV
219273702|NCT05989828|PROCEDURE|Echocardiography|Undergo ECHO
219273703|NCT05989828|DRUG|Fludarabine|Given IV
219273704|NCT05989828|PROCEDURE|Leukapheresis|Undergo leukapheresis
219273705|NCT05989828|PROCEDURE|Magnetic Resonance Imaging|Undergo breast MRI
219273706|NCT05989828|PROCEDURE|Mammogram|Undergo mammogram
219273707|NCT05989828|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219273708|NCT05989828|PROCEDURE|Ultrasound Imaging|Undergo ultrasound of breast
219273709|NCT00580489|DRUG|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
219273710|NCT05022537|DEVICE|retrograde nephrostomy|this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
219273711|NCT05022537|DEVICE|antegrade nephrostomy|this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
219273712|NCT04632043|OTHER|Endotracheal intubation|Endotracheal intubation
219273713|NCT02820064|PROCEDURE|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
219273714|NCT01710059|BEHAVIORAL|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
219273715|NCT01710059|BEHAVIORAL|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
219273716|NCT01710059|BEHAVIORAL|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
219273717|NCT01710059|BEHAVIORAL|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
219273718|NCT03922022|BEHAVIORAL|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
219273719|NCT01606319|DRUG|Acetaminophen|15 mg/kg every 6 hours as needed
219273720|NCT01606319|DRUG|Ibuprofen|9.4 mg/kg every 6 hours as needed
219273721|NCT00162617|DRUG|Red blood cell transfusion|
219273722|NCT04584892|DRUG|Turoctocog alfa|Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
219273723|NCT05603364|COMBINATION_PRODUCT|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
219273724|NCT05603364|OTHER|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
219273725|NCT04073342|GENETIC|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
219273726|NCT04232904|PROCEDURE|Transversus abdominous plane block (TAP Block)|TAP block which is a peripheral nerve block preferred to postoperative pain management.
219273727|NCT06092320|OTHER|Simulation on Pediatric Status Epilepticus|The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.
219273728|NCT06092320|OTHER|Didactic Lecture on Pediatric Status Epilepticus|The participants will complete a lecture on pediatric status epilepticus
219273729|NCT00463671|DRUG|N-acetylcysteine|
219273730|NCT00966563|DRUG|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
219273731|NCT00966563|DRUG|Placebo|
219273732|NCT03508947|DRUG|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
219273733|NCT03508947|DRUG|Placebo|Sodium Chloride
219273734|NCT06370845|COMBINATION_PRODUCT|Inhalation - Natural Odour|Inhalation of 50 uL of a natural odour via nasal septum mini-inhaler.
219273735|NCT06370845|COMBINATION_PRODUCT|Inhalation - Placebo|Inhalation of 50 uL of Placebo via nasal septum mini-inhaler.
219273736|NCT02878694|BIOLOGICAL|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
219273737|NCT05661435|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
219273738|NCT00390520|DRUG|Vildagliptin|
219273739|NCT05655923|BIOLOGICAL|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
219273740|NCT05655923|BIOLOGICAL|xenograft bone substitute|Xenograft bone substitutes in all Groups
219273741|NCT03907267|DRUG|Taurine Solution|Taurine Solution
219273742|NCT03907267|DIETARY_SUPPLEMENT|Normal Saline|Normal Saline
219273743|NCT00398281|DRUG|dutasteride|Given orally
219273744|NCT00398281|OTHER|placebo|Given orally
219273745|NCT04603742|DRUG|Anakinra|100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
219273746|NCT04603742|DRUG|0.9% Saline|The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
219273747|NCT01517204|DEVICE|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
219273748|NCT01517204|DEVICE|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
219273749|NCT00880022|DEVICE|Flexitouch System|( 10 to 30 treatments depending on group assignment)
219273750|NCT04476940|BEHAVIORAL|COVID-19 Breastfeeding Support|Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
219273751|NCT01634269|DEVICE|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
219273752|NCT06433895|OTHER|Manual Therapy|Manual Therapy
219273753|NCT06433895|OTHER|Exercise|Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
219273754|NCT03069144|DRUG|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219273755|NCT03069144|DRUG|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
219273756|NCT03709108|OTHER|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
219273757|NCT02634424|DEVICE|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
219273758|NCT01594827|DRUG|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
219273759|NCT01594827|DRUG|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
219273760|NCT01594827|DRUG|Rifampin|"Oral Rifampin by mouth for 28 days~1. \>45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily"
219273761|NCT01594827|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. \>45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)"
219273762|NCT01594827|DRUG|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
219273763|NCT01594827|DRUG|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
219273764|NCT01594827|DRUG|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
219273765|NCT02291822|DRUG|Gadobenate Dimeglumine|gadolinium contrast agent
219273766|NCT04480606|BEHAVIORAL|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
219273767|NCT06359496|OTHER|No intervention factor|No intervention factor
219273768|NCT00865852|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
219273769|NCT00865852|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
219273770|NCT02987647|OTHER|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
219273771|NCT02987647|OTHER|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
219273772|NCT02987647|OTHER|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
219273773|NCT02987647|OTHER|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
219273774|NCT03038204|PROCEDURE|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
219273775|NCT01795599|DRUG|Mifegyne ®|
219273776|NCT01795599|DRUG|Gymiso®|
219273777|NCT04510298|DRUG|SP-624|Oral Capsule
219273778|NCT04510298|DRUG|Placebo|Oral Capsule
219273779|NCT00824330|BEHAVIORAL|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
219273780|NCT02153905|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
219273781|NCT02153905|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
219273782|NCT02153905|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
219273783|NCT02153905|BIOLOGICAL|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
219273784|NCT00577135|DRUG|Furosemide-Q12 hour bolus|Q12 hours bolus
219273785|NCT00577135|DRUG|Furosemide-Continuous Infusion|Continuous infusion
219273786|NCT00577135|DRUG|Furosemide-Low Intensification|1x oral dose
219273787|NCT00577135|DRUG|Furosemide-High Intensification|2.5x oral dose
219273788|NCT03904940|DEVICE|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
219273789|NCT03904940|DEVICE|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
219273790|NCT06463236|OTHER|Guiding treatment|Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
219273791|NCT06463236|OTHER|empirical therapy|Experiential treatment by grassroots doctors
219273792|NCT02909465|DRUG|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
219273793|NCT02909465|DRUG|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
219273794|NCT02909465|DRUG|placebo|distilled water
219273795|NCT02909465|DRUG|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
219273796|NCT00046306|DRUG|Antioxidants|
219273797|NCT01621243|DRUG|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
219273798|NCT01621243|DRUG|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
219273799|NCT01621243|DRUG|placebo|Placebo will be dosed daily
219273800|NCT01621243|DRUG|Necuparanib|Necuparanib will be dosed daily
219273801|NCT04392492|DEVICE|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
219273802|NCT05847049|OTHER|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
219273803|NCT01607879|DRUG|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
219273804|NCT01607879|OTHER|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
219273805|NCT02607787|BEHAVIORAL|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
219273806|NCT02607787|OTHER|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
219273807|NCT02964702|DEVICE|Thrombectomy Device T-01|
219273808|NCT04089397|DEVICE|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
219273809|NCT02106962|DRUG|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
219273810|NCT02106962|OTHER|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
219273811|NCT04324905|DRUG|HIP1802|Test drug
219273812|NCT04324905|DRUG|HGP1705|Reference drug
219273813|NCT04211259|DRUG|Loratadine|Given PO
219273814|NCT04211259|OTHER|Placebo|Given PO
219273815|NCT04211259|OTHER|Questionnaire Administration|Ancillary studies
219273816|NCT04550819|PROCEDURE|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
219273817|NCT04550819|PROCEDURE|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
219273818|NCT01418404|OTHER|Noxious TS|hot, cold alternately, noxious TS in study A
219273819|NCT01418404|OTHER|Innocuous TS|warm, cool alternately, Innocuious TS in study A
219273820|NCT01418404|OTHER|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
219273821|NCT01418404|OTHER|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
219273822|NCT01418404|OTHER|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
219273823|NCT01418404|OTHER|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
219273824|NCT05292053|DRUG|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
219273825|NCT04788745|DRUG|Trimetazidine Dihydrochloride|Oral tablet, twice-daily
219273826|NCT01592045|BIOLOGICAL|ch14.18 -NCI|25 mg/m\^2/day IV for four consecutive days
219273827|NCT01592045|BIOLOGICAL|ch14.18-UTC|17.5 mg/m\^2/day IV for four consecutive days
219273828|NCT01592045|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.
219273829|NCT01592045|BIOLOGICAL|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.
219273830|NCT01592045|DRUG|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
219273831|NCT05807906|OTHER|virtual reality application|The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
219273832|NCT03994731|BIOLOGICAL|Pegloticase|IV pegloticase 8 mg Q2W
219273833|NCT03994731|DRUG|methotrexate|Oral MTX 15 mg weekly
219273834|NCT03994731|DRUG|placebo|Oral placebo for MTX
219273835|NCT03994731|DIETARY_SUPPLEMENT|folic acid|Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
219273836|NCT03994731|DRUG|gout flare prophylaxis regimen|Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
219273837|NCT03994731|DRUG|fexofenadine|For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
219273838|NCT03994731|DRUG|acetaminophen|For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
219273839|NCT03994731|DRUG|methylprednisolone|For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
219273840|NCT02395419|DEVICE|Orotracheal intubation with Totaltrack|
219273841|NCT02395419|DEVICE|Orotracheal intubation with Airtraq|
219273842|NCT00500968|PROCEDURE|stent|ERCP guided stent insertion before transection of the gland
219273843|NCT00500968|PROCEDURE|Distal pancreatectomy|conventional distal pancreatectomy
219273844|NCT06042972|OTHER|Questionnaire including Edinburgh postnatal depression scale, Patient Health Questionnaire 2 and background variables|"Patients meeting the inclusion criteria will be recruited by health professionals who have agreed to participate in the study.~Patients must fill out an anonymous self-questionnaire which will consist of 2 tests aimed to help diagnose postpartum depression, recommended in France by the Haute Autorité de Santé (HAS), and background variables.~The self-questionnaire will be given back by the patient in a sealed envelope. Each questionnaire will only be filled out once per patient."
219273845|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
219273846|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
219273847|NCT00915824|OTHER|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
219273848|NCT00027391|DRUG|Albuterol|
219273849|NCT00027391|DRUG|Oxandrolone|
219273850|NCT00793247|DRUG|PRU-PLA-PRU-PLA|
219273851|NCT00793247|DRUG|PLA-PRU-PLA-PRU|
219273852|NCT00793247|DRUG|PLA-PRU-PRU-PLA|
219273853|NCT00793247|DRUG|PRU-PLA-PLA-PRU|
219273854|NCT02968238|BEHAVIORAL|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
219273855|NCT02968238|BEHAVIORAL|Yoga|10 weeks of biweekly yoga sessions (N = 20)
219273856|NCT02516865|DEVICE|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
219273857|NCT02516865|DEVICE|Ankle weights|Worn during typical daily activities.
219273858|NCT02838979|DIETARY_SUPPLEMENT|First Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
219273859|NCT02838979|OTHER|Washout (3 weeks)|No study product is taken prior to beginning crossover
219273860|NCT02838979|DIETARY_SUPPLEMENT|Second Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
219273861|NCT01415934|OTHER|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
219273862|NCT03585088|DEVICE|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score \<=60.
219273863|NCT03142269|PROCEDURE|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
219273864|NCT04709458|BIOLOGICAL|TBX-2400|Hematopoietic stem cells transplantation
219273865|NCT02579590|DRUG|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
219273866|NCT02579590|DRUG|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
219273867|NCT02579590|DRUG|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
219273868|NCT03488680|BEHAVIORAL|Behavior change communication|Behavior change communication about optimal complementary feeding
219273869|NCT03414021|DIAGNOSTIC_TEST|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
219273870|NCT00959686|DRUG|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
219273871|NCT02594787|DIETARY_SUPPLEMENT|Phosphorus|
219273872|NCT02594787|DIETARY_SUPPLEMENT|Placebo|
219273873|NCT06179147|OTHER|cervical traction|Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
219273874|NCT00354757|DRUG|rabeprazole|
219273875|NCT04627610|OTHER|Rectal prolapse, rectocele and elytrocele|Recurrence of dyschesia on rectal prolapse, rectocele and elytrocele
219273876|NCT01721733|DRUG|Placebo|
219273877|NCT01721733|DRUG|EPI-743 15 mg/kg|
219273878|NCT01721733|DRUG|EPI-743 5 mg/kg|
219273879|NCT04977570|DRUG|SYHA1805 tablets|Oral tablets of SYHA1805 with three pre-designed doses
219273880|NCT04977570|DRUG|Placebo|Oral tablets of placebo with matching doses
219273881|NCT02963948|BEHAVIORAL|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
219273882|NCT02963948|BEHAVIORAL|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
219273883|NCT02963948|BEHAVIORAL|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
219273884|NCT03516305|DRUG|Staccato Alprazolam 1 mg|alprazolam I mg administered via the Staccato hand-held inhaler device system.
219273885|NCT03444402|DRUG|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
219273886|NCT03444402|DRUG|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
219273887|NCT03444402|DRUG|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
219273888|NCT03498703|DRUG|Azathioprine Pill|Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
219273889|NCT03498703|DRUG|Placebo Oral Tablet|Placebo tablets
219273890|NCT04699942|DEVICE|Conventional (low flow) oxygen delivery via nasal cannula|Conventional (low flow) oxygen delivery via nasal cannula or face mask for 20 minutes
219273891|NCT04699942|DEVICE|Revoxa Oxygen Rebrearther|Oxygen delivery via Revoxa Oxygen Rebreather device for 20 minutes
219273892|NCT01351168|DRUG|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
219273893|NCT01351168|DRUG|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
219273894|NCT01351168|DRUG|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
219273895|NCT01351168|DRUG|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
219273896|NCT01528319|DEVICE|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
219273897|NCT02614612|DRUG|Itacitinib (200 mg)|
219273898|NCT02614612|DRUG|Itacitinib (300 mg)|
219273899|NCT02614612|DRUG|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
219273900|NCT03812029|DRUG|Vonafexor|Oral tablets
219273901|NCT03812029|OTHER|Placebo|Oral tablets
219273902|NCT03149042|DIAGNOSTIC_TEST|CCTA|Diagnostic Test
219273903|NCT02600390|BIOLOGICAL|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
219273904|NCT05451667|DRUG|YJ001 for Spray Use|YJ001 (active ingredient)
219273905|NCT05451667|DRUG|Placebo of YJ001 for Spray Use|Hydroxypropyl Methylcellulose
219273906|NCT05724927|BEHAVIORAL|Animal assisted activity|The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
219273907|NCT04267068|BEHAVIORAL|Growth Mindset and Modifiable Risk Factor Information|15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
219273908|NCT04267068|BEHAVIORAL|Control|30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
219273909|NCT02917772|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
219273910|NCT00790205|DRUG|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
219273911|NCT00790205|DRUG|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
219273912|NCT05906797|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
219273913|NCT02643628|PROCEDURE|Microneedling|
219273914|NCT02643628|DEVICE|Microneedling followed by Bellafill treatment|
219273915|NCT02016209|DRUG|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
219273916|NCT03321279|BEHAVIORAL|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
219273917|NCT01206699|DRUG|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
219273918|NCT01206699|DRUG|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
219273919|NCT04937920|BIOLOGICAL|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
219273920|NCT04937920|BIOLOGICAL|Aqueous gel|Topical application on skin affected with tinea versicolor
219273921|NCT00226122|DRUG|Indomethacin|Indomethacin capsules 50 mg
219273922|NCT01356771|OTHER|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma"
219273923|NCT02394652|DRUG|Metformin|Metformin is an antidiabetic agent given orally.
219273924|NCT02394652|DRUG|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
219273925|NCT02394652|DRUG|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
219273926|NCT05505370|DEVICE|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
219273927|NCT06771830|DEVICE|Pediatric eCART|Integration of the pediatric version of electronic Cardiac Arrest Risk Triage as a clinical decision support tool within Epic for use by clinicians
219273928|NCT05580497|DEVICE|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
219273929|NCT00259571|DRUG|retarded release phosphatidylcholine|2g daily, given orally QTD
219273930|NCT03632083|DEVICE|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
219273931|NCT03632083|DEVICE|Lite Contact Lens Solution|Lite Contact Lens Solution
219273932|NCT03632083|DEVICE|fanfilcon A soft contact lens|fanfilcon A soft contact lens
219273933|NCT03632083|DEVICE|comfilcon A soft contact lens|comfilcon A soft contact lens
219273934|NCT03450499|DRUG|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
219273935|NCT03450499|DRUG|Placebo|the analgesic requirement will be calculated in placebo group.
219273936|NCT04012086|OTHER|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
219273937|NCT03569592|BEHAVIORAL|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
219273938|NCT00265720|OTHER|Control|Written materials only
219273939|NCT00265720|OTHER|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
219273940|NCT00265720|BEHAVIORAL|one on one education|one on one education with a health educator
219273941|NCT00265720|BEHAVIORAL|Group education|Education in a small group
219273942|NCT01531101|BEHAVIORAL|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
219273943|NCT01617122|BIOLOGICAL|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
219273944|NCT00967083|BEHAVIORAL|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
219273945|NCT03338647|DRUG|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
219273946|NCT03338647|RADIATION|SBRT|High precision radiation therapy to the liver tumor(s)
219273947|NCT02686099|DEVICE|SternaLock 360|Sternal closure with SternaLock 360
219273948|NCT02686099|DEVICE|Wire Cerclage|Sternal closure with standard wire cerclage
219273949|NCT04777110|DRUG|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
219273950|NCT04777110|OTHER|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
219273951|NCT02432833|DRUG|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
219273952|NCT02432833|DRUG|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
219273953|NCT02432833|DRUG|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
219273954|NCT05006326|DRUG|68Ga-PSMA|Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
219273955|NCT05006326|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
219273956|NCT05006326|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
219273957|NCT04092452|DRUG|PF-06650833|400 mg QD
219273958|NCT04092452|DRUG|PF-06700841|45 mg QD
219273959|NCT04092452|DRUG|PF-06826647|400 mg QD
219273960|NCT04092452|DRUG|Placebo|placebo
219273961|NCT03463499|DRUG|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
219273962|NCT04368845|DEVICE|Telerehabilitation|The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
219273963|NCT02127125|DRUG|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
219273964|NCT02127125|DRUG|Synbiotic|Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
219273965|NCT02127125|DRUG|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
219273966|NCT03645148|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
219273967|NCT03645148|OTHER|GM-CSF|immune adjuvant
219273968|NCT00003626|DRUG|dolastatin 10|
219273969|NCT01356563|BEHAVIORAL|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
219273970|NCT00855413|DRUG|Darunavir|800 mg orally once daily
219273971|NCT00855413|DRUG|Ritonavir|100 mg orally once daily
219273972|NCT00855413|DRUG|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
219273973|NCT02493842|DEVICE|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
219273974|NCT02736279|DRUG|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
219273975|NCT03869177|OTHER|Implementation support program|"The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures"
219273976|NCT02184299|DRUG|Nevirapine|
219273977|NCT02184299|DRUG|Prednisone|
219273978|NCT02296216|DEVICE|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
219273979|NCT02353468|DRUG|Bortezomib|Given IV
219273980|NCT02353468|DRUG|Lenalidomide|Given PO
219273981|NCT02353468|DRUG|Dexamethasone|Given PO or IV
219273982|NCT00729638|DRUG|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
219273983|NCT00729638|DRUG|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
219273984|NCT02793310|PROCEDURE|DMEK|The intervention group will receive cornea transplantation by DMEK
219273985|NCT02793310|PROCEDURE|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
219273986|NCT02344342|DEVICE|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
219273987|NCT02344342|OTHER|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
219273988|NCT00825539|DRUG|AQW051|
219273989|NCT00825539|DRUG|Placebo|
219273990|NCT05105048|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline
219273991|NCT05105048|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219273992|NCT02526498|RADIATION|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
219273993|NCT02526498|RADIATION|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
219273994|NCT02526498|OTHER|Questionnaire Administration|Ancillary studies
219296296|NCT06478511|PROCEDURE|Immediate implant combined with subepithelial connective tissue graft|Connective tissue graft was harvested from palate using trap door technique utilizing a horizontal incision 3-4 mm away from the gingival margin with two vertical incisions on the either end of the first incision, the door is then undermined and opened using a sharp dissection, the underlying connective tissue is then harvested using a periosteal elevator, and the door was then sutured using 4 0 silk sutures Finally, the connective tissue graft was immediately placed into the recipient site after a tunneling procedure and sutured with 6-0 nonresorbable monofilament sutures.
219273995|NCT04857567|BEHAVIORAL|TSC program (Three Self-Commitment program)|"1. Self-Competence program~   \- A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   \- A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
219273996|NCT04192110|DRUG|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
219273997|NCT04375553|OTHER|Aerobic exercise|Intradialytic aerobic exercise
219273998|NCT00848484|DRUG|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
219273999|NCT00848484|DRUG|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
219274000|NCT00002145|DRUG|Foscarnet sodium|
219274001|NCT01907698|BEHAVIORAL|Vaginal intercourse|vaginal intercourse at least twice a week
219274002|NCT05808296|OTHER|Lavander oil Aromatherapy|Lavander oil Aromatherapy
219274003|NCT05808296|OTHER|Saline Solution|Saline solution application
219274004|NCT03151746|DRUG|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
219274005|NCT03151746|DRUG|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
219274006|NCT00785954|DRUG|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
219274007|NCT01234415|DEVICE|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
219274008|NCT01059305|DRUG|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
219274009|NCT00290901|DRUG|Tramadol Hydrochloride 50mg|
219274010|NCT00290901|DRUG|Celebrex 200mg|
219274011|NCT03355209|DRUG|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
219274012|NCT03355209|DRUG|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
219274013|NCT03109236|DRUG|GCSF|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
219274014|NCT03109236|PROCEDURE|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10\^6 and up to 50-100 x 10\^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
219274015|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
219274016|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
219274017|NCT02595099|OTHER|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
219274018|NCT00153985|DRUG|Busulfex|Given once daily for 4 days
219274019|NCT00153985|DRUG|Fludarabine|Given intravenously once daily for 4 days
219274020|NCT00153985|DRUG|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
219274021|NCT00153985|PROCEDURE|Stem Cell Transfusion|Performed three days after the end of chemotherapy
219274022|NCT00535379|DRUG|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
219274023|NCT02102412|BIOLOGICAL|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
219274024|NCT01225497|PROCEDURE|Standard eccentric exercise|"Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain."
219274025|NCT01225497|PROCEDURE|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
219274026|NCT02097303|DRUG|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
219274027|NCT05051969|BEHAVIORAL|Remote Mindfulness-Based Stress Reduction Program|Enrolled participants will participate in a remote-delivered (online with audio and video) Mindfulness-Based Stress Reduction (MBSR) program. MBSR is a well established behavioral health intervention consisting of 10-sessions lasting 2.5 hours, with one session lasting 7.5 hours in an all-day retreat format over a 2-month period.
219274028|NCT03530748|PROCEDURE|Endovascular therapy and Imaging Acquisition|"1. Endovascular repair for renal artery stenosis;~2. Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
219274029|NCT01983423|DEVICE|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
219274030|NCT01715883|DRUG|Sodium Nitrite|Same as the details in Arm Description.
219274031|NCT00854204|DRUG|TMC114; TMC41629|
219274032|NCT00005637|DRUG|carmustine|
219274033|NCT00005637|DRUG|temozolomide|
219274034|NCT00251342|PROCEDURE|Edinburgh Postnatal Depression Scale|
219274035|NCT01806012|DEVICE|Sealing tissue with the Enseal device|
219274036|NCT01806012|PROCEDURE|Conventional supracervical hysterectomy|
219274037|NCT00356005|DRUG|azithromycin plus artesunate|
219274038|NCT00356005|DRUG|Artesunate|
219274039|NCT02975102|DEVICE|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
219274040|NCT02975102|DEVICE|Vismed® Multi Eye Drops|Vismed® Multi 3 to 6 times per day for 3 months.
219274041|NCT04038242|OTHER|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
219274042|NCT03928223|OTHER|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
219274043|NCT00950482|PROCEDURE|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
219274044|NCT00950482|OTHER|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
219274045|NCT00950482|OTHER|WC|Waiting Group
219274046|NCT03017742|DEVICE|Pulse Oximeter|
219274047|NCT00537342|BIOLOGICAL|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
219274048|NCT00154687|DRUG|Paclitaxel, Cisplatin, 5-Fluorouracil|
219274049|NCT03952442|OTHER|standardized nutrition education|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
219274050|NCT03952442|OTHER|routine nutrition education|Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
219274051|NCT05741190|DEVICE|Pentacam Imaging|Imaging of the corneal surface
219274052|NCT02883036|OTHER|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
219274053|NCT02883036|OTHER|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
219274054|NCT03330613|DIAGNOSTIC_TEST|PAEDS|pediatric emergency delirium scale
219274055|NCT03330613|PROCEDURE|TIVA|Total intravenous anesthesia with propofol
219274056|NCT03330613|PROCEDURE|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
219274057|NCT06061237|OTHER|Aerobic Thai dance exercise|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
219274058|NCT05941117|COMBINATION_PRODUCT|stretching exercises|stretching exercises for Hamstring, quadriceps and calf muscle for both lower limbs of the same patients. each exercise was repeated 5 times and each repetition hold for 30 seconds in the same session.
219274059|NCT05941117|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation|it is one of the electrical stimulation modalities which is used to relief pain, each patient receive it on both knees every session.
219274060|NCT05941117|COMBINATION_PRODUCT|weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of weight bearing from standing position each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
219274061|NCT05941117|COMBINATION_PRODUCT|Non-weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of non-weight bearing from lying and setting positions each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
219274062|NCT04492813|DRUG|Pharmacokinetic of propofol and remifentanil|Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
219274063|NCT04160806|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
219274064|NCT00208247|BEHAVIORAL|Cognitive behavioral psychotherapy|
219274065|NCT04069585|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
219274066|NCT04069585|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
219274067|NCT02649205|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
219274068|NCT03544294|DEVICE|Xience alpine, ultimaster, resolute onyx, synergy|PCI will be performed
219274069|NCT01075477|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
219274070|NCT04560647|OTHER|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
219274071|NCT04560647|OTHER|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
219274072|NCT00160277|DRUG|Moxonidine|
219274073|NCT02272829|BEHAVIORAL|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
219274074|NCT02272829|OTHER|Health Education|
219274075|NCT02089555|PROCEDURE|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
219274076|NCT02089555|PROCEDURE|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
219274077|NCT02089555|PROCEDURE|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
219274078|NCT01636245|BIOLOGICAL|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
219274079|NCT01636245|BIOLOGICAL|placebo|placebo, two doses, 28 days interval
219274080|NCT01783132|DEVICE|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
219274081|NCT02614690|PROCEDURE|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
219274082|NCT02614690|PROCEDURE|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
219274083|NCT02614690|PROCEDURE|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
219274084|NCT03688776|OTHER|1805AA|A moist snuff product
219274085|NCT03688776|OTHER|1805AB|A moist snuff product
219274086|NCT01441635|DRUG|Elagolix|Elagolix tablets
219274087|NCT01441635|DRUG|Placebo|Matching placebo tablets
219274088|NCT01441635|DRUG|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
219274089|NCT01441635|DRUG|Estradiol|1.0 mg micronized estradiol tablets administered once a day
219274090|NCT01441635|DRUG|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
219274091|NCT03470636|DEVICE|HeartLight X3|Pulmonary vein isolation
219274092|NCT01658111|DEVICE|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
219274093|NCT01658111|PROCEDURE|Traditional physiotherapy|Active or passive exercises.
219274094|NCT05037643|PROCEDURE|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
219274095|NCT03827447|DRUG|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
219274096|NCT03827447|DRUG|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
219274097|NCT01825577|DRUG|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
219274098|NCT05010876|DRUG|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
219274099|NCT05010876|DRUG|Icatibant Injection|a single injection of 30 mg subcutaneously
219274100|NCT05010876|OTHER|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
219274101|NCT00004077|DRUG|cisplatin|
219274102|NCT00004077|DRUG|ifosfamide|
219274103|NCT00004077|DRUG|paclitaxel|
219274104|NCT03202680|OTHER|USDA Style Diet|USDA style healthy diet, low in saturated fats.
219274105|NCT03202680|OTHER|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
219274106|NCT04969705|DRUG|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
219274107|NCT00358644|DRUG|Decitabine|20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
219274108|NCT04557358|OTHER|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
219274109|NCT04557358|OTHER|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
219274110|NCT04557358|OTHER|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
219274111|NCT04557358|OTHER|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
219274112|NCT04557358|OTHER|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
219274113|NCT05390177|BEHAVIORAL|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
219274114|NCT02975076|DRUG|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
219274115|NCT02975076|DRUG|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
219274116|NCT02975076|DRUG|Aspirin|
219274117|NCT02975076|DRUG|Clopidogrel|
219274118|NCT02975076|DRUG|placebo of clopidogrel|
219274119|NCT04515498|DEVICE|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
219274120|NCT01358331|DRUG|MK-8353|Administered orally twice daily for 28 days for each cycle
219274121|NCT00911651|DRUG|Salbutamol|400 µg inhalation once
219274122|NCT00911651|DRUG|ipratropium bromide|80 µg inhalation once
219274123|NCT00064142|DRUG|halofuginone hydrobromide|Applied topically
219274124|NCT00064142|OTHER|placebo|Applied topically
219274125|NCT00064142|OTHER|laboratory biomarker analysis|Correlative studies
219274126|NCT00064142|OTHER|pharmacological study|Correlative studies
219274127|NCT03477357|DEVICE|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
219274128|NCT00639522|DRUG|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
219274129|NCT02895932|RADIATION|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
219274130|NCT03876470|OTHER|Hepatitis C treatment as chosen by provider|Participants' providers will determine the type of HCV treatment as appropriate.
219274131|NCT02866032|DRUG|MOB015B|
219274132|NCT02866032|DRUG|Ciclopirox 80 mg/g|
219274133|NCT03327831|DRUG|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
219274134|NCT01851551|DRUG|Vincristine Sulfate Liposome Injection plus rituximab|
219274135|NCT05788692|DEVICE|electric tootbrush|Participants will brush twice per day with an electric toothbrush
219274136|NCT05788692|DEVICE|manual toothbrush|Participants will brush twice per day with a manual toothbrush
219274137|NCT05788692|DEVICE|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
219274138|NCT03053453|PROCEDURE|Spinal Surgery|TKA under standard of care spinal surgery.
219274139|NCT03053453|DEVICE|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
219274140|NCT02700360|DIETARY_SUPPLEMENT|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
219274141|NCT02700360|DRUG|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
219274142|NCT02727153|OTHER|"Ultra E.R.A.S."|
219274143|NCT02727153|OTHER|Classic E.R.A.S.|
219274144|NCT03332784|DRUG|TAK-925|TAK-925 Intravenous Infusion
219274145|NCT03332784|DRUG|Placebo|TAK-925 Placebo Intravenous Infusion
219274146|NCT02985359|DIETARY_SUPPLEMENT|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
219274147|NCT02985359|BEHAVIORAL|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
219274148|NCT04600388|DEVICE|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
219274149|NCT06047574|OTHER|This study does not involve any interventions|This study does not involve any interventions
219274150|NCT04922177|PROCEDURE|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
219274151|NCT04922177|PROCEDURE|Direct restoration|Restoration using a Glass Ionomer Cement
219274152|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
219274153|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
219274154|NCT06180213|DIAGNOSTIC_TEST|FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.
219274155|NCT00600470|BEHAVIORAL|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
219274156|NCT00600470|BEHAVIORAL|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
219274157|NCT00788970|BEHAVIORAL|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
219274158|NCT02337621|OTHER|No intervention|
219274159|NCT06018662|OTHER|A medication management mobile application|A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
219274160|NCT03346005|DEVICE|Aeonose|An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
219274161|NCT01969851|DRUG|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
219274162|NCT01055704|DRUG|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
219274163|NCT01055704|DRUG|Codeine only|30 mg taken orally four times daily for 5 days
219274164|NCT01055704|DRUG|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
219274165|NCT01055704|DRUG|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
219274166|NCT01971151|BEHAVIORAL|Exposure therapy|"Treatment protocol:~1\) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
219274167|NCT01133080|DRUG|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
219274168|NCT01133080|DRUG|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
219274169|NCT05029453|DRUG|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
219274170|NCT02731079|DEVICE|Covidien iDrive|Surgery performed with Covidien powered stapler
219274171|NCT02731079|DEVICE|Ethicon Echilon|Surgery performed with Ethicon powered stapler
219274172|NCT00065624|DRUG|lipoic acid|
219274173|NCT04727177|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive biological stimulation technique born in the middle of 1980's.
219274174|NCT04640740|PROCEDURE|hip arthroplasty|two different approaches of total hip arthroplasty
219274175|NCT05615584|DIAGNOSTIC_TEST|Quantitative mass spectrometry assay|ORX-A determination by quantitative mass spectrometry
219274176|NCT04248478|OTHER|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
219274177|NCT04248478|OTHER|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
219274178|NCT03122470|DEVICE|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
219274179|NCT03122470|PROCEDURE|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
219274180|NCT01722279|PROCEDURE|Bariatric surgery|
219274181|NCT03913572|PROCEDURE|Injection of adipose-derived stem cells into perianal fistula|The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
219274182|NCT00292968|BEHAVIORAL|Computer based care|
219274183|NCT00292968|BEHAVIORAL|Telephone counseling|
219274184|NCT00292968|BEHAVIORAL|Group visits|
219274185|NCT00292968|BEHAVIORAL|Usual care|
219274186|NCT03570268|OTHER|Experimental Group: Education|Participants in the experimental intervention group received an educational program and tailored home exercises.
219274187|NCT03570268|OTHER|Control Group: Usual care|Participants allocated to the control group received stretching exercises.
219274188|NCT00566891|DRUG|tirofiban|tirofiban high dose bolus 25µ/Kg
219274189|NCT00566891|DRUG|Clopidogrel|
219274190|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 14
219274191|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 23
219274192|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 8
219274193|NCT05594602|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
219274194|NCT05594602|DRUG|Carbamazepine|Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
219274195|NCT05594602|DRUG|Quinidine|Subjects will receive quinidine BID Days 5-12
219274196|NCT00763490|PROCEDURE|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
219274197|NCT00763490|DRUG|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
219274198|NCT00763490|RADIATION|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
219274199|NCT00763490|DRUG|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
219274200|NCT00763490|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) \< 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
219274201|NCT01661764|DRUG|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
219274202|NCT01661764|DRUG|Oleic Acid|Placebo
219274203|NCT03808792|DIAGNOSTIC_TEST|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
219274204|NCT04906681|DEVICE|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
219274205|NCT01357122|DEVICE|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
219274206|NCT01357122|PROCEDURE|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
219274207|NCT01430468|PROCEDURE|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
219274208|NCT04592159|DRUG|Nabiximols|oromucosal spray
219274209|NCT04592159|DRUG|Placebo|oromucosal spray
219274210|NCT02700659|OTHER|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
219274211|NCT03072524|DIAGNOSTIC_TEST|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
219274212|NCT04625959|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
219274213|NCT04625959|BEHAVIORAL|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
219274214|NCT04625959|BEHAVIORAL|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
219274215|NCT04625959|BEHAVIORAL|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
219274216|NCT04625959|BEHAVIORAL|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
219274217|NCT05674162|BEHAVIORAL|Unobserved|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.
219274218|NCT05674162|BEHAVIORAL|Observed|Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.
219274219|NCT05674162|RADIATION|Unobserved & Measured|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
219274220|NCT04662229|DEVICE|Eco-guided Percutaneous Electrical Stimulation|Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
219274221|NCT04662229|DEVICE|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
219274222|NCT00391703|BEHAVIORAL|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
219274223|NCT00391703|BEHAVIORAL|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
219274224|NCT03394131|DRUG|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
219274225|NCT03394131|DRUG|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
219274226|NCT03394131|OTHER|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
219274227|NCT00012753|PROCEDURE|Automated telephone health status assessments with nurse follow-up.|
219274228|NCT04874753|OTHER|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
219274229|NCT03470259|DRUG|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
219274230|NCT03470259|DEVICE|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
219274231|NCT03470259|DEVICE|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
219274232|NCT03570723|PROCEDURE|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
219274233|NCT03570723|PROCEDURE|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
219274234|NCT06533488|OTHER|Perceptual learning module|Perceptual learning module providing feedback on the most relevant image for clinical practice in a spinal ultrasound video.
219274235|NCT06533488|OTHER|Control|Participants in the control group will view the same videos as participants in the intervention group without feedback on the best image.
219274236|NCT00329680|DIETARY_SUPPLEMENT|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
219274237|NCT00329680|DIETARY_SUPPLEMENT|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
219274238|NCT02583529|DEVICE|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
219274239|NCT02583529|DEVICE|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
219274240|NCT02847039|GENETIC|Blood samples|Blood samples at baseline.
219274241|NCT05011344|OTHER|Blood sample|Seroneutralization and Elisa tests
219274242|NCT04176731|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
219274243|NCT02984007|BEHAVIORAL|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
219274244|NCT02984007|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
219274245|NCT03157245|DIAGNOSTIC_TEST|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
219274246|NCT03556800|DRUG|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel"
219274247|NCT00276198|DIETARY_SUPPLEMENT|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
219274248|NCT00276198|DIETARY_SUPPLEMENT|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
219274249|NCT00122213|BEHAVIORAL|Behavior change on physical activity and diet|
219274250|NCT03518567|DRUG|Smoked marijuana cigarettes: High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose \[6% THC\])
219274251|NCT05887739|DIAGNOSTIC_TEST|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
219274252|NCT01884220|OTHER|There are no interventions in this study.|
219274253|NCT04686682|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
219274254|NCT04686682|DRUG|JAB-8263|RP2D dose, orally Q2D with 28 days each cycle
219274255|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
219274256|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
219274257|NCT01320878|DRUG|distilled water|distilled water 2 ml per session
219274258|NCT02401971|DRUG|Thalidomide|Given orally
219274259|NCT02401971|DRUG|CPT-11|Given Ivgtt
219274260|NCT02498236|DRUG|Intranasal Oxytocin|
219274261|NCT06023810|BEHAVIORAL|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
219274262|NCT00383123|BIOLOGICAL|Fluarix™|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
219274263|NCT00383123|BIOLOGICAL|Fluzone|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
219274264|NCT01568125|DRUG|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
219274265|NCT00656747|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
219274266|NCT00656747|DRUG|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
219274267|NCT00029224|DRUG|zoledronic acid|
219274268|NCT03329677|OTHER|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
219274269|NCT04982575|DRUG|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
219274270|NCT04982575|DRUG|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
219274271|NCT04982575|DRUG|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
219274272|NCT04982575|DRUG|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
219274273|NCT04471909|DEVICE|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
219274274|NCT05521997|DRUG|Telaglenastat|-800 mg twice per day by mouth
219274275|NCT05521997|RADIATION|Radiation treatment|"* Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
219274276|NCT05521997|DRUG|Cisplatin|"* Standard of care~* Weekly administration of cisplain"
219274277|NCT06481163|DRUG|Telacebec|The test product will be supplied as Telacebec 100mg tablets.
219274278|NCT03921944|DIAGNOSTIC_TEST|CT scan of the shoulders|studies of both operative and nonoperative shoulders
219274279|NCT01609777|PROCEDURE|SBAR|situation, background, assessment, recommendation
219274280|NCT02304081|DRUG|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
219274281|NCT02304081|DRUG|Placebo for Saxagliptin|
219274282|NCT04966065|DEVICE|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
219274283|NCT01151423|BIOLOGICAL|Caplacizumab|"* Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session."
219274284|NCT01151423|BIOLOGICAL|Placebo|"* Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session."
219274285|NCT01249508|OTHER|nutrition label|
219274286|NCT04141722|BEHAVIORAL|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
219274287|NCT04141722|BEHAVIORAL|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
219274288|NCT02772237|BIOLOGICAL|Riboflavin|Riboflavin 400mg daily
219274289|NCT02772237|BIOLOGICAL|Placebo|
219274290|NCT01515852|PROCEDURE|general anesthesia in stereotactic biopsy|stereotactic biopsy
219274291|NCT01515852|PROCEDURE|local anesthesia in stereotactic biopsy|stereotactic biopsy
219274292|NCT00338988|DRUG|Capecitabine|1500 mg/m\^2 PO twice daily x 14 days.
219274293|NCT00338988|DRUG|Oxaliplatin|130 mg/m\^2 IV over 2 hours on day 1 of cycle.
219274294|NCT02984254|DEVICE|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
219274295|NCT02984254|DEVICE|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
219274296|NCT02984254|DEVICE|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
219274297|NCT02984254|DEVICE|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
219274298|NCT02984254|DEVICE|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
219274299|NCT02984254|DEVICE|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
219274300|NCT02984254|DEVICE|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
219274301|NCT01675349|BIOLOGICAL|Prick test Chenopodium album allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
219274302|NCT05225987|BEHAVIORAL|Postpartum Nurse Navigation Program based care|In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times.
219274303|NCT02671110|BEHAVIORAL|Transforming Your Life|See Transforming Your Life Arm
219274304|NCT02671110|BEHAVIORAL|Diabetes Prevention Program|See Diabetes Prevention Program Arm
219274305|NCT04328103|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
219274306|NCT04328103|BEHAVIORAL|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
219274307|NCT03542110|DRUG|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
219274308|NCT03542110|DRUG|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
219274309|NCT06239415|OTHER|observation|Observation for 1 year of patients suffering from symptomatic peripheral atherosclerotic disease of the lower limb, with or without chronic ischemic heart disease, and indication for treatment with rivaroxaban 2.5 mg bid and acetylsalicylic acid 100 mg.
219274310|NCT00962806|BEHAVIORAL|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
219274311|NCT00962806|BEHAVIORAL|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
219274312|NCT01137669|BIOLOGICAL|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
219274313|NCT01137669|OTHER|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
219274314|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|Low Dose- 70g bar
219274315|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|High Dose- 100g bar
219274316|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
219274317|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|High dose: 100g bar
219274318|NCT00691249|DIETARY_SUPPLEMENT|Shredded Wheat|70g bar
219274319|NCT04652661|DRUG|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
219274320|NCT04652661|DRUG|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
219274321|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
219274322|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
219274323|NCT00693433|DRUG|dexamethasone|Given orally
219274324|NCT00693433|DRUG|temsirolimus|Given IV
219177931|NCT01088542|BEHAVIORAL|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
219274325|NCT00693433|OTHER|laboratory biomarker analysis|Correlative studies
219274326|NCT03498352|PROCEDURE|Thoracic surgery|Lung resection surgery
219274327|NCT05794477|BIOLOGICAL|Adebrelimab|Specified dose on specified days
219274328|NCT05794477|BIOLOGICAL|SHR-1802|Specified dose on specified days
219274329|NCT05794477|DRUG|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219274330|NCT05794477|DRUG|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
219274331|NCT01498315|OTHER|Ultrasound examination|Ultrasound examination following hysterectomy
219274332|NCT00403910|DRUG|Canrenone|
219274333|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
219274334|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
219274335|NCT04067271|OTHER|Analyze changes in intestinal microbiome|Descriptive Analysis
219274336|NCT04166396|DRUG|Resveratrol|500 mg resveratrol, BID
219274337|NCT04166396|DRUG|NR|500 mg NR BID
219274338|NCT04166396|DIETARY_SUPPLEMENT|Placebo|Placebo
219274339|NCT04893850|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
219274340|NCT04893850|BEHAVIORAL|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
219274341|NCT06537271|COMBINATION_PRODUCT|experimental group|Autism awareness, breastfeeding cessation and toilet training knowledge and attitude training guide and weekly training content animation videos will be prepared for the experimental group and uploaded via WhatsApp and training will be provided. All participants will be interviewed face to face before the training and the necessary information about our study will be provided. Feedback will be received from the researcher regarding the videos, and participants in the study will be able to ask their questions via WhatsApp and share digital content in a digital environment. Evaluation will be made by conducting group work with individuals. Reminders such as mobile phone messages will be used. Training will be carried out within an 8-week program. Each week, training videos on the topics prepared in line with the training guide will be prepared and shared via WhatsApp. Feedback will be received by creating interactive communication environments.
219274342|NCT06537271|COMBINATION_PRODUCT|Control Group|After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of the training, survey forms will be filled out by the researcher for the control group and post-test data will be collected.
219274343|NCT02065882|DRUG|BT524 (Part I)|Single intravenous infusion of 70 mg BT524 per kg body weight.
219274344|NCT02065882|DRUG|BT524 (Part II)|Single or repetitive intravenous infusion(s) of BT524, depending on the severity of the disorder, location and extent of the bleeding and patient's clinical condition. Dosage based on individual body weight and fibrinogen level.
219274345|NCT06618794|OTHER|Recovery Legal Care|These patients will receive support from our HVIP standard of care (Violence Recovery Program) plus our Medical Legal Partnership (Recovery Legal Care) for additional legal support to address health-harming legal needs and public benefits.
219274346|NCT06618794|OTHER|HVIP Standard of Care|These patients will receive HVIP standard of care (Violence Recovery Program Support)
219274347|NCT02775006|DRUG|Docetaxel|75mg/m2
219274348|NCT02775006|DRUG|Erlotinib|150mg/day
219274349|NCT07041619|DEVICE|Intersection short-pulse (ISP) stimulation|The intervention aims to terminate pathological brain oscillations (i.e. epileptiform activity) in patients.
219274350|NCT07039669|DRUG|611|611 subcutaneous (SC) injection
219274351|NCT07039669|DRUG|Placebo|placebo Q2W, subcutaneous (SC) injection
219274352|NCT07039864|DIAGNOSTIC_TEST|protein bar first|Take protein bar(after one week fried eggs intake) to evaluate the size of the gallbladder with ultrasound
219274353|NCT07039864|DIAGNOSTIC_TEST|fried eggs first|Take fried eggs (after one week protein bar intake) to evaluate the size of the gallbladder with ultrasound
219274354|NCT05944614|OTHER|Magnetic Resonance imaging (MRI) examination|3D CINE and 4 dimensional (4D) flow MRI sequence
219274355|NCT07044583|BEHAVIORAL|Opioid Educational Video|The video includes information on (1) how to consume appropriate over-the-counter pain medication alongside opioids for optimal pain control, (2) how prescribed opioids should be used only to treat pain related to the surgery, and (3) the proper disposal of unused opioids. The video was created through the University of Utah Office of Patient Experience. Feedback regarding the educational content was provided by surgeons, pain management physicians, and pharmacists throughout the process.
219274356|NCT06921746|DIAGNOSTIC_TEST|Urine Microbiological and Metabolomic Analysis|Microbiological and metabolomic analysis of a urine sample will be performed in the study subjects, before and after the end of the treatment.
219274357|NCT07049588|OTHER|Quantitative neuromuscular MRI|Quantification of biomarkers as fat fraction, magnetization Transfer Ratio, muscular volume, relaxation time T2
219274358|NCT07049588|OTHER|Skin biopsy|Performed on the arm or index finger, depending on patient age
219274359|NCT07049588|OTHER|Clinical scores|ONLS, CMTES-R, CMT-Peds, CMT-FOM
219274360|NCT07049588|OTHER|Blood test|10 ml sample
219274361|NCT07049588|OTHER|Patient Report Outcomes Measures|pCMT-QoL, EVA, WALK-12, PGI-c, SF-12
219274362|NCT07049471|BEHAVIORAL|Swallowing Exercise and Maneuver Program for Older Adults with Dysphagia|The intervention is a structured swallowing exercise and maneuver program designed specifically for older adults with oropharyngeal dysphagia in nursing homes. It combines four evidence-based techniques: Masako Maneuver, Chin Tuck Against Resistance (CTAR), Supraglottic Swallow, and Super-Supraglottic Swallow. The program was delivered by nurses using video-guided instructions and was conducted three times daily before meals for six weeks. Unlike interventions targeting post-stroke dysphagia, this program focuses on non-stroke-related swallowing difficulties in frail elderly populations residing in long-term care facilities.
219274363|NCT07050069|DEVICE|Transcranial Magnetic Stimulation (TMS) Device / Respiratory Training Device|Participants received group-specific interventions 5 days/week for 4 weeks.
219274364|NCT07050485|DIETARY_SUPPLEMENT|PoZibio|1 gummy once daily
219274365|NCT07050485|DIETARY_SUPPLEMENT|Inert placebo|1 gummy once daily
219274366|NCT07050615|PROCEDURE|Continuous suturing|In this group, episiotomy repair was done using the continuous suturing.
219274367|NCT07050615|PROCEDURE|Interrupted suturing|In this group, episiotomy repair was done using the interrupted suturing.
219274368|NCT07046637|DEVICE|Inspiratory muscle fatigue group|The subjects will perform deep inspirations against a threshold device with varying resistances
219274369|NCT07046637|DEVICE|Inspiratory muscle warm-up group|The subjects will perform deep inspirations against a threshold device with varying resistances
219274370|NCT07050329|DEVICE|Electrocautery|Axillary dissection was done through bipolar electrocautery
219274371|NCT07050329|DEVICE|Ultrasonic dissector|Axillary dissection was done through ultrasonic dissector.
219274372|NCT07049250|BEHAVIORAL|Evidence-Based Nursing Intervention under Quantitative Evaluation Strategy|A multifaceted nursing program incorporating comprehensive risk assessment, dynamic risk stratification, psychological and cognitive interventions (including cognitive-behavioral techniques, peer mentoring, family counseling), systematic complication prevention strategies (including prophylactic antiemetics, dietary guidance, infection control), and sleep optimization protocols.
219274373|NCT07049250|BEHAVIORAL|Routine Nursing Care|Standard disease education on chemotherapy side effects and self-management, personalized exercise guidance, and medication adherence counseling. Delivered in 30-minute sessions twice weekly for two months.
219274374|NCT07050940|DIETARY_SUPPLEMENT|Postbiotic|postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day
219274375|NCT07050940|DRUG|AntiPD1|Antibody to PD1 approved for standard of care
219274376|NCT07050004|BEHAVIORAL|SMOKING|Patients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle
219274377|NCT07048886|DRUG|Rocklatan (netarsudil 0.02% and latanoprost 0.005%)|Additional intraocular eye pressure lowering post-Hydrus
219274378|NCT07048886|DRUG|Systane|Placebo Comparator (artificial tears)
219274379|NCT07050342|OTHER|Personalized Nutrition-Based Psychosomatic Care|This intervention involves personalized, nutrition-focused care provided in a specialized outpatient clinic for individuals with psychosomatic and mental health conditions. The care model integrates nutritional counseling, education on gut-brain interactions, and patient-centered support to promote psychological well-being and reduce stress. No experimental drugs or diets are administered. Instead, the intervention focuses on individualized recommendations based on clinical assessments and ongoing routine laboratory markers (e.g., inflammatory markers, vitamin levels). Participants also receive guidance aimed at improving dietary habits and resilience within a biopsychosocial framework. The intervention is part of regular clinical care and not blinded or randomized.
219274380|NCT07048899|DRUG|Chlorhexidine|Intraperitoneal irrigation with Irrisept solution
219274381|NCT07048899|DRUG|Normal Saline|Intraperitoneal irrigation with normal saline
219274382|NCT07049406|DIAGNOSTIC_TEST|Structured Pre-tested|This will analyzed forthe differences in cultural perceptions and their Influence on health-seeking behavior.
219274383|NCT07049770|DIETARY_SUPPLEMENT|Eczeva supplementation|Intervention contains 0.2g of eczefolia extracts, and 0.01g of rice ceramides as main active ingredients.
219274384|NCT07051096|DEVICE|A novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium.|This device will be provided on top of routine post-operative management and standard delirium reduction measures. It has proven effective in a previous clinical trial by reducing agitation and unscheduled medications. It displays nature-driven responsive imagery through an available mobile screen/device for the first 7 days after surgery or discharge, whichever comes first. The imagery adapts in real-time to the participant's movement and sound. The device will be placed at the foot of the bed while the patient is awake and may be interrupted at the discretion of the patient, bedside RN or attending physician.
219274385|NCT07051096|PROCEDURE|Routine post-operative management and standard delirium reduction measures.|Examples of routine post-operative care are sleep optimization, avoidance of delirium-promoting medications, orientation, and mobilization.
219274386|NCT07051083|DIAGNOSTIC_TEST|Risk Stratification|Risk Stratification for Assessing Muscle Infiltration in Bladder Cancer.
219274387|NCT07049185|DRUG|QL1706 Plus Celecoxib Group|QL1706 (anti-PD-1/CTLA-4 bispecific antibody) will be administered at 5 mg/kg by intravenous infusion every 3 weeks. Celecoxib 200 mg will be taken orally twice daily starting on Day 1 of each 3-week treatment cycle. Treatment continues until disease progression, intolerable toxicity, or for a maximum of 2 years.
219274388|NCT07050979|OTHER|Goal-Directed Fluid Therapy (GDFT)|This arm administers fluid and vasopressor therapy based on SVV (less than 15%) and CI (\>2.6 L/min/m²) targets using the Pressure Recording Analytical Method (PRAM) system with the help of intra-arterial pressure monitoring method. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
219274389|NCT07050979|OTHER|Conventional Fluid Therapy|This arm administers fluid and vasopressor therapy based on targets of Mean Arterial Pressure (MAP) 65-95 mmHg and hourly urine output minimum of 0.5 mL/kg/hr. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
219274390|NCT07050888|DIETARY_SUPPLEMENT|Inulin (prebiotic, fermentable fiber)|inulin (prebiotic, fermentable fiber)
219274391|NCT07050888|DIETARY_SUPPLEMENT|Placebo|placebo (matodextrin)
219274392|NCT07049003|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of the Deep Cerebellar Nuclei
219274393|NCT07050095|OTHER|Virtual Reality Group|Patient will undergo virtual reality (VR) immersion using oculus.
219274394|NCT07050095|DRUG|Midazolam Group|Patient will receive midazolam premedication only.
219274395|NCT07050992|PROCEDURE|Laser posterior nasal nerve neurolysis|Posterior nasal nerve ablation using laser is performed through an angled nasal probe at 20 degrees and a 90-degree endoscope to deliver laser energy to the posterior nasal nerve area. The thermal energy is conducted to the middle meatus and the posterior superior part of the inferior turbinate, targeting the area supplied by the posterior nasal nerve. The ablation continues until there is widespread mucosal blanching and the formation of at least one continuous brown eschar
219274396|NCT07050992|PROCEDURE|Sham surgery|The same laser surgical instrument is used to enter the nasal cavity for a sham procedure with minimal dosage. The energy setting uses the lowest limit of 0.5W with intermittent emission (0.01 second emission with 1 second rest), and the emission mode is Super Pulse to reduce heat dispersion. It is applied to the mucosal surface without blood supply at the lower edge of the middle turbinate for 2 minutes on each side, totaling only 1.2 seconds of cumulative laser emission. Compared to the experimental group using 2W energy with continuous irradiation for 2 minutes, the total energy release difference in the sham surgery group is only 1/400 of the experimental group (2W120sec/0.5W1.2sec). This is to produce the sound, light, and tactile effects of the laser, but without sufficient energy transfer to cause high-temperature mucosal changes and tissue alterations, serving as a high-quality sham surgery control group.
219274397|NCT01507077|DRUG|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
219274398|NCT01507077|DRUG|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
219274399|NCT07050498|DEVICE|Virtual reality|"Virtual reality hypnosis software applications are Class I medical devices according to Rule 12 of Directive 93/42/EC. They allow, through a virtual reality headset and headphones, to immerse the patient in a hypnotic sound and visual environment. Several visual scenarios can be proposed, allowing the patient to virtually travel to a beach, the seabed, on an alpine walk, etc.).~The HypnoVR Biofeedback virtual reality device is provided by the HypnoVR company."
219274400|NCT07050498|PROCEDURE|Usual Care Group|Routine preoperative procedure (local anesthesia)
219274401|NCT06581536|BEHAVIORAL|Yes and Know curriculum|Yes and Know is fully virtual intervention that integrates group-based education with digital tools to support young people ages 14 to 19 by increasing their relationship and healthy life skills. The curriculum focuses on sexual and reproductive health; healthy relationships; life skills; and educational and career success. It is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
219274402|NCT06581536|BEHAVIORAL|Nutrition Education for Adolescents|Youth will receive a fully virtual intervention that integrates group-based education with digital tools focused on adolescent nutrition and wellness. The curriculum is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
219274403|NCT07050537|PROCEDURE|Constant oxygen concentration protocols in embryo culture|Participants were randomly assigned to constant (5%) oxygen concentration group and received different blastocyst culture protocols.
219274404|NCT07050537|PROCEDURE|Sequential oxygen concentration protocols in embryo culture|Participants were randomly assigned to sequential (5%-2%) oxygen concentration group and received different blastocyst culture protocols.
219274405|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
219274406|NCT06735456|OTHER|Mandala|The patient will undergo mandala painting during 1 session of chemotherapy.
219274407|NCT06880627|BEHAVIORAL|Brain Boost group|There will be 8 group educational sessions over an 8-week program period to learn strategies for improving cognitive function. Participants will also be asked to engage in 20 minutes, at least 5 times per week online game-like cognitively stimulating activities to improve cognitive health. In addition, surveys will be completed as certain timepoints.
219274408|NCT06880627|OTHER|Waitlist group|This group will continue to receive usual health and care routines. Participants will be asked to complete surveys at certain timepoints that are the same as the boost group. After the 6-month follow-up, participants will receive the intervention materials, which include 8 weekly educational session recordings with slides, 8 weeks' subscription to online brain games, and biweekly online office hours. The office hours, hosted by the principal investigator and a trained patient co-facilitator, will give participants a chance to discuss participant's progress and ask questions.
219274409|NCT05899816|DRUG|Rocatinlimab|Subcutaneous (SC) injection
219274410|NCT05899816|DRUG|Placebo|SC injection
219274411|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
219274412|NCT06911112|DRUG|NBI-1065845|NBI-1065845 tablets
219274413|NCT06911112|DRUG|Placebo|Matching placebo tablets
219274414|NCT06871904|DRUG|Metformin Hydrochloride 500Mg Tablet|"Metformin 500 mg is being tested for its potential role in treating oral submucous fibrosis (OSF) due to its antifibrotic and anti-inflammatory effects. This intervention will be administered orally at a dose of 500 mg twice daily (OD) for a specified 6 months treatment period for Group 2 .~Metformin activates AMPK (AMP-activated protein kinase), which inhibits TGF-β signaling and collagen deposition, reducing fibrosis and inflammation.~Distinction from Other Arms: Unlike Pirfenidone, which directly targets profibrotic cytokines, Metformin modulates metabolic pathways to exert antifibrotic effects. The Control Group will receive supportive care for OSF."
219274415|NCT06871904|DRUG|Pirfenidone (PFD)|"Pirfenidone 200 mg (Pirfibet by Mactor Pharma, Pakistan) is an antifibrotic drug being tested for its potential role in treating oral submucous fibrosis (OSF). This intervention will be administered orally at a dose of 200 mg, twice daily for a specified treatment period which will be 6 months for Group 3 .~Pirfenidone modulates fibrotic pathways by inhibiting TGF-β and collagen synthesis, reducing fibrosis progression.~Distinction from Other Arms: Unlike Metformin, which has antifibrotic effects via AMPK activation, Pirfenidone specifically targets profibrotic cytokines. The Control Group will receive either a supportive care for OSF"
219274416|NCT06871904|DRUG|Beclomaethasone and Vitamin E|"The Supportive Care Group will receive Beclomethasone mouthwash (three times daily) and Vitamin E 400 mg (once daily) as part of supportive care for oral submucous fibrosis . This intervention serves as a comparison group to evaluate the efficacy of Metformin and Pirfenidone.~Beclomethasone is a topical corticosteroid that reduces inflammation and provides symptomatic relief in OSF.~Vitamin E is an antioxidant that may help reduce oxidative stress and improve tissue healing.~Distinction from Other Arms:~Unlike Pirfenidone and Metformin, which target fibrosis at the molecular level, Beclomethasone + Vitamin E primarily focus on symptom relief.~This arm will serve as an active comparator to determine whether the antifibrotic effects of Metformin and Pirfenidone provide superior therapeutic benefits."
219274417|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
219274418|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
219274419|NCT06945081|OTHER|Preparation of forearm molds with SILFLO® silicone|Preparation of forearm molds with SILFLO® silicone (MONADERM, Monaco), CE-marked and already used routinely in dermocosmetics. These molds will, then, be analyzed.
219274420|NCT05350969|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
219274421|NCT05350969|DRUG|Placebo to CDR132L|Placebo to CDR132L
219274422|NCT02107976|DIETARY_SUPPLEMENT|Vitamin E|400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
219274423|NCT02107976|DIETARY_SUPPLEMENT|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
219274424|NCT04103996|DIAGNOSTIC_TEST|Ultrasound|Sonographic measurements (diaphragm, abdominal muscle, and quadriceps thickness) will be acquired when listed for lung transplantation. Sonographic measurements will be recorded on a daily basis for up to 1 week after transplantation (while the patient remains intubated).
219274425|NCT04103996|DIAGNOSTIC_TEST|Respiratory function measurements|Maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) will be acquired after listing for lung transplantation. After transplant, MIP will be recorded once patients are eligible for a trial of spontaneous breathing and weekly thereafter. MEP will also be recorded at ICU discharge.
219274426|NCT00380315|DRUG|AG1321001(drug)|
219274427|NCT02177253|DRUG|Ipratropium bromide / Salbutamol|
219274428|NCT02177253|DRUG|Placebo Inhalation solution|
219274429|NCT02177253|DRUG|Ipratropium bromide|
219274430|NCT02177253|DRUG|COMBIVENT Inhalation Aerosol|
219274431|NCT02177253|DRUG|Placebo Inhalation Aerosol|
219274432|NCT03963869|OTHER|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
219274433|NCT01764893|OTHER|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
219274434|NCT01764893|OTHER|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
219274435|NCT05174533|OTHER|Data collection|electrocardiogram
219274436|NCT02593877|DEVICE|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
219274437|NCT03708497|DRUG|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
219177932|NCT05141487|DEVICE|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
219177933|NCT05141487|DEVICE|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
219177934|NCT03899103|DRUG|Rituximab|First course Course Rituximab at Randomization.
219177935|NCT03899103|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
219177936|NCT05050591|DEVICE|Patient-Specific Silicone Airway Stent|The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
219177937|NCT03900793|DRUG|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily, dose level 2 dosing will not exceed 100 mg daily, and dose level 3 dosing will not exceed 150 mg total daily (75 mg twice daily). Doses should be taken at approximately the same time daily and patients should fast for at least 4 hours prior to dosing
219177938|NCT03900793|DRUG|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2. Sunitinib is given as capsules or liquid formulation. Doses should be taken at approximately the same time daily.
219177939|NCT04053283|BIOLOGICAL|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
219177940|NCT05740904|OTHER|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
219177941|NCT05740904|OTHER|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
219177942|NCT03609593|DRUG|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
219177943|NCT03609593|DRUG|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
219177944|NCT03609593|DRUG|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
219177945|NCT06254846|OTHER|Urine sample, 1st stream|Use of the Colli-Pee® device for collecting the first urine stream
219177946|NCT06254846|OTHER|Cervico-vaginal swab|"Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged)."
219177947|NCT05191901|OTHER|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
219177948|NCT06073119|DRUG|SAR441566|Tablet
219177949|NCT06073119|DRUG|Placebo|Tablet
219177950|NCT05238285|BEHAVIORAL|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
219177951|NCT06199869|OTHER|Evaluation of risk factors by direct interview with subjects who have atherosclerotic cardiovascular patients|Individuals identified with a diagnosis of ASCVD will fill a one page form of the associated risk factors they have
219177952|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
219177953|NCT05360680|DRUG|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
219274438|NCT03708497|DRUG|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
219274439|NCT03708497|DRUG|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
219274440|NCT01757951|PROCEDURE|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
219274441|NCT01757951|PROCEDURE|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
219274442|NCT04601324|DRUG|Fluticasone Propionate|Participants will be required to use fluticasone propionate nasal spray twice daily.
219274443|NCT04601324|DRUG|Azelastine hydrochloride and fluticasone propionate|Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
219274444|NCT04601324|DRUG|Rupatadine|Rupatadine once daily for a total of 2 weeks.
219274445|NCT03554408|DRUG|10-1074-LS|Subcutaneous injection of 10-1074-LS
219274446|NCT03554408|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS
219274447|NCT03554408|DRUG|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
219274448|NCT03554408|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
219274449|NCT00863759|PROCEDURE|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
219274450|NCT00278447|BEHAVIORAL|Chronic Disease Management for substance abuse|Referral to primary medical care \& longitudinal, multidisciplinary care for persons with substance dependence.
219274451|NCT00278447|BEHAVIORAL|Standard care|Referral to primary medical care for persons with substance dependence.
219274452|NCT02774811|DRUG|Prostaglandin analogue|Topical therapy
219274453|NCT02774811|PROCEDURE|Selective laser trabeculoplasy|Laser therapy into drainage angle
219274454|NCT02774811|DEVICE|laser|
219274455|NCT05071638|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks who suffer BPD and also stored cord blood are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg).
219274456|NCT02120001|DEVICE|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
219274457|NCT02763215|DRUG|Standard of Care Medications|Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
219274458|NCT00347698|DRUG|intravitreal injection of bevacizumab|
219274459|NCT00347698|PROCEDURE|panretinal photocoagulation|
219274460|NCT05302440|DEVICE|remote real-time health monitoring system with ring-like sensor|The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
219274461|NCT02039076|DRUG|avatrombopag|
219274462|NCT00475644|DRUG|Enzastaurin|Administered orally
219274463|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
219274464|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
219274465|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneous
219274466|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
219274467|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
219274468|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
219274469|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
219274470|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneously
219274471|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
219274472|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
219274473|NCT00600327|DEVICE|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
219274474|NCT00600327|DEVICE|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
219274475|NCT00790387|DRUG|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
219274476|NCT00790387|DRUG|Tirofiban|
219274477|NCT00790387|DRUG|unfractionated heparin|
219274478|NCT05147870|PROCEDURE|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
219274479|NCT05147870|PROCEDURE|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
219274480|NCT04395170|BIOLOGICAL|COVID-19 convalescent plasma|Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
219274481|NCT04395170|BIOLOGICAL|Anti-COVID-19 human immunoglobulin|"Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met."
219274482|NCT04395170|DRUG|Standard (specific) therapy for COVID-19|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
219274483|NCT05407831|GENETIC|Genetic|Calculate MODY probability
219274484|NCT05407831|BEHAVIORAL|Social habits|Alcohol vs Smoking vs Drug use
219274485|NCT05407831|OTHER|Perinatal stress|Survey
219274486|NCT02958605|DEVICE|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
219274487|NCT02958605|DEVICE|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
219274488|NCT03981848|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
219274489|NCT06062004|PROCEDURE|Small Incision Lenticule Extraction (SMILE)|"All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~* Cap thickness of 120 μm~* Cap diameter of 1 mm larger than the lenticule diameter~* Cap side cut angle 70°~* 3 mm incision positioned at 100° and angled at 45°~* Transition zone of 0.1 mm and clearance of 0.5 mm~* Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm"
219274490|NCT04958577|DEVICE|Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)|This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
219274491|NCT03798275|DIETARY_SUPPLEMENT|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
219274492|NCT03205670|PROCEDURE|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
219274493|NCT00269412|DRUG|Rifaximin|
219274494|NCT04465266|DRUG|Tolperisone|tablets
219274495|NCT04912830|PROCEDURE|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
219274496|NCT02387151|DRUG|mesenchymal stromal cells|2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
219274497|NCT03745677|BEHAVIORAL|Advanced and Integrated MicroSystems (AIMS) interventions|Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
219274498|NCT02436291|DEVICE|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
219274499|NCT04315753|OTHER|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
219274500|NCT00725335|PROCEDURE|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
219274501|NCT00725335|PROCEDURE|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
219274502|NCT03513926|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
219274503|NCT03592043|DEVICE|MitraClip|Transcatheter Mitral Valve Repair with MitraClip
219274504|NCT05305170|DIAGNOSTIC_TEST|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
219274505|NCT00230750|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
219274506|NCT00230750|DRUG|Placebo|Saline placebo.
219274507|NCT00949377|DRUG|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
219274508|NCT00949377|DRUG|Placebo|Normal saline
219274509|NCT00295815|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
219274510|NCT00295815|DRUG|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
219274511|NCT02784457|DRUG|Cetrorelix|
219274512|NCT01784120|DRUG|Doxorubicin/Genexol-PM|
219274513|NCT04415320|DRUG|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
219274514|NCT03355339|DEVICE|Binasal occlusion|Binasal occlusion glasses
219274515|NCT03355339|DEVICE|No binasal occlusion|Non-occluded glasses
219274516|NCT03941600|BEHAVIORAL|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
219274517|NCT03941600|BEHAVIORAL|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
219274518|NCT04489290|DEVICE|D005 Vaginal Mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
219274519|NCT04489290|OTHER|Placebo|Placebo
219274520|NCT02356705|DRUG|Midazolam|midazolam 0.2 mg/kg given intranasally
219274521|NCT02356705|DRUG|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
219274522|NCT02356705|DRUG|saline placebo|intranasal saline given as placebo
219274523|NCT01107899|DRUG|clopidogrel|taken orally, day one, single dose
219274524|NCT01107899|DRUG|prasugrel|taken orally, day one, single dose
219274525|NCT06146777|DRUG|Pembrolizumab|Intravenous infusion
219274526|NCT06146777|DRUG|Placebo|Intravenous infusion
219274527|NCT00605488|PROCEDURE|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
219274528|NCT03689751|OTHER|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
219274529|NCT03689751|OTHER|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
219274530|NCT04425590|DRUG|DLBS1033|DLBS 1033 490 mg tablet 3 times daily
219274531|NCT04425590|DRUG|Aspirin|Aspirin 100 mg tablet once daily
219274532|NCT04425590|DRUG|Statin|Atorvastatin 20 mg tablet once daily
219274533|NCT04425590|DRUG|Vit B12|Vit B12 100 mg tablet three times daily
219274534|NCT00974259|DEVICE|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (\> 20 mm Hg) or pBrO2 (\< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
219274535|NCT00974259|DEVICE|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
219274536|NCT04893681|OTHER|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
219274537|NCT04893681|OTHER|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
219274538|NCT06024278|BEHAVIORAL|Caregiver educational videos for African American caregivers|The intervention will be culturally tailored education videos for African American caregivers receiving hospice services.
219274539|NCT06024278|BEHAVIORAL|Caregiver educational videos for Puerto Rican caregivers|The intervention will be culturally tailored education videos for Puerto Rican caregivers receiving hospice services.
219274540|NCT00776477|DRUG|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
219274541|NCT00776477|DRUG|aspirin|aspirin 100mg daily
219274542|NCT03177720|DRUG|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
219274543|NCT03177720|DRUG|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
219274544|NCT00044746|DRUG|Piperacillin/Tazobactam|
219274545|NCT03112109|OTHER|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
219274546|NCT00448877|DEVICE|fNIR light emitting and sensing device|
219274547|NCT00223301|DRUG|Mycophenolate Mofetil (cellcept)|
219274548|NCT03251729|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
219274549|NCT03251729|DRUG|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
219274550|NCT00066651|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
219274551|NCT00561717|DRUG|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
219274552|NCT00561717|DRUG|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
219274553|NCT00561717|DRUG|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
219274554|NCT00561717|DRUG|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
219274555|NCT00944229|DRUG|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
219274556|NCT00944229|DRUG|Placebo|4 capsules of placebo every 24 hours
219274557|NCT03708237|DRUG|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
219274558|NCT03708237|DRUG|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
219274559|NCT03708237|DRUG|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
219274560|NCT03663907|PROCEDURE|Telemonitoring|"The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily."
219274561|NCT01901822|PROCEDURE|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
219274562|NCT01901822|PROCEDURE|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
219274563|NCT02530710|DRUG|Q203|
219274564|NCT02530710|DRUG|Placebo|
219274565|NCT01278706|PROCEDURE|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
219274566|NCT06512844|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Intervention|The MBSR training program consist of 8-week group session with the duration of 45-60 minutes each. Participants of the experimental group were given Mindfulness based stress reduction intervention in which they practice different mindfulness techniques. Each week focused on motor, cognitive and emotional issues of students with physically disabled. All the techniques also included psycho education
219274567|NCT05519566|DIAGNOSTIC_TEST|Retrograde Urethrogram|Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram
219274568|NCT03209869|BIOLOGICAL|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
219274569|NCT03209869|BIOLOGICAL|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
219274570|NCT02957955|BEHAVIORAL|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
219274571|NCT04292470|DRUG|Amitriptyline|Amitriptyline tablet
219274572|NCT00283283|BIOLOGICAL|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
219274573|NCT00867100|DRUG|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
219274574|NCT00867100|DRUG|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
219274575|NCT00867100|DRUG|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
219274576|NCT00867100|DRUG|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
219274577|NCT04654910|BEHAVIORAL|PROMIS Score Explanation|The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
219274578|NCT04654910|BEHAVIORAL|Placebo|Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
219274579|NCT04556812|PROCEDURE|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
219274580|NCT04556812|PROCEDURE|soft-tissue surgery|traditional soft-tissue surgery
219274581|NCT02906020|DRUG|venglustat GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
219274582|NCT02906020|DRUG|Placebo|Pharmaceutical form: capsule Route of administration: oral
219274583|NCT02765789|DEVICE|Immunoadsorption (Immunosorba)|Immunoadsorption as an alternative to plasma exchange
219274584|NCT04061369|OTHER|Low fat meal|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
219274585|NCT04061369|OTHER|Moderate fat meal|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
219274586|NCT04061369|OTHER|High fat meal|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
219274587|NCT04061369|OTHER|High fat liquid meal|Liquid meal that is high (60% of energy) in fat calories.
219274588|NCT01810939|DRUG|Patiromer|
219274589|NCT01810939|DRUG|Placebo|
219274590|NCT02963090|DRUG|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
219274591|NCT02963090|DRUG|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
219274592|NCT05065606|DIAGNOSTIC_TEST|Dual-energy computed tomography|Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively
219274593|NCT02944929|OTHER|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
219274594|NCT02484586|DEVICE|Etafilcon A|Prototype lens material
219274595|NCT02484586|DEVICE|Etafilcon A|Control lens for presbyope group
219274596|NCT02484586|DEVICE|Nelfilcon A|Control lens for presbyope group
219274597|NCT02484586|DEVICE|Nesofilcon A|Control lens for presbyope group
219274598|NCT02484586|DEVICE|Nelfilcon A|Control lens for non-presbyope group
219274599|NCT02484586|DEVICE|Etafilcon A|Control lens for non-presbyope group
219274600|NCT02484586|DEVICE|Somofilcon A|Control lens for presbyope group
219274601|NCT02484586|DEVICE|58% Poly-HEMA|Control lens for presbyope group
219274602|NCT02484586|DEVICE|Omafilcon A|Control lens for non-presbyope group
219274603|NCT01375673|OTHER|Exercise|Walking Strength Training Bicycling
219274604|NCT03953131|PROCEDURE|Computed Tomography|Undergo PET/CT
219274605|NCT03953131|RADIATION|Gallium Ga 68-DOTATATE|Given IV
219274606|NCT03953131|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219274607|NCT06417034|DEVICE|Game Software|The software is interfaced with a modified version of Frets on Fire (FOF)-an open source computer game similar to Guitar Hero.
219274608|NCT01863147|DRUG|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
219274609|NCT00374751|DRUG|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
219274610|NCT00513162|DRUG|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
219274611|NCT00513162|DRUG|Etoposide|25 - 50 mg/m\^2 By Mouth Daily
219274612|NCT03059277|DRUG|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
219274613|NCT02700542|OTHER|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
219274614|NCT06198270|OTHER|Closed Kinetic Chain Exercise|Closed chain exercise plan of 5 exercises, 10reps x 3sets of each, 3 days in a week for 4-weeks, all values measured before and after 4-weeks.
219274615|NCT06198270|OTHER|Neuromuscular Training with K Tape|Neuromuscular training plan of 5 exercises, 10reps x 3sets of each, 3 days in a week, for 4-weeks, all values measured before and after 4-weeks. Just After the session k-tape applied.
219274616|NCT02179177|DRUG|Apixaban|Drug is taken by mouth twice a day for 6 months
219274617|NCT02179177|DRUG|Placebo|
219274618|NCT04770727|BEHAVIORAL|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
219274619|NCT03995927|OTHER|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
219274620|NCT03995927|OTHER|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
219274621|NCT02438553|DEVICE|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
219274622|NCT02438553|DEVICE|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
219274623|NCT01660386|DRUG|Sitagliptin|100mg po once
219274624|NCT01660386|DRUG|Saxagliptin|5mg po once
219274625|NCT01660386|DRUG|Glimepiride|2mg po once
219274626|NCT01660386|DRUG|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
219274627|NCT04974333|DEVICE|Mobile health application on phone|Patients will use a mobile app on their smart phones
219274628|NCT04340661|DIETARY_SUPPLEMENT|BIOintestil|Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)
219274629|NCT04340661|DIETARY_SUPPLEMENT|PLACEBO|Cornstarch
219274630|NCT03843853|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
219274631|NCT03843853|DRUG|S-1|S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14
219274632|NCT03843853|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg d1
219274633|NCT05127759|DRUG|HLX208|HLX208 450mg bid po
219274634|NCT00008476|DRUG|Capsaicin|
219274635|NCT06273449|DEVICE|Group 3 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing
219274636|NCT06273449|DEVICE|Group 2 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
219274637|NCT00137410|DRUG|Celebrex|
219274638|NCT02036437|DRUG|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
219274639|NCT02036437|DRUG|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
219274640|NCT05678283|DRUG|[14C]CC-90010|Specified dose on specified days
219274641|NCT05678283|DRUG|CC-90010|Specified dose on specified days
219274642|NCT05044923|DEVICE|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
219274643|NCT02349152|DRUG|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
219274644|NCT02349152|DRUG|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
219274645|NCT04873427|GENETIC|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
219274646|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
219274647|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
219274648|NCT06074705|DRUG|DS-1471a|Intravenous administration on Day 1 of each 28-day cycle
219274649|NCT00884650|DRUG|oral analgesic|per clinical standard of care
219274650|NCT00884650|DRUG|intravenous analgesic per pump|per clinical standard of care
219274651|NCT00919204|DRUG|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
219274652|NCT02054676|RADIATION|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~* Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~* Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
219274653|NCT02054676|PROCEDURE|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~* implant drill slippage deeper than planned;~* implant threads coverage;~* etc."
219274654|NCT02054676|DEVICE|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
219274655|NCT02054676|RADIATION|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
219274656|NCT02054676|DRUG|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
219274657|NCT02054676|PROCEDURE|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
219274658|NCT02385383|DRUG|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
219274659|NCT02385383|OTHER|Standard Care|Standard Care in a historical control cohort
219274660|NCT02605746|DRUG|ceritinib 750mg|
219274661|NCT05932147|OTHER|Pilates exercise|"1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise."
219274662|NCT05932147|OTHER|Manual lymphatic massage|"procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes."
219274663|NCT06009042|DRUG|IVIG 20g/d|The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
219274664|NCT06009042|DRUG|IVIG 10g/d|The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
219274665|NCT00003058|DRUG|troglitazone|
219274666|NCT00531622|DRUG|saredutant (SR48968)|oral administration, capsules
219274667|NCT00531622|DRUG|escitalopram|oral administration, capsules
219274668|NCT00531622|DRUG|placebo|oral administration, capsules
219274669|NCT05688618|DIETARY_SUPPLEMENT|Enteroccocus Facieum and Agave Inulin|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
219274670|NCT05688618|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
219274671|NCT06155097|DRUG|transversus thoracis muscle plane block (TTP)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.
219274672|NCT06155097|DRUG|parasternal intercostal nerve block (PSI block)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
219274673|NCT03670251|PROCEDURE|Blood sampling|Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
219274674|NCT03272503|DRUG|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
219274675|NCT03272503|DRUG|Placebo Oral Tablet|Identical matching placebo lactose tablets
219274676|NCT00979953|DRUG|ADL5859|
219274677|NCT00979953|DRUG|ADL5747|
219274678|NCT00979953|DRUG|Oxycodone CR|
219274679|NCT00979953|DRUG|Placebo|
219274680|NCT03681743|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
219274681|NCT05625932|DRUG|Tinzaparin|Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.
219274682|NCT02154906|DEVICE|DFDBA|
219274683|NCT02154906|DEVICE|autologous platelet rich fibrin|
219274684|NCT03755011|DEVICE|white noise|Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
219274685|NCT03755011|BEHAVIORAL|usual care|normal ICU activity noise
219274686|NCT03903718|DRUG|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
219274687|NCT03903718|BIOLOGICAL|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
219274688|NCT03903718|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
219274689|NCT01173978|BEHAVIORAL|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
219274690|NCT01173978|OTHER|No intervention|
219274691|NCT02847442|DRUG|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
219274692|NCT02847442|DRUG|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
219274693|NCT04619602|DRUG|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
219274694|NCT03023553|BIOLOGICAL|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
219274695|NCT03023553|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
219274696|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
219274697|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
219274698|NCT05187429|DRUG|Saline|Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
219274699|NCT03526653|OTHER|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
219274700|NCT03526653|OTHER|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
219274701|NCT03526653|OTHER|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
219274702|NCT05344677|OTHER|Trendelenburg Position|Group 1 (trendlenburg position group) in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period.
219274703|NCT05344677|OTHER|Warm Pad Application|• Group 2 (warm pad application group) in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
219274704|NCT05344677|BEHAVIORAL|Deep Breathing Exercise|• Group 3: (deep breathing group) the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers.
219274705|NCT04829747|DRUG|Atogepant|Oral Tablet
219274706|NCT02330094|DRUG|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
219274707|NCT02330094|DRUG|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
219274708|NCT00787306|BEHAVIORAL|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
219274709|NCT02667106|DRUG|RX0041-2|Pharmacokinetic study
219274710|NCT01168947|OTHER|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
219274711|NCT02615509|RADIATION|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
219274712|NCT05410093|DRUG|Resveratrol|Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
219274713|NCT05410093|DRUG|Vitamin E|Take vitamin E at a dose of 100 mg per day for three months
219274714|NCT02563548|DRUG|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
219274715|NCT02563548|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
219274716|NCT03321110|OTHER|Placebo|Placebo (dextrin)
219274717|NCT03321110|DIETARY_SUPPLEMENT|Coenzyme Q10|150 mg or 300 mg
219274718|NCT02946671|BIOLOGICAL|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
219274719|NCT02946671|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
219274720|NCT05096039|DRUG|Sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
219274721|NCT05096039|DRUG|ACEI or ARB and no sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
219274722|NCT01233661|OTHER|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
219274723|NCT02497846|DEVICE|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
219274724|NCT02420249|BEHAVIORAL|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
219274725|NCT01322191|DRUG|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
219274726|NCT03274453|DRUG|Ketamine|0.12 mg/kg/hr of ketamine post surgery
219274727|NCT03274453|DRUG|Saline|Saline will be administered at the same rate as the ketamine infusion.
219274728|NCT02503319|DRUG|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
219274729|NCT02503319|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
219274730|NCT02503319|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
219274731|NCT00583466|DRUG|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
219274732|NCT00583466|DRUG|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
219274733|NCT00583466|DRUG|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
219274734|NCT01516749|DRUG|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
219274735|NCT01732549|DRUG|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
219274736|NCT01732549|DRUG|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
219274737|NCT00351377|DRUG|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
219274738|NCT04035980|BEHAVIORAL|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
219274739|NCT04076462|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
219274740|NCT04076462|DRUG|Matching placebo|Matching placebo for CAM2029
219274741|NCT03432468|DRUG|Valsartan 1|the high dose of valsartan
219274742|NCT03432468|DRUG|Valsartan 80 mg|a single dose of valsartan
219274743|NCT02932930|PROCEDURE|QLB bloc|
219274744|NCT02932930|DRUG|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
219274745|NCT02932930|DRUG|0.9% normal saline|0,2ml/kg of 0.9% normal saline
219274746|NCT05580835|DIAGNOSTIC_TEST|PET MRI with PSMA|A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
219274747|NCT04324216|OTHER|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
219274748|NCT02036138|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
219274749|NCT02036138|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
219274750|NCT02036138|DRUG|Advanced Medical Therapy|
219274751|NCT02209090|PROCEDURE|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
219274752|NCT02209090|PROCEDURE|maternal free positions|At least 40 minutes each hour during labour
219274753|NCT02723227|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
219274754|NCT02723227|BEHAVIORAL|Referral to Social Services|
219274755|NCT02935803|PROCEDURE|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
219274756|NCT01661608|DEVICE|Using the EOS for gastric restriction|
219274757|NCT00001039|DRUG|Ethambutol hydrochloride|
219274758|NCT00001039|DRUG|Clarithromycin|
219274759|NCT05063877|DRUG|Placebo|Matched placebo
219274760|NCT05063877|DRUG|EQU-001|EQU-001 in 10 mg and 20 mg capsules
219274761|NCT02897505|BEHAVIORAL|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
219274762|NCT02727244|PROCEDURE|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
219274763|NCT02805712|OTHER|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
219274764|NCT02805712|OTHER|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
219274765|NCT04355377|OTHER|Non intervention|Non intervention
219274766|NCT04487678|DIETARY_SUPPLEMENT|Ketone ester supplement|Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
219274767|NCT02492230|DEVICE|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
219274768|NCT02492230|DRUG|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
219274769|NCT02849613|OTHER|Adipose Derived Stem Cells|
219274770|NCT02849613|OTHER|Vehicle media|
219274771|NCT00280215|DRUG|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
219274772|NCT00280215|DRUG|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
219274773|NCT00280215|DRUG|Placebo|Patients will receive placebo for 24 months
219274774|NCT03845140|DRUG|L-PZQ ODT 50 mg/kg|Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
219274775|NCT03845140|DRUG|Biltricide®|Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.
219274776|NCT03845140|DRUG|L-PZQ ODT 60 mg/kg|Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
219274777|NCT05689892|OTHER|Decision Coach Sessions|"Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors."
219274778|NCT02986945|BEHAVIORAL|Resiliency App|
219274779|NCT00013585|DRUG|Selegiline hydrochloride|
219274780|NCT00200070|DEVICE|Spinal Cord Stimulation|
219274781|NCT03724253|DRUG|[68Ga]-NeoBOMB1|\[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
219274782|NCT03186001|DRUG|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
219274783|NCT01150461|DRUG|losartan|Losartan 50 mg b.i.d
219274784|NCT01150461|DRUG|placebo|Placebo b.i.d.
219274785|NCT01681992|BIOLOGICAL|Priorix|Subjects receive one dose of either minimum (Inv\_MMR\_Min) or medium (Inv\_MMR\_Med) potency lot at Day 0 and a dose of separate potency lot (Inv\_MMR\_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
219274786|NCT01681992|BIOLOGICAL|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
219274787|NCT01681992|BIOLOGICAL|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
219274788|NCT01681992|BIOLOGICAL|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
219274789|NCT01681992|BIOLOGICAL|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
219274790|NCT03728751|PROCEDURE|Dry needling|Paravertebral dry needling C7-T4. Total of 8 needles.
219274791|NCT04785118|DRUG|Hyoscine N Butylbromide|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
219274792|NCT04785118|DRUG|Ondansetron|Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
219274793|NCT04785118|DRUG|Saline|Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
219274794|NCT03750864|BEHAVIORAL|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance \& Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
219274795|NCT04043897|DRUG|Rifaximin 550mg|Rifaximin 550mg
219274796|NCT01267773|BEHAVIORAL|Integrated Treatment|
219274797|NCT01546246|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
219274798|NCT05230953|BIOLOGICAL|mRNA1273 vaccine|fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM
219274799|NCT01891019|DRUG|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
219274800|NCT04849767|OTHER|Questionnaire|Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
219274801|NCT04223544|DIAGNOSTIC_TEST|Influenza POC and laboratory testing|Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
219274802|NCT05627453|OTHER|Arm-in-arm gait training|An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
219274803|NCT05627453|OTHER|Normal gait training|An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
219274804|NCT02194504|OTHER|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
219274805|NCT02194504|OTHER|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
219274806|NCT04991376|DIAGNOSTIC_TEST|Blood-specific miRNA levels|Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.
219274807|NCT03840005|DRUG|Ursonorm|Ursodeoxycholic acid
219274808|NCT03471858|DEVICE|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
219274809|NCT03471858|DRUG|Prostaglandins|Prostin will be used in the control arm.
219274810|NCT04867447|DIAGNOSTIC_TEST|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE)."
219274811|NCT04351945|PROCEDURE|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
219274812|NCT01434745|DRUG|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
219274813|NCT01434745|DIETARY_SUPPLEMENT|Lactose|Lactose will be administered in a capsule formula.
219274814|NCT03209947|DIAGNOSTIC_TEST|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
219274815|NCT01046045|DRUG|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
219274816|NCT06186947|OTHER|No intervention|Participants are not subjected to any specific intervention.
219274817|NCT03644524|BEHAVIORAL|Heat therapy|Regular hot tub use
219274818|NCT06429982|DRUG|Dexamethasone|Steroid five day treatment
219274819|NCT06429982|DRUG|Placebo|Placebo control group
219274820|NCT03085056|DRUG|Trametinib|trametinib orally 2mg daily during each 4 week cycle
219274821|NCT03085056|DRUG|Paclitaxel|paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
219274822|NCT06555393|DIETARY_SUPPLEMENT|Egg White Powder|"Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption."
219274823|NCT04229810|PROCEDURE|STD-02|Conventional standardized ventilatory approach.
219274824|NCT04229810|PROCEDURE|iOLA-iHFNC|Indivudualized perioperative open lung ventilatory approach.
219274825|NCT00525278|DRUG|Levocetirizine dihydrochloride|
219274826|NCT02281123|OTHER|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
219274827|NCT06243237|PROCEDURE|Acupuncture|Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
219274828|NCT06243237|PROCEDURE|Sham Acupuncture(Superficial Acupuncture)|Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
219274829|NCT03509246|DRUG|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
219274830|NCT06383650|DRUG|Acetylsalicylic Acid|Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
219274831|NCT01139853|DEVICE|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
219274832|NCT02712749|DEVICE|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
219274833|NCT02712749|DEVICE|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
219274834|NCT03034590|OTHER|questionnaire|
219274835|NCT02117986|DRUG|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
219274836|NCT03937141|DRUG|ADU-S100|intratumoral
219274837|NCT03400683|DRUG|Misoprostol|200 microgram misoprostol in sublingual every four hours for a maximum of five doses
219274838|NCT03400683|DRUG|Letrozole|15mg( letrozole 2.5mg) on three successive day
219274839|NCT03400683|PROCEDURE|Foley's catheter|transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions
219274840|NCT00335101|DRUG|Iodixanol, Ioversol, Iopromide|
219274841|NCT04779437|BEHAVIORAL|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
219274842|NCT04779437|BEHAVIORAL|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
219274843|NCT00780455|DRUG|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
219274844|NCT00780455|DRUG|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
219274845|NCT05780086|DRUG|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
219274846|NCT03690427|OTHER|Traditional hookah smoking|Charcoal-heated hookah smoking
219274847|NCT03690427|OTHER|Electronic hookah vaping|Electronic hookah bowl inhalation
219274848|NCT00673907|OTHER|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
219274849|NCT02510833|BEHAVIORAL|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
219274850|NCT02510833|BEHAVIORAL|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
219274851|NCT02251236|DRUG|Stribild|To be administered orally, once daily with food.
219274852|NCT02251236|DRUG|Genvoya|To be administered orally, once daily with food.
219274853|NCT03002298|BEHAVIORAL|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
219274854|NCT03002298|BEHAVIORAL|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
219274855|NCT03002298|BEHAVIORAL|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
219274856|NCT03002298|BEHAVIORAL|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
219274857|NCT00136643|DRUG|Invisible Condom®|
219274858|NCT04591171|PROCEDURE|n-of-1 trial guided clinical decision making|The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
219274859|NCT02609672|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
219274860|NCT02609672|OTHER|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
219274861|NCT05725772|OTHER|Location of Visit|Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
219274862|NCT00509132|DRUG|trodusquemine|
219274863|NCT00867971|OTHER|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
219274864|NCT04122547|DRUG|Roflumilast|Active drug
219274865|NCT04122547|DRUG|Placebo|Placebo one tablet oral od
219274866|NCT03353597|BIOLOGICAL|Plasma Transfusion|All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
219274867|NCT06297044|OTHER|Neuropsychological assessment|"* APACS assessing various aspects of pragmatic communication abilities;~* SET assessing cognitive and emotional theory of mind;~* COAST assessing functional communication impairments in daily activities and their impact on the quality of life after the illness onset;~* PWB assessing the individual's perceived quality of life and psychological well-being;~* other neuropsychological assessment tools depending on the participant's pathology and routinely used in the clinical practice within the Institution."
219274868|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219274869|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219274870|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219274871|NCT02956837|DRUG|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
219274872|NCT02597712|DRUG|YF476|gastrin receptor antagonist
219274873|NCT02597712|DRUG|YF476 placebo|placebo
219274874|NCT00263653|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
219274875|NCT05276089|BEHAVIORAL|Video message|"The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses:~1. I would like to reduce my opioid medication with support.~2. I understand this video but I want to continue my current dose.~3. I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information."
219274876|NCT00001072|BIOLOGICAL|ALVAC-HIV MN120TMGNP (vCP300)|
219274877|NCT00001072|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
219274878|NCT00001072|BIOLOGICAL|rgp120/HIV-1 SF-2|
219274879|NCT02637323|DRUG|FX006 32 mg|Single 5 mL IA injection
219274880|NCT02637323|DRUG|TCA IR 40|Single 1 mL IA injection
219274881|NCT02437942|OTHER|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
219274882|NCT06126679|PROCEDURE|1-year dietary and physical activity intervention of childhood obesity|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The participants in the intervention group are advised and motivated to increase their regular daily physical activity and to reduce sedentary habits. They have one group session for the training in the gymnasium with physical education instructor. The physical education instructor gives a voluntary lecture for parents about increasing physical activity and reducing sedentary time."
219274883|NCT01121705|DRUG|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
219274884|NCT05719753|DEVICE|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
219274885|NCT05719753|DEVICE|Standard Care|Bard Catheter
219274886|NCT00513708|BEHAVIORAL|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
219274887|NCT00513708|BEHAVIORAL|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
219274888|NCT03377296|OTHER|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
219274889|NCT03377296|PROCEDURE|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
219274890|NCT06089005|DEVICE|Instrument Assisted Soft Tissue Mobilization device|Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
219274891|NCT00292097|PROCEDURE|Early tracheostomy|early conversion - less than or equal to 72 hours
219274892|NCT00292097|PROCEDURE|Late tracheostomy|Late conversion (10-14 days)
219274893|NCT04017338|DRUG|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
219274894|NCT04017338|DRUG|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
219274895|NCT04017338|DEVICE|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
219274896|NCT02164903|OTHER|QoL Survey Booklet|
219274897|NCT03308175|DEVICE|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
219274898|NCT03308175|DEVICE|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
219274899|NCT00607581|DRUG|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
219274900|NCT00607581|DRUG|lenalidomide|lenalidomide: 15 mg orally on days 1-21
219274901|NCT00607581|DRUG|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
219274902|NCT02588872|BIOLOGICAL|Platelet-rich Plasma (PRP)|
219274903|NCT02588872|BIOLOGICAL|Hyaluronic Acid|
219274904|NCT06453070|OTHER|No intervention was made|No intervention was made
219274905|NCT01998789|DRUG|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
219274906|NCT01998789|DRUG|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
219274907|NCT05105776|DEVICE|Galvanic stimulation|Galvanic stimulation during physiotherapy sessions
219274908|NCT05114343|BEHAVIORAL|Exercise|Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.
219274909|NCT02770729|DRUG|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
219274910|NCT02770729|DRUG|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
219274911|NCT04781270|DRUG|mFOLFOXIRI regimen|oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
219274912|NCT04781270|DRUG|mFOLFOX regimen|oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
219274913|NCT04781270|DRUG|Bevacizumab|5 mg/kg on day 1
219274914|NCT02464605|BIOLOGICAL|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
219274915|NCT04277884|DRUG|Firibastat|Oral administration 2×250 mg capsules bid
219274916|NCT04277884|DRUG|Placebo|Oral administration 2 capsules bid
219274917|NCT03274895|DRUG|PHMB 0.08%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
219274918|NCT03274895|DRUG|Propamidine 0.1%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
219274919|NCT03274895|DRUG|placebo|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
219274920|NCT03274895|DRUG|PHMB 0.02%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
219274921|NCT01093469|DRUG|Atopiclair Nonsteroidal Cream|
219274922|NCT01093469|OTHER|Aquaphor Healing Ointment|
219274923|NCT01093469|DRUG|EpiCeram|
219274924|NCT06086288|DRUG|Pembrolizumab, Etoposide, Cisplatin or Carboplatin|Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg
219274925|NCT00401258|DRUG|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
219274926|NCT00521157|DRUG|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
219274927|NCT02469142|PROCEDURE|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
219274928|NCT02497989|OTHER|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
219274929|NCT02497989|OTHER|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
219274930|NCT01328353|OTHER|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
219274931|NCT00343070|DRUG|Oral administration of escitalopram during 8 weeks|
219274932|NCT00360295|DRUG|Azithromycin SR|
219274933|NCT04309591|DEVICE|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
219274934|NCT03037203|DRUG|JZP-110|75 mg, 150 mg, 300 mg
219274935|NCT03037203|OTHER|Placebo|
219274936|NCT01549834|DRUG|ABT-126|Low Dose
219274937|NCT01549834|DRUG|ABT-126|High Dose
219274938|NCT01549834|DRUG|placebo|Placebo
219274939|NCT02546297|DRUG|Symbicort|drug are used for 12 months
219274940|NCT02546297|DRUG|Spiriva|drug are used for 12 months
219274941|NCT03949400|OTHER|Exercise therapy and education.|Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
219274942|NCT04239677|PROCEDURE|Conventional crystalloid solution-based priming|CPB circuit is also prepared with crystalloid solution-based priming in all participants (same as the RAP group). In this group (control group), CPB is initiated with antegrade priming (conventional priming).
219274943|NCT04239677|PROCEDURE|Retrograde autologous priming|CPB circuit is prepared with crystalloid solution-based priming in all participants. In RAP group, retrograde autologous priming is performed by displacing the crystalloid priming volume of arterial and venous lines via passive exsanguination of native blood prior to CPB initiation.
219274944|NCT04356534|OTHER|plasma therapy using convalescent plasma with antibody against SARS-CoV-2|convalescent patient plasma plus routine local standard of care
219274945|NCT04356534|OTHER|Routine care for COVID-19 patients|local standard of care which include antivirals and supportive care
219274946|NCT05714605|BEHAVIORAL|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
219274947|NCT05616676|BEHAVIORAL|Brief digital imagery-competing task|"First session guided by a researcher: A memory cue followed by playing a computer game with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session."
219274948|NCT05616676|BEHAVIORAL|Brief digital music-listening task|"First session guided by a researcher: Information about the composer's music followed by listening to classical music.~Option to engage in self-administered/guided sessions after the first session."
219274949|NCT05616676|OTHER|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events.
219274950|NCT01004523|GENETIC|fluorescence in situ hybridization|
219274951|NCT01004523|GENETIC|loss of heterozygosity analysis|
219274952|NCT01004523|GENETIC|polymerase chain reaction|
219274953|NCT01004523|OTHER|flow cytometry|
219274954|NCT01004523|OTHER|immunohistochemistry staining method|
219274955|NCT04743531|BEHAVIORAL|HEROs|Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
219274956|NCT05299255|DRUG|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
219274957|NCT05299255|DRUG|Placebo|the placebo as control group.
219274958|NCT01788293|OTHER|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports \[Cannesson et al., 2008; Zimmermann et al., 2010\].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
219274959|NCT05165927|DEVICE|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
219274960|NCT05170815|PROCEDURE|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
219274961|NCT04380883|DEVICE|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
219274962|NCT04380883|DEVICE|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
219274963|NCT06069453|DEVICE|Hyaluronic Acid (HA) sodium salt and Hydeal-D|intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
219274964|NCT00020761|DRUG|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
219274965|NCT00020761|DRUG|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
219274966|NCT01405677|BIOLOGICAL|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
219274967|NCT01405677|BIOLOGICAL|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
219274968|NCT01405677|BIOLOGICAL|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
219274969|NCT01584518|DRUG|Furosemide|Based on clinical standard per clinician
219274970|NCT03124147|DEVICE|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
219274971|NCT03013140|DRUG|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%"
219274972|NCT03013140|PROCEDURE|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
219274973|NCT01383330|DRUG|megace|800mg
219274974|NCT01383330|DRUG|DW-ES(A)|625mg
219274975|NCT01383330|DRUG|DW-ES(B)|625mg
219274976|NCT00603811|BIOLOGICAL|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
219274977|NCT00603811|BIOLOGICAL|Placebo|Placebo
219274978|NCT04792398|DRUG|Incobotulinumtoxin A (BTX A) Xeomin®|Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
219274979|NCT02803099|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
219274980|NCT04751240|BEHAVIORAL|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
219274981|NCT00617929|BIOLOGICAL|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
219274982|NCT00617929|BIOLOGICAL|rituximab|administered 375 mg/m\^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
219274983|NCT00617929|DRUG|clofarabine|administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
219274984|NCT00617929|PROCEDURE|stem cell transplantation|administered on Day 0 per institutional guidelines.
219274985|NCT04355936|DRUG|Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.|Control arm will receive standard care.
219274986|NCT04479072|DRUG|Aspirin 81 mg|Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
219274987|NCT04479072|DRUG|Placebo|Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
219274988|NCT02134509|BEHAVIORAL|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
219274989|NCT02134509|BEHAVIORAL|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
219274990|NCT00107523|DRUG|cytarabine|
219274991|NCT00107523|DRUG|idarubicin|
219274992|NCT00107523|DRUG|pravastatin|
219274993|NCT04502992|BEHAVIORAL|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
219274994|NCT01309698|DRUG|Vildagliptin (LAF237)|
219274995|NCT01309698|DRUG|Voglibose|
219274996|NCT01309698|DRUG|Vildagliptin and Voglibose|
219274997|NCT01035541|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
219274998|NCT00724386|DRUG|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
219274999|NCT00724386|DRUG|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
219275000|NCT00724386|DRUG|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
219275001|NCT00724386|RADIATION|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
219275002|NCT01638845|PROCEDURE|continuous perineural catheter|continuous perineural catheter
219275003|NCT01512550|PROCEDURE|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
219275004|NCT01512550|PROCEDURE|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
219275005|NCT01512550|DEVICE|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
219275006|NCT05284955|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
219275007|NCT05284955|DRUG|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
219275008|NCT05672771|BEHAVIORAL|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
219275009|NCT05672771|BEHAVIORAL|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
219275010|NCT05672771|BEHAVIORAL|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
219275011|NCT05672771|BEHAVIORAL|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
219275012|NCT03374293|RADIATION|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
219275013|NCT03374293|DRUG|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
219275014|NCT01838954|DEVICE|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
219275015|NCT00760747|DRUG|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
219275016|NCT01443923|DRUG|Boceprevir|
219275017|NCT01443923|DRUG|Peg-Interferon-alfa 2B|
219275018|NCT01443923|DRUG|Ribavirin|
219275019|NCT02083289|DRUG|ONO-9054|
219275020|NCT02083289|DRUG|Latanoprost|
219275021|NCT02784964|BIOLOGICAL|Elixcyte 8 ml|ADSC 6.4\*10\^7 cells, allogeneic injection
219275022|NCT02784964|DEVICE|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
219275023|NCT02784964|BIOLOGICAL|Elixcyte 4 ml|ADSC 3.2\*10\^7 cells, allogeneic injection
219275024|NCT02784964|BIOLOGICAL|Elixcyte 2 ml|ADSC 1.6\*10\^7 cells, allogeneic injection
219275025|NCT01021371|BEHAVIORAL|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
219275026|NCT02529423|DIETARY_SUPPLEMENT|Multi-nutrient supplement|"* Omega 3 fatty acids~* Folic acid~* Calcium~* Selenium~* Vitamin D3"
219275027|NCT02529423|BEHAVIORAL|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood-related snacking) and helpful food-related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
219275028|NCT02529423|OTHER|Placebo|Placebo pills identical in look and taste but including no active ingredients
219275029|NCT00061425|DRUG|radiolabeled epratuzumab|
219275030|NCT03566979|DRUG|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
219275031|NCT03566979|DRUG|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
219275032|NCT03566979|DRUG|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
219275033|NCT03566979|DRUG|Placebo tablet|2 placebo tablets
219275034|NCT01856517|DRUG|Clonidine|
219275035|NCT01856517|DRUG|Placebo|
219275036|NCT03941899|OTHER|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
219275037|NCT05961540|OTHER|Conventional care|"1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
219275038|NCT05961540|BEHAVIORAL|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD."
219275039|NCT00480051|DEVICE|Cardiac Resynchronization Pacing|
219275040|NCT00902811|DRUG|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
219275041|NCT00902811|DRUG|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
219275042|NCT00902811|DRUG|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
219275043|NCT00902811|DRUG|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group \<6yrs of age, a subdivision according to weight is made
219275044|NCT00902811|DRUG|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
219275045|NCT04622098|PROCEDURE|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci."
219275046|NCT06222242|BEHAVIORAL|mychoiceTM|mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
219275047|NCT00000104|PROCEDURE|ERP measures of attention and memory|
219275048|NCT02498262|OTHER|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
219275049|NCT00323206|BIOLOGICAL|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
219275050|NCT00323206|PROCEDURE|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
219275051|NCT01642433|DRUG|Placebo|Placebo capsules, 3x daily
219275052|NCT01642433|DRUG|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
219275053|NCT05440747|OTHER|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
219275054|NCT02761447|OTHER|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
219275055|NCT02761447|OTHER|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
219275056|NCT01082237|DRUG|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
219275057|NCT02808247|DRUG|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
219275058|NCT02808247|DRUG|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
219275059|NCT06319183|DRUG|Salbutamol|We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
219275060|NCT01303315|DEVICE|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
219275061|NCT00108745|OTHER|Clinical Observation|Undergo observation
219275062|NCT00108745|OTHER|Laboratory Biomarker Analysis|Correlative studies
219275063|NCT00108745|DRUG|Paclitaxel|Given IV
219275064|NCT00108745|DRUG|Paclitaxel Poliglumex|Given IV
219275065|NCT00108745|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219275066|NCT00307476|DEVICE|Rusch Nasopharyngeal Airway|For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
219275067|NCT01889069|DRUG|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
219275068|NCT01889069|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
219275069|NCT01889069|DRUG|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
219275070|NCT01889069|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
219275071|NCT01889069|DRUG|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
219275072|NCT01889069|DRUG|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
219275073|NCT00665093|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
219275074|NCT00665093|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
219275075|NCT03302390|PROCEDURE|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than \<3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
219275076|NCT06339749|DIAGNOSTIC_TEST|blood pressure|Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
219275077|NCT06339749|OTHER|Clinical protocols for preeclampsia risk screening|"In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester."
219275078|NCT00723749|DRUG|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
219275079|NCT06156917|DIAGNOSTIC_TEST|diagnostic accuracy|Aims of the present project are: to investigate the relationship between incident PD dementia and multimodal parameters as cardiovascular autonomic dysfunction, altered cerebral glucose metabolism, and genetic biomarkers; development of an algorithm predictive for PD-related dementia, combining the rele- vant multidimensional parameters under study; longitudinal follow-up of clinical and cognitive status in PD patients with and without dementia along four years.
219275080|NCT00533364|DRUG|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
219275081|NCT00002489|BIOLOGICAL|dactinomycin|
219275082|NCT00002489|BIOLOGICAL|filgrastim|
219275083|NCT00002489|DRUG|carboplatin|
219275084|NCT00002489|DRUG|cyclophosphamide|
219275085|NCT00002489|DRUG|doxorubicin hydrochloride|
219275086|NCT00002489|DRUG|etoposide|
219275087|NCT00002489|DRUG|leucovorin calcium|
219275088|NCT00002489|DRUG|methotrexate|
219275089|NCT00002489|DRUG|vincristine sulfate|
219275090|NCT00002489|PROCEDURE|conventional surgery|
219275091|NCT01426347|DRUG|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
219275092|NCT01426347|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
219275093|NCT03203837|OTHER|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
219275094|NCT00135681|DRUG|nedocromil budesonide|
219275095|NCT00455741|DRUG|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
219275096|NCT00455741|DRUG|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
219275097|NCT05102058|DRUG|Magnesium-Dexmedetomidine|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
219275098|NCT01635023|DRUG|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
219275099|NCT01635023|DRUG|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
219275100|NCT01635023|DRUG|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
219275101|NCT01635023|DRUG|AZD6244 Dosing Period 4|Treatment B
219275102|NCT00989547|OTHER|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
219275103|NCT05987254|PROCEDURE|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
219275104|NCT05987254|PROCEDURE|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
219275105|NCT01727869|DRUG|REGN1400|
219275106|NCT01727869|DRUG|Erlotinib|
219275107|NCT01727869|DRUG|Cetuximab|
219275108|NCT04699760|DIETARY_SUPPLEMENT|Fish Oil|8 weeks, 2.2 G EPA/day
219275109|NCT04699760|DIETARY_SUPPLEMENT|Placebo|Placebo
219275110|NCT01606410|OTHER|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
219275111|NCT01292304|DRUG|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
219275112|NCT03028597|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
219275113|NCT03028597|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
219275114|NCT02903017|DRUG|Tranexamic acid 5%|Via nasogastric tube, 100 mL
219275115|NCT02903017|DRUG|Placebo|Via nasogastric tube, 100 mL
219275116|NCT02332902|DRUG|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
219275117|NCT04682132|DIAGNOSTIC_TEST|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
219275118|NCT02043743|BIOLOGICAL|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
219275119|NCT03998449|BIOLOGICAL|Vaccination against cholera|Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
219275120|NCT04865042|DRUG|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
219275121|NCT04865042|DRUG|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
219275122|NCT01160627|OTHER|Hydration|Saline hydration
219275123|NCT01160627|DRUG|Acetylcysteine|Acetylcystein tablets for 2 days
219275124|NCT01160627|DRUG|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
219275125|NCT01160627|DRUG|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
219275126|NCT00002341|DRUG|Itraconazole|
219275127|NCT05345730|DIAGNOSTIC_TEST|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
219275128|NCT05614518|DRUG|Sodium Fluoride F-18 Injection|Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
219275129|NCT05614518|DRUG|Technetium[99mTc] Methylenediphosphonate Injection|Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
219275130|NCT00574418|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
219275131|NCT02848768|DRUG|Sunitinib|
219275132|NCT01476605|PROCEDURE|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
219275133|NCT01476605|PROCEDURE|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
219275134|NCT01476605|PROCEDURE|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
219275135|NCT01245374|DEVICE|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
219275136|NCT02762188|DEVICE|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
219275137|NCT06211777|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219275138|NCT06211777|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219275139|NCT06211777|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219275140|NCT00935532|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
219275141|NCT00935532|DRUG|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
219275142|NCT01935752|OTHER|blood samples|blood samples
219275143|NCT01935752|OTHER|vascular echotracking|endothelial function study and virtual histology study
219275144|NCT06236633|PROCEDURE|Ischemic preconditioning|Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).
219275145|NCT06236633|PROCEDURE|Arteriogram|The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).
219275146|NCT02592915|DRUG|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
219275147|NCT02592915|OTHER|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
219275148|NCT05445947|BEHAVIORAL|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
219275149|NCT00658294|OTHER|Stop treatment|
219275150|NCT02809560|PROCEDURE|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
219275151|NCT00614562|DEVICE|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
219275152|NCT02280876|DRUG|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."
219275153|NCT02280876|DRUG|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"
219275154|NCT02380053|DRUG|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
219275155|NCT02380053|DRUG|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
219275156|NCT00178854|DRUG|Risperidone|
219275157|NCT00000685|DRUG|Zidovudine|
219275158|NCT05516043|PROCEDURE|Implantation with POLYTHESE®|thoracic vascular surgery, abdominal vascular surgery and peripheral vascular surgery
219275159|NCT01422473|DEVICE|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
219275160|NCT04174209|BEHAVIORAL|Cylinder|Patients who receive the Jackson Cross Cylinder Method
219275161|NCT04174209|BEHAVIORAL|Dial|Patients who receive the Astigmatic Dial Technique Method.
219275162|NCT04174209|BEHAVIORAL|Slit|Patients who receive the Stenopeic slit Method.
219275163|NCT00001046|BIOLOGICAL|MF59|
219275164|NCT00001046|BIOLOGICAL|rgp120/HIV-1 SF-2|
219275165|NCT00223275|DRUG|Naltrexone|
219275166|NCT04954326|DRUG|Lyophilized S95014|"Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
219275167|NCT04954326|DRUG|Liquid S95014|"Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
219275168|NCT00475228|DRUG|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem
219275169|NCT05331469|DRUG|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
219275170|NCT03188653|OTHER|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
219275171|NCT03188653|OTHER|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
219275172|NCT03188653|OTHER|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
219275173|NCT03188653|OTHER|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
219275174|NCT03188653|OTHER|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
219275175|NCT03188653|OTHER|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
219275176|NCT03188653|OTHER|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
219275177|NCT03033758|OTHER|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
219275178|NCT04554537|BEHAVIORAL|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
219275179|NCT04554537|BEHAVIORAL|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
219275180|NCT03763045|DRUG|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
219275181|NCT03763045|DRUG|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
219275182|NCT03763045|OTHER|Placebo|Placebo tablet.
219275183|NCT04721015|DRUG|ABBV-637|Intravenous (IV) Infusion
219275184|NCT04721015|DRUG|Docetaxel|Intravenous (IV) Infusion
219275185|NCT04721015|DRUG|Osimertinib|Oral Tablets
219275186|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
219275187|NCT06630221|DRUG|Eltrombopag (EPAG)|50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)
219275188|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
219275189|NCT07047586|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219275190|NCT07047586|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219275191|NCT07047456|PROCEDURE|Time of umbilical cord blood infusion|Randomization of patients according to the time of umbilical cord blood infusion
219275192|NCT07049120|DEVICE|ZENFLEX Pro™ Peripheral Drug-eluting Stent System|The ZENFLEX Pro™ Peripheral Drug-eluting Stent System will be implanted in patients with femoropopliteal artery lesions to evaluate safety and efficacy outcomes. The device is designed to provide mechanical support and deliver antiproliferative drug locally to reduce restenosis. The procedure will be performed via standard endovascular techniques.
219275193|NCT07050420|OTHER|Training|Education on Child Abuse and Neglect
219275194|NCT07049965|PROCEDURE|Suture ligation|Participants will undergo laparoscopic appendectomy in which the base of the appendix is ligated using intracorporeal suturing with absorbable material. This is the conventional technique used to prevent stump leakage.
219275195|NCT07049965|DEVICE|Harmonic Scalpel|Participants will undergo laparoscopic appendectomy where the base of the appendix is sealed and divided using the harmonic scalpel. This ultrasonic energy-based device cuts and coagulates tissue simultaneously, potentially reducing operative time and blood loss.
219275196|NCT07049016|OTHER|restoring the MIH affected young permanent molars using Direct nanohybrid flowable composite|(Shofu)is a bioactive flowable nano-hybrid restorative with a newly developed patented nanofiller. It is indicated for all classes including occlusal and cusp. It has all of the Giomer Technology attributes, anti-bacterial, acid neutralization, and fluoride release and recharge, with improved handling and effortless polishing, and maintains a long-lasting shine. Beautifil Flow Plus X has the strength, durability, and aesthetics of a hybrid composite.
219275197|NCT07049016|OTHER|restoring the MIH affected young permanent molars using IPS e.max CAD|glass-ceramic-based restorations still offer the best translucency and esthetic qualities. The novel generation of lithium disilicate-based materials as IPS e.max CAD provides standard thickness and quick fabrication. Moreover, the adhesive technique used with this restoration type significantly raises its mechanical properties.
219275198|NCT07049211|DEVICE|Individualized online stimulation|The individualized online stimulation group will calculate precise targets based on the collected multimodal MRI (structural images, resting-state/task-state functional images, and diffusion tensor imaging), plan the coil position and placement angle of TMS through electric field simulation, and achieve individualized intervention. At the same time, when patients receive TMS treatment, they are matched with specific upper limb motor tasks. When the task starts autonomously, TMS stimulation is triggered by acceleration-EMG feedback. When the task stops or is completed, TMS stimulation also stops immediately according to the acceleration-EMG feedback to achieve real-time effects.
219275199|NCT07049211|DEVICE|Non-individualized online stimulation|In the non-individualized online stimulation group, patients receive TMS treatment synchronized with task training. However, the targeting uses traditional positioning methods, i.e., determining the target with a positioning cap instead of precise target localization.
219275200|NCT07049211|DEVICE|Sham stimulation|In the individualized online sham stimulation group, patients receive TMS treatment combined with specific tasks. The stimulation targets are the same as those in the online stimulation group, all determined by precise target localization, except that a sham stimulation coil is used for TMS stimulation.
219275201|NCT07049094|DRUG|scalp nerve block with 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution|Using 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution for scalp nerve block
219275202|NCT07049094|DRUG|scalp nerve block with 0.50% hydrochloride bupivacaine|Using 0.50% hydrochloride bupivacaine for scalp nerve block
219275203|NCT07050667|DEVICE|Cold atmospheric plasma|Treatment of chronic wounds with cold plasma
219275204|NCT07050667|DEVICE|Placebo treatment|Treatment of chronic wounds with the placebo device
219275205|NCT07050459|DRUG|SIM0686|Administered intravenously
219275206|NCT07050459|DRUG|SIM0686|Administered intravenously
219275207|NCT07050875|DEVICE|ABLE Exoskeleton|Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.
219275208|NCT06735820|DRUG|APG-115|Combination therapy of APG-115 and Selumetinib
219275209|NCT06735820|DRUG|Selumetinib|Combination therapy of APG-115 and Selumetinib
219275210|NCT07049614|DIAGNOSTIC_TEST|Diabetic Patients|"This group consists of 66 adult diabetic patients (Type 1 or Type 2) undergoing elective general surgical procedures. These patients will be managed as per standard clinical protocols, including preoperative evaluation, glycemic control assessment (via recent HbA1c and blood glucose levels), and administration of prophylactic broad-spectrum antibiotics-typically second-generation cephalosporins and metronidazole.~Postoperative follow-up will be conducted on Day 1, Day 7, and Day 14 to monitor for the development of surgical site infections (SSIs), which will be classified by the unit chief as superficial, deep, or organ/space infections."
219275211|NCT07049614|DIAGNOSTIC_TEST|Non-Diabetic Patients|This group includes 66 adult non-diabetic patients undergoing elective general surgical procedures at DHQ Hospital, Dera Ismail Khan. These participants will serve as the comparison group for evaluating the incidence and characteristics of postoperative surgical site infections (SSIs). All patients will receive standard preoperative assessments and prophylactic antibiotics (second-generation cephalosporins with metronidazole) as per institutional protocols. Postoperative follow-up will be carried out on Day 1, Day 7, and Day 14, and SSIs, if any, will be classified based on CDC criteria into superficial, deep, or organ/space infections
219275212|NCT06742333|DRUG|Bimekizumab|Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
219275213|NCT06742333|DRUG|Clobetasol|Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
219275214|NCT06854393|DRUG|0.00025% Lacripep ophthalmic solution and Placebo|Participant will receive Lacripep in one eye and placebo in the other eye at the same time.
219275215|NCT06205498|DRUG|acalabrutinib|patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
219275216|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
219275217|NCT04748042|DRUG|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
219275218|NCT04748042|DRUG|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
219275219|NCT04748042|RADIATION|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
219275220|NCT04748042|BIOLOGICAL|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
219275221|NCT04748042|DRUG|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
219275222|NCT06538844|DRUG|Intravenous infusion of human albumin|Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
219275223|NCT06538844|DRUG|Saline|Equivalent volume of isotonic saline control
219275224|NCT04383847|BEHAVIORAL|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
219275225|NCT01161381|DEVICE|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
219275226|NCT01225380|DRUG|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
219275227|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
219275228|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
219275229|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
219275230|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
219275231|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
219275232|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
219275233|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
219275234|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
219275235|NCT01225380|DRUG|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
219275236|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
219275237|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), 48 weeks
219275238|NCT03931746|DEVICE|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
219275239|NCT05454813|DEVICE|Wetness Sensing System Validation|Participants will use the Wetness Sensing System in a simulated setting in the sitting, supine and side position (participants are randomized to either the left or right side position).
219275240|NCT02758743|DRUG|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
219275241|NCT02758743|DRUG|Placebo|Placebo with no active substance will not have the effect on intervention device.
219275242|NCT00910286|OTHER|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
219275243|NCT04678531|DRUG|Swabs containing tea tree oil and chamomile oil|Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
219275244|NCT04678531|DRUG|Baby shampoo|Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
219275245|NCT04949802|DEVICE|ViaLase Laser|ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
219275246|NCT02473965|DRUG|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
219275247|NCT02473965|DRUG|Placebo|
219275248|NCT03848039|BIOLOGICAL|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
219275249|NCT03848039|DRUG|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
219275250|NCT01183390|DRUG|Anastrozole|1 mg Tablets
219275251|NCT01183390|DRUG|Anastrozole|1 mg Tablets
219275252|NCT03816761|DRUG|Fast-acting insulin aspart|In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
219275253|NCT03816761|DEVICE|iLet™|The bionic pancreas including pigtail adapters, used in insulin-only configuration
219275254|NCT04400110|DRUG|Amoxicillin and Clavulanic Acid in Oral Dose Form|50 mg/kg three times daily administered orally
219275255|NCT03384303|OTHER|Standardized meal test|Preoperatively and postoperatively standardized meal test
219275256|NCT04920266|DEVICE|Smart Cap, running and fitness exercisers only|Bottle cap
219275257|NCT04920266|DEVICE|Sweat Patch, all subjects- running, fitness, cycling|Regional contralateral forearm patch
219275258|NCT04920266|DEVICE|Reference sweat patch, all subjects - running, fitness, cycling|Regional contralateral forearm patch
219275259|NCT04920266|OTHER|Bottle Scale, all subjects - running, fitness, cycling|Bottle weight
219275260|NCT01174069|PROCEDURE|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
219275261|NCT00128297|DRUG|Pamidronate|
219275262|NCT02952859|OTHER|Irreversible electroporation|
219275263|NCT01507649|BEHAVIORAL|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
219275264|NCT01255254|PROCEDURE|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
219275265|NCT01240551|DRUG|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
219275266|NCT00398190|BEHAVIORAL|Control|Standard anti-tobacco programming
219275267|NCT00398190|BEHAVIORAL|Media Literacy|Anti-smoking media literacy curriculum intervention
219275268|NCT04331483|OTHER|Physical activity program|"Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge."
219275269|NCT04266015|DIETARY_SUPPLEMENT|Enteral nutrition formula|Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
219275270|NCT05648487|DRUG|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy."
219275271|NCT04403542|DEVICE|Lehfilcon A contact lens|Investigational silicone hydrogel contact lens
219275272|NCT04403542|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
219275273|NCT02981927|OTHER|Physical inactivity|
219275274|NCT03191513|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
219275275|NCT03191513|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
219275276|NCT03191513|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
219275277|NCT03325790|DRUG|200mg SPI-1005 BID|Active: low dose
219275278|NCT03325790|DRUG|400mg SPI-1005 BID|Active: high dose
219275279|NCT03325790|OTHER|Placebo|Placebo Comparator
219275280|NCT05864651|OTHER|Tele-exercise program|The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program
219275281|NCT05864651|OTHER|Conventional Fencing Exercise|The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite \& Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
219275282|NCT04198155|RADIATION|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
219275283|NCT00336518|DRUG|peginterferon alfa-2a|
219275284|NCT00336518|DRUG|ribavirin|
219275285|NCT01730950|BIOLOGICAL|bevacizumab|Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.
219275286|NCT01730950|RADIATION|radiation therapy|Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
219275287|NCT06249997|DRUG|Leniolisib|The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
219275288|NCT00006501|PROCEDURE|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
219275289|NCT04091698|DRUG|Co-Enzyme Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
219275290|NCT05591053|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
219275291|NCT05168462|DRUG|Reduced noradrenaline use|Reduced noradrenaline by using a lower MAP target
219275292|NCT02080962|RADIATION|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
219275293|NCT02080962|RADIATION|40 Gy in 10 fractions|tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
219275294|NCT04317378|DEVICE|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
219275295|NCT03689634|DEVICE|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
219275296|NCT00243594|BIOLOGICAL|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
219275297|NCT00396695|PROCEDURE|Blood test|
219275298|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
219275299|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
219275300|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
219275301|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
219275302|NCT00667459|DEVICE|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
219275303|NCT00667459|DEVICE|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
219275304|NCT04822779|DEVICE|Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands|"Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
219275305|NCT04822779|OTHER|Placebo|"Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
219275306|NCT04851158|DEVICE|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
219275307|NCT04851158|DEVICE|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
219275308|NCT05914870|OTHER|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~* 10 minutes of joint mobility exercises and dynamic stretching.~* 20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~* 20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~* 10 minutes of cool down and static stretching."
219275309|NCT05914870|OTHER|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
219275310|NCT02155270|PROCEDURE|Corneal precut 600µm|
219275311|NCT02155270|PROCEDURE|Corneal stabincision|
219275312|NCT02568397|DRUG|Lanabecestat|Administered orally
219275313|NCT02568397|DRUG|Dabigatran etexilate|Administered orally
219275314|NCT03863977|DRUG|Dexamethasone|After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
219275315|NCT03863977|DRUG|Bupivacaine|After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
219275316|NCT03647904|BEHAVIORAL|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
219275317|NCT01627535|OTHER|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
219275318|NCT06155188|PROCEDURE|applying of FLU+CY post-HSCT|The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
219275319|NCT00721201|DRUG|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
219275320|NCT00821262|DRUG|sevoflurane|
219275321|NCT00821262|DRUG|propofol|
219275322|NCT02916550|BEHAVIORAL|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
219275323|NCT03715777|DRUG|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
219275324|NCT04592094|DEVICE|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
219275325|NCT05169892|PROCEDURE|Aquablation|Aquablation
219275326|NCT01200342|DRUG|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
219275327|NCT01200342|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
219275328|NCT01200342|DRUG|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
219275329|NCT05459155|OTHER|Synapse medicine platform|Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
219275330|NCT02748889|DRUG|Carboplatin|Standard chemotherapy
219275331|NCT02748889|DRUG|Etoposide|Standard chemotherapy
219275332|NCT02748889|BIOLOGICAL|MPDL3280A|Experimental biologic
219275333|NCT04747223|OTHER|Run Gait Retraining|Running step rate will be retrained by real-time biofeedback via a watch accelerometer. Recent literature showed that performing gait retraining by altering step rate reduces loading rates and joint stress that are associated with lower extremity injuries (Wilson et al 2014, Lenhart et al 2014, Heidersheit et al 2011).
219275334|NCT03076905|DRUG|F901318|Evaluation of AUC0-t
219275335|NCT05614492|BEHAVIORAL|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
219275336|NCT05614492|BEHAVIORAL|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
219275337|NCT05614492|BEHAVIORAL|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
219275338|NCT03065140|OTHER|Training or detraining|A period of detraining or a supervised exercise program.
219275339|NCT00258739|DRUG|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
219275340|NCT00258739|OTHER|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
219275341|NCT04546217|COMBINATION_PRODUCT|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
219275342|NCT04546217|DEVICE|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
219275343|NCT02086318|OTHER|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
219275344|NCT00297921|DRUG|tandutinib|
219275345|NCT06317324|OTHER|Different treatments|NSCLC patients receive the treatment of SBRT
219275346|NCT03684564|DRUG|Rivaroxaban|Oral tablet 15 mg twice daily for 24 months
219275347|NCT03684564|DRUG|Warfarin|Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
219275348|NCT02793739|PROCEDURE|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
219275349|NCT05314270|DIAGNOSTIC_TEST|Diagnostic tests|Diaagnostic tests for all pt diagnosed as Non-B Non-C Liver Cirrhosis
219275350|NCT00453167|DRUG|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
219275351|NCT00453167|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
219275352|NCT00598845|PROCEDURE|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
219275353|NCT04144712|DRUG|Caffeine Citrate|study rate of occurrence of Apnea of Prematurity between the 2 groups
219275354|NCT02223910|PROCEDURE|Neurofeedback training of functional connectivity|
219275355|NCT05429242|OTHER|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
219275356|NCT05141851|DEVICE|Implants with 0,7 mm threads|Implants were placed, with threads of 0.7 mm in the location of premolars and molars.
219275357|NCT05141851|DEVICE|Implants with 0.3 mm threads|Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
219275358|NCT04358770|DRUG|Clocortolone Pivalate|Cream, 0.1%
219275359|NCT03773575|DEVICE|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
219275360|NCT05083390|DRUG|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
219275361|NCT04292704|RADIATION|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m
219275362|NCT04292704|DRUG|Clotrimazole|Clotrimazole vaginal tablets
219275363|NCT00570284|DRUG|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
219275364|NCT03235700|OTHER|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
219275365|NCT03235700|OTHER|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
219275366|NCT02550938|DEVICE|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
219275367|NCT05102877|DEVICE|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
219275368|NCT02294357|DRUG|Carfilzomib|
219275369|NCT02294357|DRUG|Dexamethasone|If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
219275370|NCT02294357|DRUG|Prednisone|f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
219275371|NCT02294357|DRUG|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
219275372|NCT02294357|DRUG|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
219275373|NCT02294357|DRUG|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
219275374|NCT04411004|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
219275375|NCT04411004|BEHAVIORAL|5-point Likert scale|Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
219275376|NCT06044506|DRUG|Autologous Natural Killer Cell Therapy|The therapy will be administered intravenously
219275377|NCT06044506|DEVICE|Clinimacs Plus|The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
219275378|NCT04131816|BEHAVIORAL|HeartHome|The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
219275379|NCT03063151|DIAGNOSTIC_TEST|Surface Electromyography (EMG)|
219275380|NCT03285607|BIOLOGICAL|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
219275381|NCT03285607|DRUG|Doxorubicin|-Standard of care
219275382|NCT03285607|DRUG|Cyclophosphamide|-Standard of care
219275383|NCT03285607|DRUG|Paclitaxel|-Standard of care
219275384|NCT03285607|PROCEDURE|Bone marrow aspirate|-Time of enrollment and at time of surgery
219275385|NCT03285607|PROCEDURE|Peripheral blood samples|-Time of enrollment and at time of surgery
219275386|NCT03285607|PROCEDURE|Tumor tissue|-Time of enrollment and at time of surgery
219275387|NCT01860599|BEHAVIORAL|Exercise|150 minutes of moderate exercise per week
219275388|NCT01860599|BEHAVIORAL|Without exercise|Pre-study activity level (i.e. no exercise)
219275389|NCT03854747|OTHER|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
219275390|NCT01484431|DRUG|Tadalafil- Tablet or Oral suspension|Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
219275391|NCT01703728|OTHER|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
219275392|NCT03085836|DRUG|TAK-438|TAK-438 tablets.
219275393|NCT02895204|DIETARY_SUPPLEMENT|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
219275394|NCT02895204|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin
219275395|NCT02514239|DRUG|BI 836909|Intravenous Infusion of BI 836909.
219275396|NCT02613377|OTHER|Blood transfusion|
219275397|NCT03683992|DEVICE|Triathlon total knee system|Implantable
219275398|NCT01004887|OTHER|diagnostic laboratory biomarker analysis|
219275399|NCT00894400|PROCEDURE|catheter ablation|catheter ablation using radiofrequency energy
219275400|NCT04559321|PROCEDURE|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
219275401|NCT00107887|DRUG|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
219275402|NCT00107887|DRUG|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
219275403|NCT05691946|PROCEDURE|Kinesiology Taping|The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.
219275404|NCT05691946|PROCEDURE|Placebo Taping|The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.
219275405|NCT03251092|DRUG|PTI-808|Active
219275406|NCT03251092|DRUG|Placebo|Placebo
219275407|NCT03251092|DRUG|PTI-428|Active
219275408|NCT03251092|DRUG|PTI-801|Active
219275409|NCT04374747|BEHAVIORAL|Dietary Counseling|The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
219275410|NCT05464407|DIETARY_SUPPLEMENT|Cubitan|2 bottles of Cubitan daily, for 12 weeks.
219275411|NCT01065467|DRUG|LBH589|Taken orally three times per week.
219275412|NCT02751749|BEHAVIORAL|Unified Protocol|
219275413|NCT04897204|PROCEDURE|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
219275414|NCT04897204|PROCEDURE|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
219275415|NCT01888874|DRUG|GLPG0634|GLPG0634 capsules.
219275416|NCT01888874|DRUG|Placebo|Placebo capsules.
219275417|NCT03550469|DEVICE|Computer-assisted Oxygen Weaning|Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
219275418|NCT05037747|BEHAVIORAL|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
219275419|NCT01060891|DRUG|colimycin|
219275420|NCT04420247|DRUG|Chloroquine|5 days of treatment with Chloroquine + Standard Care
219275421|NCT04420247|DRUG|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
219275422|NCT04420247|OTHER|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
219275423|NCT00903825|PROCEDURE|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (\< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
219275424|NCT00903825|PROCEDURE|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
219275425|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
219275426|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
219275427|NCT02858570|BIOLOGICAL|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
219275428|NCT02858570|BIOLOGICAL|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
219275429|NCT03969680|BIOLOGICAL|Auotologous BMSCs plus autologous PRP|30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
219275430|NCT03969680|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
219275431|NCT00306813|DRUG|Revlimid|
219275432|NCT01155414|OTHER|Hydrolysate based infant formula|Infant formula ad lib
219275433|NCT01155414|OTHER|Investigational Infant Formula A|Investigational infant formula ad lib
219275434|NCT01155414|OTHER|Investigational Infant Formula B|Investigational infant formula ad lib
219275435|NCT03063684|DEVICE|Fractional / Pixel CO2 Laser|"The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application."
219275436|NCT00429013|DEVICE|Tongue Display Unit|lingual electric stimulation
219275437|NCT06381167|PROCEDURE|Endoscopic Decompressive Laminectomy|the patients will undergo block randomization for either endoscopic or microscopic decompression
219275438|NCT04009031|DEVICE|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
219275439|NCT01853501|PROCEDURE|Autologous fat grafting|ADSC ovary injection
219275440|NCT01976273|DEVICE|1064nm Q-switch Laser|
219275441|NCT01976273|OTHER|Glycolic Acid Peels|
219275442|NCT02571088|OTHER|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
219275443|NCT06156553|BEHAVIORAL|PULSE school-based intervention|"PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?"
219275444|NCT02980042|DRUG|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
219275445|NCT02980042|DRUG|Rituximab|A chimeric monoclonal antibody against CD20.
219275446|NCT00725270|DRUG|Mifepristone|600 mg of mifepristone
219275447|NCT00725270|DRUG|Placebo Oral Tablet|Placebo comparator
219275448|NCT02301377|DEVICE|Spiro PD personal spirometer|
219275449|NCT04962529|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
219275450|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom.|Ingredients: celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
219275451|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
219275452|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
219275453|NCT05594329|OTHER|Control instant noodle soup|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
219275454|NCT05640492|BEHAVIORAL|Metacognitive Training for Depression in Later Life (MCT-Silver)|"MCT-Silver consists of eight modules, each of which begins with psychoeducational and normalizing elements. A mastery is presented through examples and exercises, and the fallibility of human cognition is discussed and illustrated. In a second phase, the pathological extremes of each cognitive bias are highlighted and the participant is shown how the exacerbation of (normal) thinking biases can lead to problems in daily life. It is intended with this exercise that participants learn how to identify and mitigate cognitive traps. Dysfunctional coping strategies (social isolation and negative thoughts) are highlighted, and suggestions for replacing them with adaptive strategies are given. Homework assignments are distributed at the end of each session (Schneider et al., 2018)."
219275455|NCT05549492|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present."
219275456|NCT05410080|DIAGNOSTIC_TEST|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
219275457|NCT00769600|DRUG|Itraconazole|Itraconazole 200 mg once daily
219275458|NCT00769600|DRUG|Pemetrexed|Pemetrexed every 21 days.
219275459|NCT02673632|DRUG|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
219275460|NCT03744013|DEVICE|Fortiva® 1mm|Post mastectomy immediate reconstruction
219275461|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with double-lumen tube)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, a double-lumen tube will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
219275462|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with endobronchial blocker)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, endotracheal tube-bronchial blocker will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
219275463|NCT00601263|DRUG|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
219275464|NCT01473277|DRUG|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
219275465|NCT03466047|DIETARY_SUPPLEMENT|Protein stomach|encapsulated protein stomach
219275466|NCT03466047|DIETARY_SUPPLEMENT|Protein distal small intestine|encapsulated protein distal small intestine
219275467|NCT03466047|DIETARY_SUPPLEMENT|CHO stomach|encapsulated CHO stomach
219275468|NCT03466047|DIETARY_SUPPLEMENT|CHO distal small intestine|encapsulated CHO distal small intestine
219275469|NCT03466047|DIETARY_SUPPLEMENT|Fat stomach|encapsulated Fat stomach
219275470|NCT03466047|DIETARY_SUPPLEMENT|Fat distal small intestine|encapsulated Fat distal small intestine
219275471|NCT02747823|BIOLOGICAL|CBT124|1 mg/kg IV infusion
219275472|NCT02747823|BIOLOGICAL|EU Sourced Avastin®|1 mg/kg IV infusion
219275473|NCT02747823|BIOLOGICAL|US Sourced Avastin®|1 mg/kg IV infusion
219275474|NCT04342143|DEVICE|Blood pressure and ultrasound assessment|No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
219275475|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
219275476|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
219275477|NCT01653938|BEHAVIORAL|video decision aid|
219275478|NCT04237389|PROCEDURE|Ablation Index Guided endocardial catheter radiofrequency ablation|Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
219275479|NCT04237389|PROCEDURE|minimally invasive thoracoscopic surgical epicardial ablation.|"Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA."
219275480|NCT03814577|DIAGNOSTIC_TEST|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
219275481|NCT03814577|DIAGNOSTIC_TEST|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
219275482|NCT03814577|DEVICE|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
219275483|NCT03814577|OTHER|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
219275484|NCT02749097|DRUG|SHR0534|
219275485|NCT02749097|DRUG|Placebo|
219275486|NCT01978951|BEHAVIORAL|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
219275487|NCT01978951|BEHAVIORAL|Conventional CKD care|group counselling about optimal diets for CKD patients
219275488|NCT04160442|BEHAVIORAL|Carevive CarePlanning System|Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
219275489|NCT01400360|OTHER|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
219275490|NCT05917353|DIETARY_SUPPLEMENT|Hinex Jelly|"1. Name: Hinex Jelly~2. Dosage form: Semi-solid jelly/ A-114001297-00000-2~3. Dose(s): 300g/pack (per serving)~4. Dosing schedule: one pack (serving) per day~5. Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food."
219275491|NCT00664963|DEVICE|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
219275492|NCT00664963|DEVICE|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
219275493|NCT00641680|DRUG|Budesonide|
219275494|NCT00641680|DRUG|Fluticasone propionate|
219275495|NCT00641680|DRUG|Placebo|
219275496|NCT01376453|DRUG|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
219275497|NCT01376453|DRUG|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.
219275498|NCT01376453|RADIATION|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
219275499|NCT02277054|DEVICE|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
219275500|NCT00777075|DRUG|L-arginine|
219275501|NCT00777075|DRUG|Placebo|
219275502|NCT06297720|BEHAVIORAL|Oral hydration|"* Researchers moisten the patient's throat with a wet cotton swab. If no nausea or vomiting occurs after five minutes, proceed to the next stage.~* Provide an ice cube of potable water for the patient to hold in their mouth. If no nausea or vomiting occurs after ten minutes, proceed to the next stage.~* Offer 10-20ml of potable water for the patient to drink under medical supervision. If no nausea or vomiting occurs and the patient requests more water, administer 10-20ml every ten minutes, assessing for any adverse effects each time. The total water intake should not exceed 500ml."
219275503|NCT00317018|BEHAVIORAL|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
219275504|NCT05916703|DIAGNOSTIC_TEST|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
219275505|NCT01125033|DRUG|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
219275506|NCT01125033|DRUG|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
219275507|NCT01125033|DRUG|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
219275508|NCT01125033|DRUG|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
219275509|NCT04465799|BEHAVIORAL|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
219275510|NCT04465799|BEHAVIORAL|ENTREN-F|ENTREN intervention for children + family intervention.
219275511|NCT04465799|BEHAVIORAL|Control group|Behavioral modification of habits
219275512|NCT05091177|DIAGNOSTIC_TEST|Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation|Use relevant instruments for inspection
219275513|NCT05461287|DRUG|QLS31904|QLS31904 ONLY
219275514|NCT02936726|BEHAVIORAL|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
219275515|NCT02936726|BEHAVIORAL|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
219275516|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
219275517|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
219275518|NCT05135676|DEVICE|Blinded CGM|A masked CGM sensor will be worn
219275519|NCT05135676|DEVICE|real-time CGM|An unmasked CGM sensor will worn
219275520|NCT00266123|DRUG|Sirolimus|
219275521|NCT03061422|OTHER|Xylitol|caries prevention chewing gum
219275522|NCT03061422|OTHER|xylitol with bicarbonate|caries prevention chewing gum
219275523|NCT03061422|OTHER|paraffin|chewing gum
219275524|NCT05104489|BIOLOGICAL|AdimrSC-2f|IM injection
219275525|NCT03405090|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
219275526|NCT03405090|DRUG|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
219275527|NCT03473353|OTHER|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
219275528|NCT01483144|DRUG|Eflornithine|Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
219275529|NCT01483144|DRUG|Eflornithine Placebo|Eflornithine placebo \[three tablets orally once a day\]
219275530|NCT01483144|DRUG|Sulindac 150 MG|Sulindac \[one tablet orally once a day\]
219275531|NCT01483144|DRUG|Sulindac placebo|Sulindac placebo \[one tablet orally once a day\]
219275532|NCT05306249|DRUG|CBD LGP 50|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
219275533|NCT05306249|DRUG|Placebo|Patients will receive the MCT oil placebo without CBD until the end of week 12.
219275534|NCT04267965|PROCEDURE|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
219275535|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
219275536|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|
219275537|NCT02679326|DEVICE|Therapeutic ultrasound|
219275538|NCT06056843|OTHER|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.|Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
219275539|NCT05959798|PROCEDURE|High power short duration ablation|Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
219275540|NCT00547612|OTHER|high performance liquid chromatography|
219275541|NCT00547612|OTHER|pharmacological study|
219275542|NCT00547612|RADIATION|[18F]-labeled substance P antagonist receptor quantifier|
219275543|NCT02460575|BIOLOGICAL|Lactobacillus reuteri 17938|probiotic
219275544|NCT02460575|BIOLOGICAL|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
219275545|NCT02162004|PROCEDURE|Continuous Correction|
219275546|NCT00218114|DRUG|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
219275547|NCT00218114|DRUG|Placebo|Participants will be on matching placebo.
219275548|NCT03997487|OTHER|TOFTEE|Smartphone app for taking quality images of conjunctivae
219275549|NCT03821103|BEHAVIORAL|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
219275550|NCT03821103|BEHAVIORAL|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
219275551|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
219275552|NCT01345864|DRUG|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
219275553|NCT01345864|DRUG|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
219275554|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
219275555|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
219275556|NCT05969301|OTHER|Specific spinal exercises for idiopathic scoliosis|The spinal esercises mainly include: active self-correction, strengthening spinal deep muscles while maintaining self-correction, segmentary stretching involving the limbs and back muscles, and postural task-oriented exercises (e.g. walking, standing, sitting).
219275557|NCT02883595|DRUG|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
219275558|NCT02883595|OTHER|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
219275559|NCT02799459|PROCEDURE|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
219275560|NCT02799459|PROCEDURE|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
219275561|NCT00734136|PROCEDURE|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
219275562|NCT00734136|PROCEDURE|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
219275563|NCT05518474|OTHER|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
219275564|NCT00910897|DRUG|Velcade-Dexamethasone|
219275565|NCT00910897|DRUG|Velcade-Thalidomide-Dexamethasone|
219275566|NCT00005593|DRUG|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
219275567|NCT00005593|DRUG|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
219275568|NCT00005593|DRUG|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
219275569|NCT03192345|BIOLOGICAL|SAR439459|"Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion"
219275570|NCT03192345|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
219275571|NCT02499939|BEHAVIORAL|Standard Care|Education and home exercises
219275572|NCT02499939|OTHER|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
219275573|NCT02339623|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound~2. \- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~3. \- CL measurement using 2D ultrasound"
219275574|NCT05970705|DRUG|Regorafenib|this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
219275575|NCT05970705|DRUG|Trifluridine/Tipiracil|this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
219275576|NCT06427889|DRUG|Canoderm|humectant
219275577|NCT06427889|DRUG|Oviderm|humectant + antimicrobial
219275578|NCT06427889|DRUG|Decubal|Non-humectant
219275579|NCT03422575|DRUG|Etoricoxib 120Mg Film-coated Tablet|One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
219275580|NCT03422575|DRUG|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)|One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
219275581|NCT04776642|OTHER|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
219275582|NCT04776642|OTHER|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
219275583|NCT04776642|OTHER|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
219275584|NCT02580929|RADIATION|radiotherapy|radiotherapy before surgery
219275585|NCT04747600|PROCEDURE|surgical resection|surgical resection
219275586|NCT04497389|BIOLOGICAL|Human Amniotic Fluid|Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
219275587|NCT04038918|OTHER|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
219275588|NCT04038918|OTHER|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
219275589|NCT02582294|OTHER|Questionnaire|
219275590|NCT01845506|DEVICE|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
219275591|NCT01845506|DEVICE|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
219275592|NCT00325689|DRUG|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
219275593|NCT00325689|DRUG|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
219275594|NCT03025750|BIOLOGICAL|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
219275595|NCT03025750|BIOLOGICAL|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
219275596|NCT01037556|DRUG|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
219275597|NCT06485583|OTHER|Constraint-induced movement therapy|is a rehabilitation technique used to improve motor function in people who have had a stroke or other neurological conditions. CIMT restricts the use of the unaffected limb, typically with a mitt or sling, to encourage the use of the affected limb.
219275598|NCT06485583|OTHER|Neurodevelopmental Treatment|Therapy, is a rehabilitation approach used to address movement and motor control deficits in people with neurological illnesses such as stroke, cerebral palsy, or traumatic brain injury.
219275599|NCT03804216|OTHER|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
219275600|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
219275601|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
219275602|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
219275603|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219275604|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219275605|NCT04334278|BEHAVIORAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
219275606|NCT04334278|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
219275607|NCT02418936|DEVICE|gene diagnostic kit|
219275608|NCT00170183|DRUG|Nesiritide|
219275609|NCT01981005|DRUG|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
219275610|NCT03020459|PROCEDURE|peeling-reposition|"After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively."
219275611|NCT03020459|PROCEDURE|peeling|After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.
219275612|NCT03020459|DRUG|Brilliant Blue G|We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
219275613|NCT03020459|OTHER|postoperative posture|Patients of both two groups need to keep prone position for two weeks after the operation.
219275614|NCT03020459|DEVICE|Constellation 23-gauge vitrectomy system|All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
219275615|NCT05090527|DIAGNOSTIC_TEST|Risk stratification|advanced penicillin challenge after risk stratification
219275616|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
219275617|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with infloran \[Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)\] and Bifidobacteria bifidum \[(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)\]; Laboratorio Farmaceutico S.I.T S.r.I ITALY\] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
219275618|NCT06159179|PROCEDURE|Medical thoracoscopy|Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic. A Flex-rigid thoracoscope will be inserted through the trocar cannula in the rigt or left mid axillary line of the hemithorax
219275619|NCT02922283|DEVICE|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
219275620|NCT02922283|PROCEDURE|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
219275621|NCT02922283|DEVICE|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
219275622|NCT02922283|PROCEDURE|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
219275623|NCT04361812|DRUG|HS632|Subcutaneous injection of HS632
219275624|NCT04361812|DRUG|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
219275625|NCT04199286|PROCEDURE|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
219275626|NCT02339597|PROCEDURE|Automatic Positive Airway Pressure (APAP) initiation|
219275627|NCT02790879|OTHER|Transition pediatric - adult|
219275628|NCT03622255|PROCEDURE|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
219275629|NCT03622255|PROCEDURE|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
219275630|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
219275631|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
219275632|NCT03158909|DEVICE|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
219275633|NCT03158909|OTHER|Orientation about space and time|Information and orientation about space and time, given every night.
219275634|NCT00425607|DRUG|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
219275635|NCT02211547|DEVICE|Epic 10 Diode Laser by Biolase Inc.|
219275636|NCT02211547|OTHER|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
219275637|NCT00079339|RADIATION|radiation therapy|Undergo radiotherapy
219275638|NCT00079339|DRUG|tipifarnib|Given orally
219275639|NCT06109610|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
219275640|NCT05332470|DRUG|Lamivudine and Dotiravir Sodium Tablets|3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)
219275641|NCT02453243|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
219275642|NCT02453243|BEHAVIORAL|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
219275643|NCT00520845|DRUG|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
219275644|NCT00520845|DRUG|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
219275645|NCT00520845|DRUG|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
219275646|NCT00520845|OTHER|laboratory biomarker analysis|Blood collection
219275647|NCT03267446|DEVICE|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
219275648|NCT05573581|DRUG|Botox|Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
219275649|NCT03453697|DEVICE|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
219275650|NCT02294851|DRUG|BMS-986168|
219275651|NCT02294851|DRUG|BMS-986168 Placebo|
219275652|NCT01686867|DEVICE|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
219275653|NCT01189110|DEVICE|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
219275654|NCT04710199|DRUG|Maraviroc experimental group|300-milligram dose of the drug two times daily , oral way. During 14 days.
219275655|NCT04710199|OTHER|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
219275656|NCT01210326|PROCEDURE|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
219275657|NCT01210326|PROCEDURE|testicular sperm extraction|testicular sperm extraction
219275658|NCT01210326|PROCEDURE|testicular sperm aspiration|testicular sperm aspiration
219275659|NCT00390260|DRUG|MK0966 / Duration of Treatment: 1 Days|
219275660|NCT00390260|DRUG|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
219275661|NCT00390260|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
219275662|NCT01476683|DRUG|Racecadotril|Film-coated tablet
219275663|NCT01476683|DRUG|Racecadotril|Racecadotril Powder Blend
219275664|NCT01476683|DRUG|Racecadotril|Marketed Capsule
219275665|NCT01476683|DRUG|Racecadotril|Marketed Film-coated Tablet
219275666|NCT00333749|BIOLOGICAL|Drinking or rinsing the mouth 2-3 times for 1 day|
219275667|NCT00333749|BIOLOGICAL|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
219275668|NCT04231045|DEVICE|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
219275669|NCT00662597|DRUG|ASA404|
219275670|NCT00662597|DRUG|Placebo|
219275671|NCT00662597|DRUG|carboplatin|
219275672|NCT00662597|DRUG|Paclitaxel|
219275673|NCT05494970|OTHER|Accompaniment by the dental assistant.|"Inclusion visit (before radiotherapy treatment):~* oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~* a written information guide on oral hygiene will be given to the patient.~* the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient."
219275674|NCT05317676|DRUG|Palmitoylethanolamide|2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
219275675|NCT05317676|DRUG|Placebo|2-month supply of placebo will be given upon discharge. Placebo will taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
219275676|NCT00703339|DRUG|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~* Cohort 1: dosed at 3 breaths (18 mcg)~* Cohort 2: dosed at 6 breaths (36 mcg)~* Cohort 3: dosed at 9 breaths (54 mcg)~* Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
219275677|NCT00945672|BIOLOGICAL|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
219275678|NCT00945672|BIOLOGICAL|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
219275679|NCT00945672|DRUG|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
219275680|NCT04492059|DEVICE|Blood flow restriction augmented physical therapy|Using a blood flow restriction cuff during physical therapy. It is a pressurized cuff that is used to decrease the amount of oxygen that is available to the muscle during exercise. This stimulates the muscle to believe it is in an anoxic state and can produce greater strength and hypertrophy with fewer reps and less weight which would mean less stress on a surgically repaired tendon.
219275681|NCT04492059|OTHER|Physical therapy|Completing traditional physical therapy.
219275682|NCT05214664|PROCEDURE|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~* The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~* The Surgery practitioner starts the surgical procedure.~* In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
219275683|NCT05997628|OTHER|Detection of NAD+/NADH concentration of Peripheral Blood Samples|Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.
219275684|NCT03045705|BEHAVIORAL|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
219275685|NCT03045705|BEHAVIORAL|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
219275686|NCT00872209|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
219275687|NCT00872209|DRUG|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
219275688|NCT04053998|PROCEDURE|Pancreaticoduodenectomy with portal vein resection|Pancreatic surgery with vein resection to achieve disease clearance.
219275689|NCT04566562|DIAGNOSTIC_TEST|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
219275690|NCT04566562|DIAGNOSTIC_TEST|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
219275691|NCT04566562|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory Markers
219275692|NCT02885662|DRUG|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
219275693|NCT03054337|DRUG|Vadadustat|
219275694|NCT03054337|DRUG|Placebo|
219275695|NCT01395004|DRUG|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
219275696|NCT02403518|DEVICE|Freedom Spinal Cord Stimulator System|
219275697|NCT00692731|DIETARY_SUPPLEMENT|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
219275698|NCT00692731|OTHER|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
219275699|NCT01762904|OTHER|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
219275700|NCT01762904|OTHER|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
219275701|NCT00447590|DEVICE|LAP-BAND System|Restriction of food intake
219275702|NCT01967069|DRUG|DFD01 Spray|
219275703|NCT01967069|DRUG|Vehicle Spray|
219275704|NCT03609268|DEVICE|microwave ablation (MWA)|microwave ablation (MWA) for recurrent small liver cancer
219275705|NCT03609268|RADIATION|stereotactic body radiotherapy (SBRT)|stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
219275706|NCT01028677|DRUG|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
219275707|NCT01028677|OTHER|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
219275708|NCT00452907|DRUG|Artesunate|oad, per os, 3 days of treatment
219275709|NCT00452907|DRUG|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
219275710|NCT00452907|DRUG|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
219275711|NCT04688177|DEVICE|Body Composition|The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
219275712|NCT04688177|DEVICE|Heart rate variability|After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
219275713|NCT04688177|DEVICE|Grip Strength|The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
219275714|NCT04688177|DEVICE|Exhale Carbon Monoxide Concentration|Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
219275715|NCT04688177|DEVICE|Pulmonary Function Test|Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
219275716|NCT04688177|DEVICE|Respiratory Muscle Function|Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
219275717|NCT04688177|BEHAVIORAL|Fagerström Test for Nicotine Dependence|Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
219275718|NCT04688177|BEHAVIORAL|Seven-Day Physical Activity Recall Questionnaire|Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
219275719|NCT04688177|DEVICE|Cardiopulmonary exercise testing|Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
219275720|NCT02345590|DRUG|Eplerenone|25mg of eplerenone
219275721|NCT00256022|DRUG|Lactobacillus Probiotic|
219275722|NCT00256022|OTHER|Lactose Powder|
219275723|NCT03638076|DRUG|GLS4|Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
219275724|NCT03638076|DRUG|RTV|Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
219275725|NCT02301338|OTHER|Usual care|
219275726|NCT02301338|OTHER|Phone Calls|
219275727|NCT02806362|DRUG|Ombitasvir/paritaprevir/ritonavir|Tablet
219275728|NCT00025077|BIOLOGICAL|filgrastim|
219275729|NCT00025077|DRUG|carboplatin|
219275730|NCT00025077|DRUG|cyclophosphamide|
219275731|NCT00025077|DRUG|thiotepa|
219275732|NCT00025077|PROCEDURE|conventional surgery|
219275733|NCT00025077|PROCEDURE|peripheral blood stem cell transplantation|
219275734|NCT00025077|RADIATION|radiation therapy|
219275735|NCT00529880|DRUG|Fludarabine , cytarabine|
219275736|NCT04496323|OTHER|EE Golf|Exercise in Golf and Playing 9 holes
219275737|NCT01739257|BEHAVIORAL|Medical Lecture|
219275738|NCT01739257|BEHAVIORAL|Dramatic Reading|
219275739|NCT03820297|BEHAVIORAL|10 sessions of ASGI|10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
219275740|NCT00287443|PROCEDURE|Oral Glucose tolerance test|
219275741|NCT00287443|PROCEDURE|Whole body protein turnover|
219275742|NCT00287443|PROCEDURE|IV glucose tolerance test|
219275743|NCT00287443|PROCEDURE|Indirect Calorimetry|
219275744|NCT00287443|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
219275745|NCT00287443|PROCEDURE|Growth Hormone Stimulation Test|
219275746|NCT00202189|DRUG|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
219275747|NCT01661205|DEVICE|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
219275748|NCT00775411|DRUG|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
219275749|NCT00775411|BIOLOGICAL|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
219275750|NCT04358718|PROCEDURE|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
219275751|NCT04358718|PROCEDURE|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
219275752|NCT05387967|DRUG|Sacubitril/valsartan|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
219275753|NCT01445119|DRUG|Enzastaurin (LY317615)|
219275754|NCT01445119|DRUG|Carboplatin|
219275755|NCT01111253|DRUG|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
219275756|NCT00346905|DRUG|Enteryx|
219275757|NCT02393742|DRUG|Sodium nitrite|
219275758|NCT02393742|DRUG|Placebo|
219275759|NCT00224744|DEVICE|ultracision|Surgery by Ultracision
219275760|NCT00224744|DEVICE|classical lymphadenectomy|classical lymphadenectomy
219275761|NCT04191421|BIOLOGICAL|Siltuximab|Given IV
219275762|NCT04191421|BIOLOGICAL|Spartalizumab|Given IV
219275763|NCT05424835|DRUG|SHR-A1811|SHR-A1811 4.8mg/kg
219275764|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
219275765|NCT05424835|DRUG|SHR-A1811|SHR-A1811 6.4mg/kg
219275766|NCT03111095|OTHER|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
219275767|NCT05631041|DRUG|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
219275768|NCT04709588|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml every night for 14, 28 days
219275769|NCT04709588|DIETARY_SUPPLEMENT|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
219275770|NCT06311903|DRUG|Low dose of Norepinephrine (NE)|Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure \>70 mmHg)\] followed by low dose of NE (0.05-0.2 μg/kg/min).
219275771|NCT06311903|DRUG|High dose of Norepinephrine (NE)|Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
219275772|NCT00504075|BIOLOGICAL|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
219275773|NCT05260879|BEHAVIORAL|Diabetes prevention program|Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
219275774|NCT03120429|BEHAVIORAL|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
219275775|NCT03120429|BEHAVIORAL|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
219275776|NCT05035147|DRUG|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
219275777|NCT01186705|DRUG|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
219275778|NCT01035853|DRUG|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
219275779|NCT02639455|BEHAVIORAL|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
219275780|NCT04052815|BEHAVIORAL|Diabetes prevention program culturally tailored|Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
219275781|NCT01258257|PROCEDURE|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
219275782|NCT02330770|DRUG|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
219275783|NCT02330770|DRUG|GnRHa then HCG (single low-dose)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
219275784|NCT02330770|DRUG|GnRHa then HCG (multiple low-doses)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
219275785|NCT01914770|DRUG|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
219275786|NCT01914770|DRUG|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
219275787|NCT01914770|DRUG|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
219275788|NCT06179745|COMBINATION_PRODUCT|EEG-based brain-computer interface|EEG-based brain-computer interface detecting the patient's EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient.
219275789|NCT06179745|COMBINATION_PRODUCT|Sham EEG-based brain-computer interface|Fake (Sham) EEG-based brain-computer interface which outputs a decision at random about whether EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient are currently detected.
219275790|NCT06179745|DEVICE|Functional Electrical Stimulation|Neuromuscular stimulation of several upper limb muscles (elbow extensors, hand extensors/flexors) to effectuate reach, grasp and release movements of the affected upper limb.
219275791|NCT06179745|DEVICE|Active hand orthosis|Active hand orthosis effectuating reach, grasp and release movements of the affected uppe r limb.
219275792|NCT04700553|DEVICE|Localized muscle vibration|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
219275793|NCT04700553|OTHER|Conventional physiotherapy intervention|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
219275794|NCT00767429|DEVICE|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
219275795|NCT04079634|DEVICE|Esophageal warming|Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
219275796|NCT04079634|DEVICE|Control|Standard temperature probe monitoring
219275797|NCT04148989|OTHER|Code Sepsis protocol (full implementation)|Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
219275798|NCT00590655|BEHAVIORAL|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
219275799|NCT00590655|BEHAVIORAL|weight loss programme|
219275800|NCT01178008|PROCEDURE|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
219275801|NCT01178008|PROCEDURE|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
219275802|NCT03423329|DRUG|Brufen|Brufen Syrup
219275803|NCT03423329|DRUG|Cital|Cital Cyrup
219275804|NCT03423329|DRUG|Placebo for Brufen|Sansovit Syrup
219275805|NCT02833298|BEHAVIORAL|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
219275806|NCT02833298|BEHAVIORAL|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
219275807|NCT02522988|BEHAVIORAL|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
219275808|NCT00537121|DRUG|fluorouracil|Given IV
219275809|NCT00537121|DRUG|irinotecan hydrochloride|Given IV
219275810|NCT00537121|DRUG|leucovorin calcium|Given IV
219275811|NCT00537121|DRUG|vorinostat|Taken Orally
219275812|NCT00537121|OTHER|pharmacological study|Correlative Study
219275813|NCT00543153|BEHAVIORAL|Interview|Interview lasting approximately 30-45 minutes.
219275814|NCT04245345|DEVICE|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
219275815|NCT00504283|DRUG|Toradol|
219275816|NCT00504283|DRUG|Morphine|
219275817|NCT01729468|DRUG|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
219275818|NCT01729468|DRUG|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
219275819|NCT05585918|BEHAVIORAL|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
219275820|NCT05585918|BEHAVIORAL|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
219275821|NCT01782768|DEVICE|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
219275822|NCT04559178|OTHER|Fluid challenge|fluid challenge administration when patient is in the gray zone
219275823|NCT05196282|OTHER|Smoking cessation|Patients are forced to stop smoking
219275824|NCT03438682|DEVICE|Essure|Essure hysteroscopic sterilization
219275825|NCT03438682|PROCEDURE|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
219275826|NCT03438682|DEVICE|Intrauterine Device (IUD)|Intrauterine Device (IUD)
219275827|NCT00706654|DRUG|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
219275828|NCT00706654|DRUG|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
219275829|NCT00706654|DRUG|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
219275830|NCT00706654|DRUG|Placebo depot|Placebo depot was supplied in lyophilized vials.
219275831|NCT00706654|DRUG|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
219275832|NCT03119545|BEHAVIORAL|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
219275833|NCT00335751|PROCEDURE|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
219275834|NCT00657462|OTHER|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
219275835|NCT06160661|DEVICE|mandibular saggital split osteotomy|orthognathic surgery
219275836|NCT06062524|DEVICE|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
219275837|NCT01035268|PROCEDURE|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
219275838|NCT00002439|DRUG|Alitretinoin|
219275839|NCT04729205|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
219275840|NCT00625300|DEVICE|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
219275841|NCT00625300|DEVICE|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
219275842|NCT05219838|DRUG|Lu AG06466|Lu AG06466 will be administered per dose and schedule specified in the arm description.
219275843|NCT00961506|PROCEDURE|LESS cholecystectomy|LESS cholecystectomy
219275844|NCT00961506|PROCEDURE|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
219275845|NCT04943471|OTHER|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
219275846|NCT06031636|DRUG|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
219275847|NCT06031636|DRUG|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
219275848|NCT01335347|BIOLOGICAL|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
219275849|NCT01335347|BIOLOGICAL|Placebo control|Capsules of the same size and shape as experimental groups
219275850|NCT00594022|DEVICE|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
219275851|NCT00594022|DEVICE|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
219275852|NCT05926869|DRUG|Clindamycin and Dapsone gel for 03 months|Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
219275853|NCT04944498|PROCEDURE|Modified Tarsorrhaphy|A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip
219275854|NCT04944498|PROCEDURE|Gold Weight Implant|Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
219275855|NCT02626442|OTHER|Exercise|6 month group exercise class
219275856|NCT01001390|DEVICE|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
219275857|NCT05396508|PROCEDURE|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
219275858|NCT05396508|PROCEDURE|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
219275859|NCT03194997|OTHER|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
219275860|NCT03194997|OTHER|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
219275861|NCT01246089|DRUG|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
219275862|NCT06117423|DRUG|Adalimumab-680LT|First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.
219275863|NCT06117423|OTHER|Control|Fluorescence Molecular Imaging was performed to enable the visualisation and detection of fluorescence signals.
219275864|NCT05284630|OTHER|Exercise follow up with mobile application|Exercises will be followed by mobile application. Electrotherapy will be performed.
219275865|NCT05284630|OTHER|Home-Based Exercise Program followed by paper booklet|Exercise will be followed by paper booklet. Electrotherapy will be performed.
219275866|NCT05284630|PROCEDURE|Electrotherapy|Electrotherapy will be performed.
219275867|NCT01906697|PROCEDURE|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
219275868|NCT01906697|PROCEDURE|middle turbinate resection|middle turbinate resection
219275869|NCT01906697|PROCEDURE|middle turbinate medialization|middle turbinate medialization
219275870|NCT00831077|DRUG|ORM-14540|i.v.
219275871|NCT00831077|DRUG|ORM-12741|i.v.
219275872|NCT01151215|DRUG|AZD8931|Tablet, oral, bd
219275873|NCT01151215|DRUG|anastrozole|Tablet, oral, od
219275874|NCT01151215|DRUG|Placebo|Tablet, oral
219275875|NCT01120873|DRUG|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
219275876|NCT00118612|BIOLOGICAL|Tree MATA MPL - Therapeutic Regimen|600, 1600, 4000, 4000 SU/0.5 mL
219275877|NCT00118612|BIOLOGICAL|Tree MATA MPL - Intermediate dose|300, 600, 1600, 1600 SU/0.5 mL
219275878|NCT00118612|BIOLOGICAL|Tree MATA MPL - Low dose|300, 300, 300, 300 SU/0.5 mL
219275879|NCT00118612|BIOLOGICAL|Placebo|L-tyrosine 2% w/v , 4 injections
219275880|NCT02225262|RADIATION|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
219275881|NCT02968615|BEHAVIORAL|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
219275882|NCT03392168|DRUG|ARQ-151 cream 0.5%|0.5% active concentration
219275883|NCT03392168|DRUG|ARQ-151 cream 0.15%|0.15% active concentration
219275884|NCT03392168|DRUG|ARQ-151 vehicle cream|Vehicle cream
219275885|NCT01721954|DRUG|FOLFOX6m|
219275886|NCT01721954|DEVICE|SIR-Spheres microspheres|
219275887|NCT00351572|PROCEDURE|Cell Search Assay|
219275888|NCT00727740|DRUG|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
219275889|NCT00727740|DRUG|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
219275890|NCT03266718|BEHAVIORAL|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
219275891|NCT00653731|BEHAVIORAL|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
219275892|NCT00653731|BEHAVIORAL|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
219275893|NCT00653731|BEHAVIORAL|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
219275894|NCT00653731|BEHAVIORAL|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
219275895|NCT02840864|DEVICE|Sonography assisted breast surgery|
219275896|NCT00098527|DRUG|romidepsin|Given IV
219275897|NCT00098527|OTHER|laboratory biomarker analysis|Correlative studies
219275898|NCT01465945|PROCEDURE|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
219275899|NCT01465945|PROCEDURE|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
219275900|NCT06003205|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
219275901|NCT00196391|DRUG|DR-2021a|1 capsule daily for 10 days
219275902|NCT00196391|DRUG|DR-2021b|1 capsule daily for 10 days
219275903|NCT00196391|DRUG|DR-2021c|1 capsule daily for 10 days
219275904|NCT00196391|DRUG|DR-2021d|1 capsule daily for 10 days
219275905|NCT00196391|DRUG|DR-2021e|1 capsule daily for 10 days
219275906|NCT00196391|OTHER|Placebo|1 matching placebo capsule for 10 days
219275907|NCT01803581|OTHER|X92001327|
219275908|NCT01803581|OTHER|RID shampoo|
219275909|NCT01824589|DEVICE|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
219275910|NCT01824589|DEVICE|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
219275911|NCT00002068|DRUG|Fluconazole|
219275912|NCT00002068|DRUG|Amphotericin B|
219275913|NCT03388476|DIAGNOSTIC_TEST|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
219275914|NCT04760262|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
219275915|NCT04760262|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
219275916|NCT03327272|DRUG|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
219275917|NCT03327272|DRUG|Saline|Administration of saline at surgical site prior to incision closure
219275918|NCT03104010|DRUG|Somatropin Injection|Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
219275919|NCT02224547|RADIATION|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
219275920|NCT03176004|OTHER|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
219275921|NCT00555243|PROCEDURE|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
219275922|NCT00555243|PROCEDURE|Traditional Surgical Education|Traditional surgical teaching (no simulator)
219275923|NCT00268372|DRUG|cisplatin|
219275924|NCT00268372|DRUG|docetaxel|
219275925|NCT00268372|DRUG|5-fluorouracil|
219275926|NCT00268372|PROCEDURE|surgery|
219275927|NCT00268372|RADIATION|radiation therapy|
219275928|NCT01397279|BIOLOGICAL|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
219275929|NCT01397279|BIOLOGICAL|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
219275930|NCT00684905|DRUG|bicalutamide|
219275931|NCT00684905|DRUG|leuprolide acetate|
219275932|NCT00684905|PROCEDURE|adjuvant therapy|
219275933|NCT00684905|PROCEDURE|neoadjuvant therapy|
219275934|NCT00684905|PROCEDURE|quality-of-life assessment|
219275935|NCT00684905|RADIATION|brachytherapy|
219275936|NCT00129753|DRUG|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
219275937|NCT06254170|DIETARY_SUPPLEMENT|Euterpe Edulis juice|The preparation will be obtained with the same methods already well established in previous studies (SCHULZ et al., 2016.; MENDES et al., 2021). Participants will receive commercial samples of juçara (E.edulis) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
219275938|NCT06254170|DIETARY_SUPPLEMENT|Placebo|Participants will receive 250 ml of water + purple dye + pectin (control) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
219275939|NCT02521714|DRUG|Lenalidomide|
219275940|NCT06415110|DEVICE|Allosync Expand|Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)
219275941|NCT00689182|PROCEDURE|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
219275942|NCT02754362|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
219275943|NCT02754362|BIOLOGICAL|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
219275944|NCT02754362|DRUG|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
219275945|NCT02754362|DRUG|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
219275946|NCT01059162|DEVICE|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
219275947|NCT01162486|DRUG|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275948|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275949|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275950|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275951|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275952|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
219275953|NCT01790919|BEHAVIORAL|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
219275954|NCT06273280|PROCEDURE|SOC|Physician-guided GDMT up-titration
219275955|NCT06273280|PROCEDURE|Protocolized up-titration|Renal-based protocolized GDMT up-titration
219275956|NCT04600986|OTHER|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
219275957|NCT04118881|OTHER|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
219275958|NCT02259023|OTHER|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
219275959|NCT02259023|OTHER|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
219275960|NCT04766723|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219275961|NCT04766723|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
219275962|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
219275963|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
219275964|NCT02907437|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
219275965|NCT02907437|DRUG|Placebo|(200 mg/day)
219275966|NCT02907437|OTHER|Probiotics|(450 mg/day)
219275967|NCT03722511|DIETARY_SUPPLEMENT|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
219275968|NCT01495910|DRUG|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
219275969|NCT06237777|GENETIC|SKG0106 intravitreal injection dose level 1, 2 or 3|SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
219275970|NCT05588583|DEVICE|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~* a soft silicone wound contact layer (Safetac)~* a flexible absorbent pad of compressed polyurethane foam~* an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
219275971|NCT00002264|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
219275972|NCT01485107|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
219275973|NCT06051071|DEVICE|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
219275974|NCT00288223|DRUG|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
219275975|NCT05765201|OTHER|High IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
219275976|NCT05765201|OTHER|Low IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
219275977|NCT00844597|DRUG|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
219275978|NCT04811144|DEVICE|Er:YAG dental laser|To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
219275979|NCT05360628|DRUG|D-0120 in combination with Allopurinol|noted above
219275980|NCT05253599|DEVICE|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
219275981|NCT05253599|DEVICE|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
219275982|NCT05253599|OTHER|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
219275983|NCT00219479|DRUG|Phenytoin (Dilantin) levels during change in enteral feeding|
219275984|NCT00565071|DEVICE|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
219275985|NCT00098397|DRUG|romidepsin|Given IV
219275986|NCT00098397|OTHER|laboratory biomarker analysis|Optional correlative studies
219275987|NCT02781649|DRUG|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
219275988|NCT02781649|DRUG|Ribavirin|Ribavirin 1200 mg/d (\> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses
219275989|NCT02781649|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily
219275990|NCT01722747|BEHAVIORAL|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
219275991|NCT03714568|DRUG|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
219275992|NCT03714568|DRUG|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
219275993|NCT04099654|OTHER|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
219275994|NCT04099654|OTHER|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
219275995|NCT02762903|PROCEDURE|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
219275996|NCT02762903|PROCEDURE|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
219275997|NCT02762903|DEVICE|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
219275998|NCT01066715|DRUG|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
219275999|NCT01066715|DRUG|Placebo|Sterile solution subcutaneously administered monthly for 6 months
219276000|NCT01228175|DRUG|Placebo|25mg look alike riboflavin tablets to match active study medication.
219276001|NCT01228175|DRUG|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
219276002|NCT02421536|OTHER|Vibrogent Smartphone Application|
219276003|NCT00544232|DRUG|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
219276004|NCT00544232|DRUG|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
219276005|NCT03352154|DIAGNOSTIC_TEST|P300 - Auditory long latency potential|Perform the P300 exams.
219276006|NCT04621461|DIETARY_SUPPLEMENT|Zinc Sulfate 220 MG|220mg once daily for 5 days
219276007|NCT04621461|DRUG|Placebo|Once daily for 5 days
219276008|NCT01079910|DRUG|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
219276009|NCT01079910|DRUG|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
219276010|NCT00984191|RADIATION|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
219276011|NCT03742375|DIAGNOSTIC_TEST|HPV genotyping|Quantitative HPV genotyping on anal swab
219276012|NCT02227992|BIOLOGICAL|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
219276013|NCT02227992|DEVICE|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
219276014|NCT02715141|BEHAVIORAL|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
219276015|NCT00223509|DRUG|Lamotrigine|
219276016|NCT05044676|OTHER|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
219276017|NCT06020950|OTHER|Control|Low-calorie diet with the use of placebo pearls (containing sunflower oil)
219276018|NCT06020950|DIETARY_SUPPLEMENT|Omega-3 supplementation|Low-calorie diet with the use of marine omega-3 pearls (containing 1200 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid/day)
219276019|NCT06020950|OTHER|Chia seed|Low-calorie diet with the consumption of 30 grams of powdered chia seeds
219276020|NCT06289595|DEVICE|PBM Ortho device|Device emits light for photobiomodulation (light therapy).
219276021|NCT02038387|BEHAVIORAL|normocaloric low cholesterol diet|
219276022|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
219276023|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
219276024|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
219276025|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
219276026|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
219276027|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
219276028|NCT06181370|OTHER|placebo|placebo inhaled drug
219276029|NCT04873882|DEVICE|Acoustic ventilation|"1. Placement and removal of the esophageal stethoscope~2. Connection of a microphone to the esophageal stethoscope outside of and removed from the patient's body at the location on the figure above Connection fo monaural earpiece.~3. Digital breath sound real-time monitoring will be collected as .wav files from the device with no identifiable elements and the data from the device will be downloaded onto a desktop and we will keep and store the data on a secure departmental server.~4. Additional monitoring schedule includes evaluation of breath sounds with a conventional stethoscope every 30 minutes intraoperatively, at the start of one-lung ventilation, at the return to two-lung ventilation and prior to extubation and during any changes on the digital breath sounds recording monitor."
219276030|NCT00500032|PROCEDURE|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
219276031|NCT02358668|DRUG|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
219276032|NCT02358668|DRUG|BTI320 matching placebo|Placebo
219276033|NCT04057573|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219276034|NCT04057573|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
219276035|NCT03455998|OTHER|questionnaires|
219276036|NCT03064945|DEVICE|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
219276037|NCT02592213|PROCEDURE|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
219276038|NCT03348410|BEHAVIORAL|Motivational interviewing|Motivational interviewing with insurance officer
219276039|NCT00693979|DEVICE|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
219276040|NCT05609604|DEVICE|tDCS|Electric current will be delivered to the pre-frontal cortex for 30 minutes.
219276041|NCT05609604|DEVICE|Shame- No current|
219276042|NCT03987971|OTHER|acupuncture|Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
219276043|NCT05654233|DRUG|Sulodexide|The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
219276044|NCT02646787|BEHAVIORAL|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
219276045|NCT02646787|BEHAVIORAL|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
219276046|NCT05436405|PROCEDURE|Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb|"Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases."
219276047|NCT01109511|DRUG|naloxone|
219276048|NCT01109511|DRUG|oxycodone|
219276049|NCT02702778|DRUG|Delayed-Release (DR) Prednisone|delayed release prednisone
219276050|NCT02702778|DRUG|Immediate Release (IR) Prednisone|standard prednisone
219276051|NCT01317875|DRUG|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
219276052|NCT01381575|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
219276053|NCT05078541|PROCEDURE|Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor|"The Procedure~1. Injection of local subcutaneous and pericapsular anaesthesia~2. Needle radiofrequency ablation under ultrasound guidance~3. Patients should communicate with operating surgeon upon excessive heat or pain~4. The procedure usually lasts 30-45 minutes"
219276054|NCT01145989|DRUG|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
219276055|NCT01002677|BEHAVIORAL|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
219276056|NCT01002677|BEHAVIORAL|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
219276057|NCT01443403|DRUG|Placebo|Matching placebo tablets administered orally once a day.
219276058|NCT01443403|DRUG|Naldemedine|Naldemedine tablets administered orally once a day.
219276059|NCT00557557|DRUG|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
219276060|NCT00557557|DRUG|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
219276061|NCT03563326|BIOLOGICAL|CAR-T cells targeting EpCAM|Biological: CAR-T cells targeting EpCAM
219276062|NCT03563326|BIOLOGICAL|Chemotherapy|Chemotherapy: determined by medical Oncologist
219276063|NCT01529489|OTHER|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
219276064|NCT01529489|OTHER|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
219276065|NCT01529489|OTHER|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
219276066|NCT01529489|OTHER|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
219276067|NCT06509399|OTHER|care package|"Before the patients in the application group started to be observed, the nurses working in the clinic were trained about the risk assessment, skin assessment, incontinence management, nutrition assessment, positioning, support surfaces and injuries caused by the devices in the BP content to be used in the prevention of IU. After the trainings given to the nurses were completed, care was given to the patients in the practice group in accordance with BP. In addition, patient information was collected from patient information files, nurse observation forms and hospital automation system. In the evaluation step, full compliance with the 7 compliance steps specified in the BP was sought. If any one of these parameters was incomplete, the others were considered as incomplete.~The patients in the control group were followed up for 30 days until the determined number of patients was reached and their data were collected."
219276068|NCT00249938|DRUG|Minute Maid Heart Wise orange juice|
219276069|NCT00249938|DRUG|Welchol|
219276070|NCT00803192|DRUG|Famotidine Tablets, 40 mg|
219276071|NCT01913457|RADIATION|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
219276072|NCT00474526|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|
219276073|NCT00474526|BIOLOGICAL|DTaP-IPV-HBV|
219276074|NCT00474526|BIOLOGICAL|Hib|
219276075|NCT00474526|BIOLOGICAL|Rotavirus|
219276076|NCT00474526|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|
219276077|NCT00474526|BIOLOGICAL|HAV|
219276078|NCT00474526|BIOLOGICAL|MMR-V|
219276079|NCT00474526|BIOLOGICAL|DTaP|
219276080|NCT04093089|DEVICE|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
219276081|NCT04093089|DEVICE|Bionode IOP Lowering System|Control: No stimulation
219276082|NCT03222505|DEVICE|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
219276083|NCT03222505|OTHER|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
219276084|NCT06108518|DRUG|Carvedilol|Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
219276085|NCT02224404|DEVICE|Fast Gelling Dressing (Exufiber)|
219276086|NCT01251770|DRUG|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
219276087|NCT01251770|DRUG|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
219276088|NCT03245905|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
219276089|NCT03867695|DRUG|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
219276090|NCT03867695|DRUG|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
219276091|NCT01508949|DRUG|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
219276092|NCT01508949|DRUG|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
219276093|NCT01049451|DRUG|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
219276094|NCT01049451|DRUG|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
219276095|NCT04307940|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg per tablet, two tablets (440 mg), intake a single dose orally.
219276096|NCT04307940|DRUG|Hydrocodone/Acetaminophen|5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
219276097|NCT04307940|DRUG|Placebo|two tablets, intake a single dose orally.
219276098|NCT04517097|BIOLOGICAL|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
219276099|NCT01644864|DRUG|0.375% ROPIVACAINE|
219276100|NCT01644864|DRUG|placebo|
219276101|NCT04233112|DRUG|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
219276102|NCT04233112|DEVICE|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
219276103|NCT04233112|DEVICE|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
219276104|NCT04233112|DRUG|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
219276105|NCT04169321|DRUG|Single Arm|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
219276106|NCT06737861|OTHER|Group A|Participants will perform Buerger exercises three times daily, with each session including three cycles. Additionally, they will receive Whole Body Vibration therapy at a frequency of 25 Hz, three times per week. Each WBV session will last 12 minutes, divided into four 3-minute bouts, aiming to improve pain, balance, and lower limb circulation in diabetic peripheral neuropathy patients.
219276107|NCT06737861|OTHER|Group B|Participants will perform Buerger exercises three times daily, with each session consisting of three cycles. This exercise regimen is aimed at assessing its effectiveness on pain, balance, and circulation in diabetic peripheral neuropathy patients, serving as a comparison to the combined intervention with WBV therapy.
219276108|NCT05543174|DRUG|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
219276109|NCT06523140|DEVICE|Boracare remote monitoring solution|Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
219276110|NCT05281874|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
219276111|NCT05281874|BEHAVIORAL|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
219276112|NCT05281874|BEHAVIORAL|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
219276113|NCT04074720|PROCEDURE|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
219276114|NCT04074720|OTHER|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
219276115|NCT04074720|OTHER|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
219276116|NCT03489252|DEVICE|Monitoring Device|Wear Fitbit Charge 3
219276117|NCT06156059|DRUG|Oral Bedtime Melatonin|100 mg oral suspension or capsule given at bedtime
219276118|NCT06156059|DRUG|Placebo suspension or capsule|Indistinguishable suspension or capsule
219276119|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation alone|Ablation of the pulmonary veins for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
219276120|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation|Ablation of the pulmonary veins and the left atrium posterior wall for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
219276121|NCT00953771|DRUG|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
219276122|NCT06794008|DRUG|BCMA-CD19 CAR-T therapy|Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.
219276123|NCT03132532|DRUG|Carboplatin|Chemotherapy
219276124|NCT03132532|DRUG|Cisplatin|Chemotherapy
219276125|NCT03132532|DRUG|Etoposide|Chemotherapy
219276126|NCT03132532|DRUG|Paclitaxel|Chemotherapy
219276127|NCT03132532|DRUG|Pemetrexed|Chemotherapy
219276128|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
219276129|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
219276130|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
219276131|NCT04951999|OTHER|Blood sampling|For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
219276132|NCT04596982|OTHER|Placement of IMPELLA®|ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
219276133|NCT06079294|OTHER|FDG PET|Brain FDG PET performed 3 months after treatment initiation
219276134|NCT06842628|OTHER|Savoring|"Participants will follow an e-savoring training for 3 weeks. The first week will be focused on savoring past positive experiences (positive reminiscence and life lessons); the second week will be focused on savoring the present (absorption during an activity and writing a letter of gratitude to a significant person); and the third week will be focused on savoring the future (anticipating positive future events and making kind gestures to a significant person). After each activity, they will be guided to reflect and savor the positive emotions that emerge from the activity.~The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
219276135|NCT06842628|OTHER|Positive Emotional Induction|"Participants will follow a positive emotional induction training for 3 weeks, with 2 exercises per week.~The first week, they will listen to a piece of music and watch a video that elicits positive emotions; the second week, they will do an activity that they particularly enjoy in solitude and listen to a narrative about gratitude; the third week, they will listen to a narrative about hope and carry out an activity they like with a loved one. The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
219276136|NCT05950334|DRUG|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
219276137|NCT05950334|DRUG|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
219276138|NCT05950334|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
219276139|NCT05950334|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
219276140|NCT05950334|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
219276141|NCT03356392|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
219276142|NCT04896008|DRUG|Sotatercept|SC injection
219276143|NCT04896008|OTHER|Placebo|Placebo-matched SC injection
219276144|NCT03223779|DRUG|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
219276145|NCT03223779|RADIATION|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
219276146|NCT06476132|DRUG|Belumosudil|Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
219276147|NCT06476132|DRUG|Placebo for Belumosudil|Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
219276148|NCT06316986|DIAGNOSTIC_TEST|pH indication with NGPOD|"The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach."
219276149|NCT06564077|OTHER|Eldoa technique with conventional therapy|"is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
219276150|NCT06564077|OTHER|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
219276151|NCT04027413|DIETARY_SUPPLEMENT|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
219276152|NCT04027413|DIETARY_SUPPLEMENT|preOp|(100% carbohydrate).
219276153|NCT01270828|DRUG|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
219276154|NCT01270828|DRUG|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
219276155|NCT03195361|DEVICE|SRS - Self Retaining Support system|
219276156|NCT04845399|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
219276157|NCT04940364|DRUG|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
219276158|NCT04940364|DRUG|Cemdisiran|Administered SC per protocol
219276159|NCT06456385|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The intervention applied is called transcutaneous auricular vagus nerve stimulation (taVNS) which administers electrical stimulation at the ear which targets the auricular branch of the vagus nerve.
219276160|NCT06456385|DEVICE|Sham Auricular Stimulation|The sham auricular stimulation administers electrical stimulation at the ear lobe which has less auricular branch of the vagus nerve.
219276161|NCT02643264|OTHER|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
219276162|NCT02643264|OTHER|Sham rTMS|Sham stimulation with the same regimen as active treatment
219276163|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
219276164|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
219276165|NCT00015847|BIOLOGICAL|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
219276166|NCT00015847|DRUG|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
219276167|NCT00636415|DRUG|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
219276168|NCT01877148|DEVICE|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
219276169|NCT01877148|BEHAVIORAL|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
219276170|NCT00709228|DRUG|PegIntron|1.5 ug/kg/week
219276171|NCT00709228|DRUG|Rebetol|800-1200 mg/day
219276172|NCT00975468|OTHER|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
219276173|NCT01007110|DIETARY_SUPPLEMENT|DHA|Docosahexaenoic Acid (DHA) from algal oil
219276174|NCT01007110|OTHER|Placebo|Placebo capsule
219276175|NCT05984927|GENETIC|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
219276176|NCT05614726|DIETARY_SUPPLEMENT|575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase|A multi-strain probiotic blend
219276177|NCT02870972|DRUG|BCX7353|Plasma kallikrein inhibitor
219276178|NCT02870972|DRUG|Placebo|
219276179|NCT05444608|BEHAVIORAL|Breast milk olfactory stimulation|Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
219276180|NCT05444608|BEHAVIORAL|White noise auditory stimulation|Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
219276181|NCT02617953|DEVICE|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
219276182|NCT02617953|DEVICE|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
219276183|NCT02617953|DEVICE|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
219276184|NCT02714712|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
219276185|NCT05272709|DRUG|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
219276186|NCT05272709|DRUG|Darolutamide|Darolutamide will be administered orally, twice daily, for up to 12 months.
219276187|NCT06179121|OTHER|DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease|Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S\&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.
219276188|NCT00168389|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
219276189|NCT00168389|OTHER|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
219276190|NCT04828941|DEVICE|Electronic Headache Diary|The electronic headache diary is an app-based diary that permits the registration of headaches, their acute treatment and their associated work incapacity. It also permits real-time monitoring of these data.
219276191|NCT04828941|DEVICE|Paper Diary|The paper diary permits the registration of the same variables as the electronic diary in paper format.
219276192|NCT05217667|DRUG|ARO-ANG 3 Injection|Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
219276193|NCT01183039|OTHER|Training|20 sessions of training
219276194|NCT03735043|DEVICE|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
219276195|NCT02493062|DEVICE|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
219276196|NCT00016588|DRUG|Tenofovir disoproxil fumarate|
219276197|NCT05043922|DRUG|CYH33|a Selective PI3Kα Inhibitor
219276198|NCT04201873|BIOLOGICAL|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
219276199|NCT04201873|BIOLOGICAL|Pembrolizumab|Given IV
219276200|NCT04201873|OTHER|Placebo Administration|Given IV
219276201|NCT04201873|DRUG|Poly ICLC|Given IM
219276202|NCT00566540|DRUG|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
219276203|NCT00566540|DRUG|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
219276204|NCT00566540|RADIATION|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
219276205|NCT00566540|PROCEDURE|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
219276206|NCT01290276|DRUG|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
219276207|NCT01290276|DRUG|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
219276208|NCT01290276|DRUG|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
219276209|NCT01290276|DRUG|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
219276210|NCT01327612|DRUG|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
219276211|NCT01327612|BIOLOGICAL|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
219276212|NCT01327612|BIOLOGICAL|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
219276213|NCT01327612|BIOLOGICAL|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
219276214|NCT01276808|PROCEDURE|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
219276215|NCT01276808|PROCEDURE|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
219276216|NCT04014244|DRUG|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
219276217|NCT04014244|PROCEDURE|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
219276218|NCT02906826|DEVICE|Video game|Video game operated by performing therapy correctly
219276219|NCT02777437|DRUG|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
219276220|NCT02470676|DEVICE|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
219276221|NCT02470676|DRUG|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
219276222|NCT05563389|DRUG|Atorvastatin 20mg|active arm
219276223|NCT05563389|DRUG|Placebo|placebo arm
219276224|NCT01167790|PROCEDURE|buccal cavity examination|autofluorescence examination
219276225|NCT05569421|DRUG|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
219276226|NCT05569421|DRUG|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
219276227|NCT06690372|OTHER|virtual reality exercise|"Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced."
219276228|NCT05770960|DRUG|Naloxegol|Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
219276229|NCT05770960|DRUG|codeine phosphate|Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
219276230|NCT05770960|OTHER|Placebo|Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
219276231|NCT03242512|BIOLOGICAL|TK006|Subcutaneous injection
219276232|NCT00527761|DRUG|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
219276233|NCT00527761|DRUG|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
219276234|NCT00527761|DRUG|Temodar|150 mg by mouth (PO) on Days 1 - 5.
219276235|NCT01689857|DEVICE|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
219276236|NCT01689857|DEVICE|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
219276237|NCT03555253|BEHAVIORAL|Resilience-Based Program for Support Partners of PwMS|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
219276238|NCT03944655|DRUG|Strepsils Anaesthetic Formula|Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
219276239|NCT03944655|DIETARY_SUPPLEMENT|Clear Mint Drops|Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
219276240|NCT03965442|DRUG|Control|Patients who underwent mastectomy under standard general anesthesia
219276241|NCT03965442|DRUG|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
219276242|NCT05105087|DRUG|Perflubutane Microbubble|Given subdermally
219276243|NCT05105087|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo ultrasound
219276244|NCT02171299|PROCEDURE|Wound infiltration with local anaesthetic|
219276245|NCT02171299|DRUG|Ropivacaine|
219276246|NCT04631731|DIAGNOSTIC_TEST|Blood screening|Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
219276247|NCT04631731|DIAGNOSTIC_TEST|Tissue screening|Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.
219276248|NCT04113070|DEVICE|Anthropometric measuring|To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
219276249|NCT04113070|OTHER|Growth environment evaluation|The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
219276250|NCT05614622|DRUG|Cyclopentolate Hydrochloride 1.0% eye drops|A short-acting mydriatic agent
219276251|NCT04544150|OTHER||
219276252|NCT03730506|DEVICE|Intra oral scanner|computer guided implant
219276253|NCT01991327|DRUG|Androxal|
219276254|NCT01991327|DRUG|Placebo|
219276255|NCT03738475|DRUG|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
219276256|NCT03738475|DRUG|Placebo|Administered intravenously on days 1 and 8.
219276257|NCT00737477|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
219276258|NCT04966975|OTHER|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
219276259|NCT04139382|OTHER|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
219276260|NCT04139382|OTHER|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
219276261|NCT00002475|BIOLOGICAL|allogeneic tumor cell vaccine|
219276262|NCT00002475|BIOLOGICAL|autologous tumor cell vaccine|
219276263|NCT00002475|BIOLOGICAL|recombinant interferon alfa|
219276264|NCT00002475|BIOLOGICAL|recombinant interferon gamma|
219276265|NCT00002475|BIOLOGICAL|sargramostim|
219276266|NCT00002475|DRUG|cyclophosphamide|
219276267|NCT03477487|BIOLOGICAL|XT-150|Human IL-10 variant transgene in a plasmid DNA vector
219276268|NCT00581477|DRUG|Droxidopa Oral Product|Droxidopa administered in increasing dosages up to 300 mg
219276269|NCT04659564|DEVICE|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
219276270|NCT05695560|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
219276271|NCT00562458|DRUG|anastrozole|
219276272|NCT03106753|DRUG|Bupivacaine|intrathecal bupivacaine 7.5 mg
219276273|NCT03106753|DRUG|Terbutaline|0.25 mg Terbutaline subcutaneously
219276274|NCT02323958|OTHER|acupoint stimulation|stimulation is given at acupoints
219276275|NCT02323958|OTHER|non-acupoint stimulation|stimulation is given at acupoints
219276276|NCT02323958|OTHER|electrode attached|electrodes are attached to skin
219276277|NCT02323958|DEVICE|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
219276278|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
219276279|NCT03924102|DRUG|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with \[11C\] Acetate.
219276280|NCT02885584|DEVICE|High frequency percussive ventilation|
219276281|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing to start with home respiratory polygraphy (APNIA)
219276282|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
219276283|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)
219276284|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
219276285|NCT04060693|DEVICE|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
219276286|NCT01336049|DRUG|Nimotuzumab|Nimotuzumab 200mg/week
219276287|NCT05762952|DRUG|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
219276288|NCT05762952|DRUG|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
219276289|NCT01853475|DRUG|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
219276290|NCT01853475|DRUG|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
219276291|NCT01853475|DRUG|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
219276292|NCT01853475|DRUG|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
219276293|NCT06228716|DEVICE|Training with hybrid simulation method|Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher. The application was considered successful if they completed all application steps correctly from start to finish. The training took approximately 40 minutes. After the practical training, the individuals' questions, if any, were answered and the training was terminated.
219276294|NCT06228716|OTHER|Broshure|Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training. After the training, any questions the individuals had were answered and the training was ended.
219276295|NCT03836859|DRUG|rhNGF 20μg/mL|"Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days."
219276296|NCT03836859|OTHER|Placebo|Vehicle: formulation containing L-methionine as excipient.
219276297|NCT05575817|BEHAVIORAL|Web Based Patient Tutorial on Prolonged Grief Disorder Therapy|"The patient tutorial will contain 9 modules, each designed to be used flexibly in conjunction with Prolonged Grief Disorder Therapy (PGDT) telehealth sessions with the therapist. Each module takes about 15-30 minutes to complete. The patient tutorial consists of information about grief and adaptation to loss, including a description of seven healing milestones that are the focus of PGDT and an explanation of prolonged grief and how to understand it. In addition, the tutorial has descriptions of the procedure, goals and rationale for a series of in-session therapeutic exercises to be undertaken with the therapist, as well as descriptions and encouragement to participate in interim therapeutic activities (i.e., homework) assigned by the therapist after each treatment session. The tutorial also contains a self-assessment component for each module that can be completed by the patient and shared with the therapist."
219276298|NCT05824000|DEVICE|Eye drops for itchy and water eyes|Ocular drops for itchy and watery eyes
219276299|NCT02859090|PROCEDURE|tonsillectomy|
219276300|NCT02859090|BIOLOGICAL|blood sample|
219276301|NCT01484600|DRUG|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
219276302|NCT01484600|DRUG|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
219276303|NCT05005962|DEVICE|Neurothrombectomy|Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
219276304|NCT00605332|DEVICE|inferior vena cava filter|Crux Biomedical IVC Filter
219276305|NCT03106454|DRUG|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
219276306|NCT03106454|DRUG|Norethindrone|Norethindrone 1.05mg
219276307|NCT01285700|DRUG|Lamazym|ERT, infusion weekly
219276308|NCT05701878|BEHAVIORAL|SMARTest mobile app for COVID-19 self-testing|The mobile app has self-testing features and information with regard to self-testing and COVID-19.
219276309|NCT02207855|DRUG|Chloroprocaine|
219276310|NCT01359787|DRUG|Mapracorat|Daily topical application
219276311|NCT01359787|DRUG|Vehicle without active|Daily topical application
219276312|NCT04851639|OTHER|Wolverhampton Assessment Tool|a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
219276313|NCT06189885|DRUG|Cefazolin with Daptomycin|For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.
219276314|NCT06189885|DRUG|Cefazolin with vancomycin|Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
219276315|NCT05905159|BEHAVIORAL|ABM|Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures
219276316|NCT05905159|BEHAVIORAL|Control|Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
219276317|NCT05861245|RADIATION|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~* For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~* For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
219276318|NCT00054678|DRUG|MyoCell™|
219276319|NCT00054678|DEVICE|MyoCath™|
219276320|NCT01932476|DIETARY_SUPPLEMENT|Gluten Challenge|Three-day gluten containing dietary challenge.
219276321|NCT01932476|DIETARY_SUPPLEMENT|Sham Challenge|Three-day sham (gluten free) dietary challenge
219276322|NCT03982212|DRUG|Copaxone|"* Agent: Glatiramer acetate (Copaxone®)~* Dose: 40 mg~* Route: Intratumoral injection~* Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
219276323|NCT03145922|OTHER|Observational Study|Observational study utilizing bronchoscopy, and imaging
219276324|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
219276325|NCT05969860|PROCEDURE|Clinical Encounter|Receive treatment in clinic
219276326|NCT05969860|OTHER|Home Health Encounter|Receive at-home treatment
219276327|NCT05969860|OTHER|Quality-of-Life Assessment|Ancillary studies
219276328|NCT05969860|OTHER|Questionnaire Administration|Ancillary studies
219276329|NCT05347862|OTHER|Control group|At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.
219276330|NCT05347862|OTHER|Physical activity promotion|"The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study."
219276331|NCT00759642|DRUG|lapatinib|lapatinib 1500 mg PO daily
219276332|NCT04545528|BEHAVIORAL|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
219276333|NCT05333822|DIETARY_SUPPLEMENT|Bashan|a vegetable plant based compound drink add after three meals for 14 days
219276334|NCT05333822|OTHER|water|water as placebo
219276335|NCT01340001|PROCEDURE|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
219276336|NCT06456489|DRUG|Solumedrol|125 mg methylprednisolone intravenous pulse on 2 consecutive days
219276337|NCT05335200|DIAGNOSTIC_TEST|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
219276338|NCT06377085|DRUG|Placebo for the AZA 10mg/m^2|Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.
219276339|NCT06377085|DRUG|Placebo for the AZA 20mg/m^2|Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.
219276340|NCT06377085|DRUG|Placebo for the AZA 35mg/m^2|Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.
219276341|NCT06377085|DRUG|Placebo for the AZA 75mg/m^2|Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.
219276342|NCT06377085|DRUG|5-Azacytidine 10mg/m^2|5-Azacytidine 10mg/m\^2, one-time subcutaneous injection
219276343|NCT06377085|DRUG|5-Azacytidine 20mg/m^2|5-Azacytidine 20mg/m\^2, one-time subcutaneous injection
219276344|NCT06377085|DRUG|5-Azacytidine 35mg/m^2|5-Azacytidine 35mg/m\^2, one-time subcutaneous injection
219276345|NCT06377085|DRUG|5-Azacytidine 75mg/m^2|5-Azacytidine 75mg/m\^2, one-time subcutaneous injection
219276346|NCT05636228|DRUG|INV-102|INV-102 Ophthalmic Solution
219276347|NCT05636228|DRUG|Vehicle|Vehicle Ophthalmic Solution
219276348|NCT00004178|BIOLOGICAL|therapeutic autologous lymphocytes|
219276349|NCT00884416|DRUG|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
219276350|NCT02803593|BEHAVIORAL|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
219276351|NCT02803593|BEHAVIORAL|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
219276352|NCT00005871|DRUG|fluorouracil|
219276353|NCT00005871|DRUG|rubitecan|
219276354|NCT06355323|OTHER|Blood test|Blood test
219276355|NCT06355323|OTHER|chest CT scan|chest CT scan
219276356|NCT05143138|DEVICE|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
219276357|NCT00302523|DRUG|Tacrolimus|FK506,0.1mg/kg/d
219276358|NCT01993849|DRUG|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
219276359|NCT01993849|OTHER|Placebo|Placebo, designed to match in appearance to NAC
219276360|NCT00164710|DRUG|sulfadoxine-pyrimethamine|
219276361|NCT00164710|DRUG|amodiaquine plus sulfadoxine-pyrimethamine|
219276362|NCT00164710|DRUG|amodiaquine plus artesunate|
219276363|NCT00164710|DRUG|chlorproguanil-dapsone plus artesunate|
219276364|NCT00164710|DRUG|lumefantrine-artemether|
219276365|NCT00480675|PROCEDURE|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
219276366|NCT00480675|PROCEDURE|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
219276367|NCT02023749|DIETARY_SUPPLEMENT|Nut group|
219276368|NCT06411509|OTHER|TC plus active rTMS|The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.
219276369|NCT06411509|OTHER|Tai Chi plus sham rTMS|Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.
219276370|NCT06411509|BEHAVIORAL|TC-alone|Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down
219276371|NCT06411509|BEHAVIORAL|Low intensity physical exercise|To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
219276372|NCT05450536|OTHER|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
219276373|NCT00927498|DRUG|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
219276374|NCT00927498|DRUG|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
219363017|NCT05420389|OTHER|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
219276375|NCT05289219|BEHAVIORAL|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
219276376|NCT00728299|DRUG|PomWonderful Juice|8 oz per day each day for 78 weeks
219276377|NCT00728299|DRUG|Placebo juice|8 oz per day for 78 weeks
219276378|NCT04430803|DIETARY_SUPPLEMENT|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
219276379|NCT04430803|OTHER|Control Water|A glass of tap water
219276380|NCT03659383|COMBINATION_PRODUCT|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
219276381|NCT02735434|BEHAVIORAL|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
219276382|NCT02735434|OTHER|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
219276383|NCT00499278|BEHAVIORAL|Rehabilitation after joint replacement surgery|
219276384|NCT05773911|DEVICE|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
219276385|NCT05773911|DEVICE|Reciprocal Chitosan brush|Reciprocal Chitosan brush
219276386|NCT05584605|BEHAVIORAL|Aerobic treadmill training|The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
219276387|NCT05584605|BEHAVIORAL|Stretching exercise|Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
219276388|NCT03924115|DEVICE|Transmedial Psychoeducational Program to improve adherence full or partial (PS)|Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
219276389|NCT02627378|OTHER|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
219276390|NCT02627378|OTHER|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
219276391|NCT04088045|DEVICE|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
219276392|NCT02704013|DRUG|Oxybutynin|Anticholinergic
219276393|NCT01497106|BEHAVIORAL|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
219276394|NCT01497106|BEHAVIORAL|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
219276395|NCT03443414|DRUG|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
219276396|NCT03443414|DRUG|Placebo|Placebo solution
219276397|NCT06485739|DRUG|Irinotecan liposomes combined with cisplatin/carboplatin|Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
219276398|NCT01518907|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
219276399|NCT02353416|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
219276400|NCT02353416|OTHER|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
219276401|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
219276402|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
219276403|NCT01079247|OTHER|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
219276404|NCT01079247|OTHER|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
219276405|NCT00000598|BEHAVIORAL|diet, fat-restricted|
219276406|NCT00000598|BEHAVIORAL|exercise|
219276407|NCT04569019|OTHER|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
219276408|NCT00760344|DRUG|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
219276409|NCT00760344|DRUG|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
219276410|NCT00760344|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
219276411|NCT00760344|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
219276412|NCT00760344|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
219276413|NCT00760344|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
219276414|NCT04380077|PROCEDURE|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
219276415|NCT04380077|PROCEDURE|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
219276416|NCT00377988|DRUG|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
219276417|NCT00377988|DRUG|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
219276418|NCT02660515|PROCEDURE|Additional wrist arthroscopy|
219276419|NCT02660515|PROCEDURE|ORIF|
219276420|NCT00940745|DEVICE|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
219276421|NCT00940745|DRUG|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
219276422|NCT01708434|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
219276423|NCT01389089|BEHAVIORAL|ice gel pack|ice gel pack combined with elevation
219276424|NCT01389089|OTHER|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
219276425|NCT01389089|DEVICE|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
219276426|NCT01181791|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
219276427|NCT01181791|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
219276428|NCT05692583|DIAGNOSTIC_TEST|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
219276429|NCT05490212|OTHER|Single Molecule Array (SiMoA)|The Single Molecule Array (SiMoA), capable of quantifying multiple salivary cytokines from a single sample source at a femtoscale level. The SiMoA platform has been adapted to detect up to nine inflammatory biomarkers, including CRP, PCT, tumor necrosis factor α (TNF α) and ILs 1ß, 6, and 8 in neonatal saliva.
219276430|NCT02165995|PROCEDURE|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
219276431|NCT02165995|PROCEDURE|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
219276432|NCT02103114|DRUG|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay"
219276433|NCT02103114|OTHER|Placebo|Normal saline placebo
219276434|NCT03004404|DRUG|Placebo|Placebo
219276435|NCT03004404|DRUG|BI 730357|powder for reconstitution of an oral solution (PfoS)
219276436|NCT03004404|DRUG|BI 730357|BI 730357 film-coated tablet
219276437|NCT06154928|OTHER|Drinking Warm Water Intervention|Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
219276438|NCT06798753|DEVICE|Occlusion Balloon Catheter|The occlusion balloon catheter (OBC) is a type of ureteral catheter equipped with a small inflatable balloon at its tip. When inflated, the balloon can help prevent the migration of stone fragments.
219276439|NCT06798753|DEVICE|5FR Ureteral Catheter|The 5FR ureteral catheter (5FR-UC) is an open-ended small-caliber tube inserted at the beginning of PCNL to facilitate visualization of the collecting system using fluoroscopy and assist with renal access.
219276440|NCT05553093|DRUG|Tirzepatide|Tirzepatide ih qw
219276441|NCT05553093|DRUG|Insulin Glargine|6 IU ih qd
219276442|NCT06497803|OTHER|Nurse-Led Body Protection Education|"Based on BST and Safe Touches education programs and in line with the studies conducted in the literature on children who are not visually impaired, NLBPE was created by the researchers (Akgul et al., 2021; Citak-Tunc et al., 2018; Pulido, 2019; Wurtele, 2007). The program aims to teach visually impaired children how to protect the private parts of their bodies, to distinguish between good and bad touch, to distinguish between good and bad secrets, to say no, scream, and ask for help when necessary. As education tools, dolls and distress whistles were used. In order for children to learn the private parts of their bodies, a doll was used. The practice of Say No, Scream, Run, and Blow Your Whistle While Running in order for the students to protect their body from bad touch was applied by the students one by one firstly, and in groups later."
219276443|NCT06497803|OTHER|Reminder Education Brochure|The brochure was prepared in line with the NLBPE and included what is a good touch and a bad touch, how to distinguish a good touch from a bad touch, examples of good touch and bad touch, and what to do when encountered with a bad touch (Say No, Scream, Run, and Blow Your Whistle While Running). The brochure, the content of which was prepared by the researcher, was translated into Braille Alphabet by a visually impaired teacher working at the school where the research was conducted, before it was distributed to the intervention group members.
219276444|NCT03883464|OTHER|Diet|Restriction in postoperative fat diet
219276445|NCT04883112|DEVICE|Magnetic Tape®|Magnetic tape® is applied without creating any tension over low back
219276446|NCT04883112|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension over low back
219276447|NCT03773913|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
219276448|NCT01530737|DRUG|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
219276449|NCT01530737|OTHER|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
219276450|NCT01336998|DIETARY_SUPPLEMENT|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
219276451|NCT03933462|DEVICE|InnoSpire Go|Participants will use for 30 days.
219276452|NCT03933462|DEVICE|Jet Nebulizer|Participants will use for 30 days.
219276453|NCT04011007|PROCEDURE|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
219276454|NCT01937975|DRUG|Grazoprevir|100 mg oral tablet administered once a day for 10 days
219276455|NCT01937975|DRUG|Elbasvir|50 mg oral tablet administered once a day for 10 days
219276456|NCT06327776|OTHER|Serum and saliva biomarkers|2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.
219276457|NCT02028325|DRUG|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
219276458|NCT02522728|DEVICE|Triathlon CR|Implantation of Knee Prosthesis
219276459|NCT02522728|DEVICE|Triathlon PS|Implantation of Knee Prosthesis
219276460|NCT00276835|BIOLOGICAL|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
219276461|NCT00276835|DIETARY_SUPPLEMENT|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
219276462|NCT06102447|DRUG|Netopitam Palonosetron capsules and dexamethasone|On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
219276463|NCT02465736|DRUG|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
219276464|NCT02465736|DRUG|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
219276465|NCT02465736|RADIATION|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
219276466|NCT02465736|PROCEDURE|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
219276467|NCT02465736|DRUG|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
219276468|NCT02465736|DRUG|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
219276469|NCT03131947|OTHER|HIV positive patients|As above
219276470|NCT05210075|BEHAVIORAL|Mindful with your Baby program|The training Mindful with your baby consists of eight weekly 2-h sessions, plus a follow-up session 8 weeks later. The first and the fifth sessions are with the mothers only. The rest of the sessions are with both mothers and babies present. The sessions are finished by explaining the new home practices. Home practice consists of reading handouts about mindfulness and mindful parenting for mothers with a baby, formal and informal meditation practice.
219276471|NCT00711308|DRUG|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
219276472|NCT00711308|DRUG|acenocoumarol|acenocoumarol for 6 months
219276473|NCT04852913|OTHER|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
219276474|NCT04852913|OTHER|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
219276475|NCT01099917|DRUG|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
219276476|NCT02850042|BEHAVIORAL|Occupation-based practice (OBP)|
219276477|NCT02850042|BEHAVIORAL|Modified-constraint induced therapy (m-CIT)|
219276478|NCT00980746|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
219276479|NCT00980746|DRUG|Placebo|oral route
219276480|NCT00914745|DRUG|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
219276481|NCT02767752|DIETARY_SUPPLEMENT|T-ChOS|
219276482|NCT02767752|DRUG|Gemcitabine|
219276483|NCT02767752|DIETARY_SUPPLEMENT|Placebo|
219276484|NCT02767752|DRUG|Capecitabine|
219276485|NCT04692467|DRUG|Amlodipine 5mg|Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
219276486|NCT05262452|DEVICE|ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system|Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound
219276487|NCT05262452|DRUG|FOLFIRINOX regimen|"a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis"
219276488|NCT01160237|BIOLOGICAL|PandemrixTM|One dose intramuscular injection
219276489|NCT01160237|BIOLOGICAL|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
219276490|NCT00169247|DRUG|cetuximab|
219276491|NCT00169247|DRUG|Cisplatin|
219276492|NCT00169247|PROCEDURE|Radiotherapy 70 Gy, 35 fractions|
219276493|NCT00422734|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
219276494|NCT00422734|DRUG|Placebo|placebo tablet taken by mouth once a day for 12 weeks
219276495|NCT02400008|PROCEDURE|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
219276496|NCT01831037|OTHER|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (\>50% of cases).
219276497|NCT01831037|OTHER|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
219276498|NCT02441998|OTHER|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
219276499|NCT01445327|OTHER|Specimen collection|
219276500|NCT03431753|DIAGNOSTIC_TEST|PSA, STHLM3 and mpMRI for PC detection|"Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination."
219276501|NCT04193423|OTHER|Neck extensors training versus deep cervical flexors training, compared to a control group.|"During the first month, the participants of the experimental groups will come at Rehabilitation Service to do the exercises individually and supervised by the physiotherapist and to received the conventional treatment (10 minutes of infrared heat, 10 minutes of massage and 15 minutes of TENS). The last six months, they will perform daily home exercises.~* A-group: the degrees respect to the floor in wich each participant can hold the craniocervical extension and the cervicothoracic extension during 5 seconds will bo measured with the BDI.~* B-group: Using an air-filled pressure sensor placed behind the neck, the physiotherapist will identify the target level that the patient can hold steadily a craniocervical flexion (CCF) for 5 seconds in a controlled manner. They will train following the protocol described by Jull et al.~Of each of this exercises, they will perform 10 isometric contractions, at the corresponding degrees or target level, of 10 seconds with a rest of 3-5 seconds."
219276502|NCT02432651|DRUG|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
219276503|NCT02432651|DRUG|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
219276504|NCT02432651|DRUG|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
219276505|NCT02432651|DRUG|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
219276506|NCT05317442|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"
219276507|NCT04513093|OTHER|Aromatherapy Massage|The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
219276508|NCT02718261|DRUG|Pantoprazole|
219276509|NCT02718261|DRUG|Saline 0.9% (matching placebo)|
219276510|NCT00368875|DRUG|vorinostat|Given orally
219276511|NCT00368875|DRUG|paclitaxel|Given IV
219276512|NCT00368875|BIOLOGICAL|bevacizumab|Given IV
219276513|NCT05212753|DEVICE|Conventional physical therapy|Hot packs or hot water bags are superficial warming agents that will be used to heat muscle tissue, reduce muscle spasms and pain sensation. TENS is a pain reliever application.
219276514|NCT05212753|OTHER|Lumbar stabilization exercises|Training about the concepts of stabilization and abdominal bracing is given before starting the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface. The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
219276515|NCT05212753|OTHER|Breathing exercises|Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During diaphragmatic breathing, attention is focused on the correct abdominal breathing. The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over-breathing. This intervention also includes Sleep Hygiene education to the subjects,
219276516|NCT01613144|DEVICE|OsseoScrew Spinal Fixation System|Surgical intervention
219276517|NCT05610124|OTHER|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276518|NCT05610124|OTHER|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276519|NCT05610124|OTHER|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276520|NCT05610124|OTHER|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276521|NCT05610124|OTHER|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276522|NCT05610124|OTHER|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
219276523|NCT03482089|PROCEDURE|Cystoprostatectomy|Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
219276524|NCT03482089|RADIATION|external beam radiotherapy|Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
219276525|NCT03663062|DIAGNOSTIC_TEST|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
219276526|NCT03586908|DRUG|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
219276527|NCT05844059|OTHER|Validated questionnaires|BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
219276528|NCT01305239|DRUG|Aromasin|Aromasin 25 mg daily.
219276529|NCT01512316|DRUG|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
219276530|NCT01512316|DRUG|Lactose pill|one dose, 2hrs prior to fmri
219276531|NCT01512316|GENETIC|Saliva sample|Buccal cell material will be sampled from all participants on day3
219276532|NCT01512316|OTHER|Functional neuroimaging (fMRI)|
219276533|NCT00213200|DRUG|morphine, amethocaine|
219276534|NCT02865512|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
219276535|NCT00211224|DRUG|Riluzole|
219276536|NCT05756296|PROCEDURE|Therapeutic hypothermia|whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
219276537|NCT03362385|OTHER|Patients with OSA based on sleep study|Polysomnography or Polygraphy
219276538|NCT03362385|OTHER|Patients without OSA based on sleep study|Polysomnography or Polygraphy
219276539|NCT04237532|DRUG|Intranasal Dexmedetomidine|The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.
219276540|NCT04237532|DRUG|Sublingual Dexmedetomidine|The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.
219276541|NCT05932953|OTHER|questionary|questionary about cutaneous tolerance
219276542|NCT01690377|BIOLOGICAL|PDC or myDC|PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.
219276543|NCT01173068|DRUG|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
219276544|NCT00334334|BIOLOGICAL|Pneumococcal (vaccine)|
219276545|NCT02800551|RADIATION|dose-intensified image-guided SBRT using simultaneous integrated boost|
219276546|NCT02800551|RADIATION|External 3-dimensional conformal radiotherapy (3D-CRT)|
219276547|NCT01522690|OTHER|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
219276548|NCT04317261|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
219276549|NCT03289702|DRUG|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
219276550|NCT03289702|DRUG|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
219276551|NCT03908593|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
219276552|NCT04662983|DEVICE|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
219276553|NCT02761863|OTHER|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
219276554|NCT05974683|DRUG|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
219276555|NCT05974683|DRUG|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
219276556|NCT04268537|DRUG|PD-1 blocking antibody+standard treatment|After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219276557|NCT04268537|DRUG|Thymosin+standard treatment|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219276558|NCT04268537|OTHER|standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219276559|NCT03557606|PROCEDURE|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
219276560|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
219276561|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
219276562|NCT00120809|DRUG|Sulfadoxine-pyrimethamine|
219276563|NCT03229486|DRUG|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
219276564|NCT03229486|DRUG|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
219276565|NCT01228877|OTHER|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
219276566|NCT02858128|OTHER|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
219276567|NCT00359047|BEHAVIORAL|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
219276568|NCT00359047|BEHAVIORAL|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
219276569|NCT02078492|DRUG|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
219276570|NCT02078492|DRUG|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
219276571|NCT02078492|DRUG|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
219276572|NCT05578508|DRUG|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
219276573|NCT03828188|DIETARY_SUPPLEMENT|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
219276574|NCT03828188|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
219276575|NCT00832468|OTHER|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
219276576|NCT00832468|OTHER|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
219276577|NCT01461005|DEVICE|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
219276578|NCT01544634|DRUG|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
219276579|NCT01544634|DRUG|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
219276580|NCT01544634|DRUG|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
219276581|NCT01544634|DRUG|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
219276582|NCT00808002|DRUG|Raltegravir|Raltegravir 400 mg every 12 hours
219276583|NCT00808002|DRUG|Maraviroc|Maraviroc 300 mg every 12 hours
219276584|NCT00808002|DRUG|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
219276585|NCT02080546|PROCEDURE|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
219276586|NCT02080546|PROCEDURE|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
219276587|NCT02080546|DEVICE|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
219276588|NCT04423419|PROCEDURE|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
219276589|NCT04423419|PROCEDURE|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
219276590|NCT04423419|OTHER|IV analgesia|IV analgesia
219276591|NCT01403649|BEHAVIORAL|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
219276592|NCT01403649|OTHER|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
219276593|NCT00983112|DRUG|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
219276594|NCT00983112|DRUG|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
219276595|NCT01666093|PROCEDURE|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
219276596|NCT03999632|OTHER|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
219276597|NCT03702387|PROCEDURE|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
219276598|NCT02670122|DEVICE|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
219276599|NCT03321253|DEVICE|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
219276600|NCT01262547|DEVICE|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
219276601|NCT01262547|PROCEDURE|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
219276602|NCT03035669|BEHAVIORAL|Mindfulness group|8 week program
219276603|NCT03035669|BEHAVIORAL|Reading group|8 week program
219276604|NCT03659331|DIETARY_SUPPLEMENT|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
219276605|NCT00303706|PROCEDURE|Endoscopic Radial Artery Harvest|
219276606|NCT02901847|OTHER|PAD tailored care|PAD tailored care
219276607|NCT02690844|DRUG|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
219276608|NCT02690844|DRUG|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
219276609|NCT02690844|DRUG|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
219276610|NCT00781495|DEVICE|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
219276611|NCT01299311|BEHAVIORAL|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
219276612|NCT01299311|BEHAVIORAL|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
219276613|NCT03774147|DEVICE|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
219276614|NCT01888549|DRUG|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
219276615|NCT01888549|DRUG|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
219276616|NCT01888549|DRUG|placebo|
219276617|NCT02683499|PROCEDURE|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
219276618|NCT03212768|PROCEDURE|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
219276619|NCT03510767|DRUG|TQ-B3525|TQ-B3525 p.o. qd
219276620|NCT05790070|DIETARY_SUPPLEMENT|Betaine|3g/ twice daily (separated by \~12 hours) betaine anhydrous
219276621|NCT05790070|OTHER|Placebo|3g/ twice daily (separated by \~12 hours) cellulose placebo
219276622|NCT00243074|DRUG|cediranib maleate|Given orally
219276623|NCT00243074|OTHER|laboratory biomarker analysis|Correlative studies
219276624|NCT06442124|DIAGNOSTIC_TEST|Electromyography (EMG)|The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction
219276625|NCT04033965|GENETIC|Corellation of Mutations, TILs and Age in Breast Cancer|
219276626|NCT05962190|BEHAVIORAL|Diet|High fat (\~60% of total energy intake) diet enriched with either SFA or UFA
219276627|NCT05321849|OTHER|Echocardiography guide|Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
219276628|NCT02909933|DRUG|liraglutide|
219276629|NCT02909933|DRUG|metformin and liraglutide|
219276630|NCT04288349|PROCEDURE|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
219276631|NCT04288349|DRUG|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
219276632|NCT04288349|DRUG|epinephrine + saline|epinephrine + saline
219276633|NCT03570762|PROCEDURE|hybrid percutaneous intervention|
219276634|NCT06012981|BEHAVIORAL|ACT|"The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree."
219276635|NCT02481570|OTHER|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
219276636|NCT00664534|DRUG|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
219276637|NCT00664534|DRUG|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
219276638|NCT00542204|BEHAVIORAL|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
219276639|NCT05879237|DRUG|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
219276640|NCT05879237|DRUG|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
219276641|NCT04626349|OTHER|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
219276642|NCT04626349|OTHER|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
219276643|NCT05421468|OTHER|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
219276644|NCT01535027|DRUG|teriparatide|teriparatide 20 ug/day, sc.
219276645|NCT01535027|DRUG|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
219276646|NCT01535027|DRUG|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
219276647|NCT04996433|BEHAVIORAL|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
219276648|NCT04996433|BEHAVIORAL|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
219276649|NCT04996433|BEHAVIORAL|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
219276650|NCT04996433|BEHAVIORAL|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
219276651|NCT04996433|BEHAVIORAL|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
219276652|NCT04996433|BEHAVIORAL|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
219276653|NCT04996433|BEHAVIORAL|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
219276654|NCT04996433|BEHAVIORAL|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
219276655|NCT04996433|BEHAVIORAL|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
219276656|NCT04996433|BEHAVIORAL|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
219276657|NCT04996433|DRUG|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant."
219276658|NCT05078177|DRUG|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
219276659|NCT03041792|DRUG|Liraglutide|Liraglutide
219276660|NCT03041792|OTHER|Placebo|Placebo
219276661|NCT02623998|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
219276662|NCT02623998|DRUG|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
219276663|NCT02623998|BEHAVIORAL|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
219276664|NCT00851565|PROCEDURE|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~1. Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~2. Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~3. High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~4. High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
219276665|NCT00851565|PROCEDURE|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
219276666|NCT01857336|OTHER|infusion of G-CSF mobilized peripheral harvest|
219276667|NCT04978090|DEVICE|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
219276668|NCT01337362|PROCEDURE|Insulin clamp|Patients will be exposed to low bloodsugar
219276669|NCT05030051|DEVICE|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
219276670|NCT06239233|PROCEDURE|Laparoscopic cholecystectomy|"The surgeon makes small incisions in the abdominal wall, usually around the navel.~Trocars (hollow tubes) are inserted through these incisions to provide access for the laparoscope and specialized instruments.~A laparoscope, a thin tube with a light and camera, is inserted through one of the trocars. It allows the surgical team to visualize the abdominal cavity on a monitor.~The surgeon carefully identifies the gallbladder and the cystic duct, which connects the gallbladder to the common bile duct.~The cystic duct and artery are clipped and cut to disconnect the gallbladder from the biliary system. This step ensures the safe removal of the gallbladder.~The surgeon gently detaches the gallbladder from the liver bed and removes it through one of the small incisions.~Any bleeding vessels are sealed, and the small incisions are closed with stitches or surgical glue."
219276671|NCT04263987|PROCEDURE|Moses laser enucleation of prostate|Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
219276672|NCT04565002|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
219276673|NCT00035386|PROCEDURE|trans-right ventricular alcohol septal ablation (TRVASA)|
219276674|NCT03344068|RADIATION|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
219276675|NCT03344068|DRUG|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
219276676|NCT03344068|DIETARY_SUPPLEMENT|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
219276677|NCT00373451|DRUG|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)
219276678|NCT00373451|DRUG|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
219276679|NCT00373451|DRUG|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
219276680|NCT01508663|DEVICE|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
219276681|NCT01508663|DRUG|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
219276682|NCT00735280|DRUG|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
219276683|NCT03138642|RADIATION|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
219276684|NCT02786472|BEHAVIORAL|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
219276685|NCT02786472|BEHAVIORAL|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
219276686|NCT02786472|BEHAVIORAL|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
219276687|NCT02786472|BEHAVIORAL|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
219276688|NCT04051086|BIOLOGICAL|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples"
219276689|NCT04051086|BIOLOGICAL|Urine and blood samples|"Only one visit for each participant~* Medical history~* Urine and blood samples"
219276690|NCT00439192|DRUG|ELB245|
219276691|NCT00439192|DRUG|Tolterodine|
219276692|NCT02727569|DEVICE|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
219276693|NCT02727569|DEVICE|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
219276694|NCT02727569|DEVICE|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
219276695|NCT03862014|DEVICE|SDF+KI|Molar with MIH will be treated with SDF+KI
219276696|NCT03862014|DEVICE|SDF+KI+GIC(SMART)|Molar with MIH will be treated with SDF+KI+GIC(SMART)
219276697|NCT02963662|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
219276698|NCT02963662|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
219276699|NCT01731223|BEHAVIORAL|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
219276700|NCT02834299|BEHAVIORAL|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
219276701|NCT02834299|BEHAVIORAL|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
219276702|NCT02834299|BEHAVIORAL|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
219276703|NCT03655743|DEVICE|LASIK, PRK, Phacoemulsification|"Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive\_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification"
219276704|NCT00996606|DRUG|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
219276705|NCT00996606|DRUG|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
219276706|NCT03354468|BEHAVIORAL|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
219276707|NCT00532870|OTHER|laparoscopic|
219276708|NCT00305344|PROCEDURE|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
219276709|NCT00305344|BIOLOGICAL|Cord blood|Develop Cord blood vaccine
219276710|NCT05235282|DEVICE|IQoro|An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
219276711|NCT05235282|OTHER|Usual care for swallowing function|Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
219276712|NCT00632502|DRUG|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
219276713|NCT00632502|DRUG|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
219276714|NCT00632502|DRUG|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
219276715|NCT03075527|DRUG|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
219276716|NCT03075527|DRUG|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
219276717|NCT04108624|OTHER|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
219276718|NCT04108624|DEVICE|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
219276719|NCT05053971|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
219276720|NCT05053971|PROCEDURE|Core Biopsy|Undergo core needle biopsy
219276721|NCT05053971|DRUG|Entinostat|Given PO
219276722|NCT00947947|BEHAVIORAL|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
219276723|NCT06032507|PROCEDURE|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
219276724|NCT00912145|DRUG|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
219276725|NCT01022411|DIETARY_SUPPLEMENT|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
219276726|NCT00391339|DRUG|Bryophyllum p.|
219276727|NCT03496376|OTHER|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
219276728|NCT03496376|OTHER|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
219276729|NCT01103921|OTHER|Glucose|25% dose at 2-week intervention assigned to subjects.
219276730|NCT01103921|OTHER|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
219276731|NCT01103921|OTHER|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
219276732|NCT01103921|OTHER|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
219276733|NCT04714398|BEHAVIORAL|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
219276734|NCT04714398|BEHAVIORAL|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
219276735|NCT00681668|DRUG|Quetiapine|150-800 mg, oral, twice a day (bid)
219276736|NCT01786304|PROCEDURE|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
219276737|NCT03489876|DEVICE|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
219276738|NCT03489876|PROCEDURE|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
219276739|NCT06231537|DIAGNOSTIC_TEST|Visual oral examination|"Oral preventive examinations in the three groups will be conducted over a one-year period. Individuals with oral injuries will be referred to stomatology, aligning with the existing protocol. Histopathological examinations of the biopsied lesions will be performed at the Oral Pathology Laboratory of the Faculty of Dentistry at the Federal University of Rio de Janeiro, following the established procedures.~Users diagnosed with malignancy will be directed to receive treatment at the reference hospital, with monitoring carried out by the Basic Health Unit responsible for coordinating care, in accordance with the current protocol.~In addition to histopathological examinations, the Faculty of Dentistry will be available to conduct a physical examination and biopsy if the user is not attended to by the Municipal Health Department. This additional resource ensures comprehensive care for individuals who may not have immediate access to municipal health services."
219276740|NCT01301599|DRUG|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
219276741|NCT01301599|DRUG|alpha blocker monotherapy|alpha blocker monotherapy group
219276742|NCT01301599|DRUG|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
219276743|NCT02466347|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
219276744|NCT02466347|DRUG|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
219276745|NCT02476942|DRUG|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
219276746|NCT02476942|DRUG|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
219276747|NCT03648528|DRUG|cholecalciferol|
219276748|NCT03648528|DRUG|placebo|
219276749|NCT02280512|DEVICE|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
219276750|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
219276751|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
219276752|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
219276753|NCT02209181|DRUG|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
219276754|NCT01657747|OTHER|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
219276755|NCT03000790|DEVICE|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
219276756|NCT00920647|OTHER|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
219276757|NCT00920647|DRUG|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
219276758|NCT00920647|DRUG|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
219276759|NCT00920647|DRUG|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
219276760|NCT05716568|OTHER|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
219276761|NCT03855176|DRUG|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
219276762|NCT01215578|DRUG|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
219276763|NCT04072445|DRUG|Irinotecan|Given IV
219276764|NCT04072445|DRUG|Irinotecan Hydrochloride|Given IV
219276765|NCT04072445|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
219276766|NCT03630406|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal Tactile Imaging
219276767|NCT04980079|PROCEDURE|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
219276768|NCT04980079|PROCEDURE|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
219276769|NCT04641962|DRUG|Bocidelpar|Oral
219276770|NCT04641962|DRUG|Placebo|Oral
219276771|NCT01562106|PROCEDURE|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
219276772|NCT00320229|DRUG|abciximab|
219276773|NCT01376154|DRUG|Lamivudine|
219276774|NCT01690468|DRUG|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
219276775|NCT01690468|DRUG|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
219276776|NCT00160550|DRUG|Levetiracetam|
219276777|NCT04295850|DRUG|Aspirin 81 mg|Aspirin 81mg daily PO
219276778|NCT02712190|DEVICE|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
219276779|NCT05251675|BEHAVIORAL|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
219276780|NCT05251675|BEHAVIORAL|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
219276781|NCT01550055|DRUG|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
219276782|NCT01550055|DRUG|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
219276783|NCT05790005|OTHER|therapeutic play|2 days after the operation, 1 hour before the dressing, a warm-up game will be played with the child in the playroom of the pediatric surgery service, aiming to put the organs prepared by the researcher in their correct places on the picture for the first 10 minutes. Then, the teddy bear, which is given the appearance of an operation area by sewing a zipper on his stomach, will be given to the child and he will be asked to make the first dressing of the teddy bear. therapeutic game, in which the dramatization method is used, will last 20 minutes. During the 30-minute play practice, the child's questions will be answered.
219276784|NCT06555939|BEHAVIORAL|Collaborative Care Model|The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.
219276785|NCT06555939|BEHAVIORAL|Promoting Resilience in Stress Management|PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
219276786|NCT07024017|DEVICE|Foam roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
219276787|NCT07024017|OTHER|dynamic stretch|"10 different exercises will be performed over a 13-meter distance, with a 10-second rest period between exercises.~During the session, participants will receive verbal feedback to ensure proper posture and technique. Exercises will be video recorded and shared with participants for review and consistency."
219276788|NCT07029919|BEHAVIORAL|PATH-S app|PATH-S will use casual gaming and intermittent reinforcement techniques to encourage high risk teens to adopt and persist with personalized habits to improve sleep.
219276789|NCT07030686|BEHAVIORAL|Exercise|Exercise following completion of active treatment for the primary index cancer
219276790|NCT07034027|BEHAVIORAL|Project WAVE (Wise Awareness of Visiting Emotions)|Project WAVE is an online, self-directed single-session intervention designed to foster emotional nonreactivity skills in young adults aged 18-29.
219276791|NCT07034027|BEHAVIORAL|Emotionally Neutral Writing Control|The control condition is an online, self-directed single-session activity that includes an emotionally neutral writing task.
219296297|NCT06478511|PROCEDURE|Immediate dental implant placement using socket shield technique|The crown of the involved tooth will be removed and the root will be then sectioned in a mesiodistal direction along its long axis as far apical as was possible using a long shank fissure bur. Preserving the facial root section unmanipulated and attached to the tooth socket. Periotomes will be then inserted between the palatal root removed gentelly.The remaining root section will be then reduced coronally to 1 mm above the alveolar crest.The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants and the root section will be checked for immobility with a sharp probe. With the preparation steps complete, the tooth root hereafter will be known as the socket-shield. An osteotomy will be then sequentially prepared and internal conical connection implant was inserted palatal to the shield with the implant 2 mm below the facial crest.
219276792|NCT06707402|BEHAVIORAL|WALK|The intervention covers a personalized 24-week progressive brisk walking program. The program consists of moderate to high-intensity walking (i.e., 55-85% maximal heart rate) performed as both continuous and interval training sessions 2-3 times/week lasting 30-60 min/session. Four individually supervised sessions will be conducted in the first 2 weeks, while 1 supervised group session will be received bi-weekly. Furthermore, the group will receive an activity tracker and monthly telephone calls will be offered to adjust the intensity of the program (if necessary), clarify any questions regarding the intervention, and give verbal motivation. At the baseline assessment and at week 12, during a group training session, the figure of 8 walk test will be conducted to gain insigh tinto the current status of the training program. Lastly, after completion of the baseline test, the participants are given a brief educational session (walking advice) on recommended guidelines for physical activity
219276793|NCT06707402|BEHAVIORAL|ACTIVE|Will receive an activity tracker is provided alongside monthly telephone calls and walking advice after the baseline test. Similar to WALK, 3 telephone calls are provided during the follow-up period.
219276794|NCT06707402|BEHAVIORAL|CON|Receives a brief educational session (walking advice) is provided at baseline, after which no further contacts are made.
219276795|NCT06926673|DRUG|Dostarlimab|Dostarlimab will be administered
219276796|NCT06926673|DRUG|Belrestotug.|Belrestotug will be administered
219276797|NCT06926673|DRUG|Nelistotug|Nelistotug will be administered.
219276798|NCT07050303|OTHER|Mobile Application Developed Based on Social Cognitive Theory|Measuring the Benefits of a 3-Month Mobile Application Use in Hypertension Patients
219276799|NCT07049367|DIAGNOSTIC_TEST|Hand Function Improvement|Finger Extension and Tripod Grip as Indicators of Hand Function Improvement in Subacute Stroke Patients
219276800|NCT07049419|DEVICE|Provision of an environmental control system|Part of standard clinical care for patients referred to the NHS Lothian environmental control service.
219276801|NCT07044778|OTHER|Questionnaire|An online Questionnaire designed by Google Forms will be shared on social media for medical students in Egypt to fill
219276802|NCT07049510|BEHAVIORAL|Experimental: Experimental: Combating violence against women|"After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.~8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test."
219276803|NCT07050108|OTHER|neurodynamic mobilization|the patients will receive neurodynamic mobilization in the form of opening technique which include; static opening and dynamic opening. also, sliding and tensioning technique+ selected physical therapy program
219276804|NCT07050108|OTHER|mulligan therapy|sustained natural apophyseal glide SNAGs are mobilisation techniques and are used as part of the Mulligan Concept+ selected physical therapy program The patient position is stitting on the edage of the plenth non weight bearing position. The therapist will stand behind the patient, the therapist will apply SNAG for 3 repetitions during the initial screening session,the patient will be asked to lean forwared while applying the technique .the therapist apply onle from fove to seven repetitions.patients who experienced no worsening or showed improvement of pain and ROM were considered good indication for the effectivness of treatment .
219276805|NCT07050108|OTHER|selected physical therapy program|"The program of therapeutic exercises consisted of upper and lower back exercises. Each exercise will repeat from ten to thirty times, three repetitions in three sets with rest one to two minutes between the sets. The repetition of each exercise vary according to the physical ability of each patient.~Lower back strengthening exercises: From prone lying position, the patient will asked to raise one lower limb then the other then both lower limbs+ TENS and US"
219276806|NCT07050966|PROCEDURE|Group A (Active Comparator) 1. Mulligan's Spinal Mobilization with Leg Movement (SMWLM) 2.Lower Limb Neurodynamic Mobilization|This group will receive Mulligan's Spinal Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set). This protocol is given to the patient for a total of 6 sessions (1 session per day).
219276807|NCT07050966|PROCEDURE|Group B (Experimental) 1. Maitland's Lumbar Rotation Mobilization 2.Lower Limb Neurodynamic Mobilization|This group will receive Maitland's Lumbar Rotation Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set).This protocol is given to the patient for a total of 6 sessions (1 session per day).
219276808|NCT07051031|DRUG|Nuvaxovid (NVX-CoV2705)|COVID-19 vaccination
219276809|NCT07051031|DRUG|Pfizer-BioNTech COVID-19 vaccine|COVID-19 vaccination
219276810|NCT07048873|DRUG|Dexmedetomidine|IV dexmedetomidine
219276811|NCT07048873|DRUG|Ketamine|IV ketamine
219276812|NCT07048873|DRUG|Saline (control group)|no drugs
219276813|NCT05165940|BEHAVIORAL|Treatment As Usual|Care Coordination Treatment as usual with a VA mental health treatment coordinator
219296298|NCT05785923|DIAGNOSTIC_TEST|Point-of-Care Echocardiogram|Four view ultrasound of the heart performed at the bedside by trained emergency medicine physicians.
219276814|NCT05165940|BEHAVIORAL|New Health Services Intervention|The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
219276815|NCT00170287|PROCEDURE|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
219276816|NCT00170287|DEVICE|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
219276817|NCT06945484|OTHER|Precision Exercise Regimen for Cancer Care (PERCC)|PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually
219276818|NCT06945744|OTHER|Standard Treatment|The control group followed a standard diabetic habitual diet
219276819|NCT06945744|DEVICE|Carbohydrate|"Eligible participants provided informed consent and underwent baseline assessments, including demographics, medical history, insulin doses, and fasting blood samples for HbA1c and lipid profile. Participants used the FreeStyle Libre 2 sensor, with AGP data collected bimonthly. The primary outcome was Time in Range (TIR, 70-180 mg/dL), while secondary outcomes included TAR, TBR, GV%, GMI, HbA1c, and BMI.~A registered dietitian provided structured CHOC-BC education. The intervention group used the CHOC-BC app, validated against expert-calculated carbohydrate counts, while the control group followed standard diabetes education. Virtual follow-ups occurred bimonthly for three months. At study completion, HbA1c, lipid profile, insulin doses, weight, and AGP data were collected for comparison."
219276820|NCT02401659|DEVICE|CareLinK|
219276821|NCT06947499|BIOLOGICAL|LBVD|Intramuscular injection into the anterolateral area of the thigh
219276822|NCT06947499|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine|Intramuscular injection into the anterolateral area of the thigh
219276823|NCT06952452|DRUG|Bevacizumab|The dosage for each intravitreal injection is 1.25mg of BVZ in 0.05ml
219276824|NCT06952452|DRUG|Ranibizumab Ophthalmic|The dosage for each intravitreal injection contains 0.5mg of RBZ in 0.05ml
219276825|NCT00769457|DEVICE|Access Arm|Active OptiVol-System with CareAlert via CareLink
219276826|NCT01551797|DRUG|Paracetamol 500 mg|Standard Paracetamol formulation
219276827|NCT01551797|DRUG|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
219276828|NCT01551797|DRUG|Paracetamol 750 mg|Paracetamol Sustained Release formulation
219276829|NCT00730548|BEHAVIORAL|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
219276830|NCT06371976|OTHER|Blood sampling|Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.
219276831|NCT06371976|OTHER|Vital status|Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.
219276832|NCT05855525|BEHAVIORAL|Experience sampling|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
219276833|NCT04856735|OTHER|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
219276834|NCT04856735|OTHER|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
219276835|NCT04856735|OTHER|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
219276836|NCT02328118|DRUG|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
219276837|NCT02328118|DRUG|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
219276838|NCT04086277|PROCEDURE|Continuous Intrapartum Support|Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
219276839|NCT01920477|BIOLOGICAL|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
219276840|NCT01920477|BIOLOGICAL|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
219276841|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
219276842|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
219276843|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
219276844|NCT01681277|DRUG|Placebo to BI 113608 PIB qd|powder for oral solution
219276845|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
219276846|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
219276847|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
219276848|NCT01681277|DRUG|BI 113608 PIB qd|powder for oral solution
219276849|NCT06523296|PROCEDURE|Adults with Alzheimer's disease|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
219276850|NCT06523296|PROCEDURE|Adults with Myasthenia|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
219276851|NCT06523296|OTHER|Healhty controls|Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
219276852|NCT06190106|OTHER|Cognitive Behavioral Therapy (Psychotherapeutic Intervention)|A psychotherapeutic intervention CBT is given to assess the improvement and betterment in mental health and to assess the reduction of Psychiatric symptoms like depression, anxiety and stress
219276853|NCT01504776|DRUG|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
219276854|NCT01504776|DRUG|Bortezomib|
219276855|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Spontaneous partner notification practices collected one month after STIs diagnosis"
219276856|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Experiences with partner notification and use of STI testing following notification"
219276857|NCT05629299|BIOLOGICAL|Samples|Men will give semen, saliva, skin, urine and blood specimens
219276858|NCT00088933|DRUG|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
219276859|NCT00088933|DRUG|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
219276860|NCT00088933|DRUG|docetaxel|Given IV
219276861|NCT00088933|DRUG|sargramostim|Given subcutaneously
219276862|NCT06331637|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal Anastomosis (IPAA)
219276863|NCT06331637|PROCEDURE|Double-stapled anastomosis|Restorative proctectomy with Tdouble-stapled Ileal Pouch-Anal Anastomosis (IPAA)
219276864|NCT05364567|DRUG|cholecalciferol (vitamin D3)|The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.
219276865|NCT05364567|PROCEDURE|Phototherapy|The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
219276866|NCT01346631|OTHER|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
219276867|NCT01124383|PROCEDURE|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
219276868|NCT01124383|PROCEDURE|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score \< 4.
219276869|NCT02597335|RADIATION|Spectro-MRI|Spectro-MRI for D-2HG detection
219276870|NCT02597335|OTHER|Dosage of free circulating plasmatic DNA|
219276871|NCT02597335|OTHER|Dosage of D-2HG in the urine|
219276872|NCT05692700|OTHER|aromatherapy|essential oil application by inhalation
219276873|NCT05692700|OTHER|Placebo|Placebo essential oil
219276874|NCT02381093|OTHER|Modified BLS course|BLS using CI
219276875|NCT02381093|OTHER|Standard BLS Course|Usual BLS teaching
219276876|NCT05266443|DIETARY_SUPPLEMENT|Lactobacillus containing cultured milk drink|Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
219276877|NCT05266443|DIETARY_SUPPLEMENT|Placebo cultured milk drink|The placebo prepared was identical to the probiotic-containing product in terms of color, taste and packaging. However, there is no trace of live microorganism in this product.
219276878|NCT05737862|DIETARY_SUPPLEMENT|Moringa oleifera capsules|In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
219276879|NCT05737862|DIETARY_SUPPLEMENT|iron and folic acid supplements|In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
219276880|NCT03165487|OTHER|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
219276881|NCT03165487|OTHER|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
219276882|NCT03668639|DRUG|Akynzeo|Weekly administration of akynzeo for five weeks.
219276883|NCT03668639|DRUG|Dexamethasone|Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
219276884|NCT02260713|BIOLOGICAL|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
219276885|NCT03621462|DEVICE|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
219276886|NCT04699968|DRUG|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
219276887|NCT04699968|DRUG|SHR-1701|SHR -1701, Intravenous
219276888|NCT02320526|BEHAVIORAL|Control|
219276889|NCT02320526|BEHAVIORAL|Continuous walking|
219276890|NCT02320526|BEHAVIORAL|Interval walking|
219276891|NCT06444490|BEHAVIORAL|General Approach Instruction|Oral health instruction focused more broadly on the different topics of oral diseases and oral hygiene care.
219276892|NCT06444490|BEHAVIORAL|Personalised Technique Instruction|Oral health instruction based on the specific needs of each participant.
219276893|NCT01906983|OTHER|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
219276894|NCT04486625|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
219276895|NCT04486625|DRUG|Aztreonam-Avibactam|675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
219276896|NCT00263237|DRUG|STA-5326|
219276897|NCT04226989|BIOLOGICAL|CT-RD06|CT-RD06 cell injection by intravenous infusion
219276898|NCT00551330|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily
219276899|NCT00551330|DRUG|Placebo|One tablet of placebo once daily
219276900|NCT03613389|DIETARY_SUPPLEMENT|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
219276901|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
219276902|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
219276903|NCT01762332|OTHER|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
219276904|NCT05003492|COMBINATION_PRODUCT|Combination therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
219276905|NCT05003492|RADIATION|Photodynamic therapy|After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.
219276906|NCT05003492|DRUG|Standard therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
219276907|NCT05942820|DRUG|BWC0977|SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
219276908|NCT05942820|DRUG|Placebo|"SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977"
219276909|NCT06066411|OTHER|Massage Ball|The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
219276910|NCT00402012|DRUG|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
219276911|NCT03211234|DRUG|2.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
219276912|NCT03211234|DRUG|4.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
219276913|NCT03211234|DRUG|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
219276914|NCT01619189|BIOLOGICAL|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
219276915|NCT01619189|PROCEDURE|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
219276916|NCT04802889|OTHER|scanning electron microscopy|scanning electron microscopy of the сentral retina and preretinal structures
219276917|NCT01457638|PROCEDURE|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
219276918|NCT01457638|PROCEDURE|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
219276919|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
219276920|NCT02271984|DRUG|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
219276921|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
219276922|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
219276923|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
219276924|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
219276925|NCT00115908|DRUG|Albuferon|
219276926|NCT00115908|DRUG|Ribavirin|
219276927|NCT00115908|DRUG|PEG-IFNalfa2a|
219276928|NCT03620539|OTHER|Lifestyle intervention|Sauna bathing
219276929|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536|2 capsules od
219276930|NCT01201577|DIETARY_SUPPLEMENT|Active hexose correlated compound (AHCC)|One capsule tds
219276931|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
219276932|NCT01201577|DIETARY_SUPPLEMENT|Corn starch placebo capsule|One capsule tds and two capsules od
219276933|NCT01201577|DRUG|Azithromycin|250mg od
219276934|NCT04821557|DIETARY_SUPPLEMENT|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
219276935|NCT04821557|DIETARY_SUPPLEMENT|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
219276936|NCT04246164|DEVICE|HD-tDCS combined with CT|HD-tDCS treatments will be administered during a cognitive training session.
219276937|NCT04246164|DEVICE|sham HD-tDCS combined with CT|sham-HD-tDCS treatments will be administered during a cognitive training session.
219276938|NCT04730141|OTHER|Patient mobilization with pre-operative mobilization training and mobilization protocol|Postoperative mobilization for the first 24 hours
219276939|NCT01423591|DRUG|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
219276940|NCT01423591|DRUG|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
219276941|NCT02349997|OTHER|no interventions|This is an observational study and no intervention applied.
219276942|NCT03546153|BEHAVIORAL|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
219276943|NCT02772939|DEVICE|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
219276944|NCT04553562|DEVICE|Acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
219276945|NCT04553562|DEVICE|Sham acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
219276946|NCT00003391|BIOLOGICAL|monoclonal antibody muJ591|
219276947|NCT06341777|BEHAVIORAL|Audio-visual training (AVT) telerehabilitation|Participants are trained at home, with remote supervision, for 3 weeks (5 days/week, 2 hours/day) using an audio-visual device suitable for telerehabilitation (AVDESK, Linari Medical). Specifically, visual stimuli (LEDs) appear on a semicircular panel, either alone or paired with an acoustic cues, at different eccentricities. Stimuli to the blind visual field (70%) and intact visual field (30%) are presented in random sequence. Patients are trained to scan the visual field by shifting their gaze (from the central fixation point) towards the visual target (with or without sounds), without head movements, and to report its presence by pressing the response key.
219276948|NCT03633292|DRUG|Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)|"Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use."
219276949|NCT03633292|DRUG|Master formula of aloe vera gel 80%|Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
219276950|NCT06451640|DRUG|210mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
219276951|NCT06451640|DRUG|420mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
219276952|NCT06334315|DRUG|Desogestrel / Ethinyl Estradiol Pill|Standard pill packs containing 21 active pills and 7 placebo pills
219276953|NCT02912390|PROCEDURE|Cerclage|Macdonald cerclage placed in standard fashion
219276954|NCT02912390|OTHER|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
219276955|NCT04548284|DRUG|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
219276956|NCT00370864|BIOLOGICAL|H5N1 pandemic influenza vaccine|
219276957|NCT00348270|DEVICE|Tecnis Z9000 intraocular lens|
219276958|NCT00348270|DEVICE|MA60 intraocular lens|
219276959|NCT03714698|OTHER|Pilates exercise group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
219276960|NCT03714698|OTHER|Control Group|The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
219276961|NCT02535039|DRUG|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery
219276962|NCT02535039|OTHER|Physiological saline|The same volume of physiological saline will be given in Placebo group
219276963|NCT04624243|DRUG|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
219276964|NCT04624243|DRUG|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
219276965|NCT04624243|DRUG|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
219276966|NCT04624243|DRUG|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
219276967|NCT01546506|DRUG|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
219276968|NCT05293405|DIAGNOSTIC_TEST|18F-DPA-714 PET|TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET
219276969|NCT00248352|BEHAVIORAL|Consultation with Endocrinologist|
219276970|NCT00248352|BEHAVIORAL|Counseling from Dietician|
219276971|NCT00248352|BEHAVIORAL|Counseling from Diabetes Educator|
219276972|NCT06508489|BIOLOGICAL|SAR443579|Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
219276973|NCT06508489|DRUG|venetoclax|Pharmaceutical form :Film coated tablet Route of administration: oral
219276974|NCT06508489|DRUG|azacitidine|Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
219296299|NCT01361191|DRUG|R-MEGACHOP|"* If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
219276975|NCT03381872|PROCEDURE|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~1. Intravascular imaging arm~2. Angiography arm~   * Definition of Complex Lesions~     1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~    2. Chronic total occlusion (≥3 months) as target lesion~    3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~    4. Implanted stent length ≥38mm~    5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~    6. Multiple stent needed (≥3 more stent per patient)~    7. In-stent restenosis lesion as target lesion~    8. Severely calcified lesion (encircling calcium in angiography)~    9. Ostial coronary lesion (LAD, LCX, RCA)"
219276976|NCT03381872|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
219276977|NCT03381872|DEVICE|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden \<50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: \[1\] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~\[2\] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
219276978|NCT03381872|DEVICE|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
219276979|NCT03374488|DRUG|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
219276980|NCT03374488|DRUG|Epacadostat|Epacadostat administered orally twice daily.
219276981|NCT03374488|DRUG|Placebo|Matching placebo administered orally twice daily.
219276982|NCT06398847|DEVICE|Virtual Reality headset|Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.
219276983|NCT06479382|DEVICE|ETX-4143 2.0|Treatment of the eye with the ETX-4143 2.0 device
219276984|NCT03475186|DRUG|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
219276985|NCT06291766|DEVICE|FreeStyle Libre 2, continous glucose monitoring|The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
219276986|NCT03104075|BIOLOGICAL|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
219276987|NCT03104075|BIOLOGICAL|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
219276988|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
219276989|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
219276990|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
219276991|NCT04024462|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
219276992|NCT04024462|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
219276993|NCT04024462|DRUG|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
219276994|NCT04024462|DRUG|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
219276995|NCT04024462|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
219276996|NCT04024462|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
219276997|NCT04024462|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
219276998|NCT04024462|RADIATION|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
219276999|NCT04024462|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
219277000|NCT05154981|BEHAVIORAL|Education communication skills (ECS) training|Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
219277001|NCT05154981|BEHAVIORAL|Partners in School|Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
219277002|NCT03309540|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
219277003|NCT04495153|BIOLOGICAL|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
219277004|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
219277005|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
219277006|NCT04587128|DRUG|Panitumumab|Epidermal growth factor receptor inhibitor, anti-neoplastic
219277007|NCT04587128|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor, anti-neoplastic
219277008|NCT04587128|DRUG|Irinotecan|anti-neoplastic, chemotherapy drug
219277009|NCT04587128|DRUG|FOLFIRI Protocol|folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab
219277010|NCT04587128|DRUG|Bevacizumab|Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)
219277011|NCT01933243|DRUG|Fish oil|Participants will take 4 capsules daily
219277012|NCT01933243|DRUG|Placebo pill|Participants will take 4 capsules daily
219277013|NCT05163405|DRUG|Bortezomib|Self-administration of subcutaneously Velcade.
219277014|NCT04557995|PROCEDURE|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
219277015|NCT06215378|DRUG|Antagonization of heparin with protamine sulfate|A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
219277016|NCT02135562|DIETARY_SUPPLEMENT|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
219277017|NCT02135562|OTHER|Informational Material|Receive carbohydrate reintroduction handout
219277018|NCT02135562|OTHER|Dietary Education|Receive education on nutrition label reading for carbohydrates
219277019|NCT02135562|DIETARY_SUPPLEMENT|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
219277020|NCT02135562|OTHER|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
219277021|NCT04101955|PROCEDURE|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
219277022|NCT04101955|PROCEDURE|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
219277023|NCT00713986|PROCEDURE|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
219277024|NCT00713986|PROCEDURE|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
219277025|NCT00713986|PROCEDURE|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
219277026|NCT00713986|PROCEDURE|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
219277027|NCT06490302|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear
219277028|NCT06490302|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear
219277029|NCT05044507|DEVICE|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
219277030|NCT05044507|DEVICE|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
219277031|NCT00041652|DRUG|hMN14 (labetuzumab)|
219277032|NCT06157567|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
219277033|NCT05234840|DRUG|platelet rich plasma|1\. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
219277034|NCT05234840|DRUG|Triamcinolone|40 mg triamcinolone with 1% lidocaine, total of 2 ml
219277035|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277036|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277037|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277038|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277039|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277040|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277041|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
219277042|NCT03901001|DRUG|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
219277043|NCT03901001|DRUG|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
219277044|NCT02724852|BIOLOGICAL|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
219277045|NCT03065075|DRUG|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
219277046|NCT01022541|DRUG|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
219277047|NCT01022541|DRUG|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
219277048|NCT01022541|DRUG|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
219277049|NCT01022541|PROCEDURE|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
219277050|NCT04687462|DEVICE|1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
219277051|NCT01796626|DEVICE|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
219277052|NCT02988323|OTHER|Cervicovestibular Physio (CV PT)|See description in CVPT arm
219277053|NCT02988323|OTHER|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
219277054|NCT02988323|OTHER|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
219277055|NCT00789360|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
219277056|NCT00789360|DRUG|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
219277057|NCT03806283|PROCEDURE|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
219277058|NCT01929824|OTHER|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
219277059|NCT04400487|DRUG|Voxelotor|500 mg Tablet, Oral, With or Without Food
219277060|NCT05330598|DEVICE|Connected Catheter|The Connected Catheter System is a replaceable wireless urinary prosthesis that is indicated for bladder emptying in male patients who have impaired bladder emptying due to chronic Urinary Retention. The Connected Catheter resides fully internally in the male lower urinary tract (urethra and bladder neck) and remains in place for up to 7 days before removal.
219277061|NCT01802905|GENETIC|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
219277062|NCT02735928|DEVICE|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (\< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
219277063|NCT02908295|DRUG|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
219277064|NCT02908295|DRUG|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
219277065|NCT00412412|DRUG|CNF2024|Oral doses of CNF2024 as specified in the protocol.
219277066|NCT00412412|DRUG|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
219277067|NCT05408195|DEVICE|CHATBOT use|Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
219277068|NCT06373198|OTHER|standard of care|An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.
219277069|NCT06328218|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
219277070|NCT02963012|OTHER|ultrasound examination|
219277071|NCT05176938|PROCEDURE|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients of the group will be placed supine and elevate arm to the head, Serratus intercostal plane block will be with the probe in the midaxillary line, The subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction after giving 3 ml lidocaine locally. In-plane technique was used until the tip of the needle placed between the serratus anterior muscle and the external intercostals muscle a volume of 20 ml plain bupivacaine will be injected.
219296300|NCT01758900|DEVICE|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
219296301|NCT01758900|DEVICE|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
219296302|NCT03122691|DRUG|cannabis|Cannabis will be self-administered by study participants
219296303|NCT01707745|PROCEDURE|Intravitreal Bevacizumab|
219277072|NCT05176938|PROCEDURE|Ultrasound guided Erector Spinae plane Block (ESPB)|The patient will be placed in setting position and a superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation, 3 cm lateral to the T4 spinous process. An 8-cm 22-gauge spinal needle will be inserted in cephalic direction after giving 3 ml lidocaine locally until the needle tip hit the transverse process of T4 under ultrasound image visualization, then the needle will be withdrawn slowly to be within the interfacial plane below the erector spinae muscle, then the anesthetic mixture will be injected here. Successful injection will be evidenced by visible linear free spread (cranially and caudally) of injectate below the muscle.
219277073|NCT00022659|BIOLOGICAL|bevacizumab|Given IV
219277074|NCT00022659|OTHER|laboratory biomarker analysis|Correlative studies
219277075|NCT03559062|DRUG|TEZ/IVA|Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
219277076|NCT03559062|DRUG|IVA|Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
219277077|NCT03559062|DRUG|Placebo|Placebo matched to TEZ/IVA FDC
219277078|NCT03559062|DRUG|Placebo|Placebo matched to IVA
219277079|NCT04490759|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219277080|NCT02154880|PROCEDURE|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
219277081|NCT02154880|PROCEDURE|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
219277082|NCT02154880|PROCEDURE|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
219277083|NCT02154880|OTHER|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
219277084|NCT03073252|OTHER|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
219277085|NCT03073252|OTHER|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
219277086|NCT02079324|BIOLOGICAL|GX-051|intratumoral injection
219277087|NCT05927857|DRUG|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
219277088|NCT05927857|DRUG|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
219277089|NCT05927857|DRUG|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
219277090|NCT04697927|OTHER|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
219277091|NCT03445533|DRUG|Ipilimumab|Arm A: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.
219277092|NCT03445533|DRUG|Tilsotolimod with Ipilimumab|IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24. WITH (Arm B): Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11. in combination with tilsotolimod
219277093|NCT03920098|OTHER|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level \>100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels \> 92 mg/dL and/or plasma glucose levels \> 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose \>100 mg/dL and/or \> 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
219277094|NCT05182307|DEVICE|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
219277095|NCT04548986|DEVICE|Aktiia.product|The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
219277096|NCT00778232|DRUG|Gabapentin tablets 800 mg|
219277097|NCT04310332|DRUG|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
219277098|NCT04310332|DRUG|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
219277099|NCT01783340|DRUG|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
219277100|NCT01783340|DRUG|Placebo|Placebo capsules will be administered at each immunization
219277101|NCT01783340|BIOLOGICAL|Immunization with falciparum|three inoculations with 5 infected mosquito bites
219277102|NCT00012064|BIOLOGICAL|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
219277103|NCT04505839|DRUG|STP1002|Oral capsule, QD
219277104|NCT00968526|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
219277105|NCT02134938|DIETARY_SUPPLEMENT|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
219277106|NCT04801732|OTHER|mulligan thoracic Sustained Natural Apophyseal Glides|"Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment."
219277107|NCT04801732|OTHER|traditional treatments|"includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles)."
219277108|NCT03926195|DRUG|Filgotinib|200-mg tablet administered orally once daily
219296304|NCT00435175|DRUG|estradiol|
219277109|NCT03926195|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
219277110|NCT03926195|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
219277111|NCT02373540|DEVICE|Algovita Spinal Cord Stimulation system|
219277112|NCT01236378|DRUG|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
219277113|NCT03882151|DIAGNOSTIC_TEST|electrical source imaging|automated analysis of surface EEG with electrocal source imaging
219277114|NCT00872053|DEVICE|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
219277115|NCT00872053|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
219277116|NCT00426127|DRUG|Docetaxel|
219277117|NCT00426127|DRUG|Liposomal Doxorubicin|
219277118|NCT00426127|DRUG|Enoxaparin|
219277119|NCT02370264|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219277120|NCT02370264|OTHER|Questionnaire Administration|Ancillary studies
219277121|NCT02370264|OTHER|Medical Chart Review|Ancillary studies
219277122|NCT00663585|BEHAVIORAL|Vipassana Meditation|12 day retreat where participants learn to meditate
219277123|NCT06116747|BEHAVIORAL|Intervention|Support for fathers of preterm infants
219277124|NCT03990740|PROCEDURE|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
219277125|NCT03610672|BEHAVIORAL|OD prevention/response training|Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
219277126|NCT03610672|BEHAVIORAL|OD prevention/response training + PI mobile application|Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
219277127|NCT05778942|DEVICE|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
219277128|NCT02465918|DEVICE|motor cortex stimulation (Change of Stimulation Timing)|
219277129|NCT05399901|OTHER|Electromyographic biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
219277130|NCT05399901|OTHER|M-mode US biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
219277131|NCT01249846|DRUG|PerioChip ®|
219277132|NCT02264119|DRUG|Lefradafiban tablet|
219277133|NCT02264119|DRUG|Pantoprazole tablet|
219277134|NCT02264119|DEVICE|Lefradafiban double chamber sachet|
219277135|NCT01277692|DRUG|GSK2336805 10mg|single dose once daily
219277136|NCT01277692|DRUG|GSK2336805 30mg|single dose once daily
219277137|NCT01277692|DRUG|GSK2236805 100mg|single dose once daily
219277138|NCT01277692|DRUG|GSK2236805 200mg|single dose once daily
219277139|NCT01277692|DRUG|GSK2236805 10mg|repeat dose once daily for 7 days
219277140|NCT01277692|DRUG|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
219277141|NCT01277692|DRUG|GSK2236805 5mg|single dose in HCV infected patients
219277142|NCT01277692|DRUG|GSK2236805 30mg|single dose in HCV infected patients
219277143|NCT01277692|DRUG|GSK2236805 100mg|single dose in HCV infected patients
219277144|NCT02318615|PROCEDURE|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
219277145|NCT00458952|DRUG|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
219277146|NCT03099902|DIAGNOSTIC_TEST|Lung function|Spirometry test
219277147|NCT03099902|DIAGNOSTIC_TEST|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
219277148|NCT03099902|DIAGNOSTIC_TEST|Urinary testing|Urinary nicotine and cotinine detection
219277149|NCT03937102|PROCEDURE|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
219277150|NCT03937102|PROCEDURE|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
219277151|NCT03831542|BEHAVIORAL|direct follicular aspiration|direct follicular aspiration
219277152|NCT03831542|BEHAVIORAL|follicular flushing|follicular flushing
219296305|NCT00086255|DRUG|Tiagabine|
219277153|NCT06404853|DIETARY_SUPPLEMENT|Manna|"Administration is by the oral route according to weight at a dosage of 1 g/kg/day, dissolved in a glass of water, up to a maximum of 30 g. Administration should be repeated every 24 h for 8 weeks, accompanied by plenty of hydration.~In case an effective dosage is achieved (evacuation within 72 h) it will be maintained until the end of the study. If evacuation has not occurred after 72 h, evacuative enema and increased dosage to 1.5 g/kg/day will be indicated. If further evacuative enema is needed, product administration will be discontinued and classical polyethylene glycol therapy will be started as per guidelines."
219277154|NCT05048238|DRUG|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
219277155|NCT04648137|DIAGNOSTIC_TEST|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
219277156|NCT04648137|DIAGNOSTIC_TEST|Control intervention: Placebo|Identical placebo (only mannitol) capsules
219277157|NCT02657499|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
219277158|NCT02261077|DRUG|Hyoscine butylbromide|
219277159|NCT02261077|DRUG|Placebo|
219277160|NCT00158704|DRUG|Hepsera|
219277161|NCT06034691|BIOLOGICAL|pcsk9 inhibitor|The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
219277162|NCT01702857|BIOLOGICAL|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
219277163|NCT01702857|BIOLOGICAL|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
219277164|NCT01702857|OTHER|Phosphate buffered saline|
219277165|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
219277166|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with AS01E adjuvant|
219277167|NCT00692549|DEVICE|ultrasound|
219277168|NCT01627015|OTHER|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
219277169|NCT01627015|OTHER|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
219277170|NCT05238831|DRUG|Alectinib|Given orally (PO)
219277171|NCT05238831|DRUG|Alpelisib|Given PO
219277172|NCT05238831|DRUG|Anastrozole|Given PO
219277173|NCT05238831|BIOLOGICAL|Atezolizumab|Given IV
219277174|NCT05238831|BIOLOGICAL|Bevacizumab|Given IV
219277175|NCT05238831|PROCEDURE|Biopsy|Undergo tissue biopsy
219277176|NCT05238831|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219277177|NCT05238831|DRUG|Capecitabine|Given PO
219277178|NCT05238831|DRUG|Carboplatin|Given IV
219277179|NCT05238831|DRUG|Cobimetinib|Given PO
219277180|NCT05238831|DRUG|Entrectinib|Given PO
219277181|NCT05238831|DRUG|Eribulin|Given IV
219277182|NCT05238831|DRUG|Fulvestrant|Given by injection
219277183|NCT05238831|BIOLOGICAL|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given phesgo SC
219277184|NCT05238831|DRUG|Irinotecan|Given IV
219277185|NCT05238831|DRUG|Letrozole|Given PO
219277186|NCT05238831|DRUG|Nab-paclitaxel|Given IV
219277187|NCT05238831|DRUG|Niraparib|Given PO
219277188|NCT05238831|DRUG|Olaparib|Given PO
219277189|NCT05238831|DRUG|Paclitaxel|Given IV
219277190|NCT05238831|DRUG|Palbociclib|Given IV
219277191|NCT05238831|BIOLOGICAL|Pertuzumab|Given subcutaneously (SC)
219277192|NCT05238831|OTHER|Quality-of-Life Assessment|Ancillary studies
219277193|NCT05238831|BIOLOGICAL|Trastuzumab|Given SC
219277194|NCT05238831|BIOLOGICAL|Trastuzumab Emtansine|Given intravenously (IV)
219277195|NCT05238831|DRUG|Vemurafenib|Given PO
219277196|NCT05238831|DRUG|Vinorelbine|Given IV
219277197|NCT05238831|DRUG|Vismodegib|Given PO
219277198|NCT01746589|DEVICE|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
219277199|NCT01730378|BIOLOGICAL|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
219277200|NCT01730378|BIOLOGICAL|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
219277201|NCT03160846|DRUG|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
219277202|NCT02565433|OTHER|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
219277203|NCT02450812|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
219277204|NCT02443753|DEVICE|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
219277205|NCT00955708|DEVICE|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
219296306|NCT01892540|DIAGNOSTIC_TEST|positron emission tomography/computed tomography|Undergo PET/CT
219277206|NCT01016262|DRUG|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
219277207|NCT01016262|DRUG|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
219277208|NCT01016262|DRUG|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
219277209|NCT04490577|OTHER|Pilates exercises|Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.
219277210|NCT04490577|OTHER|Whole body vibration|Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
219277211|NCT00514579|PROCEDURE|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
219277212|NCT00458081|DRUG|Rimonabant|20 mg once per day + slightly reduced calorie diet
219277213|NCT00458081|DRUG|Placebo|placebo once per day + slightly reduced calorie diet
219277214|NCT05338125|PROCEDURE|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
219277215|NCT01405651|DRUG|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
219277216|NCT01405651|DRUG|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
219277217|NCT03776305|DRUG|Imipenem|1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
219277218|NCT03364777|OTHER|emotional state|anxiety or depression state evaluated by emotional scale
219277219|NCT01736540|DEVICE|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2\*, respectively).
219277220|NCT06122922|DRUG|Hyperpolarized Xe129|Hyperpolarized Xenon Gas
219277221|NCT01458054|DRUG|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
219277222|NCT01458054|DRUG|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
219277223|NCT05616299|DEVICE|BrightPoint|Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.
219277224|NCT01076777|BEHAVIORAL|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
219277225|NCT01076777|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
219277226|NCT00479882|DRUG|Comparator: simvastatin|
219277227|NCT00479882|DRUG|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
219277228|NCT00479882|DRUG|Placebo|
219277229|NCT00479882|DRUG|MK-0524B|
219277230|NCT03728270|DEVICE|Patient Specific Titanium Eminoplasty|"* The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl"
219277231|NCT03728270|PROCEDURE|Inlay Autogenous Bone Graft|"\* Steps to harvest the bone graft:~* Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~* To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis."
219277232|NCT02129868|DEVICE|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
219277233|NCT01083953|DRUG|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
219277234|NCT01083953|DRUG|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
219277235|NCT05084339|DIAGNOSTIC_TEST|CGM|blinded CGM used at 4 different time points in pregnancy
219277236|NCT05977205|OTHER|No interventions, observational study|Not applicable, no interventions, observational study
219277237|NCT01024153|BEHAVIORAL|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
219277238|NCT05872191|OTHER|No intervention|There is no intervention to be administered, only collection of data through various tests and questionnaires.
219277239|NCT04538846|OTHER|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
219277240|NCT01370655|DRUG|MK-7145|
219277241|NCT01370655|DRUG|Hydrochlorothiazide (HCTZ)|
219277242|NCT01370655|DRUG|Placebo to MK-7145|
219277243|NCT01370655|DRUG|Placebo to HCTZ|
219277244|NCT00296257|DRUG|SMP-114|
219277245|NCT03733353|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbial
219277246|NCT03733353|DRUG|Placebo oral capsule|Placebo
219277247|NCT03733353|DRUG|Placebo oral tablet|Placebo
219277248|NCT02872558|OTHER|Acute Otitis Media Choice Decision Aid|Decision Aid
219277249|NCT02872558|OTHER|Usual Care|Usual Care
219277250|NCT03248544|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
219277251|NCT03248544|OTHER|control|No intervention
219277252|NCT02660645|DRUG|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
219277253|NCT02660645|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
219277254|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
219277255|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
219277256|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
219277257|NCT06771765|OTHER|Chia Seeds|Chia seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
219277258|NCT06771765|OTHER|Hemp Seeds|Hemp seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
219277259|NCT06771765|OTHER|Control (placebo) group|This intervention is a lunch meal made from standard recipes. This intervention is the placebo control intervention.
219277260|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 1|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
219277261|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 2|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
219277262|NCT06253884|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
219277263|NCT06181071|OTHER|Distal Muscle Fatigue Protocol|Initially, sociodemographic data, muscle viscoelastic properties, foot plantar pressure, and static and dynamic balance are assessed. Additionally, the strengths of the plantar flexor and dorsiflexor muscles are evaluated. After these assessments, the heel raise exercise will be implemented in this protocol. Firstly, dominant leg, the heel raise exercise will be performed for 3 sets with the knees in full extension until the individual reaches fatigue. Subsequently, the heel raise exercise will be conducted for another 3 sets with the knee in flexion until the individual reaches fatigue. Following these exercises, Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
219277264|NCT06181071|OTHER|Proximal Muscle Fatigue Protocol|One week after the application of the distal muscle fatigue protocol, the same individuals will undergo the proximal fatigue protocol. In this protocol, individuals will perform, dominant leg, a single-leg squat exercise targeting the fatigue of the hip flexor and extensor muscles. Prior to this exercise, the viscoelastic properties of the muscles, foot plantar pressure, static and dynamic balances, as well as the strengths of the hip flexor and extensor muscles will be assessed. Then, individuals will perform the single-leg squat exercise, 3 sets. When the individual indicates fatigue, the set will conclude, allowing a 30-second rest between sets. Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
219277265|NCT02874014|RADIATION|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
219277266|NCT02838992|DRUG|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
219277267|NCT02838992|DRUG|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
219277268|NCT02838992|DRUG|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
219277269|NCT02838992|BIOLOGICAL|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
219277270|NCT04763226|DRUG|BMS-986308|Specified dose on specified days
219277271|NCT04763226|OTHER|Placebo (for BMS-986308)|Specified dose on specified days
219277272|NCT04763226|DRUG|Furosemide|Specified dose on specified days
219277273|NCT06250790|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
219296307|NCT01892540|DIAGNOSTIC_TEST|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
219296308|NCT01892540|DEVICE|Position Device|
219277274|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
219277275|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
219277276|NCT06287151|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
219277277|NCT06287151|DRUG|Clonidine|Clonidine is an alpha-2-agonist which is commonly used as an adjunct in spinal anesthesia and caudal anesthesia to improve both the quality and duration of blockade.
219277278|NCT06287151|DRUG|Sevoflurane|5.3. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
219277279|NCT05418127|DIETARY_SUPPLEMENT|Active|Traditionally-fermented coconut milk kefir
219277280|NCT05418127|OTHER|Placebo|Solution of Calcium Carbonate and coconut extract
219277281|NCT04161729|DRUG|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
219277282|NCT04161729|DRUG|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
219277283|NCT00485277|BIOLOGICAL|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
219277284|NCT02735746|RADIATION|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
219277285|NCT02735746|RADIATION|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
219277286|NCT02735746|RADIATION|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
219277287|NCT02735746|DEVICE|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
219277288|NCT00245180|BEHAVIORAL|Diet|
219277289|NCT00245180|BEHAVIORAL|Exercise|
219277290|NCT03586791|PROCEDURE|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
219277291|NCT03586791|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
219277292|NCT03586791|PROCEDURE|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
219277293|NCT02035618|OTHER|Exercises|Strengthening and stretching
219277294|NCT02035618|OTHER|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
219277295|NCT05850195|OTHER|non invasive ventilation|compare indices and diaphragmatic ultrasonography for prediction of NIV failure in acute RF patients
219277296|NCT03119233|DEVICE|DETOUR System|The DETOUR System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
219277297|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
219277298|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
219277299|NCT04701346|OTHER|Low SAA diet|Diet with low content of methionine and cysteine
219277300|NCT04701346|OTHER|High SAA diet|Diet with high content of methionine and cysteine
219277301|NCT04151836|OTHER|Exercise education|"weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects."
219277302|NCT02228902|DRUG|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
219277303|NCT02228902|DRUG|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
219277304|NCT06240819|OTHER|Sleeper Stretch|They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position
219277305|NCT06240819|OTHER|Cross Body Stretch|They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
219277306|NCT06381986|DRUG|SHJ002|Topical ophthalmic
219277307|NCT06381986|OTHER|Vehicle|Topical ophthalmic
219277308|NCT05039073|DRUG|Brentuximab Vedotin|Given IV
219277309|NCT05039073|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
219277310|NCT05039073|BIOLOGICAL|Nivolumab|Given IV
219277311|NCT05039073|OTHER|Quality-of-Life Assessment|Ancillary studies
219277312|NCT05039073|OTHER|Questionnaire Administration|Ancillary studies
219277313|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
219277314|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
219277315|NCT02057575|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
219277316|NCT02057575|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
219277317|NCT00332462|DRUG|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
219277318|NCT00332462|DRUG|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
219277319|NCT04389034|DRUG|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
219277320|NCT01643044|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
219277321|NCT01643044|BEHAVIORAL|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
219277322|NCT03129126|DRUG|LP-10|Intravesical tacrolimus
219277323|NCT05169840|OTHER|Genetic Risk Score for Coronary Artery Disease|Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)
219277324|NCT06533319|DRUG|sofosbuvir/velpatasvir|Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.
219277325|NCT02451176|DEVICE|Davol Bard Soft Mesh synthetic|soft mesh synthetic
219277326|NCT02451176|DEVICE|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
219277327|NCT01527747|DRUG|Saxagliptin|5 mg daily
219277328|NCT02377167|PROCEDURE|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
219277329|NCT02472340|PROCEDURE|Muscle Biopsy|Muscle Biopsy
219277330|NCT04061876|DRUG|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
219277331|NCT04061876|DRUG|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
219277332|NCT03884322|OTHER|Prepod|the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.
219277333|NCT03884322|PROCEDURE|Joint compression exercises|Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
219277334|NCT03080168|DEVICE|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
219277335|NCT06359418|DEVICE|Acupuncture|The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
219277336|NCT06359418|DEVICE|Sham acupuncture|The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
219277337|NCT06169072|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
219277338|NCT06169072|DEVICE|Technetium99|Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
219277339|NCT03032718|BEHAVIORAL|Whole-body vibration training|Whole-body vibration exercise
219277340|NCT04278027|BEHAVIORAL|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
219277341|NCT01835405|DEVICE|LiquiBand Flex|
219277342|NCT01835405|DEVICE|Dermabond Advanced|
219277343|NCT01835405|DEVICE|Sutures (Prolene)|
219277344|NCT05161598|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
219277345|NCT05108753|OTHER|Procedure/Surgery|Transanal Total Mesorectal Excision
219277346|NCT02042027|DRUG|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
219277347|NCT00578162|BEHAVIORAL|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
219277348|NCT03897231|OTHER|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
219277349|NCT03578588|DRUG|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
219277350|NCT05138289|OTHER|Total Plaque Volume|Compare total plaque volume with IVUS obtained during ICA (invasive coronary angiography)
219277351|NCT00021424|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|
219277352|NCT04222777|DIAGNOSTIC_TEST|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
219277353|NCT02974400|BEHAVIORAL|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
219277354|NCT01735175|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
219277355|NCT01735175|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
219277356|NCT02694367|OTHER|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
219277357|NCT03423927|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
219277358|NCT05833646|DEVICE|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
219277359|NCT05833646|DEVICE|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
219277360|NCT05833646|DEVICE|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
219277361|NCT01956604|DRUG|Clonidine|
219277362|NCT01956604|DRUG|Placebo|
219277363|NCT00462878|DRUG|Meropenem|antibiotic
219277364|NCT00462878|DRUG|Vancomycin|Antibiotic
219277365|NCT00462878|DRUG|Teicoplanin|Antibiotic
219277366|NCT05431218|DRUG|Cholecalciferol Liquid|daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
219277367|NCT02345109|DEVICE|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
219277368|NCT02345109|DEVICE|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
219277369|NCT03992391|BEHAVIORAL|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
219277370|NCT05531071|DEVICE|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
219277371|NCT05531071|PROCEDURE|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
219277372|NCT05531071|COMBINATION_PRODUCT|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
219277373|NCT04570696|OTHER|NON INTERVENTIONAL|NON INTERVENTIONAL
219277374|NCT02470780|DRUG|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
219277375|NCT02470780|DRUG|Placebo|Placebo matching Rifaximin treatment.
219277376|NCT01667809|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
219277377|NCT01667809|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
219277378|NCT01023958|DRUG|BI 6727, IV infusion|phase II
219277379|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
219277380|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
219277381|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
219277382|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
219277383|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
219277384|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
219277385|NCT00905905|DRUG|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
219277386|NCT00905905|DRUG|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
219277387|NCT02159040|DRUG|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
219277388|NCT02159040|DRUG|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
219277389|NCT01301040|DRUG|epirubicin, cyclophosphamide, docetaxel|"* Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
219277390|NCT06372704|DEVICE|HIFEM|All patients had a total of 6 sessions lasting 28 minutes, twice a week, sitting on an electromagnetic chair (BTL EMSELLA®, BTL Industries Inc, Boston, MA, USA).
219277391|NCT04766359|DRUG|Albumin-Bound Paclitaxel|Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.
219277392|NCT06378684|DRUG|Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277393|NCT06378684|DRUG|Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277394|NCT06378684|DRUG|Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277395|NCT06378684|DRUG|Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277396|NCT06378684|DRUG|Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277397|NCT06378684|DRUG|Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
219277398|NCT01424462|DRUG|A|Single dose treatment IR formulation
219277399|NCT01424462|DRUG|B|Low Extended release single dose
219277400|NCT01424462|DRUG|C|Medium extended release formulation
219277401|NCT01424462|DRUG|D|High extended release rate single dose
219277402|NCT01972932|DIETARY_SUPPLEMENT|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
219277403|NCT01972932|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
219277404|NCT02656589|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
219277405|NCT02656589|DRUG|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
219277406|NCT03080493|DRUG|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
219277407|NCT03080493|DRUG|Placebo oral capsule|Packaged identical to gabapentin dosing
219277408|NCT03080493|DRUG|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
219277409|NCT00801463|DRUG|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
219277410|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
219277411|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
219277412|NCT00755417|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
219277413|NCT02676843|DRUG|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
219277414|NCT06055946|DEVICE|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
219277415|NCT04773925|BEHAVIORAL|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
219277416|NCT00813722|BEHAVIORAL|phone call|patients received or not phone calls to give orientation abou treatment
219277417|NCT00813722|DRUG|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
219277418|NCT00813722|DRUG|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
219277419|NCT02362503|DRUG|BMS-663068|BMS-663068
219277420|NCT02362503|OTHER|Placebo|Placebo
219277421|NCT03867539|OTHER|Differing pain management strategy|"The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
219277422|NCT02306590|DIETARY_SUPPLEMENT|Calogen|
219277423|NCT02306590|DIETARY_SUPPLEMENT|Placebo|
219277424|NCT06423950|OTHER|Peds Evolutionary Tumor Board (pedsETB)|The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
219277425|NCT04197479|DRUG|Placebo|Matching tablets
219277426|NCT04197479|DRUG|Resmetirom|Tablet
219277427|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
219277428|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
219277429|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
219277430|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
219277431|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
219277432|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
219277433|NCT00002668|BEHAVIORAL|Observation|
219277434|NCT00002668|BEHAVIORAL|Educational Intervention and Behavioral Skills Training|
219277435|NCT02562144|DRUG|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
219277436|NCT02562144|DRUG|Placebo|Cutaneous placebo before intravenous cannulation.
219277437|NCT02977286|DRUG|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
219277438|NCT02977286|DRUG|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
219277439|NCT02977286|DRUG|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
219277440|NCT02977286|DRUG|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
219277441|NCT02977286|DRUG|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
219277442|NCT02977286|DRUG|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
219277443|NCT02977286|DRUG|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.
219277444|NCT02977286|DRUG|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
219277445|NCT00038480|DRUG|Lopinavir/Ritonavir|
219277446|NCT03329300|BEHAVIORAL|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
219277447|NCT02264262|OTHER|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
219277448|NCT04218747|BEHAVIORAL|VA 365 Demonstration Benefits|Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
219277449|NCT05021471|OTHER|biofeedback|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
219277450|NCT05021471|OTHER|hamstrings stretching|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
219277451|NCT04346810|OTHER|Patient management suffering of coronavirus infection|Welle-being and stress of the caregivers
219277452|NCT03516097|BEHAVIORAL|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
219277453|NCT03516097|DEVICE|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
219277454|NCT03325777|BEHAVIORAL|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
219277455|NCT03325777|BEHAVIORAL|SHAM Training|SHAM Training
219277456|NCT01013142|DRUG|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
219277457|NCT01013142|DRUG|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
219277458|NCT01013142|DRUG|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
219277459|NCT01055236|DRUG|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
219277460|NCT00786643|DRUG|5-Fluorouracil|5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
219277461|NCT00786643|DRUG|Leucovorin (LV)|Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
219277462|NCT00786643|DRUG|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
219277463|NCT00786643|DRUG|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
219277464|NCT02145845|DEVICE|Injectable SIS|Injectable SIS
219277465|NCT06342336|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
219277466|NCT02949245|PROCEDURE|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
219277467|NCT01025505|DRUG|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
219277468|NCT01025505|DRUG|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
219277469|NCT01266161|DRUG|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
219277470|NCT01266161|DRUG|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
219277471|NCT06091059|DIAGNOSTIC_TEST|Ultrasound MRI fusion|Fused MRI images with direct ultrasound guidance
219277472|NCT00003564|DRUG|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
219277473|NCT00003564|DRUG|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
219277474|NCT06439732|DEVICE|Acumen IQ cuff|Use of Acumen IQ cuff for haemodynamic monitoring
219277475|NCT01224522|PROCEDURE|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
219277476|NCT01224522|PROCEDURE|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
219277477|NCT04467047|BIOLOGICAL|Mesenchymal Stromal Cells infusion|Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
219277478|NCT02136368|BEHAVIORAL|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
219277479|NCT02136368|BEHAVIORAL|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
219277480|NCT02136368|BEHAVIORAL|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
219277481|NCT03828890|OTHER|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
219277482|NCT02335905|DRUG|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
219277483|NCT04296747|DRUG|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
219277484|NCT04296747|PROCEDURE|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
219277485|NCT04296747|RADIATION|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
219277486|NCT01436305|DRUG|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
219277487|NCT01436305|DRUG|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
219277488|NCT01436305|BIOLOGICAL|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication\[s\])
219277489|NCT01436305|DRUG|Short-term Tac|Short-term (3 months)
219277490|NCT01436305|DRUG|tacrolimus|maintenance
219277491|NCT01436305|BIOLOGICAL|Belatacept|maintenance
219277492|NCT01436305|DRUG|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
219277493|NCT01049438|DRUG|nasal mupirocin|twice daily for 10 days
219277494|NCT01049438|DRUG|topical 3% hexachlorophene body wash|daily for 10 days
219277495|NCT01049438|DRUG|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
219277496|NCT05390814|DRUG|PET-MRI|\[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
219277497|NCT02281162|OTHER|Blood Draw|Blood Draw
219277498|NCT02813044|DRUG|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
219277499|NCT02813044|DRUG|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
219277500|NCT00751543|RADIATION|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
219277501|NCT04641169|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
219277502|NCT03435731|COMBINATION_PRODUCT|Dual Therapy|Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
219277503|NCT01322737|PROCEDURE|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
219277504|NCT02876445|OTHER|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
219277505|NCT02019862|DEVICE|TRJ® Total Hip Arthroplasty|
219277506|NCT02926287|OTHER|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
219277507|NCT02740738|DEVICE|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
219277508|NCT02740738|DEVICE|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
219277509|NCT01485120|DEVICE|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
219277510|NCT03058393|OTHER|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
219277511|NCT04771377|DIETARY_SUPPLEMENT|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
219277512|NCT03071237|PROCEDURE|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
219277513|NCT01817920|BEHAVIORAL|integrated multidisciplinary fall prevention program|
219277514|NCT00289250|DRUG|Sulfadoxine-pyrimethamine|
219277515|NCT00289250|DRUG|Sulfadoxine-pyrimethamine plus artesunate|
219277516|NCT01081886|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
219277517|NCT01081886|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
219277518|NCT02567708|DRUG|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
219277519|NCT02567708|DRUG|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
219277520|NCT05392647|DRUG|Hetrombopag|All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (\>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
219277521|NCT05761613|DEVICE|CeraShield Endotracheal Tube|An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
219277522|NCT05761613|DEVICE|Endotracheal tube with subglottic secretion drainage|An endotracheal tube with subglottic secretion drainage
219277523|NCT00108251|DRUG|Eplerenone|aldosterone receptor blocker
219277524|NCT00108251|DRUG|Placebo|matching placebo
219277525|NCT00654797|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
219277526|NCT05083845|PROCEDURE|Same blocks with different local anesthetic volume|Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
219277527|NCT02405598|DRUG|Salbutamol|"1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
219277528|NCT02495766|DRUG|XCEL-MC-ALPHA|Single infusion
219277529|NCT02495766|DRUG|Placebo|Single infusion
219277530|NCT06026930|DEVICE|low-level laser therapy|LLLT and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
219277531|NCT06511492|OTHER|No intervention in this study|No intervention in this study
219277532|NCT00022945|DRUG|Iodine-131 Anti-B1 Antibody|
219277533|NCT00022945|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
219277534|NCT04325633|DRUG|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
219277535|NCT04325633|DRUG|2: Standard of care|Standard of care
219277536|NCT01193010|PROCEDURE|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
219277537|NCT01193010|PROCEDURE|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
219277538|NCT04148651|DEVICE|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
219277539|NCT04970719|DRUG|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
219277540|NCT04970719|DRUG|Dexamethasone|and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
219277541|NCT04970719|DRUG|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
219277542|NCT00003877|BIOLOGICAL|filgrastim|
219277543|NCT00003877|DRUG|carboplatin|
219277544|NCT00003877|DRUG|cyclophosphamide|
219277545|NCT00003877|DRUG|paclitaxel|
219277546|NCT00003877|DRUG|thiotepa|
219277547|NCT00003877|PROCEDURE|in vitro-treated bone marrow transplantation|
219277548|NCT00003877|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219277549|NCT05262751|DRUG|Ofev®|Ofev®
219277550|NCT05262751|DRUG|Nintedanib formulation 1|Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
219277551|NCT05262751|DRUG|Nintedanib formulation 2|Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
219277552|NCT02463045|DRUG|TOP1288|
219277553|NCT01798342|DIETARY_SUPPLEMENT|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
219277554|NCT01798342|DIETARY_SUPPLEMENT|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
219277555|NCT00643292|DRUG|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
219277556|NCT00643292|DRUG|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
219277557|NCT02655926|PROCEDURE|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
219277558|NCT03185884|OTHER|Control|control carbohydrate blend
219277559|NCT03185884|OTHER|Experimental|experimental carbohydrate blend
219277560|NCT01391637|BIOLOGICAL|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
219277561|NCT03832842|DIAGNOSTIC_TEST|Blood sample|Blood sample
219277562|NCT02144103|OTHER|Subtenon administration of autologous ADRC|
219277563|NCT02144103|PROCEDURE|Liposuction|
219277564|NCT02144103|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
219277565|NCT05089045|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219277566|NCT04341129|DRUG|Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)|To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
219277567|NCT05446753|DIETARY_SUPPLEMENT|Animal-based meats|Animal-based meats from beef, pork and chicken
219277568|NCT05446753|DIETARY_SUPPLEMENT|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
219277569|NCT00806481|DRUG|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
219277570|NCT00806481|DRUG|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
219277571|NCT04549818|DEVICE|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
219277572|NCT04553055|OTHER|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
219277573|NCT03600025|BIOLOGICAL|Typbar-TCV vaccine|vaccine will receive intramuscularly
219277574|NCT04301895|BEHAVIORAL|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
219277575|NCT04301895|DRUG|Remifentanil infusion|10 minute remifentanil infusion
219277576|NCT06128096|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."
219277577|NCT03335436|DRUG|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
219277578|NCT03335436|DRUG|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
219277579|NCT05988723|OTHER|ELISA kits|Making biochemical measurements with the ELISA kit
219277580|NCT01154140|DRUG|treatment|crizotinib 250mg orally continuous twice daily dosing
219277581|NCT01154140|DRUG|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
219277582|NCT04039373|DRUG|BMS-986256|specified dose on specified days
219277583|NCT04039373|DRUG|Mycophenolate Mofetil|specified dose on specified days
219277584|NCT03452852|DEVICE|PICO|NPWT with PICO (Smith and Nephew)
219277585|NCT03452852|OTHER|Coban 2 lite|Compression bandaging with Coban 2 lite
219277586|NCT00571181|DEVICE|Closed-loop system|Automatic delivery of propofol and remifentanil
219277587|NCT00571181|DEVICE|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
219277588|NCT03969134|BIOLOGICAL|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
219277589|NCT03969134|OTHER|Placebo|The placebo will be injected intramuscularly into the arm.
219277590|NCT05315570|OTHER|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
219277591|NCT04571190|BEHAVIORAL|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
219277592|NCT00478192|DRUG|Conivaptan|premix bag
219277593|NCT00478192|DRUG|Placebo|premix bag
219277594|NCT03664102|DEVICE|Cor Knot|Heart valve replacement with or without the use of automated fastener device Cor Knot
219277595|NCT05967325|PROCEDURE|Stromal Vascular Fraction (SVF) combined with Functional self-assembling peptide nanofiber hydrogels|Transplantation of SVF and biomimetic nanohydrogel
219277596|NCT01243788|DRUG|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
219277597|NCT05788627|DRUG|Tap water|Oral lactulose in a dose of 30ml BD and tap water enema 1000ml BD
219277598|NCT05788627|DRUG|Lactulose|Oral lactulose in a dose of 30ml BD and lactulose enema (300ml lactulose and 700ml water) in a dose of 1000ml BD.
219277599|NCT04489277|DEVICE|Endovascular Arch Procedures|Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
219277600|NCT04012177|DIETARY_SUPPLEMENT|Balanced-energy protein (BEP)|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
219277601|NCT04012177|DRUG|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
219277602|NCT04012177|DRUG|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
219277603|NCT04012177|DRUG|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
219277604|NCT00358020|DRUG|THALIDOMIDE|
219277605|NCT00358020|DRUG|BORTEZOMIB|
219296309|NCT02538952|DEVICE|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
219277606|NCT02931370|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
219277607|NCT00061594|DRUG|rhuFab V2 (ranibizumab)|
219277608|NCT01653054|PROCEDURE|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
219277609|NCT06380452|DRUG|5% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
219277610|NCT06380452|DRUG|10% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
219277611|NCT04905368|OTHER|SS-POR11|Topical composition containing probiotic strains derived from human skin (SS-POR11). Participants will be instructed to apply it topically to face, twice weekly for the duration of the trial.
219277612|NCT01712269|PROCEDURE|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
219277613|NCT00343993|DEVICE|noninvasive positive pressure ventilation|
219277614|NCT04727983|DEVICE|Electrotherapy|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS) (NMES group)
219277615|NCT04727983|DEVICE|Sham Electrotherapy|The second group will be given sham NMES in addition to LSS (SHAM ES group)
219277616|NCT00157235|DRUG|Tiotropium bromide|
219277617|NCT02125071|OTHER|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
219277618|NCT02869256|OTHER|Practices evaluation|Practices evaluation
219277619|NCT00862836|DRUG|Vandetanib|100mg doses orally, once daily
219277620|NCT03007797|BEHAVIORAL|vaccination rate for influenza|
219277621|NCT03876106|DRUG|LUT014|Topical
219277622|NCT04001335|DIAGNOSTIC_TEST|Dental Broach|Dental broach, RDT and PCR
219277623|NCT05132894|OTHER|Osteopathic Assessment|As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
219277624|NCT04568863|DRUG|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
219277625|NCT04568863|DRUG|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
219277626|NCT02413281|DRUG|ALKS 5461|Sublingual tablets, single administration
219277627|NCT02413281|DRUG|Buprenorphine|Sublingual tablets, single administration
219277628|NCT02413281|DRUG|Placebo|Sublingual tablets, single administration
219277629|NCT04463680|DRUG|Rifampin 600 MG|Administered daily for 2 weeks
219277630|NCT00205595|DEVICE|Positron Emission Tomography|
219277631|NCT02171247|DRUG|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
219277632|NCT02171247|DRUG|Visipaque 320|Visipaque 320 is standard protocol.
219277633|NCT00938405|DRUG|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
219277634|NCT00938405|DRUG|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
219277635|NCT05389605|OTHER|No intervention was undertaken|This was an observational study, no intervention was done.
219277636|NCT05239598|DRUG|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
219277637|NCT05038540|PROCEDURE|Scaling and root planing|Phase 1 periodontal therapy
219277638|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
219277639|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
219277640|NCT04391543|OTHER|Experimental session|"* comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index"
219277641|NCT05223218|OTHER|Schirmer strip, a Class I Medical Device typically used to test for dry eye.|Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
219277642|NCT04224168|DIETARY_SUPPLEMENT|Green Beans|Please see arm group Green beans for description
219277643|NCT04224168|DIETARY_SUPPLEMENT|Liquid Pectin|Please see arm group liquid pectin for description
219277644|NCT02416245|DIETARY_SUPPLEMENT|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
219277645|NCT02416245|OTHER|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
219277646|NCT06064656|OTHER|Non-Interventional|No study treatment will be administered in this study.
219277647|NCT04147195|DRUG|LYS006|5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
219277648|NCT04147195|DRUG|Tropifexor|100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
219277649|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
219277650|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
219277651|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
219277652|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
219277653|NCT06994286|DRUG|MT-7117|Oral
219277654|NCT06994286|DRUG|Placebo|Oral
219277655|NCT06421831|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
219277656|NCT07049757|OTHER|Smoking cessation education|Quit Smoking for a Healthy Family (QS) and Smokefree Family Living (SFL) education sessions to promote smoking cessation and reduce tobacco smoke exposure.
219277657|NCT07049757|BEHAVIORAL|Survey Administration|Administered for ancillary studies
219277658|NCT07049757|BEHAVIORAL|Telephone-Based Intervention|Participants will receive follow-up calls
219277659|NCT07049757|PROCEDURE|Urine Specimen Collection|Undergo urine sample collection at baseline
219277660|NCT07049757|OTHER|Silicone Wrist Band|Non-smoking family/household members will wear a silicone wristband for 2 days at each assessment for ancillary studies
219277661|NCT07049757|OTHER|Interview|Selected participants will take part in an interview for ancillary studies
219277662|NCT07049757|OTHER|Focus Group|Participants will review and comment on materials under development to be used in randomized clinical trial.
219277663|NCT07050810|DEVICE|TheraClean|Begins after Week 0 visit and continues through Week 8. Participants will take at least 3 baths/week (20-30 minutes each bath) but may bathe daily, if desired.
219277664|NCT07050862|DEVICE|Transcranial Magnetic Stimulation|The first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex.
219277665|NCT07050862|DEVICE|personalized-image-guided and E-field-modeling dose rTMS (precision TMS)|with a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left DLPFC.
219277666|NCT07051109|DEVICE|multimodal analgesia via dual-chamber PCA|combination of fentanyl and ketorolac through dual-chamber PCA
219277667|NCT07051109|DEVICE|single regimen (only fentanyl)|fentanyl only through dual-chamber PCA
219277668|NCT07050797|BEHAVIORAL|Individualised whole-school intervention, developed using data sharing and co-design.|Individualised whole-school intervention, developed using data sharing and co-design.
219277669|NCT06805786|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
219277670|NCT01424813|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
219277671|NCT01424813|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
219277672|NCT07135739|DEVICE|funcional Electrical stimulation combined with mirror therapy|"* Subjects were treated with a combination therapy of task specific mirror therapy and functional electrical stimulation, consisting of two tasks, for a total duration of thirty minutes.~* The subject was positioned on a height adjustable table with the mirror placed in front of the mid line.~* The positive electrode and negative electrode of the muscle simulator were placed over the muscle belly of the wrist extensors on forearm over the motor (between one-third and half-way from the proximal end of the dorsal forearm) of the affected upper limb.~* The subject was then instructed to observe the mirror reflection for one to two minutes, trying to visualize the mirror image as the affected limb, asked to perform slow, easy to achieve simultaneous bilateral movements (perceived bilateral movements) while continuing to look at ,with the affected limb performing synchronously with the duty cycle of electrical stimulation."
219277673|NCT07135739|OTHER|Physical therapy program|"The program will be applied to all children in both groups (A and B). The exercise session for one hour for each child in both groups, conducted 3times/ week for 3 successive months.~1. Flexibility exercises for shorted muscles and spastic muscles.~2. Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles.~3. Postural control exercise in different positions and different surfaces~4. General endurance training (Sherief et al., 2020).~5. Exercises to facilitate hand function including basic reaching grasping, carrying, release and the more complex skills of in-hand manipulation and bilateral hand use were conducted."
219277674|NCT07138235|PROCEDURE|laparoscopic hiatal hernia repair|"Intraoperative endoscopic control and the use of calibration bougies allow for increasing the accuracy of cardiac sphincter reconstruction and reducing the risk of hyper- or hypocorrection. Endoscopic equipment. The Olympus EVIS EXERA III endoscopic video system (Olympus Medical Systems Corp., Tokyo, Japan), series 190, was used for diagnostic and therapeutic endoscopic examinations.~The complex included:~* CV-190 video processor with digital image magnification,~* CLV-190 light source (xenon/LED), providing high brightness and uniformity of illumination, a high definition (HD) video monitor,~* GIF-HQ190, GIF-H190 high-resolution series gastroscopes,~* CF-HQ190L/I series colonoscopes (if necessary). These functions made it possible to more accurately assess the condition of the mucous membrane of the esophagus and stomach, as well as to identify pathological changes.~Medications: omeprazole/esomeprazole, ondansetron, cephalosporins intravenously, metoclopramide."
219277675|NCT01686139|BIOLOGICAL|ABMD-MSC|10-20 x 10\^6 cells/20mL
219277676|NCT06100913|BIOLOGICAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
219277677|NCT06100913|OTHER|Deuterium Labeled Water|An Emory Investigational Drug Service pharmacist will prepare sterile 50 ml aliquots of D2O with a tamper seal and stored at room temperature. Participants will be asked to drink a pre-measured volume of water three times a day and on days according to their assigned group schedule.
219277678|NCT05274204|DRUG|CA102N|
219277679|NCT03763136|BIOLOGICAL|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
219277680|NCT03710122|DRUG|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
219277681|NCT03710122|OTHER|Placebo|Placebo for Vancomycin
219277682|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a gambling task evaluated
219277683|NCT04715984|OTHER|Neural stimulation|Neural stimulation will be delivered during a gambling task and its impact on task performance quantified
219277684|NCT05636774|DRUG|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
219277685|NCT05636774|DRUG|Placebo|Placebo tables / infusion
219277686|NCT03557645|DEVICE|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
219277687|NCT03557645|DEVICE|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
219277688|NCT03557645|DEVICE|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
219277689|NCT06325917|BEHAVIORAL|what's app ongoing support|"daily educational messages and reminders sent through WhatsApp. The educational material related to diabetes self-management behaviors (AADE7 Self-Care Behaviors, diabetes and genetics, and endocrinology center, also the Ministry of Health in Jordan diabetes.~individual bidirectional communication between the participants and the investigator, which will allow participants to seek advice and get free-of-charge feedback and consultation."
219277690|NCT06325917|BEHAVIORAL|usual care|monthly visit and follow-up at the diabetes education clinic by a diabetes nurse specialist providing DSMES
219277691|NCT03078569|DRUG|Testosterone gel|treatment with testosterone gel
219277692|NCT02319473|OTHER|JAC Registry|patients who received acute reperfusion therapy
219277693|NCT03402698|DIETARY_SUPPLEMENT|cholecalciferol|supplementation at a dose 1000 IU/d
219277694|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
219277695|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
219277696|NCT03080948|BEHAVIORAL|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
219277697|NCT03080948|OTHER|Saliva samples|Germline DNA analysis
219277698|NCT05248477|OTHER|Premex Protocol|"This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents."
219277699|NCT06223360|DRUG|Low Dose Benfotiamine|300mg benfotiamine capsules (BID, twice a day)
219277700|NCT06223360|DRUG|High Dose Benfotiamine|600mg benfotiamine capsules (BID, twice a day)
219277701|NCT06223360|DRUG|Placebo|Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
219277702|NCT01385046|BEHAVIORAL|Project Fit|physical activity and nutrition education
219277703|NCT01817322|DRUG|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
219277704|NCT01817322|DRUG|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
219277705|NCT01817322|DRUG|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
219277706|NCT00993005|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
219277707|NCT00993005|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
219277708|NCT01848613|DRUG|Vinorelbine|
219277709|NCT03388268|DRUG|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
219277710|NCT03388268|DRUG|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
219277711|NCT03388268|DEVICE|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
219277712|NCT03388268|DEVICE|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
219277713|NCT05420233|DIAGNOSTIC_TEST|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
219277714|NCT05867823|BEHAVIORAL|OcuApp|The participants will have instaled a mobile aplication (OcuApp) by a member of the researchs team who will teach them how to use it. The person must register the activities they carry out throughout a week and mark each one of them with a punctuation (from 1 to 5) related to the meaning of the following dimensions: identity, pleasure, competence, importance and value of the activity by other people.The application also allows to collect other information such as where the activity takes place, its duration, and the people with whom it is carried out. Also, at the end of the week, the application will ask users about their perceived occupational balance. All the information registered in the mobile application will be returned to the person in a dynamic and understandable way. Based on this, the person can establish two goals to accomplish. In this sense, OcupApp will offer personalized recommendations based on the objectives to be achieved related to the dimensions of meaning.
219277715|NCT05867823|BEHAVIORAL|Three-part work|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities to control anxiety and depression. After providing this information, any doubts in this regard will be answered.
219277716|NCT00176982|DRUG|Hydroxychloroquine|
219277717|NCT05067595|PROCEDURE|Colonoscopy|Undergo lower FMT via colonoscopy
219277718|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Given upper FMT PO or via post-pyloric or NG feeding tube
219277719|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
219277720|NCT05067595|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
219277721|NCT05067595|OTHER|Survey Administration|Ancillary studies
219277722|NCT05067595|PROCEDURE|Biospecimen Collection|Undergo tissue, stool, stool swabs, and blood sample collection
219277723|NCT05357976|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
219277724|NCT02696876|DEVICE|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
219277725|NCT02696876|PROCEDURE|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
219277726|NCT04673266|DRUG|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
219277727|NCT03518190|DEVICE|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
219277728|NCT02812095|PROCEDURE|Refeeding|when amount of feeding reach to 120mL/kg a day,
219277729|NCT06556433|BEHAVIORAL|Financial Incentive Rewards|Participants in the Rewards Group will have abstinence reinforced through escalating financial incentives.
219277730|NCT03956251|PROCEDURE|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
219277731|NCT03956251|PROCEDURE|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
219277732|NCT00371384|PROCEDURE|massage|UP to 10 massages over 10 weeks
219277733|NCT04392024|DEVICE|Triumf|Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
219277734|NCT00547014|DRUG|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
219277735|NCT00547014|DRUG|52364 3 mg|3 mg capsule single dose administered orally as a single dose
219277736|NCT00547014|DRUG|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
219277737|NCT00547014|DRUG|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
219277738|NCT00547014|DRUG|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
219277739|NCT00547014|DRUG|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
219277740|NCT00547014|DRUG|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
219277741|NCT05050825|OTHER|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
219277742|NCT01249495|PROCEDURE|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
219277743|NCT03680547|OTHER|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
219277744|NCT02575716|DEVICE|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
219277745|NCT03923517|DEVICE|RHAPSODY online program and MEET online sessions|"internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings."
219277746|NCT04220398|DRUG|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
219277747|NCT04220398|DRUG|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
219277748|NCT04220398|PROCEDURE|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
219277749|NCT04056988|DRUG|Perflutren Lipid Microsphere|Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
219277750|NCT01079351|DRUG|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
219277751|NCT00557908|DRUG|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
219277752|NCT02819167|OTHER|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
219277753|NCT01516255|DRUG|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
219277754|NCT01516255|DRUG|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
219277755|NCT01516255|DRUG|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
219277756|NCT01516255|DRUG|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
219277757|NCT01516255|PROCEDURE|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
219277758|NCT01516255|PROCEDURE|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
219277759|NCT03455257|BEHAVIORAL|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
219277760|NCT03299049|DRUG|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
219277761|NCT03299049|DRUG|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
219277762|NCT03299049|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
219277763|NCT03299049|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
219277764|NCT03310034|DIETARY_SUPPLEMENT|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
219277765|NCT03310034|DIETARY_SUPPLEMENT|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
219277766|NCT05559970|DRUG|Inhalational sedation|Inhalational sedation with isoflurane for 12 hours
219277767|NCT05559970|DRUG|Convention sedation|Conventional sedation receiving analgosedation with fentanyl
219277768|NCT01637805|BIOLOGICAL|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
219277769|NCT05869318|OTHER|ECIG own|Participants will vape using their own ecig device
219277770|NCT05869318|OTHER|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
219277771|NCT01901419|DRUG|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
219277772|NCT03683303|BEHAVIORAL|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
219277773|NCT03683303|BEHAVIORAL|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
219277774|NCT02296502|OTHER|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
219277775|NCT02639039|DRUG|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
219277776|NCT02639039|PROCEDURE|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
219277777|NCT06061822|DIAGNOSTIC_TEST|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
219277778|NCT03712878|RADIATION|Total-Body Irradiation|Undergo TBI
219277779|NCT03712878|PROCEDURE|Donor Lymphocyte Infusion|Given IV
219277780|NCT03712878|DRUG|Cyclophosphamide|Given IV
219277781|NCT03712878|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
219277782|NCT03712878|DRUG|Tacrolimus|Given IV
219277783|NCT03712878|DRUG|Mycophenolate Mofetil|Given IV
219277784|NCT05677386|DIAGNOSTIC_TEST|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
219277785|NCT05677386|OTHER|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
219277786|NCT02051062|BIOLOGICAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
219277787|NCT05525247|DRUG|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
219277788|NCT05525247|COMBINATION_PRODUCT|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
219277789|NCT05271344|DIETARY_SUPPLEMENT|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
219277790|NCT06503484|DEVICE|Brain-computer interface|Patients will perform kinesthetic motor imagery of the affected upper extremity in response to auditory cues from the BCI system. The averaged oxygenated hemoglobin (HbO) level, extracted from optimal channels identified during the localizer session, will serve as signal intensity. This intensity, quantified as percent signal change relative to baseline, will trigger neurofeedback when reaching a predefined threshold. Visual feedback, delivered via the digital mirror therapy system, will guide patients to perform observational imitation tasks using bilateral upper extremities. Each session will include 5-6 movements tailored to the patient's functional performance. After observational imitation training, patients will practice functional adaptation tasks in a virtual environment, where they apply learned movements to functional activities. Sessions will last approximately 75 minutes.
219277791|NCT06503484|DEVICE|Sham brain-computer interface|In the sham group, patients will wear a similar headset equipment as those in the BCI group. However, the visual feedback provided through the digital mirror therapy system will not be based on their own brain activity. Instead, it will be derived from the brain activity of a participant in the BCI group using the simulation mode of Turbo-Satori. Patients in the sham group will receive constant visual feedback, with a fixed duration of 60 seconds for motor imagery, regardless of their actual brain signals. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback, and practice functional adaptation tasks after observational imitation training. The sham training will also last for around 75 minutes per session.
219277792|NCT03142854|DRUG|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
219277793|NCT03142854|DRUG|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
219277794|NCT05121389|DRUG|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
219277795|NCT03274115|DEVICE|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
219277796|NCT06832540|DRUG|[14C]TJ0113|Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.
219277797|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
219277798|NCT00064649|DEVICE|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
219277799|NCT00064649|DEVICE|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
219277800|NCT00064649|DRUG|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
219277801|NCT04112706|DRUG|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
219277802|NCT05257447|DRUG|Baclofen 20 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
219277803|NCT05257447|DRUG|Chlorzoxazone 500 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
219277804|NCT05257447|DRUG|Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet|Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
219277805|NCT04706936|BIOLOGICAL|anti-BCMA CAR-T|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
219277806|NCT04706936|DRUG|Cyclophosphamid|300mg/m2/d
219277807|NCT04706936|DRUG|Fludarabine|30mg/m2/d
219277808|NCT01667926|DRUG|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
219277809|NCT01667926|DRUG|Placebo|
219277810|NCT03572647|DRUG|Eritromax|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
219277811|NCT03572647|DRUG|Eprex|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
219277812|NCT00558922|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
219277813|NCT05311722|DRUG|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
219277814|NCT05311722|DRUG|Ketamine|Ketamine
219277815|NCT05311722|DRUG|Tramadol|Tramadol
219277816|NCT01750970|OTHER|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
219277817|NCT01205022|DRUG|irinotecan hydrochloride|Given IV
219277818|NCT01205022|DRUG|leucovorin calcium|Given IV
219277819|NCT01205022|DRUG|fluorouracil|Given IV
219277820|NCT01205022|BIOLOGICAL|bevacizumab|Given IV
219277821|NCT01205022|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
219277822|NCT01205022|OTHER|laboratory biomarker analysis|Correlative studies
219277823|NCT01431820|DRUG|Luliconazole Solution, 10%|Topical
219277824|NCT01431820|DRUG|Vehicle Solution|Topical
219277825|NCT03283475|PROCEDURE|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
219277826|NCT00777738|DRUG|BORTEZOMIB|"* Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~* For responding patients : up to 6 cycles~* For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
219277827|NCT03774615|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
219277828|NCT04651140|BEHAVIORAL|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
219277829|NCT01833377|DIETARY_SUPPLEMENT|caraway sample|
219277830|NCT01833377|DIETARY_SUPPLEMENT|placebo|
219277831|NCT04127981|DIAGNOSTIC_TEST|18F-FDG PET + Dexa Scan|18F-FDG PET will be compared with Dexa Scan result within and between arms.
219277832|NCT04467918|DRUG|Cannabidiol|Already described
219277833|NCT04467918|OTHER|PLACEBO|Already described
219277834|NCT01908504|OTHER|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
219277835|NCT01202149|DEVICE|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
219277836|NCT00623259|BIOLOGICAL|MVA-mBN120B|
219277837|NCT04523675|DIETARY_SUPPLEMENT|N-acetylcysteine|Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
219277838|NCT04523675|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
219277839|NCT03591484|RADIATION|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
219277840|NCT03591484|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
219277841|NCT03591484|PROCEDURE|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
219277842|NCT03591484|PROCEDURE|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
219277843|NCT01225653|DRUG|Latanoprost|Topical application
219277844|NCT02244970|OTHER|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
219277845|NCT02244970|OTHER|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
219277846|NCT06530004|DRUG|Rituximab|B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
219277847|NCT00167804|BEHAVIORAL|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
219277848|NCT05509049|OTHER|Precision nudging|Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
219277849|NCT05509049|OTHER|Standard of care|Standard of care communication (e.g., personalized letters and patient portal notices)
219277850|NCT05034406|DRUG|2% Lidocaine|6 mL of 2% lidocaine injected at the trocar insertion site.
219277851|NCT05034406|DRUG|0.5% levobupivacaine|6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
219277852|NCT05529680|OTHER|Scapular mobilization and Scapular strengthening exercises|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
219277853|NCT05529680|OTHER|Conventional physical therapy program|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
219277854|NCT00506246|DRUG|Propofol|"* intravenous (total intravenous anaesthesia)~* induction and maintenance"
219277855|NCT03485664|PROCEDURE|tooth extraction|tooth extraction
219277856|NCT02412735|DRUG|Rexlemestrocel-L|Rexlemestrocel-L injection
219277857|NCT02412735|DRUG|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
219277858|NCT02412735|DRUG|Placebo|Saline control solution
219277859|NCT02468362|PROCEDURE|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
219277860|NCT02468362|PROCEDURE|open intersphincteric resection|
219277861|NCT00234702|DRUG|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
219277862|NCT00234702|DRUG|Placebo|Placebo
219277863|NCT02566057|BIOLOGICAL|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
219277864|NCT00876824|DRUG|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
219277865|NCT00876824|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
219277866|NCT04743609|DIAGNOSTIC_TEST|nasopharyngeal samples|rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
219277867|NCT05753436|DIETARY_SUPPLEMENT|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
219277868|NCT05528523|OTHER|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
219277869|NCT00362245|DRUG|Systemic and Intra-Thecal Amikacin Therapy|
219277870|NCT03459872|PROCEDURE|Acupuncture|Alternative medicine therapeutic intervention
219277871|NCT03459872|DEVICE|RU-Fit|FDA approved medical device for the measurement of fine motor control
219277872|NCT06446687|PROCEDURE|Dental implant with sinus lifting.|Surgery will be performed under local infiltration anaesthesia. Flap will be done. For maxillary sinus lifting by using Crestal approach with Membrane Control Technique by Wang (Wang, 2017) will be employed. After reflecting on the flap, Magic Split will be used to confirm bone quality clinically. This will be followed by site preparation using Magic Marking Drill. Bone drilling will then be performed by Magic Drill shorter by 2 mm from the sinus floor. This will be followed by sinus lifting by using Magic Sinus Lifter (MSL). The 3mm space of the apex of the Sinus Lifter instrument enables direct control of the bone-block and consequently the membrane, which is connected to the bone-block. the fixture will be installed in the conventional method. Then cover the fixture with the cover screw. The flap will be sutured. An immediate CBCT will be requested to ensure the implant is in its proper position.
219277873|NCT04717453|OTHER|No Intervention|No Intervention
219277874|NCT04508855|DRUG|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
219277875|NCT00136877|PROCEDURE|(adeno)tonsillectomy|
219277876|NCT04043143|OTHER|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
219277877|NCT04043143|OTHER|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
219277878|NCT00254826|BIOLOGICAL|YF-VAX® plus saline|YF-VAX® plus saine
219277879|NCT00254826|BIOLOGICAL|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
219277880|NCT06134999|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
219277881|NCT06134999|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219277882|NCT00703417|DEVICE|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
219277883|NCT00703417|DEVICE|Computed Tomography|CT scan of the lower back and hip
219277884|NCT00703417|DEVICE|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
219277885|NCT01409551|PROCEDURE|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
219277886|NCT01409551|PROCEDURE|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
219277887|NCT02521363|DEVICE|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.
219277888|NCT02521363|DRUG|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
219277889|NCT02552628|DEVICE|"Medtronic, Activa® PC on"|
219277890|NCT02552628|DEVICE|"Medtronic, Activa® PC off"|
219277891|NCT03561298|DRUG|BGB-3111 and Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
219277892|NCT06791239|OTHER|Thoracic squeeze technique|The Thoracic Squeeze Technique is a manual therapy method used primarily in respiratory physiotherapy to improve lung expansion, enhance respiratory function, and facilitate secretion clearance in patients with respiratory conditions.
219277893|NCT06791239|OTHER|Manual diaphragmatic release technique|The Manual Diaphragmatic Release Technique is a soft tissue manipulation technique used to improve the mobility, function, and efficiency of the diaphragm. It is commonly applied in physiotherapy, particularly in respiratory, musculoskeletal, and manual therapy practices, to address breathing dysfunctions, postural imbalances, and associated pain or discomfort.
219277894|NCT04975841|DEVICE|Adipose Derived Regenerative Cells|"The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility."
219277895|NCT03494153|OTHER|Non applicable - Non interventional study|Non interventional study
219277896|NCT06797674|DRUG|MK-7602|Capsule
219277897|NCT06797674|DRUG|Efavirenz|Tablet
219277898|NCT06509100|DEVICE|Device: Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
219277899|NCT05973656|DRUG|Alcohol|Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
219277900|NCT05973656|PROCEDURE|Biospecimen Collection|Undergo saliva, mouthwash, and cheek brush collection
219277901|NCT05973656|PROCEDURE|Breath Test|Undergo breathalyzer testing
219277902|NCT06090721|DRUG|DMT310|Topical Powder
219277903|NCT06090721|DRUG|Placebo|Placebo Topical Powder
219277904|NCT01480063|DRUG|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
219277905|NCT06329258|DRUG|Enstilar|Add on Enstilar
219277906|NCT06329258|DRUG|Deucravacitinib|6mg QD
219277907|NCT00142090|DRUG|3% Hypertonic saline|
219277908|NCT00142090|DRUG|Placebo|Normal saline
219277909|NCT04654949|OTHER|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
219277910|NCT03405675|OTHER|SLAS 1|NA. Observational study, no interventions administered.
219277911|NCT03405675|OTHER|SLAS 2|NA. Observational study, no interventions administered.
219277912|NCT01735903|PROCEDURE|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
219277913|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
219277914|NCT02453984|OTHER|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
219277915|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
219277916|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
219277917|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
219277918|NCT03181659|PROCEDURE|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
219277919|NCT03181659|PROCEDURE|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
219277920|NCT05005377|PROCEDURE|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
219277921|NCT05005377|PROCEDURE|Socket Preservation with Freeze-Dried Bone Allograft|The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
219277922|NCT05428995|DEVICE|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
219277923|NCT05428995|DEVICE|Airtraq videolaryngoscope.|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
219277924|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 25 mg.
219277925|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 50 mg.
219277926|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 75 mg.
219277927|NCT00903500|BEHAVIORAL|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
219277928|NCT05071053|DRUG|Ramucirumab (CYRAMZA®)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
219277929|NCT05071053|DRUG|Tusamitamab ravtansine (SAR408701)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
219277930|NCT02019186|DIETARY_SUPPLEMENT|Vitamin C|\<30 kg 250 mg 30-60 kg 500 mg \>60 kg 750 mg
219277931|NCT02019186|DIETARY_SUPPLEMENT|Vitamin E|\<30 kg 100 IU, 30-60 kg 200 IU, \>60 kg 300 IU
219277932|NCT01871337|BEHAVIORAL|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
219277933|NCT01937169|BEHAVIORAL|Motor Task|A motor task executed for 30 minutes after drug adminidtration
219277934|NCT01937169|DRUG|Levodopa tablet|
219277935|NCT01937169|BEHAVIORAL|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
219277936|NCT01937169|DRUG|Placebo pill|
219277937|NCT03573869|PROCEDURE|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
219277938|NCT04670445|OTHER|Educational Video and QPL List|The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.
219277939|NCT04670445|OTHER|Usual Care|Surveys
219277940|NCT00798252|DRUG|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
219277941|NCT00798252|DRUG|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
219277942|NCT00798252|DRUG|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
219277943|NCT00798252|DRUG|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
219277944|NCT00798252|DRUG|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
219277945|NCT00798252|DRUG|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
219277946|NCT01602510|DRUG|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
219277947|NCT01602510|DRUG|Placebo|Placebo
219277948|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
219277949|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
219277950|NCT04053062|BIOLOGICAL|LIGHT-PSMA-CART cells|LIGHT-PSMA-CART cells will be given IV at split doses
219277951|NCT04127097|OTHER|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
219277952|NCT03519204|DEVICE|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
219277953|NCT03519204|OTHER|No-treatment Control|No-treatment was administered.
219277954|NCT03377686|DIAGNOSTIC_TEST|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
219277955|NCT04419233|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
219277956|NCT03678090|DRUG|tPA standard dosage|Tissue plasminogen activator 25mg dosage
219277957|NCT03678090|DRUG|tPA low dosage|Tissue plasminogen activator 2.5mg
219296310|NCT02538952|OTHER|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
219296311|NCT02846272|PROCEDURE|Observation|Observation of MRI changes in subjects
219277958|NCT05946720|OTHER|Training including aggression and the use of BVC.|After obtaining verbal consent from the nurses who met the inclusion criteria of the study before the pre-test was applied to the nurses, the nurses who volunteered to participate in the study were randomized within their own clinic using the simple randomization method. For this, after the data collection form was distributed before the pre-test, the nurses were asked to write the letter that came to them on the data collection form and not forget it. In order for nurses to be included in the training or comparison group, the letter A, written on the closed papers in the box prepared for simple randomization, represents the Education group, and the letter B represents the comparison group.
219277959|NCT02627118|DEVICE|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
219277960|NCT02627118|DEVICE|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
219277961|NCT03965715|DEVICE|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
219277962|NCT03133832|DRUG|Companion Tablet|Chinese-made drug for schistosomiasis treatment
219277963|NCT03274973|DRUG|Zomacton|Injection
219277964|NCT06306469|OTHER|Meditation practice|physical and breathing exercises
219277965|NCT06457243|DEVICE|Closed-loop cTBS stimulation based on addiction induced states|We conducted a longitudinal controlled study of closed-loop cTBS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed loop cTBS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
219277966|NCT06068764|DRUG|Etomidate|The type of general anesthesia induction agent for CABG surgery
219277967|NCT06068764|DRUG|Propofol|The type of general anesthesia induction agent for CABG surgery
219277968|NCT02721992|OTHER|No intervention|No intervention
219277969|NCT03900910|OTHER|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
219277970|NCT03900910|OTHER|Execution of the program|Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
219277971|NCT01572740|DRUG|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
219277972|NCT01572740|DRUG|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
219277973|NCT01572740|DRUG|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
219277974|NCT00211380|DRUG|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
219277975|NCT01289210|DRUG|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
219277976|NCT03423576|BEHAVIORAL|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
219277977|NCT01224834|DRUG|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
219277978|NCT03952091|DRUG|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
219277979|NCT03952091|DRUG|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
219277980|NCT05837377|OTHER|Control- standard medication education|"Common Procedure:~\- Student Information and Consent Form will be obtained from the students.~For the control group~* Theoretical training in drug administration skills is provided.~* Skill training: Skill training on intramuscular and subcutaneous injection and intravenous medication administration using task trainers in the simulation laboratory.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
219277981|NCT05837377|OTHER|Experiment- cognitive load theory based on medication education|"For the experiment group~* Theoretical training will be provided based on the results of both the knowledge test and the self-efficacy test, and will be designed according to the principles of cognitive load theory.~* Skills training: includes the necessary skill applications for students with task trainers and a virtual simulation designed according to the cognitive load theory for these skills.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
219277982|NCT05926778|OTHER|Liver allograft fibrosis|Observational studies without intervention
219277983|NCT00573742|DRUG|Candesartan Cilexeotil 16mg|
219277984|NCT03513705|OTHER|Best practices in pancreatic cancer care|All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
219277985|NCT01818531|DRUG|Adductor canal block|
219277986|NCT01818531|DRUG|Lumbar plexus block|
219277987|NCT06117228|OTHER|Data collection|Data collection
219277988|NCT05910905|PROCEDURE|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
219277989|NCT05910905|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
219277990|NCT00477490|DRUG|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
219277991|NCT00477490|DRUG|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
219277992|NCT00137969|DRUG|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
219277993|NCT00137969|DRUG|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
219277994|NCT00137969|DRUG|Prednisone|
219277995|NCT00137969|DRUG|Acetaminophen|
219277996|NCT00137969|DRUG|Diphenhydramine|
219277997|NCT02391142|DRUG|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
219277998|NCT04278170|OTHER|no attempt was made to patients|no attempt was made to patients
219277999|NCT05226936|DIAGNOSTIC_TEST|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
219278000|NCT02092623|DEVICE|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
219278001|NCT02757677|DEVICE|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
219278002|NCT01110408|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
219278003|NCT01110408|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
219278004|NCT01110408|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
219278005|NCT01110408|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
219278006|NCT01110408|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
219278007|NCT03242902|DEVICE|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
219278008|NCT03242902|DEVICE|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
219278009|NCT02812056|DRUG|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
219278010|NCT02812056|DRUG|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
219278011|NCT05116826|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
219278012|NCT06376877|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.
219278013|NCT06376877|PROCEDURE|Sham transcranial magnetic stimulation|The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
219278014|NCT00286806|DRUG|AT-101|
219278015|NCT01646177|DRUG|Placebo|Administered SC
219278016|NCT01646177|DRUG|50 mg etanercept|Administered SC
219278017|NCT01646177|DRUG|80 mg ixekizumab|Administered SC
219278018|NCT02993185|BEHAVIORAL|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
219278019|NCT02993185|BEHAVIORAL|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
219278020|NCT01465763|DRUG|tofacitinib|10 mg oral BID
219278021|NCT01465763|DRUG|Placebo|Plabebo oral BID
219278022|NCT00749229|DEVICE|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
219278023|NCT05261308|OTHER|new prosthesis|Operation to fix the new prosthesis
219278024|NCT02920970|DEVICE|narafilcon A|contact lens
219278025|NCT02920970|DEVICE|stenfilcon A|contact lens
219278026|NCT05733182|DEVICE|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
219278027|NCT05733182|DEVICE|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
219278028|NCT05733182|DEVICE|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
219296312|NCT04893577|DRUG|EDTA|Patients will treat their cold sore with EDTA eye drops based upon their randomization.
219278029|NCT00580060|BIOLOGICAL|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
219278030|NCT03944590|OTHER|patient survey|patient survey on clinical outcome after screw osteosynthesis of radial head fractures
219278031|NCT03944590|OTHER|analysis of radiographs|analysis of radiographs on radiological outcome after screw osteosynthesis of radial head fractures
219278032|NCT03615053|OTHER|Implementation of WAPPS-Hemo personalized dosing regimen|Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
219278033|NCT00770744|DRUG|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
219278034|NCT00770744|DRUG|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
219278035|NCT02204657|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
219278036|NCT02378038|DRUG|PNT2258|
219278037|NCT01711853|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
219278038|NCT05689775|PROCEDURE|Reconstruction with robot-assisted rectus abdominis muscle flap|Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
219278039|NCT01582230|DRUG|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
219278040|NCT01582230|DRUG|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
219278041|NCT04659122|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
219278042|NCT00218049|DRUG|GBR 12909|50mg GBR 12909 over 12 days
219278043|NCT00218049|DRUG|GBR 12909|GBR 12909 75 mg over 12 day period
219278044|NCT00218049|DRUG|GBR 12909|GBR 12909 100 mg over 12 day period
219278045|NCT00802347|DRUG|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
219278046|NCT00802347|DRUG|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
219278047|NCT05538026|DRUG|Mesalazine|daily dose of 3 g (2 g orally + 1 g rectally)
219278048|NCT05538026|BIOLOGICAL|Fecal transplantation|Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
219278049|NCT03364075|DRUG|Duloxetine|30 mg for seven days, then increased to 60 mg for seven days
219278050|NCT03364075|DRUG|Propranolol|40 mg for seven days, then increase to 60 mg for seven days
219278051|NCT03364075|GENETIC|Genotype for SNPs associated to Serotonin and COMT|DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
219278052|NCT03364075|DRUG|Placebo Treatment|1 capsule BID for two weeks
219278053|NCT01387191|DRUG|Epoprostenol|
219278054|NCT01343758|OTHER|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
219278055|NCT03697122|DEVICE|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
219278056|NCT00003094|OTHER|preventative dietary intervention|
219278057|NCT02651025|OTHER|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
219278058|NCT03261687|OTHER|water based exercise|
219278059|NCT03261687|OTHER|land based exercise|
219278060|NCT03261687|BEHAVIORAL|advice|general advice given to all subjects
219278061|NCT02334280|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
219278062|NCT02261753|DIETARY_SUPPLEMENT|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
219278063|NCT01016847|DRUG|Montelukast|10 mg Q day
219278064|NCT01016847|OTHER|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
219278065|NCT00476164|DRUG|Rituximab|2 doses of 1g 14 days apart
219278066|NCT00476164|OTHER|Control arm|Continue of optimised oral immunosuppression
219278067|NCT00000683|BIOLOGICAL|HIVAC-1e|
219278068|NCT00000683|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
219278069|NCT02795364|PROCEDURE|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
219278070|NCT02795364|PROCEDURE|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
219278071|NCT00807339|RADIATION|Stereotactic radiation|Dose escalation three consecutive treatments
219278072|NCT00807339|DEVICE|CyberKnife Robotic Radiosurgery System|
219278073|NCT04988789|DRUG|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
219278074|NCT02992691|DRUG|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
219278075|NCT02992691|DRUG|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
219278076|NCT02992691|DRUG|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
219278077|NCT02992691|DRUG|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
219278078|NCT02992691|DRUG|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
219278079|NCT02906436|DEVICE|Xvivo Chamber|
219278080|NCT05419622|BIOLOGICAL|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
219278081|NCT04916951|DRUG|Amoxicillin|oral one-time dose of amoxicillin
219278082|NCT04916951|DRUG|Cephalexin|oral one-time dose of cephalexin
219278083|NCT02977767|PROCEDURE|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
219278084|NCT05433649|BEHAVIORAL|Therapeutic exercise|The therapeutic exercise intervention with the help of elastic bands was carried out for 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration.
219278085|NCT04276051|DEVICE|Cryoablation of the Vagus Nerve|The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
219278086|NCT04276051|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
219278087|NCT03872245|BIOLOGICAL|Probiotics|The patients will receive Adomelle 1caps/12h during 10 weeks
219278088|NCT03872245|PROCEDURE|PENS T6|The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
219278089|NCT05071586|DEVICE|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
219278090|NCT00392925|DRUG|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
219278091|NCT00392925|DRUG|metreleptin|subcutaneous injection, twice a day, 5mg
219278092|NCT00392925|DRUG|placebo-pramlintide 600 uL|twice a day
219278093|NCT00392925|DRUG|placebo-metreleptin 1 mL|twice a day
219278094|NCT00392925|DRUG|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
219278095|NCT03843697|DEVICE|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
219278096|NCT03647761|DEVICE|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
219278097|NCT04186104|OTHER|Routine diagnostic process|Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.
219278098|NCT04186104|OTHER|Artificial intelligence assisted diagnosis process|Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
219296313|NCT04893577|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
219278099|NCT04081064|BEHAVIORAL|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
219278100|NCT04441944|OTHER|Telemedicine|Use of provider-to-provider telemedicine
219278101|NCT00522821|DRUG|intravenous immunoglobulins|"* Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week"
219278102|NCT00522821|DRUG|antibiotics|"* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
219278103|NCT03764176|PROCEDURE|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
219278104|NCT03764176|PROCEDURE|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
219278105|NCT05645601|BIOLOGICAL|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy.
219278106|NCT00318721|DEVICE|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
219278107|NCT04472884|BEHAVIORAL|mWACh-PrEP|Participants randomized to mWACh-PrEP will be registered into the system, in addition to receipt of SOC services. Women registered into the mWACh-PrEP platform will indicate their preferences for message delivery including a preferred name for messaging, language (English or Kiswahili or Dholuo), and day of the week and time for SMS delivery. Once registered, women will receive weekly automated push messages on the day/time of their choice from enrollment through 6-months postpartum. All automated push messages will include participant nickname, clinic and nurse name, an educational message or actionable advice targeting PrEP adherence and continuation and/or maternal and child health (MCH) topics, and a question related to the content. SMS topics will include adherence encouragement, PrEP efficacy and safety, self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications) and visit reminders.
219278108|NCT04472884|OTHER|Standard of Care|All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
219278109|NCT00798291|OTHER|Ad lib diet and Control placebo|one packet with water two times a day
219278110|NCT00798291|OTHER|Ad lib diet and An 777|one packet with water two times a day
219278111|NCT00798291|OTHER|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
219278112|NCT00798291|OTHER|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
219278113|NCT05761470|DRUG|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
219278114|NCT05761470|DRUG|Fluzoparib|Fluzoparib
219278115|NCT05761470|DRUG|Nab-paclitaxel|Nab-paclitaxel
219278116|NCT05251142|OTHER|Plyometric training|"Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~* Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~* Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~* Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~* Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting."
219278117|NCT05251142|OTHER|General exercises|Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
219278118|NCT00195065|BEHAVIORAL|Semi-structured, open-ended interviews|
219278119|NCT06240338|DIAGNOSTIC_TEST|laboratory investigation and Imaging|laboratory parameters (white blood cell count,neutrophil count, lymphocyte count, hemoglobin level, platelet level, red cell distribution width (RDW) level, hematocrit (HCT), renal function, hepatic function, electrolytes, arterial blood gas, HOMA-IR) will be assessed and imaging: Abdominal ultrasonography, Abdominal CT or MRI if needed
219278120|NCT06378736|OTHER|Electroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest.|The proposed study is to determine whether EEG signals, namely theta-gamma coupling (TGC); The investigators are testing whether TGC can be used as a non-invasive novel biomarker in diagnosis and monitoring of insidious and difficult to detect cognitive dysfunction in SLE patients.
219278121|NCT00666692|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
219278122|NCT02924090|DRUG|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
219278123|NCT02924090|DRUG|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
219278124|NCT02924090|PROCEDURE|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
219278125|NCT02924090|PROCEDURE|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
219278126|NCT03799913|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
219278127|NCT03799913|DRUG|Fludarabine|30mg/m2/d
219278128|NCT03799913|DRUG|Cyclophosphamide|300mg/m2/d
219278129|NCT04623749|PROCEDURE|US|Percutaneous Ultrasound guided FNAC
219278130|NCT04623749|PROCEDURE|EUS|Endoscopic Ultrasound guided FNAC
219278131|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
219278132|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
219278133|NCT05331690|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
219278134|NCT03285555|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
219278135|NCT03285555|DEVICE|VICRYL|Vicryl #1
219278136|NCT05762562|OTHER|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
219278137|NCT04588129|DRUG|LB-102|(N-Methyl amisulpride)
219278138|NCT00267514|DRUG|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
219278139|NCT00267514|DRUG|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
219278140|NCT06336187|OTHER|active surveillance|Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter.
219278141|NCT06336187|GENETIC|molecular investigation|Transcriptomic analysis of tissues
219278142|NCT01792791|PROCEDURE|Tissue sample collection at the time of surgery|"Spanning surgery~* A blood sample (32.5 ml)~* joint aspirate (removal of synovial fluid) from both knees~* urine sample~ORIF surgery~* Joint aspirate (removal of synovial fluid) from both knees~* A blood sample (32.5 ml)~* Urine Sample~If patients only require one surgery, sample will be collected only once."
219278143|NCT02102438|DRUG|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
219278144|NCT02102438|DRUG|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
219278145|NCT02102438|DRUG|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
219278146|NCT00499967|DRUG|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
219278147|NCT00499967|DRUG|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
219278148|NCT00499967|DRUG|Placebo|Placebo matching GS-9191 ointment
219278149|NCT04181372|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
219278150|NCT04181372|DRUG|platinum-based chemotherapy medicine|(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
219278151|NCT01281839|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
219278152|NCT01281839|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
219278153|NCT01281839|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
219278154|NCT01281839|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
219278155|NCT02892227|PROCEDURE|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
219278156|NCT00001005|DRUG|Zidovudine|
219278157|NCT00001005|DRUG|Aldesleukin|
219278158|NCT00304759|PROCEDURE|7800 cGy/39 fractions in 8 weeks|see above
219278159|NCT00304759|PROCEDURE|6000 cGy/20 fractions in 4 weeks|see above
219278160|NCT03399253|PROCEDURE|surgery|D2 gastrectomy + metastasectomy
219278161|NCT03399253|DRUG|chemotherapy|capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
219278162|NCT00209404|DRUG|Iodixanol 320 mg I/Ml|
219278163|NCT03452865|DRUG|Esomeprazole|"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."
219278164|NCT03452865|DRUG|Placebo|0.9% sodium chloride (same ml of the study drug)
219278165|NCT02954705|OTHER|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
219278166|NCT03854357|PROCEDURE|Subscapularis Rehabilitation|Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.
219278167|NCT03854357|PROCEDURE|Standard Rehabilitation|Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
219278168|NCT03530137|BEHAVIORAL|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
219278169|NCT03530137|BEHAVIORAL|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
219278170|NCT03530137|BEHAVIORAL|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
219278171|NCT02704650|PROCEDURE|fluid sample|taking a vaginal fluid sample
219278172|NCT01715207|DRUG|Aliskiren|
219278173|NCT01715207|DRUG|Atenolol|
219278174|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
219278175|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
219278176|NCT05442684|BIOLOGICAL|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
219278177|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 1|2 capsules taken daily for 30 days
219278178|NCT05510050|DIETARY_SUPPLEMENT|Control|2 capsules taken daily for 30 days
219278179|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 2|2 capsules taken daily for 30 days
219278180|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/folic acid|
219278181|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/placebo|
219278182|NCT03487965|DIETARY_SUPPLEMENT|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
219278183|NCT03487965|DIETARY_SUPPLEMENT|High dose Polyphenol|botanical supplement with 13 mg polyphenol
219278184|NCT03487965|DIETARY_SUPPLEMENT|Placebo Control|inert tablet made to mimic the experimental tablets
219278185|NCT05590429|OTHER|Blood transfusion|No intervention
219278186|NCT02307045|DRUG|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
219278187|NCT02307045|DRUG|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
219278188|NCT00561145|OTHER|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
219278189|NCT01509547|DRUG|Varenicline|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
219278190|NCT01509547|DRUG|placebo|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
219278191|NCT03181490|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
219278192|NCT00102024|DRUG|Unconjugated IDEC-159|
219278193|NCT00102024|DRUG|111In-IDEC-159|
219278194|NCT00102024|DRUG|90Y-IDEC-159|
219278195|NCT01909297|DEVICE|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
219278196|NCT01909297|DEVICE|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
219278197|NCT01909297|DEVICE|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
219278198|NCT03910322|DIETARY_SUPPLEMENT|Bif195|Two different doses of the bacterial strain Bif195 is compared to placebo
219278199|NCT03910322|DIETARY_SUPPLEMENT|Placebo|Placebo
219278200|NCT02544165|DIETARY_SUPPLEMENT|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
219278201|NCT02544165|OTHER|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
219278202|NCT02544165|OTHER|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
219278203|NCT04618367|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
219278204|NCT04618367|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219278205|NCT04618367|DRUG|Sintilimab|200mg intravenously every 3weeks
219278206|NCT05396937|RADIATION|Multifocal Stereotactic Radiotherapy|Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
219278207|NCT05396937|DRUG|Atezolizumab Injection [Tecentriq]|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
219278208|NCT05396937|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
219278209|NCT03242343|DEVICE|VasQ|An external support device for AV fistula
219278210|NCT00402051|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
219278211|NCT00402051|DRUG|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
219278212|NCT00402051|DRUG|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
219278213|NCT02204553|DRUG|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
219278214|NCT02142153|DRUG|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile"
219278215|NCT02142153|DRUG|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
219278216|NCT03507907|OTHER|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
219278217|NCT03507907|OTHER|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
219278218|NCT00618579|DRUG|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
219278219|NCT03749135|DRUG|Dupilumab|anti-IL4-Receptor alpha
219278220|NCT03749135|DRUG|Placebo|Placebo
219278221|NCT02928731|OTHER|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
219278222|NCT02928731|OTHER|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
219278223|NCT02338063|BEHAVIORAL|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
219278224|NCT02338063|BEHAVIORAL|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
219278225|NCT02604823|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
219278226|NCT03257527|BEHAVIORAL|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
219278227|NCT03257527|BEHAVIORAL|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
219278228|NCT05863468|DEVICE|ArchSinus implantation|Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
219278229|NCT04529005|DRUG|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP \< 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
219278230|NCT00833378|DRUG|Eltrombopag|Eltrombopag 100 mg single oral dose
219278231|NCT00833378|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
219278232|NCT00833378|DRUG|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
219278233|NCT03520218|DEVICE|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
219278234|NCT01686737|BEHAVIORAL|Iyengar Yoga|"* 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes"
219278235|NCT01686737|BEHAVIORAL|Walking|"* 12 weeks of walking~* 2 weekly sessions of 60 minutes"
219278236|NCT02170545|OTHER|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
219278237|NCT00167206|PROCEDURE|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
219278238|NCT00167206|PROCEDURE|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
219278239|NCT00167206|PROCEDURE|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
219278240|NCT00167206|DRUG|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
219278241|NCT01791972|DRUG|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
219278242|NCT01791972|DRUG|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
219278243|NCT02539316|DRUG|Smoflipid|
219278244|NCT02539316|DRUG|Médialipides|
219278245|NCT00545649|BEHAVIORAL|Exercise and education|
219278246|NCT00545649|BEHAVIORAL|Education|
219296314|NCT06804616|DRUG|20% benzocaine Gel|Participants in this group received 20% Benzocaine Gel applied to the injection site for 5 minutes prior to local anesthesia administration. The gel acts as a topical anesthetic to numb the area and reduce pain perception during the injection procedure.
219278247|NCT03605888|BEHAVIORAL|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
219278248|NCT04047173|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
219278249|NCT04047173|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual, no more than 2 times.
219278250|NCT00797888|BEHAVIORAL|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
219278251|NCT02803281|OTHER|Frailty Assessment|Various physiologic and frailty assessment tests
219278252|NCT00570908|DRUG|sunitinib|Sutent
219278253|NCT00570908|DRUG|capecitabine|concurrently
219278254|NCT00570908|RADIATION|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
219278255|NCT03497403|PROCEDURE|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
219278256|NCT03497403|PROCEDURE|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
219278257|NCT00987662|DRUG|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.
219278258|NCT00987662|DRUG|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
219278259|NCT03694977|DRUG|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
219278260|NCT00346853|DRUG|4-Methylpyrazole|15 mg/kg dose
219278261|NCT00346853|OTHER|saline|
219278262|NCT01474629|DIETARY_SUPPLEMENT|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
219278263|NCT01474629|DIETARY_SUPPLEMENT|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
219278264|NCT00132275|DRUG|Amoxicillin potassium clavulanate|
219278265|NCT00002377|DRUG|Valganciclovir|
219278266|NCT00002377|DRUG|Ganciclovir|
219278267|NCT02880943|DRUG|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
219278268|NCT01250795|BIOLOGICAL|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
219278269|NCT01250795|OTHER|Saline|
219278270|NCT03455270|DRUG|G1T48|oral SERD
219278271|NCT03455270|DRUG|Palbociclib|CDK 4/6 Inhibitor
219278272|NCT05191602|DIAGNOSTIC_TEST|drainge fluid|including bilirubin
219278273|NCT03287895|BEHAVIORAL|Decision Support|A two-part intervention to help patients make better decisions about CPR
219278274|NCT00602849|DRUG|Sertraline|
219278275|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
219278276|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder Extra Strength|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
219278277|NCT05521243|DIETARY_SUPPLEMENT|Placebo|"The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor"
219278278|NCT06106139|DIETARY_SUPPLEMENT|Strict ketogenic diet group|the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
219278279|NCT06106139|DIETARY_SUPPLEMENT|Cyclic ketogenic diet group|"the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group."
219278280|NCT06106139|DIETARY_SUPPLEMENT|Autonomous ketogenesis group|Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
219278281|NCT03016351|OTHER|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
219278282|NCT03016351|OTHER|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
219278283|NCT01930097|OTHER|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
219278284|NCT01213524|BEHAVIORAL|sensorimotor replacement|denicotinized cigarettes
219278285|NCT01213524|DRUG|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
219278286|NCT01213524|DRUG|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
219278287|NCT01213524|OTHER|usual brand smoking|participant smokes usual brand of cigarette
219278288|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
219278289|NCT00630734|DRUG|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
219278290|NCT00630734|DRUG|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
219278291|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
219278292|NCT00630734|OTHER|Washout|Washout (no medication) on days 5-11.
219278293|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
219296315|NCT06804616|DEVICE|Powered Toothbrush|Participants in this group received vibration stimulation using a powered toothbrush applied to the injection site for 1 minute before the local anesthesia injection. The vibration works on the principle of gate control theory, aiming to disrupt pain signals and reduce discomfort during the injection procedure.
219278294|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
219278295|NCT06152224|DEVICE|The Leva Pelvic Health System|The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
219278296|NCT05306886|OTHER|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
219278297|NCT05306886|OTHER|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
219278298|NCT06246929|BEHAVIORAL|MBCT+w|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
219278299|NCT06246929|BEHAVIORAL|ALED|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
219278300|NCT05362045|DRUG|Mavacamten|Specified dose on specified days
219278301|NCT05777109|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
219278302|NCT05777109|DRUG|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
219278303|NCT04608838|BIOLOGICAL|JTR-161|JTR-161 (1 or 3 × 10\^8 cells/subject) will be suspended and administered in an intravenously infusion.
219278304|NCT04608838|BIOLOGICAL|Placebo|Placebo will be suspended and administered in an intravenously infusion.
219278305|NCT05291377|OTHER||
219278306|NCT00921947|BIOLOGICAL|VAX102|Universal M2e influenza vaccine
219278307|NCT00281320|DRUG|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
219278308|NCT01647945|DRUG|Placebo|placebo pill
219278309|NCT01647945|DRUG|FK506 level < 2 ng/ml|FK506 goal trough blood level \< 2 ng/ml
219278310|NCT01647945|DRUG|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
219278311|NCT01647945|DRUG|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
219278312|NCT06184035|DRUG|[177Lu]Lu-SN201|Intravenous infusion
219278313|NCT02902770|DRUG|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
219278314|NCT02902770|DRUG|Ketorolac Tromethamine|IV ketorolac 30mg push
219278315|NCT02902770|DRUG|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
219278316|NCT02902770|DRUG|Normal Saline Push|Normal Saline Push Placebo
219278317|NCT03432741|DRUG|Belinostat|Given intralesionally
219278318|NCT03432741|DRUG|Carfilzomib|Given intralesionally
219278319|NCT03432741|DRUG|Copanlisib Hydrochloride|Given intralesionally
219278320|NCT03432741|BIOLOGICAL|Daratumumab|Given intralesionally
219278321|NCT03432741|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET
219278322|NCT03432741|DRUG|Gemcitabine Hydrochloride|Given intralesionally
219278323|NCT03432741|OTHER|Laboratory Biomarker Analysis|Correlative studies
219278324|NCT03432741|BIOLOGICAL|Nivolumab|Given intralesionally
219278325|NCT03432741|BIOLOGICAL|Obinutuzumab|Given intralesionally
219278326|NCT03432741|BIOLOGICAL|Pembrolizumab|Given intralesionally
219278327|NCT03432741|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
219278328|NCT03432741|BIOLOGICAL|Rituximab|Given intralesionally
219278329|NCT03432741|DRUG|Romidepsin|Given intralesionally
219278330|NCT03432741|OTHER|Saline|Given intralesionally
219278331|NCT03432741|BIOLOGICAL|Trastuzumab|Given intralesionally
219278332|NCT03958006|DEVICE|Cochlear implant|Tumor resection with cochlear implant
219278333|NCT03097406|PROCEDURE|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
219278334|NCT03097406|PROCEDURE|Global Advantage|A total shoulder prosthesis used for osteoarthritis
219278335|NCT03097406|PROCEDURE|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
219278336|NCT03097406|PROCEDURE|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
219278337|NCT05239715|DIAGNOSTIC_TEST|Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement
219278338|NCT02755129|OTHER|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
219278339|NCT02755129|OTHER|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
219278340|NCT02755129|OTHER|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
219278341|NCT02755129|OTHER|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
219278342|NCT02755129|OTHER|Reveal LINQ accelerometer|Walking exercises test
219278343|NCT02755129|OTHER|3D accelerometer|Walking exercises test
219278344|NCT04601636|DEVICE|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
219278345|NCT04601636|OTHER|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
219278346|NCT01447576|DRUG|ADT|Once daily dosing during the duration of the study.
219278347|NCT01447576|DRUG|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
219278348|NCT04382846|DRUG|Nitazoxanide|Nitazoxanide
219278349|NCT00557661|DRUG|CD-NP|24 hr intravenous infusion
219278350|NCT01530893|DIETARY_SUPPLEMENT|Flavanone - supplement|acute single optimal dose
219278351|NCT01530893|OTHER|Flavanone - food|acute single dose
219278352|NCT01530893|OTHER|Flavanone - placebo|acute single dose (flavanone free)
219278353|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - supplement|acute single optimal dose
219278354|NCT01530893|OTHER|Isoflavone - food|acute single optimal dose
219278355|NCT01530893|OTHER|Isoflavone - placebo|acute single dose (isoflavone free)
219278356|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
219278357|NCT01530893|DIETARY_SUPPLEMENT|Flavan-3-ol - supplement|acute single optimal dose
219278358|NCT01530893|OTHER|Flavan-3-ol - food|acute single optimal dose
219278359|NCT01530893|OTHER|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
219278360|NCT01530893|DIETARY_SUPPLEMENT|Anthocyanin - supplement|acute single optimal dose
219278361|NCT01530893|OTHER|Anthocyanin - food|acute single optimal dose
219278362|NCT01530893|OTHER|Anthocyanin - placebo|acute single dose (anthocyanin free)
219278363|NCT04925869|OTHER|Observational study|Observational study
219278364|NCT06423651|BEHAVIORAL|Cognitive Remediation (REHACOP)|REHACOP is a structured neuropsychological rehabilitation program that covers most of the cognitive deficits present in psychotic disorder: attention, learning and memory, executive functions, language, social cognition, daily life activities, social skills and psychoeducation. The modules of language, social cognition and psychoeducation will not be used in the present clinical trial. Each module includes a hierarchy of exercises based on the cognitive subarea to be worked on and the grade of difficulty demanded for the performance of each task.The format of the sessions will be the same as MCT, that is, groups of 6-10 patients who will receive weekly sessions of 45-60 minutes in length. In this case, the duration of the intervention will be 12 sessions.
219278365|NCT06423651|BEHAVIORAL|Metacognitive Training (MCT)|The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.
219278366|NCT00146445|BEHAVIORAL|Peer Mentoring Intervention|
219278367|NCT02546947|OTHER|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
219278368|NCT02538315|DRUG|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
219278369|NCT00975676|OTHER|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
219278370|NCT04036851|BEHAVIORAL|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
219278371|NCT02548078|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
219278372|NCT02548078|BIOLOGICAL|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
219278373|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
219278374|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
219278375|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
219278376|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
219278377|NCT03745547|OTHER|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
219278378|NCT03538782|PROCEDURE|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
219278379|NCT03697694|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
219278380|NCT03697694|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
219278381|NCT02579772|DRUG|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
219278382|NCT02579772|DRUG|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
219278383|NCT03128671|BEHAVIORAL|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
219278384|NCT04788342|DEVICE|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
219296316|NCT03140839|BEHAVIORAL|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
219278385|NCT05586412|DEVICE|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
219278386|NCT02281500|BIOLOGICAL|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
219278387|NCT03850132|BEHAVIORAL|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~1. Drawing forward narratives about the pre- and post-loss experience.~2. Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~3. Validating/acknowledging emotional responses.~4. Assessing the need for specific information and recommendations regarding bereavement.~5. The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
219278388|NCT00203034|DRUG|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
219278389|NCT00203034|DRUG|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
219278390|NCT00203034|OTHER|Placebo|oral placebo once daily
219278391|NCT00777764|DRUG|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
219278392|NCT00777764|DRUG|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
219278393|NCT00433758|DEVICE|GlucoTrack|GT
219278394|NCT06488443|BEHAVIORAL|Yoga|Participants in yoga arm will receive intervention from an instructor who would be trained in the intervention by the yoga adviser.All the yoga exercises selected for this study are low-impact and involve highly controlled movements. All yoga exercises will be taught and supervised by a skilled yoga-instructor. The yoga-instructor will take great care to emphasize to participants that they should not go beyond their usual range of motion/comfort for any of the yoga exercises.
219278395|NCT06488443|BEHAVIORAL|WHO 5As model intervention|"WHO 5As model to help patients ready to quit. The five major steps to intervention are the 5 A's: Ask, Advise, Assess, Assist, and Arrange."
219278396|NCT06480331|PROCEDURE|Ultrasound-guided fistuloplasty|Radiation free fistuloplasty
219278397|NCT06480331|PROCEDURE|Fluoroscopy-guided fistuloplasty|Conventional fistuloplasty
219278398|NCT03556787|DEVICE|BPI 1000013 (Dr Scholls Insole)|Full length foam insole
219296317|NCT03140839|BEHAVIORAL|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
219296318|NCT03140839|OTHER|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
219296319|NCT01370590|DRUG|Atorvastatin|20 mg tablet administered orally once daily
219278399|NCT05730491|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|Participants assigned to this group will complete an online program with 3 core skills, which will include strategies to promote wellness behaviors, use adaptive cognitive coping strategies, model wellness behaviors for their children, and determine when it is appropriate to take further action re: potential illness in their child. The website is interactive and self-guided. All participants will have access to the same resources and content, although based on responses to quizzes and skills practice questions, the automated feedback may differ slightly. The website includes treatment modules that share content via text, images, videos and recordings, a skills library that includes audio recordings of relaxation exercises, infographics to support skills practice, and behavioral assignments to record skills practice and receive automated feedback. Participants will review their knowledge at the end of each treatment module with brief quizzes.
219278400|NCT05730491|BEHAVIORAL|Attention Education Control|Participants assigned to the control group will receive access to a web program and complete 3 modules focused on child health and safety behaviors, such as sports and water safety. These participants will review written/visual content on the above topics, take quizzes to test knowledge gained, and will be provided with brief assignments to increase child safety behaviors. All participants assigned to the control group will have access to the same educational content.
219278401|NCT06417450|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
219278402|NCT06417450|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219278403|NCT01398696|PROCEDURE|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
219278404|NCT01398696|PROCEDURE|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
219278405|NCT01181453|DEVICE|Dermagraft|Weekly application of Dermagraft(R) with standard care
219278406|NCT01181453|OTHER|Comparator|Weekly application of standard care
219278407|NCT06853938|DEVICE|Myoelectric prosthesis|The interventions in this study are (1) an enhanced muscle training protocol and (2) fitting with a myoelectric (muscle signal-controlled) prosthetic device after receiving an osseointegrated implant and targeted muscle reinnervation.
219278408|NCT04732845|BIOLOGICAL|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
219278409|NCT04732845|DRUG|Fludarabine|25 mg/m2 daily from day -5 to -3
219278410|NCT04732845|DRUG|Cyclophosphamide|60mg/Kg on day -6
219278411|NCT05115045|DIAGNOSTIC_TEST|plasmatic SARS-CoV-2 RNA quantification|plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
219278412|NCT06855719|OTHER|Training in high-fidelity simulation and knowledge of care protocols in patients with multimorbidity and heart failure|Participants will perform an individual simulation as nurses related to the patient profile in their home (pretest and postest). After each simulation, each participant will receive a recording of their simulation, and both individual and group debriefings will be conducted. In addition, they will be trained in scientific evidence and international and national protocols regarding the care of these patients in the context of home health nursing.
219278413|NCT02474849|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
219278414|NCT00402805|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|
219296320|NCT01370590|DRUG|Ezetimibe|10 mg tablet administered orally once daily
219278415|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 1 combined with antidepressant medication|The self-composed musical piece Five Elements Music 1 was selected to intervene with the patients, with the songs primarily based on the Gong tone and Zhi tone in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
219278416|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 2 combined with antidepressant medication|The self-composed musical piece Five Elements Music 2 was selected to intervene with the patients, with the songs primarily based on the Shang mode (A) and Yu (E) mode in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
219278417|NCT07048938|OTHER|No Intervention: Observational Cohort|No intervention will be applied to healthy people
219278418|NCT07050680|OTHER|Dietary intervention|Single dose of commercially available Oat food test meal
219278419|NCT07049874|DIETARY_SUPPLEMENT|Huel|Ready to eat huel foods. Containing 2 ready to drink shakes, one savoury meal pack and meal replacement powder. Consumption amounts were based on energy needs of each person
219278420|NCT05823012|DRUG|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
219278421|NCT07049107|DRUG|HRS-8427|HRS-8427
219278422|NCT07050251|BEHAVIORAL|Mentoring Intervention Delivery|The intervention will utilize a culturally specific, socio-emotional learning (SEL) curriculum, adapted based on feedback from the focus groups. The intervention will consist of 10 weekly mentoring sessions lasting 1 hour each. Licensed clinicians will lead sessions and will also serve as mentors.
219278423|NCT07057063|DEVICE|810 nm Light Therapy|Light therapy at 810 nm, 39 J/cm², delivered via wearable device.
219278424|NCT07057063|DEVICE|Sham Light Therapy|Identical device, no light output, delivered via wearable device.
219278425|NCT01395069|DRUG|Nepafenac 0.1%|1 drop QID for 1 month
219278426|NCT01395069|DRUG|Ketorolac 0.5%|1 drop QID for 1 month
219278427|NCT01395069|OTHER|Placebo (sterile saline drops)|1 drop QID for 1 month
219278428|NCT06771414|OTHER|data collection|data collection
219278429|NCT06641180|BIOLOGICAL|High-Dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
219278430|NCT06641180|BIOLOGICAL|Standard-dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
219278431|NCT05847868|DEVICE|Moment Tumour Hip Prothesis|"In the case of irreversible bone loss due to bone tumors, large and multi-part fractures, and pseudarthrosis in the proximal region of the femur bone, the defective bone area is removed and implants made of artificial materials are placed in order to replace the integrity of the bone. In addition, implant applications are made to the proximal femur region for the purpose of revision arthroplasty, which is typically replaced by total hip prosthesis depending on the wear condition.~In this way, the bone integrity will be preserved, long-term stabilization will be provided to the patient and existing pain will be eliminated.~Moment Tumor Hip Replacement Systems consist of proximal main body, extension pieces and intramedullary stems. Components are available in a variety of sizes to meet anatomical requirements and surgeon needs."
219278432|NCT05153330|DRUG|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
219278433|NCT06853613|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
219296321|NCT01370590|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
219296322|NCT01370590|DRUG|Placebo to atorvastatin|Administered orally once daily
219296323|NCT01370590|DRUG|Placebo to ezetimibe|Administered orally once daily
219296324|NCT01370590|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
219296325|NCT04723966|DIETARY_SUPPLEMENT|TPN|Total parenteral nutrition
219278434|NCT06853613|OTHER|Aerobic Training Protocol|"Each training session will include an initial 10-minute muscle activation phase (low-intensity walking, Borg = 10-11) to increase heart rate, improve muscle blood flow, and prepare the major joints for the next work phase.~main exercise period (40-minute):~25 minutes of progressive aerobic exercises (controlled and rhythmic jumping jacks, step-ups on a sturdy platform (such as a low step or stable surface), standing knee raises (alternating legs), fast side steps or side leg raises).~15 minutes of walking, exercises will be performed at an intensity to ensure that perceived exertion (RPE) will remain between 13 and 15 points on the Borg Scale (6-20). Progression over the weeks will be by maintaining intensity in this range.~Cool down period: breathing and stretching exercises on all major muscle groups."
219278435|NCT06800651|DRUG|JMKX003142 will be administered orally|JMKX003142 will be administered orally
219278436|NCT06800651|DRUG|Plcacebo|matched to JMKX003142
219278437|NCT06744595|PROCEDURE|Biospecimen Collection|Undergo collection of blood or salvia samples
219278438|NCT06744595|OTHER|Educational Intervention|Receive personalized EPIC message
219278439|NCT06744595|OTHER|Electronic Health Record Review|Ancillary studies
219278440|NCT06744595|OTHER|Genetic Counseling|Receive pre-genetic test counseling
219278441|NCT06744595|OTHER|Genetic Counseling|Receive post-genetic test counseling
219278442|NCT06744595|GENETIC|Genetic Testing for Cancer Risk|Undergo SOC genetic testing
219278443|NCT06744595|OTHER|Survey Administration|Ancillary studies
219278444|NCT06774313|DRUG|ABBV-142|Intravenous (IV) Infusion
219278445|NCT06774313|DRUG|ABBV-142|Subcutaneous (SC) Injection
219278446|NCT06774313|DRUG|Placebo|IV Infusion
219278447|NCT06774313|DRUG|Placebo|SC Injection
219278448|NCT07136974|DRUG|TQB2102|TQB2102 is administered intravenously at 6 mg/kg every 3 weeks for 6 cycles.
219278449|NCT07136974|DRUG|Docetaxel + Carboplatin + Trastuzumab +Pertuzumab|Docetaxel 75 mg/m2(day 1) , Carboplatin (AUC=6) (day 1), Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Pertuzumab (840mg first dose, 420mg/kg sequential) are administered intravenously every 3 weeks for 6 cycles.
219278450|NCT00002198|DRUG|Abacavir sulfate|
219278451|NCT06841133|BEHAVIORAL|Chinese Art Activities|"This activity based on Recreation therapy, aims to heal the psychological symptom cluster and enhance the PWB of the old Chinese transit to the elderly center. The activity follows the usual care during the process with the addition of Chinese art activities. It employed the following two main activities:~(1) Traditional Chinese landscape painting; (2) Calligraphy. The activity will be conducted 50min by researchers. It can be conducted at hall, conference room, etc. in the elderly center (EC), and it is a group intervention"
219278452|NCT06841133|BEHAVIORAL|Chinese Art Activities combined with Peer Group Participation (PGP)|The activity follows the usual care during the process with the addition of Chinese art activities combined with Peer Group Participation. The activity will be conducted 80min by researchers. In groups of 5 people, after the painting and calligraphy activity, under the organization of peers, each group member will show their works and talk about their feelings and views on their works. They will also share the reasons why they chose these words or sentences. Everyone must say words of comfort and encouragement to others' work.
219278453|NCT06874283|PROCEDURE|Eye exam|Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. A standard of care exam will be performed to the reason for the visit. In addition to the standard of care exam, those in the Cancer Therapy arm will have certain biological samples (tear collection, impression cytology, and/or blood) collected, stored, and analyzed so we may obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.
219278454|NCT06765499|OTHER|Chinese medicine - Silkworm pupa powder|Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable.
219278455|NCT06765499|OTHER|Ultra-low dose silkworm pupa powder|0.5% of the effective components in the experimental group
219278456|NCT02875197|OTHER|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
219278457|NCT02614183|DRUG|Galcanezumab|Administered SC
219278458|NCT02614183|DRUG|Placebo|Administered SC
219278459|NCT04716751|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with tracheal malignant tumor received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
219278460|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
219278461|NCT05962034|OTHER|Placebo|placebo capsule
219278462|NCT07097285|BEHAVIORAL|sensory awareness training|Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program. protocol will be applied. Graded Sensory Discrimination protocol, localization training It includes level 1, localization training level 2 and graphesthesia training. Graded Engine Visualization (DMI) protocol includes right/left discrimination training and visual imagery training.
219278463|NCT07137169|PROCEDURE|LIMA protocol|Cleft palate repair using Hybrid / One-flap technique
219278464|NCT07137169|PROCEDURE|RSCM Protocol|Cleft palate repair using Two-flap technique
219278465|NCT07138469|OTHER|Questionnaire|The questionnaire was offered on a voluntary basis and completed online by the participants. At the end of the inclusion period, the responses were analyzed. Participant indicated in the questionnaire whether or not they had already undergone oocyte cryopreservation. The responses were analyzed to assess demographic characteristics, the level of knowledge regarding the bioethics law on non-medical fertility preservation, and future perspectives in the event of use (desired parental model, likelihood of use) or non-use.
219278466|NCT02928705|PROCEDURE|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
219278467|NCT02928705|PROCEDURE|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
219278468|NCT05540730|DIAGNOSTIC_TEST|Gait Analysis|Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
219278469|NCT01469520|DRUG|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
219278470|NCT01469520|DRUG|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
219278471|NCT01469520|DRUG|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
219278472|NCT03319940|DRUG|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
219278473|NCT03319940|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
219278474|NCT03319940|DRUG|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
219278475|NCT06916845|DEVICE|Colon Capsule|All participants will swallow the CapsoCam® Colon (CV-3E) for this study.
219278476|NCT06920914|OTHER|Low-potassium, ultra-processed diet|A diet restricted in potassium, primarily composed of industrially processed foods such as packaged snacks and processed meals.
219278477|NCT06920914|OTHER|Low-potassium, minimally processed diet|A diet restricted in naturally occurring potassium, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods.
219278478|NCT06920914|OTHER|Normal potassium-rich, minimally processed diet|A diet with normal potassium content, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods, rich in naturally occurring potassium, following a Mediterranean-style pattern.
219278479|NCT06920914|OTHER|Normal potassium-rich, ultra-processed diet|A diet with normal potassium content, primarily composed of industrially processed foods such as packaged snacks and processed meals
219278480|NCT04340934|DEVICE|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
219278481|NCT06927284|OTHER|Neurocognitive Therapy with Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy with soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object repositioned, and another object of a different shape or size offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object with soft robotic hand.
219278482|NCT06927284|OTHER|Neurocognitive Therapy without Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy without soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object will be repositioned, and another object of a different shape or size will be offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object .
219278483|NCT06932536|DRUG|SR750 tablet|Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally
219278484|NCT06932536|DRUG|Placebo|Ascending single and multiple doses of placebo orally
219278485|NCT06931418|OTHER|Early Strengthening Protocol|Patients in the ESP intervention arm will undergo active and passive exercises as well as strengthening exercises after their initial assessment by rehabilitation therapists within 2 weeks of their discharge. Early use of strength and passive stretching will be encouraged immediately after allocation.
219278486|NCT06931418|OTHER|Early Motion Protocol|Patients are instructed for active flexion, extension, supination, pronation and finger flexion of the operated wrist along with motion of the shoulder and elbow after operation. Active mobilization is continued for the initial post-operative 6 weeks with allied health therapists. Passive mobilization and strengthening is started at the post-operative 8-10-week period.
219278487|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol \[10 mL. or 8 g of pure ethanol\]) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
219278488|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
219278489|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
219278490|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
219278491|NCT04198493|DEVICE|CPAP|CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling
219278492|NCT04198493|OTHER|CONSERVATIVE TREATMENT for OSA|Conservative treatment for OSA: sleep hygiene and dietary counseling
219278493|NCT06938776|BEHAVIORAL|Musical Toy (Xylophone)|Children in this group will play with a colorful xylophone toy for 5 minutes before and during peripheral intravenous cannulation. A nurse (researcher) will assist the child in playing with the toy to distract them from the procedure. The toy will be cleaned between uses. This non-pharmacological method aims to reduce pain and fear.
219278494|NCT06938776|OTHER|Standard Care (in control arm)|Children in this group will receive routine peripheral intravenous cannulation according to standard hospital protocols. No distraction or behavioral intervention will be applied.
219278495|NCT06938282|DRUG|HRS-4642|HRS-4642 in Combination with Immunotherapy and Chemotherapy
219278496|NCT06939686|DEVICE|Miro3D Wound Matrix|Miro3D is a sterile, acellular, three-dimensional biologic wound matrix derived from porcine liver via perfusion decellularization and drying. It is trimmed to fit the wound and rehydrated with sterile saline or Lactated Ringer's solution before application. It provides a porous scaffold to support granulation and healing in chronic or post-surgical wounds.
219278497|NCT06939686|OTHER|Standard of Care (SOC)|SOC includes standard wound care practices such as wound cleansing, debridement, infection management (if applicable), use of protective dressings (e.g., Aquacel or foam covered with Adaptic), and offloading devices (e.g., Foot Defender boot) to relieve pressure on the wound.
219278498|NCT06941701|OTHER|Mild-intensity physical fatigue|Participants will undergo mild-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 50-60% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
219278499|NCT06941701|OTHER|Moderate-intensity physical fatigue|Participants will undergo Moderate-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 60-70% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
219278500|NCT06941701|OTHER|High-intensity physical fatigue|Participants will undergo High-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 70-80% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce sufficient physiological stress while maintaining safety and feasibility for all participants.
219278501|NCT06944080|OTHER|base material(Tetric® N-Flow,Beautifil-Flow PLUS,GC fuji II LC capsule)|subgingival restoration, deep marginal elevation procedure with different base materials will be applied then plaque index, gingival index, probing depth, clinical attachment level and biochemical marker will be measured at base line and after 3 months.
219278502|NCT06952907|OTHER|Femoral artery catheterization for continuous invasive arterial blood pressure monitoring|Femoral artery catheterization allow for continuous invasive arterial blood pressure monitoring.
219278503|NCT06952907|OTHER|Radial artery catheterization for continuous invasive arterial blood pressure monitoring|Radial artery catheterization allows for continuous invasive arterial blood pressure monitoring
219278504|NCT01531777|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
219278505|NCT01531777|DRUG|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
219278506|NCT00329212|DRUG|San Huang Xie Jin Tang|
219278507|NCT07136181|DRUG|NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.|NBM-BMX is a small molecule inhibitor of HDAC8. The majority of metastasizing uveal melanoma (UM) cases are characterized by the presence of BAP1 mutations. However, as BAP1 mutations lead to a loss of function, therapeutic strategies have primarily focused on exploiting vulnerabilities resulting from BAP1 loss or targeting downstream effectors affected by the BAP1-deficient phenotype. In uveal melanocytes, the absence of BAP1 disrupts their differentiated cell identity, potentially contributing to the metastatic behavior observed in BAP1-mutant UM cells. This differentiation block in the melanocytic lineage is thought to be influenced, at least in part, by the activation of HDAC8 downstream, which leads to the repression of differentiation genes through acetylation of the histone H3K27 at the promoter and enhancers associated with these genes. Consequently, inhibiting HDAC8 could potentially reverse the differentiation block caused by the loss of BAP1.
219278508|NCT01165606|PROCEDURE|Chest physiotherapy|
219278509|NCT05120037|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
219278510|NCT01446120|DRUG|NPH-Insulin Injection|
219278511|NCT01446120|DRUG|Insulin loaded Orally Dissolved Films (insulin-ODF|
219278512|NCT03572881|DEVICE|Endocardial mapping|An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
219278513|NCT05319015|DRUG|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
219278514|NCT05319015|DRUG|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
219278515|NCT05319015|PROCEDURE|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
219278516|NCT05319015|DRUG|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
219278517|NCT00132899|DRUG|Methotrexate|Methotrexate and infliximab combination
219278518|NCT00132899|DRUG|Placebo|Placebo and infliximab combination therapy.
219278519|NCT04076709|PROCEDURE|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
219278520|NCT00783276|DRUG|SYN115|100 mg single dose
219278521|NCT00783276|DRUG|PLACEBO|PLACEBO
219278522|NCT02385058|DRUG|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
219278523|NCT02385058|DRUG|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
219278524|NCT02385058|DRUG|Placebo|Placebo tablet orally once starting on Day 21.
219278525|NCT05743881|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
219278526|NCT05743881|BIOLOGICAL|mRNA-1365|Sterile liquid for injection
219278527|NCT05743881|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) solution for injection
219278528|NCT05743881|DRUG|Nimenrix|Solution for injection
219278529|NCT04245553|DIAGNOSTIC_TEST|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
219278530|NCT03360734|DRUG|First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
219278531|NCT02422576|OTHER|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
219278532|NCT02422576|OTHER|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
219278533|NCT02422576|OTHER|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
219278534|NCT02422576|OTHER|Thicken Up clear: TUC|
219278535|NCT05396651|OTHER|low fodmap diet|elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners
219278536|NCT05396651|OTHER|NICE guidelines for IBS|"follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks."
219278537|NCT01798875|DRUG|oral metformin|
219278538|NCT01798875|DRUG|oral contraceptive|
219278539|NCT03429777|DEVICE|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
219278540|NCT04557267|DRUG|low-dose|Dosage 1
219278541|NCT04557267|DRUG|Middle-dose|Dosage 2
219278542|NCT04557267|DRUG|Higher-dose|Dosage 3
219278543|NCT04557267|DRUG|Placebo|Placebo
219278544|NCT00002385|DRUG|Fozivudine tidoxil|
219278545|NCT02084758|DIETARY_SUPPLEMENT|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
219278546|NCT02084758|DIETARY_SUPPLEMENT|Placebo supplementation|7 days of supplementation with sodium chloride solution
219278547|NCT02701881|DEVICE|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
219278548|NCT02701881|DEVICE|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
219278549|NCT05106777|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
219278550|NCT04227145|BEHAVIORAL|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
219278551|NCT05034172|OTHER|Clinical follow-up|"Clinical Follow-up:~demographic data and history,~* Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only);~* Family history - Neurological examination:~* Diagnosis Clinical examination;~* Rating scales specific to the pathology under investigation;~* Cerebral MRI (optional)~* Biological samples (optional)"
219278552|NCT03404895|DEVICE|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
219278553|NCT03404895|DEVICE|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
219278554|NCT00666900|DRUG|Low Strength IDP-107|Once a day for 12 weeks
219278555|NCT00666900|DRUG|High Strength IDP-107|Once a day for 12 weeks
219278556|NCT00666900|DRUG|Placebo Comparator|Once a day for 12 weeks
219278557|NCT02976077|BEHAVIORAL|RC2S+|new cognitive remediation program
219278558|NCT02976077|BEHAVIORAL|active comparator|cognitive remediation program
219278559|NCT04161053|DRUG|Rifaximin|Rifaximin 550 mg twice daily for 6 months
219278560|NCT04161053|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
219278561|NCT01478451|BEHAVIORAL|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
219278562|NCT01478451|OTHER|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
219278563|NCT00703495|DEVICE|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
219278564|NCT02872805|OTHER|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
219278565|NCT02872805|BEHAVIORAL|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
219278566|NCT05444634|BEHAVIORAL|Distraction Card|"Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do."
219278567|NCT05444634|BEHAVIORAL|Stress Ball|Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
219278568|NCT04905953|DRUG|Neostigmine|Intrathecal injection of two doses of neostigmine (10 \& 20 mic) during spinal anesthesia for cesarean section.
219278569|NCT01088984|DRUG|Bendamustine|
219278570|NCT03745742|OTHER|HRV measurement|"Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~* Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App."
219278571|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
219278572|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
219278573|NCT00004551|DRUG|nicotine replacement patch|
219278574|NCT00004551|BEHAVIORAL|mood management|
219278575|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant|Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
219278576|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant Placebo|Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
219278577|NCT04855006|OTHER|No intervention|Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
219278578|NCT01982305|PROCEDURE|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
219278579|NCT01982305|PROCEDURE|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
219278580|NCT04707664|DRUG|Sargramostim|All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
219278581|NCT04707664|DRUG|Placebo|All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
219278582|NCT03134677|DRUG|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
219278583|NCT03134677|DRUG|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
219278584|NCT00427505|DRUG|Deferasirox|
219278585|NCT01549704|DRUG|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
219278586|NCT01549704|DRUG|Saline|please see intervention description for ropivacaine
219278587|NCT03691077|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
219278588|NCT00090155|DRUG|MK0869, aprepitant|
219278589|NCT00090155|DRUG|Comparator: ondansetron IV|
219278590|NCT04660136|BIOLOGICAL|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
219278591|NCT05476315|OTHER|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
219278592|NCT00699153|DRUG|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
219278593|NCT00699153|DRUG|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
219278594|NCT02344264|DRUG|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
219278595|NCT02344264|DRUG|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
219278596|NCT04663412|OTHER|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
219278597|NCT03054051|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
219278598|NCT00089960|DRUG|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
219278599|NCT03523026|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
219278600|NCT03523026|OTHER|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
219278601|NCT03523026|OTHER|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
219278602|NCT03236623|OTHER|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
219278603|NCT02456519|OTHER|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
219278604|NCT00140010|DRUG|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
219278605|NCT01857375|DEVICE|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
219278606|NCT01824927|PROCEDURE|First eye (FE)|Phacoemulsification cataract extraction surgery
219278607|NCT01824927|PROCEDURE|Second eye (SE)|Phacoemulsification cataract extraction surgery
219278608|NCT01824927|DRUG|Steroids eye drops|Use steroids eye drops to decrease the pain.
219278609|NCT01006980|DRUG|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
219278610|NCT01006980|DRUG|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
219278611|NCT00527358|BEHAVIORAL|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
219278612|NCT05445453|OTHER|Museum visit|"The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient."
219278613|NCT05193903|BEHAVIORAL|Simulation|The participants in the intervention group receive two interactive simulations in addition to a general text module that provides sequential, animated information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.
219278614|NCT05193903|BEHAVIORAL|Text|"The participants in the control group receive two text-based information in addition to a general text module that provides information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.~Both conditions ensure the provision of a level of knowledge that at least corresponds to standard care."
219278615|NCT00107094|DRUG|Abraxane|
219278616|NCT05717894|DRUG|Vitex Agnus Castus Extract|The patient group received two pills containing 200mg of VAC daily for six months
219278617|NCT03416322|OTHER|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
219278618|NCT02666144|DEVICE|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
219278619|NCT01287325|DRUG|DNK333 100 mg twice daily|
219278620|NCT01287325|DRUG|Placebo|
219278621|NCT05909826|DRUG|Carfilzomib|70 mg/m2 IV days 1, 8 and 15, every 4 weeks
219278622|NCT05909826|DRUG|Cyclophosphamide|50 mg PO days 1 to 21, every 4 weeks
219278623|NCT05909826|DRUG|Dexamethasone|40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
219278624|NCT03076073|OTHER|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
219278625|NCT04020315|PROCEDURE|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
219278626|NCT03412851|OTHER|A Direct Aspiration First Pass Technique|Distal aspiration technique
219278627|NCT03412851|OTHER|Stentriever Thrombectomy|Thrombectomy with stent retriever
219278628|NCT03312023|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
219278629|NCT03312023|DRUG|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
219278630|NCT03312023|DRUG|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
219278631|NCT04263168|DIAGNOSTIC_TEST|Continuous Glucose monitoring in the perioperative period|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
219278632|NCT02706405|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
219278633|NCT02706405|DRUG|Cyclophosphamide|Given IV
219278634|NCT02706405|BIOLOGICAL|Durvalumab|Given IV
219278635|NCT02706405|DRUG|Fludarabine|Given IV
219278636|NCT04442100|PROCEDURE|valve prosthetics|"prosthetics of heart valves with dentures MedEng-Bio"
219296326|NCT05172050|DRUG|Raloxifene|Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
219278637|NCT04447105|DRUG|total intravenous anesthesia with propofol|In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
219278638|NCT04447105|DRUG|inhalation anesthesia with desflurane|In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
219278639|NCT01228318|DRUG|Zoledronic acid|"1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
219278640|NCT02886039|OTHER|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
219278641|NCT00225238|DRUG|esomeprazole (PPI)|
219278642|NCT03085823|DEVICE|Sirolimus Coated Balloon|
219278643|NCT03011567|DRUG|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
219278644|NCT03011567|DRUG|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
219278645|NCT01182441|DEVICE|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
219278646|NCT01182441|DRUG|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
219278647|NCT00603525|DRUG|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
219278648|NCT00603525|DRUG|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
219278649|NCT03473600|PROCEDURE|Cryotherapy|Liquid Nitrogen spray
219278650|NCT03473600|DRUG|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
219278651|NCT04329637|OTHER|Integrative healt care|Meditation and use of a care cordinator
219278652|NCT05931029|DRUG|Idebenone|The control group took Idebenone orally for 12 weeks.
219278653|NCT05931029|DRUG|Naohuan Dan and Idebenone|The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
219278654|NCT00146731|DRUG|SP|
219278655|NCT00146731|DRUG|SP + amodiaquine|
219278656|NCT00146731|DRUG|AQ + artesunate|
219278657|NCT00146731|DRUG|chlorproguanil-dapsone|
219278658|NCT06427421|BIOLOGICAL|Frequency of Treg and Teffs|additionnal blood sampling at inclusion
219278659|NCT06427421|BIOLOGICAL|Phenotype of Treg and Teffs|additionnal blood sampling at inclusion
219278660|NCT06427421|BIOLOGICAL|RNA seq analysis|additionnal blood sampling at inclusion
219278661|NCT06427421|BIOLOGICAL|HLA typing|additionnal blood sampling at inclusion
219278662|NCT06427421|BIOLOGICAL|beta-cell autoantibody dosage|additionnal blood sampling at inclusion
219278663|NCT06427421|BIOLOGICAL|Glycated haemoglobin (HbA1C) dosage|additionnal blood sampling at inclusion
219278664|NCT06427421|BIOLOGICAL|blood glucose dosage|additionnal blood sampling at inclusion
219278665|NCT06427421|BIOLOGICAL|C-peptide dosage|additionnal blood sampling at inclusion
219278666|NCT05673031|DIAGNOSTIC_TEST|68Ga-HA-DOTATATE PET/CT imaging|"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."
219278667|NCT03357419|DRUG|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
219278668|NCT03357419|DRUG|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
219278669|NCT02672943|BEHAVIORAL|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
219278670|NCT02672943|OTHER|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
219278671|NCT03171662|OTHER|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
219278672|NCT02950597|DEVICE|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
219296327|NCT05172050|OTHER|Placebo|Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
219296328|NCT04910451|OTHER|No Intervention|
219278673|NCT03950752|COMBINATION_PRODUCT|Optimized Bagel|Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
219278674|NCT03950752|COMBINATION_PRODUCT|Conventional Bagel|Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
219278675|NCT03568773|OTHER|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (\> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
219278676|NCT03568773|OTHER|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, \<threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
219278677|NCT03568773|OTHER|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
219278678|NCT02304705|DRUG|Sildenafil|20 mg three times daily by mouth for 90 days
219278679|NCT02304705|DRUG|Placebo|One capsule three times daily by mouth for 90 days
219278680|NCT04075877|BEHAVIORAL|FOCUS|See prior section.
219278681|NCT04263272|OTHER|Upper Body Circuit Training Program|16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
219278682|NCT04361955|OTHER|EMG|recordings of muscle electrical activity during nerve stimulation using EMG
219278683|NCT04361955|OTHER|EEG|recordings of brain activity using EEG
219278684|NCT04498637|OTHER|'Attitudes towards people with disability Scale'|The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
219278685|NCT04462783|OTHER|Symptoms entered into the CovidX application|Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
219278686|NCT04782440|OTHER|Telerehabilitaton|Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
219278687|NCT04782440|OTHER|Home exercise|Patients will be given a home-based exercise program without telerehabilitation supervision
219278688|NCT01395459|BEHAVIORAL|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
219278689|NCT01395459|BEHAVIORAL|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
219278690|NCT00449267|DEVICE|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
219278691|NCT00736268|BEHAVIORAL|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
219278692|NCT00736268|OTHER|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
219278693|NCT02124811|DRUG|Minocycline|
219278694|NCT03480932|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
219278695|NCT03480932|DRUG|Daclatasvir|Direct acting antiviral agent used for the treatment of hepatitis C
219278696|NCT03480932|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
219278697|NCT03480477|OTHER|ACE questionnaire|No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
219278698|NCT05757076|PROCEDURE|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
219278699|NCT02092597|DRUG|Exenatide|
219278700|NCT02092597|DRUG|Linagliptin|
219278701|NCT02092597|DRUG|Gliclazide|
219278702|NCT03435445|BEHAVIORAL|Online platform group|The online platform has social network, gamification and short-text sessions.
219278703|NCT03435445|BEHAVIORAL|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
219278704|NCT03435445|BEHAVIORAL|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
219278705|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
219278706|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
219278707|NCT04941599|DRUG|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
219278708|NCT04941599|OTHER|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
219278709|NCT05658003|DRUG|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
219278710|NCT05658003|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
219278711|NCT05658003|DRUG|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
219278712|NCT05658003|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
219278713|NCT05608668|DEVICE|Pro2 - 60% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
219278714|NCT05608668|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
219278715|NCT05947955|DRUG|Rhu-pGSN|Intravenous administration based on actual body weight
219278716|NCT05947955|DRUG|normal saline|intravenous administration in the same volume as the active therapy
219278717|NCT06484829|DRUG|Purinostat Mesylate 4 mg/m2|4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
219278718|NCT06484829|DRUG|Purinostat Mesylate 6 mg/m2|6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
219278719|NCT06484829|DRUG|Purinostat Mesylate 8.4 mg/m2|8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
219278720|NCT06840106|PROCEDURE|Nasal steam therapy|Nasal steam therapy is performed once a every other day for a total of 3three times. The steam inhalation stimulates the acupoints of bilateral LI20, EX-HN8, and EX-HN9
219278721|NCT06840106|PROCEDURE|Routine management strategy|Depending on the patient's symptoms and degree of improvement, the clinician may utilize all drugs currently used in clinical practice to improve upper respiratory symptoms, if necessary. All drugs that fall under the Anatomical Therapeutic Chemical Classification System (ATC) codes of non-disease treatment (R01), throat disease treatment (R02), lung disease or expectorant (R03, R05), and other respiratory organ drugs (R06, R07) and other drugs. The usage and dosage should be within the range of the current clinical guidelines.
219278722|NCT05846646|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
219278723|NCT05846646|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
219278724|NCT05846646|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
219278725|NCT06522204|DRUG|%5 Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
219278726|NCT06374849|OTHER|phone interview|Patient's phone interview 3 months after operating room discharge. The interview consisting of 3 questionnaires to detect the presence of CPSP, its intensity, its characteristics and its related analgesic consumption.
219278727|NCT05878236|DIAGNOSTIC_TEST|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
219278728|NCT04611009|BEHAVIORAL|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
219278729|NCT04611009|BEHAVIORAL|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
219296329|NCT03974477|DEVICE|SALT CONTROL H equipment to control and monitor salt during cooking process|Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
219296330|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
219278730|NCT05504954|BEHAVIORAL|IMARA-SA (intervention group)|The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
219278731|NCT05504954|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
219278732|NCT02601118|OTHER|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
219278733|NCT01896427|DRUG|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
219278734|NCT03043703|DEVICE|AirSense 10 AutoSet for Her|Positive airway pressure
219278735|NCT05949320|OTHER|e-Motivational Interviewing|"This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes."
219278736|NCT01634386|DRUG|Torrent's Quetiapine Fumarate Tablets|
219278737|NCT05310422|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
219278738|NCT05310422|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
219278739|NCT05352841|DIAGNOSTIC_TEST|Salivary sample analysis|The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
219278740|NCT05272943|OTHER|Oxgen saturation measurement with validated pulse oximetry|Oxgen saturation will be measured with validated pulse oximetry
219278741|NCT05272943|OTHER|Oxgen saturation measurement with smart electronics|Oxgen saturation will be measured with smart electronics
219278742|NCT01757197|DRUG|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
219278743|NCT04302688|OTHER||
219278744|NCT04200222|DIAGNOSTIC_TEST|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1\. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
219278745|NCT00150878|OTHER|Conditioning therapy|Preparation before allogeneic transplantation
219278746|NCT04200001|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ-BR23~* EORTC SHQ-C22~* CUPIDON 2 specific questionnaire"
219278747|NCT03674775|OTHER|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
219278748|NCT00776906|DEVICE|Advance® 18PTX® Balloon Catheter|
219278749|NCT00776906|DEVICE|Advance® 18LP Balloon Catheter|
219278750|NCT05435950|DEVICE|Sono-Intruments|"Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~* The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~* The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley."
219278751|NCT05530577|DRUG|Semaglutide|Semaglutide (subcutaneous)
219278752|NCT05530577|DRUG|Sham/placebo|Sham subcutaneous injection
219278753|NCT06088498|BEHAVIORAL|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
219278754|NCT06088498|BEHAVIORAL|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
219278755|NCT06088498|BEHAVIORAL|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
219278756|NCT00460395|PROCEDURE|Surgery|
219278757|NCT00460395|PROCEDURE|Stereotactic radiosurgery|
219278758|NCT01503762|OTHER|Mirror therapy|mirror therapy
219278759|NCT01503762|OTHER|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
219278760|NCT04210427|DRUG|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
219278761|NCT04210427|DEVICE|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
219278762|NCT01482936|DRUG|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
219278763|NCT01174446|BIOLOGICAL|BAX 326|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~* Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~* Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
219278764|NCT01174446|BIOLOGICAL|BeneFIX|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~* BeneFIX only used in Part 1 of this study.~* Study Part 2 and 3 only utilized BAX326"
219278765|NCT02845232|OTHER|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
219278766|NCT04706897|DRUG|Dexmedetomidine, ketamine and lidocaine|A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
219278767|NCT04706897|DRUG|Normal saline|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
219278768|NCT03374943|DRUG|KB004|KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
219278769|NCT05102318|PROCEDURE|Direct Pulp Capping|Direct Pulp Capping
219278770|NCT05102318|PROCEDURE|Partial Pulpotomy|Partial Pulpotomy
219278771|NCT05102318|PROCEDURE|Pulpotomy|Pulpotomy
219278772|NCT02815020|OTHER|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
219278773|NCT03676478|OTHER|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
219278774|NCT04949256|BIOLOGICAL|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
219278775|NCT04949256|DRUG|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
219278776|NCT04949256|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
219278777|NCT04949256|DRUG|5-FU|4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
219278778|NCT04949256|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
219278779|NCT04949256|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
219278780|NCT04949256|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
219278781|NCT04949256|DRUG|Paclitaxel|175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
219278782|NCT05736172|BEHAVIORAL|Pain neuroscience grupal education|The face to face education group will be carried out with a physiotherapist addressing various topics in the neurosciences of pain. In the active control group, information will only be provided in written form for the individual patient to read.
219278783|NCT04634474|BEHAVIORAL|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
219278784|NCT04964856|BEHAVIORAL|ERAS exercise|Take ERAS exercise twice a day from hospitalization to 30 days after surgery
219278785|NCT04964856|BEHAVIORAL|No ERAS exercise|Don't take ERAS exercise in perioperative period
219278786|NCT02039245|DRUG|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
219278787|NCT00480142|DRUG|Oxycodone 10 mg|
219278788|NCT02417649|BIOLOGICAL|Placebo|"1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
219278789|NCT02417649|BIOLOGICAL|Ismigen|"1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
219278790|NCT05690997|OTHER|Intensive treatment|If the mean home SBP preceding clinic follow-up is \>130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
219278791|NCT05690997|OTHER|Standard treatment|If the mean home SBP preceding clinic follow-up is \>140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
219278792|NCT06147492|PROCEDURE|transanal total mesorectal excision|a transanal bottom-up approach was employed for the TME procedure
219278793|NCT06147492|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic Total Mesorectal Excision
219278794|NCT00804505|DEVICE|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
219278795|NCT00804505|DEVICE|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
219278796|NCT02547272|PROCEDURE|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
219278797|NCT00929253|DRUG|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
219278798|NCT00929253|BEHAVIORAL|CRA|Computer-delivered Community Reinforcement Approach
219278799|NCT00929253|BEHAVIORAL|Therapy|Therapist-delivered therapy
219278800|NCT00929253|BEHAVIORAL|CM|Contingency management (vouchers) for providing a drug negative urine sample.
219278801|NCT05518071|DRUG|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
219278802|NCT05518071|DEVICE|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
219278803|NCT03959761|DRUG|Intraperitoneal (IP) nivolumab infusion|"Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~* Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~* Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions"
219278806|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
219278807|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
219278808|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
219278809|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
219278810|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
219278811|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
219278812|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
219278813|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
219278814|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
219278815|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
219278816|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
219278817|NCT06052527|OTHER|Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning|A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning
219278818|NCT05976776|BEHAVIORAL|The Childbirth and Parenthood Preparation Education|"The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions)."
219278819|NCT03471546|BEHAVIORAL|Palliative Care|Initial consultation and follow-up with a palliative care provider
219278820|NCT05515354|OTHER|Timing of nicotine replacement therapy start date|Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
219278821|NCT05515354|DRUG|Nicotine Replacement Therapy Agent|Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
219278822|NCT01461889|OTHER|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
219278823|NCT01461889|OTHER|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
219278824|NCT03909490|OTHER|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
219278825|NCT03909490|OTHER|handout|handout with information about trigger fingers
219278826|NCT02497495|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
219278827|NCT03057847|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
219278828|NCT04765917|OTHER|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Strengthening exercises for weakened muscles in upper and lower limbs muscle.~* Strengthening exercises for back and abdominal muscles.~* Stretching exercises for tight muscles in upper and lower limbs.~* Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Jumping in place and jumping a board."
219278829|NCT04765917|OTHER|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
219278830|NCT04283539|DRUG|systemic corticosteroid or biologic|Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
219278831|NCT01706705|DEVICE|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
219278832|NCT01706705|OTHER|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
219278833|NCT01706705|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
219278834|NCT06179225|BEHAVIORAL|HMD AR|Older adults will wear head mounted display to engage in collaborative augmented reality activities: sharing a meal, playing board games, and decorating home.
219278835|NCT06179225|BEHAVIORAL|2-D AV|Older adults will use 2-D AV to engage with family members at a distance.
219278836|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg IV of Remimazolam Tosilate, Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1mg/kg/h
219278837|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection
219278838|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
219278839|NCT06245408|DRUG|Dazodalibep|IV infusion
219278840|NCT06245408|DRUG|Placebo|IV infusion
219278841|NCT00285701|DRUG|hexaminolevulinate|
219278842|NCT06317532|OTHER|Lifestyle modification advice|All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.
219278843|NCT06317532|OTHER|Functional exercises|Each female in group (B) will perform the exercise program three times a week for eight weeks at the University Women's Health Unit Exercise protocols mainly consist of relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga, and Pilates
219278844|NCT02911233|BIOLOGICAL|Thromboelastograpgy|
219278845|NCT04773067|BIOLOGICAL|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
219278846|NCT04773067|BIOLOGICAL|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
219278847|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
219278848|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
219278849|NCT02138786|DRUG|selinexor|"* 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~* 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0)."
219278850|NCT06460792|PROCEDURE|Ultrasound-guided peripheral nerve block|Ultrasound-guided peripheral nerve blocks. Registration of quality, complications and learning as detailed in the description
219278851|NCT02308397|OTHER|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
219278852|NCT02308397|OTHER|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
219278853|NCT02308397|OTHER|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
219278854|NCT02308397|OTHER|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
219278855|NCT03540745|DEVICE|TES Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
219278856|NCT03540745|DEVICE|TES-SHAM Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
219278857|NCT01979406|BIOLOGICAL|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
219278858|NCT01979406|BIOLOGICAL|Ad4-PA-1|Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
219278859|NCT01979406|BIOLOGICAL|Ad4-PA-GPI-1|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
219278860|NCT02029963|DEVICE|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
219278861|NCT02029963|BEHAVIORAL|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
219278862|NCT04440020|OTHER|Beverage of Olive Oil Leaves|Beverage of Olive Oil Leaves,Oleuropein
219278863|NCT04440020|OTHER|Mediterranean Diet|Mediterranean Diet ,for a personal nutrition with the same dietary habits
219278864|NCT02088957|DRUG|Brivaracetam intravenous solution|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use"
219278865|NCT02088957|DRUG|Brivaracetam oral tablets|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use"
219278866|NCT02088957|DRUG|Phenytoin intravenous solution|"* Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use"
219278867|NCT02088957|DRUG|Phenytoin oral tablets|"* Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use"
219278868|NCT04420429|PROCEDURE|Descemet membrane endothelial keratoplasty (DMEK)|All participants underwent DMEK surgery
219278869|NCT01523067|DRUG|Vasomera (PB1046)|Single dose of Vasomera
219278870|NCT01523067|DRUG|0.9% Sodium Chloride|Placebo injection
219278871|NCT00095277|DRUG|Darbepoetin Alfa|
219278872|NCT03078335|OTHER|Glove based care|Described in Experimental Arm: Glove based care
219278873|NCT03078335|OTHER|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
219278874|NCT03251053|DEVICE|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
219278875|NCT03251053|OTHER|Control regular cigarette smokers|
219278876|NCT04862442|OTHER|Qigong exercises|Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
219278877|NCT04370015|DRUG|Hydroxychloroquine|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
219278878|NCT04370015|DRUG|Placebo oral tablet|• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
219278879|NCT06147297|BEHAVIORAL|Tuned In|The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
219278880|NCT04030871|DEVICE|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
219278881|NCT04030871|DEVICE|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
219278882|NCT02570659|BEHAVIORAL|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
219278883|NCT06319742|DIAGNOSTIC_TEST|Extracellular vescicles (EV) analysis|"The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed."
219278884|NCT01923662|DEVICE|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
219278885|NCT04567381|OTHER|Enhanced Services|In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.
219278886|NCT04567381|OTHER|Treatment as Usual|Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
219278887|NCT00322569|DEVICE|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
219278888|NCT00322569|DEVICE|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
219278889|NCT00322569|DEVICE|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
219278890|NCT03245047|DIETARY_SUPPLEMENT|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
219278891|NCT03245047|OTHER|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
219278892|NCT05022433|PROCEDURE|UVC insertion|To compare two formulae namely UN-1 and Shukla method to estimate the UVC insertion length in achieving optimum UVC tip position.
219278893|NCT06344468|OTHER|Early Mobilization|Essentially, early mobilization practices consist of two parts: in-bed and out-of-bed. In-bed mobilization; Active-passive joint range of motion (ROM) Exercises include raising the head in bed, turning in bed, in-bed exercises and sitting at the end of the bed. Out-of-bed mobilization includes the process of transferring from bed to chair, standing up, and returning to bed after standing up. In studies conducted on cardiac surgery, the early mobilization period is the first 12 hours.
219278894|NCT06329323|DIAGNOSTIC_TEST|Blood test|Serum and plasma microRNA quantification
219278895|NCT06329323|DIAGNOSTIC_TEST|Pathology specimen miRNA expression|Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
219278896|NCT04890405|PROCEDURE|Standardized FMT|The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.
219278897|NCT04890405|COMBINATION_PRODUCT|Precision Flora Transplantation|The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
219278898|NCT06415136|DEVICE|SeaSpine Shoreline|The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
219278899|NCT00780728|DRUG|Sildenafil|
219278900|NCT01939353|DRUG|CTN SR|CTN SR tablets
219278901|NCT01939353|DRUG|Placebo|CTN SR-matching placebo tablets
219278902|NCT03337438|OTHER|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
219278903|NCT03337438|OTHER|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
219278904|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
219278905|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
219278906|NCT01342198|DRUG|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
219278907|NCT04980222|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
219278908|NCT04980222|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
219278909|NCT04980222|DRUG|Doxorubicin|Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
219278910|NCT04980222|DRUG|Vincristine|Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
219278911|NCT04980222|DRUG|Prednisone|Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
219278912|NCT04980222|DRUG|Rituximab|Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
219278913|NCT04980222|DRUG|Cyclophosphamide|Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
219278914|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
219278915|NCT02413645|BIOLOGICAL|TriMix_100|100 μg of TriMix in
219278916|NCT02413645|BIOLOGICAL|TriMix_300|300 μg of TriMix in
219278917|NCT02413645|BIOLOGICAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
219278918|NCT02413645|BIOLOGICAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
219278919|NCT02413645|BIOLOGICAL|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
219278920|NCT03137043|OTHER|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
219278921|NCT03137043|OTHER|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
219278922|NCT00186017|DRUG|Olanzapine/Zyprexa|Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
219278923|NCT00874731|DRUG|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
219278924|NCT00874731|DRUG|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
219278925|NCT00874731|DRUG|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
219278926|NCT01506440|PROCEDURE|cognitive assessment|Given cognitive assessments
219278927|NCT01506440|PROCEDURE|quality-of-life assessment|Ancillary studies
219278928|NCT00538772|OTHER|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
219278929|NCT06518811|OTHER|Video-Based Exercise Programme|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided. The participants were used exercise balls and resistance bands distributed by the researchers according to exercise programme.
219278930|NCT02132832|DRUG|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
219278931|NCT02132832|DRUG|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
219278932|NCT02791568|PROCEDURE|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
219278933|NCT02791568|PROCEDURE|MRI Scan|MR imaging will take approximately 30 minutes.
219278934|NCT02791568|DRUG|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
219278935|NCT06290245|DEVICE|PEP Buddy|It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O
219278936|NCT06290245|OTHER|aerobic exercise|Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
219278937|NCT04968431|OTHER|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
219278938|NCT04968431|OTHER|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
219296331|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
219296332|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
219278939|NCT05411172|BEHAVIORAL|Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses|"The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice."
219278940|NCT02646020|DRUG|Aprepitant|aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
219278941|NCT02646020|DRUG|Desloratadine|Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
219278942|NCT02646020|DRUG|Placebo of aprepitant|Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
219278943|NCT02646020|DRUG|Placebo of desloratadine|Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
219278944|NCT05688631|OTHER|Dietary antioxidant intake|Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.
219278945|NCT03157297|DEVICE|MARVEL algorithm|Software download into implanted Micra device
219278946|NCT02931253|DRUG|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
219278947|NCT01132820|DRUG|Cediranib Maleate|Given PO
219278948|NCT01132820|OTHER|Laboratory Biomarker Analysis|Correlative studies
219278949|NCT06166550|BEHAVIORAL|Parent's Emotional Intelligence Network|A two-day in-person training session will be arranged for the participating parents at least one week apart. The psychologists will conduct the training session on emotional intelligence. A training of the trainer manual will be developed to train the psychologists. The training session will include a power point presentation and certain group and individual activities to practice emotional intelligence. The participants will also be given a diary and a mobile app in order to practice emotional intelligence at home.
219278950|NCT06166550|DEVICE|Mobile App|A mobile app (MonKotha) has been developed along with user manual. It contains different videos, audios, and texts related to emotional intelligence. It also provides a communication platform where users can communicate through texts and upload documents.
219278951|NCT06166550|DEVICE|Diary|A diary (Onuvutir Diary) is also developed that contain different practice materials regarding emotional intelligence. It is a personal diary given to the participants to take to home.
219278952|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
219278953|NCT02136953|BEHAVIORAL|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
219278954|NCT02136953|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
219278955|NCT05108441|OTHER|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
219278956|NCT05017051|BEHAVIORAL|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
219278957|NCT05017051|BEHAVIORAL|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
219278958|NCT05017051|DEVICE|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
219278959|NCT05017051|OTHER|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
219278960|NCT02668276|OTHER|Standard NCCN counseling|
219278961|NCT02668276|OTHER|Standard NCCN counseling and Oncotype DX results|
219278962|NCT04615195|OTHER|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
219278963|NCT02026492|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
219278964|NCT02026492|OTHER|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
219278965|NCT02026492|OTHER|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
219278966|NCT01048697|DRUG|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
219278967|NCT03033940|RADIATION|Observational use of fluoroscopy|
219278968|NCT03214653|DRUG|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
219278969|NCT03214653|DRUG|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
219278970|NCT00333086|DRUG|Letrozole|
219278971|NCT03416660|DEVICE|Fractional Carbon Dioxide laser|
219278972|NCT00409526|DRUG|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
219278973|NCT00667394|BIOLOGICAL|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
219278974|NCT00667394|DRUG|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
219278975|NCT00667394|PROCEDURE|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
219278976|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
219278977|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
219278978|NCT00250549|BEHAVIORAL|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
219278979|NCT03837951|OTHER|Figure-of-eight tape measure measurements on both hands|Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.
219278980|NCT03837951|OTHER|Volumeter measurements|Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
219278981|NCT05369559|COMBINATION_PRODUCT|Mini bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
219278982|NCT05369559|DIAGNOSTIC_TEST|passive leg rising test|Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
219278983|NCT05835609|DRUG|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
219278984|NCT05000216|BIOLOGICAL|Moderna mRNA-1273|Administration: One dose administered intramuscularly.
219278985|NCT05000216|BIOLOGICAL|BNT162b2|Administration: One dose administered intramuscularly.
219278986|NCT05000216|BIOLOGICAL|Ad26.COV2.S|Administration: One dose administered intramuscularly.
219278987|NCT05000216|DRUG|Continue IS (MMF or MPA)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
219278988|NCT05000216|DRUG|Continue IS (MTX)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
219278989|NCT05000216|BIOLOGICAL|Continue IS (B cell depletion therapy)|Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.
219278990|NCT05000216|BIOLOGICAL|Monovalent [B.1.351] CoV2 preS dTM-AS03|One dose administered intramuscularly
219278991|NCT05000216|DRUG|Withhold IS (MMF or MPA)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
219278992|NCT05000216|DRUG|Withhold IS (MTX)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
219278993|NCT05000216|DRUG|Withhold IS (B cell depletion therapy)|Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
219278994|NCT05000216|BIOLOGICAL|Moderna mRNA-1273, Bivalent|Administration: One dose administered intramuscularly.
219278995|NCT05000216|BIOLOGICAL|BNT162b2, Bivalent|Administration: One dose administered intramuscularly.
219278996|NCT04680195|DRUG|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
219278997|NCT04605640|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
219278998|NCT05758168|PROCEDURE|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
219278999|NCT06557707|OTHER|Childhood stress|Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
219279000|NCT06268197|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of twice weekly, in-person, gentle Hatha yoga classes delivered by a certified yoga instructor. Each class will last 60-75 minutes and will include an introduction to the day's topic, an opening breathing/meditation practice, yoga postures, a closing breathing/meditation practice, and end with a savasana pose and intention setting for a home practice.
219279001|NCT03882177|DRUG|Pravastatin|Tablets, administered orally
219279002|NCT03882177|DRUG|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
219279003|NCT03882177|DIETARY_SUPPLEMENT|Vitamin B6|Administered orally.
219279004|NCT02777892|OTHER|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
219279005|NCT00509249|BIOLOGICAL|ziv-aflibercept|Given IV
219279006|NCT00509249|OTHER|laboratory biomarker analysis|Correlative studies
219279007|NCT00509249|OTHER|pharmacological study|Correlative studies
219279008|NCT00245908|DRUG|azithromycin|
219279009|NCT02224703|DRUG|GWP42003-P|
219279010|NCT02224703|DRUG|Placebo Control|
219279011|NCT03873753|OTHER|Cleaning|Gauze and mineral water
219279012|NCT03873753|OTHER|No oral cleaning|Absence of cleaning
219279013|NCT04048902|DEVICE|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
219279014|NCT04048902|DEVICE|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
219279015|NCT00927134|GENETIC|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
219296333|NCT02576119|DRUG|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
219279016|NCT04956874|BEHAVIORAL|FL-REACH|The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
219279017|NCT05909553|DRUG|Venetoclax|Oral; Tablet
219279018|NCT03177239|DRUG|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
219279019|NCT03177239|DRUG|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
219279020|NCT04447508|BEHAVIORAL|Participants receive one on one motivational interviewing and participate in a group exercise class virtually.|Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
219279021|NCT00196157|PROCEDURE|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
219279022|NCT00196157|PROCEDURE|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
219279023|NCT02932540|OTHER|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
219279024|NCT02922023|DEVICE|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
219279025|NCT02922023|OTHER|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
219279026|NCT04182295|DEVICE|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
219279027|NCT04182295|DEVICE|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. \& DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
219279028|NCT00233974|PROCEDURE|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
219279029|NCT06405100|DRUG|Supportive care+Prednisone|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Induction period: 1mg/kg/day. The maximum dose is not more than 60mg. The duration of adequate prednisone is a minimum of 4 weeks and a maximum of 16 weeks.~Maintenance period: A reduction of 5-10mg/wk was initiated after 2 weeks of complete remission and finally discontinued after 6 months of maintenance at 5mg/day."
219279030|NCT06405100|DRUG|Supportive care+Tacrolimus+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Tacrolimus：Induction period: 0.05mg/kg/d. It will be given in two doses 12 hours apart. The blood concentration should be up to 5-10ng/ml. Maintenance therapy was initiated two weeks after complete remission; Maintenance period: Reduced to a blood concentration of 3-8ng/ml, and stopped after 6 months of maintenance treatment.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
219279031|NCT06405100|DRUG|Supportive care+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
219279032|NCT03943472|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
219279033|NCT03943472|DRUG|Fludarabine|30mg/m2/d
219279034|NCT03943472|DRUG|Cyclophosphamide|300mg/m2/d
219279035|NCT03943472|DRUG|Immune inhibitors|Immune inhibitors
219279036|NCT01224977|DRUG|azithromycin|azithromycin 500 mg 3/week for 3 months
219279037|NCT01759524|DRUG|Bupivacaine|
219279038|NCT01759524|DRUG|Lidocaine|
219279039|NCT05759962|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
219279040|NCT05759962|OTHER|Placebo|Matching Placebo
219279041|NCT01720160|DEVICE|BAROSTIM NEO® System|Implant procedure
219279042|NCT01720160|OTHER|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
219279043|NCT00799032|DEVICE|PCI|coronary stent implantation
219279044|NCT04756102|OTHER|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
219279045|NCT03600415|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219279046|NCT03600415|OTHER|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
219279047|NCT02287298|PROCEDURE|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
219279048|NCT00659880|OTHER|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
219279049|NCT06436768|DRUG|Sugammadex|"After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight."
219279050|NCT06436768|DRUG|Neostigmine|"After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight."
219279051|NCT02963155|OTHER|Blood samples|
219279052|NCT04076787|DRUG|Sunitinib|patients who received sunitinib as first line therapy for mRCC
219279053|NCT04646291|DEVICE|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
219279054|NCT04004104|DIAGNOSTIC_TEST|Upright Exercise|Exercise is generally performed in the upright position.
219279055|NCT04004104|DIAGNOSTIC_TEST|Supine Exercise|Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.
219279056|NCT01518959|DRUG|Cholecalciferol|180.000 IU monthly
219279057|NCT01518959|DRUG|oleum neutralicum|Placebo comparator, 9 ml monthly
219279058|NCT00045526|DRUG|erlotinib hydrochloride|Given PO
219279059|NCT00045526|OTHER|laboratory biomarker analysis|Correlative studies
219279060|NCT02833324|BEHAVIORAL|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
219279061|NCT02833324|BEHAVIORAL|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
219279062|NCT02833324|OTHER|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
219279063|NCT03699891|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
219279064|NCT01886287|DRUG|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
219279065|NCT02954978|DRUG|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
219279066|NCT02954978|DRUG|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
219279067|NCT02954978|DRUG|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
219279068|NCT01279928|PROCEDURE|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
219279069|NCT01279928|DEVICE|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
219279070|NCT01279928|PROCEDURE|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
219279071|NCT01279928|PROCEDURE|Laser Doppler Flowmetry|Examination of vascular flow
219279072|NCT04533048|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
219279073|NCT04533048|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
219279074|NCT02990468|DRUG|BMX-001|Subcutaneous injection.
219279075|NCT02990468|RADIATION|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
219279076|NCT02990468|DRUG|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
219279077|NCT06215209|OTHER|position|patients will be in supine position and prone position
219279078|NCT05930808|DRUG|First Test Concor (Fasted)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
219279079|NCT05930808|DRUG|First Reference Concor (Fasted)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
219279080|NCT05930808|DRUG|First Test Concor (Fed)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
219279081|NCT05930808|DRUG|First Reference Concor (Fed)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
219279082|NCT03563066|DRUG|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.
219279083|NCT03563066|DRUG|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
219279084|NCT05884814|BEHAVIORAL|Morning exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
219279085|NCT05884814|BEHAVIORAL|Afternoon exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
219279086|NCT05884814|BEHAVIORAL|Habitual physical activity levels|Participants will be asked to maintain their normal activity levels
219279087|NCT03345745|DIAGNOSTIC_TEST|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
219279088|NCT04574817|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
219279089|NCT02309671|DRUG|FE 999049|
219279090|NCT02309671|DRUG|follitropin beta|
219279091|NCT05070364|DRUG|Peginterferon Lambda-1a|Immunomodulator
219279092|NCT01649154|PROCEDURE|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
219279093|NCT04210999|OTHER|Homebased resistance training|Resistance training at home instructed via a smart phone training app
219279094|NCT04210999|OTHER|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
219279095|NCT00795223|DRUG|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
219279096|NCT00795223|DRUG|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
219279097|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
219279098|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
219279099|NCT03124654|BEHAVIORAL|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
219279100|NCT05858684|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
219279101|NCT02834338|DEVICE|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
219279102|NCT00459797|DEVICE|Conventional (reusable) Glidescope|
219279103|NCT00459797|DEVICE|Single-use Glidescope videolaryngoscope|
219279104|NCT03993210|DEVICE|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
219279105|NCT03993210|DEVICE|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
219279106|NCT03993210|DEVICE|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
219279107|NCT02656719|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
219279108|NCT02656719|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
219279109|NCT06117553|PROCEDURE|thorough flushing|The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
219279110|NCT03447301|DIETARY_SUPPLEMENT|Extra virgin olive oil (30mL daily)|Intervention arm will take 30 mL of Extra virgin olive oil daily.
219279111|NCT04385706|BEHAVIORAL|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
219279112|NCT04480775|DRUG|Triamcinolone|transversus abdominis plane block with bupivacain and triamicinolone
219279113|NCT04480775|DRUG|Methylprednisolone|transversus abdominis plane block with bupivacaine and methylprednisolone
219279114|NCT04480775|DRUG|bupivacaine|transversus abdominis plane block with bupivacaine alone
219279115|NCT02126852|DEVICE|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
219279116|NCT02126852|DEVICE|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
219279117|NCT02126852|DEVICE|Electromyography (EMG)|Neuromuscular monitoring
219279118|NCT00239408|DEVICE|Pulmonary function Testing|
219279119|NCT00239408|DRUG|tiotropium bromide|
219279120|NCT04212351|GENETIC|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
219279121|NCT01204411|DRUG|Artesunate-amodiaquine fixed-dose combination|"* artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~* artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~* artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
219279122|NCT05526469|PROCEDURE|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
219279123|NCT05526469|PROCEDURE|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
219279124|NCT05526469|DRUG|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
219279125|NCT04038164|BEHAVIORAL|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
219279126|NCT03113318|PROCEDURE|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
219279127|NCT03113318|PROCEDURE|Only pulmonary metastasectomy|
219279128|NCT00669877|DRUG|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
219279129|NCT00669877|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
219279130|NCT00669877|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
219279131|NCT00669877|DRUG|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
219279132|NCT00669877|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
219279133|NCT00669877|DRUG|G-CSF|10 mcg/kg
219279134|NCT00669877|DRUG|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
219279135|NCT00669877|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
219279136|NCT05316792|OTHER|walking|30 min walking on the treadmill and tartan floor
219279137|NCT02534571|DEVICE|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once
219279138|NCT02534571|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
219279139|NCT02534571|DRUG|Epinephrine|epinephrine injection endoscopically \<20 mls
219279140|NCT02534571|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 4 pulses
219279141|NCT01791504|DEVICE|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
219279142|NCT00077389|DRUG|carboplatin|
219279143|NCT00077389|DRUG|cisplatin|
219279144|NCT00077389|DRUG|doxorubicin hydrochloride|
219279145|NCT00077389|PROCEDURE|adjuvant therapy|
219279146|NCT00077389|PROCEDURE|conventional surgery|
219279147|NCT00077389|PROCEDURE|neoadjuvant therapy|
219279148|NCT02199158|PROCEDURE|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
219279149|NCT05584358|DIETARY_SUPPLEMENT|Dry protein blend ingestion|Ingestion of protein blend powders mixed in water
219279150|NCT05584358|DIETARY_SUPPLEMENT|Extruded protein blend ingestion|Ingestion of protein blend powders mixed in water
219279151|NCT02690116|OTHER|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
219279152|NCT02690116|OTHER|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
219279153|NCT02690116|OTHER|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
219279154|NCT05449405|COMBINATION_PRODUCT|Chlorpheniramine Maleate 1% Nasal Spray|Chlorpheniramine Maleate 1% Nasal Spray
219279155|NCT05449405|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
219279156|NCT05306743|OTHER|CONQUEST Quality Improvement Program|"CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations."
219279157|NCT04982770|OTHER|Survey|Reading of ethical guidelines.
219279158|NCT01229605|DRUG|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
219279159|NCT02885558|DRUG|Efonidipine|8 weeks treatment with either efonidipine
219279160|NCT02885558|DRUG|Nifedipine|8 weeks treatment with either nifedipine
219279161|NCT04745975|DRUG|Personalized treatment guided by mini-PDX and RNA sequencing|Personalized treatment guided by mini-PDX and RNA sequencing
219279162|NCT04745975|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w
219279163|NCT04745975|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1,8 q3w
219279164|NCT04745975|DRUG|Vinorelbine|Vinorelbine 25mg/m2 d1,8, q3w
219279165|NCT04745975|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, d1,8, q3w
219279166|NCT04745975|DRUG|Capecitabine|Capecitabine 1250 mg/m2 bid po
219279167|NCT03434444|DRUG|Oxytocin|Oxytocin in solution, ranging from 10 -12M to 10 -5M
219279168|NCT03434444|DRUG|Propranolol|Propranolol in solution, 10-6M
219279169|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
219279170|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
219279171|NCT03722225|OTHER|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
219279172|NCT04848818|PROCEDURE|Distal radial metaphyseal fracture fixation with percutaneous K-wires|Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..
219279173|NCT04848818|PROCEDURE|Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants|Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
219279174|NCT02740725|OTHER|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
219279175|NCT02740725|DEVICE|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
219279176|NCT02334475|BIOLOGICAL|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
219279177|NCT02334475|BIOLOGICAL|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
219279178|NCT02879786|OTHER|Posturographic tests|
219279179|NCT02879786|OTHER|Questionnaire of motion sickness susceptibility|
219279180|NCT03566745|DIAGNOSTIC_TEST|Blood for protein activity|Blood for protein activity
219279181|NCT02079025|DEVICE|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
219279182|NCT02079025|DEVICE|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
219279183|NCT03265353|OTHER|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
219279184|NCT03265353|OTHER|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
219279185|NCT03265353|OTHER|High Potassium/High Sodium Diet|7 days of the prescribed diet
219279186|NCT02358434|RADIATION|Observational use of fluoroscopy|
219279187|NCT01427725|DRUG|Lipacreon|This study was an observational study and no intervention was specified
219279188|NCT04871399|PROCEDURE|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
219279189|NCT04871399|PROCEDURE|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~* The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~* The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
219279190|NCT01299051|BEHAVIORAL|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~* Face-to-face visit with counselor during Month 1 to set specific health goals.~* Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~* Monthly generic health education materials sent via e-mail.~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
219279191|NCT01299051|BEHAVIORAL|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~* Face-to-face visit with counselor at Month 1~* Meeting with exercise physiologist in Month 2~* Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~* Meeting with exercise physiologist during Month 5~* Quarterly biometric feedback (Months 3, 6, 9, and 12)~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
219279192|NCT00517023|DEVICE|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
219279193|NCT00517023|OTHER|Other|Routine care and tests usually offered for syncope patients.
219279194|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
219279195|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
219279196|NCT01005082|BEHAVIORAL|Low salt diet|
219279197|NCT01005082|BEHAVIORAL|Water therapy alone|
219279198|NCT04225481|OTHER|isolation of waste material and culturing with different supplement culture media|isolation of waste material and culturing with different supplement culture media
219279199|NCT05661318|OTHER|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
219279200|NCT03176147|OTHER|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
219279201|NCT05693298|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
219279202|NCT05693298|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
219279203|NCT05431764|DRUG|Camrelizumab, gemcitabin, cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.
219296334|NCT02576119|DRUG|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
219296335|NCT04419129|DEVICE|Oxford UKA|knee arthroplasty
219279204|NCT05431764|RADIATION|Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy|"IMRT: 5 fractions per week for 6 weeks to a total dose of 70 Gy and 33 fractions to the primary tumor.~SBRT: 3 months after locoregional IMRT, patients receive SBRT for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.~Camrelizumab (200mg, iv drip for over 60min) every 2 weeks began on the first day of IMRT until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
219279205|NCT04863482|PROCEDURE|IOC|intra-operative cholangiography near-infrared fluorescence cholangiography
219279206|NCT03693976|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
219279207|NCT03693976|DEVICE|Ectoin Rhinosinusitis Nasal Spray|Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
219279208|NCT01621776|DRUG|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
219279209|NCT01621776|DRUG|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
219279210|NCT01621776|DRUG|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
219279211|NCT02269423|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
219279212|NCT02269423|OTHER|Placebo|Normal saline placebo.
219296336|NCT04419129|DEVICE|Vanguard TKA|knee arthroplasty
219279213|NCT01593605|DIETARY_SUPPLEMENT|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
219279214|NCT01593605|DIETARY_SUPPLEMENT|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
219279215|NCT01593605|OTHER|Placebo treatment|Placebo - one tablet taken twice a day by mouth
219279216|NCT05576376|PROCEDURE|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
219279217|NCT05576376|PROCEDURE|plantar fascia open release|open partial release with or without baxter's nerve decompression
219279218|NCT05576376|PROCEDURE|plantar fascia endoscopic release|endoscopic partial plantar fascia release
219279219|NCT05057338|BEHAVIORAL|CoreDISTparticipation|CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
219279220|NCT05057338|BEHAVIORAL|Standard care|The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
219279221|NCT02221557|DEVICE|easy-graft (beta-Tricalcium Phosphate)|
219279222|NCT03846440|OTHER|No intervention|Cross-sectional
219279223|NCT02830477|BIOLOGICAL|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
219279224|NCT00896727|GENETIC|gene expression analysis|
219279225|NCT00896727|GENETIC|protein expression analysis|
219279226|NCT00896727|OTHER|fluorescent antibody technique|
219279227|NCT00896727|OTHER|laboratory biomarker analysis|
219279228|NCT03219957|DRUG|AT-527|Ascending doses of AT-527 administered orally.
219279229|NCT03219957|OTHER|Placebo Comparator|Matching placebo
219279230|NCT00043433|DRUG|intravenous T900607-sodium|
219279231|NCT02228759|PROCEDURE|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
219279232|NCT01709175|BEHAVIORAL|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
219279233|NCT01277887|BEHAVIORAL|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
219279234|NCT01277887|BEHAVIORAL|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
219279235|NCT00415051|BIOLOGICAL|RVF MP-12|Administer 1 ml SQ
219279236|NCT04409171|DIAGNOSTIC_TEST|oral glucose tolerance test|
219279237|NCT01424605|PROCEDURE|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
219279238|NCT02756533|OTHER|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
219279239|NCT02756533|OTHER|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
219279240|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire|A self-report questionnaire for assessing level of adaptive functioning
219279241|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire - adapted|A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
219279242|NCT02506049|DEVICE|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
219279243|NCT03838523|OTHER|Open Label Placebo|See group description
219279244|NCT05167136|BEHAVIORAL|Awareness Level|"Demands and expectations about the green hospital were measured with a questionnaire applied to 287 people, consisting of health professionals and employees in a small private hospital that does not have a green hospital certificate in the province of Istanbul."
219279245|NCT00452231|DRUG|D-cycloserine|
219279246|NCT00452231|BEHAVIORAL|Cognitive-Behavioral Therapy|
219279247|NCT02919553|PROCEDURE|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
219279248|NCT02919553|PROCEDURE|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
219279249|NCT01183247|DRUG|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
219279250|NCT01183247|DRUG|Everolimus|Add everolimus de novo to tacrolimus and MMF
219279251|NCT01183247|DRUG|Prednisone|Add prednisone de novo to tacrolimus and MMF
219279252|NCT00203268|DRUG|dihydroergotamine mesylate|1.0 mg. intramuscularly
219279253|NCT01739023|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
219279254|NCT00600613|RADIATION|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
219279255|NCT02348944|OTHER|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
219279256|NCT05994638|DIETARY_SUPPLEMENT|Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)|Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
219279257|NCT02514551|DRUG|Ramucirumab|Administered IV
219279258|NCT02514551|DRUG|Paclitaxel|Administered IV
219279259|NCT02398253|BEHAVIORAL|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
219279260|NCT02398253|BEHAVIORAL|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
219279261|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
219279262|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
219279263|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
219279264|NCT06331624|DRUG|Tazarotene (GRI-0621)|Oral 4.5mg soft gel capsule
219279265|NCT06331624|DRUG|Placebo|Oral 4.5mg soft gel capsule
219279266|NCT05217940|DIAGNOSTIC_TEST|Diagnostic tests for anal cancer screening|The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
219279267|NCT05380362|OTHER|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
219279268|NCT05380362|OTHER|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
219279269|NCT06053333|OTHER|Non-Interventional Study|Non-interventional study
219279270|NCT05415748|DRUG|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
219279271|NCT05415748|DRUG|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
219279272|NCT05975099|BIOLOGICAL|mRNA-1975|Dispersion delivered IM
219279273|NCT05975099|BIOLOGICAL|mRNA-1982|Dispersion delivered IM
219279274|NCT05975099|BIOLOGICAL|Placebo|Solution delivered IM
219279275|NCT03312400|DRUG|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
219279276|NCT02729142|PROCEDURE|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
219279277|NCT04970992|DRUG|DZ-002|DZ-002 Injection
219279278|NCT04906265|OTHER|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)
219279279|NCT04906265|OTHER|Control|Standard rehabiliation
219279280|NCT03564353|DEVICE|tDCS|tDCS
219279281|NCT02712489|OTHER|No intervention|
219279282|NCT02645123|DEVICE|TENS|Enraf-Nonius Sonopuls 692
219279283|NCT02645123|PROCEDURE|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
219279284|NCT02645123|PROCEDURE|swedish type massage|petrissage, effleurage, tapotement
219279285|NCT02645123|PROCEDURE|static hamstring stretch|static hamstring stretching
219279286|NCT02645123|PROCEDURE|sham treatment|touching of the skin overlying the lumbar area
219279287|NCT01164111|OTHER|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
219279288|NCT02570997|DRUG|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
219279289|NCT02570997|DRUG|Placebo|Matching placebo administered.
219279290|NCT00388804|PROCEDURE|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
219279291|NCT00388804|DRUG|Bicalutamide|50 mg By Mouth (PO) Daily
219279292|NCT00388804|DRUG|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
219279293|NCT00388804|DRUG|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
219279294|NCT00388804|DRUG|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
219279295|NCT00388804|BEHAVIORAL|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
219279296|NCT00023998|DRUG|doxorubicin hydrochloride|Given IV
219279297|NCT00023998|DRUG|cisplatin|Given IV
219279298|NCT00023998|DRUG|methotrexate|Given IV
219279299|NCT00023998|DRUG|leucovorin calcium|Given IV or orally
219279300|NCT00023998|BIOLOGICAL|filgrastim|Given IV
219279301|NCT00023998|PROCEDURE|therapeutic conventional surgery|Undergo resection
219279302|NCT00023998|RADIATION|radiation therapy|Undergo radiotherapy
219279303|NCT00023998|DRUG|etoposide|Given IV
219279304|NCT00023998|DRUG|ifosfamide|Given IV
219279305|NCT00023998|BIOLOGICAL|trastuzumab|Given IV
219279306|NCT00023998|OTHER|laboratory biomarker analysis|Correlative studies
219279307|NCT02600312|DEVICE|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
219279308|NCT02502747|DRUG|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
219279309|NCT02502747|DRUG|optimal standard of care|Optimal standard of care
219279310|NCT02502747|PROCEDURE|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
219279311|NCT03006640|DRUG|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
219279312|NCT03006640|DRUG|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
219279313|NCT06237166|BEHAVIORAL|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
219279314|NCT02437357|OTHER|Metacognitive Training|8 group sessions á 60 min
219279315|NCT02437357|OTHER|Positivity Training|8 group sessions á 60 min
219279316|NCT02605369|BEHAVIORAL|Intervention arm: An integrated package|See description in previous column
219279317|NCT04566913|PROCEDURE|Pontic Shield Technique|• Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
219279318|NCT01317329|OTHER|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
219279319|NCT00092092|DRUG|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
219279320|NCT00092092|DRUG|Budesonide inhaler|Budesonide 200 mcg inhalation powder
219279321|NCT00092092|DRUG|Placebo to montelukast chewable tablets|Placebo chewable tablets
219279322|NCT00092092|DRUG|Placebo to budesonide inhaler|Placebo inhalation powder
219279323|NCT00134355|DRUG|PTK787|
219279324|NCT00999999|PROCEDURE|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
219279325|NCT00925678|DRUG|DSP-3025|
219279326|NCT00925678|DRUG|Placebo|
219279327|NCT05472740|DEVICE|TENS 7000|TENS device to be used in both the active and placebo groups
219279328|NCT07138404|OTHER|self administration questioner|A self questionnaire will be distributed to evaluate the levels of stress experienced by dental students currently undertaking clinical training in 4th and 5th academic years at Cairo University during the performance of specific clinical procedures in conservative and endodontics treatment.The data obtained from the questionnaire will be statistically analyzed to identify and interpret the variations in the results.
219279329|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
219279330|NCT07126288|DRUG|GB08|"In Phase II trial, eligible PGHD patients will receive GB08 0.4mg/kg, 0.8mg/kg, or 1.2mg/kg subcutaneous injection, once a week for 24 weeks.~In Phase III trial, the individuals will receive GB08 subcutaneous injection, once a week for 52 weeks. The dose of GB08 at this stage will be determined by the outcomes of Phase II."
219279331|NCT07126288|DRUG|Norditropin NordiFlex|Norditropin NordiFlex 0.035 mg/kg subcutaneous injection, daily, for 24 weeks (Phase II) or 52 weeks (Phase III)
219279332|NCT05903261|RADIATION|SBRT|stereotactic body radiation therapy (SBRT)
219279333|NCT06934668|DEVICE|Extracorporeal Shock Wave Therapy|A single session of focused extracorporeal shock wave therapy (ESWT) applied to the upper trapezius muscle (2300 shocks). The treatment is applied to the muscle belly region with coupling gel, without local anesthesia. The protocol is designed to assess the acute effects of ESWT on muscle stiffness measured using shear-wave elastography.
219279334|NCT06933199|RADIATION|Neoadjuvant Stereotactic Radiotherapy (NaSRT)|Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
219279335|NCT06933199|RADIATION|Postoperative Stereotactic Radiotherapy (SRT)|Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
219279336|NCT06934447|BIOLOGICAL|anti-BCMA/CD70-CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
219279337|NCT06936774|OTHER|Intensified follow-up program|The study intervention will be an intensified follow-up program which consists of different measures. Patients will attend follow-up visits 1, 4, 7 and 13 months after ileostomy repositioning, at which LARS symptoms, quality of life as well as sexual and urinary function will be recorded using various questionnaires. In case of LARS symptoms patients will receive medical treatment with loperamide and metamucil as well as pelvic floor muscle training (including biofeedback and home exercises). Regarding pelvic floor muscle training we are planning nine sessions instructed by physiotherapy staff. In case of therapy-resistant LARS symptoms after 6 months sacral neurostimulation is offered to the patients with a focus on incontinence symptoms and desire for surgery or transanal irrigation in patients with a focus on voiding disorders. In case of urinary and sexual complaints patients are referred to our urology or gynaecology department for further diagnostic and treatment.
219279338|NCT06937983|PROCEDURE|Optimised DeEP-guided ablation|Optimised decrement evoked potential (DeEP) mapping in VT ablation.
219279339|NCT06937255|DIAGNOSTIC_TEST|computerized Dynamic Assessment|The DA tests (with a duration of about 30 minutes) can be administered by accessing the digital platform MuLiMi, individually with the experimenter or examiner. The tests are in game form and require children to learn the names of characters presented in the context of stories (preschool version) or to learn new codes for reading and writing (primary school version). In both cases, the new materials (names or codes) are repeatedly presented to the child until (s)he reaches an accuracy threshold. The number of repetitions needed to reach the threshold constitutes the main measure of the child's learning capacity, together with the number of errors committed during the various cycles.
219279340|NCT05899413|DEVICE|Transcutaneous vagal nerve stimulation|The intervention consists of neurostimulation device that is programmed to a stimulus intensity at 0.5mA with a stimulation frequency of 25 Hz at the outer auditory canal.
219279341|NCT06942832|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has 3 phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
219279342|NCT06942832|OTHER|Control|Participants maintain their routine activities.
219279343|NCT01555489|DRUG|Ascorbic Acid|3x per week
219279344|NCT06939777|BIOLOGICAL|SNA02-48|intramuscular injection
219279345|NCT06939777|BIOLOGICAL|Placebo|intramuscular injection
219279346|NCT06939777|BIOLOGICAL|HTIG|intramuscular injection
219279347|NCT06939777|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
219279348|NCT07136558|DRUG|ICP-B794|Intravenous administration once every 3 weeks
219279349|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
219279350|NCT02994771|DRUG|Lymfactin® [1 x 10E10 vp]|Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
219279351|NCT02994771|DRUG|Lymfactin® [1 x 10E11 vp]|Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
219279352|NCT03313947|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
219279353|NCT03313947|OTHER|Questionnaire|"The following 6 questions will be asked during the preoperative visit:~1. While sleeping, does your child snore more than half the time?~2. While sleeping, does your child always snore?~3. Have you ever seen your child stop breathing during the night?~4. Does your child occasionally wet the bed?~5. Did your child stop growing at a normal rate at any time since birth?~6. Is your child overweight"
219279354|NCT04944290|DRUG|Brinzolamide/brimonidine ophthalmic suspension|Test product
219279355|NCT04944290|DRUG|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
219279356|NCT04115657|OTHER|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
219279357|NCT04115657|OTHER|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
219279358|NCT04115657|OTHER|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
219279359|NCT04115657|OTHER|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
219279360|NCT04115657|OTHER|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
219279361|NCT04115657|OTHER|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
219279362|NCT04018274|DRUG|PF-06651600|50 mg by mouth (PO) once daily (QD)
219279363|NCT04018274|DRUG|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
219279364|NCT02097953|DRUG|Daptomycin|
219279365|NCT02097953|DRUG|Rifampin|
219279366|NCT01027052|OTHER|Hamburger meat patty with salt|hamburger meat cooked with salt
219279367|NCT01027052|OTHER|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
219279368|NCT03838731|DRUG|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
219279369|NCT03838731|DRUG|Placebo|Single subcutaneous (SC) dose of matching placebo
219279370|NCT01997905|DEVICE|AtriClip LAA Exclusion Device|
219279371|NCT02188680|OTHER|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
219279372|NCT03004001|DRUG|Alirocumab|150 mg biweekly
219279373|NCT03004001|DRUG|Alirocumab placebo|placebo
219279374|NCT03004001|DRUG|Atorvastatin|20 mg/day
219279375|NCT02775370|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
219279376|NCT03937518|DRUG|Strontium Ranelate|"Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min ("
219296337|NCT04083820|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
219279377|NCT03937518|OTHER|physiotherapy|"Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis"
219279378|NCT05817383|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
219279379|NCT05817383|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
219279380|NCT05483413|BEHAVIORAL|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
219279381|NCT00835744|DRUG|clomiphene citrate|ovulation induction
219279382|NCT00835744|DRUG|gonadotropins|ovulation induction
219279383|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
219279384|NCT02239874|DIETARY_SUPPLEMENT|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
219279385|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D placebo and fish oil placebo|placebo
219279386|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
219279387|NCT05723757|DIAGNOSTIC_TEST|blood sampling|Draw a 8.5mL blood sample for detection of SNPs of genomic origin
219279388|NCT02961439|BEHAVIORAL|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
219279389|NCT03637218|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
219279390|NCT03637218|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
219279391|NCT04394377|DRUG|Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Routine full anticoagulation strategy
219279392|NCT04394377|DRUG|Group 2: control group with enoxaparin 40mg/d|Usual standard of care and currently have no indication of full anticoagulation.
219279393|NCT00032175|DRUG|capecitabine|
219279394|NCT00032175|DRUG|gemcitabine hydrochloride|
219279395|NCT00770029|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
219279396|NCT00770029|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
219279397|NCT02535975|DRUG|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
219279398|NCT02535975|DRUG|Placebo|Tablets placebo PO three times a day for 24 weeks
219279399|NCT03688165|DEVICE|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
219279400|NCT03688165|OTHER|Traditional Over-ground Gait Training|Traditional treatment for gait training consists in any conventional technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids.
219279401|NCT00513188|BIOLOGICAL|denileukin diftitox|
219279402|NCT00513188|DRUG|cyclophosphamide|
219279403|NCT00513188|DRUG|cytarabine|
219279404|NCT00513188|DRUG|doxorubicin hydrochloride|
219279405|NCT00513188|DRUG|leucovorin calcium|
219279406|NCT00513188|DRUG|methotrexate|
219279407|NCT00513188|DRUG|prednisone|
219279408|NCT00513188|DRUG|vincristine sulfate|
219279409|NCT00513188|GENETIC|protein expression analysis|
219279410|NCT00513188|OTHER|flow cytometry|
219279411|NCT00513188|OTHER|laboratory biomarker analysis|
219279412|NCT03260478|PROCEDURE|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
219279413|NCT05162274|DRUG|Lazertinib(G001)|Current formulation
219279414|NCT05162274|DRUG|Lazertinib(G002)|New formulation
219279415|NCT04984005|BEHAVIORAL|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
219279416|NCT04984005|BEHAVIORAL|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
219279417|NCT04984005|BEHAVIORAL|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
219279418|NCT02523547|DRUG|Cavir|0.5mg/day
219279419|NCT02523547|DRUG|Baraclude|0.5mg/day
219279420|NCT03030313|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
219279421|NCT00743977|DRUG|Phenazopyridine HCl|100mg tablet in fasting state
219279422|NCT02901769|OTHER|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
219279423|NCT03653767|DEVICE|Adjustable Furniture|The intervention will include adjustable school furniture.
219279424|NCT03895047|OTHER|tomographic EEG Neurofeedback Training|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
219279425|NCT03056651|OTHER|treatment in day-care heart failure unit|
219279426|NCT06507423|DEVICE|Septicyte Lab Test pre operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
219279427|NCT06507423|DEVICE|Septicyte Lab Test post operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
219279428|NCT02876289|DRUG|Perampanel|
219279429|NCT03577847|DIAGNOSTIC_TEST|Rural CT scanning|Rural computer tomography for acute stroke
219279430|NCT00381927|BEHAVIORAL|Physician Counseling|
219279431|NCT04190576|DEVICE|Low Level Laser Therapy|Hydroxyapatite bone graft with collagen
219279432|NCT00003337|PROCEDURE|immunoscintigraphy|
219279433|NCT00003337|RADIATION|technetium Tc 99m epratuzumab|
219279434|NCT05889767|OTHER|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)"
219279435|NCT06316518|OTHER|mindfulness group|In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.
219279436|NCT03386825|DRUG|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
219279437|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS, a broadly neutralizing monoclonal antibody targeting the HIV-1 envelope CD4 binding site.
219279438|NCT03476759|PROCEDURE|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
219279439|NCT03476759|DRUG|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
219279440|NCT02480192|OTHER|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
219279441|NCT02671188|DRUG|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
219279442|NCT02671188|DRUG|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
219279443|NCT06050616|OTHER|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
219279444|NCT06050616|OTHER|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
219279445|NCT06050616|OTHER|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
219279446|NCT06050616|BIOLOGICAL|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
219279447|NCT06050616|OTHER|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
219279448|NCT05249608|DEVICE|A prospective, open-label, multicenter, single-arm clinical study to evaluate the safety and performance of the Gastric Bypass Stent System as a weight loss treatment for obesity|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 9 months.
219279449|NCT01199068|DRUG|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
219279450|NCT01199068|DRUG|Erlotinib|Erlotinib 150 mg once daily
219279451|NCT01294397|DRUG|Etanercept|Administered by subcutaneous injection once a week
219279452|NCT01294397|DRUG|Denosumab|Administered by subcutaneous injection
219279453|NCT04735848|DIETARY_SUPPLEMENT|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
219279454|NCT01815086|BIOLOGICAL|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
219279455|NCT00678301|BIOLOGICAL|GSK Biologicals' Synflorix™|3 IM doses.
219279456|NCT00678301|BIOLOGICAL|GSK Biologicals' Polio Sabin™|3 oral doses
219279457|NCT00678301|BIOLOGICAL|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
219279458|NCT01653600|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
219279459|NCT01653600|DEVICE|LifeStent|same to SMART STENT
219279460|NCT00966121|PROCEDURE|endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
219279461|NCT00966121|PROCEDURE|EBL+Propranolol|"* Start with 20 mg b.i.d~* Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
219279462|NCT01053767|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
219279463|NCT02725021|BEHAVIORAL|Education Against Tobacco school-based intervention by medical students|
219279464|NCT00387244|DEVICE|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
219279465|NCT03901716|DRUG|Sufentanil|Patients in Group S received sufentanil 0.1 mcg/kg.
219279466|NCT03901716|DRUG|Fentanyl|Patients in Group F received fentanyl 1 mcg/kg.
219279467|NCT03901716|DRUG|Remifentanil|Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
219279468|NCT03901716|DRUG|Midazolam|Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
219279469|NCT01128270|DRUG|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
219279470|NCT01128270|DRUG|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
219279471|NCT01128270|DRUG|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
219279472|NCT01128270|DRUG|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
219279473|NCT01269151|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
219279474|NCT05082753|DRUG|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
219279475|NCT05082753|DRUG|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
219279476|NCT03969368|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
219279477|NCT03969368|PROCEDURE|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
219279478|NCT04962737|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
219279479|NCT02212353|OTHER|Observational study, not interventional|
219279480|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
219279481|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
219279482|NCT04258332|DIETARY_SUPPLEMENT|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
219279483|NCT04258332|DIETARY_SUPPLEMENT|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
219279484|NCT04419298|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to acute CO poisoned patients with elevated TnI \[during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)\]~2. TTE be taken to acute CO poisoned patients with elevated TnI \[At the ED and during admission (within 7 days after CO exposure)\]"
219279485|NCT02687035|DEVICE|SAPIEN S3 valve|Transcatheter aortic valve replacement
219279486|NCT03254043|BEHAVIORAL|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
219279487|NCT01539369|OTHER|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
219279488|NCT02032082|OTHER|Carbone monoxide|
219279489|NCT03400111|RADIATION|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
219279490|NCT03400111|DRUG|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
219279491|NCT02160730|DRUG|R-roscovitine|See Arm Description
219279492|NCT04076943|DRUG|Roxadustat|Roxadustat will be administered per schedule specified in the arm description.
219279493|NCT01312259|OTHER|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
219279494|NCT03596762|DRUG|Elinzanetant (BAY3427080)|BAY3427080 capsules
219279495|NCT03596762|DRUG|Placebo|Placebo capsules
219279496|NCT06314100|DEVICE|Tobacco heating systems|The study aims to explore the effect of tobacco heating system consumption on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
219279497|NCT06314100|BEHAVIORAL|cigarette smoking|The study aims to explore the effect of cigarette smoking on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
219279498|NCT06314100|BEHAVIORAL|non smoking|The non smoking group of subjects serve as control for the other two groups
219279499|NCT04483180|OTHER|Comparison of sweetener blends in liquid form (cross-over study)|The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
219279500|NCT02231073|BEHAVIORAL|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
219279501|NCT03099252|OTHER|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
219279502|NCT00594698|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
219279503|NCT06022445|OTHER|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
219279504|NCT01031628|DRUG|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
219279505|NCT01031628|DRUG|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
219279506|NCT01031628|DRUG|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
219279507|NCT06076317|BEHAVIORAL|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
219279508|NCT06273813|DRUG|Ketorolac Tromethamine 15 MG/ML|Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
219279509|NCT06273813|DRUG|Ketorolac Tromethamine|Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
219279510|NCT02430753|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
219279511|NCT02430753|DEVICE|NanoKnife|
219279512|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
219279513|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
219279514|NCT04771364|OTHER|ASAP care's protocol|Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
219279515|NCT01857726|DRUG|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
219279516|NCT01857726|DRUG|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
219279517|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
219279518|NCT04374786|DEVICE|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
219279519|NCT02593123|DRUG|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
219279520|NCT02593123|BIOLOGICAL|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
219279521|NCT02593123|BIOLOGICAL|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
219279522|NCT01777165|DRUG|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
219279523|NCT01777165|DRUG|Placebo|Placebo infusion
219279524|NCT02650713|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
219279525|NCT02650713|DRUG|RO6958688|"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
219279526|NCT02780518|DEVICE|Airvo|Applying high flow nasal oxygen
219279527|NCT05129332|OTHER|Vaginal Moisturizer|Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
219279528|NCT05129332|DEVICE|Vaginal Dilator|Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
219279529|NCT03428906|DRUG|Oxytocin|intranasally administrated
219279530|NCT03428906|DRUG|Placebo|intranasally administrated
219279531|NCT06515938|BIOLOGICAL|20μg Engerix-B hepatitis B vaccine|
219279532|NCT06515938|BIOLOGICAL|20μg Kangtai hepatitis B vaccine|
219279533|NCT06515938|BIOLOGICAL|60μg Kangtai hepatitis B vaccine|
219279534|NCT06515938|BIOLOGICAL|20μg CHO|
219279535|NCT04967898|OTHER|bowen technique|Bowen technique is a soft tissue mobilization technique. This medical care involves short mild rolling moves over the muscles, nerves, ligaments, and tendons of flesh utilizing the hands, fingers and thumb. Sequence of receiving bilateral rolling moves over segments of the erector spinae from the lumber toward cervical spine, latissimus dorsi, the gluteal, the hamstring muscles proximally and distally, tensor facia Lata and a medial hip striated muscle move.
219279536|NCT04967898|OTHER|sustained stretching|static stretching is one of the most common and safest technique used for hamstring tightness. A static stretch is performed by inserting muscles at their greatest attainable length and holding that position for an amount of your time.
219279537|NCT00532207|DRUG|teriparatide|subcutaneous 20 micrograms
219279538|NCT02467439|OTHER|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
219279539|NCT00895895|DRUG|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
219279540|NCT00895895|DRUG|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
219279541|NCT00895895|DRUG|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
219279542|NCT00895895|DRUG|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
219279543|NCT00895895|DRUG|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
219279544|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D2|Daily enteral dose of 100IU/kg
219279545|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D3|Daily enteral dose of 100IU/kg
219279546|NCT01261000|DRUG|Pegvisomant|Pegvisomant used as indicated
219279547|NCT00560144|DRUG|RG1507|3mg/kg iv weekly
219279548|NCT00560144|DRUG|RG1507|9mg/kg iv weekly
219279549|NCT00560144|DRUG|RG1507|Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
219279550|NCT03338439|DEVICE|CSII|This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
219279551|NCT03193983|PROCEDURE|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
219279552|NCT03193983|PROCEDURE|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
219279553|NCT00855647|PROCEDURE|Hypo-fractionated Radiotherapy|
219279554|NCT06520150|PROCEDURE|Regional anaesthetic combined fascial plane block|Prior to the procedure, the anaesthetists will receive an envelope from a person not related to the project (a hospital administrative staff member). This envelope will contain a randomly indicated method of anaesthesia based on simple randomisation. This will determine the type of regional block used during the procedure. It is important to note that the patient will not know which study group they have been classified in. Furthermore, the operator performing the procedure will not be informed of the type of anaesthesia performed. This is to ensure double-blinding. In order to ensure the highest standards of objectivity, the operator performing the procedure will not be informed about the type of block performed. This will allow us to assess the extent and quality of anaesthesia after the procedure, We will use a proprietary scale of subjective operator comfort scale.
219279555|NCT06520150|DRUG|Ropivacaine 0.125% Injectable Solution +Lignocaine 0,25% Injectable Solution|administration under ultrasound guidance of a mixture of 2 local anaesthetics in a fixed total volume
219279556|NCT06153992|DEVICE|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
219279557|NCT06153992|DEVICE|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
219279558|NCT06153992|OTHER|without test training|Treatment was performed without using any isokinetic muscle strength test training system
219279559|NCT03101202|DEVICE|SSD tube|The SSD tube allows the suction of subglottic secretions that collect above the cuff of the endotracheal tube
219296338|NCT06239389|DRUG|Thalidomide 100mg|Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
219279560|NCT00445835|OTHER|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
219279561|NCT00445835|OTHER|Conservative arm|Conservative medical approach
219279562|NCT04417205|OTHER|Carbohydrate Rich Breakfast|Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
219279563|NCT04417205|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
219279564|NCT02944162|BIOLOGICAL|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
219279565|NCT02090010|PROCEDURE|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
219279566|NCT02090010|PROCEDURE|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
219279567|NCT00708318|DRUG|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
219279568|NCT05631704|DRUG|VH4524184|VH4524184 will be administered.
219279569|NCT05631704|DRUG|Midazolam|Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
219279570|NCT05631704|DRUG|Placebo|Placebo will be administered.
219279571|NCT02744248|DRUG|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
219279572|NCT02744248|DRUG|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
219279573|NCT00504777|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
219279574|NCT00504777|DRUG|Methotrexate|10-25mg/week po or parenteral
219279575|NCT00990444|DRUG|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
219279576|NCT04413305|OTHER|screen of CRKP and infection control measure|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
219279577|NCT04366505|BEHAVIORAL|Treatment as usual (TAU) and neurofeedback (NFB)|This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.
219279578|NCT04366505|BEHAVIORAL|mindfulness-based relapse prevention (MBRP) and NFB|This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.
219279579|NCT04366505|BEHAVIORAL|TAU and sham NFB|This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
219296339|NCT06239389|DRUG|Hydroxyurea|Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
219177954|NCT06257576|DRUG|Tamsulosin|"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."
219279580|NCT04366505|BEHAVIORAL|MBT and sham NFB|This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
219279581|NCT05517226|COMBINATION_PRODUCT|Cotadutide|Participants will receive cotadutide subcutaneously.
219279582|NCT05492851|DRUG|Zilretta|Intra-articular injection to treat knee osteoarthritis
219279583|NCT05492851|DRUG|Synvisc-One 48 MG in 6 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
219279584|NCT05492851|DRUG|Monovisc 88 MG Per 4 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
219279585|NCT03240653|OTHER|Stratified response to Enzyme Therapy|Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
219279586|NCT01169012|DRUG|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
219279587|NCT05842642|OTHER|Cervical|6 weeks of treatment
219279588|NCT05842642|OTHER|Oculomotor|6 weeks of treatment
219279589|NCT00668265|DRUG|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
219279590|NCT01699113|DRUG|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
219279591|NCT01699113|DRUG|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
219279592|NCT00636935|DRUG|Antibiotics only|Antibiotic only for treatment for mild (pO2 \> 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
219279593|NCT00636935|DRUG|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
219279594|NCT00636935|DRUG|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.
219279595|NCT05260177|DEVICE|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
219279596|NCT05260177|DEVICE|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
219279597|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
219279598|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
219279599|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
219279600|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
219279601|NCT05620277|DIAGNOSTIC_TEST|Digital Camera|Tooth color changes of 30 patients will be evaluated using a Digital Camera
219279602|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
219279603|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
219279604|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
219279605|NCT05620277|DIAGNOSTIC_TEST|Rayplicker|Tooth color changes of 30 patients will be evaluated using Rayplicker
219279606|NCT05620277|DIAGNOSTIC_TEST|Rayplicker with gray reference card|Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
219279607|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade|Tooth color changes of 30 patients will be evaluated using Vita Easyshade
219279608|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade with gray reference card|Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
219279609|NCT03332043|DEVICE|HIRREM|HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
219279610|NCT03332043|OTHER|Ambient Nature Sounds|Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
219279611|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg|will be administered 1 hour before arrival to operating room
219279612|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg|will be administered 1 hour before arrival to operating room
219279613|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg|will be administered 1 hour before arrival to operating room
219279614|NCT05223010|DRUG|Sevoflurane|for anaesthesia induction 3-8 MAC
219279615|NCT05772182|DEVICE|ACORYS MAPPING SYSTEM|"Diagnostic Test: ECG-Imaging~Diagnostic Test: Standard 12-lead ECG~Diagnostic Test: Endocardial mapping and/or pacing"
219279616|NCT01374568|DRUG|sitagliptin|sitagliptin 100mg daily
219279617|NCT01374568|OTHER|Placebo|1 pill daily
219279618|NCT03622970|DEVICE|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
219177955|NCT06257576|OTHER|Control Group|A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
219177956|NCT05700474|BEHAVIORAL|Comprehensive outpatient behavioral health care|Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
219177957|NCT02924818|OTHER|Clinical assessment|
219177958|NCT02924818|BEHAVIORAL|questionnaires|
219177959|NCT02924818|OTHER|pulmonary function test|
219177960|NCT02924818|BIOLOGICAL|blood test|
219177961|NCT02924818|BIOLOGICAL|microbiology|
219177962|NCT02924818|BIOLOGICAL|histology|
219177963|NCT02924818|OTHER|imaging|
219177964|NCT04147832|OTHER|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
219177965|NCT05087693|DRUG|Salbutamol|Inhaling 200ug of salbutamol
219279619|NCT03622970|BEHAVIORAL|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
219279620|NCT05497544|BEHAVIORAL|Exercise recommendation group|A verbal exercise recommendation will be provided. This recommendation will be reported also in the hospital resignation letter.
219279621|NCT05497544|BEHAVIORAL|Exercise recommendation plus guidebook group|This group will receive the exercise (verbal and written) recommendation. Additionally, the oncologist hand the patient a guidebook about exercise, specifically designed for cancer patients.
219279622|NCT01912404|DRUG|IDN-6556|25 mg BID for 28 days
219279623|NCT01912404|DRUG|Placebo|Placebo controlled
219279624|NCT03462862|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
219279625|NCT03462862|OTHER|Bre-Flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
219279626|NCT00006375|DRUG|LY293111|
219279627|NCT01138618|DEVICE|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
219279628|NCT01138618|DEVICE|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
219279629|NCT05259423|OTHER|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
219279630|NCT05259423|OTHER|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
219279631|NCT00455806|DRUG|esomeprazole|
219279632|NCT00455806|DRUG|moxifloxacin|
219279633|NCT00455806|DRUG|amoxicillin|
219279634|NCT04910139|DEVICE|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
219279635|NCT03804177|PROCEDURE|immediate implant placement with melatonin hyaluronic acid vit C|immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
219279636|NCT03804177|PROCEDURE|immediate implant placement without melatonin hyaluronic acid vit C|immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
219279637|NCT00642408|DIETARY_SUPPLEMENT|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
219279638|NCT00642408|DIETARY_SUPPLEMENT|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
219279639|NCT04513067|BIOLOGICAL|YQ23|YQ23 as a single agent will be given in Stage 1.
219279640|NCT04513067|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be given in combination with YQ23 in Stage 2
219279641|NCT04789031|DIETARY_SUPPLEMENT|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
219279642|NCT00820170|DRUG|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
219279643|NCT02663531|DEVICE|DVA|
219279644|NCT02663531|DEVICE|FDOCT|
219279645|NCT02663531|DEVICE|Pattern ERG|
219279646|NCT02663531|DEVICE|Optical Coherence Tomography|
219279647|NCT04815980|OTHER|Exercise|Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
219279648|NCT06479369|BEHAVIORAL|Teaching training program|The investigators will try to carry out a training based on motivational strategies for physical education teachers of the experimental group, with the aim of improving their motivational teaching style during physical education classes, and finally, to obtain benefits in their students, such as a greater adherence to physical activity.
219279649|NCT00691795|DRUG|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
219279650|NCT02531555|DEVICE|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
219279651|NCT02531555|DEVICE|Gracey curettes|
219279652|NCT01161238|OTHER|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
219279653|NCT03553108|DRUG|Olaparib Treatment A|Olaparib Tablet 25 mg
219279654|NCT03553108|DRUG|Olaparib Treatment B|Olaparib Tablet 100 mg
219279655|NCT03553108|DRUG|Olaparib Treatment C|Olaparib Tablet 150 mg
219279656|NCT03553108|DRUG|Olaparib Treatment D|Olaparib Tablet 250 mg
219279657|NCT00208559|DRUG|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
219279658|NCT05153876|OTHER|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
219296340|NCT06487429|DRUG|Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab|"Short range radiotherapy, PCTV (clinical planned target area) DT 25Gy/5F, once a day, for a total of 5 days, continuous irradiation, and IMRT (intensity modulated radiation therapy) technology; After a week of rest, radiotherapy and chemotherapy combined with immunotherapy will be performed~* Disitamab Vedotin: 2.5 mg/kg, intravenous infusion, d1, Q3W;~* Sintilimab: 200mg, iv;~* S-1: 40 mg/dose, oral, bid, d1-14; Q3W Whether to undergo adjuvant therapy after surgery is determined by the researcher"
219296341|NCT04229264|DRUG|Apixaban|Oral Apixaban 2.5 mg twice daily for one year
219296342|NCT04229264|DRUG|ASA|Acetil Salicilic Acid 100mg once daily for one year
219296343|NCT04229264|DRUG|Clopidogrel 75mg|Clopidogrel 75mg once daily for 3 months
219279659|NCT03995316|BEHAVIORAL|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
219279660|NCT03995316|BEHAVIORAL|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
219279661|NCT00072501|PROCEDURE|breast imaging study|
219279662|NCT00072501|PROCEDURE|comparison of screening methods|
219279663|NCT00072501|PROCEDURE|magnetic resonance imaging|
219279664|NCT00072501|PROCEDURE|radiomammography|
219279665|NCT00072501|PROCEDURE|ultrasound imaging|
219279666|NCT03202017|PROCEDURE|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
219279667|NCT03202017|PROCEDURE|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
219279668|NCT02765334|DEVICE|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
219279669|NCT02570919|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
219279670|NCT02570919|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
219279671|NCT03219047|OTHER|Best Practice|Receive standard of care
219279672|NCT03219047|DRUG|Ibrutinib|Given at standard dose and schedule
219279673|NCT03219047|OTHER|Patient Derived Xenograft|Xenograft developed
219279674|NCT03219047|OTHER|Personalized Medicine|Receive treatment based on the results of the PDX models
219279675|NCT04372862|PROCEDURE|Plane block|Two different plane blocks to control post-mastectomy pain
219279676|NCT03340831|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
219279677|NCT01361594|OTHER|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
219279678|NCT01361594|OTHER|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
219279679|NCT01516619|DRUG|Romiplostim|"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."
219279680|NCT01425619|BIOLOGICAL|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
219279681|NCT01425619|DRUG|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
219279682|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
219279683|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
219279684|NCT01670253|BEHAVIORAL|Group 1|"* 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
219279685|NCT03697551|DRUG|Satoreotide trizoxetan|Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
219279686|NCT06165757|BEHAVIORAL|noise stimulation|Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
219279687|NCT01987362|DRUG|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
219279688|NCT02169570|DIETARY_SUPPLEMENT|Vitamin D|
219279689|NCT02169570|DIETARY_SUPPLEMENT|Calcium|
219279690|NCT02169570|DIETARY_SUPPLEMENT|Placebo Vit D|
219279691|NCT02169570|DIETARY_SUPPLEMENT|Placebo Calcium|
219279692|NCT02200653|DRUG|High dose of MICARDIS®, once daily|
219279693|NCT02200653|DRUG|Low dose of MICARDIS®, once daily|
219279694|NCT02200653|DRUG|Low dose of COZAAR® / LORZAAR®, once daily|
219279695|NCT02200653|DRUG|High dose of COZAAR® / LORZAAR®, once daily|
219279696|NCT02200653|DRUG|Placebo|
219279697|NCT03532659|OTHER|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
219279698|NCT04654572|DIAGNOSTIC_TEST|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
219279699|NCT02985840|DRUG|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
219279700|NCT02985840|DRUG|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
219279701|NCT03985696|OTHER|blood sample|1 blood volume (5-7 ml EDTA)
219279702|NCT00780559|BEHAVIORAL|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
219279703|NCT00780559|BEHAVIORAL|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
219279704|NCT03735797|DIAGNOSTIC_TEST|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
219279705|NCT02871505|DRUG|Benzathine Penicillin G|
219279706|NCT01546532|DRUG|RLX030|RLX030 as intravenous infusion for 24 hours.
219279707|NCT01546532|DRUG|Placebo|Intravenous infusion of Placebo over 24 hours
219279708|NCT01495572|DRUG|Fludarabine|25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)
219279709|NCT01495572|DRUG|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
219279710|NCT01495572|DRUG|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
219279711|NCT01495572|DRUG|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
219279712|NCT04109781|PROCEDURE|Microscope assisted discectomy|Microdiscectomy
219279713|NCT00541177|DRUG|atropine|0.25% atropine
219279714|NCT00541177|DRUG|tropicamide|0.5% tropicamide
219279715|NCT00571467|DRUG|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg"
219279716|NCT04462289|BEHAVIORAL|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
219279717|NCT00002277|DRUG|Fluconazole|
219279718|NCT00002277|DRUG|Amphotericin B|
219279719|NCT02104778|DRUG|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
219279720|NCT02104778|DRUG|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
219279721|NCT04577053|DEVICE|Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device|Manufactured by QX World Ltd. in Budapest, Hungary
219279722|NCT03793036|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
219279723|NCT01518153|DRUG|Fludarabine|40 mg/m\^2 by vein on Day -6 to -3.
219279724|NCT01518153|DRUG|Melphalan|140 mg/m\^2 by vein on Day -2.
219279725|NCT01518153|DRUG|Alemtuzumab|50 mg by vein on Day -1.
219279726|NCT01518153|PROCEDURE|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
219279727|NCT01518153|DRUG|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
219279728|NCT01518153|DRUG|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
219279729|NCT01518153|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
219279730|NCT01518153|PROCEDURE|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64.
219279731|NCT01518153|PROCEDURE|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64.
219279732|NCT03112460|DEVICE|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
219279733|NCT02421575|DRUG|Hydroxychloroquine|Given PO
219279734|NCT02421575|OTHER|Laboratory Biomarker Analysis|Correlative studies
219296344|NCT02726100|BEHAVIORAL|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
219279735|NCT05873829|OTHER|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
219279736|NCT03329729|OTHER|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
219279737|NCT01754753|OTHER|Telephone Friendship groups|
219279738|NCT06125158|PROCEDURE|Conventional ankle training|The program included ankle elastic band resistance training and balance training, in which the elastic band resistance training required subjects to complete resistance training in ankle plantarflexion, dorsiflexion, inversion and eversion directions with the help of elastic bands; and the balance training required subjects to complete the movements of standing with eyes open, standing with eyes closed, and throwing and catching the ball on flat ground and BOSU ball.
219279739|NCT06125158|PROCEDURE|Hip strength training|Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
219279740|NCT06125158|PROCEDURE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
219279741|NCT04526730|DRUG|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3
219279742|NCT04526730|DRUG|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
219279743|NCT04526730|DEVICE|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
219279744|NCT06240221|DEVICE|Elevation Spine Saber-C System|Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
219279745|NCT00899977|DRUG|Placebo|Matching placebo
219279746|NCT00899977|DRUG|TC-5214|
219279747|NCT04539483|DRUG|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
219279748|NCT04539483|DRUG|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
219279749|NCT04539483|BEHAVIORAL|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
219279750|NCT04539483|BEHAVIORAL|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
219279751|NCT04539483|PROCEDURE|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
219279752|NCT04539483|PROCEDURE|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
219279753|NCT02888236|DRUG|LEO 32731|
219279754|NCT02888236|DRUG|LEO 32731 Placebo|
219279755|NCT00705601|PROCEDURE|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
219279756|NCT00047255|BIOLOGICAL|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
219279757|NCT00047255|DRUG|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
219296345|NCT00349934|BIOLOGICAL|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
219279758|NCT00047255|DRUG|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
219279759|NCT00047255|BIOLOGICAL|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
219279760|NCT00047255|DRUG|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
219279761|NCT03751670|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation programmes will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training, education and psychosocial support.
219279762|NCT03751670|DRUG|Daily medical treatment|Patients will be treated with daily medication prescribed by the physician.
219279763|NCT05992857|PROCEDURE|Pancreaticoduodenectomy without retromesenteric omental flap|Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.
219279764|NCT05992857|PROCEDURE|Pancreaticoduodenectomy with retromesenteric omental flap|All exposed peripancratic arteries should be covered with a retromesentric omental flap
219279765|NCT02265666|DRUG|BIIL 284 BS Tablet FF|
219279766|NCT02265666|DRUG|BIIL 284 BS tablet C|
219279767|NCT02265666|OTHER|standard breakfast|
219279768|NCT00856245|DRUG|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
219279769|NCT01701336|BIOLOGICAL|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
219279770|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + OTf|OTf (apo ovotransferrin) + FeSO4
219279771|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + Lf|Lf (lactoferrin) + FeSO4
219279772|NCT05233709|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate
219279773|NCT01816347|PROCEDURE|Routine PCI|
219279774|NCT00624247|OTHER|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
219279775|NCT06265519|PROCEDURE|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH
219279776|NCT01046006|DRUG|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
219279777|NCT01250509|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
219279778|NCT01766713|DRUG|Ezetimibe|10mg daily oral dose of ezetimibe
219279779|NCT02383251|DRUG|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
219279780|NCT02383251|DRUG|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
219279781|NCT03044977|DRUG|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
219279782|NCT03044977|DRUG|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
219279783|NCT02205034|DRUG|oxytocin|Intranasal administration
219279784|NCT05031949|COMBINATION_PRODUCT|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
219279785|NCT04540237|DIAGNOSTIC_TEST|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
219279786|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
219177966|NCT05087693|DRUG|Placebo medication|Inhaling placebo medication
219177967|NCT05087693|OTHER|Ozone|Breathing 170ppb ozone
219177968|NCT05087693|OTHER|Filtered Air|Breathing filtered air
219177969|NCT05087693|OTHER|Exercise|Cycling at 60% of VO2max on a cycle ergometer
219177970|NCT04645550|DRUG|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
219177971|NCT04645550|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
219177972|NCT04645550|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
219177973|NCT04645550|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
219177974|NCT04645550|DRUG|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
219177975|NCT05424237|BEHAVIORAL|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
219177976|NCT05290792|BIOLOGICAL|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
219177977|NCT05931614|BEHAVIORAL|Free fluid intake|Patients are recommended a free fluid intake
219177978|NCT04409600|BEHAVIORAL|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
219177979|NCT04409600|BEHAVIORAL|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
219177980|NCT04409600|DRUG|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
219177981|NCT04409600|DRUG|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
219177982|NCT00881621|DRUG|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
219177983|NCT03158714|BEHAVIORAL|Couples Connecting Mindfully|
219177984|NCT03158714|BEHAVIORAL|ELEVATE|
219177985|NCT05921747|OTHER|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
219177986|NCT05921747|DEVICE|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
219177987|NCT02118272|DEVICE|Physica KR|
219177988|NCT04574024|DRUG|NBT-NM108|MS Patients received NBT-NM108 at 60 g/day.
219177989|NCT03936322|DEVICE|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
219177990|NCT05474404|DIAGNOSTIC_TEST|Cervical smear test|collection of cervical cells using spatula
219177991|NCT06439004|OTHER|Quantitative Sensory Testing|Performing QST on the dominant hand, right forearm, right flank and lower back.
219177992|NCT05760885|BEHAVIORAL|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
219177993|NCT05760885|BEHAVIORAL|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
219177994|NCT02672917|DRUG|MVT-5873|intravenous infusion (IV)
219177995|NCT02672917|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|IV
219177996|NCT02672917|DRUG|gemcitabine + nab-paclitaxel|IV
219177997|NCT04979104|PROCEDURE|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
219177998|NCT06042569|DRUG|Cyclophosphamide|Given IV
219177999|NCT06042569|DRUG|Docetaxel|Given IV
219279787|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
219296346|NCT04245943|BEHAVIORAL|Exercise training|18 weeks supervised strength and aerobic exercise training.
219178000|NCT06042569|OTHER|Medical Chart Review|Ancillary studies
219178001|NCT06042569|OTHER|Questionnaire Administration|Ancillary studies
219178002|NCT06799611|DRUG|CM336 Injection|subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
219178003|NCT06293079|OTHER|Exercise Program|Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
219178004|NCT04447911|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
219178005|NCT04447911|DRUG|Placebo|Placebo per os once daily for 30 days
219178006|NCT05275231|BEHAVIORAL|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
219178007|NCT05994157|DRUG|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
219178008|NCT05856786|DIAGNOSTIC_TEST|Optical coherence tomography|Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
219178009|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
219178010|NCT01504815|DRUG|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
219178011|NCT01504815|RADIATION|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
219178012|NCT01504815|RADIATION|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
219178013|NCT06771570|BIOLOGICAL|Silver Nanoparticles Irrigation|to evaluate the postoperative pain, antimicrobial efficiency, and periapical tissue healing following the use of silver nano particles solution as a final irrigation, using either conventional needle irrigation or XP-Endo Finisher activation, in necrotic mandibular molar teeth.
219178014|NCT05434078|DEVICE|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
219178015|NCT05206630|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
219178016|NCT05846594|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
219178017|NCT05846594|DIAGNOSTIC_TEST|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
219178018|NCT01160211|DRUG|Lapatinib|1000 mg by mouth once a day
219178019|NCT01160211|DRUG|Trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks)
219178020|NCT01160211|DRUG|Aromatase Inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
219178021|NCT01160211|DRUG|Lapatinib|1500 mg by mouth once daily
219178022|NCT06161818|DRUG|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
219178023|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit|Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
219178024|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit + Food Care|Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
219279788|NCT05424146|DIETARY_SUPPLEMENT|Prebiotic Bar +CPT|Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
219279789|NCT05424146|BEHAVIORAL|Non-Prebiotic Bar +CPT|Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
219279790|NCT01843725|DRUG|capecitabine|escalation dose of capecitabine continuously
219279791|NCT01843725|DRUG|aflibercept|Intravenous 6mg/kg every 3 weeks
219279792|NCT01843725|DRUG|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
219279793|NCT01377246|DRUG|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
219279794|NCT01377246|OTHER|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
219279795|NCT04814498|DRUG|Geneva Cocktail|Fixed sequence use of drug cocktail
219279796|NCT04814498|DRUG|BLD-0409|Fixed sequence use of active product
219279797|NCT03168542|DEVICE|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
219279798|NCT04535245|DIAGNOSTIC_TEST|LCI testing|all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
219279799|NCT01064700|DEVICE|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
219279800|NCT01064700|DEVICE|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
219279801|NCT05338697|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
219279802|NCT01722370|DRUG|Oxygen|
219279803|NCT01722370|DRUG|Medical air equivalent|
219279804|NCT00900263|GENETIC|cytogenetic analysis|
219279805|NCT00900263|GENETIC|microarray analysis|
219279806|NCT00900263|OTHER|biologic sample preservation procedure|
219279807|NCT00900263|OTHER|laboratory biomarker analysis|
219279808|NCT05136053|DRUG|Lu AG22515|sterile solution for infusion
219279809|NCT05136053|DRUG|Placebo|sterile solution for infusion
219279810|NCT05136053|DRUG|Immune System Activator|sterile powder for injection
219279811|NCT04175314|OTHER|Clinical examination of gingival tissues|Measure of the periodontal recession
219279812|NCT06098053|OTHER|muscle energy technique|Muscle energy technique is used at a rate of three sessions per week for four and half weeks
219279813|NCT06098053|OTHER|Muscel energy technique along with interferential therapy|Muscle energy technique along with interferential therapy is used at a rate of three sessions per week for four and half weeks
219279814|NCT02448329|DRUG|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
219279815|NCT02448329|DRUG|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
219279816|NCT05231525|DEVICE|WiTOF|Data collection on the WiTOF monitor
219279817|NCT05231525|DEVICE|TOFscan|Data collection on the TOFscan monitor
219279818|NCT02071277|OTHER|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
219279819|NCT04797234|OTHER|Control|There will be no intervention to the control group.
219279820|NCT04797234|OTHER|Experiment|The experimental group will be trained for 6 weeks.
219279821|NCT00847522|DRUG|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
219279822|NCT00438841|DRUG|bortezomib|
219279823|NCT00438841|DRUG|cyclophosphamide|
219279824|NCT00438841|DRUG|dexamethasone|
219279825|NCT00438841|DRUG|thalidomide|
219279826|NCT05131802|DEVICE|upper GIT endescopy|Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
219279827|NCT00450229|DRUG|diindolylmethane|Given PO
219279828|NCT00450229|DRUG|placebo|Given PO
219279829|NCT00450229|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219279830|NCT00450229|OTHER|laboratory biomarker analysis|Correlative studies
219279831|NCT00450229|OTHER|pharmacological study|Correlative studies
219279832|NCT00388440|BIOLOGICAL|MMR vaccine (Priorix)|
219279833|NCT03745898|DRUG|Oxygen|Active nocturnal oxygen concentrator
219279834|NCT03745898|OTHER|Room Air|Sham nocturnal oxygen concentrator (room air)
219279835|NCT00839956|DRUG|Bortezomib|Given IV
219279836|NCT00839956|DRUG|Vorinostat|Given PO
219296347|NCT03313375|OTHER|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
219279837|NCT02807883|DRUG|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
219279838|NCT02807883|PROCEDURE|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
219279839|NCT03656250|DIAGNOSTIC_TEST|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
219279840|NCT02091115|DIETARY_SUPPLEMENT|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
219279841|NCT02091115|DIETARY_SUPPLEMENT|Dairy drink|
219279842|NCT03404544|DRUG|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
219279843|NCT03404544|DRUG|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
219279844|NCT06144619|GENETIC|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
219279845|NCT00219011|DRUG|aliskiren|
219279846|NCT00003485|DRUG|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219279847|NCT01521247|OTHER|Asthma Transition Program|Asthma Education.
219279848|NCT04494204|COMBINATION_PRODUCT|Immunofree tablets and Reginmune capsule|2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
219279849|NCT04835792|OTHER|Stool and blood collection|One-time stool and blood collection
219279850|NCT02623660|DEVICE|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
219279851|NCT02623660|OTHER|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
219279852|NCT02623660|DEVICE|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
219279853|NCT00011934|BIOLOGICAL|recombinant interferon alfa|
219279854|NCT00011934|BIOLOGICAL|sargramostim|
219279855|NCT00011934|PROCEDURE|autologous bone marrow transplantation|
219279856|NCT00534170|DIETARY_SUPPLEMENT|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
219279857|NCT03652441|DRUG|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
219279858|NCT04236687|DEVICE|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
219279859|NCT04236687|PROCEDURE|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
219279860|NCT00022737|BIOLOGICAL|filgrastim|Given SC
219279861|NCT00022737|DRUG|asparaginase|Given IM
219279862|NCT00022737|DRUG|cyclophosphamide|Given IV
219279863|NCT00022737|DRUG|cyclosporine|Given IV
219279864|NCT00022737|DRUG|cytarabine|Given IT and IV
219279865|NCT00022737|DRUG|daunorubicin hydrochloride|Given IV
219279866|NCT00022737|DRUG|dexamethasone|Given orally
219279867|NCT00022737|DRUG|etoposide|Given IV
219279868|NCT00022737|DRUG|ifosfamide|Given IV
219279869|NCT00022737|DRUG|imatinib mesylate|Given orally
219279870|NCT00022737|DRUG|leucovorin calcium|Given IV or orally
219279871|NCT00022737|DRUG|mercaptopurine tablet|Given orally
219279872|NCT00022737|DRUG|methotrexate|Given IT, IV, and orally
219279873|NCT00022737|DRUG|pegaspargase|Given IM
219279874|NCT00022737|DRUG|vincristine sulfate|Given IV
219279875|NCT00022737|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
219279876|NCT00022737|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
219279877|NCT00022737|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
219279878|NCT00022737|RADIATION|radiation therapy|Undergo radiation therapy
219279879|NCT04041037|DEVICE|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
219279880|NCT04148781|DRUG|Fampridine SR|Fampridine-SR 10 mg twice daily for 8 weeks
219279881|NCT02130323|DRUG|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
219279882|NCT02130323|PROCEDURE|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
219279883|NCT04693039|DRUG|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
219279884|NCT04693039|DRUG|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
219279885|NCT01399918|DRUG|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
219279886|NCT01462006|DRUG|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
219279887|NCT01462006|OTHER|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
219279888|NCT01871688|BEHAVIORAL|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
219279889|NCT06237088|OTHER|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
219279890|NCT06237088|OTHER|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
219279891|NCT06022341|OTHER|Multiomic characterization|Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
219279892|NCT06022341|OTHER|In vitro drug screening|The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
219279893|NCT03197766|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
219279894|NCT03197766|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
219279895|NCT05700968|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
219279896|NCT00021138|BEHAVIORAL|smoking cessation intervention|
219279897|NCT00021138|DRUG|nicotine|
219279898|NCT03911934|OTHER|Polypharmacy intervention|A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
219279899|NCT03911934|OTHER|Usual care|Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
219279900|NCT00672737|DRUG|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
219279901|NCT00672737|PROCEDURE|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
219279902|NCT00672737|DEVICE|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
219279903|NCT00672737|PROCEDURE|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
219279904|NCT00280722|BEHAVIORAL|patient information leaflet|
219279905|NCT03363139|DRUG|Tirosin Kinase Inhibitors|Patients that received Tyrosin Kinase inhibitors and progressed
219279906|NCT02274155|DRUG|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
219279907|NCT02274155|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
219279908|NCT04531020|DIAGNOSTIC_TEST|PAED measurement|The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
219279909|NCT00972322|DRUG|MK-8245|MK-8245 50 mg twice daily for 28 days
219279910|NCT00972322|DRUG|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
219279911|NCT02625064|OTHER|Blood samples collection before treatment|
219279912|NCT02625064|OTHER|Blood samples collection after treatment|
219279913|NCT02625064|OTHER|laboratory biomarker proteomic analysis|
219279914|NCT02334579|RADIATION|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
219279915|NCT02908763|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
219279916|NCT02002377|DRUG|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
219279917|NCT03991208|DRUG|Malarone|Malarone
219279918|NCT03439813|BEHAVIORAL|TASK-CBT|.Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
219279919|NCT03439813|BEHAVIORAL|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
219279920|NCT02826382|DRUG|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
219279921|NCT06503081|PROCEDURE|Colonoscopy|Colonoscopy with video recording and biopsy collection
219279922|NCT05795803|OTHER|Forced isolation context|Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
219279923|NCT02614053|DEVICE|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI \& spHB
219279924|NCT04033302|BIOLOGICAL|CD7-specific CAR gene-engineered T cells|Infusion of CD7-specific CAR-T cells
219279925|NCT00671177|PROCEDURE|water immersion colonoscopy|instillation of 300cc of water in the rectum
219279926|NCT00671177|PROCEDURE|standard air colonoscopy|air instillation in colon for visualization
219279927|NCT06384105|RADIATION|frames per second|Other settings for frames per second
219279928|NCT01878396|DRUG|Anti-B-RAF|
219279929|NCT04224402|DRUG|mFOLFORINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
219279930|NCT02661191|DRUG|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
219279931|NCT04004689|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|"Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry."
219279932|NCT04837339|OTHER|Collection of biological samples|Blood sample, biopsies sample, hair sample.
219279933|NCT03066882|DIETARY_SUPPLEMENT|NCD|negative calorie diet
219279934|NCT03066882|DIETARY_SUPPLEMENT|LCD|low calorie diet
219279935|NCT05125926|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
219279936|NCT05125926|BIOLOGICAL|Placebo|Aluminum hydroxide
219279937|NCT05602753|BEHAVIORAL|Lifestyle Counseling|Referring to Stop smoking hotline, given pamphlets to encourage quitting smoking, pharmacy guidance, and possible referral to smoking cessation clinic.
219279938|NCT02214875|OTHER|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
219279939|NCT02214875|OTHER|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
219279940|NCT00277095|DEVICE|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
219279941|NCT05327556|DRUG|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
219279942|NCT05327556|DRUG|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
219279943|NCT03899831|BEHAVIORAL|Function-Based Elopement Treatment (FBET)|"The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~* to create a safer environment~* teach adaptive skills to replace elopement~* arrange the environment and rewards to reduce elopement~* and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding."
219279944|NCT03899831|BEHAVIORAL|Parent Education Program (PEP)|The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
219279945|NCT05141942|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
219279946|NCT01460225|DRUG|lubiprostone|24 micrograms twice daily for 1 week
219279947|NCT03501953|BEHAVIORAL|Physical Activity|Six weeks of instructor-led physical activity sessions.
219279948|NCT02893839|OTHER|Prick to prick test|
219279949|NCT00430833|DRUG|candesartan|
219279950|NCT01981226|DEVICE|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
219279951|NCT00426959|DEVICE|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
219279952|NCT06064071|DEVICE|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
219279953|NCT06064071|PROCEDURE|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
219279954|NCT06064071|DEVICE|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
219279955|NCT00003768|DRUG|fosbretabulin disodium|
219279956|NCT05335746|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCT-A)|Optical coherence tomography angiography scanning will be done for all subjects in the study.
219279957|NCT06374875|PROCEDURE|Metabolic surgery|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure
219279958|NCT06374875|DRUG|Incretin-Based Therapy|Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.
219279959|NCT03979508|DRUG|Abemaciclib|Given PO
219279960|NCT03979508|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
219279961|NCT05898100|DEVICE|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
219279962|NCT05898100|BEHAVIORAL|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
219279963|NCT03561571|OTHER|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
219279964|NCT03561571|OTHER|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
219279965|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
219279966|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
219279967|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
219279968|NCT03598530|PROCEDURE|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
219279969|NCT06120842|DRUG|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
219279970|NCT06120842|DRUG|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
219279971|NCT06120842|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
219279972|NCT06120842|DEVICE|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
219279973|NCT06120842|DEVICE|SpyGlass IOL|SpyGlass Intraocular Lens
219279974|NCT04486352|DRUG|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
219279975|NCT04486352|DRUG|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
219279976|NCT04486352|DRUG|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
219279977|NCT04486352|DRUG|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
219279978|NCT04486352|DRUG|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
219279979|NCT04486352|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
219279980|NCT04486352|DRUG|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
219279981|NCT04486352|DRUG|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
219279982|NCT04486352|DRUG|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
219279983|NCT04486352|DRUG|Giredestrant|Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
219279984|NCT04486352|DRUG|Abemaciclib|Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
219279985|NCT05410340|OTHER|Vojta Therapy|Minimal digital pressure at costal level to assess the activation and oxygenation occurring at the cerebral level
219279986|NCT05410340|OTHER|Massotherapy|Baby body massage with gliding
219279987|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
219279988|NCT04225117|DRUG|pembrolizumab|IV infusion
219279989|NCT04520659|BIOLOGICAL|RSV LID/ΔM2-2/1030s|10\^5 plaque-forming units (PFU); administered as nose drops
219279990|NCT04520659|BIOLOGICAL|Placebo|Administered as nose drops
219279991|NCT04430439|BEHAVIORAL|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
219279992|NCT04430439|BEHAVIORAL|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
219279993|NCT05194137|OTHER|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
219279994|NCT05194137|OTHER|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
219279995|NCT05459922|DEVICE|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
219279996|NCT05459922|DEVICE|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
219279997|NCT06303570|DRUG|CBL-514 injection|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL ; total of 5 mg CBL-514.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL ; total of 15 mg CBL-514.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL ; total of 25 mg CBL-514.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL ; total of 40 mg CBL-514.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL ; total of 60 mg CBL-514."
219279998|NCT06303570|DRUG|0.9% Sodium chloride|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL."
219279999|NCT05194293|BIOLOGICAL|Durvalumab|Given IV
219280000|NCT05194293|DRUG|Regorafenib|Given PO
219280001|NCT05883878|GENETIC|PRS|genetic test for the evaluation of PRS cardiovascular risk
219280002|NCT05883878|DEVICE|Digital app and wearable device|a wearable device connected with its app
219280003|NCT03361865|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
219280004|NCT03361865|DRUG|Epacadostat|Epacadostat administered orally twice daily.
219280005|NCT03361865|DRUG|Placebo|Matching placebo administered orally twice daily.
219280006|NCT00469339|BEHAVIORAL|Family Health History|
219280007|NCT06444763|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
219280008|NCT06444763|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
219280009|NCT05935384|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
219280010|NCT03852719|DRUG|Bulevirtide|Administered via SC injections
219280011|NCT02112617|RADIATION|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
219280012|NCT05543187|DRUG|TAK-625|TAK-625 orally, twice daily (BID)
219280013|NCT05930379|OTHER|LSVT-Loud delivered by telerehabilitation|LSVT-Loud treatment delivered by telerehabilitation
219280014|NCT05930379|OTHER|LSVT-Loud in the clinic|LSVT-Loud delivered face-to-face in the clinic
219280015|NCT04306536|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
219280016|NCT05619575|DEVICE|CP1170 Sound Processor|The CP1170 Sound Processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
219280017|NCT05619575|DEVICE|CP1150 Sound Processor|Active comparator off-the-ear sound processor.
219280018|NCT03588091|DRUG|Pyrotinib|pyrotinib: 400mg orally daily;
219280019|NCT03588091|DRUG|Placebo Oral Tablet|placebo: 400mg orally daily;
219280020|NCT03588091|DRUG|Trastuzumab|trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
219280021|NCT03588091|DRUG|Docetaxel|docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
219280022|NCT05499858|OTHER|Spiced|Vegetables provided to volunteers will be spiced.
219280023|NCT05499858|OTHER|Plain|Vegetables provided to volunteers will be plain.
219280024|NCT03562221|OTHER|Gluten free diet|Controlled gluten free diet
219280025|NCT03562221|DIETARY_SUPPLEMENT|Probiotics|Capsules
219280026|NCT03562221|DIETARY_SUPPLEMENT|Placebo|Capsules
219296348|NCT03313375|OTHER|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
219296349|NCT00684619|DRUG|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
219296350|NCT02125045|DIETARY_SUPPLEMENT|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
219280032|NCT02819024|DRUG|Dexamethasone|Given PO BID
219280033|NCT02819024|DEVICE|Device for PET|Undergo 18F-FLT PET scan
219280034|NCT02819024|OTHER|Laboratory Biomarker Analysis|Correlative studies
219280035|NCT02819024|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET scan
219280036|NCT06780878|OTHER|Progressive muscle relaxation technique|"PMR focuses on the relationship between muscle tension and relaxation. By deliberately tensing a muscle group for a few seconds and then releasing the tension, individuals become more aware of the sensation of relaxation.~Group A Participants will receive PMR for 10 minutes each session, 3 sessions per week for 2 weeks and outcome measures will be recorded pre and post for each session."
219280037|NCT06780878|OTHER|Stretching exercises|"Stretching exercises are physical activities designed to improve the flexibility of muscles and joints. These exercises involve elongating specific muscle groups to enhance their elasticity and improve the range of motion around a joint.~Participants will be given 15 second stretches for each large muscle group, 3 sessions per week, for 2 weeks. Outcome measures will be assessed pre and post intervention."
219280038|NCT06780878|OTHER|Control Group|This group will consist of 12 participants who will not be given any physical therapy interventions. Same measurements will be taken at same intervals as the experimental groups.
219280039|NCT05589597|DRUG|EO4010|Sequential assignment
219280040|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator|Nerve stimulator that is traditionally used for nerve localization during block placements.
219280041|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator sham control|Stimulator will be placed and turned on, but the grounding electrode will not be connected to prevent nerve stimulation.
219280042|NCT00792948|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
219280043|NCT00792948|DRUG|Cyclophosphamide|Given IV
219280044|NCT00792948|DRUG|Cytarabine|Given IT
219280045|NCT00792948|DRUG|Dasatinib|Given PO
219280046|NCT00792948|DRUG|Dexamethasone|Given IV or PO
219280047|NCT00792948|DRUG|Doxorubicin Hydrochloride|Given IV
219280048|NCT00792948|DRUG|Etoposide|Given IV
219280049|NCT00792948|BIOLOGICAL|Filgrastim|Given SC
219280050|NCT00792948|OTHER|Laboratory Biomarker Analysis|Correlative studies
219280051|NCT00792948|DRUG|Leucovorin Calcium|Given IV
219280052|NCT00792948|DRUG|Methotrexate|Given IV or IT
219280053|NCT00792948|DRUG|Methylprednisolone|Given IV
219280054|NCT00792948|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
219280055|NCT00792948|DRUG|Prednisone|Given PO
219280056|NCT00792948|DRUG|Sirolimus|Given PO
219280057|NCT00792948|DRUG|Tacrolimus|Given IV
219280058|NCT00792948|RADIATION|Total-Body Irradiation|Undergo TBI
219280059|NCT00792948|DRUG|Vincristine Sulfate|Given IV
219280060|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
219280061|NCT06094478|BEHAVIORAL|HI-SPEED Protocol|The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool. This protocol will be implemented at each participating health system in clusters of 2 health systems.
219280062|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
219280063|NCT06169137|BEHAVIORAL|Early Time-Restricted Eating|Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
219280064|NCT06169137|BEHAVIORAL|Conventional dietary regimen (12-hr, 9:30a-9:30p)|Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
219280065|NCT00460902|DEVICE|Transcranial Magnetic Stimulation (TMS)|
219280066|NCT03356964|DRUG|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
219280067|NCT01755377|DRUG|Benznidazole|
219280068|NCT00852605|OTHER|Intermittent Non-Invasive Ventilation|
219280069|NCT05500170|DIETARY_SUPPLEMENT|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
219280070|NCT05500170|DIETARY_SUPPLEMENT|Placebo|The placebo pill will contain micro cellulose powder.
219280071|NCT02998476|DRUG|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
219280072|NCT03039413|DRUG|Copper Cu 64 TP3805|Given IV
219280073|NCT03039413|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
219280074|NCT03039413|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
219280075|NCT05987332|DRUG|IDE196|Dosed orally, twice daily
219280076|NCT05987332|DRUG|Crizotinib|Dosed orally, twice daily
219280077|NCT05987332|DRUG|Pembrolizumab|IV administration every 3 weeks
219280078|NCT05987332|DRUG|Ipilimumab|IV administration every 3 weeks for 4 Cycles
219280079|NCT05987332|DRUG|Nivolumab|IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
219280080|NCT05987332|DRUG|Dacarbazine|IV administration every 3 Weeks
219280081|NCT03567629|DRUG|Irinotecan|Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
219280082|NCT03567629|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
219280083|NCT06027034|BEHAVIORAL|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
219280084|NCT03080337|OTHER|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
219280085|NCT06051331|BEHAVIORAL|simulation-based breast health education|The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
219280086|NCT03832595|OTHER|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
219280087|NCT03832595|OTHER|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
219296351|NCT02125045|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
219296352|NCT02056990|OTHER|Advice|
219296353|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
219296354|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
219280088|NCT05426863|BEHAVIORAL|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
219280089|NCT03729557|PROCEDURE|Nephrectomy|Unilateral nephrectomy
219280090|NCT05759832|DEVICE|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
219280091|NCT05759832|DEVICE|Non-rebreathing reservoir mask|In the non-rebreathing reservoir mask group, oxygen was delivered via a non-rebreathing reservoir mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen \> 90%.
219280092|NCT04157933|DRUG|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
219280093|NCT04157933|DRUG|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
219280094|NCT04157933|DRUG|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
219280095|NCT04157933|DRUG|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
219280096|NCT04157933|DRUG|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
219280097|NCT04157933|DRUG|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
219280098|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
219280099|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
219280100|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
219280101|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
219280102|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
219280103|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
219280104|NCT00119561|BEHAVIORAL|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
219280105|NCT03277352|DRUG|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
219280106|NCT03277352|DRUG|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
219280107|NCT03277352|DRUG|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
219280108|NCT00707499|DRUG|BMS747158|Single dose administration.
219280109|NCT06546228|OTHER|No intervention. Only observational.|Only collection of data or parameters already required by the medical examination programmed.
219280110|NCT02923505|PROCEDURE|polygraphy or polysomnography|
219280111|NCT02760147|DEVICE|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
219280112|NCT02760147|DEVICE|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
219280113|NCT02760147|DEVICE|PEEP Over Level|PEEP Level upward by 50%, 2 hours
219280114|NCT02760147|DEVICE|PEEP Under Level|PEEP Level downward by 50%, 2 hours
219280115|NCT03140852|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
219280116|NCT02397447|DRUG|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
219280117|NCT02397447|DRUG|Placebo|Placebo: 2000 mg per day for three months
219280118|NCT04439045|BIOLOGICAL|VPM1002|VPM1002 is a recombinant BCG (rBCG)
219280119|NCT04439045|OTHER|Placebo|0.9% sodium chloride
219280120|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
219280121|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
219280122|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
219280123|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
219280124|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
219280125|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
219280126|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
219280127|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
219280128|NCT05398445|DRUG|Rocatinlimab|Participants will receive Rocatinlimab subcutaneously.
219280129|NCT05398445|DRUG|Placebo|Participants will receive a placebo subcutaneously.
219280130|NCT06502119|OTHER|Designed Questionnaire|Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
219280131|NCT03003585|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
219280132|NCT03003585|OTHER|Fiberoptic bronchoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
219280133|NCT00505310|BEHAVIORAL|Writing|20 minutes of writing on different topics at four different times.
219280134|NCT00505310|BEHAVIORAL|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
219280135|NCT05652803|BEHAVIORAL|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
219280136|NCT05652803|BEHAVIORAL|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
219280137|NCT05954572|DIAGNOSTIC_TEST|standardized skin surface biopsy (SSSB)|This technique is applied in four facial localizations, including the forehead, cheeks, and nose. The surface biopsy procedure is performed as follows: one cm² area was marked on a glass slide using a fine ruler. The designated skin area for sampling is gently swabbed with a dry gauze pad to create mild irritation. Subsequently, one drop of cyanoacrylate adhesive is applied to the marked area on the glass slide. The glass slide is carefully pressed onto the skin, allowing the adhesive to adhere. After approximately one minute, the glass slide is gently lifted. The sampled area on the glass slide is examined under x10 and x40 magnification. Immersion oil is applied to enhance visualization and determine the number of Demodex parasites within the marked area. An increased demodicosis is defined as the presence of five or more Demodex parasites per square centimeter of skin.
219280138|NCT00160797|DEVICE|MIS™ Minimally Invasive Solutions™ TKA System|
219280139|NCT00002154|DRUG|Thioctic acid|
219280140|NCT00002154|DRUG|Selegiline hydrochloride|
219280141|NCT07135401|DIAGNOSTIC_TEST|Breath-hold conditions|Functional Residual Capacity/End-Expiration (breath-hold technique) with/without oxygen to optimize MRI image quality.
219280142|NCT07135791|DIAGNOSTIC_TEST|Real-time monitoring|Complete a brief 20-item survey 10 times a day for seven consecutive days, while wearing an accelerometer and completing daily sleep diaries.
219280143|NCT01435772|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
219280144|NCT03238963|DRUG|BI 1467335|Once daily
219280145|NCT03238963|DRUG|Placebo|Once daily
219280146|NCT07041281|DRUG|spironolactone 25 mg orally once daily|Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
219280147|NCT07041281|DRUG|Placebo tablet to match spironolactone|Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
219280148|NCT07049562|DRUG|HRS-8427|\[14C\] HRS-8427 for injection
219280149|NCT07050290|PROCEDURE|Restoring segmental lordosis at the lumbar spine|All patients will undergo restoring segmental lordosis via one previous posterior approach after failed fusion at the same level.
219280150|NCT07045441|OTHER|Conservative Management for TMD|This intervention includes a standardized conservative treatment protocol for TMDs, comprising splint therapy and a structured counseling program. The counseling covers education on diagnosis, medication adherence, dietary modifications, posture and behavior correction, sleep hygiene, parafunctional habit avoidance, physiotherapy exercises, pain and stress management, and importance of follow-up visits. Patients receive individualized instructions and monitoring as part of their routine clinical care. Adherence to these components is measured after 6 months of treatment using a validated adherence questionnaire.
219280151|NCT07046611|DRUG|Ketamine|Intravenous ketamine (5 mg/ml concentration) 2 mg/kg (max 90 mg) over 2 minutes
219280152|NCT07046611|DRUG|Levetiracetam|Intravenous levetiracetam (50 mg/ml concentration) 60 mg/kg (max 4500 mg) over 5 minutes
219280153|NCT07046611|DRUG|Placebo|Intravenous isotonic saline 0.4 mL/kg (maximum 18 mL) over 2 minutes
219280154|NCT07048912|DIETARY_SUPPLEMENT|Beetroot Juice (BJ)|This intervention involves a single 140 mL dose of a commercially available concentrated beetroot juice supplement (Beet-It Pro Elite Shot, James White Drinks Ltd., UK), containing approximately 12.8 mmol (800 mg) of dietary nitrate. Participants consume the juice 2.5 hours prior to performing a 30-second Wingate anaerobic test. The purpose of this intervention is to examine its acute effects on anaerobic performance, muscle oxygenation, and metabolic responses.
219280155|NCT07048912|DIETARY_SUPPLEMENT|Blackcurrant Juice (Placebo)|This intervention involves a single 140 mL dose of a low-calorie blackcurrant juice (Pfanner, Austria) with negligible nitrate content (\<0.1 mmol). The placebo is matched to beetroot juice in appearance, taste, and packaging to ensure double-blind conditions. It is consumed 2.5 hours before the Wingate test and serves as the control condition.
219280156|NCT07049289|OTHER|Telemonitoring|Patients randomized to intervention group will receive biweeky telephone calls and adaption of antiyhpertensive medication if needed
219280157|NCT07051044|DIAGNOSTIC_TEST|AIR-DS|AIR-DS is a supportive, non-diagnostic, risk-indicating software that assists healthcare providers in the early detection and risk assessment of lung cancer in high-risk populations, aiming to improve the cost-effectiveness and accessibility of lung cancer screening. It is imperative to note that the efficacy of the AIR-DS may be affected by the completeness and accuracy of the input data. Hence, any missing data fields should be identified, as they could impact the risk assessment's accuracy.
219280158|NCT07050927|BEHAVIORAL|Online occupational therapy group training|The intervention is a 4-week online parent training program based on occupational therapy principles, delivered via secure Zoom sessions once per week. Each session lasts approximately 60-75 minutes and focuses on topics such as feeding skill development, sensory-based feeding difficulties, responsive parenting strategies, and stress management techniques. The training includes interactive discussions and practical suggestions for daily feeding routines. Supporting materials, such as PDF slides and short demonstration videos, are shared with participants after each session. Attendance in at least three sessions is required to remain in the study.
219280159|NCT07048951|DIAGNOSTIC_TEST|The Near-Death Experience Content (NDE-C) scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 27/80
219280160|NCT07048951|OTHER|Threat perception measure|7 items scale investigating the participant's psychological vulnerability during their stay at the ICU
219280161|NCT07048951|OTHER|Interview about the participant's memories of the ICU|"Participants will be asked to describe any dream, hallucination, or any other unusual experience they can recall from their stay at the ICU.~Additionally, the participants will be asked to describe any memory they have of the environment of the ICU, such as the appearance of the room, medical staff, family visiting, noises, etc."
219280162|NCT05626452|BEHAVIORAL|PrEP Education|Education for participants regarding PrEP
219280163|NCT05626452|BEHAVIORAL|Provider training|Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
219280164|NCT05626452|OTHER|EMR Optimization|EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
219280165|NCT05626452|OTHER|PrEP Navigation|Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
219280166|NCT05626452|OTHER|Provider Audit and Feedback|Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
219296355|NCT06575790|BEHAVIORAL|Simple Meal Bolusing|Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting
219296356|NCT06575790|BEHAVIORAL|Carbohydrate counting|Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks
219296357|NCT06572449|DRUG|KarXT|Specified dose on specified days
219280167|NCT07051005|BEHAVIORAL|Feasibility RCT of a tailored online self-compassion intervention|"This is a four-week online self-compassion course supplied by Balanced Minds. The researches of this study and an Expert by Experience have consulted with the owner of Balanced Minds to tailor this programme to people with diabetes.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~The Foundations of Self-Compassion Developing your Compassionate Self Deepening the Compassionate Relationship with Yourself Self-compassion in Everyday Life."
219280168|NCT07049380|DIAGNOSTIC_TEST|Comparative cross sectional|evaluating the efficacy of two analgesics, tramadol and nalbuphine. The primary objectives are to estimate pain severity in smokers versus nonsmokers and identify the effect of tramadol and nalbuphine between these groups
219280169|NCT07048847|OTHER|Exercise|The exercise program will be started with 25 Watt (W) for 5 minutes of warm-up. Then it is steadily increased automatically by 5W in 5 minutes apart for 25 minutes for the loading period. The last 5 minutes which will be started by lowering the load to 25 W for cooling will be implemented for cooling down. To prevent acommodation, the warm-up period will be modified by increasing nearly 10% of its previous rate three weeks apart.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.
219280170|NCT07050511|DRUG|GB-0669|Single IV infusion of GB-0669.
219280171|NCT07050511|DRUG|Placebo|Single IV infusion of placebo. Sterile 0.9% (w/v) sodium chloride solution.
219280172|NCT07049445|BEHAVIORAL|Music Activity Program|Participants in the experimental group will receive the standard day care center activities plus a music activity intervention. The music activity consists of pre-recorded video sessions conducted twice a week, each lasting one hour, for a total duration of 8 weeks.
219280173|NCT07050576|DIAGNOSTIC_TEST|The prediction model of lymph node metastasis in early esophageal squamous cell carcinoma|The predictive performance of the model was validated in the test set. The optimal prediction model was determined based on the AUC and ACC. To assess the robustness of the chosen model, ROC analysis was conducted on the external validation set.
219280174|NCT07050628|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
219280175|NCT07049991|PROCEDURE|surgical or percutaneous heart valve replacement.|para-prosthetic heart valve leakage after after surgical or percutaneous heart valve replacement
219280176|NCT01986088|DRUG|Placebo|matching placebo
219280177|NCT01986088|DRUG|Eletriptan 40 mg|40mg oral
219280178|NCT01986088|DRUG|Eletriptan 80 mg|80mg oral
219280179|NCT01986088|DRUG|Sumatriptan 50 mg|50mg oral
219280180|NCT01986088|DRUG|Sumatriptan 100 mg|100mg oral
219280181|NCT07051070|DRUG|RTX treatment|This study used a drug dosage based on previous domestic and international literature as well as clinical experience from our center, set at 375mg/m2 per dose. During the course of the disease, TB lymphocyte subsets are monitored, and if the proportion of B lymphocytes is greater than or equal to 1%, a second dose will be administered.
219280182|NCT07049198|DEVICE|Real-time 2D motion capture and visual feedback system gait training|The difference between the VF group and the PT group lies in the use of real-time visual feedback during gait training; the VF group receives real-time visual feedback, while the PT group undergoes gait training without visual feedback.
219280183|NCT07049198|OTHER|Conventional physical therapy group|Ten minutes of strength training followed by thirty minutes of gait training, during which the 2DMV system is not used to provide visual feedback. During the gait training, the therapist provides gait correction feedback typically used in conventional physical therapy.
219280184|NCT05840770|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219280185|NCT05840770|BIOLOGICAL|Cemiplimab|Given IV
219280186|NCT05840770|PROCEDURE|Computed Tomography|Undergo CT scan
219280187|NCT05840770|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219280188|NCT05840770|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219280189|NCT02506933|OTHER|Laboratory Biomarker Analysis|Correlative studies
219280190|NCT02506933|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219280191|NCT02506933|OTHER|Placebo|Given IM
219280192|NCT06832085|DRUG|Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)|Participants in this group will apply 1 NRT patch each morning for up to 26 weeks. Patches will be titrated based on cigarettes consumed. Short-acting NRT products (gum and lozenge) will be used as needed by the participants in this group.
219280193|NCT06832085|DRUG|Cytisine|Participants in this group will take 3mg of cytisine 3 times per day for 12 weeks.
219280194|NCT06832085|DRUG|Varenicline (Champix)|Participants in this group will take 1mg of varenicline 2 times per day for 12 weeks.
219280195|NCT05812092|DEVICE|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
219280196|NCT07135817|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Hypofractionated SBRT delivered in 1-3 fractions within 10 days before surgery, using MRI-based planning and institutional immobilization standards according to ESTRO guidelines.
219280197|NCT07135817|PROCEDURE|Spinal Surgery for Decompression and/or Stabilization|Surgical intervention is performed following SBRT, based on clinical indication. It includes decompression of the spinal canal in cases of spinal cord or nerve compression (via laminectomy and/or foraminotomy), and/or dorsal instrumentation for unstable spines using pedicle screws guided by a neuronavigation system (Brainlab, Munich, Germany)
219280198|NCT04303117|DRUG|NHS-IL12|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
219280199|NCT04303117|DRUG|M7824|1200 mg administered IV every two weeks while on NHS-IL12.
219280200|NCT06747910|OTHER|Exercise Intervention - Ewing Battery Assessment|Undergo in-person Ewing battery assessment
219280201|NCT06747910|OTHER|Questionnaire Administration|Receive COMPASS31 questionnaire
219280202|NCT06747910|DEVICE|Medical Device Usage and Evaluation|Wear biosensensor heart monitor that remotely collects heart rate variability.
219280203|NCT06265324|DEVICE|Angioplasty|Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
219280204|NCT06927141|DEVICE|Bilateral Peripheral Intravenous Catheterisation|Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.
219280205|NCT06155812|OTHER|Simultaneous administration of vasopressors|Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.
219280206|NCT06155812|OTHER|Successive administration of vasopressors|Administration and titration of norepinephrine and vasopressin. Administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II or dopamine) as per clinical team. Initiation of inotropes (dobutamin, levosimendan, milrinone) as per clinical team decision.
219280207|NCT06922994|DRUG|Atorvastatin 80 mg/day|Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
219280208|NCT06922994|DRUG|Placebo atorvastatin|One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
219280209|NCT06923384|BEHAVIORAL|F2F|After T1 assessment, students meet with a trained provider and receive prevention or brief intervention. Students then complete assessments at two additional times.
219280210|NCT06923384|BEHAVIORAL|eSBI|After T1 assessment, students watch and respond to a prevention or brief intervention video series. Students then complete assessments at two additional times.
219280211|NCT06923384|BEHAVIORAL|Control|Students complete the assessments at each time point, but do not receive any intervention or informational material.
219280212|NCT07125027|BEHAVIORAL|Move-MORE|Move-MORE is a multicomponent intervention which combines mindfulness training, physical activity, and motivational interviewing informed by the principles of self-determination theory. The version of Move-MORE being used in this study is specifically designed for use in patients with lumbosacral radiculopathy.
219280213|NCT07124130|DRUG|5% Dextrose (D5) in Normal Saline (NS)|A solution of 5% dextrose and lactate ringer will be given to one group of participants.
219280214|NCT07124130|DRUG|Lactate Ringer|A Lactate Ringer solution will be given to one group of participants.
219280215|NCT07124052|DEVICE|SleeperOne 5|A computerized local anesthetic delivery system (manufactured by Dental Hi-Tec, France) designed to minimize pain perception in children during dental procedures by controlling the pressure and flow rate of anesthetic injection. It will be used to deliver 3% mepivacaine (Mepecaine-L®, Alexandria Co. for Pharmaceuticals, Egypt) during maxillary primary molar extraction in pediatric patients.
219280216|NCT07124052|PROCEDURE|(Conventional Infiltration Anesthesia)|Local anesthetic solution (3% mepivacaine with no vasoconstrictor), manufactured by Alexandria Co. for Pharmaceuticals, Egypt. It will be administered using a 30-gauge short dental needle and standard dental syringe for conventional infiltration anesthesia during primary maxillary molar extraction in pediatric patients.
219280217|NCT07124078|DRUG|INCA034176|Axatilimab at the protocol-defined dose.
219280218|NCT07124078|DRUG|Best available Treatment (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
219280219|NCT07126418|OTHER|observation (cervical proprioception, neck pain and neck disability)|"1\) Assessment of cervical proprioception using CROM device: Head reposition accuracy tests: neutral head position (NHP) and target head position (THP) tests are common tests used to assess cervical proprioception. Repositioning to the NHP and repositioning into THP. The test procedures were the same as those described by Lee et al., 2006. The NHP test measures the subject's ability to actively reposition their head to their self-selected neutral position. The THP test measures the individual's ability to actively reposition the head to a previously demonstrated target position. A) Neutral head position: After explaining the testing procedure, the CROM device will securely fixed on the head of the subject. The participants will instructed to sit upright with their feet flat on the floor, their back against the chair backrest and facing straight ahead, this position will established as their self-selected NHP.~The magnetic part of the unit was then placed so that it was put"
219280220|NCT04959864|DIETARY_SUPPLEMENT|Isitol®|"1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
219280221|NCT04959864|OTHER|Placebo|"1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30."
219280222|NCT07137039|DRUG|Adebrelimab+Albumin paclitaxel +Cisplatin|"1. Adebrelimab：1200mg, ivgtt, D1, Q3W;~2. Albumin paclitaxel :260mg/m2, ivgtt, D1, Q3W;~3. Cisplatin :60mg/m2, ivgtt, D1, Q3W."
219280223|NCT07137364|DRUG|spironolactone|The patients receive spironolactone treatment based on their conditions
219280224|NCT07137156|DIAGNOSTIC_TEST|cytobrush|buccal smear
219280225|NCT07137156|DEVICE|next-generation sequencing|next-generation sequencing
219280226|NCT05261373|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
219280227|NCT05261373|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
219280228|NCT05261373|OTHER|Behavioral: Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
219280229|NCT03610711|DRUG|Nivolumab|240mg administered IV over 30 minutes every 2 weeks for one year
219280230|NCT03610711|DRUG|Relatlimab|every 2 weeks for one year
219280231|NCT05689242|DRUG|Dexmedetomidine Injection [Precedex]|intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
219280232|NCT05981742|DRUG|Metformin Hydrochloride 500 MG|Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
219280233|NCT05981742|DRUG|Cabergoline 0.5 MG|Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
219280234|NCT05981742|DRUG|Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG|"Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration"
219280235|NCT03438357|OTHER|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
219280236|NCT02143011|OTHER|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
219280237|NCT02143011|OTHER|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
219280238|NCT02354820|OTHER|Evidence Based Constipation Reminders|
219280239|NCT01134224|DRUG|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
219280240|NCT01134224|DRUG|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
219280241|NCT01134224|DRUG|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
219280242|NCT01134224|DRUG|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
219280243|NCT01134224|DRUG|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
219280244|NCT01134224|DRUG|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
219280245|NCT00378664|PROCEDURE|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
219280246|NCT04317391|BEHAVIORAL|Pain management program|Mindfulness based stress reduction
219280247|NCT01195948|DRUG|B27PD|
219280248|NCT01195948|DRUG|Placebo|Capsule with no active ingredients to mimic B27PD
219280249|NCT01941173|BIOLOGICAL|ziv-aflibercept|Given IV
219280250|NCT01941173|DRUG|leucovorin calcium|Given IV
219280251|NCT01941173|DRUG|irinotecan hydrochloride|Given IV
219280252|NCT01941173|DRUG|fluorouracil|Given IV
219280253|NCT02771821|OTHER|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
219280254|NCT05751278|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
219280255|NCT05751278|DEVICE|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
219280256|NCT04684823|DEVICE|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
219280257|NCT04684823|DEVICE|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
219280258|NCT00876564|OTHER|Trauma patients|
219280259|NCT01762969|OTHER|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
219280260|NCT06405763|PROCEDURE|Snodgrass repair|"A relaxing incision is made in the midline by using scalpel or scissors~A 6 F stent is passed into the bladder. The neourethra is closed"
219280261|NCT06405763|PROCEDURE|Snodgrass repair with graft|A relaxing incision is made in the midline by using scalpel or scissors In grafted Snodgrass repairA free graft was measured and harvested from the inner prepuce and was defatted and sutured onto the incised urethral plate The graft was sutured overlying the incision line A 6 F stent is passed into the bladder. The neourethra is closed
219280262|NCT01947569|BIOLOGICAL|Biological|
219280263|NCT05422183|DRUG|Envafolimab|400mg，sc，d1，Q3W
219280264|NCT05422183|DRUG|Lenvatinib|8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
219280265|NCT05422183|DRUG|VP-16|50 mg/d, po,d1-14，Q3W
219280266|NCT06287645|DIAGNOSTIC_TEST|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Participants will undergo retinal imaging by fundus camera. Three specialists will independently grade images for common retinal disorders like Diabetic Retinopathy. Final grading decisions will be unanimous among the specialists.
219280267|NCT03354936|BIOLOGICAL|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
219280268|NCT06169462|PROCEDURE|PENG block|Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
219280269|NCT06169462|PROCEDURE|PENG block+ SIFCB|Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
219280270|NCT05171790|DRUG|QL1706 injection|5 mg/kg, IV, Q3w
219280271|NCT03826524|DRUG|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
219296358|NCT06643039|BIOLOGICAL|Nasopharyngeal swab|Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
219280272|NCT03498469|BEHAVIORAL|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
219280273|NCT03498469|BEHAVIORAL|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
219280274|NCT06221501|DRUG|Efgartigimod Alfa|Efgartigimod will be administered intravenously on Day (D)1, D8, D15, and D22 at a dose of 10 mg/kg according to the patient's weight (maximum infusion dose of 1200 mg) over approximately 1 hour for a total of 4 doses. Thymectomy will be performed on Day 9.
219280275|NCT00448201|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
219280276|NCT00448201|BIOLOGICAL|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) \< 1000/microliter (uL) past day 20
219280277|NCT00448201|BIOLOGICAL|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10\^6 cells/kg and a maximum 8 x 10\^6 cells/kg will be infused on day 0
219280278|NCT00448201|DRUG|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
219280279|NCT00448201|DRUG|fludarabine phosphate|fludarabine 30 mg/m\^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
219280280|NCT00448201|DRUG|methotrexate|Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
219280281|NCT00448201|DRUG|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
219280282|NCT00448201|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
219280283|NCT00448201|PROCEDURE|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
219280284|NCT05222594|OTHER|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
219280285|NCT02769442|DEVICE|Terumo SurFlash Plus catheter|
219280286|NCT02769442|DEVICE|BD Insyte Autoguard catheter|
219280287|NCT06337487|OTHER|QoL questionnaires|"The EORTC QLQ-C30 questionnaire is a specific cancer questionnaire. A score is calculated per dimension reflecting the patient's level for the corresponding QoL scale (dimension). These scores are calculated according to the EORTC recommendations.~Research work was recently developed by Giesinger et al. within the EORTC QoL group, with the aim of providing thresholds of clinical importance for the different dimensions of the QLQ-C30.~An item was added to complete the QLQ-C30. It comes from the EORTC bank library item based on the INCa organizational framework. This item was chosen because it addressed a theme not addressed in the QLQ-C30, sexual health. After consultation with a multidisciplinary team, the threshold was determined for this additional item. Has your illness or treatment had a negative effect on your sex life? , the threshold is reached when the answer is enough or a lot."
219280288|NCT06337487|OTHER|Qualitative Interview (for one part of nurses only)|At the end of the study, semi-directed qualitative interviews will be conducted with the nurses carrying out the TAS with the aim of understanding the obstacles and facilitators of the routine implementation of the QoL assessment to early identify the SOS needs of patients treated in medical oncology. The semi-structured interviews will be accompanied by an interview grid composed of main questions and follow-up questions. The main questions help introduce the theme. The follow-up questions make it possible to clarify the participants' comments without interrupting the fluidity of the exchanges. The themes discussed between the researcher and the participant during the interview will be as follows: Personal information and overall professional experiences, Knowledge of the study and experience of training with tools (questionnaire and software), Perception of tools (questionnaire and software) and their implementation, Definition and perception of key concepts.
219280289|NCT06337487|OTHER|ORIC questionnaire|Organisational readiness is a factor known to influence the predisposition of individuals to change within an organisation. Based on Weiner's organisational theory, Organizational Readiness for Implementing Change (ORIC) is a questionnaire that has been developed and validated, particularly in French, to measure the organisation's state of in the field of healthcare. It comprises ten items which measure two concepts: commitment to change and effectiveness of change.
219280290|NCT06337487|OTHER|Professionals satisfaction survey|"A satisfaction questionnaire will be offered to all professionals involved once the last patient has been included. This questionnaire has previously been developed by the UMQVC team to assess investigator satisfaction for other studies and adapted to the context of SOS-Deteqt.~This questionnaire evaluates in particular :~* the quality of training~* ease of use of the CHES~* the relevance of using the CHES and the PROs~* the relevance of maintaining the PRO evaluation approach in current clinical practice."
219280291|NCT06337487|OTHER|Patients satisfaction survey|"A patient satisfaction questionnaire was drawn up for the study. It includes items taken from :~* the EORTC's PATSAT33 satisfaction questionnaire, and in particular items relating to the quality of information provided by nurses and the time spent~* the EORTC COMU26 communication evaluation questionnaire, and in particular the items on being comfortable asking questions, professional responses to difficult difficult subjects, explanation of treatment objectives, etc.~* the questionnaire developed jointly by the UMQVC team and the psychology laboratory of the psychology laboratory at the University of Franche Comté as part of the REMOQOL-Poumon study and assessing in particular~* understanding of the purpose of using the QoL questionnaire~* ease of completion and use of the tablet~* satisfaction with the questionnaire and the tablet~* intention to use in the future"
219280292|NCT00398372|DRUG|Rituximab|
219280293|NCT00398372|DRUG|Epratuzumab|
219280294|NCT03809039|DRUG|MT-6345|MT-6345
219280295|NCT03809039|DRUG|MT-6345 Placebo|MT-6345 Placebo
219280296|NCT00967967|DRUG|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
219280297|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display can be seen|Pain scores are displayed on the screen when the participant presses the corresponding button
219280298|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display is hidden|Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
219280299|NCT01869504|DEVICE|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
219280300|NCT03272906|DEVICE|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
219280301|NCT03272906|DEVICE|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
219280302|NCT03272906|BEHAVIORAL|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
219280303|NCT01738659|DIETARY_SUPPLEMENT|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
219280304|NCT05209516|BEHAVIORAL|Behavioral data|Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
219280305|NCT05209516|DIAGNOSTIC_TEST|Single-pulse transcranial magnetic stimulation (TMS)|While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
219280306|NCT05209516|OTHER|Questionnaires|Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
219280307|NCT05209516|OTHER|MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)|Specific Parkinson Questionnaire on Clinical motor status
219280308|NCT00696943|DRUG|([18F]-ML-10)|\[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
219280309|NCT00843505|BEHAVIORAL|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
219280310|NCT00843505|BEHAVIORAL|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
219280311|NCT01510080|BEHAVIORAL|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
219280312|NCT01510080|BEHAVIORAL|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
219280313|NCT05198102|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
219280314|NCT05853952|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
219280315|NCT05853952|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
219280316|NCT03236584|DRUG|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
219280317|NCT03236584|DRUG|Tenofovir Disoproxil Fumarate|switching to tenofovir
219280318|NCT04291053|DRUG|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
219280319|NCT04905576|BEHAVIORAL|Relaxation training|Muscle relaxation training
219280320|NCT04905576|BEHAVIORAL|Therapeutic touch|Healing Touch (HT) therapy
219280321|NCT04905576|OTHER|Questionnaire administration|
219280322|NCT04905576|OTHER|Ancillary studies|Subjects in all groups will give 4 blood samples during the study
219280323|NCT02360722|OTHER|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
219280324|NCT02360722|OTHER|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
219280325|NCT03329469|DEVICE|Toshiba CT-FFR|Patients receiving CCTA to diagnose acute chest pain or unstable angina will receive CT-FFR to estimate rate of blood flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
219280326|NCT02658877|DRUG|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
219280327|NCT02658877|DRUG|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
219280328|NCT01928238|DEVICE|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
219280329|NCT01928238|DEVICE|Noninvasive pressure support ventilation (NPSV)|
219280330|NCT00988299|OTHER|exercise|exercise sessions at 45% and 60% of maximum effort
219280331|NCT01541852|DRUG|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
219280332|NCT01541852|DRUG|Placebo|One tablet twice daily
219280333|NCT05766527|BIOLOGICAL|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
219280334|NCT04866381|DRUG|SHR-6390|SHR-6390
219280335|NCT04866381|DRUG|SHR-6390 + Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
219280336|NCT04866381|DRUG|Camrelizumab (SHR-1210) + SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
219280337|NCT00999739|BIOLOGICAL|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
219280338|NCT01250925|DRUG|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
219280339|NCT01250925|DRUG|OPTI-FREE® RepleniSH®|Contact Lens care regimen
219280340|NCT01250925|DRUG|Clear Care®|Contact lens care regimen
219280341|NCT04000984|BEHAVIORAL|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
219280342|NCT04000984|BEHAVIORAL|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
219280343|NCT05465590|DRUG|MB1707|"MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism."
219280344|NCT03215862|DRUG|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
219280345|NCT03215862|DRUG|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
219280346|NCT05059444|DIAGNOSTIC_TEST|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
219280347|NCT03338296|DRUG|lorcaserin hydrochloride XR|oral tablet
219280348|NCT03338296|DRUG|Placebo|oral tablet
219280349|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
219280350|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
219280351|NCT06215820|DRUG|MR-107A-02|tablet
219280352|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
219280353|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
219280354|NCT04421950|DIETARY_SUPPLEMENT|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
219280355|NCT04421950|DIETARY_SUPPLEMENT|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
219280356|NCT03993808|BEHAVIORAL|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
219280357|NCT03993808|BEHAVIORAL|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
219280358|NCT03993808|BEHAVIORAL|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
219280359|NCT03993808|BEHAVIORAL|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
219280360|NCT03993808|BEHAVIORAL|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
219280361|NCT01252355|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219280362|NCT01252355|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
219280363|NCT01252355|DRUG|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
219280364|NCT06064968|OTHER|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
219280365|NCT06441253|DIAGNOSTIC_TEST|Deep Friction massage|The calf muscles received a firm, deep-circulation massage with fingertip pressure
219280366|NCT06441253|COMBINATION_PRODUCT|Therapeutic exercises|Four stretching exercises were performed for twenty minutes, five minutes for each technique, and eight to ten repetitions of each exercise (calf wall stretch, back knee straight, bilateral calf stretches, knees straight, ankle plantarflexion/dorsiflexion)
219280367|NCT03934151|PROCEDURE|intracorporeal ileocolic anastomosis|laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
219280368|NCT03934151|PROCEDURE|extracorporeal ileocolic anastomosis|ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
219280369|NCT04773743|OTHER|Yoga|Remotely delivered yoga intervention
219280370|NCT00002622|DRUG|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
219280371|NCT00002622|DRUG|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
219280372|NCT03461770|OTHER|CPAP|Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
219280373|NCT01725126|DRUG|GSK2890457|Provided as powder and capsule.
219280374|NCT01725126|DRUG|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
219280375|NCT01725126|DRUG|Placebo|Provided as powder and Capsule.
219280376|NCT01725126|DRUG|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
219280377|NCT01849640|DRUG|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
219280378|NCT01022905|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
219280379|NCT03296800|DRUG|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
219280380|NCT03296800|DRUG|Probenecid|Probenecid tablets, 500 mg; bid
219280381|NCT03296800|DRUG|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
219280382|NCT03296800|DRUG|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
219280383|NCT03435913|OTHER|Standard PEEP ventilation|During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
219280384|NCT03435913|OTHER|Matched PEEP ventilation|During mechanical ventilation PEEP is matched to IAP level
219280385|NCT06349447|DEVICE|LED|308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. 830 nm LED and 590 nm LED were irradiated, respectively. For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.
219280386|NCT06349447|OTHER|without any LED exposition|without any LED exposition
219280387|NCT05185505|DRUG|Atezolizumab|1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
219280388|NCT05185505|DRUG|Bevacizumab|15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
219280389|NCT05714280|BEHAVIORAL|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
219280390|NCT06000540|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
219280391|NCT00677534|DRUG|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
219280392|NCT00690053|PROCEDURE|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
219280393|NCT02695875|PROCEDURE|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
219280394|NCT02695875|PROCEDURE|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
219280395|NCT01779570|DRUG|Macrolide treatment|
219280396|NCT00773331|DRUG|epoetin beta|As prescribed
219280397|NCT00773331|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
219280398|NCT05106205|DRUG|DA-5213 10mg|single dose administration (one tablet once a day)
219280399|NCT05106205|DRUG|DA-5213-R 10mg|single dose administration (one tablet once a day)
219280400|NCT01102764|BEHAVIORAL|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
219280401|NCT01102764|BEHAVIORAL|In Person|PE therapy delivered in person at the VAMC
219280402|NCT00200291|BEHAVIORAL|hypocaloric, low-fat diet|hypocaloric, low-fat diet
219280403|NCT04256863|BEHAVIORAL|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (\>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
219280404|NCT04256863|BEHAVIORAL|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume \>50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
219280405|NCT05110170|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
219280406|NCT05110170|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
219280407|NCT00089882|PROCEDURE|APOE Genetic susceptibility testing|
219280408|NCT02506751|DRUG|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
219280409|NCT05716724|DRUG|Semaglutide|Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
219280410|NCT04915274|OTHER|uses of an application|Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
219280411|NCT03408587|BIOLOGICAL|CVA21|Oncolytic virus
219280412|NCT03408587|BIOLOGICAL|Ipilimumab|Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
219280413|NCT00446888|BEHAVIORAL|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
219280414|NCT00446888|DIETARY_SUPPLEMENT|Forticare|400 ml of commercially-available nutritional supplement.
219280415|NCT00446888|DIETARY_SUPPLEMENT|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
219280416|NCT02797652|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
219280417|NCT02797652|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
219280418|NCT04830553|BEHAVIORAL|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
219280419|NCT05355740|DRUG|Corsodyl|Corsodyl (a chlorhexidine mouthwash) will be used to rinse the mouth for one minute with 10 ml twice daily during ten days after oral surgery
219280420|NCT04434326|DRUG|[14]CM082 suspension|Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
219280421|NCT00960453|DRUG|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
219280422|NCT03273842|BIOLOGICAL|PF-06881894|pre-filled syringe 6 mg
219280423|NCT03273842|BIOLOGICAL|US-approved Neulasta|pre-filled syringe 6 mg
219280424|NCT01133223|DEVICE|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
219280425|NCT01133223|DRUG|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
219280426|NCT01384162|DRUG|sNN0029|ICV infusion
219280427|NCT00223223|DRUG|Levetiracetam, Keppra|
219280428|NCT02081053|DEVICE|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
219280429|NCT03870009|OTHER|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
219280430|NCT05214378|DEVICE|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
219280431|NCT02999074|OTHER|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
219280432|NCT02999074|OTHER|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
219280433|NCT02999074|OTHER|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
219280434|NCT05224089|DRUG|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
219280435|NCT05224089|DRUG|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
219280436|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
219280437|NCT04028921|OTHER|No intervention|This is a cross-sectional study; no intervention
219296359|NCT06643039|OTHER|Questionnaire|questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
219280438|NCT05349227|BEHAVIORAL|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
219280439|NCT05349227|DEVICE|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
219280440|NCT03085043|PROCEDURE|Bone Scan|Undergo bone scan
219280441|NCT03085043|PROCEDURE|Computed Tomography|Undergo CT of the abdomen and pelvis
219280442|NCT03085043|PROCEDURE|Magnetic Resonance Imaging|Undergo pelvic MRI
219280443|NCT03085043|PROCEDURE|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
219280444|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
219280445|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
219280446|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
219280447|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
219280448|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
219280449|NCT00572364|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
219280450|NCT06157281|BEHAVIORAL|Connect|A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
219280451|NCT03451019|DRUG|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
219280452|NCT03451019|DRUG|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
219280453|NCT02420613|RADIATION|Radiation Therapy|Undergo radiation therapy
219280454|NCT02420613|DRUG|Temsirolimus|Given IV
219280455|NCT02420613|DRUG|Vorinostat|Given PO
219280456|NCT05575375|BEHAVIORAL|Values Affirmation + Usual Care|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. The participant's study medication monitoring devices will be labeled with the participants' most important core value(s). Participants will also continue with their usual care.
219280457|NCT05575375|OTHER|Usual Care|Participants will be asked to continue with their usual care (e.g., cardiac rehabilitation, ongoing medical management)
219280458|NCT05345990|DRUG|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
219280459|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)|25mg/kg SUL and 25mg/kg DUR
219280460|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)|20mg/kg SUL and 20mg/kg DUR
219280461|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)|25mg/kg SUL and 25mg/kg DUR
219280462|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)|20mg/kg SUL and 20mg/kg DUR
219280463|NCT01734239|BIOLOGICAL|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
219280464|NCT04018677|BEHAVIORAL|Use of TOGETHERCare app|TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
219280465|NCT05551325|OTHER|Chronobundle - light|"Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance."
219280466|NCT05551325|OTHER|chronobundle - feeding|For patients receiving enteral feeds, time-restricted (daytime) intermittent feeding will include 4 meals delivered at 08:00, 12:00, 16:00 and 20:00. Each meal will include one-fourth of the recommended daily tube feed volume.
219296360|NCT01028313|DRUG|LBH589|20 mg PO three times weekly
219296361|NCT01028313|DRUG|Methylprednisolone|1 mg/kg/day PO continuously
219296362|NCT00440921|DRUG|Single donor Allogenous Fibrin Sealant|
219280467|NCT05551325|OTHER|chronobundle - mobility|While in the MICU, exercise/mobility sessions led by physical therapy or occupational therapy providers will occur twice daily between 09:00 and 16:00 (i.e., one additional session beyond usual care); intensity will be determined by clinical status and documented in the chart by our physical therapy service. Patients in other hospital locations (e.g., general medical ward post-MICU discharge) will receive one additional session beyond usual care via a study staff-led exercise/mobility session; intensity will be determined by clinical status.
219280468|NCT05551325|OTHER|chronobundle - sleep|Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
219280469|NCT03390959|OTHER|Proprioceptive Training|"Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints."
219280470|NCT03390959|OTHER|Control Group|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
219280471|NCT03889353|DEVICE|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
219280472|NCT06003842|OTHER|exercise|Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
219280473|NCT06003842|OTHER|taping|After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
219280474|NCT05765305|DRUG|Letrozole with chromium|Letrozole versus letrozole with chromium
219280475|NCT06331390|OTHER|niacinamide cosmetic product|immortella skincare product
219280476|NCT06331390|OTHER|placebo|nothing
219280477|NCT05248126|OTHER|Standard patient education|The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region \[Agence Régional de Santé Occitanie\].
219280478|NCT05248126|OTHER|Chatbot patient education|"The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention."
219280479|NCT06415123|DEVICE|MagnetOs Flex Matrix|MagnetOsTM Flex Matrix is a resorbable and osteoconductive bone graft for the repair of bony defects.
219280480|NCT01482689|DIETARY_SUPPLEMENT|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
219280481|NCT01482689|DIETARY_SUPPLEMENT|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
219280482|NCT01408420|PROCEDURE|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP \> 60 mmHg during extracorporeal circulation is used.
219280483|NCT00307762|BEHAVIORAL|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
219280484|NCT02859129|DRUG|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
219280485|NCT02859129|DRUG|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
219296363|NCT00604825|DRUG|Other: Placebo|
219296364|NCT00604825|DRUG|GSK232802|
219296365|NCT00604825|DRUG|PREMARIN|
219280486|NCT02859129|DRUG|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
219280487|NCT02859129|DRUG|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
219280488|NCT03572426|OTHER|genotyping all subjects|genotyping using SNaPshot genotyping method.
219280489|NCT04614701|PROCEDURE|Carotid Artery Ultrasound Measure|"Cardiac output will be assessed by measuring the LVOT diameter in parasternal long-axis window and the LVOT VTI in apical-four window. Carotid artery flow will be measured on the right neck 1-2cm from the bifurcation of the common carotid artery. All measurements will be taken with participants supine and the head of the bed elevated to 45°. measures all at 3 minute intervals.~1. One-leg compression test: Thigh-sized blood pressure cuff inflated to 60mmHg on middle part of one thigh for 60 seconds. LVOT and CCA measurements taken separately.~2. Two-leg compression test: Thigh-sized blood pressure cuff inflated on middle part of both thighs for 60 seconds. LVOT and CCA measurements taken separately.~3. Passive leg raise test: Bed adjusted to place participant at 0° and legs elevated at 45° by use of pillows. After 1 minute, measurements repeated. LVOT and CCA measurements taken separately."
219280490|NCT04331457|RADIATION|Brain magnetic resonance imaging (MRI) , computed tomography (CT)|imaging
219280491|NCT01627951|OTHER|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
219280492|NCT01627951|OTHER|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
219280493|NCT01627951|OTHER|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
219280494|NCT03342274|BEHAVIORAL|Lifestyle Program|Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.
219280495|NCT03342274|OTHER|Usual Care|Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
219280496|NCT04403568|DRUG|Ursolic Acid|Ursolic Acid 150mg
219280497|NCT04403568|DRUG|Curcumin|Curcumin 600mg
219280498|NCT00863681|DRUG|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
219280499|NCT04850664|DRUG|CBOT + TAU|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
219280500|NCT04850664|DRUG|Sham + TAU|Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
219280501|NCT03031496|DRUG|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
219280502|NCT03031496|DRUG|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
219280503|NCT00895557|DRUG|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
219280504|NCT01254552|DRUG|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
219280505|NCT01254552|DRUG|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
219280506|NCT05057871|DEVICE|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
219280507|NCT05057871|DEVICE|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
219280508|NCT06256081|DEVICE|Hear Glue ear application|Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
219280509|NCT00821340|GENETIC|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
219280510|NCT02103517|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
219280511|NCT02103517|DIETARY_SUPPLEMENT|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
219280512|NCT01533818|DRUG|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
219280513|NCT01533818|DRUG|Sugar Syrup|It will be given 2 times/day for 7 days
219280514|NCT00175643|DRUG|imiquimod|
219280515|NCT05785403|OTHER|No intervention|No intervention
219280516|NCT02579135|BEHAVIORAL|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
219280517|NCT02579135|BEHAVIORAL|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
219280518|NCT04647838|DRUG|Tepotinib|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
219280519|NCT01146600|DRUG|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
219280520|NCT01146600|DRUG|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
219280521|NCT05085171|OTHER|Enhanced care package|The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections
219280522|NCT03507426|PROCEDURE|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% \& Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
219280523|NCT03507426|PROCEDURE|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
219280524|NCT06107868|DRUG|RP-6306|RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
219280525|NCT06107868|DRUG|Carboplatin|Carboplatin is an antineoplastic agent.
219280526|NCT06107868|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent.
219280527|NCT02812940|DRUG|Everolimus|GvHD prophylaxis
219280528|NCT05143398|DIETARY_SUPPLEMENT|Diet + protein|Comparison of the efficacy
219280529|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA|Comparison of the efficacy
219280530|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA and TCA|Comparison of the efficacy
219280531|NCT05143398|OTHER|Diet|Comparison of the efficacy
219280532|NCT04870268|PROCEDURE|percutaneous drainage|
219280533|NCT04870268|PROCEDURE|endoscopic approach|
219280534|NCT04870268|PROCEDURE|surgical internal derivation of WON|
219280535|NCT04870268|PROCEDURE|surgical necrosectomy|
219280536|NCT04218032|DEVICE|sphygmomanometer, SpyghmoCor, CNAP500|blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
219280537|NCT05378477|DEVICE|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
219280538|NCT05378477|DEVICE|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
219280539|NCT05378477|DRUG|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
219280540|NCT05378477|DEVICE|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
219280541|NCT02766777|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration.
219280542|NCT04243551|DRUG|Latiglutenase|Administered orally (daily)
219280543|NCT04243551|OTHER|Placebo|Administered orally (daily)
219280544|NCT04996732|PROCEDURE|hospitalization|Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
219280545|NCT02182050|DRUG|BIBF 1120 ES low dose|
219280546|NCT02182050|DRUG|BIBF 1120 ES high dose|
219280547|NCT02182050|DRUG|Placebo to BIBF 1120 ES|
219280548|NCT04995770|BEHAVIORAL|Praise Text Messages|Texting messages with praise content, to positive reinforce medication adherence
219280549|NCT05684549|OTHER|No intervention|Observational study, no intervention
219280550|NCT02157051|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
219280551|NCT02157051|OTHER|Laboratory Biomarker Analysis|Correlative studies
219280552|NCT06064019|DEVICE|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
219280553|NCT06382662|DRUG|metaxalone m640|A single dose of micronize metaxalone 640 mg
219280554|NCT06382662|DRUG|tizanidine|A single dose of tizanidine 8 mg
219280555|NCT00612118|DRUG|GSK256066|200mcg bd
219280556|NCT00612118|DRUG|azelastine hydrochloride|140mcg
219280557|NCT02358447|PROCEDURE|TKR|non-navigated versus computer-navigated total knee replacement
219280558|NCT01238536|PROCEDURE|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
219280559|NCT01238536|PROCEDURE|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
219280560|NCT01238536|DRUG|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
219280561|NCT01238536|DRUG|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
219280562|NCT00967005|DRUG|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
219280563|NCT00967005|OTHER|Sugar Pill|placebo control
219280564|NCT00423566|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
219280565|NCT05529888|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
219280566|NCT01371825|DRUG|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
219280567|NCT05435053|DRUG|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
219280568|NCT05435053|DEVICE|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
219280569|NCT05729308|PROCEDURE|caudal epidural block|"The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space"
219280570|NCT05729308|PROCEDURE|bilateral erector spinae plane block|The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
219280571|NCT05729308|PROCEDURE|general anesthesia with intravenous analgesia.|"* Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~* Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~* The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered."
219280572|NCT03362983|OTHER|CareHND|Multidisciplinary, integrated, person-centered care at the integrated HND-clinic
219280573|NCT03019640|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
219280574|NCT03019640|DRUG|Carmustine|Given IV
219280575|NCT03019640|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
219280576|NCT03019640|DRUG|Cytarabine|Given IV
219280577|NCT03019640|DRUG|Etoposide|Given IV
219280578|NCT03019640|BIOLOGICAL|Filgrastim|Given SC
219280579|NCT03019640|DRUG|Lenalidomide|Given PO
219280580|NCT03019640|DRUG|Melphalan|Given IV
219280581|NCT03019640|BIOLOGICAL|Rituximab|Given IV
219280582|NCT00065923|DRUG|Topiramate|
219280583|NCT03566004|DIAGNOSTIC_TEST|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
219280584|NCT05723445|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
219280585|NCT03766776|DRUG|Anlotinib|Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
219280586|NCT05372107|DRUG|AG-80308|AG-80308 Eye Drop Solution
219280587|NCT06390384|OTHER|blinded-care counselling|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 2) weekly counselling over 6 weeks via videoconference for adolescents and their parents.~The counselling will be provided by experienced psychologists as employers of the Clinic of Child and Adolescent Psychiatry, RWTH Aachen University, the counselling will be supervised by the leading psychologist of the clinic. The counselling will include psychoeducative elements about psychological and psychosocial problems, behavioral interventions from cognitive-behavioral therapy, psychological techniques for better coping with stress, different therapeutic tasks such as fear exposure, activation exercises e.c. The students will be instructed to use the mobile treatment system STEPS in order to continue therapy at home."
219280588|NCT06390384|OTHER|App STEPS|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 3) blinded-care use of the mobile treatment system STEPS®.~This is transdiagnostic digital treatment system which consists of a students front-end as an App and a therapist front-end as an online platform. The App and the platform are connected to each other. In such a way, an effective data transter (for example, symptom evaluation by the student and tasks and requests by the therapist), direct communication between a student and a therapist, as well as registration of emergency situation, are possible."
219280589|NCT06390384|OTHER|digital and mental literacy training|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®.~The intervention will include: 1) digital and mental literacy training for children, parents and teachers in the school.~This training program (4 weeks, 8 session a 2 lesson units, 2 sessions a week) includes information about rules and functions by using mobile applications, safety aspects of personal data, risks associated with data sharing, sexing and cybergrooming, managing social media, handling with fake news, influence of social media on mental health, forms of digital violence and strategies to cope with them."
219280590|NCT05910970|DRUG|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
219280591|NCT05910970|DRUG|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
219280592|NCT01162863|DRUG|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
219280593|NCT01162863|DRUG|Placebo|taken orally for 28 days
219280594|NCT01162863|OTHER|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
219280595|NCT00588692|DEVICE|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
219280596|NCT01274325|DRUG|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
219280597|NCT01274325|DRUG|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
219280598|NCT02867917|DRUG|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
219280599|NCT02867917|DRUG|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
219280600|NCT02867917|DRUG|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
219280601|NCT02498782|DRUG|Fexinidazole|
219280602|NCT02498782|DRUG|Placebo|
219280603|NCT05142007|BEHAVIORAL|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
219280604|NCT05142007|BEHAVIORAL|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
219280605|NCT00000920|DRUG|Ritonavir|
219280606|NCT00000920|DRUG|Saquinavir|
219280607|NCT00000920|DRUG|Lamivudine|
219280608|NCT00000920|DRUG|Zidovudine|
219280609|NCT01228253|DEVICE|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
219280610|NCT01228253|DEVICE|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
219280611|NCT04449419|OTHER|There is not intervention.|There is not intervention
219280612|NCT03552523|DEVICE|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
219280613|NCT03552523|OTHER|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
219280614|NCT01872559|OTHER|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
219280615|NCT03538938|BEHAVIORAL|1-Call Quitline Counseling|The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
219280616|NCT03538938|BEHAVIORAL|4-Call Quitline Counseling|The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
219280617|NCT03538938|DRUG|Nicotine patch|Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
219280618|NCT03538938|DRUG|Nicotine Patch and Nicotine Lozenge|The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
219280619|NCT03538938|BEHAVIORAL|SmokefreeTXT|SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
219280620|NCT03538938|BEHAVIORAL|No SmokefreeTXT|Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
219280621|NCT03538938|BEHAVIORAL|Financial Incentives for Treatment Engagement|Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
219280622|NCT03538938|BEHAVIORAL|No Financial Incentives for Treatment Engagement|No Financial Incentives for Treatment Engagement are offered.
219280623|NCT02758275|BEHAVIORAL|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~1. Behavior Modification (4360) Promotion of a behavior change.~2. Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~3. Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~4. Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~5. Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~6. Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
219280624|NCT00469690|DRUG|Acular, Xibrom|"1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
219280625|NCT01343862|DRUG|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
219280626|NCT01343862|DRUG|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
219280627|NCT03824652|OTHER|walnuts|2 ounces of walnuts daily for 4-10 weeks
219280628|NCT03824652|OTHER|usual diet|Subject continues usual diet
219280629|NCT03824652|OTHER|phone counseling with dietitian|Weekly calls with dietitian
219280630|NCT05780021|BEHAVIORAL|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
219280631|NCT05649969|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.
219280632|NCT05649969|BEHAVIORAL|Daily Food Intake Diary with Fitbit smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks
219280633|NCT05649969|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
219280634|NCT04312269|OTHER|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
219280635|NCT06319274|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
219280636|NCT06319274|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
219280637|NCT04311645|DRUG|Activated charcoal|Activated charcoal
219280638|NCT04311645|DIETARY_SUPPLEMENT|Dry seeds|Dry seeds
219280639|NCT00613743|DRUG|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
219280640|NCT00613743|DRUG|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
219280641|NCT02744170|DEVICE|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
219280642|NCT02744170|DEVICE|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
219280643|NCT02744170|DEVICE|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
219280644|NCT05208177|DRUG|SHR-1802＋camrelizumab + famitinib|SHR-1802 for injection，q3w； Camrelizumab for injection, q3w; Famitinib malate capsules, qd.
219280645|NCT05936424|OTHER|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
219280646|NCT05936424|OTHER|Non-Exercise Control Leg|One leg will serve as a non-exercise control
219280647|NCT01371708|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
219280648|NCT02523690|DRUG|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
219280649|NCT02523690|DRUG|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
219280650|NCT05141552|DRUG|Dapagliflozin 10Mg Tab|In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
219280651|NCT05650762|DEVICE|Cinesteam|Cinnamon-based Secondary dressing
219280652|NCT03617835|DRUG|R - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
219280653|NCT03617835|DRUG|T1 - Low dose of BI 655130|Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
219280654|NCT03617835|DRUG|T2 - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
219280655|NCT03617835|DRUG|T3 - High dose of BI 655130|Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
219280656|NCT06045715|OTHER|follow-up with different time intervals|After radical surgery, patients are followed up with different time intervals
219280657|NCT01067846|DRUG|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
219280658|NCT01067846|DRUG|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
219280659|NCT01067846|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
219280660|NCT00753064|DRUG|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8"
219280661|NCT00753064|DRUG|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
219280662|NCT00753064|DRUG|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
219280663|NCT02831023|DRUG|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
219280664|NCT02831023|DRUG|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
219280665|NCT02831023|DRUG|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
219280666|NCT02831023|DRUG|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
219280667|NCT02831023|DRUG|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
219280668|NCT01173432|DEVICE|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
219280669|NCT01077518|DRUG|Ofatumumab|Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
219280670|NCT01077518|DRUG|Bendamustine infusion|Bendamustine 100 mg/vial, injection
219296366|NCT06076395|DEVICE|LMA (Laryngeal Mask Airway)|Pressure controlled versus Volume controlled ventilation using LMA
219296367|NCT04617275|DRUG|PF-06882961|PF-68882961 will be provided as tablets twice a day (BID)
219296368|NCT04617275|OTHER|Placebo|Placebo comparator will be provided as tablets twice daily for 12 weeks
219280671|NCT01077518|DRUG|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
219280672|NCT01077518|DRUG|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
219280673|NCT04197375|BEHAVIORAL|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
219280674|NCT04197375|BIOLOGICAL|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
219280675|NCT05876390|PROCEDURE|Breast surgery|Breast surgery
219280676|NCT05876390|DRUG|analgesia|Multimodal analgesia
219280677|NCT05223075|DRUG|articaine local anethesia with vasoconstrictor|buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth
219280678|NCT05223075|DRUG|lidocaine local anethesia with vasoconstrictor|buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
219280679|NCT01495598|DRUG|Pomalidomide|5 mg by mouth (p.o.) for 21 of 28 days
219280680|NCT00121927|BEHAVIORAL|Atkins diet (15 grams/day carbohydrates)|
219280681|NCT03599687|OTHER|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
219280682|NCT00762775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
219280683|NCT03635372|DRUG|Alginate|10 cc of Alginate peroral
219280684|NCT03635372|DRUG|Sucralfate|10 cc of Sucralfate peroral
219280685|NCT03635372|DRUG|Hydrotalcite|10 cc of Hydrotalcite peroral
219280686|NCT05499273|PROCEDURE|scalpel-bougie tracheostomy|"1. The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~2. The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~3. Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~4. Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~5. An 8 FR Frova catheter is inserted through the orifice into trachea.~6. A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
219280687|NCT05499273|PROCEDURE|rapid sequence tracheotomy|"1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
219280688|NCT01836939|DRUG|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
219280689|NCT01836939|DRUG|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
219280690|NCT02479724|DEVICE|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
219280691|NCT01807000|DRUG|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
219280692|NCT04536129|DRUG|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
219280693|NCT05998408|DRUG|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
219280694|NCT05511038|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
219280695|NCT05543447|DEVICE|Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device|Flow diversion therapy fpr intracranial aneurysm treatment.
219280696|NCT01366144|DRUG|Carboplatin|Given IV
219280697|NCT01366144|OTHER|Laboratory Biomarker Analysis|Correlative studies
219280698|NCT01366144|DRUG|Paclitaxel|Given IV
219280699|NCT01366144|OTHER|Pharmacological Study|Correlative studies
219280700|NCT01366144|DRUG|Veliparib|Given PO
219280701|NCT05140915|BEHAVIORAL|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
219280702|NCT05140915|BEHAVIORAL|Peer Coaching via Text|Peer coaching, facilitated by texting
219280703|NCT05140915|BEHAVIORAL|Gamification|Gamification, designed to motivate participation
219280704|NCT05140915|OTHER|E-Cigarette Cessation Materials|E-cigarette cessation materials by the Research Coordinator at the time of study enrollment.
219280705|NCT05867407|DEVICE|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
219280706|NCT05867407|OTHER|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
219280707|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
219280708|NCT04078997|OTHER|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
219280709|NCT04879849|DRUG|Pembrolizumab|IV infusion.
219280710|NCT04879849|DRUG|TAK-676|IV infusion.
219280711|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
219280712|NCT05360719|BEHAVIORAL|Group tele-exercise|This tele-exercise class will be tailored to the physical and emotional needs of individuals with SCI based on results of our feasibility study, the initial emergent themes from qualitative data collection in this study, and input from our co-leader with lived experience (examples: seated exercise to accommodate wheelchair users, active co-leader with SCI).The research clinician will lead the instruction of each class while our co-leader will model movements alongside her and offer tailored modifications as needed. Each 45-minute class provides a comprehensive fitness experience to maximize functional independence and improve global physical activity engagement. Elements incorporated into each class session include a collective check-in and breathing meditation, postural control, trunk and shoulder strength, cardiovascular fitness, and body awareness.
219280713|NCT03156790|DRUG|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
219280714|NCT06963957|OTHER|ChatGPT-4o Recommendations with Hallucinations|ChatGPT-4o's differential diagnoses of six clinical vignettes, three of which will contain deliberately introduced inaccurate information.
219280715|NCT05698173|BIOLOGICAL|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
219280716|NCT05698173|BIOLOGICAL|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
219280717|NCT03629171|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
219280718|NCT03629171|DRUG|Venetoclax|Given PO
219280719|NCT05985122|DIAGNOSTIC_TEST|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
219280720|NCT02468765|OTHER|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
219280721|NCT03746392|BEHAVIORAL|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
219280722|NCT03810235|DRUG|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
219280723|NCT03810235|DRUG|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
219280724|NCT05593094|DRUG|ZN-A-1041|ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
219280725|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
219280726|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
219280727|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b|ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
219280728|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
219280729|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
219280730|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c|ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
219280731|NCT04777864|BEHAVIORAL|Decision Aid|In addition to usual care, participants (parents and adolescents) receive the newly developed decision aid prior to their clinic visit(s). Clinicians receive a summary to review and use to help facilitate the decision making process.
219280732|NCT05538806|DEVICE|TTFields|all patients will receive routine clinical care and TTFields
219280733|NCT01647542|DRUG|TAK-875|TAK-875 tablets
219280734|NCT01647542|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
219280735|NCT05370651|DEVICE|BTL Emsella Chair|Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
219280736|NCT04045093|DRUG|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
219280737|NCT04045093|DRUG|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
219280738|NCT06457048|OTHER|Stroke Unit|The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
219280739|NCT03086655|BEHAVIORAL|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
219280740|NCT03086655|BEHAVIORAL|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
219280741|NCT03977896|PROCEDURE|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
219280742|NCT03976414|OTHER|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
219280743|NCT05269823|OTHER|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
219280744|NCT05269823|OTHER|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
219280745|NCT04153331|OTHER|Nasal swab|Patient included in emergency with a nasal swab
219280746|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
219280747|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
219280748|NCT04987203|DRUG|Tivozanib|Tivozanib will be administered orally.
219280749|NCT04987203|DRUG|Nivolumab|Nivolumab will be administered via intravenous infusion.
219280750|NCT04358575|DEVICE|Triathlon CS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
219280751|NCT04358575|DEVICE|Triathlon CS Knee System with metal-backed modular components|Primary Total Knee Replacement
219280752|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
219280753|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
219280754|NCT06967272|BIOLOGICAL|Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)|The controlled vaccine three doses administered orally
219280755|NCT05576662|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours
219280756|NCT05576662|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
219280757|NCT05576662|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours
219280758|NCT05323253|DEVICE|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
219280759|NCT04900974|DRUG|Doravirine|100mg
219280760|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
219280761|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219280762|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219280763|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
219280764|NCT02556099|DRUG|Hydroxyurea|drug to be administered
219280765|NCT03008005|DRUG|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
219280766|NCT03008005|DRUG|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
219280767|NCT03008005|DRUG|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
219280768|NCT06026410|DRUG|KO-2806|Oral administration
219280769|NCT06026410|DRUG|Cabozantinib|Oral administration
219280770|NCT06026410|DRUG|Adagrasib|Oral administration
219280771|NCT05534191|OTHER|Experimental, comparator and control|To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.
219280772|NCT05929898|BEHAVIORAL|Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback|fMRI neurofeedback training of sustained midbrain/VTA activation via motivational imagery.
219280773|NCT06967818|DRUG|Potassium Nitrate Gel|Topical application of a 5% potassium nitrate gel (Emofrom Actisens) used to treat dentin hypersensitivity.
219280774|NCT06967818|DEVICE|Diode Laser (Active)|Application of a 980 nm diode laser at 1.5 W/cm² for 1 minute without contact and 1 minute with contact, using a sweeping motion perpendicular to the long axis of the tooth.
219280775|NCT06967818|DEVICE|Diode Laser (Sham)|Inactive diode laser device used for 1 minute without contact and 1 minute with contact, mimicking the active laser procedure but without energy output.
219280776|NCT04569773|BEHAVIORAL|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
219280777|NCT04569773|BEHAVIORAL|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
219280778|NCT04569773|BEHAVIORAL|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
219280779|NCT05499832|DRUG|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
219280780|NCT02465151|OTHER|Protein-based beverage|protein-based beverage
219280781|NCT06413953|DRUG|TQB3107 Tablets|TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.
219280782|NCT05826145|BEHAVIORAL|Vocal Expression|There will be a total of 8 sessions. At baseline (week 0), only questionnaires will be completed. There will be 7 treatment sessions beginning at week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration where the vocal expression sessions will be provided.
219280783|NCT05826145|BEHAVIORAL|Cognitive Behavioral|There will be 8 treatment sessions where part of the baseline session of session 1 (week 0) will include some instruction, session 2 will occur in week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration. Sessions will include various cognitive-behavioral techniques including completing a grief monitoring diary, imaginal revisiting, cognitive restructuring, describing positive memories of the deceased, and identifying future goals.
219280784|NCT04296968|DEVICE|Painful stimulation using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In the experimental paradigm, 160 painful stimuli of two intensities (3 J, 3.5 J) will be applied to the dorsum of the left hand using the laser device listed above.
219280785|NCT04296968|DEVICE|Visual cueing|Preceding to each painful stimulus, visual cues (e.g., blue dot and yellow square) will be presented on a screen indicating the intensity of the subsequent stimulus (low and high intensity) with an accuracy of 75%. The contingencies of the visual cues will be explicitly stated to the participants.
219280786|NCT01744704|DRUG|rhNGF 0.5 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
219280787|NCT01744704|DRUG|rhNGF 5 µg/mL Sentinel|Part 0 represented a sentinel group.
219280788|NCT01744704|DRUG|rhNGF 20 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
219280789|NCT01744704|DRUG|rhNGF 20 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
219280790|NCT01744704|DRUG|rhNGF 60 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
219280791|NCT01744704|DRUG|rhNGF 180 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
219280792|NCT01744704|DRUG|rhNGF 20 µg/mL Part B|In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
219280793|NCT01744704|DRUG|rhNGF 60 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
219280794|NCT01744704|DRUG|rhNGF 180 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
219280795|NCT01744704|DRUG|Placebo Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
219280796|NCT01744704|DRUG|Placebo Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
219280797|NCT04522921|DIETARY_SUPPLEMENT|Diet with a higher amount of protein (25E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a higher protein (25E%/day) diet.
219280798|NCT04522921|BEHAVIORAL|Increased follow-up contact after the 10-week intervention|Both the control-group and the intervention-group were offered an increased follow-up contact after camp.
219280799|NCT04522921|DIETARY_SUPPLEMENT|Diet with a lower amount of protein (15E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a low-moderate protein (15E%/day) diet.
219280800|NCT00281268|PROCEDURE|pulmonary artery catheter|
219280801|NCT00281268|PROCEDURE|central venous catheter|
219280802|NCT00281268|PROCEDURE|fluid management|
219280803|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
219280804|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
219280805|NCT01040169|DEVICE|Arginine/Calcium Carbonate|One application
219280806|NCT01040169|DEVICE|Mint Prophy paste - Fluoride free|one application
219280807|NCT04201587|OTHER|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
219280808|NCT00350727|DRUG|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
219280809|NCT00350727|DRUG|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
219280810|NCT00966147|OTHER|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
219280811|NCT05202054|OTHER|mindfulness stress reduction program|Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
219280812|NCT00558792|DRUG|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
219280813|NCT00558792|DRUG|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
219280814|NCT00558792|DRUG|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
219280815|NCT03243435|PROCEDURE|Native 1,5 Tesla breast MRI|
219280816|NCT05371665|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Prevention and Early Intervention (PEI) Program|The prevention and early intervention is originally an indicated cognitive-behavioral program for 8-13-year-old youth with higher anxiety. Our CAB adapted it as a universal prevention and early intervention for all American Indian youth in the tribal community. It was delivered across six weeks with 20-30 min weekly sessions. Youth engaged in games and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involved introductions, relaxation training, and discussing emotions. Session 2 taught youth about worries and how to handle them. Session 3 focused on having conversations with others. Session 4 taught youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 taught youth how to face their fears. Session 6 was a review session. Parents and teachers were sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
219280817|NCT06374095|DRUG|RATG|Thymoglobulin, Genzyme corporation, Italy.
219280818|NCT06374095|DRUG|Basiliximab|Simulect, Novartis, Italy.
219280819|NCT01760798|DRUG|Teriparatide|
219280820|NCT03633799|DRUG|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
219280821|NCT02373631|OTHER|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
219280822|NCT02373631|OTHER|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
219280823|NCT04694807|BEHAVIORAL|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
219280824|NCT04694807|BEHAVIORAL|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
219280825|NCT06553391|DRUG|The tetralogy of medication regimen|"During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment."
219280826|NCT00631553|DRUG|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
219280827|NCT02082470|OTHER|follow-up care|Undergo survivorship care planning
219280828|NCT02082470|OTHER|active surveillance|Undergo cancer surveillance
219280829|NCT02082470|OTHER|questionnaire administration|Ancillary studies
219280830|NCT05691608|BIOLOGICAL|Solid tumor and CT DNA|Biopsy and blood sample
219280831|NCT04993469|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament testing and questionnaires|Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
219280832|NCT06389292|DRUG|APG-2575(Lisaftoclax )|QD, oral administration, every 28 days for a dosing cycle.
219280833|NCT06389292|OTHER|Placebo|QD, oral administration, every 28 days for a dosing cycle.
219280834|NCT06389292|DRUG|Azacitidine Injection|QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.
219280835|NCT06398912|OTHER|Music Based Intervention|Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
219280836|NCT05676463|PROCEDURE|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
219280837|NCT05676463|DRUG|Antiandrogen Therapy|Receive SOC ADT
219280838|NCT05676463|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
219280839|NCT05676463|PROCEDURE|Computed Tomography|Undergo CT
219280840|NCT05676463|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219280841|NCT05676463|PROCEDURE|Bone Scan|Undergo bone scan
219280842|NCT05676463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219280843|NCT05676463|OTHER|Quality-of-Life Assessment|Ancillary studies
219280844|NCT04554641|OTHER|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
219280845|NCT04554641|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
219280846|NCT04554641|OTHER|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
219280847|NCT02370901|DEVICE|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
219280848|NCT02370901|BEHAVIORAL|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
219280849|NCT00178451|DRUG|Abciximab|
219280850|NCT04200534|OTHER|Best Practice|Receive usual care counseling
219280851|NCT04200534|DRUG|Nicotine Patch|Given nicotine patches
219280852|NCT04200534|OTHER|Quality-of-Life Assessment|Ancillary studies
219280853|NCT04200534|OTHER|Questionnaire Administration|Ancillary studies
219280854|NCT04200534|OTHER|Tobacco Cessation Counseling|Receive counseling over the phone
219280855|NCT00004068|DRUG|irinotecan hydrochloride|
219280856|NCT00004068|DRUG|temozolomide|
219280857|NCT00004068|PROCEDURE|conventional surgery|
219280858|NCT00004068|RADIATION|radiation therapy|
219280859|NCT01348334|PROCEDURE|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
219280860|NCT03551691|DRUG|Omeprazole 20mg Capsule|Omeprazole 20mg daily for 28 days
219280861|NCT03551691|DRUG|Placebo oral capsule|Identically-appearing capsule to omeprazole for 28 days
219280862|NCT04187859|BEHAVIORAL|Education Session|Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
219280863|NCT04187859|DEVICE|Prompting Cup|The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
219280864|NCT00022581|DRUG|thalidomide|Given orally
219280865|NCT00022581|OTHER|laboratory biomarker analysis|Correlative studies
219280866|NCT03732768|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
219280867|NCT06202274|DEVICE|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
219280868|NCT06109467|DRUG|Neratinib|All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
219280869|NCT06109467|DRUG|Trastuzumab|All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
219280870|NCT06109467|DRUG|Oxaliplatin|All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
219280871|NCT06109467|DRUG|5-Fluorouracil + leucovorin|All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
219280872|NCT06109467|DRUG|Pembrolizumab|All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
219280873|NCT03520712|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
219280874|NCT06493409|DRUG|Repotrectinib|Specified dose on specified days
219280875|NCT06493409|DRUG|Voriconazole|Specified dose on specified days
219280876|NCT06493409|DRUG|Quinidine|Specified dose on specified days
219280877|NCT03694483|DIAGNOSTIC_TEST|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
219280878|NCT05494918|DRUG|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
219280879|NCT05846698|DRUG|Luo-Bu-Fu-Ke-Bi-RI Pill|10 pills twice daily
219280880|NCT05846698|DRUG|tibolone|2.5 mg once daily
219280881|NCT03788811|DEVICE|ERG assessment (RSPA)|Processing and analysis of retinal signals
219280882|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
219280883|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
219280884|NCT05436717|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
219280885|NCT06539390|OTHER|Transforaminal Epidural Injections?|Pain, lumbar disc herniation,Transforaminal Epidural Injections?
219280886|NCT05855967|DRUG|Ixekizumab|Administered SC
219280887|NCT07120919|OTHER|Peer Educatıon|The peer educators provided training on reproductive health and safe sexuality for young people and completed the intervention part by giving training brochures to the participants.
219280888|NCT07122180|DEVICE|CT3 Series Continuous Glucose Monitoring System:|The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated
219280889|NCT02446821|DRUG|VeraCept|IUD placement of VeraCept
219280890|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
219280891|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
219280892|NCT01894997|DEVICE|Neuromuscular electrical stimulator|
219280893|NCT01894997|DEVICE|AV Impulse System Model 6000|
219280894|NCT06600854|DEVICE|BoneTape|"BoneTape is a craniofacial fracture repair device intended for use in the fixation of non-load-bearing bones of the craniofacial and midfacial skeleton. It can be used in skeletally mature individuals but is not intended for use in the mandible and/or full load bearing procedures. It is composed of: 1) BoneTape implant (device), and 2) BoneTape applicator (applicator)."
219280895|NCT04254133|BEHAVIORAL|Questionnaire|Complete questionnaire
219280896|NCT04254133|PROCEDURE|Biospecimen Collection|Provide saliva samples
219280897|NCT04254133|DIAGNOSTIC_TEST|Genetic Testing|Undergo genetic testing
219280898|NCT04254133|OTHER|Genetic Counseling|Undergo counseling
219280899|NCT04254133|OTHER|Laboratory Biomarker Analysis|Correlative Studies
219280900|NCT02638883|DEVICE|Hybrid SRW cochlear implant|Subjects will be implanted with the Hybrid SRW
219280901|NCT04647747|OTHER|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
219280902|NCT05743699|BEHAVIORAL|Bright Horizons|Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
219280903|NCT05743699|BEHAVIORAL|Case Management|Placebo condition
219280904|NCT02284009|BIOLOGICAL|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
219280905|NCT02284009|BIOLOGICAL|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
219280906|NCT02284009|BIOLOGICAL|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
219280907|NCT06666036|BEHAVIORAL|Connect|Community level enhancements
219280908|NCT06604832|DRUG|PrabotulinumtoxinA-Xvfs|Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
219280909|NCT06604832|DRUG|IncobotulinumtoxinA|Each vial of incobotulinumtoxinA contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the right side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
219280910|NCT06604832|DRUG|saline solution (placebo)|As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
219280911|NCT06026553|DRUG|Ketorolac (Toradol)|IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
219280912|NCT06026553|OTHER|Placebo (saline)|IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
219280913|NCT02902159|OTHER|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
219280914|NCT02902159|OTHER|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
219280915|NCT02967640|DRUG|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
219280916|NCT02967640|DRUG|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
219280917|NCT04281251|PROCEDURE|Endoscopic retrograde appendicitis therapy|"Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith."
219280918|NCT02469883|DRUG|Sinotecean|
219280919|NCT03652350|PROCEDURE|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
219280920|NCT00075777|DRUG|valproic acid|250 mg by mouth twice a day
219280921|NCT03749304|DEVICE|ANI monitor|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
219280922|NCT03468790|DRUG|CMAB007|the study drug
219280923|NCT03468790|DRUG|Symbicort|asthma-controlled drug
219280924|NCT03468790|DRUG|Seretide|asthma-controlled drug
219280925|NCT03468790|DRUG|Ventolin|asthma rescue drug
219280926|NCT03468790|DRUG|placebo|No active components
219280927|NCT03882086|OTHER|foot reflexology|Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
219280928|NCT01349153|BEHAVIORAL|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
219280929|NCT01349153|BEHAVIORAL|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
219280930|NCT06859957|DRUG|Melatonin 10 mg|10 mg melatonin daily for a period of 6 weeks
219280931|NCT06859957|DRUG|Placebo|Daily placebo for a period of 6 weeks
219280932|NCT06860022|BEHAVIORAL|Shape Coding|Intervention will include introducing and reviewing the relevant shapes from Shape Coding and the order in which the shapes go in a sentence. The researcher will then model how to put the word tiles in order according to the shapes. Next the researcher and student work together to construct sentences. The student is then given the opportunity to independently construct sentences using the word tiles and Shape Coding. At the end of instruction, the researcher and student review the shapes and the student has the opportunity to independently construct sentences without shape coding.
219280933|NCT05427084|DRUG|Canagliflozin|Canagliflozin tablet 300mg PO daily
219280934|NCT05427084|DRUG|Placebo|Placebo tablet
219280935|NCT06611930|DRUG|CK-0045|Interleukin-22 agonist
219280936|NCT06611930|DRUG|Placebo|Placebo (liquid for injection, which includes no active ingredient).
219280937|NCT06586190|OTHER|Floor Pedal Bike with Guided Instructions for Home|Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.
219280938|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 1|Medium dose, approximately 10\^4.5 TCID50/mL
219280939|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 2|High dose, approximately 10\^5.5 TCID50/mL
219280940|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 3|TBD, depending on outcome of Part A
219280941|NCT06995196|BEHAVIORAL|ReLiver-N App|"Intervention for intervention group: Patients will access all content of ReLiver-N App. The ReLiver-N App has comprehensive health education, patient activation practices, care algorithm, and clinical decision system, to provide and maintain the hepatic rehabilitation of patients with liver cirrhosis and to evaluate the effect of the use of ReLiver-N App on hepatic rehabilitation. Care algorithm and clinical decision system will be evaluated results of patient activation as normal, controllable, urgent. Feedbacks will be sent to patients based on the evaluations."
219280942|NCT06669728|DIAGNOSTIC_TEST|AI diagnostic algorithm|The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
219280943|NCT06996249|BEHAVIORAL|Health-related quality of life and treatment outcome questionnaires|Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.
219280944|NCT06996249|GENETIC|(Tumor) tissue and other biomaterials|Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.
219280945|NCT06996249|PROCEDURE|Blood samples|Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).
219280946|NCT06996769|OTHER|constraint induced therapy|Constraint induced movement therapy (CIMT) is a treatment approach that can be used with patients who have had a CVA. In order to be eligible for the therapy, the clients must have at least 10 degrees of active wrist and finger extension. During this treatment the unaffected limb is restrained (usually with a sling or a mitt) for 90% of their waking hours. This treatment forces the client to use the affected limb throughout their daily tasks in order to combat learned non-use of the affected limb.
219280947|NCT06996769|OTHER|Conventional therapy for stroke patient|general exercises
219280948|NCT05687188|OTHER|Blood Sample Collection|Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
219280949|NCT05687188|OTHER|Tissue Sample Collection|At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
219280950|NCT05687188|OTHER|Data Collection|Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
219280951|NCT05687188|OTHER|Medical Image Collection|Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
219280952|NCT06673056|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
219280953|NCT06673056|OTHER|Placebo|Matching Placebo Sachet
219280954|NCT06324747|PROCEDURE|Vestibular socket therapy|Vestibular socket therapy will be used for the intervention.
219280955|NCT06324747|PROCEDURE|conventional full thickness flap|reflecting the mucoperiosteum to access the extraction socket
219280956|NCT05295433|DRUG|mRNA-3705|A sterile liquid for injection
219280957|NCT04897841|DRUG|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
219280958|NCT04897841|DRUG|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
219280959|NCT04897841|OTHER|saline|post-surgical saline
219280960|NCT07000240|OTHER|Midwife-led ultrasound-guided pushing training group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation.~Women randomized to the ultrasound-guided pushing training group will receive additional transperineal ultrasound (TPU) evaluations during practical exercises, performed by a midwife trained in ultrasound imaging. These assessments will ensure effective LAM relaxation during pushing practices and provide real-time visual feedback to optimize muscle coordination."
219280961|NCT07000240|OTHER|Midwife-led pushing training only group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation."
219280962|NCT06999863|OTHER|Patients of a surgical intensive care unit|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of BP in 3 situations (thick sleeve, thin sleeve, bare arm) and with 2 algorithms (for bare arm measurement only).
219280963|NCT06670287|OTHER|Single-Sensor Tracking (In-Lab)|In-lab sleep tracking using only raw accelerometer data from a single sensor collected and processed with legacy actigraphy algorithms.
219280964|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (In-Lab)|In-lab sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
219280965|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (At-Home)|At-home sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
219280966|NCT02769845|DRUG|Hydroxyurea|drug to be administered
219280967|NCT02769845|PROCEDURE|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
219280968|NCT02603328|DRUG|Atorvastatin|40-80 mg OD
219280969|NCT02603328|OTHER|Placebo|inactive
219280970|NCT06920225|BEHAVIORAL|Maintain home-based schedule|The team will maintain their home-based time zone schedule despite being in a location that is three time zones away
219280971|NCT07126873|BIOLOGICAL|Allogeneic Human E-islet (E-islet 01)|Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein
219280972|NCT07005427|OTHER|dysphagia therapy|"This group will receive usual dysphagia care as provided in ICU settings~* Standard bedside swallowing evaluation~* Conventional compensatory strategies (postural changes, diet modifications)~* Traditional exercises focusing on oral motor control~* Therapy sessions 3 times per week for 30 minutes"
219280973|NCT07005427|BEHAVIORAL|Designed protocol for dysphagia|"* Innovative strengthening exercises adapted for ICU setting~* Early mobilization component~* ICU-specific compensatory strategies~* Therapy sessions 5 times per week for 30 minutes with additional brief daily reinforcement"
219280974|NCT05915234|DEVICE|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
219280975|NCT05915234|DEVICE|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
219280976|NCT05915234|DEVICE|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
219280977|NCT06870201|DIETARY_SUPPLEMENT|Lipid-Based Nutrient Supplement|LNS labeled with a stable iron isotope
219280978|NCT06886139|DRUG|TRS005|Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.
219280979|NCT03898778|DEVICE|Minnesota Medical Technologies Anal Insert Device|Non-sterile soft, flexible, liquid-filled anal insert either 10 mm size or 13 mm size, meant for single use only
219280980|NCT07012525|PROCEDURE|Photobiomodulation Therapy + Hyaluronic Acid Gel Injection|This arm includes the test sites (e.g., left maxillary quadrant) in each participant. The same dose of hyaluronic acid (0.2 mL of 0.8% gel) will be injected in the same manner as in the control group. However, photobiomodulation therapy (PBMT) using a diode laser (wavelength 630-670 nm, 25 mW, 1.875 J/cm² for 20 seconds) will be applied before and after the injection. Laser application will be repeated at every follow-up appointment to promote tissue healing, angiogenesis, and papillary regeneration.
219280981|NCT07012525|DRUG|Hyaluronic Acid Gel Injection|This arm includes the control sites (e.g., right maxillary quadrant) in each participant. The interdental papilla with Class I deficiency will be treated using 0.2 mL of 0.8% commercial hyaluronic acid gel, injected 2-3 mm apical to the papilla tip. This is a commonly used non-surgical soft tissue filler in periodontal and esthetic procedures. No photobiomodulation therapy will be applied in this arm.
219280982|NCT05739331|DEVICE|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
219280983|NCT05430815|BEHAVIORAL|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
219280984|NCT06632015|DRUG|Calcium Hydroxide (CH)|1 mL distilled water mixed with 1 g calcium hydroxide powder, placed into the root canals using a lentulo spiral.
219280985|NCT06632015|DRUG|Diclofenac Sodium (DCS)|1 mL distilled water mixed with 1 g diclofenac sodium powder, placed into the root canals using a lentulo spiral.
219280986|NCT06632015|DRUG|Calcium Hydroxide + Diclofenac Sodium (CH + DCS)|1 mL distilled water mixed with 950 mg calcium hydroxide powder and 50 mg diclofenac sodium powder, placed into the root canals using a lentulo spiral.
219280987|NCT06810765|OTHER|Hormone Replacement Therapy (HRT)|Hormone Replacement Therapy (HRT) is a medical treatment that involves restoring healthy endocrine functioning through supplementing or balancing hormones, such as testosterone or estrogen, to address deficiencies caused by injury, aging, or stress.
219280988|NCT06810765|OTHER|Magnetic Resonance Therapy (MeRT)|MeRT, an EEG (electroencephalography)-guided Repetitive Transcranial Magnetic Stimulation therapy, is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain, guided by an individual's brain patterns. MeRT is a neuromodulatory tool that has shown therapeutic efficacy in relation to a number of psychopathological targets including PTSD, depression, and TBI-related cognitive impairment through promoting cortical excitability, modulating neurotransmission, and restoring neuroplasticity.
219280989|NCT06810765|DRUG|ibogaine with magnesium treatment|Ibogaine, an indole alkaloid that interacts with mu opioid, kappa opioid, N-methyl-D-aspartate receptor (NMDA), and nicotinic acetylcholine receptors, shows early signs of effectiveness as a rapid-acting treatment for a number of mental health disorders including addiction. It is believed to work by promoting neuroplasticity and modulating brain chemistry, which may help reset dysfunctional neural circuits. The treatment is unique in its psychoactive properties, offering a deeply introspective experience that may help individuals process emotional material from the individual's lives.
219280990|NCT06810765|DRUG|5-MeO-DMT|5-MeO-DMT, as described in the study, is a 5-HT 2A agonist compound used in previous clinical research to address depression. Unlike other treatments, 5-MeO-DMT acts rapidly and has a short duration of action, offering an intense but time-limited psychoactive state. Its potential to enhance neuroplasticity and recalibrate dysfunctional brain networks makes it a unique approach for addressing the complex interplay of psychological and neurological symptoms.
219280991|NCT06697301|DRUG|EIK1001|EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.
219280992|NCT06697301|DRUG|Pembrolizumab (KEYTRUDA® )|Pembrolizumab is a PD-1 inhibitor.
219280993|NCT07026084|OTHER|Bio feedback training|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~1\. BPU (Biofeedback Pressure Unit): performed at 5 pressure levels (22, 24, 26, 28, 30 mmHg).~Each level involves a 10-second hold, with 30 seconds rest between levels.~Targeted muscles:~* Deep Cervical Flexors (Capitus Longus, Capitus Colli).~* Rhomboids~* Trapezius Total duration (BPU): 20 minutes/session, performed 3 times/week."
219280994|NCT07026084|OTHER|conventional exercise program|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~EXERCISE PROGRAM:~* 1\. Supine: Neck curl with Chin Tucks (Deep Cervical Flexors Capitus Longus, Capitus Colli): 10 reps/session, holding each for 5 seconds.~* 2\. Sitting: Chin tuck with Head pushing against palm.~* 3\. Chin Up (Middle and Lower Trapezius): 10 reps/session, holding each for 5 seconds.~* 4\. Scapular Squeezes (Rhomboids): 2-3 sets of 10 reps/session, holding each for 5 seconds• 5. Doorway Pectoral Stretch (pect major) 2-3 reps, 30 sec hold (36)Total duration: 20 minutes/session, performed 3 times/week."
219280995|NCT06701032|OTHER|Cardiovascular rehabilitation program|The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)
219280996|NCT06626503|DRUG|Methadone based ERAS|Methadone intervention includes intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.05 mg/kg up to a maximum of 2.5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
219280997|NCT06626503|DRUG|Non-methadone based group|Non-methadone intervention includes standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards. Postoperative pain medication is recommended when reported pain level is considered moderate or higher (≥4 on NRS and FLACC).
219280998|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 1|Low dose, approximately 10\^4 TCID50/mL
219280999|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 2|Medium dose, approximately 10\^5 TCID50/mL
219281000|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 3|High dose, approximately 10\^6 TCID50/mL
219281001|NCT07025148|DRUG|Prasugrel|Prasugrel 5 mg od for 30 ± 5 days
219281002|NCT07025148|DRUG|Clopidogrel|Clopidogrel 75 mg od for 30 ± 5 days
219281003|NCT07137325|BEHAVIORAL|play therapy|"The intervention consisted of a structured play therapy program specifically designed for children residing in institutional care settings. What distinguishes this intervention from others is its targeted focus on reducing learned helplessness and improving social comparison tendencies, two psychological constructs particularly relevant to children in residential care.~The program was conducted over six weekly sessions, each lasting approximately 60 minutes, and implemented in a one-on-one format within a safe, quiet room in the child care facility. The content was developmentally appropriate and included modules on emotional expression, communication, realistic goal setting, resource awareness, problem-solving, and positive self-perception. The therapeutic techniques were based on principles of non-directive and humanistic play therapy, allowing children to express themselves freely while being guided through structured themes.~Unlike general play therapy programs, this intervention"
219281004|NCT07135882|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.~Radiotherapy Techniques:~* Highly conformal techniques (IMRT/VMAT)~* High-precision techniques are allowed for non-centrally located primaries~Radiotherapy Dose:~\- Several fractionation schedules allowed; minimum biological effective dose approximating 50Gy (α/β ratio = 10); 50Gy in 20 fractions, 40Gy in 15 fractions, and 35Gy in 5 fractions"
219281005|NCT07135882|DRUG|Standard of Care (SOC)|Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.
219281006|NCT07136519|DRUG|Toripalimab|240mg Q3W
219281007|NCT07136519|DIETARY_SUPPLEMENT|Omega-3|During radiotherapy, take 6 capsules once a day
219281008|NCT07136519|RADIATION|radiotherapy|radiotherapy
219281009|NCT07136519|DRUG|Paclitaxel (albumin bound)|260mg/m2 d1,Q3W
219281010|NCT07136519|DRUG|Cisplatin|80mg/m2 d2, Q3W
219281011|NCT07135336|PROCEDURE|surgery|Patients with preexisting cognitive impairment undergoing elective non-cardiac surgery under general anesthesia.
219281012|NCT07135336|OTHER|norma|Cognitively normal individuals who do not undergo surgery but complete the same cognitive assessments at baseline, 3 months, and 12 months for normative reference.
219281013|NCT07137299|OTHER|Questionnaire and Physical Exam|"All study participants will be evaluated to assess:~* Healing of the vaginal stump in the case of a total hysterectomy (normal/abnormal),~* Symptoms of stress urinary incontinence (Ingelmann-Sundber scale, where 0 - no symptoms, Grade I - symptoms with coughing, pressure on the suprapubic area, laughing, or strenuous exertion, Grade II - loss of urine when levering, running, or climbing stairs, Grade III - loss of urine when lying down or standing without physical exertion)~* Symptoms of an overactive bladder - present, absent~* Symptoms of prolapse in the anterior and posterior compartments (assessed based on the POPQ scale) with an assessment of the defect site based on the de Lancey classification The examination will be performed by or with the assistance of a specialist in obstetrics and gynecology"
219281014|NCT07136142|DRUG|FH-006 for Injection|FH-006 for injection.
219281015|NCT07137507|PROCEDURE|Uniportal VATS|Decortication of pleural empyema is done using single-port VATS
219281016|NCT07137507|PROCEDURE|Multi-portal VATS|Decortication of pleural empyema is done using two or more ports with VATS
219296369|NCT05853380|DEVICE|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
219296370|NCT02549105|DRUG|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
219296371|NCT02549105|DRUG|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
219296372|NCT05177887|DEVICE|Traumacel PULVIS, Traumacel ENDO Applicator|Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
219281017|NCT07135570|DIAGNOSTIC_TEST|Multimodal Screening for Eye Disease|The eye disease screening process involved twelve distinct steps were that organized through a corresponding software platform (electronic health record). These steps included: (1) community awareness campaign, (2) participant registration, (3) blood pressure and finger-stick blood glucose measurement, (4) basic vision test, (5) on-site optometrist evaluation, (6) obtaining informed consent for imaging, (7) fundus imaging, (8) automated AI-based disease detection, (9) on-site ophthalmologist examination, (10) remote eye specialist review, (11) on-site counselor discussion, (12) referral for local surgery. This standardized protocol promoted the alignment of eye screening with data gathering and ongoing follow-up eye care interventions. All participants were offered steps 1 to 5. Those participants eligible for fundus imaging (Steps 6-8) included those with diabetes, hypertension, age 50+, or optometrist recommendation based on presenting symptoms.
219281018|NCT07135570|PROCEDURE|cataract surgery|Individuals diagnosed with high grade cataracts associated with moderate to sever visual impairment were offered cataract surgery, either through local surgery services or regional specialized vision services.
219281019|NCT07137559|DRUG|CELZ-201-DDT|"CELZ-201-DDT is administered via intramuscular injection.~Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations."
219281020|NCT07137949|BEHAVIORAL|Music therapy|Live music therapy (MT) sessions will occur 3 times/week, up to 5 sessions. Sessions will be responsive to patient preferences, culture, and identity using information gained from medical record review, intake assessment, and in the moment therapeutic assessments.
219281021|NCT07136649|DEVICE|Custom CAD/CAM Insoles|Custom insoles will be designed using 3D plantar scanning and pedobarographic analysis, produced with CAD/CAM technology. The insoles will be fitted into participants' regular footwear and worn daily for eight consecutive weeks. The design aims to optimize plantar pressure distribution and improve foot biomechanics in individuals with foot deformities.
219281022|NCT07136506|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219281023|NCT07136506|OTHER|Post-recording questionnaire|The post-recording questionnaire aims at describing as much as possible the subject activity and quality of life during the recording period while being as low a burden as possible for the subject. The question formats are, on one hand, inspired by Quality of life and Physical Activity questionnaires usually used in Clinical Research and, on the other hand, based on device-specific needs for an optimal analysis. It covers fatigue status, physical status, physical activity with the Syde®, event(s) or condition(s) that may have impacted the ability to wear the Syde® during the recording.
219281024|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 2hr wear|400mg progesterone Callavid, 2 hour wear, twice daily for 7 days
219281025|NCT07136922|DRUG|Cyclogest 400 mg|Cyclogest 400 mg pessary, twice daily for 7 days
219281026|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 3hr wear|400mg progesterone Callavid, 3 hour wear, twice daily for 7 days
219281027|NCT07136935|DRUG|Traditional Chinese Medicine treatment|"1. Oral Chinese herbal medicine or decoction: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them once a week.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint, the application time is 2 to 4 hours.~5. Nursing and health education and guidance.~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes.~7. Lifestyle health education and sports rehabilitation: Playing Baduanjin, ten skilled hand exercise, and health preservation videos, and providing personalized TCM exercise recommendations."
219281028|NCT07136363|DEVICE|DynamiCare|DynamiCare is a mobile contingency management (CM) platform. Participants randomized to this intervention receive access to the DynamiCare app, an FDA-approved mobile application that delivers CM through features such as at-home saliva drug testing, appointment check-ins, and incentives for healthy behaviors. The app is designed to promote substance use reduction and engagement in care by providing financial rewards for meeting health-related goals. The intervention aims to improve initiation and retention in HIV prevention or treatment (PrEP or ART), reduce stimulant use, and enhance overall health outcomes among justice-involved individuals.
219281029|NCT07136363|BEHAVIORAL|Patient Navigation (PN)|Participants work with a trained patient navigator (PN) who provides individualized support, assists with linkage to medical and social services, and helps address barriers to care. The PN meets with participants weekly during the first month and biweekly thereafter to conduct a comprehensive needs assessment and provide tailored support. This includes assistance with obtaining housing, identification, insurance, transportation, and linkage to health and social services such as HIV prevention or treatment (PrEP/ART), substance use disorder treatment, and other community-based care. The navigation protocol follows established procedures from prior studies (e.g., ACTION). All participants receive a smartphone to support communication and appointment coordination.
219281030|NCT07138170|PROCEDURE|Proximal Radial Artery Access|Using Proximal Radial Artery Access for Cardiac Catheterization
219281031|NCT07138170|PROCEDURE|Distal Radial Artery Access|Using Distal Radial Artery access for Cardiac Catheterization
219296373|NCT00695032|DRUG|cisplatin|
219281032|NCT07135622|DIAGNOSTIC_TEST|Xpert® MTB/RIF Ultra|Xpert® MTB/RIF Ultra test introduced for tuberculosis diagnosis at clinical trial sites randomized to interventional arm
219281033|NCT07135622|OTHER|Referral to the specialized TB clinics|No intervention introduced at clinical trial sites randomized to control arm, patients follow standard care: referral to specialized TB clinics
219281034|NCT07135661|RADIATION|moderate hypofractionated proton radiotherapy|moderate hypofractionated proton radiotherapy: Whole Breast Irradiation, at 40 Gy(RBE) in 15 fractions, tumor bed SIB to 48Gy(RBE)
219281035|NCT07135661|RADIATION|ultra-hypofractionated proton radiotherapy|Ultra-hypofractionated proton radiotherapy:Whole breast radiotherapy, 26 Gy(RBE) in 5 fractions，tumor bed boost with 10Gy(RBE) in 2 fractions.
219281036|NCT07136428|COMBINATION_PRODUCT|Asciminib and Trastuzumab|Each study treatment cycle will last 21 days. Asciminib will be taken orally every day during the treatment period at the dose determined as the MTD during the safety lead-in in combination with trastuzumab at a standard dose of 6mg/kg IV. Asciminib dose will begin at 80 mg daily (dose level 1), with a potential range from 40 mg daily (dose level -1A, with trastuzumab) to 200 mg bid (dose level 3, with trastuzumab) depending on the results of the safety lead-in. Trastuzumab will be given intravenously (IV) or subcutaneously (SQ) on Day 1 of each 21 day cycle.
219281037|NCT07138183|BEHAVIORAL|NP-led MDT|a nurse practitioner-led multidisciplinary team (MDT).
219281038|NCT07138183|BEHAVIORAL|Usual Care|Participants will receive usual inpatient care provided by the primary care team.
219281039|NCT07137897|OTHER|Telerehabilitation|"Telerehabilitation involves a physiotherapy program delivered remotely using digital tools. Participants perform exercises independently with remote support from a physiotherapist, including:~Weekly scheduled phone consultations~Live virtual consultations via MS Teams, Zoom, or Skype~Text messages and emails for personalized guidance, motivation, and ongoing problem-solving~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
219281040|NCT07137897|OTHER|Control group|"Patients in the control group will receive written instructions for a home exercise program. They will independently perform the rehabilitation program at home without remote supervision.~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
219281041|NCT07137715|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
219281042|NCT07137715|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
219281043|NCT07137715|OTHER|Usual Care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
219281044|NCT07136415|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-i)|This is a program called SHUT-i and is composed of six self-guided sessions on a website over 6-9 weeks. Each session will be about 45-60 minutes long. CBT-I involves changing behaviors that cause sleep problems to persist. However, it also includes teaching skills to teach the participant to identify thoughts and feelings that may contribute to sleep problems.
219281045|NCT07136415|DRUG|Trazodone|"Trazodone is a heterocyclic medication that is FDA-approved for depression (starting dose 150mg). An estimated 4 in 5 trazodone prescriptions are for insomnia. Low-dose trazodone's frequent off-label use stems from a long-standing perception that trazodone is an effective and safer sleep aid compared to other drugs despite potential risks documented in small studies.~A starting dosage of 25 mg will be used. After 1 week, patients will be instructed to increase the dose as needed to 50mg if tolerated. A second dose adjustment will be made at 4 weeks. At four weeks, study staff will contact participants and review medication adherence, and a standardized checklist will be used to assess ongoing symptoms and side effects and to consider an increase in dose to 100mg."
219281046|NCT07136415|DRUG|Daridorexant|"Daridorexant is a DORA drug. Dual orexin receptor antagonists (DORAs) are the newest class of FDA-approved medications for insomnia based on efficacy data from pivotal clinical trials demonstrating their efficacy for sleep onset and maintenance.~A single dose of 50 mg (1 pill each night within 30 minutes of bedtime) was selected based on better efficacy without evidence of higher risks than the 25mg dose."
219281047|NCT07136337|DIAGNOSTIC_TEST|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by flow cytometry
219281048|NCT07135232|DIETARY_SUPPLEMENT|Sarmentosin - L- theanine|A capsule containing 275.184 mg of Sarmentosin and 400mg of L-theanine
219281049|NCT07135232|OTHER|Resistance Training|Home-based Resistance training. Exercises will target the lower and upper body and utilise body weight, resistance bands, dumbbells and push-up handles.
219281050|NCT07135232|DIETARY_SUPPLEMENT|Placebo Supplement|Capsule matched for taste and appearance, without any active ingredients.
219281051|NCT07138378|DRUG|XS003 (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
219281052|NCT07138378|DRUG|Tasigna (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
219281053|NCT07137104|DRUG|HeXell-2020|"Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose.~Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose.~Phase IIa: RP2D from phase I."
219281054|NCT07137871|DRUG|Avasopasem|Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy
219281055|NCT07137078|OTHER|pilates|"Pilates exercises, particularly those focusing on core stability, balance, and flexibility, are highly beneficial for individuals at risk of falls. These exercises enhance proprioception, which is the body's ability to sense movement, action, and location, thereby improving coordination and balance. For example, exercises like the Single Leg Stretch and Roll-Up target the abdominal muscles, which are crucial for maintaining stability. Additionally, Leg Circles and Side Planks help strengthen hip abductors and stabilizers, contributing to better postural alignment and reducing the likelihood of falls. By regularly incorporating Pilates into a fitness routine, individuals can build strength and confidence, ultimately helping to prevent falls and maintain independence."
219281056|NCT07137078|OTHER|gyrotonic expansion exercise|Exercise phase Training Time Warm-Up Gentle, dynamic stretches focusing on the spine, hips, and legs. Gently roll the head from side to side to release tension, Move shoulders in a circular motion to loosen muscles, While standing, rotate the torso gently from side to side, Rotate each ankle in both directions to improve mobility. 5 minutes Core Activation Using pulley rope system the Arch and Curl, to engage the abdominal muscles, Focus on maintaining proper alignment and breathing deeply. 13 minutes Balance and Coordination Using pulley rope system Standing Series, shifting weight, such as the Spiral Sequence, to improve coordination. 12 minutes Flexibility and Range of Motion Leg stretches using the Leg Extension Unit to improve hip and knee range of motion. 5 minutes
219281057|NCT07138092|OTHER|i jel LMA|Patients will be inserted i jel laryngeal mask under general anesthesia.
219281058|NCT07138092|OTHER|proseal LMA|Patients will be inserted proseal laryngeal mask under general anesthesia.
219281059|NCT07135492|DIAGNOSTIC_TEST|continuous noninvasive hemoglobin monitoring|noninvasive hemoglobin monitoring, Rainbow® Adult ReSposable™ sensors (Rev E) were placed on either the ring or middle fingertip of each participant and connected to a Radical-7 Pulse CO-Oximeter (SET version 7601; Masimo Corp., Irvine, CA).
219281060|NCT07137689|DRUG|LY3537982|Administered orally
219281061|NCT07136480|DEVICE|Microwave Diathermy|Continuous mode microwave diathermy (2,450 MHz) will be applied to the lumbar region using a standard physiotherapy unit. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
219296374|NCT00695032|DRUG|ifosfamide|
219296375|NCT00695032|OTHER|laboratory biomarker analysis|
219296376|NCT05772273|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
219281062|NCT07136480|DEVICE|Shortwave Diathermy|Continuous mode shortwave diathermy (27.12 MHz) will be delivered to the lumbar region using capacitive or inductive electrodes according to manufacturer guidelines. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
219281063|NCT07136480|DEVICE|Therapeutic Ultrasound|Continuous mode therapeutic ultrasound at 1 MHz frequency and 1.5 W/cm² intensity will be applied to the lumbar paraspinal muscles with slow circular movements using a coupling gel. Treatment will last 10 minutes per session, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
219281064|NCT07136480|BEHAVIORAL|Lumbar Stabilization and Flexibility Exercise|Participants will perform a home-based lumbar stabilization exercise program, including stretching, core strengthening, and posture correction exercises, supervised weekly by a physiotherapist. The program will be performed 3 sessions per week for 4 consecutive weeks.
219281065|NCT07135544|DRUG|Adebrelimab combined with the GC regimen and Apatinib|Adebrelimab 1200mg, intravenous infusion, on day 1, repeated every 3 weeks; Gemcitabine 1000mg/m2, on days 1 and 8, every 3 weeks Cisplatin 50mg/m2, on day 1, every 3 weeks Apatinib 250mg, once daily, orally
219281066|NCT07136662|OTHER|educational|see arm description
219281067|NCT07137780|DEVICE|Lokomat® V6 (GF < 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of less than 90%. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
219281068|NCT07137780|DEVICE|Lokomat® V6 (GF ≥ 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
219281069|NCT07137780|DEVICE|RoboGait®|Robotic-assisted gait training using the RoboGait® system (BAMA Teknoloji, Türkiye) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
219281070|NCT02169310|DEVICE|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
219281071|NCT02169310|DRUG|[11C] Raclopride|\[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
219281072|NCT06737705|DRUG|Baritinib|Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
219281073|NCT06889038|OTHER|Hyperbaric oxygen therapy combined with polarized light therapy|Optimum regime of therapy increase healing rate of neuropathic foot ulcer is a challenge for researchers to save patient normal life
219281074|NCT06889038|OTHER|traditional treatment|topical medication
219281075|NCT06551064|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
219281076|NCT06551064|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
219281077|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
219281078|NCT06409390|DRUG|Taxotere|75 mg/m2 once every 21 days for 4 cycles
219281079|NCT06409390|DRUG|Cytoxan|600 mg/m2 once every 21 days for 4 cycles
219281080|NCT06409390|DRUG|Trastuzumab deruxtecan|5.4 mg/kg once every 21 days for 5 cycles
219281081|NCT06409390|DRUG|Sacituzumab govitecan|10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
219281082|NCT06409390|DRUG|Xeloda|1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
219281083|NCT06409390|DRUG|Fulvestrant|500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
219281084|NCT06409390|DRUG|Ribociclib|600 mg orally daily 21 days on, 7 days off
219281085|NCT06409390|DRUG|Abemaciclib|150 mg by mouth twice daily
219281086|NCT06063850|GENETIC|AAV9-hSyn1-miGRIK2|AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
219281087|NCT04092530|BEHAVIORAL|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
219281088|NCT04494451|DRUG|Vit C|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
219281089|NCT04494451|DRUG|Standard medical Treatment|iv antibiotics alone
219281090|NCT05082168|DEVICE|Capnodynamic monitoring|"In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2."
219281091|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
219281092|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
219281093|NCT04942366|OTHER|High intensity interval training|HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
219281094|NCT04942366|OTHER|Strength training|Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
219281095|NCT04471831|OTHER|Rehabilitation exercise protocol|"The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions."
219281096|NCT03395977|DRUG|Placebos|Lactose placebo for pills and saline for perfusion.
219281097|NCT03395977|DRUG|Febuxostat|Febuxostat tablet.
219281098|NCT03395977|DRUG|Rasburicase|Rasburicase injectable solution.
219281099|NCT06791486|OTHER|AI-assisted predictive model|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.
219281100|NCT04829097|COMBINATION_PRODUCT|Temozolomide|The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
219296377|NCT05772273|BIOLOGICAL|Donor lymphocyte infusion|The 4 DLI doses (dose range: ±10%) of sib-matched donor HSCT patients were 1×10\^6/kg, 5×10\^6/kg, 1×10\^7/kg, 5×10\^7/kg; The 4 DLI doses (dose range: ±10%) of haploidentical or unrelated donor HSCT patients were 1×10\^5/kg, 5×10\^5/kg, 1×10\^6/kg, 5×10\^6/kg.
219296378|NCT05772273|DRUG|Camrelizumab|Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
219296379|NCT00231803|OTHER|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
219281101|NCT05441709|BEHAVIORAL|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
219281102|NCT01478997|DIETARY_SUPPLEMENT|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
219281103|NCT01478997|DIETARY_SUPPLEMENT|Placebo Capsules|Carboxy Methyl Cellulose
219281104|NCT05190783|DRUG|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
219281105|NCT05190783|DRUG|MTA|material used for pulp regeneration, direct and indirect pulp capping
219281106|NCT05190783|DRUG|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
219281107|NCT05190783|PROCEDURE|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
219281108|NCT05190783|PROCEDURE|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
219281109|NCT02243111|RADIATION|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
219281110|NCT01605578|PROCEDURE|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
219281111|NCT01342289|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
219281112|NCT01342289|DRUG|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.
219281113|NCT01342289|RADIATION|Total body irradiation|Day -1: 200 centigray in one fraction.
219281114|NCT01342289|DRUG|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
219281115|NCT01342289|DRUG|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
219281116|NCT01342289|DRUG|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
219281117|NCT01342289|DRUG|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
219281118|NCT01342289|BIOLOGICAL|Bone marrow transplant|Donor stem cells infused IV on Day 0.
219281119|NCT04996004|DRUG|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
219281120|NCT04996004|DRUG|Doxorubicin|75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
219281121|NCT04749251|PROCEDURE|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
219281122|NCT04749251|PROCEDURE|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
219281123|NCT04439227|DRUG|Adavosertib|Given PO
219281124|NCT06540235|DEVICE|Otolith Device Active|The device will be providing different levels of stimulation hypothesized to affect the vestibular system
219281125|NCT06540235|DEVICE|Otolith Device Inactive|The device will be providing no stimulation to measure test-retest
219281126|NCT02942277|BIOLOGICAL|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
219281127|NCT02942277|BIOLOGICAL|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
219281128|NCT02942277|OTHER|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
219281129|NCT02942277|BIOLOGICAL|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
219281130|NCT02942277|BIOLOGICAL|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
219281131|NCT02942277|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
219281132|NCT02942277|DRUG|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
219281133|NCT05180864|PROCEDURE|Gastrectomy|Open or minimally invasive (sub)total gastrectomy
219281134|NCT06155435|BEHAVIORAL|solution focused approach training|To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
219281135|NCT05363267|DIETARY_SUPPLEMENT|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
219281136|NCT05577715|DRUG|MORAb-202|Specified dose on specified days
219281137|NCT04176198|DRUG|Nusivertib|Oral PIM Inhibitor
219281138|NCT04176198|DRUG|Ruxolitinib|Oral JAK inhibitor
219281139|NCT04176198|DRUG|Momelotinib|Oral JAK inhibitor
219281140|NCT05949814|DIAGNOSTIC_TEST|acceptability of a PrEP program among HIV-negative MSM and TG|STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
219281141|NCT05241834|DRUG|LOXO-260|Oral
219281142|NCT05608044|DRUG|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
219281143|NCT05608044|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
219281144|NCT05608044|DRUG|Standard of Care|Regorafenib or trifluridine and tipiracil.
219281145|NCT05641168|OTHER|Adhesive material|Newly developed adhesive material
219281146|NCT05641168|OTHER|Standard adhesive material|Standard adhesive material
219281147|NCT06444750|OTHER|Blood sample collection|Blood samples of 30 mL will be collected at admission. For the groups that receive a blood transfusion an extra 30 mL blood sample will be collected.
219281148|NCT04872595|OTHER|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
219281149|NCT04872595|RADIATION|Hyper fractionated total body irradiation|"(1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
219281150|NCT04872595|DRUG|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
219281151|NCT04872595|DRUG|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
219281152|NCT04872595|DRUG|GCSF|Day +7
219281153|NCT04872595|DRUG|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
219281154|NCT04872595|DRUG|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
219281155|NCT04872595|DRUG|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
219281156|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
219281157|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
219281158|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
219281159|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
219281160|NCT05796505|BEHAVIORAL|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
219281161|NCT06062888|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
219281162|NCT04933149|DRUG|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
219281163|NCT01514253|DRUG|Glucose 25%|1 ml glucose 25%, once
219281164|NCT01514253|DIETARY_SUPPLEMENT|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
219281165|NCT01514253|OTHER|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
219281166|NCT02552979|OTHER|atopic patch test|
219281167|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
219281168|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
219281169|NCT05674396|RADIATION|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
219281170|NCT05674396|RADIATION|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
219281171|NCT01656252|DRUG|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
219281172|NCT01656252|DRUG|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
219296380|NCT00231803|OTHER|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
219296381|NCT00231803|OTHER|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
219281173|NCT01656252|DRUG|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
219281174|NCT01969682|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
219281175|NCT01969682|DRUG|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
219281176|NCT04903392|OTHER|Backward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks"
219281177|NCT04903392|OTHER|Forward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks"
219281178|NCT05278819|OTHER|upper extremity elevation|5 repetitions of active upper extremity elevation in a sitting position
219281179|NCT05278819|OTHER|upper extremity elevation with deep breathing|5 repetitions of active upper extremity elevation with deep breathing in a sitting position
219281180|NCT05471284|BEHAVIORAL|Proximal|The first factor tested framing of the near, proximal threat of continued smoking.
219281181|NCT05471284|BEHAVIORAL|Distal|The first factor tested framing of the long-term, distal threat of continued smoking.
219281182|NCT05471284|BEHAVIORAL|Cost|Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
219281183|NCT05471284|BEHAVIORAL|Benefit|Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
219281184|NCT05471284|BEHAVIORAL|Loss|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
219281185|NCT05471284|BEHAVIORAL|Gain|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
219281186|NCT05471284|BEHAVIORAL|Control|Does not include any of the three message factors.
219281187|NCT03297177|PROCEDURE|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
219281188|NCT03297177|DEVICE|Centricyte 1000|Closed System, Digestive Isolation \& Concentration of AD-cSVF
219281189|NCT03297177|PROCEDURE|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
219281190|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws ,The block was coated with a nonporous d-PTFE membrane
219281191|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws. The block was coated with a nonporous d-PTFE membrane
219281192|NCT02022904|DEVICE|Near infrared (NIR) emissive nanotechnology|
219281193|NCT02021552|OTHER|blood sampling|5 ml blood sampling
219281194|NCT01450384|DRUG|sorafenib tosylate|Given PO
219281195|NCT01450384|DRUG|pemetrexed disodium|Given IV
219281196|NCT01450384|OTHER|laboratory biomarker analysis|Correlative studies
219281197|NCT01450384|PROCEDURE|biopsy|Optional correlative studies
219281198|NCT01194375|DRUG|Low Strength IDP-107|Once a day for 16 weeks
219281199|NCT01194375|DRUG|High Strength IDP-107|Once a day for 16 weeks
219281200|NCT01194375|DRUG|Placebo|Once a day for 16 weeks
219281201|NCT00001534|DRUG|Losartan|
219281202|NCT05120869|BEHAVIORAL|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
219281203|NCT05120869|BEHAVIORAL|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
219281204|NCT02894996|DRUG|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
219281205|NCT02296918|DRUG|acalabrutinib|Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.
219281206|NCT02296918|DRUG|Obinutuzumab|Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.
219281207|NCT02296918|DRUG|Venetoclax|Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.
219281208|NCT02296918|DRUG|Rituximab|Participants will receive intravenous rituximab in Cohort 3. The details are mentioned in the cohort description.
219281209|NCT06458127|OTHER|Tele-palliative care visit|Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
219281210|NCT04098146|PROCEDURE|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
219281211|NCT00942864|DRUG|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
219281212|NCT02855736|BEHAVIORAL|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
219281213|NCT02855736|BEHAVIORAL|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
219281214|NCT04835454|DIAGNOSTIC_TEST|piRNAs, miRNA-194, regucalcin and plasma aminoacids levels|PIWI-interacting RNAs (piRNAs), a class of small nuclear RNA molecules, are associated with the PIWI proteins. MicroRNAs (miRNAs) are conserved small non-coding RNAs (19-22 nucleotide-long) that mediate post-transcriptional regulation of gene expression, affecting mRNA stability and translation by binding complementary sites on target mRNAs. Regucalcin (RGN) is an inhibitory protein of calcium signaling with calcium-binding properties. It plays a multifunctional role in the regulation of cell functions, including maintenance of intracellular calcium homeostasis, inhibitions of protein kinases and protein phosphatases linked to cell signaling process, suppressions of protein production and nuclear DNA and RNA synthesis.Free amino acids, in biological fluids can be a reduced invasive method associated to a high diagnostic potential. It was found that free amino acid profiles vary depending on type of cancer and its stage.
219281215|NCT05282121|DRUG|Avenciguat|one film-coated tablet orally twice a day, at least 10 hours apart. The starting dose (1 mg) was up-titrated up to 3 mg
219281216|NCT05282121|DRUG|Empagliflozin|one 10 mg film-coated tablet of orally once a day
219281217|NCT04209569|BEHAVIORAL|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
219281218|NCT00429780|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
219281219|NCT05198245|DRUG|Rimegepant|Rimegepant 75mg
219281220|NCT05198245|DRUG|Various|Various
219281221|NCT05198245|OTHER|No intervention|No intervention
219281222|NCT01218347|DRUG|Rosuvastatin|20 mg once daily for 21 days
219281223|NCT06220305|DIAGNOSTIC_TEST|DNA methylation joint AI imaging|DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
219281224|NCT04672811|DEVICE|Study App and Apple Watch|Study App and Apple Watch
219281225|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
219296382|NCT00231803|OTHER|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
219296383|NCT01853202|BEHAVIORAL|Supervised aerobic exercise training|
219296384|NCT05708807|OTHER|Observational - all|All stroke patients are included.
219281226|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
219281227|NCT06797609|OTHER|Sample analyses|Immunoturbidimetric assay for determination of serum Cys-C levels and the Chronic Kidney Disease Epidemiology (CKD-EPI) equation for GFR estimation
219281228|NCT01736189|DRUG|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
219281229|NCT06799936|OTHER|"CKD Jumpstart- Tips priming intervention"|"The intervention includes 2 components:~1. Patient Priming: Patients will receive the Jumpstart CKD- Tips communication priming tool within 1 week before and on the day of a target clinic visit, which includes surveys on (i) Understanding of illness and possible treatment options, (ii) Readiness for treatment discussion and information preferences, (iii) Health priorities, goals, and preferences (iv) Preferred roles in decision-making. The Jumpstart CKD- Tips patient priming sheet includes (a) A summary of their survey responses that can be shared with their healthcare team, and (b) Tips on communication with clinician during upcoming visit.~2. Clinician Priming: Within 1 week before and on the day of the target clinic visit, clinicians will receive a Jumpstart CKD- Tips clinician priming sheet which contains (a) An abstracted version of the patients' survey responses and (b) Communication tips tailored to the patient's responses based on Vitaltalk curricula materials."
219281230|NCT03459222|BIOLOGICAL|Relatlimab|Specified dose on specified days
219281231|NCT03459222|BIOLOGICAL|Nivolumab|Specified dose on specified days
219281232|NCT03459222|DRUG|BMS-986205|Specified dose on specified days
219281233|NCT03459222|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219281234|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
219281235|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
219281236|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
219281237|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
219281238|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
219281239|NCT06552637|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
219281240|NCT05675462|DRUG|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
219281241|NCT05675462|DRUG|Tislelizumab|PD-1inhibitor
219281242|NCT05675462|DRUG|Lenvatinib|TKI
219281243|NCT06345469|OTHER|Patient blood management (PBM)|PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.
219281244|NCT06345469|BIOLOGICAL|Allogeneic transfusion|transfusion of donor red cells
219281245|NCT00450021|DRUG|[(11)C] MePPEP|
219281246|NCT01603888|OTHER|no intervention|
219281247|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate bar|Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
219281248|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate mousse|Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
219281249|NCT03022955|DIETARY_SUPPLEMENT|White chocolate bar|White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
219281250|NCT03022955|DIETARY_SUPPLEMENT|White chocolate mousse|White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
219281251|NCT00597051|DRUG|ARD-0403|
219281252|NCT01416857|OTHER|RDDT|
219296385|NCT03691480|PROCEDURE|simple exsufflation|simple exsufflation
219296386|NCT03691480|PROCEDURE|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
219281253|NCT05281497|BEHAVIORAL|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
219281254|NCT05281497|BEHAVIORAL|Social media|We built a LINE group to inspire the intervention group.
219281255|NCT05281497|OTHER|Exercise training|exercise including walk and an 18-minutes calisthenics
219281256|NCT03301155|DRUG|Anaferon for children|Tablet for oral use.
219281257|NCT03301155|DRUG|Placebo|Tablet for oral use.
219281258|NCT04875442|DEVICE|Memowave emitting sounds|Memowave is worn during one night and emits sounds to increase slow brain waves
219281259|NCT04875442|DEVICE|Memowave not emitting sounds|Memowave is worn during one night and doesn't emit sounds
219281260|NCT06084767|DIAGNOSTIC_TEST|68Ga-TCR-FAPI PET/CT|A dose of 3.7 MBq/kg 68Ga-TCR-FAPI will be intravenously injected and PET examination will be carried out within the specified time.
219281261|NCT04329377|DIAGNOSTIC_TEST|blood test|complete blood count and platelet function
219281262|NCT03270202|BEHAVIORAL|PAI group|"* physical activity defined as 100 weekly PAI during 1 year~* smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
219281263|NCT03270202|BEHAVIORAL|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
219281264|NCT03950700|DRUG|Bupivacaine-epinephrine|BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
219281265|NCT03950700|DRUG|Saline Solution|Saline solution 0.9% (Baxter laboratories).
219281266|NCT00384189|DRUG|Ciclesonide|inhaled Ciclesonide
219281267|NCT00384189|DRUG|Placebo|Ciclesonide placebo-matching inhaler
219281268|NCT00384189|DRUG|Salbutamol|Salbutamol inhalation powder
219281269|NCT03912662|DEVICE|Mesh augmented reinforcement|Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
219281270|NCT02316327|DRUG|gemcitabine, cisplatin and bevacizumab|Therapeutic
219281271|NCT05017090|PROCEDURE|M-TAPA block|After tracheal intubation, a high-frequency linear probe will placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
219281272|NCT05017090|OTHER|Standard perioperative and postoperative multimodal analgesia|The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
219281273|NCT06408701|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
219281274|NCT00809367|OTHER|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
219281275|NCT01126645|PROCEDURE|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA."
219281276|NCT01126645|PROCEDURE|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
219281277|NCT00608868|DRUG|Gefitinib|Gefitinib tablet 250mg once daily orally
219281278|NCT04924712|OTHER|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
219281279|NCT02630875|DRUG|A4250|A4250
219281280|NCT03507946|DEVICE|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
219281281|NCT06196775|BIOLOGICAL|AK104+AK112|Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.
219281282|NCT04727138|DRUG|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
219281283|NCT04727138|DRUG|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
219281284|NCT04727138|OTHER|Midazolam|Interaction
219281285|NCT04727138|OTHER|Food Effect|Fed/Fasted
219281286|NCT04727138|OTHER|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension
219281287|NCT00531336|DRUG|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
219281288|NCT00531336|DRUG|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
219281289|NCT05686798|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)|Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
219281290|NCT04427943|PROCEDURE|revision surgery|The intervention is the planned revision surgery according to local guidelines.
219281291|NCT02057211|BIOLOGICAL|autologous mesenchymal stem cell transplantation|
219281292|NCT02057211|PROCEDURE|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
219281293|NCT04517708|OTHER|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
219281294|NCT03289351|DRUG|Piperacillin, Tazobactam Drug Combination|Single drug therapy
219281295|NCT02566564|DRUG|Lopain|intra-articular injection
219281296|NCT00338143|DRUG|efalizumab|
219281297|NCT00335140|BIOLOGICAL|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
219281298|NCT00335140|DRUG|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
219281299|NCT00335140|DRUG|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
219281300|NCT00335140|DRUG|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
219281301|NCT00335140|DRUG|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
219281302|NCT00335140|DRUG|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
219281303|NCT00335140|DRUG|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
219281304|NCT05900414|BEHAVIORAL|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
219281305|NCT05900414|OTHER|Information|Link to website with information about atrial fibrillation treatments
219281306|NCT05090943|OTHER|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
219281307|NCT04390932|OTHER|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
219281308|NCT04390932|OTHER|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
219281309|NCT04390932|OTHER|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
219281310|NCT00431353|DRUG|Ganciclovir|5mg/kg iv bid for 21 days
219281311|NCT00431353|DRUG|valganciclovir [Valcyte]|900mg po bid for 21 days
219281312|NCT02237677|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
219281313|NCT04546425|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
219281314|NCT04546425|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
219281315|NCT03582527|OTHER|all study participants|patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
219281316|NCT05524090|OTHER|Implementation - International best-practice care|The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
219281317|NCT05866042|DEVICE|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
219281318|NCT01753726|OTHER|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
219281319|NCT01753726|OTHER|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
219281320|NCT03266926|DRUG|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
219281321|NCT03266926|DRUG|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
219281322|NCT03982251|PROCEDURE|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
219281323|NCT03982251|PROCEDURE|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
219281324|NCT06539468|OTHER|Best Practice|Receive SOC treatment
219281325|NCT06539468|OTHER|Educational Activity|Watch an educational video on AS for LR-BCC
219281326|NCT06539468|OTHER|Patient Observation|Undergo active surveillance
219281327|NCT06539468|OTHER|Survey Administration|Ancillary studies
219281328|NCT05484414|DRUG|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
219281329|NCT05484414|DRUG|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
219281330|NCT04798170|OTHER|Utrasound|Ultrasound examination
219281331|NCT05788874|DIAGNOSTIC_TEST|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
219281332|NCT04468594|OTHER|rigid tapping|Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
219281333|NCT04468594|OTHER|scapular stabilizing excercise|"consisted of:~1. wall slides with squat,~2. wall push-ups plus ipsilateral leg extension,~3. lawnmower with diagonal squat,~4. resisted scapular retraction with contralateral leg squat and robbery with squat.~5. Robbery with squat~6. Resisted shoulder internal rotation with step~7. Resisted shoulder external rotation with step~8. Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly."
219296387|NCT04101188|OTHER|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
219296388|NCT04101188|OTHER|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
219296389|NCT04101188|OTHER|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
219281334|NCT04468594|OTHER|therapeutic exercises|"1. Pectoralis minor stretching~2. Posterior shoulder stretching~3. Levator scapula stretching~4. Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~5. Resisted shoulder internal rotation~6. Resisted shoulder external rotation~7. Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets."
219281335|NCT03165747|DRUG|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
219281336|NCT03165747|OTHER|Placebo|Two placebo sachets taken orally daily in a single administration.
219281337|NCT04320342|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
219281338|NCT04320342|DRUG|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
219281339|NCT04320342|DRUG|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
219281340|NCT06557265|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
219281341|NCT06557265|DRUG|Fludarabine, Cyclophosphamide|Lymphodepletion
219281342|NCT06641362|DEVICE|Ultra High Frequency Electrocardiogram (UHF-ECG)|Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
219281343|NCT05461495|BEHAVIORAL|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
219281344|NCT04047251|DRUG|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
219281345|NCT05441462|PROCEDURE|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
219281346|NCT06795022|DRUG|AZD9793 Intravenous (IV) monotherapy|T cell-engaging antibody that targets GPC3 on tumour cells
219281347|NCT06795022|DRUG|AZD9793 Subcutaneous (SC) monotherapy)|T cell-engaging antibody that targets GPC3 on tumour cells
219281348|NCT01430234|DRUG|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
219281349|NCT04737876|BIOLOGICAL|BX002-A|bacteriophage cocktail
219281350|NCT04737876|OTHER|Placebo|Placebo
219281351|NCT00271310|DRUG|hypertonic saline|
219281352|NCT03664440|DRUG|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
219281353|NCT03664440|DRUG|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
219281354|NCT05564000|OTHER|Dating Violence Prevention Program|We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
219281355|NCT03809598|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
219281356|NCT03478449|PROCEDURE|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
219281357|NCT02764268|DRUG|Apatinib|
219281358|NCT04848324|OTHER|Corticosteroid Hydrodissection|The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
219281359|NCT04848324|OTHER|Corticosteroid Injection|1 mL of triamcinolone was delivered via the in-plane ulnar approach
219281360|NCT00130325|DRUG|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
219281361|NCT00130325|DRUG|Isoniazid|INH 900mg twice weekly for 6 months
219281362|NCT00130325|DRUG|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
219281363|NCT04914598|DRUG|ENDOSTAR，cisplatin|After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
219281364|NCT04914598|DRUG|Placebo , cisplatin|Placebo , cisplatin
219281365|NCT02716636|PROCEDURE|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
219281366|NCT03908151|DEVICE|CMK21 Hip system|Total hip arthroplasty
219281367|NCT01236638|DRUG|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
219281368|NCT02979249|DRUG|Oral Iron|for one year
219281369|NCT01125046|BIOLOGICAL|bevacizumab|Given IV
219281370|NCT06799169|DRUG|Nortriptyline|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
219281371|NCT06799169|DRUG|Topiramate|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
219281372|NCT06799169|DRUG|Paroxetine|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
219281373|NCT06799169|DRUG|Verapamil|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
219281374|NCT00909129|DRUG|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
219281375|NCT00909129|DRUG|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
219281376|NCT02339545|DEVICE|Coronary Orbital Atherectomy plus Stenting|
219281377|NCT06365151|OTHER|Osteopathic manual therapy|osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.
219281378|NCT06365151|OTHER|Sham osteopathic manual therapy|a sham osteopathic manual treatment without therapeutic effect
219281379|NCT02620605|DRUG|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
219281380|NCT02620605|DRUG|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
219281381|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
219281382|NCT00443924|DRUG|Placebo|One drop of placebo in each eye every 12 hours for three days
219281383|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
219281384|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
219281385|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
219281386|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
219281387|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
219296390|NCT05604001|DEVICE|hysteroscopic ablation of submucous uterine fibroid using diode laser|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
219281388|NCT00425464|DEVICE|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
219281389|NCT00425464|DEVICE|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
219281390|NCT04074668|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
219281391|NCT04074668|DRUG|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
219281392|NCT04074668|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
219281393|NCT04074668|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
219281394|NCT05078788|PROCEDURE|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
219281395|NCT05078788|PROCEDURE|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
219281396|NCT03868787|DEVICE|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
219281397|NCT03868787|DEVICE|Sham TENS|Non-active TENS unit
219281398|NCT02306551|OTHER|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
219281399|NCT05048498|DRUG|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
219281400|NCT05048498|DRUG|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
219281401|NCT01685229|DEVICE|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
219281402|NCT01685229|DRUG|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
219281403|NCT06267144|DRUG|Sintilimab plus chemotherapy|"Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly."
219281404|NCT03705598|BEHAVIORAL|Light physical exercise|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/walking, upper and lower body strength exercise/walking, and stretching exercise/balance exercise/walking, respectively), each ending with a short break to record the Borg Rating of Perceived Exertion (RPE), followed by a 5-minute break time or cool-down/wrap-up session. The session will be taught by a certified exercise physiologist and a research assistant.
219281405|NCT03705598|BEHAVIORAL|Tai Chi|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/breathing exercise, Tai Chi walking drills, and Tai Chi 8-form, respectively), each ending with a short break to record the RPE, and followed by a 5-minute break or cool-down/wrap-up session. The session will be taught by an experienced Tai Chi instructor and a research assistant.
219281406|NCT04684719|BIOLOGICAL|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
219281407|NCT04684719|BIOLOGICAL|Standard Care|crystalloid infusion or blood component transfusion resuscitation
219281408|NCT01635738|BIOLOGICAL|LP GMNL-133 capsule|One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO
219281409|NCT01635738|BIOLOGICAL|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO
219281410|NCT01635738|BIOLOGICAL|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10\^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
219281411|NCT01635738|BIOLOGICAL|Placebo|Placebo
219281412|NCT05937867|DRUG|HS-10353 Capsules 30 mg, Oral, QN for 14 days|HS-10353 Capsules 30 mg
219281413|NCT05937867|DRUG|HS-10353 Capsules 50 mg, Oral, QN for 14 days|HS-10353 Capsules 50 mg
219281414|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.|Placebo
219281415|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days|Placebo
219281416|NCT04378673|OTHER|not interventional|This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
219281417|NCT05113108|DEVICE|CUS|All neonates undergoing CUS at nursery unit at assiut university hospital. Cranial ultrasound is performed with basic grayscale imaging. For optimal resolution and good overview, a multifrequency (5-10 MHz) linear or convex sector transducer is used. Imaging is obtained through the anterior fontanel in the coronal and sagittal planes.{12,13} Typically, six to eight coronal images are obtained beginning at the frontal lobes just anterior to the frontal horns and extending to the occipital lobes posterior to the lateral ventricle trigones.{14} The transducer is then rotated 90°, and approximately five images are obtained, including a midline sagittal view of the corpus callosum and cerebellar vermis in addition to bilateral parasagittal images beginning in the midline and progressing laterally through the peripheral cortex.Doppler ultrasound may be added to assess ischemic areas.{13-15}
219281418|NCT05648630|DIETARY_SUPPLEMENT|PB125|PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.
219281419|NCT05648630|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
219281420|NCT05648630|BEHAVIORAL|Exercise Rehabilitation|A 12-week treadmill based supervised rehabilitation
219281421|NCT00241046|DRUG|Letrozole|
219281422|NCT01012362|DRUG|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
219281423|NCT01012362|DRUG|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
219281424|NCT01310608|OTHER|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
219281425|NCT00558844|DRUG|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
219281426|NCT00558844|DRUG|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
219281427|NCT00558844|DRUG|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
219281428|NCT00558844|DRUG|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
219281429|NCT00558844|DRUG|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
219281430|NCT01720277|BIOLOGICAL|HD Fluzone Vaccine|Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
219281431|NCT01720277|BIOLOGICAL|SD Fluzone Vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
219281432|NCT06136104|DIETARY_SUPPLEMENT|Mixhers HERTIME|A daily self-administered powder supplement packet mixed into water.
219281433|NCT06136104|DIETARY_SUPPLEMENT|Placebo|A daily self-administered powder placebo supplement packet mixed into water.
219281434|NCT03333213|OTHER|Gua Sha|
219281435|NCT01907867|DRUG|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
219281436|NCT06044038|BEHAVIORAL|Physical activity|Bi-weekly supervised physical activity intervention
219281437|NCT06044038|BEHAVIORAL|Cognitive rehabilitation program|weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
219296391|NCT03387137|BIOLOGICAL|RSV 6120/∆NS2/1030s|Delivered as nose drops
219281438|NCT02277184|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
219281439|NCT02277184|DRUG|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
219281440|NCT02277184|RADIATION|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
219281441|NCT01399697|DRUG|methotrexate|orally, Week 1 - 16
219281442|NCT01399697|DRUG|methotrexate|orally, Week 17-28
219281443|NCT01399697|DRUG|placebo|methotrexate placebo orally, Week 17-28
219281444|NCT01399697|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
219281445|NCT04324450|DEVICE|MRI|"The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging"
219281446|NCT04324450|BEHAVIORAL|Cognitive assessment|Battery of neuropsychological tests
219281447|NCT01796054|BEHAVIORAL|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
219281448|NCT01796054|BEHAVIORAL|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
219281449|NCT00477503|DRUG|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
219281450|NCT00477503|DRUG|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
219281451|NCT01448629|DEVICE|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
219281452|NCT01448629|DEVICE|River|River is a new developed product with Coloplast as manufacturer
219281453|NCT01921153|OTHER|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
219281454|NCT01428375|DRUG|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
219281455|NCT01428375|OTHER|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
219281456|NCT04387500|DRUG|Sintilimab injection plus Inlyta treatment|Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
219281457|NCT04594044|BEHAVIORAL|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
219281458|NCT02627417|DRUG|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
219281459|NCT02627417|DRUG|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
219281460|NCT02627417|DRUG|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
219281461|NCT04715373|PROCEDURE|LISA|LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
219281462|NCT01624077|BIOLOGICAL|Regulatory T cells|Tregs will inject after liver transplantation
219281463|NCT02619903|PROCEDURE|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
219281464|NCT02649738|PROCEDURE|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
219281465|NCT01857089|DEVICE|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
219281466|NCT06305052|OTHER|Milk|"Premature newborns allocated to the intervention group will receive olfactory and taste stimuli immediately before feeding through an oral/nasal gastric tube.~In the intervention group, the taste stimulus will be carried out through a drop of milk administered directly to the tongue of the premature baby if he is awake, if the newborn is sleeping the milk will be placed on his lips.~The olfactory stimulus will be offered through a drop of milk using a cotton swab, positioned close to the premature baby's nostrils as close as possible without touching them, immediately before the tube diet."
219281467|NCT06305052|OTHER|Water|In the control group, the taste stimulus will be done through a drop of double-distilled water on a cotton swab, then administered directly to the tongue of the premature baby if he is awake, however, when he is sleeping, the drop of water will be deposited on his lips. The olfactory stimulus in the control group will be carried out with a drop of double-distilled water using a cotton swab, positioned close to the nostrils as close as possible without touching them, immediately before carrying out the tube diet.
219281468|NCT02179567|DRUG|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
219281469|NCT02179567|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
219281470|NCT01457898|DEVICE|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
219281471|NCT03461159|OTHER|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
219281472|NCT03461159|OTHER|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
219281473|NCT06027606|DRUG|Salbutamol 400mcg|Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma
219281474|NCT06027606|DRUG|Budesonide/formoterol|Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma
219281475|NCT06027606|DRUG|Placebo|Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
219281476|NCT02238418|DRUG|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
219281477|NCT01162577|BEHAVIORAL|Weight Concerns|Standard Quitline plus weight coaching
219281478|NCT04313608|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
219281479|NCT04313608|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
219281480|NCT04313608|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
219281481|NCT04313608|DRUG|Mosunetuzumab|Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
219281482|NCT04313608|DRUG|Obinutuzumab|Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
219281483|NCT04313608|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
219281484|NCT06160817|PROCEDURE|Conservative sharp debridement|The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
219281485|NCT00504673|DRUG|insulin detemir|
219281486|NCT00504673|DRUG|insulin NPH|
219281487|NCT00504673|DRUG|insulin aspart|
219281488|NCT03799744|GENETIC|VCN-01|Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient
219281489|NCT03799744|BIOLOGICAL|Durvalumab|Dose: 1500 mg Q4W
219281490|NCT05134987|DRUG|NNC0363-0845|Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
219281491|NCT05134987|DRUG|Insulin detemir|Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
219281492|NCT04099797|GENETIC|C7R-GD2.CART cells (IV and ICV infusion)|"Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion."
219281493|NCT04099797|GENETIC|C7R-GD2.CAR T cells (IV infusion)|Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.
219281494|NCT03079284|OTHER|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
219281495|NCT03966014|DRUG|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
219281496|NCT03966014|DRUG|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
219281497|NCT03966014|DRUG|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
219281498|NCT03966014|OTHER|Controls|No intervention.
219281499|NCT06545812|DRUG|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
219281500|NCT06545812|DEVICE|Physical therapy for disc herniation|BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
219281501|NCT05827003|OTHER|Exercise|Supervised exercise program with a physiotherapist for 6 weeks, two days a week
219281502|NCT05827003|OTHER|Exercise&Topical Agent|Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
219281503|NCT05827003|OTHER|Topical Agent|Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
219281504|NCT05933681|DEVICE|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
219281505|NCT02400216|DRUG|dual cholate|test for defining disease severity
219281506|NCT04554745|RADIATION|Ultrasound|ultrasound assessment of pregnant women
219281507|NCT04430166|DRUG|PD-1 monoclonal antibody|200mg / intravenous drip, once every three weeks
219281508|NCT05263674|DRUG|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
219281509|NCT02323568|OTHER|Gynecological consultation|
219281510|NCT03866369|DRUG|Moxifloxacin|Single oral dose at D-8
219281511|NCT03866369|DRUG|Placebo|Single oral dose at D-1
219281512|NCT03866369|DRUG|Lanifibranor|Single daily oral dose during 14 days
219281513|NCT03866369|DRUG|Placebo|Single daily oral dose during 14 days
219281514|NCT00001197|DRUG|Hydroxyurea|
219281515|NCT00656045|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
219281516|NCT00656045|BEHAVIORAL|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
219281517|NCT00656045|BEHAVIORAL|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
219281518|NCT04792476|OTHER|High Intensity Interval Training|Experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
219281519|NCT05890053|DRUG|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
219281520|NCT05256615|BEHAVIORAL|30-minute walking intervention|Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
219281521|NCT05256615|BEHAVIORAL|10-minute|Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
219281522|NCT00758342|DRUG|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
219281523|NCT00758342|DRUG|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
219296392|NCT03387137|BIOLOGICAL|Placebo|Delivered as nose drops
219281524|NCT00900692|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
219281525|NCT04653233|DEVICE|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
219281526|NCT05715749|OTHER|In-home body weight support harness system|A portable, adjustable body weight support harness system that occupies roughly 9 feet x 9 feet space in the home. The system allows 360 degrees of mobility anywhere within the footprint of the frame. The amount of body weight support is adjustable.
219281527|NCT05338385|BEHAVIORAL|Mental Skills Coaching|Participants will partake in a 1-hour pre-op initial intake, followed by five 30-min follow-up sessions at 2 weeks, 6 weeks, 3 months, 6 months and 9-months post-op. All sessions will be one-on-one with the same master's-level mental skills coach. At each session, the provider will allow time for participants to share their current injury experience to date (i.e. how they are doing, challenges they have encountered). Following this, participants will be introduced to a series of mental skills tools, including but not limited to mindset awareness, motivation, cognitive restructuring, goal setting, and objective performance assessment. Participants will be provided with handouts outlining the strategies addressed to help maintain consistency of mental skills engagement between sessions.
219281528|NCT00891033|DRUG|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
219281529|NCT00891033|DRUG|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
219281530|NCT02893189|GENETIC|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
219281531|NCT02633436|OTHER|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
219281532|NCT05443113|DIAGNOSTIC_TEST|Genetic analysis|Genetic analysis by geneticists
219281533|NCT02977390|OTHER|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
219281534|NCT04630704|DEVICE|Pedra|Diffuse speckle contrast analysis perfusion system
219281535|NCT03514277|DRUG|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
219281536|NCT03514277|DRUG|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
219281537|NCT05017077|DEVICE|DynaVision System|Telemonitoring for pediatric heart failure
219281538|NCT06579326|DIAGNOSTIC_TEST|Photoacoustic imaging|It could provide three-dimensional ultrasound images of vessels in the target area. It could also provides super-resolution and large-depth photoacoustic images. By effectively extracting photoacoustic spectral features and using spectral feature unmixing algorithm, blood oxygen saturation can be calculated.
219281539|NCT02223104|DEVICE|Flexima Active|
219281540|NCT02223104|DEVICE|Sensura|
219281541|NCT04300465|BEHAVIORAL|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
219281542|NCT00328289|DEVICE|transcutaneous muscle stimulation, treadmill|
219281543|NCT03333759|DEVICE|Alma - Harmony XL Laser|The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
219281544|NCT02741453|PROCEDURE|Standard Practice|
219281545|NCT02741453|PROCEDURE|Bilateral IJ Ultrasound Scanning|
219281546|NCT02440425|DRUG|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
219281547|NCT02440425|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
219281548|NCT06292949|DIETARY_SUPPLEMENT|Resistant starch|Constipated patients take 1 pack of resistant starch (20g/pack) daily for 14 days
219281549|NCT05471531|BIOLOGICAL|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
219281550|NCT05471531|BIOLOGICAL|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
219281551|NCT02866513|OTHER|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
219281552|NCT01567631|PROCEDURE|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
219281553|NCT01567631|PROCEDURE|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
219281554|NCT04261764|DEVICE|"Fastening-mimicking diet combined with a dispelling dampness meal replacement"|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
219281555|NCT04261764|OTHER|Normal diet|Carrying out normal diet under the guidance of a dietitian.
219281556|NCT03432442|DRUG|Ivermectin|Ivermectin once every 24 hours for three administrations
219281557|NCT02807272|DRUG|Tipifarnib|Oral tablet
219281558|NCT02884284|OTHER|clinical biological database collection|
219281559|NCT00218153|DRUG|Naltrexone|
219281560|NCT05840068|DRUG|MetFORMIN 500 Mg Oral Tablet|MetFORMIN 500 Mg Oral Tablet
219281561|NCT05840068|DRUG|Chemotherapy|The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
219281562|NCT05963945|DEVICE|Carebot AI CXR|The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
219281563|NCT03117491|PROCEDURE|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
219281564|NCT03117491|PROCEDURE|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
219281565|NCT03117491|PROCEDURE|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
219281566|NCT01038427|DRUG|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
219281567|NCT01038427|DRUG|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
219281568|NCT01038427|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
219281569|NCT00002653|DRUG|carmustine|
219281570|NCT00002653|DRUG|cyclophosphamide|
219281571|NCT00002653|DRUG|doxorubicin hydrochloride|
219281572|NCT00002653|DRUG|melphalan|
219281573|NCT00002653|DRUG|prednisone|
219281574|NCT00002653|RADIATION|radiation therapy|
219281575|NCT04878315|DRUG|Capoten|Capoten will be administered per the treatment sequence
219281576|NCT04878315|DRUG|Captopril|Captopril will be administered per the treatment sequence
219281577|NCT05802823|OTHER|Standardized Simülation Patient|There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
219281578|NCT00101946|DRUG|683699|
219296393|NCT02437253|DRUG|Adalimumab|Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
219296394|NCT02437253|OTHER|Placebo|Saline placebo
219281579|NCT04243746|BEHAVIORAL|Time Restricted Feeding|Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
219281580|NCT04243746|BEHAVIORAL|Standard Care|Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
219281581|NCT01063998|OTHER|Urine Marker|Urinary KIM-1 measurements
219281582|NCT01364337|OTHER|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
219281583|NCT01364337|OTHER|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
219281584|NCT00924742|DRUG|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
219281585|NCT01952067|PROCEDURE|line-to-line reaming and cementing technique|
219281586|NCT01952067|PROCEDURE|standard over-reaming with 2 broach sizes|
219281587|NCT04654559|OTHER|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
219281588|NCT00604708|BIOLOGICAL|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
219281589|NCT00604708|BIOLOGICAL|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
219281590|NCT03731897|OTHER|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
219281591|NCT03731897|OTHER|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
219281592|NCT00002687|BIOLOGICAL|aldesleukin|
219281593|NCT00691587|BIOLOGICAL|KB001|Single low-dose, administered intravenously
219281594|NCT00691587|BIOLOGICAL|KB001|Single high-dose, administered intravenously
219281595|NCT00691587|BIOLOGICAL|Placebo|Placebo single-dose, administered intravenously
219281596|NCT00880204|BEHAVIORAL|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
219281597|NCT02152943|DRUG|Everolimus|Given PO
219281598|NCT02152943|OTHER|Laboratory Biomarker Analysis|Correlative studies
219281599|NCT02152943|DRUG|Letrozole|Given PO
219281600|NCT02152943|BIOLOGICAL|Trastuzumab|Given IV
219281601|NCT03162198|OTHER|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
219281602|NCT03162198|OTHER|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
219281603|NCT03746587|DRUG|Arimoclomol|Arimoclomol in 3 different dosages
219281604|NCT03746587|DRUG|Placebo oral capsule|Matching placebo capsule
219281605|NCT03552952|OTHER|No intervention|No intervention
219281606|NCT05009160|DEVICE|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
219281607|NCT04904198|BEHAVIORAL|Care Management Intervention for non-cardiac chest pain|Multicomponent eight-week care management intervention involving a consultation visit with a cardiologist and nurse. Recommendations from the consultation visit are conveyed to the primary care physician. Following the visit, the participant has eight weekly phone calls with a nurse to provide support, introduce therapeutic principals, and assess symptoms. The study nurse is supervised by a psychiatrist.
219281608|NCT04775706|DRUG|HM15912 Active|Randomized, double-blind, placebo-controlled
219281609|NCT04775706|DRUG|Placebo|Randomized, double-blind, placebo-controlled
219281610|NCT06306131|DRUG|Levonorgestrel 0.15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
219281611|NCT06306131|DRUG|Meloxicam 15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
219281612|NCT06306131|OTHER|calcium carbonate 750 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
219281613|NCT06234514|DRUG|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
219281614|NCT06234514|DRUG|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
219281615|NCT01229878|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
219281616|NCT04728139|DIAGNOSTIC_TEST|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
219281617|NCT03326362|OTHER|Resistance training|Comparison between high and low intensities trainings described in arms
219281618|NCT06120868|OTHER|Surefil one®|For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
219281619|NCT06120868|OTHER|Filtek One|Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
219281620|NCT01327846|DRUG|Canakinumab|
219281621|NCT01327846|DRUG|Placebo|
219281622|NCT01327846|DRUG|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
219281623|NCT04135612|OTHER|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
219281624|NCT05173337|DRUG|Nefopam|"Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery."
219281625|NCT01523600|BEHAVIORAL|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
219281626|NCT01523600|BEHAVIORAL|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
219281627|NCT06432673|DRUG|ATR-258 Oral solution|Oral solution
219281628|NCT06432673|DRUG|ATR-258 Oral capsule|Oral capsule
219281629|NCT05167422|BEHAVIORAL|Trusted Messenger|A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
219281630|NCT01509001|DRUG|Metformin|750 to 2500 mg/day, two times a day during 4 months
219281631|NCT01509001|DRUG|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
219281632|NCT06554340|BEHAVIORAL|Home-based aerobic training|The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
219281633|NCT04515433|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
219281634|NCT04343976|DRUG|Pegylated interferon lambda|180 mcg subcutaneous injection of pegylated interferon lambda
219281635|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
219281636|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
219296395|NCT05574517|PROCEDURE|Without reverse insertion of a ureteral catheter|Traditional tubeless percutaneous nephrolithotomy usually need retrograde ureteral catheter insertion. Our intervention is that the tubeless percutaneous nephrolithotomy is executed without reverse insertion of a ureteral catheter.
219281637|NCT02217215|DEVICE|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
219281638|NCT00661297|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
219281639|NCT00661297|DRUG|Placebo|Matching placebo
219281640|NCT00694109|DRUG|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
219281641|NCT00208455|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
219281642|NCT03557671|DIETARY_SUPPLEMENT|rice formula|new rice based thickened formula
219281643|NCT03557671|DIETARY_SUPPLEMENT|placebo|formula previously tolerated by the subject - only for the 1st part of the study
219281644|NCT00040417|DRUG|FLUDARABINE|
219281645|NCT00040417|DRUG|CAMPATH-IH|
219281646|NCT00040417|PROCEDURE|Total Body Irradiation|
219281647|NCT00040417|DRUG|FK506|
219281648|NCT00040417|DRUG|G-SCF (Granulocyte-colony stimulating factor)|
219281649|NCT02390453|BEHAVIORAL|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
219281650|NCT02390453|BEHAVIORAL|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
219281651|NCT02390453|BEHAVIORAL|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
219281652|NCT02390453|BEHAVIORAL|Active Control|Control modules provide social contact for group discussion of health and successful aging.
219281653|NCT04134624|OTHER|Sepsis care bundle|Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
219281654|NCT02487043|BEHAVIORAL|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
219281655|NCT03349151|BEHAVIORAL|Early feeding|Feeding on postoperative 2nd hour on return to the ward
219281656|NCT03349151|BEHAVIORAL|On- Demand feeding|Feeding whenever the patient asks for on return to the ward
219281657|NCT04954092|BIOLOGICAL|Gam-COVID-vac M|The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus
219281658|NCT04954092|BIOLOGICAL|Placebo|Composition without active ingredients
219281659|NCT02532127|OTHER|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
219281660|NCT00613899|OTHER|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
219281661|NCT05395195|DRUG|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
219281662|NCT05395195|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
219281663|NCT02097589|DRUG|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
219281664|NCT02097589|DRUG|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
219281665|NCT02097589|OTHER|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
219296396|NCT05248906|DIAGNOSTIC_TEST|Giant cell arteritis|Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy
219281666|NCT06358248|DEVICE|Physician-modification of Valiant Captivia Endograft (Medtronic, Minneapolis, MN-USA).|"On a sterile back-table a Valiant Captivia thoracic graft is deployed. A dotted line is drawn to mark the graft anterior 0° degree, and fabric holes are performed with cautery in the desired position. The fenestrations need to be 6x6 mm for the renals and 8x8 mm for superior mesenteric artery (SMA) and celiac trunk (CT), and are reinforced with the tip of a 0.018 guidewire through a continuous 5-0 locking suture.~A posterior constraining wire is created to reduce the diameter of the graft by 20-30%, in order to allow rotation during the deployment phase. The four 8 markers on the top of the graft are carefully removed with a scalpel; one of these is modified as an S and re-sutured on the anterior aspect at 0 degree position, with a 5-0 prolene continuous suture. This S marker will allow anteroposterior graft orientation. Finally, the graft is re-sheathed and deployed."
219281667|NCT05367700|DRUG|HS-10382(Part 1: Dose escalation)|Single or multiple dose(s) of HS-10382 once daily.
219281668|NCT05367700|DRUG|HS-10382(Part 2: Dose expansion)|HS-10382 is administered orally once daily.
219281669|NCT01167491|BIOLOGICAL|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
219281670|NCT02817906|DRUG|ITI-007|
219281671|NCT02817906|DRUG|Placebo|
219281672|NCT02305602|BIOLOGICAL|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
219281673|NCT02578446|DEVICE|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
219281674|NCT02578446|DEVICE|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
219281675|NCT04912427|DRUG|Isatuximab|Isatuximab is supplied by Sanofi.
219281676|NCT04912427|DRUG|Bortezomib|Bortezomib is commercially available.
219281677|NCT04912427|DRUG|Dexamethasone|Dexamethasone is commercially available.
219281678|NCT03818126|DRUG|del Nido cardioplegia|"The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit."
219281679|NCT03818126|DRUG|cold blood cardioplegia|"The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius."
219281680|NCT03686423|PROCEDURE|Exercise Program|The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
219281681|NCT01943942|DRUG|Montelukast 10 mg|Reference product
219281682|NCT01943942|DRUG|Montelukast 10 mg|Test product
219281683|NCT02833077|DEVICE|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
219281684|NCT02541370|BIOLOGICAL|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
219281685|NCT01310231|DRUG|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
219281686|NCT01310231|DRUG|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
219281687|NCT02084199|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 10 days
219281688|NCT00494520|PROCEDURE|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
219281689|NCT00494520|PROCEDURE|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
219281690|NCT01436253|BEHAVIORAL|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
219281691|NCT01436253|DRUG|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
219281692|NCT06307717|DRUG|volatile anaesthetic (sevoflurane, isoflurane, desflurane)|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
219281693|NCT00271206|DRUG|Progesterone|compared to placebo
219281694|NCT00271206|DRUG|sugar pill|Compared to progesterone
219281695|NCT06365788|DRUG|Abemaciclib|150 mg tablet orally twice daily
219281696|NCT06365788|DRUG|Bicalutamide|150 mg tablet orally once daily
219281697|NCT03835741|DEVICE|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
219281698|NCT03835741|OTHER|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
219281699|NCT02858310|BIOLOGICAL|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
219281700|NCT02858310|DRUG|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
219281701|NCT02858310|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219281702|NCT02858310|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
219281703|NCT01517100|OTHER|Nabilone|CB agonist
219281704|NCT01517100|DRUG|CP-945,598|Cannabinoid Receptor 1 antagonist
219281705|NCT01517100|OTHER|hyperglycemic clamp|assesses beta cell response
219281706|NCT01517100|OTHER|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
219281707|NCT01517100|OTHER|Nabilone|cannabinoid receptor agonist
219281708|NCT01198067|DRUG|Pomalidomide|Given PO
219281709|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
219281710|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
219281711|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
219281712|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
219281713|NCT02101398|DEVICE|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
219281714|NCT06966024|DRUG|DCC-2812|Administered orally
219281715|NCT05656807|BEHAVIORAL|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
219281716|NCT05656807|BEHAVIORAL|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
219281717|NCT02236832|DEVICE|transcranial magnetic stimulation|
219281718|NCT02236832|OTHER|MRI imaging|
219281719|NCT02236832|OTHER|EEG recording|
219281720|NCT02236832|BEHAVIORAL|Neuropsychological examination|
219281721|NCT04929392|DRUG|Carboplatin|Given IV
219281722|NCT04929392|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
219281723|NCT04929392|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219281724|NCT04929392|DRUG|Lenvatinib Mesylate|Given PO
219281725|NCT04929392|DRUG|Paclitaxel|Given IV
219281726|NCT04929392|BIOLOGICAL|Pembrolizumab|Given IV
219281727|NCT04929392|PROCEDURE|Resection|Undergo surgical resection
219281728|NCT06019767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
219281729|NCT03490682|OTHER|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
219281730|NCT06488378|DRUG|Axatilimab|Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
219281731|NCT06488378|DRUG|Olaparib|Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
219281732|NCT05841589|PROCEDURE|Green tea extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
219281733|NCT05841589|PROCEDURE|Garlic with lime extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
219281734|NCT05841589|PROCEDURE|Pomegranate extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
219281735|NCT05841589|PROCEDURE|Chlorhexidine mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
219281736|NCT01043003|OTHER|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
219281737|NCT01043003|PROCEDURE|quality-of-life assessment|Ancillary studies
219281738|NCT01043003|OTHER|Questionnaire Administration|Ancillary studies
219281739|NCT01043003|OTHER|psychosocial support for caregiver|Support for caregiver
219281740|NCT01043003|PROCEDURE|assessment of therapy complications|Ancillary study
219281741|NCT01043003|OTHER|informational intervention|Undergo evaluation sessions
219281742|NCT03350399|DIAGNOSTIC_TEST|placenta growth factor|estimation level of derum placenta growth factor
219281743|NCT00441922|DRUG|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
219281744|NCT00441922|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
219281745|NCT00871286|PROCEDURE|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
219281746|NCT00871286|PROCEDURE|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
219281747|NCT03682185|BEHAVIORAL|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
219281748|NCT03682185|BEHAVIORAL|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
219281749|NCT02630407|BIOLOGICAL|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
219281750|NCT02630407|OTHER|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
219281751|NCT04908631|DEVICE|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
219281752|NCT04908631|OTHER|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
219281753|NCT00518895|DRUG|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
219281754|NCT00518895|DRUG|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
219281755|NCT05774288|DEVICE|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
219281756|NCT05774288|DEVICE|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
219281757|NCT00036348|DRUG|Aripiprazole|
219281758|NCT05665543|BEHAVIORAL|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
219281759|NCT05485987|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
219281760|NCT04947254|DRUG|Abiraterone Acetate|Given PO
219281761|NCT04947254|DRUG|Antiandrogen Therapy|Given ADT
219281762|NCT04947254|DRUG|Apalutamide|Given PO
219281763|NCT04947254|PROCEDURE|Biopsy|Undergo biopsy
219281764|NCT04947254|DRUG|Niraparib|Given PO
219281765|NCT04947254|DRUG|Prednisone|Given PO
219281766|NCT04947254|RADIATION|Radiation Therapy|Undergo radiation therapy
219281767|NCT03641755|DRUG|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
219281768|NCT03641755|DRUG|Olaparib|Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
219281769|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)|625 mg/m2 IV over 30 minutes, q2weeks
219281770|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)|320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
219281771|NCT04150042|DRUG|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
219281772|NCT04150042|DRUG|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
219281773|NCT04150042|DRUG|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
219281774|NCT04150042|DRUG|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
219281775|NCT04150042|DRUG|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
219281776|NCT04150042|DEVICE|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
219281777|NCT03681210|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
219281778|NCT04531982|DRUG|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
219281779|NCT04531982|DRUG|Placebo|Placebo, taken as two blinded tablets once daily by mouth
219281780|NCT05922930|DRUG|TROP2-CAR-NK|Given by IP (intraperitoneal)
219281781|NCT05922930|DRUG|Cyclophosphamide|Given by IV (vein)
219281782|NCT05922930|DRUG|Fludarabine|Given by IV (vein)
219281783|NCT06555263|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
219281784|NCT07124585|DIETARY_SUPPLEMENT|Sucralose|Participants will consume one capsule containing sucralose 5mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
219281785|NCT07124585|DIETARY_SUPPLEMENT|Saccharin|Participants will consume one capsule containing saccharin 2mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
219281786|NCT07124585|OTHER|Placebo (Calcium Carbonate)|Participants will consume one capsule per day, containing a fixed dose of 500 mg. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
219281787|NCT06324461|DRUG|Dulaglutide 0.75mg subcutaneous injection|Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery
219281788|NCT02478645|DRUG|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
219281789|NCT02478645|DRUG|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
219281790|NCT02478645|DRUG|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
219281791|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
219281792|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
219281793|NCT01026129|DRUG|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
219281794|NCT04839185|DRUG|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
219281795|NCT04839185|PROCEDURE|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
219281796|NCT05181787|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
219281797|NCT05181787|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
219281798|NCT06982963|BIOLOGICAL|FB102|FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.
219281799|NCT06982963|OTHER|Placebo|Placebo
219281800|NCT06509620|OTHER|Fatigue severity scale|fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.
219281801|NCT06983327|BEHAVIORAL|Trauma Focused Emotional Awareness and Expression Therapy (EAET)|The intervention is three-session program which includes pain neuroscience education, education on the relationship between trauma and chronic pain, and skills training to reduce pain- and stress-related symptoms.
219281802|NCT06522269|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
219281803|NCT06522269|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
219281804|NCT06824194|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219281805|NCT06824194|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219281806|NCT06824194|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219281807|NCT06824194|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
219281808|NCT06824194|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
219281809|NCT06824194|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
219281810|NCT06824194|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
219281811|NCT06824194|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
219281812|NCT06824194|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
219281813|NCT06824194|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
219281814|NCT03119883|OTHER|5-Carbon C 13-labeled Glutamine|Given IV
219281815|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219281816|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
219281817|NCT03119883|OTHER|Uniformly-labeled [13C]glucose|Given IV
219281818|NCT06508775|BIOLOGICAL|MB-CART19.1|Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
219281819|NCT06508775|BIOLOGICAL|MB-CART20.1|Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
219281820|NCT06508775|BIOLOGICAL|MB-CART2019.1|Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
219281821|NCT00759122|DRUG|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
219281822|NCT00759122|DRUG|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
219281823|NCT06699706|OTHER|Continuous theta-burst stimulation|"cTBS targets two regions: the dorsolateral prefrontal cortex (dlPFC) and the M1 area. Before the first treatment, each participant's resting motor threshold (RMT) will be determined using a five-step procedure for the primary motor cortex. RMT is defined as the minimum intensity required to elicit a motor response greater than 50 µV in at least 5 out of 10 consecutive trials in the right first dorsal interosseous muscle.~Participants will then undergo daily cTBS treatment three times a day for 7 consecutive days. Each stimulation session lasts 40 seconds, consisting of triplets of 50 Hz theta-burst stimulation repeated at 5 Hz, delivering a total of 600 pulses. Stimulation of the dlPFC target will be immediately followed by stimulation of the M1 target. To achieve cumulative aftereffects, the protocol will be repeated three times per day (a total of 3600 pulses/day) with two 15-minute breaks between sessions, timed with a stopwatch."
219281824|NCT06699706|OTHER|sham continuous theta-burst stimulation|The treatment pattern for the sham continuous theta-burst stimulation was similar to that for real stimulation. The sham coil is identical in appearance to the active coil, but it only produces sounds and sensations similar to those of the active coil on the scalp without generating a current, preventing participants from identifying their group assignment.
219281825|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
219281826|NCT07136948|BEHAVIORAL|Mindfulness Meditation|Participants will be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. The control group will not see the graph tracking their physiological responses or the predictive mindfulness skill scores based on the algorithm development.
219281827|NCT07136948|BEHAVIORAL|Mindfulness Meditation with Respiration Feedback Chart and Predictive Mindfulness Skill Scores|Participants will then be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. Following the guided meditation lessons, a subset of participants (the experimental group) will see a graph tracking their physiological responses from the guided meditation lesson and predictive mindfulness skill scores based on our algorithm development. The feedback chart is produced by the physiological measures tracked throughout the duration of the lesson, and is displayed within the Equa app, moments after the meditation lessons concludes.
219281828|NCT07136831|DEVICE|Primary Percutaneous Coronary Intervention (PPCI)|A catheter-based invasive procedure used to open blocked coronary arteries in patients presenting with ST-elevation myocardial infarction (STEMI).
219281829|NCT07135518|BEHAVIORAL|Compassion Focused Staff Support|The Compassion Focused Staff Support (CFSS) intervention is designed to promote emotional resilience, compassion, and affect regulation. The intervention begins with a half-day introductory workshop covering the evolution-informed model of emotion regulation, the three-affect system framework, social mentalities, and the nature of compassion. This workshop provides psychoeducation and experiential exercises to introduce key concepts. Following the workshop, staff participate in six monthly 60-minute team sessions over a six-month period. These sessions involve reflective dialogue, experiential exercises, compassion-focused practices, and group-based exploration of emotionally challenging work situations.
219281830|NCT07135518|BEHAVIORAL|CFT Workshop|Participants attend a single half-day workshop providing psychoeducation and experiential exercises on compassion, affect regulation, and social mentalities based on Compassion Focused Therapy.
219281831|NCT07137819|DRUG|Topical treatment|Self-treatment of patients with ointment of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
219281832|NCT07135752|OTHER|Precision assessment|Digital tools, imaging markers and biological markers
219281833|NCT07137975|OTHER|autogenous bone plug|"Preoperative assessment of the alveolar defect began with intraoral examination to check a proper transverse relationship between the maxillary segments and the presence of a normal upper arch form.~After the decision on alveolar bone grafting, Radiologic data from the cleft area will be required. Standard protocol is to take a high resolution CT scan of the patient's skull or at least the whole maxilla. Using the DICOM data acquired from the cleft area the bony defect will be segmented with specific software, in our daily routine blender for dental is used. The same program could be used to design the rough shape of the nasoalveolar graft, and this image could be exported in STL (standard tessellation language) format. and once the desired form is aquired, the final step is to construct a mold. For this purpose, the open-source software Blender (Blender Foundation, Amsterdam, and The Netherlands) will be used. After preoperative planning, the designed mold will be printed using polyam"
219281834|NCT07137975|OTHER|regular autogenous bone grafting|Gold standard grafting of alveolar cleft
219281835|NCT07137832|COMBINATION_PRODUCT|Intra-arterial thrombolysis as adjunct to endovascular treatment|Intra-arterial thrombolysis as adjunct to endovascular treatment, in addition to standard medical treatment
219281836|NCT07137832|OTHER|Standard medical treatment|Standard medical treatment
219281837|NCT07136987|DRUG|Metformin|Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment
219281838|NCT07136987|DIETARY_SUPPLEMENT|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment
219281839|NCT07136987|COMBINATION_PRODUCT|Standard TB treatment|Standard TB treatment
219281840|NCT07135635|DIAGNOSTIC_TEST|Middle Cerebral Artery doppler|All cases of pregnant women diagnosed with anemia at 3rd trimester will have baseline assessment of history, clinical examination, HB level, obstetric ultrasonography done then they will have Middle Cerebral Artery Doppler done to assess correlation between MCA Doppler indices \& neonatal outcomes. Then appropriate treatment of anemia will be taken.
219281841|NCT07138300|DEVICE|Low Level Laser Therapy by (Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy)|"(Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy) .~Patient lies in side lying on the non-affected side which is opposite to the side of radicular pain, hip and knee in flexion 90. Twenty points were established for treatment, 12 over the lumbar spine, at the same Side of the radicular pain, from l2 to s1 vertebra, distance between these points is 2 cm. In the thigh, eight points were marked at equal distances from each other, four in the path of l5 root and four in the path of s1 root from hip to knee. The leaser probe is held in 90 degree over the skin with complete skin contact"
219281842|NCT07138300|PROCEDURE|neural mobilization|"Mobilization will be through using slump sitting maneuver (Both techniques slider and tensioner.~•The slider neurodynamic mobilization technique: The patient moves actively and conversely from a position of neck and trunk flexion, knee flexion, and ankle plantar flexion, to a position of neck and trunk extension, knee extension and ankle dorsiflexion~The tension neurodynamic mobilization technique:~The patient moves actively and conversely from a position of neck and trunk extension, knee flexion, and ankle plantar flexion, to a position of neck and trunk flexion, knee extension, and ankle dorsiflexion"
219281843|NCT07138300|OTHER|placebo laser therapy|patients receive the same treatment on the same area as experimental group for the same period without turning on the device.
219281844|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
219281845|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
219281846|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
219281847|NCT07136389|DRUG|Divozilimab|Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously
219281848|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
219281849|NCT07027982|DRUG|Diluted Intravenous DA-5217|once a day
219281850|NCT07027982|DRUG|Undiluted Intravenous DA-5217|once a day
219281851|NCT04047862|DRUG|Ociperlimab|Administered as an intravenous (IV) injection
219281852|NCT04047862|DRUG|Tislelizumab|Administered as an IV injection
219281853|NCT04047862|DRUG|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
219281854|NCT04047862|DRUG|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
219281855|NCT04047862|DRUG|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
219281856|NCT04047862|DRUG|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
219281857|NCT04047862|DRUG|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
219281858|NCT04047862|DRUG|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
219281859|NCT04047862|DRUG|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
219281860|NCT04047862|DRUG|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
219281861|NCT04047862|DRUG|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
219281862|NCT07052695|DRUG|Mosunetuzumab|Subcutaneous injection of a CD20xCD3 bispecific antibody
219281863|NCT07052695|DRUG|Ibrutinib|For participants who have been ibrutinib PO prior to enrollment
219281864|NCT07052695|DRUG|Acalabrutinib|For participants who have been acalabrutinib PO prior to enrollment
219281865|NCT07052695|DRUG|Zanubrutinib|For participants who have been zanubrutinib PO prior to enrollment
219281866|NCT07052695|DRUG|Pirtobrutinib|For participants who have been pirtobrutinib PO prior to enrollment
219281867|NCT07052097|DRUG|TQC2938 injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
219281868|NCT07052097|DRUG|TQC2938 Placebo|TQC2938 placebo, 4 weeks as a treatment cycle.
219281869|NCT06794775|DRUG|Nivolumab|Adjuvant monotherapy with Nivolumab
219281870|NCT06794775|DRUG|Nivolumab + Ipilimumab|Adjuvant combination therapy with Nivolumab and Ipilimumab
219281871|NCT06839248|OTHER|24-hour clear liquid diet|Participants randomly assigned to this arm will be instructed to follow a 24-hour clear liquid diet, defined as NPO for solids and last intake of clear liquids no less than 2 hours prior to the trial visit.
219281872|NCT06839248|OTHER|Standard fasting guidelines|Participants randomly assigned to this arm will be instructed to follow the ASA and ANZCA standards for preoperative fasting prior to presenting for their trial visit. This requires participants to only consume clear liquids up to 2 hours, a light or low calorific meal up to 6 hours, and fasting from fried foods, fatty foods, or meat for at least 8 hours prior to the trial visit.
219281873|NCT07056556|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
219281874|NCT07053683|DEVICE|Combined RME and Facemask Therapy|This intervention involves two components. First, a tooth-borne Hyrax-type rapid maxillary expander is banded to the maxillary first permanent and deciduous molars. The screw is activated twice daily until posterior crossbite is overcorrected. Second, immediately following expansion, a Petit-type facemask is used to apply orthopedic protraction forces to the maxilla.
219281875|NCT07053683|DEVICE|Facemask Therapy Alone|This intervention involves the use of a Petit-type facemask to apply orthopedic protraction forces (400-500g per side, 12-14 hours/day) to the maxilla. A removable mandibular occlusal splint (flat bite plane) is used concurrently to facilitate anterior crossbite correction.
219281876|NCT06722365|DEVICE|Backscatter Quantitative Ultrasound|The intervention consists of a regular abdominal ultrasound scan for fetal evaluation. The difference with a regular scan is that the scanner used to image the fetus provides access to raw/unprocessed ultrasound echo data that can be extracted from the scanner and processed offline (after acquisition) to extract compute backscatter quantitative ultrasound (bQUS) features. Thus, data acquisition does not represent a significant departure from conventional fetal imaging protocols. Other than the time needed to acquire the images, the participant will not perceive any difference from a regular fetal ultrasound scan.
219281877|NCT06805890|PROCEDURE|Colonoscopy - IBD inflamed tissue|Collection of 10 colonic biopsies in IBD inflamed tissue
219281878|NCT06805890|PROCEDURE|Surgical resection - IBD inflamed mucous membrane|Collection of a portion of IBD inflamed mucous membrane
219281879|NCT06805890|PROCEDURE|Colonoscopy - biopsies in healthy tissue|Collection of 10 colonic biopsies in healthy tissue
219281880|NCT06805890|PROCEDURE|Surgical resection - healthy mucous membrane|Collection of a portion of healthy mucous membrane
219281881|NCT07059377|DRUG|Semaglutide|Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
219281882|NCT07059377|DRUG|Nicotine replacement|Nicotine patch plus short-acting NRT gum or lozenge
219281883|NCT07054619|BEHAVIORAL|Experiential First Aid Training|A first aid training program based on Kolb's Experiential Learning Model conducted in four sessions using real-life scenarios and group exercises.
219281884|NCT07058194|PROCEDURE|Preoperative Erector Spinae Plane Block|This procedure involves bilateral ultrasound-guided erector spinae plane block at the T7 level using 20 mL of 0.25% bupivacaine per side (total 40 mL) before the induction of general anesthesia. The intervention aims to evaluate the effects of preoperative ESP block on changes in frontal QRS-T angle and other ECG-derived cardiac electrophysiological parameters.
219281885|NCT07058194|PROCEDURE|Postoperative Erector Spinae Plane Block|Patients in this group will undergo standard general anesthesia. At the end of the surgery, bilateral ESP block will be performed under ultrasound guidance at the T7 level using 0.25% bupivacaine (20 mL per side, total 40 mL). The aim is to evaluate the effect of postoperative ESP block on changes in frontal QRS-T angle and other cardiac electrophysiological parameters.
219281886|NCT07058194|PROCEDURE|Standard General Anesthesia|This group will receive standard general anesthesia without any additional regional block. ECG data will be collected preoperatively and 1 hour postoperatively to serve as a comparison for electrophysiological changes observed in the intervention groups.
219281887|NCT07058194|DRUG|Bupivacaine|0.25% bupivacaine, 20 mL per side (total 40 mL), administered bilaterally at T7 level under ultrasound guidance as part of ESP block.
219281888|NCT04731506|BEHAVIORAL|Family Connections|Parent participants will receive an activity workbook that promotes increased physical activity and consumption of fruits and vegetables and decreased screen time and intake of sugary drink consumption, two in-person support sessions to help parents to develop an action plan spaced one week apart \& Interactive Voice Response (IVR) automated telephone system calls of 5 to 10 minutes that provide health education messages over 6 months (4 weekly, 4 biweekly (4), and 2 monthly). During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
219281889|NCT06693011|DEVICE|Contour Neurovascular System Treatment Attempt|The subject is brought into the procedure room, an angiogram on the day of the procedure indicates that the subject is anatomically eligible for the trial and any part of the investigational device comes in contact with the patient
219281890|NCT05468619|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
219281891|NCT07064083|DRUG|intracanal nano-ketrolac|For the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
219281892|NCT07064083|DRUG|ketrolac gel|For the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
219281893|NCT07064083|DRUG|A placebo gel|a placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
219281894|NCT07069166|DRUG|Para-probiotic oral care|This intervention includes the home use of a para-probiotic-based toothpaste (Biorepair Plus Parodontogel) and mouthwash (Biorepair Plus with para-probiotics), applied twice daily for 15 days after each recall visit, over a 6-month period. The products contain microRepair® (zinc hydroxyapatite), lactoferrin, zinc PCA, and para-probiotic extracts aimed at modulating the oral microbiota and improving periodontal health.
219281895|NCT07069166|DRUG|Chlorhexidine oral care|This intervention includes the home use of toothpaste and mouthwash containing 0.20% chlorhexidine digluconate, applied twice daily for 15 days after each recall visit, over a 6-month period. Chlorhexidine is used for its antimicrobial properties to control dental plaque and gingival inflammation.
219281896|NCT07069153|DEVICE|Laser Therapy|High-power diode laser therapy is applied to the oral mucosa using the Garda Laser LEO PLUS device with a flat-top handpiece at 660 nm wavelength. Treatment is delivered once daily over five consecutive days according to a standardized photobiomodulation protocol (energy density: 2-4 J/cm²).
219281897|NCT07069153|DEVICE|Ozone therapy|Medical ozone gas is delivered intraorally using the Sweden \& Martina DTA device. The treatment is administered once daily over five consecutive days. A flat-tipped probe is used to apply ozone directly to the mucosal lesions at a concentration of 30-40 µg/mL, following a standardized safety protocol.
219281898|NCT07066332|BEHAVIORAL|Cornell Note Taking education group|Students will be trained in the Cornell note-taking technique.
219281899|NCT07069140|DRUG|Lactoferrin-based Toothpaste and Mouthwash (Emoform Glic)|Participants in the experimental arm will receive professional supragingival and subgingival dental hygiene sessions every three months over a six-month period. In addition, they will follow a home oral care protocol consisting of twice-daily use of a lactoferrin-based toothpaste and a lactoferrin-based mouthwash, both commercially available as Emoform Glic (Polifarma Benessere S.r.l.). The toothpaste will be applied with a soft-bristle toothbrush for two minutes, and the mouthwash will be used at a dosage of 10 mL, rinsed for 60 seconds after toothbrushing, twice a day. The intervention aims to assess whether the combined use of lactoferrin-based toothpaste and mouthwash can enhance clinical outcomes related to plaque accumulation and periodontal inflammation in pregnant women between the fourth and eighth month of gestation.
219281900|NCT07069140|DRUG|Lactoferrin-Based Toothpaste Only (Emoform Glic)|Participants in the control arm will also undergo professional dental hygiene sessions every three months for a total duration of six months. At home, they will follow an oral hygiene protocol limited to the twice-daily use of a lactoferrin-based toothpaste (Emoform Glic, Polifarma Benessere S.r.l.), applied with a soft-bristle toothbrush for two minutes. No mouthwash will be used in this arm. The purpose of this intervention is to evaluate the effectiveness of lactoferrin toothpaste alone and to serve as an active comparator for assessing the additional benefit of the mouthwash in improving periodontal parameters.
219281901|NCT07069127|DEVICE|Biorepair Toothpaste and Mousse|Participants assigned to the experimental arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) and apply Biorepair® Plus Intensive Enamel Repair mousse once daily before bedtime, for a total of 6 months. The toothpaste contains microRepair® particles (zinc-substituted hydroxyapatite), designed to occlude dentinal tubules and promote enamel remineralization. The mousse, applied at night, enhances remineralization through higher concentrations of active hydroxyapatite. This combined regimen targets the reduction of dentin hypersensitivity and enamel demineralization in adult patients with celiac disease.
219281902|NCT07069127|DEVICE|Biorepair® Toothpaste|Participants assigned to the control arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) for 6 months. The toothpaste formulation contains microRepair® (zinc hydroxyapatite) to support daily enamel protection and tubule occlusion, without the adjunctive effect of the mousse. This arm is used to assess the baseline efficacy of the toothpaste alone compared to the combined regimen.
219281903|NCT03041688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219281904|NCT03041688|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219281905|NCT03041688|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219281906|NCT03041688|DRUG|Decitabine|Given IV
219281907|NCT03041688|DRUG|Navtemadlin|Given PO
219281908|NCT03041688|DRUG|Venetoclax|Given PO
219281909|NCT07135934|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Gelatin capsules each containing 1g sodium bicarbonate (NaHCO₃)
219281910|NCT07135934|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules each containing 1g food-grade starch
219281911|NCT07129135|PROCEDURE|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter before uterine incision or bladder dissection to help determine the borders better and enable dissection of the lower uterine segment without excessive bleeding or unintended Bladder kept distended during dissection.
219281912|NCT07138105|OTHER|National AI in Surgical Practice Survey - Sudan|An online, cross-sectional national survey targeting Sudanese doctors who provide surgical care in any capacity. The survey collects data on awareness, prior experience, perceived benefits, barriers, and training needs for adopting artificial intelligence in surgical practice. Participants include house officers, medical officers, registrars/residents, specialists, consultants, and general practitioners performing surgical procedures in public, private, NGO, or military hospitals. The study does not involve the implementation or testing of AI tools but aims to inform the design of future AI solutions tailored for low-resource and conflict-affected health systems.
219281913|NCT07135804|DRUG|Iparomlimab and Tuvonralimab Injection|Patients will receive Iparomlimab and Tuvonralimab Injection on the basis of 3 cycles of induction chemotherapy, followed by standard concurrent chemoradiotherapy, and then 9 cycles of Iparomlimab and Tuvonralimab Injection as adjuvant therapy
219281914|NCT07084610|DRUG|Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)|Patients will receive neoadjuvant treatment with nivolumab (3 mg/kg, IV) combined with platinum-based chemotherapy (cisplatin 75 mg/m² or carboplatin AUC 5, plus pemetrexed 500 mg/m² for non-squamous or paclitaxel 175 mg/m² for squamous tumors) every 21 days for two cycles. All patients will undergo invasive mediastinal staging before treatment and will be treated with robotic-assisted anatomical lung resection and mediastinal lymphadenectomy after neoadjuvant therapy.
219281915|NCT07085026|BEHAVIORAL|Yoga Intervention|There are studies that have evaluated the effects of prenatal yoga on sleep. None of these studies have reported any negative effects of yoga on pregnancy. In all studies, yoga practice was applied with varying frequencies, durations, and techniques. However, no research has been found that evaluates the effects of a yoga program conducted in accordance with the World Health Organization (WHO) guideline recommendations on both sleep and stress. Therefore, the aim of this study is to evaluate the effects of yoga, practiced during the third trimester of pregnancy in line with WHO guideline recommendations, on sleep and stress.
219281916|NCT07084792|DEVICE|Direct cortical stimulation|Stimulation
219281917|NCT07085728|DRUG|Cyclophosphamide|Arm A
219281918|NCT07085728|DRUG|Bortezomib (VELCADE)|Arm A, Arm B
219281919|NCT07085728|DRUG|Dexamethasone|Arm A, Arm B
219281920|NCT07085728|DRUG|Daratumumab-hyaluronidase|Arm B
219281921|NCT06088004|DRUG|ABO2011 Injection|Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
219281922|NCT06088004|DRUG|Toripalimab|Anti-PD-1 antibody
219281923|NCT06789302|DRUG|DT2-SCT intravenous infusion|"DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects."
219281924|NCT06789302|OTHER|Placebo|Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
219281925|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
219281926|NCT05254834|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
219281927|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
219281928|NCT05564650|DRUG|Venetoclax|Given PO
219281929|NCT05564650|DRUG|Decitabine|Given IV
219281930|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219281931|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219281932|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
219281933|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
219281934|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
219281935|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
219281936|NCT07096011|OTHER|Meal Test - Human Milk|Infants will be fed a mixed meal test (meal challenge test) of human milk from his/her human milk donor (e.g., mother). Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents their standard meal, at a larger size. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of human milk that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for human milk is be estimated at 20 kcals/ounce.
219281937|NCT07096011|OTHER|Meal Test - Infant Formula|Infants will be fed a mixed meal test (meal challenge test) of ready-to-feed infant formula. Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents a meal different from their habitual food intake and is a standard meal that all participants receive. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of infant formula that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for the ready-to-feed infant formula is 20 kcals/ounce.
219281938|NCT07136688|DEVICE|Stamobil electric stimulator|The electric stimulation protocol will use stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode for 30 minutes daily. The goal is daily use of tTNS for 4 weeks , 5 days per week.
219281939|NCT07136688|DEVICE|sham tTNS device|The electric sham stimulation protocol will use sham stimulation (low intensity) for 30 minutes daily, for 4 weeks , 5 days per week
219281940|NCT07138196|DRUG|Adrixetinib|Administered orally
219281941|NCT07135362|DIETARY_SUPPLEMENT|TCI604 probiotics|TCI604 probiotics sachet
219281942|NCT07135362|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
219281943|NCT07135973|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:Oral
219281944|NCT07136961|PROCEDURE|Robot-Assisted Bronchoscopy (RAB)|"1. Preoxygenation \& Navigation Registration~2. Robotic-Guided Navigation~3. Puncture Tunnel Establishment~4. Position Verification \& Adjustment~   Perform confirmatory CT scan to assess tool-nodule relationship:~   Tool-in-lesion (TIL) : Biopsy tool penetrates nodule Center Strike : Tool tip reaches central 1/3 of nodule (coronal/sagittal/horizontal planes) Tool-touch-lesion : Tool contacts but does not enter nodule~  * 4mm deviation : Proceed to biopsy \>4mm deviation : Adjust based on operator judgment~5. Biopsy \& Rapid Evaluation Obtain tissue samples Conduct ROSE (Rapid On-Site Evaluation) to guide next steps~6. Post-Procedure Safety Check Perform postoperative CT to exclude pneumothorax/hemorrhage Maintain identical ventilation settings during imaging and biopsy phases to prevent target shift"
219281945|NCT07136311|DIAGNOSTIC_TEST|DPOAE with Contralateral Suppression|Participants will undergo distortion evoked otoacoustic emissions (DPOAE) testing with contralateral broadband noise stimulation. The test is performed to evaluate auditory efferent system function, specifically the presence and degree of contralateral suppression. No medication or treatment is administered as part of the study. The procedure is non-invasive and commonly used in auditory diagnostics.
219281946|NCT07136571|DEVICE|bland particles|embolization with bland particles of appropriate size
219281947|NCT07135557|DEVICE|R-One vascular interventional navigation control system|"The interventional cardiologist sits at the cockpit and remotely performs the PCI using the console joysticks. The cassette, which is loaded with the interventional devices and connected to the guiding catheters, imposes axial and rotational forces on the intracoronary devices. Fluoroscopic, electrocardiographic, and hemodynamic images are slaved to the duplicate monitors inside the cockpit, enabling visualization from a closer distance. After completion of diagnostic angiography, the guiding catheter was positioned at the ostium of the coronary artery and connected to the disposable cassette on the robotic drive. The guidewire was loaded into the cassette. Treatment was administrated according to local site protocols. Pre and post dilation was done per operator discretion. All intracoronary devices were to be manipulated exclusively by the robotic system, with bailout to manual conversion when needed."
219281948|NCT07137234|PROCEDURE|Modified Millard rotation advancement flap technique|the cleft is repaired by surgical intervention
219281949|NCT07137234|DRUG|botulinum toxin injection (BTX A) before surgical intervention|the patient will receive Botulinum toxin type A followed by surgical closure of cleft lip
219281950|NCT07137793|DRUG|Pentoxifylline 400mg plus chemotherapy|patient will receive standard chemotherapy for breast cancer plus pentoxifylline 400 mg orally 3 times per day with meals.
219281951|NCT07135505|BEHAVIORAL|Early time-restricted eating|The participants will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-8:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.
219281952|NCT07135271|OTHER|Bespoke Decision Support tool|A newly-developed online patient decision aid offering comparative information of prostate cancer treatments (active surveillance, focal therapy, radical prostatectomy and external beam radiotherapy), personalised estimates of oncological and functional outcomes for each treatment and a value-clarification exercise.
219281953|NCT07135271|OTHER|Standard of Care (SOC) decision support material|"Standard of care information to inform the prostate cancer treatment decision. This includes the nationally approved Prostate Cancer UK information booklet Prostate Cancer - A guide if you have just been diagnosed in all sites. Further educational material may be provided as part of standard of care depending on local practice at each site."
219281954|NCT07137533|OTHER|Mandibular Four-Implant-Retained Overdenture (PEEK Framework); Mandibular All-on-4 Fixed Prosthesis (PEEK Framework)|"Group I: Four-implant-retained mandibular overdenture with a CAD/CAM-milled PEEK framework and acrylic denture teeth, retained via attachment mechanisms; implants placed in lateral incisor and first premolar sites; delayed loading protocol.~Group II: Mandibular All-on-4 fixed prosthesis with a CAD/CAM-milled PEEK framework and acrylic denture teeth; two anterior straight and two posterior tilted implants placed in lateral incisor and first premolar sites; delayed loading protocol."
219281955|NCT07136285|DRUG|Olvi-Vec|Olvi-Vec will be administered to patient for 3 days during C1
219281956|NCT07136285|DRUG|platinum (cisplatin or carboplatin)|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
219281957|NCT07136285|DRUG|Etoposide|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
219281958|NCT07136792|DRUG|Pegmolesatide 2mg SC|All patients will receive pegmolesatide 2mg subcutaneously once every 4 weeks.
219281959|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
219281960|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
219281961|NCT07136792|DRUG|Pegmolesatide 6mg SC|All patients will receive pegmolesatide 6mg subcutaneously once every 4 weeks.
219281962|NCT07138144|DRUG|Standard Medical Therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet.
219281963|NCT07138144|DRUG|dual therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs
219281964|NCT07088679|DRUG|Sterify Gel (mucoadhesive bioactive gel)|Sterify Gel® is a sterile, ready-to-use mucoadhesive hydrogel formulated with polyvinyl polymers, hydroxytyrosol (a natural antioxidant), magnesium ascorbyl phosphate (a stable vitamin C derivative), and nisin (a naturally occurring antimicrobial peptide). In this study, it is applied into the peri-implant pocket using a 0.6 mm - 23GA sterile needle (Gerhò®) immediately after non-surgical debridement. Application is performed at baseline and at follow-up visits (1, 3, 6, and 9 months). Patients are instructed to avoid rinsing, eating, or using oral hygiene aids at the treated sites for at least 2 hours post-application, and to follow specific hygiene instructions for 48 hours.
219281965|NCT07088679|PROCEDURE|Standard Non-Surgical Peri-Implantitis Therapy|Standard therapy consists of supra- and subgingival professional mechanical debridement of peri-implant sites using ultrasonic inserts and manual curettes covered with biocompatible materials (PEEK, teflon, or titanium) to avoid damage to the implant surface. This is followed by air-polishing using erythritol powder (Air-Flow Plus®, EMS; 14 µm) for supragingival biofilm removal and glycine powder (Air-Flow Perio®, EMS; 25 µm) for subgingival polishing. This procedure is repeated at baseline and at 1, 3, 6, and 9 months without the adjunctive use of any topical gel.
219281966|NCT06889584|COMBINATION_PRODUCT|All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin))|Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin.
219281967|NCT06889584|COMBINATION_PRODUCT|AM Active Supplement Combination (Ashwagandha and Rhodiola rosea)|Ashwagandha and Rhodiola rosea
219281968|NCT06889584|COMBINATION_PRODUCT|PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin)|Magnesium threonate, L-theanine, and apigenin.
219281969|NCT06889584|OTHER|AM and PM Placebo|Placebo AM and PM
219281970|NCT05478759|BEHAVIORAL|Multimodal affect recognition training|8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.
219281971|NCT05478759|BEHAVIORAL|Attention Training|computerized attention drill training
219281972|NCT05478759|BEHAVIORAL|Brain Health Workshop|an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.
219281973|NCT05478759|BEHAVIORAL|National Geographic Movies|participant will watch movies and answer questions after
219281974|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
219281975|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
219281976|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
219281977|NCT01920698|OTHER|control|
219281978|NCT01876082|DRUG|PAZOPANIB treatment|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
219281979|NCT01876082|DRUG|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
219281980|NCT04854850|DEVICE|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
219281981|NCT01483456|OTHER|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases"
219281982|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
219281983|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5 millilitres (mL)) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
219281984|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
219281985|NCT02999685|BEHAVIORAL|Home-base Pulmonary Rehab with Health Coaching|
219281986|NCT04299243|DEVICE|Contact Lenses|Contact lenses for vision correction
219281987|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
219281988|NCT06045975|DRUG|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"* Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions."
219281989|NCT01230866|RADIATION|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
219281990|NCT01230866|RADIATION|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
219281991|NCT05043766|DRUG|PF614|PF614 is an oxycodone prodrug
219281992|NCT05043766|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
219281993|NCT05043766|DRUG|OxyContin|Bioequivalence single-dose comparison to OxyContin
219281994|NCT06199180|DEVICE|pulmonary vein isolation with RFA|Patients randomised to RFA will undergo PVI with point-by-point RFA.
219281995|NCT06199180|DEVICE|pulmonary vein isolation with PFA|Patients randomised to PFA will undergo PVI with PFA.
219281996|NCT04683627|DRUG|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
219281997|NCT04683627|DRUG|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
219281998|NCT03829501|DRUG|Alomfilimab|A human anti-ICOS monoclonal antibody
219281999|NCT03829501|DRUG|Atezolizumab|An anti-PD-L1 monoclonal antibody
219282000|NCT03625544|PROCEDURE|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
219282001|NCT03625544|DEVICE|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
219282002|NCT03625544|PROCEDURE|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
219282003|NCT03024463|PROCEDURE|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
219282004|NCT06276400|OTHER|Emotion valence|Positive vs. Negative (temporally extended sequence)
219282005|NCT06276400|OTHER|Time|∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)
219282006|NCT06276400|DEVICE|TMS Stimulation|FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
219282007|NCT02446665|DEVICE|MR Elastography (MRE) and FibroScan|
219282008|NCT06280742|RADIATION|PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-DPA-714
219282009|NCT05642611|PROCEDURE|Biospecimen Collection|Undergo collection of blood, plasma, and serum
219282010|NCT05642611|PROCEDURE|Cryocompression Therapy|Undergo cryocompression
219282011|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo continuous compression
219282012|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo low cyclic compression
219282013|NCT05642611|OTHER|Quality-of-Life Assessment|Ancillary studies
219282014|NCT05642611|OTHER|Questionnaire Administration|Ancillary studies
219282015|NCT03642847|BIOLOGICAL|Prevnar 13|13 valent Pneumococcal Conjugate
219282016|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
219282017|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
219282018|NCT01758445|RADIATION|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
219282019|NCT01123070|BIOLOGICAL|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
219282020|NCT01123070|BIOLOGICAL|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
219282021|NCT03270410|OTHER|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
219282022|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
219282023|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
219282024|NCT02891538|DRUG|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*
219282025|NCT00084344|DRUG|4-hydroxytamoxifen|
219282026|NCT00084344|PROCEDURE|breast imaging study|
219282027|NCT00084344|PROCEDURE|radiomammography|
219282028|NCT03663673|DRUG|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
219282029|NCT03663673|DRUG|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
219282030|NCT00660322|BEHAVIORAL|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~1. Using asthma controller medications as prescribed~2. Having and Asthma Action Plan available to all who may need it.~3. Using asthma rescue medications with the child's first symptoms.~4. Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
219282031|NCT05873478|OTHER|High Intensity Interval Training|The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
219282032|NCT00263172|BEHAVIORAL|behavior modification for weight loss|
219282033|NCT02207504|DRUG|Crizotinib|Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
219282034|NCT02207504|DRUG|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
219282035|NCT01887704|DEVICE|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
219282036|NCT01887704|PROCEDURE|conventional angioplasty|Conventional angioplasty was used in both arms.
219282037|NCT01887704|PROCEDURE|stenting|Stenting was implanted in both arms.
219282038|NCT01887704|DEVICE|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
219282039|NCT01887704|DRUG|Aspirin|Aspirin will be administrated in participants in both arms.
219282040|NCT01887704|DRUG|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
219282041|NCT01887704|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
219282042|NCT01887704|DEVICE|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
219282043|NCT01887704|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
219282044|NCT01887704|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
219282045|NCT03520738|OTHER|Blood samples|Blood samples on an empty stomach
219282046|NCT03520738|OTHER|Urinary samples|first urinary in the morning
219282047|NCT03264937|BEHAVIORAL|Social-software management|Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
219282048|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
219282049|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
219282050|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
219282051|NCT01056705|BIOLOGICAL|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
219282052|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
219282053|NCT03284229|DEVICE|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
219282054|NCT01702324|DRUG|DD-25|A topical DD-25 cream at 0.025% concentration.
219282055|NCT05411133|DRUG|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
219282056|NCT05914116|DRUG|DB-1311|Administered I.V.(intravenous infusion)
219282057|NCT05914116|DRUG|Lopinavir and Ritonavir Tablets|Lopinavir and Ritonavir Tablets
219282058|NCT05914116|DRUG|itraconazole|itraconazole
219282059|NCT06316895|PROCEDURE|thyroid surgery|thyroid lobectomy
219282060|NCT06316895|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation; microwave ablation or laser ablation
219282061|NCT04087811|DEVICE|Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) (Superion® implant)
219282062|NCT04407689|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
219282063|NCT04407689|DRUG|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
219282064|NCT02986308|OTHER|No intervention|
219282065|NCT04288518|DRUG|SPECT or SPECT-CT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
219282066|NCT04101253|PROCEDURE|new screening procedure with small variations in electrode positioning|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
219282067|NCT00974818|DRUG|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
219282068|NCT00974818|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
219282069|NCT05794490|BEHAVIORAL|Learning from excellence|Health care professionals´ experiences of learning from excellence in a hospital unit
219282070|NCT02570204|BEHAVIORAL|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
219282071|NCT00626197|DRUG|Corticosteroids|Intravenous and oral repeating dose
219282072|NCT00626197|DRUG|Cyclophosphamide|Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
219282073|NCT00626197|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
219282074|NCT00626197|DRUG|Ocrelizumab|Ocrelizumab was administed at a dose and as per schedule in arm description
219282075|NCT00626197|DRUG|Placebo|Placebo was administered as per schedule in arm description
219282076|NCT00626197|DRUG|Azathioprine|Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
219282077|NCT04200638|DIAGNOSTIC_TEST|ProTaper Next|The canal fluid sample before and after will evaluate after root canal instrumentation
219282078|NCT03750929|OTHER|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
219282079|NCT00497731|DRUG|AZD1152|2-hour continuous intravenous infusion
219282080|NCT04833127|BEHAVIORAL|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
219282081|NCT04833127|BEHAVIORAL|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
219282082|NCT04440839|OTHER|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
219282083|NCT04468945|OTHER|mirror box therapy|"* Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~* The patient is seated close to a table a mirror (33\*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~* The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~* During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously."
219282084|NCT04468945|OTHER|Repetitive Facilitation Exercise|"* The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~* Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~* Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~* Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~* Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)"
219282085|NCT03605576|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
219282086|NCT03605576|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
219282087|NCT01071655|DRUG|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
219282088|NCT01071655|DRUG|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
219282089|NCT04552899|DRUG|PRM-151 (Zinpentraxin Alfa)|A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
219282090|NCT04552899|DRUG|Placebo|Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
219282091|NCT00288184|DRUG|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
219282092|NCT00288184|DRUG|Placebo|
219282093|NCT04051502|DRUG|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
219282094|NCT04051502|DRUG|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"
219282095|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
219282096|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
219282097|NCT05162573|DRUG|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)
219282098|NCT05162573|RADIATION|EBRT|External Beam Radiotherapy
219282099|NCT04999618|DRUG|Haemoblock|Delivering with transdermal patches
219282100|NCT04999618|OTHER|Placebo|Delivering with transdermal patches
219282101|NCT05846841|BEHAVIORAL|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
219282102|NCT05846841|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
219282103|NCT00561431|DEVICE|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
219282104|NCT00561431|DEVICE|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
219282105|NCT06357988|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219282106|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219282107|NCT06357988|PROCEDURE|Echocardiography Test|Undergo echocardiography
219282108|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
219282109|NCT06357988|DRUG|Vismodegib|Given PO
219282110|NCT02900547|OTHER|Patients with systolic heart failure|
219282111|NCT05658653|OTHER|Educational Materials for Chronic Disease Management Test (CDMT)|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
219282112|NCT03512964|DRUG|Dolutegravir 50 MG|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
219282113|NCT03512964|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
219282114|NCT00785811|DRUG|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
219282115|NCT00785811|DRUG|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
219282116|NCT03780361|DRUG|Aflibercept Injection|Total 5 times of monthly intravitreal aflibercept injections will be done.
219282117|NCT04703205|DRUG|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
219282118|NCT04703205|DRUG|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
219282119|NCT04255953|BEHAVIORAL|behavioral telehealth|Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
219282120|NCT04255953|OTHER|Treatment as Usual|Treatment as Usual
219282121|NCT03657602|DRUG|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
219282122|NCT03657602|DRUG|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
219282123|NCT02523703|BIOLOGICAL|glutamate and aspartate|
219282124|NCT02388126|DEVICE|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
219282125|NCT02388126|DEVICE|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
219282126|NCT01576380|DRUG|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
219282127|NCT02597244|DEVICE|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
219282128|NCT02849444|OTHER|Anti-myeloma treatment at physician discretion|non Interventional Study
219282129|NCT00461981|BIOLOGICAL|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
219282130|NCT00461981|BIOLOGICAL|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
219282131|NCT01588964|PROCEDURE|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
219282132|NCT05354414|DEVICE|Virtual reality|Administered as specified in the treatment arm.
219282133|NCT05354414|PROCEDURE|Standard of Care|Administered as specified in the treatment arm.
219282134|NCT02509832|DEVICE|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
219282135|NCT02509832|DEVICE|PCI only|Standard of Care for PCI
219282136|NCT05467293|DRUG|0.3% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
219282137|NCT05467293|DRUG|1% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
219282138|NCT05467293|DRUG|YP-P10 Placebo Ophthalmic Solution (vehicle)|Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
219282139|NCT03978039|DRUG|Chemotherapy|treatment as per standard of care
219282140|NCT03978039|DRUG|Immunotherapeutic Agent|treatment as per standard of care
219282141|NCT03978039|DRUG|target treatment|treatment as per standard of care
219282142|NCT03978039|PROCEDURE|Surgery|treatment as per standard of care
219282143|NCT03978039|RADIATION|Radiotherapy|treatment as per standard of care
219282144|NCT03832218|DIAGNOSTIC_TEST|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~* Test : Wechsler Intelligence Scale for Children (WISC-V)~* Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~* Global Assessment of Functioning Scale~* Scale : Brief Psychiatric Rating Scale (BPRS)~* Test : Children Depression Inventory (CDI)~* Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~* Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~* Scale : Conners' scale (parents and teachers)"
219282145|NCT05287997|DIAGNOSTIC_TEST|Neurolytixs Index|Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
219282146|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
219282147|NCT00196469|DRUG|heparin|
219282148|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
219282149|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
219282150|NCT04393311|DRUG|Ulinastatin|Ulinastatin administered via IV infusion (200,000/infusion)
219282151|NCT04393311|DRUG|Placebo|Placebo to match ulinastatin administered via IV infusion
219282152|NCT04542967|BIOLOGICAL|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
219282153|NCT00731133|DRUG|Disulfiram|250 mg/day
219282154|NCT05643755|OTHER|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
219282155|NCT01052610|DRUG|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
219282156|NCT01052610|DRUG|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
219282157|NCT05408247|DRUG|N-acetyl cysteine|2400mg/day
219282158|NCT05408247|DRUG|Placebo|Matched placebo
219282159|NCT00004442|DRUG|chenodeoxycholic acid|
219282160|NCT00004442|DRUG|cholic acid|
219282161|NCT00004442|DRUG|ursodiol|
219282162|NCT03510455|DRUG|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
219282163|NCT04396249|DEVICE|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
219282164|NCT04396249|DEVICE|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
219282165|NCT04411329|DRUG|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
219282166|NCT04411329|DRUG|Dexamethasone|dexamethazone
219282167|NCT04411329|DRUG|Dexmedetomidine|dexmedetomidine
219282168|NCT04411329|DRUG|Hyalouridinase|hyalouridinase
219282169|NCT01534065|DEVICE|Barricaid|Implanted intra-operatively during discectomy
219282170|NCT01046929|DIETARY_SUPPLEMENT|limonene|oral dosing at 2 gram QD
219282171|NCT02190903|OTHER|General endotracheal anesthesia|"General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol."
219282172|NCT02190903|OTHER|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
219282173|NCT06131151|OTHER|Nerve block|Nerve block in percutaneous nephrolithotomy
219282174|NCT05179070|DRUG|Carvedilol|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
219282175|NCT00078351|PROCEDURE|High molecular weight hylan (Synvisc) injection|
219282176|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
219282177|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
219282178|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
219282179|NCT03414177|OTHER|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
219282180|NCT03336359|DIAGNOSTIC_TEST|Tandem colonoscopy|Different image enhanced endoscopy systems
219282181|NCT04498364|BEHAVIORAL|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics.
219282182|NCT02526966|BIOLOGICAL|blood sample|dosage of anti-hinge region antibodies
219282183|NCT03098563|DRUG|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
219282184|NCT00827476|PROCEDURE|ovarian transplantation|ovarian xenotransplantation or in vitro culture
219282185|NCT02218723|DRUG|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
219282186|NCT02218723|DRUG|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
219282187|NCT00455221|BIOLOGICAL|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
219282188|NCT00455221|GENETIC|Cytokine gene adjuvant|Cytokine gene adjuvant
219282189|NCT05539443|BEHAVIORAL|Intensive Clinic Management (ICM)|An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
219282190|NCT05539443|BEHAVIORAL|Intensive tailored telehealth management (ITTM)|A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
219282191|NCT01790841|DEVICE|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
219282192|NCT05925231|DIAGNOSTIC_TEST|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
219282193|NCT01209377|BEHAVIORAL|standard|EMDR treatment with bilateral stimulation via eye movement
219282194|NCT01209377|BEHAVIORAL|fixed|EMDR treatment with fixed eyes
219282195|NCT01209377|BEHAVIORAL|no focus|trauma exposure without external focus
219282196|NCT01209377|PROCEDURE|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
219282197|NCT04059627|DEVICE|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
219282198|NCT04150159|DIETARY_SUPPLEMENT|FMD Arm|ProLon Fasting Mimicking Diet Plan
219282199|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
219282200|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
219282201|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
219282202|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
219282203|NCT01509144|BIOLOGICAL|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
219282204|NCT04682743|DRUG|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
219282205|NCT04682743|DRUG|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
219282206|NCT04682743|DRUG|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
219282207|NCT04797052|DEVICE|Prefrontal EEG (VEEGix by NeuroServo)|Prefrontal EEG reading
219282208|NCT02086890|DEVICE|Electro-acupuncture|
219282209|NCT02086890|DEVICE|Laser Acupuncture|
219282210|NCT02086890|DEVICE|Transcorneal Electrical Stimulation|
219282211|NCT02086890|DEVICE|Sham Electro-acupuncture|
219282212|NCT02086890|DEVICE|Sham laser acupuncture|
219282213|NCT02086890|DEVICE|Sham transcorneal electrical stimulation|
219282214|NCT04958642|DRUG|Adrabetadex|Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
219282215|NCT06037473|DRUG|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
219282216|NCT01796015|OTHER|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
219282217|NCT03916406|DRUG|PF 06835919|300 mg
219282218|NCT03916406|DRUG|Midazolam|7.5 mg
219282219|NCT01541384|DEVICE|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
219282220|NCT06595459|DRUG|Nicotine Pouches|3mg or 6mg nicotine pouches
219282221|NCT06595459|DRUG|Mini Nicotine lozenges|2mg to 4mg mini lozenges
219282222|NCT01246505|DEVICE|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
219282223|NCT04808986|DIAGNOSTIC_TEST|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
219282224|NCT02878447|RADIATION|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
219282225|NCT03853551|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
219282226|NCT06489860|DRUG|HIV|"Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5% Dosage Form:~Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date"
219282227|NCT06489860|DRUG|Malignant Neoplasms Safety Study for the Treatment of Neoplasms|Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.
219282228|NCT06230172|RADIATION|Weaning incubator (heat) at an lower postnatal weight|"Infants in the intervention group are weaned in the same manner as the infants in the control arm; however, the wean begins at a lower postnatal weight.~Our institutional guidelines for weaning infants from incubator to crib was unchanged for both groups."
219282229|NCT06161207|PROCEDURE|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection|Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
219282230|NCT02476175|DRUG|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
219282231|NCT02397551|PROCEDURE|IVF/ICSI|
219282232|NCT02397551|DRUG|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
219282233|NCT06213818|DRUG|INCB160058|Oral; Immediate release solid tablet
219282234|NCT06213818|DRUG|Placebo|Oral; Tablet
219282235|NCT06213818|DRUG|Esomeprazole|Oral; Delayed-release capsule or tablet
219282236|NCT06213818|DRUG|Famotidine|Oral; Tablet
219282237|NCT03398304|OTHER|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
219282238|NCT03398304|OTHER|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
219282239|NCT06847204|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine is anti inflammatory drug which will be given to Covid pneumonia patients and their benefit will be observed in them
219282240|NCT05286125|PROCEDURE|erector spinae plane (ESP) block|Using the in plane technique, the needle will be advanced between the transverse process and erector spinae muscle. The correct location will be confirmed using 1ml of Local Anesthetic (LA) to view hydrodissection(12). 19ml of LA will be injected between the muscle and transverse process.
219282241|NCT05286125|PROCEDURE|oblique subcostal transverse abdominis plane (TAP) block|An echogenic needle will be inserted in-plane until the needle tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles. Once the needle enters the TAP plane, a dynamic injection can be performed by advancing the needle under ultrasound guidance laterally in the pocket created by the initial injection of 5 - 10 mL of local anesthetic; as the needle is advanced, the remaining local anesthetic will be injected. This allows for a more lateral spread of the local anesthetic
219282242|NCT00002320|DRUG|Lamivudine|
219282243|NCT00002320|DRUG|Zidovudine|
219282244|NCT05233475|BEHAVIORAL|Enhanced usual care (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
219282245|NCT05233475|BEHAVIORAL|Get Going after concussIoN Lite|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
219282246|NCT06082570|DRUG|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
219282247|NCT04057027|PROCEDURE|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
219282248|NCT04057027|PROCEDURE|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
219282249|NCT05038124|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
219282250|NCT01495897|DEVICE|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
219282251|NCT01495897|DEVICE|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
219282252|NCT06224777|BIOLOGICAL|5% Albumin (human) Solution|Albumin is a biological product derived from human blood donors.
219282253|NCT06224777|DRUG|Paeds solution|Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
219282254|NCT02410616|BEHAVIORAL|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
219282255|NCT02410616|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
219282256|NCT06223919|BIOLOGICAL|LC16m8|"LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses"
219282257|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
219282258|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
219282259|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
219282260|NCT00045201|DRUG|Erlotinib Hydrochloride|Given orally
219282261|NCT00045201|DRUG|Irinotecan Hydrochloride|Given IV
219282262|NCT04439292|DRUG|Dabrafenib Mesylate|Given PO
219282263|NCT04439292|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
219282264|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
219282265|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
219282266|NCT03805776|OTHER|Fasting (diet restruction for specific period)|12-14 hours fasting
219282267|NCT00990795|DRUG|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
219282268|NCT00990795|DRUG|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
219282269|NCT05380557|DIAGNOSTIC_TEST|Germline genetic testing|Germline genetic testing will be provided to each patient
219282270|NCT05104203|PROCEDURE|Thoracolumbar Interfascial Plane block|Interfascial block done by injection between m. multifidus and m. longissimus
219282271|NCT05104203|PROCEDURE|Modified Thorcolumbar Interfascial Plane block|Injection of local anesthetics between m. longissimus and m. illiocostalis
219282272|NCT05854407|OTHER|skim milk|pasteurized or high-pasteurized skim milk
219282273|NCT00447746|PROCEDURE|D1 or D2 lymphadenectomy for gastric cancer patients|
219282274|NCT03290053|DRUG|SonoVue|SonoVue-infusion over 1 hour
219282275|NCT03290053|DRUG|Sodium chloride|Placebo
219282276|NCT03290053|PROCEDURE|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
219282277|NCT03290053|PROCEDURE|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
219282278|NCT02964325|DEVICE|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
219282279|NCT02964325|DEVICE|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
219282280|NCT05552300|PROCEDURE|SAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
219282281|NCT05552300|DRUG|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
219282282|NCT00800553|DRUG|donepezil|5mg o.m. p.o. for approx. 2 weeks
219282283|NCT00800553|DRUG|Placebo|5mg of placebo for approx. 2 weeks
219282284|NCT04659330|BEHAVIORAL|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
219282285|NCT04659330|DEVICE|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
219282286|NCT02510040|DEVICE|Prism|Ground-in or Fresnel prism
219282287|NCT02510040|OTHER|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
219282288|NCT02510040|PROCEDURE|Eye Muscle Surgery|"* Bilateral medial rectus muscle resection surgery~* Single medial rectus muscle resection surgery~* Recess lateral rectus muscle resection medial rectus muscle surgery~* Bilateral lateral rectus muscle recession surgery~* Single lateral rectus muscle recession surgery~* Bilateral lateral rectus muscle resection surgery~* Single lateral rectus muscle resection surgery~* Recess medial rectus muscle resection lateral rectus muscle surgery~* Bilateral medial rectus muscle recession surgery~* Single medial rectus muscle recession surgery~* Vertical rectus muscle recession surgery~* Vertical rectus muscle mini-tenotomy (snip) surgery"
219282289|NCT02510040|PROCEDURE|Botox Injection|Botulinum toxin injection
219282290|NCT01133782|PROCEDURE|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
219282291|NCT01368471|DEVICE|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
219282292|NCT01368471|DEVICE|Control BMS or DES|Control BMS or DES
219282293|NCT02338453|BEHAVIORAL|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
219282294|NCT02338453|BEHAVIORAL|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
219282295|NCT01860326|DRUG|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
219282296|NCT04695184|DIAGNOSTIC_TEST|ICG-NIRF Imaging|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
219282297|NCT03225326|DRUG|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
219282298|NCT03225326|DRUG|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
219282299|NCT00198276|COMBINATION_PRODUCT|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
219282300|NCT02145832|DRUG|Fluconazole|
219282301|NCT02145832|DRUG|Micafungin|
219282302|NCT03705897|OTHER|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
219282303|NCT03705897|OTHER|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
219282304|NCT03705897|OTHER|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
219282305|NCT06471075|BEHAVIORAL|Mindful Pain Management|The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
219282306|NCT06471075|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
219282307|NCT06372106|DEVICE|SaO2 Sampling|CO-Oximetry analysis of arterial blood samples
219282308|NCT02885415|PROCEDURE|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
219282309|NCT03250988|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
219282310|NCT03085225|DRUG|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
219282311|NCT06407024|PROCEDURE|laparoscopic transabdominal adrenalectomy|Adrenalectomy performed by laparoscopic approach
219282312|NCT06407024|PROCEDURE|robotic transabdominal adrenalectomy|Adrenalectomy performed by robotic approach
219282313|NCT05859880|BEHAVIORAL|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
219282314|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
219282315|NCT00826332|PROCEDURE|transabdominal ultrasound|transabdominal ultrasound
219282316|NCT00826332|PROCEDURE|transvaginal ultrasound|transvaginal ultrasound
219282317|NCT01264432|OTHER|Laboratory Biomarker Analysis|Correlative studies
219282318|NCT01264432|OTHER|Quality-of-Life Assessment|Ancillary studies
219282319|NCT01264432|RADIATION|Radiation Therapy|Undergo LDFWAR
219282320|NCT01264432|DRUG|Veliparib|Given PO
219282321|NCT05843292|DRUG|Taxane and Carboplatin|"Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles."
219282322|NCT05843292|DRUG|Short-term Sintilimab|Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
219282323|NCT05843292|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
219282324|NCT04977453|DRUG|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
219282325|NCT04977453|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
219282326|NCT04977453|DRUG|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
219282327|NCT04977453|RADIATION|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
219282328|NCT04977453|DRUG|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
219282329|NCT01376492|OTHER|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
219282330|NCT01376492|OTHER|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
219282331|NCT04606901|DRUG|neostigmine/glycopyrrolate|neuromuscular blockade reversal agents
219282332|NCT04606901|DRUG|sugammadex|neuromuscular blockade reversal agent
219282333|NCT02175953|BEHAVIORAL|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
219282334|NCT03169400|DEVICE|Theranova dialyzer|Hemoadialysis
219282335|NCT00269321|PROCEDURE|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
219282336|NCT00269321|PROCEDURE|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
219282337|NCT00269321|BEHAVIORAL|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
219282338|NCT01724034|OTHER|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
219282339|NCT01724034|OTHER|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
219282340|NCT01724034|OTHER|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
219282341|NCT01724034|OTHER|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
219282342|NCT01724034|OTHER|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
219282343|NCT01724034|OTHER|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
219282344|NCT04953962|DRUG|CBP501 (16)|16 mg/m2
219282345|NCT04953962|DRUG|CBP501 (25)|25 mg/m2
219282346|NCT04953962|DRUG|Cisplatin|60mg/m2
219282347|NCT04953962|DRUG|Nivolumab|240 mg
219282348|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219282349|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219282350|NCT03822429|DRUG|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
219282351|NCT05355675|OTHER|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
219282352|NCT05355675|OTHER|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
219282353|NCT03671577|BEHAVIORAL|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
219282354|NCT03435042|BEHAVIORAL|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
219282355|NCT00534495|BIOLOGICAL|Rilonacept|2.2 mg/kg subcutaneously
219282356|NCT01809860|DRUG|isavuconazole|Oral
219282357|NCT01809860|DRUG|sirolimus|Oral
219282358|NCT06037304|OTHER|no intervention|no intervention
219282359|NCT05494957|DRUG|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
219282360|NCT04990362|DIETARY_SUPPLEMENT|Pomegranate oil, Mediterranean Diet|Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
219282361|NCT04990362|DIETARY_SUPPLEMENT|Mediterranean Diet|Dietary Supplement: Mediterranean dietary protocol
219282362|NCT05809505|DIAGNOSTIC_TEST|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
219282363|NCT05809505|OTHER|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
219282364|NCT05809505|OTHER|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
219282365|NCT01371292|BEHAVIORAL|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
219282366|NCT01371292|BEHAVIORAL|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
219282367|NCT05985226|DEVICE|intraoral scan|All the experimental groups will be developed with an intraoral scanner, a device that emits light and collects the image projected by that light, to build a 3-dimensional digital model. It is more comfortable than conventional impressions and it is a harmless, non-intrusive, and painless procedure.
219282368|NCT02927353|DRUG|DMB-3113|subcutaneously injected in a single dose of 40 mg.
219282369|NCT02927353|DRUG|Adalimumab|subcutaneously injected in a single dose of 40 mg.
219282370|NCT03574662|OTHER|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
219282371|NCT03574662|OTHER|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
219282372|NCT01068665|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219282373|NCT01068665|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
219282374|NCT00344864|DEVICE|LADARWave|
219282375|NCT04230122|DRUG|LY3478006 - IV|Administered IV
219282376|NCT04230122|DRUG|LY3478006 - SC|Administered SC
219282377|NCT04230122|DRUG|Placebo - IV|Administered IV
219282378|NCT04230122|DRUG|Placebo - SC|Administered SC
219282379|NCT00237536|DRUG|Lonidamine|
219282380|NCT02690753|PROCEDURE|A protocol tailored to individual risk factors|
219282381|NCT02690753|DEVICE|The Prevalon® Turn and Position System 2.0|
219282382|NCT02690753|DEVICE|Comfort Shield® barrier cream cloths|
219282383|NCT05029713|DIAGNOSTIC_TEST|Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)|The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
219282384|NCT02202785|DRUG|MLN0264|MLN0264 IV infusion
219282385|NCT01137578|PROCEDURE|Ultrasound|Ultrasounds to be performed on children with central venous catheters
219282386|NCT01137578|DRUG|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
219282387|NCT01137578|PROCEDURE|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
219282388|NCT02395731|BEHAVIORAL|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
219282389|NCT04145700|DRUG|Ramucirumab|Ramucirumab given IV
219282390|NCT04145700|DRUG|Gemcitabine|Gemcitabine given IV
219282391|NCT04145700|DRUG|Docetaxel|Docetaxel given IV
219282392|NCT00658905|DRUG|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
219282393|NCT00658905|DRUG|Placebo|One week treatment
219282394|NCT02293577|DEVICE|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
219282395|NCT00818779|DRUG|Aliskiren|150 - 300 mg once daily for 6 weeks
219282396|NCT00818779|DRUG|Amlodipine|5-10 mg once daily for 6 weeks
219282397|NCT04978493|DRUG|BI 706321|One dose of 8 mg as tablets orally once per day in the morning
219282398|NCT04978493|DRUG|Ustekinumab|A single intravenous infusion of 260 mg (body weight ≤55 kg), 390 mg (body weight 55-85 kg), or 520 mg (body weight \>85 kg) was administered on Day 0, followed by subcutaneous injection of 90 mg every 8 weeks.
219282399|NCT04978493|DRUG|Placebo|One dose of placebo matching BI 706321 as tablets orally once per day in the morning
219282400|NCT03575195|DRUG|Rifaximin|Rifaximin 550mg orally
219282401|NCT03575195|OTHER|Placebo|Placebo control
219282402|NCT01808677|OTHER|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
219282403|NCT01342432|OTHER|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
219282404|NCT01342432|OTHER|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
219282405|NCT02012023|DEVICE|Low anterior resection|
219282406|NCT02012023|DEVICE|tube ileostomy|
219282407|NCT02012023|DEVICE|loop ileostomy|
219282408|NCT02012023|DEVICE|accept reversal operation|
219282409|NCT02012023|DEVICE|remove the tube ileostomy|
219282410|NCT05613777|DRUG|Microgynon®|ethinylestradiol (EE) and levonorgestrel (LNG)
219282411|NCT05613777|DRUG|BI 425809|BI 425809
219282412|NCT03921853|OTHER|Behavioral|The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
219282413|NCT01254747|DEVICE|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
219282414|NCT01254747|DEVICE|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
219282415|NCT01254747|DEVICE|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
219282416|NCT01254747|DEVICE|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
219282417|NCT00245960|DRUG|etanercept|
219282418|NCT00245960|DRUG|etanercept|
219282419|NCT00245960|DRUG|Placebo|
219282420|NCT00930670|DRUG|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
219282421|NCT00930670|DRUG|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
219282422|NCT00930670|DRUG|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
219282423|NCT00930670|DRUG|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
219282424|NCT00930670|DRUG|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
219282425|NCT00930670|DRUG|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
219282426|NCT00930670|DRUG|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
219282427|NCT00930670|DRUG|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
219282428|NCT03924700|PROCEDURE|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
219282429|NCT03924700|PROCEDURE|Microdiscectomy|Using microscope for discectomy
219282430|NCT00147589|DRUG|Eplerenone|
219282431|NCT00737698|OTHER|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
219282432|NCT00737698|OTHER|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
219282433|NCT00912392|DRUG|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
219282434|NCT00912392|DRUG|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
219282435|NCT00004877|DRUG|BMS-214662|
219282436|NCT03444896|DEVICE|Acupuncture group|Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
219282437|NCT03444896|DEVICE|Sham acupuncture group|Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
219282438|NCT02360735|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
219282439|NCT02360735|OTHER|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
219282440|NCT00034788|DRUG|Becaplermin|
219282441|NCT00126698|DRUG|trimethoprim-sulfamethoxazole|
219282442|NCT00126698|DRUG|ciprofloxacin|
219282443|NCT00831662|DRUG|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
219282444|NCT00831662|DRUG|Placebo|One to two drops in each eye QID for 6 weeks
219282445|NCT05821920|DEVICE|MUST MINI system|cervical posterior fixation system
219282446|NCT01839942|PROCEDURE|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
219282447|NCT01839942|PROCEDURE|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
219282448|NCT01396772|BEHAVIORAL|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
219282449|NCT01396772|OTHER|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
219282450|NCT03299751|BIOLOGICAL|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
219282451|NCT01755572|DRUG|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
219282452|NCT01755572|DRUG|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
219282453|NCT00095953|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
219282454|NCT04744753|DRUG|Calcium Ionophore A23187|"Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF."
219282455|NCT05524662|DEVICE|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
219282456|NCT04652505|OTHER|Questionnaire Administration|Complete questionnaires
219282457|NCT00260377|PROCEDURE|Coronary artery bypass surgery|
219282458|NCT02458222|OTHER|language game therapy|participants will take part in game therapy
219282459|NCT02458222|OTHER|standard therapy|usual clinical care
219282460|NCT00201877|DRUG|Velcade|"Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 \& 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23."
219282461|NCT00201877|DRUG|Rituximab|"Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks."
219282462|NCT03658759|PROCEDURE|Extracorporeal Cardiopulmonary Resuscitation|local ECPR clinical pathway, including transport with mechanical chest compression device and rapid response VA-ECMO
219282463|NCT04332055|OTHER|ERVIN|ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
219282464|NCT00577057|PROCEDURE|Conventional Radiotherapy|
219282465|NCT00577057|PROCEDURE|Accelerated Radiotherapy|
219282466|NCT00577057|DRUG|Cisplatin|
219282467|NCT00577057|DRUG|5-fluorouracil|
219282468|NCT00577057|DRUG|Capecitabine|
219282469|NCT01361542|DRUG|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
219282470|NCT01361542|DRUG|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
219282471|NCT06246695|DRUG|Jaktinib Hydrochloride Tablets|Oral Jaktinib 100 mg for 1 day
219282472|NCT06246695|DRUG|Itraconazole capsule|Oral Itraconazole 200 mg for 9 day
219282473|NCT06246695|DRUG|Rifampicin Capsules|Oral Rifampicin 600 mg for 11 day
219282474|NCT04796077|OTHER|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
219282475|NCT06035302|PROCEDURE|Madany Closure|Madany Closure is a new technique for the porte site closure
219282476|NCT06035302|PROCEDURE|Standard closure|Standard closure technique of the port site from ecternal
219282477|NCT04608773|OTHER|Remineralizing Extreme Dry Mouth Spray with Xylitol|oral hydrating spray
219282478|NCT04608773|DEVICE|Alcohol-Free Moisturizing Dry Mouth Spray|oral hydrating spray
219282479|NCT05444270|OTHER|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
219282480|NCT05444270|RADIATION|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
219282481|NCT02710175|OTHER|serum TSH level|
219282482|NCT04843267|DRUG|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
219282483|NCT01938053|OTHER|Call when test results are ready|Patients are called when the test results are ready
219282484|NCT01938053|OTHER|Text message when test results are ready|Patients receive a text message when results are ready
219282485|NCT01938053|OTHER|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
219282486|NCT04195802|OTHER|Salt and potassium Diet|Self-administration questionnary to evaluate the salt and potassium consumption
219282487|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
219282488|NCT03312413|DRUG|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
219282489|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
219282490|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
219282491|NCT02387970|PROCEDURE|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
219282492|NCT02387970|PROCEDURE|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
219282493|NCT02387970|DEVICE|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
219282494|NCT02387970|DEVICE|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
219282495|NCT02271360|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
219282496|NCT02271360|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
219282497|NCT04160377|DRUG|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
219282498|NCT00781105|DRUG|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
219282499|NCT03704168|DEVICE|CRYOABLATION|The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
219282500|NCT04662060|DRUG|Acebilustat|100 mg capsule administered orally once daily
219282501|NCT04662060|DRUG|Placebo|Placebo to match acebilustat administered orally once daily
219282502|NCT03534895|DRUG|Midazolam Injectable Solution|intravenous
219282503|NCT03534895|OTHER|Normal saline|intravenous
219282504|NCT03534895|PROCEDURE|Spinal anesthesia|8mg of heavy bupivacaine 0.5% injected in the subarachnoid space, during lateral decubitus
219282505|NCT03534895|PROCEDURE|Surgery|Open inguinal hernia repair, varicose vein stripping, knee arthroscopy or hallux valgus surgery
219282506|NCT03534895|DRUG|Postoperative analgesia|IV acetaminophen 1g + IV ketorolac 30mg
219282507|NCT03534895|DRUG|Rescue analgesia|Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS\>3.
219282508|NCT03534895|DRUG|Wound infiltration|Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
219282509|NCT03534895|DRUG|Analgesia at home|Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
219282510|NCT02172001|DRUG|Iron isomaltoside 1000|
219282511|NCT02172001|DRUG|Natrium Chloride 0,9%|100 ml or 5 ml
219282512|NCT05266703|OTHER|Isotopically labelled iron sulfate 15mg|test drink: water containing isotopic iron solution with vitamin C
219282513|NCT02847286|DRUG|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
219282514|NCT02847286|DRUG|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
219282515|NCT02847286|DRUG|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
219282516|NCT03807895|BEHAVIORAL|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
219282517|NCT03807895|BEHAVIORAL|Regular Career Intervention|Eight sessions of regular career intervention.
219282518|NCT01947699|DRUG|Glyburide|
219282519|NCT01947699|DEVICE|Continuous glucose monitor|
219282520|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
219282521|NCT01390870|DRUG|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
219282522|NCT06418009|PROCEDURE|Cold needle application|Before use, the needle will be removed from the refrigerator and kept on the nurse's table. When the temperature of the needle reaches 0-2 °C, the patient will be cannulated.
219282523|NCT05988944|OTHER|TT+CIMT+VR|TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
219282524|NCT05988944|OTHER|TT+CIMT|TT: Traditional Techniques CIMT: constraint-induced movement therapy
219282525|NCT05988944|OTHER|TT|TT: Traditional Techniques
219282526|NCT00316017|DRUG|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
219282527|NCT00316017|DRUG|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
219282528|NCT00316017|DRUG|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
219282529|NCT02445053|DRUG|ivacaftor|
219282530|NCT02671500|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
219282531|NCT03410498|OTHER|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
219282532|NCT00059189|DEVICE|Magstim Rapid Magnetic Stimulator|
219282533|NCT02215525|DEVICE|UVA|device uses UVA
219282534|NCT02215525|DIETARY_SUPPLEMENT|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
219282535|NCT04749680|DEVICE|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
219282536|NCT05032976|BIOLOGICAL|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
219282537|NCT05032976|BIOLOGICAL|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
219282538|NCT05032976|BIOLOGICAL|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
219282539|NCT05032976|BIOLOGICAL|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
219282540|NCT05032976|BIOLOGICAL|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
219282541|NCT05032976|BIOLOGICAL|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
219282542|NCT05032976|BIOLOGICAL|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
219282543|NCT05032976|BIOLOGICAL|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
219282544|NCT06354829|DIAGNOSTIC_TEST|Medical imaging procedures|The following medical imaging procedure will b applied: Magnetic resonance images (MRI), computerized tomography images (CT), and ultrasound images (US).
219282545|NCT06302621|DRUG|Afatinib|Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
219282546|NCT06302621|DRUG|Pemigatinib|Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
219282547|NCT06121180|DRUG|ZIV-Aflibercept|Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
219282548|NCT06121180|DRUG|Cemiplimab|"Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells."
219282549|NCT03110861|DEVICE|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
219282550|NCT03789240|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
219282551|NCT03789240|DRUG|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
219282552|NCT06581159|BIOLOGICAL|HS135|Subcutaneous Injection
219282553|NCT06581159|OTHER|Placebo|Subcutaneous Injection
219282554|NCT04557709|OTHER|Medical Chart Review|Review of medical charts
219282555|NCT02470897|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
219282556|NCT02470897|RADIATION|SBRT|Undergo moderate dose SBRT with SIB
219282557|NCT02470897|RADIATION|SBRT|Undergo uniform dose SBRT
219282558|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
219282559|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
219282560|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
219282561|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
219282562|NCT06853132|BEHAVIORAL|Baduanjin with Resistance Training Program|Baduanjin with Resistance Training Program
219282563|NCT02203526|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
219282564|NCT02203526|DRUG|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
219282565|NCT02203526|BIOLOGICAL|Rituximab|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
219282566|NCT02203526|DRUG|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
219282567|NCT02203526|DRUG|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
219282568|NCT02203526|DRUG|Ibrutinib (Arms 2, 3 and 4)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
219282569|NCT02203526|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
219282570|NCT02203526|DRUG|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
219282571|NCT02203526|DRUG|Ibrutinib (Arm 4)|Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
219282572|NCT05292586|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
219282573|NCT05292586|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
219282574|NCT03502668|DRUG|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
219282575|NCT03502668|DRUG|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
219282576|NCT01217437|BIOLOGICAL|Bevacizumab|Given IV
219282577|NCT01217437|DRUG|Irinotecan Hydrochloride|Given IV
219282578|NCT01217437|DRUG|Temozolomide|Given PO
219282579|NCT04478253|DEVICE|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
219282580|NCT00343551|DRUG|Aliskiren|
219282581|NCT05826093|PROCEDURE|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
219282582|NCT06984120|DIAGNOSTIC_TEST|Lung ultrasound|Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome.
219282583|NCT06984120|DIAGNOSTIC_TEST|Peripheral oxygen saturation|Peripheral oxygen saturation measured by non-invasive pulse oxymetry
219282584|NCT06984120|DIAGNOSTIC_TEST|Lung auscultation|Clinical auscultation of lungs
219282585|NCT06984120|DIAGNOSTIC_TEST|Body temperature|Body temperature measured by ear thermometer.
219282586|NCT03198026|DRUG|Ibrutinib|Given PO
219282587|NCT03198026|BIOLOGICAL|Obinutuzumab|Given IV
219282588|NCT03198026|OTHER|Laboratory Biomarker Analysis|Correlative studies
219282589|NCT06663163|OTHER|Observation|This study was an observational study without intervention
219282590|NCT03468478|DRUG|Sirolimus|sirolimus combined to reduced dose of tacrolimus
219282591|NCT03468478|DRUG|Everolimus|everolimus combined to reduced dose of tacrolimus
219282592|NCT03468478|DRUG|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
219282593|NCT00531089|DRUG|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
219282594|NCT04584476|PROCEDURE|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
219282595|NCT04584476|PROCEDURE|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
219282596|NCT03841526|DRUG|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
219282597|NCT03841526|OTHER|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
219282598|NCT03841526|DRUG|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
219282599|NCT00886353|BIOLOGICAL|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
219282600|NCT00886353|OTHER|Placebo|Physiological saline administrated i.v.
219282601|NCT06997029|DRUG|BMS-986500|Specified dose of specified days
219282602|NCT06997029|DRUG|Palbociclib|Specified dose on specified days
219282603|NCT06997029|DRUG|Fulvestrant|Specified dose on specified days
219282604|NCT06673134|DRUG|enteral nutrition|exclusive enteral nutrition therapy or Partial enteral nutrition
219282605|NCT06673134|DRUG|Immunotherapy|Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
219282606|NCT06673134|DRUG|biological agents|Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
219282607|NCT06673134|DRUG|Glucocorticoids|Glucocorticoids treatments are given
219282608|NCT06673134|OTHER|fecal microbiota transplantation|Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc
219282609|NCT06672419|OTHER|AI-Guided Exercise and Pain Neuroscience Education|This intervention consists of a 12-week tele-rehabilitation program using AI and computer vision technology to guide personalized exercise sessions (three per week). Exercises are adjusted in real time by the AI system, and participants also attend weekly sessions of pain neuroscience education to develop improved pain management strategies. The program is delivered remotely via a digital platform that is visually identical for all participants. Supervising physiotherapists oversee progress and provide standardized support but remain blinded to group allocation.
219282610|NCT06672419|OTHER|Usual Care for Fibromyalgia|"Standard care includes pharmacological management (pain relievers, antidepressants, anticonvulsants) and general recommendations on physical activity and disease management.~Drug: Pain Relievers - e.g., paracetamol, tramadol~Drug: Antidepressants - e.g., amitriptyline, duloxetine~Drug: Anticonvulsants - e.g., pregabalin, gabapentin~Other: General Physical Activity and Disease Education - recommendations consistent with current clinical guidelines"
219282611|NCT00786552|DRUG|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
219282612|NCT06004037|DRUG|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
219282613|NCT07006220|BEHAVIORAL|COPE Program|"The COPE Program (Coping Options for Parent Empowerment) is a brief, structured, transdiagnostic intervention designed to enhance parents' emotional regulation skills, improve parenting strategies, and foster a positive family environment. The program consists of four in-person group sessions, each lasting 90 minutes, conducted over four consecutive weeks.~Each session focuses on specific emotional regulation and parenting skills:~Session 1: Understanding emotional responses and parenting strategies based on positive reinforcement, selective attention, and empathy.~Session 2: Identifying family values, promoting healthy routines, and planning alternative parenting behaviors.~Session 3: Practicing mindfulness techniques and modeling emotional regulation in the presence of children.~Session 4: Addressing intolerance to uncertainty, cognitive distortions, and promoting healthy independence in adolescents."
219282614|NCT07011004|BIOLOGICAL|Cytokine Induced Memory-Like Natural Killer Cells|Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.
219282615|NCT07011004|BIOLOGICAL|Atezolizumb|Single dose of Atezolizumab IV over 60 minutes IV.
219282616|NCT07011004|BIOLOGICAL|CIML-NK cell therapy|CIML-NK cell therapy as an intravenous (IV) infusion
219282617|NCT06389786|PROCEDURE|Bilateral Pelvic Lymph Node Dissection|Undergo bilateral pelvic lymph node dissection
219282618|NCT06389786|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
219282619|NCT06389786|PROCEDURE|Bone Scan|Undergo bone scan
219282620|NCT06389786|PROCEDURE|Computed Tomography|Undergo CT
219282621|NCT06389786|OTHER|Electronic Health Record Review|Ancillary studies
219282622|NCT06389786|OTHER|Flotufolastat F-18 Gallium|Given IV
219282623|NCT06389786|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic radical prostatectomy
219282624|NCT06389786|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
219282625|NCT06389786|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
219282626|NCT00545415|DIETARY_SUPPLEMENT|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282627|NCT00545415|DIETARY_SUPPLEMENT|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282628|NCT00545415|DIETARY_SUPPLEMENT|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282629|NCT00545415|DIETARY_SUPPLEMENT|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282630|NCT00545415|DIETARY_SUPPLEMENT|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282631|NCT00545415|DIETARY_SUPPLEMENT|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
219282632|NCT06682039|OTHER|Internet-Based Intervention|Engage in ABM + text messaging prompts
219282633|NCT06682039|OTHER|Internet-Based Intervention|Engage in inert attention task sessions
219282634|NCT06682039|OTHER|Interview|Ancillary studies
219282635|NCT06682039|OTHER|Questionnaire Administration|Ancillary studies
219282636|NCT06682039|OTHER|Text Message-Based Navigation Intervention|Participants will respond to daily messaging prompts.
219282637|NCT06867809|DEVICE|Epidural spinal cord stimulation and paired spine and brain stimulation|The spinal cord and brain stimulator allows for stimulation of the spinal cord and brain. Spinal cord stimulation (SCS) is provided by temporarily implanted SCS catheter electrode leads (Medtronic) that are connected to an external stimulator (Digitimer); brain stimulation is provided by transcranial magnetic stimulation (TMS).
219282641|NCT06700811|DRUG|Ketogenic diet|The ketogenic diet formula will be KetoVie®, supplied by Ajinomoto Cambrooke. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 1.0mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1. Ratio will increase per standard clinical care for ketogenic diet initiation. For the trial we will aim to reach a maximum of 4:1 by the 6 week follow-up visit, but stopping at a lower ratio if BHB is ≥ 5mmol/L, CO2 ≤ 18 mmol/L, for tolerance, or to meet protein needs. A minimum 1:1 ratio is required to continue in the trial. Ratios higher than 1:1 are often required to obtain ketosis of ideally 2-5mmol/L in infants.
219282642|NCT07138482|OTHER|Survey using a questionnaire.|REDCap Survey
219282643|NCT07137130|DRUG|Concentrated secretome Injection 3 mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
219282644|NCT07137130|DRUG|Concentrated secretome Injection 3 mL with addition of TGF Beta 3|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
219282645|NCT07138248|BIOLOGICAL|2D Transvaginal Ultrasound|Three-dimensional transvaginal ultrasound used to assess the same outcomes as 2D, providing volumetric imaging and coronal reconstruction to detect displacement or malposition of the IUD
219282646|NCT07138157|OTHER|External Focus Exercises|The commands given during the exercises will encourage the participants to focus their attention on the effect of the movement/ external focus of attention
219282647|NCT07138157|OTHER|Internal Focus Exercises|The commands given in the second group will encourage the participants to focus their attention on the body part performing the movement/ Internal focus of attention
219282648|NCT07135466|OTHER|CD22 CAR-T cells|CD22 CAR-T cells
219282649|NCT07135830|OTHER|Handball training|Athletes will perfrom their regular handball training
219282650|NCT07137494|BIOLOGICAL|MB-CART19.1 Cellular Therapy|MB-CART19.1 will be infused as a single infusion during an inpatient admission.
219282651|NCT07033130|DEVICE|OMRP R2 + Percepolis Accessory Software|The Oticon Medical Research Platform Release 2 (OMRP R2) + Percepolis Accessory Software is an investigational or research tool that includes hardware, firmware and software elements, which can connect to an Oticon Medical Cochlear Implant (CI). It is intended to be used exclusively for research with Oticon Medical CI users participating in research experiments or clinical studies. The hardware components are referred to as 'OMRP R2' and the software components are called 'Percepolis Accessory Software'.
219282652|NCT07033130|DEVICE|Nuc8 Sound Path|Nuc8 is the sound path used in Cochlear Nucleus Sound Processors.
219282653|NCT07033130|DEVICE|Neu2 Sound Path|Neu2 is the sound path that is currently used in the Neuro 2 Sound Processor.
219282654|NCT07138313|OTHER|Low-fat dietary intervention|Low-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
219282655|NCT07138313|OTHER|High-fat dietary intervention|High-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
219282656|NCT07137663|OTHER|Educational and practical intervention on menstrual cup use|The intervention implemented in this study is a unique approach tailored to menstrual hygiene management among women who use wheelchairs. What distinguishes this intervention from others is the combination of both education and practical support for menstrual cup use. While menstrual hygiene management in the literature generally targets the general population, this study specifically addresses the unique needs and challenges faced by women with disabilities by providing individualized menstrual cup selection and usage guidance. Additionally, the intervention includes repeated follow-ups over six menstrual cycles, allowing continuous support and monitoring of the participants' experiences. This approach aims not only to improve hygiene practices but also to enhance user satisfaction and long-term adherence. The comprehensive and personalized nature of this intervention differentiates it from most existing studies and seeks to offer practical, sustainable solutions for menstrual hygiene
219282657|NCT07138079|OTHER|edentulous geriatric patients|Edentulous geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
219282658|NCT07138079|OTHER|dentate geriatric patients|Dentate geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
219282659|NCT07135908|BEHAVIORAL|solution-oriented approach|"In this study, the solution-focused intervention was a structured psychosocial support program based on the principles of Solution-Focused Brief Therapy (SFBT). It consisted of six weekly sessions, each lasting 60 minutes, and was designed to help institutionalized children improve their hope levels and social participation skills.~The sessions included:~Enhancing communication and interpersonal skills~Identifying personal strengths and sources of hope~Developing social engagement strategies~Teaching simple problem-solving techniques~The approach focused on children's existing resources and future goals rather than their past problems. It encouraged positive thinking, goal setting, and active participation, promoting emotional resilience and social functioning."
219282660|NCT07136064|BEHAVIORAL|Emotion Regulation Skills Training|This arm will receive training in emotion regulation skills, including mindfulness skills to help redeploy their attention, cognitive reappraisal skills to analyze stimuli or emotion-eliciting events from a more comprehensive perspective, situation change skills to regulate emotions by exposing oneself to nature, and experiential acceptance skills through self-talk. This arm will also receive training in theories of the family emotion system.
219282661|NCT07136064|BEHAVIORAL|Moderation in Consumer Electronics Use Training|This arm will be trained to moderate their and their family members' use of commercial electronics. They will do so by learning mechanisms behind addictions, family communication skills, and various substitute activities for commercial electronics usage.
219282662|NCT07136779|DRUG|VBC101|VBC101
219282663|NCT07136532|DIAGNOSTIC_TEST|echocardiography|"Echocardiography will be performed using the ultrasound system echocardiographic equipment (Siemens Advanced Clinical Ultrasound Systems Optimized Navigation (ACUSON) P500), carotid doppler ultrasonography (Carotid blood flow and Corrected flow time) by using the ultrasound system echocardiographic equipment (Siemens ACUSON P500) .~Those measurements will be done at time zero and upon completion of fluid resuscitation .~• Statistical Analysis: All data will be collected, tabulated, and statistically analysed using International Business Machines\_Statistical Package for the Social Sciences (IBM SPSS) version 27."
219282664|NCT07137637|DRUG|HPB-092 tablet|HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles. This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays a crucial role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in acute myeloid leukemia (AML) and other malignancies.
219282665|NCT07136025|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
219282666|NCT07136025|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
219282667|NCT07136844|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
219282668|NCT07136844|DIAGNOSTIC_TEST|Dynamometric measurements of muscle strength|Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.
219282669|NCT07136844|DIAGNOSTIC_TEST|The 6-minute walk test (6MWT)|This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.
219282670|NCT07136844|DIAGNOSTIC_TEST|The 10-meter test (10MWT)|During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.
219282671|NCT07136844|DIAGNOSTIC_TEST|The 4 stair-climbing test (4SC)|This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.
219282672|NCT07136844|DIAGNOSTIC_TEST|Test of rising from the floor (TRF)|This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.
219282673|NCT07136844|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
219282674|NCT07136844|DIAGNOSTIC_TEST|The Progressive Supranuclear Palsy Rating Scale (PSP-RS)|This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.
219282675|NCT07136844|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment (MOCA)|The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.
219282676|NCT07136844|DIAGNOSTIC_TEST|The Charcot-Marie-Tooth examination score (CMTES)|The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.
219282677|NCT07136844|DIAGNOSTIC_TEST|9-Hole Peg Test (9-HPT)|The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.
219282678|NCT07136844|DIAGNOSTIC_TEST|The Unified Huntington's Disease Rating Scale (UHDRS)|This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.
219282679|NCT07136844|DIAGNOSTIC_TEST|Quantitative Myasthenia Gravis (QMG)|The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).
219282680|NCT07136844|DIAGNOSTIC_TEST|The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL)|This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.
219282681|NCT07136844|DIAGNOSTIC_TEST|The Scale for the Assessment and Rating of Ataxia (SARA)|This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.
219282682|NCT07136844|OTHER|Patient's Global Impression of Change (PGIC)|PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.
219282683|NCT07137468|OTHER|Surveys|Electronic surveys will completed via REDCap.
219282684|NCT07137468|OTHER|Video|Focus group sessions and community forums will be conducted via videoconference (Zoom)
219282685|NCT07135674|DRUG|placebo gel|local drug delivery of placebo gel
219282686|NCT07135674|DRUG|herbal drug|local drug delivery of herbal gel
219282687|NCT07135726|DEVICE|Patient Portal-Based Access to Clinical Notes|An intra-individual comparison of patient-reported outcomes is planned for the intervention group. For this purpose, the pre-intervention survey of the intervention group is conducted upon inclusion in the study, the post-intervention survey at the earliest after the intervention has been used once (accessing their open note). Due to potential selection bias of the intervention group, which occurs due to voluntary participation in the intervention, a control group is surveyed at t0, which does not participate in the intervention, so that an adjustment for the systematic differences, if any, between the intervention and control group is possible at t0. The survey of a post-intervention control group (t1) serves to adjust for any time-varying effects so that a general time effect can be ruled out.
219282688|NCT07138274|DRUG|Metyrapone 250 mg Oral Tablets|Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg
219282689|NCT07138274|DRUG|Placebo|Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding
219282690|NCT07136246|DEVICE|InBody S10|Bioelectrical Impedance Phase Angle Technology Measured via InBody S10 at six frequencies (1kHz-1000kHz) during each follow-up
219282691|NCT07035379|DRUG|TRS005|TRS005 will be administered at a starting dose of 0.8mg/kg IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles (up to 8).
219282692|NCT07035379|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
219282693|NCT07035379|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
219282694|NCT07035379|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
219282695|NCT04571541|DEVICE|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
219282696|NCT07029360|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis®|Daily administration of Limosilactobacillus reuteri Prodentis® (1 oral tablet per day, taken after brushing in the evening), as an adjunct to non-surgical periodontal therapy and standard home care. Administered for 6 months only in the experimental arm.
219282697|NCT07029360|OTHER|Coenzyme Q10 Toothpaste|Twice-daily use of a commercially available toothpaste containing coenzyme Q10, used as part of a home oral hygiene regimen for 6 months. All participants in both study arms will use the same toothpaste, with or without adjunctive probiotic supplementation.
219282698|NCT07039253|BEHAVIORAL|Engaging Together for Health Relationships|Dating violence intervention for caregivers and adolescents to be delivered within pediatric primary care
219282699|NCT07041216|OTHER|Squishy Toy Squeezing|In the intervention group, vein suitability was checked using the DIVA score. A tourniquet was applied, the area was cleaned with antiseptic, and the child squeezed a squishy toy 10 times. Afterward,
219282700|NCT07041216|OTHER|Palpation|In this group, once the vein was identified, the area was gently tapped 8 to 10 times using the inner surfaces of four fingers to stimulate blood flow and enhance vein visibility. This light palpation helped increase local circulation, making the vein easier to access. After the tapping procedure, the area was thoroughly cleaned with an antiseptic solution. Once the skin was completely dry, the catheter was inserted under sterile conditions.
219282701|NCT07041216|OTHER|Routine medical care|This group received standard IV insertion with no extra techniques applied.
219282702|NCT04643483|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
219282703|NCT04643483|DRUG|Adalimumab|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
219282704|NCT04643483|DRUG|Placebo|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
219282705|NCT06717971|OTHER|Exergame-based multicomponent training program.|"The training program for the intervention group utilized the Nintendo Switch game WarioWare: Move It,. Participants engaged with the game through Joy-Con controllers, completing rapid micro-games designed to meet specific movement-oriented objectives. Each game session lasted approximately five seconds, requiring participants to quickly adapt to various physical actions and postures, such as waving, jumping, swinging arms, rotating, and mimicking object movements. The game's dynamic structure provides an engaging experience that promotes physical coordination, reaction speed, upper and lower limb strength, and hand-eye coordination through diverse movement patterns. Switching between tasks compels players to adjust to varying motion demands swiftly, enhancing physical agility while strengthening attention-shifting and quick decision-making skills."
219282706|NCT06717971|OTHER|Standard care|The standard care program for the control group is grounded in routine practices of long-term care facilities, aiming to sustain and enhance the physical and mental well-being of elderly residents through structured group activities. These activities encompass tailored fitness exercises, horticultural therapy, and sedentary group engagements for older adults. The fitness exercises are adapted to meet the varying physical conditions of participants, ensuring a safe and comfortable environment that promotes moderate physical activity. Horticultural therapy involves hands-on planting and tending to plants, stimulating the senses, and fostering emotional regulation, contributing to improved psychological health. Sedentary activities, such as tabletop games, emphasize social interaction and cognitive maintenance by promoting a relaxed social environment that helps participants remain cognitively engaged.
219282707|NCT06707103|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
219282708|NCT06707103|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
219282709|NCT07043595|PROCEDURE|Whole-Body Vibration (WBV)|Participants will stand quietly in an upright position while whole-body vibration (WBV) is applied through a vibration platform. The vibration stimulus is delivered while the participant's left foot remains on the vibration surface and the right foot is elevated or isolated. H-reflex recordings are taken from the soleus muscle during the procedure to assess spinal reflex modulation due to mechanical loading.
219282710|NCT02755870|OTHER|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
219282711|NCT02755870|OTHER|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
219282712|NCT06888557|BEHAVIORAL|Smartphone-based self-management support program ( 3S-C)|The 3S-C include: (1) two 30-minute individual sessions ; (2) a set of instant messages, 10-minute telephone-delivered health coaching ; (3) continuous personalized chat-based messaging, phone call support, and hotline service ; (4) an e-platform for goal setting and self-monitoring ; (5) A mutual support group session.
219282713|NCT07047976|DIETARY_SUPPLEMENT|Sulforaphane|This intervention involves the administration of Sulforaphane, a compound derived from glucoraphanin found in cruciferous vegetables. Participants will receive Avmacol® tablets, each containing 30 mg of glucoraphanin (approximately 68 μmol per tablet). They will take 3 tablets daily, resulting in a total daily dosage of approximately 90 μmol of Sulforaphane. The intervention will last for 8 weeks, during which participants will be monitored for clinical and biological outcomes.
219282714|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)
219282715|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - Control lunch (no fish) and omega 3 supplement
219282716|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Placebo comparator - Control lunch (no fish) and placebo supplement
219282717|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - 2 portions of fish (280g) per week and omega 3 supplement
219282718|NCT06717178|DRUG|Chemotherapy|Admission to the hospital for a new chemotherapy regimen (initial or change)
219282719|NCT06732648|DRUG|HRS8179 injection|HRS8179 injection; high dose
219282720|NCT06732648|DRUG|HRS8179 blank preparation.|HRS8179 blank preparation.
219282721|NCT07044401|DRUG|KAI-9531|SC Injection.
219282722|NCT05040347|OTHER|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
219282723|NCT06745765|DEVICE|Virtual reality headset|Patients will use virtual reality before the procedure in addition to usual preoperative care.
219282724|NCT06015750|DRUG|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
219282725|NCT06015750|DRUG|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
219282726|NCT06015750|DRUG|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
219282727|NCT06015750|DRUG|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
219282728|NCT06015750|DRUG|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
219282729|NCT06792500|DRUG|Glycerol Tributyrate|Participants will be administered orally three times a day enteric hard capsules containing 500 mg of glycerol tributyrate with an 8-ounce glass of water on an empty stomach: morning, noon, and evening during the dose-escalation phase. Each MELAS participant will undergo a six-month dose escalation phase of glycerol tributyrate, starting at a dose of 1,000 mg (tid) per day during the first month followed by a monthly increase of 500 mg (tid) per dose of glycerol tributyrate with the maximal oral dose of glycerol tributyrate 3,500 mg (tid) per dose at the end of six-month-long dose escalation phase. Once the participant-specific fixed maximum tolerated dose (MTD) is determined, MELAS participants will take an oral administration of this MTD three times a day during the 12-month-long clinical phase.
219282730|NCT07069218|DRUG|Biorepair® Total Protection Plus Toothpaste|Participants will use Biorepair® Total Protection Plus toothpaste twice daily for 6 months. The toothpaste contains biomimetic microRepair® particles based on zinc-substituted hydroxyapatite, intended to promote enamel remineralization, reduce sensitivity, and protect against erosion and plaque accumulation. Professional dental cleanings will also be performed every 3 months.
219282731|NCT07069218|DRUG|Bioniq® Toothpaste|Participants will use Bioniq® Repair toothpaste twice daily for 6 months. The toothpaste contains 20% conventional hydroxyapatite and is designed to restore enamel, reduce dentin hypersensitivity, and protect against erosion. Professional dental cleanings will also be performed every 3 months.
219282732|NCT07064564|DRUG|Naltrexone implant, 14.4 grams|Subcutaneous bioresorbable implant containing 14.4 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
219282733|NCT07064564|DRUG|Naltrexone implant, 9.6 grams|Subcutaneous bioresorbable implant containing 9.6 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
219282734|NCT07064564|DRUG|Extended-release naltrexone injection, 380 mg|Intramuscular injection of 380 mg extended-release naltrexone (Vivitrol), administered every 4 weeks for 12 months as the active comparator.
219282735|NCT07137260|DEVICE|Accelerometer (measurement of walking activity)|Wearing an accelerometer (size 23x32,5x8,9 mm, weight 11g) on the lower back consistently for one week at a time to measure walking activity. The sensor is fixed with waterproof plasters. No feedback is given to the participant while wearing the sensor and no data can be read directly from the sensor.
219282736|NCT07138365|PROCEDURE|oral Cryotherapy|custom made plastic pack measuring 2.5 X5 cm containing ice gel will be placed intraorally in the mouth on the vestibular surface of the treated tooth.
219282737|NCT07138365|PROCEDURE|Intra radicular Cryotherapy|Final flush was done with cold (2-4 oC) Saline for 10 mins.
219282738|NCT07137520|OTHER|Observation without intervention|Observation without intervention
219282739|NCT07138352|DRUG|XS003 under fed and fasted condition|XS003 under fed and fasted condition
219282740|NCT07138131|DRUG|Omega 3|Patients received omega-3 supplementation for 3 months.
219282741|NCT07138131|OTHER|Standard follow-up|Patients received standard follow-up without treatment.
219282742|NCT06623097|BEHAVIORAL|Supervised Exercise and Diet Program|A home-based, virtually supervised, moderate-to-vigorous aerobic and resistance exercise intervention with a certified cancer exercise trainer. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch, and Wi-Fi enabled tablet (if needed) will be provided to participants. Dyads will receive remotely delivered nutrition coaching sessions (via telephone or video conferencing) with a health coach each week. Mediterranean eating pattern goals will be tracked using the journal feature of the My Wellness Research platform website.
219282743|NCT06623097|BEHAVIORAL|Unsupervised Exercise and Diet Program|A home-based, unsupervised moderate-to-vigorous aerobic and resistance exercise intervention. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch will be provided to participants. Dyads will receive Mediterranean eating pattern goals, with an introductory session conducted by research staff. Diet intake will be tracked using the journal feature My Wellness Research platform website.
219282744|NCT07089147|OTHER|questionnaire|Paris questionnaire, EuroQool (EQ-5D-3L) Questionnaire, Low Back Outcome Score
219282745|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TMAO Mesurement|Salivary and serum TMAO levels were measured by liquid chromatography-mass spectrometry (LC-MS/MS)
219282746|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TNF-α Mesurement|Salivary and serum TNF-α levels were measured by ELISA
219282747|NCT06907602|DRUG|Chemotherapy|carboplatin plus nab-paclitaxel
219282748|NCT06907602|DRUG|Immunotherapy (Pembrolizumab)|Pembrolizumab
219282749|NCT06907602|RADIATION|radiotherapy|40-45Gy/20fx，5 times a week
219282750|NCT07089745|BEHAVIORAL|Mindfulness-Based Intervention|MBI is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
219282751|NCT07089745|BEHAVIORAL|Organizational Skills Training|OST is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
219282752|NCT06912529|PROCEDURE|Leukapheresis|Axicabtagene ciloleucel is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure.
219282753|NCT06912529|DRUG|Bridging Therapy|Bridging therapy refers to treatment used to control a patient's disease or disease related inflammation prior to lymphodepletion.
219282754|NCT06912529|DRUG|Lymphodepletion|Patients will receive a non-myeloablative lymphodepleting regimen consisting of fludarabine and cyclophosphamide (FC) to induce lymphocyte depletion and create an optimal environment for expansion of axicabtagene ciloleucel in vivo.
219282755|NCT06912529|GENETIC|Axicabtagene Ciloleucel|Patient will receive the axicabtagene ciloleucel infusion in the hospital followed by daily monitoring in the hospital.
219282756|NCT07136727|OTHER|AI-assisted comprehensive management system|Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)
219282757|NCT07137806|PROCEDURE|sacroiliac joint injection|Ultrasound-guided injection of the SI joints The patient is placed in a prone position to receive this injection treatment. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified. The cleft between the bony contours of the sacrum and ileum represents the posterior aspect of the SI joint. By tilting the transducer in a caudal direction, the lower one third of the SI joint is identified. Because of its synovial component, the lower one third of the SI joint is the portion of the entire SI joint in which the injection should be performed. The medial to lateral approach and intraarticular deposition is preferred for the ultrasound-guided SI joint
219282758|NCT07137806|PROCEDURE|combined sacroiliac joint injection and sub maltifidous plane block|patients will be positioned prone. A 6-13 MHz linear array ultrasound transducer was placed in the parasagittal orientation with the second sacral foramen (SF-2) in the field. A 21G short bevel needle is inserted in-plane approach from the cephalad to the caudad direction. After hitting the underlying bone, twenty millilitres of local anaesthetic solution (1:1 mixture of lidocaine 2% and bupivacaine 0.25%) will be injected. An anechoic LA spread in the plane between the multifidus muscle (MFM) and the hyperechoic bony area (between the median and intermediate sacral crests) will be confirmed. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified.
219282759|NCT07138391|DRUG|chamomile gummy|The chamomile gummy used in this study was Zarbee's Gentle Bedtime Gummies for Kids (Zarbee's Inc., USA).
219282760|NCT07138391|DIETARY_SUPPLEMENT|a multivitamin gummy|multivitamins gummies for kids
219282761|NCT06927362|OTHER|Lee Silverman treatment big|"Half of the treatment sessions consist of standardized multidirectional whole-body movements performed with maximal amplitude of reaching and stepping. The second half is designed to address individual deficits in movement that occur in activities of daily living.~Dosage: 4 consecutive days a week for 12 weeks (16 sessions in one month) for 60 minutes Repetitions: minimum 8-16 repetitions/task"
219282762|NCT06927362|OTHER|Dual task training|Group B will receive cognitive motor dual task training for 60 minutes, 4 times a week for 12 weeks. The intervention include both motor and cognitive components.
219282763|NCT06137287|DRUG|BOTOX|Intramuscular Injection
219282764|NCT06137287|DRUG|Placebo for BOTOX|Intramuscular Injection
219282765|NCT07105319|DRUG|Ropeginterferon|"1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24~2. Comparator arm (50 patients): Patients will be followed with no further CML treatment"
219282766|NCT07100990|DRUG|High-dose corticosteroids (HDCS)|"Subjects will receive initial treatment with high-dose corticosteroids (HDCS) in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~Subjects will be escalated to PLEX if there is an insufficient response to HDCS (decision point at 14±2 days for the ON sub-trial and 7±2 days for the TM sub-trial) PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
219282767|NCT07100990|DRUG|High-dose corticosteroids (HDCS) and PLEX|"Subjects will receive treatment with high-dose corticosteroids (HDCS) and PLEX initiated concurrently.~HDCS will be administered in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
219282768|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
219282769|NCT07113626|BEHAVIORAL|Mobile app|The intervention will be a mobile app adapted from HealthMindr - an app based on Social Cognitive Theory - for young men who have sex with men in Vietnam. The app, which was developed and tested in the US, offers a range of testing and prevention services, including self-screening for HIV and sexually transmitted infection (STI) risk, a scheduling and reminder system for HIV/ STI testing, PrEP eligibility screener, an ordering platform for delivery of at-home test kits and condoms, and locators for HIV services. Additional features and contents might be revised and added depending on the needs of young men who have sex with men in Vietnam.
219282770|NCT07116096|DEVICE|Jamar Hand Dynamometer, Hand Dynamometer|Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests
219282771|NCT06918119|DEVICE|Transcutaneous stimulation|DS8R (Digitimer LLC) for transcutaneous neurostimulation.
219282772|NCT07129122|OTHER|Transventricular access|Transventricular access will perform with LBBAP lead from left subclavian way.
219282773|NCT04746846|DEVICE|UG motion sensor with PDVibe3|UG motion sensor (which detects FoG) on worn each ankle. PDVibe3 (which provides vibration) on worn each ankle
219282774|NCT07135440|DEVICE|OCT angiography RTVue XR Avanti; Optovue, Inc, Fremont, California, USA|OCTA is a fast, non-invasive, and contactless imaging technique that enables detailed visualization of the retinal microvasculature by tracking erythrocyte movement within blood vessels in real time. It provides layer-by-layer analysis of the retina and choroid without the need for intravenous contrast, significantly reducing patient risk and improving accessibility. Increasing evidence suggests that neurodegenerative and vascular changes precede clinically visible signs of disease, making OCTA a valuable diagnostic tool for early detection of diabetic retinopathy before it can be confirmed through standard fundus examination. The MoCA test includes assessments of executive functions, high-level language abilities, and complex visuospatial tasks, making it suitable for detecting even mild cognitive dysfunction.
219282775|NCT07138287|PROCEDURE|Concerned Growth factor in management of Mature permanent Molar with irreversible pulpitis|Concerned Growth factor in management of Mature permanent Molar of children with irreversible pulpitis
219282776|NCT07137195|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
219282777|NCT07137884|DRUG|Anlotinib+Cyclophosphamide+Vinorelbine|"Anlotinib hydrochloride capsules combined with Cyclophosphamide+Vinorelbine), Anlotinib hydrochloride capsules 8mg (weight ≤35kg) or 12mg (weight \> 35kg), po, qd, D1-D14;on an empty stomach ,Two weeks off for one week，with a cycle of 3 weeks.~Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60g/m2, po, qw, D1, 8,15, with a cycle of 4 weeks."
219282778|NCT07137884|DRUG|Cyclophosphamide+Vinorelbine|Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60mg/m2, po, qw, D1, 8,15, with a cycle of 4 weeks.
219282779|NCT07135414|PROCEDURE|iTBS|Intermittent theta burst stimulation (iTBS) targeting the left Dorsolateral Prefrontal Cortex (LDLPFC) will be delivered using a figure-of-eight coil at 50 Hz (3 pulses per burst, 5 Hz burst frequency), with 10 bursts over 2 seconds, followed by an 8-second pause, resulting in a 10-second cycle duration, repeated 60 times for a total of 1800 pulses.
219282780|NCT07135414|PROCEDURE|dTMS|Deep TMS (dTMS) targeting the medial prefrontal cortex (MPFC) will be delivered using an H7 coil at 20 Hz for 2 seconds per cycle, followed by a 20-second pause, resulting in a 22-second cycle duration, repeated 50 times for a total of 2000 pulses.
219282781|NCT07135414|BEHAVIORAL|ERP|Patients are admitted to a residential program that includes nonverbal therapies, cognitive behavioural therapy, and from week 3 onward, weekly Exposure Relapse Prevention (ERP) sessions (3 hours/week for 8 weeks; total admission = 10 weeks). ERP includes an inventory of OCD symptoms, psychoeducation on the difference between obsessions and compulsions using an OCD model, and the creation of a stepwise fear hierarchy with exposure and response prevention exercises. Patients practice both during and outside sessions, including at home on weekends. Family involvement is integrated: relatives are invited every three weeks to receive psychoeducation on OCD and ERP, are informed about accommodation behaviors, and may attend a session.
219282782|NCT07136584|OTHER|Screening, Outcomes and Referral Pathways|"All participants complete baseline screening with follow up at 3 and 6 months. A key feature of the study is that a standardised information resource sheet (to community-based services) is provided to all caregivers, regardless of their screening scores. Primary outcomes focus on implementation feasibility and acceptability, while secondary outcomes examine service uptake and longitudinal measurement of caregiver wellbeing.~This differs from existing research by providing resources universally rather than only to those scoring above clinical thresholds. Our longitudinal follow-up addresses an evidence gap identified in our systematic review - limited published data on downstream effects on actual service uptake and mental health outcomes over time. The services in the resource sheet also link to routine clinical care that doesn't require specialist support programs with dedicated funding."
219282783|NCT07139197|BEHAVIORAL|Cognitive Behavioral Approach-Based Psychoeducation Program|"Intervention Group: Cognitive Behavioral Approach-Based Psychoeducation Program Participants will receive a cognitive-behavioral psychoeducation program designed to improve cognitive flexibility and reduce rumination. The sessions include structured activities, discussions, and exercises based on cognitive-behavioral principles. Pre-test assessments will be conducted before group allocation.~Control Group: No intervention will be provided during the study period. Participants will complete pre-test assessments administered by an independent evaluator. After the study concludes, control group participants will be offered the opportunity to participate in the psychoeducation program if they wish."
219282784|NCT06927310|DRUG|Inpegsomatropin Injection|Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 consecutive weeks.
219282785|NCT06927310|DRUG|Recombinant Human Growth Hormone Injection|Recombinant Human Growth Hormone Injection, 350 μg/kg/week, s.c., divided into 7 doses, i.e., 50 μg/kg/day (0.15 IU/kg/day), once daily for 52 consecutive weeks.
219282786|NCT05951985|BEHAVIORAL|HIFT|Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
219282787|NCT07136597|BEHAVIORAL|Narrative Medicine Workshop|participants will be asked to attend 3/6 monthly narrative medicine workshops through the study's duration following an initial workshop that will be used to introduce the concepts of narrative medicine and flash writing.
219282788|NCT07135648|OTHER|VM16|VM16 contains a liquid with a nicotine concentration of 1.6%
219282789|NCT07135648|OTHER|VM32|VM32 contains a liquid with a nicotine concentration of 3.2%
219282790|NCT07135648|OTHER|Cigarette (CC)|Subjects will provide their own usual brand of commercially available cigarettes
219282791|NCT07137702|PROCEDURE|Erector Spinae Plane Block|A standardized perioperative care management protocol is applied for all breast-conserving surgery procedures in our department. All patients are informed about ESPB and offered its application preoperatively. Patients who accept the procedure receive ESPB (preoperatively, in the sitting position, at the level of ipsilateral T4 vertebra, USG guided, out-of-plane approach) while those who refuse are subjected to routine intravenous analgesia protocols. All blocks were performed by an anesthesiologist experienced in the application of truncal blocks and 20 cc 0.5% bupivacaine (within the safe dose range for all patients to be used according to their weight) are injected and its spread is visualized under USG.
219282792|NCT07138326|DIAGNOSTIC_TEST|Monitoring|Monitoring
219282793|NCT07136376|OTHER|Physical and social environmental interventions.|To be determined in the co-creation groups at the five sites (Denmark, Germany, Poland, Spain, the Netherlands)
219282794|NCT07135219|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
219282795|NCT07137026|BEHAVIORAL|Personnel intervention and patients|The personnel intervention has three components. They are listed above. The patient intervention will include a brief assessment and intervention.
219282796|NCT07135596|DEVICE|OviTex PRS|A multi-layer construct of extracellular matrix (ECM) derived from ovine forestomach and embroidered with polymer filament.
219282797|NCT07136233|BEHAVIORAL|Informational Flyer Insert on Enhanced Silver Plan Benefits|Alongside the standard eligibility notice informing participants about their upcoming coverage renewal, an informational flyer is also included. The flyer explains that everyone is eligible in 2025 for the Silver plan regardless of income and highlights its benefits, such as $0 deductibles, lower monthly premiums, free preventive visits, and reduced costs for primary care, emergency care, and medications.
219282798|NCT07136298|OTHER|Clinical Opinion|Staff participants will be asked to review video clips of events captured during EEGs performed on the ICU and asked to state whether they think the event was an epileptic seizure or not, and what aspects of each event led them to that decision
219282799|NCT07137676|BEHAVIORAL|AX-CPT|administration of the AX-CPT
219282800|NCT07137676|OTHER|No Interventions|Control group with no intervention treatment
219282801|NCT04255810|PROCEDURE|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
219282802|NCT06935344|GENETIC|Polygenic Risk Score|For the PRS analysis, SNPs for genotyping will be selected based on the latest findings from GWAS on EOC, particularly leveraging the results, as reported by Dareng et al. (doi:10.1038/s41431-021-00987-7). The PRS will be calculated as a weighted sum of risk alleles based on the selected SNPs.
219282803|NCT01835353|DRUG|Prasugrel 100mg loading dose|
219282804|NCT01835353|DRUG|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
219282805|NCT06939153|OTHER|LBNP|Participants will be exposed to a lower body negative pressure chamber protocol consisting of 5-min stages in the order of 20, -30, -40 and -50 mmHg.
219282806|NCT06939153|OTHER|LBNP + Isometric handgrip exercise|Participants will undergo 5-minute stages of LBNP at -20, -30, -40, and -50 mmHg in sequence. During the -30, -40, and -50 mmHg stages, they will perform a 2-minute isometric handgrip exercise, starting at the third minute and sustaining it for the remaining duration.
219282807|NCT07135609|DEVICE|Low-level laser therapy (LLLT)|Patients managed by Low-level laser therapy (LLLT).
219282808|NCT07135609|DRUG|Apitoxin|Patients managed with 0.3% Apitoxin Gel.
219282809|NCT07138443|DIETARY_SUPPLEMENT|Melatonin 3 MG Oral Tablet|Participants will ingest an acute 3mg oral melatonin tablet
219282810|NCT07138443|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Participants will ingest a placebo tablet (sugar pill) of the same size, shape, and color of the active melatonin supplement
219282811|NCT07136714|DRUG|Semaglutide Injectable Product|Semaglutide (Wegovy) once-weekly injection s.c
219282812|NCT07136714|DRUG|Placebo|Placebo (BD Posiflush) once-weekly injection s.c
219282813|NCT07136740|DEVICE|Cerebri-TTH biofeedback|Cerebri-TTH biofeedback device is a therapist-independent home-based smartphone treatment application (app). Cerebri-TTH is a medical device in risk class IIa, according to MDR, and includes two non-invasive wireless sensors and a smartphone application. Both sensors shall be in contact with the skin: one sensor is applied on the index finger and measures heart rate (HR), heart rate variability (HRV) and peripheral skin temperature. The second sensor is applied on the trapezius muscle using adhesive electrodes and measures muscle tension. The sensors transmit the measurements to the user's smartphone where the user is instructed to perform a biofeedback session. The sensors are to be used for 10 minutes per session per day. The user can choose to use the device more frequently if desired - up to 6 sessions per day.
219282814|NCT07136740|OTHER|headache diary|"Participants randomized to the wait-list arm, are instructed to keep daily eDairy entries for 12 weeks.~The wait list control group will be offered active treatment for 12 weeks after the initial 12-week wait-list period is completed in an extension phase."
219282815|NCT07135947|DEVICE|Point Powered partial hand prosthetic system|The Point Powered system includes 1-4 3-joint mechatronic digits, low-profile EMG electrodes, a low-profile controller, and flexible batteries. These components will be integrated into a waterproof and dustproof packaging
219282816|NCT07136155|PROCEDURE|Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation in one side.
219282817|NCT07136155|PROCEDURE|Indirect pulp capping|Selective caries removal to hard dentin followed with G.I base material and subsequent preformed metal crown (PMC).
219282818|NCT07137338|GENETIC|RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)|One-time treatment with a single ascending dose
219282819|NCT07135284|DEVICE|Airway clearance system|The device is prescribed as part of each participant's regular medical care, independently of the study. The study does not assign the device or alter standard treatment. Participants are observed while using the device as part of their usual care.
219282820|NCT07135297|DEVICE|Ultrathin bronchoscope (UTB)|A UTB will be used to perform white light bronchoscopy, then the rEBUS probe was inserted into the working channel and advanced to the PPL to obtain a rEBUS view per the navigation path created by VBN workstation. The probe will be withdrawn from the working channel when an optimal rEBUS view obtained. A 1.5-mm biopsy forceps and 1.4-mm cytology brush will be used to collect samples through the working channel.
219282821|NCT07135297|DEVICE|Thin bronchoscope (TB1)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 1.95-mm outer diameter guide sheath, 1.5-mm biopsy forceps, and 1.4-mm cytology brush, will be used to obtain samples with the guidance of VBN.
219282822|NCT07135297|DEVICE|Thin bronchoscope (TB2)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 2.55-mm outer diameter guide sheath, 1.9-mm biopsy forceps, and 1.8-mm cytology brush, will be used to obtain samples with the guidance of VBN.
219282823|NCT07135323|GENETIC|Opioid Used Disorder Risk Assessment|Determine the likelihood of Opioid Used Disorder prior to prescribing opioids
219282824|NCT06942819|DEVICE|VersaWrap Nerve Protector|VersaWrap Nerve Protector is applied to the nerve root to protect the surrounding tissues
219282825|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
219282826|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
219282827|NCT02665767|DEVICE|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
219282828|NCT02908932|DIETARY_SUPPLEMENT|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
219282829|NCT02908932|DIETARY_SUPPLEMENT|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
219282830|NCT02833870|BEHAVIORAL|Musical intervention|
219282831|NCT02833870|BEHAVIORAL|Non-musical (cooking) intervention|
219282832|NCT02833870|BEHAVIORAL|Control with no intervention|
219282833|NCT03122132|DRUG|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
219282834|NCT03122132|DRUG|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
219282835|NCT06446999|OTHER|Yoga-Based Breathing Exercise|"Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)"
219282836|NCT04318288|OTHER|Observational|Observational
219282837|NCT02165813|DRUG|Nitazoxanide|Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
219282838|NCT02165813|DRUG|placebo|An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
219282839|NCT03281161|BEHAVIORAL|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
219282840|NCT03281161|BEHAVIORAL|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
219282841|NCT03766477|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
219282842|NCT03766477|DIAGNOSTIC_TEST|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
219282843|NCT03766477|DIAGNOSTIC_TEST|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
219282844|NCT04519905|DRUG|Paclitaxel plus carboplatin|Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw
219282845|NCT04519905|RADIATION|radiotherapy|Different radiotherapy dose in different groups.
219282846|NCT04569201|PROCEDURE|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
219282847|NCT05877911|DRUG|Sodium Sulfate|Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.
219282848|NCT05877911|OTHER|Hydration|On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
219282849|NCT05877911|DRUG|Cisplatin|Infuse cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
219282850|NCT01332630|DRUG|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
219282851|NCT01332630|DRUG|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
219282852|NCT01332630|DRUG|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
219282853|NCT01332630|DRUG|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
219282854|NCT04853446|DRUG|Dexamethasone 12 mg|Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
219282855|NCT04853446|DRUG|Placebo|Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
219282856|NCT04853446|DRUG|Dexamethasone 24 mg|Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
219282857|NCT03140280|DRUG|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
219282858|NCT01125631|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
219282859|NCT01125631|DRUG|Placebo|Placebo every 8 weeks (4 doses total)
219282860|NCT02981108|DRUG|HS-10296|HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
219282861|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage|The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.
219282862|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage|The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)
219282863|NCT06028243|BEHAVIORAL|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage|The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
219282864|NCT04896424|PROCEDURE|cryoballoon-based pulmonary veins isolation|A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases \< -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation\<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
219282865|NCT00949000|DEVICE|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
219282866|NCT00073268|BEHAVIORAL|Exercise|
219282867|NCT00193232|DRUG|Docetaxel|
219282868|NCT00193232|DRUG|Bortezomib|
219282869|NCT05444582|DRUG|Levonorgestrel 52 MG Intrauterine System|"Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days."
219282870|NCT00469105|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
219282871|NCT00469105|BEHAVIORAL|Control Group|Receives standard diabetes disease management
219282872|NCT05474339|OTHER|Cardiac rehabilitation|Using Cardiac rehabilitation for patients after coronary artery bypass graft
219282873|NCT02754349|DEVICE|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
219282874|NCT05415670|DIAGNOSTIC_TEST|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
219282875|NCT04571840|DIAGNOSTIC_TEST|Multiparametric MRI +/- prostate biopsy|MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
219282876|NCT04571840|DIAGNOSTIC_TEST|Biparametric MRI +/- prostate biopsy|MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
219282877|NCT01132443|DRUG|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
219282878|NCT00250445|DRUG|MK0663, etoricoxib|
219282879|NCT00250445|DRUG|Comparator: Diclofenac sodium|
219282880|NCT00954187|DRUG|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
219282881|NCT00954187|DRUG|pregabalin|50 mg PO TID
219282882|NCT02914418|DEVICE|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
219282883|NCT00003236|BIOLOGICAL|ISIS 3521|
219282884|NCT00003236|DRUG|ISIS 5132|
219282885|NCT00019552|DRUG|irofulven|
219282886|NCT03189940|BEHAVIORAL|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
219282887|NCT03189940|BEHAVIORAL|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
219282888|NCT06299800|OTHER|phenotyping of patients followed at a third-level diabetes centre with cancer|"Collection of the following data for each patient enrolled, where possible:~* Gender and age;~* Smoking habits and alcohol consumption (units per day);~* Weight and body mass index (BMI) at first (T0) and last visit (T1);~* Given by the diagnosis of type 2 diabetes mellitus;~* Treatment of type 2 diabetes at T0 and T1;~* Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar;~* Creatinine clearance at T0 and T1;~* Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST);~* T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG);~* Complications of type 2 diabetes;~* Treatment of cancer;~* Family history of cancer."
219282889|NCT05104359|OTHER|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
219282890|NCT04078295|DRUG|E7389-LF|E7389-LF Intravenous infusion.
219282891|NCT04078295|DRUG|Nivolumab|Nivolumab Intravenous infusion.
219282892|NCT04898959|OTHER|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
219282893|NCT03988244|DEVICE|HeartLight X3|Pulmonary vein isolation
219282894|NCT04315350|DRUG|Curcumin Liposome|Curcumin is given together with prednisolone
219282895|NCT04315350|DRUG|Prednisolone|Prednisolone is given together with curcumin-placebo
219282896|NCT04315350|DRUG|Placebos|Prednisolone-placebo is given together with curcumin-placebo
219282897|NCT03329755|OTHER|Dedicated and coordinated e-follow-up during the treatment period|"* Completion of questionnaires using an electronic tool~* Telephone follow-up between the nurse and the patient~* Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)"
219282898|NCT03329755|OTHER|Standard follow-up during the treatment period|\- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
219282899|NCT00192868|PROCEDURE|Distal protection and drug eluting stent|
219282900|NCT04192695|DEVICE|Cytosponge cell collection device|The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus. Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
219282901|NCT02937467|DEVICE|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
219282902|NCT00489944|DRUG|cisplatin|
219282903|NCT00489944|DRUG|sunitinib malate|
219282904|NCT00489944|DRUG|tamoxifen citrate|
219282905|NCT00489944|PROCEDURE|adjuvant therapy|
219282906|NCT05305729|OTHER|No intervention|No intervention
219282907|NCT01282502|DRUG|Midostaurin|50 mg BID for 8 cycles
219282908|NCT04546503|PROCEDURE|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~\+ General anaesthesia"
219282909|NCT04546503|PROCEDURE|Control Group|General anaesthesia without regional analgesia
219282910|NCT06804551|DEVICE|iovera system|Reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study.
219282911|NCT06804551|DEVICE|Radiofrequency ablation alone|An electrode at the tip of the needle sends radio waves that lesion the nerve bundles.
219282912|NCT04654637|BEHAVIORAL|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
219282913|NCT02629653|DEVICE|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
219282914|NCT00663702|DRUG|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
219282915|NCT04490590|DRUG|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
219282916|NCT02627703|OTHER|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
219282917|NCT04940975|BEHAVIORAL|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
219282918|NCT04940975|BEHAVIORAL|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
219282919|NCT03354585|BEHAVIORAL|mindfulness training|A well-validated brief mindfulness-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
219282920|NCT03354585|BEHAVIORAL|non-mindfulness training|A well-validated brief meditation-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice deep breathing. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
219282921|NCT03354585|BEHAVIORAL|book-listening|Study volunteers will listen to The Natural History and Antiquities of Selborne throughout the intervention.
219282922|NCT00579800|PROCEDURE|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
219282923|NCT05784623|OTHER|User experience|User experience is assessed by validated scales
219282924|NCT00689585|DRUG|Placebo|250mg matching placebo capsules
219282925|NCT00689585|DRUG|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
219282926|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
219282927|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
219282928|NCT00472810|DEVICE|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
219282929|NCT00472810|DRUG|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
219282930|NCT06175377|PROCEDURE|Percutaneous coronary intervention|A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
219282931|NCT06175377|DRUG|Short dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
219282932|NCT06175377|OTHER|Long dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
219282933|NCT06175377|OTHER|Follow-up visit at 1 month|At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
219282934|NCT06175377|OTHER|Follow-up visit at 6 months|At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
219282935|NCT06175377|OTHER|Follow-up visit at 12 months|At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
219282936|NCT04774653|OTHER|No intervention|Associations and prevalence will be calculated
219282937|NCT01097122|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
219282938|NCT02767284|DEVICE|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
219282939|NCT02767284|DEVICE|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
219282940|NCT02767284|DEVICE|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
219282941|NCT02767284|DEVICE|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
219282942|NCT02767284|DEVICE|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
219282943|NCT02767284|DEVICE|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
219282944|NCT04596943|DIAGNOSTIC_TEST|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), \[68Ga\]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
219282945|NCT00992043|DIETARY_SUPPLEMENT|creatine|
219282946|NCT00992043|OTHER|Exercise training|
219282947|NCT01977677|RADIATION|radiation therapy|Undergo radiation therapy
219282948|NCT01977677|DRUG|temozolomide|Given PO
219282949|NCT01977677|DRUG|plerixafor|Given IV
219282950|NCT01977677|OTHER|laboratory biomarker analysis|Correlative studies
219282951|NCT01977677|OTHER|pharmacological study|Correlative studies
219282952|NCT01498887|DRUG|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
219282953|NCT00064233|DRUG|dasatinib|
219282954|NCT01215487|PROCEDURE|Stem Cell and Mutational Assay|Laboratory blood testing
219282955|NCT01520805|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
219282956|NCT03079297|DRUG|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
219282957|NCT03079297|OTHER|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
219282958|NCT02384187|DRUG|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
219282959|NCT02384187|DRUG|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
219282960|NCT00667225|DRUG|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
219282961|NCT00667225|DRUG|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
219282962|NCT05737615|DIAGNOSTIC_TEST|PET Scan|Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination
219282963|NCT05737615|DRUG|hu5B1-TCO|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
219282964|NCT05737615|DRUG|64Cu-Tz-SarAr|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
219282965|NCT05737615|DIAGNOSTIC_TEST|Pharmacokinetics|All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
219282966|NCT03551964|DRUG|Cangrelor|"Cangrelor: IV bolus 30 µg/kg (application \< 1 minute) followed immediately by continuous infusion at 4 µg/kg. Tables to calculate bolus dose in ml and infusion (in ml per hour) rate for each body weight group will be prepared in advance and will be included in the study medication kit to accelerate treatment start.~* Cangrelor treatment will be discontinued after circulatory stabilization (but no earlier than 2 hours after infusion initiation) i.e. after systolic Blood Pressure (sBP) is maintained at the level \> 100 mmHg for one hour after the end of IABK and/or vasoactive treatment is discontinued, but no later than 4 hours after PCI,~* 30 minutes before the end of Cangrelor infusion, administration of Ticagrelor 180 mg (crushed tablets) and then dose 90 mg every 12 hours."
219282967|NCT03551964|DRUG|Ticagrelor|Ticagrelor: 180 mg loading dose - crushed tablets, 2 x 90 mg maintenance dose
219282968|NCT04402931|PROCEDURE|Transcatheter Valve-in-Valve Intervention|Transcatheter mitral valve-in-valve implantation with SAPIEN 3
219282969|NCT04402931|PROCEDURE|Redo Mitral valve surgery|Transcatheter Valve-in-Valve Intervention
219282970|NCT06776289|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be used to fill an osteotomy after endodontic microsurgery is completed.
219282971|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the Micro Hand S robot group.
219282972|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the da Vinci robot group
219282973|NCT06547164|DRUG|Midazolam|Midazolam will be administered orally.
219282974|NCT06547164|DRUG|Camizestrant|Camizestrant will be administered orally.
219282975|NCT06547164|DRUG|Carbamazepine|Carbamazepine will be administered orally.
219282976|NCT02993406|DRUG|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
219282977|NCT02993406|DRUG|Matching placebo tablet|Patients take matching placebo tablet orally once daily
219282978|NCT04959539|PROCEDURE|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
219282979|NCT04959539|PROCEDURE|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
219282980|NCT05776043|DRUG|Empagliflozin 10 MG|once daily for 6 or 9 months
219282981|NCT05776043|DRUG|Dapagliflozin 10 MG|once daily for 6 or 9 months
219282982|NCT05776043|DRUG|Placebo|once daily for 3 months
219282983|NCT06788314|DRUG|Enalapril|"Each participant will receive a dose of enalapril 5 mg once daily. If the participant doesn't have effect of the intervention after 3 months, the dose of enalapril will be increased to 10 mg daily, if the tolerance of enalapril is good. Lack of effect will be defined as unchanged or increased NRS score.~Treatment duration will be 12 months."
219282984|NCT04537013|PROCEDURE|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
219282985|NCT04537013|DEVICE|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
219282986|NCT06787586|DRUG|ATTO-1310|ATTO-1310 Attobody
219282987|NCT06787586|DRUG|ATTO-1310 Placebo|Placebo preparation to match ATTO-1310 Dose
219282988|NCT04656873|PROCEDURE|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
219282989|NCT04656873|OTHER|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
219282990|NCT04656873|OTHER|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
219282991|NCT02912546|PROCEDURE|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
219282992|NCT05262517|DRUG|Rimegepant|75 mg ODT
219282993|NCT05262517|DRUG|Placebo|matching placebo
219282994|NCT05163769|DEVICE|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
219282995|NCT05163769|DEVICE|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
219282996|NCT05446727|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine bilaterally
219282997|NCT01708343|PROCEDURE|DIMMST|
219282998|NCT02222298|PROCEDURE|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
219282999|NCT02222298|PROCEDURE|Bascom Cleft lift procedure|
219283000|NCT01666587|DIETARY_SUPPLEMENT|Antioxidant|
219283001|NCT01666587|DRUG|Prostaglandin inhibitor (Ibuprophen)|
219283002|NCT03203187|OTHER|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
219283003|NCT03203187|OTHER|No intervention|No mango intake for two weeks.
219283004|NCT02185222|DRUG|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
219283005|NCT02185222|DRUG|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
219283006|NCT03430947|DRUG|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
219283007|NCT03430947|DRUG|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
219283008|NCT04211597|OTHER|Control|No scar prevention or treatment.
219283009|NCT04211597|OTHER|Silicone gel|Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
219283010|NCT04211597|OTHER|microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg|4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
219283011|NCT01272154|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
219283012|NCT05990114|OTHER|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
219283013|NCT06334692|DIAGNOSTIC_TEST|"In-house ELISA, and ELISA kits from DBA Italy (Abbexa)."|"Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm."
219283014|NCT06609603|DIETARY_SUPPLEMENT|HTGT compound|oral administration of HTGT compound once daily
219283015|NCT06609603|DIETARY_SUPPLEMENT|Placebo|Oral administration of placebo once daily
219283016|NCT04325282|DEVICE|Active rTMS|1Hz rTMS delivered for 15-20 minutes
219283017|NCT04325282|DEVICE|Sham rTMS|sham rTMS delivered for 15-20 minutes
219283018|NCT06411353|DIAGNOSTIC_TEST|MRI acquisition|Non-contrast enhanced acquisitions will be performed using a whole-body MRI scanner operating at 1.5 Tesla or greater.
219283019|NCT06411353|DIAGNOSTIC_TEST|US examination|A complete assessment of the AVF vessels is performed using advanced 3D US procedures.
219283020|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
219283021|NCT00545194|DRUG|Prostaglandin E2|
219283022|NCT01628562|DRUG|Esmolol|Esmolol 50 mcg/kg/min
219283023|NCT01628562|DRUG|Remifentanil|Remifentanil 0.5 mcg/kg/min
219283024|NCT00144352|DRUG|sulfadoxine-pyrimethamine|
219283025|NCT03901599|OTHER|Alveolar ventilation monitoring estimated by the capnographic ventilation|Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
219283026|NCT01831947|BIOLOGICAL|Ranibizumab|
219283027|NCT05189210|DRUG|GV1001 Placebo|0.9% normal saline
219283028|NCT05189210|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
219283029|NCT05189210|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
219283030|NCT01953705|DRUG|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
219283031|NCT01953705|DRUG|Placebo|
219283032|NCT00283751|DRUG|insulin detemir|
219283033|NCT00283751|DRUG|insulin glargine|
219283034|NCT03069703|BIOLOGICAL|PCV13|one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
219283035|NCT03069703|BIOLOGICAL|PPV23|one dose of PPV23 at M5
219283036|NCT03069703|DRUG|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
219283037|NCT01460459|BEHAVIORAL|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
219283038|NCT06799247|BIOLOGICAL|Decartes-08|Autologous mRNA CAR T-cell therapy
219283039|NCT06799247|OTHER|Placebo Drug|infusion without Decartes-08
219283040|NCT02750449|DRUG|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
219283041|NCT02750449|OTHER|Untreated skin|This site is patched without treatment as control
219283042|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
219283043|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
219283044|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
219283045|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
219283046|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
219283047|NCT05922982|DRUG|norepinephrine weaning protocol|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
219283048|NCT05922982|DRUG|norepinephrine weaning protocol and guided by the HPI|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
219283049|NCT02762643|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
219283050|NCT02762643|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
219283051|NCT02762643|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
219283052|NCT02542800|BEHAVIORAL|Episodic memory task|
219283053|NCT02542800|DEVICE|fMRI|
219283054|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
219283055|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
219283056|NCT02565524|OTHER|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
219283057|NCT01158287|DRUG|sorafenib tosylate|
219283058|NCT01158287|OTHER|laboratory biomarker analysis|
219283059|NCT02672852|DRUG|Risankizumab|Risankizumab administered by subcutaneous injection
219283060|NCT02672852|DRUG|Placebo|Placebo for risankizumab administered by subcutaneous injection
219283061|NCT05532514|OTHER|MICRONUCLEI COUNT|MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
219283062|NCT03523611|PROCEDURE|Lung Resection|Lung resection surgery
219283063|NCT04183036|PROCEDURE|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
219283064|NCT02839525|DIETARY_SUPPLEMENT|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
219283065|NCT02839525|DIETARY_SUPPLEMENT|Isolate whey protein|23g of protein of whey protein
219283066|NCT02839525|DIETARY_SUPPLEMENT|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
219283067|NCT02839525|OTHER|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
219283068|NCT02474719|OTHER|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
219283069|NCT02511262|DEVICE|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
219283070|NCT02219165|DRUG|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
219283071|NCT02219165|DRUG|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
219283072|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
219283073|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
219283074|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219283075|NCT04549571|OTHER|Interview|Participate in interview
219283076|NCT04549571|OTHER|Training|Receive training
219283077|NCT04549571|OTHER|Media Intervention|Utilize the CDB
219283078|NCT04549571|OTHER|Best Practice|Utilize usual care
219283079|NCT04549571|OTHER|Survey Administration|Ancillary studies
219283080|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
219283081|NCT00821951|DRUG|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
219283082|NCT00821951|RADIATION|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
219283083|NCT03791554|PROCEDURE|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
219283084|NCT03791554|PROCEDURE|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
219283085|NCT00560846|DIETARY_SUPPLEMENT|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
219283086|NCT00560846|DIETARY_SUPPLEMENT|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
219283087|NCT03414385|OTHER|Exercise|Acute bout of aerobic exercise at moderate intensity for 2 hours
219283088|NCT06223022|BEHAVIORAL|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
219283089|NCT04396288|DEVICE|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
219283090|NCT04548323|BEHAVIORAL|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
219283091|NCT04137328|DRUG|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
219283092|NCT04137328|DRUG|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
219283093|NCT01162070|OTHER|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
219283094|NCT01162070|OTHER|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
219283095|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
219283096|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
219283097|NCT05945823|DRUG|Futibatinib|TAS-120 20 mg tablets, oral; once daily
219283098|NCT05945823|DRUG|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
219283099|NCT05945823|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy
219283100|NCT05945823|DRUG|5-FU|"4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy."
219283101|NCT05945823|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.
219283102|NCT05945823|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
219283103|NCT05945823|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
219283104|NCT05945823|DRUG|Irinotecan|150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
219283105|NCT03282825|DRUG|Decitabine|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
219283106|NCT03282825|DRUG|Paclitaxel|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
219283107|NCT01598662|DEVICE|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
219283108|NCT00002107|DRUG|Aldesleukin|
219283109|NCT03689777|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
219283110|NCT03689777|PROCEDURE|gastric bypass|gastric bypass
219283111|NCT01093677|DRUG|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
219283112|NCT01093677|DRUG|Placebo|Oral solution placebo BID for 14 days.
219283113|NCT04941053|DIAGNOSTIC_TEST|laboratory test|seroprevalnce
219283114|NCT00596882|OTHER|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
219283115|NCT00596882|OTHER|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
219283116|NCT06295198|OTHER|Single lep drop jump test|All evaluations will be repeated before and after the treatment.
219283117|NCT04199559|DRUG|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
219283118|NCT00310557|DRUG|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
219283119|NCT03250793|DEVICE|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
219283120|NCT06268457|PROCEDURE|Chemoembolization with Doxorubicin|"* Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
219283121|NCT00458276|DRUG|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
219283122|NCT00458276|DRUG|placebo|Placebo (i.e., normal saline) for i.v. use.
219283123|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Low Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate
219283124|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Intermediate Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
219283125|NCT06472726|BEHAVIORAL|IONA Mind app|The IONA Mind app is a smartphone app that delivers mental health support.
219283126|NCT03684278|DRUG|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
219283127|NCT03684278|DRUG|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
219283128|NCT03684278|OTHER|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
219283129|NCT05716048|BEHAVIORAL|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
219283130|NCT05716048|BEHAVIORAL|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
219283131|NCT06503302|DIAGNOSTIC_TEST|ultrasound Doppler function detection|Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
219283132|NCT03877211|OTHER|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
219283133|NCT03877211|OTHER|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
219283134|NCT03877211|OTHER|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
219283135|NCT03877211|OTHER|Tonal audiometry|Tonal audiometry will be performed with headphones
219283136|NCT03877211|OTHER|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
219283137|NCT01423110|BIOLOGICAL|BYM338|
219283138|NCT01423110|BIOLOGICAL|Placebo|
219283139|NCT03680352|DRUG|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
219283140|NCT06176976|DIETARY_SUPPLEMENT|Lugol's iodine solution 5%|4 drops of LS every 8 hours for 10 days preoperatively will be given
219283141|NCT02860897|DRUG|Premarin|Vaginal estrogen cream
219283142|NCT02860897|DRUG|Vagifem|Vaginal estrogen tablet
219283143|NCT00905320|PROCEDURE|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
219283144|NCT00905320|PROCEDURE|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
219283145|NCT00223847|BEHAVIORAL|Constraint Induced Language Therapy|
219283146|NCT05946603|DRUG|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
219283147|NCT05946603|DEVICE|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
219283148|NCT05946603|PROCEDURE|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
219283149|NCT05846958|DEVICE|laser acupuncture|"Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks ."
219283150|NCT05846958|DEVICE|night splint|wearing night splint for 4 weeks
219283151|NCT05634148|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
219283152|NCT02551653|DRUG|[11C]-GSK2256098 500 MBq|\[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
219283153|NCT03161613|OTHER|Non-Interventional|Non-Interventional
219283154|NCT01820884|PROCEDURE|TH|Total hysterectomy
219283155|NCT01820884|PROCEDURE|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
219283156|NCT01820884|PROCEDURE|BPLND|bilateral pelvic and para-aortic lymph node dissection
219283157|NCT02683785|DRUG|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
219283158|NCT02683785|DRUG|Placebo|Matching placebo will be administered as above.
219283159|NCT00403936|PROCEDURE|OA decompression manipulation|
219283160|NCT04921891|PROCEDURE|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
219283161|NCT04921891|PROCEDURE|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
219283162|NCT01823705|DEVICE|Exilis Implantable Gastric Electrical Stimulation (GES)|
219283163|NCT01049867|PROCEDURE|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
219283164|NCT02168348|OTHER|biological examination at consultations at 3 and 6 months|
219283165|NCT04324723|BEHAVIORAL|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear \[First name\], Your BP reading during Beirut Marathon was \[reading\]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
219283166|NCT04457349|PROCEDURE|Therapeutic Plasma Exchange (TPE)|Treatment with Therapeutic Plasma Exchange (TPE)
219283167|NCT02748551|PROCEDURE|Laparoscopic procedures|Laparoscopic surgery
219283168|NCT02748551|PROCEDURE|Open Surgery|Open surgery
219283169|NCT02459457|DRUG|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
219283170|NCT02459457|DRUG|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
219283171|NCT02459457|DRUG|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
219283172|NCT02459457|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
219283173|NCT03153553|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
219283174|NCT03153553|OTHER|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
219283175|NCT00441259|BIOLOGICAL|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged \> 3 years and 0.5 ml to children and infants aged \< 3 years administered subcutaneously
219283176|NCT00441259|BIOLOGICAL|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged \> 3 years and 0.5 ml is given to children and infants aged \< 3 years administered subcutaneously
219283177|NCT02108002|DRUG|Vorinostat|
219283178|NCT03862677|OTHER|No intervention|Observational study, no intervention
219283179|NCT01839097|DRUG|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
219283180|NCT01839097|DRUG|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
219283181|NCT04689945|DRUG|Morphine|"PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol"
219283182|NCT04689945|PROCEDURE|Erector Spinae Block|"PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
219283183|NCT04689945|DRUG|Control|"PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
219283184|NCT06046417|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
219283185|NCT06046417|DRUG|Lyumjev|Lyumjev delivered in a basal-bolus manner.
219283186|NCT06046417|DEVICE|Automated Insulin Delivery (AID) system|The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
219283187|NCT03952052|OTHER|Determination of mutation|Recurrent mutation determination by digital PCR and next generation sequencing
219283188|NCT01346072|DRUG|tolvaptan|oral, 30 mg, single dose, one time administration
219283189|NCT00162916|DRUG|citalopram|20mg or 40mg, once daily, for 40 weeks
219283190|NCT00162916|DRUG|Placebo|Cornstarch
219283191|NCT02562170|DEVICE|TiLoop Bra|
219283192|NCT02562170|DEVICE|Protexa|
219283193|NCT01682265|OTHER|Stretta procedure|
219283194|NCT01682265|OTHER|Sham procedure|No radiofrequency delivered
219283195|NCT01653977|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
219283196|NCT01653977|OTHER|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
219283197|NCT02233803|DRUG|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
219283198|NCT02233803|DRUG|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
219283199|NCT02233803|DRUG|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
219283200|NCT02233803|DRUG|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
219283201|NCT03132831|OTHER|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
219283202|NCT04247477|OTHER|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
219283203|NCT05752526|DRUG|Diclofenac 1%|vaginal hydrogel containing 1% Diclofenac
219283204|NCT05752526|DRUG|Diclofenac 3%|vaginal hydrogel containing 3% Diclofenac
219283205|NCT05752526|DRUG|Placebo|vaginal hydrogel, no active ingredient
219283206|NCT03259477|PROCEDURE|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
219283207|NCT03259477|PROCEDURE|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
219283208|NCT03635099|DRUG|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
219283209|NCT03635099|DRUG|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
219283210|NCT03635099|DRUG|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
219283211|NCT03635099|DRUG|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
219283212|NCT03635099|DRUG|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
219283213|NCT03635099|DRUG|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
219283214|NCT03635099|DRUG|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
219283215|NCT03635099|DRUG|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
219283216|NCT02457377|PROCEDURE|laparoscopic cerclage|The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
219283217|NCT03197753|DEVICE|Laryngeal mask airway|Laryngeal mask airway
219283218|NCT03197753|DEVICE|Nasotracheal intubation|Nasotracheal intubation
219283219|NCT01546077|PROCEDURE|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
219283220|NCT05768165|BEHAVIORAL|High intensity exercise|"Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness."
219283221|NCT05588050|DEVICE|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
219283222|NCT05715177|OTHER|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
219283223|NCT05715177|OTHER|Placebo kinesio-taping|Placebo kinesiotaping
219283224|NCT01987492|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
219283225|NCT01987492|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
219283226|NCT03983967|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
219283227|NCT01373580|DEVICE|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
219283228|NCT03578653|BEHAVIORAL|Merging Yoga and Occupational Therapy for Parkinson disease|The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
219283229|NCT00569023|DIETARY_SUPPLEMENT|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
219283230|NCT00858689|DRUG|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
219283231|NCT05240326|OTHER|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
219283232|NCT05240326|OTHER|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
219283233|NCT04191616|DRUG|Carfilzomib|Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.
219283234|NCT04191616|DRUG|Dexamethasone|Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.
219283235|NCT04191616|DRUG|Pomalidomide|Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
219283236|NCT03276650|OTHER|data collection|biological, administrative, clinical, outcome date
219283237|NCT03723018|BEHAVIORAL|Meditation|10 minutes a day of meditation, done on your own time.
219283238|NCT02951520|PROCEDURE|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
219283239|NCT05822739|DRUG|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
219283240|NCT04223986|DIAGNOSTIC_TEST|Ultrasound|decide between the need for intervention or not (Percutaneous coronary intervention)
219283241|NCT04223986|DIAGNOSTIC_TEST|Troponin- T quick test|Quick test for Troponin T blood assessment
219283242|NCT05568953|BIOLOGICAL|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
219283243|NCT05568953|BIOLOGICAL|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
219283244|NCT05568953|BIOLOGICAL|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
219283245|NCT04235517|OTHER|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
219283246|NCT06250959|DRUG|Blinatumomab Injection [Blincyto]|Reduced-intensity chemotherapy followed by Blinatumomab
219283247|NCT06250959|DRUG|Doxorubicin|HyperCVAD regimen
219283248|NCT00655525|DIETARY_SUPPLEMENT|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
219283249|NCT00655525|DIETARY_SUPPLEMENT|placebo|placebo administered orally every day for 3 months
219283250|NCT00770900|DRUG|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children \>15 years took 10mg tablet of montelukast"
219283251|NCT00770900|DRUG|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
219283252|NCT02180243|BEHAVIORAL|Mindfulness meditation/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
219283253|NCT02180243|OTHER|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
219283254|NCT00968071|DRUG|Decitabine|20 mg/m\^2 IV over an hour and half daily for 5 days.
219283255|NCT00968071|DRUG|Gemtuzumab Ozogamicin|3 mg/m\^2 IV on day 5.
219283256|NCT06086899|PROCEDURE|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
219283257|NCT06086899|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
219283258|NCT06094946|DRUG|Ropivacaine Hydrocloride|1 mg/ml
219283259|NCT06094946|DRUG|Fentanyl Citrate|2.5 micrograms/ml
219283260|NCT01409629|BEHAVIORAL|Computer game|Participants will play a computer game
219283261|NCT00353041|DRUG|lidocaine topical|
219283262|NCT00158314|BEHAVIORAL|Referral to Gamblers Anonymous|
219283263|NCT00158314|BEHAVIORAL|Cognitive behavioral therapy|
219283264|NCT00158314|BEHAVIORAL|Cognitive behavioral self-help manual|
219283265|NCT00872755|PROCEDURE|Nissen|Laparoscopic Nissen Fundoplication
219283266|NCT00872755|PROCEDURE|Gastropexy|posterior gastropexy
219283267|NCT02798042|OTHER|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
219283268|NCT03170687|DEVICE|short foot cast|metatarsal foot cast
219283269|NCT03170687|DEVICE|short leg cast|full short leg cast
219283270|NCT05028114|DRUG|AC-1202|Tricaprilin formulated as AC-1202
219283271|NCT05028114|DRUG|AC-OLE-01|Tricaprilin Formulation
219283272|NCT05028114|DRUG|AC-OLE-02|Tricaprilin Formulation
219283273|NCT05028114|DRUG|AC-OLE-03|Tricaprilin Formulation
219283274|NCT05028114|DRUG|AC-OLE-04|Tricaprilin Formulation
219283275|NCT05028114|DRUG|AC-OLE-05|Tricaprilin Formulation
219283276|NCT05028114|DRUG|AC-OLE-06|Tricaprilin Formulation
219283277|NCT05028114|DRUG|AC-OLE-07|Tricaprilin Formulation
219283278|NCT05028114|DRUG|AC-OLE-08|Tricaprilin Formulation
219283279|NCT05028114|DRUG|AC-OLE-09|Tricaprilin Formulation
219283280|NCT05028114|DRUG|AC-OLE-010|Tricaprilin Formulation
219283281|NCT05028114|DRUG|AC-OLE-P|Placebo to tricaprilin formulation
219283282|NCT03598153|DRUG|Shujinjianyao Pill|According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
219283283|NCT02473731|BIOLOGICAL|KTN3379|
219283284|NCT03398902|BEHAVIORAL|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
219283285|NCT03398902|OTHER|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
219283286|NCT05646576|BEHAVIORAL|Palliative Care|"* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.~* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.~* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot."
219283287|NCT05646576|BEHAVIORAL|Usual Care|Standard care for ACT per the treating team.
219283288|NCT06172192|PROCEDURE|Core Strengthening|"1. Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~2. Core Strengthening:~   Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~3. Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise."
219283289|NCT06172192|PROCEDURE|Self-Diaphragm breathing exercises|"Participants will place one hand on the chest and other on the abdomen, feeling the swelling of the stomach and the movement of the chest. It will be performed in supine position.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
219283290|NCT06172192|PROCEDURE|Resistive-Diaphragm breathing exercises|"Participants will place one hand on the chest and another on the sand bag placed over abdomen. This sand bag weighing 3-5 Kgs will provide resistance to breathing. These exercises will be performed in supine position. We will adjust the weight of the sandbag as per individual's level of 11-13 of 'Rating of Perceived Exercise (RPE)'.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
219283291|NCT02240953|DRUG|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
219283292|NCT02240953|DRUG|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
219283293|NCT02240953|DRUG|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
219283294|NCT02240953|DRUG|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
219283295|NCT03112824|DIETARY_SUPPLEMENT|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
219283296|NCT03112824|OTHER|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
219283297|NCT03741920|DEVICE|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~* A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.~* A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
219283298|NCT06228209|BEHAVIORAL|Tier - Palliative Care|TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
219283299|NCT02712164|DEVICE|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
219283300|NCT02712164|DEVICE|Tegaderm|Standard of care for STSG donor sites.
219283301|NCT06492772|OTHER|experimental group|The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
219283302|NCT06021626|DRUG|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"
219283303|NCT04820998|OTHER|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
219283304|NCT04820998|OTHER|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
219283305|NCT04629456|OTHER|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
219283306|NCT04629456|OTHER|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
219283307|NCT01840410|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
219283308|NCT01840410|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
219283309|NCT03759782|DRUG|Ribavirin|Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
219283310|NCT03759782|DRUG|Tenofovir|Tenofovir as per standard of care
219283311|NCT00178555|DEVICE|DCI Video Intubation System-Macintosh Laryngoscope|
219283312|NCT00178555|DEVICE|Macintosh Laryngoscope|
219283313|NCT06366412|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
219283314|NCT06366412|OTHER|normal saline|normal saline will be administrated in placebo group
219283315|NCT00000300|DRUG|LAAM|
219283316|NCT00318539|DRUG|Quetiapine|
219283317|NCT02654652|DIETARY_SUPPLEMENT|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
219283318|NCT02654652|DIETARY_SUPPLEMENT|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
219283319|NCT03508401|OTHER|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
219283320|NCT03508401|DEVICE|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
219283321|NCT01275742|BEHAVIORAL|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
219283322|NCT01868425|DRUG|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
219283323|NCT01868425|DRUG|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
219283324|NCT04538612|DEVICE|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~* Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~* Veinous vascular occlusion test (30mmHg),~* Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
219283325|NCT03339232|DIETARY_SUPPLEMENT|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
219283326|NCT03339232|OTHER|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
219283327|NCT05559151|PROCEDURE|Remimazolam Benzenesulfonate|"In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation."
219283328|NCT02843451|DRUG|Milk Thistle|
219283329|NCT02843451|DRUG|Placebo|
219283330|NCT03394677|DRUG|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
219283331|NCT03394677|DRUG|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
219283332|NCT04127500|DRUG|dexmedetomidine|dexmedetomidine
219283333|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.
219283334|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
219283335|NCT04014595|PROCEDURE|Rotational atherectomy in combination with cutting balloon|Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
219283336|NCT02870049|BEHAVIORAL|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
219283337|NCT02870049|BEHAVIORAL|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
219283338|NCT02870049|BEHAVIORAL|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
219283339|NCT02870049|BEHAVIORAL|Usual care|Usual care: FIT kit delivery as part of usual care
219283340|NCT04078698|DEVICE|Immunoadsorber GLOBAFFIN®|Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
219283341|NCT06802276|OTHER|High Cysteine Diet|A healthy diet pattern which contains high levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. No additional supplementation of cysteine will be used. Examples of high cysteine foods: chicken, eggs, lentils, yogurt, garlic, cheese, soybeans
219283342|NCT06802276|OTHER|Low Cysteine Diet|A healthy diet pattern which contains low levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. The low cysteine diet includes lower-protein food sources. Examples of low cysteine foods: rice, bread, oranges, bananas, lettuce, snow peas, peppers
219283343|NCT06803446|OTHER|physical test|continuous and intermittent exercise on cycloergometer
219283344|NCT05686122|BEHAVIORAL|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
219283345|NCT05235269|DRUG|124I-AT-01|All participants received 1 mCi 124I-AT-01 on Day 1 and at Week 6 via IV infusion over 2-5 minutes or slow IV bolus at 1 mL/5 seconds.
219283346|NCT00720785|DRUG|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
219283347|NCT00720785|BIOLOGICAL|NK cells|NK Cell Infusion
219283348|NCT05660122|DRUG|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
219283349|NCT01492972|RADIATION|Radiation|"Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
219283350|NCT01492972|DRUG|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
219283351|NCT02585544|PROCEDURE|day-care surgery|day-care surgery
219283352|NCT03050736|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
219283353|NCT05070858|DRUG|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
219283354|NCT05070858|DRUG|Cemdisiran|SC administration as described in the protocol
219283355|NCT05070858|OTHER|Placebo|SC administration as described in the protocol
219283356|NCT05070858|DRUG|Pozelimab|SC administration as described in the protocol
219283357|NCT00798434|DRUG|Placebo|placebo administered orally in the morning or evening.
219283358|NCT00798434|DRUG|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
219283359|NCT06415266|OTHER|Quality of life questionnaire (QLQ)|Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
219283360|NCT06415266|OTHER|Satisfaction survey|The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
219283361|NCT06415266|OTHER|Assessment of patient needs in the field of oncosexology|Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
219283362|NCT03898167|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
219283363|NCT03898167|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
219283364|NCT03898167|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
219283365|NCT03180034|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
219283366|NCT03180034|OTHER|Questionnaire Administration|Ancillary studies
219283367|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
219283368|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
219283369|NCT06136481|OTHER|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT). CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. Prior to engaging in therapy, one session will be devoted to gathering information regarding psychosocial history, trauma, and current functioning. The following sessions will follow the standard outpatient CPT protocol. The standard outpatient CPT consists of 12 one-hour sessions conducted over a 6- to 12-week period. An additional 3 weeks will be provided in case of participant and therapist vacation and/or sick days. CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
219283370|NCT05773586|DRUG|APG-5918|oral tablets 10mg, 50mg, 200mg.
219283371|NCT05773586|DRUG|Placebo|Matching placebo
219283372|NCT01370798|DRUG|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
219283373|NCT01370798|DRUG|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
219283374|NCT01370798|PROCEDURE|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
219283375|NCT01370798|RADIATION|Wrist X ray|Wrist X ray to follow the degree of bone maturation
219283376|NCT01370798|PROCEDURE|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
219283377|NCT04726618|DRUG|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
219283378|NCT04949646|OTHER|Pelvic Intraoperative Neuromonitoring|Pelvic Intraoperative Neuromonitoring (pIONM) allows mapping of the pelvic autonomous plexus during total mesorectal excision (TME).
219283379|NCT05093959|DRUG|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
219283380|NCT05093959|DRUG|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
219283381|NCT02579395|BEHAVIORAL|Collaborative implementation Intentions|With spouse/romantic partner
219283382|NCT02579395|BEHAVIORAL|Individual implementation Intentions|Without spouse/romantic partner
219283383|NCT02579395|BEHAVIORAL|Control|
219283384|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
219283385|NCT02265809|DRUG|Aldesleukin|
219283386|NCT02593799|PROCEDURE|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
219283387|NCT03653000|PROCEDURE|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
219283388|NCT03653000|DRUG|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
219283389|NCT00455897|DRUG|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
219283390|NCT00455897|DRUG|CHOP|Administered as part of standard care
219283391|NCT00455897|DRUG|Rituximab|Administered as part of standard treatment
219283392|NCT01072708|OTHER|Prospective cohort with an annual follow-up|"Annualfollow-up including :~* oral glucose tolerance test~* dietary survey~* biological evaluation~* bacteriological and respiratory measures~* dual-energy x-ray absorptiometry~* physical activity survey"
219283393|NCT01607151|OTHER|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
219283394|NCT01607151|OTHER|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
219283395|NCT02646956|OTHER|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
219283396|NCT00004449|BEHAVIORAL|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
219283397|NCT00004449|BEHAVIORAL|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
219283398|NCT05164380|OTHER|Picture naming tasks|PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
219283399|NCT05177354|DEVICE|Inceptiv|Implantable Neurostimulator with Neuro Sense
219283400|NCT05318859|OTHER|Pharmacopuncture|Registry (observational study)
219283401|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (10G-A)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
219283402|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (20G-A)|Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
219283403|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-A)|Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
219283404|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-B)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth three times per day (30 total grams of R-1,3-Butanediol) for 12 weeks, with a possible additional 12 week extension
219283405|NCT03469401|OTHER|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
219283406|NCT05444205|BEHAVIORAL|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
219283407|NCT05444205|BEHAVIORAL|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
219283408|NCT05444205|BEHAVIORAL|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
219283409|NCT05444205|BEHAVIORAL|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
219283410|NCT05444205|BEHAVIORAL|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
219283411|NCT05444205|BEHAVIORAL|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
219283412|NCT05444205|BEHAVIORAL|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
219283413|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
219283414|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
219283415|NCT02342938|PROCEDURE|MEG or fMRI And INtracranial EEG|
219283416|NCT02342938|PROCEDURE|fMRI|
219283417|NCT04542733|DRUG|Everolimus|Everolimus will be given with tacrolimus.
219283418|NCT04542733|DRUG|reduced dose tacrolimus and Leflunomide|Reduced dose tacrolimus will be given with leflunomide
219283419|NCT00462605|DRUG|entinostat|Given PO
219283420|NCT00462605|DRUG|sargramostim|Given SC
219283421|NCT00002539|BIOLOGICAL|filgrastim|
219283422|NCT00002539|DRUG|cisplatin|
219283423|NCT00002539|DRUG|doxorubicin hydrochloride|
219283424|NCT00002539|PROCEDURE|conventional surgery|
219283425|NCT04439188|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
219283426|NCT06360354|DRUG|AMG 193|Administered Orally
219283427|NCT06360354|DRUG|Gemcitabine|Administered IV
219283428|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
219283429|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
219283430|NCT06360354|DRUG|RMC-6236|Administered orally
219283431|NCT03548220|DRUG|Placebo|Placebo matching AG-348 tablets, administered to maintain the blind.
219283432|NCT03548220|DRUG|AG-348|AG-348 tablets.
219283433|NCT00501657|DRUG|Sitagliptin|100mg mane for 2 days
219283434|NCT00501657|DRUG|Placebo|100mg mane for 2 days
219283435|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
219283436|NCT06534502|DRUG|Zonisamide Oral Product|Zonisamide oral suspension
219283437|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
219283438|NCT06396078|DRUG|Ceftriaxone 1000 MG|Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
219283439|NCT06396078|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
219283440|NCT06396078|DRUG|Metronidazole 500 mg|Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
219283441|NCT06396078|DRUG|Ampicillin 2 GM Injection|Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
219283442|NCT06396078|DRUG|Amoxicillin 250 MG|Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
219283443|NCT06396078|DRUG|Azithromycin|Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
219283444|NCT06396078|DRUG|Erythromycin|Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
219283445|NCT04154982|DRUG|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
219283446|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
219283447|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
219283448|NCT06990087|DRUG|Application of T-lymphocytes|Dosage form: Infusion; Route of administration: Intravenous; Cell dose: 1-2 x 10.000 viable CD3+ T-lymphocytes per kg bodyweight; Application at three timepoints: baseline, after two weeks, after 6 weeks
219283449|NCT06597656|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
219283450|NCT06597656|PROCEDURE|Plasmapheresis|Therapeutic plasma exchange procedure
219283451|NCT06858137|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in four weeks using a single Polydioxaone thread. Needles have a gauge size of 30G, a shaft length of 26mm, folded in half, and are applied to nine acupoints, including Yintang (EX-HN3), Yingxiang (LI20) on both sides of the body. Needles with a gauge size of 29G, a shaft length of 30mm, and a thread length of 50mm, folded in half, are used for three acupoints, which included Hegu (LI4), Zusanli (ST36), Feishu (BL13), on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
219283452|NCT06858137|OTHER|Standal treatment|Inhaled corticosteroid spray - fluticasone propionate patients were permitted to use Fluticasone propionate 1 or 2 sprays (50 mcg/spray) in each nostril once a day as needed in four weeks and participants must change life style attaches including smoke and traffic pollution avoidant, preventing pets going into the bedroom, washing clothes.
219283453|NCT07127692|DIAGNOSTIC_TEST|Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire|Self-administered screening tool for sarcopenia
219283454|NCT07127692|DIAGNOSTIC_TEST|Hand grip strength|Used to assess sarcopenia
219283455|NCT07127692|DIAGNOSTIC_TEST|Timed Up and Go test|Screening test for falls in elderly
219283456|NCT07127692|DIAGNOSTIC_TEST|Gait speed|Assessment to check for functional mobility and risk of falls.
219283457|NCT07127692|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|Used to assess level of frailty.
219283458|NCT05582499|DRUG|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
219283459|NCT05582499|DRUG|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
219283460|NCT05582499|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
219283461|NCT05582499|DRUG|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
219283462|NCT05582499|DRUG|Camrelizumab|an anti-programmed death-1 (PD1) antibody
219283463|NCT05582499|DRUG|SHR-A1921|Trophoblast cell-surface antigen 2 (TROP2) ADC
219283464|NCT05582499|DRUG|Pertuzumab|Pertuzumab
219283465|NCT05582499|DRUG|Trastuzumab|Trastuzumab
219283466|NCT05582499|DRUG|Goserelin|goserelin
219283467|NCT05582499|DRUG|Letrozole|letrozole
219283468|NCT05582499|DRUG|Nab paclitaxel|Albumin paclitaxel
219283469|NCT05582499|DRUG|Carboplatin|Carboplatin
219283470|NCT05582499|DRUG|Epirubicin|Epirubicin
219283471|NCT05582499|DRUG|Cyclophosphamide|Cyclophosphamide
219283472|NCT05582499|DRUG|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
219283473|NCT05582499|DRUG|Apatinib|tyrosine kinase inhibitors
219283474|NCT05582499|DRUG|Famitinib|tyrosine kinase inhibitors
219283475|NCT05582499|DRUG|HB1801|Albumin docetaxel
219283476|NCT05582499|DRUG|LEM|liposome-entrapped mitoxantrone
219283477|NCT05582499|DRUG|TQB2102|an anti-HER2 ADC
219283478|NCT05582499|DRUG|Benmelstobart|an anti-PDL1 antibody
219283479|NCT05582499|DRUG|Anlotinib|an tyrosine kinase inhibitor
219283480|NCT05582499|DRUG|TQB2868|anti-PD-1/TGF-βRII
219283481|NCT05582499|DRUG|Ivonescimab|an anti-PD-1/VEGF bispecific antibody
219283482|NCT05582499|DRUG|JS207|an anti-PD-1/VEGF bispecific antibody
219283483|NCT05582499|DRUG|JSKN003|an anti-HER2 ADC
219283484|NCT05582499|DRUG|HRS-4508|an HER2 inhibitor
219283485|NCT05582499|DRUG|SHR-4602|an anti-HER2 ADC
219283486|NCT05582499|DRUG|paclitaxel|paclitaxel
219283487|NCT07016165|DRUG|Ceftazidime|Ceftazidime 150 mg/kgBW/24 hours divided into 3 doses.
219283488|NCT07016165|DRUG|Ciprofloxacin|Ciprofloxacin 10 mg/kgBW/12 hours
219283489|NCT01796600|DEVICE|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
219283490|NCT06626516|DRUG|Tebentafusp-Tebn|Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
219283491|NCT06626516|DRUG|GM-CSF (Sargramostim)|Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.
219283492|NCT06626516|DRUG|BCNU|Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
219283493|NCT07014007|DEVICE|RV4421B- EV0407|Medical device. Product application on studied areas, 5 to 15 minutes after corticosteroids application, if applicable. The maximum duration of application of medical device is 87 days.
219283494|NCT03649178|OTHER|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
219283495|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
219283496|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
219283497|NCT07030179|OTHER|Frailty status|This was an observational study with no intervention measures. The exposure factor was the frailty status of the patients.
219283498|NCT06876259|DIAGNOSTIC_TEST|Standard Clinical Ear Exam|The clinician will examine the child's ear with a standard otoscope and give a clinical diagnosis and decision to treat with antibiotics.
219283499|NCT06876259|DIAGNOSTIC_TEST|AI app ear exam and diagnosis|Using a standard otoscope with a cell phone mounted to it, research personnel will record a video image of the tympanic membrane and send it to the cloud for analysis using AI enhanced classification software to render a diagnosis and treatment recommendation
219283500|NCT07137988|DIETARY_SUPPLEMENT|600 mg grape seed extract|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
219283501|NCT07137988|DIETARY_SUPPLEMENT|600 mg Starch|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
219283502|NCT01734733|OTHER|NTCELL|
219283503|NCT06256328|DRUG|ONO-4578|Specified dose, once daily
219283504|NCT06256328|DRUG|Oxaliplatin|Specified dose on specified days
219283505|NCT06256328|DRUG|Capecitabine|Specified dose on specified days
219283506|NCT06256328|DRUG|S-1|Specified dose on specified days
219283507|NCT06256328|DRUG|Nivolumab|Specified dose on specified days
219283508|NCT06256328|DRUG|Placebo|Specified dose, once daily
219283509|NCT06728605|DEVICE|Enhanced External Counterpulsation (EECP)|Patients randomly assigned to EECP received 3 1/2-h sessions of EECP for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 300 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
219283510|NCT06728605|DEVICE|Sham Comparator|Patients randomly assigned to sham group received 3 1/2-h sessions of sham treatment for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 70 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
219283511|NCT06889324|OTHER|Vibration therapy|Its therapy uses mechanical vibrations delivered via a specialized device called Thrive vibrator device model 717 to stimulate the calf muscles, which can help reduce the severity of restless legs syndrome and sleep disturbances among patients undergoing hemodialysis.
219283512|NCT06728046|OTHER|ESPB|Participants will receive ultrasound-guided ESPB preoperatively, using 40 ml of 0.3% ropivacaine.
219283513|NCT06728046|DEVICE|PCA|Participants will receive postoperative PCA with a formulation of 200 µg sufentanil diluted to 100 ml. The PCA settings will include a background dose of 3 ml/hour, a lockout time of 15 minutes, and a bolus dose of 2 ml.
219283514|NCT07045402|OTHER|Kangaroo Care + Maternal Voice + Fetal Position Group|After ethical approval, all infants with a gestational age between 30-34 weeks in Neonatal Intensive Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. The infants will then be assigned to one of two groups: kangaroo care + mother's voice + fetal position (n=34) or fetal position only (n=34). In the first group, after tube feeding, infants will receive one hour of kangaroo care with the mother, including reading a story for the first 15 minutes. After finishing kangaroo care,they will then be placed in a fetal position in an incubator for 30 minutes. Comfort levels, weight, length, and head circumference will be measured daily until oral feeding begins, and the impact of kangaroo care and the mother's voice on the transition to full oral feeding will be assessed. All procedures will occur between 08:00 and 16:00.
219283515|NCT07045402|OTHER|control group|After ethical approval, all infants with a gestational age between 30-34 weeks in the Neonatal Intensıve Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. If infant is in the fetal position group, after being fed by a oral gastric tube, they will be placed in an incubator and positioned in a fetal position similar to that in the womb for one and a half hours. During all these procedures, infant's comfort levels will be assessed using a scale (form), and their weight, length, and head circumference will be measured every morning until they begin oral feeding. Additionally, the effect of the fetal position on infant's transition to full oral feeding will be evaluated.All procedures will take place between 08:00 and 16:00.
219283516|NCT06029907|OTHER|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
219283517|NCT06029907|DRUG|Varenicline|Patients will receive varenicline prescribed by their oncologist
219283518|NCT00896935|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
219283519|NCT06514339|DRUG|shenhuang granule|"Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification."
219283520|NCT06514339|DRUG|placebo|Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
219283521|NCT06854731|BEHAVIORAL|Balance and Strength Training Exercises with Health Coaching|The OEP+ intervention integrates the OEP with health coaching by a physical therapists or kinesiologist. The OEP is an individualized home-based balance and strength exercise training program delivered by a PT or kinesiologist coach over 5 home visits.
219283522|NCT06854731|OTHER|Education Session|All active comparator participants will be invited to join monthly interactive social and education sessions via Zoom or in-person (hybrid delivery).
219283523|NCT03570892|DRUG|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
219283524|NCT03570892|DRUG|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
219283525|NCT06782347|BEHAVIORAL|Proactive Care|The proactive care intervention was designed to be similar to proactive care approaches used successfully in the tobacco control area. These proactive care procedures have not yet been adequately evaluated in the exercise promotion area.
219283526|NCT07075406|DRUG|Luspatercept|According to product label
219283527|NCT07138001|COMBINATION_PRODUCT|KH617+TMZ|use KH617 and TMZ(5/28) as Combination Product.
219283528|NCT07138001|DRUG|KH617|Single Clinical trial investigational drug
219283529|NCT07138001|DRUG|TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16|"Comparator product, Two treatment options for physicians and subjects to choose from:~1. use TMZ(7/7)~2. Use Platinum (cisplatin or carboplatin)+VP-16"
219283530|NCT07136766|DRUG|Facial Toner|Brightening Toner
219283531|NCT07136766|OTHER|Placebo Toner|Placebo Control Toner
219283532|NCT07137065|BEHAVIORAL|PRImary care MultilEvel intervention for low back pain (PRIME)|"The multilevel intervention includes four main components:~1\. GP training. GPs will receive training to improve their confidence in LBP guidelines, diagnostic triage and best practice. Furthermore, they will be trained to provide both general and cognitive reassurance to patients, use a stratified care strategy and improve interprofessional communication. 2. Reminders. GPs will receive regular reminders by email to reinforce the integration of high-value care into practice. 3. Patient education. GPs will reassure patients, help them understand their LBP in the initial consultation and target unhelpful beliefs about LBP. 4. Clinical pathway. The clinical pathway includes a gradual stratified care pathway based on risk factors for chronicity. The core interventions of this 3-step clinical pathway are education and self-management, individual sessions with a trained physiotherapist, and multidisciplinary group management. GPs remain free to make all clinical decisions."
219283533|NCT07137065|OTHER|Usual Care|In this arm, general practitioners will treat their patients as usual. They can prescribed any treatment or diagnostic tests to their patients.
219283534|NCT07135765|PROCEDURE|Additional 5 minutes of lying down position during MRI|During axial MRI for scoliosis assessment, additional 5 minutes of lying down position in order to performing a specific sequence for the study of the vertebral muscles (Diffusion Tensor Imaging).
219283535|NCT07136454|DRUG|Rugonersen|Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).
219283536|NCT07136220|OTHER|Consumption of soy protein bar|The participants will be provided one soy protein bar to consume after dinner on day 1.
219283537|NCT07136805|DRUG|VVN461 Ophthalmic Solution 1.0%|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
219283538|NCT07136805|DRUG|1.0% prednisolone acetate|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
219283539|NCT02627443|DRUG|Berzosertib|Given IV
219283540|NCT02627443|DRUG|Carboplatin|Given IV
219283541|NCT02627443|DRUG|Gemcitabine Hydrochloride|Given IV
219283542|NCT02627443|OTHER|Laboratory Biomarker Analysis|Correlative studies
219283543|NCT02627443|OTHER|Pharmacological Study|Correlative studies
219283544|NCT07076615|DRUG|Dapagliflozin (DAPA)|Receives dapagliflozin 10 mg once daily + standard intravenous diuretic therapy
219283545|NCT07076615|DRUG|Diuretic|Arm B (Control Group): Receives standard intravenous diuretic therapy alone
219283546|NCT04111172|BIOLOGICAL|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
219283547|NCT06840886|DRUG|PHST001|"* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~* Other Names:~* Dose Level 1~* Dose Level 2~* Dose Level 3~* Dose Level 4~* Dose Level 5~* Dose Level 6~* Dose Level 7~Drug: PHST001~* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~This study is an open label, Phase 1 dose escalation trial with three expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 40-80 in total will be in enrolled in part A, covering 7 dose level.~* Part B: Expansion cohorts will be added as an amendment as further preclinical data and clinical data from Part A become available."
219283548|NCT06767111|DEVICE|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm in vitro diagnostic (IVD) device|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm to be used for AI-assisted review
219283549|NCT06755827|BEHAVIORAL|Emotion regulation and self-monitoring to treat pediatric obesity|Participants will attend telehealth group sessions once weekly and be asked to self-monitor their mood and health behaviors daily between sessions.
219283550|NCT06755827|OTHER|Psychoeducation|Participants who are randomized to the control group will receive an online, one-time, self-led psychoeducation program with information about current daily sleep, diet, and physical activity recommendations (e.g., information about sleep hygiene, the food pyramid, and recommendations for 60 minutes of moderate-to-vigorous physical activity daily).
219283551|NCT07084051|BEHAVIORAL|I-MAS|Participants will receive a one-to one session with the pharmacy technician that involves two parts; the first part include education on ischemic stroke and risk factors such as practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc., making healthier dietary choices, exercising regularly, smoking cessation, alcohol intake, and managing blood sugar. The second part involves an interview to collect information on socio-demographics, clinical factors, co-morbidities, medications, and medication adherence barriers. During the second part of the session, the pharmacy technician will identify barriers to medication adherence for secondary prevention of stroke medications including antihypertensives, antithrombotic agents, and statins. The pharmacist will collaborate with the pharmacy technician to develop an action plan to address medication adherence barriers
219283552|NCT06122870|BIOLOGICAL|CampETEC HBC product|Immunoglobulin from bovine milk/colostrum and challenge strain
219283553|NCT06122870|BIOLOGICAL|ProMilk 85|Placebo ProMilk 85
219283554|NCT06122870|BIOLOGICAL|C. jejuni CG8421 Challenge strain|Challenge strain C. jejuni CG8421
219283555|NCT02726711|DRUG|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
219283556|NCT02726711|DRUG|Placebo|0.5 - 4.0 mg IV to be infused
219283557|NCT05511467|BEHAVIORAL|Visuomotor learning task|Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
219283558|NCT07081633|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
219283559|NCT07081633|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
219283560|NCT07081633|COMBINATION_PRODUCT|Lenvatinib|Lenvatinib Oral
219283561|NCT07083271|OTHER|Administration of validated questionnaires with established Turkish versions|Participants will complete validated Turkish versions of three self-administered instruments: the Zarit Caregiver Burden Scale (ZCBS), the EORTC QLQ-C30, and the Hospital Anxiety and Depression Scale (HADS). Financial toxicity will be assessed via self-reported socioeconomic data. No clinical, behavioral, or pharmaceutical intervention will be applied.
219283562|NCT07086664|DRUG|Placebo|Oral tablet
219283563|NCT07086664|DRUG|PF-07258669|Oral tablet
219283564|NCT06926075|DRUG|A novel hGIIA-Vimentin Inhibitor|Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.
219283565|NCT06926075|DRUG|Dose expansion|Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.
219283566|NCT06927505|OTHER|Bobath based trunk control training|Participants in the Bobath based trunk training group will undergo a comprehensive intervention encompassing strengthening exercises, stretching exercises, and motor training. This group will experience a 60-minute session, including 40 minutes of Bobath based exercises along with 20 minutes routine physical therapy. 1. Strengthening the oblique abdominals 2. Weight Shifting (Side-to-Side \& Forward-Backward) 3. Pelvic Tilts 4. Functional strengthening of trunk extensors 5. Reaching 6. Latissimus dorsi stretching exercise 7. Bridging 8. Trunk rotation (supine and standing position) 9. Sitting to Standing Transitions (with emphasis on trunk control) 10. Standing Weight Shifts There will be a rest of 1 minute between each set of exercise. Progression of exercises with increase in intensity and resistance.
219283567|NCT06927505|OTHER|Unstable surface trunk training|"This group will receive 60-minute training session that consists of 40 minutes of unstable surfaces exercises and 20 minutes of routine physical therapy 3 days per week for a total of 12 weeks.~Hook-lying position: (1) Abdominal draw-in maneuver with ball under the buttocks.~(2) Abdominal muscles isometric contraction. (3) Bridging combining with abdominal draw-in maneuver. Each exercise will be performed with 5-8 repetitions. Sitting: (1) Seated balance (2) Weight shifting e.g. anterior, posterior, lateral (3) Pelvic tilts e.g. anterior and posterior tilt (4) Trunk flexion, extension and lateral flexion on both sides (5) trunk rotation on both sides (6) Reaching e.g. lateral, forward and upward reach (7) Marching while seated Each exercise will be performed with 5-8 repetitions."
219283568|NCT07077434|DRUG|BMS-986504|Specified dose on specified days
219283569|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
219283570|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
219283571|NCT06905275|BIOLOGICAL|3M-052-AF + Alum|Intramuscular (IM) injection
219283572|NCT06905275|BIOLOGICAL|UVAX-1107|IM injection
219283573|NCT06905275|BIOLOGICAL|UVAX-1197|IM injection
219283574|NCT06836739|DEVICE|Genital nerve stimulation|Genital nerve stimulation (GNS) will be administered via non-invasive surface skin electrodes. In men, two surface electrodes (1 cm diameter) will be placed on the dorsum of the penile shaft 2 cm apart. In women, one surface electrode will be placed near the clitoris and a second surface electrode will be placed on the labia majora or inner thigh. The electrodes will be connected to an electrical stimulator device.
219283575|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
219283576|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
219283577|NCT07089862|DRUG|Indobufen treatment|Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
219283578|NCT07089862|DRUG|Aspirin treatment|Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
219283579|NCT06902883|DEVICE|Serum holder connected to the wheelchair|Serum holder connected to the wheelchair
219283580|NCT06902883|DEVICE|wheelchair seat|wheelchair seat
219283581|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
219283582|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
219283583|NCT07090876|DIETARY_SUPPLEMENT|Standardized Grape Seed Extract|Grape seed dry extract standardized to provide: ≥95.0% of proanthocyanidins by spectrophotometry, ≥5.0% ≤15.0% of catechin and epicatechin by High-Performance Liquid Chromatography (HPLC)
219283584|NCT07090876|OTHER|Placebo|Placebo
219283585|NCT06908447|BEHAVIORAL|Cold-water immersion|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 10-16°C on the experimental day
219283586|NCT06908447|BEHAVIORAL|Warm-water immersion (Control)|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 30-36°C on the experimental day
219283587|NCT06907524|BEHAVIORAL|Longitudinal, Individualized Health Coaching|During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.
219283588|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
219283589|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
219283590|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
219283591|NCT07103512|OTHER|Scalene Hold Relax Technique|Scalene Hold Relax Technique Scalene Hold for 10 Second 10 Repetition. Hold your arms behind your back to keep them from rising then slowly tilt your head trying to touch your ear to your shoulder. Bend your neck only as far as it is comfortable, and hold for 5 to 10 seconds. Relax your neck and repeat 2-3 times on each side. The treatment will be provided for 1-4 weeks as per need
219283592|NCT07103512|OTHER|Conventional Physical Therapy|"Diaphragmatic Breathing Exercise Inhale through nose about 4 Seconds, hold Breath for 2 Seconds, repeat 5 times, exercise repeated for 2-3 days per week followed up to 4 weeks.~\+ Buteyko Breathing Exercise Exhale slowly and then hold that breath. Use index figure and thumb to plug nose hold that breath until there is an urge to breathe and then inhale Breathe normally at least 10 second repeat several. Frequency 2-3 days per week with Moderate Intensity follow-up to 4weeks"
219283593|NCT05590949|OTHER|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
219283594|NCT05590949|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
219283595|NCT05590949|DIAGNOSTIC_TEST|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
219283596|NCT07118527|DRUG|SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection|SHR-A1811: intravenous infusion; Adebrelimab Injection: intravenous infusion; Capecitabine Tablets: oral administration Fluorouracil Injection: intravenous infusion
219283597|NCT07118527|DRUG|Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)|Trastuzumab : intravenous infusion; Pembrolizumab: intravenous infusion; Capecitabine Tablets: oral administration; Oxaliplatin: intravenous infusion; Fluorouracil Injection: intravenous infusion; Cisplatin: intravenous infusion;
219283598|NCT00371098|BIOLOGICAL|Influenza vaccination: Influvac (SolvayPharma)|
219283599|NCT00371098|BIOLOGICAL|placebo influenza vaccine|
219283600|NCT07126795|DRUG|magnesium sulfate|IV Magnesium Sulfate 50 mg/kg (max 2 grams) over 20 minutes given immediately prior to initiation of daily sedated dressing change
219283601|NCT07126795|DRUG|Normal Saline (0.9% NaCl)|Normal Saline given in equivalent volume as study drug over 20 minutes, immediately prior to initiation of sedated dressing change
219283602|NCT07127536|BEHAVIORAL|CO-OP (Cognitive Orientation to daily Occupational Performance)|"The CO-OP approach is a client-centered, performance-based intervention that uses cognitive strategies to help individuals improve performance in meaningful daily activities. In this study, CO-OP sessions will be delivered in addition to standard occupational therapy, 5 days per week for 4 weeks, with each session lasting 45 minutes. The intervention group will receive standard occupational therapy intervention in addition to CO-OP.~Standard Occupational Therapy Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site."
219283603|NCT07127536|BEHAVIORAL|Standard Occupational Therapy|Participants in this group will receive standard occupational therapy only, without the additional CO-OP intervention. Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site.
219283604|NCT07129772|DRUG|Gemcitabine (GEM)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
219283605|NCT07129772|DRUG|Cisplatin|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
219283606|NCT07129772|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
219283607|NCT07126327|DEVICE|Peristeen Light - trans anal irrigation system|Subjects naive to TAI will use Peristeen Light trans anal irrigation
219283608|NCT07129460|DRUG|Berberine hydrochloride|Subjects will be instructed to take three tablets (300mg) of Berberine hydrochloride two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
219283609|NCT07129460|DRUG|Placebo|Subjects will be instructed to take three tablets (300mg) of placebo two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
219283610|NCT07137390|DRUG|Regorafenib|Given Orally
219283611|NCT07137390|DRUG|Lorigerlimab|Given Orally
219296397|NCT05578274|RADIATION|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
219283612|NCT07137221|OTHER|Post menopausal breast cancer patients|"All selected patients will undergo peripheral blood samplingfor the evaluation of inflammatory biomarkers and must have agreed to store and use part of their sample for research purposes.~A panel of inflammatory cytokines (IFNγ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, TNFα) will be detected by ELISA assay. Other biomarkers such as RANKL, OPG, Vitamin D levels, CTX, PTH will be evaluated by immunoenzymatic assays. In addition, mirNAs as mir-16 and mir-378 will be evaluated by RT-PCR. Glucose metabolic markers such as fasting glucose and insulin, HbA1c and other parameters such as calcemia, PTH, c-telopeptide etc. will be collected.~In particular, the evaluation of the biomarkers will be done on plasma samples at different time points (previously the administration of 10 course of weekly acupuncture; at the end and 6 months after the end of acupuncture and at the time of symptoms recurrence."
219283613|NCT07139925|OTHER|Self-care of COPD Inventory (SC-COPDI)|Self-care of COPD Inventory (SC-COPDI) - Assess the self-care of patients with IPF by adapting a tool designed for patients with COPD to those affected by IPF
219283614|NCT06927492|OTHER|Cognitive Sensorimotor training along with whole body vibration|This group will receive sensorimotor training with cognitive dual-task training in addition to whole body vibration. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes, The whole-body vibration will be administered using a vibration machine. This includes asking the patient to stand barefoot on the vibrator platform evenly distributing their body weight on both feet with knees bent at 20 degrees as flexing of knees is a common postural adaptation used to minimize transmission of vibration to the head. The patients will receive the whole body vibration at 30Hz consisting of three sessions per week with at least one day between sessions for 12 weeks. The time for each session will be 15 minutes (five bouts of 2 min) . There will be a rest of 1 minute between each bout of vibration therapy.
219283615|NCT06927492|OTHER|Cognitive Sensorimotor training|This group will receive sensorimotor training with cognitive dual task training simultaneously. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes,
219283616|NCT06929598|BEHAVIORAL|Shiatsu Therapy|Participants will receive one 30-minute session of Shiatsu therapy per week for 6 weeks. Therapy will be provided by trained Shiatsu practitioners under a standardized protocol developed for this study.
219283617|NCT06935084|OTHER|ASTHMAXcel Voice platform|ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.
219283618|NCT07136324|DEVICE|EUS-guided RFA treatment|A 19-gauge EUS-RFA catheter will be inserted into pancreatic lesions under EUS guidance. RFA energy is then applied in 2-10 cycles with each cycle lasting about 10-30 seconds and the power setting ranging from 10-30 Watts.
219283619|NCT07137858|DRUG|Preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adalimumab 1200mg are administered intravenously. According to the allocation to the short-course group or long-course group, two or three cycles are carried out respectively, and surgery is performed 21 days after the end of the last cycle of medication. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive maintenance therapy with PD-L1 inhibitor (adalimumab) alone. Patients who require radiotherapy and chemotherapy receive maintenance therapy with the drug alone at the same time. The duration of medication for all patients is one year (calculated from the time of the first medication at the initial diagnosis to the last medication after the surgery).
219283620|NCT07137858|DRUG|Two courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously. Two treatment courses were carried out in total, and surgery was performed 21 days after the end of the second course of medication. Postoperative radiotherapy and chemotherapy were administered based on the pathological stage. Patients who did not require radiotherapy received adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who required radiotherapy and chemotherapy received monotherapy maintenance during the same period. The duration of medication for all patients was one year (from the first medication time at the initial diagnosis to the last medication time after surgery).
219283621|NCT07137858|DRUG|Three courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg are administered intravenously. This treatment is carried out for a total of three cycles, and surgery is performed 21 days after the end of the third cycle. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who require radiotherapy and chemotherapy receive monotherapy maintenance simultaneously. The duration of medication for all patients is one year (from the first administration after diagnosis to the last administration after surgery).
219283622|NCT07136896|OTHER|Nutritional Assessment Protocol|Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements (weight, height, BMI, skinfold thickness), dietary intake evaluation through 24-hour recall, and bioelectrical impedance analysis to assess body composition. Relevant biochemical parameters will also be measured to evaluate nutritional status
219283623|NCT07137962|PROCEDURE|PENG Block|"The curvilinear low-frequency (2-5 MHz) ultrasound probe was placed over the line parallel to the inguinal ligament. It was subsequently rotated 45° to identify the anterior inferior iliac spine, the ilio-pubic eminence, and the psoas tendon.~A 22-gauge echogenic needle was inserted in plain to place the tip in musculo-fascial plain between pubic ramus posteriorly and psoas tendon anteriorly, using hydro-dissection technique. Following negative aspiration, a total volume of 0.5 ml/kg of 0.25% bupivacaine was injected."
219283624|NCT07137962|PROCEDURE|FICB Block|"The linear ultrasound probe was placed over the inguinal ligament in the sagittal plane, inferomedial to the anterior superior iliac spine. Upon identifying the bow-tie sign formed by the sartorius muscle and the internal oblique muscle by sliding medially and rotating the probe. 22-gauge echogenic needle was introduced 1 cm cephalad to the inguinal ligament to place the needle tip in the space between the internal oblique and iliacus muscles, using the hydro-dissection technique. A total volume of 0.5 mL/kg of bupivacaine 0.25% was injected following negative aspiration."
219283625|NCT07137962|PROCEDURE|Caudal Block|"After induction of general anesthesia, the patient was placed in the left lateral position with the upper hip flexed at 90° and the lower hip flexed at 45°. The region was then swabbed in a craniocaudal direction with a 70% alcohol solution.~After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture was performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, a needle was inserted immediately below the spinous process S4. After perforating the membrane, which occludes the sacral hiatus, the needle was advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection. Bupivacaine 0.25% at a dose of 1 ml/kg was injected."
219283626|NCT07138014|DRUG|FHND1002 100mg|Investigational oral granules containing 100mg FHND1002 (chemical entity: 3-n-butylphthalide derivative). Administered once daily for 48 weeks. Granules are packaged in unit-dose sachets with identical appearance across all study arms. Participants dissolve contents in water prior to ingestion. Stability testing confirms compatibility with fasting or fed conditions.
219283627|NCT07138014|DRUG|FHND1002 200mg|Investigational oral granules containing 200mg FHND1002 (3-n-butylphthalide derivative). Delivered as two 100mg sachets or one 200mg sachet to maintain blinding. Daily dosing regimen for 48 weeks. Granule composition matches 100mg formulation in excipients and organoleptic properties.
219283628|NCT07138014|DRUG|Placebo|Placebo granules identical to active intervention in appearance, taste, packaging, and administration method. Contains inert excipients (microcrystalline cellulose, lactose monohydrate) without active
219283629|NCT07137416|PROCEDURE|Biopsy Procedure|Undergo biopsy
219283630|NCT07137416|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219283631|NCT07137416|PROCEDURE|Echocardiography Test|Undergo ECHO
219283632|NCT07137416|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219283633|NCT07137416|DRUG|Pidnarulex|Given IV
219283634|NCT07137416|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
219283635|NCT07137416|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219283636|NCT07139327|DEVICE|Cochlear Implant|TICI G2 Clinical Investigation System
219283637|NCT07135245|DRUG|Semaglutide (Rybelsus®) combined with other interventions|The full intervention includes treatment with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®)
219283638|NCT07135245|OTHER|Placebo|A control group treated with placebo and no further intervention
219283639|NCT07135245|DRUG|Semaglutide (Rybelsus®)|An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo
219283642|NCT06939023|PROCEDURE|Laparoscopic minimally invasive left-sided pancreatecomy|Laparoscopic minimally invasive left-sided pancreatecomy
219283643|NCT06939023|PROCEDURE|Robot-assisted minimally invasive left-sided pancreatecomy|Robot-assisted minimally invasive left-sided pancreatecomy
219283644|NCT06938438|PROCEDURE|single locking miniplate|Ten patients in whom anterior mandibular fractures will be fixed with titanium single locking miniplate
219283645|NCT06938438|PROCEDURE|double conventional miniplates.|Ten patients in whom, anterior mandibular fractures will be fixed with double conventional titanium miniplates.
219296398|NCT05578274|RADIATION|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
219296399|NCT02979405|DRUG|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
219296400|NCT04153838|OTHER|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
219283646|NCT06939933|OTHER|aquatic exercise in addition to physical exercise|"Aquatic exercise refers to the use of water that facilitates the application of established therapeutic interventions, including stretching, strengthening, joint mobilization, balance and gait training and endurance training. Water has been throughout history for a variety of purposes including ; physical therapy, rehabilitation and sport. There activities are made possible by water's special qualities and the influence of these attributes on humans.~Hydrotherapy is one of the most popular forms of complementary therapies that help in the treatment of children with disabilities. It is known to provide an opportunity to the children to do easier exercise. It also improves .~Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life."
219283647|NCT06939933|GENETIC|designed physical exercises only|"Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life (Ballas et al., 2010).~benefit from anaerobic activity patterns (Dougherty et al., 2018). A study to examine maximal muscle strength and peak power in children with sickle cell anemia found that maximal muscle strength and peak power are significantly less in children with sickle cell anemia compared to the control group"
219283648|NCT07143006|DEVICE|BestShape Go Intelligent Generation Transformable Electric Vehicle|The specific applications of artificial intelligence in intelligent electric vehicles mainly include gait monitoring and analysis, real-time feedback and guidance, autonomous adaptive assistance, safety prevention and warnings, data collection and long-term tracking, as well as adding interactive and entertainment elements.
219283649|NCT07144696|BEHAVIORAL|structured education and regular follow-up|Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\&amp;#39;s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting
219283650|NCT07137481|DRUG|C9/CD5CAR/IL-15 NK cells|Given PO or IV
219283651|NCT07137481|DRUG|Rituximab|Given by IV
219283652|NCT07137481|DRUG|Fludarabine|Given by IV
219283653|NCT07137481|DRUG|Cyclophosphamide|Given by IV
219283654|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Weekly Feedback|A dual-axis management system categorizing participants into a 3x3 grid based on aerobic capacity (12-min run test) and total exercise volume (smart-device tracked). Includes weekly personalized feedback, tiered exercise prescriptions, and goal recalibration. Arm 1 receives updates every 7 days.
219283655|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Monthly Feedback|"Identical grid framework as Arm 1 (aerobic capacity + exercise volume assessment), but with monthly (30-day) feedback cycles. Participants receive delayed optimization strategies and tier adjustments once per calendar month, simulating conventional health programs."
219283656|NCT07135258|DRUG|Ivabradine + Usual Care|For patients in the ivabradine arm targeting for strict rate control, ivabradine is started at 5mg BID, and titrated at follow-up visits if needed, up to 7.5mg BID to aim at the target heart rate \<80bpm. Uptitration of other existing or additional conventional rate control agents will considered after maximally tolerated dose of ivabradine. Conversely, if not tolerated, or if resting heart rate is persistently \<50bpm, ivabradine will be reduced to 2.5mg BID, followed by reassessment.
219283657|NCT07135258|DRUG|Placebo + usual care|For patients in the lenient rate control arm, medications will be adjusted, bidirectionally as appropriate, with a maximum heart rate that is tolerable by patient which is at \<110bpm. Routine heart rate control agents included betablockers, nondihydropyridine calcium channel blockers, or digoxin. All patients will be prescribed a matching placebo (morphologically identical to the comparison arm: ivabradine) that contains pharmacologically inactive cellulose.
219283658|NCT02533024|OTHER|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
219283659|NCT05323123|DRUG|Pre-Exposure Prophylaxis (PrEP)|FDA-approved oral medication to reduce the risk of HIV infection
219283660|NCT05323123|BEHAVIORAL|SPARK|SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).
219283661|NCT05323123|BEHAVIORAL|HealthMpowerment|PrEP adherence support app that utilizes engaging social networking and game-based elements, with an in-app portal for individualized live adherence counseling.
219283662|NCT07145164|DRUG|N-803|This is the active drug.
219283663|NCT07145164|DRUG|Saline placebo|This is the placebo.
219283664|NCT07146490|BEHAVIORAL|Low Exercise|Low-Intensity Continuous Training (LICT): Participants ran continuously for 24 minutes at 50-60% of their MAS without breaks.
219283665|NCT07146490|BEHAVIORAL|Long Interval Exercise|Long-interval high-Intensity Interval Training (LI-HIIT): Participants ran at a speed corresponding to 80-90% of their MAS. The protocol consisted of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants ran at 50% of their MAS. This pattern totaled 24 minutes of exercise.
219283666|NCT07146490|BEHAVIORAL|Short Intevral Exercise|Short-interval high-Intensity Interval Training (SI-HIIT): Participants ran at 110-120% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets were completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
219283667|NCT07146620|OTHER|Forearm massage|A general massage of the forearm will be performed. The physical therapist perform deep, longitudinal strokes. Pressure will be maintained at a level the patient finds comfortable for 3 minutes.
219283668|NCT07146620|OTHER|Pressure release for forearm trigger points|Pressure will be applied to trigger points in the forearm. This will be done in three sets of 30-second applications, with 30 seconds of rest between each.
219283669|NCT07146620|OTHER|Mulligan mobilization with movement technique|A lateromedial glide will be performed. The technique will be applied for three sets of 10 repetitions, with 30 seconds of rest between each set.
219283670|NCT07146620|OTHER|Radial Nerve Neurodynamic Mobilization|Three sets of 30 nerve glides will be performed at a rhythm of one second of tension followed by one second of rest. There will be 30 seconds of rest between sets.
219283671|NCT07146620|OTHER|Diacutaneous fibrolysis (Real)|A real technique of Diacutaneous fibrolysis will be applied to the forearm region for 5 minutes.
219283672|NCT07146620|OTHER|Diacutaneous Fibrolysis (Sham)|A sham Diacutaneous Fibrolysis technique (skin pinch) will be applied to the forearm region for 5 minutes.
219283673|NCT07144072|DRUG|HeXell-2020|Cohort 1: 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 3 doses Cohort 2 : 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 6 doses
219283674|NCT07143474|DRUG|RhizomK|RhizomK 50 mg once daily
219283675|NCT07143474|OTHER|Plcebo|Placebo matching to RhizomK
219283676|NCT00466154|DRUG|Aspirin|
219283677|NCT06947447|DEVICE|No intervention|Device
219283678|NCT07137377|BEHAVIORAL|On line teaching CESARCOM teaching programe (immersive podcasts, digital flashcards)|"A short e-learning program (immersive podcasts, digital flashcards) will be carried out for the medical and paramedical staff of the cesarean section operating room, by a specialized team. It will will consist of :~* the presentation of the basic principles of therapeutic communication (listening, empathy, verbal, non-verbal, paraverbal language)~* the distribution of the HUG communication lexicon/wordbook .~* educational scenes illustrating the impact of therapeutic communication in the operating room (good versus bad words)."
219296401|NCT03831386|PROCEDURE|Vacuum-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
219296402|NCT03831386|PROCEDURE|Gravity-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
219283679|NCT06954441|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"The investigational product is V-IMMUNE®, a 5% human normal immunoglobulin I.P. (5 g/100 mL) manufactured from qualified human plasma for intravenous use. Each vial contains human immunoglobulin at 50 g/L, maltose at 100 g/L, and water for injection. The 5% Human Immunoglobulin Solution for Intravenous Administration (I.P.) is a sterile and pyrogen-free preparation of human normal immunoglobulin in a single-dose form for intravenous administration. Each 10 mL, 50 mL, or 100 mL vial contains 0.5 g, 2.5 g, or 5 g of human normal immunoglobulin, respectively, and is produced from qualified human plasma using membrane filtration and a combination of chromatographic steps and viral inactivation procedures. The IgA content does not exceed 2 mg/mL.~This manufacturing process uses plasma collected from donors who undergo screening according to guidelines set by regulatory authorities. Blood is tested for all mandatory infectious diseases."
219283680|NCT07141459|DEVICE|810 nm diode laser disinfection|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each. A 200 μm fiber optic tip (Lite medics, Italy) will be inserted 1 mm from the working length, activated and moved in slow helical motion from the apex to the cervical third with alternating between clockwise and counterclockwise direction at speed of about 2 mm/s
219283681|NCT07141459|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
219283682|NCT07143643|OTHER|Excape room game|"Application of Research:The escape room game scenario prepared by the researchers was designed according to the steps of the Nursing Process. The game consists of five stages, each conducted at different stations, and each stage includes various clues and activities. The stages were organized to cover the steps of the Nursing Process: Assessment, Nursing Diagnosis, Planning, Implementation, and Evaluation. Before starting the game, the students who will participate will be informed about the expected objectives, the game rules, and the duration. In addition, it will be stated that each group must select a group leader. The students will be given a total of 60 minutes to answer the questions in each stage, assemble puzzle pieces, unlock locked boxes, follow the clues, and find the exit key in order to leave the room. The students will be expected to complete the tasks at the stations prepared in accordance with the Nursing Process stages and to exit the room within the allotted time."
219283683|NCT07147192|DEVICE|AAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.
219283684|NCT07147192|DEVICE|BAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
219283685|NCT07147192|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.
219283686|NCT07136909|OTHER|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.
219283687|NCT07138053|OTHER|OFA group|OFA group Premedication with Midazolame and Paracetamol 30 minutes before surgery on ward, Dexamethasona and infusion of Dexmedetomidin and 2% Lidocaine 10 min before intubation( 50mcg Dexmedetomidin and 500mg 2% Lidocaine add up to 50ml normal saline) 1ml/10kg in 10 min after intubation 1ml/10kg/h discontinued after last surgical sutures. TAP bloc ultrasound guided performed after intubation. Ketamine given 60 sec before incision in doses 0.5 mg/kg, and after if it is necessary according to ER and qNOX. Provided value range between 40-60 during surgery.
219283688|NCT07137910|DRUG|AHB-137|AHB-137 will be injected
219283689|NCT06748729|DEVICE|Navii Knee|Microprocessor controlled prosthetic knee (MPK)
219283690|NCT07155629|DRUG|mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine|The benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.
219283691|NCT07155694|DRUG|Finerenone 10 MG|Take Finerenone 10 mg orally daily
219283692|NCT07155694|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
219283693|NCT07155850|DEVICE|Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas|YntraDose™ is a locoregional therapy device used for percutaneous radio-ablation of solid tumours
219283694|NCT07155902|OTHER|The community-to-facility integrated strategy|The community-to-facility integrated strategy will focus on a joined-up T2D care delivery across the primary, secondary, and healthcare facilities, and urban communities.
219283695|NCT07154212|DIAGNOSTIC_TEST|Hepatitis B virus infection|anti-hepatitis B virus core antigen positive serologic status
219283696|NCT07153757|DRUG|Endocrine Therapy of Physician's Choice|This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.
219283697|NCT07155603|BEHAVIORAL|Animated Video Group 1|The animated video intervention provides a clear and engaging multimedia explanation of the colonoscopy procedure in multiple languages. It includes visual aids to help explain the process, preparation instructions, risks, and expected outcomes, aiming to improve patient comprehension and adherence.
219283698|NCT07155837|DEVICE|TENS group|The intervention group received TENS twice a day.
219283699|NCT07153523|OTHER|High intensity interval training|High intensity interval training provides time efficient benefits for strength and endurance training. It comprises of high burst training with rest periods. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
219283700|NCT07153523|OTHER|Routine physical therapy|For control group routine physical therapy will be applied for strength training using weights and running drills for endurance training. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
219283701|NCT07155941|BEHAVIORAL|Training of reward processing/sensitivity|"Participants in the experimental group complete a two-week ecological momentary intervention (EMI) consisting of three brief training units per day, each delivered via a smartphone. The exercises target different aspects of reward processing and are scheduled at specific times throughout the day.~The morning unit (to be completed between 10:00 and 12:00 a.m.) involves a positive mental imagery task guided by audio recording. Participants are guided to vividly imagine a future situation with the most pleasurable and meaningful outcome possible. They are encouraged to mentally activate all senses, thoughts, and emotions associated with this scenario.~The afternoon unit (to be completed between 3:00 and 5:00 p.m.) consists of a savoring exercise guided by audio recording. Participants recall a positive experience from the past and are instructed to re-experience and savor it mentally by focusing on its sensory details, emotional quality, and personal significance.~The evening unit (to be"
219283702|NCT07155941|BEHAVIORAL|Relaxation Training (PMR)|"Participants in the control group complete a two-week progressive muscle relaxation (PMR) program designed to match the reward training in both frequency and duration. The intervention consists of three daily units, each delivered via a smartphone app and guided by audio recordings.~The first and second units of each day consist of short audio-guided PMR sessions (approximately 5 minutes each). These exercises systematically guide participants through alternating tension and relaxation of different muscle groups to promote physical and mental relaxation.~The third unit of the day focuses on reflection. Participants are asked to evaluate their experiences with the relaxation exercises over the course of the day. They reflect on their ability to engage with the exercises, the perceived effects (e.g., feelings of relaxation), any difficulties they encountered, and strategies to enhance the effectiveness of relaxation in their daily life beyond the intervention."
219283703|NCT07155941|OTHER|Psychoeducation|All participants receive a psychoeducation session on the day before the respective intervention starts. In this session, a graduate-level study team member introduces the rationale behind the training (PMR or reward-training), and demonstrates each exercise. Participants also practice each task.
219283704|NCT07154563|DIAGNOSTIC_TEST|NIR-II probe (i.e ICG-CK) incubation solution|After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.
219283705|NCT07153809|PROCEDURE|FMT|FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days.
219283706|NCT07153809|PROCEDURE|Placebo|Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.
219283707|NCT07154043|PROCEDURE|Complete Decongestive Therapy (CDT)|Manual lymph drainage, multilayer bandaging, skin care, and exercise. 75 minutes per session, 5 sessions per week, for 3 weeks.
219283708|NCT07154043|PROCEDURE|CDT + Intermittent Pneumatic Compression (IPC)|Complete decongestive therapy program including manual lymph drainage, multilayer bandaging, skin care, and exercise, plus intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 115 minutes per session, 5 sessions per week, for 3 weeks.
219283709|NCT07154043|PROCEDURE|CDT without Manual Lymph Drainage plus Intermittent Pneumatic Compression|Complete decongestive therapy consisting of multilayer bandaging, skin care, and exercise, with manual lymph drainage replaced by intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 75 minutes per session, 5 sessions per week, for 3 weeks.
219283710|NCT07154095|DRUG|Sustained-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
219283711|NCT07154095|DRUG|Immediate-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
219283712|NCT07153549|DIETARY_SUPPLEMENT|Biolizin|Oral zinc-containing syrup taken per age-based dosing specified in the protocol, once or twice daily for 42 consecutive days. Product is dispensed at baseline (with refill if needed); batch and expiry are recorded. Caregivers receive instructions for use and complete dosing diaries; adherence is checked by diary review and returned bottle counts. Concomitant zinc products or pharmacologic appetite stimulants are not allowed. Safety is monitored through adverse event review and routine laboratory tests at baseline and Day 42.
219283713|NCT07153549|BEHAVIORAL|Standardized caregiver counseling on responsive feeding|Structured counseling delivered to caregivers at each clinic visit (Day 0, Day 7, Day 21, Day 42). Content includes mealtime routines, recognizing hunger/satiety cues, age-appropriate portions and textures, repeated exposure to diverse foods, and strategies to manage refusal or prolonged meals. A brief checklist guides delivery to ensure consistency across visits. No dietary supplement is provided in this intervention.
219283714|NCT07156110|PROCEDURE|Traditional prosthetic procedure|Three months later, after an impression, haling abutment will be removed and a screw-retained restoration will be seated using a Ti-Base abutment.
219283715|NCT07156110|PROCEDURE|one abutment-one time|Three months later, after an impression, a screw-retained restoration will be seated directly on the connect healing
219283716|NCT07154277|PROCEDURE|Small bite closure|Small bite suturing is small tissue bite of 0.5cm depth x 0.5cm travel x 0.5cm apart, on the aponeurosis away from midline using Prolene 2/0
219283717|NCT07154277|PROCEDURE|Large bite closure|Large bite closure is defined as tissue bite of 1cm depth x 1 cm travel x 1cm apart, on the aponeurosis away from midline using Prolene 0
219283718|NCT07155772|PROCEDURE|Extracorporeal CardioPulmonary Resuscitation (eCPR)|The intervention of this study consists of moving the current eCPR program out of the hospital to reduce the time from collapse to ECMO flow (low-flow time).
219283719|NCT07156045|BIOLOGICAL|anti-PSMA CAR-NK|Targeting PSMA CAR-NK cells
219283720|NCT07153926|DIAGNOSTIC_TEST|Serum ferritin|Serum ferritin is a protein that stores iron, and high serum ferritin levels can suggest iron overload, but are also a common indicator of other conditions like inflammation, liver disease, or metabolic syndrome.
219283721|NCT07153926|DIAGNOSTIC_TEST|Serum hepcidin|"Hepcidin hormone has been found to be a key regulator of iron homeostasis. It controls plasma iron levels by regulating two key steps in iron metabolism, namely digestive iron absorption in enterocytes and iron recycling in macrophages.~Hepcidin is synthesized predominantly in the hepatocytes, which is physiologically increased by elevated serum iron level and decreased by erythropoietic activity. Recently, hepcidin has been used as a new marker for evaluation of liver fibrosis in patients with thalassemia major."
219283722|NCT07154667|PROCEDURE|Use of AuryzoN™ EAR 2.0 device|AuryzoN™ EAR 2.0 is an investigational non-significant risk device developed to improve cartilage construct shape and stability prior to use in ear reconstructive surgery.
219283723|NCT07154667|PROCEDURE|Hand carving|Standard hand carving using standard surgical blades will be performed in this intervention arm of the study.
219283724|NCT07155447|DIETARY_SUPPLEMENT|CEAA supplementation|(including calcium beta-hydroxy-beta- methylbutyrate monohydrate, L-Arginine, L-Glutamine and Ciltruline) Supplementation will be started within 72 hours of presentation and continued for a period of 28 days.
219283725|NCT07155447|OTHER|Placebo|a neutral powder containing the non- essential amino acid Alanine which will be indistinguishable from the CEAA supplement powder in in regards to packaging and supplement appearance.
219283726|NCT07154342|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
219283727|NCT07154342|BIOLOGICAL|Placebo|Placebo
219283728|NCT07155200|DRUG|Cirtuvivint|Cirtuvivint will be supplied by Biosplice.
219283729|NCT07155200|DRUG|Irinotecan|Irinotecan is commercially available.
219283730|NCT07155811|DIAGNOSTIC_TEST|test immunitaire fonctionnel automatisé VIDAS® STIMM™ T RUO|"The functional assessment of T lymphocytes is based on the use of the VIDAS® STIMM™ T RUO test, which will be performed on freshly collected whole blood in lithium heparin tubes without gel separators. Blood samples will be sent to the Immunology Laboratory at E. Herriot Hospital (Prof. Guillaume Monneret). T lymphocytes will be stimulated ex vivo for 3.5 hours (non-antigen-dependent stimulation by PHA) on the VIDAS®3 automated system (bioMérieux).~The automated system then performs a assay (immunofluorescence technique) to quantify the concentrations of IFN-γ in the supernatant of each sample. The entire process is automated, and results are obtained within 4 hours."
219283731|NCT05421741|DRUG|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
219283732|NCT05421741|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
219283733|NCT01562223|OTHER|motexafin gadolinium|
219283734|NCT06316310|OTHER|acupoint thread embedding|Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
219283735|NCT02548286|DRUG|Candesartan 8mg|PO, 1day or 22day
219283736|NCT02548286|DRUG|Amlodipine 5mg|PO, 1day or 22day
219283737|NCT02548286|DRUG|CKD-330 8/5mg|PO, 1day or 22day
219283738|NCT01099215|BIOLOGICAL|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
219283739|NCT02896075|OTHER|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
219283740|NCT02896075|OTHER|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
219283741|NCT03408405|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
219283742|NCT04358601|DEVICE|Triathlon PS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
219283743|NCT04358601|DEVICE|Triathlon PS Knee System with metal-backed modular components|Primary Total Knee Replacement
219283744|NCT03680339|PROCEDURE|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
219283745|NCT03680339|DRUG|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
219283746|NCT03680339|DRUG|Oxytocin|10 IU of oxytocin with fetal delivery
219283747|NCT00211068|DRUG|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
219283748|NCT00747227|DEVICE|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
219283749|NCT00747227|DEVICE|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
219283750|NCT01715662|DEVICE|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
219283751|NCT01715662|DEVICE|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
219283752|NCT06426212|DRUG|Use of teicoplanin three times a week|retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
219283753|NCT01612598|OTHER|counseling intervention|Undergo PCI
219283754|NCT01612598|PROCEDURE|quality-of-life assessment|Ancillary studies
219283755|NCT01612598|OTHER|questionnaire administration|Ancillary studies
219283756|NCT01612598|OTHER|educational intervention|Undergo PCI
219283757|NCT03554629|DEVICE|Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2|Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
219283758|NCT00523861|DIETARY_SUPPLEMENT|Moderate alcohol consumption|
219283759|NCT03311477|DRUG|ABBV-399|Intravenous infusion
219283760|NCT01695941|DRUG|Alisertib|Given PO
219283761|NCT01695941|DRUG|Bortezomib|Given SC
219283762|NCT01695941|OTHER|Laboratory Biomarker Analysis|Correlative studies
219283763|NCT01695941|BIOLOGICAL|Rituximab|Given IV
219283764|NCT04318106|DEVICE|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
219283765|NCT03304197|DIETARY_SUPPLEMENT|Hypotonic|N/A: see arm description
219283766|NCT03304197|DIETARY_SUPPLEMENT|Isotonic|N/A: see arm description
219283767|NCT03304197|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
219283768|NCT03304197|OTHER|Dehydrated|N/A: see arm description
219283769|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
219283770|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
219283771|NCT04223804|DRUG|ABBV-181|Intravenous (IV) Infusion
219283772|NCT04223804|DRUG|Placebo|Intravenous (IV) infusion
219283773|NCT05824598|BEHAVIORAL|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
219283774|NCT05701527|DRUG|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
219283775|NCT05701527|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
219283776|NCT01608126|PROCEDURE|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
219283777|NCT01692951|OTHER|serum sample|Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
219283778|NCT06043258|OTHER|Bond Apatite|composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
219283779|NCT06043258|OTHER|Bio-Oss|xenograft bone substitute
219283780|NCT02867215|OTHER|Barley bread|120g barley bread per day for 3 weeks.
219283781|NCT02867215|OTHER|Wheat bread|120g wheat bread per day for 3 weeks.
219283782|NCT01174576|OTHER|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
219283783|NCT01108926|DRUG|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
219283784|NCT01365936|DRUG|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
219283785|NCT01365936|DRUG|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
219283786|NCT06395025|DEVICE|Insoles|Insoles At Day 0, the patient received the insoles and adapted them to his shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled a usability's questionnaire at Day14.
219283787|NCT04616872|DRUG|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
219283788|NCT04616872|DRUG|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
219283789|NCT00237731|DRUG|morphine|morphine 0.05
219283790|NCT00237731|DRUG|morphine|morphine 0.10
219296403|NCT03171779|OTHER|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
219283791|NCT03789175|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
219283792|NCT04035902|DRUG|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
219283793|NCT04035902|DRUG|control|Ferric carboxymaltose is not administered
219283794|NCT00515671|BEHAVIORAL|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
219283795|NCT00515671|BEHAVIORAL|Problem Solving|Weekly problem-solving support group
219283796|NCT06479031|OTHER|Occupational Therapy|Occupational Therapy intervention, once a day, for 5 days, for 40 minutes each session.
219283797|NCT00678613|DRUG|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
219283798|NCT00678613|DRUG|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
219283799|NCT00814177|DRUG|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
219283800|NCT00814177|DRUG|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
219283801|NCT03955562|OTHER|Footbridge|Access to a pedestrian footbridge.
219283802|NCT03955562|OTHER|Comparison villages|Villages that do not receive a footbridge.
219283803|NCT03790553|RADIATION|Radiotherapy|Different total radiotherapy dose between two arms.
219283804|NCT04530097|PROCEDURE|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
219283805|NCT00288639|DRUG|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
219283806|NCT02894970|DEVICE|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
219283807|NCT02952534|DRUG|Rucaparib|Rucaparib will be administered daily
219283808|NCT02698943|PROCEDURE|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
219283809|NCT02779114|DRUG|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
219283810|NCT02779114|OTHER|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
219283811|NCT02779114|OTHER|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
219283812|NCT02686177|DRUG|Liraglutide|
219283813|NCT02686177|DRUG|Metformin or sulfonylurea|
219283814|NCT03245853|DRUG|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
219283815|NCT04284605|OTHER|Aerobic exercise combined with strength training|30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
219283816|NCT04284605|OTHER|Yoga|60 minute yoga intervention including different asanas, breath control and meditation
219283817|NCT03691272|DEVICE|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
219283818|NCT03691272|DEVICE|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
219283819|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
219283820|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Reference)|
219283821|NCT02385240|DRUG|Placebo gel|
219283822|NCT03341325|OTHER|animal-assisted activity|a live animal (small dog and/or rabbit)
219283823|NCT03341325|OTHER|control activity|a stuffed toy animal
219283824|NCT01014208|DRUG|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
219283825|NCT01014208|DRUG|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
219283826|NCT04651478|BEHAVIORAL|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
219283827|NCT04651478|BEHAVIORAL|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
219283828|NCT03730129|DRUG|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
219283829|NCT00133562|DRUG|Alanyl-glutamine|
219283830|NCT00133562|DRUG|Glycine|
219283831|NCT06274931|PROCEDURE|Bronchoscopy|Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
219283832|NCT04961177|OTHER|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
219296404|NCT05259592|BEHAVIORAL|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
219296405|NCT05444894|GENETIC|EDIT-301|Administered by intravenous infusion after myeloablative conditioning with busulfan.
219283833|NCT04961177|OTHER|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
219283834|NCT04961177|OTHER|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
219283835|NCT05474495|OTHER|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
219283836|NCT05474495|OTHER|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
219283837|NCT03081910|GENETIC|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
219283838|NCT03081910|GENETIC|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
219283839|NCT02795403|OTHER|blood draw of 150ml, twice|
219283840|NCT04165031|DRUG|LY3499446|Administered orally
219283841|NCT04165031|DRUG|Abemaciclib|Administered orally
219283842|NCT04165031|DRUG|Cetuximab|Administered IV
219283843|NCT04165031|DRUG|Erlotinib|Administered orally
219283844|NCT04165031|DRUG|Docetaxel|Administered IV
219283845|NCT02940600|DEVICE|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
219283846|NCT02940600|PROCEDURE|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
219283847|NCT01367288|DRUG|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
219178025|NCT06192316|BEHAVIORAL|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
219283848|NCT01367288|DRUG|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
219283849|NCT00113945|DRUG|Cinacalcet|
219283850|NCT04683068|BEHAVIORAL|Message comparison|Message comparison
219283851|NCT03691675|DEVICE|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
219283852|NCT00615875|DRUG|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
219283853|NCT00615875|DRUG|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
219283854|NCT00621075|OTHER|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
219283855|NCT03237572|DRUG|Pembrolizumab|Pembrolizumab (200 mg)
219283856|NCT03237572|DEVICE|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
219283857|NCT01956253|DRUG|Neratinib|240 mg orally once daily
219283858|NCT00225017|DRUG|Atazanavir|atazanavir 400 mg once daily
219283859|NCT00225017|DRUG|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs
219283860|NCT00140335|BEHAVIORAL|handwashing|
219283861|NCT04953598|DIAGNOSTIC_TEST|Ultrasonography|Patient undergoes diagnostic ultrasound examination
219283862|NCT04021979|DIETARY_SUPPLEMENT|Enteral Nutrition Powder Ensure|Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.
219283863|NCT04021979|DRUG|1.5L PEG|Low volume PEG
219283864|NCT04021979|OTHER|Self-controlled diet|Self-controlled low residue diet.
219283865|NCT04021979|DRUG|2L PEG|Normal volume of PEG
219283866|NCT00905385|BIOLOGICAL|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
219178026|NCT05417100|DRUG|Methadone|methadone 0.2 mg/kg IV.
219178027|NCT04719273|DRUG|Extended-release Onapristone|Given PO
219178028|NCT04719273|DRUG|Anastrozole|Given PO
219283867|NCT04279132|BEHAVIORAL|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
219296406|NCT06082947|DEVICE|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
219296407|NCT06423690|DEVICE|EAS1 System|tumor ablation system in IRE method
219283868|NCT01733173|PROCEDURE|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
219283869|NCT05344664|BIOLOGICAL|GPC3-CAR-T cells|The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10\^6 to 1×10\^8 CAR-T+/kg.
219283870|NCT02988050|DRUG|Remifentanil|Remifentanil used for conscious sedation.
219283871|NCT02988050|DRUG|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
219283872|NCT02988050|DRUG|Propofol|Used for conscious sedation.
219283873|NCT02988050|DRUG|Bupivacaine|Local anaesthetics
219283874|NCT02988050|DRUG|Lidocaine|Local anaesthetic
219283875|NCT02988050|DRUG|Epinephrine|With local anaesthetic for skin infiltration.
219283876|NCT00538148|DRUG|Telithromycin|
219283877|NCT03252717|BIOLOGICAL|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
219283878|NCT01502774|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
219283879|NCT01502774|DRUG|Placebo|One single intravenous bolus injection of Placebo
219283880|NCT01502774|PROCEDURE|Echocardiography|1 year after AMI
219283881|NCT01325753|PROCEDURE|cryotherapy|Undergo CT-guided CA
219283882|NCT01325753|PROCEDURE|quality-of-life assessment|Ancillary studies
219283883|NCT00894205|BEHAVIORAL|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
219283884|NCT03891771|DEVICE|Telemonitoring sensors|This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
219283885|NCT00124787|DRUG|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
219283886|NCT00124787|DRUG|Placebo|Placebo PO q 6 hours x 4 doses
219283887|NCT02295943|OTHER|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
219283888|NCT04274205|OTHER|Intervention group|Brief supportive psychotherapy
219283889|NCT02248818|DRUG|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
219283890|NCT02248818|DRUG|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
219283891|NCT00400998|DRUG|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~\- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
219283892|NCT00400998|OTHER|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
219283893|NCT02953405|DRUG|Clopidogrel|
219283894|NCT01825928|DRUG|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
219283895|NCT01825928|DRUG|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
219283896|NCT04993105|OTHER|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
219283897|NCT04993105|OTHER|exercise only|gastrocnemius and plantarstretching
219283898|NCT06003946|BEHAVIORAL|BreLax: Antenatal education class|An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.
219283899|NCT06003946|BEHAVIORAL|Standard care (control)|An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.
219283900|NCT00003253|DRUG|paclitaxel|
219283901|NCT00003253|OTHER|antitumor drug screening assay|
219283902|NCT06190964|OTHER|Integrative medicine|Acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) and/or mind-body medicine (for example, relaxation and breathing exercises)
219283903|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
219283904|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
219283905|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
219283906|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
219283907|NCT05996432|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants will undergo Magnetic Resonance Imaging
219283908|NCT05996432|PROCEDURE|Positron Emission Tomography (PET)|Participants will undergo Positron Emission Tomography
219283909|NCT05996432|DRUG|18F-fluoromisonidazole|Given by IV
219178029|NCT04719273|OTHER|Quality-of-Life Assessment|Ancillary studies
219178030|NCT04719273|OTHER|Questionnaire Administration|Ancillary studies
219178031|NCT04719273|DIAGNOSTIC_TEST|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
219178032|NCT04719273|DIAGNOSTIC_TEST|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
219178033|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
219178034|NCT05167409|DRUG|Evorpacept (ALX148)|IV QW
219178035|NCT05167409|DRUG|Cetuximab|IV QW
219178036|NCT05167409|DRUG|Pembrolizumab|IV Q3W
219178037|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
219178038|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
219178039|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
219178040|NCT03748524|DRUG|Influenza Vaccine|Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
219178041|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
219178042|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
219178043|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
219178044|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
219178045|NCT03158129|DRUG|Carboplatin|Given IV
219178046|NCT03158129|DRUG|Cisplatin|Given IV
219178047|NCT03158129|DRUG|Docetaxel|Given IV
219178048|NCT03158129|BIOLOGICAL|Ipilimumab|Given IV
219178049|NCT03158129|BIOLOGICAL|Nivolumab|Given IV
219178050|NCT03158129|DRUG|Pemetrexed|Given IV
219178051|NCT05435677|DRUG|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
219178052|NCT05435677|DRUG|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
219178053|NCT05435677|DRUG|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
219178054|NCT03267303|DRUG|TS-091 5mg|Orally taken once daily for 3 weeks
219178055|NCT03267303|DRUG|TS-091 10mg|Orally taken once daily for 3 weeks
219178056|NCT03267303|DRUG|Placebo|Orally taken once daily for 3 weeks
219178057|NCT05862454|DRUG|Magnesium|Magnesium injection therapy
219178058|NCT06257641|OTHER|High-intensity Mediterranean diet intervention|Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
219178059|NCT06642792|DRUG|AK129|Subjects receive AK129 intravenously.
219178060|NCT06642792|DRUG|AK117|Subjects receive AK117 intravenously.
219178061|NCT03321656|DRUG|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
219178062|NCT03321656|DRUG|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
219178063|NCT06521671|DEVICE|Dynaloc implant|Internal fixation with Dynaloc implant
219178064|NCT06521671|DEVICE|Cannulated cancellous screws|Internal fixation with two or three cannulated cancellous screws
219178065|NCT04779918|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
219178066|NCT05866211|OTHER|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
219178067|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
219178068|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
219178069|NCT04173559|BEHAVIORAL|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
219178070|NCT02206984|DRUG|Tamoxifen|
219178071|NCT02206984|DRUG|Anastrozole|
219178072|NCT02206984|DRUG|Fulvestrant|
219178073|NCT05519878|OTHER|Best Practice|Undergo routine treatment and usual follow up care
219178074|NCT05519878|DEVICE|Bright White Light Therapy|Undergo bright white therapy
219178075|NCT05519878|BEHAVIORAL|Occupational Therapy|Undergo occupational therapy
219178076|NCT05519878|OTHER|Questionnaire Administration|Complete questionnaires
219178077|NCT03292861|DRUG|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
219178078|NCT03292861|DRUG|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
219178079|NCT03292861|DRUG|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
219178080|NCT03292861|DRUG|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
219283910|NCT03972085|OTHER|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
219283911|NCT03972085|OTHER|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
219283912|NCT03896126|OTHER|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
219283913|NCT05777655|OTHER|Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)|Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
219283914|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
219283915|NCT05314686|OTHER|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
219283916|NCT05314686|OTHER|Telerehabilitation|"An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
219283917|NCT04912453|PROCEDURE|Primary anastomosis|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
219283918|NCT04912453|PROCEDURE|Enterostomy|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
219283919|NCT04287595|OTHER|Inhalation aromatherapy with orange essential oil|
219283920|NCT00569101|DRUG|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg \~0.02 mg/kg + prednisolone tapering
219283921|NCT06000345|OTHER|AOT + MI|During the AOT session, the patients were shown a video containing motor contents. In particular, the video demonstrated quadriceps concentric and isometric contractions, presented in the third person perspective. At the conclusion of each video, the patients were asked to spend 1 minute imagining what they had just seen.
219283922|NCT06000345|OTHER|Control AOT + MI|The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
219283923|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
219283924|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
219283925|NCT00703066|BIOLOGICAL|Rabies vaccine|3 doses of Rabies vaccine
219283926|NCT05683080|OTHER|Routine Clinical Care|Participants completing the research study will receive routine clinical care
219283927|NCT00369252|DRUG|Nimotuzumab (TheraCIM h-R3)|
219283928|NCT02662452|DRUG|GLPG2222 single dose|single ascending doses, oral suspension
219283929|NCT02662452|DRUG|Placebo single dose|single doses, oral suspension, matching placebo
219283930|NCT02662452|DRUG|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
219283931|NCT02662452|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
219283932|NCT03806881|DEVICE|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
219283933|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
219283934|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
219283935|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
219283936|NCT05520775|DRUG|Semaglutide|Semaglutide (subcutaneous)
219283937|NCT05520775|DRUG|Sham/placebo|Sham subcutaneous injection
219283938|NCT03213717|OTHER|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
219283939|NCT03213717|BEHAVIORAL|Standing|Study subjects will be standing for at least 50 minutes every hour
219283940|NCT03213717|DIETARY_SUPPLEMENT|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
219283941|NCT03213717|BEHAVIORAL|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
219283942|NCT03213717|OTHER|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
219283943|NCT06500468|DEVICE|PillSense System|"The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected."
219283944|NCT05906251|GENETIC|SRP-6004|Single IV infusion of SRP-6004
219283945|NCT06509373|BEHAVIORAL|Advance Care Planning Tool - ACPVoice|Eligible patients will be sent a secure MyChart message with a motivational message asking them to complete the advance care planning tool (ACPVoice) with their care partner/surrogate decision-maker or loved one before their upcoming primary care visit. The ACPVoice tool will be attached electronically to the mychart message. A reminder message will be sent to an non-responders with a different motivational message.
219283946|NCT06509373|BEHAVIORAL|Standard of Care for Advance Care Planning|Patients will have access to the standardized advance care planning questionnaires readily available already within their mychart account which is part of standard of care.
219283947|NCT06573801|DEVICE|Aktiia Bracelet|Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.
219283948|NCT06573801|DEVICE|Healthstats BPro Evo|Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.
219283949|NCT06573801|DEVICE|Spacelabs OnTrak Ambulatory Blood Pressure monitor|Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
219283950|NCT02013921|OTHER|Physical activity|
219283951|NCT00822653|DEVICE|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
219283952|NCT01283152|DRUG|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
219283953|NCT01283152|DRUG|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
219283954|NCT02961803|DRUG|MD1003 100 mg capsule|
219283955|NCT02961803|DRUG|Placebo|
219283956|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
219283957|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
219283958|NCT02441985|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
219283959|NCT02441985|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
219283960|NCT02441985|OTHER|Fullerton Advanced Balance (FAB) Scale|All participants will receive a clinical assessment of balance ability and fall risk.
219283961|NCT02441985|OTHER|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
219283962|NCT02441985|OTHER|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
219283963|NCT02441985|OTHER|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
219283964|NCT02441985|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition (CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
219283965|NCT05722353|OTHER|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
219283966|NCT06241547|DEVICE|electrical stimualtion via EmeTerm bracelet|We planned to exert electrical stimulation via the bracelet.
219283967|NCT06241547|DRUG|antimetic drugs（ dexamethasone，ondansetron）|Antimetic drugs (dexamethasone ondansetron) are used to prevent postoperative nausea and vomiting.
219283968|NCT05241314|BEHAVIORAL|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
219283969|NCT05241314|BEHAVIORAL|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
219283970|NCT03475654|BEHAVIORAL|Technology-assisted rehabilitation|The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
219283971|NCT03475654|BEHAVIORAL|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
219283972|NCT05889741|DRUG|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
219283973|NCT05889741|DRUG|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
219283974|NCT04020185|DRUG|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
219283975|NCT04020185|DRUG|Immune checkpoint inhibitor (ICI)|Administered according to product label
219283976|NCT04020185|DRUG|Immuno-oncology (IO) therapy|Administered according to product label
219283977|NCT02247453|OTHER|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
219283978|NCT06380296|OTHER|Primary molars pulpotomies with NeoMTA|Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
219283979|NCT06380296|OTHER|Primary molar pulpotomies with NeoPUTTY|Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
219283980|NCT01868932|OTHER|hypertonic saline|inhaled nebulized 3%NaCl
219283981|NCT01868932|OTHER|saline|inhaled nebulized 0.9% NaCl
219283982|NCT00330252|DRUG|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
219283983|NCT00330252|DRUG|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
219283984|NCT04414202|PROCEDURE|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
219283985|NCT04414202|RADIATION|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
219283986|NCT06075186|OTHER|A survey to assess anesthesiologists' secondary victim experience and quality of support resources.|cross-sectional descriptive questionnaire
219283987|NCT00618176|DRUG|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid
219283988|NCT00618176|DRUG|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
219283989|NCT00618176|DRUG|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
219283990|NCT06563999|DRUG|Sunvozertinib|300 mg orally once a day, 28 days as one cycle.
219283991|NCT06563999|DRUG|Crizotinib|300 mg orally once a day, 28 days as one cycle.
219283992|NCT06563999|DRUG|Pralsetinib|400 mg orally once a day, 28 days as one cycle.
219283993|NCT06563999|DRUG|Larotrectinib|100 mg orally twice daily, 28 days as one cycle.
219283994|NCT06563999|DRUG|Savolitinib|600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
219283995|NCT06563999|DRUG|Pyrotinib|400 mg orally once a day, 28 days as one cycle.
219283996|NCT06563999|DRUG|Dabrafenib+Trametinib|Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
219283997|NCT06563999|DRUG|Glecirasib|800 mg daily orally, 28 days as one cycle.
219283998|NCT06563999|DRUG|Ensartinib|225 mg daily orally, 28 days as one cycle.
219283999|NCT00717431|PROCEDURE|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
219284000|NCT05022901|COMBINATION_PRODUCT|Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)|Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
219284001|NCT03914001|DEVICE|mpMRI|all eligible patients will undergo mpMRI 4 weks after initial TURBT
219284002|NCT03914001|PROCEDURE|Second look TURBT|after mpMRI all patients will subjected to second look TURBT
219284003|NCT05829798|DEVICE|SYNOLIS VA 80/160|Single 4mL intra-articular injection of SYNOLIS VA 80/160
219284004|NCT05829798|DEVICE|SYNOLIS VA 40/80|Single 2mL intra-articular injection of SYNOLIS VA 40/80
219284005|NCT06569303|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
219284006|NCT06569303|BEHAVIORAL|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
219284007|NCT04586231|DRUG|Belzutifan|Immediate-release 40 mg tablet
219284008|NCT04586231|DRUG|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
219284009|NCT04586231|DRUG|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
219284010|NCT01012401|OTHER|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
219284011|NCT02811406|PROCEDURE|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
219284012|NCT02811406|BIOLOGICAL|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
219284013|NCT00527787|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
219284014|NCT00527787|DRUG|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
219284015|NCT02960737|DEVICE|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
219284016|NCT05017662|OTHER|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
219284017|NCT02209493|BEHAVIORAL|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
219284018|NCT02209493|BEHAVIORAL|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
219284019|NCT03237442|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
219284020|NCT03237442|BIOLOGICAL|placebo|Saline injection
219284021|NCT04825405|PROCEDURE|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
219284022|NCT04065399|DRUG|revumenib|revumenib orally
219284023|NCT04065399|DRUG|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
219284024|NCT06147349|PROCEDURE|Radical or partial nephrectomy|Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
219284025|NCT05087251|BEHAVIORAL|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
219284026|NCT05087251|BEHAVIORAL|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
219284027|NCT02075281|BIOLOGICAL|HM11260C|Glucagon-like peptide-1 analogue
219284028|NCT02075281|BIOLOGICAL|Placebo|
219284029|NCT05852665|DEVICE|Ultrasound-guided resection|Ultrasound-guided resection of buccal squamous cell carcinomas
219284030|NCT02562443|DRUG|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
219284031|NCT02562443|DRUG|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
219284032|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
219284033|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC).
219284034|NCT02847429|DRUG|Crenolanib|
219284035|NCT02847429|DRUG|Placebo|
219284036|NCT04406415|DRUG|Nafamostat Mesilate|Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days
219284037|NCT04406415|DRUG|Placebo|Oral placebo administered three times daily for up to 5 days
219284038|NCT03126669|DEVICE|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
219284039|NCT03126669|DEVICE|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
219284040|NCT06153342|DRUG|TL-925|TL-925 is an eye drop.
219284041|NCT06153342|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
219284042|NCT03570567|DEVICE|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
219284043|NCT03433677|DRUG|LY900014|Administered by CSII
219284044|NCT03433677|DRUG|Insulin lispro|Administered by CSII
219284045|NCT04609488|DIAGNOSTIC_TEST|Surfactant assessment|To determine surfactant levels in lung fluid
219284046|NCT01786226|DRUG|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
219284047|NCT01786226|DRUG|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
219284048|NCT06184126|DEVICE|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
219284049|NCT06184126|OTHER|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
219284050|NCT00003933|OTHER|laboratory biomarker analysis|
219284051|NCT03845231|BIOLOGICAL|Flucelvax(R)|Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
219284052|NCT03845231|OTHER|Human Challenge virus|A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
219284053|NCT00281060|PROCEDURE|primary stenting|
219284054|NCT00508053|PROCEDURE|Small stitches|
219284055|NCT00508053|PROCEDURE|Mass closure|
219284056|NCT00399464|DRUG|alfuzosin|
219284057|NCT00377442|DRUG|GK Activator (2)|100mg po
219284058|NCT00377442|DRUG|Simvastatin|80mg po
219284059|NCT05594381|DRUG|Sintilimab|"Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles)."
219284060|NCT03330405|DRUG|Avelumab Phase 1b|Avelumab
219284061|NCT03330405|DRUG|Talazoparib Phase 1b|Talazoparib
219284062|NCT03330405|DRUG|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
219284063|NCT03330405|DRUG|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
219284064|NCT06209853|DEVICE|PSMA PET/CT|Patients need no specific preparation. F-18 PSMA dose will be 3-4 MBq/kg and injected via IV route scan will be performed 90-120 min after injection
219284065|NCT05645341|DIAGNOSTIC_TEST|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
219284066|NCT04609202|BEHAVIORAL|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
219284067|NCT04609202|OTHER|Usual care|Usual care provided by doctors
219284068|NCT02754063|DEVICE|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
219284069|NCT02754063|OTHER|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
219284070|NCT03585010|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
219284071|NCT03585010|BEHAVIORAL|Parent Educational Support|12 sessions with parents
219284072|NCT03585010|BEHAVIORAL|Cognitive-Behavioral Therapy|12 sessions with child
219284073|NCT04137744|PROCEDURE|AXILLARY REVERSE MAPPING|subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
219284074|NCT05026762|OTHER|Treatment|Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
219284075|NCT00531219|PROCEDURE|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
219284076|NCT00531219|PROCEDURE|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
219284077|NCT01228331|DRUG|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
219284078|NCT01228331|DRUG|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
219284079|NCT01228331|DRUG|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
219284080|NCT01228331|DRUG|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
219284081|NCT01228331|DRUG|Daunorubicin hydrochloride|part of induction and reinduction therapy
219284082|NCT01228331|DRUG|Dexamethasone|part of reinduction therapy
219284083|NCT01228331|DRUG|Doxorubicin hydrochloride|part of reinduction therapy
219284084|NCT01228331|DRUG|Etoposide phosphate|part of different chemotherapy blocks
219284085|NCT01228331|DRUG|Mercaptopurine|part of different chemotherapy blocks
219284086|NCT01228331|DRUG|Methotrexate|part of different chemotherapy blocks
219284087|NCT01228331|DRUG|Methylprednisolone|part of different chemotherapy blocks
219284088|NCT01228331|DRUG|Pegaspargase|part of different chemotherapy blocks
219284089|NCT01228331|DRUG|Thioguanine|part of different chemotherapy blocks
219284090|NCT01228331|DRUG|Vincristine sulfate|part of intravenous chemotherapy
219284091|NCT01228331|RADIATION|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
219284092|NCT02643303|DRUG|Durvalumab|
219284093|NCT02643303|DRUG|Tremelimumab|
219284094|NCT02643303|DRUG|Poly-ICLC|
219284095|NCT06458270|BEHAVIORAL|Salt warning label|A salt warning label will feature on the restaurant menu next to menu items that are high in salt (\>3g, more than 50% of guideline daily amount \[GDA\] in the UK).
219284096|NCT06321601|DRUG|Avacopan|Oral administration
219284097|NCT00767390|DEVICE|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
219284098|NCT02783027|BEHAVIORAL|SleepTrackTXT2|Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
219284099|NCT05860582|DRUG|[14C]GB491|A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
219284100|NCT04744272|DEVICE|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
219284101|NCT04339959|OTHER|Remote Assessment of Physical Function with Direct Observation|An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
219296408|NCT03959826|BEHAVIORAL|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
219296409|NCT03959826|BEHAVIORAL|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
219284102|NCT04339959|OTHER|Remote Assessment of Physical Function|An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
219284103|NCT03241108|DRUG|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
219284104|NCT03241108|OTHER|Placebo|Placebo
219284105|NCT03189342|BEHAVIORAL|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
219284106|NCT03189342|BEHAVIORAL|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
219284107|NCT03189342|BEHAVIORAL|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
219284108|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
219284109|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
219284110|NCT03304678|DRUG|Sirolimus 2mg|Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.
219284111|NCT03786991|OTHER|No intervention|No intervention
219284112|NCT05755906|DRUG|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
219284113|NCT05755906|DRUG|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
219284114|NCT01499303|DRUG|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
219284115|NCT00006405|BEHAVIORAL|Exercise|
219284116|NCT00900224|GENETIC|DNA analysis|
219284117|NCT00900224|GENETIC|DNA methylation analysis|
219284118|NCT00900224|GENETIC|gene expression analysis|
219284119|NCT00900224|GENETIC|mutation analysis|
219284120|NCT00900224|GENETIC|polymerase chain reaction|
219284121|NCT00900224|GENETIC|reverse transcriptase-polymerase chain reaction|
219284122|NCT00900224|OTHER|high performance liquid chromatography|
219284123|NCT00900224|OTHER|laboratory biomarker analysis|
219284124|NCT00508313|PROCEDURE|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
219284125|NCT03389373|DEVICE|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
219284126|NCT03040934|DEVICE|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
219284127|NCT03040934|DEVICE|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
219284128|NCT03916796|OTHER|Exercise|-The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
219284129|NCT03916796|OTHER|Enhanced Recovery after surgery|-The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
219284130|NCT03916796|OTHER|Psychological screening with counselling services as needed|-The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
219284131|NCT03916796|OTHER|Dietary Counseling Services|-Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
219284132|NCT04685746|BEHAVIORAL|Balanced Growth Protocol|Assessment of the Balanced Growth Protocol, consisting of audiovestibular testing, motor and cognitive tasks
219284133|NCT01682772|DRUG|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
219284134|NCT06264128|DEVICE|TPAP|"TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase."
219284135|NCT06264128|DEVICE|CPAP|CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
219284136|NCT05336786|DRUG|Perflutren Lipid Microspheres|Given IV
219284137|NCT05336786|PROCEDURE|Ultrasound|Undergo ultrasound
219284138|NCT05302180|OTHER|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
219284139|NCT05302180|OTHER|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
219284140|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned hamstring autograft|After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.
219284141|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft|After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
219284142|NCT01485497|DEVICE|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
219284143|NCT02038712|DIETARY_SUPPLEMENT|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
219284144|NCT02038712|DIETARY_SUPPLEMENT|Fasted condition|Subjects will consume 600mL plain water.
219284145|NCT02038712|PROCEDURE|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
219284146|NCT02038712|BEHAVIORAL|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
219284147|NCT02038712|PROCEDURE|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
219284148|NCT04939701|DRUG|ASP0739|Intravenous (IV)
219284149|NCT06159699|OTHER|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
219284150|NCT06159699|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
219284151|NCT04579783|DRUG|Triamcinolone Acetonide|Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline
219284152|NCT04579783|DRUG|Dextrose 5% in water|Group B: 5mL 5% dextrose
219284153|NCT02383940|DRUG|Sotagliflozin|Sotagliflozin 400 mg, once daily before the first meal of the day
219284154|NCT02383940|DRUG|Placebo|Placebo, once daily before the first meal of the day
219284155|NCT00201708|DRUG|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
219284156|NCT00201708|DRUG|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
219284157|NCT00201708|DRUG|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
219284158|NCT05510427|DRUG|Infigratinib|Given by PO
219284159|NCT05510427|DRUG|Atezolizumab|Given by (IV) vein
219284160|NCT05510427|DRUG|Bevacizumab|Given by (IV) vein
219284161|NCT02308787|DEVICE|Spectra Optia Apheresis System|Platelet Depletion
219284162|NCT00040651|DRUG|Fludarabine|
219284163|NCT00040651|DRUG|Cyclophosphamide|
219284164|NCT00040651|DRUG|Thymoglobulin|
219284165|NCT00040651|PROCEDURE|Leukapheresis|
219284166|NCT00040651|PROCEDURE|Self bone marrow transplant|
219284167|NCT00445627|DRUG|Metformin|
219284168|NCT00445627|DRUG|Insulin|
219284169|NCT00445627|BEHAVIORAL|Nutrition counseling|
219284170|NCT00445627|BEHAVIORAL|Exercise counseling|
219284171|NCT04308590|DRUG|Relacorilant|Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
219284172|NCT04308590|OTHER|Placebo|Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
219284173|NCT05457751|PROCEDURE|Rocuronium injection pain|1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
219284174|NCT05364372|BEHAVIORAL|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
219284175|NCT05364372|BEHAVIORAL|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
219284176|NCT06013631|OTHER|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
219284177|NCT06013631|OTHER|Phantom Exercises|The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
219284178|NCT04903418|DEVICE|CBCT software|"* Retrospective Data Analysis will be performed after the CBCT images are pooled from the computer database.~* All the CBCT examinations will be obtained for patients who were scanned using CBCT Software (Planmeca Romexis® Viewer software).~* CBCT images will be analysed in different planes."
219284179|NCT06834594|DRUG|Micronized progesterone 200 MG|Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle
219284180|NCT06834594|DRUG|Micronized Progesterone 100 MG|Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
219284181|NCT05258396|OTHER|MRI without injection of contrast product|MRI without injection of contrast product
219284182|NCT05487586|DRUG|ceftazidime avibactam group|Non-Interventional Study
219284183|NCT02157389|OTHER|Administration of a pharmacological placebo|
219284184|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
219284185|NCT00565773|DRUG|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
219284186|NCT00565773|DRUG|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
219284187|NCT00565773|DRUG|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
219284188|NCT04798781|DRUG|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
219284189|NCT04798781|DRUG|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
219284190|NCT01601522|PROCEDURE|Peanut protein|500 mg
219284191|NCT01601522|PROCEDURE|Oat flour|500 mg Oat flour
219284192|NCT01601522|DRUG|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
219284193|NCT03214770|DRUG|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
219284194|NCT03214770|DRUG|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
219284195|NCT04555785|DRUG|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
219284196|NCT04555785|OTHER|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
219284197|NCT00702962|DRUG|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
219284198|NCT03120468|DRUG|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
219284199|NCT03120468|DRUG|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
219284200|NCT00210145|BEHAVIORAL|Aesthetic care|
219284201|NCT04064996|OTHER|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
219284202|NCT04064996|OTHER|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
219284203|NCT01741805|OTHER|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
219284204|NCT05735171|PROCEDURE|GTR surgery|Gross total resection of the enhancing tumor volume
219284205|NCT05735171|PROCEDURE|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
219284206|NCT04153422|DRUG|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
219284207|NCT04153422|DRUG|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
219284208|NCT03417544|DRUG|ATEZOLIZUMAB|(IV) every 3 weeks
219284209|NCT03417544|DRUG|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
219284210|NCT03417544|DRUG|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
219284211|NCT00919191|DRUG|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
219284212|NCT00919191|DRUG|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
219284213|NCT03808142|OTHER|myBETAapp|Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
219284214|NCT03808142|OTHER|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
219284215|NCT03808142|DRUG|Betaferon, BAY86-5046|Injection
219284216|NCT03808142|DEVICE|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
219284217|NCT02175641|BEHAVIORAL|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
219284218|NCT02175641|BEHAVIORAL|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
219284219|NCT04417842|DIAGNOSTIC_TEST|Respimetrix flow-volume monitoring device|The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
219284220|NCT00564746|DRUG|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"\[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed."
219284221|NCT02251769|DRUG|Tipranavir|
219284222|NCT02251769|DRUG|Ritonavir|
219284223|NCT02251769|DRUG|Clarithromycin|
219284224|NCT02251769|OTHER|High-Fat Test Meal|
219284225|NCT05049577|DEVICE|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
219284226|NCT05324670|OTHER|Didactic model for suicidal behavior in the framework of impulsivity and ideations|It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
219284227|NCT00056875|DRUG|recombinant human keratinocyte growth factor|
219284228|NCT00897793|PROCEDURE|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
219284229|NCT00897793|RADIATION|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
219284230|NCT02960698|OTHER|IRM and comportemental tasks|
219284231|NCT05481476|DRUG|Surufatinib|250mg, qd, po, 21 days for a cycle
219284232|NCT05481476|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
219284233|NCT05481476|DRUG|AG|nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
219284234|NCT03870360|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
219284235|NCT03870360|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
219284236|NCT03870360|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
219284237|NCT03870360|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
219284238|NCT03870360|BEHAVIORAL|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
219284239|NCT05964647|DRUG|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
219284240|NCT05964647|DRUG|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
219284241|NCT05964647|DRUG|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
219284242|NCT05964647|DRUG|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219284243|NCT05964647|DRUG|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
219284244|NCT06309290|OTHER|Prehabilitation with resistance-exercise training|The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
219284245|NCT06309290|OTHER|Usual care program|The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
219284246|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
219284247|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
219284248|NCT06435494|OTHER|Systematic use of patient reported outcome measures in clinical work with the patients|Se description of the arms
219284249|NCT01923467|BEHAVIORAL|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
219284250|NCT01923467|DRUG|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
219284251|NCT04721613|OTHER|Assessment of Melatonin level|Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
219284252|NCT03921723|DRUG|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
219284253|NCT03921723|DRUG|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
219284254|NCT03921723|DRUG|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
219284255|NCT02518035|DRUG|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
219284256|NCT03015129|DRUG|Durvalumab|
219284257|NCT03015129|DRUG|Tremelimumab|
219284258|NCT05917847|OTHER|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
219284259|NCT04090177|BEHAVIORAL|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
219284260|NCT03151070|OTHER|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants"
219284261|NCT00963612|PROCEDURE|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
219284262|NCT00967902|DEVICE|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
219284263|NCT00974194|PROCEDURE|Single Trocar CCK|CCK using Triport
219284264|NCT00974194|PROCEDURE|Standard CCK|CCK using three or four ports
219284265|NCT02145338|DRUG|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
219284266|NCT02145338|OTHER|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
219284267|NCT05781412|DEVICE|tDCS|Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
219284268|NCT03660644|BEHAVIORAL|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
219284269|NCT05805709|OTHER|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
219284270|NCT05805709|OTHER|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
219284271|NCT05805709|OTHER|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
219284272|NCT05805709|OTHER|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
219284273|NCT02242097|DRUG|ibrutinib|Given PO
219284274|NCT02242097|OTHER|laboratory biomarker analysis|Correlative studies
219284275|NCT05714124|PROCEDURE|Embolization|Endovascular treatment for patients with primary and secondary liver tumors
219284276|NCT04688697|PROCEDURE|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
219284277|NCT04688697|PROCEDURE|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
219284278|NCT01562041|DRUG|Ranolazine 500 mg|Ranolazine 500 mg, oral tablet, b.i.d.
219284279|NCT00188942|DRUG|Fluoxetine+Olanzapine|
219284280|NCT00188942|DRUG|Olanzapine|
219284281|NCT00188942|PROCEDURE|Functional Magnetic Resonance Imaging|
219284282|NCT00002477|DRUG|carboplatin|
219284283|NCT00002477|DRUG|cisplatin|
219284284|NCT00002477|DRUG|cyclophosphamide|
219284285|NCT00002477|DRUG|doxorubicin hydrochloride|
219284286|NCT04296266|DRUG|Alda-341|Dietary supplement d-limonene orally administered as a drug.
219284287|NCT02793271|BEHAVIORAL|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
219284288|NCT02793271|BEHAVIORAL|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
219284289|NCT06065982|OTHER|Questionnaires|Health-related quality of life will be measured using the 12-item Short Form (SF-12) and EQ5D-5L questionnaires. The SF-12 is summarized into two component scores, the Physical Component Score (PCS) and Mental Composite Score (MCS).
219284290|NCT04651790|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
219284291|NCT06135740|DEVICE|Fitbit wearing, with notification for sleep, activity and nutrition based fitbit data|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data, and Nutritional supplementation and Promotion of Exercise
219284292|NCT06135740|DEVICE|Routine care|Regular Care on sleep, activity and nutrition
219284293|NCT02184975|PROCEDURE|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
219284294|NCT02184975|PROCEDURE|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
219284295|NCT00064740|BEHAVIORAL|relaxation response|
219284296|NCT00770887|PROCEDURE|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
219284297|NCT00322075|DRUG|insulin glargine|
219284298|NCT04297631|DRUG|Tobramycin Powder|Everyone gets tobramycin powder.
219284299|NCT04297631|DEVICE|Vancomyscin|Everyone gets the vancomyscin powder.
219284300|NCT00002950|BIOLOGICAL|sargramostim|
219284301|NCT00002950|DRUG|topotecan hydrochloride|
219284302|NCT02702323|DRUG|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
219284303|NCT02702323|PROCEDURE|TACE|one times every 4-6 weeks.
219284304|NCT01575600|OTHER|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
219296410|NCT00133809|DRUG|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
219284305|NCT04193540|OTHER|ACE questionnaire|Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
219284306|NCT02574845|DRUG|Rosuvastatin|
219284307|NCT02574845|DRUG|Metformin HCl|
219284308|NCT02574845|DRUG|Furosemide|
219284309|NCT01538641|DRUG|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
219284310|NCT02374723|DEVICE|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
219284311|NCT02374723|DEVICE|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
219284312|NCT04246021|DRUG|Ferric carboxymaltose (FCM)|intravenous iron formulation
219284313|NCT00350038|DRUG|Irbesartan|
219284314|NCT00350038|DRUG|Ciprofibrate|
219284315|NCT04974762|PROCEDURE|Wound infiltration|Surgical wound infiltration by proceduralist
219284316|NCT04974762|PROCEDURE|Truncal blocks|Truncal blocks provided by anesthesiology team for device placement
219284317|NCT04412928|PROCEDURE|mid-urethral sling procedure|mid-urethral sling procedure
219284318|NCT03435692|PROCEDURE|Lumbar Plexus Catheter|lumbar plexus catheter placed intraoperatively for perioperative pain control
219284319|NCT03435692|PROCEDURE|Lumbar Epidural Catheter|lumbar epidural catheter placed intraoperatively for perioperative pain control
219284320|NCT03435692|PROCEDURE|Patient Controlled Analgesia|Patient Controlled Analgesia (PCA) was started post operatively for perioperative pain control
219284321|NCT03435692|DRUG|Fentanyl|Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and occurring more than 30 minutes after the block if applicable.
219284322|NCT03435692|DRUG|Morphine|In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
219284323|NCT03435692|DRUG|Lorazepam|Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
219284324|NCT03435692|DRUG|Ondansetron|Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
219284325|NCT03435692|DRUG|Diphenhydramine|Intravenous Diphenhydramine was administered as needed for itching postoperatively.
219284326|NCT03435692|DRUG|Acetaminophen|Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
219284327|NCT03435692|DRUG|Oxycodone|Oral Oxycodone was administered as needed for breakthrough pain post operatively.
219284328|NCT03435692|DRUG|Ropivacaine|Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
219284329|NCT03999801|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
219284330|NCT02687438|DEVICE|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
219284331|NCT02687438|OTHER|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
219284332|NCT04091061|DRUG|PF-06865571 100 mg|PF-06865571 in 100 mg oral tablet will be administered on Day 1
219284333|NCT01620918|PROCEDURE|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
219284334|NCT01620918|PROCEDURE|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
219284335|NCT00969826|DRUG|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
219284336|NCT04885985|DEVICE|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
219284337|NCT06010927|DRUG|ketamine/midazolam|premedication
219284338|NCT06010927|DRUG|Ketofol|Pre-extubation
219284339|NCT05590442|OTHER|Tests|Cognitive assessments and olfactory tests
219284340|NCT04694170|OTHER|additional therapy|Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
219284341|NCT04694170|OTHER|conventional physiotherapy|Using conventional physiotherapy only.
219284342|NCT06629181|OTHER|Education|"The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training"
219284343|NCT04712136|OTHER|MRI|MRI cardiac
219284344|NCT03045965|PROCEDURE|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
219284345|NCT02771379|DRUG|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
219284346|NCT05342805|PROCEDURE|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
219284347|NCT00667316|BEHAVIORAL|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
219284348|NCT00107939|DRUG|Licarbazepine|
219284349|NCT01853189|OTHER|OMT + Usual Care|patients from this group received 6 sessions of OMT
219284350|NCT01853189|OTHER|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
219284351|NCT03360448|DRUG|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
219284352|NCT03360448|DRUG|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
219284353|NCT00443170|DRUG|GSK626616, placebo, midazolam|
219284354|NCT00443170|DRUG|omeprazole, caffeine, flurbiprofen, rosiglitazone|
219284355|NCT01743391|PROCEDURE|Office-hysteroscopy with biopsy|
219284356|NCT06442475|PROCEDURE|Biospecimen Collection|Undergo blood, oral, and/or rectal sample collection
219284357|NCT06442475|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
219284358|NCT06442475|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219284359|NCT06442475|BIOLOGICAL|Mosunetuzumab|Given IV
219284360|NCT06442475|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219284361|NCT06442475|OTHER|Questionnaire Administration|Ancillary studies
219284362|NCT06383351|OTHER|Questionnaire|"Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire."
219284363|NCT03904862|DRUG|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
219284364|NCT04265144|BIOLOGICAL|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
219284365|NCT04265144|OTHER|Biopsy|Skin biopsies only for volunteers among patients
219284366|NCT04265144|OTHER|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
219284367|NCT04265144|OTHER|Biopsy|Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
219284368|NCT04557748|OTHER|Observational|"Treatment:~Up to five interactions: In-person visits at Baseline, 3 months, and 12 months after initial visit, and phone/online interaction at 6 months and 9 months after initial visit.~Each in-person follow up visit is expected to last up to 2 hours and each phone/online interaction is expected to last up to 1½ hours.~Answering questions about your general health and urinary symptoms - may be done remotely Physical exam Completing Self- Reported Measures questionnaires - may be done remotely Completing voiding/intake and food diaries, either online or on paper Weekly text message survey regarding symptom and treatment changes~Biosample collection:~At baseline: Up to 4 tablespoons of whole blood, dried blood spots, and urine At baseline: Whole blood will be collected with other biospecimens At 3 months: Up to 4 tablespoons of blood, dried blood spots and urine At 12 months: Dried blood spots"
219284369|NCT04557748|OTHER|Observational Controls|One in-person visit that is expected to last up to 2 hours Answering questions about your general health and urinary history Physical exam Completing Self- Reported Measures questionnaires Completing voiding/intake and food diaries, either online or on paper Biosample collection of up to 4 tablespoons of whole blood, dried blood spots, and urine
219284370|NCT04557748|OTHER|Central Sensitization|"One in-person visit expected to take up to 30 minutes, that include:~Segmental Mechanical Hyperalgesia - a hand-held device with a small flat rubber surface will be placed above the pubic bone and forearm, and will apply pressure. Participant will be asked about the intensity and unpleasantness that they experience.~Pinprick Temporal Summation - participant will receive tactile stimulation by a pointed skin probe (pinprick stimulator) being placed above the pubic bone and forearm. Participant will be asked to rate the sensation they are feeling.~Current treatment information including prior surgery or procedures, medication use, other current treatment/therapy used at the time of the visit.~Self-reported measures questionnaires"
219284371|NCT04557748|OTHER|Physical Activity and Sleep Tracker|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period starting at baseline prior to treatment and again at 3 months. During each 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
219284372|NCT04557748|OTHER|Physical Activity and Sleep Tracker Controls|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period at baseline prior to treatment. During the 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
219284373|NCT04557748|OTHER|Organ-Based|"One in-person visit involving:~Urethral vibratory sensation threshold Urethral Pressure Profilometry Cystometry Uroflowmetry Lidocaine Pre-Treatment Cystometry"
219284374|NCT04557748|OTHER|Qualitative Assessment of Patients with Urinary Urgency|"Participation will include two interviews with a research assistant over the phone and are expected to take up to 60 minutes for each interview. The first interview will be done within four weeks from enrollment, before the start of treatment. The interview will include questions about participant's urinary urgency, including symptoms experienced, the onset of symptoms and other factors that affect urgency.~Approximately three months after the start treatment the participant will be interviewed again. This interview will cover changes in symptoms and experience with treatment, such as side effects and satisfaction with treatment."
219284375|NCT06592508|OTHER|Remote Virtual Cardiology Program|Ventricle Health Program, which is a remote, virtual, cardiology program that provides heart failure education to patients, monitors for worsening heart failure, and rapidly titrates heart failure medical therapy.
219284376|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
219296411|NCT05145140|DRUG|Standardized Western Medicine Treatment|Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
219284377|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
219284378|NCT05062044|DRUG|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
219284379|NCT05062044|DIETARY_SUPPLEMENT|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
219284380|NCT05245591|DRUG|Pentosan Polysulfate Sodium 100 MG Oral Capsule|Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
219284381|NCT05245591|DRUG|Placebo|Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
219284382|NCT00998842|DEVICE|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
219284383|NCT00998842|DEVICE|GE 5000 ECG Monitor System|Wired ECG system
219284384|NCT06052358|DEVICE|LAAC with Watchman FLX device|LAAC with Watchman FLX device
219284385|NCT04259827|OTHER|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
219284386|NCT04259827|OTHER|Aspecific online games|Online gaming without cognitive training
219284387|NCT05795855|BEHAVIORAL|ADEPT|Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
219284388|NCT05764954|DEVICE|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
219284389|NCT02082171|OTHER|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
219284390|NCT05550662|DRUG|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
219284391|NCT06467175|BIOLOGICAL|blood sampling for high molecular weight DNA extraction|2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
219284392|NCT01712620|DRUG|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
219284393|NCT01712620|DRUG|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
219284394|NCT05486416|DRUG|HSK3486|HSK3486 for induction of general anesthesia
219284395|NCT05486416|DRUG|Propofol|Propofol for induction of general anesthesia
219284396|NCT06400225|PROCEDURE|Biopsy Procedure|Undergo biopsy
219284397|NCT06400225|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219284398|NCT06400225|PROCEDURE|Computed Tomography|Undergo CT scan
219284399|NCT06400225|PROCEDURE|Echocardiography Test|Undergo ECHO
219284400|NCT06400225|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219284401|NCT06400225|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
219284402|NCT06400225|DRUG|Ulixertinib|Given PO
219284403|NCT06500429|DRUG|NG101|NG101 20 mg BID
219284404|NCT06500429|DRUG|Placebo|Placebo BID
219284405|NCT06500429|DRUG|Semaglutide Injectable Product|Semaglutide 0.5 or 1 mg
219284406|NCT03993262|DRUG|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
219284407|NCT03993262|DRUG|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
219284408|NCT05572021|DEVICE|Propspective VHR with Fortiva|Ventral hernia repair using Fortiva biologic mesh
219284409|NCT05572021|DEVICE|RetroSpective VHR with Strattice|Retrospective cohort of ventral hernia repair patients using Strattice mesh
219284410|NCT01946529|DRUG|vincristine|Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
219284411|NCT01946529|DRUG|doxorubicin|Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
219284412|NCT01946529|DRUG|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
219284413|NCT01946529|DRUG|ifosfamide|Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
219284414|NCT01946529|DRUG|etoposide|Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
219284415|NCT01946529|DRUG|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
219284416|NCT01946529|DRUG|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
219284417|NCT01946529|DRUG|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
219284418|NCT01946529|DRUG|sorafenib|Dosage and route of administration: 90 mg/m\^2/dose PO BID
219284419|NCT01946529|PROCEDURE|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
219284420|NCT01946529|RADIATION|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
219284421|NCT06385496|PROCEDURE|Biopsy Procedure|Undergo biopsy
219284422|NCT06385496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219284423|NCT06385496|PROCEDURE|Computed Tomography|Undergo CT scan
219284424|NCT06385496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219284425|NCT06385496|DRUG|Sapanisertib|Given PO
219284426|NCT05820204|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
219284427|NCT05820204|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
219284428|NCT05820204|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain
219284429|NCT06493162|PROCEDURE|Intubation|Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery
219284430|NCT06493162|DEVICE|Flow Controlled Ventilation|Patients in FCV group will be ventilated with flow controlled ventilation mode
219284431|NCT06493162|DEVICE|Volume Controlled Ventilation|Patients in VCV group will be ventilated with volume controlled ventilation mode
219284432|NCT04759976|BEHAVIORAL|Robotic motor training|The experiments consist in performing motor tasks with upper-limb robotic devices.
219284433|NCT05534425|BEHAVIORAL|GenX intergenerational mentoring program|GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
219284434|NCT02919631|DRUG|Triheptanoin|Anaplerotic dietary oil
219284435|NCT02919631|DRUG|Placebo oil|Safflower oil
219284436|NCT04915820|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
219284437|NCT04218773|DRUG|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
219284438|NCT04218773|DRUG|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
219284439|NCT06408142|DIAGNOSTIC_TEST|HIV testing|Point of Care HIV testing universally regardless of risk factors
219284440|NCT06408142|OTHER|In-depth interview|In-depth interviews of providers using Normalization Process Theory semi-structured interview guide to assess provider perspectives of PrEP delivery in the ED
219296412|NCT05145140|DRUG|Tangningtongluo tablet and cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
219284441|NCT07134010|OTHER|perineural injection|"Intervention The procedure will be performed by a rehabilitation physician who has obtained hospital-level credentialing and privileging to practice Perineural Injection Therapy (PIT). The physician has undergone hands-on training with Dr. Lyftogt-certified trainers in Malaysia.~PIT will be administered weekly for six week (Total 6 sessions). In addition to this intervention, patient will also receive conventional therapy which is monthly outpatient physiotherapy with supplementary home-based exercise program, and oral analgesia (except NSAIDs).~Solution: Buffered 5% dextrose.~Pre injection: Chronic constriction injury points will be identified by palpation along the shoulder's cutaneous nerves - the suprascapular, supraclavicular, axillary, musculocutaneous, and radial nerves. These points will be marked to ensure precise targeting. Taking into account these nerve pathways, the maximum injection area for this research is set at 10 sites per session."
219284442|NCT07134010|OTHER|Physiotherapy|Patients will be receiving a structured home-based exercise program and will be instructed on how to perform these exercises at home. The exercise regime will be 30 minutes, 3 times a day to enhance shoulder mobility and strength in addition to the regular monthly outpatient physiotherapy session. Oral analgesics exclude NSAIDs will be prescribed as needed to manage pain.
219284443|NCT02726984|DRUG|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
219284444|NCT02920112|BEHAVIORAL|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
219284445|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
219284446|NCT06603324|DEVICE|CVVHD treatment in paediatric mode with multiFiltratePRO|Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
219284447|NCT06817902|DEVICE|Intermittent theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
219284448|NCT06817902|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
219284449|NCT06293794|OTHER|Personalized Clinical Decision Support (CDS)|The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.
219284450|NCT06293794|OTHER|Traditional Clinical Decision Support (CDS)|The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
219284451|NCT02525601|DEVICE|Triathlon CR cemented|Implantation of Knee Prosthesis
219284452|NCT02525601|DEVICE|Triathlon CR uncemented|Implantation of Knee Prosthesis
219284453|NCT06611371|BIOLOGICAL|IVT GBS-06|Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.
219284454|NCT06611371|BIOLOGICAL|Placebo|0.9% sodium chloride
219284455|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
219284456|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
219284457|NCT00739115|OTHER|Heliox gas|Heliox gas used in conjunction with nasal CPAP
219284458|NCT00542542|PROCEDURE|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
219284459|NCT00542542|DRUG|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
219284460|NCT00542542|DRUG|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
219284461|NCT00542542|DRUG|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
219284462|NCT00542542|DRUG|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
219284463|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 1，IVI
219284464|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 2，IVI
219284465|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 3，IVI
219284466|NCT06672536|DRUG|EYLEA 2 MG|EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period
219284467|NCT06674616|OTHER|Replicating Effective Programs|Replicating Effective Programs (REP), based on Social Learning Theory and Rogers' Diffusion of Innovations, incorporates program packaging, training, and technical support
219284468|NCT06674616|OTHER|Coaching|Coaching is based on the Positive Behavior Interventions and Supports model, addresses staff barriers by building implementers' evidence-based practice (EBP) knowledge, self-efficacy, and skills through clinical support and feedback.
219284469|NCT06674616|OTHER|Facilitation|Facilitation addresses potential organizational barriers to delivery, including leadership support and acceptance among other staff.
219284470|NCT06997718|OTHER|RV5075A MF6793|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
219284471|NCT06997718|OTHER|CO5075A|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
219284472|NCT04446728|BEHAVIORAL|Training Webinar|The training webinar is a three hour training. The purpose of the study is to implement the Psychosocial Assessment Tool (PAT) in their center.
219284473|NCT04446728|BEHAVIORAL|Training Webinar Plus Implementation Enhanced Resources (TIER)|In addition the Training Webinar, sites randomized to Strategy II will identify a Champion and will participate in monthly consultation calls in support of implementation of the PAT
219284474|NCT03549858|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
219284475|NCT06603363|DRUG|Rosuvastatin 40mg|Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.
219284476|NCT06603363|DRUG|Placebo|Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.
219284477|NCT06603363|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (Coronary CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.
219284478|NCT06603363|DIAGNOSTIC_TEST|Blood test|Blood test at baseline, 3-month, and 24-month visits.
219284479|NCT07015385|DEVICE|Lip Bumper with Integrated Distal Shoe|This novel appliance integrates a traditional lip bumper with a distal shoe extension designed to engage the mesial surface of the unerupted second permanent molar. The goal is to prevent mesial movement of the first molars and guide proper eruption of the second molars while simultaneously addressing anterior deep bite by eliminating lip pressure and promoting vertical incisor development. The device will be custom-fabricated for each participant and will be worn for 12 months, with clinical and radiographic evaluations conducted every 6 weeks.
219178081|NCT03292861|DRUG|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
219178082|NCT06271291|OTHER|Non-Interventional Study|Non-interventional study
219178083|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
219178084|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
219284480|NCT07015385|DEVICE|Conventional Lip Bumper|The conventional lip bumper is an interceptive orthodontic appliance used to alleviate lower anterior crowding, eliminate perioral muscle pressure, and promote dental arch expansion. It does not include a distal shoe component and therefore offers no guidance for second molar eruption. This device will also be custom-fabricated and worn for 12 months, with scheduled monitoring every 6 weeks to assess treatment progress and compare outcomes with the experimental device.
219284481|NCT06691464|DIAGNOSTIC_TEST|PET|FAPI - PET/CT
219284482|NCT03446001|DRUG|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
219284483|NCT03446001|DRUG|Control|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
219284484|NCT03446001|DRUG|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
219284485|NCT03987295|DRUG|AL001|60 mg/kg of AL001 every 4 weeks
219284486|NCT04432571|BEHAVIORAL|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
219284487|NCT04432571|BEHAVIORAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
219284488|NCT04432571|BEHAVIORAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
219284489|NCT04432571|BEHAVIORAL|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
219284490|NCT04432571|BEHAVIORAL|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
219284491|NCT04432571|BEHAVIORAL|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
219284492|NCT06693752|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]|Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
219284493|NCT06596135|DRUG|Setmelanotide|Open-label daily injections of setmelanotide
219284494|NCT06696079|DRUG|Early Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.
219284495|NCT06696079|DRUG|Late Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.
219284496|NCT06689267|DIAGNOSTIC_TEST|computed tomography myocardial perfusion|The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.
219284497|NCT06689267|PROCEDURE|Invasive Coronary Angiography|Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.
219284498|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
219284499|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
219284500|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
219284501|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
219284502|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
219284503|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
219284504|NCT07137000|OTHER|Art therapy|Five different art therapy methods (making bead jewelry, pencil drawing, painting, mandala, making clay figures) be used for people in this group.
219284505|NCT06721585|DRUG|Tecovirimat Oral Capsule [Tpoxx]|"Tecovirimat Oral Capsule 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
219284506|NCT06721585|OTHER|Standard of Care (SOC)|Participants are provided SOC for mpox
219284507|NCT07041736|DEVICE|diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
219284508|NCT07041736|OTHER|conventional irrigation|After each file use, the root canal will be irrigated with 5ml of freshly prepared 2.5% sodium hypochlorite (NaOCl) solution (Alex. Deteregents and Chemical Co., Egypt) for 1 minute using a 31-gauge Navi-Tip flexible irrigating needle (Navi-Tip, Ultradent product, South Jourdan, UT). 5 ml of 17% EDTA (Colgate Oral Care Company, Waverly, Australia) for 1 min will be used for smear layer removal. 5 ml of saline solutio
219284509|NCT07041736|DEVICE|Diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
219284510|NCT07041736|DEVICE|Ultrasonic|The needle will be operated using Satelec P5 Piezoelectric Ultrasonic Unit (Acteon, Mount Laurel, NJ, USA.) at power setting of 5. The stopper on the PiezoFlow needle will be set 1 mm short of binding in the canals, but not more than 75% of the WL. A syringe containing 5 mL of 2.5% NaOCl will be attached to the Piezoflow activation needle and the inactive needle will be inserted in the canal, and irrigant flow will be started before activation. During activation, the needle will be moved up and down passively in the canal
219284511|NCT07031388|COMBINATION_PRODUCT|1-Hydrogen peroxide and hyaluronic acid|"Hydrogen Peroxide (1.80%): Acts as an antiseptic agent, releasing oxygen that helps in reducing bacterial load and disrupting biofilms associated with gingivitis.~* Hyaluronic Acid (0.10%): A naturally occurring polysaccharide known for its anti-inflammatory and tissue-regenerative properties, aiding in the healing of gingival tissues Clinical studies have demonstrated the efficacy of Perhyal in managing gingivitis. In a randomized controlled trial, Perhyal showed a significant reduction in gingival inflammation compared to placebo, with no reported adverse effects over 21 days."
219284512|NCT07031388|COMBINATION_PRODUCT|2- Hyaluronic acid|This intervention involves the use of a mouthwash containing hyaluronic acid (0.12%) of high molecular weight, without any additional active agents. Hyaluronic acid is a naturally occurring substance known for its anti-inflammatory and wound-healing properties. It supports gingival tissue regeneration and hydration, which may contribute to reducing signs of gingivitis such as redness, swelling, and bleeding. Participants assigned to this arm will rinse with 10 mL of the solution twice daily for three weeks, following standardized oral hygiene instructions. This arm serves to evaluate the independent therapeutic effect of hyaluronic acid in managing gingival inflammation.
219284513|NCT07031388|COMBINATION_PRODUCT|Chlorhexidine|This intervention uses a commercially available chlorhexidine gluconate 0.12% mouthwash, widely recognized for its strong antimicrobial properties. Chlorhexidine is considered a gold-standard agent for chemical plaque control and is effective in reducing bacterial load, gingival inflammation, and bleeding. Participants in this group will rinse with 10 mL of the solution twice daily for three weeks, in addition to maintaining regular oral hygiene practices.
219284514|NCT07031388|COMBINATION_PRODUCT|Placebo mouthwash|This placebo mouthwash was specially formulated to visually and sensorially resemble the active mouthwash products without containing any active therapeutic ingredients. It was prepared in the AwaMedica laboratory using 1 liter of distilled water, 98.5% distilled water, 2 mL of glycerin for mild viscosity, 5 mL of vanilla flavoring for taste masking, and 8 mL of brown food coloring to match the appearance of chlorhexidine. The solution was stored in 120 mL opaque brown bottles, each labeled only with the participant number to ensure blinding. Participants will use 10 mL of the placebo rinse twice daily for three weeks, following the same oral hygiene protocol as other groups.
219284515|NCT06719609|OTHER|Ankle tape|The influence of ankle tape on gait biomechanics
219284516|NCT06719609|OTHER|Standard lace-up ankle brace|The influence of lace-up ankle brace on gait biomechanics
219284517|NCT06719609|OTHER|Standard high ankle-sprain (HAS) brace|The influence of standard HAS brace on gait biomechanics
219284518|NCT06719609|OTHER|Low-profile HAS brace|The influence of low-profile HAS brace on gait biomechanics
219284519|NCT06719609|OTHER|No ankle brace or tape|The influence of no ankle tape or brace on gait biomechanics
219296413|NCT05145140|DRUG|Tangningtongluo tablet|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
219284520|NCT06724003|OTHER|Computer-based virtual reality simulation|The computer-based virtual practice simulation was created as a single scenario for oral care practice in the unconscious patient. The scenario software was created and designed by the researcher who is an IT specialist. In the formation phase of the scenario, the software was realized by working together with the researcher, the expert faculty member, the nurse and the informatics specialist for the photographs required for the virtual reality application and the steps of the scenario software.
219284521|NCT03004053|DEVICE|Reflectance Confocal Microscopy (RCM) endoscope device|
219284522|NCT02995759|OTHER|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
219284523|NCT06729632|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
219284524|NCT06132256|DRUG|Axatilimab|Administered as intravenous (IV) infusion
219284525|NCT06132256|OTHER|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
219284526|NCT06923748|DEVICE|Superfloss|Use of Superfloss daily as the interproximal cleaning device, combined with an electronic toothbrush, as part of a tailored oral hygiene protocol in patients with peri-implant disease.
219284527|NCT06923748|DEVICE|Interdental brush|Use of interdental brush once daily as the interproximal cleaning device, combined with an electronic toothbrush, within a professional oral hygiene maintenance program for peri-implant disease
219284528|NCT07139938|PROCEDURE|Isolated lumbar decomression|"All patients will undergo microsurgical decompression of stenosed neural structures of the lumbar canal at all clinically significant levels with saving the posterior spinal column (type of decompression may be as unilateral, bilateral, or bilateral from a unilateral approach (over-the-top)).~Degenerative lumbar stenosis may be caused by thickened yellow and posterior longitudinal ligaments, facet joints hypertrophy, vertebral body osteophytes posteriorly, synovial (facet joints cysts) and disc cysts."
219284529|NCT07135310|BEHAVIORAL|STROKE 120 multifaceted intervention campaign|"Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period).~The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows:~1. Training medical workers in stroke center;~2. Training emergency center staff and primary care physicians;~3. Conducting public education;"
219284530|NCT01963637|DEVICE|gastric tomodensitometry with gas at 3 months and 12 months|
219284531|NCT07145983|BEHAVIORAL|Structured Diabetes Education on medication Adherence and self care|Lived-experience facilitation, goal setting, real-world problem solving, and ongoing peer accountability not provided in standard clinician-led education. Peer-led, group-based sessions emphasizing lived experiences, problem-solving, and mutual support. Participants meet regularly in small groups facilitated by trained peers with diabetes. Includes structured booster follow-ups and SMS reminders to reinforce adherence and self-care.
219284532|NCT07139743|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Obecabtagene autoleucel (obe-cel) given as a single infusion.
219284533|NCT07154264|DRUG|DZD8586|DZD8586 will be taken orally once daily on days 1-28 of each cycle.
219284534|NCT07154264|DRUG|Venetoclax|Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
219284535|NCT07154745|DRUG|Pozelimab|Administered per the protocol
219284536|NCT07154745|DRUG|Cemdisiran|Administered per the protocol
219284537|NCT07155954|DIAGNOSTIC_TEST|SRUS imaging of the lymph nodes before surgery or biopsy|Ultrasound contrast agent (Sonovue/Sonazoid) is administered to the patients through a peripheral vein. When the micro-bubbles enter the lymph nodes, super-resolution ultrasonography imaging will initiate immediately, to capture the trajectory of the micro-bubbles, thus construct a map of the microvascular distribution.
219284538|NCT07155681|DEVICE|Virtual Reality intervention|Virtual Realtiy intervention with biofeedback for 10 minutes during a shift on the ward for healthcare professionals
219284539|NCT07154251|OTHER|Community Health Worker|Community Health Worker will meet with families monthly (and more often as needed) in the role of a diabetes technology coach
219284540|NCT07154069|RADIATION|Radical radiotherapy of nasopharynx and neck|Radical radiotherapy of nasopharynx and neck
219284541|NCT07154069|DRUG|Capecitabine|Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year
219284542|NCT07154069|DRUG|Concurrent chemoradiotherapy (cCRT)|Concurrent chemoradiotherapy
219284543|NCT07154069|DRUG|Toripalimab|Adjuvant Toripalimab (240mg day1, Q3W )
219284544|NCT07154407|OTHER|AI-assisted Mastisting Training App|An artificial intelligence (AI) recognition system for the 'AI-assisted Masticatory Muscle Training,' tailored to train masticatory muscles in patients with schizophrenia. By finishing certain exercise per day, expecting the experimental oral hygience, masticating and swallowing fuction could be advanced,
219284545|NCT07153640|OTHER|1 ) Wim Hof Breathing Exercise|"1. Subjects will be asked to breathe deeply for an average of 20-30 breaths then exhale, (deep rapid inhalations and relaxed expirations)~2. Hold their breath in an unforced manner for one minute or longer until they feel the urge to breathe (retention phase).~   (For safety, they were instructed not to hold their breath longer than 3.5 min).~3. Take deep inhalation breath and hold again for 15 seconds (recovery breath).~4. This procedure was repeated a total of three times.~5. After the last cycle, subjects were instructed to return to their natural rhythm of breathing and remain lying down without moving to relax for five minutes.~6. Done every day in the morning or at least three hours postprandial for four weeks.~(Marko et al., 2022)"
219284546|NCT07153640|OTHER|2) Aerobic exercises|Aerobic exercises were performed by walking on the treadmill for 30 minutes a day (5 days/week) and at least 150 minutes per week of moderate-intensity aerobic activity at 60-75% of the maximum heart rate (HR) for four weeks. Maximum heart rate is taken from 220 - to age. Both the warm-up and cool-down were performed for five minutes. Each session concluded with stretching the calf, hamstring, quadriceps, gluteus, back, neck, and shoulder muscles (Acar et al., 2024; Shandu et al., 2023a)
219284547|NCT07154199|DEVICE|sham transcranial ultrasound stimulation|In the sham group, the transducer power was turned off, pre-recorded pulse repetition sounds were played to control for auditory confounds. The equipment appearance is consistent with the test device. Single stimulation, 60 seconds.
219284548|NCT07154199|DEVICE|real transcranial ultrasound stimulation|Ultrasound stimulation was delivered using TPO-203 and H-104MR\_4AA-4CH transducer (Sonic Concepts, Woodinville, WA, USA). In the real stimulation group, theta-burst TUS (Yaakub et al., 2024; Yaakub et al., 2023) was performed with the following parameters: pulse duration = 20 ms; pulse repetition interval = 200 ms; total duration = 80 s. The target free-field spatial peak pulse-average intensity was maintained at 33.85 W/cm². The stimulation target was defined as the overlapping region between the source localisation results and the right inferior insula in the Destrieux atlas
219284549|NCT07155824|DIETARY_SUPPLEMENT|Whey and plant protein blend|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
219284550|NCT07154238|OTHER|No treatment given|No treatment given
219284551|NCT07154537|BIOLOGICAL|2-dose PCV13|2 doses PCV13 with one month apart
219284552|NCT07154537|BIOLOGICAL|1-dose PCV13|1 dose PCV13
219284553|NCT07155044|DRUG|NAC|Participants in NAC+RNU cohort will receive 3-4 cycles of neoadjuvant chemotherapy (NAC) with the gemcitabine and cisplatin (GC) regimen prior to undergoing definitive surgery. Gemcitabine (1000 mg/m²) will be administered on Day 1 and Day 8, and cisplatin (70 mg/m²) will be administered on Day 2 of each 21-day cycle.
219284554|NCT07153393|DEVICE|Type I Bovine Collagen (HTIC)|HTIC is a sterile collagen powder (100 mg) contained in a glass vial, which is diluted by adding 5 ml of saline solution (0.9% sodium chloride solution) to obtain a suspension. This suspension will be prepared immediately before treatment. The procedure consists of performing a few microinjections of the product (0.1 ml per injection) into the dermis at intervals of approximately 2 cm, using a very fine needle (30G/32G, 4 mm) in the areas to be treated (face, neck, décolleté, and hands).
219284555|NCT07155499|BIOLOGICAL|GNR-127, 20 mcg|GNR-127, 20 mcg in 0.5 ml administered 5 times every 4 weeks
219284556|NCT07155499|BIOLOGICAL|GNR-127, 40 mcg|GNR-127, 40 mcg in 0.5 ml administered 5 times every 4 weeks
219284557|NCT07155499|BIOLOGICAL|GNR-127, 80 mcg|GNR-127, 80 mcg in 0.5 ml administered 5 times every 4 weeks
219284558|NCT07155499|BIOLOGICAL|GNR-127 placebo|GNR-127 placebo 0.5 ml administered 5 times every 4 weeks
219284559|NCT07155109|OTHER|Low pressure group|In laparoscopic gyneco-oncological surgeries, low pressure group will receive below 12 mmHg intraperitoneal pressure.
219284560|NCT07155109|OTHER|Normal pressure group|In laparoscopic gyneco-oncological surgeries, normal pressure group will receive 12 and abowe 12 mmHg intraperitoneal pressure.
219284561|NCT07156019|DRUG|Sintilimab+Temozolomide+Surufatinib|After fully informed and signed informed consent, subjects will receive Sintilimab (200mg each fixed dose, once every 21 days) combined with Temozolomide (BSA≤1.7m2; BSA \&amp;amp;gt; 1.7m2 was administered with 300mg, QD, d1-d5, and with Surufatinib (250mg, QD, continuous administration). A treatment cycle of 21 days until disease progression, death, toxicity intolerance or withdrawal of informed consent, with a maximum treatment period of 24 months.
219284562|NCT07154914|DRUG|Abiraterone + ADT|Patients receiving androgen deprivation therapy (ADT) combined with abiraterone. Abiraterone is a CYP17A1 inhibitor used in combination with prednisone and ADT for metastatic hormone-sensitive prostate cancer (mHSPC). This combination is given in real-world practice according to clinical guidelines.
219284563|NCT07153627|OTHER|Rectal ozone sessions|Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
219284564|NCT07153627|OTHER|Conventional rehabilitation program|Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
219284565|NCT07154316|RADIATION|LCRT|50Gy/25Fx
219284566|NCT07154316|RADIATION|SCRT|25Gy/5Fx
219284567|NCT07154316|DRUG|CAPOX|1000mg/m2 bid d1-14
219284568|NCT07154316|DRUG|PD-1|300mg d1，q3w
219284569|NCT07154316|DRUG|Celecoxib|200mg, bid
219284570|NCT07155642|OTHER|yoga|"Participants in the yoga group received a total of 8 weeks of intervention, conducted 3 days a week, for 60 minutes per day. The program components were: • 8 minutes of meditation practice. • 40 minutes of Yin and Yang yoga postures. (It's highly recommended to briefly explain what Yin and Yang yoga postures specifically entail in the full paper's methodology section, e.g., Yin yoga focuses on holding passive poses for longer durations to target deep connective tissues, while Yang yoga incorporates more active, flowing sequences to build strength and flexibility.) • 2 minutes of breathing exercises (pranayama). • 10 minutes of deep relaxation (savasana)."
219284571|NCT07155642|OTHER|conventional physiotheraphy|"Participants in the conventional physiotherapy group also underwent an 8-week program, 3 days a week, for 60 minutes per day. This program included:~* Aerobic exercises.~* Stretching exercises.~* Strengthening exercises.~* Spinal stabilization exercises.~* Balance exercises."
219284572|NCT07155135|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) is a vital diagnostic tool in modern medicine due to its ability to produce detailed images of the body's internal structures without using ionizing radiation.
219284573|NCT07155733|DEVICE|Transcutaneous Vagus Nerve Stimulation|Participants receive 10 sessions of transcutaneous vagus nerve stimulation over 3 weeks using a TENS device. stimulation is applied to the auricular branch of the vagus nerve (cymba conchae/tragus) for 30 minutes per session. Participants continue usual medical care. Parameters (frequency, pulse width, intencity) are standartized according to safety guidelines. This intervention specifically targets the auricular branch of the vagus nerve, distinguishing it from other device-based intervention such as conventional TENS for pain management or non-auricular vagus stimulation used in other studies.
219284574|NCT07155733|BEHAVIORAL|Myofascial Release Exercises|Participants receive 10 supervised session over 3 weeks focusing on myofascial release of cervical muscles. in addition to their usual medical management for tinnitus. Exercises are designed to reduse muscle tensionpotentially contributing to tinnitus. This intervention is distinct from general physical therapy or standart relaxation exercises beacause it specifically targets myofascial structures implicated in tinnitus pathophysiology.
219284575|NCT07155733|OTHER|Standard medical treatment|Participants continue their usual medical management for tinnitus without additional interventions. This group serves as a control to compare the effects of tVNS and myofascial exercises. It differs from sham or placebo interventions used in oter studies because no active or stimalated treatment is provided.
219284576|NCT07153367|DRUG|REKOVELLE (Follitropin Delta)|"Each patient will start the ovarian stimulation with a fixed dose of 3,66 mcg of Rekovelle ® on day 4 of the natural cycle (Stimulation day 1-S1). The stimulation period will last a maximum of 13 days.~Patients will be regularly evaluated to monitor the response to stimulation with ultrasound scan and blood sampling"
219284577|NCT07156058|OTHER|MiniPDX group|Personalized treatment for guided by mini-PDX. The MiniPDX test can provide drug sensitivity results in as little as 7 days. Drugs including but not limited to the following agents: capecitabine, gemcitabine + cis-platinum, gemcitabine + capecitabine, 5-FU + oxaliplatin, gemcitabine, 5-FU, capecitabine + cis-platinum, 5-FU + cis-platinum.
219284578|NCT07156058|DRUG|Capecitabine|Drug: Capecitabine
219284579|NCT07154511|DRUG|Tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
219284580|NCT07154511|DRUG|Placebo|Participants will take 500mg TID placebo for 90 days +/- 7 days.
219284581|NCT07154797|COMBINATION_PRODUCT|Bimatoprost Implant System / IOL Combination|Bimatoprost Implant System used in combination with the SpyGlass intraocular lens
219284582|NCT07155512|BEHAVIORAL|Mindfulness based intervention|A mindfulness intervention was designed especially for this study and delivered by a RD also qualified as a mindfulness teacher. The intervention was delivered synchronously online and consisted of 4 x 50 minute sessions delivered across 4 weeks.
219284583|NCT07155018|PROCEDURE|Micro-osteoperforations (MOPs)|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations.
219284584|NCT07155018|PROCEDURE|Conventional Canine Retraction|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations
219284585|NCT07155928|BEHAVIORAL|Cardiac Rehabilitation|"* The cardiac rehabilitation program include supervised exercise training, patient education, and risk factor modification.~* CR starts 1-3 weeks after PCI (based on the patient's general condition) and lasting 12 weeks thereafter.~* Patients will undergo a supervised CR program based on published guidelines (FITT principle). The core will be a moderate-intensity aerobic exercise regimen (e.g. treadmill or cycle ergometer) 2-3 times per week for 12 weeks. Each session will last \~20-60 minutes of exercise followed by cool-down, with intensity gradually increased to High intensity interval training (HIIT) in low-moderate risk individuals. Resistance exercises (e.g. light weights or band exercises) will also be included twice weekly. Exercise dose (frequency, intensity, time) will be tracked. Physical therapists will supervise all sessions in an outpatient CR facility or affiliated gym. Patients' vitals and ECG will be monitored during initial sessions for safety."
219284586|NCT07155928|PROCEDURE|Primary Percutaneous Coronary Intervention|Patients will undergo Primary Percutaneous Coronary Intervention (PPCI) within 24 hours of symptom onset for urgent revascularization of the occluded coronary artery.
219296414|NCT05145140|DRUG|Tangningtongluo cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
219284587|NCT07153510|OTHER|Post-Isometric Relaxation|Participants will undergo Post-Isometric Relaxation technique targeting the hamstring muscles. The technique involves an isometric contraction of the hamstring followed by a passive stretch. Participant will be in supine position; hip at 90° flexion, Isometric contraction of hamstrings for 7 seconds, Followed by 15 seconds of passive stretch, 10 repetitions, 3 times/week for 4 weeks
219284588|NCT07153510|OTHER|Active Static Stretching|Participants will perform Active Static Stretching exercises for the hamstrings, where the stretch is held actively without assistance.Seated long sitting position. Participant actively stretches hamstrings for 30 seconds. 10 repetitions, 3 times/week for 4 week
219284589|NCT07155759|DIAGNOSTIC_TEST|PSA/Stockholm3/MRI|Stockholm3+PSA followed by MRI of the prostate
219284590|NCT07155759|DIAGNOSTIC_TEST|PSA|PSA followed by standard biopsies
219284591|NCT07154355|BEHAVIORAL|community-based exercise training|The patients will engage in 40-60 minutes of exercise training, either at home or in the community, five times a week, for eight weeks. Brisk walking, jogging, swimming, cycling, and trekking were among the exercise modalities that were chosen mostly based on the patient's individual preferences and habits. To guarantee safe and efficient exercise, exercise intensity was modified based on each person's subjective effort level and the results of their individual cardiorespiratory exercise tests.
219284592|NCT07153965|DRUG|Sacituzumab Tirumotecan plus Tagitanlimab|Sacituzumab Tirumotecan 5mg/kg intravenously (IV) infusion every 2 weeks on Day 1, Tagitanlimab 900mg IV every 2 weeks on Day 1, until disease progression, unacceptable toxic effects, withdrawal from the trial, or death, whichever occurred first.
219284593|NCT03578887|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
219284594|NCT03578887|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
219284595|NCT05464615|DRUG|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
219296415|NCT04927884|BIOLOGICAL|N-803|"Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)"
219284596|NCT06118957|DRUG|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
219284597|NCT03435679|PROCEDURE|one-stage|one-stage surgery
219284598|NCT03435679|PROCEDURE|two-stage|two-stage surgery
219284599|NCT02558127|GENETIC|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
219284600|NCT02777476|DEVICE|B-Lite- Light Weight Breast Implants|
219284601|NCT02816775|DEVICE|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
219284602|NCT02816775|DEVICE|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
219284603|NCT03917862|COMBINATION_PRODUCT|TDM-621|The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
219284604|NCT05169398|DEVICE|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
219284605|NCT02309931|PROCEDURE|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
219284606|NCT02309931|PROCEDURE|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
219284607|NCT03440957|OTHER|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
219284608|NCT04164121|DRUG|Phenlarmide Tablets|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
219284609|NCT04164121|DRUG|Placebos|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
219284610|NCT05400577|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
219284611|NCT02567760|DIETARY_SUPPLEMENT|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
219284612|NCT02567760|OTHER|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
219284613|NCT06429098|DRUG|Venetoclax|Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
219284614|NCT06429098|DRUG|azacitidine|Given SC
219284615|NCT06429098|DRUG|decitabine|Given IV
219284616|NCT06429098|DRUG|Cytarabine|Given IV
219284617|NCT03619447|DRUG|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
219284618|NCT03619447|DRUG|serratus block group|USG guided serratus plane block will perform bilaterally
219284619|NCT03149809|DRUG|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
219284620|NCT03149809|BEHAVIORAL|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
219284621|NCT03486860|BEHAVIORAL|Parent Psychoeducation|6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.
219284622|NCT03486860|BEHAVIORAL|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
219284623|NCT05591014|DEVICE|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
219296416|NCT04927884|BIOLOGICAL|PD-L1 t-haNK|"Dose: \~2 × 10\^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
219284624|NCT03787056|OTHER|Blood draws|"Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort"
219284625|NCT05912829|DEVICE|IOL Master 700|Biometry using the IOL Master 700
219284626|NCT05912829|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
219284627|NCT05912829|DEVICE|MS-39|Corneal Topography using the MS-39
219284628|NCT05912829|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
219284629|NCT05912829|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
219284630|NCT05912829|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
219284631|NCT05912829|DIAGNOSTIC_TEST|Biomicroscopy|Slit Lamp Examination
219284632|NCT01290289|OTHER|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia \& a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl \& a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
219284633|NCT01985451|DRUG|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
219284634|NCT01985451|DRUG|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
219284635|NCT05540106|BEHAVIORAL|Nature Coloring Packet|Coloring packet containing nature scenes
219284636|NCT05540106|BEHAVIORAL|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
219284637|NCT05540106|BEHAVIORAL|Activity Book|Pages containing word searches, connect the dots, etc.
219284638|NCT05540106|BEHAVIORAL|Blank Paper and Pencil|Blank sheets of paper and a pencil.
219284639|NCT02860494|DRUG|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
219284640|NCT02860494|DRUG|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
219284641|NCT04045964|DRUG|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
219284642|NCT04045964|BEHAVIORAL|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
219284643|NCT04045964|BEHAVIORAL|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
219296417|NCT04927884|DRUG|Sacituzumab Govitecan-Hziy|"Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
219284644|NCT04521569|DRUG|Regadenoson|If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
219284645|NCT04521569|DRUG|Placebo|If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
219284646|NCT06011018|OTHER|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
219284647|NCT06011018|OTHER|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
219284648|NCT06011018|OTHER|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (pink noise), with 14Hz binaural beat stimulation
219284649|NCT06218823|DRUG|Transdermal Nicotine Patch|a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
219284650|NCT06218823|BEHAVIORAL|Standard Telephone Counseling|3 brief telephone-based smoking cessation counseling sessions
219284651|NCT06218823|DRUG|Varenicline|12 weeks of an oral smoking cessation medication
219284652|NCT06218823|BEHAVIORAL|Cancer-Targeted Telephone Counseling|7 telephone-based smoking cessation counseling sessions adapted for cancer patients
219284653|NCT06218823|OTHER|Mailed Information about Standard Care Resources|Publicly funded treatment resources including the SmokefreeTXT program sponsored by the National Cancer Institute and the Wisconsin Tobacco Quit Line.
219284654|NCT00700700|DEVICE|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1\. Ovatio CRT 6750"
219284655|NCT02683551|PROCEDURE|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
219284656|NCT06797336|DRUG|PT0253|PT0253 injection.
219284657|NCT05574699|OTHER|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
219284658|NCT05574699|OTHER|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
219284659|NCT05143697|BEHAVIORAL|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
219284660|NCT03711032|BIOLOGICAL|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
219284661|NCT03711032|BIOLOGICAL|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
219284662|NCT06833372|DEVICE|ESWT group|During each session, participants will receive 2000 pulses at a frequency of 4 Hz and an EDF between 0.02 and 0.2 mJ/mm2.
219284663|NCT06833372|OTHER|exercise group|daily exercise program
219296418|NCT04927884|DRUG|Cyclophosphamide|"Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)"
219296419|NCT00766545|DRUG|cilostazol|oral tablet 100 mg, twice daily, over 1 year
219284664|NCT06375629|DEVICE|FocalOne|The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device. This study is a non-interventional study. All the data will be collected from routine care. Data as indicated in the table below will be systematically recorded on the e-CRF to coincide with the scheduled follow-up visits at 3, 6 and 12 months.
219284665|NCT06223269|DRUG|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
219284666|NCT06223269|PROCEDURE|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
219284667|NCT05905419|OTHER|Opioid Phase|"Opioid-taking patients are assigned to take their prescribed opioid medication before (peak opioid phase) during 1 scan and after (trough opioid phase) during the other MRI scan"
219284668|NCT06457451|OTHER|DIAPASOM program|A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized dietetic care by a dietician for one year.
219284669|NCT04881383|DIAGNOSTIC_TEST|OGTT and HbA1c|An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
219284670|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
219284671|NCT06460259|BEHAVIORAL|Breathing Exercise|He individual will be seated in a quiet environment in a semi-fowler or fowler position with their feet pointing forward. Then, they will be asked to join their hands on their abdomen and breathe normally while focusing on their breath. They will ensure their shoulders are relaxed, their body is loose, and they will inhale and exhale slowly and deeply through the nose without rushing.Next, while sitting upright with relaxed muscles, they will close their eyes, block their right nostril with their thumb or ring finger, inhale as much air as possible through the left nostril, and hold their breath. Then, they will block the left nostril with their ring finger or thumb and exhale slowly through the right nostril. The same process will be repeated for the left nostril. They will continue this process for approximately 2 minutes.
219284672|NCT05046613|OTHER|Rimegepant|75mg
219284673|NCT05046613|OTHER|Not taking Rimegepant|No rimegepant
219284674|NCT00537589|PROCEDURE|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
219284675|NCT05854472|OTHER|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
219284676|NCT05602727|DRUG|MK-1942|MK-1942 oral capsule
219284677|NCT05602727|DRUG|Placebo|Placebo oral capsule
219284678|NCT02087449|DEVICE|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
219284679|NCT00309205|DRUG|dapivirine (TMC120) vaginal gel|
219284680|NCT03729401|DRUG|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
219284681|NCT03729401|DRUG|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
219284682|NCT03729401|DRUG|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
219284683|NCT00319462|DEVICE|hemoclip|
219284684|NCT02204332|DRUG|Cabazitaxel|
219284685|NCT02204332|OTHER|Best Supportive Care|
219284686|NCT04035278|BIOLOGICAL|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
219284687|NCT04035278|BIOLOGICAL|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
219284688|NCT01582841|PROCEDURE|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
219284689|NCT00198770|DIETARY_SUPPLEMENT|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
219296420|NCT00766545|DRUG|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
219296421|NCT00002888|DRUG|cisplatin|
219296422|NCT00002888|DRUG|fluorouracil|
219296423|NCT00002888|DRUG|paclitaxel|
219296424|NCT01511705|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
219296425|NCT01511705|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
219296426|NCT06500676|DRUG|GFH375|GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
219296427|NCT02713061|DRUG|TAK-850|TAK-850 injection
219284690|NCT04772859|BEHAVIORAL|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
219284691|NCT04772859|OTHER|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
219284692|NCT03889704|DEVICE|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
219284693|NCT03482466|BEHAVIORAL|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
219284694|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
219284695|NCT02060370|DRUG|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
219284696|NCT02060370|BEHAVIORAL|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
219284697|NCT05270369|BEHAVIORAL|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
219284698|NCT05270369|BEHAVIORAL|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
219284699|NCT03240822|PROCEDURE|Penile Transplant|Penile Allotransplantation
219284700|NCT03240822|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
219284701|NCT03240822|DRUG|Tacrolimus|
219284702|NCT05503199|DEVICE|Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).|Combined suture- and plug-based VCD strategy after TF-TAVI.
219284703|NCT05503199|DEVICE|Combination of two ProGlides or ProStyles (Abbott Vascular).|Pure suture-based VCD strategy after TF-TAVI.
219284704|NCT01684189|OTHER|Patient registry|Patient registry without study intervention
219284705|NCT06487130|OTHER|N/A Observational Registry|Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.
219284706|NCT02507453|OTHER|parabolic flight|
219284707|NCT02507453|OTHER|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
219284708|NCT02507453|DEVICE|ESA short-arm human centrifuge (SAHC)|
219284709|NCT00017368|BIOLOGICAL|filgrastim|
219284710|NCT00017368|BIOLOGICAL|sargramostim|
219284711|NCT00017368|DRUG|carboplatin|
219284712|NCT00017368|DRUG|cisplatin|
219284713|NCT00017368|DRUG|cyclophosphamide|
219284714|NCT00017368|DRUG|doxorubicin hydrochloride|
219284715|NCT00017368|DRUG|etoposide|
219284716|NCT00017368|DRUG|etoposide phosphate|
219284717|NCT00017368|DRUG|ifosfamide|
219284718|NCT00017368|DRUG|isotretinoin|
219284719|NCT00017368|DRUG|melphalan|
219284720|NCT00017368|DRUG|thiotepa|
219284721|NCT00017368|DRUG|vincristine sulfate|
219284722|NCT00017368|PROCEDURE|conventional surgery|
219284723|NCT00017368|PROCEDURE|peripheral blood stem cell transplantation|
219284724|NCT00017368|RADIATION|radiation therapy|
219284725|NCT04893252|DRUG|durvalumab and vactosertib|durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
219284726|NCT01575301|DRUG|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
219284727|NCT03412201|OTHER|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
219284728|NCT03412201|OTHER|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
219284729|NCT03028727|PROCEDURE|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
219284730|NCT03028727|PROCEDURE|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
219284731|NCT00356408|BIOLOGICAL|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
219284732|NCT00405366|DRUG|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
219284733|NCT03971383|DRUG|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
219284734|NCT03971383|DRUG|Placebo|3 tablets one time, 3 times a day(tid)
219284735|NCT02625051|PROCEDURE|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
219284736|NCT02625051|PROCEDURE|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
219284737|NCT05762913|OTHER|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
219284738|NCT03177499|PROCEDURE|Invasive PPG|Invasive PPG obtained by means of catheterization.
219284739|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
219284740|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
219284741|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
219284742|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
219284743|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
219284744|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
219284745|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
219284746|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
219284747|NCT00069173|BEHAVIORAL|Project FAB (Fitness and Bone)|
219284748|NCT05880537|OTHER|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
219284749|NCT05215964|PROCEDURE|Renal artery embolization|After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
219284750|NCT02142868|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
219284751|NCT02142868|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
219284752|NCT05959759|DRUG|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
219284753|NCT05959759|DRUG|Placebo|placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
219284754|NCT03203330|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
219284755|NCT03203330|BIOLOGICAL|Placebo Control|2 mL normal saline injection
219284756|NCT04180033|DIAGNOSTIC_TEST|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
219284757|NCT04011488|OTHER|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
219284758|NCT01493427|DRUG|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
219296428|NCT04441853|OTHER|YouTube video|Tutoral session on using YouTube personal stories on older people
219296429|NCT04441853|OTHER|Control|Tutorial session with same content without Youtube video
219284759|NCT05045651|PROCEDURE|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
219284760|NCT03864198|DIETARY_SUPPLEMENT|Genante|A dietary supplement for male infertility
219284761|NCT01390662|DIETARY_SUPPLEMENT|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
219284762|NCT01390662|DIETARY_SUPPLEMENT|placebo|one tablet of sugar pill pr. day, for 24 weeks.
219284763|NCT05061368|DRUG|Sildenafil Citrate|Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
219284764|NCT05061368|OTHER|Placebo|Placebo
219284765|NCT01219907|BIOLOGICAL|HER-2/neu peptide vaccine|Given intradermally
219284766|NCT01219907|DRUG|cyclophosphamide|Given IV
219284767|NCT01219907|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
219284768|NCT01219907|OTHER|laboratory biomarker analysis|Correlative studies
219284769|NCT01219907|OTHER|flow cytometry|Correlative studies
219284770|NCT01219907|OTHER|immunoenzyme technique|Correlative studies
219284771|NCT00868153|DRUG|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
219284772|NCT04558398|OTHER|Resistance exercise training|"Each session will be performed at home, with resistance bands used to provide resistance. Participants will be guided to increase the resistance if over 15 repetitions can be performed prior to fatigue. Weekly contact will be made with participants to encourage participation and to guide the exercise.~Each session will include:~2 min warm-up jogging on the spot~2 sets of 12-15 repetitions of:~Squats~Hip flexion~Hip extension~Hip abduction~Seated row~Bench press~Lateral raises~2 min jogging on the spot cooldown."
219284773|NCT04558398|OTHER|High-intensity interval training|"Each session will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot~Participants will be contacted weekly to encourage participation and to guide the exercise"
219284774|NCT01217853|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
219284775|NCT05762393|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
219284776|NCT05653063|OTHER|A web-based artificial intelligence (AI) auto-planning tool|"The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.~In this study patients will not be treated with the AI tool but the manual plan created by the local teams."
219284777|NCT02252770|DIETARY_SUPPLEMENT|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
219284778|NCT02252770|DIETARY_SUPPLEMENT|Placebo|Placebo will not contain nitric oxide supplement.
219284779|NCT00645268|DRUG|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
219284780|NCT00645268|DRUG|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
219284781|NCT00645268|DRUG|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
219284782|NCT01852461|DRUG|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
219284783|NCT01852461|DRUG|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
219284784|NCT06518785|DEVICE|Low Intensity Focused Ultrasound|An inhibitory LIFU protocol that allows suppression of neuronal activity in the basal ganglia and thalamus will be used.
219284785|NCT05844670|DRUG|Vincristine|"The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient."
219284786|NCT02475512|OTHER|Wash wipes (3M)|
219284787|NCT02475512|OTHER|water and pH neutral soap|
219284788|NCT00953186|DEVICE|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
219284789|NCT00953186|DEVICE|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
219284790|NCT05908851|DRUG|100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml)|Ultrasound guided brachial plexus blockade
219284791|NCT03894072|DEVICE|CPAP|Conventional CPAP
219284792|NCT03894072|DEVICE|HFHO|A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
219284793|NCT00019175|BIOLOGICAL|aldesleukin|
219284794|NCT00019175|BIOLOGICAL|fowlpox virus vaccine vector|
219284795|NCT00019175|BIOLOGICAL|gp100 antigen|
219284796|NCT06039020|DRUG|Anti-human thymocyte immunoglobulin, equine|Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
219284797|NCT05701267|DEVICE|MRI research|3T MRI protocol of \~1 hour
219284798|NCT01727284|PROCEDURE|MR-guided cryoablation|
219284799|NCT01461811|DEVICE|Nelfilcon A toric contact lenses (with comfort additives)|
219284800|NCT01461811|DEVICE|Nelfilcon A toric contact lenses|
219284801|NCT01986270|DRUG|Placebo|Matching Placebo
219284802|NCT01986270|DRUG|Eletriptan 40 mg|40mg oral
219284803|NCT01986270|DRUG|Eletriptan 80 mg|80mg oral
219284804|NCT01986270|DRUG|Sumatriptan 25 mg|25mg oral
219284805|NCT01986270|DRUG|Sumatriptan 50 mg|50mg oral
219284806|NCT05594134|OTHER|Automatic toothbrush with nylon bristle|The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch
219284807|NCT05594134|OTHER|Automatic toothbrush with silicone bristle|The automatic toothbrush with silicone bristles will be used for 10 seconds
219284808|NCT05594134|OTHER|Manual toothbrush used for 2 minutes|A conventional manual toothbrush will be used for 2 minutes
219284809|NCT05594134|OTHER|Manual toothbrush used for 45 seconds|A conventional manual toothbrush will be used for 45 seconds
219284810|NCT04454931|DEVICE|Root® with O3® Regional Oximetry|"May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device."
219284811|NCT03330145|BEHAVIORAL|Scales, questionnaires and inventory|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
219284812|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
219284813|NCT00527462|PROCEDURE|Bronchoscopy|bronchoscopy with segmental allergen challenge
219284814|NCT00527462|OTHER|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
219284815|NCT06114303|OTHER|Stool sampling|1 stool sample is taken during the study with a stool sample kit
219284816|NCT05318573|DRUG|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
219284817|NCT05318573|DRUG|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
219284818|NCT06146205|PROCEDURE|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
219284819|NCT06146205|PROCEDURE|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
219284820|NCT06412991|BEHAVIORAL|Cycle Therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
219284821|NCT05047068|DEVICE|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
219284822|NCT03783416|DRUG|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
219284823|NCT00968825|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
219284824|NCT00968825|DRUG|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
219284825|NCT04439149|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
219284826|NCT04559373|OTHER|Virtual Reality and Field Training (VRFT)|The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
219284827|NCT03788759|DRUG|Alpha-lipoic acid|Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
219284828|NCT03788759|DRUG|Placebo Oral Tablet|Administration of placebo, as an adjunct to antipsychotic medication.
219284829|NCT02954744|PROCEDURE|HIFU treatment|High intensity focused ultrasound
219284830|NCT00376077|DRUG|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
219284831|NCT00376077|DRUG|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
219284832|NCT04495075|OTHER|Visuomotor Therapy|"The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback."
219284833|NCT04495075|OTHER|Passive Motion|The knee is passively moved through a range of motion.
219284834|NCT02997826|OTHER|Infantil formula|
219284835|NCT02005575|DRUG|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
219284836|NCT02005575|DRUG|Placebo|
219284837|NCT01616004|DRUG|N2O|
219284838|NCT01616004|DRUG|Air|sham comparator
219284839|NCT00304304|BEHAVIORAL|Asthma education|Research assistant worked with CCC staff on asthma prevention
219284840|NCT03808701|DRUG|SCT200|Recombinant Anti-EGFR Monoclonal Antibody
219284841|NCT00292422|DRUG|BG9924|
219284842|NCT02073240|BEHAVIORAL|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~1. Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~2. Audits and Feedback of performance~3. A TB IC collaborative membership~4. A standardized unit-level daily checklist of critical IC activities"
219284843|NCT05025670|BEHAVIORAL|Supportive psychotherapy|Participants will receive monthly 30-45 minute supportive psychotherapy sessions. Supportive psychotherapy is an integrative and eclectic psychotherapeutic approach, based upon the individual's needs and symptoms. It draws from elements of a variety of psychotherapeutic disciplines, including cognitive-behavior, psychodynamic, and interpersonal therapies.
219284844|NCT05049057|DRUG|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
219284845|NCT05049057|DRUG|Placebo|Placebo delivered via subcutaneous injection.
219284846|NCT04037176|DRUG|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
219284847|NCT04037176|OTHER|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
219284848|NCT03553199|DEVICE|TRS, Tissue Retraction System|Tissue Retraction System
219284849|NCT03733314|DRUG|E6011|E6011, infusion, intravenously.
219284850|NCT03733314|DRUG|Placebo|Placebo, infusion, intravenously.
219284851|NCT04204746|OTHER|We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.|
219284852|NCT05304455|DRUG|Apixaban 2.5 MG|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
219284853|NCT05304455|DRUG|Dipyridamole 25Mg Tab|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
219284854|NCT05304455|DRUG|subcutaneous Low Molecular Weight Heparin|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
219284855|NCT02594657|PROCEDURE|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
219284856|NCT02594657|PROCEDURE|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
219284857|NCT05955508|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
219284858|NCT02791997|OTHER|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
219284859|NCT02791997|OTHER|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
219284860|NCT01240915|DRUG|placebo|once every 7 days for 1- 3 doses
219284861|NCT01240915|DRUG|MultiStem low dose|1-3 doses
219284862|NCT01240915|DRUG|placebo|Single dose at week 8
219284863|NCT01240915|DRUG|MultiStem low dose|Single dose at week 8
219284864|NCT01240915|DRUG|placebo|Single dose Day 1
219284865|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
219284866|NCT01240915|DRUG|placebo|Single dose at week 8
219284867|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
219284868|NCT01240915|DRUG|placebo|Single dose Day 1
219284869|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
219284870|NCT01240915|DRUG|placebo|Single dose at week 8
219284871|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
219284872|NCT02441478|RADIATION|functional magnetic resonance imaging exam|
219284873|NCT02982551|DRUG|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
219284874|NCT02982551|OTHER|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
219284875|NCT02982551|OTHER|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
219284876|NCT02982551|DRUG|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
219284877|NCT03847792|DRUG|Group DB/Dexamethasone-Bupivacaine|The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
219284878|NCT03847792|DRUG|Group FB /Fentanyl-Bupivacaine|The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
219284879|NCT03847792|DRUG|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
219284880|NCT01694316|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
219284881|NCT02234505|PROCEDURE|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
219284882|NCT01164618|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
219284883|NCT01164618|OTHER|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
219284884|NCT00845962|DRUG|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
219284885|NCT00845962|DRUG|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
219284886|NCT00682981|DRUG|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
219284887|NCT00682981|DRUG|Carboplatin/etoposide|Carboplatin/etoposide combination
219284888|NCT01581502|OTHER|This is an observational study.|This is an observational, not intervention, study.
219284889|NCT06381544|OTHER|Aromatherapy application|Applying lemon, orange and frankincense oils via inhalation
219284890|NCT05850728|DRUG|TLC-ART|TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
219284891|NCT03500991|BIOLOGICAL|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
219284892|NCT01035359|PROCEDURE|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
219284893|NCT01035359|PROCEDURE|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
219284894|NCT00981877|DRUG|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
219284895|NCT00981877|DRUG|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
219284896|NCT00981877|DRUG|GC (placebo)|Placebo 1 gram twice daily for 5 days.
219284897|NCT06317467|OTHER|Blood sampling|Four blood samples will be collected, in conjunction with the collection of samples already programmed for assistance during pregnancy: blood sampling for the B-test (within the 13th week of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo; blood sampling for toxoplasmosis or blood sugar level, upon execution of the morphological ultrasound scanning (around the 20th and 34th weeks of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo, as well. Finally, 40 days after delivery, during routine gynaecological control after the puerperium.
219284898|NCT06317467|OTHER|Blood sampling|For patient of group 2, the blood sample will be collected at the time of the diagnosis of PE and 40-50 days after delivery in Obstetrics and Gynaecology Department of the institute or in Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
219284899|NCT04571788|PROCEDURE|Foldable Capsular Buckle|Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera \>10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
219284900|NCT04571788|PROCEDURE|Silicone scleral padding|Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
219284901|NCT04514510|DRUG|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
219284902|NCT04514510|DRUG|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
219284903|NCT05892705|DRUG|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
219284904|NCT02291939|PROCEDURE|Parotidectomy|Surgical Intervention with the FMwand Surgical System
219284905|NCT01250561|DRUG|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
219284906|NCT01250561|DRUG|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
219284907|NCT01068275|PROCEDURE|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
219284908|NCT01068275|PROCEDURE|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
219284909|NCT01068275|PROCEDURE|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
219284910|NCT00031668|RADIATION|radiation therapy|
219284911|NCT05811962|OTHER|No intervention|No intervention, only comparison
219284912|NCT00406692|DRUG|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
219284913|NCT02361268|BEHAVIORAL|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
219284914|NCT02361268|BEHAVIORAL|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
219284915|NCT05905627|BEHAVIORAL|exercise|intervention group
219284916|NCT00821587|DRUG|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
219284917|NCT00821587|DRUG|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
219284918|NCT02941900|GENETIC|MC1R genotyping|
219284919|NCT02941900|BEHAVIORAL|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
219284920|NCT02941900|BEHAVIORAL|Baseline Survey|
219284921|NCT03846180|DRUG|Terlipressin|Continuous or intermittent intravenous infusion of terlipressin was given.
219284922|NCT03846180|DRUG|Somatostatin|Continuous or intermittent intravenous infusion of somatostatin was given.
219284923|NCT03846180|DRUG|Octreotide|Continuous or intermittent intravenous infusion of octreotide was given.
219296430|NCT06727747|OTHER|Cervical traction|Cervical traction procedure was performed using Saunders device. During the procedure, the patient lies in installed in a supine position with 20 degrees of cervical flexion and the physiotherapist gradually increases (5 minutes) the load to the defined kilograms which is maintained for 10 minutes then progressively decreases (5 minutes) the load to zero kilograms. The procedure is performed twice with a rest interval of 5 minutes.
219284924|NCT01693900|PROCEDURE|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
219284925|NCT01693900|PROCEDURE|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
219284926|NCT00069537|DEVICE|The GlucoWatch® G2™ Biographer (GW2B)|
219284927|NCT00069537|DEVICE|The Continuous Glucose Monitoring System (CGMS™)|
219284928|NCT01597609|DRUG|sibutramine|10 mg, taken orally once per day for 12 weeks
219284929|NCT01597609|OTHER|sibutramine placebo|taken orally once per day for 12 weeks
219284930|NCT03856983|OTHER|Point light display|Experimental group who will do usual rehabilitation and visualization of point-light human actions
219284931|NCT03524196|OTHER|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
219284932|NCT00662142|DIETARY_SUPPLEMENT|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
219284933|NCT02958046|DRUG|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
219284934|NCT04393870|OTHER|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
219284935|NCT00693940|BEHAVIORAL|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
219284936|NCT00693940|OTHER|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
219284937|NCT01378689|OTHER|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
219284938|NCT02781090|BEHAVIORAL|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
219284939|NCT02781090|BEHAVIORAL|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
219284940|NCT02781090|DRUG|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
219284941|NCT05027035|OTHER|"surgical plication or nocturnal non-invasive ventilation"|10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
219284942|NCT06063434|BEHAVIORAL|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
219284943|NCT06063434|BEHAVIORAL|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
219284944|NCT02138708|OTHER|Pharmacological test of pulmonary endothelial|
219284945|NCT03871582|OTHER|No intervention|Cross-sectional
219284946|NCT06240923|DEVICE|Maxillary molars distalization|Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
219284947|NCT00000689|DRUG|Bleomycin sulfate|
219284948|NCT00000689|DRUG|Vincristine sulfate|
219284949|NCT00000689|DRUG|Doxorubicin hydrochloride|
219284950|NCT00000689|DRUG|Cyclophosphamide|
219284951|NCT00000689|DRUG|Methotrexate|
219284952|NCT00000689|DRUG|Cytarabine|
219284953|NCT00000689|DRUG|Leucovorin calcium|
219284954|NCT00000689|DRUG|Sargramostim|
219284955|NCT00000689|DRUG|Dexamethasone|
219284956|NCT06235437|BIOLOGICAL|ASD141|Subjects will receive one of 4 dose levels of ASD141.
219284957|NCT06808022|BEHAVIORAL|Preoperative Resistance Exercise|Participants will have been deemed to be medically safe to participate in exercise-based physical therapy based on their physician recommendation and may also undergo an in-person evaluation by a licensed physical therapist to evaluate their physical capacity. This will inform the frequency and intensity of exercise prescription according to a participant's identified physical impairments and activity tolerance levels. Based on this information, an exercise program will be implemented either via web-based HIPAA compliant platforms (e.g. Zoom or WebEx) or in the clinic(e.g if the participant does not have internet access) on a 1-2x/week basis for the 4-6 week pre-operative duration. Each exercise session will be approximately 30 minutes. During these sessions, exercises including gravity-assisted, body-weighted, or body-weight-augmented resistance exercises targeting the paraspinal extensor muscles (multifidus, erector spinae, latissimus dorsi, lower trapezius) will be performed at a mo
219284958|NCT05817552|DIAGNOSTIC_TEST|Geomagic Control X|3D Surface matching and compare
219284959|NCT01157767|OTHER|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
219284960|NCT02472990|OTHER|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
219284961|NCT02162797|DIETARY_SUPPLEMENT|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
219284962|NCT02162797|DIETARY_SUPPLEMENT|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
219284963|NCT05439382|PROCEDURE|Gingival recession regenerative surgery|Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
219284964|NCT02280369|DEVICE|Automated abdominal binder|Inflatable abdominal binder
219284965|NCT01145898|DRUG|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
219284966|NCT00023894|DRUG|alvocidib|
219284967|NCT02876822|DIETARY_SUPPLEMENT|Vitamin D|
219284968|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
219284969|NCT03506659|DEVICE|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
219284970|NCT06803745|RADIATION|200 cGy or 400 cGy total body irradiation (TBI)|Either 200 or 400cGy will be given as part of reduced-intensity conditioning prior to consolidative allogeneic bone marrow transplant (alloBMT)
219284971|NCT01712061|DRUG|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
219284972|NCT01712061|DRUG|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
219284973|NCT05994469|BEHAVIORAL|Copenhagen Adduction Exercise|The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
219284974|NCT06202963|DRUG|Triamcinolone Acetonide|"1. group will receive ultrasound-guided hydrodilatation~2. group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
219284975|NCT02313389|DRUG|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
219284976|NCT04547647|RADIATION|X- Ray|X-Ray with A-P and lateral view of the whole spine.
219284977|NCT05092074|DRUG|Vosevi 400/100/100 Oral Tablet|Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
219284978|NCT04470947|DIAGNOSTIC_TEST|Next generation functional drug screening|High-throughput image based in-vitro drug screening on primary patient tumor cells
219284979|NCT04470947|DIAGNOSTIC_TEST|Comprehensive genomic profiling|Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
219284980|NCT04481568|BEHAVIORAL|PES-4-BPSD Model|We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
219284981|NCT04481568|BEHAVIORAL|The attention control condition|On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
219284982|NCT05312281|DEVICE|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Wear for 6 weeks post-surgery
219296431|NCT06727747|OTHER|Rehabilitation|The rehabilitation program compiled cervical spine mobilization, stretching of neck muscles and isometric strengthening exercises. Passive stretching of neck muscles groups was carried-out in a seated position with 3 repetition of 30 seconds each. Isometric strengthening exercises of neck extensors were performed in a seated position, against the resistance of the physiotherapist hand for 3 repetitions of 10 seconds each
219284983|NCT02108769|BEHAVIORAL|Yogic Breathing|"1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a)."
219284984|NCT02108769|BEHAVIORAL|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
219284985|NCT00345098|DRUG|SR58611A|
219284986|NCT00879775|DRUG|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
219284987|NCT00879775|DRUG|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
219284988|NCT04791098|OTHER|Specific infectious diseases consultation|"Specific infectious diseases consultation at Clermont Ferrand Hospital with a specialist doctor :~* Update vaccinations~* Advice to travelers~* Diagnostic and treatment of latent tuberculosis infection"
219284989|NCT04162379|DRUG|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
219284990|NCT02461004|DRUG|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
219284991|NCT02461004|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
219284992|NCT02282553|DEVICE|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
219284993|NCT02282553|DEVICE|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
219284994|NCT03026959|BEHAVIORAL|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, \& Bédard, (2015).
219284995|NCT03117764|DEVICE|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
219284996|NCT03117764|BEHAVIORAL|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
219284997|NCT03117764|DEVICE|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
219284998|NCT03878329|BEHAVIORAL|remote home monitoring|Will use telemedicine to guide behavior changes in outcomes
219284999|NCT00000219|DRUG|Buprenorphine|
219285000|NCT03610347|DEVICE|Bare metal Stent plus Paclitaxel Balloon|
219285001|NCT03610347|DEVICE|Drug Eluting Stent|
219285002|NCT04806204|OTHER|music therapy|Music therapy will be applied to one group before angiography and to the other group during angiography. Patients who will listen to music before angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes. Patients who will listen to music during angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the angiography hall during the angiography procedure.
219285003|NCT05941247|DRUG|Hemay005 60 mg|"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
219285004|NCT00418548|DRUG|Etanercept|
219285005|NCT00000331|DRUG|Test Drug|
219285006|NCT00000331|DRUG|Placebo Drug|
219285007|NCT01195623|PROCEDURE|preoperative duplex examination|
219285008|NCT01195623|PROCEDURE|Preoperative duplex|
219285009|NCT03842540|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~1. Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~2. Digital materials for recipients to keep and/or share with friends.~3. Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~4. Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut."
219285010|NCT03842540|BEHAVIORAL|PartyWise|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
219285011|NCT00867295|DRUG|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
219285012|NCT00867295|DRUG|placebo|placebo
219285013|NCT06016218|DRUG|Simvastatin|Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
219285014|NCT06017739|DEVICE|Bronchial Clearance A|EFA technology: the patient has to breathe at tidal volume by a mouthpiece at level 5 for half an hour twice a day.
219285015|NCT06017739|DEVICE|Bronchial Clearance B|High Flow Technology: patient has to wear nasal cannula and breathe his nose for one hour twice a day. After he has to use EFA technology level 5 for half an hour twice a day.
219285016|NCT03285698|DEVICE|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
219285017|NCT03285698|DEVICE|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
219285018|NCT02373579|DRUG|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
219285019|NCT02373579|DRUG|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
219285020|NCT06068751|OTHER|Aerobic Exercise|The initial group will receive instructions to increase their moderate to high-intensity physical activity frequency to at least 60 minutes per day (in episodes exceeding 10 minutes) by 50%, with a minimum of three days per week. They will be encouraged to engage in enjoyable and age-appropriate activities, including jogging, brisk walking, swimming, dancing, cycling, as well as sports like basketball, football, and tennis.
219285021|NCT06068751|OTHER|Neck Exercises|The second group, focused on neck exercises, will receive guidance from an experienced physiotherapist and their families. The physiotherapist will demonstrate a series of stretching and isometric strengthening exercises for specific muscle groups: upper trapezius, levator scapula, sternocleidomastoid, cervical flexors, and extensors, which have been associated with migraines in prior studies. Each patient will perform 3 sets of 10-15 repetitions for both stretching and isometric strengthening exercises per muscle group, with a 1-minute break between sets. Patients will be advised to maintain a gentle stretch during stretching exercises, avoiding excessive force to prevent discomfort. Static stretching and isometric strengthening exercises will involve holding each position for 5-10 seconds. In the initial week, a reduced set of 5 repetitions will be allowed for adaptation. Throughout the intervention, participants will follow this exercise regimen for 3 days weekly.
219285022|NCT02278484|DEVICE|XprESS device and PathAssist confirmation tools|
219285023|NCT05447234|BIOLOGICAL|Tcrx T cell|Sequential IV infusion
219285024|NCT01293942|DRUG|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
219285025|NCT01870947|BEHAVIORAL|Exercise on stationary recumbent exercise cycle|
219285026|NCT01870947|BEHAVIORAL|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
219285027|NCT01870947|BEHAVIORAL|Questionnaires|
219285028|NCT01870947|PROCEDURE|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
219285029|NCT01870947|PROCEDURE|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
219285030|NCT05862428|DRUG|Rectal misoprostol|This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
219285031|NCT01401153|OTHER|Skipping lunch|Just water.
219285032|NCT02964533|OTHER|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
219285033|NCT02964533|OTHER|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
219285034|NCT02212652|DIETARY_SUPPLEMENT|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
219285035|NCT02212652|OTHER|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
219285036|NCT02212652|OTHER|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
219285037|NCT02517762|BEHAVIORAL|Physical activity|
219285038|NCT03556904|RADIATION|Ablative Radiation Therapy|Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.
219285039|NCT03556904|DRUG|Hormone therapy or chemotherapy|Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
219285040|NCT04081870|DIAGNOSTIC_TEST|3D power doppler US|Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
219285041|NCT00953277|OTHER|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
219285042|NCT00214019|DRUG|salmeterol|salmeterol diskus 50 mcg twice per day
219178085|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
219285043|NCT00214019|DRUG|Fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
219285044|NCT00214019|DRUG|Placebo|placebo diskus
219285045|NCT00795275|DRUG|Sitagliptin Phosphate|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
219285046|NCT05303389|PROCEDURE|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
219296432|NCT06658574|DRUG|Acetaminophen|Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
219296433|NCT06056804|DRUG|capecitabine|825-1000mg/m2,po,bid
219296434|NCT06056804|DRUG|tislelizumab|200mg,iv.gtt,q3w
219296435|NCT06056804|DRUG|thymalfasin|4.8mg,sc,biw
219296436|NCT06056804|RADIATION|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
219296437|NCT05593445|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
219178086|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
219178087|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
219178088|NCT06532994|OTHER|Early rehabilitation intervention|"Based on the indications for early rehabilitation intervention outlined in the Chinese Expert Consensus on Neurological Critical Care Rehabilitation, early rehabilitation interventions are categorized into three stages according to the patient's consciousness level (GCS score), degree of cooperation (S5Q score), and sedation status (RASS score)"
219178089|NCT04700878|BEHAVIORAL|Internet-based compassion course for stress managemant|A five week long, structured self-help program with weekly reports to, and feedback from a compassion-focused (CFT) therapist over the Internet. Includes traditional CFT-methods for stress-related problems.
219178090|NCT04700878|BEHAVIORAL|General Internet-based cognitive behavioural course for stress management|A five week long, structured self-help program with weekly reports to, and feedback from a cognitive-behavioral (CBT) therapist over the Internet. Includes traditional CBT-methods for stress-related problems.
219178091|NCT03051997|BEHAVIORAL|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
219178092|NCT03051997|BEHAVIORAL|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
219178093|NCT05415501|BEHAVIORAL|Sentence training|Participants will be trained to read, make, and recall sentences during each session.
219178094|NCT04049331|DRUG|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
219178095|NCT04049331|OTHER|placebo|first two doses four weeks apart; following three more doses every ten weeks.
219178096|NCT06798727|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
219178097|NCT06798727|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
219178098|NCT06798727|DRUG|High Hyal Plus|A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
219178099|NCT06051695|BIOLOGICAL|A2B694|Autologous logic-gated Tmod CAR T cells
219178100|NCT06051695|DIAGNOSTIC_TEST|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
219178101|NCT06800365|DEVICE|Sensor|The FreeStyle Libre Pro sensor is a device whereby a sensor is inserted into subcutaneous tissue (upper arm) and measures the interstitial blood glucose which is then available for later download. It comes pre-calibrated meaning that no fingerstick glucose monitoring is required to improve accuracy of the sensor.
219178102|NCT02838381|OTHER|Additional biological samples|blood and tissue samples
219178103|NCT00131703|DRUG|Amodiaquine|
219178104|NCT00131703|DRUG|Sulphadoxine-pyrimethamine|
219178105|NCT00131703|DRUG|Chloroquine|
219178106|NCT06801392|PROCEDURE|pulsed-field ablation|PVI + PW ablation
219178107|NCT04806451|DRUG|Crinecerfont|CRF type 1 receptor antagonist
219178108|NCT04806451|DRUG|Placebo|Non-active dosage form
219285047|NCT01940432|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
219285048|NCT01940432|BEHAVIORAL|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
219285049|NCT04207580|OTHER|Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,|"The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients.~A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment)."
219285050|NCT03156972|PROCEDURE|Replacment of mitral valve|Mitral valve replacment by prothsis
219285051|NCT04314141|PROCEDURE|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes"
219285052|NCT03474926|PROCEDURE|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
219285053|NCT03474926|PROCEDURE|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
219285054|NCT04870008|PROCEDURE|Suture|The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.
219285055|NCT05727189|DRUG|TR-01-XRR (1)|Extended-release form
219285056|NCT05727189|DRUG|TR-01-XRR (2)|Extended-release form
219285057|NCT05727189|DRUG|TR-01-XRR (3)|Extended-release form
219285058|NCT05727189|DRUG|TR-01-XRS|Extended-release form
219285059|NCT05727189|DRUG|TR-01-XR|Extended-release form
219285060|NCT05727189|DRUG|TR-01-IR|Active comparator
219285061|NCT05727189|DRUG|Placebo|Placebo comparator
219285062|NCT04596839|DRUG|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
219285063|NCT04596839|OTHER|Standard of Care|Standard of Care Treatment for COVID-19 Infection
219285064|NCT05049135|DEVICE|Somnofy® sleep monitor|Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
219285065|NCT03586934|DRUG|Acetaminophen|Acetaminophen Tablet
219285066|NCT03586934|DRUG|Celecoxib 200mg|Celecoxib Tablet
219285067|NCT03586934|DRUG|Celecoxib 400 mg|Celecoxib Tablet
219285068|NCT03586934|DRUG|Ropivacaine|Ropivicaine nerve block (injection)
219285069|NCT03586934|DRUG|Ketorolac|ketorolac injection
219285070|NCT03586934|DRUG|Acetaminophen Injectable Product|Acetaminophen injection
219285071|NCT03586934|DRUG|Oxycodone|oxycodone tablet
219285072|NCT03586934|DRUG|Tramadol|Tramadol tablet
219285073|NCT03586934|DRUG|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
219285074|NCT03586934|DRUG|hydrocodone bitartrate and acetaminophen|Norco tablet
219285075|NCT03586934|DRUG|Morphine|morphine injection
219285076|NCT03586934|DRUG|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
219285077|NCT03586934|DRUG|Meloxicam|meloxicam tablet
219285078|NCT02642692|PROCEDURE|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
219285079|NCT02642692|PROCEDURE|Hamstring Graft|Acl reconstruction with hamstring graft
219285080|NCT01261117|DRUG|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
219285081|NCT03163927|OTHER|Simulation-based training|See arm description
219285082|NCT00757627|DRUG|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
219285083|NCT02303600|DRUG|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
219285084|NCT02303600|OTHER|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
219285085|NCT03846453|BIOLOGICAL|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
219285086|NCT03846453|BIOLOGICAL|Placebo|Placebo vehicle solution
219285087|NCT01173965|DEVICE|MEA|Microwave endometrial ablation device
219285088|NCT01173965|DEVICE|Novasure|Bipolar impedence control system
219285089|NCT02888574|DRUG|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
219285090|NCT02888574|DRUG|Placebo|Placebo nasal spray
219285091|NCT04210921|DEVICE|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
219285092|NCT04210921|DEVICE|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
219285093|NCT04313257|OTHER|Monocular Active Occlusion|Occlusion treatment of one hour daily with action video game.
219285094|NCT04313257|OTHER|Monocular Passive Occlusion|Occlusion treatment of two hour daily.
219285095|NCT05717491|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
219285096|NCT05717491|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
219285097|NCT00468143|DRUG|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
219285098|NCT00468143|DRUG|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
219285099|NCT01384799|DRUG|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
219285100|NCT01384799|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
219285101|NCT01384799|RADIATION|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
219285102|NCT04664075|BIOLOGICAL|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
219285103|NCT01667094|DRUG|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
219285104|NCT01667094|DRUG|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
219285105|NCT01667094|DRUG|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
219285106|NCT01667094|DRUG|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
219285107|NCT01667094|DRUG|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
219285108|NCT01667094|DRUG|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
219285109|NCT01667094|DRUG|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
219285110|NCT01667094|DRUG|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
219285111|NCT01667094|DRUG|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
219285112|NCT01667094|DRUG|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
219285113|NCT02915419|BIOLOGICAL|PRP|platelet rich plasma
219285114|NCT02915419|BIOLOGICAL|PRF|PLATELET RICH FIBRIN
219285115|NCT02636725|DRUG|Axitinib|5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
219285116|NCT02636725|DRUG|Pembrolizumab|200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
219285117|NCT04210167|BEHAVIORAL|web-based training and telephone monitoring|web-based training and telephone monitoring and short message
219285118|NCT03659864|OTHER|diesel exhaust particulate|aerosolised diesel exhaust particulate
219285119|NCT03659864|OTHER|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
219285120|NCT03659864|OTHER|small graphene oxide|aerosolised 'small' graphene oxide
219285121|NCT03659864|OTHER|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
219285122|NCT03659864|OTHER|filtered air|control: filtered air
219285123|NCT01344772|PROCEDURE|Internal fixation|Two cannulated screws are placed under x-ray guidance
219285124|NCT01344772|PROCEDURE|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
219285125|NCT02466464|DEVICE|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
219285126|NCT02466464|DEVICE|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
219285127|NCT06330012|DIAGNOSTIC_TEST|GeoMx data analysis with clinical outcome|"1. List of HER2 positive breast cancer~   * Stage IV disease~  * Treated with T-Dxd~  * Available FFPE samples~2. Prepare tissue for digital spatial proteomics~   * FFPE/H\&E slide~  * Region of Interest(ROI) check~  * Make a Tissue microarray~  * Prepare special slide for GeoMx~3. GeoMx data analysis with clinical outcome"
219285128|NCT03370744|DIAGNOSTIC_TEST|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
219285129|NCT05078593|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
219285130|NCT05247905|DRUG|Lutetium Lu 177 Dotatate|Given IV
219285131|NCT05247905|DRUG|Capecitabine|Given PO
219285132|NCT05247905|DRUG|Temozolomide|Given PO
219285133|NCT05247905|OTHER|Quality-of-Life Assessment|Ancillary studies
219285134|NCT05247905|OTHER|Questionnaire Administration|Ancillary studies
219285135|NCT00709267|DRUG|Folic acid|
219285136|NCT01585077|BIOLOGICAL|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
219285137|NCT00261976|DRUG|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
219285138|NCT01383655|DRUG|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
219285139|NCT01383655|DRUG|Placebo|NaCl
219285140|NCT03968380|OTHER|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
219285141|NCT05010343|RADIATION|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
219285142|NCT05010343|RADIATION|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
219285143|NCT05330676|PROCEDURE|coronary artery bypass grafting, valve repair/replacement|cardiovascular surgery with cardiopulmonary bypass
219285144|NCT04508127|DEVICE|Spinal cord stimulation|
219285145|NCT01529320|DRUG|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
219296438|NCT05593445|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
219285146|NCT06185231|OTHER|Percussion Massage Group|In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
219285147|NCT06185231|OTHER|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes."
219285148|NCT03878277|DRUG|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
219285149|NCT00355303|DRUG|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
219285150|NCT00355303|DRUG|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
219285151|NCT04058275|OTHER|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
219285152|NCT06345651|DEVICE|Transcranial Magnetic Stimulation|Individually MR-neuronavigated TMS, 600 pulses, 120% RMT
219285153|NCT01013038|PROCEDURE|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
219285154|NCT01013038|PROCEDURE|conventional PCI|balloon angioplasty and/or stent implantation
219285155|NCT01638143|DIETARY_SUPPLEMENT|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
219285156|NCT01638143|DIETARY_SUPPLEMENT|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
219285157|NCT01638143|DIETARY_SUPPLEMENT|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
219285158|NCT00091559|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
219285159|NCT00193752|OTHER|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
219285160|NCT03265171|BIOLOGICAL|Plasminogen (Human)|
219285161|NCT02736240|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
219285162|NCT02736240|BIOLOGICAL|13-valent pneumococcal polysaccharide conjugate vaccine|
219285163|NCT01559129|DRUG|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
219285164|NCT01559129|DRUG|Placebo|Matching placebo capsules taken orally once a day
219285165|NCT00368927|DRUG|sulindac|Given orally
219285166|NCT00368927|OTHER|placebo|Given orally
219285167|NCT00009659|DRUG|CDB 2914|
219285168|NCT03017898|PROCEDURE|Laser Coagulation|Laser coagulation of anal fistula
219285169|NCT02392052|BEHAVIORAL|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
219285170|NCT02392052|BEHAVIORAL|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
219285171|NCT00878683|DEVICE|silicone catheter boot|silicone device using Dermabond
219285172|NCT00881062|DRUG|Proellex|A single oral dose administered after at least a 10 hour fast
219285173|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (lower dose)
219285174|NCT01521936|OTHER|pharmacological study|Correlative studies
219285175|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (higher dose)
219285176|NCT01521936|OTHER|laboratory biomarker analysis|Correlative studies
219285177|NCT04606108|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
219285178|NCT04445740|BEHAVIORAL|i♥rhythm project|behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
219285179|NCT03525392|DRUG|177Lu-3BP-227 (also called 177Lu-IPN01087)|The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
219285180|NCT03750786|DRUG|Arfolitixorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
219285181|NCT03750786|DRUG|Leucovorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
219285182|NCT01922388|DEVICE|Bilateral deep brain stimulation of the subthalamic nucleus|
219285183|NCT05151900|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
219285184|NCT03284203|DEVICE|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
219285185|NCT02229851|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
219285186|NCT02229851|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
219285187|NCT02229851|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
219285188|NCT06403189|OTHER|Biologic samples and MRI|"* blood sample~* lumbar punction~* MRI"
219285189|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
219285190|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
219285191|NCT04078763|BEHAVIORAL|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
219285192|NCT04078763|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
219285193|NCT04078763|BEHAVIORAL|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
219285194|NCT05414344|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
219285195|NCT05414344|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
219285196|NCT05414344|BEHAVIORAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
219285197|NCT06436638|DEVICE|Non-invasive ventilation support equipment|Non-invasive ventilation support is provided by nasal airway and nasal CPAP mask to avoid respiratory complications such as hypoxia, desaturation, hypercarbia, respiratory depression etc. during extraction of impacted molars under deep sedation.
219285198|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
219285199|NCT02441868|BEHAVIORAL|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
219285200|NCT03873168|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
219285201|NCT06437951|DRUG|Fexuprazan Injection|20/40/80 mg
219285202|NCT06437951|DRUG|Fexuprazan Injection placebo|20/40/80 mg
219285203|NCT06437951|DRUG|Fexuprazan Injection_part 2|20mg
219285204|NCT06437951|DRUG|Fexuprazan Injection_part 3|40mg
219285205|NCT06437951|DRUG|Fexuprazan tablet|40mg
219285206|NCT04187326|BEHAVIORAL|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
219285207|NCT06042413|OTHER|Personalized CPC Prehabilitation|Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
219285208|NCT06042413|BEHAVIORAL|Cognitive Training|Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
219285209|NCT06042413|BEHAVIORAL|Meditation|A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
219285210|NCT06042413|BEHAVIORAL|Daily Exercise|Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
219285211|NCT06042413|BEHAVIORAL|Enhanced Social Support|"Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program."
219285212|NCT06042413|OTHER|Proactive Bundle Interventions|Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit \>30, MAP \>70, and anesthetic BIS \>50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
219285213|NCT06042413|PROCEDURE|Pre-operative Standard of Care|Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
219285214|NCT06042413|PROCEDURE|Intra-operative Standard of Care|This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
219285215|NCT01607476|DRUG|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
219285216|NCT01607476|DRUG|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
219285217|NCT04706299|OTHER|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
219285218|NCT04964349|DRUG|Corticosteroids Acting Locally|topical application of jessener solution
219285219|NCT05703906|BEHAVIORAL|Telerehabilitation - VRRS Khymeia|Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
219285220|NCT00002775|DRUG|docetaxel|
219285221|NCT00002775|DRUG|estramustine phosphate sodium|
219296439|NCT06610591|PROCEDURE|Achilles Lengthening Surgery|The procedure is undertaken under general anaesthetic and involves horizontal hemi-section of the Achilles tendon via small 'stab' incisions at three levels to effect a lengthening of the tendon. The patient is then placed in a walking cast for four weeks thereafter. This surgery is usual care for most children with symptomatic ITW with plantarflexion contractures who have failed non-operative management.
219285222|NCT06003322|PROCEDURE|non - Incised Papilla surgical approach NIPSA for intrabony defect|"As described by Rodríguez and Caffesse in 2018, a single incision apical to the defect ,on the buccal aspect, only one apical horizontal or oblique incision will be made in the alveolar mucosa, as far removed as possible from the interdental papillae and marginal keratinized tis- sues.~Following flap reflection, the bony defect will be examined carefully. Root planing is performed,. Flap closure will be performed by horizontal mattress sutures, placed 3 mm away from the borders, will be used as the first line of closure, promoting connective tissue contact between both edges of the incision, and single interrupted sutures will then be placed as a second line of closure. Using 5/0 polypropylene monofilament suture, Assut, Swiss"
219285223|NCT06003322|PROCEDURE|single-flap approach SFA|"As described by Trombelli et al 2010, A horizontal, butt-joint incision will be performed at the interdental papilla 1-2 mm coronal to the bone crest (as detected through pre-operative bone sounding).~-A buccal mucoperiosteal envelope flap will be elevated by using a microsurgical periosteal elevator, leaving the residual portion of the interdental supracrestal soft tissues undetached.Flap closure will be performed by a horizontal internal mattress suture,will be performed at the base of the papilla, and a second internal mattress suture (vertical or horizontal) was performed between the most coronal portion of the flap and the most coronal portion of the palatal/lingual papilla. Using a resorbable suture"
219285224|NCT02299414|DRUG|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
219285225|NCT02299414|OTHER|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
219285226|NCT01869023|DRUG|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
219285227|NCT01869023|DRUG|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
219285228|NCT03349502|DRUG|MG4101|Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
219285229|NCT00299442|BEHAVIORAL|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
219285230|NCT04098562|DRUG|LL37|cream
219285231|NCT04098562|PROCEDURE|Standard Wound Care|Standard wound debridement
219285232|NCT04958200|BEHAVIORAL|mhealth-pc for alcohol and pain|Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.
219285233|NCT04958200|BEHAVIORAL|Treatment As Usual|psychoeducation on pain and alcohol use and treatment resource information
219285234|NCT05025592|DRUG|Regorafenib|patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
219285235|NCT05025592|DEVICE|cTACE/DEB-TACE-HAIC|conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
219285236|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
219285237|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
219285238|NCT06052709|OTHER|Occupational balance assessment|There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
219285239|NCT01241825|OTHER|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
219285240|NCT01241825|OTHER|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
219285241|NCT03055429|OTHER|Full Scale Unit|Pre-test, usability, post-test
219285242|NCT00623805|DRUG|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
219285243|NCT00623805|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
219285244|NCT00623805|DRUG|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
219285245|NCT00713505|OTHER|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
219285246|NCT00713505|PROCEDURE|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
219285247|NCT03725527|PROCEDURE|Rectus Sheath Block|Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
219285248|NCT01800890|DEVICE|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
219285249|NCT01800890|DEVICE|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
219285250|NCT01800890|DEVICE|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
219285251|NCT01800890|DEVICE|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
219285252|NCT00635128|BIOLOGICAL|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
219285253|NCT02169544|DRUG|Abatacept|
219285254|NCT04818008|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
219285255|NCT04032184|OTHER|Fluoride toothpaste|regimen using fluoride toothpaste
219285256|NCT04032184|OTHER|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
219285257|NCT04032184|OTHER|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
219285258|NCT01949389|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
219285259|NCT01012297|BIOLOGICAL|Bevacizumab|Given IV
219285260|NCT01012297|DRUG|Docetaxel|Given IV
219285261|NCT01012297|BIOLOGICAL|Filgrastim|Given SC
219285262|NCT01012297|DRUG|Gemcitabine Hydrochloride|Given IV
219285263|NCT01012297|BIOLOGICAL|Pegfilgrastim|Given SC
219285264|NCT01012297|OTHER|Placebo|Given IV
219296440|NCT06611332|OTHER|Electroacupuncture|The main acupoints selected for the electroacupuncture group are bilateral BL23, bilateral BL25, bilateral GB30, bilateral LR11, bilateral LR8, GV4, GV3, and the affected BL40, and the secondary acupoints selected are bilateral BL54, the affected side BL57 and the affected side BL60.The treatment will be administered once every other day for 30 minutes each time, lasting for 8 consecutive weeks, totaling 24 sessions.
219285265|NCT04323540|PROCEDURE|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
219285266|NCT04655027|DRUG|Roxadustat|The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
219285267|NCT04655027|DRUG|rHuEPO|The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of \>6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.
219285268|NCT01297153|DEVICE|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
219285269|NCT01297153|DEVICE|No IOL|No IOL will be implanted in these eyes
219285270|NCT03350932|BEHAVIORAL|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
219285271|NCT02860689|OTHER|using questionnaires - International Index Erectile Function|using questionnaires
219285272|NCT01169922|BEHAVIORAL|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
219285273|NCT01169922|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
219285274|NCT04781413|DRUG|Nab-PTX, Sintilimab, S-1|This is a single-arm study with all patients receiving these three drugs.
219285275|NCT05504252|DRUG|Nivolumab|"Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks"
219285276|NCT05504252|DRUG|Oxaliplatin|FLOX, Q2W
219285277|NCT02245022|DRUG|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
219285278|NCT02245022|DRUG|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
219285279|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
219285280|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
219285281|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
219285282|NCT05887115|BEHAVIORAL|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
219285283|NCT02753179|OTHER|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
219285284|NCT02753179|OTHER|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
219285285|NCT02753179|OTHER|VEMPs & VEMPo|VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
219285286|NCT02753179|OTHER|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
219285287|NCT02753179|OTHER|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
219285288|NCT03519997|DRUG|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
219285289|NCT03519997|DRUG|Bavituximab|Bavituximab 3mg/kg IV weekly
219285290|NCT06271707|DRUG|0.5% bupivacaine|an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
219285291|NCT06271707|OTHER|Saline|an ultrasound guided left stellate ganglion block with 5 mL of saline
219285292|NCT06542250|DRUG|AZD5492|CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
219285293|NCT05811299|OTHER|Kinesio taping|Total of 8 sessions for 4 weeks 2 sessions in a week.
219285294|NCT05811299|OTHER|Abominal exercises|Total of 8 sessions for 4 weeks 2 sessions in a week.
219285295|NCT06533748|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
219285296|NCT06533748|DRUG|Vincristine|Given IV.
219285297|NCT06533748|DRUG|Inotuzumab|Given IV.
219285298|NCT06533748|DRUG|Blinatumomab|Given IV.
219285299|NCT06533748|DRUG|Dasatinib|Given PO.
219285300|NCT06533748|PROCEDURE|IT MHA|Given Intrathecal (IT), Age adjusted.
219285301|NCT06533748|DRUG|Cyclophosphamide|Given IV.
219285302|NCT06533748|DRUG|Cytarabine|Given IV or IT.
219285303|NCT06533748|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
219285304|NCT06533748|DRUG|6-Mercaptopurine|Given PO.
219285305|NCT06533748|DRUG|Calaspargase|Given IV.
219285306|NCT06533748|DRUG|Daunorubicin|Given IV.
219285307|NCT06533748|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
219285308|NCT06398418|DRUG|R-5780|Probiotic
219285309|NCT03777852|DIAGNOSTIC_TEST|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
219285310|NCT03777852|DIAGNOSTIC_TEST|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
219285311|NCT01681615|DRUG|Acetylsalicylate|1-2 drops
219285312|NCT01681615|DRUG|Isotonic NaCl|1 drop
219285313|NCT06415604|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving."
219285314|NCT06415604|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
219285315|NCT06177392|PROCEDURE|Secondary TAVI access|The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
219285316|NCT05048212|DRUG|Nivolumab|Given by IV
219285317|NCT05048212|DRUG|Ipilimumab|Given by IV
219285318|NCT05048212|DRUG|Cabozantinib|Given by IV
219285319|NCT05817240|DRUG|taladegib|100 mg per tablet, dosed once daily
219285320|NCT05817240|DRUG|nintedanib|100 mg per capsule, dosed once daily
219285321|NCT05141643|DIAGNOSTIC_TEST|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
219285322|NCT05418634|OTHER|point of care EEG|For pocEEG, scalp electrodes are applied in five locations.
219285323|NCT02906007|DRUG|Bedaquiline|Participants received bedaquiline (BDQ) once per day through intensive PK sampling visit, then 3 times per week on Monday, Wednesday and Friday through the week 24 visit.
219285324|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
219285325|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
219285326|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
219285327|NCT05703607|BIOLOGICAL|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
219285328|NCT05703607|BIOLOGICAL|Shingrix|Intramuscular injection
219285329|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
219285330|NCT03560375|BEHAVIORAL|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
219285331|NCT03560375|BEHAVIORAL|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
219285332|NCT03560375|DRUG|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
219285333|NCT04669496|DRUG|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
219285334|NCT05593302|BEHAVIORAL|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
219285335|NCT03960047|BEHAVIORAL|Virtual Reality Training|This group gets trained to cross streets using virtual reality
219285336|NCT03960047|BEHAVIORAL|Streetside Training|This group is trained to cross streets based on streetside experiences
219285337|NCT06511310|OTHER|Exercise|High Intensity Exercise
219285338|NCT05177835|DRUG|ABX464|All subjects will receive ABX464 given at 25 mg QD.
219285339|NCT06507293|PROCEDURE|Paravertebral block|Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
219285340|NCT06507293|PROCEDURE|Erector spiane plane block|Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
219285341|NCT06373068|OTHER|Resuscitation orders|Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
219285342|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks (56 days).
219285343|NCT00393497|DRUG|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
219285344|NCT04482933|BIOLOGICAL|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
219285345|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
219285346|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
219285347|NCT06591221|PROCEDURE|Chuna Maintenance Therapy|"it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner."
219285348|NCT06606210|DEVICE|InnovaMatrix® AC|Weekly dressing applications
219285349|NCT04866004|BEHAVIORAL|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
219285350|NCT06986772|DRUG|[14C]TGRX-678|Healthy subjects will be given TGRX-678 240 mg orally on day 1.
219285351|NCT06664034|BEHAVIORAL|Multi-component reproductive health care intervention|"The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
219285352|NCT06825364|OTHER|auricular stimulation|Different points on both ears will be repeatedly stimulated with a plastic filament. This will be felt, but not be painful and should not result in lasting irritation.
219285353|NCT06200272|COMBINATION_PRODUCT|Germ and Carob Molasses Pulp added standard whole wheat breads|Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
219285354|NCT06597279|BEHAVIORAL|Web-based dialysis decision support tool|"The intervention in this study is the Kidney Care Roadmap, a web-based dialysis decision support tool designed to assist patients with advanced chronic kidney disease and their caregivers."
219285355|NCT06106542|OTHER|assessment|assessment of motor imagery on muscle oxygenation
219285356|NCT06858280|DRUG|Patiromer 8400 MG [Veltassa]|Randomized patients will receive one 8.4 g packet of patiromer per day or one identical packet containing a placebo. To minimize the possibility of interference with gastrointestinal absorption of other orally administered medications, administration of patiromer will be separated by at least 3 hours from other oral medicinal products. Throughout the whole study period, the study drug will be administered every day in the morning.
219285357|NCT06858280|DRUG|Placebo|Randomized patients will receive one packet of placebo identical to that of patiromer. Following the same treatment sequence of patiromer, administration of the placebo will be separated by at least 3 hours from any other oral medicinal products. As for patiromer, the placebo will be administered every day in the morning.
219285358|NCT06297213|DRUG|R-2487|R-2487 DP
219285359|NCT06612710|DRUG|extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）
219285360|NCT06612710|DRUG|a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles placebo (4×10\^9 particles/kg)
219285361|NCT04089358|OTHER|Educational Intervention|Receive educational materials
219285362|NCT04089358|DEVICE|FitBit|Wear a Fitbit
219285363|NCT04089358|OTHER|Goal Setting|Set goals
219285364|NCT04089358|OTHER|Health Promotion and Education|Receive text message about goal setting
219285365|NCT04089358|OTHER|Media Intervention|Follow Instagram group
219285366|NCT04089358|BEHAVIORAL|Telephone-Based Intervention|Receive phone call about goal setting
219285367|NCT06591091|DRUG|Clemastine Fumarate|Listed in arm/group description
219285368|NCT06591091|DRUG|Placebo|Listed in arm/group description
219285369|NCT06604234|DIETARY_SUPPLEMENT|Probiotic|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule
219285370|NCT06604234|OTHER|Placebo|Placebo comparator containing maltodextrin
219285371|NCT06994468|DIAGNOSTIC_TEST|Flow-cytometry tetramer-based antigen-bait assay|"For tetramer assembly, recombinant biotinylated PLA2R will be incubated with either streptavidin-PE (Agilent) or streptavidin-APC (Agilent) conjugates according to the NIH protocol (https://tetramer.yerkes.emory.edu/support/protocols#10).~PBMCs will be thawed and resuspended in antibody cocktail medium containing 7.5ug APC- and PE- PLA2R tetramers. Multicolor flow cytometry will be used to identify B-cell subsets with standard technique and equipment (FACS FortessaX20, BD Biosciences and FlowJo software). PLA2R-specific B cells will be determined as Tetramer double (PE/APC) positive B cells that bind with proportional fluorescent intensities to each tetramer. Each sample will be incubated with only streptavidin-PE/APC conjugates to exclude B cells binding to the fluorochrome portion of the tetramers. T cell- and NK/NKT cell phenotyping will be assessed by FACS using ad-hoc antibody panels."
219285372|NCT05702684|OTHER|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
219285373|NCT03004716|OTHER|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
219285374|NCT06369298|DRUG|JK07|JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
219285375|NCT06369298|DRUG|Placebo|0.9% sodium chloride
219285376|NCT02030613|GENETIC|Blood test|
219285377|NCT07030166|OTHER|No intervention measures were used.|The exposure factors were the perioperative related operations experienced by the patients and their individual conditions
219285378|NCT06877793|DIAGNOSTIC_TEST|Administration of indocyanine green (ICG) and fluorescence imaging|Patients with clinical and lab findings consistent with a diagnosis of NSTI who consent to this study will receive a one-time, weight-appropriate dose of ICG (0.2 mg/kg, in accordance with FDA-approved recommendations). Each patient will undergo fluorescence imaging immediately before and after administration of ICG.
219285379|NCT07135479|OTHER|Youth Mental Health First Aid|This Youth Mental Health First Aid training has been adapted for South Asian American adults working with South Asian American youth. This training is a full-day, 5.25 hour blended course (some self-paced work and some live, virtual participation).
219285380|NCT00365170|DRUG|human insulin|
219285381|NCT00365170|DRUG|insulin aspart|
219285382|NCT06390865|PROCEDURE|Biopsy Procedure|Undergo biopsy
219285383|NCT06390865|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219285384|NCT06390865|PROCEDURE|Computed Tomography|Undergo CT scan
219285385|NCT06390865|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219285386|NCT06390865|DRUG|Sapanisertib|Given PO
219285387|NCT06726928|DEVICE|Sinus Stenting|Stenting of symptomatic sinus stenosis
219285388|NCT06379542|DRUG|XC8|40 mg/day or 80 mg/day for 7-14 days
219285389|NCT06379542|DRUG|Placebo|2 tablets/day for 7-14 days
219285390|NCT06729879|OTHER|Yoga eye exercises group:|Yoga eye exercises
219285391|NCT06729879|OTHER|Myofascial release-postural correction exercises group|Myofascial release-postural correction exercises
219285392|NCT06729879|OTHER|Yoga eye exercises, myofascial release-postural correction exercises group|Yoga eye exercises, myofascial release-postural correction exercises group
219285393|NCT06729879|OTHER|control group|no intervention
219285394|NCT07046260|OTHER|Blood sample collection|The study will collect up to 40 mL of whole peripheral blood in Streck Cell-Free DNA BCT® tubes from each Subject.
219285395|NCT07101419|OTHER|Long PRT|PRT (in seconds) set at 75% of inspiratory time (in seconds)
219285396|NCT07101419|OTHER|Short PRT|PRT (in seconds) set at 33% of inspiratory time (in seconds).
219285397|NCT07110584|DRUG|MDX2004|MDX2004 intravenous infusion
219285398|NCT07111481|BEHAVIORAL|Mozart music|Participants will be played Mozart's Sonata for Two Pianos in D Major, K. 448 during their surgical simulation training session with an AI tutor.
219285399|NCT06738121|PROCEDURE|Infra-umbilical incision|Traditional curvilinear infra-umbilical incision is used to repair the umbilical hernia
219285400|NCT06738121|PROCEDURE|Transumbilical incision|The incision for the repair of the umbilical hernia will be carried through the umbilicus itself.
219285401|NCT07107841|OTHER|Autologous Hair Follicle-Derived Secretome|Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.
219285402|NCT07107841|OTHER|Placebo Control|The same saline used for diluting the active treatment in will be used as a control.
219285403|NCT07109505|DIETARY_SUPPLEMENT|Nutritional Shake|The shake mixes will be dry shelf -stable powders prepared with ingredients readily available in the US food supply and contain a minimum of 990 mg total cocoa flavanols, with a profile to support general nutritional health including 10 g protein. Accordingly, each shake contains approximately 95 mg of caffeine, equivalent to a medium-sized cup of coffee. Based on prior studies of cognition, additional composition specifications are: 1600 mg DHA and up to 400 mg EPA and 550 mg choline; \>250 mg epicatechin and epigallocatechin (plant polyphenols); multivitamin/mineral fortification to ensure 50-100% of all essential micronutrients except calcium (to prevent competitive absorption with other divalent cations). Participants will be given a supply of pre-portioned daily servings upon discharge from the hospital, for 30 days after surgery.
219285404|NCT07109505|OTHER|Nutritional Instructions Only|The control arm receives the Nutrition After Surgery instructions, which provide guidelines for healthy eating after surgery but not the nutritional shake. The intervention arm receives the same instructions along with the nutrition shake mix and accompanying postoperative supplementation
219285405|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
219285406|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
219285407|NCT07119268|DEVICE|SPARK Healthy Sleep|SPARK-Healthy Sleep is a single-session digital intervention delivered via smartphone that combines stigma reduction with evidence-based sleep improvement strategies.
219285408|NCT06920251|DRUG|Letermovir|"Elranatamab: Participants will receive SC administration of elranatamab QW, Q2W or Q4W. The initial doses of elranatamab will be 12 mg (C1D1) and 32 mg (C1D4) and will serve as the 2 step-up priming regimen.~Dexamethasone: Dexamethasone is administered at the dose of 20 mg/day on C1D1, C1D4 and C1D8 as a premedication for elranatamab~Letermovir: Letermovir is administered at the dose of 480mg/day PO from C1D15 (W3) to C4 (W16) (total of 98 days)."
219285409|NCT07131007|BEHAVIORAL|Immunotherapy Monitoring and Sample Collection|For cancer patients receiving immune checkpoint inhibitors (ICIs), we conduct behavioral monitoring: collect blood, urine, and feces samples before medication and 7 days after medication for multi - omics analysis. Monitor organ function indicators at 24 hours, 72 hours, and 1 week post - medication. No interference with standard ICI treatment; focus on observational data collection to construct an organ damage early - warning system.
219285410|NCT07153718|PROCEDURE|Electrogram-guided ablation|pulmonary vein ioslation; target electrograms ablation, including (1) Spatial-temporal Dispersion Activation, (2) Locally Short Cycle Length Activity, (3) High-Frequency Potentials, (4) Focal Activity.
219285411|NCT07153718|PROCEDURE|Anatomical-guided Ablation|pulmonary vein isolation; LA roof, posterior inferior wall and mitral isthmus linear lesion; Vein of Marshall (VOM) ethanol infusion.
219285412|NCT07153718|PROCEDURE|Extensive electrogram-anatomical guided ablation|pulmonary vein isolation; target electrogram ablation; linear ablation
219285413|NCT04193826|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
219285414|NCT05576753|PROCEDURE|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
219285415|NCT05718466|DRUG|Bevacizumab|
219285416|NCT05718466|DRUG|Chemotherapy|
219285417|NCT05718466|RADIATION|Fractionated radiosurgery|
219285418|NCT02159508|BEHAVIORAL|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
219285419|NCT05947032|OTHER|Supervised endurance exercise training + Patient Education|"ENDURANCE TRAINING:~Treadmill Walking:~Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training~Recumbent Bike:~Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training~\+ Patient Education"
219285420|NCT05947032|OTHER|Home exercises + Patient Education|"HOME EXERCISES:~CONVENTIONAL Treatment:~Walking:~Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training~Stair climbing:~Frequency: 1 flight/ day Type: aerobic training~\+ Patient Education"
219285421|NCT00386282|DRUG|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
219285422|NCT04695912|DEVICE|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
219285423|NCT04009733|BIOLOGICAL|Blood sample|A study specific blood sample will be collected.
219285424|NCT04009733|BIOLOGICAL|Blood sample|Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.
219285425|NCT03861026|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
219285426|NCT00036127|DRUG|aripiprazole|
219285427|NCT04203095|DIAGNOSTIC_TEST|the level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs.
219285428|NCT05212727|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
219285429|NCT00252109|BEHAVIORAL|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
219285430|NCT04255199|BEHAVIORAL|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
219285431|NCT04255199|BEHAVIORAL|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
219285432|NCT06009484|PROCEDURE|Colon resection|Colon cancer resection
219285433|NCT02695342|BEHAVIORAL|Home balance exercise program|
219285434|NCT03065257|PROCEDURE|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
219285435|NCT01109641|DEVICE|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
219285436|NCT02801695|DRUG|Citrulline|Citrulline supplementation
219285437|NCT02801695|DRUG|Placebo|Placebo
219285438|NCT04593953|PROCEDURE|TLIP|Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
219285439|NCT01736943|DRUG|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
219285440|NCT01736943|DRUG|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
219285441|NCT01077453|DRUG|letrozole|Given orally
219285442|NCT01077453|OTHER|quality-of-life assessment|Ancillary studies
219285443|NCT01077453|OTHER|laboratory biomarker analysis|Correlative studies
219285444|NCT00387426|DRUG|sunitinib malate|Given PO
219285445|NCT00910377|BEHAVIORAL|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
219285446|NCT00282672|DEVICE|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
219285447|NCT00282672|DEVICE|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
219285448|NCT03046108|DEVICE|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
219285449|NCT03046108|DRUG|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
219285450|NCT03046108|DRUG|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
219285451|NCT03046108|DEVICE|ultrasound guided injection|Introduction of a needle based guided by ultrasound
219285452|NCT03046108|DRUG|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
219285453|NCT03046108|DRUG|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
219285454|NCT04403087|DRUG|Trimebutine 100 MG|Trimebutine 100mg three times a day
219285455|NCT04492449|OTHER|congenital malformation|congenital malformation
219285456|NCT01852318|DRUG|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
219285457|NCT01852318|DRUG|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
219285458|NCT01852318|DRUG|placebo|
219285459|NCT03247387|DEVICE|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
219285460|NCT03247387|DEVICE|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
219285461|NCT03247387|DEVICE|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
219285462|NCT02525718|DRUG|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
219285463|NCT02525718|DRUG|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
219285464|NCT01621308|OTHER|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
219285465|NCT02537210|DRUG|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
219285466|NCT02537210|DRUG|Placebo oral capsule|Patients will be prescribed placebo 5 capsules daily for 12 months
219285467|NCT01253135|BIOLOGICAL|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
219285468|NCT01253135|OTHER|White Petrolatum|Topical application
219285469|NCT02712073|OTHER|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
219285470|NCT03788603|DRUG|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
219285471|NCT02285296|OTHER|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
219285472|NCT04532229|DRUG|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
219285473|NCT06422000|DRUG|Pentoxifylline|Pentoxifylline 30 mg/kg given over 6 hours daily
219285474|NCT06422000|DRUG|Probiotic Formula|probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
219285475|NCT06455735|DRUG|68Ga-JH04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
219285476|NCT06455735|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
219285477|NCT00075842|DIETARY_SUPPLEMENT|Valeriana officinalis extract|Given orally
219285478|NCT00075842|OTHER|placebo|Given orally
219285479|NCT03915847|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.
219285480|NCT03915847|PROCEDURE|Double layer closure|The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
219285481|NCT03915847|PROCEDURE|Doble layer closure with trimming|Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
219285482|NCT03186053|DRUG|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
219285483|NCT03186053|DRUG|saline|.Loading dose followed by continuous infusion in operation
219296441|NCT06611332|OTHER|Sham electroacupuncture|In the sham electroacupuncture group, the acupoints will be at a position 2 cm lateral to the correct acupoints horizontally. The dosage and treatment course are the same as those in the electroacupuncture group.
219285484|NCT05702697|DEVICE|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
219285485|NCT05702697|BEHAVIORAL|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
219285486|NCT05290753|DRUG|Prokinetic Motility Agents as primpiram and gastreg|Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
219285487|NCT01886859|DRUG|Ibrutinib|Given PO
219285488|NCT01886859|DRUG|Lenalidomide|Given PO
219285489|NCT05726240|DRUG|Ghrelin|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
219285490|NCT01802151|DIETARY_SUPPLEMENT|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
219285491|NCT01802151|DIETARY_SUPPLEMENT|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
219285492|NCT02880787|DRUG|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
219285493|NCT02880787|DEVICE|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
219285494|NCT03663543|DRUG|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
219285495|NCT03663543|DRUG|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
219285496|NCT01901432|DRUG|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
219285497|NCT05859516|DIAGNOSTIC_TEST|Ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
219285498|NCT00129480|BEHAVIORAL|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
219285499|NCT00379288|DRUG|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
219285500|NCT00379288|DRUG|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
219285501|NCT00379288|DRUG|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
219285502|NCT00379288|DRUG|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
219285503|NCT06144021|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
219285504|NCT06144021|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
219285505|NCT03898232|RADIATION|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
219285506|NCT02297659|PROCEDURE|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
219285507|NCT02297659|DEVICE|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
219285508|NCT05457075|DIAGNOSTIC_TEST|Immune checkpoint measure|The measurement of soluble immune checkpoints of stage II-III rectal cancer before neoadjuvant treatment
219285509|NCT06298240|OTHER|nursing procedure for acute health problems of low complexity|An agreed nursing procedure is applied for users of a primary care emergency center who spontaneously consult for 5 acute health problems of low complexity: gastroenteritis, cystitis in women, dental pain, upper respiratory tract affections and acute wounds
219285510|NCT06390852|PROCEDURE|Biopsy Procedure|Undergo biopsy
219285511|NCT06390852|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219285512|NCT06390852|PROCEDURE|Computed Tomography|Undergo CT scan
219285513|NCT06390852|DRUG|Larotrectinib|Given PO
219285514|NCT06390852|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219285515|NCT03997175|OTHER|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
219285516|NCT03997175|OTHER|Placebo|Sand that looks like intervention sand but does not have high biodiversity
219285517|NCT03468062|DRUG|Dexmedetomidine|Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
219285518|NCT00918879|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
219285519|NCT00918879|DRUG|Placebo|Oral tablet, once daily for 24 weeks
219285520|NCT00491166|DRUG|Bromfenac ophthalmic solution|
219285521|NCT04606186|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
219285522|NCT04606186|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
219285523|NCT00003397|BIOLOGICAL|filgrastim|
219285524|NCT00003397|BIOLOGICAL|rituximab|
219285525|NCT00003397|BIOLOGICAL|sargramostim|
219285526|NCT00003397|DRUG|carmustine|
219285527|NCT00003397|DRUG|cisplatin|
219285528|NCT00003397|DRUG|cyclophosphamide|
219285529|NCT00003397|DRUG|dexamethasone|
219285530|NCT00003397|DRUG|etoposide|
219285531|NCT00003397|DRUG|gemcitabine hydrochloride|
219285532|NCT00003397|DRUG|melphalan|
219285533|NCT00003397|DRUG|paclitaxel|
219285534|NCT00003397|PROCEDURE|bone marrow ablation with stem cell support|
219285535|NCT00003397|PROCEDURE|peripheral blood stem cell transplantation|
219285536|NCT05321277|DIETARY_SUPPLEMENT|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
219285537|NCT05321277|DIETARY_SUPPLEMENT|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
219285538|NCT00685139|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
219285539|NCT00685139|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
219285540|NCT00833261|DRUG|cetuximab|cetuximab
219285541|NCT00833261|DRUG|cisplatin|cisplatin
219285542|NCT00833261|RADIATION|intensity-modulated radiation therapy|IMRT
219285543|NCT00833261|DRUG|Nab-Paclitaxel|Nab-Paclitaxel
219285544|NCT00259623|DEVICE|Radiofrequency ablation|
219285545|NCT00127686|DRUG|Dextromethorphan|
219285546|NCT00127686|DRUG|Buckwheat Honey|
219285547|NCT00031642|BIOLOGICAL|rituximab|
219285548|NCT00031642|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
219285549|NCT04716777|BEHAVIORAL|Brief Transdiagnostic group-based Cognitive-Behavioral Treatment|Weekly group-based transdiagnostic CBT sessions for eight weeks.
219285550|NCT04151589|BEHAVIORAL|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
219285551|NCT01805453|DRUG|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg\*2/day until the halting for any reason
219285552|NCT01805453|DRUG|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
219285553|NCT01532804|DRUG|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
219285554|NCT01532804|DRUG|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
219285555|NCT03544853|DEVICE|Prosthetic socket for transtibial amputee|To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
219285556|NCT03149575|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
219285557|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
219285558|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
219285559|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
219285560|NCT03753698|DEVICE|eCoin|"Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient."
219285561|NCT02930395|PROCEDURE|serum S100B assay|
219285562|NCT05500677|DRUG|Lidocaine topical|Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
219285563|NCT00357110|DRUG|Fulvestrant|intramuscular injection
219285564|NCT00357110|DRUG|Anastrozole|1 mg oral tablet
219285565|NCT00688129|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
219285566|NCT04496245|DRUG|Broncho-Vaxom®|Broncho-Vaxom adult capsules® (OM85)
219285567|NCT06126458|OTHER|shooting performance|collecting total points after 72 target shootings done
219285568|NCT04850872|BEHAVIORAL|PLAYwithHEART Programme for adolescent athletes|PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
219285569|NCT04542213|DRUG|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
219285570|NCT04542213|DRUG|Insulin|Basal-bolus insulin scheme
219285571|NCT00301678|BEHAVIORAL|behavioral dietary intervention|
219285572|NCT00301678|OTHER|educational intervention|
219285573|NCT00301678|OTHER|preventative dietary intervention|
219296442|NCT01577459|DRUG|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
219285574|NCT05758948|DIAGNOSTIC_TEST|NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue|In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
219285575|NCT01303653|PROCEDURE|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
219285576|NCT01531673|DRUG|VX-661|
219285577|NCT01531673|DRUG|Ivacaftor|
219285578|NCT01531673|DRUG|Placebo matched to VX-661|
219285579|NCT01531673|DRUG|Placebo matched to ivacaftor|
219285580|NCT02290808|BEHAVIORAL|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
219285581|NCT06138613|DRUG|Tradipitant|Oral Capsule
219285582|NCT02863770|OTHER|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
219285583|NCT01244932|DRUG|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
219285584|NCT02490033|DEVICE|Ablation Catheter|
219285585|NCT00954889|DRUG|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
219285586|NCT00954889|DRUG|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
219296443|NCT01577459|OTHER|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
219285587|NCT00962377|PROCEDURE|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
219285588|NCT00962377|PROCEDURE|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
219285589|NCT02116790|DRUG|Naproxen|Subjects will take one 250mg Naproxen capsule
219285590|NCT02116790|DRUG|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
219285591|NCT02116790|DRUG|Sinemet|Subjects will take one 25mg/100mg Sinemet.
219285592|NCT02116790|DRUG|Placebo|Subjects will take two placebos.
219285593|NCT00350597|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
219285594|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
219285595|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
219285596|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
219285597|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
219285598|NCT00801762|DEVICE|Fibered confocal microscope|
219285599|NCT06335485|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend 4 CBT sessions prior to surgery and 2 optional sessions after surgery.
219285600|NCT03675373|BEHAVIORAL|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
219285601|NCT03675373|BEHAVIORAL|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
219285602|NCT03919604|PROCEDURE|Extracorporeal Life Support|Any extracorporeal blood treatment technique for respiratory and/or cardiac support
219285603|NCT05070585|DIETARY_SUPPLEMENT|Isothiocyanate rich sprouts|Isothiocyanate rich sprout juice consumption for 1 week
219285604|NCT05070585|DIETARY_SUPPLEMENT|Placebo Juice|Sprout juice devoid of isothiocyanates for 1 week
219285605|NCT04292353|OTHER|Cognitive tests and Patient Reported Outcome|
219285606|NCT01695252|OTHER|MEMOS|Patient informed clinical outcomes supervision
219285607|NCT06097351|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
219285608|NCT00008359|DRUG|caspofungin acetate|
219285609|NCT00008359|DRUG|liposomal amphotericin B|
219285610|NCT01914601|DEVICE|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
219285611|NCT01914601|DEVICE|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
219285612|NCT06088459|BIOLOGICAL|1mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
219285613|NCT06088459|BIOLOGICAL|4mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
219285614|NCT06088459|BIOLOGICAL|8mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
219285615|NCT04422327|DIETARY_SUPPLEMENT|Probiotic capsule|"Each probiotic capsule contains 5 x 10\^8 CFU B. longum 35624® and 5 x 10\^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
219285616|NCT04334200|BEHAVIORAL|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
219285617|NCT01695031|BEHAVIORAL|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
219285618|NCT01695031|BEHAVIORAL|Generic web-based education|Generic, web-based asthma education
219285619|NCT03942484|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the device.
219285620|NCT00559312|DRUG|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
219285621|NCT00559312|DRUG|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
219285622|NCT03745911|COMBINATION_PRODUCT|Paclitaxel and TAK-228|Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
219285623|NCT03103984|OTHER|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
219285624|NCT00678431|DIETARY_SUPPLEMENT|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
219285625|NCT00678431|DIETARY_SUPPLEMENT|Placebo|Liquid placebo
219285626|NCT03240705|BEHAVIORAL|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
219285627|NCT04799743|DRUG|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
219285628|NCT04799743|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
219285629|NCT00902928|DRUG|YM150|oral
219285630|NCT00902928|DRUG|enoxaparin|SC injection
219285631|NCT01813877|RADIATION|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
219285632|NCT06126003|OTHER|Observation|No Intervention
219285633|NCT06151028|OTHER|No intervention|This is an observational study and did not involve interventions.
219743116|NCT07010757|BEHAVIORAL|HARPP|In HARPP, MOVE! and CPT are delivered in up to 16 individual psychotherapy sessions. While all CPT content is included, it is slightly tailored to address factors that interfere with health behavior change (e.g., hypervigilance that hinders community-based physical activity). All MOVE! materials are included; MOVE! uses cognitive-behavioral techniques and autonomy-supporting counseling to promote physical activity and healthy eating. HARPP targets other PTSD-related barriers to recovery and healthy lifestyles by promoting sleep and relationship quality, and community engagement. HARPP participants receive at least one medication management consultation (review by clinician and telephone session) focused on currently may cause weight gain and AOM options. When relevant and based upon Veteran interest, medications are changed or prescribed, in coordination with the Veteran's psychiatric and primary care teams.
219285634|NCT01242579|DRUG|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
219285635|NCT01242579|DRUG|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
219285636|NCT01242579|DRUG|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
219285637|NCT01242579|DRUG|Matching Placebo Gel|Matching placebo gel containing 2.5g
219285638|NCT04523389|BIOLOGICAL|analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
219285639|NCT04523389|OTHER|Gathering additional information about the patient's cancer|Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
219285640|NCT04523389|DIAGNOSTIC_TEST|Diagnostic test|Diagnostic test
219285641|NCT01010347|PROCEDURE|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
219285642|NCT01010347|PROCEDURE|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
219285643|NCT00220051|DRUG|Oxaliplatin, Capecitabine|
219285644|NCT00220051|PROCEDURE|Pre operative radiotherapy|
219285645|NCT00220051|PROCEDURE|Surgical Resection|
219285646|NCT01008553|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
219285647|NCT01008553|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
219285648|NCT05894395|BIOLOGICAL|MMR booster vaccination (as M-M-R-VaxPro)|a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine
219285649|NCT00130260|BIOLOGICAL|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
219285650|NCT00130260|BIOLOGICAL|placebo|placebo to match StaphVAX
219285651|NCT04998760|DRUG|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
219285652|NCT04998760|DRUG|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
219285653|NCT05671627|DRUG|DMARDs|Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
219285654|NCT03823157|BEHAVIORAL|Tai Chi|mind-body exercise
219285655|NCT03733990|BIOLOGICAL|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
219285656|NCT01571401|BEHAVIORAL|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
219285657|NCT05870839|BIOLOGICAL|VXCO-100|Sterile liquid for injection
219285658|NCT05339412|BEHAVIORAL|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
219285659|NCT05670353|DRUG|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
219285660|NCT05670353|DRUG|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
219285661|NCT05670353|DRUG|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
219285662|NCT03563157|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
219285663|NCT03563157|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]
219285664|NCT03563157|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
219285665|NCT03563157|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-\[HER2\]
219285666|NCT03563157|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
219285667|NCT03563157|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
219285668|NCT03563157|BIOLOGICAL|GI-4000|RAS yeast
219285669|NCT03563157|BIOLOGICAL|GI-6207|CEA yeast
219285670|NCT03563157|BIOLOGICAL|GI-6301|Brachyury yeast
219285671|NCT03563157|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
219285672|NCT03563157|DRUG|Avelumab|BAVENCIO® injection
219285673|NCT03563157|DRUG|Capecitabine|XELODA® tablets
219285674|NCT03563157|DRUG|Cetuximab|ERBITUX® injection
219285675|NCT03563157|DRUG|Cyclophosphamide|Cyclophosphamide Capsules
219285676|NCT03563157|DRUG|5-Fluorouracil|5-FU; Fluorouracil Injection
219285677|NCT03563157|DRUG|Leucovorin|Leucovorin Calcium
219285678|NCT03563157|DRUG|Nab-paclitaxel|ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
219285679|NCT03563157|DRUG|Oxaliplatin|ELOXATIN® injection
219285680|NCT03563157|DRUG|Regorafenib|STIVARGA® tablets
219285681|NCT03563157|PROCEDURE|SBRT|Stereotactic body radiation therapy
219285682|NCT05039216|BIOLOGICAL|Blood sampling|4 tubes of 7 mL will be sampled
219285683|NCT06632756|BEHAVIORAL|Individual and Group Treatment for Smoking Cessation|Positive psychology-based individual treatment and groups
219285684|NCT04218149|DRUG|Bupivacaine Injection|Block with bupivacaine
219285685|NCT04662723|DRUG|Corticosteroid|To reduce the progression of renal damage in IgAN Patients
219285686|NCT04662723|DRUG|Renin-angiotensin sytem blockers|To reduce the progression of renal damage in IgAN Patients
219285687|NCT04662723|DRUG|Sodium-glucose cotransporter 2 inhibitor|To reduce the progression of renal damage in IgAN Patients
219285688|NCT04795765|PROCEDURE|SpineJack system|For use in the reduction of painful osteoporotic vertebral compression fractures.
219285689|NCT04795765|PROCEDURE|Balloon kyphoplasty|Treatment of osteoporotic vertebral compression fractures.
219285690|NCT04795765|PROCEDURE|Vertebroplasty|Treatment of osteoporotic vertebral compression fractures.
219285691|NCT02187159|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
219285692|NCT02187159|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
219285693|NCT02187159|DRUG|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
219285694|NCT02187159|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
219285695|NCT03495843|DIAGNOSTIC_TEST|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
219285696|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM who can access and existing registry of patients with possible or confirmed AUD to examine quality metrics for patients with an AUD on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide performance metric data that indicates the proportion of patients on their primary care panel who are initiating and engaging in AUD treatment. Additionally, the PHM will circulate a weekly report of higher risk patients on the clinician's panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. PHM does not directly help clinicians with implementation of care with individual patients, and has no direct patient contact.
219285697|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). The clinician will be supported by a CCM who will assist in identifying patients who need further assessment on the clinician patient panel. The CCM will conduct outreach to patients regarding alcohol use care, and will communicate with the clinician to help decide potential care plans, and then assist in implementing those plans for patients. The CCM has expertise on how to provide appropriate care to patients and can help patients navigate the complex care system. Further assistance by the CCM may include facilitating prescriptions for clinician sign-off, assuring refills, finding, selecting and coordinating specialty AUD care, and contacting patients to make appointments.
219285698|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM and clinical care manager CCM. The PHM can access and existing registry of patients with possible or confirmed alcohol use disorder to examine quality metrics for patients with an alcohol use disorder on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide summaries of data of those who have initiated or engaged in treatment for alcohol use, as well as a weekly report of higher risk patients on their panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. The CCM will assist in identifying patients who need further assessment, and will assist in conducting outreach and implementing care to those patients regarding alcohol use care.
219285699|NCT03930862|DEVICE|Locator Attachment (positioner)|intra oral attachment
219285700|NCT02776839|DEVICE|Mobile sensing|
219285701|NCT00652769|PROCEDURE|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
219285702|NCT00652769|PROCEDURE|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
219285703|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1\&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
219285704|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1\&2 LNs) and para-aortic lymph nodes must be removed during the operation."
219285705|NCT02423278|DRUG|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
219285706|NCT04212637|OTHER|MRI|Examine BOLD activity in relation to eye movements measures
219285707|NCT00567567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
219285708|NCT00567567|DRUG|Carboplatin|Given IV
219285709|NCT00567567|DRUG|Cisplatin|Given IV
219285710|NCT00567567|DRUG|Cyclophosphamide|Given IV
219285711|NCT00567567|DRUG|Doxorubicin Hydrochloride|Given IV
219285712|NCT00567567|DRUG|Etoposide|Given IV
219285713|NCT00567567|RADIATION|External Beam Radiation Therapy|Undergo EBRT
219285714|NCT00567567|BIOLOGICAL|Filgrastim|Given IV or SC
219285715|NCT00567567|DRUG|Isotretinoin|Given orally
219285716|NCT00567567|OTHER|Laboratory Biomarker Analysis|Correlative studies
219285717|NCT00567567|DRUG|Melphalan|Given IV
219285718|NCT00567567|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
219285719|NCT00567567|OTHER|Pharmacological Study|Correlative studies
219285720|NCT00567567|DRUG|Thiotepa|Given IV
219285721|NCT00567567|DRUG|Topotecan Hydrochloride|Given IV
219285722|NCT00567567|DRUG|Vincristine Sulfate Liposome|Given IV
219285723|NCT06409234|OTHER|Transthoracic Echocardiography Recieved|Transthoracic Echocardiography Recieved
219285724|NCT04216563|DRUG|Asciminib|Given PO
219285725|NCT06244576|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a trans diagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
219285726|NCT03390764|PROCEDURE|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
219285727|NCT03390764|PROCEDURE|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
219285728|NCT02330705|DRUG|HCG|Women will be given HCG before IUI
219285729|NCT04847206|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
219285730|NCT04847206|DRUG|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
219285731|NCT04847206|DRUG|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
219285732|NCT04847206|DRUG|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
219285733|NCT04847206|OTHER|Placebo|Placebo (Mannitol)
219285734|NCT00847067|PROCEDURE|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
219285735|NCT00847067|PROCEDURE|Sham injections|Sham injections with Normal Saline
219285736|NCT05672901|DEVICE|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
219285737|NCT05672901|DRUG|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
219285738|NCT04335591|DRUG|75 mg linzagolix tablet|For oral administration once daily
219285739|NCT04335591|DRUG|200 mg linzagolix tablet|For oral administration once daily
219285740|NCT04335591|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
219285741|NCT04335591|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
219285742|NCT04335591|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
219285743|NCT04335591|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
219285744|NCT00239551|DRUG|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
219285745|NCT05721547|OTHER|Assessment|Assessment
219285746|NCT05816304|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
219285747|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
219285748|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
219285749|NCT01867333|BIOLOGICAL|Enzalutamide|An androgen receptor inhibitor.
219285750|NCT03390582|DRUG|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
219285751|NCT03956693|BEHAVIORAL|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
219285752|NCT00521066|DEVICE|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
219285753|NCT04654767|OTHER|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
219285754|NCT02243670|DEVICE|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
219285755|NCT05003024|DEVICE|TOF SCAN|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~Once 2 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 2 mg/kg sugammadex will be injected. Train of four ratio (delivered every minute) will be recorded.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
219285756|NCT05003024|DEVICE|ITF|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~On the ITF device side, 3 minutes after sugammadex administration, a tetanus 100 Hz stimulation will be done followed 2 minutes later by a tetanus 50 Hz stimulation.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
219285757|NCT00842244|DRUG|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
219285758|NCT00842244|DRUG|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
219285759|NCT00842244|DRUG|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
219285760|NCT00430729|DRUG|Roflumilast|
219285761|NCT00827099|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin
219285762|NCT00827099|DRUG|fludarabine phosphate|fludarabine phosphate
219285763|NCT00827099|DRUG|Melphalan|melphalan
219285764|NCT00827099|DRUG|mycophenolate mofetil|mycophenolate mofetil
219285765|NCT00827099|DRUG|tacrolimus|tacrolimus
219285766|NCT00827099|PROCEDURE|umbilical cord blood transplantation|umbilical cord blood transplantation
219285767|NCT01701102|PROCEDURE|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
219285768|NCT01701102|PROCEDURE|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
219285769|NCT01701102|PROCEDURE|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
219285770|NCT01701102|PROCEDURE|Mepivacaine|Mepivacaine 37.5 mg
219285771|NCT05899803|DIAGNOSTIC_TEST|Posture Analysis|This analysis consists of 13 different body parts and evaluates the body in terms of current posture changes. Our study evaluated children from two angles: posterior (head, shoulders, back, hips, feet, and arches) and lateral (neck, chest, shoulders, upper back, trunk, abdomen, and waist). In the scoring system, correct posture was recorded as five points, a moderate amount of deformity posture as three points, and severe deformity posture as one point. The total score calculated at the end of the questionnaire was a maximum of 65 points and a minimum of 13 points. The results of the analysis were evaluated as follows: ≥ 45 points, very good, 40-44 points good, 30-39 points moderate, 20-29 points poor, and a total score of ≤ 19 points.
219285772|NCT05899803|DIAGNOSTIC_TEST|Physical activity level|This questionnaire, administered to children aged 4-14, evaluates the activities performed during a week. The questionnaire consisted of nine questions, each of which was evaluated on a 5 points. One point indicated a low physical activity level and five points indicated a high physical activity level. Dividing the total score of the selected items by the number of items gives a summary score for the PAQ-C questionnaire. In our study, we used the Turkish version of the questionnaire, which was found to be reliable and valid.
219743117|NCT07010757|BEHAVIORAL|control arm for HARPP trial|"Participants in the control condition will receive the following:~1. Referral to MOVE!; they will select a MOVE! that fits their schedule (at VAPS MOVE! is a 12-week group).~2. Standard CPT in 60-minute individual sessions, delivered by 4 CPT-trained psychotherapists (different therapists than intervention arm therapists to avoid contamination).~3. One non-visit consult medication review using the same procedures and template outlined above. After the non-visit consult, the Dr. will alert the Veteran's relevant usual care team member(s) via the non-visit consult template in the medical record. They will not have direct contact with control participants, but the study team will monitor for safety following any medication changes."
219285773|NCT05899803|DIAGNOSTIC_TEST|Muscle strength|"Our study objectively measured muscle strength using the JTech Commander PowerTrack Muscle Dynamometer.~Right and left muscle tests: Hip flexors/hyperextensors/adductors/abductors/internal rotators/external retractors, knee flexors/extensors, and foot plantar flexors/dorsiflexors were evaluated. The measurement results were recorded in Newtons, the measurements were repeated three times, and the average of these three repetitions was recorded."
219285774|NCT02876042|DEVICE|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
219285775|NCT03427151|DRUG|IPP-201101|200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
219285776|NCT06507280|PROCEDURE|Periodontal theraphy|periodontal therapy
219285777|NCT01404364|DRUG|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
219285778|NCT01404364|DRUG|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
219285779|NCT03789331|OTHER|Anogenital distance measurement|"The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used."
219285780|NCT00472849|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
219285781|NCT00472849|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
219285782|NCT00472849|DRUG|Cytarabine|Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
219285783|NCT00472849|DRUG|Rituximab|Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).
219285784|NCT00472849|DRUG|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
219285785|NCT04085484|DIETARY_SUPPLEMENT|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight \< 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
219285786|NCT00003705|DRUG|BMS-184476|
219285787|NCT00241553|DRUG|Esomeprazole|
219296444|NCT05559476|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
219285788|NCT06225505|DIAGNOSTIC_TEST|ctDNA monitoring|For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
219285789|NCT06225505|DIAGNOSTIC_TEST|68Ga-FAPI-46-PET-CT|). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
219285790|NCT01240421|DRUG|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
219285791|NCT05821582|OTHER|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
219285792|NCT01353118|BIOLOGICAL|gastric bypass|Optimise glucose control within 3 months before operation
219285793|NCT05202392|OTHER|Myofascial release with isometric exercises|Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.
219285794|NCT05202392|OTHER|Myofascial release with scapular stabilization exercise|Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
219285795|NCT00003124|DRUG|flutamide|
219285796|NCT00003124|DRUG|leuprolide acetate|
219285797|NCT00003124|RADIATION|radiation therapy|
219285798|NCT00403767|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
219285799|NCT00403767|DRUG|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
219285800|NCT00403767|DRUG|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
219285801|NCT00403767|DRUG|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
219285802|NCT03192475|BEHAVIORAL|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
219285803|NCT03192475|BEHAVIORAL|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
219285804|NCT06310408|DEVICE|nasal mask|Give interface nasal mask
219285805|NCT06310408|DEVICE|nasal prong|give interface nasal prong
219285806|NCT03556956|DRUG|Masitinib|Tyrosine kinase inhibitor
219285807|NCT04767100|DEVICE|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
219285808|NCT00920322|DEVICE|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
219285809|NCT00920322|DEVICE|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
219285810|NCT00436605|DRUG|dasatinib|
219285811|NCT01696045|BIOLOGICAL|Ipilimumab|
219285812|NCT01184040|BEHAVIORAL|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
219285813|NCT04337671|OTHER|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
219285814|NCT01432587|DRUG|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
219285815|NCT04703998|PROCEDURE|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
219285816|NCT04703998|BIOLOGICAL|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
219296445|NCT05559476|BIOLOGICAL|FLU HD vaccine|FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
219285817|NCT03260777|DEVICE|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
219285818|NCT02294526|OTHER|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
219285819|NCT05741138|OTHER|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
219285820|NCT05741138|OTHER|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
219285821|NCT05319912|DRUG|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
219285822|NCT05319912|DRUG|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
219285823|NCT05319912|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
219285824|NCT01802177|PROCEDURE|UVB excimer light|
219285825|NCT04395300|OTHER|Web Based Survey|On line survey distributed electronically
219285826|NCT02519140|DRUG|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
219285827|NCT02297100|DRUG|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
219285828|NCT02297100|PROCEDURE|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
219285829|NCT02297100|PROCEDURE|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
219285830|NCT04198064|PROCEDURE|Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/\~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy."
219285831|NCT04198064|PROCEDURE|No Bag Squeeze|Participants will receive a standard cystocopy procedure as per standard of care.
219285832|NCT01120730|DRUG|fluid resuscitation|fluid resuscitation with HES
219285833|NCT01120730|DRUG|Fluid resuscitation|Fluid resuscitation in standardized fashion
219285834|NCT00876577|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
219285835|NCT04349839|DEVICE|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
219285836|NCT05984836|BEHAVIORAL|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
219285837|NCT02972268|DRUG|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
219285838|NCT02972268|DRUG|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
219285839|NCT03738644|OTHER|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
219285840|NCT02632604|BEHAVIORAL|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
219285841|NCT02632604|BEHAVIORAL|Computer games|
219285842|NCT01913834|DRUG|Forsteo|Subcutaneous administration 20 micrograms
219285843|NCT01913834|DRUG|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
219285844|NCT05526131|OTHER|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
219296446|NCT06403709|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
219743118|NCT07010536|BEHAVIORAL|VR-Based Music Therapy|"VR-Based Music Therapy Protocol:~Participants undergo immersive VR sessions twice weekly for 6 weeks, each lasting 30 minutes, supervised by a physiotherapist. Each session includes three 10-minute activities with 2-minute breaks:~Rhythm Exercises: Participants follow tempo by clapping on a table while watching Brooklyn Music Factory YouTube videos played within the VR headset (levels 1-4), progressing weekly.~Ocean Rift: Exploration of calming underwater environments with marine life to enhance relaxation, attention, and cognition.~PianoVision: Virtual piano exercises using hand tracking with the unaffected hand; difficulty increases from levels 0 to 4."
219178109|NCT06699433|BEHAVIORAL|Virtual standardized patients (VSPs)|Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
219178110|NCT06699433|BEHAVIORAL|Case teaching manuals|Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
219178111|NCT06699433|BEHAVIORAL|Case teaching videos|Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
219178112|NCT04893278|OTHER|Virtual reality|Use of Virtual reality goggles during procedure
219178113|NCT06801301|DEVICE|whole body vibration|Standing in different static positions or exercising on a vibrating platform.The mechanical stimuli of vibration transmitted to the body and stimulate muscle spindles which activate the alpha motor neurons and initiates muscle contractions comparable to the ''tonic vibration reflex. The effect of WBV on the neuromuscular properties of skeletal muscles and spinal mechanisms is demonstrated by a decreased electromechanical delay.
219178114|NCT06801301|OTHER|Resistance Exercise|Resistance training as a mode of exercise to promote several health benefits, including improvements in the muscle mass and strength of healthy adults.Resistance training, where muscles are required to contract against an opposing load, has been shown to be a beneficial form of rehabilitation in clinical populations prone to muscle wasting, providing stimuli to increase protein synthesis and muscle mass.
219178115|NCT06517680|OTHER|tight control management|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
219178116|NCT06517680|OTHER|standard follow-up|Patients are monitored according to standard practice
219178117|NCT04705623|BEHAVIORAL|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
219178118|NCT03530774|DIETARY_SUPPLEMENT|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
219178119|NCT03530774|DIETARY_SUPPLEMENT|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
219178120|NCT05796739|DIAGNOSTIC_TEST|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
219178121|NCT05796739|DIAGNOSTIC_TEST|Medical treatment without further testing|Optimal medical treatment for primary prevention.
219178122|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
219178123|NCT06701968|OTHER|Healthy Nordic Diet|Participants will be adviced a healthy Nordic diet and will also receive certain Nordic foods high in wholegrains and polyunsaturated fat from vegetable sources
219178124|NCT06701968|BEHAVIORAL|Usual Care|Usual care lifestyle advice and national and general recommendations on diet
219178125|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
219178126|NCT06801795|DEVICE|AviClear|"Participants will receive as many as 4 treatments, each treatment lasts approximately 10 minutes, with intervals of up to 5 weeks apart. The treatments will be conducted in person. Participants will be followed at approximately week 5 post-treatment completion (via phone) at 12 weeks and 24 weeks post treatment completion onsite.~This is a 1726 nanometer laser treatment"
219178127|NCT06797622|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtecan (T-DXd)
219178128|NCT06795841|RADIATION|Photobiomodulation|It was applied for upper respiratory tract over tonsils, trachea, and main bronchi (bilaterally parasternal at the level of angle of Lewis)
219178129|NCT06795841|PROCEDURE|Myofascial release therapy|technique was applied from supine position, with both hands cupping both diaphragmatic domes
219178130|NCT06795841|DEVICE|traditional chest physiotherapy|included traditional chest physiotherapy (postural drainage, percussion and shaking), stretching exercise
219178131|NCT05303090|DRUG|H101|H101 intratumorally injection starts at day 0.
219178132|NCT05303090|DRUG|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219178133|NCT05303090|DRUG|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
219178134|NCT02645149|DRUG|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
219285845|NCT03818360|BEHAVIORAL|an evidence-based smoking cessation intervention comprising brief advice plus active referrals|The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
219285846|NCT03198468|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
219285847|NCT01333813|BIOLOGICAL|Engerix-B™ Kinder|Intramuscular, single dose
219285848|NCT03947307|DEVICE|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
219285849|NCT03947307|PROCEDURE|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
219285850|NCT03947307|DEVICE|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
219285851|NCT00619749|DIETARY_SUPPLEMENT|juice rich in polyphenols|juice during 2 weeks
219285852|NCT00619749|DIETARY_SUPPLEMENT|juice poor in polyphenols|juice during 2 weeks
219285853|NCT01675245|DRUG|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
219285854|NCT02878707|DRUG|Dexmedetomidine|Intraoperative dexmedetomidine infusion
219285855|NCT00513487|DRUG|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
219285856|NCT01204710|BIOLOGICAL|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
219285857|NCT01204710|DRUG|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
219285858|NCT01204710|DRUG|Prednisone|5 mg orally (PO) twice daily (BID) on each day
219285859|NCT04698759|OTHER|No Intervention|no Intervention
219285860|NCT02538159|DEVICE|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
219285861|NCT02538159|DEVICE|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
219285862|NCT00002001|DRUG|Zidovudine|
219285863|NCT00002001|DRUG|Zalcitabine|
219285864|NCT00002001|DRUG|Didanosine|
219285865|NCT03039101|PROCEDURE|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
219285866|NCT03039101|PROCEDURE|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
219285867|NCT03039101|PROCEDURE|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
219285868|NCT03039101|PROCEDURE|Peripheral blood|Peripheral blood draw
219285869|NCT03039101|DRUG|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
219285870|NCT03039101|DRUG|Placebo Oral Tablet|one pill orally, daily, for 1 week
219285871|NCT05129228|DEVICE|OCT-guided saphenous vein CABG|OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
219285872|NCT05901909|BEHAVIORAL|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
219285873|NCT04270396|BEHAVIORAL|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
219285874|NCT03186573|DIETARY_SUPPLEMENT|Grape juice|400ml diary of grape juice
219285875|NCT03186573|DIETARY_SUPPLEMENT|Maltodextrin|400ml diary of maltodextrin
219285876|NCT06188429|DIAGNOSTIC_TEST|DSM-5|Using DSM-5 for diagnostic testing of the children in the study group.
219285877|NCT05865132|DRUG|Palbociclib|120mg/125mg po qd on day 1 to 21, every 28 days
219285878|NCT05865132|DRUG|Afatinib|30mg/40mg po qd on day 1 to 28, every 28 days
219285879|NCT00476073|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
219285880|NCT02824354|DRUG|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
219285881|NCT02824354|DRUG|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
219285882|NCT02639832|DEVICE|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
219285883|NCT02080559|BIOLOGICAL|4CMenB|0.5ml IM
219285884|NCT01689571|DRUG|CHF6001|
219285885|NCT01689571|DRUG|Placebo|
219285886|NCT01303679|DRUG|Paclitaxel|IV, 80mg/m² at d1, d8, d15
219285887|NCT01303679|DRUG|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
219285888|NCT01303679|DRUG|Exemestane|daily 25 mg (1 pill) oral intake
219285889|NCT05838378|OTHER|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
219285890|NCT05838378|OTHER|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
219285891|NCT05838378|OTHER|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
219285892|NCT00509431|DRUG|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
219285893|NCT03537547|OTHER|GeneSight Psychotropic test|GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
219285894|NCT03537547|DRUG|FDA-approved antidepressant or antipsychotic treatment|Participant is treated with medications included in the GeneSight Psychotropic product.
219285895|NCT01276379|DRUG|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
219285896|NCT01276379|DRUG|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
219285897|NCT01276379|DRUG|Cetuximab|\- 500 mg/m2 i.v. Every 2 weeks.
219285898|NCT01376232|DRUG|GSK1278863|GSk1278863 100mg
219285899|NCT01376232|DRUG|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
219285900|NCT01376232|DRUG|Gemfibrozil|600 mg Gemfibrozil
219285901|NCT06147908|DRUG|DW5221|megestrol acetate
219285902|NCT06147908|DRUG|DW5221-R|megestrol acetate
219285903|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.006mg|ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
219285904|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.012mg|ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
219285905|NCT04228926|DRUG|ZKY001 simulated eye drops|ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
219285906|NCT00864253|DRUG|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
219285907|NCT00864253|DRUG|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
219285908|NCT06459700|DIETARY_SUPPLEMENT|Probiotic supplements|See arm/group description
219285909|NCT06459700|DIETARY_SUPPLEMENT|Placebo supplements|See arm/group description
219285910|NCT03089138|DRUG|Regan Tangjiang|The treatment duration is 3 consecutive days.
219285911|NCT01896726|DRUG|Baricitinib|Administered orally
219285912|NCT01896726|DRUG|Microgynon|Administered orally
219285913|NCT01128114|DRUG|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
219285914|NCT06078228|DRUG|Propofol - Fentanyl- Atracurium|investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
219285915|NCT04532567|DRUG|GLPG1205|GLPG1205 film-coated tablets
219285916|NCT04532567|DRUG|Placebo|placebo film-coated tablets
219285917|NCT05538130|DRUG|PF-07799544|Tablet
219285918|NCT05538130|DRUG|PF-07799933|Tablet
219285919|NCT05538130|DRUG|encorafenib|Capsule
219285920|NCT03460808|DRUG|atorvastatin|Atorvastatin was used in combination with acetylcysteine and danazol.
219285921|NCT03460808|DRUG|Acetylcysteine|Acetylcysteine was used in combination with atorvastatin and danazol.
219285922|NCT03460808|DRUG|Danazol|Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
219285923|NCT02206061|BEHAVIORAL|School-Based Asthma Care for Teens (SB-ACT)|
219285924|NCT02206061|BEHAVIORAL|Directly Observed Therapy|
219285925|NCT02206061|BEHAVIORAL|Asthma Education|
219285926|NCT01883102|DRUG|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
219285927|NCT01883102|DRUG|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
219285928|NCT04445987|DRUG|ARQ-154|ARQ-154 foam 0.3% applied once daily for 52 weeks
219285929|NCT01675453|DRUG|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
219285930|NCT01675453|DRUG|0.9% NaCl|
219285931|NCT02193490|DRUG|DNase|DNase 0.1% eye drops four times a day for 8 weeks
219285932|NCT02193490|DRUG|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
219285933|NCT05407181|OTHER|Blood and Liver Function test|Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
219285934|NCT04913467|OTHER|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.
219285935|NCT04913467|DIETARY_SUPPLEMENT|ColoVit capsule|Vitamin B2/B3/C supplement in a ColoPulse-coated capsule
219285936|NCT04913467|OTHER|ColoPulse-placebo capsule|A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
219285937|NCT02273258|DRUG|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
219285938|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
219285939|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
219285940|NCT01260818|DRUG|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
219285941|NCT01260818|DRUG|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
219285942|NCT00397670|DRUG|Drug: BufferGel® with diaphragm|
219285943|NCT02539459|DRUG|Everolimus|10 mg tablets
219285944|NCT00543231|DRUG|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
219285945|NCT05871320|DRUG|[99mTc]Tc-TECANT1|only one arm - the administration of \[99mTC\]-Tc-TECANT1 in all patients included
219285946|NCT03000205|DEVICE|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
219285947|NCT03000205|DEVICE|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
219285948|NCT02773173|PROCEDURE|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
219285949|NCT02773173|PROCEDURE|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
219285950|NCT01533753|DRUG|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
219285951|NCT01533753|DRUG|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
219285952|NCT00749957|BIOLOGICAL|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
219285953|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot B|Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml
219285954|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot A|Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml
219285955|NCT04531098|BIOLOGICAL|Engerix-B|Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
219285956|NCT05038605|DRUG|Topical metronidazole|Topical application of metronidazole cream on the anal verge every 8 hours after surgery
219285957|NCT05038605|DRUG|oral metronidazole|Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
219285958|NCT00543023|DRUG|teriparatide 20 micrograms/day subcutaneous|
219285959|NCT00543023|DRUG|salmon calcitonin 100 IU/day subcutaneous|
219285960|NCT02628028|DRUG|LY3337641|Administered orally
219285961|NCT02628028|DRUG|Placebo|Administered orally
219285962|NCT05639712|DRUG|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
219285963|NCT05639712|DRUG|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
219285964|NCT05639712|DRUG|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
219285965|NCT05639712|DRUG|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
219285966|NCT05639712|DRUG|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
219285967|NCT05639712|DRUG|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
219285968|NCT05639712|DRUG|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
219285969|NCT05639712|DRUG|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
219285970|NCT05639712|DRUG|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
219285971|NCT05639712|DRUG|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
219285972|NCT02145468|DRUG|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
219285973|NCT02145468|DRUG|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
219285974|NCT02145468|DRUG|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
219285975|NCT03796377|DRUG|St Johns Wort Extract|20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
219285976|NCT03796377|DRUG|Rivaroxaban|20 mg rivaroxaban.
219285977|NCT01073644|DRUG|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
219285978|NCT00673621|DRUG|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
219285979|NCT00673621|DRUG|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
219285980|NCT00673621|DRUG|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
219285981|NCT02512731|DEVICE|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
219285982|NCT00218270|DRUG|Tobacco free snuff|Tobacco free snuff
219285983|NCT00135473|DRUG|10% Hemohes® (10% Hydroxyethyl starch)|
219285984|NCT00135473|DRUG|Sterofundin® (Ringer lactate solution)|
219285985|NCT00135473|DRUG|Actrapid® (Insulin)|
219285986|NCT02352519|PROCEDURE|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
219285987|NCT02352519|PROCEDURE|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
219285988|NCT00573053|OTHER|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
219285989|NCT00573053|OTHER|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
219285990|NCT04157400|DEVICE|Intraoperative Parameter Testing|"Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals."
219285991|NCT04157400|DEVICE|Proprioception Testing During Stimulation|"Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task."
219285992|NCT04157400|DEVICE|Gait Analysis During Stimulation|"Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM."
219285993|NCT04917640|RADIATION|Radiation Therapy|Either SBRT or IMRT radiation therapy
219285994|NCT05834062|DRUG|Qsymia and lifestyle management therapy|Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
219285995|NCT05834062|BEHAVIORAL|Placebo and lifestyle management therapy|Placebo will be used in lieu of Qsymia to maintain the blind. Participants will be offered lifestyle management therapy.
219285996|NCT01809834|DEVICE|Etafilcon A|
219285997|NCT01809834|DEVICE|Stenfilcon A|
219285998|NCT02296736|RADIATION|Computerised tomography (CT) scan|Retrospective review of CT scans
219285999|NCT04920942|DRUG|Ivermectin 0.4mg/kg/day for 5 days|Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
219286000|NCT05684718|DRUG|BV100 (300 mg)|Intravenous solution
219286001|NCT05684718|DRUG|Itraconazole 200 mg|Oral solution
219286002|NCT03698110|BEHAVIORAL|Intervention Group|PUEDES program included eight hours in groups and activities to practice at home.
219286003|NCT05298059|RADIATION|Laser of low frequncy|Apply the laser at three points on each tooth.
219286004|NCT05298059|DRUG|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
219286005|NCT00232453|PROCEDURE|Combined Radiation and Chemotherapy|
219286006|NCT06405360|DIETARY_SUPPLEMENT|Egg consumption|Participants in the intervention group will be provided two eggs to consume daily.
219286007|NCT05082961|OTHER|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
219286008|NCT05543707|DRUG|PBI-0451 (Pomotrelvir)|2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
219286009|NCT05543707|DRUG|Placebo|2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
219286010|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
219286011|NCT00186888|PROCEDURE|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
219286012|NCT00186888|DRUG|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage\< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
219286013|NCT00186888|PROCEDURE|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
219286014|NCT00186888|RADIATION|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
219286015|NCT00186888|DRUG|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.
219286016|NCT00186888|DRUG|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
219286017|NCT00186888|DRUG|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
219286018|NCT00186888|DRUG|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
219286019|NCT00186888|PROCEDURE|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
219286020|NCT00186888|OTHER|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
219286021|NCT05691205|OTHER|PEEP|After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
219286022|NCT04752722|DRUG|EG-70 (phase 1)|Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
219286023|NCT04752722|DRUG|EG-70 (phase 2)|Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
219286024|NCT04711837|DRUG|HSK3486|HSK3486 for induction of general anesthesia.
219286025|NCT04711837|DRUG|Propofol|Propofol for induction of general anesthesia.
219286026|NCT06453811|OTHER|Self-efficacy Theory-based Childbirth Preparation Program|According to the block randomisation method, the couples who are included in the experimental group by applying the pre-test will be included in the programme in groups of 3-4 couples by planning the day and time they can participate in the programme. At the end of the sessions, the training guide reflecting the training content will be given to the couples and they will be asked to read it at home and do their homework by using the relevant parts of the guide. At the same time, these couples will continue their routine pregnancy controls in the hospital. It is planned to complete the trainings once a week, twice in total and for two weeks. After the trainings are completed, it is planned to send at least three reminders by text message until the calculated delivery date. Brochures and text message content related to the training content will be used in the reminder.
219286027|NCT04694534|DIAGNOSTIC_TEST|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
219286028|NCT04694534|DIAGNOSTIC_TEST|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
219286029|NCT04231760|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
219286030|NCT04231760|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
219286031|NCT03037437|DRUG|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
219286032|NCT03037437|DRUG|Hydroxychloroquine (HCQ)|400mg by mouth daily
219286033|NCT06964685|DEVICE|Impella|US commercially approved Impella CP is the device that study inclusion will be based on. Only patients with AMICS who receive Impella CP as the first Impella device after cardiogenic shock onset will be included in the study.
219286034|NCT03628547|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
219286035|NCT04956705|DIETARY_SUPPLEMENT|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
219286036|NCT04058834|DRUG|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
219286037|NCT04058834|DRUG|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
219286038|NCT02336451|DRUG|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
219286039|NCT04045847|BIOLOGICAL|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
219286040|NCT00587691|BIOLOGICAL|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
219286041|NCT05570630|BEHAVIORAL|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
219286042|NCT05570630|OTHER|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
219286043|NCT02172677|BEHAVIORAL|Episodic memory task|
219286044|NCT02172677|DEVICE|fMRI|
219286045|NCT06593093|OTHER|a bundled intervention|a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.
219286046|NCT06593093|OTHER|control group|participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.
219286047|NCT05811598|DEVICE|repeated ultra low lever red light|Myopia indoor lighting therapy
219286048|NCT06987981|DEVICE|Chitosan-based dressing|Chitosan-based dressing for wound and scar treatment will be used (e.g. ChitoCare® medical Wound Healing Gel)
219286049|NCT06987981|DEVICE|Silver-based dressing|Silver-based dressing (e.g. AQUACEL® Ag), followed by a cosmetic lotion (e.g.: Bepanthol® DERMA) will be used
219286050|NCT06853431|DRUG|dexmedetomidine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
219286051|NCT06853431|DRUG|Esketamine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
219286052|NCT05615766|DEVICE|Experimental: Device Intervention|The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
219286053|NCT06470360|OTHER|Surgycal procedure|surgical technique
219286054|NCT06987903|PROCEDURE|Pre- and post-operative physical exercise programme|"Pre- and post-operative physical exercise programme during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~A program will be designed according to the needs and preferences of the individual and will include:~Aerobic exercise: Activities that mobilize large muscle groups for prolonged periods of time.Walking, running at a slow or moderate pace (especially on a treadmill), cycling, cycloergometer, etc. In addition, due to the characteristics of the patients, the recommended exercises will be of low impact.~Strength exercise: Exercises of large muscle groups with intensities adapted to patients using body weight or elastic bands of different resistances.~Flexibility exercise: Stretching exercises will be included during the warm-up and cool-down of each exercise session of the program."
219286055|NCT06987903|PROCEDURE|Pre- and post-operative respiratory physiotherapy|"Pre- and post-operative respiratory physiotherapy during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~Breathing exercises:~Abdomino-diaphragmatic respiratory control exercises, costo-diaphragmatic respiratory control exercises, costo-diaphragmatic breathing control exercises, exercises with costal expansion and arm elevation and breathing exercises with pursed lips in different positions.~Incentive spirometry:~Incentive spirometry with the performance of slow, deep breaths in a volumetric incentive device."
219286056|NCT06824168|DRUG|Quizartinib High Dose|Participants in Arm 1 will receive oral daily higher dose of quizartinib,
219286057|NCT06824168|DRUG|Quizartinib Low Dose|Participants in Arm 2 will receive oral daily lower dose of quizartinib
219286058|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
219286059|NCT05820295|BEHAVIORAL|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
219286060|NCT05820295|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
219286061|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
219286062|NCT06658093|DRUG|Everolimus|mTOR inhibitor
219286063|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
219286064|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
219286065|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
219286066|NCT06613984|BIOLOGICAL|Bretovameran|Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
219286067|NCT06994767|OTHER|The Canary Application|The CANARY application will use clinically validated survey instruments and voice recordings to measure user MCI status /Alzheimer's data. These tests are designed to evaluate a user's voice characteristics and potentially identify disease-specific patterns.
219286068|NCT05874401|DRUG|Trilaciclib|Participants will receive intravenous trilaciclib infusion
219286069|NCT05874401|DRUG|Placebo|Participants will receive intravenous placebo infusion
219286070|NCT05874401|DRUG|Topotecan|Participants will receive intravenous topotecan infusion
219286071|NCT06121336|DIAGNOSTIC_TEST|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
219286072|NCT06999772|DEVICE|Active rTMS|A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). Stimulation parameters will be obtained by measuring the motor threshold of the first right interosseous muscle, then the rTMS intensity will be set at 110% of this motor threshold. High frequency (HF) rTMS consisting of 60 trains of 5 s at 10 Hz with 15 s intertrain intervals, for a total of 3000 pulses per session, will be used. The coil will be positioned over the left dorsolateral PFC using the BeamF3 methods.
219286073|NCT06999772|DEVICE|Sham rTMS|A sham coil will be used (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS and will be located over the same area (dorso-lateral prefrontal cortex).
219178135|NCT02645149|DRUG|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
219178136|NCT02645149|DRUG|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
219178137|NCT02645149|DRUG|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
219178138|NCT02645149|DRUG|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
219178139|NCT06801873|OTHER|Endotoxin (E. coli O:113, Reference Endotoxin)|Intravenous administration of 1 ng/kg (total body weight) endotoxin (Lot no. 94332B1; List Biological Laboratories, Campbell, USA). This is a non-investigational product. Endotoxin is used as challenge agent to achieve a controlled inflammatory state.
219178140|NCT06800391|COMBINATION_PRODUCT|Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day|Capecitabine (1250 mg/m2 /day) and Cyclophosphamide (50 mg/day) continuous daily dosing. Cycles are to be repeated every 28 days for a total of 6 cycles.
219178141|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
219178142|NCT06801366|DIAGNOSTIC_TEST|Parent-recorded smartphone video clips|Parents will record smartphone video clips of their child asleep, which will be scored by pediatric sleep physicians for presence of moderate-severe OSA. Children will then undergo clinically indicated polysomnography (PSG). Video clips will be evaluated for diagnostic accuracy, with PSG as the gold standard.
219178143|NCT06801457|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
219178144|NCT06801457|OTHER|Control|Best medical care
219178145|NCT02979522|DRUG|Brentuximab vedotin|Brentuximab vedotin infusion
219178146|NCT02979522|DRUG|Doxorubicin|Doxorubicin infusion
219178147|NCT02979522|DRUG|Vinblastine|Vinblastine infusion
219178148|NCT02979522|DRUG|Dacarbazine|Dacarbazine infusion
219286074|NCT06999772|OTHER|Psychologically-informed physiotherapy (PiP)|Participants will receive 6 intervention sessions (45 min) over 6 weeks by a physiotherapist. The objective of this intervention is to identify biopsychosocial factors that may impede recovery and to address these factors within the physiotherapist's scope of practice. Physiotherapists will use strategies such as the establishment of common goals and therapeutic alliance, the use of behavior change model, motivational interview, education on pain neurophysiology, gradual exposure to movement and stress management strategies (e.g. breathing techniques). Participants allocated to PiP groups will have access to a website offering support information related to understanding their pain (e.g. pain neuroscience education), myths and false beliefs related to back pain, understanding the impact of psychological factors on their pain, self-management strategies, and healthy lifestyle habits. This site will be freely available to participants during the course of the study.
219286075|NCT06999772|OTHER|Usual physiotherapy|Participants will receive 6 intervention sessions (45 min) over 8 weeks by a physiotherapist. This is a pragmatic group that aims to represent real-word clinical practice i.e. interventions commonly used in physiotherapy to manage CLBP. All interventions that a physiotherapist can deliver in the province of Quebec will be allowed (e.g. manual therapy, exercises). No training will be provided to better reflect usual clinical practice in physiotherapy.
219286076|NCT05043454|OTHER|High Intensity Interval Training (HIIT) Exercise|Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
219286077|NCT02344290|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
219286078|NCT02344290|DRUG|Placebo|One tablet taken once daily, orally with or without food
219286079|NCT07135089|DRUG|Intravenous tirofiban before endovascular thrombectomy|The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
219286080|NCT07135089|DRUG|Intravenous placebo before endovascular thrombectomy|The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
219286081|NCT07126470|PROCEDURE|CTR implantation|Device: CTR (275001G, OPHTEC BV, Netherlands) All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL (J\&J Tecnis DCB00) is implanted.
219286082|NCT07008963|OTHER|non-interventional|This is a non-interventional, observational study
219286083|NCT05765487|DRUG|Sildenafil|Sildenafil Cream, 3.6%
219286084|NCT05765487|DRUG|Vehicle|No Active or experimental ingredients
219286085|NCT05765487|DRUG|Placebo|Cream with only L-arginine
219286086|NCT06676488|DEVICE|Re-Timer glasses|Morning bright light therapy (BLT) will be administered through a safe wearable glasses device called a Re-Timer, purchased from the manufacturer Re-Timer.
219286087|NCT06676488|DEVICE|Placebo Device|Placebo glasses not providing Bright Light Therapy
219286088|NCT04998812|DRUG|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
219286089|NCT06619236|DRUG|Rina-S|Intravenous (IV) infusion
219286090|NCT06619236|DRUG|Paclitaxel|IV infusion
219286091|NCT06619236|DRUG|Topotecan|IV infusion
219286092|NCT06619236|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
219286093|NCT06619236|DRUG|Gemcitabine|IV infusion
219286094|NCT06867848|PROCEDURE|laminar bone membrane for labial bone augmentation|adding laminar bone membrane in one group and pericardium membrane in another group with sticky bone by using vestibular incision in both groups to augment the labial bone over dental implant
219286095|NCT07046494|DRUG|RAP-219|RAP-219 tablets administered orally, once daily for 21 days
219286096|NCT07046494|OTHER|Placebo|Matching placebo tablets administered orally, once daily for 21 days
219286097|NCT04545736|DRUG|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
219286098|NCT05303792|DRUG|Cyclophosphamide|Given IV
219286099|NCT05303792|DRUG|Vincristine|Given IV
219286100|NCT05303792|DRUG|Dexamethasone|Given IV or PO
219286101|NCT05303792|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219286102|NCT05303792|DRUG|Methotrexate|Given IV or PO
219286103|NCT05303792|DRUG|Cytarabine|Given IV
219286104|NCT05303792|DRUG|Methylprednisolone|Given IV
219286105|NCT05303792|BIOLOGICAL|Rituximab|Given IV
219286106|NCT05303792|DRUG|Prednisone|Given PO
219286107|NCT05303792|DRUG|Mercaptopurine|Given PO
219286108|NCT05303792|DRUG|Doxorubicin|Given IV
219286109|NCT06892418|BEHAVIORAL|Ketoflex 12/3 Diet|A plant-based ketogenic diet combined with intermittent fasting (12/3)
219286110|NCT06894537|OTHER|Experimental (percutaneous echo-guided electrical nerve stimulation)|The protocol applied in this study will consist of: 10 stimulations of 10 seconds at 10Hz with a rest of 10 seconds between one stimulation and the next one. The intensity of the current (mA) will be adapted to each of the subjects until the greatest possible muscle contraction is achieved without reaching the painful threshold.
219286111|NCT06894537|OTHER|Control (placebo) group|For the subjects in the control group, the same process shall be carried out without increasing the intensity of the current. It shall be explained to the subjects that the current will reach a non-perceptible stimulus.
219286112|NCT07051655|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will undergo two test days separated by 3-7 days. On both test days, participants will arrive fasted and consume a single dose of ketone monoester or placebo (357 mg/kg of body weight) in random order. Drinks will be prepared by non-study personnel and matched in taste, texture, and appearance to maintain blinding. Thirty minutes after consuming the ketone monoester or placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
219286113|NCT07051655|DIETARY_SUPPLEMENT|Placebo|Participants will undergo two test days separated by 3-7 days. On one test day, participants will consume a single dose of placebo (357 mg/kg of body weight). Thirty minutes after consuming the placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
219286118|NCT07049328|DRUG|HCW9302, an IL-2 fusion protein|Injection
219286119|NCT05204290|DRUG|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
219286120|NCT05204290|RADIATION|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
219286121|NCT05204290|OTHER|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
219286122|NCT05822583|DRUG|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
219286123|NCT05822583|DRUG|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
219286124|NCT06567925|BEHAVIORAL|Customized Sleep Coaching|Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.
219286125|NCT06567925|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
219286126|NCT07055945|OTHER|Experimental group|Individuals in both groups will receive a physiotherapy program for 3 sessions per week, 60 minutes per day, for a total of 8 weeks.The study consists of two groups: the experimental group and the control group. Both groups will receive a physiotherapy program of 3 sessions per week, each lasting 60 minutes, for a total of 8 weeks. Within the 60-minute physiotherapy session, patients from both groups will undergo 30 minutes of exercises based on the Neurodevelopmental Treatment (NDT) method. In addition, a 12-minute training session will be conducted using a light-based trainer system (Light Trainer® Exercise System).
219286127|NCT07055945|OTHER|Control group|"In addition to the full-body exercises mentioned, individuals in the control group will also receive upper extremity exercises based on the Neurodevelopmental Treatment approach. These exercises are as follows:~* Functional reaching activities at the table in a sitting position (e.g., pushing objects, wiping the table, touching various points)~* Ball sliding on the wall in a standing position~* Touching different targets on the wall in a standing position~* Drawing shapes on the wall in a standing position~These exercises will be performed bilaterally and on the hemiparetic side. The exercises will be given for approximately 12 minutes, in line with the exercises given to the experimental group. The difficulty level will not be increased during the training."
219286128|NCT06750432|DRUG|PMN310|A humanized immunoglobulin G1 (IgG1) monoclonal antibody
219286129|NCT06750432|DRUG|Placebo|0.9% NaCl 100 mL
219286130|NCT01934751|OTHER|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
219286131|NCT01934751|OTHER|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
219286132|NCT06747273|DRUG|SRP-9004|Intravenous (IV) infusion.
219286133|NCT04990713|PROCEDURE|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
219286134|NCT04990713|PROCEDURE|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
219286135|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
219286136|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
219286137|NCT07059312|DRUG|JADE101|JADE101 is supplied as sterile solution to be administered by SC injection.
219286138|NCT07059312|DRUG|Placebo|Placebo solution to be administered at a matching volume by SC injection.
219286139|NCT07053865|DEVICE|Surface Electromyography (dia-BRUXO)|Participants will undergo 24-hour surface electromyographic recording of the left masseter muscle using the dia-BRUXO portable device to quantify sleep bruxism activity through Bruxism Work Index (BWI) and Bruxism Time Index (BTI).
219286140|NCT07055542|DIAGNOSTIC_TEST|Observational|Prospective observational study
219286141|NCT06313710|OTHER|head down position|-10° Trendelenburg
219286142|NCT07062133|PROCEDURE|Electrical pudendal nerve stimulation|Electrical Pudendal Nerve Stimulation (EPNS) delivered by four deep acupuncture needles targeting bilateral sacrococcygeal points near the pudendal nerve. Connected to G6805-2 electrical stimulator, 2 Hz, 60 minutes/session, three times per week for 4 weeks.
219286143|NCT07062133|OTHER|Conventional conservative treatment|Conventional conservative treatment including medications (e.g., oxybutynin), clean intermittent catheterization, and diaper use as needed
219286144|NCT06770270|DRUG|Pucotenlimab|"Pucotenlimab combined with long-course concurrent chemoradiotherapy, followed by two cycles of pucotenlimab combined with chemotherapy, and then based on tumor response, TME surgery or a watch and wait strategy will be adopted."
219286145|NCT02049853|DEVICE|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
219286146|NCT06770660|BEHAVIORAL|Telemedicine|"A 10-week telemedicine-based exercise programme consisting of 90-minute sessions conducted weekly via a video conferencing platform.~All participants will also be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form."
219286147|NCT06770660|BEHAVIORAL|Lifestyle|All participants will be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form.
219286148|NCT07067684|OTHER|Low Tidal Volume Ventilation During CPB|"Group Low: Patients in this group will receive low tidal volume mechanical ventilation during cardiopulmonary bypass (CPB).~Ventilation settings will be:~Tidal Volume: 3-4 mL/kg (ideal body weight)~PEEP: 5-8 cmH₂O~Respiratory Rate: adjusted to maintain normocapnia (PaCO₂ 35-45 mmHg)"
219286149|NCT06789406|DEVICE|Axonics SNM System INS Model 5101 (R20)|Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
219286150|NCT06053164|DRUG|Exertional Oxygen|Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes
219286151|NCT06053164|BEHAVIORAL|Education and Support|Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
219286152|NCT06804109|DEVICE|Active nVNS|2-min transcutaneous nVNS stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
219286153|NCT06804109|DEVICE|Control nVNS|2-min control stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
219286154|NCT07066293|PROCEDURE|Unilateral alveolar cleft repair|10 patients in whom unilateral alveolar cleft will be repaired using sticky bone grafting combined with concentrated growth factor membrane
219286155|NCT07070336|OTHER|Neuroathletic exercise|After warm-up and resetting exercises, it will start with eye muscle training with a star chart. It then consists of exercises that regulate the accommodation reflex, balance the right and left lobes, regulate the vestibular system and rhythm exercises.
219286156|NCT06269627|DRUG|Acamprosate calcium|Two oral capsules (packaged as one) containing 666 mg of acamprosate calcium will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
219286157|NCT06269627|OTHER|Placebo|Two oral capsules (packaged as one) containing 666 mg of inactive substance (e.g., sugar) will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
219286158|NCT04666792|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
219286159|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
219286160|NCT06756074|DRUG|Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)|pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.
219286161|NCT06756074|PROCEDURE|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
219286162|NCT07073885|OTHER|Ultra-Low Tidal Volume Ventilation|Ventilation continued during CPB using volume-controlled mode with ultra-low tidal volume (3-4 mL/kg IBW(Ideal Body Weight)), 12-14 breaths/min, 5 cm H₂O PEEP, and 50% FiO₂.
219286163|NCT07073885|OTHER|Apnea Group|In this group, mechanical ventilation will be discontinued after aortic cross-clamping during CPB, and apnea will be maintained throughout the bypass period.
219286164|NCT06547151|DRUG|AMOR-1|Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
219286165|NCT06547151|DRUG|Crystalline Calcium Carbonate|Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
219286166|NCT06900647|DRUG|Bortezomib (B)|1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
219286167|NCT06900647|DRUG|Cisplatin (CDDP)|50mg/m2, IV, D1-3, every 3 weeks
219286168|NCT06900647|DRUG|Bortezomib (B)|1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
219286169|NCT06900647|DRUG|Bortezomib (B)|1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
219286170|NCT06900647|DRUG|Cisplatin (CDDP)|70mg/m2, IV, D1-3, every 3 weeks
219286171|NCT06878365|DRUG|BI 3000202_low dose|BI 3000202\_low dose
219286172|NCT06878365|DRUG|BI 3000202_high dose|BI 3000202\_high dose
219286173|NCT07074288|DEVICE|MAD|MAD intervention involves the use of a mandibular advancement device, which is designed to reposition the lower jaw and tongue to keep the airway open during sleep.
219286174|NCT07074288|DEVICE|HGNS|HGNS intervention involves a surgical procedure to implant a device that stimulates the hypoglossal nerve to prevent airway collapse during sleep.
219286175|NCT07076030|DRUG|Petrelintide|Solution administered with a syringe
219286176|NCT07135531|DEVICE|Continuous Glucose Monitoring (CGM)|Continuous glucose monitors will be placed subcutaneously every 14 days.
219286177|NCT07128576|DRUG|Romiplostim N01|Romiplostim N01: 3-10 μg/kg(Initial dose 3 μ g/kg), qw, H.
219286178|NCT05170399|BIOLOGICAL|Fluzone|Annual Influenza Vaccine
219286179|NCT05170399|BIOLOGICAL|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
219286180|NCT05170399|BIOLOGICAL|Flucelvax|Annual Influenza Vaccine
219286181|NCT05170399|BIOLOGICAL|Afluria|Annual Influenza Vaccine
219286182|NCT05170399|BIOLOGICAL|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
219286183|NCT05170399|BIOLOGICAL|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
219286184|NCT05170399|BIOLOGICAL|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
219286185|NCT05170399|BIOLOGICAL|FluLaval|Annual Influenza Vaccine
219286186|NCT05170399|BIOLOGICAL|Fluarix|Annual Influenza Vaccine
219286187|NCT05170399|BIOLOGICAL|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
219286188|NCT05170399|DRUG|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
219286189|NCT05170399|DRUG|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
219286190|NCT00900198|PROCEDURE|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
219286191|NCT07077122|PROCEDURE|Scaling and Root Planing|Mechanical debridement of tooth surfaces using hand and ultrasonic instruments
219286192|NCT07077122|DRUG|antibiotic prophylaxis|2g Amoxicillin given 1 hour prior to instrumentation
219286193|NCT07077122|DEVICE|810nm Diode Laser|Laser applied at base of gingival pockets prior to mechanical debridement.
219286194|NCT07077122|PROCEDURE|Air Polishing|air flow-based mechanical debridement with erythritol powder
219286195|NCT03826030|DEVICE|Sham|Sham group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject.
219286196|NCT03826030|DEVICE|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
219286197|NCT03826030|DEVICE|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
219286198|NCT03826030|BEHAVIORAL|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
219286199|NCT07076862|DRUG|A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.
219286200|NCT07076862|DRUG|A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
219286201|NCT07076862|DRUG|B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.
219286202|NCT07076862|DRUG|B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive 5 mCi (±20%) of \[¹⁸F\]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
219286203|NCT07086768|DRUG|BSI-082|BSI-082 is a sterile solution for injection which contains the active ingredient at the nominal concentration of 50.0 mg/mL. T
219286204|NCT07086768|OTHER|Trastuzumab deruxtecan|T-DXd: Administrate as per the drug package insert and Investigator's guidance, and T-DXd can be continued after the patients been taken off from the study.
219286205|NCT02745353|DRUG|naloxegol|
219286206|NCT06903897|OTHER|WE CARE SDOH System|The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.
219286207|NCT06903897|OTHER|Standard Pediatric Care|Standard pediatric care includes any existing screening practices, which can vary at each clinic.
219286208|NCT06852209|PROCEDURE|Cognitive remediation therapy|Cognitive remediation therapy as treatment as usual
219286209|NCT06852209|PROCEDURE|Neuropsychological assessment|Neuropsychological assessment to measure cognitive performances
219286210|NCT06852209|PROCEDURE|Real-time functional MRI neurofeedack (rt-fMRI NF)|Real-time functional MRI neurofeedack (rt-fMRI NF) is a procedure of brain-machine interface supporting self-regulation of brain activity, with promising results in the treatment of mental disorders. The main objective of the study is to evaluate in a pilot study, the ability of stroke patients to learn to self-regulate their brain activity in a priviledged direction.
219286211|NCT06852209|PROCEDURE|fMRI sessions|fMRI sessions but without receiving feedback
219286212|NCT06805994|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
219286213|NCT06805994|BIOLOGICAL|Placebo|Placebo sterile swab
219286214|NCT06906731|DRUG|SHR-9803|SHR-9803
219286215|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
219286216|NCT07137351|DIAGNOSTIC_TEST|The Biosensor Using the Target Urine Volatile Organic Compounds|"The authors opted to utilize five distinct commercially available semiconductors (metal oxide sensors) to detect all the targeted VOCs which were manufactured by Figaro company.~Urine samples from patients were placed in a urine container, which was then placed into the VOCs detection device. The lid was closed, and the system was set to operate in a closed-loop mode at a room temperature of 25 degrees Celsius. The device then vacuumed VOCs from the urine samples of the patients through a gas tube into the biosensor chamber located on top, where analysis was performed."
219286217|NCT07091955|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CRL1505|Probiotic product containing Lacticaseibacillus rhamnosus CRL1505 formulated in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
219286218|NCT07091955|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo product containing cornstarch, in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
219286219|NCT04074057|OTHER|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
219286220|NCT04074057|DEVICE|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
219286221|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
219286222|NCT05014568|DRUG|Vehicle cream|applied topically once daily
219286223|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
219286224|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
219286225|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
219286226|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
219286227|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
219286228|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
219286229|NCT06904222|BIOLOGICAL|Placebo|0.5 mL 0.9% sodium chloride (normal saline) injection per dose
219286230|NCT04893460|BEHAVIORAL|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
219286231|NCT07088900|PROCEDURE|caudal block using dexmedetomidine with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 µg/kg of dexmedetomidine (diluted in 1 mL of normal saline).
219286232|NCT07088900|PROCEDURE|caudal block with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 mL of normal saline
219286233|NCT07105371|BIOLOGICAL|AlloEx exosomes|This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
219286234|NCT07099404|OTHER|PET/CT imaging with rubidium-82|PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
219286235|NCT07102407|OTHER|Contructivist|Implementation of constructivist training on VAP in small groups
219286236|NCT07102407|OTHER|Routine training|Implementation of routine training on VAP in large groups
219286237|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
219286238|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
219296447|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
219296448|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
219286239|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
219286240|NCT04015869|DRUG|Allopregnanolone|neurosteroid
219286241|NCT04015869|DRUG|Placebos|placebo
219286242|NCT06826794|OTHER|Clinicians|Clinicians will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
219286243|NCT06826794|DEVICE|VenitlO|VentilO application (or web platerform) will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
219286244|NCT07105670|OTHER|Controlled dietary intervention|Participants will complete a 2-week baseline period consuming their standard diet without any food or beverages provided followed by a randomized, crossover-controlled feeding study of a lacto-ovo vegetarian diet versus the same diet with 20% of the protein replaced by red meat. In between the two diets, there will be a five-week washout where participants will consume their standard diet without any food or beverages provided.
219286245|NCT06381492|DEVICE|MRI|MRI using DTI technology
219286246|NCT06381492|DEVICE|Ultrasound (US)|Standard US
219286247|NCT06381492|DEVICE|Neuromuscular electric stimulation (NMES)|Standard NMES
219286248|NCT03820947|DEVICE|VenaSeal™ System|The VenaSeal™ System is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
219286249|NCT03820947|DEVICE|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
219286250|NCT03820947|PROCEDURE|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
219286251|NCT07107568|DIAGNOSTIC_TEST|Standard Invasive Coronary Angiography|Standard invasive coronary angiography performed routinely for all participants in this arm to assess coronary artery disease before TAVR.
219286252|NCT07107568|DIAGNOSTIC_TEST|PCD-CT-Guided Diagnostic Strategy|Participants randomized to this arm will undergo coronary artery disease (CAD) assessment using photon-counting detector computed tomography (PCD-CT). Invasive coronary angiography (ICA) will only be performed if PCD-CT shows significant CAD, defined as ≥70% diameter stenosis in vessels ≥2.5 mm or ≥50% in the left main artery.
219286253|NCT07112378|DRUG|dupilumab|Administered as defined in the protocol
219286254|NCT06626035|DRUG|Methadone based ERAS|Children randomized to the methadone arm will include standardized perioperative care and analgesia, including intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.1 mg/kg up to a maximum of 5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral or IV doses of methadone (0.1 mg/kg up to a maximum of 5 mg) every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
219286255|NCT06626035|DRUG|Non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
219286256|NCT06915220|BEHAVIORAL|mobile health app|HeartSteps is an innovative mobile health (mHealth) app designed for cardiac rehabilitation patients. The app features dynamic push notifications, daily and weekly surveys to capture psychosocial data, and an in-app dashboard that provides feedback on activity levels, goal progress, and reminders. Integrated with a Fitbit Charge tracker, HeartSteps emphasizes behavioral changes through engaging features. The intervention is personalized to meet individual needs and preferences, enhancing patient engagement and promoting sustained physical activity.
219286257|NCT07115953|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
219286258|NCT06905964|BEHAVIORAL|Eccentric cycling exercise (ECC)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, rest in sitting position for 20 min. Exercise intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
219286259|NCT06905964|BEHAVIORAL|Eccentric cycling exercise with assistive devices (ECA)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, receive NMES in sitting position for 20 min.~Intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
219286260|NCT01217788|DRUG|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
219286261|NCT06953089|DRUG|DB-1311/BNT324|Administered I.V.
219286262|NCT06953089|DRUG|BNT327|Administered I.V.
219286263|NCT06953089|DRUG|DB-1305/BNT325|Administered I.V.
219286264|NCT07140939|DRUG|CBL-514 Injection|Provided as a ready for use injectable CBL-514 solution
219286265|NCT07140939|OTHER|0.9% Sodium Chloride|Injectable 0.9% Sodium Chloride solution as placebo
219286266|NCT07155174|DRUG|ABBV-706|Intravenous (IV) Infusion
219286267|NCT07155174|DRUG|Atezolizumab|IV Infusion
219286268|NCT07155174|DRUG|Etoposide|IV Infusion
219286269|NCT07155174|DRUG|Carboplatin|IV Injection
219286270|NCT07155174|DRUG|Carboplatin|IV Infusion
219286271|NCT07155174|DRUG|Lurbinectedin|IV Infusion
219286272|NCT07153731|DRUG|Shenkangling|Chinese herbal tonics taken orally: Shenkangling, one dose, 2 times a day, 1 time before breakfast and 1 time 30 minutes after dinner.
219286273|NCT07153614|PROCEDURE|Intrathecal Morphine Block|Morphine 150 mcg
219286274|NCT07153614|PROCEDURE|Bilateral Quadratus Lumborum Block|30 mL of 0.25% bupivacaine and 4mg of dexamethasone
219286275|NCT07153614|PROCEDURE|Bilateral Transverse Abdominis Plane Block|Exparel-based solution mixed with 50mL of saline
219286276|NCT07153406|DRUG|Experimental regimen|Esketamine intranasal spray at flexible doses (28, 56 and 84 mg) once or twice a week
219286277|NCT07153406|DRUG|Control regimen|Oral aripiprazole 5-30 mg daily, once or twice daily for the duration of the study
219286278|NCT07154459|OTHER|Breastfeeding Education|Breastfeeding Education
219286279|NCT07155291|BEHAVIORAL|Abdominal Self-Massage|Daily self-administered visceral abdominal massage consisting of circular motions and pressure point techniques, performed for 5-20 minutes in total based on participant preference. The massage includes two parts: belly exercises (10 exercises) and pelvic exercises (3 exercises), with each exercise repeated 5-10 times or until the area feels relaxed. The app provides instructional videos and written step-by-step guides with drawings in English and German. Participants are recommended to use oil/cream, find a comfortable position, and integrate the massage into a daily routine.
219286280|NCT07154680|DIAGNOSTIC_TEST|GPT-4o mini;Claude 3 Haiku;Gemini 1.5 Flash;Llama 3.1 7OB;GPT-4o;Claude 3.5 Sonnet;Gemini 1.5 Pro;Llama 3.1 4O5B|Input all the patient's information into the large language model and process it using a pre-defined prompt.
219286281|NCT07155785|DRUG|Lidocain spray|Lidocaine spray as a local anaesthetic agent was applied to the cervix before intrauterine device application.
219286282|NCT07154836|OTHER|Telephone calls|Regular telephone reminders and health information will be sent to help mothers or caregivers of children 0-23 months to remind them to go vaccine their children
219286283|NCT07153575|PROCEDURE|suprainguinal fascia iliaca block|The ultrasound-guided suprainguinal fascia iliaca block (SFIB) procedure was first described by Hebbard et al. in 2011. It is a prevalent regional anesthesia technique employed in surgical procedures involving the hip joint and femur. Local anesthetics are administered in close proximity to the fascia iliaca. The primary objective is to obstruct the femoral, obturator and lateral femoral cutaneous nerve in a simultaneous manner. In clinical practice, it is a safe and simple alternative to lumbar plexus blocks and femoral blocks. A 30-ml solution of 0.25% bupivacaine was injected between the iliac muscle and the iliac fascia. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
219286284|NCT07153575|PROCEDURE|Pericapsular nerve group (PENG) block|In pericapsular nerve group (PENG) block the local anesthetic agent is injected into the musculofascial plane between the psoas muscle tendon and the pubic ramus. The primary objective of this technique is to obstruct the genicular branches of the femoral, obturator, and accessory obturator which innervate the hip capsule. Therefore, a comparison with the SFIB was undertaken. A 30-ml block of 0.25% bupivacaine solution was injected between the pubic ramus and the iliopsoas muscle tendon. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
219286285|NCT06475963|OTHER|surveys|telephone survey
219286286|NCT01038375|BEHAVIORAL|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
219286287|NCT03953924|OTHER|Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)|The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
219286288|NCT02218606|DRUG|Abiraterone acetate 1000 mg po daily|
219286289|NCT02218606|DRUG|Cabazitaxel 25 mg/m2 IV|
219286290|NCT02218606|DRUG|prednisone 5 mg po BID|
219286291|NCT03203473|DRUG|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
219286292|NCT03203473|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
219286293|NCT06013553|OTHER|Control Group|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
219286294|NCT06013553|OTHER|Aerobic Exercises group|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given"
219286295|NCT01431495|DRUG|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
219286296|NCT01431495|DRUG|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
219286297|NCT01844024|OTHER|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
219286298|NCT04666623|DRUG|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
219286299|NCT04666623|DRUG|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
219286300|NCT02226861|DEVICE|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
219286301|NCT02226861|BIOLOGICAL|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
219286302|NCT03222713|OTHER|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
219286303|NCT00004853|BIOLOGICAL|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC \>=10,000/microliter
219286304|NCT00004853|BIOLOGICAL|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
219286305|NCT02081430|PROCEDURE|CT Manipulation|
219286306|NCT02081430|PROCEDURE|Upper trapezius stretch|
219286307|NCT00890695|DIETARY_SUPPLEMENT|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
219286308|NCT05462158|BEHAVIORAL|Impact of Nudges on CKD Testing|The investigators will examine the impact of different messages on different dimensions of testing for CKD
219286309|NCT04420949|BEHAVIORAL|Sensory re-weighting|During training, sensory re-weighting is driven by priming upregulation of somatosensory cues. Two rounds of training, each lasting 15 minutes and block-randomized in sets of 10 trials, are conducted per training visit. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity. Immediate auditory and non-orienting, visual feedback is provided after each trial. A staircase method is used to adapt the level of difficulty based on response accuracy. After two consecutive correct responses, the difficulty increases. After each incorrect response, the difficulty decreases. This process is repeated in each round.
219286310|NCT01718808|DRUG|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
219286311|NCT01718808|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
219286312|NCT01325311|DRUG|Cholecalciferol|Given PO
219286313|NCT01325311|DRUG|Genistein|Given PO
219286314|NCT01325311|OTHER|Laboratory Biomarker Analysis|Correlative studies
219286315|NCT01325311|OTHER|Pharmacological Study|Correlative studies
219286316|NCT01325311|OTHER|Placebo|Given PO
219286317|NCT06188897|OTHER|Self-stretching of the masticatory musculature|"If the subject belonged to the Treatment group, he was instructed to self-stretch the masticatory muscle.~This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting."
219286318|NCT06188897|OTHER|Control group intervention|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
219286319|NCT04270591|DRUG|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
219286320|NCT01980680|DRUG|hCG|
219286321|NCT01980680|DRUG|Progesterone and Estradiol|
219286322|NCT01788553|OTHER|remission prevalence of generalized anxiety disorder|
219286323|NCT01696552|PROCEDURE|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
219286324|NCT01696552|PROCEDURE|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
219286325|NCT01732822|DRUG|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
219286326|NCT01732822|DRUG|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
219286327|NCT03154853|OTHER|Behavioral: short foot exercise|Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
219286328|NCT02754739|DRUG|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
219286329|NCT02754739|DRUG|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
219286330|NCT02754739|BEHAVIORAL|Nutritional education only|Only nutritional education by a nutritionist
219286331|NCT05180331|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
219286332|NCT00296985|DEVICE|Fresenius Cellsaver|
219286333|NCT05530759|PROCEDURE|Biopsy Specimen|Undergo collection of tissue samples
219286334|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal swab samples
219286335|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of archived tissue and blood samples
219286336|NCT05530759|OTHER|Medical Chart Review|Review of medical record
219286337|NCT05720845|PROCEDURE|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
219286338|NCT05720845|PROCEDURE|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
219286339|NCT04871854|DRUG|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
219286340|NCT04871854|DRUG|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
219286341|NCT03082404|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
219286342|NCT04523428|DRUG|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
219286343|NCT04497064|OTHER|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
219286344|NCT00371189|DRUG|Placebo|Normal saline.
219286345|NCT00371189|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.
219286346|NCT06208449|PROCEDURE|Robotic repair for EA|The paitents with EA were repaired by Da Vinci robot
219286347|NCT06208449|PROCEDURE|Thoracoscopic repair for EA|The patients with EA were repaired by thoracoscopy
219286348|NCT06208449|PROCEDURE|Thoracotomy repair for EA|The patients with EA were repaired by traditional open thoracotomy.
219286349|NCT02812693|DRUG|Imatinib Mesylate|Given PO
219286350|NCT02812693|OTHER|Laboratory Biomarker Analysis|Correlative studies
219286351|NCT02812693|BIOLOGICAL|Pembrolizumab|Given IV
219286352|NCT03107338|DRUG|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
219286353|NCT03107338|OTHER|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
219286354|NCT00433212|DEVICE|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
219286355|NCT00433212|DEVICE|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
219286356|NCT03029221|OTHER|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
219286357|NCT03029221|OTHER|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
219286358|NCT03029221|OTHER|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
219286359|NCT05505240|OTHER|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
219286360|NCT05505240|OTHER|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
219286361|NCT05505240|OTHER|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
219286362|NCT05505240|OTHER|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
219286363|NCT05709340|OTHER|proprioceptive neuromuscular facilitation exercises|PNF exercises will be done for Masseter, Temporalis, Lateral pterygoid and medial pterygoid muscles. Each contraction will be held for 10 seconds, and each stretch (relaxation phase) will be allowed to continue as long as the muscle tension continued to give away.
219286364|NCT05709340|OTHER|traditional physical therapy treatment|"* Ultrasound: Continuous ultrasound at 1MHZ to temporomandibular joint at 1.0-1.25 W/CM2 for 5 min over each affected TMJ and masseter area, with the mouth in a slightly open position.~* Forward head posture correction exercises including: chin tuck exercise, Strengthening shoulder retractors, stretching of sternocleidomastoid muscle, and Stretching of pectoralis muscle."
219286365|NCT05680038|DRUG|Penpulimab|Penpulimab is a modified PD1 inhibitor, which innovated the use of IgG1 subtype. On the basis of ensuring the stability of the antibody, it eliminated ADCC, ADCP, CDC and other effects that were not conducive to the efficacy of T cells and reduced the effect of ADCR by modifying the Fc segment
219286366|NCT04252443|OTHER|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
219286367|NCT04712695|OTHER|Exercise Based Interventions|Proprioception Training Interventions
219286368|NCT01183260|DEVICE|Trabecular Metal Revision Cup|Revision of the acetabular cup
219286369|NCT01183260|DEVICE|Trabecular Metal Modular Cup|Revision of the acetabular cup
219286370|NCT05403112|PROCEDURE|Bone ring with open sinus lifting|All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
219286371|NCT05055505|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
219286372|NCT06446986|OTHER|Single and Dual-Task Timed Up and Go Test|Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.
219286373|NCT06446986|OTHER|Single and Dual-Task Tandem Walking Test|"The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards"
219286374|NCT06446986|OTHER|Simple Shoulder Test|Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
219286375|NCT06025760|OTHER|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
219286376|NCT03667430|DIETARY_SUPPLEMENT|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
219286377|NCT03667430|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
219286378|NCT06079619|OTHER|Analysis of photos of pigmented tumours by the three groups|Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
219286379|NCT00023296|DRUG|Nitric Oxide|
219286380|NCT00023296|DEVICE|INO Pulse - NO Delivery System|
219286381|NCT06013696|OTHER|Adding household bleach to urine sample|Adding household bleach to urine sample
219286382|NCT03599258|DEVICE|Skylife|Newly FDA approved device
219286383|NCT03599258|DEVICE|Standard Therapy|Both devices are considered standard therapy
219286384|NCT02869529|OTHER|Data collection|
219286385|NCT01581177|DRUG|Albuterol DPI 25 mcg/inh|Albuterol DPI with 25 mcg Albuterol/inhalation
219286386|NCT01581177|DRUG|Albuterol DPI 90 mcg/inh|Albuterol DPI with 90 mcg Albuterol/inhalation
219286387|NCT01581177|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
219286388|NCT01581177|DRUG|Albuterol MDI 90 mcg/inh|Albuterol MDI with 90 mcg Albtuerol/inhalation
219286389|NCT02144792|DRUG|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
219296449|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
219286390|NCT01255631|DEVICE|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
219286391|NCT01255631|DEVICE|Sham PEMF Device|Inactive PEMF device, delivers no PMF
219286392|NCT04393194|DRUG|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
219286393|NCT00313092|DEVICE|nCPAP treatment|treatment with positive air pressure during night
219286394|NCT00384774|DRUG|Lasmiditan|Administered as intravenous infusion
219286395|NCT00384774|DRUG|Placebo|Administered as intravenous infusion
219286396|NCT04921475|DEVICE|Regional oxygen saturation monitoring|Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
219286397|NCT04631159|BEHAVIORAL|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
219286398|NCT04631159|OTHER|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
219286399|NCT04695522|BIOLOGICAL|ADR-002K administration|ADR-002K administration
219286400|NCT05473559|PROCEDURE|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
219286401|NCT04215484|DIAGNOSTIC_TEST|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
219286402|NCT02420951|DRUG|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
219286403|NCT02420951|OTHER|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
219286404|NCT04604574|OTHER|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
219286405|NCT01674829|BIOLOGICAL|MA09-hRPE|Transplantation of MA09-hRPE cells accoding to the assigned dose group
219286406|NCT03561662|DIETARY_SUPPLEMENT|Alpro soya drinks|12 weeks
219286407|NCT00568178|DRUG|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
219743119|NCT07010536|BEHAVIORAL|Conventional Physiotherapy and Rehabilitation|"Participants will receive conventional physiotherapy and rehabilitation exercises as follows:~Upper and lower extremity strengthening exercises~Resistance training exercises~Aerobic exercises~Basic and assisted parallel bar walking~Skill courses on various surfaces~Training on stable and unstable surfaces~Static and dynamic balance exercises~Fine motor skill exercises~Weight transfer exercises to improve postural stability~Exercises will be performed according to the patient's condition in standing, sitting, four-point kneeling, supine, and prone positions.~Exercise difficulty will be adjusted based on the patient's performance and functional level.~Sessions will be 60 minutes long, 5 days per week, for 6 weeks."
219286408|NCT00568178|OTHER|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
219286409|NCT00568178|DRUG|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
219286410|NCT00568178|OTHER|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
219286411|NCT00568178|OTHER|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
219286412|NCT00568178|DRUG|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
219286413|NCT02760875|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
219286414|NCT05698576|DEVICE|TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)|A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
219286415|NCT02880410|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
219286416|NCT02880410|DRUG|Radiation therapy and temozolomide|Radiation therapy and temozolomide
219286417|NCT02032589|BEHAVIORAL|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
219286418|NCT01508624|OTHER|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
219286419|NCT01508624|OTHER|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
219286420|NCT01508624|BEHAVIORAL|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
219286421|NCT01508624|BEHAVIORAL|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
219286422|NCT05651152|DRUG|JZP441|Nighttime oral dose
219286423|NCT05651152|DRUG|Placebo|Nighttime oral dose
219286424|NCT01618253|DRUG|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
219743120|NCT06088563|OTHER|Vaccine injection|Injection of the vaccine in renal transplant patients.
219743121|NCT06685016|DIAGNOSTIC_TEST|Evaluation of Dentin hypersensitivity with VAS scale|Dentin hypersensitivity and periodontal indices evaluation are performed after and before IPR, at 1 week, 1 month and 3 months
219743122|NCT06685380|OTHER|Not applicable- observational study|For observational studies, participants are not assigned an intervention as part of the study
219743123|NCT07010679|OTHER|Patient Centered CRS Treatment Decision Support|"The intervention is a web-based tool that includes:~* Educational content and Frequently Asked Questions (FAQ) about CRS and treatment options~* Patient stories from CRS patient interviews with artificial intelligence-assisted narrative writing~* A communication tool to support discussions between patients and their doctors~* Culturally tailored components, including Chinese language options and culturally relevant narratives Participants will be introduced to the PC CDS during a routine clinic visit or through a scheduled virtual meeting. They will use the tool before making treatment decisions. The tool is designed to be user-friendly and accessible across devices."
219743124|NCT06687239|DIAGNOSTIC_TEST|Blinded estimation of fetal weight|Blinded ultrasound-based estimation of fetal weight
219743125|NCT06687239|DIAGNOSTIC_TEST|Non blinded estimation of fetal weight|Non-blinded ultrasound-based estimation of fetal weight
219743126|NCT06690723|DRUG|Dapagliflozin (Forxiga)|Dapagliflozin plus lifestyle modification
219743127|NCT06690723|DRUG|Vitamin D3 ( Colecalciferol)|Vitamin D3 plus lifestyle modification
219743128|NCT06690723|DRUG|Vitamin D3 plus Dapagliflozin|Vitamin D3 plus Dapagliflozin plus lifestyle modification
219743129|NCT06690723|BEHAVIORAL|Lifestyle modification|Lifestyle modification alone
219743130|NCT06686732|OTHER|Multimodal physiotherapy|Experimental group included cold pack over lateral epicondyle. Passive stretching exercises in trapezius and levator scapulae and upper ECRB,ECRL,ECU,Extensor Digitorum, Extensor Digiti Minimi. Eccentric exercise of the extensor muscles associated with mobilization with movement. Neuromusclar Rehabilitation Excersise. In the region of origin of the tendons of the extensor muscles of the wrist and fingers for 2 min and inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide will be give at humeroradial joint during movement.
219743131|NCT06686732|OTHER|Conventional physiotherapy|Control group included Cold pack for 10 mins on the lateral epicondylitis, Extensor carpi radialis brevis stretching (hold for 15 seconds x 4 reps) Active ROM of wrist flexion and extension (10 reps x 3 sets) Active ROM of elbow flexion, extension, supination and pronation (10 reps x 3 sets) . Manually resisting wrist extensors (10 second hold x 5 reps x 3 sets) 4 sets of Maitland elbow joint mobilization with 1 min of rest between sets. Baseline Dynamometer for grip strength and VAS for pain. These pre and post intervention values were mentioned in questionnaire. The participants were administered with the protocol and data was collected again immediately after the interventions without any delay.
219286425|NCT01618253|RADIATION|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or \>10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If \>1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions \>10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
219286426|NCT04819659|DEVICE|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
219286427|NCT02823197|OTHER|Active transport lesson|
219286428|NCT02823197|OTHER|Active transport lesson and Facebook group|
219286429|NCT02815579|OTHER|Shamba Maisha Intervention|A) A loan (\~$175) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
219286430|NCT02255253|DRUG|Telmisartan|capsule,40mg per day,2 months
219286431|NCT02255253|DRUG|Hydrochlorothiazide|tablet, 25mg per day, 2 months
219286432|NCT00264303|DRUG|Levocetirizine|5mg oral capsules, once daily, 4 week duration
219286433|NCT00264303|DRUG|Desloratadine|5mg oral capsules, once daily, 4 week duration
219286434|NCT02389452|DRUG|Synvisc-One|intraarticular injection
219286435|NCT01855971|DIETARY_SUPPLEMENT|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
219286436|NCT01855971|DIETARY_SUPPLEMENT|Placebo|Same capsules containing rice flour. No active treatment is given.
219286437|NCT01855971|OTHER|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
219286438|NCT02311673|DRUG|Setmelanotide|subcutaneous injection
219286439|NCT02311673|DRUG|Placebo|Subcutaneous injection
219286440|NCT01006252|DRUG|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
219286441|NCT01006252|DRUG|Paclitaxel|80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
219286442|NCT05003518|BEHAVIORAL|ParentText|ParentText delivers content, aligning with children's developmental stages (0-23 months, 2-9 years, 10-17 years). ParentText content is delivered through text messages, images, audio and video for parents/ caregivers and their children. Parents receive parenting content surrounding three themes: 1) relationship building by spending time together, 2) positive reinforcement, 3) stress reduction for parents and caregivers. Further supportive content is available for parents of children living with disabilities, child development, online child safety, talking about COVID-19 with children, family budgeting, family harmony, helping with schoolwork and sexual violence prevention.
219286443|NCT02878226|PROCEDURE|repair of rupture|
219286444|NCT05907525|DRUG|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
219286445|NCT05907525|DRUG|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
219286446|NCT04595851|OTHER|Patient Reported Outcome Measure (PROM)|Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
219286447|NCT04595851|OTHER|Comprehensive Medication Review (CMR)|Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
219286448|NCT04595851|OTHER|Communications between oncology and primary care pharmacists|Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
219286449|NCT05064527|DEVICE|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
219286450|NCT05064527|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
219286451|NCT05064527|BEHAVIORAL|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
219286452|NCT02566044|OTHER|Placebo|Placebo
219286453|NCT02566044|DRUG|QBW276|0.3 mg and 1.5 mg strengths
219286454|NCT03156881|OTHER|Global Osteopathic Treatment|"The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance."
219286455|NCT06114316|BEHAVIORAL|individualized nursing interventions based on the Roy Adaptation Model /experimental|"The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
219286456|NCT01355861|BEHAVIORAL|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
219286457|NCT01364792|DRUG|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
219286458|NCT01077427|DEVICE|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3\* and 16, 17\* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3\*, and 16, 17\* of each course~\* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
219286459|NCT01077427|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
219286460|NCT00285662|DRUG|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
219286461|NCT02683772|DEVICE|Astral|Astral ventilator
219286462|NCT02380924|DRUG|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
219286463|NCT02380924|DRUG|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
219286464|NCT00769652|BEHAVIORAL|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
219286465|NCT00769652|BEHAVIORAL|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during \& after treatment."
219286466|NCT04945889|DIAGNOSTIC_TEST|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score \<15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
219286467|NCT04945889|DIAGNOSTIC_TEST|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
219286468|NCT04945889|DIAGNOSTIC_TEST|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
219286469|NCT00414908|DRUG|Pancrelipase delayed release capsule|24,000 unit capsule
219286470|NCT00414908|DRUG|Placebo Comparator|Placebo
219286471|NCT00271726|PROCEDURE|Osteosynthesis with palmar locking plate|
219286472|NCT00271726|PROCEDURE|Osteosynthesis with external fixator|
219286473|NCT00271726|PROCEDURE|Osteosynthesis with Kirschner wires|
219286474|NCT04245059|DEVICE|Multi-channel Transcranial direct current stimulation|A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
219286475|NCT01367925|DEVICE|Stryker Triathlon® CS Tibial Insert|
219286476|NCT01367925|DEVICE|Stryker Triathlon® PS Tibial Insert|
219743132|NCT06689319|BEHAVIORAL|Assessment of Artificial Intelligence Literacy|The Artificial Intelligence Literacy Scale will be used to determine the level of AI literacy.. The scale is a 12-item instrument designed to measure individuals' knowledge and skills in AI awareness, usage, evaluation, and ethical considerations. Items are rated on a Likert scale from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree), with some items reverse-coded (items 2, 5, and 11). The minimum possible score on the scale is 12, and the maximum score is 84; a higher score indicates a higher level of AI literacy. The Turkish version of the scale will be used in this study.
219743133|NCT07011498|OTHER|Dementia choir|Music therapy informed dementia choirs will be delivered once a week. Rehearsals last app. 2 hours, including a social break. Each choir will be led by 1 conductor and 1 accompanist. The choir leaders will have relevant professional qualifications that supplement each other, such as a music therapist, music pedagogue, conductor, singer, singing teacher, or health care professional with additional music competence. They will be trained by the research team to deliver the choirs in a dementia friendly and music therapy informed way. In addition, the choir leaders will receive supervision from the research team throughout the intervention periods. The choirs will involve volunteers to assist during rehearsals and breaks. The volunteers will also receive training on how to support the choir participants in a dementia friendly way.
219743134|NCT06681727|OTHER|Accessible Video Mental Healthcare Triage and Assessment (IP)|Patients aged 18 years and older who were registered at participating primary care centers were eligible to access the IP through a regional healthcare app. IP comprised a brief digital screening followed by a 45-minute video consultation with a mental health professional. Eligible patients could thereafter schedule appointments at cooperating healthcare centers and clinics through the app used for video consultations.
219743135|NCT05612750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
219743136|NCT05612750|BEHAVIORAL|Empowered Relief|A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
219743137|NCT05965479|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
219743138|NCT05520736|BEHAVIORAL|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
219743139|NCT06695715|BEHAVIORAL|Mindfulness Training Program|This mindfulness training program is based on the Mindfulness-Based Stress Reduction (MBSR) model developed by Jon Kabat-Zinn, incorporating elements of self-compassion and acceptance. What sets this program apart is its integration of both formal and informal practices. Participants engage in 45-minute guided sessions focused on breath awareness and the observation of thoughts, emotions, and physical sensations. Additionally, informal practices include brief daily moments of present-moment awareness. Participants will also receive 10 audio recordings for at-home practice, enhancing the program's accessibility and supporting consistency.
219286477|NCT03679715|OTHER|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops."
219286478|NCT00204321|DRUG|sirolimus (drug), mmf (drug)|
219286479|NCT02069652|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling
219286480|NCT00080353|DRUG|IL-2|
219286481|NCT00080353|DRUG|gp100:209-217|
219286482|NCT00080353|DRUG|OKT3|
219286483|NCT00080353|DRUG|rF-go 100P209|
219286484|NCT00080353|DRUG|Montanide ISA 51|
219286485|NCT01076153|DRUG|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
219286486|NCT05691803|BEHAVIORAL|Exercise intervention|"The 6 month intervention consists of usual care (PaP) plus an initial 12 weeks of instructor led exercise (described below) followed by a 12 week period in where the participant will have to conduct their physical activity on their own.~Exercise intervention:~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks in where a physiotherapist contact the participant and discuss how they will adhere to their Physical activity on prescription."
219286487|NCT04601675|DRUG|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
219286488|NCT04601675|DRUG|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
219286489|NCT06010277|DRUG|Folinic acid|Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
219286490|NCT03780218|OTHER|Respiratory function|Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
219286491|NCT04069481|OTHER|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
219286492|NCT04069481|OTHER|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
219286493|NCT06272552|OTHER|PROMs and PREMs|"Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient\&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
219286494|NCT06272552|OTHER|PREMs|"Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
219286495|NCT06272552|OTHER|Control|At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
219286496|NCT06272552|OTHER|Healthcare professionals|Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
219286497|NCT02808078|DEVICE|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
219286498|NCT02808078|DEVICE|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
219286499|NCT02823990|BIOLOGICAL|TG4010|Given SC
219286500|NCT02823990|BIOLOGICAL|Nivolumab|Given IV
219286501|NCT04633525|PROCEDURE|Optimum Cup Orientation|Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
219286502|NCT02201615|OTHER|Perineal massage in childbirth|
219286503|NCT05138354|OTHER|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
219286504|NCT05138354|OTHER|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
219286505|NCT05138354|OTHER|Standard care|"1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles."
219286506|NCT04411693|DRUG|Dexamethasone implant|A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.
219286507|NCT04411693|DRUG|Aflibercept|A single dose, 2mg, drug administered by intravitreal injection.
219286508|NCT00039390|DRUG|capecitabine|Given orally (PO)
219286509|NCT00039390|DRUG|gefitinib|Given PO
219286510|NCT00039390|OTHER|pharmacological study|Correlative studies
219286511|NCT00039390|OTHER|laboratory biomarker analysis|Correlative studies
219286512|NCT00818168|BIOLOGICAL|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
219286513|NCT01015040|DRUG|solifenacin succinate suspension|Oral
219286514|NCT01015040|DRUG|solifenacin succinate tablet|Oral
219286515|NCT00399191|DRUG|stable isotope of iron, dysprosium|
219286516|NCT00846729|PROCEDURE|CT angiogram of the remaining kidney.|
219286517|NCT00846729|PROCEDURE|Kidney Function study using Iothalamate & PAH as clearance markers|
219286518|NCT06415539|OTHER|classical physical therapy program|Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.
219286519|NCT06415539|OTHER|exercises|Children in this group will be given vestibular and proprioceptive exercise training in addition to the classical physiotherapy program. Skateboard, swing, hammock, bowl, ball, sensory pads, ball pool, slide, climbing bar, trampoline and balance board will be used as materials in vestibular and proprioceptive exercise training. In addition, at the end of the training sessions, parents will be informed about the application of exercise training to daily activities.
219286520|NCT00173992|BEHAVIORAL|Balance and Exercise|
219286521|NCT05586477|DRUG|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
219286522|NCT05586477|DRUG|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
219286523|NCT04476251|BIOLOGICAL|E7 T-Cell Receptor (TCR)|Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).
219286524|NCT02334982|DRUG|TAK-137|TAK-137 tablets
219286525|NCT02334982|DRUG|Placebo|TAK-137 placebo-matching tablets
219286526|NCT00480402|DRUG|200 mg of Progesterone|Administration of 200 mg of Progesterone
219286527|NCT00480402|DRUG|400 mg Progesterone|Administration of 400 mg Progesterone
219286528|NCT00480402|DRUG|Placebo|Administration of a Placebo
219286529|NCT00921687|BEHAVIORAL|Education only|The education will consist of a lecture and distribution of a CKD reference card.
219286530|NCT00921687|BEHAVIORAL|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
219286531|NCT01133795|DRUG|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
219286532|NCT00316602|BIOLOGICAL|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
219286533|NCT01681901|PROCEDURE|ultrasound imaging|Undergo ultrasound
219286534|NCT02710318|BEHAVIORAL|Electronic immunization alert|Immunization alert in the electronic health record
219286535|NCT04807673|BIOLOGICAL|Pembrolizumab|"Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.~Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery."
219286536|NCT04807673|DRUG|Paclitaxel|Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
219286537|NCT04807673|DRUG|Cisplatin|Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
219286538|NCT04807673|RADIATION|neoadjuvant chemoradiotherapy|neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week
219286539|NCT01663922|DRUG|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
219286540|NCT01663922|DRUG|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
219286541|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
219286542|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
219286543|NCT05350280|DEVICE|electric current|Electric current will be applied in this group of patients using removable device.
219286544|NCT05350280|DEVICE|Traditional treatment|No acceleration method will be performed in this group.
219286545|NCT05983380|OTHER|Hand Mobility and Grip Strengthening Exercises|Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
219286546|NCT05983380|OTHER|Usual Care|Manual lymphatic drainage, compression, exercise, skin hygiene.
219286547|NCT00626990|DRUG|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
219286548|NCT00626990|GENETIC|DNA methylation analysis|O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
219286549|NCT00626990|OTHER|laboratory biomarker analysis|Prognostic factor analyses
219286550|NCT00626990|PROCEDURE|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
219286551|NCT00626990|PROCEDURE|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
219286552|NCT00626990|RADIATION|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
219286553|NCT01507987|DEVICE|Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads|"Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies"
219286554|NCT02270541|OTHER|Telemedicine|In-ambulance telemedicine
219286555|NCT04357054|DIAGNOSTIC_TEST|Darwish test|Infertile women planned for combined laparoscopy and hysteroscopy as an integral part of infertility wok-up.
219286556|NCT00484081|PROCEDURE|Microdissection Testicular Sperm Extraction|
219286557|NCT00484081|PROCEDURE|ICSI|
219286558|NCT00219700|DRUG|Ibuprofen-PC|
219286559|NCT01534143|OTHER|pharmacological study|Correlative studies
219286560|NCT01534143|DRUG|tacrolimus|Given IV
219286561|NCT01534143|DRUG|sirolimus|Given PO
219286562|NCT01534143|BIOLOGICAL|anti-thymocyte globulin|Given IV
219286563|NCT01534143|DRUG|fludarabine phosphate|Given IV
219286564|NCT01534143|DRUG|busulfan|Given IV
219286565|NCT01534143|DRUG|bortezomib|Given IV
219286566|NCT01534143|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
219286567|NCT01534143|OTHER|laboratory biomarker analysis|Correlative studies
219286568|NCT04449328|DEVICE|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
219286569|NCT04449328|DEVICE|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
219286570|NCT01008410|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
219286571|NCT01008410|DRUG|Placebo|Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
219286572|NCT01477164|BEHAVIORAL|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at \~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
219286573|NCT01477164|BEHAVIORAL|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
219286574|NCT01477164|BEHAVIORAL|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
219286575|NCT01249716|DIETARY_SUPPLEMENT|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
219286576|NCT01129544|BIOLOGICAL|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
219286577|NCT02154464|DRUG|Paracetamol|
219286578|NCT02154464|DRUG|Placebo|
219286579|NCT01151852|DRUG|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
219286580|NCT01151852|DRUG|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
219286581|NCT01069653|BIOLOGICAL|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
219286582|NCT00297427|PROCEDURE|Acupuncture|Acupuncture twice weekly for 6 weeks.
219286583|NCT00297427|OTHER|Sham acupuncture|Twice a week for 6 weeks
219286584|NCT02022787|OTHER|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
219286585|NCT02807935|DEVICE|Optical coherence tomography imaging|
219286586|NCT03056300|DEVICE|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
219286587|NCT00847925|DRUG|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
219286588|NCT02888210|DEVICE|MD-15 Intraocular Lens|
219286589|NCT05042908|DRUG|LBL-003 Injection|LBL-003 was given every two weeks for treatment
219286590|NCT05440916|RADIATION|Palliative Radiotherapy: 5 x 4Gy|Palliative irradiation of 2 to 5 sites (metastatic sites or/and primary lung tumour) in one week before systemic therapy. Systemic therapy should be given as soon as possible after irradiation.
219286591|NCT05440916|DRUG|chemotherapy + immune checkpoint inhibitors|Systemic therapy according to national/European recommendations.
219286592|NCT04973501|BEHAVIORAL|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
219286593|NCT04973501|BEHAVIORAL|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
219286594|NCT01227837|DIETARY_SUPPLEMENT|placebo|placebo given to patients
219286595|NCT01227837|DIETARY_SUPPLEMENT|omga3|use of omega 3
219286596|NCT02048475|OTHER|desflurane|changing concentration
219286597|NCT03248882|DRUG|Placebo|Placebo
219286598|NCT03248882|DRUG|PF-05221304|PF-05221304, Experimental Drug
219286599|NCT01656200|BIOLOGICAL|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
219286600|NCT03546400|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
219286601|NCT01457482|OTHER|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
219286602|NCT01457482|OTHER|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
219286603|NCT03625180|BIOLOGICAL|NAMIC: nanofractured autologous matrix-induced chondrogenesis|the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
219286604|NCT01449500|DIETARY_SUPPLEMENT|L. reuteri|Chewable tablet, one tablet/day for 28 days
219286605|NCT01449500|DIETARY_SUPPLEMENT|Placebo|Chewable tablet, one tablet per day for 28 days
219286606|NCT00269438|DRUG|5 ASA, enemas, suppositories, corticosteroids|
219286607|NCT00735631|DEVICE|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
219286608|NCT03570489|BEHAVIORAL|Exercise|Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
219286609|NCT03570489|BEHAVIORAL|Relaxation|Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
219286610|NCT02557529|BEHAVIORAL|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
219286611|NCT02557529|BEHAVIORAL|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
219286612|NCT02557529|BEHAVIORAL|Diet diary|Weekly diet diary during the 12-weeks intervention
219286613|NCT03813277|DRUG|Dexmedetomidine|infusion
219286614|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for reducing risk behaviors|Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD \& SZ it is alcohol use.
219286615|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for increasing non-risk behaviors|Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.
219286616|NCT01917721|DRUG|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
219286617|NCT01917721|DRUG|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
219286618|NCT04887779|BEHAVIORAL|Pathologist intervention|viewing explanted organ and microscopy
219286619|NCT02734576|DEVICE|Venous Sinus Stenting with the Precise Pro Stent|Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
219286620|NCT02067559|BEHAVIORAL|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
219286621|NCT02067559|BEHAVIORAL|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
219286622|NCT00626626|DRUG|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
219286623|NCT00626626|DRUG|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
219286624|NCT01652495|DRUG|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
219286625|NCT01652495|DRUG|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
219286626|NCT04235829|PROCEDURE|Laparoscopic sleeve gastrectomy|Form of obesity surgery
219286627|NCT02625688|OTHER|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
219286628|NCT02625688|OTHER|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
219286629|NCT02625688|OTHER|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
219286630|NCT02553967|DEVICE|Functional MRI|Functional MRI
219286631|NCT01382368|DRUG|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
219286632|NCT06518031|OTHER|meditation|meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
219286633|NCT05358041|DEVICE|Robotic Bronchoscopy|Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
219286634|NCT01156376|DEVICE|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
219286635|NCT01156376|DEVICE|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
219286636|NCT01156376|DEVICE|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
219286637|NCT00512655|BEHAVIORAL|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
219286638|NCT05293977|BEHAVIORAL|Routine care by the dispensing pharmacist|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
219286639|NCT05293977|BEHAVIORAL|Pharmaceutical education/counseling about prescribed antibiotic|Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
219286640|NCT03858829|OTHER|Psychometric analysis|Psychometric analysis
219286641|NCT05435482|BEHAVIORAL|Education|Participants will receive two small group meetings and two follow-up calls
219286642|NCT05435482|OTHER|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
219286643|NCT05435482|OTHER|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
219286644|NCT02410460|DRUG|clonidine|
219286645|NCT02410460|DRUG|glycopyrrolate|
219286646|NCT02410460|DRUG|propofol|
219286647|NCT02410460|DRUG|ketamine|
219286648|NCT02410460|DRUG|marcaine|
219286649|NCT02410460|DRUG|scopolamine|
219286650|NCT02410460|DRUG|midazolam|
219286651|NCT02410460|DEVICE|ondansetron|
219286652|NCT02410460|DRUG|metoclopramide|
219286653|NCT02410460|DRUG|glycopyrrolate|
219286654|NCT02410460|DRUG|lidocaine|
219286655|NCT02410460|DRUG|famotidine|
219286656|NCT02410460|DRUG|desflurane|
219286657|NCT02410460|DRUG|sevoflurane|
219286658|NCT05511064|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701
219286659|NCT06396351|PROCEDURE|Laparoscopic surgery|effect of carbondioxide insufflation on abdominal compliance was evaluated
219286660|NCT04871880|BEHAVIORAL|Dietitian led life style modification intervention|All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.
219286661|NCT04871880|BEHAVIORAL|Conventional care (control)|Receive routine care
219286662|NCT00591539|PROCEDURE|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
219286663|NCT03838120|OTHER|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
219286664|NCT06130670|OTHER|nerve block|Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.
219286665|NCT03217695|BEHAVIORAL|Mindfulness-based Yoga Arm|
219286666|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
219286667|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
219286668|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
219286669|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
219286670|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.004%|
219286671|NCT01298687|DRUG|Travoprost Vehicle|Inactive ingredients used as an active comparator
219286672|NCT05565495|DRUG|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
219286673|NCT03174431|DEVICE|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
219286674|NCT03174431|DEVICE|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
219286675|NCT00181870|DRUG|carbamazepine ER (Equetro)|
219286676|NCT04746885|DIETARY_SUPPLEMENT|DHA|Oral supplement
219286677|NCT06629740|DEVICE|Measurements with a eHealth system|The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
219286678|NCT05000840|BEHAVIORAL|Enrollment in existing SDRI diabetes education programs|Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
219286679|NCT03264911|DRUG|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
219286680|NCT00573638|DEVICE|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
219286681|NCT00776217|DRUG|loratadine 10 mg orally disintegrating tablets|
219286682|NCT02137889|DRUG|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
219286683|NCT02075073|BIOLOGICAL|SB3|
219286684|NCT02075073|BIOLOGICAL|EU sourced Herceptin®|
219286685|NCT02075073|BIOLOGICAL|US sourced Herceptin®|
219286686|NCT01708304|BEHAVIORAL|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
219286687|NCT04473898|OTHER|Aerobic Exercise Training|Aerobic exercises using all body muscles and that one can do on their own after being shown online
219286688|NCT04473898|BEHAVIORAL|Patient Education|Patient education about covid-19 and hygiene education
219286689|NCT04473898|OTHER|Respiratory Exercise Training|Respiratory exercises that one can do on their own after being shown online
219286690|NCT04253873|DRUG|Apatinib|Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
219286691|NCT05731999|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
219286692|NCT02592993|DEVICE|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
219286693|NCT06349356|DEVICE|Intense pulsed light with C.STIM device|4 flashes per treatment session
219286694|NCT05527262|BEHAVIORAL|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
219286695|NCT05527262|DEVICE|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
219286696|NCT00211302|DRUG|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
219296450|NCT06611878|BEHAVIORAL|Music training - intensive|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered twice a week for 5 months.
219286697|NCT05431374|OTHER|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (10-40mg/day) or open-label mirtazapine (7.5-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
219286698|NCT05431374|OTHER|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
219286699|NCT02797080|DRUG|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
219286700|NCT00768170|DRUG|MK0633|MK0633 (50 mg) Oral, single dose
219286701|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
219286702|NCT06225440|DIETARY_SUPPLEMENT|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
219286703|NCT06225440|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
219286704|NCT02443831|PROCEDURE|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19+CD22 CAR T-cells
219286705|NCT02443831|RADIATION|Total Body Irradiation (TBI)|Participants will receive total body irradiation delivered as a single fraction (2Gy) on day -7 prior to CD19+CD22CAR T-cell infusion.
219286706|NCT02443831|DRUG|Lymphodepletion with Fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -6 to -3 prior to CD19+CD22CAR T-cell infusion.
219286707|NCT02443831|DRUG|Lymphodepletion with Cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -6 to -5 prior to CD19+CD22CAR T-cell infusion.
219286708|NCT02443831|BIOLOGICAL|CD19+CD22 CAR T-cells|Dose level 1: 2 doses of 4 x 10\^5 CD19+CD22 CAR T-cells/kg Dose level 2: 2 doses of 1 x 10\^6 CD19+CD22 CAR T-cells/kg given as a split dose as an intravenous injection through a Hickman line or PICC line (peripherally inserted central catheter) on day 0 and day 14.
219286709|NCT02638597|DRUG|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
219286710|NCT02638597|BEHAVIORAL|smoking cessation counseling|smoking cessation counseling
219286711|NCT00448942|BEHAVIORAL|Daily bathing with Chlorhexidine based product|
219286712|NCT00493740|PROCEDURE|chocolate cake|
219286713|NCT00951015|DRUG|GSK1349572|investigational HIV-1 integrase inhibitor
219286714|NCT00951015|DRUG|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
219286715|NCT04408352|DEVICE|selective bladder denervation using RF energy|RF ablation of the trigone for the treatment of UUI
219286716|NCT02180750|OTHER|Memory Work Therapy|
219286717|NCT02180750|OTHER|Standard care|Pediatric clinic, ART
219286718|NCT02635893|DRUG|D-Cycloserine|100 mg of Seromycin by mouth will be administered
219286719|NCT02635893|DRUG|Placebo|placebo pill will be administered instead of medication by mouth
219286720|NCT02635893|OTHER|Training|walking around a designated track at different speeds both forward and backward
219286721|NCT02635893|OTHER|Stimulation|magnetic stimulation and electrical stimulation may be applied
219286722|NCT02635893|OTHER|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
219286723|NCT01167452|DRUG|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
219286724|NCT00081575|DRUG|Tigecycline|
219286725|NCT00081575|DRUG|Levofloxacin|
219286726|NCT02398669|DRUG|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
219286727|NCT06541496|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle regions.
219286728|NCT03819634|DEVICE|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
219286729|NCT01208103|BIOLOGICAL|Bevacizumab|Given IV
219286730|NCT01208103|DRUG|Capecitabine|Given PO
219286731|NCT01208103|DRUG|Oxaliplatin|Given CVC
219286732|NCT01766115|DRUG|Telaprevir|HCV Protease Inhibitor
219286733|NCT03315013|PROCEDURE|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
219286734|NCT00305838|DRUG|tamoxifen citrate|
219286735|NCT00305838|OTHER|diagnostic laboratory biomarker analysis|
219286736|NCT01804868|OTHER|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
219286737|NCT01804868|OTHER|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
219286738|NCT00368342|DRUG|Erythromycin, Azithromycin , Clarithromycin|
219286739|NCT05440253|DEVICE|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
219286740|NCT05440253|PROCEDURE|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
219286741|NCT03128281|BEHAVIORAL|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
219286742|NCT03128281|DEVICE|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
219286743|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
219286744|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
219286745|NCT00771992|PROCEDURE|Bronchoscopy|Bronchoscopy with segmental allergen challenge
219286746|NCT04601025|DIETARY_SUPPLEMENT|Yoghurt|200 ml plain full-fat yoghurt
219286747|NCT04601025|DIETARY_SUPPLEMENT|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
219286748|NCT04601025|DIETARY_SUPPLEMENT|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
219286749|NCT00867984|OTHER|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
219286750|NCT00867984|OTHER|Usual Care|AV optimization (VTI) only
219286751|NCT04441177|DEVICE|PlayStation®VR training|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
219286752|NCT05905107|OTHER|Neurodynamic Slider Technique from Proximal to Distal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
219286753|NCT05905107|OTHER|Neurodynamic Slider Technique from Distal to Proximal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
219286754|NCT04016012|DIETARY_SUPPLEMENT|Local Zambian Foods|Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
219286755|NCT02299947|DRUG|Haemocomplettan P|
219286756|NCT02299947|DRUG|Placebo|
219286757|NCT03787342|PROCEDURE|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
219286758|NCT03787342|PROCEDURE|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
219286759|NCT03787342|PROCEDURE|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
219286760|NCT03787342|PROCEDURE|Periosteal releasing incision|
219286761|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
219286762|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
219286763|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
219286764|NCT00299494|DRUG|Rituximab|rituximab 375 mg/m\^2 via IV infusion on Day 1
219286765|NCT05109767|DEVICE|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
219286766|NCT05109767|DEVICE|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
219286767|NCT02121964|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
219286768|NCT02121964|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
219286769|NCT02489240|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
219286770|NCT02489240|DRUG|placebo|2000 IU placebo tablets were taken daily for 6 days
219286771|NCT02604082|OTHER|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
219286772|NCT02604082|OTHER|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
219286773|NCT02604082|OTHER|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
219286774|NCT02283476|DRUG|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
219286775|NCT02283476|DRUG|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
219286776|NCT02283476|DRUG|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
219286777|NCT02283476|DRUG|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
219286778|NCT04149431|DRUG|Derinat|desoxyribonucleate sodium
219286779|NCT02713477|DRUG|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219286780|NCT02713477|DRUG|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219286781|NCT02713477|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219286782|NCT04477395|DIETARY_SUPPLEMENT|fish oil|SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.
219286783|NCT04477395|PROCEDURE|SRP only|Scaling and root planing will be the only method of treatment.
219286784|NCT00227942|DRUG|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
219286785|NCT00227942|DRUG|Zolpidem|10 mg/day, po qhs
219286786|NCT00227942|DRUG|placebo|placebo
219286787|NCT00909831|DRUG|hydroxychloroquine|
219286788|NCT00909831|DRUG|temsirolimus|
219286789|NCT00909831|OTHER|electron microscopy|
219286790|NCT00909831|OTHER|high performance liquid chromatography|
219286791|NCT00909831|OTHER|immunologic technique|
219286792|NCT00909831|OTHER|laboratory biomarker analysis|
219286793|NCT00909831|OTHER|mass spectrometry|
219286794|NCT00909831|OTHER|pharmacological study|
219286795|NCT00909831|PROCEDURE|autophagy inhibition therapy|
219286796|NCT02760095|DRUG|3 mg zinc sulfate supplement|
219286797|NCT02760095|DRUG|0.5 mg of 13C10-retinyl-acetate|
219286798|NCT01589159|DRUG|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
219286799|NCT01589159|DRUG|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
219286800|NCT01075295|BEHAVIORAL|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:~* STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~* STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake \& physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~* STEP 3 (Nutrition \& Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~* STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
219286801|NCT01075295|OTHER|TAU|Treatment as provided by individuals' existing healthcare providers
219286802|NCT03101462|BIOLOGICAL|Inactivated Influenza Vaccine|
219286803|NCT03101462|BIOLOGICAL|Live Attenuated Influenza Vaccine|
219286804|NCT03711292|BEHAVIORAL|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
219286805|NCT02799394|OTHER|Activity modification, exercises and gradual return to sport|
219286806|NCT05963477|PROCEDURE|laparatomy|all abdominal procedures which are approached by different incisions
219286807|NCT03921099|DRUG|Ascorbic Acid|ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
219286808|NCT01055847|DRUG|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
219286809|NCT01055847|DRUG|Placebo|Saline Placebo
219286810|NCT00513877|DRUG|bortezomib|
219286811|NCT00513877|PROCEDURE|quality-of-life assessment|
219286812|NCT05385380|BEHAVIORAL|Safe motherhood Promotion|Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
219286813|NCT00077831|BEHAVIORAL|neurobehavioral development|observational study of infant and child development
219286814|NCT01745575|DRUG|Alprazolam 2mg tablets|Reference product
219286815|NCT01745575|DRUG|Alprazolam 2 mg tablets|Test product
219286816|NCT02341742|DEVICE|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
219286817|NCT00031070|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
219286818|NCT00031070|DRUG|Cyclosporine|
219286819|NCT00031070|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
219286820|NCT00031070|DRUG|Efavirenz|
219286821|NCT00031070|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
219286822|NCT00031070|BIOLOGICAL|Rabies Vaccine|
219286823|NCT02297490|DRUG|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
219286824|NCT02297490|BIOLOGICAL|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
219286825|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 3 hour.
219286826|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 3 hour.
219286827|NCT06191055|OTHER|Control group|4 intakes of 2.5 g of wheat semolina every 3 hour.
219286828|NCT03271853|DEVICE|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
219286829|NCT03719417|PROCEDURE|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
219286830|NCT03719417|PROCEDURE|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
219286831|NCT05287490|DEVICE|FormaV and VTone|Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
219286832|NCT05114486|COMBINATION_PRODUCT|Pilocarpine Ophthalmic administered with the Optejet dispenser|Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
219286833|NCT05114486|COMBINATION_PRODUCT|Placebo administered with the Optejet dispenser|Vehicle ophthalmic solution administered with the Optejet dispenser
219286834|NCT05297006|DIETARY_SUPPLEMENT|The infants who drank milk powder were given a dietary intervention four months before|The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
219286835|NCT01696955|BIOLOGICAL|Cetuximab|Given IV
219286836|NCT01696955|OTHER|Laboratory Biomarker Analysis|Correlative studies
219286837|NCT01696955|DRUG|Tivantinib|Given PO
219286838|NCT04860362|BEHAVIORAL|PEERS|Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
219286839|NCT01681121|DRUG|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
219286840|NCT01681121|DRUG|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
219286841|NCT03417570|PROCEDURE|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
219286842|NCT03417570|DEVICE|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
219286843|NCT05133349|DRUG|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
219286844|NCT00573859|DRUG|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
219286845|NCT00573859|DRUG|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
219286846|NCT00484484|DRUG|Ketamine|Ketamine
219286847|NCT04398823|DRUG|Sclerosing foam of Lauromacrogol|Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
219286848|NCT04398823|DRUG|Sclersing liqiud of Lauromacrogol|Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
219286849|NCT00144495|DRUG|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
219286850|NCT00144495|DRUG|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
219286851|NCT04488523|BEHAVIORAL|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
219286852|NCT01148329|DEVICE|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
219286853|NCT03454126|DRUG|BIIB095|Administered as specified in the treatment arm.
219286854|NCT03454126|DRUG|Placebo|Administered as specified in the treatment arm.
219286855|NCT03541200|DRUG|MT-8554|MT-8554 Oral
219286856|NCT04215445|DRUG|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
219286857|NCT04215445|DEVICE|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
219286858|NCT03377478|DRUG|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
219286859|NCT04374214|PROCEDURE|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
219286860|NCT04374214|PROCEDURE|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
219286861|NCT00208325|DEVICE|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
219286862|NCT00208325|DEVICE|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
219286863|NCT04258683|DRUG|Pembrolizumab|Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
219286864|NCT02574962|DRUG|H.P. Acthar® Gel|
219286865|NCT02623751|DRUG|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
219286866|NCT02623751|DRUG|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
219286867|NCT01913262|BEHAVIORAL|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
219286868|NCT03877861|DEVICE|Readiband Sleep Tracking|Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
219286869|NCT04606498|OTHER|Observational|Observational study only - no intervention
219286870|NCT00249964|DRUG|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."
219286871|NCT00249964|DRUG|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."
219286872|NCT00249964|DRUG|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."
219286873|NCT00249964|DRUG|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."
219286874|NCT04332159|PROCEDURE|Closed nasal fracture reduction|Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
219286875|NCT04562740|DEVICE|ABLUMINUS DES drug eluting stent|Following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
219286876|NCT04052295|PROCEDURE|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
219286877|NCT03617900|DRUG|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
219286878|NCT03617900|DRUG|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
219286879|NCT03617900|DRUG|Paracetamol|500 mg paracetamol. use in need
219286880|NCT04351035|PROCEDURE|Tumour resection|It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.
219286881|NCT02879526|DRUG|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
219286882|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
219286883|NCT01728311|DRUG|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
219286884|NCT02005042|BEHAVIORAL|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
219286885|NCT03582787|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
219286886|NCT03582787|DEVICE|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
219286887|NCT02865239|PROCEDURE|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
219286888|NCT00055588|PROCEDURE|Locomotor training|
219286889|NCT03613025|DIAGNOSTIC_TEST|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
219286890|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
219286891|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
219286892|NCT00330148|DRUG|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
219286893|NCT02302170|BIOLOGICAL|H. pylori vaccine|
219286894|NCT02302170|BIOLOGICAL|placebo|
219286895|NCT04890548|DRUG|AZD3427|Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
219286896|NCT05812742|BEHAVIORAL|Early intervention programme|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
219286897|NCT05812742|BEHAVIORAL|Enhanced usual care|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
219286898|NCT02001064|BEHAVIORAL|Care4Today v2.0 mobile application + electronic monitoring of adherence|Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
219286899|NCT03892252|OTHER|No intervention|No intervention
219286900|NCT00409721|DRUG|Memantine|
219286901|NCT05624905|PROCEDURE|Percutaneous coronary intervention|Percutaneous Coronary Intervention Procedure
219286902|NCT04936477|OTHER|Calculation of ventilation-perfusion ratio|"Three to five paired measurements of fraction of inspired oxygen and peripheral oxygen saturations.~Insertion of mainstream capnograph with combined pressure and flow sensor to perform end-tidal capnography measurement.~Echocardiogram to assess intra-cardiac shunting."
219286903|NCT05034159|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Same as is described previously.
219286904|NCT00644163|BEHAVIORAL|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
219286905|NCT00644163|BEHAVIORAL|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
219286906|NCT00565487|DRUG|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
219286907|NCT04321421|OTHER|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
219286908|NCT02944201|DRUG|Carvedilol|Carvedilol will give twice daily until prostatectomy
219286909|NCT04866953|OTHER|Blood transfusion|Number of units of blood received within 24 hours of admission
219286910|NCT02893787|OTHER|Speckle Tracking Echocardiography|Echocardiography analyses
219286911|NCT00311987|DRUG|3,5-Diiodothyropropionic acid (DITPA) therapy|
219286912|NCT04061460|PROCEDURE|mechanical plaque control|supra and sub gingival debridment ( plaque control)
219286913|NCT01941147|DEVICE|pulsed ELF-MF|(75 Hz, 1,8 mT)
219286914|NCT03568643|DRUG|Azithromycin|Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
219286915|NCT03568643|DRUG|Amoxicillin|Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
219286916|NCT00701649|BIOLOGICAL|CYT006-AngQb|s.c.
219286917|NCT00701649|BIOLOGICAL|Placebo|s.c.
219286918|NCT04684017|DRUG|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
219286919|NCT04684017|DRUG|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
219286920|NCT04684017|DRUG|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
219286921|NCT01368029|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
219286922|NCT01368029|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
219286923|NCT05249738|DIAGNOSTIC_TEST|Measuring tongue cross-sectional area by submental ultrasonography|The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
219286924|NCT01741103|DRUG|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
219286925|NCT01741103|DRUG|Placebo|Take one by mouth daily for 12 weeks
219286926|NCT05293665|BIOLOGICAL|UB-612|UB-612 (100µg), 0.5mL suspension, intramuscular injection
219286927|NCT05293665|BIOLOGICAL|BNT162b2 vaccine|BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
219286928|NCT05293665|BIOLOGICAL|ChAdOx1-S vaccine|ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
219286929|NCT05293665|BIOLOGICAL|Sinopharm BIBP|Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
219286930|NCT01500811|BIOLOGICAL|cell injection|Intra articular injection of chondrocyte
219286931|NCT01060839|BEHAVIORAL|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
219286932|NCT03018522|OTHER|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
219286933|NCT04969068|DRUG|Remimazolam|Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
219286934|NCT05697263|OTHER|Periodization of training|Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
219286935|NCT00152984|DRUG|Tiotropium inhalation capsules|
219286936|NCT00152984|DRUG|Placebo inhalation capsules|
219286937|NCT04204252|DRUG|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
219286938|NCT04204252|DRUG|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
219286939|NCT05095207|DRUG|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
219286940|NCT05095207|DRUG|Bicalutamide|150 mg orally daily, day 1 to 28.
219286941|NCT02108964|DRUG|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
219286942|NCT05020535|DRUG|MW189|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
219286943|NCT05020535|OTHER|Saline|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
219286944|NCT06073002|OTHER|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
219286945|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
219286946|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
219286947|NCT04712591|DIAGNOSTIC_TEST|Auditory stimuli|Auditory stimuli (passive, active perturbations)
219286948|NCT06963658|OTHER|Multiple repetition isometric wall squat|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold.
219286949|NCT06963658|OTHER|Multiple Isometric wall squat exercise + Double Leg Lower with Isometric Hold|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold. Immediately post 60 second rest, Determine the participant's maximum angle using the double leg lowering test from supine position let the participant with both legs straightened before lifting the posterior hip, lowering the legs to a specific angle. Turn on the stopwatch. Hold the position near--maximally, try to achieve on (IES=9/10) and hold for the longest duration. They should reach 4 minutes for 3 repetition with 30 seconds rest between repetition
219286950|NCT06963658|OTHER|Control quiet seated rest|The control group served as the control group and did not perform any exercise. Participants were instructed to sit quietly in a standard height stationary clinical room patient chair for the entire eight minutes.
219286951|NCT06418295|OTHER|Unilateral thoracotomy|Unilateral thoracotomy to proceed as per standard of care guidelines. Thoracic epidural analgesia, or patient controlled analgesia (PCA) pumps will be offered to each study participant as per standard of care. Pre- and post-operative (post-operative day 1 and 3 months) pain scores and blood samples will be collected. Blood samples will be analyzed to determine the concentration of cytokines, chemokines, and growth factors that are potentially associated with CPSP (epidermal growth factor, eotaxin, fibroblast growth factor basic, G-CSF, GM-CSF, human growth factor, IFN-α, IFN-γ, IL-1ra, IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF). DNA promotor methylation for these targets will also be investigated.
219286952|NCT01602029|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
219286953|NCT01602029|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
219286954|NCT01602029|DRUG|Placebo|Placebo added to TAU
219286955|NCT01602029|DRUG|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
219286956|NCT04836169|DEVICE|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
219286957|NCT00131105|BEHAVIORAL|The Stanford Active Choices program|
219286958|NCT06415097|DEVICE|Insulin Smart Pen|Retrospective analysis of electronic health records for individuals with type 1 diabetes receiving multiple daily doses of insulin, combined with glucose monitoring devices and who have used or are currently using insulin smart pens.
219286959|NCT01622062|BIOLOGICAL|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
219286960|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
219286961|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
219286962|NCT06266208|PROCEDURE|Exostectomy|Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.
219286963|NCT06266208|PROCEDURE|Cut fingernail|Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
219286964|NCT03322839|BEHAVIORAL|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
219286965|NCT03322839|BEHAVIORAL|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
219286966|NCT03297502|DRUG|pimecrolimus cream 1%|
219286967|NCT03297502|DRUG|Elidel (pimecrolimus) cream 1%|
219286968|NCT03297502|DRUG|placebo|
219286969|NCT01214642|DRUG|pegfilgrastim|Administered subcutaneously
219286970|NCT01214642|DRUG|LY2523355|Administered intravenously
219286971|NCT03255005|DEVICE|Endomina|Endoscopic sleeve reduction
219286972|NCT03255005|BEHAVIORAL|Diet|Multidisciplinary follow-up
219286973|NCT03095469|DRUG|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
219286974|NCT03095469|DRUG|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
219286975|NCT02868606|OTHER|Physiologic Insulin Therapy|
219286976|NCT02868606|OTHER|Sliding-Scale Insulin Therapy|
219286977|NCT06341140|OTHER|Breastfeeding support and Booklet containing information about breastfeeding|Pregnant women in the intervention group were given individual counseling with a wearable breastfeeding model. During postnatal home visits, mothers were given support on breastfeeding, breast problems were addressed, and information was given to support the mother's self-efficacy.
219286978|NCT06341140|OTHER|Booklet containing information about breastfeeding|Pregnant women in the control group were given only a breastfeeding booklet, breastfeeding status, breast problems and breastfeeding self-efficacy were evaluated during postnatal home visits and telephone interviews, and risky situations were referred to health professionals.
219286979|NCT05891951|OTHER|Fluid therapy under the guide of Carotid ultrasound|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
219286980|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
219296451|NCT06611878|BEHAVIORAL|Music training - minimal|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered once a month for 5 months.
219286981|NCT06595251|OTHER|Fit2Play curriculum|Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
219286982|NCT06605807|OTHER|Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.|All clinicians will attend an educational session where they will be provided a clinical decision framework for management of chronic conditions in hospitalized older adults, reviewing guiding principles for managing chronic disease in the hospital, and working through case-based hypothetical examples.
219286983|NCT06604650|BEHAVIORAL|Active older Adults|The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
219286984|NCT07153952|RADIATION|radiotherapy|The surgical method is determined by the gynecological oncologist, including total hysterectomy, pelvic exenteration, or radical total hysterectomy. The specific surgical choice needs to be comprehensively judged based on the patient's residual tumor location, size, and other complications. Supplementary radiotherapy is mainly image-guided brachytherapy ± external irradiation. The irradiation range and dose must be comprehensively considered based on the location and size of the residual lesions. The best local treatment plan is jointly determined by gynecological oncologists and radiotherapists.
219286985|NCT07153952|DRUG|Systemic treatment|Systemic treatment regimens include chemotherapy ± targeted therapy ± immunotherapy. According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel and cisplatin/paclitaxel. The addition of immunotherapy can be determined based on the PD-L1 expression level. The specific chemotherapy regimen will be determined by the gynecological oncologist based on the residual tumor site, the number of lesions, and other complications. In addition, if the patient's pathological results indicate HER2 positivity or the genetic test results show PIK3CA mutation, targeted therapy, such as neratinib or apelisimab, can be considered as a second-line regimen after the first-line chemotherapy regimen progresses.
219286986|NCT07156136|DRUG|IMC-P115C|IV infusion
219286987|NCT07154147|DRUG|Alprazolam|Participants will take oral alprazolam 0.5 mg 15 to 90 minutes before surgery to promote relaxation and reduce anxiety. An IV placebo (normal saline) will be administered to maintain blinding.
219286988|NCT07154147|DRUG|Midazolam|Participants will receive IV midazolam 1 mg immediately before surgery to promote relaxation and reduce anxiety. An oral placebo pill will be used to maintain blinding.
219286989|NCT07154693|DEVICE|Combination 70% FDBA and 30% DFDBA|A combination freeze-dried bone allograft consisting of 70% mineralized FDBA and 30% demineralized FDBA
219286990|NCT07154693|DEVICE|OsteoGen Plug|A synthetic calcium apatite material combined with Type 1 bovine collagen (in a sponge-like product)
219286991|NCT07153744|DRUG|Aspirin|Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
219743140|NCT06695715|BEHAVIORAL|HRV Biofeedback|This HRV biofeedback training program is distinguished by its combination of advanced technology and a novel at-home methodology. Participants will engage in five weekly sessions, with four conducted at home using a heart rate sensor and the EliteHRV mobile app, which provides real-time feedback on heart rate variability. One session per week will take place in the lab, utilizing the Procomp Infiniti biofeedback system. The at-home approach is based on recent research (Schumann et al., 2021), offering participants a flexible yet structured method to practice biofeedback and improve heart rate variability over the six-week program.
219743141|NCT06695715|BEHAVIORAL|Interoception Training|The interoception training program stands out by its focus on developing internal body awareness through structured guided sessions. Participants will engage in weekly 45-minute formal sessions at the university, where they will learn to focus on internal sensations like breath and muscle tension using specific techniques. Additionally, participants will receive 10 guided interoceptive exercises to practice at home, four times a week. This program not only focuses on the physical sensations but also integrates these practices into daily life, aiming to improve self-care and self-regulation over the six weeks, with personalized feedback provided.
219178149|NCT06453616|BEHAVIORAL|Hello bundle|"Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)"
219743142|NCT06695143|DRUG|Fusidic Acid|Fusidic acid 2% cream
219743143|NCT06695143|OTHER|Vehicle cream|Cetomacrogol cream
219743144|NCT06694207|DRUG|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients
219743145|NCT06694220|OTHER|Tailored preventive exercises|Players in the experimental group will be asked to perform the tailored preventive program 2-3 times per week for 1 hour for at least 6 weeks preseason which includes warming up for 10 mins, flexibility exercises, strengthening exercises, core and lower body stability and balance exercises and drills all these exercises for 1-4 sets x 10-20 reps and cooling down stretches for the last 10 mins.
219286992|NCT07153744|DRUG|Shexiang Baoxin Pill|Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
219286993|NCT07154771|OTHER|First with the arm circumference measurement tool, then with the traditional tape measure|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the newly developed arm circumference measurement device, followed by the traditional tape measure.
219286994|NCT07154771|OTHER|First with the traditional tape measure , then with the arm circumference measurement tool|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the traditional tape measure, and then using the newly developed arm circumference measurement device.
219286995|NCT07154849|DRUG|Hydrocortisone|received 2mg/kg.
219286996|NCT07154849|DRUG|Dexmedetomidine|received 1 µg/kg
219286997|NCT07154030|PROCEDURE|Micro needle injection|"* Disinfection: the affected area by alcohol 70 %.~* Topical anaesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with tretinoin 0.025% of the affected area will be done by dermapen that will be applied on the affected area as follows: inserting the sterilized needle into the dermapen tip, turning on using speed setting and adjusting speed on 5, needle depth of dermapen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with dermapen in a stamping pattern until pin point bleeding appear."
219286998|NCT07154030|PROCEDURE|Micro needle injection only|"* Disinfection: the affected area by alcohol 70 %.~* Topical anesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with timolol 0.5% of the affected area will be done by derma pen that will be applied on the affected area as follows: inserting the sterilized needle into the derma pen tip, turning on using speed setting and adjusting speed on 5, needle depth of derma pen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with derma pen in a stamping pattern until pin point bleeding appear."
219286999|NCT07153666|DRUG|Ruxolitinib 1.5% Cream BID|ruxolitinib twice per day
219287000|NCT07154108|BIOLOGICAL|recombinant human endostatin adenovirus|Recombinant Human Endostatin Adenovirus: Administered via intratumoral injection twice every 3 weeks for a total of eight doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first.
219287001|NCT07154108|DRUG|PD-1 Inhibitor|PD-1 inhibitor: Administered via intravenous infusion once every 3 weeks.
219287002|NCT07155343|COMBINATION_PRODUCT|Bulk Fill Composite|Orthodontic brackets will be bonded using a bulk fill composite resin, which is formulated for faster application and reduced polymerization shrinkage compared to conventional composites. This material will be used to assess its bond strength, failure rate, and overall clinical performance.
219287003|NCT07155343|COMBINATION_PRODUCT|Conventional Composite|Orthodontic brackets will be bonded using a conventional light-cured orthodontic composite resin that requires careful incremental application and standard curing time. This material is commonly used in routine clinical practice and serves as the benchmark for comparison.
219287004|NCT07155720|OTHER|Intervention (Kinesio Taping) group|No studies have been found in the literature examining whether kinesio taping increases happiness in women with PMS.
219287005|NCT07155187|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219287006|NCT07155187|DRUG|Standard of Care|Standard of Care
219287007|NCT07155278|DRUG|Elravie Re2O|Elravie Re2O is a particulated human Acellular Dermal Matrix (phADM), with each 5 mL syringe containing 150 mg of phADM. This product is classified as a human tissue product and received its approval via a tissue bank establishment permit from the Ministry of Food and Drug Safety.
219287008|NCT07155278|DRUG|Elravie Balance|Elravie Balance is a gel-type hyaluronic acid (HA) skin booster. It contains HA at a concentration of 20mg/ml in a 2.5 cc syringe with a volume of 1.5 mL.
219287009|NCT07153692|DEVICE|tDCS|The IS200 intelligent electrical stimulator, manufactured in Chengdu, Sichuan, will be used. The electrode pads are 4cm × 6cm in size. The anode of the electrode pad will be placed on the swallowing sensorimotor cortex (S1/M1). The specific positioning will follow the international 10-20 electroencephalographic system: the left S1/M1 area is located at the midpoint of the line connecting C3 and T3 in the left hemisphere; the right S1/M1 area is located at the midpoint of the line connecting C4 and T4 in the right hemisphere. The cathode will be placed on the contralateral supraorbital margin. The S1/M1 areas of the left and right hemispheres will be stimulated alternately, with a current intensity of 1.6mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere).
219287010|NCT07153692|BEHAVIORAL|Conventional Dysphagia Treatment|"1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.;~2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;"
219287011|NCT07153692|DEVICE|sham tDCS|According to previous literature, the electrode positions and treatment frequency of sham tDCS will be the same as those of real tDCS. The current will be adjusted to 0.05mA.
219287012|NCT07154485|DRUG|NS101 IV infusion|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
219287013|NCT07154485|DRUG|Placebo IV Infusion|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
219287014|NCT07155083|OTHER|Survey using a questionnaire.|REDCap Survey
219287015|NCT07155252|DIAGNOSTIC_TEST|GTT@Home|self-administered fingerstick based glucose tolerance test
219287016|NCT07154550|DEVICE|Mastisol|a liquid adhesive used to secure dressings for extended periods of time
219287017|NCT07153653|BEHAVIORAL|Prenatal Baduanjin Exercise Program|A structured 12-week program featuring Baduanjin, a traditional Chinese mind-body exercise involving gentle, flowing movements. Participants receive 24 online instructional sessions (approximately 2 s
219287018|NCT07154888|OTHER|Fast Track to Fertility Algorithmic Text Messaging Platform|"The Fast Track to Fertility algorithmic text messaging platform uses branching logic based on our standard workup protocol to text patients to schedule blood tests and an ultrasound timed to their menstrual cycle, as well as remind male partners to schedule blood and semen analyses.~The platform will use an algorithmic approach to facilitate two-way communication, and any queries with no available responses will be escalated to the clinical team. Patients are not dependent on structured messages to progress through their journey; they can ask relevant questions in real time, and they are supported with fewer reminders. Response categories include clinical guidance and FAQs (e.g., how to determine cycle start or uterine cavity evaluation pre-appointment instructions), administrative guidance and FAQs (when to schedule test/appointment or clinic locations or phone numbers), and conversational pleasantries."
219287019|NCT07153419|DEVICE|Laparoscopic and robotic (DaVinci) RYGB|Laparoscopic and robotic (DaVinci) Roux-en-Y Gastric Bypass
219287020|NCT07154082|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|Patients in the neoadjuvant treatment group will receive TACE treatment within one week after enrollment. One week after the resolution of the TACE treatment syndrome, they will be given Camrelizumab (200 mg, once every two weeks, for a total of 4 cycles) and oral Apatinib mesylate tablets (250 mg, once a day, for a total of 2 months).To ensure surgical safety, Camrelizumab should be discontinued at least two weeks before surgery, while Apatinib should be discontinued at least one week before surgery.
219287021|NCT07155356|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
219287022|NCT07155356|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care。
219287023|NCT07156006|DIAGNOSTIC_TEST|Mammography|Participants will undergo mammographic imaging using a digital full-field mammography system, following standard clinical practices and blood sampling.
219287024|NCT07155655|BEHAVIORAL|Motor Imagery (MI)|Participants followed an audio-guided motor imagery protocol describing the lumbopelvic dynamometer movement. The audio was played three times per session, with pauses for visualization. Training was delivered online via Microsoft Teams, twice weekly for four weeks, in a quiet and focused environment.
219287025|NCT07155655|BEHAVIORAL|Action Observation (AO)|Participants viewed three videos of the lumbopelvic dynamometer movement (two third-person, one first-person perspective). Each video was watched three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks, with participants instructed to remain silent and focused.
219287026|NCT07155655|BEHAVIORAL|Motor Imagery with Motivation (MIm)|Participants followed the MI protocol, combined with a motivational strategy. Intrinsic motivation was provided through self-talk statements, and extrinsic motivation through an audio simulating a weightlifting competition. Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
219287027|NCT07155655|BEHAVIORAL|Action Observation with Motivation (AOm)|Participants followed the AO protocol, combined with the same motivational strategy described for the MIm group (self-talk + extrinsic audio simulation). Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
219287028|NCT07154901|DRUG|Opemalirsen (AZD2373)|Single, subcutaneous injection of AZD2373
219287029|NCT07155980|DRUG|GSM-779690T|Opaque capsules for oral consumption.
219287030|NCT07155980|OTHER|Placebo|Opaque capsules for oral consumption.
219287031|NCT07153601|DRUG|Norepinephrine 4mcg|Norepinephrine 4 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
219287032|NCT07153601|DRUG|Phenylephrine 50 mcg|Phenylephrine 50 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
219287033|NCT07154290|DRUG|Ubamatamab|Administered per the protocol
219287034|NCT07154290|DRUG|REGN7075|Administered per the protocol
219287035|NCT07154290|DRUG|Sarilumab|Administered per the protocol
219287036|NCT07153588|OTHER|Level of awareness|"This study uses a structured, interviewer-assisted questionnaire as the main intervention. The questionnaire is designed to assess patients' awareness and perception of glaucoma. It includes four sections:~Sociodemographic information (age, gender, education, occupation, residence, family history)~Ocular history (diagnosis of glaucoma, history of eye disease, surgery, or previous eye checkups)~Awareness of glaucoma (understanding of risk factors, symptoms, prevention, and treatment options)~Perceptions and attitudes (beliefs about curability, reversibility of vision loss, and willingness for screening and education).~For illiterate participants, trained research staff will administer the questionnaire verbally without influencing responses. The data collection method distinguishes this intervention from treatment-based studies, as it focuses on knowledge assessment and perception analysis rather than a medical or surgical procedure."
219287037|NCT07155551|DEVICE|Lens A|Lens A of Study P/883/24/MO
219287038|NCT07155551|DEVICE|Lens B|Lens B of Study P/883/24/MO
219287039|NCT07155551|DEVICE|Lens C|Lens C of Study P/883/24/MO
219287040|NCT07155369|BIOLOGICAL|UCAR-T cells|UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.
219287041|NCT07155369|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
219287042|NCT07155369|DRUG|Fludarabine|Fludarabine will be administered intravenously.
219287043|NCT07155915|DIETARY_SUPPLEMENT|Sweet cherries, 280 g daily for 42 days|Participants will consume 280 grams of fresh sweet cherries daily for 42 consecutive days. Cherries are provided in pre-weighed portions to be consumed in the morning on an empty stomach
219287044|NCT07155226|DRUG|AZD3632|AZD3632 will be administered orally.
219287045|NCT07155226|DRUG|Posaconazole|Posaconazole will be administered orally.
219287046|NCT07153861|PROCEDURE|Oral mucosal graft|Patients will be admitted for the surgical management by the oral mucosal graft urethroplasty with the anterior onlay technique.
219287047|NCT07153861|PROCEDURE|Labial graft|Patients will be admitted for the surgical management by the labial graft urethroplasty with the anterior onlay technique.
219287048|NCT07155005|DEVICE|CVAC® SYSTEM|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
219287049|NCT07155005|DEVICE|FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)|Group/Cohort Description: FANS is designed to incorporate suction to facilitate stone fragment removal through its lumen and is used with a separate ureteroscope. FANS is fitted with a Y connector with a pressure control vent and connects to a standard vacuum device. A separate ureteroscope provides direct visualization and irrigation and a separate specimen collector captures stone debris.
219287050|NCT07155005|DEVICE|DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)|DISS is a system that integrates controlled suction into the working channel of a standard flexible ureteroscope during ureteroscopic lithotripsy. A suction adapter is attached externally to the ureteroscope's working port, which connects to a standard hospital suction source.
219287051|NCT07155005|PROCEDURE|URETEROSCOPY (URS) WITHOUT SUCTION|URS allows the surgeon to visualize the stone by inserting the ureteroscope into the ureter, most often a flexible scope that allows them to accommodate to the shape of the ureter and renal collecting system. A laser fiber is advanced through the working channel of the ureteroscope to perform stone fragmentation (dusting or breaking up the calculi). Once the stones are dusted or fragmented, the pieces can be removed by active extraction of individual stone fragments using a retrieval basket or using the concept of stone dusting where the fragments are small enough to be passed after the procedure.
219287052|NCT07155005|PROCEDURE|PERCUTANEOUS NEPHROLITHOTOMY (PCNL)|This is a surgical procedure under general anesthesia, where a rigid probe is placed through the flank, creating a percutaneous tract into the renal collecting system under fluoroscopy. Via nephoscopy, stones are fragmented, pulverized, and extracted.
219287053|NCT07154602|OTHER|3D printed hybrid resin ceramic crowns|3D printed hybrid resin ceramic crowns in anterior and premolar maxillary teeth
219287054|NCT07154602|OTHER|milled hybrid resin ceramic crown|milled hybrid resin ceramic crown on implants in anterior and premolar maxillary teeth
219287055|NCT07154056|DEVICE|Lead(s) and Implantable Pulse Generator implantation|8-contact lead(s) will be radiologically positioned within the spinal foramen under awake anesthesia in order to optimize paresthesia coverage. Awake anesthesia will allow patients to be tested during the surgery in order to determine the sweet spot and the optimal paresthesia coverage using the PREDI-P platform for a single lead. A trial phase will be performed for a period of 7 days in order to assess the benefits of stimulation according to the HAS (French Health Authority) guidelines. Subjects who succeed the lead trial will receive a permanent implant depending on the patient electrical consumption during the lead trial period or according to the implanter decision.
219287056|NCT07154615|OTHER|Observational Only|No intervention is included in this study
219287057|NCT07153445|DRUG|Atezolizumab|Patients will receive atezolizumab administered by intravenous infusion in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
219287058|NCT07153445|DRUG|Paclitaxel|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Paclitaxel: Intravenous infusion.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
219287059|NCT07153445|DRUG|Carboplatin|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin\*~\*Infusion according to the standard of each center~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Carboplatin: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
219287060|NCT07153770|DRUG|Bozitinib|Participants will receive bozitinib in combination with standard platinum-based doublet chemotherapy for 8 weeks. Following investigator-assessed operability, surgical resection will be performed approximately 4 weeks after completion of neoadjuvant therapy. The first MRD assessment will be conducted after completion of neoadjuvant therapy and before surgery.A second MRD assessment will be performed within 7 days to 1 month after surgery. Based on a comprehensive evaluation of MRD status, tumor markers, and imaging results, if molecular abnormalities are detected., patients will receive bozitinib within 3 months after surgery. If CEA remains within the normal range and blood cfDNA-MRD is negative, patients will enter a regular follow-up program, with MRD assessments every 3 months during the first 2 years and every 6 months from years 3 to 5. If MRD conversion to positive, abnormal CEA, or abnormal CT findings occur within 5 within 5 years, bozitinib will be administered.
219287061|NCT07153939|DEVICE|Velocity Percutaneous Arteriovenous Fistula|The Velocity pAVF is a catheter-based device used to create an arteriovenous fistula for hemodialysis access through a minimally invasive, percutaneous procedure. Unlike surgical AVF creation or other pAVF systems, Velocity is designed to simplify the procedure and improve consistency of maturation and long-term function. All participants in this study will undergo AVF creation using the Velocity pAVF.
219296452|NCT06611878|OTHER|Treatment as Usual (TAU)|Medications, behavioural interventions and other treatments that participants may receive outside the study during the period of participation.
219287062|NCT07153835|DRUG|Paliperidone extended-release (ER)|Paliperidone extended-release (ER) tablets will be administered orally once daily at flexible doses ranging from 6 mg to 12 mg, based on the clinical judgment of the treating psychiatrist. The treatment duration is 12 weeks. Dose adjustments may be made throughout the study period depending on patient response and tolerability.
219287063|NCT07154004|OTHER|Test Serum 897222 210|Repeated application
219287064|NCT07154004|OTHER|Test Serum 897222 212|Repeated application
219287065|NCT07154004|OTHER|Test Serum 897250 39|Repeated application
219287066|NCT07154004|OTHER|Test Serum 897250 102D|Repeated application
219287067|NCT07154004|OTHER|Test Serum 774569 67|Repeated application
219287068|NCT07154134|DIAGNOSTIC_TEST|Serum endocan|Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
219287069|NCT07154134|DIAGNOSTIC_TEST|Serum copeptin|Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
219287070|NCT07155265|DRUG|Remimazolam Besylate|Continuous IV infusion; start 0.10 mg/kg/h and titrate every 15-30 minutes in 0.025-0.05 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5 for clinical safety). Maximum typical rate 0.20 mg/kg/h; temporary higher rates permitted per protocol for breakthrough agitation.
219287071|NCT07155265|DRUG|Midazolam|Continuous IV infusion; start 0.04 mg/kg/h and titrate every 15-30 minutes in 0.01-0.03 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5). Maximum typical rate 0.20 mg/kg/h per protocol.
219287072|NCT07155473|DIAGNOSTIC_TEST|C-peptide dosage|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT)
219287073|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Diagnostic Test: Periodontal Examination
219287074|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Periodontal Examination
219287075|NCT04388163|DRUG|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
219287076|NCT06272500|OTHER|oral administration of receives only oral administration of placebo|receives oral administration of placebo, with two capsules before each meal.
219287077|NCT06272500|DIETARY_SUPPLEMENT|oral administration of Betaine hydrochloride|receives oral administration of Betaine hydrochloride(BHCL), with two capsules before each meal.
219287078|NCT05655273|DRUG|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
219287079|NCT05655273|DRUG|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
219287080|NCT04500769|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
219287081|NCT04642807|PROCEDURE|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
219287082|NCT04642807|PROCEDURE|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
219287083|NCT01967147|DRUG|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
219287084|NCT01967147|DRUG|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
219287085|NCT03986164|DEVICE|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
219287086|NCT03986164|DEVICE|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
219287087|NCT02912923|OTHER|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
219287088|NCT02912923|OTHER|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
219287089|NCT01620268|DRUG|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
219287090|NCT02314780|DRUG|Heme arginate 3mg/kg|
219287091|NCT02314780|DRUG|Heme arginate 1mg/kg|
219287092|NCT02314780|DRUG|Placebo|
219287093|NCT00109330|BIOLOGICAL|Combined diphtheria, tetanus, acellular pertussis vaccine|
219287094|NCT04579718|OTHER|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
219287095|NCT04579718|OTHER|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
219287096|NCT06224127|DEVICE|active heat|Users receive an active Soovu heating pod(s).
219287097|NCT06224127|DRUG|Active c tactile fiber stimulation|Hair brushes that activate c tactile fibers
219287098|NCT06224127|DEVICE|sham heat|A Soovu heating pod(s) in the subtherapeutic temperature range
219287099|NCT06224127|DEVICE|Sham c tactile fiber stimulation|Hair brushes that do not activate c tactile fibers
219287100|NCT04998929|OTHER|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
219287101|NCT02083107|DRUG|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
219287102|NCT02083107|OTHER|Placebo|
219287103|NCT01056900|PROCEDURE|Autologous Chondrocyte Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
219287104|NCT01115127|DIETARY_SUPPLEMENT|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
219287105|NCT01115127|DIETARY_SUPPLEMENT|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
219287106|NCT01115127|DIETARY_SUPPLEMENT|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
219287107|NCT00310934|DRUG|methadone|
219287108|NCT00310934|DRUG|buprenorphine / methadone sequence|
219287109|NCT00310934|BEHAVIORAL|Relapse prevention|
219287110|NCT00310934|BEHAVIORAL|Contingency management|
219287111|NCT04023773|DEVICE|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
219287112|NCT05922059|DEVICE|Transcutaneous vagus nerve stimulation|Auricular transcutaneous vagus nerve stimulation will be used in the left cavity of the external ear with a stimulation frequency of 20-30 Hz for half hour. Monophasic rectangular waveforms will be used, and the intensity will be adjusted below the patient's pain threshold.
219287113|NCT05922059|DEVICE|Heart rate variability biofeedback|The patient will receive visual HRV feedback during resonance frequency breathing. Finally, the patient will be instructed to maximize their peak-to-peak HRV and attain the phase between respiration and HRV changes as closely as possible
219287114|NCT05922059|OTHER|Standard-care physiotherapy|consists of cervical mobilization on the painful segment, isometric exercise for neck flexors, and a combination of strengthening and stretching exercises from sitting position; cervical extensors strengthening exercise using red color Thera-band and stretching exercises upper trapezius of the painful side.
219287115|NCT02468219|BEHAVIORAL|cardiovascular rehabilitation program|"Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training."
219287116|NCT00215137|DRUG|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
219287117|NCT00215137|DRUG|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
219287118|NCT00082875|DRUG|cilengitide|Given IV
219287119|NCT00082875|OTHER|pharmacological study|Correlative studies
219287120|NCT00082875|OTHER|laboratory biomarker analysis|Correlative studies
219287121|NCT03392259|BEHAVIORAL|Smartphone app|Installment and use of smartphone app
219287122|NCT01948700|BEHAVIORAL|Motivational Interviewing|
219287123|NCT01948700|OTHER|Education|
219287124|NCT01241487|DRUG|valsartan/amlodipine|160/10 mg
219287125|NCT00336700|DRUG|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
219287126|NCT00336700|DRUG|Erlotinib|150 mg/d Daily, oral 12 months
219287127|NCT02644395|DRUG|Chlorthalidone|Drug
219287128|NCT02644395|DRUG|Amlodipine|Drug
219296453|NCT05242419|DRUG|Sodium Chloride Injection|0.9% Sodium Chloride Injection
219296454|NCT05242419|DRUG|Huperzine A Injection|Huperzine A Injection
219287129|NCT02655068|OTHER|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
219287130|NCT02655068|OTHER|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
219287131|NCT00244998|DRUG|fulvestrant|IM
219287132|NCT05684263|OTHER|Weight Science Educational Video|Educational videos on the topic of weight science created by a registered clinical psychologist.
219287133|NCT05684263|OTHER|Healthy Eating Educational Video|Educational videos on the topic of healthy eating created by a registered clinical psychologist.
219287134|NCT05684263|OTHER|Healthy Sleep Educational Video|Educational videos on the topic of healthy sleep created by a registered clinical psychologist.
219287135|NCT01320059|DRUG|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
219287136|NCT01320059|PROCEDURE|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
219287137|NCT02777138|OTHER|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
219287138|NCT02844218|OTHER|Age of patient|"* Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
219287139|NCT03581604|DIAGNOSTIC_TEST|Allergy work-up|Allergy work-up
219287140|NCT03581604|OTHER|Blood samples|Blood samples
219287141|NCT06253078|DRUG|Ciprofol dose 0.4mg/Kg|The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
219287142|NCT06253078|DRUG|Ciprofol dose 0.3mg/Kg|The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
219287143|NCT06253078|DRUG|Ciprofol dose 0.2mg/Kg|The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
219287144|NCT04630392|OTHER|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
219287145|NCT04630392|OTHER|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
219287146|NCT02294903|PROCEDURE|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
219287147|NCT00207610|BEHAVIORAL|Daily iron supplements of 65 mg a day for 3 months|
219287148|NCT00207610|BEHAVIORAL|Universal anemia screening and treatment|
219287149|NCT00207610|BEHAVIORAL|Selective anemia screening and treatment|
219296455|NCT05202210|BIOLOGICAL|blood and urine sampling|extra sample of blood and urine will be collected
219287150|NCT02470156|BEHAVIORAL|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
219287151|NCT02470156|BEHAVIORAL|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
219287152|NCT06132542|BIOLOGICAL|stem cell therapy|The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.
219287153|NCT00943839|DRUG|sunitinib malate|
219287154|NCT00943839|OTHER|laboratory biomarker analysis|
219287155|NCT00943839|OTHER|pharmacological study|
219287156|NCT03995862|OTHER|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
219287157|NCT04136821|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
219287158|NCT04136821|OTHER|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
219287159|NCT04425759|DIAGNOSTIC_TEST|Blood sample|Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.
219287160|NCT05396534|PROCEDURE|Atrial Fibrillation transcatheter ablation|We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
219287161|NCT05383144|OTHER|Complete Positioning scans|Entire treatment zone imaging at mi-treatment and at end of treatment
219287162|NCT02966327|DEVICE|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
219287163|NCT02966327|BEHAVIORAL|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
219287164|NCT02966327|BEHAVIORAL|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
219287165|NCT02652325|DRUG|Saline|
219287166|NCT02652325|DRUG|Povidone-Iodine|
219287167|NCT02652325|DRUG|5% Povidone-Iodine USP swabs|
219287168|NCT01142232|DRUG|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
219287169|NCT01142232|DRUG|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
219287170|NCT01951352|OTHER|Soap|
219287171|NCT04377685|OTHER|CT-Scan|Chest CT scan on admission to the hospital
219287172|NCT00285428|DRUG|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
219287173|NCT00597246|DRUG|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
219287174|NCT00597246|OTHER|PET Scan|GE Advance PET scanner for sequential body imaging
219287175|NCT04410601|PROCEDURE|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
219287176|NCT04481308|DRUG|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
219287177|NCT00092287|DRUG|lanreotide Autogel (somatostatin analogue)|
219287178|NCT00092287|DRUG|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
219287179|NCT01385852|PROCEDURE|microcoaxial phacoemulsification|conventional longitudinal ultrasound
219287180|NCT05611112|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
219287181|NCT04300751|DRUG|Alcohol|Active alcohol or placebo, administered orally
219287182|NCT04300751|DRUG|Opioid Agonist|Active opioid agonist or placebo, administered orally
219287183|NCT03932305|DIETARY_SUPPLEMENT|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
219287184|NCT03932305|DIETARY_SUPPLEMENT|Placebo|Inactive placebo tablet
219287185|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
219287186|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
219287187|NCT05519098|DEVICE|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
219287188|NCT06797258|DEVICE|FlexHD® Pliable|Acellular Dermal Matrix
219287189|NCT06797258|OTHER|No intervention|Historical Control Arm
219287190|NCT05789056|DRUG|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
219287191|NCT05946187|BEHAVIORAL|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
219287192|NCT05946187|OTHER|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
219287193|NCT02393300|DRUG|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
219287194|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
219287195|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
219287196|NCT02787044|BIOLOGICAL|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
219287197|NCT02787044|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
219287198|NCT04900571|DRUG|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
219287199|NCT01528553|DEVICE|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
219287200|NCT01528553|DEVICE|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
219287201|NCT01056952|PROCEDURE|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
219287202|NCT01056952|PROCEDURE|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher \& Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
219287203|NCT01056952|PROCEDURE|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%
219287204|NCT05110027|DRUG|Enpatoran|Participants will receive single oral dose of enpatoran tablet on Day 1
219287205|NCT05110027|DRUG|[14C]enpatoran microtracer|Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.
219287206|NCT05110027|DRUG|[14C]enpatoran microdose|Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
219287207|NCT05076084|PROCEDURE|QUICK questionnaire and 6 additional questions|QUICK questionnaire and 6 additional questions
219287208|NCT05076084|OTHER|Retrospective collection of clinical data from the patients' medical records|Retrospective collection of clinical data from the patients' medical records
219287209|NCT03818724|DEVICE|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
219287210|NCT02156726|DRUG|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
219287211|NCT02182947|DEVICE|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
219287212|NCT01800734|OTHER|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
219287213|NCT03024905|BEHAVIORAL|Village meeting and travel vouchers|"The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery."
219287214|NCT03024905|DEVICE|Birth kit with misoprostol|Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
219287215|NCT01940068|DIETARY_SUPPLEMENT|Amino acid based formula|
219287216|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
219287217|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
219287218|NCT05847673|OTHER|Questionnaire Administration|Ancillary studies
219287219|NCT05847673|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
219287220|NCT04669015|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
219287221|NCT04669015|BIOLOGICAL|Placebo|Formulation vehicle
219287222|NCT05444023|PROCEDURE|Pubocervical fascia reconstruction|Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
219287223|NCT03872024|DEVICE|For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
219287224|NCT03872024|DEVICE|From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe)."
219287225|NCT04427059|PROCEDURE|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
219287226|NCT04427059|PROCEDURE|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
219287227|NCT01609244|DEVICE|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
219287228|NCT01609244|DEVICE|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
219287229|NCT00730275|DRUG|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
219287230|NCT00730275|DRUG|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
219287231|NCT02448433|DEVICE|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m\^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
219287232|NCT00251901|DRUG|Esomeprazole|
219287233|NCT05368792|DIETARY_SUPPLEMENT|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
219287234|NCT02920489|DRUG|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
219287235|NCT02920489|DRUG|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
219287236|NCT00480935|DRUG|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
219287237|NCT06198348|OTHER|Aerobic Exercise|"Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase."
219287238|NCT06198348|OTHER|Aerobic Exercises with Resistance training|"These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~1. Leg press (dual leg press):~   Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~2. Crunches:~   Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~3. Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set"
219287239|NCT01843153|DRUG|Ropivacaine|
219287240|NCT00327262|DRUG|Imatinib|
219287241|NCT02653612|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
219296456|NCT06485986|OTHER|DBS on/off|DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
219287242|NCT03046121|BEHAVIORAL|Family-centered Function-focused Care (Fam-FFC)|"An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period."
219287243|NCT02005770|DRUG|Sevoflurane|
219287244|NCT02005770|DRUG|Propofol|
219287245|NCT03151993|DRUG|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
219287246|NCT03151993|DRUG|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
219287247|NCT00385177|DRUG|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
219287248|NCT00004426|DRUG|gonadotropin releasing hormone|
219287249|NCT00004426|DRUG|leuprolide|
219287250|NCT04221672|DRUG|Terlipressin plus standard care|All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.
219287251|NCT04221672|OTHER|Standard care|All the participants received routine care after surgery only.
219287252|NCT04155047|COMBINATION_PRODUCT|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
219287253|NCT04155047|DRUG|Placebo administered by Magnair|Placebo Inhalation Solution
219287254|NCT03988738|OTHER|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
219287255|NCT06151093|OTHER|Video-based games intervention|"These games are applied via using Nintendo Wii~1st - 2nd Week Applications~* Basic Step~* Penguin slide (right-left weight transfer)~* Snowball flight (right-left weight transfer)~* Tilt city (right-left weight transfer)~  3rd-4th Week Applications~* Advanced Step~* Snowball flight (right-left weight transfer)~* Penguin slide (right-left weight transfer)~* Table tilt (weight transfer in 4 directions)~  5th-6th Week Applications~* Advanced Step~* Table tilt (weight transfer in 4 directions)~* Balance bubble (weight transfer to 4 directions)~* Ski slalom (weight transfer in 4 directions)"
219287256|NCT06151093|OTHER|Balance exercises|"1st-2nd Week Applications On a flat-hard surface;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Taking a step back towards the step~* Stepping on the stability ball~  3rd-4th Week Applications All exercises which applied in 1st and 2nd week are applied on mat.~  5th-6th Week Applications On the balance board;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Catching balls thrown by the enforcer"
219287257|NCT01770977|DEVICE|Light-emitting diode therapy|
219287258|NCT01770977|DEVICE|Placebo light-emitting diode therapy|
219287259|NCT01143870|OTHER|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
219287260|NCT02689843|DRUG|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
219287261|NCT02689843|DRUG|Metformin|Metformin 500mg three times daily
219287262|NCT02689843|DRUG|Pioglitazone|Pioglitazone 30mg once daily
219287263|NCT00131729|BEHAVIORAL|Educational programme|
219287264|NCT00202917|DRUG|Fludarabine|
219287265|NCT00202917|DRUG|Thiotepa|
219287266|NCT00202917|DRUG|Melphalan|
219287267|NCT00202917|DRUG|OKT-3|
219287268|NCT00202917|PROCEDURE|CD3/CD19 depletion on CliniMACS|
219287269|NCT02146404|OTHER|hypoglycemia|Blood glucose levels will be kept at \~3.0 mmol/l
219287270|NCT02146404|OTHER|euglycemia|Blood glucose levels will be kept at \~5.0 mmol/l
219287271|NCT05719740|DIAGNOSTIC_TEST|osteocrin|laboratory routine test
219287272|NCT00003187|BIOLOGICAL|filgrastim|
219287273|NCT00003187|DRUG|cyclophosphamide|
219287274|NCT00003187|DRUG|cyclosporine|
219287275|NCT00003187|DRUG|cytarabine|
219287276|NCT00003187|DRUG|methotrexate|
219287277|NCT00003187|DRUG|methylprednisolone|
219287278|NCT00003187|PROCEDURE|allogeneic bone marrow transplantation|
219287279|NCT00003187|PROCEDURE|in vitro-treated bone marrow transplantation|
219287280|NCT00003187|RADIATION|radiation therapy|
219287281|NCT04488770|DRUG|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
219287282|NCT04488770|DRUG|Placebo|Matching strength placebo capsules will be provided
219287283|NCT00913848|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
219287284|NCT00913848|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
219287285|NCT06418945|COMBINATION_PRODUCT|Tinidazole oral microneedle patch|Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.
219287286|NCT00564577|BIOLOGICAL|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
219287287|NCT06124469|DIAGNOSTIC_TEST|US-guided fine needle aspiration (FNA)|This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
219287288|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under popliteal sciatic nerve
219287289|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under an ankle block
219287290|NCT04650139|PROCEDURE|PCI - percutaneous coronary intervention|percutaneous coronary intervention
219287291|NCT00510640|DRUG|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
219287292|NCT05923515|DRUG|JMKX000197|for injection
219287293|NCT00785993|OTHER|Vitrification of oocytes for IVF treatment|
219287294|NCT00785993|OTHER|Protocolary IVF treatment with fresh donor oocytes|
219287295|NCT00629733|DRUG|RO-14|
219287296|NCT02786550|DRUG|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
219287297|NCT02786550|OTHER|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
219287298|NCT04073446|DEVICE|Spinal Cord Stimulation|Patients eligible for SCS
219287299|NCT02686684|DRUG|Dimethyl fumarate|
219287300|NCT00540865|BEHAVIORAL|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
219287301|NCT00540865|BEHAVIORAL|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
219287302|NCT05922384|DRUG|KL-7SHRNA injection solution|Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
219287303|NCT04458129|DRUG|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
219287304|NCT02491515|DRUG|Denosumab|every 6 month injection
219287305|NCT02586428|OTHER|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
219287306|NCT05145543|DRUG|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
219287307|NCT05145543|DRUG|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
219287308|NCT05145543|DRUG|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
219287309|NCT05145543|DRUG|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
219287310|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
219287311|NCT01611597|OTHER|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
219287312|NCT05842499|PROCEDURE|Line Set Strategy|Substrate-guided ablation procedure of atypical atrial flutter
219287313|NCT05842499|PROCEDURE|Conventional strategy|Electrical activation-guided ablation
219287314|NCT03912051|DEVICE|asymmetric balloon|Asymmetric balloon for treatment of intranasal bleeding
219287315|NCT01428427|DRUG|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
219287316|NCT01428427|DRUG|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
219287317|NCT05769946|DRUG|Hemay005|A PDE-4 inhibitor
219287318|NCT01875029|DEVICE|sham-tDCS + back school|sham tDCS + back school
219287319|NCT01875029|DEVICE|real-tDCS + back school|real tDCS + back school
219287320|NCT04481698|OTHER|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
219287321|NCT05976373|DRUG|Dupilumab (SAR231893)|injection solution subcutaneous
219287322|NCT01169376|GENETIC|DNA analysis|
219287323|NCT01169376|GENETIC|DNA methylation analysis|
219287324|NCT01169376|GENETIC|RNA analysis|
219287325|NCT01169376|GENETIC|comparative genomic hybridization|
219287326|NCT01169376|GENETIC|mutation analysis|
219287327|NCT01169376|GENETIC|polymorphism analysis|
219287328|NCT02764047|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
219287329|NCT03247868|COMBINATION_PRODUCT|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
219287330|NCT04957147|OTHER|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
219287331|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
219287332|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
219287333|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
219287334|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Control Vaccine
219287335|NCT00416195|DRUG|E2007|
219287336|NCT00416195|DRUG|Placebo|
219287337|NCT01882764|DRUG|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
219287338|NCT01882764|DRUG|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
219287339|NCT00033618|DRUG|ixabepilone|Given IV
219287340|NCT00033618|OTHER|laboratory biomarker analysis|Correlative studies
219287341|NCT04347057|OTHER|Bed bathing with 2% CHG solution|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with CHG solution for each period. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions.
219287342|NCT04347057|OTHER|Bed bathing with soap and water|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with soap and water. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions. During control period, patients were washed with soap and then rinsed with water, and dried with disposable towels
219287343|NCT00414167|DRUG|bupropion|300 mg per day for 8 weeks
219287344|NCT00414167|OTHER|Placebo|Placebo
219287345|NCT02372838|PROCEDURE|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
219287346|NCT01538966|DRUG|Pegvisomant|
219287347|NCT01538966|DRUG|Octreotide LAR|
219287348|NCT01538966|DRUG|Lanreotide|
219287349|NCT00733252|PROCEDURE|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
219287350|NCT00733252|PROCEDURE|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
219287351|NCT00733252|PROCEDURE|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
219287352|NCT00733252|PROCEDURE|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
219287353|NCT02089568|DRUG|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
219287354|NCT02089568|DRUG|Normal Saline|Placebo - 0.9% saline
219287355|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
219287356|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
219287357|NCT00526253|PROCEDURE|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
219287358|NCT01417104|DRUG|Aliskiren|150 mg/300mg
219287359|NCT01417104|DRUG|Placebo|150mg/300mg
219287360|NCT00451724|DRUG|Intranasal ketamine|
219287361|NCT05418751|OTHER|Manual therapy|Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
219287362|NCT05418751|OTHER|Placebo treatment|Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
219287363|NCT03361605|DRUG|Propofol|Propofol administration
219287364|NCT02727855|BIOLOGICAL|Shanchol|Oral Cholera Vaccine
219287365|NCT03042923|DRUG|lactulose:mannitol (L:M) oral challenge|
219287366|NCT04823676|DIETARY_SUPPLEMENT|Probiotic composition|Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)
219287367|NCT04823676|OTHER|Placebo|Maltodextrin (E1400, qs)
219287368|NCT05775172|PROCEDURE|Sleeve gastrectomy|laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.
219287369|NCT05775172|DIETARY_SUPPLEMENT|Lifestyle intervention|balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification
219287370|NCT05775172|OTHER|Control|No interventions were applied
219287371|NCT03225690|DRUG|Morphine|Prevention of remifentanil induced hyperalgesia
219287372|NCT03225690|DRUG|Serum physiologic|For placebo, serum physiologic will use
219287373|NCT05150977|OTHER|Polysomnography|Reviewing collected data
219287374|NCT04708951|DEVICE|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
219287375|NCT04708951|DEVICE|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
219287376|NCT05090670|OTHER|Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy|Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy
219287377|NCT05090670|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
219287378|NCT01305408|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
219287379|NCT01305408|DRUG|Placebo|Matching placebo tablets, taken orally, once daily in the morning
219287380|NCT00377689|BEHAVIORAL|high intensity functional exercise|high intensity functional exercise
219287381|NCT02899351|DEVICE|Respiratory Volume Monitor|
219287382|NCT02864277|PROCEDURE|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
219287383|NCT02864277|PROCEDURE|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
219287384|NCT04523753|PROCEDURE|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
219287385|NCT01315470|DRUG|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
219287386|NCT05017428|DIETARY_SUPPLEMENT|Spermidine|Spermidine in the form of a 0.1% spermidine wheat germ extract
219287387|NCT05017428|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide given as niacinamide
219287388|NCT05017428|DIETARY_SUPPLEMENT|PEA|Palmitoylethanolamide given at 98% purity
219287389|NCT05017428|DIETARY_SUPPLEMENT|OEA|Oleoylehtanolamide given at 90% purity
219287390|NCT05017428|DIETARY_SUPPLEMENT|Wheat Flour|Wheat flour given as a placebo control
219287391|NCT05269953|DEVICE|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
219287392|NCT05269953|DEVICE|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
219287393|NCT04391998|DRUG|Iron Supplement|oral tablet twice daily after meals
219287394|NCT04391998|DRUG|Metronidazole Oral|500 mg oral twice daily
219287395|NCT04391998|DRUG|Albendazole|200 mg oral single dose
219287396|NCT02699138|DRUG|Trazodone|100mg of trazodone to be administered orally once.
219287397|NCT02699138|DRUG|Placebo|Compounded sugar pill
219287398|NCT02699138|DEVICE|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
219287399|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting
219287400|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
219287401|NCT02060877|OTHER|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
219287402|NCT04678505|DRUG|MK-3402|"MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2"
219287403|NCT06399562|DIAGNOSTIC_TEST|carbon-13 urea breath test (13C-UBT)|The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.
219287404|NCT06399562|BEHAVIORAL|questionnaires|The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.
219287405|NCT01005069|DRUG|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
219287406|NCT01005069|DRUG|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
219287407|NCT01005069|DRUG|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
219287408|NCT01005069|DRUG|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
219287409|NCT01005069|DRUG|Placebo capsule|Placebo capsules once daily and lifestyle modification
219287410|NCT02712268|OTHER|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
219287411|NCT04940338|DRUG|Bromfenac Ophthalmic 0.09% Ophthalmic Solution|topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
219287412|NCT04940338|DRUG|Dexamethasone Ophthalmic|topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
219287413|NCT04940338|DRUG|Placebo|topical placebo (artificial tears substitute) 2x daily before the surgery
219287414|NCT04940338|PROCEDURE|Phacoemulsification surgery (PHACO)|About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
219287415|NCT03586011|BEHAVIORAL|Predicting factors for increased physical activity|
219287416|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
219287417|NCT04160026|DRUG|Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
219287418|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer|Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
219287419|NCT00484029|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
219287420|NCT00484029|OTHER|Air|Air (Medical Grade)
219287421|NCT04148664|PROCEDURE|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard."
219287422|NCT04148664|PROCEDURE|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard."
219287423|NCT04224857|DRUG|AMT-101|Single or daily dosing at doses A, B, C, D, E, F
219287424|NCT04224857|DRUG|Placebos|Single or daily dosing at doses A, B, C, D, E, F
219287425|NCT02909218|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
219287426|NCT00483990|DRUG|PSD502|
219287427|NCT04792619|OTHER|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
219287428|NCT04792619|OTHER|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
219287429|NCT00799981|DEVICE|A=SpeediCath Compact 7 cm and B=POBE 10 cm|Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
219287430|NCT03296670|DRUG|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
219287431|NCT03296670|DRUG|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
219287432|NCT02436434|DEVICE|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
219287433|NCT04680806|DEVICE|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
219287434|NCT04680806|DEVICE|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
219287435|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
219287436|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
219287437|NCT03041974|PROCEDURE|Red Blood Cell transfusion|
219287438|NCT03041974|PROCEDURE|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
219287439|NCT01641159|DRUG|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
219287440|NCT01641159|DRUG|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
219287441|NCT04484116|DIAGNOSTIC_TEST|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
219287442|NCT00632489|DRUG|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
219287443|NCT00632489|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
219287444|NCT00632489|DRUG|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
219287445|NCT00883064|DRUG|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
219287446|NCT00883064|DRUG|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
219287447|NCT02826928|BIOLOGICAL|blood sample withdrawn|
219287448|NCT05563350|DIAGNOSTIC_TEST|Blood samples|p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping
219287449|NCT03653208|DRUG|hzVSF-v13|Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
219287450|NCT03653208|DRUG|Placebo|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
219287451|NCT00805805|DRUG|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
219287452|NCT00805805|OTHER|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
219287453|NCT01939444|DRUG|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
219287454|NCT01939444|DRUG|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
219287455|NCT01249027|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
219287456|NCT03545477|OTHER|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
219287457|NCT03545477|OTHER|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
219287458|NCT03545477|OTHER|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
219287459|NCT03778268|PROCEDURE|sentinel lymph node biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
219287460|NCT03752970|DRUG|Spesolimab|Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
219287461|NCT03752970|DRUG|Placebo|Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
219287462|NCT00556465|DRUG|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
219287463|NCT02690259|PROCEDURE|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
219287464|NCT00354575|DRUG|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
219287465|NCT04625699|DRUG|Durvalumab|4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
219287466|NCT04625699|DRUG|Tremelimumab|2 doses of Tremelimumab 300 mg IV Day 1, q56 days
219287467|NCT04344080|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
219287468|NCT02984722|DRUG|Metformin|
219287469|NCT03117829|BEHAVIORAL|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
219287470|NCT05215028|DEVICE|web-application|web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
219287471|NCT02605551|PROCEDURE|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~1. OM Occipitomastoid release technique~2. Sub-Occipital Release Technique~3. Rib Raising Technique~4. Rotatory stimulation of posterior Chapman's Reflexes~5. Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
219287472|NCT02605551|BEHAVIORAL|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
219287473|NCT00685451|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
219287474|NCT04479228|DEVICE|Endosonography guided transmural drainage|The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
219287475|NCT04179916|DIAGNOSTIC_TEST|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
219287476|NCT04573088|BEHAVIORAL|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
219287477|NCT02158923|PROCEDURE|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
219287478|NCT02158923|PROCEDURE|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
219287479|NCT02158923|PROCEDURE|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
219287480|NCT03478904|DRUG|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
219287481|NCT03478904|DRUG|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
219287482|NCT02630589|DEVICE|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
219287483|NCT03385590|DIETARY_SUPPLEMENT|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
219287484|NCT03385590|DIETARY_SUPPLEMENT|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
219287485|NCT00418769|DRUG|Nilotinib|
219287486|NCT04839822|OTHER|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time."
219287487|NCT04839822|OTHER|Health tips|Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.
219287488|NCT04839822|DIAGNOSTIC_TEST|Surveys|Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.
219287489|NCT04839822|OTHER|Popular psychological interventions|Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
219287490|NCT04521751|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
219287491|NCT04521751|DRUG|EMP16-02 150 mg orlistat/50 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
219287492|NCT04521751|DRUG|Placebo|Matching oral placebo capsules
219287493|NCT00193167|DRUG|Topotecan|
219287494|NCT01152814|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
219287495|NCT04682860|DRUG|Hyoscine N Butylbromide|Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
219287496|NCT04682860|OTHER|Placebo|2 ml of normal saline injection as placebo
219287497|NCT04525794|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
219287498|NCT04314635|BEHAVIORAL|Brief family engagement intervention for CHR|The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
219287499|NCT04314635|BEHAVIORAL|Treatment as usual (TAU)|The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
219287500|NCT01486290|BEHAVIORAL|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
219287501|NCT03720951|RADIATION|pudendal nerve|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
219287502|NCT03720951|RADIATION|sacral n roots|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
219287503|NCT01593475|RADIATION|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~\- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
219287504|NCT00359983|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
219287505|NCT00359983|BIOLOGICAL|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
219287506|NCT04408703|DIAGNOSTIC_TEST|Red Density|Image analysis of endoscopic images in patients with ulcerative colitis
219287507|NCT02320981|DIAGNOSTIC_TEST|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
219287508|NCT04025489|DIETARY_SUPPLEMENT|Randomized control trial of vitamin D supplementation|This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
219287509|NCT05512689|DEVICE|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
219287510|NCT03560024|OTHER|PACAP27|PACAP27 is vasodilator of cerebral vessels
219287511|NCT03560024|OTHER|Placebo|Saline
219287512|NCT03101839|DRUG|AZD4785|KRAS Antisense Oligonucleotide
219287513|NCT02145559|DRUG|Metformin XR|
219287514|NCT02145559|DRUG|Delayed Metformin|
219287515|NCT02145559|DRUG|Sirolimus|
219287516|NCT02167009|DEVICE|Embosphere Microspheres|Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
219287517|NCT05945589|BEHAVIORAL|Singapore A-Health Intervention|The Singapore A-Health Intervention spanned 12 weeks, with each weekly session lasting for two hours. The program is structured around three thematic domains of the past, present, and future. In each thematic domain consisting of four weeks, participants were tasked with creating an artwork related to the theme and incorporating the learned art techniques. The structure of each thematic domain follows the same structure: the first week involved a 45-minute docent-led gallery tour on three selected pieces of artworks, followed by a 75-minute artist-led brainstorming session where participants were introduced to the techniques and discuss ideas on the artwork to be created. The subsequent three sessions involved further guidance from the artist and a scaffolded delivery of art techniques for participants to incorporate their learning to their artwork. At the end of each domain, there was a showcase where participants present their artwork.
219287518|NCT00728897|DRUG|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
219287519|NCT00728897|DRUG|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
219287520|NCT00111410|DRUG|Anakinra (r-metHuIL-1ra)|
219287521|NCT03162562|BIOLOGICAL|Oregovomab|Monoclonal antibody against CA 125
219287522|NCT03162562|DRUG|Poly ICLC|Immune adjuvant
219287523|NCT02893384|DRUG|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
219287524|NCT03235752|DRUG|TJ301 300mg|TJ301 300mg IV infusion
219287525|NCT03235752|DRUG|TJ301 600mg|TJ301 600mg IV infusion
219287526|NCT03235752|DRUG|Placebo|Placebo IV infusion
219287527|NCT00831129|DRUG|Rosiglitazone|4 mg daily
219287528|NCT00831129|DRUG|Placebo Rosiglitazone|1 tab daily
219287529|NCT00831129|DRUG|Simvastatin|40 mg daily
219287530|NCT02818725|DRUG|Chemotherapy|METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
219287531|NCT02818725|DRUG|Panitumumab|PANITUMUMAB: 6 mg/kg on day 2
219287532|NCT01877239|OTHER|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
219287533|NCT02513303|DRUG|Sirolimus|A single dose of sirolimus delivered locally
219287534|NCT02513303|PROCEDURE|AV Fistula Surgery|AV Fistula Surgery
219287535|NCT02513303|DEVICE|Sirolimus-eluting Collagen Implant (SeCI)|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
219287536|NCT00285025|DRUG|SR57667B|
219287537|NCT04716062|PROCEDURE|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
219287538|NCT04278014|PROCEDURE|ultrasound-guided continuous sciatic block with longitudinal approach|ultrasound-guided continuous sciatic block with longitudinal approach
219287539|NCT02237729|BIOLOGICAL|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
219287540|NCT02237729|BIOLOGICAL|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
219287541|NCT02237729|BIOLOGICAL|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
219287542|NCT01353651|DEVICE|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
219287543|NCT01353651|DEVICE|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
219287544|NCT00306267|DRUG|epoetin alfa|
219287545|NCT00464984|BEHAVIORAL|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
219287546|NCT02429453|DRUG|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
219287547|NCT02429453|BIOLOGICAL|Fresh Frozen Plasma|A pooled collection of plasma from donors
219287548|NCT04368364|DRUG|Intrathecal morphine sulfate (ITM)|Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
219287549|NCT04368364|DRUG|Bupivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
219287550|NCT04368364|DRUG|ropivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
219287551|NCT01992601|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
219287552|NCT01669577|PROCEDURE|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
219287553|NCT00183157|BEHAVIORAL|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
219287554|NCT00183157|BEHAVIORAL|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
219287555|NCT00183157|BEHAVIORAL|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
219287556|NCT04068233|OTHER|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
219287557|NCT04906629|BIOLOGICAL|INO-4201|One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
219287558|NCT04906629|BIOLOGICAL|Placebo|One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
219287559|NCT06363682|PROCEDURE|ERCP|ERCP of the biliary duct ou the pancreatic duct, with or without the use of a stent, in a context of gallstone or tumor or other
219287560|NCT06363682|PROCEDURE|endoscopic ultrasound|The use of endoscopic ultrasound in diverse situation with the necessity of using X rays
219287561|NCT06363682|PROCEDURE|gastroscopy|"The diverse procedure in witch scopy is use in orders to place or switch or remove an oesophageal or gastroduodenal stent during a gastroscopy.~Or for oesophageal or gastroduodenal dilatation."
219287562|NCT06363682|PROCEDURE|Colonoscopy|The diverse procedure in witch scopy is use during a colonoscopy
219287563|NCT06363682|PROCEDURE|placement of a nasojejunal tube|placement of a nasojejunal tube for enteral nutritional support
219287564|NCT04404127|DRUG|Basiliximab 20 milligram [Simulect]|Basiliximab
219287565|NCT04404127|OTHER|Normal Saline|No-Induction
219287566|NCT03339739|OTHER|Isometric mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
219287567|NCT03339739|OTHER|Isotonic mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
219287568|NCT03339739|BEHAVIORAL|Counseling group|subjects included in this group get an education brochure about the disorder and receive no further interventions
219287569|NCT00495105|BEHAVIORAL|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
219287570|NCT04473599|BEHAVIORAL|Uniform random message delivery|In this arm, the categories and timings of text-messages will be delivered to participants using a random schedule
219287571|NCT04473599|BEHAVIORAL|Reinforcement learning message delivery|In this arm, the categories and timings of text-messages will be chosen by a reinforcement learning algorithm
219287572|NCT04473599|BEHAVIORAL|Mood ratings only|In this arm, participants will monitor their mood daily and receive feedback on that mood randomly
219287573|NCT05052788|DEVICE|Optical coherence tomography angiography|"OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine ."
219287574|NCT04095559|DIAGNOSTIC_TEST|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
219287575|NCT04095559|DIAGNOSTIC_TEST|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
219287576|NCT04095559|DIAGNOSTIC_TEST|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
219287577|NCT03749018|DRUG|Cyclophosphamide|Given IV
219287578|NCT03749018|DRUG|Doxorubicin Hydrochloride|Given IV
219287579|NCT03749018|DRUG|Etoposide|Given IV
219287580|NCT03749018|BIOLOGICAL|Nivolumab|Given IV
219287581|NCT03749018|DRUG|Prednisone|Given PO
219287582|NCT03749018|BIOLOGICAL|Rituximab|Given IV
219287583|NCT03749018|DRUG|Vincristine Sulfate|Give IV
219287584|NCT05845281|PROCEDURE|Bupivakain + deksametazon Adjuvant|In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
219287585|NCT00856440|DRUG|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
219287586|NCT00856440|DRUG|Colyte|Lavage preparation for colonoscopy
219287587|NCT00856440|DRUG|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
219287588|NCT03212495|DRUG|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
219287589|NCT03212495|DRUG|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
219287590|NCT04647552|DRUG|Drug Steroid|hydrocortisone injection
219287591|NCT01283516|DRUG|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
219287592|NCT04369781|DIAGNOSTIC_TEST|transcutaneous oxygen pressure recording at rest|Recording of limb and chest transcutaneous oxygen pressure
219287593|NCT06502886|PROCEDURE|combined protocol of retention (bonded lingual retainer and vacuum formed retainers)|Combined bonded retainer and vacuum formed retainer
219287594|NCT06502886|PROCEDURE|Bonded lingual retainer|Bonded retainer
219287595|NCT04094441|OTHER|chest physiotherapy|chest physiotherapy
219287596|NCT06444204|DRUG|Rilzabrutinib|Rilzabrutinib tablet administered orally
219287597|NCT01098318|DIETARY_SUPPLEMENT|Herbal extract|340-1,360 mg daily
219287598|NCT01098318|DRUG|Sertraline|50-200 mg daily
219287599|NCT01098318|OTHER|Lactose monohydrate|1-4 capsules daily
219287600|NCT00599573|DRUG|ondansetron|Ondansetron 4mg BID for six weeks
219287601|NCT00860847|DIETARY_SUPPLEMENT|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
219287602|NCT00874692|OTHER|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
219287603|NCT03593551|COMBINATION_PRODUCT|five relaxation treatments and one control|Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
219296457|NCT06675825|DEVICE|BougieCap|The BougieCap is attached to the tip of the endoscope, offers direct visual and tactile control and the endoscope acts as a carrier of the radial and longitudinal force vectors for the dilation.
219287604|NCT03369327|DRUG|sofosbuvir and daclatasvir|"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg"
219287605|NCT04076189|PROCEDURE|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
219287606|NCT04076189|PROCEDURE|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
219287607|NCT05833100|DEVICE|CareSens PRO GK Blood Glucose/b-Ketone Monitoring system|"All BG results were compared to YSI 2300 reference method results obtained from subjects' capillary blood.~All Ketone results were compared to Randox Imola D-3-Hydroxybutyrate analyzer."
219287608|NCT00132873|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
219287609|NCT03001375|PROCEDURE|Laparoscopic high anterior resection splenic flexure mobilization|
219287610|NCT03001375|PROCEDURE|Laparoscopic high anterior resection without splenic flexure mobilization|
219287611|NCT00444275|DRUG|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
219287612|NCT00444275|DRUG|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
219287613|NCT02045875|DRUG|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
219287614|NCT03798041|BEHAVIORAL|Debridement Within 24 Hours After Surgery|Debrided within 24 hours after surgery
219287615|NCT01048801|DEVICE|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
219287616|NCT01048801|OTHER|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
219287617|NCT03775928|DRUG|Apatinib|apatinib 425mg qd po
219287618|NCT03775928|DRUG|capecitabine|capecitabine 1000mg/m2 bid d1-d14
219287619|NCT04690894|PROCEDURE|erector spinae block - caudal block|the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
219287620|NCT05313659|DRUG|Ketamine Hydrochloride|intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
219287621|NCT03030859|OTHER|Usual Care|Undergo usual care only
219287622|NCT03030859|OTHER|Usual Care plus LEF-SCP|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
219287623|NCT03030859|OTHER|Usual Care plus LEF-SCP plus Follow-up|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
219287624|NCT04224376|DEVICE|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
219287625|NCT01632540|DRUG|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
219287626|NCT01780259|DRUG|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
219287627|NCT01780259|DRUG|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
219287628|NCT01780259|DRUG|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
219287629|NCT04419922|BEHAVIORAL|Smartphone Contingency Management Intervention|Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
219287630|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
219287631|NCT00636740|DRUG|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
219287632|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
219287633|NCT01070446|DIETARY_SUPPLEMENT|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
219287634|NCT04650399|BIOLOGICAL|Active|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
219287635|NCT04650399|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
219287636|NCT01114880|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
219287637|NCT01114880|OTHER|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
219287638|NCT03656224|OTHER|Survey Administration|Ancillary studies
219287639|NCT00288002|BIOLOGICAL|trastuzumab|
219287640|NCT00288002|DRUG|capecitabine|
219287641|NCT00288002|DRUG|cyclophosphamide|
219287642|NCT00288002|DRUG|docetaxel|
219287643|NCT00288002|DRUG|epirubicin hydrochloride|
219287644|NCT00288002|PROCEDURE|adjuvant therapy|
219287645|NCT00288002|PROCEDURE|conventional surgery|
219287646|NCT00288002|PROCEDURE|neoadjuvant therapy|
219287647|NCT03807960|OTHER|written form|The written form which include PCA usage information.
219287648|NCT03807960|OTHER|video|The video about PCA usage
219287649|NCT03807960|OTHER|routine care|The routine description about PCA usage
219287650|NCT02654353|PROCEDURE|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
219287651|NCT06528847|DRUG|Benmelstobart|The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.
219287652|NCT05508204|DRUG|BION-1301|A solution for SC injection administered as a single dose
219287653|NCT04218786|DRUG|Colchicine|The tablet will be given once daily for the span of the study
219287654|NCT04218786|DRUG|Placebo oral tablet|The tablet will be given once daily for the span of the study
219287655|NCT01623193|OTHER|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
219287656|NCT01623193|PROCEDURE|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
219287657|NCT05413239|BEHAVIORAL|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting \~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
219287658|NCT02613234|DEVICE|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
219287659|NCT02613234|DEVICE|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
219287660|NCT02870829|DRUG|menaquinone-7|Oral supplement given post dialysis 3x/week
219287661|NCT03178370|DEVICE|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
219287662|NCT00447564|DRUG|Probuphine|4 implants
219287663|NCT00447564|DRUG|placebo|4 implants
219287664|NCT05381545|BEHAVIORAL|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.
219287665|NCT05381545|BEHAVIORAL|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
219287666|NCT02397382|DRUG|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.
219287667|NCT02397382|DRUG|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
219287668|NCT02397382|DRUG|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
219287669|NCT02397382|DRUG|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
219287670|NCT02397382|DRUG|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
219287671|NCT02397382|DRUG|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
219287672|NCT00450541|BEHAVIORAL|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
219287673|NCT00450541|BEHAVIORAL|Interview|Interview lasting about 30 minutes.
219287674|NCT00222872|DRUG|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
219287675|NCT00222872|DRUG|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
219287676|NCT00586612|BIOLOGICAL|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
219287677|NCT00586612|BIOLOGICAL|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
219287678|NCT00586612|BIOLOGICAL|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
219287679|NCT00586612|BIOLOGICAL|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
219287680|NCT02903563|OTHER|observational|
219287681|NCT02839889|DRUG|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
219287682|NCT02839889|DRUG|Placebo|Placebo once daily for two weeks, followed by two week open-label period
219287683|NCT00315991|BEHAVIORAL|Blood Glucose Awareness Training for Parents|
219287684|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
219287685|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
219287686|NCT01406470|DRUG|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
219287687|NCT02738853|DEVICE|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
219287688|NCT02602639|DEVICE|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
219287689|NCT00413205|DRUG|Placebo|po daily
219287690|NCT00413205|DRUG|RAR Gamma|5mg po daily
219287691|NCT05512351|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
219287692|NCT02387190|OTHER|Telenursing monitoring|"The telenursing program protocol is based on:~1. Contact the patient by telephone, weekly;~2. Distribution and explanation of the educational booklet;~3. Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
219287693|NCT05276908|PROCEDURE|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
219287694|NCT05276908|PROCEDURE|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
219287695|NCT05276908|DRUG|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
219287696|NCT05276908|DRUG|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
219287697|NCT01109680|DRUG|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
219287698|NCT00081822|DRUG|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
219287699|NCT00081822|DRUG|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.
219287700|NCT02789644|DRUG|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
219287701|NCT03953755|PROCEDURE|Tricuspid valve repair|Tricuspid valve repair
219287702|NCT00659555|DRUG|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
219287703|NCT00659555|DRUG|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
219287704|NCT01940133|DRUG|PQR309|Dosing will be orally, once a day for the duration of the trial.
219287705|NCT06020183|DEVICE|Hybrid hyrax|these patents will be treated using Four mini-screws supported hybrid hyrax
219287706|NCT01891942|PROCEDURE|twitch by magstim|
219287707|NCT01008800|BEHAVIORAL|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey \& Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
219287708|NCT01008800|BEHAVIORAL|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy \& Grusec, 2001).
219287709|NCT02922504|BEHAVIORAL|Music intervention group|
219287710|NCT02922504|BEHAVIORAL|Controlled group|
219287711|NCT00072137|BIOLOGICAL|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
219287712|NCT00072137|BIOLOGICAL|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
219287713|NCT00072137|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy
219287714|NCT00072137|OTHER|Pharmacological Study|Correlative studies
219287715|NCT00072137|OTHER|Laboratory Biomarker Analysis|Correlative studies
219287716|NCT03330626|DEVICE|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
219287717|NCT03330626|OTHER|IO group|Fluid removal are guided by intake-output balance.
219287718|NCT01803282|DRUG|Andecaliximab|Administered intravenous infusion
219287719|NCT01803282|DRUG|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
219287720|NCT01803282|DRUG|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
219287721|NCT01803282|DRUG|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
219287722|NCT01803282|DRUG|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
219287723|NCT01803282|DRUG|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
219287724|NCT01803282|DRUG|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
219287725|NCT01803282|DRUG|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
219287726|NCT01803282|DRUG|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
219287727|NCT01803282|DRUG|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
219287728|NCT01803282|DRUG|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
219287729|NCT04502017|DRUG|ASA plus Clopidogrel|OAC (6 weeks) + DAPT (until 6 months) + ASA
219287730|NCT04502017|DRUG|Genetic-Tailored AntiThrombotic Strategy|Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype
219287731|NCT04502017|DRUG|Half-Dose of novel OAC|Half Dose of novel OAC post-device Implantation
219287732|NCT01743989|DRUG|Nilotinib|Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
219287733|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
219287734|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
219287735|NCT00515723|DRUG|risperidone|randomized to 12 week trial of risperidone.
219287736|NCT00515723|DRUG|olanzapine|randomized to 12 week trial of olanzapine.
219287737|NCT00515723|DRUG|quetiapine|randomized to 12 week trial of quetiapine.
219287738|NCT00515723|DRUG|ziprasidone|randomized to 12 week trial of ziprasidone.
219287739|NCT03193775|BIOLOGICAL|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
219287740|NCT02235311|DRUG|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
219287741|NCT00566605|PROCEDURE|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty \[IEK\])
219287742|NCT00566605|PROCEDURE|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
219287743|NCT04496934|BEHAVIORAL|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
219287744|NCT06336252|BEHAVIORAL|Digital nudging intervention target to change behavior|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
219287745|NCT05540613|BEHAVIORAL|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
219287746|NCT05540613|BEHAVIORAL|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
219287747|NCT05540613|BEHAVIORAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
219287748|NCT06620848|DRUG|HRS-4642 monotherapy|HRS-4642 will be administrated per dose level in which the patients are assigned.
219287749|NCT06620848|DRUG|HRS-4642 and adebrelimab combination therapy|HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
219287750|NCT04092010|BEHAVIORAL|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
219287751|NCT04092010|BEHAVIORAL|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
219287752|NCT04092010|BEHAVIORAL|Usual care|Normal services provided children and their mothers in Head Start
219287753|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
219287754|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
219287755|NCT02626455|DRUG|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
219287756|NCT02626455|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
219287757|NCT02626455|DRUG|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
219287758|NCT02626455|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
219287759|NCT02626455|DRUG|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
219287760|NCT02626455|DRUG|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
219287761|NCT02626455|DRUG|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
219287762|NCT02626455|DRUG|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
219287763|NCT00043953|DRUG|Lopinavir/ritonavir|
219287764|NCT00043953|DRUG|Saquinavir mesylate|
219287765|NCT00043953|DRUG|Lamivudine/zidovudine|
219287766|NCT01224470|DRUG|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
219287767|NCT01744470|DRUG|Tacrolimus targeted half-dose|
219287768|NCT01744470|DRUG|Tacrolimus targeted plain dose|
219287769|NCT04237311|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
219287770|NCT04237311|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb\> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).
219287771|NCT01344551|DIETARY_SUPPLEMENT|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
219287772|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete expressive disclosure writing
219287773|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete benefit finding writing
219287774|NCT02339870|OTHER|Questionnaire Administration|Ancillary studies
219287775|NCT02339870|OTHER|Sham Intervention|Complete writing on an emotionally neutral topic
219287776|NCT02127138|DEVICE|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
219287777|NCT01937026|DRUG|Baricitinib|Administered orally
219287778|NCT01937026|DRUG|Probenecid|Administered orally
219287779|NCT04902183|DRUG|CovenD24|The drug will be administrated once daily for 5 days
219287780|NCT06546722|PROCEDURE|Transversus Thoracic Plane Block|The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
219287781|NCT02447653|DEVICE|G7 HA Acetabular Component|G7 HA Acetabular Component
219287782|NCT02447653|DEVICE|G7 PPS Acetabular Component|G7 PPS Acetabular Component
219287783|NCT05550753|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
219287784|NCT05550753|BEHAVIORAL|No intervention - placebo control|No intervention - placebo control
219287785|NCT04168281|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|instead of PCI patients will be followed-up with MRI
219287786|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
219287787|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
219287788|NCT06195462|OTHER|Laying on of hands with intention health (LHHI)|The participants will receive systemic acupuncture. The no healers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
219287789|NCT06195462|OTHER|Laying on of hands by spiritist passe|The participants will receive systemic acupuncture. The healers will prepare before the start with prayer for connection with Good Spirits and will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
219287790|NCT06195462|OTHER|Control|The participants will receive systemic acupuncture and they not receive the laying on of hands.
219287791|NCT04232267|DEVICE|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
219287792|NCT05569213|DIAGNOSTIC_TEST|motor evoked potentials|see previous descriptions
219287793|NCT05333874|DRUG|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
219287794|NCT05333874|OTHER|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
219287795|NCT03228147|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given PO
219287796|NCT03228147|OTHER|Questionnaire Administration|Ancillary studies
219287797|NCT04126252|DRUG|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
219287798|NCT04126252|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
219287799|NCT04126252|COMBINATION_PRODUCT|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
219287800|NCT04126252|OTHER|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
219287801|NCT04455503|DRUG|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
219287802|NCT04455503|DRUG|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
219287803|NCT04455503|DRUG|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
219287804|NCT03166995|OTHER|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
219287805|NCT03166995|OTHER|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
219287806|NCT00000367|DRUG|Treatment of depression|
219287807|NCT00000367|BEHAVIORAL|Suicide prevention intervention|
219287808|NCT00000367|DRUG|Suicide prevention treatment|
219287809|NCT04816123|DRUG|[14C]Donafenib|Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
219287810|NCT04911478|GENETIC|ADI-001|No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
219287811|NCT03381677|DEVICE|Pedicle Lengthening Osteotomy with Altum® Device|Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
219287812|NCT03381677|DEVICE|Control|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
219287813|NCT05250427|OTHER|No treatment given|No treatment given
219287814|NCT04165044|PROCEDURE|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
219287815|NCT04165044|PROCEDURE|Connective tissue graft plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
219287816|NCT01735227|DRUG|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
219287817|NCT01735227|DRUG|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
219287818|NCT01187381|DRUG|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
219287819|NCT00407862|DRUG|Telmisartan 80 mg|
219287820|NCT00407862|DRUG|Losartan 50 mg|
219287821|NCT04685837|OTHER|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
219287822|NCT03812042|DIAGNOSTIC_TEST|Enzyme assay and molecular sequencing|Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
219287823|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
219287824|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219287825|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219287826|NCT06417710|OTHER|Neurological Assessment|Clinical neurological assessment performed by 2 raters
219287827|NCT03197168|BEHAVIORAL|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
219287828|NCT03197168|BEHAVIORAL|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
219287829|NCT02630680|DRUG|Eziclen®/Izinova®|
219287830|NCT01853267|PROCEDURE|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
219287831|NCT01853267|PROCEDURE|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
219287832|NCT03455244|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
219287833|NCT03749317|DRUG|IVIEW-1201|IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
219287834|NCT03749317|DRUG|Placebo|Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
219287835|NCT05036980|DRUG|Trans Sodium Crocetinate|Single IV bolus
219287836|NCT00482157|DRUG|Vitamin D (Calcitriol)|
219287837|NCT00720031|BIOLOGICAL|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.~After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
219287838|NCT04080037|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
219287839|NCT02353364|OTHER|PGS|Embryos screened by the validated NGS technology CNV-Seq
219287840|NCT05764135|BEHAVIORAL|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
219287841|NCT00896597|DRUG|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
219287842|NCT00007670|DRUG|Carbamazepine|
219287843|NCT00007670|DRUG|Gabapentin|
219287844|NCT00007670|DRUG|Lamotrigine|
219287845|NCT00099749|DRUG|FTY 720|
219287846|NCT04554719|DRUG|68Ga-DOTA-FAPI|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
219287847|NCT04554719|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
219287848|NCT04554719|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
219287849|NCT03758547|DEVICE|in-exufflator technique|application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
219287850|NCT03758547|DEVICE|percussion technique|sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
219287851|NCT06203353|DIAGNOSTIC_TEST|diaphragm ultrasound monitoring|Ultrasound measure the diaphragm excursion, thickening fraction and maximal contraction and relaxation velocities
219287852|NCT03942692|OTHER|Phone call questionnaire|"Questionnaire for parents of subject about :~* the frequency of consultations with an allergist~* the information of the general practitioner or pediatrician~* the prescription of epinephrin auto-injector~* the frequency of renewal of epinephrin auto-injector~* the specialty of doctor who prescribed the renewal~* the implementation of specific measures in schools~* the frequency of renewal of specific measures in schools~* the number of recurrence of anaphylactic reaction~* the use of medical advice in case of recurrence of anaphylactic reaction"
219287853|NCT04287699|OTHER|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
219287854|NCT05157243|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
219287855|NCT05157243|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
219287856|NCT05157243|DRUG|Placebo|Two matching placebo tablets administered orally with food twice daily for 5 days
219287857|NCT05157243|OTHER|Standard of Care|Local standard of care for COVID-19
219287858|NCT01220245|PROCEDURE|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
219287859|NCT01220245|PROCEDURE|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
219287860|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
219287861|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
219287862|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
219287863|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
219287864|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
219287865|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
219287866|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
219287867|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
219287868|NCT06725069|OTHER|Neuromuscular Electrical Stimulation|NMES was performed using the Enraf Nonius Myomed 632X device. Both applications were performed 5 days/week for 4 weeks. NMES was performed with the patients in a sitting position and the affected arm resting on a table with the forearm supinated (Agonist group) / forearm pronated (Antagonist group). Surface electrodes (50x50 mm self-adhesive) were placed on the wrist and finger flexor/extensor muscle group. NMES parameters; Symmetric biphasic, pulse width 200 μs, on time 6 seconds (ramp up 1 second, ramp down 2 seconds), off time 12 seconds, stimulation intensity according to the patient's tolerance (not exceeding 90 mA), frequency 50 Hz and was adjusted to elicit contraction in the flexor and extensor muscles of the wrist and fingers.
219287869|NCT06725069|OTHER|Control (Standard treatment)|In addition to conventional treatment, participants were included in an occupational rehabilitation program for 20 minutes to improve upper extremity functions.
219287870|NCT06727968|PROCEDURE|Compression Stocking|Wear the compression stockin at least 6-8 hours/day
219287871|NCT06727968|PROCEDURE|Therapeutic exercise|Home-based exercise programm based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting, and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day.
219287872|NCT06727968|PROCEDURE|Self-massage|Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.
219287873|NCT06727968|PROCEDURE|Prevention measures|"General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC."
219287874|NCT06729047|DRUG|normal Saline|patients will receive placebo (normal saline)
219287875|NCT06729047|DRUG|Neostigmine|patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
219287876|NCT06729047|DRUG|Ketorolac|patients will receive ketorolac (0.5 mg/kg)
219287877|NCT06727474|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL) with EQ-5D-3L|The EQ-5D-3L and EQ-VAS questionnaires, administered at all visits, evaluated five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Responses generated a Health Status sequence and calculated the EQ-5D-3L Index. A visual analogue scale (VAS) rated health from 0 (worst) to 100 (best). Functional capacity was assessed using the Katz Index (IK) and Timed Up and Go (TUG), which measured the time to rise from a chair, walk 3 meters, and return. Anthropometric variables, measured by the same researcher (LP) at 1 month and 1 year, included limb circumferences using specific techniques. Muscle strength, evaluated with the EF-MRC scale, involved verbal commands for movement tests. Calf circumference was measured on the largest circumference area. Living conditions and work reintegration were recorded. Health issues detected during follow-up were referred to the clinic's coordinating physician for appropriate care.
219287878|NCT06891560|DRUG|Enfortumab Vedotin|intravenously on Days 1, 8 and 15 of a 28-day cycle
219287879|NCT01477580|BIOLOGICAL|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287880|NCT01477580|BIOLOGICAL|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287881|NCT01477580|BIOLOGICAL|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
219287882|NCT01477580|BIOLOGICAL|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287883|NCT01477580|BIOLOGICAL|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287884|NCT01477580|BIOLOGICAL|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
219287885|NCT01477580|BIOLOGICAL|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
219287886|NCT01477580|BIOLOGICAL|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287887|NCT01477580|BIOLOGICAL|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287888|NCT01477580|BIOLOGICAL|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287889|NCT01477580|BIOLOGICAL|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287890|NCT01477580|BIOLOGICAL|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
219287891|NCT01477580|BIOLOGICAL|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
219287892|NCT03345576|DEVICE|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
219287893|NCT03345576|DRUG|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
219287894|NCT07153874|OTHER|Physical exercise rehabilitation intervention|12 weeks of physical exercise intervention, including aerobic snd anaerobic exercise at home. 36 sessions of monitorized training with distance supervision.
219287895|NCT07155408|DRUG|Povidone-Iodine 10%|Preoperative skin antisepsis performed with 10% povidone-iodine solution according to standard surgical preparation guidelines before hair transplantation.
219287896|NCT07155408|DRUG|Povidone-Iodine + Rifampicin|Preoperative skin antisepsis performed with a combination of 10% povidone-iodine and rifampicin solution according to study-specific preparation guidelines before hair transplantation.
219287897|NCT07155668|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
219287898|NCT07155668|DEVICE|Autoinjector|The autoinjector is a single-dose, disposable, ready-to-use delivery device
219287899|NCT07154498|BEHAVIORAL|Conventional physiotherapy with Cognitive Behavior Therapy|Gentle exercises include stretching and strengthening exercises. Cognitive-behavioral therapy (CBT) sessions.
219287900|NCT07154498|COMBINATION_PRODUCT|Conventional physiotherapy|Gentle exercises include stretching and strengthening exercises mobilisation, soft tissue mobilisation Interventions was applied at two sessions per week, each session is about an hour total of 24 sessions. Assessment was done at baseline in the 6th week and 12th week.
219287901|NCT07154017|OTHER|Combination of Movement Representation Techniques with neural mobilization exercises|The experimental intervention will be an exposition of movement representation techniques in an established sequential order, consisting of action observation, implicit/explicit motor imagery and visual feedback with a mirror in combination with neural mobilization exercises.
219287902|NCT07154017|OTHER|Neural mobilization exercises|The control intervention will consist in three series of active neural mobilization exercises
219287903|NCT07153679|DEVICE|1064-nm Nd:YAG Picosecond Laser|Treatment was performed using 1064 nm Nd:YAG microlens array picosecond laser (Picocare 450, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
219287904|NCT07153679|DEVICE|1927-nm Fractional Thulium Laser|Treatment was performed using 1927-nm thulium fractional laser (Lavieen, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
219287905|NCT07153978|DEVICE|Effectivity of TFL on large renal stone|While literature studies on TFL have focused on the effect of stone size on laser efficacy parameters, the present study is important as it is a prospective study examining the effects of TFL lithotripsy on SFRs in stones \>1000 mm3.
219287906|NCT07154173|PROCEDURE|Biospecimen Collection Procedure|Collection of fecal samples from healthy volunteers, non-metastatic (M0) and metastatic (M1) colorectal cancer patients. Additionally, collection of tissue samples during surgery from operable patients (M0 and M1) for subsequent research analysis.
219287907|NCT07154758|OTHER|Screening for need of HFrEF GDMT implementation through SwedeHF|Screening for need of HFrEF GDMT implementation through SwedeHF
219287908|NCT07154641|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer is a surgical procedure that aims to restore active range of motion and stability of the shoulder in patients with massive rotator cuff tears. The tendon of the latissimus dorsi muscle is dettached from its insertion in the midbicipital groove of the humerus and reattached to the greater tubetosity. Therefore, the muscle acts as an external rotator, while the forces created pull the humeral head down and stabilize it in the glenoid.
219287909|NCT07154641|PROCEDURE|Superior capsular reconstruction|Superior capsular reconstruction is a surgical procedure that aims to restore shoulder stability in patients with massive rotator cuff tears. The superior capsule of the shoulder joint is attached to the greater tuberosity and is therefore often torn in cases of supraspinatus or infraspinatus tears. A fascia lata autograft is used to reconstruct the torn capsule, between the greater tuberosity and the glenoid. Thus, superior migration of the humeral head is prevented, and pain and functionality are improved.
219287910|NCT07154719|DRUG|Tirzepatide|GLP-1 based treatment for obesity
219287911|NCT07154719|BEHAVIORAL|Lifestyle toolkit|2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
219287912|NCT07155486|OTHER|Interview|Interview
219287913|NCT07155616|OTHER|Blood flow measurement|Intraoperative blood flow measurement
219287914|NCT07156097|OTHER|Mediterranean-style Diet (SAFF)|Participants followed a 4-week Mediterranean-style dietary pattern (SAFF), characterized by high intake of vegetables, fruits, whole grains, olive oil, and lean protein sources. This arm served as a comparator for the boron-rich diet.
219287915|NCT07156097|OTHER|Boron-rich Diet|Participants assigned to this arm will follow a boron-rich dietary pattern for 4 weeks. The diet includes foods naturally high in boron (e.g., dried fruits, nuts, legumes, and boron-rich water). Daily dietary intake will be monitored and adjusted to ensure consistent boron exposure.
219287916|NCT07155304|PROCEDURE|percutaneous sigmoid colon fixation|after endoscopic sigmoid colon untwisting , percutaneous colon fixation using anchor device
219287917|NCT06180642|OTHER|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
219287918|NCT06180642|OTHER|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
219287919|NCT05812820|COMBINATION_PRODUCT|LiveSpo DIA30|LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
219287920|NCT05812820|COMBINATION_PRODUCT|LiveSpo CLAUSY|LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
219287921|NCT05812820|OTHER|RO|"Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle"
219287922|NCT06225908|PROCEDURE|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
219287923|NCT06003231|DRUG|disitamab vedotin|Given into the vein (IV, intravenous) every 2 weeks
219287924|NCT04852341|DEVICE|Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth|observation
219287925|NCT01882543|DRUG|AQX-1125|Synthetic SHIP1 activator
219287926|NCT01882543|DRUG|Placebo|Double blind placebo capsule
219287927|NCT01774877|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
219287928|NCT01774877|DRUG|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
219287929|NCT05199987|BEHAVIORAL|Standard Occupational Therapy|Standard occupational therapy sessions include patient therapeutic education (implementation of strategies and/or technical aids promoting autonomy and independence), walking and stair exercises in real-life conditions (weighted shopping bag, unstable ground, ...), as well as work on activities of daily living aiming to improve toileting skills (includes individual assessment, the use of technical aids depending of this assessment, and personalised strategies to conserve energy).
219287930|NCT05199987|BEHAVIORAL|Occupational Therapy with Breathing Control Exercises|Includes the same treatment than the one described in standard occupation therapy but with the addition of 30-minute sessions per day on breathing control exercises. These exercises included the reproduction of gestures reproducing daily activities and simultaneous explanations of breathing techniques that the patient can perform in order to set up strategies for saving breath during exercise.
219296458|NCT06675825|DEVICE|Savary-Bougie (A) or balloon dilation (B)|"A: In the Savary- Bougie treatment, dilators of different sizes are advanced to dilate the stenosis. The same procedure is then repeated with the next larger dilator, with the position of the dilator being checked radiologically each time.~B: In the case of balloon dilation, a balloon is inserted and inflated at the level of the stenosis. Depending on the age of the child and possibly also the etiology of the stenosis, different balloons sizes are applied, which are then maintained inflated for about one until three minutes and the respective pressure. This procedure could take place under endoscopic or radiological control."
219287931|NCT04222764|DIAGNOSTIC_TEST|Real-time three-dimensional echocardiography|"The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers."
219287932|NCT03505177|DIETARY_SUPPLEMENT|Chitin-glucan fiber|4.5g per day of chitin-glucan during 3 weeks
219287933|NCT02315300|DEVICE|medilog® DARWIN FD12|
219287934|NCT02315300|DEVICE|Continuous Glucose Monitoring|
219287935|NCT04396652|PROCEDURE|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
219287936|NCT04396652|PROCEDURE|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
219287937|NCT04396652|PROCEDURE|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
219287938|NCT02413853|DRUG|CBP/beta-catenin Antagonist PRI-724|Given IV
219287939|NCT02413853|BIOLOGICAL|Bevacizumab|Given IV
219287940|NCT02413853|DRUG|Leucovorin Calcium|Given IV
219287941|NCT02413853|DRUG|Oxaliplatin|Given IV
219287942|NCT02413853|DRUG|Fluorouracil|Given IV
219287943|NCT02413853|OTHER|Laboratory Biomarker Analysis|Correlative studies
219287944|NCT04659577|BEHAVIORAL|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
219287945|NCT05205187|PROCEDURE|Healthy control specimen collection|Collecting blood and feces from healthy population.
219287946|NCT05205187|PROCEDURE|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
219287947|NCT05205187|PROCEDURE|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
219287948|NCT04725877|BIOLOGICAL|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
219287949|NCT04725877|DRUG|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
219287950|NCT02504983|DRUG|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
219287951|NCT02504983|PROCEDURE|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
219287952|NCT06090188|OTHER|A Culture-Based Multicomponent Cognitive Training Program|Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
219287953|NCT05799651|BIOLOGICAL|Glycovax-002|Intramuscular injection of vaccine against SARS-CoV-2
219287954|NCT05550545|OTHER|cohort study|Please note that this is an observational study; not applicable
219287955|NCT04458805|DRUG|NX-13 250 mg|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
219287956|NCT04458805|DRUG|Placebo|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
219287957|NCT04963790|BEHAVIORAL|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
219287958|NCT04963790|OTHER|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
219287959|NCT02432508|DEVICE|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
219287960|NCT02432508|DEVICE|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
219287961|NCT05630820|DRUG|Bepirovirsen|Bepirovirsen will be administered.
219287962|NCT05630820|OTHER|Placebo|Matching placebo will be administered.
219287963|NCT03002220|DRUG|radium-223|Radium-223 at a dose of 55 kBq
219287964|NCT04201054|DRUG|Fluconazole|50 mg of fluconazole administered orally in a single dose.
219287965|NCT01425905|OTHER|The Blues Program|
219287966|NCT01425905|OTHER|Hey Durham|
219287967|NCT00926497|OTHER|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
219287968|NCT04110704|PROCEDURE|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
219287969|NCT03143647|OTHER|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
219287970|NCT04854876|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA+SFC)|The food supplement 5-Aminolevulinic acid phosphate and Sodium ferrous citrate (5-ALA-Phosphate + SFC) will be administered orally daily for 28 days. The dose will be in total 3 capsules of 50 mg 5-ALA-Phosphate and 28.68 mg SFC (3.04 mg as Fe) per day, 2 capsules in the morning and 1 capsule in the evening resulting in 150 mg 5-ALA-Phosphate and 86.04 mg SFC ( 9.12 mg as Fe).
219287971|NCT05926440|BIOLOGICAL|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
219178150|NCT06196099|DEVICE|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
219287972|NCT05926440|BIOLOGICAL|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
219287973|NCT06342414|DIAGNOSTIC_TEST|ELUCIDATE|ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
219287974|NCT00693667|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
219287975|NCT02225132|DRUG|Hydroxyurea|"The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium."
219287976|NCT05814588|OTHER|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
219287977|NCT05814588|OTHER|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
219287978|NCT01302080|DRUG|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
219287979|NCT01302080|BEHAVIORAL|psychotherapy|Non-interventional study- as above
219287980|NCT03729375|DRUG|10cc injection of bupivacaine|10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
219287981|NCT03729375|DRUG|20cc injection of bupivacaine|20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
219287982|NCT03425097|DRUG|Fexofenadine|Fexofenadine 180 mg in the morning
219287983|NCT03425097|DRUG|Placebo - Cap|Placebo cap in the morning
219287984|NCT00106210|BEHAVIORAL|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
219287985|NCT00106210|BEHAVIORAL|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
219287986|NCT00817713|DRUG|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
219287987|NCT05537168|PROCEDURE|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
219287988|NCT00475124|DEVICE|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
219287989|NCT00475124|DEVICE|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
219287990|NCT00449618|DRUG|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
219287991|NCT00449618|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
219287992|NCT00449618|PROCEDURE|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
219287993|NCT00449618|DRUG|Placebo|Use of placebo on awakening versus bedtime
219287994|NCT05656235|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)
219287995|NCT05656235|DRUG|Pembrolizumab|Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)
219287996|NCT05293756|BEHAVIORAL|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
219287997|NCT06609824|BEHAVIORAL|Leer te Durven!|'Leer te Durven!' is an eight-week preventative group training for children between the ages of 8 and 12. This training is evidence-based and is based on the principles of Cognitive Behavioral Therapy. With this program children learn to stand up for themselves in a safe environment, to face the situations that they find exciting and to be more confident in their own abilities. The training consists, among other things, of psychoeducation, exposure, and relaxation.
219287998|NCT05434052|OTHER|Turkish Validity and Reliability of The CIQ-R Scale|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
219287999|NCT04806438|OTHER|Group A|Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
219288000|NCT04806438|OTHER|Group B|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice
219288001|NCT05401006|DRUG|Acitretin 25Mg Cap|Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
219288002|NCT05401006|RADIATION|Narrowband ultraviolet B|Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
219288003|NCT01281059|DEVICE|BreathID - Breath Test - 13C Octanoate|
219288004|NCT02324608|BIOLOGICAL|cetuximab|Given IV
219288005|NCT02324608|OTHER|laboratory biomarker analysis|Correlative studies
219288006|NCT03434990|OTHER|Spinal manipulation/myofascial release|The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
219288007|NCT03434990|OTHER|Spinal manipulation|The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
219288008|NCT04761900|DIAGNOSTIC_TEST|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
219288009|NCT04338659|BIOLOGICAL|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
219296459|NCT00727311|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
219288010|NCT05374200|OTHER|Mind-body intervention with 1-1 support from study personnel|"The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (\~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered."
219288011|NCT05838560|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
219288012|NCT05838560|DRUG|quercetin|The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
219288013|NCT02040584|DRUG|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
219288014|NCT02040584|DRUG|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
219288015|NCT03457870|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
219288016|NCT03457870|BEHAVIORAL|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
219288017|NCT03457870|BEHAVIORAL|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
219288018|NCT05094024|DIETARY_SUPPLEMENT|Central kitchen-prepared version of MDCF-2|Kitchen-prepared MDCF-2 containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be freshly prepared in central kitchens on a daily basis and provided to participants on the same day. Every child in this arm will be offered 25g of the MDCF-2 formulation twice daily.
219288019|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with green banana powder|This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 21.77g of the formulation twice daily.
219288020|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with sweet potato|This shelf-stable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 23.34g of the MDCF formulation twice daily.
219288021|NCT05094024|DIETARY_SUPPLEMENT|Freshly reconstituted MDCF-2 ingredients|This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding session. Every child in this arm will be offered 21.72g of the formulation twice daily.
219288022|NCT05094024|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF) arm|Locally-produced ready-to-use supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean flour, sugar, and micronutrient mix. Every child in this arm will be offered 25g of the formulation twice daily.
219288023|NCT06466720|BEHAVIORAL|Neurocognitive testing|The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
219288024|NCT06466720|BEHAVIORAL|Quality of Life questionnaire|The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
219288025|NCT06466720|RADIATION|Stereotactic radiosurgery|This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
219288026|NCT04285138|OTHER|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
219288027|NCT04285138|OTHER|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror \[Figure 1\]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
219288028|NCT01410123|OTHER|Integrated Stepped Care (ISC)|"1. At risk drinking:~   Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~2. Alcohol abuse/dependence:~   Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~3. Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
219288029|NCT01410123|OTHER|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
219288030|NCT06436443|OTHER|SMS Counseling|In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
219288031|NCT04290559|PROCEDURE|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
219288032|NCT06040593|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
219288033|NCT01802567|DEVICE|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
219288034|NCT02488538|DRUG|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
219288035|NCT02488538|DRUG|Fluoxetine|women will receive oral fluoxetine 20 mg daily
219288036|NCT02488538|DRUG|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
219288037|NCT02488538|DRUG|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
219288038|NCT02488538|PROCEDURE|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
219288039|NCT00588978|BEHAVIORAL|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
219288040|NCT02626988|BEHAVIORAL|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
219288041|NCT01001182|OTHER|non interventional|non interventional
219288042|NCT03825731|BIOLOGICAL|GC022|GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
219288043|NCT04786964|DRUG|Cosibelimab|IV infusion
219288044|NCT04786964|DRUG|Cisplatin|IV infusion
219288045|NCT04786964|DRUG|Carboplatin|IV infusion
219288046|NCT04786964|DRUG|Pemetrexed|IV infusion
219288047|NCT04786964|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
219288048|NCT04786964|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
219288049|NCT04786964|DRUG|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
219288050|NCT06788600|DRUG|EBV mRNA vaccine (WGc-043)|"Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.~The specific dose of mRNA vaccine will be determined according to the experimental group."
219288051|NCT04371120|DIAGNOSTIC_TEST|BICS Q|assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
219288052|NCT02591953|PROCEDURE|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
219288053|NCT02591953|PROCEDURE|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
219288054|NCT02591953|DRUG|Methylprednisolone|Corticosteroid used in injection (40 mg)
219288055|NCT02591953|DRUG|Lidocaine 1%|Anesthesic used in injection
219288056|NCT01603901|DEVICE|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
219288057|NCT00673959|OTHER|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
219288058|NCT00673959|OTHER|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
219288059|NCT02753153|PROCEDURE|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
219288060|NCT02753153|PROCEDURE|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
219288061|NCT02753153|PROCEDURE|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
219288062|NCT05870605|OTHER|No Intervention|This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.
219288063|NCT04157725|DRUG|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
219288064|NCT04157725|DRUG|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
219288065|NCT04028089|BEHAVIORAL|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
219288066|NCT04028089|OTHER|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
219288067|NCT00615745|DRUG|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
219288068|NCT03969381|RADIATION|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
219288069|NCT03167359|RADIATION|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
219288070|NCT00162448|DRUG|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
219288071|NCT00162448|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
219288072|NCT03735589|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
219288073|NCT03735589|BIOLOGICAL|Autologous Natural Killer Cell-like CTLs|Given IP
219288074|NCT03649438|DRUG|131 I-Metaiodobenzylguanidine|"* Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
219288075|NCT03649438|DRUG|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
219288076|NCT03649438|DRUG|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
219288077|NCT05820165|RADIATION|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
219288078|NCT05820165|RADIATION|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
219288079|NCT05820165|RADIATION|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
219288080|NCT05820165|RADIATION|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
219288081|NCT05820165|RADIATION|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
219288082|NCT03805542|COMBINATION_PRODUCT|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
219288083|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
219288084|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
219288085|NCT01896557|DRUG|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
219288086|NCT01896557|DRUG|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
219288087|NCT01896557|DRUG|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
219288088|NCT02811718|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
219288089|NCT02811718|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
219288090|NCT03635203|DEVICE|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
219288091|NCT00013247|BEHAVIORAL|Prostate Cancer Screening Education|
219288092|NCT01221636|DRUG|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
219288093|NCT01205854|DEVICE|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
219288094|NCT01230346|OTHER|questionnaire administration|Ancillary studies
219288095|NCT01230346|OTHER|survey administration|Ancillary studies
219288096|NCT01230346|OTHER|counseling intervention|Telephone intervention
219288097|NCT01230346|OTHER|educational intervention|Telephone intervention
219288098|NCT05597813|PROCEDURE|microneedling|15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
219288099|NCT05597813|PROCEDURE|microneedling with topical timolol 0.5%|15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
219288100|NCT04449380|DRUG|Interferon-ß-1a|IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
219288101|NCT04449380|COMBINATION_PRODUCT|Standard of Care (SOC)|Any pharmacological (e.g. antibiotics, etc.) and non-pharmacological (e.g. oxygen, ventilation, etc.) treatments prescribed on clinical grounds
219288102|NCT02564380|DRUG|Pembrolizumab|
219288103|NCT02564380|DRUG|Placebo|
219288104|NCT00681148|DRUG|Botox injection|Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
219288105|NCT00681148|DRUG|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
219288106|NCT03021980|BEHAVIORAL|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
219288107|NCT04371523|DRUG|Apo-Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
219288108|NCT04371523|DRUG|Matched Placebo|Matching Placebo
219288109|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (250 mg)|Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
219288110|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (500 mg)|Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
219288111|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (1000 mg)|Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
219288112|NCT05611827|DIETARY_SUPPLEMENT|Regular/standard Quercetin (500 mg)|Total dose of 500 mg of quercetin
219288113|NCT00013260|PROCEDURE|Integrated model of primary care|
219288114|NCT01514708|BIOLOGICAL|AdimFlu-S Influenza Vaccine|Suspension for injection
219288115|NCT03183219|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
219288116|NCT03183219|BIOLOGICAL|γδ T cell|γδ T cells will be used against Liver Cancer
219288117|NCT03183219|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
219288118|NCT05353205|DRUG|Flumatinib mesylate tablets (400mg)|Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
219288119|NCT05353205|DRUG|Flumatinib mesylate tablets (600mg)|Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
219288120|NCT01517295|DRUG|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
219288121|NCT02819427|DEVICE|Near Infra Red Spectroscopy (NIRS)|
219288122|NCT02819427|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
219288123|NCT00281515|DRUG|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
219288124|NCT06031103|PROCEDURE|mini-PCNL procedure|"Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age"
219288125|NCT06031103|PROCEDURE|RIRS procedure|RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
219288126|NCT03966768|DEVICE|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
219288127|NCT03966768|DEVICE|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
219288128|NCT00958503|DRUG|Thiamphenicol|750 and 1500 mg/day;tablets
219288129|NCT00958503|DRUG|Placebo|Matched tablets without active ingredient
219288130|NCT01749111|DRUG|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
219288131|NCT01749111|DRUG|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
219288132|NCT02840344|BEHAVIORAL|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
219288133|NCT02840344|BEHAVIORAL|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
219288134|NCT01511783|DRUG|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
219288135|NCT01511783|DRUG|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
219288136|NCT03798782|PROCEDURE|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
219288137|NCT03798782|PROCEDURE|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
219288138|NCT04237168|DIAGNOSTIC_TEST|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
219288139|NCT04110353|OTHER|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
219288140|NCT04110353|OTHER|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
219288141|NCT04110353|OTHER|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
219288142|NCT01955967|DRUG|Lidocaine|
219288143|NCT05622916|DRUG|Topical Ethanol Extract (Piper crocatum)|Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
219288144|NCT05622916|DRUG|Trichloroacetic Acid Topical|Trichloroacetic acid topical 90%
219288145|NCT05410639|OTHER|online education program|The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.
219288146|NCT05410639|OTHER|no online education program|Parents and their infants in the control group did not receive any online education program
219288147|NCT00639782|DEVICE|On-X Heart valve replacement|On-X Heart valve replacement
219288148|NCT00639782|DEVICE|SJM Heart valve replacement|SJM Heart valve replacement
219288149|NCT05451823|DEVICE|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
219288150|NCT06092424|BEHAVIORAL|Relocation from HA to LA|Patients will be relocated by bus from Quito (2840m) to Pedernales (sea level) and have investigations at both altitudes
219288151|NCT01644448|OTHER|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
219288152|NCT01644448|OTHER|Standard Therapy|Topical Applications as directed by the investigator
219288153|NCT04627779|DRUG|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
219288154|NCT02236988|DRUG|Apremilast Immediate Release|30 mg immediate release tablets
219288155|NCT02236988|DRUG|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
219288156|NCT02236988|DRUG|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
219288157|NCT02236988|DRUG|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
219288158|NCT02236988|DRUG|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
219288159|NCT02236988|DRUG|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
219288160|NCT02236988|DRUG|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
219288161|NCT02236988|DRUG|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
219288162|NCT02236988|DRUG|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
219288163|NCT02236988|DRUG|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
219288164|NCT02236988|DRUG|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
219288165|NCT02236988|DRUG|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
219288166|NCT02236988|DRUG|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
219288167|NCT04032613|OTHER|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
219288168|NCT00011752|DRUG|FCWAY|
219288169|NCT03526276|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
219288170|NCT03526276|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily
219288171|NCT03526276|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
219288172|NCT02404727|PROCEDURE|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
219288173|NCT02404727|DEVICE|Avantage® Cup|
219296460|NCT00727311|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
219288174|NCT04334187|BEHAVIORAL|Mindfulness Based addition treatment|The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
219288175|NCT01659853|DRUG|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
219288176|NCT01659853|DRUG|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
219288177|NCT00961480|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
219288178|NCT00961480|DRUG|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
219288179|NCT00961480|DRUG|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
219288180|NCT00961480|DRUG|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
219288181|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
219288182|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
219288183|NCT00961480|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
219288184|NCT00961480|DRUG|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
219288185|NCT04556903|COMBINATION_PRODUCT|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
219288186|NCT04556903|COMBINATION_PRODUCT|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~* Block placement- 10minutes~* Peg targeting- 10 minutes~* Peg inversion-10miutes~* Transferring objects- 10minutes"
219288187|NCT03053518|DEVICE|Abbott Freestyle Libre Pro|A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
219288188|NCT03053518|BEHAVIORAL|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
219288189|NCT02071290|DEVICE|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
219288190|NCT04938167|OTHER|95% - 99% SpO2 target|If the infant is randomized to the intervention arm, the oxygen saturation goal will be changed from the standard goal of 91% - 95% to the experimental goal of 95%-99%. The treating medical team will then adjust the oxygen and respiratory support to maintain these goals (SpO2 alarm levels will be set at 93% and 100%).
219288191|NCT00656708|OTHER|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
219288192|NCT06502730|BEHAVIORAL|Creating Opportunities for Parent Empowerment (COPE) Program|It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
219288193|NCT04578353|DEVICE|The AquaPass System|The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
219288194|NCT04907019|DRUG|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
219288195|NCT04374539|BIOLOGICAL|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick \<50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
219288196|NCT04374539|DRUG|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
219288197|NCT05951270|DIETARY_SUPPLEMENT|Apple Polyphenols|ApplePhenon® is prepared from unripe green apples (malus domestica) and contains a large amounts of polyphenols. The supplement contains 63.8% procyanidins, 12.4% flavon-3-ols, 6.5% chalcones and 10.8% phenolcarboxylic acids
219288198|NCT05951270|OTHER|Control|The placebo used in this study is 1100 mg maltodextrin (Avebe, Veendam, the Netherlands). This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
219288199|NCT03374449|PROCEDURE|continuation of the RAS-inhibitors|drug intake
219288200|NCT03374449|PROCEDURE|discontinuation of the RAS-inhibitors|no drug intake
219288201|NCT04472416|DEVICE|VRD in addition to standardized analgesic protocol|Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
219288202|NCT04489953|OTHER|Viral Load|For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time
219288203|NCT04326322|DIETARY_SUPPLEMENT|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
219288204|NCT04482309|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
219288205|NCT06145854|DRUG|Cabotegravir Injection [Apretude]|Apretude for PrEP
219288206|NCT04702321|OTHER|Procedure: Biospecimen Collection|Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction
219288207|NCT04702321|OTHER|Procedure: Medical Chart Review|Collection of clinical data
219288208|NCT06161727|OTHER|HPV exposure|According to group descriptions
219288209|NCT06224062|BIOLOGICAL|SARS-CoV-2|Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
219288210|NCT06224062|BIOLOGICAL|Adenovirus (AdV)|Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
219288211|NCT06224062|BIOLOGICAL|Rhinovirus|RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
219288212|NCT06224062|BIOLOGICAL|No Intervention|no infection
219288213|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
219288214|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
219288215|NCT05187364|BEHAVIORAL|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
219288216|NCT05870774|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
219288217|NCT05870774|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
219288218|NCT06120985|DEVICE|Countertop pitcher water filter|Point-of-use drinking water filter
219288219|NCT05803018|DRUG|BL-B01D1|Administration by intravenous infusion
219288220|NCT05560243|BEHAVIORAL|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
219288221|NCT06504394|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|SC injection
219288222|NCT04903262|PROCEDURE|Ultraprotective ventilation with Extracorporeal CO2 removal|HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.
219288223|NCT04903262|PROCEDURE|Conventional protective ventilation|"Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)"
219288224|NCT04004468|BEHAVIORAL|Resistance Training|Standard barbell resistance training programs
219288225|NCT06010433|DEVICE|CERAMENT G|"* Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~* Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
219288226|NCT04116892|PROCEDURE|the Cover group|The internal limiting membrane around the MH was left to cover the hole
219288227|NCT04116892|PROCEDURE|the Fill group|The internal limiting membrane around the MH was left to fill the hole
219288228|NCT04116892|PROCEDURE|the peeling group|the internal limiting membrane was discarded
219288229|NCT05945485|BIOLOGICAL|DCVC H1 HA mRNA vaccine|A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
219288230|NCT05945485|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
219288231|NCT05945485|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
219288232|NCT06612645|BIOLOGICAL|B7H3-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
219288233|NCT03335839|DRUG|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
219288234|NCT03335839|OTHER|Saline|Placebo
219288235|NCT06643728|DRUG|Bimagrumab|Administered SC
219288236|NCT06643728|DRUG|Tirzepatide|Administered SC
219288237|NCT06643728|DRUG|Bimagrumab Placebo|Administered SC
219288238|NCT06643728|DRUG|Tirzepatide Placebo|Administered SC
219288239|NCT05868954|BEHAVIORAL|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
219288240|NCT05868954|BEHAVIORAL|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
219288241|NCT05485753|DRUG|GNC-038|Administration by intravenous infusion
219288242|NCT02631759|DRUG|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
219288243|NCT02631759|DRUG|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
219288244|NCT06576089|OTHER|Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)|"Participants randomized into ORDER will be approached by the Site Coordinator for interest in the host trial. The Coordinator will introduce the trial and share a brief, women-centred, aphasia-friendly, close-captioned video that further describes the trial procedures and an accompanying leaflet.~ORDER recruitment materials will be saved to a mobile tablet. The Coordinator will watch the video together with the potential participant, engage in discussion about the host trial and answer any questions they may have. The Coordinator will offer to leave the tablet with the potential participant, along with printed copies of the leaflet and participant information letter. The Coordinator will encourage them to share these materials with their family members, friends or member of their healthcare team who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial."
219288245|NCT06576089|OTHER|Traditional recruitment and enrollment processes (TRAD)|Participants randomized into the traditional recruitment process (TRAD) will be approached by the Site Coordinator for interest in the CAMAROS trial and presented with the standard participant information letter and full informed consent form. The information letter and consent form will be left with the potential participant to view again; the Coordinator will encourage them to share these materials with their family members or friends who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.
219288246|NCT06152627|BEHAVIORAL|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
219288247|NCT06152627|BEHAVIORAL|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
219288248|NCT06131450|DRUG|BL-M07D1|Administration by intravenous infusion
219288249|NCT03147703|BEHAVIORAL|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
219288250|NCT03674580|BEHAVIORAL|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
219288251|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.25%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
219288252|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.125%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
219288253|NCT01417624|OTHER|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
219288254|NCT05228743|PROCEDURE|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
219288255|NCT05228743|DRUG|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
219288256|NCT05228743|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
219288257|NCT06801756|OTHER|Questionnaire|The patients will respond to a questionnaire about their parental project, the occurence or not of complications during the pregnancy, and the impact of pregnancy on craniopharyngioma.
219288258|NCT01021618|DRUG|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
219288259|NCT01021618|OTHER|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
219288260|NCT00939822|DRUG|Simvastatin|40 mg Simvastatin/day
219288261|NCT00939822|DRUG|Placebo|Matching Placebo
219288262|NCT03652727|DEVICE|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) \[CE marked device, C. R. Bard, Inc.\].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
219288263|NCT03652727|DEVICE|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
219288264|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
219288265|NCT02757872|DRUG|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
219288266|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
219288267|NCT02757872|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
219288268|NCT05915949|DRUG|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
219288269|NCT05915949|DRUG|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
219288270|NCT05915949|DRUG|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
219288271|NCT00318162|DRUG|low dose naltrexone|
219288272|NCT05183789|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
219288273|NCT00146367|BEHAVIORAL|Active Living Every Day|
219288274|NCT03395262|DIETARY_SUPPLEMENT|Active with caffeine|Novel formula with caffeine
219288275|NCT03395262|DIETARY_SUPPLEMENT|Active without caffeine|Novel formula without caffeine
219288276|NCT03395262|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
219288277|NCT01783964|DRUG|[14C]-Elacytarabine|Single intravenous administration
219288278|NCT01072630|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
219288279|NCT01072630|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
219288280|NCT05183529|DEVICE|Vitals Monitoring Pill System|The Celero Vitals Monitoring Pill (VM Pill) uses 3 axis accelerometry to measure physiological signals from within the GI tract.
219288281|NCT01232738|DRUG|rasagiline|rasagiline 2 mg daily for 12 months
219288282|NCT01341054|OTHER|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
219288283|NCT01341054|OTHER|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
219288284|NCT00683683|BEHAVIORAL|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
219288285|NCT03099564|DRUG|Pembrolizumab|pembrolizumab 200mg IV every three weeks
219288286|NCT03099564|DEVICE|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
219288287|NCT00910039|DRUG|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
219288288|NCT00910039|OTHER|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
219288289|NCT03415737|OTHER|Questionnaire|Profile Fitness Mapping Neck Questionnaire
219288290|NCT04529772|DRUG|acalabrutinib|Investigational Product
219288291|NCT04529772|DRUG|placebo|Placebo comparator
219288292|NCT04529772|DRUG|Prednisone|Investigational Product
219288293|NCT04529772|DRUG|Rituximab|Investigational Product
219288294|NCT04529772|DRUG|Cyclophosphamide|Investigational Product
219288295|NCT04529772|DRUG|Vincristine|Investigational Product
219288296|NCT04529772|DRUG|Doxorubicin|Investigational Product
219288297|NCT02147899|DRUG|SYM-1219|Oral
219288298|NCT02147899|DRUG|Placebo|Oral
219288299|NCT04565275|DRUG|Drug ICP-192|"1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase."
219288300|NCT06340477|OTHER|Thoracic SNAGs with conventional therapy|"Thoracic (T1- T5) SNAGs 3 repetitions x 1 set, 2 days/week Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
219288301|NCT06340477|OTHER|conventional therapy|"Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
219288302|NCT04329468|DEVICE|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
219288303|NCT00078000|DRUG|SU011248|
219288304|NCT03303768|DIAGNOSTIC_TEST|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
219288305|NCT04394546|DEVICE|WATCHMAN FLX LAAC Device|WATCHMAN FLX LAAC Device Implantation
219288306|NCT04394546|DRUG|Non-Vitamin K Oral Anticoagulant|Initiation or continuation of a NOAC drug
219288307|NCT06431815|DEVICE|FARAPULSE™ Pulsed Field Ablation System|De-novo pulmonary vein isolation (PVI) will be performed with the FARAPULSE Pulsed Field Ablation (PFA) System.
219288308|NCT05705323|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
219288309|NCT05705323|BEHAVIORAL|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
219288310|NCT05341401|DRUG|Budesonide MMX|Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
219288311|NCT05341401|DRUG|Prednisolone|It is a corticosteroid used as a standard therapy for management of ulcerative colitis
219288312|NCT01454687|PROCEDURE|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
219288313|NCT03342989|BEHAVIORAL|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
219288314|NCT03342989|BEHAVIORAL|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
219288315|NCT05041010|DRUG|Neu2000KWL group|1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
219288316|NCT05041010|DRUG|Placebo group|1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
219288317|NCT06487117|DRUG|Huafu Shengji Ointment|"Huafu Shengji Ointment~1. The experimental group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The experimental group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks."
219288318|NCT06487117|DRUG|ethacridine lactate solution|"ethacridine lactate solution~1. The control group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The control group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks."
219288319|NCT04590157|DEVICE|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
219288320|NCT04590157|OTHER|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
219288321|NCT03727542|DEVICE|adjustment of atrioventricular delay in DDD packers|Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
219288322|NCT06012227|DIETARY_SUPPLEMENT|kent'erbas cheese study|"Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming"
219288323|NCT05308706|DEVICE|8 weeks of home based use.|Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
219288324|NCT01911390|DIETARY_SUPPLEMENT|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
219288325|NCT01911390|DIETARY_SUPPLEMENT|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
219288326|NCT01911390|DIETARY_SUPPLEMENT|Control arm|No bean or rice bran additive in smoothie or muffin.
219288327|NCT01911390|DIETARY_SUPPLEMENT|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
219288328|NCT01066429|DRUG|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
219288329|NCT04969315|DRUG|TT-10|TT-10 orally administered BID
219288330|NCT04969315|DRUG|TT-4|TT-4 is orally administered QD
219288331|NCT04208490|OTHER|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
219288332|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
219288333|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
219288334|NCT00558038|DRUG|AST-120|AST-120
219288335|NCT00558038|DRUG|lactulose|lactulose
219288336|NCT06588855|DRUG|Afimkibart|Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.
219288337|NCT06588855|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
219288338|NCT04577456|DEVICE|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
219288339|NCT04124029|DEVICE|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
219288340|NCT04124029|PROCEDURE|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
219288341|NCT04928287|BIOLOGICAL|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
219288342|NCT04928287|OTHER|Placebo|Placebo will be administered intravenously to study participants who qualify.
219288343|NCT06422143|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
219288344|NCT06422143|BIOLOGICAL|sac-TMT|IV infusion
219288345|NCT06422143|DRUG|Carboplatin|Participants receive AUC 6 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
219288346|NCT06422143|DRUG|Paclitaxel|Participants receive 200 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
219288347|NCT06422143|DRUG|Nab-paclitaxel|Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
219288348|NCT03949855|DRUG|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
219288349|NCT03949855|DRUG|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
219288350|NCT03949855|DRUG|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
219288351|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.
219288352|NCT04501120|DRUG|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
219288353|NCT04501120|DRUG|standard-dose HHT|2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
219288354|NCT04501120|DRUG|Azacitidine|75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
219288355|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.
219288356|NCT04501120|DRUG|olverembatinib|orally, with meals, QOD, every 28 days as a cycle.
219288357|NCT04035499|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
219288358|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
219288359|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
219288360|NCT03156192|BEHAVIORAL|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
219288361|NCT00582413|BEHAVIORAL|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
219288362|NCT02119442|DEVICE|Transcather Valve Implantation|Transcather Valve Implantation
219288363|NCT04875299|OTHER|The study is observational|The study is observational
219288364|NCT02770612|OTHER|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
219288365|NCT05816772|DRUG|Endosequence Bio ceramic Sealer|Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
219288366|NCT05816772|DRUG|Sealapex Calcium hydroxide Based Sealer|KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
219288367|NCT01367470|DIETARY_SUPPLEMENT|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
219288368|NCT01367470|OTHER|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
219288369|NCT04213742|OTHER|Thanksgiving diary intervention|Record gratitude.
219288370|NCT04365231|DRUG|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~\- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
219288371|NCT04365231|OTHER|conventional management of patients|conventional management of patients
219288372|NCT03599102|BEHAVIORAL|LOVED Intervention|
219288373|NCT00417742|BEHAVIORAL|Service delivery through a Headache Management Program|
219288374|NCT01492153|DRUG|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
219288375|NCT01492153|DRUG|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
219288376|NCT01492153|DRUG|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
219288377|NCT04646863|RADIATION|laser therapy|performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
219288378|NCT04646863|OTHER|exercise|"The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~1. Modified Hundred~2. Modified Single Leg Stretch~3. One Leg Circle~4. Modified Scissors"
219288379|NCT04646863|OTHER|combination|laser therapy + Pilates exercises
219288380|NCT04080453|OTHER|Septic shock|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
219288381|NCT04080453|OTHER|Systemic Inflammatory Response Syndrome|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
219288382|NCT05716295|DRUG|MDK-703|MDK-703 will be administered as specified under Arm description.
219288383|NCT05716295|DRUG|Checkpoint Inhibitor, Immune|Checkpoint inhibitor will be administered as specified under Arm description.
219288384|NCT01655953|DIETARY_SUPPLEMENT|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
219288385|NCT01655953|OTHER|Control: high NaCl|7.7 mmol Na/kgBW/d
219288386|NCT01613482|RADIATION|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
219288387|NCT01613482|DRUG|Trastuzumab|Weekly, 2mg/kg of corporal weight
219288388|NCT01613482|DRUG|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
219288389|NCT02822430|OTHER|Pain scales|"* Visual analogic scale of pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Clinical Global impression~* Mini International Neuropsychiatric Interview (MINI)"
219288390|NCT04853641|PROCEDURE|Cadaveric|Cadaveric Organ Transplant
219288391|NCT04853641|PROCEDURE|Living Donor|Living Donor Organ Transplant
219288392|NCT00056277|DRUG|lamotrigine|
219288393|NCT02015364|PROCEDURE|Controlled early mobilization|1\. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
219288394|NCT03202953|PROCEDURE|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~* Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
219288395|NCT03202953|PROCEDURE|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.~\- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
219288396|NCT05315739|DEVICE|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
219288397|NCT05315739|DEVICE|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
219288398|NCT02003222|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
219288399|NCT02003222|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219288400|NCT02003222|BIOLOGICAL|Blinatumomab|Given IV
219288401|NCT02003222|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219288402|NCT02003222|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219288403|NCT02003222|DRUG|Cyclophosphamide|Given IV
219288404|NCT02003222|DRUG|Cytarabine|Given IT, IV, or SC
219288405|NCT02003222|DRUG|Daunorubicin|Given IV
219288406|NCT02003222|DRUG|Daunorubicin Hydrochloride|Given IV
219288407|NCT02003222|DRUG|Dexamethasone|Given PO
219288408|NCT02003222|DRUG|Etoposide|Given IV
219288409|NCT02003222|DRUG|Leucovorin Calcium|Given IV or PO
219288410|NCT02003222|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219288411|NCT02003222|DRUG|Mercaptopurine|Given PO
219288412|NCT02003222|DRUG|Methotrexate|Given PO, IT or IV
219288413|NCT02003222|DRUG|Pegaspargase|Given IM or IV
219288414|NCT02003222|DRUG|Prednisone|Given PO
219288415|NCT02003222|BIOLOGICAL|Rituximab|Given IV
219288416|NCT02003222|DRUG|Vincristine|Given IV
219288417|NCT02003222|DRUG|Vincristine Sulfate|Given IV
219288418|NCT02003222|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219288419|NCT01365481|DRUG|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
219288420|NCT01365481|DRUG|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
219288421|NCT01365481|DRUG|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
219288422|NCT03834324|DEVICE|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
219288423|NCT05702385|OTHER|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
219288424|NCT03221166|DRUG|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
219288425|NCT03221166|DRUG|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
219288426|NCT05097196|OTHER|Moderate-intensity aerobic activities|The exercise intensity of the individual is planned at 50-60% heart rate reserve using the Karvonen method.
219288427|NCT00047697|DRUG|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
219288428|NCT00047697|DRUG|Placebo|Placebo used in placed of Donepezil HCL
219288429|NCT05315505|OTHER|Maintenance programme|"Continuous educational support, exercise training, behaviour change intervention, and self-management.~Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision"
219288430|NCT05315505|OTHER|Usual Care|No maintenance programme, and the patient has the usual follow-up and medical appointments
219288431|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
219288432|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
219288433|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
219288434|NCT03698253|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
219288435|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
219288436|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
219288437|NCT03698253|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
219288438|NCT01745692|DEVICE|Mechanical thrombectomy|
219288439|NCT01745692|DRUG|Intravenous rtPA|All patients receive IV alteplase
219288440|NCT02369068|DRUG|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
219288441|NCT02369068|DRUG|Kenalog|Intravaginal pelvic floor injection one series
219288442|NCT06401070|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
219288443|NCT06401070|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
219288444|NCT01291030|DIETARY_SUPPLEMENT|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of \> 1,9 mg/dl.
219288445|NCT05648929|OTHER|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
219288446|NCT05648929|DIAGNOSTIC_TEST|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
219288447|NCT05648929|PROCEDURE|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
219288448|NCT05648929|PROCEDURE|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
219288449|NCT05648929|PROCEDURE|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
219288450|NCT05648929|OTHER|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
219288451|NCT00958841|DRUG|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
219288452|NCT05416944|OTHER|Personalized blood pressure management|Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
219288453|NCT00260286|BEHAVIORAL|Energy availability|
219288454|NCT05219994|OTHER|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
219288455|NCT05219994|OTHER|Normoxia Exposure|2 hours of normoxia exposure during OGTT
219288456|NCT05871684|DRUG|BTK inhibitor|Intervention were given during bridging therapy and maintanance treament of CAR-T cell therpay.
219288457|NCT05871684|DRUG|PD-1 inhibitor|Intervention were given during maintanance treament of CAR-T cell therpay.
219288458|NCT03908957|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
219288459|NCT02402153|DEVICE|Hyposafe device|Subcutaneous EEG recorder for EEG measurements
219288460|NCT05732753|OTHER|Mindfulness + Education in Neurophysiology of pain|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
219288461|NCT00355290|BEHAVIORAL|Changes on Oral Vitamin K Intake|
219288462|NCT00932542|DRUG|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
219288463|NCT00932542|DRUG|placebo|placebo
219288464|NCT00932542|DRUG|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
219288465|NCT01962532|DRUG|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
219288466|NCT01962532|DRUG|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
219288467|NCT02915484|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
219288468|NCT04646967|DRUG|Bupivacain|See active comparator description
219288469|NCT04646967|DRUG|Sevoflurane|See active comparator description
219288470|NCT04646967|DRUG|Acetaminophen|See active comparator description
219288471|NCT04646967|DRUG|Ibuprofen|See active comparator description
219288472|NCT04646967|DRUG|Ketorolac|See experimental arm description
219288473|NCT05254080|DEVICE|Active taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).
219288474|NCT05254080|DEVICE|Sham taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.
219288475|NCT02803008|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - SR15-46-Z13-072)
219288476|NCT00002305|DRUG|Flucytosine|
219288477|NCT00002305|DRUG|Fluconazole|
219288478|NCT00002305|DRUG|Amphotericin B|
219288479|NCT03466905|OTHER|Ambulant assessment|
219288480|NCT02928497|DEVICE|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
219288481|NCT02928497|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
219288482|NCT03325491|DIETARY_SUPPLEMENT|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
219288483|NCT03325491|DIETARY_SUPPLEMENT|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
219288484|NCT05591261|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
219288485|NCT04641676|DIAGNOSTIC_TEST|NGS testing|NGS test will be performed
219288486|NCT03183505|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
219288487|NCT03183505|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
219288488|NCT06186921|DRUG|Dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
219288489|NCT04716270|PROCEDURE|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
219288490|NCT02449551|DRUG|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
219288491|NCT05045274|DRUG|Dapagliflozin 10Mg Tab|"1. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.~2. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~3. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~4. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
219288492|NCT05045274|DRUG|Placebo|"1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
219288493|NCT01158079|DRUG|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
219288494|NCT00452777|DRUG|BVT.115959|
219288495|NCT00452777|DRUG|Placebo|
219288496|NCT06415149|PROCEDURE|High power short duration ablation with 50 W|Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
219288497|NCT06415149|PROCEDURE|High power short duration ablation with 45 W|Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
219288498|NCT04705116|BIOLOGICAL|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
219288499|NCT03014011|OTHER|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
219288500|NCT03014011|OTHER|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
219288501|NCT04101630|BEHAVIORAL|Activity Monitoring|Monitoring with FitBit
219288502|NCT04889105|BEHAVIORAL|Smart MOVE!|"Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring"
219288503|NCT04889105|BEHAVIORAL|General walking advice|Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
219288504|NCT04889105|BEHAVIORAL|Performance evaluation|"Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2\) N-of-1 trials to refine the intervention"
219288505|NCT03551327|BEHAVIORAL|Experimental: Intervention plus information|The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
219288506|NCT03551327|OTHER|Active Comparator: Information only|Participants in this arm will be provided with information about fatigue.
219288507|NCT00956176|DRUG|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
219288508|NCT02416453|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.
219288509|NCT02416453|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
219288510|NCT02416453|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
219288511|NCT01986764|DRUG|Lisdexamfetamine|
219288512|NCT01986764|DRUG|Estradiol|
219288513|NCT01986764|DRUG|Placebo|Placebo capsules will be filled with lactose powder.
219288514|NCT01955408|OTHER|Questionnaires, anticholinergic treatment, urodynamic study|
219288515|NCT01143181|DRUG|Brincidofovir|Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
219288516|NCT01266551|DEVICE|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
219288517|NCT00697645|DEVICE|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
219288518|NCT00697645|DEVICE|Brainsway Deep TMS|Deep TMS applied over the motor strip
219288519|NCT05614193|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
219288520|NCT02328859|OTHER|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
219288521|NCT02328859|OTHER|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
219288522|NCT04445727|COMBINATION_PRODUCT|Vitamin C|Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
219288523|NCT04445727|COMBINATION_PRODUCT|spinal manipulation|Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.
219288524|NCT04445727|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation (TENS)|Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
219288525|NCT02009098|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
219288526|NCT02054559|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
219288527|NCT02054559|RADIATION|Radiotherapy|
219288528|NCT04184232|BIOLOGICAL|Dendritic cells|Autologous dendritic cells primed with muc-1/wt-1 peptides
219288529|NCT04184232|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder cancer according to the Clinical protocols
219288530|NCT00195468|DRUG|CYCLOSPORINE|
219288531|NCT06474819|DEVICE|Pacemaker implant|All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.
219288532|NCT01124331|PROCEDURE|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
219288533|NCT01124331|PROCEDURE|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
219288534|NCT01038739|DRUG|Mesalazine|3 g per day
219288535|NCT01038739|DRUG|Mesalazine|1.5 g per day
219288536|NCT01038739|DRUG|Placebo|0 g per day
219288537|NCT05880901|BEHAVIORAL|After school program|The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.
219288538|NCT05880901|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
219288539|NCT04531501|DIAGNOSTIC_TEST|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
219288540|NCT00105599|BEHAVIORAL|End of life care coordination|
219288541|NCT00105599|PROCEDURE|FairCare System|
219288542|NCT02160236|DRUG|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
219288543|NCT02160236|DRUG|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
219288544|NCT02160236|DRUG|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
219288545|NCT00743431|DRUG|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
219288546|NCT04104828|BIOLOGICAL|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
219288547|NCT04104828|BIOLOGICAL|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
219288548|NCT04104828|BIOLOGICAL|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
219288549|NCT05978206|DRUG|Nandrolone Decanoate|Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
219288550|NCT05978206|BEHAVIORAL|Physiotherapy Intervention|"The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate."
219288551|NCT05978206|BEHAVIORAL|Nutritional Intervention|An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
219288552|NCT05978206|DRUG|Placebo|Placebo
219288553|NCT03291288|DRUG|Tolbutamide|Commercially available tolbutamide
219288554|NCT03291288|DRUG|Midazolam|Commercially available midazolam
219288555|NCT03291288|DRUG|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
219288556|NCT01671397|BEHAVIORAL|Diet and exercise counseling|Not needed
219288557|NCT01671397|BEHAVIORAL|Diet, exercise, sleep hygiene counseling|None needed
219288558|NCT04276415|DRUG|DS-6157a|Administered as a single agent intravenously (IV) every 3 weeks
219288559|NCT04385550|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
219288560|NCT04385550|DRUG|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
219288561|NCT04385550|DRUG|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
219288562|NCT04385550|DRUG|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
219288563|NCT06137326|DEVICE|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
219288564|NCT06137326|DEVICE|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
219288565|NCT03887949|DEVICE|Group VCV|Volume controlled ventilation
219288566|NCT03887949|DEVICE|Group PCV|Pressure controlled ventilation
219288567|NCT03887949|DEVICE|Group PCV-VG|Pressure controlled ventilation with volume guarantee
219288568|NCT01353768|OTHER|retrospective chart review|retrospective chart review
219288569|NCT02461784|PROCEDURE|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
219288570|NCT04434573|OTHER|Observation study|French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
219288571|NCT04173351|BEHAVIORAL|Education and Counseling|Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
219288572|NCT00074477|DRUG|R092670|
219288573|NCT03091231|DIAGNOSTIC_TEST|mpUS multiparametric Ultrasound|compare the mpUS to other methods
219288574|NCT03309813|DEVICE|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
219288575|NCT03309813|DEVICE|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
219288576|NCT03309813|DEVICE|Crossover Transcranial Exablate|Subjects randomized to the Sham Exablate could opt for the Crossovover Transcranial Exablate Arm (Exablate Thalamotomy) after completing the Month 3 visit in the Sham Arm.
219288577|NCT06283966|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
219288578|NCT06283966|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and formoterol fumarate pressurized inhalation suspension
219288579|NCT03981328|DEVICE|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
219288580|NCT03981328|DEVICE|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
219288581|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
219288582|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions
219288583|NCT04561778|DEVICE|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
219288584|NCT04561778|DEVICE|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
219288585|NCT06266624|DIAGNOSTIC_TEST|Tourniquet Test|Tourniquet Test was performed in patients with HHT
219288586|NCT00312598|DRUG|Aripiprazole|
219288587|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
219288588|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
219288589|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
219288590|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
219288591|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
219178151|NCT06196099|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
219178152|NCT06196099|BEHAVIORAL|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
219178153|NCT06226662|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
219288592|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
219288593|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
219288594|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
219178154|NCT06226662|DRUG|Placebo|Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
219178155|NCT06245369|BEHAVIORAL|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes"
219178156|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
219178157|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
219178158|NCT06801249|DRUG|Metarapone|Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
219178159|NCT06801249|DRUG|Standardized antihypertensive therapy|Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.
219178160|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns with retention grooves|Zirconia-based primary anterior crowns with retention grooves
219178161|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns without retention grooves|Zirconia-based primary anterior crowns without retention grooves
219178162|NCT06801353|BIOLOGICAL|Stapokibart|Stapokibart subcutaneously every two weeks
219178163|NCT06801353|DRUG|Mometasone Furoate Nasal Spray (MFNS)|mometasone furoate nasal spray 200 μg once daily
219288595|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
219288596|NCT02686619|DRUG|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
219288597|NCT02686619|DRUG|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
219288598|NCT02686619|DRUG|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
219288599|NCT02686619|DRUG|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
219288600|NCT02686619|DRUG|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
219288601|NCT03752086|PROCEDURE|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
219288602|NCT03752086|PROCEDURE|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
219288603|NCT00251706|DRUG|amiodarone|
219288604|NCT05914051|OTHER|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
219288605|NCT01580553|DRUG|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
219288606|NCT01580553|DRUG|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
219288607|NCT01989169|DRUG|Midazolam|
219288608|NCT01989169|DRUG|SSP-004184SS|
219288609|NCT00936572|PROCEDURE|Probiotics (La1, BB536)|
219288610|NCT00936572|BIOLOGICAL|probiotics (La1, BB536)|
219288611|NCT00936572|BIOLOGICAL|placebo|Maltodoxtrin
219288612|NCT00106301|DRUG|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
219288613|NCT02749110|DEVICE|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
219288614|NCT05912205|DRUG|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
219288615|NCT05912205|RADIATION|radiotherapy|radiotherapy
219288616|NCT04761432|DEVICE|neoGuard|NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
219288617|NCT00139880|DRUG|Parcopa|
219288618|NCT05099432|PROCEDURE|CARMA technique|Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
219288619|NCT00948649|DRUG|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
219288620|NCT00948649|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
219288621|NCT02406677|OTHER|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
219288622|NCT05754164|BEHAVIORAL|Attention Control Training|Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
219288623|NCT02766101|BEHAVIORAL|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
219288624|NCT02766101|BEHAVIORAL|Standard PE|Non-aerobic skill building.
219288625|NCT04672785|BEHAVIORAL|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
219288626|NCT04531904|DEVICE|EMBOVAC Aspiration Catheter|The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.
219288627|NCT02251249|DRUG|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
219288628|NCT00566189|PROCEDURE|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
219288629|NCT04997772|DEVICE|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
219288630|NCT04461444|GENETIC|Skin biopsy|"COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~* risk of pain due to the procedure performed under local anaesthesia~* can leave a visible scar (about 2 x 1 cm)"
219288631|NCT03585803|DRUG|KMRC011 5μg or Placebo|Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
219288632|NCT03585803|DRUG|KMRC011 10μg or Placebo|Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
219288633|NCT03585803|DRUG|KMRC011 15μg or Placebo|Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
219288634|NCT03585803|DRUG|KMRC011 20μg or Placebo|Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
219288635|NCT03585803|DRUG|KMRC011 25μg or Placebo|Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
219288636|NCT03655457|DEVICE|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
219288637|NCT03655457|DEVICE|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
219288638|NCT06272396|DEVICE|Smart watch|ECG 1D/6D
219288639|NCT02260323|OTHER|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
219288640|NCT02260323|OTHER|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
219288641|NCT00283244|DRUG|erlotinib hydrochloride|given orally
219288642|NCT00283244|DRUG|gemcitabine hydrochloride|given IV
219288643|NCT05670015|DRUG|Low dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
219288644|NCT05670015|DRUG|High dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
219288645|NCT01934348|BEHAVIORAL|Psychological First Aid|
219288646|NCT01934348|BEHAVIORAL|Usual victim advocacy Services|
219288647|NCT02929277|OTHER|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
219288648|NCT06143592|OTHER|Inspiratory Muscle Training|Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.
219288649|NCT00515684|DRUG|bevacizumab (Avastin)|
219288650|NCT04944745|OTHER|Myofascial Release|Moderate pressure manual treatment to the pectoral fascia.
219288651|NCT04944745|OTHER|Soft-touch Control|No pressure manual treatment to the pectoral fascia.
219288652|NCT05827913|DEVICE|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
219288653|NCT05827913|DEVICE|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
219288654|NCT05827913|DEVICE|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
219288655|NCT04190836|BEHAVIORAL|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
219288656|NCT03636191|DIETARY_SUPPLEMENT|Probiotic strain|Lactobacillus
219288657|NCT03636191|DIETARY_SUPPLEMENT|Placebo|Placebo
219288658|NCT00449722|DRUG|mesalazine|
219288659|NCT00658788|DRUG|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
219288660|NCT00658788|DRUG|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
219288661|NCT05181059|DIAGNOSTIC_TEST|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
219288662|NCT00653523|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
219288663|NCT00653523|DRUG|Simvastatin|Simvastatin 20 mg daily
219288664|NCT01891201|DRUG|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
219288665|NCT03909438|PROCEDURE|Endovascular Thrombectomy|Endovascular therapy includes direct mechanical thrombectomy or intravenous thrombolysis with mechanical thrombectomy. Endovascular Thrombectomy Device: Trepo trevor Retriever Device: SolitaireTM FR Revascularization Device
219288666|NCT05286827|DRUG|Olaparib|Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
219288667|NCT05439590|BEHAVIORAL|High dose CSO|Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
219288668|NCT05439590|BEHAVIORAL|Low dose CSO|Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
219288669|NCT05439590|BEHAVIORAL|Low dose OO|Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
219288670|NCT05439590|BEHAVIORAL|High dose OO|Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
219296461|NCT06688422|DEVICE|incentive spirometry|The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment.
219288671|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
219288672|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
219288673|NCT00854893|DEVICE|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
219288674|NCT04251507|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
219288675|NCT04958031|DRUG|CVL-871 1.0 mg|CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)
219288676|NCT04958031|DRUG|CVL-871 3.0 mg|CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
219288677|NCT04958031|DRUG|Placebo|Placebo QD, oral (tablet), once per day for 12 weeks
219288678|NCT06511453|DEVICE|Acupressure (using AcuWand or pencil eraser)|"The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure."
219288679|NCT02603653|DEVICE|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
219288680|NCT04713891|DRUG|KF-0210 tablets, 120 mg|KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
219288681|NCT04713891|DRUG|KF-0210 tablets, 240 mg|KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
219288682|NCT04713891|DRUG|KF-0210 tablets, 450 mg|KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
219288683|NCT04713891|DRUG|KF-0210 tablets, 600 mg|KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
219288684|NCT04713891|DRUG|KF-0210 (dosage RP2D-2) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
219288685|NCT04713891|DRUG|KF-0210 (dosage RP2D-1) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
219288686|NCT04713891|DRUG|KF-0210 (dosage RP2D) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
219288687|NCT04711109|DRUG|Denosumab|Given SC
219288688|NCT04711109|DRUG|Placebo|Given SC
219288689|NCT04711109|OTHER|Quality-of-Life Assessment|Ancillary studies
219288690|NCT05384938|BIOLOGICAL|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
219288691|NCT06295536|DEVICE|Comparator device, Closed-field autorefractometer|"* Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia"
219288692|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
219288693|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
219288694|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
219288695|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
219288696|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
219288697|NCT06451133|OTHER|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
219288698|NCT00724165|BEHAVIORAL|Intervention|Culturally-modified, individually tailored physical activity print materials
219288699|NCT00724165|BEHAVIORAL|Control|Bilingual health education booklets
219288700|NCT06142110|OTHER|Funcional movement screen|FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
219288701|NCT06142110|DIAGNOSTIC_TEST|Respiratory muscle strength|Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
219288702|NCT04822077|RADIATION|Proton radiation|"* Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
219288703|NCT00380302|DRUG|AVE1625|
219288704|NCT01293253|BEHAVIORAL|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
219288705|NCT03435302|DRUG|Temozolomide Plus Cisplatin|"Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide."
219288706|NCT03435302|DRUG|High-Dose IFN-a2b|Interferon belongs to the large class of glycoproteins known as cytokines.
219288707|NCT03008798|DRUG|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
219288708|NCT03008798|DRUG|The Placebo of Herbal Medicine C-117|
219288709|NCT00157027|PROCEDURE|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy \[ECP\]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
219288710|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
219288711|NCT06573749|DIETARY_SUPPLEMENT|Whey protein isolate supplement|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
219288712|NCT05355857|DIAGNOSTIC_TEST|brain PET-MRI with 18F-FDG|Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
219288713|NCT00994175|DRUG|Pioglitazone|
219288714|NCT00994175|DRUG|Placebo|
219288715|NCT00003072|DRUG|amifostine trihydrate|
219288716|NCT00003072|DRUG|carboplatin|
219288717|NCT00003072|DRUG|paclitaxel|
219288718|NCT05802316|DEVICE|tracheal intubation using videolaryngoscope with a hyperangulated blade or standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)|In the awake group tracheal intubation performed by an videolaryngoscope with a hyperangulated blade. In the asleep group the standard intubation were performed by videolaryngoscopy (VL) and direct laryngoscopy (DL)
219288719|NCT02954198|DRUG|Tacrolimus|goal trough level 5-12ng/mL
219288720|NCT02954198|DRUG|Prednisone|goal dose 5mg QD
219288721|NCT02954198|DRUG|Mycophenolate mofetil|goal dose 1g BID
219288722|NCT02954198|DRUG|Everolimus|goal trough level 3-8ng/mL
219288723|NCT05774197|BEHAVIORAL|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
219288724|NCT01470053|DRUG|mometasone furoate plus azelastine HCl|
219288725|NCT01470053|DRUG|mometasone furoate|
219288726|NCT01470053|DRUG|azelastine HCl|
219288727|NCT03442153|DIETARY_SUPPLEMENT|Solgar No7 Complex|Solgar No7 Capsules
219288728|NCT03442153|DIETARY_SUPPLEMENT|placebo|Placebo tablets Cellulose
219288729|NCT01663051|DEVICE|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
219288730|NCT02906163|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
219288731|NCT02906163|DRUG|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
219288732|NCT06402565|DRUG|NOX1416 and SOC|Topical Nitric Oxide
219288733|NCT06402565|PROCEDURE|SOC (Standard of care)|SOC as provided in the Arm/Group description.
219288734|NCT06703229|DRUG|The Transversus Abdominis Plane (TAP) block|or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.
219288735|NCT06703229|DRUG|The transverse abdominis plane (TAP) block|Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
219288736|NCT02304692|DEVICE|Bone anchored hearing aid|
219296462|NCT06619951|DRUG|VC004 and Itraconazole|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.
219288737|NCT06715878|PROCEDURE|Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation|Under the visualization of ultrasound contrast imaging through the operative channel, a microwave ablation probe was inserted into the tumor (at the interface between the tumor and kidney, close to the tumor base). The microwave ablation device was used, with a power setting of 70 W for initiating microwave ablation. Depending on the tumor volume and depth, 1-3 ablation cycles were performed, with each cycle lasting 1-3 minutes. After reaching the pseudocapsule of the tumor, a combination of blunt dissection, sharp cutting, and blunt dissection was employed to separate the tumor from the renal parenchyma . The renal artery was not occluded during the procedure.If intraoperative injury to the collecting system is suspected, the collecting system should be sutured normally, while simultaneously suturing the outer layer of renal parenchyma to prevent urine leakage.
219288738|NCT06715878|PROCEDURE|robotic-assisted laparoscopic partial nephrectomy|robotic-assisted laparoscopic partial nephrectomy
219288739|NCT06729398|DEVICE|NIRS|NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours
219288740|NCT06729398|OTHER|SafeboosC|SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
219288741|NCT06729008|DIETARY_SUPPLEMENT|Diabetes-specific nutrition formula (DSNF)|The diabetes-specific nutrition formula to be used in this study will be Glucerna (Abbott Laboratories). It features an advanced blend of low-glycemic carbohydrates for steady energy release, a dual fiber blend to support digestive health, and a unique lipid blend free from trans fats, cholesterol, and low in saturated fat. Additionally, Glucerna is enriched with 4x more inositol and high levels of trivalent chromium, which contribute to maintaining normal blood glucose levels. It provides 28 essential vitamins and minerals, is low in lactose, and gluten-free, making it a suitable option for various dietary needs. 5 scoops will be mixed in 200 mL of water, and this amounts to 228 calories, with 30.01g of carbohydrates, 10.16g of protein, and 8.70g of fat. This will be given twice, as a breakfast replacement and an afternoon snack replacement.
219288742|NCT06729008|OTHER|Medical Nutrition Therapy|Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
219288743|NCT06728111|OTHER|High sensitive Troponin T|The baseline population will consist of all patients who underwent a form of non-cardiac surgery. Baseline variables, medication use, type of surgery and perioperative hemodynamic and laboratory variables will be extracted from the hospital information system. One year mortality is registered, as well as major vascular events. This is in line with previous publications from our group. The adjudication strategy used for patients with myocardial injury. For the adjudication process minimal two senior anesthesiologists will be invited. Two members with at least one senior anesthesiologist will receive a sample of patients to adjudicate. Together the entire panel will adjudicate all patients. The goal to investigate the differences between the raters.
219288744|NCT06731803|DRUG|Trastuzumab deruxtecan + 5FU/LV|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
219288745|NCT06731803|DRUG|Trastuzumab deruxtecan + FLO|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles FLO: oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
219288746|NCT06728514|PROCEDURE|Erector spinae plane block group.|In ESPB technique the linear transducer will be placed over the spinous process of the vertebra and a point 3 cm lateral to it are marked at the T10-T11 level before performing the block. Under aseptic precautions, the 23G spinal needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra. The transverse process of the thoracic vertebra lies at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, local anesthetic is injected in 3-5 ml aliquots. A volume of 20-25 ml of 0.25% bupivacaine will be used for analgesia on each side depending upon the surgery and requirements. The number of attempts will be noted.Time taken to perform block in minutes will be noted from placing transducer to taking out needle after injecting drug in plane.
219288747|NCT06728514|PROCEDURE|Paravertebral Nerve Block|In PVB technique the patient will be placed in the lateral position, and the superior aspect of the T9,T10 and T11 spinous processes will be identified. Under complete aseptic precautions and after skin infiltration with LA, 23G spinal needle will be inserted perpendicular to the skin, with the goal of contacting the tranverse process. Once the TP is contacted, generally at a depth of 2 to 5 cm in adults, the needle is withdrawn into the subcutaneous tissue, redirected in a caudal direction, and then slowly advanced with the purpose of entering the PVS at an approximate depth of 1.0 to 1.5 cm past the initial contact with the TP. After perforating the costotransverse ligament and negative aspiration for blood, air, or spinal fluid,10 mL of 0.25% bupivacaine will be injected at each level superficial to to the pleural line. Displacement of the pleura line anteriorly will be confirmed proper injection of the local anaesthetic solution. The number of attempts will be noted.
219288748|NCT06728514|DRUG|Inj Bupivacaine|Inj Bupivacaine 0.25% (10ml) in both groups
219288749|NCT06727942|DEVICE|V-TARGET intervention|V-TARGET intervention will be delivered through a 360 degree self-paced treadmill in a university clinical laboratory for 5-weeks (2 days/week, 30 minutes/session) with total 10 sessions. The treadmill is the first-of-kind motion platform that an individual can walk and run at self-paced speed in 360 degree (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. During the V-TARGET intervention, participants will self-pace their locomotor action (walking/running) while they wear the HTC vivo headset and experience daily exercises/games augmented by the VR Therapy System. Therapy System is a library of VR exercises/games targeted on neurological rehabilitation, balance improvement training as well as cognitive therapy suited for variety of conditions, and includes various daily living simulation activities such as Retail Shopping, Gait Training, Cafeteria Experience, and Nature Walk.
219288750|NCT06897033|BEHAVIORAL|Health education followed by AI-generated Whatsapp reminders|Participants will receive dental health education in a one to one personal session followed by Text messages generated by AI large language model (ChatGPT free version) about oral hygiene practices for three month in a tapering frequency. These messages will be designed based on Fogg's Behavior Model, focusing on enhancing motivation, ability, and providing clear triggers for action.
219296463|NCT06619951|DRUG|VC004 and rifampicin|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.
219288751|NCT06897033|BEHAVIORAL|Oral Health Education|Oral health education in a one to one session explaining the importance of oral hygiene measures and demonstrating teeth brushing techniques and healthy dietary guidelines and recommendations.
219288752|NCT06897813|DRUG|WD-910 tablet|Administered P.O.
219288753|NCT06897813|DRUG|WD-910 Tablets Placebo|Administered P.O.
219288754|NCT06897150|DRUG|Carotegrast methyl|a dosage of 960 mg three times daily
219288755|NCT06900257|PROCEDURE|Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.|All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
219288756|NCT04962997|OTHER|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient."
219288757|NCT06906380|OTHER|Non interventional study|Non Intervention, an observation LTFU study
219288758|NCT03553511|PROCEDURE|Vaginal vault suspension to the uterosacral ligaments|Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments
219288759|NCT03553511|PROCEDURE|McCall culdoplasty|Vaginal hysterectomy with McCall culdoplasty
219288760|NCT07153991|DRUG|Donepezil group|Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months
219288761|NCT07153991|DRUG|Placebo group|35 Pacients with tinnitus received for 3 months placebo medication
219288762|NCT07154966|OTHER|Standard Chemotherapy (Carboplatin-Paclitaxel)|Standard-of-care chemotherapy with carboplatin (AUC 5, every 21 days) and paclitaxel (175-200 mg/m², every 21 days) for six cycles. No additional drugs, dose modifications, or alternative regimens introduced.
219288763|NCT07155798|DEVICE|bamboo toothbrush|recent toothbrush
219288764|NCT07155798|DEVICE|conventional toothbrush|conventional toothbrush
219288765|NCT07154303|DIAGNOSTIC_TEST|Computer algorithms|Computer algorithms that are designed to perform heart sound, ECG, and/or facial photoplethysmography analysis on data collected from smartphone's internal hardware and/or external accessories.
219288766|NCT05020457|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
219288767|NCT05020457|DRUG|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
219288768|NCT05020457|DRUG|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
219288769|NCT00146094|PROCEDURE|BMD Measurement|
219288770|NCT00146094|DRUG|antiretrovirals|Treated with antiretrovirals
219288771|NCT06477250|BEHAVIORAL|Empathy-based socio-emotional mental training|The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
219288772|NCT06398457|DRUG|Darzalex Faspro (Daratumumab and hyaluronidase-fihj)|Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.
219288773|NCT06398457|DEVICE|JH-DSA Semi-Quant Screen and Response Score|Serum based semi-quantifiable investigational testing regimen used to screen for high DSA level or assess response to desensitization. It is based on results from cross-matched flow cytometric assessment cellular-based and solid phase immunoassays (SPI) that estimates antibody level.
219288774|NCT05501769|DRUG|ARV-471 in combination with Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
219288775|NCT06834724|OTHER|Standard OSA care|All people will undergo standard care.
219288776|NCT04965675|DRUG|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
219288777|NCT04965675|DRUG|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
219288778|NCT06632483|DRUG|Vericiguat (Verquvo, BAY1021189)|Prescibed as per local label
219288779|NCT05038735|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
219288780|NCT05038735|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
219288781|NCT05038735|DRUG|Alpelisib-matching placebo|"Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~After Protocol Amendment 5 is implemented, alpelisib matching-placebo will no longer be supplied or administered once participants have been unblinded."
219288782|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
219288783|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
219288784|NCT05977491|OTHER|addressing psycholsocial problems|"1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics"
219288785|NCT05245513|BEHAVIORAL|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
219288786|NCT05245513|BEHAVIORAL|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
219288787|NCT05385692|DRUG|BL-M02D1|Administration by intravenous infusion
219288788|NCT05944978|DRUG|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
219288789|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
219288790|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
219288791|NCT00988767|BIOLOGICAL|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
219363018|NCT05420389|OTHER|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
219288792|NCT05253157|OTHER|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
219288793|NCT05189600|DEVICE|Mechnical Insufflation:Exsufflation|Cough Augmentation device
219288794|NCT00012324|DRUG|doxorubicin hydrochloride|
219288795|NCT00012324|DRUG|nolatrexed dihydrochloride|
219288796|NCT06429059|DRUG|Astaxanthin|Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).
219288797|NCT06429059|DRUG|Protandim|Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
219288798|NCT06429059|DRUG|Melatonin|Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
219288799|NCT06429059|DRUG|MitoQ|The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.
219288800|NCT04777370|OTHER|posterior glide mobilization|The participant will be positioned supine on a plinth, with their scapula stabilized against a firm wedge on the table, and the shoulder joint in the resting position (approx. 55 degrees abduction, 30 degrees horizontal adduction, and slight external rotation). With the extremity held in the same position, the researcher will then apply a grade III (into tissue stretch) PG mobilization. This will consist of five 30-second bouts of sustained gr III posterior glide mobilizations.
219288801|NCT04777370|OTHER|Sleeper stretch|All participants randomized to the stretching group will perform five 30-second holds of the sleeper stretch. This is performed by lying on the side to be stretched, elevating the upper arm to 90° on the support surface with the elbow bent 90°, then passively internally rotating the shoulder with force provided by with the opposite arm.
219288802|NCT04777370|OTHER|thoracic manipulation|"Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed."
219288803|NCT06791109|DIAGNOSTIC_TEST|Primary care physicians|For participants in Group A, a nonblinded independent staff member will first collect medical history, followed by sequential auscultation and CHD assessment by a specialist physician and a primary care physician, with an echocardiogram performed last.
219288804|NCT06791109|DIAGNOSTIC_TEST|AI + Primary care physicians|For participants in Group B, after medical history collection, both a specialist physician and a primary care physician will perform auscultation and CHD assessment. Subsequently, the primary care physician will use an electronic stethoscope to collect heart sound data according to the protocol and upload the recordings to a cloud platform. The AI model will analyze the data on the cloud platform and provide a diagnostic result within 5-10 seconds for the primary care physician's reference. The primary care physician may reassess the findings based on the AI model's feedback, and the participant will then undergo an echocardiogram.
219288805|NCT01788462|DRUG|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
219288806|NCT04122976|DRUG|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
219288807|NCT02070939|DRUG|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
219288808|NCT02070939|DRUG|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
219288809|NCT02070939|DRUG|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
219288810|NCT02070939|DRUG|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
219288811|NCT02070939|DRUG|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
219288812|NCT02070939|DRUG|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
219288813|NCT02523859|DRUG|Propofol|Hypnotic drug used for anesthesia
219288814|NCT02523859|DRUG|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
219288815|NCT00389701|DRUG|bortezomib|
219288816|NCT00389701|DRUG|dexamethasone|
219288817|NCT00001629|DRUG|Angiotensin II type 1 receptor antagonists|
219288818|NCT04505423|PROCEDURE|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
219288819|NCT04505423|PROCEDURE|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
219288820|NCT00329147|DRUG|desvenlafaxine SR|
219288821|NCT00329147|DRUG|desipramine|
219288822|NCT00329147|DRUG|paroxetine|
219288823|NCT01502683|PROCEDURE|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
219288824|NCT01502683|PROCEDURE|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
219288825|NCT01502683|PROCEDURE|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
219288826|NCT01502683|PROCEDURE|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
219288827|NCT06957327|DRUG|ERAS-601|ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy
219288828|NCT00898209|GENETIC|protein expression analysis|Blood and exhaled breath condensate will be collected.
219288829|NCT00898209|GENETIC|proteomic profiling|Blood and exhaled breath condensate will be collected.
219288830|NCT00898209|OTHER|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
219288831|NCT00898209|OTHER|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
219288832|NCT00898209|OTHER|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
219288833|NCT00898209|OTHER|questionnaire administration|Questionnaire will be completed.
219288834|NCT00544310|BIOLOGICAL|Anti adhesion agent|Adhesions prevention
219288835|NCT00223639|DRUG|Topiramate|200mg twice a day
219288836|NCT05302492|DEVICE|CPAP|CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.
219288837|NCT05302492|DEVICE|Light box|Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
219288838|NCT03455803|DEVICE|CPAP|Continuous positive airway pressure
219288839|NCT00979550|DRUG|Imiquimod|commercially available topical antiviral drug
219288840|NCT00979550|DRUG|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
219288841|NCT02885844|PROCEDURE|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
219288842|NCT02885844|PROCEDURE|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
219288843|NCT04147520|BEHAVIORAL|Brief Motivational Interview|Single (60 min) session discussion of alcohol use and associated experiences.
219288844|NCT02862587|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
219288845|NCT02862587|BIOLOGICAL|precision cells|precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
219288846|NCT05301647|DIAGNOSTIC_TEST|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
219288847|NCT05301647|OTHER|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
219288848|NCT05301647|OTHER|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
219288849|NCT05301647|OTHER|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
219288850|NCT06146127|OTHER|phenotyping|Large scale molecular phenotyping
219288851|NCT04997681|BEHAVIORAL|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
219288852|NCT04997681|BEHAVIORAL|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
219288853|NCT04997681|BEHAVIORAL|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
219288854|NCT04997681|BEHAVIORAL|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
219288855|NCT01350284|DIETARY_SUPPLEMENT|Cinnamon|acute oral administration of 3 g cinnamon
219288856|NCT01350284|DIETARY_SUPPLEMENT|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
219288857|NCT01293045|DIETARY_SUPPLEMENT|hydrolyzed collagen|10g/day at breakfast during 90 days
219288858|NCT01293045|DIETARY_SUPPLEMENT|wheat protein|10g/day at breakfast during 90 days
219288859|NCT01733537|OTHER|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
219288860|NCT01733537|BEHAVIORAL|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
219288861|NCT03976492|DIAGNOSTIC_TEST|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
219288862|NCT04237025|OTHER|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
219288863|NCT04752410|PROCEDURE|Selective Brachial Plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
219288864|NCT05626114|BIOLOGICAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
219288865|NCT04396366|DRUG|QBW251|QBW251, 300 mg, oral use, one capsule, twice daily.
219288866|NCT04396366|DRUG|Placebo|Matching placebo, 300 mg, oral use, one capsule, twice daily.
219288867|NCT01497353|PROCEDURE|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
219288868|NCT01497353|PROCEDURE|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
219288869|NCT00550589|DRUG|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
219288870|NCT00550589|GENETIC|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
219288871|NCT00550589|GENETIC|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
219288872|NCT00550589|GENETIC|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
219288873|NCT00550589|PROCEDURE|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
219288874|NCT00550589|PROCEDURE|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
219288875|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
219288876|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
219288877|NCT05470647|BIOLOGICAL|Placebo|Placebo was injected subcutaneously.
219288878|NCT06029894|DIETARY_SUPPLEMENT|Citicoline Supplement|Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
219288879|NCT06029894|OTHER|Placebo|Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
219288880|NCT02333305|DIETARY_SUPPLEMENT|CoQ10|• 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
219288881|NCT02333305|OTHER|Sanomit Placebo|• according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
219288882|NCT03164694|DRUG|Apatinib|Apatinib was given 850 mg per day orally.
219288883|NCT03164694|DRUG|Pemetrexed|pemetrexed (500 mg/m2)
219288884|NCT03164694|DRUG|Carboplatin|carboplatin (AUC =5)
219288885|NCT00166712|DRUG|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
219288886|NCT00166712|DRUG|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
219288887|NCT00166712|DRUG|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
219288888|NCT00166712|DRUG|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
219288889|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
219288890|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
219288891|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
219288892|NCT00350350|DEVICE|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
219288893|NCT00350350|DEVICE|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :~* 94.4% of oxygenated oil~* Silicium dioxide~* aspartame artificial flavoring"
219363019|NCT05268406|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
219288894|NCT04764461|OTHER|Use of customised GROW Charts|Intervention group will follow the same antenatal visit plan and two ultrasounds will be offered (NT 11-13+6 weeks \& anomaly scan 19-22 weeks of gestation) in routine. A third trimester scan will not be offered in routine to Intervention group. Serial SFH measurements will be plotted against estimated date of delivery at each review from 26 weeks of gestation on the customized GROW chart already attached in the maternity notes. On each visit patient will be examined after emptying bladder in a semi-recumbent position, using non-elastic tape with cm side hidden; measurement will be taken from the fundus to upper margin of pubic symphysis. Abnormal SFH measurements, when plotted below the 10th or does not follow its trajectory on customized growth charts will be referred for growth scan suspecting SGA. SFH plotted above 90th centile will also be referred for growth scan, as a part of antenatal care.
219288895|NCT06835972|DRUG|Abemaciclib|twice a day, orally
219288896|NCT06835972|DRUG|Cabozantinib|once daily, orally
219288897|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
219288898|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
219288899|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
219288900|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
219288901|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
219288902|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
219288903|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
219288904|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
219288905|NCT04771754|DRUG|Dolutegravir|50 mg once daily orally
219288906|NCT00245921|DRUG|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
219288907|NCT02409069|DEVICE|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
219288908|NCT02409069|DEVICE|Sham stimulation (Nemos®, Cerbomed GmbH)|
219288909|NCT03866291|OTHER|No intervention, observational|See above
219288910|NCT02420197|BEHAVIORAL|High-intensity resistance training|
219288911|NCT02420197|BEHAVIORAL|General physical activity|
219288912|NCT02420197|BEHAVIORAL|Multidisciplinary rehabilitation program|
219288913|NCT06150482|OTHER|No intervention|No intervention
219288914|NCT01015560|DRUG|anti-CCR2 monoclonal antibody MLN1202|
219288915|NCT01015560|GENETIC|polymorphism analysis|
219288916|NCT01015560|OTHER|laboratory biomarker analysis|
219363020|NCT00003378|DRUG|carboplatin|
219363021|NCT00003378|DRUG|gemcitabine hydrochloride|
219363022|NCT00003378|DRUG|paclitaxel|
219288917|NCT00640133|DEVICE|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
219288918|NCT00640133|DEVICE|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
219288919|NCT02717221|OTHER|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
219288920|NCT01847677|DRUG|Bevacizumab|
219288921|NCT01847677|DRUG|Paclitaxel|
219288922|NCT01847677|DRUG|Carboplatin|
219288923|NCT01096654|OTHER|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
219288924|NCT03704623|DRUG|Paracetamol|Paracetamol 1g IV
219288925|NCT03704623|DRUG|Parecoxib|Parecoxib 40 mg IV
219288926|NCT05298722|DIAGNOSTIC_TEST|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"* The images from CT scans and MRI with DWI will be processed using specialized software to determine the direction of diffusion tensors. This will indicate the diffusion direction using color coding (red, green, and blue for the x, y, and z components of the vector) and the intensity using anisotropy (brightness of voxels). Further analysis will be performed using fiber tracking, which provides a clear representation of the functional connectivity of adjacent tissues.~* Genetic profiling of liquid biopsies: Multi-omics profiling of liquid biopsies (blood samples) will be conducted, followed by cell phenotyping, longitudinal analysis of driver mutations and epigenetic changes in cfDNA, and genotyping of germline variations.~* Questionnaires for patient-reported outcomes and health economic analysis:~EQ-5D-5L PAN 26 HADS"
219288927|NCT00589589|DEVICE|Endo Tool|Computer tool to help achieve glucose control
219288928|NCT03795753|DEVICE|F2S Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
219288929|NCT03795753|OTHER|Non-functioning Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
219288930|NCT00924690|OTHER|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
219288931|NCT00924690|OTHER|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
219288932|NCT03990116|PROCEDURE|Lateral|Posture lateral kangaroo care
219288933|NCT03990116|PROCEDURE|Prone|Posture prone kangaroo care
219288934|NCT00128102|DRUG|Vorinostat|Vorinostat 100 mg oral capsules
219288935|NCT00128102|DRUG|Placebo|Vorinostat-matching placebo oral capsules
219288936|NCT04929275|PROCEDURE|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
219288937|NCT01202903|DRUG|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
219288938|NCT01202903|DRUG|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
219288939|NCT04808752|DRUG|Almonertinib|Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
219288940|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
219288941|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
219288942|NCT00352326|DEVICE|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
219288943|NCT04586764|DEVICE|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
219288944|NCT03081364|OTHER|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
219288945|NCT06964776|DRUG|LY4268989|Administered orally
219288946|NCT06964776|DRUG|Placebo|Administered placebo
219288947|NCT06964776|DRUG|Midazolam|Administered orally
219288948|NCT06964776|DRUG|Midazolam|Administered intravenously (IV)
219288949|NCT02117453|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day
219288950|NCT02117453|DRUG|Placebo|Placebo
219288951|NCT03282669|DRUG|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
219288952|NCT03282669|DRUG|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
219288953|NCT05781191|BIOLOGICAL|COMIRNATY|Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
219288954|NCT02768532|DRUG|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
219288955|NCT03339245|OTHER|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
219288956|NCT03339245|OTHER|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
219288957|NCT02897050|DRUG|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
219288958|NCT02897050|DRUG|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
219288959|NCT02897050|DRUG|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
219288960|NCT02897050|DRUG|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
219288961|NCT02897050|DRUG|Epirubicin|Epirubicin 100mg/m2, iv, d1
219288962|NCT02897050|DRUG|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
219288963|NCT00633646|DIETARY_SUPPLEMENT|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
219288964|NCT03916679|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
219288965|NCT00964275|PROCEDURE|diagnostic procedure|Standard diagnostic procedures followed
219288966|NCT00964275|RADIATION|fludeoxyglucose F 18|PET with flueoxyglucose F 18
219288967|NCT06182553|OTHER|Expiratory Rib Cage Compression|Expiratory rib cage compression (ERCC) In this study, ERCC is a technique consisting of bilateral manual compression of the lower rib cage (anterolateral region of the chest at the level of the six last ribs) gradually during the expiratory phase of the ventilatory cycle and release from the compression at the end of the expiration.
219288968|NCT06182553|OTHER|PEEP-ZEEP Maneuver|PEEP-ZEEP maneuver In this study, PEEP-ZEEP maneuver refers to PEEP which stands for positive end-expiratory pressure, and ZEEP which stands for zero end-expiratory pressure. In this maneuver PEEP will be incremented to 15 cmH2O throughout five consecutive respiratory cycles, then immediately after the inspiratory phase of the fifth cycle has been ended ZEEP should be done by abruptly reducing PEEP value to 0 cmH2O. The PEEP-ZEEP maneuver should be performed in two sets, consisting of a total of 10 consecutive breathing cycles. Subsequently, the patient is ventilated according to his/her baseline ventilator parameters.
219288969|NCT06182553|OTHER|ERCC + PEEP-ZEEP maneuver|\- The ERCC technique will be applied as mentioned above, then followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before.
219288970|NCT01570959|DRUG|Quetiapine Fumarate|300 mg tablet
219288971|NCT04389151|DRUG|Toripalimab|Toripalimab union CAPEOX scheme： Toripalimab 240mg, ivgtt, Q3w Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w
219288972|NCT00000444|DRUG|nicotine replacement patch|
219288973|NCT05154877|DEVICE|OMNI PET/CT Scan|The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.
219288974|NCT02166996|PROCEDURE|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
219288975|NCT02166996|PROCEDURE|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
219288976|NCT04630041|BEHAVIORAL|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
219288977|NCT05557175|DEVICE|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
219288978|NCT05557175|DEVICE|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
219288979|NCT04143945|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
219288980|NCT04143945|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
219288981|NCT04370548|DRUG|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
219288982|NCT00306670|DRUG|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
219288983|NCT00306670|DRUG|prednisone|\<30 mg/day
219288984|NCT04850677|OTHER|Observational Cohort|Observational study
219288985|NCT00159939|PROCEDURE|prone positioning|prone positioning
219288986|NCT03450837|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
219288987|NCT03450837|DIAGNOSTIC_TEST|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
219288988|NCT02776722|OTHER|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
219288989|NCT00072228|DRUG|gemcitabine|
219288990|NCT00072228|DRUG|soblidotin|
219288991|NCT00072228|PROCEDURE|chemotherapy|
219288992|NCT02735655|OTHER|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
219288993|NCT02169362|DEVICE|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
219288994|NCT01178697|DRUG|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
219288995|NCT01178697|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
219288996|NCT06229652|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
219288997|NCT06229652|OTHER|Body-oriented Yoga|"Body-oriented Yoga following the Ashtanga style will be held by certified yoga teacher parallel to the experimental one hour per week 10 times.~Each yoga session will start with the proper warming up of the whole body with some stretching exercises (20 min). The main part will last about 30 minutes and consist of dynamic and active yoga sequencing containing sun salutation with a mix of exercises. A relaxation phase with controlled breathing and meditation-elements will finish the class (10 min). Each exercise has different complexity levels of implementation and will be adapted to the performance abilities of each participant."
219288998|NCT03275597|DRUG|Durvalumab|Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
219288999|NCT03275597|DRUG|Tremelimumab|Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
219289000|NCT03275597|RADIATION|Stereotactic Body Radiotherapy|SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
219289001|NCT03695939|BIOLOGICAL|realSKIN (skin xenotransplant)|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
219289002|NCT03695939|BIOLOGICAL|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
219363023|NCT00931489|DRUG|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
219289003|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL of\[ 5\]µg dexmedetomidine. The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
219289004|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL normal saline . The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
219289005|NCT00503139|DRUG|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
219289006|NCT03690583|DRUG|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
219289007|NCT03690583|OTHER|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
219289008|NCT02735577|DRUG|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
219289009|NCT01640470|DEVICE|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
219289010|NCT01640470|DEVICE|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
219289011|NCT01800682|DRUG|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
219289012|NCT04340791|BEHAVIORAL|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
219289013|NCT04340791|BEHAVIORAL|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
219289014|NCT04723914|BIOLOGICAL|dual target CAR-T cell therapy|CD19/CD20 dual target CAR-T cell therapy
219289015|NCT05253300|OTHER|Positioning the patient|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
219289016|NCT00833833|DRUG|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
219289017|NCT00833833|DRUG|Dexamethasone|oral dexamethasone
219289018|NCT00833833|DRUG|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
219289019|NCT01291823|DRUG|gefitinib|gefitinib 250mg/day
219289020|NCT01291823|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
219289021|NCT02365727|DRUG|Liposomal bupivacaine|
219289022|NCT02365727|DRUG|Ropivacaine|
219289023|NCT02365727|DRUG|Epinephrine|
219289024|NCT02365727|DRUG|Clonidine|
219289025|NCT02365727|DRUG|Saline|
219289026|NCT02814084|DEVICE|Bilateral Internal Mammary Artery grafts|Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
219289027|NCT02814084|DEVICE|Prevena|The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
219289028|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
219289029|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
219289030|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
219289031|NCT06019624|BEHAVIORAL|Fresh Takes!|Receipt of a fresh produce box, nutritional education and support in a 6 month program
219289032|NCT06056791|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
219289033|NCT05715021|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
219289034|NCT01994837|DRUG|ABT-199|Tablet
219289035|NCT04135690|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
219289036|NCT04135690|DRUG|Toripalimab|240mg intravenously every 3 weeks
219289037|NCT04135690|DRUG|Sorafenib|400mg bid po
219289038|NCT04135690|DRUG|systemic treatment|atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on
219289039|NCT00518544|DRUG|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
219289040|NCT02630108|PROCEDURE|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
219289041|NCT02630108|DRUG|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
219289042|NCT02630108|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
219289043|NCT02630108|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
219289044|NCT03206892|DEVICE|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
219289045|NCT06463665|BIOLOGICAL|Olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
219289046|NCT06463665|DRUG|Platinum chemotherapy: carboplatin or cisplatin|Administered according to local practice.
219289047|NCT06463665|DRUG|Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|Administered according to local practice.
219289048|NCT06463665|DRUG|Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|Administered according to local practice.
219289049|NCT06463665|DRUG|Docetaxel|Administered according to local practice.
219289050|NCT06363071|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
219289051|NCT06363071|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
219289052|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
219289053|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
219289054|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
219289055|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
219289056|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
219289057|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
219289058|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
219289059|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
219289060|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
219289061|NCT01262677|DRUG|placebo|matched to the active drug
219289062|NCT02913053|BEHAVIORAL|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
219289063|NCT02913053|BEHAVIORAL|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
219289064|NCT03356782|BIOLOGICAL|Sarcoma-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
219289065|NCT02928276|OTHER|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
219289066|NCT02905071|OTHER|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
219289067|NCT02905071|OTHER|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
219289068|NCT02905071|OTHER|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
219289069|NCT00574873|DRUG|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
219289070|NCT00574873|DRUG|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
219289071|NCT05416073|DRUG|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
219289072|NCT05416073|DRUG|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
219289073|NCT05316272|BEHAVIORAL|Exercise|Supervised bone-loading exercise on 3 days per week for 36 weeks
219289074|NCT05316272|DIETARY_SUPPLEMENT|DHEA|DHEA in pill form 50 milligrams taken daily for 36 weeks
219289075|NCT04603287|DRUG|SI-B001|Administration by intravenous infusion.
219289076|NCT05621577|DEVICE|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
219289077|NCT02043964|PROCEDURE|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
219289078|NCT05628805|DEVICE|iTBS|intermittent theta burst stimulation with TMS
219289079|NCT06504160|DRUG|ShA9 Topical Gel|The ShA9 topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose containing lyophilized ShA9 bacteria. The ShA9 bacteria is derived from a healthy donor-derived (allogeneic) commensal Staph species. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
219289080|NCT06504160|DRUG|Hydrocortisone Ointment|All participants will apply hydrocortisone ointment 2.5% alongside the study product in sensitive body areas (e.g., face, neck, intertriginous regions) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
219289081|NCT06504160|DRUG|Clobetasol Ointment|All participants will apply clobetasol ointment 0.05% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It will be applied twice daily to lesional skin and selected sampling areas from Baseline to Week 2. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
219289082|NCT06504160|DRUG|Fluocinonide Ointment|Participants with a past intolerance to clobetasol or who become too sensitive to clobetasol in the initial two-week cotreatment period will apply fluocinonide ointment 0.05% as an alternative. In these cases, fluocinonide ointment 0.05% will be applied alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
219289083|NCT06504160|DRUG|Placebo (Vehicle) Topical Gel|The placebo (vehicle) topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
219289084|NCT06370520|BEHAVIORAL|Validated Questionnaires|Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), The Rivermead Post Concussion Symptom Questionnaire (Rivermead), Pediatric Quality of Life Inventory (PedsQL), Strengths and Difficulties Questionnaire (SDQ)
219289085|NCT06370520|BEHAVIORAL|Questionnaires|Early Physical Activity/Return to School Questionnaire, Mental Health Utilization Questionnaire
219289086|NCT06370520|OTHER|Clinician / Medical Record Variables|Medical History, Emergency Department Clinical Variables
219289087|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
219289088|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
219289089|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
219289090|NCT01440998|DRUG|Carboplatin|Given IV
219289091|NCT01440998|DRUG|Dasatinib|Given PO
219289092|NCT01440998|OTHER|Laboratory Biomarker Analysis|Correlative studies
219289093|NCT01440998|DRUG|Paclitaxel|Given IV
219289094|NCT03674359|DIAGNOSTIC_TEST|BDG analysis|BDG analysis
219289095|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
219289096|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
219289097|NCT05571579|BIOLOGICAL|blood and/or csf collection|"blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
219289098|NCT03581383|BEHAVIORAL|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
219289099|NCT03581383|BEHAVIORAL|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
219289100|NCT03581383|BEHAVIORAL|Patient Telemedicine Questionnaire|The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
219289101|NCT01808937|OTHER|Morphea|
219289102|NCT04195139|DRUG|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
219289103|NCT04195139|DRUG|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
219289104|NCT03283254|BEHAVIORAL|Practical Resources for Effective Postpartum Parenting (PREPP)|A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
219289105|NCT03283254|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|"Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate."
219289106|NCT02541955|DRUG|Acthar|Injections will be self administered
219289107|NCT02055781|DRUG|Pacritinib|
219289108|NCT02055781|DRUG|Best Available Therapy|
219289109|NCT03831126|DRUG|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
219289110|NCT05689710|DIETARY_SUPPLEMENT|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
219289111|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
219289112|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
219289113|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
219289114|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
219289115|NCT03623945|OTHER|Collection of blood|Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
219289116|NCT03017573|PROCEDURE|Tumor biopsies / Tumor surgery|"Tumoral tissues samples must be collected at different times points :~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)~OR~* before neoadjuvant therapy~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)"
219289117|NCT03017573|PROCEDURE|Blood withdrawal|"Blood samples must be collected at different times points :~* at the time of surgery or before the beginning of chemoradiotherapy~* after surgery or after chemoradiotherapy~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression~OR~* before neoadjuvant therapy~* during neoadjuvant therapy (post cycle 1)~* at the time of surgery~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression"
219289118|NCT05286684|PROCEDURE|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
219289119|NCT05286684|PROCEDURE|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
219289120|NCT05286684|BIOLOGICAL|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
219289121|NCT06204445|DIETARY_SUPPLEMENT|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
219289122|NCT06204445|DIETARY_SUPPLEMENT|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
219289123|NCT05745922|BEHAVIORAL|Moderate intensity exercise|Treadmill walking/running with moderate intensity
219289124|NCT05745922|BEHAVIORAL|High intensity exercise|Treadmill walking/running with high intensity
219289125|NCT02246153|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
219289126|NCT02246153|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
219289127|NCT06233890|DEVICE|Motion watch|Actigraphy watch to be worn for 14 days
219289128|NCT06195540|DRUG|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
219289129|NCT06195540|DRUG|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
219289130|NCT00736905|DRUG|TMC278|
219289131|NCT05769556|OTHER|Brain Gym Exercises|Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.
219289132|NCT05769556|OTHER|Traditional physiotherapy|A Group of exercises
219289133|NCT00242905|BEHAVIORAL|Study of memory using MRI|Study of memory using MRI
219289134|NCT00201643|DRUG|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
219289135|NCT00201643|DRUG|Placebo|Course of Placebo (NS)
219289136|NCT01791387|DRUG|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
219289137|NCT04330001|DEVICE|Alcon Fluid Accommodating Intraocular Lens|Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.
219289138|NCT04330001|OTHER|Top Con Autorefractor|Device intended to automatically determine the focusing characteristics of the eye
219289139|NCT01355900|PROCEDURE|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
219289140|NCT01231009|DRUG|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
219289141|NCT01231009|OTHER|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
219289142|NCT03837210|DRUG|Pylorin|Poly Herbal formulation
219289143|NCT01671254|DIETARY_SUPPLEMENT|FishOil|
219289144|NCT01671254|DIETARY_SUPPLEMENT|CBE75|
219289145|NCT01671254|DIETARY_SUPPLEMENT|CBE150|
219289146|NCT01671254|DIETARY_SUPPLEMENT|placebo|
219289147|NCT04199832|DIETARY_SUPPLEMENT|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
219289148|NCT03883139|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
219289149|NCT03883139|BEHAVIORAL|DTT (Discrete Trial Training)|"DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction."
219289150|NCT05137132|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
219289151|NCT05137132|DIETARY_SUPPLEMENT|Placebo|MCT oil
219289152|NCT05830864|DRUG|Isoflurane|no other intervention
219289153|NCT05225428|BEHAVIORAL|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
219289154|NCT05225428|BEHAVIORAL|Genetic Counseling|Standard genetic counseling
219289155|NCT03866798|BIOLOGICAL|Panzyga|Immune Globulin, intravenous, human-ifas
219289156|NCT06629649|OTHER|Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.|Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
219289157|NCT04142359|BIOLOGICAL|BCG in Combination with N-803|BCG in Combination with N-803
219289158|NCT04142359|DRUG|N-803 alone|N-803 alone
219289159|NCT05663970|BEHAVIORAL|VG Social ABCs|The Social ABCs is an evidence-based caregiver-mediated early intervention. This trial examines the 6-week Virtual Group Social ABCs; an adapted model of the existing evidence-based Social ABCs. The targets are functional directed vocalizations and positive emotion sharing with a caregiver. It is provided to small groups of parents (4-8 per group) who meet virtually for a series of 6 didactic learning sessions led by two trained Coaches, supported by the programs Parent Manual, PowerPoint slides, facilitated discussion, reflection, and idea generation. Each family is assigned a Coach, and one parent per family receives 9 individualized, 1:1 live coaching sessions over a 6-week period via the virtual platform with the goal of learning to implement the Social ABCs strategies with their child. 10-min video recordings of caregiver and child are taken at baseline(time 0), post intervention (time 1),and follow up (time 2) as a measurement of fidelity of implementation and child responsivity.
219289160|NCT03786042|BEHAVIORAL|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
219289161|NCT03786042|OTHER|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
219289162|NCT05924841|DRUG|BL-B01D1|Administration by intravenous infusion
219289163|NCT05924841|DRUG|SI-B003|Administration by intravenous infusion
219289164|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.
219289165|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 225 IU fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose could be adjusted by 75 IU based on the participant's response. The minimum GONAL-F dose was 75 IU and the maximum GONAL-F dose was 300 IU. Participants could be treated for a maximum of 20 days.
219289166|NCT06080243|BIOLOGICAL|R21/Matrix-M1|10 µg of R21 and 50 µg of Matrix-M1
219289167|NCT06080243|BIOLOGICAL|Saline and R21/Matrix-M1|Saline and 10 µg of R21 and 50 µg of Matrix-M1
219289168|NCT06080243|OTHER|Sterile isotonic (0.9%) normal saline|Saline
219289169|NCT05720156|OTHER|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
219289170|NCT06845852|DRUG|varegacestat|Single oral dose of varegacestat
219289171|NCT00056992|DRUG|ADI-PEG 20|
219289172|NCT06133153|DEVICE|THIODERM ELATE|Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
219289173|NCT06133153|DEVICE|Juvéderm Ultra 3|BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
219289174|NCT04907565|BIOLOGICAL|Blood sampling|4 tubes of 7 mL of blood will be collected
219289175|NCT04907565|BIOLOGICAL|white adipose tissue sampling|At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.
219289176|NCT01899898|OTHER|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~1. Pictorial representation of various food items and exchange lists will be provided.~2. Instead of weights, we will provide standardized measures~3. We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~4. We will formulate recipes and diets based on locally available and culturally acceptable foods.~5. We will develop a parent instruction manual.~6. We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~7. We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
219289177|NCT01899898|DRUG|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
219289178|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
219289179|NCT02508220|DRUG|Syntocinon|Oxytocin nasal spray
219289180|NCT02508220|DRUG|Placebo|distilled water in nasal spray
219289181|NCT02093949|PROCEDURE|Routine substrate ablation without pulmonary vein Isolation|
219289182|NCT02093949|PROCEDURE|Routine conventional ablation with pulmonary vein Isolation|
219289183|NCT06241898|DRUG|BB-1709|Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
219289184|NCT06184581|DRUG|Lithium Carbonate|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
219289185|NCT06184581|DRUG|Lamotrigine|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
219289186|NCT05331573|DEVICE|apomorphine pump|observationnal
219289187|NCT02450045|PROCEDURE|Continuous femoral nerve block|
219289188|NCT02450045|DRUG|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
219289189|NCT05490238|PROCEDURE|Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)|Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
219289190|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
219289191|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
219289192|NCT05141500|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~* 1859 \& 2329~* MAX-A \& MAX-N"
219289193|NCT02590900|DRUG|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
219289194|NCT03819790|DRUG|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
219289195|NCT03819790|DRUG|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
219289196|NCT03819790|DRUG|Metformin|Patients can be administered with most tolerant dose of metformin
219289197|NCT06420518|OTHER|Ketogenic diets|During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.
219289198|NCT06420518|OTHER|8-hour insulin-suspension period|Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.
219289199|NCT02140255|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
219289200|NCT02140255|DRUG|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
219289201|NCT02140255|DRUG|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
219289202|NCT02140255|DRUG|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
219289203|NCT02140255|DRUG|VRC01|40 mg/kg administered subcutaneously.
219289204|NCT02140255|DRUG|DTG|Administered orally. Dosed according to participant's weight.
219289205|NCT02140255|DRUG|VRC07-523LS|40 mg/kg administered subcutaneously.
219289206|NCT03568318|DRUG|Placebo|Tablets taken orally once a day
219289207|NCT03568318|DRUG|Upadacitinib|Tablets taken orally once a day
219289208|NCT03568318|DRUG|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
219289209|NCT00542776|OTHER|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
219289210|NCT00897117|GENETIC|gene expression analysis|Blood and lung tissue collection
219289211|NCT00897117|GENETIC|microarray analysis|Blood and lung tissue collection
219289212|NCT00897117|GENETIC|protein expression analysis|Blood and lung tissue collection
219289213|NCT00897117|OTHER|biologic sample preservation procedure|Blood and lung tissue collection
219289214|NCT00897117|OTHER|laboratory biomarker analysis|Blood and lung tissue collection
219289215|NCT00897117|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
219289216|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
219289217|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
219289218|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
219289219|NCT05594797|DRUG|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
219289220|NCT00449605|DRUG|Rimonabant|Tablet, oral administration
219289221|NCT00449605|DRUG|Glimepiride|Tablet, oral administration
219289222|NCT00449605|DRUG|Metformin|Metformin continued at stable dose as background therapy
219289223|NCT05246527|BEHAVIORAL|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
219289224|NCT05246527|BEHAVIORAL|Control Intervention|30 min of watching a movie
219289225|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
219289226|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
219289227|NCT04063475|DRUG|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
219289228|NCT06364787|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
219289229|NCT06364787|DRUG|Targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
219289230|NCT06364787|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
219289231|NCT01638429|DRUG|Neomycin|Neomycin: 500mg po bid for 10 days
219289232|NCT01638429|DRUG|Rifaximin|Rifaximin: 550mg po tid for 10 days
219289233|NCT04909398|BEHAVIORAL|Dynamic pupillometry sessions|"The evaluation protocol will include the following steps:~* Installation of the subject, adaptation of the chin rest for the best comfort of the participant~* Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen~* Final validation of the eligibility of the subject in the study according to the success or not of the calibration."
219289234|NCT03483259|DRUG|Sulfatinib T capsule|Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
219289235|NCT03483259|DRUG|Sulfatinib R capsule|Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
219289236|NCT06426420|DIAGNOSTIC_TEST|FTIR spectroscopy analysis|ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.
219289237|NCT02703181|DRUG|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
219289238|NCT02703181|DRUG|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
219289239|NCT05880602|DIETARY_SUPPLEMENT|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
219289240|NCT05880602|DIETARY_SUPPLEMENT|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
219289241|NCT03823573|BEHAVIORAL|Walk within 24 hours|Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
219289242|NCT04116580|OTHER|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
219289243|NCT04333251|BIOLOGICAL|high-titer anti-Sars-CoV-2 plasma|Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer \>1:64 vs best supportive care
219289244|NCT04333251|OTHER|oxygen therapy|oxygen therapy
219289245|NCT04610541|DRUG|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
219289246|NCT03207451|DRUG|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
219289247|NCT03207451|DRUG|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
219289248|NCT03207451|DRUG|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
219289249|NCT03207451|DRUG|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
219289250|NCT02486276|DRUG|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219289251|NCT02486276|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219289252|NCT02486276|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219289253|NCT02240459|DRUG|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
219289254|NCT02240459|DRUG|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
219289255|NCT02240459|DRUG|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
219289256|NCT02240459|DRUG|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
219289257|NCT05589805|DEVICE|Extracorporeal shock wave therapy|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
219289258|NCT05589805|DEVICE|Laser therapy|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
219289259|NCT05589805|OTHER|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
219289260|NCT05044897|DRUG|SI-B001|administration weekly by intravenous infusion（QW）.
219289261|NCT06308887|DRUG|Triamcinolone Hexacetonide|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 0.5 mg/5 ml of triamcinolone acetonide was injected.
219289262|NCT06308887|DRUG|Dextrose 5% in water|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 5 ml of 5% dextrose was injected.
219289263|NCT01205334|BIOLOGICAL|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
219289264|NCT05635201|DRUG|Anesthesia induction with propofol|After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
219289265|NCT05635201|DRUG|Anesthesia induction with remimazolam|After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
219289266|NCT03257943|DRUG|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
219289267|NCT03257943|DRUG|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
219289268|NCT03257943|DRUG|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
219289269|NCT06475430|BIOLOGICAL|fecal microbiota transplantation|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration.
219289270|NCT06475430|DIETARY_SUPPLEMENT|Formulated probiotic supplements|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the control group receiving a standardized probiotic formula.
219289271|NCT00841217|DRUG|GW501516|2.5mg/day
219289272|NCT00841217|DRUG|placebo pill|
219289273|NCT04398290|DRUG|Inhaled nitric oxide (iNO)|iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
219289274|NCT04398290|DRUG|Nitrogen gas|250 mcg/kg ideal body weight (IBW)/hour
219289275|NCT04398290|DRUG|Oxygen gas|Supplemental oxygen administered via nasal cannula
219289276|NCT01261065|DRUG|carvedilol|Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
219289277|NCT04439162|PROCEDURE|retrograde cardioplegia protection|antegrade-retrograde cardioplegia
219289278|NCT00859729|BIOLOGICAL|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
219289279|NCT00859729|DEVICE|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
219289280|NCT04421443|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
219289281|NCT06306716|DEVICE|RENASYS Film with AIRLOCK Technology|RENASYS Film with AIRLOCK Technology intended for use with Smith+Nephew RENASYS NPWT Systems
219289282|NCT02885324|DRUG|Cabozantinib|Subjects will receive Cabozantinib
219289283|NCT00628576|DRUG|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
219289284|NCT00628576|DRUG|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
219289285|NCT04763317|GENETIC|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
219289286|NCT00996476|DRUG|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
219289287|NCT00996476|DRUG|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
219289288|NCT00996476|DRUG|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
219289289|NCT06281821|BEHAVIORAL|mhealth-pc|Participants meet with an interventionist who explains the rationale for the mobile app. They complete video and survey-based intervention content each week for 8 weeks. App-based sessions are supplemented with brief chat-based coaching weekly.
219289290|NCT01507519|DEVICE|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
219289291|NCT06291675|DRUG|gender-affirming hormone therapy|We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
219289292|NCT02415673|DEVICE|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
219289293|NCT05540717|BIOLOGICAL|PQ Grass|Suspension for Injection
219289294|NCT05540717|BIOLOGICAL|Placebo|Solution for injection
219289295|NCT01322802|BIOLOGICAL|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
219289296|NCT01322802|OTHER|laboratory biomarker analysis|Correlative studies
219289297|NCT02881320|DRUG|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food.
219289298|NCT02881320|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food.
219289299|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.
219289300|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
219289301|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
219289302|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
219289303|NCT01851499|DIETARY_SUPPLEMENT|Ultramicronized PEA (Normast)|600 mg
219289304|NCT05527652|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
219289305|NCT00473265|DRUG|PTH|
219289306|NCT00519519|DRUG|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
219289307|NCT04513652|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
219289308|NCT04513652|DRUG|Placebo|Placebo Topical Ophthalmic Solution
219289309|NCT00692276|DEVICE|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
219289310|NCT00692276|DEVICE|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
219289311|NCT04538911|DRUG|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
219289312|NCT05612503|OTHER|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
219289313|NCT05612503|OTHER|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
219289314|NCT01828489|DRUG|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
219289315|NCT01828489|DRUG|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
219289316|NCT01940939|DEVICE|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
219289317|NCT01470001|DRUG|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
219289318|NCT00717327|OTHER|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
219289319|NCT01895101|DRUG|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
219289320|NCT01895101|DRUG|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
219289321|NCT02077101|OTHER|Questionnaire|
219289322|NCT02077101|OTHER|Interview|
219289323|NCT04546490|OTHER|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
219289324|NCT04546490|OTHER|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
219289325|NCT02126761|BIOLOGICAL|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
219289326|NCT02126761|BIOLOGICAL|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
219289327|NCT02126761|BIOLOGICAL|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
219289328|NCT02126761|BIOLOGICAL|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
219289329|NCT04500795|PROCEDURE|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
219289330|NCT03246776|DRUG|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
219289331|NCT03879369|DIAGNOSTIC_TEST|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
219289332|NCT04635969|BEHAVIORAL|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
219289333|NCT05826470|DEVICE|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
219289334|NCT03085173|BIOLOGICAL|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
219289335|NCT06358638|DRUG|Daratumumab|Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
219289336|NCT06358638|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
219289337|NCT06358638|DRUG|Sirolimus|Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
219289338|NCT06358638|RADIATION|Total Body Irradiation|Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
219289339|NCT06472102|PROCEDURE|Cardioneuroablation|Endocardial radio-frequency ablation of areas of ganglionated plexi in the left and the right atrium
219289340|NCT04254822|PROCEDURE|Transjugular intrahepatic portosystemic shunt|The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
219289341|NCT04254822|DRUG|Carvedilol|Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
219289342|NCT04254822|PROCEDURE|Endoscopic variceal ligation|For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
219289343|NCT02728739|PROCEDURE|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (\>30 pg/ ml) for grading of MR severity within 7 days.
219289344|NCT04836403|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
219289345|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
219289346|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
219289347|NCT05304234|DIAGNOSTIC_TEST|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
219289348|NCT04293003|OTHER|fasting|6-hour fasting
219289349|NCT04293003|OTHER|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
219289350|NCT04293003|OTHER|Mediterranean|Consumption of a Mediterranean-type breakfast
219289351|NCT03732742|PROCEDURE|TOF repair with trans-annular patch VS preservation of PV|One group study
219289352|NCT06138652|BEHAVIORAL|App|Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
219289353|NCT06325644|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
219289354|NCT06325644|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
219289355|NCT06325644|BIOLOGICAL|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
219289356|NCT06325644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
219289357|NCT06325644|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
219289358|NCT06325644|OTHER|Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .|Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
219289359|NCT03339583|BEHAVIORAL|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
219289360|NCT03339583|DRUG|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
219289361|NCT04974125|PROCEDURE|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
219289362|NCT04974125|PROCEDURE|Manual exsufflation|Exsufflation through the trocar opening.
219289363|NCT05990803|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
219289364|NCT05990803|DRUG|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
219289365|NCT00734591|DRUG|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
219289366|NCT00734591|OTHER|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
219289367|NCT05881993|DRUG|CBP-4888|siRNA therapeutic
219289368|NCT05881993|OTHER|Placebo|Normal Saline
219289369|NCT01085968|BEHAVIORAL|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
219289370|NCT05949866|BEHAVIORAL|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
219289371|NCT05949866|BEHAVIORAL|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
219289381|NCT06121206|OTHER|Altitude-like hypoxia (12% O2)|Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
219289382|NCT06121206|OTHER|Normoxia (20% O2)|Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
219289383|NCT06121206|BEHAVIORAL|Cognitive training|The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
219289384|NCT06121206|BEHAVIORAL|Sham training|Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
219289385|NCT06527937|DRUG|DESF|DESF administered in the sublingual space.
219289386|NCT06527937|DRUG|Epinephrine Injection|Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
219289387|NCT05156151|OTHER|Relex-Smile|
219289388|NCT01996462|DRUG|Escitalopram Oxalate Tablets|
219289389|NCT06042894|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
219289390|NCT06042894|DRUG|SI-B003|SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
219289391|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
219289392|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
219289393|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
219289394|NCT06962280|DRUG|Tirzepatide|Administered SC
219289395|NCT06962280|DRUG|Placebo|Administered SC
219289396|NCT06431048|OTHER|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).
219289397|NCT06431048|OTHER|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
219289398|NCT06150859|DRUG|Ayahausca-Assisted psychotherapy|"Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions."
219289399|NCT06150859|BEHAVIORAL|Constructivist Psychotherapy|Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions
219289400|NCT06150859|OTHER|No treatment|No treatment during the control period
219289401|NCT00263016|DRUG|Docetaxel|
219289402|NCT03415373|DEVICE|Microneedle Adapter (Model UAR-2S)|Investigational device
219289403|NCT03415373|DEVICE|Hypodermic needle + syringe|Control device
219289404|NCT03301441|OTHER|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
219289405|NCT00338962|DRUG|paroxetine|paroxetine (40mg/day)
219289406|NCT00338962|DRUG|desipramine|200 mg per day
219289407|NCT00338962|DRUG|Naltrexone|50 mg per day
219289408|NCT00338962|DRUG|Placebo|placebo
219289409|NCT05178069|DRUG|: Placebo for Probiotic|Capsule manufactured without active ingredients.
219289410|NCT05178069|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
219289411|NCT03121209|PROCEDURE|Revascularization|Patients in this arm are randomized to CEA/CAS plus IMM
219289412|NCT03121209|OTHER|Intensive Medical Management (IMM) alone|Patients in this arm are randomized to intensive medical management (IMM) alone
219289413|NCT02974777|DRUG|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
219289414|NCT02974777|DRUG|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
219289415|NCT02974777|DRUG|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
219289416|NCT03214640|DEVICE|Rivanna Accuro US Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
219289417|NCT03214640|OTHER|Palpation|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method using conventional landmarks (spinous process and iliac crest). For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
219289418|NCT03214640|PROCEDURE|Neuraxial Analgesia|Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
219289419|NCT03214640|PROCEDURE|Spinal Block|Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
219289420|NCT00528619|DRUG|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
219289421|NCT05893368|OTHER|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~* a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~* report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~* digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
219289422|NCT04620343|PROCEDURE|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
219289423|NCT04620343|PROCEDURE|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
219289424|NCT04620343|PROCEDURE|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
219289425|NCT04620343|PROCEDURE|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
219289426|NCT04620343|PROCEDURE|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
219289427|NCT04620343|PROCEDURE|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
219289428|NCT04620343|PROCEDURE|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
219289429|NCT05252442|OTHER|Pre-COVID-19|Pre-COVID-19 period
219289430|NCT05252442|OTHER|COVID-19|COVID-19 period
219289431|NCT05252442|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
219289432|NCT02276144|OTHER|Liver ultrasound|For evaluate whether fatty liver is exist or not
219289433|NCT00599703|OTHER|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
219289434|NCT03882580|DRUG|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
219289435|NCT06196320|DRUG|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
219289436|NCT06196320|DRUG|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
219289437|NCT01259089|DRUG|erlotinib hydrochloride|Given orally
219289438|NCT01259089|DRUG|Hsp90 inhibitor AUY922|Given IV
219289439|NCT01259089|OTHER|laboratory biomarker analysis|Correlative studies
219289440|NCT01259089|PROCEDURE|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
219289441|NCT01259089|GENETIC|mutation analysis|Correlative studies
219289442|NCT01259089|OTHER|pharmacological study|Correlative studies
219289443|NCT01280357|DEVICE|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
219289444|NCT01280357|DEVICE|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
219289445|NCT00886795|DRUG|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
219289446|NCT02818244|DEVICE|Fit Bit Blaze Heart Rate Monitoring Device|
219289447|NCT02818244|DEVICE|Garmin Forerunner 235 Heart Rate Monitoring Device|
219289448|NCT02818244|DEVICE|Tom Tom Spark Cardio Heart Rate Monitoring Device|
219289449|NCT02818244|DEVICE|Apple Watch Heart Rate Monitoring Device|
219289450|NCT02818244|DEVICE|Scosche Rhythm + Heart Rate Monitor|
219289451|NCT05890001|DRUG|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
219289452|NCT02310100|DEVICE|TactiCath Quartz treatment|
219289453|NCT02837003|DRUG|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
219289454|NCT02837003|DRUG|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
219289455|NCT05020587|BEHAVIORAL|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
219289456|NCT02580721|DEVICE|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
219289457|NCT03262662|DRUG|Varenicline|oral varenicline tablets
219289458|NCT03262662|BEHAVIORAL|Brief smoking cessation counseling|\~10-minute individual counseling at each of 6 clinic visits
219289459|NCT01828762|BIOLOGICAL|DC-TC+GM-CSF|
219289460|NCT00688870|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
219289461|NCT00688870|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
219289462|NCT02905448|OTHER|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
219289463|NCT00937677|DRUG|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
219289464|NCT03537495|DRUG|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
219289465|NCT00477659|DRUG|Donepezil hydrochloride|Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
219289466|NCT02878005|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
219289467|NCT02878005|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
219289468|NCT00625547|DRUG|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
219289469|NCT00625547|DRUG|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
219289470|NCT00329173|DRUG|Rosuvastatin|
219289471|NCT00329173|DRUG|Atorvastatin|
219289472|NCT03924440|DIAGNOSTIC_TEST|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
219289473|NCT05833477|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin treatment three times per week for three weeks
219289474|NCT06194552|DRUG|NTRX-07|Investigational orally administered CB2 agonist
219289475|NCT06194552|DRUG|Placebo|Matched placebo administered orally
219289476|NCT04059302|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy for Insomnia|The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
219289477|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
219289478|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention"
219289479|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
219289480|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
219289481|NCT05751954|RADIATION|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
219289482|NCT05751954|DEVICE|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
219289483|NCT02571153|DRUG|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
219289484|NCT02571153|DRUG|Normal saline|Intravenous normal saline 0.9% 5 mL
219289485|NCT02571153|DRUG|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
219289486|NCT05723159|DEVICE|Clinical Validation of the Hyfe Cough Monitoring System|The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.
219289487|NCT02324400|DEVICE|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
219289488|NCT02324400|DEVICE|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
219289489|NCT02094287|DRUG|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
219289490|NCT02094287|BEHAVIORAL|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
219289491|NCT02094287|OTHER|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
219289492|NCT01140295|DRUG|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age \>12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
219289493|NCT06270043|PROCEDURE|Focal Therapy|"Focal ablation of prostate cancer using different modalities. These modalities include:~* Cryoablation or Cryotherapy~* Irreversible Electroporation - Nanoknife~* High Intensity Frequency Ultrasound - FocalOne~* Transurethral Ultrasound Ablation - TULSA - PRO"
219289494|NCT01821352|DEVICE|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
219289495|NCT01821352|DEVICE|Placebo Laser|Emits light that has no therapeutic effect
219289496|NCT05180643|BEHAVIORAL|Mindfulness-Based Stress Reduction-based program (MBSR).|The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
219289497|NCT02753569|OTHER|Imaging - DW-MRI|
219289498|NCT02753569|RADIATION|FDG PET-CT|
219289499|NCT01966172|DRUG|Ibuprofen|oral ibuprofen 400mg 4 times daily
219289500|NCT01966172|DRUG|Gabapentin|Oral Gabapentin 300mg twice daily
219289501|NCT01966172|DRUG|Morphine|10 mg morphine orally 4 times daily
219289502|NCT01966172|DRUG|Paracetamol|oral paracetamol 1000mg four times daily
219289503|NCT00163280|DRUG|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
219289504|NCT02604303|OTHER|No Intervention|No intervention; prospective observational study
219289505|NCT04419376|DEVICE|driving pressure|Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
219289506|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
219289507|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
219289508|NCT01791075|DEVICE|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
219289509|NCT01791075|DEVICE|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
219289510|NCT04538560|PROCEDURE|polar body biopsy|Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
219289511|NCT06198322|OTHER|Platelet-rich Fibrin|Platelet-rich Fibrin will be injected distal to the canine on the experimental side
219289512|NCT06198322|OTHER|Vitamin D3|Vitamin D3 will be injected distal to the canine on the experimental side
219289513|NCT00036387|DRUG|Infliximab|
219289514|NCT03401008|OTHER|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
219289515|NCT05684744|DRUG|Roflumilast|The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks
219289516|NCT05684744|DRUG|Methotrexate|The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
219289517|NCT02982824|DIETARY_SUPPLEMENT|Magnesium|Oral magnesium
219289518|NCT02982824|DRUG|Placebo - Concentrate|Placebo will be given
219289519|NCT03472716|PROCEDURE|Biological Samples|"5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)"
219289520|NCT01580891|DRUG|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
219289521|NCT01580891|DRUG|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
219289522|NCT01580891|DRUG|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
219289523|NCT02917603|BEHAVIORAL|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
219289524|NCT01998074|DIETARY_SUPPLEMENT|extensively hydrolyzed rice protein formula|
219289525|NCT03479853|PROCEDURE|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
219289526|NCT01941433|BEHAVIORAL|Arthritis Health Journal|
219289527|NCT04734054|DEVICE|Modified Hyrax Palatal Expander|The rapid maxillary expansion will be performed. The expansion should be accomplished between 10 to 15 days at most. The screw is going to be turned in a rapid manner.
219289528|NCT04734054|DEVICE|Removable Palatal Expander|The slow maxillary expansion will be performed. The expansion will be performed in a slow manner. Patients may need between 6 to 8 months to achieve the required expansion.
219289529|NCT02427945|BEHAVIORAL|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
219289530|NCT02427945|BEHAVIORAL|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
219289531|NCT01129700|RADIATION|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
219289532|NCT05619757|BEHAVIORAL|Compliance with medical treatment for endometriosis|"During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.~Patients will be included once they log in and complete the questionnaire."
219289533|NCT03714087|DEVICE|T1 before aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
219289534|NCT03714087|OTHER|T2 after the aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
219289535|NCT03714087|OTHER|Historic control group|
219289536|NCT02006524|DEVICE|'MyDiagnostick|
219289537|NCT06000033|DRUG|Disitamab Vedotin+Anlotinib|Disitamab Vedotin:2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
219289538|NCT03331913|DRUG|Botulinum Toxin type A (intradermal / submucosal injection at pain area)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
219289539|NCT03331913|DRUG|Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
219289540|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
219289541|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
219289542|NCT03520101|PROCEDURE|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is \>18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
219289543|NCT03520101|PROCEDURE|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
219289544|NCT01253018|BEHAVIORAL|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
219289545|NCT01253018|BEHAVIORAL|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
219289546|NCT00002248|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
219289547|NCT03449901|DRUG|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
219289548|NCT03449901|DRUG|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
219289549|NCT03449901|DRUG|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
219289550|NCT03449901|PROCEDURE|Tumor biopsy|"* Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort"
219289551|NCT03449901|PROCEDURE|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
219289552|NCT06424431|PROCEDURE|stapler combined with electrocautery|Closure with a closure device combined with electrocoagulation for pancreatic stump closure in distal pancreatectomy
219289553|NCT06424431|PROCEDURE|simple closure with a closure device|Simple closure with a closure device for pancreatic stump closure in distal pancreatectomy
219289554|NCT02185001|PROCEDURE|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
219289555|NCT02185001|PROCEDURE|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
219289556|NCT03466073|DRUG|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
219289557|NCT03466073|OTHER|Normal Saline Placebo|Normal saline in volume equivalent to drug
219289558|NCT03269682|DEVICE|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
219296464|NCT04491396|BEHAVIORAL|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
219289559|NCT06046105|DRUG|Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
219289560|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
219289561|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
219289562|NCT00744757|DRUG|Decitabine|Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
219289563|NCT02249598|BIOLOGICAL|lactamica|
219289564|NCT02249598|BIOLOGICAL|Placebo|
219289565|NCT01600248|BEHAVIORAL|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
219289566|NCT02832401|DRUG|Caffeine|
219289567|NCT02832401|DRUG|Placebo|
219289568|NCT03682302|DRUG|Exparel|EXPAREL 4mg/kg (maximum 266 mg)
219289569|NCT03682302|DRUG|0.5% Bupivacaine HCl|Bupivacaine HCl 2mg/kg
219296465|NCT04877353|DEVICE|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
219289570|NCT02707549|DRUG|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
219289571|NCT02707549|DRUG|0.9% sodium chloride|
219289572|NCT03083418|DEVICE|control group|No EDP treatment
219289573|NCT03083418|DEVICE|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
219289574|NCT06305754|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg via IV infusion
219289575|NCT06305754|DRUG|Pemetrexed|500 mg/m\^2 via IV infusion
219289576|NCT06305754|DRUG|Carboplatin|AUC 5 mg/mL\*min via IV infusion
219289577|NCT06305754|DRUG|H1 Receptor Antagonist|Administered as rescue medication per approved product label
219289578|NCT06305754|DRUG|H2 Receptor Antagonist|Administered as rescue medication per approved product label
219289579|NCT06305754|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication per approved product label
219289580|NCT06305754|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication per approved product label
219289581|NCT06305754|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered as rescue medication per approved product label
219289582|NCT05010018|BEHAVIORAL|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
219289583|NCT05271604|BIOLOGICAL|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
219289584|NCT05271604|BIOLOGICAL|Pembrolizumab|PD-1 inhibitor
219289585|NCT05271604|BIOLOGICAL|Evalstotug (BA3071)|Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody
219289586|NCT05271604|BIOLOGICAL|Cetuximab|Epidermal growth factor receptor (EGFR) antagonist
219289587|NCT05355948|DEVICE|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
219289588|NCT05355948|DEVICE|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
219289589|NCT05510687|DEVICE|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
219289590|NCT05631964|DRUG|BL-M07D1|Administration by intravenous infusion
219289591|NCT05238376|BEHAVIORAL|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
219289592|NCT06356311|BIOLOGICAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
219289593|NCT06356311|DRUG|Trifluridine-Tipiracil|Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
219289594|NCT06356311|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
219289595|NCT06356311|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
219289596|NCT06356311|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
219289597|NCT06356311|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
219289598|NCT06356311|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
219289599|NCT05051462|BEHAVIORAL|Family / systemic constellation therapy|Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
219289600|NCT04655976|BIOLOGICAL|Cobolimab|Cobolimab will be administered.
219289601|NCT04655976|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
219289602|NCT04655976|DRUG|Docetaxel|Docetaxel will be administered.
219289603|NCT02425904|DRUG|Clofarabine|second-generation purine nucleoside analog
219289604|NCT05461768|DRUG|BL-M07D1|Administration by intravenous infusion
219289605|NCT05452278|OTHER|Product A|Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
219289606|NCT05452278|OTHER|Product B|Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
219289607|NCT05452278|OTHER|Product C|Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
219289608|NCT05452278|OTHER|Product D|Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
219289609|NCT06616363|BEHAVIORAL|Questionnaires to be competed|"* The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)"
219289610|NCT06616363|BEHAVIORAL|Provide list of medication and lifetime events|Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
219289611|NCT06616363|BEHAVIORAL|Use phone App to record new life events|Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
219289612|NCT06616363|DEVICE|Will wear an activity monitor|Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
219289613|NCT06616363|OTHER|Periodic 24-hour urine sodium check|POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
219289614|NCT06616363|DIAGNOSTIC_TEST|A fMRI scan|• Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
219289615|NCT06616363|DIAGNOSTIC_TEST|A bedside tilt test will be performed|A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
219289616|NCT06616363|OTHER|IV placed to collect blood samples|• An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
219289617|NCT06616363|OTHER|Stool Sample|• Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
219289618|NCT06463587|OTHER|Placebo|Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
219289619|NCT06463587|DRUG|Cladribine Low Dose|Participants will receive cladribine low dose in two courses separated by 4 weeks.
219289620|NCT06463587|DRUG|Cladribine High Dose|Participants will receive cladribine high dose in two courses separated by 4 weeks.
219289621|NCT05260021|DRUG|Tirzepatide Dose 1|Administered SC
219289622|NCT05260021|DRUG|Tirzepatide Dose 2|Administered SC
219289623|NCT05260021|DRUG|Placebo|Administered SC
219289624|NCT05393427|DRUG|BL-B01D1|Administration by intravenous infusion
219296466|NCT06716658|DRUG|JAK1 Inhibitor|Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
219296467|NCT06727838|DRUG|HRS-7535 tablets|HRS-7535 tablets.
219296468|NCT06727838|DRUG|Metformin Hydrochloride Extended-release Tablets|Metformin Hydrochloride Extended-release Tablets.
219296469|NCT06727838|DRUG|Metformin Hydrochloride Tablets|Metformin Hydrochloride Tablets.
219289625|NCT03663257|DEVICE|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
219289626|NCT05705479|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
219289627|NCT05705479|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
219289628|NCT03730649|DRUG|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
219289629|NCT03730649|RADIATION|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
219289630|NCT03688126|BEHAVIORAL|Self-Guided Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
219289631|NCT03688126|BEHAVIORAL|Structured Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
219289632|NCT03842358|DEVICE|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
219289633|NCT06034262|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
219289634|NCT03800953|DRUG|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
219289635|NCT06686758|DIETARY_SUPPLEMENT|Sugar cane polysaccharide|Sugar cane polysaccharide
219289636|NCT06686758|DIETARY_SUPPLEMENT|Control|placebo
219289637|NCT06688799|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
219289638|NCT04537533|DRUG|Tranexamic acid|Intraoperative infusion
219289639|NCT04537533|OTHER|Normal saline|intravenous infusion
219289640|NCT06898242|OTHER|Manual myofascial treatment direct to upper and lower limb|Manual treatment direct specifically on fascia connective tissue
219289641|NCT06898242|OTHER|Rehabilitative treatment following rehabilitation project|Intensive multidisciplinary rehabilitation program for at least 180 minutes/day, 6 days a week, following rehabilitation project
219289642|NCT06876766|DEVICE|Lung Ultrasound|Lung ultrasound (LUS) is a non-invasive, radiation-free imaging technique that uses sound waves to visualize the lungs. It will be used in the experimental arm to help guide decisions regarding antibiotic therapy in hospitalized children and adolescents with lower respiratory tract infections (LRTIs). The LUS will be performed within 24 hours of enrollment.
219289643|NCT06876766|DEVICE|Sham|In the sham group, participants will undergo a mock or placebo version of the lung ultrasound. This involves performing the procedure in a way that mimics the real ultrasound process but does not provide any diagnostic results or influence clinical decision-making regarding antibiotic therapy.
219289644|NCT06822569|OTHER|Cue reactivity paradigm|Participants will be exposed to cues in a fixed sequence while they answer questions about their emotions and thoughts. The cues will include everyday items (e.g., an ink pen) and substance-related items (e.g., a vape pen).
219289645|NCT06900725|DRUG|edoxaban|edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.
219289646|NCT06900725|DRUG|Edoxaban 30 mg|edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.
219289647|NCT06900218|DRUG|Sintilimab|Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles
219289648|NCT06900218|DRUG|Capecitabine|Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.
219289649|NCT06907927|BEHAVIORAL|Control group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
219289650|NCT06907927|BEHAVIORAL|Experimental group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
219289651|NCT06906757|DRUG|Erythromycin 250mg + placebo|Antibiotic.
219289652|NCT06906757|DRUG|Azithromycin 500mg + placebo|Antibiotic.
219289653|NCT06906757|DRUG|Erythromycin 250mg and Amoxicillin 500mg|Antibiotics.
219289654|NCT06906692|DIAGNOSTIC_TEST|Serum Bactericidal Assay|The Serum Bactericidal Assay (SBA) will be used for the analysis of the antibody titer, which represents a valid surrogate for the efficacy of the tetravalent vaccine. Subjects' sera will be serially diluted and incubated with a solution containing a certain strain of meningococcus. At this point, an exogenous source of rabbit complement will be added. Bactericidal activity will be assessed against controls. Neutralizing antibody titers will be defined as the highest dilution of sera at which at least 50% of bacteria death occurs. Antibody titers will be considered protective with a cut-off greater than or equal to 1:8.
219289655|NCT07155460|DEVICE|HDC-GCog|Surface electromyography records
219289656|NCT07156032|DEVICE|Starpen automatic injection device|Starpen device will be used on high speed 45-150s with the conventional carpule of articaine HCL 4% with 1:100,000 epinephrine and short needle
219289657|NCT07156032|PROCEDURE|conventional syringe|injection will be done using conventional metal syringe with articaine HCL 4% with 1:100,000 epinephrine and short needle
219289658|NCT04917107|BEHAVIORAL|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
219289659|NCT04693546|DIAGNOSTIC_TEST|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
219289660|NCT04693546|DIAGNOSTIC_TEST|FIT Test|Procedure: Colonoscopy
219289661|NCT05630703|BEHAVIORAL|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
219289662|NCT05630703|OTHER|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
219289663|NCT03843554|OTHER|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
219289664|NCT03843554|PROCEDURE|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
219289665|NCT05958875|DRUG|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
219289666|NCT05958875|DRUG|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
219289667|NCT04963452|OTHER|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
219289668|NCT06115629|OTHER|Surveillance protocol|Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
219289669|NCT05973786|DRUG|Escitalopram|See arm description
219289670|NCT05973786|DRUG|Sertraline|See arm description
219289671|NCT05973786|DRUG|Venlafaxine|See arm description
219289672|NCT05973786|DRUG|Lithium|See arm description
219289673|NCT05973786|DRUG|Valproate acid|See arm description
219289674|NCT05973786|DRUG|Quetiapine|See arm description
219289675|NCT05973786|DRUG|Bupropion|See arm description
219289676|NCT05134480|PROCEDURE|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
219289677|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC tablet for oral administration.
219289678|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration.
219289679|NCT05113745|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
219289680|NCT05113745|DRUG|Placebo|Placebo tablets, taken twice daily
219289681|NCT05213897|DEVICE|SARS-CoV-2 Antigen Assay|To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
219289682|NCT05331313|GENETIC|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
219296470|NCT02818959|DEVICE|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
219289683|NCT05229276|OTHER|Sternum Guard|"The intervention being assessed is a surgical drape used as a cover of sternal bones and the neighboring structures exposed during median sternotomy named Sternum Guard.~Sternum guard® is a single use, sterile surgical drape with modified cellulose designed specifically to reduce the risk of surgical site infection (SSI).~It is made of 4 parts, the main part is in contact with the retractors and the sternum edge. It is made of carboxymethylated cellulose (CMC) spunlace which makes direct contact with the sternum edges. It contributes to blood absorption, to decreasing of pH environment, and to haemostatic action through a physical effect (compression); another part was made from hydrophilic spunbond (swabs) allowing blood absorption, comfort and protection"
219289684|NCT05229276|OTHER|Bone Wax|patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
219289685|NCT00085553|DRUG|Erlotinib Hydrochloride|Given PO
219289686|NCT00085553|OTHER|Laboratory Biomarker Analysis|Correlative studies
219289687|NCT00085553|OTHER|Pharmacological Study|Correlative studies
219289688|NCT00085553|DRUG|Tipifarnib|Given PO
219289689|NCT05775081|OTHER|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
219289690|NCT01827475|DRUG|Ibuprofen|single dose
219289691|NCT01827475|DRUG|Acetaminophen|single dose
219289692|NCT01827475|DRUG|Ibuprofen-acetaminophen combination|single dose
219289693|NCT02731690|DRUG|Aceneuramic Acid Extended-Release|oral tablets
219289694|NCT00522405|PROCEDURE|TACE|"* Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization"
219289695|NCT05180929|DEVICE|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
219289696|NCT05180929|DEVICE|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
219289697|NCT05180929|DEVICE|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
219289698|NCT04512703|DEVICE|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
219289699|NCT04344652|DEVICE|Photoscreening -|external picture taken with a an phone based app
219289700|NCT04681599|DEVICE|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
219289701|NCT04681599|DEVICE|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
219289702|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
219289703|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
219289704|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
219289705|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
219289706|NCT06034509|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
219289707|NCT06385249|DEVICE|Navina Mini|Trans-anal irrigation (TAI) with a new CE-marked device, Navina Mini
219289708|NCT05147558|DRUG|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
219289709|NCT05147558|DRUG|Lenvatinib|Lenvatinib (20mg once daily orally)
219289710|NCT06440291|PROCEDURE|Cardioneuroablation|Cardioneuroablation procedure performed according to the protocol
219289711|NCT03387748|BEHAVIORAL|Gesture elicitation|"* Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~* Participants retell a cartoon to the researcher~* The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
219289712|NCT05550090|DRUG|Chemotherapy|All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
219289713|NCT03446781|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
219289714|NCT03446781|BIOLOGICAL|Placebo|Placebo
219289715|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
219289716|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
219289717|NCT05262491|DRUG|BL-B01D1|Administration by intravenous infusion
219289718|NCT06169722|DRUG|TDI01 suspension|200mg or 400mg oral once a day
219289719|NCT04712461|OTHER|SUPPORTS|The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
219289720|NCT01158482|PROCEDURE|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
219289721|NCT02551718|OTHER|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
219289722|NCT02551718|OTHER|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
219289723|NCT02551718|GENETIC|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
219289724|NCT02551718|GENETIC|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
219289725|NCT02551718|DRUG|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
219289726|NCT00858377|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
219289727|NCT00858377|DRUG|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
219289728|NCT05879133|BEHAVIORAL|Questionnaires|Survey
219289729|NCT05879133|OTHER|Fit Bit|measures physical activity
219289730|NCT05177991|DRUG|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
219289731|NCT05177991|DRUG|Bupivacaine|20cc of Bupivacaine for TAP block
219289732|NCT05875805|BEHAVIORAL|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
219289733|NCT05875805|OTHER|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
219289734|NCT02796300|DEVICE|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
219289735|NCT02796300|DEVICE|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
219289736|NCT00957177|DRUG|Pregabalin|300mg pregabalin orally 1 hour before operation
219289737|NCT00957177|DRUG|Placebo|Placebo
219289738|NCT02078843|DRUG|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
219289739|NCT02078843|DRUG|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
219289740|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
219289741|NCT06520826|DRUG|Vadadustat|A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
219289742|NCT06520826|DRUG|Erythropoiesis Stimulating Agent|Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
219289743|NCT04534972|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \> 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
219289744|NCT04790370|DRUG|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
219289745|NCT04790370|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
219289746|NCT05185934|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with COVID-19 infection will be randomized to receive food supplement Endocalyx for 4 months.
219289747|NCT05185934|DIETARY_SUPPLEMENT|Placebo|Patients with COVID-19 infection will be randomized to receive placebo for 4 months.
219289748|NCT06078345|OTHER|Carbohydrate|400 Kcal glucose (100g oGTT)
219289749|NCT06078345|OTHER|Fat|400 Kcal glucose rapeseed oil.
219289750|NCT06078345|OTHER|Protein|400 Kcal Moltein PURE (111g)
219289751|NCT02625961|BIOLOGICAL|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
219289752|NCT02625961|BIOLOGICAL|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
219289753|NCT02625961|BIOLOGICAL|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
219289754|NCT01881555|PROCEDURE|invasive coronary angiography|
219289755|NCT01881555|PROCEDURE|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
219289756|NCT05987800|DIAGNOSTIC_TEST|Titration procedure|"The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV."
219289757|NCT05987800|DIAGNOSTIC_TEST|Electrical impedance tomography|This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.
219289758|NCT05987800|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|"Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure."
219289759|NCT05010590|DRUG|Romosozumab|Monthly romosozumab
219289760|NCT05010590|DRUG|Denosumab|Every 6 months denosumab
219289761|NCT03093376|BEHAVIORAL|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
219289762|NCT00044265|DRUG|ramipril|
219289763|NCT00249262|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.
219289764|NCT04410523|DRUG|CSJ117|"CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment"
219289765|NCT04410523|DRUG|Placebo|"Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device."
219289766|NCT05396833|DRUG|Tuvusertib|Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
219289767|NCT05396833|DRUG|Lartesertib|Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
219289768|NCT05396833|DRUG|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
219289769|NCT00490490|DRUG|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
219289770|NCT00490490|PROCEDURE|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
219289771|NCT00490490|DRUG|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
219289772|NCT04681768|DRUG|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
219289773|NCT06233344|DRUG|Psilocybin plus mindfulness training|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists. The psilocybin dosing session will take place approximately halfway through an 8-week mindfulness training course. The mindfulness training course will consist of weekly 2-hour classes with experienced mindfulness teachers; participants will be encouraged to practice mindfulness for 45 minutes per day between classes.
219289774|NCT06233344|DRUG|Psilocybin|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists.
219289775|NCT01475279|DRUG|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
219289776|NCT04307771|BEHAVIORAL|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
219289777|NCT00363688|DRUG|Penicillin test and challenge|
219289778|NCT04158232|OTHER|Method|treatment of mature teeth with apical periodontitis
219289779|NCT05871606|DRUG|iNO|Inhaled Nitrous Oxide
219289780|NCT03619551|DRUG|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
219289781|NCT03619551|DEVICE|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
219289782|NCT06639464|DRUG|Semaglutide|This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
219289783|NCT06639464|OTHER|Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
219289784|NCT05501873|DEVICE|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
219289785|NCT06008054|DRUG|SI-B003|Administered by intravenous infusion every 3 weeks (Q3W).
219289786|NCT06008054|DRUG|BL-B01D1|Administered by intravenous infusion for a cycle of 3 weeks.
219289787|NCT06008054|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
219289788|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
219289789|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
219289790|NCT04435678|DIAGNOSTIC_TEST|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
219289791|NCT00823576|DRUG|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
219289792|NCT02632435|DEVICE|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
219289793|NCT02632435|DEVICE|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
219289794|NCT00370682|BIOLOGICAL|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
219289795|NCT00370682|BIOLOGICAL|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
219289796|NCT00370682|OTHER|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
219289797|NCT01885520|DIETARY_SUPPLEMENT|fasting condition|eperisone SR tablet 75mg administrated under fasting
219289798|NCT01885520|DIETARY_SUPPLEMENT|fed condition|eperisone SR tablet 75mg administrated fed condition
219289799|NCT03293875|BEHAVIORAL|Community Events|The coalitions in collaboration with CABs and peer leaders in their respective cities convened community meetings and events and invited PWID who had participated in other intervention components, who were receiving services at the partner organizations, and members at-large to participate. Events and meetings were advertised at the partner organizations offices, by staff during delivery of harm reductions supplies at places where PWID congregated to use drugs, and through social media. Events and meetings took place at community venues including parks, neighborhood gathering spaces, and at organizations. Events covered topics about HIV, sexual health, and human rights and included health fairs.
219289800|NCT03293875|BEHAVIORAL|Social Network HIV Testing|The social network HIV testing intervention consisted of offering rapid HIV tests to PWID using a social network referral methodology.
219289801|NCT03293875|BEHAVIORAL|Peer Network Intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 PWID.
219289802|NCT06091293|BEHAVIORAL|Narrative Intervention for Long COVID-19 (NICO)|The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
219289803|NCT03585491|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
219289804|NCT03585491|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
219289805|NCT05109572|OTHER|Hospitalized|It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.
219289806|NCT05109572|OTHER|Non-hospitalized with emergency care|It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
219289807|NCT05109572|OTHER|Non-hospitalized and non-emergency care|"Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always."
219289808|NCT00002870|BIOLOGICAL|filgrastim|
219289809|NCT00002870|DRUG|cyclophosphamide|
219289810|NCT00002870|DRUG|epirubicin hydrochloride|
219289811|NCT00002870|DRUG|fluorouracil|
219289812|NCT00002870|DRUG|thiotepa|
219289813|NCT00002870|PROCEDURE|peripheral blood stem cell transplantation|
219289814|NCT03223831|OTHER|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 \& 12cm.
219289815|NCT03223831|OTHER|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
219289816|NCT03651622|BEHAVIORAL|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
219289817|NCT03651622|BEHAVIORAL|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
219289818|NCT03651622|BEHAVIORAL|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
219289819|NCT03096080|DRUG|Tesevatinib|One dose of the study drug in liquid form
219289820|NCT01519089|DRUG|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
219289821|NCT01519089|DRUG|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
219289822|NCT05649722|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
219289823|NCT05649722|DRUG|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
219289824|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
219289825|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
219289826|NCT00165204|DRUG|Tibolone|
219289827|NCT00734357|PROCEDURE|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
219289828|NCT00127205|DRUG|clodronate disodium|Given orally
219289829|NCT00127205|DRUG|ibandronate sodium|Given orally
219289830|NCT00127205|DRUG|zoledronic acid|Given IV
219289831|NCT00673036|OTHER|Blood sample|60 ml of whole blood
219289832|NCT00822211|DRUG|Vildagliptin 50 mg bid|
219289833|NCT00822211|DRUG|Vildagliptin 50 mg qd|
219289834|NCT00822211|DRUG|Placebo|
219289835|NCT00126802|PROCEDURE|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
219289836|NCT04343287|DRUG|BRM421|The active control with BRM421 solution
219289837|NCT04343287|DRUG|Placebo|The vehicle solution
219289838|NCT03582943|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
219289839|NCT03582943|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
219289840|NCT03582943|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
219289841|NCT02708563|PROCEDURE|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
219289842|NCT02708563|PROCEDURE|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
219289843|NCT01134068|OTHER|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
219289844|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
219289845|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
219289846|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
219289847|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
219289848|NCT01373073|OTHER|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
219289849|NCT01373073|OTHER|Control human milk fortifier|Control human milk fortifier to be added to human milk
219289850|NCT04656496|BEHAVIORAL|NOURISH-T+|NOURISH-T+ (Nourishing Our Understanding of Role Modeling to Improve Support and Healthy - Transitions) is a 6 session, psychoeducational program designed to teach parents of childhood cancer survivors with overweight/obesity knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
219289851|NCT04656496|BEHAVIORAL|Brief NOURISH-T+|Enhanced Usual Care (or Brief NOURISH-T+) is an abbreviated version of the full NOURISH-T+ intervention in which parents are engaged in a one-time information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
219289852|NCT04747327|BEHAVIORAL|mandate public|mandate by airlines, bars, restaurants
219289853|NCT04747327|BEHAVIORAL|employer mandate|your employer requires vaccination
219289854|NCT04747327|BEHAVIORAL|incentive reward|$1,000 tax credit
219289855|NCT04747327|BEHAVIORAL|penalty|$1000 tax penalty
219289856|NCT04747327|BEHAVIORAL|incentive lottery small|100,000 smaller monetary amount
219289857|NCT04747327|BEHAVIORAL|incentive lottery medium|200,000 mid monetary amount
219289858|NCT04747327|BEHAVIORAL|incentive lottery large|1 million dollar lottery
219289859|NCT04747327|BEHAVIORAL|cash small|smaller guaranteed cash amount
219289860|NCT04747327|BEHAVIORAL|cash medium|mid sized quarenteed cash amount
219289861|NCT04747327|BEHAVIORAL|cash large|large quarenteed cash amount
219289862|NCT04747327|BEHAVIORAL|invitation for exercise financial incentive study|financial incentives earned when increasing exercise behaviors
219289863|NCT04747327|BEHAVIORAL|invitation for exercise social incentive study|social incentives earned when increasing exercise behaviors
219289864|NCT04747327|BEHAVIORAL|invitation for sleep social incentive study|social incentives earned when increasing sleep
219289865|NCT04747327|BEHAVIORAL|invitation for sleep financial incentive|Financial incentives earned when increasing sleep
219289866|NCT03592810|OTHER|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
219289867|NCT05526066|BIOLOGICAL|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).
219289868|NCT05526066|OTHER|Placebo|Normal Saline
219289869|NCT06088654|DRUG|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
219289870|NCT06830798|DRUG|Ravulizumab|Participants will receive ravulizumab via intravenous (IV) infusion.
219289871|NCT06830798|DRUG|Placebo|Participants will receive placebo via intravenous (IV) infusion.
219289872|NCT03907644|DEVICE|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
219289873|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
219289874|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
219289875|NCT03535506|DRUG|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
219289876|NCT05126563|BIOLOGICAL|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
219289877|NCT05126563|OTHER|Placebo|Placebo comarator
219289878|NCT05081882|DRUG|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
219289879|NCT05081882|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
219289880|NCT04284267|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
219289881|NCT06612255|DRUG|Delafloxacin|Delafloxacin tablet
219289882|NCT06612255|DRUG|Delafloxacin Powder|Delafloxacin powder for oral suspension formulation
219289883|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.
219289884|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant
219289885|NCT06190509|BIOLOGICAL|Vaccine|The placebo is administered twice, 2 months apart
219289886|NCT04891705|DEVICE|Lung Ultrasound Scan|Ultrasound scan of subjects in up to 14 lung zones
219289887|NCT02545829|DRUG|HIP1302|Tenofovir 292mg
219289888|NCT02545829|DRUG|HGP1406|Tenofovir 300mg
219289889|NCT04797143|DEVICE|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
219289890|NCT05458297|BIOLOGICAL|Zilovertamab vedotin|IV infusion
219289891|NCT05458297|DRUG|Nemtabrutinib|Oral tablet
219289892|NCT05254743|DRUG|Pirtobrutinib|Administered orally.
219289893|NCT05254743|DRUG|Ibrutinib|Administered orally.
219289894|NCT06420752|DEVICE|Calf Plantar flexion|Daily passive calf stretching
219289895|NCT06420752|DIETARY_SUPPLEMENT|Dietary nitrate|Weekday 140 ml dietary nitrate consumption two hours prior to passive stretching
219289896|NCT06190210|DIAGNOSTIC_TEST|electroencephalography|Pre-, per- and postoperative electroencephalography
219289897|NCT06190210|DIAGNOSTIC_TEST|Near-Infrared Spectroscopy|Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
219289898|NCT06190210|DIAGNOSTIC_TEST|neuronal cell-free DNA|CfDNA which is characterized based on methylation patterns to determine the tissue of origin
219289899|NCT04202640|PROCEDURE|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
219289900|NCT04202640|PROCEDURE|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~* One part muscle exercise~* One part skin work (drainage)"
219289901|NCT01172470|DRUG|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
219289902|NCT01172470|DRUG|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
219289903|NCT01172470|DRUG|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
219289904|NCT00873028|OTHER|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
219289905|NCT00004572|PROCEDURE|Sustacal challenge|
219289906|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
219289907|NCT05926453|OTHER|Maximal cardiorespiratory exercise test|previously described
219289908|NCT04848389|PROCEDURE|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
219289909|NCT04848389|PROCEDURE|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
219289910|NCT05268536|OTHER|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
219289911|NCT05268536|OTHER|resistance exercise|resistance exercise
219289912|NCT06029348|BEHAVIORAL|Paced Auditory Serial Addition Task|Study volunteers will be asked to complete a 4-minute Paced Auditory Serial Addition Task, which is a standardized task that is widely used to study cardiovascular responses to acute psychological challenges (or stressors) in a laboratory setting.
219289913|NCT06341686|DRUG|Letermovir 480 MG|Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
219289914|NCT06341686|DRUG|Ganciclovir|The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
219289915|NCT02950610|DEVICE|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
219289916|NCT05020769|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
219289917|NCT05020769|DRUG|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
219289918|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
219289919|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
219289920|NCT04399759|BEHAVIORAL|Approach-Instrumental Activities of Daily Living|Individualized instrumental activities of daily living training
219289921|NCT04399759|BEHAVIORAL|Home health education|Individualized home health education
219289922|NCT03231280|DEVICE|SB-061|delivered via intra-articular injection
219289923|NCT03231280|OTHER|Placebo|Placebo delivered via intra-articular injection
219289924|NCT05032872|BEHAVIORAL|Social Exergame Treatment Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~* Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~* In-app rewards (unlock new flowers to grow each week) if participants post stories"
219289925|NCT05032872|BEHAVIORAL|Control Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit and use the app"
219289926|NCT06233227|DRUG|Dutasteride-Test product|Dutasteride soft capsule 0.5 mg Test product Manufactured by: Phil Inter Pharma Co., Ltd., Vietnam
219289927|NCT06233227|DRUG|Dutasteride-Reference product|Dutasteride soft capsule 0.5 mg Reference product Manufactured by: DELPHARM POZNAN S.A., Poland
219289928|NCT01155089|DRUG|Anastrozole|1 mg tablet
219289929|NCT05130294|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
219289930|NCT05130294|DIETARY_SUPPLEMENT|Placebo|MCT oil
219289931|NCT06393387|DRUG|DTG/3TC versus BIC/F/TAF|A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
219289932|NCT00956553|BIOLOGICAL|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
219289933|NCT00956553|BIOLOGICAL|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
219289934|NCT05870228|BEHAVIORAL|Strathclyde Sleep Intervention|Manual-based CBT-I
219289935|NCT06249958|OTHER|Rehabilitation|Specific rehabilitation exercises
219289936|NCT06249958|OTHER|Verticalisation|Day of patient verticalisation after surgery
219289937|NCT01481987|PROCEDURE|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
219289938|NCT04522622|DRUG|Teriparatide|20 micrograms
219289939|NCT04522622|DIAGNOSTIC_TEST|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
219289940|NCT04522622|PROCEDURE|Bone biopsy|All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.
219289941|NCT04522622|DIAGNOSTIC_TEST|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
219289942|NCT04522622|OTHER|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
219289943|NCT06636110|DEVICE|Jun mHealth app|The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
219289944|NCT00488475|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219289945|NCT05192486|DRUG|GNC-038|Administration by intravenous infusion
219289946|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
219289947|NCT06534957|OTHER|Online mindfulness-based stress reduction|The online MBSR intervention sessions will be available in a website created specifically for this purpose, where each pre-recorded session will be uploaded so that each patient can begin the intervention at the same time as their chemotherapy regimen. Each session will last approximately 1 hour, for a total of 6 sessions. The topics that will be covered in these sessions include: mindfulness overview, stress and suffering, emotional regulation, meditation, management of stressful situations, self-compassion and acceptance. Participants will watch 1 session per week following the order that will be indicated on the website; patients will be encouraged to watch the sessions during their chemotherapy infusions. During these sessions, patients will be instructed in mindfulness practice and will perform targeted exercises to promote complete consciousness, including mindful body awareness (body scan), gentle yoga exercises, and meditation.
219289948|NCT04883242|DRUG|Carfilzomib|Given IV
219289949|NCT04883242|DRUG|Dexamethasone|Given PO or IV
219289950|NCT04883242|BIOLOGICAL|Isatuximab|Given IV
219289951|NCT04883242|DRUG|Pomalidomide|Given PO
219289952|NCT04883242|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219289953|NCT04883242|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219289954|NCT04883242|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal x-ray
219289955|NCT04883242|PROCEDURE|Computed Tomography|Undergo CT
219289956|NCT04883242|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
219289957|NCT04883242|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219289958|NCT00263341|COMBINATION_PRODUCT|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
219289959|NCT01525654|BEHAVIORAL|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
219289960|NCT00267085|BIOLOGICAL|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
219289961|NCT03894618|DRUG|SL-279252|The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
219289962|NCT05530317|BEHAVIORAL|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols with special attention to post-exertional malaise. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Most participants will participate in a hybrid approach (12-16 sessions in person), but participants will be allowed to select a fully in-person approach (36 sessions).
219289963|NCT03250442|DEVICE|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
219289964|NCT03250442|OTHER|Standard Dry Dressing|These are customary dry dressings.
219289965|NCT02074189|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
219289966|NCT04493775|DEVICE|Brainwave Entrainment|Alpha frequency visual and auditory stimulation delivered through a smartphone application, with the use of a virtual reality headset and earphones respectively.
219289967|NCT01584960|BEHAVIORAL|endurance training|2 years of home-based endurance training
219289968|NCT02946853|PROCEDURE|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
219289969|NCT02946853|DEVICE|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
219289970|NCT04073992|BEHAVIORAL|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
219289971|NCT04582136|DRUG|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
219289972|NCT04582136|DRUG|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
219289973|NCT06393374|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg intravenous (IV) infusion q6w
219289974|NCT06393374|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
219289975|NCT06393374|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
219289976|NCT04662931|DRUG|crizanlizumab|Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
219289977|NCT03736226|DEVICE|SYNERGYTM Stent System|no intervention design in the study
219289978|NCT06485635|DRUG|Nintedanib|Nintedanib
219289979|NCT06485635|DRUG|Pirfenidone|Pirfenidone
219289980|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
219289981|NCT05893186|OTHER|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
219289982|NCT05893186|OTHER|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
219289983|NCT06616025|COMBINATION_PRODUCT|NTX-001 (PEG-Fusion)|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
219289984|NCT06053450|OTHER|Oil Inhalation Patch|Each participant will wear a patch for a work week (3 worked shifts) and then no patch is worn for a week. This alternates for a total of a month.
219289985|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
219289986|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
219289987|NCT05399537|DRUG|Prismocitrate 18|Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
219289988|NCT05399537|DEVICE|PrisMax System Version 3.x with calcium line accessory|The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
219289989|NCT05660291|BEHAVIORAL|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
219289990|NCT05660291|BEHAVIORAL|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
219289991|NCT04366531|BEHAVIORAL|START-VET|prison reentry program
219289992|NCT04366531|OTHER|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
219289993|NCT05576246|DIAGNOSTIC_TEST|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
219289994|NCT03691909|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
219289995|NCT03075423|DRUG|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
219289996|NCT03075423|DRUG|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
219289997|NCT06291922|BEHAVIORAL|Exercise Intervention|See arm description.
219289998|NCT06291922|BEHAVIORAL|Usual Care|See arm description.
219289999|NCT06556407|DEVICE|renal denervation|ultrasound based renal denervation
219290000|NCT05139017|BIOLOGICAL|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
219290001|NCT05139017|BIOLOGICAL|Rituximab|IV Infusion 375 mg/m\^2
219290002|NCT05139017|DRUG|Gemcitabine|IV Infusion 1000 mg/m\^2
219290003|NCT05139017|DRUG|Oxaliplatin|IV Infusion 100 mg/m\^2
219290004|NCT05139017|DRUG|Bendamustine|IV Infusion 90 mg/m\^2
219290005|NCT05139017|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.
219290006|NCT05804747|DRUG|Edoxaban|This is observational, non-interventional study. No study drug will be administered during this study.
219290007|NCT06690996|DRUG|LY4005130|Administered IV
219290008|NCT06690996|DRUG|LY4005130|Administered SC
219290009|NCT06690996|DRUG|Placebo|Administered IV
219290010|NCT06690996|DRUG|Placebo|Administered SC
219290011|NCT05608499|DRUG|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
219290012|NCT05608499|DRUG|Placebo|Topical does not contain active properties of study drug
219290013|NCT05608499|DRUG|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
219290014|NCT06143345|BEHAVIORAL|High-intensity interval training and eucaloric diet|Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants\&amp;#39; tolerance and instructor recommendations. Intensity will start at 75% of estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.
219290015|NCT06143345|BEHAVIORAL|No intense physical activity and eucaloric diet|Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.
219290016|NCT06143345|DEVICE|Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)|The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
219290017|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
219290018|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
219290019|NCT05535881|BEHAVIORAL|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
219290020|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
219290021|NCT02332447|DRUG|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
219290022|NCT02332447|DRUG|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
219290023|NCT05905328|DRUG|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
219290024|NCT05905328|DRUG|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
219290025|NCT05905328|DRUG|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
219290026|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
219290031|NCT04606472|DRUG|SI-B003|Administration by intravenous infusion.
219290032|NCT03269669|DRUG|Bendamustine Hydrochloride|Given IV
219290033|NCT03269669|PROCEDURE|Biopsy Procedure|Undergo biopsy
219290034|NCT03269669|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219290035|NCT03269669|PROCEDURE|Computed Tomography|Undergo PET/CT scans
219290036|NCT03269669|DRUG|Cyclophosphamide|Given IV
219290037|NCT03269669|DRUG|Doxorubicin Hydrochloride|Given IV
219290038|NCT03269669|PROCEDURE|Echocardiography Test|Undergo ECHO
219290039|NCT03269669|DRUG|Lenalidomide|Given PO
219290040|NCT03269669|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219290041|NCT03269669|BIOLOGICAL|Obinutuzumab|Given IV
219290042|NCT03269669|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
219290043|NCT03269669|DRUG|Prednisone|Given PO
219290044|NCT03269669|DRUG|Umbralisib|Given PO
219290045|NCT03269669|DRUG|Vincristine Sulfate|Given IV
219290046|NCT06387355|DIAGNOSTIC_TEST|Coronary computed topography (CT) angiography with FFR-CT|The investigational treatment strategy will have a coronary CT angiography diagnostic imaging with computational analysis FFR-CT (Fractional Flow Reserve from the coronary CTA)
219290047|NCT04505566|DRUG|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
219290048|NCT04505566|DRUG|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
219290049|NCT04505566|OTHER|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
219290050|NCT06404879|OTHER|determining scores with tests|"Parents of children preparing for the operation will be given a child and family information form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will be asked to fill them out themselves.~An anesthesia technician blind to the content of the study will calculate and take notes on the children\&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative Anxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation mask is shown (T4).~FLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and complications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th minutes of all children taken to the recovery unit in the postoperative period will be recorded by the recovery unit nurse. . Children who are thought to have pain according to the FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be taken."
219290051|NCT05785039|DRUG|BL-B01D1|Administration by intravenous infusion
219290052|NCT05143554|DEVICE|Auricular percutaneous neurostimulation|Percutaneous neurostimulation
219290053|NCT05143554|DEVICE|Sham percutaneous neurostimulation|Sham percutaneous neurostimulation
219290054|NCT03158922|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
219290055|NCT03158922|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
219290056|NCT03158922|PROCEDURE|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
219290057|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
219290058|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
219290059|NCT05983588|DRUG|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
219290060|NCT05983588|DRUG|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
219290061|NCT06326697|DRUG|Azacitidine|Azacitidine 300 mg Film coated tablets
219290062|NCT06326697|DRUG|Onureg|Azacitidine 300 mg Film coated tablets
219290063|NCT05160545|DRUG|GNC-035|Administration by intravenous infusion
219290064|NCT06176001|OTHER|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
219290065|NCT05097274|OTHER|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
219290066|NCT05097274|OTHER|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
219290067|NCT05097274|OTHER|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
219290068|NCT05696496|DEVICE|night recording|"The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera."
219290069|NCT05913479|DEVICE|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
219290070|NCT06069375|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day
219290071|NCT04458207|PROCEDURE|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
219290072|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
219290073|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
219290074|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
219290075|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
219290076|NCT06965582|DEVICE|ALPFA BPH PFA System|PFA system for treatment of Benign Prostatic Hyperplasia
219290077|NCT00261456|DIAGNOSTIC_TEST|PSA test|Patients tested for their level of Prostate Specific Antigen.
219290078|NCT00261456|PROCEDURE|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
219290079|NCT05906381|DIETARY_SUPPLEMENT|Probiotics|A specific probiotics capsule product, containing Streptococcus thermophilus will be given to participants for oral intake for 35 days.
219290080|NCT05906381|DIETARY_SUPPLEMENT|Placebo|A specific capsule product, containing microcrystalline cellulose will be given to participants for oral intake for 35 days.
219290081|NCT05457283|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
219290082|NCT04905069|DEVICE|SpaceOAR Vue System|"The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
219290083|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
219290094|NCT06540391|BIOLOGICAL|MB097|Live bacterial therapeutic for oral administration
219290095|NCT06540391|BIOLOGICAL|Pembrolizumab|IV infusion
219290096|NCT06540391|DRUG|Vancomycin|Antibiotic
219290097|NCT03964090|DRUG|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
219290098|NCT03964090|DRUG|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
219290099|NCT03964090|DRUG|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
219290100|NCT03964090|DRUG|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
219290101|NCT03964090|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
219290102|NCT03964090|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
219290103|NCT06067802|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin
219290104|NCT04906395|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
219290105|NCT04906395|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet or solution
219290106|NCT04906395|DRUG|Letrozole Tablets|One 2.5 mg tablet taken orally once daily
219290107|NCT04906395|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
219290108|NCT04906395|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
219290109|NCT05437575|DRUG|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
219290110|NCT05437575|DRUG|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
219290111|NCT04937062|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/203284s005lbl.pdf)."
219290112|NCT04435288|DRUG|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~1. In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~2. In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~3. In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
219290113|NCT04435288|DRUG|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
219290114|NCT04435288|DRUG|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~1. If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~2. If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~3. If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
219290115|NCT04435288|DRUG|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
219290116|NCT06252493|DRUG|Radiotracer Injection|"Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall."
219290117|NCT06252493|DRUG|Contrast Media, Magnetic Resonance|Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
219290118|NCT06252493|DIAGNOSTIC_TEST|Blood Draw|All subjects will undergo placement of an intravenous catheter (IV). Through the same catheter, 10 mL of venous blood will be collected to evaluate blood markers for fibrostenosis.
219290119|NCT06252493|DRUG|Glucagon|Glucagon will be injected into the subject's indwelling i.v. catheter (0.3-0.5 mg) before imaging acquisition; or intramuscularly (1-2 mg) prior to imaging the abdomen and pelvis. A second administration of IV glucagon (0.3-0.5mg) may take place during image acquisition.
219290120|NCT06252493|DIAGNOSTIC_TEST|Imaging|MR and PET images of the abdomen and pelvis will be acquired using the Siemens 3 Tesla Biograph mMR scanner. Multiple anatomical and functional imaging sequences may be run to assess specific image quality measures in addition to those used for anatomical diagnosis. Among the sequences, patients will undergo a full set of standard of care MR enterography sequences to ensure they get at least same quality of study and of clinical information they would gain from a clinical study. Certain MR sequences scans may be repeated after varying a limited range of pulse sequence parameters to assess their effect on the image contrast, image artifacts and signal to noise ratio.
219290121|NCT06252493|DRUG|Oral contrast media application|Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
219290122|NCT05924750|DRUG|BL-M11D1|Administration by intravenous infusion
219290123|NCT05421728|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
219290124|NCT05421728|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
219290125|NCT02963025|PROCEDURE|PEEP level|
219290126|NCT02963025|PROCEDURE|Use of recruitment maneuvers|
219290127|NCT05565378|DRUG|Pembrolizumab|Pembrolizumab will be administered.
219290128|NCT05565378|DRUG|Dostarlimab|Dostarlimab will be administered
219290129|NCT05565378|DRUG|Belrestotug|Belrestotug will be administered.
219290130|NCT05565378|DRUG|Nelistotug|Nelistotug will be administered.
219290131|NCT04824859|BEHAVIORAL|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
219290132|NCT06972472|DRUG|Orforglipron|Administered orally
219290133|NCT06972472|DRUG|Placebo|Administered orally
219290134|NCT06665919|OTHER|CYP2C19 Genotype-Guided Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
219290135|NCT06665919|OTHER|CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel|An antiplatelet drug alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor, or prasugrel).
219290136|NCT06665919|OTHER|The Conventional Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or clopidogrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
219290137|NCT06972446|DRUG|Lutikizumab|Subcutaneous (SC) injection
219290138|NCT06972446|DRUG|Placebo|Subcutaneous (SC) injection
219290139|NCT06972446|DRUG|Ravagalimab|Subcutaneous (SC) injection
219290140|NCT05433090|BEHAVIORAL|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
219290141|NCT06564506|DEVICE|Disposable acupuncture needles (0.30 × 75 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
219290142|NCT06564506|DEVICE|Placebo needles (0.30 × 25 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.
219290143|NCT06564506|DEVICE|SDZ-V electroacupuncture devices|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
219290144|NCT06972459|DRUG|Orforglipron|Administered orally
219290145|NCT06972459|DRUG|Placebo|Administered orally
219290146|NCT06320067|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
219290147|NCT06320067|OTHER|177Lu-PSMA-617|177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
219290148|NCT06320067|DRUG|Androgen Deprivation Therapy (ADT)|Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
219290149|NCT06320067|DRUG|Androgen Receptor Signalling Inhibitor (ARPI)|"Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles."
219290150|NCT06320067|RADIATION|Radiotherapy to Prostate ± Pelvic Nodes|Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
219290151|NCT06320067|DRUG|Docetaxel|Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
219290152|NCT05377996|DRUG|XMT-1660|XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
219290153|NCT06046014|OTHER|BI Focused writing|BI Focused writing program
219290154|NCT06046014|OTHER|Control|Attention Control Writing
219290155|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
219290156|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
219290157|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
219290158|NCT05223608|OTHER|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
219290159|NCT05666921|OTHER|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
219290160|NCT06464549|DIAGNOSTIC_TEST|EEG-EOG recording at rest and during an auditory oddball paradigm|Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
219290161|NCT04150068|DRUG|Oral Lenacapavir|Tablets administered without regard to food
219290162|NCT04150068|DRUG|Oral Lenacapavir Placebo|Tablets administered without regard to food
219290163|NCT04150068|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
219290164|NCT04150068|DRUG|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
219290165|NCT04150068|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
219290166|NCT06265272|DRUG|Injection of a gadolinium contrast agen|"All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;"
219290167|NCT06265272|DRUG|Radiotracer Injection|"All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan"
219290168|NCT06265272|DIAGNOSTIC_TEST|Imaging|PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
219290169|NCT04615130|OTHER|Rehabilitation|Rehabilitation, exercise training
219290170|NCT05054439|DRUG|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
219290171|NCT05054439|DRUG|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
219290172|NCT04141735|DIAGNOSTIC_TEST|ultrasound|no intervention
219290173|NCT05890898|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
219290174|NCT05890898|DRUG|Nitrous Oxide|Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
219290175|NCT04625413|BEHAVIORAL|Behavioral: UR-GOAL communication tool|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
219290176|NCT06318390|DIETARY_SUPPLEMENT|XO Genius|This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health
219290177|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
219290178|NCT04679935|BIOLOGICAL|Brolucizumab|Intravitreal injection
219290179|NCT04112667|OTHER|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
219290180|NCT04112667|OTHER|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
219290181|NCT04112667|OTHER|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
219290182|NCT02577120|DEVICE|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
219290183|NCT02577120|BIOLOGICAL|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
219290184|NCT06973577|DRUG|Centanafadine|Centanafadine QD XR fixed dose 328.8mg
219290185|NCT06973577|OTHER|Placebo|Placebo
219290186|NCT06575426|COMBINATION_PRODUCT|OPF-310|"Dose(Part1): 6,000 islet equivalents (IEQ)/kg or 12,000 islet equivalents (IEQ)/kg~Dose(Part2): Recommended Phase II Dose(RP2D), which will be determined based on the data of Part1~* In Part1, three subjects will be enrolled into the first dosing cohort (Cohort 1: 6,000 IEQ/kg) and they will undergo safety monitoring. Three subjects in Cohort 2 will be dosed with 12,000 IEQ/kg and will undergo safety monitoring.~* In Part2, 7 subjects will be enrolled into the Part 2 dose-expansion part."
219290187|NCT05085210|DEVICE|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
219290188|NCT05085210|BEHAVIORAL|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
219290189|NCT05085210|DEVICE|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
219290190|NCT05085210|BEHAVIORAL|Virtual Reality Based Visual Training|• Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center point within the VR headset during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
219290191|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System|Standard of Care Surgery + Embolization
219290192|NCT04816591|OTHER|Standard of Care Surgery|Standard of Care Surgery Only
219290193|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System|Standard of Care Medical Management + Embolization
219290194|NCT04816591|OTHER|Standard of Care Medical Management|Standard of Care Medical Management Only
219290195|NCT04901195|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219290196|NCT06853665|DRUG|Adderall XR (mixed salts amphetamine)|Capsule
219290197|NCT06853665|DRUG|Placebo|Capsule
219290198|NCT06357533|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
219290199|NCT06357533|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
219290200|NCT06357533|DRUG|Pembrolizumab|Pembrolizumab IV (intravenous)
219290201|NCT06597773|OTHER|Online patient navigation and supportive care referrals|In the online patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to web-based, systematic supportive care resources consisting of pre-recorded videos led by specialists and which will be available on a study-specific website, allowing each participant to access the resources as soon as they receive a referral. Additionally, online support groups will be held monthly to complement the supportive care programs.
219290202|NCT06597773|OTHER|In-person patient navigation and supportive care referrals|In the in-person patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to supportive care services available at their healthcare institution.
219290203|NCT03598595|DRUG|Docetaxel|Given IV
219290204|NCT03598595|DRUG|Gemcitabine|Given IV
219290205|NCT03598595|DRUG|Hydroxychloroquine|Given PO
219290206|NCT02683980|DEVICE|Lumenis Pulse P120H and Xpeeda side firing fiber|
219290207|NCT06814028|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During the Second and Third Menstruations, participants will self-administer daily active tAN sessions Volta System Device beginning Day 1 of menstruation through the final day of menstruation.
219290208|NCT06138067|BEHAVIORAL|High intensity approach|PEM, cancer center support services material, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the participants appointment with the medical oncologist. If enrolled in a clinical trial, the patient navigator will call the participant biweekly, or more often if they are working to resolve any needs identified in the needs assessment) until the participant is successfully enrolled in the therapeutic clinical trial. The patient navigator will call the participant once weekly for 4 weeks, or less than 4 weeks in other cases including withdrawal from the clinical trial or this navigation study, disease progression, or death. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
219290209|NCT06138067|BEHAVIORAL|Low intensity approach|The participant will receive PEM, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the appointment with the medical oncologist. The patient navigator will call the participant 4 weeks after enrollment on the trial. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
219290210|NCT00317733|DRUG|Ketoprofen in Transfersome|
219290211|NCT05022654|DRUG|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
219290212|NCT05022654|DRUG|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
219290213|NCT06985940|OTHER|Visual stimulation|Participants will watch a 10-minute snow- or fire-themed video
219290214|NCT06985940|OTHER|Acoustic stimulation|Participants will listen to a natural sound from fire burning or snow falling
219290215|NCT06985940|OTHER|Combination|Participants will undergo both visual and acoustic stimulation
219290216|NCT04504019|DEVICE|USCTR|Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR
219290217|NCT04504019|PROCEDURE|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
219290218|NCT02993146|OTHER|Laboratory Biomarker Analysis|Correlative studies
219290219|NCT02993146|OTHER|Pharmacological Study|Correlative studies
219290220|NCT02993146|OTHER|Quality-of-Life Assessment|Ancillary studies
219290221|NCT02993146|DRUG|Ropidoxuridine|Given PO
219290222|NCT02993146|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219290223|NCT06824662|DRUG|Quisinostat|a highly potent and orally active HDAC inhibitor
219290224|NCT06817356|DRUG|Mazdutide|Administered SC
219290225|NCT06817356|DRUG|Placebo|Administered SC
219290226|NCT05470348|DRUG|BL-B01D1|Administration by intravenous infusion
219290227|NCT06824675|OTHER|Teledidactic Training|Participants will take part in a tele-didactic training session, matching the duration of the control group's training. This workshop will cover the same content as the control group's session, but instead of in-person instruction, teaching experts will deliver the training remotely using telemedicine software.
219290228|NCT06824675|OTHER|In-Person Hands-on Training|Participants will attend a face-to-face, hands-on workshop led by experts to learn the eFAST protocol.
219290229|NCT06859177|DEVICE|Remote eCTG|"Device: Remote eCTG monitoring~A remote self-administered electrophysiological cardiotocography (eCTG) monitoring (using Nemo Remote®), daily in a Home@Hospital setting, or at least twice weekly at the outpatient clinic, between 32 and 37 weeks of pregnancy."
219290230|NCT06859970|DEVICE|PAS-C System|All patients will undergo catheterization with the PAS-C System to create an interatrial shunt to reduce left atrial pressure in the heart.
219290231|NCT05753501|DRUG|ABBV-101|Oral:Tablet
219290232|NCT06595602|DEVICE|Artificial intelligence based decision support system (AI-DSS); software|"The device is intended for monitoring and recommending ventilator settings, ventilation mode to qualified Intensive Care Unit (ICU) health care professionals (HCP). This is for medical indications that require invasive mechanical ventilation of the respiratory system in the ICU under international / EU guidelines.~The device receives clinical data via the ICU's data integration platform that includes patient physical and demographic data as well as current vital signs, ventilation parameters, blood gas analysis, general blood laboratory reports, fluid balance and medication. Prediction models based on artificial intelligence algorithms are used to deduce therapy suggestions from received data. The algorithm is carried out on a secured cloud platform."
219290233|NCT06864026|DRUG|Tirzepatide|Administered SC
219290234|NCT06677060|DRUG|Baxdrostat and dapagliflozin|baxdrostat tablet and dapagliflozin tablet
219290235|NCT06677060|OTHER|Placebo and dapagliflozin|placebo tablet and dapagliflozin tablet
219290236|NCT05116540|BIOLOGICAL|HB-adMSCs|Autologous product
219290237|NCT05116540|DRUG|Placebo|Normal Saline
219290240|NCT06857942|DRUG|Tirzepatide|Administered SC
219290241|NCT06858878|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be adminstered SC.
219290242|NCT06858878|DRUG|Placebo|Placebo will be adminstered SC.
219290243|NCT04684563|BIOLOGICAL|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
219290244|NCT06478017|DRUG|Belatacept|"Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter"
219290245|NCT06478017|DRUG|Tacrolimus|Prograf (tacrolimus) or tacrolimus generic
219290246|NCT06478017|DRUG|Mycophenolate Mofetil/Sodium|CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)
219290247|NCT06478017|DRUG|Prednisone|Prednisone
219290248|NCT06869889|PROCEDURE|Retrolaminar plane block|Retrolaminar plane infiltration with the local anesthetic mixture.
219290249|NCT06869889|PROCEDURE|Local wound infiltration|Local infiltration along the surgical incision.
219290250|NCT05319730|DRUG|Paclitaxel|80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
219290251|NCT05319730|DRUG|Irinotecan|180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.
219290252|NCT05319730|BIOLOGICAL|Pembrolizumab|200 mg IV infusion, administered every Q3W up to 35 infusions.
219290253|NCT05319730|BIOLOGICAL|MK-4830|800 mg IV infusion, administered Q3W up to 35 infusions.
219290254|NCT05319730|DRUG|Lenvatinib|20 mg oral administration every day.
219290255|NCT05319730|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
219290256|NCT05319730|DRUG|Antihistamine|Administered per product label.
219290257|NCT05319730|DRUG|H2 Receptor Antagonist|Administered per product label.
219290258|NCT05319730|DRUG|Acetaminophen (or equivalent)|Administered per product label.
219290259|NCT05319730|DRUG|Dexamethasone (or equivalent)|Administered per product label.
219290260|NCT05319730|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered per product label.
219290261|NCT05319730|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.
219290262|NCT06624982|OTHER|observational study|Observational study; alveolar ridge preservation
219290263|NCT06170606|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
219290264|NCT06875206|DEVICE|Low-intensity focused ultrasound|Low-intensity focused Ultrasound (LIFU) is a noninvasive brain stimulation technique that uses low-intensity ultrasound to stimulate specific parts of the brain.
219290265|NCT06875206|DEVICE|Immersive virtual reality|IVR is a noninvasive, computer-based audiovisual therapy designed to enhance visual function. Using a VR headset, the system delivers targeted visual stimulation through an interactive game that the participant engages with during each session.
219290266|NCT06875206|DEVICE|Inactive Low-intensity focused ultrasound|High acoustic impedance disk placed between LIFU and scalp that mimics the audible sensation of a slight buzzing but attenuates more than 95% of the energy into the brain.
219290267|NCT06686394|BIOLOGICAL|Patritumab deruxtecan|Patritumab deruxtecan administered via IV infusion
219290268|NCT06686394|BIOLOGICAL|Trastuzumab|Trastuzumab administered via IV infusion
219290269|NCT06686394|BIOLOGICAL|Trastuzumab Biosimilar|Trastuzumab biosimilar administered via IV infusion
219290270|NCT06686394|BIOLOGICAL|Pertuzumab|Pertuzumab administered via IV infusion
219290271|NCT06686394|BIOLOGICAL|Tucatinib|Tucatinib administered as oral tablets
219290272|NCT06697600|BEHAVIORAL|UR-GOAL|Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.
219290273|NCT05335369|BEHAVIORAL|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
219290274|NCT05513547|OTHER|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
219290275|NCT05513547|OTHER|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
219290276|NCT05513547|OTHER|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
219290277|NCT06697314|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 for the treatment of acute pulmonary embolism
219290278|NCT06698770|OTHER|Anticipated long-term use of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.
219290279|NCT06698770|OTHER|Period re-evaluation of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.
219290280|NCT06710197|DRUG|Anakinra (Kineret®)|100 mg/daily subcutaneously
219290281|NCT06715241|COMBINATION_PRODUCT|combination of relatlimab and nivolumab wich are two immunotherapy treatments|Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks
219290282|NCT06715241|OTHER|Nivolumab alone|Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
219290283|NCT06721013|DRUG|Pirtobrutinib|Administered orally
219290284|NCT06721013|DRUG|Placebo|Administered orally
219290285|NCT07033117|OTHER|Performance Feedback Reports on Referral and Evaluation Closures|Performance feedback reports will reflect each transplant center's performance related to kidney transplant evaluation initiation and referral closure. These reports aim to help centers understand common reasons why patients do not initiate the evaluation process or failed to proceed beyond the evaluation process, and to identify patterns in referral and evaluation closure practices. Reports will be individualized and distributed quarterly to the transplant center champion by the intervention lead.
219290286|NCT07033117|OTHER|Dialysis Facility Awareness Campaign|As part of the intervention, dialysis centers will participate in an Awareness Campaign designed to educate staff about transplant center quality improvement efforts and how they may be contacted as part of the project. This campaign may include brief webinars or informative documents distributed via platforms such as IPRO Learn.
219290287|NCT07033117|OTHER|Patient Contact via Preferred Method|Transplant centers will contact patients using their preferred method of communication.
219290288|NCT07033117|OTHER|Phone Call to Dialysis Facility During the Patient's Dialysis Session|Facilities will enhance their patient communication procedures by making a phone call to the dialysis facility during the patient's dialysis session if the patient has not responded to initial outreach attempts. This additional step increases the likelihood of reaching the patient during a time when they are accessible and can engage in scheduling or follow-up.
219290289|NCT07033117|OTHER|Phone Call to Provider|"Transplant centers will enhance their outreach procedures by making a phone call to the referring provider (e.g., nephrologist, medical assistant) or another provider involved in the patient's care (e.g., primary care provider) in the event of self-referral if the patient has not responded to initial outreach attempts or no-shows an initial evaluation appointment. This additional step ensures that the referring provider is informed of the patient's progress and can assist in re-engagement or decision-making prior to referral closure."
219290290|NCT07033117|OTHER|Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show|Transplant center staff will utilize transplant referral communication platforms and/or email to communicate updates to dialysis staff regarding patient status (e.g., unable to contact the patient or no-show) before referral closure.
219290291|NCT07033117|OTHER|Audit and Tracking of Patient Contact Attempts Prior to Referral Closure|Transplant center staff will continue internally tracking the frequency that a patient is contacted before closure and the date of closure, in alignment with center standard practice. This intervention introduces an audit process to be conducted before closure to ensure that all contact attempts (including one or more attempts to contact the patient directly, one or more phone calls to the alternate preferred contact, or one or more attempted contacts to the dialysis unit to connect with the patient), in alignment with center communication procedures, are appropriately executed.
219290292|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
219290293|NCT05931913|BEHAVIORAL|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
219290294|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
219290295|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
219290296|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
219290297|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
219290298|NCT06885658|BEHAVIORAL|Visual Storytelling Intervention for Antibiotic Adherence|The intervention involves the use of a visual storytelling approach designed to improve antibiotic adherence in patients diagnosed with urinary tract infections (UTIs). The intervention consists of a sticker featuring simple, visually appealing illustrations and a narrative highlighting the importance of completing the full course of prescribed antibiotics. The story contrasts the positive outcomes of adhering to the treatment with the negative consequences of stopping early, such as increased bacterial resistance. Key messages are reinforced through bold text and visual cues. This intervention aims to engage patients emotionally and cognitively, promoting behavior change by making the concept of antibiotic adherence more relatable and memorable.
219290299|NCT06725329|BEHAVIORAL|A tailored psychosocial education intervention|"Participants will get ten 60-minute psychoeducational group sessions about chronic pain and its management. The group sessions will be conducted by the PI and a bilingual project director at Korean churches or daycare centers in Baltimore-Washington Metropolitan area.~The psychoeducational group session will be adapted from LAMP intervention that has been previously developed. The intervention provides biopsychosocial education sessions about chronic pain and its management. For example, sessions focus on providing information regarding: (1) pain and the biological stress response and the gate control theory of pain, (2) the psychological impact of thoughts and emotions on pain and (3) facilitated group discussions to help participants develop a new understanding of pain through shared social experiences, all of which have been shown to improve pain outcomes."
219290300|NCT07048197|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of Rapcabtagene autoleucel
219290301|NCT04806347|BIOLOGICAL|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
219290302|NCT04806347|DEVICE|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
219290303|NCT05973851|DRUG|Esketamine Nasal Product|See arm description
219290304|NCT05973851|DRUG|Ketamine Hydrochloride|See arm description
219290305|NCT05973851|DRUG|Esketamine hydrochloride|See arm description
219290306|NCT05973851|DRUG|Second-line Antidepressants|See arm description
219290307|NCT07049900|DEVICE|NeoBelly Band|The DandleLion NeoBellyBand (NBB) is an FDA listed Class 1 medical device that is 510k exempt and is categorized under therapeutic medical binders. This device is indicated to be used while the infant is receiving CPAP support in order to reduce CBS. The NBB is made of a medical-grade blend of fabric and foam that is latex and neoprene-free and is reported as safe to use on premature infant skin. There are two sizes available and the outer fabric is attached with adjustable Velcro. It is a single baby use and may be hand washed and reused. This device is currently in use in multiple NICUs around the country, and as it has already been FDA-approved for the purpose of our investigation.
219290308|NCT07044817|BEHAVIORAL|Stroke Rehabilitation Guideline Adherence Survey|"This intervention consists of a structured online survey, the Stroke Rehabilitation Guideline Adherence Survey, designed to assess physiotherapists' and physiotherapy internship students' adherence to stroke rehabilitation clinical practice guidelines, their attitudes toward implementing evidence-based post-stroke care, and the perceived barriers-such as time constraints, limited resources, or insufficient training-that influence their compliance. No clinical treatments or procedures are administered; the sole intervention is the delivery of this comprehensive questionnaire."
219290309|NCT06745843|OTHER|Questionnaire|The patient information, informed consent form and questionnaire will collectively be distributed digitally or by mail to all patients.
219290310|NCT06890884|BIOLOGICAL|Zilovertamab vedotin|IV infusion
219290311|NCT06890884|BIOLOGICAL|Rituximab|IV infusion
219290312|NCT06890884|DRUG|Cyclophosphamide|IV infusion
219290313|NCT06890884|DRUG|Doxorubicin|IV infusion
219290314|NCT06890884|BIOLOGICAL|Rituximab Biosimilar|IV infusion
219290315|NCT06890884|DRUG|Prednisone|Oral administration or IV infusion
219290316|NCT06890884|DRUG|Prednisolone|Oral administration or IV infusion
219290317|NCT06890884|BIOLOGICAL|Polatuzumab vedotin|IV infusion
219290318|NCT06890884|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).
219290319|NCT06739122|DRUG|Dulaglutide|Administered SC
219290320|NCT06784466|DEVICE|Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Ablation using the Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
219290321|NCT02407405|DRUG|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
219290322|NCT05956587|DRUG|BL-B01D1|Administration by intravenous infusion
219290323|NCT05956587|DRUG|SI-B003|Administration by intravenous infusion
219290324|NCT06744712|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
219290325|NCT06893705|OTHER|Conventional Therapy|Conventional Therapy Group: Group A will be control group which will receive conventional physical therapy program for the affected neck like stretching exercises, active range of motion exercise, and neck isometrics for 6 weeks (3 sessions per week).
219290326|NCT06893705|OTHER|Pilates+Conventional Therapy|Group B will be experimental group, which will receive Pilate's exercises like cat stretch, swan dive/roll up along with conventional therapy for 6 weeks(3 sessions per week). In each session there will be 25 minutes of conventional therapy and 25 minutes of Pilate's exercises program.
219290327|NCT06482073|OTHER|Non-Interventional Study|Non-interventional study
219290328|NCT07051330|OTHER|Healthy Minds Program (HMP) app|"All participants will complete baseline surveys, weekly questionnaires (for 4 weeks) through the HMP app intervention, and will be surveyed again at 3-months post-intervention. Participants are randomized to each of the following binary conditions.~1. Introduction video for the app (yes / no)~2. Introduction video for the training modules (yes / no)~3. Module order based on ACIP score (highest-first / lowest-first)~4. Practice-nudging text messages (yes / no)~5. Microsupport messages during the intervention period (yes / no)~6. Microsupport messages during the follow-up period (yes / no"
219290329|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
219290330|NCT07056309|DRUG|Remternetug (Test)|Administered SC
219290331|NCT07056309|DRUG|Remternetug (Reference)|Administered SC
219290332|NCT06090669|DRUG|imatinib|Imatinib at 300-400 mg PO QD based on arm assignment/dose level
219290333|NCT06090669|DEVICE|TruSight Oncology|Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
219290334|NCT06813274|DRUG|hypoglycemic treatment|"The diabetes management adheres to the The 2025 Guidelines for Standards of Diabetes Care issued by the American Diabetes Association (ADA)."
219290335|NCT06813274|DRUG|Tangshen'an Granules|Tangshen'an Granules comprises a meticulously blended mix of Astragalus, Prepared Rehmannia Root, Dodder Seed, Kudzu Root, Millettia Speciosa Champ, Salviae Miltiorrhizae Radix et Rhizoma, Poria Cocos, and Polygala Tenuifolia. Tangshen'an Granules is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
219290336|NCT06813274|DRUG|Ginkgo Leaf Tablets|The primary active ingredients of Ginkgo Leaf Tablets are ginkgo flavonoid glycosides and terpene lactones. The prescribed oral dosage is one tablet each time, administered three times a day.
219290337|NCT06813274|DRUG|Mecobalamin Tablets|Mecobalamin Tablets primarily contain mecobalamin, which is a coenzyme-active form of vitamin B12. The prescribed oral dosage is 0.5mg, administered three times a day.
219290338|NCT06813274|DRUG|placebo|The placebo contains 10% of the active ingredients in Tangshen'an Granules, formulated by controlling the concentration to mimic Tangshen'an Granules. The placebo is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
219290339|NCT06717347|BIOLOGICAL|Zilovertamab vedotin|IV infusion
219290340|NCT06717347|BIOLOGICAL|Rituximab|IV infusion
219290341|NCT06717347|DRUG|Cyclophosphamide|IV infusion
219290342|NCT06717347|DRUG|Doxorubicin|IV infusion
219290343|NCT06717347|BIOLOGICAL|Rituximab Biosimilar|IV infusion
219290344|NCT06717347|DRUG|Prednisone|Per Approved Product Label
219290345|NCT06717347|DRUG|Prednisolone|Oral administration
219290346|NCT06717347|DRUG|Vincristine|IV infusion
219290347|NCT06717347|DRUG|Rescue medication|Participants receive rescue medication at the investigator's discretion, per approved product label. The recommended rescue medication is granulocyte colony-stimulating factor (G-CSF).
219290348|NCT05897320|DRUG|Eptinezumab|Solution for infusion
219290349|NCT05897320|DRUG|Placebo|Solution for infusion
219290350|NCT05668858|DRUG|SI-B001|Administration by intravenous infusion
219290351|NCT05668858|DRUG|SI-B003|Administration by intravenous infusion
219290352|NCT06550388|BEHAVIORAL|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
219290353|NCT06550388|BEHAVIORAL|Physical Activity|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
219290354|NCT03598257|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219290355|NCT03598257|DRUG|Olaparib|Given PO
219290356|NCT03598257|RADIATION|Radiation Therapy|Undergo radiation therapy
219290357|NCT03598257|OTHER|Survey Administration|Ancillary study
219290358|NCT05563220|DRUG|Elacestrant|Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
219290359|NCT05563220|DRUG|Alpelisib|Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
219290360|NCT05563220|DRUG|Everolimus|Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
219290361|NCT05563220|DRUG|Ribociclib|Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
219290362|NCT05563220|DRUG|Palbociclib|Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
219290363|NCT05563220|DRUG|Capivasertib|Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
219290364|NCT05563220|DRUG|Abemaciclib|Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
219290365|NCT07053774|DRUG|Intravenous oxytocin|Oxytocin, 10 International Units (IU) will be administered by IV infusion over 30 minutes and, 30 minutes later, a second 10 IU will be administered over 30 min, for a total dose of 20 IU. The first infusion will be at a rate of 0.125 IU/min for the first 5 min, then at 0.375 IU/min for the remaining 25 min. The second 30-min infusion will be at a fixed rate of 0.333 IU/min.
219290366|NCT07053774|DRUG|Intravenous placebo|Saline will be administered as two 30-min IV infusions separated by 30-min, using the same volume of infusion solution and rates of administration as in the intravenous oxytocin intervention.
219290367|NCT07053774|DRUG|Intranasal oxytocin|Oxytocin will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray (20 IU) in each nostril followed in 5 min by another spray in each nostril. The total dose of oxytocin is 80 IU.
219290368|NCT07053774|DRUG|Intranasal placebo|Placebo (solution containing the excipients in the oxytocin solution but without oxytocin) will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray in each nostril followed in 5 min by another spray in each nostril.
219290369|NCT06896669|DIETARY_SUPPLEMENT|vitamin D3|600IU of vitamin D3 and 1.5 to 2g of calcium will be provided for time period of 6 weeks once daily. In addition, Participants dietary intake will be assessed through 24 hours dietary recall.
219290370|NCT06768827|OTHER|Lactulose Oral Product|Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
219290371|NCT07063095|DRUG|Ceftazidime± avibactam with fosfomycin|"The intervention will last 72h (±6h). Ceftazidime will be administered intravenously in 5% glucose serum (per hospital standard), either intermittently (divided into three doses daily) or as continuous infusion; doses will be adapted to renal function. The decision to administer CAZ by continuous infusion and to add AVI will be left to the attending physician. CAZ±AVI will be adjusted for renal insufficiency per internal guidelines of dosing and international recommendations.~The use of CAZ with its paired beta-lactamase inhibitor avibactam, i.e., the use of ceftazidime-avibactam (Zavicefta®) instead of CAZ will occur in case of suspicion of infection by either extended-spectrum-beta-lactamase-producing Enterobacterales (ESBL-E), cephalosporinase-carrying Enterobacterales (ampC-E) or carbapenem-resistant Enterobacterales (CRE), as determined by treating physician and/or the infectious diseases consultant."
219290372|NCT07063095|DRUG|Ceftazidime± avibactam with placebo|Participants randomized to the control arm will receive placebo infusion. Placebo will be 5% glucose serum and will be administered IV with the same frequency as FOS would be for the participant's renal function.
219290373|NCT06777368|DEVICE|Medtronic TAV|Medtronic TAV where commercially available
219290374|NCT06777368|DEVICE|Edwards TAV|Edwards TAV where commercially available.
219290375|NCT06808217|DEVICE|FARAPULSE Pulsed Field Ablation System|Subjects who have provided written informed consent are considered enrolled. Subjects who have received ablation treatment with the FARAPULSE™ System are assigned to the 'TREATMENT' group.
219290376|NCT06834932|DRUG|Placebo|Administered orally as tablets
219290377|NCT06834932|DRUG|Rosuvastatin Dose 1|Administered orally as tablets
219290378|NCT06834932|DRUG|Rosuvastatin dose 2|Administered orally as tablets
219290379|NCT06834932|DRUG|AZD0780|Administered orally as tablets
219290380|NCT04536584|OTHER|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
219290381|NCT04536584|OTHER|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
219290382|NCT07069725|DRUG|AZD2389|Doses of AZD2389 will be administrated orally
219290383|NCT07069725|DIAGNOSTIC_TEST|PET scan and radioligand|PET scan and radioligand
219290384|NCT07062614|OTHER|Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment|at inclusion, 3 months and 6 months of follow-up, patients must answer the Girerd compliance questionnaire. After 6 months of follow-up, two strands of hair will be taken from the base of the skull using scissors
219290385|NCT07071948|DEVICE|Multifunctional Integrated Flexible Ureteroscope|"Investigational ureteroscope with three integrated functions:~1. Real-time pressure control: Continuous renal pelvic pressure monitoring with auto-adjustment of irrigation/aspiration flow to maintain pressure \<30 mmHg (safety threshold)~2. Simultaneous lithotripsy \& fragment removal: Holmium laser lithotripsy (200-365 μm fiber) coordinated with suction through working channel~3. Single-pass stone clearance: Designed to reduce residual fragments requiring secondary procedures~Distinguishing features vs conventional ureteroscopes:~1. Eliminates need for separate suction devices~2. Prevents intraoperative washout failure causing obscured vision~3. Patent-pending pressure sensor"
219290386|NCT06900374|DEVICE|GynWave-360|"For patients randomized to the experimental group:~3 sessions of 20 minutes each, spaced 4 to 6 weeks apart (M0, M1, M2) ideally, with +/- 1 maintenance session between 8 and 12 months after the first session (M8-12)."
219290387|NCT06900374|OTHER|Local hydratation|Reference treatment combining local hydration (hyaluronic acid-based treatment, 3 times a week), with the possibility of using associated measures at the investigator's discretion (physiotherapy, vaginal dilators, etc.).
219290388|NCT07069569|DRUG|AHB-137|AHB-137 will be injected.
219290389|NCT07069569|DRUG|Peg-IFN|Peg-IFN will be administered .
219290390|NCT07069569|DRUG|Hepatitis B Vaccine|Hepatitis B vaccine will be administered.
219290391|NCT06816329|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
219290392|NCT06634719|DEVICE|Juveena Hydrogel System|The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
219290393|NCT05310448|DEVICE|Optune device|Wear Optune device
219290394|NCT06215066|DEVICE|Virtual reality|The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.
219290395|NCT06215066|OTHER|Modified Progressive Muscle Relaxation|The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.
219290396|NCT06533826|DRUG|Trastuzumab Deruxtecan|A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
219290397|NCT06533826|DRUG|Datopotamab Deruxtecan|A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
219290398|NCT06040086|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
219290399|NCT06040086|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study.
219290400|NCT06621524|DEVICE|EucaLimus coronary stent system|The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
219290401|NCT06890598|DRUG|Olomorasib|Administered orally.
219290402|NCT06890598|DRUG|Pembrolizumab|Administered intravenously (IV).
219290403|NCT06890598|DRUG|Durvalumab|Administered IV.
219290404|NCT06890598|DRUG|Placebo|Administered orally.
219290405|NCT02379377|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative 18F-FSPG|Undergo 18F-FSPG PET scan
219290406|NCT02379377|BIOLOGICAL|Carbon C 11 Acetate|Undergo 11C-acetate PET scan
219290407|NCT02379377|PROCEDURE|Positron Emission Tomography|Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
219290408|NCT02379377|OTHER|Laboratory Biomarker Analysis|Correlative studies
219290409|NCT02379377|BIOLOGICAL|Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose|Undergo 18F-FDG PET scan
219290410|NCT05886621|BEHAVIORAL|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
219290411|NCT05886621|BEHAVIORAL|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
219290412|NCT06926920|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
219290413|NCT06623136|DRUG|ES102|ES102 is administered via intravenous infusion, once every 21 days.
219290414|NCT06623136|DRUG|Toripalimab|Toripalimab is administered via intravenous infusion, once every 21 days.
219290415|NCT07094685|PROCEDURE|Biopsy Procedure|Undergo biopsy
219290416|NCT07094685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219290417|NCT07094685|PROCEDURE|Computed Tomography|Undergo PET-CT and CT scan
219290418|NCT07094685|BIOLOGICAL|Ivonescimab|Given IV
219290419|NCT07094685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219290420|NCT07094685|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
219290421|NCT07094685|PROCEDURE|Surgical Procedure|Undergo surgical dissection
219290422|NCT07095231|BIOLOGICAL|STX-S|A proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express spike proteins on the surface
219290423|NCT07095933|DRUG|Everolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 2.5 mg per dose for BSA \<1.2 m², 5 mg per dose for BSA 1.3-2.1 m², and 7.5 mg per dose for BSA \>2.2 m².
219290424|NCT07136077|DRUG|Tislelizumab|Given by IV
219290425|NCT07136077|DRUG|Fruquintinib|Give by PO
219290426|NCT06910566|PROCEDURE|Chemoradiotherapy or radiotherapy alone|Patients included in the study receive standard treatment with chemoradiotherapy or radiotherapy alone for their head and neck cancer or lung cancer. These treatments are part of their routine care and are not part of the observational study.
219290427|NCT07099898|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
219290428|NCT07099898|DRUG|Topotecan|Topotecan will be administered
219290429|NCT06762717|DEVICE|FARAPULSE™ Pulsed Field Ablation system|no intervention design in the study
219290430|NCT04349631|BIOLOGICAL|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
219290431|NCT06706284|DRUG|Semaglutide Injectable Product|A GLP-1 inhibitor used to control T2DM
219290432|NCT06706284|OTHER|Placebo|Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
219290433|NCT06921928|DRUG|AZD4360|Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
219290434|NCT06921759|DRUG|Lebrikizumab|Administered SC
219290435|NCT06921759|DRUG|Placebo|Administered SC
219290436|NCT06921850|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
219290437|NCT06919003|BIOLOGICAL|Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
219290438|NCT06919003|OTHER|Placebo for Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
219290439|NCT07124650|DRUG|Hydrocortisone Acetate 1% Ointment|Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.
219290440|NCT07124650|DRUG|Lidocaine hydrochloride 0,05% with chlorhexidine|Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.
219290441|NCT06919497|BEHAVIORAL|Spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
219290442|NCT06919497|BEHAVIORAL|No spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
219290443|NCT06931093|BEHAVIORAL|Group Guided Written Exposure Therapy for CPTSD (GWE-C)|"Group Guided Written Exposure Therapy for CPTSD (GWE-C) is a manualized, exposure-based therapeutic program consisting of 7 to 10 sequential sessions. The intervention follows a structured sequence of trauma processing that addresses trauma details, associated emotions, cognitions, and impacts. Writing tasks incorporate imagery dialogues, self-compassion exercises, and resource identification to help participants alleviate C-PTSD symptoms.~The interval between two consecutive sessions ranges from 0 to 2 days, with participants expected to complete all sessions within 1 to 2 weeks. The first and last sessions are scheduled to last 1.5 hours each, while the intermediate sessions are 60 minutes in duration. Each group will consist of 6 to 10 participants and will be facilitated by one counselor and one assistant."
219290444|NCT06931093|BEHAVIORAL|Supportive counselling|Supportive counselling, the comparator intervention, is a non-trauma-focused treatment based on the Rogerian psychotherapy model and has been used as an active comparator in previous trials of trauma-focused therapies. The program comprises seven sessions: the first two employ group activities such as card games and interactive drawing to build a sense of belonging; sessions three to six focus on stress management and emotion regulation skills through methods including expressive drawing, relaxation training, and resource identification; the final session emphasizes reflection and sharing. Throughout, counsellors provide supportive guidance to encourage emotional expression, mutual listening, and peer support, while discussions deliberately exclude participants' individual traumatic experiences.
219290445|NCT06929559|OTHER|Pain expectation conditioning|Participants receive application of a neutral cream (MEDICAFARM) with verbal and behavioral suggestions that it may cause localized pain. Researchers wear gloves during application and emphasize potential discomfort, stating effects may intensify with movement.
219290446|NCT06929559|OTHER|Comparator (Control Group)|Participants receive identical application of the neutral cream but are informed it is inert and harmless. Researchers apply the cream without gloves and provide neutral instructions.
219290447|NCT06929559|OTHER|Intervention: Gait|"Participants undergo assessment procedures including:~* Pre- and post-application gait analysis (GAITRite mat, Zebris treadmill)~* Physiological monitoring (EMG, HRV, EDA)~* Identical questionnaires (BPI, TSK, FACS, PCS, VAS)"
219290448|NCT06935604|BEHAVIORAL|VR with a trained facilitator|"Intervention Group 1 - VR with a facilitator:~Each participant in the intervention group will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Facilitator training: The facilitator group will include trained healthcare professionals skilled in VR technology, C-I-CARE, and empathetic patient engagement. All facilitators also complete the Creative \& Healing Arts Heart-to-Heart training which includes observation, empathy training, and reflection to support complex communication, and companionship needs of adult patients ."
219290449|NCT06935604|BEHAVIORAL|VR without a trained facilitator.|"Intervention Group 2 - VR without an inperson facilitator:~Each participant in the intervention groups will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Instructional video: A research assistant will use C-I-CARE to give the patient an instructional video and the headset to engage in the VR technology.~Patients will take a surveys before and after the intervention"
219290450|NCT06938074|DIAGNOSTIC_TEST|CT and MRI|All participants will undergo both CT imaging and MRI imaging to identify areas of ischemic scar. Treatment plans will be created based on CT scans, for all participants using various treatment delivery and motion management techniques.
219290451|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
219290452|NCT06937229|DRUG|KarXT|Specified dose on specified days
219290453|NCT06937229|DRUG|KarX-EC|Specified dose on specified days
219290454|NCT06944379|DRUG|ORKA-002|ORKA-002 is supplied as sterile solution to be administered by SC injection
219290455|NCT06944379|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
219290456|NCT07144306|DIAGNOSTIC_TEST|Smartphone-based AI skin lesion analysis (NuvanaDx platform).|Smartphone-based AI skin lesion analysis (NuvanaDx platform).
219290457|NCT07140900|DRUG|Xaluritamig|Participants will receive xaluritamig intravenously.
219290458|NCT07140900|DRUG|Darolutamide|Participants will receive darolutamide orally.
219290459|NCT07140900|DRUG|Abiraterone|Participants will receive abiraterone orally.
219290460|NCT06952530|DRUG|Orforglipron|Administered orally
219290461|NCT06952530|DRUG|Placebo|placebo administered
219290462|NCT07150247|DRUG|Iparomlimab and Tuvonralimab|3mg/kg，ivdrip
219290463|NCT07150247|DRUG|Bevacizumab|5mg/kg，ivdrip
219290464|NCT07150247|DRUG|5-Fluorouracil|400mg/m2 iv followed by 2.4g/m2 civ 48h
219290465|NCT07150247|DRUG|Irinotecan (drug)|180mg/m2
219290467|NCT07153471|DRUG|Orforglipron|Administered orally
219290468|NCT07153471|DRUG|Placebo|Administered orally
219290469|NCT07158593|OTHER|Claudia carraro prevention program|"The Claudia Carraro prevention program is grounded in a cognitive-behavioral conceptualization of the development of eating disorders or disordered eating. The program was designed to address specific and non-specific risk factors that appear relevant: body dissatisfaction and unhealthy weight control behaviors. Its dual objective is to help participants reduce the importance they place on body weight and shape in self-evaluation while simultaneously promoting healthy weight regulation through adherence to Mediterranean dietary guidelines and an active lifestyle.~The strategies and procedures used are derived from cognitive behavioral therapy protocols for eating disorders (Dalle Grave \& Calugi, 2020). The intervention is delivered by psychologists specialized in eating and weight disorders using an interactive, rather than didactic, format, involving small group activities and assigned homework tasks between sessions."
219290470|NCT07162363|DRUG|Alteplase|Up to nine doses of 1.0 mg alteplase will be administered via the catheter placed directly into the intracerebral hemorrhage using minimally invasive surgery.
219290471|NCT07162363|DRUG|Deferoxamine|Deferoxamine will be administered as a continuous intravenous infusion at a dose of 32 mg/kg/day over 24 hours for a total of 3 consecutive days.
219290472|NCT07162363|OTHER|Standard Medical Care (SMD)|We will follow the American Heart Association and European Stroke Organization guidelines for the management of non-traumatic spontaneous intracerebral hemorrhage, ensuring a standardized approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacologic management of intracranial mass effect.
219290473|NCT07162181|DRUG|Pirtobrutinib|Administered orally.
219290474|NCT07165015|DRUG|LY3537031|Administered SC
219290475|NCT07167706|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|BBTI is a multi-component intervention consisting of techniques from sleep restriction and stimulus control therapy. It targets behavioral elements of insomnia using four techniques: 1) reduce time in bed, 2) get up at the same time every day, 3) do not go to bed unless sleepy, and 4) do not stay in bed unless asleep.
219290476|NCT07167706|BEHAVIORAL|Sleep Hygiene Therapy|SHE consists of education on lifestyle factors (diet, exercise, substance use) and enviromental variables (noise, light, temperature) affecting sleep quality.
219290477|NCT07169747|DRUG|Psilocybin|The intervention consists of two oral doses of 25 mg synthetic psilocybin administered in a controlled clinical setting, combined with psychological support. The psychological support includes preparatory sessions prior to psilocybin administration, support during the drug experience and integration sessions following each dosing session.
219290478|NCT07190131|DIAGNOSTIC_TEST|Investigational Flu A/B And Covid-19 Diagnostic Test|A diagnostic test in lateral flow cassette format designed to detect Influenza A, Influenza B and SARS-CoV-2 from anterior nasal swab specimens.
219290479|NCT07188896|DRUG|Fianlimab|Fianlimab will be co-administered by IV.
219290480|NCT07188896|DRUG|Ipilimumab|Ipilimumab will be administered by IV.
219290481|NCT07188896|DRUG|Nivolumab|Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
219290482|NCT07188896|DRUG|Cemiplimab|Cemiplimab will co-administered by IV.
219290483|NCT07195422|DEVICE|Japet.W+|Current care of low back pain and wearing the Japet.W+
219290484|NCT07195422|DEVICE|Control (Standard treatment)|Current care of low back pain
219290485|NCT07195513|BEHAVIORAL|ePRO-Directed Referral and Navigation to Palliative/Supportive Care|This intervention combines routine electronic patient-reported outcome (ePRO) symptom monitoring with additional components designed to connect patients more directly to palliative/supportive care. In addition to weekly ePRO symptom surveys, participants complete a monthly palliative care-focused ePRO survey, receive structured palliative care education from a trained study coordinator, and are offered navigation support to facilitate access to palliative/supportive care services. Severe or persistent symptoms or unmet needs reported on ePROs generate an alert to the oncology team along with a recommendation for palliative care referral. This multicomponent approach is intended to address gaps in timely referral and access to palliative/supportive care that are not addressed through symptom monitoring alone.
219290486|NCT07195513|OTHER|ePRO Symptom Monitoring with Usual Palliative Care Referral|Participants complete weekly electronic patient-reported outcome (ePRO) symptom monitoring surveys. Survey results are shared with the oncology team to support routine care. Referral to palliative/supportive care is made according to usual clinical practice at the discretion of the oncology team. Unlike the intervention arm, participants do not receive structured palliative care education, a monthly palliative care-focused ePRO survey, navigation support, or referral alerts generated from persistent or severe symptoms and unmet care needs.
219290487|NCT07193563|DRUG|ENX-102|oral capsule
219290488|NCT07193563|OTHER|Placebo|oral capsule
219290489|NCT07187479|OTHER|Physiologic Insulin Resensitization (PIR)|PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.
219290490|NCT07194187|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound (HIFU) works with an image-guided transrectal probe that utilizes 3-10 MHz ultrasound waves at very high powers (200W). These waves can be very precisely directed at target tissue. Through both thermal and mechanical forces (shearing motion and mechanical energy leading to hyperthermia) the focal point core temperature can be raised significantly (\> 80°C) leading to coagulative necrosis to the target tissue while sparing surrounding tissue. The degree of tissue injury is based on the temperature and the duration of exposure, with the cooling off time allowing for the heat to dissipate to prevent the damage to surrounding tissues. The most common device involves a transrectal transducer with ultrasound guidance that can be performed under either general or spinal anesthesia. The device has been FDA approved to be used in ablation of prostatic tissue since 2018.
219290491|NCT07194278|DEVICE|Blue-blocking glasses|The intervention will last for 7 days, during which patients are required to wear the glasses from 6 p.m. to 8 a.m. and whenever a light is turned on during this interval. Additionally, patients will be asked to wear an actimeter and fill out a sleep diary each day. Doctors will conduct daily interviews to assess manic symptoms, with more in-depth assessments scheduled on days 0, 3, and 7 to evaluate other clinical characteristics.
219290492|NCT07194577|DIETARY_SUPPLEMENT|Moringa oleifera|5.6 grams of Moringa oleifera Lam dried leaf powder administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
219290493|NCT07194577|DIETARY_SUPPLEMENT|Placebo|Starch placebo administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
219290494|NCT07194590|DRUG|Equol|This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
219290495|NCT07194590|DRUG|Placebo|This group will receive 2 placebo capsules per day.
219290496|NCT07193589|DRUG|The high-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.
219290497|NCT07193589|DRUG|The low-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.
219290498|NCT07193589|DRUG|The placebo group|The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.
219290499|NCT07195305|PROCEDURE|Radiofrequency endometrial ablation|Radiofrequency endometrial ablation
219290500|NCT07195305|PROCEDURE|Uterine artery embolization|Uterine artery embolization
219290501|NCT07195305|PROCEDURE|Hysterectomy|Hysterectomy
219290502|NCT07194304|DRUG|alpha-Tocopherol|patients in the intervention group received parenteral alpha-tocopherol at a dose of 4 mg/kg body weight
219290503|NCT07194304|DRUG|Sterile Water for Injection|the control group received a placebo (sterile water for injection/aquabidest)
219290504|NCT07195071|DEVICE|Natera empower comprehensive hereditary cancer panel|Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers
219290505|NCT07195071|DEVICE|Obstetrical carrier screening|Obstetrical carrier screening for genetic conditions
219290506|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)|2.5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
219290507|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2)|5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
219290508|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)|10 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
219290509|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4)|20 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
219290510|NCT07195357|OTHER|epidemiological|collection of data from all participating subjects involving tooth erosion examinations, tooth sensitivity and questionnaire data collection
219290511|NCT07194980|DRUG|Nemtabrutinib|Given PO
219290512|NCT07194980|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
219290513|NCT07194343|PROCEDURE|Laparoscopic colposacropexy with levator ani muscle mesh fixation|The standard technique includes dissection of the rectovaginal space and bilateral mesh fixation to the levator ani muscle at the deep limit of the pararectal fossae dissection.
219290514|NCT07194343|PROCEDURE|Simplified modification of laparoscopic colposacropexy|Rectovaginal dissection is avoided, and the mesh is anchored to the posterior aspect of the cervix or vaginal vault rather than to the levator ani muscle, representing the specific modification from the standard technique.
219290515|NCT07195201|DEVICE|3D Printed Onlay Restoration|Onlay restorations will be fabricated using a 3D printer and a biocompatible permanent resin (Bego VarseoSmile TriniQ). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
219290516|NCT07195201|DEVICE|CAD/CAM Onlay Restoration|Onlay restorations will be fabricated using a CAD/CAM milling unit and hybrid ceramic blocks (GC Cerasmart 270). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
219290517|NCT07195370|OTHER|peripheral iridotomy|This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.
219290518|NCT07195097|DRUG|Oral intake of sildosin|Oral intake of sildosin in male non hormonal contraception
219290519|NCT07195097|OTHER|Oral intake of placebo|Intake of placebo to compare effecacy of other group
219290520|NCT07195136|BEHAVIORAL|Essential Oil|essential oil
219290521|NCT07193836|DRUG|Normal Saline (0.9% NaCl)|Participants in the control group received a single intravenous injection of 0.9% normal saline at induction of anesthesia.
219290522|NCT07193836|DRUG|Lidocaine|Participants in this group received a single intravenous bolus of lidocaine (1.5 mg/kg) at anesthesia induction. No additional lidocaine was administered thereafter.
219290523|NCT07193836|DRUG|Lidocaine Bolus + Infusion|Participants in this group received a bolus of lidocaine (1.5 mg/kg) at induction followed by continuous intravenous infusion of lidocaine (2 mg/kg/h) until the end of surgery.
219290524|NCT07193888|DEVICE|Navitor Transcatheter Aortic Valve Implantation|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System.
219290525|NCT07194772|OTHER|Low-calorie sweeteners (LCS)|"Consumption of sucralose-sweetened beverages (LCS) using doses and formulations reflecting real-world conditions.~Individualized dose equivalent volume (mL) to SSB group. Average dose received of 150 mg (±30 mg) of pure sucralose per day (2.00 ± 0.23 mg/Kg BW) among participants, which is below Acceptable Daily Intake for sucralose (5 mg/Kg BW/day). LCS matched for sweetness to SSB based on the manufacturer's information."
219290526|NCT07194772|OTHER|Refined sugars (SSB)|"Consumption of sugar-sweetened beverages (SSB) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada. SSB matched total free sugar concentration of 100% natural orange juice (FJ)."
219290527|NCT07194772|OTHER|Natural sugars (FJ)|"Consumption of natural fruit juice (100% natural orange juice) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada."
219290528|NCT07193810|BIOLOGICAL|CC312|CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.
219290529|NCT07193706|BEHAVIORAL|Traditional group training program|This intervention consists of two supervised plyometric training sessions per week, each lasting about 40 minutes. It represents the traditional approach with fewer but longer sessions. The total weekly training volume is equivalent to the micro-dosed group but distributed differently.
219290530|NCT07193706|BEHAVIORAL|Micro-dosed group training program|This intervention consists of three to four shorter supervised plyometric sessions per week, each lasting about 20 minutes. It represents a micro-dosed approach, with higher frequency but shorter duration per session. The total weekly training volume is equivalent to the traditional group but distributed across more frequent sessions.
219290531|NCT07195643|OTHER|Drain|We want to put a assess the predictive factors for prophylactic drain after cholecystectomy.
219290532|NCT07194408|OTHER|Sunscreen RV4620A RP2552|"Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product.~Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon."
219290533|NCT07193862|COMBINATION_PRODUCT|Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373|"Patients with diagnosed liver metastasis from a colorectal primary deemed resectable. The study intervention will be limited to the percutaneous placement of up to 2 IMDs per lesion with a maximum of 4 devices total, with the subsequent en bloc resection of the tumor plus IMD within 3 (+2) days after placement. The microdevices will remain in the tumor for a minimum of a 2-day incubation period, although ideally for 3 days.~The IMD is a small cylindrical device approximately 750 um in diameter and 5 mm in length (Figure 2), housing up to 21 reservoirs. It is made of PEEK, biocompatible material used in other implantable constructs, including joint replacements. 11-13 Drugs are solubilized with poly-ethylene glycol (PEG) and loaded into the individual reservoirs. The drug diffusion has been mapped extensively to ensure that the weight of PEG is selected such that drug diffusion is limited and will not mix or interfere with another drug."
219290534|NCT07195344|BIOLOGICAL|Pharmacokinetics blood samples|Blood samples will be collected at different time points during the first four treatment cycles and at the end of T-DXd treatment or at 24 months after inclusion in case of T-DXd continuation beyond this time period.
219290535|NCT07194928|OTHER|We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.|We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
219290536|NCT07195435|BEHAVIORAL|Genital Hygiene Education|Genital Hygiene Training: Young girls who agree to participate will receive two sessions of two hours of genital hygiene training on a predetermined date, as appropriate. Genital hygiene training will be delivered via PowerPoint presentation, and at the end of the training, a training booklet and brochure, developed in accordance with the relevant literature, will be distributed to the participating girls to ensure retention. The training booklet and brochure will be prepared by the researcher based on current literature sources. Expert opinions will be sought from obstetrics and gynecology nursing experts regarding the training content and will be revised as necessary. The content of the training booklet will cover the female internal and external genital organs, the importance of genital infections for women's health, factors affecting genital hygiene, characteristics of normal and abnormal genital discharge, common genital infections, signs and symptoms of genital infection, and pro
219290537|NCT07195019|BEHAVIORAL|Integrative Yoga & Mindful Self-Compassion training|Group Integrative Yoga \& Mindful Self-Compassion training for women with a history of interpersonal violence exposure and distress
219290538|NCT07195019|BEHAVIORAL|Women's Wellbeing Education|Group women's wellbeing education for women with a history of interpersonal violence exposure and distress
219290539|NCT07195058|BEHAVIORAL|Trauma Informed Obstetric Care (TIOC)|"TIOC providers will receive a training that was developed for this study. Elements of trauma-informed care described in the literature -combined with the experience of the study team, with deep expertise in trauma-informed obstetric care, were used to create three training modules, each of which includes didactics and role-plays to help participants practice and embody skills they learn. The three modules are:~1. Effects of trauma on physiological and psychological process relevant to pregnancy and childbirth.~2. Body language and verbal language for safety, respect, and patient agency~3. Recognizing and responding to distress and dissociation"
219290540|NCT07195539|OTHER|Tranexamic Acid sprinkle with CO2 LASER|tranexamin acid will be sprayed after CO2 LASER
219290541|NCT07193667|DRUG|CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases|"This is a prospective, single-center, open, single-arm, dose-escalation clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory autoimmune diseases. Intravenous infusion will be used, and the trial procedure will be divided as follows:~1. Screening period (D-28 to D-6):~   After subjects voluntarily sign an informed consent form, a screening period will be conducted to determine whether subjects are eligible for the trial based on inclusion and exclusion criteria.~2. Lymphocyte depletion pretreatment (Study D-5 to Study D-3):~   Subjects will be pre-treated with Lymphocyte depletion starting 5 days prior to CAR-T cell infusion (FC regimen)~3. Rest and Observation (Study D-2 to Study D-1):~   Follow the study procedures and perform the relevant examinations during the rest and observation period.~4. Cell Infusion and Primary Study Endpoint Observation Period (Study D0 to W12 post-infusion):Subjects will undergo CAR-T cell infusion at 2-da"
219290542|NCT07194083|BEHAVIORAL|Function-Based Elopement Treatment|"FBET is a structured, caregiver-implemented behavioral intervention targeting elopement in children. It includes:~* Psychoeducation and Behavioral Assessment-caregivers receive training on elopement, behavioral principles, and assessment strategies~* Functional Analysis Coaching-therapists guide caregivers through a latency-based functional analysis to identify the function of elopement~* Individualized Treatment Implementation-caregivers apply a function-based plan using differential reinforcement, providing preferred items/activities contingent on safe behavior~* Treatment Modification-therapists support caregivers in adjusting the plan based on child's response.~There will be 12 2-hour, caregiver-mediated sessions across 20 weeks Caregivers also learn safety and prevention strategies, including the use of resources like the Big Red Safety Toolkit."
219290543|NCT07194083|BEHAVIORAL|Treatment as Usual|TAU consists of ongoing Applied Behavior Analysis (ABA) services, including caregiver training as it normally exists, provided by the family's Board Certified Behavior Analyst (BCBA), independent of the study protocol. The BCBA determines session frequency, content, and focus based on clinical judgment and the child's individual needs. Topics may include skill acquisition, behavior reduction (including elopement), or other areas deemed relevant to the child's care. The research team does not influence or standardize the TAU content, but will monitor and document the services delivered for descriptive and comparative purposes
219290544|NCT07195383|OTHER|Nutrion plan based on GUSS-ICU scale|To ensure a rapid and accurate transition to post-extubation nutrition, patients will be assessed using the GUSS-ICU scale at 4 hours after extubation. A nutrition plan will be created based on the patient's GUSS-ICU score and will be maintained for 4 days.
219290545|NCT07194031|OTHER|Ankle Exercise|In the literature, studies have evaluated ankle proprioception following interventions applied to the knee. However, no studies report the effects of ankle exercises on knee proprioception
219290546|NCT07194031|OTHER|Knee Exercise|The literature emphasizes that long-term and multidirectional exercise programs provide proprioceptive improvements
219290547|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (1 per day)|Children consume one yogurt smoothie per day for 4 weeks (93 mL and \~70 kcal).
219290548|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (2 per day)|Children consume two yogurt smoothies per day for 4 weeks (186 mL and \~140 kcal).
219290549|NCT07195474|DIETARY_SUPPLEMENT|Fruit Juice Control|Children consume one fruit juice per day for 4 weeks (\~140 kcal, isocaloric with 2 yogurt smoothie).
219290550|NCT07195240|DIETARY_SUPPLEMENT|Active: Lemongrass|200mg of lemongrass extract
219290551|NCT07195240|DIETARY_SUPPLEMENT|Control: Placebo|microcrystalline cellulose
219296471|NCT06906146|DEVICE|CRET therapy|Capacitive Resistive Electric Transfer (CRET) therapy is a treatment modality that applies high-frequency electrical currents to stimulate tissue regeneration, enhance blood circulation, and reduce muscle pain. It operates through two modes: the capacitive mode, which targets superficial tissues such as skin and muscle, and the resistive mode, which penetrates deeper structures like tendons, ligaments, and joints. This technique is widely used in rehabilitation, sports physiotherapy, and pain management to accelerate muscle recovery and optimize neuromuscular function.
219296472|NCT06906146|DEVICE|Sham CRET Therapy|Same as CRET therapy but in a aham form.
219290552|NCT07188675|OTHER|Functional Inspiratory Muscle Training (FIMT)|Participants will begin with Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks. Training will be performed once a week face-to-face, while adherence will be monitored on other days via WhatsApp. During each face-to-face session, MIP will be reassessed and training loads adjusted. Participants will perform 30 dynamic inspiratory efforts twice daily. In the following 4 weeks, Functional Inspiratory Muscle Training (FIMT) will be applied: once face-to-face, twice online under physiotherapist supervision, and twice unsupervised IMT. FIMT exercises will be performed with the POWERbreathe Classic Light Resistance device, consisting of 10 breaths lasting 15-30 seconds in 2 sets. Each session will include warm-up (diaphragmatic breathing and trunk stretches), loading (core stabilization exercises), and cool-down (trunk stretches). IMT intensity will be adjusted weekly using MIP measurement
219290553|NCT07188675|OTHER|Inspiratory Muscle Training (IMT)|Participants will perform IMT daily for 8 weeks. Training will be conducted once a week face-to-face, while on other days adherence will be monitored via WhatsApp. The group will complete 30 dynamic inspiratory efforts twice daily. The POWERbreathe Classic Light Resistance device (PowerBreathe, IMT Technologies Ltd, Birmingham, UK) will be used to strengthen the diaphragm and chest wall muscles by breathing against a set pressure load. Training intensity will be set at 50% of maximal inspiratory pressure (MIP). After 10-15 consecutive breaths, participants will perform 3-4 recovery breaths before continuing. IMT intensity will be re-adjusted weekly during face-to-face sessions using MIP measurements to maintain 50% loading.
219290554|NCT07195461|DEVICE|Magnetic Bead Tracking System|The Magnetic Beads will be implanted in a subject during either an already required revision of an existing unilateral or bilateral transtibial amputation or during the performance of a unilateral or bilateral transtibial amputation.
219290555|NCT07193602|DEVICE|VR-based dexterity training in MS|Training of limited manual dexterity in people with multiple sclerosis through a specially developed home-based dexterity training programm using a virtual headset
219290556|NCT07193602|OTHER|mediation program|Sham Training is the comparator. The Sham group is performing a commercially available mediation programm TRIPP:
219290557|NCT07194824|OTHER|Pragmatic allergy management according to risk stratification|"Intervention based on allergy risk stratification. Tipus A) Patients in this group can undergo direct delabeling without the need for exposure, with this being documented in the EMR. If the patient refuses, an exposure to penicillin and/or cephalosporin will be performed. Once completed, de-labeling can proceed without the need for re-exposure.~Tipus B) Indication for use of a penicillin: Oral exposure to 250 mg of amoxicillin.~\- Indication for cephalosporin : administration of a cephalosporin that exhibits the lowest level of cross-reactivity with penicillin.~Re-exposure to penicillin/ cephalosporin or both is performed at least 2 weeks after the first tolerated exposure. De-labeling is performed when tolerance to re-exposure is verified.~Tipus C) These high-risk patients are managed following the protocol for the treatment of patients with beta-lactam allergy, referring them to allergy consultation for further specific test."
219290558|NCT07193784|BEHAVIORAL|Reiki|Reiki therapy applied by trained practitioner for 30 minutes.
219290559|NCT07193784|BEHAVIORAL|Sham reiki|Sham Reiki applied by same practitioner, mimicking Reiki without actual energy technique.
219290560|NCT07194967|DEVICE|Virtual Reality Hypnosis for Labor Pain and Anxiety Management|"For patients randomized to the intervention arm, the investigator will provide a clear explanation of the procedure and the use of the HypnoVR virtual reality headset. The investigator will remain present throughout the session to supervise the experience, using the companion tablet to monitor the visualization in real time.~Participants will be invited to select one of eight immersive visual environments designed to promote relaxation and analgesia during labor. Available options include: Tropical Beach, Underwood, Underwater Dive, Zen Garden, Astral Travel, Winter Landscape, Aurora Borealis, and Oasis.~Patients will be informed that they may discontinue the use of the headset at any time and for any reason, without any consequences for their standard medical care."
219290561|NCT07194109|DRUG|Remimazolam based total intravenous anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with remimazolam in a dose of 0.4 - 0.5 mg/kg anesthesia maintenance was administered with remimazolam at a rate of 1.0 - 3.0 mg/kg/h.
219290562|NCT07194109|DRUG|Propofol based general anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with propofol in a dose of 2.0 - 3.5 mg/kg , anesthesia maintenance was administered with propofol at a rate of 4 - 12 mg/kg/h.
219290563|NCT07194395|DEVICE|PatenSee System|Contactless AV access monitoring device
219290564|NCT07193524|DEVICE|3D Fracture Analysis Tool|"Based on a pre-operative computed tomography (CT) scan, fractured bone fragments of a proximal tibia are segmented and aligned to achieve adequate fracture reduction.~Bone material properties for each fragment are derived from Hounsfield Units (HU) of the CT scan, based on internal density calibration with air, fat, muscle, and cortical bone. Screws and implants are then modelled based on the manufacturer's design and material properties Placement of off-the-shelf plate and screws can be analyzed and support a personalized plan on how to individually treat a patient with a specific fracture pattern and anatomical biometric data.~Surgeons can define up to three approaches (different placement of implants and screws) to be visualized and analyzed for construct stability.~The surgeons will receive a visualization of the fracture, fracture-reduction, implant and screw placement in 3D as well as a comparison of construct stabilites of the submitted approaches"
219290565|NCT07194551|COMBINATION_PRODUCT|Vaginal DNA swab, microbiome swab and pH test|Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.
219290566|NCT07194876|OTHER|No Intervention (subjects were previously treated with Onglyza®)|no intervention
219290567|NCT07194668|BIOLOGICAL|10μg R21/50μg Matrix-M|Adults and adolescents receiving the standard adult vaccine dose: 10μg R21/50μg Matrix-M (n=125)
219290568|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with adaptor preservative free|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with adaptor Preservative Free (n=125)
219290569|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with 2PE preservative|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with 2PE Preservative (n=125)
219290570|NCT07195318|DIETARY_SUPPLEMENT|Fisetin|One capsule (100 mg) daily
219290571|NCT07195318|DIETARY_SUPPLEMENT|Placebo|One capsule daily
219290572|NCT07193901|DRUG|Low Dose PRT042 nasal spray|two times a week, for 4 weeks
219290573|NCT07193901|DRUG|median Dose PRT042 nasal spray|two times a week, for 4 weeks
219290574|NCT07193901|DRUG|high dose PRT042 nasal spray|two times a week, for 4 weeks
219290575|NCT07193901|DRUG|placebo|two times a week, for 4 weeks
219290576|NCT07194200|BIOLOGICAL|Lactobacillus plantarum|Intervention measures for the experimental group: Apply 5ml of Lactobacillus plantarum solution extracted from the skin surface of healthy individuals to the psoriatic lesions daily, for a duration of 2 months.
219290577|NCT07194200|BIOLOGICAL|inactivated Lactobacillus plantarum|Intervention measures for the control group: Apply 5ml of inactivated Lactobacillus plantarum solution to the psoriatic lesions daily, for a duration of 2 months.
219290578|NCT07195604|DRUG|HRS-2162|HRS-2162
219290579|NCT07195604|DRUG|Placebo|Placebo
219290580|NCT07194057|GENETIC|Whole genome sequencing|Whole genome sequencing (WGS) is an advanced genomic technique that allows for the comprehensive analysis of an individual's entire DNA sequence, including both coding and non-coding regions. In the context of pediatric transplantation, WGS offers a powerful tool for uncovering underlying genetic disorders that may influence transplant eligibility, donor-recipient compatibility, immune response, or risk of post-transplant complications. It enables the identification of rare monogenic diseases, pharmacogenomic markers relevant to immunosuppressive therapy, and potential genetic predispositions to graft rejection or infection. Integrating WGS into transplant evaluation process enhances personalized medicine approaches, contributing to improved long-term outcomes in pediatric transplant recipients.
219290581|NCT07194057|GENETIC|Polygenic Risk Score Calculation|A polygenic risk score (PRS) calculation will be performed to quantitatively estimate the an individual's genetic predisposition to the original disease that led to transplantation. These scores are calculated by aggregating the weighted sum of risk alleles-most commonly single nucleotide polymorphisms (SNPs)-each of which contributes a small effect size as determined by genome-wide association studies (GWAS).
219290582|NCT07194057|DIAGNOSTIC_TEST|Methylome and episignatures|"Methylomic analysis in paediatric transplantation refers to the comprehensive profiling and study of DNA methylation patterns across the genome to understand epigenetic modifications associated with transplant-related outcomes.~This epigenetic approach enables the identification of differentially methylated regions (DMRs) that may correlate with clinical phenotypes, such as graft acceptance or rejection, infectious complications, or immune dysregulation.~The studies withjin the Protect\_Child\_101 project will be aimed at: 1) Refinement of episignatures, to increase specificity, sensitivity and robustness of those episignatures that already exist and 2) Discovery and validation of new disease, gene or variant specific mDNA signatures."
219290583|NCT07194265|DEVICE|TAVR with DurAVR THV|Transcatheter aortic valve replacement (TAVR)
219290584|NCT07194265|DEVICE|TAVR with SAPIEN THV series or the Evolut THV series|Transcatheter aortic valve replacement (TAVR)
219290585|NCT07193641|RADIATION|Spatially Fractionated Radiotherapy (SFRT)+Stereotactic Body Radiation Therapy (SBRT)|"The intervention includes SFRT for larger oligoprogressive lesions (≥4.5 cm in diameter), utilizing image-guided CT, including 4D-CT, with Lattice technique planning. The dose fractionation will be determined by the radiation oncologist based on clinical parameters, with peak doses ranging from 6-15 Gy/Fx and valley doses from 1.8-4 Gy/Fx, typically in 1-5 fractions.~For smaller oligoprogressive lesions, stereotactic body radiotherapy (SBRT) or intensity-modulated radiotherapy (IMRT) will be selected based on clinical parameters."
219290586|NCT07193641|DRUG|The systemic therapy|Continuation or switch of prior standard regimen (chemotherapy, targeted TKI, or PD-1/PD-L1 inhibitor) at investigator discretion until further progression or intolerable toxicity.
219290587|NCT07195253|DIAGNOSTIC_TEST|Polysomnography (PSG) to explore OSA|"Patients will undergo full-night PSG (including electrocardiogram to monitor heart rate and the JAWAC system to record mandibular movements) in the sleep unit of Hôpital Femme-Mère-Enfant (Bron, France) to explore OSA, included in the routine care of children with DS.~OSA diagnosis will be made based on the obstructive apnea-hypopnea index (OAHI) resulting from the PSG. OSA will be diagnosed when OAHI ≥1.5/hour."
219290588|NCT07195253|BEHAVIORAL|Oro-myo-functional clinical evaluation|Orofacial myofunctional evaluation will be conducted by a physiotherapist according to the OMES-E (Orofacial Myofunctional Evaluation with Scores for Nursing Infants).
219290589|NCT07195253|OTHER|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children is a short questionnaire answered by parents about their child's sleep disorders.~Total score and scores for each sleep disorder will be calculated, according to the classical procedures during hospitalization of all children in our sleep unit."
219290590|NCT07195253|OTHER|Non-nutritive sucking recording|Non-nutritive sucking performance will be recorded through an experimental method using a classical pacifier, equipped with pressure sensors. Recording will last about 10 minutes. Variables related to sucking performance (maximum amplitude, frequency of sucking bursts, etc.) will be recorded.
219290591|NCT07195253|OTHER|Neurocognitive evaluation|The Brunet-Lézine test will be administered by a neuropsychologist. Global score will be calculated along with its four subscores (posture, hand-eye coordination, language, sociability).
219290592|NCT07195253|OTHER|PedsQL-Infants|The PedsQL-Infants questionnaire is designed to evaluate quality of life in infants. It will be given to parents during their child's hospitalization.
219290593|NCT07194993|OTHER|Nonradioactive stable oral isotope|"NaH13CO3 \[99% atom percent excess (APE) and L-\[1-13C\]Leu (99% APE) will be given orally.~Isotope administration will begin with the fifth meal on each study day with each remaining meal.~The nonradioactive stable oral isotope is being administered to study the physiological process of amino acid oxidation."
219290594|NCT07194993|OTHER|Test diet|"Test diets will be provided on study days in 8 hourly isocaloric and isonitrogenous meals to maintain a metabolic steady state.~Each meal will provide one-twelfth of the participant's daily needs to model a 12-hour fasted and 12-hour fed feeding pattern.~The diet will be composed of PFD2 (Mead Johnson), Tang and Kool-Aid (Kraft), corn oil, and protein-free wheat starch cookies. Each participant will receive 1 of 7 test protein intakes (0.2-3.2 g ⋅ kg-1 ⋅ d-1) on each study day. Protein will be provided as a crystalline L-amino acid mixture based on an egg protein pattern. Phe will be provided separately based on the Phe tolerance for each patient established by the metabolic dietitian listed on the IRB protocol. Leucine will be provided at a constant amount of 82.6 mg/kg/day as it is used as the indicator amino acid. The medical food used in this study is being fed to subjects for nutritional purposes to study the oxidation of the nonradioactive oral isotope."
219290595|NCT07193407|DEVICE|Sacral Neuromodulation System|INOPASE Sacral Neuromodulation System (INO-SNM-01) for treatment of overactive bladder.
219290596|NCT07194512|OTHER|Taekwondo-Specific Agility Test (TSAT), Frequency Speed of Kick Test (FSKT), Frequency Speed of Kick Test (FSKT10s), Multiple Frequency Speed of Kick Test (FSKTmult), Kick Decrement Index (KDI)|After pre-test measurements, the experimental group performed an eight-week high-intensity interval training (HIIT) program three times per week (Monday, Wednesday, Friday) alongside their regular taekwondo training. The control group continued with their regular taekwondo training only. After the eight-week intervention, post-tests were administered to both groups, and the results were recorded by the researchers.
219290597|NCT01982448|DRUG|Cisplatin|
219290598|NCT01982448|DRUG|Paclitaxel|
219290599|NCT07195578|OTHER|Three Dimensional Puzzle Game (3D puzzle)|Individuals in the intervention group were exposed to the 3D puzzle game three days a week for a total of 10 weeks. Three-dimensional puzzle figures, ranging in size from 20 to 50 pieces, were used in 30 sessions, each with a different figure.
219290600|NCT07194655|OTHER|Acupuncture at the Yanglingquan point|Acupuncture at the Yanglingquan point
219290601|NCT07194655|OTHER|Acupuncture at the Xiabai Point|Acupuncture at the Xiabai Point
219290602|NCT07194655|OTHER|Acupuncture at non-meridian points|Acupuncture at non-meridian points
219290603|NCT07195279|OTHER|Experimental Group|The VR intervention consisted of a simulated driving experience delivered over nine sessions, three times per week, each lasting 20 minutes, over a three-week period. The virtual reality (VR) therapy employed a full immersion approach, delivering intense multisensory visual-auditory stimulation. Patients were exposed to diverse driving scenarios, specifically: urban streets (featuring intersections, traffic lights, and pedestrians to simulate complex urban environments), ring roads (designed for practicing smooth and confident high-speed driving in dense traffic), and tunnels (sections aimed at gradually desensitizing users to claustrophobic responses during driving).
219296473|NCT06906159|DIETARY_SUPPLEMENT|Cricket protein|Muffins made with cricket-derived protein from house crickets (Acheta domesticus )
219290604|NCT07195279|OTHER|Control Group|Conventional cardiac rehabilitation protocol consisted of 1.5-hour group calisthenics sessions with a 10-minute break, held six times per week. This was accompanied by aerobic reconditioning exercises on a stationary bike or treadmill, depending on medical prescription and the patient's health status.
219290605|NCT05498987|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant Achilles Tendon
219290606|NCT03333876|DEVICE|Nasal Dilator|Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.
219290607|NCT03333876|DEVICE|Mandibular Advancement|"For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States."
219290608|NCT03333876|DEVICE|Positional Therapy|Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
219290609|NCT01587859|PROCEDURE|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
219290610|NCT00095498|DRUG|placebo|placebo subcutaneous injection
219290611|NCT00095498|DRUG|denosumab|For subcutaneous injection
219290612|NCT04684394|BIOLOGICAL|GEM103|GEM103 500 mcg/50 mcL intravitreal injection
219290613|NCT04684394|DRUG|Aflibercept|"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
219290614|NCT04684394|DRUG|Sham|Sham intravitreal injection
219290615|NCT05749484|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
219290616|NCT01094210|DRUG|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
219290617|NCT01558401|OTHER|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
219296474|NCT06906159|DIETARY_SUPPLEMENT|Whey protein|Muffins made with whey protein
219296475|NCT06906445|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
219290618|NCT05199415|BEHAVIORAL|Health and Well-being Committee|Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
219296476|NCT06906445|OTHER|Anti-Inflammatory Diet|The modified diet plan will be given to each study participant
219296477|NCT06906445|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
219296478|NCT06906445|OTHER|Sham Diet|Dietary counselling alone
219296479|NCT06906445|OTHER|Advanced Therapy|Advanced therapy as standard dose and schedule
219290619|NCT03407937|BEHAVIORAL|Hypnosis|Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.
219290620|NCT03407937|BEHAVIORAL|Meditation|Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
219290621|NCT03407937|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.
219290622|NCT03407937|DRUG|Placebo Oral Tablet|A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
219290623|NCT05808881|DRUG|Nalmefene Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
219290624|NCT05808881|DRUG|Naloxone Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
219290625|NCT03143621|DIETARY_SUPPLEMENT|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
219290626|NCT03143621|OTHER|Water|Tap water heated to same temperature as coffee
219290627|NCT00482690|DRUG|nicotine polacrilex|
219290628|NCT00482690|DRUG|nicotine transdermal system|
219290629|NCT00482690|DRUG|nicotine inhaler|
219290630|NCT02037633|DRUG|Fentanyl|Fentanyl IV
219290631|NCT02037633|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
219290632|NCT02037633|DRUG|ropivacaine|
219290633|NCT02932566|DRUG|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
219290634|NCT02932566|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
219290635|NCT05747300|OTHER|Premixed bioceramic paste wellroot PT|Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
219290636|NCT00591370|DRUG|Temozolomide (TMZ)|One group treatment study
219290637|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.
219290638|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.
219290639|NCT05952687|DRUG|Selinexor|Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
219290640|NCT03439254|DRUG|Obeticholic acid (10 mg)|Tablets administered orally once daily.
219290641|NCT03439254|DRUG|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
219290642|NCT03439254|DRUG|Placebo|Tablets administered orally once daily.
219290643|NCT04101214|OTHER|Dry needling|Dry needling into spastic muscle
219290644|NCT04101214|OTHER|Sham dry Needling|Sham dry needling into spastic muscle
219290645|NCT02442492|DRUG|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
219290646|NCT02442492|DRUG|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
219290647|NCT04556292|DRUG|SC10914|SC10914 400mg tid
219290648|NCT06531993|DRUG|Pectin|Using pectin as tablets 600 mg per day for 6 months
219290649|NCT02780154|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
219290650|NCT02780154|BIOLOGICAL|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
219290651|NCT00770705|DRUG|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
219290652|NCT00770705|OTHER|Standard surgical approach|Historical controls
219290653|NCT04399070|DRUG|S-ketamine|The depression patients received propofol and S-ketamine before ECT
219290654|NCT04399070|DRUG|ketamine|The depression patients received propofol and ketamine before ECT
219290655|NCT04399070|DRUG|saline|The depression patients received propofol and saline before ECT
219290656|NCT00271960|BEHAVIORAL|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
219290657|NCT00271960|BEHAVIORAL|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
219290658|NCT00271960|BEHAVIORAL|Usual care|Participants will receive usual prenatal care.
219290659|NCT03232580|DRUG|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
219290660|NCT04362943|DRUG|Baricitinib or Anakinra|Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
219290661|NCT02265289|DRUG|Lefradafiban|
219290662|NCT02265289|DRUG|Clopidogrel|
219290663|NCT06281106|DRUG|Deucravacitinib|Daily drug intake for 4 weeks.
219296480|NCT06906666|OTHER|Athletes sample|Elite athletes in whom the risk of injury will be calculated and the influence of confounding factors will be assessed through a personal interview.
219290664|NCT06254937|OTHER|Reproductive Life Plan training|Reproductive Life Plan trainings; It will be done in the form of group training, which is considered an advantageous health education method in terms of low cost, wide scope and practicality. During the training, after the power point presentation to the initiative group, question-answer, discussion, brainstorming and visualizations will be made with the Pecha Kucha Technique. Presentations prepared in line with the Reproductive Life Plan Training Booklet will be used as training tools. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in booklet.
219290665|NCT04506645|DRUG|REGN5381|Single dose REGN5381 administered via IV infusion
219290666|NCT04506645|OTHER|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
219290667|NCT05490901|DIAGNOSTIC_TEST|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
219290668|NCT05139251|OTHER|Recovering from Intimate partner violence through Strengths and Empowerment (RISE)|RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician
219290669|NCT05139251|OTHER|ePALS|"Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently."
219290670|NCT04379362|PROCEDURE|Focal laser ablation|Focal laser ablation
219290671|NCT02371291|BEHAVIORAL|Memory Flexibility Training|As in experimental arm description.
219290672|NCT02371291|BEHAVIORAL|Psychoeducation|As in experimental arm description.
219290673|NCT01051934|DRUG|SS1 (dsFv) PE38|
219290674|NCT01051934|DRUG|Paclitaxel|
219290675|NCT01051934|DRUG|Carboplatin|
219290676|NCT01051934|DRUG|Bevacizumab|
219290677|NCT02075476|PROCEDURE|Hemiarthroplasty|
219290678|NCT02075476|PROCEDURE|reverse arthroplasty|
219290679|NCT00301587|DRUG|Norgestimate-ethinyl estradiol, with or without folic acid|
219290680|NCT06042322|OTHER|Educational intervention|Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
219290681|NCT05882409|BEHAVIORAL|Education|Education covers women's education on violence, conflict and awareness.
219290682|NCT00567203|DRUG|PF-3463275|PF-3463275 10mg
219290683|NCT00567203|DRUG|PF-3463275|PF-3463275 25mg
219290684|NCT00567203|DRUG|Placebo|Placebo
219290685|NCT05617664|DRUG|desmopressin 120 mcg oral tablets|treatment for three months then will stop
219290686|NCT05617664|DRUG|Mirabegron 25 MG Oral Tablet, Extended Release|treatment for three months then will stop
219290687|NCT05617664|BEHAVIORAL|behavioral therapy alone|no medications will be given to the patient
219290688|NCT01015859|DEVICE|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
219290689|NCT05452200|BEHAVIORAL|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
219290690|NCT05452200|OTHER|added exams to the usual lung cancer screening|"* spirometry examination~* Questionnaires~* Blood samples and breath samples to find biomarkers"
219290691|NCT04019990|OTHER|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
219290692|NCT03918499|DRUG|Cyclophosphamide|Given IV
219290693|NCT03918499|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
219290694|NCT03918499|BIOLOGICAL|Pembrolizumab|Given IV
219290695|NCT06245148|OTHER|Observation|Observation
219290696|NCT01882205|DEVICE|Virtual chromoendoscopy|
219290697|NCT01882205|PROCEDURE|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
219290698|NCT02321202|DRUG|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
219290699|NCT02321202|DRUG|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
219290700|NCT03498859|OTHER|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
219290701|NCT03498859|OTHER|Home-based training|The intervention is home-based training during 10 weeks
219290702|NCT01169740|PROCEDURE|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
219290703|NCT06162962|OTHER|Retrospective analysis|Retrospective analysis
219290704|NCT00682851|DEVICE|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
219290705|NCT00682851|DEVICE|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
219290706|NCT00363350|DRUG|rituximab (anti-CD20)|2 infusions of 1000 mg
219290707|NCT02209662|DEVICE|APIC-PRP|APIC-PRP
219290708|NCT02209662|OTHER|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
219290709|NCT02746432|DRUG|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
219290710|NCT03114839|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of LcS.
219290711|NCT03700112|OTHER|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
219290712|NCT03700112|OTHER|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
219290713|NCT03700112|OTHER|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
219290714|NCT03700112|OTHER|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
219290715|NCT03700112|OTHER|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
219290716|NCT03700112|OTHER|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
219290717|NCT03700112|OTHER|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
219290718|NCT03700112|OTHER|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
219290719|NCT01242735|BEHAVIORAL|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
219290720|NCT01242735|BEHAVIORAL|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
219290721|NCT04539080|PROCEDURE|transversus abdominis plane block|transversus abdominis plane block group
219290722|NCT03601377|BEHAVIORAL|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
219290723|NCT03601377|BEHAVIORAL|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
219290724|NCT03601377|BEHAVIORAL|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
219290725|NCT03293160|OTHER|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
219290726|NCT00535756|DRUG|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
219290727|NCT00535756|DRUG|Placebo|Placebo
219290728|NCT04734743|OTHER|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
219290729|NCT06316453|OTHER|Evaluating ASCVD risk over 10 and 30 year and lifetime|Utilizing validated tools such as the Pooled Cohort Equations (PCE) for 10-year ASCVD risk, the 30-year ASCVD risk prediction tool, and lifetime ASCVD risk categories, participants will undergo a thorough risk assessment. This multi-dimensional approach ensures a nuanced understanding of short and long-term cardiovascular risks. Further, The genetic risk for ApoB will be meticulously assessed by genotyping the APOB rs1042031 variant. Subsequently, the calculation of the genetic risk score (GRS) based on risk alleles will provide personalized insight into genetic predispositions related to ASCVD risk. Moreover, Participants will receive personalized management recommendations derived from the ACC/AHA Cardiovascular Risk Assessment Guidelines. These tailored suggestions may encompass dietary programs, lifestyle modifications, and, when indicated, pharmaceutical therapies like statins, aiming to mitigate identified risks effectively
219290730|NCT00687687|DRUG|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
219290731|NCT00687687|DRUG|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
219290732|NCT00687687|DRUG|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
219290733|NCT03472053|DRUG|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
219290734|NCT03472053|DRUG|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
219290735|NCT00082940|BIOLOGICAL|denileukin diftitox|
219290736|NCT04844619|DRUG|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
219290737|NCT04844619|DRUG|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
219290738|NCT05183126|DRUG|Paclitaxel|Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
219290739|NCT05183126|DRUG|Paclitaxel|"Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time."
219290740|NCT00588991|DRUG|Carboplatin|Given IV
219290741|NCT00588991|OTHER|Laboratory Biomarker Analysis|Correlative study
219290742|NCT00588991|DRUG|Topotecan Hydrochloride|Given IV
219290743|NCT00588991|DRUG|Veliparib|Given orally
219290744|NCT04967807|DIAGNOSTIC_TEST|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
219290745|NCT04967807|DIAGNOSTIC_TEST|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
219290746|NCT04981795|DRUG|Tafasitamab|Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
219290747|NCT05459376|OTHER|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
219290748|NCT01330849|BEHAVIORAL|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
219290749|NCT01330849|OTHER|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
219290750|NCT04709289|OTHER|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
219290751|NCT02133222|PROCEDURE|blood sample|
219290752|NCT02898077|DRUG|Ramucirumab|Administered IV
219290753|NCT02898077|DRUG|Paclitaxel|Administered IV
219290754|NCT02898077|DRUG|Placebo|Administered IV
219290755|NCT04845204|OTHER|Relaxation Treatment|Relaxation Group recieve progressive muscle relaxation exercises additional to the standard exercises. The relaxation exercises are applied two times a day till the discharge day starting on the postoperative day one. Progressive muscle relaxation included the relaxing of different muscle groups along with deep breathing. The maximal contraction period consist of the contraction of muscle groups around ankle, calf, knee, hip, lumbar, thoracic and cervical regions, shoulder, arm, forearm for 5 s and continued with a relaxation period for 30 s while focusing on breathing. These two periods ware repeated for each muscle groups and lasted approximately 30 min
219290756|NCT04845204|OTHER|Standard Exercises|The physiotherapy protocol is applied under the supervision of the same physiotherapist within a progressive manner immediately after surgery. Continued passive range of motion is applied twice a day starting with 45º of knee flexion range of motion and increased gradually as tolerated. All patients performed same isometric, isotonic and active exercises. Patients were instructed to bear weight as tolerated on the postoperative day 1
219290757|NCT03584542|OTHER|No interventional study|No Interventional study - Only one questionnaire will be done for patients and for general practitioners
219290758|NCT00621777|DRUG|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
219290759|NCT00621777|DRUG|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
219290760|NCT06363760|OTHER|Safety and efficacy assessments|Assessed throughout the duration of the study.
219290761|NCT04905459|DIAGNOSTIC_TEST|ARDA software application|Subject images will be sent to the investigational ARDA software
219290762|NCT03492749|DIAGNOSTIC_TEST|Saliva monitoring|The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
219290763|NCT02138955|DRUG|Liposomeal curcumin|
219290764|NCT01239043|BIOLOGICAL|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
219290765|NCT01239043|BIOLOGICAL|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
219290766|NCT01952353|PROCEDURE|Preoprative TACE|
219290767|NCT01952353|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
219290768|NCT04129697|DRUG|Dexamethasone or Methylprednisolone|steroids
219290769|NCT00353522|DRUG|Placebo|po daily for 24 weeks
219290770|NCT00353522|DRUG|dalcetrapib|900mg po daily for 24 weeks
219290771|NCT02469103|DEVICE|C2|C2 and colonoscopy will be performed one after another on the same day
219290772|NCT02469103|PROCEDURE|colonoscopy|
219290773|NCT00553072|DRUG|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
219290774|NCT00553072|DRUG|Normal saline|1 ml/kg/dose
219290775|NCT01066520|DRUG|Traumeel S ointment|2 g, 3 times daily topical during 14 days
219290776|NCT01066520|DRUG|Traumeel S gel|2 g, 3 times daily topical during 14 days
219290777|NCT01066520|DRUG|Diclofenac gel|2 g, 3 times daily topical during 14 days
219290778|NCT00436852|DRUG|ABT-751|Given orally
219290779|NCT00436852|PROCEDURE|quality-of-life assessment|Ancillary studies
219290780|NCT04135768|PROCEDURE|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
219290781|NCT04135768|PROCEDURE|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
219290782|NCT00167167|PROCEDURE|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
219290783|NCT04218045|PROCEDURE|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
219290784|NCT04218045|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
219290785|NCT02883998|OTHER|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
219290786|NCT02883998|OTHER|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
219290787|NCT02934256|DRUG|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
219290788|NCT05953649|DEVICE|Extracorporeal Diaphragm Pacing|In the EDP group, a pacer using the extracorporeal diaphragm pacemaker provided by Guangzhou Xueliang Biotechnology Developing Co., Ltd., the pacing electrode is pasted on the body surface closest to the phrenic nerve at the outer edge of the lower end of the sternocleidomastoid muscle under ultrasound guidance, and the auxiliary electrode is placed between the second intercostal of the midline of the clavicle. The intensity of treatment parameters was set from low to high, and the intensity of treatment was increased when the patient could tolerate it, pacing 12-18 times/min at a frequency of 40 hertz (Hz)/30min/time, and performed every 12 hours for a week.
219290789|NCT05953649|DEVICE|Tilt Table Verticalization|VitalGo bed (VitalGo Systems Ltd., Fort Lauderdale） is used for verticalization. Verticalization was set to minimum 30°, depending on cardiopulmonary parameters (respiratory rate, heart rate, blood pressure, oxygen saturation), vertical position was gradually increased (in 5° steps) to a maximum of 90°, as long as the above-named cardiopulmonary parameters of the patient remained stable and remain this position for 30 minutes simultaneously with extracorporeal diaphragm pacing for a week.
219290790|NCT05953649|OTHER|Conventional Physiotherapy|Patients receive early mobilization, which refers to a series of clinical intervention protocols (such as passive movement or active exercises, etc.) that confers physical benefits at an early period in collaboration with a multidisciplinary team (intensive care physicians, rehabilitation physicians, physical therapists, occupational therapists, respiratory therapists, and nurses). The study intervention take place during working time between 8 a.m. and 17 p.m. Patients of all three study groups receive this rehabilitation program until they transfer out of ICU.
219290791|NCT02938026|PROCEDURE|Bariatric surgery|
219290792|NCT02938026|BEHAVIORAL|Telephone Intensive Lifestyle Counselling|
219290793|NCT05195502|DIAGNOSTIC_TEST|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
219290794|NCT02548975|DRUG|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
219290795|NCT02548975|OTHER|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
219290796|NCT05461833|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
219290797|NCT05461833|DRUG|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
219290798|NCT05461833|DIETARY_SUPPLEMENT|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
219290799|NCT04640831|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
219290800|NCT00733876|BIOLOGICAL|Multipotent Stromal Cells|Post-operative administration of MSC
219290801|NCT00733876|BIOLOGICAL|Administration of MSC|Dose escalation protocol
219290802|NCT01062802|DRUG|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
219290803|NCT01062802|OTHER|Placebo|Placebo given once daily for 4 weeks.
219290804|NCT02141620|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
219290805|NCT02141620|DRUG|n-Acetylcysteine|
219290806|NCT02141620|DRUG|Placebo|
219290807|NCT04777877|OTHER|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
219290808|NCT06546917|BEHAVIORAL|bWell Cognitive Remediation|"Patients will take part in the bWell cognitive remediation protocol, consisting of 40-minute sessions of bWell, administered 2 times a week for 8 weeks. These sessions consist of tasks that target various cognitive domains and increase in complexity and difficulty as training progresses. The tasks are as follows:~1. Lab Exercise: participant alternates between two different, increasingly complex 'recipes', targeting executive functioning and divided attention.~2. Egg Exercise: In an office environment, participants must seek out and maintain their gaze on certain objects in order to collect them in the presence of visual distractors, targeting sustained attention.~3. Mole Exercise: participants must strike moles with the matching coloured hammer as fast as possible, targeting selective attention.~4. Theatre Exercise: participants must remember objects presented on stage and recreate the sequence after the curtains close, targeting working memory."
219290809|NCT06546917|BEHAVIORAL|VR Experience|Patients will take part in the viewing of VR scenes which contain no instructed cognitive tasks. This consists of 40-minute sessions of viewing VR scenes, administered 2 times a week for 8 weeks.
219290810|NCT02051959|DEVICE|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
219290811|NCT02051959|DEVICE|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
219290812|NCT02051959|DEVICE|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
219290813|NCT02051959|DEVICE|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
219290814|NCT04459117|DRUG|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
219290815|NCT04459117|DRUG|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
219290816|NCT02718430|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
219290817|NCT02757040|DRUG|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
219290818|NCT02757040|DRUG|ibrutinib|ibrutinib
219290819|NCT02940587|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
219290820|NCT03856190|OTHER|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
219290821|NCT03856190|OTHER|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
219290822|NCT04239469|DRUG|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
219290823|NCT04239469|DRUG|Placebo|Placebo
219290824|NCT00307684|DRUG|double blind placebo|matching placebo tablets once daily for 4 weeks
219290825|NCT00307684|DRUG|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
219290826|NCT00307684|DRUG|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
219290827|NCT03784001|BEHAVIORAL|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
219290828|NCT03784001|BEHAVIORAL|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
219290829|NCT03784001|BEHAVIORAL|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
219290830|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
219290831|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
219290832|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
219290833|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
219290834|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
219290835|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
219290836|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
219290837|NCT03517813|DEVICE|Contrast-enhanced Spectral Mammography (CESM)|Dual energy mammography images obtained after the administration of an intravenous contrast agent
219290838|NCT01189175|DRUG|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
219290839|NCT01189175|DRUG|BI 113823|single oral dose
219290840|NCT03377699|DRUG|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
219290841|NCT03377699|DRUG|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
219290842|NCT03377699|DRUG|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
219290843|NCT04068961|OTHER|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
219290844|NCT00004487|DRUG|chondrocyte-alginate gel suspension|
219290845|NCT02580305|DRUG|SUVN-502|Once-daily, tablets, orally
219290846|NCT02580305|DRUG|Placebo|Once-daily, tablets, orally
219290847|NCT02580305|DRUG|Donepezil|Donepezil HCl (10 mg, once a day)
219290848|NCT02580305|DRUG|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
219290849|NCT03525067|OTHER|Bile sampling for bacterial examination|At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
219290850|NCT02370927|OTHER|Control|Non pulse extruded cereal
219290851|NCT02370927|OTHER|Pea protein|Pulse extruded cereal
219290852|NCT02370927|OTHER|Pea Starch|Pulse extruded cereal
219290853|NCT02370927|OTHER|Pea fibre + pea starch|Pulse extruded cereal
219290854|NCT02370927|OTHER|Pea protein + pea starch|Pulse extruded cereal
219290855|NCT02370927|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
219290856|NCT00224887|BEHAVIORAL|In home nutrition counseling|In home family-based behavioral counseling
219290857|NCT00224887|OTHER|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
219290858|NCT03199118|PROCEDURE|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
219290859|NCT03199118|OTHER|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
219290860|NCT02309151|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
219290861|NCT05831722|PROCEDURE|Rapid Maxillary Expansion|Rapid Maxillary Expansion consists in the mid palatal suture opening through temporary anchorage mini implants placed in the palatal area.
219290862|NCT05625451|DEVICE|Elastic Tension Digital Neoprene Orthosis|The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
219290863|NCT02277353|OTHER|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
219290864|NCT00348530|DRUG|Verapamil|
219290865|NCT00754364|DRUG|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
219290866|NCT00754364|DRUG|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
219290867|NCT01422551|BEHAVIORAL|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
219290868|NCT01422551|BEHAVIORAL|a psycho-educational control|a single-day psycho-educational seminar
219290869|NCT00270140|DRUG|epoetin alfa|
219290870|NCT02874417|BEHAVIORAL|CAST psychoeducation|
219290871|NCT02874417|BEHAVIORAL|PHET|
219290872|NCT03114787|OTHER|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
219290873|NCT06373523|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.
219290874|NCT06373523|DRUG|Placebo|The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).
219290875|NCT06373523|DRUG|Levothyroxine Replacement daily|Levothyroxine Replacement daily for 28 weeka
219290876|NCT05861700|OTHER|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|A change Dbic in a middle of hemodialysis
219290877|NCT05861700|OTHER|Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L|A change Dbic in a middle of hemodialysis
219290878|NCT03916939|OTHER|osteopathy|osteopathy treatment
219290879|NCT03916939|OTHER|simulated osteopathy|simulated osteopathic sessions
219290880|NCT03942900|OTHER|Additional biological samples|"* Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~  * at baseline,~ * at first tumor assessment (phase 2 in OPTIMANAL study),~ * at second tumor assessment (phase 4 in OPTIMANAL study),~ * at end-point visit.~* A tumor biopsy or archived tumor sample will be mandatory at baseline."
219290881|NCT05310305|COMBINATION_PRODUCT|Radiotherapy for targeted lesions and PD-1 antibody|Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
219290882|NCT00620295|DRUG|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
219290883|NCT00620295|DRUG|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.
219290884|NCT00171717|DRUG|Cyclosporine - cyclosporine microemulsion|
219290885|NCT00870077|DIETARY_SUPPLEMENT|ProWHEY 94 CFM, SponserR|3 times 20g per day
219290886|NCT04242043|DIAGNOSTIC_TEST|intel@med-feasibility|"Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care."
219290887|NCT04515290|DRUG|TSG-01|Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
219290888|NCT04515290|DRUG|TSG-01 and Placebo|One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
219290889|NCT04515290|DRUG|Placebo|Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
219290890|NCT05441644|DEVICE|Bispectral index|A new placemewnt to monitor intraoperative BIS
219290891|NCT02854878|DEVICE|The Lucy ultrasonic comb models A and B combined with the LucyGel|
219290892|NCT00798590|DRUG|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
219290893|NCT00798590|DRUG|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
219290894|NCT01404429|DRUG|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
219290895|NCT03934177|DIETARY_SUPPLEMENT|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
219290896|NCT03934177|DIETARY_SUPPLEMENT|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
219290897|NCT00001145|DRUG|Bacteriophage|
219290898|NCT00001145|DRUG|rhuCD40L|
219290899|NCT00001145|DRUG|KLH|
219290900|NCT03693859|BEHAVIORAL|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
219290901|NCT03693859|BEHAVIORAL|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
219290902|NCT03573076|COMBINATION_PRODUCT|Photodynamic therapy|Photodynamic therapy with Methyl Aminolevulinate creme and red light.
219290903|NCT03573076|DEVICE|Non-ablative Thulium laser (NAFL)|Non-ablative Thulium laser (NAFL).
219290904|NCT03573076|DEVICE|Radio-frequency microneedles (RF-MN)|Radio-frequency microneedles (RF-MN).
219290905|NCT04618562|OTHER|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
219290906|NCT05850559|DIAGNOSTIC_TEST|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer by Enzyme-linked immunosorbent assay (ELISA
219290907|NCT03297424|DRUG|PLX2853|tablets
219290908|NCT05155176|BEHAVIORAL|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.
219290909|NCT02716259|PROCEDURE|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
219290910|NCT02716259|PROCEDURE|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
219290911|NCT03794700|OTHER|Hospice Decision Aids|Paper and video hospice decision aid
219290912|NCT00293501|DRUG|tinzaparin sodium|
219290913|NCT04097353|BEHAVIORAL|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
219290914|NCT04097353|BEHAVIORAL|Surviving Strong for Kids (SS4K)|Enhanced usual care
219290915|NCT00744562|DRUG|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
219290916|NCT02120287|DRUG|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
219290917|NCT02120287|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
219290918|NCT02120287|PROCEDURE|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
219290919|NCT03905343|DRUG|Ribociclib|Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
219290920|NCT03905343|OTHER|Mono-chemotherapy|mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
219290921|NCT03905343|OTHER|Endocrine-Therapy|The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
219290922|NCT01579500|DRUG|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
219290923|NCT01579500|DRUG|normal saline|Subcutaneous injection of normal saline
219290924|NCT00517400|DEVICE|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
219290925|NCT00311389|DRUG|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219290926|NCT00311389|DRUG|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
219290927|NCT01482923|BEHAVIORAL|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
219290928|NCT01482923|BEHAVIORAL|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
219290929|NCT05841992|DRUG|Al18F-PSMA-617|Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617. Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
219290930|NCT05841992|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
219290931|NCT06347328|PROCEDURE|echo-guided infiltration|the subjects will receive their injection in the ultrasound room. a glucocorticoid injection is given at the time of consultation, using anatomical ultrasound scan to guide needle placement
219290932|NCT06347328|PROCEDURE|non-echo-guided infiltration|"the subjects will receive their injection in the ultrasound room.~a glucocorticoid injection is given at the time of consultation, using anatomical landmarks to guide needle placement.~The investigator simulate an ultrasound scan with a film shown on the screen."
219290933|NCT04179942|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide and CRP levels|measurement of FeNO and Hs-CRP after 3months of CPAP
219290934|NCT03223662|OTHER|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
219290935|NCT03223662|PROCEDURE|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
219290936|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
219290937|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
219290938|NCT02217475|DRUG|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
219290939|NCT02217475|DRUG|Placebo|Placebo administered orally once daily and taken every morning with food.
219290940|NCT06024434|OTHER|Exercises|Experimental Group Exercises for Core: Crunches, Glute bridges Crunches Glute bridge Week 1-2 (set/rep/sec) Week 3-4 (set/rep/sec) Week 5-6 (set/rep/sec) Exercises for upper body: Push up (4), Bicep curls Exercises Weeks Reps/sets Push up walk out Bicep curls 1-3 16-20\*3 Push up Bicep curl with Dumbbell 4-6 12-15\*3 Exercises for Lower body: Lunges and Squats Exercises Weeks Reps/set Split Squat with body weight Body weight Squat 1-3 16-20\*3 Split Squat with Dumbbell Squat with Dumbbell 4-6 12-15\*
219290941|NCT06024434|OTHER|Walking|Walking for 30min, 5 days a week
219290942|NCT04276753|OTHER|Terminalia Chebula Fruit Extract|Standardized fruit extract
219290943|NCT04276753|OTHER|Placebo|Placebo
219290944|NCT02643472|BEHAVIORAL|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
219290945|NCT02643472|BEHAVIORAL|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
219290946|NCT01215188|BIOLOGICAL|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
219290947|NCT01215188|BIOLOGICAL|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
219290948|NCT01215188|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
219290949|NCT00506441|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
219290950|NCT00506441|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
219290951|NCT01012414|DRUG|paricalcitol|2 mcg oral paricalcitol daily
219290952|NCT01012414|DRUG|placebo|placebo
219290953|NCT02506075|DEVICE|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
219290954|NCT02506075|BEHAVIORAL|Visual inattention training|
219290955|NCT03656172|BIOLOGICAL|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
219290956|NCT04955782|BEHAVIORAL|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability|"The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer"
219290957|NCT05787327|DRUG|Chinese Herb|Yinqiaosan-Maxingganshitang granules
219290958|NCT05787327|DIAGNOSTIC_TEST|Placebo|Placebo
219290959|NCT00673400|PROCEDURE|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
219290960|NCT00335933|DRUG|Gabapentin extended-release tablets|
219290961|NCT05447572|OTHER|FIT + FC|FIT + FC
219290962|NCT05072028|DRUG|[14C]DBPR108|\[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
219290963|NCT00853944|DRUG|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
219290964|NCT01258842|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
219290965|NCT01258842|DIETARY_SUPPLEMENT|Placebo|Placebo sachet, consumed once per day for 12 weeks
219290966|NCT01691170|OTHER|Stretching Hamstring|
219290967|NCT01691170|OTHER|Quadriceps Strengthening|
219290968|NCT01249950|OTHER|feasibility|feasibility
219290969|NCT00528931|BIOLOGICAL|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
219290970|NCT06132438|DRUG|PEP-CMV vaccine|The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
219290971|NCT03262142|DRUG|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam four times daily
219290972|NCT03262142|DRUG|Ciprofloxacin|Oral Ciprofloxacin twice daily
219290973|NCT00480480|BEHAVIORAL|Trauma and Grief Component Therapy for Adolescents (Group Version)|
219290974|NCT02605655|DRUG|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
219290975|NCT02605655|OTHER|Placebo|Instant noodles without drug
219290976|NCT02920437|BEHAVIORAL|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
219290977|NCT02920437|OTHER|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
219290978|NCT02459002|BEHAVIORAL|QOL Questionnaire|Participant outcomes assessed with survey
219290979|NCT02459002|BEHAVIORAL|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
219290980|NCT02756221|DIETARY_SUPPLEMENT|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
219290981|NCT02756221|OTHER|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
219290982|NCT03835351|DEVICE|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
219290983|NCT01823939|DRUG|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
219290984|NCT05841329|DEVICE|tDCS|High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001\&4×1-C3A). The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex). The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig. 3). Participants were randomized to receive 20 minutes of active(1.5mA) or sham (0 mA) tDCS in a single-blind design. In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation. For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
219290985|NCT05841329|BEHAVIORAL|virtual reality exposure therapy|The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
219290986|NCT03644303|RADIATION|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
219290987|NCT02943239|DRUG|REGN1033|REGN1033
219290988|NCT02943239|DRUG|REGN2477|REGN2477
219290989|NCT02943239|OTHER|Placebo|Placebo
219290990|NCT03032432|DEVICE|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
219290991|NCT03032432|DRUG|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
219290992|NCT05216159|BEHAVIORAL|HAPA behavioural counselling + weekly HAPA worksheets|Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
219290993|NCT02064348|DRUG|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
219290994|NCT02064348|DRUG|placebo|Solution for s.c. injection or tablets for oral administration
219290995|NCT02064348|DRUG|moxifloxacin|Tablets for oral administration
219290996|NCT06065683|PROCEDURE|surgery|Surgical procedures performed in the study period
219290997|NCT03764527|DRUG|Artemether-lumefantrine|Two doses a day for 3 days, under supervision
219290998|NCT03764527|DRUG|Coadministered Artesunate plus Amodiaquine|One dose a day for 3 days, under supervision
219290999|NCT06400940|DRUG|ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).|Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
219291000|NCT06400940|DRUG|combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).|Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
219291001|NCT00230880|BEHAVIORAL|follow-up phone counseling|9 calls over 12 months
219291002|NCT00291642|DRUG|Placebo drops|"* Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use"
219291003|NCT00291642|DRUG|Placebo tablets matching to levocetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
219291004|NCT00291642|DRUG|Placebo tablets matching to cetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
219291005|NCT00291642|DRUG|Levocetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use"
219291006|NCT00291642|DRUG|Levocetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use"
219291007|NCT00291642|DRUG|Cetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use"
219291008|NCT00291642|DRUG|Cetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use"
219291009|NCT01875289|PROCEDURE|obturator nerve block|
219291010|NCT02341729|DRUG|ticagrelor|crushed tablets and non-crushed tablets
219291011|NCT02881346|DRUG|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
219291012|NCT03904225|DRUG|Tegafur-Gimeracil-Oteracil|oral administration for 12 months
219291013|NCT02028078|DRUG|Insulin human|Induces hypoglycaemia
219291014|NCT00684723|DRUG|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
219291015|NCT00684723|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
219291016|NCT00924118|DRUG|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
219291017|NCT03013075|PROCEDURE|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
219291018|NCT03013075|DRUG|Bupivacaine heavy and Morphine|
219291019|NCT03013075|DRUG|General Anesthetics|
219291020|NCT04440852|BEHAVIORAL|TEACCH|The Treatment and Education of Autistic and Communication Handicapped Children
219291021|NCT03540563|OTHER|Blood draw|Blood will be drawn to assess ctDNA
219291022|NCT05770518|BEHAVIORAL|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
219291023|NCT05770518|BEHAVIORAL|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
219291024|NCT03055052|OTHER|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
219291025|NCT03055052|OTHER|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
219291026|NCT02576587|OTHER|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI \>=15) will be place on CPAP therapy.
219291027|NCT00341432|BEHAVIORAL|Nicotine Replacement Therapy|
219291028|NCT00532493|DRUG|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
219291029|NCT00532493|OTHER|placebo|"sugar pill"
219291030|NCT02157701|DIETARY_SUPPLEMENT|Polyherbal capsule|
219291031|NCT02157701|DIETARY_SUPPLEMENT|Placebo capsule|
219291032|NCT00375440|DRUG|Tranexamic Acid|
219291033|NCT04981171|PROCEDURE|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
219291034|NCT04981171|PROCEDURE|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
219291035|NCT02405143|DEVICE|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
219291036|NCT02405143|DEVICE|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
219291037|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
219291038|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
219291039|NCT01579331|DEVICE|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
219291040|NCT00399243|DRUG|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
219291041|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
219291042|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
219291043|NCT01769326|OTHER|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
219291044|NCT01769326|DEVICE|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
219291045|NCT01769326|OTHER|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
219291046|NCT01769326|DEVICE|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
219291047|NCT01657786|DIETARY_SUPPLEMENT|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100\_-102delAAG).
219291048|NCT01278173|DRUG|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
219291049|NCT00857129|PROCEDURE|Normal Unit|low-risk patients randomised to Normal Unit
219291050|NCT00857129|PROCEDURE|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
219291051|NCT01549938|DIETARY_SUPPLEMENT|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
219291052|NCT01549938|DIETARY_SUPPLEMENT|Placebo|Microcellulose capsule identical in appearance to treatment
219291053|NCT02713087|DRUG|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
219291054|NCT02713087|DRUG|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
219291055|NCT00224679|DRUG|Aspirin|
219291056|NCT04064073|DRUG|DWP16001|Tablets, Oral, once daily single dose
219291057|NCT04064073|DRUG|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
219291058|NCT04064073|DRUG|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
219291059|NCT03085654|DRUG|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
219291060|NCT03085654|DRUG|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
219291061|NCT05745701|DRUG|PF-07081532|Oral Tablet
219291062|NCT05745701|DEVICE|Cyclosporine|Oral Solution
219291063|NCT05745701|DRUG|Itraconazole|Oral Capsule
219291064|NCT04501913|PROCEDURE|Patient Monitoring|Undergo remote perioperative telemonitoring
219291065|NCT04501913|OTHER|Questionnaire Administration|Complete questionnaires
219291066|NCT00046969|BIOLOGICAL|epoetin beta|
219291067|NCT00046969|DRUG|cisplatin|
219291068|NCT00046969|RADIATION|brachytherapy|
219291069|NCT00046969|RADIATION|radiation therapy|
219291070|NCT01186822|DEVICE|Lung Flute|Used twice daily
219291071|NCT02870374|BEHAVIORAL|Answering specific quality of life questionnaire in kidneys transplantation population|
219291072|NCT02936882|PROCEDURE|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
219291073|NCT05009784|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
219291074|NCT05009784|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
219291075|NCT05009784|OTHER|Traffic Sound|Active Comparator: Traffic Sound (Played through speakers)
219291076|NCT05009784|OTHER|Traffic and Masking Sound|Experimental: Traffic and Masking Sound (Played through speakers)
219291077|NCT05009784|OTHER|Silence|No Intervention: No sound (Played through speakers)
219291078|NCT03328104|DRUG|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
219291079|NCT03328104|DRUG|Nelarabine|650 mg/m2 IV daily x Day 1-5
219291080|NCT03328104|DRUG|Cyclophosphamide|440 mg/m2 IV x Day 1-5
219291081|NCT03328104|DRUG|Etoposide|100 mg/m2 IV x Day 1-5
219291082|NCT04589481|OTHER|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
219291083|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Tandem Stance Test (ATST) and Physical Therapist's Measurements of Tandem Stance Test (PTST)|For the Tandem Stance Test comparisons, the Azure Kinect-based Tandem Stance Test system quantified the distance traveled by the pelvic point to X, Y, and Z coordinates over a 30-second duration while the physical therapist measured the time elapsed until the participant lost balance was measured with a maximum of 30 seconds. Participants remained a tandem stance, positioning their preferred leg in front such that the heel of the front foot touched the toes of the back foot, ensuring both feet were aligned as straight as possible. They stood with holding on to two chairs each placed on their sides for stability and safety. Upon the cue to 'start', the participants let their hands go and both the Azure Kinect-based system and the physical therapist's stopwatch initiated their measurements. Participants tried to maintain their stance for 30 seconds. The participants had to reposition themselves when they stepped, used hands or lose balance for 30 seconds
219291084|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Five Times Sit-to-Stand Test (AFTSS) and Physical Therapist's Measurements of Five Times Sit-to-Stand Test (PFTSS)|The Five Times Sit-to-Stand Test (FTSS), standardized by Csuka and McCarty, has been designed to assessing lower limb strength as well as balance and postural control among elder population with high level of reliability. A previous study reported excellent intra-rater reliability (ICC=.914-.933) and inter-rater reliability (ICC=.988-.995) among healthy older adults. In addition, Five Times Sit-to-Stand Test more than 11.50 seconds had been reported to represent risk of falls among elders over 65-year-old. To assess Five Times Sit-to-Stand Test , a chair, 45cm in height and fixed to the ground, was placed three meters from the camera. Participants began seated, and on start cue, repeatedly stood up and sat down five times. The Azure Kinect-based system automatically ended its measurement as the participant completed the fifth stand, whereas the physical therapist manually measured time using the stopwatch. The time measures from the system and therapist were compared.
219291085|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Timed Up and Go Test (ATUG) and Physical Therapist's Measurements of Timed Up and Go Test (PTUG)|The Timed Up and Go test (TUG) has been employed as a straightforward assessment of an individual's mobility, necessitating both static and dynamic balance. A Timed Up and Go test duration exceeding 9.50 seconds has been identified as indicative of a heightened fall risk in individuals aged 65 and older. A previous study reported excellent intra-rater reliability (ICC=.97) and inter-rater reliability (ICC=.96). Initiating in a seated position, participants stood upon commencement of the test. Simultaneously, the Azure Kinect-based system and stopwatch began the time measurements. Participants then walked a distance of three meters, turned around, retraced their steps, and resumed their seated position. The Azure Kinect-based system automatically terminated its timing once the participant was seated, while the physical therapist manually stopped the stopwatch. The time measures from the system and therapist were compared.
219291086|NCT06519864|DIAGNOSTIC_TEST|Short Physical Performance Battery (SPPB)|The assessment includes three tests: a Timed Up and Go test test where participants walked a distance of 3 meters at their comfortable pace; a Five Times Sit-to-Stand Test which the duration is also measured; and the standing balance test which determines a participant's capacity to maintain three different stances of side-by-side, semi-tandem, and full tandem, each for 10 seconds.
219291087|NCT06519864|DIAGNOSTIC_TEST|Berg Balance Scale (BBS)|Participants are scored on a 5-point scale for each task, where a score of 0 signifies an inability to perform, while a 4 denotes independence in execution. A perfect score of 56 is a marker of excellent balance. Administering the Berg Balance Scale is efficient, taking between 10 to 20 minutes, and requires only basic equipment such as a chair, stopwatch, ruler, and step within a small space.
219291088|NCT06519864|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|Participants, standing barefoot, aligned the side of their body with a wall, ensuring no contact. Their stance was parallel with feet comfortably spaced. With their shoulders flexed at a 90° angle adjacent to the wall, they kept their elbows straight and hands clenched. The starting point on a horizontally affixed measuring tape, level with the floor, was determined by where the third metacarpal touched. This tape was aligned with each participant's acromion height. Without taking a step, lifting heels or losing balance, participants leaned forward to their maximum extent. The difference between the initial and final third metacarpal positions on the tape denoted the reach distance.
219291089|NCT06519864|DIAGNOSTIC_TEST|Four-Square Step Test (FSST)|During the Four-Square Step Test, participants were instructed to step over four straight tapes, each 90 cm in length, laid out in a cross-shape configuration on the floor. Beginning in square 1 and facing square 2, participants followed a specific sequence: they stepped forward into the next quadrant, then to the right, backward, and finally to the left, moving in a clockwise direction. This sequence was then retraced in a counterclockwise manner. It was essential for both feet to touch down in each quadrant. Participants aimed to complete this pattern as fast as they could, avoiding stepping the tapes. The duration taken to finish the sequence was recorded.
219291090|NCT06519864|DIAGNOSTIC_TEST|Grip Strength (GS)|The strength of the dominant hand's maximal grip force, indicative of upper extremity muscle strength, was gauged using a digital isometric hand dynamometer.
219291091|NCT02102607|OTHER|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
219291092|NCT05624671|OTHER|bupivacaine,fentanyl|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
219291093|NCT00213889|OTHER|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
219291094|NCT05054803|DRUG|WJ-MSC (XCEL-UMC-BETA)|Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
219291095|NCT05054803|DRUG|Placebo|Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
219291096|NCT04950595|OTHER|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
219291097|NCT04950595|OTHER|Beef mince|Spaghetti bolognaise meal made with beef mince
219291098|NCT05843422|DRUG|0.1% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
219291099|NCT05843422|DRUG|0.3% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
219291100|NCT05843422|DRUG|0.8% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
219291101|NCT05843422|DRUG|1.5% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
219291102|NCT00301938|DRUG|7-hydroxystaurosporine|Given IV
219291103|NCT00301938|DRUG|perifosine|Given orally
219291104|NCT00301938|OTHER|pharmacological study|Correlative studies
219291105|NCT00929942|DEVICE|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
219291106|NCT01504477|DRUG|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
219291107|NCT03420248|DEVICE|Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere|One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
219291108|NCT01546675|OTHER|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
219291109|NCT03863015|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
219291110|NCT03863015|DRUG|isotonic saline|A one hour infusion of 100mL isotonic saline
219291111|NCT04730817|DEVICE|Virtual Reality Motor-Cognitive Training System|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong. The VR training system is designed as a game with 16 progressive levels (anticipating intervention group participants to complete 2 levels per week for 8 weeks) which aim to train their motor and cognitive functions.
219291112|NCT03064399|PROCEDURE|without lateral ligament repairment|microfracture without repairment of the lateral ligament
219291113|NCT03064399|PROCEDURE|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
219291114|NCT05474053|DRUG|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
219291115|NCT05474053|DRUG|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
219291116|NCT03242967|DRUG|Vadadustat|Oral tablet
219291117|NCT03242967|DRUG|Darbepoetin alfa|subcutaneous or intravenous
219291118|NCT05781126|DIAGNOSTIC_TEST|The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires|a) medical history record, b) ENT examination, c) pure tone audiogram and speech audiometry (with and without the hearing amplification) d) listening effort evaluation (with and without the hearing amplification) Self-report and behavioral methods will be used: Evaluation of subjective performance (Spatial Hearing Questionnaire (SHQ) Evaluation of time response in auditory message Evaluation of speech comprehension with background noise or a competitive speaker e) cognitive function evaluation by using the Greek version of Mini-Mental State Examination, f) evaluation of hearing-aid satisfaction, by using the Glasgow Hearing Aid Benefit Profile (GHABP), and International Outcome Inventory - Hearing Aid (IOI-HA), questionnaires and g) evaluation of stress level and depression by using BECK-II and STAI questionnaires.
219291119|NCT04812197|PROCEDURE|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
219291120|NCT01721928|DEVICE|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
219291121|NCT00680992|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
219291122|NCT00175201|PROCEDURE|Proactive care and rehabilitation|
219291123|NCT02275429|PROCEDURE|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
219291124|NCT01585155|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
219291125|NCT04812002|DRUG|PD-1 inhibitor， bevacizumab|Both drugs are given intravenously
219291126|NCT00422812|DRUG|Inhaled Placebo|Inhaled Staccato Placebo
219291127|NCT00422812|DRUG|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
219291128|NCT00422812|DRUG|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
219291129|NCT00422812|DRUG|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
219291130|NCT04197362|OTHER|Evaluation|Subjects will be asked to walk across the gait laboratory floor at their self-selected walking speed. They will complete a 3-5 minute warm up period, as it was found to produce stable estimates of kinetic parameter mean values during treadmill activity. The positions of each marker will be recorded through the motion capture system. Ground reaction force will be obtained in real time from the gait laboratory force plates as marker dimensions are recorded. For walking data, two trials of 15 seconds each will be recorded. The second trial will be a redundancy in the setting of potential significant marker dropout.
219291131|NCT04690153|OTHER|Patients with three vertical Hayman Sutures|Patients who are referred to our clinic due to postpartum hemorrhage between the ages of 18-45 and who need to undergo a surgical procedure (not responding to medical treatment) due to abnormal uterine bleeding in our clinic will be included. Patients with a previously known diagnosis of bleeding and coagulation disorders will not be included in the study. Considering that we are one of the primary referral centers in Istanbul in terms of deliveries and post-partum bleeding in our hospital, it is aimed to terminate the study with approximately 50 participants.
219291132|NCT02318459|OTHER|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
219291133|NCT02318459|OTHER|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
219291134|NCT03660423|OTHER|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
219291135|NCT01397422|DRUG|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
219291136|NCT02627053|DRUG|rivaroxaban|
219291137|NCT03921385|DEVICE|Augmented Reality Headset|Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
219291138|NCT04337853|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
219291139|NCT04337853|OTHER|No intraoral stent|Radiotherapy without intraoral stent
219291140|NCT05039294|BEHAVIORAL|School-Based Physical Activity Educational Program|The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
219291141|NCT04730193|DRUG|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
219291142|NCT04730193|DRUG|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
219291143|NCT02140840|DRUG|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
219291144|NCT03772587|DRUG|M281|M281 administered as IV infusion
219291145|NCT03772587|OTHER|Placebo|Placebo administered as intravenous (IV) infusion
219291146|NCT01456572|DIETARY_SUPPLEMENT|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
219291147|NCT01456572|DIETARY_SUPPLEMENT|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
219291148|NCT06226272|DEVICE|Spinal Fusion|Cervical Spinal Fusion
219291149|NCT06226272|DEVICE|Spinal Fusion|Thoracic / Lumbar Spinal Fusion
219291150|NCT06226272|DEVICE|Spinal Deformities Correction|Spinal Deformities Correction
219291151|NCT03311464|DRUG|adalimumab|Study drug will be administered subcutaneously.
219291152|NCT04293458|DEVICE|EsoGuard|EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
219291153|NCT06150274|DEVICE|Percutaneous Balloon Mitral Valvulotomy|Stenotic mitral valve will be dilated to open the commissures
219291154|NCT00513305|DRUG|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
219291155|NCT00513305|DRUG|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
219291156|NCT01827644|DRUG|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
219291157|NCT01827644|DRUG|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
219291158|NCT01827644|DRUG|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
219291159|NCT01827644|DRUG|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
219291160|NCT01827644|DRUG|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
219291161|NCT01827644|DRUG|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
219291162|NCT03464851|DIAGNOSTIC_TEST|Carotid Stenotic Scan (CSS)|"Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart."
219291163|NCT04613544|DEVICE|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
219291164|NCT06259578|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
219291165|NCT00636805|DRUG|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
219291166|NCT04642248|OTHER|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
219291167|NCT03613376|OTHER|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
219291168|NCT02856100|DRUG|18F DCFPyL- Radiopharmaceutical|
219291169|NCT02367547|DRUG|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
219291170|NCT02367547|DRUG|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
219291171|NCT02367547|DRUG|Methylaminolevulinate cream|In the study we use Metvix.
219291172|NCT05640271|DRUG|Tocilizumab|Tocilizumab 80 mg IV dose (one time per patient)
219291173|NCT00596700|DEVICE|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
219291174|NCT05008939|DRUG|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
219291175|NCT05008939|DRUG|Placebo|Patients received 30% oxygen for 1 hour.
219291176|NCT03446833|DEVICE|The LFP Beta aDBS System|The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
219291177|NCT06168539|OTHER|Emboless|Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
219291178|NCT06168539|OTHER|Standard|Standard dialysis set is used as comparative
219291179|NCT03329859|PROCEDURE|High resolution standardized laparoscopic cholecystectomy|High resolution standardized laparoscopic cholecystectomy
219291180|NCT03065062|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
219291181|NCT03065062|DRUG|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
219291182|NCT04557150|DRUG|Forimtamig|Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
219291183|NCT04876456|DRUG|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
219291184|NCT05745038|BEHAVIORAL|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
219291185|NCT02966665|OTHER|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
219291186|NCT02966665|DRUG|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
219291187|NCT02966665|DRUG|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
219291188|NCT02966665|DRUG|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
219291189|NCT02966665|OTHER|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
219291190|NCT02966665|DRUG|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
219291191|NCT02966665|DRUG|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
219291192|NCT05148962|BIOLOGICAL|GRT-R910|Injection administered intramuscularly
219291197|NCT05965856|DRUG|BL-B01D1|Administration by intravenous infusion
219291198|NCT05965856|DRUG|SI-B003|Administration by intravenous infusion
219291199|NCT06481891|DRUG|Sotagliflozin|Sotagliflozin will be administered as a tablet(s), orally once daily.
219291200|NCT06481891|DRUG|Placebo|Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
219291201|NCT05858281|BEHAVIORAL|Survey|Black adolescent girls (aged 12-17) will participate in an online survey and will be asked questions regarding their strengths, family, school and community experiences, sexual education knowledge, physical health and mental wellbeing, etc.
219291202|NCT05858281|BEHAVIORAL|Interviews|Parents/guardians of Black girls (aged 12-17) and Black emerging adult women aged 18-22 will participate in individual interviews and will be asked questions about their understanding of Black girls' strengths and resources.
219291203|NCT05858281|BEHAVIORAL|Focus group|Black adolescent girls (aged 12-17) will participate in a focus group and will be asked questions regarding their strengths, family, school and community resources, etc.
219291204|NCT05929183|DEVICE|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
219291205|NCT05929183|DEVICE|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
219291206|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
219291207|NCT05847907|DEVICE|Implant placement|Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
219291208|NCT05173389|OTHER|TechnoBody|"1\. Group-TechnoBody balance training (15 min / 5 days a week, 4 weeks) In the study, the first group will be included in the balance program with the TechnoBody device Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
219291209|NCT05173389|OTHER|Thera-Trainer|"2\. Group-Thera-Trainer balance training (15 min / 5 days a week, 4 weeks) the second group will be taken into the balance program with the Thera-Trainer device and the results of both groups will be compared after 4 weeks.~Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
219291210|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
219291211|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
219291212|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
219291213|NCT03883646|BEHAVIORAL|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
219291214|NCT03883646|BEHAVIORAL|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
219291215|NCT00555529|PROCEDURE|radial artery applanation tonometry (RAAP)|non-invasive tonometry
219291216|NCT06519084|OTHER|Home based exercise training|"Intervention: home based physical exercise performed 4 times a week, each session lasting 40 minutes each. Aerobic and muscular resistance exercises, using body weight and elastic bands.~The sessions were proposed through video classes, in total 12 video classes during the 12 weeks of physical training. Patients monitored their heart rate during exercise and wrote it down on spreadsheets that were monitored weekly."
219291217|NCT04311710|DRUG|ipilimumab|Specified Dose on Specified Days
219291218|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
219291219|NCT04311710|DRUG|ENHANZE (rHuPH20)|Specified Dose on Specified Days
219291220|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
219291221|NCT05194982|DRUG|BL-B01D1|Administration by intravenous infusion.
219291222|NCT06575699|PROCEDURE|Rectus sheath block|bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
219291223|NCT06575699|PROCEDURE|Thoracic Epidural Analgesia|Low thoracic Epidural Analgesia.
219291224|NCT06575699|DRUG|Liposomal bupivacaine|133 mg liposomal bupivacaine per side for rectus sheath block
219291225|NCT06575699|DRUG|Bupivacaine Hydrochloride|20 mL bupivacaine 0.25% per side for rectus sheath block
219291226|NCT06575699|DRUG|Bupivacaine-Hydromorphone Cassette|Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
219291227|NCT04095923|BEHAVIORAL|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
219291228|NCT04095923|BEHAVIORAL|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
219291229|NCT00558077|DRUG|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
219291230|NCT00558077|PROCEDURE|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
219291231|NCT00151281|DRUG|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
219291232|NCT00151281|DRUG|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
219291233|NCT00151281|DRUG|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
219291234|NCT06651281|DRUG|Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
219291235|NCT06651281|DRUG|Placebo to tulisokibart|Placebo matching SC tulisokibart
219291236|NCT01133418|OTHER|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
219291237|NCT01133418|OTHER|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
219291238|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
219291239|NCT06455787|DEVICE|J-Valve Transfemoral (TF) System|Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.
219291240|NCT05316701|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
219291241|NCT05316701|BIOLOGICAL|Standard-of-Care|unmanipulated donor allograft
219291242|NCT04696653|OTHER|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
219291243|NCT05013632|DRUG|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
219291244|NCT05013632|DRUG|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
219291245|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
219291246|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
219291247|NCT05760001|OTHER|Assigned Interventions|"Financial well-being interventions:~• Tax preparation; access to public benefits; financial counseling and microgrants~Place-based interventions:~• Vacant lot greening; abandoned house remediation; trash cleanup; tree planting"
219291248|NCT06818643|BIOLOGICAL|MK-3120|IV infusion
219291249|NCT06817668|RADIATION|ePURT 5Gy x 5 fractions with single HDR boost of 15Gy|ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.
219291250|NCT06820463|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219291251|NCT06820463|DRUG|Fluorouracil|IV Infusion; IV Injection
219291252|NCT06820463|DRUG|Oxaliplatin|IV Infusion
219291253|NCT06820463|DRUG|Leucovorin|IV Infusion; IV Injection
219291254|NCT06820463|DRUG|Bevacizumab|IV Infusion
219291255|NCT06820463|DRUG|Panitumumab|IV Infusion
219291256|NCT01828905|DEVICE|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
219291257|NCT01828905|PROCEDURE|Autologous cancellous bone graft|autologous cancellous bone graft
219291258|NCT06658405|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.
219291259|NCT04362189|BIOLOGICAL|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
219291260|NCT04362189|OTHER|Placebo|Saline
219291261|NCT02111681|DEVICE|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
219291262|NCT06597474|BEHAVIORAL|Food-Body-Mind|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
219291263|NCT05500391|OTHER|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
219291264|NCT06603571|DRUG|LY3841136|Administered SC
219291265|NCT06603571|DRUG|Tirzepatide|Administered SC
219291266|NCT06603571|DRUG|Placebo|Administered SC
219291267|NCT04258449|DEVICE|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
219291268|NCT06809400|DRUG|LY4006896|Administered intravenously (IV)
219291269|NCT06809400|DRUG|Placebo|Administered IV
219291270|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
219291271|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
219291272|NCT06859294|DRUG|LY3541860|Administered IV
219291273|NCT06825000|BEHAVIORAL|neuro-education|30 minutes of videos about the neuroscience of stress, fear, emotion-regulation, and therapy.
219291274|NCT06825000|BEHAVIORAL|psycho-education|30 minutes of videos about the psychological science of stress, fear, emotion-regulation, and therapy.
219291275|NCT06857253|DRUG|HRS-1301|HRS-1301.
219291276|NCT06857253|DRUG|HRS-1301 placebo|HRS-1301 placebo.
219291277|NCT04728204|BEHAVIORAL|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
219291278|NCT06596694|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
219291279|NCT05406622|DEVICE|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
219291280|NCT05406622|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
219291281|NCT06274190|DIAGNOSTIC_TEST|bowel e-diary|This bowel diary will be available on the smartphone in the form of an application.
219291282|NCT00809172|DRUG|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
219291283|NCT00809172|DRUG|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
219291284|NCT07001293|BEHAVIORAL|MomMA Intervention|The MomMA program is a CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings.
219291285|NCT07001293|OTHER|Treatment as Usual (TAU)|Participants will receive treatment as usual, including but not limited to medication and behavioral therapy. No participation in treatment is required.
219291286|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
219291287|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
219291288|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
219291289|NCT05949606|DRUG|SI-B001|Administration by intravenous infusion
219291290|NCT05949606|DRUG|SI-B003|Administration by intravenous infusion
219291291|NCT06680232|BIOLOGICAL|PBGENE-HBV|PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.
219291292|NCT06869018|DRUG|LY3549492|Administered orally
219291293|NCT06869018|DRUG|Placebo|Administered orally
219291294|NCT05627856|DRUG|GNC-038|Administration by intravenous infusion
219291295|NCT06674460|DRUG|Edaravone Dexborneol Sublingual Tablets|One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
219291296|NCT06674460|DRUG|Placebo|One placebo tablet, to be taken sublingually, twice daily
219291297|NCT07010978|BEHAVIORAL|Recovery Community Center Participation|Recovery community centers are brick and mortar buildings that house recovery-oriented organizations, located in the heart of their communities. They act as recovery hubs, offering a variety of recovery support services in house as well as connecting participants to resources in their area. They are peer-led organizations that are open to anyone in early or long-term recovery from substance use and that recognize that there are multiple pathways to recovery. Study participants will be provided with information about their local RCC (including a video link, contact information, a monthly calendar of events, a list of services and activities offered by the RCC, transportation options, etc.) and will be asked to visit the RCC on two different occasions within one month of enrollment.
219291298|NCT07010978|BEHAVIORAL|Enhance Treatment as Usual|In this study, the enhanced treatment as usual intervention will encompass providing participants with information about diverse recovery activities (e.g., mutual help group meetings, exercise, job search, recovery coach meetings, etc.) and then to assign participants to complete a recovery activity of their choosing one two different days within one month after enrollment. Participants can do the same activity twice, or different activities on each of the two days assigned.
219291299|NCT05145400|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab:10 mg/kg intravenous or 1400 mg subcutaneous (SC) via on-body delivery system (OBDS) will be administered in cycles 1-24.
219291300|NCT05145400|DRUG|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
219291301|NCT05145400|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
219291302|NCT07009522|BEHAVIORAL|Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents - HEART|The group program for adolescents with ASD takes place weekly. Each session lasts 100 minutes (including a break), and the training includes a total of 12 sessions. The intervention is manualized and is based on the theoretical foundations of Cognitive Behavioral Therapy, Mindfulness-Based Therapy, and the TEACCH approach (Mesibov et al., 2005). Parallel to the adolescents, their parents will participate in a separate group training, which will be conducted in five sessions of 100 minutes each and is closely linked in content to the adolescent group training.
219291303|NCT06672939|DRUG|Orforglipron|Administered orally
219291304|NCT06672939|DRUG|Placebo|Administered orally
219291305|NCT04348435|BIOLOGICAL|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
219291306|NCT04348435|OTHER|Placebos|Saline
219291307|NCT05668637|OTHER|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
219291308|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
219291309|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
219291310|NCT07012135|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response will be tested.
219291311|NCT07014111|BEHAVIORAL|Fight Fatigue|Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
219291312|NCT07014111|OTHER|Attention Control|End-stage kidney disease education
219291313|NCT07025291|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated salivav was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219291314|NCT07017179|DRUG|AZD6234|Participants will receive a subcutaneous injection weekly
219291315|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly.
219291316|NCT07017179|DRUG|AZD9550|Participants will receive a subcutaneous injection weekly
219291317|NCT07017179|DRUG|Plocebo|Participants will receive a subcutaneous injection weekly
219291318|NCT07017179|DRUG|AZD6234 in combination with AZD9550|Participants will receive a subcutaneous injection weekly
219291319|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly
219291320|NCT05085782|DRUG|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
219291321|NCT05085782|DRUG|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
219291322|NCT05085782|BEHAVIORAL|Reactivation procedure|Description/visualization of painful movements/activities
219291323|NCT05085782|BEHAVIORAL|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
219291324|NCT06698042|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered subcutaneously on Day 1 of each cycle
219291325|NCT06698042|BIOLOGICAL|Pembrolizumab|Administered intravenously on Day 1 of each cycle
219291326|NCT07028905|PROCEDURE|Total caries removal|Total caries removal and application of bioactive material
219291327|NCT07028905|PROCEDURE|Partial caries removal|Partial caries removal then application of biodentin
219291328|NCT07029711|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in high-density polyethylene (HDPE) bottles.
219291329|NCT07029711|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
219291330|NCT07029711|DRUG|Placebo|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
219291331|NCT07029555|BIOLOGICAL|PIT565|Study treatment will be provided in vials as open-label participant specific supply.
219291332|NCT07030530|DEVICE|Virtual Glasses Group|Virtual Glasses Group; Pregnant women in the virtual reality group will be shown a virtual reality video in VR mode via smartphone during the NST procedure (with the pregnant woman lying on her left side). It will be watched with virtual reality glasses containing nature sounds (streams, birds, etc.). Pregnant women will be informed about the use of virtual reality goggles before being shown the virtual reality video and will be asked to stop watching the video if they feel any discomfort. It is recommended to watch virtual reality videos for 5-20 minutes because they may cause nausea and vomiting (23). Since this study includes pregnant women, it is planned to play the virtual reality videos for 5-10 minutes.
219291333|NCT07030530|OTHER|Mandala Coloring activity group;|Mandala Coloring activity group; In studies examining the effect of art therapy on the reduction of psychological symptoms, it has been shown that the use of round patterns is more effective in symptom management. In line with these studies, ready-made mandala coloring templates with round shapes will be used in our study. Each participant will be asked to choose one of the mandala coloring templates. Each participant will be given colored pencils and asked to color the mandala template of their choice during the NST
219291334|NCT06710132|DRUG|M9140|All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
219291335|NCT06876649|DRUG|Pirtobrutinib|Administered orally.
219291336|NCT06875427|DRUG|Ropivacaine 2-2.5mg/kg + dexmedetomidine 1 mcg/kg delivered via a single-shot adductor canal block under ultrasound guidance|The local anesthetic (ropivacaine) + dexmedetomidine will be administered via single-shot adductor canal block under ultrasound guidance
219291337|NCT07036835|PROCEDURE|LASIK Surgery|Laser assisted in situ keratomileusis (LASIK) surgery conducted for the purpose of correcting refractive error
219291338|NCT07036835|DEVICE|UV fs-Laser|WaveLight Ultraviolet Femtosecond Laser used for creating a corneal flap during LASIK surgery
219291339|NCT07036835|DEVICE|IR fs-Laser|WaveLight FS200 Infrared Femtosecond Laser used for creating a corneal flap during LASIK surgery
219291340|NCT07036835|DEVICE|Anesthetic 1 eye drops|Topical anesthetic used to numb the surface of the eye
219291341|NCT07036835|DEVICE|Anesthetic 2 eye drops|Topical anesthetic used to numb the surface of the eye
219291342|NCT07032038|DRUG|Otic neural progenitors|Advanced Cell Therapy - tissue engineered product
219291343|NCT07032038|DEVICE|cochlear implantation|cochlear implant
219291344|NCT06709820|DRUG|LY4060874|Administered SC
219291345|NCT06709820|DRUG|LY4060874|Administered IV
219291346|NCT06709820|DRUG|Placebo|Administered SC
219291347|NCT06709820|DRUG|Placebo|Administered IV
219291348|NCT06451055|BEHAVIORAL|Low-calorie diet|The low-calorie diet consists of approximately 1,300 kcal/day (37% carbohydrates, 25% protein, 39% fat, and 7 g of fiber per meal) over an eight-week period. Participants receive weekly pre-prepared meals from Trifecta Nutrition (Trifecta Inc. California, USA) with options for breakfast, lunch, and dinner, meticulously crafted by certified dieticians and expert chefs. Participants are encouraged to consume 1-2 liters of water daily and maintain their habitual physical activity levels.
219291349|NCT06451055|BEHAVIORAL|Routine dietary and physical activity habits|Participants are asked to maintain their habitual dietary and physical activity habits for the 8-week study period.
219291350|NCT04993508|DIAGNOSTIC_TEST|PSA test|testing for blood levels of PSA
219291351|NCT04993508|DEVICE|multiparametric prostate Magnetic Resonance Imaging (mpMRI)|mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD \> 0.15 will considered suspicious for csPCa.
219291352|NCT04993508|PROCEDURE|targeted MRI/US fusion-guided biopsy|Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
219291353|NCT04993508|PROCEDURE|combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)|The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
219291354|NCT04993508|PROCEDURE|MRI inbore biopsy|MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
219291355|NCT07093281|BIOLOGICAL|Live Attenuated Influenza Vaccine|Nasal spray
219291356|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
219291357|NCT07136857|DRUG|EPTACOG BETA|"Eptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously.~SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity."
219291358|NCT07134972|DRUG|Ozone treatment|Ozone treatment was administered to study group only. 90 ml of blood was collected into a vacuum sterile glass bottle (Ozonosan). To prevent clotting, 10 ml of 3.8% Na Citrate solution was added to the glass vial. The blood to citrate volume ratio is 9:1. After blood collection, the O3 concentration is ozonized to 20-50 mcg/ml. After at least 5 minutes of mixing, ozonized blood was infused over 20 minutes. Ozone/oxygen mixture was administered intravenously. Ozone therapy was administered twice a week for a total of 16 sessions.
219291359|NCT07092865|BIOLOGICAL|Adjuvanted RSVPreF3 vaccine|1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).
219291360|NCT06914895|DRUG|Tirzepatide|Administered SC
219291361|NCT06914895|DRUG|Placebo|Administered SC
219291362|NCT01621594|DEVICE|Cannon Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
219291363|NCT06832631|DEVICE|Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon|Balloon angioplasty for the treatment of symptomatic peripheral arterial disease with a paclitaxel drug-coated balloon
219291364|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
219291365|NCT05949684|BIOLOGICAL|Luspatercept|Specified dose on specified days
219291366|NCT05949684|BIOLOGICAL|Epoetin Alfa|Specified dose on specified days
219291367|NCT04009499|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
219291368|NCT06223568|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
219291369|NCT06223568|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
219291370|NCT06223568|DRUG|PRGN-2009|PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
219291371|NCT06916065|DRUG|Eloralintide and Tirzepatide|Administered SC
219291372|NCT06916065|DRUG|Eloralintide|Administered SC
219291373|NCT06916078|DRUG|Lepodisiran|Lepodisiran administered SC
219291374|NCT07104578|DIAGNOSTIC_TEST|Pleuropulmonary ultra sound|pleuropulmonary ultrasound performed as part of the treatment
219291375|NCT07115576|PROCEDURE|Radiofrequency ablation alone|Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat benign thyroid nodules without surgery. It involves inserting a thin, needle-like electrode into the nodule under ultrasound guidance. Using high-frequency alternating current, the electrode generates heat to destroy targeted thyroid tissue, causing the nodule to shrink over time.
219291376|NCT07115368|DRUG|GS-1219|Administered orally
219291377|NCT07115368|DRUG|BVY|Administered orally
219291378|NCT07115368|DRUG|Standard of Care|Antiretroviral therapy, administered orally non nonnucleoside reverse transcriptase inhibitor (NNRTIs), examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
219291379|NCT07119593|OTHER|Intradialytic Cycling|Intradialytic exercise has emerged as a safe and effective non-drug therapeutic approach to improve cardiovascular health and is now recommended for people undergoing hemodialysis treatment. Administration of a higher intensity exercise could offer better cardio-protective mechanisms and if the efficacy of cardiovascular protection is proven, it could be developed as a therapeutic option in the dialysis population.
219291380|NCT07122102|DRUG|Cofrogliptin|10mg administered once every two weeks
219291381|NCT07122102|DRUG|Acarbose|50mg administered 3 times daily
219291382|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (2 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 2 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
219291383|NCT06933732|DEVICE|Device: Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (4 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 4 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
219291384|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (6 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 6 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
219291385|NCT06931405|DRUG|BLU-808|Oral administration
219291386|NCT06931405|DRUG|Placebo|Oral administration
219291389|NCT06937086|DRUG|Mirikizumab|Administered IV
219291390|NCT06937086|DRUG|Mirikizumab|Administered SC
219291391|NCT06937086|DRUG|Tirzepatide|Administered SC
219291392|NCT06937086|DRUG|Placebo|Administered SC
219291393|NCT06937099|DRUG|Mirikizumab|Administered IV
219291394|NCT06937099|DRUG|Mirikizumab|Administered SC
219291395|NCT06937099|DRUG|Tirzepatide|Administered SC
219291396|NCT06937099|DRUG|Placebo|Administered SC
219291397|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
219291398|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
219291399|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
219291400|NCT06943755|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
219291401|NCT06943755|DRUG|Everolimus|Administered as specified in the treatment arm.
219291402|NCT06939478|DEVICE|Arrhythmia Mapping|vMap is indicated for analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.
219291403|NCT06945419|DRUG|LY4086940|Administered orally
219291404|NCT06945419|DRUG|Placebo|Administered orally
219291405|NCT07136350|OTHER|Communication Coaching|Nurses in this group will receive caring communication coaching (2 CEUs).
219291406|NCT07136350|BEHAVIORAL|Implement S.M.A.R.T. Discharge Tool|Implement the S.M.A.R.T. discharge tool.
219291407|NCT07142551|DRUG|Testosterone cypionate|Intermittent intramuscular testosterone cypionate (T) at a dose of 400 mg every 4 weeks.
219291408|NCT07142551|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Eligible patients will initiate combined androgen deprivation therapy (ADT) with an LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx) in combination with standard dose darolutamide (600 mg twice daily) for a total of 6 months.
219291409|NCT07142551|DRUG|Darolutamide|600 mg twice daily during the lead-in phase and on darolutamide cycle.
219291410|NCT06948422|DRUG|Orforglipron|Administered orally.
219291411|NCT06948422|DRUG|Placebo|Administered orally.
219291412|NCT06948435|DRUG|Orforglipron|Administered orally
219291413|NCT06948435|DRUG|Placebo|placebo administered.
219291414|NCT07148765|DEVICE|Fitbit Sense 2|Continuous biometric monitoring (e.g., heart rate, pulse oximetry, respiratory rate, etc.) that will trigger alerts based on predefined threshold criteria for health care providers to respond to by contacting patients within 24 hours of alert.
219291415|NCT07148765|OTHER|Smartphone application survey|Daily questionnaire to record PROs will be administered via patient smartphones. Concerning PROs will trigger alerts which health care providers will respond to by contacting patients within 24 hours of alert.
219291416|NCT07152002|DRUG|LY4064912|Administered SC
219291417|NCT07152002|DRUG|LY4064912|Administered IV
219291418|NCT07152002|DRUG|Placebo|Administered SC
219291419|NCT07152002|DRUG|Placebo|Administered IV
219291420|NCT07155876|OTHER|Aromatherapy plus standard of care|"The participant is offered an aromatherapy scented tab that is attached to their gown based on symptoms (anxiety, pain, and/or nausea/vomiting):~1. Pain or anxiety: lavender or lavender sandalwood,~2. Nausea/vomiting: orange ginger, or~3. Despite the type of discomfort, the participant may request the alternate scent if the scent offered is not to their liking.~Plus, the patient receives SoC for treatment based on symptoms (anxiety, pain, and/or nausea/vomiting) as prescribed by the physician."
219291421|NCT07155876|OTHER|Standard of Care Only|Participant receives symptom management medications for pain, nausea/vomiting, and/or anxiety as prescribed by the physician.
219291422|NCT05095415|OTHER|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
219291423|NCT05095415|OTHER|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
219291424|NCT07165002|DRUG|LY3537031|Administered SC
219291425|NCT07194421|OTHER|Sunscreen RV4620A RP2552|Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon.
219291426|NCT07194070|OTHER|Standard of Care|No study treatment will be administered as part of this study. Participants will receive standard of care therapy as per local clinical practice.
219291427|NCT07194629|DRUG|Silver diamine Fluoride 38%|SDF 38%, applied on tooth surface for arrestation of active carious lesions and prevention of development of new carious lesions
219291428|NCT07194629|DRUG|placebo solution|bluish liquid designed to mimic the appearance of SDF 38%
219291429|NCT07194707|OTHER|Intraoperative Noise Monitoring|Noise levels will be passively measured during surgery using a calibrated sound level meter (CEM DT-8850) placed near the patient's head. Measurements will be taken every 10 minutes without physical contact or interference with clinical care. The procedure is purely observational and does not modify anesthesia or surgical practice.
219291430|NCT07193654|DRUG|Intrathecal injection of thiotepa|Intrathecal injection of thiotepa: Administered via lumbar puncture or OMMAYA reservoir according to the study protocol.
219291431|NCT07193654|DRUG|Stupp regimen (oral temozolomide)|Stupp regimen (oral temozolomide)::75 mg/m² daily during radiotherapy; 150-200 mg/m² daily for 5 days every 28 days for 6 cycles after radiotherapy;
219291432|NCT07193654|RADIATION|Radical radiotherapy|Radical radiotherapy: Delivery of 60 Gy of radiation, typically divided into 30 fractions of 2 Gy each;
219291433|NCT07193654|PROCEDURE|Maximal surgical resection|Maximal surgical resection: Removal of as much tumor as possible while preserving neurological function;
219291434|NCT07195617|DRUG|BCMA-GPRC5D CART|The entire study process was as follows: Screening period (V1) : Informed consent was signed, screening was checked, criteria were evaluated, and baseline demographic information and subject status were recorded. Blood collection period (V2) : For subjects who meet the inclusion and exclusion criteria, the blood required for CAR-T preparation will be obtained by leukocyte isolation monopexy or intravenous collection according to the conditions of the subjects. Preconditioning phase (V3) : cytokine and cell changes. Pre-transfusion assessment (V4) : The investigator assessed that the test results met the cell transfusion criteria, and D0 CAR T cell infusion could be performed with investigator permission. Infusion phase (V5) : CAR-T cells were transfused according to the dosage and method specified in the protocol. Safety and efficacy were followed up on D1, D4, D7, D10, D14, D21, D28, M3, M6, M9, M12, and M24.
219291435|NCT07194902|BEHAVIORAL|"HIVST for Partners and PrEP uptake for HIV-uninfected Postpartum Women (H4P)."|"For female participants, the intervention includes a 30-45 minute counseling session that will cover (1) SOC PrEP information, (2) communications skills training for HIVST kit distribution, (3) Motivational interviewing strategies (e.g., PrEP/HIVST pros/cons), (4) problem-solving barriers to PrEP uptake or HIVST distribution, (5) linkage enablers (e.g., care sites, transportation, asking questions of providers). For their male partners, an informative video will cover geographically diverse HIV treatment resources, as well as on why linkage to HIV care is needed in the context of the relationship with his female partner and gender norms. The video will also demonstrate a brief motivational exercise whereby men are asked to consider the pros and cons of linking to HIV care versus not (with examples), as well as a step-by-step guide to generate a concrete plan for linkage to care based on linkage enablers."
219291436|NCT07195149|DRUG|High-Dose Aspirin 300 mg|High-dose Aspirin 300 mg once daily taken orally for three months
219291437|NCT07195149|DRUG|DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)|"Drug: Prasugrel 10 mg~Prasugrel 10 mg once daily taken orally for 3 months~Drug: Low-Dose Aspirin~75 mg once daily taken orally"
219291438|NCT07195149|DRUG|Low-Dose Aspirin 75 mg|Low-Dose Aspirin 75 mg once daily taken orally
219291439|NCT07193550|DRUG|Zanzalintinib|Participants will take zanzalintinib 100mg daily by mouth
219291440|NCT07195123|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional psychoeducational content regarding self-management skills will be provided in-app.
219291441|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 1|10g single oral dose dissolved in water
219291442|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 2|10g single oral dose dissolved in water
219291443|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 3|10g single oral dose dissolved in water
219291444|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 4|10g single oral dose dissolved in water
219291445|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 5|10g single oral dose dissolved in water
219291446|NCT07194850|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
219291447|NCT07194850|OTHER|Placebo IV|Intravenous infusion of placebo
219291448|NCT07195331|DRUG|Intravenous injection of indocianine green at least three hours before surgery at a dose of 2.5 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 10 mL of water for injectable solutions, yielding a concentration of 2.5 mg/mL. Once the solution is prepared, 1 mL will be administered directly via a peripheral venous line in the patient's upper limb.
219291449|NCT07195331|DRUG|Intravenous injection of indocianine green 15 to 30 minutes before surgery at a dose of 0.25 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 25 mL of water for injectable solutions, yielding a concentration of 1 mg/mL. Subsequently, 0.25 mL will be administered as a direct intravenous injection via a peripheral venous line in the patient's upper limb.
219291450|NCT07194434|OTHER|No.intervrntion|No intervention
219291451|NCT07194252|OTHER|Guided imagery technique application|Intervention is a guided imagery technique designed for patients undergoing total joint arthroplasty. It will be administered in a total of 4 sessions: once daily on the day before surgery, twice daily on the day of surgery, and once daily on the 2nd and 3rd days after surgery, accompanied by imagery scenarios developed in accordance with the Compact Disc (CD) and literature developed by the Turkish Psychological Association. The study aims to examine its effects on surgical anxiety levels, postoperative pain intensity, and analgesic consumption. This approach is structured as a non-pharmacological method specific to surgical nursing practice and differs from previous similar studies in that it is applied in both the preoperative and postoperative periods using the same sample in the literature.
219291452|NCT07195175|DRUG|MAR002|subcutaneous injection
219291453|NCT07195175|DRUG|Placebo|Subcutaneous injection
219291454|NCT07194018|DRUG|Use of cannabis oil|Use of cannabis oil on pain relief in patients suffering from fibromyalgia syndrome
219291455|NCT07195266|BEHAVIORAL|Strategic Psychoterapy|Strategic psychotherapy as described in scientific literature
219291456|NCT06069817|DEVICE|High flow nasal cannula|home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
219291457|NCT06069817|DEVICE|nebulized normal saline|home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
219291458|NCT01464372|DEVICE|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
219291459|NCT01464372|DEVICE|Sham Nerve Stimulation Device|Use of the sham device
219291460|NCT06357325|OTHER|a qualitative study.|"Before the interview process began, an interview form was created in accordance with the study design. In the study, care was taken to use open-ended general questions that would allow the participant to provide detailed information on the subject and did not require short answers such as short and clear questions, multiple choice questions, and yes-no questions.~For the analysis and reporting phase, an introduction was made in the form of a conversation with the participant before starting the interview, and then the interview was started if the participant was available. During the transcription phase, the questions were asked during the interview in such a way as to allow the participant to express themselves in detail without any direction or comment. The interview was conducted individually by calling each woman by telephone. During the interview, the researcher transcribed the interviewee's sentences exactly as she expressed them."
219291461|NCT02261987|OTHER|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
219291462|NCT02261987|OTHER|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
219291463|NCT02261987|OTHER|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
219291464|NCT05020327|DRUG|Graded Oral Amoxicillin Challenge|Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
219291465|NCT05020327|OTHER|De-labelling in electronic medical record|Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
219291466|NCT05020327|OTHER|Referral to Allergy Immunology/Retention of Allergy Label|Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
219291467|NCT05599503|BEHAVIORAL|Behavioral Interventions|Traditional SimpleC Wellness
219291468|NCT05599503|BEHAVIORAL|Robot Interventions|Robot interventions
219291469|NCT04874285|DIETARY_SUPPLEMENT|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
219291470|NCT00080457|DRUG|sitaxsentan sodium|
219291471|NCT02952118|DEVICE|Forrest Snoring device|
219291472|NCT02851888|DRUG|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
219291473|NCT02851888|OTHER|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
219291474|NCT02851888|PROCEDURE|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
219291475|NCT02392520|DRUG|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
219291476|NCT02392520|DRUG|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
219291477|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
219291478|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
219291479|NCT02492022|OTHER|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
219291480|NCT02084563|DRUG|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
219291481|NCT02084563|DRUG|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
219291482|NCT02084563|DRUG|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
219291483|NCT02084563|DRUG|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
219291484|NCT02084563|DRUG|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
219291485|NCT02084563|DRUG|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
219291486|NCT05894902|DRUG|SM-001|The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
219291487|NCT05201391|BEHAVIORAL|"Eat Right Now (ERN) mobile application"|"Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete."
219291488|NCT06191822|OTHER|Nutrition|Interact with mobile app and work toward personalized nutrition goals
219291489|NCT06191822|OTHER|Fitness|Interact with mobile app and work toward personalized fitness goals
219291490|NCT06191822|OTHER|Sleep|Interact with mobile app and work toward personalized sleep goals
219291491|NCT02780908|OTHER|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
219291492|NCT02780908|OTHER|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
219291493|NCT00530140|BIOLOGICAL|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
219291494|NCT00095056|DRUG|sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
219291495|NCT00095056|DRUG|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
219291496|NCT00095056|DRUG|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
219291497|NCT00095056|DRUG|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
219291498|NCT02999802|BEHAVIORAL|Exercise|Progressive resistance exercise training
219291499|NCT02886273|OTHER|Group 1|Observation
219291500|NCT02886273|OTHER|Group 2|Observation
219291501|NCT02886273|OTHER|Group 3|Observation
219291502|NCT02886273|OTHER|Group 4|Observation
219291503|NCT00396760|DRUG|aprotinin or tranexamic acid|
219291504|NCT02914340|DEVICE|Spiration Valve System|
219291505|NCT00923260|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
219291506|NCT00923260|PROCEDURE|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
219291507|NCT03100643|OTHER|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
219291508|NCT06213259|DRUG|KD6005|Biological: KD6005, SQ
219291509|NCT06213259|DRUG|Placebo|Placebo, SQ
219291510|NCT03704675|DRUG|TEW-7197|Administered orally
219291511|NCT04565093|PROCEDURE|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
219291512|NCT04565093|PROCEDURE|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
219291513|NCT04997447|BEHAVIORAL|Step-reduction/Exercise Rehab|2-week limited daily steps (\<2000), and then 4 weeks of typical strength+endurance exercise for older adults
219291514|NCT05617729|OTHER|Saline applied via swab|sterile saline applied via swab
219291515|NCT05617729|OTHER|Povidone-iodine based gel|gel applied via swab
219291516|NCT03260257|OTHER|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
219291517|NCT00660543|DRUG|Gadolinium|Given IV
219291518|NCT00660543|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
219291519|NCT00660543|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
219291520|NCT00660543|OTHER|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
219291521|NCT00660543|OTHER|Diffusion Weighted Imaging|Undergo DWI
219291522|NCT00660543|OTHER|MRI-Based Angiogram|Undergo TOF MR angiography
219291523|NCT03429829|DEVICE|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
219291524|NCT02116673|OTHER|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
219291525|NCT02116673|OTHER|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
219291526|NCT03388697|DIAGNOSTIC_TEST|Quantose IR and Quantose IGT analysis|Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
219291527|NCT03388697|DIAGNOSTIC_TEST|HOMA IR the standard testing for insulin resistance|Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.
219291528|NCT04242836|DIAGNOSTIC_TEST|MNREAD testing|One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
219291529|NCT05999695|OTHER|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
219291530|NCT05999695|OTHER|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
219291531|NCT00689975|BEHAVIORAL|behavioral dietary intervention|
219291532|NCT00689975|BEHAVIORAL|exercise intervention|
219291533|NCT00689975|OTHER|counseling intervention|
219291534|NCT00689975|OTHER|flow cytometry|
219291535|NCT00689975|OTHER|immunoenzyme technique|
219291536|NCT00689975|OTHER|laboratory biomarker analysis|
219291537|NCT00689975|PROCEDURE|complementary or alternative medicine procedure|
219291538|NCT00689975|PROCEDURE|standard follow-up care|
219291539|NCT03930290|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation by vaginal tactile imaging analysis.
219291540|NCT05261919|PROCEDURE|Acupuncture manipulation|The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
219291541|NCT03646591|DRUG|Chemotherapy|Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
219291542|NCT00197587|DRUG|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
219291543|NCT00197587|DRUG|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
219291544|NCT03022253|BIOLOGICAL|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~1. PDA closes or~2. A maximum of 120 hours after the point of randomisation"
219291545|NCT03022253|BIOLOGICAL|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is \< 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count \< 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count \< 1, 00,000 per microliter and requires a neurosurgical procedure"
219291546|NCT03022253|DRUG|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
219291547|NCT03022253|DRUG|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
219291548|NCT02717351|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
219291549|NCT04585854|OTHER|Caffeine|Consumption of 3 shots of espresso
219291550|NCT01451892|OTHER|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
219291551|NCT01451892|OTHER|patient education|overweight individuals participating in a patient education program
219291552|NCT02480959|PROCEDURE|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
219291553|NCT04838951|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
219291554|NCT01276938|RADIATION|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
219291555|NCT01276938|RADIATION|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
219291556|NCT00886496|BIOLOGICAL|recombinant human mannose-binding lectin|
219291557|NCT04576403|DEVICE|activated mittens|activated mittens (with electronic heat)
219291558|NCT04576403|DEVICE|deactivated mittens|deactivated mittens (without electronic heat)
219291559|NCT05442905|DRUG|propofol|Anesthesia will be induced with propofol 2-3mg/kg
219291560|NCT05442905|DRUG|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
219291561|NCT05442905|DRUG|sevoflurane|sevoflurane(1%-2%) used during anesthesia
219291562|NCT06431100|BIOLOGICAL|TCR T-cells|The strengthened T cells are re-infused into the patient to achieve the killing effect
219291563|NCT01316406|DRUG|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
219291564|NCT03603249|DRUG|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
219291565|NCT00039312|OTHER|Papanicolaou test|
219291566|NCT00039312|OTHER|cytology specimen collection procedure|
219291567|NCT00039312|PROCEDURE|annual screening|
219291568|NCT00039312|PROCEDURE|colposcopic biopsy|
219291569|NCT00039312|PROCEDURE|comparison of screening methods|
219291570|NCT03829475|DRUG|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
219291571|NCT03829475|DRUG|Placebo|placebo is an infusion of normal saline.
219291572|NCT03829475|DRUG|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
219291573|NCT04978272|DRUG|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
219291574|NCT04978272|OTHER|DP Placebo|Placebos will be identical appearance to DP.
219291575|NCT04500249|DRUG|infiltration rescue intraoperative analgesia|in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
219291576|NCT04500249|DRUG|rescue IA|in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
219291577|NCT04500249|DRUG|rescue antyhypertensive medication|in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
219291578|NCT04500249|DRUG|rescue antyemetic medication|in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
219291579|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
219291580|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
219291581|NCT00836745|OTHER|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
219291582|NCT04837651|DEVICE|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
219291583|NCT04837651|DEVICE|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
219291584|NCT02060539|DEVICE|Biofinity XR|
219291585|NCT05458947|PROCEDURE|pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
219291586|NCT05458947|PROCEDURE|electrical stimulation (ES)|high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
219291587|NCT05458947|PROCEDURE|electrical stimulation (ES) and pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
219291588|NCT04835337|BEHAVIORAL|Air Purifiers|Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.
219291589|NCT04835337|BEHAVIORAL|Sham Air Purifiers|The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
219291590|NCT05299814|BEHAVIORAL|Behavioral Parenting Intervention|8 session evidence based parenting intervention
219291591|NCT04488393|DEVICE|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
219291592|NCT06051136|BEHAVIORAL|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
219291593|NCT04288102|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
219291594|NCT04288102|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
219291595|NCT00752947|DRUG|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
219291596|NCT00752947|DRUG|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
219291597|NCT00752947|DRUG|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
219291598|NCT05016362|PROCEDURE|medial fat preservation upper blepharoplasty|medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
219291599|NCT02533817|DIETARY_SUPPLEMENT|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
219291600|NCT04687059|BIOLOGICAL|PQ Grass|Suspension for injection
219291601|NCT04687059|DRUG|Placebo Option 1|Suspension for injection
219291602|NCT04687059|DRUG|Placebo Option 2|Solution for injection
219291603|NCT04394208|DRUG|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
219291604|NCT04394208|DRUG|Placebo|Placebo comparator
219291605|NCT04155736|BEHAVIORAL|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
219291606|NCT05961787|DEVICE|SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)|"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"
219291607|NCT01756768|RADIATION|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
219291608|NCT00359216|DRUG|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
219291609|NCT00359216|DRUG|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
219291610|NCT02121301|DRUG|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
219291611|NCT02121301|DRUG|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
219291612|NCT02121301|DRUG|Placebo (Vehicle) opthalmic solution|eyedrops
219291613|NCT01473446|PROCEDURE|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV\> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding \>1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
219291614|NCT05323760|DEVICE|Cardiopulmonary exercise test (CPET)|A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
219291615|NCT05142852|DEVICE|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
219291616|NCT05142852|OTHER|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
219291617|NCT01769768|DRUG|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
219291618|NCT01769768|DRUG|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
219291619|NCT01769768|DRUG|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
219291620|NCT00334464|DRUG|Standard of care or genotyping dosing of warfarin dosing|
219291621|NCT00180063|DRUG|L-NMMA(drug)|
219291622|NCT00476970|BEHAVIORAL|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
219291623|NCT04311528|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV vaccine
219291624|NCT04721535|DRUG|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
219291625|NCT04721535|DRUG|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
219291626|NCT01033422|DRUG|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
219291627|NCT01033422|DRUG|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
219291628|NCT02663518|DRUG|PF-0791800 (TTI-621)|Monotherapy
219291629|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Rituximab|Combination therapy
219291630|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Nivolumab|Combination therapy
219291631|NCT03805620|OTHER|Combined physical-cognitive training|combined physical-cognitive training
219291632|NCT03805620|OTHER|Physical training|Multi-component physical exercise
219291633|NCT03805620|OTHER|Cognitive training|cognitive training
219291634|NCT04392661|PROCEDURE|Laparoscopic Sleeve Gastrectomy|bariatric surgeries and data collection
219291635|NCT04174794|DEVICE|Lung ultrasound|The two different lung ultrasound protocols are performed initially within 48 hours of internal medicine ward admission by a pair of expert-beginner echographers. In case of admission during non-working days, the first scan can be done within 72 hours from admission. Follow-up scans are repeated 4 to 6 days later or on the day of discharge if it occurs before de fourth day. Experts and beginners execute the lund ultrasound protocols in sequence, reciprocally blinded, without accessing to clinical data files.
219291636|NCT02935725|DRUG|Low dose AUT00206 800mg|
219291637|NCT02935725|DRUG|High dose AUT00206 2000 mg|
219291638|NCT02935725|DRUG|Placebo|
219291639|NCT02935725|DRUG|Ketamine|
219291640|NCT02935725|OTHER|Saline|
219291641|NCT04713800|DEVICE|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR-TiB)|In group ZR-TiB the implant impressions will be taken using an intra-oral scanner and the respective scanbody. The restorations will be manufactured by means of CAD/CAM procedures using monolithic zirconia. For sufficient aesthetics, the zirconia restorations can be manually veneered with veneering ceramic only at the buccal surface, while the occlusal surface will remain monolithic and will be high-gloss polished. The zirconia restorations will be extra-orally cemented onto titanium base abutments (Straumann® Variobase® for crown, Straumann AG), correctly polished and delivered to the patient, by screw-retention onto the implant.
219291642|NCT04713800|DEVICE|porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM-GA)|In group PFM-GA implant impression will be taken using a polyvinyl siloxane or polyether impression material in a conventional manner with the use of stock trays and corresponding impression copings. The framework will be manufactured by the lost wax-technique using a gold-abutment (Straumann® Gold abutment for crown, Straumann AG) and a gold-alloy. All metal frameworks will be manually veneered with veneering ceramic, polished and glazed, and delivered to the patient, by screw-retention onto the implant.
219291643|NCT02289092|BEHAVIORAL|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
219291644|NCT04167527|DEVICE|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
219291645|NCT04167527|COMBINATION_PRODUCT|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
219291646|NCT06002633|OTHER|Alcohol|Participants will consume beverages containing alcohol.
219291647|NCT06002633|OTHER|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
219291648|NCT02569593|DIETARY_SUPPLEMENT|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
219291649|NCT04820218|DEVICE|With Try-on glasses|Subjects will be asked to measure their visual acuity with their try-on glasses
219291650|NCT01658332|OTHER|blood samples|3 tubes (15 ml)
219291651|NCT02163005|DRUG|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
219291652|NCT05210751|OTHER|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
219291653|NCT03896152|DRUG|LNP023|approximately 2 year of Treatment with LNP023
219291654|NCT01296802|DRUG|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
219291655|NCT01698190|PROCEDURE|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
219291656|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
219291657|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
219291658|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
219291659|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
219291660|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
219291661|NCT01629732|DRUG|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
219291662|NCT01629732|DRUG|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
219291663|NCT00943852|DRUG|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
219291664|NCT00943852|DRUG|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
219291665|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
219291666|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
219291667|NCT00943852|DRUG|Comparator: Placebo|Single dose placebo only in one of five treatment periods
219291668|NCT00419978|PROCEDURE|Colectomy|
219291669|NCT00720772|DRUG|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
219291670|NCT04134988|OTHER|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
219291671|NCT04134988|OTHER|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
219291672|NCT00575120|OTHER|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
219291673|NCT04916093|DRUG|Vildagliptin 50 MG|Galvus 50 mg oral tablets
219291674|NCT04916093|DRUG|Sitagliptin 100mg|Januvia 100mg oral tablets
219291675|NCT04916093|DRUG|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
219291676|NCT01744938|PROCEDURE|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
219291677|NCT05422404|PROCEDURE|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
219291678|NCT05422404|PROCEDURE|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
219291679|NCT01253109|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
219291680|NCT05880745|DIAGNOSTIC_TEST|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
219291681|NCT04487704|OTHER|camrelizumab|camrelizumab 200 mg, intravenous infusion (no need for prophylactic administration), no less than 30 min ，No more than 60 min, one cycle every 2 weeks (14 days) or one cycle every 3 weeks (21 days). Try to complete the administration before the ECG
219291682|NCT00574756|DRUG|ranolazine|extended release 500 mg twice a day for two weeks
219291683|NCT02261259|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
219291684|NCT01107821|DEVICE|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
219291685|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ less than 10 minutes|lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
219291686|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
219291687|NCT05949073|DRUG|impregnated gingival retraction cord - less than 10 minutes|lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
219291688|NCT05949073|DRUG|impregnated gingival retraction cord - more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
219291689|NCT01493843|DRUG|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
219291690|NCT01493843|DRUG|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
219291691|NCT01493843|DRUG|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
219291692|NCT01493843|DRUG|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
219291693|NCT01493843|DRUG|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
219291694|NCT03663491|PROCEDURE|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
219291695|NCT03663491|PROCEDURE|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
219291696|NCT03663491|PROCEDURE|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
219291697|NCT03663491|PROCEDURE|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
219291698|NCT05784831|DEVICE|Reappraisal training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
219291699|NCT05784831|DEVICE|Ecological Momentary Assessment|The EMA tested here collects data on participants' mood and behavior.
219291700|NCT00417105|PROCEDURE|hemodialysis|group 1: twice weekly, four hours
219291701|NCT00417105|PROCEDURE|hemodialysis|group 2: twice weekly, eight hours
219291702|NCT00417105|PROCEDURE|hemodialysis|group 3: every other day, eight hours
219291703|NCT00417105|PROCEDURE|hemodialysis|group 4: six days a week, eight hours
219291704|NCT03871673|DIETARY_SUPPLEMENT|Sweet manioc starch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
219291705|NCT03871673|DIETARY_SUPPLEMENT|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
219291706|NCT00094289|DRUG|Disulfiram|
219291707|NCT05499845|DIAGNOSTIC_TEST|butanol threshold test and smell identification tests|no additional intervention
219291708|NCT02321332|PROCEDURE|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
219291709|NCT02321332|PROCEDURE|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
219291710|NCT04573829|PROCEDURE|Home visit|Psychologist come once a week for the carer and three times a week for the patient
219291711|NCT06129578|DIETARY_SUPPLEMENT|Mediterranean diet supplement with 20 g / day of hemp protein.|"All participants followed a low-energy diet (1315 kcal/daily) based on Mediterranean diet for 12 weeks, supplement with 20 g / day of hemp protein. The specific menu was designed by a trainee nutritionist. The program prescribed five meals a day, with the time customized to fit the lifestyle of each patient. Based on the baseline metabolism, the energy and nutritional parameters of every patient were computed. Patients reported the dietary intake data daily.~The intervention included face to face visit every two weeks, individual nutrition counseling and education sessions."
219291712|NCT06268548|OTHER|Manual diaphragmatic activation|Manual diaphragm release on diaphragm
219291713|NCT02797431|DRUG|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000
219291714|NCT02797431|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
219291715|NCT03502031|DRUG|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
219291716|NCT03502031|DRUG|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
219291717|NCT06419400|BEHAVIORAL|Supportive text messages|The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency.
219291718|NCT00484133|DRUG|Dopamine|
219291719|NCT00484133|DRUG|dobutamine|
219291720|NCT00484133|DRUG|enoximone|
219291721|NCT00484133|DRUG|nitroglycerine|
219291722|NCT00484133|DRUG|noradrenaline|
219291723|NCT00579267|OTHER|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
219291724|NCT05269745|OTHER|Stretching through immobilisation (IG)|The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
219291725|NCT05269745|OTHER|Stretching through immobilisation and activity (IAG)|The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
219291726|NCT05269745|OTHER|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
219291727|NCT03093103|DRUG|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
219291728|NCT03093103|DRUG|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
219291729|NCT00457860|DRUG|Immunotoxin therapy|
219291730|NCT00457860|DRUG|CAT-8015 immunotoxin|
219291731|NCT00457860|PROCEDURE|Biological therapy|
219291732|NCT02384265|BEHAVIORAL|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
219291733|NCT05816226|DRUG|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
219291734|NCT05816226|DRUG|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
219291735|NCT01828632|PROCEDURE|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
219291736|NCT00730873|DEVICE|Continuous positive airway pressure|
219291737|NCT04585867|DRUG|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
219291738|NCT04585867|DRUG|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
219291739|NCT01244529|DEVICE|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
219291740|NCT01244529|DEVICE|seno A|senofilcon A, BC:8.4 or 8.8
219291741|NCT01244529|DEVICE|galy A|galyfilcon A , BC: 8.3 or 8.7
219291742|NCT03746782|DIAGNOSTIC_TEST|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
219291743|NCT03974139|DRUG|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
219291744|NCT00351208|DEVICE|Medtronic Manufactured Spinal Cord Stimulators|
219291745|NCT04940819|BEHAVIORAL|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
219291746|NCT03583567|DRUG|Chlorpheniramine and ranitidine|Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
219291747|NCT03583567|DRUG|0.9% Normal Saline|Patient will receive normal saline as placebo.
219291748|NCT00941070|DRUG|triapine|Given IV
219291749|NCT00941070|DRUG|cisplatin|Given IV
219291750|NCT00941070|RADIATION|external beam radiation therapy|Undergo pelvic external beam radiation therapy
219291751|NCT00941070|PROCEDURE|quality-of-life assessment|Ancillary studies
219291752|NCT00941070|OTHER|questionnaire administration|Ancillary studies
219291753|NCT00941070|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET/CT
219291754|NCT00941070|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
219291755|NCT00941070|PROCEDURE|computed tomography|Undergo FDG-PET/CT
219291756|NCT04436575|DEVICE|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
219291757|NCT03428529|DRUG|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
219291758|NCT03428529|DRUG|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
219291759|NCT04025541|BIOLOGICAL|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
219291760|NCT04025541|BIOLOGICAL|Blood sampling C3|"Blood samples will be collected at four key time points:~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
219291761|NCT04025541|BIOLOGICAL|Blood sampling C4/7/10/13|Blood samples will be collected before any treatment
219291762|NCT04025541|BIOLOGICAL|Blood sampling C5|"Blood samples will be collected at four key time points:~* At the inclusion (T1)~* Before the beginning of the treatment (cycle 1 day 1) (T2)~* After the first cycle of T-DXd (cycle 2 day 1) (T3)~* At progression or at the end of the follow-up (after 3 years) (T4)"
219291763|NCT04025541|BIOLOGICAL|Blood sampling C6|"Blood samples will be collected at three key time points:~* At the inclusion (T1)~* For patients starting treatment at the time of inclusion (T2):~* Chemotherapy: 3 months after inclusion,~* Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy,~* For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3)."
219291764|NCT04025541|BIOLOGICAL|Blood sampling C8|"Blood samples will be collected at five key time points:~* At the inclusion~* At follow-up visit 2 to 6, every 3 months"
219291765|NCT04025541|BIOLOGICAL|Blood sampling C9|"Blood samples will be collected at four key time points:~* At the inclusion before the beginning of the treatment (Cycle 1 Day 1)~* After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1)~* After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1)~* After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery"
219291766|NCT04025541|BIOLOGICAL|Blood sampling C11 + FFPE|"Blood samples will be collected at five key time points:~* At the inclusion (T1)~* At first clinical evaluation (T2): 4th week after start of treatment~* At first scan evaluation (T3a): 8th week after start of treatment~* At the Nth scan evaluation (T3b, c, ...)~* At progression (T4)~Tumor sampling :~* At the inclusion~* At tumor progression"
219291767|NCT04025541|BIOLOGICAL|Blood sampling C12|"Blood samples will be collected at several points :~* Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment,~* Every 4 weeks until meningeal progression, or for a maximum of 4 months,~* Then every 3 months beyond 4 months until meningeal progression."
219291768|NCT04041674|BIOLOGICAL|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
219291769|NCT04041674|BIOLOGICAL|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
219291770|NCT04041674|BIOLOGICAL|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
219291771|NCT04041674|BIOLOGICAL|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
219291772|NCT04041674|BIOLOGICAL|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
219291773|NCT03026699|BEHAVIORAL|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
219291774|NCT03026699|BEHAVIORAL|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
219291775|NCT00150865|DRUG|ropivacaine|
219291776|NCT05422664|DRUG|Lacosamide|Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
219291777|NCT04075994|BEHAVIORAL|Relational Agent and heart rate and rhythm monitor|Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.
219291778|NCT04075994|BEHAVIORAL|Usual Care|Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
219291779|NCT06121167|DIAGNOSTIC_TEST|urinary partial oxygen pressure|arterial blood gas
219291780|NCT06218160|DRUG|Hydromorphone combined with ropivacaine|1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
219291781|NCT06218160|DRUG|Ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
219291782|NCT04143958|DRUG|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
219291783|NCT04143958|DRUG|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
219291784|NCT01984138|DRUG|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
219291785|NCT01984138|DRUG|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
219291786|NCT05158816|PROCEDURE|ECMO|Patients undergoing extracorporeal membrane oxygenation
219291787|NCT04668430|OTHER|imaging and motion analysis|performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
219291788|NCT01998503|DRUG|Bortezomib|
219291789|NCT01998503|DRUG|dexamethasone|Given orally
219291790|NCT01998503|BIOLOGICAL|filgrastim|Given subcutaneous
219291791|NCT01998503|PROCEDURE|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
219291792|NCT01998503|DRUG|Melphalan|
219291793|NCT03182192|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
219291794|NCT03510494|BEHAVIORAL|Augmented physical education program|Augmented physical education program
219291795|NCT01896323|DRUG|CC-223|CC-223 20 mg tablets
219291796|NCT01896323|DRUG|Ketoconazole|Ketoconazole 400 mg tablets
219291797|NCT01452373|DRUG|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
219291798|NCT01452373|DRUG|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
219291799|NCT01247285|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
219291800|NCT01247285|DRUG|PROZAC WEEKLY®|90 mg Capsules
219291801|NCT02722642|BIOLOGICAL|Bronchial basal cells|Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
219291802|NCT03803124|DRUG|Tolvaptan|1 tablet before renography
219291803|NCT03803124|DRUG|Placebo|1 tablet before renography
219291804|NCT05551533|OTHER|Kampung Care App|Please refer to the previous session
219291805|NCT04677829|BIOLOGICAL|PNT001|30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg
219291806|NCT04677829|BIOLOGICAL|%5 dextrose for infusion|30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg
219291807|NCT01141647|BEHAVIORAL|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
219291808|NCT02750982|OTHER|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
219291809|NCT04727892|PROCEDURE|epilepsy surgery|Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
219291810|NCT05416190|DIAGNOSTIC_TEST|Lupus anticoagulant testing|The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
219291811|NCT00371332|DRUG|Minocycline HCL Microspheres|
219291812|NCT04850794|BEHAVIORAL|Decision Support Tool|The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
219291813|NCT04625387|OTHER|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
219291814|NCT02436473|DRUG|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
219291815|NCT02436473|OTHER|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
219291816|NCT02436473|DRUG|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
219291817|NCT02436473|DRUG|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
219291818|NCT00577876|PROCEDURE|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
219291819|NCT00816478|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
219291820|NCT04775199|BEHAVIORAL|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
219291821|NCT00461513|BEHAVIORAL|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
219291822|NCT04416373|DIAGNOSTIC_TEST|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
219291823|NCT02645227|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
219291824|NCT02645227|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
219291825|NCT02645227|PROCEDURE|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
219291826|NCT03316820|DRUG|K0706|Study treatment with water after an overnight fast
219291827|NCT03316820|DRUG|K0706|Study treatment with water after food
219291828|NCT01009151|BEHAVIORAL|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
219291829|NCT01009151|BEHAVIORAL|Heart Care Self Tracker|Web-based Home Tele-monitoring System
219291830|NCT06204874|PROCEDURE|Pulsed radiofrequency ablation|See left.
219291831|NCT06204874|PROCEDURE|Sham ablation|See left.
219291832|NCT02811731|DRUG|CKD-330 16/5mg - B|
219291833|NCT02811731|DRUG|Candesartan 16mg and Amlodipine 5mg|
219291834|NCT01075802|DRUG|Tamoxifen|Dose escalation
219291835|NCT03435354|BEHAVIORAL|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
219291836|NCT04160065|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
219291837|NCT00243048|DIETARY_SUPPLEMENT|soy protein isolate|
219291838|NCT00243048|RADIATION|radiation therapy|
219291839|NCT06344546|DIAGNOSTIC_TEST|Metabolomics|Analysis of the metabolome in plasma samples.
219291840|NCT04306016|OTHER|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
219291841|NCT01125514|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
219291842|NCT01125514|DRUG|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
219291843|NCT01125514|DRUG|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
219291844|NCT01125514|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet
219291845|NCT02033083|DEVICE|Laminaria|
219291846|NCT02033083|DEVICE|Dilapan-S|
219291847|NCT04864262|OTHER|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
219291848|NCT02512640|PROCEDURE|Volume-controlled ventilation|a tidal volume of 8 ml/kg
219291849|NCT02512640|PROCEDURE|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
219291850|NCT00858364|DRUG|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
219291851|NCT00858364|DRUG|Placebo|Administered subcutaneously once every 3 weeks
219291852|NCT01729442|OTHER|Shear-wave ultrasound elastography (SWUE)|
219291853|NCT05833490|OTHER|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at \~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
219291854|NCT05833490|OTHER|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
219291855|NCT00418340|DRUG|probiotic (bacterial/dietary supplement)|
219291856|NCT01971801|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Capsule given by mouth once a week
219291857|NCT01971801|OTHER|Placebo|One capsule given by mouth weekly
219291858|NCT03684668|BEHAVIORAL|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
219291859|NCT04716335|DRUG|DMT|DMT
219291860|NCT04716335|DRUG|Harmine|Harmine
219291861|NCT04716335|DRUG|Placebo (Harmine)|Placebo for Harmine
219291862|NCT04716335|DRUG|Placebo (DMT)|Placebo for DMT
219291863|NCT00214552|DRUG|rabeprazole|
219291864|NCT02680990|BEHAVIORAL|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
219291865|NCT02680990|OTHER|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
219291866|NCT04061044|DRUG|Ophthalmic Insert|Travoprost, 0.32 mg
219291867|NCT00157508|DRUG|nitroaspirin|
219291868|NCT03913923|BIOLOGICAL|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
219291869|NCT03913923|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
219291870|NCT03913923|OTHER|Placebo|Placebo
219291871|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
219291872|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
219291873|NCT02794415|OTHER|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for \~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
219291874|NCT02755818|DRUG|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
219291875|NCT02741323|DRUG|Maraviroc|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
219291876|NCT02741323|DRUG|Placebo|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
219291877|NCT00972660|BIOLOGICAL|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
219291878|NCT00972660|DRUG|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
219291879|NCT03369171|DEVICE|Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)|"MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2)."
219291880|NCT05271721|DRUG|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
219291881|NCT05271721|DRUG|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
219291882|NCT05271721|DRUG|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
219291883|NCT01170676|BEHAVIORAL|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
219291884|NCT01170676|BEHAVIORAL|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
219291885|NCT04419272|DRUG|Methylphenidate|10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.
219291886|NCT04419272|OTHER|Placebo|When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
219291887|NCT04419272|DRUG|Methylphenidate|During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
219291888|NCT02015208|DRUG|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
219291889|NCT06182891|DRUG|Dulaglutide Injection|Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
219291890|NCT04549649|OTHER|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
219291891|NCT04127851|DRUG|TJO-018 (HA 0.15%)|TJO-018 / one drop / 6 times daily in both eyes
219291892|NCT04127851|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)|Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes
219291893|NCT04127851|DRUG|TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%|TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
219291894|NCT05857189|DEVICE|Digitalized printed paper|Patients will receive a newly formed digitalized printed paper inserted into eyeglasses
219291895|NCT05857189|DEVICE|Traditional drawing image|Patients will receive eyeglasses that hold a traditional drawing image of the eye
219291896|NCT05857189|OTHER|Healthy controls|Patients will include volunteering participants with un defected eye
219291897|NCT01555840|DEVICE|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
219291898|NCT02535091|DRUG|YKP3089|see above
219291899|NCT05617430|DRUG|HAIC|"Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W"
219291900|NCT05617430|DRUG|Sintilimab|200mg IV d1, Q3W
219291901|NCT05617430|DRUG|Bevacizumab Biosimilar IBI305|7.5mg/kg IV d1, Q3W
219291902|NCT03045835|DEVICE|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
219291903|NCT03045835|DEVICE|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
219291904|NCT00004242|DRUG|fluorouracil|
219291905|NCT00004242|DRUG|gemcitabine hydrochloride|
219291906|NCT00004242|DRUG|oxaliplatin|
219291907|NCT06065254|OTHER|Efficacy of free gingival grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Two vertical incisions will be made in the previously elevated flap against the placed implant , where these two incisions will be 10 mm apart from each other, and the free graft to will be placed in this distance (10 x 10 mm). The graft will be obtained from the donor site (the hard palate), and will be thinned to obtain a regular graft with the required thickness. After that, the graft will be moved to its correct place accurately, while avoiding leaving a distance between the graft and the tissue underneath, and the graft will be sutured well to ensure its stability and correct placement.
219291908|NCT06065254|OTHER|Efficacy of connective tissue grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Vertical incisions will not be made in the previously elevated flap against the placed implant, where there is no need to suture the flap apically of the grafting place because the graft will be covered with it after fixing it in place. The area will be washed with the serum to remove the clot before fixing the graft.The graft will be obtained from the donor site according to the previously mentioned method. Then the epithelium will be removed to leave the connective tissue underneath, and then the graft will be moved to its place (buccally dental implant site) and the flap will be sutured over it.
219291909|NCT06065254|OTHER|No types of grafts will be made to improve the quality of the peri-implant mucosa|The simple suturing of the two surgical incisions will be done after the completion of the dental implant process, with no procedure will be made to improve the quality of the peri-implant mucosa.
219291910|NCT05956275|DRUG|Tramadol|ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
219291911|NCT05956275|DRUG|Morfin|No block was applied to the patients in control
219291912|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with limited application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.
219291913|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with full application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
219291914|NCT04235153|OTHER|Evaluation of the 9 dimensions of the CANUT-QVA questionnaire|"Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~1. Making food~2. Place where the meals are eaten~3. Eating and drinking: Nutrition~4. Eating and drinking: The pleasure of tasting, chewing~5. Eating and drinking: Satiated, well being~6. Food preparation: Supply, choice, presentation~7. Eating and drinking: Feelings~8. After eating: heaviness, discomfort, hunger~9. Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions."
219291915|NCT03581903|BIOLOGICAL|H7N3 pLAIV|Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
219291916|NCT03581903|BIOLOGICAL|H7N9 pIIV|30 micrograms administered by intramuscular (IM) injection
219291917|NCT05955300|OTHER|Training program|The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.
219291918|NCT05955300|OTHER|Nutrition therapy|Nutrition therapy based on the New Nordic Diet
219291919|NCT02830126|OTHER|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
219291920|NCT04177043|DIAGNOSTIC_TEST|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
219291921|NCT04177043|DRUG|DAAs|Treatment with different regiments with DAAs
219291922|NCT02601300|DRUG|GED-0301|
219291923|NCT01217177|DRUG|everolimus|
219291924|NCT01018238|DRUG|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
219291925|NCT01018238|DRUG|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
219291926|NCT04909827|PROCEDURE|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
219291927|NCT04909827|PROCEDURE|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
219291928|NCT01127763|DRUG|RAD001|
219291929|NCT01127763|DRUG|Carboplatin|
219291930|NCT01680640|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic to be used is fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
219291931|NCT01680640|DIETARY_SUPPLEMENT|Maltodextrin|
219291932|NCT02471105|DRUG|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
219291933|NCT02471105|DRUG|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
219291934|NCT00992225|DRUG|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
219291935|NCT01208649|DRUG|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
219291936|NCT05945004|OTHER|ChatGPT-4|Subjects' clinical records will be read by ChatGPT-4 to write preoperative visit sheets.
219291937|NCT05945004|OTHER|Clinician|Subjects' clinical records will be read by clinicians to write preoperative visit sheets.
219291938|NCT05131269|DRUG|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
219291939|NCT05131269|DRUG|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
219291940|NCT03018431|OTHER|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
219291941|NCT00879073|DRUG|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
219291942|NCT06377046|DEVICE|Accelerated pacing|The lower rate of the pacemaker will be programmed to 80 bpm in DDDR mode with mode switch to DDIR mode.
219291943|NCT06377046|DEVICE|Current standard of care|The lower rate of the pacemaker will be programmed to the current standard of care which is 60 bpm in DDDR mode with mode switch to DDIR mode.
219291944|NCT05106413|OTHER|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.
219291945|NCT05106413|OTHER|Monaural fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.~Monaural hearing aid fitting acts as control intervention."
219291946|NCT05106413|OTHER|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
219291947|NCT05106413|OTHER|CROS baseline|"Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.~This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention."
219291948|NCT00738894|DEVICE|Septal Occluder Device|PFO closure with study septal occluder device
219291949|NCT00738894|DRUG|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
219291950|NCT04326166|DRUG|Evogliptin|Evogliptin
219291951|NCT04326166|DRUG|Evogliptin|Evogliptin
219291952|NCT04326166|DRUG|Metformin and Evogliptin|Metformin and Evogliptin
219291953|NCT04449120|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
219291954|NCT04449120|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
219291955|NCT02297321|DEVICE|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
219291956|NCT02597647|BIOLOGICAL|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
219291957|NCT02597647|OTHER|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
219291958|NCT01275781|DRUG|[14C]-AZD9742|1000 mg intravenous over 2 hours
219291959|NCT00719329|DRUG|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
219291960|NCT00719329|BEHAVIORAL|Dry Cord Care|Educational messages regarding clean cord care
219291961|NCT03211117|DRUG|Docetaxel|Given IV
219291962|NCT03211117|DRUG|Doxorubicin Hydrochloride|Given IV
219291963|NCT03211117|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219291964|NCT03211117|OTHER|Laboratory Biomarker Analysis|Correlative studies
219291965|NCT03211117|BIOLOGICAL|Pembrolizumab|Given IV
219291966|NCT03211117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219291967|NCT05351320|DRUG|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
219291968|NCT05351320|DRUG|chemotherapy|Platinum-based chemotherapy
219291969|NCT05351320|RADIATION|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
219291970|NCT05232747|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test
219291971|NCT02649504|DRUG|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
219291972|NCT02649504|DRUG|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
219291973|NCT02649504|DRUG|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
219291974|NCT02649504|DRUG|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
219291975|NCT02773004|OTHER|EPClin genomic test|
219291976|NCT05475275|PROCEDURE|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
219291977|NCT03878992|DRUG|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
219291978|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
219291979|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
219291980|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
219291981|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
219291982|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
219291983|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
219291984|NCT02546921|DRUG|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
219291985|NCT00495443|DEVICE|Peterio|
219291986|NCT04255472|BEHAVIORAL|WHO Caregiver skills training (CST) program|Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
219291987|NCT04255472|BEHAVIORAL|Treatment as usual|WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
219291988|NCT05271968|PROCEDURE|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
219291989|NCT04779762|OTHER|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
219291990|NCT04779762|DRUG|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
219291991|NCT02186600|DRUG|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
219291992|NCT02186600|DRUG|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
219291993|NCT02186600|DRUG|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
219291994|NCT02186600|BEHAVIORAL|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
219291995|NCT01647555|DRUG|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
219291996|NCT01647555|RADIATION|Radiotherapy|Curative dose: 66 to 70 Gy
219291997|NCT03154970|DEVICE|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
219291998|NCT00677105|DRUG|JNJ-26481585|
219291999|NCT02573389|DEVICE|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
219292000|NCT03026075|DEVICE|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
219292001|NCT05478889|PROCEDURE|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
219292002|NCT04022512|RADIATION|computed tomography|thoracic CT examinations for pre-treatment staging and/or subsequent post-treatment follow-up.
219292003|NCT05679089|DEVICE|early detection test|Blood collection and early detection testing
219292004|NCT00625651|DRUG|Placebo|Inactive dummy AMG 655 (to maintain blind)
219292005|NCT00625651|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
219292006|NCT00625651|DRUG|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
219292007|NCT00625651|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
219292008|NCT05675813|DRUG|CHOP+selinexor+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
219292009|NCT05675813|DRUG|CHOP+duvelisib+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
219292010|NCT05675813|DRUG|CHOP+chidamide+tislelizumab|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
219292011|NCT05675813|DRUG|standard CHOP|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
219292012|NCT02731144|OTHER|Peptamen intense|
219292013|NCT02731144|OTHER|Novasource senior|
219292014|NCT05155670|DEVICE|WRL HX MCP|WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
219292015|NCT01640639|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
219292016|NCT01640639|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
219292017|NCT03058575|DIETARY_SUPPLEMENT|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement"
219292018|NCT03058575|OTHER|Control|No Intervention for 8 weeks
219292019|NCT02753543|DRUG|Chidamide|
219296481|NCT06907264|DEVICE|Wearable ECG Garment for Continuous Atrial Fibrillation Screening and Stroke Risk Assessment|This intervention utilizes a wearable ECG garment, a non-invasive, textile-based device for continuous 24-hour ECG monitoring. The garment features embedded electrodes to capture heart rate, rhythm, HRV parameters (e.g., SDNN, RMSSD, LF/HF), and P-wave indices (e.g., P-wave duration, PtfV1), enabling comprehensive assessment of atrial fibrillation (AF) and stroke risk. The device is lightweight, comfortable, and supports wireless data transmission to the cloud for real-time analysis. The study incorporates machine learning algorithms to identify AF patterns and explore stroke risk predictors, targeting individuals aged 40+ at high stroke risk. It also evaluates device acceptability and usability, aiming to improve AF detection rates, enable early intervention, and reduce stroke risk.
219292020|NCT04322903|BEHAVIORAL|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
219292021|NCT04469049|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
219292022|NCT02086305|BEHAVIORAL|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
219292023|NCT02086305|BEHAVIORAL|Usual care|Usual care is the routine practice in the hospital
219292024|NCT00830505|DRUG|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
219292025|NCT00830505|DRUG|fluticasone|2 puffs twice a day for 2 weeks
219292026|NCT01065142|PROCEDURE|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
219292027|NCT02918305|DEVICE|PRDS-001 Renal Denervation Ultrasound System|
219292028|NCT02918305|PROCEDURE|Sham Procedure|
219292029|NCT00929747|DEVICE|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
219292030|NCT00929747|PROCEDURE|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
219292031|NCT05930613|DRUG|Certolizumab (CIMZIA® ; TNF-α antagonist)|400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
219292032|NCT05930613|DRUG|Placebo (NaCl 0.9 % solution)|NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
219292033|NCT00710905|DEVICE|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
219292034|NCT02461953|DEVICE|hemoperfusion apparatus|
219292035|NCT02461953|DEVICE|low flux dialyzer|
219292036|NCT02461953|DEVICE|high flux dialyzer|
219292037|NCT02888652|DRUG|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
219292038|NCT03776539|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
219292039|NCT00052000|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
219292040|NCT05901064|PROCEDURE|Axillary clearance|Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
219292041|NCT04765332|OTHER|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
219292042|NCT05476302|OTHER|Cognitive digital treatment|The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
219292043|NCT03007446|DRUG|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
219292044|NCT03007446|DRUG|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
219292045|NCT03007446|DRUG|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
219292046|NCT04425304|BEHAVIORAL|Group counseling|4 times
219292047|NCT04425304|BEHAVIORAL|Intensive group counseling|14 times
219292048|NCT04425304|BEHAVIORAL|Persuasive ICT support|Weekly reminders for 12 months
219292049|NCT03403582|OTHER|Raspberries|250g frozen whole red raspberries
219292050|NCT00760968|DRUG|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
219292051|NCT00760968|DRUG|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
219292052|NCT03994354|PROCEDURE|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
219292053|NCT06058975|OTHER|Observational|Review the management of duodenal trauma in France
219292054|NCT04788043|DRUG|Magrolimab|45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
219292055|NCT04788043|DRUG|Pembrolizumab|200 mg IV infusion
219292056|NCT04788043|PROCEDURE|PET/CT|Scan
219292057|NCT04730154|BEHAVIORAL|Pain Neuroscience Education (PNE)|PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.
219292058|NCT04730154|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.
219292059|NCT04730154|BEHAVIORAL|Biomedically-focused education|The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
219292060|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
219292061|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
219292062|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
219292063|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
219292064|NCT05417958|OTHER|Extremely thick blenderized tube feed|Commercial blenderized tube feed, not diluted
219292065|NCT05417958|OTHER|Mildly thick blenderized tube feed|Commercial blenderized tube feed, diluted with ingredients contained in blend
219292066|NCT06211322|DEVICE|"Urika, a self-management application for patients with gout"|The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
219292067|NCT05336630|DEVICE|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
219292068|NCT06260683|DRUG|Nicotine Replacement|Given nicotine patches and nicotine lozenges
219292069|NCT06260683|OTHER|Questionnaire Administration|Ancillary studies
219292070|NCT06260683|DEVICE|Vaping|Given Preferred Flavor e-liquid
219292071|NCT06260683|DEVICE|Vaping|Given Tobacco flavored e-liquid
219292072|NCT06199336|BIOLOGICAL|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
219292073|NCT06199336|BIOLOGICAL|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
219292074|NCT06199336|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
219292075|NCT04924166|DRUG|Placebo|Inactive dose of capsules that appear identical to active dose
219292076|NCT04924166|DRUG|Hydrocortisone|Hydrocortisone 180 mg in capsule form
219292077|NCT01934790|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
219292078|NCT01519505|BEHAVIORAL|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
219292079|NCT02365090|OTHER|patching|covering the sound eye with a patch to force use of the amblyopic eye
219292080|NCT02365090|OTHER|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
219292081|NCT05766384|DRUG|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
219292082|NCT05742438|DRUG|Lidocaine IV|Continuous intravenous infusion of lidocaine
219292083|NCT05742438|DRUG|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
219292084|NCT05742438|DRUG|intrathecal morphine|intrathecal morphine injection
219292085|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
219292086|NCT03437395|DEVICE|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
219292087|NCT03437395|RADIATION|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
219292088|NCT05806151|DIAGNOSTIC_TEST|Genetic and immunologic assessments|Definitive Local Therapies including surgery, radiotherapy, radio-frequency ablation of metastases.
219292089|NCT01372839|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
219292090|NCT01372839|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
219292091|NCT02595580|DEVICE|Glucopred|
219292092|NCT01115179|DRUG|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
219292093|NCT01115179|DRUG|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
219292094|NCT01115179|DRUG|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
219292095|NCT02944812|DRUG|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
219292096|NCT06292442|OTHER|traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
219292097|NCT06292442|OTHER|High intensity interval training|This group received High Intensity interval training along with conventional treatment for lower limb muscles, performed 3 times per week fr 4 weeks.
219292098|NCT05722639|DEVICE|X-Trodes acquisition system|No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
219292099|NCT04478136|DIAGNOSTIC_TEST|Blood test of factor levels|Blood draw from central line to check coagulation factors
219292100|NCT06450847|OTHER|Soleus Muscle Push Up Exercise|"Members will be asked to do the SPUs for 270 minutes/day for most days of the week (minimum 5 days) for 3 months:~1. Begin seated on a bench or chair so knees form a 90-degree angle with feet flat on the floor and toes pointed forward. Keep spine straight and shoulders back (not hunched or rounded forward).~2. Using a slow and controlled tempo, push toes into the floor and lift heels off the ground.~3. Hold for one to two seconds, pushing down on the balls of feet. Keep your thigh muscles relaxed.~4. Slowly lower heels and return to start. That's 1 rep. Without shoes Educational session will be given before the intervention time WhatsApp messages will be sent 1-2 times/day to remind the participants to continue doing the exercise and ascertain compliance. Also, the participants are required to daily fill logbook about the duration (in minutes) of the SPU that they did."
219292101|NCT06450847|OTHER|Other Exercise|Participants will be asked to continue their regular lifestyle
219292102|NCT05371106|OTHER|exposure to mycotoxins|self-report eating questionnaire
219292103|NCT03549390|BEHAVIORAL|Physical activity|Light-moderate intensity physical activities
219292104|NCT02368457|DRUG|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
219292105|NCT01144377|DRUG|LY2541546|Administered subcutaneously
219292106|NCT01144377|DRUG|Placebo|Administered subcutaneously
219292107|NCT05623696|DEVICE|Sham or actual non-invasive (Magnetic) brain stimulation|5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
219292108|NCT03410004|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
219292109|NCT05974670|DEVICE|Consumer wearable device|The subjects are required to wear the consumer wearable devices continuously during the whole study period. The device can provided several physiological parameters, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep.
219292110|NCT05216822|DRUG|Racecadotril|racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
219292111|NCT03636529|DIETARY_SUPPLEMENT|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
219292112|NCT03636529|OTHER|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
219292113|NCT03776708|OTHER|Spinal manipulation|Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
219292114|NCT03776708|OTHER|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires"
219292115|NCT02932098|BEHAVIORAL|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
219292116|NCT02932098|BEHAVIORAL|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
219292117|NCT02932098|BEHAVIORAL|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
219292118|NCT00607724|DRUG|GDC-0449|
219292119|NCT06269094|OTHER|CGM|CGM use for 6 weeks during virtual focus groups
219292120|NCT01419327|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
219292121|NCT03738423|DRUG|REGN3500|Administered subcutaneous (SC)
219292122|NCT03738423|DRUG|REGN3500-Matching Placebo|Administered subcutaneous (SC)
219292123|NCT06578741|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)|Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
219292124|NCT02642562|DRUG|Ferric Derisomaltose|
219292125|NCT03771794|DEVICE|ReguRate neurostimulation|"Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode"
219292126|NCT03539588|DEVICE|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
219292127|NCT03539588|DEVICE|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
219292128|NCT02844634|DRUG|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
219292129|NCT02844634|DRUG|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
219292130|NCT02844634|DRUG|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
219292131|NCT04224012|OTHER|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
219292132|NCT01974778|DIETARY_SUPPLEMENT|Meal|Meal
219292133|NCT05785377|DRUG|Bupivacaine-Neostigmine|20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
219292134|NCT05785377|DRUG|Bupivacaine|20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
219292135|NCT01279213|DRUG|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
219292136|NCT02592876|DRUG|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
219292137|NCT02592876|DRUG|rituximab|375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
219292138|NCT02592876|DRUG|ifosfamide|5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
219292139|NCT02592876|DRUG|carboplatin|AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
219292140|NCT02592876|DRUG|etoposide|100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
219292141|NCT04196127|OTHER|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
219292142|NCT04527432|OTHER|Survey|Survey at baseline, 6 and 12 months
219292143|NCT04527432|DIAGNOSTIC_TEST|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
219292144|NCT01464775|OTHER|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
219292145|NCT01464775|OTHER|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
219292146|NCT00611975|DRUG|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
219292147|NCT00611975|DRUG|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
219292148|NCT04299022|OTHER|Vivigen Cellular Bone Matrix|Allograft bone matrix
219292149|NCT05962554|BEHAVIORAL|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
219292150|NCT06430476|OTHER|EMI|A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path
219292151|NCT06430476|OTHER|EMA|A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
219292152|NCT05167669|DEVICE|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
219292153|NCT06472336|PROCEDURE|Intracranial stenting|Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.
219292154|NCT06472336|PROCEDURE|Continuation of conventional endovascular therapy (EVT)|Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
219292155|NCT05997199|DIETARY_SUPPLEMENT|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
219292156|NCT06115603|DRUG|Cannabigerol|1 mL of 80mg Cannabigerol once during experimental session
219292157|NCT06115603|OTHER|Placebo|1 mL of placebo once during experimental session
219292158|NCT03342833|DEVICE|Blood flow restriction|Occlusion of venous flow between bouts of HIIT training exercise
219292159|NCT04639297|DEVICE|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
219292160|NCT04639297|DEVICE|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
219292161|NCT06609109|DRUG|THC High Dose|Low dose of THC (30 mg)
219292162|NCT06609109|DRUG|THC Low Dose|Low dose of THC (5 mg)
219292163|NCT06609109|DRUG|THC 0mg|Placebo dose of THC (0 mg)
219292164|NCT06609109|DRUG|E-Cigarette Full Nicotine|E-Cigarette with Nicotine
219292165|NCT06609109|DRUG|E-Cigarette Placebo Nicotine|E-Cigarette with No Nicotine
219292166|NCT05917028|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
219292167|NCT07169851|DRUG|LY3537021|Administered SC
219292168|NCT07169851|DRUG|Placebo|Administered SC
219292169|NCT07169851|DRUG|Standard of Care Antiemetic Therapies|5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally
219292170|NCT07169851|DRUG|Background Chemotherapy|Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV
219292171|NCT07167862|DIAGNOSTIC_TEST|Butterfly iQ3 ultrasound system for determination of postpartum volume status|"A trained study staff member will perform point-of-care ultrasound (POCUS) of the lungs and the inferior vena cava (IVC). All POCUS assessments will be performed using either the curvilinear or phased array settings on a portable Butterfly iQ3 ultrasound system. Images obtained via the Butterfly iQ3 ultrasound system will be labeled according to the subject's unique identification number and transmitted directly to a digital study archive. The lead investigator or physician of record will review all captured ultrasound images to ensure that an appropriate therapy is selected moving forward.~Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider."
219292172|NCT07167862|DRUG|Oral furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The first cohort of 48 patients will be treated with oral furosemide 20mg daily and oral potassium chloride 40mEq daily for a total of 5-days. As patients delivered vaginally are typically discharged 2-3 days after birth and delivered via cesarean are typically discharged 4-5 days after birth, patients who have not yet completed the medication course by the time of planned discharge will be prescribed the remainder of their medications before departing the hospital.
219292173|NCT07167862|DRUG|Intravenous furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The second cohort of 48 patients will be treated with a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq on postpartum day 1.
219292174|NCT07167966|DRUG|AADvac1|Subcutaneous injection of AADvac1
219292175|NCT07167966|DRUG|Anti-amyloid Monoclonal Antibody (mAb)|Active comparator: intravenous infusion of an anti-amyloid mAb
219292176|NCT07171840|DRUG|10 cc of oxygen-ozone plus thumb splint|Oxygene-Ozone therapy plus splint therapy
219292177|NCT07171840|DEVICE|thumb splint|thermoplastic splint
219292178|NCT07172672|DIETARY_SUPPLEMENT|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer
219292179|NCT07174583|DRUG|IDE849|IV administration
219292180|NCT07174986|DEVICE|Double sequential defibirllation|A second defibrillator will be applyed with electrodes placed in the A-P position and defibrillation will be performed with two defibrllators in a sequential manner
219292181|NCT07174986|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
219292182|NCT07174336|DRUG|LY4064809|Administered orally
219292183|NCT07174336|DRUG|Placebo|Administered orally
219292184|NCT07174336|DRUG|Ribociclib|Administered orally
219292185|NCT07174336|DRUG|Palbociclib|Administered orally
219292186|NCT07174336|DRUG|Abemaciclib|Administered orally
219292187|NCT07174336|DRUG|Anastrozole|Administered orally
219292188|NCT07174336|DRUG|Letrozole|Administered orally
219292189|NCT07174336|DRUG|Exemestane|Administered orally
219292190|NCT07174336|DRUG|Fulvestrant|Administered intramuscular
219292191|NCT07177339|DRUG|Depemokimab|Depemokimab will be administered.
219292192|NCT07177339|DRUG|Placebo|Matching placebo will be administered.
219292193|NCT07178288|OTHER|Physiological/measurement-validation study|"Protocols PPT Reliability The assessor measured Pressure Pain Threshold; PPT, using an electronic digital algometer. Measurements will be taken at two test sites wrist at baseline, at 1, 3 and 5 minutes. Three PPT measurements were taken at each time point with a 15-20 seconds interval between each. Mean values will then be used in analysis.~Conditioned Pain Modulation In order to assess CPM, PPT was used as a tested stimulus on the painful arm (elbow and wrist). Baseline PPTs will assessed three times with an interval of 30 seconds between the repetitions. A Cold Pressure Task (CPT) will be used as the conditioning stimulus. Participants will be instructed to immerse their uninvolved hand in the ice water for 2 minutes. PPT will be measured at baseline pre and 1 minute during immersion to calculate CPM response, and then at various time points post immersion (minutes: 1, 5, 15, 30, 45, and 60) to determine the time point at which PPT returns to baseline."
219296482|NCT02439047|PROCEDURE|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~\- Adipose tissue samples : will be collected during surgery for breast reconstruction"
219296483|NCT02697994|OTHER|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
219296484|NCT02697994|OTHER|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
219292194|NCT07179250|DEVICE|Volume-Oriented Incentive Spirometer|Participants in the experimental group will perform volume-oriented incentive spirometry training twice daily (morning and evening) for 6 weeks. Each session consists of 10 deep inspirations using the spirometer, with the target volume initially set according to the participant's predicted maximum inspiratory capacity and increased by approximately 5% each week starting from week 2. For each breath, participants inhale to reach the target volume, hold their breath for 3-5 seconds, and then exhale. A rest period of 30-60 seconds is allowed between maneuvers, and the pace is adjusted according to individual tolerance. Training is performed in a seated or semi-recumbent position.
219292195|NCT07179250|BEHAVIORAL|Diaphragmatic Breathing Exercise (DBE)|Participants in the control group will perform diaphragmatic breathing exercises twice daily (morning and evening) for 6 weeks. During weeks 1-2, each session consists of 10 breaths per set; from week 3 to week 6, each session consists of 15 breaths per set. The exercise is performed without devices and includes the following sequence: slow inspiration through the nose with abdominal expansion, holding the breath for 5 seconds, followed by exhalation through the mouth with visible abdominal contraction. After each set, participants rest with natural breathing for 1-2 minutes to prevent hyperventilation or diaphragmatic fatigue. Training is conducted in a semi-recumbent position with both hands placed behind the head, focusing on abdominal movement control and breathing rhythm.
219292196|NCT07179250|BEHAVIORAL|Usual Care and Education|Participants in the control group will receive usual clinical care for gastroesophageal reflux disease (GERD) without structured breathing training. At study entry, participants are provided with standardized patient education regarding GERD and lifestyle modification strategies, along with an educational leaflet. No specific posture or breathing exercises are required during the study period.
219292197|NCT07178977|BEHAVIORAL|Psychoeducation group|"A structured, group-based psychoeducation program designed for parents of adolescents with anorexia nervosa. The intervention consists of four weekly sessions, each lasting 90 minutes, delivered in small groups (up to 7 families) at the Child Psychiatry Department, University Medical Centre Ljubljana. Each session follows a standardized structure. The session topics are: Understanding eating disorders; Maintaining factors in anorexia nervosa and strategies to address them; Establishing and supporting normal eating patterns, Promoting and sustaining change.~The program is adapted from evidence-based approaches, including family-based treatment (FBT) and enhanced cognitive-behavioral therapy (CBT-E), and is tailored to a psychoeducational group format for parents. The aim is to reduce parental distress, improve coping, and enhance adolescent treatment outcomes (BMI, eating disorder symptoms, anxiety, depression)."
219292198|NCT07181941|BIOLOGICAL|Linvoseltamab|Given IV
219292199|NCT07181941|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219292200|NCT07181941|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219292201|NCT07181941|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219292202|NCT07181941|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219292203|NCT07181941|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219292204|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.
219292205|NCT07183319|DRUG|Pembrolizumab|Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.
219292206|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.
219292207|NCT07184983|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (19 minutes), and then ramp down (for 30 seconds) at the end.
219292208|NCT07184983|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 18 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end.
219292209|NCT07184983|BEHAVIORAL|Mindfulness meditation|Participants will follow an audio track for guided mindfulness during the stimulation.
219292210|NCT07186660|DRUG|CIR-0602K|mitochondrial pyruvate carrier inhibitor
219292211|NCT07186660|DRUG|Placebo|Placebo tablet
219292212|NCT07187765|DRUG|Oliceridine|Oliceridine will be administered intravenously at a dose of 1 mg for gastroscopy or 1.5 mg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
219292213|NCT07187765|DRUG|Sufentanil|Sufentanil will be administered intravenously at a dose of 5 μg for gastroscopy or 7.5 μg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
219292214|NCT07184190|OTHER|Trancutaneous Auriculotemporal Nerve Stimulation|Trancutaneous Auriculotemporal Nerve Stimulation
219292215|NCT07185022|PROCEDURE|Intra-arterial Thrombolysis|rhTNK-tPA（Tenecteplase）dose: 0.4 - 0.8 mg/min, maximum dose: 16mg.
219292216|NCT07185022|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
219292217|NCT07194174|OTHER|Strength exercise|3 weekly supervised trainings with specific strengt exercises
219292218|NCT07194226|OTHER|No intervention (observational study)|This is an observational survey; participants complete an anonymous questionnaire and no medical or behavioral intervention is applied.
219292219|NCT07194746|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
219292220|NCT07194746|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
219292221|NCT07194941|BIOLOGICAL|Freeze-dried product made of fresh feces|"FMT represents an ecological alternative for restoring the damaged intestinal ecosystem in this infection, increasing ecological diversity and thus limiting the spread of the pathogen. Recurrence of C. difficile is its only approved indication.~The impact of FMT on the intestinal ecosystem is attributable to intraspecific bacterial competition: commensal microorganisms (sensitive and non-virulent) have more effective growth rates than pathogenic bacteria (resistant and virulent), so FMT produces an ecological replacement in favor of grafting the donor microbiota and eliminating antibiotic-resistant clones."
219292222|NCT07195032|DRUG|Commercial measles, mumps, and rubella (MMR) vaccine|Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
219296485|NCT06374173|DRUG|TGI-6 Injection|TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
219292223|NCT07193953|DEVICE|Next Generation Dome Helmet Focused Ultrasound|Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.
219292224|NCT07193953|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|"Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose.~Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight."
219292225|NCT07193953|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.
219292226|NCT07188922|OTHER|Non-invasive intraocular pressure measurement during ventilator weaning Description: Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from|Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from mechanical ventilation to spontaneous breathing. Measurements will be performed as part of routine clinical care and will not involve any experimental intervention.
219292227|NCT07193797|OTHER|Phenotypes of ICU delirium|The included delirium patients will be divided into different phenotypes, according to delirium risk factors such as age, history of cerebrovascular accident, blood transfusion, surgery duration etc.
219292228|NCT07194603|PROCEDURE|Spinal mobilization (SM) of the neck|This cohort intervention study has only one arm and this arm has only one intervention, the one described above. Both SM and JM mean the same thing and are synonymous.
219292229|NCT07195409|BEHAVIORAL|Out of School Time Coach (OST-Coach)|Four data coaching session (investigate, design, practice, reflect) will be conducted over an academic year. Each session will involve: a customized site level data report, goal setting and implementing strategies to address child physical activity, motor competence, and staff physical activity promoting behaviors.
219292230|NCT07195006|OTHER|Malnutrition in pregnancy as exposure|MUAC ≤23 cm in pregnancy at least 20 weeks gestational age
219292231|NCT07195006|OTHER|Poor WASH living conditions as exposure|"Poor water (source, quality, access, reliability), sanitation (toilet type, cleanliness, number of people using toilet) and personal (hand wash practices) and household hygiene (dumpster availability and emptying frequency) index scores.~WASH Index score ranges; 1.Basic services (76-100%), 2.Semi-basic services (51-75%) 3.Poor services (26-50%) 4.No services (0-25%)"
219292232|NCT07193875|DRUG|Efavirenz 600mg|Take One pill daily for 6 months in addition to baseline combination antiretroviral therapy regimen
219292233|NCT07194499|OTHER|No interventions|No intervention
219292234|NCT07194473|BEHAVIORAL|ZeroOCD|"The ZeroOCD app contains the following components:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
219292235|NCT07194473|BEHAVIORAL|Videoconferencing CBT|"Videoconferencing CBT contains the following chapters:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
219292236|NCT07193966|BIOLOGICAL|NG2 and DLL3 CAR-T cells|Infusion of NG2 and DLL3-specific CAR-T via intravenous route
219292237|NCT07195552|DIETARY_SUPPLEMENT|Agaricus blazei|Agaricus blazei mushroom capsules. 2000 mg per serving
219292238|NCT07195552|DIETARY_SUPPLEMENT|Reishi|Reishi mushroom capsules. 2000 mg per serving.
219292239|NCT07195552|DIETARY_SUPPLEMENT|Turkey Tail|Turkey tail mushroom capsules. 2000 mg per serving.
219292240|NCT07195552|OTHER|Placebo|Placebo
219292241|NCT07194616|PROCEDURE|Primary Surgery|Patients undergo radical surgical resection with TME without preceding neoadjuvant therapy
219296486|NCT00565851|BIOLOGICAL|Bevacizumab|Given IV
219296487|NCT00565851|DRUG|Carboplatin|Given IV
219292242|NCT07194616|PROCEDURE|Neoadjuvant radiochemotherapy and surgery|Neoadjuvant treatment: long-course pelvic radiotherapy (conventional fractionation) with concurrent chemotherapy (standard fluoropyrimidine-based regimen)
219292243|NCT07195188|BEHAVIORAL|"Let's Learn Diabetes Game-Based Education"|"Participants in the experimental group will receive diabetes education using the Let's Learn Diabetes board game. The program consists of four weekly sessions, each lasting two hours, over one month. The intervention is designed to improve diabetes knowledge, reduce anxiety, and enhance treatment adherence among patients with Type 2 Diabetes Mellitus on insulin therapy."
219292244|NCT07195188|BEHAVIORAL|Traditional Diabetes Education|Participants in the control group will receive standard diabetes education through traditional lecture-based presentations. The education schedule matches the experimental group with four weekly sessions, each lasting two hours, over one month.
219292245|NCT07195526|BEHAVIORAL|Bicycle balance control training|The intervention involves three components: (1) training on an exercise bicycle, (2) a balance control training on a bicycle simulator, and (3) cycling on the public roads with a safe start-and-stop technique that was practiced on the bicycle simulator. In the bicycle simulator training, the difficulty of the balance control will be increased gradually, slowly approaching the difficulty of bicycle balance control on the public roads.
219292246|NCT07194317|DEVICE|Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)|55 participants will be recruited (target to complete the study n=50). The acceptability trial will be conducted remotely. A baseline questionnaire will capture demographic data. Over three weeks participants will be asked to record three random consecutive days of dietary intake each week using a different tool. Participants will be randomised to the order they complete the tools. To minimise potential biases. Participants will be randomly assigned to one of the six possible tool completion sequences (Table 1) using a relevant participant randomization package (e.g., rempsyc) in R (v4.4.2), which is a free, open-source statistical software used for data analysis and randomisation.
219292247|NCT07194291|OTHER|Follow up of female sexual function|We follow up menstrual changes in diabetic adolescent girls to improve the outcome
219292248|NCT07194356|PROCEDURE|Pericapsular nerve group (PENG) block|A single-shot PENG block was administered preoperatively using ultrasound guidance. The block was performed with the patient in the supine position, and 20 mL of local anesthetic (0.25% bupivacaine) was injected between the psoas tendon and the superior pubic ramus to achieve analgesia of the anterior hip capsule.
219292249|NCT07194356|PROCEDURE|Standard Spinal Anesthesia (Control)|Patients in this arm were managed according to standard care protocols for spinal anesthesia in hip fracture surgery. No preoperative regional block was performed. Pain scores and postoperative tramadol use were measured for comparison with the experimental arm.
219292250|NCT07193576|DRUG|flunotinib|100mg
219292251|NCT07195084|RADIATION|Hypervision proton surgery|Proton radiaotherapy (34GyE or 39GyE)
219292252|NCT07193849|DRUG|MEBO Wound Ointment|both are used for second pressure ulcer
219292253|NCT07193849|DRUG|zinc oxide|both are used to treat second degree pressure ulcer but with no superiority
219296488|NCT00565851|DRUG|Docetaxel|Given IV
219296489|NCT00565851|DRUG|Gemcitabine Hydrochloride|Given IV
219296490|NCT00565851|OTHER|Laboratory Biomarker Analysis|Correlative studies
219296491|NCT00565851|DRUG|Paclitaxel|Given IV
219296492|NCT00565851|OTHER|Quality-of-Life Assessment|Ancillary studies
219296493|NCT00150423|DRUG|Pregabalin|
219292254|NCT07195487|OTHER|Fermented Extract Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
219292255|NCT07195487|OTHER|Placebo Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
219292256|NCT07193615|DRUG|YOLT-202|The IP is administered intravenously at the predetermined dose; Administration frequency: Once
219292257|NCT07194447|DRUG|Simvastatin Gel|A single local application of 1.2% simvastatin incorporated into 4% methylcellulose gel, placed around the implant site immediately after implant placement and before flap closure.
219292258|NCT07194447|DRUG|Methylcellulose Gel|A single local application of 4% methylcellulose gel without simvastatin, placed around the implant site immediately after implant placement and before flap closure.
219292259|NCT07194785|DIAGNOSTIC_TEST|AI-Assisted Cardiac Auscultation using the HearTech Smart Stethoscope|This intervention utilizes the HearTech smart stethoscope, where trained research personnel perform standardized examinations of four cardiac auscultation areas on subjects. The integrated AI algorithm analyzes heart sounds in real time and automatically generates reports. An initial positive detection triggers a repeat testing process, with the algorithm ultimately determining a positive screening result based on three detection outcomes (any two positive). This AI-assisted auscultation system is designed to achieve large-scale, standardized, and highly efficient preliminary heart murmur screening.
219292260|NCT07194382|DRUG|AP02|Oral inhalation solution
219292261|NCT07194382|DRUG|Placebo|Placebo oral inhalation solution
219292262|NCT07193914|OTHER|ECCCLORE program|2-hour sessions in groups of up to 10 people, once a week for 12 weeks plus 30-minute individual sessions after each group session At the beginning of each session, there will be a discussion about the past week and home practices. This will be followed by an alternation between presentations/explanations of key concepts and associated practices. In the individual sessions the previous session and any difficulties encountered during the group session will be reviewed, as well as to address the implementation of home practices.
219292263|NCT07194330|DIAGNOSTIC_TEST|None-placebo|Not be displayed, only retrospective data will be required
219292264|NCT07195630|OTHER|Moderate-Intensity Continuous Exercise|15 recreationally active males completed the \~21 min of exercise at 55% of VO2max, consisting of a 3-minute warm-up and 3-minute cool-down at 60 W.
219292265|NCT07195630|OTHER|High-Intensity Interval Exercise|15 recreationally active males performed 10 x 1-minute intervals at 90% of VO2max, separated by 75 s of active recovery at 60 W, and a final 3-minute cool-down period at 60 W.
219292266|NCT07193537|OTHER|Virtual reality exercises|Thirty one subjects will receive virtual reality exercises by VR Training using Xbox Kinect. The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor. Before the start of the training session, the research assistant adjusted the position of the sensor while the patient is sitting to ensure optimal position and motion capture, and loaded games into the system. After the setup is completed, the research assistant demonstrated games included in the Kinect adventure
219296494|NCT02214056|OTHER|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
219292267|NCT07193537|OTHER|Motor control training|Thirty one subjects will receive motor control training two times a week for eight weeks in form of deep cervical flexors strengthening using pressure biofeedback unit (craniocervical flexor exercise) :Pressure biofeedback unit will be used to perform Cranio-cervical flexor muscle training. Through which an endurance and isometric exercise for DNFs in progressive range positions will be performed each session, the PBU's air bag will be positioned below the occiput, and the inflatable cuff pressure sensor will be inflated to a baseline of 20 mmHg. Participants will instruct to target five pressure levels between 22 and 30 mmHg by nodding. scapular exercises .With patient in prone position, pillow under the chest and upper limb in varying degree of shoulder abduction, the participant lifts the hand toward the ceiling while retracting the scapula
219292268|NCT07193537|OTHER|conventional treatment|"Thirty one subjects will receive conventional treatment for 3 times per week for 4 weeks. Conventional treatment will include the following:~1-Posture correction (chin tuck exercise) Stand with the upper back against the wall, with the feet shoulder-width apart. Tuck the chin in and hold for 5 seconds 10 repetitions .Return to the starting position and repeat a number of times. This can help stretch the muscles in the upper neck 2. Stretching exercise: Self-stretching exercise for most common tight muscles. These muscles include upper trapezius (by contralateral side bending), levator scapulae (flexion, contralateral side bending and rotation) and sternocleidomastoid muscle (slight flexion with ipsilateral side bending and rotation). Each position should be maintained for 30 seconds and repeated for 3 times."
219292269|NCT07194005|DRUG|Disitamab vedotin(RC48)|2.5 mg/kg, administered intravenously every 3 weeks (Q3W) on Day 1 of each cycle.
219292270|NCT07194005|DRUG|Sintilimab|200 mg, administered intravenously, d1, every 3 weeks.
219292271|NCT07194005|DRUG|S-1|Oral, 40-60 mg, twice daily (bid), d1-14, every 3 weeks.
219292272|NCT07194005|DRUG|Oxaliplatin|130 mg/m², administered intravenously on Day 1 (d1), every 3 weeks.
219292273|NCT07194135|DRUG|Tenoxicam|Intra-articular administration of tenoxicam, 20 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
219292274|NCT07194135|DRUG|Triamcinolone Acetonide|Intra-articular administration of triamcinolone acetonide, 40 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
219292275|NCT06332963|BEHAVIORAL|Floatation-REST|Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
219292276|NCT06332963|BEHAVIORAL|IFT|Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
219292277|NCT06332963|BEHAVIORAL|EFT|Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
219292278|NCT04840225|OTHER|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
219292279|NCT07195591|DEVICE|GammaTile®|GammaTiles are a U.S. FDA-cleared, surgically targeted radiation therapy for patients with certain brain tumors. GammaTile consists of bioresorbable collagen tiles embedded with Cesium-131 (Cs-131) radioactive seeds
219292280|NCT07195591|RADIATION|External Beam Radiation Therapy|External beam radiation therapy (EBRT) is a type of radiation therapy that is standard of care. EBRT uses a machine outside the body to deliver high-energy beams of radiation to cancerous areas within the body
219292281|NCT07195591|DRUG|Temozolomide|TMZ (Chemotherapy) is used as a first-line treatment, often in combination with radiation therapy after surgical resection of the tumor
219292282|NCT07193732|BEHAVIORAL|Psychotherapy-Empathic Attunement Phase|The initial focus of our therapeutic intervention is on establishing empathic attunement to aid individuals in processing the inherent pain of grief in a constructive manner. For this phase, therapists will focus solely on adhering to the relationship formation and introspective exploration. Practitioners aimed at empathetically tuning into the patient's emotional experience, validating and reassuring the patient's emotional state, and adhering to the fundamental principles of empathy, sincerity, and positive regard for establishing and upholding a strong therapeutic alliance. Also, accompanying the patients to uncover and process the natural pain to gain self-awareness about their emotions.
219292283|NCT07193732|BEHAVIORAL|Psychotherapy - Chair-work intervention phase|During this phase, bereavement person will conduct imaginal conversation with a deceased. Practitioners utilized the resolution model including 5 components: (1) emotional reaction of the bereavement (blame, hurt, regret etc.) and enactment of the deceased; (2) differentiation of the bereavement's feelings and deceased's specific negative aspects accessed; (3) intense expression of the bereavement's specific emotions; (4) expression of the bereavement's previously unmet interpersonal needs from the deceased and the deceased validates bereavement's feelings; (5) understanding and forgiveness of the deceased or shift in view of the deceased.
219292284|NCT07193732|BEHAVIORAL|Psychotherapy - Cognitive consolidation and spiritually behavioral activation phase|Cognitive consolidation and spiritually behavioral activation complement the emotional interventions implemented in earlier stages. This cognitive process aids in the transformation and integration of adaptive growth, enabling patients to assimilate the knowledge and insights acquired during therapy. Therapists take a directive and co-constructivist approach, guiding patients to discover emotionally adaptive reconciliations and meanings that challenge and reshape their emotional and cognitive frameworks in the cognitive consolidation and spiritually behavioral activation phase. Aligned with this cognitive shift, spiritual behavioral activations involve creating plans to address unmet needs.
219292285|NCT07193680|OTHER|Intervention arm: expectant management if sFlt-1/PlGF<38|If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.
219292286|NCT07193680|OTHER|Standard care: elective delivery at 37 weeks of gestation|In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.
219292287|NCT07194239|BEHAVIORAL|Lifestyle medicine Health coaching|Participants assigned to this group will have 4 face-to-face sessions with the health coach. Lifestyle modifications with the aim of pain reduction will be determined in a shared decision-making approach. Lifestyle modifications will be based on the 6 pillars of lifestyle medicine: Physical activity, Healthy eating, Stress reduction, Sleep restoration, Social Support, and Avoiding risky substances. The health coach will make use of motivational techniques such as motivational interviewing to guide and assist participants in realizing the lifestyle modifications.
219292288|NCT07194460|DEVICE|Peripheral Magnetic Stimulation (PMS)|Treatment will be administered using a Peripheral Magnetic Stimulation (PMS) device. The intervention involves directing magnetic fields to stimulate specific peripheral nerve regions to regulate neural activity and improve symptoms.
219292289|NCT07194460|DEVICE|ham control group receiving PMS intervention|Identical to the experimental group in all procedures, except that no electrical stimulation is delivered.
219292290|NCT07194460|OTHER|Exercise|See previous sections
219292291|NCT07194460|OTHER|PMS＋Exercise|See previous sections
219292292|NCT07194096|OTHER|no intervention|no intervention
219292293|NCT07194525|OTHER|A standardized treatment algorithm for postoperative ileus after abdominal surgery, based on nasogastric tube output and including stepwise use of water-soluble contrast, imaging, and prokinetic medic|"The Ileus Management Protocol (I-MAP) is a standardized algorithm for the treatment of postoperative ileus (POI) after abdominal surgery. Management decisions are based on nasogastric tube (NGT) output measured every 12 hours. Depending on output and tolerance, patients may receive:~Water-soluble contrast (Telebrix® gastro, ioxitalamic acid 300 mg/mL) administered via NGT, followed by a clamp test at 4 hours.~Diagnostic imaging (CT-scan or X-ray) if ileus persists or small bowel obstruction is suspected.~Intravenous Neostigmine® (2.5 mg diluted in 500 mL NaCl 0.9%, infused over 5 hours) as a prokinetic, only after small bowel obstruction is excluded.~The protocol is applied until resolution of POI or requirement of further intervention."
219292294|NCT02736461|PROCEDURE|Floor repair surgery|
219292295|NCT01843127|DRUG|Ranolazine|
219292296|NCT01843127|DRUG|Placebo|
219292297|NCT01843127|DRUG|Exenatide|
219292298|NCT05762289|OTHER|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
219292299|NCT05162989|DEVICE|iCare HOME2 vs iCare IC200|Measurement of IOP with iCare HOME2 compared with iCare IC200.
219292300|NCT04790656|OTHER|Conventional Therapy|Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
219292301|NCT04790656|OTHER|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
219292302|NCT04341402|DRUG|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
219292303|NCT05497973|BEHAVIORAL|E-health ecosystem of stepped psychosocial care|"1. Screening and monitoring: weekly administration of an emotional state thermometer. If the score is \>5, participants are asked to complete the HADS. If HADS' score \>10, step 2 is assigned. The same procedure is followed for steps 3 \& 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~2. Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~3. Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q\&As.~4. Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
219292304|NCT05497973|BEHAVIORAL|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
219292305|NCT04465253|OTHER|Best Practice|Undergo standard of care occupational therapy
219292306|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in discussions via videoconferencing
219292307|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in interview via videoconferencing
219292308|NCT04465253|OTHER|Quality-of-Life Assessment|Ancillary studies
219292309|NCT04465253|OTHER|Questionnaire Administration|Ancillary studies
219292310|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
219292311|NCT01198756|BIOLOGICAL|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
219292312|NCT01198756|BIOLOGICAL|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
219292313|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
219292314|NCT05676853|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
219292315|NCT02402673|OTHER|Temporary activity modification and graded exercises|
219292316|NCT03462173|DRUG|yimitasvir|Capsule administered orally once daily
219292317|NCT03462173|DRUG|placebo|Matching Placebo Capsule
219292318|NCT00670631|COMBINATION_PRODUCT|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 \& 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
219292319|NCT05837962|BEHAVIORAL|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|"The nursing professional will perform 1 session weekly, for 4 weeks, lasting 90 minutes each. The contents that make up each of the sessions are:~Session 1. Knowledge about the risk factors, signs and symptoms, maternal and fetal complications of HDP.~Session 2. Control over behaviour, positive attitude and family and social support: essential components for conducting self-care behaviour.~Session 3. Nutritional recommendations: eating healthy helps prevent or reduce the risk of developing HDP.~Recommendations to improve sleep, rest and physical exercise: key routines in my health to prevent or reduce the risk of developing HDP.~Session 4. Mental health promotion: managing my stress, anxiety and depression levels help prevent or decrease the risk of HDP"
219292320|NCT00269360|PROCEDURE|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
219292321|NCT00269360|PROCEDURE|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
219292322|NCT00269360|BEHAVIORAL|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
219292323|NCT01386762|OTHER|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
219292324|NCT02699086|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
219292325|NCT05577884|DIAGNOSTIC_TEST|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
219292326|NCT04407871|OTHER|Acupuncture and Chinese Herbal Medicine|1\) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
219292327|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
219292328|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
219292329|NCT05872360|DIETARY_SUPPLEMENT|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
219292330|NCT05872360|DIETARY_SUPPLEMENT|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
219292331|NCT04103060|DRUG|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
219292332|NCT04103060|DRUG|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
219292333|NCT01597141|BEHAVIORAL|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
219292334|NCT01597141|BEHAVIORAL|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
219292335|NCT02299154|BEHAVIORAL|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
219292336|NCT04007380|OTHER|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
219292337|NCT00964587|BEHAVIORAL|Education + Problem-Solving Training Self-Study|"* Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
219292338|NCT00964587|BEHAVIORAL|Education + Group Problem-Solving Training|"* Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions"
219292339|NCT00964587|BEHAVIORAL|Education + Individual Problem-Solving Training|"* Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)"
219292340|NCT00964587|BEHAVIORAL|Usual Care|"* Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
219292341|NCT05816330|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
219292342|NCT05816330|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
219292343|NCT06492915|DRUG|Chiauranib|Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
219292344|NCT06492915|DRUG|Albumin-paclitaxel Injection|Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
219292345|NCT06492915|DRUG|Gemcitabine Injection|Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
219292346|NCT04445532|OTHER|Gene expression analysis|Gene expression analysis
219292347|NCT04445532|OTHER|Genomic analysis|Genomic analysis
219292348|NCT04445532|OTHER|Protein expression analysis|Protein expression analysis
219292349|NCT04445532|OTHER|Proteomic profiling|Proteomic profiling
219292350|NCT04445532|OTHER|Polymerase chain reaction|Polymerase chain reaction
219292351|NCT04445532|OTHER|Mass spectrometry|Mass spectrometry
219292352|NCT04445532|OTHER|Immunohistochemistry|Immunohistochemistry
219292353|NCT04445532|OTHER|Metabolomics profiling|Metabolomics profiling
219292354|NCT04445532|OTHER|Methylation and epigenetic analysis|Methylation and epigenetic analysis
219292355|NCT04445532|OTHER|Liquid biopsy analysis|Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
219292356|NCT04445532|OTHER|Laboratory biomarker analysis|Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
219292357|NCT00899782|OTHER|cytology specimen collection procedure|correlative studies
219292358|NCT00978523|DRUG|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
219292359|NCT01854853|BEHAVIORAL|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
219292360|NCT01854853|BEHAVIORAL|Health Promotion|Health promotion intervention
219292361|NCT05865015|OTHER||
219292362|NCT01959997|PROCEDURE|Redo PVI|
219292363|NCT01959997|PROCEDURE|PVI + RDN|
219292364|NCT06261632|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
219292365|NCT01269723|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
219292366|NCT01269723|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
219292367|NCT02742402|OTHER|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
219292368|NCT02742402|OTHER|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
219292369|NCT06009757|DEVICE|GUIDEX® guiding catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
219292370|NCT06009757|DEVICE|Launcher™ coronary guide catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
219292371|NCT01291940|OTHER|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
219292372|NCT01291940|OTHER|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
219292373|NCT01786759|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
219292374|NCT01786759|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
219292375|NCT01353859|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
219292376|NCT01353859|DRUG|methotrexate|10-25 mg orally weekly
219292377|NCT02541877|DEVICE|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
219292378|NCT02541877|DEVICE|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
219292379|NCT02541877|DEVICE|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
219292380|NCT02347423|BIOLOGICAL|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
219292381|NCT02347423|BIOLOGICAL|IPV Vaccine SSI|
219292382|NCT04073251|DIETARY_SUPPLEMENT|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
219292383|NCT04073251|DIETARY_SUPPLEMENT|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
219292384|NCT04033666|OTHER|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
219292385|NCT04033666|OTHER|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
219292386|NCT00469573|DRUG|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
219292387|NCT03596333|OTHER|Retrospective chart review|We conducted a retrospective chart review to evaluate the stored ultrasound images used during labor epidural placement, as well as demographic and anesthetic variables.
219292388|NCT05330689|BIOLOGICAL|PRP injection dose (<5 billion platelets)|PRP injection with a dose of platelets that is less than 5 billion platelets
219292389|NCT05330689|BIOLOGICAL|PRP injection dose (between 5 and <10 billion platelets)|PRP injection with a dose of platelets that is between 5 and \<10 billion platelets
219292390|NCT05330689|BIOLOGICAL|PRP injection dose (between 10 and <20 billion platelets)|PRP injection with a dose of platelets that is between 10 and \<20 billion platelets
219292391|NCT05330689|BIOLOGICAL|PRP injection dose (20 billion or greater platelets)|PRP injection with a dose of platelets that is 20 billion platelets or greater
219292392|NCT05330689|OTHER|Saline injection control|Saline control
219292393|NCT03811262|PROCEDURE|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
219292394|NCT03811262|PROCEDURE|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
219292395|NCT05182281|DEVICE|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
219292396|NCT05182281|DEVICE|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
219292397|NCT05182281|OTHER|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
219292398|NCT02083120|DEVICE|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
219292399|NCT02083120|OTHER|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
219292400|NCT04617977|BEHAVIORAL|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
219292401|NCT04617977|BEHAVIORAL|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
219292402|NCT01315210|DRUG|D-Ribose Powder|5 g TID for 12 Weeks
219292403|NCT01315210|DIETARY_SUPPLEMENT|Placebo Powder|5 g TID for 12 Weeks
219292404|NCT00700427|DRUG|atomoxetine hydrochloride|Oral 40-100 mg/day
219292405|NCT00700427|DRUG|Placebo|Oral delivery of matching placebo
219292406|NCT03025685|PROCEDURE|TRUST technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
219292407|NCT03025685|PROCEDURE|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
219292408|NCT03025685|PROCEDURE|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
219292409|NCT05962801|DEVICE|Lumoral device, Lumorinse|Regular use of dual-light photodynamic therapy at home
219292410|NCT03482401|DIETARY_SUPPLEMENT|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
219292411|NCT06419426|OTHER|Battery incidence|Incidence of batteries from negative Gram germs; Incidence of batteries from gram positive germs; Incidence of fungemie; Incidence of septic shock; Incidence of batteries from colonising germs; Incidence of resistance to the main classes of antibiotics
219292412|NCT05151705|DRUG|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
219292413|NCT05151705|DRUG|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
219292414|NCT05151705|DRUG|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
219292415|NCT01941719|BEHAVIORAL|Enhanced foot care education|In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
219292416|NCT01941719|BEHAVIORAL|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
219292417|NCT02138084|DRUG|BMS-663068|BMS-663068
219292418|NCT02138084|DRUG|Rifabutin|Rifabutin
219292419|NCT02138084|DRUG|Ritonavir|Ritonavir
219292420|NCT01480219|DRUG|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
219292421|NCT01480219|OTHER|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
219292422|NCT01744392|BEHAVIORAL|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
219292423|NCT00851838|DRUG|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
219292424|NCT04024774|BIOLOGICAL|Biological samples|blood samples, urine samples, tissue samples
219292425|NCT04024774|GENETIC|Genetic test|anamnesis and NGS sequencing
219292426|NCT00334672|BIOLOGICAL|anti-thymocyte globulin|
219292427|NCT00334672|DRUG|busulfan|
219292428|NCT00334672|DRUG|cyclophosphamide|
219292429|NCT00334672|DRUG|cyclosporine|
219292430|NCT00334672|DRUG|dexamethasone|
219292431|NCT00334672|DRUG|etoposide|
219292432|NCT00334672|DRUG|methotrexate|
219292433|NCT00334672|DRUG|mycophenolate mofetil|
219292434|NCT00334672|DRUG|therapeutic hydrocortisone|
219292435|NCT00334672|OTHER|laboratory biomarker analysis|
219292436|NCT00334672|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219292437|NCT00334672|PROCEDURE|biopsy|
219292438|NCT03253445|BEHAVIORAL|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
219292439|NCT03253445|OTHER|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
219292440|NCT06371638|DRUG|Dexmedetomidine|General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml
219292441|NCT06371638|DRUG|Sevoflurane|General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.
219292442|NCT01416389|DRUG|LY2523355|Administered intravenously as a one hour infusion
219292443|NCT01416389|DRUG|ixabepilone|Administered intravenously
219292444|NCT01416389|DRUG|pegfilgrastim|Administered intravenously
219292445|NCT01416389|DRUG|filgrastim|Administered intravenously
219292446|NCT04406506|DEVICE|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
219292447|NCT04406506|DEVICE|nasojejunal|"* The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~* Patients were placed in right lateral position"
219292448|NCT04406506|DRUG|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
219292449|NCT03711422|DRUG|Afatinib|40mg daily
219292450|NCT03711422|DRUG|Afatinib|160mg for 3 days every 3 weeks
219292451|NCT02927197|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
219292452|NCT04037657|DRUG|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
219292453|NCT04037657|DRUG|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
219292454|NCT04650542|DRUG|HBI-3000|small molecule, multi-ion channel blocker
219292455|NCT04650542|DRUG|Paroxetine|serotonin uptake inhibitor, CYP2D6 inhibitor
219292456|NCT00538694|DRUG|daptomycin|
219292457|NCT00254046|DRUG|TMC125|2 X100 mg tablets b.i.d.96 weeks
219292458|NCT00254046|DRUG|Placebo|2 tablets b.i.d.96 weeks
219292459|NCT00151580|DRUG|Ribavirin|18 months of oral ribavirin maintenance treatment
219292460|NCT00151580|DRUG|Placebo|18 months oral placebo treatment
219292461|NCT03992131|DRUG|Rucaparib|Rucaparib will be administered per schedule specified in the arm description.
219292462|NCT03992131|DRUG|Lucitanib|Lucitanib will be administered per schedule specified in the arm description.
219292463|NCT03992131|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered per schedule specified in the arm description.
219292464|NCT05653102|DEVICE|Truliant Total Knee System|Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
219292465|NCT02850289|DRUG|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
219292466|NCT02850289|DRUG|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
219292467|NCT05485545|OTHER|Electrophysiological exploration of the right ventricle|"* CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI"
219292468|NCT03980808|BEHAVIORAL|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
219292469|NCT03980808|BEHAVIORAL|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
219292470|NCT01655693|DRUG|Doxorubicin 20 mg/m2|
219292471|NCT01655693|DRUG|Doxorubicin 30 mg/m2|
219292472|NCT01655693|DRUG|Best Standard of Care|
219292473|NCT05521815|OTHER|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
219292474|NCT05521815|OTHER|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
219292475|NCT04602559|DEVICE|MOBIDERM Panty group|"In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance)."
219292476|NCT00357331|DRUG|potassium citrate|20 meq by mouth in capsule form twice daily
219292477|NCT01637948|DRUG|Listerine mouthrinse|For six months
219292478|NCT01637948|DRUG|Chinese Medicine mouthrinse|six months
219292479|NCT04348253|PROCEDURE|Berger|Treatment 1
219292480|NCT04348253|PROCEDURE|3LT|Treatment 2
219292481|NCT02904070|DEVICE|Vaginal swabbing|
219292482|NCT02604888|OTHER|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
219292483|NCT03189459|BEHAVIORAL|Home Visit Program|RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
219292484|NCT03189459|BEHAVIORAL|Caregiver Mentorship Program|"Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor"
219292485|NCT01756378|PROCEDURE|joint mobilization with movement|
219292486|NCT01756378|PROCEDURE|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
219292487|NCT04220619|DIAGNOSTIC_TEST|Tranesophageal Echocardiography|RescueTEE during ACLS versus Conventional ACLS
219292488|NCT00225823|DRUG|GW685698X|
219292489|NCT01240187|DRUG|perampanel|Single dose of 6 tablets 2 mg orally
219292490|NCT01240187|DRUG|perampanel|Single dose of 1 tablet 12 mg orally
219292491|NCT02416960|OTHER|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
219292492|NCT02416960|OTHER|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
219292493|NCT00929110|DRUG|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219292494|NCT00929110|DRUG|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
219292495|NCT00929110|DRUG|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
219292496|NCT03993600|DIAGNOSTIC_TEST|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects"
219292497|NCT04385381|DEVICE|URECA CTO device|facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
219292498|NCT02757690|DEVICE|3-dimensional distal pancreatectomy|3D laparoscopy
219292499|NCT02757690|DEVICE|2-dimensional distal pancreatectomy|2D laparoscopy
219292500|NCT04197739|DRUG|Amikacin|"Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram"
219292501|NCT00031798|DRUG|methylphenidate hydrochloride|
219292502|NCT00031798|PROCEDURE|quality-of-life assessment|
219292503|NCT00031798|RADIATION|radiation therapy|
219292504|NCT04642313|OTHER|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
219292505|NCT00701857|DRUG|cisplatin|Standard weekly dose
219292506|NCT00701857|DRUG|Pemetrexed|Biweekly pemetrexed dose escalation
219292507|NCT00701857|RADIATION|radiation therapy|Weekly standard dose radiation therapy
219292508|NCT04990011|PROCEDURE|BioXclude amnion chorion membrane|The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
219292509|NCT00647933|DRUG|Org 36286|Subcutaneous Org 36286
219292510|NCT00647933|DRUG|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
219292511|NCT02199223|DRUG|regorafenib + panitumumab|
219292512|NCT03501602|DEVICE|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
219292513|NCT03501602|DEVICE|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
219292514|NCT02942524|OTHER|Communication Intervention|Complete TEPID
219292515|NCT02942524|OTHER|Questionnaire Administration|Ancillary studies
219292516|NCT02942524|OTHER|Survey Administration|Ancillary studies
219292517|NCT01226342|DEVICE|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
219292518|NCT03975751|DIAGNOSTIC_TEST|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
219292519|NCT05084170|PROCEDURE|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
219292520|NCT00412152|DRUG|Oxycodone nalaxone prolonged release tablets (OXN)|
219292521|NCT02703259|DRUG|Gabapentin|
219292522|NCT02703259|DRUG|Acetaminophen|
219292523|NCT02703259|DRUG|Celecoxib|
219292524|NCT02682277|DEVICE|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
219292525|NCT02682277|OTHER|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
219292526|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Lumenless leads|Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
219292527|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Stylet-driven leads|Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE \& Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
219292528|NCT02666859|DEVICE|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
219292529|NCT02615002|DRUG|Piromelatine|
219292530|NCT02615002|DRUG|Placebo|
219292531|NCT06352684|DEVICE|CadAI-B for Breast|CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.
219292532|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
219292533|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
219292534|NCT05308797|PROCEDURE|ESP block|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
219292535|NCT05308797|PROCEDURE|CASP block|Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
219292536|NCT01834872|DEVICE|Amigo|
219292537|NCT01834872|DEVICE|Manual ablation|
219292538|NCT02920580|PROCEDURE|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
219292539|NCT02920580|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
219292540|NCT04670289|DRUG|TenoMiR (Low Dose)|Mimic of miR29a
219292541|NCT04670289|DRUG|TenoMiR (Medium Dose)|Mimic of miR29a
219292542|NCT04670289|DRUG|TenoMiR (High Dose)|Mimic of miR29a
219292543|NCT04670289|DRUG|Placebo|0.9% saline
219292544|NCT04835350|DEVICE|Pancreas4ALL - meal announcement or full closed loop|Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
219292545|NCT00294606|DRUG|Comparison of Effects of Phenylephrine and Norepinephrine|
219292546|NCT04549896|PROCEDURE|CT scan|Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.
219292547|NCT04549896|PROCEDURE|No CT scan|The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
219292548|NCT02544451|DRUG|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
219292549|NCT02544451|DRUG|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
219292550|NCT04306406|OTHER|Raspberries|Red raspberry smoothies drink
219292551|NCT04642300|PROCEDURE|Holmich Protocol|"Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board"
219292552|NCT04642300|PROCEDURE|Myofascial Release Technique|"1. Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~2. Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique"
219292553|NCT05068141|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
219292554|NCT05068141|DRUG|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
219292555|NCT02417519|OTHER|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
219292556|NCT02417519|OTHER|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
219292557|NCT02417519|OTHER|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
219292558|NCT02554227|OTHER|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
219292559|NCT02555852|DRUG|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
219292560|NCT02555852|DRUG|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
219292561|NCT02555852|DRUG|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
219292562|NCT02555852|DRUG|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
219292563|NCT02555852|DRUG|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
219292564|NCT02555852|DRUG|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
219292565|NCT02555852|DRUG|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
219292566|NCT02555852|DRUG|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
219292567|NCT02555852|DRUG|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
219292568|NCT02555852|DRUG|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
219292569|NCT02555852|DRUG|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
219292570|NCT02555852|DRUG|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
219292571|NCT02555852|DRUG|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
219292572|NCT02555852|DRUG|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
219292573|NCT02555852|DRUG|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
219292574|NCT03001076|DRUG|Bempedoic acid|bempedoic acid 180 mg tablet
219292575|NCT03001076|DRUG|Ezetimibe|ezetimibe 10 mg tablet
219292576|NCT03001076|OTHER|Placebo|matching placebo tablet
219292577|NCT02316951|DEVICE|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
219292578|NCT01369771|DRUG|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
219292579|NCT03581760|OTHER|Cycling Exercise|Cycling exercise will be performed in the patients once a day.
219292580|NCT03581760|OTHER|Conventional Physiotherapy|Conventional physiotherapy will be performed in the patients twice a day.
219292581|NCT02823405|DRUG|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
219292582|NCT02823405|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
219292583|NCT05253287|DRUG|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
219292584|NCT04463966|DRUG|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
219292585|NCT01327443|BEHAVIORAL|Weight loss|Nutritional counseling
219292586|NCT01327443|BEHAVIORAL|Exercise|Under direct supervision
219292587|NCT02505438|BEHAVIORAL|Exercise|
219292588|NCT00948766|DRUG|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.
219292589|NCT00948766|DRUG|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.
219292590|NCT00948766|DRUG|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.
219292591|NCT00948766|DRUG|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
219292592|NCT04394468|DEVICE|PlasmaJet|Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
219292593|NCT02769767|GENETIC|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
219292594|NCT00351663|DRUG|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day"
219292595|NCT04937972|DRUG|SHR-1701 Combined With Fluazopalil|SHR-1701 +fluzoparib
219292596|NCT02235389|DRUG|Alteplase (Actilyse)|
219292597|NCT02235389|DRUG|Standard therapy|
219292598|NCT00841555|DRUG|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
219292599|NCT00841555|RADIATION|Hypofractionated radiation therapy|Patients will undergo HIMRT
219292600|NCT00841555|RADIATION|Intensity-modulated radiation therapy|Patients undergo HIMRT
219292601|NCT03803839|DRUG|Clodronate|
219292602|NCT03803839|DRUG|Saline|
219292603|NCT01843790|DRUG|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
219292604|NCT01843790|DRUG|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
219292605|NCT05460403|RADIATION|Adjuvant Radiotherapy|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
219292606|NCT02773563|OTHER|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
219292607|NCT02773563|OTHER|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
219292608|NCT05613387|DRUG|ZP8396|"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
219292609|NCT05613387|DRUG|Drug: Placebo (ZP8396)|"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
219292610|NCT02842801|OTHER|Hip manipulation|High-amplitude and low-velocity thrust mobilization
219292611|NCT01036438|DEVICE|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
219292612|NCT01036438|DEVICE|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
219292613|NCT00655018|DIETARY_SUPPLEMENT|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
219292614|NCT00655018|DIETARY_SUPPLEMENT|Placebo|placebo and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
219292615|NCT05714345|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
219292616|NCT05714345|DRUG|Fludarabine|Chemotherapy for lymphodepletion
219292617|NCT05714345|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
219292618|NCT05714345|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
219292619|NCT00659659|DRUG|MEDI-563|1.0 mg/kg IV: MEDI-563
219292620|NCT00659659|DRUG|MEDI-563|100 mg, 200 mg SC
219292621|NCT00659659|OTHER|Placebo Comp.|Placebo SC
219292622|NCT00659659|OTHER|Placebo|Placebo as a single IV infusion (Certain number of subjects)
219292623|NCT04592120|BEHAVIORAL|Coalition Check-Up|The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
219292624|NCT02977273|OTHER|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
219292625|NCT02977273|OTHER|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
219292626|NCT02977273|OTHER|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
219292627|NCT02977273|OTHER|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
219292628|NCT02153073|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
219292629|NCT05333692|DIETARY_SUPPLEMENT|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
219292630|NCT05333692|DIETARY_SUPPLEMENT|NEPRO® , Abbott|2-4 cans NEPRO® per day
219292631|NCT05812417|DRUG|DA-8010|DA-8010 5mg single dose administration
219292632|NCT03592550|DEVICE|Ultrasound imaging|Abdominal ultrasound imaging of the liver
219292633|NCT03702231|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
219292634|NCT05924308|OTHER|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
219292635|NCT05924308|OTHER|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
219292636|NCT02076438|DIETARY_SUPPLEMENT|Probiotics|Randomized to receive probiotics or placebo
219292637|NCT02443454|DEVICE|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
219292638|NCT02443454|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
219292639|NCT02039232|DEVICE|Pedicle screw system|
219292640|NCT03134794|BEHAVIORAL|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
219292641|NCT02505386|DRUG|Ertapenem|
219292642|NCT03301129|BEHAVIORAL|Smoke|See arm/group descriptions.
219292643|NCT03090828|BEHAVIORAL|app-based therapeutic education|Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
219292644|NCT03090828|BEHAVIORAL|enhanced app-based therapeutic education|Patients in the enhanced app group will also have access to a social network. (forum, chat room)
219292645|NCT01367639|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
219292646|NCT03590366|BIOLOGICAL|B244|B244 Suspension
219292647|NCT03590366|BIOLOGICAL|Vehicle|Vehicle suspension
219292648|NCT05305924|DRUG|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
219292649|NCT04570215|OTHER|Gotcha! Therapy application|"Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item."
219292650|NCT04570215|OTHER|Gotcha Therapy application: Maintenance|Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
219292651|NCT03796962|DRUG|XEN1101|Oral dose
219292652|NCT02137317|DEVICE|LAPPE (locally adapted personal protective equipment)|"* Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
219292653|NCT01413503|RADIATION|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
219292654|NCT01373151|DRUG|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
219292655|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
219292656|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
219292657|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
219292658|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
219292659|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
219292660|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
219292661|NCT01373151|DRUG|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
219292662|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
219292663|NCT01373151|DRUG|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
219292664|NCT01373151|DRUG|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
219292665|NCT04519866|OTHER|Electroacupuncture|"Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms."
219292666|NCT04519866|OTHER|Manual acupuncture|"After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above)."
219292667|NCT01363544|OTHER|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
219292668|NCT01363544|BEHAVIORAL|Exercise|30 sessions of individual sports training during 10 weeks.
219292669|NCT01363544|DRUG|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
219292670|NCT00128531|DRUG|leuprolide acetate|
219292671|NCT05458570|OTHER|Breast Cancer positive patients|
219292672|NCT01714661|DRUG|EVP-6124|Arms 1, 2
219292673|NCT01714661|DRUG|Placebo|Arm 3
219292674|NCT00293059|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
219292675|NCT00293059|DRUG|Placebo|Matching placebo to be taken orally daily.
219292676|NCT05630534|DRUG|Minocycline|Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
219292677|NCT05630534|OTHER|starch|Use starch capsules as placebo
219292678|NCT00970762|DRUG|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
219292679|NCT00970762|DRUG|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
219292680|NCT00970762|DRUG|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
219292681|NCT00970762|DRUG|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
219292682|NCT00970762|DRUG|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
219292683|NCT00970762|DRUG|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
219292684|NCT00970762|DRUG|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
219292685|NCT03970538|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
219292686|NCT04548102|OTHER|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
219292687|NCT01983189|PROCEDURE|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
219292688|NCT03583775|OTHER|Cardiovascular Magnetic Resonance Imaging|Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
219292689|NCT02408991|DRUG|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
219292690|NCT02408991|DEVICE|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
219292691|NCT00704899|PROCEDURE|Physiotherapy|Structured exercise regimen
219292692|NCT00704899|DRUG|Amitryptiline|Amitryptiline 25mg once daily
219292693|NCT03506074|DIAGNOSTIC_TEST|Flavor test|The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
219292694|NCT02290080|DRUG|Oxygen|see arm description
219292695|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
219292696|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
219292697|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
219292698|NCT01035567|PROCEDURE|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
219292699|NCT01035567|PROCEDURE|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
219292700|NCT04270253|PROCEDURE|Conservative therapy|Conservative therapy including aquatic exercises, land-based exercises, balneotherapy, TENS therapy
219292701|NCT04270253|PROCEDURE|Manual therapy|End-range mobilization
219292702|NCT04744493|DEVICE|ExaBlate 4000|The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
219292703|NCT00501280|BEHAVIORAL|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
219292704|NCT04327297|DIETARY_SUPPLEMENT|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
219292705|NCT00045773|DRUG|Sertraline|50 - 200mg, once per day for 12 weeks.
219292706|NCT03399851|DEVICE|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
219292707|NCT03399851|DEVICE|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
219292708|NCT04827472|DRUG|Normal saline|100ml
219292709|NCT04827472|DRUG|DWJ1521|Single dose
219292710|NCT04827472|DRUG|DWP14012 Tablet|Single dose, Tablet
219296495|NCT02214056|PROCEDURE|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
219292711|NCT02790827|BEHAVIORAL|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
219292712|NCT02790827|BEHAVIORAL|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
219292713|NCT04152057|DRUG|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
219292714|NCT04152057|DRUG|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
219292715|NCT04152057|DRUG|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
219292716|NCT01447940|DEVICE|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
219292717|NCT00143208|DRUG|Xalacom|
219292718|NCT00419081|DRUG|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
219292719|NCT00419081|DRUG|Forodesine Hydrochloride Capsules (100 mg)|
219292720|NCT00878826|DRUG|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
219292721|NCT01468181|DRUG|LY2189265|
219292722|NCT01468181|DRUG|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
219292723|NCT01468181|DRUG|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
219292724|NCT01468181|DRUG|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
219292725|NCT01468181|DRUG|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
219292726|NCT01468181|DRUG|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
219292727|NCT04888962|OTHER|OUD|History of opioid use disorder.
219292728|NCT04337541|OTHER|Surgical facial mask|Participants will follow normal Authority recommendations AND wear mask outside their homes, or when receiving visits in their home.
219292729|NCT05353075|OTHER|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
219296496|NCT02588105|DRUG|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
219296497|NCT02588105|DRUG|Olaparib|Module 1 combination with olaparib
219296498|NCT02588105|DRUG|irinotecan|Module 2 combination with irinotecan/FOLFIRI
219296499|NCT02588105|DRUG|Fluorouracil|Module 2 combination with irinotecan/FOLFIRI
219296500|NCT02588105|DRUG|Folinic Acid|Module 2 combination with irinotecan/FOLFIRI
219296501|NCT00950222|DRUG|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
219292730|NCT05353075|OTHER|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
219292731|NCT04828837|DEVICE|bubble PEP|Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
219292732|NCT04953559|DEVICE|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
219292733|NCT04953559|DEVICE|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
219292734|NCT02209870|BEHAVIORAL|E-checklist Group|The patient group after E-checklist system deployed
219292735|NCT02729064|DRUG|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
219292736|NCT02729064|DRUG|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
219292737|NCT06150170|OTHER|Proprioceptive training|Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.
219292738|NCT00297505|DRUG|citalopram|
219292739|NCT00545753|DRUG|Spinosad|10 minute topical application product, following by a complete rinse off.
219292740|NCT00545753|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
219292741|NCT00545753|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
219292742|NCT05031715|DIETARY_SUPPLEMENT|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
219292743|NCT01383564|PROCEDURE|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
219292744|NCT01383564|PROCEDURE|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
219292745|NCT04851353|BEHAVIORAL|GT+VC|Gentle touch and verbal comfort,
219292746|NCT04851353|BEHAVIORAL|Smell|Smell breast milk
219292747|NCT04851353|BEHAVIORAL|Taste|Taste breast milk
219292748|NCT04616729|DRUG|Triptorelin 3.75 MG Injection|Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
219292749|NCT04616729|PROCEDURE|Transvaginal oocyte retrieval|Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
219292750|NCT04616729|DRUG|Triptorelin Injection|Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
219292751|NCT06005545|DEVICE|Passive Ultrasonic Irrigation (PUI) group|Passive ultrasonic irrigation is the current golden standard in root canal cleaning and irrigation devices. It is used after root canal shaping using manual or rotary instruments. It uses sodium hypochlorite which is mobilized in the canal using ultrasonic non-cutting tips to clean, debride, disinfect, and prepare the root canal for obturation.
219292752|NCT06005545|DEVICE|Endoclean (EC) group|Endoclean is a novel device that uses hydraulic inertial cavitation with the help of pressure and saline solution to debride the root canal after minimal shaping using manual or rotary shaping instruments. It is used to effectively clean, debride and prepare the root canal before obturation in the root canal treatment procedure.
219292753|NCT06005545|DEVICE|Conventional group|Conventional root canal preparation uses manual or rotary files along with manual irrigation using syringes and irrigant solutions like sodium hypochlorite or EDTA to clean, debride and prepare the root canal for obturation.
219292754|NCT03529682|OTHER|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
219292755|NCT03529682|OTHER|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
219292756|NCT05637359|DEVICE|Tracked ultrasound measurement|"Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself."
219292757|NCT01026506|DIETARY_SUPPLEMENT|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
219296502|NCT00544375|DEVICE|Optical measurement|Optical measurement neonatal tissues
219296503|NCT02199743|DRUG|Lurasidone|Compare to haloperidol and perphenazine
219296504|NCT02199743|DRUG|Haloperidol|Compare to lurasidone
219296505|NCT02199743|DRUG|Perphenazine|Compare to lurasidone
219296506|NCT00775463|DRUG|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
219296507|NCT00775463|DRUG|placebo|
219292758|NCT06131606|BEHAVIORAL|experimental group|Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
219292759|NCT00119457|DRUG|TTP889|
219292760|NCT01696903|PROCEDURE|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
219292761|NCT05539144|RADIATION|"Oropharyngeal mucosa"|"Oropharyngeal mucosa was delineated as OARs and limiting its dose"
219292762|NCT05539144|RADIATION|oropharynx|oropharynx was delineated as OARs and limiting its dose
219292763|NCT05539144|RADIATION|"oropharynx and oropharyngeal mucosa"|"oropharynx and oropharyngeal mucosawere delineated as OARs and limiting its dose"
219292764|NCT04389203|PROCEDURE|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
219292765|NCT04389203|PROCEDURE|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
219292766|NCT01810458|DEVICE|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
219292767|NCT01810458|PROCEDURE|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
219292768|NCT01810458|PROCEDURE|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
219292769|NCT01810458|PROCEDURE|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
219292770|NCT01810458|OTHER|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
219292771|NCT01810458|PROCEDURE|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
219292772|NCT01810458|DRUG|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219296508|NCT03274167|DRUG|Gabapentin 300mg|
219296509|NCT03274167|DRUG|Placebo oral capsule|
219292773|NCT01810458|DRUG|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219292774|NCT01810458|DRUG|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219292775|NCT01810458|DRUG|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219292776|NCT01810458|DRUG|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219292777|NCT01810458|DRUG|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219292778|NCT01810458|DRUG|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
219296510|NCT04310384|DEVICE|ShuttleScope|Alternative intervention
219292779|NCT02310867|DRUG|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
219292780|NCT02310867|PROCEDURE|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
219292781|NCT03787836|BEHAVIORAL|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
219292782|NCT03787836|BEHAVIORAL|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
219292783|NCT02861235|OTHER|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
219292784|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
219292785|NCT02861235|OTHER|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
219292786|NCT02861235|OTHER|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
219292787|NCT02861235|OTHER|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
219292788|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
219292789|NCT05424497|OTHER|Vignettes|Presenting vignettes with fictive cases
219292790|NCT00821717|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
219292791|NCT00821717|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
219292792|NCT00102739|DRUG|SB497115|
219292793|NCT04904939|PROCEDURE|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
219292794|NCT00685906|DRUG|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
219292795|NCT00685906|DRUG|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
219292796|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
219292797|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
219292798|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
219292799|NCT01453400|DRUG|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
219292800|NCT01453400|DRUG|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
219292801|NCT01453400|DRUG|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
219292802|NCT03676491|OTHER|Music Intervention|Music intervention
219292803|NCT03545802|BEHAVIORAL|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
219292804|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
219292805|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
219292806|NCT04281459|OTHER|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
219292807|NCT01423227|BEHAVIORAL|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
219292808|NCT01423227|BEHAVIORAL|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
219292809|NCT02025959|BEHAVIORAL|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
219292810|NCT00031876|DRUG|capecitabine|
219292811|NCT00031876|DRUG|paclitaxel|
219292812|NCT04044898|DRUG|ALA 5%|prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose
219292813|NCT04044898|DRUG|ALA 10%|prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
219292814|NCT02297139|DRUG|Dasatinib|
219292815|NCT01651221|OTHER|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
219292816|NCT00606060|DRUG|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
219292817|NCT05213494|OTHER|Inulin|Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
219296511|NCT04310384|DEVICE|MacIntosh Laryngoscope|Gold Standart
219296512|NCT00346671|OTHER|Rest|30 min supine rest
219292818|NCT05213494|OTHER|soluble corn fiber|soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
219292819|NCT04451967|PROCEDURE|thrombolysis|transfer after thrombolysis for STEMI patients within 6h since onset
219292820|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
219292821|NCT05171478|DIAGNOSTIC_TEST|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
219292822|NCT00066313|DRUG|vandetanib|
219292823|NCT00066313|PROCEDURE|adjuvant therapy|
219292824|NCT03367429|DRUG|Botox|THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
219292825|NCT01921010|DRUG|Niaspan|See Arm Description
219292826|NCT01921010|DRUG|Placebo|See Arm Description
219292827|NCT00867204|PROCEDURE|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
219292828|NCT01942785|DRUG|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
219292829|NCT05657652|DRUG|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
219292830|NCT06374017|DRUG|Normal saline, Lidocaine, dexmetomidine|The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.
219292831|NCT06251284|OTHER|Saline nasal spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
219292832|NCT06089096|DIAGNOSTIC_TEST|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
219292833|NCT05170633|DEVICE|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
219292834|NCT06027671|BEHAVIORAL|Group SPARCS Intervention|Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
219292835|NCT06027671|BEHAVIORAL|ART-SPARCS Intervention|"ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
219292836|NCT06417697|DRUG|XEN-101|capsule formulation
219292837|NCT06417697|DRUG|Placebo|capsule formulation
219292838|NCT02227199|DRUG|Brentuximab Vedotin|Given IV
219292839|NCT02227199|DRUG|Carboplatin|Given IV
219292840|NCT02227199|DRUG|Etoposide|Given IV
219292841|NCT02227199|DRUG|Ifosfamide|Given IV
219292842|NCT02227199|OTHER|Laboratory Biomarker Analysis|Correlative studies
219292843|NCT05003856|OTHER|Quality-of-Life Assessment|Ancillary studies
219292844|NCT05003856|PROCEDURE|Radiofrequency Ablation|Undergo RFA
219292845|NCT06414720|DRUG|Dienogest 2 MG|The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
219292846|NCT05183152|DEVICE|NMES Feedback|Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
219292847|NCT05183152|DEVICE|Visual Feedback|Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
219292848|NCT05183152|DEVICE|TESS|Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
219292849|NCT04613583|OTHER|SAFeR fetuses|NO active intervention performed.
219292850|NCT06784999|DRUG|sufentanil|1\. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
219292851|NCT06784999|DRUG|methadone|2\. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
219292852|NCT06260397|PROCEDURE|serratus anterior plane block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
219292853|NCT06260397|PROCEDURE|costotransverse block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
219292854|NCT06260397|PROCEDURE|patient controlled analgesia|PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
219292855|NCT04375072|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
219292856|NCT04375072|DEVICE|sham tDCS paired with active MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
219292857|NCT04375072|DEVICE|active tDCS paired with sham MBM|Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
219292858|NCT04375072|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
219292859|NCT05717101|OTHER|Electronic Health Record Review|Review of medical records
219292860|NCT05676034|DRUG|AMX0035|AMX0035
219292861|NCT06202612|DRUG|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
219292862|NCT06202612|DRUG|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
219292863|NCT05866822|OTHER|APA|24 APA sessions
219292864|NCT05866822|OTHER|PAE|8 individuals sessions of PAE
219292865|NCT04903197|DRUG|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
219292866|NCT04903197|DRUG|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
219292867|NCT05597787|BEHAVIORAL|HIV Connect|online education and clinical skills
219292868|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention|education and clinical skills
219292869|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
219292870|NCT06520124|DEVICE|Essilor® Stellest® spectacle lens|Spectacle lens with highly aspherical lenslets.
219292871|NCT06520124|DEVICE|Single-vision spectacle lens|Standard single-vision distance spectacle lens.
219292872|NCT06222580|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219292873|NCT06222580|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219292874|NCT06222580|DRUG|Gilteritinib|Given PO
219292875|NCT06222580|DRUG|Revumenib|Given PO
219292876|NCT04827901|DRUG|XEN1101|two 10 mg capsules
219292877|NCT04827901|DRUG|Placebo|matching placebo
219292878|NCT04874818|DIAGNOSTIC_TEST|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
219292879|NCT05646888|BIOLOGICAL|Blood sampling|the blood sample will be taken during a planned blood sampling
219292880|NCT06006780|DEVICE|Porcine acellular dermal matrix|Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage
219292881|NCT06006780|OTHER|Coronally advanced flap (CAF)|Coronally advanced flap for root coverage
219292882|NCT05695846|DEVICE|externally applied cricoid cartilage pressure|
219296513|NCT00346671|OTHER|Sham|30 min session with Sham practitioner
219296514|NCT00346671|OTHER|Reiki|30 min session with Reiki practitioner
219296515|NCT00555724|DRUG|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
219296516|NCT02368028|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
219292883|NCT04758065|OTHER|Radial pressure waves Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Experimental Group: Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves."
219296517|NCT05163782|DEVICE|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
219292884|NCT04758065|OTHER|Therapeutic Exercise and Manual Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy."
219292885|NCT05169593|DRUG|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
219292886|NCT04512430|DRUG|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles \> 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
219292887|NCT04512430|DRUG|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
219292888|NCT04512430|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
219292889|NCT04512430|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
219292890|NCT05598281|DRUG|AMG 510|Oral tablet
219292891|NCT05598281|DRUG|Digoxin|Oral tablet
219292892|NCT05920720|BEHAVIORAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
219292893|NCT05937373|DEVICE|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
219292894|NCT05937373|OTHER|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
219292895|NCT05453201|BEHAVIORAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
219292896|NCT04242069|BEHAVIORAL|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
219292897|NCT04242069|OTHER|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
219292898|NCT04040218|PROCEDURE|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
219292899|NCT04168970|PROCEDURE|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
219292900|NCT05308030|DRUG|Rivaroxaban and Aspirin|After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
219292901|NCT03453853|DEVICE|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
219292902|NCT02284217|DEVICE|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
219292903|NCT05479032|DRUG|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
219292904|NCT04534959|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
219292905|NCT01363570|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
219292906|NCT04265352|OTHER|No intervension|There is intervention at all.
219292907|NCT04073004|BEHAVIORAL|Rapid Resolution Therapy|psychotherapy that includes trance states
219292908|NCT06340360|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
219292909|NCT06340360|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
219292910|NCT04688320|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
219292911|NCT04688320|DRUG|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
219292912|NCT04777201|DRUG|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
219292913|NCT04777201|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
219292914|NCT00552929|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered."
219292915|NCT05456906|OTHER|No intervention|No interventions
219292916|NCT05701774|DRUG|DCCR|Once daily oral administration
219292917|NCT04809506|BIOLOGICAL|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
219292918|NCT06050759|DIAGNOSTIC_TEST|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
219292919|NCT05881135|DRUG|Citicoline|i.v. bolus administration every 12 hours for 5 days.
219292920|NCT05881135|DRUG|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
219292921|NCT00181142|DRUG|Zenapax|
219292922|NCT05241353|BEHAVIORAL|Reduced Frequency Self-Monitoring|Participants will be asked to record only a subset of daily eating throughout the intervention, with the prescription for self-monitoring individually tailored at baseline dependent on participants' self-reported eating patterns.
219292923|NCT05241353|BEHAVIORAL|Full-Frequency Self-Monitoring|Participants will be asked to record all contents of their diet throughout the intervention.
219292924|NCT05241353|BEHAVIORAL|Standard Behavioral Treatment|Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
219292925|NCT01200290|DRUG|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
219292926|NCT03725111|DEVICE|venous compression|venous compression
219292927|NCT03532503|DEVICE|Foley catheter|Transcervical foley catheter will be applied
219296518|NCT05163782|DEVICE|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
219292928|NCT05555147|DRUG|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
219292929|NCT05555147|OTHER|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
219292930|NCT05375097|OTHER|Erenumab|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
219292931|NCT04419727|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
219292932|NCT03092817|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
219292933|NCT03092817|OTHER|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
219292934|NCT03889145|DRUG|Telmisartan 80mg|Telmisartan 80mg
219292935|NCT03889145|DRUG|Amlodipine10mg|Amlodipine 10mg
219292936|NCT03889145|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
219292937|NCT00728910|DRUG|Atorvastatin|10 mg QD for 4 weeks
219292938|NCT00728910|DRUG|ABT335|135 mg QD added to atorvastatin for 8 weeks
219292939|NCT00728910|DRUG|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
219292940|NCT00769262|OTHER|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
219292941|NCT00769262|OTHER|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
219292942|NCT05845541|BEHAVIORAL|Technology Supported Meditation and Biofeedback|"Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed."
219292943|NCT05845541|OTHER|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
219296519|NCT05163782|DEVICE|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
219296520|NCT05163782|DEVICE|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
219296521|NCT00003424|DRUG|tamoxifen citrate|
219296522|NCT06422468|DEVICE|FibriCheck recordings|PPG, ACC, GYR, ECG and sound measurements
219296523|NCT04541784|OTHER|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
219292944|NCT06248437|OTHER|innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage|All participants completed a survey on sociodemographic data (age, sex, respiratory problems, smoking, among others). Weight, height, skin folds, and a blood sample were taken to quantify the Oxygen Radical Absorption Capacity (ORAC) units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and lipid profile. At that time, they were explained how they should eat the nutraceutical food, starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant
219292945|NCT04155203|DRUG|Mupirocin Calcium|mupirocin cream
219292946|NCT04155203|DRUG|Mupirocin Calcium|Reference mupirocin cream
219292947|NCT04155203|DRUG|Vehicle|vehicle control cream
219296524|NCT04541784|OTHER|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
219292948|NCT06240013|OTHER|Foam Rolling|Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.
219292949|NCT06240013|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
219292950|NCT04199845|DIETARY_SUPPLEMENT|PS128|PS128 or placebo will be given twice daily for 8 weeks.
219292951|NCT05756270|DIAGNOSTIC_TEST|pCASL|Brain 3 Tesla MRI with pCASL sequence
219292952|NCT05867277|OTHER|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
219292953|NCT06052670|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)
219292954|NCT00669279|DRUG|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
219292955|NCT00669279|DRUG|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
219292956|NCT04168983|OTHER|sophrology|Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
219292957|NCT01147536|BIOLOGICAL|HSPPC-96|
219292958|NCT00116597|GENETIC|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
219292959|NCT00116597|BIOLOGICAL|Intranodal booster immunizations with synthetic melanoma associated epitopes|
219292960|NCT04747197|DRUG|EYP-1901|Intravitreal injection
219292961|NCT04914429|DRUG|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
219292962|NCT04914429|DRUG|Placebo|Matching placebo will be administered as a SC injection.
219292963|NCT05963347|DRUG|Golidocitinib|Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
219292964|NCT05963347|DRUG|CHOP Regimen|CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
219292965|NCT00576563|DRUG|FDG|contrast medium
219292966|NCT06104813|OTHER|Interviews|Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
219292967|NCT00246220|DRUG|methylphenidate hydrochloride|
219292968|NCT06045052|DRUG|Eltrombopag|Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
219292969|NCT02489968|DRUG|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
219292970|NCT02489968|DRUG|empagliflozin 10 mg|empagliflozin low dose once daily
219292971|NCT02489968|DRUG|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
219292972|NCT02489968|DRUG|empagliflozin 25 mg|empagliflozin high dose once daily
219292973|NCT02489968|DRUG|Placebo|
219292974|NCT01728337|DRUG|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
219292975|NCT01728337|DRUG|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
219296525|NCT03289429|DRUG|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
219292976|NCT03011762|DEVICE|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
219292977|NCT02651532|DEVICE|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
219292978|NCT06415526|PROCEDURE|OPERA|Robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction
219292979|NCT04637269|BIOLOGICAL|anti-BCMA CAR-T|5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
219292980|NCT02371590|DRUG|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
219292981|NCT02371590|DRUG|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
219292982|NCT00263367|OTHER|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
219292983|NCT03890003|DEVICE|AID System|AID system
219292984|NCT03890003|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
219292985|NCT01640405|DRUG|modified FOLFOX6 + bevacizumab|"* Bevacizumab 5 mg/kg iv, day 1, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~  * LV 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
219292986|NCT01640405|DRUG|FOLFOXIRI + Bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~* LV 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
219292987|NCT02156323|DRUG|CMS|Multiple doses of CMS over 2.5 days
219292988|NCT02156323|DRUG|RO7033877|Multiple doses of RO7033877 over 2.5 days
219292989|NCT02156323|DRUG|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
219292990|NCT04577001|DRUG|Letrozole|2.5 mg orally daily for 6 months
219292991|NCT04577001|DRUG|Placebo|No active ingredient taken orally daily for 6 months
219292992|NCT00507403|DRUG|infliximab|
219292993|NCT05986500|OTHER|Galactose|The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)
219292994|NCT05986500|OTHER|No intervention|The participants will receive a saline infusion
219292995|NCT04558892|DRUG|Enoxaparin|
219292996|NCT01241604|DEVICE|BiPAP S/T|Mechanical Non-invasive Ventilation
219292997|NCT01241604|DEVICE|BiPAP Auto SV3|Auto Servo Ventilation Device
219292998|NCT00360217|DRUG|docosahexanoic acid (DHA)|
219292999|NCT03093623|BEHAVIORAL|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points \* time of each exercise (hours) \* Number of times per week + moderate level 5 points \* time per activity (hours) \* number of times per week + low level 3 points \* time per activity (hours) \* number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (\>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
219293000|NCT05148910|DEVICE|Silver and copper IUD (TCu380Ag)|An intrauterine device containing 380mm² of copper with a silver core.
219293001|NCT05148910|DEVICE|Copper IUD (TCu380A)|An intrauterine device containing 380mm² of copper.
219293002|NCT06170177|PROCEDURE|Radical Cystectomy|A radical cystectomy is an operation to remove the whole bladder
219293003|NCT04668040|OTHER|Muscle energy technique|Muscle energy technique for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
219293004|NCT04668040|OTHER|Stretching|Stretching exercises for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
219293005|NCT02960243|DEVICE|Deep Brain Stimulation|"* DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well"
219293006|NCT05359887|OTHER|standardized liquid mixed meal Nutridrink®|Administration of food in controlled situation
219293007|NCT00631839|RADIATION|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies \>=6MV.
219293008|NCT01593787|DRUG|LCZ696|100 mg, 200 mg, 400 mg tablets.
219293009|NCT04002843|OTHER|paraclinical evaluation of single fibre|ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
219293010|NCT02296333|DRUG|ondansetron|8 mg intravenous in the skin closure
219293011|NCT02296333|DRUG|isotonic|8 mg intravenous in the skin closure
219293012|NCT00588900|DRUG|cediranib maleate|
219293013|NCT00588900|DRUG|irinotecan hydrochloride|
219293014|NCT02828787|OTHER|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
219293015|NCT05526651|OTHER|true electroacupuncture|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
219293016|NCT05526651|OTHER|sham electroacupuncture|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
219293017|NCT05241600|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
219293018|NCT05241600|BEHAVIORAL|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
219293019|NCT00816790|DRUG|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
219293020|NCT00816790|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
219293021|NCT04353505|DRUG|Ketorolac|Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
219293022|NCT04353505|DRUG|Dexamethasone|Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
219293023|NCT04996446|DRUG|Tislelizumab|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
219293024|NCT04996446|PROCEDURE|ALPPS surgery|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
219293025|NCT01865747|DRUG|Cabozantinib tablets|
219293026|NCT01865747|DRUG|Everolimus (Afinitor) tablets|
219293027|NCT01717742|DRUG|TPA (Tissue Plasminogen Activator)|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
219293028|NCT01717742|DRUG|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
219293029|NCT01717742|OTHER|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (\>10 kg)
219293030|NCT06215885|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics|Detecting genomic and proteomic information
219293031|NCT02859740|OTHER|SIGAM Questionnaire|
219293032|NCT04192253|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
219293033|NCT05609903|DRUG|Atezolizumab in combination with nab-paclitaxel|Treatment of patients with stage IV triple negative breast cancer with Atezolizumab in combination with nab-paclitaxel
219293034|NCT03066349|OTHER|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
219293035|NCT05454332|DRUG|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
219293036|NCT05454332|OTHER|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
219293037|NCT01970722|DRUG|Carboplatin|Given IP or IV
219293038|NCT01970722|DRUG|Cisplatin|Given IP
219293039|NCT01970722|DRUG|Gemcitabine Hydrochloride|Given IP or IV
219293040|NCT01970722|OTHER|Laboratory Biomarker Analysis|Correlative studies
219293041|NCT01970722|DRUG|Paclitaxel|Given IP or IV
219293042|NCT01970722|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
219293043|NCT01970722|OTHER|Quality-of-Life Assessment|Ancillary studies
219293044|NCT01970722|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219293045|NCT03465904|DEVICE|Verum Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
219293046|NCT03465904|DEVICE|Sham Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
219293047|NCT01916148|DRUG|18F-DOPA|18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.
219293048|NCT03899402|DRUG|Insulin|Standard of care insulin for pump or injection and serves as a control
219293049|NCT03899402|DRUG|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
219293050|NCT03899402|DRUG|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
219293051|NCT03899402|DRUG|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
219293052|NCT03696797|PROCEDURE|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
219293053|NCT03696797|PROCEDURE|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
219293054|NCT03222804|DIETARY_SUPPLEMENT|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
219293055|NCT05397691|OTHER|Modified Family Talk|The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
219293056|NCT05397691|OTHER|Control-like parameter estimation|Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
219293057|NCT05816538|PROCEDURE|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
219293058|NCT05816538|PROCEDURE|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
219293059|NCT05816538|DEVICE|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
219293060|NCT05816538|DEVICE|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)\], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
219296526|NCT03289429|DRUG|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
219293061|NCT05816538|DRUG|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
219293062|NCT05816538|PROCEDURE|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium \[Zemuron®, Schering - Plow\] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium \[Zemuron®, Schering - Plow\] 0.01 mg / kg / min per perfusor.
219293063|NCT06414603|DIAGNOSTIC_TEST|The Prospera™ Test|"The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory."
219293064|NCT03877497|BEHAVIORAL|Adapted SBIRT-T for transgender women|Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
219293065|NCT05119179|DRUG|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
219293066|NCT05924438|DRUG|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
219293067|NCT05924438|DRUG|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
219293068|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
219293069|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at HCG|Ultrasound
219293070|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
219293071|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
219293072|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at HCG|Ultrasound
219293073|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at TVOR|Ultrasound
219293074|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at ET|Ultrasound scan
219293075|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at coordination scan|Ultrasound scan
219293076|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at HCG|Ultrasound scan
219293077|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at TVOR|Ultrasound scan
219293078|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at ET|Ultrasound scan
219293079|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at coordination scan|Ultrasound scan
219293080|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at HCG|Blood test
219293081|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at TVOR|Blood test
219293082|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at ET|Blood test
219293083|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at coordination scan|Blood test
219293084|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between TVOR and ET|Ultrasound scan
219293085|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at HCG|Blood test
219293086|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at TVOR|Blood test
219293087|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at ET|Blood test
219293088|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at coordination scan|Blood test
219293089|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at HCG|Ultrasound scan
219293090|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
219293091|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at ET|Ultrasound scan
219293092|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
219293093|NCT03860636|DIAGNOSTIC_TEST|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
219293094|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
219293095|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between HCG and ET|Ultrasound scan
219293096|NCT04423523|DIAGNOSTIC_TEST|Blood drop sampling|For each patient included, 1 additional EDTA blood tube (2 ml) will be collected for research purposes at different times (4 visits), and 1 PAXgene-type tube adapted for pediatric collection of only 500 μl (2 visits).
219293097|NCT05087758|OTHER|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
219293098|NCT05087758|OTHER|Conventional Care Wound Management|Advanced wound care with debridement and dressings
219293099|NCT05543382|DEVICE|Axonics System|The Axonics System will be implanted as standard care
219293100|NCT00673010|RADIATION|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
219293101|NCT05284695|PROCEDURE|Bariatric surgery|Patients undergoing elective bariatric surgery
219293102|NCT03621787|DEVICE|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
219293103|NCT05339386|DRUG|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
219293104|NCT06342479|BEHAVIORAL|Discharge Education|Discharge education will be provided.
219293105|NCT01305200|DRUG|supersaturated calcium phosphate rinse|Mouth rinse
219293106|NCT01305200|OTHER|placebo|Mouth rinse
219293107|NCT01305200|OTHER|questionnaire administration|Ancillary studies
219293108|NCT01305200|PROCEDURE|quality-of-life assessment|Ancillary studies
219293109|NCT04210440|PROCEDURE|Core decompression procedure|Core Decompression with Bone Chips Allograft adjuvanted by Fibrin Platelet Rich-plasma (PRP) and Concentrated Autologous Mesenchymal Stromal Cells (MSCS), isolated from Bone Marrow
219293110|NCT04536870|DIAGNOSTIC_TEST|Echocardiography|Ultrasound of heart
219293111|NCT04536870|DIAGNOSTIC_TEST|ECG screening|Single lead ECG screening twice daily for two weeks
219293112|NCT04536870|DIAGNOSTIC_TEST|ECG Screening|12-lead ECG screening
219293113|NCT05713955|DEVICE|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
219293114|NCT06610604|PROCEDURE|thermal ablation|thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
219293115|NCT06610604|PROCEDURE|thyroidectomy|surgical resection of thyroid nodules
219293116|NCT03079453|DRUG|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
219293117|NCT06619756|BEHAVIORAL|Phonomotor Treatment (PMT)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
219293118|NCT06619756|BEHAVIORAL|Phonological Components Analysis (PCA)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
219293119|NCT04939363|COMBINATION_PRODUCT|Obinutuzumab with Ibrutinib and Venetoclax|"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
219293120|NCT02928159|DEVICE|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
219293121|NCT01209234|BEHAVIORAL|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
219293122|NCT01209234|DRUG|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
219296527|NCT03289429|OTHER|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
219296528|NCT03289429|OTHER|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
219293123|NCT06723184|BEHAVIORAL|The training|"Behavioral: Antenatal Education Education Hours: The training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be in a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Grandmothers in both the control and intervention groups will be asked to fill out the Introductory Information Form, Pharis Self-Confidence Scale, State-Trait Anxiety Scale and Knowledge Measurement Questionnaire for Grandchild Care measurement tools. The data of the intervention group will be filled in before and after the training. The data of the control group will be filled in parallel with the intervention group. At the end of the study, the same training will be applied to the control group.~Group to receive training: Grandmothers who are expecting a grandchild and have a grandchild will be included in the training."
219293124|NCT06729840|DRUG|Injection|Vitamin D , botox , tramcinolone intralesionally injected in keloid
219293125|NCT06735625|BIOLOGICAL|Measurement of AHSP concentration|"Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory."
219293126|NCT06896344|OTHER|In vitro culture|In vitro culture of bone marrow MNCs to obtain mesenchymal stromal cells
219293127|NCT06836856|DRUG|control|Patients will receive standard care with no interventions until end of treatment.
219293128|NCT06836856|DRUG|propranolol|starting at 20mg propranolol three times daily by mouth or per feeding tube. The dose was increased daily in 20mg three times daily increments (60mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 640mg/day in addition to standard care until end of treatment.
219293129|NCT06836856|DRUG|Carvedilol|starting at 6.25mg carvedilol three times daily by mouth or per feeding tube. The dose was increased daily in 6.25 mg three times daily increments (18.75 mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 100 mg/day in addition to standard care until end of treatment.
219293130|NCT06816875|DEVICE|NozeBot Electric Nasal Aspirator|The NozeBot is a rechargeable, battery-operated baby nasal aspirator with a nosepiece that loops directly onto the caregivers fingers for ease of use, and is intended to be held so it sits just inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
219293131|NCT06816875|DEVICE|NoseFrida the SnotSucker|The NoseFrida is nose-to-mouth nasal suctioning device with a disposable hygienic filter. The nosepiece is a larger tube that is to be held so it sits against and not inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
219293132|NCT06816875|DEVICE|hydraSense Baby Nasal Care Nasal Aspirator Starter Kit|The hydraSense Baby Nasal Aspirator Starter Kit is a nose-to-mouth nasal suctioning device with a disposable hygienic filter. The kit contains pre-proportioned saline solution vials to liquify mucus prior to suctioning. The nosepiece is intended to be held so it sits inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
219293133|NCT06816875|DEVICE|Braun Nasal Aspirator|The Braun nasal aspirator is a battery-operated nasal suctioning device with a washable collection chamber for mucus. There are two nosepiece sizes to accommodate a best fit in the nose. It will be used according to its manufacturer's instructions for use in this study.
219293134|NCT06895720|OTHER|Myofascial Self-Release|Athletes will be asked to use the myofascial release roller for 2 minutes before training on each of the three muscle groups: anterior and posterior thigh and posterior leg. They will be instructed to roll while applying as much pressure as possible on the roller. For the anterior thigh, the roller will be moved along the entire front part of the thigh; for the posterior thigh, it will be rolled from just below the gluteal region to just above the knee; and for the posterior leg, it will be rolled from just below the knee to just above the heel.
219293135|NCT06907810|OTHER|Blood sample + questionnaire|"* blood sample before tumor surgery and at every follow-up visit~* questionnaire before tumor surgery and at every follow-up visit"
219293136|NCT06906224|DRUG|Control group (clozapine, placebo)|Patients received oral clozapine (Jiangsu Pharmaceutical Co., Ltd., Approval No. H32022963) in combination with a placebo. Each dose of the placebo was 1 mg, taken three times a day.
219293137|NCT06906224|DRUG|Low-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Approval No. H19991024) in combination with clozapine. The total daily dose of buspirone was 15 mg, divided into three administrations. The dose remained unchanged throughout the entire study period.
219293138|NCT06906224|DRUG|High-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets in combination with clozapine. The initial total daily dose of buspirone was 15 mg, divided into three administrations. One week later, the dose was increased to a total daily dose of 30 mg, also divided into three administrations.
219293139|NCT06907251|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10mg orally once a day for 12 months
219293140|NCT06907251|DRUG|Placebo|Participants will receive a matching placebo taken once daily by mouth for 12 months.
219293141|NCT06906211|DEVICE|low intensity focused ultrasound (LIFU)|Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
219293142|NCT06906354|PROCEDURE|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
219293143|NCT06621576|DRUG|HM2002 injection|Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
219293144|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
219293145|NCT01185275|DEVICE|Alair system|Bronchial thermoplasty
219293146|NCT06906913|DIAGNOSTIC_TEST|HPV testing|Oropharyngeal and anal swab samples are evaluated in the Microbiology laboratory for the existence of HPV.
219293147|NCT00550303|DRUG|bazedoxifene/conjugated estrogens combination|
219293148|NCT00248482|DRUG|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
219293149|NCT00248482|DRUG|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
219293150|NCT00248482|DRUG|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
219293151|NCT04554524|DRUG|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
219293152|NCT02227979|BEHAVIORAL|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
219293153|NCT02227979|BEHAVIORAL|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
219293154|NCT05161221|DRUG|OxyCODONE 5 mg Oral Tablet|Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
219293155|NCT05161221|DRUG|Naproxen 500 Mg|Participant will receive Naproxen 500 Mg post surgery for pain control
219293156|NCT05161221|DRUG|Tylenol Pill|Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
219293157|NCT05161221|DRUG|Liposomal bupivacaine|Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
219293158|NCT05161221|PROCEDURE|Femoral Nerve Catheter|Participants will receive pre-operative femoral nerve catheter
219293159|NCT04196491|BIOLOGICAL|bb2121|CAR-T Cell Therapy
219293160|NCT04196491|DRUG|Fludarabine|Lymphodepleting Chemotherapy
219293161|NCT04196491|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
219293162|NCT04196491|DRUG|Lenalidomide|Maintenance Therapy
219293163|NCT01787149|DRUG|DMARDs|
219293164|NCT02016040|PROCEDURE|High Intensity Focused Ultrasound|
219293165|NCT02968316|OTHER|BIA measurement|observation only
219293166|NCT05396768|OTHER|Assessment using the ACTION-tool.|Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
219293167|NCT05322993|DEVICE|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
219293168|NCT05322993|DEVICE|Standard white light colonoscope|Standard colonoscopy.
219293169|NCT03470246|BEHAVIORAL|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
219293170|NCT03470246|BEHAVIORAL|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
219293171|NCT03470246|BEHAVIORAL|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
219293172|NCT04393337|OTHER|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
219293173|NCT04393337|OTHER|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
219293174|NCT04359043|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
219293175|NCT04359043|BEHAVIORAL|Treatment as Usual|Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
219293176|NCT01572168|OTHER|Acupuncture|Eight session of weekly acupuncture
219293177|NCT05589324|BEHAVIORAL|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
219293178|NCT02992821|PROCEDURE|Bed-side pocket size ultrasound imaging|
219293179|NCT02992821|PROCEDURE|High frame rate tracking doppler|
219293180|NCT04031807|PROCEDURE|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
219293181|NCT00004444|DRUG|paromomycin|
219293182|NCT00004444|DRUG|streptomycin|
219293183|NCT02124447|DRUG|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
219293184|NCT02124447|DRUG|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
219293185|NCT02124447|DRUG|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
219293186|NCT02124447|DRUG|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
219293187|NCT04822493|OTHER|Counseling Aid|Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
219293188|NCT01290315|DRUG|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
219293189|NCT01290315|DRUG|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
219293190|NCT02724059|PROCEDURE|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
219293191|NCT00591721|BEHAVIORAL|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
219293192|NCT00599911|DRUG|Lu AA24530|per oral, once daily for 6 weeks
219293193|NCT00599911|DRUG|Duloxetine|per oral, once daily for 6 weeks
219293194|NCT00599911|DRUG|Placebo|per oral, once daily for 6 weeks
219293195|NCT06433973|PROCEDURE|Test group 1 - CM+LLLT+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. LLLT will be applied on the site for 10 sec.
219293196|NCT06433973|PROCEDURE|Test group 2 - CM+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts. Adequate size of CM will be trimmed and applied over the recession defect using minimally invasive technique and secured with sutures.
219293197|NCT06433973|PROCEDURE|Control group - SCTG+VISTA|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
219293198|NCT01953653|BEHAVIORAL|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
219293199|NCT04669353|DRUG|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
219293200|NCT02909530|DEVICE|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
219293201|NCT02909530|DEVICE|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
219293202|NCT05035784|DRUG|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
219293203|NCT05035784|DRUG|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
219293204|NCT06206187|OTHER|Automated detection of the intracardiac thrombus through deep learning|A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.
219293205|NCT06206187|OTHER|Electrophysiologist judgment of the intracardiac thrombus|Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
219293206|NCT01837784|OTHER|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
219293207|NCT01670955|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
219293208|NCT01670955|DRUG|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
219293209|NCT02896049|DEVICE|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
219293210|NCT02716818|DRUG|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
219293211|NCT02716818|DRUG|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
219293212|NCT00901186|DRUG|RFB002|0.5 mg
219293213|NCT00901186|PROCEDURE|Laser photocoagulation|
219293214|NCT01016743|DEVICE|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
219293215|NCT00541060|GENETIC|mutation|a mutation of a gene coding
219293216|NCT03842722|DEVICE|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
219293217|NCT03980600|DEVICE|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
219293218|NCT03980600|DEVICE|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
219293219|NCT03980600|DEVICE|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
219293220|NCT01543984|OTHER|Tailored Physical Activity|Tailored Physical Activity (3\*50 min/week in 10 weeks)
219293221|NCT01543984|BEHAVIORAL|Health Counselling|Health guidance (1,5h)
219293222|NCT05222724|DRUG|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
219293223|NCT05222724|DRUG|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
219293224|NCT01762319|DRUG|Misoprostol|
219293225|NCT01762319|DRUG|Vitamin B6|
219293226|NCT00294203|DRUG|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
219293227|NCT00294203|OTHER|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
219293228|NCT00581555|DRUG|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
219293229|NCT00581555|OTHER|Placebo|Randomized to placebo during taper of ciclosporin
219293230|NCT03336567|OTHER|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
219293231|NCT05807529|DRUG|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
219293232|NCT05807529|DRUG|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
219293233|NCT05303220|DRUG|Branebrutinib|Specified dose on specified days
219293234|NCT05303220|DRUG|Placebo|Specified Dose on specified days
219293235|NCT05225727|BEHAVIORAL|Me & You - Tech|The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
219293236|NCT03828747|DRUG|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
219293237|NCT03828747|DRUG|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
219293238|NCT03828747|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
219293239|NCT05009953|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
219293240|NCT05009953|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
219293241|NCT05009953|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
219293242|NCT05009953|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
219293243|NCT03900416|BEHAVIORAL|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
219293244|NCT03534128|OTHER|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
219293245|NCT04465500|RADIATION|External Beam Radiation|EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
219293246|NCT04465500|RADIATION|HDR Brachytherapy|HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
219293247|NCT04465500|DRUG|Androgen Deprivation Therapy|The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
219293248|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises|In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks
219293249|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises with dual task|In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
219293250|NCT03069755|OTHER|No intervention|No intervention
219293251|NCT01699659|OTHER|allergen immunotherapy|allergy shots
219293252|NCT03141697|DEVICE|Carbon Dioxide|Insufflation of Carbon Dioxide
219293253|NCT03141697|DEVICE|Room air|Insufflation of room air
219296529|NCT03750045|DIAGNOSTIC_TEST|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
219293254|NCT06371859|BEHAVIORAL|"XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions"|"This study includes 1840 ultrasound images, split into UA and MCA flow and spectrum images, each duplicated for a total of 3680 images to compare explainable AI (XAI) feedback vs. no feedback. The investigators will provide matched sets of 40 images (one for the XAI group and one for the non-XAI group) to participants. Participants are matched based on their level of experience within each hospital (Resident physicians, obstetricians, and gynecologists with obstetric ultrasound experience).~All participants are instructed to place gates on the flow images of the umbilical artery and the middle cerebral artery and to assess the quality of the resulting flow curves. Specifically, for flow images, participants must identify the most appropriate gate placement. For spectral flow curves, they are to decide if the curves are of sufficient quality to guide medical management decisions."
219293255|NCT00699049|DRUG|Alpha blocker|oral
219293256|NCT00699049|DRUG|placebo|oral
219293257|NCT00699049|DRUG|solifenacin|oral
219293258|NCT02984293|DRUG|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
219293259|NCT02984293|DRUG|Placebo|Placebo once daily for 28 days.
219293260|NCT02527642|OTHER|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
219293261|NCT04403464|BEHAVIORAL|HABIT-ILE with REAtouch®|65h HABIT-ILE including 30h REAtouch®
219293262|NCT04403464|BEHAVIORAL|HABIT-ILE without REAtouch®|65h HABIT-ILE
219293263|NCT01883232|DEVICE|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
219293264|NCT01883232|DEVICE|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
219293265|NCT00772330|DEVICE|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
219293266|NCT01056497|DRUG|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
219293267|NCT02654301|DIETARY_SUPPLEMENT|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
219293268|NCT02654301|DIETARY_SUPPLEMENT|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
219293269|NCT02654301|DIETARY_SUPPLEMENT|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
219293270|NCT02654301|DIETARY_SUPPLEMENT|Control|sucrose 50 g + deionized water 100 g
219293271|NCT04893343|OTHER|Antibiotic treatment|Antibiotic treatment
219293272|NCT04893343|OTHER|No antibiotic treatment|No antibiotic treatment
219293273|NCT03887078|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
219293274|NCT02849522|PROCEDURE|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
219293275|NCT02849522|PROCEDURE|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
219293276|NCT02849522|PROCEDURE|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
219293277|NCT02849522|PROCEDURE|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
219293278|NCT01870908|DRUG|tacrolimus|
219293279|NCT01870908|DRUG|biological agents|
219293280|NCT02232607|DRUG|Lacidipine, low dose|
219293281|NCT02232607|DRUG|Lacidipine, medium dose|
219293282|NCT02232607|DRUG|Lacidipine, high dose|
219293283|NCT02232607|DRUG|Placebo|
219293284|NCT01581359|DRUG|Triptorelin acetate|"* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
219293285|NCT02935985|OTHER|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
219293286|NCT00901433|DEVICE|Personal WheezoMeter|pulmonary sounds analyzer
219293287|NCT01805401|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
219293288|NCT01792050|DRUG|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
219293289|NCT01792050|OTHER|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
219293290|NCT01792050|DRUG|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
219293291|NCT01792050|DRUG|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
219293292|NCT01348568|DIETARY_SUPPLEMENT|low glycemic index diet with canola oil bread|
219293293|NCT01348568|DIETARY_SUPPLEMENT|High fiber diet|
219293294|NCT00625261|OTHER|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
219293295|NCT04938700|DRUG|probiotics|Probiotics as granules can be used for infants and adolescents
219293296|NCT04938700|DRUG|conventional medical treatment|Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
219293297|NCT00424385|DRUG|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
219293298|NCT05564416|BIOLOGICAL|Atezolizumab|Given IV
219293299|NCT05564416|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219293300|NCT05564416|PROCEDURE|Biospecimen Collection|Correlative studies
219293301|NCT05564416|PROCEDURE|Computed Tomography|Undergo CT
219293302|NCT05564416|PROCEDURE|Cystoscopy|Undergo cystoscopy
219293303|NCT05564416|DRUG|Erdafitinib|Given PO
219293304|NCT05564416|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219293305|NCT00373477|PROCEDURE|Generalist Care Manager vs Usual Care|
219293306|NCT05907109|BEHAVIORAL|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"* Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic."
219743146|NCT06694220|OTHER|Traditional exercises|The players will be warmed up as usual, with jogging and ball-based exercises following FIFA 11+ warming up program which consist of three steps with 15 specific exercises running exercises for 8 mins, starting warming up in pairs; Path consists of 6-10 pairs of parallel cones: (Running Straight Ahead, Running Hip Out, Running Hip In, Running Circling Partner, Running Shoulder Contact, Running Quick Forwards and Backwards, Rep. x2). Strength, plyometric, balance for 10 minutes (The Bench, Sideways Bench, Single-leg Stance, Squats, Jumping Rep. 2x 30 sec each side). Running Exercises for 2 minutes (End of heating): (running across the pitch, running bounding, running plant, and cut. Rep x 2). Techniques need to be performed correctly and with an emphasis on maintaining the correct posture of the body. This exercise program should be done at least twice a week
219293307|NCT00355199|DRUG|Rituximab-HDS|Rituximab-HDS
219293308|NCT00355199|DRUG|Rituximab-CHOP|Rituximab-CHOP
219293309|NCT02104050|DRUG|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
219293310|NCT02104050|DRUG|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
219293311|NCT00582686|PROCEDURE|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
219293312|NCT00582686|PROCEDURE|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
219293313|NCT02503189|DRUG|KCT-0809 ophthalmic solution|
219293314|NCT02503189|DRUG|Placebo|
219293315|NCT06250244|DRUG|177Lu-LNC1011|\[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.
219293316|NCT06130280|RADIATION|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
219293317|NCT00319410|PROCEDURE|vaginoscopic hysteroscopy|
219293318|NCT01308138|BEHAVIORAL|Exercise training|exercise training
219293319|NCT01308138|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning
219293320|NCT00085787|DRUG|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
219293321|NCT02405728|DEVICE|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
219293322|NCT02405728|DEVICE|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
219293323|NCT01978327|DRUG|GSK2647544|repeat dose
219293324|NCT01978327|DRUG|drug-drug interaction|drug-drug interaction
219293325|NCT04120571|OTHER|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
219293326|NCT04120571|OTHER|sham control|no noise
219293327|NCT02503852|DEVICE|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
219293328|NCT02503852|DEVICE|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
219293329|NCT02503852|PROCEDURE|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
219293330|NCT02503852|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
219293331|NCT03231800|DRUG|dasotraline|dasotraline 2mg capsule once daily
219293332|NCT03231800|DRUG|Placebo|Placebo capsule once daily
219293333|NCT00110877|DRUG|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
219293334|NCT00110877|DRUG|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
219293335|NCT00859222|DRUG|LBH589|
219293336|NCT00859222|DRUG|bevacizumab|
219293337|NCT00034060|DRUG|Etanercept|
219293338|NCT00701831|DRUG|Insulin glargine|The dose is titrated according to patient needs
219293339|NCT05715385|PROCEDURE|laser photocoagulation|"Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500"
219293340|NCT05715385|DRUG|eye drop bromfenac 0.09%|twice daily e/d bromfenac 0.09% for 6 weeks
219293341|NCT05715385|DRUG|Placebo|Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
219293342|NCT03670095|DRUG|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
219293343|NCT03670095|DRUG|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
219293344|NCT04984447|DEVICE|TNIB Catheter|Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
219293345|NCT00942305|DRUG|Brincidofovir|Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
219293346|NCT00942305|DRUG|Placebo|"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
219293347|NCT02342470|DRUG|Placebo|Drug : Placebo
219293348|NCT02342470|DRUG|PMK-S005 1|Drug : PMK-S005 1 (50mg)
219293349|NCT02342470|DRUG|PMK-S005 2|Drug : PMK-S005 2 (100mg)
219293350|NCT02342470|DRUG|PMK-S005 3|Drug : PMK-S005 3 (150mg)
219743147|NCT06695039|DIAGNOSTIC_TEST|Fluoroestradiol (18F)|images for 90 minutes after F-18 FES injection
219743148|NCT06695091|PROCEDURE|Monolithic zirconia crown|All-ceramic crown
219293351|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
219293352|NCT00400725|DRUG|Clobex® Vehicle Shampoo|Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
219293353|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
219293354|NCT02668549|OTHER|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
219293355|NCT01081600|OTHER|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
219293356|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
219293357|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
219293358|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
219293359|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
219293360|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
219293361|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
219293362|NCT03233139|DRUG|Fianlimab|To be administered per protocol
219293363|NCT00018239|PROCEDURE|Exercise|
219293364|NCT05303259|DRUG|Bevacizumab|Bevacizumab 2.5mg/kg, q2w, 4 cycles.
219293365|NCT04220840|PROCEDURE|Damage control strategy|"The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~1. definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~2. lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery"
219293366|NCT04611308|OTHER|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
219293367|NCT01593956|BEHAVIORAL|tDCS|
219293368|NCT05229042|DRUG|Ricolinostat|Oral
219293369|NCT02721667|DEVICE|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
219293370|NCT02721667|OTHER|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
219293371|NCT03620916|PROCEDURE|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days
219293372|NCT03620916|PROCEDURE|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days in the postoperative period
219293373|NCT04496531|DEVICE|Portable Neuromodulation Stimulator|
219293374|NCT04081623|DEVICE|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
219293375|NCT02545023|OTHER|Quality-of-Life Assessment|Complete an in-person one-on-one interview
219293376|NCT02545023|OTHER|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
219293377|NCT01375231|PROCEDURE|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
219293378|NCT01375231|PROCEDURE|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
219293379|NCT00142181|DRUG|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
219293380|NCT03108456|DEVICE|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
219293381|NCT03108456|DEVICE|Balloon|Vessel preparation with conventional and/or specialty balloons
219293382|NCT00252577|DRUG|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
219293383|NCT03929172|BIOLOGICAL|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
219293384|NCT03929172|DRUG|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
219293385|NCT06096454|DRUG|Metformin|effect of life style modification and metformin on hypothyroidism with insulin resistance
219293386|NCT02046889|BEHAVIORAL|Bicycle Training Intervention|
219743149|NCT06695091|PROCEDURE|Monolithic lithium disilicate crown|All-ceramic crown
219743150|NCT06688643|DEVICE|ITM group|Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
219293387|NCT05774743|OTHER|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
219293388|NCT00251823|DRUG|Eptifibatide facilitated PCI|
219293389|NCT04700020|DIAGNOSTIC_TEST|ITT|In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
219293390|NCT01670760|DEVICE|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
219293391|NCT01949038|DRUG|Oral alprazolam|
219293392|NCT01949038|DRUG|Sublingual alprazolam|
219293393|NCT01949038|DRUG|Oral placebo|
219293394|NCT01949038|DRUG|Sublingual placebo|
219293395|NCT04773197|BEHAVIORAL|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
219293396|NCT04773197|BEHAVIORAL|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
219293397|NCT04773197|BEHAVIORAL|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
219293398|NCT03203395|BEHAVIORAL|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
219293399|NCT02496689|BIOLOGICAL|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
219293400|NCT01971710|BEHAVIORAL|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
219293401|NCT01971710|BEHAVIORAL|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
219293402|NCT01971710|BEHAVIORAL|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
219293403|NCT00560066|BIOLOGICAL|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
219293404|NCT00560066|BIOLOGICAL|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
219293405|NCT01748877|DRUG|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
219293406|NCT01748877|DRUG|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
219293407|NCT05033171|DIAGNOSTIC_TEST|3D Scanning|3D scanning of the rod using Artec Eva Spider type manual 3D scanner
219293408|NCT05033171|DIAGNOSTIC_TEST|EOS 2D/3D scanning|EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
219293409|NCT05145959|DEVICE|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
219293410|NCT05884177|OTHER|Short-term cold exposure|Short-term cold exposure
219743151|NCT06688643|DEVICE|EA group|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
219743152|NCT06688110|DEVICE|Gixam System|Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
219293411|NCT03697317|BEHAVIORAL|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
219293412|NCT03697317|BEHAVIORAL|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
219293413|NCT00324558|DRUG|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
219293414|NCT04718779|OTHER|Digital Engagement Application (GD App)|This is a chart review (prospective) data analysis study to describe the effect of the treatment change on the clinical parameters and patient reported outcomes (PROs) with the use of a digital engagement application (GD app) (to evaluate participants clinical engagement, shared decision making, emotional wellbeing, activities of daily living, goal attainment and Gaucher Disease specific measures).
219293415|NCT04718779|OTHER|No Intervention|This is a chart review (retrospective) data analysis study to describe the effect of the treatment change on the clinical parameters.
219293416|NCT00741390|DEVICE|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
219293417|NCT00741390|DEVICE|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
219293418|NCT00741390|DEVICE|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
219293419|NCT00741390|DEVICE|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
219293420|NCT00741390|DEVICE|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
219293421|NCT06263127|BEHAVIORAL|oral stimulation|Prefeeding OS is a 5-minute oral sensorimotor intervention, containing peri- and intra-oral stimulation for 3 minutes and pacifier sucking for 2 minutes.
219293422|NCT06263127|BEHAVIORAL|infants massage|IM is a 15-minute intervention, involving 5-min manual stroking on the infant's head, neck, back, upper limbs, and lower limbs twice and 5-min gentle flexion and extension exercises on the infant's arms and legs.
219293423|NCT00236379|DRUG|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
219293424|NCT00236379|DRUG|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
219293425|NCT06525714|DRUG|cisplatin oxaliplatin tegafur|Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg/m2 cisplatin at 43°C, with an infusion rate of 600 ml/min for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg/m2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \<1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \>1.5m2, 60 mg bid) from day 1 to 14.
219293426|NCT05901623|OTHER|'Ages and Stages Questionnaries' (ASQ)|''ASQ' is a screening tool for assessing the development of infants and preschoolers in the areas of communication, fine motor, gross motor, problem-solving and personal-social development, and 'ASQ:SE' is a screening tool for social-emotional development
219293427|NCT00620282|DRUG|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
219293428|NCT00620282|DRUG|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
219293429|NCT00620282|DRUG|glimepiride|Tablets, 1 - 4 mg daily
219293430|NCT04671966|DRUG|Estradiol patch|Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
219293431|NCT04671966|DRUG|Cetrotide|Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
219293432|NCT04671966|OTHER|Fasting|Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
219293433|NCT04671966|OTHER|Lower Body Negative Pressure|This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
219293434|NCT03718351|PROCEDURE|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
219293435|NCT03718351|PROCEDURE|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
219293436|NCT01044017|DRUG|Placebo|single oral dose
219293437|NCT01044017|DRUG|RO4998452|single oral doses
219743153|NCT06691646|BEHAVIORAL|Gaze-control training game|An eyetracker-controlled computer game designed to improve attentional control by training inhibitory control over direction of gaze. It includes six mini-games, each designed to train different aspects of oculomotor control, including selective attention, motor inhibition, motor timing, and spatial working memory.
219743154|NCT06689358|DRUG|0.4 ml/kg of 0.5% bupivacaine|0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
219743155|NCT06686199|DIETARY_SUPPLEMENT|steamed potato|135 g per day 4-5 times per week for 8 weeks
219743156|NCT06686199|DIETARY_SUPPLEMENT|fried potato|135 g per day 4-5 times per week for 8 weeks
219743157|NCT06688149|DIAGNOSTIC_TEST|Derivation algorithms|Derivation algorithm based on non-invasive methods, to standardise the continuum of care for diabetic patients with NAFLD from primary care and endocrinology settings to NAFLD specialised units (NSU)
219743158|NCT06688773|BEHAVIORAL|Progressive relaxation exercise|In this study, the relaxation exercises CD, which is a material created by the Turkish Psychological Association, was used. This CD consists of three parts. The first part consists of 10 minutes and this part explains the definition and purpose of deep relaxation exercise and the points to be considered during the exercise. The second part of the CD consists of 30 minutes of verbal explanation of the items of relaxation exercises accompanied by the sound of a stream. The third part consists of 30 minutes and includes only relaxation music.
219743159|NCT06688773|OTHER|Control group: Standart nursing care group|Routine postoperative patient care in the clinic was applied.
219743160|NCT06689930|OTHER|PDSA Cycles|Conduct PDSA cycle and follow-up interviews and surveys for patients (5 per cycle, 10 total) and CBO staff (no less than 2)
219743161|NCT06690476|DRUG|Dose escalation(IPM514 monotherapy)|Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
219743162|NCT06690476|DRUG|Dose expansion (IPM514 combined with tislelizumab)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
219743163|NCT06690476|DRUG|Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
219743164|NCT06688682|OTHER|PRP joint injection combined with acupoint injection|PRP acupoint injection
219743165|NCT06689280|BEHAVIORAL|Video-supervised home-based exercise training|12 weeks of patient-centered video-supervised home-based exercise training that will be kick-started during hospitalization and continued for 12 weeks after discharge, followed by 12 weeks of self-directed maintenance exercise.
219743166|NCT06690541|DRUG|Lorlatinib 100 mg|Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
219293438|NCT02141022|OTHER|plasticity-based computerized cognitive remediation program|
219293439|NCT02141022|DRUG|Gileyna|
219293440|NCT01258595|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
219293441|NCT01258595|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
219293442|NCT05423990|DIAGNOSTIC_TEST|Video-Electroencephalography|Three types of video EEG monitoring equipment produced by Nicolet, Bio-logic and Nihon Kohden were used to collect data in the multi-center. The 19-lead recording electrode was placed according to the international 10-20 system, and the average lead was used. The recording time was 24h. All patients underwent eyes open and closed test, intermittent photic stimulation and hyperventilation induction test.
219293443|NCT06270706|DRUG|PLN-101095|PLN-101095
219293444|NCT06270706|DRUG|Pembrolizumab|Pembrolizumab
219293445|NCT02643043|OTHER|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
219293446|NCT02338180|OTHER|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
219293447|NCT02338180|OTHER|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
219293448|NCT01565278|DRUG|Soybean oil (Standard treatment)|1\. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
219293449|NCT01565278|DRUG|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
219293450|NCT03451682|DIETARY_SUPPLEMENT|procyanidine|Natural antioxidant
219293451|NCT03863873|PROCEDURE|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
219293452|NCT03090139|DRUG|Anti-TNF Therapy|Anti-TNF therapy.
219293453|NCT00002003|DRUG|Mitoxantrone hydrochloride|
219293454|NCT00002003|DRUG|Etoposide|
219293455|NCT04573348|DIAGNOSTIC_TEST|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
219293456|NCT02311231|DRUG|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
219293457|NCT02311231|DRUG|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
219293458|NCT04206202|DEVICE|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
219293459|NCT04138264|OTHER|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
219293460|NCT00440440|DRUG|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
219293461|NCT00440440|DRUG|placebo|placebo gel apply daily
219293462|NCT01170104|DRUG|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
219293463|NCT01170104|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
219293464|NCT03678428|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
219293465|NCT03678428|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
219293466|NCT03678428|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
219293467|NCT03678428|DRUG|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
219293468|NCT03678428|DRUG|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
219293469|NCT03678428|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
219293470|NCT05769712|DIAGNOSTIC_TEST|Shear wave ultrasonic imaging|Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.
219293471|NCT03293004|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
219293472|NCT03293004|DIETARY_SUPPLEMENT|Vitamin C|Escalating dose of Vitamin C
219293473|NCT03293004|DIETARY_SUPPLEMENT|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
219293474|NCT03293004|DIETARY_SUPPLEMENT|Gummy Placebo|Gummy placebo
219293475|NCT05176041|OTHER|Naser Al-Husban|observation
219293476|NCT03097081|OTHER|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
219293477|NCT03097081|DEVICE|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
219293478|NCT05465447|DEVICE|subjective refraction|Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
219293479|NCT02408601|OTHER|Helioseal - F|"Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepeted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion"
219293480|NCT02408601|OTHER|ART sealant|"Fuji IX extra strength~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes."
219293481|NCT00918892|GENETIC|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
219293482|NCT00918892|OTHER|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
219293483|NCT00918892|OTHER|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
219293484|NCT00817700|OTHER|Sleep restriction|Sleep restriction.
219293485|NCT04559763|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
219293486|NCT04559763|OTHER|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
219293487|NCT01182883|DRUG|IMC-A12|
219293488|NCT01182883|DRUG|Temsirolimus|
219293489|NCT02642263|DRUG|Carbetocin|Postpartum uterotonic drug
219293490|NCT02935660|DEVICE|enLighten Laser|Laser tattoo removal treatment
219293491|NCT00400127|DEVICE|Silesian suspension belt|
219293492|NCT00935727|OTHER|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
219293493|NCT04714749|PROCEDURE|Endovenous treatment|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
219293494|NCT04714749|DEVICE|Cyanoacrylate glue|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
219293495|NCT03277092|DEVICE|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
219293496|NCT03277092|PROCEDURE|Usual care|The blood drawing is performed traditionally
219293497|NCT01109927|DRUG|Insulin|Insulin treatment in accordance to glucose values
219293498|NCT04305717|DEVICE|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
219293499|NCT00965367|DEVICE|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
219293500|NCT04012476|DRUG|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
219293501|NCT06218862|DRUG|Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.
219293502|NCT06218862|DRUG|Control|Not use Sivelestat sodium
219293503|NCT02802189|OTHER|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles"
219293504|NCT02802189|OTHER|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~* Upper border of the trapezius muscle~* sternocleidomastoid~* levator scapulae muscle~* splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~* Ischemic compression~* Muscle energy technique~* Strain-counterstrain technique"
219293505|NCT05517187|OTHER|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
219293506|NCT05517187|BIOLOGICAL|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
219293507|NCT02296723|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
219293508|NCT01827995|OTHER|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
219293509|NCT01827995|OTHER|Routine assessment|Follow up in the clinic
219293510|NCT02293213|BEHAVIORAL|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
219293511|NCT02293213|BEHAVIORAL|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
219293512|NCT02293213|BEHAVIORAL|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
219293513|NCT02293213|BEHAVIORAL|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
219293514|NCT02293213|BEHAVIORAL|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
219293515|NCT02293213|BEHAVIORAL|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
219293516|NCT00182559|DRUG|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
219293517|NCT00182559|DRUG|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
219293518|NCT02807818|BEHAVIORAL|Home visiting Program for Young Pregnant Women|
219293519|NCT01462032|BEHAVIORAL|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
219293520|NCT01462032|BEHAVIORAL|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
219293521|NCT02925598|DEVICE|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
219293522|NCT02925598|DEVICE|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
219293523|NCT02925598|DEVICE|ETT insertion|'ETT insertion' was done following anesthesia induction.
219293524|NCT02285153|DRUG|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
219293525|NCT02285153|DRUG|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
219293526|NCT00939159|DRUG|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
219293527|NCT02155751|BEHAVIORAL|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
219293528|NCT02155751|BEHAVIORAL|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
219293529|NCT03815682|BIOLOGICAL|Arm A: RPTR-147:1|Escalating doses of RPTR-147:1 as a monotherapy
219293530|NCT03815682|BIOLOGICAL|Arm B: RPTR-147:1 and Pembrolizumab|Escalating doses of RPTR-147:1 in combination with Pembrolizumab
219293531|NCT03815682|BIOLOGICAL|Arm C: RPTR-147:2|Escalating doses of RPTR-147:2 in patients with HPV positive tumors
219293532|NCT04363034|BIOLOGICAL|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
219293533|NCT00085462|BIOLOGICAL|aldesleukin|
219293534|NCT00085462|BIOLOGICAL|filgrastim|
219293535|NCT00085462|BIOLOGICAL|gp100-fowlpox vaccine|
219293536|NCT00085462|BIOLOGICAL|therapeutic autologous lymphocytes|
219293537|NCT00085462|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219293538|NCT00085462|DRUG|cyclophosphamide|
219293539|NCT00085462|DRUG|fludarabine phosphate|
219293540|NCT02888873|OTHER|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
219293541|NCT02888873|OTHER|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
219293542|NCT01472549|DRUG|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
219293543|NCT01472549|DRUG|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
219293544|NCT00526500|BEHAVIORAL|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
219293545|NCT01303029|DRUG|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
219293546|NCT01303029|DRUG|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
219293547|NCT01489891|DRUG|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
219293548|NCT01489891|DRUG|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
219293549|NCT00998790|DEVICE|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
219293550|NCT01979627|PROCEDURE|transulnar approach interventional procedure|
219293551|NCT01979627|PROCEDURE|transradial approach interventional procedure|
219293552|NCT04662853|DIAGNOSTIC_TEST|Gut microbiota determination from feces samples.|Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
219293553|NCT02148640|DRUG|Innovator infliximab|
219293554|NCT02148640|DRUG|Biosimilar infliximab|
219293555|NCT02976571|DRUG|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
219293556|NCT06113887|OTHER|psychoeducation based on acceptance and commitment therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
219293557|NCT06200129|DIAGNOSTIC_TEST|sws grade 1|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 1.
219293558|NCT06200129|DIAGNOSTIC_TEST|sws grade 2|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 2
219293559|NCT06200129|DIAGNOSTIC_TEST|control|Group of patients without scattered white lesions in the dueodenum on endoscopy.
219293560|NCT00095420|BEHAVIORAL|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
219293561|NCT00095420|BEHAVIORAL|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
219293562|NCT00095420|BEHAVIORAL|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
219293563|NCT00095420|BEHAVIORAL|Usual training|Participants will receive the usual training offered in their local school districts.
219293564|NCT04802616|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
219293565|NCT04802616|DRUG|Placebo|Matched tablets without any active substance.
219293566|NCT01712945|DRUG|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
219293567|NCT01712945|DRUG|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
219293568|NCT04072692|OTHER|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
219293569|NCT04072692|OTHER|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
219293570|NCT04072692|OTHER|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
219293571|NCT00156689|DRUG|levetiracetam|
219743167|NCT06688513|DEVICE|Carealth Phone App|The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
219743168|NCT06688513|BEHAVIORAL|Let's Talk: Sharing information about Family Cancer Risk|An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
219293572|NCT05599841|PROCEDURE|PI solution|3,000 cc of \<2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
219293573|NCT05599841|PROCEDURE|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
219293574|NCT06058312|OTHER|Self-questionnaire|The self-administered questionnaires to be completed at the time of inclusion will be presented to the patient on a tablet during the inclusion visit and will be completed on the same day in the Day Hospital using the Compusense software. Online self-questionnaires and sensory tests at the 9th week of treatment will also be conducted using the Compusense software in small groups at a designated location within the center.
219293575|NCT06058312|OTHER|Self-questionnaire|The MediLite questionnaire consists of nine items that assess daily consumption of fruits, vegetables, grains, meats and meat products, dairy products, alcohol, and olive oil, as well as weekly consumption of legumes and fish.
219293576|NCT06058312|OTHER|Self-questionnaire|"The CITAS is a self-administered questionnaire consisting of 18 items evaluated on a five-point Likert scale and divided into three dimensions: 1) quantitative changes in taste perception (hypogeusia and ageusia), 2) qualitative changes in taste perception (heterogeusia, cacogeusia), and 3) nutrition-related problems (difficulty eating hot or fatty foods).~Using a Likert scale ranging from 1 to 5 (where 1 = no difficulty or absence of disturbance and 5 = maximum difficulty or disturbance), CITAS assesses the four dimensions of taste disturbances: taste intensity, discomfort, phantogeusia, and parageusia, as well as overall taste alterations.~For the original version by Kano and Kanda (2013), five items assessing changes in smell from the modified CITAS version by Drareni et al. 2021 will be added in this study."
219293577|NCT06058312|OTHER|Self-questionnaire|"Food neophobia will be assessed using the Food Neophobia Scale (FNS) developed by Pliner \& Hobden (1992). The FNS consists of ten statements evaluated on a 7-point agreement scale ranging from 1 = I strongly disagree to 7 = I strongly agree. Individual FNS scores are calculated as the sum of the ratings given to the ten statements after reversing the neophilic items; thus, scores theoretically range from 10 to 70, with higher scores reflecting higher levels of food neophobia."
219293578|NCT06058312|OTHER|Self-questionnaire|The quality of life related to food in cancer patients is composed of 46 items with a 4-point scale (never, almost never, almost always, always). The questionnaire is divided into different subdomains: Cooking, where one eats and conviviality, Eating and drinking, After eating.
219293579|NCT06058312|OTHER|Self-questionnaire|Individual baseline disgust sensitivity is assessed using the Disgust Sensitivity-Short Form (DS-SF) questionnaire; this questionnaire is a shortened version of the disgust scale aimed at measuring disgust of animal origin, based on contamination and revulsion (Haidt, 2004; Haidt et al., 1994; Inbar, Pizarro, and Bloom, 2009; Olatunji et al., 2007). This measure consists of 8 items divided into 2 parts. In the first part, statements were rated on a scale from 1 (not at all agree-very false about me) to 5 (completely agree-very true about me); for the second part, additional statements were rated from 1 (not at all disgusting) to 5 (extremely disgusting). The total disgust sensitivity score is obtained by summing the scores after two items have been reversed and ranges from 8 to 40.
219293580|NCT06058312|OTHER|Self-questionnaire|The subscale of reward sensitivity from the short version of reward and punishment sensitivity has been selected (17 items). Each item will be assessed on a 4-point Likert scale, ranging from 1 (completely no) to 4 (completely yes).
219293581|NCT06058312|OTHER|Self-questionnaire|"The EmoPrefMed questionnaire was developed to measure declared appreciation and emotional responses to selected Mediterranean diet (RM) products and changes in appreciation before and after chemotherapy.~The assessment of the acceptability of a series of RM foods (listed in the questionnaire appendix) will be evaluated using a nine-point hedonic scale ranging from a minimum of 1 = I don't like it at all to a maximum of 9 = I like it a lot (Peryam \& Pilgrim, 1957).~Emotions will be assessed using a check-all-that-apply (CATA) list of emotions, including 4 negative and 4 positive emotions with low, moderate, and high arousal levels (It brings me joy, It intrigues me, It relaxes me, It annoys me, It leaves me indifferent, It makes me sad, It's monotonous, It disgusts me). Patients will be asked to select all the emotions they deem appropriate to describe the food product."
219293582|NCT06058312|OTHER|Self-questionnaire|"Food-related attitudes will be measured using the HTAS (Health and Taste Attitude Scale) proposed by Roininen et al. (1999), consisting of six subscales focusing on perceived health and taste aspects of foods. The two scales selected in this study are general interest in health (eight items, measuring overall interest in a healthy diet) and the use of food as a reward (six items, measuring attitudes towards using food as a reward). Each subscale consists of an equal number of statements phrased positively and negatively (Roininen et al., 1999). All items were rated on a seven-point category scale, ranging from strongly disagree to strongly agree. As suggested by Roininen et al. (1999), negative statements were reversed and recoded for the calculation of final scores."
219293583|NCT06058312|OTHER|Self-questionnaire|"The response to PROP (6-n-propyl-2-thiouracil) is measured using 1.5 cm diameter paper disks previously soaked in a solution of deionized water with a concentration of 3.2 mM PROP, dissolving 0.5477 g/L of PROP. Each paper disk will contain approximately 0.280 mg of PROP. Participants are asked to place the paper disk on the tip of their tongue for 20 seconds, then remove it and assess the perceived bitter intensity on a Labelled Magnitude Scale (LMS).~The LMS scale consists of a vertical line of 100 units with labels placed at no sensation, 0; barely detectable, 1.4; weak, 6; moderate, 17; strong, 34.7; very strong, 52.5; and the strongest imaginable sensation of any kind, 100. Numeric labels are not reported on the scale. Participants are instructed to think of the strongest imaginable sensation as the most intense sensation they can imagine in the realm of taste. Participants are encouraged to ask questions about the use of the scale if they need more clarification."
219293584|NCT06058312|OTHER|Self-questionnaire|The odors (Mint, Anise, Banana, Pine, Garlic, Cinnamon, Lemon) are trapped in tightly packed microcapsules (aminoplast type, diameter: 4-8 μm). Microcapsule-based ink is printed on cardboard paper (SILK-250 g; Size: 11 cm × 21 cm). Each odorant has been printed in a defined area (2 cm in diameter). The odor is released by simply rubbing the printed microcapsule reserve (scratch-and-sniff method).Patients receive a disposable single-use sample and are asked to identify the odors and evaluate on a visual analog scale the perceived intensity, perceived irritation, and appreciation of each odor.
219293585|NCT06058312|OTHER|Self-questionnaire|"Two model foods were developed to investigate responses to variations in sweetness, acidity, and freshness. The first range consists of Apple-Mint Juice, composed of four samples containing different concentrations of mint syrup (0, 15, 60, 240 g/kg). The second range is a chickpea mousse made up of four samples containing different quantities of citric acid and glucose-fructose syrup (glucose-fructose syrup: 0, 50, 100, 200 g/kg; citric acid: 8, 6, 4, 4 g/kg). Participants are asked to evaluate the samples using the Labelled Affective Magnitude Scale. Regarding the LAM scale, subjects are instructed to consider the extremes of appreciation, the best I can imagine and the worst I can imagine. After a break, they are asked to taste the samples again and rate the intensity of sweetness, acidity, apple flavor, mint flavor, and freshness on the Labeled Magnitude Scale: from 'not detectable' to 'the strongest imaginable'."
219293586|NCT05187143|DEVICE|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
219293587|NCT00100087|DEVICE|Ocular Brachytherapy|
219293588|NCT03374527|OTHER|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
219293589|NCT03374527|PROCEDURE|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
219293590|NCT05087901|DIAGNOSTIC_TEST|Multifocal electroretinogram|A device that records electric potentials generated by the retinal photoreceptors and neural elements in a multifocal fashion
219293591|NCT04831918|DEVICE|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
219293592|NCT00229138|DRUG|EC-MPS, Tacrolimus|
219293593|NCT02810587|DRUG|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
219293594|NCT04469127|DRUG|Lutetium-177-DOTAGA-IAC|Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.
219293595|NCT05419973|OTHER|Anthropometric measurement for pregnant women|Weight, length, upper arm circumference
219293596|NCT05419973|OTHER|Anthropometric measurement for infants|birth weight, length, head circumference, nutritional status
219293597|NCT05419973|OTHER|Blood sampling|3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.
219293598|NCT03350373|DRUG|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
219293599|NCT00888927|BIOLOGICAL|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
219293600|NCT01291459|DRUG|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
219293601|NCT03459443|DRUG|Danicopan|Danicopan was to be administered as an oral tablet.
219293602|NCT06249659|PROCEDURE|Extubation in operative room|Extubation takes place in operative room
219293603|NCT06249659|PROCEDURE|Extubation in post anesthesia care unit|Extubation takes place in post anesthesia care unit
219293604|NCT04656704|DRUG|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
219293605|NCT02440945|DEVICE|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
219293606|NCT00566592|OTHER|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
219293607|NCT00566592|OTHER|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
219293608|NCT00566592|OTHER|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
219293609|NCT00566592|OTHER|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
219293610|NCT01757431|DRUG|Eculizumab|
219293611|NCT05438628|DIAGNOSTIC_TEST|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
219293612|NCT00537654|DRUG|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
219293613|NCT00537654|DRUG|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
219293614|NCT00537654|DRUG|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
219293615|NCT00537654|DRUG|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
219293616|NCT04141059|DIETARY_SUPPLEMENT|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
219293617|NCT04141059|DIETARY_SUPPLEMENT|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
219293618|NCT05958550|BEHAVIORAL|The tympanic membrane temperature of patients was measured.|After the patient entered the anesthesia recovery room ( PACU ) at the end of the operation, the ear canal was cleaned with cotton swabs by nurses trained in the use of ear temperature guns to avoid the impact of earwax. The patient was in a supine position, the patient 's head was fixed, the patient 's auricle was gently pulled back and up, the ear canal was straight, the ear temperature gun was put into the ear canal, the temperature of the patient 's left and right ears was measured uniformly, and the average value was taken as the final body temperature value. Thereafter, the same measurement was performed every 20 minutes until the patient left the resuscitation room.
219293619|NCT02806648|DRUG|Palbociclib|Palbociclib
219293620|NCT03189745|BIOLOGICAL|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
219293621|NCT01056718|DRUG|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
219293622|NCT00502463|DRUG|Docetaxel|75mg/m² day 1
219293623|NCT00502463|DRUG|Cisplatin|75mg/m² day 1
219293624|NCT00502463|DRUG|5-FU|750mg/m²/day day 1-5
219293625|NCT00502463|RADIATION|Radiotherapy|standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks
219293626|NCT00502463|DRUG|Cetuximab|250mg/m²/week after an initial loading dose of 400mg/m²
219293627|NCT02022189|PROCEDURE|Renal Biopsy|
219293628|NCT00160602|DRUG|Certolizumab Pegol|
219293629|NCT04192903|DRUG|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
219293630|NCT05086276|DRUG|FX-322|Active Comparator
219293631|NCT05086276|DRUG|Placebo|Placebo
219293632|NCT06018727|DRUG|Hydrocortisone|Hydrocortisone 20 mg capsule will be administered orally.
219293633|NCT06018727|DIETARY_SUPPLEMENT|Yohimbine|Yohimbine 20 mg capsule will be administered orally.
219293634|NCT06018727|DRUG|Placebo|Two placebos will be administered orally.
219293635|NCT00727701|BEHAVIORAL|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
219293636|NCT00777088|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
219293637|NCT05240079|DEVICE|Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).|Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
219296530|NCT03750045|DIAGNOSTIC_TEST|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
219296531|NCT03750045|OTHER|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
219293638|NCT04018573|BEHAVIORAL|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
219293639|NCT04018573|BEHAVIORAL|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
219293640|NCT04648722|PROCEDURE|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
219293641|NCT02063373|OTHER|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
219293642|NCT00672945|DRUG|PRX-03140|
219293643|NCT00672945|DRUG|Placebo|
219293644|NCT03592745|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
219293645|NCT03592745|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
219293646|NCT06155994|DRUG|68Ga-DOTA-MGS5|intravenous administration
219293647|NCT02047331|PROCEDURE|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
219293648|NCT02047331|PROCEDURE|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
219293649|NCT02712710|DEVICE|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
219293650|NCT00151632|DRUG|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
219293651|NCT00151632|DRUG|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
219293652|NCT06108011|OTHER|Lollipop|sucking of lollipop after operation
219293653|NCT03206762|DEVICE|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
219293654|NCT00004815|DRUG|growth hormone|
219293655|NCT05473611|PROCEDURE|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
219293656|NCT02527863|DRUG|Tolvaptan|60 mg Tolvaptan pr day for 1 day
219293657|NCT02527863|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
219293658|NCT05404724|DRUG|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
219293659|NCT02835118|DRUG|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
219293660|NCT02835118|DRUG|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
219293661|NCT03243682|PROCEDURE|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
219293662|NCT03243682|PROCEDURE|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
219293663|NCT04821024|DIAGNOSTIC_TEST|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
219293664|NCT06233604|DRUG|0.9%sodium chloride|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
219293665|NCT06233604|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
219293666|NCT06233604|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
219293667|NCT05557500|DEVICE|Repitetive transcranial magnetic stimulation|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
219293668|NCT02708407|PROCEDURE|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
219293669|NCT00763776|DEVICE|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
219293670|NCT00763776|DEVICE|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
219293671|NCT04557553|DIETARY_SUPPLEMENT|Lagenbone|Traditional Chinese medicine herbal formula
219293672|NCT02776995|OTHER|Thermography imaging|Thermography imaging of the treated - irradiated body area.
219293673|NCT06311344|DIAGNOSTIC_TEST|Molecular biology analyses|Samples of M. perstans microfilariae will be processed by PCR to investigate the presence (or absence) of Wolbachia using a set of primers targeting the genes ftsZ and 16S and optimized using reference material during the first year of the study. Samples of Schistosoma eggs from urine and feces will be processed for DNA extraction. Each sample will be genetically characterised by multi locus analysis of the mitochondrial cox1 region and the nuclear ITS and 18S rRNA regions. PCR products will be analysed by agarose gel electrophoresis and selected amplicons will be purified and Sanger sequenced. For the individuation of Schistosoma hybrids, the nuclear DNA for each sample will be confirmed by analysis of the species-specific polymorphic positions of the ITS1+2 and 18S. The mitochondrial and nuclear DNA genetic profiles for each individual sample will be recorded to determine the species involved in the infections and also any hybrid schistosomes
219293674|NCT02193126|OTHER|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
219293675|NCT05630729|OTHER|My Kidney Guru|My Kidney Guru is a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.
219293676|NCT06274229|OTHER|Air pollution and noise reducing installations|A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
219293677|NCT05195021|DEVICE|EDDY|EDDY (VDW) sonic irrigation activation system
219293678|NCT05195021|DEVICE|Diode Laser device|980-nm diode laser device
219293679|NCT05195021|DEVICE|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
219293680|NCT03381339|DEVICE|Oscillating rotating power toothbrush|a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
219293681|NCT00587626|DEVICE|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
219293682|NCT00587626|DEVICE|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
219293683|NCT00004583|DRUG|Lopinavir/Ritonavir|
219293684|NCT00004583|DRUG|Nelfinavir mesylate|
219293685|NCT00004583|DRUG|Lamivudine|
219293686|NCT00004583|DRUG|Stavudine|
219293687|NCT02097173|DRUG|Methotrexate|
219293688|NCT03230877|DEVICE|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
219293689|NCT03230877|DEVICE|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
219293690|NCT02387268|DEVICE|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
219293691|NCT00157313|BEHAVIORAL|Integrated treatment, family involvement|
219293692|NCT00157313|BEHAVIORAL|Social skills training|
219293693|NCT00644670|DRUG|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
219296532|NCT02173847|PROCEDURE|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
219296533|NCT02173847|DEVICE|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
219743169|NCT06687083|DEVICE|nasal high frequency oscillatory ventilation mode|"Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter."
219743170|NCT06687083|DRUG|nasal continuous positive pressure ventilation mode|Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
219743171|NCT06690697|DRUG|JS004|200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
219293694|NCT00644670|DRUG|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
219293695|NCT03117998|BIOLOGICAL|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
219293696|NCT03117998|BIOLOGICAL|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
219293697|NCT04624087|BEHAVIORAL|food-specific go/no-go computerized training|Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
219293698|NCT04624087|BEHAVIORAL|nonfood-specific go/no-go computerized training|Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
219293699|NCT04927247|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
219293700|NCT04927247|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
219293701|NCT01796379|BEHAVIORAL|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
219293702|NCT01796379|BEHAVIORAL|Moderate Training|
219293703|NCT04846777|DEVICE|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
219293704|NCT04846777|DEVICE|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
219293705|NCT01636323|OTHER|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
219293706|NCT01485146|DRUG|ETC-1002|escalating doses
219293707|NCT01170390|DRUG|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
219293708|NCT01170390|DRUG|Portia|30 mcg EE/0.15 mg LNG cyclically
219293709|NCT01170390|DRUG|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
219293710|NCT04295967|OTHER|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
219293711|NCT05596253|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
219293712|NCT00612872|DRUG|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
219293713|NCT04188275|DIAGNOSTIC_TEST|Periodic ARV7 and miRNA evaluation|Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
219293714|NCT03408977|OTHER|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
219293715|NCT00438672|DRUG|Placebo Injection|Injection without steroid
219293716|NCT00438672|DRUG|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
219293717|NCT02995642|DRUG|18F-FPPRGD2|One single intravenous injection.
219293718|NCT02995642|DEVICE|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
219293719|NCT02995642|PROCEDURE|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
219293720|NCT02995642|DEVICE|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
219293721|NCT01161875|DEVICE|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~* facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~* helmet use with non-invasive pressure support ventilation mode to define adequate settings~* helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
219293722|NCT02657044|PROCEDURE|EMR|
219293723|NCT02657044|PROCEDURE|ESD|
219293724|NCT02712905|DRUG|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
219293725|NCT02712905|DRUG|all-trans retinoic acid (ATRA)|
219293726|NCT02712905|DRUG|azacitidine|
219293727|NCT02712905|DRUG|nivolumab|
219293728|NCT03391817|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation administered in gastroscopy
219293729|NCT00320528|DRUG|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
219293730|NCT03591653|DRUG|LXI-15028|The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.
219293731|NCT03591653|DRUG|Placebo|Placebo
219293732|NCT02815943|PROCEDURE|biliopancreatic diversion with duodenal switch|
219293733|NCT02815943|PROCEDURE|sleeve gastrectomy|
219293734|NCT02815943|OTHER|liquid meal|will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
219293735|NCT02815943|RADIATION|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
219293736|NCT02815943|OTHER|[7,7,8,8-2H]-palmitate|i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.
219293737|NCT02815943|DEVICE|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
219293738|NCT06220136|DEVICE|TOFscan monitoring|observation and data recording
219293739|NCT04593043|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
219293740|NCT04593043|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure
219293741|NCT00349362|DRUG|Testosterone|Sustanon- 200mg intramuscular testosterone
219293742|NCT00349362|DRUG|0.9% saline|Saline intramuscular injection every two weeks
219293743|NCT05119062|OTHER|Usual care|Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
219293744|NCT05119062|OTHER|an online intergenerational co-parenting programme+usual care|The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
219293745|NCT04664400|BEHAVIORAL|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
219293746|NCT04664400|BEHAVIORAL|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
219293747|NCT04664400|BEHAVIORAL|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
219293748|NCT04664400|BEHAVIORAL|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
219293749|NCT01472458|BEHAVIORAL|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
219293750|NCT02801032|DRUG|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
219293751|NCT02801032|DRUG|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
219293752|NCT05196490|DEVICE|Micro-CT|Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.
219296534|NCT02173847|DEVICE|Diode laser|Low power, near infrared diode laser for welding the surgical wound
219743172|NCT06690697|DRUG|Toripalimab|240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
219743173|NCT06690697|DRUG|Axitinib|5 mg, po, bid, each 21 days as a treatment cycle
219743174|NCT06690697|DRUG|Sorafenib|0.4 g, po, bid, each 21 days as a treatment cycle
219743175|NCT06501339|PROCEDURE|maintenance ECT|Frequency of weekly sessions for 1 month, then fortnightly for 5 months
219743176|NCT06501339|DRUG|Aripiprazole tablet|Aripiprazole 10 mg in the morning throughout the study period
219743177|NCT06355284|OTHER|Functional MRI|While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
219743178|NCT02251470|OTHER|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
219743179|NCT02251470|OTHER|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
219743180|NCT06694740|DRUG|Interferon Gamma 1-b|interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
219743181|NCT06694740|DRUG|Placebo|Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
219743182|NCT06695403|PROCEDURE|Pilates Exercise|"1. Pilates Exercise: The Pilates method is a low-intensity form of movement based on body control, which works the body in a complete way, promoting physical and mental health. PET is different when compared to traditional exercises, which, in turn, tend to isolate the working muscles and have specific training approaches using repetitive motions.~2. Telerehabilitation: Telehealth is emerging as a key method for delivering essential healthcare. Primary care research suggests that telehealth is acceptable and has potential to overcome geographical barriers for individuals needing many times rehabilitation by eliminating the need for extensive and costly travel~3. Diet approach: A customized low-carbohydrate high-fat (LCHF) restricted caloric diet in women with lipedema will be used for 12 weeks. The LCHF diet may be a valuable nutritional strategy for lipedema and overweight/obese women, reducing inflammatory status with a beneficial effect on weight, glucose profile the concentration of"
219743183|NCT06694597|DRUG|Astragalus Membranaceus Root|Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
219743184|NCT06695455|BEHAVIORAL|Swallowing rehabilitation by rhythmic auditory cue|"Three assessments, each spread over two days, will be administered at three different time points during the study: before the experiment (T0), after 7 weeks of the experiment (T1), and 3 months after the intervention (T2). The evaluation will include a pharyngography as well as a clinical assessment of swallowing and rhythmic abilities.~Each subject will be invited to participate in 3 individual rehabilitation sessions per week for 7 weeks, conducted by a speech therapist at La Musse Hospital. Each session will be structured similarly: the subject will be asked to swallow their saliva, followed by a nectar-like texture (IDDSI 2) and a pudding-like texture (IDDSI 4), timed to the rhythm of a metronome. The rhythm will vary throughout the sessions. The goal will be to get as close as possible to the rhythm of a healthy swallow."
219743185|NCT06690073|OTHER|Motor Relearning Program|"Total duration of the intervention is 45 minutes per session (30 minutes of CPT treatment followed by 15 minutes MRP), three sessions per week.~MRP of sitting and standing activities: The physical therapist will instruct the participant, who will be seated in an armrest-equipped chair, to keep their feet back and position their trunk forward.. The participant will then be guided to press down through the affected foot, stand up quickly, and move their hips forward. The therapist will suggest pressing down through the participant's knee along the leg while moving it forward through the affected foot.~MRP of standing to sitting: The participant will stand while the physiotherapist assists with anterior shoulder movement and knee bending at the start of the transition. The therapist will then help maintain weight on the affected leg while sitting. The participant will progress by standing and sitting at different seat heights, stopping at various points in the ROM, and changing speed."
219743186|NCT06690073|OTHER|Conventional Physical Therapy|Conventional Physical Therapy (CPT) will be administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training will be given to the control group.
219743187|NCT06687863|OTHER|Exercise training|Includes aerobic exercise, strength training, streching
219743188|NCT06686225|OTHER|Bowen's technique.|"This group will receive 20 mint per session for 6 weeks of bowen's technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 20 mints~* Type: Bowen's technique"
219743189|NCT06686225|OTHER|Mulligan bent leg raise technique|"This group will receive 15 mints per session for 6 weeks of mulligan's bent leg raise technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 15 mints~* Type: Mulligan bent leg raise technique"
219743190|NCT06686940|DEVICE|intervention group|The monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.
219743191|NCT06689332|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
219743192|NCT06689787|OTHER|Self-Guided STAIR Coach with Real-Time Assessment|Two mobile apps to be used as one intervention package to support participants in their progress through STAIR (Skills Training in Affective and Interpersonal Regulation) with self-monitoring of symptoms and functioning
219743193|NCT06689787|OTHER|Real-Time Assessment|One mobile app to support participants in self-monitoring of symptoms and functioning
219293753|NCT05196490|DEVICE|CAD/CAM|CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
219293754|NCT04041453|DRUG|Ivermectin|Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
219293755|NCT04041453|DRUG|Albendazole|Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
219293756|NCT04870229|DRUG|Carnosine|
219293757|NCT04870229|DRUG|Placebo|Placebo
219293758|NCT03957824|DIAGNOSTIC_TEST|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
219293759|NCT01334424|DRUG|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
219293760|NCT04225689|OTHER|CD-TREAT diet|Dietary intervention
219293761|NCT05606510|OTHER|Mindful exercise|In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.
219293762|NCT05606510|OTHER|usual care|Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
219293763|NCT00002229|DRUG|Saquinavir|
219293764|NCT02923791|BIOLOGICAL|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
219293765|NCT02923791|BIOLOGICAL|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
219293766|NCT06486792|DRUG|Apixaban|Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.
219293767|NCT06486792|DRUG|Aspirin|Aspirin is used as the standard of care
219293768|NCT01856452|DEVICE|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
219293769|NCT01856452|DEVICE|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
219293770|NCT05197283|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219293771|NCT05197283|OTHER|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219293772|NCT05197283|OTHER|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219293773|NCT05197283|OTHER|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219293774|NCT05197283|OTHER|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219293775|NCT01860378|OTHER|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
219293776|NCT01860378|OTHER|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
219293777|NCT03883100|DRUG|HQP1351|40 mg tablet, taken orally once every other day
219293778|NCT00733187|DRUG|ABT-869|0.25 mg/kg
219293779|NCT04520503|DRUG|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
219293780|NCT04520503|DEVICE|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
219293781|NCT00955175|RADIATION|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
219293782|NCT02688218|BEHAVIORAL|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
219293783|NCT02688218|BEHAVIORAL|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
219293784|NCT03457051|PROCEDURE|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
219293785|NCT03457051|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
219293786|NCT04705701|PROCEDURE|Hemodialysis|Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
219293787|NCT04668404|DIAGNOSTIC_TEST|Sonoclot|Sonoclot machine
219293788|NCT01781078|RADIATION|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
219293789|NCT01781078|DEVICE|ImageReady System implant|Pacemaker and lead(s) implant
219293790|NCT05570097|DEVICE|intercostal nerves cryoanalgesia|Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
219293791|NCT01986452|DEVICE|CPAP therapy|
219293792|NCT01986452|OTHER|Support|
219293793|NCT03588559|DIAGNOSTIC_TEST|Blood Pressure Measurement|Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
219293794|NCT02957032|DRUG|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
219293795|NCT02957032|DRUG|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
219293796|NCT01420887|PROCEDURE|Continuous Passive Motion|Continuous passive motion.
219293797|NCT01420887|PROCEDURE|Physical Therapy|Physical therapy.
219293798|NCT05523843|OTHER|Tulsa Life Chart (TLC)|The TLC is a self-administered, interactive assessment of patient history. Participants are asked to provide information from birth to their current age in developmental epochs (i.e., ages 0 to 5; 6 to 10; 11 to 14; 15 to 18; 19 to 25; 26 to 35; and so on in 10-year increments). Participants are first asked to rate their average mood during the epoch. They are then asked about locations lived, schools attended, people they were close to, hobbies, medical conditions, medications, hospitalizations, direct and indirect substance use exposure, mental health symptoms, mental health treatment, and important life events. The information is then displayed in an interactive, graphic of the individual's life that is reviewable by the patient and the healthcare providers enrolled in the study that the patient consents to having access.
219293799|NCT04839952|BEHAVIORAL|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
219293800|NCT04839952|BEHAVIORAL|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
219293801|NCT04174898|BIOLOGICAL|human Mesenchymal Stem Cell (MSC) infusion therapy|Subjects will be infused with 100million human MSCs
219293802|NCT01805752|OTHER|Task-shifting to lower-cadre providers at PMTCT sites|
219293803|NCT01805752|OTHER|POC CD4+ cell count testing|
219293804|NCT01805752|OTHER|integrated mother-infant care|
219293805|NCT01805752|OTHER|Prominent role for influential family members (male partners) in collaboration with CHWs|
219293806|NCT00000686|DRUG|Stavudine|
219293807|NCT05600686|DRUG|Cyclophosphamide|Given IV
219293808|NCT05600686|DRUG|Doxorubicin|Given IV
219293809|NCT05600686|DRUG|Etoposide|Given IV
219293810|NCT05600686|BIOLOGICAL|Loncastuximab Tesirine|Given IV
219293811|NCT05600686|DRUG|Prednisone|Given PO
219293812|NCT05600686|BIOLOGICAL|Rituximab|Given IV
219293813|NCT05600686|DRUG|Vincristine|Given IV
219293814|NCT05069675|PROCEDURE|vitrectomy|vitrectomy with gas tamponade
219293815|NCT04600830|PROCEDURE|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
219293816|NCT00018278|DRUG|Aricept|
219293817|NCT00018278|DRUG|Exelon|
219293818|NCT00018278|DRUG|Nicoderm Patch|
219293819|NCT00649636|DRUG|Fluoxetine Capsules 40 mg|40mg, single dose fasting
219293820|NCT00649636|DRUG|Prozac Pulvules 40 mg|40mg, single dose fasting
219293821|NCT06158932|DIETARY_SUPPLEMENT|Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement|This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
219293822|NCT00003489|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219293823|NCT02062853|OTHER|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
219293824|NCT02062853|OTHER|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
219293825|NCT00000739|DRUG|Dapsone|
219293826|NCT01081132|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
219293827|NCT01081132|OTHER|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
219293828|NCT02019667|DRUG|SGS-742|
219293829|NCT02019667|DRUG|Placebo|
219293830|NCT00021736|DRUG|EYE001 anti-VEGF aptamer|
219293831|NCT05321654|BEHAVIORAL|Education for Behavior Modification|Please see arm description for a detailed description of the intervention
219293832|NCT05321654|BEHAVIORAL|Corrective Exercise Program|Please see arm description for a detailed description of the intervention
219293833|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
219293834|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
219293835|NCT00964964|DRUG|placebo|Placebo injected s.c. (under the skin) four times weekly
219293836|NCT02577822|DEVICE|Taperloc standard length stem|
219293837|NCT02577822|DEVICE|Taperloc short length stem|
219293838|NCT03763890|DEVICE|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
219293839|NCT00015899|DRUG|lonafarnib|
219293840|NCT05398991|DEVICE|the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.|the Coronary Covered Stents System contains a covered stent and a delivery system
219293841|NCT00128089|BEHAVIORAL|Dietary treatment|
219293842|NCT01410968|DRUG|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
219293843|NCT02101385|DRUG|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
219293844|NCT02101385|OTHER|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
219293845|NCT02432196|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
219293846|NCT00287807|BEHAVIORAL|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
219293847|NCT01557114|DRUG|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
219293848|NCT01557114|RADIATION|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
219293849|NCT05607537|DRUG|E7386 Tablet|E7386 40 mg tablet.
219293850|NCT05607537|DRUG|(14C)E7386 Capsule|(14C)E7386 40 mg capsule.
219293851|NCT05607537|DRUG|(14C)E7386|(14C)E7386 administered intravenously.
219296535|NCT02142140|BEHAVIORAL|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
219296536|NCT02142140|BEHAVIORAL|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
219293852|NCT05375032|OTHER|Cycling combined with cognitive tasks|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
219293853|NCT05375032|OTHER|Cycling|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
219293854|NCT06296979|DEVICE|Phrenic nerve neuromodulation|The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
219293855|NCT06296979|PROCEDURE|common Physical therapy|the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
219293856|NCT05038163|OTHER|Nutrition Facts|The nutritional information label for each beverage is enlarged.
219293857|NCT05038163|OTHER|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
219293858|NCT05038163|OTHER|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
219293859|NCT06642896|DEVICE|pupillometer|describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children in intensive care and the operating room
219293860|NCT06642896|DEVICE|pupillometer|Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
219293861|NCT01905150|DRUG|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
219293862|NCT01905150|DRUG|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
219293863|NCT01905150|DIETARY_SUPPLEMENT|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
219293864|NCT00981136|PROCEDURE|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
219293865|NCT00981136|PROCEDURE|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
219293866|NCT02409524|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
219293867|NCT02409524|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
219293868|NCT02409524|BIOLOGICAL|CRCL|Autologous tumor-derived chaperone protein mixture
219293869|NCT05153720|PROCEDURE|Erector spinae plane block|Ultrasound guided erector spinae plane block
219293870|NCT05153720|PROCEDURE|Caudal block|Ultrasound guided caudal block
219293871|NCT05423652|DEVICE|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
219293872|NCT05423652|OTHER|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
219293873|NCT06478342|PROCEDURE|ablation|Pulsed field ablation, MRI and TEE examinations (LA strain)
219293874|NCT05620797|OTHER|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
219293875|NCT05620797|OTHER|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
219293876|NCT05572593|GENETIC|Pharmacogenomics (PGx) genetic testing|A buccal swab to collect cells from the inside the cheek
219293877|NCT01511341|BEHAVIORAL|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
219293878|NCT05625178|DEVICE|Transcutaneous vagus nerve stimulation|tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
219293879|NCT00002745|DRUG|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
219293880|NCT06092567|PROCEDURE|Group A ( Oblique Incremental Placement Technique)|In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
219293881|NCT06092567|PROCEDURE|Group B (Bulk-fill Placement technique)|In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm
219293882|NCT04715438|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
219293883|NCT04116801|PROCEDURE|microsurgical resection|resection of cerebral metastases by microsurgery
219293884|NCT02085395|DRUG|SR-T100 ® Gel|
219293885|NCT03762200|DEVICE|SURGICEL Powder|SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
219293886|NCT03984981|OTHER|Assessment of process required to diagnose brain death in adult patients|Assessment of process required to diagnose brain death in adult patients (demographics, clinical, laboratory, imaging, and treatment data). No questionnaires or study visits will be used.
219293887|NCT04902677|OTHER|Cross-sectional|No intervention
219293888|NCT05918276|DRUG|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
219293889|NCT02417077|OTHER|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
219293890|NCT06194487|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50mL) per day
219293891|NCT06194487|DIETARY_SUPPLEMENT|MAXI Collagen drink|consume 1 bottle (50mL) per day
219293892|NCT06194487|DIETARY_SUPPLEMENT|Normal fish collagen drink|consume 1 bottle (50mL) per day
219293893|NCT02241590|DRUG|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
219293894|NCT02241590|DRUG|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
219293895|NCT04206657|DRUG|1mg KHK7580|Single oral dose administration of 1mg KHK7580
219293896|NCT04206657|DRUG|3mg KHK7580|Single oral dose administration of 3mg KHK7580
219293897|NCT04206657|DRUG|6mg KHK7580|Single oral dose administration of 6mg KHK7580
219293898|NCT04206657|DRUG|12mg KHK7580|Single oral dose administration of 12mg KHK7580
219293899|NCT04206657|DRUG|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
219293900|NCT00004094|DRUG|carboplatin|
219293901|NCT00004094|DRUG|fluorouracil|
219293902|NCT00004094|DRUG|hydroxyurea|
219293903|NCT00004094|DRUG|paclitaxel|
219293904|NCT00004094|PROCEDURE|conventional surgery|
219293905|NCT00004094|RADIATION|radiation therapy|
219293906|NCT00071461|DRUG|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
219293907|NCT00071461|DRUG|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
219293908|NCT05436990|DRUG|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
219293909|NCT06405568|BEHAVIORAL|Physical activity intervention|Participants will receive a copy of physical activity (PA) recommendations plus a PA motivation package - namely three 20-minute online webinars (explaining PA benefits and how to get started), digitized PA materials (integrating evidence-based behaviour change tools, and a digitized logbook (to track PA).
219293910|NCT06649331|DRUG|SHR-A1811|A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
219293911|NCT06649331|DRUG|SHR-A1921|A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
219293912|NCT06649331|DRUG|SHR-A2009|A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
219293913|NCT06649331|DRUG|SHR-A2102|A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
219293914|NCT06589700|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder.
219293915|NCT06678880|BEHAVIORAL|Phase Advanced Intervention (PAI)|Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
219293916|NCT06678880|BEHAVIORAL|Phase Delay Intervention (PDI)|Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
219293917|NCT06243354|DRUG|Test product: HYP-2090PTSA|"Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest)."
219293918|NCT06682481|OTHER|Measurement of biomarker|Measurement of blood levels of 1,5-anhydroglucitol
219293919|NCT03797690|PROCEDURE|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
219293920|NCT03797690|PROCEDURE|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
219293921|NCT02522559|OTHER|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
219293922|NCT05110690|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
219293923|NCT05110690|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
219293924|NCT06870214|OTHER|relaxation|Women in the 3rd trimester will receive routine care only.
219293925|NCT03091660|BIOLOGICAL|BCG Solution|Given intravesically
219293926|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Solution|Given intravesically
219293927|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Vaccine|Given ID
219293928|NCT03091660|OTHER|Laboratory Biomarker Analysis|Correlative studies
219293929|NCT06872723|BEHAVIORAL|Lung Cancer Screening|Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening
219293930|NCT06708832|DEVICE|SIMBA ingestion|Ingestion of 2 SIMBA capsules at the same time and their excretion.
219293931|NCT06715150|DRUG|Azithromcyin|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
219293932|NCT06715150|OTHER|Placebo|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
219293933|NCT02328235|OTHER|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
219293934|NCT06723886|DIETARY_SUPPLEMENT|Experimental arm: Olive pomace oil|Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
219743194|NCT06695871|OTHER|Patient navigation-based health management|A patient navigation-based health management model for individuals with cervical lesions post-LEEP procedure, encompassing healthcare consultation services, personalized health guidance, and routine follow-up assessments.
219743195|NCT06686160|OTHER|Plyometrics Training|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise, Plyometrics are primarily used by athletes to improve performance and are used in the fitness field to a much lesser degree. This training focuses on learning to move from a muscle extension to a contraction in a explosive way, for example repeated jumping.
219743196|NCT06686160|OTHER|Theraband Resistance Exercise|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise Therabands is a Set of bands which are primarily use for resistance Training for strength and Power.
219743197|NCT06686706|OTHER|IASTM|"Graston therapy-8 min per session~Procedure:~The patient will be lying down with their knee bent 30 degrees. After a 5-minute ultrasound treatment and static stretching exercises.Treatment will be administered using the Graston tool (using the sweep approach). Applying a moderate amount of effort from the medial side of the heel to the metatarsals and from the metatarsals to the medial side of the heel, to-and-fro stroking at a 60° angle will be done on the sole of the foot for approximately eight minutes (60-70 strokes per minute with a 5- to 10-second rest interval. A cold pack will be used for five minutes after therapy. The GT session will last approximately 30 minutes.~Conventional Therapy:~Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min Functional status and Quality of Life (QOL) will be assessed before and after treatment of 4 weeks using using tools.~Intervention will be conducted once a week for 4 weeks."
219293935|NCT06723886|DIETARY_SUPPLEMENT|High-oleic acid sunflower oil|Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
219293936|NCT06728124|DRUG|GZR18|Used as specified in the protocol
219293937|NCT06728124|OTHER|Placebo|Administered the same volume as GZR18
219293938|NCT06729372|BEHAVIORAL|Deliberate Flawed Performance|Deliberate Flawed Performance during simulation-based training
219293939|NCT06729372|BEHAVIORAL|Error Avoidance Training|Error Avoidance during simulation-based training
219293940|NCT06886529|OTHER|ML-based intervention|ML model predicting a serious cardiac event in cardiac patients, defined as VAD procedure, being wait listed for heart transplant or death within the next three months.
219293941|NCT06726707|COMBINATION_PRODUCT|Diaper with a copper-based product + usual care|The intervention is an incontinence aid product and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
219293942|NCT06726707|COMBINATION_PRODUCT|Barrier product with common diaper|The common diaper is an incontinence aid and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
219293943|NCT06743685|BEHAVIORAL|HEALthy Beginnings|HEALthy Beginnings, an innovative, enhanced, trauma-informed, chronic disease self-care program and nurse-driven intervention, developed and tailored for middle-aged, and older, homeless women (MAO-HW).
219293944|NCT06896617|DRUG|Estradiol + Progesterone|Pregnancies with absence of corpus luteum(PC-FET)
219293945|NCT06896617|DRUG|Ovitrelle ( Hcg 250 mcg)|NC-FET(natural cycle FET, endometrial preparation with presence of CL)
219293946|NCT06900803|DEVICE|interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)|The dashboard serves as an interactive communication tool during education sessions, promoting real-time dialogue between patients and pharmacists. By collaboratively entering patient-specific data, patients gain insight into personalized visual representations of actionable risk factors. Initially, data specific to the patient are inputted to generate a baseline assessment, presenting hazard ratios that indicate the current condition and pinpoint areas needing improvement. To simulate potential changes, an alternative dataset is deliberately entered, portraying either improvement or deterioration in the patient's status, thereby acting as a motivational tool. Throughout the education session, the dashboard continuously updates hazard ratios, enabling direct comparisons of patient outcomes under varying conditions or treatment scenarios. This dynamic process clearly demonstrates individualized risk-benefit trade-offs in diverse treatment contexts.
219293947|NCT06546020|DIETARY_SUPPLEMENT|Haskap berry smoothie|A smoothie blend of berries and water
219293948|NCT06546020|DIETARY_SUPPLEMENT|Placebo comparator|A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
219293949|NCT03973931|BEHAVIORAL|Nudge|Interventions will include a variety of text messages aimed at improving medication adherence.
219293950|NCT06907316|DRUG|Cefixime 400mg|cefixime 400 mg taken orally two times a day for 14 consecutive days
219293951|NCT06907316|DRUG|Benzathine penicillin 2.4 million units|single dose of benzathine penicillin G 2.4 MIU intramuscularly
219293952|NCT06906003|OTHER|visual rehabilitation program|"I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of table activities V. meeting: meeting with caregivers."
219293953|NCT06906484|DEVICE|echocardiography|analyse echocardiographic reports on cardiac abnomalies
219293954|NCT06907121|DRUG|Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma|Intervention will be an intra-articular injection of 10 units of HGH and 10 mL PRP conjunct. Three total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.
219293955|NCT04574856|RADIATION|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
219293956|NCT04574856|DRUG|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
219293957|NCT04574856|DRUG|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
219293958|NCT06906289|OTHER|resumption of enteral feeding within 24 hours of surgery|Patients will be subjected to resumption of enteral feeding within 24 hours of surgery
219293959|NCT06906289|OTHER|resumption of enteral feeding after 24-48 hours|Patients will be subjected to late resumption of enteral feeding after 24 to 48 hours of surgery
219293960|NCT06907589|DEVICE|Motor Data Analysis|The SensMode System includes wearable devices for upper and lower limb motion analysis. The upper limb device, SensHand, consists of 3 sensorized elements: 2 sensorized rings to be placed at the level of the distal phalanx of the thumb and forefinger of the hand and 1 sensorized wristband to be placed at the level of the distal portion of the forearm near the wrist. Each element of SensHand allows the acquisition of inertial data with respect to the biomechanics of the arm-forearm-wrist and the first three fingers of the hand, measuring the 3 components in space of linear acceleration, angular velocity, and magnetic field. The lower limb device, SensFoot, is a device that integrates the same electronic components as the bracelet and is placed in a plastic housing shaped like a small rectangular parallelepiped that is placed over the shoe.
219293961|NCT06906172|BEHAVIORAL|Plant-based intensive lifestyle intervention|The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.
219293962|NCT06906172|OTHER|Standard of Care|Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.
219293963|NCT06907368|OTHER|Quantitative Gait Analysis|"The following explorations will be carried out pre-operatively (pre-OP), then post-operatively at 3 months (post-OP3) and 12 months (post-OP12) :~* Quantified gait analysis (QGA)~* Functional tests (mechanical analysis of everyday tasks):~  * SIT-TO-STAND test (test consisting of standing up and sitting down on a chair)~ * STEP INITIATION test (test consisting of walking up a step and then down)~* Proprioceptive tests :~  * Joint Position Sense (JPS) (angle memorization and reproduction test at the knee joint)~ * OBSTACLE CLEARANCE test (test consisting in simulating the clearance of an obstacle)~* Questionnaires :~  * Functional questionnaires :~ * KSS (Knee Society Score)~ * SKV (Simple knee value)~ * KOOS (Knee Injury and Osteoarthritis Outcome Score)~ * Quality of life (EQ5D-5L) The total duration of each exploration session is estimated at 1 hour ."
219293964|NCT06906055|DEVICE|Multicath|Use of a multifunctional catheter for revascularization of blocked arteries below the knee
219293965|NCT06906055|DEVICE|Standard of Care (SOC)|Use of single function crossing catheters, diagnostic catheters, angioplasty balloon catheters
219293966|NCT06907069|DRUG|Intravenously atomized polycolistin E sodium mesylate|To explore the therapeutic effect of CMS combined with intravenous atomization in patients with carbapenem resistant gram-negative bacteria in lung infection.
219293967|NCT06907641|DRUG|64Cu-SAR-bisPSMA|All participants will receive a single administration of 200 MBq of 64Cu-SAR-bisPSMA
219293968|NCT05762055|DEVICE|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
219293969|NCT05762055|DEVICE|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
219293970|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
219293971|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
219293972|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
219293973|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
219293974|NCT06094387|DIAGNOSTIC_TEST|Thrombin generation assay|Thrombin generation parameters in patients receiving central catheter insertion
219293975|NCT01022112|DRUG|TA-7284-Low|TA-7284-Low
219293976|NCT01022112|DRUG|TA-7284-Low-middle|TA-7284-Low-middle
219293977|NCT01022112|DRUG|TA-7284-High-middle|TA-7284-High-middle
219293978|NCT01022112|DRUG|TA-7284-High|TA-7284-High
219293979|NCT01022112|DRUG|Placebo|Placebo
219293980|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
219293981|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
219293982|NCT05521438|DRUG|Vehicle|Vehicle Lotion
219293983|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
219293984|NCT00925353|DRUG|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
219293985|NCT00006353|DRUG|temozolomide|
219293986|NCT00006353|RADIATION|radiation therapy|
219293987|NCT01153867|BEHAVIORAL|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
219293988|NCT00905515|DRUG|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
219293989|NCT00905515|DRUG|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
219293990|NCT00358176|DRUG|Risedronate (HMR4003)|
219293991|NCT00563888|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
219293992|NCT04013048|DRUG|[14C]-Fluzoparib|Patients will receive single dose of orally \[14C\]- Fluzoparib on Day 1.
219293993|NCT01455389|DRUG|DOTAP:Chol-TUSC2|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
219293994|NCT01455389|DRUG|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
219293995|NCT01455389|DRUG|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
219293996|NCT01455389|DRUG|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
219293997|NCT04187807|DRUG|Melatonin 5 mg|Placebo
219293998|NCT05103787|PROCEDURE|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
219293999|NCT05103787|PROCEDURE|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
219294000|NCT03057522|BEHAVIORAL|Change in running cadence|The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
219294001|NCT04312334|OTHER|Control|Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
219294002|NCT04312334|OTHER|Treatment|The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
219294003|NCT03394001|PROCEDURE|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
219294004|NCT03394001|DRUG|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
219294005|NCT03394001|DRUG|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
219294006|NCT00081627|DRUG|CoFactor and 5FU|
219294007|NCT05401825|BIOLOGICAL|pfizer, astrazeneca,moderna,sinofac|effect of COVID 19 vaccination on pregnancy outcomes
219294008|NCT05616520|DEVICE|drug-coated balloon|The intervention relates to a drug-coated balloon catheter includes a balloon and cover the drug-coated balloon surface.
219294009|NCT01835938|DRUG|1- Erlotinib|"* Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,"
219294010|NCT01835938|DRUG|placebo|"* Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,"
219294011|NCT03123601|DEVICE|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~* Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~* Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
219294012|NCT01234077|DEVICE|CPC M1|CPC M1
219294013|NCT02980731|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
219294014|NCT03552432|DRUG|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
219294015|NCT04694209|PROCEDURE|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
219294016|NCT04694209|PROCEDURE|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
219294017|NCT03037931|DRUG|Ferric Carboxymaltose|Intravenous Iron
219294018|NCT03037931|DRUG|Placebo|Normal Saline Solution
219294019|NCT00605215|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
219294020|NCT00605215|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
219294021|NCT00605215|DRUG|Avonex®|Avonex® will be administered per dose and schedule specified in the arm description.
219294022|NCT04140019|DIAGNOSTIC_TEST|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
219294023|NCT04123574|DRUG|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
219294024|NCT00214578|DRUG|Seroquel (quetiapine)|
219294025|NCT02474485|DEVICE|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
219294026|NCT02474485|DEVICE|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
219294027|NCT02474485|PROCEDURE|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
219294028|NCT02474485|PROCEDURE|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
219294029|NCT02474485|OTHER|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
219294030|NCT02837224|DEVICE|The Situate Detection System|The Situate Detection System for locating surgical sponges
219294031|NCT01716897|DRUG|E2609|
219294032|NCT02081443|DRUG|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
219294033|NCT02081443|DRUG|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
219294034|NCT00658255|DRUG|budesonide/formoterol|
219294035|NCT00658255|DRUG|formoterol|
219294036|NCT03053687|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
219294037|NCT03053687|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
219294038|NCT02121951|PROCEDURE|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
219296537|NCT02142140|BEHAVIORAL|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
219294039|NCT02121951|PROCEDURE|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
219294040|NCT02121951|DRUG|MAC|Incremental doses are given to the targed sedation and analgesia
219294041|NCT02914275|BIOLOGICAL|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
219294042|NCT02914275|BIOLOGICAL|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
219294043|NCT03134105|OTHER|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
219294044|NCT03134105|OTHER|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
219294045|NCT06138314|OTHER|Physical Exercise Program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
219294046|NCT06138314|OTHER|Neural Mobilization|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
219294047|NCT00134745|DRUG|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
219294048|NCT03191500|DEVICE|steerable catheter|peripheral vascular disease
219294049|NCT04049734|DRUG|oral losatan|50 mg of oral losartan one hour before the ERCP once
219294050|NCT04869228|DRUG|GT0918 tablets or placebo|GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
219294051|NCT06301425|OTHER|Intervention group|"Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7."
219294052|NCT06301425|OTHER|Control group|Receive allo-HSCT directly without the second consolidation chemotherapy.
219294053|NCT01275950|BEHAVIORAL|Health Education|"1. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~2. Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~3. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
219294054|NCT03074890|DEVICE|Application Protocol|Application lMassive Transfusion Protocol
219294055|NCT02766192|DRUG|Ketamine|
219294056|NCT02766192|BEHAVIORAL|TIMBER Psychotherapy|
219294057|NCT02766192|DRUG|Placebo (normal saline)|
219294058|NCT02139293|DEVICE|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
219294059|NCT03635528|DEVICE|Test Lens 1|EMO-114
219294060|NCT03635528|DEVICE|Test Lens 2|EMO-116
219294061|NCT03635528|DEVICE|Test Lens 3|EMO-118
219294062|NCT03635528|DEVICE|Test Lens 4|RMY-100
219294063|NCT03635528|DEVICE|Test Lens 5|Biofinity multifocal D Lens
219294064|NCT03635528|DEVICE|Control Lens 1|EMO-117
219294065|NCT03635528|DEVICE|Control Lens 2|Proclear 1 day
219294066|NCT00551590|DRUG|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
219294067|NCT00551590|DRUG|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
219294068|NCT00551590|DRUG|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
219294069|NCT00551590|DRUG|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
219294070|NCT00661479|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
219294071|NCT00661479|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
219294072|NCT00661479|DRUG|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
219294073|NCT00661479|OTHER|Sham (no implant)|Sham in the fellow eye on Day 1.
219294074|NCT01084837|DRUG|velcade|"INDUCTIoN (Cycles 1-4)~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~* Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~* Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
219294075|NCT03090243|DEVICE|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
219294076|NCT03208777|GENETIC|taking blood samples|taking blood samples and measure telomeric abnormalities
219294077|NCT02259647|DRUG|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
219294078|NCT02259647|DRUG|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
219294079|NCT01302067|DRUG|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
219294080|NCT01302067|DRUG|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
219294081|NCT01302067|DRUG|Placebo|Oral, 1 tablet per day, 12 weeks duration
219294082|NCT04864288|DEVICE|Shear Wave Elastography|is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
219294083|NCT00834626|PROCEDURE|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
219294084|NCT04613232|DEVICE|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
219294085|NCT02738203|DRUG|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
219294086|NCT02738203|DRUG|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
219294087|NCT04330924|OTHER|Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)|3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
219294088|NCT05022160|DRUG|pudendal nerve block|All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
219294089|NCT04675190|PROCEDURE|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
219294090|NCT03934138|OTHER|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
219294091|NCT03934138|OTHER|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
219294092|NCT03241927|BIOLOGICAL|Pembrolizumab|Day 1 of each 3 week cycle
219294093|NCT04107987|DIETARY_SUPPLEMENT|Reglicem|Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
219294094|NCT04107987|OTHER|Placebo|Placebo
219294095|NCT05887154|DEVICE|Microwave ablation|microwave ablation
219294096|NCT03559231|PROCEDURE|dFTRD|Duodenal Full-Thickness Resection
219294097|NCT03559231|PROCEDURE|EMR|Endoscopic Mucosal Resection
219294098|NCT03866499|DRUG|BPI-7711|180 mg, oral, QD
219294099|NCT03866499|DRUG|Gefitinib|250 mg, oral, QD
219294100|NCT03866499|DRUG|Placebo Tablet|250 mg gefitinib placebo tablet, QD
219294101|NCT03866499|DRUG|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
219294102|NCT02275832|DRUG|3 % Minoxidil lotion|
219294103|NCT02275832|DRUG|Placebo|
219294104|NCT00828477|DRUG|Xibrom|Xibrom: two times a day for seven days in the first eye.
219294105|NCT00828477|DRUG|Nevanac|Nevanac: three times a day for seven days in the second eye.
219294106|NCT00153881|DRUG|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
219294107|NCT02704754|DRUG|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
219294108|NCT02704754|OTHER|placebo|Pill with inactive ingredients
219294109|NCT01900197|DRUG|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
219294110|NCT04698642|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
219294111|NCT00423943|DRUG|modafinil|200 milligrams daily dose
219294112|NCT00423943|DRUG|Placebos|capsule containing placebo
219294113|NCT04032587|BEHAVIORAL|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
219294114|NCT04032587|BEHAVIORAL|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
219294115|NCT01048554|DRUG|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
219294116|NCT01048554|DRUG|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
219294117|NCT05216497|DRUG|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
219294118|NCT05216497|DRUG|Placebo|1-2 capsules for 7 days on top of standard therapy
219294119|NCT05999643|DIAGNOSTIC_TEST|Drug: 68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image SpA lesions in SI joints, spine, musculoskeletal and the extra-articular involvement by PET/CT.
219294120|NCT04464954|DEVICE|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
219294121|NCT04464954|DEVICE|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
219294122|NCT04464954|DEVICE|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
219294123|NCT03636282|BEHAVIORAL|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
219294124|NCT05611008|DEVICE|CDSS|A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.
219294125|NCT05611008|DEVICE|Patient Portal|A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
219294126|NCT05972031|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
219294127|NCT03809429|DRUG|FE 999049 + GnRH agonist (GONAPEPTYL)|Pre-filled injection pen
219294128|NCT03809429|DRUG|FE 999049 + GnRH antagonist (CETROTIDE)|Powder and solvent for solution for injection
219294129|NCT04447664|DEVICE|Inclouded telespirometry system|Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
219294130|NCT02050711|BEHAVIORAL|Pulmonary rehabilitation|
219294131|NCT02050711|OTHER|Usual care|
219294132|NCT02596438|OTHER|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
219294133|NCT00538915|BIOLOGICAL|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
219294134|NCT00840151|BEHAVIORAL|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
219294135|NCT04639271|DRUG|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
219294136|NCT04639271|DRUG|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
219294137|NCT04639271|DRUG|Abraxane|Abraxane 125mg/M2, qw iv
219294138|NCT01251185|DEVICE|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
219294139|NCT02323282|DRUG|ropivacaine|
219294140|NCT03464799|OTHER|immunohistochemical staining|immunohistochemical staining
219294141|NCT02273817|DRUG|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
219294142|NCT05273697|PROCEDURE|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
219294143|NCT05273697|PROCEDURE|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
219294144|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
219294145|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
219294146|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
219294147|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
219294148|NCT02943486|OTHER|dac-MSCs|Cell-free therapy
219294149|NCT02943486|OTHER|MSCs|Cell-based therapy
219294150|NCT02943486|DRUG|Fitostimoline|Triticum vulgare
219294151|NCT00987246|DRUG|Placebo Gel|Topical
219294152|NCT00987246|DRUG|LAS41005|Topical
219294153|NCT00987246|DRUG|LAS106521|Topical
219294154|NCT01327859|DRUG|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
219294155|NCT01327859|DRUG|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
219294156|NCT01327859|DRUG|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
219294157|NCT03611413|PROCEDURE|ERAS care|ERAS PROTOCOL
219294158|NCT01329692|BEHAVIORAL|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
219294159|NCT02383056|DEVICE|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
219294160|NCT02383056|DEVICE|Omnilux Sham|Sham light instead of phototherapy from the same light device
219294161|NCT04214600|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills"
219294162|NCT01181388|PROCEDURE|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
219294163|NCT01181388|PROCEDURE|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
219294164|NCT05351359|BEHAVIORAL|mHealth|A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
219294165|NCT05351359|BEHAVIORAL|phone counselling|Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.
219294166|NCT05351359|BEHAVIORAL|Fitbit tracker|Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
219294167|NCT05351359|BEHAVIORAL|brief advice|A brief advice will be provided by the general practitioner at the start of the study.
219294168|NCT06799481|OTHER|Aerobic Exercise|Participate in personalized, progressive aerobic training
219294169|NCT06799481|BEHAVIORAL|Behavioral Intervention|Receive active lifestyle behavior coaching
219294170|NCT06799481|PROCEDURE|Follow-Up|Receive calls from the trainer
219294171|NCT06799481|OTHER|Internet-Based Intervention|Receive access to Physitrack
219294172|NCT06799481|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit monitor
219294173|NCT06799481|OTHER|Questionnaire Administration|Ancillary studies
219294174|NCT06799481|OTHER|Resistance Training|Participating in strength training exercises
219294175|NCT02978378|OTHER|biomarker levels|The level of the biomarker hyaluronic acid will be measured
219294176|NCT02485782|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
219294177|NCT02485782|DEVICE|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
219294178|NCT02485782|DEVICE|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
219294179|NCT03111251|BEHAVIORAL|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
219294180|NCT03111251|BEHAVIORAL|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
219294181|NCT03111251|BEHAVIORAL|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
219294182|NCT03111251|BEHAVIORAL|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
219294183|NCT03111251|BEHAVIORAL|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
219294184|NCT02501798|DRUG|Methylphenidate|Drug: Methylphenidate
219294185|NCT02501798|DRUG|Placebo|Drug: Placebo
219294186|NCT01968993|DEVICE|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
219294187|NCT03245151|DRUG|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
219294188|NCT03245151|DRUG|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
219294189|NCT02571595|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
219294190|NCT00601770|BIOLOGICAL|IC41|injection
219294191|NCT04079751|PROCEDURE|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
219294192|NCT04079751|PROCEDURE|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
219294193|NCT06002893|DIETARY_SUPPLEMENT|Cholesfytol NG®) supplement|General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement
219294194|NCT02611336|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
219294195|NCT03507777|DEVICE|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
219294196|NCT03507777|DEVICE|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
219294197|NCT00169078|DRUG|Chloroquine|
219294198|NCT01354184|DRUG|CRD007|
219294199|NCT01354184|DRUG|CRD007 matching placebo|
219294200|NCT04719975|OTHER|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
219294201|NCT04719975|OTHER|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
219294202|NCT02233452|DRUG|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
219294203|NCT02233452|DRUG|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
219294204|NCT02233452|DRUG|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
219294205|NCT04288609|OTHER|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
219294206|NCT04288609|OTHER|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
219294207|NCT00542243|DRUG|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
219294208|NCT00542243|DRUG|Placebo|Placebo will be given once a day for 6 months.
219294209|NCT06308003|PROCEDURE|Anterior hip arthroplasty|Anterior hip arthroplasty
219294210|NCT04064593|DIAGNOSTIC_TEST|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
219294211|NCT03009552|PROCEDURE|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
219294212|NCT06631950|OTHER|Educational intervention|The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
219294213|NCT05954507|DIAGNOSTIC_TEST|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
219294214|NCT04321668|DEVICE|Synvisc-One|SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication
219294215|NCT02535429|OTHER|massage|
219294216|NCT06610721|DIAGNOSTIC_TEST|Urine Biomarkers|At baseline midstream urine will be collected in a sterile urine container.
219294217|NCT04397991|OTHER|Furosemide|Patients will receive nebulised furosemide solution 1 mg/kg
219294218|NCT04397991|OTHER|Placebo|Patients will receive nebulised 0.9% saline
219294219|NCT01375400|DRUG|Aspirin|Administration of 300 mg of aspirin, per os.
219294220|NCT01375400|BIOLOGICAL|blood sample|2 blood samples will be performed
219294221|NCT02018939|OTHER|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
219294222|NCT03666377|OTHER|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
219294223|NCT00641329|DRUG|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
219294224|NCT00641329|DRUG|Placebo|Matching placebo tablets
219294225|NCT03698500|OTHER|Removal of blood|10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
219294226|NCT04484103|OTHER|Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.|"The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used."
219294227|NCT00092352|DRUG|MK0966, rofecoxib|
219294228|NCT00092352|DRUG|Comparator: celecoxib, placebo|
219294229|NCT03848013|DEVICE|Q switched Nd YAG laser|Laser device emitting Q switched Nd YAG aiming for skin toning
219294230|NCT03848013|DEVICE|Fractional CO2 laser|Laser device emitting fractionated ablative laser aiming for skin resurfacing
219294231|NCT03041051|BIOLOGICAL|PCV13|
219294232|NCT03041051|BIOLOGICAL|PPV23|
219294233|NCT04725786|OTHER|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
219294234|NCT06148363|DEVICE|High-Definition transcranial Direct Current Stimulation (HD-tDCS)|tDCS, or Transcranial Direct Current Stimulation, is a non-invasive brain stimulation technique that involves applying a small, constant direct current through electrodes placed on the scalp to modulate neuronal activity in specific brain regions.
219294235|NCT06148363|DEVICE|sham High-Definition transcranial Direct Current Stimulation (HD-tDCS)|In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
219294236|NCT00006011|DRUG|Doxorubicin Hydrochloride|Given IV
219294237|NCT00006011|DRUG|Cisplatin|Given IV
219294238|NCT00006011|BIOLOGICAL|Filgrastim|Given SC
219294239|NCT00006011|BIOLOGICAL|Pegfilgrastim|Given SC
219294240|NCT00006011|DRUG|Paclitaxel|Given IV
219294241|NCT00345527|BEHAVIORAL|Emotion and Behaviour Regulation Treatment (EBRT)|
219294242|NCT00345527|BEHAVIORAL|Cognitive Behavioural Therapy|
219294243|NCT05366101|DRUG|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
219294244|NCT05366101|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
219294245|NCT01001338|DRUG|RDEA594|Uricosuric agent for the treatment of gout.
219294246|NCT01001338|DRUG|Placebo|Matching Placebo
219294247|NCT01001338|DRUG|Allopurinol|Allopurinol
219294248|NCT03178643|DRUG|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
219294249|NCT03178643|DRUG|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
219294250|NCT03178643|DRUG|Dihydroartemisinin-Piperaquine (DP)|"3\) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
219294251|NCT06429644|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
219294252|NCT03082118|DEVICE|Vesair Bladder Control System|Intravesical balloon
219294253|NCT00774930|DRUG|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
219294254|NCT00774930|DRUG|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
219294255|NCT02890212|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
219294256|NCT02890212|DIETARY_SUPPLEMENT|placebo|administration of placebo pills for randomized subjects
219294257|NCT01153321|DRUG|AZD2423|100mg Oral dose od
219294258|NCT01153321|DRUG|AZD2423 Placebo|Oral dose od
219294259|NCT02751541|DRUG|Sunscreen Sport Spray (BAY987519)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
219294260|NCT02751541|OTHER|Untreated Skin|This site is patched without treatment as irradiated control.
219294261|NCT04461093|OTHER|Acupressure wristband and Palanosetron|"Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction."
219294262|NCT01471496|PROCEDURE|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
219294263|NCT04393753|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
219294264|NCT06332937|PROCEDURE|postmastectomy breast reconstruction|postmastectomy immediate breast reconstruction
219294265|NCT06448273|DRUG|TQB3702 tablets|TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
219294266|NCT06448273|DRUG|TQB3702 placebo|TQB3702 placebo contains no active substance.
219294267|NCT04848701|OTHER|latent phase duration|latent phase duration in post term pregnancies
219294268|NCT04848701|OTHER|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
219294269|NCT05336851|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)
219294270|NCT04325360|PROCEDURE|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
219294271|NCT04325360|PROCEDURE|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
219294272|NCT04849494|OTHER|ATS-DLD-78-C and ISAAC questionnaires|Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history
219294273|NCT04781400|BEHAVIORAL|Mobile phone support|Mobile phone support (SMS)
219294274|NCT04781400|BEHAVIORAL|Remote service delivery model|ART treatment delivery via a courier service
219294275|NCT05161728|DIAGNOSTIC_TEST|PSMA-PET/CT|PSMA-PET/CT
219294276|NCT03898037|BEHAVIORAL|weight loss intervention|weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.
219294277|NCT03898037|DRUG|metformin intervention|metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
219294278|NCT01841931|DRUG|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
219294279|NCT04284215|DRUG|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
219294280|NCT04428268|DRUG|Chloroquine Phosphate Tablets|Orally administered
219294281|NCT01498679|DRUG|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
219294282|NCT01498679|DRUG|Placebo|Placebo administered once daily in the evening via a NDPI
219294283|NCT02369146|DRUG|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
219294284|NCT05882552|DIAGNOSTIC_TEST|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
219294285|NCT05882552|DIAGNOSTIC_TEST|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
219294286|NCT02114710|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
219294287|NCT02635568|OTHER|Cannabis Use|Observational Study
219294288|NCT00157560|DRUG|Chemotherapy, multiple agents|
219294289|NCT04619940|DIAGNOSTIC_TEST|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
219294290|NCT04619940|DIAGNOSTIC_TEST|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
219294291|NCT05201118|DRUG|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
219294292|NCT05201118|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
219294293|NCT00626301|DRUG|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
219294294|NCT01424449|RADIATION|[11C]PHNO|examine the effects of \[11C\]PHNO mass carry-over and displaceable binding
219294295|NCT01424449|DRUG|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
219294296|NCT02608723|DEVICE|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
219294297|NCT02608723|DEVICE|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
219294298|NCT02608723|DEVICE|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
219294299|NCT02775773|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
219294300|NCT02775773|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
219294301|NCT04005573|DIETARY_SUPPLEMENT|VD3|VD3 50000 IU/ week for 8 weeks
219294302|NCT04005573|DIETARY_SUPPLEMENT|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
219294303|NCT04005573|DIETARY_SUPPLEMENT|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
219294304|NCT04005573|OTHER|no intervention|no intervention is given
219294305|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
219294306|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
219294307|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
219294308|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
219294309|NCT00613665|BIOLOGICAL|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
219294310|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
219294311|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
219294312|NCT03273361|BEHAVIORAL|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
219294313|NCT03212989|DRUG|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
219294314|NCT03212989|BIOLOGICAL|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
219294315|NCT02988518|BEHAVIORAL|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
219294316|NCT00003773|DRUG|oglufanide disodium|
219294317|NCT04357444|DRUG|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
219294318|NCT04357444|DRUG|2: Placebo Comparator|placebo in Subcutaneous route
219294319|NCT04241107|PROCEDURE|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
219294320|NCT04241107|PROCEDURE|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
219294321|NCT02225210|DRUG|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
219294322|NCT02225210|DRUG|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
219294323|NCT02225210|DRUG|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
219294324|NCT02302378|PROCEDURE|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
219294325|NCT02302378|PROCEDURE|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
219294326|NCT04379505|DEVICE|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
219294327|NCT04379505|RADIATION|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
219294328|NCT05854095|DEVICE|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
219294329|NCT05672420|BIOLOGICAL|umbilical cord derived mesenchymal stem cells|umbilical cord derived mesenchymal stem cells, intravenous infusion
219294330|NCT04480138|DRUG|Pegylated Interferon-α2b|1 mcg/kg on day 1 and day 8 after safety evaluations.
219294331|NCT04480138|OTHER|Standard of Care|Standard of care as per local authority
219294332|NCT04704583|BEHAVIORAL|SPACE parental-guidance|The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
219294333|NCT01035645|DRUG|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
219294334|NCT03446326|DEVICE|Pacing|Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
219294335|NCT00703209|PROCEDURE|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
219294336|NCT04972305|OTHER|Exercise and ergonomics|12 week exercise and fit bike
219294337|NCT04972305|OTHER|Ergonomics|Fit bike
219294338|NCT01566877|DRUG|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
219294339|NCT01566877|OTHER|Placebo|Normal Saline Solution (NSS)
219294340|NCT06283368|PROCEDURE|Thyroidectomy, Bilaterally Total|Thyroidectomy, Bilaterally Total
219294341|NCT06283368|PROCEDURE|Thyroidectomy, Unilaterally Total|Thyroidectomy, Unilaterally Total
219294342|NCT06283368|PROCEDURE|Thyroidectomy, Complementary|Thyroidectomy, Complementary
219294343|NCT06283368|PROCEDURE|Thyroidectomy, Near Total|Thyroidectomy, Near Total
219294344|NCT02111187|DRUG|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
219294345|NCT06243692|DRUG|Lacosamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219294346|NCT06243692|DRUG|Topiramate 50Mg Tab|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219294347|NCT00501839|DRUG|clomiphene citrate|
219294348|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
219294349|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance|Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.
219294350|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance|Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
219294351|NCT05367154|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
219294352|NCT06258226|DRUG|Conventional dosage reduction|The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
219294353|NCT06258226|PROCEDURE|Auricular acupressure|Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.
219294354|NCT06258226|PROCEDURE|Sham auricular acupressure|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
219294355|NCT03568396|DEVICE|Pupillometer|Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
219294356|NCT05697952|DRUG|E1K 1,200 ㎍/joint|Injection of E1K 1,200 ㎍/joint/ml on target lesion
219294357|NCT05697952|DRUG|E1K 2,400 ㎍/joint|Injection of E1K 2,400 ㎍/joint/ml on target lesion
219294358|NCT05697952|DRUG|placebo|Injection of 3ml saline on target lesion
219294359|NCT00142077|DEVICE|Electronic health record and messaging system|
219294360|NCT04870684|OTHER|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
219294361|NCT01383460|DRUG|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
219294362|NCT01383460|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
219294363|NCT03099746|BEHAVIORAL|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
219294364|NCT03099746|BEHAVIORAL|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
219294365|NCT03099746|BEHAVIORAL|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
219294366|NCT01788787|BEHAVIORAL|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
219294367|NCT01788787|BEHAVIORAL|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
219294368|NCT01788787|BEHAVIORAL|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
219294369|NCT01788787|BEHAVIORAL|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
219294370|NCT03751046|BEHAVIORAL|Trial-Based Cognitive Therapy|Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.
219294371|NCT03751046|OTHER|Control group. Standard healthcare.|"Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV"
219294372|NCT04916080|DRUG|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
219294373|NCT04715243|DEVICE|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
219294374|NCT04715243|DEVICE|Helmet NIV|NIV interface
219294375|NCT04715243|DEVICE|Face-mask NIV|NIV interface
219294376|NCT04230603|PROCEDURE|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
219294377|NCT04230603|DIAGNOSTIC_TEST|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
219294378|NCT04230603|DIAGNOSTIC_TEST|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
219294379|NCT06441370|PROCEDURE|waterbirth|waterbirth: laboured for all or part of the first stage of labour and remained in the water for birth of newborn
219294380|NCT04224207|BIOLOGICAL|Wharton's jelly derived mesenchymal stem cell|The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
219294381|NCT01763515|PROCEDURE|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
219294382|NCT04701359|DEVICE|TiN-alloy based total knee arthroplasty|TiN-alloy based TKA implanted for knee osteoarthritis.
219294383|NCT04701359|DEVICE|CoCr-coating based total knee arthroplasty|CoCr-coating based TKA implanted for knee osteoarthritis.
219294384|NCT00240799|DRUG|acetaminophen extended release|
219294385|NCT00240799|DRUG|placebo|
219294386|NCT05794308|BEHAVIORAL|Non-Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.
219294387|NCT05794308|BEHAVIORAL|Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
219294388|NCT04738292|DRUG|Onapristone|Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
219294389|NCT04738292|DRUG|Fulvestrant|Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
219294390|NCT02948673|DIETARY_SUPPLEMENT|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
219294391|NCT02948673|OTHER|Placebo|4 oral placebo tablets for 4 weeks
219294392|NCT04542889|DIAGNOSTIC_TEST|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
219294393|NCT04542889|DIAGNOSTIC_TEST|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
219294394|NCT02850510|BEHAVIORAL|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
219294395|NCT01556191|DRUG|Gefitinib|250 mg per day (oral)
219294396|NCT01556191|DRUG|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
219294397|NCT01556191|DRUG|Erlotinib|150 mg per day (oral)
219294398|NCT00236600|DRUG|topiramate|
219294399|NCT03618043|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
219294400|NCT02848287|DRUG|normal saline|1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
219294401|NCT02848287|DRUG|ropivacaine|1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
219294402|NCT01967589|DRUG|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
219294403|NCT01967589|DRUG|placebo|Once-daily doses for oral administration
219294404|NCT03950843|DRUG|CKD-825|"* Dosage Form: capsule~* Dosage: 3 types(low/medium/high dose)~* Frequency: QD(once daily) administration"
219294405|NCT03950843|DRUG|Placebo oral capsule|"Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration"
219294406|NCT03122223|BIOLOGICAL|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
219294407|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
219294408|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
219294409|NCT03122223|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
219294410|NCT02910050|DRUG|Bicalutamide|50mg once a day orally
219294411|NCT02910050|DRUG|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
219294412|NCT03280589|OTHER|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
219294413|NCT03280589|OTHER|Sitting Quietly|Participant breaths in their natural way with out instruction
219294414|NCT03280589|OTHER|Deep breathing|Participant is required to pay attention to each breath
219294415|NCT00503100|DEVICE|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
219294416|NCT05842772|OTHER|Shared decision making intervention for patients with kidney failure when planning end-of-life care|Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
219294417|NCT04512794|DEVICE|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
219294418|NCT01820585|DRUG|Placebo|Tablets
219294419|NCT01820585|DRUG|ESL 400 mg|tablets
219294420|NCT01820585|DRUG|ESL 800 mg|tablets
219294421|NCT01820585|DRUG|ESL 1200 mg|tablets
219294422|NCT03111459|DEVICE|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
219294423|NCT04142229|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
219294424|NCT04142229|OTHER|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
219294425|NCT06396364|DEVICE|Cryotherapy|Treatment group: the ankle was immobilized in a walking boot, then a third-generation cryotherapy device (Z- One®, Zamar) was applied daily for 2 hours two times a day up to the day of surgery. The walking boot was removed when the cryotherapy device was applied.
219294426|NCT04385589|DRUG|Dapagliflozin|Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
219294427|NCT04385589|DRUG|insulin|insulin
219294428|NCT04648644|OTHER|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
219294429|NCT06110390|DEVICE|High flow nasal oxygen|An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0
219294430|NCT00313625|DRUG|busulfan|
219294431|NCT00313625|DRUG|melphalan|
219294432|NCT00313625|DRUG|methotrexate|
219294433|NCT00313625|DRUG|tacrolimus|
219294434|NCT00313625|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219294435|NCT00313625|PROCEDURE|peripheral blood stem cell transplantation|
219294436|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
219294437|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
219294438|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
219294439|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
219294440|NCT00548262|DRUG|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
219294441|NCT00548262|DRUG|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).
219294442|NCT06263764|OTHER|Listening to Qur'an Recital|Listening to Surah Ar Rahman twice a day for minimum 15 minutes each for 40 days
219294443|NCT05198895|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)
219294444|NCT04535310|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
219294445|NCT02184364|DRUG|Low dose of Klimadynon®|
219294446|NCT02184364|DRUG|Medium dose of Klimadynon®|
219294447|NCT02184364|DRUG|High dose of Klimadynon®|
219294448|NCT02184364|DRUG|Oestrofeminal®|
219294449|NCT02184364|DRUG|Placebo|
219294450|NCT01390077|DRUG|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
219294451|NCT03095131|DEVICE|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
219294452|NCT05869578|PROCEDURE|Anesthesia Intervention|Patients exposed to any anesthesia intervention will be assessed to whether the exposure to anesthesia confers a risk for perioperative outcomes
219294453|NCT00601159|DRUG|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
219294454|NCT03573687|DIETARY_SUPPLEMENT|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
219294455|NCT03573687|OTHER|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
219294456|NCT02878889|DRUG|S-1|
219294457|NCT03235102|OTHER|No treatment given|Completion of a survey
219294458|NCT04259944|DRUG|CAPOX|"DAY 1~* OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~* CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting."
219294459|NCT04259944|DRUG|Capecitabine|"DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting."
219294460|NCT04259944|DRUG|FOLFIRI|"Day 1:~* IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~* LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~* 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest."
219294461|NCT00003827|DRUG|amifostine trihydrate|
219294462|NCT00003827|DRUG|cytarabine|
219294463|NCT00003827|DRUG|topotecan hydrochloride|
219294464|NCT03182218|DRUG|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
219294465|NCT05421507|RADIATION|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
219294466|NCT03222388|OTHER|Questionnaire - IIEF 5/15|International Index of Erectile Function
219294467|NCT00318071|DEVICE|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
219294468|NCT04247763|OTHER|Saturated Fat Meal|
219294469|NCT04247763|OTHER|Oleic Sunflower Oil Meal|
219294470|NCT02744911|DEVICE|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
219294471|NCT02744911|BEHAVIORAL|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
219294472|NCT02744911|BEHAVIORAL|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
219294473|NCT05805228|OTHER|Sexual Counseling|Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
219294474|NCT01080716|BIOLOGICAL|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
219294475|NCT01080716|BIOLOGICAL|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
219294476|NCT01080716|BIOLOGICAL|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
219294477|NCT01080716|BIOLOGICAL|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
219294478|NCT03812302|DIAGNOSTIC_TEST|68-Ga HA-DOTATATE PET/CT|See arm description.
219294479|NCT04600492|DRUG|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
219294480|NCT01466101|DRUG|Placebo administration|Administration of placebo
219294481|NCT01466101|DRUG|Pregabalin administration|Administration of pregabalin
219294482|NCT06326593|OTHER|Wii aerobic training|Nintendo Wii Fit Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character
219294483|NCT06326593|OTHER|conservative chest care|Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
219294484|NCT02293564|DRUG|gevokizumab|Solution for subcutaneous injection
219294485|NCT04836689|DEVICE|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen\&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate\<100 bpm), saturation\<90% and\>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
219294486|NCT04976504|DEVICE|Oxygen reserve index|This is an observational study of the routine clinical practice with no specific additional interventions required. The investigators enrolled the ASA physical status I to III patients scheduled for elective surgery with planned arterial catheter placement before induction. ORi and standard monitors were placed. The patients were preoxygenated and received anesthesia induction as routine clinical practice. Intubation was done by video-laryngoscope. The endotracheal tube was not connected to the breathing circuit to avoid apneic oxygenation. Ventilation was resumed when SpO2 fell to 90%. ORi and SpO2 were recorded every ten seconds.
219294487|NCT01993927|DRUG|Voglibose|Voglibose Tablets / Voglibose OD Tablets
219294488|NCT00895154|BEHAVIORAL|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
219294489|NCT00895154|BEHAVIORAL|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
219294490|NCT06571565|COMBINATION_PRODUCT|conservative treatment|Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
219294491|NCT05084469|PROCEDURE|PET-MRI in pain-free remission period|Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic \[18F\]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
219294492|NCT04495101|BIOLOGICAL|Prolastin|Intravenous infusion 120 mg/kg
219294493|NCT04495101|DRUG|Standard Medical Treatment|Standard medical treatment per local policies or guidelines
219294494|NCT02955732|DEVICE|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
219294495|NCT05609110|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
219294496|NCT05609110|DEVICE|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
219294497|NCT02247973|BIOLOGICAL|mesenchymal stem cells|Intravenous administration of up to 1\~2x10\^6 MSCs per kg,for 2 times,d0 and d14
219294498|NCT02247973|BIOLOGICAL|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
219294499|NCT00287690|DRUG|Genistein|Drink taken once daily
219294500|NCT00287690|DRUG|Placebo|Drink taken once daily
219294501|NCT03300973|PROCEDURE|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
219294502|NCT04715165|DRUG|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
219294503|NCT04715165|DRUG|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
219294504|NCT06380673|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
219294505|NCT06380673|OTHER|Implementation of heated cow's milk|Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
219294506|NCT06380673|OTHER|No intervention|Healthy subjects undergo no intervention.
219294507|NCT02497248|PROCEDURE|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
219294508|NCT04428073|BIOLOGICAL|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
219294509|NCT04933773|OTHER|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
219294510|NCT04933773|OTHER|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
219294511|NCT04933773|OTHER|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
219294512|NCT04933773|OTHER|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
219294513|NCT04933773|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
219294514|NCT03286101|DRUG|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
219294515|NCT03286101|DRUG|Vehicle|The intervention is composed of a single application of the vehicle control.
219294516|NCT00488332|PROCEDURE|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
219294517|NCT00488332|PROCEDURE|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
219294518|NCT00488332|BEHAVIORAL|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
219294519|NCT04670939|PROCEDURE|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
219294520|NCT02850484|DRUG|Budesonide|Inhaled corticosteroid
219294521|NCT02850484|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
219294522|NCT03948165|PROCEDURE|Distal Transradial Access|The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
219294523|NCT05591885|DIETARY_SUPPLEMENT|Study product group (Nutrilite Memory Builder)|During study intervention, subjects are required to take the randomly assigned study product following the instructions.Take one tablet twice daily with meals.
219294524|NCT05591885|DIETARY_SUPPLEMENT|Placebo group|During study intervention, subjects are required to take the randomly assigned placebo following the instructions.Take one tablet twice daily with meals.
219294525|NCT04289831|PROCEDURE|Preoperative Biliary Drainage (PBD)|Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
219294526|NCT04289831|PROCEDURE|Surgery|The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
219294527|NCT01018147|PROCEDURE|4-dimensional computed tomography|Undergo 4-D CT imaging
219294528|NCT00138567|DRUG|vildagliptin|
219294529|NCT06306339|DRUG|Burfiralimab|Humanized monoclonal antibody.
219294530|NCT06306339|DRUG|SOC (Standard of care)|"The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)"
219294531|NCT06306339|DRUG|Placebo|The placebo for Burfiralimab (hzVSF-v13)
219294532|NCT02819830|BEHAVIORAL|Exercise Intervention|Combined strength and aerobic exercise
219294533|NCT04328883|DRUG|Aspirin|Oral and inhaled ASA formulations
219294534|NCT06378385|BEHAVIORAL|Childhood Early Oral Aging Syndrome index|Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
219294535|NCT04065945|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
219294536|NCT03517033|DRUG|Torrent's Nebivolol Tablets|
219294537|NCT03517033|DRUG|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
219294538|NCT00421954|DRUG|Ziprasidone|subjects will use ziprasidone
219294539|NCT01850277|DRUG|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
219294540|NCT01850277|PROCEDURE|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
219294541|NCT01850277|DRUG|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% \>95%
219294542|NCT01850277|PROCEDURE|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
219294543|NCT05156684|DRUG|Placebo|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
219294544|NCT05156684|DRUG|Pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
219294545|NCT05156684|DRUG|zinc|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
219294546|NCT05156684|DRUG|zinc + pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
219294547|NCT04261426|DRUG|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
219294548|NCT04261426|OTHER|Standard care|Standard care
219294549|NCT02729831|BEHAVIORAL|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
219294550|NCT02729831|BEHAVIORAL|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
219294551|NCT02729831|BEHAVIORAL|Provider Report|A short report that includes the patients' goals and treatment preferences
219294552|NCT04869293|DEVICE|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
219294553|NCT02996331|OTHER|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
219294554|NCT02996331|OTHER|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
219294555|NCT02996331|OTHER|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
219294556|NCT02305836|PROCEDURE|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
219294557|NCT02305836|DRUG|donepezil|cholinesterase inhibitors (ChE-Is)
219294558|NCT00294918|DRUG|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
219294559|NCT01996189|DEVICE|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
219294560|NCT01996189|DEVICE|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
219294561|NCT06290674|OTHER|Extracorporeal Shockwave therapy|2000 shots, 120mJ pulse energy setting, 3 bar pressure, and 15 Hz for 15 minute per session.
219294562|NCT06290674|OTHER|Balanced low-calorie diet|1500 k/cal for 6 weeks
219294563|NCT00994084|BEHAVIORAL|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
219294564|NCT00994084|BEHAVIORAL|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
219294565|NCT01719354|OTHER|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
219294566|NCT01719354|OTHER|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
219294567|NCT05089253|OTHER|Dry Needling|"The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks."
219294568|NCT05089253|OTHER|Kinesio tapping|"The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks."
219294569|NCT06306547|OTHER|no interventions were involved|no interventions were involved
219294570|NCT00927030|DRUG|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
219294571|NCT00927030|DRUG|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
219294572|NCT03482830|PROCEDURE|Major emergency gastrointestinal surgery|"* Open, laparoscopic, or laparoscopically-assisted procedures~* Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction"
219294573|NCT03046654|DIAGNOSTIC_TEST|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
219294574|NCT03046654|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
219294575|NCT03046654|DIAGNOSTIC_TEST|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
219294576|NCT00460226|DRUG|lamotrigine|lamotrigine treatment for 12weeks
219294577|NCT05017103|BIOLOGICAL|Sintilimab|Given IV
219294578|NCT05194332|DEVICE|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
219294579|NCT00614965|DRUG|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
219294580|NCT00614965|DRUG|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
219294581|NCT00614965|DRUG|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
219294582|NCT05321459|OTHER|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
219294583|NCT01747551|DRUG|Oxaliplatin|
219294584|NCT01747551|DRUG|Leucovorin|
219294585|NCT01747551|DRUG|Fluorouracil|
219294586|NCT01747551|DRUG|Ziv-aflibercept|
219294587|NCT01382277|DRUG|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
219294588|NCT04265326|OTHER|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
219294589|NCT01142115|DEVICE|Intermittent catheter CP063CC|intermittent catheterisation
219294590|NCT01142115|DEVICE|SpeediCath|intermittent catheterisation
219294591|NCT05953168|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression
219294592|NCT03406078|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
219294593|NCT03406078|OTHER|Placebo|Placebo subcutaneous injection
219294594|NCT02720120|DRUG|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
219294595|NCT02720120|DRUG|Placebo|Participants will receive single IV infusion of placebo.
219294596|NCT00599443|BIOLOGICAL|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
219294597|NCT00599443|BIOLOGICAL|Placebo Comparator|0.5 mL im, single dose
219294598|NCT00211211|DEVICE|Balloon Kyphoplasty|
219294599|NCT03321877|DRUG|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
219294600|NCT00453791|DRUG|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
219294601|NCT00453791|DRUG|Placebo|Placebo MDI will be given to the subjects.
219294602|NCT02091206|DRUG|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
219294603|NCT02091206|DRUG|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219294604|NCT02091206|DRUG|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
219294605|NCT02091206|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
219294606|NCT00759005|DRUG|propranolol and cortisol|
219294607|NCT00700778|BIOLOGICAL|recombinant human chorionic gonadotropin|
219294608|NCT00700778|GENETIC|microarray analysis|
219294609|NCT00700778|OTHER|immunohistochemistry staining method|
219294610|NCT00700778|OTHER|laboratory biomarker analysis|
219294611|NCT00700778|PROCEDURE|needle biopsy|
219294612|NCT00544986|DRUG|Anastrozole|
219294613|NCT06172153|OTHER|No interventions|No intervention
219294614|NCT03378453|DEVICE|PET-scan18F-AV-45|The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
219294615|NCT03378453|DEVICE|PET-scan18F-AV-45|PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
219294616|NCT05096520|PROCEDURE|radiofrequency|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
219294617|NCT05096520|PROCEDURE|control|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
219294618|NCT05096520|DRUG|2% lidocaine|2% lidocaine
219294619|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
219294620|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
219294621|NCT02341443|PROCEDURE|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
219294622|NCT03440060|DIAGNOSTIC_TEST|procalcitonin|procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
219294623|NCT05412251|RADIATION|health promotion program|Multi-domain intervention 120 minutes cognitive training, 120 \~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
219294624|NCT00350103|DRUG|SPM 929|"* Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use"
219294625|NCT00350103|DRUG|Placebo|"* Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use"
219294626|NCT02862522|OTHER|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
219294627|NCT04050657|OTHER|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
219294628|NCT05155215|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level: 100×10\^6 CAR-T cells or 200×10\^6 CAR-T cells
219294629|NCT05155215|DRUG|Cyclophosphamide|300 mg/m\^2 per day for 3 days (IV)
219294630|NCT05155215|DRUG|Fludarabine|30 mg/m\^2 per day for 3 days (IV)
219294631|NCT00002324|DRUG|Nevirapine|
219294632|NCT00002324|DRUG|Zidovudine|
219294633|NCT04847791|DIETARY_SUPPLEMENT|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
219294634|NCT04847791|DIETARY_SUPPLEMENT|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
219294635|NCT00760474|DRUG|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
219294636|NCT00760474|DRUG|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
219294637|NCT01227200|DRUG|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
219294638|NCT00656097|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
219294639|NCT00656097|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
219294640|NCT00656097|BIOLOGICAL|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
219294641|NCT03695653|BEHAVIORAL|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
219294642|NCT03695653|BEHAVIORAL|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
219294643|NCT03695653|BEHAVIORAL|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
219294644|NCT01307683|BEHAVIORAL|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
219294645|NCT04768855|DRUG|LY3540378|Administered IV or SC.
219294646|NCT04768855|DRUG|Placebo|Administered IV or SC.
219294647|NCT04768855|DRUG|LY3540378|Administered SC.
219294648|NCT06462703|DEVICE|Tablet-based neurorehabilitation with myReha|The myReha therapy software provides cognitive therapy in the domains attention, executive functions, perception, language, speech, arithmetics, and memory. It automatically creates weekly plans that are individually tailored to a patient's abilities and provides real-time feedback when completing tasks. Intelligent algorithms ensure that the exercises always remain at the optimum level of difficulty.
219294649|NCT01526239|OTHER|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
219294650|NCT01318395|DRUG|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
219294651|NCT01318395|DRUG|Placebo|orally once per day
219294652|NCT04259151|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
219294653|NCT04259151|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
219294654|NCT03014479|DRUG|Trelagliptin|Trelagliptin 100 mg or 50 mg
219294655|NCT03014479|DRUG|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
219294656|NCT04793789|OTHER|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
219294657|NCT04201340|DEVICE|DRI OCT Triton with SS-OCT Angio software|The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
219294658|NCT04201340|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
219294659|NCT04201340|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
219294660|NCT01394978|OTHER|Control|Standard surgical techniques including staples and sutures.
219294661|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant with standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
219294662|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant without standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
219294663|NCT00675675|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
219294664|NCT00675675|BEHAVIORAL|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
219294665|NCT04787887|DRUG|Abcertin|60IU/kg Single Intravenous Administration
219294666|NCT04787887|DRUG|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
219294667|NCT01044225|DRUG|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
219294668|NCT01044225|DRUG|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
219294669|NCT02007915|DRUG|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
219294670|NCT02350985|DRUG|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
219294671|NCT02350985|DRUG|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
219294672|NCT03825549|BEHAVIORAL|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
219294673|NCT03825549|BEHAVIORAL|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
219294674|NCT02286986|DRUG|Cannabidiol|
219294675|NCT06404801|BEHAVIORAL|Stance Control|Instead of stability coming from a locked knee joint, the brace is able to lock and unlock at just the right time while walking
219294676|NCT04917445|BEHAVIORAL|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
219294677|NCT04408053|DEVICE|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
219294678|NCT03223051|OTHER|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
219294679|NCT03916640|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
219294680|NCT03916640|DRUG|Placebo|Subcutaneous injection of 0.9% NaCl
219294681|NCT03916640|DRUG|Symlin®|Subcutaneous injection of pramlintide
219294682|NCT03916640|DRUG|Humulin®|Subcutaneous injection of human insulin
219294683|NCT03916640|DRUG|Humalog®|Subcutaneous injection of insulin lispro
219294684|NCT04785105|OTHER|No intervention|No intervention
219294685|NCT02631577|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
219294686|NCT02631577|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
219294687|NCT02631577|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
219294688|NCT04436770|OTHER|Non-immersive virtual reality therapy|"Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used."
219294689|NCT04436770|OTHER|Standard Physiotherapy|"Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used."
219294690|NCT02299089|DRUG|octreotide FluidCrystal® injection depot|
219294691|NCT04949243|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionaires
219294692|NCT02451852|DRUG|AZD9291|AZD9291 80mg tablet once daily, open label
219294693|NCT02491476|DEVICE|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
219294694|NCT06645080|OTHER|Focus group or interview participation|90 minute focus group or 60 minute interview participation
219294695|NCT06645080|OTHER|Delphi survey participation|Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
219294696|NCT00722280|PROCEDURE|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
219294697|NCT04346459|PROCEDURE|"Tracheal intubation through Fastrach - Group A"|"Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device"
219294698|NCT04346459|PROCEDURE|"Tracheal intubation through I-gel - Group B"|"Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope"
219294699|NCT04346459|PROCEDURE|"Tracheal intubation through Protector - Group C"|"Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope"
219294700|NCT03397875|PROCEDURE|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
219294701|NCT03397875|PROCEDURE|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
219294702|NCT03397875|PROCEDURE|Bioactive silicone based sealer|
219294703|NCT05922501|DRUG|Isatuximab|An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
219294704|NCT05922501|DRUG|Belantamab mafodotin|An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
219294705|NCT05922501|DRUG|Pomalidomide|An immunomodulatory agent, capsule taken orally.
219294706|NCT05922501|DRUG|Dexamethasone|A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
219294707|NCT05748223|OTHER|Mindfulness Meditation|Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
219294708|NCT05642832|DEVICE|Throughflow titration phase|"Ventilation will be applied in the TF mode with TF set to 0 LPM for 10 minutes. Patients will receive assist through the NAVA line of the tri-piece (NAVA set to similar settings as Servo period, \~60-80 LPM flow). Ventilation with Throughflow will be started at a TF flow of 5 LPM, and the NAVA flow will be reduced by 5 LPM. After 10 minutes measurements will be collected. If Edi is greater than or equal to 4 µV, TF flow will be increased to 10 LPM and NAVA flow will be adjusted to keep total flow constant. Measurements will be collected again after 10 minutes. TF flow will be increased in steps of 5 LPM and measurements collected every 10 minutes until Edi is below 3 µV or TF flow reaches the total flow observed during the NAVA period.~After either the Edi target has been met or TF flow has reached the total flow, ventilation with TF will be reduced in steps of 5 LPM every 10 minutes (the reverse of the above), while NAVA flow is accordingly adjusted to keep total flow constant."
219294709|NCT05594706|OTHER|Measurement of blood levels of 1,5-anhydroglucitol|Measurement of blood levels of 1,5-anhydroglucitol
219294710|NCT06303258|OTHER|Core Stabalization Exercises|Low Intensity Warm Up Exercises Core Stabilization Exercises Cool Down Stretching Exercises
219294711|NCT06303258|OTHER|Generalized Antenatal Exercises|Low Intensity WarmUp Exercise Aerobic Training Endurance Training Pelvic Floor Muscle Training Cool Down Stretching Exercises
219294712|NCT06605846|OTHER|otago excercises|"Otago training is helpful, and one of the most powerful interventions where the original randomized controlled trials reported improvements in functional outcomes and a 35% reduction in falls for frail, high-risk older adults (Shubert et al., 2018). In Egypt, there are little researches about Otago Exercise Program.~Exercise is well-known as an economic and key adjuvant treatment in clinical oncology that improves QOL of cancer survivors. Many studies focused on investigating the benefits of exercise interventions on preventing falls and improving physical performance of older adults. Combination of strength and functional balance exercise has been demonstrated as an effective method to improve balance performance, rather than strength training alone"
219294713|NCT06605846|OTHER|Medical ADT treatment|Medical ADT treatment according to patient age, prostatic cancer stage
219294714|NCT03430180|DRUG|Naloxone hydrochloride|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
219294715|NCT03430180|DRUG|Placebo|One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
219294716|NCT06598410|OTHER|Digital gaming|Children in this group will be allowed to play digital games 5 minutes before the procedure starts. They will continue to play the game during the procedure.
219294717|NCT06598410|OTHER|watching cartoon|Children in this group will be shown a cartoon film 5 minutes before the procedure. They will continue to play the game during the procedure.
219294718|NCT03981861|DRUG|Metformin and Spironolactone|Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
219294719|NCT06856460|DIETARY_SUPPLEMENT|powder shake with very low glycemic index|2 weeks of cereal and standard process glucose assist shake as part of breakfast. The diet for the remainder of the day will remain unchanged.
219294720|NCT06856460|DIETARY_SUPPLEMENT|Ceral Breakfast|consume of 400kcal of oat-based cereal with honey for breakfast
219294721|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
219294722|NCT06660069|DRUG|CPC Mouthwash (Parodontax Active Gum Health Mouthwash)|Mouthwash containing 0.07% w/w CPC.
219294723|NCT06660069|DRUG|Regular Fluoride Toothpaste (Crest Cavity Protection)|Toothpaste containing 0.243% w/w sodium fluoride.
219294724|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454% w/w SnF2.
219294725|NCT06862401|PROCEDURE|Glass ceramic onlay preparation|The participants engaged in two practice sessions, each lasting two hours. They either started with their dominant hand followed by non-dominant hand or practiced solely with their non-dominant hand. Each participant prepared a mandibular left first molar resin typodont fixed to the table for a glass ceramic onlay restoration. Preparation was conducted extraorally.
219294726|NCT06336356|DRUG|Baxdrostat|Baxdrostat will be administered orally once daily.
219294727|NCT06336356|DRUG|Placebo|Placebo will be administered orally once daily.
219294728|NCT04613414|OTHER|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
219294729|NCT06588491|BIOLOGICAL|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219294730|NCT06610487|DRUG|FT1|Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.
219294731|NCT06610487|DRUG|Placebo|Placebo will be administered.
219294732|NCT05618912|DEVICE|Hydrocolloid dressing|A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
219294733|NCT05618912|OTHER|Petrolatum jelly dressing|The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
219294734|NCT06871488|DRUG|CNS Stimulant|The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo for a total of 14 days of data collection.
219294735|NCT06871488|DRUG|Placebo|Placebo is only used during the second of two treatment phases. The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo.
219294736|NCT06871488|OTHER|CNS Stimulant open label first phase|The first treatment phase will optimize CNS stimulant dose under open label conditions using any approved FDA medication for pediatric ADHD at the FDA approved doses.
219294737|NCT05967169|DEVICE|Nasal Septal Strap implantation|Correction of NSD with Nasal Septal Strap implant
219294738|NCT06718335|DRUG|Pyrotinib|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.
219294739|NCT06718712|OTHER|Lower body resistance training|The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.
219294740|NCT06727708|DEVICE|Tone Your Body BioCircuit Program|Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.
219294741|NCT06727708|DEVICE|Boost Performance BioCircuit Program|Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
219294742|NCT06727630|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day
219294743|NCT06727695|DEVICE|BioStrength Intervention|Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week
219294744|NCT06727695|DEVICE|Conventional training|Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
219294745|NCT06727786|OTHER|Serious game training|A serious game featuring a dramatic/realistic film, pauses with questions for active learning, and practice administration of naloxone and performing CPR
219294746|NCT06729684|DEVICE|digital health (application and smartwatch)|The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
219294747|NCT06007222|DRUG|Aspirin group|Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
219294748|NCT06007222|DRUG|Non-antithrombotic group|No antithrombotic agents will be administered after randomization until the end of the study period.
219294749|NCT06732960|BIOLOGICAL|Efsubaglutide Alfa|Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.
219294750|NCT06732960|OTHER|Placebo|Placebo subcutaneous injection weekly
219294751|NCT06743100|DIAGNOSTIC_TEST|18F-Floretyrosine|Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine.
219294752|NCT06845826|DEVICE|Point-of-Care high-sensitivity troponin testing|To establish in a randomized interventional controlled trial whether a novel POC test-guided strategy in acute chest pain patients in the ED results in a reduced length of stay compared to the usual central laboratory testing strategy when managing patients with a suspicion of NSTEMI
219294753|NCT03414541|DRUG|DS102|DS102
219294754|NCT03414541|OTHER|Placebo|Placebo
219294755|NCT06898853|DRUG|0.1% Ciclosporin A eye drops|The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
219294756|NCT06898853|DRUG|Mineral oils eye drops|This arm is the comparator arm has mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
219294757|NCT06901024|OTHER|Tendon Gliding Exercise|Tendon gliding exercises were performed for both hands in a sequential manner, with 20 repetitions in 3 sets. The exercises started with fingers and wrist positioned in extension. Subsequent positions included the hook position, full fist position, MCP joint at 90° flexion with finger extension, and MCP and proximal interphalangeal (PIP) joints at 90° flexion positions, with a 5-second hold at each position. During the TG exercises, the hand and fingers are brought to five different positions
219294758|NCT06901024|OTHER|Neuromobilization Exercise|The neuromobilization exercises included median, radial and ulnar nerve mobilizations. For median nerve mobilization, the patient's wrist was placed in extension, the shoulder in 90° abduction, the forearm in supination, the elbow extended, and the head positioned in lateral flexion toward the same side. For radial nerve mobilization, the wrist was initially placed in flexion and ulnar deviation, the forearm in pronation, with the elbow extended, and the head positioned in lateral flexion toward the same side. For ulnar nerve mobilization, the wrist was positioned in extension and radial deviation, the elbow fully flexed, the forearm in pronation, the shoulder in 90°abduction, and the head in lateral flexion toward the same side. The head was then moved into lateral flexion toward the opposite side while extending the elbow. The neuromobilization protocol was performed in 4 sets of 10 repetitions, with a 5-second hold for each movement.
219294759|NCT06901024|OTHER|Robotic Assitive Exercise|The robotic glove set used in this study weighs 497 grams, powered by a battery weighing 170 grams that provides a 5 V voltage and 1 A current. Made from elastic fabric, the glove wraps around all fingers on both the dorsal and palmar sides. The palm section of the glove is hollow. The device features four Velcro straps: one at the wrist, one across the web space between the thumb and index finger, one between the second and third fingers, and one between the fourth and fifth fingers, securing the inner side of the wrist. The robotic glove facilitates passive joint movements through pneumatic air pressure. The device offers several benefits, including proprioceptive stimulation, visual input, increased functional independence, pain and edema reduction, enhanced lymphatic and blood circulation, improved coordination and hand dexterity, as well as increased grasp and compression strength.
219294760|NCT06901024|OTHER|Conventional Exercises|Wrist extensor exercise, wrist radial deviation exercise, and wrist flexor exercise were perfomed using a 1-kg dumbbell. Holding the 1-kg dumbbell against gravity for 10 seconds, with the shoulder flexed at 90°, elbow extended, and forearm in pronation position. Squeezing exercise with a green soft ball (Thera-Band; diameter: 5 cm); the ball was squeezed for 10 seconds, followed by relaxing. Pushing a blue Pilates ball (Thera-Band; diameter: 20 cm) against the wall with fingers in extension position. Squeezing a black Pilates ring (Thera-Band; diameter: 38 cm) with the fingers, while the MCP joints are in extension and the wrist in a neutral position.
219294761|NCT06898411|DEVICE|Single tooth restoration with IPS e.max|Examination of single tooth restorations with IPS e.max after a wearing time of more than 15 years. Intraoral situation will be examined similar to a standard dental examination while single tooth restorations will be documneted by photos.
219294762|NCT05963100|BIOLOGICAL|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
219294763|NCT06900049|DRUG|LE051|LE051 dose escalation : dose 1 and dose 2.
219294764|NCT06735001|PROCEDURE|FA ablation|Ablation of the FA
219294765|NCT06735001|BIOLOGICAL|Lab test|Blood collection
219294774|NCT05342090|OTHER|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
219294775|NCT06898424|BEHAVIORAL|Ketoflex 12/3 Diet|plant-based ketogenic diet combined with intermittent fasting (12/3)
219294776|NCT04807712|OTHER|non interventional study|
219294777|NCT06905860|DRUG|Platelet-rich fibrin (PRF)|"The Intervention Group consists of the intra-articular application of PRF in the knee. The applications will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. A total of 3 applications of PRF will be conducted, with intervals of 14 to 28 days between them.~10ml of PRF will be applied intra-articularly, on an outpatient basis, with patients being instructed to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
219294778|NCT06905860|DRUG|Corticosteroid|"The procedures will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. In this group, 40ml of peripheral blood will also be collected and placed for centrifugation. During the preparation for the application, a nurse (who will not participate in the study) will have a list of the randomization and will prepare the material in an opaque syringe (blinding both the applicator and the patient).~In this group of patients, a solution of 10ml containing 40mg of Triamcinolone will be administered in the first application and 10ml of saline in the second and third applications, with intervals of 14 to 28 days between the applications. The applications will be performed on an outpatient basis, with patients being advised to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
219294779|NCT06907082|DRUG|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.
219294780|NCT06906991|BEHAVIORAL|FIBROWALK|"FIBROWALK is a structured, multicomponent therapeutic program designed specifically for patients with fibromyalgia, combining evidence-based interventions that target both physical and emotional symptoms of the condition. Unlike traditional standalone interventions (e.g., exercise-only or CBT-only), FIBROWALK integrates multiple therapeutic modalities in a holistic, group-based format to address the broad symptom profile of fibromyalgia, including chronic pain, fatigue, and impaired functionality. Sessions are delivered in groups of up to 20 participants, fostering peer support and shared learning.~Key Components of FIBROWALK:~* Therapeutic Exercise~* Pain Neuroscience Education~* Cognitive-Behavioral Therapy~* Mindfulness-Based Stress Reduction~* Psychoeducation"
219296538|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
219294781|NCT06906991|BEHAVIORAL|Unified Protocol|"The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy (CBT) intervention designed to address emotional dysregulation across a range of mental health conditions. Unlike traditional disorder-specific CBT interventions (e.g., CBT for anxiety or depression), the UP targets core emotional processes common to multiple disorders, making it particularly suitable for fibromyalgia patients who often experience comorbid anxiety, depression, and emotional distress. Unlike condition-specific therapies, the UP addresses the shared emotional mechanisms underlying anxiety, depression, and chronic pain, making it well-suited for fibromyalgia patients with complex emotional and physical symptomatology. UP emphasizes increasing tolerance to emotional and physical discomfort, a critical area for fibromyalgia patients who often experience heightened emotional reactivity and pain sensitivity.~The UP is delivered individually and consists of 12 structured, manualized modules."
219294782|NCT06907862|OTHER|Reference Treatment|≥4 servings/day of soy products categorized as non-ultra processed according to the NOVA classification system (NOVA non-Group 4): ≥2 servings/day of a Group 1 soy milk and ≥1 serving/day of another Group 1 food, such as edamame or roasted soy nuts, and ≥1 serving/day of a Group 3 food, such as tofu or tempeh) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
219294783|NCT06907862|OTHER|Control|Usual care provided by their primary care physician and/or specialist.
219294784|NCT06907862|OTHER|Active Treatment|≥4 servings/day of soy products categorized as ultra processed according to the NOVA classification system (NOVA Group 4): ≥2 servings/day of soy milk and ≥2 servings/day of other soy-based products such as soy yogurt, soy burgers, or soy ground round) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
219294785|NCT06907225|OTHER|None-placebo|None - observational study
219294786|NCT06907108|DEVICE|Systemic vibratory therapy|The interventions were performed on a vibratory platform with side-alternating displacement of the base (Novaplate Fitness Evolution model, DAF Produtos Hospitalares Ltda, São Paulo). The individual was positioned barefoot, with knees flexed at 130º on the base of the vibratory platform. The protocol was performed over a 6-week period with 2 weekly sessions, totaling 12 sessions. The frequency was 5-16Hz according the protocol, and the peak-to-peak displacement was 2.5, 5.0, and 7.5 mm in all sessions. During the protocol, the individuals performed static and dynamic squats, with one static and one dynamic session (interleaved). The variables were evaluated before and after the interventions.
219294787|NCT06901947|DIETARY_SUPPLEMENT|Glucose drink|Intervention group will receive maltodextrin glucose drinks 2 hours prior to the operation
219294788|NCT06906939|DEVICE|repetetive transcranial magnetic stimulation|rTMS treatments will be performed with the MagVenture MagPro X100 stimulator equipped with the Cool-B70 A/P for sham-controlled stimulation. The coil has two sides, one of which is shielded so that no energy is imparted to the brain when the shielded side is applied to the subject's head. Small skin electrodes are applied to the scalp under the coil that impart a small microcurrent to the scalp simulating the sensation of active treatment. The operator receives a code from the device instructing them which side of the coil to use for each subject, ensuring complete treatment blinding.
219294789|NCT06906575|BEHAVIORAL|A Comprehensive Intervention to Improve Sexual and Relationship Well-being for Cancer Patients and Their Partners|"This intervention targets three core areas:~Body Image Improvement - Supports patients in understanding and accepting physical changes resulting from cancer treatments, fostering positive attitudes toward body image and self-esteem.~Psychological Flexibility Enhancement - Utilizes ACT-based strategies to help participants acknowledge and adaptively manage difficult emotions, thoughts, and experiences related to cancer diagnosis and treatment.~Dyadic Coping Skill Training - Provides structured skill-building exercises to strengthen mutual support mechanisms, enhance effective partner communication, and promote collaborative problem-solving when facing cancer-related stressors.~The intervention consists of six weekly sessions (90-120 minutes each), delivered in a hybrid format (virtual and in-person) to maximize accessibility. Each session integrates psychoeducational presentations, facilitated discussions, guided experiential exercises."
219294790|NCT06907303|DIAGNOSTIC_TEST|EndoDx|PCR assay for Endometriosis diagnosis
219294791|NCT06906393|BEHAVIORAL|Preventive treatment|4-second Sprint Interval Training (SIT) over 8 weeks to improve cardiovascular health.
219294792|NCT06906718|DEVICE|Implantation of an intraocular lens|Successful bilateral IOL implantation into the capsular bag with at least 12 months follow-up.
219294793|NCT05524753|BEHAVIORAL|AquOTic|group-based aquatic occupational therapy sessions with 1:1 support
219294794|NCT03063801|OTHER|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
219294795|NCT00330265|DEVICE|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
219294796|NCT00330265|OTHER|Conventional Wound Therapy|Normal Saline Dressings
219294797|NCT00432666|DRUG|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
219294798|NCT00432666|DRUG|Placebo|Placebo
219294799|NCT00978627|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
219294800|NCT00978627|DRUG|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
219294801|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
219294802|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
219294803|NCT02247557|DRUG|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
219294804|NCT02247557|DRUG|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
219294805|NCT02247557|DRUG|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
219294806|NCT02130921|BEHAVIORAL|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
219294807|NCT02345187|DIETARY_SUPPLEMENT|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
219294808|NCT02345187|DIETARY_SUPPLEMENT|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
219294809|NCT00004404|DRUG|clotrimazole|
219294810|NCT00004404|DRUG|hydroxyurea|
219294811|NCT05183776|DEVICE|Fractional administration device|The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
219294812|NCT06209333|OTHER|Standard Patient Education|Standard Patient Education will take approximately 20 minutes. Within the scope of standard patient education, some recommendations will be made to the patient to lose weight, drink sufficient water, avoid consuming caffeinated foods and beverages, acidic/carbonated or alcoholic beverages, spicy/acidic foods, and quit smoking. Patients will be evaluated on the day they receive standard patient training (before receiving this training) and 10 weeks after the training.
219294813|NCT06209333|OTHER|bladder training|Interval urination in bladder training in bladder training will be determined according to the bladder diaries filled in by the patients. If the patient is able to do it, bladder education will be improved by increasing the interval urination in bladder training. A total of 5 sessions of bladder training will be applied to patients, the first session of which will be face-to-face. Within the scope of Bladder Training, the patient will be given information about bladder, pelvic floor, incontinence and relaxation techniques. The patient will be asked to fill out a 3-day bladder diary before starting bladder training, and an appropriate progressive timed voiding program will be drawn according to the bladder diaries, and the patient will be given a training brochure to implement this program.
219294814|NCT06209333|OTHER|pelvic floor exercise|This training will take between 45 and 60 minutes.Within the scope of exercise training, patients will be taught 3 types of contractions: maximal (fast), slow and submaximal contractions. The patient will be asked to continue the maximum and submaximal contraction for 1-2 seconds, and to continue the Deceleration contraction for 3-10 seconds. These contractions will be performed in different positions such as supine, lying on the side, sitting, crawling, squatting and standing, specifically for the pelvic floor November muscle strength of the patient. These exercises will be performed every day and each type of contraction (maximal, slow and submaximal contraction) will be performed 8-12 repetitions, 3 sets per day. Progress will be achieved with follow-ups.
219294815|NCT00976872|DRUG|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
219294816|NCT00976872|DRUG|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
219294817|NCT04674787|OTHER|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
219294818|NCT02500810|DRUG|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
219294819|NCT02799264|DRUG|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
219294820|NCT05405439|DRUG|TQB3823 tablets|TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
219294821|NCT05405439|DRUG|Abiraterone acetate tablets|Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
219294822|NCT05405439|DRUG|prednisone acetate tablets|Prednisone acetate tablet is a kind of glucocorticoids
219294823|NCT04101552|PROCEDURE|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
219294824|NCT00283088|PROCEDURE|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
219294825|NCT00283088|DRUG|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
219294826|NCT02237443|DRUG|Rocuronium|Administration of a NMBD
219294827|NCT02237443|DRUG|Vecuronium Bromide|Administration of a NMBD
219294828|NCT02237443|DRUG|Succinylcholine|Administration of a NMBD
219294829|NCT05838144|DEVICE|Acapella device|Group A. Will use Acapella device.
219294830|NCT05838144|OTHER|Only routine chest physical therapy program|Group B. Will take medications and perform routine chest physical therapy program.
219294831|NCT02628639|DEVICE|high-density electroencephalography|
219294832|NCT02113345|BEHAVIORAL|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
219294833|NCT00743301|OTHER|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
219294834|NCT02158052|DRUG|Tacrolimus|Tacrolimus starting on Day -1
219294835|NCT02158052|DRUG|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
219294836|NCT02158052|PROCEDURE|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
219294837|NCT02158052|DRUG|Bone marrow transplant from a related donor|Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
219294838|NCT02158052|RADIATION|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
219294839|NCT06246266|PROCEDURE|Helfer Skin Tap Technique group|During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
219294840|NCT06246266|PROCEDURE|ShotBlocker Technique group|"The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain."
219294841|NCT05016518|DRUG|Arm I (Propofol group)|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
219294842|NCT05016518|DRUG|Arm II (Remimazolam group)|Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
219294843|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
219294844|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
219294845|NCT05470049|DRUG|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
219294846|NCT03258684|DRUG|Hydrocortisone, Vitamin C, and Thiamine|Intervention
219294847|NCT03258684|OTHER|Normal saline|Placebo
219294848|NCT04984434|DRUG|F182112|Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
219294849|NCT05144126|OTHER|CT radioraphic assessment|CT radioraphic assessment
219294850|NCT00014807|BEHAVIORAL|Reducing Pesticide Exposure in Minority Families|
219294851|NCT00155974|BIOLOGICAL|Community-based vaccine outreach intervention|
219294852|NCT05900362|DEVICE|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
219294853|NCT05919862|PROCEDURE|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
219294854|NCT05919862|PROCEDURE|Freehand surgery|Freehand implant placement by experienced surgeon.
219294855|NCT04633798|PROCEDURE|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
219294856|NCT04633798|PROCEDURE|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
219294857|NCT04490967|COMBINATION_PRODUCT|Silymarin|Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
219294858|NCT04490967|PROCEDURE|Salicylic acid|Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
219294859|NCT03838887|DEVICE|ultrasound machine|Ultrasound machine with a vocal software
219294860|NCT02516332|DRUG|Lexapro|
219294861|NCT02516332|DRUG|Placebo|
219294862|NCT02516332|BEHAVIORAL|Supervised Aerobic Exercise|
219294863|NCT05389085|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids|In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
219294864|NCT02482168|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
219294865|NCT00543712|DRUG|PRO95780|Intravenous repeating dose
219294866|NCT04068766|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219294867|NCT04068766|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219294868|NCT04068766|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
219294869|NCT04095481|DEVICE|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
219294870|NCT00233870|DRUG|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
219294871|NCT05432726|OTHER|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
219294872|NCT06145477|BEHAVIORAL|Chicago Parent Program - individualized for families (CPPi)|CPPi is a 8-12 session individual- based parenting skills program
219294873|NCT01405326|BIOLOGICAL|adalimumab|40mg sc. every two weeks for six months
219294874|NCT06198205|OTHER|Fundamental motor skills|This will receive fundamental motor skills(FMS) program include 12 basic motor skills(running,hopping,galloping,leaping,jumping,sliding,strinking,dribbling,catching overhand throwing and underhand rolling)
219294875|NCT06198205|OTHER|Regular after school program|This group will receive regular afterschool programs unstructured child's free play which include sliding, hide and seek, sea-saw, and running along with reading, drawing. Each intervention session lasted 60 minutes. The study will be conducted in the duration of 8 weeks with 3 sessions per week (total 24 sessions) will be given to the students.
219294876|NCT01342341|DRUG|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
219294877|NCT03975777|OTHER|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)
219294878|NCT03975777|OTHER|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)
219294879|NCT03042897|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo DASH diet
219294880|NCT03042897|BEHAVIORAL|Exercise Intervention|Undergo in aerobic exercise
219294881|NCT03042897|OTHER|Laboratory Biomarker Analysis|Correlative studies
219294882|NCT03042897|OTHER|Quality-of-Life Assessment|Ancillary studies
219294883|NCT04268290|COMBINATION_PRODUCT|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
219294884|NCT06274372|DEVICE|flow controlled ventilation|effects of flow controlled ventilation
219294885|NCT06274372|DEVICE|volume controlled ventilation|effects of volume controlled ventilation
219294886|NCT04620304|BIOLOGICAL|UB-421 SC(dB4C7C22-6 mAb)|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
219294887|NCT00875498|PROCEDURE|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
219294888|NCT00875498|PROCEDURE|sham iTBS|iTBS placebo (placebo coil)
219294889|NCT02830360|DRUG|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
219294890|NCT02830360|PROCEDURE|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
219294891|NCT05444218|PROCEDURE|Open flap debridement|After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
219294892|NCT05444218|OTHER|Er: YAG irradiation|An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
219294893|NCT05444218|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
219294894|NCT05444218|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
219294895|NCT05444218|DRUG|Placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
219294896|NCT00442273|DRUG|Umbilical cord serum eyedrops|
219294897|NCT00442273|DRUG|Autologous serum eyedrops|
219294898|NCT03250923|DRUG|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
219294899|NCT05689203|DRUG|QLS1128|dose 1
219294900|NCT05689203|DRUG|QLS1128|dose 2
219294901|NCT05689203|DRUG|Placebo|Placebo
219294902|NCT02593721|PROCEDURE|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
219294903|NCT02593721|DRUG|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
219294904|NCT00171041|DRUG|valsartan|
219294905|NCT00229437|DRUG|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
219294906|NCT00229437|DRUG|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
219294907|NCT00229437|DRUG|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
219294908|NCT00229437|DRUG|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
219294909|NCT04410640|OTHER|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
219294910|NCT06226675|PROCEDURE|PENG Block|To apply local anesthetic under psoas tendon
219294911|NCT06226675|PROCEDURE|LFCN block|to apply local anesthetic around lateral femoral cutaneous nerve
219294912|NCT03299998|PROCEDURE|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
219294913|NCT03299998|PROCEDURE|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
219294914|NCT00688883|DRUG|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
219294915|NCT00509691|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
219294916|NCT00509691|GENETIC|polymerase chain reaction|
219294917|NCT00509691|OTHER|diagnostic laboratory biomarker analysis|
219294918|NCT00509691|OTHER|flow cytometry|
219294919|NCT00509691|OTHER|immunologic technique|
219294920|NCT01534377|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
219294921|NCT01534377|BEHAVIORAL|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
219294922|NCT04107168|DRUG|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
219294923|NCT04107168|DRUG|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
219294924|NCT04107168|DRUG|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
219294925|NCT04107168|DRUG|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
219294926|NCT04107168|DRUG|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
219294927|NCT04107168|DRUG|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
219294928|NCT04107168|DRUG|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
219294929|NCT00670839|BIOLOGICAL|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
219294930|NCT00670839|BIOLOGICAL|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
219294931|NCT02905955|DEVICE|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
219294932|NCT02241005|OTHER|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
219294933|NCT02241005|OTHER|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
219294934|NCT05920460|BEHAVIORAL|Cognitive Behavioral Therapy Program|"Brief description of the Cognitive Behavioral Therapy program is given below:~* Session 1: Mutual understanding and rapprochement~* Session 2: Sleep hygiene education~* Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~* Session 4: Training on relaxation techniques~* Session 5: Psycho education about depression~* Session 6: Cognitive restructuring~* Session 7: The terminating session"
219294935|NCT02366468|DRUG|ranibizumab 0.5 mg|intravitreal injection
219294936|NCT02622776|OTHER|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
219294937|NCT00873431|BIOLOGICAL|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
219294938|NCT04553289|OTHER|exercising into pain|the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
219294939|NCT04553289|OTHER|exercising with no/slight pain|the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
219294940|NCT01552603|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
219294941|NCT03882541|OTHER|Music therapy|To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
219294942|NCT03882541|DRUG|Sedation with midazolam|To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
219294943|NCT04285203|OTHER|Educational Video Intervention|Educational videos
219294944|NCT04293692|BIOLOGICAL|UC-MSCs|0.5\*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
219294945|NCT04293692|OTHER|Placebo|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
219294946|NCT00002459|RADIATION|radiation therapy|
219294947|NCT02699723|DRUG|Arsenic Trioxide|Given PO
219294948|NCT02699723|DRUG|Itraconazole|Given PO
219294949|NCT02699723|OTHER|Laboratory Biomarker Analysis|Correlative studies
219294950|NCT01587027|DRUG|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
219294951|NCT01587027|DRUG|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
219294952|NCT01587027|DRUG|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
219294953|NCT04744545|BEHAVIORAL|Meru Health Program|12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
219294954|NCT04744545|DIETARY_SUPPLEMENT|Curcumin|1500mg/day curcumin plus black pepper to aid absorption
219294955|NCT01417143|DRUG|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
219294956|NCT01164644|DRUG|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
219294957|NCT01164644|DRUG|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
219294958|NCT03051789|DEVICE|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect \~30 ml of menstrual blood when inserted into the vaginal canal
219294959|NCT03051789|OTHER|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
219294960|NCT03051789|OTHER|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
219294961|NCT05710159|DEVICE|iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes|Development and implementation of a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study.
219294962|NCT01004055|DEVICE|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
219294963|NCT01004055|DRUG|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
219294964|NCT01004055|DRUG|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
219294965|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219294966|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219294967|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219294968|NCT00504998|GENETIC|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
219294969|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
219294970|NCT04547868|OTHER|Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
219296539|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
219296540|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
219294971|NCT04547868|OTHER|Decaffeinated Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
219294972|NCT04547868|OTHER|Warm water|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
219294973|NCT02819362|DEVICE|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
219294974|NCT04096053|OTHER|TEACHH|See arm/group description.
219294975|NCT02708264|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
219294976|NCT04797650|DRUG|CTP-543 matching placebo|Administered as tablets.
219294977|NCT04797650|DRUG|CTP-543|Administered as tablets.
219294978|NCT00446043|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
219294979|NCT01800552|PROCEDURE|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
219294980|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
219294981|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
219294982|NCT03271567|DIAGNOSTIC_TEST|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
219294983|NCT04950829|DEVICE|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
219294984|NCT04950829|DEVICE|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
219294985|NCT04950829|PROCEDURE|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
219294986|NCT00944398|DIETARY_SUPPLEMENT|Zinc fortified food|Daily consumption
219294987|NCT00944398|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement containing zinc sulfate
219294988|NCT00944398|OTHER|Placebo supplement|Liquid placebo supplement
219294989|NCT00944398|DIETARY_SUPPLEMENT|Non-fortified food|Non-fortified complementary food.
219294990|NCT03787927|DRUG|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
219294991|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
219294992|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
219294993|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
219294994|NCT03787927|DRUG|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
219294995|NCT03787927|DRUG|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
219296541|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
219296542|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
219296543|NCT00969709|DRUG|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
219296544|NCT02140281|DRUG|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
219296545|NCT02140281|DRUG|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
219294996|NCT05436197|BEHAVIORAL|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
219294997|NCT01423032|DRUG|bendamustine|100 mg/m² iv, day 1+2, q4w
219294998|NCT01423032|DRUG|Fludarabine|25 mg/m² iv, days 1-5, q4w
219294999|NCT00465920|BEHAVIORAL|modified cognitive behavioural therapy (mCBT)|
219295000|NCT04100876|GENETIC|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
219295001|NCT01473004|DEVICE|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
219295002|NCT06338930|OTHER|Remote monitoring|The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
219295003|NCT00657020|DRUG|Nicotine|Nicotine lozenge containing 4 mg of nicotine
219295004|NCT00657020|DRUG|Placebo|Placebo lozenge
219295005|NCT00703937|DRUG|Ferric Carboxymaltose (FCM)|
219295006|NCT00703937|DRUG|Standard Medical Care (SMC) for the treatment of IDA|
219295007|NCT03084341|PROCEDURE|Neuromuscular Electrical Elongation|Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
219295008|NCT03084341|PROCEDURE|Proprioceptive Neuromuscular Facilitation|Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
219295009|NCT03095690|OTHER|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
219295010|NCT03789448|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
219295011|NCT03862001|BEHAVIORAL|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
219295012|NCT06245993|OTHER|EOS imaging|EOS imaging 3 years after skin traction treatment for femoral shaft fracture.
219295013|NCT04925687|BIOLOGICAL|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
219295014|NCT00244816|DRUG|Taxoprexin|
219295015|NCT04744168|OTHER|Acupuncture|Puncture of 5 points 4GI, 6RP, 34VB, 36E, 3F
219295016|NCT04744168|OTHER|Placebo Acupuncture|Puncture of point HM
219295017|NCT00408239|DRUG|YM150|Oral
219295018|NCT00408239|DRUG|enoxaparin|Sub cutaneous
219295019|NCT04365023|DRUG|platinum chemotherapy|First line platinum chemotherapy
219295020|NCT04661800|OTHER|Sniffin's stick test|The sniffin's stick test is a three-part test consisting of smelling odor pens: 1) determining a detection threshold, 2) discriminating ability, 3) ability to identify odors. It lasts about 30 minutes, is achievable in the room.
219295021|NCT00370305|DRUG|rosiglitazone|89 mg BID for 8 weeks, orally
219295022|NCT00964093|DEVICE|Silver Alginate|(Algidex ™)
219295023|NCT04220697|OTHER|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
219295024|NCT04220697|OTHER|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
219295025|NCT04220697|OTHER|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
219295026|NCT04220697|OTHER|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
219295027|NCT06524206|BEHAVIORAL|The Awareness, Courage and Love Intervention|Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
219295028|NCT04772898|BEHAVIORAL|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
219295029|NCT02651857|DEVICE|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
219295030|NCT02651857|DEVICE|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
219295031|NCT00336089|BEHAVIORAL|exercise intervention|
219295032|NCT00336089|OTHER|educational intervention|
219295033|NCT00336089|PROCEDURE|complementary or alternative medicine procedure|
219295034|NCT00336089|PROCEDURE|fatigue assessment and management|
219295035|NCT00336089|PROCEDURE|management of therapy complications|
219295036|NCT00336089|PROCEDURE|pain therapy|
219295037|NCT00336089|PROCEDURE|quality-of-life assessment|
219295038|NCT03368339|DRUG|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
219295039|NCT03368339|DRUG|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
219295040|NCT03368339|DRUG|Vehicle|Vehicle
219295041|NCT02436590|DEVICE|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
219295042|NCT00279643|PROCEDURE|Laser Hair Removal|
219295043|NCT03623854|BIOLOGICAL|Nivolumab|Given IV
219295044|NCT03623854|BIOLOGICAL|Relatlimab|Given via infusion
219295045|NCT01144052|DRUG|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units \[MIU\])
219295046|NCT01144052|DRUG|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
219295047|NCT02389582|DRUG|Dabigatran|Use for 5 days
219295048|NCT02389582|DRUG|Enoxaparin|Use for 5 days
219295049|NCT02530164|DEVICE|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
219295050|NCT05297669|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
219295051|NCT05297669|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
219295052|NCT04444973|PROCEDURE|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
219295053|NCT02947087|DRUG|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
219295054|NCT02947087|DRUG|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
219296546|NCT03639831|DIETARY_SUPPLEMENT|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
219296547|NCT03639831|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|2 capsules/ day providing no active component
219296548|NCT01140698|OTHER|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
219296549|NCT02907307|DEVICE|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
219295055|NCT05070442|BEHAVIORAL|Norm-based messaging and peer comparison features|"Participants are shown a version of NUSMart which includes Nutri-Score labels that are enabled and displayed besides all the products in the store. Additionally, they are shown a video that gives them background information about Nutri-Score labels and describes the following features enabled in this intervention:~* Norm-based messaging will be displayed in the form of a happy or sad emoticon based on whether the participant's current basket average Nutri-Score (weighted by number of servings) is above or below other shoppers (Nutri-Score=3.98).~* Peer comparison will be implemented as a vertical ruler display of the participant's current basket average Nutri-Score (weighted by number of servings) as well as that of their peers.~Nutri-Score=3.98 was chosen as it is 10% better than the mean Nutri-Score of baskets purchased by participants in the Nutri-Score labelled intervention arm of a prior study."
219295056|NCT05070442|BEHAVIORAL|Financial Incentives leveraging on loss aversion|"Participants are informed that they have received an additional $5 towards their participant reimbursement. However, this amount will be forfeited if they check-out with a basket average Nutri-Score (weighted by the number of servings) that falls below the average Nutri-Score of other shoppers i.e. 3.98. An indicator on the screen that informs the participants of this potential forfeiting will be included."
219295057|NCT02206477|DRUG|Dimethyl Sulfoxide|
219295058|NCT02206477|DRUG|Saline 0.9%|
219295059|NCT05014711|DRUG|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
219296550|NCT02907307|DEVICE|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
219296551|NCT02907307|DRUG|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
219295060|NCT05014711|DRUG|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
219295061|NCT01057329|DRUG|Atomoxetine|mg according to body weight
219295062|NCT01057329|DRUG|Duloxetine|30 mg / die
219295063|NCT01057329|DRUG|Olanzapine|5mg 1 wwek and 10 mg from second week
219295064|NCT01057329|DRUG|Aripiprazole|5 mg from week 1, 10 mg from week 2
219295065|NCT05109182|DEVICE|Innersight3D|Innersight3D generates a virtual interactive 3D model of the CT scan.
219295066|NCT01736800|DRUG|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
219295067|NCT01736800|DRUG|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
219295068|NCT03448770|DRUG|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
219295069|NCT03448770|DRUG|Lactulose : 20-30gm|Lactulose : 20-30gm
219295070|NCT06226324|OTHER|neuropsychological test|The subjects were evaluated for memory, cognition, mood and sleep
219295071|NCT04782336|OTHER|Sample Collection|"Sample Collection - Adult Population:~* Two (2) Nasal AND/OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample~Sample Collection - Paediatric Population:~* Two (2) Nasal OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample"
219295072|NCT04357600|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell|All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
219295073|NCT05557513|DEVICE|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
219295074|NCT00105001|DRUG|Fludarabine Phosphate|Given IV
219295075|NCT00105001|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
219295076|NCT00105001|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219295077|NCT00105001|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219295078|NCT00105001|DRUG|Tacrolimus|Given IV or PO
219295079|NCT00105001|DRUG|Mycophenolate Mofetil|Given PO
219295080|NCT00105001|DRUG|Sirolimus|Given PO
219295081|NCT05514041|DRUG|Varenicline solution|OC-01 nasal spray 0.03 mg
219295082|NCT05514041|DRUG|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
219295083|NCT00253084|DRUG|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
219295084|NCT00253084|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
219295085|NCT00253084|DRUG|IPX054 Placebo|Placebo to match IPX054 200 mg
219295086|NCT00253084|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
219295087|NCT03475277|DRUG|Ketamine|Acute administration
219295088|NCT02143752|BEHAVIORAL|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
219295089|NCT02143752|BEHAVIORAL|Quit Line|see arm
219295090|NCT01579279|DRUG|ABT-652 6 mg|6 mg capsules
219295091|NCT01579279|DRUG|ABT-652 12 mg|12 mg capsules
219295092|NCT01579279|DRUG|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
219295093|NCT01579279|DRUG|Placebo|Placebo capsules
219295094|NCT01579279|DRUG|Duloxetine|Duloxetine capsules
219295095|NCT03323073|OTHER|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
219295096|NCT02230098|OTHER|Remote Ischemic Conditioning|
219295097|NCT05839392|BIOLOGICAL|Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal
219295098|NCT05978973|DIETARY_SUPPLEMENT|Elemental Diet|. Elemental diets contain all daily required vitamins, micronutrients and macronutrients. The ingredients are readily digestible (carbohydrates, amino acids and medium chain fatty acids) and are absorbed within the proximal small bowel. One main disadvantage of elemental diets such as Vivonex is their unpalatability3 which has limited their use.
219295099|NCT00234845|DRUG|adalimumab|
219295100|NCT00234845|DRUG|methotrexate|
219295101|NCT05377437|OTHER|Natural Language Processing|Natural Language Processing: classification and regression tasks.
219295102|NCT02877329|BEHAVIORAL|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
219295103|NCT02630602|DIETARY_SUPPLEMENT|Functional goat cheese|60 g per day during 12 weeks
219295104|NCT02630602|DIETARY_SUPPLEMENT|Control cheese|60 g per day during 12 weeks
219295105|NCT01879722|DRUG|TAK-063|TAK-063 tablets
219295106|NCT01879722|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
219295107|NCT05909852|DRUG|ABP 501-HCF|Participants will receive a single-dose SC injection of ABP 501-HCF.
219295108|NCT05909852|DRUG|ABP 501-LCF|Participants will receive a single-dose SC injection of ABP 501-LCF
219295109|NCT03211754|DIETARY_SUPPLEMENT|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
219295110|NCT05149053|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
219295111|NCT05149053|OTHER|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
219295112|NCT00434213|DRUG|Daytrana|Methylphenidate Transdermal System (MTS)
219295113|NCT00697697|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
219295114|NCT00697697|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
219295115|NCT06039631|PROCEDURE|Surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended.
219295116|NCT06039631|RADIATION|Radiation|"In the surgical group, depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended.~In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin at a dosage of 30 mg/m²."
219295117|NCT06039631|DRUG|Toripalimab|In the both groups, starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
219295118|NCT03454841|DRUG|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
219295119|NCT03454841|DRUG|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
219295120|NCT02892695|BIOLOGICAL|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
219295121|NCT05141240|DRUG|Ribiciclib|Participants who initiated CDK4/6i therapy
219295122|NCT05141240|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
219295123|NCT05141240|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
219295124|NCT05379036|DRUG|prescribing anapproved drug, examination|"* Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months."
219295125|NCT00063427|DRUG|MAC-321|
219295126|NCT01327495|OTHER|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
219295127|NCT01327495|OTHER|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
219295128|NCT01327495|DRUG|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
219295129|NCT01327495|DRUG|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
219295130|NCT01327495|DRUG|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
219295131|NCT01327495|DRUG|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
219295132|NCT01327495|DRUG|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
219295133|NCT01327495|DRUG|Acyline|300 ug/kg subcutaneous injection every 2 weeks
219295134|NCT00741364|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
219295135|NCT01534689|DEVICE|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
219295136|NCT00481624|DRUG|Epoetin Alfa plus Iron|"1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
219295137|NCT03384160|DIAGNOSTIC_TEST|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
219295138|NCT03384160|DIAGNOSTIC_TEST|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
219295139|NCT04488627|DIAGNOSTIC_TEST|Conventional transthoracic echocardiographic examination at the intensive care unit.|Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
219295140|NCT05243238|DIETARY_SUPPLEMENT|dietary supplement flavonoids|patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention
219295141|NCT00003601|DRUG|fenretinide|
219295142|NCT00003601|DRUG|tretinoin|
219295143|NCT05115643|BEHAVIORAL|Immobilization|Immobilization of left arm using a brace and sling.
219295144|NCT04361851|DRUG|Pembrolizumab|Experimental
219295145|NCT02015455|OTHER|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
219295146|NCT02415517|BEHAVIORAL|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken \& Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
219295147|NCT02415517|BEHAVIORAL|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
219295148|NCT01104597|PROCEDURE|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
219295149|NCT01104597|DRUG|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
219295150|NCT06017843|OTHER|Camps site selection for active case finding for TB using MATCH-AI|The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
219295151|NCT01181323|OTHER|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
219295152|NCT01181323|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
219295153|NCT01181323|OTHER|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
219295154|NCT01181323|BIOLOGICAL|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
219295155|NCT01631227|DRUG|Eprosartan|Eprosartan 450 mg
219295156|NCT01631227|DRUG|Eprosartan Mesylate|Eprosartan mesylate 600 mg
219295157|NCT01631227|DRUG|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
219295158|NCT01631227|DRUG|Placebo Eprosartan|Placebo Eprosartan
219295159|NCT02857569|DRUG|Ipilimumab IT|
219295160|NCT02857569|DRUG|Ipilimumab IV|
219295161|NCT02857569|DRUG|Nivolumab IV|
219295162|NCT05294601|OTHER|High-Intensity Interval Training|high intensity exercise with games
219295163|NCT05294601|OTHER|Medium-Intensity Interval Training|medium intensity exercise with games
219295164|NCT01242826|DRUG|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
219295165|NCT00766363|DRUG|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
219295166|NCT00766363|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
219295167|NCT00766363|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
219295168|NCT00766363|DRUG|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
219295169|NCT00766363|DRUG|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
219295170|NCT00766363|DRUG|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
219295171|NCT00167089|BEHAVIORAL|Treadmill Training|Partian body weight support treadmill training, 30 min/day \* 3 days /week
219295172|NCT02548598|PROCEDURE|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
219295173|NCT03020576|DEVICE|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
219295174|NCT03020576|OTHER|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
219295175|NCT03385343|DIAGNOSTIC_TEST|VLE imaging for staging EAC|Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
219295176|NCT05108129|PROCEDURE|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
219295177|NCT05108129|PROCEDURE|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
219295178|NCT00002987|BIOLOGICAL|bleomycin sulfate|
219295179|NCT00002987|DRUG|cyclophosphamide|
219295180|NCT00002987|DRUG|doxorubicin hydrochloride|
219295181|NCT00002987|DRUG|etoposide|
219295182|NCT00002987|DRUG|prednisolone|
219295183|NCT00002987|DRUG|vincristine sulfate|
219295184|NCT00002987|RADIATION|radiation therapy|
219296552|NCT01495832|OTHER|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
219295185|NCT01994759|OTHER|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
219295186|NCT01994759|DRUG|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
219295187|NCT01994759|BEHAVIORAL|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
219295188|NCT01177800|DRUG|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
219295189|NCT01177800|DRUG|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
219295190|NCT04472559|BEHAVIORAL|Self-acupressure|Self-acupressure
219295191|NCT05526079|OTHER|Watchfuf waiting|Careful review of patient response with the hope of avoiding radical surgery.
219295192|NCT04399811|DIAGNOSTIC_TEST|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
219295193|NCT03527550|OTHER|Cognitive Control Training|Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
219295194|NCT00940732|OTHER|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
219295195|NCT00940732|OTHER|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
219295196|NCT00940732|OTHER|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
219295197|NCT02729662|DRUG|Tolvaptan|"* Before administration of tolvaptan~  * TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~ * 24-hour urine collection・Hematology/urinalysis: Once/year~ * Physical findings: Blood pressure and medical interview at ambulatory visit~* Hospitalization for education and examination at the start of tolvaptan administration~  * 24-hour urine collection・Hematology/urinalysis・Inulin clearance~ * Physical findings: Body weight, blood pressure~ * Adverse Events~* After administration of tolvaptan~  * TKV・Liver capacity・inulin clearance: Once/year~ * 24-hour urine collection: Once/6 months~ * Hematology/urinalysis: Once/month in principle~ * Physical findings: Blood pressure and medical interview at ambulatory visit~ * Adverse Events"
219295198|NCT04678999|BEHAVIORAL|Mind-body exercise and education|The intervention will delivered via a secure Zoom video platform.
219295199|NCT01912560|DRUG|CAT-2003|
219295200|NCT01912560|DRUG|Placebo|
219295201|NCT01912560|DRUG|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
219295202|NCT06279026|BIOLOGICAL|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
219295203|NCT06281899|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg once daily
219295204|NCT06281899|BEHAVIORAL|Low protein diet|Plant based low protein diet (0.6 g/kg IBW)
219295205|NCT04896151|DIAGNOSTIC_TEST|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath \& Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
219295206|NCT01010334|OTHER|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
219295207|NCT00911937|DRUG|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
219743198|NCT06686706|OTHER|KT group|"Kinesio tapping (left there for 3 days)~Procedure:~We will use a standard 2 (5 cm) kinesiology tape. Fascia tape will be applied to the plantar fascia, and it will be left there for three days. For four weeks, it will be applied once a week. The patient will be in a prone position, lying with the ankle joints in a neutral position while applying tape. With the toes extended against the bed or ground. The tape will be marked on the Achilles tendon. It will be cut longitudinally into five slices of equal width. It will be applied to the forefoot by stretching it by 25%. The last strap will be applied with gentle compression across the bases of the five slices beneath the foot and wrapped around the rear foot.(5) Conventional Therapy Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min"
219743199|NCT06686290|OTHER|Post-Isometric Relaxation Technique|Post isometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.
219743200|NCT06686290|OTHER|Static Stretching|Static Stretching
219743201|NCT06689514|DRUG|alpha receptor antagonist|Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)
219743202|NCT06689514|DRUG|Low dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID
219743203|NCT06689514|DRUG|High dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
219743204|NCT06695884|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
219743205|NCT06695273|DIAGNOSTIC_TEST|AI-derived probability of coronary heart disease.|Physician readers will be assisted with AI-derived probability of coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
219743206|NCT06695273|DIAGNOSTIC_TEST|PCEs derived ASCVD risk|Physicians use a PCEs to calculate the probability of 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
219295208|NCT00911937|DRUG|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
219295209|NCT05573867|OTHER|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
219295210|NCT03398213|OTHER|Acupuncture|Acupuncture
219295211|NCT03398213|OTHER|Sham procedure|Ear stimulation with plaster
219295212|NCT02861547|OTHER|death|
219295213|NCT01767701|DRUG|Raltegravir|400mg twice daily for 3 months
219295214|NCT00583193|DRUG|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
219295215|NCT05033951|OTHER|Standard care|Both groups: standard care+ questionnaires
219295216|NCT04940403|DEVICE|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
219295217|NCT04940403|DEVICE|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
219295218|NCT00566878|BIOLOGICAL|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
219295219|NCT05152420|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
219295220|NCT05152420|DRUG|Placebo|VMX-C001 matched placebo
219295221|NCT05152420|DRUG|Apixaban|FXa Inhibitor
219295222|NCT05152420|DRUG|Rivaroxaban|FXa Inhibitor
219295223|NCT05152420|DRUG|Edoxaban|FXa Inhibitor
219295224|NCT03002831|BIOLOGICAL|Cytokine-induced Killer Cells|
219295225|NCT03002831|DRUG|Tegafur-Gimeracil-Oteracil Potassium|
219295226|NCT02109315|DRUG|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
219295227|NCT02109315|DRUG|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
219295228|NCT00201227|OTHER|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
219295229|NCT06186661|OTHER|neurophysiological exercise|The content of the treatment program consisted of neurophysiological exercises based on Bobath.
219295230|NCT06186661|OTHER|cognitive rehabilitation|Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
219295231|NCT03410368|BIOLOGICAL|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
219295232|NCT00795366|DRUG|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
219295233|NCT00795366|DRUG|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
219295234|NCT00187564|DRUG|controlled-release oral alpha-lipoic acid|
219295235|NCT04531644|PROCEDURE|double stimulation|the patients will be treated with two consecutive ovarian stimulations in one cycle
219295236|NCT04531644|PROCEDURE|conventional ovarian stimulation|the patients will be treated with one conventional ovarian stimulation in one cycle
219295237|NCT04539535|OTHER|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
219295238|NCT04948281|OTHER|no intervention|no intervention
219295239|NCT00106587|DEVICE|PTCA|
219295240|NCT00106587|COMBINATION_PRODUCT|paclitaxel coated balloon catheter (device with drug)|
219295241|NCT01844687|DRUG|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
219295242|NCT01465529|DRUG|OligoG CF-5/20|6% OligoG CF-5/20 in water
219295243|NCT01465529|DRUG|Saline|0.9% NaCl in water
219295244|NCT00933855|BEHAVIORAL|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
219295245|NCT01283204|DRUG|SP|"\<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest."
219295246|NCT01283204|DRUG|FL/Tax|"\<Every q 3 weeks\>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
219295247|NCT01283204|DRUG|FL/Doc|"\<Every q 3 weeks\>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
219295248|NCT01283204|DRUG|FOLFOX|\<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
219295249|NCT00669370|DRUG|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
219295250|NCT00002323|DRUG|Nevirapine|
219295251|NCT00002323|DRUG|Zidovudine|
219295252|NCT04539782|OTHER|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
219295253|NCT03196154|DIAGNOSTIC_TEST|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
219295254|NCT03196154|DIAGNOSTIC_TEST|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
219295255|NCT00640081|BIOLOGICAL|cetuximab|
219295256|NCT00640081|DRUG|capecitabine|
219295257|NCT00640081|DRUG|fluorouracil|
219295258|NCT00640081|DRUG|leucovorin calcium|
219295259|NCT00640081|DRUG|oxaliplatin|
219295260|NCT00640081|OTHER|immunohistochemistry staining method|
219295261|NCT00640081|OTHER|laboratory biomarker analysis|
219295262|NCT05333952|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
219296553|NCT01495832|OTHER|Control Group|The control group will consume comparator foods for 12 weeks.
219296554|NCT05146180|DEVICE|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
219296555|NCT00061984|BIOLOGICAL|pegfilgrastim|
219295263|NCT05333952|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
219295264|NCT06445829|DRUG|Magnesium sulfate|adding 300mg magnesium sulfate into cocktail injection
219295265|NCT05567354|DRUG|PF614|PF614 100 mg capsules
219295266|NCT05567354|DRUG|Oxycodone|Oxycodone HCl IR 40mg
219295267|NCT05567354|OTHER|Placebo|placebo powder
219295268|NCT02015182|OTHER|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
219295269|NCT05626790|OTHER|Exercise|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
219296556|NCT00061984|DRUG|doxorubicin hydrochloride|
219296557|NCT00061984|DRUG|ifosfamide|
219296558|NCT00061984|PROCEDURE|multimodality therapy|
219296559|NCT06019741|DRUG|Rivaroxaban and aspirin 80|rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
219296560|NCT06019741|DRUG|Aspirin 80|aspirin 80 mg orally post coronary bypass surgery
219743207|NCT06694038|PROCEDURE|Needle Knife Fistulotomy|Biliary access using needle knife fistulotomy technique
219743208|NCT06694038|PROCEDURE|standard biliary cannulation|standard biliary cannulation
219743209|NCT06695481|PROCEDURE|Conventional RF|The conventional RF group consists of patients who received medial branch RF with a duration of 2 minutes, at 80̊ C temperature, and 7 Volts.
219743210|NCT06695481|PROCEDURE|Combined RF|In the combined RF group, treatment was initiated first with a conventional RF duration of 2 minutes at a temperature of 80̊ C at 7 Volts. Then, pulsed RF duration was applied for 6 minutes at a temperature of 42 C at 45 Volts, with a pulse frequency of 2 Hz and a width of 20 ms.
219743211|NCT06693973|DRUG|AcNK-Sup003 cell injection solution|The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
219743212|NCT06688604|BEHAVIORAL|skin contact|Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth
219743213|NCT06687109|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
219743214|NCT06687109|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty
219743215|NCT06688019|DEVICE|conventional oxygenation (nasal cannula)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
219743216|NCT06688019|DEVICE|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
219743217|NCT06691061|DRUG|Vedolizumab|UC patients treated with vedolizumab
219743218|NCT06691061|DRUG|Ustekinumab - Standard Dosage|UC patients treated with ustekinumab
219743219|NCT06691061|DRUG|JAK Inhibitor|UC patients treated with JAK inhibitors
219743220|NCT06688045|DRUG|Nemtabrutinib|Oral administration
219743221|NCT06688045|DRUG|Itraconazole|Oral administration
219743222|NCT06686212|OTHER|Sensory re-education+ strengthening exercises+ kinesio taping|"Sensory re-education. Splinting: as constant maintained touch with wrist holding in neutral position for 15 minutes.~Topical anesthesia spray on affected area for 10 minutes. Massage: apply massage over sensitive areas with same speed and pressure, then the light pressure with cotton, velvet, terry cloth, polyester and wool over sensitive area for 10 minutes.~PNF using upper extremity (D2) pattern including shoulder extension, adduction, internal rotation, wrist and fingers flexed and wrist ulnar deviated. 10-15 repetitions for 5 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions of each exercise for 20 minutes.~Kinesio taping: Taping will be applied twice a week for 12 weeks."
219743223|NCT06686212|OTHER|Neural mobilization+ Strengthening exercises+ Kinesio taping.|"The median nerve is mobilized through wrist flexion and extension with elbow straight and palm facing up.~Wrist flexion and extension with elbow flexed to 90 degrees with palm facing up 10-15 repetitions.~Wrist flexors stretch with extended arm and palm facing down 10-15 repetitions. Straight fist: hold your hand up with fingers straight. Full fist: bend your fingers to form a full fist. Median nerve stretch and wrist extension exercises for 30 minutes. Free the bird exercises, busy bee flexion shape of Z exercises and wall stretch exercise. (10-15 repetitions) for 10 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions each for 20 minutes.~Kinesio taping: The taping will be applied twice a week for 12 weeks."
219296561|NCT01149109|DRUG|Temozolomide and lomustine|
219296562|NCT01149109|DRUG|Temozolomide|
219296563|NCT04725474|BIOLOGICAL|visugromab (CTL-002)|monoclonal antibody
219296564|NCT03086525|OTHER|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
219296565|NCT00016601|DRUG|Indinavir sulfate|
219296566|NCT00016601|DRUG|Ritonavir|
219743224|NCT06694103|OTHER|Reverse Kangaroo Care Position|"* Babies will be taken to the examination table and their clothes other than diapers will be removed.~* Mothers will take off their upper clothes and lie on the examination table and position their babies in the reverse kangaroo care position, with the baby's back against the mother's bare chest.~* Babies will be monitored with disposable probes from their right feet.~* Video recording will be started. -While the position applied to the babies is maintained, the speculum will be placed in the eye by the ophthalmologist and the examination will be recorded on video from the beginning to end.~* After the completion of both eye examinations, the position of the babies whose monitoring continues will be maintained while the video recording will be taken for another 1 minute. The SPO2, HR, PIPP-R score at the end of the 15th second before the examination, the first minute during the examination and the 30th second after the examination will be evaluated."
219743225|NCT06694103|OTHER|ROP Position|"* Babies will be taken to the examination table and monitored with disposable probes from their right feet.~* The nurse will place the infant's own palms on the temporal region and hold them with her hands to support their head, while the mother will also support the infant by holding their legs.~* The video recording will be started.~* SPO2, HR, PIPP-R values will be recorded on video for one minute.~* While the ROP position applied to the babies is maintained, the speculum is placed in the eye by the ophthalmologist and the examination begins.~* SPO2, HR, PIPP-R evaluation at the 1st minute of the examination.~* After the completion of both eye examinations, the babies whose monitoring continues will be kept in their positions and a video recording will be taken for another 1 minute.~* The SPO2, HR values and PIPP-R pain score at the end of the 30 seconds after the examination will be evaluated."
219743226|NCT06691412|DRUG|Obeticholic Acid 5 mg|\- Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
219743227|NCT06686966|DIAGNOSTIC_TEST|gastric cancer|be diagnosed as gastric cancer
219743228|NCT06686810|PROCEDURE|Endoscopic Retrogradade CholangioPancreatography (ERCP)|ERCP is an endoscopic therapeutic procedure to drain the bile ducts in case of stones or biliary strictures that can be treated by balloon dilatation or stents (plastic or metal) insertion
219743229|NCT06686563|OTHER|Intervention Group: Gamma stimulation|Participants in this group be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
219743230|NCT06686563|OTHER|Control Group: Theta stimulation|Participants in this group will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
219743231|NCT06694844|PROCEDURE|Socket preservation with M1|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).
219743232|NCT06694844|PROCEDURE|Socket preservation with M2|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
219743233|NCT06729996|DRUG|Pioglitazone (PIO)|Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
219743234|NCT06729996|DRUG|Empagliflozin (EMPA)|Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
219743235|NCT00028288|DRUG|Daclizumab|
219743236|NCT06359626|DRUG|YHP2205|Test drug: YHP2205
219743237|NCT06359626|DRUG|YHR2401|comparator: YHR2401
219743238|NCT06113302|DRUG|Luspatercept|Given by SC or (Injection)
219743239|NCT04912531|DEVICE|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
219743240|NCT04912531|DEVICE|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
219295270|NCT05626790|OTHER|PNF Stretching|"In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~1. Biceps: Flex-Add-ER repositioned half pattern~2. Brachioradialis: Flex-Abd-ER repositioned half pattern~3. Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches."
219295271|NCT05626790|OTHER|Prolonged Stretching|"In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~1. In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~2. In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched."
219295272|NCT04245228|BEHAVIORAL|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
219295273|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo"
219296567|NCT00016601|DRUG|Nelfinavir mesylate|
219296568|NCT00016601|DRUG|Efavirenz|
219296569|NCT00016601|DRUG|Nevirapine|
219296570|NCT00016601|DRUG|Medroxyprogesterone acetate|
219295274|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
219295275|NCT01994967|DRUG|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
219295276|NCT01994967|DRUG|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
219295277|NCT03865927|OTHER|Placebo Oral Tablet|see Arm/Group description
219295278|NCT03865927|DRUG|GKT137831|GKT137831 is a NOX enzyme inhibitor
219295279|NCT03499470|OTHER|Protocol for structured discharge and follow-up|
219295280|NCT03047395|BIOLOGICAL|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
219295281|NCT04949061|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
219295282|NCT04949061|OTHER|Enhanced Treatment as Usual (ETA-U)|Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
219295283|NCT00941967|DRUG|gemcitabine hydrochloride|Given IV
219295284|NCT00941967|DRUG|oxaliplatin|Given IV
219295285|NCT00941967|DRUG|sorafenib tosylate|Given orally.
219295286|NCT05912101|PROCEDURE|Pericapsular Nerve Group Block|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
219295287|NCT05912101|PROCEDURE|Suprainguinal Fascia Compartment Block|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
219295288|NCT05912101|PROCEDURE|3-1 Block|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
219295289|NCT00650884|DEVICE|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
219295290|NCT04798859|OTHER|Family centered in-home rehabilitation|Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
219295291|NCT04798859|OTHER|Control|Usual follow-up in the municipality
219295292|NCT04719546|OTHER|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
219295293|NCT05659498|BEHAVIORAL|Cardiac Rehabilitation Program|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
219295294|NCT04702698|DRUG|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
219295295|NCT04702698|DRUG|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
219295296|NCT01145209|DRUG|Fludarabine Phosphate|Given IV
219295297|NCT01145209|BIOLOGICAL|Ofatumumab|Given IV
219295298|NCT01145209|DRUG|Cyclophosphamide|Given IV
219295299|NCT00407108|PROCEDURE|Vitrectomy|
219295300|NCT05271370|DRUG|PRO 140 350|Pro140 SC injection 350 mg
219295301|NCT05271370|DRUG|PRO 140 525|525 mg
219295302|NCT05271370|DRUG|PRO 140 700|700 mg
219295303|NCT00124683|DRUG|Bupropion|
219295304|NCT00124683|DRUG|nicotine transdermal patch|
219743241|NCT04912531|DEVICE|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
219743242|NCT06687473|DRUG|Bismuth-based susceptibility-guided treatment|"The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens."
219743243|NCT01511237|DRUG|Nevirapine, zidovudine, lamivudine|"* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks."
219743244|NCT00152958|DRUG|Pramipexole|
219743245|NCT02620865|BIOLOGICAL|Aldesleukin|Given SC
219743246|NCT02620865|BIOLOGICAL|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
219743247|NCT02620865|DRUG|Fluorouracil|Given IV
219743248|NCT02620865|DRUG|Gemcitabine Hydrochloride|Given IV
219743249|NCT02620865|DRUG|Irinotecan Hydrochloride|Given IV
219295305|NCT05890859|DIAGNOSTIC_TEST|DXA scan|The patients will undergo 5 DXA scans fro pre- to post treatment
219295306|NCT05890859|BEHAVIORAL|Physical testing|The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
219295307|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: POCT|measurement of blood glucose concentration using 5 different POCT glucometer
219295308|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: reference|measurement of blood glucose concentration using 2 different laboratory analyzer
219295309|NCT04550338|DRUG|Tranexamic acid|Oral administration of blinded medications
219295310|NCT04550338|DRUG|Placebo|Oral administration of blinded medications
219295311|NCT04694261|BEHAVIORAL|SM-ART|Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
219295312|NCT06069310|DRUG|Mepolizumab 100 MG|Monthly administartion of mepolizumab 100mg
219295313|NCT02550353|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
219295314|NCT02550353|PROCEDURE|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
219295315|NCT06339853|DEVICE|WELT-IP with wearable devices (Apple/galaxy watch. Oura ring)|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot. By using WELT-IP simultaneously with wearing an Apple Watch/Galaxy Watch and Oura Ring, sleep and environmental data can be collected.
219295316|NCT04331678|BEHAVIORAL|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
219295317|NCT03100877|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
219295318|NCT03100877|DRUG|Cyclophosphamide|Given IV
219295319|NCT03100877|BIOLOGICAL|Filgrastim|Given SC or IV
219295320|NCT03100877|OTHER|Laboratory Biomarker Analysis|Correlative studies
219295321|NCT03100877|DRUG|Lenalidomide|Given PO
219295322|NCT03100877|PROCEDURE|pheresis|Undergo apheresis
219295323|NCT03100877|DRUG|Melphalan|Given IV
219295324|NCT03100877|BIOLOGICAL|Palifermin|Given IV
219295325|NCT03100877|RADIATION|Total Marrow Irradiation|Undergo TMI
219295326|NCT01737424|DRUG|LC28-0126|LC28-0126
219295327|NCT01737424|DRUG|Placebo|Placebo
219295328|NCT01563159|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
219295329|NCT03804489|OTHER|Decision aids|Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
219295330|NCT03859245|BEHAVIORAL|Photobiomodulation|Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
219295331|NCT03859245|BEHAVIORAL|Ketogenic diet|Experimental group will follow a clinically prescribed ketogenic diet.
219295332|NCT03307005|DRUG|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
219295333|NCT03307005|DRUG|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
219295334|NCT00298259|PROCEDURE|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
219295335|NCT00635427|BIOLOGICAL|VPRIV®|Intravenous infusion, every other week (EOW)
219295336|NCT06228391|DRUG|IV ketamine|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.
219295337|NCT06228391|DRUG|Midazolam|Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.
219295338|NCT04654026|DRUG|Aspirin/Clopidogrel|No intervention, only observational studies
219295339|NCT06292052|DRUG|Immunotherapy|Received neoadjuvant chemotherapy plus immunotherapy
219295340|NCT00562055|DRUG|Atomoxetine|
219295341|NCT00562055|DRUG|PNU-165442G; [S,S]-reboxetine|
219295342|NCT06100081|DIAGNOSTIC_TEST|Detection of lesions using fluorescence molecular imaging|Using a fluorescence camera, lesions will be detected and biopsies will be taken to try and find cancer of unknown primary
219295343|NCT05299294|OTHER|Data collection|Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain
219295344|NCT02213341|PROCEDURE|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
219295345|NCT02213341|PROCEDURE|Blood draw|
219743250|NCT02620865|OTHER|Laboratory Biomarker Analysis|Correlative studies
219743251|NCT02620865|DRUG|Leucovorin Calcium|Given IV
219743252|NCT02620865|DRUG|Oxaliplatin|Given IV
219743253|NCT02620865|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219743254|NCT02620865|BIOLOGICAL|Sargramostim|Given SC
219743255|NCT04231565|DRUG|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
219743256|NCT06070532|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
219295346|NCT02054611|OTHER|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
219295347|NCT02054611|OTHER|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
219295348|NCT05343520|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
219295349|NCT06086600|OTHER|Instrument Assisted Soft Tissue Mobilization|"give gentle strokes from proximal to distal to check for trigger point or taut band. After knowing the exact location, give gentle strokes with minimal pressure in all directions by keeping the instrument in 30 to 60 degree angle. Application time will be between 40- 120 seconds.~Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles)"
219295350|NCT06086600|OTHER|Dynamic oscillatory stretch technique|"Passively dorsiflexe the ankle to a point of the first stretch sensation. The next component to DOS, 2- second, passive stretch with slow oscillations at end range was applied. This procedure is repeated 10 times in each set with total of 3 sets .Therefore,10reps x2 second hold oscillation x 3 sets are given.Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles"
219295351|NCT00366002|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
219295352|NCT06461702|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
219295353|NCT03484273|DEVICE|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
219295354|NCT02197559|PROCEDURE|DES group|all the participants in this group will be performed with drug -eluting stents
219295355|NCT02197559|PROCEDURE|BMS group|all the participants in this group will be performed with bare-metal stents
219295356|NCT02644291|DRUG|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
219295357|NCT04144101|DRUG|Etoricoxib|Etoricoxib 60 mg QD Oral
219295358|NCT04144101|DRUG|Aceclofenac|Aceclofenac 100 mg BID Oral
219295359|NCT05469750|DRUG|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
219295360|NCT00014651|DRUG|vapreotide|
219295361|NCT00014651|PROCEDURE|conventional surgery|
219295362|NCT01721460|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
219295363|NCT02960750|BEHAVIORAL|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
219295364|NCT02960750|BEHAVIORAL|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
219295365|NCT04580082|BEHAVIORAL|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
219295366|NCT00913315|DRUG|tolterodine|4 mg of tolterodine ER
219295367|NCT00913315|DRUG|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
219295368|NCT00913315|DRUG|placebo|placebo once a day for 8 weeks
219295369|NCT06414707|DRUG|Vonoprazan, Amoxicillin and Levofloxacin|Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
219295370|NCT06414707|DRUG|Pantoprazole 40mg, Amoxicillin and Levofloxacin|Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
219295371|NCT01254240|DEVICE|UVA / UVB phototherapy|UVA / UVB phototherapy
219295372|NCT01254240|DEVICE|UVB phototherapy|UVB phototherapy
219295373|NCT00445354|DRUG|cinnamon|
219295374|NCT03983629|OTHER|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
219295375|NCT01227382|PROCEDURE|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
219295376|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 100 days
219295377|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 200 days
219295378|NCT02706899|DRUG|vadastuximab talirine|Intravenous (IV) push every 4 weeks
219295379|NCT02706899|DRUG|Azacitidine|75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks
219295380|NCT02706899|DRUG|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
219295381|NCT00324675|DRUG|Rosiglitazone|4 mg tablets, bid, 12 months
219295382|NCT00324675|DRUG|Placebo|2 tablets per day
219295383|NCT04550533|OTHER|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
219295384|NCT05703997|DIETARY_SUPPLEMENT|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
219295385|NCT05703997|DRUG|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
219295386|NCT05551312|OTHER|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
219295387|NCT05675787|DRUG|Medroxyprogesterone acetate + Atorvastatin|MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
219295388|NCT05137015|OTHER|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~1. Balance~2. Core stability~3. Hamstring eccentrics~4. Glute activation~5. Plyometrics~6. Running~7. Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
219295389|NCT02534454|BEHAVIORAL|Active Retraining|
219295390|NCT02534454|BEHAVIORAL|Sham Retraining|
219295391|NCT02534454|DEVICE|Active transcranial direct current stimulation (TDCS)|
219295392|NCT02534454|DEVICE|Sham transcranial direct current stimulation (TDCS)|
219295393|NCT02534454|DRUG|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
219295394|NCT04206930|OTHER|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
219295395|NCT03606434|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia
219295396|NCT01627977|OTHER|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
219295397|NCT06072508|BIOLOGICAL|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
219295398|NCT02335710|DEVICE|Journey II BCS TKA|
219295399|NCT01801735|DRUG|Meloxicam Test Capsules|
219295400|NCT04483505|DRUG|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
219295401|NCT01435616|DRUG|Glargine|
219295402|NCT01435616|DRUG|LY2605541|
219295403|NCT03686631|BEHAVIORAL|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
219295404|NCT03152097|DIETARY_SUPPLEMENT|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
219295405|NCT03152097|OTHER|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
219295406|NCT04860297|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219295407|NCT00396019|DRUG|PEG-Intron|
219295408|NCT04811131|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
219295409|NCT04811131|DRUG|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
219743257|NCT00908661|DEVICE|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
219743258|NCT02946411|PROCEDURE|Cardiac surgery|Glucose level will be measured after cardiac surgery.
219743259|NCT03189953|RADIATION|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
219295410|NCT04811131|DEVICE|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
219295411|NCT04811131|DEVICE|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
219295412|NCT02782312|DRUG|ICS+LABA|Seretide is inhaled for one year
219295413|NCT02782312|OTHER|routine therapy|routine therapy for one year
219743260|NCT03033693|OTHER|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
219743261|NCT03033693|OTHER|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
219743262|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
219743263|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
219295414|NCT02631824|PROCEDURE|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
219295415|NCT02631824|DEVICE|TFNA|Trochanteric Femoral Nail Advance
219295416|NCT02631824|DEVICE|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
219295417|NCT00003453|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
219295418|NCT06251362|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
219295419|NCT00133510|BIOLOGICAL|Trivalent Subviron Influenza vaccine (Fluzone)|
219295420|NCT02843061|DRUG|Rituximab|
219295421|NCT02843061|BIOLOGICAL|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
219295422|NCT02751268|DRUG|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
219295423|NCT02751268|DRUG|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
219295424|NCT02072785|DRUG|Vincristine Sulfate Liposome|
219295425|NCT02072785|DRUG|Vincristine Sulfate|
219295426|NCT02223676|PROCEDURE|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
219295427|NCT03955523|OTHER|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation \>5% VO2peak for at least 3 minutes of exercise.
219295428|NCT03955523|DIETARY_SUPPLEMENT|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
219295429|NCT05251194|DEVICE|video laryngoscope at thyroid surgical position|After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.
219295430|NCT02129270|DRUG|Lidocaine HCl 2% .|comparison of different dosages of drug
219295431|NCT02129270|DRUG|Lidocaine HCl 1%|comparison of different dosages of drug
219295432|NCT00148070|DRUG|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
219295433|NCT00148070|PROCEDURE|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
219295434|NCT03664934|OTHER|Exercises|Neck-specific exercises for chronic whiplash associated disorders
219295435|NCT03100487|DEVICE|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
219295436|NCT06280040|DIAGNOSTIC_TEST|Clinical examination and multimodal ocular imaging|Imaging consists of sonography, fundus photography, oximeter, optical coherence tomography angiography, and Microperimetry.
219295437|NCT00564694|PROCEDURE|psychosocial assessment and care|
219295438|NCT00564694|PROCEDURE|quality-of-life assessment|
219743264|NCT05153486|PROCEDURE|Surgical ablation|Patients receive surgical ablation.
219295439|NCT05918718|DRUG|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
219295440|NCT05918718|DRUG|methotrexate|methotrexate
219295441|NCT05938140|DRUG|Nirmatrelvir/ritonavir|Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
219295442|NCT03698903|BEHAVIORAL|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
219295443|NCT00371683|DRUG|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
219295444|NCT00371683|DRUG|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
219295445|NCT04717245|DRUG|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
219295446|NCT04717245|OTHER|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
219296571|NCT01238900|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
219295447|NCT04717245|OTHER|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
219295448|NCT02601976|DRUG|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
219295449|NCT02601976|DRUG|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219296572|NCT02784054|DRUG|Carboplatin|
219296573|NCT02784054|DRUG|Etoposide|
219295450|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents and active parents"|"Prevention program: Millie, with the participation of adolescents and parents"
219295451|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents only"|"Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program"
219295452|NCT03181789|BIOLOGICAL|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
219295453|NCT03181789|BIOLOGICAL|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
219295454|NCT03181789|BIOLOGICAL|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
219295455|NCT03181789|BIOLOGICAL|Placebo|Administered bilaterally using the TDS-IM EP device
219295456|NCT03181789|DEVICE|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
219295457|NCT01569672|BEHAVIORAL|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
219295458|NCT01569672|BEHAVIORAL|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
219295459|NCT01119872|OTHER|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
219295460|NCT01151410|DRUG|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
219295461|NCT01151410|DRUG|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
219295462|NCT05885087|DEVICE|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
219295463|NCT00200629|PROCEDURE|Adenosine SPECT myocardial perfusion imaging|
219295464|NCT00200629|PROCEDURE|Combined adenosine / exercise SPECT myocardial perfusion imaging|
219295465|NCT00700492|DRUG|progesterone|vaginal capsules 3X200mg daily
219295466|NCT04831541|DRUG|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
219295467|NCT02483026|DIETARY_SUPPLEMENT|Multi vitamin|Multi vitamin
219295468|NCT02483026|DIETARY_SUPPLEMENT|vitamin D|Vitamin D
219295469|NCT04642716|OTHER|Saliva collection of patients and salivary free amino acids analysis|
219295470|NCT02008851|BIOLOGICAL|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
219296574|NCT02784054|DRUG|Cyclophosphamide|
219743265|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
219743266|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
219743267|NCT01306994|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
219743268|NCT01306994|PROCEDURE|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
219743269|NCT01306994|OTHER|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
219743270|NCT01306994|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
219296575|NCT02784054|DRUG|Bleomycin|
219743271|NCT01306994|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
219743272|NCT01306994|OTHER|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
219743273|NCT01306994|OTHER|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
219743274|NCT05339659|DEVICE|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
219743275|NCT03151603|DRUG|Arctuvan|application of a herbal drug
219743276|NCT03151603|DRUG|Fosfomycin|application of an antibiotic drug
219743277|NCT03151603|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan
219743278|NCT03151603|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin
219743279|NCT00100477|DRUG|Topotecan|
219743280|NCT00100477|DRUG|Mitozantrone|
219743281|NCT00100477|DRUG|Etoposide|
219743282|NCT00561821|DRUG|Esmirtazapine|one tablet daily
219743283|NCT00561821|DRUG|Placebo|one tablet daily
219743284|NCT01724385|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
219295471|NCT03182361|DEVICE|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
219295472|NCT02755051|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~1. Sleep education~2. Sleep scheduling, limit setting, and stimulus control~3. Teaching relaxation strategies and other adaptive coping skills~4. Parenting strategies (differential attention, rewards, consequences)~5. Identification of maladaptive \& adaptive cognitions~6. Problem solving \& communication skills~7. Sleep restriction; bright light to change circadian rhythms~8. Review gains and plan for long-term maintenance"
219295473|NCT00464867|BIOLOGICAL|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
219295474|NCT00735475|BIOLOGICAL|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
219295475|NCT00735475|BIOLOGICAL|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
219295476|NCT03814148|DRUG|LENINGRADO 5 association|1 coated sustained-release tablet, oral, once a day.
219295477|NCT03814148|DRUG|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
219295478|NCT03814148|OTHER|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
219295479|NCT03814148|OTHER|Leningrado 5 association Placebo|1 coated sustained-release tablet, oral, once a day.
219295480|NCT04405349|BIOLOGICAL|VB10.16|Vaccination
219295481|NCT04405349|BIOLOGICAL|Atezolizumab|Intravenously infusion
219295482|NCT01769651|OTHER|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
219295483|NCT00526838|DRUG|XL228|1-hour IV infusion
219295484|NCT04192019|DRUG|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
219295485|NCT04192019|DRUG|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
219295486|NCT05746364|BEHAVIORAL|Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating|The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
219295487|NCT04258202|OTHER|Alveolar recruitment maneuver|The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
219295488|NCT03626987|DIAGNOSTIC_TEST|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
219295489|NCT05661422|DEVICE|RESP™ Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
219295490|NCT06095687|BEHAVIORAL|Mindfulness Meditation|Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.
219295491|NCT06095687|BEHAVIORAL|Clinical Hypnosis|Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
219296576|NCT02784054|DRUG|Thiotepa|
219296577|NCT02784054|DRUG|Melphalan|
219296578|NCT02784054|RADIATION|Reduced dose radiotherapy|
219295492|NCT01917539|DEVICE|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
219295493|NCT01917539|DEVICE|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
219295494|NCT04995939|PROCEDURE|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
219295495|NCT02442336|BEHAVIORAL|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
219295496|NCT01302860|DRUG|ACZ885|
219295497|NCT00844532|DEVICE|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
219295498|NCT03111511|DRUG|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
219295499|NCT03111511|DRUG|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
219295500|NCT03111511|DRUG|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
219295501|NCT04736901|DRUG|Enoxaparin|0.5 mg/kg every 12 hours
219295502|NCT04736901|DRUG|Enoxaparin|40 mg/day
219295503|NCT04736901|DRUG|Rivaroxaban|10 mg once daily
219295504|NCT04736901|DRUG|Rivaroxaban|20 mg once daily
219295505|NCT04736901|DRUG|Apixaban|2.5 mg twice daily
219295506|NCT04736901|DRUG|Apixaban|5 mg twice daily
219295507|NCT04621513|DEVICE|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
219295508|NCT04621513|DRUG|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
219295509|NCT00484822|DRUG|Bemiparina Sodica|3.500 UI/día.
219295510|NCT00484822|DRUG|Heparina Cálcica|10.000 UI/día.
219295511|NCT00475397|DRUG|Duloxetine|
219295512|NCT00475397|DRUG|Placebo|
219295513|NCT05873764|DRUG|200 mg RV521/78 µCi [ 14C]-RV521.|200 mg RV521/78 µCi \[ 14C\]-RV521
219295514|NCT02478710|DRUG|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
219295515|NCT02478710|DRUG|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
219295516|NCT02880891|PROCEDURE|prothetic procedure|splinted crown
219295517|NCT06292962|DEVICE|non-invasive transcutaneous vagal nerve stimulation (tVNS)|The device is used stimulate the vagus nerve
219295518|NCT06292962|DEVICE|Sham device|Sham device that does not stimulate the vagus nerve
219295519|NCT01237587|DRUG|Duloxetine|Administered orally
219295520|NCT01237587|DRUG|Placebo|Administered orally
219295521|NCT04114864|BEHAVIORAL|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
219295522|NCT03053154|OTHER|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
219295523|NCT03693885|OTHER|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
219295524|NCT00465075|DRUG|Bazedoxifene/conjugated estrogens combination|
219295525|NCT01520220|DRUG|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
219295526|NCT00293514|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|
219295527|NCT00740987|DEVICE|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
219295528|NCT03699826|DEVICE|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
219295529|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
219295530|NCT00672334|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
219295531|NCT00672334|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
219295532|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
219295533|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
219295534|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
219295535|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
219295536|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
219295537|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
219295538|NCT06502431|OTHER|phase contrast sequences|patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.
219295539|NCT01118013|BIOLOGICAL|anti-thymocyte globulin|
219295540|NCT01118013|BIOLOGICAL|donor lymphocytes|
219295541|NCT01118013|BIOLOGICAL|filgrastim|
219295542|NCT01118013|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219295543|NCT01118013|DRUG|busulfan|
219295544|NCT01118013|DRUG|fludarabine phosphate|
219295545|NCT01118013|DRUG|methotrexate|
219295546|NCT01118013|DRUG|mycophenolate mofetil|
219295547|NCT01118013|DRUG|tacrolimus|
219295548|NCT01118013|OTHER|reduced-intensity transplant conditioning procedure|
219295549|NCT01118013|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219295550|NCT01118013|PROCEDURE|peripheral blood stem cell transplantation|
219295551|NCT03814551|BEHAVIORAL|Signage|Placement of signage discouraging consumption of beverages with added sugar
219295552|NCT03208036|DEVICE|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
219295553|NCT03208036|DEVICE|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
219295554|NCT03208036|BEHAVIORAL|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
219295555|NCT03208036|BEHAVIORAL|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
219295556|NCT03849677|OTHER|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
219295557|NCT04512131|PROCEDURE|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
219295558|NCT02906189|RADIATION|MRI|
219295559|NCT04482959|DRUG|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
219295560|NCT04482959|DRUG|Sodium chloride 0.9%|Physiological solution will be used as placebo
219295561|NCT01865175|DRUG|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
219295562|NCT01865175|DRUG|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
219295563|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
219295564|NCT03767829|DRUG|Placebo|Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
219295565|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
219295566|NCT04278196|OTHER|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
219295567|NCT02767336|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
219295568|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
219295569|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
219295570|NCT00847080|DRUG|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
219295571|NCT00847080|DRUG|Placebo|Placebo 1 tablet per day per 2 weeks
219295572|NCT04164342|OTHER|surveys|Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
219296579|NCT03955796|DEVICE|Hydrophobic IOL|RayOne Hydrophobic Aspheric, hydrophobic IOL
219295573|NCT03049553|DEVICE|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
219295574|NCT04662177|DRUG|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
219295575|NCT04237870|DEVICE|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
219295576|NCT04237870|DEVICE|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
219295577|NCT06294405|DEVICE|Intraocular lens Implantation|Intraocular lenses are implanted during cataract surgery to replace the human crystalline lens.
219295578|NCT02919930|DEVICE|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
219295579|NCT02919930|DEVICE|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
219295580|NCT00165100|PROCEDURE|Dynamic Area Telethermometry (DAT)|
219295581|NCT02323178|DRUG|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
219295582|NCT04670718|DEVICE|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
219295583|NCT02204501|DRUG|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
219295584|NCT02204501|DRUG|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
219295585|NCT02204501|DRUG|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
219295586|NCT04887064|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
219743285|NCT06688318|BIOLOGICAL|Intra-articular secretome injection therapy|Intra-articular secretome injection therapy from hypoxic umbilical cord mesenchymal stem cell conditioned media
219295587|NCT05299593|DRUG|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
219295588|NCT00652470|PROCEDURE|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
219743286|NCT06690437|DEVICE|Galaxy Fixation System and Orthofix implantable devices|"It is planned to include 118 patients in 3 sites in Italy treated with GALAXY FIXATION™ System and Orthofix implantable devices for the following indications:~* fractures of the long bones or;~* Vertically stable pelvic fractures or vertically unstable pelvic fractures as a treatment adjunct Clinical data will be collected only from patients with a regular indication for GALAXY FIXATION™ System and Orthofix implantable devices as per IFUs (no off-label use will be included) and who underwent surgery performed with the specific devices."
219743287|NCT06686524|DRUG|Anti-CD19 UCAR-T cells|A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
219295589|NCT00652470|PROCEDURE|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
219295590|NCT04831151|DRUG|Yasmin|Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
219295591|NCT04831151|DRUG|Diane-35|Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
219295592|NCT05834205|OTHER|Plyometric Training|"Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1\&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3\&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5\&6"
219295593|NCT05834205|OTHER|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
219295594|NCT02079480|DRUG|BMS-986090|
219295595|NCT02079480|DRUG|Placebo matching with BMS-986090|
219295596|NCT02079480|DRUG|Keyhole limpet hemocyanin|
219295597|NCT03419832|OTHER|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
219295598|NCT03419832|OTHER|Standard Form|The regular IRB approved version.
219295599|NCT05599659|BEHAVIORAL|Palliative care|"It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant."
219295600|NCT03656952|DRUG|PF-06700841|a single oral dose of 200 mg PF-06700841
219295601|NCT03656952|DRUG|Placebo|Placebo matching PF-06700841
219295602|NCT03656952|DRUG|moxifloxacin|a single oral dose of 400 mg moxifloxacin
219295603|NCT02217501|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
219295604|NCT02217501|DRUG|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
219296580|NCT03955796|DEVICE|Non-hydrophobic IOL|RayOne Aspheric, non-hydrophobic IOL
219296581|NCT01877772|PROCEDURE|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
219296582|NCT01877772|PROCEDURE|Control|The control group will undergo standard rotator cuff repair.
219295605|NCT02654951|OTHER|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
219295606|NCT02654951|OTHER|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
219295607|NCT00000998|DRUG|Trimetrexate glucuronate|
219295608|NCT00000998|DRUG|Leucovorin calcium|
219295609|NCT03653325|DEVICE|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
219295610|NCT03653325|DEVICE|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
219295611|NCT04636736|DIAGNOSTIC_TEST|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
219295612|NCT00337259|DRUG|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
219295613|NCT04580927|BEHAVIORAL|Breastfeeding self-efficacy (BSE)|Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
219295614|NCT01844960|PROCEDURE|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
219295615|NCT01844960|PROCEDURE|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
219295616|NCT04997980|DRUG|Amiodarone Injection|
219295617|NCT05362500|DRUG|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
219295618|NCT05362500|DRUG|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
219295619|NCT02866630|BIOLOGICAL|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
219295620|NCT02457988|DEVICE|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
219295621|NCT02800018|OTHER|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
219295622|NCT03104946|DIAGNOSTIC_TEST|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
219295623|NCT04817943|OTHER|Non applicable|When the patient enters the operating room, oxygen saturation, blood pressure, and electrocardiogram are monitored, and general anesthesia is induced using 1-2 mg/kg of 1% propofol. 0.8 mg/kg of rocuronium, a neuromuscular blocker, is injected intravenously, and a human endotracheal tube is intubated. A thermometer is attached to the inside of the double-layered endotracheal tube cuff, which measures the temperature in the trachea. After the endotracheal intubation is performed, the esophageal thermometer is inserted, and from this point, the temperature measured by the esophageal thermometer and the thermometer of the endotracheal tube are recorded. The temperature immediately after insertion of the esophageal thermometer is set as Tbaseline, and the temperature of the esophagus and trachea, the temperature of the operating room, and the temperature of breathing circuit with heated wire humidifier are recorded every 5 minutes from thereafter until the end of the operation.
219295624|NCT04011943|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
219295625|NCT00057031|DRUG|DN-101 (calcitriol)|
219295626|NCT02461043|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
219295627|NCT02461043|RADIATION|radiation|radiation
219295628|NCT01619397|DEVICE|Test condom with new Xanthan gum condom coating|
219295629|NCT02627092|OTHER|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
219295630|NCT03935802|RADIATION|radiation|
219295631|NCT03063333|OTHER|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
219295632|NCT03063333|OTHER|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
219295633|NCT01503593|DEVICE|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
219295634|NCT05121246|DRUG|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
219295635|NCT05121246|DRUG|EU-Synagis®|Single IM dose of 3 mg/kg
219295636|NCT05121246|DRUG|US-Synagis®|Single IM dose of 3 mg/kg
219295637|NCT04154059|OTHER|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
219296583|NCT05130047|DRUG|Aldafermin|1 mg solution
219296584|NCT05130047|DRUG|Placebo|Aldafermin placebo solution
219296585|NCT00508703|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
219743288|NCT02288962|DRUG|cabergoline|
219743289|NCT04695119|OTHER|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
219743290|NCT06380686|OTHER|data collection|Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
219743291|NCT00335426|PROCEDURE|Spinal manipulative therapy|
219743292|NCT05943990|DRUG|GSK3845097|GSK3845097 was administered.
219743293|NCT05943990|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
219743294|NCT05943990|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
219743295|NCT03407833|OTHER|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
219743296|NCT03407833|OTHER|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
219743297|NCT03407833|OTHER|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
219743298|NCT03407833|OTHER|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
219743299|NCT01258985|BEHAVIORAL|Tai Chi|12 weeks of Tai Chi
219743300|NCT01258985|BEHAVIORAL|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
219743301|NCT06470919|OTHER|SMS reminders for upcoming vaccination(s)|All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
219743302|NCT06438250|DRUG|68Ga-JH04|The dose will be 148-222 MBq given intravenously.
219743303|NCT05972681|DRUG|Bupivacaine|10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
219295638|NCT06619067|DIETARY_SUPPLEMENT|PROBAFLOR|PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.
219295639|NCT06619067|OTHER|Placebo|Placebo
219295640|NCT00427570|BIOLOGICAL|BCG vaccine|
219295641|NCT00427570|BIOLOGICAL|biological therapy|
219295642|NCT00427570|DRUG|fluorouracil|
219295643|NCT00427570|DRUG|semustine|
219295644|NCT00427570|DRUG|vincristine sulfate|
219295645|NCT02428062|PROCEDURE|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~1. vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~2. intravenous fluids~3. patient's positioning~4. reduction of depth of anesthesia"
219295646|NCT02428062|DRUG|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
219295647|NCT02428062|DRUG|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
219295648|NCT02428062|PROCEDURE|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
219295649|NCT02428062|PROCEDURE|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
219295650|NCT02428062|DRUG|Ephedrine|Ephedrine 5-25 mg intravenous bolus
219295651|NCT02428062|DRUG|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
219295652|NCT02428062|DRUG|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
219295653|NCT02428062|DRUG|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
219295654|NCT00045227|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
219295655|NCT00045227|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
219295656|NCT00045227|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
219295657|NCT00045227|BIOLOGICAL|sargramostim|
219295658|NCT00045227|DRUG|docetaxel|
219295659|NCT06610656|OTHER|Pacifier and White Noise Therapy|Infants will receive both pacifier and white noise therapy to enhance sleep quality and reduce restlessness
219295660|NCT06610656|OTHER|pacifier therapy|Infants will receive pacifier therapy to enhance sleep quality and reduce restlessness
219295661|NCT02648490|DRUG|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
219295662|NCT02648490|DRUG|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
219295663|NCT02648490|DRUG|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
219295664|NCT02648490|DRUG|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
219295665|NCT02648490|DRUG|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
219295666|NCT05732051|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
219295667|NCT05732051|DIETARY_SUPPLEMENT|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
219295668|NCT06083779|GENETIC|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
219295669|NCT01015339|DRUG|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
219295670|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
219295671|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
219295672|NCT01015339|DRUG|cisplatin|80mg/m2, day 1 of every 3 weeks
219295673|NCT05589168|BEHAVIORAL|Triage nurse|Triage nurse joins 911 call
219295674|NCT05589168|BEHAVIORAL|No triage nurse|Triage nurse does not join 911 call (business as usual)
219295675|NCT00002332|DRUG|Thymopentin|
219295676|NCT05443646|DRUG|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
219295677|NCT05443646|RADIATION|hypofractionated radiotherapy|45Gy/3Gy/3week
219295678|NCT05443646|RADIATION|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
219295679|NCT04898439|OTHER|greening of the school environment|The school will be greened and biodiversity will be increased. This will be done on the playground and area around the school. Special needs corners for playing, relaxing or gardening will be installed.
219295680|NCT04369482|DEVICE|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
219295681|NCT04369482|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
219295682|NCT05102604|OTHER|Avocado|Subjects will eat one avocado in addition to their usual diet
219295683|NCT05102604|OTHER|Habitual diet|Subjects will eat their usual diet
219295684|NCT02590705|DRUG|Lidocaine|surface anesthesia with lidocaine
219295685|NCT04479345|OTHER|Questionnaire|Online questionnaire
219295686|NCT00435591|DRUG|Conivaptan|ampoule or premix bag
219295687|NCT00435591|DRUG|placebo|ampoule or premix bag
219295688|NCT00210470|BIOLOGICAL|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
219295689|NCT00210470|DRUG|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
219295690|NCT00210470|DRUG|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
219295691|NCT00210470|DRUG|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
219295692|NCT00210470|DRUG|Omeprazole|21 days of 20 mg. orally
219295693|NCT05438017|DEVICE|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
219295694|NCT00936741|DRUG|mifepristone|Mifepristone 300 mg to 1200 mg once daily
219295695|NCT02245737|DRUG|Lanabecestat|Administered orally
219295696|NCT02245737|DRUG|Placebo|Administered orally
219295697|NCT06062290|DEVICE|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
219295698|NCT06062290|DEVICE|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
219295699|NCT06106932|DRUG|Leuprolide Acetate|Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
219295700|NCT05295420|PROCEDURE|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
219295701|NCT03711344|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
219295702|NCT04083677|DEVICE|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
219295703|NCT05925361|PROCEDURE|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
219295704|NCT02470910|DEVICE|Magnetic Resonance Imaging|
219295705|NCT04401852|DRUG|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
219295706|NCT04401852|DRUG|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
219295707|NCT02516020|DRUG|Global|Embryos are cultured in single step culture from day 1 to day 5
219295708|NCT02516020|DRUG|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
219295709|NCT01075828|DRUG|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
219295710|NCT06048679|DEVICE|Endovascular pulmonary artery flow-limiting covered stent implantation|selective reduction of flow in the pulmonary arteries affected by anomalous pulmonary venous drainage using a modified flow-limiting covered stent
219295711|NCT05560438|DEVICE|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
219295712|NCT00272675|DRUG|Chlorhexidine gluconate (drug) vs placebo|
219295713|NCT02355054|DRUG|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
219295714|NCT05734352|OTHER|Questionnaire|Completion of the patient reported experience measurements (PREMs) questionnaire
219295715|NCT03012698|DEVICE|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
219295716|NCT04580342|DRUG|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
219295717|NCT04580342|DRUG|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
219295718|NCT02099045|DEVICE|Point of Care Ultrasonography|
219295719|NCT05304052|BEHAVIORAL|Mindfulness Meditation classes|The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
219295720|NCT01983254|BEHAVIORAL|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
219295721|NCT01983254|OTHER|education program|web-based, ICU-specific education program
219295722|NCT06502912|OTHER|no intervention|no intervention
219295723|NCT06169683|DEVICE|Lyric4|Lyric4 Hearing instrument use
219295724|NCT00191178|DRUG|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
219295725|NCT00191178|DRUG|insulin glargine|
219295726|NCT04337892|DEVICE|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
219295727|NCT05180188|BEHAVIORAL|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
219295728|NCT04591431|DRUG|Erlotinib|TT arm
219295729|NCT04591431|DRUG|Trastuzumab|TT arm
219295730|NCT04591431|DRUG|Trastuzumab emtansine|TT arm
219295731|NCT04591431|DRUG|Pertuzumab|TT arm
219295732|NCT04591431|DRUG|Lapatinib|TT arm
219295733|NCT04591431|DRUG|Everolimus|TT arm
219295734|NCT04591431|DRUG|Vemurafenib|TT arm
219295735|NCT04591431|DRUG|Cobimetinib|TT arm
219295736|NCT04591431|DRUG|Alectinib|TT arm
219295737|NCT04591431|DRUG|Brigatinib|TT arm
219295738|NCT04591431|DRUG|Palbociclib|TT arm
219295739|NCT04591431|DRUG|Ponatinib|TT arm
219295740|NCT04591431|DRUG|Vismogedib|TT arm
219295741|NCT04591431|DRUG|Itacitinib|TT arm
219295742|NCT04591431|DRUG|Ipatasertib|TT arm
219295743|NCT04591431|DRUG|Entrectinib|TT arm
219295744|NCT04591431|DRUG|Atezolizumab|TT arm
219295745|NCT04591431|DRUG|Nivolumab|TT arm
219295746|NCT04591431|DRUG|Ipilimumab|TT arm
219295747|NCT04591431|DRUG|Pemigatinib|TT arm
219295748|NCT04591431|DRUG|Oncology Drugs|Standard of Care Arm
219295749|NCT04591431|DRUG|Pralsetinib|TT arm
219295750|NCT04591431|DRUG|Selpercatinib|TT arm
219295751|NCT04591431|DRUG|Talazoparib|TT arm
219295752|NCT04591431|DRUG|Tepotinib|TT arm
219295753|NCT04591431|DRUG|Alpelisib|TT arm
219295754|NCT01954966|DRUG|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
219295755|NCT01954966|DRUG|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
219295756|NCT01939665|DEVICE|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
219295757|NCT04322838|DIAGNOSTIC_TEST|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
219295758|NCT04322838|DIAGNOSTIC_TEST|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
219295759|NCT04322838|DIAGNOSTIC_TEST|Skin Prick Test|Diagnostic skin test for sensitization to allergens
219295760|NCT04322838|DIAGNOSTIC_TEST|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
219295761|NCT04322838|DIAGNOSTIC_TEST|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
219295762|NCT04322838|DIAGNOSTIC_TEST|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
219295763|NCT04641377|OTHER|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
219296586|NCT00508703|PROCEDURE|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
219296587|NCT05342506|DRUG|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
219295764|NCT04641377|OTHER|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
219295765|NCT02610907|OTHER|Buffer|The sleeve contains phosphate buffered saline buffer
219295766|NCT02610907|OTHER|Own output|The sleeve contains the subject own ileal effluent
219295767|NCT02610907|OTHER|simulated output|The sleeve contains simulated output
219295768|NCT02034370|DEVICE|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
219295769|NCT02034370|DEVICE|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
219295770|NCT01559753|DRUG|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
219296588|NCT05939973|DEVICE|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
219296589|NCT00266227|DRUG|placebo|Intravenous repeating dose
219295771|NCT01559753|DRUG|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
219295772|NCT06191497|PROCEDURE|non surgical periodontal therapy|NSPT based on Guided biofilm therapy principle (EMS Dental, Switzerland)
219295773|NCT06191497|DRUG|Chlorhexidine mouthwash|0.12% chlorhexidine based mouthwash used twice a day for 15 days after therapy
219295774|NCT03743285|DEVICE|AID System|AID system
219295775|NCT03743285|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
219295776|NCT00000632|BIOLOGICAL|Env 2-3|
219295777|NCT05464797|PROCEDURE|Pulp therapy|partial or complete removal of inflamed pulp tissue
219295778|NCT05464797|DIAGNOSTIC_TEST|Cytokines level in pulpal blood.|Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
219295779|NCT04208945|DRUG|Colistin|500000 units of inhaled colistin three times daily for 10 days
219295780|NCT04988867|DRUG|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
219295781|NCT02414737|DRUG|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
219296590|NCT00266227|DRUG|rituximab|Intravenous repeating dose
219296591|NCT00266227|DRUG|methotrexate|Oral or parenteral repeating dose
219296592|NCT00266227|DRUG|folate|Intravenous repeating dose
219295782|NCT06337604|DRUG|TNP-2092 capsules|TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
219295783|NCT06337604|DRUG|TNP-2092 capsules placebo|TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
219295784|NCT06337604|DRUG|Rabeprazole sodium enteric-coated tablets|Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
219295785|NCT02435121|DRUG|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
219295786|NCT02951689|DIETARY_SUPPLEMENT|Probiotic|
219295787|NCT02951689|DIETARY_SUPPLEMENT|Placebo|
219295788|NCT01253304|DRUG|LY2189265|Subcutaneous (SC) injection
219295789|NCT00741559|DEVICE|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
219295790|NCT00741559|DEVICE|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
219295791|NCT00741559|DEVICE|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
219295792|NCT04492800|DEVICE|Paxman Scalp Cooling Device|Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
219295793|NCT02407158|DEVICE|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
219295794|NCT02442089|BEHAVIORAL|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
219295795|NCT01503385|DRUG|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
219295796|NCT01854138|DEVICE|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
219295797|NCT01699503|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
219295798|NCT00912262|DRUG|Capsaicin Topical Liquid|
219295799|NCT01432184|PROCEDURE|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
219295800|NCT02828540|DRUG|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
219295801|NCT02828540|DRUG|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
219295802|NCT02828540|DRUG|Placebo|placebo having the same appearance as HT047 Tab. 250mg
219295803|NCT04278222|DRUG|Anlotinib Plus Toripalimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
219295804|NCT02478268|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
219295805|NCT02478268|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
219295806|NCT01990729|DIETARY_SUPPLEMENT|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
219295807|NCT00951002|PROCEDURE|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
219295808|NCT03420170|OTHER|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
219295809|NCT03420170|OTHER|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
219295810|NCT04096833|OTHER|Virtual Reality Group|Participants are from 3 to 14 years old who attend a pediatric primarey health care of the Fuensanta Health Center (Valencia) for immunization by vaccine.
219295811|NCT05565027|DEVICE|Dynamic digital radiography|The use of advanced dynamic X-ray photography and acquisition technology can obtain high-definition dynamic lung images of patients throughout the respiratory cycle for analysis.
219295812|NCT05565027|DEVICE|Pneumotachograph|The pneumotachograph monitors the flow rate, and the lung volume is calculated by integrating.
219295813|NCT00831753|BIOLOGICAL|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
219295814|NCT00831753|BIOLOGICAL|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
219295815|NCT05335551|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
219295816|NCT02842762|DEVICE|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
219295817|NCT02842762|PROCEDURE|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
219295818|NCT02842762|DEVICE|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
219295819|NCT02842762|DEVICE|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
219295820|NCT05108545|DRUG|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
219295821|NCT02587988|DRUG|HCP1302|
219295822|NCT02587988|DRUG|HGP0904|
219295823|NCT02587988|DRUG|Placebo (for HCP1302)|
219295824|NCT02587988|DRUG|Placebo (for HGP0904)|
219295825|NCT01090479|DRUG|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
219295826|NCT00768079|OTHER|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
219295827|NCT00768079|BIOLOGICAL|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
219295828|NCT00666601|DRUG|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
219295829|NCT00666601|DRUG|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
219295830|NCT03460691|PROCEDURE|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
219295831|NCT01097707|DRUG|LY500307|Administered orally, daily for 24 weeks
219295832|NCT01097707|DRUG|Placebo|Administered orally, daily for 24 weeks
219295833|NCT01015547|DRUG|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
219295834|NCT01015547|DRUG|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
219295835|NCT01015547|DRUG|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
219295836|NCT02704793|OTHER|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
219295837|NCT02704793|OTHER|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
219295838|NCT00116883|DRUG|GW685698X aqueous nasal spray|
219295839|NCT00146120|DRUG|Idarubicin|
219295840|NCT00146120|DRUG|Cytosin-Arabinosid|
219295841|NCT00146120|DRUG|Etoposide|
219295842|NCT00146120|DRUG|All-trans Retinoid acid|
219295843|NCT01530451|DRUG|Desmopressin|120mg OD
219295844|NCT01530451|DRUG|Placebo|one tab OD
219295845|NCT02393027|DRUG|[18F] LBT-999 PET|
219295846|NCT01560468|DRUG|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
219295847|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via Cowhorn forcep technique|Cowhorn forceps technique used to extract the tooth results in less post operative pain and swelling also it makes the extraction easier.
219295848|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via conventional technique|Conventional method of extraction uses dental elevator and forceps resulting in post operative pain and swellig.
219295849|NCT04568694|PROCEDURE|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
219295850|NCT04568694|PROCEDURE|Conventional Lung Transplantation|Reference Therapy
219295851|NCT02207569|DEVICE|CoreValve Evolut R TAVR system|
219295852|NCT01833845|DRUG|Ribavirin|weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
219295853|NCT01833845|DRUG|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
219295854|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Single dose
219295855|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Multiple dose
219295856|NCT04470232|OTHER|Self-assessment questionnaires|"120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
219295857|NCT03138772|OTHER|This is an observational study, no intervention used.|No intervention is being used in this study.
219295858|NCT01236534|DRUG|Lubiprostone|24 mcg twice daily for 21 days.
219295859|NCT01236534|DRUG|Placebo|matching placebo twice daily for 21 days.
219295860|NCT06410768|BEHAVIORAL|multistage shared decision-making program|The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
219295861|NCT01611805|DRUG|GSK1605786|Opaque Swedish orange body and cap.
219295862|NCT01611805|DRUG|GSK1605786 Placebo|Opaque Swedish orange body and cap.
219295863|NCT02235831|DEVICE|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
219295864|NCT02235831|DEVICE|Nelfilcon A single vision contact lenses (DACP)|
219743304|NCT05972681|DRUG|Epinephrine|Epinephrine (1:200,000) injected to the vaginal laceration site.
219295865|NCT05918237|OTHER|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
219295866|NCT04921787|OTHER|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
219295867|NCT04921787|OTHER|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
219295868|NCT02029872|DRUG|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
219295869|NCT02029872|DRUG|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
219295870|NCT02029872|DRUG|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
219295871|NCT03932669|DRUG|Nilotinib|150-300mg daily dose of nilotinib
219295872|NCT02719587|PROCEDURE|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
219295873|NCT02719587|PROCEDURE|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
219295874|NCT02719587|PROCEDURE|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
219295875|NCT03751579|PROCEDURE|coelioscopic surgery|observational study based on the computation of respiratory quotient in patient cohort treated by routine coelioscopic surgery
219295876|NCT01170793|BEHAVIORAL|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
219295877|NCT05383508|OTHER|CA35|Nicotine concentration: 3.5 % e-liquid flavor: Tobacco
219295878|NCT05383508|OTHER|CM35|Nicotine concentration: 3.5 % e-liquid flavor: Menthol
219295879|NCT05383508|OTHER|Cig|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
219295880|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
219295881|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2mg/L) without lactoferrin|
219295882|NCT02103205|DIETARY_SUPPLEMENT|Formula with normal iron concentration (8 mg/L) without lactoferrin|
219295883|NCT05979415|DRUG|Apomorphine Cartridge|Staccato Cartridge
219295884|NCT06256237|DRUG|JS004|Specified dose on specified days.
219295885|NCT06256237|DRUG|Toripalimab|Specified dose on specified days.
219295886|NCT06256237|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
219295887|NCT06256237|DRUG|Etoposide|Specified dose on specified days.
219295888|NCT06256237|DRUG|Platinum|Specified dose on specified days.
219295889|NCT05138744|OTHER|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
219295890|NCT00005645|DRUG|ILX-295501|
219295891|NCT00020735|DRUG|toremifene|
219295892|NCT00020735|PROCEDURE|conventional surgery|
219295893|NCT00020735|PROCEDURE|neoadjuvant therapy|
219295894|NCT02396329|DRUG|Chlorhexidine|
219295895|NCT02396329|DRUG|Povidone-Iodine|
219295896|NCT04560010|DRUG|Tranexamic Acid Injection (TXA)|Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
219295897|NCT02234648|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
219295898|NCT02234648|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
219295899|NCT03412747|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
219295900|NCT03412747|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
219295901|NCT03412747|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
219295902|NCT02854969|BEHAVIORAL|Device: Anapphylaxis|
219295903|NCT02720302|BEHAVIORAL|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
219295904|NCT02720302|BEHAVIORAL|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
219295905|NCT00727779|BEHAVIORAL|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
219295906|NCT02081417|BEHAVIORAL|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
219295907|NCT01405833|DRUG|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
219295908|NCT01405833|DRUG|Placebo|Single dose IV matched placebo
219295909|NCT03121248|RADIATION|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
219295910|NCT03121248|RADIATION|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
219295911|NCT03121248|RADIATION|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
219295912|NCT03121248|RADIATION|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
219295913|NCT03121248|RADIATION|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
219295914|NCT03121248|RADIATION|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
219295915|NCT03121248|RADIATION|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
219295916|NCT03121248|RADIATION|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
219295917|NCT03469531|DRUG|Nimotuzumab|Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
219295918|NCT03469531|DRUG|Cisplatin|Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
219295919|NCT03469531|RADIATION|external-beam radiation|Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
219295920|NCT03469531|RADIATION|brachytherapy|high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
219295921|NCT00525382|DRUG|levocetirizine dihydrochloride|
219295922|NCT03097484|DRUG|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
219295923|NCT01157676|PROCEDURE|Open radical cystectomy|Standard of care removal of urinary bladder.
219295924|NCT01157676|PROCEDURE|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
219295925|NCT01157676|DEVICE|DaVinci robot|DaVinci robotic surgical system.
219295926|NCT01170559|DEVICE|Implantable Loop Recorder|
219295927|NCT02437071|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
219295928|NCT02437071|RADIATION|Radiotherapy|
219295929|NCT02437071|PROCEDURE|Radiofrequency ablation|
219295930|NCT03268525|DRUG|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
219295931|NCT03268525|DRUG|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
219295932|NCT02856854|DRUG|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
219295933|NCT02856854|DRUG|Placebo|EMB-001 matched placebo
219295934|NCT02856854|DRUG|Cocaine IV|Cocaine administered at doses of 20 and 40mg
219295935|NCT02856854|DRUG|Saline IV|Cocaine matched placebo
219295936|NCT00555594|DRUG|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
219295937|NCT06086366|OTHER|[11C]DTBZ PET scan|One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
219295938|NCT06086366|OTHER|[18F]SDM8 PET scan|One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
219295939|NCT06086366|OTHER|MRI scan|One MRI scan
219295940|NCT06415565|OTHER|conventional physiotherapy|Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.
219295941|NCT06415565|OTHER|thoracic mobilization methods|Methods applied as conventional physiotherapy methods: hotpack, Transcutaneous electrical nerve stimulation and ultrasound applications will be applied. Also within the scope of thoracic mobilization: thoracic region extension stretching in the kneeling position, thoracic flexion in the crawling position, halo exercise, thoracic rotation exercises in the crawling position, thoracic rotation in the side lying position. , quadruped extension and rotation exercises will be applied. Patients will be informed that these exercises can also be done as home exercises and they will be asked to practice for 8 weeks.
219295942|NCT01096485|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
219295943|NCT01096485|DRUG|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
219295944|NCT01426867|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
219295945|NCT01426867|DRUG|Brinzolamide ophthalmic suspension, 1%|
219295946|NCT01426867|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
219295947|NCT05462301|OTHER||Neonatal bedside echocardiography was performed by a trained neonatologist or sonographer
219295948|NCT02021097|DRUG|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
219295949|NCT02021097|DRUG|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
219295950|NCT03231631|BEHAVIORAL|Education plan and adherence to exercise|"* Send text messages with motivational sense at any time of the day, every 3 or 4 days.~* They will be given the option of performing directed exercise at the cardiac rehabilitation center.~* It will be recorded in an Excel table every time that text is sent to the patient.~* At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
219295951|NCT01812551|DRUG|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
219295952|NCT01812551|DRUG|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
219295953|NCT00468104|DRUG|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
219295954|NCT00468104|DRUG|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
219295955|NCT02293304|OTHER|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
219295956|NCT02293304|OTHER|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
219295957|NCT01351831|OTHER|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
219295958|NCT01351831|OTHER|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
219295959|NCT01683656|DRUG|niacin/laropiprant|
219295960|NCT01683656|DRUG|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
219295961|NCT01263665|DEVICE|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
219295962|NCT05164029|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
219295963|NCT00636311|DRUG|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
219295964|NCT00636311|DRUG|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
219295965|NCT03518827|OTHER|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
219295966|NCT01681173|DIETARY_SUPPLEMENT|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
219295967|NCT01681173|DIETARY_SUPPLEMENT|Placebo|200ml Placebo, BID, over 24 months
219295968|NCT00086333|DRUG|SGN-15, Docetaxel|
219295969|NCT03191773|COMBINATION_PRODUCT|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
219295970|NCT04292184|DRUG|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
219295971|NCT02646007|BIOLOGICAL|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
219295972|NCT01667211|DRUG|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
219295973|NCT01710891|PROCEDURE|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
219295974|NCT01710891|PROCEDURE|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
219295975|NCT03922646|BEHAVIORAL|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
219295976|NCT03922646|BEHAVIORAL|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
219295977|NCT02428361|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
219295978|NCT02518321|DEVICE|Technology-Assisted Toileting|
219295979|NCT03990493|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
219295980|NCT03990493|BIOLOGICAL|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
219295981|NCT02031692|DRUG|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
219295982|NCT04696380|DRUG|Nicotine|Participants will sample high vs low nicotine.
219295983|NCT04696380|DEVICE|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
219295984|NCT02261597|BEHAVIORAL|Cold Pressor Test|Repeated immersion of hand in ice-cold water
219295985|NCT05071196|OTHER|Facilitated Vegan Diet|Vegan boxed meal kits
219295986|NCT05071196|OTHER|Omnivorous Diet|Non-vegan boxed meal kits
219295987|NCT05366790|BEHAVIORAL|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
219295988|NCT05923671|DIAGNOSTIC_TEST|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
219295989|NCT05923671|DIAGNOSTIC_TEST|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
219295990|NCT05915650|BEHAVIORAL|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
219295991|NCT05915650|BEHAVIORAL|Routine Education|Carry out routine education intervention for TKA patients
219295992|NCT06572098|OTHER|Complex decongestive therapy|Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
219295993|NCT05635942|DRUG|optimized quadruple therapy|Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
219295994|NCT05635942|DRUG|standard quadruple therapy|Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
219295995|NCT02947269|DRUG|Prucalopride|Prucalopride 2mg capsule
219295996|NCT02947269|DRUG|Placebo Oral Capsule|Placebo capsule
219295997|NCT05501977|PROCEDURE|thoracotomy|thoracic surgery for pulmonary diseases
219295998|NCT01464840|DRUG|Azithromycin|500 mg intravenous infused over 1 hour
219295999|NCT00421031|DRUG|DVS-233 SR|
219296000|NCT05667103|DEVICE|Embotrap stent retriever|Embotrap has a novel design of an open outer cage for clot capture and a closed inner channel for clot stabilization, with great thrombus fixation and anti-escape ability, to improve the successful recanalization rate and good prognosis of patients.
219296001|NCT05667103|DEVICE|Solitaire FR, Trevo stent retriever without inner channel|Other stent retriever without inner channel, such as Solitaire FR, Trevo, and other stent retrievers approved by FDA or NMPA.
219296002|NCT00944515|DRUG|placebo|placebo tablet or syrup 3 days/week
219296003|NCT00944515|DRUG|azithromycin|azithromycin 3 days/week
219296004|NCT05012553|OTHER|education of self and peer assesment|Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
219296005|NCT05705843|DRUG|Intraosseous Vancomycin Injection|• IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
219296006|NCT05705843|DRUG|Intravenous Vancomycin|IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
219296007|NCT02910284|BIOLOGICAL|Observational|
219296008|NCT02536820|BEHAVIORAL|psychoneuroimmune therapy|
219296009|NCT02536820|DRUG|Conventional treatment|Actual diabetes treatment in each participant
219296010|NCT04986839|DRUG|Paracetamol injection|Intravenous Paracetamol
219296011|NCT04986839|DRUG|Ibuprofen injection|Intravenous Ibuprofen
219296012|NCT02703064|DIETARY_SUPPLEMENT|Furocyst|Furocyst caps BD
219296013|NCT03914638|DRUG|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
219296014|NCT03914638|DRUG|Placebo oral capsule|Placebo, three times daily
219296015|NCT03236038|DIAGNOSTIC_TEST|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
219296016|NCT02647775|PROCEDURE|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
219296017|NCT02647775|PROCEDURE|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
219296018|NCT01923090|DRUG|Finasteride|Finasteride 5mg once daily for 3 weeks
219296019|NCT01923090|DRUG|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
219296020|NCT03888157|DRUG|Liraglutide|Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
219296021|NCT00133406|DRUG|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
219296022|NCT00133406|DRUG|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
219296023|NCT00133406|DRUG|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
219296024|NCT00133406|DRUG|zinc|40 mg twice weekly for 12 months
219296025|NCT04323176|OTHER|Village Model implementation|Participate in the Village Model using a website
219296026|NCT02528526|DRUG|OXY111A|OXY111A intravenous infusion
219296027|NCT01528345|DRUG|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
219296028|NCT01528345|DRUG|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
219296029|NCT01528345|DRUG|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
219296030|NCT03014076|DRUG|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
219296031|NCT03014076|DRUG|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
219296032|NCT00473148|PROCEDURE|BNP-guided weaning|BNP-guided weaning
219296033|NCT00473148|PROCEDURE|Standard physician-directed weaning|Standard physician-directed weaning
219296034|NCT01010659|DEVICE|Lacrimal Tube|Lacrimal Tube
219296035|NCT04563208|DRUG|Placebo|Placebo administered on Days 1-5
219296036|NCT04563208|DRUG|DuACT|Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
219296037|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
219296038|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
219296039|NCT02624791|OTHER|No contact lenses|simulated driving tests
219296040|NCT04012801|DIAGNOSTIC_TEST|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
219296041|NCT02423148|DRUG|Indocyanine green (ICG)|
219296042|NCT02423148|DEVICE|FluoSCOPE|
219296043|NCT01350739|PROCEDURE|intraumbilical incision|vertical, intraumbilical incision
219296044|NCT01350739|PROCEDURE|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
219296045|NCT06387628|DRUG|LM-108|LM-108, 10mg/kg, d1, q6w
219296046|NCT06387628|DRUG|Toripalimab|Toripalimab, 240 mg, d1, q3w
219296047|NCT06387628|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1, 8 , q3w
219296048|NCT06387628|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m2, d1, 8 , q3w
219296049|NCT00659178|DRUG|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
219296050|NCT02534506|DRUG|Urelumab|
219296051|NCT02534506|DRUG|Nivolumab|
219296052|NCT02338973|DRUG|Interferon gamma-1b|
219296053|NCT02884310|DRUG|Remifentanil adapted to SPI|
219296054|NCT02884310|DRUG|Remifentanil fixed|
219296055|NCT02327351|OTHER|Biological: TCR alfa beta T cell depletion|
219296056|NCT03619304|DIETARY_SUPPLEMENT|coffee|coffee beverage
219296057|NCT04802798|DIETARY_SUPPLEMENT|Fibre 1|Food derived fibre presented as a white powder
219296058|NCT04802798|DIETARY_SUPPLEMENT|Fibre 2|Food derived fibre presented as a white powder
219296059|NCT04802798|DIETARY_SUPPLEMENT|Placebo|Simple sugar, presented as a white powder
219296060|NCT00723541|PROCEDURE|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
219296061|NCT00574613|DRUG|P144|Cream 0,3 ml once a day (3 months)
219296062|NCT00574613|DRUG|placebo|Cream 0,3 ml once a day (3 months)
219296063|NCT05737368|RADIATION|fractionated radiotherapy|fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume)
219296064|NCT05737368|DRUG|cadonilimab|Cardunizumab (10mg/kg, Q3W, d1)
219296065|NCT01026532|BIOLOGICAL|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
219296066|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
219296067|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
219296068|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
219296069|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
219296070|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
219296071|NCT00439803|BIOLOGICAL|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
219296072|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
219296073|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
219296074|NCT03922516|DIAGNOSTIC_TEST|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
219743305|NCT05972681|OTHER|Sham normal saline arm|10 milliliter (ml) of normal saline injected to the vaginal laceration site.
219743306|NCT02657356|DRUG|Placebo capsules|
219743307|NCT02657356|DRUG|Bardoxolone methyl capsules|
219743308|NCT06018519|OTHER|Clinical endpoints|"1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner"
219743309|NCT06018519|OTHER|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
219743310|NCT06018519|OTHER|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
219743311|NCT06018519|OTHER|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
219743312|NCT06018519|OTHER|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
219743313|NCT06018519|OTHER|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
219296075|NCT04490200|DEVICE|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
219296076|NCT04490200|DEVICE|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
219296077|NCT00688558|DRUG|JTT-705 600 mg and simvastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
219296078|NCT00688558|DRUG|Placebo and simvastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
219296079|NCT03988920|DRUG|Tenapanor|NHE3 Inhibitor
219296080|NCT03988920|DRUG|Sevelamer Carbonate|Phosphate binder
219296081|NCT05286320|DRUG|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
219296082|NCT00008073|DRUG|doxorubicin hydrochloride|
219296083|NCT00008073|DRUG|octreotide acetate|
219296084|NCT03741452|OTHER|transversalis fascia plane block|patient controlled analgesia devices with tramadol
219296085|NCT05029232|DIAGNOSTIC_TEST|MLPA for duchenne|MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
219296086|NCT02341131|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
219296087|NCT02341131|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
219296088|NCT01533480|DRUG|Zirgan|0.15% ganciclovir gel(Zirgan)
219296089|NCT01533480|DRUG|genteal gel|0.3% Hypromellose gel
219296090|NCT03309462|DEVICE|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
219296091|NCT05307211|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
219296092|NCT05307211|OTHER|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
219743314|NCT06018519|OTHER|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
219743315|NCT06018519|OTHER|3T MRI|37- Structural, metabolic and functional data
219743316|NCT06018519|OTHER|Cardiac assessments|"38- ECG~39- Ultrasound"
219743317|NCT06018519|OTHER|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
219743318|NCT06095037|BEHAVIORAL|Mindful yoga|12 week mindful yoga intervention
219743319|NCT06095037|BEHAVIORAL|Psychoeducation|12 week psychoeducation sessions
219743320|NCT02965313|PROCEDURE|SSLS Procedure|Synthetic suture repair
219743321|NCT02965313|PROCEDURE|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
219743322|NCT00410657|BIOLOGICAL|alemtuzumab|
219743323|NCT00410657|DRUG|methylprednisolone|
219743324|NCT00410657|DRUG|prednisone|
219743325|NCT00410657|OTHER|flow cytometry|
219743326|NCT00410657|OTHER|immunologic technique|
219743327|NCT00410657|OTHER|pharmacological study|
219743328|NCT05193383|BEHAVIORAL|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
219743329|NCT05193383|BEHAVIORAL|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
219743330|NCT05193383|BEHAVIORAL|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
219743331|NCT05193383|BEHAVIORAL|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
219743332|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
219743333|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
219743334|NCT05299190|OTHER|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
219743335|NCT05299190|OTHER|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
219743336|NCT03849144|BEHAVIORAL|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
219743337|NCT03849144|BEHAVIORAL|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
219743338|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
219743339|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Full-electric stimulation fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
219743340|NCT00667043|DRUG|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
219743341|NCT00667043|DRUG|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
219743342|NCT05988281|PROCEDURE|Type I Dental implant placement.|Placement of dental implant.
219743343|NCT05988281|PROCEDURE|Type II Dental implant placement.|Placement of dental implant.
219743344|NCT05988281|PROCEDURE|Type III/IV dental implant placement.|Placement of dental implant.
219743345|NCT04215458|OTHER|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
219743346|NCT02562703|DEVICE|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
219743347|NCT05996653|DIAGNOSTIC_TEST|Saturation Transfer (ST)-MRI|"Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)"
219296093|NCT05307211|OTHER|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
219296094|NCT02216045|DRUG|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
219296095|NCT02216045|DRUG|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
219296096|NCT02318173|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
219296097|NCT04080921|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
219296098|NCT03636425|OTHER|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
219296099|NCT02799901|BIOLOGICAL|Nivolumab|Injection of nivolumab
219296100|NCT02799901|RADIATION|hypofractionned radiotherapy|radiation
219296101|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
219296102|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
219296103|NCT02656329|DRUG|Thyroid blocking|Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
219296104|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
219296105|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|All participants allocated to the SoC (control) group underwent ICD implantation.
219296106|NCT01139580|DRUG|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
219296107|NCT01139580|DRUG|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
219296108|NCT05654142|BEHAVIORAL|Base intervention|12 Group Lifestyle Balance videos and digital motivational messages
219296109|NCT05654142|BEHAVIORAL|Augmented Intervention|12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
219296110|NCT05067153|DRUG|Fragmin 5000 UNT in 0.2 ML Prefilled Syringe|30 days postoperative prophylactic treatment.
219296111|NCT02546622|BIOLOGICAL|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
219296112|NCT02546622|BIOLOGICAL|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
219296113|NCT01164904|DRUG|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
219296114|NCT05774132|PROCEDURE|ultrasound guided Subgluteal sciatic nerve block|Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .
219296115|NCT05774132|PROCEDURE|ultrasound guided Caudal block|Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
219296116|NCT02784249|PROCEDURE|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
219296117|NCT02784249|DEVICE|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
219296118|NCT02784249|PROCEDURE|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
219296119|NCT04713449|OTHER|Empowered Survivor Online|Informational online intervention for head and neck cancer survivors
219296120|NCT04713449|OTHER|Springboard Beyond Cancer|Informational online intervention for all cancer survivors
219296121|NCT04713449|OTHER|Survey Administration|Survey measures administered at BL, two and 6 months post-baseline
219296122|NCT01135303|DEVICE|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
219296123|NCT00667147|DRUG|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
219296124|NCT00667147|DRUG|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
219296125|NCT04556487|OTHER|evaluation|we will evaluate the home environment of the children asking by parents
219296126|NCT00633880|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219296127|NCT00633880|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
219296128|NCT02734953|DRUG|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
219296129|NCT02729883|OTHER|Quality-of-Life Assessment|Ancillary studies
219296130|NCT02729883|OTHER|Questionnaire Administration|Complete interviews
219296131|NCT02729883|PROCEDURE|Supportive Care|Receive patient navigation via the Take the Fight strategists
219296132|NCT03857997|BIOLOGICAL|Patient blood sampling|sequencing by WGS and RNA-seq
219296133|NCT03857997|BIOLOGICAL|Parents blood sampling|sequencing by WGS
219296134|NCT01666964|OTHER|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
219296135|NCT00329810|DRUG|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
219296136|NCT02627404|OTHER|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
219296137|NCT02627404|DEVICE|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
219296138|NCT01422642|DEVICE|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
219296139|NCT01422642|DEVICE|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
219296140|NCT00478387|BIOLOGICAL|The current season's trivalent killed influenza vaccine|
219296141|NCT00591851|DRUG|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
219296142|NCT04571450|BEHAVIORAL|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
219296143|NCT00259402|DRUG|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
219296144|NCT02078908|DRUG|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
219296145|NCT02078908|DRUG|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
219296146|NCT02078908|DRUG|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
219296147|NCT02078908|DRUG|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
219296148|NCT02158988|PROCEDURE|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
219296149|NCT01099475|PROCEDURE|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
219296150|NCT01099475|PROCEDURE|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
219296151|NCT01511094|PROCEDURE|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
219296152|NCT02622529|OTHER|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
219296153|NCT00515853|BEHAVIORAL|Biofeedback|Biofeedback sessions or biofeedback exercises
219296154|NCT03609892|DRUG|Berberine|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.
219296155|NCT03609892|DRUG|Amoxicillin|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID
219296156|NCT03609892|DRUG|Esomeprazole|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID
219296157|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
219296158|NCT03609892|DRUG|Tetracycline|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
219296159|NCT03609892|DRUG|Furazolidone|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
219296160|NCT03609892|DRUG|Esomeprazole|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID
219296161|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
219296162|NCT04554017|OTHER|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
219296163|NCT05010239|OTHER|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
219296164|NCT05010239|OTHER|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
219296165|NCT01998100|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
219296166|NCT01998100|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
219296167|NCT05564260|BEHAVIORAL|Kaleidescope|watching kaleidescope
219296168|NCT05564260|BEHAVIORAL|Virtual Reality|wearing virtual reality glasses
219296169|NCT01453543|OTHER|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
219296170|NCT01307657|OTHER|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
219743348|NCT05281575|BEHAVIORAL|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
219743349|NCT05157997|DRUG|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
219743350|NCT05550428|OTHER|home-based-exercise|"All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions."
219743351|NCT05550428|DEVICE|active pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.
219743352|NCT05550428|DEVICE|shame pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
219743353|NCT04229017|PROCEDURE|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
219743354|NCT04229017|DEVICE|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
219743355|NCT00153231|DEVICE|IVS|Infracoccygeal sacropexy
219743356|NCT00153231|PROCEDURE|Sacrospinofixation|
219296171|NCT03688451|DRUG|Rituximab|Intrathecal administration over 3-5 minutes
219296172|NCT00262145|DRUG|tea extracts|
219296173|NCT03638167|BIOLOGICAL|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
219296174|NCT00476866|DEVICE|intermittent positive-pressure breathing (IPPB)|
219296175|NCT03782675|DEVICE|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
219296176|NCT03782675|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
219296177|NCT00531453|DRUG|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
219296178|NCT00531453|DRUG|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
219296179|NCT00589121|DRUG|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
219296180|NCT00589121|RADIATION|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
219296181|NCT00589121|PROCEDURE|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
219296182|NCT01315691|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
219296183|NCT01315691|DRUG|Placebo for liposomal amikacin for inhalation|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days."
219296184|NCT02661919|DEVICE|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
219296185|NCT06417580|OTHER|Placebo Treatment|Desensitizing protocol with none active ingredient to evaluate the control of cervical dentin hypersensitivity
219296186|NCT06417580|OTHER|Nitrate Potassium Treatment|Desensitizing protocol with potassium nitrate gel to analyze and compare with other groups the effects of controlling cervical dentin hypersensitivity
219296187|NCT06417580|OTHER|Pregabalin Treatment|Desensitizing protocol with experimental 10% pregabalin gel to evaluate the control of cervical dentin hypersensitivity
219743357|NCT06168344|OTHER|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
219743358|NCT04083027|DEVICE|MRI|Breast MRI
219743359|NCT03858868|BEHAVIORAL|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
219743360|NCT03858868|BEHAVIORAL|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
219743361|NCT06135090|BEHAVIORAL|Trauma Recovery Program (official title TBD)|See arm description
219296188|NCT03748992|DRUG|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
219296189|NCT00490230|DRUG|WR 279396|
219296190|NCT00847808|DRUG|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
219296191|NCT03893669|BIOLOGICAL|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
219296192|NCT03893669|BIOLOGICAL|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
219296193|NCT00007449|DRUG|DPC 083|
219296194|NCT01134536|DRUG|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight \<20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight \>=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
219296195|NCT03404453|DIAGNOSTIC_TEST|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
219296196|NCT04204603|DRUG|CKD-506|Tablets for oral administration
219296197|NCT04204603|DRUG|Placebo|Tablets for oral administration
219296198|NCT01681888|DEVICE|Sanger EMG Biofeedback Device|
219296199|NCT04708730|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
219743362|NCT01394185|DRUG|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
219743363|NCT01394185|DRUG|Placebo|Participants receive placebo
219743364|NCT01394185|DRUG|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
219743365|NCT00633958|DRUG|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
219743366|NCT00633958|RADIATION|PET Imaging|
219743367|NCT00953628|DRUG|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
219743368|NCT00953628|DRUG|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
219743369|NCT02875418|DEVICE|EUM|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
219743370|NCT02875418|DEVICE|Tocodynamometry|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
219296200|NCT04224337|DRUG|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
219296201|NCT03924765|DEVICE|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
219296202|NCT05410431|OTHER|clinical and radiologic manifestations of rare presentations of Dermoid cyst|
219296203|NCT05702814|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
219296204|NCT04336787|OTHER|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
219296205|NCT03480308|DRUG|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
219296206|NCT03480308|DRUG|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
219296207|NCT03480308|DRUG|Bupivacaine|Bupivacaine
219296208|NCT02593266|BEHAVIORAL|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up"
219296209|NCT03814096|DIAGNOSTIC_TEST|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
219296210|NCT03417895|DRUG|SHR-1210|A humanized anti-PD-1 monoclonal antibody
219296211|NCT03417895|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
219296212|NCT02824081|BIOLOGICAL|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
219296213|NCT06212882|DIAGNOSTIC_TEST|Lower concentration and lower volume contrast agent group|CT images using lower concentration and lower volume contrast material
219296214|NCT03821753|OTHER|Case|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
219296215|NCT03821753|OTHER|Control|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
219296216|NCT04059172|DRUG|Ibuprofen 200 mg and acetaminphen 650 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
219296593|NCT03927339|DIAGNOSTIC_TEST|pre and post excercise group|"Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C)."
219296618|NCT04775771|BEHAVIORAL|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
219296619|NCT00090129|DRUG|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
219296620|NCT00090129|DRUG|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
219296621|NCT06417528|PROCEDURE|Chronic Post Surgery Pain (CPSP)|"The outcome variable is the presence of CPSP assessed 3 months after surgery and defined as an average pain intensity of at least 3 on the NRS scale (11-point one-dimensional pain scale) in the last three days, and pain localized to the surgical field (or in the lesion area) projected into the innervation territory of a nerve located in this area or referred to a dermatome.~Separate prediction models will be developed using data derived from surveys conducted at the relevant time points for the development of the risk index."
219296622|NCT01458431|DRUG|Levobupivacaine|continuous levobupivacaine subfascial infusion
219296623|NCT01458431|DRUG|NaCl|continuous NaCl subfascial infusion
219296624|NCT04338087|OTHER|Questionnaire and personal interviews.|Questionnaire and personal interviews.
219296625|NCT04021550|DEVICE|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
219296626|NCT04021550|DRUG|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
219296627|NCT04021550|DIETARY_SUPPLEMENT|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
219296628|NCT04021550|OTHER|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
219296629|NCT01313247|DRUG|paracetamol|1000 mg 4 times daily
219296630|NCT01313247|DRUG|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
219296631|NCT05452174|DRUG|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
219296632|NCT01823692|OTHER|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
219296633|NCT01227577|DRUG|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
219296634|NCT03597074|DIAGNOSTIC_TEST|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
219296635|NCT02790944|GENETIC|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
219296636|NCT04822974|OTHER|blood collection|longitudinally collection of blood samples for each patient included.
219296637|NCT02879474|BEHAVIORAL|Melanoma scale questionnair|
219296638|NCT02323451|DEVICE|Medical Chitosan|intra-articular injection
219296639|NCT02323451|DRUG|Sodium Hyaluronate Injection|intra-articular injection
219296640|NCT03856489|OTHER|Richards-Campbell Sleeping Questionnaire (RCSQ)|This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
219296641|NCT00446628|BEHAVIORAL|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
219296642|NCT02970331|DRUG|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
219296643|NCT00737971|DRUG|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
219296644|NCT00737971|DRUG|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
219296645|NCT00737971|DRUG|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
219296646|NCT05331677|PROCEDURE|correction of deformities around the knee with external fixator|minimally invasive surgery
219296647|NCT00669994|DRUG|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
219296648|NCT04236505|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
219296649|NCT04236505|BEHAVIORAL|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
219296650|NCT04236505|BEHAVIORAL|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
219296651|NCT02853838|OTHER|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
219296652|NCT02853838|OTHER|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
219296653|NCT02853838|OTHER|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
219296654|NCT00852540|DRUG|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
219296655|NCT00852540|DRUG|Linezolid|Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
219296656|NCT00421044|DRUG|Patupilone/EPO906|
219296657|NCT01119105|DRUG|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
219296658|NCT01119105|DRUG|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
219296659|NCT01119105|DRUG|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
219296660|NCT01639495|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
219296661|NCT03701529|DRUG|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
219296662|NCT03701529|DRUG|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
219296663|NCT01775475|DRUG|cyclophosphamide|Given IV
219296664|NCT01775475|DRUG|doxorubicin hydrochloride|Given IV
219296665|NCT01775475|DRUG|vincristine sulfate|Given IV
219296666|NCT01775475|DRUG|prednisone|Given PO
219296667|NCT01775475|DRUG|lomustine|Given PO
219296668|NCT01775475|DRUG|etoposide|Given PO
219296669|NCT01775475|DRUG|cyclophosphamide|Given PO
219296670|NCT01775475|DRUG|procarbazine hydrochloride|Given PO
219296671|NCT01775475|OTHER|laboratory biomarker analysis|Correlative studies
219296672|NCT05351684|DRUG|Dolutegravir 50 MG|already included in arm/group descriptions.
219296673|NCT00416832|DRUG|cyclophosphamide|
219296674|NCT00416832|DRUG|dacarbazine|
219296675|NCT00416832|DRUG|doxorubicin hydrochloride|
219296676|NCT00416832|DRUG|etoposide|
219296677|NCT00416832|DRUG|prednisone|
219296678|NCT00416832|DRUG|procarbazine hydrochloride|
219296679|NCT00416832|DRUG|vincristine sulfate|
219296680|NCT00416832|RADIATION|radiation therapy|
219296681|NCT04168333|BIOLOGICAL|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
219296682|NCT04168333|BIOLOGICAL|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
219296683|NCT00995969|DRUG|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
219296684|NCT00995969|DRUG|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
219296685|NCT05384405|DEVICE|Active iTBS|MagPro X100
219296686|NCT05384405|DEVICE|Sham iTBS|MagPro X100
219296687|NCT01299870|DRUG|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
219296688|NCT01299870|DRUG|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
219296689|NCT05166187|OTHER|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
219296690|NCT04661956|PROCEDURE|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
219296691|NCT02888704|DRUG|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
219296692|NCT04708210|DRUG|IBI319|Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
219296693|NCT02838927|OTHER|No intervention|No intervention
219296694|NCT01415362|DEVICE|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
219296695|NCT02926599|BEHAVIORAL|Personal Optimization Training|
219296696|NCT03867032|BEHAVIORAL|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
219296697|NCT01593345|OTHER|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
219296698|NCT01593345|OTHER|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
219296699|NCT03756987|DRUG|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
219296700|NCT03756987|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane.
219296701|NCT01694173|OTHER|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
219296702|NCT01694173|OTHER|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
219296703|NCT01694173|OTHER|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
219296704|NCT01694173|OTHER|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
219296705|NCT00618618|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
219296706|NCT00618618|DRUG|Placebo|
219296707|NCT00431080|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
219296708|NCT00431080|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
219296709|NCT00431080|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
219296710|NCT00431080|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
219296711|NCT00431080|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
219296712|NCT00431080|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
219296713|NCT04974242|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
219296714|NCT05631470|DIAGNOSTIC_TEST|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
219296715|NCT02197403|DRUG|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion
219296716|NCT02197403|DRUG|Propofol|25\~75mcg/kg/min continuous infusion
219296717|NCT02929329|DRUG|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
219296718|NCT02929329|DRUG|Placebo|Matching placebo tablets
219296719|NCT02929329|DRUG|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
219296720|NCT01531010|DEVICE|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
219296721|NCT02371213|OTHER|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
219296722|NCT03433508|BIOLOGICAL|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
219296723|NCT03433508|OTHER|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
219296724|NCT05837715|DEVICE|Chattanooga Stabilizer pressure biofeedback|"Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error."
219296725|NCT05837715|DEVICE|VibraSens - Focal Vibration Therapy (TechnoConcept - France)|"Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation."
219296726|NCT05837715|OTHER|Telerehabilitation|Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
219296727|NCT01183234|DRUG|SPD544|two 30mg capsules, single oral dose
219296728|NCT01183234|DRUG|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
219296729|NCT04960189|PROCEDURE|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
219296730|NCT04735328|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
219296731|NCT04735328|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
219296732|NCT04735328|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
219296733|NCT00363909|DRUG|citalopram hydrobromide|
219296734|NCT00363909|OTHER|placebo|
219296735|NCT04401501|OTHER|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
219296736|NCT04401501|OTHER|Exercise|Exercises for cervicogenic headache
219296737|NCT00377494|BIOLOGICAL|MVA-CSO Vaccine|
219296738|NCT00377494|BIOLOGICAL|PfCSP DNA (VCL-2510) Vaccine|
219296739|NCT00704379|DRUG|Placebo|an inactive substance
219296740|NCT00704379|DRUG|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
219296741|NCT03840915|DRUG|Cisplatin|Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
219296742|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
219296743|NCT03840915|DRUG|Pemetrexed|Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
219296744|NCT03840915|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
219296745|NCT03840915|DRUG|Gemcitabine|Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
219296746|NCT03840915|DRUG|Docetaxel|Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
219296747|NCT03840915|DRUG|M7824|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
219296748|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
219296749|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
219296750|NCT03840915|DRUG|Bintrafusp alfa|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
219296751|NCT03840915|DRUG|Paclitaxel|Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
219296752|NCT06074965|DEVICE|Medtronic Extended Infusion Set|Each subject will be given 2 types of infusion sets to wear and change sets per label use (3 days for Medtronic Quick-set™ and 7 days for Medtronic Extended).
219296753|NCT01431222|DEVICE|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
219296754|NCT03787082|DRUG|Nitrates|1,000 mg/11.18 mmol, oral
219296755|NCT03787082|DRUG|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
219296756|NCT03787082|DRUG|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
219296757|NCT03250234|OTHER|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
219296758|NCT03250234|OTHER|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
219296759|NCT00962403|BEHAVIORAL|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
219296760|NCT01819259|DRUG|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
219296761|NCT01819259|DRUG|Placebo|
219296762|NCT00309959|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219296763|NCT00309959|OTHER|Laboratory Biomarker Analysis|Correlative studies
219296764|NCT05325801|BIOLOGICAL|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
219296765|NCT00821574|DRUG|Fluvastatin|Fluvastatin: daily 80 mg, oral
219296766|NCT00821574|DRUG|Valsartan|Valsartan: daily 160 mg, oral
219296767|NCT00821574|DRUG|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
219296768|NCT03925545|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
219296769|NCT03925545|DEVICE|AcrySof IQ monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
219296770|NCT03925545|PROCEDURE|Cataract surgery|Standard cataract extraction with phacoemulsification
219296771|NCT04301531|OTHER|Mass testing using RDTs|To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
219296772|NCT04301531|DRUG|Treatment for all cases confirmed positive malaria cases with ACTs|During each mass testing, all confirmed positive cases are treated in both arms.
219296773|NCT04301531|OTHER|Determination of Hb|Hb of all children in the subgroup study are measured using a haemocure photometer.
219296774|NCT04301531|OTHER|Household survey|Determine the prevalence of febrile illnesses among children in the subgroup study
219296775|NCT04301531|OTHER|Community-base management of malaria|Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
219296776|NCT04212520|OTHER|No intervention|No intervention
219296777|NCT05778669|OTHER|Monitoring of medical, health and psychosocial conditions|"Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system."
219296778|NCT02056353|DEVICE|LOGIC-Insulin algorithm|
219296779|NCT02056353|DEVICE|Paper protocol|
219296780|NCT03167372|OTHER|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
219296781|NCT03167372|OTHER|Fitbit Flex2 TM|Standard system activity and sleep tracker
219296782|NCT03268447|DIETARY_SUPPLEMENT|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
219296783|NCT03268447|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
219296784|NCT01940224|DRUG|Pregabalin|Preoperative administration of pregabalin 300mg
219296785|NCT01940224|DRUG|Placebo|Preoperative administration of placebo
219296786|NCT01940224|DRUG|Morphine|Postoperative administration of morphine via PCA pump for 48h
219296787|NCT00406159|DEVICE|Hyperbaric Oxygen Therapy|
219296788|NCT03497416|OTHER|No intervention|No intervention
219296789|NCT02856477|BIOLOGICAL|urine analysis|a sample of urine is collected during 8 hours.
219296790|NCT02381600|DRUG|Vitamin D|"Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
219296791|NCT00560560|BIOLOGICAL|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
219296792|NCT02869516|OTHER|Clinical data collection|
219296793|NCT00140985|DRUG|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
219296794|NCT00140985|DRUG|Comparator: amlodipine / Duration of Treatment: 20 weeks|
219296795|NCT00322543|DEVICE|Corio™ Pimecrolimus-eluting stent|
219296796|NCT00184665|DRUG|insulin detemir|
219296797|NCT00184665|DRUG|insulin NPH|
219296798|NCT00184665|DRUG|insulin aspart|
219296799|NCT02134418|BEHAVIORAL|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
219296800|NCT05898347|OTHER|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
219296801|NCT03836716|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
219296802|NCT01165853|OTHER|Glucose|25% dose at 8-week intervention assigned to subjects.
219296803|NCT01165853|OTHER|Fructose|25% dose at 8-week intervention assigned to subjects.
219296804|NCT03870347|DIAGNOSTIC_TEST|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
219296805|NCT03347097|DRUG|TIL|
219296806|NCT03347097|DRUG|PD1-TIL|
219296807|NCT04571359|OTHER|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
219296808|NCT01102010|BIOLOGICAL|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
219296809|NCT03037853|OTHER|Healthy volunteers|MRI scanner
219296810|NCT02731183|PROCEDURE|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
219296811|NCT02539147|BIOLOGICAL|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
219296812|NCT05442996|DRUG|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
219296813|NCT05442996|DRUG|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
219296814|NCT00335647|DRUG|fluphenazine hydrochloride|
219296815|NCT06417567|DRUG|NEPA|NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
219296816|NCT00037830|DRUG|GM1 ganglioside|100 mg twice per day by subcutaneous injection
219296817|NCT00037830|DRUG|Placebo|Twice per day subcutaneous injection, equal volume as active drug
219296818|NCT05486962|BEHAVIORAL|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
219296819|NCT05377775|DEVICE|Iliac Stenting|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
219296820|NCT03114800|DEVICE|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
219296821|NCT01767571|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
219296822|NCT01767571|DRUG|Cephalexin 250mg/5ml|Test product 10 ml
219296823|NCT05059743|DRUG|[14C]-Larotinib|Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.
219296824|NCT03251391|OTHER|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
219296825|NCT03251391|OTHER|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
219296826|NCT04266600|PROCEDURE|Extensive mesentery resection|Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
219296827|NCT03959410|DIAGNOSTIC_TEST|Cervical biopsy|in office Cervical biopsy
219296828|NCT00099827|BEHAVIORAL|Education|Individuals will receive information about depression
219296829|NCT03909529|DRUG|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
219296830|NCT03909529|DRUG|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
219296831|NCT01141556|DRUG|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
219296832|NCT04545229|OTHER|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
219296833|NCT02855697|DRUG|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
219296834|NCT02855697|DRUG|Cediranib|20mg dose of cediranib was selected for this study
219296835|NCT02855697|DRUG|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
219296836|NCT04325243|DRUG|Sildenafil 50 mg|50 mg oral Sildenafil tablet
219296837|NCT04325243|DRUG|Placebo oral tablet|placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
219296838|NCT03292432|BEHAVIORAL|TERA Intervention (TERA)|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
219296839|NCT03292432|BEHAVIORAL|Standard of Care (SOC)|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
219296840|NCT05332353|DRUG|Bacillus Calmette-Guerin|Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
219296841|NCT03193359|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
219296842|NCT05364892|OTHER|Blood samples (80 mL)|Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
219296843|NCT05364892|OTHER|Fecal samples|Fecal samples at inclusion
219296844|NCT05364892|OTHER|Urinary sample (20-40 mL)|Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
219296845|NCT05364892|OTHER|Questionnaires|Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
219296846|NCT00343447|BIOLOGICAL|autologous tumor cell vaccine|
219296847|NCT00343447|BIOLOGICAL|rituximab|
219296848|NCT00343447|DRUG|cyclophosphamide|
219296849|NCT00146627|DRUG|Eflornithine|
219296850|NCT00146627|DRUG|Nifurtimox|
219296851|NCT05847959|DRUG|Traditional Chinese medicine prescription：XinKang-I|XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
219296852|NCT05271552|DRUG|BXCL501|Sublingual Film
219296853|NCT05271552|DRUG|Matching Placebo|Sublingual Placebo Film
219296854|NCT02698085|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
219296855|NCT02698085|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
219296856|NCT04223739|DRUG|Landiolol|"Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate \< 90 bpm. Doses are modified every 10 minutes if necessary.~Once heart rate goal is obtained, switch to an oral dose of Bisoprolol."
219296857|NCT04223739|DRUG|Amiodarone|Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day
219296858|NCT02876159|BIOLOGICAL|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
219296859|NCT00152932|DRUG|Dorzolamide 2% drops|
219296860|NCT00152932|DEVICE|HRF and CLBF|
219296861|NCT05347043|OTHER|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
219296862|NCT06540534|PROCEDURE|Dexamethasone|In the adjuvan group (dexamethasone)group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of dexamethasone(8mg).
219296863|NCT06540534|PROCEDURE|kontrol group|In the control group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of 0.9% saline.
219296864|NCT00497185|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
219296865|NCT01076426|DRUG|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
219296866|NCT01076426|DIETARY_SUPPLEMENT|Oligosaccharide|oligosaccharide one pack per day
219296867|NCT02796625|OTHER|Painful Stimuli|warm or painful heat administration
219296868|NCT01915472|DRUG|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
219296869|NCT02502903|DRUG|BIV009|
219296870|NCT02502903|OTHER|Placebo|
219296871|NCT01014143|DRUG|Fluoride|Half mouth toothbrushing twice a day for four days.
219296872|NCT01014143|DRUG|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
219296873|NCT01014143|DRUG|Fluoride, triclosan|Half mouth Brushing twice daily
219296874|NCT03902925|PROCEDURE|Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
219296875|NCT03902925|PROCEDURE|Peribulbar injection|Peribulbar injection of 4-6 ml of ropivacaine 10%
219296876|NCT06172387|DRUG|intra-arterial infusion albumin|The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.
219296877|NCT06172387|OTHER|mechanical thrombectomy and a standard clinical therapy|mechanical thrombectomy and a standard clinical therapy
219296878|NCT02405403|DRUG|[18F]DPA-714 PET|\[18F\]DPA-714 Positron Emission Tomography
219296879|NCT06301984|DEVICE|Insight GS|"The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.~The Andromeda Insight Growing System consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. The implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. The components are implanted from a posterior approach and are made from Titanium alloy (Ti6AL-4V-ELI), and High Density Polyethylene (HDPE)."
219296880|NCT05613374|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
219296881|NCT05613374|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~* Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~* Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
219296882|NCT04592042|BEHAVIORAL|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
219296883|NCT00665158|BEHAVIORAL|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
219296884|NCT00665158|BEHAVIORAL|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
219296885|NCT00447811|DRUG|MOA-728|
219296886|NCT03224754|BEHAVIORAL|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
219296887|NCT03450512|OTHER|prospective study on digestive affections in an homogeneous cohort of hematological patients|"Systematic realization during the induction and/or every consolidation of a CTscan with injection, at the same time as the thoracic CTscan (to research an invasive fungal bronchopulmonary infection), in front of a febrile neutropenia with persistent fever after 5 days of antibiotics and presence of digestive signs.~Statement of the information characterizing the digestive affection: clinical symptoms, microbiological, characteristic, realized additional explorations, infectious complications and specific therapeutics.~The abdominal scanner will be repeated in case of suspicion of complication or clinical worsening. In case of EC, the abdominal scanner will be realized before beginning the next cycle of AML treatment to evaluate digestive remission. Finally, a CT scan, will be performed when digestive disease, digestive neoplasia or digestive symptoms are noted at AML diagnosis."
219296888|NCT06271460|OTHER|Traditional physiotherapy|All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.
219296889|NCT06084091|DEVICE|Myocardial spectrometric measurement|Myocardial spectrometric measurement during open-heart Surgery
219296890|NCT03234985|BIOLOGICAL|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
219296891|NCT01963923|BEHAVIORAL|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
219296892|NCT04855838|DEVICE|Oral neuromuscular training|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
219296893|NCT04637178|BEHAVIORAL|Resistance training|Resistance training sessions twice a week for ten weeks
219296894|NCT04637178|BEHAVIORAL|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
219296895|NCT04603638|DRUG|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
219296896|NCT04603638|DRUG|Isotonic|100 ml
219296897|NCT00662935|PROCEDURE|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
219296898|NCT03699085|BEHAVIORAL|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
219296899|NCT00168623|DRUG|Vitamin A|
219296900|NCT02789046|PROCEDURE|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
219296901|NCT02952807|DRUG|Misoprostol|vaginal Misoprostol Plus Foley Catheter
219296902|NCT02952807|DEVICE|Foley Catheter|
219296903|NCT00875654|GENETIC|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke
219296904|NCT03248154|DEVICE|Procellera|burn dressing
219296905|NCT04646538|OTHER|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
219296906|NCT03407664|OTHER|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
219296907|NCT04638920|OTHER|No intervention|No intervention
219296908|NCT04865341|BEHAVIORAL|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
219296909|NCT04865341|BEHAVIORAL|Information-Only Control|Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
219296910|NCT03629379|DRUG|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
219296911|NCT03629379|DRUG|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
219296912|NCT01419470|DRUG|dapoxetine|"1. multiple dosing~2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
219296913|NCT03775434|DRUG|Experimental: B244|B244 suspension in 30ml/bottle
219296914|NCT04100278|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
219296915|NCT06442007|BEHAVIORAL|Behavioral Activation - single session intervention (BA-SSI)|Single session intervention
219296916|NCT06442007|BEHAVIORAL|4-session Mindset intervention|This is comprised of 4 sessions.
219296917|NCT01859988|DRUG|Dupilumab|
219296918|NCT01859988|DRUG|Placebo|
219296919|NCT02842177|PROCEDURE|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
219296920|NCT02842177|PROCEDURE|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
219296921|NCT02842177|RADIATION|Transvaginal ultrasound|
219296922|NCT02842177|DEVICE|Cu-IUD|
219296923|NCT00712140|BIOLOGICAL|trastuzumab|Given IV
219296924|NCT00712140|DRUG|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
219296925|NCT04040790|DEVICE|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
219296926|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
219296927|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
219296928|NCT04040790|DRUG|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
219296929|NCT03693326|DRUG|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
219296930|NCT02065687|DRUG|Carboplatin|Given IV
219296931|NCT02065687|OTHER|Laboratory Biomarker Analysis|Correlative studies
219296932|NCT02065687|DRUG|Metformin Hydrochloride|Given PO
219296933|NCT02065687|DRUG|Paclitaxel|Given IV
219296934|NCT02065687|OTHER|Placebo Administration|Given PO
219296935|NCT02065687|OTHER|Quality-of-Life Assessment|Ancillary studies
219296936|NCT02065687|OTHER|Questionnaire Administration|Ancillary studies
219296937|NCT01569477|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
219296938|NCT01569477|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
219296939|NCT01854398|DEVICE|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
219296940|NCT01854398|DEVICE|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
219296941|NCT01903824|DRUG|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
219296942|NCT01903824|DRUG|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
219296943|NCT01903824|DRUG|modafinil|modafinil 200 mg tablet, over-encapsulated
219296944|NCT01903824|DRUG|Placebo|Placebos formulated to match each active drug
219296945|NCT01665131|DEVICE|Cameron Health S-ICD SQ-RX|
219296946|NCT00706290|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
219296947|NCT03228628|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
219296948|NCT03228628|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
219296949|NCT04138108|OTHER|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
219296950|NCT05019404|PROCEDURE|Functional anterior temporal lobectomy (FATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. The 3D model of incision and bone flap is printed prior to surgery by the slicer software based on the MRI data. Slightly curve incision with the length of about 6 cm in the temporal region is marked according to the 3D model. Temporal craniotomy via small bone window with the diameter of about 3 cm is performed. From the temporal pole along T1 about 5 cm posteriorly, temporal horn is opened by dissecting the middle temporal gyrus. The head of temporal horn is exposed. The amygdala is resected. Then, the parahippocampal gyrus and hippocampus are en bloc resected. The lateral temporal lobotomy is easy due to large view following the removal of mesial structures. The lateral posterior temporal lobotomy is no more than 5 cm from the temporal pole.
219296951|NCT05019404|PROCEDURE|Anterior temporal lobectomy (ATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. Large frontotemporal craniotomy is performed. Question mark-shaped incision with the length of 20- 25 cm in the frontotemporal region is marked. The size of the bone flap is approximately 5×7 cm for the exposure of lateral temporal lobe. ATL consists of en bloc resection of the anterior 5 cm of lateral temporal lobe, followed by the removal of mesial structures including the amygdala, parahippocampal gyrus, and hippocampus.
219296952|NCT00089921|DRUG|SCIO-469|60 mg capsule three times daily for 12 weeks
219296953|NCT00089921|DRUG|SCIO-469|30 mg capsule three times daily for 12 weeks
219296954|NCT00089921|DRUG|Placebo|2 capsules three times daily and one tablet daily
219296955|NCT00089921|DRUG|SCIO-469|100 mg tablet once daily for 12 weeks
219296956|NCT04767243|PROCEDURE|open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
219296957|NCT04767243|PROCEDURE|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
219296958|NCT04767243|DRUG|open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
219296959|NCT00778960|BEHAVIORAL|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
219296960|NCT00778960|BEHAVIORAL|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
219296961|NCT00778960|BEHAVIORAL|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
219296962|NCT00778960|BEHAVIORAL|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
219296963|NCT02360033|BEHAVIORAL|Systemic Therapy for Social Anxiety Disorder|
219296964|NCT02360033|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|
219296965|NCT01234051|DRUG|Docetaxel, Oxaliplatin|"1\. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
219296966|NCT03699553|BEHAVIORAL|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
219296967|NCT03699553|BEHAVIORAL|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
219296968|NCT02880267|DEVICE|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
219296969|NCT01167764|DRUG|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
219296970|NCT03188913|DIAGNOSTIC_TEST|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
219296971|NCT05928351|OTHER|Pain Neuroscience Education|"The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience."
219296972|NCT05928351|OTHER|Standard Physiotherapy Program (SPP)|The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
219296973|NCT03827083|OTHER|cerebral pulse oximetry|Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
219296974|NCT01871805|DRUG|Alectinib|Participants will receive alectinib as described in the arm descriptions.
219296975|NCT02006251|DEVICE|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
219296976|NCT02006251|PROCEDURE|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
219296977|NCT04491552|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
219296978|NCT03028753|DEVICE|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
219296979|NCT03028753|PROCEDURE|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
219296980|NCT03028753|PROCEDURE|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
219296981|NCT01973244|DRUG|somapacitan|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
219296982|NCT01973244|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
219296983|NCT06218654|DIAGNOSTIC_TEST|biomarkers|"Serum tests for specific cardiac troponin (cTPI), neuron-specific enolase (NSE), natriuretic peptides (NT-ProBNP), S100 protein (S100B), Soluble Suppressor of Tumorigenesis-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR) tests will be performed, as well as urinary tests for epinephrine and norepinephrine. On these samples, conducted according to clinical practice, additional measurements will also be taken for glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH-L1) as specific study biomarkers on blood samples.~All samples will be collected within 24 hours of admission to the Emergency Department (T0) and after 72 hours (T1). A sample at day 7 (T2) will be taken."
219296984|NCT05197725|DEVICE|Face mask|Individuals in intervention communities will be given surgical or KF94 face masks.
219296985|NCT05197725|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
219296986|NCT05197725|BEHAVIORAL|Face mask promotion through community values or individual information|"In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)"
219296987|NCT06179784|BEHAVIORAL|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
219296988|NCT04679480|DRUG|Cemiplimab Injection [Libtayo]|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
219296989|NCT02615080|DRUG|CRD007|
219296990|NCT02615080|DRUG|Placebo|
219296991|NCT02723526|OTHER|Blood drawing|
219296992|NCT02518737|OTHER|Meal Test|
219296993|NCT02510209|BEHAVIORAL|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
219296994|NCT06294054|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
219296995|NCT03254446|DRUG|TRC150094|TRC150094 Tablet 45 mg
219296996|NCT03254446|DRUG|Placebo|Matching Placebo Tablet
219296997|NCT00381615|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
219296998|NCT00381615|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
219296999|NCT00381615|BIOLOGICAL|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
219297000|NCT00381615|BIOLOGICAL|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
219297001|NCT00381615|BIOLOGICAL|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
219297002|NCT00381615|BIOLOGICAL|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
219297003|NCT00381615|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
219297004|NCT04161625|BEHAVIORAL|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)"
219297005|NCT02942992|BEHAVIORAL|Resistance exercise|resistance exercise
219297006|NCT00468559|DRUG|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
219297007|NCT00468559|DRUG|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
219297008|NCT00468559|DRUG|Double Blind Placebo|Double Blind Placebo
219297009|NCT00044798|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
219297010|NCT00044798|DRUG|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
219297011|NCT00044798|PROCEDURE|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
219297012|NCT01594775|DRUG|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
219297013|NCT01594775|DRUG|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
219297014|NCT04417738|DEVICE|unilateral transcranial photobiomodulation, near infrared mode|The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.
219297015|NCT04417738|DEVICE|Sham treatment|The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
219297016|NCT06488989|DEVICE|left bundle branch area pacing|Cardiac resynchronization therapy obtained by conduction system pacing
219297017|NCT06003140|DEVICE|Celsi Warmer|A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
219297018|NCT01131182|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
219297019|NCT01131182|DRUG|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
219297020|NCT01131182|DRUG|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
219297021|NCT04294927|PROCEDURE|Risk-reducing salpingectomy with delayed oophorectomy|"* BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~* BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~* BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)"
219297022|NCT04294927|PROCEDURE|Risk-reducing salpingo-oophorectomy|"* BRCA1 at a maximum age of 40 (advised between age 35 and 40)~* BRCA2 at a maximum age of 45 (advised between age 40 and 45)~* BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)"
219297023|NCT03343327|DRUG|Chronocort®|Single dose of 20mg Chronocort® administered in one treatment period
219297024|NCT03343327|DRUG|Cortef®|Single dose of 20mg Cortef® administered in one treatment period
219297025|NCT05110352|DIAGNOSTIC_TEST|Polysomnography|A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).
219297026|NCT05110352|DIAGNOSTIC_TEST|Pharyngeal ph-metry Restech|Pharyngeal ph-metry Restech over 24 hours (night and day)
219297027|NCT05110352|PROCEDURE|Peptest|Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome
219297028|NCT05110352|BEHAVIORAL|Questionnaire RSS-12|Questionnaire with 12 items about quality of life. Score between 0 and 5.
219297029|NCT05110352|PROCEDURE|Reflux Sign Assessment|RSA score about anatomy and morphology of the mouth
219297030|NCT01763801|DEVICE|P-Max|tip placement in correspondence to the P-Max on the ECG
219297031|NCT01763801|DEVICE|P-Submax|tip placement in correspondence to the P-Submax on the ECG
219297032|NCT04339530|OTHER|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
219297033|NCT00662818|DRUG|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
219297034|NCT00662818|DRUG|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
219297035|NCT00662818|DRUG|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
219297036|NCT00662818|DRUG|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
219297037|NCT02055391|BEHAVIORAL|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
219297038|NCT02055391|BEHAVIORAL|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
219297039|NCT06204952|DRUG|Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)|In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
219297040|NCT06204952|DRUG|Placebo|In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
219297041|NCT04602221|DRUG|Lamotrigine|Tablet
219297042|NCT04602221|DRUG|BI 409306|Film-coated tablet
219297043|NCT04602221|DRUG|Placebo|Tablet, Film-coated tablet
219297044|NCT04602221|DRUG|BI 425809|Film-coated tablet
219297045|NCT00749034|BIOLOGICAL|VPM1002|live vaccine
219297046|NCT00749034|BIOLOGICAL|BCG|commercially available live vaccine BCG
219297047|NCT02586571|BEHAVIORAL|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
219297048|NCT03780075|DRUG|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
219297049|NCT03780075|DRUG|2.00 GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
219297050|NCT03780075|DRUG|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
219297051|NCT01386073|DRUG|FreshKote|Three times a day for three months
219297052|NCT01386073|DRUG|Systane|three times a day for three months
219297053|NCT00029133|PROCEDURE|mild intraoperative hypothermia (33 degrees Celsius)|
219297054|NCT06298929|PROCEDURE|medial rectus fenestration|Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.
219297055|NCT06298929|PROCEDURE|medial rectus recession|recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.
219297056|NCT01146782|DEVICE|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
219297057|NCT02211885|DRUG|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
219297058|NCT03390647|DRUG|E6130|Oral dose
219297059|NCT03390647|DRUG|Placebo|E6130-matched placebo
219297060|NCT00936546|DRUG|Rituximab|Mabthera, Rituximab 1000 mg I.V.
219297061|NCT05963373|DIAGNOSTIC_TEST|Urine analysis|Diagnostic test
219297062|NCT02685345|DRUG|DS-8500a 25 mg|
219297063|NCT02685345|DRUG|DS-8500a 75 mg|
219297064|NCT02685345|DRUG|placebo|
219297065|NCT02037464|DIETARY_SUPPLEMENT|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
219297066|NCT03384901|PROCEDURE|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
219297067|NCT00538200|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
219297068|NCT00538200|OTHER|Dietary Advice|Standard dietary advice
219297069|NCT02729285|DRUG|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
219297070|NCT02729285|DRUG|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
219297071|NCT02729285|PROCEDURE|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
219297072|NCT00710359|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
219297073|NCT03392285|DEVICE|Internal fixation or hip arthroplasty|Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
219297074|NCT01174290|DRUG|Haloperidol decanoate|"IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
219743911|NCT05251805|PROCEDURE|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
219743912|NCT02842242|DRUG|MYK-461|
219297075|NCT01174290|DRUG|Placebo|"D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
219297076|NCT02270515|OTHER|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
219297077|NCT04684407|PROCEDURE|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
219297078|NCT06077253|PROCEDURE|Iridotomy|Peripheral iridotomy (size \>200µm)
219297079|NCT02930031|DIETARY_SUPPLEMENT|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
219297080|NCT02930031|DIETARY_SUPPLEMENT|Placebo|500 mL orally, daily for eight days following exercise
219297081|NCT01912677|DRUG|Nifedipine|
219297082|NCT01912677|DRUG|Labetalol|
219297083|NCT01912677|DRUG|Methyldopa|
219297084|NCT00173654|PROCEDURE|blood drawing|
219297085|NCT00956059|DRUG|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
219743913|NCT00982579|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
219297086|NCT00956059|DRUG|prednisone|In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
219297087|NCT03358251|DEVICE|Pocket-X Gel|Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
219297088|NCT03358251|PROCEDURE|Scaling and root planing|Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
219297089|NCT00677716|DRUG|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
219297090|NCT02220231|PROCEDURE|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
219297091|NCT03941951|BEHAVIORAL|Non-impositive Program for Optimizing the Use of Antimicrobials|Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
219297092|NCT01487447|OTHER|Customized sound|treatment with customized sound therapy
219297093|NCT01487447|OTHER|Regular Masker|treatment with white noise
219297094|NCT00130624|PROCEDURE|Multidisciplinary intervention: primary or secondary care|
219297095|NCT02135354|DRUG|Azithromycin|"* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
219297096|NCT02135354|DRUG|Placebo|"* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
219297097|NCT03806101|DRUG|PF-04965842|200 mg dose of PF-04965842 once daily (QD) for 3 days
219297098|NCT03806101|DRUG|Rosuvastatin|Single 10 mg dose of rosuvastatin
219297099|NCT00719147|PROCEDURE|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
219297100|NCT00719147|OTHER|Functional Status and Symptom Questionnaire|Questionnaire
219297101|NCT00447889|DRUG|gadoteric acid|
219297102|NCT04973904|DRUG|Toripalimab|IV infusion
219297103|NCT04973904|DRUG|Paclitaxel|IV infusion
219297104|NCT04973904|DRUG|Cisplatin|IV infusion
219297105|NCT04973904|DRUG|Bevacizumab|IV infusion
219297106|NCT05406076|BEHAVIORAL|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
219297107|NCT05406076|BEHAVIORAL|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
219297108|NCT01089738|DRUG|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
219297109|NCT01089738|DRUG|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
219297110|NCT01089738|DRUG|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
219297111|NCT01089738|DRUG|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
219297112|NCT04739943|BEHAVIORAL|Mobile Monitoring|Participants use a smartphone app for self monitoring of respiratory symptoms
219297113|NCT05540067|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
219297114|NCT05540067|OTHER|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
219297115|NCT00911768|DIETARY_SUPPLEMENT|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
219297116|NCT00911768|DIETARY_SUPPLEMENT|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
219297117|NCT02149953|DIETARY_SUPPLEMENT|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
219297118|NCT04630288|DRUG|Clopidogrel|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
219297119|NCT04630288|DRUG|Ticagrelor|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
219297120|NCT00258557|DRUG|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
219297121|NCT00258557|DRUG|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
219297122|NCT00866970|BIOLOGICAL|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
219297123|NCT00866970|BIOLOGICAL|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
219297124|NCT00866970|BIOLOGICAL|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
219297125|NCT00866970|BIOLOGICAL|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
219297126|NCT06090006|OTHER|Screening package|Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).
219297127|NCT06090006|DIAGNOSTIC_TEST|Psychosocial and mental health disorder screening|HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
219297128|NCT06090006|DIAGNOSTIC_TEST|Alcohol, tobacco and substance use screening|World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated
219297129|NCT06090006|BEHAVIORAL|Diet and physical activity screening|HEEADSSS (Klein et al., 2014) and counselling and advice
219297130|NCT06090006|DIAGNOSTIC_TEST|Underweight and overweight screening|MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated
219297131|NCT06090006|DIAGNOSTIC_TEST|Anemia|Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (\<8g/dl) refer to health facility.
219297132|NCT06090006|BEHAVIORAL|Oral health screening|Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
219297133|NCT06090006|BEHAVIORAL|Circumcision screening|Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)
219743914|NCT05444439|GENETIC|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
219297134|NCT06090006|BEHAVIORAL|Risky behaviours|Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)
219297135|NCT06090006|DIAGNOSTIC_TEST|HIV testing|HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated
219297136|NCT06090006|DIAGNOSTIC_TEST|STI (CT, NG, TV) testing|Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
219297137|NCT06090006|BEHAVIORAL|Immunization screening|Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization
219297138|NCT06090006|DIAGNOSTIC_TEST|Visual impairment screening|Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated
219297139|NCT06090006|DIAGNOSTIC_TEST|Hearing screening|"HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated"
219297140|NCT06090006|DIAGNOSTIC_TEST|Physical impairment screening|Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated
219297141|NCT06090006|DIAGNOSTIC_TEST|Uncontrolled epilepsy screening|Questions on experience of convulsions followed by referral to specialist if indicated
219297142|NCT06090006|DIAGNOSTIC_TEST|Pre-hypertension screening|Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
219297143|NCT00467350|DRUG|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
219297144|NCT00467350|DRUG|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
219297145|NCT03192657|DRUG|Basiliximab|The first administration should be within 8 weeks after disease onset.
219297146|NCT03192657|DRUG|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
219297147|NCT03192657|DRUG|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
219297148|NCT00534898|DRUG|Bexarotene|
219297149|NCT00534898|DRUG|Fenretinide|
219297150|NCT00534898|DRUG|Placebo|
219297151|NCT02231801|BEHAVIORAL|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
219297152|NCT03851718|DEVICE|Acupuncture Procedure|Each session will run about 30\~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
219297153|NCT03851718|BEHAVIORAL|Power pumping|It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
219297154|NCT04554043|DRUG|SHR7280|treatment
219297155|NCT04554043|DRUG|Placebo oral tablet|blank control
219297156|NCT03538301|DRUG|ND-L02-s0201 (Low Dose)|Intravenous administration every 2 weeks
219297157|NCT03538301|DRUG|ND-L02-s0201 (High Dose)|Intravenous administration every 2 weeks
219297158|NCT03538301|OTHER|Other: Placebo|Saline
219297159|NCT02893007|OTHER|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
219297160|NCT00453193|DRUG|Pentostatin|4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks
219297161|NCT00453193|DRUG|Alemtuzumab|30 mg IV three times weekly
219297162|NCT01357291|BEHAVIORAL|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
219297163|NCT01357291|BEHAVIORAL|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
219297164|NCT05843825|PROCEDURE|Surgical placement of dental implants|Three dental implants were placed (one anterior in midline area and two posterior at first molar area).
219297165|NCT05843825|DEVICE|Overdenture supported by locator attachment system|"Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer"
219297166|NCT04136743|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
219297167|NCT04136743|DRUG|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
219297168|NCT04801277|PROCEDURE|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
219297169|NCT03795129|BEHAVIORAL|SleepLife Application w/FitBit|"Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application."
219297170|NCT03795129|BEHAVIORAL|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
219297171|NCT00546026|OTHER|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
219297172|NCT01312636|DRUG|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
219297173|NCT04825561|DRUG|AD-208|PO, Once daily(QD), 24weeks
219297174|NCT04825561|DRUG|AD-2081|PO, Once daily(QD), 24weeks
219297175|NCT04825561|DRUG|placebo of AD-208|PO, Once daily(QD), 24weeks
219297176|NCT04825561|DRUG|placebo of AD-2081|PO, Once daily(QD), 24weeks
219297177|NCT03685851|PROCEDURE|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
219297178|NCT01887886|DRUG|erlotinib|150 mg orally daily
219297179|NCT01887886|DRUG|onartuzumab|15 mg/kg IV every 3 weeks
219297180|NCT01887886|DRUG|placebo|IV every 3 weeks
219297181|NCT03661762|DEVICE|CAVA|prototype device for monitoring dizziness
219297182|NCT03732404|DRUG|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
219297183|NCT03732404|DRUG|Placebo|The control group will receive plain water with the same volume and timing of treatment.
219297184|NCT03745261|DRUG|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
219297185|NCT03745261|DRUG|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
219297186|NCT03745261|DRUG|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
219297187|NCT03745261|DRUG|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
219297188|NCT03745261|DRUG|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
219297189|NCT00557180|DRUG|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
219297190|NCT00557180|DRUG|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
219297191|NCT00557180|DRUG|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
219297192|NCT04184843|OTHER|iWalk Toolkit|"Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone"
219297193|NCT02158351|PROCEDURE|liver and white adipose tissue biopsies|
219297194|NCT02842151|PROCEDURE|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
219297195|NCT02842151|DEVICE|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
219297196|NCT02842151|DEVICE|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
219297197|NCT01879553|BIOLOGICAL|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
219297198|NCT05863728|PROCEDURE|Piezosurgery assisted group|apicectomy will be done using the Piezosurgery device
219297199|NCT05863728|PROCEDURE|Trephine Bur assisted group|apicectomy will be done using the trephine burs
219297200|NCT01253070|PROCEDURE|Biopsy|Undergo biopsy
219297201|NCT01253070|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
219297202|NCT01253070|DRUG|Cytarabine|Given IV
219297203|NCT01253070|DRUG|Daunorubicin Hydrochloride|Given IV
219297204|NCT01253070|OTHER|Laboratory Biomarker Analysis|Correlative studies
219297205|NCT01253070|OTHER|Quality-of-Life Assessment|Ancillary studies
219297206|NCT01253070|OTHER|Questionnaire Administration|Ancillary studies
219297207|NCT01253070|DRUG|Sorafenib Tosylate|Given PO
219297208|NCT02739555|DEVICE|Thermal destruction with radiofrequency or laser|
219297209|NCT02739555|DRUG|Acide Zoledronique|
219297210|NCT05218070|DRUG|EgyVax Vaccine Candidate|EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
219297211|NCT05218070|DRUG|Placebo|0.5ml Saline (0.9%)
219297212|NCT04898491|OTHER|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
219297213|NCT05381415|OTHER|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
219297214|NCT05381415|OTHER|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
219297215|NCT05734898|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
219297216|NCT04433546|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
219297217|NCT04433546|DRUG|Low Dose (10 mg) Control|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
219743915|NCT05444439|DIAGNOSTIC_TEST|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
219297218|NCT01398995|OTHER|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
219297219|NCT02758067|DRUG|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
219297220|NCT02758067|DRUG|risperidone|4-6 mg/day, tablets, oral, 28-weeks
219297221|NCT03598010|DEVICE|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
219297222|NCT03598010|DEVICE|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
219297223|NCT05573880|DEVICE|Galileo Med35|whole-body vibration training on the platform
219297224|NCT03654521|DIAGNOSTIC_TEST|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
219297225|NCT02544477|DEVICE|High-flow Nasal Cannula Oxygen (HFNCO)|
219297226|NCT02544477|DEVICE|Conventional oxygen treatment|
219297227|NCT03767140|PROCEDURE|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
219297228|NCT01580254|DRUG|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
219297229|NCT01580254|DRUG|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
219297230|NCT01580254|DRUG|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
219297231|NCT01974401|DEVICE|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
219297232|NCT00387946|DRUG|SSR591813L (dianicline)|
219297233|NCT04834544|COMBINATION_PRODUCT|DCVAC/OvCa|An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines
219297234|NCT04834544|COMBINATION_PRODUCT|Placebo|Placebo
219297235|NCT04107298|DEVICE|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
219297236|NCT04247334|DEVICE|Transcranial direct current stimulation|20 minutes of 2 milliamp transcranial direct current stimulation
219297237|NCT00577967|DRUG|Gabapentin|
219297238|NCT03318224|OTHER|none (observational study)|only assessments via questionnaires, no interventions
219297239|NCT03802461|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Feces from healthy donor
219297240|NCT02355990|PROCEDURE|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
219297241|NCT04360343|DRUG|Film-coated tablet|uncoated tablet
219297242|NCT05902949|PROCEDURE|Streching Group|The Streching group will perform a conventional stretching exercise.
219297243|NCT05902949|PROCEDURE|Heel group|The heel pad group will be applied a plantar support during the months of the study.
219297244|NCT02559895|DRUG|ALD403|
219297245|NCT02559895|DRUG|Placebo|
219297246|NCT04693195|DRUG|BLU-5937|Oral administration of BLU-5937 tablets
219297247|NCT04693195|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 tablets
219297248|NCT02352168|DRUG|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
219297249|NCT02352168|DRUG|Placebo|1 putt/nostril,b.i.d
219297250|NCT02046629|DRUG|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
219297251|NCT02046629|DRUG|cholestyramine|Pharmaceutical form:power Route of administration: oral
219297252|NCT06268067|DEVICE|PET/CT|F-18 FDG PET/CT studies
219297253|NCT05808777|OTHER|Phone interview|A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
219297254|NCT01030406|DRUG|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
219297255|NCT01030406|DRUG|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
219297256|NCT01030406|DRUG|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
219297257|NCT01030406|DRUG|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
219297258|NCT01030406|DRUG|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
219297259|NCT03666572|OTHER|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
219297260|NCT03666572|OTHER|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
219297261|NCT03666572|OTHER|Placebo (Lactose)|Placebo (Lactose)
219297262|NCT01852253|PROCEDURE|2% chlorhexidine|
219297263|NCT01852253|PROCEDURE|0.12% chlorhexidine|
219297264|NCT00588653|DEVICE|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
219297265|NCT02573194|DIETARY_SUPPLEMENT|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
219297266|NCT04824690|DEVICE|Virtual reality|Immersive virtual reality tour of the operating theatre before surgery and distraction methods both using VR headset
219297267|NCT05484362|OTHER|D-Glucose beverage as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
219297268|NCT05484362|OTHER|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
219297269|NCT05484362|OTHER|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
219297270|NCT05366036|OTHER|No Intervention|This is a non-interventional study.
219297271|NCT04263753|PROCEDURE|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~\* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~\* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
219297272|NCT05972928|DRUG|Sitagliptin 100mg|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
219297273|NCT01445600|DRUG|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
219297274|NCT01216800|PROCEDURE|adjuvant therapy|
219297275|NCT01216800|PROCEDURE|assessment of therapy complications|
219297276|NCT01216800|PROCEDURE|quality-of-life assessment|
219297277|NCT01216800|RADIATION|3-dimensional conformal radiation therapy|
219297278|NCT01216800|RADIATION|intensity-modulated radiation therapy|
219297279|NCT05960253|PROCEDURE|Pericapsular Nerve Group Block|1st group to be applied PENG block
219297280|NCT05960253|PROCEDURE|Lumber Erector Spinae Plane Block|2nd group to be applied Lumber ESP block
219297281|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
219297282|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
219297283|NCT01685723|BEHAVIORAL|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
219297284|NCT01685723|BEHAVIORAL|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
219297285|NCT04220762|DRUG|WIN-1001X|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
219297286|NCT04220762|DRUG|Placebo|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
219297287|NCT04540887|DEVICE|Pulsed Electromagnetic Field (PEMF) Therapy|PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
219297288|NCT01929629|DRUG|Part A|Single ascending doses
219297289|NCT01929629|DRUG|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
219297290|NCT03598959|DRUG|tofacitinib|orally 10 mg daily
219297291|NCT03598959|DRUG|chidamide|orally 20 mg twice weekly
219297292|NCT02700347|DRUG|Pyrazinamide|
219297293|NCT02700347|DRUG|Allopurinol|
219297294|NCT00899873|GENETIC|cytogenetic analysis|
219297295|NCT00899873|OTHER|flow cytometry|
219297296|NCT00899873|OTHER|fluorescence activated cell sorting|
219297297|NCT00899873|OTHER|immunoenzyme technique|
219297298|NCT00899873|OTHER|laboratory biomarker analysis|
219297299|NCT02186249|DRUG|Nivolumab|
219297300|NCT02186249|DRUG|Ipilimumab|
219297301|NCT02733055|OTHER|posturographic evaluation|subjects will undergo CDP testing using one of the ext\_mCTSIB tests without (baseline) and with oculomotor task
219297302|NCT02794922|DRUG|Neurovit Forte|
219297303|NCT02794922|DRUG|Corn Starch|
219297304|NCT05255887|OTHER|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
219297305|NCT00278837|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
219297306|NCT01262027|DRUG|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
219297307|NCT03856385|BEHAVIORAL|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
219297308|NCT02469272|DRUG|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
219297309|NCT04435210|DRUG|Hydralazine|Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
219297310|NCT04435210|DRUG|Nifedipine|Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
219743916|NCT05444439|OTHER|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
219743917|NCT05444439|PROCEDURE|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
219297311|NCT06397326|BEHAVIORAL|Return to work coordinator + PRATICAdr 2.0|The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).
219297312|NCT06397326|BEHAVIORAL|Return to work coordinator only|The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual
219297313|NCT00035191|DRUG|galantamine|
219297314|NCT02819557|DRUG|Ataluren|White to off-white powder for oral suspension.
219297315|NCT05252104|DIAGNOSTIC_TEST|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
219297316|NCT05789368|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
219297317|NCT05789368|DIETARY_SUPPLEMENT|VeCollal sachet|consume 1 sachet per day
219297318|NCT05789368|DIETARY_SUPPLEMENT|Collagen sachet|consume 1 sachet per day
219297319|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
219297320|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
219297321|NCT01831479|DRUG|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
219297322|NCT01831479|DRUG|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
219297323|NCT01831479|DRUG|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
219297324|NCT05121558|OTHER|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants will be provided with a home-based guided program for days classes are not held. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
219297325|NCT05121558|OTHER|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN), how yoga may help with CIPN, and how different therapies may help with CIPN. To encourage participation and adherence, patients in the EC group will receive sixteen free yoga sessions after completing the study. Patients in the EC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
219297326|NCT05121558|OTHER|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
219297327|NCT06149325|PROCEDURE|Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes
219297328|NCT06149325|PROCEDURE|Sham Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
219297329|NCT03106168|PROCEDURE|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
219297330|NCT02604875|OTHER|observation|blood sampling during 24 hours
219297331|NCT05482334|DRUG|Sargramostim for Injection|Recombinant human GM-CSF
219297332|NCT05482334|DRUG|Saline Placebo|Bacteriostatic Saline
219297333|NCT02305654|PROCEDURE|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
219297334|NCT02305654|DRUG|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
219297335|NCT02305654|DRUG|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
219297336|NCT02305654|DRUG|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
219297337|NCT02305654|RADIATION|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
219297338|NCT02305654|PROCEDURE|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
219297339|NCT04891562|OTHER|interlimb coordination of the lower limbs and synchronization|4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
219297340|NCT06715618|OTHER|FMS test|Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
219297341|NCT06729580|BEHAVIORAL|Behavioural Activation|10-week standardized behavioural activation program.
219297342|NCT06729151|DRUG|Onabotulinum toxin A|Cystoscopic injection of Onabotulinum toxin A per standard clinic protocol.
219297343|NCT06729151|BEHAVIORAL|Conservative management (dietary and behavioral)|Dietary and behavioral modifications consistent with recommendations from the American Urogynecological Society
219297344|NCT06729515|DEVICE|PCA|Immediately post-surgery, patients in the PCA group received a programmed PCA infusion (YG-B-3; Jiangsu Yaguang Medical Device Co., Ltd., China) containing either ketorolac (180 mg) or sufentanil (200 µg) in 100 mL, delivered as a 2 mL/h basal infusion with 0.5 mL boluses; lockout interval: 15 min.
219297345|NCT06729515|DEVICE|CEA|Following epidural catheter placement in the operating room, the CEA group received an initial bolus of 2% lidocaine (3 mL). Once sensory blockade was confirmed, continuous epidural infusion of 0.1% ropivacaine (8 mL/h) commenced.
219297346|NCT06729515|DEVICE|RISS|RISS blocks were performed at the T4-T10 level under ultrasound guidance (EPIQ5 with L12-4 linear 7.5 MHz transducer; Philips Healthcare, Best, Netherlands). A 19-gauge, 40-cm catheter was advanced 3-5 cm beyond the needle tip into the subserratus plane, its position confirmed by injecting 5 mL of 0.2% ropivacaine. A further 15 mL of 0.2% ropivacaine was then administered. The catheter was connected to a PCA pump programmed to deliver a 7 mL/h basal infusion with 2 mL boluses; lockout interval: 30 min.
219743918|NCT05444439|DRUG|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
219743919|NCT05444439|DIAGNOSTIC_TEST|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
219743920|NCT06670586|PROCEDURE|conventional in vitro fertilization|Fertilization via conventional In Vitro Fertilization
219297347|NCT06729086|DRUG|sedation using propofol|The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.
219297348|NCT06729086|DRUG|sedation using sevoflurane|The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
219743921|NCT06670586|PROCEDURE|intracytoplasmic sperm injection (ICSI)|Fertilization via intracytoplasmic sperm injection
219297349|NCT01551459|DRUG|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
219297350|NCT01551459|DRUG|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
219297351|NCT06905912|DEVICE|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses
219297352|NCT06905977|DEVICE|pentacam|we will follow up on cases of thick cornea with high back elevation
219354698|NCT03346460|RADIATION|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
219354699|NCT03346460|RADIATION|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
219354700|NCT05000346|DRUG|Drug, inhalation|Solution administered by inhalation
219354701|NCT00697671|OTHER|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
219354702|NCT00697671|BIOLOGICAL|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354703|NCT00697671|DEVICE|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354704|NCT00697671|DRUG|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354705|NCT00697671|DRUG|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354706|NCT00697671|DRUG|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354707|NCT00697671|DRUG|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
219354708|NCT06414512|DRUG|AMBITION trial control|Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
219297353|NCT03695237|DRUG|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
219297354|NCT04601701|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
219297355|NCT04601701|DRUG|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
219297356|NCT04772482|DIAGNOSTIC_TEST|Sensitivity Patch Testing|Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
219297357|NCT02807662|BEHAVIORAL|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
219297358|NCT00305240|PROCEDURE|T Wave Alternans Test|
219297359|NCT02110719|DRUG|Celebrex|
219297360|NCT02110719|DRUG|Gabapentin|
219297361|NCT02110719|DRUG|IV acetaminophen|
219297362|NCT02110719|DRUG|oral acetaminophen|
219297363|NCT02110719|DRUG|oral ibuprofen|
219297364|NCT02110719|DRUG|percocet|
219297365|NCT02110719|DRUG|vicodin|
219743922|NCT06407401|DRUG|Duloxetine 60 MG|"Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week."
219743923|NCT06407401|DRUG|Furosemide 40 mg|Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
219297366|NCT02110719|DRUG|Oxycodone|
219297367|NCT02110719|DRUG|dilaudid|
219297368|NCT02110719|DRUG|Dexamethasone|
219297369|NCT02110719|DRUG|zofran|
219297370|NCT00452426|DEVICE|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
219297371|NCT00452426|OTHER|benzodiazepines and opioid sedation|per site's current standard of care
219297372|NCT04752982|BEHAVIORAL|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
219297373|NCT04752982|BEHAVIORAL|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
219297374|NCT03224923|DRUG|Ticagrelor 60mg|twice daily
219297375|NCT03224923|DRUG|Clopidogrel 75mg|once daily
219297376|NCT03224923|DRUG|Aspirin 81 mg|once daily
219297377|NCT03890718|PROCEDURE|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
219297378|NCT00418626|DRUG|Nilotinib|
219297379|NCT00839904|BEHAVIORAL|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
219297380|NCT02770456|DIETARY_SUPPLEMENT|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
219297381|NCT02770456|DIETARY_SUPPLEMENT|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
219297382|NCT02770456|DIETARY_SUPPLEMENT|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
219297383|NCT01444833|DRUG|Candesartan|32 mg per day duration 6 months
219297384|NCT01635205|PROCEDURE|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
219297385|NCT01635205|PROCEDURE|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
219297386|NCT03769662|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
219297387|NCT01789567|DEVICE|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
219297388|NCT04764643|DRUG|N-acetylcysteine solution|use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
219297389|NCT04764643|DRUG|sodium thiosulfate solution|use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
219297390|NCT05916339|DRUG|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
219354709|NCT06414512|DRUG|Flucytosine|Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
219354710|NCT01394081|OTHER|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
219743924|NCT06407401|BEHAVIORAL|Booklet for healthy behaviors|All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
219297391|NCT05916339|DRUG|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
219297392|NCT00903604|DRUG|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
219297393|NCT00903604|DRUG|Placebo|Three 10-minutes infusions of isotonic saline solution
219297394|NCT01029951|PROCEDURE|manipulation|
219297395|NCT01029951|PROCEDURE|Mobilisation|
219297396|NCT01029951|DEVICE|Activator instrument|
219743925|NCT06671301|BEHAVIORAL|PSAI|Holistic stress management program implementing the pillars of Lifestyle Medicine
219743926|NCT06671301|OTHER|Usual Care|Usual care without specific treatment
219743927|NCT06613139|DRUG|YHP2305|Test drug: YHP2305 Comparator: YHR2404
219743928|NCT06613139|DRUG|YHR2404|Test drug: YHP2305 comparator: YHR2404
219743929|NCT06673914|BEHAVIORAL|Control Group: Diet Group|"Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician."
219743930|NCT06673914|DIETARY_SUPPLEMENT|Oleuropein and Diet Group|"Dietary Supplement: Oleuropein (Olive Leaf Extract) Patients in Oleuropein and Diet Group will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician."
219297397|NCT05268445|PROCEDURE|Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis|Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
219297398|NCT00091169|DIETARY_SUPPLEMENT|levocarnitine|Given orally
219297399|NCT00091169|OTHER|placebo|Given orally
219297400|NCT00872989|DRUG|docetaxel|Given IV
219297401|NCT00872989|DRUG|vandetanib|Given orally
219297402|NCT02706613|BEHAVIORAL|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
219297403|NCT02706613|BEHAVIORAL|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
219297404|NCT00817973|DIETARY_SUPPLEMENT|Casein|
219297405|NCT00817973|DIETARY_SUPPLEMENT|Whey|
219297406|NCT00817973|DIETARY_SUPPLEMENT|Cod|
219297407|NCT00817973|DIETARY_SUPPLEMENT|Gluten|
219297408|NCT00734383|DRUG|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
219297409|NCT00734383|DRUG|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
219297410|NCT02407990|BIOLOGICAL|BGB-A317|In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
219297411|NCT02407990|BIOLOGICAL|BGB-A317|Participants were assigned to different groups based on their tumor types
219297412|NCT01608763|BEHAVIORAL|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
219743931|NCT06673771|OTHER|Vestibular Rehabiliation Therapy|"Moving the eye horizontally between two stationary target while keeping the head still Moving the eye vertically between two stationary target while keeping the head still Moving the target horizontally and tracking it with the eye while keeping the head still Moving the target vertically and tracking it with the eye while keeping the head still Moving the head horizontally while a keeping a look on stationary target Moving the head vertically while a keeping a look on stationary target Moving the head and target in opposite direction horizontally while tracking the target with eyes Moving the head and target in opposite direction vertically while tracking the target with eyes.~Sit down and stand up, sit down and stand up with eye open and eye close Stand up, but turn to the right while standing Stand up, but turn to the left while standing Place an object on the floor. Take it and bring it above your head and place it on the floor again"
219743932|NCT06673771|OTHER|Conventional treatment|Standing balance training, weight shifting training, walking training, muscle strength training, step-up-and-down training.
219743933|NCT05483140|OTHER|Option 1|Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
219743934|NCT05483140|OTHER|Option 2|Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
219743935|NCT05483140|OTHER|Option 3|A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
219743936|NCT07004712|DRUG|Adebelizumab combined with irinotecan liposome as second-line therapy|Adebellizumab: intravenous drip, 1200mg, the infusion time is controlled between 30-60 minutes, and the infusion is completed within 2 hours at most. It is administered on the first day of each cycle and repeated once every 3 weeks.Irinotecan liposome: intravenous drip, 80mg/m2, infusion time of 30 minutes, the first dose of each cycle, repeated once every 3 weeks.After 4-6 cycles of adebelizumab combined with irinotecan liposome treatment, the subjects who did not develop the disease continued to use adebelizumab (1200mg, D1, Q3W) for maintenance treatment until the disease progressed, the toxicity was intolerable, the subjects voluntarily asked to withdraw and the researchers judged that the subjects needed to withdraw from the study.
219297413|NCT06236659|DIETARY_SUPPLEMENT|Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
219297414|NCT06236659|DIETARY_SUPPLEMENT|Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
219743937|NCT05893732|DEVICE|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
219743938|NCT05893732|DEVICE|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
219743939|NCT04331769|DEVICE|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
219743940|NCT04331769|DRUG|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
219743941|NCT07010367|PROCEDURE|Acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the acupoints area, acupuncture needles will be inserted into the Baliao points (inserted at the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 3-4 cm). The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
219743942|NCT07010367|PROCEDURE|Sham acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the sham acupoints area, acupuncture needles will be inserted lateral to the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 1 cm.The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
219743943|NCT07011251|BEHAVIORAL|Food as Medicine Program|Grocery Prescription - participants will receive a card loaded with $100 per month to be used on the Instacart Fresh Funds program website/app or a SodaHealth grocery prescription card to be used inside a Kroger or Food City stores. Patients who select grocery delivery where Instacart is not available will receive Food City meals for the same value. or 2) Medically Tailored Meals (MTM) - participants receive approximately 5 frozen meals per week from Mom's Meals that follow an approved diet for those with hypertension. Participants will complete screening questions (screening decision tree attached) after informed consent to determine which food package the participant will receive. The screening decision tree is a tool that asks about kitchen availability for preparing foods, skills, and access to transportation. Depending on how the patient answers they will receive either grocery prescription or MTM for 3-months or 12-weeks.
219743944|NCT07011251|OTHER|Survey|"Participants answering no to assistance but agreeing to the 20-30 minute survey will receive a direct link to a survey related to reasons for not wanting assistance to answer questions at one time point."
219743945|NCT07011238|DIAGNOSTIC_TEST|Patients meeting HLA immunization criteria|At enrollment visit, a single sample of a volume of 50 ml of blood will be taken as part of routine care in order to directly and simultaneously explore the clonality (BCR repertoire), the phenotype of membrane markers and the transcriptome of Bmem alloreactive with respect to a restricted panel of HLA alleles chosen according to the HLA antibody reactivity profile of the patients analyzed
219743946|NCT06626347|OTHER|TREAT-ED Virtual Group Diabetes Self-Management Education and Support|TREAT-ED is an innovative group telehealth delivery model designed to engage emerging adults in DSMES services. TREAT-ED sessions are facilitated by a Diabetes Care and Education Specialist and include content centered around the ADCES7 Self-Care Behaviors and applied learning strategies, e.g., case scenarios integrating glucose monitoring, and group discussions to drive knowledge transfer and skill development for diabetes self-care behaviors within the context of issues that are salient to the target population.
219743947|NCT07011095|DRUG|VKA|Warfarin
219743948|NCT07011095|DRUG|Direct Oral Anticoagulant (DOAC)|Locally approved DOACs
219743949|NCT06683898|OTHER|External Focused Pilates|Pilates training was implemented with an external focus (EF).
219743950|NCT06683898|OTHER|Internal Focused Pilates|Pilates training was implemented with an internal focus (IF).
219743951|NCT06690268|DIAGNOSTIC_TEST|Multimodal AI-driven predictive model|This intervention involves a multimodal artificial intelligence (AI) model that integrates clinical data, imaging results, and pathology findings to predict the risk of postoperative recurrence in patients with locally advanced gastric cancer. Unlike traditional methods that may rely on single data sources, this AI-driven model synthesizes multiple types of patient information, offering a comprehensive and personalized prediction of recurrence risk. This approach aims to improve accuracy in identifying high-risk patients, allowing for more tailored follow-up and treatment planning to enhance patient outcomes.
219743952|NCT06689176|DEVICE|Irrisept® Antimicrobial Wound Lavage|Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
219743953|NCT06691789|OTHER|Social support|This intervention includes a social support given to the students during COVID-19 pandemic
219743954|NCT06687811|OTHER|preoperative carbohydrate loading|Patients receive 200 ml drink containing Maltodextrin 12.5%, 2 hours prior to surgery
219297415|NCT00606125|DRUG|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
219297416|NCT05596058|OTHER|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
219297417|NCT05596058|OTHER|active exercise|Physical activity and motor task only
219297418|NCT05596058|OTHER|cognitive task only|cognitive exercise in executive functions
219297419|NCT03505034|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
219297420|NCT04929405|BEHAVIORAL|ADAPT|ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
219297421|NCT06014840|OTHER|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
219297422|NCT04476368|OTHER|weekly yoga classes|Weekly 90 min pregnancy-adapted yoga classes lead by certified yoga instructors.
219297423|NCT04476368|OTHER|walk|20-30 min easy walking
219297424|NCT00000500|DRUG|aspirin|
219297425|NCT00000500|DRUG|carotene|
219297426|NCT02747641|PROCEDURE|Pixel CO2 Laser System|
219297427|NCT03284801|OTHER|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
219297428|NCT00607347|OTHER|Glucose|Oral Glucose Tolerance Test
219297429|NCT00641901|BEHAVIORAL|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
219297430|NCT01074918|DRUG|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
219297431|NCT01074918|DRUG|Potassium Chloride|Potassium Chloride
219297432|NCT04782401|OTHER|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
219297433|NCT04782401|DEVICE|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
219743955|NCT06687811|OTHER|Placebo|Patients receive 200 ml regular drinking water with zero-calorie sweetener, 2 hours prior to surgery
219743956|NCT06690853|OTHER|Experimental Coordinative training|The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.
219743957|NCT06690853|OTHER|Traditional training (control group)|The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
219743958|NCT06688487|OTHER|early extubation of hypoxemic patients|patient extubated after the spontaneous ventilation trial despite the presence of hypoxemia defined by SpO2 ≤ 90% either in T-piece under 6 L/min, or under FiO2 = 40% if SBT is performed in spontaneous ventilation with minimal inspiratory assistance.
219297434|NCT00734097|DRUG|Esomeprazole 40 mg|Once a day
219297435|NCT00734097|PROCEDURE|Physical Exam|every visit
219297436|NCT00734097|OTHER|Quality of Life Questionnaires|every visit
219297437|NCT00734097|PROCEDURE|pregnancy test, if applicable|as needed
219297438|NCT00919347|OTHER|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~1. RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~2. LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~3. SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~* Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa \< 0.1 bpm2.~* Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa \< 0.5 bpm2 or 0.1 \< RFa \< 0.5 bpm2.~* Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
219297439|NCT01550445|DRUG|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
219297440|NCT05478850|PROCEDURE|radiotherapy under anesthesia|Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
219297441|NCT04037267|PROCEDURE|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
219297442|NCT03147404|DRUG|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
219297443|NCT01946763|BEHAVIORAL|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
219297444|NCT01946763|BEHAVIORAL|pre operative education|
219297445|NCT03484845|DRUG|Lactoferrin and ferrous fumarate|"* Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
219297446|NCT02512367|OTHER|Dental care education program|Dental care education program
219297447|NCT02512367|OTHER|Surveillance|Surveillance
219297448|NCT03723616|BEHAVIORAL|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
219297449|NCT03723616|BEHAVIORAL|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
219297450|NCT03723616|BEHAVIORAL|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
219297451|NCT01745731|OTHER|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
219297452|NCT02540928|DRUG|AMG 319 hydrate|
219297453|NCT02540928|DRUG|Placebo|
219297454|NCT06135428|OTHER|Education Group|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
219297455|NCT02792673|OTHER|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
219297456|NCT02792673|OTHER|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
219297457|NCT02792673|OTHER|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
219297458|NCT02792673|DEVICE|Labotect embryo transfer catheter|
219297459|NCT01553773|DRUG|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
219297460|NCT01553773|DRUG|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
219297461|NCT06408480|DIAGNOSTIC_TEST|Neonatologist-performed lung ultrasound|lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants
219297462|NCT02609347|OTHER|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
219297463|NCT02609347|OTHER|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
219297464|NCT03566446|BIOLOGICAL|CALRLong36 peptide|200 ug CALRLong36 peptide in water mixed with 500ul montanide
219297465|NCT05198011|PROCEDURE|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
219297466|NCT05198011|PROCEDURE|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
219297467|NCT01764685|DRUG|Topiramate|Max therapeutic dose of 150mg/day
219354711|NCT01394081|OTHER|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
219743959|NCT06688565|DEVICE|Hativ® electrocardiogram monitoring|Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis
219743960|NCT06694129|DRUG|Entrectinib|Patients in each cohort were treated with Entrectinib.
219743961|NCT06694636|PROCEDURE|endovascular radiofrequency ablation and desympathetic nerve surgery|endovascular radiofrequency ablation and desympathetic nerve surgery
219743962|NCT06689254|DRUG|Mifepristone 1200 mg daily|Oral tablets
219743963|NCT06689254|DRUG|Placebo|Oral tablet
219743964|NCT06695052|DEVICE|multi modal Us|Greyscale US: grey scale ultrasound Color Doppler US: Color Doppler ultrasound Elastography US: Elastography ultrasound
219743965|NCT06690684|BIOLOGICAL|Hematological indicators|This project is a retrospective clinical cohort study. STEMI patients undergoing PCI were selected to explore whether hematological indicators such as PIV, SHR, and Lp(a) can improve the accuracy of predicting short-term MACE events in STEMI patients.
219743966|NCT06690684|BIOLOGICAL|Serological indicators in patients with myocardial infarction|This study selected STEMI patients who underwent PCI and collected their hematological indicators to explore the value of PIV, SHR, Lp(a) and other indicators in improving the accuracy of predicting MACE in STEMI patients in the short term.
219297468|NCT01764685|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
219297469|NCT01764685|DRUG|Placebo|Placebo
219297470|NCT06015828|DIETARY_SUPPLEMENT|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
219297471|NCT01546636|OTHER|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
219297472|NCT01546636|OTHER|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
219297473|NCT04619979|PROCEDURE|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
219297474|NCT01750203|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
219297475|NCT03013153|PROCEDURE|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
219297476|NCT03013153|PROCEDURE|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
219297477|NCT02233543|DRUG|QVA149|Delivered once daily via single-dose dry powder inhaler
219297478|NCT02233543|DRUG|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
219297479|NCT00447655|BEHAVIORAL|Self-management and peer support|
219297480|NCT00561366|DRUG|Placebo|Placebo t.i.d.
219297481|NCT00561366|DRUG|Arimoclomol|capsule, 400 mg t.i.d.
219297482|NCT06034418|DEVICE|Pulse radiofrequency treatment|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.
219743967|NCT06690684|BIOLOGICAL|Levels of biomarkers in blood of patients with acute myocardial infarction|Hemoglobin, neutrophil count, lymphocyte count, monocyte count and platelet count values, N-terminal pro-B type natriuretic peptide (NT-proBNP), peak creatine kinase isoenzymes (CK-MB), peak troponin T levels, total cholesterol (TC), fasting blood glucose (FBG), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood urine nitrogen, blood creatinine (Cr) and other indicators
219743968|NCT06695624|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganglion block group 4cc (80mg) 2% lidocaine + 1cc (4mg) dexamethasone in total 5cc volume will be prepared under sterile conditions before the procedure, 2.5 cc will be given to both nostrils. Sphenopalatine ganglion block will be applied by transnasal endoscopic method.
219743969|NCT06694532|DRUG|Hyaluronic acid|Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device
219743970|NCT06694532|DEVICE|Syringes|Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .
219743971|NCT06689384|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Trios 3, 3Shape; Primescan, Dentsply; Element 5D, iTero; Lumina, iTero) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
219743972|NCT06689384|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|"The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth.~A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology."
219743973|NCT06690827|DRUG|Anti-CD123 CAR NK cells|Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
219743974|NCT05954494|BIOLOGICAL|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
219743975|NCT06690866|BEHAVIORAL|Stress|Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
219743976|NCT06689124|DRUG|Nebulized fentanyl|After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
219297483|NCT06034418|DRUG|Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
219297484|NCT06471777|PROCEDURE|Fluid removal|Fluid removal during kidney replacement therapy
219297485|NCT00616902|DRUG|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
219297486|NCT00616902|DRUG|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
219297487|NCT05851703|OTHER|Manual therapy application|"In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, instrument-assisted pushing technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present."
219297488|NCT05851703|OTHER|Proprioceptive Neuromuscular Facilitation|With the rhythmic initiation technique, it is to teach the movement to the person, to improve the feeling of movement, coordination and to help relaxation. With rhythmic initiation, we want the patient's initial passive and then active participation to understand the movement, the direction and rhythm of the movement. After people actively participate, they can use active joint movement.
219297489|NCT03573583|BEHAVIORAL|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
219297490|NCT03573583|BEHAVIORAL|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
219297491|NCT04682444|DRUG|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
219297492|NCT04682444|DRUG|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
219297493|NCT02107183|DEVICE|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
219297494|NCT02107183|DEVICE|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
219297495|NCT04004936|OTHER|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
219297496|NCT04004936|OTHER|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
219297497|NCT00619333|DRUG|follitropin and lutropin|follitropin and lutropin
219297498|NCT01800084|DEVICE|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
219297499|NCT04865198|DIAGNOSTIC_TEST|Neurl1 gene expression|This observational case control study. The gene expression was examined.
219297500|NCT04865198|DIAGNOSTIC_TEST|RGS14 gene expression|This observational case control study. The gene expression was examined.
219297501|NCT05612152|OTHER|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
219297502|NCT05612152|OTHER|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
219297503|NCT05189873|DRUG|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
219297504|NCT05189873|DRUG|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
219297505|NCT06419478|OTHER|postoperative symptoms|Observational study, focusing solely on symptom surveys of patients.
219297506|NCT06335602|DEVICE|LASER acupuncture|Low level LASER therapy
219297507|NCT02062593|PROCEDURE|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
219297508|NCT02708329|PROCEDURE|T-provisional stenting|Standard endovascular T-provisional stenting technique
219297509|NCT02708329|PROCEDURE|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
219297510|NCT02708329|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
219297511|NCT04666402|OTHER|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
219297512|NCT04666402|DIAGNOSTIC_TEST|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
219297513|NCT04666402|DIAGNOSTIC_TEST|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
219297514|NCT03531385|DIAGNOSTIC_TEST|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
219297515|NCT03531385|DIAGNOSTIC_TEST|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
219297516|NCT03531385|OTHER|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
219297517|NCT03531385|OTHER|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
219297518|NCT04343872|BEHAVIORAL|Receive lifestyle modification alone|Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
219297519|NCT04343872|BEHAVIORAL|Metformin therapy|The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
219297520|NCT04033185|OTHER|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
219297521|NCT04033185|OTHER|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
219297522|NCT03730480|DEVICE|Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes|Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
219297523|NCT03138928|DEVICE|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
219297524|NCT02480153|BIOLOGICAL|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
219297525|NCT02480153|BIOLOGICAL|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
219297526|NCT00239343|DRUG|gefitinib|
219297527|NCT03234101|BEHAVIORAL|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1\) Healthy body weight (Minimum: BMI \<30kg/m2 or WC of \<88 in females or \<92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits \& vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation \>12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (\>6 hours)"
219297528|NCT02164123|OTHER|Spinal mobilization|Experimental group
219297529|NCT02164123|OTHER|Spinal Mobilization II|Active comparator group
219297530|NCT02164123|OTHER|Placebo|Placebo group
219297531|NCT00495586|DRUG|Placebo|One pill to be taken every eight hours for 8 days
219297532|NCT00495586|DRUG|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
219297533|NCT01955889|BEHAVIORAL|Mobile Health Technology|
219297534|NCT01955889|BEHAVIORAL|Stretching & Strengthening Exercises|
219297535|NCT01955889|BEHAVIORAL|Walking with Pedometer|
219297536|NCT02641600|DEVICE|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
219297537|NCT02641600|DEVICE|Placebo stockings|Placebo stocking with pressure applied to the legs
219297538|NCT01795573|BIOLOGICAL|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
219297539|NCT03487354|DRUG|Misoprostol|Misoprostol
219297540|NCT02301260|BEHAVIORAL|Speed of Processing Training (SPT)|
219297541|NCT02301260|BEHAVIORAL|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
219297542|NCT04814641|BIOLOGICAL|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
219297543|NCT02038543|DRUG|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
219297544|NCT04451174|DRUG|Prednisone|Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
219297545|NCT00158860|DRUG|Valaciclovir|1g once daily
219297546|NCT00158860|DRUG|Placebo|placebo
219297547|NCT00827866|OTHER|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
219297548|NCT00827866|OTHER|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
219297549|NCT02216305|PROCEDURE|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
219297550|NCT02216305|PROCEDURE|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
219297551|NCT02117947|BEHAVIORAL|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
219297552|NCT02117947|BEHAVIORAL|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
219297553|NCT00563485|DRUG|Doxazosin GITS (Cardura XL)|
219297554|NCT00563485|DRUG|Terazosin (Hytrin)|
219297555|NCT06434454|BEHAVIORAL|EFT Group:Emotional Free Technıcal|The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
219297556|NCT05333770|DEVICE|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
219297557|NCT02372656|DRUG|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
219297558|NCT02372656|DRUG|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
219297559|NCT02372656|DRUG|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
219297560|NCT01436851|BIOLOGICAL|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
219297561|NCT01029652|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
219297562|NCT01029652|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
219297563|NCT01029652|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
219297564|NCT01029652|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
219297565|NCT04553250|PROCEDURE|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
219297566|NCT05525884|OTHER|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
219297567|NCT06327750|DEVICE|Hemodialysis (DNa = PNa)|High-flux hemodialysis with an expected zero diffusive sodium balance (DNa = PNa)
219297568|NCT06327750|DEVICE|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
219297569|NCT06327750|DEVICE|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with an expected zero diffusive sodium balance (DNa=PNa)
219297570|NCT06327750|DEVICE|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with an expected zero diffusive sodium balance (DNa=PNa) Convection volume: ≥23L/session
219297571|NCT06327750|DEVICE|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L) Convection volume: ≥23L/session
219297572|NCT02095951|DRUG|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
219297573|NCT02631512|DEVICE|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
219297574|NCT02631512|DEVICE|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
219297575|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with intracorporeal anastomosis.|Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector
219297576|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with extracorporeal anastomosis.|Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
219297577|NCT02503033|DRUG|HMPL-523|Oral administration, once daily
219297578|NCT02001298|DRUG|remifentanil|
219297579|NCT02001298|DRUG|nitroprusside|
219297580|NCT03392545|COMBINATION_PRODUCT|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
219297581|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
219297582|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
219297583|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
219297584|NCT00964886|DRUG|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
219297585|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
219297586|NCT02758847|DEVICE|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
219297587|NCT02758847|DEVICE|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
219297588|NCT05071820|OTHER|Health U mobile application|Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
219297589|NCT05071820|OTHER|National Diabetes Prevention Program|CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
219297590|NCT06203366|PROCEDURE|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
219297591|NCT02449369|DRUG|Preop acetaminophen IV|
219297592|NCT02449369|DRUG|Preop orphenadrine IV|
219297593|NCT02449369|DRUG|Postop oral oxycodone & acetaminophen|
219297594|NCT02449369|DRUG|Postop hydromorphone IV|
219297595|NCT02449369|DRUG|Postop oral orphenadrine|
219297596|NCT02449369|DRUG|Postop oral oxycodone|
219297597|NCT02449369|DRUG|Postop acetaminophen IV|
219297598|NCT02449369|DRUG|Postop orphenadrine IV|
219297599|NCT05184712|DRUG|Ivonescimab (SMT112 or AK112) Injection|Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
219297600|NCT05184712|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
219297601|NCT03139669|DEVICE|Viba collection brush|HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
219297602|NCT00366080|DRUG|GSK189254|
219297603|NCT05305612|OTHER|early anticoagulation|Anticoagulation prior to transseptal puncture
219297604|NCT05305612|OTHER|late anticoagulation|Anticoagulation after transseptal puncture
219297605|NCT04367259|PROCEDURE|TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
219297606|NCT05301491|OTHER|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
219297607|NCT05301491|OTHER|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~1. Unilateral hip-knee flexion (self-assisted exercise)~2. Bilateral hip-knee flexion (self-assisted exercise)~3. Straight leg lifting with the aid of a sheet/rigid band~4. Posterior pelvic tilt~5. Bridge building exercise~6. Cat-camel exercise~7. Half shuttle in sagittal plane~8. Right and left rotational shuttle~9. Trunk hyperextension in prone position~10. Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
219297608|NCT05301491|OTHER|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
219297609|NCT05192148|OTHER|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
219297610|NCT05084859|DRUG|SM08502|SM08502 to be administered orally.
219297611|NCT05084859|DRUG|Abiraterone|Abiraterone to be administered orally.
219297612|NCT05084859|DRUG|Prednisone|Prednisone to be administered orally.
219297613|NCT05084859|DRUG|Docetaxel|Docetaxel to be administered intravenously.
219297614|NCT05084859|DRUG|FOLFIRI Protocol|FOLFIRI Protocol to be administered intravenously.
219297615|NCT05084859|DRUG|Panitumumab|Panitumumab to be administered intravenously.
219297616|NCT04708353|DRUG|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
219297617|NCT04708353|DRUG|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
219297618|NCT04708353|DRUG|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
219297619|NCT05052177|DEVICE|Edge to edge repair in systemic tricuspid valve regurgitation|Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
219297620|NCT01071343|DEVICE|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
219297621|NCT04531826|OTHER|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
219297622|NCT04185129|DRUG|Foster|a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation
219297623|NCT04723238|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
219297624|NCT04723238|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
219297625|NCT04587752|BEHAVIORAL|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
219297626|NCT01621568|DRUG|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
219297627|NCT01621568|DRUG|Sunitinib|50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
219297628|NCT03130881|DRUG|PLB1003|PLB1003 is a capsule and is administered orally.
219297629|NCT01662375|OTHER|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
219297630|NCT05687357|DRUG|Tislelizumab|IV infusion
219297631|NCT05687357|DRUG|S-1|Oral tablets
219297632|NCT05687357|DRUG|Oxaliplatin|IV infusion
219297633|NCT05687357|DRUG|Nab paclitaxel|IV infusion
219297634|NCT05687357|RADIATION|Radiation|TOMO/VMAT
219297635|NCT05399914|OTHER|S-NIPPV|Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
219297636|NCT01051830|OTHER|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
219297637|NCT00201890|PROCEDURE|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
219297638|NCT01379378|DEVICE|Artificial urinary sphincter|Standard of care
219297639|NCT01379378|DEVICE|InVance Sling|Standard of care
219297640|NCT01379378|DEVICE|AdVance Sling|Standard of care
219297641|NCT01379378|DEVICE|Virtue Sling|Standard of care
219297642|NCT01379378|DRUG|Contigen|2.5-10 cc
219297643|NCT05057780|OTHER|Communication Skills Curriculum|Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
219297644|NCT02334423|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
219297645|NCT02334423|OTHER|0.9% sterile, unpreserved saline|Placebo
219297646|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 12 weeks
219297647|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 8 weeks
219297648|NCT05845034|PROCEDURE|PVI + SPEs ablation|electrophysiology substrate mapping is the critical difference between both groups.
219297649|NCT05845034|PROCEDURE|PVI ablation|electrophysiology substrate mapping is the critical difference between both groups.
219297650|NCT03232853|OTHER|Elearning|Elearning
219297651|NCT00042718|DRUG|levofloxacin, azithromycin, amoxicillin/clavulanate|
219297652|NCT02930226|BIOLOGICAL|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
219297653|NCT02930226|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
219297654|NCT01846377|BEHAVIORAL|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
219297655|NCT04211662|BEHAVIORAL|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
219297656|NCT05502549|DRUG|CB03-154|CB03-154 tablet once daily.
219297657|NCT05502549|DRUG|Placebo|Placebo tablet once daily.
219297658|NCT03758859|OTHER|sodium hyaluronate eyedrops|sodium hyaluronate eyedrops administered - route ocular -topical
219297659|NCT00652327|DRUG|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
219297660|NCT00652327|DRUG|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
219297661|NCT00848731|DRUG|nitric oxide|nitric oxide gas is delivered by facemask
219297662|NCT01076647|DRUG|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
219297663|NCT01076647|DRUG|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
219297664|NCT02765802|DRUG|Peginterferon Lambda-1A|
219297665|NCT00920075|DRUG|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
219297666|NCT02582112|OTHER|Active Comparator: Warming group|Placebo Comparator: Control group
219297667|NCT04677634|DIETARY_SUPPLEMENT|ISOThrive Prebiotic Nectar|The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
219297668|NCT04538001|DEVICE|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
219297669|NCT04538001|PROCEDURE|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
219297670|NCT03210922|DEVICE|Miami cervical collar|Collar group is put on the Miami cervical collar.
219297671|NCT01599494|DRUG|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
219297672|NCT01599494|DRUG|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
219297673|NCT01599494|DRUG|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
219743977|NCT06690463|DIAGNOSTIC_TEST|sacroiliac joint injection|"The procedure involves the administration of a 2.5 cc injection of 2% lidocaine to the sacroiliac joint, targeting the articular or periarticular areas. The injection is performed under real-time ultrasound guidance to ensure accurate placement of the needle.~The 2% lidocaine solution is injected into both the joint space (articular area) and the surrounding soft tissues (periarticular area), which may include ligaments, capsules, and adjacent muscles. The goal is to temporarily anesthetize the joint and surrounding structures to assess the contribution of the sacroiliac joint in the patient's pain, as well as to provide therapeutic pain relief. The use of ultrasound ensures minimal risk of injury to surrounding structures and enhances the accuracy of the injection.~This intervention is commonly used in both diagnostic and therapeutic settings, helping to confirm the role of the sacroiliac joint in a patient's symptoms and providing relief in cases of sacroiliac joint dysfunction."
219743978|NCT06689657|BEHAVIORAL|Cognitive behavioral group therapy for adolescents and non violent resistance group for parents|"In the adolescents group, this cognitive-behavioral group therapy will include emotion regulation skills, distress tolerance skills, cognitive strategies, work on values and problem-solving strategies~Those sessions will include psychoeducation about adolescents, about suicidal ideation and suicidal behavior, coping with adolescent emotional distress, support on how to be a parent today (screen regulation...) and manage daily life"
219297674|NCT01599494|DRUG|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
219297675|NCT01599494|DRUG|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
219297676|NCT00254618|DRUG|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
219297677|NCT00254618|DRUG|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
219297678|NCT00254618|DRUG|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
219297679|NCT02133209|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
219297680|NCT02133209|BEHAVIORAL|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
219297681|NCT02926898|DRUG|ZX008 (Fenfluramine Hydrochloride)|"ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base."
219297682|NCT02926898|DRUG|Matching Placebo|Matching Placebo
219297683|NCT06397300|PROCEDURE|bilateral Ultrasound guided erector spinae plane (ESP) block|To perform ESP block in the lateral position bilaterally ,the skin will be disinfected with 70% alchol bilaterally and a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle (rhomboid major muscle is absent below T6 level) and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.
219297684|NCT06397300|PROCEDURE|quadratus lumborum block|In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
219297685|NCT06397300|PROCEDURE|lumbar epidural|"under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia."
219297686|NCT03481543|PROCEDURE|In-line nebulization through NIV mask|In-line nebulization will be given through NIV circuit.
219297687|NCT03481543|PROCEDURE|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
219297688|NCT06533358|DRUG|MT1002 Injection|MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI
219297689|NCT06292468|OTHER|Traditional physical therapy|This group received 30 minutes of muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training and foot care guidelines, 3 times a week for a duration of six weeks.
219297690|NCT06292468|OTHER|Plantar cutaneous sensory stimulation|This group received 45 minutes of plantar cutaneous sensory stimulation, TENS, muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training, and foot care guidelines, 3 times a week for a duration of six weeks.
219297691|NCT04984538|OTHER|Pharmacogenomic Testing|Cheek swab as a part of routine care
219297692|NCT02752698|PROCEDURE|Micro Hand S robotic surgery|20-70 patients undergo Micro Hand S robotic surgeries
219297693|NCT02752698|PROCEDURE|laparoscopic surgery|20-70 patients undergo laparoscopic surgeries
219297694|NCT02752698|PROCEDURE|da Vinci robotic surgery|20-70 patients undergo da Vinci robotic surgeries
219297695|NCT02570087|PROCEDURE|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
219297696|NCT03477773|OTHER|High-intensity exergaming|Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (\~70% HRmax). Periods of exercise were performed at an intensity \>85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
219297697|NCT00564889|DRUG|cyclophosphamide|300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
219297698|NCT00564889|DRUG|dexamethasone|40 mg weekly taken orally
219297699|NCT00564889|DRUG|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
219743979|NCT06689657|OTHER|Adolescent group therapy (CARES) and parent group therapy (RNV)|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week). There also will be a boost session 3 month after the last session. Parents will attend 4 group sessions during 1 month too (1 session/week). There will be 2 boost sessions : 1 month and 3 month after the last session Patients will be randomized in each group with blinded assessment"
219743980|NCT06685939|PROCEDURE|LPD|The patients who received the LPD
219297700|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test with walker|to walk during 6 minutes with walker
219297701|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test|to walk during 6 minutes with walker
219297702|NCT04373824|DRUG|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
219297703|NCT00398268|PROCEDURE|Kirschner-wire fixation|
219297704|NCT03500159|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
219297705|NCT03500159|DRUG|Placebo|Appearance and weight matched tablets without the active product ingredient
219297706|NCT01710644|DRUG|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
219297707|NCT01710644|DRUG|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
219297708|NCT03535597|DEVICE|Quikclot Radial (QC) Pad|The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.
219297709|NCT00603252|BIOLOGICAL|Twinrix|
219297710|NCT00603252|BIOLOGICAL|Engerix-B|
219297711|NCT00603252|BIOLOGICAL|Havrix|
219297712|NCT00603252|BIOLOGICAL|HBVAXPRO|
219297713|NCT00603252|BIOLOGICAL|Vaqta|
219297714|NCT04565847|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
219297715|NCT04565847|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
219297716|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
219297717|NCT03942185|DRUG|Oral Chinese Herbal Medicine according with syndrome differentiation therapy|Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
219297718|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
219297719|NCT00407576|DRUG|[11C]MeS-IMPY|
219297720|NCT02292927|BEHAVIORAL|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
219297721|NCT00653445|DRUG|Rosuvastatin|40mg
219297722|NCT00653445|DRUG|Ezetimibe|10mg
219297723|NCT03262324|OTHER|VAS-FA Turkish version|Self-reported outcome questionnaires
219297724|NCT00568802|DRUG|Hydroxyurea|
219297725|NCT00568802|DRUG|Placebo to match hydroxyurea|
219297726|NCT01277900|PROCEDURE|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
219743981|NCT06689670|DEVICE|Needle based delivery of INT001 into liver tumors under real-time image guidance|Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
219743982|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A|0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.
219743983|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B|0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.
219297727|NCT01039792|DRUG|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
219297728|NCT01039792|DIETARY_SUPPLEMENT|Placebo|placebo
219297729|NCT03394729|DRUG|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
219297730|NCT03394729|DRUG|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
219297731|NCT05823831|DIAGNOSTIC_TEST|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
219297732|NCT05823831|DIAGNOSTIC_TEST|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
219297733|NCT05823831|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
219297734|NCT05823831|DIAGNOSTIC_TEST|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
219297735|NCT05296018|OTHER|Mandala coloring page|Mandala program will be applied three days a week (30 minutes) for 8 weeks.
219297736|NCT04280341|BIOLOGICAL|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
219297737|NCT03117322|BIOLOGICAL|agave inulin|Duration: four weeks Dosage: powder 4 g/d
219297738|NCT03117322|BIOLOGICAL|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
219297739|NCT03117322|OTHER|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
219297740|NCT03117322|OTHER|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
219297741|NCT01476098|DRUG|Placebo|SB-705498 placebo
219297742|NCT01476098|DRUG|SB-705498|400 or 600mg oral SB-705498
219297743|NCT04067648|DRUG|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
219297744|NCT00950586|DRUG|GSK1043702|Oral dose in liquid or tablet formulation
219297745|NCT00950586|DRUG|Dextromethorphan|30mg Oral dose
219297746|NCT00950586|DRUG|Placebo|To match GSK1034702
219297747|NCT00725933|DRUG|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
219297748|NCT05786430|DRUG|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
219297749|NCT05721404|DRUG|Icodextrin Peritoneal Dialysis Solution|Icodextrin (Extraneal) for long night dwell
219297750|NCT05721404|DRUG|Hypertonic Dextrose solution|Hypertonic Dextrose solution for long night dwell
219297751|NCT05300347|DIAGNOSTIC_TEST|adenosine deaminase enzyme deficiency test|adenosine deaminase enzyme deficiency
219297752|NCT02825173|DEVICE|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
219297753|NCT04361682|PROCEDURE|Surgical Drain Management|
219297754|NCT03117231|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
219297755|NCT03117231|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
219297756|NCT03773315|DIETARY_SUPPLEMENT|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
219297757|NCT03773315|DIETARY_SUPPLEMENT|Placebo|Starch placebo 500 mg/day for 12 weeks
219297758|NCT02139761|DRUG|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
219297759|NCT02139761|DRUG|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
219297760|NCT03786523|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
219297761|NCT03786523|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
219297762|NCT00141219|DRUG|pregabalin|150-600mg/day, BID
219297763|NCT00141219|DRUG|Placebo|Placebo
219297764|NCT02224690|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219297765|NCT02224690|DRUG|Placebo|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
219297766|NCT05949294|DRUG|ARO-SOD1 Injection|single doses of ARO-SOD1 Injection by IT infusion
219297767|NCT05325580|DRUG|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
219297768|NCT02244021|DRUG|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
219297769|NCT00297596|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
219297770|NCT00297596|DRUG|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
219297771|NCT05179382|OTHER|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
219297772|NCT05179382|OTHER|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
219297773|NCT02580643|BIOLOGICAL|APS|intra-articular injection
219297774|NCT06265064|DIAGNOSTIC_TEST|STOP-Bang score >= 3 with factors predicting difficult intubation|patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm
219297775|NCT02314845|OTHER|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
219297776|NCT02314845|OTHER|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
219297777|NCT02730637|OTHER|Early nephrologist consultation|
219297778|NCT00645866|DRUG|capecitabine|
219297779|NCT00645866|DRUG|docetaxel|
219297780|NCT00645866|DRUG|epirubicin hydrochloride|
219297781|NCT00645866|OTHER|laboratory biomarker analysis|
219297782|NCT00645866|OTHER|pharmacogenomic studies|
219297783|NCT00645866|PROCEDURE|biopsy|
219297784|NCT00645866|PROCEDURE|neoadjuvant therapy|
219297785|NCT00645866|PROCEDURE|therapeutic surgical procedure|
219297786|NCT02274532|DEVICE|SoftHand|Biomechanical, ADL, and functional testing.
219297787|NCT00002768|BIOLOGICAL|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
219297788|NCT00002768|DRUG|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
219297789|NCT00002768|DRUG|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
219297790|NCT00002768|DRUG|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
219297791|NCT00002768|DRUG|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
219297792|NCT00002768|PROCEDURE|peripheral blood stem cell transplantation|Infusion on Day 0
219297793|NCT02317133|BIOLOGICAL|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
219297794|NCT02317133|BIOLOGICAL|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
219297795|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
219297796|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
219297797|NCT00122460|DRUG|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
219297798|NCT00122460|DRUG|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
219297799|NCT02595073|DRUG|DSXS|Active treatment
219297800|NCT02595073|DRUG|Placebo|Placebo treatment
219297801|NCT02962960|DRUG|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
219297802|NCT02962960|DRUG|Placebo|subcutaneous administration every two weeks from week 0 to week 50
219297803|NCT00568035|DRUG|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
219297804|NCT04491565|OTHER|educational video|an interactive educational video was viewed by participants in the intervention arm.
219297805|NCT01060579|DRUG|AR-12286 0.5% ophthalmic solution|q.d. PM
219297806|NCT01060579|DRUG|AR-12286 0.25% Ophthalmic solution|q.d. PM
219297807|NCT01060579|DRUG|Latanoprost ophthalmic solution|q.d. PM
219297808|NCT03500601|OTHER|Nut components|nut components consumed daily for a period of 28 days
219297809|NCT03500601|OTHER|Placebo|Placebo consumed daily for a period of 28 days
219297810|NCT04110639|DEVICE|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
219297811|NCT04110639|OTHER|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
219297812|NCT03896412|OTHER|Detecton of circulating tumor DNA|7 blood samples to design a molecular probe
219297813|NCT01103362|DRUG|flibanserin|all patients will receive open-label flibanserin 100mg
219297814|NCT00065377|DRUG|Glucosamine Hydrochloride|
219297815|NCT01178554|BEHAVIORAL|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
219297816|NCT01178554|BEHAVIORAL|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
219297817|NCT01178554|BEHAVIORAL|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita \& Weisz, 2004)
219297818|NCT01854723|DRUG|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
219297819|NCT01854723|DRUG|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
219297820|NCT02998580|DEVICE|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
219297821|NCT02998580|DEVICE|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
219297822|NCT01980927|PROCEDURE|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
219297823|NCT00765453|OTHER|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
219297824|NCT00765453|OTHER|Placebo infusion|Placebo infusion
219297825|NCT00610740|DRUG|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
219297826|NCT00610740|PROCEDURE|therapeutic conventional surgery|hysterectomy
219297827|NCT06550089|DRUG|Oxytocin|Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
219297828|NCT02665338|DEVICE|Transcranial Magnetic Stimulation|
219297829|NCT00942760|DEVICE|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
219297830|NCT03007043|OTHER|blood sample|
219297831|NCT03580005|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
219297832|NCT03580005|DRUG|Placebo|Placebo to Match Quillichew ERCT
219297833|NCT06486207|COMBINATION_PRODUCT|Gong's mobilization|increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula
219297834|NCT06486207|OTHER|Kendall Exercise|The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
219297835|NCT05682703|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
219297836|NCT03539887|DRUG|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
219297837|NCT03539887|DRUG|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
219297838|NCT00998998|BEHAVIORAL|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
219297839|NCT00998998|BEHAVIORAL|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
219297840|NCT00998998|DIETARY_SUPPLEMENT|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
219297841|NCT01755208|PROCEDURE|light-scattering spectroscopy|Undergo light-scattering spectroscopy
219297842|NCT01239459|DRUG|Teriflunomide HMR1726|"Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition"
219297843|NCT01239459|DRUG|Cholestyramine|"Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55"
219297844|NCT04355247|DRUG|MethylPREDNISolone 80 Mg/mL Injectable Suspension|"* Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
219297845|NCT05570773|OTHER|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
219297846|NCT05447091|BEHAVIORAL|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
219297847|NCT05447091|BEHAVIORAL|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
219297848|NCT05447091|BEHAVIORAL|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
219297849|NCT02793388|DRUG|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
219743984|NCT06690515|BIOLOGICAL|Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®|The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region
219743985|NCT06687200|OTHER|Setup with neutral pelvic positioning technique|Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography)
219743986|NCT06687200|OTHER|Standard setup|Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT)
219743987|NCT06691009|PROCEDURE|Group 1 (mechanical pleurodesis)|pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps , intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed
219297850|NCT02793388|DRUG|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
219297851|NCT01856777|DEVICE|Semi-quantitative panel test|
219297852|NCT01856777|DEVICE|High sensitivity urine pregnancy test|
219297853|NCT02811952|OTHER|without intervention|without intervention
219297854|NCT04208282|DEVICE|7 day infusion set|7 days survival of the sets
219297855|NCT03438877|PROCEDURE|Intensive dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
219297856|NCT03438877|PROCEDURE|Regular dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
219297857|NCT06540625|DEVICE|the use of CP device application on human subjects.|"Trained providers will be asked to apply CP at 10N of force to the marked location using the cricoid applicator for one minute. Data relating to applied force across the whole one minute will be measured continuously and will be captured and stored. The CP device will have a microdisc port for internal memory and then the wifi on the board will transfer the information to a cloud server for backup and storage for redundancy.~A threshold of 10 ± 2 N applied force will be set to define successful CP attempts. Participants must remain in this range for 95% of the trial time after the first five seconds have passed.~At any point during the CP application, if the volunteer experiences pain, they can request that the pressure be stopped. However, we do not expect any pain with 10N, except for minor discomfort."
219297858|NCT04108143|DEVICE|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
219297859|NCT06429007|DRUG|Metformin|"Metformin will be initiated at 25% of the target dose (4 mg/kg administered twice daily, total daily dose 8 mg/kg) for three weeks. In the absence of adverse effects, metformin dose will be escalated to 50% of the target dose (8 mg/kg administered twice daily for a total daily dose of 16mg/kg) for remaining 3 weeks to minimize potential gastrointestinal upset at higher doses. Parents will be documenting adverse events and performing glucometer checks twice a day for 3 days post dose escalation.~Parents will then receive a 6-week supply of metformin at the target dose (16 mg/kg administered twice daily, total daily dose 32 mg/kg). Adverse events will be documented and glucometer checks will be performed twice a day for 3 days following dose escalation."
219297860|NCT04662034|DEVICE|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
219297861|NCT04662034|DRUG|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
219297862|NCT05591989|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
219297863|NCT05215665|DRUG|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
219743988|NCT06691009|PROCEDURE|Group 2 chemical pleurodesis by bleomycin)|Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours
219743989|NCT06687187|DRUG|Neostigmine|two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
219743990|NCT06690177|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
219743991|NCT06690177|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
219743992|NCT06691477|OTHER|No Interventions|No intervention required. Subjects accepted regular medical treatment
219743993|NCT06686550|OTHER|This is a observational study and there is no intervention.|This is a observational study and there is no intervention.
219743994|NCT06689020|PROCEDURE|Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy|During application of CPEP and CHFO, EIT is monitored.
219743995|NCT06686186|OTHER|No Intervention: Observational Cohort|There were no interventions in our cohort. The subjects of our cohort were and will be followed up at the regular intervals.
219743996|NCT06688526|OTHER|Quiet Sounds|Quiet sounds are played during sleep
219743997|NCT06688526|OTHER|Sham sounds|No sounds are played during sleep
219297864|NCT05215665|DRUG|Lenvatinib|8/12mg PO QD continuously
219297865|NCT05215665|DRUG|Toripalimab|240mg IV d1 Q3W
219297866|NCT05652647|DRUG|Oral [14C]PF-07081532|A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
219297867|NCT05652647|DRUG|Oral PF-07081532 and IV [14C]PF-07081532|In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
219297868|NCT03848676|DIAGNOSTIC_TEST|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
219297869|NCT04743791|DRUG|Dupilumab|Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
219297870|NCT04743791|OTHER|Placebo|Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
219297871|NCT05982795|OTHER|Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge|"A CultureSwab MaxV(+) (BD, Franklin Lakes, NJ) will be placed under endoscopic visualization to the middle meatus through a sterile sheath (red rubber urinary catheter) and gently rotated 5 full turns or until the tip is saturated with mucus (no more than 20 seconds).~Under direct visualization, a sterile Leukosorb sponge (Leukosorb; Pall Scientific, Port Washington, NY) will be placed in the middle meatus. A piece of Leukosorb filter paper will additionally be placed in the olfactory cleft. The sponge and paper will be left for 5 minutes and will then be removed under direct visualization and collected for analysis."
219297872|NCT05982795|OTHER|Olfactory Function Testing|"Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Odors will be delivered using felt-tip pens (Sniffin' Sticks, MediSense, NL). The pen cap will be removed from the pen for approximately 3 seconds, and the pen's tip will be brought in front of the subject's nose and carefully moved from left to right nostril. Threshold testing will be obtained by asking the subject to identify the pen containing the odor from two pens containing only solvent. This will be conducted starting with the lowest concentration of odor and moving stepwise until patient is no longer able to identify the odor from the solvent.~Subjects may also be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT can be self-administered and uses microencapsulated odorants which are released by scratching standardized odor-impregnated test booklets."
219297873|NCT05982795|OTHER|Survey Completion|"Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised (CFQ-R) survey. This survey evaluates Cystic Fibrosis-specific and general quality of life metrics.~Participants will also be asked to complete the validated Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with chronic rhinosinusitis.~Participants will also be asked to complete the validated Sinus Control Test (SCT) - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis.~Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a 25-question validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease."
219297874|NCT05465083|DEVICE|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
219297875|NCT05253794|DRUG|Colchicine 0.6 mg|oral tablet daily for 6 months
219297876|NCT05253794|DRUG|Placebo|oral tablet daily for 6 months
219297877|NCT05326815|DIAGNOSTIC_TEST|N-Telopeptide, Bone Marker|"This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest (N-Telopeptide), and their association with baseline DEXA scan measures and fracture risk within 6 months.~Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn."
219297878|NCT03562975|DRUG|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
219297879|NCT05709600|DIETARY_SUPPLEMENT|Fasting mimicking diet|"Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.~The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet."
219297880|NCT05709600|DIETARY_SUPPLEMENT|Ketogenic diet|"Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.~The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption"
219297881|NCT05709600|DIETARY_SUPPLEMENT|Dietary restriction of sulfur containing amino acids|"Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.~A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption."
219297882|NCT05709600|DIETARY_SUPPLEMENT|Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)|Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.
219297883|NCT02539745|OTHER|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
219297884|NCT02539745|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
219297885|NCT00351312|DEVICE|special socks|
219297886|NCT05490342|DIAGNOSTIC_TEST|Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.|Blood test to value the antibody response to vaccination
219297887|NCT06498011|OTHER|Home Graded Repetitive Arm Supplementary Program (GRASP)|The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
219297888|NCT06498011|OTHER|integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)|The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
219297889|NCT04055532|OTHER|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
219297890|NCT01296789|OTHER|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
219297891|NCT01296789|OTHER|Usual Care|Usual Care
219297892|NCT02545933|DRUG|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
219297893|NCT02545933|DRUG|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
219297894|NCT02545933|DRUG|Aspirin|Aspirin will be administered at the dose of 81mg once daily
219297895|NCT02545933|DRUG|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
219297896|NCT04133051|DRUG|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
219297897|NCT04133051|DRUG|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
219297898|NCT00901654|BIOLOGICAL|ACE527 vaccine|"First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21"
219297899|NCT00901654|BIOLOGICAL|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
219297900|NCT05571345|DRUG|PF614|PF614 capsules (50 mg or 100 mg)
219297901|NCT05571345|DRUG|Oxycodone Hydrochloride 40 mg|Oral 20 mg tablets (two each)
219297902|NCT05571345|DRUG|Placebo|Placebo to match PF614 capsules will be provided by the sponsor.
219297903|NCT05488145|OTHER|Best Practice|Receive standard of care
219297904|NCT05488145|OTHER|Internet-Based Intervention|Receive application intervention
219297905|NCT05488145|OTHER|Questionnaire Administration|PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.
219297906|NCT05488145|OTHER|Survey Administration|Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
219297907|NCT05118828|BEHAVIORAL|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
219297908|NCT05118828|BEHAVIORAL|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
219297909|NCT06374108|BEHAVIORAL|Progressive resistance training|The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
219297910|NCT04517214|DRUG|Toripalimab|PD-1 inhibitor
219297911|NCT04517214|RADIATION|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
219297912|NCT04517214|DRUG|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
219297913|NCT04517214|DRUG|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
219297914|NCT06081153|DRUG|Evolocumab|See arm description.
219297915|NCT06081153|DRUG|Placebo|See arm description.
219297916|NCT06089850|OTHER|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
219297926|NCT00835900|DRUG|varenicline|variable dosing schedule
219297927|NCT00835900|DRUG|placebo|placebo
219297928|NCT05520372|COMBINATION_PRODUCT|Autologous immune enhancement therapy (AIET) for cancer patients|Autologous NK cell and CD8 T cell therapy for cancer patients
219297929|NCT02817802|DEVICE|Magmaris|PCI (Magmaris)
219297930|NCT04631900|BEHAVIORAL|Christianity approach as framework for spiritual intervention|Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
219297931|NCT00935818|DRUG|Varenicline|varenicline - 1 mg bid for 12 weeks
219297932|NCT00935818|DRUG|placebo|placebo for 12 weeks
219297933|NCT00935818|DRUG|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
219297934|NCT02437201|BEHAVIORAL|Liberty Program|
219297935|NCT05624151|DRUG|Dexmedetomidine +Bupivacaine|infraorbital nerve block by dexmedetomidine plus bupivacaine
219297936|NCT05624151|DRUG|Magnesium Sulfate + Bupivacaine|infraorbital nerve block by magnesium sulphate plus bupivacaine
219297937|NCT05624151|DRUG|Bupivacaine|infraorbital nerve block by bupivacaine only
219297938|NCT03397043|OTHER|Protein intake (dose)|Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
219297939|NCT02527824|DRUG|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7"
219297940|NCT05390021|COMBINATION_PRODUCT|PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent|The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.
219297941|NCT03373942|OTHER|Choroidal thickness measurements with SD-OCT device|
219297942|NCT00732589|DRUG|1% xylocaine|10 cc. of 1%xylocaine, once a week
219297943|NCT00732589|OTHER|ultrasound|ultrasound at shoulder area about 10 mins.
219297944|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
219297945|NCT00979134|DRUG|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
219297946|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
219297947|NCT00000747|DRUG|Nevirapine|
219297948|NCT05060640|PROCEDURE|Detection of anal HSIL in a routine colonoscopy.|Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
219297949|NCT04083105|DRUG|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
219297950|NCT04083105|DRUG|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
219297951|NCT06533085|PROCEDURE|Adductor canal block by surgeon|"Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)"
219297952|NCT05822830|DRUG|Tirzepatide|Administered SC
219297953|NCT05822830|DRUG|Semaglutide|Administered SC
219297954|NCT05937893|OTHER|Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans|Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
219297955|NCT01739439|DRUG|gemcitabine hydrochloride|Given IV
219297956|NCT01739439|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
219297957|NCT01739439|RADIATION|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
219297958|NCT01739439|RADIATION|radiosurgery|Undergo radiosurgery boost
219297959|NCT01739439|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
219297960|NCT04352998|DIETARY_SUPPLEMENT|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
219297961|NCT04352998|DIETARY_SUPPLEMENT|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
219297962|NCT04352998|DIETARY_SUPPLEMENT|Placebo condition|one dose of a placebo
219297963|NCT00352638|OTHER|counseling intervention|
219297964|NCT00352638|OTHER|educational intervention|
219297965|NCT00352638|OTHER|study of socioeconomic and demographic variables|
219297966|NCT04676061|DRUG|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
219297967|NCT04676061|DRUG|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
219297968|NCT00933790|DRUG|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
219297969|NCT04252274|DRUG|Darunavir and Cobicistat|Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
219297970|NCT00963053|DRUG|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
219297971|NCT02271438|DRUG|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.
219297972|NCT02271438|DRUG|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
219297973|NCT02271438|DRUG|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
219297974|NCT02271438|DRUG|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
219297975|NCT01719705|DRUG|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
219297976|NCT01719705|DRUG|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
219297977|NCT01719705|DRUG|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
219297978|NCT06084923|OTHER|Observation|Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
219297979|NCT06012422|OTHER|evaluation group|Elderly individuals will be evaluated once, by face-to-face interview method.
219297980|NCT00380224|DRUG|bifeprunox, olanzapine|
219297981|NCT00539435|PROCEDURE|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
219297982|NCT00353288|BIOLOGICAL|MeMuRu-OKA (study vacc)|
219297983|NCT00353288|BIOLOGICAL|MMR, Varicella vacc (control)|
219297984|NCT02272673|DIETARY_SUPPLEMENT|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
219297985|NCT05180500|DRUG|Q-Griffithsin|Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
219297986|NCT05180500|DRUG|Placebo|A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
219297987|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
219297988|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
219297989|NCT04605289|DRUG|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
219297990|NCT04605289|DRUG|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
219297991|NCT04605289|PROCEDURE|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
219297992|NCT03280147|DRUG|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
219297993|NCT03280147|DRUG|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
219297994|NCT04720248|DRUG|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
219297995|NCT00867308|DRUG|Lenalidomide 50 mg|
219297996|NCT00867308|DRUG|Lenalidomide 15 mg|
219297997|NCT00002851|PROCEDURE|adjuvant therapy|
219297998|NCT00002851|RADIATION|low-LET electron therapy|
219297999|NCT00002851|RADIATION|low-LET photon therapy|
219298000|NCT02822105|BIOLOGICAL|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
219298001|NCT02822105|OTHER|Placebo|saline
219298002|NCT06509815|DEVICE|MIRA|The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
219298003|NCT05586802|DRUG|Anastrozole|This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D
219298004|NCT05586802|DRUG|Semaglutide|This will be an experimental treatment for 26 weeks in Group 2 Arm E
219298005|NCT05586802|DRUG|human chorionic gonadotropin|This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B
219298006|NCT05586802|DRUG|Testosterone gel|This will be an active comparator for 26 weeks in Group 2 - Arm C
219298007|NCT00067262|DRUG|Divalproex Sodium Extended-Release Tablets|
219298008|NCT04906252|DIAGNOSTIC_TEST|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
219298009|NCT04906252|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
219298010|NCT03337659|OTHER|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
219298011|NCT04502732|OTHER|NSSM and GEBT|The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
219298012|NCT00452023|DRUG|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
219298013|NCT06180031|DRUG|Pericapsular nerve group block using bupivicaine and magnesium sulphate|This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
219298014|NCT06273982|BEHAVIORAL|STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)|STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
219743998|NCT06686836|PROCEDURE|Sinus lift augmentation with bone substitute (Bio-Oss)|A maxillary sinus lift augmentation was performed with a lateral window approach that was filled with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®).At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
219743999|NCT06686836|PROCEDURE|Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland)) - L-PRF Block|"A maxillary sinus lift augmentation was performed with a lateral window approach that was filled using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®) (L-PRF block).~L-PRF block will be performed as described by Cortellini et al. 2018. L-PRF membranes are cut into small pieces and mixed with Bio-Oss® at a ratio of 2 membranes / 0.5 g biomaterial. Pieces of the block will be removed and compacted in the sinus cavity until it is filled.~At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically."
219744000|NCT06688656|DRUG|Pemetrexed 500 mg/m2|1\. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.
219744001|NCT06688656|DRUG|carboplatin|AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.
219744002|NCT06688656|DRUG|Sintilimab|Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.
219744003|NCT06687993|DRUG|Donepezil 2.5 mg|2.5 mg daily oral intake for 90 days
219744004|NCT06687993|DRUG|Donepezil 5 mg|5 mg daily oral intake for 90 days
219744005|NCT06687993|DRUG|Placebo Comparator|daily oral intake for 90 days
219744006|NCT06699134|DEVICE|Total knee arthroplasty|Primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
219744007|NCT06699134|DEVICE|Total Hip arthroplasty|Primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
219744008|NCT06632873|DRUG|177Lu-TATE-RGD|accepted intravenous injection of 177Lu-TATE-RGD
219298015|NCT06273982|BEHAVIORAL|ARC (assisted referral to community care)|ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
219298016|NCT05535218|DRUG|Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi|"Neoadjuvant treatment: 7,5mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
219298017|NCT04381897|DRUG|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
219298018|NCT04381897|OTHER|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
219298019|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
219298020|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
219298021|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
219298022|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
219298023|NCT03152058|DRUG|Certolizumab Pegol|"Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
219298024|NCT05859451|DEVICE|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
219298025|NCT05859451|OTHER|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
219298026|NCT06640634|DEVICE|active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
219298027|NCT06640634|DEVICE|sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
219298028|NCT06640634|DEVICE|active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
219298029|NCT06640634|DEVICE|sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
219298030|NCT00706953|DRUG|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
219298031|NCT06600776|DRUG|Ultra Rapid Lispro (URLi)|"Dosage Form:~Subcutaneous insulin infusion~Dosage:~Based on individual carbohydrate counting, adjusted using the MiniMed 780G hybrid closed-loop system.~Frequency:~Administered at mealtime (premeal) during one phase and immediately after meals (postmeal) during the other phase.~Duration:~Each intervention phase lasts up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~Both interventions (mealtime and postmeal dosing) are applied to the single arm of the study."
219298032|NCT06600776|DEVICE|Insulin pump with continuous glucose monitoring (CGM)|"The insulin pump with continuous glucose monitoring (CGM) system is used by patients with Type 1 Diabetes Mellitus (T1DM) as part of their regular treatment regimen. This system combines an insulin pump with real-time glucose monitoring, adjusting basal insulin delivery every 5 minutes based on continuous glucose data. In this study, participants are already using the system before the trial begins. The research does not examine the effect of the CGM itself but rather focuses on the timing of insulin bolus delivery (mealtime vs. postmeal) using their existing treatment system.~Frequency:~The system delivers basal insulin continuously and requires the patient to manually deliver bolus doses at mealtime (premeal) or postmeal, depending on the study phase.~Duration:~The device is used continuously throughout the entire study period, with each intervention phase (premeal vs. postmeal dosing) lasting up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~This device will be us"
219298033|NCT04260178|OTHER|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
219298034|NCT04260178|OTHER|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
219298035|NCT06071897|DRUG|monoclonal antibodies GD2|"Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy"
219298036|NCT05101824|RADIATION|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
219298037|NCT05917470|DRUG|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
219298038|NCT04302974|PROCEDURE|Different structures and processes of primary care management strategies|Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
219298039|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
219298040|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
219354974|NCT01558661|DRUG|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
219298041|NCT04302974|PROCEDURE|Patient Support Call Centre (PSCC)|RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
219298042|NCT02549456|PROCEDURE|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
219298043|NCT02549456|PROCEDURE|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
219298044|NCT05361564|DRUG|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
219298045|NCT04781257|DIAGNOSTIC_TEST|New test candidates|"The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial"
219298046|NCT04854824|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
219298047|NCT04854824|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family physician personal practice
219298048|NCT02031549|OTHER|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
219298049|NCT01149577|DRUG|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
219298050|NCT02317432|BEHAVIORAL|Comparison of a combined CBT + exercise intervention and enhanced usual care|
219298051|NCT00967031|DRUG|capecitabine|
219298052|NCT00967031|DRUG|lapatinib ditosylate|
219298053|NCT00967031|OTHER|circulating tumor cell analysis|
219298054|NCT00967031|OTHER|laboratory biomarker analysis|
219298055|NCT06663592|OTHER|Conventional treatment|hot pack, stretching of the neck muscles, cervical isometrics exercise
219298056|NCT06663592|OTHER|Tensioner Neuro Dynamic Mobilization|Median nerve tensioner neural mobilization with addition to conventional treatment
219298057|NCT06663592|OTHER|Slider Neuro Dynamic Mobilization|Median nerve neural sliding mobilization with addition to conventional treatment
219298058|NCT01533597|DRUG|Solifenacin|Solifenacin (5mg, qd, oral)
219298059|NCT01533597|DRUG|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
219298060|NCT05165888|BEHAVIORAL|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
219298061|NCT05165888|BEHAVIORAL|Communication skills training|Training to improve communication skills between physicians and caregivers.
219298062|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in low dose.
219298063|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in high dose.
219298064|NCT06825416|DRUG|Enoxaparin sodium injection|Enoxaparin sodium injection.
219298065|NCT06825416|DRUG|Enoxaparin sodium injection placebo|Enoxaparin sodium injection placebo.
219298066|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in low dose.
219298067|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in high dose.
219298068|NCT02248181|DRUG|Pramipexole|
219298069|NCT03507751|DRUG|Meropenem|1.0 gram of meropenem given intravenously every 8 hours
219298070|NCT03507751|DEVICE|CRRT|Continuous renal replacement therapy for three days
219298071|NCT06607757|DRUG|Capivasertib|find arm A description
219298072|NCT06607757|DRUG|Fulvestrant injection|find arm B description
219298073|NCT06608147|OTHER|Sampling|sternal bone marrow aspiration
219354975|NCT05020600|DRUG|Duloxetine|First-line fibromyalgia treatment
219354976|NCT05020600|DRUG|Pregabalin|First-line fibromyalgia treatment
219298074|NCT06607354|OTHER|Grass fed lamb|This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.
219298075|NCT06598436|OTHER|Digital Health Coaching (Patient-Level Intervention)|The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.
219298076|NCT06598436|OTHER|Practice Facilitation (Clinic-Level Intervention)|The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).
219298077|NCT06604520|DRUG|Vortioxetine|Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
219298078|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
219298079|NCT06609135|DEVICE|Sentec LuMon Device (EIT system)|Sentec EIT belts will be placed on infants up to once daily from consent through NICU discharge.
219298080|NCT06609135|DEVICE|Sentec Digital Monitoring System (transcutaneous CO2 monitor)|Sentec transcutaneous CO2 monitors will be placed on infants concurrently with EIT belts.
219298081|NCT06610877|DEVICE|Focused Ultrasound Neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
219298082|NCT06610877|DEVICE|Focused ultrasound neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
219298083|NCT00231452|DRUG|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
219298084|NCT05595252|BIOLOGICAL|cervical biopsy|cervical biopsy made during and after pregancy
219298085|NCT04807582|OTHER|[18F]FPIA PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
219298086|NCT05599555|BIOLOGICAL|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
219298087|NCT05599555|BIOLOGICAL|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
219354977|NCT05020600|DRUG|Amitriptyline|First-line fibromyalgia treatment
219354978|NCT00958139|OTHER|Permethrin|Permethrin 0.5% treatment of clothing one time
219354979|NCT00958139|OTHER|Placebo|water sprayed on clothing one time
219744009|NCT06694896|DIAGNOSTIC_TEST|Microarray Application|Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
219744010|NCT06697951|DEVICE|bilevel ventilation with the Neovent|Newborn infants with respiratory distress will be placed on the Neovent and we will see if study staff set up, use, and trouble shoot the Neovent correctly and see if study staff can monitor for safety problems in lower-resourced nurseries and to determine if the infants have any more problems than seen with bubble CPAP or Neovent in a higher resourced nursery including any more nasal irritation, abdominal distention, or clinically important amount of air around the lung (pneumothorax)
219298088|NCT04631692|BEHAVIORAL|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
219354980|NCT05462210|OTHER|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
219298089|NCT06611202|OTHER|Exercise|"A multidisciplinary six-minute walking group intervention-spearheaded by physiotherapists, occupational therapists, and psychologists-in enhancing physical activity, mobility, cognitive function, and functional independence among patients with dementia.~Physiotherapy Component: A six-minute walking group will be conducted twice a week for 8 weeks, targeting improvements in mobility, endurance, and balance. Occupational Therapy Intervention: Occupational therapists will integrate functional tasks (Games and throwing of balls to court, bean bag target game to enhance exercise relevance to daily activities. A psychologist will provide mental health support during the sessions, utilising techniques like time focus reminiscence therapy to engage patients and reduce anxiety."
219298090|NCT06611202|DRUG|Clonazepam|Medication on our dementia wards are being review during ward round and when needs arise. The medication management in drugs will be fully documented and accounted for in the course of the study.
219298091|NCT06611189|OTHER|surgery|In order to preserve kidney from warm ischemia during graft implantation, on the back table, graft were prepared for implantation with standard techniques. The kidney was introduced into the bag which was filled with a small amount of ice and preservation fluid (Figure 1). After inplacement of the graft, a small hole was made near the hilum and the renal artery and vein were passed through the hole. A Kocher clamp was used to maintain the fluid and ice in place and as a handle. Also, a Hartman Mosquito Clamp was used to mark urether-side, and to maintain orientation.
219298092|NCT06611189|OTHER|Ray-Tech sponge technique|On the back table, graft were prepared for implantation with standard techniques. A Raytech sponge is soaked in ice-cold preservative solution, and wrapped around the kidney and held with a clamp (Figure 2). Position and oriantation of the graft was done by direct vision of urether.
219298093|NCT02791178|PROCEDURE|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
219298094|NCT02791178|PROCEDURE|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
219298095|NCT02791178|OTHER|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
219298096|NCT05157269|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
219298097|NCT05157269|DRUG|Placebo|Two matching placebo tablets administered orally twice daily for 5 days
219298098|NCT05157269|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
219298099|NCT05587790|BEHAVIORAL|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
219298100|NCT06609980|DRUG|autologous fecal matter transplant|Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
219298101|NCT06611046|OTHER|organ donor|"Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group."
219298102|NCT03005353|DRUG|Cumin seed extract|patients will receive the drug in suppository form
219298103|NCT03005353|DRUG|clotrimazole|patients will receive the drug in suppository form
219354981|NCT03961282|OTHER|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
219298104|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 12-18 months, or earlier if they develop symptoms. While 12-18 months is the preferred window for repeat imaging, if imaging during this time frame is not achievable, the patient may return anytime throughout the remainder of the study.
219298105|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
219298106|NCT04489134|DRUG|Treatment A|Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
219298107|NCT04489134|DRUG|Treatment B|Administration of a 2 mg dose of LCP-tacro (Envarsus®)
219298108|NCT04489134|DRUG|Treament C|Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
219298109|NCT04489134|DRUG|Treatment D|Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
219298110|NCT04489134|BIOLOGICAL|Pharmacocinetik|Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.
219298111|NCT04489134|GENETIC|Genetic|A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.
219298112|NCT04489134|OTHER|Selection visit:|"During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal."
219298113|NCT06685848|DEVICE|Hemanext ONE system|Hypoxic red blood cells
219298114|NCT06685848|DEVICE|Conventional RBCs|Conventional manufactured Red blood cells
219298115|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
219298116|NCT06723197|DRUG|vonoprazan+amoxicillin|Drug combinations for dual regimens：vonoprazan+amoxicillin
219298117|NCT06723197|OTHER|Duration of eradication regimen: 7-day|Duration of eradication regimen: 7-day
219298118|NCT06723197|DRUG|vonoprazan+amoxicillin+tetracycline+bismuth|Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
219298119|NCT06723197|OTHER|Duration of eradication regimen: 10-day|Duration of eradication regimen: 10-day
219298120|NCT06723197|OTHER|Duration of eradication regimen: 14-day|Duration of eradication regimen: 14-day
219298121|NCT06887751|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"The self-guided Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos.~The intervention is expected to have the following overall structure: Session 1: Introduction to the intervention and promotion of creative hopelessness, Awareness of bodily sensations, Values clarification Session 2: Committed action, Acceptance, Cognitive defusion Session 3: Self as context, Conclusions Session 4-8: personalised content (in-depth material and tasks based on individual difficulties assessed with diary)"
219298122|NCT06887751|OTHER|Psychoeducation|"Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company.~The content of the education course will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS, such as disease pathophysiological me"
219298123|NCT06728033|OTHER|supra-inguinal fascia iliaca compartment block|Supra-inguinal fascia iliaca compartment block with 40 ml of 0.25% ropivacaine
219298124|NCT06728033|DRUG|Tramadol|intravenous tramadol at a dose of 2 mg/kg
219298125|NCT06728956|OTHER|READY for MS UK digital programme|Online self-directed programme supported by HCPs
219298126|NCT06728865|DRUG|The treatment regimen is Furmonertinib combined with Bevacizumab.|The treatment regimen is Furmonertinib combined with Bevacizumab.
219298127|NCT06727994|OTHER|Providing Genital Hygiene training|"After the informed consent of all participants in the study is obtained, pre-test data, Self-Care Power Scale and Genital Hygiene Behavior Scale will be collected face-to-face.~Genital Hygiene training will be given. Reminder training will be given 15 days, 1 month and 2 months after the training, and 1 month after the reminder training, the Self-Care Power Scale and Genital Hygiene Behavior Scale will be re-administered to women as a final test."
219298128|NCT06729671|DIETARY_SUPPLEMENT|Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule|Bifidobacterium longum APC1472 capsule
219298129|NCT06729671|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
219298130|NCT05798793|DRUG|Camrelizumab plus TP|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
219298131|NCT05798793|DRUG|TP|The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
219298132|NCT06728670|BEHAVIORAL|Tranexamic acid Intravenous Infusion|A slow intravenous infusion of 1g TXA was administered at a rate of about 1ml/min.
219298133|NCT06728670|BEHAVIORAL|TXA intramuscular injection|5ml intramuscular injections of TXA with twice, each injection time no more than 30 seconds, the injection site was selected as triangle
219298134|NCT06728306|BEHAVIORAL|Immersive Virtual Reality-Based Relaxation|"Participants experienced a 20-minute immersive relaxation session using the virtual reality headset and the Nature Treks application, while seated comfortably. Participants were instructed to select the natural environment they found most relaxing from options such as Blue Ocean, Orange Sunset, Violet Down, White Winter, and Green Meadows, and spent 20 minutes immersed in their chosen virtual environment."
219744011|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
219744012|NCT06691048|OTHER|Description of an adult population diagnosed late with a neurodevelopmental disorder|Clinical description during diagnostic interview
219744013|NCT06690528|PROCEDURE|Surgical resection of both the primary tumor and liver metastases|Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
219744014|NCT06689371|OTHER|Group A (Dry Needling)|The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.
219744015|NCT06689371|OTHER|Group B (Dry cupping)|Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.
219744016|NCT06689371|OTHER|Group C (control)|will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
219744017|NCT06688097|BEHAVIORAL|Compression of esophageal|Before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.
219744018|NCT00690352|BEHAVIORAL|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
219744019|NCT06720259|DRUG|Oxantel Pamoate|Tablets containing 250 mg oxantel pamoate
219744020|NCT06720259|DRUG|Mebendazole|Tablets containing 500 mg mebendazole
219744021|NCT05103735|DRUG|Propofol|awake neurosurgery under propofol-remifentanil sedation
219744022|NCT06742684|PROCEDURE|PCI with following SSO2 Therapy|SSO2 Therapy
219744023|NCT00972257|DRUG|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
219744024|NCT00972257|DRUG|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
219744025|NCT03607058|OTHER|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
219744026|NCT03607058|OTHER|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
219744027|NCT03595722|DEVICE|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
219744028|NCT03838328|DRUG|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
219744029|NCT02194686|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
219744030|NCT02194686|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
219744031|NCT05459714|DEVICE|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
219744032|NCT03800628|OTHER|qualitative study|semi-structured interviews
219744033|NCT03621215|DIETARY_SUPPLEMENT|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
219298135|NCT06728306|BEHAVIORAL|Non-immersive VR-Based Exergaming|"Participants engaged in a 20-minute calisthenic exercise session guided by the Kinect Adventures game on the Xbox Kinect 360 system. The exercise session consisted of playing two rounds each of the game segments 20,000 Leaks, Reflex Ridge, and River Rush, each lasting approximately 3 minutes"
219298136|NCT06728306|BEHAVIORAL|Jacobson's Relaxation|Participants underwent 20 minutes of progressive relaxation training as developed by Dr. Jacobson. The training involves a series of deep diaphragmatic breaths followed by the systematic tensing and relaxing of 16 major muscle groups throughout the body. Participants were guided through the exercise by an approximately 20-minute audio recording prepared by a psychologist and available online
219298137|NCT06729034|DRUG|Apixaban (Eliquis)|5 mg twice daily
219298138|NCT06729034|DRUG|Placebo|placebo twice daily
219298139|NCT06729359|DIAGNOSTIC_TEST|Ultrasonography of the abdomen and pelvis|ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe
219298140|NCT06729749|OTHER|Bioptron Pro 1 Class II|Bioptron Pro 1 Class II: Made by Bioptron AG, Wollerau, Switzerland, a device with a floor stand emits a polarized light lamp. The device has an ergonomic table stand that can be combined with a functional floor stand, allowing flexible use in domestic and professional environments. easily adjustable height and head inclination and the ability to rotate the device head up to 360 allow a convenient usage of nearly any position. Treatments can easily be timed by a control panel down to 30 seconds, an integrated distance rod ensures the recommended distance from the skin surface It will be used for the treatment procedures for all participants in group B only with the following parameters, Wavelengths ranging from 480-3400 nm, Degree of polarization \>95% (590 - 1550 nm), Specific power density Av. 40 mW/cm2 Light energy per minute av.2.4 J/cm2, Light Intensity per min. 10.000 lux, Weight without stand 3.4 kg and Weight with stand7.8 kg ,Energy consumption in sleep mode0.5
219298141|NCT06729749|OTHER|Vitamin D|All participants in both groups will take this supplements daily for 3 months
219298142|NCT04207177|DRUG|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
219298143|NCT04207177|DRUG|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
219298144|NCT06867718|DRUG|RGT001-075|RGT001-075 is a small molecule GLP-1 agonist
219298145|NCT06867718|DRUG|Placebo Comparator|Placebo comparator
219298146|NCT06897605|DRUG|Dapagliflozin (DAPA)|Dapagliflizin 10 mg tablets once daily for 12 weeks
219298147|NCT06897605|DRUG|Erythropoiesis Stimulating Agent|Erythropoiesis stimulating agent (ESA) therapy
219298148|NCT06774001|PROCEDURE|Appendicectomy|Both open and minimally invasive (laparoscopic and robotic) interventions are eligible for inclusion. Laparoscopic and robotic converted to open cases are also eligible.
219298149|NCT06900894|BIOLOGICAL|Platelet-Rich Fibrin (PRF)|PRF was prepared using a centrifugation protocol and applied to the extraction socket.
219298150|NCT06900894|DEVICE|Kinesio Taping|Kinesio Tape was applied postoperatively to the masseter and submandibular region.
219298151|NCT06900894|OTHER|Standard Postoperative Care|Patients in the control group received standard postoperative care.
219298152|NCT06896981|DRUG|Metformin with Semaglutide|One arm: Metformin 500 mg bd, Other arm: Metformin 500 mg bd + Semaglutide 0.5 mg once weekly
219298153|NCT02390700|BIOLOGICAL|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
219298154|NCT03227406|BEHAVIORAL|Sleep deprivation|Subjects are kept awake all night.
219298155|NCT03227406|BEHAVIORAL|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
219298156|NCT02691533|DRUG|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
219298157|NCT02691533|DRUG|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
219298158|NCT02691533|DRUG|No Lipid Emulsion/Placebo|
219298159|NCT05939856|OTHER|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
219298160|NCT05939856|OTHER|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
219298161|NCT06906068|DIETARY_SUPPLEMENT|Three strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®|A probiotic beverage (98 g) at dose of 50.10\^9 CFU, taken once daily for 14 weeks.
219298162|NCT06906068|OTHER|Placebo|Non fermented beverage (98 g) with no probiotic strains, taken once daily for 14 weeks.
219298163|NCT06907472|DRUG|Protocol-based treatment|"PROTOCOL:~Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5: Metformin 1000 mg twice daily + glibenclamide 5 mg twice daily"
219744034|NCT03621215|OTHER|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
219744035|NCT04632030|BEHAVIORAL|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
219744036|NCT03220555|DEVICE|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
219744037|NCT03220555|DRUG|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
219744038|NCT00964678|DRUG|Carvedilol|twice daily oral treatment in escalating dose
219744039|NCT04380025|DIETARY_SUPPLEMENT|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
219744040|NCT04380025|DIETARY_SUPPLEMENT|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
219744041|NCT05202171|OTHER|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
219298164|NCT06907459|OTHER|upper Track of Deep Front Facial Line realese|The MFR techniques were applied to the designated regions, with soft, steady pressure lasting 90 to 120 seconds postural correction exercises The upper track of deep front facial line release procedures were applied. Hyoid mobilization; Larynx mobilization; Sternal oscillations; and Barral's Transversus Thoracis mobilization. The thoracic inlet releasing ; intrathoracic fascia elongation; scalene releasing and diaphragm relaxation
219298165|NCT06907459|OTHER|Myofascial Release With IASTM|The instrument is designed to mobilize soft tissues. Facilitation approaches were employed to break apart adhesions. Emollient Gel/Lubrication Gel (Hawk Grips product) was also used to lubricate the skin and allow the instrument to move more easily. The tool has two sides: one for therapy and the other for holding plus postural correction exercises
219298166|NCT06907459|OTHER|supervised corrective exercises|The exercise program included cervical stabilization exercises performed in 3 sets of 10 repetitions with a 10-second maintenance, scapular stabilization exercises plus stretching of cervical muscles.
219298167|NCT06906328|BEHAVIORAL|Cognitive remediation program, with the PRESCO® software|"The program runs for 12 weeks, with two sessions per week, one with a neuropsychologist. In the first 4 weeks, the patient will have weekly sessions at the center and complete the other session at home using the app provided for the study. For the next 8 weeks, sessions with the neuropsychologist will be every other week, with the other session at home. The neuropsychologist will track progress through the software history and follow up by phone if needed.~The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron)."
219298168|NCT06906328|BEHAVIORAL|Control program, with the AUDITICO® software|"Control program, with the same functional characteristics but without the targeted cognitive functions.~For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users."
219298169|NCT06906952|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
219298170|NCT06906952|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
219298171|NCT04198753|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
219298172|NCT04198753|DEVICE|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
219298173|NCT04198753|DIAGNOSTIC_TEST|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
219298174|NCT06905899|OTHER|audiobook app|audio book listening
219744042|NCT05202171|OTHER|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
219744043|NCT04081012|DRUG|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
219744044|NCT04081012|DRUG|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
219744045|NCT02292355|OTHER|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
219744046|NCT02169258|PROCEDURE|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
219744047|NCT06144658|DEVICE|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
219744048|NCT02605616|DRUG|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
219298175|NCT06906653|BEHAVIORAL|Augmented Initial Type 2 Diabetes Care|"The intervention will include 4 components: 1) Making primary care providers (PCPs) aware that the patient has been selected to receive Augmented Initial Type 2 Diabetes (T2D) Care, 2) encouraging early care manager outreach to establish care, ensure prescribing of appropriate medications, and support medication adherence, 3) a one-on-one virtual health educator visit to reinforce self-management education and ensure set-up of remote glucose monitoring or continuous glucose monitoring (if eligible), and 4) a one-on-one virtual nutrition visit to provide individualized counseling."
219298176|NCT06907277|DRUG|Dexmedetomidine|Dexmedetomidine (DXM) loading dose of 0.6 µg/kg followed by DXM infusion given at a rate of 0.4 ml/kg/h and was provided as 0.15 µg/kg/h for 24-h PO.
219298177|NCT06907277|DRUG|Fentanyl|A bolus of fentanyl 5 µg/kg followed by an intraoperative (IO) fentanyl infusion of 3-5 µg/kg/h that was continued as PO analgesia for 24 hours in a dose of 0.3 µg/kg/h.
219298178|NCT06907277|DRUG|Lidocain|Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.
219298179|NCT06907394|OTHER|Osteopathic Manipulations|Osteopathic Manipulations (a. Myofascial release technique: Direct scar release+ Indirect scar release 'Fascial unwinding'; b. Grand Maneuver; Visceral manipulations of uterus
219298180|NCT06907394|OTHER|Control Group|Paracetamol tablets
219298181|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
219298182|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
219298183|NCT03754114|OTHER|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
219744049|NCT02605616|OTHER|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
219744050|NCT05362799|DRUG|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
219744051|NCT05362799|DRUG|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
219744052|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
219744053|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
219298184|NCT03754114|OTHER|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
219298185|NCT00484107|DRUG|Conjugated Estrogen Cream (Premarin®)|
219298186|NCT03449251|DRUG|Apelin|Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
219298187|NCT03449251|DRUG|Relaxin|Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
219298188|NCT03449251|DRUG|Normal saline|Vehicle
219744054|NCT03359395|DRUG|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
219744055|NCT03359395|DRUG|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
219298189|NCT03449251|DIAGNOSTIC_TEST|Verapamil|NO independent challenge agent
219298190|NCT03449251|DIAGNOSTIC_TEST|LN Monomethyl arginine|Basal NO synthase inhibitor
219744056|NCT03164356|DEVICE|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
219298191|NCT06017934|BEHAVIORAL|Volunteer-led physical activity|Participants will be assessed by the therapy team who will prescribe tailored activity and then liaise with the mobility volunteers, who will deliver the intervention. Participants who can mobilise independently will be encouraged to perform walking exercises, progressing their walking distance over set markers in the hospital (e.g., to the end of the bed and back; to the doorway and back; to the toilet and back). Participants who require assistance in mobility will perform bed (e.g., hip abduction, static quads), or chair exercises (e.g., ankle pumps, knee extension, arm raise), and will be progressed to performing walking exercises when their physical function improves. Volunteers will check with nursing staff that participants are safe to exercise before each activity session. Participants will receive the mobility sessions twice daily, starting upon recruitment and continuing until the day of discharge from hospital.
219298192|NCT06524765|OTHER|Living conditions|There are many patients with multi-resistant bacterial infections in intensive care units (ICU), making it possible for a great deal of these pathogens to exist in the ICU environment. The exposure factors in this study were ICU environment or daily living environment.
219298193|NCT05767060|DRUG|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
219298194|NCT03236987|DRUG|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
219298195|NCT03236987|DRUG|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
219298196|NCT03236987|DRUG|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
219298197|NCT03236987|DRUG|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
219298198|NCT04381650|DRUG|TAK-981|TAK-981 IV infusion.
219298199|NCT04381650|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
219298200|NCT03992846|DRUG|75 mg linzagolix tablet|For oral administration once daily
219298201|NCT03992846|DRUG|200 mg linzagolix tablet|For oral administration once daily
219298202|NCT03992846|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
219298203|NCT03992846|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
219298204|NCT03992846|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
219298205|NCT03992846|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
219298206|NCT04954404|DEVICE|transcatheter mitral valve repair/transcatheter mitral valve replacement|transcatheter mitral valve repair/transcatheter mitral valve replacement
219298207|NCT03647488|DRUG|Capmatinib|Capmatinib 400 mg (tablets) orally taken twice daily
219298208|NCT03647488|DRUG|Spartalizumab|Spartalizumab 400 mg via intravenous infusion once every 28 days
219298209|NCT03647488|DRUG|Docetaxel|Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
219298210|NCT03694275|DRUG|Soticlestat|TAK-935 tablets
219298211|NCT01274845|OTHER|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
219298212|NCT05331092|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
219298217|NCT05077085|DRUG|Bezlotoxumab|single intravenous infusion of bezlotoxumab 10 mg/kg
219298218|NCT05077085|PROCEDURE|Fecal Microbiota Transplantation (FMT)|single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
219298219|NCT05077085|DRUG|Vancomycin oral|14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
219298220|NCT02498431|PROCEDURE|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
219298221|NCT02498431|PROCEDURE|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
219298222|NCT02498431|DEVICE|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
219298223|NCT02666469|OTHER|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
219298224|NCT02666469|OTHER|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
219298225|NCT02666469|DEVICE|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
219298226|NCT02708654|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
219298227|NCT02708654|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
219298228|NCT02708654|BEHAVIORAL|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
219298229|NCT02708654|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
219298230|NCT05353946|DEVICE|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
219298231|NCT01319630|DEVICE|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
219744057|NCT03377998|OTHER|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
219744058|NCT02712216|PROCEDURE|Laparoscopy|Determine best port sites to insert bariatric trocars
219744059|NCT02868879|OTHER|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
219744060|NCT03189927|DEVICE|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
219744061|NCT01415453|PROCEDURE|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
219744062|NCT02207101|DIETARY_SUPPLEMENT|E-OJ-01 (OXYJUN)|
219744063|NCT02207101|DIETARY_SUPPLEMENT|Placebo|
219744064|NCT06752499|DEVICE|Online stimulation|5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
219744065|NCT06752499|DEVICE|Offline stimulation|After 5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere, the patients perform motor tasks.
219744066|NCT06752499|DEVICE|Sham stimulation|Sham rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
219744067|NCT06929936|DRUG|Trilaciclib combined with Docetaxel|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to chemotherapy.~Docetaxel: 75mg/m2, iv. infusion for 1 hour on days 1 of each 21-day cycle, totaling 4 cycles of medication."
219744068|NCT01812746|DRUG|BIND-014|
219744069|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
219744070|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
219744071|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
219744072|NCT02441400|DEVICE|EndoStim LES Stimulation System|
219744073|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
219744074|NCT06047587|BEHAVIORAL|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
219744075|NCT06047587|OTHER|Care as Usual|Care as usual as provided in prison.
219744076|NCT04410796|DRUG|Osimertinib|80mg orally daily
219744077|NCT04410796|DRUG|Carboplatin|Carboplatin (AUC 5 IV q 3 weeks)
219744078|NCT04410796|DRUG|Pemetrexed|Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles
219744079|NCT05381753|DRUG|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
219744080|NCT05381753|DRUG|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
219744081|NCT04619147|OTHER|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
219744082|NCT00385489|DRUG|LXR-623|
219744083|NCT03571633|DRUG|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
219744084|NCT03571633|DRUG|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
219744085|NCT05712538|DRUG|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
219744086|NCT05712538|OTHER|Placebo|Normal saline
219744087|NCT05998564|DEVICE|Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.|All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
219744088|NCT01720563|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
219744089|NCT01720563|DRUG|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
219744090|NCT01720563|PROCEDURE|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
219744091|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
219744092|NCT05670756|OTHER|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
219744093|NCT04089111|OTHER|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
219744094|NCT04089111|OTHER|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
219744095|NCT06423794|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
219744096|NCT03263533|DRUG|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
219298232|NCT01319630|DEVICE|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
219298233|NCT02417402|OTHER|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
219298234|NCT02417402|OTHER|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
219298235|NCT05444569|DRUG|LY3537021|Administered SC.
219298236|NCT05444569|DRUG|Liraglutide|Administered SC.
219298237|NCT05444569|DRUG|Placebo|Administered SC.
219298238|NCT02772419|DRUG|benralizumab|SC administration
219298239|NCT02772419|DRUG|benralizumab|SC administration
219298240|NCT02772419|DRUG|Placebo|SC administration
219298241|NCT02956785|DRUG|10 mg Dinoprostone; CTS, UK|
219298242|NCT02956785|DRUG|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
219298243|NCT02956785|DRUG|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
219298244|NCT04714931|DIAGNOSTIC_TEST|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
219298245|NCT01924728|DEVICE|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
219298246|NCT01924728|DEVICE|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
219298247|NCT03963531|OTHER|chemotherapy, surgery, radiotherapy, interventional radiology.|
219298248|NCT03542370|OTHER|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
219298249|NCT00136539|DRUG|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
219298250|NCT00136539|DRUG|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
219298251|NCT00136539|DRUG|Adriamycin|Given every three weeks for 12 weeks after surgery.
219298252|NCT00136539|DRUG|Cytoxan|Given every three weeks for 12 weeks after surgery.
219298253|NCT03541174|DRUG|Aprocitentan 12.5 mg|Tablet, oral use
219298254|NCT03541174|DRUG|Aprocitentan 25 mg|Tablet, oral use
219298255|NCT03541174|DRUG|Placebo|Matching placebo tablet
219298256|NCT03618121|DEVICE|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
219298257|NCT03618121|DEVICE|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax \& Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
219298258|NCT03618121|BEHAVIORAL|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
219298259|NCT03618121|BEHAVIORAL|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
219298260|NCT01574391|DEVICE|Epidrum|Epidrum is used
219298261|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
219298262|NCT00000145|DIETARY_SUPPLEMENT|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
219298263|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
219298264|NCT00472160|PROCEDURE|Non Invasive Ventilation|Non Invasive Ventilation
219298265|NCT04183309|OTHER|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
219298266|NCT04928430|DRUG|XAV-19|150 mg of XAV-19 single IV perfusion
219298267|NCT04928430|DRUG|Placebo|Single IV infusion
219298268|NCT02775825|OTHER|survey|
219298269|NCT05559008|DRUG|Azacitidine Injection|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
219298270|NCT05559008|DRUG|Dasatinib|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
219298271|NCT05559008|DRUG|Linperlisib|Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
219298272|NCT05559008|DRUG|Tucidinostat|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
219298273|NCT05559008|DRUG|SHR2554|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
219298274|NCT05559008|DRUG|Camrelizumab|Camrelizumab and Apatinib will be administered in T3.2 subtypes
219298275|NCT05559008|DRUG|Apatinib|Camrelizumab and Apatinib will be administered in T3.2 subtypes
219298276|NCT02002650|DRUG|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
219298277|NCT02002650|DRUG|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
219298278|NCT01978522|OTHER|Randomisation of questionnaire receipt.|"1. The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~2. Self-completion questionnaire handed to participants immediately after completing the CAPI."
219298279|NCT02217332|DRUG|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
219298280|NCT04719325|OTHER|Herbert screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
219298281|NCT04719325|OTHER|Lag screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
219298282|NCT04058366|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
219298283|NCT04058366|DRUG|IVA|Tablet for oral administration.
219298284|NCT00330486|DRUG|Acamprosate|
219298285|NCT02466750|BIOLOGICAL|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
219298286|NCT05560334|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
219298287|NCT05971459|BEHAVIORAL|Improvised Active Music Therapy|During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
219298288|NCT03437681|BEHAVIORAL|Insufficient sleep|Four days of insufficient sleep
219298289|NCT05079451|DRUG|3BNC117-LS|3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
219298290|NCT05079451|DRUG|10-1074-LS|10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
219298291|NCT02751411|DEVICE|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
219298292|NCT02751411|DRUG|Macrogol 4000|Stool softener
219298293|NCT00534144|DRUG|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
219298294|NCT00534144|DRUG|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
219298295|NCT05834439|OTHER|flower printing activities for the elderly|Experimental group
219298296|NCT05834439|OTHER|Routine activities in nursing home|Control group
219298297|NCT03056027|DIAGNOSTIC_TEST|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
219298298|NCT00098332|DRUG|forodesine hydrochloride|
219298299|NCT01446757|PROCEDURE|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
219298300|NCT01446757|PROCEDURE|control group|No intervention
219298301|NCT00347607|BEHAVIORAL|community surveillance and re-treatment|
219298302|NCT05233332|DRUG|HL-085|12mg BID HL-085
219298303|NCT05233332|DRUG|Vemurafenib|720mg BID Vemurafenib
219298304|NCT00006230|DRUG|rubitecan|
219298305|NCT02984202|DEVICE|auditory midbrain implant (AMI)|
219298306|NCT00603304|DRUG|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
219298307|NCT00603304|DRUG|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
219298308|NCT00603304|DRUG|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
219298309|NCT00603304|DRUG|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
219298310|NCT00603304|DRUG|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
219298311|NCT00603304|DRUG|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
219298312|NCT05077644|DEVICE|Stella (TM) Mobile Application|Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
219298313|NCT06248099|DRUG|Nebivolol-Test product|Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India
219298314|NCT06248099|DRUG|Nebivolol-Reference product|Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
219298315|NCT00682747|DRUG|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
219298316|NCT01483547|DEVICE|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
219298317|NCT02253901|DRUG|BILR 355 BS|
219298318|NCT02253901|DRUG|Ritonavir|
219298319|NCT02253901|DRUG|TRUVADA|
219298320|NCT05415943|DEVICE|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
219298321|NCT01859273|BEHAVIORAL|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
219298322|NCT03805347|DRUG|Helminthostachys zeylanica(L.)Hook|Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
219298323|NCT03805347|DRUG|Starch|Starch in capsule, 1gm/time, 3 times daily
219298324|NCT01295762|OTHER|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
219298325|NCT00808054|DRUG|EMLA|0.5g topical EMLA
219298326|NCT03797261|DRUG|Venetoclax|tablet, oral
219298327|NCT03797261|DRUG|AMG 176|solution, intravenous
219298328|NCT00667771|DRUG|Naltrexone|
219298329|NCT03361280|DRUG|Beta blocker|Beta blockers are administered as described in arms.
219298330|NCT01869582|DEVICE|Fetoscope, Fetal heart rate|
219298331|NCT01869582|DEVICE|Upright Resuscitator, Resuscitation|
219298332|NCT01869582|DEVICE|Doppler, Fetal heart rate|
219298333|NCT01869582|DEVICE|Standard Resuscitator, Resuscitation|
219298334|NCT01378780|BEHAVIORAL|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
219298335|NCT01378780|BEHAVIORAL|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
219298336|NCT01085266|DRUG|Dimebon (latrepirdine)|
219298337|NCT06153225|DIETARY_SUPPLEMENT|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
219298338|NCT03546322|OTHER|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
219298339|NCT04452565|DRUG|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
219298340|NCT04452565|COMBINATION_PRODUCT|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
219298341|NCT04452565|COMBINATION_PRODUCT|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
219298342|NCT04452565|COMBINATION_PRODUCT|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
219298343|NCT01886612|DEVICE|Duo-STIM neuromuscular electrical stimulator|
219298344|NCT01886612|DEVICE|AV Impulse System Model 6000|
219298345|NCT04843553|DRUG|Oral Nicotinamide|
219298346|NCT00633724|BIOLOGICAL|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
219298347|NCT05272956|PROCEDURE|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
219298348|NCT03898401|COMBINATION_PRODUCT|Platelet rich plasma|After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
219298349|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
219298350|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
219298351|NCT05251467|OTHER|Focus group|Focus group to confirm PROM conceptual framework
219298352|NCT05251467|OTHER|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
219298353|NCT05251467|OTHER|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
219298354|NCT05251467|DEVICE|Testing of the pilot PROM in a smartphone app (n = 150)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
219298355|NCT05566977|OTHER|autologous adoptive T regulatory cell transfer.|Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
219298356|NCT05513924|DRUG|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
219298357|NCT05513924|DRUG|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
219298358|NCT01435330|DRUG|BVS857|
219298359|NCT01435330|DRUG|Placebo|
219298360|NCT00512317|DRUG|ganaxolone|liquid suspension dosed tid
219298361|NCT04729413|BEHAVIORAL|Couples Counseling|Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
219298362|NCT04729413|OTHER|Enhanced Standard of Care|Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
219298363|NCT02619149|DRUG|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
219298364|NCT02619149|DRUG|Saline solution|Saline iv as placebo control
219298365|NCT05174455|DRUG|Niraparib Tosylate Monohydrate|Given PO
219298366|NCT05149911|BEHAVIORAL|Life Coaching|Sessions with a professional life coach.
219298367|NCT01717690|DRUG|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
219298368|NCT00159133|DRUG|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
219298369|NCT05406830|DEVICE|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
219354982|NCT03961282|OTHER|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
219298370|NCT05406830|BEHAVIORAL|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
219298371|NCT05406830|DEVICE|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
219298372|NCT04433585|DRUG|LY3471851|Administered SC
219298373|NCT04433585|DRUG|Placebo|Administered SC
219298374|NCT02436785|OTHER|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
219298375|NCT02436785|OTHER|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
219298376|NCT00824356|DRUG|GSK1004723 (200mg)|Intranasal antihistamine.
219298377|NCT00824356|OTHER|Placebo|Equivalent to GSK1004723 in presentation etc.
219298378|NCT00824356|DRUG|GSK1004723 (1000mg)|Intranasal antihistamine.
219298379|NCT01039623|BIOLOGICAL|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
219298380|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
219298381|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
219298382|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
219298383|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
219298384|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
219298385|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
219298386|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
219298387|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
219298388|NCT02486133|DRUG|Prezista|once daily
219298389|NCT02486133|DRUG|Norvir|once daily
219298390|NCT02486133|DRUG|Tivicay|once daily
219298391|NCT02486133|DRUG|Truvada|once daily
219298392|NCT02486133|DRUG|Kivexa|once daily
219298393|NCT02486133|DRUG|Descovy|once daily
219298394|NCT04875676|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
219298395|NCT00460200|GENETIC|polymorphism analysis|
219298396|NCT00460200|OTHER|laboratory biomarker analysis|
219298397|NCT00460200|OTHER|physiologic testing|
219298398|NCT00460200|OTHER|questionnaire administration|
219298399|NCT00460200|PROCEDURE|conventional surgery|
219298400|NCT00460200|PROCEDURE|fatigue assessment and management|
219298401|NCT00460200|PROCEDURE|psychosocial assessment and care|
219298402|NCT00409266|DEVICE|Computer assisted navigation|
219298403|NCT00852033|BEHAVIORAL|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
219298404|NCT00852033|BEHAVIORAL|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
219298405|NCT00852033|BEHAVIORAL|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
219298406|NCT00852033|OTHER|Assessment only|No intervention, assessment only.
219298407|NCT00531739|OTHER|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
219298408|NCT04962932|BEHAVIORAL|Internet-deliviered exposure-based CBT|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
219298409|NCT04962932|BEHAVIORAL|Internet-delivered stress management treatment|The intervention last for 10 weeks and include: Internet-SMT include life-style advice (e.g., exercise, sleep advice), relaxation and problem-solving skills to reduce stress. Patients are offered regular online contact with a psychologist with the same frequency and intensity as in the CBT arm.
219298410|NCT01739842|DIETARY_SUPPLEMENT|Kudzu extract|
219298411|NCT02265627|DRUG|BIIL 284 BS|
219298412|NCT03455621|PROCEDURE|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
219298413|NCT00252837|DRUG|Tesaglitazar|
219298414|NCT00252837|BEHAVIORAL|Dietary and Lifestyle counseling|
219298415|NCT02510898|BEHAVIORAL|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
219298416|NCT00884494|DRUG|Ghrelin infusion to assess effects on insulin sensitivity|
219298417|NCT02937454|DRUG|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
219298418|NCT02937454|OTHER|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
219298419|NCT03276325|DRUG|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
219298420|NCT03276325|DRUG|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
219298421|NCT01264822|DRUG|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
219298422|NCT02703051|DRUG|GMI-1271|
219298423|NCT02703051|DRUG|Filgrastim|
219298424|NCT02703051|DRUG|Placebo Injection|
219298425|NCT02703051|DRUG|Placebo Infusion|
219298426|NCT06327581|DRUG|Lactic Acid|patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
219298427|NCT06327581|DRUG|vit D|patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
219298428|NCT06327581|DRUG|Triamcinolone Acetonide|patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
219298429|NCT06327581|DRUG|Saline|patients will be treated with MN combined with normal saline 0.9%
219298430|NCT04152304|OTHER|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
219298431|NCT00113100|DRUG|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
219298432|NCT00626132|DIETARY_SUPPLEMENT|Eucommia|two capsules three times a day orally for 2 weeks
219298433|NCT00875927|OTHER|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
219298434|NCT00875927|OTHER|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
219298435|NCT00875927|OTHER|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
219298436|NCT00875927|OTHER|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
219298437|NCT00875927|OTHER|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
219298438|NCT06081504|OTHER|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
219298439|NCT06081504|OTHER|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
219298440|NCT06081504|OTHER|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
219298441|NCT05466409|OTHER|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
219298442|NCT05466409|OTHER|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
219298443|NCT05466409|OTHER|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
219298444|NCT05466409|OTHER|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
219298445|NCT05466409|OTHER|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
219354983|NCT01515774|DRUG|Mirapex ER|Change Requip or Mirapex to Mirapex ER
219298446|NCT05466409|OTHER|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
219298447|NCT05466409|OTHER|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
219298448|NCT05466409|OTHER|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
219298449|NCT05466409|OTHER|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
219298450|NCT05466409|OTHER|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
219298451|NCT00975767|DRUG|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
219298452|NCT00975767|DRUG|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
219298453|NCT02163564|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
219298454|NCT01778257|DIETARY_SUPPLEMENT|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
219298455|NCT01778257|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Mate extracts.
219298456|NCT00316628|BIOLOGICAL|influenza vaccine|
219298457|NCT04844645|OTHER|mini program|To design, construct, and test the mini program in patients managing cancer pain
219298458|NCT04844645|OTHER|conventional pharmaceutical care|conventional pharmaceutical care
219298459|NCT01004848|BEHAVIORAL|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
219298460|NCT01639560|DRUG|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
219298461|NCT01639560|DRUG|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
219298462|NCT00833768|DRUG|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
219298463|NCT00833768|DRUG|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
219298464|NCT01160289|DRUG|LY2452473|Administered orally, once daily for 12 weeks
219298465|NCT01160289|DRUG|tadalafil|Administered orally, once daily for 12 weeks
219298466|NCT01160289|DRUG|placebo (tadalafil)|Administered orally, once daily for 12 weeks
219298467|NCT01160289|DRUG|placebo (LY2452473)|Administered orally, once daily for 12 weeks
219298468|NCT05696587|OTHER|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~* Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~* Mechanical desensitization;~* Transcutaneous electric nerve stimulation (TENS) electrotherapy;~* Aquatherapy (arm or leg whirlpool bath of the affected extremity);~* Graded Motor Imagery, including the Recognise™ app and mirror therapy;~* Psychoeducation on relaxation and coping with chronic pain."
219298469|NCT01467882|DRUG|Triptorelin|Powder and solution for solution for injection
219298470|NCT04875559|OTHER|Standardised multimodal pain treatment regimen|"Preoperatively:~* Paracetamol 1000 mg p.o.~* Celecoxib 400 mg p.o.~* Dexamethasone 12 mg p.o.~Perioperatively:~* Ondansetron 4 mg IV~* Bupivacaine 2.5 mg/mL, 20 mL LIA~* Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~* Paracetamol 1000 mg p.o. every 6h PRN~* Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~* Oxycodone 5 mg IV or 10 mg p.o. PRN~* Ondansetron 4 mg IV or p.o. PRN"
219298471|NCT03712059|DIAGNOSTIC_TEST|FIT test and colonoscopy|All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
219298472|NCT03712059|DIAGNOSTIC_TEST|Polypectomy and biopsy|All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
219298473|NCT03712059|DIAGNOSTIC_TEST|Classification|Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
219298474|NCT03724773|DEVICE|Long-Arm Cast|A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.
219298475|NCT03724773|DEVICE|Sugar-Tong Splint|A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
219298476|NCT01156792|DRUG|FP 100|FP 100mcg BID
219298477|NCT01156792|DRUG|GSK2190915 100|GSK2190915 100mg QD (AM)
219298478|NCT01156792|DRUG|GSK2190915 300|GSK2190915 300mg QD (AM)
219298479|NCT01156792|DRUG|montelukast|montelukast 10mg QD (PM)
219298480|NCT01156792|DRUG|placebo|placebo BID
219298481|NCT01156792|DRUG|FP/SAL 100/50|FP/SAL 100/50mcg BID
219298482|NCT02487732|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
219298483|NCT02487732|DRUG|Prasugrel|Prasugrel 10mg once daily for 5 weeks
219298484|NCT01474434|DRUG|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
219298485|NCT01474434|DRUG|Placebo|matching placebo tablets
219298486|NCT03312283|DRUG|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
219298487|NCT03312283|DRUG|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
219298488|NCT03711331|OTHER|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
219298489|NCT03711331|OTHER|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
219298490|NCT00057629|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
219298491|NCT00057629|BEHAVIORAL|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
219298492|NCT00057629|BEHAVIORAL|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
219298493|NCT01045343|OTHER|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
219298494|NCT01045343|OTHER|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
219298495|NCT02871531|PROCEDURE|Pneumatic retinopexy|
219298496|NCT02871531|PROCEDURE|Vitrectomy|
219298497|NCT02289573|DEVICE|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
219298498|NCT00901706|OTHER|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
219298499|NCT00901706|OTHER|APS usual care|APS usual care consists of social, medical, and legal assistance.
219298500|NCT04859569|DRUG|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
219298501|NCT04859569|DRUG|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
219298502|NCT02483000|BIOLOGICAL|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
219298503|NCT02483000|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
219298504|NCT02483000|DRUG|Carmustine|Given IV
219298505|NCT02483000|DRUG|Clearing Agent|Given IV
219298506|NCT02483000|DRUG|Cytarabine|Given IV
219298507|NCT02483000|DRUG|Etoposide|Given IV
219298508|NCT02483000|RADIATION|Indium In 111-DOTA-Biotin|Given IV
219298509|NCT02483000|OTHER|Laboratory Biomarker Analysis|Correlative studies
219298510|NCT02483000|DRUG|Melphalan|Given IV
219298511|NCT02483000|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
219298512|NCT02483000|OTHER|Pharmacological Study|Correlative studies
219298513|NCT02483000|RADIATION|Yttrium Y 90-DOTA-Biotin|Given IV
219298514|NCT03403218|BEHAVIORAL|Case group|assessment of quality on posture, transfers and displacement
219298515|NCT04579822|BIOLOGICAL|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
219298516|NCT03753659|DRUG|Pembrolizumab|IV infusion
219298517|NCT03753659|PROCEDURE|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
219298518|NCT03753659|PROCEDURE|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
219298519|NCT03753659|RADIATION|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
219298520|NCT03753659|DRUG|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
219298521|NCT00993668|OTHER|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
219298522|NCT00993668|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
219298523|NCT06196632|DRUG|Peginterferon-α; Nucleoside analogs|Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
219298524|NCT04894760|DIAGNOSTIC_TEST|Rapid Antigen Test (PanBio Ag test)|Rapid Antigen Test (PanBio Ag test)
219298525|NCT00208780|DRUG|Tetrahydrobiopterin|
219298526|NCT00208780|DRUG|Tetrahydrobiopterin|
219298527|NCT04955444|OTHER|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
219298528|NCT00999674|OTHER|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
219298529|NCT06526013|OTHER|Cholesterol self-measurement|Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
219298530|NCT02351518|OTHER|No intervention|There will be no interventions in this study
219298531|NCT02136160|BEHAVIORAL|attitude change, behavioral change|
219298532|NCT02136160|BEHAVIORAL|prevention program|
219298533|NCT03606668|DEVICE|HTC Vive Virtual Reality (VR) system|VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
219298534|NCT00952120|DEVICE|GSUC|Gauze-based wall suction negative pressure wound therapy
219298535|NCT00952120|DEVICE|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
219298536|NCT01639781|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
219298537|NCT01639781|DIETARY_SUPPLEMENT|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
219298538|NCT01452321|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
219298539|NCT00160043|DRUG|SH T00268C|1250 mg experimental drug od
219298540|NCT00160043|DRUG|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
219298541|NCT06261580|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, and FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
219298542|NCT06261580|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
219298543|NCT03710031|OTHER|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
219298544|NCT02238353|DRUG|azelastine + fluticasone|
219298545|NCT02238353|DRUG|Placebo|
219298546|NCT01944813|BEHAVIORAL|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
219298547|NCT00080132|DRUG|implitapide|
219298548|NCT01770106|DRUG|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
219298549|NCT01770106|DRUG|Alendronate|Alendronate 70mg once weekly
219298550|NCT00730457|BIOLOGICAL|VAX125|Single intramuscular dose
219298551|NCT04641494|DIETARY_SUPPLEMENT|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
219298552|NCT04641494|DIETARY_SUPPLEMENT|High oleic acid safflower oil capsules|
219298553|NCT02677454|DEVICE|Flash Glucose Monitor|
219298554|NCT04227964|DEVICE|Enamel matrix derivative, bone replacement graft, barrier membrane|
219298555|NCT04227964|PROCEDURE|Tooth extraction and replacement|
219298556|NCT02541123|OTHER|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
219298557|NCT03422523|DRUG|Atezolizumab|Intravenous drip
219298558|NCT03422523|DRUG|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
219298559|NCT03422523|DRUG|Gemcitabine 1000 mg|intravenous drip
219298560|NCT03422523|DRUG|Oxaliplatin 100 MG|intravenous drip
219298561|NCT04943367|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
219298562|NCT00470340|DRUG|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
219298563|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
219298564|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
219298565|NCT01444573|DEVICE|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
219298566|NCT00002448|DRUG|Ritonavir|
219298567|NCT00002448|DRUG|Efavirenz|
219298568|NCT00002448|DRUG|Saquinavir|
219298569|NCT02426346|BEHAVIORAL|Behavioral weight control|Prescription of diet \& physical activity and behavioral strategies for weight control
219298570|NCT02426346|BEHAVIORAL|Group-based physical activity|Teens exercise for 60 minutes with their group
219298571|NCT02426346|BEHAVIORAL|Group-based incentives|Adolescents earn reinforcements within group
219298572|NCT02426346|BEHAVIORAL|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
219298573|NCT03660800|DRUG|CTAP101 Capsules|Calcifediol Extended-Release Capsules
219298574|NCT01942265|DRUG|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
219298575|NCT01942265|DRUG|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
219298576|NCT01942265|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
219298577|NCT02057523|DRUG|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
219298578|NCT03098420|DRUG|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
219298579|NCT03098420|DRUG|4mg Dexamethasone|1 mL (4mg) of dexamethasone
219298580|NCT03098420|DRUG|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
219298581|NCT03098420|DRUG|Morphine|
219298582|NCT03098420|DRUG|Bupivacaine Hydrochloride|
219298583|NCT03098420|DRUG|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
219298584|NCT03098420|DRUG|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
219298585|NCT05253677|DEVICE|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
219298586|NCT05253677|DEVICE|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
219298587|NCT04355910|BEHAVIORAL|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
219298588|NCT02835833|DRUG|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
219298589|NCT02835833|DRUG|Bevacizumab|Bevacizumab will be given at 15 mg/kg
219298590|NCT05621603|BEHAVIORAL|Training|"The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session"
219298591|NCT06378489|DRUG|Etonogestrel implant|The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management
219298592|NCT00558337|DRUG|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
219298593|NCT06301282|BEHAVIORAL|assessment during the transition between OFF-levodopa (i.e. withdrawal of levodopa phase) and ON-levodopa (i.e. effect of Levodopa phase)states|Electroencephalographic measurements are taken during both motor and non-motor assessments while the transition between the OFF-levodopa and ON-levodopa states occurs
219298594|NCT03618823|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219298595|NCT03618823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219298596|NCT03618823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
219298597|NCT00454389|DEVICE|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
219298598|NCT00454389|DRUG|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
219298599|NCT01319214|DRUG|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
219298600|NCT01498159|BEHAVIORAL|Pharmacist disease/medication management|
219298601|NCT01498159|BEHAVIORAL|Pharmacist-patient encounters|
219298602|NCT01498159|BEHAVIORAL|Pharmacist medication intensification and adherence support|
219298603|NCT01498159|BEHAVIORAL|Pharmacist communication with primary care physicians|
219298604|NCT01498159|BEHAVIORAL|Pharmacist documentation in electronic medical record|
219298605|NCT01498159|BEHAVIORAL|Health promoter-patient encounters in-person or by phone|
219298606|NCT01498159|BEHAVIORAL|Health promoter medication and lifestyle support|
219298607|NCT01498159|BEHAVIORAL|Health promoter communication with pharmacists|
219298608|NCT00523640|DRUG|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
219298609|NCT00670345|DRUG|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
219298610|NCT00670345|DRUG|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
219298611|NCT02218294|DRUG|BCX4161|
219298612|NCT01506609|DRUG|Placebo|
219298613|NCT01506609|DRUG|Veliparib|
219298614|NCT01506609|DRUG|Carboplatin|
219298615|NCT01506609|DRUG|Temozolomide|
219298616|NCT01506609|DRUG|Paclitaxel|
219298617|NCT05128461|OTHER|Exercise|M-CIMT-based telerehabilitation will be implemented.
219298618|NCT05128461|OTHER|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
219298619|NCT05253820|PROCEDURE|distal radial approach|coronary diagnosis and intervention via distal vs conventional radial approach
219298620|NCT05253820|PROCEDURE|conventional radial access|conventional radial access
219298621|NCT00950794|DRUG|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
219298622|NCT00950794|DRUG|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
219298623|NCT05413109|RADIATION|Coronary CT angiography|"A coronary CT angiography will be used to study the relationship between the PA and the LMCA and 4 radiological patterns will be considered:~1. Normal: minimum distance between the two vessels\> 1 mm;~2. Proximity: distance between the two vessels ≤1 mm without displacement or stenosis of the LMCA;~3. Dislocation: dislocation of the LMCA by the main branch of the PA with a take-off angle \<60 ° (the take-off angle is defined by the angle formed by the perpendicular to the aortic valve ring and the longitudinal axis of the LMCA);~4. Compression: stenosis of the LMCA ≥50% due to extrinsic compression by the PA."
219298624|NCT02276183|DIETARY_SUPPLEMENT|Nutrition intervention, test formula|
219298625|NCT02276183|BEHAVIORAL|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
219298626|NCT04418570|BEHAVIORAL|cognitive remediation|
219298627|NCT04418570|OTHER|attendance to an Early Intervention Service for Psychosis|
219298628|NCT00002996|DRUG|flecainide acetate|
219298629|NCT05252650|BEHAVIORAL|pain|postoperative pain
219298630|NCT05352568|BEHAVIORAL|Cognitive Training|Computer-Based Cognitive Training from BrainHQ (Posit Science)
219298631|NCT02395029|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
219298632|NCT00457652|DRUG|Rosuvastatin|7 day treatment rosuvastatin 20mg
219298633|NCT05842239|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
219298634|NCT02090036|DRUG|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
219298635|NCT02090036|DRUG|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
219298636|NCT03302078|DRUG|BI 1015550|Fed state
219298637|NCT03302078|DRUG|BI 1015550|Fasted state
219298638|NCT02971761|DRUG|Enobosarm|Given PO
219298639|NCT02971761|OTHER|Laboratory Biomarker Analysis|Correlative studies
219298640|NCT02971761|BIOLOGICAL|Pembrolizumab|Given IV
219298641|NCT01462123|OTHER|endoscopic assessment of colonic polyps|
219298642|NCT03677765|PROCEDURE|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
219298643|NCT00379028|DRUG|Budesonide/Formoterol Turbuhaler|
219298644|NCT00379028|DRUG|Salmeterol/Fluticasone Diskus|
219298645|NCT06507995|DRUG|thoracic interlaminar epidural injection|. Injections were administered under sedation and sterile conditions, with all patients positioned prone and monitored. A single physician performed all injections using an 18 gauge Tuohy needle, employing the loss of resistance technique and confirming the epidural space placement with 5 mL of nonionic contrast.
219298646|NCT01757444|DEVICE|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
219298647|NCT01757444|DEVICE|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
219298648|NCT00492102|DRUG|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing \>1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
219298649|NCT05786105|OTHER|Bone Marrow samples collection|Bone Marrow samples collection - one ethylenediaminetetraacetic acid (EDTA) tube - for Optical Genome Mapping
219298650|NCT04051736|BIOLOGICAL|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
219298651|NCT04328116|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
219298652|NCT03515343|DIAGNOSTIC_TEST|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
219298653|NCT01566253|DRUG|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
219298654|NCT01566253|DRUG|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
219298655|NCT04673253|OTHER|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
219298656|NCT04673253|OTHER|control|The controlled group was positioned in the normal supine position.
219298657|NCT04315259|DEVICE|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
219298658|NCT01857128|DEVICE|Drawtex dressing|
219298659|NCT01857128|DEVICE|Negative Pressure Wound Therapy|
219298660|NCT01795482|DEVICE|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
219298661|NCT02884895|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
219298662|NCT02884895|DEVICE|Direct Laryngoscopy|Direct Laryngoscopy
219298663|NCT00989534|BEHAVIORAL|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
219298664|NCT00989534|BEHAVIORAL|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
219298665|NCT01960777|PROCEDURE|Onstep|
219298666|NCT01960777|PROCEDURE|Laparoscopic repair|
219298667|NCT02424734|DRUG|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
219298668|NCT02424734|DRUG|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
219298669|NCT02424734|DRUG|Aminoglycoside|Optional, will be given as per local standard of care.
219298670|NCT00223873|PROCEDURE|Penile Vibratory Stimulation|
219298671|NCT01240473|DRUG|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
219298672|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
219298673|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
219298674|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
219298675|NCT00313131|DRUG|tinidazole+fluconazole vs metronidazole+clotrimazole|
219298676|NCT04600154|DRUG|MS-20|Specific fraction from fermented soy milk
219298677|NCT04600154|OTHER|Placebo|Fermented soy milk without active component
219298678|NCT01460173|OTHER|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
219298679|NCT01058031|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
219298680|NCT02627170|DEVICE|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
219298681|NCT02641860|BIOLOGICAL|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
219298682|NCT01642251|DRUG|Cisplatin|Given IV
219298683|NCT01642251|DRUG|Etoposide|Given IV
219298684|NCT01642251|DRUG|Veliparib|Given PO
219298685|NCT01642251|DRUG|Placebo|placebo of Veliparib
219298686|NCT04431700|OTHER|Anti-inflammatory diet|Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.
219298687|NCT04431700|OTHER|Regular diet|Focus on food journal and recording all food intake.
219298688|NCT01578200|DRUG|Lanthanum Carbonate|
219298689|NCT01578200|DRUG|Calcium Carbonate|
219298690|NCT04054700|DEVICE|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
219298691|NCT04054700|DEVICE|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
219298692|NCT01445301|DRUG|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
219298693|NCT01445301|DRUG|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
219298694|NCT02614417|OTHER|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
219298695|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
219298696|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
219298697|NCT00752557|DRUG|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
219298698|NCT02881905|DEVICE|ball attachment|it is attachment part that connects the overdenture to the implant
219298699|NCT02881905|DEVICE|cm loc attachment|It is a new attachment made of peek material
219298700|NCT06226740|OTHER|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
219298701|NCT05372952|DEVICE|Dynetic-35 Peripheral Balloon-Expandable Stent System|Stenotic iliac lesions will be treated with the Dynetic 35 stent via a radial access
219298702|NCT03755375|DEVICE|TENS|transcutaneous electrostimulation to improve the pain.
219298703|NCT03755375|BEHAVIORAL|Postural exercises|breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position
219298704|NCT03755375|DEVICE|Biofeedback|pelvic floor muscle coordination and relaxation exercises using intravaginal probes
219298705|NCT03755375|BEHAVIORAL|Manual therapy|myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
219298706|NCT02141451|DRUG|Rituximab|Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
219298707|NCT02141451|DRUG|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
219298708|NCT04223817|DEVICE|7.0 T RMI|Single 7.0 Tesla MRI of both hands in the same time
219298709|NCT05083000|DRUG|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
219298710|NCT05571371|OTHER|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
219298711|NCT05644860|COMBINATION_PRODUCT|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
219298712|NCT05644860|COMBINATION_PRODUCT|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
219298713|NCT06093776|DEVICE|ioveraº system|the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold
219298714|NCT03575988|OTHER|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
219298715|NCT04441060|OTHER|Distress intervention (CBT & Mindfulness-based program)|Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
219298716|NCT02262091|DIETARY_SUPPLEMENT|Food fibers|
219298717|NCT02262091|DIETARY_SUPPLEMENT|Maltodextrin|
219298718|NCT02262091|BIOLOGICAL|Influenza vaccine (incl. criterion)|
219298719|NCT02166294|OTHER|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
219298720|NCT02166294|PROCEDURE|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
219298721|NCT01587391|DRUG|Placebo to BI 163538 XX|1 single dose per subject as oral solution
219298722|NCT01587391|DRUG|BI 163538 XX|1 single dose per subject as oral solution
219298723|NCT05012501|DIAGNOSTIC_TEST|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
219298724|NCT01605916|DRUG|AZD6244|Tablet Oral bid
219298725|NCT03744104|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
219298726|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
219298727|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
219298728|NCT02073747|DRUG|Normal Saline|One hour inhaled normal saline
219298729|NCT02073747|DRUG|Albuterol|One hour inhaled ten milligrams of albuterol
219298730|NCT05064683|OTHER|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
219298731|NCT05849831|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
219298732|NCT03983603|DIETARY_SUPPLEMENT|Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)|Soft chews containing 0.5g plant stanols delivered as plant stanol esters
219298733|NCT03983603|DIETARY_SUPPLEMENT|Placebo soft chew|Soft chew that does not contain plant stanols
219298734|NCT03594201|OTHER|semen pretreatment|semen pretreatment
219298735|NCT05766085|DIAGNOSTIC_TEST|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
219298736|NCT06171581|OTHER|stress ball|In the study, the experimental group was given a round, compressible ball for stress ball application and it was planned to squeeze this ball in their hands as often as they wanted during anaesthesia and endometrial biopsy application. The endometrial biopsy procedure is a procedure that usually takes between 8-10 minutes. The results will be evaluated considering these average times. As it is foreseen that individuals may experience the most intense anxiety and stress during anaesthesia and biopsy, it was preferred to cover this time period.
219298737|NCT06171581|OTHER|control|In the study, the no intervention group ( control group) will receive no intervention and blood pressure and stress measurements will be made with routine care and nursing interventions.
219298738|NCT06520254|OTHER|Massage therapy|"A 30-minute massage session will be applied in the following structures:~* Flexor hallucis longus muscle,~* Flexor digitorum longus muscle,~* Tibialis posterior muscle,~* Semitendinosus muscle,~* Semimembranosus muscle,~* Gluteus maximus muscle,~* Longissimus muscle,~* Levator costarum muscles 1-5 During the massage session basic Swedish massage techniques were used."
219298739|NCT06275139|OTHER|Integrated Assessment of Cervicocerebral Vessels|Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.
219298740|NCT05515380|OTHER|8-stage model based exercise program|The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.
219298741|NCT05515380|OTHER|Conventional exercise program|The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
219298742|NCT01984073|DRUG|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
219298743|NCT01984073|DRUG|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
219298744|NCT01984073|OTHER|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
219298745|NCT00470366|BIOLOGICAL|pegfilgrastim|
219298746|NCT00470366|DRUG|cisplatin|
219298747|NCT00470366|DRUG|ifosfamide|
219298748|NCT00470366|DRUG|paclitaxel|
219298749|NCT03639467|DRUG|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
219298750|NCT00602563|BEHAVIORAL|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
219298751|NCT00602563|BEHAVIORAL|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
219298752|NCT00602563|BEHAVIORAL|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
219354984|NCT01847885|DEVICE|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
219354985|NCT04397705|DEVICE|Patient Status Engine|Wearable sensors
219354986|NCT04743947|OTHER|No intervention; observational study|no intervention
219298753|NCT00602563|BEHAVIORAL|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
219298754|NCT06193304|DRUG|Eliglustat|Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
219298755|NCT04100577|OTHER|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
219298756|NCT02996474|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
219298757|NCT02996474|DRUG|Decitabine|Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
219298758|NCT04493502|DRUG|Placebo|Administered IV
219298759|NCT04493502|DRUG|LY3041658|Administered IV
219298760|NCT04277182|BIOLOGICAL|burn wound dressing|"1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."
219298761|NCT02379104|DEVICE|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
219298762|NCT00377923|DRUG|Progesterone|
219298763|NCT00540046|DEVICE|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
219298764|NCT01269515|DRUG|Etoricoxib|90 mg QD
219298765|NCT05310851|OTHER|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
219298766|NCT02108990|DRUG|Acetaminophen|
219298767|NCT02598024|BEHAVIORAL|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
219298768|NCT02598024|BEHAVIORAL|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
219298769|NCT00493298|DRUG|Tysabri|According to the local prescribing information
219298770|NCT02891837|DRUG|L-citrulline|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
219298771|NCT02891837|OTHER|Placebo|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
219744097|NCT03263533|DRUG|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
219744098|NCT06154824|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
219354987|NCT00079859|DRUG|Implitapide|
219744099|NCT06154824|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
219298772|NCT04971278|BEHAVIORAL|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
219298773|NCT04662099|BIOLOGICAL|Conditioning chemotherapy followed by CAR T cell infusion|Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10\^6-3.0X10\^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 3.0X10\^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.
219298774|NCT03037073|DRUG|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
219298775|NCT03037073|DRUG|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
219298776|NCT01588431|DRUG|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
219298777|NCT04881981|RADIATION|SCART radiation therapy|We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
219298778|NCT06470061|DRUG|Resveratrol, Quercetin, and Curcumin (RQC)|"2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)"
219298779|NCT06470061|DRUG|Curcumin|2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
219298780|NCT02632526|DRUG|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
219298781|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
219298782|NCT02632526|DRUG|AZD5718 placebo oral suspension|Single and multiple doses
219298783|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
219298784|NCT06315504|OTHER|Observation|Observation
219298785|NCT01986673|DRUG|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
219298786|NCT01986673|DRUG|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
219298787|NCT04498338|OTHER|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
219298788|NCT04498338|OTHER|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
219298789|NCT04659941|BIOLOGICAL|BCG vaccine|Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.
219298790|NCT04659941|BIOLOGICAL|0.9% sodium chloride (NaCl) saline solution|A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
219298791|NCT02816944|PROCEDURE|EUS-guided laser ablation for refractory neoplasms|
219298792|NCT01976117|DEVICE|enose|
219298793|NCT04318847|DRUG|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
219298794|NCT01994655|OTHER|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
219298795|NCT01994655|OTHER|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
219298796|NCT02120742|BEHAVIORAL|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
219298797|NCT02751320|DRUG|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298798|NCT02751320|DRUG|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298799|NCT02751320|DRUG|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298800|NCT02751320|OTHER|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298801|NCT02751320|DRUG|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298802|NCT02751320|DRUG|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
219298803|NCT01021215|DRUG|Zileuton|1200 mg twice daily given orally (PO) for 6 days
219298804|NCT01021215|DRUG|Celecoxib|200 mg twice daily given orally for 6 days
219298805|NCT01021215|OTHER|laboratory biomarker analysis|Correlative studies
219298806|NCT04867928|DRUG|Venetoclax+azacitidine|subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
219298807|NCT02549196|DRUG|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
219298808|NCT02549196|DRUG|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
219298809|NCT03860701|PROCEDURE|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
219298810|NCT06375447|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for insomnia.
219298811|NCT00410943|DRUG|OROS Hydromorphone HCI SR (slow release)|
219298812|NCT03096704|DIAGNOSTIC_TEST|vitamine d dosage|dosage of vitamine D in slow transit time constipation
219298813|NCT02679027|OTHER|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
219298814|NCT02679027|OTHER|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
219298815|NCT03505541|BIOLOGICAL|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
219298816|NCT01244854|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
219298817|NCT04579289|OTHER|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~* morbidity and mortality linked with COVID-19~* structural features of the facility (location, architecture, residents characteristics)~* human resources~* crisis management (visits and circulation restrictions, personal protective equipment)"
219298818|NCT00283127|PROCEDURE|Home sampling (urine test) for uro-genital C.trachomatis.|
219298819|NCT06211881|DRUG|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
219298820|NCT03994289|BEHAVIORAL|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
219298821|NCT03994289|BEHAVIORAL|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
219298822|NCT03954392|BEHAVIORAL|Cognitive behavior therapy with social cognitive training (CBT+SCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.
219298823|NCT03954392|BEHAVIORAL|CBT-only|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
219298824|NCT00185965|DRUG|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
219298825|NCT04496492|DRUG|Tocotrienol|Tocotrienol 200 mg orally twice a day
219298826|NCT01010191|OTHER|Sugar pill|
219298827|NCT00254631|DRUG|Oxycodone hydrochloride|
219298828|NCT04611321|DRUG|IBI318|IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
219298829|NCT04132531|PROCEDURE|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
219298830|NCT02533531|DEVICE|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
219298831|NCT00648154|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
219298832|NCT00648154|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fed
219298833|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
219298834|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
219298835|NCT02002793|OTHER|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
219298836|NCT02002793|OTHER|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
219298837|NCT01423721|DRUG|Bromihexine hydrochloride syrup|syrup
219298838|NCT01423721|DRUG|Bromihexine hydrochloride granules|granules
219298839|NCT02032979|BEHAVIORAL|Psychiatric test|
219298840|NCT02567773|DRUG|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
219298841|NCT02567773|DRUG|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
219298842|NCT02567773|DRUG|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
219298843|NCT02195154|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
219298844|NCT02047903|DRUG|Afatinib|50, 40, 30 or 20 mg
219298845|NCT00376831|DRUG|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
219298846|NCT00376831|DRUG|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
219298847|NCT00057174|DRUG|Disease management of gastroesophageal reflux disease|
219298848|NCT01014533|DRUG|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
219298849|NCT01014533|DRUG|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
219298850|NCT02810574|BEHAVIORAL|Cognitive training|
219298851|NCT02810574|DEVICE|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
219298852|NCT02810574|DEVICE|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
219298853|NCT02588300|PROCEDURE|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
219298854|NCT03496831|DRUG|Biologic Agents|
219298855|NCT05769647|DEVICE|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
219298856|NCT05769647|DEVICE|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
219298857|NCT00559611|PROCEDURE|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
219298858|NCT00559611|PROCEDURE|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
219298859|NCT03901482|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
219298860|NCT03901482|DRUG|Placebos|Placebo for STS101
219298861|NCT00543374|DRUG|Placebo|Placebo
219298862|NCT00543374|DRUG|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
219298863|NCT02097082|DEVICE|STANZA Drug-eluting resorbable Scaffold|
219298864|NCT01140711|PROCEDURE|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
219298865|NCT01321320|OTHER|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
219298866|NCT00669682|OTHER|Congestive heart failure|Spontaneous occurrence of fluid overload.
219298867|NCT04157374|OTHER|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
219298868|NCT04157374|OTHER|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
219298869|NCT00312923|DRUG|Policosanol|20 mg of policosanol in capsular form daily
219298870|NCT00312923|DIETARY_SUPPLEMENT|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
219298871|NCT01011387|PROCEDURE|NPWT System|Dressing change 3 times per week
219298872|NCT01011387|DEVICE|NPWT system|3 dressing changes/week for maximum 4 weeks.
219298873|NCT00653666|OTHER|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is \< 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
219298874|NCT02880384|OTHER|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
219298875|NCT04307420|PROCEDURE|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
219298876|NCT04307420|PROCEDURE|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
219298877|NCT02518789|DRUG|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
219298878|NCT02518789|DRUG|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
219298879|NCT02518789|DRUG|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
219298880|NCT02518789|DRUG|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate."
219298881|NCT02518789|DRUG|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg
219298882|NCT02518789|DRUG|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
219298883|NCT02708914|BIOLOGICAL|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
219298884|NCT02708914|BIOLOGICAL|Eprex|Eprex® is chosen as the comparator.
219298885|NCT06327932|PROCEDURE|TURBT|Transurethral Resection of Bladder Tumors
219298886|NCT06327932|PROCEDURE|HIVEC|Hyperthermic Intravesical Chemotherapy with Gemcitabine (3g/150ml NS) at 45 °C for 60 minutes. Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
219298887|NCT06327932|PROCEDURE|Intravesical Chemotherapy|Intravesical Chemotherapy with Gemcitabine (3g/150ml NS). Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
219298888|NCT06327932|DRUG|Gemcitabine|Gemcitabine (3g/150ml NS).
219298889|NCT01097382|DRUG|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
219298890|NCT06414187|DEVICE|Intra-Aortic Balloon Pump|Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
219298891|NCT01022060|DIETARY_SUPPLEMENT|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
219298892|NCT01022060|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
219298893|NCT01182467|RADIATION|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
219354988|NCT04123899|DRUG|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
219298894|NCT04557943|DRUG|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
219298895|NCT04557943|DRUG|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
219298896|NCT02794753|BEHAVIORAL|Working memory training|
219298897|NCT02794753|BEHAVIORAL|Game|
219298898|NCT01422421|OTHER|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
219298899|NCT01422421|OTHER|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
219298900|NCT03655821|DRUG|Pemetrexed|Dosing is either based on BSA or renal function
219298901|NCT02433340|DRUG|ABT-122|
219298902|NCT00622258|DRUG|Everolmus|
219298903|NCT00386139|DRUG|Aliskiren/HCTZ|
219298904|NCT04428372|DRUG|Mannitol|Hypertonic mannitol infusion
219298905|NCT04428372|DRUG|0.9% saline|Normal saline 'placebo' arm
219298906|NCT00000731|DRUG|Zidovudine|
219298907|NCT00000731|DRUG|Acetaminophen|
219298908|NCT04182945|OTHER|Data collection for algorithm development|50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
219298909|NCT03971630|OTHER|Telemedicine|Patients will be followed up using the MyVENT System and APP
219298910|NCT00806572|DRUG|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
219298911|NCT02291081|OTHER|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~* Anamnesis with the participants~* File recherche,Physical examination~* Documentation of the cardiovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Exercise Montreal Cognitive Assessment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
219298912|NCT05285930|COMBINATION_PRODUCT|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
219298913|NCT05285930|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
219298914|NCT02325427|DEVICE|tDCS|tDCS could deliver either real or sham stimulation.
219298915|NCT00611429|BEHAVIORAL|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
219298916|NCT00611429|BEHAVIORAL|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
219298917|NCT02501915|DEVICE|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
219298918|NCT02810548|PROCEDURE|OFD alone|Periodontal surgical cleaning procedure
219298919|NCT02810548|DRUG|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
219298920|NCT02810548|DRUG|Nanohydroxyapatite|Synthetic bone graft
219744100|NCT04684862|DEVICE|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
219744101|NCT04876287|DRUG|Radioiodine|cancer therapy
219744102|NCT04744103|DRUG|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
219744103|NCT04580550|OTHER|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
219298921|NCT02516475|DIETARY_SUPPLEMENT|zinc sulfate|1 zinc sulfate capsule for 15 weeks
219298922|NCT02516475|OTHER|corn starch|1 corn starch capsule for 15 weeks
219298923|NCT00058760|BEHAVIORAL|NIA intervention (after school health promotion didactic program)|
219298924|NCT03802084|DRUG|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
219298925|NCT03868072|DRUG|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
219298926|NCT03868072|DRUG|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
219298927|NCT03774485|DEVICE|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
219298928|NCT05639660|OTHER|non-interventional|The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
219298929|NCT02039453|DRUG|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
219298930|NCT02039453|DRUG|pethidine dose|pethidine dose 50mg, IV bolus (25mg if \< 50kg or \>70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
219298931|NCT06112561|DEVICE|CO/CI/SVR|fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
219298932|NCT02238665|DEVICE|Endomicroscopy|
219298933|NCT00485901|DRUG|Olanzapine Hydrochloride|
219298934|NCT00485901|DRUG|Haloperidol|
219298935|NCT04822597|DRUG|Lidocaine patch|Lidocaine is a local anesthetic.
219298936|NCT04822597|DEVICE|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
219298937|NCT04822597|OTHER|Ice pack|Ice cools the skin and can provide some numbing for pain.
219298938|NCT00209716|DRUG|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
219298939|NCT00209716|DRUG|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.
219298940|NCT00209716|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.
219298941|NCT06181565|OTHER|Datas of Medistim machine|Datas will be collected by Medistim machine before and after pericardial closure: Flow through the grafts, Resistance on grafts, Pulsatility of the grafts, Systolic and diastolic curves before and after pericardial closure
219298942|NCT00015041|DRUG|Buprenorphine|
219298943|NCT06074029|DRUG|Immune Checkpoint Inhibitors|Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
219298944|NCT02279225|RADIATION|Group Phototherapy|
219298945|NCT02279225|RADIATION|Phototherapy + Physical activity|
219298946|NCT02279225|OTHER|Physical activity|
219298947|NCT02279225|OTHER|Placebo|
219298948|NCT00100581|DRUG|Efavirenz|
219298949|NCT00100581|DRUG|Lamivudine|
219298950|NCT00100581|DRUG|Lopinavir/ritonavir|
219298951|NCT00100581|DRUG|Pegylated interferon alfa-2a|
219298952|NCT00100581|DRUG|Ribavirin|
219298953|NCT00100581|DRUG|Tenofovir disoproxil fumarate|
219298954|NCT00414245|DRUG|metformin|
219298955|NCT05354180|OTHER|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
219298956|NCT05354180|OTHER|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
219298957|NCT05354180|OTHER|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
219298958|NCT01645293|GENETIC|Genetically modified T cells # 1138|
219298959|NCT00349674|DRUG|Azathioprine: 2 mg/kg/day|
219298960|NCT00349674|DRUG|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
219298961|NCT00939666|PROCEDURE|Wait&see or TEM with intensive follow-up|Wait\&see or TEM with intensive follow-up
219298962|NCT03800615|PROCEDURE|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
219298963|NCT06425874|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery
219298964|NCT06425874|PROCEDURE|Mastectomy|Mastectomy without reconstruction
219298965|NCT06425874|PROCEDURE|Mastectomy with reconstruction|Any type of reconstruction(include implant and autologous)
219298966|NCT01892826|DRUG|hCG|5000IU
219298967|NCT00225966|DEVICE|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
219298968|NCT04708925|OTHER|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
219298969|NCT03265938|DEVICE|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
219298970|NCT01543529|DRUG|RO4917838|Single dose of RO4917838
219298971|NCT01543529|DRUG|Placebo to RO4917838|Single dose of placebo to RO4917838
219298972|NCT01543529|OTHER|Alcohol|Standard alcoholic drink
219298973|NCT02202382|DRUG|Korean Red Ginseng, Varicocelectomy|
219298974|NCT02202382|DRUG|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
219298975|NCT02202382|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
219298976|NCT00002570|DRUG|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
219298977|NCT00002570|DRUG|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
219298978|NCT05598671|PROCEDURE|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
219298979|NCT02617849|DRUG|Pembrolizumab|200 mg IV every 3 weeks
219298980|NCT02617849|DRUG|Carboplatin|AUC=6, every 3 weeks x 4
219298981|NCT02617849|DRUG|Paclitaxel|175 mg/m2, every 3 weeks x 4
219298982|NCT02679508|DRUG|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
219298983|NCT02679508|DRUG|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
219298984|NCT01285271|DRUG|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
219298985|NCT01285271|DRUG|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
219298986|NCT01513980|PROCEDURE|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
219298987|NCT01513980|PROCEDURE|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
219298988|NCT03143166|DRUG|Dabigatran Etexilate|Tablet, film coated
219298989|NCT03143166|DRUG|Rabeprazol sodium|Tablet
219298990|NCT01906970|DEVICE|ClampArt|
219298991|NCT00002197|DRUG|Abacavir sulfate|
219298992|NCT04360486|BIOLOGICAL|Anti-Sars-CoV-2 Convalescent Plasma|Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
219298993|NCT01702272|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
219298994|NCT04842370|DRUG|PHI-101|PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
219298995|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
219298996|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
219298997|NCT06262074|OTHER|Structured Exercise Program|30 minutes of structured exercise programs
219298998|NCT06262074|OTHER|Non structured exercise program|Non structured exercises
219298999|NCT06248970|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
219299000|NCT06248970|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
219299001|NCT06248970|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
219299002|NCT03499145|DEVICE|Ophthalmology diagnostic system.|An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
219299003|NCT06127823|BEHAVIORAL|Dietary treatment|Dietary counselling
219299004|NCT01173497|DRUG|INIPARIB + irinotecan|21 day cycle
219299005|NCT03638973|PROCEDURE|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
219299006|NCT02167737|BEHAVIORAL|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
219299007|NCT02167737|BEHAVIORAL|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
219299008|NCT01116102|DRUG|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
219299009|NCT04687280|OTHER|non interventional|non interventional, study on data
219299010|NCT03906422|DEVICE|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
219299011|NCT03906422|DEVICE|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
219299012|NCT03906422|DEVICE|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
219299013|NCT05000931|DEVICE|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
219299014|NCT04168528|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
219299015|NCT00925132|DRUG|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
219299016|NCT06458413|DRUG|Utidelone Capsule Plus Capecitabine|"Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle ."
219299017|NCT05987202|OTHER|DA closure in a population of premature infants|Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
219299018|NCT04638634|BIOLOGICAL|CSL760|An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
219299019|NCT06654102|OTHER|Deep UVA Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 1 and 2 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
219299020|NCT06654102|OTHER|Deep UVA+HEV Blue Light Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 3 and 4 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
219299021|NCT06247059|DEVICE|Box Fan|Classrooms assigned to this arm will be equipped with 2 - 8 box fans each with a single minimum efficiency reporting value-14 (MERV-14) filter sufficient to increase effective air changes per hour to 12 based on the clean air delivery rate measured in cubic feet per minute of the box fan + filter \* 60 divided by the room volume.
219299022|NCT06247059|DEVICE|UV Germicidal Irradiation Lamp Unit|Classrooms assigned to this arm will be equipped with one or two 222nm wavelength light ultraviolet germicidal irradiation lamp units (number of units per classroom based on room volume).
219299023|NCT06247059|DEVICE|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms assigned to this arm will be equipped with both box fans and UV germicidal irradiation lamp units.
219299024|NCT06609629|PROCEDURE|Selective lung recruitment|A bronchial blocker with a lumen is inserted in one inferior pulmonary lobe using a fibroscope. The baloon of the blocker is expended to isolate the lobe. A second ventilator is used to apply a pressure of 45cmH2o through the lumen of the blocker. The recruiting pressure is maintained 30 to 60 second. After the procedure, the blocker is removed and the procedure is repeated in the controlateral inferior lobe.
219299025|NCT06610331|PROCEDURE|FREE GİNGİVAL GRAFT|Free Gingival Graft removal from the palate donor area for the treatment of gingival recession
219299026|NCT06610331|DEVICE|polyvinylpyrrolidone sodium hyaluronate gel|Patients are told to gargle with a mouthwash containing polyvinyl pyrrolidone sodium hyaluronate twice a day for 2 weeks. 15 ml (1 tablespoon) of mouthwash containing polyvinyl pyrrolidone sodium hyaluronate is poured into a glass and approximately 40 ml (3 tablespoons) of water is added and mixed well, then it is shaken for at least 1 minute, making contact with the entire mouth.
219299027|NCT06729320|BIOLOGICAL|Umbilical cord blood mononuclear cells|Intravenous infusion of UCB-MNCs (3×10\^8/ time, once a week, four times in total)
219299028|NCT06729320|COMBINATION_PRODUCT|Conventional hematopoietic recovery therapy|Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
219299029|NCT06905847|DRUG|HSK39004 in healthy|1.5-12mg
219299030|NCT06905847|DRUG|HSK39004|Placebo
219299031|NCT06905847|DRUG|HSK39004 in COPD|1.5-6mg
219299032|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
219299033|NCT06056544|BEHAVIORAL|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
219299034|NCT04199897|DIETARY_SUPPLEMENT|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
219299035|NCT04199897|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
219299036|NCT04199897|OTHER|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
219299037|NCT04199897|OTHER|Placebo tablets|Placebo lozenges 2 times a day for 35 days
219299038|NCT00593294|BEHAVIORAL|Physical exercise|45 minutes each day for three times/week for 6 months
219299039|NCT00593294|DRUG|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
219299040|NCT00593294|DIETARY_SUPPLEMENT|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
219299041|NCT03605173|DIAGNOSTIC_TEST|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
219299042|NCT03605173|DIAGNOSTIC_TEST|total vitamin d|routinely measured from serum
219299043|NCT01851954|DRUG|Clarithromycin|IV clarithromycin infusion
219299044|NCT02946190|BIOLOGICAL|Pertagen® aP + Td-pur®|see arm/group descriptions
219299045|NCT02946190|BIOLOGICAL|Boostrix® dTpa|see arm/group descriptions
219299046|NCT04694430|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
219299047|NCT04694430|OTHER|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool."
219299048|NCT04694430|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
219299049|NCT02637973|DRUG|Empagliflozin|25 mg once daily
219299050|NCT02637973|DRUG|Placebo|once daily
219299051|NCT01304238|DRUG|lepirudin|lepirudin
219299052|NCT01304238|DRUG|danaparoid|danaparoid
219299053|NCT01304238|DRUG|argatroban|argatroban
219299054|NCT01304238|DRUG|fondaparinux|fondaparinux
219299055|NCT03532087|DRUG|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
219299056|NCT03532087|DRUG|Denosumab 60 mg|Denosumab 60 mg every 6 months.
219299057|NCT05834426|DIAGNOSTIC_TEST|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
219299058|NCT04452968|BEHAVIORAL|intermittent fasting|Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.
219299059|NCT04452968|BEHAVIORAL|Caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
219299060|NCT02851641|PROCEDURE|"pushed mono-canaliculonasal intubation"|
219299061|NCT01621737|DRUG|Oxytocin|42 IU BID for six weeks
219299062|NCT01621737|DRUG|Oxytocin|84 IU BID for six weeks
219299063|NCT01621737|DRUG|Placebo|Vehicle placebo
219299064|NCT06074276|OTHER|Food: whole almonds|60 grams or (\~2 oz) will be consumed 5 times per week.
219299065|NCT06074276|OTHER|Food: non-nut snack|Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
219299066|NCT02112032|DRUG|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
219299067|NCT02112032|DRUG|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
219299068|NCT05610202|DRUG|TQB3702 tablets|TQB3702 tablets are selective BTK inhibitors.
219299069|NCT00477360|DEVICE|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
219299070|NCT06372873|OTHER|re-evaluate by two senior radiologists in our medical center|The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
219299071|NCT02511912|PROCEDURE|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
219299072|NCT03029351|DRUG|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
219299073|NCT03029351|DRUG|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
219299074|NCT04027192|DRUG|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
219299075|NCT04027192|DRUG|BAY2328065 tablet|50 mg tablet, orally
219299076|NCT04027192|DRUG|Placebo LSF|Matching Placebo LSF, orally
219299077|NCT04027192|DRUG|Placebo tablet|Matching Placebo tablet, orally
219299078|NCT04027192|DRUG|Midazolam|1 mg per day, orally
219299079|NCT06334484|DEVICE|Advanced hybrid closed loop systems|Collect data from advanced hybrid closed loop users
219299080|NCT01572103|DIETARY_SUPPLEMENT|Coffee|Administration of 4 cups of coffee per day for 1 month
219299081|NCT01572103|DIETARY_SUPPLEMENT|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
219299082|NCT05420376|PROCEDURE|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
219299083|NCT00491569|DRUG|Sarcosine and D-serine|
219299084|NCT03062579|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
219299085|NCT02892786|OTHER|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
219299086|NCT01092741|DRUG|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
219299087|NCT01034176|DRUG|levofloxacin|500 mg tablet, daily, 30 days
219299088|NCT01034176|DRUG|placebo|no dose, tablet, daily, 30 days
219299089|NCT04362384|DRUG|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
219299090|NCT04362384|DRUG|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
219299091|NCT00715962|BEHAVIORAL|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
219299092|NCT00715962|OTHER|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
219299093|NCT00715962|OTHER|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
219299094|NCT02567747|OTHER|Data collection|Data will be collected retrospectively for cases identified through RIPS\*/ DANE\*\* from 2008 until 2014 and through PAI\*\*\* from 2009 until 2014. \*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. \*\*Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. \*\*\*Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
219299095|NCT04165876|DEVICE|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
219299096|NCT04165876|DEVICE|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
219299097|NCT04165876|DEVICE|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
219299098|NCT04165876|DEVICE|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
219299099|NCT05087979|DEVICE|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
219299100|NCT00698945|DRUG|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
219299101|NCT00698945|DRUG|Alphagan|Alphagan: two drops a day for 28 days
219299102|NCT03207009|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
219299103|NCT04558879|BEHAVIORAL|CT|12 weeks of exercise Cardiovascular Training
219299104|NCT04558879|BEHAVIORAL|RT|12 weeks of exercise Resistance Training
219299105|NCT05074927|DIAGNOSTIC_TEST|diaphragm ultrasonography|For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
219299106|NCT00625248|DRUG|Antithrombotics|With or without or discontinuted use of Antithrombotics
219299107|NCT04026880|DRUG|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
219299108|NCT04026880|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
219299109|NCT00607685|DRUG|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
219299110|NCT00607685|DRUG|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
219299111|NCT04837898|DIETARY_SUPPLEMENT|Haskapa|Haskapa Ltd, Oxford, UK
219299112|NCT04837898|DIETARY_SUPPLEMENT|Placebo|isocaloric to the haskap powder
219299113|NCT03468231|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
219299114|NCT03468231|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
219299115|NCT03468231|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
219299116|NCT02924428|DEVICE|Venus Versa|
219299117|NCT00183001|DRUG|Vitamin K|
219299118|NCT06054282|BEHAVIORAL|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
219299119|NCT01850446|DRUG|Ergoferon|Safety and Efficacy
219299120|NCT01850446|DRUG|Oseltamivir|Safety and Efficacy
219299121|NCT01347801|DRUG|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
219299122|NCT01347801|DRUG|Placebo (Saline)|Normal saline (NaCl 0,9%)
219299123|NCT01347801|DRUG|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
219299124|NCT01347801|OTHER|OGTT|Oral glucose tolerance test with 75 g glucose
219299125|NCT01347801|OTHER|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
219299126|NCT05060978|BEHAVIORAL|Watch your Weight During the Holidays Program|Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
219299127|NCT05060978|OTHER|Relative 5:2 Fasting|Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
219299128|NCT05060978|OTHER|Control Group|Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
219299129|NCT01451125|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
219354989|NCT04123899|DRUG|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
219299130|NCT03820674|OTHER|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
219299131|NCT03820674|OTHER|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
219299132|NCT04499820|DIETARY_SUPPLEMENT|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
219299133|NCT04499820|DIETARY_SUPPLEMENT|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
219299134|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Single dose of theobromine
219299135|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Multiple doses of theobromine
219299136|NCT01544829|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
219299137|NCT00759915|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
219299138|NCT00759915|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
219299139|NCT02272296|DEVICE|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
219299140|NCT02272296|DEVICE|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
219299141|NCT04330885|OTHER|Supervised abdominal exercises and stationary biking|Explain pain to the patients in order to minimize fear of movement
219299142|NCT04314804|COMBINATION_PRODUCT|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
219299143|NCT04314804|COMBINATION_PRODUCT|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
219299144|NCT00897312|BIOLOGICAL|infliximab|
219299145|NCT00897312|BIOLOGICAL|pegylated interferon alfa|
219299146|NCT00897312|BIOLOGICAL|ticilimumab|
219299147|NCT00897312|DRUG|ribavirin|
219299148|NCT00897312|OTHER|high performance liquid chromatography|
219299149|NCT00897312|OTHER|laboratory biomarker analysis|
219299150|NCT04487912|DRUG|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
219299151|NCT04487912|DRUG|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
219299152|NCT04390022|DRUG|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
219299153|NCT04390022|DRUG|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
219299154|NCT03241225|BEHAVIORAL|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
219299155|NCT03241225|BEHAVIORAL|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
219299156|NCT04420715|OTHER|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
219299157|NCT03290209|PROCEDURE|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
219299158|NCT03290209|PROCEDURE|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
219299159|NCT05228041|DRUG|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
219299160|NCT06064175|DRUG|Ibuprofen 400 mg|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
219299161|NCT06064175|DRUG|Ibuprofen 800 mg|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
219299162|NCT03720054|BEHAVIORAL|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
219299163|NCT03720054|BEHAVIORAL|Fitbit|Fitbit Only
219299164|NCT05997368|OTHER|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
219299165|NCT05997368|OTHER|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
219299166|NCT05997368|OTHER|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
219299167|NCT00947739|DRUG|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
219299168|NCT02618915|GENETIC|DTX101|solution for IV infusion
219299169|NCT01864057|DRUG|thiamine hydrochloride 100 mg|
219299170|NCT01635920|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
219299171|NCT01635920|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
219299172|NCT01893125|DRUG|CNV2197944|
219299173|NCT01893125|DRUG|Placebo|
219299174|NCT01738425|DRUG|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
219299175|NCT01738425|DRUG|GIC-1001 matching placebo|"Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]"
219299176|NCT02844426|DRUG|bifid triple viable capsule and pectin|
219299177|NCT02844426|DRUG|maltodextrin|
219299178|NCT04568460|OTHER|Intervention Group Sessions|Participants will undergo a multi-session group intervention over the course of six months.
219299179|NCT05788393|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
219299180|NCT05788393|DRUG|Lidocaine IV|lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
219299181|NCT05674331|PROCEDURE|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
219299182|NCT05674331|DEVICE|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
219299183|NCT05674331|PROCEDURE|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
219299184|NCT04647045|DIETARY_SUPPLEMENT|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
219299185|NCT04644562|OTHER|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
219299186|NCT01556477|DRUG|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
219299187|NCT01556477|DRUG|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
219299188|NCT01470313|DRUG|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
219299189|NCT01470313|DRUG|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
219299190|NCT00007345|DRUG|Romidepsin|
219299191|NCT04217733|DRUG|pentoxyifylline|Pentoxyifylline two times daily for 3 months
219299192|NCT04217733|DRUG|Mebeverine|Mebeverine 3 times for 3 months
219299193|NCT04217733|DRUG|ethosuximide|ethosuximide 3 times for 3 months
219299194|NCT02800577|DEVICE|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
219299195|NCT04095741|DIAGNOSTIC_TEST|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
219299196|NCT05977504|OTHER|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
219299197|NCT03975738|OTHER|To be part of a blog|To be part of a blog - to respond to questions and free to comment on other participants comments
219299198|NCT02709915|OTHER|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
219299199|NCT02709915|OTHER|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
219299200|NCT00988520|DRUG|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
219299201|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
219299202|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
219299203|NCT00988520|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
219299204|NCT00988520|DRUG|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
219299205|NCT02074553|DRUG|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
219299206|NCT02074553|DRUG|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
219299207|NCT02074553|DRUG|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
219299208|NCT02074553|DRUG|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
219299209|NCT01600521|DRUG|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
219299210|NCT04278040|DRUG|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
219299211|NCT00194987|DRUG|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
219299212|NCT00194987|DRUG|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
219299213|NCT01633918|BEHAVIORAL|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
219299214|NCT01633918|BEHAVIORAL|Usual health education|Usual health education lessons
219299215|NCT01487408|DRUG|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
219299216|NCT03085030|DRUG|Antioxidant Formula|Antioxidant tablet will be taken by the patients
219299217|NCT03085030|DRUG|Placebo|The placebo will be taken by the patients
219299218|NCT01664598|DRUG|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
219299219|NCT00118833|DRUG|Hypericum perforatum (St. John's wort)|
219299220|NCT01465204|BEHAVIORAL|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
219299221|NCT01465204|BEHAVIORAL|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
219299222|NCT01658150|DRUG|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
219299223|NCT04508231|OTHER|Gender-affirming hormone therapy|Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
219299224|NCT03325920|DEVICE|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
219299225|NCT04123834|PROCEDURE|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
219299226|NCT04123834|PROCEDURE|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
219299227|NCT04123834|DEVICE|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
219299228|NCT05787028|DRUG|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
219299229|NCT05787028|DRUG|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
219299230|NCT05172141|BIOLOGICAL|IBI314(low dose)|intravenously, once, on Day 1
219299231|NCT05172141|BIOLOGICAL|IBI314(high dose)|intravenously, once, on Day 1
219299232|NCT05172141|BIOLOGICAL|IBI314(medium dose)|intravenously, once, on Day 1
219299233|NCT05172141|OTHER|Placebo|intravenously, once, on Day 1
219299234|NCT02057120|PROCEDURE|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
219299235|NCT02057120|DEVICE|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
219299236|NCT02898844|BEHAVIORAL|Mixed Diet Condition|One roommate dieted and the other ate normally.
219299237|NCT02898844|BEHAVIORAL|Both Diet Condition|Both roommates dieted.
219299238|NCT00321113|DRUG|tacrolimus|immunosuppression
219299239|NCT00321113|DRUG|mycophenolate mofetil|oral
219299240|NCT00321113|DRUG|steroids|oral
219299241|NCT02342743|DEVICE|CEFALY|
219299242|NCT04187989|BEHAVIORAL|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
219299243|NCT03305354|BEHAVIORAL|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
219299244|NCT03305354|BEHAVIORAL|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
219299245|NCT03602066|DRUG|Chlorine Dioxide Sterilization|Given via oral rinse
219299246|NCT03602066|OTHER|Laboratory Biomarker Analysis|Correlative studies
219299247|NCT03602066|OTHER|Placebo|Given via oral rinse
219299248|NCT03646656|BEHAVIORAL|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
219354990|NCT02424838|PROCEDURE|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
219354991|NCT02424838|DEVICE|22 gauge needle|
219354992|NCT02424838|DEVICE|25 gauge needle|
219354993|NCT05060588|DRUG|Sacubitril/Valsartan 49/51mg/Tab|patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
219354994|NCT05060588|DRUG|Valsartan 80mg/Tab|Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
219354995|NCT05997641|DRUG|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
219744104|NCT04745780|DIETARY_SUPPLEMENT|Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin|Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months
219744105|NCT04745780|DIETARY_SUPPLEMENT|Placebo|Placebo - Two-times daily on an empty stomach, for 6 months
219744106|NCT04164186|OTHER|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
219744107|NCT01204385|PROCEDURE|Sample collection|Middle ear fluid and urine
219744108|NCT01558258|BEHAVIORAL|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
219744109|NCT02569008|DRUG|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
219744110|NCT00991978|OTHER|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
219744111|NCT03795519|DRUG|[14C]-olinciguat|oral capsule
219744112|NCT05553236|DIAGNOSTIC_TEST|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
219744113|NCT00088699|DRUG|Ketamine|
219744114|NCT00088699|DRUG|Placebo|
219744115|NCT01756742|OTHER|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
219744116|NCT01756742|OTHER|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
219744117|NCT02244398|OTHER|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
219744118|NCT02244398|OTHER|FP services|VHTs in the control arm only provide family planning services
219744119|NCT04347109|DIAGNOSTIC_TEST|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
219744120|NCT06461494|OTHER|baseline treatment|hot pack will be applied for 10 minutes
219744121|NCT01524744|DRUG|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
219744122|NCT01524744|DRUG|Adcortyl|triamcinolone acetonide 0.1% in orabase
219744123|NCT02326584|DRUG|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
219744124|NCT02326584|DRUG|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
219744125|NCT02326584|DRUG|Daunorubicin|60 mg/m2/day Days 1-3
219744126|NCT02326584|DRUG|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
219744127|NCT03416816|DRUG|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
219744128|NCT01556334|DRUG|Azithromycin|Azithromycin 1g po
219744129|NCT01556334|DRUG|Erythromycin|Erythromycin IV then PO
219744130|NCT06515613|DRUG|CTIM-76|Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.
219744131|NCT06145711|OTHER|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
219744132|NCT05679622|OTHER|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
219744133|NCT06132204|DRUG|HRS-7535 Tablets|HRS-7535 Tablets
219744134|NCT04874194|DRUG|Omacetaxine Mepesuccinate|Given SC
219744135|NCT04874194|DRUG|Venetoclax|Given PO
219744136|NCT02615275|PROCEDURE|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
219744137|NCT02615275|PROCEDURE|Computed Tomography|Undergo CT
219744138|NCT02615275|PROCEDURE|Positron Emission Tomography|Undergo PET
219744139|NCT02615275|OTHER|Quality-of-Life Assessment|Ancillary studies
219744140|NCT02615275|OTHER|Questionnaire Administration|Ancillary studies
219744141|NCT02615275|RADIATION|Radiation Therapy|Undergo RT
219744142|NCT03443401|PROCEDURE|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
219299249|NCT06445426|DEVICE|Cystometry|The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure. The investigational device is inserted into a 12F single-use hydrophilic catheter. After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter. The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder. The investigational device is connected to a data logger. In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate. The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder. The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
219299250|NCT00092495|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
219299251|NCT01793311|OTHER|decaffeinated coffee|contains caffeine 0.5-2 mg
219299252|NCT01793311|OTHER|regular dose coffee|contains 91.8 mg of caffeine
219299253|NCT01793311|OTHER|high dose coffee|contains 144 mg of caffeine
219299254|NCT02454179|DRUG|pembrolizumab|
219299255|NCT02454179|DRUG|Acalabrutinib|
219299256|NCT02859532|RADIATION|elastography SWIRE|
219299257|NCT00712309|DEVICE|Lifestent|Stent for endovascular treatment of popliteal artery lesions
219299258|NCT00712309|DEVICE|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
219299259|NCT05105451|OTHER|Collecting clinical data, EGG，arterial blood gas data and venous blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），arterial blood gas data(before induction of anesthesia and first day after surgery) and venous blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
219299260|NCT02853253|DIETARY_SUPPLEMENT|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
219299261|NCT02853253|DIETARY_SUPPLEMENT|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
219299262|NCT03356626|DEVICE|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
219299263|NCT03356626|DEVICE|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
219299264|NCT03356626|DEVICE|Thunderbeat|to use Thunderbeat when performing gastrectomy
219299265|NCT05680623|DIAGNOSTIC_TEST|PPAP diagnosis|"Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.~A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications."
219299266|NCT03927573|DRUG|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
219299267|NCT04413487|OTHER|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
219299268|NCT03266705|DRUG|tafamidis|bioequivalence study
219299269|NCT04535024|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
219354996|NCT05997641|DRUG|Placebo|Visually matching 0 mg DF-003 capsules.
219744143|NCT03753516|PROCEDURE|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
219744144|NCT03753516|PROCEDURE|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
219744145|NCT06060509|DIETARY_SUPPLEMENT|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
219744146|NCT06060509|DIETARY_SUPPLEMENT|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
219744147|NCT04272034|DRUG|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
219744148|NCT06446037|DEVICE|Non-invasive EMG band instrumentation|The sensed EMG signals from the subjects will be decoded by Phantom X algorithm and used to drive various gestures in a desk-mounted hand prosthesis
219744149|NCT03302663|DIAGNOSTIC_TEST|MRI scan|Addition of advanced imaging sequences for fetal MRI
219299270|NCT04535024|DRUG|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
219299271|NCT00600678|DIETARY_SUPPLEMENT|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
219299272|NCT01283477|DEVICE|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
219299273|NCT01283477|DEVICE|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
219299274|NCT01119599|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
219299275|NCT01119599|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219299276|NCT01119599|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219299277|NCT01119599|OTHER|Laboratory Biomarker Analysis|Correlative studies
219299278|NCT01119599|OTHER|Pharmacological Study|Correlative studies
219299279|NCT01119599|DRUG|Temozolomide|Given PO
219299280|NCT01119599|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219299281|NCT00406055|DEVICE|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
219299282|NCT06020053|PROCEDURE|saline irrigation at various temperatures (4°C, 25°C)|cold serum application
219299283|NCT04009915|PROCEDURE|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
219299284|NCT04009915|PROCEDURE|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
219299285|NCT01600820|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
219299286|NCT01600820|OTHER|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
219299287|NCT01600820|OTHER|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
219299288|NCT04643522|OTHER|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
219299289|NCT04417296|DIAGNOSTIC_TEST|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
219299290|NCT02313376|BIOLOGICAL|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
219299291|NCT00171808|DRUG|Letrozole|
219299292|NCT04897750|COMBINATION_PRODUCT|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
219299293|NCT03534401|BEHAVIORAL|ARCHES Kenya|ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
219299294|NCT05104281|DRUG|osimertinib oral and bevazizumab intravenously|osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
219299295|NCT06463561|DEVICE|Continuous positive airway pressure|Treatment will start with an empirical pressure of 8 cmH2O and, within a maximum of 3 weeks, the pressure will be adjusted by means of automatic titration, establishing the pressure corresponding to the 95th percentile.
219299296|NCT06463561|OTHER|Hygienic-dietary recommendations and daily physical activity promotion|Hygienic-dietary recommendations on sleep and intervention for the promotion of daily physical activity, establishing walking as a goal 10,000 steps per day. To do this, they will be provided with a pedometer and asked to fill out a form with the steps walked each day. At each visit, the distance walked will be reviewed and the goal set will be reiterated.
219299297|NCT02630693|DRUG|Palbociclib 100mg|100mg PO daily
219299298|NCT02630693|DRUG|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
219299299|NCT02630693|DRUG|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
219299300|NCT05396469|DIAGNOSTIC_TEST|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
219299301|NCT01175447|DRUG|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
219299302|NCT02004470|PROCEDURE|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
219299303|NCT04601870|OTHER|No Financial Incentive|No monetary incentive to participate in quit planning and quit counseling with a tobacco cessation specialist.
219299304|NCT04601870|OTHER|Financial Incentive (100 dollars)|Financial incentive (100 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
219299305|NCT04601870|OTHER|Financial Incentive (50 dollars)|Financial incentive (50 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
219299306|NCT01879059|BEHAVIORAL|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
219299307|NCT03472248|BEHAVIORAL|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
219299308|NCT03026192|DEVICE|near infrared spectroscopy|Near infrared spectroscopy will be placed on infants both with and without hsPDA
219299309|NCT03759314|OTHER|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
219299310|NCT03461536|BEHAVIORAL|Ultrasound-first Clinical Decision Support tool|"Intervention: The intervention is the CDS tool, which consists of 4 components:~1. Four questions which assess the appropriateness of ultrasound for this patient~2. A link to the evidence~3. Buttons to remove CT scan and order ultrasound~4. If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~1. Adults aged \>18 and \< 76~2. Non-obese (men \< 285lbs, women \< 250lbs)~3. Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~4. Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided."
219299311|NCT03932812|BEHAVIORAL|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
219299312|NCT02016859|OTHER|Immature Platelet Fraction|
219299313|NCT03161600|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
219299314|NCT02822859|DEVICE|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
219299315|NCT02822859|DEVICE|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
219299316|NCT02822859|DEVICE|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
219299317|NCT06352476|BEHAVIORAL|Sleep Hygiene Training|The effect of sleep hygiene education in a pre-test quasi-experimental study.
219299318|NCT04193436|DRUG|PF-06835919 25 mg|PF-06835919 in 25 mg oral tablet will be administered on Day 1
219299319|NCT02878577|DEVICE|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
219299320|NCT06078865|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
219299321|NCT04719624|DEVICE|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
219299322|NCT04719624|DEVICE|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
219299323|NCT04719624|DEVICE|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
219299324|NCT04719624|PROCEDURE|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
219299325|NCT04719624|DEVICE|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
219299326|NCT02585232|BEHAVIORAL|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
219299327|NCT02585232|BEHAVIORAL|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
219299328|NCT03781999|DIETARY_SUPPLEMENT|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
219744150|NCT01823055|PROCEDURE|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
219744151|NCT02016521|OTHER|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
219744152|NCT02016521|OTHER|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
219744153|NCT04500145|RADIATION|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
219299329|NCT03781999|OTHER|Placebo|Maltodextrin
219299330|NCT03215810|PROCEDURE|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
219299331|NCT03215810|DRUG|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
219299332|NCT03215810|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
219299333|NCT03215810|DRUG|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
219299334|NCT03215810|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
219299335|NCT03215810|DRUG|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
219299336|NCT02630888|DRUG|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
219299337|NCT02630888|DRUG|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
219299338|NCT00064610|DRUG|VELCADE TM (bortezomib) for Injection|
219299339|NCT02313233|DIETARY_SUPPLEMENT|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
219299340|NCT02313233|DIETARY_SUPPLEMENT|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
219299341|NCT03018054|DRUG|E6007|once daily administration
219299342|NCT03018054|DRUG|Placebo|once daily administration
219299343|NCT03445923|OTHER|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
219299344|NCT01859286|OTHER|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
219299345|NCT05345808|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
219299346|NCT04316351|DRUG|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
219299347|NCT01965353|DRUG|Panobinostat|\- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
219299348|NCT01965353|DRUG|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
219299349|NCT01965353|DRUG|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
219299350|NCT01965353|DRUG|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
219299351|NCT02318953|DEVICE|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
219299352|NCT02318953|OTHER|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
219299353|NCT04130763|BIOLOGICAL|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
219299354|NCT00809744|DRUG|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
219299355|NCT00830089|DRUG|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
219299356|NCT04976244|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata
219299357|NCT01073787|DRUG|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
219299358|NCT03078777|DRUG|Fexofenadine|Fexofenadine will be administered to patients.
219299359|NCT00810433|PROCEDURE|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
219299360|NCT05347251|OTHER|Cervicothoracic mobility program|"Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed"
219299361|NCT05347251|OTHER|Conventional Treatment|"It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed."
219299362|NCT01180205|DRUG|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
219299363|NCT01180205|DRUG|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
219299364|NCT01180205|DRUG|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
219299365|NCT01180205|DRUG|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
219299366|NCT00219102|DRUG|aliskiren|
219299367|NCT02441231|DRUG|Visbiome|Visbiome probiotic
219299368|NCT02441231|OTHER|Placebo|Placebo
219299369|NCT02774239|DRUG|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
219299370|NCT05365360|DEVICE|LaserCap SD|LaserCap SD
219299371|NCT05365360|DEVICE|Sham LaserCap|Sham LaserCap
219299372|NCT05365360|DEVICE|LaserCap HD+|LaserCap HD+
219299373|NCT01290653|OTHER|Dry needling|Deep dry needling until achieving twitch response of the muscle
219299374|NCT01290653|OTHER|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
219299375|NCT01290653|OTHER|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
219299376|NCT04595318|DRUG|Standard clinical care first, followed by standard clinical care and varenicline|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
219299377|NCT04595318|DRUG|Standard clinical care and varenicline first, followed by standard clinical care|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
219299378|NCT02907515|DEVICE|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
219354997|NCT00374309|DRUG|VRC-EBOADV018-00-VP|
219354998|NCT02889458|OTHER|Not Provided|
219299379|NCT02907515|DEVICE|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
219299380|NCT02851927|PROCEDURE|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
219299381|NCT02851927|PROCEDURE|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
219299382|NCT02898415|PROCEDURE|Liver transplantation|
219299383|NCT01466933|BEHAVIORAL|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
219299384|NCT01466933|BEHAVIORAL|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
219299385|NCT01656733|DRUG|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
219299386|NCT01656733|DRUG|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
219299387|NCT04762121|PROCEDURE|Peripheral IV|Insertion of peripheral intravenous catheter
219299388|NCT01354561|PROCEDURE|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
219299389|NCT00054054|DRUG|cisplatin|
219299390|NCT00054054|DRUG|docetaxel|
219299391|NCT00054054|DRUG|fluorouracil|
219299392|NCT00054054|RADIATION|radiation therapy|
219299393|NCT02183844|BEHAVIORAL|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
219299394|NCT06476613|OTHER|Permissive Hypotension|Patients will be randomized in 1:1 fashion to either a) Permissive Hypotension (MAP target \> 60mmHg) or b) Usual Care. The duration of the intervention will extend until the patient no longer needs vasopressors to maintain prespecified MAP.
219299395|NCT02684448|PROCEDURE|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
219299396|NCT04660591|DEVICE|femoral stem in hip arthroplasty|using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
219299397|NCT02412410|BEHAVIORAL|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
219299398|NCT04617561|DRUG|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
219299399|NCT04617561|DRUG|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
219299400|NCT02479321|OTHER|GDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
219299401|NCT02479321|DEVICE|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
219299402|NCT02084173|BEHAVIORAL|MET + CRA|
219299403|NCT00580645|DRUG|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
219299404|NCT00580645|DRUG|placebo|placebo
219299405|NCT03390218|BEHAVIORAL|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
219299406|NCT03390218|BEHAVIORAL|Treatment as usual|Individual and group therapy, generic in nature
219299407|NCT04374851|DEVICE|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
219299408|NCT04374851|DEVICE|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
219299409|NCT01927926|DIETARY_SUPPLEMENT|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
219299410|NCT01927926|DIETARY_SUPPLEMENT|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
219299411|NCT04083573|OTHER|application of medical augmented reality glasses|Endoscopic images from medical monitor and medical augmented reality glasses will be collected and reviewed. Outcomes from both series of images will be compared
219299412|NCT02679573|DRUG|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
219299413|NCT02679573|DRUG|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
219299414|NCT02679573|DRUG|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
219299415|NCT06243861|BEHAVIORAL|Mother-child bond|assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
219299416|NCT03180177|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.
219299417|NCT03180177|PROCEDURE|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
219299418|NCT03180177|DRUG|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
219299419|NCT03180177|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
219299420|NCT04738227|RADIATION|Low-Level Laser Therapy|Low level laser will be applied and post laser results will be seen to assess any improvements.
219299421|NCT04326595|PROCEDURE|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
219299422|NCT03545503|DRUG|Etomidate|Etomidate will be administered as the sedative for RSI on even days
219299423|NCT03545503|DRUG|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
219299424|NCT00682890|DRUG|placebo|placebo birth control pill daily
219299425|NCT00682890|DRUG|metformin|2000 mg per day for 3 months daily birth control pill
219299426|NCT00004204|DRUG|temozolomide|
219299427|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
219299428|NCT01344954|DRUG|Rivaroxaban|Administered orally as a capsule once a day for 35 days
219299429|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
219299430|NCT01046773|DRUG|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
219299431|NCT01046773|DRUG|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
219299432|NCT03996343|DEVICE|Endotracheal intubation|COMPLETE
219299433|NCT03996343|DEVICE|Laryngeal mask airway|COMPLETE
219299434|NCT03801122|DRUG|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
219354999|NCT00006479|DRUG|FOLFOX regimen|
219299435|NCT05347368|OTHER|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
219299436|NCT05347368|OTHER|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
219299437|NCT06154109|DRUG|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
219299438|NCT06154109|DRUG|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
219299439|NCT06154109|DRUG|Placebo|The placebo does not contain any active pharmaceutical ingredients .
219299440|NCT00212420|PROCEDURE|parenteral nutrition; enteral nutrition|
219299441|NCT03170999|OTHER|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
219299442|NCT03170999|OTHER|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
219299443|NCT03170999|OTHER|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
219299444|NCT03028220|DEVICE|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
219299445|NCT03028220|DEVICE|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
219299446|NCT04156854|DIAGNOSTIC_TEST|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
219299447|NCT01214265|DEVICE|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
219299448|NCT05636423|OTHER|Survey|Online survey via a questionnaire composed of 28 questions.
219299449|NCT01143779|DRUG|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
219299450|NCT05619029|RADIATION|X-ray|Chest radiographs
219299451|NCT00802698|DEVICE|Transcorneal electric stimulation|central artery occlusion
219299452|NCT00802698|DEVICE|Transcorneal stimulation|new waveform
219299453|NCT00802698|DEVICE|transcorneal electric stimulation|Novel waveform central artery occlusion
219299454|NCT00836420|PROCEDURE|no intervention|the value of the clinical use of microdialysis monitoring of the brain
219299455|NCT03561831|DRUG|Propofol|propofol based anesthesia
219299456|NCT03561831|DRUG|Sevoflurane|sevoflurane based anesthesia
219299457|NCT02389920|DRUG|Nilotinib|
219299458|NCT01777451|OTHER|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
219299459|NCT05319301|DIETARY_SUPPLEMENT|Melatonin|A single dose of melatonin (1.9 mg)
219299460|NCT01478529|DRUG|mirabegron OCAS|oral administration
219299461|NCT01478529|DRUG|mirabegron|iv administration
219299462|NCT00090077|DRUG|GW695634|
219355000|NCT00006479|DRUG|fluorouracil|
219355001|NCT00006479|DRUG|leucovorin calcium|
219355002|NCT00006479|DRUG|oxaliplatin|
219355003|NCT00006479|PROCEDURE|adjuvant therapy|
219299463|NCT02192125|DEVICE|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database"
219299464|NCT04612959|OTHER|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
219299465|NCT03704246|DRUG|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
219299466|NCT01873066|DEVICE|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
219299467|NCT01873066|DEVICE|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
219299468|NCT05839015|BEHAVIORAL|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
219299469|NCT02850120|PROCEDURE|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
219299470|NCT02850120|PROCEDURE|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
219299471|NCT02850120|PROCEDURE|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
219299472|NCT00003025|BIOLOGICAL|vitespen|
219299473|NCT00174512|DRUG|GTN|
219299474|NCT00174512|DRUG|Moxifloxacin|
219299475|NCT04705636|DEVICE|"Connected device named Leo from Ludocare society"|"Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device."
219299476|NCT04709315|DRUG|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
219299477|NCT04709315|DRUG|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
219299478|NCT04629573|PROCEDURE|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
219299479|NCT04629573|PROCEDURE|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
219299480|NCT00862719|DRUG|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
219299481|NCT05885243|DEVICE|ESWT|will be given once a week, total 5 sessions ofESWT+ home exercises program
219299482|NCT05885243|DEVICE|customized insoles|Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
219299483|NCT05885243|COMBINATION_PRODUCT|combined ESWT and custtomized insoles|Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
219299484|NCT04654845|PROCEDURE|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
219355004|NCT00006479|PROCEDURE|conventional surgery|
219355005|NCT00006479|PROCEDURE|neoadjuvant therapy|
219355006|NCT05946408|OTHER|Supervised antenatal exercises|"Supervised antenatal exercises along with education twice a week. Protocol consists of warm up (10 min), Aerobic training (20 mins, 60-75% of max. HR), Strength training (25 minutes), followed by a cool down of 15 minutes.~The Interventions to be provided for a period of 12 weeks."
219299485|NCT04654845|PROCEDURE|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
219299486|NCT00324116|DRUG|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
219299487|NCT05786703|DIAGNOSTIC_TEST|Biochemical, weight measurements, Blood pressure and blood sugar level|At first visit short interview using the STEPwise approach of the STEPS surveillance tool for NCDs from the WHO will be conducted. On subsequent visits, hypertension and blood sugar level and cholesterol levels will be measured and adherence to medication will be assessed. The patient's registry will be developed following recommendation from the HEARTS technical package of World Health Organization (WHO) with some modification if needed.
219299488|NCT01806623|DRUG|Fluconazole|Single oral dose of 150mg Fluconazole
219299489|NCT00751361|DEVICE|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
219299490|NCT00153153|DRUG|polyethyleneglycol3350|
219299491|NCT00568412|DEVICE|Zarzenda|Topical cream, applied twice daily for three weeks
219299492|NCT00568412|DRUG|Elidel|1% cream, applied topically twice daily for three weeks
219299493|NCT01215201|PROCEDURE|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
219299494|NCT01215201|PROCEDURE|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
219299495|NCT01908192|DRUG|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
219299496|NCT01908192|DRUG|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
219299497|NCT01266681|DRUG|amiodarone|"Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
219299498|NCT01266681|DRUG|Dronedarone|"Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
219299499|NCT01737827|DRUG|INC280|INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.
219299500|NCT02521987|PROCEDURE|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
219299501|NCT02521987|PROCEDURE|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
219299502|NCT04454775|DIAGNOSTIC_TEST|coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.|
219299503|NCT01451827|DRUG|Tolvaptan MR|50/80 mg capsules
219299504|NCT01451827|DRUG|Tolvaptan IR|60/30 mg capsules
219299505|NCT01451827|DRUG|Placebo|tablet
219299506|NCT04572308|BIOLOGICAL|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
219299507|NCT00922753|OTHER|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
219299508|NCT00922753|OTHER|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
219299509|NCT00922753|OTHER|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
219299510|NCT03695458|DEVICE|Phototherapy|The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
219299511|NCT03003455|PROCEDURE|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
219299512|NCT03003455|PROCEDURE|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
219299513|NCT00473005|DRUG|Capecitabine|825 mg/m2 bid, Oral
219299514|NCT00473005|DRUG|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
219299515|NCT01034605|DIETARY_SUPPLEMENT|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
219299516|NCT02854787|DRUG|Phenylephrine|A bolus of 100 mcg
219299517|NCT02854787|DRUG|Norepinephrine|A bolus of 0,2 mcg/kg
219299518|NCT00876681|PROCEDURE|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
219299519|NCT02133118|DRUG|individual SUs, insulin, pioglitazone|
219299520|NCT03971903|BEHAVIORAL|Attention bias modification|The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
219299521|NCT05382143|DRUG|Atosiban|Pilot study
219299522|NCT03281655|DRUG|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
219299523|NCT02627729|DEVICE|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
219299524|NCT02627729|DEVICE|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
219299525|NCT02407301|OTHER|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
219299526|NCT02407301|OTHER|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
219299527|NCT02407301|OTHER|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
219299528|NCT02407301|OTHER|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
219299529|NCT02407301|OTHER|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
219299530|NCT05239637|OTHER|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
219299531|NCT05239637|OTHER|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
219299532|NCT05792358|PROCEDURE|wet cupping therapy|wet cupping therapy will be applied to participants in this arm for three sessions once a month
219299533|NCT01147276|DRUG|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
219299534|NCT04184739|OTHER|My Braces App|An App designed to support patients undertaking orthodontic treatment.
219299535|NCT00296400|DRUG|Rosuvastatin|
219299536|NCT00296400|DRUG|Atorvastatin|
219299537|NCT04291222|DEVICE|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
219299538|NCT06439459|PROCEDURE|Stromal vascular fraction transplantation|"Stromal vascular fraction was extracted from subcutaneous fat harvested from either the abdomen or the posterior inner thigh region. The SVF cell-pellet was washed and was adjusted to 2×10\^6 cells/mL. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares.~The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg. This procedure was repeated until adequate skin area was achieved for subsequent facial restoration surgery."
219299539|NCT00412061|DRUG|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
219299540|NCT00412061|DRUG|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
219299541|NCT00412061|DRUG|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
219299542|NCT01739491|DRUG|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
219299543|NCT04881604|DEVICE|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
219299544|NCT04881604|DEVICE|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
219299545|NCT00578461|DRUG|Ara C|3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
219299546|NCT00578461|DRUG|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
219299547|NCT00578461|DRUG|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
219299548|NCT00578461|RADIATION|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
219744154|NCT04500145|RADIATION|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
219744155|NCT00175279|BEHAVIORAL|Opinion leader generated and endorsed evidence summaries|
219744156|NCT04287959|DEVICE|High flow nasal cannula support|airvo2 highflow devices will be used.
219744157|NCT06635863|DRUG|Prednisone 40mg|Prednisone 40mg x 8weeks
219744158|NCT05544487|PROCEDURE|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
219744159|NCT04868032|BEHAVIORAL|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
219744160|NCT04868032|BEHAVIORAL|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
219744161|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
219744162|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
219744163|NCT06419348|DRUG|99mTc-QULIC-5-P1|Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
219744164|NCT06844916|OTHER|AI-Assisted PEEP Optimization|"In this study, three artificial intelligence (AI) models (ChatGPT, DeepSeek, and Gemini) will analyze mechanical ventilation data, including compliance, elastance, auto-PEEP, time constant, and pressure-volume (P-V) curves, to generate patient-specific PEEP recommendations.~These AI-generated recommendations will be compared with manual PEEP titration performed by experienced ICU specialists. The AI models will also provide abnormal ventilation parameter detection, diagnostic suggestions, and treatment recommendations. The study aims to evaluate the reliability, accuracy, and clinical applicability of AI-generated outputs in optimizing PEEP settings for mechanically ventilated ICU patients."
219744165|NCT05146778|PROCEDURE|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
219744166|NCT05146778|PROCEDURE|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
219744167|NCT05799092|DIAGNOSTIC_TEST|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
219744168|NCT05799092|DIAGNOSTIC_TEST|Non-invasive functional test|Standard non-invasive functional testing will be performed.
219744169|NCT02466997|DRUG|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
219744170|NCT02466997|DRUG|Placebo|
219744171|NCT02904265|DRUG|Diazepam|
219299549|NCT03481192|BEHAVIORAL|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
219299550|NCT00410982|DRUG|Busulfan|Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous
219299551|NCT00410982|DRUG|Gemcitabine|Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.
219299552|NCT00410982|DRUG|Melphalan|Day -3 and Day -2 = 60 mg/m\^2 Intravenous.
219299553|NCT00410982|OTHER|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
219299554|NCT00410982|DRUG|Rituximab for Patients with B-Cell Malignancies|375 mg/m\^2 Intravenous on Days 1 and 8.
219299555|NCT00410982|DRUG|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
219299556|NCT03451617|DEVICE|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
219299557|NCT03451617|DEVICE|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
219299558|NCT02307461|DRUG|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
219299559|NCT02307461|DRUG|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
219299560|NCT02307461|DRUG|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
219299561|NCT00221026|DRUG|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
219299562|NCT00221026|PROCEDURE|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
219299563|NCT00289497|DEVICE|TempTouch®|
219299564|NCT02647216|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
219299565|NCT02647216|BEHAVIORAL|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
219299566|NCT01942590|DRUG|Clenbuterol|
219299567|NCT01942590|DRUG|Placebo|
219299568|NCT05332145|BEHAVIORAL|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
219299569|NCT05101031|DEVICE|Starling SV|The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
219299570|NCT00111215|DRUG|Tranexamic Acid|
219299571|NCT00111215|DRUG|Desmopressin Acetate|
219299572|NCT01618604|PROCEDURE|Quantitative Sensory Testing|following the standardized protocol of DFNS
219299573|NCT01618604|PROCEDURE|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
219299574|NCT01618604|PROCEDURE|Repetition of four QST parameters|"* warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)"
219299575|NCT03589508|BEHAVIORAL|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
219299576|NCT03589508|BEHAVIORAL|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
219299577|NCT03368638|OTHER|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
219299578|NCT00350116|DRUG|topical vitamin B12|
219299579|NCT06132243|DRUG|Jaktinib Hydrochloride Tablets|Orally, one tablet at a time
219299580|NCT01178385|BEHAVIORAL|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
219299581|NCT01178385|BEHAVIORAL|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
219299582|NCT06253091|PROCEDURE|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist laparoscopic radical cystectomy was performed extraperitoneal
219299583|NCT01786733|BEHAVIORAL|Behavioral Activation|
219299584|NCT01786733|BEHAVIORAL|Supportive Therapy|
219299585|NCT00297687|BIOLOGICAL|MnB rLP2086|
219355007|NCT05946408|OTHER|Antenatal Education|Antenatal education at 12th week of pregnancy. Which consists of education on Posture in pregnancy, Role of pelvic floor muscles, Labor and breathing and relaxation techniques.
219355008|NCT03669315|DEVICE|Transcranial Magnetic stimulation|Neuromodulation tool
219744172|NCT02904265|DRUG|Acetazolamide|
219744173|NCT00592280|DRUG|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
219744174|NCT00592280|DEVICE|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
219744175|NCT01337505|DRUG|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
219744176|NCT02346812|OTHER|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
219744177|NCT02346812|OTHER|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
219744178|NCT04384497|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
219744179|NCT00814736|DRUG|UK369,003|oral tablet, once a day
219744180|NCT00814736|DRUG|sildenafil|single oral dose on day 14 or day 17
219744181|NCT00814736|DRUG|sildenafil matching placebo|single oral dose on day 14 or day 17
219744182|NCT00205322|DRUG|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
219744183|NCT06572020|OTHER|education|simulation-based training on blood pressure and ECG measurement
219744184|NCT06122597|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
219744185|NCT02862262|DEVICE|ARIES Bordetella Assay|
219744186|NCT03193580|DEVICE|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
219744187|NCT03193580|DEVICE|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
219744188|NCT03193580|DEVICE|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
219744189|NCT03942744|DEVICE|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
219744190|NCT01917032|DIETARY_SUPPLEMENT|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
219744191|NCT01917032|DIETARY_SUPPLEMENT|placebo|
219744192|NCT04822883|DRUG|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
219744193|NCT04822883|DRUG|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
219299586|NCT06341348|OTHER|Case management|Case Management (CM) is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone. All interventions were delivered by a nursing case manager who had over 5 years of nursing experience and received more than 20 hours of CM training.
219299587|NCT05132192|PROCEDURE|living donor liver transplantation|Living donor liver transplantation
219299588|NCT05132192|PROCEDURE|Thrombectomy or interposition graft|Portal flow restoration due to PVT in any manner
219299589|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
219299590|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
219299591|NCT02876276|PROCEDURE|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
219299592|NCT04650308|DIAGNOSTIC_TEST|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
219299593|NCT02395874|PROCEDURE|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
219299594|NCT01688830|DRUG|Dabigatran|
219299595|NCT01688830|DRUG|BI 655075|
219299596|NCT01688830|DRUG|Placebo|
219299597|NCT01285609|DRUG|Ipilimumab|
219299598|NCT01285609|DRUG|Placebo|
219299599|NCT01285609|DRUG|Paclitaxel|
219299600|NCT01285609|DRUG|Carboplatin|
219299601|NCT03283072|DEVICE|Intervention 1|15 bouts of 2mins:1min hypoxia:hyperoxia
219299602|NCT03283072|DEVICE|Intervention 2|15 bouts of 1mins:1min hypoxia:hyperoxia
219299603|NCT03283072|DEVICE|Intervention 3|8 bouts of 2mins:1min hypoxia:hyperoxia
219299604|NCT03283072|DEVICE|Intervention 4 (sham)|15 bouts of 1min:1min normoxia
219299605|NCT05880615|OTHER|collection of datas|"collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery"
219299606|NCT03797677|DEVICE|MN 4000|Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
219299607|NCT04563286|OTHER|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
219299608|NCT03219515|DRUG|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
219299609|NCT03219515|DRUG|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
219299610|NCT02552368|DEVICE|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
219299611|NCT02772406|DEVICE|Linked Color Imaging|
219299612|NCT02772406|DEVICE|white light imaging|
219299613|NCT03002753|BEHAVIORAL|detached mindfulness|Please see detailed study description.
219299614|NCT03002753|BEHAVIORAL|cognitive restructuring|Please see detailed study description.
219299615|NCT01957449|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
219299616|NCT01957449|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
219299617|NCT05302349|OTHER|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * Active pelvic floor exercise (supine position)~  * Bridge exercise (supine position)~  * Back Extension and Ball Back Extension exercises (prone position)~  * Abdominal and Oblique Crunch exercises (supin position)~  * Leg lift exercise (prone position)~  * Plank and Side Plank exercise~  * Superman exercise~Weeks 5-8 (Three days a week)~1. Stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * The same exercises as for Weeks 1-4 will perform."
219299618|NCT05302349|OTHER|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1\. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
219299619|NCT02704468|OTHER|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
219299620|NCT02911415|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
219299621|NCT01526031|PROCEDURE|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
219299622|NCT01526031|PROCEDURE|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
219299623|NCT01526031|PROCEDURE|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
219299624|NCT01526031|PROCEDURE|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program"
219299625|NCT00882154|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
219299626|NCT00882154|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
219299627|NCT05094505|OTHER|Exercise in normoxia|Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
219355009|NCT01055002|BIOLOGICAL|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
219355010|NCT03591445|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
219299628|NCT05094505|OTHER|Control diet|Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
219299629|NCT05094505|OTHER|Exercise in hypoxia|Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
219299630|NCT05094505|OTHER|Low carbohydrate diet|Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
219299631|NCT06485453|DRUG|Botox 200 UNT Injection|Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
219299632|NCT00201994|DRUG|Tolvaptan|
219299633|NCT05636956|OTHER|Education and Counseling Program|Researches created an education and counseling program. In this context, patients receive an one hour education. Education program consist of face-to-face informing and teach-back method. At the end of the face-to-face informing, researchers give a comicbook about instructions of living with CIEDs as a written material. After discharge, researches follow-up patients with phone calls. In the context of phone calls researches continue to informing patients, remind related instructions for that time and answer questions of patients. Patients are allowed to reach reserarches any time if they have any concern or question. This program lasts for six months.
219299634|NCT03871842|DEVICE|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
219299635|NCT03871842|DEVICE|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
219299636|NCT06485362|DIAGNOSTIC_TEST|Termography|Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).
219299637|NCT00573495|BIOLOGICAL|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
219299638|NCT01574196|OTHER|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
219299639|NCT01453426|DRUG|BG00012 Dose 1|
219299640|NCT01453426|DRUG|BG00012 Dose 2|
219299641|NCT04341467|DRUG|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
219299642|NCT04341467|DRUG|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
219299643|NCT05249491|DIAGNOSTIC_TEST|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
219299644|NCT02894567|DEVICE|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
219299645|NCT00094042|DRUG|Iron Supplement, 120mg|
219299646|NCT06058754|BEHAVIORAL|The ADAPT Program|The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0
219744194|NCT06304012|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
219744195|NCT06304012|DEVICE|Intermittent Oro-esophageal Tube Feeding|The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
219744196|NCT06304012|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
219744197|NCT05536791|DRUG|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
219299647|NCT06058754|BEHAVIORAL|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
219299648|NCT02531945|DEVICE|Use of Biomod device|
219299649|NCT03664362|BEHAVIORAL|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
219299650|NCT03616977|DRUG|LY900014 U-200|Administered SC
219299651|NCT03616977|DRUG|LY900014 U-100|Administered SC
219299652|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
219299653|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
219299654|NCT04013087|DIETARY_SUPPLEMENT|Breast feeding|Breast feeding of human milk for 16 weeks
219299655|NCT02104297|DRUG|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
219299656|NCT02104297|DRUG|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
219299657|NCT02104297|DRUG|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
219299658|NCT04013568|OTHER|Exercise|"First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students~Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes"
219299659|NCT04879953|DRUG|PIPAC with systemic chemotherapy|PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
219299660|NCT04879953|DRUG|Systemic chemotherapy alone|Intravenous chemotherapy
219299661|NCT04395872|BEHAVIORAL|Psychiatric counseling|Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
219299662|NCT00223717|DRUG|Clonidine|0.1-0.2mg po. Single dose.
219299663|NCT00223717|DRUG|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
219299664|NCT00223717|DRUG|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
219299665|NCT00223717|DRUG|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
219299666|NCT00223717|DRUG|Sildenafil|25- 100 mg po. Single dose.
219744198|NCT02695888|BEHAVIORAL|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
219744199|NCT02695888|BEHAVIORAL|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
219744200|NCT02254460|DIETARY_SUPPLEMENT|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
219744201|NCT02254460|OTHER|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
219744202|NCT05559385|DEVICE|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
219744203|NCT05559385|PROCEDURE|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
219744204|NCT04861701|BEHAVIORAL|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
219744205|NCT01808170|PROCEDURE|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
219299667|NCT00223717|DRUG|Nifedipine|10-30 mg po. Single dose.
219299668|NCT00223717|DRUG|Hydralazine|10-50 mg po. Single dose
219299669|NCT00223717|DRUG|Hydrochlorothiazide|12.5-100 mg po. Single dose.
219299670|NCT00223717|DRUG|Placebo|Po or patch. Single dose.
219299671|NCT00223717|DRUG|Bosentan|62.5 -125 mg po. Single dose.
219299672|NCT00223717|DRUG|Diltiazem|30-60 mg po. Single dose.
219299673|NCT00223717|DRUG|Eplerenone|50-100 mg po. Single dose.
219299674|NCT00223717|DRUG|guanfacine|1-3 mg po. Single dose.
219299675|NCT00223717|DIETARY_SUPPLEMENT|L-arginine|6-17 g po. Single dose
219299676|NCT00223717|DRUG|captopril|25-50 mg PO. Single dose.
219299677|NCT00223717|DRUG|carbidopa|25-200 mg PO. Single dose.
219299678|NCT00223717|DRUG|losartan|25-200 mg PO. Single dose.
219299679|NCT00223717|DRUG|metoprolol tartrate|25-100 mg PO. Single dose.
219299680|NCT00223717|DRUG|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
219299681|NCT00223717|DRUG|prazosin hydrochloride|0.5-1 mg PO. Single dose.
219299682|NCT00223717|DRUG|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
219299683|NCT00223717|OTHER|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
219299684|NCT00223717|DRUG|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
219299685|NCT00223717|OTHER|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
219299686|NCT01815762|OTHER|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
219299687|NCT01725789|DRUG|Ferinject®|"Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .~Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight \<50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value \<15ng/mL and Hb\<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)"
219299688|NCT01725789|DRUG|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
219299689|NCT03683823|BEHAVIORAL|Attention guidance|Explicitly guiding attention towards faces during public speaking exposures
219299690|NCT03683823|BEHAVIORAL|Control intervention|Public speaking exposures
219299691|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
219299692|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
219299693|NCT06049576|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
219299694|NCT06049576|PROCEDURE|Bone Scan|Undergo bone scan
219299695|NCT06049576|PROCEDURE|Computed Tomography|Undergo CT
219299696|NCT06049576|BIOLOGICAL|Ipilimumab|Given IV
219299697|NCT06049576|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219299698|NCT06049576|DRUG|Myrciaria dubia Prebiotic Supplement|Given PO
219299699|NCT06049576|BIOLOGICAL|Nivolumab|Given IV
219299700|NCT02774967|PROCEDURE|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
219299701|NCT03456427|DEVICE|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) \& Mediolateral Oblique (MLO).
219299702|NCT03456427|DEVICE|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
219299703|NCT06452498|DRUG|Metformin Hydrochloride|Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
219299704|NCT06452498|DRUG|Placebo|Capsule filled with cellulose.
219299705|NCT05299697|DRUG|TG103 15 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
219299706|NCT05299697|DRUG|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
219299707|NCT05299697|DRUG|Placebo|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
219299708|NCT02813876|OTHER|Enhanced recovery protocol|
219299709|NCT01323972|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
219299710|NCT03804970|BEHAVIORAL|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
219299711|NCT03804970|BEHAVIORAL|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
219299712|NCT03804970|BEHAVIORAL|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
219299713|NCT03804970|BEHAVIORAL|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
219299714|NCT03804970|BEHAVIORAL|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
219299715|NCT00060762|BEHAVIORAL|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
219299716|NCT00060762|BEHAVIORAL|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
219299717|NCT00060762|BEHAVIORAL|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
219299718|NCT04268927|DRUG|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
219299719|NCT04268927|DRUG|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
219299720|NCT02651597|OTHER|Oatmeal|
219744206|NCT01808170|PROCEDURE|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
219299721|NCT04072068|DRUG|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
219299722|NCT05728320|DEVICE|Glucose monitoring with flash glucose monitor|All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.
219299723|NCT05316623|DEVICE|TENS|TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
219744207|NCT00583154|DRUG|BLI-801|Dose 1
219744208|NCT00583154|DRUG|BLI-801|Dose 2
219744209|NCT00583154|DRUG|BLI-801|Dose 3
219744210|NCT00583154|DRUG|BLI-801|Dose 4
219744211|NCT02758730|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
219744212|NCT02758730|BIOLOGICAL|Adjuvant without active component|s.c. injection
219744213|NCT00137449|DRUG|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
219744214|NCT01356940|DRUG|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
219744215|NCT01356940|DRUG|placebo|identical placebo tablet administered bid for four weeks
219744216|NCT06478524|BEHAVIORAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week. The live music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
219744217|NCT06478524|BEHAVIORAL|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week. The pre-recorded music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
219744218|NCT06367101|OTHER|AR training with gait and HRV feedback|Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
219744219|NCT03683979|BEHAVIORAL|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
219744220|NCT03683979|BEHAVIORAL|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
219744221|NCT00078260|DRUG|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
219744222|NCT01137084|DRUG|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
219744223|NCT01137084|DRUG|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
219744224|NCT02373657|BEHAVIORAL|instruction in soap-making and hygiene education|
219299724|NCT04129827|OTHER|Clinical, self-reported psychological and biomechanical assessments|"1. medical check up~   * active and passive Range Of Motion (ROM)~  * anterior drawer test~  * knee's alignment~  * modified cincinnati rating system questionnaire (mCRSQ)~  * tegner lysholm knee scoring scale (TLKS)~  * Tegner Activity Level Score (TALS)~2. self-reported psychological questionnaires~   * Tampa Scale of Kinesiophobia (TSK)~  * ACL Return to Sport after Injury (ACL-RSI) score~3. biomechanical tests~   * Stability test: to balance on one/two legs on a free to move disc for 30s~  * Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~  * Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~  * fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
219299725|NCT03993951|DEVICE|ICT System|Update the Information and Communications Technology System in Family Service Agencies
219299726|NCT00051259|DRUG|Extended-Release Bupropion Hydrochloride|
219299727|NCT05189392|DEVICE|PICO|after hip arthroplasty application of visible opsite plaster on the surgical wound
219299728|NCT04007250|DEVICE|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~* FENIX™ System Implant~* FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
219299729|NCT02008877|DRUG|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
219299730|NCT02008877|DRUG|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
219299731|NCT01740141|PROCEDURE|Plexus brachialis block|
219299732|NCT05922254|OTHER|Active cycle of breathing technique|The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
219299733|NCT05922254|OTHER|Autogenic drainage|Huffing or blowing the nose helped to get rid of any secretions in the upper airways. The therapist was placed close enough to hear the subject's breathing while sitting to the side and slightly behind the patient. Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency.
219299734|NCT02769403|DEVICE|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
219299735|NCT02769403|OTHER|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
219299736|NCT02769403|OTHER|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
219299737|NCT02769403|OTHER|Sick Days|Sick days during the 12 week study period will be collected
219299738|NCT02769403|OTHER|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
219299739|NCT01159210|BIOLOGICAL|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
219299740|NCT01100827|OTHER|EGFR mutation status in patients|
219299741|NCT00856037|DRUG|Doxorubicin Hydrochloride|Given IV
219299742|NCT00856037|OTHER|Laboratory Biomarker Analysis|Correlative studies
219299743|NCT00856037|OTHER|Quality-of-Life Assessment|Ancillary studies
219299744|NCT00856037|DRUG|Topotecan Hydrochloride|Given PO
219299745|NCT02923492|BEHAVIORAL|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
219299746|NCT04664803|DRUG|Cefecin Tab.|
219299747|NCT04664803|DRUG|Omnicef Cap.|
219299748|NCT04463316|DIAGNOSTIC_TEST|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
219299749|NCT05120726|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Dehydrated human amnion/chorion membrane (dHACM) has been commercially available for nearly 15 years. dHACM has been shown to elute growth factors including platelet-derived growth factors, fibroblast growth factors (PDGF), fibroblast growth factors (FGF), transforming growth factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Additionally, dHACM exerts immunomodulatory effects by releasing anti-inflammatory interleukins and factors which help regulate the matrix metalloproteinase (MMP) activity. Furthermore, dHACM has also been shown to stimulate mesenchymal stem cell migration and recruitment. dHACM is routinely utilized in the management of chronic wounds including diabetic ulcer and venous ulcers.
219299750|NCT04422444|DIAGNOSTIC_TEST|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
219299751|NCT00480129|BEHAVIORAL|Probiotic or placebo yogurt consumed daily|
219299752|NCT00480129|DEVICE|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
219299753|NCT00480129|PROCEDURE|Blood sample|
219299754|NCT00480129|PROCEDURE|Nasal lavage|
219299755|NCT02412371|DRUG|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
219299756|NCT02412371|DRUG|Placebo for Veliparib|Capsule for oral administration
219299757|NCT02412371|DRUG|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
219299758|NCT02412371|DRUG|Veliparib|Capsule for oral administration
219299759|NCT02412371|RADIATION|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
219299760|NCT03383822|DRUG|Intranasal insulin|Humalog lispro 40 IU intranasally
219299761|NCT03383822|DRUG|Intranasal placebo|Diluent intranasally
219299762|NCT05568732|PROCEDURE|Root coverage procedure will be done with VCMX|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
219299763|NCT05568732|PROCEDURE|Root coverage procedure will be done with CTG|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
219299764|NCT00040027|DRUG|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
219299765|NCT00040027|DRUG|placebo + PEGinterferon alfa-2a|
219299766|NCT05096585|BEHAVIORAL|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
219299767|NCT05096585|BEHAVIORAL|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
219299768|NCT00682773|OTHER|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
219299769|NCT05470192|OTHER|Qigong exercise training|"Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~1. Raising arms with palms up,~2. Shooting arrows left and right like an archer in a semi-crouching position~3. Keeping one arm up~4. Looking back with trunk rotations in a semi-crouching position~5. Nodding the head and lowering the body to relieve stress,~6. Fisting and staring~7. Touching feet with hands touching back and legs~8. Raising and lowering heels"
219299770|NCT01270074|DRUG|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
219299771|NCT01270074|DRUG|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
219299772|NCT02217124|OTHER|dried apples|120 calories
219299773|NCT02217124|OTHER|muffin|120 calories
219299774|NCT01935973|OTHER|Laboratory Biomarker Analysis|Correlative studies
219299775|NCT01935973|DRUG|Trametinib|Given PO
219299776|NCT01935973|DRUG|Uprosertib|Given PO
219299777|NCT00000167|PROCEDURE|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
219299778|NCT06444230|OTHER|Routine Physical therapy with Neurodevelopmental technique|participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks
219299779|NCT06444230|OTHER|Routine Physical therapy|participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo
219299780|NCT03796702|PROCEDURE|Deileostomy|Deileostomy
219299781|NCT01449136|OTHER|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
219299782|NCT04654975|PROCEDURE|Esophagectomy for esophageal cancer|Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
219299783|NCT01375088|DRUG|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
219299784|NCT02053792|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
219299785|NCT00391131|DRUG|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
219299786|NCT00124293|DRUG|activated recombinant human factor VII|
219299787|NCT00701532|DRUG|Modafinil and PET (brain imaging)|duration 90 days
219299788|NCT00701532|DRUG|placebo|duration 90 days
219299789|NCT01666938|OTHER|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
219299790|NCT01666938|OTHER|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
219299791|NCT02170818|OTHER|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
219299792|NCT02170818|OTHER|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
219299793|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
219299794|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
219299795|NCT03643393|PROCEDURE|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
219299796|NCT03149549|DRUG|CX-2009|CX-2009 Monotherapy
219299797|NCT03799835|DRUG|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
219299798|NCT03799835|DRUG|Atezolizumab|IV perfusion
219299799|NCT02909764|OTHER|Low Sodium Group|Breakfast Cereal
219299800|NCT02686827|DRUG|Paricalcitol|Vitamin D3 analogue
219299801|NCT02686827|DRUG|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
219299802|NCT03183726|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."
219299803|NCT03141905|OTHER|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
219299804|NCT03141905|OTHER|Usual Care|Standard clinical care
219299805|NCT01002300|DRUG|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
219299806|NCT00427310|DRUG|fluorouracil|
219299807|NCT00427310|OTHER|Observation|
219299808|NCT00427310|DRUG|sodium heparin|
219299809|NCT04706559|DRUG|Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii|Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
219299810|NCT04706559|DRUG|Conventional treatment|topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
219744225|NCT02489279|BEHAVIORAL|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
219744226|NCT02489279|BEHAVIORAL|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
219744227|NCT05558579|OTHER|No sling use|Patients will not use standard of care sling
219744228|NCT05323344|OTHER|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
219744229|NCT05323344|OTHER|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
219744230|NCT05613127|BIOLOGICAL|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
219744231|NCT05613127|BIOLOGICAL|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
219744232|NCT00685295|DRUG|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
219744233|NCT00685295|DRUG|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
219744234|NCT00685295|DRUG|Oxycodone|Oxycodone 5/325 mg tablet
219744235|NCT05409794|BIOLOGICAL|Blood sample|Blood sample for the determination of plasma lithium levels
219744236|NCT01900184|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
219744237|NCT01900184|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
219299811|NCT06863324|DIAGNOSTIC_TEST|Radiation induced Lymphocyte Apoptosis diagnostic test|Diagnostic test for estimation of individual radiosensitivity, based on blood test, whose clinical value has been demonstrated in predicting complications in patients irradiated for breast or prostate cancer. These tests are based on the rate of radiation-induced lymphocyte apoptosis, known as the RILA (Radiation Induced Lymphocyte Apoptosis) score
219299812|NCT06885970|DRUG|Cytisinicline administration|Participants will receive in the smoki
219299813|NCT06728150|RADIATION|computerized tomography|The patients will have 3 monthly CT scans of the brain for 2 years and 6 monthly CT scans for 2 years for total of 4 years.
219299814|NCT06728501|BEHAVIORAL|Diabetes education|Patients receive 5 hours of diabetes education
219299815|NCT06728618|DRUG|Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel|"Neoadjuvant treatment: the participants will receive Tislelizumab 200 mg, Cisplatin 75 mg/m2, Nab-paclitaxel 260 mg/m2 (each 3-week cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles.~Adjuvant treatment: the participants will receive Tislelizumab 200 mg (each 3-week cycle, a total of 8 cycle) and Cetuximab (250 mg/m2, each 2-week, a total of 12 cycle) for a total of half a year."
219299816|NCT06729736|PROCEDURE|ERAS protocol|"The ERAS protocol includes:~* Pre-admission education, counselling and nutritional support~* Pre-induction oral analgesics~* Minimal fasting and carbohydrate loading~* Omission of nasogastric intubation~* Intra-operative abdominal nerve block~* Early mobilization~* Early oral nutrition and minimal IV fluids~* Multimodal opioid sparing analgesia~* Postoperative nausea and vomiting prophylaxis~* Early removal of urinary catheters"
219299817|NCT06729593|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
219299818|NCT06729593|BIOLOGICAL|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
219299819|NCT06729593|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
219299820|NCT06729476|DEVICE|Uroshield vibrator device|UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
219299821|NCT06745934|BEHAVIORAL|Healthy Minds Program|Participants in this arm engage with the Healthy Minds Program app/
219299822|NCT01732159|OTHER|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
219299823|NCT06906016|BIOLOGICAL|Collection of blood samples for the study of HBV biomarkers|The intervention involves the additional and minimal collection of two blood samples during routine care procedures (9mL in a dry tube and 9mL in a Paxgene tube). These samples are specifically collected for research purposes and will be stored in the laboratory at the Henri Mondor Biobank Platform under the responsibility of Pr Bijan Ghaleh-Marzban for 15 years. The samples will be preserved under strict conditions and may be used for future analyses related to the pathology of HBV infection or other scientific advancements, with the patient's informed consent.
219299824|NCT06907420|DEVICE|Visual stimulation|40 Hz visual stimulation will be delivered at the same time of day over 5 consecutive days. Participants will lay down while wearing the customized sleep mask with inbuilt red LEDs flickering at 40 Hz linked to a microcontroller. Participants will be asked to keep their eyes closed and encouraged to fall asleep for the full stimulation duration of 60 minutes.
219299825|NCT06907433|OTHER|Kinesiotaping|The lymphatic correction technique described by Kase for use in sacroiliac sprains or inflammations was used in KT of the dysfunctional sacroiliac joint. While the patient is standing with the spine in a neutral position, the base part of the fan-shaped cut Kinesio tape will be attached approximately 2-3 inches (approximately 5-8 cm) above the dysfunctional sacroiliac joint. Then, the patient is asked to lean forward and rotate in the opposite direction to the dysfunctional side. The tail parts of the fan-shaped tape are passed downward and inward at a 45-degree angle over the sacroiliac joint and attached to the superior edge of the gluteus maximus. The base of another kinesio tape was attached approximately 2-3 inches (approximately 5-8 cm) below the dysfunctional sacroiliac joint, the tails of the fan-shaped tape were passed upward and inward at a 45-degree angle over the sacroiliac joint and attached approximately to the upper edge of the PSIS.
219744238|NCT00973128|DRUG|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
219744239|NCT00973128|DRUG|Meglumine antimoniate|20mg/daily for 20 days
219744240|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
219744241|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
219744242|NCT04448379|DRUG|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
219744243|NCT04277247|DRUG|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
219744244|NCT04277247|DRUG|Placebo|0.9% saline placebo injection
219744245|NCT04927702|DEVICE|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
219744246|NCT04927702|DEVICE|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
219299826|NCT06907433|OTHER|Rigid taping|The technique specified in the study by Allah et al. was taken as a reference for RT of the dysfunctional sacroiliac joint. Patients were placed in a lateral position on their healthy side, with the affected side uppermost, hip flexed to 45 degrees, and the femur in a neutral position. The rigid tape was attached to the anterior superior iliac spine of the upper hip and pulled tight, and attached linearly to the posterior superior iliac spine. Another piece was attached between the same points, but in a curved shape with the opening facing downward.
219299827|NCT06907433|OTHER|Exercise|Patients in all 3 groups were shown an exercise program by a physiotherapist that included lumbopelvic stabilization, flexibility and strengthening exercises for the low back and hip, and were asked to apply the exercise program for 15 days by providing visual material showing the exercises.
219299828|NCT06906198|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461, 1.0%
219299829|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461, 0.5%
219299830|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.25%|VVN461, 0.25%
219299831|NCT06906198|DRUG|VVN461 Ophthalmic Solution Placebo|Vehicle
219299832|NCT06907498|DRUG|Paromomycin|Paromomycin 500mg X3 / day
219299833|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
219299834|NCT05565352|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
219299835|NCT04538443|OTHER|functional capacity|impact of hemodialysis on functional capacity in children with CKD
219299836|NCT04538443|OTHER|muscle strength|impact of hemodialysis on muscle strength in children with CKD
219299837|NCT04538443|OTHER|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
219299838|NCT04538443|OTHER|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
219299839|NCT00763737|PROCEDURE|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
219299840|NCT00589238|DRUG|carboplatin|
219299841|NCT00589238|DRUG|cyclophosphamide|
219299842|NCT00589238|DRUG|doxorubicin hydrochloride|
219299843|NCT00589238|DRUG|paclitaxel|
219299844|NCT05125705|BIOLOGICAL|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
219299845|NCT05125705|OTHER|Saline injection|Saline injection
219299846|NCT02502799|BEHAVIORAL|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
219299847|NCT02502799|BEHAVIORAL|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
219299848|NCT02502799|DRUG|Methylphenidate|Adolescents will receive methylphenidate.
219299849|NCT02301715|DRUG|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
219299850|NCT02301715|DRUG|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
219299851|NCT01710332|DRUG|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
219299852|NCT06432608|DIETARY_SUPPLEMENT|fermented milk, Yakult|Study subjects will be provided with a product based on fermented milk, Yakult (80mL) daily for four weeks in order to know the effects of clinical manifestation of functional constipation and short-fatty acids in the Mexican population
219299853|NCT04324203|OTHER|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
219299854|NCT02166125|PROCEDURE|Endosuturing|Endoscopic suturing
219299855|NCT00201786|DRUG|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
219299856|NCT05259254|OTHER|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
219299857|NCT05259254|OTHER|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
219299858|NCT01345773|PROCEDURE|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
219299859|NCT00119210|DRUG|Bupropion SR|
219299860|NCT00119210|OTHER|placebo|
219299861|NCT02632162|OTHER|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
219299862|NCT00339456|DRUG|HAART|
219299863|NCT05715918|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
219299864|NCT05715918|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
219299865|NCT05480579|BIOLOGICAL|placebo|Dose4 placebo of single IV injection
219299866|NCT05480579|BIOLOGICAL|IBI311|Dose2 IBI311 of single IV injection
219299867|NCT05480579|BIOLOGICAL|IBI311|Dose4 IBI311 of single IV injection
219299868|NCT05480579|BIOLOGICAL|placebo|Dose3 placebo of single IV injection
219299869|NCT05480579|BIOLOGICAL|placebo|Dose1 placebo of single IV injection
219299870|NCT05480579|BIOLOGICAL|IBI311|Dose1 IBI311 of single IV injection
219299871|NCT05480579|BIOLOGICAL|IBI311|Dose 3 IBI311 of single IV injection
219299872|NCT05480579|BIOLOGICAL|placebo|Dose2 placebo of single IV injection
219299873|NCT05037877|DIETARY_SUPPLEMENT|HUM supplement|HUM supplement - 1 capsule per day
219299874|NCT05037877|DIETARY_SUPPLEMENT|Placebo|Placebo supplement - 1 capsule per day
219299875|NCT04290936|DRUG|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
219299876|NCT04290936|DRUG|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
219299877|NCT03429231|DIETARY_SUPPLEMENT|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
219299878|NCT00001396|DEVICE|Paragon Pacemaker|
219299879|NCT00040677|DRUG|Low Dose ICA-17043|Low dose arm
219299880|NCT00040677|DRUG|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
219299881|NCT00040677|DRUG|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
219299882|NCT02863497|BEHAVIORAL|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
219299883|NCT03251781|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
219299884|NCT02687893|BEHAVIORAL|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
219299885|NCT02687893|BEHAVIORAL|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
219299886|NCT06271629|DIAGNOSTIC_TEST|Insomnia severity index|"The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties."
219299887|NCT02680002|BIOLOGICAL|7.5 mcg H5N1 (stored as monobulk)|
219299888|NCT02680002|BIOLOGICAL|15 mcg H5N1 (stored as monobulk)|
219299889|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored as monobulk)|
219299890|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored in vials)|
219299891|NCT02680002|OTHER|MF59|
219299892|NCT02680002|OTHER|MF59 (stored as monobulk)|
219299893|NCT04200885|DRUG|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
219299894|NCT04200885|DRUG|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
219299895|NCT04200885|DEVICE|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
219299896|NCT04889547|DRUG|Dexamethasone|Intraoperative intravenous dexamethasone
219299897|NCT04889547|OTHER|No dexamethasone|No intraoperative intravenous dexamethasone
219299898|NCT02442154|PROCEDURE|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
219299899|NCT03508037|OTHER|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
219299900|NCT04088487|BEHAVIORAL|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
219299901|NCT04259645|DRUG|Drug: Bupivacaine 0.375% 20 mL|20 mL 0.375% Bupivacaine
219299902|NCT04259645|DRUG|Drug: Bupivacaine 0.375% diluted to 0.1875%|Each block of 0.375% Bupivacaine x 20 ml mixed (diluted) with Normal Saline Solution 20 mL (total 40 mL)
219299903|NCT03173573|DRUG|FDL176|CFTR modulator
219299904|NCT03173573|DRUG|Placebo|Placebo for FDL176
219299905|NCT06016673|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
219299906|NCT03527173|BIOLOGICAL|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
219299907|NCT03527173|DRUG|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
219299908|NCT03527173|BIOLOGICAL|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
219299909|NCT03790319|BEHAVIORAL|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
219299910|NCT03790319|BEHAVIORAL|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
219299911|NCT02856828|DEVICE|DIE|digital image enhancement
219299912|NCT00284687|DRUG|Artesunate|PO Artesunate
219299913|NCT03187691|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
219299914|NCT02977585|DEVICE|10 cmH2O peep|positive end expiratory pressure
219299915|NCT04312893|OTHER|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
219299916|NCT04312893|OTHER|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
219299917|NCT03701815|BEHAVIORAL|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
219299918|NCT00504660|DRUG|Capecitabine|Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
219299919|NCT00504660|DRUG|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
219299920|NCT00504660|DRUG|Temozolomide|Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.
219299921|NCT00504660|DRUG|Lomustine|Arms 2,3 = 100 mg/m\^2 PO on Day 4.
219299922|NCT00504660|DRUG|6-Thioguanine|Arms 1,2,3 = 80 mg/m\^2 PO Every 6 Hours on Day 1-3.
219299923|NCT03029312|DEVICE|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
219299924|NCT05601947|OTHER|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
219299925|NCT05601947|OTHER|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
219299926|NCT01662726|DRUG|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
219299927|NCT05974215|DEVICE|assessment of change in bone height by cone beam computed tomography|bone height was measured at 1 ,30 ,90 days after denture insertion
219299928|NCT01248780|DRUG|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
219299929|NCT01248780|DRUG|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
219299930|NCT01248780|DRUG|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
219299931|NCT00001267|DRUG|zidovudine|
219299932|NCT00001267|DRUG|2',3'-dideoxyinosine|
219299933|NCT01481220|DRUG|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
219299934|NCT02134977|DRUG|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
219299935|NCT00798915|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
219299936|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
219299937|NCT00798915|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
219299938|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
219299939|NCT00672893|OTHER|Vibration Response Imaging|12 seconds of recording lung sounds
219299940|NCT06050187|PROCEDURE|implant casts fabrication|four implant casts fabricated
219299941|NCT02148549|DRUG|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
219299942|NCT04975477|PROCEDURE|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
219299943|NCT04975477|PROCEDURE|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
219299944|NCT02010008|BEHAVIORAL|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
219299945|NCT02198079|BIOLOGICAL|Sputum|
219299946|NCT03383120|DEVICE|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
219299947|NCT03383120|PROCEDURE|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
219299948|NCT04097301|DRUG|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
219299949|NCT01773291|OTHER|acupuncture|acupuncture on GV26 and 12 Well points
219299950|NCT01773291|OTHER|laser acupuncture|laser acupuncture on GV26 and 12 Well points
219299951|NCT01773291|OTHER|control|sham laser acupuncture
219299952|NCT02522351|OTHER|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299953|NCT02522351|OTHER|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299954|NCT02522351|OTHER|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299955|NCT02522351|OTHER|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299956|NCT02522351|OTHER|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299957|NCT02522351|OTHER|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
219299958|NCT05986747|BEHAVIORAL|Video-based CBT guided self-help Interventions|"Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments."
219299959|NCT00006342|GENETIC|chromosomal translocation analysis|
219299960|NCT00006342|GENETIC|gene rearrangement analysis|
219299961|NCT00006342|GENETIC|mutation analysis|
219299962|NCT04004247|DEVICE|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
219299963|NCT05160792|DEVICE|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
219744247|NCT04927702|DEVICE|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
219744248|NCT03088683|DEVICE|Nathanson Retractor|Liver will be retracted with Nathanson retractor
219744249|NCT03088683|DEVICE|Reveel Retractor|Liver will be retracted with Reveel retractor
219744250|NCT03235804|DIETARY_SUPPLEMENT|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
219299964|NCT06460584|OTHER|Pursed Lip Breathing|In each set, 10 times will be included. Reading will be taken from 1st POD and comparison will be done on each 4rth POD. Ask the patient to sit in a comfortable position and relax. Then, instruct the patient to take deep breath 12 through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
219299965|NCT06460584|OTHER|Incentive Spirometer|For the use of flow based IS, the Patient will be sited in a comfortable Position (Semi-Recumbent Position Of 45 Degrees), With a Pillow under the knees or Semi-Fowler Position on bed, and then asked to perform this technique with the same order to ensure that she / he understands the process. The patient will be instructed to inhale with a slow continuous and deep breathing, and hold for a period of not less than 5 seconds and exhale passively. And is instructed to hold the spirometry upright to perform slowly inhalation, thus lifting the ball. At the end of the evaluation of respiratory measures for patients with lung function, and then compare the results with the previous results. IS will be recommended to be performed by patient every 10 breaths hourly and 5 times per day.
219299966|NCT00827320|DRUG|Levetiracetam|1000 mg tablet
219299967|NCT03821441|BIOLOGICAL|bOPV(Candy)|"A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
219299968|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
219299969|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
219299970|NCT00203476|DRUG|Niacin|
219299971|NCT00203476|DRUG|Colestipol|
219299972|NCT00203476|DRUG|Ezetimibe|
219299973|NCT03068533|OTHER|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
219299974|NCT03068533|OTHER|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
219299975|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
219299976|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
219299977|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
219299978|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
219299979|NCT02207348|DRUG|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
219299980|NCT04628819|DIETARY_SUPPLEMENT|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
219299981|NCT04685057|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo for 6 months
219299982|NCT04685057|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic for 6 months
219299983|NCT04685057|DIETARY_SUPPLEMENT|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
219299984|NCT02054988|OTHER|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake."
219299985|NCT02054988|OTHER|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
219299986|NCT00892931|DRUG|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
219299987|NCT05029180|OTHER|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
219299988|NCT02839759|OTHER|TELLYHealth|Educational videos and questions.
219299989|NCT02080312|DRUG|Magnevist (gadopentetate dimeglumine)|
219299990|NCT06384638|BIOLOGICAL|topical application of coconut oil|topical application of coconut oil
219299991|NCT06384638|OTHER|scaling and debridement|scaling and debridement
219299992|NCT04257591|OTHER|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
219299993|NCT06101849|BEHAVIORAL|I-Can-Manage-Pain after cancer (Pain Management Program)|6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
219299994|NCT00107120|DRUG|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
219299995|NCT00107120|DRUG|Placebo|Placebo once daily for up to 8 weeks
219299996|NCT02088307|DIETARY_SUPPLEMENT|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
219299997|NCT06093854|RADIATION|Intraoperative radiotherapy (IORT)|Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)
219299998|NCT06093854|RADIATION|Stereotactic body radiotherapy (SBRT)|postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
219299999|NCT01013454|DRUG|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
219300000|NCT00294853|PROCEDURE|MDCT calcium score|
219300001|NCT06258460|OTHER|psychotherapy training program intervention|The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
219300002|NCT06258460|OTHER|the wail-list control intervention|The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
219300003|NCT01281150|DRUG|Carboplatin|Given IV
219300004|NCT01281150|OTHER|Laboratory Biomarker Analysis|Correlative studies
219300005|NCT01281150|DRUG|Paclitaxel|Given IV
219300006|NCT01281150|OTHER|Pharmacological Study|Correlative studies
219300007|NCT01281150|DRUG|Veliparib|Given PO
219300008|NCT02068209|DRUG|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
219300009|NCT02068209|DRUG|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
219300010|NCT03620370|DRUG|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
219300011|NCT02377115|OTHER|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
219300012|NCT02774031|DEVICE|Aisys with Et control|
219300013|NCT02774031|DEVICE|Aisys conventional|
219300014|NCT02774031|DEVICE|Flow-i with ACG|
219300015|NCT02774031|DEVICE|Flow-i conventional|
219300016|NCT00414037|DRUG|Eszopiclone|
219300017|NCT00414037|DRUG|Placebo|Placebo-treatment
219300018|NCT02055196|BIOLOGICAL|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
219300019|NCT02055196|DRUG|irinotecan hydrochloride|Given IV
219300020|NCT02055196|OTHER|laboratory biomarker analysis|Correlative studies
219300021|NCT01706887|OTHER|Diet Amiloride|only arm of the trial
219300022|NCT04574752|DIAGNOSTIC_TEST|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
219300023|NCT00005829|DRUG|gemcitabine hydrochloride|
219300024|NCT03173677|DIETARY_SUPPLEMENT|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
219300025|NCT03173677|DIETARY_SUPPLEMENT|Glucose intake|300 calories of glucose
219300026|NCT03173677|DIETARY_SUPPLEMENT|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
219300027|NCT02032277|DRUG|Cyclophosphamide|Cyclophosphamide
219300028|NCT02032277|DRUG|Placebo|Placebo for Carboplatin
219300029|NCT02032277|DRUG|Doxorubicin|Doxorubicin
219300030|NCT02032277|DRUG|Paclitaxel|Paclitaxel
219300031|NCT02032277|DRUG|Carboplatin|Carboplatin
219300032|NCT02032277|DRUG|Veliparib|Veliparib
219300033|NCT02032277|DRUG|Placebo|Placebo for Veliparib
219300034|NCT00610103|DRUG|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
219300035|NCT05080816|DIETARY_SUPPLEMENT|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
219300036|NCT05080816|DIETARY_SUPPLEMENT|Enteral nutrition|Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.
219300037|NCT05080816|OTHER|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
219300038|NCT05316415|OTHER|Acemaşiran Music Group|Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
219300039|NCT04616703|RADIATION|CT imaging|CT of abdomen
219300040|NCT05384353|OTHER|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
219300041|NCT03650517|PROCEDURE|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
219300042|NCT03650517|PROCEDURE|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
219300043|NCT03650517|PROCEDURE|Robotic Surgery|Procedure is performed using robotic instruments
219300044|NCT03650517|PROCEDURE|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
219300045|NCT00559858|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|
219300046|NCT00559858|OTHER|placebo|
219300047|NCT00559858|PROCEDURE|quality-of-life assessment|
219300048|NCT02838433|OTHER|biological samples|blood and tissue samples
219300049|NCT02907164|BEHAVIORAL|Email invitation|Receive emails encouraging them to sign up
219300050|NCT02907164|BEHAVIORAL|Social norm|Receive information about how many people have signed up
219300051|NCT02907164|BEHAVIORAL|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
219300052|NCT02907164|BEHAVIORAL|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
219300053|NCT04937803|DEVICE|Drug-coated balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
219300054|NCT04937803|DEVICE|Zotarolimus-Eluting Coronary Stent|Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
219300055|NCT00420433|PROCEDURE|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
219300056|NCT00420433|PROCEDURE|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
219300057|NCT00420433|PROCEDURE|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
219300058|NCT01813929|DRUG|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
219300059|NCT01813929|DRUG|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
219300060|NCT05999097|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
219300061|NCT05999097|DIETARY_SUPPLEMENT|Placebo Group|This group will receive 12 g of corn starch as a control group.
219300062|NCT06164080|OTHER|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
219300063|NCT04593316|OTHER|Saliva collection|A saliva sample will be collected before physical exercise.
219300064|NCT04593316|BEHAVIORAL|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
219300065|NCT04593316|OTHER|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
219300066|NCT04593316|OTHER|Physical exercise|The participant will perform a walk/run test.
219300067|NCT04593316|OTHER|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
219300068|NCT04593316|OTHER|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
219300069|NCT04012138|DRUG|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
219300070|NCT04012138|DRUG|Insulin Aspart|"Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
219300071|NCT03130803|BEHAVIORAL|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
219300072|NCT03182725|DRUG|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
219300073|NCT03182725|DRUG|Placebo|A substance that has no therapeutic effect and will act as a control.
219300074|NCT04697771|OTHER|Fine Motor Skills Training|The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani \& Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith \& O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
219300075|NCT02558686|OTHER|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
219300076|NCT02558686|OTHER|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
219300077|NCT02558686|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
219300078|NCT00938470|DRUG|capecitabine|Given PO
219300079|NCT00938470|DRUG|docetaxel|Given IV
219300080|NCT00938470|DRUG|fluorouracil|Given IV
219300081|NCT00938470|DRUG|oxaliplatin|Given IV
219300082|NCT00938470|RADIATION|radiation therapy|Undergo radiation therapy
219300083|NCT00938470|PROCEDURE|therapeutic conventional surgery|Undergo surgery
219300084|NCT04851925|OTHER|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
219300085|NCT02808637|OTHER|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
219300086|NCT02808637|OTHER|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
219300087|NCT02808637|OTHER|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
219300088|NCT02808637|OTHER|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
219300089|NCT01412463|DEVICE|stent placement|"* pre-dilation of the study lesion is mandatory~* stent placement with 1 Protégé Everflex+ stent~* only 1 stent is allowed within the study protocol~* post-dilation may be performed but is not mandatory"
219300090|NCT04171323|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
219300091|NCT04171323|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
219300092|NCT00267839|BEHAVIORAL|physical exercise, wellness|
219300093|NCT00767416|BIOLOGICAL|MEDI-559|Cohort 1 (5 to \<24 months): N=80 MEDI-559 at 10\^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10\^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
219300094|NCT00767416|OTHER|Placebo|Cohort 1 (5 to \< 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
219300095|NCT04952454|PROCEDURE|External Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.
219300096|NCT04952454|PROCEDURE|Endonasal Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.
219300097|NCT04952454|PROCEDURE|Transcanalicular Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.
219300098|NCT03760731|BEHAVIORAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
219300099|NCT03760731|BEHAVIORAL|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
219300100|NCT04821687|DRUG|Ongentys 50mg|Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
219300101|NCT04821687|DRUG|Madopar Tab. 125 or Perkin Tab. 25-100mg|Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
219300102|NCT00551265|DRUG|Cyclophosphamide|Given IV
219300103|NCT00551265|PROCEDURE|Laboratory Biomarker Analysis|Correlative studies
219300104|NCT00551265|BIOLOGICAL|Oregovomab|Given IV
219300105|NCT01246557|DRUG|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
219300106|NCT01246557|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
219300107|NCT01505218|DRUG|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
219300108|NCT01505218|DRUG|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
219300109|NCT00070824|PROCEDURE|acupuncture|
219300110|NCT06101043|PROCEDURE|Pectoral nerve block|An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).
219300111|NCT01413776|DIETARY_SUPPLEMENT|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
219300112|NCT06312228|OTHER|Helfer Skin Tap|Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
219300113|NCT06312228|OTHER|Buzzy|The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
219300114|NCT02982395|DRUG|Nanoxel®M|Intravesical
219300115|NCT02982395|DRUG|Mitomycin-C|Intravesical
219300116|NCT05643352|PROCEDURE|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
219300117|NCT02982460|OTHER|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
219300118|NCT02982460|OTHER|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
219300119|NCT04680338|DIAGNOSTIC_TEST|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
219300120|NCT05564780|DRUG|RASI and/or a single pill combination based RASI|The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
219300121|NCT01678105|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
219300122|NCT01814852|DEVICE|Shockwave system|
219300123|NCT01814852|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
219300124|NCT05389917|PROCEDURE|Pancreaticoduodenectomy|"In Pre Operative phase~64 Slice MD CT scan will be taken in all patients undergoing PD in pre op period 3D reconstruction of Peripancreatic vascular system using MDCT images Measure longitudinal distance between Root of Left renal vein, origin of IPDA Measure distance between origin of SMA , MCA and the IPDA~In Intraoperative period~Distance will be measured using standard disposable ruler from Root of Left renal vein to IPDA after Transection of Pancreas followed by specimen removal and to measure the distance between MCA, SMA and IPDA using standard disposable ruler ."
219300125|NCT00434005|DRUG|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
219300126|NCT00434005|DRUG|Placebo|matched appearance to acetylcysteine and ascorbate intervention
219300127|NCT06118203|DRUG|Semaglutide|Semaglutide in addition to standard of care
219300128|NCT06242860|DEVICE|ELM|Treatment of dry eye with ELM device
219300129|NCT03870217|BEHAVIORAL|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
219300130|NCT04020627|OTHER|BiPAP Group|"BIPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
219300131|NCT04020627|OTHER|CPAP Group|"CPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
219300132|NCT04207151|BEHAVIORAL|SNAPS intervention|"The intervention is multi-level yet, targets the weakest chains in the link of PrEP initiation at safety-net hospitals designed for scalability, sustainability, and implementability across a wide range of settings. It consists of Surveillance by STI testing, Navigation by unannounced patient navigators to the Sexual Health Clinic (SHC), Accelerated follow-up with providers with PrEP expertise, Point-of-care PrEP counseling and laboratory testing, and Seamless, consistent, longitudinal, comprehensive care (SNAPS). SNAPS will selectively target those care settings where PrEP prescribing is particularly rare or absent (eg, OB/GYN). Study team will utilize a quasi- experimental design to compare rates of PrEP uptake overall, PrEP initiation in disproportionately-impacted groups, and PrEP retention pre-versus post-initiation of SNAPS, controlling for secular trends."
219300133|NCT04722939|DIAGNOSTIC_TEST|Cerebral oxygenation|Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
219300134|NCT04279392|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zoledronic acid infusion
219300135|NCT04279392|DRUG|Placebos|Saline infusion
219300136|NCT06155227|OTHER|aerobic exercise combined with blood flow restriction|aerobic exercise combined with blood flow restriction for 18 sessions
219300137|NCT06155227|OTHER|aerobic exercise|aerobic exercise for 18 sessions
219300138|NCT03017534|PROCEDURE|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
219300139|NCT04019223|DIAGNOSTIC_TEST|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
219300140|NCT04019223|DIAGNOSTIC_TEST|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
219300141|NCT02961543|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
219300142|NCT02961543|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
219300143|NCT01171807|DRUG|Dex 21-P|At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.
219300144|NCT01171807|DRUG|Placebo|Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
219300145|NCT00136942|DRUG|Atorvastatin|
219300146|NCT01488877|DRUG|PF-03882845|3 mg tablet once daily
219300147|NCT01488877|DRUG|PF-03882845|up to 10 mg tablet once daily
219300148|NCT01488877|DRUG|PF-03882845|up to 30 mg once daily
219300149|NCT01488877|DRUG|Spironolactone|spironolactone 25 mg once daily
219300150|NCT01488877|OTHER|placebo|placebo once daily
219300151|NCT04294953|DRUG|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
219300152|NCT04294953|DRUG|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
219300153|NCT03318042|OTHER|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
219300154|NCT03318042|OTHER|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
219300155|NCT01035073|DRUG|Duloxetine|30-60 mg daily for 8 weeks
219300156|NCT00602940|PROCEDURE|Acupuncture|12 treatments over 8 weeks
219300157|NCT00602940|PROCEDURE|Sham Acupuncture|12 treatments over 8 weeks
219300158|NCT01693705|PROCEDURE|Tracheostomy|
219300159|NCT04955340|DRUG|[14C]-resminostat|1 single dose of 400 mg \[14C\]-resminostat
219300160|NCT05145153|PROCEDURE|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
219300161|NCT02957851|DRUG|Medical Air|
219300162|NCT02957851|DRUG|EMONO|
219300163|NCT04209959|DRUG|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
219300164|NCT00030498|DRUG|erlotinib hydrochloride|Given orally
219300165|NCT00030498|OTHER|laboratory biomarker analysis|Correlative studies
219300166|NCT04109105|OTHER|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
219300167|NCT04277351|DEVICE|Transcranial alternating current stimulation|Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
219300168|NCT01567904|DRUG|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
219300169|NCT04101318|DEVICE|Non-Conformité Européene marked product|New Baseplate is not named at this point
219300170|NCT04101318|DEVICE|Conformité Européene marked competitor products|The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
219300171|NCT02443090|DRUG|fispemifene|
219300172|NCT02443090|OTHER|Placebo|
219300173|NCT02969239|DRUG|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
219300174|NCT02969239|DRUG|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
219300175|NCT01244178|DRUG|Insulin|Intravenous Hyperinsulinemic therapy
219300176|NCT01244178|DRUG|Insulin|Standard Intravenous Insulin Therapy
219300177|NCT04289051|DEVICE|HYDRAL Oral Rinse|Application 4 times a day for two weeks
219300178|NCT04289051|DEVICE|BIOTENE® Oral Rinse|Application 4 times a day for two weeks
219300179|NCT04289051|DEVICE|Placebo Oral Rinse|Application 4 times a day for two weeks
219300180|NCT01901341|DRUG|CB-5945|
219300181|NCT01901341|DRUG|Placebo|
219300182|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"* 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment"
219300183|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
219300184|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
219300185|NCT05927662|PROCEDURE|lumbar discectomy|mini-open discectomy
219300186|NCT01806103|BEHAVIORAL|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
219300187|NCT00864201|DRUG|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
219300188|NCT02093559|BEHAVIORAL|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
219300189|NCT02977637|PROCEDURE|Feraheme MRI/MRA|
219300190|NCT01152632|OTHER|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
219300191|NCT02944591|DEVICE|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
219300192|NCT01630746|DRUG|TAK-438|
219300193|NCT01630746|DRUG|TAK-438|
219300194|NCT02787889|OTHER|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.
219300195|NCT02787889|OTHER|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
219300196|NCT01182701|BEHAVIORAL|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
219300197|NCT03450187|DRUG|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
219300198|NCT06155448|OTHER|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
219300199|NCT00169052|BEHAVIORAL|Health Care Management and Supported Rehabilitation|
219300200|NCT02749435|OTHER|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
219300201|NCT02156128|BEHAVIORAL|Cogmed working memory training|
219300202|NCT02156128|BEHAVIORAL|Control group|
219300203|NCT02479048|DIETARY_SUPPLEMENT|Test meal 1|High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
219300204|NCT02479048|DIETARY_SUPPLEMENT|Test meal 2|High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.
219300205|NCT02479048|DIETARY_SUPPLEMENT|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
219300206|NCT06284720|DEVICE|Gamma tACS (40 Hz) over the precuneus|5 sessions of gamma tACS (40 Hz) over the precuneus
219300207|NCT06284720|DEVICE|Sham tACS over the precuneus|5 sessions of sham tACS over the precuneus
219300208|NCT03809559|DEVICE|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
219300209|NCT00003493|DRUG|dexamethasone|
219300210|NCT00003493|DRUG|pegylated liposomal doxorubicin hydrochloride|
219300211|NCT00003493|DRUG|vincristine sulfate|
219300212|NCT06277544|PROCEDURE|lateral ankle ligament repair or reconstruction|repair or reconstruction procedure for lateral ankle ligament
219300213|NCT01072760|PROCEDURE|K wire|Mallet finger treatment
219300214|NCT01528176|DRUG|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
219300215|NCT05741359|DRUG|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
219300216|NCT03061071|DEVICE|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
219300217|NCT03061071|DEVICE|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
219355011|NCT05824429|OTHER|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
219355012|NCT05824429|OTHER|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
219300218|NCT05515003|OTHER|Individualized patient education|"In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes."
219300219|NCT00768794|DIETARY_SUPPLEMENT|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
219300220|NCT00768794|DIETARY_SUPPLEMENT|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
219300221|NCT01376427|DRUG|Dexamethasone|Dexamethasone
219300222|NCT01376427|DRUG|Methotrexate|Methotrexate
219300223|NCT01376427|DRUG|Vincristine|Vincristine
219300224|NCT04374344|OTHER|Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements|Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
219300225|NCT01981473|OTHER|no intervention|
219300226|NCT01981473|OTHER|no intervention|
219300227|NCT01981473|OTHER|no intervention|
219300228|NCT01336803|DRUG|Feraheme|5 mg/kg by intravenous (IV) administration
219300229|NCT01336803|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
219300230|NCT03235960|DEVICE|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
219300231|NCT00452062|DRUG|Dexamethasone|
219300232|NCT05251662|DRUG|Sintilimab|200mg IV d1 Q3W
219300233|NCT05251662|DRUG|IBI305|7.5mg/kg IV d1 Q3W
219300234|NCT05251662|DRUG|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
219300235|NCT03354091|DEVICE|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
219300236|NCT00514891|BIOLOGICAL|Vitamin A|The effect of vitamin A given with different vaccines will be studied
219300237|NCT04540393|BIOLOGICAL|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
219300238|NCT05901662|OTHER|Competence training program|A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
219300239|NCT05901662|OTHER|Control|This group provided their routine services at senior activity centers.
219300240|NCT04223427|PROCEDURE|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
219300241|NCT01147601|DRUG|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
219300242|NCT01147601|DRUG|Control (placebo) group|Control (placebo) group
219300243|NCT01711723|DRUG|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
219300244|NCT02335528|BEHAVIORAL|SimCoach|
219300245|NCT05900687|BEHAVIORAL|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
219300246|NCT03404687|RADIATION|ultrasound|for assessment of adnexal masses size and pattern
219300247|NCT03404687|DIAGNOSTIC_TEST|cancer antigen 125 level|for prediction of malignancy
219300248|NCT03404687|RADIATION|Doppler|for detection of blood flow
219300249|NCT05963139|DRUG|Bupivacaine|US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
219300250|NCT05963139|DRUG|Morphine Sulfate|In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
219300251|NCT01888900|DRUG|DUAL|Asunaprevir and Daclatsvir
219300252|NCT01888900|DRUG|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
219300253|NCT05686538|OTHER|iDLI|TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: \>10e7 NK cells/kg and \>10e6 TCRgd cells/kg
219300254|NCT05467189|DRUG|Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)|As part of routine treatment.
219300255|NCT04645667|DRUG|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
219300256|NCT01548378|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
219300257|NCT01548378|GENETIC|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
219300258|NCT01548378|GENETIC|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
219300259|NCT01548378|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
219300260|NCT02192879|DEVICE|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
219300261|NCT02192879|DEVICE|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
219300262|NCT02192879|DRUG|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
219300263|NCT05117164|OTHER|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
219300264|NCT03034538|DRUG|Zonegran|100mg
219300265|NCT03034538|DRUG|Zonegran|200mg
219300266|NCT00154765|DEVICE|sling suspension exercises|
219300267|NCT01847469|BEHAVIORAL|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
219300268|NCT01847469|DRUG|Zonisamide|
219300269|NCT01847469|DRUG|Placebo|
219300270|NCT04303767|DRUG|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
219300271|NCT04303767|PROCEDURE|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
219300272|NCT01478139|PROCEDURE|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
219300273|NCT01478139|PROCEDURE|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
219300274|NCT03912246|BIOLOGICAL|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
219300275|NCT03912246|PROCEDURE|lumbar puncture|collection of cerebrospinal fluid
219300276|NCT04318067|DRUG|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
219300277|NCT00287495|DRUG|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
219355013|NCT05824429|OTHER|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
219300278|NCT01739816|BEHAVIORAL|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
219300279|NCT00180323|DEVICE|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
219300280|NCT02734927|OTHER|realization of computerized exercises|
219300281|NCT02717403|BEHAVIORAL|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
219300282|NCT02717403|BEHAVIORAL|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
219300283|NCT02717403|BEHAVIORAL|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
219300284|NCT02717403|BEHAVIORAL|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
219300285|NCT02257567|DRUG|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
219300286|NCT02257567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
219300287|NCT02257567|DRUG|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
219300288|NCT02257567|DRUG|Rituximab|Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
219300289|NCT02257567|DRUG|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
219300290|NCT02350777|PROCEDURE|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
219300291|NCT02350777|DEVICE|CliniMACS Cell Selection System|
219300292|NCT02115516|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
219300293|NCT02115516|BIOLOGICAL|0.9% Sodium Chloride (Placebo)|
219300294|NCT03018951|OTHER|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
219300295|NCT03018951|OTHER|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
219300296|NCT03018951|OTHER|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
219300297|NCT04460274|OTHER|Model Building|Model building
219300298|NCT04460274|OTHER|Model validation|Model validation
219300299|NCT04016467|OTHER|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
219300300|NCT04016467|OTHER|Sham thoracic treatment|Hand placement on thorax without thrust.
219300301|NCT06032936|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
219300302|NCT06032936|DRUG|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
219300303|NCT00944073|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
219300304|NCT02275975|DRUG|K-877|
219300305|NCT02275975|DRUG|Fluconazole|
219300306|NCT00504608|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
219300307|NCT02712086|OTHER|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
219300308|NCT03814031|OTHER|NO internvention|NO internvention
219300309|NCT01632982|BEHAVIORAL|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
219300310|NCT01632982|BEHAVIORAL|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
219300311|NCT01632982|BEHAVIORAL|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
219300312|NCT05688345|DRUG|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
219300313|NCT05688345|DRUG|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
219300314|NCT05688345|DRUG|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
219300315|NCT03141723|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
219300316|NCT03141723|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
219300317|NCT03141723|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
219300318|NCT03141723|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\]
219300319|NCT04006054|DRUG|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
219300320|NCT04006054|DRUG|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
219300321|NCT01065844|DRUG|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
219300322|NCT01288521|DRUG|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
219300323|NCT01288521|DRUG|Tacrolimus alone, Then Tacrolimus + Ketoconazole|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
219300324|NCT06421610|DRUG|PITAC|Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
219300325|NCT03106597|DRUG|Manidipine 20mg|"After a 1\~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
219300326|NCT03106597|DRUG|Amlodipine 10mg|"After a 1\~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
219300327|NCT03896204|BEHAVIORAL|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
219300328|NCT03896204|BEHAVIORAL|joint protection technique training|Training will be given to individuals about joint protection technique
219300329|NCT01580423|DRUG|aprepitant|125 mg capsule
219300330|NCT01580423|DRUG|placebo|capsule identical to aprepitant
219300331|NCT05564728|OTHER|Conversational Agent/Chatbot App|Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
219300332|NCT05780320|OTHER|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
219300333|NCT02884908|DRUG|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
219300334|NCT02884908|OTHER|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
219300335|NCT03830749|DRUG|Eltrombopag|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
219300336|NCT01775280|RADIATION|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
219300337|NCT01240226|DRUG|GDC-0941|Oral repeating dose
219300338|NCT01240226|DRUG|GDC-0941|Oral repeating dose
219300339|NCT01240226|DRUG|ketoconazole|Oral repeating dose
219300340|NCT05663879|DRUG|ID120040002|Drug: ID120040002
219300341|NCT05663879|DRUG|Compound-X|Drug: Compound-X
219300342|NCT05663879|DRUG|Placebo comparator|Placebo comparator
219300343|NCT04913454|OTHER|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
219300344|NCT04913454|OTHER|Cognitive training|Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
219300345|NCT03390374|DRUG|Nystatin Oral|Nystatin oral suspension
219300346|NCT01501760|DRUG|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
219300347|NCT01501760|DRUG|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
219300348|NCT00950274|DRUG|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
219300349|NCT00950274|DRUG|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
219300350|NCT05114239|DRUG|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
219300351|NCT05114239|OTHER|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
219300352|NCT01485081|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
219300353|NCT02684851|DRUG|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
219300354|NCT02684851|DRUG|Placebo|Placebo
219300355|NCT03213860|OTHER|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
219300356|NCT05050994|PROCEDURE|Microwave ablation|Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
219300357|NCT03326453|DEVICE|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
219300358|NCT00164931|DRUG|Intravenous omeprazole infusion|
219300359|NCT00164931|PROCEDURE|Scheduled second endoscopy|
219300360|NCT02238574|PROCEDURE|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
219300361|NCT02238574|OTHER|follow up|Intensified outpatient follow up (16 visits in 5 years)
219300362|NCT00681330|BIOLOGICAL|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219300363|NCT04618328|DRUG|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
219300364|NCT05023083|OTHER|Functional Status Questionnaire Urdu version|The FSQ instrument translated into Urdu consists of only 34 items, main sections addressed physical function in the activities of daily living, psychological function, role function, social function and variety of performance measures.(8) Scores range from a 0 - 4, 1 - 4, and 1 - 6 scale per question depending on section. It increases reliability and patients ease and comfort. Total score range from 0 to 100 higher score represents the more severe condition.
219300365|NCT05023083|OTHER|Original Functional Status Questionnaire|FSQ was developed to allow the comprehensive and efficient assessment of physical, psychosocial, social, and role functioning in ambulatory patients. It is a self-administered survey that takes approximately 15 min to complete. The results can be scored to produce a one-page report for clinicians to use in their practices. The responses to items within a scale are averaged and transformed to a scale with a potential range of 0 to 100.Higher score represents the more severe condition.
219300366|NCT01502631|DRUG|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
219300367|NCT01502631|DRUG|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
219300368|NCT00313001|DRUG|biphasic insulin aspart|
219300369|NCT00313001|DRUG|exenatide|
219300370|NCT00419133|BIOLOGICAL|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
219300371|NCT00419133|BIOLOGICAL|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
219300372|NCT05078320|BEHAVIORAL|Exposure and response prevention (ERP)|"The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).~Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns."
219300373|NCT05660239|OTHER|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
219300374|NCT01798121|BIOLOGICAL|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
219300375|NCT01798121|BIOLOGICAL|Reference standard|Response of reference standard material compared to Aplisol@.
219300376|NCT05309915|DRUG|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
219300377|NCT04923074|OTHER|diffusion tensor imaging(DTI) evaluation|DTI is a new kind of MRI technique to evaluate peripheral neuropathy
219300378|NCT06109025|COMBINATION_PRODUCT|FESIA GRASP|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
219300379|NCT06109025|COMBINATION_PRODUCT|VIRTUAL REHAB|VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.
219300380|NCT06109025|COMBINATION_PRODUCT|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
219300381|NCT05506657|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
219300382|NCT05506657|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
219300383|NCT01115296|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
219300384|NCT01115296|OTHER|Placebo|Placebo
219300385|NCT02084056|DRUG|Linagliptin|Linagliptin
219300386|NCT02084056|DRUG|Metformin|Metformin
219300387|NCT02084056|DRUG|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
219300388|NCT04080908|DRUG|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
219300389|NCT01293487|BIOLOGICAL|RN564|Intravenous, single dose with experimental dose
219300390|NCT04643288|PROCEDURE|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
219300391|NCT04643288|PROCEDURE|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
219300392|NCT03936582|BEHAVIORAL|Treatment|information already included in arm/group descriptions
219300393|NCT00395460|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
219300394|NCT00395460|DRUG|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
219300395|NCT01975974|DEVICE|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
219300396|NCT04984733|DRUG|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
219300397|NCT04984733|DRUG|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
219300398|NCT04984733|DRUG|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
219300399|NCT04984733|DRUG|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
219300400|NCT04399590|OTHER|Interficial Intelligence|Interficial Intelligence
219300401|NCT01124409|RADIATION|EPID Verification|Set up error verification and correction by EPID
219300402|NCT01124409|RADIATION|CBCT verification|Setup error verification and correction by CBCT
219300403|NCT01679574|DRUG|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
219300404|NCT01679574|DRUG|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
219300405|NCT01679574|DRUG|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
219300406|NCT00580346|DEVICE|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
219300407|NCT05715866|DEVICE|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
219300408|NCT05715866|PROCEDURE|therapeutic exercise|patients receive adapted therapeutic exercise
219300409|NCT05715866|BEHAVIORAL|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
219300410|NCT05849948|BEHAVIORAL|choronobiological nutrition|Providing infant nutrition in accordance with crinobiological nutrition
219300411|NCT01164124|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
219300412|NCT01164124|OTHER|Placebo|routine feedings
219300413|NCT04452396|DEVICE|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
219300414|NCT04841356|PROCEDURE|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
219300415|NCT02489123|DRUG|Enzalutamide|Given PO
219300416|NCT02489123|OTHER|Laboratory Biomarker Analysis|Correlative studies
219300417|NCT02974439|DRUG|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
219300418|NCT02974439|DRUG|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
219300419|NCT01605019|DEVICE|CoSeal|3 - 8mls of Coseal
219744251|NCT00772057|DRUG|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
219744252|NCT00772057|DRUG|Placebo|Placebo tablets given two times daily.
219300420|NCT01605019|DEVICE|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
219300421|NCT04299438|DRUG|Propranolol Hydrochloride|2mg/mL vials
219300422|NCT04299438|OTHER|Saline|0.9% saline in vials matching the vials of the active drug
219300423|NCT04771611|DRUG|Fisetin|\~20mg/kg /day oral for four days (days 0,1 and days 8,9)
219300424|NCT04771611|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
219300425|NCT04223830|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
219300426|NCT05468892|DRUG|Trifluridine Tipiracil|"Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest"
219300427|NCT05468892|DRUG|Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]|Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
219300428|NCT03635723|DEVICE|Activity monitor|Technology allowing measurement of physical activity
219300429|NCT05690724|DIETARY_SUPPLEMENT|Mitocholine™ or Placebo|Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
219300430|NCT05417022|DEVICE|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
219300431|NCT04411160|DRUG|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
219300432|NCT04411160|DRUG|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
219300433|NCT04411160|DEVICE|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
219300434|NCT06532786|OTHER|Fractal Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
219300435|NCT06532786|OTHER|Isochronous Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) single in leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
219300436|NCT06532786|OTHER|Self Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at their own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
219300437|NCT01964924|DRUG|Akt Inhibitor GSK2141795|Given PO
219300438|NCT01964924|OTHER|Laboratory Biomarker Analysis|Correlative studies
219300439|NCT01964924|DRUG|Trametinib|Given PO
219300440|NCT00680446|DRUG|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
219300441|NCT06142266|OTHER|Exercise rehabilitation program|This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs for 12-week
219300442|NCT03524053|OTHER|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
219300443|NCT03524053|OTHER|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
219300444|NCT01153958|DRUG|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
219300445|NCT01153958|DRUG|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
219300446|NCT01127152|PROCEDURE|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
219300447|NCT01340677|DRUG|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
219300448|NCT01340677|DRUG|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
219300449|NCT01340677|DRUG|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
219300450|NCT02670759|DRUG|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
219300451|NCT02670759|DRUG|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
219300452|NCT03299972|DIETARY_SUPPLEMENT|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
219300453|NCT03299972|DIETARY_SUPPLEMENT|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
219300454|NCT03299972|OTHER|Resistance Exercise|60 minutes of resistance exercise twice a week
219300455|NCT02299180|BEHAVIORAL|ACP|
219300456|NCT01780181|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
219300457|NCT01780181|DRUG|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
219300458|NCT03819998|DIAGNOSTIC_TEST|measurement of Fetuin-A level in serum|Fetuin A level will be measured in blood of the PCOS women
219300459|NCT06180018|OTHER|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
219300460|NCT01865968|BIOLOGICAL|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
219300461|NCT01865968|BIOLOGICAL|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
219300462|NCT01034163|DRUG|Panobinostat|
219300463|NCT01034163|DRUG|Placebo|Placebo
219300464|NCT05412797|BEHAVIORAL|Cycling/Using a DeskCycle|The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2
219300465|NCT05412797|BEHAVIORAL|Regular activities|The active comparator performed normal daily activities
219300466|NCT01876459|OTHER|MRI|
219300467|NCT01876459|PROCEDURE|lumbar puncture|
219300468|NCT01876459|BEHAVIORAL|neuropsychological tests|
219300469|NCT03950050|DRUG|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
219300470|NCT03891693|DEVICE|Passeo-18 Lux and SUPERA® stent|Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
219300471|NCT02086604|DRUG|Brentuximab vedotin|
219300472|NCT02086604|DRUG|Lenalidomide|
219300473|NCT03026751|PROCEDURE|Bone Marrow Aspirate|Bone marrow aspirate
219300474|NCT04159623|DEVICE|Belk Device|Knee exoskeleton with electrostimulation
219300475|NCT04159623|OTHER|Standard Rehabilitative treatment|Use the standard rehabilitative treatment
219300476|NCT02849717|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
219300477|NCT00528645|DRUG|saracatinib|Given orally
219300478|NCT03710668|RADIATION|MRI if indicated|MRI brain if indicated
219300479|NCT00350480|DRUG|Provera|
219300480|NCT00350480|DRUG|Combination Birth Control pills|
219300481|NCT02150343|DRUG|HDM-SPIRE|1 dose every 4 weeks
219300482|NCT02150343|DRUG|Placebo|1 dose every 4 weeks
219744253|NCT04729439|BEHAVIORAL|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
219744254|NCT04729439|DEVICE|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
219744255|NCT04408612|DIAGNOSTIC_TEST|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
219744256|NCT00642291|DRUG|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
219744257|NCT00642291|DRUG|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
219744258|NCT06192420|DRUG|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
219744259|NCT06192420|DRUG|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
219744260|NCT06192420|DRUG|Placebo|3g of gel three times daily for 7days (+1 day visit window)
219744261|NCT06340867|DEVICE|CEREC primescan intra-oral scanner|intra-oral scanner
219744262|NCT04908228|DRUG|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
219744263|NCT05598788|OTHER|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
219300483|NCT05192668|OTHER|Quiet time care|This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected
219300484|NCT04572113|DEVICE|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
219300485|NCT02187627|DRUG|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
219300486|NCT02187627|DRUG|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi).
219300487|NCT02187627|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
219300488|NCT02729753|DEVICE|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
219300489|NCT02729753|DEVICE|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
219300490|NCT06238518|PROCEDURE|Intravascular Lithotripsy|The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.
219300491|NCT06238518|PROCEDURE|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
219300492|NCT00190749|DRUG|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
219300493|NCT00190749|DRUG|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
219300494|NCT05660343|DRUG|Ozonized Olive Oil Solutions|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.
219300495|NCT05660343|DEVICE|Low Level Laser LLL Therapy|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
219300496|NCT03946579|OTHER|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
219300497|NCT05420844|OTHER|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
219300498|NCT00036023|DRUG|darbepoetin alfa|
219300499|NCT04127708|BIOLOGICAL|acupuncture|acupuncture group and control group
219300500|NCT05941728|OTHER|Avocado|The intervention treatment will contain avocado
219300501|NCT05941728|OTHER|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
219300502|NCT05941728|OTHER|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
219300503|NCT01090427|DRUG|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
219300504|NCT01090427|DRUG|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
219300505|NCT01090427|OTHER|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
219300506|NCT02865837|OTHER|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
219300507|NCT01200589|BIOLOGICAL|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
219300508|NCT01200589|BIOLOGICAL|Rituximab|sourced locally from commercial stock
219300509|NCT01200589|BIOLOGICAL|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
219300510|NCT01200589|BIOLOGICAL|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
219300511|NCT04235179|RADIATION|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
219300512|NCT04085185|DRUG|IBI110|Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
219300513|NCT04085185|DRUG|IBI110|IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
219300514|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
219300515|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
219300516|NCT01154010|DEVICE|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
219300517|NCT01154010|DEVICE|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
219300518|NCT05045508|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
219300519|NCT05045508|DRUG|Placebo (vehicle) Nasal Spray|Placebo (vehicle) nasal spray \[control\]
219300520|NCT04232059|DEVICE|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
219300521|NCT01025401|DEVICE|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
219300522|NCT02000193|DRUG|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."
219300523|NCT00439231|DRUG|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
219300524|NCT01660581|BIOLOGICAL|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
219300525|NCT01660581|BIOLOGICAL|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
219300526|NCT00837798|DEVICE|CRM Device|Pacemaker, ICD, or CRT device
219300527|NCT03566654|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
219300528|NCT03566654|DEVICE|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
219300529|NCT03566654|DEVICE|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
219300530|NCT03541031|DIETARY_SUPPLEMENT|Micronutrient & Fish oil|Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
219300531|NCT03541031|DIETARY_SUPPLEMENT|Olive oil & Safflower oil|Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
219300532|NCT04602273|DRUG|Azacitidine Injection [Vidaza]|
219300533|NCT00287066|DRUG|Inhaled Human Insulin|
219300534|NCT00287066|DRUG|Regular Human Insulin|
219300535|NCT00296673|DEVICE|Rehabilitation device|
219300536|NCT00178100|BEHAVIORAL|Interpersonal Psychotherapy|
219300537|NCT00178100|DRUG|paroxetine|
219300538|NCT02413333|DEVICE|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
219300539|NCT02413333|DEVICE|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
219300540|NCT02413333|DEVICE|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
219300541|NCT04486326|DRUG|Crofelemer|Crofelemer
219300542|NCT04486326|DRUG|Placebo|placebo
219300543|NCT00125073|BEHAVIORAL|Postoperative nutritional counseling|
219300544|NCT03664089|BEHAVIORAL|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
219300545|NCT03664089|BEHAVIORAL|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
219300546|NCT03743454|OTHER|No intervention|No intervention will be applied.
219300547|NCT00423631|BEHAVIORAL|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
219300548|NCT00423631|BEHAVIORAL|Standard Care|Standard care delivered by the primary care provider.
219300549|NCT04767139|BEHAVIORAL|counseling for family planning|all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
219300550|NCT04805229|OTHER|Retrospective analysis of opioid use after surgery|Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
219300551|NCT02374684|DRUG|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
219300552|NCT02374684|DRUG|Placebo|Placebo to match with experimental groups
219300553|NCT01425424|OTHER|Vitamin D supplementation|Vitamin D
219300554|NCT05134831|DIAGNOSTIC_TEST|Rhinomanometry|"At Day 0, before the hyaluronic acid injection, the patient's nasal breathing is assessed by 4-phase rhinomanometry (bilaterally: right nostril AND left nostril).~At Month 1, the patient's nasal breathing is re-assessed by 4-phase rhinomanometry, in the same conditions as Day 0."
219300555|NCT02407392|DRUG|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
219300556|NCT02407392|PROCEDURE|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
219300557|NCT00320827|DRUG|CS-1008 (humanized anti-DR5 antibody)|
219300558|NCT04265820|DEVICE|unilateral implantation of IOL|unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
219300559|NCT04265820|DEVICE|bilateral implantation of IOL|bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
219300560|NCT00000473|BEHAVIORAL|dietary supplements|
219300561|NCT00000473|DRUG|fatty acids, omega-3|
219300562|NCT00000473|BEHAVIORAL|diet, fat-restricted|
219300563|NCT02175251|PROCEDURE|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
219300564|NCT02175251|PROCEDURE|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
219300565|NCT02175251|PROCEDURE|Sham Comparator|10 session in 5 days with sham-controlled
219300566|NCT01540864|DRUG|HPP404|Administered orally once daily for 26 weeks
219300567|NCT01540864|DRUG|Placebo|Administered orally once daily for 26 weeks
219300568|NCT01992952|DRUG|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
219300569|NCT01992952|DRUG|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
219300570|NCT01992952|DRUG|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
219300571|NCT05352659|BEHAVIORAL|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
219300572|NCT05352659|BEHAVIORAL|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
219300573|NCT03760445|DRUG|HDM201|2.5 mg and 10mg capsules, given orally
219300574|NCT03760445|DRUG|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
219300575|NCT03760445|DRUG|anthracycline|20mg or other strength as locally available given intravenously
219300576|NCT03760445|DRUG|midostaurin|25mg capsules given orally
219300577|NCT03760445|DRUG|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
219300578|NCT03760445|DRUG|posaconazole|100mg delayed release tablet or other strength as locally available given orally
219300579|NCT03760445|DRUG|midazolam|2mg/mL oral solution or in other strength as locally available
219300580|NCT01049217|DRUG|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
219300581|NCT01049217|DRUG|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
219300582|NCT02111317|DRUG|ASP015K|oral
219300583|NCT02111317|DRUG|verapamil|oral
219300584|NCT03341689|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
219300585|NCT03341689|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
219300586|NCT03341689|DRUG|Placebo|microcrystalline cellulose capsule
219300587|NCT00834327|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
219300588|NCT01038622|DRUG|L-arginine|5-day L-arginine treatment
219300589|NCT01038622|DRUG|placebo|5-day placebo treatment
219300590|NCT05134077|PROCEDURE|CT scan with contrast|CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
219300591|NCT05134077|RADIATION|Nephroscintigraphy|Nephroscintigraphy is necessary to determine the renal function
219300592|NCT03495947|BEHAVIORAL|high flow nasal cannula|24 hours of continuous use in the immediate post-extubation period.
219300593|NCT00903682|DRUG|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
219300594|NCT00903682|DRUG|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
219300595|NCT02495792|DEVICE|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
219300596|NCT00359125|DRUG|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
219300597|NCT00359125|OTHER|Placebo|Placebo, 600 mg/day for 1 week.
219300598|NCT02589561|DEVICE|Remote fitting|remote fitting of hearing aids
219300599|NCT02589561|DEVICE|Face to face fitting|face to face fitting of hearing aids
219300600|NCT04351568|OTHER|quesionnair|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
219300601|NCT06502223|PROCEDURE|Pain Perception in Patients Undergoing Lumbar Disc Herniation Surgery|Analyze tryptophan metabolites (picolinic acid, 3- Hydroxykynurenine, anthranilic acid, kynurenine, quinolinic acid, kynurenic acid, xanthurenic acid). Concurrent VAS pain assessments were conducted, and correlations between tryptophan metabolites and VAS were evaluated.
219300602|NCT03671694|PROCEDURE|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
219300603|NCT04783831|DEVICE|Biodegradable stent|Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.
219300604|NCT05800418|DRUG|Ramucirumab Injection|Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
219300605|NCT05800418|DRUG|Ramucirumab Injection [Cyramza]|Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
219300606|NCT06171347|OTHER|Oral cold spray (tap water)|Oral cold spray (tap water)
219300607|NCT02813629|DEVICE|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
219300608|NCT01028027|DRUG|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
219300609|NCT01028027|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
219300610|NCT03228745|BEHAVIORAL|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
219300611|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control bread|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination
219300612|NCT05955131|OTHER|Nutritional acute postprandial intervention: bread suppelmented with Chilean beans|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.
219300613|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control glucose|Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.
219300614|NCT04062487|DEVICE|Mixed Reality technology|combine image with real body
219300615|NCT01027182|DRUG|Raltegravir|One 400mg tablet on day 1.
219300616|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
219300617|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
219300618|NCT03732599|PROCEDURE|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
219300619|NCT03732599|PROCEDURE|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
219300620|NCT03629639|DRUG|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
219300621|NCT04048421|PROCEDURE|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
219300622|NCT02336295|OTHER|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
219300623|NCT02374892|BEHAVIORAL|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
219300624|NCT04213950|OTHER|Rabies PEP quality improvement bundle|The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
219300625|NCT05174936|BEHAVIORAL|PLWH intervention|The intervention curriculum will consist of five interactive training sessions (2 hours each) with four specific areas of resilience-building: individual assets (self-esteem, emotion regulation, positive future orientation), coping with infection/illness (medical adherence, stress reduction, healthy lifestyle, self-care), relationship building (family relationship, provider-patient relationship), and social support (identifying and seeking social support at various socioecological levels).
219300626|NCT05174936|BEHAVIORAL|Family member intervention|The intervention will consist of five sessions of group activities (2 hours each), with each session addressing one or more of the following areas: 1) HIV and ART knowledge; 2) support to strengthen the capacity of PLWH and their family members to adapt to living with HIV; 3) relationship building (family relationships, intimate relationships); 4) emotional and behavioral support for PLWH's adherence to care and treatment, including tailored coping or support strategies to address unique needs of some participants who may be more prone to HIV stigma (e.g., MSM and their family members); and 5) self-care.
219300627|NCT05174936|BEHAVIORAL|Healthcare provider intervention|The HCP intervention will adapt Popular Opinion Leaders (POL) principles by teaching participants skills for initiating/disseminating stigma reduction messages/practices to colleagues in the workplace. The HCP intervention will consist of four 1.5-hour sessions addressing the following topics: 1) universal HIV precautions and occupational safety (e.g., correctly knowing and practicing universal precautions and decreasing fear of PLWH); 2) intersecting stigma against PLWH (e.g., manifestations of intersecting stigma in clinical settings); 3) provider-patient relationship (e.g., reducing stigmatizing attitudes and behaviors toward PLWH, respecting patients' rights for privacy related to care and disclosure); 4) improving quality of patient care (e.g., increasing skills and comfort in working with PLWH); 5) building a supportive medical environment for better care of PLWH; and 6) skills and confidence in delivering stigma reduction messages to coworkers.
219300628|NCT02396628|DRUG|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
219300629|NCT02396628|DRUG|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
219300630|NCT05977036|DEVICE|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
219300631|NCT05977036|DRUG|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
219300632|NCT00784940|DRUG|Anastrozole|1mg, orally, once daily
219300633|NCT00784940|DRUG|Tamoxifen|20mg, orally, once daily
219300634|NCT06610812|BEHAVIORAL|KETOGENIC MEDITERRANEAN diet|"each patient in group A was instructed briefly about the nature of the treatment regimen to gain the patient's confidence and cooperation. the patient will receive ketogenic Mediterranean diet with aerobic training program. The diet will contain approximately 9300 kJ accordingly, 37% as total fat, 18% as monounsaturated and 9% as saturated, and 33 g of fiber per day for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.~This procedure performed by using the components of ketogenic Mediterranean diet:~* Protein source: fatty fish, seafood, poultry, and eggs.~* Fats and oils: olive oil, avocado oil, and MCT oil (medium-chain triglycerides oil).~* Low carb vegetables: leafy greens, cruciferous vegetables, and other low carb veggies.~* Low carb fruits: avocados, olives, and tomato.~* Flavourings: paprika, cumin, cinnamon, coriander, anise, lemon or lime juice , mint , parsley and garlic ."
219355014|NCT05824429|OTHER|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
219744264|NCT00505687|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
219744265|NCT01290991|DEVICE|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
219300635|NCT06610812|BEHAVIORAL|hypo-caloric diet:|"Group (b) received low caloric balanced diet regimen with aerobic exercise for 3 months in the form of moderate aerobic exercises in the form of walking for 30 to 45 minutes a day, 3 times per week for 3 months. This group received a diet of 1800 calories or lower accordingly including a combination of two or more of the following in each meal: Non starchy vegetable: spinach, broccoli, cauliflower, peppers, mushrooms, tomatoes, etc.~Fruits: berries, apples bears, citrus fruits, melon, grapes bananas, etc. Starchy vegetables: potatoes peas, sweet potatoes etc. Fish and shellfish: salmon, clams, Trouts, oysters, etc. Eggs: whole eggs are more nutrient dense than white eggs. Poultry and meat: chicken turkey, beef, lamb, etc. Whole grains: oats, brown rice, farro etc. Legumes: chickpeas, kidney beans, lentils etc. Healthy fats: avocados, olive oil, unsweetened coconut, avocado oil. Dairy products: full-fat or reduced fat plain yogurt kefir and full-fat cheese."
219300636|NCT06610812|BEHAVIORAL|moderate aerobic exercises|moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
219300637|NCT06907706|BEHAVIORAL|Physical Activity/Physical Functioning|"The physical activity portion of the program sessions focuses on teaching cognitive and behavioral skills to increase physical activity, including goalsetting, self-monitoring, overcoming barriers to physical activity, enlisting social support, and how to handle high risk situations that may result in relapses to a sedentary lifestyle. The health educator teaches participants about various forms of moderate intensity activity and has them practice brief bouts of activity of various types to ensure that they are doing the activities safely and correctly. Each week participants receive a handout to provide information about the behavioral skill taught that week. The program also provides activity trackers (week 1) and resistance bands (week 5). The pedometer assists participants in self-monitoring their activity, and the resistance bands provide a form of home-based exercise that participants can do even with limited space."
219300638|NCT06907706|BEHAVIORAL|Quality of Life|The survivorship portion of the program features a guided discussion on a different topic each session. The goals of the discussion are to present information about the topic, answer participants' questions about the topic, encourage participants to share solutions and ideas relevant to the topic with each other, and provide information on community resources participants can access if they require additional help. The health educator makes a brief presentation about the topic, answers questions, and then asks a series of 2-3 open-ended questions to facilitate discussion about the topic. At the end of the session, the health educator navigates participants who need additional information or service related to the topic to resources in the community.
219300639|NCT06329700|PROCEDURE|Hepatectomy|Surgical removal of a part of the liver
219300640|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
219300641|NCT05404581|DEVICE|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
219300642|NCT05176483|DRUG|Zanzalintinib|Zanzalintinib orally once daily (qd)
219300643|NCT05176483|DRUG|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
219300644|NCT05176483|DRUG|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
219300645|NCT05176483|DRUG|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
219300646|NCT05176483|DRUG|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
219300647|NCT05176483|DRUG|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
219300648|NCT05992350|OTHER|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
219300649|NCT00947557|DRUG|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
219300650|NCT00947557|DRUG|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
219300651|NCT01617304|OTHER|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
219300652|NCT02708719|PROCEDURE|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
219300653|NCT03167931|OTHER|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
219300654|NCT03167931|OTHER|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
219300655|NCT03540953|DRUG|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
219300656|NCT05412849|RADIATION|Radiotherapy|Radiotherapy site, time perspective and dose
219300657|NCT05624320|DRUG|AGN-190584|miotic for treatment of presbyopia
219300658|NCT01657955|DRUG|Bendamustine Hydrochloride Injection|
219300659|NCT01657955|DRUG|Chlorambucil|
219300660|NCT00003555|DRUG|amifostine trihydrate|
219300661|NCT00003555|DRUG|paclitaxel|
219300662|NCT00383136|DRUG|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
219300663|NCT00383136|DRUG|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
219300664|NCT03200600|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
219300665|NCT03200600|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
219300666|NCT03200600|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
219300667|NCT03200600|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
219300668|NCT00534573|DRUG|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
219300669|NCT04834206|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
219300670|NCT04834206|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
219300671|NCT04834206|DRUG|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
219300672|NCT05344482|OTHER|Secukinumab|Included all the patients treated with secukinumab
219300673|NCT04716491|DEVICE|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
219300674|NCT00533741|DRUG|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
219300675|NCT00533741|DRUG|Placebo|Saline for injection.
219355015|NCT03147469|PROCEDURE|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
219300676|NCT00533741|BIOLOGICAL|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
219300677|NCT03023228|BEHAVIORAL|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
219300678|NCT00273767|DRUG|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
219300679|NCT00273767|DRUG|placebo|60ml of NaCl IV slow
219300680|NCT06071260|DRUG|0.01% atropine eye drop|One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.
219300681|NCT02833532|DEVICE|Volus/Powerfill|Maximum: 22ml
219300682|NCT04956172|DEVICE|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
219300683|NCT05534256|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
219300684|NCT02001610|DIETARY_SUPPLEMENT|Acidophilus pearls|"* Acidophilus pearls are encapsulated using patented process~* Subjects take one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
219300685|NCT02001610|DIETARY_SUPPLEMENT|Hard shell gelatin capsules|"* Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~* Subjects consume one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
219300686|NCT04014725|DEVICE|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
219300687|NCT04847726|DIAGNOSTIC_TEST|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
219300688|NCT04847726|DIAGNOSTIC_TEST|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
219300689|NCT04847726|DIAGNOSTIC_TEST|Liver MRI|Participants underwent liver MRI for hepatic lesion
219300690|NCT01203280|OTHER|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
219300691|NCT00728715|DRUG|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
219300692|NCT00728715|DRUG|High dose of budesonide|1600 mcg/d of budesonide
219300693|NCT00728715|DRUG|A|medium dose of budesonide-formoterol
219300694|NCT00728715|DRUG|B|High Dose Inhaled Budesonide
219355016|NCT03147469|PROCEDURE|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
219355017|NCT03147469|PROCEDURE|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
219744266|NCT04305210|DRUG|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
219744267|NCT04305210|DRUG|18F-florbetapir|18F-florbetapir
219744268|NCT04608708|OTHER|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
219744269|NCT00654602|DRUG|Rosuvastatin|
219744270|NCT00654602|BEHAVIORAL|Maintenance of specific diet|
219744271|NCT00006427|DRUG|Amitriptyline|
219744272|NCT00000600|DRUG|Vitamin E|
219744273|NCT00000600|DRUG|Vitamin C|
219744274|NCT03626233|OTHER|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
219744275|NCT03116126|DRUG|Guanfacine|2mg oral daily tablet
219744276|NCT03116126|DRUG|Placebo|inactive oral daily tablet
219744277|NCT03205267|DRUG|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
219744278|NCT01712373|DRUG|Ginseng|it is kind of drug
219744279|NCT01712373|DRUG|Placebo|it is placebo
219744280|NCT02177162|OTHER|Education to physiotherapists|
219744281|NCT01027676|DRUG|Study treatment|Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
219744282|NCT01631266|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219744283|NCT01631266|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
219744284|NCT05997901|OTHER|Varenicline healthbot|The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
219744285|NCT03171948|BEHAVIORAL|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
219744286|NCT03171948|BEHAVIORAL|Nut Free group|continue their diet without any nut consumption.
219300695|NCT04762654|OTHER|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
219300696|NCT01950026|PROCEDURE|cryotherapy application|"* Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
219300697|NCT04254302|OTHER|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
219300698|NCT00260663|PROCEDURE|Group hearing aid fittings|
219300699|NCT00260663|PROCEDURE|Group hearing aid follow-up|
219300700|NCT02650245|DIETARY_SUPPLEMENT|EAS Myoplex Protein Drink + 10gm lactulose|
219300701|NCT03457207|PROCEDURE|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
219300702|NCT00686725|DRUG|Temozolomide|
219300703|NCT00686725|RADIATION|Radiotherapy|
219300704|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
219300705|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
219300706|NCT06148974|DIETARY_SUPPLEMENT|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
219300707|NCT06148974|OTHER|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
219300708|NCT04969887|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
219300709|NCT04969887|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
219300710|NCT02358382|DRUG|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
219300711|NCT03237351|DEVICE|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
219300712|NCT00629434|OTHER|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
219300713|NCT00629434|OTHER|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
219300714|NCT04362605|PROCEDURE|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
219300715|NCT05694754|DEVICE|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
219300716|NCT00002151|DRUG|Celgosivir hydrochloride|
219300717|NCT05335720|DRUG|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
219300718|NCT03642951|DEVICE|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
219300719|NCT03642951|DEVICE|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
219300720|NCT00292162|PROCEDURE|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
219300721|NCT00292162|DRUG|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
219300722|NCT00292162|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
219300723|NCT00292162|DRUG|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
219300724|NCT02924974|DRUG|Morphine|mixed with bupivacaine
219300725|NCT02924974|DRUG|Lidocaine|sham procedure (s.c. lidocaïne)
219300726|NCT04581889|OTHER|Diagnostic test|Presence of antibodies in saliva
219300727|NCT05615090|PROCEDURE|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
219300728|NCT05615090|PROCEDURE|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
219300729|NCT02774161|OTHER|Ultrasound Tomography|Undergo B-mode ultrasound imaging
219300730|NCT03064035|DRUG|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
219300731|NCT06385405|DEVICE|Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment|The target site for alpha frequency Transcranial Magnetic Stimulation (αTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
219300732|NCT06385405|DEVICE|10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)|Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.
219300733|NCT00233805|DEVICE|Sirolimus coated Bx Velocity™|drug-eluting stent
219300734|NCT00233805|DEVICE|Bare metal Bx Velocity™|bare-metal stent
219300735|NCT00553423|DRUG|Lactulose|Lactulose 30 ml q6h for 48 hrs
219300736|NCT00553423|DRUG|Placebo|Placebo 30 ml q6hrly for 48 hrs
219300737|NCT03103763|DRUG|Warfarin|Patients on warfarin for atrial fibrillation
219300738|NCT04482686|DRUG|Ivermectin|Treatment days 1, 4, and 8
219300739|NCT04482686|DRUG|Doxycycline Hcl|10 day treatment
219300740|NCT04482686|DIETARY_SUPPLEMENT|Zinc|10 Day treatment
219300741|NCT04482686|DIETARY_SUPPLEMENT|Vitamin D3|10 day treatment
219300742|NCT04482686|DIETARY_SUPPLEMENT|Vitamin C|10 day treatment
219300743|NCT03011502|OTHER|Biological samples collection of blood and feces|
219300744|NCT02839954|BIOLOGICAL|anti-MUC1 CAR-pNK cells|
219300745|NCT04162340|BIOLOGICAL|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
219300746|NCT03168789|BEHAVIORAL|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
219300747|NCT03168789|BEHAVIORAL|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
219300748|NCT01344512|DRUG|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
219300749|NCT01344512|DRUG|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
219300750|NCT01344512|DRUG|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
219300751|NCT04511182|BEHAVIORAL|Exercise-based cardiac rehabilitation|"Exercise program is based on aerobic exercise and supplemented by strength training following the principle of gradual improvement. The type of exercise, such as walking, jogging, cycling, and the intensity of exercise which is recommended to use a cardiotach or pedometer to detect, are both defined by the results of CPET, such as METs value. Participators must be prepared for about 5-10 minutes to warm up and recover before and after exercise. 30-50 minutes a day, 5 days a week, with a total exercise time of not less than 150 minutes per week. It can be carried out in different stages according to the physical condition. After 1-3 months, the exercise prescription will be re-adjusted according to the results of reexamination.~All patients will undergo Cardiopulmonary Exercise Test, SF-36, echocardiography and laboratory examination prior to initiation of the trial, and which will be checked again after 3 months, and 6 months."
219300752|NCT01970631|BEHAVIORAL|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
219300753|NCT01970631|OTHER|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
219300754|NCT03592901|DRUG|brachial plexus anesthesia|Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
219300755|NCT01970345|DRUG|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
219300756|NCT01970345|DRUG|Placebo/saline|Placebo
219300757|NCT00536302|DIETARY_SUPPLEMENT|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
219300758|NCT00536302|DIETARY_SUPPLEMENT|Placebo|Matching placebo solution per day by mouth for 48 weeks.
219300759|NCT00413998|PROCEDURE|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
219300760|NCT00413998|PROCEDURE|CABG|Patients will undergo coronary artery bypass grafting alone.
219300761|NCT00714545|RADIATION|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
219300762|NCT06414837|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
219300763|NCT06414837|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
219300764|NCT00759018|BIOLOGICAL|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10\^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
219300765|NCT02277041|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
219300766|NCT02277041|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
219300767|NCT00400348|DRUG|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
219300768|NCT00005951|DRUG|irinotecan hydrochloride|
219300769|NCT00005951|DRUG|temozolomide|
219300770|NCT02617303|PROCEDURE|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
219300771|NCT02617303|PROCEDURE|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
219744287|NCT06022640|BEHAVIORAL|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
219744288|NCT04509388|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
219744289|NCT02001792|PROCEDURE|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
219744290|NCT02001792|DEVICE|pulse oximeter|
219300772|NCT03346161|OTHER|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
219300773|NCT03346161|OTHER|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
219744291|NCT02974192|OTHER|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
219300774|NCT03346161|OTHER|Usual Care Group - Outcome Measures|"* Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
219300775|NCT03346161|OTHER|Decision Group - Outcome Measures|"* Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
219300776|NCT03346161|OTHER|Demographic and Background Questions|"* Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
219300777|NCT00433940|DRUG|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
219300778|NCT05324397|DEVICE|NEUROMARK System|The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
219300779|NCT06043583|PROCEDURE|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
219300780|NCT06043583|PROCEDURE|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
219300781|NCT04860076|DRUG|Pembrolizumab|Standard of care
219300782|NCT02342431|DEVICE|Forced air warming compressible|Warming with a compressible forced air mattress
219300783|NCT02342431|DEVICE|Forced air non-compressible|Warming with a non-compressible forced air mattress
219300784|NCT00955253|DRUG|Guanfacine|2mg oral guanfacine (encapsulated)
219300785|NCT00955253|DRUG|Placebo|placebo
219300786|NCT05212805|BEHAVIORAL|Aerobic exercise|Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
219300787|NCT05212805|BEHAVIORAL|Task-oriented upper-limb training|The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
219300788|NCT05212805|BEHAVIORAL|Sport events participation|A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
219300789|NCT03057990|DRUG|Pyrimethamine|Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
219300790|NCT01128816|DEVICE|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
219300791|NCT00537953|DRUG|Miltefosine , meglumine antimoniate|
219744292|NCT00740675|OTHER|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
219744293|NCT06528080|GENETIC|LY-M001|LY-M001 Injection by Single Intravenous Infusion
219744294|NCT04826302|OTHER|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
219744295|NCT04826302|OTHER|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
219744296|NCT00448513|DIETARY_SUPPLEMENT|catechin extracts|comparison with placebo
219300792|NCT00702351|DRUG|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
219300793|NCT00217308|DRUG|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
219300794|NCT00558259|DRUG|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
219300795|NCT00558259|DRUG|matching placebo twice daily (BID)|Matching placebo BID
219300796|NCT06181487|OTHER|High Intensity Functional Training|12 weeks of high-intensity functional training, 3 times/week. Each class lasts 60 minutes, including warm-up, physical training, and cool down.
219300797|NCT03170895|DRUG|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
219300798|NCT03170895|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
219300799|NCT00148512|DRUG|1. Tesofensine (NS 2330)|
219300800|NCT04391634|OTHER|volume guarantee|volume guarantee assist-control mechanical ventilation
219300801|NCT04391634|OTHER|pressure-controlled|pressure-controlled assist-control mechanical ventilation
219300802|NCT06055348|DRUG|SC0191|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
219300803|NCT06055348|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
219300804|NCT06055348|DRUG|Paclitaxel|Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
219300805|NCT02415452|PROCEDURE|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
219300806|NCT05356299|OTHER|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
219300807|NCT04229875|OTHER|CAG Bipolar|See description of CAG Bipolar
219300808|NCT02093000|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
219300809|NCT02874924|DRUG|Rapamycin|treatment
219300810|NCT02874924|DRUG|Placebo|control
219300811|NCT02874924|DRUG|Rapamycin|No placebo control in this substudy group
219300812|NCT02316860|OTHER|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
219300813|NCT04609306|OTHER|H2O2 application to incision|A lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes.
219300814|NCT00737373|DRUG|Docetaxel|50mg/m2 qd15
219300815|NCT00737373|DRUG|5-Fluorouracil|2600mg/m2 qd15
219300816|NCT00737373|DRUG|Oxaliplatin|85mg/m2 qd15
219300817|NCT00737373|DRUG|folinic acid|200mg/m2 qd15
219300818|NCT04950504|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
219300819|NCT04950504|DRUG|Placebo|CNP-201 Placebo
219300820|NCT04991532|OTHER||
219744297|NCT00831389|DEVICE|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
219744298|NCT00278161|BIOLOGICAL|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
219300821|NCT02529631|DRUG|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
219300822|NCT02529631|DEVICE|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
219300823|NCT03306459|DIAGNOSTIC_TEST|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
219300824|NCT00234767|DEVICE|Pulmonary Artery Catheter|
219300825|NCT00234767|BEHAVIORAL|Protocolized Fluid Management|
219300826|NCT06063018|DRUG|RC48 + Tislelizumab|RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
219300827|NCT00920049|BEHAVIORAL|Persuasion|
219300828|NCT04871022|PROCEDURE|Double layer closure of the hysterotomy|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
219300829|NCT04871022|PROCEDURE|Purse closure of the hysterotomy|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
219300830|NCT02728869|BIOLOGICAL|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
219300831|NCT02728869|BIOLOGICAL|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
219300832|NCT02728869|BIOLOGICAL|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
219300833|NCT02771080|PROCEDURE|Cardiac surgery|
219300834|NCT02732977|OTHER|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
219300835|NCT00459615|DRUG|Artesunate for Injection|
219300836|NCT02190045|OTHER|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
219300837|NCT02190045|OTHER|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
219300838|NCT02029846|DRUG|Standard Treatment|traditional drugs only
219300839|NCT02029846|DRUG|Incretin-Based Treatment|incretin-based drugs
219300840|NCT04762823|DEVICE|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
219300841|NCT04762823|DEVICE|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
219300842|NCT02966301|DRUG|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
219300843|NCT02561754|DIETARY_SUPPLEMENT|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
219300844|NCT02561754|DIETARY_SUPPLEMENT|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
219300845|NCT02561754|BEHAVIORAL|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
219300846|NCT02561754|BEHAVIORAL|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
219300847|NCT02561754|OTHER|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
219300848|NCT04219579|DRUG|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
219300849|NCT04219579|DRUG|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
219300850|NCT02579499|DRUG|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
219744299|NCT00278161|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
219744300|NCT00278161|DRUG|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
219744301|NCT01993082|BEHAVIORAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
219744302|NCT04382092|DIAGNOSTIC_TEST|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
219744303|NCT03223675|RADIATION|hippocampal-sparing WBRT|
219744304|NCT03409198|DRUG|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
219744305|NCT03409198|DRUG|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
219744306|NCT03409198|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
219744307|NCT03409198|DRUG|Cyclophosphamide|Chemotherapy
219744308|NCT05655767|OTHER|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
219300851|NCT02579499|DRUG|targeted LDL-C goal statin|"1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
219300852|NCT00677326|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
219300853|NCT00822172|DIETARY_SUPPLEMENT|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
219300854|NCT00822172|DRUG|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
219300855|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
219300856|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
219300857|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
219300858|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
219300859|NCT00700258|DRUG|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
219300860|NCT05057299|OTHER|retrospective data analysis|chart review, analysis and reporting outcomes
219300861|NCT00832637|DRUG|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
219300862|NCT00832637|DRUG|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
219300863|NCT00832637|DRUG|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
219300864|NCT01874431|DRUG|Finerenone (BAY94-8862)|
219300865|NCT01874431|DRUG|Placebo|
219300866|NCT03834051|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Rectal Administration Open Label
219300867|NCT04261998|OTHER|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
219300868|NCT00889668|DEVICE|GlucoTrack|comparison of different glucose monitoring devices
219300869|NCT02367820|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
219300870|NCT00710853|OTHER|YiRen Qi gong|One hour weekly class for 8 week duration
219300871|NCT00710853|OTHER|Tai Chi|One hour weekly class for 8 week duration
219300872|NCT00710853|OTHER|Hatha yoga|One hour weekly class for 8 week duration
219300873|NCT00677001|DRUG|R306465|
219300874|NCT05423626|DEVICE|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
219300875|NCT05423626|DEVICE|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers."
219300876|NCT00738582|DRUG|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
219300877|NCT00738582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
219300878|NCT00738582|DRUG|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
219300879|NCT00642772|OTHER|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
219300880|NCT05344820|BEHAVIORAL|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
219300881|NCT01873820|DIETARY_SUPPLEMENT|Calcium ascorbate|
219300882|NCT01873820|DIETARY_SUPPLEMENT|Ascorbic acid|
219300883|NCT05352243|BEHAVIORAL|Expressive Disclosure|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write about their deepest thoughts and feelings surrounding their bereavement experience.
219300884|NCT05352243|BEHAVIORAL|Expressive Helping|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their first two writing will remain confidential, and their final essay will be de-identified before being provided to newly bereaved young adults. Three writing sessions will be spaced 1-2 weeks apart. In the first two writing sessions, participants will receive a writing prompt that will instruct them to write about their deepest thoughts and feelings surrounding their bereavement experience. For the final writing session, participants will receive a writing prompt instructing them to provide advice and support for a newly bereaved young adult.
219300885|NCT05352243|BEHAVIORAL|Fact-Writing|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
219300886|NCT01827618|DRUG|Rapamycin|
219300887|NCT00545051|DRUG|Placebo|po monthly for 12 months
219300888|NCT00545051|DRUG|ibandronate|150mg po monthly for 12 months
219300889|NCT00480376|DRUG|ofloxacin|
219300890|NCT00480376|DRUG|gentamicin|
219300891|NCT02778854|GENETIC|detection of driver mutation|participants are received gene detection via the liquid biopsy
219300892|NCT02468180|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
219300893|NCT02468180|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
219300894|NCT02468180|DRUG|N-butyl-2-cyanoacrylate|
219300895|NCT02468180|DRUG|Lauromacrogol|
219300896|NCT00200993|BEHAVIORAL|physical activity|
219300897|NCT01241175|DRUG|Magnesium Sulfate|
219300898|NCT01241175|DRUG|normal saline|
219300899|NCT01237275|DRUG|SSRI treated group|characterize in arm of a study (SSRI treated group)
219300900|NCT01812434|DRUG|Sildenafil|20mg three time daily for 28 days
219300901|NCT01812434|DRUG|Placebo|20 mg three times daily for 28 days
219300902|NCT02234973|BEHAVIORAL|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
219300903|NCT01123876|DRUG|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
219300904|NCT00903006|DRUG|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
219300905|NCT00903006|DRUG|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
219300906|NCT00903006|DRUG|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
219300907|NCT04137159|OTHER|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
219300908|NCT00990977|BEHAVIORAL|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
219300909|NCT05956639|DRUG|6-month course of antiandrogen drugs|6-month course of Rezvilutamide and ADT + chemotherapy
219300910|NCT05956639|DRUG|Long-term course of antiandrogen drugs|Long-term course of Rezvilutamide and ADT + chemotherapy
219300911|NCT02875886|DRUG|Amiloride|Combined with hydrochlorothiazide
219300912|NCT02875886|DRUG|Hydrochlorothiazide|Combined with amiloride
219300913|NCT02875886|OTHER|Low-sodium diet|
219300914|NCT02234687|DRUG|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
219300915|NCT02234687|DRUG|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
219300916|NCT02234687|DRUG|Placebo|Placebo, one dose, one time
219300917|NCT03271021|DRUG|FMX101|FMX101, 4% minocycline foam
219300918|NCT03271021|DRUG|Vehicle Foam|Vehicle Foam
219744309|NCT00443456|DRUG|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
219744310|NCT05107076|DIAGNOSTIC_TEST|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"* Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
219744311|NCT02587455|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
219744312|NCT02587455|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
219744313|NCT04768244|OTHER|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
219744314|NCT03733327|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
219744315|NCT03733327|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
219744316|NCT03733327|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
219744317|NCT03057184|BEHAVIORAL|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
219744318|NCT05333926|DEVICE|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
219744319|NCT00664222|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
219744320|NCT05724030|DEVICE|integrated pulmonary index|integarted pumobary index monitoring
219744321|NCT05724030|DEVICE|saturation|saturation monitorization
219744322|NCT04389060|DIETARY_SUPPLEMENT|Grape seed extract|Two capsule grape seed extract (total 600 mg)
219744323|NCT01001689|BEHAVIORAL|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
219744324|NCT00490711|DRUG|gemcitabine|
219744325|NCT00490711|DRUG|carboplatin|
219744326|NCT00490711|DRUG|paclitaxel|
219744327|NCT04669795|DRUG|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
219300919|NCT04331145|DRUG|Ticagrelor 60mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
219300920|NCT02903264|OTHER|Gestational diabetes mellitus|
219300921|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
219300922|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
219300923|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
219300924|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
219300925|NCT05277103|BEHAVIORAL|Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD|The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
219300926|NCT01159002|DEVICE|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
219744328|NCT03527667|BEHAVIORAL|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
219744329|NCT05904483|OTHER|PFA|PFA
219744330|NCT02228928|DRUG|CAPNP, 50 ug/cm2 capsaicin patch|
219744331|NCT02228928|DRUG|CAPNP, 100 ug/cm2 capsaicin patch|
219744332|NCT02228928|DRUG|0.075% capsaicin cream|
219744333|NCT02228928|OTHER|Placebo patch|
219744334|NCT02644551|DRUG|CELEXT07|
219744335|NCT02644551|DRUG|Penlac|
219744336|NCT02644551|OTHER|vehicle solution|
219744337|NCT02477748|DRUG|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
219744338|NCT02477748|DRUG|Placebo|Tablet PO, taken once daily for 10 weeks.
219744339|NCT05775250|DRUG|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
219744340|NCT02157610|BEHAVIORAL|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
219300927|NCT02469389|BEHAVIORAL|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
219300928|NCT02469389|BEHAVIORAL|Health & Wellness (H&W)|"Health \& Wellness (H\&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
219300929|NCT04275089|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
219300930|NCT01452659|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
219300931|NCT01452659|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
219300932|NCT01452659|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
219300933|NCT01452659|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
219300934|NCT05416541|BEHAVIORAL|social media|ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
219300935|NCT01079663|DRUG|Chlorhexidine 2.5 mg|
219300936|NCT01079663|DRUG|Placebo chip|
219300937|NCT02372500|DIETARY_SUPPLEMENT|Chewing gum|Sugar free chewing gum
219300938|NCT03421626|DEVICE|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
219300939|NCT03657654|OTHER|No intervention: observational only|No intervention: observational only
219300940|NCT02768311|PROCEDURE|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
219300941|NCT02768311|PROCEDURE|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
219300942|NCT02768311|PROCEDURE|hand files k-files|Procedure: hand files k-files
219300943|NCT04125732|BIOLOGICAL|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
219300944|NCT03831373|OTHER|Physical exercise|Three physical exercise programs, two of resistance training with elastic bands and one of stretching exercises, all performed in a sitting position.
219300945|NCT03131583|DRUG|Colchicine|Day-14\~Day16 qd
219300946|NCT03131583|DRUG|Febuxostat|Day1 and Day8 qd
219300947|NCT03131583|DRUG|SHR4640|Day3\~Day8 qd
219300948|NCT00297232|DRUG|Natalizumab|
219300949|NCT04367012|OTHER|Abdominal Ultrasound|patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
219300950|NCT04635592|DIAGNOSTIC_TEST|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
219300951|NCT00596479|DRUG|Filgrastim (rG-CSF)|
219300952|NCT03562650|BEHAVIORAL|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
219300953|NCT03562650|BEHAVIORAL|Present Centered|Participants are asked to try to increase their focus on the present.
219300954|NCT02443974|DEVICE|Brace (Fisiotensor®)|
219300955|NCT02443974|DEVICE|Sleeve (Fisiotensor®)|
219300956|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
219300957|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Test product 20 ml
219300958|NCT05074485|DRUG|anakinra|intravenous injection of 100 milligrams anakinra
219300959|NCT05074485|DRUG|Placebo|intravenous injection of 1 milliliter normal saline
219300960|NCT05074485|OTHER|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
219300961|NCT03038438|DEVICE|Abre venous self-expanding stent system|venous stent
219300962|NCT01847300|BEHAVIORAL|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
219300963|NCT05788211|OTHER|standard of care|retrospective study: standard of care
219300964|NCT02822313|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76\_V27-006)
219300965|NCT02845206|PROCEDURE|Patient specific cutting blocks|'MyKnee' Instrumentation
219300966|NCT02845206|PROCEDURE|Conventional cutting blocks|Standard Instrumentation
219300967|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
219300968|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
219300969|NCT05729971|PROCEDURE|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
219300970|NCT00900744|DRUG|Tamoxifen|20 mg daily
219300971|NCT00954486|DRUG|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
219300972|NCT01948726|RADIATION|Hypofractionation with simultaneous integrated boost|
219300973|NCT04703738|PROCEDURE|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
219300974|NCT04703738|DEVICE|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
219300975|NCT02206594|PROCEDURE|Descemetorhexis|
219300976|NCT01360710|DRUG|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
219300977|NCT01360710|DRUG|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
219300978|NCT02819154|BEHAVIORAL|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~* Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~* Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~* ADL: Assessment of independence in activities of daily life"
219300979|NCT02440009|DRUG|Itraconazole|Oral itraconazole 200 mg BD for 6 months
219300980|NCT02440009|DRUG|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
219300981|NCT03864822|DEVICE|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
219300982|NCT02674815|OTHER|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
219300983|NCT01863576|DIETARY_SUPPLEMENT|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
219300984|NCT01863576|DIETARY_SUPPLEMENT|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
219300985|NCT04985968|DRUG|Cobitolimod 250 mg|Rectal administration
219300986|NCT04985968|DRUG|Cobitolimod 500 mg|Rectal administration
219300987|NCT04985968|DRUG|Placebo|Rectal administration
219300988|NCT04961658|BIOLOGICAL|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
219300989|NCT04304521|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
219300990|NCT03614637|OTHER|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
219300991|NCT00327496|BIOLOGICAL|DC vaccine|
219300992|NCT04789772|DEVICE|Laser acupuncture|The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
219300993|NCT00577473|DRUG|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
219300994|NCT00577473|DRUG|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
219300995|NCT02013518|BEHAVIORAL|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
219300996|NCT05827432|DEVICE|Field-cycling imaging (FCI)|FCI scan
219300997|NCT02610127|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
219300998|NCT01130584|OTHER|Pyruvate kinase isoform M2|
219300999|NCT04002193|OTHER|volume expansion|To assess fluid responsiveness
219301000|NCT00824811|DRUG|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
219301001|NCT00824811|DRUG|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
219301002|NCT00824811|DRUG|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
219301003|NCT02982733|OTHER|ABS|Ankaferd Blood Stopper
219301004|NCT02982733|DEVICE|TR Band|Transradial band
219301005|NCT02982733|OTHER|CS|Sterile Gauze
219301006|NCT05912582|RADIATION|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
219301007|NCT02388243|BEHAVIORAL|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
219301008|NCT02388243|BEHAVIORAL|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
219301009|NCT02388243|BEHAVIORAL|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
219301010|NCT02388243|BEHAVIORAL|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
219301011|NCT04303715|PROCEDURE|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
219301012|NCT04303715|PROCEDURE|SLNB|BCS with SLNB(+/-ALND)
219301013|NCT01818583|DRUG|Potassium chloride|
219301014|NCT01818583|DRUG|Glucose 50 MG/ML|
219301015|NCT05965804|DIAGNOSTIC_TEST|McMurray knee examination test|The McMurray test will be performed in different knee flexion and rotation angles.
219301016|NCT01808326|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
219301017|NCT06131489|OTHER|Segmental bowel resection combined with the DEP regimen|Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
219301018|NCT00577577|DRUG|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
219301019|NCT00577577|DRUG|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
219301020|NCT03572387|DRUG|5-Azacitidine|subcutaneously on days 1-5 at a dose of 40 mg/m\^2
219301021|NCT03572387|DRUG|all trans retinoic acid|45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses
219301022|NCT03572387|DRUG|Lupron|7.5 mg x 1
219301023|NCT02458703|OTHER|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
219301024|NCT00968227|BIOLOGICAL|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
219301025|NCT01856868|DRUG|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
219301026|NCT02103244|DRUG|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
219744341|NCT02157610|DRUG|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
219301027|NCT00232544|DEVICE|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
219744342|NCT02157610|BEHAVIORAL|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
219744343|NCT02157610|PROCEDURE|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
219744344|NCT02157610|BEHAVIORAL|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
219744345|NCT02157610|DRUG|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
219744346|NCT03862417|OTHER|Schroth exercises|An exercise program begun individually and then continued in groups.
219744347|NCT01705392|DRUG|Bevacizumab|Bevacizumab 10 mg/kg q3w
219744348|NCT01705392|DRUG|Propranolol|Propranolol 80 mg x 1
219744349|NCT01705392|DRUG|Enalapril|Enalapril 5 mg x 1
219744350|NCT01705392|DRUG|Dacarbazine|dacarbazine 1000 mg/m2 q3w
219744351|NCT00855361|DRUG|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
219744352|NCT00124657|DRUG|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
219744353|NCT06276140|DIAGNOSTIC_TEST|Laboratory analyses for the detection of iron deficiency anaemia|"Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected."
219744354|NCT00205959|DEVICE|Locking proximal humerus plate|
219744355|NCT00205959|DEVICE|Proximal Humerus Internal Locking System|
219744356|NCT00205959|DEVICE|Proximal Humerus Nail|
219744357|NCT03410771|DRUG|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
219301028|NCT00232544|OTHER|TLC-Control|A TLC system for providing general health education
219301029|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
219301030|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
219301031|NCT04742127|DIAGNOSTIC_TEST|Single surgical debridement|To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
219301032|NCT02862834|GENETIC|High-throughput exome sequencing|
219301033|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
219301034|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
219301035|NCT06021171|DIETARY_SUPPLEMENT|Maltodextrin|5 g Maltodextrin
219301036|NCT00518492|PROCEDURE|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
219301037|NCT02619981|PROCEDURE|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
219301038|NCT02619981|DRUG|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
219301039|NCT00513513|DRUG|TMC114 (darunavir) / ritonavir|
219301040|NCT06454994|DEVICE|Eyebrow lift|Upper face lifting
219301041|NCT06454994|DEVICE|Jaw lift|Mid-face and low-face lifting
219301042|NCT01424904|DIETARY_SUPPLEMENT|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
219301043|NCT05712473|DIAGNOSTIC_TEST|PYLARIFY|PYLARIFY PET
219301044|NCT00986973|DRUG|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
219301045|NCT02575001|BEHAVIORAL|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~1. Child Attachment Interview (CAI)~2. General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~3. Parenting Stress Index with the 19-item Life Stress Scale (PSI)~4. Achenbach System of Empirically Based Assessment (CBCL, YSR)~5. Holmes and Rahe Social readjustment rating scale~6. Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~7. Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
219301046|NCT02575001|GENETIC|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
219301047|NCT02575001|PROCEDURE|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
219301048|NCT02575001|PROCEDURE|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
219301049|NCT00174343|DRUG|exemestane (Aromasin®)|
219301050|NCT03776227|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219301051|NCT06520800|BEHAVIORAL|Treatment and handling obesity-related comorbidities in adolescents through exercise|Tailor-made, one-to-one, physical exercise program
219301052|NCT01940185|DEVICE|LINX device|
219301053|NCT03446820|OTHER|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
219744358|NCT03410771|DEVICE|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
219744359|NCT02576626|DRUG|indacaterol/glycopyrronium 110/50 Breezhaler®|
219744360|NCT02576626|DEVICE|Placebo by Breezhaler®|
219744361|NCT02576626|DRUG|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
219744362|NCT02576626|DEVICE|Placebo by nebulisation|
219744363|NCT00681070|OTHER|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
219744364|NCT00681070|OTHER|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
219744365|NCT01935947|DRUG|Azacitidine|Given SC
219744366|NCT01935947|DRUG|Azacitidine|Given PO
219744367|NCT01935947|DRUG|Docetaxel|Given IV
219744368|NCT01935947|DRUG|Entinostat|Given PO
219744369|NCT01935947|DRUG|Gemcitabine Hydrochloride|Given IV
219744370|NCT01935947|DRUG|Irinotecan Hydrochloride|Given IV
219744371|NCT01935947|OTHER|Laboratory Biomarker Analysis|Correlative studies
219744372|NCT01935947|DRUG|Pemetrexed Disodium|Given IV
219744373|NCT00338611|BEHAVIORAL|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
219744374|NCT00338611|BEHAVIORAL|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
219744375|NCT00338611|BEHAVIORAL|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
219301054|NCT05010837|OTHER|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
219301055|NCT05010837|OTHER|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
219301056|NCT05550701|OTHER|lymph node yield|We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer
219301057|NCT05002829|OTHER|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
219301058|NCT05002829|OTHER|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
219301059|NCT00371228|PROCEDURE|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
219301060|NCT04931082|DIETARY_SUPPLEMENT|Probiotics|Capsule
219301061|NCT04931082|DIETARY_SUPPLEMENT|Placebo|Capsule
219301062|NCT04569643|DIAGNOSTIC_TEST|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
219301063|NCT04569643|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
219301064|NCT04569643|DIAGNOSTIC_TEST|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
219301065|NCT04569643|OTHER|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
219301066|NCT04569643|OTHER|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
219744376|NCT00338611|BEHAVIORAL|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
219744377|NCT00156195|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 months
219744378|NCT00156195|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
219744379|NCT04696003|COMBINATION_PRODUCT|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
219301067|NCT06202586|PROCEDURE|low FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
219301068|NCT06202586|PROCEDURE|high FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
219301069|NCT03299868|DEVICE|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
219301070|NCT01337583|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
219301071|NCT01337583|OTHER|Placebo|Vaginal Ring containing no drug substance
219301072|NCT01337583|DRUG|Dapivirine|
219301073|NCT01465347|DRUG|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
219301074|NCT04772820|BEHAVIORAL|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
219301075|NCT01590082|DRUG|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
219301076|NCT01590082|DRUG|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
219301077|NCT01590082|DRUG|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
219301078|NCT00363870|BIOLOGICAL|Fluarix vaccine|
219301079|NCT00950326|PROCEDURE|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
219301080|NCT00950326|PROCEDURE|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
219301081|NCT00950326|PROCEDURE|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
219301082|NCT00561132|DIETARY_SUPPLEMENT|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
219301083|NCT00561132|OTHER|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
219301084|NCT02414932|DRUG|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
219301085|NCT02414932|DRUG|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
219301086|NCT00250939|BIOLOGICAL|Myozyme|20 mg/kg qow
219301087|NCT01239485|DRUG|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, \& 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~\*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
219301088|NCT05429905|BIOLOGICAL|Phase I|"* Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."
219301089|NCT05429905|BIOLOGICAL|Phase II|RP2D will be determined in Phase I
219301090|NCT00797251|PROCEDURE|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
219301091|NCT00294177|DEVICE|atomic force microscopy|
219301092|NCT00294177|DEVICE|dual polarisation interferometry|
219301093|NCT02434497|DRUG|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
219301094|NCT01210664|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
219301095|NCT02020759|DEVICE|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
219301096|NCT02958631|DRUG|Fimasartan|
219301097|NCT02958631|DRUG|Losartan|
219301098|NCT02657512|DRUG|rivaroxaban|rivaroxaban 40 mg/day (1 day)
219301099|NCT02657512|DRUG|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
219301100|NCT00621361|DRUG|AZD2171|Oral
219301101|NCT00621361|DRUG|Etoposide|Intravenous
219301102|NCT00621361|DRUG|Cisplatin|Intravenous
219301103|NCT02632422|OTHER|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
219301104|NCT02632422|OTHER|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily room air (dSHAM).
219301105|NCT02632422|OTHER|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.~Walking practice will incorporate 5 walking-related tasks:~1. walking balance (e.g., walking with turns)~2. skilled walking tasks (e.g., negotiating obstacles)~3. walking with secondary task (e.g., walking and talking)~4. endurance~5. speed"
219301106|NCT05959954|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
219301107|NCT01853644|DRUG|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
219301108|NCT00156637|BEHAVIORAL|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
219301109|NCT00156637|BEHAVIORAL|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
219301110|NCT00156637|BEHAVIORAL|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
219301111|NCT00541021|DRUG|gemcitabine hydrochloride|
219301112|NCT00541021|DRUG|sorafenib tosylate|
219301113|NCT02891408|DRUG|Firsocostat|Capsule(s) administered orally on Day 1
219301114|NCT02891408|DRUG|Fenofibrate|Tablet administered orally on Day 1
219301115|NCT00619203|DRUG|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
219301116|NCT00619203|DRUG|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
219301117|NCT00619203|DRUG|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
219301118|NCT00619203|DRUG|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
219744380|NCT04507763|DRUG|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
219301119|NCT00619203|DRUG|Placebo|2 placebos, one po, one suppository
219301120|NCT00619203|DRUG|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
219301121|NCT00619203|DRUG|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
219301122|NCT04621318|DRUG|Denosumab|60 mg, single-dose
219301123|NCT05517837|DRUG|BMS-986421|Specified dose on specified days
219301124|NCT05517837|OTHER|Placebo|Specified dose on specified days
219301125|NCT02534298|OTHER|functional magnetic resonance imaging|functional magnetic resonance imaging
219301126|NCT05101967|PROCEDURE|Dynamic Cervical Implant|Cervical discectomy through anterior approach with replacement of disc by dynamic implant
219301127|NCT05101967|PROCEDURE|Anterior Cervical Discectomt and Fusion|Cervical discectomy through anterior approach with putting of cervical cage.
219301128|NCT03095001|DRUG|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
219301129|NCT03095001|DRUG|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
219301130|NCT03095001|DRUG|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
219301131|NCT00757341|DRUG|SKI-606|
219301132|NCT02951767|DRUG|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
219301133|NCT00709852|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
219301134|NCT00709852|DRUG|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
219301135|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
219301136|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
219301137|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
219301138|NCT06079541|DRUG|Placebo in Cohorts 1 to 7|oral once
219301139|NCT06079541|DRUG|Placebo in 3 Cohorts|oral once
219301140|NCT04545684|BEHAVIORAL|Motor imagery|The person will have to imagine different scenarios of manual gripping
219301141|NCT04545684|BEHAVIORAL|Placebo intervention|The placebo group will imagine a place without the presence of humans.
219301142|NCT01442779|DRUG|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
219301143|NCT06407596|DEVICE|high intensity laser|3 times per week, for 9 sessions
219301144|NCT06407596|DEVICE|tens+us|5 times per week, total 15 sessions for 3 weeks
219301145|NCT05629754|DIAGNOSTIC_TEST|MRI, radiological assessment|MRI and radiological assessment of the involved knee
219301146|NCT04664543|OTHER|Free diet|To follow the regular dietary habits with no restriction nor modification.
219301147|NCT04664543|OTHER|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
219301148|NCT01719419|DRUG|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
219301149|NCT01719419|DRUG|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
219301150|NCT03436251|DEVICE|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
219301151|NCT03436251|DEVICE|LEEP or cold knife|For patients with HPV+ / CIN-2
219301152|NCT03436251|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
219301153|NCT01048671|DRUG|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
219301154|NCT01048671|DRUG|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
219301155|NCT02171416|DRUG|Rilonacept|
219301156|NCT02171416|DRUG|Placebo|
219301157|NCT03814187|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
219301158|NCT02703090|DRUG|Remifentanil|
219301159|NCT02703090|DRUG|Normal saline|
219301160|NCT02047864|DIETARY_SUPPLEMENT|Creatine monohydrate|
219301161|NCT04260880|OTHER|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
219301162|NCT04260880|OTHER|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
219301163|NCT04260880|OTHER|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
219301164|NCT01335087|OTHER|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
219744381|NCT05059275|PROCEDURE|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
219744382|NCT01146002|DRUG|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
219744383|NCT04183686|DRUG|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
219744384|NCT04183686|DRUG|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
219744385|NCT04183686|DRUG|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
219744386|NCT04183686|DRUG|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
219744387|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
219744388|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
219744389|NCT00710619|DRUG|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
219744390|NCT00710619|DRUG|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
219744391|NCT01021527|OTHER|Comparator: Treatment A|No Treatment
219744392|NCT01021527|DRUG|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
219301165|NCT01335087|DEVICE|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
219301166|NCT04059653|DEVICE|Electrical stimulation|Electrical stimulation device
219301167|NCT04059653|OTHER|Treatment as usual|GP treatment as usual
219301168|NCT00196976|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
219301169|NCT00196976|BIOLOGICAL|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
219301170|NCT00196976|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
219301171|NCT00196976|BIOLOGICAL|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
219301172|NCT00196976|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
219301173|NCT01326754|DRUG|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
219301174|NCT01326754|DRUG|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
219301175|NCT01326754|DRUG|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
219301176|NCT03231501|DRUG|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
219301177|NCT02105922|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
219301178|NCT02105922|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
219301179|NCT02105922|PROCEDURE|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
219301180|NCT04236115|DRUG|Articaine 4%|Articaine 4% is dental local anaesthetic agent
219301181|NCT04236115|DRUG|Prilocain 3%|prilocaine is dental local anaesthetic agent
219301182|NCT04236115|DRUG|Adrenalin|adrenaline is a vasoconstrictor
219301183|NCT04236115|DRUG|Felypressin|Felypressin is a vasoconstrictor
219301184|NCT03228602|OTHER|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
219301185|NCT01405365|DRUG|Metronidazole|Metronidazole 400mg TID for 10 days
219301186|NCT01405365|DRUG|Placebo|Placebo pill TID for 10 days
219301187|NCT01405365|PROCEDURE|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
219301188|NCT02388854|GENETIC|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
219301189|NCT03060668|OTHER|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
219301190|NCT03060668|OTHER|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
219301191|NCT04860167|DRUG|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
219301192|NCT04860167|DRUG|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
219301193|NCT00678184|DRUG|Atorvastatin|80 mg atorvastatin on two following days each
219301194|NCT04270201|OTHER|Saliva collection|Saliva collection
219301195|NCT05361525|PROCEDURE|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
219301196|NCT05361525|PROCEDURE|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
219301197|NCT01714531|BEHAVIORAL|Telephone-Based Goal Management Training|
219301198|NCT01714531|BEHAVIORAL|Telephone-Based Attention-Control|
219301199|NCT02673073|OTHER|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
219301200|NCT02673073|OTHER|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
219301201|NCT02689518|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
219301202|NCT02878902|OTHER|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
219301203|NCT03334136|DRUG|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
219301204|NCT03334136|DRUG|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
219301205|NCT01853774|BEHAVIORAL|Tailored navigation|
219301206|NCT06276907|BIOLOGICAL|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
219301207|NCT06276907|OTHER|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
219301208|NCT02740374|DEVICE|ROTEM|ROTEM coagulation assessment and guided transfusion management.
219301209|NCT02740374|OTHER|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
219301210|NCT01598623|DRUG|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
219301211|NCT01598623|BEHAVIORAL|Social Skills Training|three times a week for three weeks.
219301212|NCT01598623|BEHAVIORAL|Placebo + Non Specific Counselling|
219301213|NCT00825825|DRUG|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
219301214|NCT00825825|DRUG|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
219301215|NCT00825825|DRUG|Placebo|Two weeks of placebo taken orally.
219301216|NCT02697292|DRUG|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
219301217|NCT02697292|DRUG|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.
219744393|NCT01021527|DRUG|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
219744394|NCT01021527|PROCEDURE|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
219744395|NCT01378195|BEHAVIORAL|CBT-based program for dementia caregivers|Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
219744396|NCT01378195|BEHAVIORAL|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
219744397|NCT00406926|DRUG|Somatropin|
219744398|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
219744399|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
219744400|NCT03070067|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
219744401|NCT03781063|DRUG|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
219744402|NCT03781063|DRUG|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
219744403|NCT02248233|DRUG|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
219744404|NCT02248233|DRUG|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
219744405|NCT03113344|DRUG|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
219744406|NCT03868696|PROCEDURE|MUA with sham ultrasound|Standard MUA with sham ultrasound
219744407|NCT03868696|PROCEDURE|MUA with active ultrasound|Standard MUA guided by ultrasound
219744408|NCT02003703|BIOLOGICAL|Recombinant Hepatitis B Virus Vaccine|
219744409|NCT02500108|DRUG|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
219744410|NCT00425555|DRUG|Panobinostat|
219301218|NCT02697292|DRUG|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
219301219|NCT03367650|DIETARY_SUPPLEMENT|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
219301220|NCT04987086|DIAGNOSTIC_TEST|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
219301221|NCT04039477|DRUG|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
219301222|NCT02395146|PROCEDURE|Monitoring|intraoperative EBSLN monitoring
219301223|NCT04041531|OTHER|blood sampling|venous blood sampling for oxygen affinity in-vitro test
219301224|NCT02328339|OTHER|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
219301225|NCT02328339|OTHER|Placebo|Placebo matched to tea with respect to taste and appearance
219301226|NCT03402815|DRUG|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
219301227|NCT00163397|DRUG|Ciclesonide|
219301228|NCT04160520|DRUG|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
219301229|NCT04160520|DRUG|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
219301230|NCT04160520|DRUG|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
219744411|NCT00684684|DEVICE|Chartis System|Assessment of airway flow and pressure
219744412|NCT03064607|OTHER|Fluid collection|Fluids tested for biomarker S100beta
219744413|NCT06642701|DEVICE|Electrical Impedance Tomography|According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy
219301231|NCT04555031|DEVICE|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
219301232|NCT04555031|DEVICE|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
219744414|NCT06642701|BEHAVIORAL|chest physiotherapy|Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
219744415|NCT04709523|PROCEDURE|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
219301233|NCT04555031|DEVICE|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
219301234|NCT04555031|DEVICE|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
219301235|NCT00645307|DRUG|Extended Release OROS® Paliperidone|
219301236|NCT00804089|PROCEDURE|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
219301237|NCT00804089|PROCEDURE|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
219301238|NCT00804089|PROCEDURE|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
219301239|NCT01398722|OTHER|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
219301240|NCT01398722|OTHER|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
219301241|NCT02617680|DRUG|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
219301242|NCT02617680|DRUG|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
219301243|NCT02311868|DIETARY_SUPPLEMENT|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
219744416|NCT04709523|PROCEDURE|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
219744417|NCT06167148|DEVICE|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
219744418|NCT06167148|DEVICE|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
219744419|NCT06638749|DRUG|Tranexamic Acid|Administration of tranexamic acid
219744420|NCT06638749|DRUG|Normal Saline|Administration of normal saline
219744421|NCT06638359|BEHAVIORAL|moderate exercise|moderate exercise for 47 minutes
219744422|NCT06638359|BEHAVIORAL|interval exercise|interval exercise for 28 minutes
219301244|NCT02311868|DIETARY_SUPPLEMENT|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
219301245|NCT01045395|DIETARY_SUPPLEMENT|Corn starch|90mg/d
219301246|NCT01045395|DIETARY_SUPPLEMENT|Unique Marine Algae Concentrate (UMAC)|90mg/d
219301247|NCT01045395|DIETARY_SUPPLEMENT|Golden brown algae|90mg/d
219301248|NCT01920854|DRUG|soluble ferric pyrophosphate|
219301249|NCT01920854|DRUG|Placebo|
219301250|NCT00000823|DRUG|Zidovudine|
219301251|NCT00000823|DRUG|Didanosine|
219301252|NCT00456677|DRUG|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
219301253|NCT00456677|DRUG|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
219301254|NCT04280068|BEHAVIORAL|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
219301255|NCT04280068|BEHAVIORAL|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
219301256|NCT02978573|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
219301257|NCT00201747|DRUG|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
219301258|NCT00201747|DRUG|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
219301259|NCT02686047|DEVICE|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
219301260|NCT02686047|DEVICE|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
219301261|NCT04059003|DRUG|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
219301262|NCT05727969|DRUG|Dexmedetomidine|Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
219301263|NCT05727969|DRUG|Lactated Ringer|Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
219301264|NCT05727969|PROCEDURE|Hypospadias|Children who will undergone hypospadias surgery
219301265|NCT05727969|DEVICE|Surgical pleth index|The SPI value will be measured using Datex-Ohmeda (GE Healthcare,Madison,WI 53707-7550 USA) monitoring system.
219301266|NCT02293915|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
219301267|NCT02293915|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
219301268|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
219301269|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
219301270|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
219301271|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
219301272|NCT00757783|DRUG|darunavir|800 mg tablet once daily for 48 weeks
219301273|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
219301274|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
219301275|NCT00757783|DRUG|atazanavir|300 mg capsule once daily for 48 weeks
219301276|NCT01303731|DRUG|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
219301277|NCT01303731|DRUG|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
219301278|NCT04680754|OTHER|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
219301279|NCT03433248|DRUG|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
219744423|NCT06638359|BEHAVIORAL|Control (placebo) group|without exercise
219744424|NCT06001255|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219744425|NCT06564350|DEVICE|IMU (Inertial Measurement Unit) sensors|IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
219744426|NCT06639802|OTHER|Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)|HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
219744427|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
219744428|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
219744429|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
219744430|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
219744431|NCT01464606|DRUG|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
219744432|NCT01464606|DRUG|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
219744433|NCT01464606|DRUG|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
219744434|NCT01464606|DRUG|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
219744435|NCT01464606|DRUG|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
219744436|NCT06639763|DIAGNOSTIC_TEST|Questionnaire|Questionnaire containing a combination of basic epidemiological questions, questions regarding recent sexual activity, questions regarding sexual preference and sexual activity, questions regarding the use of different types of erectile aids, questions regarding satisfaction with the use of these different erectile aid and questions regarding the satisfaction with sexual functioning and the partner relation. Al patients at least 6 months after primary genital gender-affirming surgery and who are sexually active are eligible.
219744437|NCT06197581|RADIATION|Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)|Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
219744438|NCT02957240|BEHAVIORAL|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
219301280|NCT03433248|DRUG|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
219301281|NCT03433248|DRUG|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
219301282|NCT04806217|OTHER|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
219301283|NCT02293031|DEVICE|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
219301284|NCT03032393|OTHER|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
219301285|NCT03032393|OTHER|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
219301286|NCT02757391|BIOLOGICAL|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
219301287|NCT02757391|BIOLOGICAL|Aldesleukin|Given SC
219301288|NCT02757391|DRUG|Cyclophosphamide|Given IV
219301289|NCT02757391|OTHER|Laboratory Biomarker Analysis|Correlative studies
219301290|NCT02757391|BIOLOGICAL|Pembrolizumab|Given IV
219301291|NCT04044274|DEVICE|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
219301292|NCT04044274|DEVICE|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
219301293|NCT01043393|DRUG|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
219301294|NCT00901823|DRUG|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
219301295|NCT00901823|DRUG|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
219301296|NCT04320706|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
219301297|NCT04320706|DRUG|Oral Placebo|Administration of placebo orally
219301298|NCT00645554|DRUG|Galantamine oral solution|
219301299|NCT01775150|OTHER|health education|Health education via text messaging
219301300|NCT02372136|DIETARY_SUPPLEMENT|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
219301301|NCT02372136|DIETARY_SUPPLEMENT|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
219301302|NCT00280943|BEHAVIORAL|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
219301303|NCT00985946|DRUG|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
219301304|NCT01080833|DEVICE|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
219301305|NCT04480125|DRUG|Azacitidine|100mg D1-7
219301306|NCT04480125|DRUG|Chidamide|30mg BIW PO
219301307|NCT03093077|DEVICE|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
219301308|NCT02881580|OTHER|No intervention : descriptive study|
219301309|NCT04937712|OTHER|RT-PCR SARS-COV2 in urine|proteinuria/renal phosphate leak/uricosuria/glycosuria/ aminoaciduria)
219301310|NCT00585416|DRUG|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
219301311|NCT05880394|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
219301312|NCT05880394|DRUG|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
219301313|NCT03035968|OTHER|Vojta therapy|
219301314|NCT03035968|OTHER|conventional physiotherapy|
219301315|NCT01538329|DRUG|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
219301316|NCT01538329|DRUG|placebo|200mg / day once daily in the morning and at noon - oral administration -
219301317|NCT05584969|BEHAVIORAL|Peer-led integrated nutrition education intervention delivered through Care Groups|The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
219301318|NCT04143074|BEHAVIORAL|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
219301319|NCT06531161|DRUG|Suxiao Jiuxin Pill|Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
219301320|NCT06531161|DRUG|Placebo|Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
219301321|NCT00861523|DRUG|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
219301322|NCT02621671|BEHAVIORAL|Cognitive interview|
219301323|NCT02621671|OTHER|Survey|
219301324|NCT06015425|DEVICE|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
219301325|NCT02471833|DRUG|Telmisartan 20mg|Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
219301326|NCT02471833|DRUG|Telmisartan 40mg|Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
219301327|NCT02471833|DRUG|Placebo|Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
219301328|NCT02850211|DRUG|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
219301329|NCT02850211|DRUG|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
219301330|NCT02850211|DRUG|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
219301331|NCT00002565|BIOLOGICAL|bleomycin sulfate|
219301332|NCT00002565|DRUG|CHOP regimen|
219301333|NCT00002565|DRUG|cisplatin|
219744439|NCT02957240|BEHAVIORAL|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
219301334|NCT00002565|DRUG|cyclophosphamide|
219301335|NCT00002565|DRUG|cytarabine|
219301336|NCT00002565|DRUG|doxorubicin hydrochloride|
219301337|NCT00002565|DRUG|etoposide|
219301338|NCT00002565|DRUG|idarubicin|
219301339|NCT00002565|DRUG|ifosfamide|
219301340|NCT00002565|DRUG|mesna|
219301341|NCT00002565|DRUG|methylprednisolone|
219301342|NCT00002565|DRUG|mitoxantrone hydrochloride|
219301343|NCT00002565|DRUG|prednisone|
219301344|NCT00002565|DRUG|vincristine sulfate|
219301345|NCT04222361|PROCEDURE|Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI|Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
219301346|NCT00496951|DEVICE|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
219301347|NCT05606835|OTHER|Postural stability assessment|The Biodex Balance System SD (BDS) (Biodex Medical Systems Inc., Shirley, New York, USA) assesses postural stability (PS). Both static PS (SPS) and dynamic PS (DPS) will be assessed. In the DPS assessment, the platform can be tilted 20° in any direction. For static measurement, participants will be asked to stand barefoot on the platform, stand on one leg, keep the knees in 20-30° flexion. Meanwhile the contralateral knee will be asked to keep in 90° flexion, and stabilize their feet until the end of the test. Upon completion of the SPS assessment, the DPS assessment will be performed. The difficulty level of the DPS test will accepted as 4. For both SPS and the DPS assessment, the test consists of 3 trials of 20 seconds each with a 10-second break between trials.
219744440|NCT00655655|DRUG|everolimus|Given orally
219301348|NCT05606835|OTHER|Frontal plan prjection angle|Frontal Plan Projection Angle (FPPA) is calculated as the angle between the thigh segment and the trunk segment based on the postural image, considering the position of the thigh and tibia. The FPPA will be evaluated using the Spark motion Pro™ application (2D). Before measurement, markers will be placed bilaterally at the SIAS, at the midpoint of the femoral condyles, and at the midpoint of the ankle bones. Participants will stand on the floor barefoot and arms crossed over the chest. Subjects will be asked to squat in a controlled manner and perform a 60° knee bend without losing balance before returning to the starting position. Test will be performed by using single leg squat test. The one-legged squat will be performed for 5 seconds at a standard pace with the researcher acting as the counter. Degrees smaller than 165 will be accepted as increase in knee valgus.
219301349|NCT05606835|OTHER|Foot and Ankle Ability Measure|The Foot and Ankle Ailability Measure (FAAM) is used to assess the self-reported overall functional level of patients with leg, foot, and ankle musculoskeletal injuries and conditions. It consists of 1) activities of daily living \[ADL\] and 2) sports \[S\] and can be scored from 0 to 100%. In the FAAM, there are 29 items that are scored from 0 to 4. There are 21 items related to various functional activities under the subtitle activities of daily living, and 8 items related to various activities related to participation in sports under the subtitle sports. Standardized response options are answered on five-point likert scales ranging from 0 (I cannot) to 4 (no difficulty). Point totals between 0 and 84 for the ADL subtitle and between 0 and 32 for the Sports subtitle are converted to percentage points.
219301350|NCT05606835|OTHER|Navicular Drop Test|The navicular drop test (NDT) is a clinical method for assessing the mobility of the medial longitudinal arch (MLA). The extent of navicular subsidence is assessed to determine the flexibility of the MLA and the position of the navicular with and without transfer of body weight. To assess navicular drop, the subtalar joint will be positioned in neutral position and the height of the navicular will be measured in non-weight bearing position. Then the measurement will be repeated in weightbearing position. The height difference between the two measurements in sitting and standing is recorded as the NDT value. Values more than 10mm is accepted as pathological.
219301351|NCT05606835|OTHER|Calcaneotibial Angle Measurement|Measurement of the calcaneotibial angle (CTA) is one of the methods used in the evaluation of the foot and ankle. By measuring this angle, it is assessed whether the ankle problems are related to the hindfoot. In the CTA measurement, the angle between the vertical axis of the calcaneus and the longitudinal axis of the achilles tendon is measured in the standing and prone positions, and the differences will be recorded. Values more than 8 degrees is accepted as calcaneal valgus.
219301352|NCT05606835|OTHER|Tibial Torsion Angle|Tibial torsion is a rotational deformity which can be measured between the long axis of the tibia and the transmalleolar axes. This measurement can be used to determine the extent to foot malalignment is due to bone torsion. Measurement will be done by a goniometer. Participants will be asked to lie prone and will be positioned with the knee joint in 90° flexion and the ankle joint in a neutral position. Normal alignment is 20 degrees external rotation. Any increase or decrease accepted as pathological.
219301353|NCT05606835|OTHER|Femoral internal and external rotation measurement|Accurate assessment of hip joint range of motion (ROM) is an important component in the overall clinical evaluation of lower extremity injuries, particularly those of the hip and groin. The expected hip rotational range of motion for internal rotation (IR) is 45°, and for external rotation (ER) is 0° to 45°. In this study, a smartphone-based inclinometer will be used to measure femoral IR and ER. The inclinometer will be placed vertically so that the top edge is just below the tibial tuberosity and the bottom edge is pointed at the midpoint of the medial and lateral malleoli.
219301354|NCT01986075|BEHAVIORAL|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
219301355|NCT01986075|DRUG|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
219301356|NCT01986075|DRUG|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
219301357|NCT02104843|DRUG|Daclatasvir, Asunaprevir and BMS-791325 FDC|
219301358|NCT02104843|DRUG|BMS-791325|
219301359|NCT02104843|DRUG|Rosuvastatin|
219301360|NCT04242251|OTHER|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
219301361|NCT05994404|PROCEDURE|ACDF|
219301362|NCT05994404|PROCEDURE|Posterior Cervical Fusion|
219301363|NCT05994404|PROCEDURE|Cervical Laminoplasty|
219301364|NCT02105623|BEHAVIORAL|Standard Therapy|Risk factor control Diet Exercise for 24months
219301365|NCT02105623|DRUG|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
219301366|NCT03789838|OTHER|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
219301367|NCT05363462|DRUG|Vancomycin 1000 MG|Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
219301368|NCT05790577|DRUG|Metformin and Nicotinamide vs Kligman Formula|Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
219301369|NCT05939531|BEHAVIORAL|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
219301370|NCT05939531|BEHAVIORAL|Standard Care|Standard post-stroke care
219301371|NCT02673515|BEHAVIORAL|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
219301372|NCT06424405|PROCEDURE|titration procedure for MAD treatment|The OSAHS patients referred for MAD treatment will experience either the objective titration procedure or the subjective titration procedure.
219301373|NCT02842450|DEVICE|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
219301374|NCT02842450|OTHER|definitions only|
219301375|NCT05128994|DEVICE|User-controlled FES system|Wearable FES sleeve with non-invasive user controls
219301376|NCT05851053|DIAGNOSTIC_TEST|Echocardiography|"During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality"
219301377|NCT03148444|DRUG|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
219301378|NCT03103490|DRUG|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
219301379|NCT02271776|DIETARY_SUPPLEMENT|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
219301380|NCT02271776|DIETARY_SUPPLEMENT|maltodextrin|
219301381|NCT06529055|OTHER|Oral Pouch - Nicotine|Ingestion of a randomized oral nicotine pouch
219301382|NCT06529055|OTHER|Oral Pouch - Caffeine|Ingestion of a randomized oral caffeine pouch
219301383|NCT06529055|OTHER|Oral Pouch - Placebo|Ingestion of a randomized oral placebo pouch
219301384|NCT03965351|DRUG|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
219301385|NCT03965351|OTHER|Placebo|placebo
219301386|NCT03479762|DRUG|Liraglutide|No treatment given
219744441|NCT00655655|DRUG|vatalanib|Given orally
219744442|NCT00655655|OTHER|pharmacological study|Correlative study (Cohort IIA only)
219744443|NCT00655655|OTHER|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
219744444|NCT00655655|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
219301387|NCT04322877|PROCEDURE|Temporary pacing Study|Temporary delivery of CRT
219301388|NCT04322877|RADIATION|Thoracic CT|As part of non-invasive mapping protocol
219301389|NCT04322877|DIAGNOSTIC_TEST|Acute hemodynamic study|Measurement of invasive dP/dTmax
219301390|NCT04322877|DIAGNOSTIC_TEST|Non-invasive body surface mapping|Cardioinsight body surface mapping
219301391|NCT04322877|DIAGNOSTIC_TEST|Invasive catheter-based mapping|Invasive electroanatomical mapping
219744445|NCT00655655|PROCEDURE|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
219744446|NCT06561776|OTHER|Physical Evaluations of individuals|Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
219744447|NCT06562829|DEVICE|Virtual reality technology|Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
219301392|NCT05221359|DEVICE|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
219301393|NCT05221359|DRUG|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
219301394|NCT05832697|DRUG|Ursodeoxycholic Acid 250 Mg Oral Tablet|Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
219301395|NCT04892914|DEVICE|Embr thermal device|Participants use the Embr thermal device for 4 weeks
219301396|NCT00169377|PROCEDURE|deep brain stimulation|Stimulator on followed by off
219301397|NCT00169377|PROCEDURE|No stimulation|Stimulator off followed by on
219301398|NCT03397732|PROCEDURE|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
219301399|NCT01638351|BEHAVIORAL|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
219301400|NCT01638351|BEHAVIORAL|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
219301401|NCT04021329|BEHAVIORAL|CBT Therapy|information added previously
219301402|NCT02770417|DIETARY_SUPPLEMENT|beta-alanine|Patients receive beta-alanine
219301403|NCT02770417|DIETARY_SUPPLEMENT|placebo|Patients receive placebo
219301404|NCT02770417|OTHER|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
219301405|NCT00490724|DRUG|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
219301406|NCT00490724|DRUG|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
219301407|NCT00490724|DRUG|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
219301408|NCT05179213|DRUG|Azacitidine|75 mg/m2 subcutaneously on days 1-7
219301409|NCT05179213|DRUG|Chidamide|20mg orally per week continuously
219301410|NCT05793008|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) analysis|18F-FDG-PET/CT imaging will be performed 3 months after the acute event at the Department of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS using an integrated scanner. Intravenous 18F-FDG (370 MBq) will be given following an overnight fast. Three-dimensional PET imaging will be performed after 1 h of quiet waiting. A non-gated, non-contrast CT will be acquired for attenuation correction. Brain structures analyzed will include the neocortex, limbic system (insula, amygdala, cingulate cortex, and hippocampus), reticular formation, brainstem, and spinal cord.
219301411|NCT05793008|DIAGNOSTIC_TEST|Blood samples collection|"At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis."
219301412|NCT05793008|OTHER|Clinical follow up visit|Participation in this study requires for patients with primary vs secondary TTS, a follow-up visit at 3 months (90 +/- 5 gg) after enrollment to assess a Positron Emission Tomography (PET) analysis, and during the same visit, venous blood sampling as described above will be further performed.
219301413|NCT00924261|OTHER|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
219301414|NCT00924261|OTHER|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
219301415|NCT04709952|DEVICE|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
219301416|NCT04709952|DEVICE|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
219301417|NCT04709952|DEVICE|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
219301418|NCT03765008|OTHER|Water intake manipulation|for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
219301419|NCT05616000|DRUG|Acetyl-l-carnitine, folic acid|Acetyl-l-carnitine 2gm once a day\& folic acid will be given to 43 primary infertile men
219301420|NCT02877888|DRUG|fluoride varnish 22600ppm|topical application on teeth every 6months
219301421|NCT03384277|DRUG|Steroid|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
219301422|NCT03384277|DRUG|Rituximab|375mg/m2 for one dose
219301423|NCT03384277|DRUG|Cyclophosphamide|cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
219301424|NCT02697370|DRUG|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
219301425|NCT00994682|DRUG|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
219301426|NCT00994682|DRUG|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
219301427|NCT00994682|DRUG|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
219301428|NCT00083213|BIOLOGICAL|ziv-aflibercept|
219301429|NCT04727268|OTHER|No intervention|No interventions present in this study.
219301430|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
219301431|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
219301432|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
219301433|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
219301434|NCT01409304|DEVICE|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
219301435|NCT00126230|DRUG|docetaxel and samarium|
219301436|NCT04567277|PROCEDURE|External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)|EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
219301437|NCT03427853|DRUG|LY06006|LY06006 18mg, 60mg, 120mg subcutaneous injection
219301438|NCT03427853|DRUG|Placebos|Placebo subcutaneous injection
219301439|NCT02677428|BEHAVIORAL|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
219301440|NCT02677428|BEHAVIORAL|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation \& Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C\&P office where issues pertaining to an individual Veteran's specific application are addressed.
219301441|NCT03795259|DRUG|Rocuronium|After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
219301442|NCT03795259|DRUG|Sugammadex|Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
219301443|NCT05660759|PROCEDURE|Portal vein embolization|Portal vein emboliazation with either NBCA or micro particles.
219301444|NCT03211767|DIETARY_SUPPLEMENT|Aged garlic extract|Each capsule contains 600mg of aged garlic extract powder
219301445|NCT03211767|DIETARY_SUPPLEMENT|Placebo|Each capsule contains cellulose as a filler.
219301446|NCT03069001|DRUG|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
219301447|NCT03069001|DRUG|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
219301448|NCT04890119|DIAGNOSTIC_TEST|tenosynovial tissue biopsy|Biopsy of tenosynovial tissue during surgery for amyloid aggregate search
219301449|NCT04512859|PROCEDURE|Stellate Ganglion Block|Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL
219301450|NCT04512859|PROCEDURE|Placebo|Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL
219301451|NCT03580668|DRUG|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
219301452|NCT01272128|DRUG|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
219301453|NCT06445413|OTHER|Tai Chi|Ten weekly 60-minute Tai Chi classes
219301454|NCT01541098|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
219301455|NCT01541098|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
219301456|NCT03753737|OTHER|Questionnaires and semi-structured interview|"* Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
219301457|NCT01810601|DRUG|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
219301458|NCT03720743|OTHER|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
219301459|NCT00066014|PROCEDURE|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
219301460|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
219744448|NCT06562829|OTHER|different timing of lidocaine injection|Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
219744449|NCT06641921|DEVICE|Seerlinq haemodynamically-guided heart failure treatment|Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
219744450|NCT02853136|DRUG|Fluvoxamine|Fluvoxamine
219744451|NCT02853136|DRUG|BI 409306 - Powder for oral solution (PfOS)|BI 409306 - Powder for oral solution (PfOS)
219744452|NCT02853136|DRUG|BI 409306 - film coated tablet|BI 409306 - film coated tablet
219744453|NCT00841815|DRUG|Amlodipine Besylate|10 mg Tablet
219744454|NCT00841815|DRUG|Norvasc®|10 mg Tablet
219744455|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+8Gy x 3f|Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
219744456|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+16Gy x 1f|Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
219744457|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+2.67Gy x 15f|Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
219744458|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f|Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
219744459|NCT06434493|RADIATION|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
219744460|NCT06434493|DRUG|Concurrent oral capecitabine chemotherapy|All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
219744461|NCT06434493|DRUG|Cisplatin & Gemcitabine intravenous chemotherapy|Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
219744462|NCT06434493|PROCEDURE|Orthotropic Liver Transplant|If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
219301461|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
219301462|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
219301463|NCT00377091|DRUG|Fondaparinux|
219301464|NCT00812331|DRUG|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
219301465|NCT01506453|DRUG|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
219301466|NCT01506453|DRUG|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
219301467|NCT02560311|OTHER|observation|
219301468|NCT02866500|BEHAVIORAL|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
219301469|NCT05786989|DRUG|selinexor|Given PO
219301470|NCT01809496|BEHAVIORAL|Informational Counseling|
219301471|NCT01809496|BEHAVIORAL|Patient Centered Counseling|
219301472|NCT05346133|BEHAVIORAL|Suicide Prevention Intervention for Adolescents|Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
219301473|NCT01783847|DRUG|Recombinant human erythropoietin (EPO)|4000 units per vial
219301474|NCT01783847|OTHER|Observation|Just observation
219301475|NCT01783847|DRUG|Methyl prednisolone|250 mg every 6 hours for 3 days.
219301476|NCT05615493|DEVICE|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
219301477|NCT05615493|DEVICE|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), \& frequency 4 Hz every week for one month without operating the machine .
219301478|NCT01007643|OTHER|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
219301479|NCT01007643|OTHER|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
219744463|NCT06639048|BEHAVIORAL|Questionnaire|Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
219744464|NCT05210543|OTHER|not applicable, observational study|Patients do not receive intervention; observational study
219744465|NCT04409431|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
219744466|NCT01532739|BEHAVIORAL|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
219744467|NCT00867334|DRUG|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
219744468|NCT00867334|DRUG|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
219744469|NCT01148771|DRUG|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
219744470|NCT01148771|DRUG|ertapenem|1 gram 30 minute infusion q24h for 3 days
219744471|NCT03787615|DEVICE|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
219301480|NCT05803031|DRUG|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
219301481|NCT05803031|PROCEDURE|Non-surgical periodontal debridement|Scaling and root surface debridement
219301482|NCT02610166|BEHAVIORAL|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
219301483|NCT02610166|OTHER|Usual Care|Children in usual care group receive standard medical care.
219301484|NCT01206036|DRUG|Docetaxel|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
219301485|NCT01206036|DRUG|Temsirolimus|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
219301486|NCT04323631|DRUG|Hydroxychloroquine|Oral
219301487|NCT04323631|OTHER|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
219301488|NCT02877238|DRUG|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
219301489|NCT02877238|DRUG|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
219301490|NCT03706313|DRUG|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
219301491|NCT03706313|PROCEDURE|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
219301492|NCT03706313|DRUG|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
219301493|NCT04789278|OTHER|Notification|Notification of coronary calcium to the patient and their clinician
219301494|NCT02455154|DRUG|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
219301495|NCT02455154|DRUG|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
219301496|NCT02455154|DRUG|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
219301497|NCT00612469|DRUG|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
219301498|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
219301499|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
219301500|NCT00612469|DRUG|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
219301501|NCT02480257|BEHAVIORAL|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
219301502|NCT05468346|DRUG|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
219301503|NCT06168097|PROCEDURE|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
219301504|NCT06168097|PROCEDURE|women with intraoperative and / or histopathology findings suggestive of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
219301505|NCT01377597|DRUG|ranibizumab|
219301506|NCT05921825|DIAGNOSTIC_TEST|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
219301507|NCT05921825|DIAGNOSTIC_TEST|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
219301508|NCT05448612|OTHER|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
219301509|NCT00055601|DRUG|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
219301510|NCT00055601|DRUG|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
219301511|NCT00055601|DRUG|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
219301512|NCT00055601|RADIATION|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
219301513|NCT00055601|DRUG|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
219301514|NCT00055601|PROCEDURE|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
219301515|NCT06208319|OTHER|data collection|data collection from the patient's medical record. The data will be that of routine care, with no procedures added by the research.
219301516|NCT02675868|DRUG|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
219301517|NCT02675868|DRUG|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
219301518|NCT02675868|DRUG|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
219301519|NCT02675868|DRUG|Placebo|NaCl 0.9% infusion
219301520|NCT00530907|DRUG|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
219301521|NCT00530907|DRUG|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
219301522|NCT04787497|DIETARY_SUPPLEMENT|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
219301523|NCT04555538|DIAGNOSTIC_TEST|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
219301524|NCT03272581|OTHER|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
219301525|NCT04536987|DEVICE|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
219301526|NCT00117845|BIOLOGICAL|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
219301527|NCT04112329|BEHAVIORAL|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
219301528|NCT05871567|PROCEDURE|colorectal resection|potential resective surgery
219301529|NCT03312452|DEVICE|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
219301530|NCT03312452|DEVICE|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
219301531|NCT05020288|DRUG|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
219301532|NCT00474877|DEVICE|Static resting splints|
219301533|NCT04369859|BEHAVIORAL|Examine the impact of COVID-19 during pregnancy|clinical data collection
219301534|NCT00036959|DRUG|ABT-751|
219301535|NCT03910686|COMBINATION_PRODUCT|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
219301536|NCT01789645|OTHER|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
219301537|NCT01789645|PROCEDURE|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
219301538|NCT01680484|DIETARY_SUPPLEMENT|Bitter chocolate|
219301539|NCT01680484|DIETARY_SUPPLEMENT|Orange juice|
219301540|NCT03644953|DRUG|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
219301541|NCT04746053|OTHER|Pelvic ultrasound|Pelvic or vaginal ultrasound
219301542|NCT04746053|BIOLOGICAL|blood sample|blood sample (5ml)
219301543|NCT00909337|DRUG|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
219301544|NCT00910689|DRUG|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
219301545|NCT00910689|DRUG|Placebo control|Placebo
219301546|NCT00910689|BEHAVIORAL|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
219301547|NCT00910689|DRUG|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
219301548|NCT00071747|DRUG|lamotrigine|
219301549|NCT03339700|DRUG|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
219301550|NCT03339700|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
219301551|NCT03339700|DRUG|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
219301552|NCT03339700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
219301553|NCT00618527|DRUG|mycophenolate mofetil (Cellcept)|1 gram po, bid
219301554|NCT00618527|DRUG|human interferon beta 1a (Rebif)|44mcg sq injection every other day
219301555|NCT00006373|DRUG|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
219301556|NCT00006373|DRUG|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
219301557|NCT00006373|DRUG|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
219301558|NCT00006373|PROCEDURE|autologous bone marrow transplantation|
219301559|NCT00006373|DRUG|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
219301560|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
219301561|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
219301562|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
219301563|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
219301564|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
219301565|NCT00484289|DRUG|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
219301566|NCT00507195|DRUG|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
219301567|NCT04852367|DEVICE|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
219301568|NCT04852367|DRUG|Doxorubicin|Doxorubicin infusion
219301569|NCT04852367|DRUG|ThermoDox|ThermoDox infusion
219301570|NCT01849159|BIOLOGICAL|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
219301571|NCT01849159|OTHER|Reference therapy: 400 mL of 0.9% NaCl solution|
219301572|NCT02727062|DEVICE|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
219301573|NCT02727062|DEVICE|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
219301574|NCT00564460|DRUG|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
219301575|NCT00564460|DRUG|Placebo|Placebo once daily for 8 weeks
219301576|NCT04734093|DIAGNOSTIC_TEST|Evaluation of sonographic signs of gouty arthritis|the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
219301577|NCT05402696|PROCEDURE|Endoscopic tissue resection|Endoscopic resection techniques for removal of large polyps
219301578|NCT06000137|DRUG|Dezocine|dezocine for patient-controlled analgesia
219301579|NCT06000137|DRUG|Sufentanil injection|sufentanil for patient-controlled analgesia
219301580|NCT06000137|DRUG|Flurbiprofen|Flurbiprofen for patient-controlled analgesia
219301581|NCT06000137|DRUG|Granisetron Injection|granisetron has antiemetic function.
219301582|NCT02349425|DRUG|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
219301583|NCT02349425|DRUG|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
219301584|NCT05617482|OTHER|General anesthesia|All patients undergoing ceaserian section under general anesthesia
219301585|NCT05617482|OTHER|Ilioinguinal, iliohypogastric nerve blocks|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
219301586|NCT05617482|OTHER|TAP block|In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.
219301587|NCT05617482|OTHER|Quadratus lumborum block|For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
219301588|NCT04369716|OTHER|Whole oranges|Navel oranges (227 g total)
219301589|NCT04369716|OTHER|Whole Apples|Red Delicious apple with skin (230 g)
219301590|NCT04369716|OTHER|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
219301591|NCT04369716|OTHER|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
219301592|NCT04369716|OTHER|Orange juice|Orange Juice (250 g)
219301593|NCT04369716|OTHER|Apple juice|Apple Juice (235 g)
219301594|NCT01832285|DRUG|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
219301595|NCT05641181|DRUG|CRB4101|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
219301596|NCT05641181|DRUG|Placebo|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
219301597|NCT05568238|PROCEDURE|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM)|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM) in patients with open abdomen.
219301598|NCT00053560|DRUG|Prasterone (GL701)|
219301599|NCT01135407|OTHER|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
219301600|NCT01135407|OTHER|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
219301601|NCT01135407|OTHER|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
219301602|NCT05446233|DRUG|[14C] Antaitavir Hasophate|100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
219301603|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
219301604|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
219301605|NCT03372707|DIAGNOSTIC_TEST|Cuff Leak Test|The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
219301606|NCT00110110|BIOLOGICAL|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
219301607|NCT00110110|DRUG|Carboplatin|Given at 28 mg/kg/dose.
219301608|NCT00110110|DRUG|Cyclosporine|Given at 33 mg/kg/dose
219301609|NCT00110110|DRUG|Etoposide|Given at 12 mg/kg/dose
219301610|NCT00110110|DRUG|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
219301611|NCT00110110|PROCEDURE|cryosurgery|Local application of extreme cold to destroy residual tumor.
219301612|NCT00110110|PROCEDURE|laser therapy|Local and precise application of laser beams to destroy residual tumor.
219301613|NCT04970030|PROCEDURE|ML lithotripsy|we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
219301614|NCT04970030|PROCEDURE|EHL lithotripsy|after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
219301615|NCT05548140|DEVICE|Novel Motorized Spiral Enteroscopy|This study involves performance of spiral enteroscopy in one arm and single balloon enteroscopy in the other arm in patients who satisfy inclusion criteria
219301616|NCT05339217|DRUG|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
219301617|NCT05339217|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
219301618|NCT04751266|PROCEDURE|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
219301619|NCT04914299|BEHAVIORAL|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
219301620|NCT04914299|BEHAVIORAL|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
219301621|NCT05453123|BEHAVIORAL|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
219301622|NCT00775320|PROCEDURE|FLT-PET scan|Imaging test
219301623|NCT00286260|DRUG|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
219301624|NCT02594761|BIOLOGICAL|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
219301625|NCT02594761|BIOLOGICAL|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
219301626|NCT02594761|BIOLOGICAL|Herceptin US|Intravenous Infusion, 440 mg/vial
219301627|NCT00697333|PROCEDURE|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
219301628|NCT04552977|DRUG|fluzoparil|a PARP1 inhibitor
219301629|NCT04552977|DRUG|temozolomide|an alkylating chemotherapeutic agent
219301630|NCT04258501|OTHER|Mulberry fruit|
219301631|NCT04258501|OTHER|Mulberry leaf|
219301632|NCT04258501|OTHER|White bean|
219301633|NCT04258501|OTHER|Apple|
219301634|NCT04258501|OTHER|Elderberry|
219301635|NCT04258501|OTHER|Turmeric|
219301636|NCT04258501|OTHER|Rice porridge|
219301637|NCT02423928|BIOLOGICAL|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
219301638|NCT02423928|DRUG|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
219301639|NCT02423928|DRUG|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
219301640|NCT05479201|DIAGNOSTIC_TEST|Home based sleep test|Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
219301641|NCT04719884|PROCEDURE|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) \>10% and SI and CI \>10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of \>10% and the SVV still \>10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI \<10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
219301642|NCT03116737|DRUG|Benzocaine Otic Solution|
219301643|NCT03116737|DRUG|Placebo|
219301644|NCT04839874|OTHER|No intervention|Semi-structured qualitative interviews
219301645|NCT03382379|DEVICE|Active transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
219301646|NCT03382379|DEVICE|Sham transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
219301647|NCT01189084|BIOLOGICAL|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
219301648|NCT02789254|BIOLOGICAL|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA\* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~\* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
219301649|NCT05866068|DRUG|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
219301650|NCT02343874|OTHER|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
219301651|NCT02830945|BEHAVIORAL|Motivational Interviewing Intervention Arm|
219301652|NCT02830945|OTHER|Control Brochure Arm|
219301653|NCT02009254|OTHER|Dietary treatment|
219301654|NCT05015907|DRUG|Ropivacaine|The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
219301655|NCT05015907|OTHER|Control (without intervention)|No intervention
219301656|NCT04171453|DRUG|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
219301657|NCT04784260|OTHER|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
219301658|NCT01877837|DRUG|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued \>48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
219301659|NCT01877837|DRUG|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
219301660|NCT01877837|DRUG|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
219301661|NCT01877837|PROCEDURE|Stem Cells|Infusion of Hematopoietic Stem Cells
219301662|NCT01135537|BIOLOGICAL|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
219301663|NCT01786473|DRUG|Testogel 1%|
219301664|NCT01786473|DRUG|Placebo|
219301665|NCT02683005|DRUG|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
219301666|NCT04953325|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
219301667|NCT04953325|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
219301668|NCT04953325|BIOLOGICAL|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
219301669|NCT02860780|DRUG|prexasertib|Administered IV
219301670|NCT02860780|DRUG|ralimetinib|Administered orally
219301671|NCT03341767|DRUG|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
219301672|NCT03341767|DRUG|Placebo|Oil-wax in gelatin capsule
219301673|NCT04327076|DEVICE|Using robot system of endotracheal intubation and airway cleaning|"1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
219301674|NCT00716508|PROCEDURE|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
219301675|NCT00716508|PROCEDURE|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
219301676|NCT00645801|DRUG|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
219301677|NCT00645801|DRUG|Placebo|Amitiza Placebo
219744472|NCT00901914|BIOLOGICAL|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
219744473|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
219744474|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
219744475|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
219744476|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
219744477|NCT04550728|COMBINATION_PRODUCT|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
219744478|NCT04550728|COMBINATION_PRODUCT|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
219301678|NCT02761876|BEHAVIORAL|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
219301679|NCT02761876|BEHAVIORAL|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
219301680|NCT02761876|BEHAVIORAL|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
219301681|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
219301682|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
219301683|NCT00705679|DRUG|Tenofovir disoproxil fumarate|300 mg tablet
219301684|NCT00705679|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet
219301685|NCT00705679|DRUG|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
219301686|NCT00705679|DRUG|Tenofovir placebo|placebo gel
219301687|NCT00872677|BEHAVIORAL|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
219301688|NCT00872677|OTHER|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
219301689|NCT04660604|DEVICE|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
219301690|NCT03129880|BEHAVIORAL|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
219301691|NCT03129880|BEHAVIORAL|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
219301692|NCT00444899|BEHAVIORAL|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
219301693|NCT00444899|OTHER|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
219301694|NCT00819962|DRUG|Bupivacaine|Local anesthetic
219301695|NCT00819962|OTHER|TAP|
219301696|NCT04017039|OTHER|Targeted Sleep Intervention|
219301697|NCT04628351|BEHAVIORAL|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
219301698|NCT00932113|DRUG|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
219301699|NCT00932113|DRUG|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
219301700|NCT03818685|DRUG|Nivolumab|Radiotherapy will be maintained in each Arm.
219301701|NCT03818685|DRUG|Ipilimumab|Radiotherapy will be maintained in each Arm.
219301702|NCT03818685|DRUG|Capecitabine|Radiotherapy will be maintained in each Arm.
219301703|NCT04217629|DRUG|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
219301704|NCT06472193|PROCEDURE|Shanfield implantation technique in Mitroffanof procedure|a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
219301705|NCT05938374|DRUG|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
219301706|NCT05938374|RADIATION|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
219301707|NCT04360317|DRUG|Combination of SH003 and Docetaxel|Combination of SH003 and Docetaxel
219301708|NCT01403610|DRUG|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
219301709|NCT01403610|DRUG|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
219301710|NCT01403610|DRUG|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
219301711|NCT05657886|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
219301712|NCT05657886|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
219301713|NCT00626678|DRUG|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
219301714|NCT00626678|DRUG|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
219301715|NCT00626678|DRUG|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
219301716|NCT04123392|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
219301717|NCT04123392|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
219301718|NCT04123392|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
219301719|NCT03296033|DRUG|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
219301720|NCT03296033|DRUG|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
219301721|NCT04660630|DIAGNOSTIC_TEST|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
219301722|NCT04660630|BEHAVIORAL|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
219301723|NCT04178044|BIOLOGICAL|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
219301724|NCT04178044|BIOLOGICAL|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
219301725|NCT04178044|BIOLOGICAL|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
219301726|NCT04178044|BIOLOGICAL|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
219301727|NCT04178044|BIOLOGICAL|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
219301728|NCT00842270|DRUG|AB1010|3 mg/kg/day
219301729|NCT00842270|DRUG|AB1010|4,5 mg/kg/day
219301730|NCT00842270|DRUG|AB1010|6 mg/kg/day
219301731|NCT00842270|DRUG|placebo|matching placebo to AB1010 dosages
219301732|NCT00718354|DRUG|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
219301733|NCT00718354|DRUG|Standard Chemotherapy|Investigator's discretion
219301734|NCT03076333|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
219301735|NCT00896051|DRUG|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
219301736|NCT00896051|DRUG|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
219301737|NCT00896051|DRUG|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
219301738|NCT00896051|DRUG|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
219301739|NCT00896051|DRUG|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
219301740|NCT00896051|DRUG|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
219301741|NCT02935452|BEHAVIORAL|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
219301742|NCT00944177|DRUG|Metformin HCl|
219301743|NCT03217643|DRUG|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
219301744|NCT03133754|PROCEDURE|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
219301745|NCT03133754|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
219301746|NCT00876928|DRUG|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
219301747|NCT00876928|DRUG|placebo|medium chain triglyceride given once per week
219301748|NCT00044538|DRUG|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
219301749|NCT03719170|BEHAVIORAL|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
219301750|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
219301751|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
219301752|NCT00451880|DRUG|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
219301753|NCT00451880|DRUG|famotidine|single dose, supplied as 20-mg or 40-mg tablets
219301754|NCT05052866|BEHAVIORAL|Social Robot|Participants will interact with a social robot companionbot for a period of 8-10 weeks. The robot will stay in participants' apartments.
219301755|NCT00433524|PROCEDURE|computed tomography|
219301756|NCT03970460|DEVICE|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
219301757|NCT03970460|DEVICE|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
219301758|NCT00978796|DRUG|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
219301759|NCT00978796|DRUG|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
219301760|NCT05165797|BIOLOGICAL|platelet activation factors|platelet activation factors of subject blood
219301761|NCT00123552|DRUG|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
219301762|NCT00123552|DRUG|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
219301763|NCT00123552|DRUG|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
219301764|NCT05025202|OTHER|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
219301765|NCT00001407|DRUG|Interferon Gamma|
219301766|NCT02091648|BEHAVIORAL|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
219301767|NCT02091648|BEHAVIORAL|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
219301768|NCT00445900|DRUG|cyclophosphamide|
219301769|NCT00445900|DRUG|prednisone|
219301770|NCT00445900|DRUG|thalidomide|
219301771|NCT00445900|OTHER|immunohistochemistry staining method|
219301772|NCT00445900|OTHER|laboratory biomarker analysis|
219301773|NCT00445900|PROCEDURE|biopsy|
219301774|NCT01954381|DEVICE|transthoracic echocardiographic|
219301775|NCT01954381|DEVICE|Doppler ultrasound.|
219301776|NCT01954381|BIOLOGICAL|blood samples|
219301777|NCT01094860|DRUG|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
219301778|NCT05409833|DIAGNOSTIC_TEST|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
219301779|NCT00118755|DRUG|capecitabine|850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
219301780|NCT00118755|DRUG|Oxaliplatin|130 mg/m\^2 IV on Day 1 of each 3-week cycle
219301781|NCT00118755|DRUG|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
219301782|NCT00118755|DRUG|capecitabine|1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
219301783|NCT00118755|DRUG|Oxaliplatin|85 mg/m\^2 IV on Day 1 of each 2-week cycle
219301784|NCT00118755|DRUG|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
219301785|NCT03867058|BEHAVIORAL|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
219301786|NCT01652599|DRUG|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
219301787|NCT02887807|DRUG|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
219301788|NCT02887807|DRUG|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
219301789|NCT04862871|BEHAVIORAL|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
219301790|NCT04124081|DRUG|Hydronidone capsules& Entecavir capsules|take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
219301791|NCT05747053|DIAGNOSTIC_TEST|AlloSure|AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
219301792|NCT05747053|DIAGNOSTIC_TEST|PAXGene|1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
219301793|NCT02562495|DEVICE|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
219301794|NCT06110325|OTHER|Cawthorne and Cooksey exercise program|Participants in this group will receive an exercise program based on Cawthorne and Cooksey exercises. The intervention will last for 4 weeks, taking place three times a week, with the first session conducted in person and the remaining two assisted via video from their homes.
219301795|NCT06110325|OTHER|Control|Control group will receive counseling focused on fall prevention and promotion of an active, healthy lifestyle through informational leaflets.
219301796|NCT00701233|DRUG|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
219301797|NCT00701233|DRUG|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
219301798|NCT05022225|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
219301799|NCT00517907|DRUG|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
219301800|NCT02118558|DEVICE|Negative Pressure Wound Therapy (NPWT)|
219301801|NCT02118558|DRUG|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
219301802|NCT01143038|BIOLOGICAL|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
219301803|NCT03344653|DEVICE|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
219301804|NCT03344653|DEVICE|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
219301805|NCT00650351|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
219301806|NCT00650351|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
219301807|NCT04826861|BEHAVIORAL|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
219301808|NCT01197833|DRUG|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
219301809|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
219301810|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
219301811|NCT02178670|BIOLOGICAL|CSC-DC|
219301812|NCT04900987|DEVICE|Steri-strips|Pneumatic TR band compression with use of steri-strips
219301813|NCT00562133|DRUG|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
219301814|NCT00562133|DRUG|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
219301815|NCT05760053|DRUG|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
219301816|NCT00465556|BEHAVIORAL|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
219301817|NCT00465556|BEHAVIORAL|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
219301818|NCT02998736|DRUG|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
219301819|NCT02998736|BIOLOGICAL|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
219301820|NCT03881488|DRUG|CTX-471|IV infusion every 2 weeks
219301821|NCT03881488|DRUG|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
219301822|NCT00892073|DRUG|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
219301823|NCT00892073|DRUG|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
219301824|NCT02272088|BEHAVIORAL|physical activity-moderate|cross -over of moderate and intense physical activity
219301825|NCT02272088|BEHAVIORAL|Intense physical activity|cross -over of moderate and intense physical activity
219301826|NCT01346475|DRUG|valacyclovir|1000 mg orally three times daily for 5 weeks
219301827|NCT01346475|DRUG|Valacyclovir|500 mg orally once daily for 5 weeks
219301828|NCT00582868|DEVICE|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
219301829|NCT00582868|OTHER|CSF|analysis of CSF for cleaved tau protein
219301830|NCT00582868|OTHER|Whole blood|Analysis of whole blood for cleaved-tau protein
219301831|NCT04119258|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
219301832|NCT04147117|DEVICE|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
219301833|NCT05813639|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
219301834|NCT05813639|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
219301835|NCT05813639|PROCEDURE|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
219301836|NCT04674696|OTHER|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
219301837|NCT01572376|PROCEDURE|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
219301838|NCT03629327|DRUG|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
219301839|NCT03629327|OTHER|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
219301840|NCT03629327|DRUG|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
219301841|NCT02704663|PROCEDURE|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
219301842|NCT02704663|PROCEDURE|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
219301843|NCT06236555|DIAGNOSTIC_TEST|8-iso Prostaglandin F2α and Adenosine Deaminase|We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
219301844|NCT00355459|DRUG|Tetracycline: Doxycycline analog|
219301845|NCT03689959|PROCEDURE|Eight plate hemiepiphysiodesis|Patient is positioned in a classic supine position. Under fluoroscopic guidance and tourniquet hemostasis, the distal femoral physis is identified. Two 3-cm incisions are made, one on either side of the patella, centred at the level of the physis. The capsule and synovium are opened to visualize the sulcus and place the plates just outside the articular portion of the joint surface, medially and laterally. Care is taken not to damage the periosteum and a needle is inserted into the physis. The 8-plate, which has a central hole, is slipped over the needle and screws inserted. After wound closure, a soft dressing is used, and the patient is allowed to ambulate as tolerated.
219301846|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 3|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves
219301847|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 4|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
219301848|NCT01280162|DRUG|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
219301849|NCT03051243|DRUG|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
219301850|NCT03051243|DRUG|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
219301851|NCT00461838|PROCEDURE|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
219301852|NCT00461838|OTHER|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
219301853|NCT04533568|DRUG|Ibuprofen 400 mg|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
219301854|NCT04533568|DRUG|Dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
219301855|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
219301856|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
219301857|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
219301858|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
219301859|NCT02389608|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
219301860|NCT02389608|DEVICE|Functional electrical stimulation (FES)|
219301861|NCT02389608|DEVICE|Sham stimulation|
219301862|NCT01666379|DRUG|Fentanyl|
219301863|NCT03782077|PROCEDURE|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
219301864|NCT00370331|DRUG|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
219301865|NCT00370331|DRUG|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
219301866|NCT03507465|DRUG|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
219301867|NCT03507465|DRUG|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
219301868|NCT01703351|DRUG|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
219301869|NCT01703351|DRUG|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
219301870|NCT01638832|DEVICE|Transient Elastography (FibroScan), Echosens, Paris, France|
219301871|NCT01638832|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
219301872|NCT06476756|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUE|Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.
219301873|NCT06476756|OTHER|Buteyko techniques|Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1.
219301874|NCT01610141|OTHER|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
219301875|NCT01610141|OTHER|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
219301876|NCT00809601|DEVICE|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
219301877|NCT02416817|OTHER|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
219301878|NCT02416817|OTHER|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
219301879|NCT00757588|DRUG|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
219301880|NCT00757588|DRUG|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
219301881|NCT00220467|BEHAVIORAL|Aerobic exercise|
219301882|NCT04665999|DEVICE|Continuous Glucose Monitor|Data collection only
219301883|NCT06394232|DRUG|Eyecyte-RPE™|Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
219301884|NCT04073459|BIOLOGICAL|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
219301885|NCT04073459|BIOLOGICAL|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
219301886|NCT03023761|DEVICE|low level laser|low level laser irradiation
219301887|NCT03023761|DEVICE|laser sham|laser without irradiation
219301888|NCT02030301|BIOLOGICAL|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
219301889|NCT02030301|BIOLOGICAL|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
219301890|NCT02030301|BIOLOGICAL|PBS|Phosphate-buffered saline
219301891|NCT01052103|DRUG|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
219301892|NCT01052103|DRUG|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
219301893|NCT01052103|DRUG|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
219301894|NCT02947893|DRUG|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
219301895|NCT02947893|DRUG|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
219301896|NCT03929445|DEVICE|Endotracheal tube introducers|"Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie."
219301897|NCT04800432|BEHAVIORAL|ADAPT+|ADAPT+ is designed as an 6-week intervention. For each session, children and parents participate in separate 1.5-hour group meetings, followed by a joint goal setting session. Practical strategies related to improving diet and physical activity as well as the role of dealing with parent stress-related factors related to making long-lasting behavioral changes in the family are addressed.
219301898|NCT04800432|BEHAVIORAL|EUC|Enhanced Usual Care is an abbreviated version of the full ADAPT+ intervention in which parents are engaged in a one-time, two hour information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
219301899|NCT04280302|BEHAVIORAL|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
219301900|NCT04280302|BEHAVIORAL|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
219301901|NCT00888628|BIOLOGICAL|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
219301902|NCT00888628|DRUG|Etanercept|Given as induction for islet cell transplant
219301903|NCT02999126|DRUG|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
219301904|NCT02999126|DRUG|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
219301905|NCT05273593|DEVICE|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
219301906|NCT03768804|OTHER|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
219301907|NCT03768804|OTHER|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
219301908|NCT05196568|DIETARY_SUPPLEMENT|Fasting mimicking diet|Women will be given three administrations of fasting mimicking diet once a month
219301909|NCT05505331|RADIATION|three-Dimensional ultrasonography|transadominal and transvaginal examination
219301910|NCT05505331|RADIATION|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
219301911|NCT05505331|PROCEDURE|myomectomy|myoma excision
219301912|NCT04459013|OTHER|Salivary samples|The salivary samples will be collected at 5 defined times
219301913|NCT05398237|OTHER|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
219301914|NCT01234753|OTHER|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
219301915|NCT02877836|OTHER|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
219301916|NCT06359834|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion. Remimazolam 2mg is added in case of inadequate sedation.
219301917|NCT06359834|DRUG|Propofol|Patients in this group receives 1mg/kg of propofol to induce sedation prior to endoscope insertion. Propofol 20mg is added in case of inadequate sedation.
219301918|NCT05936294|DIAGNOSTIC_TEST|Optimization of CRT Device|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
219301919|NCT04023500|BEHAVIORAL|Motivational interview vs. prevailing education|"In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care."
219301920|NCT04261491|PROCEDURE|scaling and root planing|scaling and root planing
219301921|NCT00691327|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
219301922|NCT04317365|OTHER|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
219301923|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
219301924|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
219301925|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
219301926|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
219301927|NCT01174732|DRUG|Placebo|placebo, lactose inhalation carrier
219301928|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
219301929|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
219301930|NCT01220518|DRUG|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
219301931|NCT02220673|DRUG|BHT 0.1%|
219301932|NCT02220673|DRUG|BHT 0.5%|
219301933|NCT02220673|DRUG|Placebo for RMT-B|
219301934|NCT02220673|DRUG|Placebo for HFA-MDI|
219301935|NCT02162589|PROCEDURE|POEM|Per oral endoscopic myotomy
219301936|NCT01749904|DRUG|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
219301937|NCT01749904|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
219301938|NCT01749904|DRUG|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
219301939|NCT00614601|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
219301940|NCT00386373|DRUG|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
219301941|NCT00321373|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
219301942|NCT00321373|BIOLOGICAL|FluarixTM|Single dose, Intramuscular injection
219301943|NCT00731809|RADIATION|FDG PET CT|FDG PET CT
219301944|NCT05337358|PROCEDURE|endocrown|endocrown
219301945|NCT05729178|OTHER|observational study|analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
219301946|NCT04684251|PROCEDURE|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
219301947|NCT04962243|PROCEDURE|Repair surgery for Achilles tendon rupture|Repair surgery for Achilles tendon rupture
219301948|NCT00079989|DRUG|tigecycline|
219301949|NCT00819520|DRUG|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
219301950|NCT00819520|DRUG|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
219301951|NCT00992433|BIOLOGICAL|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
219301952|NCT02179099|DEVICE|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
219301953|NCT02236104|DEVICE|Plethysmography opto electronic|
219301954|NCT02236104|PROCEDURE|respiratory parameters|
219301955|NCT02318992|BIOLOGICAL|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
219301956|NCT00994500|DRUG|vorinostat|Given orally
219301957|NCT00994500|DRUG|bortezomib|Given IV
219301958|NCT00994500|OTHER|pharmacological study|Correlative studies
219301959|NCT00994500|OTHER|laboratory biomarker analysis|Correlative studies
219301960|NCT02196454|OTHER|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
219301961|NCT01925287|DIETARY_SUPPLEMENT|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
219301962|NCT02358759|PROCEDURE|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
219301963|NCT04490382|DEVICE|32 channel external stimulator|Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
219301964|NCT05370001|OTHER|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
219301965|NCT03391401|PROCEDURE|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
219301966|NCT05490719|DRUG|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
219301967|NCT04810143|DEVICE|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
219301968|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
219301969|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
219301970|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
219301971|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
219301972|NCT00552240|DRUG|Nevirapine 200 mg BID|200 mg BID
219301973|NCT00552240|DRUG|Atazanavir 300 mg|300 mg QD
219301974|NCT00552240|DRUG|Ritonavir 100 mg|100 mg QD
219301975|NCT01453803|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
219301976|NCT06020742|PROCEDURE|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
219301977|NCT00681460|DRUG|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
219301978|NCT00681460|DRUG|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
219301979|NCT00801931|DRUG|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
219301980|NCT00801931|RADIATION|Total Body Irradiation|
219301981|NCT00801931|DRUG|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
219301982|NCT00801931|DRUG|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
219301983|NCT00801931|DRUG|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
219301984|NCT00801931|DRUG|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
219301985|NCT00801931|DRUG|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
219301986|NCT00801931|DRUG|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG \[horse\]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
219301987|NCT00801931|DRUG|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
219301988|NCT00801931|DRUG|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
219301989|NCT02784951|DRUG|Red blood cells (0Rh D-neg)|Fresh produced RBC
219301990|NCT02784951|DRUG|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
219301991|NCT02784951|DRUG|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
219301992|NCT02783768|DEVICE|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
219301993|NCT02783768|OTHER|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
219301994|NCT02783768|DRUG|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
219301995|NCT02783768|DRUG|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
219301996|NCT01934361|DRUG|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
219301997|NCT01934361|DRUG|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
219301998|NCT01934361|DRUG|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
219301999|NCT01934361|DRUG|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
219302000|NCT02938533|BEHAVIORAL|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
219302001|NCT04247087|DRUG|phytomenadione|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
219302002|NCT04247087|DRUG|placebo solution|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
219302003|NCT01323647|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration
219302004|NCT01323647|BIOLOGICAL|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
219302005|NCT06227143|PROCEDURE|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
219302006|NCT04847076|BEHAVIORAL|m-health version of WWWT intervention|m-health version of Chilean adaptation of WWWT intervention: a) Psychoeducational information for understanding and managing infant behavior and on parenting. b) Contact with the program facilitator. c) A virtual group meeting
219302007|NCT04847076|OTHER|Treatment as usual|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age
219302008|NCT04295876|BEHAVIORAL|The BRIDGES Project Intervention|The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
219302009|NCT00149760|BEHAVIORAL|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
219302010|NCT00149760|BEHAVIORAL|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
219302011|NCT04206033|OTHER|Observational study|Observational study
219302012|NCT02262624|DRUG|Telmisartan|
219302013|NCT02262624|DRUG|Hydrochlorthiazide (HCTZ)|
219302014|NCT02262624|DRUG|Telmisartan/HCTZ fixed combination|
219302015|NCT00238147|DRUG|capecitabine|
219302016|NCT00238147|DRUG|carboplatin|
219302017|NCT00238147|DRUG|docetaxel|
219302018|NCT00238147|PROCEDURE|conventional surgery|
219302019|NCT00238147|PROCEDURE|neoadjuvant therapy|
219302020|NCT00238147|RADIATION|radiation therapy|
219302021|NCT00458991|DRUG|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
219302022|NCT05358106|BIOLOGICAL|AntiBKV|AntiBKV neutralising antibody
219302023|NCT05358106|BIOLOGICAL|Placebo|Solution with no active ingredients
219302024|NCT04589949|BIOLOGICAL|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
219302025|NCT04589949|BIOLOGICAL|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
219302026|NCT03293693|OTHER|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
219302027|NCT03293693|OTHER|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
219302028|NCT03293693|OTHER|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
219302029|NCT03270397|BEHAVIORAL|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
219302030|NCT05319782|OTHER|Urethral stenosis assesment|Auto-questionnaires + Clinical examination + Flow metry and post-mictional residue
219302031|NCT03375216|BEHAVIORAL|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
219302032|NCT03375216|BEHAVIORAL|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
219302033|NCT05494177|DIAGNOSTIC_TEST|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART)."
219302034|NCT05494177|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
219302035|NCT06124781|PROCEDURE|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
219302036|NCT06124781|PROCEDURE|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
219302037|NCT06124781|PROCEDURE|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
219302038|NCT05396482|DIAGNOSTIC_TEST|Pure tone audiometer|Pure tone audiometer
219302039|NCT01096823|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
219302040|NCT05097222|DEVICE|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
219302041|NCT05097222|DEVICE|Sham device|Control
219302042|NCT01935180|DEVICE|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
219302043|NCT04312217|BEHAVIORAL|Medical clowning|Medical clowning
219302044|NCT00732225|DEVICE|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
219302045|NCT00732225|DEVICE|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
219302046|NCT00732225|DEVICE|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
219302047|NCT00732225|DEVICE|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
219302048|NCT00732225|DEVICE|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
219302049|NCT02450799|DEVICE|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
219302050|NCT02450799|DEVICE|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
219302051|NCT02450799|DEVICE|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
219302052|NCT03418831|DRUG|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
219302053|NCT03418831|OTHER|Placebo|1 tablet daily for 12 weeks
219302054|NCT03468738|OTHER|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
219302055|NCT05024227|BEHAVIORAL|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
219302056|NCT04896112|DRUG|LNK01002|LNK01002 will be administrated orally.
219302057|NCT00163306|DRUG|Pantoprazole|
219302058|NCT01945060|DEVICE|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server."
219302059|NCT01945060|OTHER|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
219302060|NCT01704768|BEHAVIORAL|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
219302061|NCT01704768|BEHAVIORAL|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
219302062|NCT00402597|DRUG|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
219302063|NCT00402597|DRUG|Placebo|1 placebo tablet twice daily for 6 months.
219302064|NCT00402597|DRUG|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
219302065|NCT02754817|DRUG|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
219302066|NCT00440258|DRUG|Cabergoline|
219302067|NCT00440258|PROCEDURE|MR|
219302068|NCT00440258|PROCEDURE|Ultrasound|
219302069|NCT00440258|PROCEDURE|Blood Analysis|
219302070|NCT02319525|OTHER|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
219302071|NCT02319525|OTHER|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
219302072|NCT03005964|DRUG|AM001 Cream, 7.5%|Active Cream
219302073|NCT03005964|DRUG|Vehicle Cream|Placebo
219302074|NCT04890925|BEHAVIORAL|Community Support Network (CSN) intervention|The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.
219302075|NCT04890925|BEHAVIORAL|Usual care|Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
219302076|NCT00938860|DRUG|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
219302077|NCT00938860|DRUG|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
219302078|NCT02222051|BEHAVIORAL|Tai Chi|traditional chinese martial art meditative movement technique
219302079|NCT02222051|BEHAVIORAL|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
219302080|NCT03035266|OTHER|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
219302081|NCT03035266|OTHER|Standard rehabilitation|Standard of care for post-operative condition
219302082|NCT00672191|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
219302083|NCT00366808|PROCEDURE|LASIK surgery|
219302084|NCT03294148|OTHER|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
219302085|NCT03294148|BEHAVIORAL|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
219302086|NCT01869127|DEVICE|Shoes|A unisex canvas slip-on with a sturdy sole.
219302087|NCT01581138|DRUG|VX-222|400 mg tablets twice daily for oral administration
219302088|NCT01581138|DRUG|telaprevir|1125 mg tablets twice daily for oral administration
219302089|NCT01581138|DRUG|ribavirin|1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
219302090|NCT04032054|DEVICE|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
219302091|NCT03854773|OTHER|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219302092|NCT03854773|OTHER|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219302093|NCT03854773|OTHER|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
219302094|NCT03770910|OTHER|GIP receptor antagonist|GIP receptor antagonist
219302095|NCT03770910|OTHER|GIP receptor agonist|GIP(1-42)
219302096|NCT03770910|OTHER|Saline|Placebo (vehicle for infusions)
219302097|NCT00577837|DRUG|risedronate|tablet, 5 mg risedronate daily for 6 months
219302098|NCT00577837|DRUG|risedronate|tablet, 100 mg risedronate monthly for 6 months
219302099|NCT00577837|DRUG|risedronate|tablet, 150 mg risedronate monthly for 6 months
219302100|NCT00577837|DRUG|experimental|tablet, 200 mg risedronate monthly for 6 months
219302101|NCT06143969|PROCEDURE|ultrasound-assisted, catheter-directed thrombolysis|After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
219302102|NCT00398554|DRUG|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
219302103|NCT00398554|DRUG|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
219302104|NCT00398554|DRUG|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
219302105|NCT00398554|DRUG|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
219302106|NCT00398554|DRUG|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
219302107|NCT00398554|DRUG|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
219302108|NCT00398554|RADIATION|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
219302109|NCT05857982|DRUG|Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
219302110|NCT01054170|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
219302111|NCT01054170|DRUG|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
219302112|NCT01081054|OTHER|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
219302113|NCT05040984|DRUG|Solifenacin Oral Tablet|Solifenacin 1 tablet per day
219302114|NCT05040984|DRUG|Mirabegron 25mg|Mirabegron 1 tablet per day
219302115|NCT00329511|DRUG|methyldopa vs. clonidine|Comparison of compliance
219302116|NCT00329511|DRUG|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
219302117|NCT03650309|DEVICE|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
219302118|NCT05033431|DRUG|Brazikumab|Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
219302119|NCT00291850|DRUG|Paclitaxel, Cisplatin, Pegfilgrastim|
219302120|NCT05249829|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
219302121|NCT05249829|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219302122|NCT05249829|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219302123|NCT01096277|DRUG|Sitagliptin|oral tablets 100 mg per day for two weeks
219302124|NCT01096277|DRUG|Placebo|oral tablet, one per day for two weeks
219302125|NCT01096277|OTHER|Control|no intervention
219302126|NCT03160508|PROCEDURE|Fracture fixation with the TFNA|Fracture fixation with the TFNA
219302127|NCT00513604|BIOLOGICAL|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
219302128|NCT00513604|BIOLOGICAL|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
219302129|NCT00513604|DRUG|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
219302130|NCT00513604|DRUG|Fludarabine phosphate|Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
219302131|NCT00513604|RADIATION|Total body irradiation|600 cGy
219302132|NCT05529147|DRUG|Antihypertensive Agents|Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
219302133|NCT02666846|DRUG|Ibuprofen|
219302134|NCT02666846|DRUG|Diclofenac|
219302135|NCT02666846|DRUG|Methyl-salicylate / Menthol|
219302136|NCT02666846|DRUG|Placebo|
219302137|NCT04555980|DEVICE|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
219302138|NCT04555980|DEVICE|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
219302139|NCT02791074|OTHER|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
219302140|NCT02791074|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
219302141|NCT02791074|OTHER|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
219302142|NCT00060424|DRUG|Cyclosporine|Given PO
219302143|NCT00060424|DRUG|Fludarabine Phosphate|Given IV
219302144|NCT00060424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
219302145|NCT00060424|OTHER|Laboratory Biomarker Analysis|Correlative studies
219302146|NCT00060424|DRUG|Mycophenolate Mofetil|Given PO
219302147|NCT00060424|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
219302148|NCT00060424|RADIATION|Total-Body Irradiation|Undergo TBI
219302149|NCT04565379|DRUG|NuSepin® 0.1 mg|NuSepin® 0.1 mg
219302150|NCT04565379|DRUG|NuSepin® 0.2 mg|NuSepin® 0.2 mg
219302151|NCT04565379|DRUG|Placebo|Normal Saline
219302152|NCT04212273|DIAGNOSTIC_TEST|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
219302153|NCT00038974|DRUG|peginterferon alfa-2a|
219302154|NCT00038974|DRUG|Ribavirin|
219302155|NCT01535560|DRUG|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
219302156|NCT01535560|DRUG|AL-60371 Vehicle|Inactive ingredients used as placebo
219302157|NCT03019731|BEHAVIORAL|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
219302158|NCT03019731|BEHAVIORAL|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
219302159|NCT02914977|DRUG|Daunorubicin|"* Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle"
219302160|NCT06140654|DIAGNOSTIC_TEST|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
219302161|NCT06140654|DIAGNOSTIC_TEST|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
219302162|NCT05983224|DIETARY_SUPPLEMENT|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
219302163|NCT05983224|OTHER|Placebo|The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
219302164|NCT02009761|DRUG|BI 655064|subcutaneous injection
219302165|NCT04771949|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
219302166|NCT04771949|OTHER|Questionnaires|"After the periodontal chart, patients will be administered the italian version of 4 questionnaires regarding:~1. Adherence to Mediterranean Diet (Gnagnarella et al. 2018);~2. International Physical Activity Questionnaire (IPAQ) (Mannocci et al. 2010);~3. Pittsburgh Sleep Quality Index (PSQI) (Curcio et al. 2013);~4. Italian Perceived Stress Scale (Fossati, 2010)."
219302167|NCT06183957|OTHER|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
219302168|NCT02901782|PROCEDURE|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
219302169|NCT03587051|DIETARY_SUPPLEMENT|Low glycemic index post-exercise diet|Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
219302170|NCT03587051|DIETARY_SUPPLEMENT|High glycemic index post-exercise diet|Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
219302171|NCT03915704|DEVICE|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
219302172|NCT03915704|PROCEDURE|Control|No intervention was made in the children.
219302173|NCT03915704|DEVICE|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
219302174|NCT00537693|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
219302175|NCT02842827|DRUG|bomedemstat|oral administration
219302176|NCT02842827|DRUG|tretinoin|oral administration
219302177|NCT05830045|DRUG|QLP2117|Specified dose on specified days
219302178|NCT03386110|BEHAVIORAL|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
219302179|NCT03386110|BEHAVIORAL|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
219302180|NCT03241303|DRUG|Acarbose|Glucobay tablets on experimental day.
219302181|NCT03241303|DRUG|Placebo Oral Tablet|Placebo tablets on experimental day.
219302182|NCT03241303|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
219302183|NCT03241303|DRUG|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
219302184|NCT05636605|DIAGNOSTIC_TEST|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
219302185|NCT03770533|OTHER|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
219302186|NCT00407277|DRUG|Nicotine patch|21 mg of nicotine via a dermal patch
219302187|NCT00407277|OTHER|placebo|placebo via a dermal patch
219302188|NCT00407277|BEHAVIORAL|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
219302189|NCT00300898|PROCEDURE|Nucleoplasty|
219302190|NCT00300898|PROCEDURE|Percutaneous decompression|
219302191|NCT00300898|PROCEDURE|Intervertebral electrothermal disc decompression (IDET)|
219302192|NCT00300898|BEHAVIORAL|Conservative treatment|
219302193|NCT05320549|BEHAVIORAL|Community Programme|Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
219302194|NCT02660463|OTHER|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
219302195|NCT03300115|DRUG|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
219302196|NCT05414487|DRUG|Ofatumumab|There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
219302197|NCT05077657|DEVICE|Early Bird® Bleed Monitoring System|The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
219302198|NCT05077657|DEVICE|Impella®|Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
219302199|NCT02990312|DRUG|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
219302200|NCT03356457|DRUG|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
219302201|NCT03356457|DRUG|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
219302202|NCT01987141|OTHER|EMR Intervention|Electronic medical record flag/notification in the patient's chart
219302203|NCT02739295|DRUG|recombinant granulocyte - colony stimulating factor|
219302204|NCT02739295|DRUG|NaCl 0.9%|
219302205|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
219302206|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
219302207|NCT05488223|DIETARY_SUPPLEMENT|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
219302208|NCT04720872|OTHER|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
219302209|NCT01148147|DRUG|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
219302210|NCT01148147|DRUG|Placebo|Intracoronary Placebo administration
219302211|NCT02695303|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219302212|NCT04524026|DRUG|Letrozole 5 mg|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
219302213|NCT05731453|GENETIC|Polygenetic risk score|Polygenetic risk score assessment for breast cancer
219302214|NCT03130153|DRUG|Aspirin Powder|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
219302215|NCT03130153|DRUG|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
219302216|NCT03031145|BIOLOGICAL|Felis Domesticus|Nasal Administration of Felis Domesticus
219302217|NCT01364103|OTHER|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
219302218|NCT02650687|PROCEDURE|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
219302219|NCT02169167|DEVICE|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
219302220|NCT02169167|DEVICE|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
219302221|NCT00943111|DRUG|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (\>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
219302222|NCT00943111|DRUG|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was \>=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
219302223|NCT01796548|DRUG|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
219302224|NCT02859324|DRUG|CC-122|
219302225|NCT02859324|DRUG|Nivolumab|
219302226|NCT02174666|DIETARY_SUPPLEMENT|Red clover extract|Aglycone isoflavones 80mg/d
219302227|NCT02174666|DIETARY_SUPPLEMENT|Supplementation (placebo)|
219302228|NCT02608957|DEVICE|Latella Knee Implant System|
219302229|NCT03170791|DEVICE|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
219302230|NCT04556721|DRUG|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
219302231|NCT04876235|PROCEDURE|endoscopic ultrasound|All patients were implanted with stents（DPPS or LAMS）under the EUS
219302232|NCT04876235|DEVICE|lumen-apposing metal stent|In the LAMS group, patients were stented with LAMS
219302233|NCT04876235|DEVICE|double-pigtail plastic stents|In the DPPS group, patients were stented with DPPS
219302234|NCT03567824|DRUG|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
219302235|NCT03567824|DRUG|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
219302236|NCT01052129|DRUG|Naproxen sodium|Naproxen Sodium Tablets 550 mg
219302237|NCT04006353|DRUG|ABT|320 mg, Intravenous infusion
219302238|NCT04006353|DRUG|RIF|600mg q.d.
219302239|NCT03229590|PROCEDURE|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
219302240|NCT01322997|DEVICE|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
219302241|NCT01322997|BEHAVIORAL|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
219302242|NCT01322997|DEVICE|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
219302243|NCT00335439|DRUG|ketorolac tromethamine 0.5% (Acular®)|
219302244|NCT02940184|DRUG|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
219302245|NCT02940184|OTHER|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
219302246|NCT02861469|OTHER|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
219302247|NCT00547768|DRUG|Fexofenadine HCI|
219302248|NCT00001689|DRUG|Vincristine|
219302249|NCT02239900|DRUG|Ipilimumab|"Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4"
219302250|NCT02239900|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1."
219302251|NCT02882529|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
219302252|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food - MAM|Each MAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
219302253|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF)|Each MAM child will be supplemented with RUSF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
219302254|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food (MDF) - SAM|Each SAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
219302255|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|Each SAM child will be supplemented with RUTF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
219302256|NCT04474509|BEHAVIORAL|FACT Module Engagement|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
219302257|NCT04474509|BEHAVIORAL|FACT Module Openness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
219302258|NCT04474509|BEHAVIORAL|FACT Module Awareness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
219302259|NCT01453868|OTHER|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
219302260|NCT01453868|OTHER|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
219302261|NCT02144727|PROCEDURE|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
219302262|NCT02144727|PROCEDURE|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
219302263|NCT04472000|DRUG|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
219302264|NCT04472000|DRUG|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
219302265|NCT00038012|DRUG|Thrombopoietin|
219302266|NCT00038012|PROCEDURE|Platelet-pheresis|
219302267|NCT00038012|DRUG|Carboplatin|
219302268|NCT03738345|OTHER|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
219302269|NCT02745574|PROCEDURE|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
219302270|NCT02745574|PROCEDURE|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
219302271|NCT00974376|DRUG|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
219302272|NCT00974376|DRUG|Placebo|1200mg/day of placebo for 12 weeks
219302273|NCT00974376|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
219302274|NCT01668901|DRUG|warfarin|anticoagulation
219302275|NCT01668901|DRUG|Aspirin|antiplatelet
219302276|NCT01193426|OTHER|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
219302277|NCT02547259|PROCEDURE|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
219302278|NCT02547259|PROCEDURE|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
219302279|NCT01614535|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
219302280|NCT03217682|OTHER|Music Therapy|Music therapy sessions
219302281|NCT03217682|OTHER|Massage Therapy|Massage therapy sessions
219302282|NCT03861208|OTHER|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
219302283|NCT03861208|OTHER|usual diet|foods representing the usually provided foods at childcare are offered
219302284|NCT01540331|DEVICE|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
219302285|NCT02377141|PROCEDURE|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
219302286|NCT02377141|PROCEDURE|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
219302287|NCT02807103|DRUG|Rituximab|1 g intravenous pulse at day1 and day15
219302288|NCT02807103|DRUG|Placebo-rituximab|intravenous pulses at day1 and day15
219302289|NCT02807103|DRUG|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
219302290|NCT02807103|DRUG|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
219744479|NCT04632654|BEHAVIORAL|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
219744480|NCT04375826|DEVICE|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
219744481|NCT04375826|DEVICE|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
219744482|NCT06636695|DEVICE|Cellular Matrix|Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
219744483|NCT06636695|DEVICE|Orthovisc|Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
219744484|NCT06638827|PROCEDURE|Thoracic Sympathectomy|"Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3).."
219744485|NCT06644664|BEHAVIORAL|Health Education|Receive control MMS messages
219744486|NCT06644664|OTHER|Interview|Ancillary studies
219744487|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive AR MMS messages
219744488|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive RR MMS messages
219744489|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resources
219302291|NCT03218540|PROCEDURE|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV \> 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg
219302292|NCT01134952|DRUG|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
219302293|NCT03888053|BIOLOGICAL|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
219302294|NCT01055301|DRUG|bortezomib|
219302295|NCT01055301|DRUG|cisplatin|
219302296|NCT01055301|DRUG|cyclophosphamide|
219302297|NCT01055301|DRUG|dexamethasone|
219302298|NCT01055301|DRUG|doxorubicin hydrochloride|
219302299|NCT01055301|DRUG|etoposide|
219302300|NCT01055301|DRUG|lenalidomide|
219302301|NCT01055301|DRUG|melphalan|
219302302|NCT01055301|DRUG|thalidomide|
219302303|NCT01055301|GENETIC|gene expression analysis|
219302304|NCT01055301|GENETIC|microarray analysis|
219302305|NCT01055301|OTHER|laboratory biomarker analysis|
219302306|NCT01055301|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
219302307|NCT01389505|PROCEDURE|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
219744490|NCT06644664|OTHER|Survey Administration|Ancillary studies
219744491|NCT06644664|OTHER|Text Message-Based Navigation Intervention|Receive check-in text message
219744492|NCT06643559|OTHER|cognitive rehabilitation|Cognitive rehabilitation started to one group at the beginning of the antiseizure medicine. Participants underwent computer-based cognitive rehabilitation for 3 sessions per week, with each session lasting an average of 60 minutes. Before the sessions, all participants were given detailed information about the programme and its use. The rehabilitation process was carried out in three areas of cognitive functions: memory, executive functions, and language skills.
219744493|NCT06645288|OTHER|Emergency Reflex Action Drill|Emergency Reflex Action Drill in performing Emergency Surgical Airway
219744494|NCT06644677|DIAGNOSTIC_TEST|HPV integration|Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
219744495|NCT06643533|OTHER|Fecal Microbiota Transplantation|The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
219744496|NCT06644547|BEHAVIORAL|Gezond en goed met elkaar|"The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention."
219744497|NCT06371352|DEVICE|iTBS|Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
219744498|NCT06371352|DEVICE|cTBS|Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
219744499|NCT06371352|DEVICE|Sham|Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
219744500|NCT05418426|DEVICE|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
219744501|NCT05418426|DEVICE|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
219744502|NCT05418426|DRUG|Oral Reference|estradiol 1mg/progesterone 100 mg
219744503|NCT01674062|DRUG|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
219744504|NCT01674062|DRUG|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
219744505|NCT04620668|DEVICE|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
219744506|NCT01397591|BIOLOGICAL|Ofatumumab|Given intravenously
219744507|NCT01397591|DRUG|Bortezomib|Given intravenously
219744508|NCT02826187|OTHER|Early complications data|"Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection"
219744509|NCT02826187|OTHER|Late stage complications data|"Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection"
219744510|NCT02826187|OTHER|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
219744511|NCT02826187|OTHER|Efficacity|Efficacity as evaluated by Harris HIP score
219744512|NCT02826187|OTHER|Radiographic evaluation|Bone reaction visible in radiography
219744513|NCT06630130|DRUG|Trastuzumab deruxtecan|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"
219744514|NCT06630130|DRUG|Capecitabine|"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
219744515|NCT06630130|DRUG|Rilvegostomig|"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"
219302308|NCT01389505|PROCEDURE|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
219302309|NCT04452760|OTHER|Physical exercise|Physical exercise intervention
219302310|NCT04452760|OTHER|Testing sessions|Testing sessions
219302311|NCT00063752|DRUG|PI-0824|
219302312|NCT03422198|RADIATION|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
219302313|NCT03422198|RADIATION|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
219302314|NCT00350233|DEVICE|ExAblate 2000|
219302315|NCT04635475|BEHAVIORAL|RISE Bundle|Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
219302316|NCT00466375|GENETIC|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
219302317|NCT00466375|GENETIC|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
219302318|NCT04227704|DRUG|Ketamine 50 MG/ML|Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
219302319|NCT04227704|DRUG|Control|Administration of 0.9% Sodium Chloride (N/S)
219302320|NCT03599609|DRUG|Simvastatin 40mg|Simvastatin 40mg, once daily
219302321|NCT04092361|DEVICE|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
219302322|NCT01771640|BIOLOGICAL|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
219302323|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the morning|The patients in this group underwent impacted tooth surgery at 08:30 in the morning.
219302324|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the afternoon|Impacted tooth surgery was performed on the patients in this group at 15:30.
219302325|NCT00112047|DRUG|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
219302326|NCT00112047|DRUG|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
219302327|NCT00112047|DRUG|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
219302328|NCT00112047|DRUG|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
219302329|NCT00112047|DRUG|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
219302330|NCT00112047|DRUG|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
219302331|NCT01307579|DRUG|Caspofungin Acetate|Given IV
219302332|NCT01307579|DRUG|Fluconazole|Given IV or PO
219302333|NCT01307579|OTHER|Laboratory Biomarker Analysis|Correlative studies
219302334|NCT03612583|PROCEDURE|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
219302335|NCT03103451|DRUG|BCD-121|
219302336|NCT03103451|OTHER|Placebo|
219302337|NCT06907745|PROCEDURE|Bimaxillary Osteotomy|Maxillary LeFort I osteotomy and mandible osteotomy (BSSO) without intermediate splint.
219302338|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
219302339|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
219302340|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
219302341|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
219302342|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
219302343|NCT01277367|BEHAVIORAL|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
219302344|NCT01277367|BEHAVIORAL|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
219302345|NCT01277367|BEHAVIORAL|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
219302346|NCT01277367|BEHAVIORAL|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
219302347|NCT01277367|BEHAVIORAL|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
219302348|NCT01277367|BEHAVIORAL|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
219302349|NCT04310891|RADIATION|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
219302350|NCT02049164|DRUG|AR08|
219302351|NCT02049164|DRUG|Placebo|
219302352|NCT04595383|DEVICE|ti.care|Electronic platform for doctor-patient communication
219302353|NCT04121494|BIOLOGICAL|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
219302354|NCT04121494|BIOLOGICAL|ChadOx1 85A - IM|Intramuscular administration
219302355|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
219302356|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
219302357|NCT00153062|DRUG|Clopidogrel placebo|placebo
219302358|NCT00153062|DRUG|Clopidogrel placebo|placebo
219302359|NCT00153062|DRUG|Micardis|80 mg micardis
219302360|NCT00153062|DRUG|Micardis|80 mg micardis
219302361|NCT00153062|DRUG|Aggrenox placebo|placebo
219302362|NCT00153062|DRUG|Aggrenox placebo|placebo
219302363|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
219302364|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
219302365|NCT00153062|DRUG|Micardis placebo|placebo
219302366|NCT00153062|DRUG|Micardis placebo|placebo
219302367|NCT00679393|PROCEDURE|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
219302368|NCT00679393|PROCEDURE|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
219302369|NCT06063785|DIAGNOSTIC_TEST|Acoustic Radiation Forced Impulse Imaging|Measurement of Liver stiffness
219302370|NCT06063785|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|Measurement of optoacoustic spectra in liver and gastrointestinal tract
219302371|NCT05596838|PROCEDURE|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
219302372|NCT02396043|DRUG|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
219302373|NCT02396043|DRUG|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
219302374|NCT02396043|DRUG|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
219302375|NCT02396043|DRUG|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
219302376|NCT02396043|DRUG|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
219302377|NCT02396043|DRUG|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
219302378|NCT02396043|DRUG|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
219302379|NCT04461483|DRUG|TAK-935|TAK-935 Tablets
219302380|NCT04461483|DRUG|Placebo|TAK-935 placebo-matching tablets
219302381|NCT04690842|DIAGNOSTIC_TEST|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
219302382|NCT01095107|DIETARY_SUPPLEMENT|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
219302383|NCT01095107|DIETARY_SUPPLEMENT|Increased fat intake|increased fat intake : Intake \> 50 grams of fat per day between meals and snacks
219302384|NCT00275262|DRUG|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
219302385|NCT00275262|DRUG|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
219302386|NCT00690040|DEVICE|Foley catheter|Single balloon catheter
219302387|NCT00690040|DEVICE|Atad catheter|Double balloon catheter
219302388|NCT04721028|DEVICE|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
219302389|NCT02110147|DRUG|uridine triacetate|
219302390|NCT05186194|DRUG|Vitamin D, Calcium|Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
219302391|NCT05186194|DRUG|Placebo|Placebo
219744516|NCT04103814|DRUG|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
219744517|NCT04103814|DRUG|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
219744518|NCT06293287|DRUG|Subcutaneous enoxaparin sodium|Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
219744519|NCT06293287|DRUG|Placebo|placebo (0.9% saline solution)
219744520|NCT01384045|OTHER|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
219302392|NCT02429674|BEHAVIORAL|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
219302393|NCT03059225|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
219302394|NCT03059225|DEVICE|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
219302395|NCT02035592|OTHER|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
219302396|NCT02035592|OTHER|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
219302397|NCT02035592|OTHER|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
219302398|NCT01747525|DEVICE|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
219302399|NCT02390830|OTHER|Falls Prevention|
219302400|NCT02390830|OTHER|Reduction of limitations at body function and activity levels|
219302401|NCT00831285|DIETARY_SUPPLEMENT|food product|food product given at one of six visits
219302402|NCT04483076|DRUG|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.
219302403|NCT04483076|PROCEDURE|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
219302404|NCT04483076|PROCEDURE|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
219302405|NCT02707731|PROCEDURE|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
219302406|NCT02340767|DEVICE|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
219302407|NCT02340767|DEVICE|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
219302408|NCT01589237|DRUG|LCQ908|
219302409|NCT04448509|OTHER|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
219302410|NCT03437343|PROCEDURE|Hip arthroplasty|
219302411|NCT02594163|DRUG|Brentuximab Vedotin|
219744521|NCT02315976|DRUG|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
219744522|NCT02395328|BEHAVIORAL|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
219302412|NCT02594163|DRUG|Rituximab|
219302413|NCT02594163|DRUG|Bendamustine|
219302414|NCT03732313|PROCEDURE|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
219302415|NCT03732313|PROCEDURE|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
219302416|NCT02794168|DRUG|VAS203|Treatment
219302417|NCT02794168|DRUG|Saline|Placebo
219302418|NCT00448409|BIOLOGICAL|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
219302419|NCT00448409|DRUG|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
219302420|NCT04497142|DRUG|Perampanel|Tablet taken orally 1x daily.
219302421|NCT04497142|DRUG|Standard of Care|Predetermined standard of care drug and dosing
219302422|NCT00221182|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
219302423|NCT00289432|BEHAVIORAL|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
219302424|NCT00289432|OTHER|Support group|Standard Hospital follow-up support group
219302425|NCT02576301|DRUG|Phase 1 - OXi4503|Determination of MTD of OXi4503
219302426|NCT02576301|DRUG|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
219302427|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
219302428|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
219302429|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
219302430|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
219302431|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
219302432|NCT00691405|DRUG|Placebo|Placebo inhalation solution BID
219302433|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
219302434|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
219302435|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
219302436|NCT00691405|DRUG|Placebo|Placebo inhalation solution QD
219302437|NCT00238524|DRUG|SPM 927|
219302438|NCT01703650|DRUG|iopromide|"1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤."
219302439|NCT01703650|PROCEDURE|CT|"1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
219302440|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
219302441|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
219302442|NCT03715582|DRUG|trimetazidine|Pills of masking drug - trimetazidine
219302443|NCT03715582|DRUG|Placebo Oral Tablet|Pills of masking drug - placebo
219302444|NCT02844725|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
219302445|NCT02844725|DRUG|Placebo|water for injection
219302446|NCT01290029|DRUG|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
219302447|NCT05555407|DIAGNOSTIC_TEST|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
219302448|NCT05555407|DEVICE|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
219302449|NCT02745262|OTHER|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
219302450|NCT04364243|OTHER|Digitally supported home exercises|The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
219302451|NCT04025346|OTHER|Capsimax|1 capsule to be taken before breakfast.
219302452|NCT04025346|OTHER|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
219302453|NCT03849950|OTHER|SMARTCare|"1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~2. An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~3. An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~4. Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
219302454|NCT03849950|OTHER|Control|1\. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
219302455|NCT04271631|OTHER|Mobile Application-Based Diabetes Education|Additional education was given using application, subjects were asked to open the application at least once a day
219302456|NCT04271631|OTHER|Health Coaching|Health coaching was given as face to face with a coach
219302457|NCT00189488|DRUG|Palifermin|Administered as an intravenous (IV) bolus.
219302458|NCT00189488|DRUG|Placebo|Administered as an intravenous (IV) bolus.
219302459|NCT00189488|OTHER|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])"
219302460|NCT00189488|PROCEDURE|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
219302461|NCT00189488|DRUG|Methotrexate|
219302462|NCT02176213|DRUG|Pomalidomide|4 mg PO x 21 days
219302463|NCT02176213|DRUG|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
219302464|NCT02176213|DRUG|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
219302465|NCT05223777|DEVICE|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
219302466|NCT05223777|DEVICE|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
219302467|NCT02145234|DRUG|BMS-986089|
219302468|NCT02145234|DRUG|Placebo matching with BMS-986089|
219302469|NCT05696431|OTHER|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
219302470|NCT05696431|OTHER|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
219302471|NCT05696431|OTHER|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
219302472|NCT04758689|COMBINATION_PRODUCT|Laser, exercise, and methotrexate|Laser therapy at acupuncture points, aerobic exercise, and methotrexate
219302473|NCT04758689|COMBINATION_PRODUCT|Exercise, and methotrexate|Aerobic exercise, and methotrexate
219302474|NCT04326517|PROCEDURE|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
219302475|NCT00987454|DRUG|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
219302476|NCT00987454|DRUG|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
219302477|NCT04330131|BEHAVIORAL|3Ts - Newborn|A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
219302478|NCT04330131|BEHAVIORAL|3Ts - Well Baby|Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
219302479|NCT04330131|BEHAVIORAL|3Ts - Let's Talk!|A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
219302480|NCT04200976|BEHAVIORAL|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
219302481|NCT04200976|BEHAVIORAL|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
219302482|NCT00316160|DRUG|Bupropion Hydrochloride Extended-release|
219302483|NCT00316160|DRUG|Extended-release Venlafaxine|
219302484|NCT02824666|DRUG|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
219302485|NCT02824666|RADIATION|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
219302486|NCT02726685|OTHER|respiratory training.|breathing exercise.
219302487|NCT02726685|OTHER|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
219302488|NCT05369273|OTHER|intra-articular injection|intra-articular injection
219302489|NCT05369273|RADIATION|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
219302490|NCT05369273|OTHER|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
219302491|NCT05369273|OTHER|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
219302492|NCT00002521|DRUG|cisplatin|
219302493|NCT00002521|DRUG|cyclophosphamide|
219302494|NCT00002521|DRUG|etoposide|
219302495|NCT00002521|PROCEDURE|autologous bone marrow transplantation|
219302496|NCT00002521|PROCEDURE|bone marrow ablation with stem cell support|
219302497|NCT00002521|PROCEDURE|peripheral blood stem cell transplantation|
219302498|NCT00002521|PROCEDURE|syngeneic bone marrow transplantation|
219302499|NCT00002521|RADIATION|radiation therapy|
219302500|NCT01893931|BEHAVIORAL|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
219302501|NCT01893931|BEHAVIORAL|Placebo Comparator|
219302502|NCT03237637|DRUG|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
219302503|NCT03237637|DRUG|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
219302504|NCT05969743|DRUG|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
219302505|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
219302506|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
219302507|NCT00258063|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
219302508|NCT00306696|DRUG|Rosiglitazone|
219302509|NCT00306696|DRUG|spironolactone|
219302510|NCT00306696|DRUG|hydrochlorothiazide|
219302511|NCT00306696|DRUG|frusemide|
219302512|NCT03010930|OTHER|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
219302513|NCT03010930|OTHER|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
219302514|NCT02204176|OTHER|Exercise info|"Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries"
219302515|NCT02204176|OTHER|Implementation intentions|"Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans"
219302516|NCT02204176|OTHER|Industriousness|"Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise"
219302517|NCT02204176|DEVICE|pedometer|
219302518|NCT03969550|OTHER|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
219302519|NCT02445950|BEHAVIORAL|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
219302520|NCT02445950|BEHAVIORAL|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
219302521|NCT02466438|DRUG|Piperacillin-tazobactam|"* Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician"
219744523|NCT03647137|OTHER|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
219744524|NCT01176500|DRUG|(18)Fluciclatide|
219744525|NCT03116022|DRUG|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
219744526|NCT03116022|DRUG|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
219744527|NCT03116022|DRUG|Vaginal Gel|Women using a base water gel lubricant during intercourse
219744528|NCT01881932|DEVICE|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
219744529|NCT01881932|DEVICE|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
219744530|NCT01248819|DRUG|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
219302522|NCT05031169|PROCEDURE|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
219302523|NCT01001923|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
219302524|NCT01001923|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
219302525|NCT05419362|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
219302526|NCT05419362|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
219302527|NCT00093171|DRUG|rFIX|
219302528|NCT01095263|DEVICE|DBS|130Hz, 90us pulsewidth, 4V Amplitude
219302529|NCT01095263|DEVICE|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
219302530|NCT06347653|DRUG|linperlisib combined with CHOP regimen|"Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles."
219302531|NCT02090959|DRUG|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
219302532|NCT02503878|DEVICE|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
219302533|NCT02536391|DRUG|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
219302534|NCT02536391|DRUG|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
219302535|NCT02349646|DEVICE|Implantation with the commercially available Axium neurostimulator|
219302536|NCT02970474|DEVICE|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
219302537|NCT02970474|DEVICE|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
219302538|NCT02072161|DRUG|ETC-1002|ETC-1002 capsules, taken once daily oral
219302539|NCT02072161|DRUG|Placebo|Placebo capsules, taken once daily oral
219302540|NCT02072161|DRUG|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
219302541|NCT03237039|RADIATION|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
219302542|NCT03237039|OTHER|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
219302543|NCT03237039|OTHER|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
219302544|NCT00599885|DRUG|telmisartan|telmisartan 40-80mg once per day for 8 months
219302545|NCT00599885|DRUG|valsartan|valsartan 80-160mg once per day for 8 months
219302546|NCT05310149|DEVICE|Prosthetic intervention with maxillary obturator prosthesis|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
219302547|NCT01148914|OTHER|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
219302548|NCT00406523|DEVICE|JANUS Stent|
219302549|NCT01122251|DRUG|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
219302550|NCT01122251|DRUG|Lercanidipine or Valsartan|L10, L20, V80, V160
219302551|NCT01122251|DRUG|Placebo|Placebo of Lercanidipine and Valsartan
219302552|NCT04520360|DRUG|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
219302553|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
219302554|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
219302555|NCT05973695|OTHER|clamshell exercise|For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
219302556|NCT05973695|OTHER|Gluteal Bridge exercises|Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
219302557|NCT05217498|DRUG|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
219302558|NCT05217498|DEVICE|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
219302559|NCT00539565|DRUG|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
219302560|NCT00539565|DRUG|placebo|
219302561|NCT05811923|OTHER|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
219302562|NCT05811923|OTHER|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
219302563|NCT05811923|OTHER|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
219302564|NCT05811923|OTHER|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
219302565|NCT02661087|PROCEDURE|Hysteroscopic resection with bipolar energy|Hysteroscopic resection with bipolar energy
219302566|NCT02661087|PROCEDURE|Hysteroscopic resection with monopolar energy|Hysteroscopic resection with monopolar energy
219302567|NCT00276029|DRUG|Etanercept|
219302568|NCT04037618|DRUG|[14C]-EYP001a|Oral drinking suspension
219302569|NCT02791425|DEVICE|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
219302570|NCT02791425|OTHER|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
219302571|NCT01683929|OTHER|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
219302572|NCT01683929|OTHER|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
219302573|NCT04020705|DEVICE|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
219302574|NCT04020705|OTHER|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
219302575|NCT01248065|DRUG|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
219302576|NCT01248065|DRUG|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
219302577|NCT00893984|DRUG|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
219302578|NCT01820013|DEVICE|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
219302579|NCT01820013|DEVICE|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
219302580|NCT01762501|DRUG|Azilsartan|Azilsartan 20mg/day
219302581|NCT01762501|DRUG|Amlodipine|Amlodipine 5mg/day
219302582|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
219302583|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
219302584|NCT04903587|DEVICE|Ultrasonography and MRI|Abdominal Ultrasonography and axial MRI
219302585|NCT03010176|DRUG|Ulevostinag|IT injection
219302586|NCT03010176|BIOLOGICAL|Pembrolizumab|IV infusion
219302587|NCT01176279|PROCEDURE|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
219302588|NCT01176279|PROCEDURE|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
219302589|NCT04256629|DRUG|Verinurad|Randomized subjects will receive oral dose of verinurad
219302590|NCT04256629|DRUG|Placebo|Randomized subjects will receive oral dose of placebo
219302591|NCT04256629|DRUG|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
219302592|NCT01404195|DIETARY_SUPPLEMENT|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
219302593|NCT02738944|BEHAVIORAL|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
219302594|NCT02738944|BEHAVIORAL|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
219302595|NCT00140192|DRUG|creatine|
219302596|NCT00536783|DRUG|Quetiapine|
219302597|NCT06098456|DRUG|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
219302598|NCT05600296|DRUG|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
219302599|NCT05600296|PROCEDURE|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
219302600|NCT05600296|PROCEDURE|IINB+ Spermatic cord block|IINB+ Spermatic cord block
219302601|NCT01774487|DRUG|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
219302602|NCT05690113|PROCEDURE|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
219744531|NCT01248819|DRUG|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
219744532|NCT01443026|DRUG|Lycopene 30mg|Lycopene 30 mg.
219744533|NCT01443026|DRUG|Placebo|Placebo
219302603|NCT04695743|OTHER|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
219302604|NCT05220787|BIOLOGICAL|Cold stored platelets in 100% plasma stored for 10-14 days|Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery
219302605|NCT05220787|BIOLOGICAL|Room temperature stored platelets in 100% plasma stored for up to 7 days|Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
219302606|NCT04686201|DEVICE|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
219302607|NCT05202639|OTHER|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
219302608|NCT00461032|DRUG|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
219302609|NCT00461032|DRUG|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
219302610|NCT04447846|DRUG|Cannabidiol|Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
219302611|NCT00074971|DRUG|Fabrazyme (agalsidase beta)|
219302612|NCT00767975|DRUG|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
219302613|NCT00767975|DRUG|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
219302614|NCT03212300|BEHAVIORAL|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
219302615|NCT05657015|DRUG|Lepidium Sativum|2 ml of LS in situ gel at baseline
219302616|NCT05657015|DRUG|Simvastatin|1.2% of SMV in situ gel at baseline
219302617|NCT00283218|DRUG|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
219302618|NCT02619487|OTHER|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
219302619|NCT02619487|OTHER|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
219302620|NCT04059419|BEHAVIORAL|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
219302621|NCT04059419|BEHAVIORAL|Geriatric Care|Remain under geriatric care as usual
219302622|NCT05248074|OTHER|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
219302623|NCT05248074|DRUG|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
219302624|NCT03619070|OTHER|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
219302625|NCT03619070|OTHER|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
219302626|NCT03619070|OTHER|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
219302627|NCT03619070|OTHER|Control group, CG|The CG groups do not will performed the exercise.
219302628|NCT01878214|BEHAVIORAL|Targeted messaging|6 targeted mailed messages and 6 booster text messages
219302629|NCT01878214|BEHAVIORAL|Standard messaging|1 informational letter
219302630|NCT03568331|DRUG|Tradipitant|Oral Capsule
219302631|NCT03568331|DRUG|Placebo|Oral Capsule
219302632|NCT00946101|BIOLOGICAL|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
219302633|NCT00946101|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
219302634|NCT04224571|DRUG|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
219302635|NCT04224571|DRUG|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
219302636|NCT01553305|OTHER|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
219302637|NCT01553305|OTHER|Exercise programme|Supervised exercise programme
219302638|NCT04513184|DRUG|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
219302639|NCT04513184|DRUG|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
219302640|NCT02647866|DRUG|KHK4083|IV Infusion
219302641|NCT02647866|DRUG|Placebo|IV Infusion
219302642|NCT01562509|OTHER|Implementation tools|"* Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings."
219302643|NCT01562509|OTHER|Standard intervention|Standard intervention consists of audit\&feedback
219302644|NCT02052089|PROCEDURE|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
219302645|NCT02052089|PROCEDURE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (\<0.2 mJ/mm2) or high energy (\>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
219302646|NCT02052089|PROCEDURE|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
219302647|NCT02052089|PROCEDURE|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
219302648|NCT04687449|DIETARY_SUPPLEMENT|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
219302649|NCT04687449|OTHER|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
219302650|NCT04687449|OTHER|Standard care|The standard of care for COPD.
219302651|NCT01966393|OTHER|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
219302652|NCT00850785|BIOLOGICAL|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
219302653|NCT01928251|BEHAVIORAL|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
219302654|NCT01928251|BEHAVIORAL|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
219302655|NCT04994353|DIETARY_SUPPLEMENT|No supplementation|1st Week: No supplementation
219302656|NCT04994353|DIETARY_SUPPLEMENT|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
219302657|NCT04994353|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
219302658|NCT04994353|DIETARY_SUPPLEMENT|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
219302659|NCT04994353|DIETARY_SUPPLEMENT|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
219302660|NCT04994353|DIETARY_SUPPLEMENT|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
219302661|NCT01331486|DIETARY_SUPPLEMENT|Hawthorn|Hawthorn standardized extract liquid capsule
219302662|NCT01331486|DIETARY_SUPPLEMENT|Placebo capsule|Matched placebo liquid capsule
219302663|NCT04242953|DRUG|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
219302664|NCT04242953|DRUG|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
219302665|NCT01944371|DRUG|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
219302666|NCT00069108|DRUG|5 FU|As prescribed, in 2 week cycles
219302667|NCT00069108|DRUG|Leucovorin|As prescribed, in 2 week cycles
219302668|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 3 week cycles
219302669|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 2 week cycles
219302670|NCT00069108|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
219302671|NCT02611791|DEVICE|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
219302672|NCT02611791|DEVICE|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
219302673|NCT05026333|OTHER|Cognitive Stress Testing|Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
219302674|NCT04413773|OTHER|Treatment as usual + Video|Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
219302675|NCT04413773|OTHER|Treatment as usual|Explanation of standard procedures before, during and after surgery by nurse
219744534|NCT04569825|DRUG|Ophtamesone|local application intranasally as drops
219744535|NCT00581919|DRUG|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
219744536|NCT00738660|DRUG|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
219744537|NCT06569745|OTHER|Verbal Explanation|In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
219744538|NCT06569745|OTHER|Animation Video Display|"In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content."
219744539|NCT06569745|OTHER|Peer-Led Reels Video Display|In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
219744540|NCT05651490|BEHAVIORAL|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
219744541|NCT05651490|BEHAVIORAL|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
219302676|NCT05318547|OTHER|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
219302677|NCT05318547|OTHER|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
219302678|NCT03486847|PROCEDURE|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
219302679|NCT03486847|PROCEDURE|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
219302680|NCT01468467|DRUG|AC220|Oral Liquid
219302681|NCT02826915|DEVICE|Near Infra Red Spectroscopy (NIRS)|
219302682|NCT02826915|DEVICE|Electroencephalogram (EEG)|
219302683|NCT02652871|DRUG|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
219302684|NCT02652871|DRUG|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
219302685|NCT02652871|DRUG|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
219302686|NCT05784220|BEHAVIORAL|DPP Curriculum for Lifestyle Intervention|See arms.
219302687|NCT01245985|RADIATION|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
219302688|NCT05485467|DIAGNOSTIC_TEST|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
219302689|NCT01246739|PROCEDURE|Adrenalectomy|Adrenalectomy (open or laparoscopic)
219302690|NCT04912271|DRUG|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
219302691|NCT04912271|DRUG|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
219302692|NCT04912271|DRUG|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
219302693|NCT04912271|DRUG|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
219302694|NCT04912271|DRUG|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
219302695|NCT01415531|DRUG|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
219302696|NCT01415531|DRUG|Placebo|Dose-match placebo
219302697|NCT04262973|OTHER|education|six-hour dementia care course
219302698|NCT04262973|OTHER|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
219302699|NCT02796157|DEVICE|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
219302700|NCT02796157|DEVICE|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
219302701|NCT05976893|DRUG|Evolocumab|Evolocuma:420 mg every 4 weeks
219302702|NCT05976893|DRUG|Statin|The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
219302703|NCT01927029|DRUG|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
219302704|NCT01927029|DRUG|Placebo|
219302705|NCT04226885|DRUG|fentanyl|nebulized fentanyl 2μg/kg body weigh
219302706|NCT04226885|DRUG|midazolam|nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
219302707|NCT04226885|DRUG|dexmedetomidine|nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
219302708|NCT04001231|DRUG|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
219302709|NCT00662506|DRUG|Cediranib Maleate|Given PO
219302710|NCT00662506|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
219302711|NCT00662506|PROCEDURE|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
219302712|NCT00662506|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
219302713|NCT00662506|RADIATION|Fludeoxyglucose F-18|Undergo 18 FDG PET
219302714|NCT00662506|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219302715|NCT00662506|OTHER|Laboratory Biomarker Analysis|Correlative studies
219302716|NCT00662506|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo PWI
219302717|NCT00662506|PROCEDURE|Positron Emission Tomography|Undergo 18 F FDG-PET
219302718|NCT00662506|DRUG|Temozolomide|Given PO
219302719|NCT05069103|DEVICE|Intervention|"Similar to the original TWIST trial , patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s)."
219302720|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
219302721|NCT01236339|PROCEDURE|LVP|Large Volume Paracentesis
219302722|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
219302723|NCT02042222|DRUG|Hydroxyurea|
219302724|NCT01810120|BIOLOGICAL|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
219302725|NCT02054741|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
219302726|NCT02054741|OTHER|Quality-of-Life Assessment|Ancillary studies
219302727|NCT02054741|OTHER|Survey Administration|Ancillary studies
219302728|NCT00159276|PROCEDURE|Induced Sputum|
219302729|NCT00601094|BIOLOGICAL|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
219302730|NCT04196101|DRUG|EDP-938|Four tablets daily for 5 days
219302731|NCT04196101|DRUG|Placebo|Four tablets daily for 5 days
219302732|NCT00394082|DRUG|ABI-007|125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
219302733|NCT00394082|DRUG|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
219302734|NCT00369720|PROCEDURE|Titration of oxygen in delivery room|
219302735|NCT03293641|DIETARY_SUPPLEMENT|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
219302736|NCT03293641|DRUG|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
219302737|NCT00292721|DRUG|Celecoxib|celecoxib: loading and maintenance for 6 months
219302738|NCT03742921|DRUG|Istodax|Istodax
219302739|NCT05068245|BEHAVIORAL|Preselected classical music|Preselected classical music
219302740|NCT03377309|DRUG|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
219302741|NCT03430531|DRUG|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
219302742|NCT00176397|PROCEDURE|Percutaneous coronary intervention (left main)|
219302743|NCT01139060|BEHAVIORAL|organized care program for chronic or recurrent depression|
219302744|NCT01932554|DRUG|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
219302745|NCT01932554|DRUG|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
219302746|NCT01932554|OTHER|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
219302747|NCT01932554|DRUG|Ibuprofen|Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
219302748|NCT01932554|DRUG|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
219302749|NCT01932554|OTHER|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
219302750|NCT01932554|OTHER|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
219302751|NCT04384315|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
219302752|NCT04778423|OTHER|Avatar Therapy|In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
219302753|NCT02344004|DRUG|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
219302754|NCT01994668|DRUG|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
219302755|NCT01994668|DRUG|Placebo|A single intravenous administration of 0.9% saline over 1 minute
219302756|NCT02665637|DRUG|Trastuzumab|Each patient may receive single dose by intravenous infusion
219302757|NCT00411346|PROCEDURE|Nurse-led telemonitoring|
219302758|NCT03482154|PROCEDURE|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
219302759|NCT04463017|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
219302760|NCT03226236|RADIATION|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
219302761|NCT03226236|BIOLOGICAL|Autologous DC vaccine|The first dose (7 to 14 x 10\_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
219302762|NCT03226236|DRUG|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
219302763|NCT00866853|DRUG|TMC435|
219302764|NCT01583231|OTHER|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
219302765|NCT02925026|DIETARY_SUPPLEMENT|Lactoferrin|
219302766|NCT02925026|DIETARY_SUPPLEMENT|Lysozyme|
219302767|NCT02925026|DIETARY_SUPPLEMENT|Placebo|
219302768|NCT04942730|DRUG|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
219302769|NCT04942730|DRUG|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
219302770|NCT04942730|DRUG|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
219302771|NCT04942730|DRUG|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
219302772|NCT04942730|DRUG|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
219302773|NCT04942730|DRUG|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
219302774|NCT00010985|PROCEDURE|Acupuncture|
219302775|NCT00010985|PROCEDURE|Chiropractic|
219302776|NCT00010985|PROCEDURE|massage|
219302777|NCT04253574|DIAGNOSTIC_TEST|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
219302778|NCT02493543|OTHER|Blood collection|Blood collection from the subject's arm
219302779|NCT02777385|DRUG|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
219302780|NCT02777385|DRUG|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
219302781|NCT02777385|RADIATION|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
219302782|NCT03690648|OTHER|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
219302783|NCT03690648|GENETIC|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
219302784|NCT03690648|GENETIC|Blood collection|Collection of 20 ml of blood with kit of blood collection
219302785|NCT04651517|DEVICE|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
219302786|NCT03174912|PROCEDURE|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
219302787|NCT06164067|OTHER|abortus within 24 hours or 24-48 hours|second trimester medical termination
219302788|NCT00279786|PROCEDURE|Blood draw|blood drawn
219302789|NCT05508620|DRUG|Sirolimus for Injection (Albumin-bound)|Intravenous infusion
219302790|NCT02295657|DEVICE|standard double-lumen tube|intubation using standard double-lumen tube
219302791|NCT02295657|DEVICE|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
219302792|NCT06001931|OTHER|handgrip force and bioimpedance values in healthy Turkish children.|Demographic characteristics, calf circumference , Hand grip strength , TANITA BIA analysis
219302793|NCT00250926|DRUG|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
219302794|NCT00250926|DRUG|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
219302795|NCT00250926|DRUG|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
219302796|NCT03495570|DIAGNOSTIC_TEST|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
219302797|NCT05864261|DRUG|JT1801 60ug|JT1801, 60ug, IV injection
219302798|NCT05864261|DRUG|NESP 60ug|NESP, 60ug, IV injection
219302799|NCT04101604|OTHER|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
219302800|NCT03333239|BEHAVIORAL|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)
219302801|NCT03333239|BEHAVIORAL|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)
219302802|NCT03333239|BEHAVIORAL|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
219302803|NCT04698941|DRUG|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.
219302804|NCT04698941|DRUG|Simvastatin|20mg daily oral tablet taken.
219302805|NCT00676819|DRUG|insulin aspart|
219302806|NCT00676819|DRUG|human insulin|
219302807|NCT05997888|BEHAVIORAL|At-Home Strength Training Intervention|A six-week strength training intervention in which participants will choose workouts to complete on their own. These workouts are 20-25 minutes light-intensity strength training with light strength bands. Exercises will have multiple options to account for various levels of ability. Additionally, there will be a group counseling session once per week via Zoom and a group strength training program.
219302808|NCT00002428|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
219302809|NCT00002428|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
219302810|NCT02354443|BIOLOGICAL|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
219302811|NCT02996565|OTHER|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~1. Improved recognition of uncontrolled BP at primary care encounters,~2. Therapeutic action to address uncontrolled BP at primary care encounters,~3. Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
219302812|NCT02996565|OTHER|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~1. Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~2. Systematic home BP telemonitoring with data transmitted into patient medical record~3. Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
219302813|NCT03463967|DIETARY_SUPPLEMENT|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
219302814|NCT03463967|OTHER|Energy-restricted diet|
219302815|NCT01208441|DRUG|letrozole|
219302816|NCT01208441|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
219302817|NCT01208441|PROCEDURE|therapeutic conventional surgery|
219302818|NCT01208441|PROCEDURE|breast biopsy|
219302819|NCT01208441|OTHER|diagnostic laboratory biomarker analysis|
219302820|NCT01208441|OTHER|pharmacological study|
219302821|NCT05312788|OTHER|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
219302822|NCT04246320|OTHER|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
219302823|NCT00606970|DIETARY_SUPPLEMENT|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
219302824|NCT00606970|DIETARY_SUPPLEMENT|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
219302825|NCT04551625|DEVICE|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
219302826|NCT03075007|RADIATION|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
219302827|NCT03075007|PROCEDURE|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
219302828|NCT00891345|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
219302829|NCT01517646|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
219302830|NCT00482950|DRUG|PHX1149T|
219302831|NCT06318767|PROCEDURE|hemodynamic measure of the Systolic Time Rise|The hemodynamic measure of the Systolic Time Rise will be added in the routine doppler echography, planned in preoperative, postoperative and at 6 months of following up. This measure is taken on the foot, with ultrasound probe.
219302832|NCT06081023|BEHAVIORAL|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
219302833|NCT06529510|BEHAVIORAL|REThink therpeutic game|REThink is an online therapeutic game aimed at enhancing the emotional health of young people, grounded in Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who guides players through seven levels, each focused on teaching a specific emotional regulation skill. Each level has three sub-levels that progressively increase in difficulty. REThink can be used as a standalone intervention, an adjunct to self-help psychotherapeutic approaches, or for targeted skills training.
219302834|NCT03913780|OTHER|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
219302835|NCT03142126|DEVICE|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
219302836|NCT03129139|DRUG|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
219302837|NCT04901260|DEVICE|AMAZE™ Disease Management Platform|The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
219302838|NCT04705129|DRUG|Zanubrutinib|160mg Bid, D1-21, po
219302839|NCT04705129|DRUG|Tislelizumab|200mg, D1, ivgtt
219302840|NCT02364843|DIETARY_SUPPLEMENT|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
219302841|NCT02731053|BEHAVIORAL|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
219302842|NCT04288999|DRUG|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
219302843|NCT04288999|RADIATION|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
219302844|NCT04288999|OTHER|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
219302845|NCT00336895|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
219302846|NCT06182943|OTHER|electroacupuncture combined with surrounding acupuncture|electroacupuncture combined with surrounding acupuncture
219302847|NCT06182943|OTHER|sham electroacupuncture|sham electroacupuncture
219302848|NCT06182943|OTHER|ice compress combined with brake rest|ice compress combined with brake rest
219302849|NCT04120636|DRUG|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
219302850|NCT02300441|OTHER|ECG, blood pressure and oximetry|
219302851|NCT02013960|DRUG|Cytotec|Cytotec medication compared with cytotec and laminaria
219302852|NCT04987736|DIAGNOSTIC_TEST|RT-PCR|COVID 19 diagonostic test
219302853|NCT03367390|DEVICE|AID System|AID system
219302854|NCT03367390|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
219302855|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
219302856|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219302857|NCT00598273|DRUG|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
219302858|NCT01332773|PROCEDURE|Artery first procedure|early identification of SMA to evaluate infiltration
219302859|NCT01332773|PROCEDURE|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
219302860|NCT04667832|DIAGNOSTIC_TEST|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
219302861|NCT01607632|BEHAVIORAL|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
219302862|NCT02097901|PROCEDURE|Microfracture|Rotator Cuff Repair AND Microfracture
219302863|NCT02097901|PROCEDURE|NO microfracture|Rotator Cuff Repair without microfracture
219302864|NCT03989518|BEHAVIORAL|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
219302865|NCT03989518|BEHAVIORAL|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
219302866|NCT03989518|BEHAVIORAL|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
219302867|NCT04540250|OTHER|questionnaire|conventional intra-oral examination and questionnaire
219302868|NCT00623402|DRUG|Sorafenib|2x 400 mg orally per day (4 tablets)
219302869|NCT00623402|DRUG|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
219302870|NCT06149910|OTHER|Multiple Myeloma Pathway|Use and adherence to a multiple myeloma pathway.
219302871|NCT06149910|OTHER|All4Cure Platform|Participant in the All4Cure platform.
219302872|NCT06149910|OTHER|Documentation Pathway|Use of multiple myeloma pathway through written documentation.
219302873|NCT00906945|DRUG|G-CSF|
219302874|NCT00906945|DRUG|Plerixafor|
219302875|NCT00906945|DRUG|Mitoxantrone|
219302876|NCT00906945|DRUG|Etoposide|
219302877|NCT00906945|DRUG|Cytarabine|
219302878|NCT01602107|OTHER|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
219302879|NCT02481947|DRUG|BLI400 Laxative|21 gm BLI400 powder
219302880|NCT02481947|DRUG|Lubiprostone|24 mcg capsule bid
219302881|NCT00647491|BIOLOGICAL|adalimumab|20 mg sc eow
219302882|NCT00647491|BIOLOGICAL|adalimumab|40 mg sc eow
219302883|NCT00647491|BIOLOGICAL|adalimumab|80 mg sc eow
219302884|NCT00647491|BIOLOGICAL|placebo|placebo sc eow
219302885|NCT03945682|OTHER|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
219302886|NCT03871023|DEVICE|Smith & Nephew PICO Negative wound pressure versus standard dresing|To investigate if negative wound pressure improves wound outcome
219302887|NCT03871023|DEVICE|PREVENA Negative pressure wound versus standard dressing|To investigate if negative wound pressure improves wound outcome
219302888|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
219302889|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
219302890|NCT03426605|DRUG|Open Label LAM-003|LAM-003
219302891|NCT02033161|BEHAVIORAL|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
219302892|NCT02865980|OTHER|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
219302893|NCT02865980|OTHER|Betadine|in control group, will be washed the Catheter with Betadine
219302894|NCT05332431|DEVICE|Optical coherence tomography (OCT)|"Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT."
219302895|NCT01258413|PROCEDURE|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
219302896|NCT01258413|PROCEDURE|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
219302897|NCT03816267|DEVICE|Nebulizer|Nebulization via mask
219302898|NCT03816267|DRUG|Salbutamol|Delivery of appropriate dose according to weight
219302899|NCT03816267|DEVICE|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
219302900|NCT05578144|OTHER|Patients Decision Aids (PDA)|Patient Decision Aids (PDA) administer to case group
219302901|NCT02754986|OTHER|Analysis of the holter electrocardiogram|
219302902|NCT02743156|PROCEDURE|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
219302903|NCT02743156|PROCEDURE|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
219302904|NCT02968082|DRUG|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
219302905|NCT02968082|DRUG|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
219302906|NCT00831337|DIETARY_SUPPLEMENT|VSL3|2 times daily 450 billion live bacteria (in each saschet)
219302907|NCT06409429|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
219302908|NCT06409429|DRUG|GX|Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.
219302909|NCT06409429|DRUG|Placebo|Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
219302910|NCT04085965|BEHAVIORAL|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
219302911|NCT06385431|OTHER|observational study|obeservational study with none intervention
219302912|NCT04555382|DIAGNOSTIC_TEST|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
219302913|NCT04803331|DIAGNOSTIC_TEST|SPIO-enhanced MRI|SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
219302914|NCT02628496|DRUG|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
219302915|NCT02628496|DEVICE|Confocal laser microlaryngoscopy|
219302916|NCT02628496|PROCEDURE|Biopsy (standard of care)|
219302917|NCT02628496|PROCEDURE|KTP laser photoablation (standard of care)|
219302918|NCT06255327|OTHER|I COUGH care program|"The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees."
219302919|NCT02822586|RADIATION|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
219302920|NCT02822586|DRUG|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
219302921|NCT06302517|DEVICE|BIS-guided|underwent intraoperative monitoring of BIS anesthesia depth
219302922|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
219302923|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
219302924|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
219302925|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
219302926|NCT02309255|OTHER|no intervention|
219302927|NCT03009760|DRUG|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
219302928|NCT03009760|DRUG|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
219302929|NCT03009760|DRUG|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
219302930|NCT03009760|DRUG|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
219302931|NCT00006260|DRUG|cisplatin|cisplatin IV over 30 minutes on days 1-3.
219302932|NCT00006260|DRUG|etoposide|etoposide IV over 60-90 minutes on days 1-3.
219302933|NCT00006260|DRUG|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
219302934|NCT00006260|DRUG|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
219302935|NCT01457989|DRUG|retigabine/ezogabine|dose range up to 1200 mg/day
219302936|NCT01474928|BEHAVIORAL|patient role played community video|Group two viewed the patient role played community video
219302937|NCT01474928|BEHAVIORAL|both videos group|Group three viewed both the knowledge and community videos
219302938|NCT01474928|BEHAVIORAL|Pamphlet group|Group four read an educational pamphlet only
219302939|NCT01474928|BEHAVIORAL|physician-led knowledge video|Group one viewed a physician-led knowledge video
219302940|NCT01474928|BEHAVIORAL|Community video group|Group two viewed the patient role played community video
219302941|NCT01474928|BEHAVIORAL|knowledge video|Group one viewed a physician-led knowledge video
219302942|NCT03426267|DRUG|SDN-037|twice daily
219302943|NCT03426267|DRUG|Placebo|twice daily
219302944|NCT02364791|DEVICE|standard techniques used to achieve air leak control|
219302945|NCT02364791|DEVICE|Hemopatch|
219302946|NCT04010825|OTHER|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
219302947|NCT04602416|BEHAVIORAL|Training sessions|
219302948|NCT01981772|DRUG|4% lidocaine with 1:100,000 epinephrine|see arm/group description
219302949|NCT01981772|DRUG|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
219302950|NCT01184261|BEHAVIORAL|behavioral intervention|8 session behavioral intervention.
219302951|NCT03587077|DRUG|Misoprostol|vaginal application
219302952|NCT03587077|DRUG|Placebos|vaginal application
219302953|NCT03587077|DRUG|isosorbide mononitrate|vaginal application
219302954|NCT00609765|DRUG|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
219302955|NCT00609765|DRUG|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
219302956|NCT00609765|DRUG|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
219302957|NCT00609765|DRUG|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
219302958|NCT00609765|DRUG|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
219302959|NCT00609765|DRUG|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
219302960|NCT03946150|DIAGNOSTIC_TEST|P/FP Ratio|PaO2/Fio2 X PEEP
219744542|NCT02655601|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
219744543|NCT02655601|RADIATION|Radiation Therapy|RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
219744544|NCT02655601|DRUG|Temozolomide|Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
219744545|NCT03523663|OTHER|no intervention. measure eye movement data|
219744546|NCT00916526|PROCEDURE|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
219744547|NCT01600651|OTHER|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
219744548|NCT01600651|OTHER|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
219744549|NCT02398799|BEHAVIORAL|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
219744550|NCT00778401|DRUG|Gabapentin tablets 800 mg|
219744551|NCT02209675|OTHER|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
219744552|NCT00200746|DRUG|Arginine|Amino Acid Arginine
219744553|NCT00802503|DIETARY_SUPPLEMENT|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
219744554|NCT01177358|DRUG|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
219744555|NCT01177358|DRUG|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
219744556|NCT05029388|OTHER|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
219744557|NCT05029388|OTHER|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
219302961|NCT03995693|DIETARY_SUPPLEMENT|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
219302962|NCT03995693|BEHAVIORAL|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
219302963|NCT03995693|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
219302964|NCT03995693|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
219302965|NCT03995693|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
219302966|NCT03995693|BEHAVIORAL|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
219302967|NCT03995693|DIAGNOSTIC_TEST|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
219302968|NCT03995693|DIAGNOSTIC_TEST|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
219302969|NCT03995693|DIAGNOSTIC_TEST|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
219744558|NCT05197374|DRUG|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
219744559|NCT01603368|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
219744560|NCT01603368|DIETARY_SUPPLEMENT|Placebo|Oil drops without Lactobacillus reuteri
219744561|NCT06152926|OTHER|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
219744562|NCT01873508|DRUG|RO4917523|Fast release MR capsule, single dose
219744563|NCT01873508|DRUG|RO4917523|Target release MR capsule, single dose
219744564|NCT01873508|DRUG|RO4917523|Slow release MR capsule, single dose
219744565|NCT01873508|DRUG|RO4917523|\[13C\]-labeled tracer dose i.v.
219744566|NCT05725434|BIOLOGICAL|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
219744567|NCT05725434|BIOLOGICAL|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
219744568|NCT03829683|DRUG|Vitamin C|200mg/kg/24hours
219744569|NCT03829683|DRUG|Dextrose 5% in water|50mL intravenously every 6 hours
219744570|NCT01251757|OTHER|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
219744571|NCT01251757|OTHER|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
219744572|NCT04546243|PROCEDURE|resection group|patients received VATS
219744573|NCT04546243|RADIATION|radiotherapy group|patients received radiotherapy
219744574|NCT04450212|GENETIC|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
219302970|NCT03995693|PROCEDURE|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
219302971|NCT02125747|OTHER|No Respiratory Therapy|Patients received conventional treatment.
219302972|NCT02125747|OTHER|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
219302973|NCT02526147|OTHER|Cash|
219302974|NCT02526147|OTHER|Voucher|
219302975|NCT02526147|OTHER|Food|
219302976|NCT03970070|OTHER|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
219302977|NCT03970070|OTHER|Quality-of-Life Assessment|Ancillary studies
219302978|NCT03970070|OTHER|Questionnaire Administration|Ancillary studies
219302979|NCT03970070|OTHER|Survey Administration|Ancillary studies
219302980|NCT01195051|OTHER|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
219302981|NCT05801744|BEHAVIORAL|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
219744575|NCT04450212|DIETARY_SUPPLEMENT|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
219744576|NCT03890107|DEVICE|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
219744577|NCT06019494|PROCEDURE|Oocyte retrieval with low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.
219744578|NCT06019494|PROCEDURE|Oocyte retrieval with high aspiration flow rate|High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
219744579|NCT04010838|PROCEDURE|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
219302982|NCT02439073|BEHAVIORAL|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
219302983|NCT02041234|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
219302984|NCT02041234|DRUG|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
219302985|NCT02041234|DRUG|Xenical|Xenical: Up to 120 mg tds
219302986|NCT02041234|DRUG|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
219302987|NCT02041234|DRUG|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
219302988|NCT00464009|BEHAVIORAL|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
219302989|NCT02622009|PROCEDURE|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
219302990|NCT03548246|DRUG|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
219302991|NCT03548246|DRUG|Placebo|Daily placebo for 2 years.
219302992|NCT03548246|DRUG|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
219302993|NCT03548246|DRUG|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
219302994|NCT04897906|BEHAVIORAL|Education Group|Mother care, newborn care and breastfeeding education will be provided to pregnant women in the third trimester of pregnancy.
219302995|NCT00577356|DRUG|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
219302996|NCT00577356|BIOLOGICAL|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
219302997|NCT02919904|DEVICE|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~* NREM and REM sleep frequency and duration~* Duration and number of arousal~* Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~* Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~* Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~* Apnea/hypopnea index and respiratory disturbance index"
219302998|NCT02094755|OTHER|Blood draw only|Blood draw only
219302999|NCT00882687|DRUG|Lifitegrast|Ophthalmic Solution
219303000|NCT00882687|OTHER|Placebo|Ophthalmic Solution
219303001|NCT06231446|OTHER|No intervention|This was an observational cohort study with no intervention for all enrolled patients.
219303002|NCT02690922|DRUG|Dasatinib|100mg (d1-d84)
219303003|NCT02690922|DRUG|prednisone|60mg/m2 d1-24
219303004|NCT02690922|DRUG|dexamethasone|10mg/d 3-7days
219303005|NCT02690922|DRUG|methotrexate|3g/m2 1day
219303006|NCT05405452|DEVICE|Vibration Anesthesia Device by Blaine Labs|Device which vibrates on top of skin
219303007|NCT05405452|DRUG|Gebauers Ethyl Chloride 100% Topical Spray|Sterile ethyl chloride spray
219303008|NCT01958307|BEHAVIORAL|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
219303009|NCT02290730|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
219303010|NCT03631160|DEVICE|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
219303011|NCT03631160|DEVICE|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
219303012|NCT04201782|DRUG|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
219303013|NCT05342025|OTHER|PNF|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. Breathing PNF patterns, pressure, and stretches will be applied inward and upwards into the rib cage so that they do not cause pain. Diaphragmatic stimulation will be performed on both sides with repeated contractions, hand contacts, and stabilization techniques. Facilitation techniques will be used to stimulate the intrinsic respiratory muscles. Again, with respect to inspiration, the patterns will be studied in neck extension, upper and lower trunk extension, and upper extremities flexion patterns. Neck flexion, upper and lower trunk flexion, and extension patterns of the upper extremities will be applied in relation to expiration. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases.
219303014|NCT05342025|OTHER|Breathing exercises|Breathing exercises: diaphragmatic breathing, thoracic expansion, pursed-lip breathing and respiratory control for 15 minutes a day, every day of the week.
219303015|NCT03186131|DRUG|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
219303016|NCT03186131|DRUG|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
219303017|NCT01708993|DRUG|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
219303018|NCT01708993|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
219303019|NCT01708993|DRUG|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
219303020|NCT01708993|DRUG|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
219303021|NCT02592408|DRUG|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
219303022|NCT02592408|DRUG|SDPQ|single dose primaquine on day 2
219303023|NCT02592408|DRUG|14DPQ|14 day primaquine starting on day 2
219303024|NCT02592408|DRUG|14DPQ on Day 42|14 day primaquine starting on day 42
219303025|NCT02418221|DIETARY_SUPPLEMENT|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
219303026|NCT02418221|PROCEDURE|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure \& pulse
219303027|NCT02550665|DRUG|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
219303028|NCT05169138|OTHER|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
219303029|NCT05169138|OTHER|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
219303030|NCT03594604|DRUG|Norethindrone|Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
219303031|NCT03594604|DRUG|oral contraceptive pill|Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
219303032|NCT01251731|DRUG|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
219303033|NCT01251731|DRUG|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
219303034|NCT01251731|DRUG|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
219303035|NCT01251731|DRUG|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
219303036|NCT03614910|DEVICE|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
219303037|NCT01063660|DRUG|Treosulfan|14 g/m²/d day -6 to -4
219303038|NCT00729872|BIOLOGICAL|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
219303039|NCT00729872|OTHER|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
219303040|NCT03687047|DEVICE|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
219303041|NCT04828200|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|The ultrasonographic assesment will be used to examine the rectus femoris, gastrocnemius medailalis and rectus abdominis subcutaneous and muscle thickness. Additionally, fascicle length and pennation angle were measured between the two parallel aponeuroses of the gastrocnemius muscle (bulkiest part of medial head) in the longitudinal view when subjects were in prone position with their ankles at 90°.
219303042|NCT04828200|DIAGNOSTIC_TEST|Dual-X-ray absorptiometry|The muscle masses of the patients were evaluated by measuring the fat mass (Fat Mass-FM), fat mass index (FMI), lean body mass (LBM) and skeletal muscle index (SMI) calculated by DEXA. Appendicular muscle mass (ASM) is calculated by summing the lean soft tissue of the two upper limbs and the two lower limbs. Skeletal muscle mass index is calculated by dividing the appendicular lean mass by the square of the neck height \[SMI = ASM / height2 (kg / m2)\].
219303043|NCT04828200|DIAGNOSTIC_TEST|Isokinetic dynamometer|Quadriceps-hamstring Peak Torque (PT) values and the ratio of PT values to body weight (PT / VA) (at 60 and 180 ° / sec speeds) were evaluated with an isokinetic dynamometer
219303044|NCT02649946|DEVICE|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
219303045|NCT02649946|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
219303046|NCT02783521|BEHAVIORAL|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
219303047|NCT02783521|BEHAVIORAL|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
219303048|NCT04097392|OTHER|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
219303049|NCT04097392|OTHER|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
219303050|NCT03862846|DRUG|REN001|Once daily
219303051|NCT02102477|PROCEDURE|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
219303052|NCT02102477|OTHER|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
219303053|NCT02639598|DRUG|Flunarizine|"as in arm descriptions"
219303054|NCT02639598|DRUG|Topiramate|"as in arm descriptions"
219303055|NCT01871701|DRUG|Escitalopram|Escitalopram
219303056|NCT01871701|DRUG|Quetiapine|Quetiapine
219303057|NCT01871701|DRUG|Moxifloxacin|Moxifloxacin
219303058|NCT01871701|OTHER|Placebo|Placebo
219303059|NCT00950950|DRUG|Romosozumab|Administered by subcutaneous injection
219303060|NCT00950950|DRUG|Placebo|Administered by subcutaneous injection
219303061|NCT04612374|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
219303062|NCT04612374|BEHAVIORAL|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
219303063|NCT00491829|DRUG|50 mg qhs|flibanserin 50 mg
219303064|NCT00491829|DRUG|100 mg|flibanserin 100mg
219303065|NCT00491829|DRUG|placebo|placebo
219303066|NCT00104663|DRUG|Quinacrine|
219303067|NCT01235104|PROCEDURE|Total nephrectomy|Total nephrectomy
219303068|NCT01809002|BIOLOGICAL|Processed Nerve Allograft (human)|
219303069|NCT01809002|DEVICE|Collagen Nerve Cuff|Bovine collagen based nerve cuff
219303070|NCT01047293|DRUG|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
219303071|NCT01047293|DRUG|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
219303072|NCT01047293|DRUG|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
219303073|NCT02957526|BEHAVIORAL|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
219303074|NCT02957526|BEHAVIORAL|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
219303075|NCT00784355|PROCEDURE|Laparoscopic cholecystectomy|Surgery
219303076|NCT04137094|BEHAVIORAL|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
219303077|NCT02192021|DRUG|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
219303078|NCT02375178|DRUG|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
219303079|NCT02375178|DRUG|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
219303080|NCT02375178|DRUG|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
219303081|NCT02528383|BEHAVIORAL|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life"
219303082|NCT02054520|DRUG|HyperAcute®-Melanoma (HAM) Immunotherapy|
219303083|NCT02054520|DRUG|Ipilimumab|
219303084|NCT02054520|DRUG|Pembrolizumab|
219303085|NCT02054520|DRUG|Nivolumab|
219303086|NCT04818333|DRUG|SHR-A1811|Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
219303087|NCT01272804|DRUG|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
219303088|NCT01272804|DRUG|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
219744580|NCT03419624|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
219744581|NCT03419624|DRUG|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
219744582|NCT03419624|DRUG|Placebo Oral Tablet|Placebo oral tablet once daily
219744583|NCT03419624|DRUG|Placebo injection|Placebo injection once weekly
219744584|NCT03419624|DRUG|Insulin|daily Insulin injections
219744585|NCT03419624|DRUG|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
219744586|NCT03191331|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
219303089|NCT05236478|OTHER|CoviMouv' program|"* An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
219303090|NCT05236478|OTHER|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
219303091|NCT02318797|BEHAVIORAL|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
219303092|NCT02318797|BEHAVIORAL|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
219303093|NCT03172182|BEHAVIORAL|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
219303094|NCT02589860|OTHER|Melphalan kinetic study|Concentration of Melphalan in plasma samples
219303095|NCT02589860|GENETIC|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
219303096|NCT02589860|GENETIC|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
219303097|NCT02348762|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
219303098|NCT05143983|BEHAVIORAL|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
219303099|NCT05143983|BEHAVIORAL|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
219303100|NCT02308020|DRUG|Abemaciclib|Administered orally
219303101|NCT02811185|DRUG|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
219303102|NCT02829788|OTHER|Non interventional|Peroperative data collection
219303103|NCT01127269|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
219303104|NCT01964885|DIETARY_SUPPLEMENT|IQP-AS-105|
219303105|NCT01964885|DIETARY_SUPPLEMENT|Placebo|
219303106|NCT01906554|OTHER|Egg Dose|Different quantities of eggs
219744587|NCT05395312|OTHER|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
219744588|NCT00260338|BIOLOGICAL|stem cell|mesenchymal stromal cell
219744589|NCT06570317|DRUG|Nintedanib|For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy
219744590|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
219744591|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
219744592|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers earned independent of cocaine use
219744593|NCT01743144|DRUG|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
219744594|NCT01743144|DRUG|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
219744595|NCT02709707|DEVICE|Blood glucose monitor|
219744596|NCT02121639|DRUG|Placebo|
219744597|NCT02121639|DRUG|AZD5363|
219303107|NCT02433574|RADIATION|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
219303108|NCT06103968|DEVICE|LMA BLOCKBUSTER|In this study we wish to evaluate weather gastric tube inserted through LMA helps in maintaining the LMA blockbuster placement by comparing fibreoptic bronchoscope (FOB) scores recorded immediately after LMA placement and at the end of the surgical procedure.
219303109|NCT02232243|DRUG|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
219303110|NCT02232243|DRUG|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
219303111|NCT01856556|DRUG|NRX-1074|Single IV or PO administration
219303112|NCT01856556|DRUG|Placebo|Single IV or PO placebo administration
219303113|NCT01975870|OTHER|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
219303114|NCT04689282|BIOLOGICAL|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
219303115|NCT04824495|DIAGNOSTIC_TEST|Blood sample|Blood samples at different timepoints during SARS-CoV2 infection
219303116|NCT04300075|DEVICE|CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
219303117|NCT01959477|DRUG|busulfan|Given IV
219303118|NCT01959477|DRUG|etoposide|Given IV
219303119|NCT01959477|DRUG|cyclophosphamide|Given IV
219303120|NCT01959477|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
219303121|NCT01959477|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
219303122|NCT00080678|DRUG|Docetaxel|
219303123|NCT00080678|DRUG|Imatinib Mesylate|
219303124|NCT06341660|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
219303125|NCT00704405|DRUG|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
219303126|NCT00704405|DRUG|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
219303127|NCT00704405|DRUG|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.
219303128|NCT00704405|DRUG|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
219303129|NCT01395888|DRUG|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
219303130|NCT01395888|DRUG|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
219303131|NCT02136082|BEHAVIORAL|Asha Support + Training|
219744598|NCT05102448|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
219744599|NCT05102448|DRUG|Methotrexate|"1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
219744600|NCT01257750|DRUG|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
219744601|NCT02510248|DRUG|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
219303132|NCT02136082|BEHAVIORAL|Asha Support + Food|
219744602|NCT02510248|DRUG|Placebo|Placebo to match AL-704
219303133|NCT02136082|BEHAVIORAL|Asha Support + Training + Food|
219303134|NCT02136082|BEHAVIORAL|Asha Support Only|
219303135|NCT03438500|DEVICE|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
219303136|NCT03218397|DEVICE|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
219303137|NCT03218397|DEVICE|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
219303138|NCT06460753|DIAGNOSTIC_TEST|CT of the chest organs, blood biochemical parameters|Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.
219303139|NCT01027832|DRUG|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
219303140|NCT05769569|BIOLOGICAL|VRC07-523LS|VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
219303141|NCT05769569|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
219303142|NCT05769569|BIOLOGICAL|N-803|N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
219303143|NCT05769569|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
219303144|NCT05769569|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
219303145|NCT05769569|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
219303146|NCT05769569|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
219303147|NCT05769569|COMBINATION_PRODUCT|Antiretroviral Therapy (ART)|This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
219303148|NCT02965677|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
219303149|NCT02965677|DEVICE|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
219303150|NCT00465387|BEHAVIORAL|Falls, Fractures & Osteoporosis Risk Assessment & Management|
219303151|NCT03698812|COMBINATION_PRODUCT|Colonoscope|take off specimen
219303152|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
219303153|NCT01946438|BIOLOGICAL|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
219303154|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
219303155|NCT01946438|BIOLOGICAL|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
219303156|NCT05790330|DRUG|Methotrexate|As per usual standard of care
219303157|NCT05790330|DRUG|Dupilumab|As per usual standard of care
219303158|NCT04289012|DIAGNOSTIC_TEST|Helicobacter Pylori screening by UBT|The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
219303159|NCT03256981|RADIATION|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
219303160|NCT03256981|DRUG|TKI|Continued background TKI alone
219303161|NCT04625179|OTHER|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
219303162|NCT04625179|PROCEDURE|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
219303163|NCT00353249|BEHAVIORAL|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
219303164|NCT00567034|DRUG|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
219303165|NCT00567034|DRUG|placebo|lactose placebo, 1 capsule every day for 12 weeks
219303166|NCT00531700|OTHER|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
219303167|NCT00531700|OTHER|Health messages|community level health messages unrelated to the study originating exposures
219303168|NCT03450226|DRUG|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
219303169|NCT03801473|OTHER|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
219303170|NCT03801473|OTHER|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
219303171|NCT04328454|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
219303172|NCT04377750|DRUG|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
219303173|NCT02743026|BEHAVIORAL|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
219303174|NCT05357118|BEHAVIORAL|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
219303175|NCT05334251|OTHER|combined spinal-epidural anesthesia|Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
219303176|NCT02097940|OTHER|proprioceptive exercises|Exercises with movements, jumping and imbalance.
219303177|NCT05614986|OTHER|5 minute Montreal Cognitive Assessment (mini MoCA)|The mini MoCA will be completed by the patient before TAVR, and 30 days and 6 months after TAVR
219303178|NCT02760277|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
219303179|NCT02760277|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
219303180|NCT02760277|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
219303181|NCT02760277|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
219303182|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|"The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
219303183|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle|"The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
219303184|NCT02892084|DEVICE|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
219303185|NCT02892084|DEVICE|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
219303186|NCT01300962|DRUG|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
219303187|NCT01300962|DRUG|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
219303188|NCT01300962|DRUG|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
219303189|NCT01300962|DRUG|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
219303190|NCT01300962|DRUG|Lapatinib|lapatinib daily for 21 days in each cycle.
219303191|NCT01324596|DRUG|Intravenous|Chemoimmunotheraphy
219303192|NCT01324596|DRUG|Bortezomib|Chemoimmunotheraphy
219303193|NCT01522469|DRUG|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
219303194|NCT04831073|PROCEDURE|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
219303195|NCT05860634|PROCEDURE|Catheter self-discontinuation|Self-discontinuation of a transurethral catheter
219303196|NCT03432260|DRUG|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
219303197|NCT03432260|DRUG|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
219303198|NCT03432260|DRUG|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
219303199|NCT04763421|DEVICE|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
219303200|NCT05910944|PROCEDURE|Shunt surgery|Shunt surgery according to each local centers routine
219303201|NCT00165373|DRUG|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
219303202|NCT03237546|PROCEDURE|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
219303203|NCT03237546|PROCEDURE|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
219303204|NCT06606301|DIAGNOSTIC_TEST|BioSB EGFR antibody|Appropriate sections from the tumor will be selected basing the choice on tumor content and viability eventually followed by EGFR application which will reveal a brown membrane positivity for the tumor. Total score for RGFR will be calculated by the histopathologists.
219303205|NCT05287711|BEHAVIORAL|Motivational Enhancement Therapy|In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.
219303206|NCT05287711|BEHAVIORAL|Alcohol Education Control|Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
219303207|NCT05287711|BEHAVIORAL|Treatment as Usual|Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.
219303208|NCT05287711|BEHAVIORAL|Strength at Home|IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
219303209|NCT06609525|DRUG|CTO0303-A|eye drop, 1 drop 3 times (every 5 minutes) a day
219303210|NCT06609525|DRUG|CTO0303-B|eye drop, 1 drop 3 times (every 5 minutes) a day
219303211|NCT06609525|DRUG|CTO0303-C|eye drop, 1 drop 3 times (every 5 minutes) a day
219303212|NCT06610500|OTHER|Questionnaires|Questionnaires investigating the prescription and dispensing of clozapine.
219303213|NCT06610513|BEHAVIORAL|Guided imagery|"First meeting: The women will be introduced to the clinic, the purpose of the study will be explained, and a written consent form will be filled out. A Personal Information Form and the Pregnancy Stress Assessment Scale (GSDS-36) and the Richard-Campbell Sleep Scale will be filled out. After the questionnaires are filled out, the vital signs of the pregnant woman will be measured and then a 15-minute guided imagery video will be shown. The vital signs of the patient will be measured again 10 minutes after the guided imagery video is watched."
219303214|NCT02533141|DEVICE|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
219303215|NCT02533141|DEVICE|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
219303216|NCT02533141|DRUG|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
219303217|NCT02533141|OTHER|Placebo|Placebo, once daily for 4 weeks
219303218|NCT01877473|PROCEDURE|Ablation|
219303219|NCT01586637|OTHER|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
219303220|NCT01586637|OTHER|Walking|The group walked twice a week during one hour.
219303221|NCT06905938|OTHER|no intervention|no intervention
219303222|NCT06116864|DEVICE|Endocuff and GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
219303223|NCT06116864|DEVICE|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
219303224|NCT02943811|DEVICE|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
219303225|NCT03520946|DRUG|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
219303226|NCT03520946|DRUG|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
219303227|NCT05053607|BEHAVIORAL|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
219303228|NCT05053607|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
219303229|NCT06905951|OTHER|Exercise|Mouth, tongue, and throat exercise to strengthen the airway, reducing its collapsibility.
219303230|NCT05256446|DRUG|AMG 701|
219303231|NCT05623176|OTHER|Standardised laparotomy care|This is a cohort study and no intervention as part of the study has been introduced. We are studying two groups and comparing the two before and after the introduction of a standardised laparotomy care protocol as part of a clinical quality improvement measure.
219303232|NCT06544512|OTHER|progressive relaxation exercise|looking at pain and anxiety by practicing progressive relaxation exercises
219303233|NCT03620331|PROCEDURE|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
219303234|NCT03620331|PROCEDURE|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
219303235|NCT00031551|DRUG|Etanercept|
219303236|NCT00031551|DRUG|Placebo|
219303237|NCT02823535|BEHAVIORAL|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
219303238|NCT05717608|OTHER|high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects|oral ingestion of food supplement for 4 weeks
219303239|NCT03788083|DRUG|Trimix|Intratumoral TriMix injection
219303240|NCT03788083|DRUG|Placebo|Intratumoral placebo injection
219303241|NCT02330146|DRUG|RCT-01|
219303242|NCT02330146|DRUG|Placebo|
219303243|NCT03527368|BEHAVIORAL|Time-restricted feeding|Participants consume food earlier in the day
219303244|NCT03527368|BEHAVIORAL|Usual feeding pattern|Participants consume food later in the day
219303245|NCT00409773|DRUG|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
219303246|NCT00409773|DRUG|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
219303247|NCT00409773|DRUG|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
219303248|NCT00081406|BEHAVIORAL|Individual Child CBT|
219303249|NCT00081406|BEHAVIORAL|Family CBT|
219303250|NCT00081406|BEHAVIORAL|Education/Support/Attention|
219303251|NCT01047423|DRUG|Simvastatin|40mg encapsulated once daily for 12 weeks
219303252|NCT01047423|DRUG|Placebo|Encapsulated oral once daily for 12 weeks
219303253|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
219303254|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
219303255|NCT00676377|DRUG|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
219303256|NCT00676377|DRUG|Saline|Saline Placebo
219303257|NCT02359877|DRUG|BCD-054|
219303258|NCT02359877|DRUG|Rebif|
219303259|NCT02359877|DRUG|Avonex|
219744603|NCT05753228|OTHER|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
219744604|NCT05753228|OTHER|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
219744605|NCT05753228|OTHER|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
219744606|NCT05753228|OTHER|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
219744607|NCT06196034|GENETIC|No intervention|No intervention
219303260|NCT01919814|DIETARY_SUPPLEMENT|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
219303261|NCT01919814|OTHER|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
219303262|NCT04623970|PROCEDURE|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
219303263|NCT02164383|DRUG|Nicotine patch|4-week starter kit of nicotine patch
219303264|NCT02164383|BEHAVIORAL|Cessation Counseling|5 brief counseling sessions
219303265|NCT02164383|DEVICE|Mobile Games|
219303266|NCT02334501|DRUG|Lansoprazole|
219303267|NCT02334501|DRUG|Neratinib|
219303268|NCT02345785|OTHER|urologic surgery and caudal block|
219303269|NCT04834453|DIAGNOSTIC_TEST|transcranial ultrasound|\- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
219303270|NCT03531970|DRUG|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
219303271|NCT03531970|DRUG|Dexamethasone|Corticostroide
219303272|NCT03531970|DRUG|Placebo|Placebo
219303273|NCT01813370|OTHER|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
219303274|NCT05569720|DRUG|ApTOLL|"ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
219303275|NCT02050152|BEHAVIORAL|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
219303276|NCT02050152|DRUG|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
219303277|NCT04102306|OTHER|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
219303278|NCT00575029|DRUG|megestrol acetate|600 mg by mouth daily
219303279|NCT03929744|DRUG|LY3502970|Administered orally.
219303280|NCT03929744|DRUG|Placebo|Administered orally.
219303281|NCT03929744|DRUG|Atorvastatin|Administered orally.
219303282|NCT03929744|DRUG|Simvastatin|Administered orally.
219303283|NCT03929744|DRUG|Midazolam|Administered orally.
219303284|NCT01893294|DRUG|gemcitabine hydrochloride|Given IT
219303285|NCT01893294|DRUG|fluorouracil|Given IV
219303286|NCT01893294|RADIATION|radiation therapy|Undergo radiation therapy
219303287|NCT01893294|OTHER|laboratory biomarker analysis|Correlative studies
219303288|NCT02831387|DRUG|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
219303289|NCT02831387|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
219303290|NCT06071403|OTHER|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
219303291|NCT01321385|OTHER|laboratory biomarker analysis|
219303292|NCT01321385|OTHER|study of socioeconomic and demographic variables|
219303293|NCT00192647|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
219303294|NCT00192647|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
219303295|NCT00862147|BEHAVIORAL|ICDP|Parent training group
219303296|NCT00862147|BEHAVIORAL|Treatment as usual|Parent and/or child focused interventions
219303297|NCT01828073|DRUG|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
219303298|NCT00206661|DRUG|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
219303299|NCT00206661|DRUG|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
219303300|NCT00925431|BEHAVIORAL|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
219303301|NCT00925431|BEHAVIORAL|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
219303302|NCT00202293|DRUG|Olanzapine|
219303303|NCT00202293|DRUG|Lithium|
219303304|NCT00202293|DRUG|Chlorpromazine|
219303305|NCT02943291|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
219303306|NCT02943291|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
219303307|NCT02275000|OTHER|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
219303308|NCT02275000|OTHER|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
219303309|NCT00000241|DRUG|Flupenthixol|
219303310|NCT05157165|BIOLOGICAL|Convalescent plasma|Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
219303311|NCT02110615|OTHER|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
219303312|NCT03624348|BEHAVIORAL|meditation|10 minute per day, 8 week digital meditation
219303313|NCT00690443|DRUG|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
219303314|NCT00690443|DRUG|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
219303315|NCT05444153|DRUG|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
219303316|NCT05444153|DRUG|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
219303317|NCT00095732|DRUG|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
219303318|NCT00095732|DRUG|Placebo|Administered orally in either Size 2 or Size 5 capsules
219303319|NCT02819466|DEVICE|3D echography|ultrasound visualization of the stomach in fasting patients.
219303320|NCT06408974|DRUG|Ketamine|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition
219303321|NCT06408974|DRUG|dexamethasone|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
219303322|NCT04778241|PROCEDURE|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
219744608|NCT06541587|BEHAVIORAL|mindfulness based virtual reality|mindfulness based virtual reality
219744609|NCT06541587|BEHAVIORAL|mindfulness based audio practice|mindfulness based audio practice
219744610|NCT04448847|DIETARY_SUPPLEMENT|Bif195|Active trial product with minimum 100 billion CFU daily dose
219744611|NCT04448847|OTHER|Placebo|Placebo similar to trial product but without Bif195
219744612|NCT06558435|OTHER|FEES|Single group
219744613|NCT00255502|DRUG|metoprolol succinate|
219744614|NCT00691509|GENETIC|gene expression analysis|
219744615|NCT00691509|GENETIC|polymorphism analysis|
219744616|NCT00691509|OTHER|high performance liquid chromatography|
219744617|NCT00691509|OTHER|laboratory biomarker analysis|
219744618|NCT00691509|OTHER|mass spectrometry|
219744619|NCT00691509|OTHER|questionnaire administration|
219744620|NCT05105620|DIAGNOSTIC_TEST|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
219744621|NCT05105620|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
219744622|NCT06014801|DRUG|Dialysate fluid, Filtration replacement fluid|Dose of continuous hemodialysis and/or hemofiltration
219744623|NCT03770611|DIETARY_SUPPLEMENT|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
219744624|NCT03770611|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic fiber is Agave inulin
219744625|NCT03770611|DIETARY_SUPPLEMENT|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
219744626|NCT03770611|DIETARY_SUPPLEMENT|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
219744627|NCT02796651|DRUG|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
219744628|NCT02796651|DRUG|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
219744629|NCT02796651|DRUG|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
219744630|NCT02796651|DRUG|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
219744631|NCT02796651|DRUG|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
219744632|NCT05701345|DEVICE|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
219744633|NCT05701345|OTHER|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
219744634|NCT04248153|DRUG|BR55|BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
219303323|NCT02335177|BEHAVIORAL|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
219303324|NCT00706199|PROCEDURE|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
219303325|NCT02872831|DEVICE|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
219303326|NCT02872831|DEVICE|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
219303327|NCT01350336|DEVICE|Alair System|Treatment of airways with the Alair System
219303328|NCT02203123|DEVICE|Ultrasound|
219303329|NCT02203123|DRUG|normal saline|
219303330|NCT03390920|OTHER|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
219303331|NCT02835326|BEHAVIORAL|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
219303332|NCT02835326|BEHAVIORAL|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
219303333|NCT01553097|OTHER|Neurocognitive impairment observation|None - observational
219303334|NCT03775070|DRUG|Simvastatin|"* Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
219303335|NCT03967639|PROCEDURE|Elective cardiac surgery|Elective cardiac surgery
219303336|NCT00003600|BIOLOGICAL|epoetin alfa|
219303337|NCT00003600|OTHER|placebo|
219303338|NCT04292678|BEHAVIORAL|Progressive muscle relaxation|The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
219303339|NCT04292678|OTHER|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
219303340|NCT05769127|OTHER|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
219303341|NCT05405712|BEHAVIORAL|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
219303342|NCT02071667|OTHER|Blood draw|
219303343|NCT03013660|OTHER|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
219303344|NCT02066428|BIOLOGICAL|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
219303345|NCT02066428|BIOLOGICAL|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
219303346|NCT03279263|DRUG|MLR-1023|MLR-1023 Tablets
219303347|NCT03279263|OTHER|Placebo|Matching Placebo Tablets
219303348|NCT00491543|DRUG|ALT-2074|
219303349|NCT05392153|OTHER|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
219303350|NCT05342220|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values \> 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
219303351|NCT05342220|PROCEDURE|Sham preconditioning|Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion
219303352|NCT02744326|BEHAVIORAL|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
219303353|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
219303354|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
219303355|NCT00285337|PROCEDURE|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
219303356|NCT01688674|DRUG|10% dextrose|
219303357|NCT05084443|DIETARY_SUPPLEMENT|Drink|Roselle and placebo drink for 6 months
219303358|NCT00261911|DRUG|sibutramine|
219303359|NCT02826330|OTHER|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
219303360|NCT04788498|PROCEDURE|Laparoendoscpoic single site surgery LESS|• A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
219303361|NCT04788498|PROCEDURE|Conventional multiport laparoscopy|• It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
219303362|NCT01111474|OTHER|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
219303363|NCT01111474|RADIATION|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
219303364|NCT04266665|DRUG|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
219303365|NCT04266665|OTHER|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
219303366|NCT04931186|OTHER|retrospective analyis|retrospective analysis of data
219303367|NCT03404830|OTHER|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
219303368|NCT03681704|DRUG|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
219303369|NCT03681704|DRUG|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
219303370|NCT00782522|PROCEDURE|Eccentric training program|Eccentric training program
219303371|NCT00782522|PROCEDURE|Traditional training program|Traditional training program
219303372|NCT01016977|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
219303373|NCT01016977|DRUG|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
219303374|NCT02179723|DEVICE|Leukosan Adhesive|Leukosan adhesive applied to one wound
219744635|NCT06211218|DIAGNOSTIC_TEST|Cornea diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
219744636|NCT03741842|BEHAVIORAL|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
219303375|NCT02179723|DEVICE|Transcutaneous suture|Transcutaneous suture applied to one wound
219303376|NCT02430974|DRUG|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
219303377|NCT02768051|PROCEDURE|AF Ablation|
219303378|NCT01481389|DIETARY_SUPPLEMENT|Theobromine|200 ml drink with added theobromine (no cocoa added)
219303379|NCT01481389|DIETARY_SUPPLEMENT|Cocoa|200 ml drink with cocoa (no theobromine added)
219303380|NCT01481389|DIETARY_SUPPLEMENT|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
219303381|NCT01481389|DIETARY_SUPPLEMENT|Placebo|200 ml drink (no added theobromine or cocoa)
219303382|NCT02306486|OTHER|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
219303383|NCT03413657|PROCEDURE|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
219303384|NCT04186299|DRUG|Clonidine|Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
219303385|NCT04186299|DRUG|Articaine Hydrochloride + Epinephrine|Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
219303386|NCT02954640|BIOLOGICAL|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
219303387|NCT01648738|OTHER|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
219303388|NCT01648738|OTHER|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
219303389|NCT01019512|OTHER|questionnaire administration|Ancillary studies
219744637|NCT03779620|DEVICE|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
219744638|NCT06395220|OTHER|Detection of donor-specific anti-HLA antibody (DSA)|"Detection methods~1. . Morphology: using microscope to observe the morphology of bone marrow.~2. . Immunophenotyping: using multi-color flow cytometry (MFC) to detect immunophenotype of leukemia cells and leukemia-associated immunophenotype of bone marrow samples.~3. . Cytogenetics analysis: G-band and/or fluorescence in situ hybridization (FISH) analysis are used in this study~4. . Molecular detection: Real-time quantitative RT-PCR (RQ-PCR) and/or next generation sequencing techniques are used to detect the molecular marker, such as: PML/RARA, AML-ETO, BCR/ABL, and WT1.~5. . HLA-Typing: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined according to the literatures published by our group \[Huo MR, et al. Bone Marrow Transplant. 2018;53(5):600-608\]..~6. . Other analyses: Detection of minimal residual diseases were performed using MFC and RQ-PCR according to the methods reported by our group \[Li SQ, et al. Blood,2022;140(5):516-520\]."
219744639|NCT06332755|DRUG|LB-LR1109|intravenous administration
219744640|NCT05430919|DRUG|REGN5713|Administered subcutaneously (SC)
219744641|NCT05430919|DRUG|REGN5714|Administered SC
219744642|NCT05430919|DRUG|REGN5715|Administered SC
219744643|NCT05430919|OTHER|Placebo|Administered SC
219303390|NCT01019512|OTHER|lymphedema management|
219303391|NCT02490553|OTHER|heteroevaluation scale by a nurse or doctor|
219303392|NCT01838252|PROCEDURE|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
219303393|NCT01838252|PROCEDURE|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
219303394|NCT00261768|BEHAVIORAL|Digital noise reduction|
219303395|NCT04252768|DRUG|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
219303396|NCT04252768|DRUG|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
219303397|NCT03641612|OTHER|one shape|canal fluid sample before and after root canal instrumentation
219303398|NCT03641612|OTHER|protaper next|canal fluid sample before and after root canal instrumentation
219303399|NCT02336178|DRUG|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
219303400|NCT05504863|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
219303401|NCT05504863|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
219303402|NCT05504863|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
219303403|NCT01108250|GENETIC|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
219303404|NCT00009841|BIOLOGICAL|EGFR antisense DNA|
219303405|NCT00009841|BIOLOGICAL|growth factor antagonist therapy|
219303406|NCT00009841|DRUG|DC-cholesterol liposome|
219303407|NCT03181750|BEHAVIORAL|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
219303408|NCT02781272|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
219303409|NCT02781272|PROCEDURE|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
219303410|NCT02781272|PROCEDURE|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
219303411|NCT04552483|DRUG|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
219303412|NCT04552483|DRUG|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
219303413|NCT00618982|DRUG|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
219303414|NCT03637985|DEVICE|resistive exercise|resistive exercise by elastic band for 12 weeks
219303415|NCT03637985|DEVICE|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
219303416|NCT04988815|DRUG|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
219303417|NCT02394951|DRUG|Pregabalin|Anticonvulsant
219303418|NCT02394951|DRUG|Placebo|Identical, matching inactive substance
219303419|NCT05692297|DRUG|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
219303420|NCT05692297|DRUG|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
219303421|NCT02057978|PROCEDURE|EXCEL DES implatation|Implant DES for CAD cases
219303422|NCT02057978|PROCEDURE|EXCEL-II DES implantation|Implant DES for CAD cases
219303423|NCT01200420|DRUG|miravirsen|SC injection
219303424|NCT01200420|DRUG|saline|SC injection
219303425|NCT06209346|OTHER|TeleRehab Group|"The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform."
219303426|NCT06209346|OTHER|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
219303427|NCT06059781|OTHER|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
219303428|NCT06059781|OTHER|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
219303429|NCT05708404|BEHAVIORAL|Outpatient treatment of severe and enduring anorexia nervosa|A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm
219303430|NCT04536753|PROCEDURE|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
219303431|NCT04439721|DRUG|γδT Cell infusion agent|γδT
219303432|NCT05114577|BEHAVIORAL|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (\~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
219303433|NCT05114577|BEHAVIORAL|Email recommendations|Receive recommendations (via email) to help improve sleep
219303434|NCT02863471|DRUG|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
219744644|NCT02594579|DRUG|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
219744645|NCT02594579|DRUG|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
219744646|NCT03794726|PROCEDURE|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
219744647|NCT03794726|PROCEDURE|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
219744648|NCT05627986|OTHER|No intervention|No intervention
219744649|NCT05014919|DRUG|Vortioxetine|Tablets
219744650|NCT05014919|DRUG|Placebo|Tablets
219303435|NCT06349746|OTHER|therapeutic exercises|stretching exercise to posterior capsule and progressive resistance exercise for rotator cuff and scapula stabilizer and home exercise 3 sessions per week for 6 week.
219303436|NCT06349746|OTHER|mobilization exercise|cervical unilateral antero-posterior mobilization and thoracic central postro-anterior mobilization
219303437|NCT01789151|DEVICE|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
219303438|NCT00871299|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
219303439|NCT00871299|BEHAVIORAL|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
219303440|NCT06268223|OTHER|Chewing Exercise Training|All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.
219303441|NCT01776541|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
219303442|NCT04408261|DRUG|Buqitongluo Granule|Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
219303443|NCT04408261|DRUG|Buqitongluo Granule Placebo|Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
219303444|NCT04408261|OTHER|Standard care|Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
219303445|NCT04084184|DRUG|HGP1812|Dapagliflozin (Forxiga) 10mg
219303446|NCT04084184|DRUG|HGP1602|Dapagliflozin 10mg
219303447|NCT02715349|BEHAVIORAL|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
219303448|NCT05443152|BEHAVIORAL|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
219303449|NCT04603651|DRUG|Bamlanivimab|Administered intravenously (IV).
219303450|NCT02938260|DRUG|Metoprolol vs Diltiazem|
219303451|NCT00156819|DRUG|fluticasone|fluticasone (100 microgram twice daily) treatment
219303452|NCT00156819|DRUG|montelukast|Montelukast (5 or 10 mg each night).
219303453|NCT00156819|DRUG|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
219303454|NCT05753371|DRUG|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
219303455|NCT03480217|BEHAVIORAL|Multifaceted Implementation Strategy|"Key components include:~* educational presentations to primary care providers at grand rounds~* patient information materials on ABPM and HBPM~* training registered nurses to assist providers with teaching patients to conduct HBPM~* information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~* a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~* periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~* an accessible, culturally-adapted and locally tailored ABPM service"
219303456|NCT03480217|OTHER|Usual care|Primary care clinicians diagnose hypertension according to usual care
219303457|NCT00522873|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
219303458|NCT00522873|DRUG|0.5mg NETA / 1.0mg E2 (Activella)|One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
219303459|NCT04617210|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
219303460|NCT04610437|PROCEDURE|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
219303461|NCT04556461|DRUG|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
219303462|NCT05496946|OTHER|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
219303463|NCT00326833|DRUG|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
219303464|NCT03169504|OTHER|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.
219303465|NCT03169504|DRUG|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
219303466|NCT03169504|OTHER|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
219303467|NCT01184144|DRUG|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
219303468|NCT05039528|BEHAVIORAL|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
219303469|NCT05039528|OTHER|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
219303470|NCT02634489|DRUG|Tamsulosin HCl|Oral
219303471|NCT02634489|DRUG|Solifenacin Succinate|Oral
219303472|NCT02634489|DRUG|EC905|Oral
219303473|NCT02907229|DEVICE|NCVC-CS1|Intervention Description
219303474|NCT05378971|DRUG|Pomalidomide|Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
219303475|NCT03170037|PROCEDURE|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
219303476|NCT03170037|PROCEDURE|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
219303477|NCT03860285|OTHER|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
219303478|NCT04584775|OTHER|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
219303479|NCT04584775|OTHER|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
219303480|NCT02312388|OTHER|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
219303481|NCT02312388|OTHER|Thin-wall needle technique|using 18 - 21 G introducer needle
219303482|NCT00799513|DRUG|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
219303483|NCT00624923|DRUG|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
219303484|NCT00624923|DRUG|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
219303485|NCT03843931|BEHAVIORAL|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
219303486|NCT03843931|DRUG|Intra-articular saline injection|"Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
219303487|NCT04459247|DRUG|Vit D|Oral liquid formulation of 60000 IU
219303488|NCT03280667|DRUG|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
219303489|NCT00666679|DRUG|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
219303490|NCT00666679|DRUG|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
219303491|NCT00666679|DRUG|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
219303492|NCT02702726|OTHER|Congee and juice with coconut gel|25g coconut oleogel
219303493|NCT02702726|OTHER|Congee and juice with coconut oil|25g coconut oil
219303494|NCT02702726|OTHER|Congee and juice with sunflower gel|25g sunflower oleogel
219303495|NCT02702726|OTHER|Congee and juice with sunflower oil|25g sunflower oil
219303496|NCT02370810|BEHAVIORAL|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
219303497|NCT04317703|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
219303498|NCT04317703|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
219303499|NCT01080495|PROCEDURE|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
219303500|NCT01490671|DRUG|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
219303501|NCT01490671|DRUG|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
219303502|NCT01529203|DRUG|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
219303503|NCT01529203|DEVICE|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
219303504|NCT03690232|DRUG|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
219303505|NCT03690232|DRUG|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
219303506|NCT05062759|DRUG|Tezepelumab|210 mg SC injection Q4W.
219303507|NCT05062759|DRUG|Placebo|SC injection Q4W.
219303508|NCT05937334|DIAGNOSTIC_TEST|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
219744651|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
219744652|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
219303509|NCT04498091|BIOLOGICAL|Biological data|Biological data
219303510|NCT04498091|OTHER|Clinical data|Clinical data
219303511|NCT01830959|DRUG|Roflumilast|Roflumilast
219303512|NCT01830959|DRUG|Placebo|Placebo one a day
219303513|NCT03203031|PROCEDURE|General anesthesia|Standard general anesthesia
219303514|NCT03203031|PROCEDURE|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
219303515|NCT00584649|PROCEDURE|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
219303516|NCT05682391|OTHER|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
219303517|NCT00236093|DRUG|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
219303518|NCT05970679|DRUG|Ezetimibe/Atorvastatin 10/5 mg|DW1125
219303519|NCT05970679|DRUG|Atorvastatin 5mg|DW1125A
219303520|NCT05970679|DRUG|Ezetimibe 10mg|DW1125E
219303521|NCT05970679|DRUG|Atorvastatin 10mg|DW1125A-1
219303522|NCT05970679|DRUG|DW1125 placebo|Ezetimibe/Atorvastatin 10/5 mg placebo
219303523|NCT05970679|DRUG|DW1125A placebo|Atorvastatin 5mg placebo
219303524|NCT05970679|DRUG|DW1125E placebo|Ezetimibe 10mg placebo
219303525|NCT05970679|DRUG|DW1125A-1 placebo|Atorvastatin 10mg placebo
219303526|NCT02781844|DRUG|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
219303527|NCT02781844|DRUG|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
219303528|NCT02781844|DRUG|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
219303529|NCT02725801|DEVICE|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
219303530|NCT02725801|DEVICE|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
219303531|NCT02518490|DEVICE|Sapphire Lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
219303532|NCT02518490|DEVICE|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
219303533|NCT00140751|DRUG|Lopinavir/ritonavir (drug)|
219303534|NCT04078633|BEHAVIORAL|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
219303535|NCT02349373|BEHAVIORAL|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
219303536|NCT02349373|BEHAVIORAL|16 week training period|Receipt of a weekly running schedule through an online training diary.
219303537|NCT02843893|DEVICE|Measure the minimum intensity of a painful stimulation|With Neurolight device.
219744653|NCT00680914|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
219744654|NCT00680914|BIOLOGICAL|Prevenar|3 doses administered intramuscularly.
219744655|NCT00680914|BIOLOGICAL|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
219744656|NCT01469156|DRUG|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
219744657|NCT05721729|DRUG|Mizagliflozin|Encapsulated
219744658|NCT05721729|DRUG|Placebo|Encapsulated
219744659|NCT01321905|DIETARY_SUPPLEMENT|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
219744660|NCT05888233|DRUG|Allopurinol|Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
219744661|NCT05745961|RADIATION|TSPO PET scan (11C-PBR28)|PET scan
219744662|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
219744663|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
219303538|NCT00346632|DRUG|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
219303539|NCT00616057|DIETARY_SUPPLEMENT|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
219303540|NCT00616057|DIETARY_SUPPLEMENT|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
219303541|NCT00918580|BIOLOGICAL|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
219303542|NCT00277576|BIOLOGICAL|ppdpSC18 administered by PMED|
219303543|NCT06208098|DIAGNOSTIC_TEST|Salivary cortisol dosage|saliva sample at 8 - 9h \& at T30
219303544|NCT04253080|BIOLOGICAL|Blood sample|Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.
219303545|NCT04253080|BIOLOGICAL|Cutaneous melanoma biopsy|Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
219303546|NCT05074797|DIAGNOSTIC_TEST|laboratory|laboratory data
219303547|NCT03897764|PROCEDURE|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
219303548|NCT00477334|DRUG|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
219303549|NCT00477334|DRUG|Placebo|oral; two tablets twice a day; single day treatment
219303550|NCT05985421|OTHER|Fecal collection|approximate volume of 2 ml
219303551|NCT05985421|OTHER|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
219303552|NCT05985421|OTHER|Polysomnography|Polysomnography
219303553|NCT05985421|OTHER|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
219303554|NCT02270918|DRUG|Kcentra|IV infusion
219303555|NCT02270918|DRUG|Apixaban|
219303556|NCT02270918|DRUG|Placebo|
219303557|NCT04593927|DRUG|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
219303558|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
219303559|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
219303560|NCT00226031|PROCEDURE|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
219303561|NCT03587974|BEHAVIORAL|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
219303562|NCT02868385|DRUG|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
219303563|NCT02868385|DRUG|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
219303564|NCT01028937|DEVICE|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
219303565|NCT02354508|DRUG|Pasireotide LAR|Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
219303566|NCT02907645|BEHAVIORAL|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
219303567|NCT02907645|BEHAVIORAL|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
219303568|NCT00628004|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
219303569|NCT00628004|DEVICE|Local best practice|"N/A - since intervention is local best practice"
219303570|NCT03700073|OTHER|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
219303571|NCT03700073|OTHER|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
219303572|NCT01493232|OTHER|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
219303573|NCT02438501|RADIATION|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
219303574|NCT02438501|RADIATION|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
219303575|NCT02290132|DRUG|Rabbit Anti-human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
219303576|NCT03543657|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
219303577|NCT03543657|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
219303578|NCT03543657|DRUG|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
219303579|NCT03543657|DRUG|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
219303580|NCT02355080|BEHAVIORAL|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
219303581|NCT02355080|BEHAVIORAL|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
219303582|NCT00760006|DRUG|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
219303583|NCT00760006|OTHER|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
219303584|NCT04910607|OTHER|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
219303585|NCT04910607|OTHER|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
219303586|NCT01455805|DEVICE|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
219303587|NCT01455805|PROCEDURE|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
219303588|NCT00160862|DRUG|SLV317|
219303589|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
219303590|NCT03486457|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
219303591|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
219303592|NCT00038168|DRUG|Estramustine|Intravenous dose
219303593|NCT00038168|DRUG|Taxol|Intravenous dose
219303594|NCT00372229|DRUG|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
219303595|NCT00372229|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
219303596|NCT00372229|DRUG|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
219303597|NCT01378923|BEHAVIORAL|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
219303598|NCT01378923|BEHAVIORAL|TAU|have access to standard jail programs and services
219303599|NCT00783900|OTHER|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
219303600|NCT03133052|BEHAVIORAL|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
219303601|NCT03133052|BEHAVIORAL|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
219303602|NCT02797574|PROCEDURE|Punch Biopsy at a Lesional Site|
219303603|NCT02797574|PROCEDURE|Punch Biopsy at a Non- Lesional site|
219303604|NCT06153953|DEVICE|vacuum device|use of vacuum device in dressing of diabetic wounds
219303605|NCT06153953|OTHER|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
219303606|NCT04298021|DRUG|AZD6738|"* In AZD6738+Durvalumab cohort~  \- AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"
219303607|NCT04298021|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
219303608|NCT04298021|DRUG|Olaparib|Olaparib 300 mg bid on D1-28 Every 4 weeks
219303609|NCT00139191|PROCEDURE|C-11 acetate PET scan|
219303610|NCT03363763|DRUG|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
219303611|NCT03363763|DRUG|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
219303612|NCT03363763|DRUG|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
219303613|NCT01365949|GENETIC|microarray analysis|
219303614|NCT01365949|GENETIC|protein analysis|
219303615|NCT01365949|OTHER|immunohistochemistry staining method|
219303616|NCT01365949|OTHER|laboratory biomarker analysis|
219303617|NCT02878681|DRUG|Ranibizumab|0.5 mg intravitreal injections
219303618|NCT02878681|DRUG|Aflibercept|2 mg intravitreal injections
219303619|NCT00093808|BIOLOGICAL|trastuzumab|
219303620|NCT00093808|DRUG|capecitabine|
219744664|NCT03851666|OTHER|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
219303621|NCT00093808|DRUG|vinorelbine tartrate|
219303622|NCT02931071|DRUG|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
219303623|NCT02931071|DRUG|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
219303624|NCT02222636|DRUG|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
219303625|NCT02222636|DRUG|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
219303626|NCT02222636|DRUG|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
219303627|NCT02222636|DRUG|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
219303628|NCT02222636|DRUG|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
219303629|NCT05030987|PROCEDURE|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
219303630|NCT05030987|PROCEDURE|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
219303631|NCT03956823|DRUG|telmisartan|Telmisartan group: telmisartan 80 mg once a day
219303632|NCT03956823|DRUG|amlodipine|amlodipine group: amlodipine 5 mg once a day
219303633|NCT03476707|OTHER|Anemia|Hematocrit less than 0.39
219303634|NCT02699034|PROCEDURE|ablation for typical atrial flutter|
219303635|NCT02699034|DEVICE|Vision-MR ablation catheter|
219303636|NCT03805087|PROCEDURE|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
219744665|NCT02971163|BEHAVIORAL|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
219303637|NCT03951506|OTHER|Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
219303638|NCT03951506|OTHER|Conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
219303639|NCT01049295|DIETARY_SUPPLEMENT|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
219303640|NCT01049295|OTHER|corn oil pearls|corn oil pearls 3 times a day
219303641|NCT04100031|DEVICE|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
219303642|NCT04100031|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
219303643|NCT02199704|OTHER|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study."
219303644|NCT00262951|BIOLOGICAL|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
219303645|NCT00262951|DRUG|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
219303646|NCT00262951|DRUG|fluorouracil|administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
219303647|NCT00262951|RADIATION|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
219303648|NCT00262951|PROCEDURE|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
219303649|NCT02923687|DRUG|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
219303650|NCT02923687|DRUG|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
219303651|NCT04175821|RADIATION|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
219303652|NCT05220384|BEHAVIORAL|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
219303653|NCT05220384|BEHAVIORAL|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
219303654|NCT01657513|DRUG|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
219303655|NCT06391060|PROCEDURE|Impact of Gender on Davinci rectal surgery|gender-specific considerations in the surgical management and post-operative care of rectal cancer patients undergoing robotic surgery
219303656|NCT02052830|BEHAVIORAL|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
219303657|NCT05521945|BEHAVIORAL|Intermittent Fasting|16 hours fasting and 8 hours eating window
219303658|NCT05521945|BEHAVIORAL|Calorie Restricted Diet|The customized diet plan will be given to the participants according to their calorie intake requirements
219303659|NCT05521945|BEHAVIORAL|Normal dietary intake|normal diet without any customization
219303660|NCT02943226|DEVICE|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
219303661|NCT02943226|DEVICE|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
219303662|NCT04068259|DRUG|PBI-4547|PBI-4547 tablet
219303663|NCT04068259|OTHER|Placebo|Placebo tablet
219303664|NCT05210218|DIETARY_SUPPLEMENT|Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
219303665|NCT05210218|DIETARY_SUPPLEMENT|placebo|cellulose
219303666|NCT01041352|DEVICE|laryngeal mask|LMA Proseal
219303667|NCT01041352|DEVICE|endotracheal tube|Unomedical endotracheal tube
219303668|NCT00829582|DRUG|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
219303669|NCT00829582|OTHER|placebo|single intravenous infusion
219303670|NCT05158556|OTHER|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
219303671|NCT05158556|OTHER|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
219303672|NCT03493841|DRUG|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
219303673|NCT01602562|DRUG|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
219303674|NCT05065333|OTHER|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
219303675|NCT05065333|OTHER|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
219303676|NCT03881553|DEVICE|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
219303677|NCT03881553|DEVICE|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
219303678|NCT01098565|DEVICE|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
219303679|NCT01046890|DRUG|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
219303680|NCT00536536|BEHAVIORAL|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
219303681|NCT04780022|OTHER|Clinical events at last follow-up|Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
219303682|NCT02241954|DEVICE|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
219303683|NCT01568437|PROCEDURE|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
219303684|NCT01568437|OTHER|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
219303685|NCT04834349|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
219303686|NCT04834349|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
219303687|NCT04834349|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219303688|NCT04834349|BIOLOGICAL|Pembrolizumab|Given IV
219303689|NCT04834349|OTHER|Quality-of-Life Assessment|Ancillary studies
219303690|NCT04834349|OTHER|Questionnaire Administration|Ancillary studies
219303691|NCT04834349|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219303692|NCT05064189|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
219303693|NCT01477333|DRUG|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
219303694|NCT01477333|DRUG|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
219303695|NCT02501538|DEVICE|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
219303696|NCT05121987|PROCEDURE|Erector Spinae Plane block|An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
219303697|NCT05121987|PROCEDURE|Continuous Wound Infusion|Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
219303698|NCT00100386|PROCEDURE|Intensive Control Strategy|
219303699|NCT00100386|BEHAVIORAL|Standard Control Strategy|
219303700|NCT03035903|DEVICE|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
219303701|NCT03035903|DEVICE|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
219303702|NCT02088346|OTHER|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
219303703|NCT00979784|BEHAVIORAL|Better Weight|Standard cognitive behavioral treatment focused on dietary \& exercise behavior
219303704|NCT00979784|BEHAVIORAL|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
219303705|NCT02316366|DEVICE|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
219303706|NCT05660460|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
219303707|NCT00212160|PROCEDURE|omentectomy|RYGB with omentectomy
219303708|NCT05234112|BEHAVIORAL|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
219303709|NCT05234112|DIAGNOSTIC_TEST|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
219303710|NCT05234112|BEHAVIORAL|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
219303711|NCT05234112|DIAGNOSTIC_TEST|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
219303712|NCT05234112|PROCEDURE|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
219303713|NCT05234112|DIAGNOSTIC_TEST|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
219303714|NCT05455515|PROCEDURE|IVL procedures|Intravascular Lithotripsy (IVL)
219303715|NCT04271501|PROCEDURE|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
219303716|NCT04271501|DEVICE|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
219303717|NCT04271501|DEVICE|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
219303718|NCT04271501|DEVICE|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
219303719|NCT02628782|DEVICE|InSeal's Vascular Closure Device|Intravascular closure device
219303720|NCT02874274|BEHAVIORAL|Standard of Care|
219303721|NCT02874274|BEHAVIORAL|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
219303722|NCT00527592|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
219303723|NCT00527592|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
219303724|NCT05441241|DEVICE|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
219303725|NCT05441241|OTHER|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
219303726|NCT03801915|DRUG|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
219303727|NCT03801915|PROCEDURE|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
219303728|NCT06244446|OTHER|No intervention|No intervention. It is an observational study
219303729|NCT01736865|DRUG|Cholecalciferol|
219303730|NCT01736865|DRUG|Placebo|
219303731|NCT06062732|BEHAVIORAL|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
219303732|NCT06062732|BEHAVIORAL|Control|Services as usual
219303733|NCT05401760|PROCEDURE|Group A :combined phacoaspiration and angle surgery|"* Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture."
219303734|NCT05401760|PROCEDURE|Group B : phacoaspiration only|"* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture."
219303735|NCT04647812|BEHAVIORAL|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
219303736|NCT04647812|BEHAVIORAL|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
219303737|NCT03056989|DRUG|SPX-101|Inhalation solution twice daily for 7 days.
219303738|NCT04438577|DRUG|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
219303739|NCT02641678|DEVICE|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
219303740|NCT01048580|DRUG|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
219303741|NCT01048580|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
219303742|NCT02376374|OTHER|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
219303743|NCT04061395|BIOLOGICAL|Guselkumab|See study arm description.
219303744|NCT01211288|DEVICE|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
219303745|NCT02475239|BEHAVIORAL|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
219303746|NCT02475239|BEHAVIORAL|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
219303747|NCT03802942|DIETARY_SUPPLEMENT|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
219303748|NCT01751074|DRUG|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
219303749|NCT01751074|DRUG|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
219303750|NCT00001984|DRUG|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
219303751|NCT06294132|PROCEDURE|Lumbar Manipulation|"The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed to the level to be manipulated, and the left foot is placed behind the right lower leg. The caregiver introduces rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver then rolls the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. If a cavitation pop is not heard the first time, a second attempt is made. The procedure is repeated on the opposite side."
219303752|NCT06294132|PROCEDURE|Sham Lumbar Manipulation|The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed SLIGHTLY, and the left foot is placed behind the right lower leg. The caregiver DOES NOT introduce rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver DOES NOT roll the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. NO ROTATION OCCURS IN THE SPINE. The procedure is repeated on the opposite side.
219303753|NCT03809741|OTHER|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
219303754|NCT00241852|BEHAVIORAL|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
219303755|NCT00241852|BEHAVIORAL|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
219303756|NCT03333837|BEHAVIORAL|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
219303757|NCT03333837|BEHAVIORAL|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
219303758|NCT03333837|BEHAVIORAL|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
219303759|NCT03333837|BEHAVIORAL|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
219303760|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
219303761|NCT01436188|PROCEDURE|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
219303762|NCT01436188|PROCEDURE|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
219303763|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
219303764|NCT01436188|PROCEDURE|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
219303765|NCT04834856|DRUG|ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
219303766|NCT02464033|DRUG|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
219303767|NCT02464033|DRUG|Vitamin D|
219303768|NCT02464033|DRUG|Etanercept|
219303769|NCT04217122|OTHER|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
219303770|NCT04217122|OTHER|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
219303771|NCT04217590|DRUG|Sodium Zirconium Cyclosilicate|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
219303772|NCT04217590|DRUG|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
219303773|NCT02270138|BEHAVIORAL|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
219303774|NCT02866097|OTHER|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
219303775|NCT02866097|OTHER|Supportive supervision|Strengthening of supportive supervision using DHIS2
219303776|NCT02866097|OTHER|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
219303777|NCT04294732|DRUG|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
219303778|NCT04294732|DRUG|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
219303779|NCT02949466|DRUG|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
219303780|NCT02949466|DEVICE|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
219303781|NCT04547283|OTHER|Usual Care|No clinical team recommendation, patients will remain in their natural choice of position
219303782|NCT04547283|OTHER|APPS|Clinical team guidance on prone positioning of patients
219303783|NCT02437461|DRUG|Triamcinolone hexacetonide|intraarticular knee injection
219303784|NCT04619251|DRUG|BI 1323495|BI 1323495
219303785|NCT04619251|DRUG|Placebo|Placebo
219303786|NCT04619251|DRUG|Itraconazole|Itraconazole
219303787|NCT02019303|PROCEDURE|FNA and Core biopsy|Both procedures will be performed on the same lymph node
219303788|NCT04262752|DEVICE|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
219303789|NCT05709301|DRUG|Donepezil Hydrochloride|Donepezil 10mg once daily
219303790|NCT05709301|DRUG|Placebo|Matching placebo
219303791|NCT02730949|DIETARY_SUPPLEMENT|D-chiro-inositol|Treated group
219303792|NCT02730949|DIETARY_SUPPLEMENT|Folic Acid|Control group
219303793|NCT00112424|PROCEDURE|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
219303794|NCT00112424|PROCEDURE|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
219303795|NCT02003573|DRUG|decitabine iv|decitabine iv fixed dose
219303796|NCT02003573|DRUG|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
219303797|NCT00803751|DEVICE|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
219303798|NCT00803751|DEVICE|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
219303799|NCT05023681|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
219303800|NCT05023681|DRUG|normal saline|Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
219303801|NCT04466995|DEVICE|manometer|cuff pressure to be measured with manometer
219303802|NCT02747199|DEVICE|SYNERGY stent|
219303803|NCT02747199|DEVICE|BVS ABSORB scaffold|
219303804|NCT05563285|BEHAVIORAL|Exercise and Mindfulness-Based Intervention|"1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2\. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running"
219303805|NCT05563285|BEHAVIORAL|Control Group|The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
219303806|NCT02112708|OTHER|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
219303807|NCT02112708|OTHER|Control Group usual care|In the control group the dysthymia is treated as usual with the conventional treatment.
219303808|NCT02688907|DRUG|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
219303809|NCT03196895|BEHAVIORAL|Weight reduction training|6 one-hour sessions of conventional weight reduction training
219303810|NCT03196895|BEHAVIORAL|PPG training|Four 90-minute sessions of glycemic load and exercise training
219303811|NCT03196895|BEHAVIORAL|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
219303812|NCT03196895|BEHAVIORAL|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
219303813|NCT00502086|DIETARY_SUPPLEMENT|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
219303814|NCT00502086|OTHER|Placebo|Placebo three sachets daily during 96 weeks
219303815|NCT03782220|OTHER|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
219303816|NCT03782220|OTHER|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
219303817|NCT03102645|DRUG|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
219303818|NCT03102645|DRUG|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
219303819|NCT02858843|DRUG|lumacaftor-ivacaftor|Drug given for cystic fibrosis
219303820|NCT05110768|DRUG|Triferic AVNU|Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
219303821|NCT05110768|OTHER|Placebo|normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
219303822|NCT01413087|BIOLOGICAL|Biological/Vaccine: BC-819|"Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)"
219303823|NCT03895905|DIAGNOSTIC_TEST|colposcopy and colposcopic biopsy|high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
219303824|NCT00127777|DRUG|Amantadine sulphate (in addition to standard treatment)|
219303825|NCT04310280|DRUG|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
219303826|NCT04310280|DRUG|Saline|Half of the wound surface is injected daily with topical saline solution
219303827|NCT00928018|DRUG|Sirolimus|Taken orally for at least 12 months
219303828|NCT00928018|DRUG|Methotrexate|Given intravenously on the first, third and sixth day after transplant
219303829|NCT00928018|DRUG|Tacrolimus|Taken orally or given intravenously for at least 6 months
219303830|NCT00928018|DRUG|Cyclosporine|Taken orally or given intravenously for at least 6 months
219303831|NCT00928018|DRUG|MMF|Taken orally for about 2 months
219303832|NCT05267431|DRUG|Biological Drug|Different biological drugs
219303833|NCT03174587|BIOLOGICAL|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10\^6cells/kg Step 1 dose : 2.0x10\^6cells/kg Step 2 dose : 3.0x10\^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
219303834|NCT00016939|DRUG|alvocidib|
219303835|NCT00126503|BIOLOGICAL|Bevacizumab|Given IV
219303836|NCT00126503|DRUG|Sorafenib Tosylate|Given PO
219303837|NCT00126503|OTHER|Pharmacological Study|Correlative studies
219303838|NCT00126503|OTHER|Laboratory Biomarker Analysis|Correlative studies
219303839|NCT00061139|BEHAVIORAL|Pediatric Constraint-Induced Movement therapy|
219303840|NCT00061139|BEHAVIORAL|Conventional pediatric motor rehabilitation therapy|
219303841|NCT00203762|BEHAVIORAL|Public sector antiretroviral treatment programmes|
219303842|NCT02575859|DRUG|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
219303843|NCT02575859|PROCEDURE|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
219303844|NCT02457559|DRUG|Tirabrutinib|Tablets or capsules administered orally
219303845|NCT05408832|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
219303846|NCT05408832|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
219303847|NCT05408832|BEHAVIORAL|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
219303848|NCT04819776|DRUG|Iloperidone|Oral iloperidone
219303849|NCT04819776|DRUG|Iloperidone Placebo|Oral placebo
219303850|NCT02010853|OTHER|IRMf|"evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months"
219303851|NCT00476710|DRUG|Colesevelam HCl|
219303852|NCT00235482|DRUG|Coxsackievirus A21|
219303853|NCT01232179|PROCEDURE|conventional prp|pan retinal photocoagulation
219303854|NCT01232179|PROCEDURE|targeted prp|1200-1600 spot in far periphery retin, anterior equator
219303855|NCT00875602|DEVICE|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
219303856|NCT00998335|DRUG|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
219303857|NCT00998335|DRUG|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
219303858|NCT04873739|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
219303859|NCT00682669|BEHAVIORAL|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
219303860|NCT00682669|BEHAVIORAL|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
219303861|NCT03854045|OTHER|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
219303862|NCT04230291|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
219303863|NCT04230291|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
219744666|NCT02959346|PROCEDURE|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
219303864|NCT02883127|BEHAVIORAL|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.~2. Eat mainly carbohydrates of low glycaemic index.~3. Reduce the intake of carbohydrate of high glycaemic index.~4. Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
219303865|NCT02700477|DIETARY_SUPPLEMENT|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
219303866|NCT02700477|OTHER|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
219303867|NCT01406964|OTHER|CAT test|A CAT test is performed in order to diagnose tubal factor causes
219303868|NCT01406964|OTHER|Histerosalpingography|A Histerosalpingography is performed.
219303869|NCT05337085|DRUG|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
219303870|NCT05337085|DRUG|Midazolam|Midazolam
219303871|NCT00355485|DEVICE|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
219303872|NCT01545154|DEVICE|Transperineal Ultrasound|
219303873|NCT02798965|BIOLOGICAL|serodiagnosis|
219303874|NCT00807287|PROCEDURE|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
219303875|NCT00807287|PROCEDURE|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
219303876|NCT06147050|DRUG|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
219303877|NCT06147050|OTHER|Placebo|Patients will receive matching placebo control twice daily.
219303878|NCT02112747|OTHER|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
219303879|NCT03106909|RADIATION|pulmonary computed tomography (CT)|Pulmonary CT imaging
219303880|NCT00790751|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
219303881|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
219303882|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
219303883|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
219303884|NCT03716700|BIOLOGICAL|CUVITRU|CUVITRU
219303885|NCT06487611|BEHAVIORAL|A humanoid social robot|A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
219303886|NCT03681847|PROCEDURE|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
219303887|NCT03681847|PROCEDURE|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
219303888|NCT03681847|PROCEDURE|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
219303889|NCT02973711|DRUG|Nilotinib|Nilotinib 300 mg BID
219303890|NCT02973711|DRUG|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
219303891|NCT02764216|RADIATION|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
219303892|NCT02091453|BEHAVIORAL|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
219303893|NCT02091453|BEHAVIORAL|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
219303894|NCT04431167|BEHAVIORAL|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
219303895|NCT02817022|OTHER|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
219303896|NCT06239636|BIOLOGICAL|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
219303897|NCT05330312|DEVICE|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
219303898|NCT02549014|DRUG|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
219303899|NCT02549014|DRUG|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
219303900|NCT03433079|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
219303901|NCT03433079|DIAGNOSTIC_TEST|Arterial lactate|Arterial lactate level was assessed in all patients.
219303902|NCT03433079|DIAGNOSTIC_TEST|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
219303903|NCT03433079|DIAGNOSTIC_TEST|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
219303904|NCT03433079|DIAGNOSTIC_TEST|Myoglobin|The level of myoglobin was assessed in all patients.
219303905|NCT01078454|DRUG|melphalan|Given PO
219303906|NCT01078454|DRUG|dexamethasone|Given PO
219303907|NCT01078454|DRUG|bortezomib|Given IV
219303908|NCT00756691|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
219303909|NCT02902939|DEVICE|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
219303910|NCT02902939|PROCEDURE|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
219303911|NCT01791374|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
219303912|NCT01791374|DRUG|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
219303913|NCT02274974|DRUG|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
219303914|NCT02274974|DRUG|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
219303915|NCT04993482|OTHER|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
219303916|NCT02330289|BEHAVIORAL|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
219303917|NCT01720680|RADIATION|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
219303918|NCT01720680|DEVICE|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
219303919|NCT03957889|OTHER|Educational simulation|
219303920|NCT05188339|DRUG|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
219303921|NCT05188339|DRUG|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
219303922|NCT04672629|DEVICE|echocardiography|follow up echocardiography
219303923|NCT06071559|PROCEDURE|Laparoscopic Roux-en-y gastric bypass|Obesity surgery
219303924|NCT06298669|DEVICE|Biventricular Pacing|The CRT device will be reprogrammed to coordinate contractions of the left and right ventricles.
219303925|NCT06298669|DEVICE|Right Ventricular Pacing|The CRT device will be reprogrammed for right ventricular contractions.
219303926|NCT02864030|DRUG|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
219303927|NCT05428930|DRUG|CKDB-501B|Intramuscular injection CKDB-501B
219303928|NCT05428930|DRUG|Botox®50U|Intramuscular injection Botox®50U
219303929|NCT02641574|OTHER|compare complication|
219303930|NCT02390050|DRUG|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
219303931|NCT02390050|DRUG|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
219303932|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
219303933|NCT06056362|DIAGNOSTIC_TEST|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
219303934|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
219303935|NCT06056362|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
219303936|NCT06438497|PROCEDURE|RIRS with f-UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
219303937|NCT06438497|PROCEDURE|RIRS with f-UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
219303938|NCT06438497|PROCEDURE|RIRS with traditional UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
219303939|NCT06438497|PROCEDURE|RIRS with traditional UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
219303940|NCT06487845|DRUG|BAY3283142|IR tablets, oral
219303941|NCT06487845|DRUG|Placebo|Placebo matched to BAY3283142
219303942|NCT05677997|BEHAVIORAL|Intervention|Sessions to go through goals, problem areas, areas they want to improve.
219303943|NCT03912376|DIAGNOSTIC_TEST|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
219303944|NCT06144970|BIOLOGICAL|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
219303945|NCT06144970|BIOLOGICAL|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
219303946|NCT06144970|BIOLOGICAL|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
219303947|NCT06144970|BIOLOGICAL|Sham Control|Single subcutaneous injection of normal saline
219303948|NCT04062968|OTHER|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
219303949|NCT01775124|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
219303950|NCT01737554|OTHER|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
219744667|NCT02959346|PROCEDURE|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
219303951|NCT06602635|DIAGNOSTIC_TEST|ECG and clinical score|The Hybrid Score (HS), detailed in previous literature involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.
219303952|NCT00098501|DRUG|pelitinib|
219303953|NCT00098501|DRUG|temsirolimus|Given PO
219303954|NCT01372423|DRUG|Lubiprostone|24 mcg capsules
219303955|NCT01372423|DRUG|Placebo|24 mcg capsules
219303956|NCT06609395|BEHAVIORAL|Brief online CBT targeting excessiv worry|The intervention with a focus on excessive worry lasted five weeks and was delivered through five online modules with therapist support. Modules covered psychoeducation, problem-solving, reducing excessive media consumption, detached mindfulness, and shifting focus from worry. The final module offered relapse prevention strategies.
219303957|NCT06610565|DIETARY_SUPPLEMENT|FASTING-MIMICKING DIET PROGRAM|Nutritional intervention via fasting-mimicking diet. Patients receiving adjuvant therapy with aromatase inhibitors will be randomized 1:1 into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months,and a control one, where they will receive only nutritional counseling.
219303958|NCT06610435|PROCEDURE|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Soft tissue mobilization techniques were applied bilaterally on the trigger points in the masseter, temporal, lateral and medial pterygoid muscles of the masticatory muscles in the transverse direction from inside and outside the mouth. In addition, deep friction massage and myofascial relaxation techniques were applied to suprahyoid and infrahyoid muscles, sternocleidomastoid, scalene, upper trapezius, levator scapula and suboccipital muscles until relaxation was felt. In addition, distraction and bridging techniques were applied in the suboccipital region to release the tissue and fascia techniques were applied in the cervical region to loosen the fascia. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
219303959|NCT06610435|PROCEDURE|Home Exercise|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. These exercises consist of resistant isometric jaw movements to increase coordination and relaxation of the masticatory muscles (post isometric relaxation technique), Rocabado exercises, stretching and posture exercises for temporal, masseter and suprahyoid muscles as well as neck muscles. All individuals in this group were taught the programmed exercises practically and were asked to repeat the home exercises (lasting approximately 25 minutes) three times a week for 8 weeks. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
219303960|NCT06610773|BIOLOGICAL|hUC-MSCs|1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.
219303961|NCT06610773|BIOLOGICAL|Saline+albumin|Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs
219303962|NCT01064661|DIETARY_SUPPLEMENT|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10\^10 cfu total bacteria per day)
219303963|NCT01064661|DIETARY_SUPPLEMENT|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10\^10 cfu total bacteria per day)
219303964|NCT00230087|PROCEDURE|blood donation|phlebotomy until iron depleted
219303965|NCT04018638|OTHER|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
219303966|NCT04064398|PROCEDURE|Aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
219303967|NCT04973787|BIOLOGICAL|biological disease-modifying antirheumatic drugs (bDMARDs)|bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
219303968|NCT02869100|OTHER|Blood sample|
219303969|NCT02869100|PROCEDURE|Sodium fluoride Positron Emission Tomography|
219303970|NCT02869100|OTHER|Magnetic Resonance Imaging|
219303971|NCT02869100|OTHER|Radiography|
219303972|NCT06728826|PROCEDURE|Posterior Pericardiotomy|The surgeon will perform a posterior pericardiotomy while the patient is on cardiopulmonary bypass. In detail, the surgeon will use cautery to make a 4- to 5-cm opening in pericardium between the left inferior pulmonary vein and the diaphragm. Then a soft channel drain will be placed through the posterior pericardium, the pericardiotomy and into the left pleural space.
219303973|NCT06727643|OTHER|trunk muscle strength|force that represents the endurance of the body.
219303974|NCT06727643|OTHER|Core Strength|back and abdominal muscle endurance
219303975|NCT06727643|OTHER|Balance|steady state
219303976|NCT06727981|DRUG|ICI plus Chemothearpy|This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.
219303977|NCT06727981|DRUG|Chemotherapy|This intervention involves the administration of standard chemotherapy alone.
219303978|NCT05978115|PROCEDURE|implant supported prosthesis|Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture
219303979|NCT06727916|BEHAVIORAL|BBT-I|Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care. Healthcare provider provided BBT-I to the patients.
219303980|NCT06727916|OTHER|Non BBT-I|Patients in the control group will receive standard care.
219303981|NCT06729307|DRUG|Oral ondansetron and dyclonine hydrochloride mucilage|Patients will take 8 mg oral ondansetron 2 hours prior to EGD process in addition to dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to EGD process.
219303982|NCT06729307|DRUG|Dyclonine hydrochloride mucilage|Patients will be instructed to gurgle 10 mL of dyclonine chloride mucilage (0.01 g/mL) and gurgle for 1 minute 15 minutes prior to endoscopic process.
219303983|NCT06727656|COMBINATION_PRODUCT|Nitrate + Hypoxia|The combined effect of nitrate supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
219303984|NCT06727656|DIETARY_SUPPLEMENT|Placebo + Hypoxia|The combined effect of placebo supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
219303985|NCT06727656|OTHER|Control|The combined effect of placebo supplementation and normoxia training on both performance and health at sea-level and altitude conditions.
219303986|NCT06728839|DRUG|1L PEG + 50g magnesium sulfate|Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.
219303987|NCT06728839|DRUG|3L PEG|Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
219303988|NCT06728839|DRUG|4L PEG|Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
219303989|NCT06729788|DRUG|ICON resin infiltration Material group in vivo|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK).
219303990|NCT06729788|DRUG|Resin-based fissure sealant group in vivo|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)
219303991|NCT06729788|DRUG|ICON resin infiltration in vitro|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK) in vitro
219303992|NCT06729788|DRUG|Resin-based fissure sealant in vitro|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael) in vitro
219303993|NCT05366426|OTHER|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
219303994|NCT05366426|OTHER|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
219303995|NCT05366426|OTHER|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
219303996|NCT06906432|DIAGNOSTIC_TEST|Multi-disciplinary assessment|Multi-disciplinary assessment including blood tests, CSF test, electrocardiograms, ultrasound, imaging, etc
219303997|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
219303998|NCT03887390|BEHAVIORAL|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
219303999|NCT03218748|BEHAVIORAL|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
219304000|NCT05598073|BEHAVIORAL|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
219304001|NCT05267340|BEHAVIORAL|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
219304002|NCT05267340|BEHAVIORAL|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
219304003|NCT01170611|DEVICE|PACEMAKER SYMPHONY 2550|
219304004|NCT02359682|OTHER|No intervention|No Intervention
219304005|NCT04731519|BEHAVIORAL|Continuous Identity Cognitive Therapy (CI-CT)|CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The recovery oriented CI-CT for post acute suicidal episode Veterans includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
219304006|NCT04731519|BEHAVIORAL|General Health Education|General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
219304007|NCT05746208|DRUG|Lenvatinib|Given orally
219304008|NCT05746208|DRUG|Pembrolizumab|Given IV
219304009|NCT05746208|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
219304010|NCT05027594|DRUG|NMS-03597812|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
219304011|NCT05027594|DRUG|NMS-03597812 + dexamethasone|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
219304012|NCT06032832|OTHER|soy protein concentrate-meat analog|Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate
219304013|NCT06032832|OTHER|soy protein concentrate-meat analog_dephytinization|Baked dephytinized\_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate
219304014|NCT06032832|OTHER|pork meat|Meals made with minced pork meat labelled with 57Fe.
219304015|NCT00346268|DRUG|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
219304016|NCT00346268|DRUG|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
219304017|NCT01548079|DRUG|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
219304018|NCT01149356|DRUG|Exemestane|Given orally
219304019|NCT01149356|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
219304020|NCT01149356|DRUG|Goserelin Acetate|Given subcutaneously to premenopausal patients
219304021|NCT03368469|DEVICE|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
219304022|NCT05428761|OTHER|TP1|Participants will receive TP1 during one experimental visit.
219304023|NCT05428761|OTHER|TP2|Participants will receive TP2 during one experimental visit.
219304024|NCT05428761|OTHER|Placebo|Participants will receive placebo during one experimental visit.
219304025|NCT05257031|DRUG|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
219304026|NCT01681056|BEHAVIORAL|Autosuggestion for 30 days|
219304027|NCT01588834|PROCEDURE|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
219304028|NCT02972463|DIETARY_SUPPLEMENT|Immunoglobulin Y|
219304029|NCT02972463|OTHER|Placebo|
219304030|NCT03996499|DIAGNOSTIC_TEST|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
219304031|NCT00195858|BEHAVIORAL|aerobic and resistance exercise|aerobic and resistance exercise
219304032|NCT01592500|DRUG|MOD-4023|Once weekly subcutaneous injection
219304033|NCT01592500|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin
219304034|NCT02157922|DRUG|alginate oligosaccharide|Inhalation
219304035|NCT04832425|DRUG|PRAX-114|40 mg once daily
219304036|NCT04832425|DRUG|Placebo|Placebo once daily
219304037|NCT02502097|DRUG|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
219304038|NCT02502097|OTHER|Placebo|Matching placebo to gefapixant, tablet administered by mouth
219304039|NCT00567710|DRUG|BL - 1020|10 mg/day
219304040|NCT00567710|DRUG|BL - 1020|BL 1020 20-30 mg/day
219304041|NCT00567710|DRUG|Placebo|Capsules
219304042|NCT00567710|DRUG|Risperidone|Capsules
219304043|NCT02186223|DEVICE|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
219304044|NCT01201317|DRUG|AZD2423|20 mg tablet
219304045|NCT01201317|DRUG|AZD2423|150 mg tablet
219304046|NCT01201317|DRUG|Placebo|Placebo
219304047|NCT02293148|DRUG|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
219304048|NCT02293148|DRUG|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
219304049|NCT02293148|DRUG|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
219304050|NCT02293148|DRUG|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
219304051|NCT02293148|DRUG|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
219304052|NCT05283486|DRUG|MYMD-1 600MG|Cohort 1: 600mg drug
219304053|NCT05283486|DRUG|MYMD-1 750mg|Cohort 2: 750mg drug
219304054|NCT05283486|DRUG|MYMD-1 900mg|Cohort 3: 900mg drug
219304055|NCT05283486|DRUG|MYMD-1 1050mg|Cohort 4: 1050mg drug
219304056|NCT05283486|DRUG|placebo 600mg|Cohort 1: 600mg placebo
219304057|NCT05283486|DRUG|placebo 750mg|Cohort 2: 750mg placebo
219304058|NCT05283486|DRUG|placebo 900mg|Cohort 3: 900mg placebo
219304059|NCT05283486|DRUG|placebo 1050mg|Cohort 4: 1050mg placebo
219304060|NCT04238065|DEVICE|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
219304061|NCT04238065|DEVICE|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
219304062|NCT04238065|DEVICE|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
219304063|NCT00252733|DRUG|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
219304064|NCT00004660|RADIATION|Radiotherapy|
219304065|NCT00004660|RADIATION|Sham treatment|
219304066|NCT01874301|OTHER|High quantity probiotic|The intervention type is food product
219304067|NCT01874301|OTHER|Low quantity probiotic|The intervention type is food product
219304068|NCT01874301|OTHER|placebo|
219304069|NCT00666523|DIETARY_SUPPLEMENT|phytalgic|3/day
219304070|NCT00666523|DIETARY_SUPPLEMENT|placebo|3/Day
219304071|NCT02738736|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
219304072|NCT00128076|PROCEDURE|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
219304073|NCT00128076|PROCEDURE|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
219304074|NCT01491672|DRUG|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
219304075|NCT06108882|OTHER|Experimental: Manual Ischemic Compression with Strain Counter Strain technique|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
219304076|NCT06108882|OTHER|Active Comparator: Manual Ischemic Compression|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
219304077|NCT02550470|DEVICE|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
219304078|NCT02550470|DEVICE|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
219304079|NCT02550470|DRUG|Sevoflurane|
219304080|NCT03244085|DRUG|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
219304081|NCT06176677|DEVICE|Videolaryngoscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
219304082|NCT06176677|DEVICE|Boroscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
219304083|NCT05680064|BEHAVIORAL|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
219304084|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
219304085|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
219304086|NCT04657419|OTHER|survey|"Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID"
219304087|NCT04130529|BEHAVIORAL|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
219304088|NCT04130529|OTHER|Sleep lectures|Lectures on the topic of sleep.
219304089|NCT01902056|PROCEDURE|One layer allograft|The acellular dermal matrix was placed on the facial surface.
219304090|NCT01902056|PROCEDURE|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
219304091|NCT01690312|DIETARY_SUPPLEMENT|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].
219304092|NCT01690312|DIETARY_SUPPLEMENT|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
219304093|NCT03575767|OTHER|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
219304094|NCT03939455|OTHER|Mobile Augmented Screening tool|Tablet-based intervention
219304095|NCT03507374|DRUG|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
219304096|NCT03507374|DRUG|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
219304097|NCT01669304|DRUG|Verapamil|
219304098|NCT01669304|DRUG|Sertraline|
219304099|NCT06115551|COMBINATION_PRODUCT|Fasting Mimicking Diet|FMD is a 5-day low calorie fasting-mimicking diet.
219304100|NCT00473941|BEHAVIORAL|Expressive writing|Behavioral intervention using writing about cancer to improve quality of life outcomes
219304101|NCT02564354|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
219304102|NCT00679237|BEHAVIORAL|smoking cessation|NRT and varenicline
219304103|NCT00679237|DRUG|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
219304104|NCT00679237|DRUG|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
219304105|NCT00679237|BEHAVIORAL|training|daily walking
219304106|NCT00679237|BIOLOGICAL|influenza vaccine|vaccine (FLuarix, Influvac etc)
219304107|NCT00679237|DRUG|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
219304108|NCT00679237|BEHAVIORAL|weight reduction|diet tips
219304109|NCT06071273|OTHER|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
219304110|NCT06071273|OTHER|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
219304111|NCT06300385|DEVICE|Electromyostimulation|Electromyostimulation (EMS), a low-frequency current, will be used for electrical stimulation of the wrist flexor muscle group. Stimulation frequency will be applied as 25 Hertz. Care will be taken to ensure that the current intensity does not cause pain in the patient. The size of the EMS electrodes is 2 cm2 and they will be placed in the form of 4 electrodes on the wrist flexor muscles (inner wrist area) with a distance of 1 cm between them. Each strengthening session will be 15 minutes for 6 weeks, 3 days a week, for a total of 18 sessions. EMS application will be carried out together with strengthening exercises. Laica MD6078 branded device belonging to the researchers will be used.
219304112|NCT06300385|OTHER|Strengthening exercises|All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.
219304113|NCT05273853|PROCEDURE|Partial Adenoidectomy|Partial removal of adenoid
219304114|NCT02146651|DRUG|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
219304115|NCT02146651|DRUG|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
219304116|NCT02146651|DRUG|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
219304117|NCT02146651|DRUG|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
219304118|NCT00706433|DRUG|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
219304119|NCT00706433|OTHER|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
219304120|NCT06026228|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit"
219744668|NCT05698498|OTHER|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
219304121|NCT06026228|OTHER|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
219304122|NCT01782118|DIETARY_SUPPLEMENT|Lactobacillus GG|
219304123|NCT04450017|DIAGNOSTIC_TEST|The demographic, clinical, laboratory, and instrumental data|Measurement of the demographic, clinical data, laboratory data, and instrumental data
219304124|NCT04743310|DRUG|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
219304125|NCT04743310|DEVICE|Canvas imaging system|imaging device attached to surgical microscope
219304126|NCT04743310|PROCEDURE|Surgical resection of tumor|Standard of care surgical resection of tumor
219304127|NCT02698605|DEVICE|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
219304128|NCT01850732|OTHER|Ultrasound of aorta|
219304129|NCT05288153|DRUG|Metformin|Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
219304130|NCT05288153|DRUG|Folate|Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
219304131|NCT05867316|BEHAVIORAL|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
219304132|NCT04300998|BEHAVIORAL|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
219304133|NCT04300998|BEHAVIORAL|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
219304134|NCT04300998|BEHAVIORAL|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
219304135|NCT04300998|BEHAVIORAL|Cognition|Mini-Cognition test: CDT and 3-word recall
219304136|NCT04300998|BEHAVIORAL|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
219304137|NCT04300998|BEHAVIORAL|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
219304138|NCT04300998|BEHAVIORAL|Brief Test of Attention|assess selective auditory attention.
219304139|NCT04300998|BEHAVIORAL|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
219304140|NCT04300998|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency
219304141|NCT04300998|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
219304142|NCT04300998|OTHER|Blood draw|collection of blood tests
219304143|NCT01236365|DRUG|Atorvastatin|10 or 20 mg daily
219304144|NCT01236365|DRUG|Atorvastatin Placebo|10 or 20 mg daily
219304145|NCT06079125|PROCEDURE|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
219304146|NCT06079125|PROCEDURE|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
219304147|NCT04415723|OTHER|supportive care management programme|nurse-led management programme
219304148|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
219304149|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
219304150|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
219304151|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
219304152|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
219304153|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
219304154|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
219304155|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
219304156|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
219304157|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
219304158|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
219304159|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
219304160|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
219304161|NCT03489473|DIAGNOSTIC_TEST|18F-FES PET CT scan|PET CT scan with estrogen tracer
219304162|NCT00898898|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
219304163|NCT04751708|PROCEDURE|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
219304164|NCT04751708|OTHER|best medical management|best medical management
219304165|NCT03060460|DIAGNOSTIC_TEST|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
219304166|NCT00166426|DRUG|Exisulind|
219304167|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
219304168|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
219304169|NCT01689337|DRUG|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
219304170|NCT01638234|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
219304171|NCT01638234|DIETARY_SUPPLEMENT|Placebo|starch pill
219304172|NCT05306405|DRUG|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
219304173|NCT05323201|BIOLOGICAL|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.
219304174|NCT05323201|DRUG|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)
219304175|NCT05323201|DRUG|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
219304176|NCT02742259|DEVICE|Blood Draw|Blood draws only - non-diagnostic, non-treatment
219304177|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
219304178|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
219304179|NCT02184650|OTHER|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
219304180|NCT00003382|BIOLOGICAL|filgrastim|
219304181|NCT00003382|DRUG|gemcitabine hydrochloride|
219304182|NCT00003382|DRUG|topotecan hydrochloride|
219304183|NCT02314182|PROCEDURE|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~* Within 3 weeks after randomization~* Immunonutrition given 7 days prior to PT resection~* Mechanical bowel preparation performed before surgery according to the local practices~* Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~* Must be performed within 4 weeks after surgery~* CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~* Within 4 weeks after the surgery~* Chemotherapy administered according to the usual scheme for the chosen protocol~* All validated and/or registered perioperative rectal cancer treatments authorized~* The duration of one treatment cycle depending on the type of treatment administered~* Radiotherapy is allowed after randomization if indicated"
219304184|NCT02314182|DRUG|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
219304185|NCT00559702|DRUG|natalizumab|natalizumab
219304186|NCT00559702|OTHER|standard of care|standard of care as determined by the Investigator and Treating Neurologist
219304187|NCT03856554|PROCEDURE|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
219304188|NCT03856554|PROCEDURE|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
219304189|NCT02952378|DRUG|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
219304190|NCT02070003|BEHAVIORAL|Motivational Interviewing and Physician Guided Opioid Weaning|
219304191|NCT02842606|OTHER|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
219304192|NCT06355193|DRUG|Langenlianqiao|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
219304193|NCT06355193|DRUG|LianhuaQingWen|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
219304194|NCT06355193|OTHER|placebo control group|placebo control group
219304195|NCT06323577|PROCEDURE|Restricted kinematic alignment|TKA using restricted kinematic alignment under robotic assisted surgery (MAKO).
219304196|NCT06323577|PROCEDURE|Mechanical alignment|TKA using mechanical alignment under robotic assisted surgery (MAKO).
219304197|NCT02877979|DRUG|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
219304198|NCT02877979|DRUG|Placebo|
219304199|NCT00824161|DRUG|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
219304200|NCT00199940|DRUG|Ziprasidone|
219304201|NCT05603130|OTHER|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
219304202|NCT02125708|DEVICE|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
219304203|NCT04575506|OTHER|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
219304204|NCT05023421|OTHER|no intervention|no intervention
219304205|NCT00004468|DRUG|calcitriol|
219304206|NCT05757284|DIAGNOSTIC_TEST|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
219304207|NCT04491669|DIAGNOSTIC_TEST|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~* Stage1 in which GFR\>90 mil/min but evidence of kidney damage.~* Stage 2 GFR 60-89 mil/min.~* Stage 3 GFR 30-95 mil/min.~* Stage 4 GFR 15-29 mil/min.~* Stage 5 GFR\<15 mil/min."
219304208|NCT05314790|OTHER|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
219304209|NCT03720873|DRUG|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
219304210|NCT03720873|DRUG|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
219304211|NCT00003849|BIOLOGICAL|rituximab|
219304212|NCT02551406|DEVICE|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
219304213|NCT03058835|DRUG|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
219304214|NCT04100668|DEVICE|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
219304215|NCT04100668|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
219304216|NCT04100668|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
219304217|NCT04882995|DIETARY_SUPPLEMENT|Psyillium fiber|Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
219304218|NCT04361188|PROCEDURE|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
219304219|NCT04361188|PROCEDURE|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
219304220|NCT00580242|DRUG|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
219304221|NCT00580242|DRUG|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
219304222|NCT00580242|DRUG|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
219304223|NCT00580242|DRUG|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
219304224|NCT01218893|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
219304225|NCT01218893|BIOLOGICAL|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
219304226|NCT01218893|BIOLOGICAL|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
219304227|NCT01218893|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
219304228|NCT05333679|DEVICE|UTRA|Collect urine on intervention participants and screen for presence of TFV.
219304229|NCT05333679|BEHAVIORAL|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
219304230|NCT04443101|OTHER|different types of intracular lens|different types of intracular lens
219304231|NCT02572882|DIETARY_SUPPLEMENT|p-inulin|12 week self-administered treatment phase
219304232|NCT00014131|BIOLOGICAL|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
219304233|NCT02802826|BEHAVIORAL|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
219304234|NCT02418676|DRUG|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
219304235|NCT02418676|DRUG|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
219304236|NCT02418676|DRUG|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
219304237|NCT04371198|OTHER|Biopsy|Tissue biopsy
219304238|NCT01604629|DRUG|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
219304239|NCT01604629|DRUG|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
219304240|NCT04845243|BEHAVIORAL|Emotionen Verstehen und Ausdrücken (E.V.A.)|The online training is focused on the strengthening of socioemotional competences and consists of different training tasks (up to 3 million) presented to the participant as mini games. These training tasks are specifically designed according to empirical findings to match the socio-emotional recognition needs of people with ASD. During these games, an adapted Elo-Algorithm allows to automatically evaluate the participants' performance and adapts the difficulty levels throughout the users' progress in the training.
219304241|NCT03536143|BIOLOGICAL|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
219304242|NCT03536143|BIOLOGICAL|Placebo gel|Placebo gel
219304243|NCT04754477|DEVICE|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
219304244|NCT04342793|DRUG|Placebo oral tablet|Placebo
219304245|NCT04342793|DRUG|ALS-L1023 1,200mg|ALS-L1023
219304246|NCT04342793|DRUG|ALS-L1023 1,800mg|ALS-L1023
219304247|NCT01347762|DRUG|Nabilone|nabilone titrated to 1 mg by mouth twice daily
219304248|NCT01347762|DRUG|Placebo|one placebo capsule by mouth twice daily
219304249|NCT00657670|DEVICE|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
219304250|NCT00657670|DEVICE|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
219304251|NCT02621320|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
219304252|NCT02621320|DIETARY_SUPPLEMENT|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
219304253|NCT03879837|DRUG|Fluticasone propionate pressurized metered dose inhaler|110 mcg per actuation
219304254|NCT03879837|DRUG|Flovent HFA pressurized metered dose inhaler|110 mcg per actuation
219304255|NCT03879837|DRUG|Placebo pressurized metered dose inhaler|no active content
219304256|NCT06069674|DIAGNOSTIC_TEST|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
219304257|NCT02927860|OTHER|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
219304258|NCT03406260|DRUG|Lasmiditan|Administered orally.
219304259|NCT03406260|DRUG|Placebo|Administered orally.
219304260|NCT00398736|PROCEDURE|sonographic measurement of inferior caval vein diameter|
219304261|NCT00871780|DRUG|BG00002 (natalizumab)|
219304262|NCT02799953|DEVICE|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
219304263|NCT04061538|DIETARY_SUPPLEMENT|zinc sulfate|zinc 20mg tablets
219304264|NCT04061538|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
219304265|NCT06463925|OTHER|acneic participants group|Application of Effaclar Duo+M to the face and trunk twice daily (morning and evening) after washing with the cleansing gel.
219304266|NCT02593409|DRUG|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
219304267|NCT00407212|DRUG|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
219304268|NCT01814202|OTHER|PTM202|
219304269|NCT01814202|OTHER|Placebo|
219304270|NCT03064386|PROCEDURE|Plate fixation|internal fixation with the plate
219304271|NCT03064386|PROCEDURE|Screw fixation|internal fixation with the screw
219304272|NCT04600232|DIAGNOSTIC_TEST|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
219304273|NCT00701220|DRUG|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
219304274|NCT03965325|OTHER|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
219304275|NCT03235284|OTHER|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
219304276|NCT03235284|OTHER|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
219304277|NCT03235284|OTHER|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
219304278|NCT03428737|PROCEDURE|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
219304279|NCT03428737|PROCEDURE|Pressure support ventilation|use of a pressure support level identical during the night to the pressure support level at the end of the day.
219304280|NCT00214838|DRUG|Atiprimod|
219304281|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
219304282|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
219304283|NCT00221169|PROCEDURE|Surgical resection|pet ct prior to surgery
219304284|NCT01333163|BIOLOGICAL|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
219304285|NCT01333163|BIOLOGICAL|Isotone NaCl|2 hours IV infusion.
219304286|NCT02769546|OTHER|Surveys|
219304287|NCT01746680|DRUG|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
219304288|NCT03354806|PROCEDURE|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
219304289|NCT03354806|PROCEDURE|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
219304290|NCT02873143|OTHER|No intervention|No intervention
219304291|NCT05467397|DRUG|[11C]acetate|Positron Emission Tomography (PET)
219304292|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
219304293|NCT01589666|DRUG|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
219304294|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
219304295|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
219304296|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
219304297|NCT04599400|OTHER|There is no intervention in our study|There is no intervention in our study
219304298|NCT04370977|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
219304299|NCT04370977|DRUG|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
219304300|NCT02467218|OTHER|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
219304301|NCT03539341|BEHAVIORAL|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
219304302|NCT03539341|OTHER|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
219304303|NCT00156884|DRUG|strontium-89|
219304304|NCT00156884|DRUG|cisplatin|
219304305|NCT00402038|DRUG|SC Methylnaltrexone|Dose 1
219304306|NCT00402038|DRUG|SC Placebo|
219304307|NCT00440999|DRUG|Pyronaridine artesunate|
219304308|NCT00440999|DRUG|Chloroquine|
219304309|NCT05963490|DRUG|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
219304310|NCT05963490|DRUG|Toripalimab|240 mg intravenously every 3 weeks
219304311|NCT05963490|RADIATION|Radiotherapy|hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).
219304312|NCT05963490|DRUG|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
219304313|NCT02428764|DRUG|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
219304314|NCT02428764|DRUG|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
219304315|NCT02428764|DRUG|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
219304316|NCT02428764|PROCEDURE|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
219304317|NCT05019378|PROCEDURE|SVF treatment|autologous SVF (10E8 cells)
219304318|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
219304319|NCT06498544|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 nights at an altitude of 3600 m.
219304320|NCT00509678|DRUG|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
219304321|NCT01795664|RADIATION|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
219304322|NCT01795664|DRUG|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
219304323|NCT01795664|DRUG|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
219304324|NCT01795664|DRUG|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
219304325|NCT01795664|DRUG|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
219304326|NCT03259451|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
219304327|NCT04090255|PROCEDURE|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
219304328|NCT05041101|DRUG|Eribulin Mesylate|Given IV
219304329|NCT05041101|DRUG|Grapiprant|Given PO
219304330|NCT01568853|DRUG|Norepinephrine|Intravenously, 10 ug/min, 24 hours
219304331|NCT01568853|PROCEDURE|Open abdomen|IAH \>=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
219304332|NCT01568853|OTHER|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
219304333|NCT01568853|OTHER|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
219304334|NCT01205152|BIOLOGICAL|asfotase alfa|
219304335|NCT05726630|DRUG|Divozilimab|anti CD20 monoclonal antibody
219304336|NCT05726630|DRUG|Placebo|Placebo
219304337|NCT04924543|OTHER|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
219304338|NCT04924543|OTHER|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
219304339|NCT02802254|BEHAVIORAL|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
219304340|NCT02802254|DEVICE|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
219304341|NCT02667197|OTHER|Algorithm to determine overdose from opioid abuse|
219304342|NCT00249002|DRUG|ABI-007|
219304343|NCT02502123|OTHER|No Intervention|No intervention was administered in this study.
219304344|NCT05730062|DRUG|Oxycodone Hydrochloride|Oxycodone 10 mg IR
219304345|NCT05730062|DRUG|Placebo|placebo comparator
219304346|NCT03768583|OTHER|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
219304347|NCT03768583|OTHER|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
219304348|NCT03768583|OTHER|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
219304349|NCT03768583|OTHER|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
219304350|NCT02873091|PROCEDURE|Epidural analgesia|
219304351|NCT02873091|PROCEDURE|Continuous epidural infusion|
219304352|NCT02873091|PROCEDURE|Intermittent epidural bolus|
219304353|NCT02873091|DRUG|ropivacaine|
219304354|NCT02873091|DRUG|sufentanil|
219304355|NCT05126758|BIOLOGICAL|Deramiocel (CAP-1002)|Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
219304356|NCT05126758|BIOLOGICAL|Placebo|Placebo
219304357|NCT00116337|PROCEDURE|Spinal Cord Stimulation to restore cough|Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
219304358|NCT00116337|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
219304359|NCT05379660|DEVICE|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 \~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
219304360|NCT00319839|DRUG|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
219304361|NCT00319839|DRUG|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
219304362|NCT03287531|OTHER|conventional therapy|Exercise therapeutic Ultrasound
219304363|NCT03287531|OTHER|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
219304364|NCT02814201|BEHAVIORAL|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
219304365|NCT03017300|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
219304366|NCT03017300|DEVICE|PFLEX®|A device used to offer resisive to inspiratory muscle
219304367|NCT04694443|PROCEDURE|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
219304368|NCT04694443|OTHER|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
219304369|NCT02847247|DRUG|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
219304370|NCT05973435|OTHER|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
219304371|NCT05279001|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
219304372|NCT04894487|BEHAVIORAL|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
219304373|NCT06414694|PROCEDURE|Direct Oral Challenge|Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose
219304374|NCT02285465|DRUG|ASP3700|Oral
219304375|NCT02285465|DRUG|Placebo|Oral
219304376|NCT04086654|DIAGNOSTIC_TEST|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
219304377|NCT04256577|DIAGNOSTIC_TEST|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
219304378|NCT00361010|DRUG|Levetiracetam|
219304379|NCT01577745|BIOLOGICAL|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
219304380|NCT03553680|BEHAVIORAL|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
219304381|NCT04315051|DRUG|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
219304382|NCT04315051|OTHER|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
219304383|NCT05574491|BEHAVIORAL|Super Skills for Life: traditional version|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández."
219304384|NCT05574491|BEHAVIORAL|Super Skills for Life: computerized version|Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
219304385|NCT02483585|DRUG|Erenumab|Administered once a month by subcutaneous injection
219304386|NCT02483585|DRUG|Placebo|Administered once a month by subcutaneous injection
219304387|NCT06336954|DRUG|Adibelimab|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)
219304388|NCT01485055|DRUG|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
219304389|NCT04891822|PROCEDURE|ERAS protocol|E: ERAS protocol C: control
219304390|NCT02963103|DRUG|Tacrolimus|Oral
219304391|NCT02910154|DIETARY_SUPPLEMENT|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
219304392|NCT02910154|BEHAVIORAL|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
219304393|NCT02910154|DRUG|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
219304394|NCT00912301|DRUG|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
219304395|NCT00912301|OTHER|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
219304396|NCT05175638|GENETIC|Gene Expression|the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.
219304397|NCT01759576|DRUG|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
219304398|NCT01324440|BIOLOGICAL|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
219304399|NCT01324440|BIOLOGICAL|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
219304400|NCT03404141|OTHER|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
219304401|NCT03404141|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
219304402|NCT00903630|DRUG|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
219304403|NCT00903630|DRUG|liposomal doxorubicin|administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
219304404|NCT04076839|BEHAVIORAL|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
219304405|NCT00464607|DRUG|hMG-IBSA|
219304406|NCT00464607|PROCEDURE|Ovarian stimulation|
219304407|NCT03154060|DEVICE|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
219304408|NCT02325557|DRUG|ADXS31-142|ADXS31-142 IV infusion
219304409|NCT02325557|DRUG|Pembrolizumab|Pembrolizumab IV infusion
219304410|NCT02534038|DRUG|AVP-786|d6-DM/Q
219304411|NCT02534038|DRUG|Placebo|matching placebo
219304412|NCT01038063|DRUG|Artemether-lumefantrine combination|
219304413|NCT03952429|BEHAVIORAL|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
219304414|NCT03952429|BEHAVIORAL|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
219304415|NCT00055523|DRUG|Adalimumab (D2E7)|
219304416|NCT03869723|PROCEDURE|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
219304417|NCT03869723|PROCEDURE|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
219304418|NCT00000263|DRUG|30% Nitrous oxide|
219304419|NCT00000263|OTHER|0.25 g/Kg ethanol|
219304420|NCT00000263|OTHER|0.5 g/KG ethanol|
219304421|NCT00000263|OTHER|0 g/Kg ethanol|
219304422|NCT00277706|PROCEDURE|Periodontal surgery|
219304423|NCT00277706|DRUG|FORTEO|parathyroid hormone; self-administration for 6 weeks
219304424|NCT00277706|DRUG|Placebo|placebo; self administration for 6 weeks
219304425|NCT00277706|DIETARY_SUPPLEMENT|Vitamin D and Calcium|PO, QD, for six weeks
219304426|NCT04658082|DEVICE|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
219304427|NCT01136772|DRUG|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
219304428|NCT01136772|DRUG|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
219304429|NCT05336331|PROCEDURE|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
219304430|NCT03741569|DEVICE|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
219304431|NCT03622554|OTHER|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
219304432|NCT03622554|OTHER|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
219304433|NCT02202005|DRUG|Nevirapine|Nevirapine 400mg PR tablet
219304434|NCT02202005|DRUG|Viramune®|Viramune® 400 mg Retardtabletten
219304435|NCT00502827|BEHAVIORAL|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
219304436|NCT00502827|OTHER|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
219304437|NCT01340820|DRUG|AERAS-422|rBCG
219304438|NCT01340820|DRUG|BCG Tice|1-8 x 10\^5 CFU
219304439|NCT00828880|DEVICE|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
219304440|NCT02288533|DEVICE|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
219304441|NCT01959516|DRUG|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
219304442|NCT01959516|DRUG|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
219304443|NCT01959516|DRUG|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
219304444|NCT01959516|DRUG|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
219304445|NCT03322787|DEVICE|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
219304446|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
219304447|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
219304448|NCT04129918|BEHAVIORAL|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
219304449|NCT04417374|OTHER|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
219304450|NCT03812497|BEHAVIORAL|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
219304451|NCT00669799|DRUG|gentamyacin|topical internasal
219304452|NCT00669799|DRUG|gentamyacin|intranasal
219304453|NCT00553956|BEHAVIORAL|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
219304454|NCT00144651|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
219304455|NCT06394440|COMBINATION_PRODUCT|Self-Adhesive Bulkfill Composite (Surefil One)|It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
219304456|NCT00928746|DEVICE|Ipratropium bromide|
219304457|NCT04065009|DRUG|Ropivacaine|Experimental drug will be administered intraperitoneally
219304458|NCT04065009|DRUG|Saline Solution|Placebo will be administered intraperitoneally
219304459|NCT05736991|DIAGNOSTIC_TEST|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
219304460|NCT02993484|DRUG|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
219304461|NCT02993484|BIOLOGICAL|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
219304462|NCT02993484|OTHER|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
219304463|NCT02993484|OTHER|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
219304464|NCT02711618|DEVICE|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
219304465|NCT04460677|BEHAVIORAL|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
219304466|NCT04460677|BEHAVIORAL|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
219304467|NCT05729880|DIAGNOSTIC_TEST|MRI, MRS|Scan of right calf and thigh
219304468|NCT05729880|DIAGNOSTIC_TEST|Ultrasound|Scan of right calf and thigh
219304469|NCT00523042|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
219304470|NCT00523042|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
219304471|NCT02475174|OTHER|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
219304472|NCT02475174|OTHER|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
219304473|NCT03559998|OTHER|lecture|"* Empathy (1 hour)~* Doctor- patient relationship (1, 5 hour)"
219304474|NCT03559998|OTHER|Simulation using Role play|"* serious illness announcement~* abuse demand management~* reticent patient management"
219304475|NCT03559998|OTHER|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
219304476|NCT03559998|OTHER|Simulation using Simulated patient|"* HIV announcement~* Refuse of antibiotic prescription"
219304477|NCT06475872|DRUG|Crecheck Tablet 2.5 mg|2 tablets orally once a day
219304478|NCT06475872|DRUG|Crestor Tablet 5 mg|1 tablet orally once a day
219304479|NCT04217928|PROCEDURE|Arthroscopic Debridement|Arthroscopic debridement will be performed under portal site local anaesthesia.
219304480|NCT04217928|PROCEDURE|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
219304481|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Newborns (Aged 1-7 Days)|Neonatal blood samples will be taken from healthy infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards.
219304482|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8 Days - 7 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
219304483|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8-18 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
219304484|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk Newborns (Aged 1-7 Days)|Blood samples will be taken from high-risk infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers.
219304485|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 Days- 7 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
219304486|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 - 18 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
219304487|NCT00001024|DRUG|Zidovudine|
219304488|NCT00001024|DRUG|Didanosine|
219304489|NCT02825862|BEHAVIORAL|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
219304490|NCT02825862|BEHAVIORAL|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
219304491|NCT02955147|DRUG|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
219304492|NCT02955147|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
219304493|NCT06441500|OTHER|Daily tooth brushing programme|Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
219304494|NCT01969370|BEHAVIORAL|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
219304495|NCT05597462|DRUG|Minocycline hydrochloride capsules|Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
219304496|NCT05597462|OTHER|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
219304497|NCT06437587|OTHER|Home-based rehabilitation appropriate technology (S-HRAT) training|The S-HRAT training instruction consists of two phases: in-hospital training and post-discharge remote home training. Based on the S-HRAT list, we select individualized home rehabilitation training exercises for the participants and conduct five offline training instruction sessions one week before discharge to ensure that the participants master the correct method for each exercise and clarify precautions. At discharge, participants will receive an S-HRAT brochures, which will include detailed text, pictures and video demonstrations of exercises, to visualize the rehabilitation instructions and make them easy to understand. Participants learn how to use the S-HRAT booklet and follow a daily training program to complete the prescribed content. They will be asked to record a video of their training and send it to the researcher via WeChat for monitoring purposes and feedback.
219304498|NCT04129216|DRUG|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
219304499|NCT04129216|DRUG|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
219304500|NCT04129216|DRUG|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
219304501|NCT04129216|DIAGNOSTIC_TEST|Blueprint|studies the genomics of the tumor and tumor behavior
219304502|NCT04129216|DIAGNOSTIC_TEST|Mammaprint|studies the genomics of the tumor
219304503|NCT01477554|OTHER|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
219304504|NCT02835300|BEHAVIORAL|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
219304505|NCT02835300|BEHAVIORAL|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
219304506|NCT01181427|DRUG|ABT-267|See arm description
219304507|NCT01181427|DRUG|Placebo|See arms description
219304508|NCT01181427|PROCEDURE|Blood Sample Collection|See arm description
219304509|NCT01181427|DRUG|Cytochrome P450 inhibitor|See arm description
219304510|NCT06119672|DRUG|Probiotic Blend Oral capsules|probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
219304511|NCT06119672|DRUG|Corticosteroids for Local Oral Treatment|topical clobetasol probionate in orabase application 4 times daily
219304512|NCT02004353|DEVICE|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
219304513|NCT02581631|BIOLOGICAL|Nivolumab|
219304514|NCT02581631|DRUG|Brentuximab Vedotin|
219304515|NCT01690598|DRUG|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
219304516|NCT01690598|DRUG|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
219304517|NCT04580576|PROCEDURE|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
219304518|NCT00898027|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219304519|NCT00819390|DRUG|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
219304520|NCT00819390|DRUG|Placebo|Taken orally, once daily for 12 weeks.
219304521|NCT01651442|BEHAVIORAL|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
219304522|NCT01651442|DRUG|Zolpidem|5mg or 10mg
219304523|NCT01651442|DRUG|Trazodone|50mg to 150mg
219304524|NCT01651442|BEHAVIORAL|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
219304525|NCT06199674|DEVICE|photobiomodulation therapy|Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
219304526|NCT06199674|OTHER|orthodontic fixed-appliance|All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
219304527|NCT01845909|OTHER|ECG and survey screening|
219304528|NCT04768374|OTHER|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
219304529|NCT04768374|OTHER|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
219304530|NCT05054153|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
219304531|NCT05054153|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
219304532|NCT05054153|OTHER|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
219304533|NCT05692479|OTHER|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
219304534|NCT04448197|OTHER|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
219304535|NCT03735212|BEHAVIORAL|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
219304536|NCT03554668|DIAGNOSTIC_TEST|Blood draw|We take blood samples at pre-op and subsequent time points, up to three months post op.
219304537|NCT00669448|BEHAVIORAL|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
219304538|NCT04651075|OTHER|music listening|The music selected by the participants was played to the music listening group.
219304539|NCT04651075|OTHER|individual training|Individual training group was trained on coronary angiography.
219304540|NCT00479492|DRUG|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
219304541|NCT00479492|DRUG|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
219304542|NCT00479492|DRUG|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
219304543|NCT00479492|DRUG|placebo|placebo administered QD for 84 days
219304544|NCT05664867|OTHER|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
219304545|NCT05664867|OTHER|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
219304546|NCT00617474|DRUG|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
219304547|NCT00617474|DRUG|Placebo|placebo
219304548|NCT01762891|DRUG|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
219304549|NCT01762891|DRUG|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
219304550|NCT01762891|DRUG|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
219304551|NCT01762891|DRUG|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
219304552|NCT02733393|PROCEDURE|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
219304553|NCT02733393|DRUG|lidocaine|
219304554|NCT00334035|DRUG|Quetiapine|
219304555|NCT05205915|DEVICE|tDCS intervention applied by Starstim device|Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
219304556|NCT03861377|DRUG|Remifentanil R2|0,7 microg/kg
219304557|NCT03861377|DRUG|Remifentanil R4|1,1 microg/kg
219304558|NCT03861377|DRUG|Remifentanil R8|1,7 microg/kg
219304559|NCT04490187|BEHAVIORAL|Motor Learning|"Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995)."
219304560|NCT05522621|DRUG|TJAOA102|Once enrolled, participants will be administrated TJAOA102
219304561|NCT00461136|DRUG|Aliskiren|
219304562|NCT02805881|DEVICE|Neurolief system|Non-invasive cephalic neurostimulation device
219304563|NCT03139110|BEHAVIORAL|Presence of a mediator in the emergency departments|"The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
219304564|NCT01771120|OTHER|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
219304565|NCT00002209|DRUG|CPI-1189|
219304566|NCT00482560|DRUG|Sucrose solution 30%1 ml|
219304567|NCT00482560|BEHAVIORAL|Breastfeeding|
219304568|NCT02912676|DRUG|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
219304569|NCT01270971|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
219304570|NCT01270971|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
219304571|NCT02539953|DEVICE|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
219304572|NCT01958970|DRUG|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
219304573|NCT01958970|DRUG|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
219304574|NCT04524325|OTHER|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
219304575|NCT00690118|DRUG|pioglitazone|45 mg/day, 18 months
219304576|NCT00690118|DRUG|placebo|once daily, 18 months
219304577|NCT03159533|BEHAVIORAL|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
219304578|NCT03159533|BEHAVIORAL|Wait List Control Group|4 education sessions beginning 6-12 months later.
219304579|NCT06115447|PROCEDURE|lung suturing with polyglactin|lung suturing with polyglactin
219304580|NCT06115447|PROCEDURE|ung suturing with polypropylene|ung suturing with polypropylene
219304581|NCT04654065|DRUG|IN-C004|One time dose of IN-C004 taken orally.
219304582|NCT03178929|DRUG|S-Adenosyl Methionine|2000mg, po
219304583|NCT03667976|BEHAVIORAL|SATHI|see above
219304584|NCT02518126|OTHER|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
219304585|NCT01445587|DRUG|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
219304586|NCT01445587|DRUG|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
219304587|NCT01445587|DRUG|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
219304588|NCT01445587|DRUG|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
219304589|NCT03814772|PROCEDURE|Liver transplant|blood transfusion
219304590|NCT03107234|OTHER|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
219304591|NCT02908919|PROCEDURE|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
219304592|NCT03324451|BEHAVIORAL|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
219304593|NCT03324451|BEHAVIORAL|Usual care|Regular patient education on insulin injection at the control arm hospital.
219304594|NCT05777096|DIAGNOSTIC_TEST|Standardised Nordic questionnaires|participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
219304595|NCT02463110|DRUG|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
219304596|NCT02463110|DRUG|No treatment|
219304597|NCT02463110|DRUG|Placebo|
219304598|NCT04054518|DRUG|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
219304599|NCT03182452|OTHER|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
219304600|NCT05379582|OTHER|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
219304601|NCT02746198|OTHER|probiotic dairy drink|
219304602|NCT02746198|OTHER|acidified milk|
219304603|NCT04757662|DRUG|Tadalafil|Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
219304604|NCT00188786|PROCEDURE|daily Cone Beam CT for imaging guidance for radiotherapy|
219304605|NCT03723252|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
219304606|NCT03723252|DRUG|Placebo|Participants will receive placebo po qd
219304607|NCT01242800|PROCEDURE|palliative surgery|Undergo standard palliative surgery
219304608|NCT01242800|PROCEDURE|therapeutic conventional surgery|Undergo early surgery
219304609|NCT01242800|RADIATION|palliative radiation therapy|Undergo standard palliative radiotherapy
219304610|NCT01242800|RADIATION|radiation therapy|Undergo radiotherapy
219304611|NCT00237289|DRUG|topiramate|
219304612|NCT02191410|PROCEDURE|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio \> 0.3, RR 60 breaths min-1 and a FGF of \< 2 L min-1, using a second identical ventilator with low compliant internal circuit
219304613|NCT02191410|PROCEDURE|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
219304614|NCT02165254|BEHAVIORAL|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
219304615|NCT02165254|BEHAVIORAL|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
219304616|NCT03229070|OTHER|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
219304617|NCT03229070|OTHER|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
219304618|NCT00609375|DRUG|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
219304619|NCT00609375|DRUG|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
219304620|NCT03900364|PROCEDURE|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
219304621|NCT00982995|DRUG|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
219304622|NCT05681689|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
219304623|NCT05681689|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.
219304624|NCT05681689|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
219304625|NCT05681689|COMBINATION_PRODUCT|Comparator Breath Test|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
219304626|NCT05681689|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patient's stool for H. pylori
219304627|NCT01632670|OTHER|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
219304628|NCT06448832|DIAGNOSTIC_TEST|Ultrasound|An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
219304629|NCT02640157|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
219304630|NCT02640157|DRUG|Sofosbuvir|Tablet
219304631|NCT02640157|DRUG|Daclatasvir|Tablet
219304632|NCT06085001|DIAGNOSTIC_TEST|Lumella finger prick blood test|Finger prick blood test
219304633|NCT00839657|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
219304634|NCT00839657|BEHAVIORAL|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
219304635|NCT00215735|DEVICE|debridement, dressing, and APC|ebridement, dressing, and APC
219304636|NCT01308944|DRUG|Propranolol|
219304637|NCT04812275|PROCEDURE|Skin closure|Skin closure
219304638|NCT04138693|DEVICE|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
219304639|NCT04138693|DEVICE|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
219304640|NCT04138693|DEVICE|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
219304641|NCT00117923|DRUG|Resiquimod|
219304642|NCT02851225|OTHER|telemedicine transmission of biological results|telemedicine transmission of biological informations
219304643|NCT00271518|DRUG|growth hormone (somatropin)|dosing regimen is weight based.
219304644|NCT02506517|DRUG|Afatinib|
219304645|NCT03858699|OTHER|Recording of electroencephalographic (EEG) data|Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
219304646|NCT00417339|PROCEDURE|hemodialysis|individualised
219304647|NCT05860660|BEHAVIORAL|survey|questionnaires
219304648|NCT01679405|DRUG|BIBW 2992|once daily per os
219304649|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
219304650|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
219304651|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
219304652|NCT03952325|DRUG|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
219304653|NCT03952325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
219304654|NCT03952325|DRUG|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
219304655|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
219304656|NCT05253989|DEVICE|VR Intervention|VR Device that allows a patient to play games based on the EMG activity in the upper limb.
219304657|NCT05253989|DEVICE|FES|Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
219304658|NCT00271687|BEHAVIORAL|Exercise training|
219304659|NCT02142296|DRUG|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
219304660|NCT00914901|DRUG|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
219304661|NCT04966845|DIAGNOSTIC_TEST|measurement of concentration on exhaled Carbon Monoxide|exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]
219304662|NCT03546764|DEVICE|Percutaneous catheter|tube inserted to drain hemothorax
219304663|NCT04677179|DRUG|LY3471851|administered SC
219304664|NCT04677179|DRUG|Placebo|administered SC
219304665|NCT00002674|BIOLOGICAL|filgrastim|
219304666|NCT00002674|DRUG|cytarabine|
219304667|NCT00002674|DRUG|etoposide|
219304668|NCT00002674|DRUG|hydroxyurea|
219304669|NCT00002674|DRUG|mitoxantrone hydrochloride|
219304670|NCT00002674|PROCEDURE|peripheral blood stem cell transplantation|
219304671|NCT01427595|DRUG|Metformin|500-2000 mg PO BID (X12 weeks)
219304672|NCT01427595|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
219304673|NCT01427595|DRUG|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
219304674|NCT04538690|OTHER|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
219304675|NCT04538690|OTHER|Electrotherapy|TENS, US
219304676|NCT04330352|BEHAVIORAL|"Mindfulness-based STOP touching your face practice"|1\. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
219304677|NCT02926404|DEVICE|UNiD Rods|Spinal osteosynthesis
219304678|NCT00926627|DRUG|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight \< 40 kg/90 lb)
219304679|NCT00926627|DRUG|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
219304680|NCT02691117|DRUG|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
219304681|NCT00231946|DRUG|VP4896|
219304682|NCT02762149|DEVICE|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
219304683|NCT03107832|PROCEDURE|thoracic epidural anesthesia procedure|general anesthesia procedure
219304684|NCT02244645|BEHAVIORAL|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
219304685|NCT02244645|BEHAVIORAL|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
219304686|NCT02374671|DEVICE|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
219304687|NCT02942433|BEHAVIORAL|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
219304688|NCT02942433|BEHAVIORAL|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
219304689|NCT02942433|BEHAVIORAL|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
219304690|NCT00457808|DRUG|Rapamycin, sirolimus|
219304691|NCT00492362|BEHAVIORAL|ergometer exercise during hemodialysis|
219304692|NCT00492362|BEHAVIORAL|pedometer activity outside of hemodialysis|
219304693|NCT02776384|OTHER|Observational study|
219304694|NCT03494478|OTHER|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
219304695|NCT03494478|OTHER|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
219304696|NCT03494478|OTHER|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
219304697|NCT00441662|DRUG|Sub-Tenon triamcinolone 40mg|
219304698|NCT04532554|DRUG|Growth Hormone|Recombinant growth hormone will be used
219304699|NCT04532554|DRUG|Placebo|Saline injection with the same amount
219304700|NCT00462332|DRUG|Fludarabine|Induction therapy
219304701|NCT00462332|DRUG|Campath|Induction therapy
219304702|NCT00462332|PROCEDURE|Transplant|Post-induction therapy
219304703|NCT00462332|DRUG|Campath|Post-induction therapy
219304704|NCT00462332|DRUG|Fludarabine|Induction therapy
219304705|NCT00462332|DRUG|Campath|Induction therapy
219304706|NCT00462332|DRUG|Campath|Post-induction therapy
219304707|NCT03866473|DEVICE|Retilux|670nm wavelength light
219304708|NCT03866473|DEVICE|Sham Light Device|Broad spectrum light device
219304709|NCT00067509|DRUG|emergency contraception (estrogen/progesterone)|
219304710|NCT01049932|DRUG|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
219304711|NCT01261637|DRUG|Saline placebo|20ml saline
219304712|NCT01261637|DRUG|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
219304713|NCT01177982|BEHAVIORAL|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
219304714|NCT01177982|BEHAVIORAL|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
219304715|NCT01177982|BEHAVIORAL|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
219304716|NCT01177982|BEHAVIORAL|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
219304717|NCT01177982|BEHAVIORAL|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
219304718|NCT01177982|BEHAVIORAL|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
219304719|NCT01177982|BEHAVIORAL|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
219304720|NCT01177982|BEHAVIORAL|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
219304721|NCT01688687|PROCEDURE|Endoscopic submucosal dissection|
219304722|NCT00979810|DRUG|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
219304723|NCT02828878|BIOLOGICAL|Allogeneic MPBC transplantation from matched related donor|
219304724|NCT03169101|DRUG|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
219304725|NCT03169101|BEHAVIORAL|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
219304726|NCT02951364|DRUG|LDV/SOF|90/400 mg tablet administered orally once daily
219304727|NCT03143946|DIETARY_SUPPLEMENT|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
219304728|NCT03143946|OTHER|Diet advice|
219304729|NCT02845362|OTHER|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
219304730|NCT02825784|DIETARY_SUPPLEMENT|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
219304731|NCT01993173|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
219304732|NCT01993173|BIOLOGICAL|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
219304733|NCT01993173|BIOLOGICAL|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
219304734|NCT03049033|OTHER|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
219304735|NCT03049033|OTHER|Occupational Therapy|Occupational Therapy uses traditional motor training.
219304736|NCT03049033|OTHER|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
219304737|NCT04967638|PROCEDURE|tumor resection and mandible reconstruction|The patients who underwent primary ablative tumor resection with segmental mandibulectomy and immediate VFF reconstruction were retrieved from the database
219304738|NCT03865264|OTHER|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
219304739|NCT05458700|OTHER|Collect information|Collect information from the patients to support the design of innovate clinical trials
219304740|NCT03542773|DRUG|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
219304741|NCT02250092|DEVICE|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
219304742|NCT02250092|DEVICE|Placebo Comparator|
219304743|NCT03510585|OTHER|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
219304744|NCT03510585|OTHER|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
219304745|NCT01391039|DRUG|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
219304746|NCT02641496|BEHAVIORAL|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
219304747|NCT02641496|BEHAVIORAL|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
219304748|NCT02822144|DRUG|Etomidate|
219304749|NCT02822144|DRUG|Succinylcholine|
219304750|NCT02822144|DRUG|Propofol|
219304751|NCT02822144|DRUG|Remifentanil|
219304752|NCT02822144|DRUG|Lidocaine|
219304753|NCT01243632|DRUG|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
219304754|NCT03997084|OTHER|phone interviews|phone interviews
219304755|NCT01417650|RADIATION|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
219304756|NCT01417650|RADIATION|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
219304757|NCT02072915|PROCEDURE|Suction|
219304758|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
219304759|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
219304760|NCT05187468|DEVICE|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
219304761|NCT03443050|OTHER|Unstable|This group will train over unstable surfaces to enhance balance abilities
219304762|NCT03443050|OTHER|Stable|This group will train over stable surface to enhance balance abilities
219304763|NCT04949347|BIOLOGICAL|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
219304764|NCT02571647|OTHER|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
219304765|NCT00600886|DRUG|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
219304766|NCT00600886|DRUG|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
219304767|NCT03686332|DRUG|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
219304768|NCT03686332|DRUG|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
219304769|NCT01843894|BIOLOGICAL|RU-101|Recombinant human serum albumin
219304770|NCT05191992|OTHER|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
219304771|NCT03075410|DRUG|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
219304772|NCT03075410|DRUG|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
219304773|NCT03047304|DIAGNOSTIC_TEST|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
219304774|NCT01427751|DRUG|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
219304775|NCT01427751|BIOLOGICAL|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
219304776|NCT03716115|DIETARY_SUPPLEMENT|Colostrum high protein powder (Neovite)|Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
219304777|NCT03716115|DRUG|N-Acetyl Glucosamine (GInNAC)|N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
219304778|NCT03716115|DRUG|Teduglutide|Teduglutide will be administered daily as subcutaneous injection
219304779|NCT03716115|DRUG|Budesonide|Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
219304780|NCT05984004|DRUG|0.9% NaCl isotonic saline solution|The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
219304781|NCT05984004|COMBINATION_PRODUCT|Bacillus subtilis DSM32444, inactivated|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
219304782|NCT02523599|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
219304783|NCT02523599|OTHER|Placebo|Plain collagen implant (vehicle)
219304784|NCT02457169|BEHAVIORAL|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
219304785|NCT02457169|BEHAVIORAL|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
219304786|NCT00510237|BEHAVIORAL|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
219304787|NCT04406740|DEVICE|TwitchView EMG Unit|The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
219304788|NCT04406740|DEVICE|Novel QTOF Device|The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
219304789|NCT00531102|OTHER|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
219304790|NCT00531102|OTHER|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
219304791|NCT04191473|PROCEDURE|EMR-P|After submucosal injection, we use ESD knife or the tip of the entrapment device to loop around the lesion, and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
219304792|NCT04191473|PROCEDURE|CEMR|A liquid pad was formed by injecting 0.9% normal saline with meilan solution into submucosa,and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
219304793|NCT01274832|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
219304794|NCT05893628|OTHER|muscle length and muscle endurance assessment|Pectoralis Minor Length and muscle endurance evaluation
219304795|NCT06088147|DRUG|Methotrexate|A standard derma pen 12 pins with of 0,5 mm depth was used, dermapen as a tool of infusion of our treatments works in a few ways to target hair loss, firstly by breaking down the scar tissue that covers or compromises the hair follicles which are not growing, stimulating new hair growth and also by enhancing infusion of mesotherapy ingredients to increase hair follicle size and therefore hair volume ,here we will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2
219304796|NCT06088147|DRUG|Triamcinolone Acetonide|A standard derma pen 12 pins with of 0,5 mm depth was used, will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution
219304797|NCT04309136|DRUG|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
219304798|NCT04309136|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
219304799|NCT04309136|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
219304800|NCT03815786|DIETARY_SUPPLEMENT|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
219304801|NCT03815786|DIETARY_SUPPLEMENT|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
219304802|NCT00539773|DRUG|BCG, Interferon|Chemotherapy
219304803|NCT01321151|DRUG|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
219304804|NCT01321151|DRUG|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
219304805|NCT04780347|DRUG|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
219304806|NCT04780347|DRUG|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
219304807|NCT03166410|PROCEDURE|Cell injection|
219304808|NCT02775695|DRUG|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
219304809|NCT05744752|OTHER|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
219304810|NCT05744752|DIETARY_SUPPLEMENT|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
219304811|NCT05744752|DIETARY_SUPPLEMENT|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
219304812|NCT05744752|OTHER|Placebo|1ml NaCl 0.9% daily for 12 weeks
219304813|NCT03981562|DRUG|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
219304814|NCT03981562|DRUG|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
219304815|NCT05216887|BIOLOGICAL|Aducanumab|Administered as specified in the treatment arm.
219304816|NCT03618368|DEVICE|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
219304817|NCT03618368|DEVICE|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
219304818|NCT03824782|DEVICE|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
219304819|NCT04014491|PROCEDURE|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
219304820|NCT04014491|PROCEDURE|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
219304821|NCT04014491|OTHER|No intervention|No intervention
219304822|NCT01219868|BEHAVIORAL|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
219304823|NCT02570685|BEHAVIORAL|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
219304824|NCT02570685|BEHAVIORAL|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
219304825|NCT02570685|BEHAVIORAL|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
219304826|NCT01991054|DIETARY_SUPPLEMENT|vitamin D3|
219304827|NCT03044925|PROCEDURE|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
219304828|NCT03044925|PROCEDURE|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
219304829|NCT05090280|DRUG|PF614 solution|PF614 solution is an oxycodone prodrug
219304830|NCT05090280|DRUG|Naltrexone Hydrochloride|Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
219304831|NCT05090280|DRUG|Nafamostat Mesylate|Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
219304832|NCT06513065|DRUG|Mitomycin c|"Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy."
219304833|NCT03319849|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
219304834|NCT03319849|PROCEDURE|Sham|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
219304835|NCT01195285|PROCEDURE|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
219304836|NCT01195285|PROCEDURE|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
219304837|NCT03543800|DEVICE|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
219304838|NCT03543800|DEVICE|PRP kit|PRP kit legally marketed in Canada for PRP
219304839|NCT02904031|DRUG|5-fluorouracil|
219304840|NCT02904031|DRUG|oxaliplatin|
219304841|NCT02904031|DRUG|l-leucovorin|
219304842|NCT02904031|DRUG|panitumumab|
219304843|NCT06728202|PROCEDURE|A Horizontal Ridge Augmentation in Atrophic Maxillary Ridge|Aiming to enhance bone volume (Quantity) in horizontal maxillary bone defects and density (Quality) , providing a viable solution for implant stability and long-term success.
219304844|NCT06727487|BEHAVIORAL|Basic recommendations|Daily basis activity counseling by WHO recommendations
219304845|NCT06727487|BEHAVIORAL|Physical exercise|A complete program of active physical exercise of medium and high intensity
219304846|NCT06727487|BEHAVIORAL|Nutritional advice|A complete program of nutritional counseling
219304847|NCT06727487|BEHAVIORAL|Psycho-oncological support|A program related with a patient Psycho-oncological follow-up
219304848|NCT06728163|OTHER|written education group|group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.
219304849|NCT06728163|OTHER|VR educational material + breathing relaxation with verbal instruction|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. Verbal instructions for breathing are provided for about 3 minutes and 3 seconds.
219304850|NCT06728163|OTHER|VR educational material + breathing relaxation with music intervention|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
219304851|NCT06728163|OTHER|written educational material + breathing relaxation with music intervention.|"group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.~The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion."
219304852|NCT06729619|DRUG|The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.|Blood and cerebrospinal fluid concentrations of anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam and ceftazidime ababactam will be monitored after the drug reaches a steady state.
219304853|NCT06728345|DRUG|Rimegepant|Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks
219304854|NCT06729177|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
219304855|NCT03455608|BEHAVIORAL|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
219304856|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
219304857|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
219304858|NCT00642733|DRUG|erlotinib [Tarceva]|100mg po daily
219304859|NCT00642733|DRUG|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
219304860|NCT05353335|OTHER|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
219304861|NCT05353335|OTHER|Current regimen|The participants will begin on their current regimen.
219304862|NCT05433181|DRUG|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
219304863|NCT05433181|OTHER|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
219304864|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
219304865|NCT05611021|BEHAVIORAL|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
219304866|NCT03496584|OTHER|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
219304867|NCT03496584|OTHER|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
219304868|NCT05664893|DRUG|Ribociclib Oral Tablet|"600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance"
219304869|NCT05550818|OTHER|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
219304870|NCT05550818|OTHER|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
219304871|NCT06457009|COMBINATION_PRODUCT|Multi-component Intervention Package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
219304872|NCT04448964|DRUG|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
219304873|NCT05189769|BEHAVIORAL|CP no REACT|Coping Power no REACT
219304874|NCT05189769|BEHAVIORAL|CP+/No REACT|CP+ and no REACT
219304875|NCT05189769|BEHAVIORAL|CP and REACT|Coping Power traditional and REACT
219304876|NCT05189769|BEHAVIORAL|CP+ and REACT|CP+ and REACT
219304877|NCT05562895|DEVICE|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
219304878|NCT04963439|DRUG|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
219304879|NCT02937233|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine|
219304880|NCT02937233|OTHER|Placebo|
219304881|NCT03198182|DRUG|Placebo|Specified dose on specified days
219304882|NCT03198182|DRUG|BMS-986036|Specified dose on specified days
219304883|NCT05134441|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
219304884|NCT05134441|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
219304885|NCT01416415|OTHER|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
219304886|NCT01416415|OTHER|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
219304887|NCT02871856|DIAGNOSTIC_TEST|Low dose CT|low-dose screening CT of chest for lung cancer detection
219304888|NCT01133951|DRUG|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
219304889|NCT01133951|DRUG|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
219304890|NCT03407443|OTHER|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
219304891|NCT03407443|OTHER|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
219304892|NCT03457038|BIOLOGICAL|Blood Test|"Addition to the current care but during the normal follow-up visit :~* At the entrance to the service: search for bacterial 16S RNA in the blood~* Additional blood tests (4) at T6-12-18 and 36h~* At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~* 1 time per day: Assay of CRP and PCT from samples taken in common practice~* J30: Assessment of the vital status of the patient"
219304893|NCT05252052|OTHER|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
219304894|NCT01672723|DRUG|Naltrexone|
219304895|NCT00743275|BIOLOGICAL|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
219304896|NCT01966380|DEVICE|Leia|
219304897|NCT04191018|DIAGNOSTIC_TEST|Liver elastography|Liver stiffness measurement
219304898|NCT04191018|DIAGNOSTIC_TEST|Splenic elastography|Splenic stiffness measurement
219304899|NCT04191018|DIAGNOSTIC_TEST|Gastrointestinal endoscopy|Gastrointestinal endoscopy
219304900|NCT02882724|BEHAVIORAL|Exercise|8-week aquatic exercise training program
219304901|NCT02882724|BEHAVIORAL|Control|Control group did not do the exercise training.
219304902|NCT03674463|DRUG|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
219304903|NCT00619762|DEVICE|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
219304904|NCT04815967|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
219304905|NCT04815967|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
219304906|NCT04815967|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
219304907|NCT04815967|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
219304908|NCT04815967|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
219304909|NCT02609854|DEVICE|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
219304910|NCT02609854|DEVICE|Sham Device|Inactive ultrasound device
219304911|NCT03195738|OTHER|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
219304912|NCT03435523|PROCEDURE|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
219304913|NCT05003726|PROCEDURE|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
219304914|NCT05003726|PROCEDURE|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
219304915|NCT03730857|DRUG|Olanzapine|olanzapine tablet
219304916|NCT03730857|DRUG|risperidone|risperidone tablet
219304917|NCT03730857|DRUG|Paliperidone|paliperidone tablet
219304918|NCT06225934|BEHAVIORAL|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
219304919|NCT00752310|DRUG|Darunavir|
219304920|NCT01836653|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304921|NCT01836653|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304922|NCT01836653|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304923|NCT01836653|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304924|NCT01836653|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304925|NCT01836653|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
219304926|NCT02133053|OTHER|Medical Device, drug-like|Ectoin Allergy Nasal Spray
219304927|NCT02133053|DRUG|Beclomethasone|Beclomethasone nasal spray
219304928|NCT02070133|DRUG|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
219304929|NCT02070133|DRUG|Placebo|Placebo once a day during 12 weeks
219304930|NCT01845220|DRUG|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
219304931|NCT01845220|DRUG|Placebo|80% acetone
219304932|NCT01236248|BEHAVIORAL|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
219304933|NCT02314910|OTHER|Sample histology|
219304934|NCT06280326|OTHER|Sunflower oil|In the experimental group, patch removal will be performed using sunflower oil.
219304935|NCT06280326|OTHER|Slicone based spray|In the control group, clinical routine procedure will be used to remove the patch (silicone based spray.
219304936|NCT01945541|DEVICE|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
219304937|NCT03938545|DRUG|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
219304938|NCT03938545|OTHER|Placebo (Administered via subcutaneous injection)|Placebo
219304939|NCT05041036|DRUG|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
219304940|NCT00183365|BEHAVIORAL|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
219304941|NCT00183365|BEHAVIORAL|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
219304942|NCT01060540|GENETIC|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
219304943|NCT01060540|BEHAVIORAL|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
219304944|NCT01060540|BEHAVIORAL|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
219304945|NCT04605887|DRUG|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
219304946|NCT03200379|OTHER|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
219304947|NCT04502628|PROCEDURE|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
219304948|NCT05384444|OTHER|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
219304949|NCT04028882|OTHER|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
219304950|NCT02391272|DRUG|rhTPO|
219304951|NCT00336752|PROCEDURE|non operative treatment|non operative treatment -casting for 6 weeks
219304952|NCT00336752|PROCEDURE|operative treatment of ankle fractures|operative treatment of ankle fractures
219304953|NCT02783664|OTHER|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
219304954|NCT03310268|OTHER|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
219304955|NCT03310268|OTHER|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
219304956|NCT03310268|OTHER|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
219304957|NCT04417946|BEHAVIORAL|PrEP messages|The peer leaders and the study staff will post PrEP related health messages
219304958|NCT04417946|BEHAVIORAL|Heath messages|The peer leaders and study staff will post general health messages that are not related to sexual health
219304959|NCT04498455|DIETARY_SUPPLEMENT|Prebiotin|Fructo-oligosaccharide dietary supplement powder
219304960|NCT05015933|PROCEDURE|Pump refill procedure at home|Implantable pump refill is performed at home
219304961|NCT03972254|BEHAVIORAL|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
219304962|NCT05639400|DEVICE|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
219304963|NCT05639400|DEVICE|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
219304964|NCT02930356|OTHER|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
219304965|NCT02930356|OTHER|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
219304966|NCT01647269|PROCEDURE|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
219304967|NCT00411853|DRUG|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
219304968|NCT02344563|DRUG|Meropem|
219304969|NCT02344563|DRUG|Mepem|
219304970|NCT01524601|DRUG|Rosuvastatin|20 mg rosuvastatin for 4 weeks
219304971|NCT05991843|BEHAVIORAL|Instructions of breathing|Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
219304972|NCT00240045|DRUG|Midodrine, albumin, octreotide LAR|
219304973|NCT00240045|DRUG|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
219304974|NCT04984525|DRUG|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
219304975|NCT04984525|DRUG|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
219304976|NCT03183700|DEVICE|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
219304977|NCT03183700|OTHER|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
219304978|NCT04025112|DEVICE|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
219304979|NCT04025112|OTHER|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
219304980|NCT01179425|OTHER|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
219304981|NCT04942834|DRUG|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
219304982|NCT04942834|DEVICE|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
219304983|NCT00050037|PROCEDURE|CBT|
219304984|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
219304985|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
219304986|NCT01590017|DRUG|cisplatin|
219304987|NCT01590017|RADIATION|external beam radiation therapy|
219304988|NCT05049954|OTHER|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
219304989|NCT05049954|OTHER|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
219304990|NCT00146354|BEHAVIORAL|Hospitalists Results Manager|
219304991|NCT00000577|DRUG|Albuterol|
219304992|NCT00000577|DRUG|Colchicine|
219304993|NCT00000577|DRUG|Adrenal Cortex Hormones|
219304994|NCT00000577|DRUG|Adrenergic-Beta Agonists|
219304995|NCT02255266|DRUG|liraglutide|No treatment given.
219304996|NCT00129597|DRUG|ketalar|
219304997|NCT02527343|DRUG|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
219304998|NCT02527343|DRUG|Placebo|Volanesorsen-matching placebo administered SC injection.
219304999|NCT02640885|DEVICE|Foley's cather ballon|
219305000|NCT06082089|BEHAVIORAL|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
219305001|NCT00151957|DRUG|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
219305002|NCT03513874|DRUG|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
219305003|NCT03513874|DRUG|Insulin|Patients will continue insulin therapy following physicians' instructions.
219305004|NCT04294069|DRUG|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
219305005|NCT04294069|DRUG|Azithromycin Oral Product|1000mg azithromycin PO once at admission
219305006|NCT00521547|PROCEDURE|Electroacupuncture|
219305007|NCT03575754|DEVICE|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
219305008|NCT05681858|DIAGNOSTIC_TEST|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
219305009|NCT01450254|DEVICE|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
219305010|NCT01450254|OTHER|Control|No intervention will be prescribed to the control group during participation in the study.
219305011|NCT02700945|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
219305012|NCT04745026|DRUG|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
219305013|NCT04745026|DRUG|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
219305014|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
219305015|NCT02183051|DRUG|Meloxicam 7.5 mg|
219305016|NCT02183051|DRUG|Meloxicam 3.75 mg|
219305017|NCT02183051|DRUG|Meloxicam 1.875 mg|
219305018|NCT02183051|DRUG|Ibuprofen 200 mg|
219305019|NCT02183051|DRUG|Placebo|
219305020|NCT02183051|DRUG|Meloxicam 15 mg|
219305021|NCT02183051|DRUG|Ibuprofen 400 mg|
219305022|NCT04426851|DRUG|BI 1358894|Tablet
219305023|NCT04426851|DRUG|BI 1358894 (C-14) intravenous solution|BI 1358894 mixed with \[carbon labelled (C-14)\] BI 1358894
219305024|NCT04426851|DRUG|BI 1358894|Oral suspension
219305025|NCT04049799|OTHER|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
219305026|NCT04049799|OTHER|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
219305027|NCT04049799|BEHAVIORAL|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
219305028|NCT03256851|BEHAVIORAL|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week telephone call with an investigator."
219305029|NCT03256851|BEHAVIORAL|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
219305030|NCT03168607|DRUG|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
219305031|NCT01875549|DEVICE|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
219305032|NCT01875549|PROCEDURE|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
219305033|NCT04504604|DIAGNOSTIC_TEST|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
219305034|NCT05537831|DEVICE|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
219305035|NCT04677166|DEVICE|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
219305036|NCT04677166|DEVICE|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
219305037|NCT00569556|OTHER|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
219305038|NCT03869151|DIAGNOSTIC_TEST|CBC|lymphocyte and monocyte count
219305039|NCT03775889|BEHAVIORAL|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
219305040|NCT02208999|DEVICE|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
219305041|NCT03765099|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
219305042|NCT02625727|OTHER|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
219305043|NCT02625727|OTHER|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
219305044|NCT05712122|PROCEDURE|stellate block|stellate blockade effect on Ventricular arrytmia
219305045|NCT04647643|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
219305046|NCT05293951|DEVICE|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
219305047|NCT05293951|DEVICE|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
219305048|NCT03226951|DEVICE|Subthreshold 532nm laser|Subthershold 532nm laser
219305049|NCT00484731|PROCEDURE|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
219305050|NCT00484731|PROCEDURE|Infiltration with Bupivacaine|
219305051|NCT00632437|PROCEDURE|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
219305052|NCT01684332|OTHER|Strawberry Jam|
219305053|NCT00986674|BIOLOGICAL|cixutumumab|Given IV
219305054|NCT00986674|DRUG|carboplatin|Given IV
219305055|NCT00986674|DRUG|paclitaxel|Given IV
219305056|NCT00986674|BIOLOGICAL|cetuximab|Given IV
219305057|NCT02709213|DIAGNOSTIC_TEST|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
219305058|NCT02128542|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
219305059|NCT02128542|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
219305060|NCT04754308|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
219305061|NCT04528927|DRUG|HCQ|600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
219305062|NCT04528927|DRUG|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
219305063|NCT04528927|DRUG|Doxycycline|200 mg per day for 10 days
219305064|NCT04528927|DIETARY_SUPPLEMENT|Zinc|220 mg per day for 10 days
219305065|NCT03085615|OTHER|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
219305066|NCT05629403|OTHER|observe|no intervention
219305067|NCT02825030|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation-SR15-78\_Y73-167).
219305068|NCT02570932|BIOLOGICAL|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
219305069|NCT02905136|OTHER|Fundamental research|serum, whole blood, cerebrospinal fluid
219305070|NCT05109754|DEVICE|BiPAP EFL|Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
219305071|NCT05159869|BEHAVIORAL|User-Led Meaningful Activity Plan|The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
219305072|NCT00833131|RADIATION|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
219305073|NCT00833131|RADIATION|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
219305074|NCT01358487|BEHAVIORAL|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
219305075|NCT01358487|BEHAVIORAL|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
219305076|NCT05025046|DIAGNOSTIC_TEST|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
219305077|NCT00669526|BEHAVIORAL|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
219305078|NCT00669526|BEHAVIORAL|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
219305079|NCT00671944|OTHER|Low protein diet|Low protein diet for 6.5 weeks
219305080|NCT00006165|BEHAVIORAL|'Ohana (Family) Support Lifestyle Intervention|
219305081|NCT03465098|OTHER|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
219305082|NCT06156618|DIETARY_SUPPLEMENT|Nitrate|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
219305083|NCT01853137|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
219305084|NCT05812287|OTHER|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
219305085|NCT04248231|OTHER|CINSARC signature|CINSARC molecular signature analysis
219305086|NCT00647725|PROCEDURE|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
219305087|NCT00647725|PROCEDURE|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
219305088|NCT00257062|DRUG|Levofloxacin|
219305089|NCT04822831|BEHAVIORAL|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
219305090|NCT04822831|BEHAVIORAL|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
219305091|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219305092|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219305093|NCT00825916|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219305094|NCT01653067|DRUG|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
219305095|NCT00638781|DRUG|Desmoteplase|Desmoteplase 62.5 µg/kg BW
219305096|NCT00638781|DRUG|Desmoteplase|Desmoteplase 90 µg/kg BW
219305097|NCT00638781|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW
219305098|NCT00638781|DRUG|Placebo|Placebo
219305099|NCT04831294|DRUG|Cannabidiol|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
219305100|NCT04831294|DRUG|Placebo|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
219305101|NCT03966807|BEHAVIORAL|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
219305102|NCT03966807|BEHAVIORAL|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
219305103|NCT03475615|DRUG|Oxaliplatin|130mg/m2, d1, q3w
219305104|NCT03475615|DRUG|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
219305105|NCT03475615|DRUG|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
219305106|NCT02671370|OTHER|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
219305107|NCT03081754|RADIATION|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
219305108|NCT04637854|PROCEDURE|Operating microscope|Third molar extraction using microscope
219305109|NCT04637854|PROCEDURE|Surgical loupes|Third molar extraction using loupes with co-axial illumination
219305110|NCT04637854|PROCEDURE|Naked eyes|Third molar extraction using naked eyes
219305111|NCT01414140|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
219305112|NCT01532895|DRUG|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
219305113|NCT05782023|BEHAVIORAL|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
219305114|NCT05960617|DRUG|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count \> 1.0 × 10\^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
219305115|NCT04866498|DRUG|Infusion Intravenous|
219305116|NCT05147961|OTHER|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
219305117|NCT05147961|OTHER|Standard care|Conventional recommendations on diet and exercise
219305118|NCT03832413|DIAGNOSTIC_TEST|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
219305119|NCT01821287|OTHER|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
219305120|NCT01778023|DRUG|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
219305121|NCT01990560|DRUG|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
219305122|NCT03875846|DIAGNOSTIC_TEST|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
219305123|NCT03875846|DIAGNOSTIC_TEST|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
219305124|NCT00140309|DRUG|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
219305125|NCT04733521|DRUG|SC-43|SC-43 oral, every day of 21-day cycle
219305126|NCT04733521|DRUG|Cisplatin|cisplatin 75mg/m2 on day 1 of 21-day cycle
219305127|NCT06063811|OTHER|Ablation|VT ablation
219305128|NCT02979392|DRUG|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
219305129|NCT06189586|DRUG|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
219305130|NCT06189586|DRUG|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
219305131|NCT01098097|BIOLOGICAL|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
219305132|NCT01098097|DRUG|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
219305133|NCT05748496|BEHAVIORAL|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
219305134|NCT01411215|DRUG|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
219305135|NCT04333927|DRUG|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
219305136|NCT04333927|OTHER|Observation|Patients in observation group will not receive any anti-cancer therapy.
219305137|NCT04333927|PROCEDURE|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
219305138|NCT04333927|RADIATION|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
219305139|NCT00848926|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
219305140|NCT04878653|DEVICE|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
219305141|NCT05130853|BEHAVIORAL|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
219305142|NCT05130853|OTHER|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
219305143|NCT01553123|DRUG|Ulipristal Acetate|once daily, oral
219305144|NCT01553123|DRUG|Iron|once daily, dried ferrous sulfate
219305145|NCT04621591|DEVICE|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
219305146|NCT00454129|PROCEDURE|cholangiography via double-balloon enteroscopy|
219305147|NCT00454129|PROCEDURE|MR cholangiography|
219305148|NCT06147284|BEHAVIORAL|Preventive interventions|Parallel randomized controlled trial
219305149|NCT06254768|DEVICE|Continuous glucose monitor|its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
219305150|NCT03080831|DRUG|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
219305151|NCT03080831|DRUG|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
219305152|NCT04525872|OTHER|Full parenteral nutrition light protection of the bag, tubing and lipids|Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
219305153|NCT03999320|OTHER|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
219305154|NCT03999320|OTHER|usual care|usual care
219305155|NCT00945308|DRUG|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
219305156|NCT00945308|DRUG|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
219305157|NCT04485182|OTHER|Underwater jet massage (Tangentor)|"Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks."
219305158|NCT03488433|DEVICE|Abduction brace|Donjoy Ultrasling IV
219305159|NCT03488433|DEVICE|Antirotation sling|Donjoy shoulder immobilizer
219305160|NCT05127629|PROCEDURE|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
219305161|NCT05127629|PROCEDURE|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
219305162|NCT05127629|PROCEDURE|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
219305163|NCT05127629|PROCEDURE|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
219305164|NCT06352164|OTHER|Acupuncture treatment|The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
219305165|NCT04025580|BIOLOGICAL|Flucelvax|Seasonal influenza vaccine
219305166|NCT04025580|BIOLOGICAL|Fluvirin|Seasonal influenza vaccine
219305167|NCT04025580|BIOLOGICAL|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
219305168|NCT04193488|BEHAVIORAL|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
219305169|NCT04193488|BEHAVIORAL|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
219305170|NCT04193488|BEHAVIORAL|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
219305171|NCT06033014|OTHER|PM HeartIHD prediction|The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.
219305172|NCT01362257|DRUG|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
219305173|NCT01362257|DRUG|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
219305174|NCT03086213|DRUG|Propofol|anaesthetic
219305175|NCT03086213|DRUG|Sulfentanyl|anaesthetic
219305176|NCT03086213|DRUG|Dexmedetomidine|anaesthetic
219305177|NCT03086213|DRUG|Lidocaine|local anaesthetics
219305178|NCT03086213|DRUG|Ropivacaine|local anaesthetics
219305179|NCT03656523|OTHER|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
219305180|NCT02067117|DRUG|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
219305181|NCT00284986|DRUG|Prochymal®|Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
219305182|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
219305183|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
219305184|NCT04293380|PROCEDURE|amniosyntesis|
219305185|NCT02995954|DRUG|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
219305186|NCT04507126|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Vaccine
219305187|NCT03650257|BIOLOGICAL|gp96|25 mcg IH
219305188|NCT03650257|DRUG|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
219305189|NCT03650257|RADIATION|radiotherapy|Stupp regimen of radiotherapy
219305190|NCT03343457|BEHAVIORAL|Cognitive therapy|
219305191|NCT04011618|DRUG|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
219305192|NCT04011618|DRUG|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
219305193|NCT02924064|DRUG|Teneligliptin 20mg|
219305194|NCT02924064|DRUG|Placebo|
219305195|NCT02924064|DRUG|Metformin ≥ 1000 mg|
219305196|NCT02080741|OTHER|Blood sample of 12 ml|
219305197|NCT05721820|PROCEDURE|TAVR|Transcatheter aortic valve replacement
219305198|NCT03759951|BEHAVIORAL|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
219305199|NCT03759951|BEHAVIORAL|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
219305200|NCT03759951|BEHAVIORAL|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
219305201|NCT03759951|BEHAVIORAL|Control|No training will be performed during a 1-year period. Participation only in measurements.
219305202|NCT00220753|DEVICE|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
219305203|NCT01798251|DRUG|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
219305204|NCT01798251|DRUG|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
219305205|NCT06109675|BEHAVIORAL|Nutrition Education|All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
219305206|NCT03866304|DEVICE|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
219305207|NCT06262685|OTHER|Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines|"Atorvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305208|NCT06262685|OTHER|Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines|"Simvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305209|NCT06262685|OTHER|Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines|"Pitavastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305210|NCT06262685|OTHER|Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines|"Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305211|NCT06262685|OTHER|Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines|"Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305212|NCT06262685|OTHER|Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines|"Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305213|NCT06262685|OTHER|Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines|"Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
219305214|NCT06262685|OTHER|Standard of Care (SoC) dosing of atorvastatin|Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
219305215|NCT06262685|OTHER|Standard of Care (SoC) dosing of simvastatin|Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
219305216|NCT06262685|OTHER|Standard of Care (SoC) dosing of pitavastatin|Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
219305217|NCT06262685|OTHER|Standard of Care (SoC) dosing of rosuvastatin|Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
219305218|NCT06262685|OTHER|Standard of Care (SoC) dosing of prasavastatin|Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
219305219|NCT06262685|OTHER|Standard of Care (SoC) dosing of lovastatin|Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
219305220|NCT06262685|OTHER|Standard of Care (SoC) dosing of fluvastatin|Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
219305221|NCT00972452|BEHAVIORAL|Exercise|short period of exercise training (5-10 days)
219305222|NCT03501641|OTHER|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
219305223|NCT03501641|OTHER|video-based learning|voice of the staffs and standard patients.
219305224|NCT05949112|DEVICE|soft bristle toothbrush|manual toothbrushes
219305225|NCT05949112|DEVICE|mechanical toothbrush|sonic toothbrush
219305226|NCT00038909|DRUG|BDDrFVII|
219305227|NCT03253965|OTHER|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
219305228|NCT03253965|OTHER|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
219305229|NCT03253965|OTHER|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
219305230|NCT03253965|OTHER|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
219305231|NCT03253965|OTHER|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
219305232|NCT03253965|OTHER|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
219305233|NCT03253965|OTHER|No Auditory cueing|Steps are not timed with any auditory cue.
219305234|NCT04989465|BIOLOGICAL|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
219305235|NCT04989465|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
219305236|NCT00075647|DRUG|temsirolimus|Given IV
219305237|NCT00075647|OTHER|laboratory biomarker analysis|Correlative studies
219305238|NCT02832154|OTHER|Internet-Based Intervention|Complete online PA program
219305239|NCT02832154|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219305240|NCT02832154|OTHER|Questionnaire Administration|Ancillary studies
219305241|NCT01507818|DEVICE|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0\>
219305242|NCT01507818|DEVICE|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
219305243|NCT00699920|DRUG|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
219305244|NCT00699920|DRUG|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
219305245|NCT01616056|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Wear bandage lenses
219305246|NCT01616056|OTHER|questionnaire administration|Ancillary studies
219305247|NCT01616056|PROCEDURE|optical coherence tomography|Optional ancillary studies
219305248|NCT06347406|OTHER|Blood flow restriction combined with physiotherapy and education|Blood flow restriction Physiotherapy exercises Education
219305249|NCT00966277|DRUG|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
219305250|NCT00062049|BIOLOGICAL|recombinant interleukin-7|
219305251|NCT00311285|DEVICE|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
219305252|NCT02706912|BEHAVIORAL|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
219305253|NCT03609684|OTHER|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
219305254|NCT03609684|OTHER|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
219305255|NCT03609684|OTHER|Sedentary Group|People who are not interested in any sports and don't do any exercises
219305256|NCT00138671|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
219305257|NCT00138671|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
219305258|NCT01488487|DRUG|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
219305259|NCT01488487|DRUG|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
219305260|NCT06367673|BIOLOGICAL|iPSC-NK cells|iPSC-NK cells
219305261|NCT04503343|OTHER|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
219305262|NCT05898256|DRUG|Cadonilimab|10mg/kg administered intravenously (IV)
219305263|NCT05898256|DRUG|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
219305264|NCT05898256|DRUG|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
219305265|NCT02418273|DRUG|denosumab|These subjects will receive two doses of denosumab.
219305266|NCT03488641|DIAGNOSTIC_TEST|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
219305267|NCT01008215|OTHER|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
219305268|NCT04213430|OTHER|diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
219305269|NCT04084470|DIETARY_SUPPLEMENT|Different types of bread|Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
219305270|NCT01684267|DEVICE|Robotic Gait Rehabilitation (RGR) Trainer|
219305271|NCT00264953|DRUG|Adriamycin|
219305272|NCT00264953|DRUG|Bleomycin|
219305273|NCT00264953|DRUG|Vinblastine|
219305274|NCT00264953|DRUG|DTIC|
219305275|NCT00264953|DRUG|Etoposide|
219305276|NCT00264953|DRUG|Procarbazine|
219305277|NCT00264953|DRUG|Prednisone|
219305278|NCT00264953|DRUG|Vincristine|
219305279|NCT00264953|RADIATION|radiation therapy|20 or 30Gy IF-RT
219305280|NCT01100034|DRUG|Etanercept|Expected duration of 24 weeks as one course
219305281|NCT01382420|PROCEDURE|surgery|adrenalectomy
219305282|NCT00547131|DRUG|temozolomide|
219305283|NCT00547131|OTHER|laboratory biomarker analysis|
219305284|NCT00547131|OTHER|liquid chromatography|
219305285|NCT00547131|OTHER|mass spectrometry|
219305286|NCT00547131|OTHER|pharmacological study|
219305287|NCT00547131|PROCEDURE|conventional surgery|
219305288|NCT00547131|RADIATION|stereotactic radiosurgery|
219305289|NCT05868174|DIAGNOSTIC_TEST|89Zr-TLX250|Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible). The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
219305290|NCT05868174|COMBINATION_PRODUCT|177Lu-TLX250 and Peposertib|"Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose.~All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle."
219305291|NCT04606043|PROCEDURE|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
219305292|NCT04606043|PROCEDURE|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
219305293|NCT01831856|DRUG|1g of F373280|Oral administration, one capsule each evening with dinner.
219305294|NCT01831856|DRUG|Placebo|Oral administration, one capsule each evening with dinner.
219305295|NCT01873222|DEVICE|OFDI-guided PCI & IVUS|"* Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up"
219305296|NCT01873222|DEVICE|IVUS-guided PCI & OFDI|"* Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up"
219305297|NCT01832233|PROCEDURE|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
219305298|NCT01561209|DRUG|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
219305299|NCT01561209|DRUG|Placebo|"Placebo pill~1 before bedtime"
219305300|NCT05050253|DEVICE|Super-oxidized solution (SOS)|Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
219305301|NCT05050253|DEVICE|Ringer's solution|Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
219305302|NCT02279069|DEVICE|4-roll canne|
219305303|NCT06311604|DRUG|Isoflurane|"Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
219305304|NCT02424513|RADIATION|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
219305305|NCT00052182|BIOLOGICAL|EP HIV-1090|
219305306|NCT03840226|DRUG|Placebo Oral Tablet|Placebo tablets
219305307|NCT03840226|DRUG|Magnesium Oxide|Magnesium tablets
219305308|NCT03444753|DRUG|BMS-986299|Specified dose on specified day
219305309|NCT03444753|BIOLOGICAL|Nivolumab|Specified dose on specified day
219305310|NCT03444753|BIOLOGICAL|Ipilimumab|Specified dose on specified day
219305311|NCT00972205|DRUG|paclitaxel|Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
219305312|NCT00972205|DRUG|CBT-1(Registered Trademark)|CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
219305313|NCT00972205|RADIATION|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
219305314|NCT03316625|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone Densitometry and measurement of body composition
219305315|NCT00354458|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
219305316|NCT00354458|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
219305317|NCT02550717|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
219305318|NCT02550717|DRUG|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
219305319|NCT05235321|DEVICE|Standard GAT|Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice
219305320|NCT05235321|DEVICE|Fixed force GAT|An investigational device similar to standard GAT
219305321|NCT05235321|DEVICE|Upright applanating prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device
219305322|NCT05235321|DEVICE|Supine Applanating Prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
219305323|NCT02853357|OTHER|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
219305324|NCT02853357|OTHER|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
219305325|NCT02853357|OTHER|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
219305326|NCT01306487|PROCEDURE|Vitrectomy|Macular hole surgery
219305327|NCT02682641|DRUG|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
219305328|NCT02682641|DRUG|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
219305329|NCT04409886|BIOLOGICAL|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
219305330|NCT05525611|DRUG|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
219305331|NCT05525611|OTHER|Placebo|Placebo once a week in 12 weeks
219305332|NCT04255069|DRUG|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
219305333|NCT04255069|DRUG|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
219305334|NCT04255069|DRUG|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
219305335|NCT04015856|BEHAVIORAL|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
219305336|NCT04015856|BEHAVIORAL|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
219305337|NCT04105309|BEHAVIORAL|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
219305338|NCT04105309|BEHAVIORAL|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
219305339|NCT04105309|BEHAVIORAL|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
219305340|NCT04105309|BEHAVIORAL|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
219305341|NCT01849822|DEVICE|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
219305342|NCT05516550|DRUG|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
219305343|NCT05516550|DRUG|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
219305344|NCT05516550|DRUG|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
219305345|NCT05516550|DRUG|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
219305346|NCT04495803|OTHER|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
219305347|NCT02775799|OTHER|Registration|Registration according to approved data sets
219305348|NCT04620811|DRUG|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
219305349|NCT01078675|DRUG|rosuvastatin calcium|5 mg, oral, once daily, 24 months
219305350|NCT01078675|DRUG|rosuvastatin calcium|10 mg, oral, once daily, 24 months
219305351|NCT01078675|DRUG|rosuvastatin calcium|20 mg, oral, once daily, 24 months
219305352|NCT04208009|BEHAVIORAL|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
219305353|NCT01765465|DRUG|Rowachol|
219305354|NCT01765465|DRUG|Placebo|
219305355|NCT03714204|BEHAVIORAL|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
219305356|NCT00779051|DRUG|Zolpidem 10mg tablets|
219305357|NCT00874341|OTHER|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
219305358|NCT05127538|DIAGNOSTIC_TEST|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
219305359|NCT05127538|DIAGNOSTIC_TEST|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
219305360|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
219305361|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
219305362|NCT03929315|BEHAVIORAL|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
219305363|NCT06057194|DRUG|Letermovir 240 mg Oral Tablet|Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
219305364|NCT01744795|OTHER|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
219305365|NCT02341027|DEVICE|Jadelle|within 5 days of delivery and before discharge from hospital
219305366|NCT02341027|DEVICE|Jadelle|6-8 weeks (42-56 days) postpartum
219305367|NCT05435768|DRUG|Denosumab|Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
219305368|NCT01574378|DEVICE|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
219305369|NCT01574378|DEVICE|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
219305370|NCT05142488|BIOLOGICAL|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
219305371|NCT00419510|BEHAVIORAL|Culturally Tailored Genetic Counseling|
219305372|NCT01759368|DEVICE|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
219305373|NCT01191268|DRUG|Insulin Glargine|
219305374|NCT01191268|DRUG|LY2189265|
219305375|NCT01191268|DRUG|Insulin Lispro|
219305376|NCT01222026|DRUG|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
219305377|NCT01222026|DRUG|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
219305378|NCT03112564|OTHER|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
219305379|NCT03112564|DRUG|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
219305380|NCT00700973|BEHAVIORAL|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
219305381|NCT00700973|OTHER|Usual care|Substance use disorder usual care
219305382|NCT03218345|PROCEDURE|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
219305383|NCT03558373|DRUG|Immunosuppressive|Immunosuppressive therapies
219305384|NCT01620476|DRUG|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
219305385|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
219305386|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
219305387|NCT01620476|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
219305388|NCT02294227|BIOLOGICAL|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
219305389|NCT02294227|OTHER|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
219305390|NCT00851448|DIETARY_SUPPLEMENT|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
219305391|NCT00888004|DRUG|AFQ056|
219305392|NCT00888004|DRUG|Placebo|
219305393|NCT00267904|OTHER|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
219305394|NCT00267904|OTHER|Banana|Banana ingestion
219305395|NCT00267904|OTHER|Olives|Olives ingestion
219305396|NCT00267904|OTHER|Temp. manip.|Manipulate temperature at skin of the back
219305397|NCT06248385|DEVICE|2D ultrasound|2D TVUS
219305398|NCT06354231|DRUG|DV|2.0 mg/kg, intravenously administered every 2 weeks
219305399|NCT06354231|DRUG|Toripalimab|3.0mg/kg, intravenously administered every 2 weeks
219305400|NCT06354231|PROCEDURE|Laser surgery|Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
219305401|NCT02701140|PROCEDURE|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
219305402|NCT02701140|PROCEDURE|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
219305403|NCT02701140|PROCEDURE|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
219305404|NCT02701140|PROCEDURE|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
219305405|NCT02701140|PROCEDURE|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
219305406|NCT02838771|OTHER|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
219305407|NCT02838771|OTHER|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
219305408|NCT01636960|BIOLOGICAL|PegIFN alfa-2b|
219305409|NCT01209780|BIOLOGICAL|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
219305410|NCT01209780|BIOLOGICAL|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
219305411|NCT01209780|BIOLOGICAL|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
219305412|NCT00133146|BIOLOGICAL|Grass MATA MPL|
219305413|NCT04234854|DIAGNOSTIC_TEST|Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent|IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
219305414|NCT04690868|DRUG|AD-213-A|1 tablet administered before the breakfast during 5 days
219305415|NCT04690868|DRUG|AD-2131|1 tablet administered before the breakfast during 5 days
219305416|NCT04176146|BEHAVIORAL|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
219305417|NCT00728585|DRUG|Palifermin|Given IV
219305418|NCT00728585|OTHER|Placebo|Given IV
219305419|NCT02675504|OTHER|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
219305420|NCT01304433|DRUG|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
219305421|NCT02709096|DRUG|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
219305422|NCT02709096|DRUG|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
219305423|NCT00511472|DRUG|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
219305424|NCT00511472|DRUG|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
219305425|NCT00511472|DRUG|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
219305426|NCT02515877|RADIATION|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
219305427|NCT02515877|DRUG|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
219305428|NCT02515877|DRUG|Carboplatin|AUC= 2,5 (Calvert formula)
219305429|NCT01091077|DIETARY_SUPPLEMENT|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
219305430|NCT06254547|OTHER|Daily updated ranking on leaderboard|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service and view a daily updated leaderboard ranking.~Leaderboards will demonstrate participant's ranking in their respective group, participant's (anonymized) name, cumulative point total, total case amount, and current level. Participant ranking will be based on the cumulative point total. All groups will have continual access to their personal score.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
219305431|NCT06254547|OTHER|Daily motivational message|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service encouraging training.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
219305432|NCT02146456|DRUG|Tranexamic Acid|
219305433|NCT02574156|DRUG|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
219305434|NCT01599715|BEHAVIORAL|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
219305435|NCT01599715|BEHAVIORAL|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
219305436|NCT00505284|DRUG|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
219305437|NCT00505284|DRUG|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
219305438|NCT00505284|DRUG|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
219305439|NCT00505284|DRUG|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
219305440|NCT00505284|DRUG|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
219305441|NCT00351130|DRUG|valsartan|
219305442|NCT00351130|DRUG|amlodipine|
219305443|NCT04302441|DRUG|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
219305444|NCT04302441|DRUG|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
219305445|NCT02872883|PROCEDURE|Expectant management|
219305446|NCT02872883|PROCEDURE|Minimal Vaginal examinations (only when necessary)|
219305447|NCT02872883|PROCEDURE|Active management|
219305448|NCT02872883|PROCEDURE|Routine vaginal examinations|
219305449|NCT02957864|DRUG|tenofovir alafenamide|
219305450|NCT02957864|DRUG|abacavir|
219305451|NCT03027492|OTHER|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
219305452|NCT02925637|OTHER|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
219305453|NCT06004011|OTHER|ARROW strategies|ARROW strategies are peer-to-peer support at the patient, provider and health system levels
219305454|NCT06004011|OTHER|One-time education|The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
219305455|NCT05822778|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
219305456|NCT05822778|DEVICE|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
219305457|NCT01600573|DRUG|pazopanib in combination with weekly topotecan|"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
219305458|NCT02521220|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
219305459|NCT02521220|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
219305460|NCT01981395|DRUG|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
219305461|NCT01981395|DRUG|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
219305462|NCT02800239|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
219305463|NCT00073866|DRUG|celecoxib|
219305464|NCT00073866|DRUG|docetaxel|
219305465|NCT00073866|DRUG|irinotecan hydrochloride|
219305466|NCT00519311|BEHAVIORAL|Health Intervention Package|CHAP and Ask Diary
219305467|NCT05566496|DIAGNOSTIC_TEST|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
219305468|NCT00978653|DRUG|allopurinol|150 mg once a day
219305469|NCT01762033|DRUG|ASONEP|Intravenous infusion
219305470|NCT05008861|PROCEDURE|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
219305471|NCT05008861|DRUG|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
219305472|NCT05008861|DRUG|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
219305473|NCT00711893|DEVICE|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
219305474|NCT03759860|COMBINATION_PRODUCT|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
219305475|NCT02859363|GENETIC|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
219305476|NCT01789736|DRUG|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
219305477|NCT01789736|DRUG|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
219305478|NCT01789736|DRUG|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
219305479|NCT02722720|PROCEDURE|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
219305480|NCT02722720|PROCEDURE|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
219305481|NCT04237766|OTHER|Experimental group|"The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively)."
219305482|NCT01588496|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219305483|NCT01588496|DRUG|Placebo|Administered by subcutaneous injection
219305484|NCT03126045|DEVICE|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
219305485|NCT03126045|DEVICE|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
219305486|NCT03601533|DRUG|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
219305487|NCT01551212|DRUG|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
219305488|NCT01551212|DRUG|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
219305489|NCT01551212|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
219305490|NCT00705523|DRUG|varenicline|1.0 mg BID for 12 weeks
219305491|NCT00705523|DRUG|placebo|BID 12 weeks
219305492|NCT03311542|BIOLOGICAL|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
219305493|NCT00568945|DRUG|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
219305494|NCT03616925|BIOLOGICAL|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
219305495|NCT03616925|PROCEDURE|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
219305496|NCT03218241|BIOLOGICAL|PRT064445|Intravenous
219305497|NCT03218241|DRUG|Placebo|Intravenous to mimic PRT064445
219305498|NCT05685589|BEHAVIORAL|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
219305499|NCT01013285|BIOLOGICAL|bevacizumab|
219305500|NCT01013285|DRUG|temozolomide|
219305501|NCT01013285|RADIATION|external beam radiation therapy|
219305502|NCT06185647|OTHER|No intervention. Observational retrospective study|No intervention.
219305503|NCT01648335|DEVICE|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
219305504|NCT01648335|DEVICE|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
219305505|NCT03975166|DRUG|Test Product|2 inhalations in one study period
219305506|NCT03975166|DRUG|Reference Product|2 inhalations in one study period
219305507|NCT03402490|BEHAVIORAL|Motivational interviewing|
219305508|NCT01453829|PROCEDURE|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
219305509|NCT03358966|OTHER|Doubly-labelled water technique|
219305510|NCT03358966|OTHER|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
219305511|NCT05003427|DRUG|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
219305512|NCT03347890|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
219305513|NCT02531347|BEHAVIORAL|Telemedical home blood pressure measurements|
219305514|NCT02531347|BEHAVIORAL|Conventional blood pressure monitoring|
219305515|NCT05780892|BEHAVIORAL|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
219305516|NCT05780892|BEHAVIORAL|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
219305517|NCT05780892|BEHAVIORAL|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
219305518|NCT05780892|BEHAVIORAL|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
219305519|NCT00386269|DRUG|Codeine Phosphate Analgesia|
219305520|NCT04310033|OTHER|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
219305521|NCT05206097|DEVICE|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
219305522|NCT01535755|DEVICE|protocol|In this group, the patients were weaned as the protocol.
219305523|NCT01535755|OTHER|physician's orders|In this group, the patients were weaned as the clinicians' order.
219305524|NCT01835418|DRUG|Amlodipine|crossover comparison of amlodipine vs lisinopril
219305525|NCT00953745|DRUG|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
219305526|NCT00953745|DRUG|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
219305527|NCT00953745|DRUG|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
219305528|NCT00953745|DRUG|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
219305529|NCT01534572|DIETARY_SUPPLEMENT|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
219305530|NCT01534572|DIETARY_SUPPLEMENT|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
219305531|NCT03527238|OTHER|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
219305532|NCT03527238|DRUG|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
219305533|NCT03375567|PROCEDURE|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
219305534|NCT03375567|PROCEDURE|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
219305535|NCT02484053|DRUG|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
219305536|NCT05369195|PROCEDURE|LAAC procedure with the use of transcatheter cerebral protection system|After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
219305537|NCT05369195|PROCEDURE|LAAC procedure without the use of transcatheter cerebral protection system|Only the aortography through radial access will be done before accessing the left atrium.
219305538|NCT06212401|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr
219305539|NCT06212401|DRUG|Ketofole|Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
219305540|NCT04913389|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
219305541|NCT04913389|DRUG|Placebo|Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
219305542|NCT03985085|OTHER|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
219305543|NCT00415077|PROCEDURE|PRK|PRK
219305544|NCT00415077|PROCEDURE|MMC PRK|mitomycin C PRK
219305545|NCT00415077|PROCEDURE|LASEK|LASEK
219305546|NCT02918227|PROCEDURE|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
219305547|NCT03110185|DEVICE|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
219305548|NCT03110185|DEVICE|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
219305549|NCT03110185|DEVICE|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
219305550|NCT05737537|DIAGNOSTIC_TEST|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
219305551|NCT01911598|DRUG|5-FU|5-FU will be administered as per schedule specified in the respective arm.
219305552|NCT01911598|DRUG|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
219305553|NCT01911598|DRUG|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
219305554|NCT01911598|DRUG|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
219305555|NCT01911598|DRUG|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
219305556|NCT00416234|PROCEDURE|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
219305557|NCT00416234|PROCEDURE|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
219305558|NCT00705861|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
219305559|NCT00705861|DRUG|SK3530|SK3530 100mg
219305560|NCT05385432|DRUG|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
219305561|NCT05385432|DRUG|Basiliximab|Simulect® IV 40mg D0 and D4
219305562|NCT01026285|DRUG|Risperidone Long-Acting injectable or oral antipsychotics|According to label
219305563|NCT03073954|OTHER|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
219305564|NCT03073954|BEHAVIORAL|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
219305565|NCT06416709|DRUG|mesenchymal stem cells|Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times
219305566|NCT06416709|OTHER|saline|10 ml saline is used as placebo once every three days and for three times
219305567|NCT04329507|DIAGNOSTIC_TEST|Breath test|collection of an exhaled breath sample
219305568|NCT05806307|DRUG|Misoprostol|(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
219305569|NCT05806307|DEVICE|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
219305570|NCT05806307|DRUG|Carbetocin|(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
219305571|NCT05806307|DRUG|Oxytocin|(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
219305572|NCT05806307|DRUG|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
219305573|NCT05806307|DRUG|Vasopressin|15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
219305574|NCT05806307|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine|15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
219305575|NCT05322746|DEVICE|Focal muscle vibration|Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
219305576|NCT05503472|OTHER|observational|observational
219305577|NCT01741896|PROCEDURE|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
219305578|NCT03810131|OTHER|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
219305579|NCT02112838|DRUG|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
219305580|NCT02112838|DRUG|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
219305581|NCT02112838|DRUG|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
219305582|NCT01575028|DRUG|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
219305583|NCT01575028|DRUG|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
219305584|NCT03430206|DEVICE|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
219305585|NCT00552487|DRUG|synacthen|1 µg synacthen in the vein
219305586|NCT03383315|DRUG|Tramadol|One dose of intravenous tramadol 50mg
219305587|NCT03383315|DRUG|Metoclopramide|One dose of intravenous metoclopramide 10mg
219305588|NCT03383315|DRUG|Placebo|Sodium chloride 0.9%
219305589|NCT03948555|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)|All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
219305590|NCT05877313|OTHER|Sterile water foot bath|Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
219305591|NCT05877313|DRUG|Nitric Oxide|Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
219305592|NCT03503461|OTHER|exosomes analysis|Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
219305593|NCT01414985|BIOLOGICAL|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
219305594|NCT00232674|DRUG|Pulmicort (budesonide) Turbuhaler|
219305595|NCT00315900|DRUG|Depakote ER|depakote ER
219305596|NCT00315900|DRUG|Seroquel|seroquel
219305597|NCT04308395|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
219305598|NCT05456802|OTHER|Standard of care treatment|Standard of care treatment including percutaneous interventions was performed in all participants.
219305599|NCT03534284|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
219305600|NCT03534284|DRUG|Trazodone|trazodone tablet
219305601|NCT03534284|DRUG|Placebo|Inactive pill manufactured to mimic trazodone tablets.
219305602|NCT02831543|DRUG|Motireb 5/100 mg|
219305603|NCT02831543|DRUG|Mosapride citrate|
219305604|NCT02831543|DRUG|Placebo|
219305605|NCT03026985|OTHER|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
219305606|NCT02059785|DRUG|Pinocembrin for Injection|
219305607|NCT03383926|PROCEDURE|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
219305608|NCT03383926|PROCEDURE|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
219305609|NCT01747993|DRUG|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
219305610|NCT01747993|DRUG|Placebo|(1 tablet / day for 6 days)
219305611|NCT05317845|OTHER|No treatment given|The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
219305612|NCT04447196|OTHER|MDP|Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
219305613|NCT04737187|DRUG|Trifluridine/Tipiracil|Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
219305614|NCT04737187|DRUG|Bevacizumab|administered every 2 weeks (Day 1 and Day 15)
219305615|NCT06143436|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
219305616|NCT06609993|DRUG|intravenous rescue opioid analgesia using fentanyl|intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
219305617|NCT06609993|DRUG|intravenous rescue atropine administration|atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50
219305618|NCT06609993|DRUG|intravenous rescue urapidil administration|urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg
219305619|NCT06609993|DRUG|intravenous rescue ephedrine administration|ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg
219744669|NCT05698498|OTHER|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
219305620|NCT06609993|BIOLOGICAL|concentrate of red blood cells|concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%
219305621|NCT06609993|BIOLOGICAL|red blood cells autotransfusion|red blood cells from the operation site will be retransfused using cell saver
219305622|NCT06609993|DRUG|primary treatment of postoperative nausea and vomiting (PONV)|dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
219305623|NCT06609993|DRUG|secondary treatment of postoperative nausea and vomiting (PONV)|Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
219305624|NCT06609993|DRUG|intraopertative fluid challenge (IFC)|3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre
219305625|NCT06609993|DRUG|postoperative rescue opioid analgesia using morphine|postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
219305626|NCT06727760|BEHAVIORAL|massage|"The mothers in the massage group applied colic massage according to the Educational Colic Massage Checklist twice a day for 15-20 minutes each time for three weeks, when the baby was calm and during colic attacks."
219305627|NCT06727760|BEHAVIORAL|kangroo care|"The mothers in the kangaroo care group applied kangaroo care according to the Educational Kangaroo Care Checklist twice a day for three weeks for 15-20 minutes each time when the baby was calm and during colic attacks."
219305628|NCT05599620|BEHAVIORAL|AWARE|AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
219305629|NCT05599620|BEHAVIORAL|General Health Promotion|General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
219305630|NCT04847193|OTHER|Dietary Intervention 1: Placebo|Participants receive a study drink supplemented with a placebo for 5 days
219305631|NCT04847193|OTHER|Dietary Intervention 2: Xanthohumol and Iso-alpha acids|Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
219305632|NCT06728189|BIOLOGICAL|CAR-NKT Cells treatment|"Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC738 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2;"
219305633|NCT06727929|DIAGNOSTIC_TEST|Collection of gingival crevicular fluid, ELISA|GCF samples were collected at baseline and at the 6-8 -week follow-up appointment after non-surgical periodontal treatment . After removing the supragingival plaque from the interproximal surfaces with sterile curettes, these sample surfaces were isolated with cotton rolls and slightly air-dried to avoid contamination. Standardized paper strips were inserted 1 to 2 mm into the gingival sulcus and held for 30 seconds to collect GCF. Strips contaminated with blood or saliva were discarded and not evaluated. The paper strips were transferred to a precalibrated Periotron 8000 device to measure the fluid volume. Paper strips were placed in sterile Eppendorf tubes and stored at -80C, until laboratory analysis. The level of GCF Dkk-1 and sFRP5 levels was measured by ELISA using commercial kits.
219305634|NCT06729606|BIOLOGICAL|Aviptidil|Administered by IV infusion over 12 hours per day for 3 days. The Day 1 infusion rate is 50 pmol/kg/hr, the Day 2 infusion rate is 100 pmol/kg/hr, and the Day 3 infusion rate is 150 pmol/kg/hr.
219305635|NCT06729606|BIOLOGICAL|Aviptidil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
219305636|NCT06729606|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
219305637|NCT06728475|DEVICE|virtual reality|"In Xbox, we will choose suitable games that aim to improve upper limb function like boxing, Darts, tennis, goalkeeping, basketball, disc throwing, balling, and volleyball.~The Kinect sensor has the advantage of auto adjustment of its camera according to the child's position and height that's to say the child can perform the game in sitting or standing according to their abilities.~They will receive 30 minutes of VR intervention in addition to the time required for the designed physical therapy program."
219305638|NCT06728475|OTHER|mirror therapy|Mirror Therapy A mirror of 30 × 20 inches was used for the MT, which was large enough to cover the entire affected limb while still allowing the reflection of the non-affected limb to be seen. The child was seated in a chair with the forearms resting on the table. In the mid-sagittal plane, the mirror box was positioned at an angle of 70° to 80° to the trunk. The affected limb was placed behind the mirror. The child was asked to perform the exercises bilaterally and symmetrically as much as possible. Even if the affected side did not move easily or fully, the child was advised to synchronize the motions with both hands and arms. The researcher constantly reminded the child to concentrate on the movement of the non-affected limb in front of the mirror, which helped to increase the mirror illusion
219305639|NCT06728475|OTHER|virtual reality with mirror therapy|group C will receive combined effect of both techniques (virtual reality and mirror therapy)
219305640|NCT06727617|DRUG|Serplulimab|intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)
219305641|NCT06727617|DRUG|Chemotherapy|"Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles."
219305642|NCT06727617|RADIATION|radiotherapy|Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
219305643|NCT00564551|BEHAVIORAL|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
219305644|NCT00564551|BEHAVIORAL|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
219305645|NCT01528501|DRUG|Panobinostat (LBH589)|
219305646|NCT00171600|DRUG|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
219305647|NCT02058654|DRUG|Creatine|Creatine powder (5 g)
219305648|NCT02058654|DRUG|Placebo|Bulking agent powder (5 g)
219305649|NCT02383004|OTHER|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
219305650|NCT05717439|DIAGNOSTIC_TEST|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
219305651|NCT05717439|DIAGNOSTIC_TEST|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
219305652|NCT05374213|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
219305653|NCT05398744|OTHER|Group Exercise Program|At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
219305654|NCT05549752|DRUG|Flecainide Injectable Solution|Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
219305655|NCT05549752|DRUG|Amiodarone Injectable Solution|Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
219305656|NCT05406752|DRUG|paracetamol Uniflash (125 mg/ 1.25 mL)|Oromucosal solution (125 mg/ 1.25 mL) for buccal route
219305657|NCT00926549|DEVICE|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
219305658|NCT03362047|DRUG|Riciguat Group|Patients will be administered 12 weeks Riciguat
219305659|NCT03362047|DRUG|Macitentan Group|Patients will be administered 12 weeks Macitentan
219305660|NCT06835608|OTHER|Schroth Exercise Group|The study group will receive electrotherapy treatment (hot pack, ultrasound, tens) to the neck area for 30 minutes in each session. After electrotherapy treatment, kyphotic posture correction exercises will be applied with the help of proprioceptive and extroceptive stimuli in the sagittal plane with mirror control and specific corrective breathing. In the exercise program, exercise practices will be performed in specific positions in supine, prone, sitting and standing. The exercise program will be planned for approximately 40 minutes in each session. A total of 20 sessions of electrotherapy and exercise will be performed for 4 weeks. At the end of the 4th week, after the electrotherapy sessions are completed, exercise applications will continue for the other 4 weeks by the physiotherapist who performs the exercise 3 days a week.
219305661|NCT06835608|OTHER|Postural Exercises Group|Patients to be included in the control group will receive electrotherapy treatment (ultrasound, tens, hotpack) to the neck area for 30 minutes in each session. After the electrotherapy treatment, posture corrective exercises will be applied. Corrective exercise program for posture will consist of deep neck flexor muscle strengthening exercises, lower and middle trapezius strengthening, neck isometric exercises. All strengthening exercises will be given 3 sets of 10 repetitions per day, each repetition for 10 seconds. Stretching exercises will be given to the shortened upper trapezius and pectoralis major muscles. Stretching exercises will be given 2 sets of 5 repetitions per day, with each repetition lasting 20 seconds. In the first 4 weeks, a total of 20 sessions of electrotherapy and exercise will be performed in corrective exercises for posture. At the end of the 4th week, exercise applications will continue for the other 4 weeks 3 days a week.
219305662|NCT06557226|OTHER|oral and nutritional examination|Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
219305663|NCT03190447|DEVICE|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
219305664|NCT03190447|DEVICE|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
219305665|NCT03190447|DEVICE|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
219305666|NCT03190447|DEVICE|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
219305667|NCT03190447|DEVICE|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
219305668|NCT05269810|DRUG|SA001 Low dose|3 tablets b.i.d for 8 weeks
219305669|NCT05269810|DRUG|SA001 Mid dose|3 tablets b.i.d for 8 weeks
219305670|NCT05269810|DRUG|SA001 High dose|3 tablets b.i.d for 8 weeks
219305671|NCT05269810|DRUG|Placebo|3 tablets b.i.d for 8 weeks
219305672|NCT01206543|OTHER|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
219305673|NCT00185679|DEVICE|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer"
219305674|NCT05968547|OTHER|Driving assessment in glaucoma patient|One group of patient will be given questionnaire while the other group will respond to a questionnaire while the other group will have vision assessment. Patients could participate in both groups.
219305675|NCT05432778|DRUG|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
219305676|NCT05397184|BIOLOGICAL|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
219305677|NCT05539274|DIAGNOSTIC_TEST|human papilloma virus testing and genotyping in cervical cancer cases|an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
219305678|NCT00552877|DEVICE|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
219305679|NCT01351103|DRUG|LGK974|
219305680|NCT01351103|BIOLOGICAL|PDR001|
219305681|NCT04450160|DRUG|Anhydrous Enol-Oxaloacetate (AEO)|Oral supplementation with AEO along with the Standard of Care (Temozolomide)
219305682|NCT04450160|OTHER|Standard of Care|Standard of Care Temozolomide
219305683|NCT00358553|DRUG|Insulin|
219305684|NCT01793220|OTHER|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
219305685|NCT04604548|DRUG|Oral administration of 100 mg KH176 twice daily|Drug: KH176
219305686|NCT00133887|DRUG|rapamycin|3 to 5 mg/day
219305687|NCT00133887|DRUG|ciclosporine|Blood residual level \< or = to 125 ng/ml
219305688|NCT00133887|DRUG|tacrolimus|Blood residual level \< or = to 8 ng/ml
219305689|NCT01833715|DRUG|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
219305690|NCT01833715|DRUG|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
219305691|NCT01833715|DRUG|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
219305692|NCT02303522|OTHER|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
219305693|NCT06085911|BEHAVIORAL|One day course|a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.
219305694|NCT06085911|BEHAVIORAL|Individual follow-ups|the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
219305695|NCT01807013|PROCEDURE|ultrasound, liver elastometry, minilaparoscopy|"* conventional high-end ultrasound technique,~* small access laparoscopy with fine laparoscopes~* Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
219305696|NCT01776801|OTHER|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
219305697|NCT02725346|PROCEDURE|Acromioplasty with planning|
219305698|NCT02725346|PROCEDURE|Acromioplasty without planning|
219305699|NCT02782689|DEVICE|Kit Biflex|Two-layer reusable compression system
219305700|NCT02782689|DEVICE|Profore|Four-layer compression system
219305701|NCT04061447|DRUG|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
219305702|NCT04061447|DRUG|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
219305703|NCT04288765|DRUG|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
219305704|NCT06090877|DEVICE|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
219305705|NCT00160784|PROCEDURE|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
219305706|NCT00160784|PROCEDURE|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
219305707|NCT00160784|OTHER|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
219305708|NCT02049151|DRUG|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
219305709|NCT02049151|DRUG|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
219305710|NCT02049151|DRUG|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
219305711|NCT02049151|DRUG|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
219305712|NCT03572478|DRUG|Rucaparib|600 mg taken by mouth twice daily.
219305713|NCT03572478|DRUG|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
219305714|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
219305715|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
219305716|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
219305717|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
219305718|NCT00284817|DRUG|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
219305719|NCT02608593|PROCEDURE|Strattice|Implant based reconstruction with strattice cover of part or all of implant
219305720|NCT04293445|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
219305721|NCT01605292|PROCEDURE|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
219305722|NCT01605292|PROCEDURE|Palpation|Manual palpation for localizing radial artery for inserting needle.
219305723|NCT01730794|OTHER|NAVA ventilation|Neurally adjusted ventilatory assist
219305724|NCT01730794|OTHER|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
219305725|NCT05510752|BEHAVIORAL|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
219305726|NCT05510752|BEHAVIORAL|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
219305727|NCT02831803|DIETARY_SUPPLEMENT|Walnuts|28 gm/day in single-serve package
219305728|NCT02831803|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
219305729|NCT01459419|DRUG|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
219305730|NCT01459419|DRUG|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
219305731|NCT02913235|PROCEDURE|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
219305732|NCT04675021|DRUG|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
219305733|NCT04675021|DRUG|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
219305734|NCT04675021|DRUG|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
219305735|NCT02669511|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
219305736|NCT03742284|DEVICE|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
219305737|NCT04265313|OTHER|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
219305738|NCT04121195|DRUG|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
219305739|NCT05374161|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.
219305740|NCT05374161|OTHER|Waitlist Control Group|Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
219305741|NCT03933930|OTHER|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct\>30%. If Hct \>30%, dopamine infusion starts.
219305742|NCT03933930|OTHER|Goal-directed therapy|If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
219305743|NCT02795429|DRUG|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
219305744|NCT02795429|DRUG|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
219305745|NCT05782452|PROCEDURE|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
219305746|NCT05782452|GENETIC|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
219305747|NCT02411500|DRUG|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
219305748|NCT00362453|BEHAVIORAL|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
219305749|NCT03187340|BEHAVIORAL|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
219305750|NCT03187340|BEHAVIORAL|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
219305751|NCT04398420|DEVICE|TVERP|Transurethral Vapor Enucleation Resection of the prostate
219305752|NCT04398420|DEVICE|TURis|Transurethral Vapor Enucleation Resection of the prostate
219305753|NCT04398420|DEVICE|HoLEP|Transurethral Vapor Enucleation Resection of the prostate
219305754|NCT01640054|DRUG|Fostamatinib|Fostamatinib 100mg once daily
219305755|NCT00165087|DRUG|asparaginase (E. Coli)|
219305756|NCT00165087|DRUG|asparaginase (Erwina)|
219305757|NCT00165087|DRUG|dexrazoxane|
219305758|NCT00165087|DRUG|doxorubicin|
219305759|NCT00165087|PROCEDURE|cranial radiation (once daily fractionation)|
219305760|NCT00165087|PROCEDURE|cranial radiation (twice-daily fractionation)|
219305761|NCT00165087|PROCEDURE|Intrathecal chemotherapy without radiation|
219305762|NCT04740008|DRUG|Low Nicotine Content Cigarettes|Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
219305763|NCT04740008|OTHER|Control message|Participants will read control message
219305764|NCT04740008|OTHER|Test message|Participants will read test message
219305765|NCT00029172|OTHER|case management|
219305766|NCT05220254|BEHAVIORAL|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
219305767|NCT04248985|OTHER|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
219305768|NCT02839837|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
219305769|NCT02839837|DEVICE|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
219305770|NCT04923854|OTHER|No intervention|No intervention
219305771|NCT03125525|DEVICE|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
219305772|NCT05694104|OTHER|Malnutrition|For the diagnosis of malnutrition, we adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
219305773|NCT04950088|OTHER|Hand-held video game device|
219305774|NCT04962802|BEHAVIORAL|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
219305775|NCT04962802|BEHAVIORAL|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
219305776|NCT01557283|OTHER|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
219305777|NCT03644251|OTHER|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
219305778|NCT05156632|BIOLOGICAL|Medium-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.
219305779|NCT05156632|BIOLOGICAL|High-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
219305780|NCT05156632|BIOLOGICAL|Placebo-comparator group|The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
219305781|NCT04820777|OTHER|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
219305782|NCT04820777|OTHER|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
219305783|NCT04980508|DIAGNOSTIC_TEST|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
219305784|NCT05486546|PROCEDURE|Contoura with Phorcides|Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
219305785|NCT05486546|DEVICE|WaveLight Wavefront Optimized|Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
219305786|NCT01416688|PROCEDURE|assessment of therapy complications|Will be given by questionnaire
219305787|NCT01416688|PROCEDURE|psychosocial assessment and care|Will be given by questionnaire
219305788|NCT01416688|PROCEDURE|quality-of-life assessment|Will be given by questionnaire
219305789|NCT00002023|DRUG|Zidovudine|
219305790|NCT03175965|DEVICE|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
219305791|NCT02080221|DRUG|FOLFOXA|
219305792|NCT02047643|DEVICE|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
219305793|NCT01386788|OTHER|There is no intervention planned (observational)|No intervention foreseen
219305794|NCT04629001|DIAGNOSTIC_TEST|Covid-19 PCR , IGM|test for Covid-19
219305795|NCT03089151|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
219305796|NCT00923533|DRUG|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
219305797|NCT00923533|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
219305798|NCT00581815|DEVICE|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
219305799|NCT00581815|DEVICE|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
219305800|NCT01432717|BIOLOGICAL|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
219305801|NCT01432717|OTHER|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
219305802|NCT05874115|OTHER|liquid biopsy|liquid biopsy
219305803|NCT04187053|PROCEDURE|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
219305804|NCT04187053|DRUG|Saline|Sham group will receive saline as a sham for methylene blue
219305805|NCT04187053|DRUG|Methylene Blue|Experimental arm will receive methylene blue
219305806|NCT04187053|DEVICE|Light emitting laser|Experimental arm will receive Light emitting laser
219305807|NCT04187053|DEVICE|Non-light emitting laser|Sham group will receive Non-light emitting laser
219305808|NCT00120406|DEVICE|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
219305809|NCT00120406|PROCEDURE|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
219305810|NCT06209671|BIOLOGICAL|INS19 CAR-T Cells|INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
219305811|NCT06381050|DRUG|SHR-7631|The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
219305812|NCT03703245|OTHER|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
219305813|NCT03703245|OTHER|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
219305814|NCT03542409|OTHER|MR Perfusion Scan|MR perfusion scan before and during surgery.
219305815|NCT03542409|OTHER|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
219305816|NCT03542409|OTHER|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
219305817|NCT05390983|PROCEDURE|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
219305818|NCT03590405|PROCEDURE|uterus transplantation surgery and IVF|IVF before surgery living donor uterus transplantation ET
219305819|NCT06283004|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
219305820|NCT06283004|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
219305821|NCT06283004|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
219305822|NCT05960565|DRUG|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
219305823|NCT04032626|DRUG|Lenalidomide 10 mg|Lenalid
219305824|NCT04032626|DRUG|Placebo|Placebo
219305825|NCT02808143|BIOLOGICAL|BCG Solution|Given intravesically
219305826|NCT02808143|OTHER|Laboratory Biomarker Analysis|Correlative studies
219305827|NCT02808143|BIOLOGICAL|Pembrolizumab|Given intravesically
219305828|NCT02808143|OTHER|Pharmacological Study|Correlative studies
219305829|NCT04964388|DRUG|GLP-1 receptor agonist|Diabetes medication
219305830|NCT03082742|DRUG|Hydrochlorothiazide|
219305831|NCT03082742|DRUG|Furosemide|
219305832|NCT02445001|PROCEDURE|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
219305833|NCT00675090|DRUG|GSK239512|GSK239512 oral tablets once a day
219305834|NCT00675090|DRUG|Placebo|Placebo tablets to match once a day
219305835|NCT06436027|DIAGNOSTIC_TEST|Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling|Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.
219305836|NCT06391502|BEHAVIORAL|Multi-component Exercise Intervention Program|"The Vivifrail program (http://vivifrail.com) is a home-based exercise program that focuses on personalized multi-component exercise prescriptions based on an elderly person's functional abilities, including resistance/strength, balance, flexibility, and cardiovascular endurance exercise (i.e., walking).~During hospitalization, patients who meet the criteria of sodium intake will be screened, and then divided into groups according to the method of randomized controlled trial. The experimental group will carry out corresponding exercise plan according to the results of SPPB."
219305837|NCT04436939|DEVICE|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
219305838|NCT00259584|BEHAVIORAL|Management and Outcome of SVCO|
219305839|NCT05334745|OTHER|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
219305840|NCT03916289|OTHER|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
219305841|NCT00250679|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
219305842|NCT00250679|DRUG|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
219305843|NCT00250679|DRUG|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
219305844|NCT00250679|DRUG|Placebo|Placebo nebule or placebo aerolizer
219305845|NCT00187967|DEVICE|pumps used for cardiopulmonary bypass|
219305846|NCT05902182|DEVICE|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
219305847|NCT06226818|OTHER|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
219305848|NCT03211910|DEVICE|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
219305849|NCT03211910|OTHER|Standard Care of Treatment|Standard Care of Treatment
219305850|NCT01093521|DRUG|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
219305851|NCT01093521|DRUG|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
219305852|NCT02207881|DRUG|VDO gel|VDO gel
219305853|NCT02207881|DRUG|placebo|matching placebo gel
219305854|NCT00448279|DRUG|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
219305855|NCT00448279|DRUG|Chemotherapy|Schedule and dose at the investigator's discretion
219305856|NCT02179320|PROCEDURE|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
219305857|NCT02179320|DEVICE|acupuncture needle 0,25 x 40mm|
219305858|NCT03947437|BIOLOGICAL|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
219305859|NCT03947437|BIOLOGICAL|Placebo|Sterile normal saline for injection.
219305860|NCT02584582|DRUG|Liraglutide|
219305861|NCT02584582|DRUG|Exenatide|
219305862|NCT02584582|PROCEDURE|Liquid meal test|
219305863|NCT02584582|OTHER|No drug (Baseline day)|
219305864|NCT03907410|OTHER|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
219305865|NCT03907410|OTHER|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
219305866|NCT06409520|DIAGNOSTIC_TEST|thyroid function tests|(TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.
219305867|NCT06409520|DIAGNOSTIC_TEST|cardiac enzymes|troponine
219305868|NCT06409520|DIAGNOSTIC_TEST|ECG|Electrocardiogram
219305869|NCT02985320|BIOLOGICAL|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
219305870|NCT02985320|BIOLOGICAL|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
219305871|NCT02985320|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
219305872|NCT02985320|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
219305873|NCT02985320|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
219305874|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
219305875|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
219305876|NCT02972866|DRUG|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
219305877|NCT01593306|DRUG|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
219305878|NCT01593306|DRUG|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
219305879|NCT03127254|BEHAVIORAL|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
219305880|NCT03127254|BEHAVIORAL|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
219305881|NCT03127254|BEHAVIORAL|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
219305882|NCT03127254|BEHAVIORAL|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
219305883|NCT03127254|BEHAVIORAL|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
219305884|NCT06186570|BEHAVIORAL|Online-Based Self-Help Intervention|See the description above.
219305885|NCT02391454|DEVICE|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
219305886|NCT02391454|OTHER|Usual care|
219305887|NCT03718533|DRUG|Eltrombopag|Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
219305888|NCT01295034|DIETARY_SUPPLEMENT|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
219305889|NCT01295034|DRUG|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
219305890|NCT02116101|DIETARY_SUPPLEMENT|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
219305891|NCT02116101|DIETARY_SUPPLEMENT|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
219305892|NCT03728322|BIOLOGICAL|iHSCs treatment group|iHSCs intravenous injection
219305893|NCT02530203|DEVICE|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
219305894|NCT02530203|DEVICE|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
219305895|NCT00135759|DRUG|Naltrexone|low dose naltrexone in addition to daily methadone taper
219305896|NCT00135759|DRUG|Placebo comparator|1 capsule/day for 6 days
219305897|NCT00135759|DRUG|naltrexone|0.125 mg capsule/day for 6 days
219305898|NCT00135759|DRUG|naltrexone|0.250 mg capsule/day for 6 days
219305899|NCT00903955|OTHER|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
219305900|NCT06456450|BIOLOGICAL|Biological Treatment for severe asthma patients|Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
219305901|NCT00781287|DRUG|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
219305902|NCT00781287|DRUG|Raltegravir|400 mg BID PO
219305903|NCT06116955|DRUG|Midazolam and sufentanil|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
219305904|NCT06116955|DRUG|Midazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
219305905|NCT06116955|DRUG|Remazolam and sufentanil.|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
219305906|NCT06116955|DRUG|Remazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
219305907|NCT05127252|DIAGNOSTIC_TEST|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
219305908|NCT04793659|DRUG|Oral Fasudil 90 mg/day|Oral tablet
219305909|NCT04793659|DRUG|Oral Fasudil 180 mg/day|Oral tablet
219305910|NCT04793659|DRUG|Oral Placebo|Oral tablet
219305911|NCT00549783|BIOLOGICAL|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
219305912|NCT00549783|BIOLOGICAL|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
219305913|NCT04806542|BEHAVIORAL|TMR-group|A mindfulness-based 8 week program.
219305914|NCT04806542|BEHAVIORAL|Treatment as usual|Individual counselling.
219305915|NCT04574050|OTHER|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
219305916|NCT00728611|BIOLOGICAL|PRGF|intra auricular injection 6mg
219305917|NCT00728611|DRUG|hyaluronic acid|20 mg / 2 ml
219305918|NCT00728611|DRUG|placebo|physiological water 3cc + lidocain 3cc
219305919|NCT05293210|DRUG|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
219305920|NCT00000301|DRUG|Amantadine|
219305921|NCT00655291|DRUG|XP20B|
219305922|NCT00655291|DRUG|Placebo|
219305923|NCT03063112|DEVICE|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
219305924|NCT03063112|DRUG|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
219305925|NCT03063112|DEVICE|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
219305926|NCT03063112|DRUG|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
219305927|NCT04253067|DEVICE|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
219305928|NCT04253067|DEVICE|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
219305929|NCT03785171|PROCEDURE|surgical revascularization|Indirect revascularization procedure
219305930|NCT00945126|OTHER|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
219305931|NCT00562705|BEHAVIORAL|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
219305932|NCT00562705|BEHAVIORAL|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
219305933|NCT01174160|DRUG|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
219305934|NCT01174160|DRUG|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
219305935|NCT02289612|OTHER|Yellow Mustard Gum Fibre|
219305936|NCT02289612|OTHER|Soluble Flaxseed Gum Fibre|
219305937|NCT02289612|OTHER|Fenugreek Gum Fibre|
219305938|NCT01137968|DRUG|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
219305939|NCT01137968|DRUG|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
219305940|NCT03452358|PROCEDURE|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
219305941|NCT02899013|OTHER|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
219305942|NCT03616197|PROCEDURE|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
219305943|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219305944|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
219305945|NCT02744378|DRUG|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
219305946|NCT02744378|DRUG|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
219305947|NCT00000837|BIOLOGICAL|Varicella Virus Vaccine (Live)|
219305948|NCT02116985|DEVICE|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
219305949|NCT02116985|DEVICE|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
219305950|NCT00108654|DRUG|VRC-HIVADV014-00-VP|
219305951|NCT03537287|DRUG|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
219305952|NCT03537287|DRUG|Vaginal progesterone|200 mg of vaginal progesterone daily
219305953|NCT03537287|DRUG|Oral dydrogesterone|2 tablets of dydrogesterone daily
219305954|NCT00892684|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
219305955|NCT00892684|DIETARY_SUPPLEMENT|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
219305956|NCT04152460|DEVICE|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
219305957|NCT04152460|OTHER|Grandioso x-tra|Nanohybrid Bulk Resin Composite
219305958|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
219305959|NCT04218084|DRUG|Voxelotor|Participants are randomized 1:1 to receive voxelotor or placebo.
219305960|NCT04218084|DRUG|Placebo|Matching placebo.
219305961|NCT06962306|DRUG|Methadone hydrochloride|Initial dosing 0.2mg/kg, potential to escalate to 0.25mg/kg following interim analysis
219305962|NCT06962306|DRUG|Fentanyl/Hydromorphone|Per routine care
219305963|NCT05133778|DIETARY_SUPPLEMENT|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
219305964|NCT05133778|OTHER|Maltodextrin control|Supplementation with 760 mg maltodextrin
219305965|NCT06643143|DRUG|IkT-001Pro|IkT-001Pro
219305966|NCT06643143|DRUG|Placebo|Placebo
219305967|NCT05580588|DRUG|SPH4336|400 mg SPH4336 PO QD
219305968|NCT04723420|OTHER|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
219305969|NCT04723420|OTHER|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
219305970|NCT06062147|BEHAVIORAL|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
219305971|NCT04912375|BEHAVIORAL|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
219305972|NCT05093699|DEVICE|Butterfly iQ+ ultrasound probe|Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
219305973|NCT05093699|DEVICE|Ultrasound probe|Standard single-view ultrasound probe
219305974|NCT00211185|DRUG|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
219305975|NCT00211185|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
219305976|NCT00211185|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
219305977|NCT00211185|DRUG|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
219305978|NCT00211185|DRUG|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
219305979|NCT00211185|OTHER|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
219305980|NCT05271292|DRUG|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
219305981|NCT00712673|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
219305982|NCT00712673|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
219305983|NCT00712673|DEVICE|Pen auto-injector|
219305984|NCT00712673|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
219305985|NCT02729428|DEVICE|MRI|Participants will undergo an MRI scan
219305986|NCT05839496|OTHER|Cervical stabilization exercises|Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
219305987|NCT04581096|OTHER|no intervention|just descriptive analysis of clinical data
219305988|NCT00969527|DIETARY_SUPPLEMENT|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
219305989|NCT00969527|DIETARY_SUPPLEMENT|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
219305990|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
219305991|NCT00471159|DRUG|docetaxel|
219305992|NCT00471159|DRUG|PF-3512676|
219305993|NCT02274818|BEHAVIORAL|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
219305994|NCT01242358|DEVICE|Capnography|Capnographic monitoring
219305995|NCT01242358|DEVICE|Standard monitoring|Standard monitoring
219305996|NCT06483529|DIAGNOSTIC_TEST|compliance measurement|compliance can be measured by analyzing pressure volume curves generated through different methods
219305997|NCT01947985|DRUG|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
219305998|NCT01947985|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
219305999|NCT04136665|OTHER|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
219306000|NCT04638595|OTHER|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
219306001|NCT03603028|DEVICE|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
219306002|NCT03806387|DRUG|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
219306003|NCT04151797|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician"
219306004|NCT00699894|DRUG|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
219306005|NCT00699894|DRUG|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
219306006|NCT00081107|DRUG|epothilone D|
219306007|NCT02717572|RADIATION|Fludeoxyglucose F 18|
219306008|NCT02717572|DEVICE|Positron Emission Tomography|
219306009|NCT02717572|DEVICE|Computerized Tomography|
219306010|NCT02717572|DEVICE|Magnetic Resonance Imaging|
219306011|NCT04819984|DEVICE|TCM5 device (Radiometer) for PtC02 continuous measurement|Evaluation of PtC02 variation as a reflect of PaC02 during 30 minutes of weaning proof for mechanical ventilation (spontaneous ventilation on T-piece)
219306012|NCT04684602|BIOLOGICAL|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
219306013|NCT04398407|BEHAVIORAL|Coaching and Advancement for Peer Providers (CAPP)|The CAPP intervention will combine executive coaching approaches and techniques with the specific needs and environmental demands of individuals working as PSS. A person who has been a PSS and trainer of PSS nationally has developed the CAPP intervention using the expertise of Center staff, the Harvard Institute of Coaching (IOC) and our Peer Advisory Group. Individuals randomized to the experimental condition will receive 16 individual coaching sessions tailored to the specific job stressors they are experiencing. CAPP is designed to address the following issues: role confusion, lack of clarity about job tasks, conflict with other providers, burnout, lack of organizational commitment and job satisfaction.
219306014|NCT05898243|PROCEDURE|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
219306015|NCT00081042|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
219306016|NCT01576250|OTHER|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
219306017|NCT04395027|DEVICE|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
219306018|NCT01468831|DRUG|Minocycline|100 mg of minocycline in a pink opaque capsule
219306019|NCT01468831|OTHER|Placebo|Pill with inactive ingredients in a pink opaque capsule
219306020|NCT01468831|DRUG|Bevacizumab|1.25 mg bevacizumab injection
219306021|NCT05540054|OTHER|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
219306022|NCT05540054|OTHER|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
219306023|NCT02764294|OTHER|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
219306024|NCT02764294|OTHER|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
219306025|NCT02764294|OTHER|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
219306026|NCT02801968|PROCEDURE|Tap block|
219306027|NCT02801968|OTHER|intravenous analgesia|
219306028|NCT01131234|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219306029|NCT01131234|DRUG|Cediranib Maleate|Given PO
219306030|NCT01131234|OTHER|Pharmacological Study|Correlative studies
219306031|NCT01131234|OTHER|Laboratory Biomarker Analysis|Correlative studies
219306032|NCT01405586|DRUG|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
219306033|NCT01405586|DRUG|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
219306034|NCT01405586|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
219306035|NCT04537182|PROCEDURE|Lung volume reduction surgery|Lung volume reduction by surgery
219306036|NCT04537182|PROCEDURE|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
219306037|NCT06044974|DEVICE|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
219306038|NCT06044974|DRUG|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
219306039|NCT00241605|DRUG|rosiglitazone/metformin|
219306040|NCT03634020|DEVICE|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
219306041|NCT06418828|OTHER|return to work|Ask patients if they are going back to work
219306042|NCT05103293|DIAGNOSTIC_TEST|patient-derived tumor-like cell clusters drug sensitivity test|Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
219306043|NCT04439682|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
219306044|NCT00027495|DIETARY_SUPPLEMENT|curcumin|
219306045|NCT04125030|OTHER|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
219306046|NCT01648881|RADIATION|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
219306047|NCT03561012|BEHAVIORAL|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
219306048|NCT03561012|OTHER|Control Condition|Standard of care
219306049|NCT00842985|DRUG|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
219306050|NCT04141969|DIETARY_SUPPLEMENT|RLP|RLP nutraceutical
219306051|NCT04141969|OTHER|Placebo|Inert brown powder
219306052|NCT01224795|DRUG|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
219306053|NCT01224795|DRUG|Placebo Comparator|Placebo Peramivir, administered intravenously.
219306054|NCT02701348|OTHER|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
219306055|NCT02701348|DRUG|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
219306056|NCT02701348|PROCEDURE|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
219306057|NCT02701348|OTHER|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
219306058|NCT04457167|DEVICE|Robot-assisted|robot-assisted surgery
219306059|NCT04457167|PROCEDURE|Not robot-assisted surgery|Not robot-assisted surgery
219306060|NCT01882933|DRUG|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
219306061|NCT01882933|PROCEDURE|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
219306062|NCT01874860|DRUG|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
219306063|NCT01874860|DRUG|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
219306064|NCT01874860|OTHER|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
219306065|NCT01874860|OTHER|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
219306066|NCT01874860|DRUG|Clindamycin|Recommended for daily use if rash returns (Topical cream)
219306067|NCT01874860|DRUG|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
219306068|NCT01952054|DRUG|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
219306069|NCT02585479|DRUG|Pirarubicin|"1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
219306070|NCT02585479|DRUG|Oxaliplatin|"1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
219306071|NCT02585479|DRUG|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
219306072|NCT02585479|DEVICE|Gelfoam|Hepatic artery embolization with Gelfoam.
219306073|NCT05664386|DRUG|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
219306074|NCT05664386|DRUG|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
219306075|NCT03459274|DEVICE|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
219306076|NCT02601664|PROCEDURE|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
219306077|NCT02601664|PROCEDURE|Conventional PCI|Conventional PCI
219306078|NCT02972125|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
219306079|NCT02972125|DRUG|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
219306080|NCT00298090|DEVICE|StO2 monitoring|placement of the StO2 device/ external noninvasive
219306081|NCT00836095|DEVICE|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
219306082|NCT00836095|DEVICE|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
219306083|NCT05373589|OTHER|conventional ventilation, group C|In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
219306084|NCT05373589|OTHER|pressure support, group PS|In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
219306085|NCT03046784|OTHER|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
219306086|NCT04795882|BIOLOGICAL|BCMA CAR T cells|Infusion with ATIMP: BCMA CAR T-cells
219306087|NCT04795882|BIOLOGICAL|BCMA/CD19 CAR T cells|Infusion with ATIMP: BCMA/CD19 CAR T-cells
219306088|NCT00882427|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
219306089|NCT02910661|OTHER|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
219306090|NCT05031403|OTHER|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
219306091|NCT05031403|OTHER|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
219306092|NCT02159196|DRUG|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
219306093|NCT02159196|DRUG|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
219306094|NCT02159196|DRUG|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
219306095|NCT02326012|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents|
219306096|NCT02931799|BEHAVIORAL|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
219306097|NCT02931799|OTHER|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~* PRO-2 Scale for patients with Crohn's Disease~* 6-Point Mayo Score for patients with Ulcerative Colitis~* Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
219306098|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
219306099|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
219306100|NCT02931799|OTHER|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
219306101|NCT01306955|DRUG|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
219306102|NCT01306955|OTHER|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
219306103|NCT03794687|PROCEDURE|Left heart catheterization|Catheterization via the distal radial artery
219306104|NCT00912691|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
219306105|NCT02145247|DRUG|hCG|"3\. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4\. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
219306106|NCT01768637|DRUG|Aspirin|Aspirin 81 mg by mouth daily
219306107|NCT01768637|DRUG|Clopidogrel|Clopidogrel 75 mg by mouth once daily
219306108|NCT01177579|DIETARY_SUPPLEMENT|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
219306109|NCT04238273|DIAGNOSTIC_TEST|Functional Echocardiography|Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
219306110|NCT02519400|DRUG|Amitriptyline|Single oral dosing
219306111|NCT00126373|DRUG|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
219306112|NCT02851485|DRUG|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
219306113|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
219306114|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
219306115|NCT00887432|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219306116|NCT00887432|OTHER|Laboratory Biomarker Analysis|Correlative studies
219306117|NCT00887432|OTHER|Patient Observation|
219306118|NCT00887432|DRUG|Placebo Administration|Given PO
219306119|NCT00887432|OTHER|Quality-of-Life Assessment|Ancillary studies
219306120|NCT00887432|OTHER|Questionnaire Administration|Ancillary studies
219306121|NCT03389906|OTHER|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
219744670|NCT04868071|BEHAVIORAL|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
219744671|NCT00804232|BEHAVIORAL|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
219744672|NCT00539500|DRUG|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
219744673|NCT00539500|DRUG|Etoposide|300 mg/m\^2 by vein over 24 hours for 4 days
219744674|NCT00539500|DRUG|Melphalan|70 mg/m\^2 Intravenous Bolus for 3 Days
219744675|NCT00539500|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
219744676|NCT00539500|DEVICE|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
219744677|NCT03376282|OTHER|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
219744678|NCT04037137|OTHER|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
219744679|NCT00104403|DRUG|GW679769|
219744680|NCT00104403|DRUG|Dexamethasone|
219744681|NCT00104403|DRUG|Ondansetron Hydrochloride|
219744682|NCT01586715|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
219744683|NCT01855503|PROCEDURE|Core Biopsy|
219744684|NCT03828526|OTHER|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
219744685|NCT03828526|OTHER|Traditional teaching strategy|Classroom-based strategy
219306122|NCT06092619|OTHER|Vojta Therapy|The therapist applied pressure to defined zones on the body whilst positioned in prone, supine and side lying, where the stimulus leads to automatically and involuntarily complex movement.The parents were also instructed on at least one of the exercises from the first session, after the initial assessment. The home program was progressively increased and supervised until the three therapy positions were mastered, during weekly or fortnightly follow ups. The recommended dose was four times per day at home, in session no longer than 15-20 minutes; however, the daily frequency of each family due to different availability was also taken in account. The frequency of the dose was divided into 3 groups: families who could carry on therapy a) three times per day, b) four times per day, c) one or two times per day, d) less than seven times per week or therapy at the clinic
219306123|NCT06092619|OTHER|Conventional physiotherapy:|Conventional physiotherapy intervention included goal-directed functional training based on tasks. These motor skills will be performed in enhanced and adapted settings, but as similar as possible to the usual activities of daily living. Family and children participated in the goal setting, and the approach will focus on overcoming the limitations of the activities to reach these, instead of the modification of the movement patterns. This intervention is founded in motor learning and behavioral neuroscience, focusing on participation and activity acquisition.
219306124|NCT04927182|OTHER|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
219306125|NCT04927182|OTHER|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
219306126|NCT04927182|OTHER|Moderate Exercise Training (Age Group 3; Above 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
219306127|NCT01055379|DRUG|Rasagiline|1 mg/day for 12 weeks; orally
219306128|NCT01055379|DRUG|Placebo|Once daily for 12 weeks; orally
219306129|NCT04945915|OTHER|blood sampling|There was no intervention because this reasearch is observational study.
219306130|NCT01515397|DRUG|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
219306131|NCT01515397|DRUG|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
219306132|NCT02927600|OTHER|Low GI Breakfast|Intake of low GI breakfast
219306133|NCT02927600|OTHER|High GI Breakfast|Intake of high GI breakfast
219306134|NCT02927600|OTHER|Low GI Dinner|Intake of Low GI dinner
219306135|NCT02927600|OTHER|High GI Dinner|Intake of high GI dinner
219306136|NCT04619901|OTHER|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
219306137|NCT04619901|OTHER|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
219306138|NCT04619901|OTHER|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
219306139|NCT00447304|DRUG|moxifloxacin|
219306140|NCT00447304|PROCEDURE|cholecystectomy|
219306141|NCT00899548|GENETIC|DNA methylation analysis|laboratory analysis
219306142|NCT00899548|GENETIC|microarray analysis|laboratory analysis
219306143|NCT00899548|GENETIC|polymerase chain reaction|laboratory analysis
219306144|NCT00899548|OTHER|laboratory biomarker analysis|laboratory analysis
219306145|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
219306146|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
219306147|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
219744686|NCT03073512|OTHER|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
219744687|NCT02082379|BEHAVIORAL|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
219744688|NCT04007731|DIETARY_SUPPLEMENT|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
219744689|NCT04007731|DIETARY_SUPPLEMENT|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
219744690|NCT02054728|OTHER|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
219744691|NCT02392169|DRUG|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
219744692|NCT00559039|OTHER|questionnaire administration|
219744693|NCT00559039|PROCEDURE|evaluation of cancer risk factors|
219744694|NCT01491919|DRUG|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
219744695|NCT04905641|PROCEDURE|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
219744696|NCT01352455|PROCEDURE|Hemodialysis|5 days per week hemodialysis
219744697|NCT04986189|DIAGNOSTIC_TEST|Low dose CT thorax|A low dose CT scan of the thorax to screen for lung cancer
219306148|NCT02561065|BEHAVIORAL|Lifestyle intervention|"1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
219306149|NCT04406090|OTHER|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
219306150|NCT01129466|DIETARY_SUPPLEMENT|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
219306151|NCT01129466|DIETARY_SUPPLEMENT|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
219306152|NCT04331223|OTHER|Observation|observational
219306153|NCT04160767|DRUG|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
219306154|NCT04160767|BEHAVIORAL|Gluten free diet|Gluten free diet will be encouraged in both arms
219306155|NCT04160767|OTHER|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
219306156|NCT00291590|BEHAVIORAL|DHEP|
219306157|NCT04479631|DRUG|BRII-196|BRII-196 given intravenously
219306158|NCT04479631|DRUG|Placebo|Placebo given intravenously
219306159|NCT01393327|BEHAVIORAL|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
219306160|NCT06036303|DEVICE|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
219306161|NCT06036303|DEVICE|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
219306162|NCT00639353|DEVICE|senofilcon A toric soft contact lens|contact lens
219306163|NCT00639353|DEVICE|senofilcon A sphere soft contact lens|contact lens
219306164|NCT01904123|OTHER|Laboratory Biomarker Analysis|Correlative studies
219306165|NCT01904123|OTHER|Pharmacological Study|Correlative studies
219306166|NCT01904123|DRUG|STAT3 Inhibitor WP1066|Given PO
219306167|NCT04379726|BEHAVIORAL|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
219306168|NCT03324191|DIETARY_SUPPLEMENT|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
219306169|NCT03324191|DIETARY_SUPPLEMENT|Tea beverage|Tea beverage
219306170|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
219306171|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
219306172|NCT03324191|OTHER|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
219306173|NCT02596165|DEVICE|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
219306174|NCT03772444|DIETARY_SUPPLEMENT|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
219306175|NCT03772444|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
219306176|NCT03772444|DIETARY_SUPPLEMENT|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
219306177|NCT04781387|DRUG|CRS3123|Study drug dosed PO BID for a total of 10 days
219306178|NCT04781387|DRUG|Active Comparator|Active comparator dosed PO QID for 10 days
219306179|NCT05822167|OTHER|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
219306180|NCT05822167|OTHER|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
219306181|NCT05822167|OTHER|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
219306182|NCT05822167|OTHER|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
219306183|NCT05822167|OTHER|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
219306184|NCT05822167|OTHER|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
219306185|NCT05822167|OTHER|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
219306186|NCT05822167|OTHER|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
219306187|NCT05822167|OTHER|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
219306188|NCT02245906|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219306189|NCT02245906|DIETARY_SUPPLEMENT|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219306190|NCT02245906|DIETARY_SUPPLEMENT|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
219306191|NCT05560100|OTHER|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
219306192|NCT00132847|BIOLOGICAL|German Cockroach Allergen extract|
219306193|NCT05963529|OTHER|Humidity-ramp protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
219306194|NCT05963529|OTHER|Above-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
219306195|NCT05963529|OTHER|Below-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
219306196|NCT05963529|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
219306197|NCT01001559|DRUG|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
219306198|NCT01001559|DRUG|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
219306199|NCT01001559|DRUG|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
219306200|NCT06342271|OTHER|Nordic walking training|Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.
219306201|NCT06342271|OTHER|Free Walking training|Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
219306202|NCT04354896|DRUG|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
219306203|NCT04354896|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
219306204|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
219306205|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
219306206|NCT04510831|OTHER|Refined maize with extrinsic addition of labelled FeSO4|Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
219306207|NCT04510831|OTHER|T.molitor native chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
219306208|NCT04510831|OTHER|T molitor reduced chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
219306209|NCT02587468|DIETARY_SUPPLEMENT|Juice Plus+(R)|before-after comparison of plasma phenolics
219306210|NCT05029479|OTHER|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
219306211|NCT05552885|OTHER|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
219306212|NCT03463161|DRUG|Pembrolizumab|Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
219306213|NCT03463161|DRUG|Epacadostat|Epacadostat (100mg) taken by mouth twice a day.
219306214|NCT05837494|DRUG|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
219306215|NCT05837494|DRUG|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
219306216|NCT04639141|COMBINATION_PRODUCT|Synbiotic|Prebiotic + Probiotic
219306217|NCT04639141|BEHAVIORAL|Gut-directed Hypnotherapy|Psychotherapy sessions
219306218|NCT02560714|DEVICE|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
219306219|NCT00102609|DRUG|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
219306220|NCT00102609|DRUG|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
219306221|NCT00102609|DRUG|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
219306222|NCT01844947|DRUG|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance \>60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
219306223|NCT01844947|DRUG|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
219306224|NCT05007808|DRUG|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
219306225|NCT05007808|DRUG|Vehicle|Vehicle Gel for topical administration
219306226|NCT00005597|DRUG|temozolomide|200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
219306227|NCT02621125|DIETARY_SUPPLEMENT|Fertilix|daily supplementation
219306228|NCT02621125|OTHER|Placebo|Placebo
219306229|NCT00645047|BEHAVIORAL|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
219306230|NCT00645047|BEHAVIORAL|In-Person CBT|In-Person Provision Of Cognitive Therapy
219306231|NCT02107053|DIETARY_SUPPLEMENT|PJ|
219306232|NCT02107053|DRUG|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
219306233|NCT02687022|DEVICE|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
219306234|NCT02687022|DEVICE|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
219306235|NCT03476213|PROCEDURE|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
219306236|NCT03476213|PROCEDURE|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
219306237|NCT00340691|DRUG|Doxycycline|
219306238|NCT02202954|OTHER|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
219306239|NCT01275131|DRUG|Insulin aspart|
219306240|NCT01275131|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
219306241|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Aerobic Walking Exercise Training|"This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance."
219306242|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Stretching and Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
219306243|NCT00731120|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
219306244|NCT00731120|DRUG|Placebo|Vortioxetine placebo-matching capsules
219306245|NCT01924520|DRUG|FK949E|Oral
219306246|NCT02457208|DRUG|Isoniazid (H)|
219306247|NCT02457208|DRUG|Rifampicin (R)|
219306248|NCT02457208|DRUG|Pyrazinamide (Z)|
219306249|NCT02457208|DRUG|Ethambutol (E)|
219306250|NCT03188757|OTHER|hyperglycaemic clamp|2h hyperglyceamic clamp
219306251|NCT02411357|BEHAVIORAL|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
219306252|NCT02411357|BEHAVIORAL|WHO contraception protocol|World Health Organization's contraception protocol
219306253|NCT02411357|BEHAVIORAL|Incentives|Financial incentives contingent on follow-up visit attendance
219306254|NCT00549133|DRUG|Irbesartan|
219306255|NCT04470466|DEVICE|short pulse and Q-switched ND-YAG laser with topical carbon|application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
219306256|NCT04470466|DEVICE|fractional CO2 laser|single pass of fractional CO2 laser on the other side of the face
219744698|NCT03833583|DEVICE|Soterix Medical mini-CT tDCS stimulator|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
219744699|NCT06536972|OTHER|knowledge|"Develop an instrument to evaluate knowledge about humidification systems among different health professionals in intensive care units (ICU).~Describe the knowledge about humidification systems among different health professionals in intensive care units (ICU)."
219744700|NCT06064162|DRUG|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
219744701|NCT05377723|DEVICE|Neodyne Device|See Arm Description: Neodyne Device
219744702|NCT02871219|DRUG|Lenalidomide|Given PO
219744703|NCT02871219|BIOLOGICAL|Obinutuzumab|Given IV
219744704|NCT06042608|PROCEDURE|intercostobrachial nerve block|injection of local anesthetic to target the intercostobrachial nerve in the axilla
219744705|NCT04255043|DEVICE|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
219744706|NCT04255043|DEVICE|Angiography guidance|DCB (Sequent® Please) treatment
219744707|NCT06324695|BEHAVIORAL|HautKompass|The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
219744708|NCT02081768|RADIATION|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
219744709|NCT06296706|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
219744710|NCT06296706|DRUG|Taxotere (docetaxel)|Taxotere, by intravenous infusion, every 3 weeks.
219744711|NCT03004807|DIETARY_SUPPLEMENT|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
219306257|NCT03433053|BEHAVIORAL|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
219306258|NCT03433053|BEHAVIORAL|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
219306259|NCT04250441|DEVICE|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
219306260|NCT05225350|BEHAVIORAL|Dietary Intervention|"See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months."
219306261|NCT03557580|DRUG|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
219306262|NCT03557580|DRUG|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
219306263|NCT03557580|DRUG|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
219306264|NCT04646954|DIAGNOSTIC_TEST|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
219306265|NCT04646954|DIAGNOSTIC_TEST|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
219306266|NCT04308161|DRUG|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
219306267|NCT04308161|DRUG|Miconazole Topical Gel|topical anti fungal agent
219306268|NCT04308161|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
219306269|NCT04308161|DRUG|Oracure gel|Topical analgesic gel
219306270|NCT04308161|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
219306271|NCT03689660|OTHER|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
219306272|NCT03689660|OTHER|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
219306273|NCT03689660|OTHER|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
219306274|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
219306275|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
219306276|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
219306277|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
219306278|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
219306279|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
219306280|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
219306281|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
219306282|NCT01822301|PROCEDURE|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
219306283|NCT04015999|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
219306284|NCT04015999|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
219306285|NCT04830423|PROCEDURE|Medical ozone injection|Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
219744712|NCT03004807|OTHER|Control|A matching tablet to the dietary supplement, but without any active ingredients
219744713|NCT06642623|DRUG|Enavogliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
219744714|NCT06642623|DRUG|Dapagliflozin or Empagliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
219744715|NCT06643013|DRUG|XBD173|4 weeks treatment
219744716|NCT06638580|DIAGNOSTIC_TEST|Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels|"Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography."
219744717|NCT06642805|PROCEDURE|duodenal atresia|surgery for duodenal atresia
219744718|NCT03248661|BEHAVIORAL|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
219744719|NCT03975660|DEVICE|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
219306286|NCT04830423|PROCEDURE|steroid injection group|In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
219306287|NCT04386811|DRUG|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
219306288|NCT04386811|OTHER|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
219306289|NCT01666457|OTHER|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
219306290|NCT01937156|DRUG|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
219306291|NCT01937156|DRUG|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
219306292|NCT00529958|PROCEDURE|Patellar Tendon|Patellar Tendon autograft
219306293|NCT00529958|PROCEDURE|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
219306294|NCT00529958|PROCEDURE|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
219306295|NCT04464785|DEVICE|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
219306296|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
219306297|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
219306298|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) attenuation measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
219306299|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) stiffness measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
219306300|NCT06102980|DEVICE|Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurement|"EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained.~In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation."
219306301|NCT01543932|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
219306302|NCT01543932|DRUG|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
219306303|NCT01543932|DRUG|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
219306304|NCT02761161|DRUG|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
219306305|NCT02761161|BEHAVIORAL|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
219306306|NCT03316300|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
219306307|NCT03316300|PROCEDURE|Sham Procedure|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
219306308|NCT00001750|DRUG|Stemgen|
219306309|NCT00557947|DEVICE|Suture|intradermal and topical suturing
219306310|NCT00557947|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
219306311|NCT04939961|DIETARY_SUPPLEMENT|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
219306312|NCT04939961|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
219306313|NCT02792751|DEVICE|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
219306314|NCT02792751|OTHER|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
219306315|NCT06259552|BIOLOGICAL|SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody|SPX- 303 Injection
219306316|NCT03071367|OTHER|Clinical Simulation|
219306317|NCT00415038|DRUG|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
219306318|NCT00415038|DRUG|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
219306319|NCT00415038|DRUG|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
219306320|NCT00415038|DRUG|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
219306321|NCT00415038|DRUG|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
219306322|NCT05635305|DRUG|Zoliflodacin Patheon|"Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)"
219306323|NCT03756129|DRUG|MIJ821|Different dosages and different regimen for MIJ821
219306324|NCT03756129|DRUG|Placebo|Infusion
219306325|NCT03756129|DRUG|Ketamine|Infusion
219306326|NCT05094557|BEHAVIORAL|Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual|The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
219744720|NCT05494073|PROCEDURE|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
219744721|NCT05494073|PROCEDURE|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
219744722|NCT04678544|DEVICE|Scalp cooling system 2|"The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial."
219744723|NCT04511468|DIETARY_SUPPLEMENT|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
219744724|NCT04511468|BEHAVIORAL|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
219744725|NCT04511468|OTHER|Placebo|Placebo with inactive ingredients
219744726|NCT06477094|DEVICE|Stratus Nimbus Electrosurgical RF Multi-Tined Expandable Electrode|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stratus Nimbus Electrode
219744727|NCT06477094|DEVICE|Stryker Venom Radiofrequency Cannula|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stryker Venom Cannula
219744728|NCT02389517|DRUG|Ixazomib Citrate|Given PO
219744729|NCT02389517|DRUG|Lenalidomide|Given PO
219744730|NCT02389517|DRUG|Dexamethasone|Given PO
219744731|NCT04437823|BIOLOGICAL|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
219744732|NCT05309746|PROCEDURE|Laparoscopic surgery|Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
219744733|NCT04283279|OTHER|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
219744734|NCT04283279|OTHER|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
219744735|NCT04283279|OTHER|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
219744736|NCT03622515|COMBINATION_PRODUCT|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
219744737|NCT00117442|DRUG|carboplatin|Chemotherapy
219744738|NCT00117442|DRUG|paclitaxel|chemotherapy
219306327|NCT05094557|BEHAVIORAL|Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
219306328|NCT05094557|BEHAVIORAL|Control Group: Psychoeducational video + Treatment As usual|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
219306329|NCT04289168|BEHAVIORAL|Music|Music class was provided for the intervention group
219306330|NCT02092688|DEVICE|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
219306331|NCT01224392|OTHER|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
219306332|NCT01224392|RADIATION|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
219306333|NCT03914729|PROCEDURE|Primary Closure|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
219744739|NCT00117442|DRUG|pegfilgrastim|Growth factor for mobilization
219744740|NCT03105765|DRUG|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
219744741|NCT03105765|DRUG|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
219744742|NCT06239285|DEVICE|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
219744743|NCT06239285|OTHER|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
219744744|NCT05302609|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
219744745|NCT03096431|BEHAVIORAL|Physical Activity|"* Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
219744746|NCT03096431|BEHAVIORAL|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
219744747|NCT06309719|COMBINATION_PRODUCT|Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). A PNHA gel will be placed on the root surfaces and supra-bony defects, followed by a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
219744748|NCT06309719|PROCEDURE|Periodontal Access Flap (AF)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). No gel will be placed before suturing the flap by tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
219744749|NCT06496659|PROCEDURE|Segmentectomy|A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
219744750|NCT05114018|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Daily oral dose
219744751|NCT05114018|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
219744752|NCT06035510|DIETARY_SUPPLEMENT|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
219744753|NCT04809714|DEVICE|Blood Flow Restriction with Delfi Tourniquet System Cuff|Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
219306334|NCT03914729|PROCEDURE|Gluteus Maximus Fascia Plasty Flap|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
219306335|NCT00061152|DRUG|Capsaicin Dermal Patch|
219306336|NCT05538559|OTHER|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
219306337|NCT05538559|OTHER|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
219306338|NCT05451498|DIETARY_SUPPLEMENT|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
219306339|NCT05451498|DIETARY_SUPPLEMENT|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
219306340|NCT00120588|DRUG|magnesium|
219306341|NCT04918446|OTHER|T-POSE|Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.
219306342|NCT04918446|OTHER|Usual Care|Printed instruction sheets on prescribed opioid.
219306343|NCT00096343|DRUG|carboplatin|
219306344|NCT00096343|DRUG|paclitaxel|
219306345|NCT00001573|DRUG|SU101|
219306346|NCT04876872|OTHER|no intervention|no intervention
219306347|NCT05670873|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation given to the left dorsolateral prefrontal cortex
219306348|NCT02465853|DRUG|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
219306349|NCT02465853|DRUG|Physiological saline solution|Injection 0.9% Physiological saline solution\<1.0 ml
219306350|NCT02465853|OTHER|physical therapy and occupational therapy|rehabilitation
219306351|NCT02877966|DIETARY_SUPPLEMENT|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
219306352|NCT02877966|OTHER|Placebo|
219306353|NCT02877914|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
219306354|NCT00079066|BIOLOGICAL|cetuximab|
219306355|NCT00079066|PROCEDURE|quality-of-life assessment|
219306356|NCT04701892|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
219306357|NCT05846347|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
219306358|NCT02857166|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
219306359|NCT01315353|PROCEDURE|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
219306360|NCT01315353|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
219306361|NCT03567434|OTHER|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
219306362|NCT05042232|OTHER|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
219306363|NCT05042232|OTHER|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
219306364|NCT06043752|DRUG|Remsima|The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is \>80 kg, 2 injections will be given.
219306365|NCT00758277|DRUG|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
219306366|NCT00758277|DRUG|Placebo|Sugar Pill
219306367|NCT06253598|DRUG|Recombinant Human Adenovirus Type 5|Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
219306368|NCT06253598|DRUG|Lenvatinib|Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing ≥60 kg, the recommended daily dose was 12 mg once daily
219306369|NCT06253598|DRUG|Tislelizumab|Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.
219306370|NCT00159692|DRUG|Amlodipine|
219306371|NCT00351520|DRUG|Miltefose|
219306372|NCT04491266|DIETARY_SUPPLEMENT|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
219306373|NCT04491266|DIETARY_SUPPLEMENT|placebo|maltodextrins
219306374|NCT04485858|DEVICE|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
219306375|NCT04518605|DIETARY_SUPPLEMENT|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.
219306376|NCT04518605|DIETARY_SUPPLEMENT|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
219306377|NCT04518605|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
219306378|NCT05281159|BEHAVIORAL|Risk Information|This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
219306379|NCT05281159|BEHAVIORAL|Risk Information + Action|This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
219306380|NCT01050790|DRUG|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
219306381|NCT03705832|DRUG|Ginger Extract|2gm Capsule of Ginger extract
219306382|NCT03705832|DRUG|Placebo|Matching Placebo
219306383|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
219306384|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
219306385|NCT00762736|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
219306386|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
219306387|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
219306388|NCT00762736|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
219306389|NCT04241601|DRUG|Interleukin-2 [IL-2]|Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
219306390|NCT04241601|OTHER|Placebo Dextrose 5% solution|Placebo Comparator: Dextrose 5% solution
219306391|NCT02785471|BEHAVIORAL|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
219744754|NCT04809714|OTHER|Routine Post-operative Physical Therapy|The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
219744755|NCT06431919|DRUG|Simvastatin 20mg|Simvastatin fixed dose of 20 mg per day
219744756|NCT06431919|DRUG|Carvedilol 3.125 mg|Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
219744757|NCT05286619|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
219744758|NCT05286619|DRUG|Cisplatin|Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
219744759|NCT05286619|DRUG|Carboplatin|Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
219744760|NCT05286619|DRUG|Gemcitabine|Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
219744761|NCT05250583|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
219744762|NCT05824702|BEHAVIORAL|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
219744763|NCT05824702|BEHAVIORAL|Standard of care educational|This is an educational equal attention control group
219744764|NCT04737603|DRUG|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
219744765|NCT06477016|DEVICE|OsciPulse|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
219306392|NCT02785471|BEHAVIORAL|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
219306393|NCT01880528|DRUG|lisinopril|Given PO
219306394|NCT01880528|DRUG|placebo|Given PO
219306395|NCT05722574|BEHAVIORAL|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
219306396|NCT05722574|BEHAVIORAL|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
219306397|NCT01439360|BIOLOGICAL|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
219306398|NCT01439360|BIOLOGICAL|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
219306399|NCT01439360|BIOLOGICAL|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
219306400|NCT01439360|BIOLOGICAL|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
219306401|NCT01439360|BIOLOGICAL|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
219744766|NCT06477016|DEVICE|Intermittent Pneumatic Compression|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
219744767|NCT06585384|COMBINATION_PRODUCT|etanercept and repeated contrast ultrasound|Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
219744768|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/100|5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
219744769|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/10|5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
219744770|NCT03213405|BIOLOGICAL|rBCG-N-hRSV full dose|1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
219744771|NCT03213405|BIOLOGICAL|Conventional BCG full dose|2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
219744772|NCT01597700|DRUG|10mg Ezetimibe|1 tablet taken by mouth
219744773|NCT01597700|DRUG|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
219744774|NCT04426591|DRUG|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
219744775|NCT04426591|DEVICE|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
219744776|NCT05375929|DRUG|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
219744777|NCT05375929|DRUG|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
219744778|NCT02873962|DRUG|Bevacizumab|"* Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab"
219744779|NCT02873962|DRUG|Nivolumab|"* Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab"
219744780|NCT02873962|DRUG|Rucaparib|"* Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort)."
219744781|NCT03916419|DEVICE|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
219744782|NCT03916419|RADIATION|Radiation therapy|-60Gy in 15 fractions
219744783|NCT03916419|DRUG|Paclitaxel|-50 mg/m\^2 intravenous
219744784|NCT03916419|DRUG|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
219744785|NCT03916419|BIOLOGICAL|Durvalumab|-10 mg/kg
219744786|NCT02941055|OTHER|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
219744787|NCT02941055|OTHER|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
219744788|NCT06636916|PROCEDURE|Short Intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
219744789|NCT06636916|PROCEDURE|Long intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
219306402|NCT06043167|DIAGNOSTIC_TEST|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
219306403|NCT04858087|OTHER|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
219306404|NCT06163911|DEVICE|ECG|Routine care 12-lead electrocardiogram
219306405|NCT06163911|DEVICE|Echocardiography|Routine care echocardiography
219306406|NCT04308343|DRUG|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
219306407|NCT04308343|DRUG|Letrozole|Drugs to treat undisturbed ectopic pregnancies
219306408|NCT04308343|DRUG|cetrotide|Drugs to treat undisturbed ectopic pregnancies
219306409|NCT03271554|DRUG|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
219306410|NCT05203068|DIAGNOSTIC_TEST|Recombinant tuberculosis allergen (RTA)|Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
219306411|NCT02852070|PROCEDURE|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
219306412|NCT02852070|PROCEDURE|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
219306413|NCT03045068|BIOLOGICAL|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient"
219306414|NCT03045068|BIOLOGICAL|FFP and Cryoprecipitate|"1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed"
219306415|NCT03045068|BIOLOGICAL|PRBC and cell saver Transfusion|1\. Transfuse for target Hematocrit \> 40 in neonates with SV physiology; Transfuse for Hematocrit\> 33 for 2-Ventricle physiology
219306416|NCT03045068|BIOLOGICAL|Factor Concentrate (Bebulin)|1\. Based on clinical bleeding and achievement of hemostasis
219306417|NCT04541498|OTHER|Impact of air pollution and climate changes|To assess the short- and long- term impact of air pollution and climate changes
219306418|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
219306419|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
219306420|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
219306421|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
219306422|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
219306423|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
219306424|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
219306425|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
219306426|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
219306427|NCT04186364|BEHAVIORAL|Assigned Ambassador|If assigned to the intervention group, participants will be assigned a medical student ambassador on arrival to the Emergency Department. A brief discussion may take place to review the child's history and survey results, and a copy of the survey will be placed near the patient's bedside for healthcare personnel to review. The student ambassador will accompany the child and their family through key points of their visit and will be expected to make accommodations for the child as determined by the accommodation survey results. The family will be required to allow the ambassador to stay throughout the ED visit.
219306428|NCT06608290|PROCEDURE|parasternal block|Administration of parasternal block with ropivacaine, bilaterally at the sternum before the start of surgery.
219306429|NCT06608290|DIAGNOSTIC_TEST|Lactate serum level|Blood samples were taken to identify serum lactate levels greater than 2 mmol/l and those that remained below this limit.
219306430|NCT03095677|OTHER|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
219306431|NCT03095677|OTHER|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
219306432|NCT06599606|DIAGNOSTIC_TEST|Ultrasonographic Assessment|A researcher will perform all ultrasonographic measurements using the ESAOTE My Lab 70 model ultrasound device with a 4-13 MHz linear probe. System settings will be kept constant throughout each study, and all images will be obtained using this single ultrasound device. Only the depth will be adjusted to optimally assess the relevant muscle. The muscle thickness measurement protocol with ultrasound includes four muscles on the dominant side of each child: two proximal upper and lower extremity muscles (biceps brachii/brachialis and quadriceps) and two distal upper and lower extremity muscles (forearm flexors and tibialis anterior). In the assessment of muscle echogenicity, images will be transferred to ImageJ software to calculate luminance ratios (LR).
219306433|NCT05615545|PROCEDURE|Cryoablation|Cryoablation of selected tumor lesions
219306434|NCT03935321|DRUG|NG-101|6 intrathecal bolus injections, each of 45mg
219306435|NCT03935321|DRUG|Placebos|6 intrathecal bolus injections, each of 45mg
219306436|NCT06431477|DRUG|telmisartan|QD, PO
219306437|NCT06431477|DRUG|Losartan|QD, PO
219306438|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 1 - Stick pack of combination 1 of two polysaccharides mixed with a glass of water each morning
219306439|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 1 - stick pack of maltodextrin 1 mixed with a glass of water each morning
219306440|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 2 - Stick pack of combination 2 of two polysaccharides mixed with a glass of water each morning
219306441|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 2 - stick pack of maltodextrin 2 mixed with a glass of water each morning
219306442|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
219306443|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
219306444|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
219306445|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
219306446|NCT06610188|DIETARY_SUPPLEMENT|Prebiotic group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
219306447|NCT06610188|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
219306448|NCT06609941|OTHER|Alternative nostril breathing|Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.
219306449|NCT06609941|DRUG|Pharmacological therapy|"Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist."
219306450|NCT06609785|BEHAVIORAL|Exercise|The volunteers successively completed both high intensity interval training (HIIT)and continuous aerobic training (CAT) under the supervision of a professional coach, and the interval between each type of exercise was 7 days. Each training session was initiated with a brief 2-minute standardized warm-up, followed by 20 minutes of cycling consisting of periods of 2 minutes at 80-95% maximal heart rate (HRmax) separated by 2 minutes of active recovery for the HIIT group or 20 minutes of cycling at 60-80% of HRmax for the CAT group.
219306451|NCT06610318|BEHAVIORAL|imagery rescripting|This condition has three stages. In the first stage, participants were asked to select their most distressing memory related to their appearance (not physical or sexual trauma). They were asked to visualize the selected memory, in detail, as if it were happening to them again. Then, interventionists used a downward arrow technique to identify two-to-three maladaptive core schema. In the second stage, participants were asked to identify a real or imagined trusted adult. Then, they were asked to imagine what their younger self might need to cope with or feel calmer in the situation of their selected memory. In the third stage, the participant was instructed to imagine asking the trusted adult for what they need and to imagine the trusted adult providing their selected interventions and describe how they feel afterwards. These procedures were then repeated with participants' most distressing memory related to eating. This session was remote delivered via Zoom.
219306452|NCT06610318|BEHAVIORAL|nutrition education|The active control condition consisted of a time- and attention-matched general nutrition education session. The curriculum for this intervention included information from the United States Department of Agriculture's Dietary Guidelines (e.g., food labels, describing the benefits of macronutrients). This session was remote delivered using Zoom.
219306453|NCT03439423|RADIATION|CT with contrast agent|
219306454|NCT03439423|DIAGNOSTIC_TEST|MR without contrast agent|"on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)"
219306455|NCT03439423|DIAGNOSTIC_TEST|Color-Doppler Ultrasound|
219306456|NCT03439423|OTHER|Questionnaire|regarding their perception of examinations
219306457|NCT00126477|PROCEDURE|cognitive assessment|
219306458|NCT00126477|PROCEDURE|management of therapy complications|
219306459|NCT00126477|PROCEDURE|psychosocial assessment and care|
219306460|NCT00126477|PROCEDURE|quality-of-life assessment|
219306461|NCT06609772|OTHER|Individualised Pain Education|Individualised Pain Education
219306462|NCT02677480|DIETARY_SUPPLEMENT|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
219306463|NCT02677480|DIETARY_SUPPLEMENT|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
219306464|NCT02871258|DEVICE|The MetaNeb® System|
219306465|NCT05502367|DRUG|ABI-2280 Vaginal Tablet/Insert|Vaginal Tablet
219306466|NCT01588132|DRUG|Anfibatide|"1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
219306467|NCT06610084|OTHER|progressive muscle relaxation exercise)|"Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls."
219306468|NCT06610084|OTHER|Hypno-breastfeeding|"Practices for experimental group 1 (Hypno-breastfeeding) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls."
219306469|NCT01122160|DRUG|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
219306470|NCT01122160|DRUG|placebo|Placebo with berries (blackberries + strawberries)
219306471|NCT02535936|PROCEDURE|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
219306472|NCT03727438|BEHAVIORAL|Tele-Self CBTI|The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
219306473|NCT03727438|OTHER|Health Education Control|The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
219306474|NCT05396677|DRUG|Acetaminophen|2 x 500 mg acetaminophen (one time)
219306475|NCT05396677|OTHER|Placebo|2 x 500 mg microcrystalline cellulose (one time)
219306476|NCT01428232|OTHER|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
219306477|NCT01428232|OTHER|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
219306478|NCT06419998|PROCEDURE|Group A: Pure transanal endorectal pull-through (TAERPT)|Patients of Group A will be treated totally by pure transanal endorectal pull-through without the assistance of laparoscopy
219306479|NCT06419998|PROCEDURE|Group B: Laparoscopic-assistance endorectal pull-through (LAERPT)|Patients of Group B will be treated transanal endorectal pull-through but with the assistance of laparoscopy
219306480|NCT06708572|DRUG|Granulocyte Colony-Stimulating Factor|20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
219306481|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
219306482|NCT00790816|DRUG|Lapatinib|Lapatinib monotherapy
219306483|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
219306484|NCT06717672|DRUG|Lidocaine 2% without vessel constrictor|"1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.~2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.~3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies."
219306485|NCT06717672|DRUG|Normal Saline|Normal saline used is an iv fluid given for fluid replacement
219306486|NCT02824419|DRUG|Methionine|Subject undergoes imaging studies with FDG and with methionine.
219306487|NCT02824419|DRUG|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
219306488|NCT06729853|DRUG|SAP-001|a single oral dose of SAP-001
219306489|NCT06727890|DRUG|Danshen Dripping Pill|Danshen Dripping Pill, 10 pills once, three times a day
219306490|NCT06727890|DRUG|Placebo|Placebo, 10 pills once, three times a day
219306491|NCT06729203|DEVICE|Ultrasound cavitation|Ultrasound Fat Cavitation (USFC) is the method in handling obesity, especially in destroying fat and shaping a particular part of the body. As one of the non-surgical correction methods, USFC is preferred at decreasing the risk of complications due to obesity.
219306492|NCT06729203|OTHER|Exercise|The female will stand on the cushioned tread and grasp by her both hands the two arms of the treadmill. Treadmill will adjust to apply moderate intensity training. It was used for 30 minutes divided into five-minutes warming up, twenty-minutes active exercise and five-minutes cooling down and it was used twice a week for twelve weeks.
219306493|NCT06728943|PROCEDURE|ureteral dilatation|Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.
219306494|NCT06729281|DEVICE|kinesio tape|The application of kinesio tape is a relatively new method, first developed in 1973 by Kenzo Kase in Japan, also known as elastic bandage, which has become popular in the last 10 years following announcements at major events such as the Olympic Games.
219306495|NCT06728969|DEVICE|MT1 Auditory startle response patterns analysis algorithm|Objective measurements of attention and inhibition.
219306496|NCT06728969|DEVICE|T.O.V.A. Continuous Performance Test|Objective measurements of attention and inhibitory control.
219306497|NCT02721173|DRUG|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
219306498|NCT02721173|DRUG|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
219306499|NCT06727591|PROCEDURE|Split Bone Block Technique|An intraoral crestal incision with/out vertical arms was performed on alveolar ridge using blade no.15. After flap reflection, patroning the defect to help guide the area to be grafted from the donor site. At the chin area (donor site) unicortical cuts will be made at least 5 mm inferior to root tips, 5 mm superior to inferior border of mandible and 5 mm away from the mental foramen. The graft was luxated and split into two bone shells each 1 \~ 2 mm in thickness using disc. The bone shells and the donor site were scrapped for autogenous graft particles. Decortication of the recipient site. The graft was stabilised into the recipient site using two or more self tapping titanium screws placed midway corono-apical in the bone shell following the ridge contour. The autogenous particles were packed into the space between the split bone block and the ridge. Collagen sponge was used to cover the donor site. After 4 months the site was approached for implant placement using crestal incision
219306500|NCT06729411|DEVICE|Minimal Offloading dressing|Metatarsal minimal offloading dressings (MODs) are standard offloading devices that are gaining attention. MODs offload a specific ulcerated area and could reduce variability when applying the device onto the skin. MODs are new predesigned devices that do not require any further adaptation or clinician skills and can be directly applied to an ulcerated metatarsal head using a non-irritating adhesive.
219306501|NCT06729411|DEVICE|Felted foam|The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.
219306502|NCT06728371|DRUG|Methadone|0.2mg/kg intravenous methadone given at induction
219306503|NCT06728371|DRUG|Morphine|0.2mg/kg intravenous morphine given at induction
219306504|NCT04415983|DRUG|Nitazoxanide|Nitazoxanide twice daily
219306505|NCT04415983|DRUG|Clarithromycin|Klacid twice daily
219306506|NCT04415983|DRUG|Metronidazole|Metronidazole twice daily
219306507|NCT04415983|DRUG|Proton pump inhibitor|Omeprazoe twice daily
219306508|NCT00904046|DRUG|Pioglitazone|30 mg orally daily for 6 months
219306509|NCT00904046|DRUG|Placebo|Placebo taken orally once a day for 6 months.
219306510|NCT03503058|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
219306511|NCT03503058|BIOLOGICAL|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
219306512|NCT03503058|OTHER|Normal Saline|0.9% Sodium chloride
219306513|NCT03503058|DRUG|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
219306514|NCT00061529|DRUG|Brimonidine Tartrate Ophthalmic Solution|
219306515|NCT04854980|OTHER|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
219306516|NCT02821741|DEVICE|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
219306517|NCT02821741|DEVICE|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
219306518|NCT06815445|PROCEDURE|None tourniquet|No tourniquet is used throughout the surgery.
219306519|NCT01912456|BIOLOGICAL|Low-volume C1-esterase inhibitor|
219306520|NCT01912456|BIOLOGICAL|Higher-volume C1-esterase inhibitor|
219306521|NCT01912456|BIOLOGICAL|Low-volume placebo|
219306522|NCT01912456|BIOLOGICAL|Higher-volume placebo|
219306523|NCT01201343|DRUG|Interferon beta-1a|
219306524|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
219306525|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
219306526|NCT00914160|DRUG|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
219306527|NCT00390585|DRUG|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
219306528|NCT00390585|DRUG|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
219306529|NCT01932567|OTHER|Physiotherapy|
219306530|NCT01932567|PROCEDURE|Electrical impedance tomography|
219306531|NCT02839642|DRUG|Rivastigmine|
219306532|NCT02839642|DRUG|Placebo|
219306533|NCT00709696|DRUG|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
219306534|NCT00709696|DRUG|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
219306535|NCT00825617|DRUG|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
219306536|NCT00823056|DIETARY_SUPPLEMENT|probiotics|placebo
219306537|NCT00823056|DIETARY_SUPPLEMENT|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
219306538|NCT04074863|PROCEDURE|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
219306539|NCT04074863|PROCEDURE|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
219306540|NCT01440374|DRUG|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
219306541|NCT01440374|DRUG|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
219306542|NCT05833633|DIAGNOSTIC_TEST|MUSCLE MAGNETIC RESONANCE IMAGING (MRI)|To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
219306543|NCT04201132|DEVICE|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
219306544|NCT00760903|OTHER|Conventional MRI of the brain|
219306545|NCT00760903|OTHER|MR spectroscopy (MRS)|
219306546|NCT00760903|OTHER|MR Diffusion Tensor Imaging (DTI)|
219306547|NCT04153123|DRUG|Epinephrine|
219306548|NCT06954116|DRUG|Iparomlimab and Tuvonralimab (QL1706)|"Neoadjuvant phase: A single cycle of Iparomlimab and Tuvonralimab (7.5 mg/kg) will be administered within 1 week prior to surgery.~Adjuvant phase: Six cycles of Iparomlimab and Tuvonralimab (7.5 mg/kg, Q3W) will be initiated starting at 2 weeks postoperatively."
219306549|NCT06954116|PROCEDURE|Partial hepatectomy|Will be performed at an appropriate interval following neoadjuvant therapy initiation.
219306550|NCT03454698|OTHER|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
219306551|NCT02966392|DEVICE|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
219306552|NCT02216617|DRUG|Taxotere, Cisplatin, Afatinib|
219306553|NCT01709747|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
219306554|NCT01709747|DEVICE|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
219306555|NCT00231153|DRUG|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
219306556|NCT00231153|DRUG|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
219306557|NCT04729998|DRUG|Rivaroxaban film-coated tablet 20 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
219306558|NCT04729998|DRUG|Xarelto® film-coated tablet 20 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
219306559|NCT02712229|BEHAVIORAL|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
219306560|NCT05648526|DRUG|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
219306561|NCT05648526|DRUG|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
219306562|NCT04680494|OTHER|moderate intensity physical exercise|
219306563|NCT04680494|OTHER|high intensity physical exercise|
219306564|NCT04680494|OTHER|rest|
219306565|NCT04487834|DRUG|Simethicone Solution|Oral daily treatment for four weeks
219306566|NCT04487834|DIETARY_SUPPLEMENT|Vivatlac Baby|Oral daily treatment for four weeks
219306567|NCT03538249|OTHER|Aerobic training|
219306568|NCT03538249|OTHER|Inspiratory muscle training|
219306569|NCT03538249|OTHER|Resistance Training|
219306570|NCT03538249|OTHER|Aerobic and Inspiratory training|
219306571|NCT03538249|OTHER|Combined|Aerobic, inspiratory and resistance training
219306572|NCT04150601|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
219306573|NCT04150601|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
219306574|NCT04150601|OTHER|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
219306575|NCT05205057|OTHER|Saliva|Unstimulated whole saliva is collected
219306576|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
219306577|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
219306578|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
219306579|NCT01177722|BIOLOGICAL|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
219306580|NCT00911079|PROCEDURE|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
219306581|NCT00911079|RADIATION|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
219306582|NCT04993612|DIAGNOSTIC_TEST|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
219306583|NCT00517777|DEVICE|continuous positive airway pressure ventilation|nighttime
219306584|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
219306585|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
219306586|NCT01969318|DRUG|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
219306587|NCT01969318|DRUG|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
219306588|NCT01969318|DRUG|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
219306589|NCT03882411|BEHAVIORAL|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
219306590|NCT04768387|DIETARY_SUPPLEMENT|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
219306591|NCT01725048|DRUG|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
219306592|NCT01725048|DRUG|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
219306593|NCT04985890|BIOLOGICAL|UB-421|10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy
219306594|NCT04985890|OTHER|UB-421+chidamide|10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
219306595|NCT05234229|OTHER|Survey|Collection of immunization status by questionnaire
219306596|NCT02304796|BEHAVIORAL|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
219306597|NCT02304796|BEHAVIORAL|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
219306598|NCT02082236|DRUG|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
219306599|NCT02082236|DRUG|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
219306600|NCT02082236|DRUG|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
219306601|NCT02082236|DRUG|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
219306602|NCT00098852|DRUG|rosiglitazone maleate|
219306603|NCT05023603|DIAGNOSTIC_TEST|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
219306604|NCT00735020|BIOLOGICAL|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
219306605|NCT00735020|BIOLOGICAL|Influenza Vaccine|1 dose of Influenza Vaccine
219306606|NCT02647320|DRUG|Sitagliptin 100 mg|Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
219306607|NCT02647320|DRUG|DS-8500a 25mg|DS-8500a 25mg tablet for oral administration
219306608|NCT02647320|DRUG|Placebo Tablet|Placebo matching DS-8500a tablet for oral administration
219306609|NCT02647320|DRUG|Placebo Capsule|Placebo matching sitagliptin over-capsule for oral administration
219306610|NCT02941250|DEVICE|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
219306611|NCT04728412|DEVICE|High Flow Oxygen Therapy (HFOT)|HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
219306612|NCT00003998|DRUG|carboplatin|
219306613|NCT00003998|DRUG|docetaxel|
219306614|NCT00003998|DRUG|paclitaxel|
219306615|NCT00003998|PROCEDURE|surgical procedure|
219306616|NCT00596427|DRUG|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
219306617|NCT00596427|DRUG|Placebo|Placebo tablets: 3 tablets twice per day
219306618|NCT00320541|DRUG|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
219306619|NCT00320541|DRUG|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
219306620|NCT00320541|DRUG|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
219306621|NCT04706767|DRUG|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
219306622|NCT04706767|DRUG|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
219306623|NCT04706767|DRUG|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
219306624|NCT04706767|DRUG|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
219306625|NCT02401360|DRUG|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
219306626|NCT02401360|DRUG|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
219306627|NCT03294746|OTHER|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
219306628|NCT03294746|OTHER|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
219306629|NCT03057977|DRUG|Empagliflozin|once daily
219306630|NCT03057977|DRUG|Placebo|once daily
219306631|NCT03836989|DEVICE|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
219306632|NCT02263937|PROCEDURE|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
219306633|NCT02263937|PROCEDURE|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
219306634|NCT02112331|OTHER|Raw human milk|
219306635|NCT02112331|OTHER|Pasteurized human milk|
219306636|NCT02112331|OTHER|Pasteurized-homogenized human milk|
219306637|NCT02112331|OTHER|Gastric samples|
219306638|NCT01688414|PROCEDURE|photoacoustic imaging|Undergo PAI
219306639|NCT01688414|PROCEDURE|fluorescence imaging|Undergo fluorescence imaging
219306640|NCT01688414|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
219306641|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
219306642|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
219306643|NCT03553368|DIAGNOSTIC_TEST|MR|MRI data will be acquired without the use of any device as a reference.
219306644|NCT03553368|DIAGNOSTIC_TEST|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
219306645|NCT03553368|DIAGNOSTIC_TEST|CPAP-MR|MRI data will be acquired with the use of CPAP.
219306646|NCT01650246|DRUG|lesinurad|Tablets, 400 mg QD
219306647|NCT04947423|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
219306648|NCT04947423|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
219306649|NCT05003817|DEVICE|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
219306650|NCT01011426|DRUG|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
219306651|NCT01011426|DRUG|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
219306652|NCT02539537|DRUG|Gemcitabine|
219306653|NCT02539537|DRUG|Folinic Acid|
219306654|NCT02539537|DRUG|5-Fluoro-uracil|
219306655|NCT02539537|DRUG|Oxaliplatin|
219306656|NCT02539537|DRUG|Irinotecan|
219306657|NCT02539537|DRUG|L-folinic|
219306658|NCT04249596|DRUG|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
219306659|NCT06137014|DRUG|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
219306660|NCT06137014|DIETARY_SUPPLEMENT|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
219306661|NCT04124393|PROCEDURE|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
219306662|NCT06432894|COMBINATION_PRODUCT|Analgesia Nociception Index, remimazolam|"The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam.~During this study, remimazolam infusion rate is determined by the pharmacopoeia.~Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model.~ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery."
219306663|NCT00953407|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219306664|NCT00953407|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219306665|NCT00953407|DEVICE|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219306666|NCT00953407|DEVICE|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219306667|NCT00953407|DEVICE|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219306668|NCT03960307|OTHER|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
219306669|NCT02268474|DEVICE|532nm KTP Laser vs 595nm Pulse Dye Laser|Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
219306670|NCT04267783|DIAGNOSTIC_TEST|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
219306671|NCT04454177|DEVICE|HUAWEI watch|HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
219306672|NCT02050230|BIOLOGICAL|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
219306673|NCT03435497|BEHAVIORAL|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
219306674|NCT05943223|DRUG|Piperacillin/tazobactam|Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)
219306675|NCT05943223|DRUG|Normal saline|Post-operative normal saline 50 mL once daily
219306676|NCT05943223|DRUG|CefTRIAXone Injection|Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)
219306677|NCT05943223|DRUG|Metronidazole Injection|Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
219306678|NCT06124872|OTHER|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
219306679|NCT06124872|OTHER|Key informant interview|Semi-structured interview with selected key informants
219306680|NCT01719926|DRUG|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
219306681|NCT04685850|OTHER|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
219306682|NCT05199220|OTHER|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
219306683|NCT04662762|OTHER|Nursing intervention programme|educational information
219306684|NCT01466634|PROCEDURE|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
219306685|NCT03432715|BEHAVIORAL|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
219306686|NCT03432715|BEHAVIORAL|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
219306687|NCT00701779|DRUG|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
219306688|NCT04700722|DIAGNOSTIC_TEST|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
219306689|NCT04648735|OTHER|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
219306690|NCT02530853|OTHER|Laser acupuncture|Laser acupuncture
219306691|NCT05624294|DRUG|CS0159|Tablets administered orally
219306692|NCT05624294|DRUG|Placebo|Tablets administered orally
219306693|NCT03448120|PROCEDURE|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
219306694|NCT03448120|PROCEDURE|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
219306695|NCT02151422|BEHAVIORAL|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
219306696|NCT00061451|DRUG|Pemetrexed|
219306697|NCT00061451|DRUG|Gemcitabine|
219306698|NCT03345134|DRUG|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
219306699|NCT03645057|DRUG|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
219306700|NCT03645057|DRUG|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
219306701|NCT01873495|DRUG|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
219306702|NCT02366377|DRUG|SHR3824|
219306703|NCT02366377|DRUG|Placebo|
219306704|NCT02366377|DRUG|Metformin|
219306705|NCT01206777|DRUG|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
219306706|NCT01315223|OTHER|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
219306707|NCT04637308|DRUG|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
219306708|NCT06450938|DEVICE|AI guidance for finding radiographic features|A secured website was made for the trial in which each student could log in using the assigned number. All the image datasets were uploaded to this website. The students will be randomly assigned to the experiment and control group. Both students were asked to segment the features associated with the quality of root canal treatment and predict the prognosis of treatment while the experiment group had access to AI guidance and the control group didn't.
219306709|NCT02601196|DRUG|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
219306710|NCT00862355|DRUG|SPARC147609|IV infusion
219306711|NCT00862355|DRUG|Reference147609|IV infusion
219306712|NCT01114061|DEVICE|Insupatch|Applying heat to the infusion site using the insupatch device
219306713|NCT03249025|DRUG|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
219306714|NCT03249025|DRUG|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
219306715|NCT05535634|DIAGNOSTIC_TEST|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
219306716|NCT02153372|OTHER|BMC2012|
219306717|NCT04429997|PROCEDURE|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
219306718|NCT04429997|PROCEDURE|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
219306719|NCT02986334|DRUG|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
219306720|NCT02986334|DRUG|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
219306721|NCT02986334|DRUG|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
219306722|NCT04265924|OTHER|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
219306723|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
219306724|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
219306725|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
219306726|NCT04386707|BIOLOGICAL|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
219306727|NCT04001985|OTHER|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
219306728|NCT04001985|OTHER|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
219306729|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
219306730|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
219306731|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
219306732|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
219306733|NCT05268614|RADIATION|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND \<95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
219306734|NCT05268614|DRUG|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition."
219306735|NCT04641039|PROCEDURE|Anterior lumbar disc annulus removal versus replacement|Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
219306736|NCT05588687|BEHAVIORAL|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
219306737|NCT05588687|DEVICE|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
219306738|NCT03507660|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
219306739|NCT02791373|DRUG|Vinorelbine|Mobilisation Chemotherapy
219306740|NCT02791373|DRUG|Gemcitabine|Mobilisation Chemotherapy
219306741|NCT06025162|DRUG|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
219306742|NCT04926220|DEVICE|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
219306743|NCT04926220|DEVICE|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
219306744|NCT04926220|DEVICE|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
219306745|NCT00914264|DEVICE|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 \& 12 months
219306746|NCT00606567|OTHER|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
219306747|NCT00571831|PROCEDURE|intraocular lens implantation|Intraocular lens implantation
219306748|NCT03982615|DEVICE|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
219306749|NCT03982615|DEVICE|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
219306750|NCT01989767|BEHAVIORAL|control Rehabilitation as usual|Rehabilitation as usual
219306751|NCT01989767|BEHAVIORAL|education|Education as add on to to rehabilitation as usual
219306752|NCT06524752|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
219306753|NCT06524752|OTHER|Non-existence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
219306754|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
219306755|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
219306756|NCT00221247|PROCEDURE|Acupuncture|acupuncture
219306757|NCT01002365|OTHER|Oxygen delivery|
219306758|NCT01002365|OTHER|Oxygen administration|
219306759|NCT01326234|BEHAVIORAL|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
219306760|NCT01326234|BEHAVIORAL|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
219306761|NCT06648733|OTHER|Structured pharmaceutical discharge management|These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
219306762|NCT01166321|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
219306763|NCT03133325|DEVICE|GP0045|Hyaluronic acid gel
219306764|NCT03133325|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid gel
219306765|NCT06426667|PROCEDURE|posterior tibial nerve radiofrequency|pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.
219306766|NCT06426667|PROCEDURE|plantar fasciitis radiofrequency|the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.
219306767|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
219306768|NCT03748407|OTHER|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
219306769|NCT00557934|OTHER|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
219306770|NCT02536807|DRUG|Hyaluronan|HA gel injection
219306771|NCT00114413|DRUG|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
219306772|NCT00114413|PROCEDURE|eNO measurement|measured by Aerocrine® NIOX device
219306773|NCT03917680|DIAGNOSTIC_TEST|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
219306774|NCT03917680|GENETIC|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
219306775|NCT03917680|DIAGNOSTIC_TEST|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
219306776|NCT02170792|DRUG|BIBR 1048 MS|Low, medium or high dose
219306777|NCT02170792|DRUG|Ranitidine|150mg
219306778|NCT02440451|DEVICE|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
219306779|NCT06185361|DRUG|Fluoxetine 20 MG|fluoxetine
219306780|NCT06185361|DRUG|Desmopressin|desmopressin
219306781|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
219306782|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
219306783|NCT03711851|OTHER|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
219306784|NCT00437580|DRUG|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
219306785|NCT02086123|PROCEDURE|Epidural Analgesia|Bupivacaine + Fentanyl
219306786|NCT02086123|PROCEDURE|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
219306787|NCT03800641|DRUG|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
219306788|NCT05335954|DRUG|noradrenaline|noradrenaline
219306789|NCT01115660|BEHAVIORAL|stroke education|call by medication coach 2 weeks after hospital discharge
219306790|NCT01313637|DRUG|GSK573719/GW642444 125/25mcg|125/25mcg
219306791|NCT01313637|DRUG|GSK573719 125mcg|125mcg
219306792|NCT01313637|DRUG|GW642444 25mcg|25mcg
219306793|NCT01313637|DRUG|Placebo only|Placebo
219306794|NCT03692260|PROCEDURE|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
219306795|NCT02441166|PROCEDURE|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
219306796|NCT04557111|DEVICE|remote monitoring|CIED monitoiring with remote monitoring device
219306797|NCT01840787|DEVICE|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
219306798|NCT01840787|DEVICE|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
219306799|NCT01840787|DEVICE|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
219306800|NCT00816348|DRUG|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
219306801|NCT02088749|BEHAVIORAL|lifestyle intervention for obesity|
219306802|NCT02425709|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
219306803|NCT02425709|DRUG|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
219306804|NCT02425709|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
219306805|NCT02838147|DEVICE|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
219306806|NCT02838147|DEVICE|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
219306807|NCT05816122|DEVICE|MSCopilot® Detect mobile application|MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
219306808|NCT01990209|DRUG|Orteronel|
219306809|NCT00879866|BIOLOGICAL|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
219306810|NCT03048799|DEVICE|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
219306811|NCT04168853|DIAGNOSTIC_TEST|vascular reactivity of internal thoracic arteries|"1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis"
219306812|NCT04312321|DEVICE|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
219306813|NCT04312321|DEVICE|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
219306814|NCT00295594|DRUG|tacrolimus|Immunosuppression
219306815|NCT00858884|OTHER|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
219306816|NCT06067568|DRUG|Lutikizumab Dose A|Injection; subcutaneous (SC)
219306817|NCT06067568|DRUG|Lutikizumab Dose B|Injection; subcutaneous (SC)
219306818|NCT01037244|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
219306819|NCT01037244|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
219306820|NCT01548560|DRUG|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
219306821|NCT01548560|DRUG|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
219306822|NCT01742611|DRUG|ASP1585|oral
219306823|NCT04833699|OTHER|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
219306824|NCT04895683|BEHAVIORAL|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
219306825|NCT04269330|PROCEDURE|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
219306826|NCT00690820|DRUG|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
219306827|NCT00690820|DRUG|Placebo Comparator|Placebo
219306828|NCT01147237|DEVICE|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
219306829|NCT02995577|OTHER|Feeding tolerant|
219306830|NCT02995577|OTHER|Feeding intolerant|
219306831|NCT02995577|OTHER|Necrotizing enterocolitis|
219306832|NCT04581668|OTHER|Neurally adjusted ventilatory assist first|Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
219306833|NCT04581668|OTHER|Conventional ventilation first|Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
219306834|NCT05342909|OTHER|5x a week BFR training group|This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
219306835|NCT05342909|OTHER|2x a week BFR training group|This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
219306836|NCT05237661|DIETARY_SUPPLEMENT|Moon Balance|Moon Balance is a blend of 6 food ingredients
219306837|NCT00624143|DRUG|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
219306838|NCT02212210|DRUG|Methylprednisolone|
219306839|NCT02212210|DRUG|Normal saline|
219306840|NCT00585377|DRUG|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
219306841|NCT03422354|PROCEDURE|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
219306842|NCT03422354|DEVICE|Ultrasound|Ultrasound
219306843|NCT03422354|DRUG|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
219306844|NCT03422354|DRUG|General Aneasthesia|General Aneasthesia
219306845|NCT02934425|OTHER|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
219306846|NCT02934425|OTHER|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
219306847|NCT01765166|BEHAVIORAL|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
219306848|NCT03728556|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
219306849|NCT03728556|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
219306850|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
219306851|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
219306852|NCT01383772|PROCEDURE|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
219306853|NCT01207297|DRUG|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
219306854|NCT01207297|DRUG|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
219306855|NCT03752918|DRUG|MDMA|A single dose of 1.5mg/kg will be administered once orally.
219306856|NCT03752918|DRUG|Niacin|A single dose of 250mg will be administered once orally.
219306857|NCT05232994|DRUG|Esomeprazole 20mg|Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
219306858|NCT03166826|OTHER|Modified Apgar Scoring System|Modified APGAR scoring system
219744790|NCT03926247|BEHAVIORAL|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
219306859|NCT05491304|DRUG|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
219306860|NCT05491304|DRUG|Etoposide|Used in severe group combined with etoposide.
219306861|NCT05491304|DRUG|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
219306862|NCT04532138|DEVICE|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
219306863|NCT04532138|DEVICE|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
219306864|NCT03784560|OTHER|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
219306865|NCT03784560|OTHER|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
219306866|NCT03784560|OTHER|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (\<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
219306867|NCT03784560|OTHER|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington \& Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
219306868|NCT04869943|DRUG|Enobosarm|Oral Enobosarm 9mg per day
219306869|NCT04869943|DRUG|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
219306870|NCT03355170|COMBINATION_PRODUCT|Lansoprazole/Domperidone|Experimental
219306871|NCT03355170|DRUG|Lansoprazole|Active comparator
219306872|NCT03765320|PROCEDURE|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
219306873|NCT03765320|PROCEDURE|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
219306874|NCT01549054|DRUG|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
219306875|NCT01549054|DRUG|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
219744791|NCT05718531|DRUG|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
219744792|NCT05718531|DRUG|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
219744793|NCT05718531|DRUG|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
219744794|NCT01603251|DRUG|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
219744795|NCT01603251|DRUG|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
219744796|NCT01603251|DRUG|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
219744797|NCT03708809|DEVICE|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
219744798|NCT03708809|OTHER|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
219744799|NCT05142293|OTHER|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
219744800|NCT01348581|DEVICE|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
219744801|NCT03767387|OTHER|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
219744802|NCT00178139|BEHAVIORAL|Music Therapy|Music Therapy
219744803|NCT03191032|OTHER|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
219744804|NCT05081271|BIOLOGICAL|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
219306876|NCT01549054|DRUG|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
219306877|NCT01549054|DRUG|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
219306878|NCT02953171|OTHER|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
219306879|NCT02953171|DIETARY_SUPPLEMENT|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
219306880|NCT02953171|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
219306881|NCT02953171|OTHER|Placebo capsule|Capsules without probiotics
219306882|NCT03794167|DRUG|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
219306883|NCT03794167|DRUG|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
219306884|NCT03794167|DRUG|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
219306885|NCT03794167|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
219306886|NCT02838693|PROCEDURE|Not applicable. This is an observational study.|Not applicable. This is an observational study.
219306887|NCT01768117|BIOLOGICAL|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
219306888|NCT04264078|BIOLOGICAL|CD7 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
219306889|NCT04264078|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
219306890|NCT04264078|DRUG|Cytoxan|600mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
219306891|NCT04264078|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
219306892|NCT01166867|DEVICE|Photo-plethysmography monitoring|monitoring vital sign in infant
219306893|NCT00622349|DRUG|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
219306894|NCT00622349|DRUG|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
219306895|NCT00622349|DRUG|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
219306896|NCT05638997|OTHER|Instrument assisted manipulation + Core exercises|The effect of Instrument assisted manipulation on chronic non-spesific low back pain
219306897|NCT05638997|OTHER|Mulligan mobilization with movement + Core exercises|The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
219306898|NCT05638997|OTHER|Core exercises|The effect of core exercises on chronic non-spesific low back pain
219306899|NCT06453785|DEVICE|Promaxo portable MRI|"The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel truly open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies."
219306900|NCT02850367|DIETARY_SUPPLEMENT|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
219306901|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
219306902|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
219306903|NCT02850367|DIETARY_SUPPLEMENT|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
219306904|NCT02850367|BIOLOGICAL|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
219306905|NCT02850367|BIOLOGICAL|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
219306906|NCT00873314|BEHAVIORAL|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
219306907|NCT00873314|BEHAVIORAL|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
219306908|NCT02447367|DRUG|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
219306909|NCT02447367|DRUG|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
219306910|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses with Molded Mark|
219306911|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses|
219306912|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
219306913|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
219306914|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
219306915|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
219306916|NCT01562457|DRUG|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
219306917|NCT01249274|DRUG|Progesterone|100mgs progesterone twice daily
219306918|NCT01249274|OTHER|Placebo|Matched placebo pills to be taken twice daily
219306919|NCT01000636|PROCEDURE|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
219306920|NCT01734174|PROCEDURE|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
219306921|NCT01734174|PROCEDURE|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
219306922|NCT01734174|PROCEDURE|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
219306923|NCT00722930|DRUG|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
219306924|NCT05748691|DIAGNOSTIC_TEST|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
219306925|NCT01725542|DRUG|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
219306926|NCT03258164|BIOLOGICAL|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
219306927|NCT03258164|BIOLOGICAL|Standard Lipofilling|Non-ASC enriched fat grafts
219306928|NCT04509115|DRUG|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
219306929|NCT02936167|BIOLOGICAL|Ringer Lactate|
219306930|NCT02936167|BIOLOGICAL|Plasmalyte|
219306931|NCT05941767|DRUG|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
219306932|NCT05941767|DRUG|Lidocaine nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
219306933|NCT05941767|DRUG|Dexmedetomidine IV|The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
219306934|NCT05941767|DRUG|Lidocaine IV|The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
219306935|NCT03451162|DRUG|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
219306936|NCT02598817|OTHER|Standard Infant Formula|Standard Infant Formula containing High Sn-2
219306937|NCT06027164|DEVICE|Portable Ultrasound System|EchoNous KOSMOS
219306938|NCT04088773|DIAGNOSTIC_TEST|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
219306939|NCT04088773|DIAGNOSTIC_TEST|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
219306940|NCT04088773|DIAGNOSTIC_TEST|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
219306941|NCT03305731|BEHAVIORAL|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
219306942|NCT03658668|DEVICE|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.
219306943|NCT03658668|DEVICE|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
219306944|NCT03658668|OTHER|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
219306945|NCT04616976|BIOLOGICAL|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
219306946|NCT01532726|DRUG|ESL|ESL 400/800/1200 mg tablets once daily
219306947|NCT05353673|DRUG|Sitagliptin|Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
219306948|NCT05353673|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
219306949|NCT01049971|DEVICE|wound protector|after minilaparotomy, the wound protector is applied
219306950|NCT01049971|DEVICE|no wound protector|use of woven drape instead of wound protector
219306951|NCT06279065|DIAGNOSTIC_TEST|Analysis of blood and microbiome samples (stool, oral lavage)|Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells
219306952|NCT00264927|DRUG|SR121463B|
219306953|NCT04631172|OTHER|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
219306954|NCT00521560|DRUG|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
219306955|NCT00002060|DRUG|Inosine pranobex|
219306956|NCT06389253|OTHER|Histological Analysis|For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed
219306957|NCT05199974|PROCEDURE|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
219306958|NCT00648817|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
219306959|NCT00648817|DRUG|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
219306960|NCT03522480|DEVICE|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
219306961|NCT03522480|OTHER|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
219306962|NCT02742636|DEVICE|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
219306963|NCT02871310|DIETARY_SUPPLEMENT|IQP-AS-118|1 tablet in the morning
219306964|NCT02871310|DIETARY_SUPPLEMENT|Placebo|1 tablet in the morning
219306965|NCT04564651|OTHER|platelet transfusion|when the ADP inhibition \>70%, give one unit platelet tansfusion
219306966|NCT03418948|DEVICE|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
219306967|NCT03418948|DEVICE|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
219306968|NCT03418948|DEVICE|2x EC|EC = endocuff assisted colonoscopy
219306969|NCT03418948|DEVICE|2x CC|CC = conventional colonoscopy
219306970|NCT06127056|DEVICE|High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
219306971|NCT06127056|DEVICE|sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
219306972|NCT04572087|OTHER|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
219306973|NCT04572087|OTHER|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
219306974|NCT03760705|OTHER|Data Collection|"1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
219306975|NCT02051270|OTHER|Descriptive study|More than 65 years old elders
219306976|NCT04756960|DRUG|CHF6001|4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
219306977|NCT01284660|DIETARY_SUPPLEMENT|DHA|DHA ingested orally by heavy smokers
219306978|NCT01284660|DIETARY_SUPPLEMENT|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
219306979|NCT02009995|BEHAVIORAL|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
219306980|NCT02009995|BEHAVIORAL|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
219306981|NCT02152657|OTHER|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
219306982|NCT01498653|DRUG|GW685698/GW642444|ICS/LABA
219306983|NCT01498653|DRUG|CCI18781|ICS
219306984|NCT02720614|RADIATION|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
219306985|NCT03672656|DEVICE|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
219306986|NCT03672656|DEVICE|conventional laser|conventional laser multiple-session treatment
219306987|NCT05208866|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
219306988|NCT06084156|DRUG|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
219306989|NCT06084156|DRUG|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
219306990|NCT05895565|DRUG|PMG1015|Including 3 dose levels: level 1, level 2 and level 3
219306991|NCT05895565|DRUG|PMG1015 placebo|Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
219306992|NCT06502873|PROCEDURE|biological samples collection|Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
219306993|NCT04646915|OTHER|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
219306994|NCT01442818|DRUG|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
219306995|NCT01442818|DRUG|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
219306996|NCT00539890|DRUG|Technosphere Insulin|
219306997|NCT04524884|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
219306998|NCT04524884|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
219306999|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.
219307000|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
219307001|NCT05612165|DEVICE|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(2000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
219307002|NCT05612165|DEVICE|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
219307003|NCT05337852|OTHER|Emotional Freedom Technique|"To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
219307004|NCT04112901|DEVICE|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
219307005|NCT04112901|DEVICE|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
219307006|NCT04175002|DRUG|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
219307007|NCT02070588|DEVICE|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
219307008|NCT05402748|OTHER|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
219307009|NCT01708213|DEVICE|Aline HA|Implantable dermal filler
219307010|NCT03572322|OTHER|Focus Group|Focus Group
219307011|NCT03572322|OTHER|Interviews|Interviews
219307012|NCT03764956|OTHER|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
219307013|NCT03764956|OTHER|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
219307014|NCT01197859|DEVICE|Definitive Contact Lens|Daily wear contact lens
219307015|NCT01197859|DEVICE|Biofinity|Daily wear contact lens
219307016|NCT02216357|DRUG|Ifetroban, Oral Capsule|
219307017|NCT02216357|DRUG|Placebo, Oral Capsule|
219307018|NCT02681133|OTHER|Epidemiological study Survey|
219307019|NCT03354442|DEVICE|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
219307020|NCT00816686|BIOLOGICAL|AGS-16M18|IV Infusion
219307021|NCT04207866|OTHER|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
219307022|NCT04207866|OTHER|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
219307023|NCT03609853|DRUG|Placebo|Placebo vapor (distilled water)
219307024|NCT03609853|DRUG|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
219307025|NCT04428125|DIAGNOSTIC_TEST|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
219307026|NCT04428125|DIAGNOSTIC_TEST|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
219307027|NCT05355233|OTHER|bebo concept|techniques to remove urinary incontinence
219307028|NCT05355233|OTHER|diaphragmatic breathing|techniques to remove urinary incontinence
219307029|NCT00693316|DRUG|ORM-12741|Alternating panel single dose escalation.
219307030|NCT05572268|DRUG|to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection|to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
219307031|NCT05635539|DIETARY_SUPPLEMENT|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
219307032|NCT04964414|OTHER|Smell Retraining|Smell practice with household scented items
219307033|NCT04964414|DRUG|Budesonide|Nasal irrigation with liquid steroid
219307034|NCT05821751|DIETARY_SUPPLEMENT|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
219307035|NCT05821751|DRUG|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
219307036|NCT05821751|DRUG|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
219307037|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
219744805|NCT05081271|BIOLOGICAL|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
219744806|NCT04691492|BEHAVIORAL|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
219744807|NCT02268487|DRUG|Sertraline|Treatment
219744808|NCT04310774|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
219744809|NCT01724814|DRUG|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
219744810|NCT01724814|DRUG|Placebo|Singe dose SC administration of Placebo
219744811|NCT01788774|DRUG|Risperidone ISM 50 mg|
219744812|NCT01788774|DRUG|Risperidone ISM 75 mg|
219744813|NCT01788774|DRUG|Risperidone ISM 100 mg|
219744814|NCT04192838|PROCEDURE|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
219744815|NCT04192838|PROCEDURE|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
219744816|NCT01270555|DRUG|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
219744817|NCT00773461|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
219744818|NCT00773461|DRUG|Placebo|iv every 4 weeks for 24 weeks
219744819|NCT04674319|BEHAVIORAL|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
219744820|NCT01754740|DRUG|Uréia|"The subjects were randomly divided into two groups:~1\. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
219744821|NCT01754740|DRUG|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
219744822|NCT01827306|DRUG|Biofreeze|
219744823|NCT01407887|DRUG|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
219744824|NCT02018679|PROCEDURE|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
219307038|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
219307039|NCT01718353|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
219307040|NCT01718353|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
219307041|NCT01718353|DRUG|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
219307042|NCT01728532|DEVICE|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
219307043|NCT01728532|DEVICE|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
219307044|NCT00526032|PROCEDURE|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
219307045|NCT02940938|OTHER|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
219307046|NCT00455325|DRUG|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
219307047|NCT00455325|DRUG|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
219307048|NCT00455325|DRUG|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
219307049|NCT00455325|DRUG|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
219307050|NCT04923841|OTHER|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
219307051|NCT04923841|OTHER|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
219307052|NCT04923841|OTHER|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
219307053|NCT04923841|OTHER|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
219307054|NCT03937726|OTHER|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
219307055|NCT03937726|OTHER|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
219307056|NCT05281965|DRUG|Retinoic acid|Retinoic acid oral
219307057|NCT01366495|BEHAVIORAL|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
219307058|NCT00509587|DRUG|pazopanib hydrochloride|Given orally
219307059|NCT00509587|PROCEDURE|pharmacological study|Correlative studies
219307060|NCT00509587|PROCEDURE|laboratory biomarker analysis|Correlative studies
219307061|NCT01839500|DRUG|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
219307062|NCT03275844|PROCEDURE|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
219307063|NCT02145689|BIOLOGICAL|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
219307064|NCT06165939|DRUG|Intra-articular corticosteroid injection|Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
219307065|NCT06165939|DRUG|hydrodilation with 15% hypertonic dextrose|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
219307066|NCT06165939|DRUG|hydrodilation with Normal saline|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
219307067|NCT03311334|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
219307068|NCT03311334|DRUG|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
219307069|NCT03311334|DRUG|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
219307070|NCT02745392|DRUG|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
219307071|NCT02745392|DRUG|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
219307072|NCT01691768|DRUG|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
219307073|NCT02830971|PROCEDURE|Doing Different ICU techniques and skills|
219307074|NCT04908462|DRUG|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
219307075|NCT04908462|DRUG|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
219307076|NCT01959334|DRUG|Nasal Glucagon (NG)|
219307077|NCT01959334|DRUG|Glucagon IM|
219307078|NCT02853747|BEHAVIORAL|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
219307079|NCT04114630|DRUG|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
219307080|NCT03453320|DRUG|Albumin solution|Infusion rate and effects
219307081|NCT00638131|DRUG|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
219307082|NCT05347420|DIAGNOSTIC_TEST|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
219307083|NCT02567500|BEHAVIORAL|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
219307084|NCT02567500|BEHAVIORAL|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
219307085|NCT05418023|OTHER|Salivary Collection|Collection of saliva via swab for miRNA processing
219307086|NCT05418023|OTHER|Adaptive Assessment|Includes Vineland Adaptive Behavior Scale or equivalent
219307087|NCT05418023|OTHER|Medical and Demographic questionnaire|Survey that collects basic medical and demographic information
219307088|NCT05418023|OTHER|Autism Assessment|Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
219307089|NCT05418023|OTHER|Intellectual Development Assessment|Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
219307090|NCT01196273|OTHER|Comprehensive non invasive cardiovascular examination|"The examination includes:~* Anamnesis incl. admission form~* Physical examination~* Documentation of the medical therapy (incl. HAART)~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* 6 minute walk test~* Blood collection~* Questionnaire to quality of life and health economics"
219307091|NCT00351949|BIOLOGICAL|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
219307092|NCT02277002|DEVICE|Cabin Air Filtration|
219307093|NCT02277002|OTHER|Placebo|No Cabin Air Filtration
219307094|NCT05971667|DRUG|tadalafil|tadalafil 10 mg one tablet daily
219307095|NCT05971667|DRUG|Sildenafil|sildenafil 20 mg two tablets daily
219307096|NCT05971667|DRUG|pentoxifylline|pentoxifylline 400 mg two tabs daily
219307097|NCT00561054|DRUG|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
219307098|NCT03715439|DEVICE|Dental implant|A single dental implant was inserted 3 months after tooth extraction
219307099|NCT00454441|DRUG|MF101|
219307100|NCT01890304|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
219307101|NCT02084745|PROCEDURE|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
219307102|NCT02084745|PROCEDURE|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
219307103|NCT05296720|BEHAVIORAL|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
219307104|NCT00312143|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
219307105|NCT00172484|PROCEDURE|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
219307106|NCT00172484|PROCEDURE|nursing program|To establish a systemic stroke prevention, education protocol
219307107|NCT00172484|PROCEDURE|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
219307108|NCT01580969|DRUG|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
219307109|NCT01580969|DRUG|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
219307110|NCT01580969|RADIATION|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
219307111|NCT03842254|DRUG|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
219307112|NCT03226210|DRUG|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
219307113|NCT06081517|BEHAVIORAL|Social Determinants of Health and toxicity questionnaires|Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
219307114|NCT03034629|BEHAVIORAL|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
219307115|NCT03523429|DRUG|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
219307116|NCT02637960|DRUG|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
219307117|NCT02637960|DRUG|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
219307118|NCT01542931|DRUG|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
219307119|NCT00454766|BEHAVIORAL|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
219307120|NCT00645541|PROCEDURE|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
219307121|NCT01538927|DRUG|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
219307122|NCT01538927|DRUG|Suture|Black silk 000
219307123|NCT04432246|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
219307124|NCT01248091|PROCEDURE|Nitroprusside Gel|10 cc nitroprusside gel
219307125|NCT01248091|PROCEDURE|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
219307126|NCT01014260|DRUG|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
219307127|NCT01014260|DRUG|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
219307128|NCT03168386|PROCEDURE|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
219307129|NCT03975205|DRUG|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
219307130|NCT05632445|DRUG|Apixaban vs. DAPT|Apixaban vs DAPT after LAAO
219307131|NCT04076748|DRUG|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
219307132|NCT04076748|DRUG|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
219307133|NCT02803892|DRUG|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
219307134|NCT02803892|DRUG|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
219307135|NCT02803892|DRUG|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
219307136|NCT02803892|DRUG|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
219307137|NCT02019043|OTHER|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
219307138|NCT02088918|DRUG|Nateglinide|
219307139|NCT02088918|DRUG|Nateglinide/Metformin|
219307140|NCT02088918|DRUG|Metformin|
219307141|NCT03646201|BEHAVIORAL|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
219307142|NCT05125263|OTHER|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
219307143|NCT05125263|OTHER|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
219307144|NCT01210066|DRUG|Fentanyl|IV fentanyl 1mcg/kg
219307145|NCT01210066|OTHER|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
219307146|NCT01210066|OTHER|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
219307147|NCT03143816|DRUG|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
219307148|NCT00815685|DRUG|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
219307149|NCT02656160|DRUG|Placebo|Placebo 3 hrs before sleep
219307150|NCT02656160|DRUG|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
219307151|NCT01079741|BIOLOGICAL|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
219307152|NCT04182594|DRUG|Degarelix|Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days
219307153|NCT04182594|DRUG|GnRH agonist|GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
219307154|NCT00446992|DRUG|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
219307155|NCT00473135|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU
219307156|NCT00473135|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
219307157|NCT02778711|DRUG|secukinumab|anti-IL-17
219307158|NCT05171023|DEVICE|ROTEM and standard coagulation tests|ROTEM and standard coagulation tests assessment
219307159|NCT03601988|RADIATION|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
219307160|NCT03601988|DRUG|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
219307161|NCT02590809|DRUG|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
219307162|NCT02590809|DRUG|Placebo|Placebo will be given for 30 days
219307163|NCT02590809|OTHER|Walk distance test|Walk distance test during 6 minutes
219307164|NCT02590809|OTHER|Exercise echocardiography|
219307165|NCT03341208|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
219307166|NCT02736305|DRUG|Regorafenib|Once a day for 21 days in a 28 days cycle
219307167|NCT01443715|BEHAVIORAL|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
219307168|NCT01443715|BEHAVIORAL|Treatment as Usual|Standard treatment in the community
219307169|NCT04320797|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
219307170|NCT01508715|OTHER|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
219307171|NCT02076178|DRUG|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
219307172|NCT02076178|DRUG|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
219307173|NCT02076178|DRUG|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
219307174|NCT02076178|DRUG|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
219307175|NCT03031860|OTHER|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
219307176|NCT01134120|DRUG|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
219307177|NCT04112121|BEHAVIORAL|Meeting with a Chaplain coupled with Biblical Readings|
219307178|NCT00282204|BEHAVIORAL|antenatal hypnosis + audio compact disc on hypnosis|
219307179|NCT00282204|BEHAVIORAL|Audio compact disc on hypnosis|
219307180|NCT02400294|OTHER|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
219307181|NCT06065969|RADIATION|Photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session.
219307182|NCT00322673|DRUG|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
219307183|NCT00414713|PROCEDURE|red blood cell transfusion|red blood cell transfusion
219307184|NCT02292654|DRUG|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
219307185|NCT02582567|OTHER|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
219307186|NCT02541760|DRUG|Monteleukast|4 ml monteleukast daily for one month
219307187|NCT02541760|DRUG|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
219307188|NCT02472769|DRUG|IBP-9414|
219307189|NCT02472769|DRUG|Placebo|Sterile water
219307190|NCT02142660|PROCEDURE|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
219307191|NCT00188175|RADIATION|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
219307192|NCT04681027|DRUG|Oxymorphone hydrochloride (HCl)|Opioid
219307193|NCT02169453|DRUG|BIA 9-1067|OPC, Opicapone
219307194|NCT02169453|DRUG|Placebo|PLC, Placebo
219307195|NCT02169453|DRUG|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
219307196|NCT02434939|DRUG|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
219307197|NCT02434939|DRUG|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
219307198|NCT03200015|DRUG|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
219307199|NCT05163587|COMBINATION_PRODUCT|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
219307200|NCT04412915|OTHER|Labor induction|Labor induction with oxytocin or prostagladin
219307201|NCT06372678|BIOLOGICAL|CM326|CM326 injection
219307202|NCT06372678|DRUG|Placebo|Placebo
219307203|NCT03942809|DEVICE|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
219307204|NCT04154176|OTHER|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
219307205|NCT02926976|DRUG|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
219307206|NCT02926976|DRUG|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
219307207|NCT02926976|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
219307208|NCT02926976|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
219307209|NCT02926976|DEVICE|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
219307210|NCT02926976|DEVICE|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
219307211|NCT02210234|DIETARY_SUPPLEMENT|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
219307212|NCT02210234|DIETARY_SUPPLEMENT|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
219307213|NCT04866446|DEVICE|endotracheal intubation and laringeal mask airway insertion|endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
219307214|NCT06423209|OTHER|Strength training program|Strength training program to be developed during 16 weeks. There will be 3 exercise sessions per week and those participants who perform at least 2 sessions during the program will be considered for the statistical analysis.
219307215|NCT01743625|DRUG|COV155|COV155 tablets
219307216|NCT01743625|DRUG|placebo|
219307217|NCT06373029|OTHER|Ultrasound examination|The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
219307218|NCT02791945|BEHAVIORAL|Medical Management Counseling|Brief alcohol counseling
219307219|NCT02791945|DRUG|N-acetylcysteine|Experimental supplement
219307220|NCT02791945|DRUG|Placebo|Placebo comparator
219307221|NCT01190137|DIETARY_SUPPLEMENT|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
219307222|NCT05350579|OTHER|Yogurt Intervention|"Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract."
219307223|NCT05975957|DEVICE|Photomodulation Therapy with the Light-Aid system|Patients in the intervention group (FBM) will be submitted to 10 treatment sessions (twice a week/five weeks) with the Light-Aid system (Bright Photomedicine, SP, Brazil), operated in continuous mode, with 100 LEDs of 850nm wave per tip, with application time varying from 4 to 8 minutes. Irradiation parameters will be customized based on pain intensity, skin phototype and Body Mass Index (BMI).
219307224|NCT05975957|DEVICE|Control|Patients in the placebo group will undergo the same therapeutic protocol as the FBM group using a device with the same appearance as the Light-Aid System, but with inert light emission. In both groups, the treatment will be administered in contact with the skin over the knee, with the patient positioned in dorsal decubitus. The three tips of the device will be positioned horizontally over the anterior region of the knee with the central tip over the patella.
219307225|NCT01071525|DRUG|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
219307226|NCT00526487|DEVICE|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
219307227|NCT00526487|DEVICE|Endovascular Repair|Endovascular Repair
219307228|NCT01911065|BIOLOGICAL|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
219307229|NCT03732560|OTHER|Non-Interventional|Non-Interventional
219307230|NCT05125484|OTHER|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
219307231|NCT05125484|OTHER|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
219307232|NCT00710021|DRUG|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
219307233|NCT00710021|DRUG|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
219307234|NCT00444171|PROCEDURE|insulin infusion rate controled by computer algorithm|
219307235|NCT00444171|PROCEDURE|insulin infusion rate guided by in-house glucose management protocol|
219307236|NCT05988359|PROCEDURE|Caries treatment with a dental turbine|G1 (n=30) conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
219307237|NCT05988359|PROCEDURE|Caries treatment with Er:YAG laser|G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
219307238|NCT01536015|DRUG|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
219307239|NCT01536015|DRUG|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
219307240|NCT04788381|DRUG|Bevacizumab|Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
219307241|NCT03028038|DRUG|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
219307242|NCT03028038|DRUG|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
219307243|NCT03598088|DEVICE|Ovaprene|non-hormonal contraceptive ring
219307244|NCT03613987|DEVICE|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
219307245|NCT00832234|DRUG|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
219307246|NCT00511901|DRUG|placebo|
219307247|NCT00511901|DRUG|epoetin alpha|
219307248|NCT00511901|DRUG|Niferex|
219307249|NCT06106620|DIETARY_SUPPLEMENT|Placebo|Placebo drink consisting of 12 oz of flavor-matched water.
219307250|NCT06106620|DIETARY_SUPPLEMENT|Safety Shot|Safety Shot consisting of a 12 oz drink containing vitamins, mineral, and botanical extracts.
219307251|NCT00003890|DRUG|MG 98|
219307252|NCT02447172|DRUG|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
219307253|NCT02447172|OTHER|Placebo|Matching placebo sponge
219307254|NCT04705207|PROCEDURE|reflexology massage|the patient receive only foot reflexology massage
219307255|NCT04705207|PROCEDURE|sham massage|the patient receive only foot traditional massage
219307256|NCT04488718|OTHER|EnergieShake® Junior Powder Complete|Oral Nutritional Supplement
219307257|NCT06203015|DIAGNOSTIC_TEST|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
219307258|NCT06203015|DIAGNOSTIC_TEST|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
219307259|NCT06203015|DIAGNOSTIC_TEST|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
219307260|NCT06203015|DIAGNOSTIC_TEST|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
219307261|NCT06203015|OTHER|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
219307262|NCT00477321|DRUG|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
219307263|NCT02096315|DRUG|POL7080|Intravenous infusion
219307264|NCT01165931|DRUG|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
219307265|NCT00032526|DRUG|Corticosteroids|
219307266|NCT00032526|BEHAVIORAL|Classical conditioning to corticosteroid|
219307267|NCT05471830|DRUG|Apixaban|No drug will be provided to participants. Patients follow routine clinical practice/administration.
219307268|NCT00485498|DRUG|Olanzapine Hydrochloride|
219307269|NCT00485498|DRUG|Risperidone|
219307270|NCT00541398|BEHAVIORAL|Implementation of guideline|Outreach visits with interactive education for health staff
219307271|NCT00300521|GENETIC|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
219307272|NCT06060015|DRUG|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
219307273|NCT06060015|DRUG|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
219307274|NCT05420285|DRUG|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
219307275|NCT01561404|DRUG|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
219307276|NCT04421183|DIAGNOSTIC_TEST|draw blood|draw blood from the all of patients
219307277|NCT00547820|OTHER|placebo|
219307278|NCT00547820|DEVICE|Urinary sensor|
219307279|NCT00557648|BEHAVIORAL|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
219307280|NCT00557648|BEHAVIORAL|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
219307281|NCT02750280|DEVICE|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
219307282|NCT02750280|DEVICE|Mepilex® [Silicone foam dressing]|primary wound dressing
219307283|NCT03588286|PROCEDURE|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
219307284|NCT03588286|OTHER|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
219307285|NCT03588286|PROCEDURE|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
219307286|NCT02963740|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
219307287|NCT02963740|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
219307288|NCT02963740|BEHAVIORAL|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
219307289|NCT02963740|BEHAVIORAL|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
219307290|NCT00432146|DRUG|lugol's solution|
219307291|NCT00518466|DRUG|topiramate|25 mg modified-release capsules
219307292|NCT00518466|DRUG|phentermine|7.5 mg immediate-release capsules
219307293|NCT00518466|DRUG|topiramate|100 and 25 mg immediate-release tablets
219307294|NCT00518466|DRUG|phentermine|37.5 and 7.5 mg immediate-release tablets
219307295|NCT04463173|DRUG|Anaprazole|single dose, oral administration 30 minutes after breakfast with high fat food.
219307296|NCT04463173|DRUG|Anaprazole|single dose, oral administration before breakfast.
219307297|NCT02534987|OTHER|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
219307298|NCT00506987|DRUG|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
219307299|NCT00506987|DRUG|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
219307300|NCT00309296|BEHAVIORAL|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
219307301|NCT01781507|DRUG|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
219307302|NCT01781507|DRUG|Placebo|This placebo ( sugar pill) will provide the negative control for this study
219307303|NCT03301896|DRUG|LHC165|LHC165 intratumoral injection
219307304|NCT03301896|BIOLOGICAL|PDR001|PDR001 infusion
219307305|NCT06286709|BIOLOGICAL|Faecal Microbiota Transplant|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
219307306|NCT06286709|OTHER|FMT Placebo|FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
219307307|NCT04420936|BEHAVIORAL|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
219307308|NCT04420936|BEHAVIORAL|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
219307309|NCT03220763|OTHER|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
219307310|NCT03701867|OTHER|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
219307311|NCT00001962|DRUG|Daclizumab|Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
219307312|NCT05224336|DRUG|Psilocybin|25mg oral psilocybin
219307313|NCT05224336|DRUG|Placebo Niacin|100mg oral niacin
219307314|NCT00458887|PROCEDURE|management of therapy complications|Undergo hearing tests
219307315|NCT00194857|DRUG|erythropoietin, GCSF|
219307316|NCT02334774|PROCEDURE|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
219307317|NCT05768256|BEHAVIORAL|Mindfulness-Based Cognitive-behavioral Therapy for Distress|Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
219307318|NCT05288803|OTHER|Clinical decision support tool (CDS tool)|The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
219307319|NCT05730270|BEHAVIORAL|Stress reduction program 1|Participants will receive daily online lessons
219307320|NCT05730270|BEHAVIORAL|Stress reduction program 2|Participants will receive daily online lessons
219307321|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
219307322|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
219307323|NCT02593669|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
219307324|NCT02593669|DRUG|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
219307325|NCT02513420|BEHAVIORAL|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
219307326|NCT02725957|DRUG|Trehalose for IV Infusion|
219307327|NCT02725957|DRUG|Saline 0.9% IV|
219307328|NCT02673151|PROCEDURE|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
219307329|NCT02673151|DRUG|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
219307330|NCT02673151|PROCEDURE|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
219307331|NCT05699135|DRUG|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
219307332|NCT04023721|DRUG|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
219307333|NCT04023721|DRUG|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
219307334|NCT03234790|OTHER|Filtered Air Exposure|Exposure to Filtered air
219307335|NCT03234790|OTHER|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
219307336|NCT03656978|BEHAVIORAL|dynamic|Use the according methods in dynamic arm descriptions.
219307337|NCT03656978|BEHAVIORAL|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
219307338|NCT00433459|DRUG|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
219307339|NCT00433459|DRUG|dacarbazine|drug is used in first line treatment in combination (COPDAC)
219307340|NCT00433459|DRUG|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
219307341|NCT00433459|DRUG|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
219307342|NCT00433459|DRUG|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
219307343|NCT00433459|DRUG|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
219307344|NCT00433459|RADIATION|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
219307345|NCT00433459|RADIATION|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
219307346|NCT06175390|RADIATION|68Ga-FAPI-46 PET/CT|"Cohort A:~Tumor assessments by 18F-FDG PET/CT (per PERCIST v1.0) will be performed at: baseline, after the first 2 treatment cycles (between C2D15 and C3D1), and before surgery (after the last administration of neoadjuvant chemotherapy) Tumor assessment by 68Ga-FAPI-46 PET/CT will be performed at: baseline and before surgery (after the last administration of neoadjuvant chemotherapy).~Cohort B:~Tumor assessments by 18F-FDG PET/CT per PERCIST v1.0 will be performed at baseline, every 8 weeks (+/- 1 week) for the first 24 weeks, and every 12 weeks (+/- 1 week) thereafter until disease progression or treatment discontinuation, whichever is later.~Tumor assessments by 68Ga-FAPI-46 PET/CT will be performed at baseline and after the first 2 treatment cycles and will be synchronized with 18F-FDG PET/CT."
219307347|NCT06175390|BIOLOGICAL|Tumor samples analysis|"Patients will undergo a mandatory biopsy of the primary tumor at baseline, after the first 2 treatment cycles and during the surgery. A lymph node biopsy will be performed at baseline if feasible in cohort A, and and in case of disease progression for cohort B (if clinically feasible).~In addition to the usual morphological and immunohistochemical (ER, PR, HER2+, CPS score, PD-L1 status with SP142 …) analyses in the cohort A and cohort B , exploratory analyses will be performed."
219307348|NCT06175390|BIOLOGICAL|Blood samples analysis: Circulating Tumor DNA|Blood samples will be collected at baseline. In addition for cohort A at cycles 2 and 3, within 21 days before surgery, 10 to 21 days after surgery and at cycle 8 after surgery. In addition for cohort B after the first 2 treatment cycles and in case of disease progression (if clinically feasible).
219307349|NCT06243393|DRUG|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG)
219307350|NCT06243393|DRUG|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
219307351|NCT00989131|DRUG|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
219307352|NCT00989131|DRUG|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
219307353|NCT05178667|DIETARY_SUPPLEMENT|High dose|Food supplements are consumed during 3 months by healthy volunteers.
219307354|NCT05178667|DIETARY_SUPPLEMENT|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
219307355|NCT05178667|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
219307356|NCT04234425|BEHAVIORAL|Trauma-Informed Yoga|Trauma-Informed Yoga practice held within a high school weight training class
219307357|NCT04759664|DRUG|LUT014 Gel (Dose 1)|Topical gel
219307358|NCT04759664|DRUG|LUT014 Gel (Dose 2)|Topical gel
219307359|NCT04759664|DRUG|Placebo|LUT014 matching placebo topical gel
219307360|NCT03965611|PROCEDURE|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
219307361|NCT03965611|PROCEDURE|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
219307362|NCT03965611|PROCEDURE|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
219307363|NCT05209750|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
219307364|NCT05690100|DRUG|GeliO3|Anti-inflammatory Gel which has a beneficial role on wound healing
219307365|NCT05690100|DRUG|Gingi gel|Anti-inflammatory Gel which has a beneficial role on wound healing
219307366|NCT01438684|DRUG|RPh201|400 microliter s.c. twice a week for 3 months
219307367|NCT01438684|DRUG|Saline|400 microliter Saline solution s.c. twice a week for 3 months
219307368|NCT00491777|DEVICE|Noninvasive Hemodynamic Patient Monitor|
219307369|NCT00425984|PROCEDURE|Adult male circumcision|
219307370|NCT00622453|OTHER|Screening|Electrocardiography Blood Test
219307371|NCT02634957|BEHAVIORAL|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
219307372|NCT01621113|DRUG|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
219307373|NCT01621113|DRUG|Placebo|Placebo tablet, twice daily, for 10 weeks.
219307374|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
219307375|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
219307376|NCT03266354|PROCEDURE|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
219307377|NCT04162613|OTHER|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
219307378|NCT00515320|DRUG|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
219307379|NCT00515320|DRUG|Placebo|Oral dispersible tablet placebo
219307380|NCT02867293|PROCEDURE|ultrasound guided ascitic fluid drainage|
219307381|NCT02867293|PROCEDURE|operative drainage of ascites through small skin incision after induction of anesthesia|
219307382|NCT02867293|DEVICE|ultrasound|
219307383|NCT03274960|COMBINATION_PRODUCT|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
219307384|NCT05276609|DRUG|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219307385|NCT05276609|DRUG|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219307386|NCT00518791|OTHER|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
219307387|NCT00518791|OTHER|Usual Care|No altered organisation of care
219307388|NCT00211497|DRUG|MBI 226 Acne Solutions|
219307389|NCT05176535|DIETARY_SUPPLEMENT|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
219307390|NCT03823560|DEVICE|Celegyn®|Medical device Celegyn® presents itself as a cream.
219307391|NCT03823560|DEVICE|Matching placebo|IP placebo presents itself as a cream.
219307392|NCT04389736|BEHAVIORAL|Sitting|Participants sat in a chair with back, arms and legs supported.
219307393|NCT04389736|BEHAVIORAL|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
219307394|NCT04389736|BEHAVIORAL|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
219307395|NCT02042612|DRUG|Sedation with sevoflurane during 48-hr in ICU|
219307396|NCT01824160|DEVICE|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
219307397|NCT02435758|PROCEDURE|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
219307398|NCT03714932|DIAGNOSTIC_TEST|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
219307399|NCT00589082|DRUG|DaunoXome|
219307400|NCT00589082|DRUG|Daunorubicine|
219307401|NCT03924739|BEHAVIORAL|Nurse-coordinated integrated care model for AF|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
219307402|NCT02137720|BEHAVIORAL|Telephonic Diabetes Self-Management Support|
219307403|NCT02137720|OTHER|Educational Print Materials|
219307404|NCT04040816|DRUG|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
219307405|NCT00450060|DEVICE|lumbar puncture with Quincke-design needles|
219307406|NCT00450060|DEVICE|lumbar puncture with Sprotte-design needles|
219307407|NCT00793000|DRUG|PF-04287881|75 mg oral dose (prepared solution) given once
219307408|NCT00793000|DRUG|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
219307409|NCT00793000|DRUG|PF-04287881|150 mg oral dose (prepared solution) given once
219307410|NCT00793000|DRUG|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
219307411|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
219307412|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
219307413|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
219307414|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
219307415|NCT00793000|DRUG|PF-04287881|1000 mg oral dose (prepared solution) given once
219307416|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
219307417|NCT00793000|DRUG|PF-04287881|1250 mg oral dose (prepared solution) given once
219307418|NCT00793000|DRUG|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
219307419|NCT00793000|DRUG|PF-04287881|1500 mg oral dose (prepared solution) given once
219307420|NCT00793000|DRUG|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
219307421|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
219307422|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
219307423|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
219307424|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
219307425|NCT00793000|DRUG|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
219307426|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
219307427|NCT00344474|BEHAVIORAL|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
219307428|NCT00831831|BEHAVIORAL|Safety planning|See detailed description
219307429|NCT02041741|BEHAVIORAL|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
219307430|NCT02041741|BEHAVIORAL|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
219307431|NCT03442985|DRUG|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
219307432|NCT03442985|DRUG|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
219307433|NCT03442985|OTHER|Placebo|Subjects received placebo, once daily, for up to 24 months.
219307434|NCT04196608|DRUG|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
219307435|NCT04196608|DRUG|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
219307436|NCT00271427|DRUG|L-Selenomethionine|
219307437|NCT01143974|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
219307438|NCT01217957|DRUG|Ixazomib|Ixazomib capsules
219307439|NCT01217957|DRUG|Lenalidomide|Lenalidomide capsules
219307440|NCT01217957|DRUG|Dexamethasone|Dexamethasone tablets
219307441|NCT01633983|DRUG|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
219307442|NCT01633983|DRUG|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
219307443|NCT05631431|DIETARY_SUPPLEMENT|Curalin|Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
219307444|NCT00790608|DRUG|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
219744825|NCT02018679|PROCEDURE|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
219744826|NCT01407614|PROCEDURE|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
219744827|NCT00322218|DRUG|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
219744828|NCT06326541|BEHAVIORAL|music therapy|Listening to the Holy Quran.
219744829|NCT00000709|DRUG|Zidovudine|
219744830|NCT06209450|PROCEDURE|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
219744831|NCT03928015|DRUG|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
219744832|NCT03928015|DRUG|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
219307445|NCT04166890|DRUG|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
219307446|NCT03077360|BEHAVIORAL|Lifestyle|Lifestyle changes to lose weight or become more fit
219307447|NCT04357860|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
219307448|NCT04357860|DRUG|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
219307449|NCT04357860|DRUG|Best available treatment|Best available treatment up to 14 days
219307450|NCT03478150|OTHER|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
219307451|NCT03478150|DEVICE|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
219307452|NCT05863312|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
219307453|NCT05863312|PROCEDURE|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
219307454|NCT05863312|OTHER|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
219307455|NCT05863312|OTHER|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
219307456|NCT00269347|PROCEDURE|Chiropractic Spinal Manipulation|
219307457|NCT00269347|PROCEDURE|Exercise|
219307458|NCT00269347|BEHAVIORAL|Self-care|
219307459|NCT00001457|DRUG|Lamivudine|
219307460|NCT00501514|DRUG|Growth hormone|
219307461|NCT06051916|OTHER|residual urine|The study includes two group, A and B. Se previously
219307462|NCT01556893|DEVICE|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
219307463|NCT00184821|PROCEDURE|Ischemic preconditioning|
219307464|NCT00184821|PROCEDURE|Forearm ischemic exercise|
219307465|NCT00184821|PROCEDURE|Annexin A5 scintigraphy|
219307466|NCT00184821|DRUG|Diazoxide|
219307467|NCT00184821|DRUG|glibenclamide|
219307468|NCT00184821|DRUG|adenosine|
219307469|NCT03982901|DIAGNOSTIC_TEST|Mental Stress Test|In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
219307470|NCT05158582|OTHER|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
219307471|NCT05158582|OTHER|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
219307472|NCT00495287|DRUG|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
219307473|NCT00744185|DRUG|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
219307474|NCT00744185|DRUG|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
219307475|NCT05316194|OTHER|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
219307476|NCT02686905|DIETARY_SUPPLEMENT|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
219307477|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
219307478|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
219307479|NCT02686905|DIETARY_SUPPLEMENT|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
219307480|NCT02686905|DIETARY_SUPPLEMENT|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
219307481|NCT02686905|DIETARY_SUPPLEMENT|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
219307482|NCT02322138|OTHER|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
219307483|NCT02322138|OTHER|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
219307484|NCT02322138|OTHER|Reference Group|Breast fed ad libitum
219307485|NCT05877287|OTHER|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
219307486|NCT00377247|BIOLOGICAL|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
219307487|NCT00629330|BEHAVIORAL|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
219307488|NCT01312012|DRUG|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
219307489|NCT00846391|DRUG|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
219307490|NCT00846391|DRUG|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
219307491|NCT00846391|DRUG|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
219307492|NCT00251420|PROCEDURE|writing about disease|writing about physical or emotional consequences of pulmonary disease
219307493|NCT01509131|DRUG|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
219307494|NCT01509131|DRUG|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
219307495|NCT02652273|DRUG|Abatacept|Abatacept 125mg/ml
219307496|NCT02442323|BEHAVIORAL|Walking Intervention|12-week walking program
219307497|NCT00635856|DRUG|Gefitinib|Iressa
219307498|NCT00913120|DRUG|YM150|oral
219307499|NCT00913120|DRUG|Placebo|oral
219307500|NCT00913120|DRUG|Enoxaparin|injection
219307501|NCT00122915|DEVICE|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
219307502|NCT03339570|PROCEDURE|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
219307503|NCT02475902|BEHAVIORAL|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
219307504|NCT02475902|BEHAVIORAL|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
219307505|NCT00648830|PROCEDURE|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
219307506|NCT00648830|DRUG|Clarithromycin|single-dose 250 mg immediate-release oral tablets
219307507|NCT00104559|BEHAVIORAL|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
219307508|NCT00104559|BEHAVIORAL|Standard paper consent form|Standard paper consent form
219307509|NCT05310487|BIOLOGICAL|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
219307510|NCT05310487|OTHER|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
219307511|NCT04634825|BIOLOGICAL|Enoblituzumab|Anti-B7-H3 antibody
219307512|NCT04634825|BIOLOGICAL|Retifanlimab|Anti-PD-1 antibody
219307513|NCT04634825|BIOLOGICAL|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
219307514|NCT02688283|OTHER|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
219307515|NCT05087485|OTHER|education|digital education in skin cancer diagnostics
219307516|NCT05624385|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
219307517|NCT00286078|DEVICE|Precision|Implantable neurostimulator
219307518|NCT02745743|DRUG|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
219307519|NCT00293631|DRUG|Lornoxicam 8 mg|
219307520|NCT00293631|DRUG|Lornoxicam 16 mg|
219307521|NCT00293631|DRUG|Ketorolac 30 mg|
219307522|NCT00293631|DRUG|Placebo|
219307523|NCT03401541|DRUG|Calcifediol|One capsule of 900 micrograms of 25(OH)D
219307524|NCT03401541|DRUG|Calciferol|One capsule of 900 micrograms of Vitamin D
219307525|NCT02388646|OTHER|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
219307526|NCT02388646|DEVICE|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
219307527|NCT02388646|OTHER|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
219307528|NCT01462838|BIOLOGICAL|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
219307529|NCT01530022|DRUG|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
219307530|NCT01530022|DRUG|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
219307531|NCT02953366|DRUG|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
219307532|NCT02953366|DRUG|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
219307533|NCT02977208|PROCEDURE|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
219307534|NCT02977208|PROCEDURE|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
219307535|NCT02977208|PROCEDURE|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms
219307536|NCT02977208|DRUG|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
219307537|NCT06164509|DRUG|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
219307538|NCT01266135|DRUG|QAX576|QAX576 10 mg/kg intravenous infusion
219307539|NCT01266135|DRUG|Placebo|Placebo to QAX576 intravenous infusion
219307540|NCT03514212|BEHAVIORAL|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
219307541|NCT05699954|DIAGNOSTIC_TEST|Presence of Blink impression features for cancer in colorectal polyps|"1. 20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~2. A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~3. The survey asks for demographics of the participant endosopists (experience, country where they work).~4. The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~   * Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~  * If yes, why do you think that? (Free comment box)~  * What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~5. Study will be closed after 2 weeks.~6. Data analysis"
219307542|NCT00640887|DRUG|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
219307543|NCT00640887|DRUG|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
219307544|NCT00640887|DRUG|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
219307545|NCT03074760|DIAGNOSTIC_TEST|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
219307546|NCT03074760|DIAGNOSTIC_TEST|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
219307547|NCT03074760|DIAGNOSTIC_TEST|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
219307548|NCT00776126|DEVICE|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
219307549|NCT01687530|PROCEDURE|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
219307550|NCT01745848|DRUG|Roflumilast|
219307551|NCT02731794|DEVICE|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
219307552|NCT02731794|PROCEDURE|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
219307553|NCT00679627|DRUG|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
219307554|NCT00679627|DRUG|Placebo|Matching placebo
219307555|NCT06305377|DEVICE|Tandem Control IQ|Use of Tandem control IQ in a group of diabetic adolescents in not good glicaemic control
219307556|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
219307557|NCT05359497|DEVICE|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
219307558|NCT05359497|DEVICE|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
219307559|NCT05359497|DIAGNOSTIC_TEST|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
219307560|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
219307561|NCT05359497|DEVICE|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
219307562|NCT05359497|DEVICE|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
219307563|NCT02707237|OTHER|Verbal counseling|Verbal counseling done by physician
219307564|NCT02707237|OTHER|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
219307565|NCT01886378|DRUG|UX007|
219307566|NCT04553198|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
219307567|NCT03369561|DIAGNOSTIC_TEST|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
219307568|NCT00272922|DEVICE|hernia repair|
219307569|NCT04343638|DEVICE|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
219307570|NCT04343638|DEVICE|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
219307571|NCT03128008|DRUG|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
219307572|NCT03128008|DRUG|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
219307573|NCT03128008|RADIATION|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
219307574|NCT03435757|PROCEDURE|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
219307575|NCT03435757|PROCEDURE|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
219307576|NCT04210869|DIETARY_SUPPLEMENT|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
219307577|NCT05311891|DIAGNOSTIC_TEST|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
219307578|NCT00947674|DEVICE|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
219307579|NCT06227078|DEVICE|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
219307580|NCT03709420|DRUG|Placebo|Placebo capsule to match active drug
219307581|NCT03709420|DRUG|FOR-6219|FOR-6219 capsule
219307582|NCT05217654|DRUG|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
219307583|NCT05217654|DRUG|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
219307584|NCT00037128|DRUG|GL701|
219307585|NCT05106829|OTHER|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
219307586|NCT05106829|OTHER|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
219307587|NCT05202548|OTHER|Immuno-histochemical staining|blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
219307588|NCT01999270|DRUG|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
219307589|NCT01999270|DRUG|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
219307590|NCT01999270|DEVICE|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
219307591|NCT01635400|DRUG|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
219307592|NCT04967534|BEHAVIORAL|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
219307593|NCT04967534|BEHAVIORAL|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
219307594|NCT02391857|PROCEDURE|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
219307595|NCT01426763|BIOLOGICAL|CINRYZE with rHuPH20|
219307596|NCT02966951|BIOLOGICAL|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
219307597|NCT03021954|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
219307598|NCT00004252|DRUG|fluorouracil|
219307599|NCT00004252|DRUG|leucovorin calcium|
219307600|NCT00004252|DRUG|semaxanib|
219307601|NCT03039257|DIETARY_SUPPLEMENT|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
219307602|NCT03821389|DEVICE|NIOD Frequencer|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
219307603|NCT00069238|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
219307604|NCT00069238|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
219307605|NCT00000198|DRUG|Piracetam|
219307606|NCT02652013|OTHER|cognitive evaluation|
219307607|NCT01346436|PROCEDURE|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
219307608|NCT02024763|BEHAVIORAL|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
219307609|NCT00729768|DRUG|basiliximab|2 intravenous doses
219307610|NCT00729768|DRUG|efalizumab|Subcutaneous repeating dose
219307611|NCT00729768|DRUG|mycophenolate mofetil|Oral repeating dose
219307612|NCT00729768|DRUG|corticosteroids|Repeating doses
219307613|NCT00729768|DRUG|cyclosporine|Oral repeating dose
219307614|NCT03201705|DEVICE|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
219307615|NCT04129853|DEVICE|Cyberlegs Xleg|Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
219307616|NCT04094025|DRUG|dATS|d-Amphetamine Transdermal System
219307617|NCT05063825|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
219307618|NCT05063825|BEHAVIORAL|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
219307619|NCT01729325|BEHAVIORAL|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
219307620|NCT00001563|BIOLOGICAL|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
219307621|NCT00001563|BIOLOGICAL|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
219307622|NCT00001563|DRUG|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
219307623|NCT01001832|DRUG|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
219307624|NCT01001832|DRUG|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
219307625|NCT03080012|OTHER|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
219307626|NCT03080012|OTHER|Plasma/serum sampling|Simultaneously with saliva sampling.
219307627|NCT03061630|DRUG|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
219307628|NCT03061630|DRUG|Cisplatin|D1: CISPLATIN 60G/M2
219307629|NCT01090622|DRUG|XPF-001|Oral capsule
219307630|NCT01090622|DRUG|Placebo|Oral capsule
219307631|NCT02453360|PROCEDURE|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
219307632|NCT02453360|DRUG|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
219307633|NCT04493190|PROCEDURE|Scapular control training|Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
219307634|NCT04493190|PROCEDURE|General exercise|Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
219307635|NCT02308826|BEHAVIORAL|Turtle Program|
219307636|NCT02308826|BEHAVIORAL|Cool Little Kids|
219307637|NCT03770559|PROCEDURE|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
219307638|NCT03770559|PROCEDURE|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
219307639|NCT04260425|OTHER|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
219307640|NCT04260425|OTHER|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
219307641|NCT06424626|DRUG|AK104+Axitinib|Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
219307642|NCT06424626|DRUG|AK112+Axitinib|Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
219744833|NCT03631511|PROCEDURE|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
219307643|NCT05884151|DRUG|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
219307644|NCT05884151|DRUG|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
219307645|NCT04019548|DEVICE|Percutaneous Endoscopic Gastrotomy tube placement|placement of the PEG tube depends on arm
219744834|NCT05730478|DEVICE|ASOCT&UBM|glaucoma assesment by ASOCT \&UBM
219744835|NCT05730478|DRUG|Glaucoma therapy|ASOCT and UBM parameters Comparison
219744836|NCT05730478|DRUG|Glaucoma therapy|Comparison
219744837|NCT03422731|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow and blood samples
219744838|NCT03422731|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
219307646|NCT04019548|DRUG|Cisplatin injection|"Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV"
219307647|NCT04019548|RADIATION|Radiotherapy|Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
219307648|NCT06172881|DEVICE|Investigational Contact Lens|A soft contact lens that will be worn only at the study visit.
219307649|NCT02722733|DRUG|G-CSF (filgrastim)|
219307650|NCT02722733|DRUG|Cytosine arabinoside with G-CSF (filgrastim)|
219307651|NCT02430688|PROCEDURE|Irreversible electroporation (IRE)|
219307652|NCT02430688|DEVICE|NanoKnife|
219307653|NCT01658722|DRUG|Bapineuzumab|
219307654|NCT04793802|OTHER|PHYSIO|session of physiotherapy
219307655|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10\^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
219307656|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
219307657|NCT02251288|DRUG|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
219307658|NCT01171105|DRUG|AZD5213|oral solution, multiple ascending doses
219307659|NCT01171105|DRUG|Placebo to AZD5213|
219307660|NCT02046824|DEVICE|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
219307661|NCT02046824|DEVICE|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
219307662|NCT02046824|DEVICE|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
219307663|NCT02046824|OTHER|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
219307664|NCT05537688|BEHAVIORAL|Identification of Graphic Markers|"The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team."
219307665|NCT00208923|DRUG|Busulfan, Cyclophosphamide and Fludarabine|"* Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
219307666|NCT02718937|DRUG|BTA-C585 oral capsule|
219307667|NCT02718937|DRUG|Matching placebo capsules|
219307668|NCT00219804|DRUG|tetrabenazine or placebo|
219307669|NCT02594826|BEHAVIORAL|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
219307670|NCT02594826|BEHAVIORAL|General health education control|General health and cancer education
219307671|NCT03438851|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
219307672|NCT01535950|DRUG|LFG316|
219307673|NCT01535950|DRUG|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
219307674|NCT02254525|DRUG|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
219307675|NCT02254525|DRUG|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
219307676|NCT04660266|DIAGNOSTIC_TEST|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
219307677|NCT00549614|DRUG|acipimox|capsule, 250 mg, 4 times daily for 28 days
219307678|NCT00549614|DRUG|placebo|capsule, 250 mg, 4 times daily for 28 days
219307679|NCT02343055|OTHER|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
219307680|NCT03986281|OTHER|Omron Wearable Device|Omron wearable device compared to arterial line readings
219307681|NCT03986281|OTHER|Standard Arterial Line|Omron wearable device compared to arterial line readings
219307682|NCT04300686|BIOLOGICAL|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
219307683|NCT04300686|BIOLOGICAL|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
219307684|NCT02866110|BEHAVIORAL|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
219307685|NCT02866110|DEVICE|MRI|Echo-planar Imaging of brain BOLD signal
219307686|NCT02700763|OTHER|[18F]dabrafenib molecular imaging|A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
219307687|NCT02805608|DRUG|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
219307688|NCT02805608|DRUG|Injection of 18F-FDG|One injection intravenously of 18F-FDG
219307689|NCT02805608|DEVICE|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
219307690|NCT02805608|DEVICE|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
219307691|NCT03933527|BEHAVIORAL|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
219307692|NCT00160238|DRUG|Betahistine 24 mg bid (Betaserc)|
219307693|NCT05751772|OTHER|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;~2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
219307694|NCT00194519|DRUG|Generic acyclovir|400 mg twice-daily oral
219307695|NCT00194519|DRUG|Placebo|twice-daily oral
219307696|NCT01520493|OTHER|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
219307697|NCT05760391|RADIATION|Radiotherapy|IMRT or SABR for patients with ESCC.
219307698|NCT03791671|OTHER|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
219307699|NCT03791671|OTHER|group balance training|Like the individual balance training
219307700|NCT02011087|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
219744839|NCT03422731|DRUG|Fluorothymidine F-18|Undergo FLT PET
219744840|NCT03422731|OTHER|Laboratory Biomarker Analysis|Correlative studies
219744841|NCT03422731|PROCEDURE|Magnetic Resonance Imaging|Undergo water-fat MRI
219744842|NCT03422731|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
219307701|NCT05918172|DEVICE|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
219307702|NCT05918172|DEVICE|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
219307703|NCT05163171|OTHER|questionnaire|questionnaire for conjugal violence prevalence
219307704|NCT05031663|DIETARY_SUPPLEMENT|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
219307705|NCT05031663|DIETARY_SUPPLEMENT|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
219307706|NCT00125502|BIOLOGICAL|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
219307707|NCT00125502|DRUG|MF59 adjuvant|Oil-in-water emulsion
219307708|NCT00125502|DRUG|Placebo|Normal saline solution
219307709|NCT04467528|DEVICE|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
219307710|NCT04467528|DRUG|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
219307711|NCT05887817|DRUG|Finerenone|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
219307712|NCT05887817|DRUG|Placebo|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
219307713|NCT06150898|PROCEDURE|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
219307714|NCT06150898|DRUG|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
219307715|NCT06150898|DRUG|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
219307716|NCT06150898|DRUG|Omeprazole 20mg Capsule|Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
219307717|NCT01088828|OTHER|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
219307718|NCT01045408|DIETARY_SUPPLEMENT|Berry extract|Berry extract for weeks
219307719|NCT06583720|PROCEDURE|Oral hygiene at home|Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
219307720|NCT06583720|PROCEDURE|aPDT|A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.
219307721|NCT06583720|DIETARY_SUPPLEMENT|Probiotics|Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
219307722|NCT04598568|DEVICE|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
219307723|NCT00042406|DRUG|HuMax-CD4|HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
219307724|NCT00042406|DRUG|Placebo|Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
219307725|NCT00042406|DRUG|Humax-CD4|HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
219307726|NCT05277220|DEVICE|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
219307727|NCT03343847|BIOLOGICAL|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
219307728|NCT03343847|OTHER|Placebo|Placebo Comparator
219307729|NCT02508246|DRUG|Cisplatin|Given IV
219307730|NCT02508246|DRUG|Docetaxel|Given IV
219307731|NCT02508246|OTHER|Laboratory Biomarker Analysis|Correlative studies
219307732|NCT02508246|OTHER|Pharmacological Study|Correlative studies
219307733|NCT02508246|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219307734|NCT02508246|DRUG|WEE1 Inhibitor AZD1775|Given PO
219307735|NCT03581825|DEVICE|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
219307736|NCT03581825|DEVICE|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
219307737|NCT03581825|DEVICE|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
219307738|NCT03581825|DEVICE|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
219307739|NCT01582685|BEHAVIORAL|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
219307740|NCT01668667|DRUG|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
219307741|NCT01668667|DRUG|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
219307742|NCT01668667|DRUG|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
219307743|NCT01668667|DRUG|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
219307744|NCT06268769|DRUG|Tacrolimus Pill|Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
219307745|NCT06268769|DRUG|Tacrolimus capsule|Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
219307746|NCT04961723|DIAGNOSTIC_TEST|(OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
219307747|NCT04465747|OTHER|Publications|Reviewing published evidence
219307748|NCT01124032|DRUG|methylphenidate|a capsule containing 20 mg
219307749|NCT03444350|DEVICE|Gaseous ozone|SRP plus gaseous ozone
219307750|NCT03444350|DEVICE|SRP plus placebo|only SRP
219307751|NCT00515632|DRUG|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
219307752|NCT02867878|DRUG|Adenosine|
219307753|NCT02867878|DRUG|Saline solution|
219307754|NCT02633579|DRUG|erythromycin lactobionate|intravenous administration of erythromycin
219307755|NCT02633579|DRUG|Atropine|intravenous administration of atropine
219307756|NCT02633579|DRUG|Erythromycin with atropine|intravenous administration of erythromycin with saline
219307757|NCT02633579|DRUG|Saline|intravenous administration of saline
219307758|NCT04838600|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
219307759|NCT03366623|BEHAVIORAL|Hospital clown|Presence of the hospital clown
219307760|NCT03366623|BEHAVIORAL|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
219307761|NCT03812393|DRUG|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
219307762|NCT03113903|BEHAVIORAL|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
219307763|NCT02652923|DRUG|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
219307764|NCT00662233|DRUG|cyclophosphamide|
219307765|NCT00662233|DRUG|doxorubicin hydrochloride|
219307766|NCT00662233|DRUG|etoposide|
219307767|NCT00662233|DRUG|ifosfamide|
219307768|NCT00662233|DRUG|vincristine sulfate|
219307769|NCT00662233|PROCEDURE|adjuvant therapy|
219307770|NCT00662233|PROCEDURE|neoadjuvant therapy|
219307771|NCT00662233|PROCEDURE|therapeutic conventional surgery|
219307772|NCT00662233|RADIATION|brachytherapy|
219307773|NCT00662233|RADIATION|intraoperative radiation therapy|
219307774|NCT00662233|RADIATION|radiation therapy|
219307775|NCT01864954|BEHAVIORAL|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
219307776|NCT03006731|BEHAVIORAL|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
219307777|NCT03006731|BEHAVIORAL|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
219307778|NCT02757027|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
219307779|NCT02757027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
219307780|NCT03991702|DIAGNOSTIC_TEST|diagnostic test|The overall motor function of the patient will be assessed using the Medical Research Council (MRC) scale and Palmar dynamometer strength
219307781|NCT00681785|DRUG|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
219307782|NCT03343301|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
219307783|NCT03343301|DRUG|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
219307784|NCT05557227|OTHER|1-hour cycling|60 % VO2 max
219307785|NCT00307502|DRUG|Nevirapine|tablets 200 mg, 400 mg/day
219307786|NCT00307502|DRUG|Efavirenz|tablets 600 mg, 600 mg/day
219307787|NCT00307502|DRUG|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
219307788|NCT00307502|DRUG|Nelfinavir|tablets 250 mg, 2500 mg/day
219307789|NCT00307502|DRUG|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
219307790|NCT00307502|DRUG|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
219307791|NCT00307502|DRUG|Atazanavir|capsules 200 mg, 400 mg/day
219307792|NCT00307502|DRUG|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
219307793|NCT00307502|DRUG|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
219307794|NCT00307502|DRUG|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
219307795|NCT00307502|DRUG|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
219307796|NCT05066737|PROCEDURE|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
219307797|NCT02325479|DRUG|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
219307798|NCT02325479|DRUG|tissue culture media|intrauterine administration after oocyte pickup as placebo
219307799|NCT05381610|DEVICE|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
219307800|NCT06161168|DEVICE|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
219307801|NCT04877730|DEVICE|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
219307802|NCT04877730|DEVICE|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
219307803|NCT04877730|DEVICE|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
219307804|NCT05012891|OTHER|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
219307805|NCT01518933|DRUG|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
219307806|NCT01518933|DRUG|Saline|Placebo
219307807|NCT00190411|DRUG|celiprolol|celiprolol
219307808|NCT00190411|DRUG|Control|Untreated controls excluding betablockers
219307809|NCT03466801|DRUG|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
219307810|NCT03466801|DRUG|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
219307811|NCT02866136|DRUG|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
219307812|NCT02866136|DRUG|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
219307813|NCT02866136|DRUG|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
219307814|NCT02866136|DRUG|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
219307815|NCT02866136|DEVICE|Laser (local treatment)|
219307816|NCT02866136|DEVICE|cryoapplication (local treatment)|
219307817|NCT02866136|RADIATION|I125 radioactive plaques (local treatment)|
219307818|NCT02866136|DRUG|intravitreal Melphalan (local treatment)|
219307819|NCT05514782|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
219307820|NCT05514782|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
219307821|NCT05514782|OTHER|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
219307822|NCT00405691|DEVICE|"TOPS System - Total Posterior Arthroplasty Implant"|
219307823|NCT05247554|DRUG|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
219307824|NCT05247554|DRUG|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
219307825|NCT03516929|DIAGNOSTIC_TEST|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
219307826|NCT04633551|DIETARY_SUPPLEMENT|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
219307827|NCT01992393|BEHAVIORAL|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
219307828|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
219307829|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
219307830|NCT05488015|OTHER|Global Postural Re-education (GPR)|GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
219307831|NCT05488015|OTHER|Lifestyle habits|No change in lifestyle habits during the 8-week trial.
219307832|NCT00556387|DRUG|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
219307833|NCT00556387|DRUG|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
219307834|NCT00088686|DRUG|Capsaicin (Intramucosal Injection)|
219307835|NCT03243877|OTHER|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
219307836|NCT02388867|PROCEDURE|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
219307837|NCT02388867|PROCEDURE|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
219307838|NCT00045513|DRUG|7-hydroxystaurosporine|
219307839|NCT00045513|DRUG|fludarabine phosphate|
219307840|NCT02790268|PROCEDURE|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
219307841|NCT04600193|OTHER|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
219307842|NCT04600193|OTHER|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
219307843|NCT02870335|OTHER|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
219307844|NCT02870335|OTHER|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
219307845|NCT05344781|OTHER|Questionnaire|Questionnaire regarding relationship and sexual satisfaction
219307846|NCT01013597|DRUG|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
219307847|NCT00652210|OTHER|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
219307848|NCT01248546|PROCEDURE|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
219307849|NCT04535804|DRUG|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
219307850|NCT02731573|DRUG|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
219307851|NCT02731573|PROCEDURE|Open heart surgery|Subject will undergo open heart surgery according to standard of care
219307852|NCT00862628|DRUG|Rebamipide|100mg tid, 4 or 8 weeks
219307853|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
219307854|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
219307855|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
219307856|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
219307857|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
219307858|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
219307859|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
219307860|NCT04320394|DIAGNOSTIC_TEST|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
219307861|NCT06108960|OTHER|Proprioceptive neuromuscular facilitation|Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
219307862|NCT06108960|OTHER|Pelvic stabilization exercises|"Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks."
219307863|NCT01907360|DRUG|HLD200 (methylphenidate hydrochloride)|
219307864|NCT03050255|OTHER|Medical air|
219307865|NCT03050255|OTHER|Oxygen (2Liter/min)|
219307866|NCT03050255|OTHER|Oxygen (4Liter/min)|
219307867|NCT01213160|DRUG|AZD4547|film coated tablet, PO, twice daily
219307868|NCT00956748|DRUG|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
219307869|NCT00956748|DRUG|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
219307870|NCT05955287|BEHAVIORAL|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
219307871|NCT05955287|BEHAVIORAL|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
219307872|NCT05955287|BEHAVIORAL|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
219307873|NCT05955287|BEHAVIORAL|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
219307874|NCT03070951|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
219307875|NCT03070951|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
219307876|NCT03070951|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
219307877|NCT03070951|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
219307878|NCT05576194|DEVICE|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
219307879|NCT05576194|DEVICE|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
219307880|NCT05576194|DRUG|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
219307881|NCT03747198|DIETARY_SUPPLEMENT|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
219307882|NCT03747198|OTHER|Placebo|Subjects will be given 2 g/day placebo (rice flour).
219307883|NCT04206579|DRUG|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
219307884|NCT04206579|DRUG|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
219307885|NCT03573726|OTHER|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
219307886|NCT02647567|OTHER|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
219307887|NCT02647567|OTHER|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
219307888|NCT00398645|DRUG|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
219307889|NCT05399420|DIAGNOSTIC_TEST|Blood sampling|One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
219307890|NCT03329560|BIOLOGICAL|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
219307891|NCT01822288|DRUG|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
219307892|NCT01822288|DRUG|Estradiol & medroxyprogesterone acetate|Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
219307893|NCT02636179|OTHER|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
219307894|NCT05331963|OTHER|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
219307895|NCT01173406|BEHAVIORAL|CPAP education|Standard CPAP education plus an session and one telephone follow up
219307896|NCT00585195|DRUG|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
219307897|NCT00585195|DRUG|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
219307898|NCT00585195|DRUG|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
219307899|NCT01523925|BEHAVIORAL|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
219307900|NCT01523925|BEHAVIORAL|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
219307901|NCT01523925|BEHAVIORAL|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
219307902|NCT01523925|BEHAVIORAL|Functional electrical stimulation|
219307903|NCT02796560|DRUG|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
219307904|NCT02796560|DRUG|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
219307905|NCT02533570|DRUG|Brentuximab vedotin|
219307906|NCT02533570|DRUG|Placebo|
219307907|NCT03995667|OTHER|Questionnaire Administration|Ancillary studies
219307908|NCT03995667|DEVICE|Tumor Treating Fields Therapy|Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
219307909|NCT03020654|OTHER|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
219307910|NCT03020654|OTHER|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
219307911|NCT01594008|OTHER|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
219307912|NCT01594008|OTHER|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
219307913|NCT01594008|OTHER|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
219307914|NCT02913534|RADIATION|whole brain radiotherapy|
219307915|NCT00515983|BIOLOGICAL|DC/Apo-Nec|
219307916|NCT02601651|DRUG|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
219307917|NCT02601651|DRUG|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
219307918|NCT00046397|DRUG|Modified Vaccinia Virus Ankara TBC-M|
219307919|NCT04978142|DEVICE|transcranial Direct Current Stimulation (tDCS)|Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
219307920|NCT03679806|OTHER|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
219307921|NCT03679806|OTHER|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
219307922|NCT05004571|DRUG|EQU-001|EQU-001 in 10 and 20 mg capsules
219307923|NCT05004571|DRUG|Placebo|Matched placebo
219307924|NCT00000201|DRUG|Selegiline|
219307925|NCT00226343|DRUG|Depakote-ER|
219307926|NCT02632032|DRUG|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice"
219307927|NCT05765162|BEHAVIORAL|Patient reported ourcomes|Full screening for the perioperative periode
219307928|NCT03408561|OTHER|Internet-Based Intervention|Receive message via Twitter
219307929|NCT03408561|OTHER|Survey Administration|Ancillary studies
219307930|NCT00437541|DEVICE|Insulation retrofitted into house|
219307931|NCT04007341|DRUG|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
219307932|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
219307933|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields sham|sham PEMF
219307934|NCT00820196|DRUG|Nexagon®|
219307935|NCT00820196|DRUG|Nexagon® vehicle|
219307936|NCT04002401|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of CAR-transduced autologous T cells administered intravenously
219307937|NCT04002401|DRUG|Rituximab|Administered intravenously
219307938|NCT04002401|DRUG|Fludarabine|Administered according to package insert
219307939|NCT04002401|DRUG|Cyclophosphamide|Administered according to package insert
219307940|NCT00423930|BIOLOGICAL|bevacizumab|
219307941|NCT00423930|DRUG|cisplatin|
219307942|NCT00423930|PROCEDURE|conventional surgery|
219307943|NCT00423930|RADIATION|intensity-modulated radiation therapy|
219307944|NCT04642872|OTHER|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
219307945|NCT04642872|OTHER|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
219307946|NCT04642872|OTHER|Conventional therapy|Following the usual therapy in the baby.
219307947|NCT04642872|OTHER|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
219307948|NCT00155935|PROCEDURE|venous puncture|
219307949|NCT06397677|GENETIC|Research Testing Performed (Laboratory)|Blood collection (DNA, RNA)
219307950|NCT06397677|DIAGNOSTIC_TEST|Information Collected as Standard of Care|High Resolution CT Scan (Chest), Pulmonary Function Testing (PFT), 6-Minute Walk Test (6MWT)
219307951|NCT06397677|OTHER|Research Testing Performed|Blood collection (non-genetic), Buccal Swab, Rheumatologic Assessment, Pulmonary Assessment, Questionnaires
219307952|NCT06390878|OTHER|Biodiversity|In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
219307953|NCT06390878|OTHER|Playground equipment|Playground equipment that increase the physical activity of children will be added to the kindergarten yards.
219307954|NCT00623701|BIOLOGICAL|Allerslit forte|sublingual placebo preparation, daily
219307955|NCT00623701|BIOLOGICAL|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
219307956|NCT03696823|PROCEDURE|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
219307957|NCT04598503|OTHER|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) \[10\]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
219307958|NCT00080093|BEHAVIORAL|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
219307959|NCT00080093|BEHAVIORAL|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
219307960|NCT05628168|OTHER|Neurodynamic Mobilization Techniques|The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.
219307961|NCT05628168|OTHER|Selected Physical Therapy Program|The participants only received a selected therapy program similar to the NMG with no change in duration.
219307962|NCT01637181|PROCEDURE|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
219307963|NCT02461329|DRUG|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
219307964|NCT02461329|DRUG|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
219307965|NCT00372645|DIETARY_SUPPLEMENT|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
219307966|NCT00372645|DIETARY_SUPPLEMENT|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
219307967|NCT00372645|DRUG|Placebo|Placebo
219307968|NCT00372645|OTHER|Folate rich foods|200 µg folate per day from folate-rich foods
219307969|NCT01622114|OTHER|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
219307970|NCT02217579|DIETARY_SUPPLEMENT|Protein|A food containing 5 grams/serving of supplemental protein.
219307971|NCT02217579|DIETARY_SUPPLEMENT|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
219307972|NCT02217579|DIETARY_SUPPLEMENT|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
219307973|NCT02217579|DIETARY_SUPPLEMENT|Control|An isocaloric food not containing the test protein and fiber.
219307974|NCT06297759|OTHER|Questionnaire|Sense of Competence in Dementia Care Staff (SCIDS) Scale
219307975|NCT02659800|OTHER|Laboratory Biomarker Analysis|Correlative studies
219307976|NCT02659800|BIOLOGICAL|NT-I7|Given IM
219307977|NCT02659800|OTHER|Placebo|Given IM
219307978|NCT02369640|PROCEDURE|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
219307979|NCT02938091|OTHER|High-fat diet|Typical Western diet
219307980|NCT02938091|OTHER|Low-fat diet|Traditional Caribbean Hispanic diet
219307981|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
219307982|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
219307983|NCT00143676|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
219307984|NCT03306017|OTHER|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
219307985|NCT05867563|DRUG|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
219307986|NCT00218660|DRUG|Naltrexone|150mg/day Naltrexone
219307987|NCT00218660|BEHAVIORAL|BRENDA|Psychosocial Treatment
219307988|NCT00218660|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
219307989|NCT00218660|DRUG|Placebo|
219307990|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish sauce|
219307991|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish/liver sauce|
219307992|NCT01724073|DIETARY_SUPPLEMENT|Misola|
219307993|NCT02638480|DEVICE|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
219307994|NCT02105584|DEVICE|Implantation of LAA closure device|
219307995|NCT03661203|BEHAVIORAL|Focus group|Focus group for qualitative group only
219307996|NCT03661203|BEHAVIORAL|Individual interview|Individual interview for qualitative group only
219307997|NCT03661203|BEHAVIORAL|online self questionnaire|online self questionnaire
219307998|NCT03661203|BEHAVIORAL|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
219307999|NCT00822523|DRUG|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
219308000|NCT00822523|DRUG|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
219308001|NCT00822523|DRUG|Saline|Single Dose, Intramuscular into right EDB muscle
219308002|NCT04924842|OTHER|Review of medical file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
219308003|NCT04924842|OTHER|Phone call interview|less than 15 minutes phone call
219308004|NCT01009580|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
219308005|NCT01009580|DRUG|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
219308006|NCT05584787|PROCEDURE|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
219308007|NCT01468129|OTHER|Cell Saver|
219308008|NCT04987437|DEVICE|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
219308009|NCT01201733|OTHER|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
219308010|NCT01201733|OTHER|Ultrasound therapy and hot pack|
219308011|NCT00911287|DRUG|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
219308012|NCT02880540|DRUG|Fentanyl|
219308013|NCT02880540|DRUG|Morphine|
219308014|NCT02880540|DRUG|Dexmedetomidine|
219308015|NCT00760773|DRUG|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
219308016|NCT00760773|DRUG|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
219308017|NCT00760773|DRUG|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
219308018|NCT05060068|DRUG|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
219308019|NCT05060068|DRUG|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
219308020|NCT05060068|DRUG|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
219308021|NCT00617253|DRUG|recombinant interleukin-21|3 mcg/kg, s.c. injection
219308022|NCT00617253|DRUG|sunitinib|Hard gelatine capsules, 12.5 mg
219308023|NCT00617253|DRUG|recombinant interleukin-21|10 mcg/kg, s.c. injection
219308024|NCT00617253|DRUG|recombinant interleukin-21|30 mcg/kg, s.c. injection
219308025|NCT00617253|DRUG|recombinant interleukin-21|100 mcg/kg, s.c. injection
219308026|NCT03163485|DEVICE|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
219308027|NCT03163485|DEVICE|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
219308028|NCT04193124|DIAGNOSTIC_TEST|transcranial doppler.|Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
219308029|NCT02720367|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
219308030|NCT05802641|RADIATION|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
219308031|NCT02855970|OTHER|completion of a quality of life questionnaire|
219308032|NCT04397341|DRUG|docetaxel, cisplatin, fluorouracil|Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
219308033|NCT04581954|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
219308034|NCT04581954|DRUG|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
219308035|NCT04581954|OTHER|Standard of care|Standard of care treatment as per site-level policies and guidelines.
219308036|NCT00193999|DEVICE|Placement of nasogastric tube|
219308037|NCT01729143|OTHER|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
219308038|NCT00611312|BEHAVIORAL|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
219308039|NCT01607112|BIOLOGICAL|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
219308040|NCT02881957|DRUG|Cholecalciferol|
219308041|NCT02881957|OTHER|Placebo|Oral syrup placebo
219308042|NCT05742022|DRUG|"Phospholipovit"|500 mg orally 2 times a day, for 12 weeks
219308043|NCT05742022|DRUG|Placebo|500 mg orally 2 times a day, for 12 weeks
219308044|NCT05687526|BIOLOGICAL|Telitacicept|"12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.~5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks."
219308045|NCT05593237|DEVICE|High Frequency rTMS|Stimulation provided at 10 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (3,000 pulses/session)
219308046|NCT05593237|DEVICE|Low Frequency rTMS|Stimulation provided at 1 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (300 pulses/session)
219308047|NCT02568865|OTHER|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
219308048|NCT02568865|OTHER|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
219308049|NCT02568865|OTHER|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
219308050|NCT02568865|OTHER|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
219308051|NCT04041011|DRUG|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
219308052|NCT04041011|DRUG|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
219308053|NCT04041011|DRUG|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
219308054|NCT05137353|BEHAVIORAL|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
219308055|NCT05137353|BEHAVIORAL|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
219308056|NCT04816331|OTHER|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
219308057|NCT04179162|DRUG|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
219308058|NCT04179162|DRUG|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
219308059|NCT06041048|DRUG|Modafinil|Single dose (200 mg) of medication versus placebo given to healthy control subjects
219308060|NCT05269355|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
219308061|NCT05269355|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
219308062|NCT05269355|OTHER|Placebo|Placebo will be administered as per the schedule specified in the arm description.
219308063|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|"DETECT is an elder mistreatment (EM) screening tool created for medics in the Fort Worth Texas area to use when responding to the homes of older adults, enabling them to screen for signs of elder mistreatment. DETECT-RPC is the adapted version of this tool designed specifically for use by home-based primary care (HBPC) clinicians.~The DETECT-RPC tool is designed to:~1. Be brief and easy to use.~2. Focus on the clinician's direct observations of the older adult and their physical and social environment.~3. Provide clear guidance on reporting suspected EM.~4. Integrate seamlessly into existing procedures and medical charting systems."
219308064|NCT04848493|BIOLOGICAL|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
219308065|NCT04317807|DRUG|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
219308066|NCT04317807|OTHER|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
219308067|NCT05322850|BIOLOGICAL|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
219308068|NCT03409627|BIOLOGICAL|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
219308069|NCT00081497|BIOLOGICAL|agalsidase beta|1.0 mg/kg every 2 weeks
219308070|NCT01315496|DRUG|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
219308071|NCT06854861|DRUG|Lyumjev 100 UNT/ML Injectable Solution|0.1 unit insulin Lyumjev /kg body weight is injected subcutaneously
219308072|NCT06854861|DRUG|Premixed Lyumjev|A solution of 5 ng glucagon /Unit Lyumjev is injcetd subcutaneously. 0.1 unit insulin / kg body weight is used.
219308073|NCT01018303|DIETARY_SUPPLEMENT|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
219308074|NCT02373943|OTHER|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
219308075|NCT02373943|OTHER|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
219308076|NCT02373943|OTHER|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
219308077|NCT06082908|DIAGNOSTIC_TEST|Diagnostic test|Subjective and objective measurement will be performed in older adults.
219308078|NCT03868488|BEHAVIORAL|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
219308079|NCT00134433|GENETIC|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
219308080|NCT00134433|DRUG|oral L-arginine supplementation (at a dose of 6 g/day)|
219308081|NCT05067465|DIETARY_SUPPLEMENT|Selected food groups|"Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)"
219308082|NCT01825733|DRUG|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
219308083|NCT01825733|DRUG|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
219308084|NCT00484458|DEVICE|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
219308085|NCT00484458|DEVICE|Total Disc Replacement|Total disc
219308086|NCT05209763|PROCEDURE|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
219308087|NCT05209763|DIETARY_SUPPLEMENT|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses"
219308088|NCT00297336|DRUG|Topiramate|80 patients with diagnosed with migraine
219308089|NCT00345293|BIOLOGICAL|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
219308090|NCT06598449|DRUG|fenfluramine|Clear, cherry flavored oral solution
219308091|NCT06598722|DRUG|BCL-2 inhibitors combined with the HyperCVAD regimen|BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
219308092|NCT06598722|OTHER|Propensity score matching historical data|Propensity score matching was conducted with historical data (matching factors included age, gender, initial LDH levels, and the presence or absence of a large mediastinal mass at diagnosis) to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols.
219308093|NCT06605495|COMBINATION_PRODUCT|fumigation with Chinese medicine|Eye fumigation with the Eyesight Eye Therapy,10 minutes once daily for 6 weeks.
219308094|NCT06605495|DRUG|Oral herbal medicine|Patients were identified into the appropriate group according to the individual evidence profile, and the herbal formula under the corresponding evidence profile was taken orally as one dose of 150 ml of water twice a day for 6 weeks.
219308095|NCT06605495|DRUG|Modern Western Medicine|Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
219308096|NCT03058029|DEVICE|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
219308097|NCT03058029|DEVICE|Placebo|Subject would take placebo capsules 2 times per day.
219308098|NCT02368678|PROCEDURE|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
219308099|NCT02368678|PROCEDURE|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
219308100|NCT00879112|DRUG|MB07811|Oral
219308101|NCT00879112|DRUG|Placebo|Oral
219308102|NCT06658366|DIAGNOSTIC_TEST|impression of the teeth|Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
219308103|NCT03944473|DRUG|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
219308104|NCT03944473|DRUG|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
219308105|NCT04501211|DRUG|Granisetron|transdermal sancuso patch
219308106|NCT05591222|DRUG|Placebo|Placebo will be administered subcutaneously as two injections for each dose.
219308107|NCT05591222|DRUG|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
219308108|NCT06589960|COMBINATION_PRODUCT|Health education and physical exercise|"Nine face to face sessions and group discussion health education sessions. An Educational booklet was prepared and distributed to all attendants.~Lab results were discussed individually with each participant.~Rheumatologist and physiotherapist also provided messages.~The exercise program targeted and strengthened the muscles around the knee especially quadriceps muscle, stretching the muscles of lower limbs, and stretching and increasing the range of motion of front and back lower limb muscles (quadriceps muscle, hamstring muscle, gluteus muscle and calf muscles).~Phone calls to follow up the participants and maximize their adherence to the health education program. WhatsApp groups was created, and messages were distributed to summarize the content of the booklet and the exercises videos.~Final reassessment to assess the effect of health education and lifestyle modification was carried out with participants who continued till the end of the study."
219308109|NCT01659788|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|
219308110|NCT01659788|DIETARY_SUPPLEMENT|Placebo|
219308111|NCT00249054|DEVICE|ASR hip prosthesis|Implantation of resurfacing prosthesis
219308112|NCT00249054|DEVICE|ReCap hip prosthesis|Implantation of resurfacing prosthesis
219308113|NCT06609733|DEVICE|Twin block|The TB group used a single appliance continuously, with appropriate reduction of occlusal surface height by 1 mm when clinically indicated. Both groups had follow-up appointments every 6 weeks.
219308114|NCT06609733|DEVICE|Clear aligner with mandibular function|The MA group underwent stepwise mandibular forward movement with clear aligners (Invisalign, Align Inc, CA, USA) worn for 22 hours/day and replaced every 7 days.
219308115|NCT06611254|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
219308116|NCT06609967|PROCEDURE|application of PRF|PRF will be randomly administered into one group of patients undergoing any extractions group A (Right after the extraction) Group B will be a control group in which extraction sockets will be left to heal with the natural blood clot. Consenting patients will be assigned into groups randomly and not informed which group they were placed into. The PRF will be administered obtained from a tube of 10 ml blood and no material will be placed in the control group. The progress of healing and post-operative complications will be tracked over a period of 7 days with patients being called for follow-up on days 3, 5 and 7
219308117|NCT06609967|PROCEDURE|application of conventional surgicel|it will be a control group in which extraction sockets will be left to heal with the natural blood clot.
219308118|NCT06610058|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
219308119|NCT06610058|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
219308120|NCT06610734|DRUG|Adebrelimab|Adebrelimab combined with chemotherapy synchronous LDRT
219308121|NCT06610734|DRUG|Chemotherapy|Chemotherapy
219308122|NCT06610734|RADIATION|low dose radiotherapy|low dose radiotherapy
219308123|NCT06610305|DRUG|Transdermal estradiol|0.1 mg/day delivered via weekly patch
219308124|NCT06610305|DRUG|Progesterone|100 mg twice daily (200 mg/day total) administered via oral capsule
219308125|NCT06610305|DRUG|Transdermal placebo patch|Once weekly via transdermal patch
219308126|NCT06610305|DRUG|placebo capsule|Twice daily via oral capsule
219308127|NCT06609551|DRUG|6-month adjuvant chemotherapy with 5-FU monotherapy|6 months of adjuvant chemotherapy with 5-FU monotherapy. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
219308128|NCT06609551|DRUG|XELOX intensive treatment group|XELOX intensive treatment group. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
219308129|NCT06609954|OTHER|Reduced Exertion High Intensity Training (REHIT)|Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform training sessions on a cycle ergometer. Each session will consist of a 3-minute warm-up period followed by two 20-second all-out sprints interspersed with 3 minutes of slow pedaling for recovery. Total of 18 sessions of REHIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
219308130|NCT06609954|OTHER|High Intensity Interval Training (HIIT)|Patients in this group will be provided with a caloric restriction plan by a nutritionist that will be followed throughout the training duration. Week 1 will be baseline fitness level and familiarization week. Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform a warm up of 5 min, then 4 bouts of 4 min of HIIT will be performed at 80%-95% of HRR separated by 3-min active recovery periods of moderate intensity cycling at 60%-70% of the HRR followed by 5 min cool down exercises. Pre and post session vitals will be noted. Total of 18 sessions of either HIIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
219308131|NCT06609447|DIETARY_SUPPLEMENT|VSL#3|VSL#3 450 billion CFU/sachet
219308132|NCT06609447|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
219308133|NCT06609447|DRUG|Vedolizumab|Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
219308134|NCT06609759|DRUG|Standard chemotherapy regimen|In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
219308135|NCT06609382|OTHER|Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)|Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
219308136|NCT06610149|DIETARY_SUPPLEMENT|Probiotic mixture|8 weeks treatment with Probiotic mixture
219308137|NCT02390245|OTHER|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
219308138|NCT02390245|OTHER|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
219308139|NCT02390245|OTHER|Usual Care|This group will receive ophthalmic referral.
219308140|NCT01111747|PROCEDURE|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
219308141|NCT01111747|PROCEDURE|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
219308142|NCT02574754|DRUG|warfarin|warfarin 10 mg PO x 1
219308143|NCT06610292|OTHER|Pharmacist-led medication reconciliation services|"Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list.~Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved.~Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs)."
219308144|NCT06610123|DIETARY_SUPPLEMENT|Caffeine and Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
219308145|NCT06610123|DIETARY_SUPPLEMENT|Placebo and Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
219354712|NCT03491332|DEVICE|conventional circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
219308146|NCT05553522|COMBINATION_PRODUCT|Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine|"SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle."
219308147|NCT02485054|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
219308148|NCT04417322|OTHER|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
219308149|NCT06729827|DEVICE|Hypotension prediction Index - HPI|"Patients in the HPI group, in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA) with ClearSight non-invasive hemodynamic monitoring and with the HPI software enabled.~The patients will be treated with a bolus of norepinephrine 5 mcg each time that HPI is 85 or higher."
219308150|NCT02788903|OTHER|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
219308151|NCT03095430|DEVICE|Monitoring|Monitoring
219308152|NCT06110143|OTHER|Periodontal treatment|Periodontal treatment
219308153|NCT05568524|OTHER|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
219308154|NCT05568524|OTHER|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
219308155|NCT06227000|BEHAVIORAL|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
219308156|NCT06227000|BEHAVIORAL|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
219308157|NCT04950322|DRUG|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
219308158|NCT04950322|DRUG|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
219308159|NCT05951933|OTHER|Strenghtening + TES|Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)
219308160|NCT03889743|DRUG|Dexamethasone treatment during 3 days|Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
219308161|NCT03889743|DRUG|placebo treatment during 3 days|1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
219308162|NCT05649852|OTHER|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
219308163|NCT05649852|OTHER|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
219308164|NCT06475183|DIETARY_SUPPLEMENT|Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum|Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
219308165|NCT03224351|DRUG|VX-659|Tablet for oral administration.
219308166|NCT03224351|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
219308167|NCT03224351|DRUG|IVA|Tablet for oral administration.
219308168|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
219308169|NCT03224351|DRUG|TEZ|Tablet for oral administration.
219308170|NCT03224351|DRUG|VX-561|Tablet for oral administration.
219308171|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
219308172|NCT01328717|DEVICE|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
219308173|NCT04321044|GENETIC|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
219308174|NCT03440320|BEHAVIORAL|MY-SKILLS - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
219308175|NCT03440320|BEHAVIORAL|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
219308176|NCT03883425|OTHER|interRAI-HC assessments|Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses
219308177|NCT05869630|OTHER|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
219308178|NCT05869630|OTHER|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
219308179|NCT00597298|DEVICE|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
219308180|NCT00597298|DEVICE|sham threshold|non-training physical activity
219308181|NCT05077865|DRUG|MYMD-1|150 mg capsule
219308182|NCT05077865|DRUG|Placebo|Matching in appearance to MyMD-1 150mg capsule
219308183|NCT04478656|BIOLOGICAL|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
219308184|NCT02648165|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
219308185|NCT02648165|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
219308186|NCT02648165|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
219308187|NCT03542513|DEVICE|Colli-Pee|Urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium).
219308188|NCT03542513|DEVICE|Qvintip|Vaginal self-samples will be collected with the Qvintip (Aprovix AB, Uppsala, Sweden).
219308189|NCT01341756|RADIATION|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
219308190|NCT01980654|DRUG|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
219308191|NCT01980654|DRUG|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
219308192|NCT00895674|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
219308193|NCT03102554|GENETIC|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
219308194|NCT06258915|DRUG|Adalimumab|Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)
219308195|NCT06258915|DRUG|Mycophenolate Mofetil|2 g/day orally for 36 weeks
219308196|NCT04557462|DRUG|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
219308197|NCT01602523|DRUG|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
219308198|NCT01602523|DRUG|Placebo|Placebo inhaler once daily 28 days
219308199|NCT02258308|BEHAVIORAL|CHW intervention|Home education and support for asthma self management
219308200|NCT06434376|BIOLOGICAL|Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology|Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
219308201|NCT03998254|DRUG|V503|9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
219308202|NCT03998254|DRUG|Gardasil|qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
219308203|NCT03141008|OTHER|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
219308204|NCT02315352|DRUG|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
219308205|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
219308206|NCT02315352|DRUG|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
219308207|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
219308208|NCT02315352|DRUG|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
219308209|NCT04712331|OTHER|Graduated abdominal strengthening exercises|"Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors)."
219308210|NCT04712331|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
219308211|NCT04712331|OTHER|Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation|"Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation."
219308212|NCT03503253|DEVICE|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
219308213|NCT03503253|DEVICE|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
219308214|NCT03503253|DEVICE|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
219308215|NCT03569657|BEHAVIORAL|A positive psychology workshop|Group workshop
219308216|NCT05112107|BEHAVIORAL|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
219308217|NCT01008293|DRUG|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
219308218|NCT01008293|DRUG|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
219308219|NCT06132126|DRUG|LY3938577|Administered SC.
219308220|NCT06132126|DRUG|Placebo|Administered SC.
219308221|NCT06132126|DRUG|Insulin degludec|Administered SC.
219308222|NCT04530409|DRUG|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
219308223|NCT00077220|DRUG|carboplatin|
219308224|NCT00077220|DRUG|paclitaxel|
219308225|NCT00077220|PROCEDURE|adjuvant therapy|
219308226|NCT00077220|RADIATION|radiation therapy|
219308227|NCT04281004|BIOLOGICAL|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
219308228|NCT04281004|OTHER|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
219308229|NCT02296970|PROCEDURE|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
219308230|NCT03628898|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
219308231|NCT02946970|OTHER|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
219308232|NCT02946970|OTHER|Control|Intragastric administration of distilled water
219308233|NCT05149430|OTHER|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
219308234|NCT04999098|DRUG|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
219308235|NCT04999098|DRUG|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
219308236|NCT04999098|DRUG|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
219308237|NCT00500162|BEHAVIORAL|Tri-Luma Maintenance regimen|
219308238|NCT05040477|OTHER|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
219308239|NCT02482870|DEVICE|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
219308240|NCT02482870|DEVICE|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
219308241|NCT01716117|DEVICE|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
219308242|NCT03165929|DRUG|Flurbiprofen|oral flurbiprofen spray
219308243|NCT03165929|DRUG|placebo|oral placebo spray
219308244|NCT03702556|DEVICE|MRI scan|7.0 tesla functional MRI scan
219308245|NCT02086266|OTHER|PILATES|
219308246|NCT02086266|OTHER|PFMT and AES|
219308247|NCT05779397|DEVICE|Masimo RAD-GT|Non-contact infrared thermometry device
219308248|NCT03794908|DEVICE|Light therapy A (Bright) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
219308249|NCT03794908|DEVICE|Light therapy B (Dim) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
219308250|NCT04725825|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
219308251|NCT04725825|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
219308252|NCT00286520|PROCEDURE|Transanal irrigation with Peristeen Anal Irrigation|
219308253|NCT04209699|DRUG|BMS-986165|Single dose
219308254|NCT04209699|DRUG|Famotidine|Single dose
219308255|NCT04531553|PROCEDURE|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
219308256|NCT04531553|PROCEDURE|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
219308257|NCT04531553|PROCEDURE|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
219308258|NCT00674869|OTHER|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
219308259|NCT00451100|DRUG|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
219308260|NCT00451100|DRUG|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
219308261|NCT03490526|DEVICE|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
219308262|NCT03490526|DEVICE|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
219308263|NCT04642768|DIETARY_SUPPLEMENT|KetoneAid Ketone Ester|Commercially available ketone supplement
219744843|NCT06992089|DEVICE|Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®)|"Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™ MRI Pacing Lead Boston®) and right ventricular lead (INGEVITY™ MRI Pacing Lead Boston®).~Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®), with rate-adaptive pacing of the ventricles. There will be a right ventricular lead (INGEVITY™ MRI P Boston®)."
219308264|NCT04642768|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
219308265|NCT02489513|DRUG|[14C]-AG-120|Labeled investigational drug
219308266|NCT00988195|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
219308267|NCT00988195|DRUG|Doxorubicin|Weeks 13-24 (once every 3 weeks)
219308268|NCT00827801|BEHAVIORAL|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
219308269|NCT05252923|DRUG|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
219744844|NCT03535701|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
219744845|NCT03535701|OTHER|Laboratory Biomarker Analysis|Correlative studies
219744846|NCT03535701|DRUG|Paclitaxel|Given standard of care therapy with paclitaxel
219744847|NCT03535701|OTHER|Quality-of-Life Assessment|Ancillary studies
219744848|NCT03535701|OTHER|Questionnaire Administration|Ancillary studies
219308270|NCT03726957|BEHAVIORAL|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
219308271|NCT00956514|DEVICE|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
219308272|NCT00762970|DEVICE|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
219308273|NCT00762970|DEVICE|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
219308274|NCT00762970|DEVICE|Control Lens|Spectacle Lenses.
219308275|NCT01749605|DRUG|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
219308276|NCT01749605|DRUG|ciprofloxacin 250 mg BID x 3 days|
219308277|NCT05785702|DEVICE|The anti-wandering system|During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
219308278|NCT04499274|DRUG|0 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron
219308279|NCT04499274|DRUG|0.2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron
219308280|NCT04499274|DRUG|2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron
219308281|NCT04499274|DRUG|20 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
219308282|NCT04242563|OTHER|VIRTUAL REALITY|Patient equipped with virtual reality in transfer room
219308283|NCT04293315|BEHAVIORAL|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
219308284|NCT00153361|BEHAVIORAL|Discussion Group|
219308285|NCT00153361|BEHAVIORAL|Video Discussion Group|
219308286|NCT03776019|DEVICE|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
219308287|NCT03844542|DEVICE|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
219308288|NCT05604638|DRUG|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
219308289|NCT05604638|DRUG|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
219308290|NCT01360060|DRUG|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
219308291|NCT02652143|DEVICE|AneVivo (Medical device for in vivo culture of embryos)|
219308292|NCT02652143|OTHER|comparator for embryo culture in vitro|
219308293|NCT02045966|DRUG|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
219308294|NCT02045966|DRUG|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
219308295|NCT02045966|DRUG|BMS-791325|
219308296|NCT01696838|OTHER|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
219308297|NCT01696838|OTHER|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
219308298|NCT03109145|OTHER|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
219308299|NCT05979454|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
219308300|NCT03407560|DEVICE|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
219308301|NCT06006689|DRUG|Qishen Yiqi Dripping Pills placebo 3 bags|Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
219308302|NCT06006689|DRUG|Low dose Qishen Yiqi Dripping Pills 3 bags|Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
219308303|NCT06006689|DRUG|High dose Qishen Yiqi Dripping Pills 3 bags|High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
219308304|NCT04703231|DIAGNOSTIC_TEST|measurement of macular thickness, corneal thickness and lens opacities|The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
219308305|NCT05998473|DIAGNOSTIC_TEST|Dynamic stability measurement|The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.
219308306|NCT03286257|BEHAVIORAL|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
219308307|NCT01337115|PROCEDURE|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
219308308|NCT01337115|PROCEDURE|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
219308309|NCT05259020|COMBINATION_PRODUCT|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
219308310|NCT05259020|COMBINATION_PRODUCT|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
219308311|NCT05528029|DEVICE|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
219308312|NCT02269332|OTHER|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
219308313|NCT05367232|DRUG|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
219308314|NCT03369990|DRUG|Botulinum toxin type A|Botulinum toxin type A(DWP450)
219308315|NCT03369990|DRUG|Placebos|Normal Saline
219308316|NCT00226837|DRUG|Nitrous oxide|nitrous oxide by inhalation during induction
219308317|NCT01130233|PROCEDURE|robotic assisted rectal resection|robotic assisted rectal resection
219308318|NCT01130233|PROCEDURE|laparoscopic rectal resection|laparoscopic rectal resection
219308319|NCT06024395|BEHAVIORAL|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
219308320|NCT02920619|DEVICE|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
219308321|NCT00610467|DEVICE|Disease Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
219308322|NCT00610467|DEVICE|Control Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
219308323|NCT02684253|DRUG|Nivolumab|
219308324|NCT02684253|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
219308325|NCT03626519|OTHER|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
219308326|NCT03626519|OTHER|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
219308327|NCT02670031|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
219308328|NCT02670031|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
219308329|NCT02670031|OTHER|Electrocardiogram|To examine specific function of the heart.
219308330|NCT02670031|DEVICE|Ambulatory Blood Pressure Monitoring|A 24-hour test.
219308331|NCT02670031|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
219308332|NCT00551460|DRUG|arsenic trioxide|
219308333|NCT00551460|DRUG|gemtuzumab ozogamicin|
219308334|NCT00551460|DRUG|mercaptopurine|
219308335|NCT00551460|DRUG|methotrexate|
219308336|NCT00551460|DRUG|tretinoin|
219308337|NCT00044031|BIOLOGICAL|G17DT Immunogen|
219308338|NCT03151096|DIETARY_SUPPLEMENT|Riboflavin|one pill of Riboflavin will be taken orally with water
219308339|NCT03151096|DIETARY_SUPPLEMENT|Placebo|one pill of placebo will be taken orally with water
219308340|NCT00519038|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
219308341|NCT00519038|OTHER|Usual Care|Usual care is the current practice actually performed in the hospital
219308342|NCT02012114|OTHER|Cysteamine bitartrate|No intervention
219308343|NCT02026310|DRUG|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
219308344|NCT02026310|DRUG|glargine and metformin|
219308345|NCT00448123|DRUG|Tamsulosin|Study Drug
219308346|NCT00448123|DRUG|Placebo|Placebo
219308347|NCT00396500|DRUG|Albendazole (400 mg) and/or Vitamin a|
219308348|NCT00419666|DRUG|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
219308349|NCT03991104|DRUG|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
219308350|NCT03991104|DRUG|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
219308351|NCT03991104|RADIATION|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
219308352|NCT02027623|BEHAVIORAL|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
219308353|NCT02027623|BEHAVIORAL|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
219308354|NCT02504944|DRUG|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
219308355|NCT04305938|DIAGNOSTIC_TEST|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
219308356|NCT04465760|DRUG|Xisomab 3G3|Given IV or via catheter
219308357|NCT02066285|DRUG|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
219308358|NCT00151151|BEHAVIORAL|Computer-Assisted Motivational Intervention|
219308359|NCT00151151|BEHAVIORAL|Didactic Educational Counseling|
219308360|NCT06299085|OTHER|50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
219308361|NCT06081582|DRUG|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
219308362|NCT04778956|DRUG|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
219308363|NCT04778956|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
219308364|NCT03997617|DIAGNOSTIC_TEST|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
219308365|NCT01808482|DRUG|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
219308366|NCT01808482|DRUG|Part A: matching placebo|Matching placebo
219308367|NCT01808482|DRUG|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
219308368|NCT01808482|DRUG|Part B: matching placebo|Matching placebo
219308369|NCT01808482|DRUG|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
219308370|NCT01105754|BEHAVIORAL|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
219308371|NCT00721669|DRUG|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
219308372|NCT05782426|DRUG|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
219308373|NCT00406653|DRUG|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
219308374|NCT00406653|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
219308375|NCT00406653|DRUG|abatacept|"\~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
219308376|NCT00818649|DRUG|bortezomib|1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
219308377|NCT00818649|DRUG|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
219308378|NCT02926144|DEVICE|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
219308379|NCT02926144|DEVICE|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
219308380|NCT03513588|DRUG|Placebo|tablet, 0 mg, 14 days, every 12 hours
219308381|NCT03513588|DRUG|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
219308382|NCT03513588|DRUG|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
219308383|NCT05955313|DRUG|Naltrexone Hydrochloride|treatment of vulvodynia
219308384|NCT03169322|PROCEDURE|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
219308385|NCT06367010|COMBINATION_PRODUCT|Iodine-125 brachytherapy combine with Anlotinib|Iodine-125 brachytherapy combine with Anlotinib
219308386|NCT01768520|DRUG|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg"
219308387|NCT01768520|DRUG|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
219308388|NCT01768520|DRUG|Placebo|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
219308389|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
219308390|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
219308391|NCT00685633|DRUG|bicalutamide|Given orally
219308392|NCT00685633|DRUG|enzastaurin hydrochloride|Given orally
219308393|NCT02075541|BIOLOGICAL|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219308394|NCT02075541|DRUG|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
219308395|NCT03149718|BEHAVIORAL|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
219308396|NCT03149718|BEHAVIORAL|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
219308397|NCT03931031|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
219308398|NCT06443554|PROCEDURE|Health Management Intervention Program|This study implemented a 12-week eye health management intervention program based on the Protection Motivation Theory (PMT). The intervention included eye health interventions conducted twice weekly at community health service locations.During the health management process, specialist doctors from higher-level comprehensive hospitals provided professional guidance, while community general practitioners took on a leading role. They provided personalized eye health management for patients under the guidance of the PMT theory. The intervention content included group education, individual guidance, experience sharing meetings, and traditional Chinese medicine appropriate technology, among other aspects.
219308399|NCT06443554|PROCEDURE|Standard Treatment|Each week, patients were subjected to standard treatment and follow-up procedures, including basic interventions, medication, and routine follow-up via phone or WeChat, during which general conditions were assessed.
219308400|NCT04842097|BEHAVIORAL|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
219308401|NCT05889481|GENETIC|cytogenetic analysis on tumour tissue|Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.
219308402|NCT05889481|BIOLOGICAL|Digital Pathology|Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma
219308403|NCT04697303|OTHER|anorectal function test|anorectal function test
219308404|NCT04388774|DRUG|Ketamine|A single 40-minute intravenous infusion
219308405|NCT00594360|BEHAVIORAL|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
219308406|NCT01190982|DRUG|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
219308407|NCT04421521|PROCEDURE|Acupuncture|Acupuncture with disposable needles will be implemented
219308408|NCT00849277|DRUG|Lactobacillus casei Shirota|
219308409|NCT05466773|BEHAVIORAL|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
219308410|NCT00722852|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
219308411|NCT00722852|DRUG|Placebo|100 mg (b.i.d.)
219308412|NCT00008489|DRUG|Didanosine|
219308413|NCT01203748|PROCEDURE|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
219308414|NCT01203748|PROCEDURE|PVI|Pulmonary vein antrum isolation
219308415|NCT01203748|PROCEDURE|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
219308416|NCT04305080|OTHER|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
219308417|NCT04305080|OTHER|Untreated abutment|Abutment will be left untreated with its gray color.
219308418|NCT05807737|DEVICE|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
219308419|NCT03139357|OTHER|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
219308420|NCT03635307|OTHER|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
219308421|NCT04169230|DRUG|Citalopram|Single dose administration of citalopram (20mg)
219308422|NCT04169230|DRUG|Placebo oral tablet|Single dose administration lactose placebo tablet
219308423|NCT05458557|DIAGNOSTIC_TEST|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
219308424|NCT03905954|OTHER|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
219308425|NCT03143660|BEHAVIORAL|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
219308426|NCT03143660|BEHAVIORAL|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
219308427|NCT02275494|PROCEDURE|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
219308428|NCT01142596|DRUG|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
219308429|NCT01142596|DRUG|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
219744849|NCT06998927|OTHER|Application of Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) to assess ventilator-displayed work of breathing and its correlation with physiologic measures.|This intervention is distinguished by applying Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) within the same patient, allowing a stepwise analysis of its effect on work of breathing. It uses real-time ventilator-displayed work of breathing, a noninvasive and underexplored tool, correlated with multiple physiological parameters such as esophageal pressure, Pocc, and P0.1. This within-subject design controls for interindividual variability, improving the precision of the analysis. Focusing on patients with spontaneous respiratory effort facilitates clinical application to optimize personalized ventilatory support. Thus, the study provides novel data to adjust support levels according to the patient's actual effort and to validate ventilator measurements against reference physiological indicators.
219744850|NCT06673849|OTHER|Rhythmic Stabilization|"Rhythmic Stabilization Program for Children with Cerebral Palsy Objective: Enhance upper extremity strength and stability through rhythmic stabilization exercises.~Program Overview:~Duration: 30-minute sessions Frequency: Once per week for 6 weeks~Exercise Steps:~Positioning: The child positions their upper extremity within their available range of motion.~Isometric Contraction: The child holds an isometric contraction, maintaining the position without movement.~Therapist's Role: Apply resistance that is sufficient to elicit a reaction but not enough to disrupt the isometric contraction.~Progression: Gradually increase the duration of the isometric hold. Increase the amount of resistance applied. Decrease the contact area between the therapist's hands and the child's upper extremity to enhance stability challenges. Monitoring and Adjustments: Assess the child's ability to maintain the contraction and adapt the resistance and support as needed. Encourage the child's engagement."
219744851|NCT06673849|OTHER|Ball Balancing|"Ball Balancing Program Objective: Improve balance and stability. Equipment: 48-inch gymnastic ball~Program Details:~* Duration: 6 weeks~* Frequency: As needed~Steps:~1. Initial Balance:~   * Eyes Open: Balance on hands for 10 seconds.~  * Progression: Increase to 3-5 repetitions of 60 seconds.~2. Eyes Closed: Repeat the above exercise with eyes closed.~3. Variations:~   * Both Hands on One Ball~  * Each Hand on Separate Balls~  * Weaker Arm on One Ball~4. Body Positions: Progress through four body positions with eyes open, then closed.~5. Correction: If the child misses a position, they open their eyes and reposition actively."
219744852|NCT06675396|OTHER|Antidepressants|control
219308430|NCT01314820|OTHER|normal saline injection|20 cc normal saline injection into knee joint
219308431|NCT01314820|OTHER|sham injection|no saline injection
219308432|NCT00200460|DRUG|Nebivolol|
219308433|NCT06168552|DIAGNOSTIC_TEST|Injection of fluorescent developer (anti-EGFR-IR800CW)|The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
219308434|NCT00520169|DRUG|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
219308435|NCT05166980|DIETARY_SUPPLEMENT|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
219308436|NCT05166980|DIETARY_SUPPLEMENT|Iodized salt|Salt fortified with iodine
219308437|NCT01054846|OTHER|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
219308438|NCT01054846|OTHER|Bicycle helmet education only|As described under the respective arm
219308439|NCT03436108|DIAGNOSTIC_TEST|Measurement of Bisphenol in urine|to see level of this material in blood of women
219308440|NCT01852474|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
219308441|NCT03457363|DEVICE|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
219308442|NCT02982915|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
219308443|NCT02982915|BIOLOGICAL|Fluzone High Dose Vaccine|Intramuscular injection
219308444|NCT01489410|DRUG|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
219308445|NCT01489410|DRUG|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
219308446|NCT00350896|DEVICE|Thumb orthoses|
219308447|NCT04107376|DIAGNOSTIC_TEST|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
219308448|NCT03872570|DRUG|Phenylephrine|intravenous administration
219308449|NCT03872570|DRUG|Norepinephrine|intravenous administration
219308450|NCT00253994|PROCEDURE|Acupuncture|
219308451|NCT02441712|DEVICE|PENS|
219308452|NCT02446886|DRUG|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
219308453|NCT01919710|DRUG|rHSA/GCSF|for treatment of neutropenia
219308454|NCT00928447|DRUG|rHuPH20|0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
219308455|NCT00928447|DRUG|Placebo|0.25 mL ID syringe push bolus injection of placebo control
219308456|NCT01259284|DRUG|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
219308457|NCT01259284|DIETARY_SUPPLEMENT|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
219308458|NCT01259284|OTHER|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
219308459|NCT04766931|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
219308460|NCT04766931|DRUG|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
219308461|NCT02667717|BEHAVIORAL|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
219308462|NCT02667717|BEHAVIORAL|Usual care|Patients will have the usual care as an intervention.
219308463|NCT05889065|PROCEDURE|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
219308464|NCT05889065|PROCEDURE|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
219308465|NCT00613262|OTHER|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
219308466|NCT02202668|DEVICE|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
219308467|NCT05268874|OTHER|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
219308468|NCT03448133|DEVICE|Magstim rTMS|The device is made in London,UK
219308469|NCT05394376|OTHER|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
219308470|NCT01971203|DRUG|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
219308471|NCT01971203|BEHAVIORAL|CBT|16 weeks of treatment
219308472|NCT00860613|OTHER|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
219308473|NCT05368051|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
219308474|NCT05395910|DRUG|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
219308475|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
219308476|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
219308477|NCT00795613|DRUG|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN\>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
219308478|NCT00795613|DRUG|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
219308479|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate
219308480|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot Placebo|Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate
219308481|NCT02389114|OTHER|Soy Protein|Soy protein is commonly consumed in Asian diet.
219308482|NCT02389114|OTHER|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
219308483|NCT01765179|DRUG|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
219308484|NCT01498029|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
219308485|NCT01498029|DEVICE|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
219308486|NCT06008327|DRUG|Topical 15% Trichloroacetic acid|Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
219308487|NCT05611437|OTHER|Ultrafast ultrasonography|Ultrasonography of the neck, patient in supine position, neck hyper-extended. Three different scanning planes containing several landmarks. Carried out in the 12h prior extubation.
219308488|NCT05329545|DRUG|Upifitimab rilsodotin|Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
219308489|NCT05329545|OTHER|Placebo|Placebo controlled arm.
219308490|NCT02259907|DRUG|KUC 7483 CL|
219308491|NCT02259907|DRUG|Placebo|
219308492|NCT02259907|OTHER|High fat meal|
219308493|NCT06328803|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
219308494|NCT06328803|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
219308495|NCT05208671|OTHER|NOURISH Food Box|Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
219308496|NCT03599973|OTHER|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
219308497|NCT03022279|PROCEDURE|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
219744853|NCT06675058|PROCEDURE|Indirect Pulp Treatment|Indirect pulp treatment is considered one of the most conservative pulp therapies, which preserves the pulp's vitality in teeth with reversible pulpitis. It has been chosen to be the intervention in both groups as the aim of this study is to assess the impact of caries location (proximal vs. occlusal caries) in influencing the success rate of IPT.
219308498|NCT03022279|PROCEDURE|local wound infiltration|local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
219308499|NCT00182299|PROCEDURE|porcine small intestine submucosa (SIS)|
219308500|NCT00005082|PROCEDURE|biopsy|
219308501|NCT00005082|PROCEDURE|magnetic resonance imaging|
219308502|NCT04951401|OTHER|lipid profile|lipid profile
219308503|NCT04951401|OTHER|ECG|ECG
219308504|NCT01198353|DRUG|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
219308505|NCT04419883|DEVICE|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
219308506|NCT01685671|DRUG|NESP 60μg|Administrated NESP 60μg once subcutaneously
219308507|NCT01685671|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
219308508|NCT05131568|DEVICE|Layered thermal insulation system|No other intervention
219308509|NCT02988622|DEVICE|Fraxel Laser|One half of the scar is treated with Fraxel Laser
219308510|NCT02988622|DEVICE|CO2 Laser|One half of the scar is treated with CO2 Laser.
219308511|NCT05011773|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
219308512|NCT00178126|DEVICE|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
219308513|NCT00178126|DEVICE|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
219744854|NCT06674200|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
219744855|NCT06674200|PROCEDURE|Regular|"The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues."
219744856|NCT03048682|DEVICE|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
219744857|NCT03048682|DEVICE|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
219744858|NCT03918031|BEHAVIORAL|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
219744859|NCT03918031|BEHAVIORAL|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
219744860|NCT06158438|DEVICE|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
219744861|NCT07010328|PROCEDURE|Neurorehabilitation|4-8 weeks of inhospital Neurorehabilitation
219744862|NCT07010328|DEVICE|AI-based home rehabilitation for postural disorders|AI-based home rehabilitation for postural disorders by means of the Kemtai platform.
219744863|NCT07010926|BIOLOGICAL|L2-01 adipose-derived mesenchymal stem cells (MSC)|L2-01 is a biological product consisting of human mesenchymal stem cells isolated from adipose tissue of the patient or a first-degree relative. The MSCs are expanded under Good Manufacturing Practice (GMP) conditions and suspended in 10 ml of lactated Ringer's solution. The product is administered as a single intravenous infusion at a dose of 1 × 10\^6 cells per kilogram of body weight, diluted in 100 ml of saline, infused over approximately 30 minutes. The infusion is closely monitored for safety.
219744864|NCT07010926|OTHER|Placebo saline solution|Placebo consists of 10 ml of lactated Ringer's solution mixed with 100 ml of saline. It is administered as a single intravenous infusion over approximately 30 minutes. The placebo is packaged identically to the active product to maintain study blinding.
219744865|NCT07011186|DRUG|TQB3909 Tablets + Azacitidine|TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue
219744866|NCT07011485|DRUG|Minoxidil 5% Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
219744867|NCT07011485|DRUG|PDFE-2304 Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
219744868|NCT07010003|PROCEDURE|Acupressure|Ear acupressure following the NADA Protocol is carried out using special acupuncture patches that press a small bead onto defined points on the ear: Shen Men, kidney, lung, liver, and vegetative. NADA ear acupressure is a non-invasive and low-risk intervention. In addition, the protocol is carried out exclusively by NADA-certified doctors, medical assistants, or nursing staff.
219744869|NCT06689631|PROCEDURE|Respiratory Physiotherapy|Mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
219744870|NCT05970939|OTHER|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
219744871|NCT04037397|DRUG|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
219744872|NCT04037397|PROCEDURE|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
219308514|NCT04579601|PROCEDURE|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
219308515|NCT02624310|DRUG|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
219308516|NCT02624310|DRUG|Placebo|
219308517|NCT02895451|BEHAVIORAL|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
219308518|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
219308519|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
219308520|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
219308521|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
219308522|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
219308523|NCT02036879|DRUG|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
219308524|NCT01687907|BEHAVIORAL|Music|
219308525|NCT02637570|DIETARY_SUPPLEMENT|Hibiscus tea|
219308526|NCT02637570|DIETARY_SUPPLEMENT|green tea|
219308527|NCT02637570|DIETARY_SUPPLEMENT|placebo (dextrose)|
219744873|NCT06694987|OTHER|Non-Physician Health Worker|"NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals."
219744874|NCT06689969|PROCEDURE|conventional implant placement method|Site marking was the first step in preparing the place for implantation. Subsequently, using a high speed surgical handpiece and a surgical motor, a pilot drill was revolved at 1200 RPM in a clockwise rotation to the desired depth, creating a 1.5 mm first pilot osteotomy. An X-ray was obtained using paralleling pins to validate the angle between the surrounding teeth and the implants. Eventually the implant's precise placement was established. To prepare the osteotomy site to the desired diameter, drills are used sequentially at 1200 RPM in a clockwise motion. Gradually bigger drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes were utilized in ascending order
219744875|NCT06689969|PROCEDURE|Osseodensification to implant placement using densah bur kit|"Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order"
219744876|NCT00821821|DRUG|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
219744877|NCT00821821|DRUG|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
219744878|NCT00908141|BIOLOGICAL|sargramostim|Given subcutaneously on varying schedule
219744879|NCT06687135|OTHER|KOKU|"KOKU is a digital strength and balance programme designed to prevent physical decline and frailty KOKU provides access to personalised, progressive strength and balance exercises.~More information can be found at: https://kokuhealth.com/"
219308528|NCT04578782|DRUG|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
219308529|NCT06020118|BIOLOGICAL|Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)|Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
219308530|NCT06020118|BIOLOGICAL|Sequential Vaccination (Influenza vaccine then mRNA COVID booster)|Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
219308531|NCT06020118|BIOLOGICAL|Sequential Vaccination (mRNA COVID booster then Influenza vaccine)|mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
219308532|NCT01204398|DRUG|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
219308533|NCT03562247|OTHER|Usual Care of IPF|standard of care given to patients with IPF
219308534|NCT03562247|OTHER|Telenursing|scheduled phone calls with the patient and care giver
219308535|NCT03562247|OTHER|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
219308536|NCT04281446|DEVICE|Photobiomodulation|Application of light at specific wavelength for interaction with biological tissue
219308537|NCT00311727|BIOLOGICAL|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
219308538|NCT02847351|DIETARY_SUPPLEMENT|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
219308539|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
219308540|NCT00983931|DRUG|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
219308541|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
219308542|NCT00544362|BIOLOGICAL|cetuximab|
219308543|NCT00544362|DRUG|cisplatin|
219308544|NCT00544362|DRUG|fluorouracil|
219308545|NCT00544362|PROCEDURE|conventional surgery|
219308546|NCT02843477|DEVICE|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
219308547|NCT04009850|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
219308548|NCT04009850|OTHER|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
219308549|NCT01558011|DRUG|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
219308550|NCT01281969|DRUG|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
219308551|NCT01281969|DRUG|Placebo|Normal saline, IV (in the vein), over 2 days
219308552|NCT01088373|DRUG|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
219744880|NCT06687135|OTHER|FaME / OTAGO leaflet and AGE UK Stay Steady Leaflet|"A leaflet with information on a combination of strength and balance exercises and walking programs, performed on a weekly basis by older adults at home, or community settings. The exercises can be done individually or in a group setting and are aimed at reducing falls in older adults.~More information can be found at: https://fameexercise.com/ and https://www.livestronger.org.nz/assets/Uploads/acc1162-otago-exercise-manual.pdf https://www.ageuk.org.uk/information-advice/health-wellbeing/exercise/staying-steady-download-page/#:\~:text=This%20guide%20outlines%20things%20you%20can"
219744881|NCT02520154|DRUG|Carboplatin|Given IV
219744882|NCT02520154|OTHER|Laboratory Biomarker Analysis|Correlative studies
219308553|NCT06158685|OTHER|Study Group|"Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks"
219308554|NCT06158685|OTHER|Control Group|"Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15"
219308555|NCT04688073|BEHAVIORAL|Exercise|Running
219308556|NCT04688073|BEHAVIORAL|Rest|sit and rest
219308557|NCT00628264|DRUG|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
219308558|NCT00628264|DRUG|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
219308559|NCT05981599|OTHER|There is no intervention|There is no intervention. Only retrieving clinical, biological and epidemiological data from patient files
219308560|NCT03743467|DIAGNOSTIC_TEST|Clinical evaluation of vision and eye tests|"* VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
219308561|NCT02675127|DRUG|Daktavira|1 tablet contains 60 mg Daclatasvir
219308562|NCT02675127|DRUG|Daklinza|1 tablet contains 60 mg Daclatasvir
219308563|NCT03525431|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
219308564|NCT04618445|BEHAVIORAL|some risk factors that might be correlated with TMD|Fonesca questionnaire
219308565|NCT04307251|DEVICE|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
219308566|NCT04307251|DEVICE|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
219308567|NCT02767713|DRUG|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
219308568|NCT02767713|OTHER|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
219308569|NCT01564628|DEVICE|CADScor1|Acoustic recording
219308570|NCT01735851|DRUG|Thoracic epidural analgesia|
219308571|NCT01735851|PROCEDURE|Bilateral Paravertebral block|
219308572|NCT02668484|DEVICE|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
219308573|NCT02668484|DEVICE|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
219308574|NCT05610332|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
219308575|NCT05610332|DRUG|Albumin Taxol|Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle
219308576|NCT05610332|DRUG|FLOT scheme|"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"
219308577|NCT01442831|DRUG|Human ADME|Oral single dose
219308578|NCT04625998|BEHAVIORAL|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
219308579|NCT04625998|BEHAVIORAL|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
219308580|NCT02299492|OTHER|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
219308581|NCT05231031|BEHAVIORAL|Aerobic exercise|continuous aerobic exercise on a treadmill
219308582|NCT05231031|BEHAVIORAL|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
219308583|NCT05231031|BEHAVIORAL|Relaxation training|continuous aerobic exercise plus relaxation training
219308584|NCT03956485|OTHER|Type of center|Tertiary versus non-tertiary
219308585|NCT02422862|OTHER|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
219308586|NCT00434473|DRUG|A-001|A-001
219308587|NCT00434473|OTHER|Placebo|Placebo
219308588|NCT04621773|PROCEDURE|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
219308589|NCT01201265|DRUG|Bevacizumab|15 mg/kg iv every 3 weeks
219308590|NCT01201265|DRUG|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
219308591|NCT01201265|DRUG|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
219308592|NCT04640077|OTHER|No Intervention|No intervention
219308593|NCT04640077|DRUG|donanemab|Administered IV
219308594|NCT02119845|DEVICE|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
219308595|NCT01257425|DRUG|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
219308596|NCT00304525|DRUG|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
219308597|NCT00680680|DRUG|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
219308598|NCT01498367|PROCEDURE|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
219308599|NCT02844647|OTHER|Hyperpolarized Pyruvate (13C)|MRI contrast agent
219308600|NCT01374373|BIOLOGICAL|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
219308601|NCT05314920|BEHAVIORAL|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
219308602|NCT05314920|BEHAVIORAL|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
219308603|NCT04925973|DRUG|Tofacitinib 10 MG [Xeljanz]|Tofacitinib 10mg PO BID
219308604|NCT00467168|BEHAVIORAL|Diet|
219308605|NCT02682745|DRUG|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
219308606|NCT02682745|DRUG|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
219308607|NCT03576170|OTHER|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
219308608|NCT00513643|DRUG|insulin aspart|6, 12, 24 U s.c.
219308609|NCT00513643|DRUG|human regular insulin|6, 12 and 24 IU sc
219308610|NCT05636722|BEHAVIORAL|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
219308611|NCT01182194|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
219308612|NCT01182194|DRUG|YAZ®|3 mg/0.02 mg Tablets
219308613|NCT04262817|DRUG|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
219308614|NCT04262817|OTHER|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
219308615|NCT02756273|DEVICE|bridge device|
219308616|NCT02756273|DEVICE|no bridge device|
219308617|NCT04992182|BIOLOGICAL|Placebo|0.3 mL IM saline solution
219308618|NCT04992182|BIOLOGICAL|Inactivated vaccine booster|0.5 mL IM
219308619|NCT04992182|BIOLOGICAL|mRNA vaccine booster|0.3 mL IM
219308620|NCT04992182|DRUG|Viral vector vaccine booster|0.5 mL IM
219308621|NCT00368992|BIOLOGICAL|cetuximab|Given IV
219308622|NCT00368992|DRUG|paclitaxel|Given IV
219308623|NCT00368992|BIOLOGICAL|bevacizumab|Given IV
219744883|NCT02520154|DRUG|Paclitaxel|Given IV
219744884|NCT02520154|BIOLOGICAL|Pembrolizumab|Given IV
219744885|NCT02520154|OTHER|Pharmacological Study|Correlative studies
219744886|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
219744887|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
219744888|NCT00826293|PROCEDURE|Stabilization belt|Patients receive true stabilization.
219744889|NCT00826293|PROCEDURE|Stabilization belt|Patients receive sham stabilization.
219744890|NCT05301972|DRUG|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
219744891|NCT04097860|BEHAVIORAL|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
219744892|NCT05964166|DEVICE|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
219744893|NCT04526925|DEVICE|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
219744894|NCT04526925|OTHER|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
219744895|NCT04354233|DEVICE|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
219744896|NCT05187650|DEVICE|Ekso (EksoNR, Ekso Bionics)|The EksoNR is a powered exoskeleton designed to be used in a rehabilitation setting. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices and is used for gait training in neurorehabilitation.
219744897|NCT05187650|DEVICE|FES (RehaMove2, Hasomed)|RehaMove 2 sends electrical impulses via electrodes to nerves to evoke muscle contraction. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices.
219308624|NCT01998087|BEHAVIORAL|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
219308625|NCT00201721|DRUG|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
219308626|NCT00201721|DRUG|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
219308627|NCT00201721|DRUG|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
219308628|NCT02902874|OTHER|Blood sample|
219308629|NCT02377804|OTHER|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
219308630|NCT02377804|OTHER|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
219308631|NCT02377804|DEVICE|stainless steel needles (0.3mm x 50mm)|
219308632|NCT01685164|OTHER|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
219308633|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
219308634|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
219308635|NCT05620368|BEHAVIORAL|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
219308636|NCT05620368|BEHAVIORAL|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
219308637|NCT00646633|PROCEDURE|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
219308638|NCT02668185|DRUG|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
219308639|NCT02668185|DRUG|Placebo|Placebo
219308640|NCT03172676|DRUG|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
219308641|NCT03172676|DRUG|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
219308642|NCT03172676|DRUG|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
219308643|NCT04497454|OTHER|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O
219308644|NCT04497454|OTHER|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
219308645|NCT04444544|OTHER|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
219308646|NCT01168323|BEHAVIORAL|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
219308647|NCT03087019|RADIATION|Radiation|Standard use of radiation is administered
219308648|NCT03087019|DRUG|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
219308649|NCT00976612|DRUG|Nilotinib|Nilotinib 400mg bid daily
219308650|NCT01372098|BEHAVIORAL|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
219308651|NCT05129553|DEVICE|Béa Applicator and Béa Cervical Cap Device|Single-use of the investigational device
219308652|NCT02373410|PROCEDURE|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
219308653|NCT02373410|PROCEDURE|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
219308654|NCT02373410|PROCEDURE|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
219308655|NCT02373410|PROCEDURE|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
219744898|NCT03864848|DEVICE|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
219744899|NCT00214565|DRUG|Galida|
219744900|NCT06448351|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
219744901|NCT06448351|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
219744902|NCT06448351|OTHER|Vaping session|Sample study e-liquids in vaping sessions at research lab with e-cig study device
219744903|NCT06448351|OTHER|Survey Administration|Ancillary studies
219744904|NCT02209987|DRUG|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
219744905|NCT02209987|DRUG|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
219744906|NCT04767321|DRUG|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
219744907|NCT04767321|DRUG|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
219744908|NCT00980044|DRUG|Tramadol|Oral Medication
219744909|NCT00980044|DRUG|Placebo|Oral Medication
219744910|NCT00000305|DRUG|Dextroamphetamine|
219744911|NCT05813418|BIOLOGICAL|blood retriewal|blood retriewal for cytokine concentration measurement
219744912|NCT05937048|BIOLOGICAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
219744913|NCT05937048|OTHER|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
219744914|NCT05811013|DEVICE|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
219744915|NCT05811013|DEVICE|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
219744916|NCT05044871|DRUG|Pamiparib|40mg PO. bid.
219744917|NCT05044871|DRUG|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
219744918|NCT05044871|DRUG|Tislelizumab|200mg IV. D1
219308656|NCT02373410|DRUG|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
219308657|NCT02373410|DRUG|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
219308658|NCT02373410|DRUG|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
219308659|NCT02373410|DRUG|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
219308660|NCT04412291|DRUG|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
219308661|NCT04412291|DRUG|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
219744919|NCT05044871|DRUG|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
219744920|NCT05044871|DRUG|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
219744921|NCT02759809|OTHER|Pasteurized donor human breastmilk|
219744922|NCT02759809|OTHER|Preterm formula|
219744923|NCT01257243|DRUG|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
219744924|NCT01257243|DRUG|Syrup of guaifenesin|5ml each 4 hours
219744925|NCT06311734|DRUG|LW231 tablets|P.O.
219744926|NCT06311734|DRUG|Placebo|P.O.
219744927|NCT04105361|PROCEDURE|Posterior neurectomy|Cut of posterior nasal nerve
219744928|NCT04839926|DRUG|0.5mg CY150112|single oral CY150112 while fasting on day 1.
219744929|NCT04839926|DRUG|1.5mg CY150112|single oral CY150112 while fasting on day 1.
219308662|NCT04412291|DRUG|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
219308663|NCT05955794|OTHER|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\]."
219308664|NCT01070030|DRUG|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
219308665|NCT01240031|OTHER|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~* Thorough sensory and nutrition assessment (questionnaire).~* Nutrition plan adjusted daily according to the assessment.~* Serving appetising, energy- and protein-dense meals, snacks and drinks."
219308666|NCT01240031|OTHER|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
219308667|NCT03707197|BEHAVIORAL|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
219308668|NCT02644486|DRUG|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
219308669|NCT02644486|DRUG|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
219308670|NCT02644486|DRUG|Irbesartan|Irbesartan 300mg/d
219308671|NCT04340323|OTHER|Pelvic Floor Muscle Training (PFMT)|The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
219308672|NCT01058408|RADIATION|Intensity modulated radiotherapy|Administered daily 5 days per week
219308673|NCT01058408|DRUG|RAD001|Taken orally once a day
219308674|NCT01058408|DRUG|cisplatin|Administered intravenously once a week
219308675|NCT03728777|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
219308676|NCT04017676|OTHER|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
219308677|NCT02279394|DRUG|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8
219308678|NCT02279394|DRUG|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
219308679|NCT02279394|DRUG|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
219308680|NCT05998538|PROCEDURE|Knee Replacement|Total vs Partial Knee Replacement
219308681|NCT05003440|DRUG|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
219308682|NCT05003440|DRUG|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
219308683|NCT03829293|DEVICE|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
219308684|NCT01895283|BEHAVIORAL|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
219308685|NCT00723021|DRUG|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
219308686|NCT00723021|DRUG|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
219308687|NCT00723021|DRUG|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
219308688|NCT00723021|DRUG|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
219308689|NCT00723021|DRUG|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
219744930|NCT04839926|DRUG|4.5mg CY150112|single oral CY150112 while fasting on day 1.
219744931|NCT04839926|DRUG|10mg CY150112|single oral CY150112 while fasting on day 1.
219744932|NCT04839926|DRUG|18mg CY150112|single oral CY150112 while fasting on day 1.
219744933|NCT04839926|DRUG|24mg CY150112|single oral CY150112 while fasting on day 1.
219744934|NCT02115672|DRUG|BL-8040|BL-8040 will be added to imatinib to improve CML response.
219744935|NCT04898309|DRUG|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
219744936|NCT04898309|DRUG|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
219744937|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
219744938|NCT04898309|DRUG|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
219308690|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
219308691|NCT01502020|DRUG|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
219308692|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
219308693|NCT02673840|DRUG|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
219308694|NCT02673840|DRUG|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
219308695|NCT00348855|OTHER|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
219308696|NCT00348855|BEHAVIORAL|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
219308697|NCT00348855|BEHAVIORAL|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
219308698|NCT00348855|BEHAVIORAL|Stop Smoking|Minimal intervention
219308699|NCT00348855|BEHAVIORAL|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
219308700|NCT00348855|OTHER|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
219308701|NCT02388685|OTHER|Exercise|Home exercise therapy
219308702|NCT02667977|OTHER|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
219308703|NCT02667977|OTHER|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
219308704|NCT02622958|DRUG|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
219308705|NCT02622958|OTHER|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
219308706|NCT01676181|PROCEDURE|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
219308707|NCT01676181|PROCEDURE|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
219308708|NCT02953860|DRUG|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
219308709|NCT05341596|PROCEDURE|repeat endotracheal intubation|repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
219308710|NCT03327337|PROCEDURE|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
219308711|NCT02006953|PROCEDURE|Bolus feeding schedule following gastrostomy tube placement|
219308712|NCT02006953|PROCEDURE|Continuous chimney feeds following gastrostomy tube placement|
219308713|NCT00770341|DRUG|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
219308714|NCT00770341|DRUG|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
219308715|NCT00770341|DRUG|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
219308716|NCT00603720|DRUG|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
219308717|NCT00603720|DRUG|L-Arginine|aids in nitric oxide production
219308718|NCT00603720|DRUG|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
219308719|NCT03876860|DEVICE|Silicone Dilator|Addition of silicone band to standard vaginal dilator
219308720|NCT03876860|DEVICE|Standard Dilator|Standard vaginal dilator
219308721|NCT03322072|DEVICE|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
219308722|NCT05146687|OTHER|Aflibercept|intravitreal injection
219308723|NCT05146687|OTHER|Ranibizumab|intravitreal injection
219308724|NCT05146687|OTHER|Bevacizumab|intravitreal injection
219308725|NCT06066450|DEVICE|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
219308726|NCT04375020|DRUG|GABA|GABA nutritional supplement 750mg per day for 6 months
219308727|NCT00960531|BIOLOGICAL|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
219308728|NCT00960531|BIOLOGICAL|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
219308729|NCT00960531|BIOLOGICAL|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
219308730|NCT01455857|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
219308731|NCT01455857|OTHER|ITCA placebo|Formulation in DUROS (no exenatide)
219744939|NCT04898309|DRUG|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
219744940|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
219744941|NCT05787782|DEVICE|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
219744942|NCT06193239|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
219744943|NCT05841667|DRUG|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
219744944|NCT01881958|DRUG|DiaPep277®|
219744945|NCT01334567|DRUG|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
219744946|NCT00747201|BEHAVIORAL|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
219744947|NCT00747201|BEHAVIORAL|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
219744948|NCT00963638|DIETARY_SUPPLEMENT|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
219744949|NCT00963638|DIETARY_SUPPLEMENT|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
219744950|NCT03453242|OTHER|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
219744951|NCT05802134|DIETARY_SUPPLEMENT|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
219744952|NCT05802134|BEHAVIORAL|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
219744953|NCT04775108|DEVICE|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
219744954|NCT00500331|DRUG|GSK189075|Experimental Drug
219744955|NCT00500331|DRUG|pioglitazone|Active Control
219744956|NCT00500331|OTHER|Placebo|Placebo Comparator
219744957|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
219744958|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
219744959|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
219744960|NCT05192070|OTHER|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
219744961|NCT05192070|OTHER|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
219744962|NCT05192070|OTHER|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
219744963|NCT00057512|DRUG|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
219744964|NCT05179577|DRUG|Arbaclofen|Arbaclofen Extended Release Tablets
219744965|NCT05179577|DRUG|Placebo|Placebo tablets
219744966|NCT04502108|BEHAVIORAL|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
219744967|NCT01760863|OTHER|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
219744968|NCT03464552|DRUG|Celecoxib 200mg|oral capsule 3 hours before procedure
219744969|NCT03464552|PROCEDURE|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
219744970|NCT03464552|DRUG|Placebo oral capsule|oral capsule 3 hours before procedure
219744971|NCT01631500|BEHAVIORAL|Conventional treatment|Conventional treatment
219308732|NCT05132283|DEVICE|3D Slicer|Navigational device used during surgery to locate abnormal lymph nodes.
219308733|NCT05132283|DEVICE|Monaco|Navigational device used during surgery to locate abnormal lymph nodes.
219308734|NCT03753620|DEVICE|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
219308735|NCT03753620|DEVICE|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
219308736|NCT00637923|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
219308737|NCT00637923|DRUG|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
219308738|NCT00637923|BIOLOGICAL|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
219308739|NCT00637923|DRUG|Ribavirin|Weight-based ribavirin for 48 weeks.
219308740|NCT00000550|BEHAVIORAL|health education|
219744972|NCT01631500|OTHER|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
219744973|NCT01631500|OTHER|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
219744974|NCT02416479|BEHAVIORAL|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
219744975|NCT02416479|BEHAVIORAL|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
219744976|NCT03158246|DRUG|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
219744977|NCT03158246|DRUG|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
219744978|NCT03158246|DIETARY_SUPPLEMENT|calcium|600mg/d calcium for oral daily
219744979|NCT03158246|DIETARY_SUPPLEMENT|vitamin D|925IU/d vitamin D for oral daily
219308741|NCT05969054|DRUG|Lacosamide 100 mg|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
219308742|NCT05969054|DRUG|Levetiracetam 250mg|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
219308743|NCT05321888|OTHER|Mechanical Ventilation|Standard Protocol
219308744|NCT05321888|OTHER|Mechanical Ventilation with Postural drainage|This Group will be treated by postural drainage and mechanical ventilation for two consecutive days
219308745|NCT02709824|DRUG|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
219308746|NCT02709824|DRUG|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
219308747|NCT03422588|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
219308748|NCT01828788|DRUG|Ropivacaine|
219308749|NCT01828788|DRUG|placebo|
219308750|NCT04538456|OTHER|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
219308751|NCT03634514|DRUG|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
219308752|NCT03634514|DRUG|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
219308753|NCT04886453|DRUG|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
219308754|NCT04886453|DRUG|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
219308755|NCT04886453|OTHER|Data collection|Data collection
219308756|NCT04886453|OTHER|Assessment of pain|visual analog scale
219308757|NCT04886453|OTHER|Recovery quality score|QoR15 questionnaire
219308758|NCT00883051|DRUG|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
219308759|NCT00883051|DRUG|Placebo|Placebo
219308760|NCT01335451|DRUG|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
219308761|NCT01335451|DRUG|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
219308762|NCT00348023|DRUG|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
219308763|NCT01408615|DRUG|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
219308764|NCT01696669|DRUG|Chemotherapy|"* Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8."
219308765|NCT01696669|PROCEDURE|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
219308766|NCT01696669|RADIATION|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
219308767|NCT02011373|PROCEDURE|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
219308768|NCT05812833|BEHAVIORAL|Education|Pregnant women will be given online baby care training
219308769|NCT05167305|OTHER|This is an observational study|This is an observational study
219308770|NCT02337751|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
219308771|NCT00002291|DRUG|Pentamidine isethionate|
219308772|NCT02711969|DRUG|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
219308773|NCT03373201|DRUG|Tasimelteon|Oral capsule
219308774|NCT03373201|DRUG|Placebo|Oral capsule
219308775|NCT02618642|RADIATION|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
219308776|NCT01459900|PROCEDURE|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
219308777|NCT01459900|PROCEDURE|Renal angiography|Renal angiography by femoral access.
219744980|NCT06571643|OTHER|Lower Abdomen MRI|The patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
219744981|NCT06570538|DRUG|Ropivacaine|300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
219744982|NCT06570538|DRUG|Sufentanil|Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
219744983|NCT06570564|DEVICE|The arm crank ergometer|Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
219308778|NCT04026659|OTHER|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
219308779|NCT02434068|OTHER|CT|followup
219308780|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
219308781|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
219308782|NCT05727345|PROCEDURE|Interscalene brachial plexus block|Preoperative ultrasound-guided interscalene brachial plexus block application
219308783|NCT05727345|PROCEDURE|Shoulder anterior capsular block|Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
219308784|NCT05028907|DRUG|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
219308785|NCT05028907|DRUG|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
219308786|NCT05444049|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
219308787|NCT00416143|PROCEDURE|bed rest|
219308788|NCT00416143|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
219308789|NCT02793076|OTHER|Bollywood Dance|8 week Bollywood Dance Program
219308790|NCT06308848|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
219308791|NCT06308848|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
219308792|NCT05602389|OTHER|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
219308793|NCT05602389|OTHER|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
219308794|NCT05602389|OTHER|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
219308795|NCT00832182|DRUG|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
219308796|NCT00832182|DRUG|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
219308797|NCT02706132|BIOLOGICAL|Mesenchymal Stem Cells(MSCs)|Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
219308798|NCT04667182|OTHER|Meal-Tagging App and Web-based Portal:|Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
219308799|NCT04667182|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 18 weeks.
219308800|NCT01365832|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
219308801|NCT03242720|PROCEDURE|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
219308802|NCT01513577|OTHER|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
219308803|NCT01513577|OTHER|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
219308804|NCT04244838|DIAGNOSTIC_TEST|Gait Analysis|The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
219308805|NCT01006473|OTHER|Exercise training|
219308806|NCT05810454|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
219308807|NCT05810454|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
219308808|NCT01380015|OTHER|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
219308809|NCT01380015|OTHER|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
219308810|NCT02391779|DIETARY_SUPPLEMENT|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
219308811|NCT02391779|BEHAVIORAL|Walking training|30-60 minutes walking training, 5 days/week.
219308812|NCT02391779|BEHAVIORAL|Flexibility training|5 days/week; e.g. stretching training at home
219308813|NCT02391779|DIETARY_SUPPLEMENT|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
219308814|NCT02391779|BEHAVIORAL|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
219308815|NCT02486744|DRUG|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
219308816|NCT02656823|DEVICE|ANKYLOS C/X implant A 6.6|Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
219308817|NCT01910181|DRUG|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
219308818|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
219308819|NCT01613560|DRUG|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
219308820|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
219308821|NCT02482077|DRUG|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
219308822|NCT02482077|DRUG|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
219308823|NCT02482077|DRUG|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
219308824|NCT00136981|DRUG|torcetrapib/atorvastatin|
219308825|NCT00136981|DRUG|atorvastatin|
219308826|NCT02070224|OTHER|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
219308827|NCT02070224|OTHER|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
219308828|NCT05663437|OTHER|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
219308829|NCT05663437|OTHER|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
219308830|NCT02842320|OTHER|biological samples|bone marrow and blood
219308831|NCT00353769|PROCEDURE|Hair Apposition Technique|
219308832|NCT05397834|DRUG|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
219308833|NCT05397834|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
219308834|NCT00408252|OTHER|biopsies|No intervention, only biopsy for translational project
219308835|NCT00408252|DRUG|SU011248|no intervention
219744984|NCT06570564|DEVICE|bicycle ergometer|bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
219744985|NCT06570564|DEVICE|treadmill|Supervised treadmill exercise as routine physiotherapy program
219744986|NCT06569862|PROCEDURE|Postoperative day 1 dressing|The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
219744987|NCT06569862|PROCEDURE|Postoperative day 6+/-1 dressing|The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
219308836|NCT01350310|PROCEDURE|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
219308837|NCT01350310|PROCEDURE|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
219308838|NCT01350310|PROCEDURE|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
219308839|NCT02174042|DRUG|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
219308840|NCT00285220|PROCEDURE|Laparoscopic Truncal Vagotomy|
219308841|NCT06027593|BEHAVIORAL|Mixed methods intervention|"Investigators will implement the intervention at the completion of the rapid user-centered design process and consultation with CDC collaborators.~During the rapid user-centered design process, the team will engage key stakeholders to create and optimize feedback reports that will fit the prescribing context, and determine appropriate implementation supports that will be needed to accompany the introduction of the feedback reports to each setting.~Following the initial awareness-building activities, investigators will circulate the antibiotic prescribing feedback reports. After the first 3 months (approximately) of report dissemination, the team will assess the feasibility and acceptability of the reports and implementation activities by administering a brief survey to prescribers and also conducting interviews with them. No direct identifiers will be collected."
219308842|NCT02513719|DEVICE|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
219308843|NCT00665912|PROCEDURE|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
219308844|NCT00665912|PROCEDURE|Standard post-lobectomy wound care|Standard post-lobectomy wound care
219308845|NCT01000285|DRUG|Bortezomib|
219308846|NCT01000285|DRUG|Etoposide|
219308847|NCT01000285|DRUG|Vincristine|
219308848|NCT01000285|DRUG|Doxorubicin|
219308849|NCT01000285|DRUG|Prednisone|
219308850|NCT01000285|DRUG|Cyclophosphamide|
219308851|NCT01000285|DRUG|Raltegravir|
219308852|NCT04558749|OTHER|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
219308853|NCT04558749|OTHER|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
219308854|NCT04672226|DIETARY_SUPPLEMENT|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
219308855|NCT05677152|DRUG|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
219308856|NCT02714387|OTHER|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
219308857|NCT00361660|BEHAVIORAL|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
219308858|NCT00361660|BEHAVIORAL|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
219308859|NCT02662101|DEVICE|Exsalt SD7, Exsalt T7 Wound Dressing|
219744988|NCT03827317|RADIATION|[18F]GE-226|\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
219744989|NCT05552365|BEHAVIORAL|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
219744990|NCT05552365|OTHER|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
219744991|NCT05067985|PROCEDURE|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
219744992|NCT05704088|DRUG|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
219744993|NCT05704088|DRUG|placebo|randomized control trial, control group will receive placebo tablets
219744994|NCT03463681|DRUG|Cabometyx|cabozantinib 60 mg orally once daily
219744995|NCT00027599|BIOLOGICAL|bevacizumab|
219744996|NCT00027599|BIOLOGICAL|prostatic acid phosphatase-sargramostim fusion protein|
219744997|NCT00027599|BIOLOGICAL|sipuleucel-T|
219744998|NCT00027599|BIOLOGICAL|therapeutic autologous dendritic cells|
219744999|NCT00027599|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219745000|NCT06389123|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
219745001|NCT05908760|DEVICE|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
219745002|NCT01161966|DRUG|Zonisamide|Zonisamide capsules 100 mg
219745003|NCT01161966|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
219745004|NCT00833703|DRUG|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
219745005|NCT00833703|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
219745006|NCT03960346|PROCEDURE|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
219745007|NCT06363708|DRUG|Tislelizumab|Tislelizumab 200mg D1 ,Q3W
219745008|NCT06363708|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 ) D1,Q3W
219745009|NCT06363708|DRUG|Carboplatin|Carboplatin(AUC=5) D1,Q3W
219745010|NCT00122473|DRUG|Imatinib (Glivec)|
219745011|NCT03368144|DEVICE|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
219745012|NCT01993550|BEHAVIORAL|Telephone counseling|
219745013|NCT01993550|BEHAVIORAL|Education|
219745014|NCT02615288|DIETARY_SUPPLEMENT|Vitamin D3|
219745015|NCT00675233|DRUG|HPPH|Given IV
219745016|NCT00675233|PROCEDURE|laser therapy|Escalating light doses with 665 nm light
219745017|NCT05538728|DEVICE|poly-l-lactic acid (Sculptra)|Sculptra
219745018|NCT01784484|OTHER|No intervention|
219745019|NCT00233246|PROCEDURE|FFP Infusion|
219745020|NCT05100992|PROCEDURE|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
219745021|NCT06327425|DEVICE|Magnetocardiography|Magnetocardiography
219745022|NCT04706325|OTHER|ACUTE KIDNEY INJURY|KDIGO LEVELS
219745023|NCT06142305|PROCEDURE|DDH surgery and casting|DDH surgery and casting
219745024|NCT01655056|DRUG|YM150|oral
219745025|NCT01655056|DRUG|Placebo|oral
219745026|NCT03616340|DRUG|Shoulder injection|intra articular or subacromial shoulder injection
219745027|NCT03616340|DRUG|knee injection|intra-articular knee injection
219745028|NCT01827020|DRUG|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
219745029|NCT01827020|DRUG|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
219745030|NCT01827020|DRUG|Saline|12 mL saline (0.9% isotonic solution)
219745031|NCT00388609|DRUG|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
219745032|NCT00388609|DRUG|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
219745033|NCT04016610|DEVICE|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
219745034|NCT01904279|DRUG|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
219745035|NCT05276856|DRUG|Levothyroxine|"Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
219745036|NCT05450237|BEHAVIORAL|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
219745037|NCT06565351|OTHER|eGFR estimated from creatinine and cystatin C|eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
219745038|NCT00629603|GENETIC|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
219745039|NCT00629603|GENETIC|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
219745040|NCT00629603|GENETIC|cytokine polymorphism|fibrosis-relating cytokine polymorphism
219745041|NCT03056469|OTHER|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
219745042|NCT04124419|DEVICE|Treatment with Evolve System|EMS and RF Treatment
219745043|NCT03583294|OTHER|MRI pelvic|Pelvic MRI
219745044|NCT03599076|OTHER|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
219745045|NCT05095285|OTHER|Swaddling|"* Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
219745046|NCT05095285|OTHER|Oropharyngeal colostrum|"* Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
219745047|NCT02208167|BIOLOGICAL|HXTC infusion|
219745048|NCT03562156|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
219745049|NCT03562156|DRUG|Placebo|matching placebo capsule
219745050|NCT04463927|OTHER|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
219308860|NCT06382454|DEVICE|Assist-On Arm Robot Group|30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
219308861|NCT06382454|OTHER|Control Group|For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
219308862|NCT04248660|OTHER|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
219308863|NCT00907790|BEHAVIORAL|Usual Care (Control Group)|
219308864|NCT00907790|BEHAVIORAL|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
219308865|NCT02087709|OTHER|Low-calorie diet|
219308866|NCT04710160|DRUG|Novel fast-setting calcium silicate cement (Protooth)|In form of power and liquid to be mixed together to form a paste.
219308867|NCT01516593|DRUG|Induction Phase|"* dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
219308868|NCT01516593|DRUG|Consolidation Phase (on day +50)|"* dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection."
219308869|NCT01516593|DRUG|Intensification phase|"1. One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~2. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~3. AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
219308870|NCT01516593|DRUG|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
219308871|NCT01516593|RADIATION|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
219308872|NCT04810754|DRUG|Daratumumab Injection|1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
219308873|NCT02132013|BEHAVIORAL|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
219308874|NCT04395898|PROCEDURE|pancreaticoduodenectomy|Whipple's procedure
219308875|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
219308876|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
219308877|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
219308878|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
219308879|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
219308880|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
219308881|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
219308882|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
219308883|NCT06606483|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
219308884|NCT06606483|DRUG|Placebo|Administered orally placebo
219308885|NCT00210977|DRUG|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
219308886|NCT00002331|DRUG|Ethambutol hydrochloride|
219308887|NCT00002331|DRUG|Clarithromycin|
219308888|NCT00002331|DRUG|Clofazimine|
219308889|NCT06609746|DIETARY_SUPPLEMENT|Thyme extract|Three Gastrolit capsules daily with a low FODMAP diet for 8 weeks
219308890|NCT06609746|OTHER|Placebo|Placebo capsules daily with a low FODMAP diet for 8 weeks
219308891|NCT06674915|DRUG|HRS-5965 capsules|Oral 50 mg.
219308892|NCT06623344|OTHER|Magnetic Resonance Imaging with or without Contrast|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
219308893|NCT00959647|DRUG|Vismodegib|Vismodegib was supplied in capsules.
219308894|NCT00959647|DRUG|FOLFOX|FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
219308895|NCT00959647|DRUG|FOLFIRI|FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
219308896|NCT00959647|DRUG|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
219308897|NCT07020208|BEHAVIORAL|Transition Shock skills|"* Assign experienced nurse mentors to new graduates.~* Conduct weekly one-on-one meetings for the first three months, then biweekly for ongoing support.~* Discuss challenges, successes, and strategies for coping with difficult situations.~* Provide case study reviews where mentors guide mentees through real-world nursing scenarios.~  * Skills Applied: interpersonal communication. 2. Peer Support Groups~ * Content:~* Establish weekly or biweekly group discussions where nurses share challenges and coping strategies.~* Use reflective journaling prompts to encourage discussion.~* Introduce role-playing exercises for dealing with complex patients, staff conflicts, and ethical dilemmas."
219308898|NCT06704334|OTHER|Median nerve electrical stimulation treatment|Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
219308899|NCT06704334|DRUG|Huperzine A injection|intramuscular
219308900|NCT06704334|DRUG|Ginkgo leaf dropping pill|oral
219308901|NCT03722147|BIOLOGICAL|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
219308902|NCT03824639|BEHAVIORAL|Structured exercise|Exercise instruction and encouragement
219308903|NCT03824639|BEHAVIORAL|Health Education|Provision of general information about a variety of health topics
219308904|NCT01079338|OTHER|caffeine|
219308905|NCT06305156|DIAGNOSTIC_TEST|Bone Mineral Density quantification|"In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications."
219308906|NCT05950022|PROCEDURE|Endoscopic tenotomy surgery of the iliopsoas tendon|The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
219308907|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
219308908|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
219308909|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
219308910|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
219308911|NCT00733928|DEVICE|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
219308912|NCT00733928|DEVICE|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
219308913|NCT04634929|PROCEDURE|bariatric surgery|bariatric surgery
219308914|NCT04634929|DIETARY_SUPPLEMENT|conservative diet|conservative diet
219308915|NCT01972711|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
219308916|NCT01972711|DRUG|Amisulpride|Amisulpride as a single oral dose of 400 mg
219308917|NCT01972711|DRUG|Placebo|single oral dose placebo
219308918|NCT00235547|BEHAVIORAL|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
219308919|NCT03584568|BEHAVIORAL|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
219308920|NCT03584568|OTHER|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
219308921|NCT00894153|DRUG|chemotherapy plus p53|chemotherapy plus p53
219308922|NCT00894153|DRUG|chemotherapy|chemotherapy
219308923|NCT00894153|RADIATION|radiotherapy|radiotherapy
219308924|NCT04929548|DRUG|Pyrotinib Maleate Tablets|Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
219308925|NCT01422226|DRUG|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
219308926|NCT01422226|OTHER|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
219308927|NCT04674670|DRUG|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
219308928|NCT04674670|DRUG|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
219308929|NCT04674670|DRUG|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
219308930|NCT05916573|DRUG|HSK16149|single oral adminiatration, 20mg
219308931|NCT02037841|OTHER|Nursing-driven clinical pathway for management of inpatient asthma|
219308932|NCT02961296|OTHER|No intervention|No intervention will be needed.
219308933|NCT06963801|BEHAVIORAL|Moms2B|An established group-based pregnancy program focusing on improving nutrition, social, and medical support.
219308934|NCT06963801|BEHAVIORAL|DBT-P|An emotional skills group where emotion regulation skills are taught in the context of the pregnancy and expected life with an infant.
219308935|NCT00873353|DRUG|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
219308936|NCT03270904|DEVICE|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
219308937|NCT04856644|DRUG|4-month rifapentine-based regimen|8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
219745051|NCT01481103|PROCEDURE|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
219745052|NCT00726479|DRUG|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
219745053|NCT01661673|DRUG|EVP-0962|Arms: 1,2,3,4
219745054|NCT01661673|DRUG|Placebo|Arm 5
219745055|NCT00959049|BIOLOGICAL|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
219745056|NCT00959049|BIOLOGICAL|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
219745057|NCT02963818|OTHER|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
219745058|NCT02963818|OTHER|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
219745059|NCT02963818|OTHER|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
219745060|NCT03575598|DRUG|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
219745061|NCT03575598|BIOLOGICAL|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
219745062|NCT05341843|DRUG|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
219308938|NCT00213291|DRUG|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
219308939|NCT05391477|DEVICE|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
219308940|NCT04677868|DRUG|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
219308941|NCT01786174|DRUG|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
219308942|NCT01786174|OTHER|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
219308943|NCT01778660|OTHER|Type of Counselling (Mnemonic)|
219308944|NCT01778660|OTHER|Standard|
219308945|NCT01620255|DRUG|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
219308946|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
219308947|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
219308948|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
219308949|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
219308950|NCT05302388|DRUG|SIBP-R002|SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
219308951|NCT05302388|DRUG|Dexamethasone or Methyl prednisolone|Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
219308952|NCT05302388|DRUG|Diphenhydramine|10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
219308953|NCT05302388|DRUG|Placebo|The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
219308954|NCT01486771|DRUG|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
219308955|NCT00861263|DEVICE|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
219745063|NCT05341843|DRUG|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
219745064|NCT03926013|DRUG|JNJ-63898081|JNJ-63898081 will be administered.
219745065|NCT03514940|DIAGNOSTIC_TEST|ultrasound|second trimester us scan will be made to pregnant women
219745066|NCT03218475|OTHER|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
219745067|NCT01498809|DRUG|Midodrine|Single 10 mg dose
219745068|NCT02704884|DIETARY_SUPPLEMENT|probiotic soy milk|
219745069|NCT02400684|BIOLOGICAL|blood samples|Evolution of AMH before and after deep endometriosis surgery
219745070|NCT04835259|DRUG|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
219745071|NCT02772692|BEHAVIORAL|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
219745072|NCT00829465|DRUG|Licartin|Licartin
219745073|NCT00829465|PROCEDURE|Transcatheter arterial chemoembolization|TACE
219745074|NCT01752179|PROCEDURE|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
219745075|NCT01078532|OTHER|SMART PHR|Patient receives an active PHR
219308956|NCT02640820|DRUG|Sensitizing DPCP Ointment|Sensitization
219308957|NCT02640820|DRUG|Treatment DPCP Ointment|Treatment
219308958|NCT00047203|DRUG|alvocidib|Given IV
219308959|NCT05998356|DEVICE|Balloon Eustachian Tuboplasty (BET) under general anesthesia.|Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer.
219308960|NCT05998356|DEVICE|Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia|Participants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study.
219308961|NCT06270433|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
219308962|NCT06270433|DRUG|Desvenlafaxine succinate sustained-release tablets|50 mg orally once daily dosing for 8 weeks
219308963|NCT05280587|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
219308964|NCT03607539|DRUG|Sintilimab|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
219308965|NCT03607539|DRUG|Pemetrexed|500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
219308966|NCT03607539|DRUG|Platinum|Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
219308967|NCT03607539|DRUG|Placebos|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
219308968|NCT01324115|DRUG|NG-nitro-L-arginine|
219308969|NCT01324115|OTHER|laboratory biomarker analysis|
219308970|NCT01324115|OTHER|pharmacological study|
219308971|NCT01324115|PROCEDURE|computed tomography|
219308972|NCT01324115|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219308973|NCT04256603|DRUG|Gabapentin|Timing of gabapentin initiation
219308974|NCT04256603|OTHER|No gabapentin|No gabapentin
219308975|NCT06444685|OTHER|Exercise and cognitive training interventino|Exercise and cognitive training based on Table tennis and Tabletop games.
219308976|NCT03682549|DIAGNOSTIC_TEST|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
219308977|NCT04017728|DEVICE|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
219308978|NCT04017728|DEVICE|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
219308979|NCT04620226|OTHER|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
219308980|NCT02463643|DRUG|Z-215 10mg|Z-215 10mg, capsules
219308981|NCT02463643|DRUG|Z-215 20mg|Z-215 20mg, capsules
219308982|NCT02463643|DRUG|Z-215 Placebo|Z-215 placebo-matching capsules
219308983|NCT02463643|DRUG|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
219308984|NCT02463643|DRUG|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
219308985|NCT04005053|DRUG|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
219308986|NCT04005053|DRUG|Placebo oral tablet|Placebo
219308987|NCT05385133|PROCEDURE|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
219308988|NCT05385133|PROCEDURE|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
219308989|NCT06397729|BEHAVIORAL|Wait-List Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
219308990|NCT06397729|BEHAVIORAL|PREVENT Tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
219745076|NCT01078532|OTHER|usual care|Usual passive PHR
219745077|NCT03512730|DEVICE|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
219745078|NCT03512730|OTHER|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
219745079|NCT05952310|OTHER|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
219745080|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
219745081|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
219308991|NCT05066308|DRUG|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
219308992|NCT05066308|OTHER|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
219308993|NCT05768841|BEHAVIORAL|mental health issues|survey on mental health issues in endurance athletes
219308994|NCT05296408|BEHAVIORAL|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
219745082|NCT06336564|OTHER|Pelvic floor muscle training|"Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days."
219308995|NCT05296408|BEHAVIORAL|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
219308996|NCT05296408|BEHAVIORAL|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
219308997|NCT02077595|DEVICE|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
219308998|NCT01092000|BEHAVIORAL|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
219308999|NCT01092000|OTHER|Education|Monthly exercise tips handout.
219309000|NCT04065152|DRUG|Talimogene laherparepvec|Talimogene laherparepvec
219309001|NCT00003193|DRUG|amifostine trihydrate|
219309002|NCT00003193|DRUG|paclitaxel|
219309003|NCT00003193|PROCEDURE|conventional surgery|
219309004|NCT00003193|RADIATION|radiation therapy|
219309005|NCT01400555|DRUG|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
219309006|NCT01400555|DRUG|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
219309007|NCT01400555|DRUG|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
219309008|NCT01400555|DRUG|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
219309009|NCT05171101|OTHER|MAVEN|The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
219309010|NCT01155375|DRUG|Ferumoxytol|Experimental: Ferumoxytol
219309011|NCT01155375|DRUG|Oral Iron|Active Comparator: Oral iron
219309012|NCT01653184|DIETARY_SUPPLEMENT|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
219309013|NCT02719678|OTHER|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
219309014|NCT00388453|DEVICE|Dx-pH Probe|24 hour ph monitoring
219309015|NCT00388453|PROCEDURE|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
219309016|NCT05417633|PROCEDURE|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
219309017|NCT05239351|DEVICE|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
219309018|NCT00005652|DRUG|rituximab|
219309019|NCT01480674|DRUG|Trastuzumab|
219309020|NCT02689596|DRUG|Oxytocin|
219309021|NCT02689596|OTHER|Placebo|
219309022|NCT03818204|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
219309023|NCT00887250|DRUG|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
219309024|NCT00887250|DRUG|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
219309025|NCT00887250|DRUG|Comparator: Placebo|Placebo to Losartan
219309026|NCT06499714|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 days at an altitude of 3600 m.
219309027|NCT06239272|PROCEDURE|Surgical resection|Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
219309028|NCT06239272|RADIATION|Proton beam radiation therapy|Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
219309029|NCT06239272|DRUG|Pazopanib|Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
219309030|NCT06239272|DRUG|Ifosfamide|Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
219309031|NCT06239272|DRUG|Doxorubicin|Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
219309032|NCT06239272|DRUG|Selinexor|"High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3"
219309033|NCT01497600|DRUG|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
219309034|NCT01497600|DRUG|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
219309035|NCT03542461|DRUG|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
219309036|NCT03542461|OTHER|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
219309037|NCT00001718|DEVICE|Electropalatography|
219309038|NCT00549809|PROCEDURE|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
219309039|NCT03616041|DEVICE|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
219309040|NCT05605574|BEHAVIORAL|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
219309041|NCT03718078|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   \- Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
219309042|NCT04876677|DRUG|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
219309043|NCT01933113|DEVICE|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
219309044|NCT00348231|DRUG|dual-action insulin analog|
219309045|NCT05627713|OTHER|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
219309046|NCT05627713|OTHER|urine sample collection|urine sample collection at inclusion
219309047|NCT05116293|DRUG|Midazolam oral solution|Oral syrup
219309048|NCT05116293|DRUG|Digoxin Oral Tablet|Oral tablet
219309049|NCT05116293|DRUG|Acetaminophen Oral Tablet|Oral tablet
219309050|NCT00879762|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
219309051|NCT00879762|OTHER|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
219309052|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
219309053|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
219309054|NCT04664439|DIAGNOSTIC_TEST|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
219309055|NCT05847725|OTHER|Elastic bandaging|"The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally."
219309056|NCT05847725|OTHER|Short stretch bandaging|Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
219309057|NCT05847725|OTHER|Kinesio taping|Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
219309058|NCT02569554|DRUG|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
219309059|NCT02569554|DRUG|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
219309060|NCT00225693|DEVICE|drug eluting coronary stent|
219309061|NCT01809223|DRUG|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
219309062|NCT01809223|DRUG|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
219309063|NCT01809223|OTHER|sham injection|sham intravitreal injection per month, fixed injection
219309064|NCT00881608|DRUG|Placebo|Placebo, 1 capsule daily for five days
219309065|NCT00881608|DRUG|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
219309066|NCT03214094|DRUG|Vonoprazan|Vonoprazan tablets
219309067|NCT01771328|DRUG|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
219309068|NCT01771328|DRUG|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
219309069|NCT02711111|DEVICE|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
219309070|NCT02711111|DEVICE|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
219309071|NCT00598143|BEHAVIORAL|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
219309072|NCT00598143|BEHAVIORAL|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
219309073|NCT03385070|DIAGNOSTIC_TEST|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
219309074|NCT00913354|DEVICE|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
219309075|NCT00913354|DEVICE|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
219309076|NCT00315432|DRUG|Pegylated Interferon and Ribavirin|
219309077|NCT02583087|PROCEDURE|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
219309078|NCT01274585|DEVICE|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
219309079|NCT01274585|DEVICE|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
219309080|NCT03177278|DRUG|[14C]-plazomicin|single intravenous dose
219309081|NCT02013505|OTHER|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
219309082|NCT02715531|DRUG|5-FU|5-FU (400 mg/m\^2) will be administered as an IV bolus, followed by 2400 mg/m\^2 by continuous IV infusion over 46 (± 1) hours, q2w.
219309083|NCT02715531|DRUG|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
219309084|NCT02715531|DRUG|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
219309085|NCT02715531|DRUG|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
219309086|NCT02715531|DRUG|Leucovorin|Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
219309087|NCT02715531|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
219309088|NCT02715531|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 will be administered IV over 120 (± 5) minutes q2w.
219309089|NCT02715531|DRUG|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
219309090|NCT02715531|DRUG|Cisplatin|Cisplatin will be administered as 80 mg/m\^2 IV over 120 minutes q3w (Group E2).
219309091|NCT02723409|PROCEDURE|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
219309092|NCT02723409|PROCEDURE|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
219309093|NCT02723409|PROCEDURE|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
219309094|NCT02723409|PROCEDURE|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
219309095|NCT02723409|PROCEDURE|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
219309096|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
219309097|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
219309098|NCT00679653|DRUG|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
219309099|NCT00679653|DRUG|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
219309100|NCT00679653|DRUG|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
219309101|NCT04308772|BEHAVIORAL|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
219309102|NCT00795951|BIOLOGICAL|T.R.U.E. Test|48 hour application of 28 allergens and negative control
219309103|NCT03126708|DRUG|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
219309104|NCT03126708|DRUG|cisplatin plus paclitaxel|Chemotherapy
219309105|NCT02277405|DEVICE|Shikani Optical Stylet|Optical intubation
219309106|NCT02277405|DEVICE|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
219309107|NCT00353379|DRUG|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
219309108|NCT00353379|DRUG|Placebo|Participants will take placebo for 6 weeks.
219309109|NCT00186771|DEVICE|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
219309110|NCT00186771|DEVICE|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
219309111|NCT01832441|OTHER|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
219309112|NCT03278951|BEHAVIORAL|Video Conferencing Group|
219309113|NCT03278951|BEHAVIORAL|In Person Group|
219309114|NCT00427336|DRUG|Fludarabine|30 mg/m\^2 by vein daily over 30 minutes
219309115|NCT00427336|DRUG|Cyclophosphamide|300 mg/m\^2 by vein daily over 2 hours
219309116|NCT00427336|DRUG|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
219309117|NCT00465725|DRUG|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
219309118|NCT01625572|PROCEDURE|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
219309119|NCT01625572|PROCEDURE|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
219309120|NCT00922103|PROCEDURE|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
219309121|NCT00922103|PROCEDURE|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
219309122|NCT03717948|OTHER|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
219309123|NCT03717948|OTHER|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
219309124|NCT01419457|DRUG|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
219309125|NCT01419457|DRUG|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
219309126|NCT01419457|DRUG|Favipiravir|800 mg Single Dose
219309127|NCT02215538|DRUG|OROS methylphenidate|
219309128|NCT02215538|DRUG|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
219309129|NCT02579174|DEVICE|Medacta GMK Sphere|
219309130|NCT00655486|DRUG|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
219309131|NCT00984425|DRUG|Lapatinib and Sorafenib|Comparison of different dosages of two drug
219309132|NCT06008886|BEHAVIORAL|Vegan diet|Normocaloric diet based solely on foods of plant sources.
219309133|NCT06008886|BEHAVIORAL|Mediterranean diet|Diet with a predominance of plant foods fruits, vegetables, whole grains, nuts and legumes); moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
219309134|NCT01057498|DRUG|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
219309135|NCT01057498|DRUG|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
219309136|NCT05536609|PROCEDURE|Epineural suture|2 or three sutures
219309137|NCT05536609|PROCEDURE|Non-operative treatment|The injured finger is protected in a plaster cast
219309138|NCT05467254|BIOLOGICAL|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
219309139|NCT02136420|DRUG|Promethazine|Subject receives promethazine
219309140|NCT02136420|BEHAVIORAL|Hyper gravity training|Subject receives hypergravity training before testing
219309141|NCT02136420|DRUG|Placebo|Placebo
219309142|NCT02136420|BEHAVIORAL|No hypergravity training|Subjects do not receive normal Earth gravity
219309143|NCT06510647|OTHER|Hormonal Therapy Agent|"With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy."
219309144|NCT06235892|DRUG|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
219309145|NCT04864106|DEVICE|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
219309146|NCT05885828|OTHER|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
219309147|NCT05885828|OTHER|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
219309148|NCT05885828|BEHAVIORAL|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
219309149|NCT05885828|OTHER|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
219309150|NCT05885828|OTHER|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
219309151|NCT06101667|DRUG|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
219309152|NCT06101667|PROCEDURE|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
219309153|NCT06130306|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
219309154|NCT06130306|PROCEDURE|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
219309155|NCT06050577|DRUG|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
219309156|NCT06050577|DRUG|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
219309157|NCT04426461|BEHAVIORAL|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
219309158|NCT04426461|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
219309159|NCT04426461|BEHAVIORAL|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
219309160|NCT02768870|DEVICE|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
219309161|NCT03401229|BIOLOGICAL|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
219309162|NCT03401229|BIOLOGICAL|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
219309163|NCT04801810|OTHER|Normobaric hypoxia|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
219309164|NCT04801810|OTHER|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
219309165|NCT01947972|DIETARY_SUPPLEMENT|Tailored protein fortification|4-4.5g of protein/kg/d
219309166|NCT06004947|DRUG|CCX168|Administered orally.
219309167|NCT06004947|DRUG|Midazolam|Administered orally.
219309168|NCT06004947|DRUG|Celecoxib|Administered orally.
219309169|NCT06004947|DRUG|Itraconazole|Administered orally.
219309170|NCT06004947|DRUG|Rifampicin|Administered orally.
219309171|NCT05718310|DRUG|Nitroglycerin|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
219309172|NCT05718310|DRUG|Saline|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
219309173|NCT04384185|OTHER|Exercise protocol|"Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation"
219309174|NCT04384185|OTHER|Manual therapy|"1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles."
219309175|NCT04580966|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
219309176|NCT03680404|DRUG|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
219309177|NCT03680404|DRUG|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
219309178|NCT03680404|DRUG|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
219309179|NCT03680404|DRUG|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
219309180|NCT03656237|OTHER|Usual Training|Training in a classroom setting of health care providers
219309181|NCT03656237|OTHER|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
219309182|NCT00029497|PROCEDURE|Acupuncture|
219309183|NCT00029497|DRUG|Amitriptyline|
219309184|NCT01122862|DRUG|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
219309185|NCT01122862|OTHER|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
219309186|NCT01122862|OTHER|Sterile water|Sterile water
219309187|NCT01551160|OTHER|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
219309188|NCT05621031|DEVICE|Whole body Vibration|Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
219309189|NCT05621031|OTHER|Habitual Therapy|Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
219309190|NCT05621031|DEVICE|Placebo whole body vibration|Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
219309191|NCT01844245|PROCEDURE|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
219309192|NCT01821716|BIOLOGICAL|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
219309193|NCT02699983|BEHAVIORAL|Behavioral Dietary Intervention|Use SparkPeople web-based program
219309194|NCT02699983|BEHAVIORAL|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
219309195|NCT02699983|DEVICE|Activity Monitoring Device|Wear Fitbit activity monitoring device
219309196|NCT00003263|BIOLOGICAL|recombinant interferon alfa|vaccine
219309197|NCT00003263|DRUG|cisplatin|
219309198|NCT00003263|PROCEDURE|surgical procedure|
219309199|NCT00003263|RADIATION|radiation therapy|
219309200|NCT04395430|BEHAVIORAL|Usual Care|"Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker"
219309201|NCT04395430|BEHAVIORAL|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
219309202|NCT00338533|DEVICE|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
219309203|NCT04259073|DRUG|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
219309204|NCT04259073|DRUG|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
219309205|NCT04259073|DRUG|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
219309206|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
219309207|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
219309208|NCT01287065|DRUG|Placebo AM|Inhalation powder
219309209|NCT01287065|DRUG|Placebo PM|Inhalation powder
219309210|NCT03800459|BEHAVIORAL|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
219309211|NCT05916118|OTHER|Aerobic Exercise|Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
219309212|NCT00259987|DRUG|Lapatinib (GW572016) oral tablets|
219309213|NCT02875977|OTHER|Educational video|A 4-minute educational video describing PFPT
219309214|NCT02875977|OTHER|Educational handout|A 2-page educational handout describing PFPT
219309215|NCT06193460|DEVICE|low-level laser therapy|photobiomodulation mode of diode laser (low-level laser therapy).
219309216|NCT05049486|RADIATION|CT scan|Patients will undergone a pelvic CT scan.
219309217|NCT05318079|BEHAVIORAL|Virtual Reality Gaming|Peer-to-peer gaming.
219309218|NCT03904355|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
219309219|NCT03904355|DRUG|human chorionic gonadotropin|HCG triggering of ovulation
219309220|NCT03904355|PROCEDURE|Ovum pick up|34 to 36 hours after oocyte retrieval
219309221|NCT03904355|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
219309222|NCT01270087|DRUG|Adalimumab|40 mg IV every 14 days
219309223|NCT02699112|OTHER|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
219309224|NCT01362660|OTHER|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
219309225|NCT01718782|DEVICE|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
219309226|NCT01718782|DEVICE|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
219309227|NCT05010187|BEHAVIORAL|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
219309228|NCT05010187|BEHAVIORAL|Behavioral: Health Coaching (HC)|Single-session health coaching.
219309229|NCT05902923|PROCEDURE|endovascular intervention|endovascular intervention
219309230|NCT02796820|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
219309231|NCT05591482|PROCEDURE|mesh repair|mesh repair of diaphragmatic hernia
219309232|NCT03834987|OTHER|Neurodevelopmental Assessment|Developmental assessment at baseline and longitudinally as measured by age and ability-appropriate scales, including: the Mullen Scales of Early Learning, the Peabody Scales of Motor Development, the Vineland 3, and Beery Visual Motor Integration
219309233|NCT04367532|OTHER|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
219309234|NCT04367532|OTHER|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
219309235|NCT03770637|DRUG|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
219309236|NCT03770637|OTHER|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
219309237|NCT01216033|DRUG|111-In-ABY-025|Intravenous injection of the agent
219309238|NCT03377426|DRUG|LYS228|LYS228 IV infusion
219309239|NCT03377426|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
219309240|NCT00098384|DRUG|rifaximin|
219309241|NCT03130010|DRUG|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
219309242|NCT02931825|BEHAVIORAL|Reminder letter|"The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
219309243|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
219309244|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
219309245|NCT01259726|OTHER|Placebo|10 mL placebo once daily for 14 days
219309246|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 14 days
219309247|NCT00841880|DRUG|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
219309248|NCT00841880|DRUG|Ramipril|10 mg once a day
219309249|NCT00841880|DRUG|Ramipril|5mg once a day
219309250|NCT02587429|BEHAVIORAL|Patient education|
219309251|NCT02076217|DRUG|Copper T-380 IUD|
219309252|NCT02076217|DRUG|LNG IUD|
219309253|NCT02076217|DEVICE|Contraceptive implant Nexplanon|
219309254|NCT02076217|DRUG|Depo-Provera|
219309255|NCT05494060|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
219309256|NCT05494060|DRUG|Penpulimab Injection|Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
219309257|NCT05494060|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
219309258|NCT00180921|DRUG|Imatinib|
219309259|NCT01679353|DRUG|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
219309260|NCT01679353|DRUG|normal saline 0.5ml|
219309261|NCT00244231|DRUG|Nidadd|
219309262|NCT00634660|DRUG|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
219309263|NCT01586000|DRUG|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
219309264|NCT01586000|DRUG|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
219309265|NCT01586000|DRUG|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
219309266|NCT05226026|BEHAVIORAL|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
219309267|NCT05226026|OTHER|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
219309268|NCT04097366|DIAGNOSTIC_TEST|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
219309269|NCT04097366|DIAGNOSTIC_TEST|CEM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
219309270|NCT04097366|DIAGNOSTIC_TEST|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
219309271|NCT00095069|DRUG|MK0928, gaboxadol / Duration of Treatment - 1 year|
219309272|NCT00095069|DRUG|Comparator: placebo / Duration of Treatment -1 year|
219309273|NCT02069210|OTHER|Blood transfusion|Intraoperative blood transfusion
219309274|NCT01886820|DRUG|[18F]NAV4694|
219309275|NCT00009620|DRUG|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
219309276|NCT00009620|DRUG|Saline|Infusion of normal sal
219309277|NCT05277129|OTHER|Analysis of post-stroke immune responses|Analysis of immune responses in peripheral blood
219309278|NCT02673957|OTHER|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
219309279|NCT02529813|DRUG|Cyclophosphamide|Given IV
219309280|NCT02529813|DRUG|Fludarabine Phosphate|Given IV
219309281|NCT02529813|OTHER|Laboratory Biomarker Analysis|Correlative studies
219309282|NCT02529813|BIOLOGICAL|Tisagenlecleucel|Given IV
219309283|NCT01581151|DRUG|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
219309284|NCT01581151|DRUG|Monthly Ranibizumab|30 days between treatments
219309285|NCT03421431|DRUG|EDP-305 Dose 1|Two tablets daily for 12 weeks
219309286|NCT03421431|DRUG|EDP-305 Dose 2|Two tablets daily for 12 weeks
219309287|NCT03421431|DRUG|Placebo|Two tablets daily for 12 weeks
219309288|NCT04923152|DRUG|moderate statin dose|5 mg rosuvastatin per day
219309289|NCT04923152|DRUG|high dose statin|40 mg rosuvastatin per day
219309290|NCT04626492|DIAGNOSTIC_TEST|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
219745083|NCT06336564|DEVICE|Microablative Radiofrequency|Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
219745084|NCT02552264|BEHAVIORAL|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
219309291|NCT02522455|OTHER|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
219309292|NCT02522455|OTHER|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
219309293|NCT02053987|OTHER|Intensive rehabilitation in the home.|
219309294|NCT00828841|DRUG|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
219309295|NCT00828841|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
219309296|NCT00828841|DRUG|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
219309297|NCT00828841|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
219309298|NCT00828841|DRUG|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
219745085|NCT05888064|DIAGNOSTIC_TEST|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
219745086|NCT05167708|PROCEDURE|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
219309299|NCT02548260|DEVICE|Syndactyly without compression|three week relative immobilization by syndactyly
219309300|NCT02548260|DEVICE|Syndactyly with compression|three week relative immobilization by syndactyly and compression
219309301|NCT02548260|DEVICE|Rigid splint without compression|three week rigid immobilization by splint
219309302|NCT02548260|DEVICE|Rigid splint with compression|three week rigid immobilization by splint and compression
219309303|NCT04147650|DRUG|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
219309304|NCT04147650|DRUG|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
219309305|NCT04147650|DRUG|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
219309306|NCT04147650|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
219309307|NCT02108587|DEVICE|optical coherence tomography|Undergo optical coherence tomography
219309308|NCT03015818|OTHER|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
219309309|NCT01188213|DIETARY_SUPPLEMENT|Methylsulfonylmethane (MSM)|
219309310|NCT01734408|BIOLOGICAL|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
219309311|NCT01734408|BIOLOGICAL|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
219309312|NCT01734408|BIOLOGICAL|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
219309313|NCT01734408|BIOLOGICAL|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
219309314|NCT01734408|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo
219309315|NCT02203292|BEHAVIORAL|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb \< 9.0 g/dL
219309316|NCT02203292|BEHAVIORAL|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
219309317|NCT01354808|DRUG|Dual Anti-Platelet Therapy (DAPT)|"* Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
219309318|NCT01354808|DRUG|Triple Anti-Platelet Therapy (TAPT)|"* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
219309319|NCT03741933|DRUG|Apremilast 30mg|Apremilast 30 mg tablet
219309320|NCT04868539|OTHER|Artificial Light At Night|90 lux lighting for 19hr/day
219309321|NCT04868539|BEHAVIORAL|Sleep Restriction|5-hr of sleep/night
219309322|NCT05222763|BEHAVIORAL|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
219309323|NCT05222763|BEHAVIORAL|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
219309324|NCT04371653|DRUG|PRIM-DJ2727|administration orally
219309325|NCT04371653|DRUG|Placebo|administration orally placebo
219309326|NCT03958786|OTHER|Simplified Geriatric Evaluation|"* Questionnaires~* Self assessment questionnaires~* Mobility and balance tests"
219309327|NCT03958786|OTHER|Sampling|\- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
219309328|NCT04138797|PROCEDURE|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
219309329|NCT04138797|DEVICE|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
219309330|NCT02880033|DRUG|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
219309331|NCT02880033|DRUG|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
219309332|NCT04487574|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
219309333|NCT04487574|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 days
219309334|NCT00010712|DRUG|Black Cohosh|
219309335|NCT02354313|DRUG|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
219309336|NCT04027322|DRUG|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
219309337|NCT04027322|DRUG|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
219309338|NCT04027322|DRUG|Normal saline|Placebo for the control group.
219309339|NCT03639233|BEHAVIORAL|YESS!|Web based self-management education
219309340|NCT01128738|DRUG|GSK1358820|Onabotulinum toxin type A
219309341|NCT01128738|DRUG|Placebo|Placebo
219309342|NCT06406556|COMBINATION_PRODUCT|Pegaspargase combined with concurrent radiotherapy.|Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.
219309343|NCT01178671|DRUG|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
219309344|NCT01178671|DRUG|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
219309345|NCT01178671|OTHER|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
219309346|NCT00573885|DRUG|defined green tea catechin extract|Given orally
219309347|NCT00573885|OTHER|placebo|Given orally
219309348|NCT04742322|DIETARY_SUPPLEMENT|Bifidobacterium Lactis CCT7858|Probiotic B Lactis
219309349|NCT04742322|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
219309350|NCT00490009|DRUG|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy"
219309351|NCT00490009|DRUG|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
219309352|NCT00490009|DRUG|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
219309353|NCT00490009|DRUG|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
219309354|NCT05472948|DRUG|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
219309355|NCT05472948|DRUG|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
219309356|NCT05472948|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
219309357|NCT02652962|DEVICE|Gelesis200|3 capsules each containing 0.70 g
219309358|NCT02652962|OTHER|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
219309359|NCT02253303|OTHER|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
219309360|NCT01211197|DRUG|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
219309361|NCT01211197|DRUG|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
219309362|NCT01211197|DRUG|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
219309363|NCT04998734|DIAGNOSTIC_TEST|ASI-SR|Psychometric properties of ASI-SR
219309364|NCT03898115|BEHAVIORAL|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
219309365|NCT02702973|OTHER|Observe the fundus characteristics after therapy.|
219309366|NCT00913666|DRUG|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
219309367|NCT05131620|PROCEDURE|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
219309368|NCT05131620|PROCEDURE|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
219309369|NCT02678013|PROCEDURE|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
219309370|NCT02678013|PROCEDURE|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
219309371|NCT04351022|BIOLOGICAL|CART-38|Split intravenous infusion of CART-38 cells \[dose escalating infusion of (5-20)x10\^6 CART-38 cells/kg\].
219309372|NCT03133520|DEVICE|High flow oxygen therapy|High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
219309373|NCT05822453|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
219309374|NCT05822453|DRUG|S1|S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
219309375|NCT05822453|DRUG|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
219309376|NCT05436080|DEVICE|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
219309377|NCT02170935|DRUG|BIBR 1048 capsule|
219309378|NCT02838485|OTHER|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
219309379|NCT02838485|OTHER|Imagery|The subject will be asked to imagine performing hand movements.
219309380|NCT06078280|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
219309381|NCT02752321|DEVICE|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
219309382|NCT04911556|DIETARY_SUPPLEMENT|Bifidobacterium longum|types of intestinal flora
219309383|NCT04911556|DIETARY_SUPPLEMENT|A placebo made of starch|placebo
219309384|NCT03539783|DIAGNOSTIC_TEST|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
219309385|NCT02844881|DRUG|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
219309386|NCT02844881|BIOLOGICAL|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
219309387|NCT04322942|DIAGNOSTIC_TEST|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
219309388|NCT04494581|OTHER|questionnaire|Questionnaire survey
219309389|NCT03643120|OTHER|Qualitative interview|Explorative study of gender dysphoria.
219309390|NCT02907931|OTHER|Point of Care Ultrasound|
219309391|NCT02301650|DRUG|Lamivudine|mothers use Lamivudine in late pregnancy
219309392|NCT02301650|DRUG|Telbivudine|mothers use Telbivudine in late pregnancy
219309393|NCT02301650|DRUG|Tenofovir|mothers use Tenofovir in late pregnancy
219309394|NCT05023395|DRUG|MEE-HU Medicus|This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
219309395|NCT05023395|OTHER|Placebo|Placebo
219309396|NCT02673203|DEVICE|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
219309397|NCT02673203|BEHAVIORAL|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
219309398|NCT01097239|DEVICE|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
219309399|NCT02386709|DEVICE|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
219309400|NCT04223869|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
219309401|NCT05116046|BIOLOGICAL|Recifercept|Recifercept
219309402|NCT05737186|DRUG|SGLT-2 inhibitor|dapagliflozin
219309403|NCT02602054|PROCEDURE|Surgical treatment|Standard left thoracotomy
219309404|NCT02602054|DRUG|Control group|"\- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~\- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
219309405|NCT00424866|DRUG|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
219309406|NCT00424866|DRUG|Placebo|Vehicle: 0 µg/kg
219309407|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
219309408|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
219309409|NCT03242551|DRUG|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
219309410|NCT05751291|DRUG|Bupivacaine Hydrochloride|"Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve."
219309411|NCT02683941|DRUG|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
219309412|NCT02683941|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
219309413|NCT02683941|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator
219309414|NCT04459065|DRUG|IRDye800CW-nimotuzumab|50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
219309415|NCT05843513|OTHER|Monitoring (observational study)|The relationship between dental wear and the behaviour of the participants will be analysed.
219309416|NCT02623153|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
219309417|NCT02623153|DRUG|capecitabine|capecitabine of 1000 mg/m2
219309418|NCT02623153|DRUG|S1|S1 of 40 mg/m2
219309419|NCT02623153|DRUG|Docetaxel|docetaxel 40 mg/m2
219309420|NCT04980937|PROCEDURE|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
219309421|NCT00261846|DRUG|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
219309422|NCT03807674|PROCEDURE|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
219309423|NCT06186453|BEHAVIORAL|Father-Preterm Newborn Bonding Program|B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
219309424|NCT03630341|DRUG|Clomiphene Citrate 50mg|oral 50 mg tablets
219309425|NCT03630341|DRUG|L-carnitine|1000 mg oral tablet
219309426|NCT03630341|DRUG|Placebo Oral Tablet|oral tablets identical to L-carnitine
219309427|NCT01228708|OTHER|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
219309428|NCT01660126|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
219309429|NCT01660126|DRUG|Placebo|
219309430|NCT00480246|DRUG|BL 1020|
219309431|NCT00480246|DRUG|Perphenazine|
219309432|NCT02639468|DEVICE|Stroke Volume estimation using electrical impedance tomography|
219309433|NCT01009203|DRUG|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
219309434|NCT01009203|DRUG|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
219309435|NCT06475573|DIETARY_SUPPLEMENT|dietary fiber probiotic beverages|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner."
219309436|NCT06475573|OTHER|whole grain porridge|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner."
219309437|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219309438|NCT00892723|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219309439|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
219309440|NCT00150969|DIETARY_SUPPLEMENT|vitamin K1 (phylloquinone)|
219309441|NCT00150969|DIETARY_SUPPLEMENT|placebo|1 pill daily
219309442|NCT05253495|DRUG|DOC Group B|Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
219309443|NCT05253495|DRUG|Pv-COMRAD 1 and 2 Group B|polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
219309444|NCT05253495|DRUG|Pv-R-CYM 1 and 2 Group B|polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
219309445|NCT05253495|DRUG|DOC Group C|cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
219309446|NCT05253495|DRUG|MAD CPR 1 and 2|methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
219309447|NCT05253495|DRUG|Pv-R CYVE 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
219309448|NCT05253495|DRUG|Pv-R CYVE-MTX 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
219309449|NCT05253495|DRUG|MAD CP|dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
219309450|NCT05253495|DRUG|Pv-Cytarabine/etoposide|polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
219309451|NCT05253495|DRUG|AD CP|polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
219309452|NCT05253495|DRUG|Bv-AVD-R 1 and 2: COHORT IIa|brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
219309453|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
219309454|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 SER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
219309455|NCT05253495|DRUG|Bv-AVD-R|Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
219309456|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 RER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
219309457|NCT05253495|DRUG|Bv-NAVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
219309458|NCT05253495|RADIATION|Involved Site Radiation Therapy|21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
219309459|NCT04579627|BEHAVIORAL|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
219309460|NCT00615836|DRUG|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
219309461|NCT06646445|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
219309462|NCT06646445|PROCEDURE|Watch-and-wait approach|"Watch-and-wait strategy:~* TAP-CT scan At months 3 and 6 during 8 cycles of treatment, at months 9 and 12, and during additional 9 cycles of treatment if performed, and every 3 months thereafter for up to 2 years,~* Colonoscopy with biopsies at months 3, 6, 9, 12, and 24."
219309463|NCT06646445|PROCEDURE|Surgery|Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from randomization.
219309464|NCT06646445|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) according to the current guidelines, at the investigator's discretion.
219309465|NCT03993821|DRUG|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
219309466|NCT04641871|DRUG|Sym021|IV infusion over 30 minutes on day 1 and 15 of each cycle.
219309467|NCT04641871|DRUG|Sym022|IV infusion over 30 minutes on day 1 and 15 of each cycle.
219309468|NCT04641871|DRUG|Sym023|IV infusion over 30 minutes on day 1 and 15 of each cycle.
219309469|NCT04641871|DRUG|Irinotecan Hydrochloride|IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
219309470|NCT04835077|OTHER|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
219309471|NCT04835077|OTHER|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
219309472|NCT04700332|DRUG|DCFPyL PET/CT|Prostate Membrane Specific Antigen-specific imaging
219309473|NCT02703493|RADIATION|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
219309474|NCT05614154|OTHER|hypochlorous active substance|Poviodin iyot
219309475|NCT05111054|OTHER|Resistance Exercise|Acute leg-based resistance exercise bout (3 sets performed to volitional failure on leg extension and leg curl machines)
219309476|NCT01545323|GENETIC|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
219309477|NCT04854668|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
219309478|NCT04854668|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
219309479|NCT04854668|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
219309480|NCT04854668|DRUG|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
219309481|NCT03046693|DRUG|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
219309482|NCT03046693|DRUG|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
219309483|NCT01313689|DRUG|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
219309484|NCT01313689|DRUG|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
219309485|NCT01657851|DRUG|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
219309486|NCT01657851|DRUG|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
219309487|NCT01657851|DRUG|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
219309488|NCT00512460|DRUG|RTA 744|4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
219309489|NCT01959022|DRUG|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
219309490|NCT05150951|BEHAVIORAL|Novel Exploration|Exploration of a novel 3D-environment in virtual reality.
219309491|NCT05150951|BEHAVIORAL|Threat conditioning|Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.
219309492|NCT05150951|BEHAVIORAL|Extinction|Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.
219309493|NCT05150951|BEHAVIORAL|Reinstatement|Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.
219309494|NCT05150951|BEHAVIORAL|Visual attention control task|Session 2. A visual attention task used as a control task instead of novel exploration.
219309495|NCT01007448|DRUG|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
219309496|NCT04327492|DIAGNOSTIC_TEST|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
219309497|NCT02770573|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
219309498|NCT02770573|OTHER|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
219309499|NCT02770573|OTHER|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
219309500|NCT02224976|BEHAVIORAL|Intensified Training|Volunteers will increase exercise training by 30% from baseline
219309501|NCT04231942|DEVICE|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
219309502|NCT04231942|DEVICE|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
219309503|NCT06398977|DRUG|Dapagliflozin|Dapagliflozin10MG, PO once daily
219309504|NCT06195254|RADIATION|Stereotactic body radiotherapy (SBRT)|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.
219309505|NCT06195254|DRUG|PD-1 blocking antibody|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
219309506|NCT00078611|DRUG|natalizumab|
219309507|NCT06266715|DRUG|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
219309508|NCT06266715|DRUG|Placebo Group|Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
219309509|NCT02121834|DRUG|LY3050258|
219309510|NCT02121834|DRUG|Placebo|
219309511|NCT02991131|DRUG|Tedizolid (Sivextro, BAY1192631)|Antibiotic
219309512|NCT02991131|DRUG|Linezolid|Antibiotic
219309513|NCT04918667|COMBINATION_PRODUCT|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
219309514|NCT04918667|DIETARY_SUPPLEMENT|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
219309515|NCT03676231|DRUG|SGM-1019|Active
219309516|NCT03676231|DRUG|Placebo|Inactive
219309517|NCT00570050|DRUG|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
219309518|NCT00570050|DRUG|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
219309519|NCT02922309|BEHAVIORAL|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
219309520|NCT02922309|BEHAVIORAL|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
219309521|NCT01173198|DEVICE|WAVEFRONT Optimized LASIK|30 patients
219309522|NCT01173198|DEVICE|WAVEFRONT GUIDED LASIK|30 patients
219309523|NCT05694572|DEVICE|Implantation of a CIED|Implantation of a CIED
219309524|NCT05647850|OTHER|No intervention|No intervention
219309525|NCT03353350|DRUG|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219309526|NCT03353350|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
219309527|NCT00373815|DRUG|Everolimus|
219309528|NCT01285050|DRUG|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
219309529|NCT01285050|DRUG|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
219309530|NCT01285050|DRUG|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
219309531|NCT05427903|PROCEDURE|Cryotherapy|Ice packs application for 5 minutes after IANB injection
219309532|NCT05427903|PROCEDURE|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
219309533|NCT01690364|OTHER|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
219309534|NCT01690364|OTHER|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
219309535|NCT04950725|BEHAVIORAL|Strength RMT|2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
219309536|NCT04950725|BEHAVIORAL|Strength RMT and nasal breathing|2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
219309537|NCT04950725|BEHAVIORAL|Endurance RMT|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
219309538|NCT04950725|BEHAVIORAL|Endurance RMT and nasal breathing|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
219309539|NCT04950725|BEHAVIORAL|Low dose RMT|10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
219309540|NCT00767273|PROCEDURE|PET Scan|
219309541|NCT00767273|DRUG|FLT|
219309542|NCT00767273|DRUG|FDG|
219309543|NCT06161935|OTHER|no intervention|no intervention, it is a retrospective study .
219309544|NCT02367365|OTHER|No Intervention|No intervention
219309545|NCT02367365|OTHER|No Intervention|No intervention
219309546|NCT03030703|DIETARY_SUPPLEMENT|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
219309547|NCT04051788|OTHER|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
219309548|NCT04051788|OTHER|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
219309549|NCT00343135|DRUG|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
219309550|NCT03954795|PROCEDURE|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
219309551|NCT03954795|PROCEDURE|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
219309552|NCT00297570|DRUG|Pegylated Interferon and Imatinib|
219309553|NCT00470145|DRUG|SB-568859|
219309554|NCT05448781|DRUG|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
219309555|NCT01519466|DEVICE|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
219309556|NCT01519466|DEVICE|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
219309557|NCT02007889|DRUG|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
219309558|NCT02844049|DEVICE|Deep Brain Stimulation|surgical procedure
219309559|NCT03545009|DIETARY_SUPPLEMENT|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
219309560|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
219309561|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice|70ml Concentrated Beetroot Juice
219309562|NCT01279096|DRUG|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
219309563|NCT06085651|PROCEDURE|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
219309564|NCT02154789|DRUG|polidocanol|
219309565|NCT02154789|PROCEDURE|infra-red coagulation|
219309566|NCT02154789|PROCEDURE|cryotherapy|
219309567|NCT02831205|DEVICE|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
219309568|NCT02831205|DEVICE|everolimus-eluting cobalt-chromium (Xience) stent|
219309569|NCT04370457|OTHER|Administration of the MyPal ePRO system|Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
219309570|NCT04158596|DEVICE|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
219309571|NCT01210079|DRUG|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
219309572|NCT01210079|DRUG|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
219309573|NCT00147823|DEVICE|Vitoss Alone|Synthetic bone graft material
219309574|NCT00147823|DEVICE|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
219309575|NCT04311060|DIAGNOSTIC_TEST|Molecular panel|"* Detection of CBF rearrangements using PCR: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~* NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
219309576|NCT06233721|OTHER|Online education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
219309577|NCT06233721|OTHER|Face-to-face education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
219309578|NCT04256382|OTHER|dementia pain care education|Participants are educated about dementia pain care.
219309579|NCT04256382|OTHER|dementia care education|Participants are educated about dementia pain care.
219309580|NCT02426879|PROCEDURE|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
219309581|NCT00028743|DRUG|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
219309582|NCT00028743|DRUG|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
219309583|NCT00028743|DRUG|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
219309584|NCT00028743|DRUG|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
219309585|NCT02963181|DRUG|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
219309586|NCT02963181|DRUG|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
219309587|NCT03545776|OTHER|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
219309588|NCT05566314|DIETARY_SUPPLEMENT|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
219309589|NCT05566314|OTHER|Placebo|12 oz. flavored beverage
219309590|NCT04572412|RADIATION|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
219309591|NCT06236282|DEVICE|ArtiSential®|Articulated laparoscopic device made by Livsmed Co, South Korea.
219309592|NCT02379481|DIETARY_SUPPLEMENT|NS 550mg|
219309593|NCT02379481|DIETARY_SUPPLEMENT|NS 1100mg|
219309594|NCT02379481|DIETARY_SUPPLEMENT|placebo|
219309595|NCT00219622|DRUG|tofimilast|
219309596|NCT01504750|PROCEDURE|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
219309597|NCT05863858|DRUG|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
219309598|NCT05863858|DRUG|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
219309599|NCT05715853|OTHER|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
219309600|NCT02564939|DRUG|ramelteon|double-blind RCT
219309601|NCT02564939|DRUG|Placebo|double-blind RCT
219309602|NCT05263479|DRUG|HS-20089 (Phase Ia：Dose escalation )|Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
219309603|NCT05263479|DRUG|HS-20089 (Phase Ib: Dose expansion)|IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
219309604|NCT05803655|OTHER|36-hour duration between ovulation triggering and oocyte pick-up procedure|36-hour duration between ovulation triggering and oocyte pick-up procedure
219309605|NCT05803655|OTHER|38-hour duration between ovulation triggering and oocyte pick-up procedure|38-hour duration between ovulation triggering and oocyte pick-up procedure
219309606|NCT03939091|DIAGNOSTIC_TEST|Ultrasonography|Renal Ultrasonography
219309607|NCT01012713|DRUG|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
219309608|NCT01012713|DRUG|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
219309609|NCT01012713|PROCEDURE|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
219309610|NCT00410397|PROCEDURE|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
219309611|NCT00410397|PROCEDURE|Sham Manipulation|Neutral positional, gentle palpation
219309612|NCT02540057|PROCEDURE|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
219309613|NCT02540057|PROCEDURE|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
219309614|NCT02571049|DRUG|DFN-11|Sumatriptan 3 mg versus 6 mg
219309615|NCT02954068|DRUG|IV Oxytocin + IM placebo|
219309616|NCT02954068|DRUG|IM Oxytocin + IV placebo|
219309617|NCT04271787|OTHER|questionnaire|Questionnaire
219309618|NCT00137124|DRUG|L-Arginine|oral administration of L-arginine for 4 weeks
219309619|NCT01055262|DEVICE|Heatwrap 1|8 hours continuous topically-applied heat
219309620|NCT01283698|DRUG|Experimental: LAS 41004 dosage 1|dosage 1, once daily
219309621|NCT01283698|DRUG|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
219309622|NCT01283698|DRUG|Experimental: LAS 41004 dosage 3|dosage 3, once daily
219309623|NCT01283698|DRUG|Placebo Comparator: placebo|once daily
219309624|NCT01283698|DRUG|Reference|Active Comparator,once daily
219309625|NCT05021094|DRUG|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
219309626|NCT05021094|DRUG|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
219309627|NCT00290043|DRUG|Insulin glulisine|
219309628|NCT03370471|BEHAVIORAL|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
219309629|NCT03370471|BEHAVIORAL|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
219309630|NCT03370471|BEHAVIORAL|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
219309631|NCT03370471|BEHAVIORAL|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
219309632|NCT00505869|BEHAVIORAL|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
219309633|NCT00505869|BEHAVIORAL|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
219309634|NCT00505869|BEHAVIORAL|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
219309635|NCT02072447|DRUG|YH4808 PO and [14C]-YH4808 IV|
219309636|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
219309637|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
219309638|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
219309639|NCT04188691|BIOLOGICAL|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
219309640|NCT04188691|BIOLOGICAL|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
219309641|NCT05969925|DIAGNOSTIC_TEST|new biomarkers for heart failure|assess efficacy of new biomarkers for heart failure
219309642|NCT01757808|DRUG|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
219309643|NCT01757808|DRUG|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
219309644|NCT02182557|DRUG|WAL 801 CL Dry Syrup|
219309645|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup|
219309646|NCT02182557|DRUG|WAL 801 CL Dry Syrup placebo|
219309647|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup placebo|
219309648|NCT01520298|DRUG|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
219309649|NCT01520298|DRUG|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
219309650|NCT03275753|OTHER|Visual Function Tests|All subjects will undergo a battery of visual function tests
219309651|NCT03253874|BEHAVIORAL|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
219309652|NCT00561951|DRUG|fesoterodine fumarate|8mg tablets OD for 12 weeks
219309653|NCT00561951|DRUG|Placebo|Corresponding placebo tablets OD for 12 weeks
219309654|NCT00561951|DRUG|fesoterodine fumarate|4mg tablets OD for 12 weeks
219309655|NCT02225951|DIETARY_SUPPLEMENT|Nutritional product|
219309656|NCT02225951|OTHER|Standard breakfast according to ADA recommendations|
219309657|NCT02949505|BEHAVIORAL|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
219309658|NCT02852473|OTHER|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
219309659|NCT02608281|DEVICE|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
219309660|NCT00435890|BEHAVIORAL|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
219309661|NCT01581541|DRUG|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
219309662|NCT00392327|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219309663|NCT00392327|DRUG|Carboplatin|Given IV
219309664|NCT00392327|DRUG|Cisplatin|Given IV
219309665|NCT00392327|DRUG|Cyclophosphamide|Given IV
219309666|NCT00392327|BIOLOGICAL|Filgrastim|Given IV or SC
219309667|NCT00392327|DRUG|Isotretinoin|Given PO
219309668|NCT00392327|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219309669|NCT00392327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219309670|NCT00392327|OTHER|Quality-of-Life Assessment|Ancillary studies
219309671|NCT00392327|RADIATION|Radiation Therapy|Undergo radiation therapy
219309672|NCT00392327|DRUG|Vincristine Sulfate|Given IV
219309673|NCT01414504|BIOLOGICAL|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
219309674|NCT01414504|BIOLOGICAL|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
219309675|NCT01414504|BIOLOGICAL|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
219309676|NCT01414504|BIOLOGICAL|Control|control, 0.1mL Pneumovax at 3-5yrs
219309677|NCT01990118|DRUG|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
219309678|NCT01990118|DRUG|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
219309679|NCT06107725|DRUG|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
219309680|NCT04508023|DRUG|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
219309681|NCT04508023|OTHER|Placebo|Participants will receive matching placebo tablet orally once daily.
219309682|NCT04508023|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
219309683|NCT04359004|OTHER|Vagus Nerve Stimulation (VNS)|Vagus Nerve Stimulation (VNS) will be performed percutaneously through the internal jugular vein during the patient's routine VT ablation procedure. The nerve will be stimulated using standard pacing systems used for clinical purposes. A series of stimulation frequencies and pulse widths will be used to define optimal effects and 'dosing'. Activation recovery interval (ARI) will be measured from the unipolar electrograms. In addition, heart rate and blood pressure responses will be continuously recorded.
219309684|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
219309685|NCT01401192|DRUG|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks
219309686|NCT01401192|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks
219309687|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
219309688|NCT04498065|BIOLOGICAL|Biological data|Biological data
219309689|NCT04498065|OTHER|Clinical data|Clinical data
219309690|NCT03295110|OTHER|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
219309691|NCT03295110|OTHER|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
219309692|NCT00437736|DRUG|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
219309693|NCT05148143|DRUG|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
219309694|NCT01330173|DRUG|Vismodegib|Given PO
219309695|NCT01330173|OTHER|Pharmacological Study|Correlative studies
219309696|NCT01330173|OTHER|Laboratory Biomarker Analysis|Correlative studies
219309697|NCT02466633|OTHER|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
219309698|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
219309699|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
219309700|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
219309701|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
219309702|NCT00116727|DRUG|ENBREL®|50 mg/wk SC
219309703|NCT06324565|DIAGNOSTIC_TEST|D-Dimer test|All patients in whom preoperative diagnostics have not been able to exclude a surgical pathology and who are candidates for diagnostic-therapeutic surgery will be referred for minimally invasive abdominal exploration in the real suspicion of ovarian torsion. During the pre-operative phase, blood exams will be performed including coagulation which will be integrated with the D-dimer values. In addition, as usual, the clinical examination of the patients will be performed integrated with the various diagnostic image tools generally used in this category of patients (abdomen ultrasound +/- magnetic resonance in urgency).
219309704|NCT03969147|DEVICE|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
219309705|NCT03969147|DEVICE|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
219309706|NCT03969147|DEVICE|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
219309707|NCT04229251|BEHAVIORAL|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
219309708|NCT04229251|BEHAVIORAL|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
219309709|NCT05198908|OTHER|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
219309710|NCT05198908|OTHER|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
219309711|NCT00556920|DRUG|COREG CR|
219309712|NCT06168188|DRUG|Neulasta® (pegfilgrastim)|Intravitreal injection of Neulasta® (pegfilgrastim) after TON
219309713|NCT00654342|PROCEDURE|Intraoperative injection (in vivo)|Intraoperative injection
219309714|NCT00654342|PROCEDURE|Postoperative injection (ex vivo)|postoperative injection
219309715|NCT04065178|BEHAVIORAL|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
219309716|NCT03154073|BEHAVIORAL|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
219309717|NCT03154073|BEHAVIORAL|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
219309718|NCT00164645|BEHAVIORAL|Problem Solving intervention|
219309719|NCT04007185|PROCEDURE|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
219309720|NCT04428827|PROCEDURE|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
219309721|NCT03261700|BEHAVIORAL|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
219309722|NCT03261700|OTHER|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
219309723|NCT05225194|OTHER|COVID-19|SARS-CoV-2 infection
219309724|NCT05225194|OTHER|ARDS|Acute respiratory distress syndrome
219309725|NCT01629602|PROCEDURE|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
219309726|NCT03302351|DRUG|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
219309727|NCT03302351|DRUG|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
219309728|NCT03302351|DRUG|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
219309729|NCT03990831|DIAGNOSTIC_TEST|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
219309730|NCT00126893|DRUG|CC-401|
219309731|NCT04185454|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daily intake of Jarlsberg cheese
219309732|NCT03866707|OTHER|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
219309733|NCT03866707|OTHER|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
219309734|NCT03866707|OTHER|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
219309735|NCT03795597|DRUG|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
219309736|NCT03795597|DRUG|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
219309737|NCT03795597|DRUG|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
219309738|NCT04531150|DRUG|INV-101|Subjects will be randomized to receive INV-101 tablets
219309739|NCT04531150|DRUG|Placebo|Subjects will be randomized to receive placebo tablets
219309740|NCT06023407|OTHER|Water Immersion Heat Therapy|10-weeks of 3 days per week in 1 of the 2 arms
219309741|NCT02193191|DRUG|Plerixafor|
219309742|NCT02673905|OTHER|Tissue Engineered Product|Implantation of tissue engineered products
219309743|NCT05357781|DIAGNOSTIC_TEST|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
219309744|NCT06458218|COMBINATION_PRODUCT|Multi-component Interventions|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, EmoEase, for individuals with mental health issues among high-risk COPD population(very familiar with intelligent mobile phone);~3. NicQuit, digital health intervention to smokers;~4. Health education to smokers and individuals with mental health issues;~5. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~6. To actively include individuals whose blood pressure and glucose are higher than the normal value into the National Essential Public Health Service in China;~7. A CBT-based health education to the BMI abnormal;~8. Pay-for-performance incentives to medical workers."
219309745|NCT06785103|BEHAVIORAL|Risk assessment messaging|"Participants who are randomized to the HIV risk assessment arm will receive a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category."
219309746|NCT06785103|BEHAVIORAL|U=U messaging|"Participants who are randomized to the U=U arm will receive a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category."
219309747|NCT06785103|BEHAVIORAL|Healthy Living messaging|"Participants who are randomized to the Healthy Living arm will receive a brief video message at their baseline visit, containing information related to Healthy Living core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Healthy Living content category."
219309748|NCT06785103|BEHAVIORAL|Community benefits messaging|"Participants who are randomized to the Community benefits arm will receive a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category."
219309749|NCT06785103|BEHAVIORAL|Fresh start effect|"Participants who are randomized to the Fresh start effect arm will receive a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category."
219309750|NCT06785103|BEHAVIORAL|Education-based messaging (#1)|"Participants who are randomized to the Education-based #1 arm will receive a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based #1 content category."
219309751|NCT06785103|BEHAVIORAL|Education-based #2 messaging (gamification)|"Participants who are randomized to the Education-based #2 arm will receive a brief video message at their baseline visit, containing information related to HIV education/gamification core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based/gamification content category."
219309752|NCT06785103|BEHAVIORAL|Default appointment messaging|"Participants who are randomized to the Default appointment arm will receive a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category."
219309753|NCT06785103|BEHAVIORAL|Reserved for you messaging|"Participants who are randomized to the Reserved for you arm will receive a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
219309754|NCT06785103|BEHAVIORAL|Social norms messaging|"Participants who are randomized to the Social norms arm will receive a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category."
219309755|NCT06785103|BEHAVIORAL|Empowerment messaging|"Participants who are randomized to the Empowerment/goal setting arm will receive a brief video message at their baseline visit, containing information related to Empowerment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Empowerment content category."
219309756|NCT04041583|DEVICE|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis \[2\]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion \[2\].
219309757|NCT05695937|DIETARY_SUPPLEMENT|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
219309758|NCT05695937|DIETARY_SUPPLEMENT|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
219309759|NCT05695937|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
219309760|NCT05695937|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
219309761|NCT02778256|DEVICE|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
219309762|NCT02778256|DEVICE|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
219309763|NCT01340196|DRUG|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
219309764|NCT06015178|OTHER|Intelligent Language Model|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
219309765|NCT06015178|OTHER|control|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
219309766|NCT03279133|DRUG|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
219309767|NCT05622617|DRUG|no intervention|no intervention
219309768|NCT04567290|DRUG|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
219309769|NCT04567290|DRUG|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
219309770|NCT05474599|OTHER|conventional physical therapy|TENS
219309771|NCT05474599|OTHER|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
219309772|NCT00108212|BEHAVIORAL|Diet|
219309773|NCT00329342|BEHAVIORAL|Occupational ergonomic training|Adequate postural habits in activities of daily living
219309774|NCT03660553|DRUG|Insulin Glargine|0.40 units/kg body weight
219309775|NCT03660553|DRUG|Insulin Glargine|0.20 units/kg body weight
219309776|NCT03660553|DRUG|Insulin Aspart|0.20 units/kg body weight
219309777|NCT03660553|DRUG|Insulin Lispro|0.20 units/kg body weight
219309778|NCT00171704|DRUG|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
219309779|NCT00171704|DRUG|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
219309780|NCT05255367|COMBINATION_PRODUCT|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
219309781|NCT02253108|DEVICE|Everolimus eluting bioresorbable polymer stent|
219309782|NCT02253108|DEVICE|Biolimus eluting bioresorbable polymer stent|
219309783|NCT02586922|DEVICE|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
219309784|NCT03336151|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
219309785|NCT04773496|DIAGNOSTIC_TEST|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
219309786|NCT04335240|OTHER|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
219309787|NCT02749630|DRUG|Placebo|Matching placebo to UTTR1147A administered intravenously
219309788|NCT02749630|DRUG|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
219309789|NCT03295994|PROCEDURE|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
219309790|NCT03295994|PROCEDURE|Non-Operative|Physical therapy (without surgery).
219309791|NCT03296891|OTHER|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
219309792|NCT04897451|OTHER|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
219309793|NCT04058613|DRUG|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
219309794|NCT04058613|OTHER|placebo|placebo
219309795|NCT06177249|BIOLOGICAL|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
219309796|NCT06177249|BIOLOGICAL|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
219309797|NCT01907802|DRUG|Dabrafenib|Given PO
219309798|NCT01907802|OTHER|Laboratory Biomarker Analysis|Correlative studies
219309799|NCT01907802|OTHER|Pharmacogenomic Study|Correlative studies
219309800|NCT01907802|OTHER|Pharmacological Study|Correlative studies
219309801|NCT00915304|BEHAVIORAL|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
219309802|NCT00223522|DEVICE|MEMS caps|
219309803|NCT05780411|OTHER|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
219309804|NCT00205491|DRUG|Venlafaxine|
219309805|NCT03225495|PROCEDURE|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
219309806|NCT03225495|PROCEDURE|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
219309807|NCT04412629|DRUG|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
219309808|NCT04412629|PROCEDURE|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
219309809|NCT04412629|PROCEDURE|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
219309810|NCT03171077|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
219309811|NCT03171077|OTHER|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
219309812|NCT03171077|OTHER|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
219309813|NCT00893282|DEVICE|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
219309814|NCT00893282|DEVICE|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
219309815|NCT03956537|DEVICE|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
219309816|NCT03956537|DEVICE|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
219309817|NCT04262947|DEVICE|Near Infrared Vein Imaging|Use of NI vein imaging device for visualization of veins during peripheral IV placement
219309818|NCT04262947|OTHER|Conventional IV placement|IV placement utilizing conventional methods
219309819|NCT00816400|DRUG|MEDI-575|MEDI-575 as an IV infusion
219309820|NCT01319188|DRUG|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
219309821|NCT01319188|PROCEDURE|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
219309822|NCT01319188|OTHER|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
219309823|NCT04127890|DIETARY_SUPPLEMENT|ELO Water|oxygen-enriched water
219309824|NCT04127890|DIETARY_SUPPLEMENT|Placebo drinking water|bottled drinking water
219309825|NCT02672215|BEHAVIORAL|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
219309826|NCT02672215|BEHAVIORAL|generic advice|general, non-tailored web-based generic advice with tips
219309827|NCT03207685|DEVICE|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
219309828|NCT05925179|PROCEDURE|Surgical crown lengthening|Surgical clinical crown lengthening with bone excision
219309829|NCT05925179|DRUG|Augmentin|Pre-operative antibiotic prophylaxis (2 g Augmentin)
219309830|NCT00428623|PROCEDURE|wound dressing|
219309831|NCT05946278|OTHER|Sample collection for gene expression|This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
219309832|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
219309833|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
219309834|NCT00081770|DRUG|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
219309835|NCT00081770|BIOLOGICAL|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
219309836|NCT00081770|DRUG|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
219309837|NCT01399333|DIETARY_SUPPLEMENT|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
219309838|NCT01399333|DIETARY_SUPPLEMENT|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
219309839|NCT01399333|DIETARY_SUPPLEMENT|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
219309840|NCT03408054|DRUG|Oxytocin|Oxytocin 10-5M solution
219309841|NCT03408054|DRUG|Nitroglycerin|Nitroglycerin 25-1000mcg
219309842|NCT00191867|DRUG|Teriparatide|
219309843|NCT02552641|OTHER|Food effect|
219309844|NCT02552641|DRUG|Esomeprazole|
219309845|NCT02552641|DRUG|Amoxicillin|
219309846|NCT02552641|DRUG|Clarythromycin|
219309847|NCT00247585|DRUG|Ethanol (Bourbon or Vodka)|
219309848|NCT05125666|OTHER|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
219309849|NCT05125666|OTHER|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
219309850|NCT06498505|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
219309851|NCT06498505|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
219309852|NCT00601419|DRUG|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
219309853|NCT06178926|DRUG|Propofol|Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
219309854|NCT06178926|DRUG|Ciprofol|Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
219309855|NCT04897672|OTHER|Observational study|Observational study
219309856|NCT01614197|DRUG|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
219309857|NCT01614197|DRUG|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
219309858|NCT01614197|DRUG|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
219309859|NCT01614197|DRUG|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
219309860|NCT01614197|DRUG|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
219309861|NCT01614197|DRUG|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age"
219309862|NCT00948142|DRUG|CEM-102|600 mg BID oral tablets for 10-14 days
219309863|NCT00948142|DRUG|Linezolid|600 mg BID oral tablets
219309864|NCT00948142|DRUG|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
219309865|NCT05545657|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
219309866|NCT05545657|OTHER|Simultaneous EEG-fMRI scan|EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.
219309867|NCT05545657|OTHER|Multimodal magnetic resonance imaging|3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.
219309868|NCT05545657|OTHER|Peripheral blood neuropathology biomarkers assay|Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
219309869|NCT01896154|DIETARY_SUPPLEMENT|NPS|Comparison of multiple dietary non-digestible polysaccharides
219309870|NCT05657717|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
219309871|NCT05637385|BEHAVIORAL|Training of perception and oculo-motor control|Behavioral training of eye movements and perception
219309872|NCT01894633|DRUG|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
219309873|NCT01894633|RADIATION|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
219309874|NCT06108037|BEHAVIORAL|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
219309875|NCT05807607|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
219309876|NCT05807607|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
219309877|NCT05807607|PROCEDURE|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
219309878|NCT01386060|OTHER|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
219309879|NCT03005860|DRUG|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
219309880|NCT03005860|DRUG|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
219309881|NCT03005860|DRUG|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
219309882|NCT03005860|DRUG|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
219309883|NCT00499356|DEVICE|pressure reducing insole|
219309884|NCT00499356|DEVICE|GlideSoft®|
219309885|NCT05140525|DRUG|Macitentan Tablets|10 mg oral once daily
219309886|NCT05140525|DRUG|Riociguat|1 mg to 2.5mg oral three times daily
219309887|NCT05140525|DEVICE|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
219309888|NCT02285426|DEVICE|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality \[visual scale adapted from Herth 2009 and Zaric 2013\] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
219309889|NCT04033848|PROCEDURE|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
219309890|NCT05407922|PROCEDURE|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
219309891|NCT04220125|DRUG|Ketamine Group|Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
219309892|NCT04220125|DRUG|Midazolam injection|Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
219309893|NCT00281333|BEHAVIORAL|"Karate exercises and strengthening exercises"|
219309894|NCT03459144|DRUG|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
219309895|NCT03459144|DRUG|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
219309896|NCT04854369|DRUG|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
219309897|NCT00288509|BIOLOGICAL|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
219309898|NCT05741151|DIAGNOSTIC_TEST|PET-Neck Parkinsonian patients|Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
219309899|NCT04547153|DRUG|5-fluorouracil|200mg/square metre/day civ D1-D21
219309900|NCT04547153|DRUG|Docetaxel|25mg/square metre ivdrip D1, D8, D15
219309901|NCT05446688|DRUG|6MW3211|6MW3211 injection, 45mg/kg, Q2W
219309902|NCT05545605|DRUG|Sodium oligomannate|Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)
219309903|NCT05545605|DRUG|Placebo capsule|the control group (receiving placebo capsule) for 24 weeks.
219309904|NCT05804760|DIAGNOSTIC_TEST|Measurement of implant parameters|"1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
219309905|NCT00683176|DRUG|Choline Fenofibrate|135 mg
219309906|NCT00683176|DRUG|Placebo|Placebo
219309907|NCT02682472|OTHER|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
219309908|NCT04930224|DIAGNOSTIC_TEST|The effect of GPER-1 on the formation of diabetic retinopathy|Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
219309909|NCT06428136|DIAGNOSTIC_TEST|Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)|"Side-lying clamshells: 3 sets of 10 repetitions per leg, 3 times per week Hip abduction with theraband: 3 sets of 10 repetitions per leg, 3 times per week Bridge with hip abduction: 3 sets of 10 repetitions per leg, 3 times per week~Electrical muscle stimulation:~Applied to the gluteus medius and minimus muscles for 20 minutes per session, 3 times per week Frequency and intensity adjusted to individual tolerance"
219309910|NCT06428136|OTHER|Conservative Treatment (CT)|Stretching: Iliotibial band stretch: 30-second hold, 3 repetitions per leg, 2 times per day Quadriceps stretch: 30-second hold, 3 repetitions per leg, 2 times per day Hamstring stretch: 30-second hold, 3 repetitions per leg, 2 times per day
219309911|NCT05911841|DRUG|LY3454738|Administered SC
219309912|NCT05911841|DRUG|Placebo|Administered SC
219309913|NCT06845150|OTHER|Dual-task training|Combined simultaneous physical and cognitive training in an immersive environment
219309914|NCT06845150|OTHER|Single task training|Sequential cognitive and then physical training
219309915|NCT06412393|DIETARY_SUPPLEMENT|Black tomato extract powder|take 2 packets per day for 8 weeks
219309916|NCT06412393|DIETARY_SUPPLEMENT|Placebo powder|take 2 packets per day for 8 weeks
219309917|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
219309918|NCT04258488|DRUG|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects\_creatinine clearance 15-49 mL/min, 15mg once daily
219309919|NCT04258488|DRUG|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
219309920|NCT06644898|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
219309921|NCT06644898|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
219309922|NCT06644898|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
219309923|NCT06337838|DRUG|Desmopressin Injectable Solution|Intravenous desmopressin, 20 mcg, single dose administration.
219309924|NCT06337838|DRUG|Tranexamic Acid Injectable Product|Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
219309925|NCT06337838|OTHER|Placebo|Intravenous 0.9% saline solution
219309926|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
219309927|NCT03840486|DEVICE|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
219309928|NCT03840486|DEVICE|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 40% FiO2 for 3 minutes, 70% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
219309929|NCT03840486|DEVICE|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
219309930|NCT03840486|DRUG|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
219309931|NCT03840486|DRUG|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 40% FiO2, 70% FiO2 or 100% FiO2 for 3 minutes each.
219309932|NCT05403138|DRUG|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
219309933|NCT05403138|DRUG|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
219309934|NCT05469399|OTHER|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
219309935|NCT05469399|OTHER|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
219309936|NCT06384911|BEHAVIORAL|Financial Incentives Program|Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.
219309937|NCT01210261|DEVICE|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
219309938|NCT01210261|DEVICE|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
219309939|NCT02904486|BEHAVIORAL|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
219309940|NCT06257524|OTHER|Education and training|Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
219309941|NCT02361138|DRUG|SHR3824|
219309942|NCT02361138|DRUG|Placebo|
219309943|NCT03105622|BEHAVIORAL|TV and music|Watching TV or listening to music while running on a treadmill
219309944|NCT04388397|PROCEDURE|Arteriovenous Grafts|Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
219309945|NCT05033873|OTHER|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
219309946|NCT05033873|OTHER|Sling Exercise Therapt (SET)|"1. The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~2. In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~3. The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~4. Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
219309947|NCT05033873|OTHER|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~* Active and passive joint movement~* Muscle strength training~* Bridging exercises~* Balance training in sitting and standing positions, according to the patients' functional state.~* Weight bearing exercises on affected Limbs"
219309948|NCT02963610|DRUG|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
219309949|NCT02963610|DRUG|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
219309950|NCT02088437|OTHER|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
219309951|NCT02088437|OTHER|Usual Care|once daily physiotherapy whilst acute hospital inpatient
219309952|NCT03141385|OTHER|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
219309953|NCT03141385|OTHER|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
219309954|NCT06340399|DIETARY_SUPPLEMENT|BCAA|patients administering BCAA
219309955|NCT06340399|OTHER|patient not administered BCAA|patients not administered BCAA
219309956|NCT00565474|DRUG|Fluvastatin|Graft vasculopathy
219309957|NCT04693494|OTHER|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
219309958|NCT01774110|OTHER|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
219309959|NCT06270927|DIAGNOSTIC_TEST|MRI|neuroimaging using MRI scanner
219309960|NCT06270927|DIAGNOSTIC_TEST|CT|neuroimaging using CT scanner
219309961|NCT00640016|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
219309962|NCT00640016|BIOLOGICAL|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
219309963|NCT00640016|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
219309964|NCT00640016|OTHER|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
219309965|NCT05617911|DEVICE|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
219309966|NCT05617911|PROCEDURE|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
219309967|NCT01222273|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
219309968|NCT04376853|DEVICE|Apple Watch Series 5|Digital monitoring via Apple Watch
219309969|NCT06154486|DRUG|semaglutide use|patient using semaglutide for at least 7 days
219309970|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
219309971|NCT05908604|OTHER|Robot for madication management|The effect of a robot in medication management for older people's home care
219309972|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
219309973|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
219309974|NCT04579133|DRUG|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)
219309975|NCT04579133|DRUG|Durvalumab|Durvalumab 1500 mg IV
219309976|NCT00544388|DRUG|levocetirizine dihydrochloride|
219309977|NCT02566265|BIOLOGICAL|Fluzone High Dose Vaccine|
219309978|NCT02566265|BIOLOGICAL|Standard of care/Placebo|
219309979|NCT00108147|PROCEDURE|Circuit Training|
219309980|NCT00108147|PROCEDURE|Cardiac Rehabilitation|
219309981|NCT00108147|PROCEDURE|Flexibility and toning|
219309982|NCT00005825|DRUG|cisplatin|
219309983|NCT00005825|DRUG|mitomycin C|
219309984|NCT00005825|DRUG|tretinoin|
219309985|NCT00005825|DRUG|vinorelbine tartrate|
219309986|NCT01847118|DRUG|Sevacizumab|
219309987|NCT01978262|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
219309988|NCT03134157|DRUG|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
219309989|NCT03134157|DRUG|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
219309990|NCT03134157|DRUG|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
219309991|NCT03595605|BEHAVIORAL|Ambulation|This group will be encouraged twice daily to ambulate
219309992|NCT03595605|OTHER|Standard of Care|Care as usual at inpatient NYU Langone
219309993|NCT06017141|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
219309994|NCT06017141|OTHER|Electronic Health Record Review|Ancillary studies
219309995|NCT06017141|DRUG|Fentanyl Citrate|Given via injection
219309996|NCT06017141|DRUG|Propofol|Given IV
219309997|NCT06017141|OTHER|Questionnaire Administration|Ancillary studies
219309998|NCT06017141|DRUG|Sevoflurane|Given via inhalation
219309999|NCT06017141|PROCEDURE|Surgical Procedure|Undergo SOC surgery
219310000|NCT06200064|OTHER|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
219310001|NCT06200064|OTHER|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
219310002|NCT04040400|RADIATION|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
219310003|NCT06135077|OTHER|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
219310004|NCT06135077|OTHER|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
219310005|NCT05785234|DRUG|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
219310006|NCT05785234|DRUG|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
219310007|NCT00460174|BIOLOGICAL|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
219310008|NCT00460174|DRUG|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
219310009|NCT00460174|PROCEDURE|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
219310010|NCT00460174|RADIATION|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
219310011|NCT02959450|DIETARY_SUPPLEMENT|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
219310012|NCT00399230|DRUG|Optive|
219310013|NCT01548157|DRUG|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
219310014|NCT00027781|DRUG|sabarubicin|
219310015|NCT06120348|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
219310016|NCT06120348|DEVICE|Sham Stimulation|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
219310017|NCT02148419|OTHER|no intervention|
219310018|NCT04540848|DRUG|Group A (Exparel plus supraclavicular block)|"Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
219310019|NCT04540848|DRUG|Group B (Bupivacaine HCL plus supraclavicular block)|"Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
219310020|NCT04540848|DRUG|Group C(supraclavicular block only)|"In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
219310021|NCT04578574|OTHER|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
219310022|NCT04578574|DEVICE|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
219310023|NCT04578574|OTHER|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
219310024|NCT00050388|GENETIC|Allovectin-7®|
219310025|NCT03909217|PROCEDURE|TECAS Procedure|"Location:~1. Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~2. Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
219310026|NCT03909217|DRUG|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
219310027|NCT03909217|DRUG|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
219310028|NCT02742623|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
219310029|NCT06450431|OTHER|SF-36 questionnaire French version and PAS.fr questionnaire|Patients will receive both the SF-36 questionnaire (control generic questionnaire for QoL evaluation validated in French language) and the PAS.fr questionnaire at the designated time (before surgery, 6, 12 or 36 months after surgery) during the consultation, or by mail. For concurrent validation of the PAS.fr questionnaire, a second questionnaire will be sent to the patients 2-4 weeks thereafter.
219310030|NCT00196404|DRUG|DR-3001a|4mg daily vaginally
219310031|NCT00196404|DRUG|DR-3001b|6 mg vaginally daily
219310032|NCT00196404|OTHER|Placebo|Administered vaginally to match experimental arms
219310033|NCT00141726|DRUG|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
219310034|NCT01980550|DRUG|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
219310035|NCT01694355|DRUG|Vitamin D|
219310036|NCT02038439|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
219310037|NCT02038439|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
219310038|NCT02038439|BEHAVIORAL|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
219310039|NCT05179720|OTHER|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
219310040|NCT04415463|DEVICE|Multisegmented fully covered self-expandable metal stent|Esophageal FC-SEMS
219310041|NCT03281837|DEVICE|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
219310042|NCT03281837|OTHER|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
219310043|NCT00473681|BEHAVIORAL|Self-Help Intervention Program-High Blood Pressure|
219310044|NCT00153517|DRUG|oral versus vaginal metronidazole|
219310045|NCT03445351|OTHER|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
219310046|NCT02590263|RADIATION|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
219310047|NCT02590263|DRUG|Temozolomide|Temozolomide will be administered per label.
219310048|NCT02590263|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
219310049|NCT01790126|DRUG|ARN-509|
219310050|NCT01790126|DRUG|LHRH Agonist|
219310051|NCT04731766|BEHAVIORAL|Citrine 5 % sodium fluoride|Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
219310052|NCT04731766|BEHAVIORAL|concocted nano-silver fluoride|Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
219310053|NCT02894112|DIETARY_SUPPLEMENT|non-fat milk|1 serving of non-fat fluid milk
219310054|NCT02894112|DIETARY_SUPPLEMENT|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
219310055|NCT02894112|DIETARY_SUPPLEMENT|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
219310056|NCT00002646|DRUG|fenretinide|
219310057|NCT00002646|DRUG|tamoxifen citrate|
219310058|NCT02435966|DEVICE|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
219310059|NCT02435966|DEVICE|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
219310060|NCT02435966|OTHER|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
219310061|NCT06064513|OTHER|verbal empathy training|Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.
219310062|NCT06064513|OTHER|video based empathy training|Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
219310063|NCT02827253|DEVICE|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
219310064|NCT04681547|PROCEDURE|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
219310065|NCT04681547|PROCEDURE|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
219310066|NCT03084224|GENETIC|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
219310067|NCT01917513|DEVICE|G-EYE™ colonoscopy|G-EYE™ colonoscopy
219310068|NCT01917513|DEVICE|Standard Colonoscopy|Standard Colonoscopy
219310069|NCT02302690|BIOLOGICAL|Blood sample for immunology|
219310070|NCT00070863|BEHAVIORAL|Individual Cognitive Behavioral Therapy|
219310071|NCT06200298|PROCEDURE|Erector spinae plane block with naropeine [3,75 mg/mL]|"Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process"
219310072|NCT06200298|PROCEDURE|ESPB with saline 0,9%|"Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process"
219310073|NCT03252951|BEHAVIORAL|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
219310074|NCT03252951|BEHAVIORAL|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
219310075|NCT03252951|BEHAVIORAL|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
219310076|NCT03252951|BEHAVIORAL|Biofeedback|Standard of Care Biofeedback Training
219310077|NCT03416998|OTHER|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
219310078|NCT00489892|DRUG|Modafinil|
219310079|NCT06494527|DRUG|RG002C0106|RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
219310080|NCT02767375|DRUG|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
219310081|NCT02767375|PROCEDURE|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
219310082|NCT05427721|DRUG|Thymol|200 mg each 8 hours for 90 days
219310083|NCT04571866|OTHER|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
219310084|NCT02349451|BIOLOGICAL|adalimumab|
219310085|NCT02349451|BIOLOGICAL|ABT-122|
219310086|NCT01103635|BIOLOGICAL|CD40 agonist monoclonal antibody CP-870,893|Given IV
219310087|NCT01103635|BIOLOGICAL|tremelimumab|Given IV
219310088|NCT01103635|OTHER|laboratory biomarker analysis|Correlative studies
219310089|NCT01756612|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
219310090|NCT02290522|PROCEDURE|Tumor biopsy|Biopsy of lesion for molecular characterization
219310091|NCT01268722|DEVICE|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
219310092|NCT01268722|DEVICE|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
219310093|NCT00429312|BIOLOGICAL|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
219310094|NCT03136328|DRUG|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
219310095|NCT04334434|OTHER|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
219310096|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
219310097|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
219310098|NCT06048354|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
219310099|NCT05032079|PROCEDURE|cryoablation|single probe ultrasound guided cryoablation
219310100|NCT00490880|DRUG|gemcitabine|
219310101|NCT00490880|DRUG|cisplatin|
219310102|NCT00490880|PROCEDURE|radical cystectomy|
219310103|NCT00490880|PROCEDURE|radiotherapy|
219310104|NCT02168842|DRUG|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
219310105|NCT02168842|DRUG|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
219310106|NCT00325039|PROCEDURE|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
219310107|NCT00325039|PROCEDURE|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
219310108|NCT00418925|DRUG|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
219310109|NCT04873414|BIOLOGICAL|Convalescent plasma treatment|Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
219310110|NCT03749603|DEVICE|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
219310111|NCT02974088|DEVICE|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
219310112|NCT02974088|DEVICE|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
219310113|NCT00277108|DRUG|Escitalopram (Lexapro)|
219310114|NCT00426153|DRUG|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
219310115|NCT00426153|DRUG|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
219310116|NCT02962544|PROCEDURE|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
219310117|NCT02962544|PROCEDURE|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
219310118|NCT02962544|DEVICE|Visumax device|
219310119|NCT02962544|DEVICE|FS 200 device|
219310120|NCT05138367|PROCEDURE|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
219310121|NCT04433273|DEVICE|Electrical vestibular nerve stimulation|Electrical vestibular nerve stimulation using a headset device
219310122|NCT00509808|DEVICE|Electrostimulation|"1. 1st month GN wearing (activated or sham mode)~2. 2nd month wearing (opposite mode)~3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
219310123|NCT02891603|DRUG|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
219310124|NCT02891603|DRUG|Sirolimus|Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
219310125|NCT02891603|DRUG|Tacrolimus|Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
219310126|NCT02891603|PROCEDURE|Allogenic hematopoietic cell transplant (alloHCT)|Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
219310127|NCT05172349|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
219310128|NCT00687973|DRUG|Valsartan/amlodipine 80/5 mg tablets|
219310129|NCT00687973|DRUG|Amlodipine 5 mg capsules|
219310130|NCT00687973|DRUG|Amlodipine 10 mg capsules|
219310131|NCT00687973|DRUG|Atenolol 50 mg tablets|
219310132|NCT00687973|DRUG|Atenolol 100 mg tablets|
219310133|NCT00219648|DRUG|PEP03|
219310134|NCT01656382|DRUG|ABLC|
219310135|NCT02816242|OTHER|concept map teaching|teaching anatomy using concept map to improve critical thinking
219310136|NCT02816242|OTHER|traditional teaching|teaching anatomy using lecture
219310137|NCT05130242|PROCEDURE|Cement-augmented Pedicle Screws (CPS)|Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
219310138|NCT05130242|PROCEDURE|Hybrid Construct (HC)|Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
219310139|NCT03049176|DRUG|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
219310140|NCT03049176|DRUG|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
219310141|NCT03049176|PROCEDURE|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
219310142|NCT03049176|PROCEDURE|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
219310143|NCT01110876|DRUG|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
219310144|NCT01110876|DRUG|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
219310145|NCT01110876|DRUG|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
219310146|NCT04932668|OTHER|Feasibility and Impact of Home-based Electrical Stimulation Program|"Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion."
219310147|NCT05169320|DEVICE|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
219310148|NCT05169320|PROCEDURE|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
219310149|NCT05169320|PROCEDURE|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~1. Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~2. Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity \[≤5 mm\] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
219310150|NCT03155256|PROCEDURE|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
219310151|NCT03155256|PROCEDURE|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
219310152|NCT05639335|OTHER|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
219310153|NCT05639335|OTHER|Experimental Characters|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
219310154|NCT02286778|DIETARY_SUPPLEMENT|Acetogenins|Acetogenins BID for 12 months
219310155|NCT02286778|DIETARY_SUPPLEMENT|Placebo|
219310156|NCT06099847|DEVICE|Sham TENS Stimulation|Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
219310157|NCT06099847|DEVICE|Sacral TENS Stimulation|Sacral TENS stimulation have been applied to directly the skin of sacral area.
219310158|NCT01005433|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
219310159|NCT01005433|DRUG|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
219310160|NCT03650478|DEVICE|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
219310161|NCT03650478|DEVICE|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
219310162|NCT05031208|DIAGNOSTIC_TEST|Memory task|Word recognition task
219310163|NCT05695625|OTHER|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
219310164|NCT05695625|OTHER|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
219310165|NCT02749240|OTHER|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
219310166|NCT00888446|BIOLOGICAL|tgAAC09|
219310167|NCT00888446|BIOLOGICAL|tgAAC09|
219310168|NCT00888446|BIOLOGICAL|tgAAC09|
219310169|NCT00888446|OTHER|Formulation buffer|Sterile isotonic buffered salt solution
219310170|NCT02483182|DRUG|ZEP-3 ointment 1.0%|
219310171|NCT02483182|DRUG|Acyclovir cream 5%|
219310172|NCT01731509|OTHER|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
219310173|NCT02261051|OTHER|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
219310174|NCT00343252|DRUG|teriparatide|20 ug/day, subcutaneous, 18 months
219310175|NCT00343252|DRUG|risedronate|35 mg/once weekly, oral, 18 months
219310176|NCT00343252|DRUG|placebo|once weekly, oral, 18 months
219310177|NCT00343252|DRUG|placebo|daily, subcutaneous, 18 months
219310178|NCT06087016|OTHER|Urine vibrational analysis|Urine vibrational analysis
219310179|NCT00459160|PROCEDURE|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
219310180|NCT02490202|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
219310181|NCT02490202|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
219310182|NCT00572390|DRUG|oestrogen|Cyclic oestrogen substitution therapy
219310183|NCT03378505|BEHAVIORAL|Mobile App|Purposeful Living Mobile App JOOL to be used daily
219310184|NCT03378505|BEHAVIORAL|Reflection|Bi-weekly online reflection question
219310185|NCT00096720|DRUG|levodopa|
219310186|NCT00096720|DRUG|Mirapex (pramipexole)|
219310187|NCT00096720|PROCEDURE|[123I]ß-CIT and SPECT imaging|
219310188|NCT01603186|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
219310189|NCT01603186|DRUG|Quetiapine Fumarate|25 mg tablet once a day
219310190|NCT02414581|DRUG|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
219310191|NCT02414581|DRUG|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
219310192|NCT02414581|DRUG|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
219310193|NCT03742167|OTHER|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
219310194|NCT00988871|DEVICE|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
219310195|NCT03453931|DRUG|Corticosteroid injection|Intravenous high dose corticosteroids
219310196|NCT03090815|GENETIC|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
219310197|NCT05831813|BEHAVIORAL|Goal-Based Cognitive Behavioural Intervention|A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
219310198|NCT01740323|DRUG|Placebo|daily placebo for 6 weeks
219310199|NCT01740323|DRUG|Curcumin|500 mg BID
219310200|NCT02083484|BIOLOGICAL|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
219310201|NCT01947192|PROCEDURE|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
219310202|NCT01947192|PROCEDURE|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
219310203|NCT02077569|DRUG|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
219310204|NCT02274194|DEVICE|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
219310205|NCT02274194|DEVICE|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
219310206|NCT04246567|PROCEDURE|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
219310207|NCT04246567|DRUG|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
219310208|NCT05286697|DIAGNOSTIC_TEST|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
219310209|NCT06486038|DIAGNOSTIC_TEST|MRI standard and qMRI|Non-contrast cervical spine MRI including morphological and quantitative MRI sequences on a 3 Tesla scanner. MRI examination includes conventional and experimental sequences
219310210|NCT06486038|OTHER|MEPs and SSEPs|Neurophysiological examination by motor and somatosensorial evocked potential using transcranial magnetic stimulation and electrical stimulation to the peripheral nerve
219310211|NCT06486038|OTHER|Neuromotor assessment|Upper and Lower limb assessment: Purdue Pegboard Test (PTT), Box and Block test (BBT), Nine Hole Peg Test (NHPT), gait analysis and 30 seconds sit to stand test (30CST)
219310212|NCT06486038|PROCEDURE|Anterior cervical discectomy and fusion|If applicable: Anterior cervical discectomy and fusion surgery using PEEK or modern carbon fiber material
219310213|NCT01589354|PROCEDURE|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
219310214|NCT01589354|PROCEDURE|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
219310215|NCT01589354|DEVICE|Ultrasound guided technique|The block will be performed under U/S guidance
219310216|NCT01589354|DRUG|Ropivacaine|20ml of 0.375% Ropivacaine
219310217|NCT01589354|DRUG|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
219310218|NCT03975595|BEHAVIORAL|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
219310219|NCT03975595|BEHAVIORAL|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
219310220|NCT05709795|PROCEDURE|Confluent areas|Use of omnipolar technology to guide CTI ablation in sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
219310221|NCT05709795|PROCEDURE|Wave Speed|Use of omnipolar technology to guide CTI ablation in sites with low wave speed. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
219310222|NCT05709795|PROCEDURE|Voltage|Use of omnipolar technology to guide CTI ablation in sites with high voltage. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then CTI line (gold standard)
219310223|NCT05709795|PROCEDURE|CTI line|Do not use omnipolar information. CTI line performance
219310224|NCT04743154|OTHER|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
219310225|NCT04743154|OTHER|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
219310226|NCT02577757|DEVICE|MRI|MRI
219310227|NCT02976454|BEHAVIORAL|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
219310228|NCT02976454|BEHAVIORAL|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
219310229|NCT05300360|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase enzyme deficiency test
219310230|NCT02875093|DRUG|ADI-PEG 20|Investigational Medicine
219310231|NCT02875093|DRUG|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
219310232|NCT01704820|PROCEDURE|Retroflexion in the right colon|
219310233|NCT00609882|OTHER|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
219310234|NCT00609882|OTHER|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
219310235|NCT00705354|DRUG|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
219310236|NCT00705354|PROCEDURE|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
219310237|NCT02019927|DEVICE|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
219310238|NCT02019927|DEVICE|Sham|Sham
219310239|NCT03421093|PROCEDURE|Surgeries|Surgeries or surgeries plus adjuvant therapies
219310240|NCT01492465|DRUG|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
219310241|NCT03524300|PROCEDURE|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
219310242|NCT03524300|PROCEDURE|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
219310243|NCT00246402|DRUG|Acipimox|
219310244|NCT02618031|PROCEDURE|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.
219310245|NCT06176339|DRUG|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
219310246|NCT06176339|DRUG|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
219310247|NCT03945825|DRUG|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
219310248|NCT03945825|BIOLOGICAL|Delta Inulin-CpG55.2|A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
219310249|NCT03945825|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
219310250|NCT03945825|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
219310251|NCT00371046|PROCEDURE|Transvaginal ultrasound cervical length|
219310252|NCT00371046|PROCEDURE|Cervicovaginal fetal fibronectin|
219310253|NCT03741647|DIAGNOSTIC_TEST|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
219310254|NCT00705835|BIOLOGICAL|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
219310255|NCT02317081|DEVICE|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
219310256|NCT02546895|OTHER|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
219310257|NCT05488574|OTHER|Deep breathing with Yoga positioning|Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
219310258|NCT05041855|BEHAVIORAL|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
219310259|NCT05041855|BEHAVIORAL|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
219310260|NCT05397860|PROCEDURE|Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes|Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
219310261|NCT04716530|OTHER|No intervention is associated with the study.|No intervention is associated with the study.
219310262|NCT02373553|OTHER|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
219310263|NCT02373553|OTHER|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
219310264|NCT01610011|DIETARY_SUPPLEMENT|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
219310265|NCT05291767|OTHER|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
219310266|NCT05291767|BEHAVIORAL|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
219310267|NCT05139433|BEHAVIORAL|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
219310268|NCT05139433|BEHAVIORAL|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
219310269|NCT00977054|DRUG|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
219310270|NCT00977054|DRUG|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
219310271|NCT01638117|OTHER|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
219310272|NCT01638117|DRUG|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
219310273|NCT01638117|DRUG|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
219310274|NCT01638117|DRUG|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
219310275|NCT01638117|OTHER|Saline|Saline, Daily for up to 21 days
219310276|NCT01638117|OTHER|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
219310277|NCT04270630|BEHAVIORAL|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
219310278|NCT02238522|DRUG|ZEN003365|
219310279|NCT02231853|BIOLOGICAL|MVST|MVST Infusion
219310280|NCT02231853|BIOLOGICAL|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
219310281|NCT04727853|DRUG|irinotecan liposome injection|Drug: irinotecan liposome injection
219310282|NCT06130748|DEVICE|Hybrid Hyrax|these patents will be treated using Two mini-screws supported hybrid hyrax
219310283|NCT01423253|DRUG|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
219310284|NCT06101433|DIETARY_SUPPLEMENT|Soy isoflavone|the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
219310285|NCT06101433|OTHER|Placebo|the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
219310286|NCT00701077|DRUG|3,4-Di-amino-Pyridine|a single 20 mg dosing
219310287|NCT00701077|DRUG|placebo|placebo
219310288|NCT03519165|DEVICE|EV1000(FloTrac System 4.0)|
219310289|NCT00307125|DRUG|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
219310290|NCT00307125|DRUG|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
219310291|NCT00051363|DEVICE|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
219310292|NCT00051363|DEVICE|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
219310293|NCT04746443|OTHER|NOT APPLICABLE (NA)|THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
219310294|NCT04722926|OTHER|PJI|patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
219310295|NCT03438786|PROCEDURE|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
219310296|NCT03438786|PROCEDURE|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
219310297|NCT01301820|DRUG|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
219310298|NCT01301820|DRUG|Lenalidomide|lenalidomide 10mg/d (d1- d21)
219310299|NCT00025103|BIOLOGICAL|dactinomycin|
219310300|NCT00025103|DRUG|carboplatin|
219310301|NCT00025103|DRUG|cyclophosphamide|
219310302|NCT00025103|DRUG|doxorubicin hydrochloride|
219310303|NCT00025103|DRUG|etoposide|
219310304|NCT00025103|DRUG|melphalan|
219310305|NCT00025103|DRUG|vincristine sulfate|
219310306|NCT00025103|PROCEDURE|autologous bone marrow transplantation|
219310307|NCT00025103|PROCEDURE|conventional surgery|
219310308|NCT00025103|PROCEDURE|peripheral blood stem cell transplantation|
219310309|NCT00025103|RADIATION|radiation therapy|
219310310|NCT01183078|PROCEDURE|free-hand|Free-hand technique utilizes x-rays to find screw holes.
219310311|NCT01183078|PROCEDURE|Wand technique|Wand technique is utilized to find screw holes.
219310312|NCT02437734|PROCEDURE|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
219310313|NCT00985153|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
219310314|NCT00985153|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
219310315|NCT00985153|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
219310316|NCT02319577|DRUG|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
219310317|NCT02319577|DRUG|Gefitinib|EGFR tyrosine kinase inhibitor
219310318|NCT03003559|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
219310319|NCT06270472|PROCEDURE|hernioplasty|"The polysome repair was carried out as described by pelisse . In the case of a lateral hernia, the spermatic cord was mobilised and the cremasteric fibers were separated (in men). The hernia sac was dissected from the cord structures and reduced in the preperitoneal space through the internal ring. A dissection gauze was inserted through the internal ring to create the preperitoneal space. The medial border of the internal ring and the epigastric vessels were lifted with a refractor and blunt digital dissection was carried out in the preperitoneal space in all directions. A pocket was created to allow a complete expansion of the mesh. The conventional mesh was introduced with blunt forceps and, after the gauze has been removed, positioned in the preperitoneal space .~In the case of a medial hernia, the preperitoneal space was reached by incising the transversalis fascia around the base of the sac. Completion of the repair is the same as the lateral hernia procedure."
219310320|NCT04219397|OTHER|Medication take back|Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
219310321|NCT04219397|OTHER|Medication home disposal|Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
219310322|NCT00865969|DRUG|Belinostat|
219310323|NCT03500250|OTHER|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
219310324|NCT05803616|DIAGNOSTIC_TEST|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
219310325|NCT03968393|DRUG|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
219310326|NCT02083666|DRUG|SOBI002|Test Product
219310327|NCT02083666|DRUG|Placebo|Reference product
219310328|NCT00221741|DRUG|Fresh Frozen Plasma (blood product)|
219310329|NCT02039960|DRUG|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
219310330|NCT00546130|DRUG|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219310331|NCT00546130|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
219310332|NCT00546130|DRUG|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
219310333|NCT02748720|OTHER|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
219310334|NCT06441721|DEVICE|Vitamin b12 measure|Measure vitamin b12 in serum and its impact on Haemodialysis patient
219310335|NCT05101616|DRUG|camrelizumab+chemotherapy|camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
219310336|NCT05101616|DRUG|Chemotherapy|albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
219310337|NCT04157140|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
219310338|NCT04157140|DEVICE|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
219310339|NCT05830578|DEVICE|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
219310340|NCT01941134|DRUG|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
219310341|NCT01329965|DRUG|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
219310342|NCT02728882|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
219310343|NCT02997371|DRUG|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
219310344|NCT02997371|DRUG|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
219310345|NCT05147883|BEHAVIORAL|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
219310346|NCT06257992|OTHER|Dry Needling|3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
219310347|NCT06257992|OTHER|Stretch|3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
219310348|NCT06493331|OTHER|Talking Circle|"step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received."
219310349|NCT00001023|DRUG|Clarithromycin|
219310350|NCT00001023|DRUG|Azithromycin|
219310351|NCT00001023|DRUG|Rifabutin|
219310352|NCT02306382|PROCEDURE|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
219310353|NCT02306382|DEVICE|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
219310354|NCT01596621|DRUG|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
219310355|NCT02373254|DRUG|Ibuprofen|Ibuprofen 400 mg and 800 mg
219310356|NCT02373254|DRUG|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
219310357|NCT04329832|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
219310358|NCT04329832|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
219310359|NCT03846141|OTHER|Placebo|Inhalation of room air for 20 min per day during 7 days
219310360|NCT03846141|OTHER|Hydrogen|Inhalation of 4% hydrogen for 20 min per day during 7 days
219310361|NCT03868605|DEVICE|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
219310362|NCT03868605|DEVICE|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
219310363|NCT02521467|BIOLOGICAL|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
219310364|NCT02521467|OTHER|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
219310365|NCT02491268|DRUG|Cilostazol|
219310366|NCT02491268|DRUG|Placebo|
219310367|NCT04757350|OTHER|Observational research, not applicable|Observational research, not applicable
219310368|NCT04283331|DRUG|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
219310369|NCT03037164|DEVICE|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
219310370|NCT03037164|DEVICE|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
219310371|NCT00253877|OTHER|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
219310372|NCT02237313|BEHAVIORAL|psychological support and therapeutic education program|
219310373|NCT02341859|DEVICE|stenfilcon A|contact lens
219310374|NCT02341859|DEVICE|delefilcon A|contact lens
219310375|NCT02341859|DEVICE|narafilcon A|contact lens
219310376|NCT05735821|OTHER|Giving breastfeeding training|The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
219310377|NCT01789125|DRUG|Nicotine Patch|
219310378|NCT01789125|BEHAVIORAL|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
219310379|NCT01789125|BEHAVIORAL|Education-Supportive Psychotherapy|
219310380|NCT03555474|PROCEDURE|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
219310381|NCT03555474|PROCEDURE|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
219310382|NCT03555474|PROCEDURE|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
219310383|NCT04729764|DRUG|GP681 Tablet|Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
219310384|NCT04613349|OTHER|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~1. New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~2. Gold standard: Intraoperative examination."
219310385|NCT03753672|DIAGNOSTIC_TEST|preload responsiveness|We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
219310386|NCT04598204|DRUG|Treatment with oral rapmycin|To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
219310387|NCT03878251|DEVICE|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
219310388|NCT04256434|DRUG|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
219310389|NCT04256434|DRUG|Nalbuphine HCl|20 mg Nalbuphine
219310390|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
219310391|NCT04584203|PROCEDURE|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
219310392|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
219310393|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
219310394|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
219310395|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
219310396|NCT04811209|OTHER|1.Baseline Measurements Before Surgery|"* Baseline demographic data~* Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~* Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~* Preoperative pain state using NRS (0-10)~* Preoperative functional state using the QoR-15 questionnaire~* Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~* Pain castastrophizing scale"
219310397|NCT04811209|OTHER|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
219310398|NCT04811209|OTHER|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~1. acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~2. NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~3. Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~4. In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
219310399|NCT04811209|OTHER|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
219310400|NCT04811209|OTHER|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
219310401|NCT04811209|OTHER|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
219310402|NCT04811209|OTHER|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
219310403|NCT04811209|OTHER|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
219310404|NCT05172427|BEHAVIORAL|14 days of EMI|Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
219310405|NCT05172427|BEHAVIORAL|Uncertainty reappraisal training|CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
219310406|NCT01439152|DRUG|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
219310407|NCT01439152|DRUG|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
219310408|NCT01439152|DRUG|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
219310409|NCT01439152|DRUG|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
219310410|NCT00334854|DRUG|doxorubicin hydrochloride|
219310411|NCT00334854|DRUG|ifosfamide|
219310412|NCT00334854|PROCEDURE|adjuvant therapy|
219310413|NCT00334854|PROCEDURE|conventional surgery|
219310414|NCT00334854|PROCEDURE|neoadjuvant therapy|
219310415|NCT00334854|RADIATION|radiation therapy|
219310416|NCT00421707|DRUG|GW876008|
219310417|NCT00421707|OTHER|Placebo|
219310418|NCT01546350|GENETIC|PGD|array CGH after blastocyst biopsy
219310419|NCT01546350|PROCEDURE|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
219310420|NCT00046254|DRUG|Zoledronic Acid|
219310421|NCT00657202|DRUG|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
219310422|NCT05261048|OTHER|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
219310423|NCT05261048|OTHER|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
219310424|NCT04331496|OTHER|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
219310425|NCT04331496|OTHER|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
219310426|NCT05386797|PROCEDURE|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
219310427|NCT03411447|OTHER|Parenteral nutrition|
219310428|NCT03411447|OTHER|Enteral nutrition|
219310429|NCT02876198|DEVICE|Gonioscopy|Study of the trabecular structure by gonioscopy
219310430|NCT05717231|BEHAVIORAL|laughter yoga|laughter yoga
219310431|NCT02880631|DEVICE|BAROSTIM NEO™ System|
219310432|NCT02868866|BEHAVIORAL|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
219310433|NCT01723254|BIOLOGICAL|IGE-1|Intramuscular, multiple dose
219310434|NCT01723254|BIOLOGICAL|IGE-2|Intramuscular, multiple dose
219310435|NCT01723254|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
219310436|NCT01074216|DRUG|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
219310437|NCT02870166|OTHER|blood sample|
219310438|NCT05848687|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
219310439|NCT05848687|DRUG|Mitoxantrone|Given IV
219310440|NCT05848687|DRUG|PEG asparaginase|Given IV
219310441|NCT05848687|DRUG|Bortezomib|Given IV
219310442|NCT05848687|DRUG|Vorinostat|Taken PO or NG
219310443|NCT05848687|DRUG|Mercaptopurine|Given PO or NG.
219310444|NCT05848687|DRUG|Methotrexate|Given IV, IM or PO
219310445|NCT05848687|DRUG|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
219310446|NCT05848687|DRUG|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
219310447|NCT00177034|DRUG|Narrow Band UVB Treatment|
219310448|NCT02763787|DRUG|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
219310449|NCT02763787|DRUG|Placebo|Identical placebo
219310450|NCT05260515|BEHAVIORAL|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
219310451|NCT05088018|OTHER|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
219310452|NCT05088018|OTHER|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
219310453|NCT02976701|DRUG|DLBS1033|
219310454|NCT02976701|DRUG|Placebo|
219310455|NCT02976701|DRUG|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
219310456|NCT03451760|DRUG|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
219310457|NCT03451760|OTHER|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
219310458|NCT04364009|DRUG|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
219310459|NCT04364009|DRUG|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
219310460|NCT01323634|DRUG|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
219310461|NCT01323634|DRUG|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
219310462|NCT05056987|DEVICE|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
219310463|NCT05056987|DEVICE|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
219310464|NCT05056987|DEVICE|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
219310465|NCT02035644|DRUG|Jinlida granules|
219310466|NCT02035644|DRUG|placebo granules|
219310467|NCT03466996|BEHAVIORAL|Intervention group|More frequent follow up with face to face interaction.
219310468|NCT03466996|BEHAVIORAL|Standard of care group|Transition goal setting during annual follow up.
219310469|NCT02294916|DEVICE|AWS|Video-laryngoscopy 1
219310470|NCT02294916|DEVICE|Intubrite|Video-laryngoscopy 2
219310471|NCT02294916|DEVICE|AirTraq|Optical-laryngoscopy
219310472|NCT02294916|DEVICE|MIL|Direct-laryngoscopy
219310473|NCT00004145|BIOLOGICAL|anti-thymocyte globulin|
219310474|NCT00004145|DRUG|cyclophosphamide|
219310475|NCT00004145|DRUG|fludarabine phosphate|
219310476|NCT00004145|PROCEDURE|peripheral blood stem cell transplantation|
219310477|NCT04497922|DEVICE|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
219310478|NCT04497922|BEHAVIORAL|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
219310479|NCT04304573|DIAGNOSTIC_TEST|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
219310480|NCT05532982|OTHER|Interviews and Surveys|Qualitative interviews and surveys
219310481|NCT00627211|PROCEDURE|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
219310482|NCT01280110|DRUG|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
219310483|NCT01280110|DRUG|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
219310484|NCT01249989|BEHAVIORAL|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
219310485|NCT01249989|BEHAVIORAL|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
219310486|NCT01249989|BEHAVIORAL|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
219310487|NCT03197779|DRUG|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
219310488|NCT03197779|DRUG|Aspirin|Oral administration
219310489|NCT03197779|OTHER|Placebo|Oral administration
219310490|NCT03080428|DIAGNOSTIC_TEST|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
219310491|NCT02678247|DEVICE|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
219310492|NCT02678247|DEVICE|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
219310493|NCT02038491|PROCEDURE|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
219310494|NCT06610708|OTHER|Cardiac Prehabilitation Program|Patients begin with a one-on-one assessment by a program cardiologist and a CR nurse, followed by a symptom-limited cardiopulmonary exercise test (CPET) to tailor their exercise regimen. The exercise program, based on the FITT (frequency, intensity, time, and type) principle, includes biweekly sessions either at home or at a commercial gym, with ongoing oversight by SJHC CRSP rehabilitation trainers. Additionally, participants have access to dietary counseling to optimize heart-healthy nutrition.
219310495|NCT06609564|DEVICE|inspiratory muscle training|Inspiratory muscle training with a pressure-adjustable device
219310496|NCT06609564|OTHER|Convantional chest physiotherapy|Chest physiotherapy
219310497|NCT07020000|DEVICE|Device: Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during standard interbody fusion surgeries.
219310498|NCT07019337|DRUG|Pyrotinib|400mg or 320mg qd
219310499|NCT07019337|DRUG|Capecitabine|500mg tid
219310500|NCT07019454|DEVICE|Physician Modified Endografting|This is the only intervention in the study
219310501|NCT07019233|DEVICE|Real Time Pressure Controller|The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance.
219310502|NCT07020299|DEVICE|Device : Digital electrical muscle stimulator is applied to induce diaphragm contraction.|TEDS group will be subjected to sessions of TEDS as follow : Digital electrical muscle stimulator (EV-906 Digital TENS/EMS made in TAIWAN) is applied to induce diaphragm contraction.
219310503|NCT07020416|DEVICE|Transcutaneous electrical acustimulation in automatic synchronization with breathing|This intervention will be carried out via the AutoSTEA device.
219310504|NCT07019623|DEVICE|Rüsch® Balloon Catheter Ch. 24|"After cesarean delivery, patients in the intervention group receive the following intervention: The Rüsch® Balloon Catheter Ch. 24 will be inserted directly into the uterus before uterotomy closure.~After insertion of the catheter, the catheter balloon is filled with 60 - 80 ml of 0.9% saline solution and connected to the vacuum device whereby an intrauterine vacuum of -60 to a maximum of -70 kPa is applied once the uterotomy is closed. Once the catheter has been positioned, it is left in place for one hour as a prophylactic measure while a vacuum is applied.~The device will be removed by draining the liquid in the balloon, after 1 hour of vacuum-induced tamponade. The final decision for removal of the catheter in this study is made by the senior physician responsible for the woman."
219310505|NCT07019623|OTHER|Ultrasonography|The position of the balloon catheter as well as the condition of the uterine cavity are assessed immediately postoperatively using ultrasonography.
219310506|NCT07019896|PROCEDURE|Minimal Vitrectomy Surgery|The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.
219310507|NCT07019896|PROCEDURE|Conventional Vitrectomy|Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.
219310508|NCT07021014|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
219310509|NCT07021014|DEVICE|Sham NightWare|NightWare decive will not deliver an intervention (i.e., no vibration)
219310510|NCT07020364|DEVICE|A single working element for bipolar enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~The bipolar energy will be used for cutting and coagulation during enucleation."
219310511|NCT07020364|DEVICE|A single working element for laser enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~Thulium or Holmium laser will be employed for tissue dissection and hemostasis."
219310512|NCT07020884|DRUG|ZT002 Injection|Administered SC
219310513|NCT07020884|DRUG|ZT002 Placebo|Administered SC
219310514|NCT07019584|OTHER|Wai Ji Match Fun card games|Group intervention using game activities with Wai Ji Match Fun cards. A total of eight group sessions, which last for 60 minutes each, will be conducted once a week for a period of 8 weeks.
219310515|NCT06187285|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
219310516|NCT06187285|DRUG|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
219310517|NCT07019545|DRUG|Belantamab Mafodotin|Belantamab mafodotin is administered intravenously (IV) at a dose of 1.9 mg/kg on Day 1 of every other 28-day cycle for the first two administrations and then 1.9 mg/kg on Day 1 of every third 28-day cycle.
219310518|NCT07019545|DRUG|Dexamethasone|Dexamethasone is administered IV or per OS (PO) at a dose of 40 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants \<75 years; at 20 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants ≥75 years.
219310519|NCT06693609|DRUG|EMP-01|EMP-01 capsules
219310520|NCT06693609|DRUG|EMP-01 Placebo|EMP-01 placebo capsules
219310521|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
219310522|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
219310523|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
219310524|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
219310525|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
219310526|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
219310527|NCT04687228|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
219310528|NCT04687228|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
219310529|NCT07020897|OTHER|Clinician-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by a physical therapist.
219310530|NCT07020897|OTHER|Self-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by the research participant.
219310531|NCT07020897|OTHER|Exercise-based physical therapy|In-clinic exercise-based physical therapy supervised by a physical therapist, with home exercises to be performed on days without a clinical visit.
219310532|NCT07020793|PROCEDURE|green subthreshold laser therapy|The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.
219310533|NCT07019493|OTHER|No Intervention: Observational Cohort|Not applicable: Observational cohort study
219310534|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
219310535|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
219310536|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
219310537|NCT05938231|DEVICE|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
219310538|NCT05938231|BEHAVIORAL|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
219310539|NCT03226275|DRUG|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
219310540|NCT03226275|DRUG|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
219310541|NCT03226275|DRUG|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
219310542|NCT02139787|OTHER|Radio Story|
219310543|NCT02139787|OTHER|Control -listened to a brochure|
219310544|NCT07019597|DEVICE|Non-invasive neuromodulation NESA(NNG)|NESA is a non-invasive monitoring device, which emits low frequency (1.3-14.28 Hz, depending on the programme), low intensity (0.1-0.9 mA), low voltage (±3 V) ultra low currents, and therefore imperceptible to the patient. It is based on neuromodulation of the autonomic nervous system.
219310545|NCT07019597|DEVICE|Non-invasive Neuromodulation Posterior Tibial (NTPG)|NTPG is an electrotherapy using a device called NEUROTRAC MYOPLUS PRO (brand name) to perform non-invasive TENS-type electrotherapy with biphasic currents.
219310546|NCT06728852|DRUG|Administration of Vorolanib|This study utilizes Vorolanib, a novel angiogenesis inhibitor, as a monotherapy for advanced non-small cell lung cancer (NSCLC) patients who have failed at least two lines of systemic therapy. Vorolanib is administered orally at a dosage of 300 mg daily. The intervention focuses on its efficacy and safety as a third-line or beyond treatment, aiming to improve progression-free survival (PFS) and other clinical outcomes. Vorolanib targets VEGFR, PDGFR, and other tyrosine kinases, distinguishing it from other therapies by its enhanced anti-angiogenesis properties and tolerable safety profile in late-stage cancer treatment.
219310547|NCT03337451|DRUG|OPN-305|Patients will receive study drug every 4 weeks
219310548|NCT05353933|OTHER|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
219310549|NCT05353933|DRUG|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
219310550|NCT06895122|PROCEDURE|High resistance training|Participants will perform the exercises at high speed, emphasizing explosive movements to maximize muscle power development.
219310551|NCT06895122|PROCEDURE|Multicomponent Training|Various exercise modalities are integrated, including aerobic training, mobility, strength, balance, and coordination exercises.
219310552|NCT03442114|BEHAVIORAL|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
219310553|NCT03442114|BEHAVIORAL|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
219310554|NCT02903368|DRUG|Apalutamide|
219310555|NCT02903368|DRUG|Leuprolide|
219310556|NCT02903368|DRUG|Prednisone|
219310557|NCT02903368|DRUG|Abiraterone Acetate|
219310558|NCT06892210|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
219310559|NCT06892210|DRUG|Hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
219310560|NCT06828172|BEHAVIORAL|Exercise|Two conditions will be tested: Arm-cranking and control condition.
219310561|NCT06888817|DRUG|Bevacizumab|Intravenous bevacizumab at a 600 mg flat dose every three weeks for four courses over 12 weeks
219310562|NCT06888817|DRUG|Dexamethasone|Daily oral dexamethasone followed by a protocol-based tapering dose over 12 weeks
219310563|NCT06805136|BEHAVIORAL|Community-based social interaction intervention|The intervention focuses on free or low-cost social interaction by offering community initiatives and activities, online spaces for interaction, and social events to young and working-age adults in London. Activities include but are not limited to social walks, bingo nights, board game afternoons and pub quizzes.
219310564|NCT06809270|BEHAVIORAL|Walking training intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
219310565|NCT06766162|OTHER|Virtual reality pain distraction|The intervention group in this study will undergo their EMR and ESD procedure with the addition of virtual reality (VR) as a supportive tool. Participants in this group will use a VR headset during the procedure, designed to provide an immersive experience that may help manage pain and anxiety. The use of VR will be integrated alongside the standard care protocol, including routine sedation and pain management practices VR headset is from DRVR, Rescope innovation which is registered as medical device in the UK.
219310566|NCT06766162|OTHER|Standard analgesia and sedation|Standard local protocol for analgesia and sedation, incorporating fentanyl and midazolam.
219310567|NCT02245672|DRUG|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
219310568|NCT02245672|DRUG|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
219310569|NCT02245672|DRUG|Placebo|Placebo administered via the CRC749 and Diskus devices
219310570|NCT00003657|BIOLOGICAL|filgrastim|
219310571|NCT00003657|DRUG|Amifostine|
219310572|NCT00003657|DRUG|Carboplatin|
219310573|NCT00003657|DRUG|Etoposide|
219310574|NCT00003657|DRUG|Ifosfamide|
219310575|NCT00003657|PROCEDURE|peripheral blood stem cell transplantation|
219310576|NCT03740594|BEHAVIORAL|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
219310577|NCT02980237|OTHER|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
219310578|NCT02980237|OTHER|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
219310579|NCT06475443|DRUG|pyrotinib plus capecitabine|oral
219310580|NCT00153504|BEHAVIORAL|Housing and Health Study housing rental assistance|
219310581|NCT00153504|BEHAVIORAL|Standard local practice housing assistance|
219310582|NCT02947776|BEHAVIORAL|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
219310583|NCT02947776|BEHAVIORAL|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
219310584|NCT02580695|BIOLOGICAL|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
219310585|NCT02580695|DRUG|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
219310586|NCT00971932|DRUG|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.
219310587|NCT00971932|DRUG|Cisplatin/Carboplatin|Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
219310588|NCT00971932|DRUG|5-Fluorouracil|Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
219310589|NCT00889317|DEVICE|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
219354713|NCT03491332|DEVICE|conventional humidification circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
219310590|NCT05363423|PROCEDURE|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
219310591|NCT05363423|PROCEDURE|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
219310592|NCT02451241|OTHER|acupuncture|electroacupuncture
219310593|NCT01749020|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
219310594|NCT01749020|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
219310595|NCT02301598|PROCEDURE|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
219310596|NCT01305525|DEVICE|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
219310597|NCT01097785|DRUG|Simvastatin|40 mg, P.O.,daily for 30 days
219310598|NCT01097785|DRUG|Placebo|1 capsule daily for 30 days
219310599|NCT04334733|OTHER|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
219310600|NCT04334733|OTHER|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
219310601|NCT04334733|OTHER|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
219310602|NCT03940053|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
219310603|NCT01765192|DRUG|Roflumilast|Roflumilast was supplied in tablets.
219310604|NCT01765192|DRUG|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
219310605|NCT01765192|DRUG|Montelukast|Montelukast was supplied in tablets.
219310606|NCT03194815|DRUG|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
219310607|NCT03194815|DRUG|Placebo|This is the control, or sham, treatment
219310608|NCT03194815|DRUG|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
219310609|NCT05032768|RADIATION|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
219310610|NCT01322048|DRUG|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
219310611|NCT01322048|DRUG|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
219310612|NCT02797353|OTHER|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
219310613|NCT06445309|OTHER|Sensory test of functional plant-based drink|Once the volunteers have been recruited, a telephone interview lasting less than 10 minutes will be carried out where what the study consists of will be explained as well as the information sheet for the participant will be read to them so that they understand what the study consists of. study. Once the necessary questions have been asked according to the inclusion criteria, if the participant enters the study, data such as name, surname, age, gender, smoker, consumer of vegetable drinks, pathologies and contact information will be collected. If the participant does not enter the study, their personal data will no longer be collected and they will be informed that according to the exclusion criteria they can no longer participate in the study. Once these data are obtained, it will be randomized using the EXCEL program.
219310614|NCT00084578|DRUG|celecoxib|
219310615|NCT00084578|DRUG|rosiglitazone maleate|
219310616|NCT00084578|PROCEDURE|conventional surgery|
219310617|NCT00084578|PROCEDURE|neoadjuvant therapy|
219310618|NCT03258333|PROCEDURE|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
219310619|NCT00519961|DEVICE|Elecsys®proBNP|
219310620|NCT04694898|BEHAVIORAL|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
219310621|NCT04694898|BEHAVIORAL|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
219310622|NCT01924351|RADIATION|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
219310623|NCT03282487|DRUG|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
219310624|NCT02918123|BIOLOGICAL|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
219310625|NCT04344600|DRUG|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
219310626|NCT04344600|OTHER|Saline|Saline subcutaneous injection
219310627|NCT00846339|DRUG|Bupropion|bupropion
219310628|NCT04261335|BIOLOGICAL|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
219310629|NCT00036686|DIETARY_SUPPLEMENT|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
219310630|NCT00036686|OTHER|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
219310631|NCT00837551|DRUG|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
219310632|NCT00876694|DRUG|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
219310633|NCT00876694|DRUG|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
219310634|NCT02773875|DEVICE|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
219310635|NCT03506282|OTHER|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
219310636|NCT03506282|OTHER|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
219310637|NCT03506282|OTHER|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
219310638|NCT04559880|DRUG|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
219310639|NCT01535014|DRUG|Dietressa|Comparison of different dosages (frequency) of drug
219310640|NCT01535014|DRUG|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
219310641|NCT01209845|DRUG|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
219310642|NCT04350216|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
219310643|NCT04549337|BEHAVIORAL|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity."
219310644|NCT01215422|PROCEDURE|timed intubation|timed intubation
219310645|NCT04925206|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
219310646|NCT01875172|DRUG|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
219310647|NCT01875172|DRUG|placebo|
219310648|NCT01875172|BEHAVIORAL|smoking cessation counseling|
219310649|NCT01816854|DEVICE|Stenting|
219310650|NCT01708122|DRUG|Fentanyl|100 mcg in 1 mL intranasal spray
219310651|NCT01708122|DRUG|saline|Sodium Chloride 0.9% intranasal spray
219310652|NCT05175651|BEHAVIORAL|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
219310653|NCT06096896|PROCEDURE|MWA|Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
219310654|NCT05817760|PROCEDURE|Z-scrotoplasty|Z shape incision of the penoscrotal web and closure
219310655|NCT05817760|PROCEDURE|Heineke-Mikulicz scrotoplasty|Transverse incision of the penoscrotal web with vertical closure
219310656|NCT00294554|DRUG|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
219310657|NCT00294554|DRUG|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
219310658|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
219310659|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
219310660|NCT00710281|RADIATION|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
219310661|NCT00219713|DRUG|nitrous oxide and oxygen|
219310662|NCT04788576|DIAGNOSTIC_TEST|Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)|In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
219310663|NCT02822170|OTHER|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
219310664|NCT02909270|DEVICE|Mediclore|to apply mediclore fully around thyroid gland
219310665|NCT03516851|PROCEDURE|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
219310666|NCT00462865|DRUG|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
219310667|NCT04592861|RADIATION|carbon ion RT|daily carbon ion radiotherapy
219310668|NCT04592861|DRUG|Chemotherapy drug|Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
219310669|NCT00863863|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
219310670|NCT00863863|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
219310671|NCT05477381|DIAGNOSTIC_TEST|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
219310672|NCT04886310|DIAGNOSTIC_TEST|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
219310673|NCT02864381|DRUG|Andecaliximab|800 mg administered via IV infusion
219310674|NCT02864381|DRUG|Nivolumab|3 mg/kg administered via IV infusion
219310675|NCT01438021|OTHER|pharmacological study|Correlative studies
219310676|NCT01438021|DRUG|methotrexate|Given intraventricularly
219310677|NCT00152139|PROCEDURE|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
219310678|NCT00152139|DRUG|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
219310679|NCT04507061|DRUG|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
219310680|NCT04507061|OTHER|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
219310681|NCT02245126|DRUG|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
219310682|NCT02245126|DRUG|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
219310683|NCT05995639|PROCEDURE|Dry Needling|Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.
219310684|NCT05995639|PROCEDURE|Ozone Injection|Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
219310685|NCT05871255|OTHER|Zantogin® Gel|Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
219310686|NCT01992042|DRUG|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
219310687|NCT01992042|DRUG|Pimonidazole|
219310688|NCT01769235|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
219310689|NCT01769235|DRUG|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
219310690|NCT01769235|DRUG|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
219310691|NCT04292002|BEHAVIORAL|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
219310692|NCT00007917|DRUG|alvocidib|
219310693|NCT00007917|DRUG|gemcitabine hydrochloride|
219310694|NCT04142450|DEVICE|CoolSculpting® System|Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
219310695|NCT02262143|DRUG|Rosuvastatin|Rosuvastatin 10 mg, qd, po
219310696|NCT02262143|DRUG|Fenofibrate|Fenofibrate 160mg, qd, po
219310697|NCT01767207|OTHER|mental disorders|mental disorders
219310698|NCT01767207|BEHAVIORAL|screening for mental disorders|screening for mental disorders
219310699|NCT00474669|DRUG|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
219310700|NCT05172167|DIAGNOSTIC_TEST|Levels of IgG and IgM SARS-CoV-2 antibodies blood test.|0,1,2 months
219310701|NCT05172167|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2 nasopharyngeal swab|0,1,2 months
219310702|NCT00480584|DRUG|gemcitabine|Levels 1 through 4: 1000 mg/m\^2
219310703|NCT00480584|DRUG|capecitabine|Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
219310704|NCT00480584|DRUG|erlotinib|Levels 1 through 4: 100 mg
219310705|NCT05579158|BEHAVIORAL|Mobile application and wearable device|Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
219310706|NCT05579158|BEHAVIORAL|Time-restricted eating|Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
219310707|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
219310708|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
219310709|NCT01177605|OTHER|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
219310710|NCT00861835|OTHER|ROSE|rapid on-site evaluation by cytopathology
219310711|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
219310712|NCT06292650|DRUG|ZM-02-L|rAAV-PsCatCh2.0 intravitreal injection of low dose
219310713|NCT06292650|DRUG|ZM-02-H|rAAV-PsCatCh2.0 intravitreal injection of high dose
219310714|NCT06292650|PROCEDURE|ZM-02-S|sham intravitreal injection of ZM-02 (not actual injection)
219745087|NCT06112015|OTHER|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
219745088|NCT06149169|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor(CAR) T Cells|Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
219745089|NCT00712283|DRUG|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
219745090|NCT05903079|DEVICE|s-Tdcs|Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
219310715|NCT05171439|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
219310716|NCT02377791|GENETIC|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5\*1/\*1 vs CYP3A5\*1/\*3 or CYP3A5\*3/\*3
219310717|NCT00647673|DRUG|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
219310718|NCT00647673|DRUG|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
219310719|NCT05165147|OTHER|no intervention|no intervention
219310720|NCT02752646|DRUG|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
219310721|NCT02752646|DRUG|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
219310722|NCT02598752|OTHER|Symptom-limited cardiopulmonary exercise test (CPET)|
219310723|NCT02598752|OTHER|Resting assessment of cardiac function by echocardiography|
219310724|NCT02598752|OTHER|Post-exercise assessment of cardiac function by echocardiography|
219310725|NCT02598752|OTHER|Pulmonary function|
219310726|NCT02598752|BEHAVIORAL|Patient-reported outcomes questionnaire|
219310727|NCT01744951|BEHAVIORAL|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
219310728|NCT01146054|DEVICE|CyberKnife based stereotactic radiotherapy|"1. Initial orthogonal images will be obtained to confirm location of fiducial seeds.~2. Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~3. Quality assurance will be performed as per standard practice at each participating institution."
219745091|NCT03709017|DRUG|Ponatinib|Iclusig 45mg, 15mg
219745092|NCT05308810|PROCEDURE|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
219745093|NCT03514576|DRUG|Pasireotide 0.3 MG/ML|See arm description
219745094|NCT03514576|DIAGNOSTIC_TEST|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
219745095|NCT01055951|DEVICE|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
219745096|NCT02892279|OTHER|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
219310729|NCT01146054|DRUG|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
219310730|NCT01146054|DRUG|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
219310731|NCT02422056|DRUG|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
219310732|NCT02422056|DRUG|Saline|Infusion of saline in the same rate used for the intervention group
219310733|NCT03439176|OTHER|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
219745097|NCT02263547|DRUG|teriflunomide|
219745098|NCT02263547|DRUG|Colestipol|
219745099|NCT00245479|DRUG|Primary nocturnal enuresis|Desmopressin
219745100|NCT00038935|DRUG|ReFacto AF|
219745101|NCT04720807|DRUG|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
219745102|NCT05751109|PROCEDURE|ipack+adduktor kanal|nerve block
219745103|NCT04519333|PROCEDURE|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
219745104|NCT00095576|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016."
219745105|NCT00095576|DRUG|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
219745106|NCT03287986|OTHER|MRI|Structural and functional sequences
219745107|NCT01344356|RADIATION|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
219745108|NCT01344356|RADIATION|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
219745109|NCT04862494|OTHER|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
219745110|NCT04862494|PROCEDURE|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
219745111|NCT02033408|DRUG|AB (antibiotics)|"1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
219745112|NCT02033408|DRUG|CS (corticosteroids) Only|"1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
219745113|NCT05858931|PROCEDURE|vaginal repair|vaginal repair
219745114|NCT01138722|RADIATION|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
219745115|NCT02911727|PROCEDURE|Fast-track discharge|As described above
219310734|NCT03439176|OTHER|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
219310735|NCT03439176|OTHER|PL4|This strip contains a new adhesive
219310736|NCT03439176|OTHER|PL16-L|This strip contains a new adhesive
219310737|NCT02237651|DEVICE|topical anesthesia multi-use device|
219310738|NCT02237651|DEVICE|topical anesthesia Intranasal Mucosal Atomization|
219310739|NCT02397811|DIETARY_SUPPLEMENT|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
219310740|NCT02397811|DIETARY_SUPPLEMENT|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
219310741|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
219310742|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
219310743|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
219310744|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
219310745|NCT04335812|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
219310746|NCT04643509|DEVICE|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
219310747|NCT02113241|DRUG|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
219310748|NCT02113241|DRUG|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
219310749|NCT02065141|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
219310750|NCT06328426|DIETARY_SUPPLEMENT|Vitamin D|The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
219310751|NCT06328426|DIETARY_SUPPLEMENT|Omega-3|The dose of omega-3 will be 1000 mg /day taken orally. The duration of the intervention will be 4 months.
219310752|NCT06328426|DRUG|Metformin|The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
219310753|NCT06328426|DIETARY_SUPPLEMENT|Placebo|The duration of the intervention will be 4 months.
219310754|NCT04847960|DIETARY_SUPPLEMENT|BioGaia Probiotic Lozenges|BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
219310755|NCT00216697|DRUG|bortezomib|
219310756|NCT02090374|OTHER|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
219310757|NCT02090374|OTHER|Poly I:C|Single dose: 500ug
219310758|NCT02090374|OTHER|R848|High dose: 10ug Low dose: 1-2ug
219310759|NCT02090374|OTHER|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
219310760|NCT02090374|OTHER|Vitamin D|4000U orally
219310761|NCT02090374|OTHER|Tuberculin|Tuberculin PPD
219310762|NCT01249937|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
219310763|NCT01249937|DRUG|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
219310764|NCT03243045|PROCEDURE|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
219310765|NCT04744051|DRUG|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
219310766|NCT04744051|DRUG|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
219745116|NCT06456892|DRUG|Pucotenlimab|Pucotenlimab Combined with Standard Chemotherapy Regimen
219745117|NCT02692534|OTHER|Urine cocaine negative|Preoperative urine cocaine negative
219745118|NCT02692534|OTHER|Urine cocaine positive|Preoperative urine cocaine positive
219745119|NCT05880524|DRUG|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
219745120|NCT05880524|DRUG|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
219745121|NCT00121979|DRUG|Racivir, a non-nucleoside reverse transcriptase inhibitor|
219745122|NCT04967456|DIAGNOSTIC_TEST|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
219745123|NCT02673021|PROCEDURE|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
219745124|NCT00674102|DRUG|ASA404|
219745125|NCT05876520|PROCEDURE|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
219745126|NCT06392425|OTHER|caspase 3 and ADAM 17 biomarkers|Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
219745127|NCT02156947|PROCEDURE|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
219745128|NCT00924092|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces Cerevisia|
219745129|NCT00924092|DRUG|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
219745130|NCT00000684|DRUG|Dextran sulfate|
219745131|NCT01128517|BEHAVIORAL|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
219745132|NCT01128517|BEHAVIORAL|Education|Maternal education on complementary food
219745133|NCT01910155|DRUG|Ciprofloxacin/Dexamethasone|
219745134|NCT01910155|DRUG|Ciprodex (R)|
219745135|NCT01910155|DRUG|Placebo|
219745136|NCT01537328|OTHER|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
219745137|NCT00145730|DRUG|Ibuprofen|
219745138|NCT04618094|OTHER|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
219745139|NCT04556006|OTHER|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
219745140|NCT02014467|DRUG|Denosumab|Injection
219745141|NCT02014467|DRUG|Placebo|Injection
219745142|NCT02014467|DIETARY_SUPPLEMENT|Elemental Calcium|Oral, at least 600 mg
219745143|NCT02014467|DIETARY_SUPPLEMENT|Vitamin D|Oral, at least 400 IU
219745144|NCT00213525|OTHER|Questionnary for environmental factors research|Questionnary for environmental factors research
219310767|NCT04744051|DRUG|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
219310768|NCT04744051|DRUG|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
219310769|NCT04047238|OTHER|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~* Welcome to the patient and reality orientation therapy (7 minutes)~* Conducting the main activity of reminiscence (40 minutes)~* Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
219310770|NCT06024681|OTHER|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
219310771|NCT03249714|DRUG|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
219310772|NCT03249714|DRUG|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
219310773|NCT05512754|DRUG|Ibuprofen 400 mg|400 mg tablet
219310774|NCT03906435|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
219310775|NCT00605644|DRUG|MOA-728|Oral Capsules
219310776|NCT00605644|DRUG|Placebo|Placebo
219310777|NCT04805190|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
219310778|NCT04805190|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
219310779|NCT02866084|DEVICE|Device|"The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
219310780|NCT04385420|DRUG|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
219310781|NCT04385420|DRUG|Placebo oral tablet|Placebo film-coated tablet administered via oral route
219310782|NCT03008707|PROCEDURE|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
219310783|NCT00180570|DEVICE|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
219310784|NCT03832634|DIAGNOSTIC_TEST|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
219310785|NCT04146415|DIAGNOSTIC_TEST|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
219310786|NCT00790764|BIOLOGICAL|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
219310787|NCT00790764|OTHER|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
219310788|NCT05781776|OTHER|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
219310789|NCT05781776|OTHER|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
219310790|NCT01607554|DRUG|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
219310791|NCT03525899|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
219310792|NCT05722132|BEHAVIORAL|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
219310793|NCT05722132|BEHAVIORAL|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
219310794|NCT05722132|BEHAVIORAL|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
219310795|NCT05722132|BEHAVIORAL|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
219310796|NCT01619150|DRUG|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
219310797|NCT01619150|DRUG|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
219310798|NCT04174144|PROCEDURE|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
219310799|NCT00882453|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
219310800|NCT01601483|DRUG|MC-1101|1% Ophthalmic Solution TID
219310801|NCT01601483|DRUG|MC-1101 Vehicle|Ophthalmic solution, TID
219310802|NCT03072277|DIETARY_SUPPLEMENT|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
219310803|NCT03072277|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
219310804|NCT06401460|OTHER|Yannianjiuzhuan method combined with reverse breathing training|"Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days."
219310805|NCT02827357|OTHER|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
219310806|NCT00096057|BIOLOGICAL|monoclonal antibody HuHMFG1|
219310807|NCT01240083|DEVICE|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
219310808|NCT01240083|DEVICE|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
219310809|NCT01240083|DEVICE|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
219310810|NCT06582719|DEVICE|GPT-based counseling|AI-based counseling provided to the patient, accessible on their smartphone device at the time of Gestational Diabetes diagnosis
219310811|NCT06582719|OTHER|Nutritional Counseling|Standard Nutritional Counselling provided by a registered dietician at the time of Gestational Diabetes diagnosis
219310812|NCT03825484|DRUG|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
219310813|NCT06186726|RADIATION|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
219310814|NCT06555588|BEHAVIORAL|ENGAGE|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.
219310815|NCT06555588|BEHAVIORAL|Supportive Care|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
219310816|NCT06801860|BEHAVIORAL|Very brief smoking cessation advice|All participants will receive very brief smoking cessation advice (guided by the AWARD model, assess, warning, refer, and do-it-again) with a smoking cessation information booklet onsite at baseline.
219310817|NCT06801860|BEHAVIORAL|Chewing gum|Participants in the intervention group will receive 1-2 packs of chewing gum over a 1-week intervention period.
219310818|NCT06801860|BEHAVIORAL|Chewing gum usage leaflet|A leaflet of usage tips for chewing gum, including 1) the potential benefits of chewing gum, 2) suitable usage time and dosage, and 3) the proper disposal of used gum.
219310819|NCT06215573|DIETARY_SUPPLEMENT|Melatonin|5mg melatonin supplement, once daily, from Ritual BioSeries
219310820|NCT06215573|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement, once daily, from Ritual BioSeries
219310821|NCT06063564|BEHAVIORAL|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
219310822|NCT06063564|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
219310823|NCT01139021|BIOLOGICAL|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
219310824|NCT00917605|OTHER|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
219310825|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight sleep and morning wake|Overnight period and morning period device measurements
219310826|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight wake and morning sleep|Overnight period and morning period device measurements
219310827|NCT00592085|BEHAVIORAL|Questionnaires|Participants will use a computer to complete a series of questionnaires.
219310828|NCT00592085|BEHAVIORAL|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
219310829|NCT00592085|BEHAVIORAL|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
219310830|NCT04140383|PROCEDURE|Cataract Surgery|Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
219310831|NCT01347346|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
219310832|NCT02573454|BEHAVIORAL|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
219310833|NCT00555542|DRUG|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
219310834|NCT04740892|OTHER|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
219310835|NCT04740892|OTHER|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
219310836|NCT04717284|OTHER|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
219310837|NCT04717284|OTHER|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
219310838|NCT04332601|BEHAVIORAL|Fatigue Management Therapy|14 sessions of 1h CBT intervention
219310839|NCT04332601|OTHER|TAU (Treatment as usual)|No CBT intervention
219310840|NCT04958850|OTHER|a cross-sectional survey|Collect the data of this year and compare it with that of ten years ago
219310841|NCT02558192|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
219310842|NCT02558192|DIETARY_SUPPLEMENT|PLACEBO|1 vials q12 for 15 days
219310843|NCT02685943|BEHAVIORAL|Psychotherapy|
219310844|NCT03333187|PROCEDURE|Allogeneic stem cell transplantation|
219310845|NCT03333187|DRUG|Ruxolitinib continuous therapy|
219310846|NCT02853721|OTHER|iPTH|iPTH assay six hours after surgery
219310847|NCT02853721|OTHER|no dosage of iPTH|Ca and P on postoperative day 1 and 2
219310848|NCT00157183|DEVICE|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
219310849|NCT00303641|DEVICE|Medtronic Resting Heart Bypass System|
219310850|NCT05592314|OTHER|No intervention|No intervention
219310851|NCT02159430|OTHER|Clinical and psychopathological assessment of HAE patients|
219310852|NCT05309343|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
219310853|NCT03203720|BEHAVIORAL|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
219310854|NCT04589754|DRUG|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
219310855|NCT04589754|DRUG|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
219310856|NCT01026454|DRUG|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
219310857|NCT01026454|DRUG|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
219310858|NCT00265421|PROCEDURE|Suture technique for perineal repair after delivery|
219310859|NCT02496520|BIOLOGICAL|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
219310860|NCT02496520|PROCEDURE|Surgery as needed by the patient´s tumor and stage|
219310861|NCT02496520|DRUG|Chemotherapy as needed by the patient´s tumor and stage|
219310862|NCT02496520|RADIATION|Radiation therapy as needed by the patient´s tumor and stage|
219310863|NCT06189560|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
219310864|NCT06189560|DRUG|SGB|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
219310865|NCT06058260|OTHER|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
219310866|NCT03231930|DEVICE|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
219310867|NCT03231930|DEVICE|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
219310868|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
219310869|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
219310870|NCT00751842|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
219310871|NCT03501160|OTHER|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
219310872|NCT01315951|BIOLOGICAL|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
219310873|NCT00430261|DRUG|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
219310874|NCT02325167|BEHAVIORAL|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
219310875|NCT02325167|BEHAVIORAL|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
219310876|NCT00394953|DRUG|Darbepoetin alfa|As prescribed, iv.
219310877|NCT00394953|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
219310878|NCT05593679|DIAGNOSTIC_TEST|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
219310879|NCT03586687|DRUG|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
219310880|NCT05712733|OTHER|Microbiological and histopathological investigation of bile and gallbladder wall specimens.|Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
219310881|NCT02629289|DRUG|HSP-130|
219310882|NCT02629289|DRUG|US-approved Neulasta|
219310883|NCT02629289|DRUG|EU-approved Neulasta|
219310884|NCT01769066|DRUG|Sequential Gefitinib With Pemetrexed/Platinum|
219310885|NCT01769066|DRUG|Pemetrexed/Platinum|
219310886|NCT01510522|DRUG|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
219310887|NCT01510522|DRUG|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month"
219310888|NCT00002184|DRUG|Nelfinavir mesylate|
219310889|NCT00002184|DRUG|Levocarnitine|
219310890|NCT00002184|DRUG|Adefovir dipivoxil|
219310891|NCT00002184|DRUG|Saquinavir|
219310892|NCT00002184|DRUG|Lamivudine|
219310893|NCT00002184|DRUG|Stavudine|
219310894|NCT00002184|DRUG|Zidovudine|
219310895|NCT00308386|BEHAVIORAL|Nurse Case Management intervention|Intervention is meeting with nurse case managers
219310896|NCT04371861|DEVICE|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
219310897|NCT03313453|DEVICE|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
219310898|NCT03313453|DEVICE|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
219310899|NCT01165645|DRUG|lopinavir|Given orally
219310900|NCT01165645|DRUG|ritonavir|Given orally
219310901|NCT01165645|GENETIC|polymerase chain reaction|Correlative studies
219310902|NCT01165645|OTHER|flow cytometry|Correlative studies
219310903|NCT01165645|OTHER|enzyme-linked immunosorbent assay|Correlative studies
219310904|NCT01165645|OTHER|laboratory biomarker analysis|Correlative studies
219310905|NCT01354171|DEVICE|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
219310906|NCT03286322|OTHER|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
219310907|NCT03286322|OTHER|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
219310908|NCT04328051|OTHER|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
219310909|NCT03549312|DRUG|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48."
219310910|NCT03549312|DRUG|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
219310911|NCT03549312|DRUG|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96."
219310912|NCT02917278|DIETARY_SUPPLEMENT|Meals|High Protein renal-specific meals
219310913|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
219310914|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
219310915|NCT02196714|DRUG|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
219310916|NCT02196714|DRUG|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
219310917|NCT00690833|DRUG|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
219310918|NCT05270174|OTHER|no intervention|no intervention
219310919|NCT03693456|OTHER|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
219310920|NCT02802098|DRUG|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
219310921|NCT02802098|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
219310922|NCT01592864|DRUG|Stannous Fluoride|dentifice
219310923|NCT01592864|DRUG|Sodium Monofluorophosphate|dentifrice
219310924|NCT04151953|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
219310925|NCT02171325|DRUG|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
219310926|NCT02271425|DRUG|Evacetrapib Tablet|Oral administration
219310927|NCT02271425|DRUG|Evacetrapib Intravenous|Intravenous administration
219310928|NCT02660307|OTHER|PROGRESS group|
219310929|NCT05090748|DEVICE|Echocardiographic.|Echocardiographic test.
219310930|NCT01365143|PROCEDURE|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
219310931|NCT01365143|PROCEDURE|Open Radical Prostatectomy|Open radical prostatectomy
219310932|NCT04652167|DIAGNOSTIC_TEST|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
219310933|NCT04652167|DIAGNOSTIC_TEST|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
219310934|NCT04652167|DIAGNOSTIC_TEST|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
219310935|NCT04626895|DEVICE|Paxman Scalp Cooling Device|Paxman scalp cooling device
219310936|NCT05792969|BEHAVIORAL|Functional measures and public health outcomes|"Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)"
219310937|NCT01185925|DRUG|Sildenafil|Sildenafil, 50 mg 3 times/day
219310938|NCT01185925|DRUG|Placebo|Placebo
219310939|NCT01384422|DRUG|GLPG0634|
219310940|NCT04189237|OTHER|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
219310941|NCT01056133|OTHER|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be\< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
219310942|NCT00073112|DRUG|ABT-751|
219310943|NCT02425930|PROCEDURE|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
219310944|NCT02425930|DRUG|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
219310945|NCT02858349|BEHAVIORAL|No intervention|No intervention
219310946|NCT02858349|BEHAVIORAL|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
219310947|NCT02120716|BEHAVIORAL|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
219310948|NCT00200434|DRUG|Nebivolol|
219310949|NCT00506233|BEHAVIORAL|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
219310950|NCT03353558|DEVICE|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
219310951|NCT05933187|DRUG|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
219310952|NCT05933187|DRUG|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
219310953|NCT05933187|DRUG|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
219310954|NCT05933187|DRUG|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
219310955|NCT00326469|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
219310956|NCT02536703|DEVICE|Lotus Valve System|Lotus Valve System
219310957|NCT00158899|DRUG|GW501516 oral tablets|
219310958|NCT05620251|DIAGNOSTIC_TEST|Blood test|Assessment of humoral immune response
219310959|NCT02166866|OTHER|Quality of Life Questionairre and Education|
219310960|NCT00231387|DRUG|rosiglitazone|
219310961|NCT01279512|DRUG|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
219310962|NCT01279512|DRUG|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
219310963|NCT01566656|DRUG|total lymphoid irradiation and anti-thymocyte globulin|"* TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
219310964|NCT04318951|BEHAVIORAL|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[…\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
219310965|NCT04318951|BEHAVIORAL|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
219310966|NCT01294683|DRUG|Simvastatin|
219310967|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
219310968|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant (N/LRPT)|
219310969|NCT01294683|DRUG|Placebo|
219310970|NCT05891912|OTHER|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~* 1 session per week: 15min small TABLET and 15min LIGHTS game.~* 1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
219310971|NCT05161832|BEHAVIORAL|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
219310972|NCT05161832|BEHAVIORAL|Placebo|Placebo ultrasound with no diagnosis of injury.
219310973|NCT01764113|BEHAVIORAL|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
219310974|NCT01764113|BEHAVIORAL|Standard dietary counselling|
219310975|NCT04669977|DIETARY_SUPPLEMENT|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
219310976|NCT00530296|BEHAVIORAL|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
219310977|NCT01975454|DRUG|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
219310978|NCT01975454|DRUG|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
219310979|NCT04258527|DRUG|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
219310980|NCT04646512|DIETARY_SUPPLEMENT|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
219310981|NCT04646512|OTHER|Physical training with Deep Water Running|There will be a physical training for eight weeks.
219310982|NCT00979433|DEVICE|Bubble CPAP|Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
219310983|NCT00979433|DEVICE|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
219310984|NCT03346941|DRUG|DAA treatment|Direct-acting antiviral-based treatment
219310985|NCT00367120|DRUG|Azithromycin Extended Release|
219310986|NCT00367120|DRUG|Amoxicillin/Clavulanate|
219310987|NCT01032382|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
219310988|NCT01032382|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
219310989|NCT02211144|DRUG|BIBR 796 BS|
219310990|NCT02211144|DRUG|Placebo|
219310991|NCT00412971|DRUG|Hexvix|Single installation, TURB
219310992|NCT00412971|OTHER|Standard white light cystoscopy|
219310993|NCT01051700|DRUG|GW786034|Investigational product
219310994|NCT01051700|OTHER|Placebo|Placebo
219310995|NCT00002566|DRUG|carboplatin|
219310996|NCT00002566|DRUG|cisplatin|
219310997|NCT00002566|DRUG|cyclophosphamide|
219310998|NCT00002566|DRUG|etoposide|
219310999|NCT00002566|DRUG|ifosfamide|
219311000|NCT00002566|DRUG|vinblastine sulfate|
219311001|NCT00002566|PROCEDURE|autologous bone marrow transplantation|
219311002|NCT00002566|PROCEDURE|conventional surgery|
219311003|NCT00002566|PROCEDURE|peripheral blood stem cell transplantation|
219311004|NCT04197726|OTHER|sbeIIa/b white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
219311005|NCT04197726|OTHER|Control white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
219311006|NCT02823626|DRUG|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
219311007|NCT05226754|DRUG|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
219311008|NCT05226754|DRUG|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
219311009|NCT05453019|DEVICE|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
219311010|NCT02934321|DIETARY_SUPPLEMENT|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
219311011|NCT02934321|DIETARY_SUPPLEMENT|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
219311012|NCT01098136|OTHER|Chiropractic|Manual treatment of musculoskeletal complaints
219311013|NCT01098136|OTHER|Conventional medical intervention|Medical, physiotherapy
219311014|NCT01098136|OTHER|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
219311015|NCT06242054|DIAGNOSTIC_TEST|Motor Function Assessment System|Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
219311016|NCT01793363|PROCEDURE|Tracheotomy|
219311017|NCT02708017|PROCEDURE|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
219311018|NCT02708017|PROCEDURE|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
219311019|NCT04005417|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
219311020|NCT04005417|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
219311021|NCT04005417|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
219311022|NCT02409368|DRUG|Nivolumab|
219311023|NCT04176302|DEVICE|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
219311024|NCT04176302|DIAGNOSTIC_TEST|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
219311025|NCT04176302|OTHER|Traditional clinical practice|The neurologists will receive the patient \& caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
219311026|NCT00186394|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
219311027|NCT03881618|PROCEDURE|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
219311028|NCT06349928|OTHER|Focus group or interview|Focus groups and qualitative interview will be conducted with dancers investigating thoughts, beliefs and behaviors related to injury. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
219311029|NCT05467423|DIETARY_SUPPLEMENT|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
219311030|NCT03634696|OTHER|mPCL|Smart phone application to support palliative care among late-stage cancer patients
219311031|NCT03634696|OTHER|Usual Care|Usual care through OCRI palliative care clinic
219311032|NCT05686382|PROCEDURE|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
219311033|NCT05686382|PROCEDURE|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
219311034|NCT02041520|DRUG|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
219311035|NCT02041520|OTHER|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
219311036|NCT05521802|BIOLOGICAL|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
219311037|NCT01759407|DRUG|Ropivicaine|
219311038|NCT01759407|DRUG|Epinephrine|
219311039|NCT01822236|OTHER|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
219311040|NCT01822236|OTHER|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
219311041|NCT02143557|OTHER|Fat-Modified Breast Milk|
219311042|NCT02143557|OTHER|MCT formula|
219311043|NCT03268122|OTHER|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
219311044|NCT03268122|OTHER|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
219311045|NCT03737474|DRUG|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
219311046|NCT04291820|PROCEDURE|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
219311047|NCT04291820|PROCEDURE|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
219311048|NCT02513745|DEVICE|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
219311049|NCT02513745|DEVICE|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
219311050|NCT01209143|DRUG|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
219311051|NCT01209143|DRUG|Rosiglitazone|Rosiglitazone was supplied in tablets.
219311052|NCT01209143|DRUG|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
219311053|NCT02954965|BEHAVIORAL|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
219311054|NCT02954965|BEHAVIORAL|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
219311055|NCT01848951|DRUG|Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
219311056|NCT01848951|DRUG|TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
219311057|NCT03068065|DRUG|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
219311058|NCT03068065|DRUG|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
219311059|NCT03068065|DRUG|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
219311060|NCT03078426|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
219311061|NCT03078426|OTHER|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
219311062|NCT00352911|DRUG|VGX-410 (Mifepristone)|
219311063|NCT00352911|DRUG|Placebo for VGX-410 (Mifepristone)|
219311064|NCT05358028|OTHER|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
219311065|NCT05358028|OTHER|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
219311066|NCT01775267|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy|
219311067|NCT01775267|PROCEDURE|Portal vein embolization or ligation|
219311068|NCT03717129|DRUG|Genvoya Oral dose|Single Genvoya oral dose directly observed
219311069|NCT03717129|DRUG|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
219311070|NCT01871753|OTHER|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
219311071|NCT00753272|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
219311072|NCT00753272|BIOLOGICAL|Fluarix TM|IM administration, two times one annual dose
219311073|NCT03107897|OTHER|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
219311074|NCT00971243|DRUG|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
219311075|NCT00971243|DRUG|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
219311076|NCT00971243|DRUG|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
219311077|NCT00971243|DRUG|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
219311078|NCT00971243|DRUG|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
219311079|NCT06046768|OTHER|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
219311080|NCT02686060|DEVICE|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
219311081|NCT01941797|BEHAVIORAL|interruption of oral hygiene|
219311082|NCT00517582|DRUG|HOE-140|Subcutaneous at time 0 and 6 hours
219311083|NCT00517582|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
219311084|NCT05631977|OTHER|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
219311085|NCT02513888|DIETARY_SUPPLEMENT|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
219311086|NCT02513888|DIETARY_SUPPLEMENT|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
219311087|NCT00414284|DRUG|Increased dose of Kaletra|
219311088|NCT04578613|DRUG|ICP-022|ICP-022 at a dose of 150mg, QD
219311089|NCT04578613|DRUG|Chlorambucil|0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
219311090|NCT04578613|DRUG|Rituximab|375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
219311091|NCT00369304|DRUG|pharmacokinetic (how the body absorbs and eliminates) interaction|
219311092|NCT06078839|DRUG|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
219311093|NCT06078839|DRUG|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
219311094|NCT00916825|BEHAVIORAL|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
219311095|NCT00697723|PROCEDURE|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
219311096|NCT02889003|DRUG|Pioglitazone + TKI|
219311097|NCT02265367|DRUG|Levomilnacipran|
219311098|NCT02265367|DRUG|Placebo|
219311099|NCT01847053|OTHER|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
219311100|NCT01847053|OTHER|Oatmeal|Oatmeal control, around 70g; without cinnamon
219311101|NCT00292877|DRUG|SB-240563 (Mepolizumab)|
219311102|NCT02866539|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
219311103|NCT02866539|DRUG|Placebo|Similar looking inactive powder
219311104|NCT04734327|PROCEDURE|Orthokine periradicular injection|Ultrasound guided injections
219311105|NCT04734327|PROCEDURE|Orthokine epidural injection|Ultrasound guided injections
219311106|NCT05900960|DIETARY_SUPPLEMENT|Tea|Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
219311107|NCT02935933|DRUG|bupivicaine|Paravertebral block
219311108|NCT02935933|DRUG|morphine|
219311109|NCT02935933|DRUG|Dexmedetomidine|
219311110|NCT02890394|OTHER|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
219311111|NCT03993860|DIETARY_SUPPLEMENT|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
219311112|NCT03993860|DIETARY_SUPPLEMENT|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
219311113|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
219311114|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
219311115|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
219311116|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
219311117|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
219311118|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
219311119|NCT05384262|DRUG|Rosuvastatin|Subjects will receive rosuvastatin orally.
219311120|NCT00606957|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
219311121|NCT04326504|OTHER|No intervention|This will be an observational study, no intervention will be performed
219311122|NCT00542529|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
219311123|NCT00002997|PROCEDURE|cryosurgery|
219311124|NCT04760054|BEHAVIORAL|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
219311125|NCT04760054|BEHAVIORAL|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
219311126|NCT04760054|BEHAVIORAL|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
219311127|NCT02924142|DEVICE|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
219311128|NCT02105350|DRUG|MEK 162|
219311129|NCT02105350|DRUG|Gemcitabine|
219311130|NCT02105350|DRUG|Oxaliplatin|
219311131|NCT04723186|DRUG|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
219311132|NCT03602456|OTHER|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
219311133|NCT04047589|BEHAVIORAL|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
219311134|NCT04047589|BEHAVIORAL|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
219311135|NCT00414687|DRUG|Ventavis (Iloprost, BAYQ6256)|
219311136|NCT01289171|DRUG|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
219311137|NCT00172107|DRUG|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
219311138|NCT00172107|DRUG|placebo|placebo powder for subcutaneous injection
219311139|NCT00172107|DRUG|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
219311140|NCT00172107|DRUG|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
219311141|NCT03244735|OTHER|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
219311142|NCT00026208|DRUG|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
219311143|NCT00026208|DRUG|Cyclophosphamide|650 mg/m², on week 1 and 5
219311144|NCT00026208|DRUG|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
219311145|NCT00026208|DRUG|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
219311146|NCT00026208|DRUG|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
219311147|NCT00026208|DRUG|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
219311148|NCT00026208|RADIATION|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
219311149|NCT00969410|BIOLOGICAL|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
219311150|NCT02846753|PROCEDURE|trans catheter heart valve replacement|trans catheter heart valve replacement
219311151|NCT05266586|DRUG|Obicetrapib|tablets
219311152|NCT05266586|DRUG|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
219311153|NCT05266586|OTHER|Obicetrapib placebo|tablets; no active ingredient
219311154|NCT05266586|OTHER|Ezetimibe placebo|capsules; no active ingredient
219311155|NCT00103051|DRUG|cisplatin|
219311156|NCT00103051|DRUG|gefitinib|
219311157|NCT00103051|DRUG|gemcitabine hydrochloride|
219311158|NCT00103051|PROCEDURE|conventional surgery|
219311159|NCT00103051|PROCEDURE|neoadjuvant therapy|
219311160|NCT02225353|DRUG|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
219311161|NCT02225353|DRUG|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
219311162|NCT02225353|DRUG|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
219311163|NCT00905112|OTHER|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
219311164|NCT00905112|OTHER|Standard OB Care|Receive standard obstetrical care
219311165|NCT02284451|OTHER|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
219311166|NCT00790322|DRUG|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
219311167|NCT00790322|OTHER|Placebo|Solution for oral use
219311168|NCT04002609|OTHER|oxygen|oxygen supplementation during brronchoscopy
219311169|NCT03528863|BEHAVIORAL|Online Mindfulness Meditation|Receive web-based mindfulness meditation
219311170|NCT03528863|OTHER|Questionnaire Administration|Ancillary studies
219311171|NCT04012229|GENETIC|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
219311172|NCT05765669|PROCEDURE|Percutaneous screw fixation|Surgical intervention in the form of percutaneous screw fixation
219311173|NCT05765669|OTHER|Pain management|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
219311174|NCT05765669|OTHER|Physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
219311175|NCT04908111|BIOLOGICAL|ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
219354714|NCT03491332|DEVICE|new humidifaction heat circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
219311176|NCT04908111|BIOLOGICAL|MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
219311177|NCT04908111|COMBINATION_PRODUCT|Standard of care treatment|Patients will continue to receive SoC treatment (chemotherapy and checkpoint inhibitor).
219311178|NCT04908111|BIOLOGICAL|MVA-NYESO (Route = IM injection, Dose = 1.5×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
219311179|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
219311180|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
219311181|NCT06565000|OTHER|AHA Not Instrumented then AHA Instrumented|First, the participant will undergo a performance assessment using the Assisting Hand Assessment test, following the standard protocol in the occupational therapy room. Subsequently, they will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Finally, a second round of assessment using the Assisting Hand Assessment will be conducted.
219311182|NCT06565000|OTHER|AHA Instrumented then AHA Not Instrumented|"First, the participant will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Then, will undergo a performance assessment using the Assisting Hand Assessment test.~Finally, they will go to the occupational therapy room where a second round of assessment using the Assisting Hand Assessment without markers will be conducted."
219311183|NCT05908045|OTHER|KAP Survey|This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
219311184|NCT04357197|DEVICE|Closed-loop|The system will be tested to see if it can avoid hypotension
219311185|NCT04020354|BEHAVIORAL|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
219311186|NCT04020354|BEHAVIORAL|Usual Care|Usual customary care
219311187|NCT02542111|DRUG|Bortezomib|Bortezomib IV
219311188|NCT02542111|DRUG|Gemcitabine|Gemcitabine IV
219311189|NCT02542111|DRUG|Dexamethasone|Dexamethasone IV
219311190|NCT02542111|DRUG|Cisplatin|Cisplatin IV
219311191|NCT00834145|DEVICE|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
219311192|NCT03207100|COMBINATION_PRODUCT|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
219311193|NCT03207100|COMBINATION_PRODUCT|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
219311194|NCT03499197|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
219311195|NCT03604523|DEVICE|Dilation by Balloon|Esophageal dilation by balloon device.
219311196|NCT03604523|DEVICE|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
219311197|NCT02074163|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
219311198|NCT02074163|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
219311199|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311200|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311201|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311202|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311203|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311204|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311205|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311206|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311207|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311208|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
219311209|NCT02074163|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219311210|NCT02074163|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
219311211|NCT05778877|DRUG|SEL-302|"SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR"
219311212|NCT05258045|RADIATION|F18 FDG|Radioactive material
219311213|NCT01162317|OTHER|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
219311214|NCT01162317|OTHER|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
219311215|NCT05462886|DEVICE|Masimo INVSENSOR00057|Noninvasive wearable health monitoring device
219311216|NCT03711175|PROCEDURE|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
219311217|NCT03711175|DEVICE|Shoulder implant|Reverse shoulder arthroplasty device
219311218|NCT06380855|PROCEDURE|Flexible colonoscope assisted hybrid transanal total mesorectal resection|Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
219311219|NCT00627263|BEHAVIORAL|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
219311220|NCT01005459|DRUG|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
219311221|NCT01005459|DRUG|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
219311222|NCT02280694|DRUG|Capecitabine|
219311223|NCT02280694|DRUG|Cyclophosphamide|
219311224|NCT02280694|DRUG|Methotrexate|
219311225|NCT02280694|DRUG|Celecoxib|
219311226|NCT03998982|DRUG|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
219311227|NCT03998982|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
219311228|NCT02730598|DEVICE|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
219311229|NCT02730598|DEVICE|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
219311230|NCT04633486|DIAGNOSTIC_TEST|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
219311231|NCT05344729|DRUG|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
219311232|NCT06176807|RADIATION|Venous Excess Ultrasound Score|"\-- The IVC diameter : Grade 0: \<5 mm with respiratory variation Grade I: 5-9 mm with respiratory variation Grade II: 10-19 mm with respiratory variation Grade III: \>20 mm with respiratory variation Grade IV: \>20 mm with minimal or no respiratory variation~\- Hepatic vein (HV) interrogation by pulsed wave Doppler identification and analysis of A, S, and D waves.~Grade 0: normal S \> D Grade I: S \< D with antegrade S Grade III: S flat or inverted or biphasic trace - Portal vein Doppler (PD)as follow: Grade 0: \<0.3 pulsatility index Grade I: 0.3-0.49 pulsatility index Grade III: 0.5-1.0 pulsatility index Pulsatility index is calculated as (Vmax - Vmin)/Vmax~\- VEXUS staging of venous congestion. (VEXUS ) Grade 0: IVC grade \<III, HD grade 0, PV grade 0 Grade I: IVC grade IV, but normal HV/PV pattern Grade II: IVC grade IV with mild flow pattern abnormalities in HV/PV Grade III: IVC grade IV with severe flow pattern abnormalities in HV/PV"
219311233|NCT03270423|DEVICE|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
219311234|NCT03270423|DEVICE|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
219311235|NCT05427604|OTHER|Olive oil|ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
219311236|NCT05427604|OTHER|Olive Oil|ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
219311237|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
219311238|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
219311239|NCT01675479|DEVICE|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
219311240|NCT02845843|DRUG|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
219311241|NCT02845843|DRUG|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
219311242|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
219311243|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
219311244|NCT04866251|DIAGNOSTIC_TEST|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
219311245|NCT01104116|RADIATION|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
219311246|NCT03813420|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
219311247|NCT03813420|BEHAVIORAL|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
219311248|NCT03813420|BEHAVIORAL|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
219311249|NCT05922293|OTHER|blow bottle|When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.
219311250|NCT05922293|OTHER|percussion|"Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises.~* Do this for a total of 10 breaths,~* Perform two huffs, and~* Cough.~* Close their mouth around the tube and exhale slightly forcefully for 3 seconds to produce bubbles. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized"
219311251|NCT02584803|RADIATION|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~1. Patient Acceptability of procedure~2. Patient Comfort:~3. Ease of exam for the examiner"
219311252|NCT06124287|DIAGNOSTIC_TEST|MR Enterography (MRE)|MRI scan
219311253|NCT05907278|BEHAVIORAL|Advanced Cooking Education|"Participants attend the ACE Program for 12 weeks after school.~On one assigned day of the week, participants attend ACE virtually. The session will begin with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes).~On any day during the week, the students will make a dish using groceries they received (1 hour)."
219311254|NCT00227474|DRUG|recombinant modified vaccinia Ankara-5T4 vaccine|
219311255|NCT00227474|PROCEDURE|adjuvant therapy|
219311256|NCT00227474|PROCEDURE|recombinant viral vaccine therapy|
219311257|NCT01340651|DRUG|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
219311258|NCT01722110|DRUG|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
219311259|NCT01722110|DRUG|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
219311260|NCT04216901|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a pathological prediction of the lesion during colonoscopy.
219311261|NCT00565539|DRUG|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
219311262|NCT04754204|DEVICE|Arrhythmia Management System (AMS)|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
219311263|NCT00125281|DRUG|S-adenosyl-methionine (SAMe) capsules|
219311264|NCT00024986|DRUG|Tenofovir DF|
219311265|NCT03622619|OTHER|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
219311266|NCT03622619|OTHER|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
219311267|NCT03531944|OTHER|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
219311268|NCT03531944|OTHER|Usual care|Usual care with physician and as needed visit to the nurse
219311269|NCT03774966|PROCEDURE|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter \& IPACK block
219311270|NCT03774966|PROCEDURE|Adductor canal block + catheter|Adductor canal block + catheter
219311271|NCT02181387|DRUG|Acetaminophen|administered every 6 hours by mouth up to 4 doses
219311272|NCT02181387|DRUG|Placebo|
219311273|NCT05678751|DIAGNOSTIC_TEST|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
219311274|NCT02715791|BEHAVIORAL|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
219311275|NCT02715791|OTHER|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
219311276|NCT01406340|DRUG|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
219311277|NCT05321147|BIOLOGICAL|lacutamab|Patients will receive a fixed dose of 750mg as 1-hour IV infusion
219311278|NCT03073265|DEVICE|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
219311279|NCT03866161|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment
219311280|NCT05367115|OTHER|longitudinal observational study|longitudinal observational study
219311281|NCT02849288|DEVICE|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
219311282|NCT01822509|BIOLOGICAL|Ipilimumab|Given IV
219311283|NCT01822509|OTHER|Laboratory Biomarker Analysis|Correlative studies
219311284|NCT01822509|BIOLOGICAL|Nivolumab|Given IV
219311285|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
219311286|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
219311287|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
219311288|NCT04740554|BEHAVIORAL|Control Group Typically Developing|Control group with tipical development.
219311289|NCT02823366|DRUG|Fenofibrate|
219311290|NCT02823366|DRUG|UDCA|
219311291|NCT05235230|DRUG|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
219311292|NCT05235230|DRUG|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
219311293|NCT01696942|DRUG|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
219311294|NCT01696942|DRUG|Mesalamine|mesalamine 800 mg orally three times daily
219311295|NCT04039256|DEVICE|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
219311296|NCT00921596|PROCEDURE|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
219311297|NCT00265746|DRUG|Metformin|
219311298|NCT00265746|BEHAVIORAL|Lifestyle intervention - diet, physical activity|
219311299|NCT06370260|DEVICE|Hydrogen Carbamide/Peroxide Gel|"UNISEPT® ORAL GEL is an oral gel containing 10% w/v urea peroxide which releases 3.50% w/w hydrogen peroxide, glycerin, propylene glycol, carbopol, disodium EDTA, sodium saccharin, methyl salicylate, menthol, and water, serving as the active ingredient.~Participants should apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0., i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following gel application.Participants are asked to maintain their usual oral hygiene routine.~UNISEPT® ORAL GEL is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A."
219311300|NCT06370260|DEVICE|Placebo Gel|"Placebo gel is a similar (look-and-taste-alike) product to UNISEPT® ORAL GEL, made by the same manufacturer, without active ingredients, containing glycerin, propylene glycol, carbomer, menthol, sodium saccharin, methyl salicylate, triethanolamine.~Participants are called upon to apply the gel in exactly the same way as the experimental product, i.e apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0."
219311301|NCT01668511|BIOLOGICAL|ABT-981|Injection
219311302|NCT01668511|BIOLOGICAL|Placebo|Placebo Injection
219311303|NCT05997498|PROCEDURE|mechanical cervical dilatation|mechanical cervical dilatation during elective cesarean section
219311304|NCT03666936|OTHER|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
219311305|NCT01142856|BIOLOGICAL|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
219311306|NCT04790019|BEHAVIORAL|Low energy availability|Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
219311307|NCT04790019|BEHAVIORAL|High impact jumping|Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
219311308|NCT03794570|DEVICE|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
219311309|NCT03794570|DEVICE|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
219311310|NCT05560347|OTHER|Hot water application|Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
219311311|NCT06499727|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
219311312|NCT06499727|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
219311313|NCT05972564|DRUG|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
219311314|NCT05972564|DRUG|Placebo|Placebo consists of gelatin capsules.
219311315|NCT00688103|DRUG|ETN Alone|etanercept (25 mg, twice/week, s.c.)
219311316|NCT00688103|DRUG|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
219311317|NCT06820710|OTHER|Physical activity|Appropriate exercises for supervised small group sessions will be prescribed by a physiotherapist or expert in exercise science. Each session will last approximately 40 minutes, three times a week, and will be based on the international guidelines for physical exercise in the elderly population, and the VIVIFRAIL Multicomponent Physical Exercise Program to Prevent Frailty and the Risk of Falls. Accelerometers and other wearable sensors (smartwatches) will be used to monitor the physical activity performed.
219311318|NCT06820710|OTHER|Cognitive stimulation|Cognitive stimulation will be delivered by expert neuropsychologists twice a week (48 sessions in total) for approximately 30 minutes. Residents will be divided into small groups (3-5 people) of similar cognitive level, and the intervention will be delivered using a computerized tool (REmote stimulation for COgnitive DEcline (RECODE) developed by researchers at the University of Padova with the aim of stimulating different domains (i.e., attention, working memory, visual memory, language, orientation and executive functions) through exercises of increasing difficulty.
219311319|NCT06820710|OTHER|Nutritional Intervention|Participants in the intervention group will be advised to follow a Mediterranean diet and will also receive functional foods; in particular, they will be offered 80 g/day of sourdough bread fortified with vegetable matrix rich in polyphenols (e.g., olive leaves) and 100 g/day of probiotic artichokes on alternate days.
219311320|NCT06820710|OTHER|Vaccinations|Participants in the intervention group will be offered to receive appropriate vaccinations according to the national vaccination calendar. Vaccine doses will be provided by the Department of Preventive Medicine, Vaccine Office, National Health Service, on prescription from the general practitioners.
219311321|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
219311322|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
219311323|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
219311324|NCT04980443|DIAGNOSTIC_TEST|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
219311325|NCT06598605|BEHAVIORAL|Parental Reflective Functioning Workshop|Four online workshop sessions via Zoom will be based on psycho-educational knowledge concerning emotional regulation and specialized in autism. The group size will be up to 15 participants, with each session lasting an hour and a half, after which participants will be asked to complete a reflective journal.
219311326|NCT06610253|DIETARY_SUPPLEMENT|Protein|"Controlled, randomized, single-blind, parallel-group, prospective. Planned, parallel, randomized, single-blind, controlled clinical trial (RCT). Participants will be randomly assigned to one of four interventions: Whey Protein Concentrate - WPC, Pea Protein Isolate - PPI, Rice Protein ISOLATE - RPI, a combination of PPI and RPI to see if the intervention works together in synergy.~The experiment was scheduled for week 8. Each participant will consume 30g of a dedicated preparation every day for 8 weeks. The planned measurements will be performed three times - before the experiment begins, after 4 and 8 weeks."
219311327|NCT06610136|DIETARY_SUPPLEMENT|Caffeine plus Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
219311328|NCT06610136|OTHER|Placebo + Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
219311329|NCT05180669|OTHER|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
219311330|NCT05180669|OTHER|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
219311331|NCT04715178|OTHER|No intervention- registry only|No intervention- registry only
219311332|NCT06991803|OTHER|root canal treatment and irrigation activation|After the teeth were isolated with a rubber dam, the endodontic access cavity was opened. Then, #10-15 K-type hand files were inserted into the canals, and after determining point 0.0 with the electronic apex locator, the working length was determined to be 0.5 mm shorter than this point and confirmed radiographically. When a discrepancy was observed, the apex locator was considered correct. The root canals were prepared with ProTaper Next up to 3 sizes larger than the initial diameter via a torque-controlled endodontic motor in 300 rpm/2-5.2 Ncm rotation mode. Between each file, the canals were irrigated with 5 ml of 2.5% NaOCl. In retreatment cases, after opening the access cavity under rubber dam isolation, the guta percha was removed with RT files, and the rest of the procedure was performed in the same manner as for primary root canal treatment.
219311333|NCT06609369|BEHAVIORAL|Experimental health intervention|Behavioral health intervention
219311334|NCT06609369|DRUG|Varenicline|Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily; Days 8-56: 1.0mg twice daily.
219311335|NCT00322205|DRUG|zyban|
219311336|NCT06527794|BEHAVIORAL|RHYTHM (Remote Hypertension Tracking Help Management)|Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners
219311337|NCT06527794|BEHAVIORAL|Enhanced usual care (UC)|All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.
219311338|NCT06609720|PROCEDURE|(guided tissue regeneration)|Randomized clinical and radiographic trial
219311339|NCT01313117|DRUG|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
219311340|NCT00434915|DRUG|DHEA|
219311341|NCT07011628|OTHER|Same Day Discharge|Patients in the same day discharge arm will be discharged from the hospital within 6 hours of arriving to the recovery unit and without an overnight stay in the hospital.
219311342|NCT01350453|BEHAVIORAL|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
219311343|NCT01350453|BEHAVIORAL|Standard Care|Participants will receive their usual care from their NHS provider.
219311344|NCT07019181|DRUG|Tislelizumab|Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
219311345|NCT07019181|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks
219311346|NCT07019181|DRUG|Nedaplatin|Nedaplatin 80mg/m2，day 1 of every 3 weeks
219311347|NCT07021261|DRUG|Utidelone plus capecitabine|UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
219311348|NCT07021261|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
219311349|NCT07019428|PROCEDURE|Free gingival graft stabilized by Titanium fixation tacs|Free gingival graft stabilized by Titanium fixation tacs , in patients with inadequate keratinized gingiva
219311350|NCT07019428|PROCEDURE|Free gingival graft stabilized by sutures|Free gingival graft stabilized by sutures , in patients with inadequate keratinized gingiva
219311351|NCT07020182|OTHER|physical therapy program|Group A will performed a physical therapy program that completed two daily sessions till discharge from the hospital .Exercise training starts from randomisation until hospital discharge,and administered twice per day, seven times per week. The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
219311352|NCT06697145|PROCEDURE|Cardioneuroablation|Ablation of parasympathetic ganglia of the heart
219311353|NCT01389427|DRUG|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311354|NCT01389427|DRUG|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311355|NCT01389427|DRUG|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311356|NCT01389427|DRUG|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311357|NCT01389427|DRUG|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311358|NCT01389427|DRUG|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311359|NCT01389427|DRUG|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311360|NCT01389427|DRUG|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311361|NCT01389427|DRUG|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311362|NCT01389427|DRUG|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311363|NCT01389427|DRUG|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311364|NCT01389427|DRUG|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
219311365|NCT06829498|DRUG|BCAA|The three BCAAs will be combined together and dissolved in a flavored solution.
219311366|NCT06829498|OTHER|Placebo|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
219311367|NCT06112834|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
219311368|NCT02123433|BIOLOGICAL|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
219311369|NCT00285987|PROCEDURE|Reconstruction of the cruciate ligament|
219311370|NCT00948493|DRUG|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
219311371|NCT03797079|PROCEDURE|ESP block|A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
219311372|NCT03797079|PROCEDURE|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
219311373|NCT03797079|DEVICE|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
219311374|NCT03797079|DRUG|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
219311375|NCT00193687|DRUG|bifeprunox|
219311376|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
219311377|NCT03017274|OTHER|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
219311378|NCT00229411|BEHAVIORAL|simulation training|
219311379|NCT03253926|DRUG|Lorcaserin|Lorcaserin 10mg BID
219311380|NCT03253926|DRUG|Placebo|Placebo capsule BID
219311381|NCT03253926|DRUG|Marijuana|Smoked marijuana cigarette
219311382|NCT05328323|OTHER|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
219311383|NCT01882751|DEVICE|Conformis CR Total Knee Replacement|iTotal CR by Conformis
219311384|NCT01882751|DEVICE|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
219311385|NCT02869776|BEHAVIORAL|Questionnaire|Behavioral questionnaires
219311386|NCT02869776|PROCEDURE|Rapid finger stick|HIV and HCV testing through rapid finger stick
219311387|NCT02869776|PROCEDURE|Venipuncture|HIV and HCV testing through venipuncture
219311388|NCT00906360|DRUG|sunitinib malate|Given orally or by percutaneous gastrostomy tube
219311389|NCT00906360|OTHER|pharmacological study|Correlative studies
219311390|NCT00906360|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
219311391|NCT00906360|BIOLOGICAL|cetuximab|Given IV
219311392|NCT02300909|PROCEDURE|Lumbar Decompression Surgery|Lumbar Decompression Surgery
219311393|NCT02300909|PROCEDURE|Microdiscectomy Surgery|Microdiscectomy Surgery
219311394|NCT02300909|OTHER|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
219311395|NCT00747825|DRUG|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
219311396|NCT05988554|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
219311397|NCT05988554|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract and collagen products|Consume 1 sachet daily
219311398|NCT02847741|OTHER|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
219311399|NCT03142763|OTHER|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
219311400|NCT03142763|DIETARY_SUPPLEMENT|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
219311401|NCT03437018|OTHER|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
219311402|NCT03675178|DRUG|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
219311403|NCT03675178|DRUG|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
219311404|NCT01101477|PROCEDURE|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~1. Patients become irritant and interfere procedures.~2. Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~1. Systolic blood pressure is less than 90mmHg;~2. Mean arterial blood pressure is less than 65mmHg;~3. Oxyhemoglobin saturation is less than 90 %~with any duration."
219311405|NCT00501527|BIOLOGICAL|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
219311406|NCT00501527|OTHER|Placebo|Placebo 2 drops daily
219311407|NCT03972007|DEVICE|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
219311408|NCT01179451|DEVICE|echocardiogram|echocardiogram
219311409|NCT03699436|OTHER|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
219311410|NCT03699436|OTHER|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
219311411|NCT00681746|DRUG|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
219311412|NCT00681746|DRUG|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
219311413|NCT04099017|OTHER|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~   Procedural detail:~   Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~2. Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~3. Kinesiotaping:"
219311414|NCT04099017|OTHER|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~   Procedural detail:~   i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:"
219354715|NCT02831465|BEHAVIORAL|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
219311415|NCT04099017|OTHER|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
219311416|NCT04160338|DEVICE|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
219311417|NCT04038593|OTHER|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
219311418|NCT04038593|DEVICE|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
219311419|NCT00520104|DRUG|intranasal ketamine|drug interaction
219311420|NCT06700096|GENETIC|ANB-002|Adeno-associated viral vector carrying the FIX gene single infusion
219311421|NCT02271516|RADIATION|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
219311422|NCT04179331|OTHER|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
219311423|NCT04179331|OTHER|Saline|Isotonic saline will serve as a placebo.
219311424|NCT01800266|BEHAVIORAL|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
219311425|NCT02956512|DRUG|Dexibuprofen|Dexibuprofen 300mg
219311426|NCT00209456|DRUG|DatSCAN|
219311427|NCT01679795|DRUG|Tibolone|
219311428|NCT01679795|DRUG|Placebo|
219311429|NCT03520933|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
219311430|NCT03520933|DIAGNOSTIC_TEST|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
219311431|NCT02870569|DRUG|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
219311432|NCT02870569|DRUG|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
219311433|NCT02579707|DRUG|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
219311434|NCT02382016|DRUG|Macitentan|Macitentan film-coated tablet 10 mg once daily.
219311435|NCT02382016|OTHER|Placebo|Matching placebo tablet once daily.
219311436|NCT00084266|DRUG|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
219311437|NCT00084266|DRUG|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
219311438|NCT03343951|OTHER|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~* diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~* if the patient needs a new appointment at the shoulder clinic~* if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
219311439|NCT00730171|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
219311440|NCT01729156|DRUG|Metformin|1000 mg metformin twice daily in 3 months
219311441|NCT01729156|DRUG|Placebo|2 tablets twice daily in 3 months
219311442|NCT03450798|DEVICE|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
219311443|NCT03450798|DEVICE|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
219311444|NCT02544217|DRUG|KH176|
219311445|NCT02544217|DRUG|placebo|
219311446|NCT01727622|DRUG|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
219311447|NCT01727622|OTHER|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
219311448|NCT01727622|PROCEDURE|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
219311449|NCT05398016|BEHAVIORAL|low-intensity intervention for anxiety|Brief (6-8 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
219311450|NCT02736773|OTHER|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
219311451|NCT02883283|PROCEDURE|Epidural loading dose|Labor epidural analgesia loading dose
219311452|NCT02883283|DEVICE|Epidural catheter|Epidural loading dose via epidural catheter
219311453|NCT02883283|DEVICE|Epidural needle|Epidural loading dose via epidural needle
219311454|NCT03651986|DIAGNOSTIC_TEST|ctDNA methylation analysis by NGS|A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)
219311455|NCT02818088|BEHAVIORAL|n-Back (Cognitive Training)|
219311456|NCT04174079|DRUG|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
219311457|NCT02901041|DRUG|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
219311458|NCT02901041|BEHAVIORAL|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
219311459|NCT02901041|DRUG|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
219311460|NCT03890419|DEVICE|Green light|Green light exposure
219311461|NCT03890419|DEVICE|Clear light|Full spectrum light exposure
219311462|NCT03890419|DEVICE|Blue Light|Blue light exposure
219311463|NCT00337519|PROCEDURE|allogeneic stem cell transplantation|see detailed description
219311464|NCT00337519|DRUG|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
219311465|NCT00975507|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
219311466|NCT00975507|BIOLOGICAL|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
219311467|NCT00975507|BIOLOGICAL|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
219311468|NCT00975507|BIOLOGICAL|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
219311469|NCT01659619|DRUG|Erythromycin|125mg in normal saline single use infusion for 5 min.
219311470|NCT00493545|BIOLOGICAL|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
219311471|NCT03404765|BEHAVIORAL|Tai Chi|
219311472|NCT06441188|DIAGNOSTIC_TEST|Thin layer conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.
219311473|NCT06441188|DIAGNOSTIC_TEST|Thick layer of conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.
219311474|NCT06441188|DIAGNOSTIC_TEST|Thin conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.
219311475|NCT06441188|DIAGNOSTIC_TEST|Thick conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
219311476|NCT00194766|DRUG|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
219311477|NCT04877795|DIAGNOSTIC_TEST|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
219311478|NCT02882113|DRUG|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
219311479|NCT05810272|BEHAVIORAL|Metabolic Trial|Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
219311480|NCT05810272|BEHAVIORAL|15 sit-to-stands with calf raises|Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
219311481|NCT01996813|DEVICE|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
219311482|NCT03497754|DEVICE|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
219311483|NCT00219453|DEVICE|Jet Injector with Protector Cap (HSI-500)|
219311484|NCT03376945|DRUG|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
219311485|NCT03376945|DRUG|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
219311486|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
219311487|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
219311488|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
219311489|NCT06016309|OTHER|There is no intervention.|There is no intervention.
219311490|NCT01306097|DRUG|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
219311491|NCT00379743|BEHAVIORAL|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
219311492|NCT00379743|BEHAVIORAL|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
219311493|NCT02679131|DRUG|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
219311494|NCT03092895|BIOLOGICAL|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
219311495|NCT03092895|DRUG|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
219311496|NCT03092895|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
219311497|NCT03092895|DRUG|GEMOX|Subjects receive GEMOX treatment every 2 weeks
219311498|NCT01112306|DRUG|ACT-293987|Tablets, twice daily
219311499|NCT02216643|PROCEDURE|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
219311500|NCT02216643|DEVICE|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
219311501|NCT06082583|DEVICE|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
219311502|NCT06082583|DRUG|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
219311503|NCT00056485|BEHAVIORAL|Pleasant Events-Based Behavioral Intervention|
219311504|NCT05085223|OTHER|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
219311505|NCT05085223|OTHER|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
219311506|NCT04446533|DRUG|Hydrogen Peroxide and Hyaluronic acid filming formulation|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
219311507|NCT04446533|DRUG|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
219311508|NCT04446533|DRUG|Placebo|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
219311509|NCT00852046|DRUG|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
219311510|NCT01074671|DEVICE|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
219311511|NCT01208493|OTHER|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
219311512|NCT01208493|OTHER|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
219311513|NCT05166460|DEVICE|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
219311514|NCT05831930|DRUG|Nituozumab|Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
219311515|NCT02767401|DEVICE|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
219311516|NCT02767401|DRUG|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
219311517|NCT00430443|DRUG|Liposomal Annamycin|3-day IV infusion
219311518|NCT00207701|DRUG|infliximab|
219311519|NCT04588623|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair (OBSR)|OBSR is given orally once daily (3g) for 3 months
219311520|NCT04588623|OTHER|Placebo|Placebo is given orally once daily (3g) for 3 months
219311521|NCT01942720|DEVICE|Capsule endoscopy and Ileocolonoscopy tests|
219311522|NCT02438319|OTHER|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
219311523|NCT02438319|OTHER|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
219311524|NCT01267877|OTHER|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
219311525|NCT01267877|OTHER|read favorable article prior to answering questions|"read A Backlash of Mistrust"
219311526|NCT05401279|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
219311527|NCT05401279|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
219311528|NCT05401279|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four to six 21-day cycles.
219311529|NCT02695641|DRUG|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
219311530|NCT02695641|DRUG|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
219311531|NCT03726814|BIOLOGICAL|EPC treatment group|Brain injection EPC
219311532|NCT02229045|DRUG|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
219311533|NCT02229045|DRUG|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
219311534|NCT03952806|DRUG|Verdiperstat|300mg 2 oral tablets, twice daily
219311535|NCT03952806|DRUG|Placebo|Matching placebo
219311536|NCT00655863|DRUG|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
219311537|NCT00655863|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
219311538|NCT00655863|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
219311539|NCT02557321|DRUG|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
219311540|NCT02557321|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
219311541|NCT04286568|BEHAVIORAL|WOW Intervention|Health education and coaching, health care navigation,
219311542|NCT01138007|DRUG|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
219311543|NCT01138007|DRUG|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
219311544|NCT02897401|BIOLOGICAL|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
219311545|NCT02897401|BIOLOGICAL|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
219311546|NCT02897401|BIOLOGICAL|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
219311547|NCT02897401|BEHAVIORAL|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
219311548|NCT02897401|PROCEDURE|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
219311549|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
219311550|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
219311551|NCT05541211|OTHER|Coeliac plexus neurolysis|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
219311552|NCT05541211|OTHER|Splanchnic nerve neurolysis|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
219311553|NCT05996783|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
219311554|NCT05996783|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
219311555|NCT04661878|BEHAVIORAL|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
219311556|NCT04661878|BEHAVIORAL|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
219311557|NCT04661878|BEHAVIORAL|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
219311558|NCT04661878|BEHAVIORAL|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
219311559|NCT04560036|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
219311560|NCT06251453|DRUG|SGLT2 inhibitor|Dapagliflozin Empagliflzoin
219311561|NCT06634459|DEVICE|Reia System|Reia pessary
219311562|NCT06634459|DEVICE|Standard of Care Pessary|Gellhorn pessary or ring with/without support without knob pessary
219311563|NCT03867175|RADIATION|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
219311564|NCT03867175|BIOLOGICAL|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
219311565|NCT04328337|DRUG|Intralipid, 20% Intravenous Emulsion|Infusion of Intralipid 20%
219311566|NCT04328337|DRUG|Placebos|saline 30 ml/hr for 12 hours through an IV
219311567|NCT06447142|OTHER|Open kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
219311568|NCT06447142|OTHER|Closed kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
219311569|NCT04828486|DRUG|Futibatinib|Given PO
219311570|NCT04828486|BIOLOGICAL|Pembrolizumab|Given IV
219311571|NCT04828486|OTHER|Quality-of-Life Assessment|Ancillary studies
219311572|NCT03144999|BIOLOGICAL|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
219311573|NCT01806129|OTHER|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
219311574|NCT01806129|OTHER|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
219311575|NCT06330779|OTHER|Trauma-adapted yoga|"Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time."
219311576|NCT05350631|OTHER|OnKO-Tips&Tricks digital phone application|Using daily OnKO-Tips\&Tricks digital phone application
219311577|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Manioc powder (placebo) 60 g/day
219311578|NCT00502021|DIETARY_SUPPLEMENT|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
219311579|NCT00502021|DIETARY_SUPPLEMENT|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
219311580|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Safflower oil 30 ml/day
219311581|NCT06311968|RADIATION|Proton radiotherapy|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
219311582|NCT06311968|OTHER|combined platinum based chemotherapy|combined platinum based chemotherapy
219311583|NCT02416804|DRUG|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr
219311584|NCT02416804|DRUG|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
219311585|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
219311586|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
219311587|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
219311588|NCT00744523|DEVICE|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
219311589|NCT02564874|OTHER|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
219311590|NCT04823221|DEVICE|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
219311591|NCT01115751|DRUG|LY2780301|"Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
219311592|NCT04869423|BEHAVIORAL|Dog-Assisted Therapy|During seven weeks patients will assist one time per week (1 hour). The therapy will be conducted by an expert psychologist. The intervention will consist of 7 weeks conducted once a week (50 minutes each session). It will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to say goodbye to the dogs.
219311593|NCT03054480|DEVICE|Fractional Micro-Needle Radiofrequency|
219311594|NCT03054480|DRUG|Botulinum toxin type A|
219311595|NCT03107104|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
219311596|NCT03107104|DEVICE|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
219311597|NCT05333224|OTHER|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
219311598|NCT05333224|OTHER|Home-based|Family-centered, goal-oriented early physiotherapy approaches will be applied.
219311599|NCT06798363|DRUG|propranolol|different dose
219311600|NCT03558360|DIAGNOSTIC_TEST|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
219311601|NCT04822285|BEHAVIORAL|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
219311602|NCT04822285|BEHAVIORAL|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
219311603|NCT00063154|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
219311604|NCT03272425|DRUG|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
219311605|NCT03272425|DRUG|lesinurad 200 mg|Comparator 1
219311606|NCT03272425|DRUG|allopurinol 300 mg|Comparator 2
219311607|NCT06056167|DRUG|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
219311608|NCT01669876|DIETARY_SUPPLEMENT|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
219311609|NCT01669876|DIETARY_SUPPLEMENT|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
219311610|NCT04248270|DRUG|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
219311611|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 80mg|The patient received one treatment of RC18 80mg in the test group
219311612|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 160mg|The patient received one treatment of RC18 160mg in the test group
219311613|NCT04235933|BIOLOGICAL|RC18 240mg|The patient received one treatment of RC18 240mg in the test group
219311614|NCT04354844|BEHAVIORAL|questionnaire|questionnaire
219311615|NCT00935194|DRUG|oseltamivir|75mg,bid,for 5 days
219311616|NCT00935194|OTHER|blank|no antiviral therapy
219311617|NCT00935194|DRUG|chinese medicinal herbs|200ml,p.o,qid,for 5 days
219311618|NCT00935194|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
219311619|NCT03588728|OTHER|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
219311620|NCT03588728|BEHAVIORAL|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
219311621|NCT00455338|BEHAVIORAL|Meal Composition|
219311622|NCT01917019|DRUG|Placebo|matching placebo tablets
219311623|NCT01917019|DRUG|BIIB041 (fampridine)|fampridine prolonged-release tablets
219311624|NCT02497625|BEHAVIORAL|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
219311625|NCT02497625|BEHAVIORAL|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
219311626|NCT02497625|OTHER|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
219311627|NCT02027701|BIOLOGICAL|IgPro20|
219311628|NCT03392506|DEVICE|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
219311629|NCT00189033|DRUG|psyllium fibre (dietary supplement)|
219311630|NCT00189033|DRUG|wheat bran (dietary supplement)|
219311631|NCT00189033|DRUG|rice wheat (placebo)|
219311632|NCT00165633|DRUG|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
219311633|NCT00165633|DRUG|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
219311634|NCT00165633|DRUG|Placebo|Placebo capsule, orally, three times a day, after meals.
219354716|NCT01407926|OTHER|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
219354717|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
219354718|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
219311635|NCT05975151|DRUG|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
219311636|NCT00388557|DRUG|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
219311637|NCT04793152|DRUG|Vancomycin|Administration as outlined
219311638|NCT04747782|OTHER|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
219311639|NCT02019589|DRUG|Progesterone|
219311640|NCT02019589|DRUG|Placebo|
219311641|NCT06001489|BEHAVIORAL|360-degree Virtual Reality Patient Tour|A 360-degree video that encompasses the entire clinical pathway. Patients are able to familiarize themselves with the hospital settings (nursery ward, operating room, intensive care unit).
219311642|NCT06001489|DIAGNOSTIC_TEST|State Trait Anxiety Inventory|Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
219311643|NCT06001489|DIAGNOSTIC_TEST|Amsterdam Preoperative Anxiety and Information Scale|This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
219311644|NCT03285178|DRUG|IW-1701|Oral Tablet
219311645|NCT03285178|DRUG|Placebo|Oral Tablet
219311646|NCT05703867|DEVICE|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
219311647|NCT03292718|DEVICE|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
219311648|NCT01388790|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
219311649|NCT01388790|DRUG|Cisplatin|Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
219311650|NCT01388790|DRUG|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
219311651|NCT01128894|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
219311652|NCT01128894|DRUG|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
219311653|NCT03758287|DRUG|CT053PTSA|
219745145|NCT03197519|BEHAVIORAL|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
219311654|NCT03758287|DRUG|Gefitinib|
219311655|NCT04785235|PROCEDURE|Non-Surgical Periodontal Therapy|
219311656|NCT02091050|OTHER|2D HDR planning|HDR planning using simple radiograph (2D)
219311657|NCT02091050|OTHER|3D HDR planning|HDR planning using computed tomography (3D)
219311658|NCT00334724|PROCEDURE|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
219311659|NCT00334724|PROCEDURE|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
219311660|NCT00755651|PROCEDURE|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
219311661|NCT02725099|DRUG|Chewing Ticagrelor|180 mg Chewing Ticagrelor
219311662|NCT02725099|DRUG|Oral Ticagrelor|180 mg oral Ticagrelor
219311663|NCT00195507|DRUG|Etanercept|
219311664|NCT00370409|PROCEDURE|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
219311665|NCT00973362|DEVICE|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
219311666|NCT00973362|DEVICE|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
219311667|NCT03754413|DEVICE|experimental|Neuramis® Deep Lidocaine
219311668|NCT03754413|DRUG|comparator|No-treatment
219311669|NCT02674789|BEHAVIORAL|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
219311670|NCT05543486|DEVICE|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
219311671|NCT05543486|DEVICE|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
219311672|NCT00897416|OTHER|laboratory biomarker analysis|
219311673|NCT03480256|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
219311674|NCT01702597|DEVICE|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
219311675|NCT01702597|OTHER|Physiotherapy|Patients will receive a standardized physical therapy.
219311676|NCT03252054|DIAGNOSTIC_TEST|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
219311677|NCT00887679|DRUG|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
219311678|NCT02843204|DRUG|Pembrolizumab|Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
219311679|NCT02843204|BIOLOGICAL|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
219311680|NCT01969825|BEHAVIORAL|Massage|
219311681|NCT00959166|OTHER|PET scan|PET brain scan
219311682|NCT05975801|OTHER|Dry Cupping Therapy|
219311683|NCT05975801|OTHER|Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound|
219311684|NCT00975351|DIETARY_SUPPLEMENT|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
219311685|NCT00210756|DRUG|epoetin alfa|
219311686|NCT01837355|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
219311687|NCT01837355|DIETARY_SUPPLEMENT|Placebo|
219311688|NCT02311998|DRUG|Bosutinib|Given PO
219311689|NCT02311998|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
219311690|NCT00769613|BIOLOGICAL|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
219311691|NCT00769613|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
219311692|NCT00769613|BIOLOGICAL|therapeutic allogeneic lymphocytes|
219311693|NCT00769613|GENETIC|polymerase chain reaction|
219311694|NCT00769613|OTHER|flow cytometry|
219311695|NCT00769613|OTHER|immunological diagnostic method|
219311696|NCT00769613|OTHER|laboratory biomarker analysis|
219311697|NCT03241212|BEHAVIORAL|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
219311698|NCT00595023|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
219311699|NCT02578862|DRUG|Propofol|
219311700|NCT02578862|DRUG|Sevoflurane|
219311701|NCT00482508|DRUG|Omalizumab|
219311702|NCT04283721|OTHER|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
219311703|NCT06435130|OTHER|Dietary intervention with chokeberry juices|The first stage of the dietary intervention lasted 8 weeks. Study participants consumed 100 ml of chokeberry juice daily. Chokeberry juice came from ecological cultivation (Poland). Participants qualified for the study had specific biochemical parameters tested: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. Blood tests were performed in a certified external laboratory before and after 8 weeks of intervention. In addition, blood pressure and waist circumference were tested.
219311704|NCT06435130|OTHER|Dietary intervention with chokeberry juices and fibers|The second stage of the dietary intervention lasted 4 weeks. Study participants consumed 100 ml of chokeberry juice daily and 10 g chokeberry fiber daily (from ecological cultivation, Poland). Blood tests were performed in a certified external laboratory after 4 weeks of intervention. The following blood tests were performed: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. In addition, blood pressure and waist circumference were tested.
219311705|NCT05737290|DEVICE|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
219311706|NCT05737290|DEVICE|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
219311707|NCT00279773|DRUG|TKI258|
219311708|NCT04671134|OTHER|Biomimetic remineralizing agent|Self-assempling peptide
219311709|NCT04671134|OTHER|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
219745146|NCT03197519|BEHAVIORAL|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
219745147|NCT04053504|BEHAVIORAL|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
219745148|NCT04409444|DIAGNOSTIC_TEST|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
219745149|NCT04409444|DIAGNOSTIC_TEST|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
219311710|NCT05659277|OTHER|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
219311711|NCT02582723|OTHER|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
219311712|NCT02582723|OTHER|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
219311713|NCT02582723|OTHER|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
219311714|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
219311715|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
219311716|NCT00550875|BIOLOGICAL|placebo|Sublingual. 2 drops/daily 2 years
219311717|NCT04078165|DEVICE|Zero-Gravity|Free-floating, suspended personal radiation protection
219311718|NCT04078165|DEVICE|Conventional radiation protection|Standard lead shields and aprons
219311719|NCT02643836|DEVICE|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
219311720|NCT02803047|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
219311721|NCT04609059|DRUG|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
219311722|NCT04609059|DRUG|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
219311723|NCT00118443|BEHAVIORAL|Question, Persuade, Refer (QPR) training|
219311724|NCT01504308|DEVICE|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
219311725|NCT01504308|DEVICE|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
219311726|NCT00442299|DEVICE|Fractionated Plasma Separation and Adsorption (FPSA)|
219311727|NCT05708625|DRUG|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
219311728|NCT05708625|PROCEDURE|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
219311729|NCT05708625|DRUG|Intralesional Voriconazole|Weekly intralesional Voriconazole
219311730|NCT05708625|DRUG|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
219311731|NCT02687425|DRUG|Pioglitazone|15mg/day,po
219311732|NCT02687425|DRUG|imatinib mesylate|400mg/day,po
219311733|NCT04071353|DRUG|Interferon|Interferon combined with ribavirin antiviral therapy
219311734|NCT04071353|DRUG|ribavirin|Interferon combined with ribavirin antiviral therapy
219311735|NCT04071353|DRUG|DAAs|DAAs antiviral treatment
219311736|NCT02369445|BEHAVIORAL|Moisture Pager Intervention for Toilet Training|
219311737|NCT02369445|BEHAVIORAL|Standard of Care|
219311738|NCT00477854|DRUG|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
219311739|NCT03878498|OTHER|therapeutic management|therapeutic management of anal fistula in Crohn Disease
219311740|NCT03373487|BEHAVIORAL|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
219311741|NCT04079803|DRUG|Placebo oral tablet|Oral placebo tablet
219311742|NCT04079803|DRUG|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
219311743|NCT04079803|DRUG|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
219311744|NCT02600455|DRUG|Orencia|
219311745|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
219311746|NCT01321346|DRUG|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
219311747|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
219311748|NCT04792658|BEHAVIORAL|Detailed interview with personal demographic data|, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
219311749|NCT04792658|BEHAVIORAL|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
219311750|NCT04792658|BEHAVIORAL|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
219311751|NCT04792658|BEHAVIORAL|the Hamilton Depression Rating Scale|it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
219311752|NCT04792658|BEHAVIORAL|The Hamilton Anxiety Rating Scale|it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
219311753|NCT04792658|BEHAVIORAL|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)|It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
219311754|NCT05591820|BEHAVIORAL|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's behavioral difficulties in three (bi)weekly sessions and optional booster sessions.
219311755|NCT05591820|BEHAVIORAL|Care as usual|The care that is usually provided by the clinical institutions to treat children's behavioral difficulties. There are no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
219311756|NCT01215500|RADIATION|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy"
219311757|NCT00770237|BEHAVIORAL|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
219311758|NCT00770237|BEHAVIORAL|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
219311759|NCT01881750|BEHAVIORAL|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
219311760|NCT01881750|BEHAVIORAL|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
219311761|NCT00508248|DIETARY_SUPPLEMENT|omega 3 fatty acids|1g daily
219311762|NCT00508248|DIETARY_SUPPLEMENT|placebo|olive oil capsule
219745150|NCT00780585|DRUG|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
219745151|NCT02069847|DRUG|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
219745152|NCT03638375|DRUG|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
219745153|NCT04433195|DIAGNOSTIC_TEST|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
219311763|NCT05223751|BEHAVIORAL|Meo Health Breathing and humming exercises|"The Intervention Group will receive training on the Meo Health breathing therapy, which will include:~* Being shown the Meo Health Breathing Therapy On-Boarding video~* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.~* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.~Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.~A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.~A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group."
219311764|NCT01779687|DRUG|raltegravir|Raltegravir 400 mg BID for 7 days
219311765|NCT01779687|DRUG|Atorvastatin|Atorvastatin 20 mg QD for 7 days
219311766|NCT00984763|BIOLOGICAL|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
219311767|NCT03379922|BEHAVIORAL|Stress balls|Squeezing stress balls while receiving ESWL treatment
219311768|NCT03379922|BEHAVIORAL|Headphones|Listening to music while receiving ESWL treatment
219311769|NCT01126151|BEHAVIORAL|parent handbook|parent handbook
219311770|NCT03708822|DRUG|Docetaxel and Cisplatin and Nimotuzumab|Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
219745154|NCT05994430|OTHER|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
219745155|NCT05126420|PROCEDURE|biopsy|biopsy to identify the lesion in the oral mucosa
219745156|NCT00480532|DRUG|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
219745157|NCT00480532|DRUG|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
219745158|NCT00480532|DRUG|Oracea|40-mg tablet daily for 84 days
219745159|NCT00480532|DRUG|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
219745160|NCT00480532|DRUG|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
219745161|NCT00480532|DRUG|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
219745162|NCT00480532|DRUG|placebo daily|Placebo daily for the first 84 days of the study
219745163|NCT03797937|OTHER|Magnetic resonance imaging (MRI)|MRI scanner
219745164|NCT06318546|DRUG|Dexmedetomidine Injection [Precedex],,,|patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
219745165|NCT06318546|DRUG|Fentanyl|will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
219745166|NCT04832659|BEHAVIORAL|CEASE|The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
219745167|NCT04832659|BEHAVIORAL|CEASE + BIO|Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
219745168|NCT05348941|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
219745169|NCT03350945|PROCEDURE|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
219745170|NCT00470522|DRUG|Methotrexate and folic acid|
219745171|NCT04774666|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
219745172|NCT02191163|DRUG|Antistax®|
219745173|NCT02191163|DRUG|Placebo|
219745174|NCT03242434|OTHER|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose \[5 grams (g)\]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
219745175|NCT03242434|OTHER|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
219745176|NCT00784017|DRUG|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
219745177|NCT00784017|DRUG|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
219745178|NCT04626934|OTHER|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
219745179|NCT04626934|OTHER|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
219745180|NCT05212207|OTHER|CGM, smartwatch, and electronic diary|Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
219745181|NCT01769027|DRUG|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
219745182|NCT01769027|DRUG|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
219745183|NCT01769027|BIOLOGICAL|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
219311771|NCT04269005|OTHER|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
219311772|NCT01134016|DRUG|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
219311773|NCT06244758|DRUG|Finerenone 20 MG Oral Tablet|The intervention is administered orally.
219311774|NCT06244758|DRUG|Placebo|The intervention is administered orally.
219311775|NCT00537368|DRUG|CNTO 888|
219311776|NCT02580396|DEVICE|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
219311777|NCT02696772|OTHER|Energy intake|
219311778|NCT00298454|DRUG|Furosemide|
219311779|NCT02841930|OTHER|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
219311780|NCT02804178|DRUG|ATR-101|125-1000 mg twice per week
219311781|NCT03159741|OTHER|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
219311782|NCT03159741|OTHER|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
219311783|NCT03159741|OTHER|Placebo + GIP|Placebo and GIP are used as study tools.
219311784|NCT03159741|OTHER|Placebo + Saline|Placebo
219311785|NCT03675672|DRUG|Misoprostol Oral Tablet|Misoprostol 200mcg
219311786|NCT03675672|DRUG|Placebo Oral Tablet|Placebo Tablet
219311787|NCT00330850|DRUG|PRO-513|
219311788|NCT00606073|OTHER|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
219311789|NCT05956054|OTHER|needle type|straight or curved
219311790|NCT00529022|DRUG|Azacitidine|75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
219311791|NCT00529022|DRUG|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
219311792|NCT00529022|DRUG|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
219311793|NCT01106404|DEVICE|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
219311794|NCT01290601|DRUG|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
219311795|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
219311796|NCT01290601|DRUG|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
219311797|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
219311798|NCT02190669|OTHER|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
219311799|NCT03099317|OTHER|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
219311800|NCT03099317|OTHER|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
219311801|NCT00939679|PROCEDURE|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
219311802|NCT00939679|DIETARY_SUPPLEMENT|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
219311803|NCT03580772|DEVICE|Persona TKR|Persona® TKR (Zimmer Biomet)
219311804|NCT03580772|DEVICE|Attune TKR|Attune® TKR (Depuy synthes)
219311805|NCT06224608|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
219311806|NCT03651583|BEHAVIORAL|Kiko exercises-combines breathing and movement|
219311807|NCT01066468|DRUG|Gleevec/Glivec|
219311808|NCT05270785|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
219311809|NCT05270785|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
219311810|NCT00803829|OTHER|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
219354719|NCT04672161|OTHER|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
219311811|NCT00931333|PROCEDURE|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
219311812|NCT01094379|PROCEDURE|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
219311813|NCT01094379|PROCEDURE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
219311814|NCT05295680|DRUG|Hymecromone|Hymecromone 400 mg 3 times daily by mouth.
219311815|NCT04460014|BEHAVIORAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
219311816|NCT04460014|BEHAVIORAL|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
219311817|NCT03820089|DIAGNOSTIC_TEST|Ultrasonography TP|TP us will be made to the included women
219311818|NCT03772353|DRUG|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
219311819|NCT03772353|DRUG|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
219311820|NCT03772353|DRUG|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
219311821|NCT03772353|DRUG|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
219311822|NCT04727879|PROCEDURE|Synovial membrane biopsy with puncture of synovial fluid|The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
219311823|NCT04727879|PROCEDURE|Joint fluid sampling|In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
219311824|NCT04727879|PROCEDURE|Blood sample|A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
219311825|NCT00005074|DRUG|alvocidib|
219311826|NCT05528250|OTHER|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
219311827|NCT05528250|DEVICE|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
219311828|NCT06421896|BEHAVIORAL|motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is a systematic intervention that focuses on eliciting and strengthening a person's intrinsic motivation to change. MET is rooted in motivational interviewing principles, emphasizing empathy, autonomy, and the evocation of the patient's own motivations for change. The therapy typically involves several sessions where therapists help patients identify personal goals, explore ambivalence towards change, and develop actionable plans to achieve their desired outcomes.
219311829|NCT01749540|DRUG|luspatercept|subcutaneous injection
219311830|NCT04864483|OTHER|Meal timing in relation to time of starting the fast|as described
219311831|NCT02729103|DRUG|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
219311832|NCT05755035|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
219311833|NCT05755035|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
219311834|NCT03506893|DEVICE|Alphapump|"Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking"
219311835|NCT03506893|PROCEDURE|Ascites puncture|Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
219311836|NCT00615238|BEHAVIORAL|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
219311837|NCT00615238|BEHAVIORAL|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
219311838|NCT00615238|BEHAVIORAL|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
219311839|NCT01474499|DRUG|Glycerine|
219311840|NCT01474499|DRUG|Docusate sodium and sorbitol rectal solution|
219311841|NCT02263534|PROCEDURE|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
219311842|NCT02263534|PROCEDURE|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
219311843|NCT03935503|PROCEDURE|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
219311844|NCT03935503|PROCEDURE|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
219311845|NCT02761551|BEHAVIORAL|Reminder notifications via autodialer|
219311846|NCT01321359|DRUG|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
219311847|NCT02939547|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
219311848|NCT01296347|DRUG|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
219311849|NCT02240693|DRUG|BI 409306|
219311850|NCT02240693|DRUG|Placebo|
219311851|NCT02240693|DRUG|BI 409306|
219311852|NCT02240693|DRUG|Placebo|
219311853|NCT02240693|DRUG|Placebo|
219311854|NCT02240693|DRUG|BI 409306|
219311855|NCT02240693|DRUG|BI 409306|
219311856|NCT02240693|DRUG|Placebo|
219311857|NCT02240693|DRUG|Placebo|
219311858|NCT02705560|OTHER|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
219311859|NCT02705560|OTHER|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
219311860|NCT02705560|OTHER|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
219311861|NCT04910789|PROCEDURE|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
219311862|NCT04910789|PROCEDURE|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
219311863|NCT01585987|BIOLOGICAL|Ipilimumab|
219311864|NCT01585987|OTHER|Best Supportive care (BSC)|
219311865|NCT05378230|DIETARY_SUPPLEMENT|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
219311866|NCT03482583|DRUG|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
219311867|NCT03482583|OTHER|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
219311868|NCT00551941|PROCEDURE|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
219311869|NCT00551941|PROCEDURE|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
219311870|NCT01386281|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
219311871|NCT04840641|DRUG|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
219311872|NCT00413972|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
219311873|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
219311874|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
219311875|NCT00413972|DRUG|Placebo|Placebo once daily for a total of eight weeks
219354720|NCT06549452|DEVICE|mHealth Intervention|Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
219311876|NCT00807261|DRUG|Gemcitabine and Docetaxel|"Drug and schedule~* Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~* Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~* Treatment should be delayed if the ANC\<1,500/ mm3, or if the platelet count \<75,000/mm3 on the first day of the next cycle.~* Gemcitabine \& docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
219311877|NCT00486629|BEHAVIORAL|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
219311878|NCT06266884|OTHER|Kangaroo care|Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
219311879|NCT03617341|PROCEDURE|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
219311880|NCT01704924|DEVICE|Prevena|Device will be applied at end of procedure over closed incision
219311881|NCT01704924|PROCEDURE|Standard of Care Dressing|Dressing applied as Standard of Care
219311882|NCT04771468|DEVICE|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
219311883|NCT04771468|DEVICE|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
219311884|NCT01724853|PROCEDURE|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
219311885|NCT01724853|OTHER|Conservative|Injection
219311886|NCT02542774|OTHER|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
219311887|NCT02331251|DRUG|Pembrolizumab|
219311888|NCT02331251|DRUG|Gemcitabine|
219311889|NCT02331251|DRUG|Docetaxel|
219311890|NCT02331251|DRUG|Nab-paclitaxel|
219311891|NCT02331251|DRUG|Vinorelbine|
219311892|NCT02331251|DRUG|Irinotecan|
219311893|NCT02331251|DRUG|Liposomal Doxorubicin|
219311894|NCT02737709|DRUG|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
219311895|NCT03013582|BIOLOGICAL|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
219311896|NCT03013582|PROCEDURE|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
219311897|NCT04289766|OTHER|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
219311898|NCT04289766|OTHER|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
219311899|NCT04289766|OTHER|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
219311900|NCT05965661|OTHER|virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
219311901|NCT05965661|OTHER|virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
219311902|NCT01145755|DRUG|AZD2066|18 mg once daily
219311903|NCT01145755|DRUG|Placebo|
219311904|NCT01145755|DRUG|Duloxetine|60 mg once daily
219311905|NCT01704638|DRUG|fluvoxamine|
219311906|NCT01704638|DRUG|Digoxin|
219311907|NCT03876782|DIAGNOSTIC_TEST|IOLMaster|IOL power calculation will be done with IOLMaster
219311908|NCT03876782|DIAGNOSTIC_TEST|Verion|IOL power calculation will be done with Verion
219311909|NCT05749289|DRUG|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
219311910|NCT05635981|OTHER|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
219311911|NCT01783041|DRUG|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
219311912|NCT01783041|DRUG|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
219311913|NCT01827293|DRUG|Promethazine|
219311914|NCT01827293|DRUG|Lorazepam|
219311915|NCT05423886|OTHER|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
219311916|NCT03796260|DRUG|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
219311917|NCT03796260|DRUG|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
219311918|NCT05429333|OTHER|Artificial intelligence-assisted personalized diet|"The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings."
219311919|NCT01295177|DRUG|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
219311920|NCT00320125|DIETARY_SUPPLEMENT|Orange juice plus calcium|\> 1,200mg Ca (four glasses of orange juice plus calcium)per day
219311921|NCT00320125|DIETARY_SUPPLEMENT|Dairy products|\> 1,200mg Ca (by consuming milk, yogurt, and cheese)
219311922|NCT04919239|BIOLOGICAL|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
219311923|NCT04919239|BIOLOGICAL|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
219311924|NCT05918250|BIOLOGICAL|mRNA-2736|mRNA-2736 will be administered IV.
219311925|NCT00343954|DRUG|L-citrulline tablets, 1000 mg|
219311926|NCT00742053|DEVICE|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
219311927|NCT02092220|DEVICE|Bionic Pancreas|
219311928|NCT02092220|DEVICE|Insulin pump with or without CGM|
219311929|NCT02739360|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
219311930|NCT01414374|DRUG|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
219311931|NCT01414374|DRUG|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
219311932|NCT02127918|DRUG|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
219311933|NCT04589429|DRUG|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
219311934|NCT04589429|DRUG|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
219311935|NCT00687817|DRUG|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
219311936|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
219311937|NCT01193920|OTHER|Saline solution|Subjects received two injection of saline solution.
219311938|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
219311939|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
219311940|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
219311941|NCT01193920|OTHER|saline solution|Subjects received one injection of saline solution.
219311942|NCT03844490|OTHER|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
219311943|NCT03844490|OTHER|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
219311944|NCT00913653|DRUG|LCZ696|
219311945|NCT00437723|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
219311946|NCT02097641|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
219311947|NCT02097641|BIOLOGICAL|Plasma-Lyte A|Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
219311948|NCT00680589|BIOLOGICAL|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
219311949|NCT01670123|BEHAVIORAL|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
219311950|NCT03894254|OTHER|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
219311951|NCT01231516|DRUG|GSK1349572|50mg once daily
219311952|NCT01231516|DRUG|Raltegravir|400mg twice daily
219311953|NCT01231516|DRUG|GSK1349572 Placebo|Inactive placebo tablet once daily
219311954|NCT01231516|DRUG|Raltegravir Placebo|Inactive placebo tablet twice daily
219311955|NCT05507918|OTHER|Oral water and clear liquids|Measured oral intake of fluids prior to tonsillectomy
219311956|NCT01749449|OTHER|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
219311957|NCT05053425|DRUG|Venetoclax|given po.
219311958|NCT05053425|DRUG|Azacitidine|given sc.
219311959|NCT05053425|DRUG|Cladribine|given ivgtt.
219311960|NCT05053425|DRUG|Cytarabine|given sc or ivgtt.
219311961|NCT05053425|DRUG|Idarubicin|given ivgtt.
219311962|NCT00409214|DRUG|LS11 (talaporfin sodium)|
219311963|NCT00409214|DEVICE|Light source (interstitial light emitting diodes)|
219311964|NCT00409214|PROCEDURE|Intraoperative placement of device in glioma|
219311965|NCT03170154|DEVICE|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
219311966|NCT02751567|OTHER|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
219311967|NCT02751567|OTHER|Untreated skin|One site is patched without treatment as control
219311968|NCT02669420|PROCEDURE|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
219311969|NCT05609201|DIAGNOSTIC_TEST|HRCT Thorax|HRCT Thorax at 0, 6 and 12 months
219311970|NCT05609201|DEVICE|Glycocheck Endothelial Glycocalyx Assessment|Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months
219311971|NCT05609201|DIAGNOSTIC_TEST|Blood biomarkers|Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months
219311972|NCT05609201|DIAGNOSTIC_TEST|Peripheral leucocyte telomere length|HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months
219311973|NCT05609201|DIAGNOSTIC_TEST|Pulmonary function testing|Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months
219311974|NCT05609201|DIAGNOSTIC_TEST|Patient reported outcome measures|Electronic collection of patient reported outcome measures
219311975|NCT06319456|DRUG|Lisaftoclax (APG-2575)|QD, oral administration, every 28 days for a dosing cycle.
219311976|NCT06319456|DRUG|Acalabrutinib|BID, oral administration, every 28 days for a dosing cycle.
219311977|NCT06319456|DRUG|Fludarabine|Every 28 days for a treatment cycle, administration of 6 cycles.
219311978|NCT06319456|DRUG|Cyclophosphamide，CTX|Every 28 days for a treatment cycle, administration of 6 cycles.
219311979|NCT06319456|DRUG|Rituximab|Every 28 days for a treatment cycle, administration of 6 cycles.
219311980|NCT06319456|DRUG|Chlorambucil|Every 28 days for a treatment cycle, administration of 6 cycles.
219311981|NCT00359190|DRUG|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
219354721|NCT06549452|DEVICE|Usual Care|Routine medical care
219311982|NCT05393284|DRUG|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
219311983|NCT05393284|DRUG|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
219311984|NCT02905760|DRUG|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
219311985|NCT02905760|DRUG|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
219311986|NCT02905760|DRUG|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
219311987|NCT02905760|DRUG|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
219311988|NCT06385756|DRUG|Amobarbital|Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.
219311989|NCT06385756|DRUG|Propofol|propofol
219311990|NCT04752878|DIAGNOSTIC_TEST|Ottawa sitting scale|The Ottawa Sitting Scale is a performance-based balance measurement consisting of 10 items that aims to evaluate the sitting balance in a comprehensive, specific, efficient and functional manner.
219311991|NCT03456271|OTHER||
219311992|NCT01117857|DRUG|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
219311993|NCT04793620|OTHER|TQL1055|Semisynthetic saponin adjuvant
219311994|NCT04793620|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis vaccine
219311995|NCT04569383|BIOLOGICAL|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
219311996|NCT04569383|BIOLOGICAL|Comirnaty|Vaccination with Comirnaty (21 day interval)
219311997|NCT00633061|DRUG|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
219311998|NCT05798611|DRUG|ART0380|Randomized patients will orally receive ART0380.
219311999|NCT03654313|BIOLOGICAL|MEDI6570|MEDI6570
219312000|NCT03654313|BIOLOGICAL|Placebo|Placebo
219312001|NCT03654313|BIOLOGICAL|Part B Placebo|Placebo
219312004|NCT06544902|OTHER|VR Stress Management|First Resort (FR) is an eight-week wellness program that comprises 22 modules, each lasting between 10 and 20 minutes, participants will complete modules weekly in person. Each module will teach participants about values-based goal setting/ behavioral activation, and cognitive restructuring.
219312005|NCT06544902|BEHAVIORAL|Education Control|Participants in this group will receive one-time educational material regarding stress. The participants can review the material remotely. American Heart Association (AHA) brochures and infographics regarding chronic stress and women's health, heart disease and mental health among black women, healthy for good sleep well, among other useful resources.
219312006|NCT06060392|DRUG|Semaglutide Pill|Patient will receive oral semaglutide
219312007|NCT06685575|PROCEDURE|Endoscopic Foraminotomy Surgery|Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis
219312008|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant low dose|The PA5108 Ocular Implant low dose is supplied preloaded into the needle of a single use administration device ready for use.
219312009|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant, high dose|The PA5108 Ocular Implant high dose is supplied preloaded into the needle of a single use administration device ready for use.
219312010|NCT06964191|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops at a concentration of 0.005%
219312011|NCT06404060|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
219312012|NCT06404060|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
219312013|NCT04206488|DRUG|JNJ-70033093|Participants will receive JNJ-70033093 orally.
219312014|NCT04206488|DRUG|Digoxin|Participants will receive digoxin orally.
219312015|NCT03123276|DRUG|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
219312016|NCT03123276|DRUG|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
219312017|NCT04559919|OTHER|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
219312018|NCT04559919|DIAGNOSTIC_TEST|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
219312019|NCT04559919|OTHER|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
219312020|NCT04559919|OTHER|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
219312021|NCT04559919|OTHER|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
219312022|NCT05245097|DEVICE|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
219312023|NCT05245097|OTHER|Standard of Care (SOC)|The standard of care (SOC) in the US for managing the fall risk of geriatric patients is the CDC's Stopping Elderly Accidents, Deaths, and Injuries (STEADI) initiative, which implements the America and British Geriatric Societies'' Clinical Practice Guidelines for fall risk management. The STEADI algorithm consists of tools and resources for healthcare providers for fall risk screening, assessment, and interventioniv,v. Screening and assessment includes identifying fall history and modifiable factors related to fall and fall injury risk (e.g. fear of falling, gait, strength, balance, medications, comorbidities, etc.); then interventions to reduce the fall and fall injury risk are applied based upon assessment findings, and can include physical therapy, medication adjustments, patient education, bed and chair alarms, bed rails, etc.
219312024|NCT04770493|DRUG|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
219312025|NCT04770493|DRUG|Placebo|Matching placebo (sugar pill)
219312026|NCT04931836|BEHAVIORAL|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
219312027|NCT04700306|BEHAVIORAL|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
219312028|NCT06529380|DEVICE|DBS ON|Electrical stimulation of the nucleus accumbens.
219312029|NCT06529380|DEVICE|DBS OFF|DBS will remain OFF (on at 0V).
219354722|NCT02814565|DRUG|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
219312031|NCT05404685|DEVICE|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
219312032|NCT05404685|DEVICE|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
219312033|NCT02791737|BEHAVIORAL|Exercise Intervention|Complete individualized exercise program
219312034|NCT02791737|OTHER|Laboratory Biomarker Analysis|Correlative studies
219312035|NCT02791737|PROCEDURE|Physical Therapy|Complete individualized exercise program
219312036|NCT02791737|OTHER|Quality-of-Life Assessment|Ancillary studies
219312037|NCT02791737|OTHER|Questionnaire Administration|Ancillary studies
219312038|NCT06035874|DRUG|Bempedoic acid|Patient willl be randomized 1:1 in both the arms
219312039|NCT05042505|DRUG|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
219312040|NCT05042505|DRUG|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
219312041|NCT05844228|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
219312042|NCT05783375|OTHER|ADUNU program for delivery of RHD care services|The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
219312043|NCT00692978|DRUG|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
219312044|NCT00692978|DRUG|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
219312045|NCT00692978|DRUG|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
219312046|NCT00692978|DRUG|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
219312047|NCT04540744|DRUG|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
219354723|NCT02814565|DRUG|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
219312048|NCT04540744|DRUG|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
219312049|NCT04540744|DRUG|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
219312050|NCT02504515|OTHER|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
219312051|NCT00607022|DEVICE|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
219312052|NCT02940821|OTHER|Toothbrushing|Mechanical plaque removal
219312053|NCT02940821|OTHER|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
219312054|NCT02940821|OTHER|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
219312055|NCT02940821|OTHER|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
219312056|NCT02940821|OTHER|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
219312057|NCT04842656|OTHER|Post isometric relaxation|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
219312058|NCT04842656|OTHER|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
219312059|NCT03511313|DEVICE|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
219312060|NCT03511313|DIAGNOSTIC_TEST|Renal angiography|A renal angiography according to standard procedure.
219312061|NCT02822638|OTHER|STEMI PATIENT Cohort|PCI
219312062|NCT00584597|DRUG|Saline|Saline Control
219312063|NCT00584597|DRUG|Traumeel S|Traumeel S 1 mL
219312064|NCT00584597|DRUG|Traumeel S|Traumeel S 2mL
219312065|NCT00584597|DRUG|Traumeel S|Traumeel S 3mL
219312066|NCT04291599|DRUG|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
219312067|NCT04291599|DRUG|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
219312068|NCT06567808|DRUG|Cefazolin|administration as outlined
219312069|NCT06567808|DRUG|Vancomycin|administered as outlined
219312070|NCT05363371|BEHAVIORAL|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
219312071|NCT05363371|BEHAVIORAL|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
219312072|NCT02769377|DEVICE|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
219312073|NCT02769377|DEVICE|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
219312074|NCT04296253|GENETIC|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
219312075|NCT01870232|PROCEDURE|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
219312076|NCT03120247|DRUG|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
219312077|NCT03120247|DRUG|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
219312078|NCT03120247|DRUG|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
219312079|NCT05425628|DEVICE|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
219312080|NCT04532203|DRUG|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
219312081|NCT04532203|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
219312082|NCT06096987|OTHER|Electronic medical record portal videos|Teen to teen videos reviewing information about electronic medical record portals and information shared in electronic medical record portals.
219312083|NCT06096987|OTHER|General adolescent health videos|Teen to teen videos reviewing information about general adolescent health issues.
219312084|NCT03987178|BEHAVIORAL|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
219312085|NCT03987178|OTHER|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
219312086|NCT06053723|OTHER|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
219312087|NCT06053723|OTHER|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
219312088|NCT06053723|OTHER|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
219312089|NCT05720988|DRUG|Azacitidine|Given SC
219312090|NCT05720988|BIOLOGICAL|Tagraxofusp-erzs|Given IV
219312091|NCT04113083|OTHER|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
219312092|NCT04398953|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
219312093|NCT05958641|OTHER|Questionnaires|Participants will be asked to complete the questionnaire including general demographic information, the cognition, resistance and use of NPS as well as the behavioral expression of addiction susceptibility genes and adverse childhood experience.
219312094|NCT05748054|DRUG|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
219312095|NCT04211272|DRUG|Macitentan|Macitentan will be administrated as film-coated tablet in Part A and Part B.
219312096|NCT04211272|DRUG|Sildenafil|Sildenafil will be administrated as film-coated tablet in Part A.
219312097|NCT04211272|DRUG|Riociguat|Riociguat will be administrated as film-coated tablet in Part A.
219312098|NCT04211272|DRUG|Rosuvastatin|Rosuvastatin will be administrated as film-coated tablet in Part B.
219312099|NCT03328403|DEVICE|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
219312100|NCT03328403|DEVICE|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
219312101|NCT04599712|DRUG|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
219312102|NCT01791036|PROCEDURE|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
219312103|NCT01791036|PROCEDURE|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
219312104|NCT06799065|DRUG|ATX-295|ATX-295 Tablets will be taken orally
219312105|NCT06523114|DEVICE|Transcatheter Arterial Embolization|After accessing the common femoral artery or radial artery, embolization is performed using embolic material after confirming abnormal blood vessel abnormalities, lesion hypervascularity, and lesion enhancement findings.
219312106|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
219312107|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
219312108|NCT05492500|DRUG|Main cohort (Cohort A): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
219312109|NCT05492500|OTHER|Main cohort (Cohort A): Matched placebo|Matched placebo subcutaneous injection
219312110|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab low dose|ponsegromab low dose subcutaneous injection
219312111|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
219312112|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
219312113|NCT05492500|DRUG|Optional Cohort C: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
219312114|NCT05492500|OTHER|Optional Cohort C: Matched placebo|Matched placebo subcutaneous injection
219312115|NCT05492500|DRUG|Optional Cohort D: Ponsegromab high dose|Ponsegromab high dose subcutaneous injection
219312116|NCT05492500|OTHER|Optional Cohort D: Matched placebo|Matched placebo subcutaneous injection
219312117|NCT04750785|OTHER|No Intervention|Administered as specified in the treatment arm.
219312118|NCT05229731|PROCEDURE|Neurovisual evaluation|Standardized tests and scales classically used during a neurovisual evaluation,
219312119|NCT05229731|PROCEDURE|Cerebral MRI|"Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir"
219312120|NCT00810394|DRUG|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
219312121|NCT00507364|DRUG|Local injection of activated macrophages to anal fissure|
219312122|NCT04742647|PROCEDURE|Double cerclage|Two cervical cerlages will be placed
219312123|NCT04742647|PROCEDURE|Single cerclage|One cerclage will be placed
219312124|NCT04903730|DRUG|AER-901 Solution for Nebulization|"Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 \& 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo)."
219312125|NCT04903730|DRUG|Placebo|0.45% sterile saline for injection delivered via the FOX MOBILE device.
219312126|NCT01927705|BIOLOGICAL|FURESTEM-AD Inj.|
219312127|NCT02949804|BEHAVIORAL|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
219312128|NCT06095700|PROCEDURE|first rib resection|standard first rib resection
219312129|NCT06095700|PROCEDURE|First rib avulsion|As the active treatment, just instead of resectioning the first rib, we will do an avulsion of the first rib through the same incision
219312130|NCT00269893|DRUG|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
219312131|NCT00269893|DRUG|Placebo|Matching Placebo soulution either bolus or infusion.
219312132|NCT01905137|DRUG|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
219312133|NCT01905137|DRUG|placebo|
219312134|NCT05786495|OTHER|Early Discontinuation of Antibiotics|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
219312135|NCT05786495|OTHER|Standard of Care|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
219312136|NCT00357851|DRUG|Aprotinin|
219312137|NCT00369473|DRUG|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
219312138|NCT00369473|DRUG|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
219312139|NCT03282240|BIOLOGICAL|QIV-HD|0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
219312140|NCT03282240|BIOLOGICAL|Licensed TIV-HD1|0.5 mL-dose was administered IM into the upper arm area.
219312141|NCT03282240|BIOLOGICAL|Investigational TIV-HD2|0.5 mL-dose was administered IM into the upper arm area.
219312142|NCT03254485|DRUG|IW-1973|Oral Tablet
219312143|NCT03254485|DRUG|Placebo Oral Tablet|Oral Tablet
219312144|NCT01225419|DRUG|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
219312145|NCT01767480|DEVICE|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
219354724|NCT04747418|PROCEDURE|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
219312146|NCT01767480|BEHAVIORAL|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
219312147|NCT05569031|DRUG|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
219312148|NCT05569031|DRUG|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
219312149|NCT02146326|BEHAVIORAL|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
219312150|NCT02146326|BEHAVIORAL|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
219312151|NCT02910739|DRUG|MK-8931|MK-8931 40 mg
219312152|NCT00106418|DRUG|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
219312153|NCT02614456|DRUG|interferon-gamma and nivolumab|
219312154|NCT03187574|DEVICE|Elevate Ant™|Surgery with Elevate Ant™
219312155|NCT03187574|DEVICE|Perigee™|Surgery with Perigee™
219312156|NCT04361942|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
219312157|NCT04361942|OTHER|Placebo|Intravenous injection of 100 ml physiological saline solution containing no cells
219312158|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
219312159|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & CS|Test meal consumed with the control supplement
219312160|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
219312161|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & CS|Test drink consumed with the control supplement
219312162|NCT04031716|BEHAVIORAL|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
219312163|NCT03413735|OTHER|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
219312164|NCT03413735|OTHER|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
219312165|NCT05312151|DRUG|Psilocybin|Open label
219354725|NCT04747418|PROCEDURE|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
219354726|NCT04656652|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
219354727|NCT04656652|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
219354728|NCT03802877|BEHAVIORAL|Resource bank|See intervention arm descriptions
219354729|NCT03802877|BEHAVIORAL|ePlatform|See intervention arm descriptions
219312166|NCT02979483|OTHER|14-EISCP|"The 14-EISCP starts with the end of the first visit medical for patients who have symptoms suspicious of or confirmed symptomatic aPDAC (ECOG PS ≥ 2 and/or initially ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel):~The The 14-EISCP will include:~* Pain management,~* Nutritional management,~* Pathological examination and site of biopsy,~* Imaging,~* Endoscopy for diagnosis purpose or for biliary/duodenal stenting.~After the 14-EISCP, patients will receive best supportive care or chemotherapy according to their ECOG PS status:~* ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~* ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patients will be treated by: FOLFOX7 lightened"
219312167|NCT01598311|DRUG|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
219312168|NCT01598311|DRUG|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
219312169|NCT01598311|DRUG|Placebo|Placebo size 00 opaque hard gelatin capsules.
219312170|NCT00680784|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
219312171|NCT00680784|OTHER|Placebo Patch|Placebo Patch
219312172|NCT04042493|BEHAVIORAL|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
219312173|NCT06610006|PROCEDURE|High Intensity Interval Training (HIIT)|High intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio followed by 5-7 min of cool-down period..A total of 15 sessions of high intensity interval training alone , for thrice a week on alternative days for 5 consecutive weeks will be given. Warm-up session consisting of stretching exercises prior to intervention and cool down session after intervention will also be done and vitals before and after the session will be taken.
219312174|NCT06610006|PROCEDURE|Isometric Wall Squat|For isometric wall squat, each training session will be composed of 4 × 2-min bouts of IWS followed by 2-min rest periods. In first week, participants will do squat training or there will be a protocol for selecting exercise intensity in which participants will be given 30-s to perform a wall squat to select a position that they predict would elicit an target RPE score by varying the squat height. Based on the final squat height and RPE score, after bout 4, participants will be given a starting squat height for training session 1 and will then be progressed in each week
219312175|NCT02664727|BEHAVIORAL|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
219312176|NCT02664727|BEHAVIORAL|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
219312177|NCT06996951|DIAGNOSTIC_TEST|:PULMONARY FUNCTION TEST|PATIENT WILL HAVE PULMONARY FUNCTION TESTING PERFORMED, MEASURING FEV1/FVC.
219312178|NCT06996951|DIAGNOSTIC_TEST|NASAL ENDOSCOPY|PATIENT WILL HAVE NASAL ENDOSCOPY TO RECORD LUND KENNEDY ENDOSCOPIC SCORE
219312179|NCT06996951|DIAGNOSTIC_TEST|LEUKOSORB FILTER PAPER APPLICATION TO NASAL CAVITY|LEUKOSORB FILTER PAPER STRIP WILL BE APPLIED INSIDE THE NOSTRIL TO SAMPLE NASAL MUCOUS TO OBTAIN IMMUNOGLOBULIN LEVELS TO MONITOR INFLAMMATION WITHIN THE NASAL MUCOUS
219312180|NCT06996951|BEHAVIORAL|SINONASAL OUTCOME TEST 22 QUESTIONNAIRE|PATIENT WILL COMPLETE THE SINONASAL OUTCOME TEST 22 QUESTIONNAIRE TO EVALUATE FOR SINONASAL SYMPTOMS DURING THE STUDY
219312181|NCT06996951|BEHAVIORAL|CYSTIC FIBROSIS QUESTIONNAIRE-REVISED|PATIENT WILL COMPLETE THE CYSTIC FIBROSIS QUESTIONNAIRE-REVISED TO EVALUATE FOR CYSTIC FIBROSIS RELATED SYMPTOMS DURING THE STUDY
219312182|NCT06996951|BEHAVIORAL|PATIENT HEALTH QUESTIONNAIRE-9|PATIENT WILL COMPLETE THE PATIENT HEALTH QUESTIONNAIRE-9 TO EVALUATE FOR QUALITY OF LIFE DURING THE STUDY
219312183|NCT06996951|DRUG|STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID|PATIENT WILL STOP USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
219312184|NCT06614764|OTHER|AG (experimental Andiroba Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the AG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
219312185|NCT06614764|OTHER|KF2G (Potassium nitrate gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the KF2G received application of the potassium nitrate gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
219312186|NCT06614764|OTHER|PG (Placebo Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the PG group received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
219312187|NCT01661478|OTHER|Training on motivational interviewing|
219312188|NCT06459466|PROCEDURE|kinesiotherapy exercises with cervical mobilization|Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction
219312189|NCT06459466|PROCEDURE|cervical Mobilization|This includes Cervical lateral glide mobilization
219354730|NCT03802877|BEHAVIORAL|Health coach|See intervention arm descriptions
219354731|NCT01411345|RADIATION|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
219312190|NCT06684652|PROCEDURE|3TB+6SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained sextant six-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
219312191|NCT06684652|PROCEDURE|3TB+12SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained fore-zone 12-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
219312192|NCT07015632|OTHER|Performance of the Upper Limb, Brooke Scale, grip strength test|Thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms.
219312193|NCT03602261|DRUG|Calcifediol Oral Capsule|Capsule, weekly
219312194|NCT03602261|DRUG|Placebo oral capsule|Capsule, weekly
219312195|NCT06690216|DIAGNOSTIC_TEST|PET/CT （[18F]AlF-NOTA-PCP2）|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
219312196|NCT06690216|DIAGNOSTIC_TEST|[18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
219312197|NCT07019220|DRUG|Gemcitabine|Intravesical installation
219312198|NCT07019194|DRUG|Senaparib capsules(20mg)|Single oral dose of Senaparib administered under fasting condition, 1\*20mg capsules in first intervention period and then 2\*10mg capsules in second intervention period (after washout period: at least 5 days)
219312199|NCT07019194|DRUG|Senaparib capsules(10mg)|Single oral dose of Senaparib administered under fasting condition, 2\*10mg capsules in first intervention period and then 1\*20mg capsules in second intervention period (after washout period: at least 5 days)
219312200|NCT07020689|PROCEDURE|CABS|Following diagnosis, individuals with OHS were counseled on therapeutic options, including CPAP therapy, body weight reduction, or CABS. The final decision was made through a shared decision-making process. The CABS procedure was conducted under general anesthesia and integrated bariatric and multilevel airway surgery within a single operative session. This transdisciplinary approach aimed to address both sleep-disordered breathing and obesity-related ventilatory compromise. A general surgeon performed the bariatric procedure, while an otorhinolaryngologist conducted the airway surgery sequentially during the same operation. For the bariatric component, laparoscopic sleeve gastrectomy (LSG) was the primary procedure, while laparoscopic Roux-en-Y gastric bypass was reserved for individuals with significant gastroesophageal reflux or poorly controlled diabetes. Airway surgery encompassed interventions at the nasal, palatal, and lingual levels.
219312201|NCT07020767|PROCEDURE|Vestibular Socket Therapy (VST) Group|A minimally invasive vestibular incision technique for atraumatic tooth extraction, followed by immediate implant placement using BioHorizons implants. The socket is augmented with MegaOss™ allograft and covered with T-barrier™ collagen membrane, stabilized with membrane tacks. Soft tissue closure is achieved with 7/0 nylon sutures. Customized composite healing abutments are used, and zirconia crowns are delivered at 3 months.
219312202|NCT07020767|PROCEDURE|Flap Elevation Group|Traditional mucoperiosteal flap elevation with intrasulcular and vertical incisions, followed by atraumatic extraction and immediate implant placement using BioHorizons implants. The socket is grafted with MegaOss™ allograft, covered with T-barrier™ collagen membrane, and stabilized with tacks. The site is closed with 7/0 nylon sutures. Healing abutments and zirconia crowns are applied following the same timeline as the VST group.
219312203|NCT07019467|OTHER|Bed Bath With Auditory Hypnosis|"In the bed bath protocol accompanied by audio suggestion, a 30-60 minute audio recording containing audio suggestions specific to the ICU patient will be prepared with the support of a specialist hypnotherapist. This audio recording will include the following messages: - The purpose of the bed bath, - Procedures to be performed during the bed bath, - The benefits of the bed bath, - Feeling safe during the bed bath, - Improvement in physiological parameters and comfort levels after the bed bath.~While it is noted that auditory suggestion typically lasts 30-60 minutes, even a 15-minute auditory suggestion has been reported to provide benefits."
219312204|NCT07018882|DEVICE|Sullivan|Patients who are clinically eligible for cochlear implant surgery and can tolerate the surgery will be asked for their consent and then undergo the cochlear implant procedure. The outcome of the cochlear implant surgery will be evaluated through auditory performance assessments. Additionally, adverse effects will be monitored to assess the efficacy and safety of the cochlear implants on auditory function.
219312205|NCT07019740|OTHER|CASE GROUP|SYMPATHETIC SKIN RESPONSE, CUTANEOUS QUIET PERIOD AND COMPASS-31 QUESTIONNAIRE EVALUATED
219312206|NCT07021326|OTHER|there is no intervention|This is an observational, cross-sectional study with no intervention. Data were collected through a single body composition measurement without any treatment or manipulation. Biochemical, clinical and anthropometric data was collected directly from the patient's clinical records. No intervention was needed.
219312207|NCT07019012|DRUG|SGLT2i+Metformin+Cofrogliptin|The combination of SGLT2i+Metformin+Cofrogliptin
219312208|NCT07019012|DRUG|SGLT2i+Metformin+Linagliptin|The combination of SGLT2i+Metformin+Linagliptin
219312209|NCT04337515|DEVICE|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
219312210|NCT05677893|DRUG|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
219312211|NCT05677893|OTHER|Placebo|Normal saline
219312212|NCT00599976|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation
219312213|NCT05791760|BEHAVIORAL|Compassion-focused therapy (CFT) for complex PTSD|The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
219312214|NCT01485354|DEVICE|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
219312215|NCT00050726|DRUG|Interleukin-2|
219312216|NCT01862302|DRUG|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
219312217|NCT01862302|DRUG|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
219312218|NCT05452850|DIAGNOSTIC_TEST|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
219312219|NCT02016456|DEVICE|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
219312220|NCT02016456|DEVICE|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
219312221|NCT02101034|BIOLOGICAL|Cetuximab|
219312222|NCT02101034|DRUG|PD 0332991|
219312223|NCT01652950|BEHAVIORAL|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was \>3000 fitness points/month - equivalent to \>20 gym visits/month."
219354732|NCT01411345|RADIATION|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
219312224|NCT06323200|PROCEDURE|lymphaticovenous anastomosis|The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
219312225|NCT04994327|OTHER|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
219312226|NCT04600700|DEVICE|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
219312227|NCT02827630|OTHER|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
219312228|NCT02827630|OTHER|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
219312229|NCT06248554|DRUG|PD-1 Inhibitors|Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
219312230|NCT00247338|DRUG|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
219312231|NCT02787525|OTHER|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
219312232|NCT03081052|DRUG|iNO|Subject will receive inhaled Nitric Oxide in this intervention
219312233|NCT03081052|DRUG|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
219312234|NCT05184686|OTHER|noise expose|simulate noise expose environments
219312235|NCT05184686|OTHER|RF expose|simulate RF expose environments
219312236|NCT01103245|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
219312237|NCT01103245|DRUG|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
219312238|NCT01103245|DRUG|Spironolactone (SPL 25)|spironolactone 25mg daily
219312239|NCT01103245|DRUG|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
219312240|NCT01103245|DRUG|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
219312241|NCT01409616|DRUG|darexaban|oral
219312242|NCT01409616|DRUG|darexaban (double dose)|oral
219312243|NCT01409616|DRUG|Acetyl Salicylic Acid|oral
219312244|NCT01409616|DRUG|clopidogrel|oral
219312245|NCT05987722|OTHER|Enoxolone|The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
219312246|NCT05987722|OTHER|Sensodyne|The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
219312247|NCT00261313|DRUG|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
219312248|NCT00261313|DRUG|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
219312249|NCT00215878|DRUG|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
219312250|NCT00457184|PROCEDURE|Blood tests|
219312251|NCT04109196|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
219312252|NCT02214433|DRUG|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
219312253|NCT02214433|DRUG|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
219312254|NCT02214433|DRUG|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
219312255|NCT02214433|DRUG|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
219312256|NCT02214433|DRUG|Debio 1450 Capsule|Debio 1450 40 mg capsules
219312257|NCT02214433|DRUG|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
219312258|NCT02214433|DRUG|Pantoprazole|Pantoprazole 40 mg orally
219312259|NCT02332109|DEVICE|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
219312260|NCT03597412|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
219312261|NCT03597412|DRUG|Monorova|Rosuvastatin 20mg
219312262|NCT06236529|BEHAVIORAL|Health Behavior Change Counseling|A telephone-based intervention employing principles and practices of motivational interviewing.
219312263|NCT06236529|BEHAVIORAL|Self-management program|An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
219312264|NCT04111432|BIOLOGICAL|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
219312265|NCT04111432|BIOLOGICAL|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
219312266|NCT04111432|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
219312267|NCT01121978|PROCEDURE|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
219312268|NCT05214196|DRUG|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
219312269|NCT05522933|OTHER|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health \& work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
219312270|NCT00432887|DRUG|caffeine administration|
219312271|NCT03635333|DRUG|Nicotine|Nicotine level (6 or 18 mg)
219312272|NCT03635333|DRUG|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
219312273|NCT06491407|DIAGNOSTIC_TEST|Chewing and swallowing performance assessment and related factors|In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
219312274|NCT06450756|BEHAVIORAL|Couples arm|The Couples Arm aims to improve family planning (FP) utilization in pastoralist communities, addressing significant disparities in contraceptive use and unmet FP needs between pastoralist and agrarian communities in Ethiopia. Pastoralist areas face challenges such as low contraceptive usage, high unmet FP needs, and elevated rates of maternal and child morbidity and mortality. In 2016, only 9.1% of women in pastoralist areas used contraceptives, compared to a 41% prevalence rate in 2019 for the general population in Ethiopia. Reasons for non-use of contraceptives include lack of knowledge, unwillingness, negative perceptions, desire for many children due to child mortality concerns, and male dominance in FP decision-making. The study hypothesizes that engaging men and educating women about FP could enhance FP utilization, increase male involvement in family planning, and empower women.
219312275|NCT06450756|BEHAVIORAL|Male arm|This arm focused on promoting male involvement in family planning (FP) through comprehensive health education and video messages. Husbands were encouraged to become supportive partners and share FP information with their wives. Separate education sessions were held for men, recognizing their greater exposure to social activities and information in pastoralist contexts. Pastoralist wives typically rely on their husbands for information due to limited social access. Women in pastoral communities have significant informal power in family decisions, influenced by factors such as age, husband's status, sons' ages, eloquence, and wisdom. Reproductive health discussions are primarily between husband and wife. Education aimed to improve modern contraceptive use, overcoming common barriers like husband objection and religious influence on decision-making.
219312276|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
219312277|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
219312278|NCT02870699|DEVICE|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
219312279|NCT02870699|DEVICE|Placebo excipient|film forming excipient solution
219312280|NCT00604279|DRUG|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
219312281|NCT00604279|DRUG|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
219312282|NCT00076492|DRUG|CoQ10|
219312283|NCT00076492|DRUG|GPI 1485|
219312284|NCT00355056|OTHER|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
219312285|NCT00355056|DEVICE|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
219312286|NCT03348865|BEHAVIORAL|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
219312287|NCT02884427|DEVICE|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
219312288|NCT02884427|DEVICE|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
219312289|NCT02884427|DEVICE|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
219312290|NCT05802758|BEHAVIORAL|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
219312291|NCT00861224|OTHER|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
219312292|NCT01894373|DRUG|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
219312293|NCT01894373|BIOLOGICAL|CIK|
219312294|NCT00901277|BEHAVIORAL|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
219312295|NCT00901277|BEHAVIORAL|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
219312296|NCT03898947|PROCEDURE|Diagnostic hysteroscopy and targeted endometrial biopsy|Diagnostic hysteroscopy and targeted endometrial biopsy
219312297|NCT01489202|DEVICE|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
219312298|NCT01489202|DEVICE|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
219312299|NCT00733993|DRUG|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
219312300|NCT00733993|DRUG|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
219312301|NCT00733993|DRUG|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
219312302|NCT00733993|DRUG|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
219312303|NCT04201600|DEVICE|Continuous Glucose Monitoring System (CGMS)|Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
219312304|NCT01072877|DRUG|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
219312305|NCT01072877|DRUG|Placebo Vehicle|Placebo vehicle
219312306|NCT02782403|DRUG|Axitinib|Given PO
219312307|NCT02782403|DRUG|Bosutinib|Given PO
219312308|NCT02782403|OTHER|Laboratory Biomarker Analysis|Correlative studies
219312309|NCT05351853|DIETARY_SUPPLEMENT|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
219312310|NCT05351853|DIETARY_SUPPLEMENT|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
219312311|NCT05351853|DIETARY_SUPPLEMENT|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
219312312|NCT02804776|DRUG|Gefitinib|250mg oral daily for 4 weeks
219312313|NCT00031187|DRUG|SGN-15 (cBR96-doxorubicin immunoconjugate)|
219312314|NCT00031187|DRUG|Taxotere (docetaxel)|
219312315|NCT00133692|DRUG|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
219312316|NCT00133692|DRUG|Atenolol/HCTZ/Trandolapril|
219312317|NCT02952287|DEVICE|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
219312318|NCT00062894|DRUG|Iodine I 131 Tositumomab|
219312319|NCT02895438|DIETARY_SUPPLEMENT|gluten|
219312320|NCT00044915|DRUG|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
219312321|NCT00044915|DRUG|Placebo|All patients receive 1.25 mg of placebo
219312322|NCT00995020|PROCEDURE|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
219312323|NCT00995020|PROCEDURE|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
219312324|NCT04131400|DIAGNOSTIC_TEST|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
219312325|NCT04279938|DRUG|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
219312326|NCT04279938|DRUG|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
219312327|NCT04279938|DRUG|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
219312328|NCT02053038|DEVICE|iFR|Treatment guided by instantaneous wave-free ratio
219312329|NCT02053038|DEVICE|FFR|Treatment guided by Fractional Flow Reserve
219312330|NCT06284148|DIAGNOSTIC_TEST|Screening for intimate partner violence|confidential screening using exam computer
219312331|NCT06284148|OTHER|Assessment and referral|confidential assessment and referral of high-risk patients using decision-support templates
219312332|NCT05858268|GENETIC|Whole-genome sequencing|Whole-genome sequencing
219312333|NCT04484181|OTHER|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
219312334|NCT04484181|OTHER|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
219312335|NCT02347228|DRUG|OB318 capsule|Oral qd, at least 30 minutes before breakfast
219312336|NCT04424797|OTHER|Prone Positioning|Intervention is patient in prone positioning
219312337|NCT04424797|OTHER|Supine Positioning|Intervention is patient in supine positioning
219312338|NCT02720536|DRUG|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
219312339|NCT03412370|OTHER|Cognitive Assessment|Complete cognitive assessments
219312340|NCT03412370|OTHER|Questionnaire Administration|Complete questionnaires
219312341|NCT02837835|DRUG|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
219312342|NCT02837835|DRUG|ceftazidime|20 mg/kg over 30 min every 8 h
219312343|NCT06409780|DIAGNOSTIC_TEST|Comparative analysis of CUS, CAD and CXR in pulmonary TB|The strumental analysis of pulmonary TB signs with chest ultrasound, chest x-ray and CAD will be compared in two different settings: index cases and household contacts
219312344|NCT04604678|DRUG|Metformin|Metformin at 1500 mg/day
219312345|NCT04604678|DRUG|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
219312346|NCT03325998|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
219312347|NCT03130543|DIETARY_SUPPLEMENT|Rice cereal|Standard formula thickened with rice cereal
219312348|NCT03130543|DIETARY_SUPPLEMENT|Enfamil AR|Enfamil AR formula
219312349|NCT04750174|OTHER|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
219312350|NCT01048567|OTHER|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
219312351|NCT01048567|OTHER|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
219312352|NCT06374355|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
219312353|NCT00234546|BIOLOGICAL|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
219312354|NCT00234546|DRUG|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
219312355|NCT05877625|PROCEDURE|Expectoration care|"1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs"
219312356|NCT00091117|DRUG|bortezomib|Given IV
219312357|NCT00091117|OTHER|pharmacological study|Correlative studies
219312358|NCT04471623|BEHAVIORAL|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
219312359|NCT05206019|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
219312360|NCT00280046|DRUG|biphasic insulin aspart|
219312361|NCT00100854|DRUG|erlotinib hydrochloride|Given orally
219312362|NCT00100854|DRUG|fulvestrant|Given intramuscularly
219312363|NCT01121120|DRUG|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
219312364|NCT01121120|DRUG|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
219312365|NCT04878731|BIOLOGICAL|PF-06741086|single dose SC injection of 300 mg PF-06741086
219312366|NCT02234245|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
219312367|NCT02411682|OTHER|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
219312368|NCT02411682|OTHER|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
219312369|NCT00699452|DRUG|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
219312370|NCT00699452|DRUG|placebo|placebo
219312371|NCT02800226|DEVICE|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
219312372|NCT02800226|DEVICE|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
219312373|NCT06411483|DEVICE|ObeEnd Band|The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
219312374|NCT06411483|OTHER|Placebo|The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
219312375|NCT00510250|DRUG|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
219312376|NCT00510250|DRUG|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
219312377|NCT00510250|PROCEDURE|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
219312378|NCT02705144|OTHER|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
219312379|NCT02730988|BEHAVIORAL|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
219312380|NCT02047292|DEVICE|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
219312381|NCT02047292|DEVICE|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
219312382|NCT02047292|DEVICE|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
219312383|NCT02221986|BEHAVIORAL|Interdisciplinary rehabilitation|
219312384|NCT03268733|DRUG|Folic Acid|Tablet 5 mg
219312385|NCT02208154|DRUG|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
219312386|NCT02208154|DRUG|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.
219312387|NCT02208154|DRUG|Selective Digestive Decontamination (SDD)|"SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
219312388|NCT00557388|DIETARY_SUPPLEMENT|Protein/Amino Acids|Casein Whey Leucine
219312389|NCT00557388|OTHER|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
219312390|NCT04548414|OTHER|No.|This is an observational study with no intervention.
219312391|NCT03330457|BIOLOGICAL|Andexanet alfa (bolus)|fXa inhibitor antidote
219312392|NCT03330457|DRUG|Betrixaban 80 mg PO QD|fXa inhibitor
219312393|NCT03330457|BIOLOGICAL|Andexanet alfa (infusion IV)|fXa inhibitor antidote
219312394|NCT03538379|BEHAVIORAL|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
219312395|NCT00659893|DRUG|PEP005 Topical gel|0.05%, two day dose
219312396|NCT00719563|DRUG|American ginseng|Given orally
219312397|NCT00719563|OTHER|placebo|Given orally
219312398|NCT05210296|BEHAVIORAL|Exercises|Therapeutic exercise will be applied to the elderly
219312399|NCT05119426|BIOLOGICAL|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
219312400|NCT02997488|DEVICE|Pentax Airwayscope|intubation using Pentax Airwayscope
219312401|NCT02997488|DEVICE|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
219312402|NCT04183972|PROCEDURE|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
219312403|NCT00420017|DRUG|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
219312404|NCT00420017|OTHER|Control|No amiodarone
219312405|NCT03235622|DIAGNOSTIC_TEST|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
219312406|NCT00440804|DRUG|ibuprofen l-lysine iv solution (NeoProfen (R) )|
219312407|NCT02950324|BEHAVIORAL|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
219312408|NCT02950324|BEHAVIORAL|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
219312409|NCT02706301|BEHAVIORAL|Telephone-Based Coping Skills Training (CST)|
219312410|NCT01631604|DEVICE|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
219312411|NCT01631604|DRUG|Muscle/nerve injection|Injection to muscle or nerve
219312412|NCT01631604|PROCEDURE|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
219312413|NCT01631604|OTHER|Physical therapy treatment|
219312414|NCT00792805|DRUG|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219312415|NCT00792805|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219312416|NCT00792805|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
219312417|NCT02649153|DRUG|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
219312418|NCT02649153|DRUG|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
219312419|NCT02120625|DEVICE|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
219312420|NCT04434950|BEHAVIORAL|Promoting and implementing repeated HIV self-testing and online real-time counseling|At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
219312421|NCT02604225|DRUG|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
219312422|NCT02604225|DRUG|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
219312423|NCT03531281|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
219312424|NCT03531281|DRUG|Cyclophosphamide|Given IV
219312425|NCT03531281|DRUG|Etoposide|Given IV
219312426|NCT03531281|DRUG|Goat Milk|Given human lysozyme goat milk PO
219312427|NCT03531281|OTHER|Laboratory Biomarker Analysis|Correlative studies
219312428|NCT03531281|BIOLOGICAL|Palifermin|Given IV
219312429|NCT03531281|DRUG|Sirolimus|Given PO
219312430|NCT03531281|DRUG|Tacrolimus|Given IV and PO
219312431|NCT03531281|RADIATION|Total-Body Irradiation|Undergo FTBI
219312432|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
219312433|NCT05792436|DEVICE|1-min interval oscillometric method|"Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period."
219312434|NCT05792436|DEVICE|arterial catheterization method|During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
219312435|NCT06357351|PROCEDURE|vestibular incision sub periosteal tunnel access ( VISTA) technique.|In comparison between the two groups, the first group uses collagen membrane and the other group uses advanced PRF using the same surgical technique (VISTA)
219312436|NCT03278106|OTHER|Laboratory Biomarker Analysis|Correlative studies
219312437|NCT03278106|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
219312438|NCT06494202|OTHER|Innovative rehabilitation|Conventional rehabilitation program associated with innovative therapies.
219312439|NCT06494202|OTHER|Conventional rehabilitation program.|Conventional rehabilitation program
219312440|NCT01956500|DIETARY_SUPPLEMENT|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
219312441|NCT01956500|DIETARY_SUPPLEMENT|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
219312442|NCT05826743|DEVICE|COLO BT™|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
219312443|NCT05826743|OTHER|Stoma Creation|Protective ileostomy
219312444|NCT04692415|DRUG|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
219312445|NCT04692415|DRUG|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
219312446|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
219312447|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
219312448|NCT01006928|OTHER|Questionaire|Questionaire to mothers
219312449|NCT00820027|DRUG|Etoricoxib 90 mg|One 90 mg tablet once daily
219312450|NCT00820027|DRUG|Etoricoxib 120 mg|Two 60 mg tablets once daily
219312451|NCT00820027|DRUG|Ibuprofen 600 mg|One tablet three times daily
219312452|NCT00820027|DRUG|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
219312453|NCT00820027|DRUG|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
219312454|NCT00820027|DRUG|Matching Placebo for Ibuprofen|One tablet three times daily
219312455|NCT00820027|DRUG|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
219312456|NCT00820027|DRUG|Oxycodone|5 mg as needed
219312457|NCT00302419|DRUG|intracoronary infusion,|streptokinase, 250,000 units
219312458|NCT00302419|PROCEDURE|primary percutaneous coronary angioplasty|
219312459|NCT00452088|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
219312460|NCT00452088|BIOLOGICAL|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
219312461|NCT00452088|BIOLOGICAL|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
219312462|NCT02982187|DEVICE|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
219312463|NCT02982187|DEVICE|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
219312464|NCT02982187|DEVICE|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
219312465|NCT02982187|DEVICE|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
219312466|NCT02982187|OTHER|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
219312467|NCT02982187|OTHER|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
219312468|NCT02982187|OTHER|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
219312469|NCT02982187|OTHER|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
219312470|NCT02376075|DRUG|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
219312471|NCT02376075|DRUG|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
219312472|NCT01366287|DRUG|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
219312473|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
219312474|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
219312475|NCT03437278|DRUG|Ligelizumab|Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
219312476|NCT03437278|DRUG|Placebo|Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
219312477|NCT04196153|PROCEDURE|Pedicle screws instrumentation|The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
219312478|NCT01412099|BEHAVIORAL|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
219312479|NCT01412099|BEHAVIORAL|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
219312480|NCT00931554|PROCEDURE|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
219312481|NCT06091761|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
219312482|NCT06091761|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
219312483|NCT06091761|OTHER|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
219312484|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
219312485|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
219312486|NCT03774251|BIOLOGICAL|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
219312487|NCT03774251|DEVICE|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
219312488|NCT01951781|OTHER|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
219312489|NCT04672174|DIAGNOSTIC_TEST|Questionnaire: DemTect|Questionnaire is handed out to subjects
219312490|NCT05155241|BEHAVIORAL|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
219312491|NCT05155241|BEHAVIORAL|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
219312492|NCT05519397|DIAGNOSTIC_TEST|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
219312493|NCT00524719|PROCEDURE|Open Reduction and Internal Fixation|Fixation with volar locked plate
219312494|NCT00524719|PROCEDURE|Non-Spanning External Fixation|Radio-radial external fixation
219312495|NCT00524719|PROCEDURE|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
219312496|NCT03462472|BEHAVIORAL|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
219312497|NCT03462472|BEHAVIORAL|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
219312498|NCT01630434|DEVICE|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
219312499|NCT01630434|DEVICE|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
219312500|NCT05445583|BEHAVIORAL|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
219312501|NCT05445583|BEHAVIORAL|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
219312502|NCT05445583|BEHAVIORAL|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
219312503|NCT05445583|BEHAVIORAL|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
219312504|NCT06310057|DRUG|Tofacitinib|Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
219312505|NCT05722054|OTHER|Diagnostic tests|"Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination."
219312506|NCT05722054|OTHER|Equilibrate diet|Nutritionally-balanced Alimentation
219312507|NCT02303691|BEHAVIORAL|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
219312508|NCT02303691|BEHAVIORAL|Neutral Training|A control version of computerized attention training.
219312509|NCT05203354|RADIATION|Narrowband Ultraviolet B|patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
219312510|NCT05203354|DRUG|Acitretin|patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
219312511|NCT01813708|BEHAVIORAL|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
219312512|NCT01813708|BEHAVIORAL|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
219312513|NCT05380492|BIOLOGICAL|VOY-101|Intravitreal injection of VOY-101
219312514|NCT06140043|OTHER|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
219312515|NCT04101708|DRUG|Lansoprazole, Amoxicillin|high dose dual regimen
219312516|NCT04101708|DRUG|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
219312517|NCT01918553|OTHER|clinical parameters|
219312518|NCT01918553|OTHER|visual acuity exams|
219312519|NCT01918553|OTHER|retinophotography|
219312520|NCT01918553|OTHER|SD-OCT|
219312521|NCT01918553|OTHER|Intra ocular Pressure (IOP)|
219312522|NCT01918553|OTHER|retinal imaging (OPTOMAP)|
219312523|NCT01918553|OTHER|axial length (IOL master)|
219312524|NCT02766894|DEVICE|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
219312525|NCT01091753|DRUG|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
219312526|NCT02920333|PROCEDURE|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
219312527|NCT02920333|DEVICE|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
219312528|NCT02920333|DEVICE|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
219312529|NCT02920333|DEVICE|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
219312530|NCT03313921|DIAGNOSTIC_TEST|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
219312531|NCT01871311|DRUG|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
219312532|NCT02580955|DEVICE|LEGFLOW DCB|
219312533|NCT05158998|DRUG|propofol infusion|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
219312534|NCT05158998|DRUG|sevoflurane inhalation|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
219312535|NCT02893930|DRUG|Sapanisertib|Given PO
219312536|NCT02498470|PROCEDURE|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
219312537|NCT05441254|DRUG|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
219312538|NCT04988256|DRUG|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
219312539|NCT04988256|DRUG|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
219312540|NCT01137526|DRUG|ABT-384|Subjects will take study drug once daily for 12 weeks
219312541|NCT01137526|DRUG|donepezil|Subjects will take study drug once daily for 12 weeks.
219312542|NCT01137526|DRUG|placebo|Subjects will take study drug once daily for 12 weeks
219312543|NCT02349360|BIOLOGICAL|L. johnsonii N6.2|L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
219312544|NCT02349360|BIOLOGICAL|Placebo|Encapsulated starch placebo administered for 8 weeks
219312545|NCT00921960|OTHER|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
219312546|NCT00512304|PROCEDURE|association chemotherapy and radiochemotherapy|
219312547|NCT02404207|OTHER|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
219312548|NCT02404207|OTHER|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
219312549|NCT02404207|OTHER|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
219312550|NCT02404207|OTHER|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
219312551|NCT01176773|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
219312552|NCT04875741|OTHER|Neural mobilization|Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.
219312553|NCT04875741|OTHER|Muscle energy technique|Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
219312554|NCT04250987|DEVICE|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
219312555|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 soft gelatine capsules|
219745184|NCT01779414|OTHER|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
219312556|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 film-coated tablets|
219312557|NCT02183285|DIETARY_SUPPLEMENT|Placebo film-coated tablets (fct)|
219312558|NCT02183285|DIETARY_SUPPLEMENT|Placebo soft gelatine capsules|
219312559|NCT01614743|DRUG|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
219312560|NCT01614743|DRUG|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
219312561|NCT00118820|DRUG|IV Preoperative antibiotic or placebo|
219312562|NCT02919657|DIETARY_SUPPLEMENT|Genepro Protein|weekly blood draws to measure blood protein levels
219312563|NCT02919657|DIETARY_SUPPLEMENT|Whey Protein|weekly blood draws to measure blood protein levels
219312564|NCT02854293|OTHER|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
219745185|NCT00694863|DRUG|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
219745186|NCT04785209|OTHER|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
219312565|NCT03181451|DRUG|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
219312566|NCT00390182|DRUG|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study."
219312567|NCT06321549|OTHER|The reference point of minimally invasive mastectomy procedure conducted|November 2018 as a temporal reference point was predicated on the milestone of the medical center's inaugural minimally invasive mastectomy procedure conducted
219312568|NCT02335125|BEHAVIORAL|Motivational Interviewing|
219312569|NCT02335125|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
219312570|NCT02335125|DRUG|Psychotropic Drugs|
219312571|NCT02335125|OTHER|Care Management|
219312572|NCT01937325|DRUG|ivacaftor|active arm
219312573|NCT01937325|DRUG|placebo|active arm
219312574|NCT06026085|OTHER|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
219312575|NCT06026085|OTHER|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
219312576|NCT06026085|OTHER|0.9% normal saline|0.9% normal saline+routine sun protection
219312577|NCT04362410|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab single dose subcutaneously injection.
219312578|NCT04362410|OTHER|Placebo|Placebo single dose subcutaneously injection.
219312579|NCT03672422|DIAGNOSTIC_TEST|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
219312580|NCT03672422|BEHAVIORAL|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
219312581|NCT03672422|DIAGNOSTIC_TEST|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
219312582|NCT03672422|DIAGNOSTIC_TEST|Urine sample|50 ml of urine in collection container.
219312583|NCT05666388|PROCEDURE|Rescue stenting|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
219312584|NCT03275129|DIAGNOSTIC_TEST|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
219312585|NCT04003220|PROCEDURE|blood sample|The extra samples will be taken Blood sampling
219312586|NCT04003220|PROCEDURE|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
219312587|NCT06018181|DRUG|Shuxuetong Injection|According to clinical real treatment records
219312588|NCT01658098|BEHAVIORAL|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
219312589|NCT03865147|DRUG|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
219312590|NCT03865147|DRUG|EMLA cream|Active Comparator
219312591|NCT03865147|DRUG|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
219312592|NCT05127369|DRUG|Dental pulp mesenchymal cell injection|Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
219312593|NCT05127369|DRUG|Dental pulp mesenchymal cell vehicle|Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
219312594|NCT05127369|DRUG|fluoxetine hydrochloride capsule|fluoxetine hydrochloride capsule
219312595|NCT04615767|DIETARY_SUPPLEMENT|D-chiro-inositol|as described previously
219312596|NCT03008447|DRUG|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
219312597|NCT03008447|DRUG|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
219312598|NCT03008447|DRUG|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
219312599|NCT03008447|DRUG|PBO|Single dose of placebo administered within 5 minutes before bedtime.
219312600|NCT03458286|DEVICE|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
219312601|NCT03920709|OTHER|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
219312602|NCT05140733|PROCEDURE|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
219312603|NCT05140733|PROCEDURE|Fusion surgery|Fusion surgery for patients with foraminal stenosis
219312604|NCT01493648|DRUG|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
219312605|NCT01493648|DRUG|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
219312606|NCT04855266|DRUG|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
219312607|NCT04855266|DRUG|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
219312608|NCT04855266|DIAGNOSTIC_TEST|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
219312609|NCT03780426|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
219312610|NCT03780426|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
219312611|NCT04359251|OTHER|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
219312612|NCT04359251|OTHER|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
219312613|NCT04359251|OTHER|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
219312614|NCT01326533|DRUG|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
219312615|NCT01326533|OTHER|Placebo|Thirteen weeks of oral placebo provided as capsules
219312616|NCT04905147|DRUG|Mosapride|Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
219312617|NCT04905147|DRUG|Placebo|Placebo drug 15 mg
219312618|NCT04782388|DRUG|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
219312619|NCT04782388|OTHER|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
219312620|NCT05422287|OTHER|Virtual Reality Glasses|Group 1
219312621|NCT05422287|OTHER|Thermomechanical Stimulation Device|Group 2
219312622|NCT00458809|DRUG|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
219312623|NCT02018835|DEVICE|MRI|
219312624|NCT02018835|DEVICE|cardiac echography transthoracic|
219312625|NCT06023277|BIOLOGICAL|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
219312626|NCT05221463|BEHAVIORAL|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
219312627|NCT05221463|BEHAVIORAL|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
219312628|NCT00298909|BEHAVIORAL|physical exercise|physical exercise
219312629|NCT00298909|DRUG|niaspan (extended-release niacin)|niaspan (extended-release niacin)
219312630|NCT00298909|DRUG|niacin|niacin extended-release
219312631|NCT00298909|OTHER|control|control
219312632|NCT02941133|OTHER|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
219312633|NCT02941133|OTHER|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
219312634|NCT04932538|OTHER|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
219312635|NCT04617756|DRUG|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
219312636|NCT01050348|DRUG|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
219312637|NCT01050348|DRUG|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
219312638|NCT00846456|BIOLOGICAL|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
219312639|NCT01135706|OTHER|No Intervention|This study does not include an intervention but is observational in nature.
219312640|NCT03193489|OTHER|Follow-up|
219312641|NCT03193489|OTHER|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
219312642|NCT03193489|OTHER|Control Parkinson group|No treatment.
219312643|NCT03525990|OTHER|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
219312644|NCT02975024|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
219312645|NCT02975024|DEVICE|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
219312646|NCT02975024|DEVICE|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
219312647|NCT04990492|DIAGNOSTIC_TEST|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
219312648|NCT04990492|DIAGNOSTIC_TEST|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
219312649|NCT01626703|OTHER|Reminding call|
219312650|NCT01862133|OTHER|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
219312651|NCT04476056|OTHER|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
219312652|NCT00926211|DEVICE|ARTAS™ System|Hair harvest using a computer-assisted system
219312653|NCT00926211|PROCEDURE|Manual Hair Harvest|Hair harvesting via the manual technique
219312654|NCT00625950|PROCEDURE|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
219312655|NCT01074619|DRUG|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
219312656|NCT01074619|DRUG|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
219312657|NCT02645695|DEVICE|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
219312658|NCT02645695|DEVICE|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
219312659|NCT01578759|PROCEDURE|Salpingectomy|Removal of the fallopian tubes
219312660|NCT04668586|DEVICE|Holmium:YAG laser machine|Ureteroscopy with Holmium:YAG laser lithotripsy
219312661|NCT04668586|DEVICE|Thulium Fiber laser machine|Ureteroscopy with Thulium Fiber laser lithotripsy
219312662|NCT06243419|DEVICE|vein viewer|The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
219312663|NCT06243419|DEVICE|virtual reality|The child watched the application by wearing virtual glasses during the PIC insertion
219312664|NCT06243419|DEVICE|vein viewer and virtual reality|"The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion"
219312665|NCT02920931|DRUG|Tenofovir disoproxil|
219312666|NCT03107650|PROCEDURE|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
219312667|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
219312668|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
219312669|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
219312670|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
219312671|NCT05169125|PROCEDURE|standard hemodialysis|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
219312672|NCT05169125|PROCEDURE|lower dialysate sodium dialysis|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
219312673|NCT02334033|OTHER|other|
219312674|NCT00874666|OTHER|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
219312675|NCT00874666|DIETARY_SUPPLEMENT|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
219312676|NCT01723813|BIOLOGICAL|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
219312677|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
219312678|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
219312679|NCT00635726|DRUG|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
219312680|NCT00635726|DRUG|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
219312681|NCT00635726|DRUG|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
219312682|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
219312683|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
219312684|NCT00635726|DRUG|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
219312685|NCT02207270|BEHAVIORAL|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
219312686|NCT02207270|BEHAVIORAL|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
219312687|NCT02004548|DRUG|Metatinib Tromethamine|
219312688|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
219312689|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
219312690|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
219312691|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
219312692|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
219312693|NCT04140279|DRUG|Latanoprostene Bunod|Ophthalmic solution
219312694|NCT04140279|DRUG|Placebo|Ophthalmic solution, no active ingredient.
219312695|NCT00438347|BEHAVIORAL|Aerobic Exercise|One hour per day three times a week for one year
219312696|NCT00438347|BEHAVIORAL|Stretching and toning|One hour per day three times a week for one year
219312697|NCT05332184|PROCEDURE|aortic valve surgery|
219312698|NCT00772213|PROCEDURE|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
219312699|NCT03552822|OTHER|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
219312700|NCT03730974|DEVICE|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
219312701|NCT04891328|OTHER|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
219312702|NCT02174796|PROCEDURE|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
219312703|NCT02174796|PROCEDURE|orthopedic treatment|orthopedic treatment by vacuum bell.
219312704|NCT00181987|DRUG|methylphenidate HCl (Concerta)|
219312705|NCT04777526|OTHER|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
219312706|NCT04777526|OTHER|Joint protection program|Reeducation in the activities daily life
219312707|NCT04777526|OTHER|Thumb orthosis|Thumb night orthosis
219312708|NCT04777526|OTHER|Manual distraction|Manual distraction of CMC joint
219312709|NCT05644457|GENETIC|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
219312710|NCT00932685|DRUG|Midazolam|Midazolam 0.5mg/kg
219312711|NCT00932685|DEVICE|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
219312712|NCT05216900|RADIATION|Neoadjuvant radiotherapy|"The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap."
219312713|NCT06498531|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
219312714|NCT06498531|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
219312715|NCT03589092|GENETIC|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
219312716|NCT05815290|DRUG|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
219312717|NCT05048537|RADIATION|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
219312718|NCT00991263|GENETIC|gene expression analysis|
219312719|NCT00991263|GENETIC|polymerase chain reaction|
219312720|NCT00991263|OTHER|laboratory biomarker analysis|
219312721|NCT04117009|DRUG|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
219312722|NCT04117009|DIAGNOSTIC_TEST|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
219312723|NCT00248690|DEVICE|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
219312724|NCT03240757|DIETARY_SUPPLEMENT|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
219312725|NCT03240757|OTHER|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
219312726|NCT00894686|BIOLOGICAL|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
219312727|NCT00505817|DRUG|Cetrorelix and Leuprolide|
219312728|NCT05082129|DEVICE|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
219312729|NCT04174456|DIAGNOSTIC_TEST|FDG PET|baseline and 6-month follow-up FDG PET
219312730|NCT00287339|DRUG|Esomeprazole|40mg capsule BID for 12 weeks
219312731|NCT00287339|DRUG|Placebo|placebo capsule BID for 12 weeks
219312732|NCT00564018|DRUG|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
219312733|NCT00564018|DRUG|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
219312734|NCT00564018|DRUG|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
219312735|NCT06261164|DEVICE|Cytosorb® and Oxiris® adsorbents|The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
219312736|NCT03267940|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
219312737|NCT03267940|DRUG|CIS|CIS will be administered as per the schedule specified in the respective arms.
219312738|NCT03267940|DRUG|GEM|GEM will be administered as per the schedule specified in the respective arms.
219312739|NCT03267940|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
219312740|NCT01869075|OTHER|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
219312741|NCT00312533|DRUG|Hylan F- 20|
219312742|NCT00388154|DRUG|Gemcitabine|900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
219312743|NCT00388154|DRUG|Cisplatin|30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
219312744|NCT01340638|DEVICE|cookgas mask|This group will be assigned to use cookgas mask
219312745|NCT01340638|DEVICE|LMA mask|LMA mask
219312746|NCT00388622|BEHAVIORAL|Pharmacist intervention|
219312747|NCT02918604|DEVICE|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
219312748|NCT02960347|DEVICE|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
219312749|NCT04580329|PROCEDURE|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(\>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
219312750|NCT04580329|PROCEDURE|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
219312751|NCT04514666|OTHER|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
219312752|NCT03731507|DEVICE|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
219312753|NCT06183749|OTHER|hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit|diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment
219312754|NCT01401907|OTHER|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
219312755|NCT05065372|DRUG|Metformin Hcl 1000Mg Tab|Agent used to modify insulin sensitivity
219312756|NCT05065372|DRUG|Aminohippurate Sodium 20 % Injection|Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
219312757|NCT05065372|DRUG|Iohexol 300 Mg/mL Injectable Solution|Diagnostic aid/agent used to measure glomerular filtration rate
219312758|NCT05065372|DRUG|Placebo|Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
219312759|NCT05286177|PROCEDURE|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for \> 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
219312760|NCT05286177|PROCEDURE|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
219312761|NCT02607696|DRUG|Zolpidem Hemitartarate|
219312762|NCT04938024|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
219312763|NCT05617352|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
219312764|NCT01496482|OTHER|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
219312765|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
219312766|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
219312767|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
219312768|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
219312769|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
219312770|NCT00446667|DRUG|mannitol|400mg BD for 2 days
219312771|NCT00767468|DRUG|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
219312772|NCT06327308|DIAGNOSTIC_TEST|MRI|The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination.
219312773|NCT06327308|BIOLOGICAL|Blood sampling|Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
219312774|NCT02925013|PROCEDURE|Blood sampling|Blood sampling for lipid profile
219312775|NCT02925013|OTHER|Dietary- Normal western diet|Normal western diet
219312776|NCT01948908|DRUG|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
219312777|NCT02350608|DEVICE|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
219745187|NCT06200948|OTHER|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
219745188|NCT06200948|OTHER|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
219745189|NCT01577407|DRUG|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
219745190|NCT05732870|PROCEDURE|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
219745191|NCT02230982|DRUG|nintedanib|soft gelatin capsule
219745192|NCT05684302|OTHER|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
219745193|NCT00626951|DEVICE|LMA Supreme|Extraglottic airway devices
219312778|NCT03291587|OTHER|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
219312779|NCT00796120|DRUG|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
219312780|NCT00796120|DRUG|Doxorubicin|Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
219312781|NCT00796120|DRUG|Ifosfamide|Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
219312782|NCT03739177|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
219312783|NCT02197767|DRUG|rituximab|1000 mg infusion
219312784|NCT03453437|BEHAVIORAL|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
219312785|NCT02027220|DRUG|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
219312786|NCT02027220|DRUG|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
219312787|NCT02027220|DRUG|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
219312788|NCT02027220|DRUG|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
219312789|NCT00182403|DRUG|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
219312790|NCT06153927|DIAGNOSTIC_TEST|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
219312791|NCT03054402|DRUG|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
219312792|NCT03054402|DRUG|Placebo|Single dose of placebo
219312793|NCT02819206|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
219312794|NCT03536299|OTHER|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
219312795|NCT03536299|OTHER|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
219312796|NCT02594605|DEVICE|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
219312797|NCT02594605|DEVICE|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
219312798|NCT04844801|PROCEDURE|Risk control strategy|"* Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance \>30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
219312799|NCT04844801|PROCEDURE|Rate control strategy:|"* Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
219745194|NCT00626951|DEVICE|LMA ProSeal|
219745195|NCT05593939|BEHAVIORAL|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
219745196|NCT05593939|BEHAVIORAL|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
219745197|NCT05593939|DIETARY_SUPPLEMENT|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
219745198|NCT04619849|DIAGNOSTIC_TEST|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
219745199|NCT04619849|DIAGNOSTIC_TEST|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
219312800|NCT04844801|PROCEDURE|Rhythm control strategy:|"* Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~\- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses \> 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus."
219312801|NCT03849001|BEHAVIORAL|Exercise Conditions|Light Exercise
219312802|NCT03849001|BEHAVIORAL|Exercise Conditions|Moderate Exercise
219312803|NCT03849001|BEHAVIORAL|Exercise Conditions|Vigorous Exercise
219312804|NCT03849001|BEHAVIORAL|Exercise Conditions|Seated Rest
219312805|NCT00003232|DRUG|clodronate disodium|
219312806|NCT00003232|DRUG|mitoxantrone hydrochloride|
219312807|NCT00003232|DRUG|prednisone|
219312808|NCT00003232|PROCEDURE|quality-of-life assessment|
219312809|NCT03845569|OTHER|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
219312810|NCT03845569|OTHER|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
219312811|NCT00658099|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
219312812|NCT00658099|DRUG|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
219312813|NCT04603950|PROCEDURE|CACB+IPACK|continue adductor canal block plus Infiltration between the Popliteal Artery and Capsule of the Knee
219312814|NCT04603950|PROCEDURE|CACB|continue adductor canal block
219312815|NCT04506268|BEHAVIORAL|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
219312816|NCT04506268|BEHAVIORAL|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
219312817|NCT03418337|DRUG|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
219312818|NCT03418337|DRUG|lansoprazole (Takepron OD 30 mg)|lansoprazole group
219312819|NCT06375707|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS|"Docetaxel: 100mg/m2 IV every 21 days Paclitaxel: 175mg/m2 every 21 days, IV drip Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week.~Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral"
219312820|NCT06375707|DRUG|Ribociclib combined with NSAI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral
219312821|NCT03726710|BEHAVIORAL|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
219312822|NCT00066989|DRUG|Staphylococcus aureus Immune Globulin (Human) 5%|
219312823|NCT04776785|DEVICE|Curodont™ Repair|"It is a product used in biomimetic remineralization of initial carious lesions. The product consists of smart P11-4 peptide molecules (CUROLOX® TECHNOLOGY) that within the lesion the molecules self-assemble to a 3D matrix. This bio-matrix enables the regeneration of the tooth tissue.~Test 1 lesions will be cleaned with a prophylaxis paste and isolated with cotton rolls. Then, the pellicle will be removed using 2% sodium hypochlorite (20 sec) and the inorganic deposits will be removed using 35% phosphoric acid (20 sec). The tooth surface will be rinsed with water and dried. Thereafter, Curodont™ Repair will be applied in compliance with the manufacturers' instructions and left for 5 minutes."
219312824|NCT04776785|DEVICE|MI Varnish™|"MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
219312825|NCT04776785|DEVICE|Profluorid® Varnish|"Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
219312826|NCT05961904|OTHER|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
219312827|NCT01898923|DRUG|ON101 Cream|
219312828|NCT01898923|OTHER|Aquacel® Hydrofiber® dressing|
219312829|NCT05097027|DEVICE|Blood flow restriction recovery|Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to \~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
219312830|NCT05097027|OTHER|Active recovery|Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
219312831|NCT01477320|DRUG|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
219312832|NCT01477320|OTHER|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
219312833|NCT03140774|BIOLOGICAL|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
219312834|NCT02730741|DRUG|Lcr restituo® sachet|symptomatic treatment of diarrhoea
219312835|NCT02730741|DRUG|Placebo|
219312836|NCT03556241|DEVICE|Case management|Case management consists keeping patient's current pacemaker mode during surgery
219312837|NCT04679688|OTHER|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
219312838|NCT01638494|DIETARY_SUPPLEMENT|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
219312839|NCT00621387|DRUG|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
219312840|NCT00621387|DRUG|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
219312841|NCT04130386|BEHAVIORAL|Motivational Interviewing|Participants receiving MI
219312842|NCT04130386|BEHAVIORAL|e-education|Participants receiving e-education
219312843|NCT01531647|DRUG|danoprevir|100 mg q12h Days 8-21
219312844|NCT01531647|DRUG|raltegravir|400 mg q12h Days 1-4 and 18-21
219312845|NCT01531647|DRUG|ritonavir|100 mg q12h Days 8-21
219312846|NCT04466826|OTHER|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
219312847|NCT04466826|DRUG|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
219312848|NCT04466826|DEVICE|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
219312849|NCT03583177|DIAGNOSTIC_TEST|No intervention|No intervention
219312850|NCT03924908|BEHAVIORAL|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
219312851|NCT03924908|BEHAVIORAL|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
219312852|NCT00815672|BEHAVIORAL|Exercise|Progressive walking and resistance exercise treatment
219312853|NCT00381303|DRUG|darunavir|600mg bid for 48 wks
219312854|NCT00381303|DRUG|ritonavir|100mg bid for 48 wks
219312855|NCT00333385|DRUG|ceftazidime|
219312856|NCT03536260|DEVICE|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
219312857|NCT03536260|DEVICE|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
219312858|NCT00167960|DRUG|Piperacillin/tazobactam and other β-lactam/β-lactamase|
219312859|NCT01800825|DRUG|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
219312860|NCT01800825|DRUG|Placebo|This will be an identical placebo comparator made of starch.
219312861|NCT05622851|DEVICE|Restylane Contour|Hyaluronic Acid dermal filler
219312862|NCT05622851|DEVICE|Juvederm Voluma|Hyaluronic Acid dermal filler
219312863|NCT03322748|OTHER|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
219312864|NCT03322748|OTHER|Usual physical therapy|Usual physical therapy
219312865|NCT06525961|DEVICE|iTEAR100 Neurostimulator|To apply an iTEAR100 Neurostimulator for the stimulation to the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
219312866|NCT03933774|DRUG|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
219312867|NCT03933774|DRUG|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
219312868|NCT04407585|DIAGNOSTIC_TEST|Covid-19 swab PCR test|Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
219312869|NCT04309344|DEVICE|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
219312870|NCT04309344|PROCEDURE|control|mechanical debridement
219312871|NCT03069612|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
219312872|NCT06089889|OTHER|ice application|"* Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential."
219312873|NCT06089889|OTHER|control group|"* Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential."
219312874|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
219312875|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
219312876|NCT01121835|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
219312877|NCT01121835|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
219312878|NCT01121835|DRUG|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
219312879|NCT02877758|OTHER|Tomorrowlabs cosmeceutical formulation|
219312880|NCT02877758|OTHER|Sham cosmeceutical formulation|
219312881|NCT01372865|DRUG|Mometasone furoate|
219312882|NCT01372865|DRUG|Mometasone furoate|
219312883|NCT04054752|BIOLOGICAL|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
219312884|NCT04054752|BIOLOGICAL|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
219312885|NCT04054752|BIOLOGICAL|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
219312886|NCT05634980|OTHER|FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam
219312887|NCT02216474|OTHER|Transcranial direct current stimulation|
219312888|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
219312889|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
219312890|NCT03728374|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
219312891|NCT05709015|OTHER|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
219312892|NCT05709015|DRUG|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
219312893|NCT05709015|DRUG|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
219312894|NCT00502957|BEHAVIORAL|Biofeedback|
219312895|NCT02652403|DEVICE|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
219312896|NCT02652403|DEVICE|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
219312897|NCT00001032|DRUG|Zidovudine|
219312898|NCT00001032|DRUG|Zalcitabine|
219312899|NCT01966471|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
219312900|NCT01966471|DRUG|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
219312901|NCT01966471|DRUG|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
219312902|NCT01966471|DRUG|Paclitaxel|IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
219312903|NCT01966471|DRUG|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
219312904|NCT01966471|DRUG|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
219312905|NCT01966471|DRUG|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
219312906|NCT01966471|DRUG|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
219312907|NCT01966471|DRUG|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
219312908|NCT02463565|OTHER|no intervention|
219312909|NCT00095654|DRUG|Ramipril|
219312910|NCT00095654|DRUG|Rosiglitazone|
219312911|NCT06323018|PROCEDURE|Remote Ischemic Preconditioning|4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)
219312912|NCT06323018|OTHER|SHAM|4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
219312913|NCT03336996|BIOLOGICAL|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
219312914|NCT03336996|PROCEDURE|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
219312915|NCT04879771|PROCEDURE|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
219312916|NCT06507202|DRUG|Remimazolam|General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.
219312917|NCT06507202|DRUG|Propofol|General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
219312918|NCT03252171|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
219312919|NCT05000892|DRUG|Sintilimab , Carboplatin, Nab-paclitaxel|Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
219312920|NCT01583153|OTHER|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
219312921|NCT01583153|OTHER|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
219312922|NCT01683487|PROCEDURE|Observation|Observational study only, no intervention.
219312923|NCT05557058|DEVICE|Gore Glaucoma Device Implant (GORE GDI)|Unilateral implantation of one of two different configurations of the GORE GDI
219312924|NCT05767671|OTHER|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
219312925|NCT06060093|DIETARY_SUPPLEMENT|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
219312926|NCT06060093|DIETARY_SUPPLEMENT|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
219312927|NCT03541382|DEVICE|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
219312928|NCT05629481|PROCEDURE|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
219312929|NCT05629481|PROCEDURE|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
219312930|NCT02343731|OTHER|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
219312931|NCT00461487|BEHAVIORAL|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
219312932|NCT00461487|BEHAVIORAL|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
219312933|NCT01030198|DEVICE|RevLite (Laser Treatment)|
219312934|NCT04050137|OTHER|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
219312935|NCT01748487|DRUG|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
219312936|NCT01453530|DRUG|Sugammadex|A single dose of sugammadex 2 mg/kg iv
219312937|NCT01453530|DRUG|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
219312938|NCT01453530|OTHER|Placebo|Placebo
219312939|NCT02370043|DRUG|KQ-791|Capsules administered orally while fasting, in up to 3 periods
219312940|NCT02370043|DRUG|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
219312941|NCT02370043|DRUG|Placebo|Capsules, administered orally, in 1 period
219312942|NCT04341766|OTHER|No special intervention|No special intervention : Ultrasound data will be collected
219312943|NCT03782025|DRUG|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
219312944|NCT03652025|PROCEDURE|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
219312945|NCT05198687|PROCEDURE|Long implant and partial overdentures|insertion of long implants anterior to the maxillary sinus to retain partial overdentures
219312946|NCT05198687|PROCEDURE|Sinus lift and long implant|performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
219312947|NCT05198687|PROCEDURE|short implant without sinus lift|placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
219312948|NCT05198687|DEVICE|Partial overdentures|Distal extension metallic partial dentures retained by attachments to the implants
219312949|NCT05198687|DEVICE|Metal ceramic prosthesis on long implants|porcelain fused to metal fixed screw-retained prosthesis supported by long implants
219312950|NCT05198687|DEVICE|Metal ceramic prosthesis on short implants|porcelain fused to metal fixed screw-retained prosthesis supported by short implants
219312951|NCT05665088|DRUG|BXCL501|Sublingual Film
219312952|NCT05665088|DRUG|Matching Placebo|Sublingual Placebo Film
219312953|NCT04137900|DRUG|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
219312954|NCT04137900|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
219312955|NCT03371030|PROCEDURE|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
219312956|NCT05000502|BEHAVIORAL|Home-based exercise intervention|A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
219312957|NCT06250556|DIETARY_SUPPLEMENT|creatine|creatine supplementation (Creapure)
219312958|NCT04563338|DRUG|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
219312959|NCT04563338|DRUG|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
219312960|NCT00662779|DRUG|arformoterol|15 mcg arformoterol nebulizer
219312961|NCT00662779|DRUG|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
219312962|NCT00662779|DRUG|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
219312963|NCT06370468|OTHER|Epidemiological investigation|Epidemiological investigation
219312964|NCT01461239|PROCEDURE|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
219312965|NCT01461239|PROCEDURE|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
219312966|NCT01461239|PROCEDURE|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
219312967|NCT02762812|BIOLOGICAL|BCD-055|
219312968|NCT02762812|BIOLOGICAL|Remicade®|
219312969|NCT03186196|DIETARY_SUPPLEMENT|Diet containing Folate|
219312970|NCT04744441|PROCEDURE|CHOLECYSTECTOMY|Surgical treatment
219312971|NCT04744441|PROCEDURE|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
219312972|NCT04744441|PROCEDURE|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
219312973|NCT05438368|BIOLOGICAL|bi-4SCAR GD2/CD70 T cells|Infusion of bi-4SCAR GD2/CD70 T cells at 10\^6 cells/kg body weight via IV
219312974|NCT04270357|PROCEDURE|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
219312975|NCT02776345|OTHER|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
219312976|NCT02776345|OTHER|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
219312977|NCT02776345|OTHER|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
219312978|NCT01004380|DRUG|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
219312979|NCT05137860|DRUG|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
219312980|NCT00688181|DEVICE|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
219312981|NCT00321659|BEHAVIORAL|Aerobic|3x/week of walking and cycling
219312982|NCT00321659|BEHAVIORAL|Strength training|3x/week of resistance training activities
219312983|NCT00321659|BEHAVIORAL|Combination|3x/week of aerobic and strength training activities
219312984|NCT00321659|BEHAVIORAL|FSHC|Biweekly group education group meetings
219312985|NCT05317988|BEHAVIORAL|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
219312986|NCT05317988|BEHAVIORAL|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
219312987|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
219312988|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
219312989|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
219312990|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
219312991|NCT06348368|OTHER|Pentacam and autorefractometry|Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children
219312992|NCT01050205|BEHAVIORAL|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
219312993|NCT01050205|BEHAVIORAL|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
219312994|NCT03706950|DRUG|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
219312995|NCT05844787|DRUG|MT101-5|Tablet
219312996|NCT03450720|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single dose
219312997|NCT05805098|DRUG|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
219312998|NCT05805098|DRUG|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
219312999|NCT05805098|DRUG|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
219313000|NCT04834687|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
219313001|NCT04834687|BEHAVIORAL|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~1. Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~2. According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
219313002|NCT03475017|DIETARY_SUPPLEMENT|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
219313003|NCT03475017|DIETARY_SUPPLEMENT|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
219313004|NCT01119001|DEVICE|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
219313005|NCT02849301|DEVICE|Arabin cervical pessary|
219313006|NCT00954421|DEVICE|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
219313007|NCT00777946|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
219313008|NCT00777946|DRUG|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
219313009|NCT00777946|DRUG|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
219313010|NCT00777946|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
219313011|NCT00777946|DRUG|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
219313012|NCT04675151|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
219313013|NCT04675151|DRUG|Pilocarpine|Pilocarpine ophthalmic solution
219313014|NCT04675151|OTHER|Placebo|Topical sterile ophthalmic solution
219313015|NCT05740436|OTHER|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
219313016|NCT03263286|DEVICE|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
219313017|NCT01767805|PROCEDURE|Standard incubator|
219313018|NCT01767805|PROCEDURE|Mini incubator|
219313019|NCT01767805|PROCEDURE|5% oxygen|
219313020|NCT01767805|PROCEDURE|20% oxygen|
219313021|NCT01377753|DEVICE|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
219313022|NCT04290169|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
219313023|NCT04290169|DEVICE|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
219313024|NCT02739373|DRUG|BMS-986189|
219313025|NCT02739373|OTHER|Placebo|
219313026|NCT01413854|DRUG|sugar pill|One tablet two times daily during four weeks
219313027|NCT01413854|DRUG|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
219313028|NCT07006571|DEVICE|Real tDCS|The electrodes of the device will be positioned according to the following scheme: one electrode (anode) will be applied on the skin overlying the motor cortices, one electrode (cathode) will be applied on the skin overlying the cervical cord, in the area corresponding to C6. Dosage: 4 mA for the anodal electrode and 4 mA for the cathodal electrode (intensity could be reduced if not tollerate by the patient). Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
219313029|NCT07006571|DEVICE|Sham tDCS|The electrodes will be positioned in the same way as the active device, but the current flow will be limited to the ramp-up (start of stimulation) and ramp-down (end of stimulation) phase, mimicking the sensation of stimulation without providing actual treatment. Dosage: Simulation of stimulation without actual current. Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
219313030|NCT07012226|OTHER|Low-calorie diet|Low-calorie diet based on calculated calorie needs
219313031|NCT07020962|OTHER|laughter therapy|Laughter therapy/yoga, classified as complementary therapy in medicine, is a unique form of exercise consisting of a combination of laughter, yoga and breathing techniques that allows us to laugh without any sense of humour.
219313032|NCT07020962|OTHER|routine nursing care|routine nursing care
219313033|NCT07019701|DEVICE|High flow oxygen through nasal cannula and face mask and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx|High flow oxygen through nasal cannula and face mask, and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions
219313034|NCT07021339|PROCEDURE|Anterior temporal lobectomy (ATL)|"Patients assigned to the experimental group will undergo an anterior temporal lobectomy (ATL) according to established protocols adapted from epilepsy surgery. ATL is a reproducible and anatomically well-defined procedure routinely performed in patients with pharmacoresistant temporal lobe epilepsy. On the non-dominant hemisphere, the neocortical resection typically extends 6.5 cm posteriorly from the temporal pole, while on the dominant side, the resection length is limited to 4.0 cm, both measured along the superior temporal gyrus and guided by the Sylvian fissure. Language dominance is determined based on handedness, as specified in the inclusion criteria. In most cases, the lateral neocortical segment can be removed en bloc.~The mesial component of ATL encompasses resection of the uncus, amygdala, and the anterior hippocampus, typically including both the head and body. Resection is carried out to the level of the tectal plate or, at minimum, to the lateral mesencephalic sulcus."
219313035|NCT07021339|PROCEDURE|Gross Total Resection (GTR)|Patients will be surgically treated with GTR in terms of removing 100% of the tumor tissue in gadolinium-enhanced MRI.
219313036|NCT07019272|DRUG|Neratinib (HKI-272)|"Sequential neratinib extended adjuvant therapy will be initiated within 6 months after completing standard trastuzumab-based adjuvant therapy, continuing for 1 year.~As a real-world non-interventional study, treating physicians will determine neratinib regimens per the prescribing information and current clinical practice.~Neratinib Dosing:~Standard regimen: 240 mg (6 tablets) once daily with food for 1 year；~Dose escalation (to mitigate diarrhea, per latest CSCO Breast Cancer Guidelines and FDA labeling):~Week 1: 120 mg/day (days 1-7) Week 2: 160 mg/day (days 8-14) Week 3 onward: 240 mg/day (days 15-365)"
219313037|NCT07019714|BEHAVIORAL|Daoyin Technique|"On the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Daoyin Technique for treatment. For patients who are able to complete the respiratory guidance technique. For patients who are unable to complete the respiratory guidance technique but have stable vital signs (referring to the Expert Consensus on Respiratory Critical Care Rehabilitation Treatment Techniques in China), the supine guidance technique is selected. It is carried out 5 days a week, 2 times a day, and each training session lasts for 30 minutes."
219313038|NCT07019714|BEHAVIORAL|Routine Comprehensive Training|"On the basis of treatment guided by IIdiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,the experimental group was given Routine Comprehensive Training. According to the patient's condition, select aerobic training (such as walking) or upper - limb and lower - limb resistance training (such as lifting, chest - expanding, foot - pedaling movements, etc.) combined with respiratory training (such as pursed - lip breathing, abdominal breathing, etc.). The heart rate should reach the target heart rate range and last for more than 10 minutes. This training is carried out 5 days a week, 2 times a day."
219313039|NCT07020455|DRUG|prolotherapy solution of 20% dextrose|Polotherapy, it involves injecting an irritant solution into weakened joints, ligaments, or tendons to stimulate collagen production and tissue repair at fibro-osseous junctions.
219313040|NCT07020455|DRUG|Arthrocentesis with ringer solution|Integrating arthrocentesis with prolotherapy may enhance therapeutic outcomes by addressing both the mechanical and inflammatory aspects of TMJ hypermobility. This dual-modality technique presents a promising minimally invasive option for clinicians managing patients with joint instability.
219313041|NCT07020819|DRUG|Tanruprubart|Solution for IV infusion.
219313042|NCT07019805|DRUG|Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam|This intervention refers to the standard induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Induction typically involves the administration of intravenous anesthetic agents such as propofol and fentanyl, based on institutional protocols and the anesthesiologist's discretion. This study does not modify or introduce any new treatment; it merely observes and records peri-induction parameters to identify factors associated with the occurrence of post-induction hypotension.
219313043|NCT07019805|DEVICE|Blood Pressure Continous Monitoring, syrnge pump for the anesthesia agent, and vasoconstrictor drug|This intervention involves the standard clinical use of non-invasive continuous blood pressure monitoring during the induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Intravenous anesthetic agents (e.g., propofol, fentanyl) and vasopressors (e.g., ephedrine, norepinephrine) are administered via syringe pumps based on the anesthesiologist's clinical judgment. The study does not introduce any experimental treatment but observes blood pressure changes in real time to identify risk factors for post-induction hypotension. The integration of continuous hemodynamic monitoring distinguishes this observational approach from routine anesthetic induction without such monitoring.
219313044|NCT07018947|DRUG|Atezolizumab and Bevacizumab|"Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy).~The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity."
219313045|NCT06783751|PROCEDURE|Modified Vertical Sleeve Gastrectomy (mVSG)|The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).
219313046|NCT06783751|PROCEDURE|Conventional Vertical Sleeve Gastrectomy (cVSG)|Vertical Sleeve Gastrectomy as standard procedure
219313047|NCT00124852|BEHAVIORAL|n-3 Fatty Acid Supplementation|
219313048|NCT01141738|BEHAVIORAL|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
219313049|NCT01141738|BEHAVIORAL|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
219313050|NCT01364363|PROCEDURE|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
219313051|NCT04510909|OTHER|COMMIT mHealth application|The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
219313052|NCT00439530|DRUG|oseltamivir|
219313053|NCT00439530|DRUG|probenecid|
219313054|NCT04206592|DEVICE|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
219313055|NCT02797210|DEVICE|Continuous theta-burst stimulation|
219313056|NCT04643860|DIAGNOSTIC_TEST|Differential Leucocyte Count (CLDC) device and algorithm|Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
219313057|NCT05188326|DRUG|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
219313058|NCT05188326|OTHER|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
219313059|NCT03305068|DRUG|Celecoxib|
219313060|NCT02570893|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
219313061|NCT02570893|RADIATION|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
219313062|NCT02570893|DRUG|Paclitaxel and carboplatin|
219313063|NCT01030679|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
219313064|NCT01030679|DRUG|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
219313065|NCT01030679|DRUG|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
219313066|NCT01030679|DRUG|Placebo|orally, 1 tablet once daily for 8 weeks
219313067|NCT03513172|DRUG|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
219313068|NCT03473704|BEHAVIORAL|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
219313069|NCT03473704|BEHAVIORAL|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
219313070|NCT00567268|DRUG|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
219313071|NCT02877472|DEVICE|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
219313072|NCT02877472|PROCEDURE|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
219313073|NCT01418820|DEVICE|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
219313074|NCT01418820|DEVICE|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
219313075|NCT01868113|DRUG|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
219313076|NCT01868113|OTHER|Placebo|Placebo to be administered 12hourly
219313077|NCT05381831|DRUG|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
219313078|NCT03218462|BEHAVIORAL|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
219313079|NCT03249077|BEHAVIORAL|Digital DPP|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
219313080|NCT03249077|BEHAVIORAL|In-person DPP|The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
219313081|NCT03249077|OTHER|DPP not enrolled|Access to usual care services without restrictions.
219313082|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
219313083|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
219313084|NCT00376181|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
219313085|NCT03393715|DRUG|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
219313086|NCT05490979|BEHAVIORAL|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
219313087|NCT05490979|BEHAVIORAL|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
219313088|NCT04603664|DIAGNOSTIC_TEST|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
219313089|NCT03224325|DRUG|TAK-831 Tablet T2|Tak-831 tablets.
219313090|NCT03224325|DRUG|Placebo|TAK-831 placebo-matching suspension.
219313091|NCT03224325|DRUG|TAK-831 Suspension|TAK-831 Suspension.
219313092|NCT01361295|PROCEDURE|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
219313093|NCT01361295|PROCEDURE|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
219313094|NCT03259594|PROCEDURE|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
219313095|NCT03259594|DRUG|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
219313096|NCT01903018|DRUG|P276-00|
219313097|NCT01903018|RADIATION|Radiation Therapy|
219313098|NCT01903018|DRUG|Cisplatin|
219313099|NCT00528164|BEHAVIORAL|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
219313100|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
219313101|NCT00230438|PROCEDURE|External Beam Radiotherapy|
219313102|NCT01889056|DRUG|Erythropoietin (Epoetin beta)|
219313103|NCT01889056|DRUG|Placebo|0.9% sodium chloride solution
219313104|NCT00849719|DRUG|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
219313105|NCT00849719|DRUG|PCA MO only|When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
219313106|NCT00134316|BEHAVIORAL|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
219313107|NCT02952001|DRUG|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
219313108|NCT02952001|DRUG|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
219313109|NCT03599557|BEHAVIORAL|STOP-HPV communication intervention|This intervention will be communication skills training.
219313110|NCT01535183|DRUG|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
219313111|NCT04062773|BEHAVIORAL|TRF|time restricted feeding group
219313112|NCT04062773|BEHAVIORAL|Normal timing of food intake|no time restricted feeding
219313113|NCT02571127|DRUG|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
219313114|NCT03686202|BIOLOGICAL|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
219313115|NCT05650099|DEVICE|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
219313116|NCT04533451|DRUG|Pembrolizumab|Given IV
219313117|NCT04533451|DRUG|Pemetrexed|Given IV
219313118|NCT04533451|DRUG|Carboplatin|Given IV
219313119|NCT04533451|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
219313120|NCT04533451|OTHER|Questionnaire Administration|Ancillary studies
219313121|NCT04533451|OTHER|Quality-of-Life Assessment|Ancillary studies
219313122|NCT02537626|DEVICE|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
219313123|NCT02537626|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
219313124|NCT04576143|DRUG|Epirubicin|i.v. 90 mg/m2
219313125|NCT04576143|DRUG|Cyclophosphamid|i.v. 600 mg/m2
219313126|NCT04576143|DRUG|Docetaxel|i.v. 100 mg/m2
219313127|NCT04576143|DRUG|Paclitaxel|i.v. 175 mg/m2
219313128|NCT05134870|BEHAVIORAL|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
219313129|NCT00420251|DRUG|Genotropin|
219313130|NCT05555056|DEVICE|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
219313131|NCT05555056|DEVICE|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
219313132|NCT04381091|DRUG|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
219313133|NCT03540472|DRUG|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
219313134|NCT02243098|DRUG|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
219313135|NCT02243098|DRUG|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
219313136|NCT02243098|DRUG|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
219313137|NCT01927328|DRUG|Iron isomaltoside 1000|
219313138|NCT02672709|DRUG|apixaban|
219313139|NCT00421200|DRUG|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
219313140|NCT00421200|DRUG|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
219313141|NCT00937833|PROCEDURE|Prostatectomy|
219313142|NCT00937833|DEVICE|Surgisis Male Sling|
219313143|NCT03608267|DEVICE|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
219313144|NCT04595253|OTHER|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
219313145|NCT06250348|OTHER|Non invasive measure of endogenous exhaled Nitric Oxyde in exhaled gaz, by a laser spectrometer|A sample of exhaled gases is taken from the expiratory part of the respirator circuit (same way as a capnometry measurement). A laser spectrometer continuously and non-invasively monitors online the concentrations of endogenous NO exhaled by patients.
219313146|NCT01707225|DRUG|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
219313147|NCT03399487|DRUG|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
219313148|NCT04730544|DRUG|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
219313149|NCT04730544|DRUG|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
219313150|NCT04984954|DRUG|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
219313151|NCT03412305|DRUG|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
219313152|NCT03412305|OTHER|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
219745200|NCT04118426|RADIATION|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
219745201|NCT02346669|PROCEDURE|gastroscopy|as detailed in arm description
219745202|NCT02346669|DRUG|Fecal Microbiota Transplantation|as detailed in arm description
219745203|NCT02346669|OTHER|high fat low fiber diet|as detailed in arm description
219313153|NCT04910854|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
219313154|NCT05711966|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
219313155|NCT05711966|DEVICE|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
219745204|NCT02346669|OTHER|sham diet|as detailed in arm description
219313156|NCT05381779|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
219313157|NCT05381779|OTHER|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
219313158|NCT05381779|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
219313159|NCT00818389|DRUG|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
219313160|NCT00818389|DRUG|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
219313161|NCT00818389|DRUG|placebo|an inactive substance
219745205|NCT02346669|OTHER|low fat high fiber diet|as detailed in arm description
219745206|NCT04427345|OTHER|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
219745207|NCT02174770|OTHER|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
219745208|NCT02174770|OTHER|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
219745209|NCT03209765|OTHER|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
219745210|NCT03427619|DRUG|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
219745211|NCT02196974|PROCEDURE|cryobiopsy|
219745212|NCT03712761|DIETARY_SUPPLEMENT|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
219745213|NCT04605250|OTHER|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
219745214|NCT03017001|DIETARY_SUPPLEMENT|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
219745215|NCT03017001|DRUG|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
219745216|NCT03017001|OTHER|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
219745217|NCT00003451|BIOLOGICAL|recombinant interferon alfa|
219745218|NCT00003451|BIOLOGICAL|recombinant interleukin-12|
219745219|NCT02998866|PROCEDURE|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
219745220|NCT02624856|DRUG|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
219745221|NCT02624856|DRUG|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
219745222|NCT04467255|OTHER|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
219313162|NCT01494454|DEVICE|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
219313163|NCT01494454|DEVICE|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
219313164|NCT03548987|DRUG|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
219313165|NCT03548987|DRUG|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
219313166|NCT03761511|DRUG|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
219313167|NCT03761511|DRUG|Placebo|Matching Placebo (capsules) once daily
219313168|NCT02741583|OTHER|altitude rehabilitation program|altitude exposure
219313169|NCT02741583|OTHER|rehabilitation program|Rehabilitation at low altitude
219313170|NCT05541315|DRUG|JNJ-88260237|JNJ-88260237 will be administered orally.
219313171|NCT05541315|DRUG|Placebo|Matching placebo will be administered orally.
219313172|NCT03686267|OTHER|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
219313173|NCT03686267|OTHER|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
219313174|NCT03686267|OTHER|titanium abutment with no color masking|color masking methods are avoided in this arm
219313175|NCT04088864|DRUG|Fludarabine|Fludarabine is a purine antagonist antimetabolite
219313176|NCT04088864|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
219313177|NCT04088864|DRUG|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
219313178|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
219313179|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
219313180|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
219313181|NCT02777723|DRUG|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
219313182|NCT02777723|DRUG|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
219313183|NCT04281550|OTHER|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
219313184|NCT04835701|BEHAVIORAL|Music|Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
219745223|NCT03988218|BEHAVIORAL|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
219745224|NCT03208790|DRUG|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
219745225|NCT03208790|DRUG|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
219745226|NCT03208790|DRUG|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
219745227|NCT03215160|BEHAVIORAL|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
219745228|NCT02150707|DRUG|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
219745229|NCT02150707|DRUG|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
219745230|NCT01997164|DRUG|REGN910-3|
219745231|NCT01997164|DRUG|REGN910|
219745232|NCT01997164|DRUG|Intravitreal Aflibercept Injection (IAI)|
219745233|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
219745234|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
219745235|NCT06637202|RADIATION|postoperative radiotherapy|50 Gy in 25 fractions
219313185|NCT06795230|OTHER|Muscle strengthening (BFRT)|"The experimental group will perform a low-intensity strengthening program (20% 1RM) in combination with the BFRT system consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, performing 4 sets of 30/15/15/15 repetitions as usual in this type of interventions.~Once the first exercise has been completed, a rest of 3 - 4 minutes should be taken depending on the fatigue perceived by the patient. Subsequently, the other two exercises will be performed following the scheme already outlined.~Taking into account the scientific evidence concerning the safety and adverse effects linked to the BFRT system, it is determined that the pressure applied in the experimental protocol will be 60% of the TRP of each subject, following the recommendations that locate the effective pressure between 50 - 80% of the TRP of each subject."
219313186|NCT06795230|OTHER|Conventional physical therapy|The control group will perform a conventional muscle strengthening protocol consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, with a dumbbell at 70% of 1RM, performing a total of 4 sets of 8 - 12 repetitions each, avoiding muscle failure in each set.
219313187|NCT00830648|BIOLOGICAL|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
219313188|NCT03289377|BEHAVIORAL|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
219313189|NCT03673865|DEVICE|office-based 3-dimensional printers (OB3DP)|In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.
219313190|NCT03673865|DEVICE|standard stock orbital plate|In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
219313191|NCT00602394|DRUG|Lithium|
219313192|NCT00069316|DRUG|Omr-IgG-am|
219313193|NCT00756470|DRUG|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
219313194|NCT00756470|DRUG|Paclitaxel|80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
219313195|NCT00756470|DRUG|5-Fluorouracil (5-FU)|500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
219313196|NCT00756470|DRUG|Epirubicin|75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
219313197|NCT00756470|DRUG|Cyclophosphamide|500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
219313198|NCT03434782|DRUG|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
219313199|NCT03434782|DRUG|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
219313200|NCT03434782|DRUG|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
219313201|NCT05535465|OTHER|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
219313202|NCT04849936|DIAGNOSTIC_TEST|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
219313203|NCT05213754|PROCEDURE|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
219313204|NCT05300074|OTHER|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
219313205|NCT04200131|DIAGNOSTIC_TEST|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
219313206|NCT04143750|DRUG|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
219313207|NCT06159322|DRUG|Olanzapine|Antipsychotic medication
219313208|NCT06159322|DRUG|Clozapine|Antipsychotic medication
219313209|NCT04581967|GENETIC|polymorphism analysis|"* DNA will be purified from whole blood samples by commercial DNA isolation kits.~* Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
219313210|NCT04581967|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
219313211|NCT05781217|DRUG|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
219313212|NCT02604433|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
219313213|NCT02604433|OTHER|Placebo|Placebo, Subcutaneous, every 21 days.
219313214|NCT04227548|DIAGNOSTIC_TEST|needle electromyography|Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
219313215|NCT06108180|OTHER|Dry Needling|3 treatment to eliminate active trigger points that patients have
219313216|NCT02357381|DEVICE|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
219313217|NCT02202551|DRUG|ADS-5102|
219313218|NCT00233844|PROCEDURE|"Venipuncture with cough-trick"|
219313219|NCT00548054|BIOLOGICAL|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
219313220|NCT00548054|BIOLOGICAL|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
219313221|NCT02779725|BEHAVIORAL|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
219313222|NCT02779725|BEHAVIORAL|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
219313223|NCT02779725|BEHAVIORAL|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
219313224|NCT02779725|BEHAVIORAL|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
219313225|NCT02779725|BEHAVIORAL|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
219313226|NCT05827211|PROCEDURE|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
219313227|NCT05827211|PROCEDURE|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
219313228|NCT00288795|OTHER|Massage Therapy|Therapeutic Touch
219313229|NCT00288795|OTHER|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
219313230|NCT05823701|DRUG|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
219313231|NCT05823701|DRUG|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
219313232|NCT05823701|BIOLOGICAL|obinutuzumab|1000mg d4 intravenous infusion per cycle
219313233|NCT05823701|DRUG|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
219313234|NCT02147353|DRUG|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
219313235|NCT02147353|DRUG|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
219313236|NCT02949960|DRUG|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
219313237|NCT02949960|DRUG|Vehicle Control|Topical Vehicle Gel applied twice daily
219313238|NCT04934488|BEHAVIORAL|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
219313239|NCT01995877|PROCEDURE|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
219313240|NCT03484520|DRUG|Venetoclax|tablet, oral
219313241|NCT03484520|DRUG|Dinaciclib|intravenous
219313242|NCT01569360|DEVICE|Corset|the patients are assigned the use of a custome made corset during daytime
219313243|NCT00404456|DRUG|Melatonin|Melatonin 3 mg once-daily
219313244|NCT05406804|BEHAVIORAL|Olfactory stimulation|1\) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time \> 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
219313245|NCT05406804|BEHAVIORAL|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
219313246|NCT01088191|BIOLOGICAL|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
219313247|NCT01088191|DRUG|Hyaluronan|Hyaluronan alone
219313248|NCT03152357|DEVICE|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
219313249|NCT04193267|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
219313250|NCT00403728|DRUG|ciclosporine A|
219313251|NCT04704011|OTHER|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
219313252|NCT04704011|OTHER|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
219313253|NCT04704011|OTHER|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
219313254|NCT04704011|OTHER|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
219313255|NCT04704011|OTHER|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
219313256|NCT02784197|DEVICE|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
219313257|NCT04200157|OTHER|Online survey|Subjects will complete a single survey that takes 5-10 minutes to complete
219313258|NCT00885651|DRUG|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
219313259|NCT00885651|DRUG|Placebo|
219313260|NCT03644407|OTHER|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
219313261|NCT00759291|DRUG|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
219313262|NCT00759291|DRUG|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
219313263|NCT05708326|BEHAVIORAL|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
219313264|NCT05708326|BEHAVIORAL|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
219313265|NCT02305537|BEHAVIORAL|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
219313266|NCT02020629|DRUG|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
219313267|NCT02626754|DRUG|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
219313268|NCT00004253|DRUG|carboplatin|
219313269|NCT00004253|DRUG|paclitaxel|
219313270|NCT00004253|RADIATION|radiation therapy|
219313271|NCT00604812|DRUG|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
219313272|NCT00604812|DRUG|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
219313273|NCT00604812|DRUG|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
219313274|NCT00604812|DRUG|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
219313275|NCT02729389|BEHAVIORAL|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
219313276|NCT02729389|BEHAVIORAL|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
219313277|NCT01603329|OTHER|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
219313278|NCT04384848|OTHER|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
219313279|NCT00604864|DRUG|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
219313280|NCT00604864|DRUG|placebo|Placebo
219313281|NCT02655302|OTHER|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
219313282|NCT02655302|OTHER|Lung function measure|Measure lung function and follow it during 4 years
219313283|NCT03124095|BEHAVIORAL|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
219313284|NCT04644458|OTHER|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
219313285|NCT03916848|PROCEDURE|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
219313286|NCT06563362|RADIATION|De-escalation of irradiated volume|De-escalation of elective clinical target volumes as recommended by a model-based approach
219313287|NCT00256451|DRUG|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
219313288|NCT00256451|DRUG|placebo|placebo pills
219313289|NCT00256451|OTHER|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
219313290|NCT00256451|OTHER|Sham alcohol|non-alcoholic placebo alcohol
219313291|NCT00316134|PROCEDURE|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
219313292|NCT04916522|DRUG|Colchicine|0.5 mg once daily
219313293|NCT04916522|DRUG|Placebo|Once daily
219313294|NCT03295656|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
219313295|NCT00079742|DRUG|Nutropin AQ [somatropin (DNA origin) injection]|
219313296|NCT00472329|PROCEDURE|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
219313297|NCT00472329|DRUG|fludarabine|
219313298|NCT00472329|PROCEDURE|TBI|
219313299|NCT03661164|PROCEDURE|corneal cross linking|Iontophoretic corneal cross linking
219313300|NCT04089969|DIAGNOSTIC_TEST|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
219313301|NCT04089969|DIAGNOSTIC_TEST|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
219313302|NCT00056355|DRUG|UVADEX and UVAR XTS Photopheresis System|
219313303|NCT00707512|DRUG|natalizumab|Administered as specified in the TOUCH Prescribing Program
219313304|NCT05828043|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
219313305|NCT03959371|DRUG|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
219313306|NCT00895336|BIOLOGICAL|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
219313307|NCT02614573|DEVICE|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is \> 4, then verification by venous measure and refer to general practitioner."
219313308|NCT04003935|OTHER|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
219313309|NCT04003935|DIETARY_SUPPLEMENT|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
219313310|NCT00078754|DRUG|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
219313311|NCT00078754|DRUG|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
219313312|NCT00078754|DRUG|Placebo|Placebo capsules by mouth, up to 8 capsules daily
219313313|NCT01520896|DRUG|NKTR-118|Oral 25 mg
219313314|NCT01520896|DRUG|Ketoconazole|Oral 400 mg
219313315|NCT04239521|OTHER|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
219313316|NCT04664673|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
219313317|NCT04664673|BEHAVIORAL|Regular care|customary or usual treatment given to any adult stroke survivor
219313318|NCT00934141|OTHER|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
219313319|NCT00934141|OTHER|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
219313320|NCT00934141|OTHER|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
219313321|NCT00934141|OTHER|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
219313322|NCT01337804|DRUG|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
219313323|NCT01337804|DRUG|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
219313324|NCT05185544|OTHER|Neoadjuvant pemetrexed and cisplatin chemotherapy|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
219313325|NCT04579965|DRUG|medical treatment of isthmocele|comparison between different drugs
219313326|NCT05945966|OTHER|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
219313327|NCT05945966|OTHER|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
219313328|NCT03351881|OTHER|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
219313329|NCT05620043|DEVICE|Sculptra|Biostimulator
219313330|NCT05620043|DEVICE|Radiesse Plus|Semi-permanent filler
219313331|NCT01349725|DRUG|ARRY-502|Oral; multiple dose, escalating
219313332|NCT01349725|DRUG|Placebo|Oral; matching placebo
219313333|NCT00639561|DIETARY_SUPPLEMENT|10 g of fibres per day|10 g of fibres per day
219313334|NCT00639561|DIETARY_SUPPLEMENT|40 g of fibres per day|40g of fibres per day
219313335|NCT00704002|PROCEDURE|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
219313336|NCT00704002|PROCEDURE|conservative treatment|conservative treatment with 2-finger splint for one week
219313337|NCT05145062|DRUG|BIVV003|Solution for intravenous administration
219313338|NCT05145062|DRUG|ST-400|Solution for intravenous administration
219313339|NCT04071795|BEHAVIORAL|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
219313340|NCT04071795|BEHAVIORAL|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
219313341|NCT05107050|DEVICE|Normal Saline and Amorphous gel|Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
219313342|NCT05107050|DEVICE|BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel|"Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
219313343|NCT05532254|DRUG|Aripiprazole 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
219313344|NCT05532254|DRUG|Abilify® 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
219313345|NCT01704963|DRUG|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
219313346|NCT03057808|BEHAVIORAL|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
219313347|NCT03057808|BEHAVIORAL|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
219313348|NCT00947713|DRUG|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
219313349|NCT00947713|DRUG|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
219313350|NCT03000361|PROCEDURE|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
219313351|NCT01585636|DRUG|SQ109|Single oral dose
219313352|NCT05526729|OTHER|Beovu|Prospective observational study. There was no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema were eligible to enroll into this study.
219313353|NCT04409249|DIAGNOSTIC_TEST|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
219313354|NCT06101823|BIOLOGICAL|OpSCF|Monoclonal Antibody
219313355|NCT06101823|BIOLOGICAL|Placebo|Formulation buffer without active agent
219313356|NCT06101823|BIOLOGICAL|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
219313357|NCT00447850|PROCEDURE|endometrial biopsy|
219313358|NCT03154762|DEVICE|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
219313359|NCT03154762|DEVICE|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
219313360|NCT01788267|OTHER|scan examination HR-pQCT|
219313361|NCT03984903|OTHER|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
219313362|NCT03984903|OTHER|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
219313363|NCT03984903|OTHER|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
219313364|NCT03984903|OTHER|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
219313365|NCT03838107|BEHAVIORAL|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
219313366|NCT00419783|DRUG|bilastine|20 mg tablets.
219313367|NCT00419783|DRUG|Bilastine|100 mg (5 tablets of 20 mg)
219313368|NCT00419783|DRUG|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
219313369|NCT00419783|DRUG|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
219313370|NCT00419783|DRUG|Placebo|Placebo tablets
219313371|NCT04828083|DRUG|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
219313372|NCT04828083|DRUG|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
219313373|NCT04987892|DEVICE|UroLift System|Prostatic lift
219313374|NCT04987892|DRUG|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
219313375|NCT00414128|DRUG|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
219313376|NCT00414128|DRUG|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
219313377|NCT05829590|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
219313378|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
219313379|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
219313380|NCT00752622|BIOLOGICAL|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
219313381|NCT01023854|PROCEDURE|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
219313382|NCT00576836|BIOLOGICAL|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not \>18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
219313383|NCT00576836|OTHER|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest \& transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced \& placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
219313384|NCT02463188|BEHAVIORAL|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
219313385|NCT05917041|DEVICE|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
219313386|NCT01523639|DRUG|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
219313387|NCT05635916|DRUG|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
219313388|NCT05635916|DRUG|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
219313389|NCT03661944|DIAGNOSTIC_TEST|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
219313390|NCT03608540|DEVICE|Endomina|Suturing system with sutures apposition then bulging then cutting
219313391|NCT05810831|DIAGNOSTIC_TEST|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
219313392|NCT05810831|DIAGNOSTIC_TEST|Massage|conservative physiotherapy protocol including massage
219313393|NCT00096811|DRUG|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
219313394|NCT03756246|BIOLOGICAL|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
219313395|NCT02520284|BIOLOGICAL|Andecaliximab|Andecaliximab 150 mg administered via SC injection
219313396|NCT02520284|BIOLOGICAL|Placebo|Placebo matched to andecaliximab administered via SC injection
219313397|NCT02926625|BEHAVIORAL|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~* Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~* Children who are getting worse should come back immediately or at any time for a re-assessment~* All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~* HEW should fill out a loose child assessment form~* If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
219313398|NCT02926625|BEHAVIORAL|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
219313399|NCT04597528|OTHER|Elective Induction|"All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet."
219313400|NCT01251250|OTHER|laboratory biomarker analysis|Correlative studies
219313401|NCT01251250|GENETIC|western blotting|Correlative studies
219313402|NCT01251250|GENETIC|gene expression analysis|Correlative studies
219313403|NCT01251250|OTHER|pharmacological study|Correlative studies
219313404|NCT01251250|OTHER|flow cytometry|Correlative studies
219313405|NCT01251250|GENETIC|fluorescence in situ hybridization|Correlative studies
219313406|NCT01251250|BIOLOGICAL|azadirachta indica|Given orally
219313407|NCT01251250|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
219313408|NCT03444727|OTHER|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
219313409|NCT03444727|OTHER|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
219313410|NCT02951741|OTHER|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
219313411|NCT05387226|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
219313412|NCT04792957|DIAGNOSTIC_TEST|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
219313413|NCT06000020|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
219313414|NCT06046963|DRUG|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
219313415|NCT06046963|OTHER|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
219313416|NCT02441062|DRUG|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
219313417|NCT01211522|DRUG|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
219313418|NCT01211522|DRUG|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
219313419|NCT01211522|DRUG|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
219313420|NCT02641223|DEVICE|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
219313421|NCT06382025|OTHER|showing cartoons -storybook|A goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period
219313422|NCT06382025|OTHER|showing cartoons - standard|standard
219313423|NCT05242185|OTHER|Observational study|\- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
219313424|NCT02740972|DRUG|NS-065/NCNP-01|
219313425|NCT02740972|DRUG|Placebo|
219313426|NCT05213910|DIETARY_SUPPLEMENT|Lactichoc|dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days
219313427|NCT05213910|OTHER|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
219313428|NCT02787954|PROCEDURE|TACE|Procedure for giving chemotherapy directly to tumor cells.
219313429|NCT02787954|PROCEDURE|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
219313430|NCT02787954|PROCEDURE|MWA|Using heat to kill tumor cells.
219313431|NCT02787954|PROCEDURE|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
219313432|NCT01116882|PROCEDURE|PCI|
219313433|NCT00547365|BIOLOGICAL|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
219313434|NCT04983641|OTHER|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
219313435|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
219313436|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
219313437|NCT01777269|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
219313438|NCT01777269|DRUG|Placebo|Take one capsule daily
219313439|NCT00504881|DRUG|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
219313440|NCT00504881|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
219313441|NCT03557723|OTHER|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~1. Cultural mediation workshop~2. Supervised visit and tour of the museum~3. Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
219313442|NCT04997759|DRUG|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
219313443|NCT05078216|OTHER|Physical exercise intervention|"12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity."
219313444|NCT05227885|OTHER|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
219313445|NCT02879422|GENETIC|genetic analysis|
219313446|NCT05830409|BEHAVIORAL|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
219313447|NCT01530165|BEHAVIORAL|Life style intervention|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
219313448|NCT04115085|PROCEDURE|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
219313449|NCT04115085|PROCEDURE|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
219313450|NCT04115085|PROCEDURE|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
219313451|NCT04115085|PROCEDURE|Sham ultrasound group (18 treatments)|Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
219313452|NCT03032471|OTHER|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
219313453|NCT03498482|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
219313454|NCT00282282|DRUG|tacrolimus|Given orally just prior to and following stem cell transplant
219313455|NCT00282282|DRUG|sirolimus|Given orally just prior to and following stem cell transplant
219313456|NCT00282282|DRUG|fludarabine|Given once daily over 30 minutes for 4 days
219313457|NCT00282282|DRUG|busulfex|Given intravenously over 3 hours for 4 days
219313458|NCT04233736|PROCEDURE|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
219313459|NCT04825483|OTHER|Weight loss|"Participants will receive resources to support the weight loss program including a recipe book, activities book and how-to guide. The diet program comprises two phases: 1) intensive weight loss through a ketogenic Very Low Calorie Diet (VLCD), including meal replacements for two meals/day, and 2) transition from ketogenic VLCD onto a longer-term eating plan for weight maintenance. Meal replacements will be provided free of charge for up to 6 months. Participants will be encouraged to lose at least 10% body weight."
219354733|NCT01414257|DRUG|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
219313460|NCT04825483|OTHER|Exercise|"Participants will receive resources to facilitate the physiotherapy management plan, including information about the video-conference platform, osteoarthritis information, an exercise plan/log book and a booklet of possible exercises. The physiotherapist consultations include a structured, progressive exercise and physical activity plan. Participants will be given exercise resistance bands and a ankle weight for home exercises.~Physiotherapists will choose from a list of exercises, aiming to prescribe 5-6 at once. Intensity is determined using a modified Rating of Perceived Exertion (RPE) scale, where it should feel hard to very hard to perform a full set of each exercises. Participants are encouraged to complete exercises three times per week. Physiotherapists encourage the participant to increase their general and incidental levels of physical/aerobic activity based on their individual needs and goals, as well as their current level of activity."
219313461|NCT00803270|DRUG|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
219313462|NCT00803270|PROCEDURE|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
219313463|NCT04748900|DIAGNOSTIC_TEST|spirometer|different values are measured on the spirometer after training in respiratory physiotherapy.
219313464|NCT04779372|BEHAVIORAL|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
219313465|NCT04779372|BEHAVIORAL|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
219313466|NCT05584267|RADIATION|radiotherapy|Different cohorts received different doses of radiotherapy
219313467|NCT05584267|DRUG|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
219313468|NCT02583139|BEHAVIORAL|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
219313469|NCT02737917|OTHER|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
219313470|NCT02737917|OTHER|Standard of care|Rapid sequence intubation
219313471|NCT04048954|DEVICE|Applitabac|Smartphone application in screening on tabagism complications
219313472|NCT06341153|BEHAVIORAL|Breast Milk Odor Stimulation|In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
219313473|NCT06341153|BEHAVIORAL|Stimulation of Breast Milk Smell and Taste|In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
219313474|NCT00569595|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
219313475|NCT00569595|BEHAVIORAL|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
219313476|NCT00302627|DRUG|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
219313477|NCT00302627|DRUG|vitamin D|baseline, 6,12 months
219313478|NCT00302627|DRUG|Calcium Carbonate|baseline, 6,12 months
219313479|NCT00210730|DRUG|epoetin alfa|
219313480|NCT06415006|PROCEDURE|Measurement of hemodynamic parameters.|The measurement and recording of Heart Rate (HR), Systolic Arterial Blood Pressure (ABPsys), Diastolic Arterial Blood Pressure (ABPdias), Mean Arterial Blood Pressure (ABPmean), and age parameters.
219313481|NCT03695666|OTHER|Clerical policy|Clerical policy introduction
219313482|NCT00327054|DRUG|Nigella sativa seed|
219313483|NCT03349892|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
219313484|NCT06178406|BEHAVIORAL|dysmenorrhea|Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.
219313485|NCT00596778|OTHER|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
219313486|NCT05274984|DRUG|Placebo|the control group will be given the same volume of saline.
219313487|NCT05274984|DRUG|Lidocaine|the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
219313488|NCT00234806|OTHER|Health-e-Access|telemedicine intervention
219313489|NCT05657483|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
219313490|NCT05657483|OTHER|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
219313491|NCT00593957|DRUG|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
219313492|NCT00593957|DRUG|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
219313493|NCT01604707|OTHER|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
219313494|NCT03481023|DEVICE|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
219313495|NCT03481023|PROCEDURE|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
219313496|NCT00494481|DRUG|Vandetanib (ZD6474)|once daily oral dose
219313497|NCT00494481|DRUG|Docetaxel|intravenous infusion
219313498|NCT02973048|DRUG|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
219313499|NCT02973048|DRUG|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
219313500|NCT04100642|DRUG|Hemay808|topical apply
219313501|NCT04100642|DRUG|Placebo|topical apply
219313502|NCT03545659|OTHER|Mode of relapse/SMN detection|Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
219313503|NCT05959694|DRUG|TQB3909 tablet|TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
219313504|NCT00332189|DRUG|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
219313505|NCT00368160|DRUG|Eszopiclone|eszopiclone 3 mg
219313506|NCT00368160|DRUG|Placebo|Placebo tablet
219313507|NCT06076603|DRUG|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
219313508|NCT03467503|DIETARY_SUPPLEMENT|Blueberry + soluble fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
219313509|NCT04233593|BIOLOGICAL|Lipopolysaccharide|Endotoxin E Coli
219313510|NCT05419063|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
219313511|NCT05419063|BEHAVIORAL|text-based and email feedback|Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
219313512|NCT03093987|OTHER|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
219313513|NCT02727465|OTHER|Meningitis cases|None - blood draw only
219313514|NCT01454518|PROCEDURE|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
219313515|NCT01454518|PROCEDURE|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
219313516|NCT03048643|BEHAVIORAL|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
219313517|NCT03364712|OTHER|routine medical care, venipuncture|
219313518|NCT02279862|DRUG|Ipilimumab|
219313519|NCT01244451|DRUG|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
219313520|NCT01244451|DRUG|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
219313521|NCT00499629|DRUG|FXR 450|capsule, single oral doses from 10 mg to 450 mg
219313522|NCT00499629|DRUG|placebo|capsule similar to active drug
219313523|NCT02928107|OTHER|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
219313524|NCT02928107|OTHER|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
219313525|NCT04144634|OTHER|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
219313526|NCT04144634|OTHER|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
219313527|NCT06328907|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
219745236|NCT06640621|DRUG|Different concentration of ropivacaine for single brachial plexus block|40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
219313528|NCT06328907|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219313529|NCT06328907|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219313530|NCT01394653|DRUG|YM060|oral, with water
219313531|NCT00797498|OTHER|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
219313532|NCT05089136|DEVICE|transcatheter paravalvular leak closure|Transcatheter paravalvular leak closure (PVLc) was first described in 1992 and has since then emerged as an attractive alternative to repeat surgery. Many implantable devices that can be used for transcatheter PVLc have been marketed, although few are specifically designed for this purpose. It consist in implanting an occluder in the paravalvular leak to stop or reduce the regurgitant flow.
219313533|NCT02457312|DRUG|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
219313534|NCT02457312|DRUG|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
219313535|NCT05204693|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219313536|NCT05204693|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
219313537|NCT04345835|PROCEDURE|Percutanous nephrolithotomy (PCNL)|different procedure positioning
219313538|NCT03099005|DRUG|Cannabis|vaporization of cannabis
219313539|NCT03431857|DEVICE|TESS V2|Patients requiring the TESS V2 prosthesis.
219313540|NCT05121363|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
219313541|NCT05121363|DRUG|Anlotinib Hydrochloride capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
219313542|NCT00666809|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
219313543|NCT00666809|DRUG|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
219313544|NCT05440266|DIAGNOSTIC_TEST|Study Intervention: 25 ms half-sine wave stimulation|Part I: Threshold detection and Flare response: 6 pulses of 25 ms half-sine are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 25 ms half-sine is administered continuously.
219313545|NCT05440266|DIAGNOSTIC_TEST|Control Intervention: 500 µs rectangular shaped stimulation|Part I: Threshold detection and Flare response: 6 pulses of 500 µs rectangular shaped stimulation are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 500 µs rectangular shaped stimulation is administered continuously.
219313546|NCT01721603|DRUG|Dabrafenib|150 mg capsule by mouth twice daily
219313547|NCT01721603|PROCEDURE|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
219313548|NCT01721603|DRUG|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
219313549|NCT05033418|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|4-session CBT-I group in addition to IPRP
219313550|NCT05033418|BEHAVIORAL|Interdisciplinary Pain Rehabilitation Program (IPRP)|10-week IPRP usual care
219313551|NCT04191044|OTHER|A complete cardiovascular and liver characterization will be carried out|A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
219313552|NCT04441112|DRUG|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
219313553|NCT04441112|DRUG|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
219313554|NCT01168739|DIETARY_SUPPLEMENT|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
219313555|NCT01168739|DIETARY_SUPPLEMENT|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
219313556|NCT01163721|DRUG|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
219313557|NCT01163721|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily
219313558|NCT00413296|DRUG|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
219313559|NCT00413296|DRUG|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
219313560|NCT00413296|DRUG|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
219313561|NCT05871866|PROCEDURE|"minimally invasive internal fixation device infix"|An INFIX involves the insertion of spinal pedicle screws in the anterior pelvis (supra-acetabular entry) and the placement of a connecting rod in the subcutaneous tissue of the patient
219313562|NCT00225576|OTHER|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
219313563|NCT01786239|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
219313564|NCT01786239|DRUG|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
219313565|NCT01786239|DRUG|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
219313566|NCT02511678|DEVICE|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
219313567|NCT01295281|DEVICE|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
219313568|NCT01295281|DEVICE|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
219313569|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
219313570|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
219313571|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
219313572|NCT02414724|DRUG|Gemcitabine Hydrochloride|Given IV
219313573|NCT02414724|OTHER|Laboratory Biomarker Analysis|Correlative studies
219313574|NCT02414724|OTHER|Pharmacological Study|Correlative studies
219313575|NCT02414724|DRUG|Ribociclib|Given PO
219313576|NCT04398641|OTHER|Evaluation of pre- and postoperative gastrointestinal functional outcomes|Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
219313577|NCT05773950|DRUG|fosaprepitant|"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
219313578|NCT05773950|DRUG|normal saline|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."
219313579|NCT02721823|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
219313580|NCT02721823|BEHAVIORAL|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
219313581|NCT05328583|DRUG|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
219313582|NCT06461429|DRUG|Erythromycin|Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
219313583|NCT06461429|DRUG|Amoxicillin and Erythromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
219313584|NCT06461429|DRUG|Azithromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
219313585|NCT06461429|DRUG|Caffeine citrate 20 mg/kg load and 10 mg/kg daily maintenance.|Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
219313586|NCT06461429|DRUG|Caffeine citrate 30 mg/kg load and 15 mg/kg daily maintenance.|Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
219313587|NCT06461429|DRUG|Caffeine citrate 40 mg/kg load and 20 mg/kg daily maintenance|Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
219313588|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 1)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
219313589|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 2)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)"
219313590|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 3)|"* 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
219313591|NCT06320535|PROCEDURE|Fine needle aspiration (FNA)|Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
219313592|NCT05163288|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
219313593|NCT05163288|OTHER|Placebo|Matching Placebo Sachet
219313594|NCT06005064|DIETARY_SUPPLEMENT|Krill oil|Superba krill oil
219313595|NCT06005064|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
219313596|NCT05838300|DEVICE|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
219313597|NCT05838300|DEVICE|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
219313598|NCT04738825|BEHAVIORAL|Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)|"Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5)."
219313599|NCT05101707|DEVICE|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
219313600|NCT05101707|OTHER|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
219313601|NCT06559527|DRUG|NNC0487-0111|Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
219313602|NCT01630044|DEVICE|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
219313603|NCT04181684|DEVICE|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
219313604|NCT04181684|RADIATION|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
219313605|NCT05484206|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection.
219313606|NCT05484206|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection.
219313607|NCT06385652|DRUG|68Ga-NB381|"Lei Kang from Peking University First Hospital and Bing Jia's team from the School of Basic Medical Sciences at Peking University have developed a targeted CD38 nanobody sequence using genetic engineering technology. They have optimized its structure, functionalized it with labeling, and conducted imaging and other evaluations, ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381. The post-labeling quality control of the drug meets clinical trial requirements with a radiochemical purity (PCR) greater than 98% and in vitro stability not less than 90%.~Preliminary PET imaging results of 68Ga-NB381 indicate that the nanobody is primarily concentrated in the kidneys, bladder, and MM.1S and Ramos or H929 tumors (CD38+). Additionally, the cold antibody NB381 significantly inhibits the uptake of 68Ga-NB381 in tumors, confirming the high specificity of this nanobody's binding to the CD38 protein."
219313608|NCT05428254|OTHER|Capacitive and Resistive Radiofrequency therapy|"TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues."
219313609|NCT05428254|OTHER|Exercise therapy|Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
219313610|NCT05833074|BEHAVIORAL|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
219313611|NCT05833074|BEHAVIORAL|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
219313612|NCT03733639|DRUG|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
219313613|NCT03733639|DEVICE|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
219313614|NCT01411839|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
219313615|NCT00898183|GENETIC|gene expression analysis|
219313616|NCT00898183|GENETIC|polymorphism analysis|
219313617|NCT00376454|DRUG|GW493838|
219313618|NCT01787409|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219313619|NCT01787409|OTHER|Laboratory Biomarker Analysis|Correlative studies
219313620|NCT06389838|DEVICE|Kranus Mictera|An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
219313621|NCT03952754|BEHAVIORAL|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
219313622|NCT03952754|BEHAVIORAL|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
219313623|NCT05461794|DRUG|Sitravatinib|100 mg orally once daily
219313624|NCT05461794|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
219313625|NCT05461794|DRUG|Docetaxel|75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle
219313626|NCT05461794|DRUG|Irinotecan|125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle
219313627|NCT02769559|PROCEDURE|Reduction mammaplasty|Surgical removal of excess breast tissue
219313628|NCT06235944|PROCEDURE|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
219313629|NCT06235944|PROCEDURE|Sacral erector spinae block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
219313630|NCT05525013|DRUG|Simvastatin Powder|Simvastatin gel placed as an intracanal medication
219313631|NCT05525013|DRUG|Calcium Hydroxide|Calcium hydroxide intracanal medication
219313632|NCT00381277|DRUG|Gatorade|
219313633|NCT00381277|DRUG|Performance|
219313634|NCT03736473|DRUG|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
219313635|NCT05373160|OTHER|Assessment study|Assessment of functional tests with and without dual tasks
219313636|NCT03751059|DRUG|Bromfenac 0.07% Oph Susp|Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
219313637|NCT03751059|DRUG|Dexamethasone|Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
219313638|NCT05764941|DRUG|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
219313639|NCT05764941|DRUG|Pyrotinib|400mg, oral, every day.
219313640|NCT05764941|DRUG|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
219313641|NCT06068595|OTHER|musculoskeletal ultrasound|After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
219313642|NCT03272126|DRUG|Vitamin D|vitamin D given as bolus versus daily dosing
219313643|NCT03272126|DRUG|Placebo|identical looking as vitamin D
219313644|NCT03668184|OTHER|preeclampsia|occurrence of pre-eclampsia
219313645|NCT03375528|DEVICE|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
219313646|NCT00109382|DRUG|Aspirin|
219313647|NCT00109382|DRUG|Clopidogrel|
219313648|NCT00109382|DRUG|Simvastatin|
219313649|NCT04848532|BEHAVIORAL|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
219313650|NCT03855423|DIETARY_SUPPLEMENT|Tocotrienol-rich Fraction (TRF)|TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
219313651|NCT01516242|OTHER|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
219313652|NCT02913417|DEVICE|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
219313653|NCT02913417|DRUG|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
219313654|NCT02913417|DRUG|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
219313655|NCT01853982|DRUG|Ceftolozane/Tazobactam|
219313656|NCT01853982|DRUG|Piperacillin/Tazobactam|
219313657|NCT01576653|OTHER|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
219313658|NCT06245720|OTHER||
219313659|NCT03221192|OTHER|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.
219313660|NCT03221192|OTHER|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
219313661|NCT03221192|OTHER|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
219313662|NCT03457454|OTHER|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
219313663|NCT03457454|OTHER|Patient Participant Interview|-Approximately 45-60 minute interview
219313664|NCT03457454|OTHER|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
219313665|NCT03457454|OTHER|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
219313666|NCT03714425|DEVICE|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
219313667|NCT03019796|DRUG|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
219313668|NCT05066724|DRUG|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
219313669|NCT00436033|DRUG|milnacipran|
219313670|NCT00436033|DRUG|Placebo|
219313671|NCT00486460|DRUG|Gemcitabine|
219313672|NCT00486460|DRUG|Curcumin|
219313673|NCT00486460|DRUG|Celebrex|
219313674|NCT05001594|DEVICE|Active vibratory knee device|The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
219313675|NCT02215382|DRUG|sugammadex|sugammadex 2 mg/kg
219313676|NCT02215382|DRUG|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
219313677|NCT04789512|OTHER|Respiratory functions|Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
219313678|NCT00181064|BEHAVIORAL|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
219313679|NCT02948023|BIOLOGICAL|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
219313680|NCT00410085|DRUG|L-NMMA (N-mono.methyl-L-arginine)|
219313681|NCT00763867|DRUG|Placebo|
219313682|NCT00763867|DRUG|Sildenafil|
219313683|NCT00475033|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
219313684|NCT00475033|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
219313685|NCT02069353|DEVICE|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
219313686|NCT02069353|DEVICE|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
219313687|NCT05773989|DRUG|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
219313688|NCT05773989|DRUG|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
219313689|NCT00753051|DRUG|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
219313690|NCT00753051|DRUG|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
219313691|NCT04891432|PROCEDURE|Lateral lumbar interbody fusion|oblique lumbar interbody fusion or direct lateral interbody fusion
219313692|NCT02858869|BIOLOGICAL|Pembrolizumab|Given IV
219313693|NCT02858869|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219313694|NCT00508352|PROCEDURE|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
219313695|NCT03516968|DRUG|Monthly bolus of cholecalciferol per os|Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks
219313696|NCT03516968|DRUG|Daily dose of cholecalciferol per os|Daily substitution, 1200 IU per day (4 drops), for 3 months
219313697|NCT02447757|DRUG|remifentanil|Remifentanil analgesia during delivery
219313698|NCT00985322|DRUG|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
219313699|NCT00985322|DRUG|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
219313700|NCT04770311|BEHAVIORAL|Microbiome friendly diet|Families in the intervention group will have a microbiome-friendly nutrition assessment and will also receive groceries one time per week for four weeks to help achieve a more microbiome-friendly diet.
219313701|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
219313702|NCT05073068|BEHAVIORAL|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
219313703|NCT05073068|BEHAVIORAL|Control|No exercise
219313704|NCT03583528|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
219313705|NCT03583528|DIAGNOSTIC_TEST|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
219313706|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires.
219313707|NCT04955743|DRUG|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
219313708|NCT04955743|DRUG|Lenvatinib|20 mg orally (PO) is administered daily
219313709|NCT03444324|BIOLOGICAL|BT524|BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
219313710|NCT03444324|BIOLOGICAL|FFP/Cryo|FFP/Cryo was administered intravenously; dosage according to local standards. FFP, 15 mL per kg body weight (BW); Cryoprecipitate, fixed dose of 10 units.
219313711|NCT06307977|BEHAVIORAL|Couples Health Project|A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
219313712|NCT02729623|DRUG|Kite Systems cannaHALER cannabis Inhaler.|
219313713|NCT03686319|OTHER|Reflexology|Reflexology: foot massage
219313714|NCT04328636|DRUG|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
219313715|NCT04328636|DRUG|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
219313716|NCT06014710|OTHER|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
219313717|NCT06150534|OTHER|No Intervention|This is a non-interventional study.
219313718|NCT05380778|DRUG|Deep anesthesia|"Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45"
219313719|NCT05380778|DRUG|Shallow anesthesia|"Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45"
219313720|NCT00658684|DRUG|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
219313721|NCT06599671|PROCEDURE|Transvaginal niche resection|In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.
219313722|NCT06017986|OTHER|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
219313723|NCT06017986|OTHER|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
219313724|NCT06017986|OTHER|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
219313725|NCT06017986|OTHER|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
219313726|NCT06017986|OTHER|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
219313727|NCT06017986|OTHER|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
219313728|NCT06611124|PROCEDURE|k -wires fixation for metacarpals fractures|reduction and fixation of metacarpal fracture with k-wire
219313729|NCT06610851|DIAGNOSTIC_TEST|Blood sample|Blood sample and centrifugation
219313730|NCT06610916|OTHER|Reinforced Communautary Support Program (PARC)|"Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \&amp;#34;before\&amp;#34;. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\&amp;#34;after\&amp;#34;) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\&amp;#39; course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach"
219313731|NCT06610786|PROCEDURE|foldable capsular scleral buckling|Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity
219313732|NCT06610786|PROCEDURE|vitrectomy|Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
219313733|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
219313734|NCT01131871|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
219313735|NCT01131871|BEHAVIORAL|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
219313736|NCT00724308|OTHER|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
219313737|NCT00724308|OTHER|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
219313738|NCT05217888|DEVICE|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
219313739|NCT06863259|DRUG|Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone|"Subjects will receive a course of inotuzumab ozogamicin administered by central venous catheter over 60 minutes on days 1, 8, and 15.~Venetoclax (by mouth or NG) and dexamethasone (by mouth, NG, or IV) are given daily per assigned dose level. Venetoclax and dexamethasone are started 2 days prior to inotuzumab to limit risk of tumor lysis syndrome with a two-day venetoclax ramp up in cycle 1. On days 1 and 8, venetoclax administration should be scheduled for 4 hours after the beginning of inotuzumab ozogamicin administration. If the patient is not able to ingest venetoclax at the scheduled time, it may still be given later in the day, but efforts should be made to administer the venetoclax within 2 hours of the scheduled time whenever possible."
219313740|NCT05437185|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
219313741|NCT05437185|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
219313742|NCT07020195|PROCEDURE|Traditional SYNTAX scoring|Using traditional SYNTAX scoring to guide the selection of revascularization strategies
219313743|NCT07020195|PROCEDURE|QFR-Based Functional SYNTAX Score System|Using QFR-Based Functional SYNTAX Score System to guide the selection of revascularization strategies
219313744|NCT07021300|PROCEDURE|Early Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed within 72 hours of diagnosis of acute cholecystitis. Surgery is done under general anesthesia by an experienced surgeon. This group receives no prolonged preoperative conservative management. Timing aligns with Tokyo Guidelines 2013 recommendation for early intervention
219313745|NCT07021300|PROCEDURE|Interval Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed after 4 weeks of initial conservative management with antibiotics and analgesics. The procedure is conducted under general anesthesia by the same experienced surgeon, using the same technique as the early group. This approach represents delayed surgical management per traditional protocols.
219313748|NCT04496986|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
219313749|NCT04496986|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
219313750|NCT04496986|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
219313751|NCT04496986|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
219313752|NCT04496986|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
219313753|NCT04496986|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
219313754|NCT06693115|DEVICE|CGM with alerts|"CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."
219313755|NCT06700707|OTHER|Survey using a questionnaire.|"Permission was obtained from the original owner of the Athlete Disability Index Questionnaire (ADI) for the Turkish cultural adaptation, validity and reliability study.~120 athletes, determined by the number of questions times the rule of 10, will be asked to fill out the ADI, Oswestry Disability Index (ODI), and Roland-Morris Disability (RMDQ) questionnaires and 60 athletes will be asked to fill out the ADI questionnaire again 7 days later for test-retest reliability."
219313756|NCT06698328|DEVICE|Transauricular Vagus Nerve Stimulation|"Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area."
219313757|NCT06698328|DEVICE|Sham Stimulation|"Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area."
219313758|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
219313759|NCT07020325|PROCEDURE|Bipolar Enucleation of the Prostate|Bipolar enucleation of the prostate involves the removal of prostate tissue using a bipolar electrode. This procedure is performed for patients with benign prostatic hyperplasia (BPH), with different electrode types used for comparison in this study
219313760|NCT07020325|DEVICE|Bipolar electrode From Wolf company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
219313761|NCT07020325|DEVICE|Bipolar electrode From Storz company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
219313762|NCT07020325|DEVICE|Bipolar electrode From Olympus company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
219313763|NCT07020325|DEVICE|Bipolar electrode From Lamidey company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
219313764|NCT06881511|OTHER|No intervention (Control Group)|Patients in this group will receive standard care and undergo regular follow-up and monitoring without any additional treatment.
219313765|NCT06881511|DIETARY_SUPPLEMENT|Oral betaine hydrochloride (2 capsules, 3 times daily)|Oral betaine hydrochloride (with pepsin). Patients will take 2 capsules (648 mg per capsule) of betaine hydrochloride, 3 times daily with meals.
219313766|NCT06886581|BEHAVIORAL|Evidence-based leadership training|The structure of the course will follow the steps of the evidence-based approach: (1) each participant will identify their specific unit problem to be solved together with the team and unit leader will work with this problem during the course; (2) organisational data will be collated and analysed to understand the key problem of the unit; (3) scientific literature will be searched for, and critically appraised; (4) the views of stakeholders (patients, family members, etc.) will be considered along with implications; and (5) all sources of information will be collated together and the solution will be implemented into practice; the real situation will be evaluated. Each module includes specific learning material (power points, scientific articles), peer-group discussions, clinical exercises, and self-assessment and self-reflection. The unit leaders will work together their unit members. The course will be run in small group (about 15/agroup) and supported by tutors.
219313767|NCT06884384|BIOLOGICAL|Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml)|"At inclusion, the blood sample is used to perform thrombin generation tests (activated protein C resistance profile and ratio), classical and innovative aPL assays centrally to limit the fluctuation inherent in the tests used and enable comparison between patients, immunothrombosis markers: circulating neutrophil extracellular traps (NETs) assay, sTREM-1 assay~In the event of recurrence, blood sampling can be used to confirm compliance with treatment by measuring the anti Xa activity of the drug or INR"
219313768|NCT06884384|BEHAVIORAL|Completion of a questionnaire on compliance with anticoagulant treatment|The Girerd questionnaire (6 questions) will be proposed to patients in order to estimate the degree of compliance with AODs and VKAs at inclusion and at each follow-up visit for the duration of their participation in the study.
219313769|NCT06884384|BEHAVIORAL|Completion of a questionnaire on satisfaction with treatment anticoagulant|The ACTS questionnaire (15 questions) will be proposed to them in order to estimate their satisfaction with their anticoagulant treatment (AOD or AVK) at inclusion and at each follow-up visit for the duration of their participation in the study.
219313770|NCT06746337|BEHAVIORAL|IMAGINE|IMAGINE is a digital group cognitive behavioral therapy intervention
219313771|NCT06859697|PROCEDURE|Herbal medicine treatment|Herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients
219313772|NCT06859697|PROCEDURE|Life Guidance|Educational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices.
219313773|NCT06897137|OTHER|Surveys/Questionnaires|Participants will complete self-report questionnaires via Slice MR's secure, web-based platform. The questionnaires should take less than 30 minutes and will include the following options based on their relevance to each sample : 1) sociodemographic and clinical information) newly developed item pools for body image, fertility, and financial burden) legacy measures for body image, fertility, and financial burden) the PROMIS AYA Health Status Profile) the PROMIS Global) items about meditation practices (for descriptive purposes to inform future research).
219313774|NCT06830031|BIOLOGICAL|C402-CD19-CAR|Enrolled subjects will undergo apheresis to acquire peripheral blood mononuclear cells. C402-CD19-CAR will be generated from the subject's autologous T cells modified from the apheresis product. After C402-CD19-CAR production and product release, subjects will be administered with a single dose of C402-CD19-CAR via subcutaneous injection.
219313775|NCT04420884|DRUG|Dazostinag|Dazostinag intravenous infusion.
219313776|NCT04420884|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
219313777|NCT04420884|DRUG|Platinum|Carboplatin or Cisplatin intravenous infusion
219313778|NCT04420884|DRUG|5-fluorouracil|5-fluorouracil intravenous infusion
219313779|NCT06196892|DIETARY_SUPPLEMENT|Probiotic BBr60|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
219313780|NCT06196892|DIETARY_SUPPLEMENT|Placebo|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking maltodextrin.
219313781|NCT06769438|OTHER|ERAS|ERAS
219313782|NCT06769438|OTHER|ROFIM|teleexpertise solution connecting extra-hospital and intra-hospital practitioners
219313783|NCT06769438|OTHER|DEEPSEN|virtual reality headset to reduce anxiety
219313784|NCT06769438|OTHER|RDS|patch to continuously monitor patients' physiological parameters at home
219313785|NCT06769438|OTHER|Get ready|digital solution for managing patients at home
219313786|NCT06769438|OTHER|Lumiradx|taking CRP at home
219313787|NCT06769438|OTHER|Digital Surgery|recording of the different operating times
219313788|NCT06747182|OTHER|mobile phone-based intervention|Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
219313789|NCT06755554|DRUG|Endoscopic injection of Indocyanine green|ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.
219313790|NCT05643963|OTHER|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
219313791|NCT06786884|DEVICE|paraffin wax|This is the treatment group that will receive exercise and paraffin wax
219745237|NCT06639139|BEHAVIORAL|CogFun RG occupational therapy|21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
219313792|NCT06786884|DEVICE|standard of care exercise therapy|This is the group that will only receive exercise therapy and no paraffin wax.
219745238|NCT06222684|OTHER|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
219745239|NCT06561243|DRUG|BTK inhibitor (Ibrutinib or Acalabrutinib)|Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
219745240|NCT05905146|OTHER|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
219745241|NCT06642493|BIOLOGICAL|Fresh frozen plasma|"Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion."
219745242|NCT06564922|OTHER|Counselling|Counselling was given for treatment group.
219745243|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave once a week
219745244|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave twice a week
219745245|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave once a week
219745246|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave twice a week
219745247|NCT06563739|PROCEDURE|Focused low energy shock wave|Receive focused low energy shock wave once a week
219745248|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave once a week
219745249|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave twice a week
219745250|NCT06563739|PROCEDURE|Non-exposed group|Traditional rehabilitation assessment and training guidance
219745251|NCT06642064|BEHAVIORAL|Intervention group|"• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes."
219745252|NCT03535129|BEHAVIORAL|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
219745253|NCT05231915|GENETIC|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
219745254|NCT04805593|DEVICE|WaveLight EX500 excimer laser system|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
219313793|NCT06810947|DEVICE|ALLERSPRAY-G (device A)|Symptomatic treatment consists of 3 sprays of medical device A in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
219313794|NCT06810947|DEVICE|PCNS (device B)|Symptomatic treatment consists of 3 sprays of medical device B in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
219313795|NCT06752421|PROCEDURE|Group B: Low tidal volume|In the LTV group, mechanical ventilation will be maintained with low tidal volume parameters after the aortic cross-clamp procedure. This intervention includes a tidal volume of 3-4 mL/kg, respiratory rate of 12-14 breaths/min, PEEP of 5-8 cmH₂O, and FiO₂ of 50%. Minute ventilation (MV) will not exceed 12 L, and the parameters are adjusted according to ideal body weight. This group is designed to evaluate the protective effects of low tidal volume ventilation during surgery.
219313796|NCT06900751|DRUG|NEU-627|Investigational medicinal product
219313797|NCT06900751|OTHER|Placebo|Placebo
219313798|NCT06903715|DRUG|Belzutifan|Oral administration
219313799|NCT06903715|DRUG|Phenytoin|Oral administration
219313800|NCT06790823|DRUG|The probiotic supplement (Moodamin capsuls)|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
219313801|NCT06790823|DRUG|Placebo|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
219313802|NCT06515483|DEVICE|Brushing and Flossing of teeth|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects in the experimental group will brush and floss with the provided stretchable loop floss at least twice a day. To assess compliance, each subject will be asked to fill out a diary every time they brush/floss. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
219313803|NCT06515483|OTHER|Brushing Only|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects assigned to the control group will brush their teeth at least twice a day only. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
219313804|NCT05401214|DRUG|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
219313805|NCT05401214|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
219313806|NCT06908473|DRUG|Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.|"Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions.~Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for Qi-deficiency and Blood Stasis syndrome, reflecting personalized and precision intervention.~Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC.~Control Design: The study employs a double-blind, randomized, placebo-controlled method."
219313807|NCT06908473|DRUG|A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC|Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.
219313808|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
219313809|NCT06795659|DRUG|Esketamine (Intranasal Spray)|Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).
219313810|NCT06795659|BEHAVIORAL|Massed Prolonged Exposure (PE)|Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)
219313811|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
219313812|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
219313813|NCT06862609|OTHER|Quadro iliac plane block|Patients in Group Q will be placed in the lateral position. A low-frequency convex transducer and a 100-mm block needle will be used. Following sterilization, the transducer will be placed parasagittally at the distal attachment of the quadratus lumborum muscle to the iliac crest. The iliac crest and quadratus lumborum muscle will be visualized, with the erector spinae muscle above and the psoas major muscle below. Using an in-plane technique, the needle will be directed toward the iliac crest. After confirmation with 5 mL of isotonic sodium chloride, 40 mL of 0.25% bupivacaine will be injected incrementally with intermittent aspiration.
219313814|NCT06862609|OTHER|Control group|All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
219313815|NCT06931522|OTHER|Mat Pilates|In Mat Pilates training, exercise balls and elastic bands will be used. The exercises will be done with 10 repetitions for the first 4 weeks, and with 20 repetitions for the last 4 weeks. The difficulty level of the exercises will be increased in the following weeks according to the patient's condition.
219313816|NCT06931522|OTHER|Reformer Pilates|In the Reformer Pilates group, the difficulty level of the exercises will be provided by different positions, and the springs' resistance will be increased.
219313817|NCT06508021|DRUG|Andecaliximab|Dose level A or B
219313818|NCT06508021|DRUG|Placebo|Blinded
219313819|NCT06508021|DRUG|Andecaliximab|Dose level A or B (or age adjusted dose)
219313820|NCT00413738|DEVICE|Antiseptic-coated central venous catheters|
219313821|NCT02591199|DRUG|URG101|
219313822|NCT02591199|DRUG|Placebo|
219313823|NCT02591199|DRUG|Lidocaine|
219313824|NCT02591199|DRUG|Heparin|
219313825|NCT00265447|BEHAVIORAL|Strength training|3 months of strength training
219313826|NCT00265447|BEHAVIORAL|Aerobic conditioning|3 months of aerobic conditioning
219313827|NCT00265447|BEHAVIORAL|Delayed exercise|delayed exercise control group
219313828|NCT01390181|DRUG|Cozaar|Angiotensin II Receptor Blocker
219313829|NCT02805725|DRUG|Phase 1: Trabectedin|"Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)"
219313830|NCT02805725|DRUG|Phase 2: Trabectedin|"Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial."
219313831|NCT02805725|DRUG|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
219313832|NCT02805725|DRUG|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
219313833|NCT01195545|DEVICE|Veritas® Collagen Matrix|biological mesh in hernia repair
219313834|NCT01062945|DRUG|Placebo|Matching administration of a placebo pill.
219313835|NCT01062945|DRUG|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
219313836|NCT02425644|DRUG|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
219313837|NCT02425644|DRUG|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
219313838|NCT03668353|BIOLOGICAL|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
219313839|NCT02549560|DEVICE|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
219313840|NCT00225992|DRUG|Arsenic Trioxide|
219313841|NCT00657059|DRUG|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
219313842|NCT00657059|DRUG|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
219313843|NCT00657059|DRUG|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
219313844|NCT02714725|DRUG|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
219313845|NCT02714725|DRUG|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
219313846|NCT02714725|DRUG|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
219313847|NCT05997927|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
219313848|NCT05997927|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
219313849|NCT02772523|OTHER|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
219313850|NCT00909792|DEVICE|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
219313851|NCT00909792|DEVICE|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
219313852|NCT05882669|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
219313853|NCT02405923|OTHER|HRF|The subject will take the formula for a period of 12 months.
219313854|NCT02405923|OTHER|eHF|The subject will take the formula for a period of 12 months.
219313855|NCT00315003|DRUG|Telithromycin|
219313856|NCT00315003|DRUG|Azithromycin|
219313857|NCT02376751|DRUG|sebelipase alfa|
219313858|NCT03096366|DEVICE|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
219313859|NCT03096366|OTHER|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
219313860|NCT01012843|DRUG|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
219313861|NCT01012843|DRUG|Placebo|oral Placebo tablets two times a day for 10 days
219313862|NCT05715970|DIAGNOSTIC_TEST|PoCT+questionnaire administration|"In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital."
219313863|NCT04862247|BEHAVIORAL|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
219313864|NCT04862247|BEHAVIORAL|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
219313865|NCT04519112|PROCEDURE|Catheter Ablation|Catheter Ablation with RMN and MCN
219313866|NCT05531253|OTHER|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
219313867|NCT06460844|GENETIC|RTx-015|Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
219313868|NCT06480370|DEVICE|ISIS IOM System|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
219313869|NCT05080166|OTHER|Interview with Clinicians|One time, qualitative interview of clinicians for feedback on UPLYFT intervention
219313870|NCT05080166|OTHER|Field Test of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors for feedback
219313871|NCT05080166|BEHAVIORAL|Pilot of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors
219313872|NCT05327933|PROCEDURE|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
219313873|NCT05327933|PROCEDURE|Surgery alone|Evacuation of cSDH
219313874|NCT05442424|BEHAVIORAL|Produce Voucher|see arm/group description
219313875|NCT05442424|BEHAVIORAL|Wait-List Control|see arm/group description
219313876|NCT03265834|OTHER|< 10 days of antibiotics|Antibiotic duration
219313877|NCT03265834|OTHER|28 days of antibiotics|Antibiotic duration
219313878|NCT03314597|OTHER|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
219745255|NCT04805593|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
219745256|NCT04540471|OTHER|music|MT group receives additional music therapy
219745257|NCT04540471|OTHER|comprehensive in-patient education program|comprehensive in-patient education program
219745258|NCT05098821|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
219745259|NCT06637085|DEVICE|LLLT|low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .
219745260|NCT06637085|OTHER|traditional physical therapy|traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
219745261|NCT06637085|DEVICE|ACU TENSE|Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
219745262|NCT06565286|PROCEDURE|inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias|compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
219745263|NCT02994719|DRUG|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
219745264|NCT02994719|DEVICE|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
219313879|NCT03314597|OTHER|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
219313880|NCT02158520|BIOLOGICAL|Bevacizumab|Given IV
219313881|NCT02158520|BIOLOGICAL|Ipilimumab|Given IV
219313882|NCT02158520|OTHER|Laboratory Biomarker Analysis|Correlative studies
219313883|NCT02158520|DRUG|Nab-paclitaxel|Given IV
219313884|NCT02158520|OTHER|Pharmacological Study|Correlative studies
219313885|NCT05350384|DRUG|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
219313886|NCT00638612|BIOLOGICAL|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
219313887|NCT00638612|DRUG|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
219313888|NCT00597467|DEVICE|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
219313889|NCT00597467|DEVICE|Acuvue 2 Soft Contact Lens|Control device
219313890|NCT03458065|DEVICE|ICD|Implantable Cardioverter Defibrillator
219313891|NCT00475618|PROCEDURE|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
219313892|NCT00475618|PROCEDURE|professional cleaning|Daily use fluoride toothpaste 500 ppm.
219313893|NCT00475618|PROCEDURE|No fluoride toothpaste|Daily use no fluoride toothpaste.
219313894|NCT05604833|BEHAVIORAL|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
219313895|NCT05024630|PROCEDURE|Renal artery cryoablation|Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
219313896|NCT05024630|PROCEDURE|Pulmonary vein cryoablation|Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
219313897|NCT05024630|PROCEDURE|Renal arteriography|Renal artery was examined by renal arteriography
219313898|NCT00293722|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
219313899|NCT04344691|PROCEDURE|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
219313900|NCT00819260|DEVICE|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
219313901|NCT00819260|DEVICE|Electrocautery|Electrocautery used to reduce breast on this side
219313902|NCT02253368|OTHER|sleep|
219313903|NCT00820976|DRUG|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
219313904|NCT03025399|DRUG|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
219313905|NCT03025399|DRUG|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
219313906|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
219313907|NCT05714007|DRUG|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
219313908|NCT05714007|DRUG|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
219313909|NCT05543044|BEHAVIORAL|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
219313910|NCT01246752|BIOLOGICAL|Human Stem Cell Transplantation|Human allogenic stem cells
219313911|NCT01246752|DRUG|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
219313912|NCT00465244|DRUG|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
219313913|NCT00465244|DRUG|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
219313914|NCT03155854|PROCEDURE|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
219313915|NCT03155854|PROCEDURE|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
219313916|NCT03811353|DIAGNOSTIC_TEST|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
219313917|NCT00572520|BEHAVIORAL|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
219745265|NCT06554639|DRUG|MK-5684|Administered via oral tablet per dosing regimen.
219745266|NCT06554639|DRUG|Prednisone|Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
219313918|NCT00572520|BEHAVIORAL|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
219313919|NCT00572520|BEHAVIORAL|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
219313920|NCT02824263|OTHER|CPAP withdrawal|CPAP is discontinued for 3 nights.
219313921|NCT06150638|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
219313922|NCT06150638|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
219313923|NCT00568321|DRUG|RN624|50 mcg/kg
219313924|NCT00568321|DRUG|RN624|200 mcg/kg
219313925|NCT00568321|DRUG|Placebo|placebo
219313926|NCT02636933|OTHER|Lung Function Assessment|Lung Function Assessment
219313927|NCT02573220|BIOLOGICAL|Cetuximab|Given IV
219313928|NCT02573220|DRUG|Fluorouracil|Given IV
219313929|NCT02573220|DRUG|Irinotecan Hydrochloride|Given IV
219313930|NCT02573220|DRUG|Leucovorin Calcium|Given IV
219313931|NCT00978692|DEVICE|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
219313932|NCT00978692|DEVICE|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
219313933|NCT00221195|DRUG|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
219313934|NCT04056936|PROCEDURE|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
219313935|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- real tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, 2 mA stimulation with 1x1 tDCS mini-CT device by Soterix Medical
219313936|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- sham tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, sham stimulation with tDCS mini-CT device by Soterix Medical
219313937|NCT06416553|BEHAVIORAL|Lee-Silverman voice treatment|Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
219313938|NCT01369511|DRUG|LY2495655|Administered subcutaneously
219313939|NCT01369511|DRUG|Placebo|Administered subcutaneously
219313940|NCT00226850|BEHAVIORAL|hypnosis|
219313941|NCT06397807|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.
219313942|NCT06397807|DRUG|Analgesic injectables|Opioids, NSAIDs or acetamol will be administrated as need.
219313943|NCT06397807|DRUG|Enteral analgesics|Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
219313944|NCT02718807|OTHER|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
219313945|NCT04782843|OTHER|HEP score assessement|Assessement of the HEP score between 2 physician.
219745267|NCT06554639|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
219745268|NCT06554639|DRUG|Diltiazem hydrocholoride|Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
219745269|NCT03464461|DRUG|Ketorolac|IV drug
219745270|NCT06771024|BEHAVIORAL|Physical Exercise|The intervention include a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. International/national exercise prescription guidelines will be applied for each clinical condition (cardio/cerebrovascular disease/risk, diabetes mellitus and osteoarthritis).
219745271|NCT06642467|DEVICE|BGEM|BGEM is an ai driven model to predict blood glucose using ppg sensor
219745272|NCT06640283|DIAGNOSTIC_TEST|ctDNA test|ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.
219313946|NCT05057923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
219313947|NCT04873219|DEVICE|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
219313948|NCT02809573|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
219313949|NCT02809573|DRUG|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
219313950|NCT02809573|DRUG|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.
219313951|NCT02809573|DRUG|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.
219313952|NCT02809573|DRUG|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
219313953|NCT00328900|DRUG|Administration of 0,7 mg of atropine|
219313954|NCT00328900|DEVICE|Measurement of skin conductance with Pain detector|
219313955|NCT01180998|DEVICE|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
219313956|NCT01180998|DEVICE|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
219313957|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
219313958|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
219313959|NCT06206369|OTHER|No intervention, retrospective study|No intervention, retrospective study
219313960|NCT05784987|DRUG|Rituximab|375 mg/m2, d0, Cycle 1\~4
219313961|NCT05784987|DRUG|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1\~4
219313962|NCT05784987|DRUG|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1\~4
219313963|NCT05784987|DRUG|Etoposide|65 mg/m2, d1-3, Cycle 1\~4
219313964|NCT05784987|DRUG|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2\~4
219313965|NCT05784987|DRUG|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4
219313966|NCT05784987|DRUG|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2\~4
219313967|NCT05784987|DRUG|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2\~4
219313968|NCT01363167|DIETARY_SUPPLEMENT|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
219313969|NCT00010062|DRUG|fluorouracil|
219313970|NCT00010062|RADIATION|radiation therapy|
219313971|NCT02031289|DRUG|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
219313972|NCT01762670|DRUG|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
219313973|NCT01762670|DRUG|Metronidazole|500 mg twice daily for 7 days
219313974|NCT04350554|OTHER|Pregnancy|To measure and characterize pregnancies and describe the clinical course during pregnancy
219313975|NCT04350554|OTHER|Pregnancy|To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
219313976|NCT02849340|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
219313977|NCT02849340|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
219745273|NCT06640283|DRUG|Pembrolizumab|Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
219313978|NCT04376970|DRUG|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
219745274|NCT06638008|DRUG|perineural injection|perineural intervention of placental growth factor in one group and PRP in other group
219313979|NCT04376970|DRUG|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
219313980|NCT00065325|DRUG|Fulvestrant|intramuscular injection
219313981|NCT00065325|DRUG|Exemestane|oral capsule
219313982|NCT01176968|DRUG|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
219313983|NCT01176968|DRUG|Placebo|Matching placebo tablets
219313984|NCT02485535|OTHER|Laboratory Biomarker Analysis|Correlative studies
219313985|NCT02485535|DRUG|Selinexor|Given PO
219313986|NCT02463825|DRUG|Pimozide 2 mg per day|
219313987|NCT02463825|DRUG|Pimozide 4 mg per day|
219313988|NCT02463825|DRUG|Placebo (Lactose tablet)|
219313989|NCT02701426|BEHAVIORAL|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
219313990|NCT00559442|OTHER|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
219313991|NCT00718640|DRUG|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
219313992|NCT00718640|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
219313993|NCT04100473|DRUG|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
219313994|NCT04100473|DRUG|Insulin Lispro (Humalog U-100)|Lispro
219313995|NCT02431650|DRUG|OZ439|
219313996|NCT02431650|DRUG|Primaquine|
219313997|NCT05628116|DRUG|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
219313998|NCT05628116|DRUG|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
219313999|NCT05628116|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
219314000|NCT05628116|DRUG|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
219314001|NCT05628116|DRUG|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
219314002|NCT05628116|DRUG|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
219314003|NCT05628116|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
219314004|NCT01742598|DEVICE|Portico Transapical Aortic Valve System|
219314005|NCT04559828|OTHER|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
219314006|NCT02272855|BIOLOGICAL|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
219314007|NCT01596907|DRUG|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
219314008|NCT01596907|DRUG|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
219314009|NCT00483314|DRUG|N-acetylcysteine|2 g p.o. BID x 60 days
219314010|NCT04660071|OTHER|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
219314011|NCT04660071|OTHER|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
219314012|NCT01207596|DRUG|Hydromorphone|Oral hydromorphone extended release, once daily
219314013|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
219314014|NCT02661698|DIETARY_SUPPLEMENT|Placebo|3 x 1 g capsules Placebo: olive oil
219314015|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
219314016|NCT00119145|DRUG|artesunate-amodiaquine|
219314017|NCT00119145|DRUG|coartem|
219314018|NCT00119145|DRUG|artesunate-lapdap|
219314019|NCT04427150|BEHAVIORAL|Auditory Training|A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
219314020|NCT04427150|BEHAVIORAL|Non-auditory training|A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
219314021|NCT06356961|BEHAVIORAL|(Feedback Informed Therapy) with Clinical Support Tools and ah hoc training|Therapists in the condition (OPM-F) will receive specific training on the procedures and techniques inherent in feedback informed therapy (FIT); during the intervention phase (lasting 15 sessions) the Clinical Support System in FIT will guide them in the clinical application of the procedures. In addition, they will receive monthly supervision (for three months) apt to provide on-going clinical support on FIT and ROM, with practical discussion of the most difficult clinical cases and possible solutions to be implemented in therapy.
219314022|NCT06356961|BEHAVIORAL|Feedback and ROM (basic)|Process and outcome monitoring (OPM) in which patients will complete process and outcome measures related to each psychotherapy session but therapists will receive basic feedback on these measures
219314023|NCT02863887|BEHAVIORAL|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
219314024|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
219314025|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
219314026|NCT05550740|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
219314027|NCT05386550|DRUG|Xevinapant|Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle.
219314028|NCT05386550|RADIATION|IMRT|Participants received 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days per week.
219314029|NCT05386550|DRUG|Placebo|Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle.
219314030|NCT06423248|DIETARY_SUPPLEMENT|Ginger|3g of dried powdered Ginger daily for 12 weeks
219314031|NCT06423248|DIETARY_SUPPLEMENT|black seed|3g of dried powdered Black Seed daily for 12 weeks
219314032|NCT06423248|DIETARY_SUPPLEMENT|cinnamon|3g of dried powdered Cinnamon daily for 12 weeks.
219314033|NCT06423248|OTHER|Placebo|3g of powdered corn starch daily for 12 weeks.
219314034|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
219314035|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
219314036|NCT06555198|BEHAVIORAL|Foot(at)Work intervention|Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
219314037|NCT04562987|BEHAVIORAL|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
219314038|NCT04562987|BEHAVIORAL|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
219314039|NCT00068588|BIOLOGICAL|GTI-2040|Given IV
219314040|NCT00068588|DRUG|capecitabine|Given orally
219314041|NCT04822168|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
219314042|NCT04822168|OTHER|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
219314043|NCT05193500|BEHAVIORAL|Verbs|New verbs are introduced that are personally relevant to the child or neutral.
219314044|NCT05193500|BEHAVIORAL|Pronouns|Pronouns are used that directly refer to the child or are neutral.
219314045|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
219314046|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
219314047|NCT06311981|OTHER|targeted therapy|targeted therapy
219314048|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
219314049|NCT04098068|DRUG|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
219314050|NCT06084494|DIAGNOSTIC_TEST|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
219314051|NCT06268990|PROCEDURE|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
219314052|NCT05489887|DRUG|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
219314053|NCT03098589|DRUG|Revlimid|Revlimid
219314054|NCT03871829|DRUG|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
219314055|NCT03871829|DRUG|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m\^2 will be administered IV.
219314056|NCT03871829|DRUG|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
219314057|NCT03871829|DRUG|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
219314058|NCT03871829|DRUG|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
219314059|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
219314060|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
219314061|NCT05645588|BEHAVIORAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
219314062|NCT05645588|BEHAVIORAL|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
219314063|NCT03844360|DRUG|Bortezomib|bortezomib was administered follow the doctor's advice.
219314064|NCT03844360|DRUG|Eltrombopag|eltrombopag was administered follow the doctor's advice.
219314065|NCT03844360|DRUG|Imatinib|imatinib was administered follow the doctor's advice.
219314066|NCT03844360|DRUG|dasatinib|dasatinib was administered follow the doctor's advice.
219314067|NCT03844360|DRUG|Pegaspargase|pegaspargase was administered follow the doctor's advice.
219314068|NCT03844360|DRUG|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
219314069|NCT03844360|DRUG|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
219314070|NCT01106014|DRUG|Selexipag|Selexipag 200 µg tablets
219314071|NCT01106014|DRUG|Placebo|Placebo tablets matching selexipag
219314072|NCT06110611|DEVICE|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
219314073|NCT06774066|OTHER|High volume image guided injection|High volume image guided injection consists of 9.5ml of bupivacaine, 0.5ml 20mg Depo-medrol, and 40ml of injectable saline. This procedure will be commenced with a thorough disinfection of the injection site. The mid-portion of the Achilles tendon will then be imaged in the short axis to obtain a cross-sectional view of the tendon, alongside the anterior region, including Kager's fat pad, particularly in areas of maximal pain and increased neovascularity. Once the needle is correctly positioned, the high-volume fluid will be infiltrated under pressure, with ultrasound guidance confirming the reduction or complete disappearance of neovascularisation.
219314074|NCT06774066|OTHER|Progressive rehabilitation exercise programme|A comprehensive explanation of the progressive exercise program will be provided to patients, along with a detailed booklet that includes four tiers of exercises, ranging from the easiest to the most challenging. Exercises include several eccentrics, isometrics and heavy slow resistance exercises. These exercises are to be performed once a day and the intensity and number of repetitions will be based on the patients' status. The progressive exercise program is designed to avoid exacerbating the patient's symptoms; however, some pain is permitted during the sessions following the pain monitoring model proposed by Thomee (1997)
219314075|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
219314076|NCT04092101|OTHER|Cigarettes with varying nicotine content|1\) Altering the nicotine content of the tobacco research cigarette
219314077|NCT04092101|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
219314078|NCT02283554|PROCEDURE|open flap debridement (OFD)|
219314079|NCT02283554|OTHER|Platelet rich fibrin (PRF)|
219314080|NCT02283554|DRUG|Metformin|
219314081|NCT02149082|DEVICE|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
219314082|NCT04977726|BEHAVIORAL|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
219314083|NCT01720173|BIOLOGICAL|Dalantercept|Given SC
219314084|NCT01720173|OTHER|Laboratory Biomarker Analysis|Correlative studies
219314085|NCT00784693|BIOLOGICAL|Tanezumab|15 mg IV single dose
219314086|NCT00784693|DRUG|Placebo|Placebo IV single dose
219314087|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
219314088|NCT02650882|PROCEDURE|Device POWERbreathe|
219314089|NCT05848505|DRUG|Dexmedetomidine|Intranasal administration Dosage 2 mcg/kg
219314090|NCT02456077|BEHAVIORAL|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
219314091|NCT00655694|PROCEDURE|sputum, blood, urine, exhaled breath, lung function|
219314092|NCT05276115|OTHER|Interview|Interview discussion with individuals with ptsd.
219314093|NCT02851082|OTHER|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
219314094|NCT00121277|DRUG|capecitabine|
219314095|NCT00121277|DRUG|vorinostat|
219314096|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
219314097|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
219314098|NCT02860663|DIETARY_SUPPLEMENT|25OHD|10 ug/d of vitamin D3 for 6 weeks
219314099|NCT03159923|OTHER|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
219314100|NCT01067157|BEHAVIORAL|LOGIC|"Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
219314101|NCT03299257|DRUG|donepezil treatment|30-day donepezil treatment
219314102|NCT04201756|DRUG|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
219314103|NCT03227796|DRUG|LEVI-04|LEVI-04 intravenous infusion
219314104|NCT03227796|DRUG|Placebo|Placebo intravenous infusion
219314105|NCT01642173|DEVICE|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
219314106|NCT01964807|OTHER|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
219314107|NCT01964807|OTHER|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
219314108|NCT01964807|OTHER|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
219314109|NCT01964807|OTHER|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
219314110|NCT01964807|OTHER|Moist snuff|Use moist snuff for 30 minutes
219314111|NCT01964807|OTHER|Sham Smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
219314112|NCT01964807|OTHER|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
219314113|NCT01964807|OTHER|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
219314114|NCT01964807|OTHER|Sham Moist Snuff|Chew gum for 30 minutes
219314115|NCT00908232|DRUG|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
219314116|NCT00908232|DRUG|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
219314117|NCT00908232|DRUG|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
219314118|NCT00908232|DRUG|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
219314119|NCT03678987|DIAGNOSTIC_TEST|P-MPA concentration|We will calculate AUC\_0-12 of MPA based on 4 measurements of P-MPA
219314120|NCT03678987|DRUG|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
219314121|NCT02025569|OTHER|Strain Counterstrain|
219314122|NCT02025569|OTHER|Sham strain counterstrain|
219314123|NCT03296462|OTHER|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
219314124|NCT03296462|OTHER|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
219314125|NCT02260882|BIOLOGICAL|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
219314126|NCT00516451|DRUG|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
219314127|NCT04034550|OTHER|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
219314128|NCT00872196|DRUG|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
219314129|NCT02119325|DIETARY_SUPPLEMENT|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
219314130|NCT02119325|DIETARY_SUPPLEMENT|0% fibre|Placebo is an energy matched powdered beverage
219314131|NCT01386658|DRUG|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
219314132|NCT05309434|BEHAVIORAL|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
219314133|NCT03575390|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
219314134|NCT03575390|DIETARY_SUPPLEMENT|Pomegranate|Pomegranate extract 500mg
219314135|NCT03291704|DEVICE|Thermal therapy device|Thermal therapy of blocked Meibomian glands
219314136|NCT04307082|DRUG|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
219314137|NCT00954174|DRUG|Carboplatin|Given IV
219314138|NCT00954174|DRUG|Ifosfamide|Given IV
219314139|NCT00954174|DRUG|Paclitaxel|Given IV
219314140|NCT00954174|OTHER|Quality-of-Life Assessment|Ancillary studies
219314141|NCT01822977|DRUG|omeprazole|
219314142|NCT02274636|DIETARY_SUPPLEMENT|Xylitol|A comparison between discs and gel
219314143|NCT05175612|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
219314144|NCT06140212|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
219314145|NCT06140212|BEHAVIORAL|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
219314146|NCT06140212|BEHAVIORAL|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
219314147|NCT01329016|DRUG|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
219314148|NCT01329016|DRUG|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
219314149|NCT01329016|DRUG|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
219314150|NCT02877160|DRUG|AL-794 suspension|
219314151|NCT02877160|DRUG|AL-794 tablet|
219314152|NCT02287376|DRUG|Diclofenac Potassium for Oral Solution|NSAID
219314153|NCT02785497|OTHER|Control group|will be turn on the equipment, positioning the patient but no put intensity
219314154|NCT02785497|OTHER|Treatment group|This group will receive electrostimulation
219314155|NCT05474066|DEVICE|ERP Testing|"* Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:"
219314156|NCT03840239|DRUG|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
219314157|NCT03840239|RADIATION|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
219314158|NCT03840239|PROCEDURE|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
219314159|NCT03840239|OTHER|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
219314160|NCT02796001|BIOLOGICAL|human rhinovirus|human rhinovirus
219314161|NCT02796001|OTHER|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
219314162|NCT03623685|DIAGNOSTIC_TEST|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
219314163|NCT00350662|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
219314164|NCT00350662|DRUG|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
219314165|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 2.5 mg, twice daily, oral
219314166|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 5 mg, twice daily, oral
219314167|NCT01776424|DRUG|Aspirin|Tablet, 100 mg, once daily, oral
219314168|NCT01776424|DRUG|Aspirin placebo|Aspirin matching placebo, once daily, oral
219314169|NCT01776424|DRUG|Rivaroxaban placebo|Rivaroxaban matching placebo, twice daily, oral
219314170|NCT01776424|DRUG|Pantoprazole|Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
219314171|NCT01776424|DRUG|Pantoprazole placebo|Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
219314172|NCT04575753|OTHER|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
219314173|NCT05601791|PROCEDURE|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
219314174|NCT05601791|PROCEDURE|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
219314175|NCT04112446|DRUG|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
219314176|NCT04100850|OTHER|Aquatic Exercises|twice a week, lasting 50 minutes, for two months.
219314177|NCT04100850|OTHER|Watsu|twice a week, lasting 50 minutes, for two months.
219314178|NCT03423823|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
219314179|NCT03423823|DRUG|Ranibizumab|Anti-VEGF standard of care injection
219314180|NCT02262923|DRUG|metoclopramide|
219314181|NCT03886792|BEHAVIORAL|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
219314182|NCT03886792|BEHAVIORAL|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
219314183|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
219314184|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
219314185|NCT04442360|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
219314186|NCT00438503|PROCEDURE|Procedure|
219314187|NCT03948217|OTHER|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
219314188|NCT04987567|DIETARY_SUPPLEMENT|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
219314189|NCT04987567|DIETARY_SUPPLEMENT|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
219314190|NCT05411367|DRUG|SI-614|1 drop in each eye
219314191|NCT05411367|DRUG|Vehicle|1 drop in each eye
219314192|NCT03733067|DRUG|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
219314193|NCT03733067|OTHER|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
219314194|NCT04773613|OTHER|Experimental SLP|SLP was given to the infant during bottle-feeding.
219314195|NCT04773613|OTHER|Experimental SEP|SEP was given to the infant during bottle-feeding.
219314196|NCT00550368|BIOLOGICAL|Biological intervention: Enteropathogenic E. coli|5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
219314197|NCT04156217|BIOLOGICAL|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
219314198|NCT05392530|DRUG|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
219314199|NCT03985215|OTHER|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
219314200|NCT01246934|OTHER|ASR METHOD|
219314201|NCT04213027|PROCEDURE|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
219314202|NCT04653168|DRUG|LY3041658|Administered SC
219314203|NCT00186069|DRUG|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
219314204|NCT00186069|OTHER|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
219314205|NCT01430806|DRUG|Dronedarone arm|PO Dronedarone 400 mg BID
219314206|NCT01430806|DRUG|Dronedarone|Dronedarone PO 400 MG BID
219314207|NCT02913729|RADIATION|partial breast irradiation|irradiation
219314208|NCT05615753|BEHAVIORAL|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
219314209|NCT04707651|DIETARY_SUPPLEMENT|Formula diet|Formula diet for 12 weeks
219314210|NCT02569203|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition
219314211|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
219314212|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
219314213|NCT03931720|BIOLOGICAL|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
219314214|NCT00562211|DRUG|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
219314215|NCT00562211|DRUG|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
219745275|NCT06639529|DIAGNOSTIC_TEST|Tests of the expression of CXCL3 in various tissues|1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
219314216|NCT06134206|DIAGNOSTIC_TEST|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
219314217|NCT00652860|BIOLOGICAL|aerosol sargramostim|
219314218|NCT00652860|BIOLOGICAL|sargramostim|
219314219|NCT00652860|DRUG|cisplatin|
219314220|NCT00652860|DRUG|doxorubicin hydrochloride|
219314221|NCT00652860|DRUG|ifosfamide|
219314222|NCT00652860|DRUG|mitomycin C|
219314223|NCT00652860|OTHER|flow cytometry|
219314224|NCT00652860|OTHER|immunological diagnostic method|
219314225|NCT00652860|OTHER|laboratory biomarker analysis|
219314226|NCT00652860|PROCEDURE|adjuvant therapy|
219314227|NCT00652860|PROCEDURE|multimodality therapy|
219314228|NCT00652860|PROCEDURE|neoadjuvant therapy|
219314229|NCT00652860|PROCEDURE|therapeutic conventional surgery|
219314230|NCT00652860|RADIATION|intraoperative radiation therapy|
219314231|NCT00652860|RADIATION|selective external radiation therapy|
219314232|NCT03392025|OTHER|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
219314233|NCT03392025|OTHER|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
219314234|NCT03392025|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
219314235|NCT01640275|DRUG|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
219314236|NCT01640275|DRUG|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
219314237|NCT02318823|OTHER|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
219314238|NCT02318823|OTHER|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
219314239|NCT01118611|DRUG|Aurora B/C kinase inhibitor GSK1070916A|
219745276|NCT06643429|DIAGNOSTIC_TEST|colorectal cancer|Patients diagnosed with colorectal cancer by pathological biopsy.
219314240|NCT01118611|OTHER|laboratory biomarker analysis|
219314241|NCT01118611|OTHER|pharmacological study|
219314242|NCT01118611|PROCEDURE|diffusion-weighted magnetic resonance imaging + PET CT|
219314243|NCT01118611|RADIATION|fludeoxyglucose F 18 dynomic contrast|
219314244|NCT00730834|DEVICE|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
219314245|NCT04290442|PROCEDURE|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
219745277|NCT06643429|DIAGNOSTIC_TEST|colorectal neoplasm|Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
219745278|NCT06644365|OTHER|Acupresure mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
219745279|NCT06644365|OTHER|Basic mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
219745280|NCT06644807|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
219314246|NCT04290442|PROCEDURE|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
219314247|NCT04290442|DRUG|Ropivacaine|ropivacaine 0.5% will be use in the block
219314248|NCT00447759|DRUG|Celecoxib|200-400mg daily in divided doses
219314249|NCT00447759|DRUG|Diclofenac|prescribed medication taken orally
219314250|NCT03321734|DRUG|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
219314251|NCT03321734|DRUG|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
219314252|NCT02727166|DIETARY_SUPPLEMENT|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
219314253|NCT02727166|DIETARY_SUPPLEMENT|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
219314254|NCT03478163|DRUG|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
219314255|NCT03478163|DRUG|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
219314256|NCT04581616|PROCEDURE|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
219314257|NCT04581616|PROCEDURE|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
219314258|NCT02422251|DEVICE|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
219314259|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
219314260|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
219314261|NCT00261001|BIOLOGICAL|Transcutaneous mode of administration|
219314262|NCT00261001|BIOLOGICAL|Intramuscular mode of administration|
219314263|NCT05572333|DRUG|EP395|Capsule for oral use
219314264|NCT05572333|DRUG|Placebo|Capsule for oral use
219314265|NCT03082703|BEHAVIORAL|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
219314266|NCT05615532|DRUG|LY3209590 (SC)|Administered SC.
219314267|NCT05615532|DRUG|LY3209590 (IV)|Administered IV.
219314268|NCT01762722|DEVICE|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
219314269|NCT00126022|DRUG|Tedisamil sesquifumarate|
219314270|NCT00577161|DRUG|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
219314271|NCT00577161|DRUG|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
219314272|NCT02624323|PROCEDURE|Real-time ultrasound-guided central vein catheterization.|
219314273|NCT01644344|OTHER|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
219314274|NCT01644344|OTHER|Xray|
219314275|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream low-dose|travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
219314276|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream mid-dose|travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
219314277|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream high-dose|travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
219314278|NCT06152861|DRUG|Timolol maleate ophthalmic solution, 0.5%|timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes
219314279|NCT06152861|DRUG|Travoprost Ophthalmic Solution, 0.004%|travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
219314280|NCT04922489|PROCEDURE|Dental implant placement|Dental implant placemente on edentulous jaw.
219314281|NCT00642551|DIETARY_SUPPLEMENT|menaquinone-7|180 µg menaquinone-7 daily for three years
219314282|NCT00642551|DIETARY_SUPPLEMENT|placebo|1 placebo capsule daily for three years
219314283|NCT00260117|BEHAVIORAL|Exercise|Referal to a website
219314284|NCT05997524|DRUG|Trastuzumab|Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).
219314285|NCT05997524|DRUG|Oxaliplatin|Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.
219314286|NCT05997524|DRUG|Capecitabine|Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
219314287|NCT00002863|DRUG|chemotherapy|
219314288|NCT00002863|PROCEDURE|conventional surgery|
219314289|NCT00002863|PROCEDURE|cryosurgery|
219314290|NCT06445283|OTHER|Determination of VTE risk levels|Determination of VTE risk levels of patients using IMPROVE risk assessment tool according to deep vein thrombosis and pulmonary embolism risk factors
219314291|NCT01207661|BIOLOGICAL|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
219314292|NCT04127149|DIAGNOSTIC_TEST|Ultrasound scan|The group uses an ultrasound device for the consultation.
219314293|NCT00696930|DRUG|90Y-SMT487|
219314294|NCT00292799|DRUG|Orlistat Vs Metformin|
219314295|NCT01938469|OTHER|Liquid Meal|
219314296|NCT01938469|OTHER|Solid Meal|
219314297|NCT05176184|DIAGNOSTIC_TEST|A deep learning model for predicting a difficult laryngoscopy based on a cervical spine lateral X-ray image|"The deep learning model uses the input of preprocessed C-spine lateral X-ray images and outputs the level of difficulty of a laryngoscopy. The easy laryngoscopy is defined as a combination of the Cormack-Lehane grades 1-2 and the difficult laryngoscopy is defined as a combination of grades 3-4.~In addition, before general anesthesia, airway evaluations related to the difficulty of laryngoscopy are performed and the results are compared with the actual level of difficulty."
219314298|NCT03037619|BEHAVIORAL|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
219314299|NCT03037619|BEHAVIORAL|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
219314300|NCT02645513|BEHAVIORAL|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
219314301|NCT02645513|BEHAVIORAL|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
219314302|NCT02645513|BEHAVIORAL|Control|No text message reminders
219314303|NCT02843971|DEVICE|Intraocular pressure measurement with the Sensimed triggerfish Device|
219314304|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume
219314305|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume
219314306|NCT00617032|GENETIC|tgAAC94 placebo|Single dose
219314307|NCT03715309|DRUG|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
219314308|NCT00802009|DRUG|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
219314309|NCT00802009|DRUG|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
219314310|NCT01498289|DRUG|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
219314311|NCT01498289|DRUG|docetaxel|30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
219314312|NCT01498289|DRUG|fluorouracil|400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
219314313|NCT01498289|DRUG|irinotecan hydrochloride|65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
219314314|NCT01498289|DRUG|leucovorin calcium|400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
219314315|NCT01498289|DRUG|oxaliplatin|85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
219314316|NCT04162223|BIOLOGICAL|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
219314317|NCT04162223|BIOLOGICAL|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
219314318|NCT02755623|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
219314319|NCT02755623|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
219314320|NCT02873507|OTHER|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
219314321|NCT04242160|OTHER|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
219314322|NCT04242160|OTHER|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
219314323|NCT01146626|DRUG|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
219314324|NCT01146626|DRUG|Peg+ Ribavirine|Peg+ Ribavirine
219314325|NCT03208322|OTHER|Non-Interventional|Non-Interventional
219314326|NCT04709822|BEHAVIORAL|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
219314327|NCT01794923|DRUG|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
219314328|NCT01794923|DRUG|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
219314329|NCT01794923|DRUG|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
219314330|NCT01794923|DRUG|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
219314331|NCT00090090|DRUG|Elsamitrucin|
219314332|NCT00759330|DRUG|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
219314333|NCT00759330|DRUG|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
219314334|NCT00759330|DRUG|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
219314335|NCT00759330|DRUG|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
219314336|NCT00735735|OTHER|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
219314337|NCT00245934|DRUG|Enbrel|
219314338|NCT06431009|OTHER|Treatment-as-usual|Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
219314339|NCT03318809|DRUG|AMG 986|tablets for oral administration
219314340|NCT01525719|DRUG|Everolimus|10 mg everolimus
219314341|NCT04181151|OTHER|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
219314342|NCT04251650|OTHER|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
219314343|NCT04251650|OTHER|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
219314344|NCT00141323|DRUG|lasofoxifene|0.5 mg once per day, orally
219314345|NCT00141323|OTHER|placebo|placebo
219314346|NCT00141323|DRUG|lasofoxifene|0.25 mg once per day, orally
219314347|NCT02022319|DEVICE|Ultrasonographic Shear Wave Elastography|
219314348|NCT00786396|BEHAVIORAL|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
219314349|NCT05033808|DRUG|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
219314350|NCT05033808|DRUG|Placebo|NaCl is given once over 15 Minutes via a central line
219314351|NCT02073734|DRUG|Dexamethasone|Dexamethasone 8mg/IV
219314352|NCT02073734|DRUG|Placebo|Placebo given IV
219314353|NCT02292966|DRUG|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
219314354|NCT02030405|DRUG|Ixazomib|Given orally (PO)
219314355|NCT00622882|OTHER|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
219314356|NCT04694404|DRUG|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
219314357|NCT02340091|DEVICE|HA IDF plus|
219314358|NCT02340091|DEVICE|HA IDF|
219314359|NCT04673565|BEHAVIORAL|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
219314360|NCT02880202|OTHER|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
219314361|NCT04523766|BEHAVIORAL|Mindfulness of Breath|The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
219314362|NCT04523766|BEHAVIORAL|Mindful Interoceptive Mapping|The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
219314363|NCT01849484|RADIATION|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
219314364|NCT01849484|RADIATION|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
219314365|NCT04386187|OTHER|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
219314366|NCT04386187|OTHER|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
219314367|NCT04386187|OTHER|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
219314368|NCT04021251|DEVICE|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
219314369|NCT03099200|OTHER|No Intervention|
219314370|NCT01936142|DEVICE|Use of RenalGuard|
219314371|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
219314372|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
219314373|NCT01220232|DRUG|Lersivirine|Lersivirine 750 mg QD for 10 days
219314374|NCT04888325|OTHER|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
219314375|NCT04888325|OTHER|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
219314376|NCT03707925|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
219314377|NCT03707925|PROCEDURE|Conventional Surgery|Undergo standard resection
219314378|NCT03707925|PROCEDURE|Laser Ablation|Undergo bronchoscopic laser ablation
219314379|NCT02957721|OTHER|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
219314380|NCT03782142|DRUG|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
219314381|NCT03782142|DRUG|Rilpivirine|NNRTI
219314382|NCT03782142|DRUG|Prezcobix|PI
219314383|NCT03782142|DRUG|Dolutegravir|II
219314384|NCT06227663|BEHAVIORAL|KOALOU(®) digital application|Digital app that prepares children for the ambulatory surgery care pathway by assessing their anxiety and educating them about anesthesia and surgery
219314385|NCT05809817|PROCEDURE|Periodontal treatment|Scaling and root planing
219314386|NCT01088100|GENETIC|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
219314387|NCT04195958|DRUG|Omalizumab|Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
219314388|NCT00818181|DRUG|Biological: AL0206st|
219745281|NCT06644807|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
219314389|NCT03501186|OTHER|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
219314390|NCT00290108|DRUG|Propofol|
219314391|NCT04657757|OTHER|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
219745282|NCT06644807|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
219745283|NCT06644807|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
219745284|NCT06644586|OTHER|videolaryngoscopy|The patients intubated with video laryngoscopy
219745285|NCT06644586|OTHER|Direct Laryngoscopy|The patients intubated with direct laryngoscopy
219745286|NCT03658304|DRUG|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
219745287|NCT05773482|BEHAVIORAL|Breathing and Attention Training (BAT)|BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
219745288|NCT05773482|BEHAVIORAL|Breathing Control|Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
219745289|NCT06571890|DEVICE|Narcotrend bispectral index anaesthesia monitor|A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
219745290|NCT06571890|DEVICE|Mdoloris Anaesthesia Nociception Monitor|A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
219745291|NCT03685149|DRUG|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
219745292|NCT03685149|DRUG|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
219745293|NCT01628952|DRUG|Transversus Abdominis Plane|PIA coelioscopic
219745294|NCT01628952|DRUG|Curare|IAP coelioscopic
219745295|NCT03697447|PROCEDURE|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
219745296|NCT04956016|DEVICE|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
219745297|NCT04956016|DEVICE|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
219745298|NCT05554731|DEVICE|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
219745299|NCT05554731|DEVICE|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
219745300|NCT02529956|DRUG|UCB4940|"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"
219314392|NCT02472080|DRUG|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
219314393|NCT00593801|DRUG|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
219314394|NCT00593801|DRUG|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
219314395|NCT04508634|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
219314396|NCT04508634|DRUG|Metformin Pill|Metformin 1000mg bid
219314397|NCT02884765|PROCEDURE|Non-surgical|Non-surgical treatment in both condylar fractures
219314398|NCT02884765|PROCEDURE|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
219314399|NCT02884765|PROCEDURE|Surgical|Surgical treatment in both condylar fractures
219314400|NCT01104142|DEVICE|CGM|Continuous Glucose Monitoring System
219314401|NCT02779738|DRUG|Merestinib|Administered orally
219314402|NCT00723879|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
219314403|NCT00723879|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
219314404|NCT00723879|BEHAVIORAL|Patient assistance program|"Patient assistance programs will be classified as follows:~1. medications, including psychiatric medications (antidepressants);~2. other interventions, including nurse telephone calls and nurse support in the office: and~3. educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
219314405|NCT02422485|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
219314406|NCT03975023|DEVICE|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
219314407|NCT01369901|BEHAVIORAL|A functional exercise program|
219314408|NCT01369901|BEHAVIORAL|A stretching exercise program|
219314409|NCT04300582|PROCEDURE|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
219314410|NCT04300582|PROCEDURE|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
219314411|NCT01472380|DRUG|efavirenz|600 mg
219314412|NCT01472380|DRUG|fenofibric acid 105 mg|fenofibric acid 105 mg
219314413|NCT06312280|BEHAVIORAL|Mediterranean diet|The composition of the diet will be distributed as follows: 55-60% of carbohydrates (45-50% complex carbohydrates and no more than 10% of simple sugars), 25-30% of lipids and 15% of proteins. It will be studied in accordance with the LARN (Italian Society of Human Nutrition, 2014) guidelines.
219314414|NCT00292461|DRUG|Zonisamide|Tablet once or twice daily orally for 16 weeks
219314415|NCT00292461|DRUG|Lamotrigine|Tablet once daily orally for 16 weeks
219314416|NCT02496910|DRUG|YH22162|
219314417|NCT02496910|DRUG|Telmisartan/Amlodipine 80/5 mg (FDC)|
219314418|NCT02496910|DRUG|Chlorthalidone 25mg|
219314419|NCT06071910|DEVICE|ER-REBOA catheter|To achieve rapid aortic occlusion
219314420|NCT00420602|DIETARY_SUPPLEMENT|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
219314421|NCT04110119|DRUG|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
219314422|NCT04110119|OTHER|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
219314423|NCT00680823|DRUG|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
219314424|NCT00680823|DRUG|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
219314425|NCT05484050|OTHER|Immunohistochemistry analysis|Estimation of VEGF through Immunohistochemistry
219314426|NCT04894162|OTHER|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
219314427|NCT00892619|PROCEDURE|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
219314428|NCT00892619|PROCEDURE|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
219314429|NCT06502106|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
219314430|NCT05497648|BEHAVIORAL|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
219314431|NCT03536390|DRUG|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
219314432|NCT03536390|DRUG|Placebo|Placebo
219314433|NCT04850157|DRUG|Tislelizumab|200mg, Q3W
219314434|NCT04850157|RADIATION|IMRT|4 Gy\* 5 Fx,5Fx/Week
219314435|NCT05625412|DRUG|BMS-986360|Specified dose on specified days
219314436|NCT05625412|DRUG|Docetaxel|Specified dose on specified days
219314437|NCT05625412|DRUG|Nivolumab|Specified dose on specified days
219314438|NCT05625412|DRUG|Capecitabine|Specified dose on specified days
219314439|NCT04687761|DRUG|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle
219314440|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
219314441|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
219314442|NCT04687761|DRUG|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
219314443|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
219314444|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
219314445|NCT06262854|DEVICE|Calcium-sulphate granules with tobramicina+vancomicina|Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
219314446|NCT00902954|DRUG|anastrozole|anastrozole 1 mg qd
219314447|NCT00902954|DRUG|letrozole|letrozole 2.5 mg qd
219314448|NCT00902954|DRUG|exemestane|exemestane 25 mg qd
219314449|NCT01674335|BEHAVIORAL|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
219314450|NCT01674335|BEHAVIORAL|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
219314451|NCT00347165|DRUG|bevacizumab intravitreal injection|
219314452|NCT05409287|PROCEDURE|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
219314453|NCT05409287|PROCEDURE|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
219314454|NCT05241782|OTHER|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks"
219314455|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
219314456|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
219314457|NCT05953064|OTHER|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
219314458|NCT05953064|OTHER|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
219314459|NCT04887324|OTHER|no intervention|no intervention
219314460|NCT04385108|BIOLOGICAL|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
219314461|NCT04385108|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
219314462|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
219314463|NCT05457582|DRUG|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
219745301|NCT02529956|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"
219314464|NCT05457582|DRUG|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
219314465|NCT05640648|BEHAVIORAL|User-Centered Implementation Strategy|"1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
219314466|NCT05640648|BEHAVIORAL|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
219314467|NCT06779591|OTHER|CareAide® Medication Adherence Mobile Application|CareAide® app is one of the mobile apps in assisting and improving patients' adherence to medications. It is an unique health-tech and insure-tech company with expertise in behavioural science, chronic condition management and technology. The app aims to help patients with chronic conditions live a better everyday life and empower their families and the ecosystem around the patients to drive better outcomes. They have the clinically validated approach to improving adherence. Using behavioural science and smart tech, they improve the day-to-day life of patients, and importantly, empower both patients and health care providers with the digital tools and near real-time insights to proactively manage risks, intervene early to avoid patient emergencies and to help to provide a better customer satisfaction.
219314468|NCT04484259|DRUG|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
219314469|NCT04484259|DRUG|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
219314470|NCT04484259|DRUG|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
219314471|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
219314472|NCT04908189|DRUG|Deucravacitinib|Specified dose on specified days
219314473|NCT04908189|OTHER|Placebo|Specified dose on specified days
219314474|NCT04908189|DRUG|Apremilast|Specified dose on specified days
219314475|NCT05236231|DRUG|Macitentan 10 mg|Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
219314476|NCT05236231|DRUG|Tadalafil 20 mg|Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
219314477|NCT05236231|DRUG|Macitentan 10 mg/Tadalafil 20mg FDC|FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
219314478|NCT06111807|DIAGNOSTIC_TEST|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
219314479|NCT05596799|BEHAVIORAL|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
219314480|NCT05834816|BEHAVIORAL|Negative Affect Task|fMRI stress task
219314481|NCT06443203|OTHER|Trimodal prehabilitation|Trimodal prehabilitation program (4-week physical exercise before surgery, nutritional optimization, and psychological support) in patients undergoing ERAS colorectal resection for cancer
219314482|NCT03685175|DRUG|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
219314483|NCT03685175|DRUG|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
219314484|NCT02857998|DRUG|HMPL-523|Oral administration, once daily
219314485|NCT02932007|DRUG|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
219314486|NCT06528067|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
219314487|NCT06528067|BEHAVIORAL|Mindful Motivation|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
219314488|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
219314489|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
219314490|NCT05714995|OTHER|hypnosis|"The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
219314491|NCT05714995|OTHER|Hypnosis with aromatherapy|"for patients in the hypnosis with aromatherapy group, before starting the hypnosis session, they will first choose an essential oil among the 5 proposed.~They will pour a drop on their wrist then they will rub it and inhale deeply.~The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
219314492|NCT06161402|BEHAVIORAL|Elastic band-based progressive resistance training (EB-PRT)|EB-PRT will be implemented during week 1-14. The EB-PRT comprises a 4-week training phase, 6-week consolidation phase and a 4-week maintenance phase.
219314493|NCT05274152|DEVICE|Immersive Virtual Reality Lower Limb and Knee Rehabilitation|Patients wore a VR headset while undergoing their rehabilitation session
219314494|NCT05455138|PROCEDURE|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
219314495|NCT06248346|DRUG|Dexmedetomidine|whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
219314496|NCT06477822|PROCEDURE|Sequence of manual therapy techniques|Receive a sequence of manual therapy techniques composed by: suboccipital decompression technique, suboccipital release technique, fourth ventricle compression technique, vagus nerve neurodynamic technique
219314497|NCT06477822|PROCEDURE|Simulated manual therapy techniques|Receive a sequence of simulated manual therapy techniques composed by four maneuvers without effect on autonomic nervous system
219314498|NCT01262703|DEVICE|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
219314499|NCT04568720|DIAGNOSTIC_TEST|blood sample|Isolated the blood sample and detected the CTC
219314500|NCT00076362|DRUG|Sandostatin LAR|
219314501|NCT05309265|OTHER|Multidisciplinary vocational rehabilitation intervention|"* Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
219314502|NCT01362777|BEHAVIORAL|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~* 15' start warming up muscles~* 30' muscle strengthening exercise for arms and abdominal muscles~* 45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~* 15' stretching~* 15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
219314503|NCT01362777|BEHAVIORAL|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~* Physiological mechanisms of apneas/hypopneas~* Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~* Beneficials effects of CPAP and/or advanced mandibular orthosis~* Description of sleep stages and physiological roles of sleep~* Known effects of exercise on sleep and metabolism~* Importance of good nutritional status and sleep hygiene on quality of life~* How to apply theses lessons of rehabilitation in daily life"
219314504|NCT02867319|BIOLOGICAL|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
219314505|NCT02180022|DRUG|Placebo|After randomization, placebo was treated for 12 weeks
219314506|NCT02180022|DRUG|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
219314507|NCT02941562|RADIATION|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
219314508|NCT02941562|DRUG|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
219314509|NCT02941562|RADIATION|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
219314510|NCT02941562|DRUG|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
219314511|NCT02941562|PROCEDURE|Radical rectal cancer resection|Radical rectal cancer resection
219314512|NCT02941562|DRUG|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
219314513|NCT03012607|DRUG|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
219314514|NCT04098757|DIETARY_SUPPLEMENT|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
219314515|NCT05764993|BIOLOGICAL|CUVITRU - Ig subcutaneous human 20%|Subcutaneous Immunoglobin Replacement Therapy, SCigR
219314516|NCT05764993|OTHER|Standard Medical Therapy|Standard Medical Therapy
219314517|NCT06347887|DIAGNOSTIC_TEST|ColonAiQ test and Colonoscopy|Diagnostic Test
219314518|NCT00162357|DRUG|Technetium Tc99m Sestamibi|
219314519|NCT03456284|DEVICE|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
219314520|NCT06307899|OTHER|Unilateral Corner Stretch|Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
219314521|NCT06307899|OTHER|Manual Stretching|Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
219314522|NCT06307899|OTHER|PNF Stretching|Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
219314523|NCT04265833|OTHER|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
219314524|NCT04265833|OTHER|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
219314525|NCT04265833|OTHER|Calcium hydroxide|Calcium hydroxide (Ca\[OH\]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
219314526|NCT03857074|DEVICE|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
219314527|NCT01003678|DRUG|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
219314528|NCT01928498|DEVICE|Paclitaxel Eluting Balloon Angioplasty|
219314529|NCT01928498|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|
219314530|NCT02684357|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
219314531|NCT02684357|DRUG|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
219314532|NCT02684357|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
219314533|NCT02684357|DRUG|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
219314534|NCT02911493|BEHAVIORAL|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
219314535|NCT02911493|BEHAVIORAL|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
219314536|NCT00002301|DRUG|Foscarnet sodium|
219314537|NCT01988623|BEHAVIORAL|Pivotal Response Treatment (PRT)|
219314538|NCT01079130|DRUG|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
219314539|NCT01079130|DRUG|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
219314540|NCT01079130|DRUG|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
219314541|NCT01079130|DRUG|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
219314542|NCT02710903|PROCEDURE|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
219314543|NCT01839487|DRUG|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
219314544|NCT01839487|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
219314545|NCT01839487|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
219314546|NCT01839487|DRUG|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
219314547|NCT01839487|DRUG|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
219314548|NCT00190567|DRUG|duloxetine|
219314549|NCT00190567|DRUG|Placebo|
219314550|NCT05517304|DEVICE|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
219314551|NCT05517304|DEVICE|sham|sham stimulation
219314552|NCT06108804|OTHER|mulligan pain release phenomenon with tapping|Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks
219314553|NCT06108804|OTHER|mulligan pain release phenomenon|Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
219314554|NCT03543501|DEVICE|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
219314555|NCT03543501|DEVICE|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
219314556|NCT02440230|DRUG|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
219314557|NCT02440230|DRUG|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
219314558|NCT01211743|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
219314559|NCT01211743|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
219314560|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
219314561|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
219314562|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
219314563|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
219314564|NCT01108107|BIOLOGICAL|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
219314565|NCT05991687|OTHER|In-home drug disposal pouch|Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
219314566|NCT05991687|OTHER|Mail-in prepaid envelope|Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
219314567|NCT05044273|DEVICE|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
219314568|NCT01491893|BIOLOGICAL|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
219314569|NCT04470167|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
219314570|NCT04470167|OTHER|Placebo|Ultrasound-guided intratendinous placebo injection
219314571|NCT01658826|DRUG|AIC316|100 mg oral administration
219314572|NCT01658826|DRUG|Valacyclovir|500 mg oral administration
219314573|NCT05923957|OTHER|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
219314574|NCT00000730|DRUG|Trimetrexate glucuronate|
219314575|NCT00000730|DRUG|Methylprednisolone|
219314576|NCT00000730|DRUG|Pentamidine isethionate|
219314577|NCT00000730|DRUG|Sulfamethoxazole-Trimethoprim|
219314578|NCT00000730|DRUG|Leucovorin calcium|
219314579|NCT04724226|DRUG|Camrelizumab; Apatinib|"Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD"
219314580|NCT05466539|DRUG|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
219745302|NCT00837135|OTHER|Screening|"A. SCREENING~1. Consent~2. Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~3. Physical Exam, History, Blood Tests~4. Skin Test (for allergy to saccaromyces cerevisiae) yeast.~5. Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~1. Consent~2. Chemotherapy~3. GI-4000 Vaccine #1 + Prevnar + Activated T Cells~4. GI-4000 Vaccine #2~5. Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
219314581|NCT05466539|DRUG|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
219314582|NCT00713115|PROCEDURE|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
219314583|NCT00591045|DRUG|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
219314584|NCT00675805|DEVICE|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
219314585|NCT00675805|DEVICE|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
219314586|NCT03744325|DIETARY_SUPPLEMENT|Hen's egg OIT|Increasing doses of egg white protein administered orally
219314587|NCT03584113|OTHER|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
219314588|NCT03584113|OTHER|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase \[5mg\] and alteplase \[10mg\] Q12hours).
219745303|NCT00837135|BIOLOGICAL|GI-4000 Vaccine|"1. Chemotherapy and Radiation~2. GI-4000 Vaccine #3~3. GI-4000 Vaccine #4"
219314589|NCT06001541|BEHAVIORAL|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
219314590|NCT04821869|DRUG|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
219314591|NCT04821869|DEVICE|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
219314592|NCT03543267|OTHER|MRI exam|MRI before and after resection surgery
219314593|NCT00006203|DRUG|Naltrexone 50 Mg|Daily 50 mg for 3 weeks
219314594|NCT00006203|DRUG|Placebo|Daily doses of placebo for 3 weeks
219314595|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
219314596|NCT01377051|DRUG|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
219314597|NCT01377051|DRUG|Placebo|Dry powered, same to study drug, only one inhalation
219314598|NCT06814743|BEHAVIORAL|Pelvic floor exercises program guided with an intravaginal biofeedback device|Use of the mobile application to perform a exercise program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure. Behavioral: mobile application with access to information about pelvic floor and direct communication with healthcare team.
219314599|NCT06814743|BEHAVIORAL|Pelvic floor exercises program|"Use of the mobile application to perform a exercise program for pelvic floor musculature.~Behavioral: Information about pelvic floor and communication with health professionals Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team."
219314600|NCT06814743|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team.
219314601|NCT06588699|DRUG|Digoxin|Taken orally once daily
219314602|NCT06588699|DRUG|Placebo|Matched Placebo taken orally once daily
219314603|NCT06979752|PROCEDURE|Tran canula|After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
219314604|NCT06979752|PROCEDURE|augmented irrigation|After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.
219314605|NCT00824447|DRUG|Oralgen|allergen solution sublingually
219314606|NCT00824447|OTHER|placebo|placebo control
219314607|NCT06265870|DRUG|Albendazole|Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
219314608|NCT06265870|DRUG|Ivermectin or albendazole|Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
219314609|NCT06588582|OTHER|Water Temperature Variation - WW|Participants are assigned to warm water temperature.
219314610|NCT06588582|OTHER|Water Temperature Variation - CW|Participants are assigned to cold water temperature and are video recorded.
219314611|NCT01455493|DRUG|GDC-0980|Oral daily dose
219314612|NCT06609915|DEVICE|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany)|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany). Initially FiO2 at 1.0, reduced to 0.3 during laser interventions. Frequency and pressure set according to the local standards
219314613|NCT06609915|DEVICE|High-flow nasal supplemental oxygen via nasal cannula with the Optiflow (Fisher & Paykel, Auckland, New Zealand)|up to 70 L/min FiO2 1.0 high flow oxygen via nasal cannula with the Optiflow (Fisher \& Paykel, Auckland, New Zealand) initially. Reduced FiO2 to 0.3 during laser intervention.
219314614|NCT06610409|DIAGNOSTIC_TEST|blood sampling|Blood sample for CXCL5 Level
219314615|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
219314616|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
219314617|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
219314618|NCT06993116|DRUG|SHR-4712 Injection|SHR-4712 injection.
219314619|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
219314620|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
219314621|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
219314622|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
219314623|NCT05647239|DEVICE|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
219314624|NCT03944135|OTHER|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
219314625|NCT04326127|DEVICE|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
219314626|NCT06092372|BEHAVIORAL|Diet intervention program|"Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI."
219314627|NCT06862323|BEHAVIORAL|Time-Restricted Eating|TRE will be defined as a 16 hour fast with an 8 hour feeding window, with the option of a longer feeding window one day per week. All participants will adhere to the fasting intervention for either 90 days (3 months) or 180 days (6 months) based on their preference. Participants will be provided guidance (see appendix 7, Fasting Guidelines) on how to achieve an 8 hour feeding window by day 9 of the study and are recommended to adhere to the 16 hour fast/8 hour feeding window daily for the remainder of the study.
219314628|NCT06588257|BIOLOGICAL|Non-infectious adjuvanted recombinant nonavalent HPV vaccine|Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
219314629|NCT04530331|BEHAVIORAL|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
219314630|NCT07020104|DRUG|Hydrochlorothiazide|"Each patient will receive 1 tablet of hydrochlorothiazide 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dosage is doubled to 2 tablets of hydrochlorothiazide 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
219314631|NCT07020104|DRUG|Spironolactone|"Each patient will receive 1 tablet of spironolacton 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of spironolacton 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
219314632|NCT07020104|DRUG|Lercanidipine|"Each patients will receive 1 tablet of lercanidipine 10mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of lercanidipine 10mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
219314633|NCT07020104|DIETARY_SUPPLEMENT|High sodium dietary intake (>200mmol/l)|The patients will receive a 2-week high sodium diet. The patients will receive dietary advice to achieve this goal of \>200mmol/l sodium (\>12g salt) intake per day.
219314634|NCT07020104|DIETARY_SUPPLEMENT|Low sodium dietary intake (<50mmol/l)|The patients will receive a 2-week low sodium diet. The patients will receive dietary advice to achieve this goal of \<50mmol/l sodium (\<3g salt) intake per day.
219314635|NCT07020104|DIETARY_SUPPLEMENT|High water intake|During the increased water intake period, the patients will be instructed to drink 1 L more than their mean 24-hour urine volume at screening and baseline.
219314636|NCT07020104|DIETARY_SUPPLEMENT|Habitual water intake|During this part of the intervention, the patients will be instructed to maintain their habitual water intake.
219314637|NCT07021001|BEHAVIORAL|UP-A, a cognitive-behavioral structured group intervention, was adapted as a universal preventive intervention to be delivered in school settings (UP-A Kind).|The UP-A Kind is a school-based universal prevention intervention that aims to promote adaptive emotion regulations strategies, enhance mental well-being and prevent emotional disorders with the following contents: motivating to take care of mental well-being, psychoeducation about emotions, awareness of physical sensations, cognitive lexibility, behavioral experiences, recognizing warning signs, and promoting a compassionate attitude towards the self and others.
219314638|NCT07020975|DEVICE|VR Glasses|VR Glasses is used to help people be in a virtual reality other than their real life. What we use this for; to get away infertile women from her stressfull environment to another virtual reality before their embryo transfer.
219314639|NCT07019649|BEHAVIORAL|AYUDA Program|Participants randomized to the intervention arm will be enrolled in the AYUDA program, where they will receive text messages twice a week over 12 weeks containing diabetes education and self-management resources, including links to resources available to all KPNC members.
219314640|NCT07019090|DRUG|HSK44459|HSK44459
219314641|NCT07018817|BEHAVIORAL|motor execution motor imagery|Participants will perform motor execution tasks and motor imagery tasks following standardized instructions under controlled conditions.
219314642|NCT07020078|RADIATION|Salivary redox biomarkers|Salivary redox biomarkers
219314643|NCT07020832|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219314644|NCT07020832|OTHER|Placebo|Sterile solution of equal volume to active arm
219314645|NCT07019363|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard endocrine therapy
219314646|NCT07019363|DRUG|Standard endocrine therapy combined with CDK4/6 Inhibitor|CDK4/6 inhibitor therapy for 2 years in combination with standard endocrine therapy
219745304|NCT00837135|BIOLOGICAL|GI-4000 Vaccine + Activated T Cells|"1. Apheresis #2~2. Chemoradiation~3. Activated T Cells + GI-4000 Vaccine #3~4. GI-4000 Vaccine #4"
219314647|NCT07020468|DRUG|NALIRIFOX|The patients with Locally Advanced Colorectal Cancer and Upper Rectal Cancer will undergo neoadjuvant treatment with irinotecan liposome combined with oxaliplatin + 5-FU/LV (NALIRIFOX), with each treatment cycle lasting 2 weeks, for a total of 3-6 cycles.
219314648|NCT07016581|DIAGNOSTIC_TEST|Daily survey|All patients undergoing an spinal cord stimulation trial procedure (which will be conducted in accordance to standard clinical practices per site) will be given daily surveys to assess their analgesic and functional benefit.
219314649|NCT07019103|DRUG|Gabapentin (Neurontin® (Registered Trademark))|Additionally, during this phase, patients will be educated on how to report their perceived pain, rated from 0 to 10 on the visual analog scale (VAS). Subsequently, another dedicated pain-management specialist will engage with each patient to formulate and document an individualized pain management plan, taking into consideration the patient's medical history, previous pain experiences, and preferences for pain management strategies. As part of preemptive analgesia, patients receive 300 mg of gabapentin orally 2 hours prior to surgery, unless contraindicated.
219314650|NCT06526832|BIOLOGICAL|BST02|BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.
219314651|NCT02112487|DRUG|Macitentan|10 mg once daily
219314652|NCT01256658|DRUG|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
219314653|NCT00470210|DRUG|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
219314654|NCT00470210|DRUG|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
219314655|NCT00470210|DRUG|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
219314656|NCT05898893|DEVICE|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
219314657|NCT00529724|BEHAVIORAL|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
219314658|NCT02693613|DRUG|ASP1517|Oral
219314659|NCT02693613|DRUG|Kremezin®|Oral
219314660|NCT01123954|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
219314661|NCT01320267|PROCEDURE|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
219314662|NCT05279703|DRUG|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
219314663|NCT05279703|DRUG|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
219314664|NCT05279703|DRUG|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
219314665|NCT00619190|DRUG|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
219314666|NCT02217943|PROCEDURE|Roux-en-Y gastric bypass|
219314667|NCT02217943|PROCEDURE|Sleeve gastrectomy|
219314668|NCT04544345|DEVICE|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
219314669|NCT04544345|DEVICE|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
219314670|NCT04010513|BEHAVIORAL|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
219314671|NCT04010513|OTHER|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
219314672|NCT05555511|OTHER|Control Group|Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
219314673|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
219314674|NCT02589717|DRUG|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
219314675|NCT00594529|PROCEDURE|Surgery|Liver resection for metastatic liver lesions
219314676|NCT05397353|OTHER|Sleepio (TM)|Sleepio is a mobile Digital Cognitive Behavior Therapy for Insomnia (dCBT-I) app.
219314677|NCT04841551|DRUG|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
219314678|NCT02525861|BIOLOGICAL|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
219314679|NCT00438321|DRUG|Zoladex|
219314680|NCT00438321|DRUG|Testosterone gel|
219314681|NCT00438321|DRUG|Anastrozole Pill|
219314682|NCT00438321|OTHER|Placebo|
219314683|NCT06018272|BEHAVIORAL|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
219314684|NCT06018272|BEHAVIORAL|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (\>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
219314685|NCT02715154|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
219314686|NCT02715154|DRUG|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
219314687|NCT00720655|OTHER|Dietary intervention|Fatty fish at least 4 meals per week.
219314688|NCT00720655|OTHER|Dietary intervention|Lean fish at least 4 meals per week.
219314689|NCT00720655|OTHER|Dietary intervention|Control diet with lean meat and chicken.
219314690|NCT02817230|DRUG|Statin|
219314691|NCT04426955|DRUG|Camrelizumab|IV infusion
219314692|NCT04426955|DRUG|Paclitaxel|IV infusion
219314693|NCT04426955|DRUG|Cisplatin|IV infusion
219314694|NCT04426955|DRUG|Placebo|IV infusion
219314695|NCT04426955|RADIATION|Radiation|Concurrent Radiation
219314696|NCT03205215|OTHER|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
219314697|NCT03205215|OTHER|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
219314698|NCT01516658|DEVICE|Hydrogel coil|at least one Hydrogel coil have to use for embolization
219314699|NCT01516658|DEVICE|Bare platinum coil|only bare platinum coil have to use for embolization
219314700|NCT01096888|BEHAVIORAL|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
219314701|NCT04081454|BEHAVIORAL|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
219314702|NCT04081454|BEHAVIORAL|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
219314703|NCT01621997|BEHAVIORAL|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
219314704|NCT02679950|GENETIC|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
219314705|NCT01794520|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
219314706|NCT01794520|DRUG|Dexamethasone|Tablets were administered by mouth per the dexamethasone prescribing information.
219314707|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
219314708|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
219314709|NCT04155268|BEHAVIORAL|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
219314710|NCT04155268|BEHAVIORAL|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
219314711|NCT02212873|OTHER|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
219314712|NCT04214314|BEHAVIORAL|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
219314713|NCT02069925|BEHAVIORAL|Early Detection (ED)|This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
219314714|NCT02069925|BEHAVIORAL|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
219314715|NCT06383156|DEVICE|Double lumen endotracheal tube|correct position of LDLT during single lung ventilation
219314716|NCT02125305|DRUG|Metformin|
219314717|NCT06241742|DRUG|HT-6184|Single, oral dose of HT-6184
219314718|NCT06241742|DRUG|HT-6184 Placebo|Single, oral dose of placebo
219314719|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
219314720|NCT05728515|DRUG|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
219314721|NCT05038462|DIETARY_SUPPLEMENT|Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
219314722|NCT05038462|OTHER|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
219314723|NCT01474798|DRUG|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
219314724|NCT06450249|BEHAVIORAL|Humanitude® Care Methodology (HCM) training sessions|During a five-day training session healthcare professionals are trained to the HCM within their own care unit
219314725|NCT06450249|BEHAVIORAL|Self-administered questionnaire|The self-administered questionnaire will be completed before and after participation in Humanitude® Care Methodology training sessions
219314726|NCT00495404|BEHAVIORAL|Physician Treatment Guidelines|
219314727|NCT00281021|DRUG|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
219314728|NCT03382184|DEVICE|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
219314729|NCT03382184|DEVICE|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
219314730|NCT04796896|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
219314731|NCT04796896|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
219314732|NCT04796896|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
219314733|NCT04189757|DRUG|Acalabrutinib|Given PO
219314734|NCT06262607|DRUG|CLE-400|Topical CLE400 gel 0.28% administered once daily
219314735|NCT06262607|DRUG|Vehicle|Topical vehicle gel administered once daily
219314736|NCT04356183|OTHER|SWET: Supervised Weight loss and Exercise Training|Weight loss will occur via a dietitian-led intervention targeting weight loss over 16 weeks, with weekly weigh-ins and group support sessions. Exercise training will consist of three times per week of an interval-based aerobic program plus twice-weekly resistance training. Both weight loss and exercise training will be supervised to maximize safety and adherence.
219314737|NCT04356183|OTHER|CHAT: Counseling Health As Treatment|Control Arm over 16 weeks.
219314738|NCT06378450|BEHAVIORAL|Mindfulness meditation guided practice|Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.
219314739|NCT03613116|DIETARY_SUPPLEMENT|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
219314740|NCT05679011|OTHER|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
219314741|NCT01177787|DEVICE|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
219314742|NCT01177787|DEVICE|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
219314743|NCT00002765|BIOLOGICAL|LMB-2 immunotoxin|
219314744|NCT02711488|BEHAVIORAL|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
219314745|NCT02170454|PROCEDURE|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
219314746|NCT00381368|DRUG|Ibandronic acid|
219314747|NCT04298463|DRUG|Xydalba|Drugs were administered i.v.
219314748|NCT04298463|DRUG|vancomycin, teicoplanin or daptomycin|Drugs were administered i.v.
219314749|NCT00402363|DRUG|omega-3-acid ethyl esters|
219314750|NCT00402363|DRUG|Placebo|
219314751|NCT03245970|DRUG|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
219314752|NCT03245970|DRUG|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
219314753|NCT03245970|DRUG|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
219314754|NCT01612741|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
219314755|NCT02259998|DRUG|Persantin® new formulation|
219314756|NCT02259998|DRUG|Persantin® commercial formulation|
219314757|NCT00320333|PROCEDURE|pulmonary rehabilitation programme|
219314758|NCT06348940|BEHAVIORAL|behavioral activation|Behavioral activation, an emerging psychological intervention approach, has potential in alleviating negative emotions among cancer patients. The intervention group underwent an eight-week behavioral activation program designed to promote engagement in meaningful activities that are physically and emotionally rewarding while reducing involvement in maladaptive emotional cycles.
219314759|NCT02300051|BEHAVIORAL|STPGP and RPGT|
219314760|NCT02300051|DRUG|TAU|
219314761|NCT00690625|DRUG|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
219314762|NCT00690625|DRUG|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
219314763|NCT04726462|OTHER|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
219314764|NCT04726462|OTHER|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
219314765|NCT04011254|PROCEDURE|haemodialysis|Routine haemodialysis session
219314766|NCT01539304|DRUG|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
219314767|NCT01539304|DRUG|Placebo|Placebo dry syrup, b.i.d
219314768|NCT04139265|DIAGNOSTIC_TEST|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
219314769|NCT05678023|OTHER|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
219314770|NCT00249353|DRUG|methylphenidate hydrochloride|
219314771|NCT02634346|DRUG|ALK3831|Daily dosing
219314772|NCT02634346|DRUG|Olanzapine|Daily dosing
219314773|NCT02634346|DRUG|Placebo|Daily dosing
219314774|NCT05933408|DIAGNOSTIC_TEST|TREM-1|The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
219314775|NCT03546933|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
219314776|NCT00167817|DRUG|Aripiprazole|
219314777|NCT03394430|DRUG|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
219314778|NCT03394430|DRUG|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
219314779|NCT03394430|DRUG|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
219314780|NCT01266733|BEHAVIORAL|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
219314781|NCT01266733|BEHAVIORAL|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
219314782|NCT00309556|DRUG|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
219314783|NCT00309556|DRUG|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
219314784|NCT00309556|DRUG|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
219314785|NCT00309556|DRUG|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
219314786|NCT04481477|OTHER|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
219314787|NCT05859438|OTHER|Communication aid support|Support to use voice input voice output communication aids
219314788|NCT01690611|PROCEDURE|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
219314789|NCT01690611|OTHER|Visual Feedback|Real time feedback regarding body motion while walking.
219314790|NCT03962452|GENETIC|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
219314791|NCT04107350|DEVICE|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
219314792|NCT02679742|DIETARY_SUPPLEMENT|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
219314793|NCT02679742|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
219314794|NCT06062225|PROCEDURE|Kamikawa|Kamikawa reconstruction after proximal gastrectomy
219314795|NCT06062225|PROCEDURE|STJI|Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy
219314796|NCT06062225|PROCEDURE|SOFY|SOFY reconstruction after proximal gastrectomy
219314797|NCT06470802|BEHAVIORAL|Familiar voice|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
219314798|NCT06470802|BEHAVIORAL|Nature sounds|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
219314799|NCT06470802|BEHAVIORAL|Control|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
219314800|NCT00667355|BIOLOGICAL|adalimumab|40 mg or 80 mg every other week, subcutaneous
219314801|NCT02141542|DRUG|Tremelimumab|
219314802|NCT02141542|DRUG|MEDI3617|
219314803|NCT01159379|DRUG|ertapenem|intravenous, 1 gram, once
219314804|NCT04226807|OTHER|Early Postpartum Phone Call|Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
219314805|NCT04212988|PROCEDURE|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
219314806|NCT01859078|DRUG|Baricitinib|Administered orally
219314807|NCT01859078|DRUG|Digoxin|Administered orally
219314808|NCT00003941|BIOLOGICAL|bleomycin sulfate|
219314809|NCT00003941|BIOLOGICAL|filgrastim|
219314810|NCT00003941|DRUG|cisplatin|
219314811|NCT00003941|DRUG|etoposide|
219314812|NCT00003941|DRUG|ifosfamide|
219314813|NCT00003941|PROCEDURE|bone marrow ablation with stem cell support|
219314814|NCT00003941|PROCEDURE|peripheral blood stem cell transplantation|
219314815|NCT01475552|DRUG|Abciximab|Patients, who showed PRU \>270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
219314816|NCT01475552|DRUG|control|"Patients,who showed PRU \>270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
219314817|NCT00912652|BEHAVIORAL|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
219314818|NCT00912652|BEHAVIORAL|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
219314819|NCT01771068|BEHAVIORAL|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
219314820|NCT04047693|DRUG|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
219314821|NCT00227188|DRUG|Pneumococcal 7-valent conjugate vaccine Prevnar|
219314822|NCT02271074|OTHER|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
219314823|NCT02271074|BEHAVIORAL|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
219314824|NCT02271074|OTHER|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
219314825|NCT01676909|BEHAVIORAL|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
219314826|NCT01676909|BEHAVIORAL|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
219314827|NCT03306836|DRUG|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
219314828|NCT03306836|DRUG|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
219314829|NCT02336750|DRUG|Aprepitant|125mg D1, 80mg D2-3
219314830|NCT02336750|DRUG|Mirtazapine|15mg D2-4
219314831|NCT01244776|DEVICE|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
219314832|NCT06960317|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
219314833|NCT06960317|OTHER|Sham Comparator|None - capped needle will not be injected nor will it contain any medication.
219314834|NCT06960317|DRUG|Unbuffered lidocaine|To determine if a 20 cc unbuffered (1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
219314835|NCT06960317|DRUG|Xylocaine jelly 2%|To determine if a Xylocaine jelly (2% infused lidocaine) decreases pain with paracervical block
219314836|NCT06960317|DRUG|Surgilube|To determine if a placebo gel is inferior to lidocaine gel for pain with paracervical block
219314837|NCT06088212|OTHER|Disease management program|"The components of our DMP include:~1. Intensive post-discharge education~2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~4. Exercise program delivered by an exercise physiologist~5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly."
219314838|NCT04455438|RADIATION|SBRT dose escalation|Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
219314839|NCT01440712|DRUG|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
219314840|NCT01440712|DRUG|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
219314841|NCT03260595|DRUG|Crisaborole ointment 2%|Crisaborole ointment 2%
219314842|NCT03260595|DRUG|Vehicle|Vehicle
219314843|NCT01677897|DRUG|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
219314844|NCT01680068|PROCEDURE|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
219314845|NCT05059834|BEHAVIORAL|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
219314846|NCT05059834|BEHAVIORAL|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
219314847|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
219314848|NCT01270945|PROCEDURE|Standard of Care|
219314849|NCT04388241|BEHAVIORAL|The Balance Program|The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
219314850|NCT02175004|DRUG|Inotersen|Inotersen SC
219314851|NCT01803568|OTHER|Exercise|12 weeks of exercise; 4 times pr week
219314852|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
219314853|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
219314854|NCT05937139|OTHER|Breastfeeding education|Breastfeeding education will be given to fathers.
219314855|NCT03138720|DRUG|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
219314856|NCT04651907|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
219314857|NCT04651907|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
219314858|NCT00701870|DRUG|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
219314859|NCT04291352|DIETARY_SUPPLEMENT|Taurine|675mg taurine four times daily
219314860|NCT04291352|OTHER|Placebo|placebo four times daily
219314861|NCT03686280|OTHER|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
219314862|NCT03686280|OTHER|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
219314863|NCT03686280|OTHER|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
219314864|NCT03686280|OTHER|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
219314865|NCT03686280|OTHER|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
219314866|NCT03686280|OTHER|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
219314867|NCT03686280|OTHER|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
219314868|NCT03188926|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
219314869|NCT01080378|PROCEDURE|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
219314870|NCT05363696|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting surgery procedure
219314871|NCT05363696|PROCEDURE|Heart valve surgery|Heart valve surgery procedure
219314872|NCT04367987|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
219314873|NCT00823901|DRUG|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
219314874|NCT00823901|DRUG|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
219314875|NCT01308957|DIETARY_SUPPLEMENT|Omega-3 fatty acids|4 grams per day for 24 weeks
219314876|NCT01308957|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 24 weeks
219314877|NCT04828694|DRUG|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
219314878|NCT04828694|DRUG|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
219314879|NCT01247571|DRUG|Pazopanib Hydrochloride|Given PO
219314880|NCT04208776|DRUG|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
219314881|NCT04208776|DRUG|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
219314882|NCT02852161|DEVICE|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
219314883|NCT02189356|BEHAVIORAL|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
219314884|NCT02189356|BEHAVIORAL|standard care|standard pregnancy follow up
219314885|NCT01297413|BIOLOGICAL|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
219314886|NCT05181865|DRUG|1 mg/kg IV FL-301|N = 1
219314887|NCT05181865|DRUG|3 mg/kg IV FL-301|N = 3-6
219314888|NCT05181865|DRUG|10 mg/kg IV FL-301|N = 3-6
219314889|NCT05181865|DRUG|20 mg/kg IV FL-301|N = 3-6
219314890|NCT05181865|DRUG|30 mg/kg IV FL-301|N = 3-6
219314891|NCT05181865|DRUG|RP2D, IV FL-301|Pancreatic Cancer N = 30
219314892|NCT05181865|DRUG|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
219314893|NCT05181865|DRUG|RP2D, IV FL-301|Other Solid Tumors N = 30
219314894|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
219314895|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
219314896|NCT01376349|DRUG|prasterone|Applied vaginally
219314897|NCT01376349|OTHER|placebo|Applied vaginally
219314898|NCT00162032|DRUG|Sestamibi|Sestamibi
219314899|NCT02442713|DRUG|fluvoxamine|fluvoxamine: 50-300mg/day
219314900|NCT04780750|DRUG|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
219314901|NCT02215837|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
219314902|NCT02215837|BIOLOGICAL|Ag-D-CIK|8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
219314903|NCT04213924|DRUG|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
219314904|NCT04213924|DRUG|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
219314905|NCT03236051|PROCEDURE|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
219314906|NCT03236051|PROCEDURE|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
219314907|NCT01842685|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
219314908|NCT02521311|DRUG|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
219314909|NCT02521311|DRUG|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
219314910|NCT02841228|RADIATION|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
219314911|NCT04058951|OTHER|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
219314912|NCT04058951|OTHER|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
219314913|NCT04286698|OTHER|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes \[25\]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
219314914|NCT04286698|OTHER|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point \[3\]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
219314915|NCT02842840|BEHAVIORAL|Patient-based intervention|
219314916|NCT02842840|BEHAVIORAL|Family based intervention|
219314917|NCT02842840|OTHER|Routine counseling|
219314918|NCT00833911|DRUG|Tramadol Once A Day|
219314919|NCT01835197|DRUG|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
219314920|NCT01835197|DRUG|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
219314921|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
219314922|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
219314923|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
219314924|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
219314925|NCT01835197|DRUG|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
219314926|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
219314927|NCT01835197|DRUG|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
219314928|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
219314929|NCT02709525|DRUG|hyaluronic acid|
219314930|NCT02709525|OTHER|Placebo|
219314931|NCT01888835|DRUG|Mirtazapine|
219314932|NCT01888835|DRUG|Placebo|
219314933|NCT00764933|BEHAVIORAL|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
219314934|NCT00764933|OTHER|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
219314935|NCT06146023|DEVICE|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
219314936|NCT06146023|PROCEDURE|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
219314937|NCT05964803|DIAGNOSTIC_TEST|Questionnaires|MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
219314938|NCT05297617|DRUG|Anti-aromatase inhibitor|"Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily"
219314939|NCT01137955|DRUG|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
219314940|NCT01137955|DRUG|Placebo|Placebo orally three times a day for 10 days total
219314941|NCT02885298|PROCEDURE|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
219314942|NCT00819286|DEVICE|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
219314943|NCT00819286|DEVICE|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
219314944|NCT03366493|COMBINATION_PRODUCT|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
219314945|NCT03366493|OTHER|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
219314946|NCT03366493|OTHER|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
219314947|NCT03366493|PROCEDURE|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
219314948|NCT03366493|PROCEDURE|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
219314949|NCT03366493|PROCEDURE|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
219314950|NCT03945006|OTHER|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
219314951|NCT03945006|OTHER|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
219314952|NCT03945006|OTHER|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
219314953|NCT03945006|OTHER|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
219314954|NCT00216203|DRUG|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
219314955|NCT00216203|DRUG|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
219314956|NCT01290705|BEHAVIORAL|High exercise therapy|
219314957|NCT01290705|BEHAVIORAL|Low exercise therapy|
219314958|NCT06568068|BEHAVIORAL|training|"The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days"
219314959|NCT06428487|DRUG|Prolgolimab|Prolgolimab infusions 1 mg/kg
219314960|NCT06321289|BIOLOGICAL|Allogeneic CD19-STAR T cell|Phase 1 dose escalation (3+3): dose 1 (2×10\^6 cells/kg), dose 2 (6×10\^6 cells/kg), dose 3 (1.8×10\^7 cells/kg); Phase 2: dose of RP2D. No more than 5 × 10\^4 per kilogram of allogenic residual TCR-positive T cells harbouring in grafts can only be released for recipient infusion.
219314961|NCT06321289|DRUG|Fludarabine|Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.
219314962|NCT06321289|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
219314963|NCT06120582|GENETIC|ANB-002, dose 1|Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
219314964|NCT06120582|GENETIC|ANB-002, dose 2|Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
219314965|NCT06120582|GENETIC|ANB-002, dose 3|Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.
219314966|NCT06236347|BEHAVIORAL|Smoking cessation e-visit|Electronic visits (e-visits) for smoking cessation
219314967|NCT06236347|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
219314968|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
219314969|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
219314970|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
219314971|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
219314972|NCT05614323|OTHER|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
219314973|NCT04823299|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation ablation
219314974|NCT04823299|PROCEDURE|Radiofrequency catheter ablation +EPS guided trigger and substrate ablation|RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
219314975|NCT06078878|DEVICE|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
219314976|NCT00006332|DRUG|Tetrathiomolybdate|
219314977|NCT00621647|DRUG|Quetiapine Fumarate|
219314978|NCT00621647|DRUG|Quetiapine Fumarate|
219314979|NCT00621647|DRUG|Placebo|
219314980|NCT02645188|OTHER|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
219314981|NCT02973074|DIETARY_SUPPLEMENT|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
219314982|NCT05042518|BEHAVIORAL|Experiment|breathing control and self-talk with objectives
219314983|NCT05042518|OTHER|Control|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month)
219314984|NCT01324323|DRUG|Romidepsin|14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
219314985|NCT01324323|DRUG|Rifampin|600 mg oral once daily on Days 4-8
219314986|NCT05023343|DRUG|Ropivacaine|30 mL Ropivacaine 0,75% administered as a unilateral TQL block
219314987|NCT05023343|OTHER|Quadriceps muscle strength|Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after
219314988|NCT05023343|OTHER|Timed Up and Go|To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after
219314989|NCT05023343|OTHER|Single-leg 6 meter timed hop test|To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after
219314990|NCT05023343|OTHER|Temperature discrimination|Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration
219314991|NCT05023343|OTHER|Pinprick test|"Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.~Approximately 60 minutes after block administration"
219314992|NCT05023343|DIAGNOSTIC_TEST|Blood samples|As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration
219314993|NCT05023343|DIAGNOSTIC_TEST|Non-invasive blood pressure measurement|Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration
219314994|NCT01148966|DRUG|aminolevulinic acid|Given PO
219314995|NCT01148966|OTHER|laboratory biomarker analysis|Correlative studies
219314996|NCT01148966|PROCEDURE|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
219314997|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
219314998|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
219314999|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
219315000|NCT04910646|DRUG|orange peel fermentation|To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
219315001|NCT04910646|DRUG|Placebo|Placebo without orange peel fermentation
219315002|NCT03153137|DRUG|Macitentan 10 mg|film-coated tablet; oral use
219315003|NCT03153137|DRUG|Placebo|film-coated tablet; oral use
219315004|NCT01821378|DRUG|Lurasidone|Lurasidone 20 mg once daily
219315005|NCT01821378|DRUG|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
219315006|NCT01821378|DRUG|Placebo|Once Daily
219315007|NCT02367326|OTHER|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
219315008|NCT02888665|DRUG|Doxorubicin Hydrochloride|Given IV
219315009|NCT02888665|OTHER|Laboratory Biomarker Analysis|Correlative studies
219315010|NCT02888665|BIOLOGICAL|Pembrolizumab|Given IV
219315011|NCT04921007|PROCEDURE|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
219315012|NCT04921007|PROCEDURE|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
219315013|NCT04921007|DRUG|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
219315014|NCT05197023|DRUG|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
219315015|NCT04045951|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
219315016|NCT00400309|BIOLOGICAL|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
219315017|NCT00400309|BIOLOGICAL|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
219315018|NCT02876666|BEHAVIORAL|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
219315019|NCT01728051|DRUG|Melphalan|
219315020|NCT01728051|DEVICE|Percutaneous Hepatic Perfusion|
219315021|NCT00993915|DRUG|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
219745305|NCT00837135|BIOLOGICAL|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
219745306|NCT04876391|DRUG|Spesolimab 1200 mg|Participants in the 1368-0052 PoCC trial's placebo arm received a 1200 mg intravenous (i.v.) loading dose at Visit 1, then 600 mg s.c. every two weeks for 12 weeks.
219745307|NCT04876391|DRUG|Spesolimab 600 mg|Participants in the 1368-0052 PoCC trial's active arm received a 600 mg subcutaneous (s.c.) loading dose of spesolimab at Visit 1, followed by 600 mg s.c. every two weeks for 12 weeks.
219745308|NCT04876391|DRUG|Placebo matching 600 mg Spesolimab|Participants from the placebo arm of the 1368-0052 PoCC trial will receive a subcutaneous (s.c.) administration of placebo matching 600 mg spesolimab at Visit 1.
219745309|NCT04876391|DRUG|Placebo matching 1200 mg Spesolimab|Participants from the active arm of the 1368-0052 PoCC trial will receive an intravenous (i.v.) infusion of placebo matching 1200 mg spesolimab at Visit 1
219745310|NCT04717739|DEVICE|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
219745311|NCT03097640|OTHER|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
219745312|NCT01310751|DRUG|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
219745313|NCT01310751|DRUG|distilled water|2 ml per session
219745314|NCT03524066|DRUG|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
219745315|NCT03524066|DRUG|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
219745316|NCT03524066|OTHER|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
219745317|NCT04426357|DRUG|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
219745318|NCT02871440|DRUG|Omega 3|
219745319|NCT02871440|DRUG|Optive Advanced|
219745320|NCT02871440|DRUG|Optive|
219745321|NCT06186284|DIAGNOSTIC_TEST|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
219745322|NCT06186284|DIAGNOSTIC_TEST|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
219745323|NCT06186284|DIAGNOSTIC_TEST|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
219745324|NCT06186284|DIAGNOSTIC_TEST|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
219745325|NCT00159445|DRUG|gemcitabine, capecitabine|
219745326|NCT06407011|OTHER|Control|The CON group did not have any intervention but usual care.
219745327|NCT06407011|OTHER|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
219745328|NCT06407011|OTHER|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
219745329|NCT04647357|DRUG|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
219745330|NCT04481841|DRUG|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
219745331|NCT06563778|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
219745332|NCT06563778|DRUG|Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody|Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
219745333|NCT04347967|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
219745334|NCT00209131|DRUG|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
219745335|NCT00209131|DRUG|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
219745336|NCT03925467|OTHER|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
219315022|NCT01875822|DIETARY_SUPPLEMENT|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
219315023|NCT01513525|DRUG|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
219315024|NCT05151848|DRUG|Adalimumab Injection|Adalimumab Injection injected subcutaneously every other week for 78 weeks
219315025|NCT05151848|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 78 weeks
219315026|NCT02267356|DRUG|VT-1161|
219315027|NCT02267356|DRUG|Placebo|
219315028|NCT05398510|DRUG|SHR-2010 injection|Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
219315029|NCT05398510|DRUG|SHR-2010 injection placebo|Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
219315030|NCT00309868|DRUG|neseritide|
219315031|NCT04052529|OTHER|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
219315032|NCT01688583|DRUG|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
219315033|NCT01522157|DIETARY_SUPPLEMENT|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
219315034|NCT01522157|DIETARY_SUPPLEMENT|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
219315035|NCT01522157|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
219315036|NCT05659355|OTHER|Constraint Induced Movement Therapy (CIMT)|I will apply CIMT on effected hand to observe the hand dexterity and grip strength
219315037|NCT05659355|OTHER|Mirror Therapy (MT)|I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
219315038|NCT06267573|DEVICE|Fenestrated and branched endovascular devices for TAAA|Devices for TAAA
219315039|NCT04845360|DEVICE|pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)|The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.
219315040|NCT00672061|DRUG|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
219315041|NCT00592761|BEHAVIORAL|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
219315042|NCT02783131|DEVICE|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
219315043|NCT03930368|OTHER|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
219315044|NCT00435474|PROCEDURE|Wound treatment|wound treatment (silver product, alginate and foam dressing)
219315045|NCT00435474|PROCEDURE|wound treatment|wound treatment (honey product, alginate and foam dressing)
219315046|NCT00435474|OTHER|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
219315047|NCT00435474|OTHER|relaxation therapy|relaxation therapy
219315048|NCT02900469|BIOLOGICAL|denosumab|denosumab: 120 mg subcutaneous injection
219315049|NCT02900469|PROCEDURE|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
219315050|NCT04624451|DRUG|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
219315051|NCT05373953|DRUG|CHF6001|CHF6001 will be administered using the NEXThaler® DPI device
219315052|NCT02157350|PROCEDURE|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
219315053|NCT05706012|OTHER|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
219315054|NCT03909204|PROCEDURE|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
219315055|NCT01919320|DEVICE|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
219315056|NCT01919320|DEVICE|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
219315057|NCT05851274|PROCEDURE|transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm
219315058|NCT05851274|PROCEDURE|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
219315059|NCT04209621|DRUG|Duvelisib|twice daily as tolerated until disease progression
219315060|NCT04209621|DRUG|Ibrutinib|daily for the first six 28-day cycles
219315061|NCT02249767|DRUG|Tretinoin|Treatment of acne once daily in evening
219315062|NCT01372410|DRUG|GSK573719|125 mcg once daily
219315063|NCT01372410|DRUG|GSK573719|62.5 mcg once daily
219315064|NCT01372410|DRUG|GSK573719|31.25 mcg once daily
219315065|NCT01372410|DRUG|GSK573719|15.6 mcg once daily
219315066|NCT01372410|DRUG|GSK573719|31.25 mcg twice daily
219315067|NCT01372410|DRUG|GSK573719|15.6 mcg twice daily
219315068|NCT01372410|DRUG|Tiotropium|18 mcg once daily
219315069|NCT01372410|DRUG|Placebo|once or twice daily
219315070|NCT00187772|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|
219315071|NCT05232123|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
219315072|NCT05232123|DRUG|Cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
219315073|NCT02091895|PROCEDURE|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
219315074|NCT02936063|PROCEDURE|Surgical staples|Closure of surgical wound at skin level with surgical staples
219315075|NCT02936063|PROCEDURE|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
219315076|NCT04585646|DEVICE|Orion daily disposable contact lens|Subjects will be randomized to wear Orion lens for 2 weeks.
219315077|NCT04585646|DEVICE|Gemini daily disposable contact lens|Subjects will be randomized to wear Gemini lens for 2 weeks.
219315078|NCT02736136|BEHAVIORAL|joint observation and video feedback|
219315079|NCT04580797|DRUG|PF-06700841 IR|Immediate release formulation
219315080|NCT04580797|DRUG|PF-06700841 MR1|Modified release formulation 1
219315081|NCT04580797|DRUG|PF-06700841 MR2|Modified release formulation 2
219315082|NCT04580797|DRUG|PF-06700841 MR3|Modified release formulation 3
219315083|NCT04580797|OTHER|Placebo|Matching placebo
219315084|NCT02223403|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
219315085|NCT02223403|DIETARY_SUPPLEMENT|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
219315086|NCT05932004|OTHER|Reformer pilates exercise|The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
219315087|NCT04032769|OTHER|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~\- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
219315088|NCT06050954|DRUG|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
219315089|NCT06050954|DRUG|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
219315090|NCT06050954|DIAGNOSTIC_TEST|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
219315091|NCT00338364|BEHAVIORAL|PAT|Coping and Distraction Intervention
219315092|NCT05878301|OTHER|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
219745337|NCT05360784|DRUG|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
219315093|NCT02465463|PROCEDURE|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
219315094|NCT02465463|DEVICE|flexible sigmoidoscopy|
219315095|NCT04720404|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
219315096|NCT04720404|OTHER|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
219315097|NCT04720404|OTHER|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
219315098|NCT01368809|DRUG|Saline|2 ml at induction 1-2 ml boluses as needed
219315099|NCT01368809|DRUG|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
219315100|NCT02719431|DRUG|Warfarin|
219315101|NCT02719431|DRUG|K-877|
219315102|NCT02191020|DRUG|Total glucosides of paeony & Acitretin Capsules|
219315103|NCT02191020|DRUG|Acitretin Capsules|
219315104|NCT02804243|DEVICE|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
219315105|NCT01606020|OTHER|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
219315106|NCT01606020|OTHER|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
219315107|NCT02905994|DRUG|Volasertib|Polo-Like Kinase Inhibitor
219315108|NCT02905994|DRUG|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
219315109|NCT02905994|DRUG|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
219315110|NCT02905994|PROCEDURE|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
219315111|NCT06441084|BIOLOGICAL|NCR300 injection|Subjects will receive at least 1 cycle of NCR300 injection.
219315112|NCT05467774|BEHAVIORAL|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
219315113|NCT01849666|DRUG|phenprocoumon|6 mg oral single dose
219315114|NCT01849666|DRUG|vemurafenib|960 mg bid orally
219315115|NCT04607525|DRUG|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\]."
219315116|NCT04607525|DRUG|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
219315117|NCT06372028|DEVICE|transcutaneous vagus nerve stimulation (tVNS)|tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
219315118|NCT05049278|DRUG|Norepinephrine|"* Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
219315119|NCT05049278|DRUG|Phenylephrine|"* Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
219315120|NCT03442049|OTHER|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
219315121|NCT03442049|OTHER|Physiotherapy - control group|Home exercise program
219315122|NCT04265560|OTHER|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
219315123|NCT03294109|DRUG|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
219315124|NCT05997251|OTHER|Keeping a 1-day food consumption record by the patient|Checking and receiving the 1-day food consumption record recorded by the patient by the researcher
219315125|NCT05997251|OTHER|Measurement of adiponectin level|Adiponectin level will be measured for each group
219315126|NCT00443638|BEHAVIORAL|nurse home visitation|Nurse home visitation
219315127|NCT03212430|DRUG|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
219315128|NCT04744285|OTHER|Cigarette packaging|receive normal packet cigarette
219315129|NCT04744285|OTHER|Data capture|Attend video sessions
219315130|NCT04744285|OTHER|Questionnaire administration|Ancillary studies
219315131|NCT00124098|DRUG|Aranesp® (darbepoetin alfa)|
219315132|NCT00597441|BIOLOGICAL|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
219315133|NCT02535663|DIETARY_SUPPLEMENT|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
219315134|NCT02535663|DIETARY_SUPPLEMENT|Placebo|Same product without RG
219315135|NCT01774084|DIETARY_SUPPLEMENT|Experimental: PreOp, NutriciaNordica AB|
219315136|NCT01774084|DIETARY_SUPPLEMENT|Placebo Comparator: Water|
219315137|NCT03739541|DRUG|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
219315138|NCT03655379|DEVICE|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
219315139|NCT00416169|DRUG|galantamine hydrobromide|
219315140|NCT00821431|DEVICE|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
219315141|NCT00821431|DEVICE|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
219315142|NCT00243360|BEHAVIORAL|diagnostic and treatment clinical algorithms|
219315143|NCT03854396|DRUG|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
219315144|NCT03854396|DRUG|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
219315145|NCT03885830|DRUG|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
219315146|NCT03885830|DRUG|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
219315147|NCT03885830|DRUG|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
219315148|NCT03885830|DRUG|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
219315149|NCT06509178|OTHER|Peyton group|The same procedures were applied to the students in the experimental group as the students in the control group, except for laboratory applications. Students were asked to watch the video contents after the theoretical course, and in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach. Before the skill demonstration, students were given information about the research. Students were given 15-20 minutes to fill out the voluntary consent form and the urinary catheterization success pre-test. Students were taught the sterile urinary catheter procedure in accordance with Peyton's 4-step approach.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
219315150|NCT06509178|OTHER|Halsed group|After the control group students attended the course in accordance with the routine procedures, the students were asked to watch videos of the online urinary catheter application course and the students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice. Students were informed about the research and voluntary consent forms were obtained. Students were given 15-20 minutes to complete the urinary catheterization success pre-test. During the demonstration, the students' questions were answered, the researcher went over the points that the student did not understand, corrected any incorrect behavior, and gave feedback. Afterwards, each student was asked to demonstrate the skill steps individually.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
219315151|NCT04056065|DRUG|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
219315152|NCT04056065|DRUG|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
219315153|NCT00294385|DRUG|Docetaxel|
219315154|NCT00294385|DRUG|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
219315155|NCT00294385|DRUG|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
219315156|NCT06502899|OTHER|Cardiac MRI|Patients with a diagnosis of MINOCA and completed CMR were included in this study
219315157|NCT05217303|DRUG|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
219315158|NCT01491217|DRUG|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
219315159|NCT04600479|DIAGNOSTIC_TEST|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
219315160|NCT05374720|PROCEDURE|salpingectomy|Removal of one of the fallopian tubes.
219315161|NCT05374720|PROCEDURE|hysterectomy|remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.
219315162|NCT02248220|DRUG|Pramipexole|
219315163|NCT04201405|DRUG|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
219315164|NCT05483400|DRUG|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
219315165|NCT03681886|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
219315166|NCT03681886|PROCEDURE|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
219315167|NCT01348386|DRUG|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
219315168|NCT01348386|DRUG|Placebo|
219315169|NCT01050907|DRUG|Miltefosine|2.5 mg/kg/day for 28 days
219315170|NCT03836755|DIAGNOSTIC_TEST|Metacos|Evaluation of stability of implant by RSA technique
219315171|NCT02294123|OTHER|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
219315172|NCT03508167|DEVICE|Thermal Band|Thermal Band used 8 hours per day
219315173|NCT03508167|DRUG|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
219315174|NCT03508167|DRUG|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
219315175|NCT06331780|DEVICE|Visual acuity|VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
219315176|NCT06331780|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
219315177|NCT06331780|DEVICE|Objective monocular accommodation amplitude measurement|Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance
219315178|NCT06331780|DEVICE|"Subjective monocular accommodation amplitude measurement with the Push-Up method"|"The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived."
219315179|NCT06331780|DEVICE|"Subjective monocular accommodation facility measurement with the Rock method:"|"The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc… You have to do the maximum number of rotations in one minute."
219315180|NCT06331780|OTHER|CISS Questionnaire|This questionnaire relating to the use of the near vision will be submitted
219315181|NCT06331780|OTHER|Difficulty assessment questionnaire|After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.
219315182|NCT06331780|OTHER|Subjective evaluation questionnaire|A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
219315183|NCT06277336|DRUG|Placebo|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)"
219315184|NCT06277336|DRUG|Apelin Low Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 1 nmol/min (60ml per h)"
219315185|NCT06277336|DRUG|Apelin High Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 10 nmol/min (60ml per h)"
219315186|NCT06277336|DRUG|Selected Apelin Dose|"Study infusions (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours based on the best performing apelin dose (from Low Dose or High Dose) in healthy volunteers corresponding to one of the following options:~  1. at an infusion rate of 1 nmol/min (60ml per h) OR~ 2. at an infusion rate of 10 nmol/min (60ml per h)~In case both apelin dosis performed equally well in the healthy volunteers population the lower dose will be selected."
219315187|NCT02039804|DRUG|Corticosteroids|Intra-bursal injection
219315188|NCT02039804|DEVICE|Hyaluronic acid|Intra-bursal injection
219315189|NCT00301223|DRUG|Pregabalin|
219745338|NCT05360784|DRUG|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
219315190|NCT05332301|OTHER|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
219315191|NCT05921396|PROCEDURE|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
219315192|NCT05921396|PROCEDURE|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
219315193|NCT04526197|DRUG|ALXN1840|ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.
219315194|NCT04526197|DRUG|Celecoxib|Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
219315195|NCT00101881|DEVICE|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
219315196|NCT03271203|OTHER|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
219315197|NCT03271203|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
219315198|NCT01744223|BIOLOGICAL|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
219315199|NCT01744223|DRUG|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
219315200|NCT01744223|BIOLOGICAL|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
219315201|NCT01744223|BIOLOGICAL|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
219315202|NCT01744223|BIOLOGICAL|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
219315203|NCT01744223|PROCEDURE|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
219315204|NCT01558895|RADIATION|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
219315205|NCT01558895|OTHER|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
219315206|NCT01879215|PROCEDURE|Intramedullary nailing of the tibia|Standard care surgery
219315207|NCT01018121|BEHAVIORAL|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
219315208|NCT01018121|OTHER|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
219315209|NCT03120767|BEHAVIORAL|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
219315210|NCT03120767|BEHAVIORAL|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
219315211|NCT02647229|OTHER|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
219315212|NCT02647229|OTHER|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
219315213|NCT04134676|DRUG|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
219315214|NCT04278001|DEVICE|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
219315215|NCT03882242|BEHAVIORAL|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
219315216|NCT00405470|DEVICE|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
219315217|NCT03875677|DEVICE|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of \~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
219315218|NCT03875677|DEVICE|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
219745339|NCT05218083|BEHAVIORAL|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation \& personalized instruction \& coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities \& general resistance exercises for major muscle groups.~Balance incorporates static \& dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward \& backward starting within base of support \& progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
219745340|NCT05142306|BIOLOGICAL|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
219745341|NCT01143441|BIOLOGICAL|DAC-HYP|
219745342|NCT02251041|DRUG|Antithrombin-III|
219745343|NCT02251041|DRUG|Infliximab|
219745344|NCT02251041|DRUG|Apotransferrin|
219315219|NCT03875677|DEVICE|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
219315220|NCT00541723|DRUG|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
219315221|NCT00541723|DRUG|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
219315222|NCT02148614|DRUG|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
219315223|NCT02148614|DRUG|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
219315224|NCT01222260|DRUG|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
219315225|NCT01222260|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
219315226|NCT04870853|OTHER|Electronic Health Record Review|Medical records reviewed
219745345|NCT02251041|DRUG|Human recombinant erythropoietin|
219745346|NCT02251041|DRUG|C1-Inhibitor|
219745347|NCT02251041|DRUG|Glutathione|
219315227|NCT03745482|OTHER|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
219315228|NCT05319275|DRUG|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
219315229|NCT05319275|DRUG|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
219315230|NCT03968120|OTHER|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
219315231|NCT03717831|OTHER|Observational study of standard of care|Observational cohort study
219745348|NCT02251041|DRUG|Alfa-tocopherol|
219745349|NCT02251041|DRUG|Melatonin|
219745350|NCT02251041|DRUG|Epoprostenol|
219745351|NCT02251041|DRUG|Sodium chloride solution|
219745352|NCT05681078|BEHAVIORAL|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
219745353|NCT04918771|DRUG|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
219745354|NCT04918771|DRUG|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
219315232|NCT02411578|DRUG|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
219315233|NCT02411578|OTHER|Glucose Tablets|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
219315234|NCT03832296|BEHAVIORAL|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
219315235|NCT03832296|BEHAVIORAL|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
219315236|NCT05706753|DRUG|Milvexian|Milvexian will be administered orally.
219315237|NCT05706753|DRUG|Midazolam|Midazolam will be administered orally.
219315238|NCT05706753|DRUG|Ethinylestradiol|Ethinylestradiol will be administered orally.
219315239|NCT05706753|DRUG|Drospirenone|Drospirenone will be administered orally.
219315240|NCT02842892|OTHER|Tissue stiffness|
219315241|NCT06001086|DRUG|Disitamb Vedotin ,pyrotinib|Disitamb Vedotin combined with pyrotinib
219315242|NCT03787225|DRUG|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
219315243|NCT03787225|DRUG|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
219315244|NCT00867282|DRUG|Treatment A|PF-00241939 750ug using inhaler A
219315245|NCT00867282|DRUG|Treatment B|PF-00241939 750ug using inhaler B
219315246|NCT00504010|DRUG|Arnica Montana|Applied to lower extremity once a day for 3 days
219315247|NCT00504010|DRUG|placebo cream|placebo cream applied to leg daily for 3 days
219315248|NCT04025463|BEHAVIORAL|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
219315249|NCT02638935|DEVICE|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
219315250|NCT02902627|DEVICE|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
219315251|NCT02311946|DRUG|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
219745355|NCT04331951|DIAGNOSTIC_TEST|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
219745356|NCT01046669|DEVICE|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
219745357|NCT01046669|OTHER|Standard medical care for septic shock|Standard medical care for septic shock
219745358|NCT02062684|DRUG|Blisibimod|
219745359|NCT02062684|DRUG|Placebo|
219745360|NCT03434899|BEHAVIORAL|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
219745361|NCT03434899|BEHAVIORAL|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
219745362|NCT00200239|BEHAVIORAL|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
219745363|NCT02915601|DRUG|Sodium bicarbonate|
219315252|NCT02311946|DRUG|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
219315253|NCT02901366|DRUG|14C-FYU-981|14C-FYU-981, (Oral single dosing)
219315254|NCT00373750|PROCEDURE|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
219315255|NCT02172339|DRUG|Tiotropium, solution ampoules|
219745364|NCT02915601|DRUG|Placebo|
219745365|NCT02848027|BIOLOGICAL|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
219315256|NCT05292820|OTHER|Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure|Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
219315257|NCT03732508|DRUG|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
219315258|NCT03732508|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
219315259|NCT03732508|DRUG|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
219315260|NCT00651157|BIOLOGICAL|wild-type reovirus|Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
219315261|NCT01885325|OTHER|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
219315262|NCT00364156|DRUG|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
219315263|NCT00364156|DRUG|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
219315264|NCT02075411|DRUG|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
219315265|NCT02075411|DRUG|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
219315266|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
219315267|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
219315268|NCT05488236|OTHER|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
219315269|NCT00979251|DRUG|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
219315270|NCT00979251|DRUG|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
219315271|NCT02208297|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
219315272|NCT02208297|DRUG|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
219315273|NCT02880826|BEHAVIORAL|Measure the culture of safety in the reanimation units|
219315274|NCT04009317|DRUG|TQ-B3139|a multi-target protein kinase inhibitor.
219315275|NCT04009317|DRUG|Crizotinib|a multi-target protein kinase inhibitor.
219315276|NCT03430219|DEVICE|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
219315277|NCT05912803|DEVICE|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed."
219315278|NCT05912803|OTHER|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
219315285|NCT03571529|DEVICE|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
219315286|NCT03571529|OTHER|Conventional physiotherapy|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale"
219315287|NCT04354090|DRUG|JY09|Subcutaneous injection
219315288|NCT05125679|DRUG|Guselkumab|Guselkumab will be administered by subcutaneous injection.
219315289|NCT05629962|DRUG|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
219315290|NCT05629962|DRUG|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
219315291|NCT01320982|DRUG|minocycline|minocycline 100 mg/bid
219315292|NCT01320982|DRUG|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
219315293|NCT01320982|DRUG|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
219315294|NCT01320982|DRUG|placebo|placebo bid
219315295|NCT01955447|DIETARY_SUPPLEMENT|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
219315296|NCT01955447|DIETARY_SUPPLEMENT|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
219315297|NCT01955447|DIETARY_SUPPLEMENT|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
219315298|NCT01955447|DIETARY_SUPPLEMENT|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
219315299|NCT03156751|DIAGNOSTIC_TEST|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
219315300|NCT06087679|BEHAVIORAL|PPS guided selfcare based intervention program|Guided selfcare programme (Please refer to project description)
219354734|NCT03002415|OTHER|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
219315301|NCT04731857|GENETIC|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
219315302|NCT06472908|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
219315303|NCT06472908|DRUG|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
219315304|NCT06472908|DRUG|Placebo|Placebo, one pill a day, oral intake
219315305|NCT05828927|BEHAVIORAL|Eco-mapping tool|The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
219315306|NCT05828927|BEHAVIORAL|Caregiver-coach study visits|Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
219315307|NCT02989636|OTHER|Laboratory Biomarker Analysis|Correlative studies
219745366|NCT05385289|BEHAVIORAL|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
219745367|NCT04832152|OTHER|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
219745368|NCT05570162|OTHER|Diabetes educational program|30-minute long diabetes educational program
219745369|NCT04297774|BEHAVIORAL|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
219745370|NCT04297774|BEHAVIORAL|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
219745371|NCT04297774|BEHAVIORAL|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
219745372|NCT04564014|BEHAVIORAL|ISSS|The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
219745373|NCT04564014|OTHER|Education Materials|Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
219315308|NCT02989636|BIOLOGICAL|Nivolumab|Given IV
219315309|NCT02989636|RADIATION|Stereotactic Radiosurgery|Undergo SRS
219315310|NCT04124341|DEVICE|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
219315311|NCT06445608|DEVICE|Percutaneous Mechanical Circulatory Support|Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
219315312|NCT05639972|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
219315313|NCT05639972|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
219315314|NCT05207917|PROCEDURE|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
219315315|NCT05207917|PROCEDURE|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
219315316|NCT05207917|PROCEDURE|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
219315317|NCT06107153|DRUG|Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
219315318|NCT06107153|DRUG|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
219315319|NCT06107153|DRUG|Pioglitazone 30mg|Pioglitazone 30mg
219315320|NCT05666050|BEHAVIORAL|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
219315321|NCT02366819|DRUG|Oxaliplatin|Given IV
219315322|NCT02366819|DRUG|Leucovorin Calcium|Given IV
219315323|NCT02366819|DRUG|Irinotecan Hydrochloride|Given IV
219315324|NCT02366819|DRUG|Fluorouracil|Given IV
219315325|NCT02366819|PROCEDURE|Conventional Surgery|Undergo surgery
219315326|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
219315327|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
219315328|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
219315329|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
219315330|NCT06105723|BEHAVIORAL|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
219315331|NCT06458205|COMBINATION_PRODUCT|Multi-component intervention for smokers|"1. Community-based spirometry pulmonary function tests and result interpretations and health education;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for smokers whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to smokers with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients or asthma patients;~7. To actively include smokers whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than11.1mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \<18.5;~9. Pay-for-population mechanism for medical practitioners."
219315332|NCT04494360|OTHER|No intervention|No investigational medicinal product will be administered as a part of this study.
219315333|NCT05928403|OTHER|total knee prosthesis|Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
219315334|NCT04108897|DRUG|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
219315335|NCT04108897|DRUG|Ivermectin Topical|1% topical ivermectin.
219315336|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
219315337|NCT04577547|OTHER|DGA diet WL & exercise|Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise
219315338|NCT04577547|OTHER|DGA diet WL & no exercise|Intake of DGA weight loss 8 day rotating menu \& no exercise
219315339|NCT04577547|OTHER|DGA diet WM & exercise|Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise
219315340|NCT04577547|OTHER|DGA diet WM & no exercise|Intake of DGA weight maintenance 8 day rotating menu \& no exercise
219315341|NCT04577547|OTHER|Western diet WL & exercise|Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise
219315342|NCT04577547|OTHER|Western diet WL & no exercise|Intake of Western-type weight loss 8 day rotating menu \& no exercise
219315343|NCT04577547|OTHER|Western diet WM & exercise|Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise
219315344|NCT04577547|OTHER|Western diet WM & no exercise|Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
219315345|NCT05825261|OTHER|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
219315346|NCT05825261|OTHER|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
219315347|NCT06506058|DEVICE|EVS and EEG|"The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included)."
219315348|NCT05492396|DEVICE|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
219315349|NCT06538597|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
219315350|NCT03187977|BEHAVIORAL|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
219315351|NCT00416377|BIOLOGICAL|bleomycin sulfate|
219315352|NCT00416377|DRUG|chlorambucil|
219315353|NCT00416377|DRUG|dacarbazine|
219315354|NCT00416377|DRUG|doxorubicin hydrochloride|
219315355|NCT00416377|DRUG|prednisolone|
219315356|NCT00416377|DRUG|procarbazine hydrochloride|
219315357|NCT00416377|DRUG|vinblastine sulfate|
219315358|NCT00416377|DRUG|vincristine sulfate|
219315359|NCT00416377|RADIATION|radiation therapy|
219354735|NCT03002415|OTHER|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
219745374|NCT03918291|OTHER|Addition of whole-body vibration to squat training|
219745375|NCT03918291|OTHER|Squat training|squatting exercises for 12 weeks, 3x/week
219745376|NCT01287208|DEVICE|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
219745377|NCT01287208|DEVICE|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
219745378|NCT02252510|OTHER|HALOSPERM|
219745379|NCT00003158|DRUG|carboplatin|
219745380|NCT00003158|DRUG|etoposide|
219745381|NCT00003158|DRUG|paclitaxel|
219745382|NCT00003158|RADIATION|radiation therapy|
219745383|NCT02839928|DRUG|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
219745384|NCT02839928|DEVICE|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
219745385|NCT02839928|DRUG|EMLA|
219745386|NCT01299961|DRUG|abatacept|125 mg once a week up to 12 months.
219745387|NCT04898179|OTHER|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
219745388|NCT04898179|OTHER|Control group|Usual care
219745389|NCT05143411|OTHER|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
219745390|NCT02904096|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
219745391|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
219315360|NCT06241508|DEVICE|Transcranial magnetic stimulation|A standard 600-pulse TBS \[16\] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology \[3, 9\]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 \[17\], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 \[4, 6\]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes \[2, 3\]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
219315361|NCT05055414|DRUG|UI030|Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
219315362|NCT03454308|BEHAVIORAL|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
219315363|NCT03454308|BEHAVIORAL|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
219315364|NCT04569695|DRUG|JNJ-70033093|JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
219315365|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
219315366|NCT05656560|OTHER|Clinician education|Brief, online education module for primary care clinicians
219315367|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
219315368|NCT05848271|OTHER|Patient Registry|Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.
219315369|NCT05848271|OTHER|Dry blood spots sampling|Dry blood splots require 500nl of blood.
219315370|NCT04634656|DRUG|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
219315371|NCT04634656|DRUG|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
219315372|NCT01197885|DRUG|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
219315373|NCT02874339|DEVICE|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
219315374|NCT02874339|DEVICE|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
219315375|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg with phytase supplement 176mg (800FTU)|zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day
219315376|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg|zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.
219315377|NCT00890487|OTHER|hyaluronic acid pill|pill, 220 mg, once a day, three months
219745392|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
219745393|NCT04403685|DRUG|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
219315378|NCT05603091|PROCEDURE|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
219315379|NCT06419829|OTHER|psychoprophylactic program aimed at normalizing body weight through medical training|"Based on the assessment of body weight and composition, a 12-week physiophylactic program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that reduce fat mass, increase the flexibility and productivity of muscle mass. The classes will be conducted as part of medical training with a training load increasing to at least 85% of HR Max.~The project will include theoretical classes for parents, children and seniors on eating habits, a proper age-appropriate diet, diet changes depending on the subject's health condition and physical activity, and the impact of diet on the process of puberty, adulthood and aging."
219315380|NCT06419829|OTHER|psychoprophylactic program aimed at improving body posture|"Based on the body posture assessment, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that strengthen the muscle corset, reducing asymmetrical positioning, habitual and during the implementation of professional tasks. The classes will be conducted using medical training and resistance exercises.~The project will include theoretical classes for parents on sitting habits, the importance of physical activity in a child's development, the selection of footwear..."
219315381|NCT06419829|OTHER|psychoprophylactic program aimed at improving physical fitness|Based on the assessment of physical fitness, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the participants. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises aimed at improving physical fitness, with particular emphasis on impaired motor skills. The classes will be conducted using functional training, resistance and stretching exercises, strengthening all muscle groups. In the case of children, special attention will be paid to the strength of the upper limbs, in the case of seniors, balance and coordination exercises will be introduced to improve time and space orientation. In all groups, the main goal is to improve functional fitness The project will include theoretical classes for parents, children and seniors on the importance of physical activity in the quality of life, in the process of maturation and aging.
219315382|NCT06419829|DIAGNOSTIC_TEST|Body composition assessment|"Body composition assessment will be carried out using the BIA method on an eight-electrode body composition analyzer from TAnita. They will be marked:~total mass, Total fat mass (FM) and segmental fat mass for five body segments: right leg (RL FM), Left leg (LL FM), right arm (RA FM), Left Arm (LA FM) trunk (TR FM).~total fat-free mass (FFM) and segmental for five body segments: right leg (RL FFM), Left leg (LL FFM), right arm (RA FFM), Left Arm (LA FMM) trunk (TR FMM).~Predicted total and segmental muscle mass (PMM) for five body segments: right leg (RL PMM), Left leg (LL PMM), right arm (RA PMM), Left Arm (LA PMM) trunk (TR PMM).~Total water content (TBW) including intracellular water (ICW) and extracellular water (ECW)"
219315383|NCT06419829|DIAGNOSTIC_TEST|assessment of body posture using the Kasperczyk method|The Kasperczyk method was used to assess body posture, including physiotherapeutic assessment in both standing and sitting positions. The symmetry of the head, shoulders, spine curvatures, knee joints and foot positioning were assessed. The symmetry of the head position was examined in all three planes and in all movements, i.e. flexion - extension, right turn - left turn, rotation and combined movements. The lateral curvatures of the spine (scoliosis) and their physiological curvatures, their deepening or shallowing in all sections of the spine, as well as the mobility of the spine in all physiological planes of movement were assessed. The position of the shoulder and hip girdle was assessed, as well as the position of the upper limbs at the level of the knees and feet. The mobility of the lower and upper limbs was examined.
219315384|NCT06419829|DIAGNOSTIC_TEST|Assessment of physical fitness|It depends on the age of the person being examined. In the case of children, the EUROFIT physical fitness test is carried out with modifications for age and gender. For the senior group, the Rikli and Jones test is used
219315385|NCT06419829|DIAGNOSTIC_TEST|Balance assessment|"Balance assessment using the Zebris platform Static measurement - with eyes open and closed, assessing the load on the limbs during standing expressed in %, Balance analysis measurement - with eyes open and closed, test in a standing position, barefoot. The measurement duration is 30 seconds and the break between measurements is 30-60 seconds.~Deflections of the center of gravity in the frontal and sagittal planes Length of the center of gravity swing path CoP - SPL \[cm\]. Inside the calculated ellipse lies 95% of the CoP location measurement data: amplitude, amplitude height, ellipse area (orientation of the direction of the ellipse's longitudinal axis relative to the platform's longitudinal axis, indicating clockwise rotation)."
219315386|NCT02950064|DRUG|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
219315387|NCT00958620|PROCEDURE|Shock Wave Therapy|Extracorporal shock-wave therapy
219315388|NCT02330783|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
219315389|NCT02330783|DRUG|Sorafenib|400mg twice daily by oral of each 4-week cycle
219315390|NCT00276588|DRUG|carboplatin|
219315391|NCT00276588|DRUG|gemcitabine hydrochloride|
219315392|NCT00276588|DRUG|paclitaxel|
219315393|NCT06387368|DRUG|Huaier Granule|Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
219315394|NCT06387368|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
219315395|NCT03178539|DRUG|diclofenac|non steroidal anti-inflammatory drug
219315396|NCT03178539|DRUG|ketorolac|non steroidal anti-inflammatory drug
219315397|NCT06062446|PROCEDURE|Modified Lumbar Puncture|The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
219315398|NCT02958267|BIOLOGICAL|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
219315399|NCT02958267|BIOLOGICAL|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
219315400|NCT02958267|DEVICE|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution \[10 mg/mL\], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
219315401|NCT04225221|DRUG|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
219315402|NCT04225221|DRUG|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
219315403|NCT04225221|DRUG|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
219315404|NCT04225221|DRUG|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
219315405|NCT03635593|DRUG|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
219315406|NCT03635593|DRUG|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
219315407|NCT03635593|OTHER|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
219315408|NCT01210118|BEHAVIORAL|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
219315409|NCT01210118|BEHAVIORAL|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
219315410|NCT01795027|DRUG|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
219315411|NCT01795027|DRUG|S-1 single|16 courses S-1 single after d D2 resection
219315412|NCT04596696|BIOLOGICAL|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
219315413|NCT03645954|PROCEDURE|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
219315414|NCT03645954|PROCEDURE|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle \& Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
219315415|NCT00000193|DRUG|Gamma hydroxybutyric|
219315416|NCT01422850|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
219315417|NCT02947477|BEHAVIORAL|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
219315418|NCT01909687|DEVICE|Blood glucose monitoring systems|
219315419|NCT04484831|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
219315420|NCT04484831|OTHER|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
219315421|NCT04525482|OTHER|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
219315422|NCT03188354|DIAGNOSTIC_TEST|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
219315423|NCT03188354|DIAGNOSTIC_TEST|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
219315424|NCT03188354|DIAGNOSTIC_TEST|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
219315425|NCT04778774|PROCEDURE|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
219315426|NCT04423354|PROCEDURE|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
219315427|NCT02370082|DEVICE|Localization of breast lesion|localization of breast lesion for removal
219315428|NCT02916680|PROCEDURE|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
219315429|NCT02244996|DIETARY_SUPPLEMENT|Lycium Barbarum|Traditional Chinese Herbs
219315430|NCT02244996|DIETARY_SUPPLEMENT|Placebo|Placebo
219315431|NCT03330353|DIAGNOSTIC_TEST|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
219315432|NCT04556058|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
219315433|NCT04556058|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
219315434|NCT01335009|BIOLOGICAL|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
219315435|NCT04492605|DIETARY_SUPPLEMENT|Placebo|consume 1 capsule per day for 2 months
219315436|NCT04492605|DIETARY_SUPPLEMENT|TCI378 Probiotics|consume 1 capsule per day for 2 months
219315437|NCT04492605|DIETARY_SUPPLEMENT|TCI507 Probiotics|consume 1 capsule per day for 2 months
219315438|NCT06281964|DRUG|PLB1004|Participants received oral PLB1004 240mg on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 240mg and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
219315439|NCT06281964|DRUG|Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab|Participants received IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 and 500 mg/m\^2 of pemetrexed on Day 1 q3w and Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. until disease progression in the maintenance period.
219315440|NCT06666322|DRUG|Standard of care|"2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum"
219315441|NCT06666322|DRUG|Oteseconazole - antifungal therapy 1|"Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)~* Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.~* Liposomal Amphotericin B 10 mg/kg IV once.~* No fluconazole or 5FC to be given."
219315442|NCT06666322|DRUG|Sfu-AM2-19 Injection - antifungal therapy 2|Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
219315443|NCT06666322|DRUG|Antifungal therapy 3|To be determined
219315444|NCT06666322|DRUG|Antifungal therapy 4|To be determined
219315445|NCT06609707|BEHAVIORAL|Tuning in to Kids|Tuning in to Kids is an evidence-based, emotion-focused, group parenting program designed to teach caregivers skills in recognizing, understanding, and managing their own and their children's emotions. The program includes six 90-minute, weekly, online group sessions and two optional 'booster' sessions to consolidate skills. Parents are taught five steps of emotion coaching and participate in exercises sequentially targeting each step. Intervention components include psychoeducation, emotion coaching demonstrations, role plays, group discussion, written resources, and home practice exercises. The program teaches parents skills in emotion coaching as a way of responding to their child's emotions. These skills help children to understand and regulate their emotions. As per the Tuning in to Kids manual, two trained, licensed health professionals will co-facilitate each group.
219315446|NCT02918578|OTHER|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
219315447|NCT02918578|OTHER|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
219315448|NCT02918578|OTHER|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
219315449|NCT06991192|BEHAVIORAL|Rehabilitation with Exercise and Psychological Support (REPS)|Rehabilitation with Exercise and Psychological Support (REPS) is a rehabilitation approach that integrates exercise with psychological support provided by physical therapist and patient training videos.
219315450|NCT07006090|DEVICE|Histolog Scanner|Histolog Scanner intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture.
219315451|NCT06496646|BEHAVIORAL|Reminders|We will send daily text messages to participants for 12 weeks reminding them to take their antidepressant medication. These reminders will be tailored, personalized and patient-centric, grounded in behavioral economics principles.
219315452|NCT06496646|BEHAVIORAL|Incentives|In addition to daily text messages, participants will receive financial incentives for 6 weeks based on contingency management principles. Participants assigned to the Reminders and Incentives arm of the study will receive a $2/day incentive, increasing by $1/day conditioned on each week that they consistently take their antidepressant over the first 6 weeks, for a maximum total payment of $189 ($2, $3, $4, $5, $6, $7 in weeks 1 through 6, respectively).
219315453|NCT07010146|DRUG|transdermal 17β-E2 with cyclic progestin|100-mcg transdermal 17β-E2 patch (to be applied twice weekly) (continuous use), with 200 mg micronized progesterone given for 12 days of every month
219315454|NCT07010146|DRUG|oral 17β-E2 with cyclic progestin|2 mg of oral 17β-E2 pills daily, with 200 mg micronized progesterone given for 12 days of every month
219315455|NCT07010146|DRUG|transdermal EE+LNG|transdermal EE (30 mcg) + LNG (120 mcg) contraceptive patch (TWIRLA). Patch will be applied once a week for 3 consecutive weeks, with the 4th week off the patch (to be repeated after 4 weeks).
219315456|NCT03237182|DRUG|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
219745394|NCT04719312|PROCEDURE|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
219745395|NCT02860403|PROCEDURE|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
219745396|NCT05679557|OTHER|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
219745397|NCT03898973|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
219745398|NCT00191698|DRUG|atomoxetine hydrochloride|
219745399|NCT00191698|DRUG|placebo|
219745400|NCT00006377|DRUG|carboplatin|
219745401|NCT00006377|DRUG|doxorubicin hydrochloride|
219745402|NCT00006377|DRUG|paclitaxel|
219745403|NCT01442610|DRUG|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
219745404|NCT01442610|DRUG|Placebo|Placebo 1tablet once daily for 8 weeks
219745405|NCT03366831|BEHAVIORAL|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
219745406|NCT06501976|DRUG|Lurbinectedin|2.6 mg/m2 , Given IV, every 21 days
219745407|NCT06501976|RADIATION|Radiation Therapy|Thoracic radiotherapy
219745408|NCT01182246|DRUG|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
219745409|NCT05305651|DRUG|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
219745410|NCT05751304|DRUG|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
219745411|NCT05751304|DRUG|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
219745412|NCT00526799|DRUG|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
219745413|NCT00526799|DRUG|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
219745414|NCT04003389|DRUG|fezolinetant|administered orally
219745415|NCT04003389|DRUG|placebo|administered orally
219745416|NCT05642975|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
219745417|NCT02603497|DRUG|ASP015K|oral
219745418|NCT03996018|OTHER|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
219745419|NCT05156203|DRUG|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
219745420|NCT04725071|DIETARY_SUPPLEMENT|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
219315457|NCT03237182|DRUG|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
219315458|NCT07020338|OTHER|Yoga Exercise Program|Participants in the intervention group received a structured yoga-based exercise program consisting of 50-minute sessions, conducted twice per week over a period of approximately 10-12 weeks (three menstrual cycles). The program was based on Hatha Yoga principles
219315459|NCT07020156|DRUG|OX118 or placebo|OX118 is a human monoclonal antibody targeting OX40 ligand (OX40L).
219315460|NCT07020845|OTHER|Observation only|This is an observational study with no intervention applied to participants. Data were collected through questionnaires and clinical assessments only
219315461|NCT07019870|DIAGNOSTIC_TEST|EBV biomarker testing|"15 ml of blood will be collected for EBV EA IgA serology and plasma EBV DNA testing by a trained nursing/phlebotomy staff. If the initial plasma EBV DNA test is positive, a second blood draw will be performed for repeat plasma EBV DNA testing.~Additionally, 2-3 ml of saliva will be collected for EBV strain identification, however, this information is not used for risk stratification in this study.~Demographic characteristics, clinical history and symptoms will be collected through a questionnaire."
219315462|NCT07019610|DEVICE|ClearGuard HD|The ClearGuard HD end cap is a male luer lock end cap that incorporates an antimicrobial treatment (Chlorhexidine) on its surface designed to reduce microbial colonisation within a haemodialysis catheter hub.
219315463|NCT07019610|DEVICE|B Braun Combi-stopper|Standard practice caps used within the Metro North Kidney Health Service
219315464|NCT07019142|DIETARY_SUPPLEMENT|HFD|Luminal challenge with standardized volume, amount, calories of fat
219315465|NCT07020442|OTHER|integrated neuromuscular training|a 12-week integrated neuromuscular training (NMT) program. All participants completed two NMT sessions weekly.
219315466|NCT07020715|BIOLOGICAL|Tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
219315467|NCT07018999|DEVICE|Immersive virtual reality operating theatre tour|In a joint project involving the Department of Computing of Hong Kong Polytechnic University, the Department of Computer science Center for Innovative Applications of Internet and Multimedia Technologies of the City University of Hong Kong and the Hong Kong Children's Hospital (HKCH), an immersive VR operating theatre tour will be designed as part of preoperative education for participants. A simulation of the perioperative journey in HKCH operating theatre will be created to help participants form realistic expectations of their perioperative journey, and virtual exposure of different medical equipment helps participants cope with their worries for the anticipated procedures. Parents/legal guardians will be able to monitor the VR experience on tablets via the monitoring software, which displays what the participants see in VR.
219315468|NCT07019311|OTHER|Thera-Band exercises|Participants in the first experimental group performed a Thera-Band exercise program 3 sessions weekly, for 8 weeks with progressive resistance, divided into four 2-week phases. Each 60-minute session included a 10-min warm-up (walking, jogging, and calisthenics), 45-min Thera-Band exercises, and 5-min cool-down. Phase 1 focused on major muscle groups (e.g., shoulder press, biceps curl). Phase 2 included trunk and leg-focused moves (e.g., reverse flies, lunge). Phase 3 added advanced resistance (e.g., chest press, deadlift). Phase 4 targeted core and lower body (e.g., diagonal chop, squat). Exercises changed every phase to progressively strengthen different muscle groups.
219315469|NCT07019311|OTHER|Swiss ball exercises|Participants in the second experimental group performed Swiss ball exercises 3 sessions weekly, for 8 weeks. Exercises included warm-up (15-5 mins), core Swiss ball training (progressing from 1 to 4 sets), and cool-down. Each session focused on abdominal, back, leg, trunk, and balance training using varied exercises performed for 30 seconds with rest. Exercise intensity ranged from 80-95% of max effort, increasing weekly. The Swiss ball size was selected based on patient height to ensure proper posture. Sessions gradually increased in duration and difficulty, ending with breathing and stretching for recovery.
219315470|NCT07019311|OTHER|Traditional physical therapy program|Participants in both experimental groups performed a traditional physical therapy program in the form of complex decongestive physical therapy(CDPT), including (manual lymphatic drainage, compression, exercise and skin care) and balance training, 3 sessions weekly, for 8 weeks.
219315471|NCT07021287|OTHER|mixed ice and water, continuous ice application|the ice pack was placed on the knee joint immediately after returning to the ward for 24 hours, and the ice pack was replaced every 3 to 4 hours, if it melted, replaced immediately.
219315472|NCT07021287|OTHER|mixed ice and water, intermittent ice compress|within 72 hours after operation, the patients were given ice compress for 20 minutes each time, with an interval of 2 hours, 3 times a day
219315473|NCT07021287|OTHER|full ice, continuous ice compress|After returning to the ward, an ice pack should be placed on the knee for 24 hours. The ice pack should be replaced every 3-4 hours and replaced immediately if melted
219315474|NCT07021287|OTHER|full ice, intermittent ice compress|Within 72h after surgery, the patient applied ice for 20min each time, with an interval of 2h,3 times a day.
219315475|NCT07020754|DIETARY_SUPPLEMENT|L-arginine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-arginine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
219315476|NCT07020754|DIETARY_SUPPLEMENT|L-glutamine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-glutamine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
219315477|NCT07020754|DIETARY_SUPPLEMENT|Maltodextrin Oral Suspension (Control)|"Type: Placebo comparator~Dosage: 10 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
219315478|NCT07020247|DRUG|Anti-PD-1 antibody drug named Serplulimab|Serplulimab
219315479|NCT07020247|RADIATION|Radiotherapy|Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/ 25-28f(1.8-2.0Gy/d, 5f/w). For patients in the experimental group who achieve partial remission (PR) or better during the induction phase, an additional local boost dose of 6Gy/3f(2.0Gy/d, 5f/w) is administered to the PGTV.(No PGTV dose was given in the control group). For the treatment of lymph node metastasis in the lateral pelvic wall outside the mesorectal area: no additional dose is required when surgery is feasible, a sequential boost dose of 15Gy/3f is added when the lymph nodes are not surgically resectable.
219315480|NCT07020247|DRUG|Chemotherapy|Capox
219315481|NCT07019675|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
219315482|NCT07020260|OTHER|CAR T-cell and Cellular Therapies|A single IV infusion of huCAR 19 T-cells on day 0. In phase I 3 dose levels are tested to determine the RP2D.
219315483|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training with Motor Imagery|Participants will perform the game consisting of 3 different stages during one session. The motor task will include crossing the street between cars and walking on the sidewalk without hitting people. The difference between the stages will be the cognitive task, which becomes more difficult with each stage. The cognitive task in the first stage of the game will involve the colors that the patient will see and the simultaneous sound of the colors. The cognitive task in the second stage of the game will involve writing the names of some colors with black paint and reading them simultaneously. In the third stage of the game, the patient will see color names written with some colors. Every 5 seconds a new match will appear and the number of errors made during the matches will be recorded. In addition, upper extremity strengthening with PNF methods such as hold relaxation, rhythmic stabilization and repetitive stretches will be studied.
219315484|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training without Motor Imagery|The difference of this group from the first group is that they will see that they provide mobility with a wheelchair instead of walking, which is a motor task. In this case, there will be no motor imagery of walking. Simultaneously with the game, an environment where the wheelchair can move safely will be created in order to prevent symptoms such as dizziness and nausea in the patients and the wheelchair will be moved in this environment by the researcher. The difference between the stages will be the cognitive task that becomes more difficult at each stage and it will take a total of 20 minutes to complete all stages of the game. In addition, upper extremity strengthening will be practiced with PNF methods of hold and relax, rhythmic stabilization and repetitive stretches.
219315485|NCT07019207|BEHAVIORAL|Proprioceptive Neuromuscular Facilitation|The patients in the group will be applied only the resistance band strengthening methods including the upper extremity proprioceptive neuromuscular facilitation (PNF) patterns and methods applied as standard in rehabilitation. Strengthening will be worked on in all upper extremity PNF patterns using the resistance band with the PNF methods of hold-relax, rhythmic stabilization and repetitive stretching.
219315486|NCT07017751|OTHER|Heart failure medication|intervention group will receive 45 minutes online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. Two weeks, one month, and two months after the initial education, participants will be contacted to obtain feedback on their post-education dietary behaviours, medication compliance, and symptoms.
219315487|NCT07021131|PROCEDURE|new type of peripheral block Serratus Posterior Plane Block|Intervention will be Serratus Posterior Plane Block.
219315488|NCT07019480|PROCEDURE|implant insertion|"Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden).~The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol)."
219315489|NCT07020624|OTHER|SAPB|Ultrasound guided serratus anterior plane block will be performed.
219315490|NCT07020624|OTHER|SPSIPB|Ultrasound guided serratus posterior superior intercostal plane block will be performed.
219745421|NCT04725071|DIETARY_SUPPLEMENT|Boost High Protein|conventional supplement
219745422|NCT06002152|DRUG|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
219745423|NCT06002152|DRUG|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
219315491|NCT07020403|BEHAVIORAL|Mindfulness-Based Emotional Eating Reduction Program (MB-EER)|The MB-EER program was delivered to participants in the intervention arm over 7 weeks. Each session lasted 2 hours and was conducted weekly via Zoom. Participants attended in small groups, and sessions were led by trained facilitators. The intervention focused on guided mindfulness practices, mindful eating exercises, and group discussions.
219315492|NCT07018921|DIETARY_SUPPLEMENT|rebaudioside A|rebaudioside A encapsulated in a vegetarian capsule
219315493|NCT07018921|DIETARY_SUPPLEMENT|Placebo|carboxymethylcellulose encapsulated in a vegetarian capsule
219315494|NCT04740528|DIAGNOSTIC_TEST|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
219315495|NCT06096389|OTHER|100 Drop Jumps|100 drop jumps from 60 cm height. Divided into 5 sets of 20 reps
219315496|NCT06096389|DIETARY_SUPPLEMENT|Whey supplementation|Consume whey protein isolate based on subjects' daily protein intake
219315497|NCT06096389|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Consume carbohydrate (isocaloric to whey)
219315498|NCT06096389|DIETARY_SUPPLEMENT|House cricket supplementation|Consume defatted house cricket powder based on subjects' daily protein intake
219315499|NCT06686693|DRUG|Injectafer|Injectafer - 15 mg/kg up to 1000 mg
219315500|NCT06686693|OTHER|Placebo|Placebo
219315501|NCT03187210|DRUG|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
219315502|NCT03187210|DRUG|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
219315503|NCT07019519|OTHER|Saline/Placebo|NaCl(9mg/ml)
219315504|NCT07019519|OTHER|GIPR antagonist|GIP(3-30)NH2
219315505|NCT07019519|OTHER|GLP-1R antagonist|GLP-1(9-39)NH2
219315506|NCT07019519|OTHER|CCK agonist|CCK-8
219315507|NCT07020286|PROCEDURE|Structural heart interventions|The study allows us to understand the trend of transcatheter interventions in structural heart disease, clinical outcomes and allows the comparison of the outcomes of structural heart interventions to medical therapy and surgery at PWH, and to HA hospitals.
219315508|NCT07020169|PROCEDURE|an AI-based real-time image-guided kidney model system|Use the AI-model to locate kidney and tumour, assisting surgeon with the operation
219315509|NCT06452186|DEVICE|direct EMG controlled prosthetic ankle|Patients are trained to use the powered prosthetic ankles
219315510|NCT06452186|BEHAVIORAL|PT guided prosthetic training|Amputees are trained to use prosthetic ankles
219315511|NCT07019298|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling.
219315512|NCT07019298|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
219315513|NCT07019298|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
219315514|NCT07019298|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability.
219315515|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
219315516|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
219315517|NCT04600791|DEVICE|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
219315518|NCT03516461|PROCEDURE|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
219315519|NCT06713811|OTHER|Telemonitoring|Cureety is a digital telemonitoring platform specially designed to monitor cancer patients through self-reporting of adverse events. It supports patients and medical teams to complement existing care practices.
219315520|NCT05414032|BIOLOGICAL|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
219315521|NCT04730882|DIETARY_SUPPLEMENT|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
219315522|NCT03024853|BEHAVIORAL|BPS PAST|
219315523|NCT03024853|BEHAVIORAL|BPS PRESENT|
219315524|NCT03024853|BEHAVIORAL|BPS FUTURE|
219315525|NCT03024853|BEHAVIORAL|CONTROL|
219315526|NCT06334302|OTHER|"Omega Galil Hazelnut Chocolate Spread O'Sweet Spread"|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
219315527|NCT06334302|OTHER|Active Control-Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
219745424|NCT03196089|PROCEDURE|Oxygen application|Supplemental oxygen via mask
219315528|NCT06181136|DRUG|DNL126|intravenous repeating dose
219315529|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
219315530|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
219315531|NCT06439056|DRUG|NEX-22A, a prolonged release formulation of liraglutide|NEX-22A, a prolonged release formulation of liraglutide
219315532|NCT05648825|DEVICE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
219315533|NCT06678659|DRUG|REC-1245|Oral
219315534|NCT06317285|DRUG|GSK3915393|GSK3915393 will be administered.
219315535|NCT06317285|DRUG|Placebo|Placebo will be administered.
219315536|NCT06819956|DRUG|Ketorolac|Ketorolac 15 mg IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The ketorolac will be diluted in a 0.9% normal saline 10 mL syringe.
219315537|NCT06819956|DRUG|Placebo|Matching placebo IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The matching placebo will be diluted in a 0.9% normal saline 10 mL syringe.
219315538|NCT06060717|DEVICE|F&P Caramel|Nasal mask
219315539|NCT06831383|BEHAVIORAL|STOP-HPV-Online|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.
219315540|NCT06831383|BEHAVIORAL|STOP-HPV-LC|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.
219315541|NCT02935257|BIOLOGICAL|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
219315542|NCT03882229|DEVICE|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
219315543|NCT06089421|OTHER|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
219315544|NCT06089421|OTHER|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
219315545|NCT06030570|OTHER|Rehabilitation program (Revita)|Multidisciplinary programs in an outpatient hospital setting are coordinated by specialists in Physical and Rehabilitation Medicine. These programs combine a physical part (e.g., specific exercises, manual techniques) with at least one other element (psychological, social, educational or occupational intervention). In a multidisciplinary spine rehabilitation program, a maximum of 36 sessions over a maximum time period of 6 months is offered. Afterwards, a (monodisciplinary) follow-up trajectory (K15) is possible, consisting of maximum 104 sessions a year.
219315546|NCT04750928|DRUG|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
219315547|NCT06146621|BEHAVIORAL|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
219315548|NCT06146621|BEHAVIORAL|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
219745425|NCT05841771|DRUG|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
219745426|NCT05841771|DRUG|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
219745427|NCT06185803|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
219745428|NCT06335706|BEHAVIORAL|Fit of underpants worn|Tight or loose-fitted underpants
219745429|NCT00257933|DRUG|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
219745430|NCT00257933|DRUG|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
219745431|NCT06127771|OTHER|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
219745432|NCT00532415|DRUG|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
219745433|NCT02821650|OTHER|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
219745434|NCT01627106|DRUG|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
219745435|NCT01627106|DRUG|Amiodarone|Administered IV as per product label
219745436|NCT02298946|DRUG|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
219745437|NCT02298946|RADIATION|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
219745438|NCT02298946|DRUG|Cyclophosphamide|200mg/m(2) IV on day 0.
219745439|NCT02510274|DRUG|ASP3325|oral
219745440|NCT03847818|DRUG|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
219745441|NCT03044899|PROCEDURE|All surgeries in adult patients|All surgeries in adult patients
219745442|NCT01514578|DRUG|TRV130A|Intravenous infusion of 1 hour duration
219745443|NCT01514578|DRUG|Dextrose in Water|Intravenous infusion of 1 hour duration
219745444|NCT05933603|DRUG|Atomoxetine and Oxybutynin (ato-oxy)|0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
219745445|NCT02019836|OTHER|Determining maternal and neonatal vitamin D levels|
219745446|NCT00140920|DRUG|MK0966; rofecoxib|
219745447|NCT00140920|DRUG|Comparator: diclofenac 2x 75 mg|
219745448|NCT06215157|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
219745449|NCT06215157|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
219745450|NCT05767086|DRUG|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
219745451|NCT05767086|DRUG|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
219315549|NCT06146621|BEHAVIORAL|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
219315550|NCT06146621|BEHAVIORAL|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
219745452|NCT05767086|DRUG|Dydrogesterone|clinical pregnancy rates
219745453|NCT06641661|DRUG|Hybutimibe 10mg QD|Hybutimibe was added to the conventional treatment
219745454|NCT04102566|DRUG|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
219745455|NCT04102566|BEHAVIORAL|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
219745456|NCT04476147|OTHER|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
219745457|NCT01549015|OTHER|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
219745458|NCT03589833|DRUG|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
219745459|NCT03589833|DRUG|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
219745460|NCT03589833|DRUG|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
219745461|NCT05881798|DEVICE|Celect Platinum Vena Cava Filter|Inferior vena cava filter
219745462|NCT05467098|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
219745463|NCT05144737|BEHAVIORAL|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
219745464|NCT04769986|BEHAVIORAL|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
219745465|NCT04769986|BEHAVIORAL|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
219745466|NCT03285893|OTHER|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
219745467|NCT06384625|OTHER|AIRWISE|AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education) utilizes personal air cleaners (PACs) to filter indoor air, while enhanced aspects focus on improving compliance to PAC use. Key components include low-cost sensors (PurpleAir, Inc, USA) that change color according to air quality index (AQI) and behavioral recommendations that correspond to varying AQI levels.
219745468|NCT05299424|DRUG|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745469|NCT05299424|DRUG|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745470|NCT05299424|DRUG|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745471|NCT05299424|DRUG|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745472|NCT05299424|DRUG|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219315551|NCT06120881|DRUG|Metformin|Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
219315552|NCT02316314|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
219315553|NCT02316314|PROCEDURE|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
219315554|NCT02316314|PROCEDURE|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
219315555|NCT02316314|PROCEDURE|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
219315556|NCT03470675|DRUG|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
219315557|NCT03470675|DRUG|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
219315558|NCT03470675|DRUG|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
219315559|NCT05798403|DEVICE|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
219315560|NCT05798403|DRUG|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
219315561|NCT04993690|DRUG|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
219315562|NCT05668338|DEVICE|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
219315563|NCT04354246|DRUG|Dose escalation: COM902 monotherapy.|COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
219315564|NCT04354246|COMBINATION_PRODUCT|Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)|Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
219315565|NCT04354246|DRUG|Cohort expansion: COM902 (RDFE) monotherapy.|COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
219315566|NCT04354246|DRUG|Cohort expansion: COM902 in combination with COM701 (both at the RDFE).|COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
219315567|NCT04354246|COMBINATION_PRODUCT|Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.|Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
219315568|NCT06243458|DRUG|RVU120 (SEL120)|RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
219315569|NCT02445222|GENETIC|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
219315570|NCT05333458|BIOLOGICAL|Atezolizumab|Given IV
219315571|NCT05333458|PROCEDURE|Biopsy Procedure|Undergo biopsy
219315572|NCT05333458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219315573|NCT05333458|PROCEDURE|Computed Tomography|Undergo CT
219315574|NCT05333458|PROCEDURE|Echocardiography Test|Undergo ECHO
219315575|NCT05333458|DRUG|Selinexor|Given PO
219315576|NCT04720157|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
219315577|NCT04720157|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
219315578|NCT04720157|DRUG|ARDT|Administered orally on a continuous basis as per package insert and guideline
219315579|NCT04720157|DRUG|ADT|ADT are administered as per physician order
219315580|NCT06007924|DRUG|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
219315581|NCT06007924|DRUG|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
219315582|NCT05847426|OTHER|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
219315583|NCT05847426|OTHER|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
219315584|NCT06551324|DRUG|PF-06821497|875 mg BID (2 times a day)
219315585|NCT06551324|DRUG|Docetaxel|75 mg/m2 IV (every 21 days)
219315586|NCT06551324|DRUG|Enzalutamide|160 mg QD
219315587|NCT06101329|DRUG|Lenacapavir Tablet|Tablets administered orally without regard of food
219315588|NCT06101329|DRUG|Lenacapavir Injection|Injection administered subcutaneously
219315589|NCT06101329|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
219315590|NCT05594563|DRUG|DFMO|DFMO orally twice a day
219315591|NCT05594563|DRUG|Placebo|Placebo orally twice a day
219315592|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
219315593|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
219315594|NCT04596384|OTHER|Best Practice|Participate in a surgeon-only perioperative care program
219315595|NCT04596384|PROCEDURE|Functional Assessment|Complete a functional assessment
219315596|NCT04596384|OTHER|Medical Device Usage and Evaluation|Wear an actigraph
219315597|NCT04596384|PROCEDURE|Nutritional Assessment|Complete a nutritional assessment
219315598|NCT04596384|OTHER|Quality-of-Life Assessment|Ancillary studies
219315599|NCT04596384|OTHER|Questionnaire Administration|Ancillary studies
219315600|NCT04596384|OTHER|TapCloud|Use TapCloud app
219315601|NCT05934786|BEHAVIORAL|Cognitive rehabilitation|Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
219315602|NCT06188481|OTHER|whole-body electromyostimulation training|The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.
219315603|NCT06188481|OTHER|activity tracker|Participants wear the activity tracker on their wrist for the entire 16-week study period.
219315604|NCT06188481|OTHER|evidence-based lifestyle education program|Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).
219315605|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
219315606|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
219315607|NCT05684068|PROCEDURE|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
219315608|NCT05684068|PROCEDURE|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
219315609|NCT04751656|BEHAVIORAL|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
219315610|NCT05945641|BEHAVIORAL|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,
219315611|NCT05945641|BEHAVIORAL|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
219315612|NCT04244487|PROCEDURE|laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation|"The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm."
219315613|NCT04960423|PROCEDURE|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
219315614|NCT03566810|DRUG|Test GXR|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
219315615|NCT03566810|DRUG|Reference GXR|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
219315616|NCT03217266|DRUG|Navtemadlin|Given PO
219315617|NCT03217266|RADIATION|Radiation Therapy|Undergo radiation therapy
219315618|NCT03217266|PROCEDURE|Surgical Procedure|Undergo surgery
219315619|NCT00301522|DEVICE|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
219315620|NCT00301522|DEVICE|Express2|Coronary Stent System
219315621|NCT04694508|DEVICE|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
219315622|NCT00164125|DRUG|polyethyleneglycol3350|
219354736|NCT04607083|DIAGNOSTIC_TEST|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
219354737|NCT00435968|DRUG|CVT E002 (Cold-fX)|
219354738|NCT06961357|DRUG|Cyclophosphamide|Part of lymphodepletion regimen.
219745473|NCT05299424|DRUG|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745474|NCT05299424|DRUG|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745475|NCT05299424|DRUG|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745476|NCT05299424|DRUG|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745477|NCT05299424|DRUG|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745478|NCT05299424|DRUG|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745479|NCT05299424|DRUG|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745480|NCT05299424|DRUG|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745481|NCT05299424|DRUG|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
219745482|NCT05299424|DRUG|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
219745483|NCT04046991|DEVICE|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
219745484|NCT04046991|BEHAVIORAL|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
219745485|NCT04235062|DRUG|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
219745486|NCT04235062|DRUG|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
219745487|NCT02456883|DRUG|gilteritinib|oral
219745488|NCT02456883|DRUG|14C-labeled gilteritinib|oral
219745489|NCT00059267|DRUG|HBIG, Epivir, Hepsera|
219745490|NCT06565663|BEHAVIORAL|MaPGAS Decision Aid|This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
219745491|NCT05644132|DEVICE|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
219745492|NCT05475171|DRUG|Lorigerlimab|Given by vein (IV)
219745493|NCT06568393|OTHER|Calisthenic exercise|Calisthenic exercise program was included: jumping jack, burpee, mountain climber, squat thrust, squat, squat jump, split and alternate exercises.
219745494|NCT06541964|OTHER|Parent-Provide Distraction|The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.
219354739|NCT06961357|DRUG|Fludarabine|Part of lymphodepletion regimen.
219354740|NCT06961357|DRUG|Interleukin-2|Standard of care.
219315623|NCT04631627|DRUG|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
219315624|NCT01475604|DEVICE|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
219315625|NCT01475604|DEVICE|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
219315626|NCT05280951|OTHER|Focused-PPC Care|Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
219315627|NCT05280951|OTHER|Usual Care|Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
219315628|NCT01062048|DRUG|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
219315629|NCT01062048|DRUG|Sulfonylurea|Sulfonylurea administered in general use according to the local label
219315630|NCT01062048|BIOLOGICAL|Insulin|Insulin administered in general use according to the local label
219315631|NCT00955487|DRUG|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
219315632|NCT00955487|DRUG|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
219315633|NCT01686854|BEHAVIORAL|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
219315634|NCT01686854|OTHER|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
219315635|NCT03786250|PROCEDURE|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
219315636|NCT05808686|OTHER|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
219315637|NCT04158635|DRUG|Bosentan|Given PO
219315638|NCT04158635|DRUG|Gemcitabine|Given IV
219315639|NCT04158635|DRUG|Nab-paclitaxel|Given IV
219315640|NCT04158635|OTHER|Quality-of-Life Assessment|Ancillary studies
219315641|NCT04158635|OTHER|Questionnaire Administration|Ancillary studies
219315642|NCT05223114|OTHER|Not applicable (N/A)|Not applicable to this study
219315643|NCT00509665|DRUG|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
219315644|NCT00509665|DRUG|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
219315645|NCT01969591|PROCEDURE|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
219315646|NCT01969591|OTHER|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
219315647|NCT03878004|BIOLOGICAL|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
219315648|NCT03878004|BIOLOGICAL|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
219315649|NCT00584168|DRUG|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
219315650|NCT00584168|DRUG|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
219315651|NCT06140472|BEHAVIORAL|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
219315652|NCT06140472|BEHAVIORAL|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
219315653|NCT01955122|DEVICE|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
219315654|NCT05903339|DRUG|V3G CH848 Pr-NP1 60mcg|(60 mcg)
219315655|NCT05903339|DRUG|3M-052-AF 5mcg|(5 mcg)
219315656|NCT05903339|DRUG|Alum 500 mcg|(500 mcg)
219315657|NCT05903339|DRUG|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
219315658|NCT05903339|DRUG|ACU-026-001-1 2.0mg|(2.0 mg)
219315659|NCT05903339|DRUG|V3G CH848 Pr-NP1 100mcg|(100 mcg)
219315660|NCT05737199|DRUG|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
219315661|NCT05452811|PROCEDURE|Burch colposuspension|Anti-incontinence surgery for stress urinary incontinence
219315662|NCT00826111|DRUG|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
219315663|NCT00826111|DRUG|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
219315664|NCT01672788|DRUG|Empagliflozin|empagliflozin tablets and metformin tablet
219315665|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
219315666|NCT01672788|DRUG|Metformin|empagliflozin tablets and metformin tablet
219315667|NCT01672788|DRUG|Metformin|empagliflozin tablet and metformin tablet
219315668|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
219315669|NCT01672788|DRUG|Empagliflozin|empagliflozin tablet and metformin tablet
219315670|NCT04229953|DEVICE|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
219315671|NCT04699734|DIAGNOSTIC_TEST|Xylocaine 1%|Nerve block
219315672|NCT04699734|DIAGNOSTIC_TEST|NaCl 9mg/ml|Nerve block
219315673|NCT04219813|OTHER|Urinary test|Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
219315674|NCT02445196|BEHAVIORAL|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
219315675|NCT02445196|DEVICE|Smartphone|All participants must have a smartphone, either apple or android.
219315676|NCT01728220|COMBINATION_PRODUCT|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
219315677|NCT01728220|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
219315678|NCT00261612|DRUG|bortezomib|
219315679|NCT00261612|DRUG|rituximab|
219315680|NCT00261612|DRUG|dexamethasone|
219315681|NCT00261612|PROCEDURE|treatment protocol|
219315682|NCT05765006|BIOLOGICAL|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
219315683|NCT01782365|DEVICE|SHAM stimulation|no stimulation
219315684|NCT01782365|DEVICE|0,75 Hz stimulation|
219315685|NCT00112931|BIOLOGICAL|rituximab|
219315686|NCT00112931|OTHER|No treatment|
219315687|NCT01099163|DIETARY_SUPPLEMENT|Tonalin SG1000T FFA|
219315688|NCT01910909|RADIATION|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
219315689|NCT01837069|DRUG|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
219315690|NCT01837069|DRUG|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
219315691|NCT01837069|DRUG|Atorvastatin|80mg PO QD at preadmission testing
219315692|NCT01837069|BEHAVIORAL|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
219315693|NCT03874325|DRUG|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
219315694|NCT03874325|DRUG|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
219315695|NCT03874325|DRUG|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
219315696|NCT03874325|DRUG|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
219315697|NCT05149183|OTHER|cervical stability training|cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
219315698|NCT05149183|OTHER|traditional treatment|TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
219315699|NCT03930147|PROCEDURE|ASV ventilation|Ventilation on ASV mode
219315700|NCT04968197|DEVICE|Vestibular Intervention via Portable Electrical Stimulator (VIPES) system|A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
219315701|NCT00234507|BIOLOGICAL|Botulinum toxin type A|
219315702|NCT06083922|DRUG|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
219315703|NCT06083922|DRUG|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
219315704|NCT06083922|DRUG|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
219315705|NCT06083922|DRUG|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
219315706|NCT01733342|DEVICE|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
219315707|NCT01733342|PROCEDURE|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
219315708|NCT01733342|DEVICE|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
219315709|NCT04586595|OTHER|REVISiT intervention|REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
219315710|NCT03873766|DRUG|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
219315711|NCT03873766|PROCEDURE|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
219315712|NCT03873766|PROCEDURE|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
219315713|NCT03873766|PROCEDURE|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (\>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
219315714|NCT03873766|RADIATION|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
219354741|NCT06961357|DRUG|TIL Product|Tumor-infiltrating lymphocytes are an investigational, personalized adoptive cell therapy.
219354742|NCT06032949|OTHER|Vialize|Any patients undergoing surgeries involving a groin incision (e.g., femoropopliteal bypass, aortofemoral bypass, loop thigh graft, femoral exposure for delivery of device) will receive Vialize subcutaneously.
219354743|NCT05006885|DRUG|ALT-801|Injected subcutaneously (SC)
219315715|NCT03873766|OTHER|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
219315716|NCT03873766|RADIATION|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
219315717|NCT03873766|BEHAVIORAL|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
219315718|NCT06617494|OTHER|Pain modulation testing|During the visit, noxious heat stimuli will be applied bilaterally to the face and distant body sites as part of conditioned pain modulation (CPM) testing. The test stimuli will be individually tailored to be moderately painful, while the conditioning stimulus will vary in intensity: moderately painful, non-painful, and sham heat. Participants will also record daily TMD pain intensity ratings for seven days before and after the visit.
219315719|NCT01805596|DRUG|clopidogrel|
219315720|NCT01805596|DRUG|Ticagrelor|
219315721|NCT05048953|DIAGNOSTIC_TEST|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~1. Muscle thickness~2. Muscle echogenicity~3. Muscle fasciculations"
219315722|NCT03511053|PROCEDURE|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
219315723|NCT03985475|OTHER|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
219315724|NCT02877563|OTHER|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
219354744|NCT05006885|OTHER|Placebo|Injected subcutaneously (SC)
219354745|NCT05564065|PROCEDURE|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
219354746|NCT05564065|PROCEDURE|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
219315725|NCT01128361|BEHAVIORAL|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
219315726|NCT01128361|BEHAVIORAL|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
219315727|NCT00626704|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
219315728|NCT00626704|OTHER|Placebo|Inactive dummy AMG 655 (to maintain blind)
219315729|NCT00626704|DRUG|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
219315730|NCT00910351|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
219315731|NCT06678555|DRUG|Lorlatinib|Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.
219315732|NCT03157505|DRUG|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
219315733|NCT03157505|OTHER|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
219315734|NCT01929980|DRUG|Bortezomib|
219315735|NCT03030170|DEVICE|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
219315736|NCT03030170|DEVICE|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
219315737|NCT03368911|DEVICE|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
219315738|NCT03368911|DEVICE|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
219315739|NCT01721005|OTHER|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
219315740|NCT00649090|DRUG|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
219315741|NCT00985166|BIOLOGICAL|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
219315742|NCT00985166|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
219315743|NCT00985166|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
219315744|NCT00985166|BIOLOGICAL|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
219315745|NCT06785818|OTHER|Tisagenlecleucel|This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.
219315746|NCT04973878|PROCEDURE|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
219315747|NCT04973878|PROCEDURE|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
219315748|NCT02765607|PROCEDURE|Heart surgery|
219315749|NCT02523053|PROCEDURE|Hepatectomy|Surgical removal of all lesions
219315750|NCT02523053|DRUG|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
219315751|NCT02855424|OTHER|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
219315752|NCT02855424|OTHER|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
219315753|NCT05241275|DRUG|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
219315754|NCT02915471|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
219315755|NCT04007510|COMBINATION_PRODUCT|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
219315756|NCT04007510|DIAGNOSTIC_TEST|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
219315757|NCT04239716|OTHER|regional anesthesia|combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
219315758|NCT04025723|OTHER|Downhill running|60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
219315759|NCT02732054|BIOLOGICAL|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
219315760|NCT05933330|OTHER|Brain MRI|All included patients receive an MRI of the brain
219315761|NCT01580280|OTHER|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
219315762|NCT01580280|OTHER|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
219315763|NCT03509233|OTHER|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
219315764|NCT03509233|OTHER|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
219315765|NCT03509233|OTHER|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
219315766|NCT03509233|OTHER|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
219315767|NCT04703478|OTHER|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
219315768|NCT02532153|DRUG|Ketamine Hydrochloride|Single open-label infusions
219315769|NCT01028222|DRUG|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
219315770|NCT01028222|DRUG|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
219315771|NCT02235974|BEHAVIORAL|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
219315772|NCT02235974|BEHAVIORAL|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
219315773|NCT02235974|BEHAVIORAL|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
219315774|NCT02235974|BEHAVIORAL|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
219315775|NCT05573087|OTHER|Aquatic Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
219315776|NCT05573087|OTHER|Land Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
219315777|NCT06296134|BEHAVIORAL|perineal massage|"women affected by LAM co-activation allocated to the intervention perineal massage are asked to perform the perineal massage once daily from 34 gestational weeks until delivery. Women are trained to correctly perform the perineal massage at 30 gestaitonal weeks."
219315778|NCT00679588|DRUG|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219315779|NCT00679588|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219315780|NCT00679588|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
219315781|NCT04393051|DRUG|Baricitinib Oral Tablet|Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
219315782|NCT04745767|DRUG|TAK-994|T2 formulation.
219315783|NCT04745767|DRUG|TAK-994|T1 formulation.
219315784|NCT04745767|DRUG|TAK-994|T3 formulation.
219315785|NCT04745767|DRUG|TAK-994|T4 formulation.
219315786|NCT04745767|DRUG|TAK-994|T5 formulation.
219315787|NCT04903808|DRUG|Allium Sativum Oil|Garlic oil Captain Company (CAP-PHARM)
219315788|NCT04903808|DRUG|Mineral Tri-Oxide Aggregate|ProRoot MTA, Dentsply
219315789|NCT05330637|OTHER|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
219315790|NCT02558933|DIETARY_SUPPLEMENT|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
219315791|NCT03903874|BEHAVIORAL|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
219315792|NCT06383026|DIAGNOSTIC_TEST|Breast Cancer Screening|Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
219315793|NCT06383026|OTHER|Survey/Interview|A mixed-methods approach including electronic surveys and one on one interviews.
219315794|NCT06383026|OTHER|Focus Group|A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.
219315795|NCT03513510|BEHAVIORAL|iChoose|
219315796|NCT02685670|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
219315797|NCT02685670|DRUG|Fludarabine|
219315798|NCT02685670|DRUG|Cyclophosphamide|
219315799|NCT00647322|OTHER|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
219315800|NCT00647322|PROCEDURE|No drug change|No change in anti-epileptic treatment
219315801|NCT02477579|DEVICE|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
219315802|NCT04697264|DIAGNOSTIC_TEST|Blood and tissue sample collection from patients|Blood and tissue sample (endometrial and adipose tissue) collection from endometrial cancer patients. Blood from all control patients, endometrial sample from benign patients having surgery for benign gynaecological conditions.
219315803|NCT03840850|OTHER|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
219315804|NCT04162925|BEHAVIORAL|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
219315805|NCT04556643|OTHER|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
219315806|NCT01257789|PROCEDURE|laparoscopic gastric bypass|laparoscopic gastric bypass
219315807|NCT00146328|DRUG|Tipranavir|
219315808|NCT05781919|OTHER|Immersive virtual reality imaging|Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
219315809|NCT05781919|OTHER|Gold standard imaging|Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
219315810|NCT04722523|DRUG|Cisplatin|Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8
219315811|NCT04722523|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 2, 5, and 8
219315812|NCT04722523|DRUG|Docetaxel|Docetaxel 75mg/m2 on weeks 2, 5, and 8
219315813|NCT04722523|DRUG|Cetuximab|Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10
219315814|NCT04722523|DRUG|Cemiplimab|Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37
219315815|NCT04722523|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
219315816|NCT04722523|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of \>0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines \[2\]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
219315817|NCT04722523|DRUG|Paclitaxel|If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
219315818|NCT00300781|DRUG|neratinib|
219315819|NCT02715167|DRUG|Budesonide novolizer|
219315820|NCT02715167|DRUG|Placebo|
219315821|NCT05813717|DRUG|BMS-986325|Specified dose on specified days
219315822|NCT05813717|DRUG|Placebo|Specified dose on specified days
219315823|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
219315824|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
219315825|NCT05202717|DEVICE|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
219315826|NCT05202717|DEVICE|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
219315827|NCT02410941|BEHAVIORAL|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
219315828|NCT05039398|BEHAVIORAL|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
219315829|NCT05039398|BEHAVIORAL|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
219315830|NCT05039398|BEHAVIORAL|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
219315831|NCT02702622|OTHER|Provitamin A-biofortified transgenic bananas|
219315832|NCT00732628|DEVICE|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
219315833|NCT04100395|DEVICE|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
219315834|NCT01351012|OTHER|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
219315835|NCT01351012|OTHER|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
219315836|NCT01351012|OTHER|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
219315837|NCT01351012|OTHER|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
219315838|NCT01351012|OTHER|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
219315839|NCT02072434|DRUG|Edoxaban|Edoxaban 30 mg tablets for oral administration
219315840|NCT02072434|DRUG|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
219315841|NCT02072434|DRUG|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
219315842|NCT02964637|OTHER|Observational Study|
219315843|NCT00120913|DRUG|Birth control pills|
219315844|NCT00253487|DRUG|O6-benzylguanine|
219315845|NCT00253487|DRUG|busulfan|
219315846|NCT00253487|DRUG|temozolomide|
219315847|NCT00253487|PROCEDURE|adjuvant therapy|
219315848|NCT00253487|PROCEDURE|autologous bone marrow transplantation|
219315849|NCT00253487|PROCEDURE|conventional surgery|
219315850|NCT00253487|PROCEDURE|peripheral blood stem cell transplantation|
219315851|NCT00253487|RADIATION|radiation therapy|
219315852|NCT03711890|PROCEDURE|Optical Coherence Tomography|Undergo OCT
219315853|NCT03711890|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection will be undertaken
219315854|NCT03711890|DIAGNOSTIC_TEST|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
219315855|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CBF|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
219315856|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CSP|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
219315857|NCT06046911|OTHER|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
219315858|NCT06046911|OTHER|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
219315859|NCT01726452|DRUG|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
219315860|NCT01726452|DRUG|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
219315861|NCT01726452|DRUG|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
219315862|NCT01726452|RADIATION|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
219315863|NCT01726452|DRUG|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
219315864|NCT01726452|DRUG|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
219315865|NCT01726452|DRUG|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
219745495|NCT06541964|OTHER|Windmill Toy Blowing|The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
219315866|NCT01726452|DRUG|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
219745496|NCT06541964|OTHER|Control|No intervention will make on the children.
219745497|NCT05360602|DIETARY_SUPPLEMENT|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
219315867|NCT01726452|DRUG|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
219315868|NCT01726452|DRUG|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
219315869|NCT03904745|DRUG|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
219315870|NCT00227565|DRUG|carboplatin|
219315871|NCT00227565|DRUG|pemetrexed disodium|
219315872|NCT00227565|RADIATION|radiation|
219315873|NCT03786159|OTHER|No intervention|No intervention
219315874|NCT02261038|OTHER|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
219315875|NCT00181584|DRUG|Zoledronic acid|Given intravenously once.
219315876|NCT00181584|OTHER|Placebo|Given intravenously once.
219315877|NCT01768897|DRUG|CPI-613|Given IV
219315878|NCT01768897|DRUG|cytarabine|Given IV
219315879|NCT01768897|DRUG|mitoxantrone hydrochloride|Given IV
219315880|NCT01768897|OTHER|laboratory biomarker analysis|Optional correlative studies
219315881|NCT01768897|OTHER|pharmacological study|Correlative studies
219745498|NCT05360602|DRUG|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
219745499|NCT04629196|DRUG|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
219745500|NCT04629196|DRUG|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
219745501|NCT04629196|DRUG|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
219745502|NCT03792737|DEVICE|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
219745503|NCT03792737|DEVICE|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
219745504|NCT03792737|DEVICE|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
219745505|NCT03792737|DEVICE|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
219745506|NCT03792737|DEVICE|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
219745507|NCT06189612|OTHER|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
219745508|NCT06189612|OTHER|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
219745509|NCT06189612|OTHER|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
219315882|NCT01468220|OTHER|Endurance training|Endurance training three times per week over six weeks
219315883|NCT03670706|BEHAVIORAL|Exercise|Package of care
219315884|NCT03670706|OTHER|analgesic optimisation|optimisation
219315885|NCT02423304|GENETIC|blood samples collected from all patients|blood samples collected from brachial pluxes
219315886|NCT03459599|DRUG|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
219315887|NCT03459599|OTHER|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
219315888|NCT06010498|BEHAVIORAL|eye mask|"* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
219315889|NCT06010498|BEHAVIORAL|standart care|"Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
219354747|NCT04957134|DEVICE|Electro-acupuncture|The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
219745510|NCT05572073|OTHER|Natural History Study|Natural History Study
219745511|NCT01450631|DEVICE|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
219745512|NCT01450631|DEVICE|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
219745513|NCT04738266|DIAGNOSTIC_TEST|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
219745514|NCT02333292|DRUG|Telaprevir|Initiation of a regimen containing TVR
219745515|NCT02333292|DRUG|Boceprevir|Initiation of a regimen containing BOC
219745516|NCT02333292|DRUG|Sofosbuvir|Initiation of a regimen containing SOF
219745517|NCT02333292|DRUG|Simeprevir|Initiation of a regimen containing SMV
219745518|NCT02333292|DRUG|Daclatasvir|Initiation of a regimen containing DCV
219745519|NCT02333292|DRUG|Ledipasvir|Initiation of a regimen containing LDV
219745520|NCT02333292|DRUG|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
219745521|NCT02333292|DRUG|Dasabuvir|Initiation of a regimen containing DBV
219745522|NCT02333292|DRUG|Velpatasvir|Initiation of a regimen containing VPV
219745523|NCT02333292|DRUG|Elbasvir|Initiation of a regimen containing EBV
219745524|NCT02333292|DRUG|Grazoprevir|Initiation of a regimen containing GZR
219745525|NCT00835354|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
219745526|NCT00835354|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
219745527|NCT04450550|DEVICE|VeNS device|VeNS treatment
219745528|NCT04450550|DEVICE|Sham VeNS device|Sham treatment of VeNS
219745529|NCT05478265|DEVICE|RS-4i Plus|RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
219745530|NCT04766684|DEVICE|J-Tip with Xylocaine MPF with placebo cream|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream
219745531|NCT04766684|DRUG|L.M.X.4 cream with J-Tip saline injection|L.M.X.4 cream with J-Tip saline injection
219745532|NCT04194697|BEHAVIORAL|Exercise|Exercise program
219745533|NCT04194697|BEHAVIORAL|No exercise|No exercise program
219745534|NCT06568575|BEHAVIORAL|experiment of music|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
219745535|NCT06568575|BEHAVIORAL|experiment of exercise|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
219745536|NCT06559241|DEVICE|14-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.
219745537|NCT06559241|DEVICE|30-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.
219745538|NCT06559241|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.
219745539|NCT06559241|DRUG|Best medical management|Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
219745540|NCT02106546|DRUG|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
219745541|NCT02106546|DRUG|Veliparib|Capsules taken orally twice a day, 12 hours apart.
219745542|NCT02106546|DRUG|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
219745543|NCT02106546|DRUG|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
219745544|NCT03110510|DRUG|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
219315890|NCT03803501|OTHER|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
219315891|NCT06560294|DRUG|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
219315892|NCT06560294|OTHER|Glue embolization|Patients will receive transcatheter glue embolization.
219315893|NCT03312348|DEVICE|Infrared imaging|Infrared image image acquisition of study participants
219315894|NCT03549000|OTHER|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
219315895|NCT03549000|OTHER|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
219315896|NCT03549000|DRUG|NIR178|NIR178 Specified dose on specified days, Orally
219315897|NCT06528210|DRUG|Gonadotropin Releasing Hormone Agonists and Antagonists|Given PO, IM, Sub-Q injection or Sub-Q implant
219315898|NCT06528210|DRUG|Bicalutamide|Given PO
219315899|NCT06528210|PROCEDURE|Biopsy Procedure|Undergo prostate biopsy
219315900|NCT06528210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219315901|NCT06528210|PROCEDURE|Computed Tomography|Undergo CT scan
219315902|NCT06528210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219315903|NCT06528210|BIOLOGICAL|Pembrolizumab|Given IV
219315904|NCT06528210|OTHER|Questionnaire Administration|Ancillary study
219315905|NCT06528210|RADIATION|Radiation Therapy|Undergo radiation therapy
219315906|NCT06528210|PROCEDURE|Bone Scan|Undergo bone scan
219315907|NCT04954820|DRUG|Lutathera|2 additional infusions of Lutathera®
219315908|NCT06313528|DRUG|LY3437943|Administered SC
219315909|NCT06313528|OTHER|Placebo|Administered SC
219315910|NCT06452654|DRUG|Comirnaty Injectable Product|Vaccination
219315911|NCT06452654|DRUG|Sodium Chloride 0.9% Inj|Vaccination
219315912|NCT06675357|RADIATION|FAPI|5 +/- 2 mCi of Ga-FAPI-46
219315913|NCT06675357|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
219315914|NCT06675357|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
219315915|NCT06490432|DEVICE|Transient elastography|Device that measures stiffness of liver tissue
219315916|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
219315917|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
219315918|NCT03681197|DRUG|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
219315919|NCT03681197|DRUG|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
219315920|NCT03681197|DRUG|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
219315921|NCT03289897|DIAGNOSTIC_TEST|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
219315922|NCT01410136|PROCEDURE|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
219354748|NCT04957134|DEVICE|Sham electro-acupuncture|The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
219745545|NCT03110510|DRUG|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
219745546|NCT03110510|DRUG|leucovorin calcium|Leucovorin 200 mg/m2
219745547|NCT03204812|BIOLOGICAL|Durvalumab|Given IV
219745548|NCT03204812|BIOLOGICAL|Tremelimumab|Given IV
219745549|NCT02399852|DRUG|Lomitapide|
219745550|NCT03990987|OTHER|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
219745551|NCT06560736|BEHAVIORAL|Show Me FIRST coping skills intervention|Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
219745552|NCT05682677|DEVICE|iTBS|iTBS over the left dorsolateral prefrontal cortex
219745553|NCT05682677|DEVICE|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
219745554|NCT05682677|BEHAVIORAL|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
219745555|NCT06106568|PROCEDURE|EOB-MRI|Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
219745556|NCT06106568|PROCEDURE|Surgery|Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
219745557|NCT06106568|PROCEDURE|Open-close Laparotomy|Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
219745558|NCT05003700|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
219315923|NCT05104008|OTHER|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
219315924|NCT05104008|OTHER|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
219315925|NCT02029820|DEVICE|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
219315926|NCT05968287|DIAGNOSTIC_TEST|The Leukocyte ImmunoTest™ (LIT™)|The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
219315927|NCT06079489|OTHER|Brochure-Based Exercise Program|Simple posture exercises
219315928|NCT06079489|OTHER|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
219315929|NCT05737966|OTHER|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
219315930|NCT05577078|PROCEDURE|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
219315931|NCT00701207|DRUG|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
219315932|NCT03696615|OTHER|Tabata Kettlebell Swing Workout|See description of experimental arm.
219315933|NCT03696615|OTHER|Control|see description of control arm
219315934|NCT00960960|DRUG|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
219315935|NCT00960960|DRUG|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
219315936|NCT00960960|DRUG|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
219315937|NCT00960960|DRUG|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
219315938|NCT00960960|DRUG|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
219315939|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
219315940|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
219315941|NCT02698969|DRUG|Sugammadex|
219315942|NCT02698969|DEVICE|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
219315943|NCT02698969|DRUG|Neostigmine|
219315944|NCT02698969|DRUG|Atropine|
219745559|NCT05003700|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
219745560|NCT05003700|DRUG|Camrelizumab|200mg intravenously every 3 weeks.
219745561|NCT05024786|OTHER|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
219745562|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
219745563|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
219745564|NCT01190371|DRUG|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
219745565|NCT03194529|BIOLOGICAL|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
219745566|NCT03340935|OTHER|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
219745567|NCT01432431|PROCEDURE|spiritual therapy|Undergo palliative spiritual care
219745568|NCT01432431|OTHER|questionnaire administration|Ancillary studies
219745569|NCT01432431|OTHER|survey administration|Ancillary studies
219745570|NCT01432431|OTHER|counseling intervention|Undergo palliative spiritual care
219745571|NCT01432431|OTHER|psychosocial support for caregiver|Undergo palliative spiritual care
219745572|NCT01432431|PROCEDURE|psychosocial assessment and care|Undergo palliative spiritual care
219745573|NCT04391608|DRUG|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
219745574|NCT01126398|PROCEDURE|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
219745575|NCT00337597|OTHER|Glucose 5%|
219745576|NCT00337597|OTHER|NaCl 0.9%|
219315945|NCT02698969|DEVICE|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
219315946|NCT02698969|DRUG|Rocuronium|Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
219315947|NCT02698969|DRUG|Fentanyl|Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
219315948|NCT02698969|DRUG|Propofol|Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia
219315949|NCT02698969|DRUG|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
219315950|NCT01570036|DRUG|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
219315951|NCT01570036|DRUG|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
219315952|NCT01570036|DRUG|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
219315953|NCT03426254|BIOLOGICAL|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
219315954|NCT03426254|DRUG|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
219315955|NCT00969878|DRUG|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
219315956|NCT00969878|OTHER|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
219315957|NCT00802425|DRUG|AM-111|single intratympanic injection
219315958|NCT00802425|DRUG|placebo|single intratympanic injection
219315959|NCT05561829|BEHAVIORAL|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
219315960|NCT05561829|BEHAVIORAL|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
219315961|NCT05561829|BEHAVIORAL|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
219315962|NCT05561829|BEHAVIORAL|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
219315963|NCT05561829|BEHAVIORAL|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
219315964|NCT02170389|OTHER|Laboratory Biomarker Analysis|Correlative studies
219315965|NCT02170389|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
219315966|NCT02170389|BIOLOGICAL|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
219315967|NCT00190632|DRUG|Duloxetine|
219315968|NCT04316208|PROCEDURE|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
219315969|NCT00171574|DRUG|Valsartan|
219315970|NCT00171574|DRUG|Valsartan plus HCTZ|
219315971|NCT00171574|DRUG|Lisinopril|
219315972|NCT04372407|DRUG|Surufatinib|Surufatinib: 200 mg as single dose on Days 1 and 9
219315973|NCT04372407|DRUG|Itraconazole|Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
219315974|NCT04242511|DIAGNOSTIC_TEST|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
219315975|NCT04780308|PROCEDURE|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
219315976|NCT05009745|PROCEDURE|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
219315977|NCT03149471|DIAGNOSTIC_TEST|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
219315978|NCT01409863|PROCEDURE|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
219315979|NCT01008696|DRUG|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
219315980|NCT01008696|DRUG|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
219315981|NCT03318705|DEVICE|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
219315982|NCT00506428|BEHAVIORAL|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
219315983|NCT01649570|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
219315984|NCT02610153|DRUG|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
219315985|NCT00016029|OTHER|screening questionnaire administration|
219315986|NCT00016029|PROCEDURE|barium enema injection|
219315987|NCT00016029|PROCEDURE|computed tomography|
219315988|NCT00016029|PROCEDURE|computed tomography colonography|
219315989|NCT00016029|PROCEDURE|diagnostic colonoscopy|
219315990|NCT00016029|PROCEDURE|screening colonoscopy|
219315991|NCT02929797|BIOLOGICAL|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
219315992|NCT02929797|DRUG|Gemcitabine|gemcitabine
219315993|NCT05178550|DRUG|Heparin|intravenous \[iv\] injection
219315994|NCT00285883|DRUG|Invirase|
219315995|NCT00285883|DRUG|Norvir|
219315996|NCT03265041|DIAGNOSTIC_TEST|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
219315997|NCT02960854|BIOLOGICAL|Nivolumab|Specified dose on specified days
219315998|NCT00122694|DRUG|carbon monoxide|
219315999|NCT06296875|DIETARY_SUPPLEMENT|Vegetable oil|mixed vegetable oil
219316000|NCT06296875|DIETARY_SUPPLEMENT|Krill oil|Krill oil
219316001|NCT00105950|DRUG|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
219316002|NCT04633707|DEVICE|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.
219316003|NCT04633707|DEVICE|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
219316004|NCT04633707|DEVICE|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
219354749|NCT02516748|BEHAVIORAL|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
219354750|NCT02479802|BIOLOGICAL|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~* three weeks of intensive treatment with two plasma exchanges per week~* twenty-one weeks of maintenance treatment with one weekly plasma exchange"
219316005|NCT05731050|DRUG|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
219316006|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
219316007|NCT06138132|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
219316008|NCT06138132|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
219316009|NCT04263909|DRUG|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
219316010|NCT04477330|OTHER|Transcranial direct current stimulation (tDCS)|1 mA tDCS
219316011|NCT04477330|OTHER|Ankle motor training|Visuomotor target tracking task
219316012|NCT04477330|BEHAVIORAL|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
219316013|NCT05173597|DRUG|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
219316014|NCT06506565|DRUG|Ketamine|Infusion during wound care
219316015|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
219316016|NCT06300957|OTHER|Help Wanted Prevention Intervention|"The intervention includes an introductory welcome place, five training sessions that deliver core intervention content, and a resources page that provides links to external sources of support.~The Help Wanted Prevention Intervention is a free, online, self-help course to address the needs of people with a sexual attraction to children. Help Wanted aims to provide knowledge, skills, and resources to support help-seekers' commitments to living safe, healthy, and fulfilling lives."
219316017|NCT06300957|OTHER|Waitlist Control|Participants will be provided with information on how to access alternative resources and help lines to support mental health, suicide prevention, and child sexual abuse prevention. After one month, they will be granted access to Help Wanted.
219316018|NCT06801886|DRUG|Silymarine supplementation|900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.
219316019|NCT06801886|OTHER|Placebo Supplementation|Placebo supplementation during the early post-transplant period (30 days) under standard treatment
219316020|NCT04288778|DRUG|Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
219316021|NCT03945747|DIAGNOSTIC_TEST|Blood draw|Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.
219316022|NCT03945747|DIAGNOSTIC_TEST|Urine sample collection|Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.
219316023|NCT03945747|DIAGNOSTIC_TEST|DXA scan|Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.
219316024|NCT02647294|DIETARY_SUPPLEMENT|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
219316025|NCT02647294|OTHER|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
219316026|NCT03963687|OTHER|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
219316027|NCT03963687|OTHER|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
219316028|NCT02624765|DRUG|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
219316029|NCT02624765|DRUG|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
219316030|NCT02624765|DRUG|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
219316031|NCT02624765|DRUG|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
219316032|NCT02624765|DRUG|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
219316033|NCT02624765|DRUG|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
219316034|NCT04557605|OTHER|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
219316035|NCT05058625|DEVICE|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
219316036|NCT05058625|OTHER|Control Group|Normal volleyball training
219316037|NCT05482152|BEHAVIORAL|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
219316038|NCT02215460|PROCEDURE|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219354751|NCT01882907|DRUG|vildagliptin|vildagliptin 50mg bid for 16 weeks
219316039|NCT02215460|PROCEDURE|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316040|NCT02215460|DRUG|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316041|NCT02215460|DRUG|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316042|NCT02215460|DRUG|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316043|NCT02215460|DRUG|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316044|NCT02215460|DRUG|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316045|NCT02215460|DRUG|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316046|NCT02215460|DRUG|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316047|NCT02215460|DRUG|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
219316048|NCT05987397|DRUG|idebenone 30 mg for 14 days|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
219316049|NCT05987397|DRUG|idebenone 30 mg for 3 months|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
219316050|NCT03118674|DRUG|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
219316051|NCT02690779|OTHER|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
219316052|NCT02690779|OTHER|Routine Care Instructions|patients will follow routine care and instructions
219354752|NCT01882907|DRUG|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
219316053|NCT01956656|DRUG|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
219316054|NCT04664010|DRUG|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
219316055|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
219316056|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
219354753|NCT01978093|BIOLOGICAL|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
219316057|NCT06494917|OTHER|pelvic floor exercises|First arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied.
219316058|NCT06494917|OTHER|Pelvic floor exercises and manual therapy techniques|Second arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied. In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods such as momentum minus mobilisation, sphincter opening, colon massage, global fascia manipulation, trigger point and myofascial release will be applied.
219316059|NCT05044026|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
219316060|NCT00800787|BIOLOGICAL|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly"
219316061|NCT02789527|DRUG|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
219316062|NCT02789527|GENETIC|Genotyping|DNA sampling from a saliva sample
219316063|NCT03864445|DRUG|KHK7791|oral administration
219316064|NCT03864445|DRUG|Placebp|oral administration
219316065|NCT04559204|BIOLOGICAL|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
219316066|NCT04559204|BIOLOGICAL|IIV4|administrated with IIV4 only
219316067|NCT04559204|BIOLOGICAL|PPV23|administrated with PPV23 only
219316068|NCT03135171|DRUG|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
219316069|NCT03135171|DRUG|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
219316070|NCT03135171|DRUG|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
219316071|NCT05303870|OTHER|Improving access to psychological therapies (IAPT)|"IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles:~1. Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes.~2. Appropriately trained and supervised workforce.~3. Routine outcome monitoring."
219316072|NCT01115842|DRUG|Vitamin D|Vitamin D 4000IU per day for 5 days
219354754|NCT01978093|BIOLOGICAL|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
219316073|NCT02615821|BEHAVIORAL|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
219316074|NCT04143399|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
219316075|NCT04143399|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
219316076|NCT03773198|OTHER|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
219316077|NCT03773198|OTHER|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
219316078|NCT02716467|OTHER|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
219316079|NCT02716467|RADIATION|Radiotherapy|All participants will receive treatment by radiotherapy
219316080|NCT03952494|GENETIC|Genomind®Professional PGx Express TM|The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
219316081|NCT02228655|DRUG|FMX-8|
219316082|NCT04395703|OTHER|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
219316083|NCT03841682|BEHAVIORAL|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
219316084|NCT03376607|OTHER|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
219316085|NCT03376607|BEHAVIORAL|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
219316086|NCT04496063|DRUG|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
219316087|NCT04496063|DRUG|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
219316088|NCT02807792|DEVICE|Perianal access device|Perianal access device
219316089|NCT00642382|DEVICE|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
219316090|NCT00642382|DEVICE|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
219316091|NCT02361151|BEHAVIORAL|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
219316092|NCT02361151|BEHAVIORAL|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
219316093|NCT01487031|OTHER|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
219316094|NCT01487031|OTHER|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
219316095|NCT01379391|DRUG|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
219316096|NCT03446729|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
219316097|NCT01414777|DRUG|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
219316098|NCT01414777|DRUG|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
219316099|NCT03622853|DRUG|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
219316100|NCT01087931|DRUG|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
219316101|NCT01087931|OTHER|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
219316102|NCT05021523|OTHER|Hot ambient conditions exposures|Participants rest or exercise for 40min to 1h daily in hot ambient conditions
219316103|NCT05021523|OTHER|Immobilization|Participants are wearing a walking boot (with crutches) for 2 weeks
219316104|NCT01067326|DRUG|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
219316105|NCT01067326|DRUG|Placebo|1 pill per day by mouth for 4 months
219316106|NCT02044211|BEHAVIORAL|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
219354755|NCT01978093|BIOLOGICAL|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
219354756|NCT01978093|BIOLOGICAL|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
219354757|NCT01978093|BIOLOGICAL|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
219316107|NCT02044211|BEHAVIORAL|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
219316108|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
219316109|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
219316110|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
219316111|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
219316112|NCT01207726|DRUG|Azacitidine|Given SC
219316113|NCT01207726|DRUG|Entinostat|Given PO
219316114|NCT01207726|OTHER|Laboratory Biomarker Analysis|Correlative studies
219316115|NCT06294522|PROCEDURE|reconstruction of alveolar cleft|after elevation of mucoperiosteal flap related to cleft side. suturing of nasal floor and palatal tissue. harvesting of autogenous graft and reconstruction of nasal floor and labial plate of cleft then suturing of flap labially without tension
219316116|NCT03851614|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
219316117|NCT03851614|DRUG|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
219316118|NCT03851614|DRUG|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
219316119|NCT02623881|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
219316120|NCT02623881|DRUG|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
219316121|NCT01174654|BEHAVIORAL|Contingency management|A 12-week contingency management intervention
219316122|NCT00000274|DRUG|Flupenthixol|
219316123|NCT00295360|BEHAVIORAL|no intervention, pathophysiological study|
219316124|NCT01230788|DRUG|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
219316125|NCT00714597|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219316126|NCT00714597|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
219316127|NCT02225496|PROCEDURE|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
219316128|NCT02225496|PROCEDURE|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
219316129|NCT02225496|BEHAVIORAL|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
219316130|NCT02092974|PROCEDURE|tDCS|
219316131|NCT02092974|DRUG|Citalopram|
219316132|NCT02092974|OTHER|sham-tDCS + placebo|
219316133|NCT02785224|DRUG|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
219316134|NCT00189566|DRUG|Paclitaxel|
219316135|NCT00189566|DRUG|Topotecan|
219316136|NCT00189566|DRUG|Carboplatin|
219316137|NCT00769860|DRUG|Arimoclomol|Arimoclomol 100 mg TID for 4 months
219316138|NCT00769860|OTHER|Placebo|Placebo for 4 months
219316139|NCT05424913|OTHER|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
219316140|NCT00969046|DRUG|EPO906 (patupilone)|
219316141|NCT01603082|DRUG|Ticagrelor|180 mg loading dose
219316142|NCT01603082|DRUG|Clopidogrel|600 mg loading dose
219316143|NCT02528565|DEVICE|Adhesix Bioring|
219316144|NCT02498496|DRUG|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
219316145|NCT02498496|DRUG|Placebo|Administration of 100 mL of Normal Saline
219316146|NCT06266819|OTHER|chewing gum|In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
219316147|NCT01522105|DRUG|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
219316148|NCT00196872|DRUG|Epirubicine|Epirbubicne is given
219316149|NCT00196872|DRUG|Cyclophosphamide|Cyclophosphamide is given
219316150|NCT00196872|DRUG|Taxol|Taxol is given
219316151|NCT00196872|DRUG|Xeloda|Xeloda is given
219316152|NCT00196872|DRUG|Ibandronat|Ibandronat is given
219316153|NCT00852592|DEVICE|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
219316154|NCT00852592|DEVICE|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
219316155|NCT04806698|DEVICE|Menicon Z Night|Children wearing Menicon Z Night orthokeratology contact lenses
219316156|NCT04806698|DEVICE|Control|Children wearing distance single-vision glasses or distance single-vision soft contact lenses
219316157|NCT00283257|BEHAVIORAL|Patients and caregivers are taught problem solving skills|
219316158|NCT04854629|OTHER|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
219316159|NCT05051137|BIOLOGICAL|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
219316160|NCT05051137|DRUG|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
219316161|NCT01019317|DRUG|Cytarabine|0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).
219316162|NCT01019317|DRUG|Fludarabine|15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
219354758|NCT01978093|BIOLOGICAL|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
219745577|NCT03238547|DIAGNOSTIC_TEST|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
219745578|NCT03238547|DIAGNOSTIC_TEST|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
219745579|NCT00190528|DRUG|neoadjuvant chemotherapy + radical hysterectomy|
219745580|NCT00190528|PROCEDURE|radical hysterectomy|
219745581|NCT00958425|DEVICE|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
219745582|NCT00958425|DEVICE|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
219745583|NCT05278715|DRUG|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
219745584|NCT05278715|DRUG|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
219745585|NCT05278715|DRUG|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
219745586|NCT05472870|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
219745587|NCT03094377|OTHER|Multisensory therapy|Sensory stimulation, motor training and ADL training
219745588|NCT03094377|OTHER|Conventional training|Motor training and ADL training
219745589|NCT05414942|BEHAVIORAL|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
219745590|NCT03118895|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
219745591|NCT04881097|BEHAVIORAL|no intervention|no intervention
219745592|NCT01385995|DEVICE|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
219745593|NCT01385995|DEVICE|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
219745594|NCT05162794|OTHER|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
219745595|NCT05162794|OTHER|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
219745596|NCT05162794|OTHER|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
219745597|NCT00112385|DRUG|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
219745598|NCT00112385|DRUG|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
219745599|NCT03686189|DEVICE|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
219316163|NCT04777253|OTHER|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
219316164|NCT04777253|OTHER|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
219316165|NCT00695253|DEVICE|Talent Endoluminal Spring Graft System|Endovascular repair for patients with AAA who meet the inclusion criteria for the study
219316166|NCT02652650|DRUG|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
219316167|NCT02652650|DRUG|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
219316168|NCT02652650|DRUG|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
219316169|NCT04430465|DIETARY_SUPPLEMENT|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
219316170|NCT04430465|DIETARY_SUPPLEMENT|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
219316171|NCT03786939|PROCEDURE|On-pump CABG.|On-pump coronary artery bypass grafting.
219316172|NCT03786939|PROCEDURE|Off-pump CABG.|Off-pump coronary artery bypass grafting.
219316173|NCT03786939|PROCEDURE|Pump-assisted CABG.|Pump-assisted CABG.
219316174|NCT00906919|BEHAVIORAL|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
219316175|NCT00906919|BEHAVIORAL|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
219316176|NCT04410250|BEHAVIORAL|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
219316177|NCT03057314|DRUG|Amorphous Calcium Carbonate|"Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
219316178|NCT06459193|DRUG|Trimetazidine|Trimetazidine 35 mg tab once daily
219316179|NCT06459193|DRUG|Placebo|Placebo once daily
219316180|NCT06472583|DRUG|Keytruda|Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
219316181|NCT06472583|RADIATION|Preoperative radiation therapy|Boost of preoperative robotic stereotactic radiotherapy
219316182|NCT06472583|DRUG|Placebo|0,9% NaCl in the volume 100 ml
219316183|NCT06248931|DRUG|Valproic acid|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219316184|NCT06248931|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
219316185|NCT01349023|OTHER|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
219316186|NCT01629784|BEHAVIORAL|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
219316187|NCT03595592|DRUG|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
219316188|NCT03595592|DRUG|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
219316189|NCT03595592|DRUG|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
219316190|NCT03595592|DRUG|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
219316191|NCT03595592|DRUG|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
219316192|NCT03595592|DRUG|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
219316193|NCT03595592|DRUG|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
219316194|NCT03595592|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
219316195|NCT02281929|DRUG|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
219316196|NCT02281929|DRUG|Placebo|Placebo in three daily doses during 30 days
219316197|NCT02281929|DRUG|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
219316198|NCT03475810|DEVICE|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
219316199|NCT03475810|DRUG|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
219316200|NCT00959972|DRUG|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
219316201|NCT00959972|DRUG|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
219316202|NCT06057545|DRUG|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
219316203|NCT06057545|DRUG|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
219316204|NCT01938807|BEHAVIORAL|CareCoach mobile application to assist in diabetes management|
219316205|NCT05208801|DRUG|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
219316206|NCT05208801|DRUG|Morphine|Intrathecal injection of morphine 400mcg
219316207|NCT05208801|DRUG|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
219316208|NCT04694872|OTHER|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
219316209|NCT04694872|OTHER|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
219316210|NCT03270332|DRUG|Albuterol|inhalation of 270μg albuterol through a spacer
219316211|NCT03270332|DRUG|Placebo|inhalation of placebo through a spacer
219316212|NCT04641507|DRUG|Tadalafil versus tamsulosin as MET|166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
219316213|NCT05761730|DRUG|Dexamethasone Oral|For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
219316214|NCT01367964|DRUG|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
219316215|NCT01691391|BEHAVIORAL|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
219316216|NCT02918760|DRUG|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
219316217|NCT02918760|OTHER|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
219316218|NCT01317225|DRUG|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
219316219|NCT01317225|DRUG|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
219316220|NCT00279630|PROCEDURE|Orthoses and Exercise|orthrose and exercise - daily
219316221|NCT05817253|BEHAVIORAL|Portrait|In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
219316222|NCT05817253|BEHAVIORAL|Therapeutics Letter|The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
219316223|NCT04061551|OTHER|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses"
219316224|NCT00986440|DRUG|CS-7017|CS-7017
219316225|NCT00986440|DRUG|Placebo|Placebo
219316226|NCT02896504|DRUG|Exposure: Adjuvant chemotherapy treatment|
219316227|NCT02896504|DRUG|Exposure: Adjuvant hormonal therapy treatment|
219316228|NCT05981911|DEVICE|XIENCE Skypoint™ stent|Percutaneous coronary intervention with Xience-Skypoint™ stent
219316229|NCT05944042|OTHER|Observational Transplant Analysis|Identify more accurate predictive models of transplant risk
219316230|NCT00684229|PROCEDURE|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
219316231|NCT00684229|DRUG|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
219316232|NCT02070796|DRUG|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
219316233|NCT02070796|DRUG|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
219316234|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
219316235|NCT00372385|DRUG|Ribavirin|tablet
219316236|NCT00372385|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
219316237|NCT00372385|DRUG|Placebo|tablet
219316238|NCT00372385|DRUG|Telaprevir|tablet
219316239|NCT04805775|DRUG|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
219316240|NCT05914441|OTHER|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
219316241|NCT05918939|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
219316242|NCT05918939|BIOLOGICAL|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
219316243|NCT02912325|DIETARY_SUPPLEMENT|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
219316244|NCT00052754|DRUG|gefitinib|
219316245|NCT05313126|OTHER|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
219316246|NCT02949258|DRUG|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
219316247|NCT02949258|DRUG|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
219316248|NCT02949258|DRUG|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
219316249|NCT02949258|DRUG|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
219316250|NCT02600338|OTHER|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
219316251|NCT06317896|DIAGNOSTIC_TEST|circulating tumor cells|blood sample and tissue specimen for circulating tumor cell and DNA will be done to patient with hepatocellular carcinoma
219316252|NCT01699789|OTHER|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
219316253|NCT01699789|BEHAVIORAL|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
219316254|NCT01699789|BEHAVIORAL|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
219316255|NCT03211650|DRUG|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
219316256|NCT03211650|DRUG|hyaluronic acid|Intra-articular injections of hyaluronic acid
219316257|NCT03211650|DRUG|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
219316258|NCT02020382|DEVICE|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
219316259|NCT05062083|DRUG|11C-MC1|Up to 20 mCi injected IV followed by PET scanning
219316260|NCT05062083|DRUG|11C-PS13|Up to 20 mCi injected IV followed by PET Scanning
219316261|NCT05062083|DRUG|Ketoprofen|Ketoprofen 75 mg orally once
219316262|NCT05062083|DRUG|Celecoxib|celecoxib 600 mg orally once
219316263|NCT05691556|PROCEDURE|HABIT ILE rehabilitation course|"The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course"
219745600|NCT02361697|OTHER|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
219745601|NCT04136288|DEVICE|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
219745602|NCT06003829|DRUG|Sinsunatovir|Single dose, to be spit out after tasting
219745603|NCT06003829|OTHER|Bitrex|Single dose, to be spit out after tasting
219745604|NCT06677086|DEVICE|Treatment with BTL-899|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
219745605|NCT03682146|PROCEDURE|Prostatectomy|Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
219745606|NCT02006290|DRUG|PF-06412562|single oral split dose 30+20 mg QD
219745607|NCT02006290|DRUG|Placebo|tablet, matching placebo, QD
219316264|NCT05691556|PROCEDURE|botulinum toxin injections|"Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy."
219316265|NCT04094792|DEVICE|Happify Breather App|Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
219316266|NCT03905161|OTHER|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
219316267|NCT06428591|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|Participants will use the Tandem Freedom system for 3 day/nights in a supervised hotel setting, performing meal and exercise challenges.
219316268|NCT01510496|PROCEDURE|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
219316269|NCT01510496|PROCEDURE|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
219316270|NCT01510496|PROCEDURE|Thoracotomy .|Thoracotomy (non laparoscopic).
219316271|NCT05937087|OTHER|Community engaged research|The university is working with Navajo communities to conduct an intervention study integrating community based participatory research using an Indigenous research paradigm. The innovative proposed project uses two approaches to build a research partnership to create capacity in the community for community-engaged multilevel behavioral and mental health research. Members from the three Navajo communities have never previously been involved in health research focused on wellbeing. Integrating CBPR with DCSR methodology becomes a powerful innovative intervention as the: 1) the community is driving the research to identify culture-based solutions for health related disparities; 2) the community is provided opportunities through research to center their perspectives and understandings about behavioral and mental health interventions; and 3) the community draws upon their collective community Indigenous knowledge.
219316272|NCT03975452|RADIATION|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
219316273|NCT00703144|DRUG|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
219316274|NCT00703144|PROCEDURE|Pharmacokinetic|
219316275|NCT03559478|PROCEDURE|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
219316276|NCT03559478|PROCEDURE|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
219316277|NCT01375361|DRUG|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
219316278|NCT01375361|DRUG|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
219316279|NCT03397849|BEHAVIORAL|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
219316280|NCT00909454|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
219316281|NCT00909454|DIETARY_SUPPLEMENT|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
219316282|NCT03328533|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
219316283|NCT03328533|DRUG|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
219316284|NCT03328533|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
219316285|NCT02460666|BEHAVIORAL|Tai-Chi-Chih (TCC)|
219316286|NCT02460666|BEHAVIORAL|Health Education and Wellness Classes (HEW)|
219316287|NCT04483986|PROCEDURE|Rectus muscle re-approximation|Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
219316288|NCT01258335|DIETARY_SUPPLEMENT|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
219316289|NCT01258335|OTHER|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
219316290|NCT04168684|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
219316291|NCT04168684|BEHAVIORAL|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
219316292|NCT05939466|DRUG|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
219316293|NCT00246428|BEHAVIORAL|Individual Motivational Interview (IMI)|Individual counseling sessions with emphasis in personal responsibility, exploration of motivation for drinking and review of potential negative consequences. will be evaluated 6, 9, and 12 months
219316294|NCT00246428|BEHAVIORAL|Individual Motivational Interview + Family Check-Up|One hour videotaped session of family assessment
219316295|NCT03688607|PROCEDURE|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
219316296|NCT00227890|BEHAVIORAL|MI/CBT|
219316297|NCT00227890|BEHAVIORAL|RT/TU|
219316298|NCT02484339|DRUG|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
219316299|NCT02484339|OTHER|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy
219316300|NCT01323621|DRUG|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
219316301|NCT01323621|DRUG|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
219316302|NCT01323621|DRUG|Double-dummy placebo|inhalation powder
219316303|NCT01323621|DRUG|Salbutamol as needed|inhalation powder
219316304|NCT06419751|BEHAVIORAL|Regular exercise|Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1\~2 muscle groups each time, 4\~5 movements, repeat each action 8\~12 times, repeat 2\~3 sets)
219316305|NCT06419751|BEHAVIORAL|Baduanjin|A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
219316306|NCT02648750|BEHAVIORAL|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
219316307|NCT01208090|DRUG|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
219316308|NCT01208090|DRUG|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
219316309|NCT04896138|OTHER|Interstitial Lung Disease|Not applicable - this is not an interventional trial
219316310|NCT04288895|DRUG|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
219316311|NCT02216487|DRUG|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
219316312|NCT02506478|OTHER|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
219316313|NCT01209312|OTHER|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
219316314|NCT00208897|DRUG|Fluoxetine|
219316315|NCT04097522|OTHER|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
219316316|NCT05419089|PROCEDURE|Robotic surgery|Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
219316317|NCT05255081|DEVICE|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
219316318|NCT05255081|PROCEDURE|Placebo-control|Spray with saline would be applied to organs under incision
219316319|NCT05300269|DRUG|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w"
219316320|NCT02320955|PROCEDURE|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
219316321|NCT06165614|DRUG|Artesunate pessary|Subjects will self-administer 200 mg of Artesunate pessary (vaginal insert) daily for 5 days, on weeks 1, 3, 5, 7.
219316322|NCT06165614|PROCEDURE|Colposcopy|Colposcopy is a procedure that allows close examination of the cervix, vagina, and vulva, performed on weeks 8 and 14.
219316323|NCT01891721|BEHAVIORAL|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
219316324|NCT01891721|BEHAVIORAL|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
219316325|NCT01891721|BEHAVIORAL|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
219316326|NCT05415384|DEVICE|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
219316327|NCT05415384|PROCEDURE|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
219316328|NCT00005002|DRUG|Lamivudine/Zidovudine|
219316329|NCT00005002|BIOLOGICAL|HIV-1 Immunogen|
219316330|NCT00005002|DRUG|Nelfinavir mesylate|
219316331|NCT05638750|OTHER|Rehabilitation Intervention|12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
219316332|NCT02827136|DRUG|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
219316333|NCT02827136|DRUG|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
219316334|NCT05358951|BEHAVIORAL|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
219316335|NCT05358951|BEHAVIORAL|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
219316336|NCT03460379|DRUG|Escitalopram|Patients are tested for their normal prescription escitalopram medication
219316337|NCT01109836|BEHAVIORAL|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
219316338|NCT06179329|PROCEDURE|Coronary artery bypass graft|Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
219316339|NCT01288872|DRUG|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
219316340|NCT01162213|DIETARY_SUPPLEMENT|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
219316341|NCT00137813|DRUG|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
219316342|NCT00137813|DRUG|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
219316343|NCT04160351|DEVICE|Theranova 400|medium cut-off dialyser
219316344|NCT04160351|DEVICE|Elisio-19H|high flux dialyser
219316345|NCT05227872|DEVICE|ultrasound|POCUS
219316346|NCT03565276|DRUG|Tranexamic Acid|A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
219316347|NCT02708095|DRUG|Baricitinib|Administered orally
219316348|NCT02708095|DRUG|Placebo|Administered orally
219316349|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 1.0 (intervention discontinued, modified to 2.0. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
219316350|NCT04438031|BEHAVIORAL|Control Intervention|Brief information will be provided about pregnancy prenatally and child development at 12, 24, and 36 months.
219316351|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
219316352|NCT04388501|DRUG|Milvexian|Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
219316353|NCT04388501|DRUG|Atorvastatin|Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
219316354|NCT02749448|OTHER|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
219316355|NCT05057806|DRUG|Empagliflozin 25 MG|Empagliflozin 25MG will be administered orally once per day for 3 months
219316356|NCT05057806|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
219316357|NCT03140423|DRUG|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
219316358|NCT03140423|DRUG|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
219316359|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
219316360|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
219316361|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
219316362|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
219316363|NCT05277883|RADIATION|CT scan|CT of the lower limb
219316364|NCT00329485|DRUG|CORvalen (D-Ribose)|
219316365|NCT01313650|DRUG|62.5/25mcg|GSK573719/GW64244
219316366|NCT01313650|DRUG|62.5mcg|GSK573719
219316367|NCT01313650|DRUG|25mcg|GW642444
219316368|NCT01313650|DRUG|Placebo|Placebo
219316369|NCT03275103|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
219316370|NCT03275103|DRUG|Tocilizumab|Tocilizumab will be administered as premedication during Cycle 1.
219316371|NCT04209790|RADIATION|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
219316372|NCT04209790|DRUG|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
219316373|NCT04209790|PROCEDURE|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
219316374|NCT06571149|DRUG|Tenecteplase or Alteplase|Patients randomized to intravenous thrombolysis (IVT) treatment will receive intravenous Tenecteplase or Alteplase.
219316375|NCT05393037|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
219316376|NCT05393037|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
219316377|NCT05393037|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
219316378|NCT05393037|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
219316379|NCT05393037|BIOLOGICAL|PCV15 - Part B|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
219745608|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
219745609|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
219745610|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
219745611|NCT05148663|DIAGNOSTIC_TEST|CCM Hemorrhagic Panel|Biomarker
219745612|NCT06593665|DRUG|Inrathecal Morphine|Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
219745613|NCT06593665|DRUG|Intravenous Methadone|Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
219745614|NCT05947890|BIOLOGICAL|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
219745615|NCT05947890|BIOLOGICAL|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
219745616|NCT06658756|BEHAVIORAL|internet-CBT|10 modules on line of I-CBT for OCD
219745617|NCT06011889|DRUG|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
219745618|NCT06011889|DRUG|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
219745619|NCT05669027|DEVICE|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
219745620|NCT05669027|DEVICE|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
219745621|NCT06612281|DEVICE|colorectal cancer (CRC) screening|Gixam test
219745622|NCT06612281|DIAGNOSTIC_TEST|colorectal cancer screening|Fecal Immunochemistry Test (FIT)
219745623|NCT06612281|PROCEDURE|Colonoscopy after bowel cleansing|Standard of care optical colonoscopy for colorectal cancer screening
219745624|NCT01688791|DRUG|Vintafolide|
219745625|NCT01688791|DRUG|Carboplatin|
219745626|NCT01688791|DRUG|Paclitaxel|
219745627|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
219745628|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
219745629|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
219745630|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
219745631|NCT05566236|BEHAVIORAL|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
219745632|NCT05700422|DRUG|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
219745633|NCT06671665|DRUG|calcium supplementation|Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
219745634|NCT06671665|OTHER|Manual therapy|Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
219745635|NCT06672133|DRUG|Adebrelimab|Given：IV
219316380|NCT06483204|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|Medrol tapered dosepak given to experimental arm patients to determine if there is a significant difference in pain, nausea, edema and ecchymosis outcomes in the postoperative period after a functional rhinoplasty procedure.
219316381|NCT03160651|DRUG|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
219316382|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
219316383|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
219316384|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
219316385|NCT00458341|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
219316386|NCT04988386|DRUG|Acoramidis (AG10)|Acoramidis (AG10) twice daily
219316387|NCT05746624|BEHAVIORAL|keypresses|benign behavioral intervention-- keypresses
219316388|NCT00510679|BEHAVIORAL|Health worker supports (supervision, job aids, incentives)|
219316389|NCT05786833|DRUG|Dexmedetomedine|Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
219316390|NCT05786833|DRUG|Ketofol|Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.
219316391|NCT05786833|DRUG|isotonic saline 0.9%|Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
219316392|NCT01110811|PROCEDURE|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
219316393|NCT03471871|DRUG|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
219316394|NCT03471871|DRUG|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
219316395|NCT03471871|DRUG|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
219316396|NCT03471871|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
219316397|NCT03471871|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
219316398|NCT01349335|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
219316399|NCT01349335|DRUG|Tolvaptan|tablet, 30 mg, Qd, 7 days
219316400|NCT01349335|DRUG|placebo|tablet, 30 mg, Qd, 7days.
219316401|NCT02736604|DRUG|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
219316402|NCT02736604|DRUG|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
219316403|NCT02736604|DEVICE|laryngeal mask airway (LMA Supreme Size 3/4|
219316404|NCT02736604|DRUG|sevoflurane|
219316405|NCT06992609|DRUG|Durvalumab|Durvalumab (IV) every 4 weeks until a maximum of 24 months.
219316406|NCT07016009|BEHAVIORAL|Thrive Program|Thrive is a person-centered planning intervention that is based on self-determination theory and integrates elements of social network interventions. The proposed Thrive intervention has four phases: 1) Strengths \& Network Assessment, 2) Network Engagement, 3) Goal Setting \& Planning, and 4) Plan Implementation \& Monitoring. It involves about 10-13 sessions and is delivered by a trained facilitator over Zoom.
219316407|NCT07010120|DRUG|Tislelizumab|200mg IV Q3W
219316408|NCT07010120|DRUG|Afatinib|30mg PO QD
219316409|NCT07010120|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
219316410|NCT07019025|OTHER|Therapeutic patient education on the use of a insulin bolus calculator app|Therapeutic patient education on the use of a insulin bolus calculator app
219745636|NCT06672133|RADIATION|Radiation Therapy|Undergo radiation therapy
219745637|NCT06673940|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS is applied on the acupuncture points Intervention arm
219745638|NCT06673940|OTHER|Physical Therapy program|Physical therapy methods
219745639|NCT06673836|DEVICE|DYNAMIC CYCLING|"Balance Training: Exercises focused on improving coordination and balance, such as standing on one leg, walking on uneven surfaces, or using balance boards.~Core Strengthening: Strengthening core muscles helps children maintain stability during dynamic movements, such as walking or running.~Proprioceptive Training: Exercises that improve awareness of the body's position in space, such as obstacle courses or activities that challenge movement coordination."
219316411|NCT06895005|DEVICE|Transcutaneous auricular vagus nerve stimulation + rehabilitation therapy|Transcutaneous auricular vagus nerve stimulation using INPULSE 3 times a week for six consecutive weeks. The stimulation parameters will be a frequency of 30Hz with a pulse width of 300 us and a stimulation time of 1.5 seconds for each respiratory cycle. The electrical current will be gradually increased to a maximum of 5 mA (0.25-mA increments) to allow adaptation to the stimulation until a comfortable tolerance level is achieved. Patients will receive physical rehabilitation therapy during stimulation, which will include reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
219316412|NCT06895005|OTHER|sham stimulation + rehabilitation therapy|Patients will receive physical rehabilitation therapy during placebo stimulation (No electrical stimulation), including reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
219316413|NCT06903143|BEHAVIORAL|Screening, brief intervention, and referral to treatment (SBIRT)|The intervention will consist of a 30 minute alcohol brief intervention based on CETA' substance use reduction element; if warranted, referral will be made for the full CETA intervention, which consists of 6-12 weekly cognitive behavioral therapy-based sessions.
219316414|NCT05809128|OTHER|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
219316415|NCT01034293|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
219316416|NCT01034293|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
219316417|NCT05954780|DRUG|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
219316418|NCT00485160|DRUG|Continuous indomethacin|
219316419|NCT00485160|DRUG|ibuprofen|
219316420|NCT04916041|DEVICE|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
219316421|NCT06769945|BEHAVIORAL|Nursing Care Based on Kolcaba's Comfort Theory|In practice, patient education, pain management, emotional support, appropriate environmental arrangements and individualised care come to the fore. Studies show that with this approach, patients' physical comfort increases, anxiety levels decrease and overall satisfaction improves. It is stated that nursing care based on Kolcaba's theory offers an effective model to improve the quality of life of postoperative patients.
219316422|NCT00841893|DIETARY_SUPPLEMENT|Mustard (dijon)|The specific spice added to a brunch meal
219316423|NCT00841893|DIETARY_SUPPLEMENT|Placebo|Placebo added to a brunch meal
219316424|NCT06332508|DEVICE|Pulsed electromagnetic fields (PEMFs)|"Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment."
219316425|NCT06332508|DRUG|Anthracycline-based chemotherapy|"Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy."
219316426|NCT05898386|BEHAVIORAL|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
219316427|NCT01141348|BEHAVIORAL|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
219316428|NCT01141348|BEHAVIORAL|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
219316429|NCT03236246|DRUG|KRX-0502|Oral ferric citrate with meals
219316430|NCT03533621|DIETARY_SUPPLEMENT|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
219316431|NCT03533621|DIETARY_SUPPLEMENT|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
219316432|NCT02882919|BEHAVIORAL|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
219316433|NCT00122928|BEHAVIORAL|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
219316434|NCT00122928|BEHAVIORAL|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
219316435|NCT00122928|BEHAVIORAL|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
219316436|NCT05794113|DEVICE|Mobile app - CanImmunize|Using a mobile app
219316437|NCT05794113|DEVICE|Web based notification|Using a web-based version of a survey
219316438|NCT00056511|DRUG|Fresh garlic or garlic supplements|
219316439|NCT01398293|DRUG|danoprevir|100 mg single dose orally
219316440|NCT01398293|DRUG|danoprevir|400 mg single dose orally
219316441|NCT01398293|DRUG|danoprevir placebo|single oral dose
219316442|NCT01398293|DRUG|moxifloxacin|400 mg single dose orally
219316443|NCT01398293|DRUG|moxifloxacin placebo|single oral dose
219316444|NCT01398293|DRUG|ritonavir|100 mg single dose orally
219316445|NCT01398293|DRUG|ritonavir placebo|single oral dose
219316446|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
219316447|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
219316448|NCT01856166|DRUG|Levobupivacaine|
219316449|NCT01856166|DRUG|Sufentanil|
219316450|NCT02823756|PROCEDURE|Physical Therapy|Exercise, education, spinal manipulation
219316451|NCT01317212|DRUG|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
219316452|NCT03970551|OTHER|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
219316453|NCT03970551|OTHER|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
219316454|NCT03970551|OTHER|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
219316455|NCT02598557|DRUG|Exemestane|Given PO
219316456|NCT02598557|OTHER|Laboratory Biomarker Analysis|Correlative studies
219316457|NCT02598557|OTHER|Pharmacological Study|Correlative studies
219316458|NCT02598557|OTHER|Placebo Administration|Given PO
219316459|NCT02598557|OTHER|Quality-of-Life Assessment|Ancillary studies
219316460|NCT02598557|OTHER|Questionnaire Administration|Ancillary studies
219316461|NCT02598557|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219316462|NCT02328287|DRUG|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
219316463|NCT05629650|BEHAVIORAL|Tai Chi for memory|The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
219316464|NCT00269568|DRUG|mifepristone and misoprostol|
219316465|NCT05055986|DEVICE|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
219316466|NCT04058379|RADIATION|CT scan|3 ct scans : D0, D1 and D3
219316467|NCT01343589|DIETARY_SUPPLEMENT|milk fat|39 g milk fat per day in 12 weeks
219316468|NCT00149422|DEVICE|NT-proBNP measurements|
219316469|NCT03483558|OTHER|Control|A standardized diet without any vegetables was provided.
219316470|NCT03483558|OTHER|Spinach|A standardized diet with 200g spinach was provided.
219316471|NCT03483558|OTHER|Celery|A standardized diet with 200g celery was provided.
219316472|NCT03483558|OTHER|Onion|A standardized diet with 200g onion was provided.
219316473|NCT03483558|OTHER|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
219316474|NCT04586517|OTHER|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
219316475|NCT04586517|OTHER|Control|Activity as usual during chemotherapy
219316476|NCT05717426|OTHER|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
219316477|NCT05717426|OTHER|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
219316478|NCT04469166|PROCEDURE|tourniquet|Use of tourniquet
219316479|NCT04469166|PROCEDURE|No tourniquet|No use of tourniquet
219316480|NCT02656498|DRUG|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
219316481|NCT01117454|DRUG|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
219316482|NCT01117454|DRUG|Placebo|placebo, similar in appearance to flecainide
219316483|NCT01117454|DRUG|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
219316484|NCT00796848|DEVICE|Navigator Continuous Glucose Monitor|
219316485|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
219316486|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
219316487|NCT06326957|OTHER|SELF-BREATHE|SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
219316488|NCT06459323|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
219316489|NCT04276766|OTHER|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
219316490|NCT00647751|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
219316491|NCT00647751|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fed
219316492|NCT06287723|BIOLOGICAL|Blood sample/Liquid biopsy|ctDNA analysis
219316493|NCT00888433|DEVICE|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
219316494|NCT06288321|DRUG|Microdrop Mydrin-P|Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.
219316495|NCT06288321|DRUG|Standard Mydrin-P|Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
219316496|NCT06196983|OTHER|Rhythmic aerobic exercises|The experimental group's pattern of functional movements includes both right and left foot movements. To improve muscle strength and the capacity to maintain balance, exercises including running in place, side steps, walking while eating, and turning in place can also be used. The rhythmic aerobic group linked their motions to the rhythmic auditory stimuli in order to perform in a rhythmic manner.
219316497|NCT06196983|OTHER|Control group, strength and balance exercises|The control group engaged in strength and balance exercises where they stood with weight on one leg and raised the other leg to the side or back. In a tandem stance, place your foot heel directly in front of your toe. Get out of a chair, then take a seat without using your hands.
219316498|NCT01500850|DRUG|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
219316499|NCT01500850|DRUG|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
219316500|NCT01500850|DRUG|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
219316501|NCT01500850|DRUG|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
219316502|NCT04628468|DEVICE|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
219316503|NCT04628468|OTHER|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
219316504|NCT00375557|DRUG|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
219316505|NCT00375557|DRUG|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
219316506|NCT05629195|DEVICE|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
219316507|NCT01681628|BEHAVIORAL|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
219316508|NCT02762825|BEHAVIORAL|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
219316509|NCT02762825|BEHAVIORAL|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
219316510|NCT02794454|OTHER|HeezOn Ultra-1|
219316511|NCT02794454|OTHER|HeezOn Ultra-2|
219316512|NCT02794454|OTHER|Placebo|
219316513|NCT01810692|DEVICE|Group1:Spiriva® Respimat®|COPD patients using Respimat®
219316514|NCT01810692|DEVICE|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
219316515|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
219316516|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
219316517|NCT06211192|OTHER|retrospective data collection|retrospective data collecting from medical records
219316518|NCT00846651|OTHER|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
219316519|NCT00846651|OTHER|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
219316520|NCT00846651|DRUG|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
219316521|NCT05809310|PROCEDURE|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
219316522|NCT00315081|DRUG|Bromocriptin|
219316523|NCT06429384|DRUG|Y-3 Injection/Y-3 blank injection|The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;
219316524|NCT05774444|DIETARY_SUPPLEMENT|Krill oil|Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
219316525|NCT05774444|DIETARY_SUPPLEMENT|Krill protein|Krill protein will be given to the participant following a resistance exercise bout.
219316526|NCT05774444|DIETARY_SUPPLEMENT|Vegetable oil|This will be the control against the Krill oil
219316527|NCT05774444|DIETARY_SUPPLEMENT|Carbohydrate|This will be the control for the Krill protein
219316528|NCT00962156|DRUG|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
219316529|NCT00962156|DRUG|Ringers acetate|Infusion for volume expansion in the ICU
219316530|NCT01937936|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
219316531|NCT01937936|BEHAVIORAL|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
219316532|NCT05187052|OTHER|Tracheal intubation|Video-assisted intubation technique
219316533|NCT04500808|DRUG|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
219316534|NCT04500808|DRUG|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
219316535|NCT04500808|DRUG|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
219316536|NCT04500808|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
219316537|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
219316538|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
219316539|NCT06845319|DRUG|Carboplatin|Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).
219316540|NCT06845319|DRUG|Paclitaxel|80mg/m2 weekly
219316541|NCT06845319|DRUG|Pembrolizumab|200 mg every 3 weeks for 4 cycles
219316542|NCT04424979|DEVICE|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
219316543|NCT06580938|BIOLOGICAL|PF-07921585|IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously
219316544|NCT06580938|BIOLOGICAL|Sasanlimab|Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
219316545|NCT06095713|DRUG|Pegunigalsidase-alfa|Standard of care
219316546|NCT00108186|DRUG|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
219316547|NCT06135714|DRUG|Systemic therapy for 12 weeks after primary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
219316548|NCT06135714|PROCEDURE|Radiation therapy (SBRT/conventional RT)|Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
219316549|NCT06135714|PROCEDURE|Surgery|Surgery for the oligometastases
219316550|NCT06135714|DRUG|Same systemic therapy after secondary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
219316551|NCT04241172|DEVICE|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
219316552|NCT04241172|PROCEDURE|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
219316553|NCT04241172|PROCEDURE|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
219316554|NCT05490121|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
219316555|NCT05842512|DRUG|ADI-PEG20|Treatment for NASH
219316556|NCT05842512|OTHER|Placebo|Treatment for NASH
219316557|NCT04396236|DRUG|Lasmiditan|Administered orally
219316558|NCT04396236|DRUG|Placebo|Administered orally
219316559|NCT05814575|BEHAVIORAL|NEXUS intervention|During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.
219316560|NCT05814575|BEHAVIORAL|Standardized Non-Medical fetal ultrasound|A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
219316561|NCT04396574|DRUG|Lasmiditan|Administered orally
219316562|NCT06078579|DIAGNOSTIC_TEST|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
219316563|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
219316564|NCT04823520|DRUG|TCA|All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
219316565|NCT05311098|DEVICE|cryoablation|Treatment of atrial fibrillation with cryoablation catheters
219316566|NCT01594866|DRUG|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
219316567|NCT01594866|DRUG|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
219316568|NCT04337333|DEVICE|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
219316569|NCT01647750|DRUG|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
219316570|NCT01647750|DRUG|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
219316571|NCT01637623|DRUG|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
219316572|NCT01637623|DRUG|Allopurinol|Allopurinol 300 mg daily for 6 weeks
219316573|NCT01637623|DRUG|Placebo|Placebo capsule daily for 6 weeks
219316574|NCT06420895|OTHER|Clinical follow-up|Clinical follow-up of patients
219316575|NCT06420895|OTHER|Transthoracic Echocardiogram (TTE)|Transthoracic Echocardiogram
219316576|NCT06420895|OTHER|Magnetic resonance imaging (MRI)|Magnetic resonance imaging
219316577|NCT06420895|OTHER|Transesophageal echocardiogram (TEE)|Transesophageal echocardiogram
219316578|NCT03829709|OTHER|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
219316579|NCT03099850|OTHER|Data Management and Monitoring|"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.~* Study participants will complete questionnaires at baseline and during yearly follow-up. In the event a participant does not complete all or part of the patient or coordinator questionnaire, the study coordinator will complete questions via medical record review (e.g., demographics and family history) or via a telephone interview.~* Biospecimen collection: blood, urine, saliva, stool. Biospecimens will be collected and processed in accordance with the CPDPC specimen collection procedures.~* EUS or EGD with pancreatic fluid collection~* imaging studies performed at baseline and at follow-up.~  * IV contrast-enhanced MRI and MRCP with secretin~ * IV contrast-enhanced CT Scan abdomen"
219316580|NCT05993949|DRUG|Dasatinib|3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
219316581|NCT01475578|DRUG|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
219316582|NCT01475578|DRUG|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
219316583|NCT00538304|DRUG|bimatoprost eye drops|1 drop in each eye daily for 1 month
219316584|NCT00538304|DRUG|placebo|1 drop in each eye daily for 1 month
219316585|NCT01727583|DIETARY_SUPPLEMENT|meal intake|Intake of meals characterized by lipid composition
219316586|NCT01727583|DIETARY_SUPPLEMENT|Placebo|
219316587|NCT05833048|PROCEDURE|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
219316588|NCT04844528|DRUG|Nicotinamide|Oral nicotinamide 500 mg twice daily (BID).
219316589|NCT04844528|DRUG|Placebo|Oral placebo twice daily for the first year.
219316590|NCT06034522|DEVICE|Adipearl|Injection of the investigational device in the face.
219316591|NCT03992469|DRUG|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
219316592|NCT03992469|DRUG|Placebo|Placebo capsules made of cornstarch
219316593|NCT04285476|DIAGNOSTIC_TEST|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
219316594|NCT03957954|BIOLOGICAL|cLSC|Transplantation of cLSC
219316595|NCT03957954|DEVICE|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
219745640|NCT06673836|DEVICE|INCLINED TREAD MILL|Dynamic Cycling: Refers to the fluctuating nature of movement patterns, often used in therapies like stationary biking or recumbe.nt cycling, where the intensity and resistance vary. Dynamic cycling can also refer to training that involves alternating between high and low-intensity phases or cycling between different positions (sitting, standing) or speeds during the activity
219745641|NCT06675279|OTHER|Survey-based study|The demographic information of individuals with migraines, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
219745642|NCT06674798|OTHER|School-based eHealth NCD Prevention Program|Students will participate in health-promoting sessions delivered by trained facilitators, with each session lasting 30 to 40 minutes. There will be a total of six health-promoting sessions conducted in the classroom for the intervention group, spanning two months with three sessions per month. The health-promoting videos from the school-based eHealth NCD prevention program will be shown in the classroom using multimedia. The drama-based videos will be developed in Urdu Language with English subtitles and will be based on based on contextually relevant content for the Pakistani secondary and higher secondary school students of age 13 to 18 years old. The content of these six sessions will be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use.
219745643|NCT06543589|DEVICE|High-flow-nasal-cannula|Respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
219745644|NCT06675474|OTHER|Clinical periodontal measurements|Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
219745645|NCT06675474|OTHER|Saliva sampling|The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
219745646|NCT06675474|OTHER|Serum Sampling|5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
219745647|NCT06675474|OTHER|GCF sampling|GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
219745648|NCT06675474|OTHER|Subgingival plaque sampling|Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
219745649|NCT06675682|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
219745650|NCT06674070|GENETIC|Valproic Acid|syrup/ tablet EPIVAL (250mg
219745651|NCT06674941|DRUG|Teprotumumab|Administered as an SC injection.
219745652|NCT07010744|DRUG|Triple drug regimen|Amoxicillin 1000mg at 12 hourly for 14 days Clarithromycin 500mg at 12 hourly for 14 days Esomeprazole 20 mg at 12 hourly for 14 days
219745653|NCT07010744|DRUG|Quadruple therapy|Bismuth subsalicylate 300mg at 6 hourly 14 days Metronidazole 400mg at 8 hourly 14 days Tetracycline 500mg at 6 hourly 14 days Esomeprazole 20 mg 12 hourly for 14 days
219745654|NCT07009938|DEVICE|Drug-Coated Balloon (DCB)|Following lesion preparation (usually with a standard balloon), a drug-coated balloon is advanced to the target lesion. The balloon is inflated and maintained to allow effective drug transfer to the vessel wall.
219745655|NCT07009938|DEVICE|Drug-Eluting Stent (DES) implantation|After coronary angiography identifies the target lesion, a DES is selected based on the vessel size. Post-deployment angiography is performed to confirm the result and check for complications.
219745656|NCT07010016|DEVICE|NaviFus Model101|FUS Neuromodulation
219745657|NCT07009873|OTHER|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.
219316596|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
219316597|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
219316598|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
219316599|NCT03252275|OTHER|Peer learning|Peer learning plus HBB and ECEB
219316600|NCT04386343|DRUG|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
219316601|NCT04386343|DRUG|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
219316602|NCT04386343|DRUG|Placebos|The placebo was used on patients as a control for the doses of CH1701
219316603|NCT01285466|DRUG|BEZ235 + paclitaxel|
219316604|NCT01285466|DRUG|BKM120 + paclitaxel|
219316605|NCT01285466|DRUG|BEZ235 + paclitaxel + trastuzumab|
219316606|NCT01285466|DRUG|BKM120 + paclitaxel + trastuzumab|
219316607|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
219316608|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
219316609|NCT03163979|BIOLOGICAL|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
219316610|NCT03163979|BIOLOGICAL|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
219316611|NCT04874181|DEVICE|Silverfit 3D|Virtual reality game used for rehabilitation of stroke patients
219316612|NCT06565455|BEHAVIORAL|Growing Healthy Children and Families in Rural Arkansas|The intervention will consist of seven healthy eating culturally developed modules, which will be implemented/delivered in the participants home and two cooking demonstration/tasting workshops for the participants in the intervention group (mothers in the church setting and individual and collective goal settings for the intervention group.
219316613|NCT02281279|BIOLOGICAL|rituximab|Given IV
219316614|NCT02281279|DRUG|lenalidomide|Given PO
219316615|NCT02281279|DRUG|romidepsin|Given IV
219316616|NCT02281279|OTHER|laboratory biomarker analysis|Correlative studies
219316617|NCT05719558|DRUG|ASP1002|intravenous (IV) infusion
219316618|NCT05097911|DRUG|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
219316619|NCT05097911|DRUG|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
219316620|NCT05097911|DRUG|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
219316621|NCT04879641|BEHAVIORAL|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
219316622|NCT04879641|BEHAVIORAL|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
219316623|NCT04879641|BEHAVIORAL|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
219316624|NCT04879641|BEHAVIORAL|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
219316625|NCT06489340|DRUG|2HPβCD|2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
219316626|NCT01318954|BIOLOGICAL|Allergen immunotherapy|
219316627|NCT05603793|BEHAVIORAL|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
219316628|NCT04791969|DRUG|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
219316629|NCT04791969|DRUG|Placebo|Intermittent Oral Placebo
219316630|NCT04791969|BEHAVIORAL|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
219316631|NCT04630847|BIOLOGICAL|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
219316632|NCT05074420|DRUG|Baricitinib|Given Orally
219316633|NCT03549533|OTHER|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
219316634|NCT02743377|OTHER|Brain PET Imaging with 11C Rolipram|Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
219316635|NCT02743377|DRUG|Whole Body PET Baseline with 11C Rolipram|Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
219316636|NCT02743377|DRUG|Whole Body PET Blocked with Roflumilast|Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
219316637|NCT00004051|DRUG|irinotecan hydrochloride|
219316638|NCT05020431|OTHER|Biological measuring of collagen fragments biomarker during orthodontic tooth movement|Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
219316639|NCT04577196|OTHER|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
219316640|NCT02075268|DRUG|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
219316641|NCT05987852|DEVICE|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
219316642|NCT05987852|OTHER|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
219316643|NCT06469346|OTHER|Nordic Hamstring Eccentric Exercise Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~Nordic eccentric exercise protocol:~* Week 1: 2 sets x 5 repetitions~* Week 2: 2 sets x 6 repetitions~* Week 3: 3 sets x 6 repetitions~* Week 4-6: 3 sets x 8 repetitions"
219316644|NCT06469346|OTHER|Passive Hamstring Static Stretching Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~* Week 1-2: 1 set x 2 repetitions of 30 seconds~* Week 3: 1 set x 3 repetitions of 30 seconds~* Week 4-6: 1 set x 3 reps of 40 seconds"
219316645|NCT06469346|OTHER|Control Group|No intervention
219316646|NCT04500431|BIOLOGICAL|Targeting CD269 chimeric antigen receptor engineered T cells|Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
219316647|NCT02942238|PROCEDURE|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
219316648|NCT02942238|PROCEDURE|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
219316649|NCT03953443|OTHER|Not interventional|
219316650|NCT03113253|DRUG|Tranexamic Acid|
219316651|NCT03113253|DRUG|Placebo|0.9% sodium chloride to mimic tranexamic acid
219316652|NCT00014326|RADIATION|radiation therapy|
219316653|NCT02076113|PROCEDURE|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
219316654|NCT02076113|PROCEDURE|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
219316655|NCT02076113|PROCEDURE|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
219316656|NCT04682977|OTHER|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
219316657|NCT04682977|OTHER|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
219316658|NCT03558594|BEHAVIORAL|Hypnosis|Behavioral Condition
219316659|NCT03558594|BEHAVIORAL|Mindfulness|Behavioral Condition
219316660|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
219316661|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
219316662|NCT06072781|DRUG|avutometinib|Avutometinib: administered orally
219316663|NCT06072781|DRUG|Defactinib|Defactinib: administered orally
219316664|NCT06072781|DRUG|Pegylated liposomal doxorubicin|administered intravenously
219316665|NCT06072781|DRUG|Paclitaxel|administered intravenously
219316666|NCT06072781|DRUG|Letrozole|administered orally
219316667|NCT06072781|DRUG|Anastrozole|administered orally
219316668|NCT05793918|OTHER|Therapeutic Percutaneous Electrolysis an neuromodulation|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
219316669|NCT05793918|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
219316670|NCT00212628|DRUG|Minodronic acid hydrate|
219316671|NCT05395481|DRUG|LY3849891|Administered SC
219316672|NCT05395481|DRUG|Placebo|Administered SC
219316673|NCT06611241|BEHAVIORAL|Hazard Anticipation Program for Parents of Teen Drivers|Parents and teens who receive the intervention will complete a web-based training that provides parents with guidance on how to teach their teen to identify potential hazards on the roadway. The program begins by providing background on teens' difficulty learning this skill and the motivational interviewing techniques that are being used in the course. Parents then engage with a series of hazard videos. For each hazard, parents watch the hazard unfold, provide an example of what they might say to their teen in that, and are provided with examples of how to coach their teen through the hazard before it becomes a critical event. Parents and teens then jointly watch 12 videos depicting hazards unfolding on the roadway. Teens are asked to identify the hazard without parental input by pressing a spacebar. Teens must also indicate what they believe was the key event that caused the hazard. Then parents and teens are given an opportunity to replay the video and discuss the hazard together.
219316674|NCT03257020|DIAGNOSTIC_TEST|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
219316675|NCT04908605|DRUG|Mirtazapine|Every patient will be given mirtazapine 30 mg tablet
219316676|NCT04908605|DRUG|Melatonin|Every patient will be given melatonin 5 mg tablet
219316677|NCT04908605|DRUG|Placebo|Every patient will be given a matching placebo tablet
219316678|NCT00692302|BEHAVIORAL|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
219316679|NCT00692302|BEHAVIORAL|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
219316680|NCT06736574|DRUG|Omecamtiv Mecarbil (OM)|Oral Tablet
219316681|NCT06736574|DRUG|Placebo|Oral Tablet
219316682|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Bolus)|IM in the deltoid
219316683|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
219316684|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Bolus)|SC in the upper arm
219316685|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
219316686|NCT06033209|BIOLOGICAL|SMNP (IM, Bolus)|IM in the deltoid
219316687|NCT06033209|BIOLOGICAL|SMNP (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
219316688|NCT06033209|BIOLOGICAL|SMNP (SC, Bolus)|SC in the upper arm
219316689|NCT06033209|BIOLOGICAL|SMNP (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
219316690|NCT00498134|DRUG|Triple therapy for H. pylori infection|
219316691|NCT00498134|DRUG|Cox-2 inhibitor|
219316692|NCT01383161|DRUG|Curcumin|Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
219316693|NCT01383161|OTHER|Placebo|Six capsules per day for 18 months.
219316694|NCT05147623|PROCEDURE|Any surgery/procedure|Any surgery/procedure in all adult patients that were performed in an operating room
219316695|NCT05873946|DIAGNOSTIC_TEST|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
219316696|NCT04852263|OTHER|Group I|Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
219316697|NCT04852263|OTHER|Group II (NPA group)|Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
219316698|NCT00710827|DRUG|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
219316699|NCT00710827|DRUG|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
219316700|NCT05903872|OTHER|aromatherapy massage|aromatherapy massage was applied using essential oils
219316701|NCT05903872|OTHER|back massage|back massage was applied using only almond oil
219316702|NCT01736085|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
219316703|NCT01736085|BEHAVIORAL|Voucher|"Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
219316704|NCT01736085|DRUG|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
219316705|NCT03080688|DEVICE|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
219316706|NCT06518174|DIAGNOSTIC_TEST|MRI, SWE, and US evaluation|"We will perform SWE and MRI sampling of the uterus from fundus to lower uterine segment with at least two points each from the upper, mid, and lower thirds of the uterus. SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, we will also collect transvaginal US. MRI images will also be sampled from existing pretreatment studies performed as standard of care. All images will be evaluated for the presence and degree of fibrosis. We will compare SWE and MRI post-treatment. We will also compare pre-and post-treatment MRI.~We will perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to age-matched controls"
219316707|NCT06836375|DIAGNOSTIC_TEST|Spirometry test with bronchodilation|this test measures how much air you can breathe in and out of your lungs, as well as how easily and fast you can then blow the air out of your lungs
219316708|NCT06836375|DIAGNOSTIC_TEST|Methacholine challenge|test used to diagnose asthma where the patient breaths in methacholine
219316709|NCT06836375|DIAGNOSTIC_TEST|impulse oscillometry|test that uses sound waves to measure how much resistance there is to the normal movement of air in and out of your lungs when you are breathing at rest
219316710|NCT06836375|OTHER|Measurement of the exhaled FeNO fraction|Measure the level of nitric oxide in parts per billion (PPB) in the air the patient slowly exhales
219316711|NCT03942406|COMBINATION_PRODUCT|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
219316712|NCT04377828|DEVICE|Pigment laser|one to two session of pigment laser (532 nm)
219316713|NCT04910321|OTHER|diet, physical activities, sleep|lifestyle factors
219316714|NCT03509896|OTHER|Non-Interventional|Non-Interventional
219316715|NCT03399409|BEHAVIORAL|Motivational Interviewing|Motivation techniques
219316716|NCT03399409|BEHAVIORAL|Anti-inflammatory Information|Provision of information on anti-inflammatory products
219316717|NCT06560996|OTHER|Very low calorie diet with low protein content (VLCD-LP group)|Very low calorie diet (850 kcals per day) with low protein content (10%)
219316718|NCT06560996|OTHER|Very low calorie diet with high protein content (VLCD-HP group)|Very low calorie diet (850 kcals per day) with high protein content (30%)
219316719|NCT02067442|DRUG|oral acetaminophen|1000 milligrams given orally before surgery
219316720|NCT02067442|DRUG|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
219316721|NCT04285242|OTHER|Observational assessments|Clinical assessments
219316722|NCT04899661|DRUG|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
219316723|NCT01054144|DRUG|Lenalidomide|"* Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~* Dose Level -4: Discontinue"
219316724|NCT01054144|DRUG|Prednisone|"* Starting Dose: 100 mg PO days 1-5 every 28 days;~* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~* Dose level -3: Discontinue"
219745658|NCT07011303|PROCEDURE|H-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the H-TZF device for centrifugation and the sample will be horizontally centrifuged (2200 RPMx8 min, 700g). After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and H-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
219316725|NCT01054144|DRUG|Dexamethasone|"* Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~* Dose level -3: Discontinue"
219316726|NCT06518564|DRUG|Avelumab|Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
219316727|NCT06518564|DRUG|M1774|Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
219316728|NCT04265547|BEHAVIORAL|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
219316729|NCT04981509|BIOLOGICAL|Atezolizumab|Given PO
219316730|NCT04981509|BIOLOGICAL|Bevacizumab|Given IV
219316731|NCT04981509|PROCEDURE|Biopsy Procedure|Undergo biopsy
219316732|NCT04981509|PROCEDURE|Biospecimen Collection|Undergo blood collection
219316733|NCT04981509|PROCEDURE|Bone Scan|Undergo bone scan
219316734|NCT04981509|PROCEDURE|Computed Tomography|Undergo CT without contrast
219316735|NCT04981509|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
219316736|NCT04981509|DRUG|Erlotinib|Given PO
219316737|NCT04981509|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219316738|NCT04981509|PROCEDURE|Positron Emission Tomography|Undergo PET
219316739|NCT04981509|DRUG|Sodium Fluoride F-18|Given F-18 sodium fluoride
219316740|NCT05628285|DEVICE|Sentio 1|Sound processor
219316741|NCT05733546|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
219316742|NCT05719415|OTHER|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
219316743|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
219316744|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
219316745|NCT06331078|OTHER|Square Stepping Exercise training|The experimental group will have Square Stepping Exercise training.
219316746|NCT06331078|OTHER|Aerobic Exercise Training|Individuals in the aerobic control cohort will partake in a treadmill walking session.
219316747|NCT06530563|DRUG|Oliceridine Injection [Olinvyk]|"Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
219316748|NCT06530563|DRUG|Sufentanil Citrate|"Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
219316749|NCT04507074|DEVICE|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
219316750|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
219316751|NCT06046040|DRUG|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
219316752|NCT05402332|DRUG|AVTX-801|D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
219316753|NCT05402332|DRUG|Placebo|placebo equivalent
219316754|NCT05050682|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
219316755|NCT05471700|DRUG|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
219316756|NCT05471700|DRUG|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
219316757|NCT05136131|PROCEDURE|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
219316758|NCT05136131|OTHER|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
219316759|NCT06963034|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
219316760|NCT06963034|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
219316761|NCT06961565|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1m and 4mg strength tablets, intended for oral administration once daily.
219316762|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
219316763|NCT04992325|DIAGNOSTIC_TEST|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
219316764|NCT04532424|DEVICE|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
219316765|NCT03918681|OTHER|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
219316766|NCT04928846|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
219316767|NCT04928846|DRUG|Docetaxel|IV Infusion
219316768|NCT03801902|RADIATION|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
219316769|NCT03801902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219316770|NCT03801902|PROCEDURE|Computed Tomography|Undergo brain CT and chest CT
219316771|NCT03801902|BIOLOGICAL|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
219316772|NCT03801902|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
219316773|NCT03801902|BIOLOGICAL|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
219316774|NCT03801902|BIOLOGICAL|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
219316775|NCT03801902|RADIATION|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
219316776|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
219316777|NCT06644937|DRUG|TACE combined with Acoradine|"Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) ."
219316778|NCT05664763|DRUG|[18F]FPEB with PET|radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
219316779|NCT05664763|BEHAVIORAL|Cannabis abstinence|Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
219316780|NCT05940662|PROCEDURE|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
219316781|NCT05940662|PROCEDURE|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
219316782|NCT05940662|PROCEDURE|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
219316783|NCT06085092|BEHAVIORAL|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
219316784|NCT06085092|BEHAVIORAL|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
219316785|NCT06397313|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
219316786|NCT06397313|DRUG|Ruxolitinib|Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
219316787|NCT03768986|BEHAVIORAL|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
219316788|NCT03768986|BEHAVIORAL|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
219316789|NCT03768986|BEHAVIORAL|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
219316790|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
219316791|NCT00334347|DRUG|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
219316792|NCT00334347|DRUG|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
219316793|NCT02404974|BEHAVIORAL|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
219316794|NCT06339619|DRUG|Adebrelimab|20mg/kg ivgtt D1 Q3W
219316795|NCT06339619|DRUG|Apatinib|250mg PO QD
219316796|NCT06339619|DRUG|Tegafur|dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
219316797|NCT06296745|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
219316798|NCT01372670|DRUG|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
219316799|NCT01372670|DRUG|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
219316800|NCT01372670|OTHER|Placebo|Placebo given 3 times per day
219316801|NCT03965078|DRUG|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
219316802|NCT05515120|DRUG|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
219316803|NCT05515120|DRUG|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
219316804|NCT05515120|DRUG|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
219316805|NCT04858854|OTHER|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
219316806|NCT01237340|DRUG|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
219316807|NCT01205997|DRUG|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
219316808|NCT01205997|DRUG|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
219316809|NCT01205997|DRUG|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
219316810|NCT04978311|BEHAVIORAL|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
219316811|NCT04978311|BEHAVIORAL|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
219316812|NCT04978311|BEHAVIORAL|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
219316813|NCT05683535|DRUG|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
219316814|NCT00151736|DRUG|Chlorambucil|Chlorambucil 2mg tablets
219316815|NCT00151736|DRUG|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
219316816|NCT02088788|DEVICE|Board|Also has radio-dense pelvic shielding
219316817|NCT02088788|DEVICE|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
219316818|NCT02423239|DRUG|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
219316819|NCT02423239|DRUG|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
219316820|NCT02423239|DRUG|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
219316821|NCT02423239|DRUG|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
219316822|NCT02701738|DIETARY_SUPPLEMENT|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
219316823|NCT00730431|DRUG|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
219316824|NCT00730431|DRUG|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
219316825|NCT04462341|DEVICE|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
219316826|NCT04462341|DEVICE|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
219316827|NCT01115972|DRUG|ASP1585|oral
219316828|NCT01115972|DRUG|valsartan|oral
219316829|NCT02876835|DRUG|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
219316830|NCT02876835|DRUG|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
219316831|NCT02876835|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
219316832|NCT02876835|DRUG|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
219316833|NCT00198549|DRUG|Vitrase (ovine hyaluronidase) Lyophilized|
219316834|NCT04537169|PROCEDURE|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
219316835|NCT02540538|BIOLOGICAL|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
219316836|NCT02540538|BIOLOGICAL|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
219316837|NCT05383404|DIAGNOSTIC_TEST|blood and urine samples|complete blood count, blood glucose, blood gases, serum bicarbonates, serum electrolytes, serum albumin ,serum creatinine. blood urea nitrogen, urine analysis.
219316838|NCT03318939|DRUG|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID"
219316839|NCT00403754|DRUG|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
219316840|NCT00403754|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219316841|NCT00403754|DRUG|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
219316842|NCT02233283|OTHER|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
219316843|NCT02233283|OTHER|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
219316844|NCT02233283|OTHER|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
219316845|NCT02233283|OTHER|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
219316846|NCT00947778|OTHER|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
219316847|NCT00947778|OTHER|1 training session|20 sessions of 30 minutes by week during 24 semaines
219316848|NCT02979925|DEVICE|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
219316849|NCT02979925|DEVICE|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
219316850|NCT04536610|BEHAVIORAL|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
219316851|NCT04536610|BEHAVIORAL|Giving informative leaflet|Leaflets containe the same information as the OP education program
219316852|NCT01548924|DRUG|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
219316853|NCT01548924|DRUG|Dovitinib + Paclitaxel|"* Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
219316854|NCT02000427|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
219316855|NCT05269836|DEVICE|Surgify Safety Burr|Use of Surgify Safety Burr in hard tissue cutting, head and spine area
219316856|NCT01655927|DRUG|Tranexamic Acid|
219316857|NCT01655927|DRUG|Placebo: Saline|
219316858|NCT02992483|DRUG|MIK665|MIK665
219316859|NCT02304848|OTHER|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
219316860|NCT03859726|DIAGNOSTIC_TEST|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
219316861|NCT03859726|DIAGNOSTIC_TEST|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
219316862|NCT00792454|BEHAVIORAL|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
219316863|NCT06239298|DRUG|ZG005 Powder for Injection|intravenous infusion(IV), once every 3 weeks
219316864|NCT06239298|DRUG|Donafenib Tosilate Tablets|The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
219316865|NCT04343248|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
219316866|NCT04343248|DRUG|Placebo|Placebo administered orally twice daily for six weeks
219316867|NCT04343248|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
219316868|NCT03829319|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
219316869|NCT03829319|DRUG|Carboplatin|IV infusion Q3W
219316870|NCT03829319|DRUG|Cisplatin|IV infusion Q3W
219316871|NCT03829319|DRUG|Pemetrexed|IV infusion Q3W
219316872|NCT03829319|DRUG|Lenvatinib|Oral capsule once daily
219316873|NCT03829319|DRUG|Placebo matching lenvatinib|Oral capsule once daily
219316874|NCT05067998|DIETARY_SUPPLEMENT|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
219316875|NCT05067998|DRUG|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
219316876|NCT04457895|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
219316877|NCT04457895|OTHER|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
219316878|NCT06518239|DEVICE|Peep Belt|Belt will be placed on the nipple line of the patient prior to the surgery start in the operating room. Data will be collected prior to the initial incision after the patient has been intubated, and then at the end of surgery before the patient has been extubated.
219316879|NCT05142189|BIOLOGICAL|BNT116|Intravenous injection
219316880|NCT05142189|BIOLOGICAL|Cemiplimab|Intravenous infusion
219316881|NCT05142189|DRUG|Docetaxel|Intravenous infusion
219316882|NCT05142189|DRUG|Carboplatin|Intravenous infusion
219316883|NCT05142189|DRUG|Paclitaxel|Intravenous infusion
219316884|NCT05142189|BIOLOGICAL|BNT316|Intravenous infusion
219316885|NCT05142189|BIOLOGICAL|anti-B7-H3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
219316886|NCT05142189|BIOLOGICAL|anti-HER3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
219316887|NCT05142189|BIOLOGICAL|Bispecific antibody for PD-L1 and VEGF-A|Intravenous infusion
219316888|NCT05045157|PROCEDURE|Percutaneous A1 Pulley Release Under Ultrasound Guidance|the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.
219316889|NCT05045157|DRUG|Corticosteroid injection|corticosteroid injection is performed
219316890|NCT04047186|DRUG|Tislelizumab Injection|Patients in the experimental group receive Tislelizumab Injection
219316891|NCT06777524|BEHAVIORAL|skin-to-skin contact education|For the intervention group, additional education on the importance and clinical benefits of mother-infant skin-to-skin contact will be provided (including an educational video). They will be instructed to engage in a minimum of 6 hours of skin-to-skin contact per day with the infant's and mother's chests exposed for at least 15 minutes per session, and to keep a record of the contact time, as well as the time spent holding the clothed infant and a daily feeding diary.
219316892|NCT04498832|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219316893|NCT04498832|BIOLOGICAL|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
219316894|NCT05607095|BIOLOGICAL|Lifileucel (LN-144/LN-145)|Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
219316895|NCT05509777|DRUG|Mirikizumab|Administered IV or SC
219316896|NCT04369066|DIAGNOSTIC_TEST|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
219316897|NCT04369066|DIAGNOSTIC_TEST|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
219316898|NCT05833087|BEHAVIORAL|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
219316899|NCT05833087|BEHAVIORAL|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
219316900|NCT05833087|OTHER|Standard care package content|"Standard care packages: The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances.~Expanded package: In one center, specialized treatment is offered for difficult-to-treat depression. Up to 9 months of psychotherapy is offered, as well as close follow-up on adjustment in medicine."
219316901|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
219316902|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
219316903|NCT05865457|DEVICE|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
219316904|NCT05865457|DEVICE|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
219316905|NCT04641143|DRUG|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
219316906|NCT04641143|DRUG|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
219316907|NCT05961592|DRUG|R-2487 DP|Probiotic
219316908|NCT05381038|DEVICE|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
219316909|NCT05381038|DEVICE|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
219316910|NCT05381038|DRUG|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
219316911|NCT05381038|DRUG|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
219316912|NCT05381038|DRUG|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
219316913|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
219316914|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
219316915|NCT04483245|BIOLOGICAL|Blood sampling|Blood sampling
219316916|NCT06263283|OTHER|session of Kine-Yoga|"Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment"
219316917|NCT06322043|DEVICE|Adipearl|Injection of the investigational device in subcutaneous tissue.
219316918|NCT05026983|DRUG|Binimetinib|Given PO
219316919|NCT05026983|DRUG|Encorafenib|Given PO
219316920|NCT05026983|OTHER|Questionnaire Administration|Ancillary studies
219316921|NCT01012739|DRUG|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
219316922|NCT01012739|DRUG|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
219316923|NCT01012739|DRUG|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
219316924|NCT01012739|DRUG|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
219316925|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
219316926|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
219316927|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
219316928|NCT04113668|DRUG|BMS-986165|Specified Dose on Specified Days
219316929|NCT04113668|DRUG|diflunisal|Specified Dose on Specified Days
219745659|NCT07011303|PROCEDURE|L-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the L-PRF device for centrifugation and the sample will be centrifuged. (2700M x 12 min, 700g) After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anaesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anaesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and L-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
219316930|NCT04321200|DIAGNOSTIC_TEST|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
219316931|NCT04321200|OTHER|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
219316932|NCT00640055|OTHER|Coordinator|Coordinator (non-physician) assigned cause of death
219316933|NCT00640055|OTHER|Physician-assigned cause of death|Physician (gold standard) cause of death
219316934|NCT02217189|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
219316935|NCT00614705|DRUG|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
219316936|NCT00614705|DRUG|Placebo|oral capsule form, once daily for 28 days
219316937|NCT01810237|DRUG|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
219316938|NCT04026061|BEHAVIORAL|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
219316939|NCT04026061|BEHAVIORAL|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
219316940|NCT05378126|OTHER|Neurological assessment|"No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation."
219316941|NCT04088396|DRUG|Baricitinib|Administered orally
219316942|NCT04088396|DRUG|Tocilizumab|Administered SC
219316943|NCT04908176|DRUG|Avapritinib|avapritinib tablets
219316944|NCT04908176|DRUG|midazolam|midazolam syrup
219316945|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
219316946|NCT06682988|DRUG|Mirvetuximab Soravtansine|intravenous (IV) infusion
219745660|NCT03907566|OTHER|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
219745661|NCT01594372|PROCEDURE|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
219745662|NCT01594372|PROCEDURE|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
219745663|NCT06689150|DRUG|Drospinetta|To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
219745664|NCT06688305|DRUG|68Ga-NI-FAPI|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
219316947|NCT05520281|BEHAVIORAL|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
219745665|NCT04635982|OTHER|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
219316948|NCT06559150|DRUG|Nebulized Ensifentrine Suspension; 3 mg|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
219316949|NCT06559150|DRUG|Nebulized Placebo Solution|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
219316950|NCT05394714|BIOLOGICAL|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
219316951|NCT05585528|PROCEDURE|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
219316952|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
219316953|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
219316954|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
219316955|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
219316956|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
219316957|NCT05165537|DEVICE|NIMM_MRS|evaluation of new MRS methods
219316958|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
219745666|NCT00969085|DRUG|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
219745667|NCT00969085|BEHAVIORAL|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
219745668|NCT00969085|OTHER|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
219745669|NCT02144818|DRUG|Ovitrel|Triggering of ovulation with Ovitrel
219745670|NCT02144818|DRUG|Decapeptyl|Triggering with GnRH agonist
219745671|NCT00223379|PROCEDURE|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
219745672|NCT05528445|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
219745673|NCT05902442|DEVICE|3DxSPLINT|Routine immobilization procedure with a patient-specific 3D printed splint instead of the use of a conventional forearm splint after one week of conventional immobilization.
219745674|NCT06928454|BEHAVIORAL|Text messages over 8 weeks|Learn about ADRD/Prepare as a care partner/Care for yourself/Get support
219745675|NCT06686368|DEVICE|I-DROP MGD|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
219745676|NCT06686368|DEVICE|Theloze Duo|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
219745677|NCT06686368|DEVICE|Systane Complete PF|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
219745678|NCT06686901|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
219745679|NCT06686901|BEHAVIORAL|Smartphone-delivered inactive Therapeutic Evaluative Conditioning|Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
219745680|NCT05833945|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of biomarkers associated to Large Vessel Occlusion in blood samples used in combination with an APP.
219745681|NCT05365880|DRUG|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
219745682|NCT05365880|DRUG|Placebo|The active placebo comparator will be provided to participant.
219316959|NCT03938701|DEVICE|Fluorescence Imaging|"Rheumatoid arthritis: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals open-air by using a black-box.~Inflammatory bowel disease: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
219316960|NCT02938793|DRUG|Durvalumab|intravenous administration
219316961|NCT02938793|DRUG|Tremelimumab|intravenous administration
219316962|NCT06390956|DRUG|Pirtobrutinib|Administered once daily as an oral medication.
219745683|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
219745684|NCT03648372|DRUG|TAK-981|Intravenous infusion.
219745685|NCT05978128|BEHAVIORAL|Health Education|Access electronic patient portal with educational material
219745686|NCT05978128|OTHER|Health Promotion and Education|Receive materials on breast/lung cancer screening
219745687|NCT05978128|BEHAVIORAL|Patient Navigation|Interact with a patient navigator
219745688|NCT05978128|OTHER|Survey Administration|Ancillary studies
219745689|NCT04211870|RADIATION|LED clusters|Each LED board contains six (6) LEDs with a wavelength of 660nm and a duration of seven (7) minutes in each muscle. The treatment was carried out in a total of four (4) sessions, one (1) session per week.
219745690|NCT06349304|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of grape powder as part of daily diet
219745691|NCT06349304|DIETARY_SUPPLEMENT|Placebo grape powder|Consumption of placebo grape powder as part of daily diet
219745692|NCT06950606|DEVICE|Pneumatic leg compression|Patients assigned to the PLC group will receive a pneumatic leg compression sleeve encompassing the calf and thigh, with sleeve size adjusted according to thigh circumference and manufacturer recommendations. The compression pump will be activated before the start of surgery. After surgery, the responsible trial personnel will deactivate the pump and remove the compression sleeves in the PLC group. There will be no standardized anesthesia management protocol; all decisions regarding hemodynamic management will be made at the discretion of the treating anesthesiologist
219745693|NCT06188975|DRUG|DRUG: ABBV-CLS-484|
219745694|NCT06295471|DEVICE|DFG Laser|Laser treatment to the upper thigh
219745695|NCT06295471|DEVICE|CO2 Laser|Laser treatment to the upper thigh
219745696|NCT06295471|DEVICE|Optical coherence tomography (OCT)|Angiographic OCT imaging at areas of interest
219354759|NCT06320483|DEVICE|Vibroacoustic device BARK VibroLUNG|"The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver."
219354760|NCT05882786|PROCEDURE|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
219354761|NCT05882786|PROCEDURE|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
219354762|NCT00428675|OTHER|ACI instrument|Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
219316963|NCT06081010|BEHAVIORAL|Community Health Worker Intervention|Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
219316964|NCT03073226|DEVICE|Olympus Elite|New generation Olympus endoscope
219316965|NCT03073226|DEVICE|Olympus Spectrum|Current generation Olympus endoscope
219316966|NCT06972719|BEHAVIORAL|Experimental Arm|Participants will be randomized to SOC plus the video.
219316967|NCT06972719|BEHAVIORAL|SOC Arm|Participants will be randomized to SOC counseling.
219316968|NCT05849181|DEVICE|Moona Device|Moona Device pillow pad
219316969|NCT05849181|DEVICE|Inactive Moona Device|Inactive Moona Device pillow pad
219316970|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
219316971|NCT05396105|DRUG|deucrictibant selected dose|deucrictibant soft capsule for oral use
219316972|NCT06269081|BEHAVIORAL|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
219316973|NCT06269081|BEHAVIORAL|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
219316974|NCT05794958|DRUG|Axicabtagene Ciloleucel|Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
219316975|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
219316976|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
219316977|NCT05701189|DRUG|Efgartigimod Alfa-Fcab|Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
219316978|NCT05701189|DRUG|Intravenous Immunoglobulin (IVIg)|IVIg is the standard-of-care treatment for GBS. Brand of IVIG used may vary per institutional standards
219316979|NCT04260217|DRUG|APG2575 400 mg|APG2575 400 mg
219316980|NCT04260217|DRUG|APG2575 600 mg|APG2575 600 mg
219316981|NCT04260217|DRUG|APG2575 800 mg|APG2575 800 mg
219316982|NCT05256238|OTHER|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~* week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…~* week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~* maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
219316983|NCT05016323|DRUG|HR19042 Capsules|HR19042 Capsules
219316984|NCT05016323|DRUG|Placebo|Placebo
219316985|NCT04282187|DRUG|Decitabine|Given IV
219316986|NCT04282187|DRUG|Ruxolitinib|Given PO
219316987|NCT04282187|DRUG|Fedratinib|Given PO
219316988|NCT04282187|OTHER|Questionnaire Administration|Ancillary studies
219316989|NCT04282187|DRUG|Pacritinib|Given PO
219316990|NCT04282187|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow samples
219316991|NCT03975959|OTHER|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
219316992|NCT06602856|OTHER|Point-of-care ultrasound examination|We are investigating the extent to which pre-hospital point-of-care ultrasound examination influences the further deployment tactics, medical treatment and choice of destination hospital for patients.
219316993|NCT06976216|DRUG|KarXT|Specified dose on specified days
219316994|NCT06976216|DRUG|KarX-EC|Specified dose on specified days
219316995|NCT06976216|OTHER|Placebo|Specified dose on specified days
219316996|NCT06976203|DRUG|KarXT|Specified dose on specified days
219316997|NCT06976203|DRUG|KarX-EC|Specified dose on specified days
219316998|NCT06976203|OTHER|Placebo|Specified dose on specified days
219316999|NCT06806046|DRUG|M9140|M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level.
219317000|NCT06805825|DRUG|NN3201|A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.
219317001|NCT06353438|OTHER|Exercise Program|Concentric strengthening of multiple muscle groups 2x/week for 6 weeks.
219317002|NCT02271477|DEVICE|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
219317003|NCT04543487|OTHER|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
219317004|NCT01118689|DRUG|MLN0128|MLN0128 administered orally once daily for 28 days
219317005|NCT04382274|PROCEDURE|Quadratus Lumborum Block|transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
219317006|NCT04382274|PROCEDURE|Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
219317007|NCT03723876|BEHAVIORAL|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
219317008|NCT04029935|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
219317009|NCT04029935|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
219317010|NCT03049735|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
219317011|NCT03049735|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
219317012|NCT03049735|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
219317013|NCT03049735|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
219317014|NCT05520255|DRUG|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
219317015|NCT06574620|GENETIC|Genetic testing|Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
219317016|NCT06574620|PROCEDURE|Optional biopsy|Optional collection of tumour tissue and normal tissue after the last dose of treatment.
219317017|NCT06574620|PROCEDURE|Tissue collection|Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.
219317018|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
219317019|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
219317020|NCT06090539|DRUG|Glofitamab/Obinutuzumab|Specified dose on specified days
219317021|NCT06090539|DRUG|Mosunetuzumab|Specified dose on specified days
219317022|NCT04003818|DRUG|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
219317023|NCT03153111|DRUG|Macitentan|macitentan 10 mg; film-coated tablet; oral use
219317024|NCT03153111|DRUG|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
219317025|NCT05558982|DRUG|BXCL701|BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days
219317026|NCT05558982|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
219317027|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
219317028|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
219317029|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
219317030|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
219317031|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
219317032|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
219317033|NCT04534504|PROCEDURE|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
219317034|NCT04046718|DEVICE|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
219317035|NCT04600362|DRUG|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
219317036|NCT01893437|DRUG|RO6799477|Single doses of RO6799477
219317037|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
219317038|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
219317039|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
219317040|NCT00390910|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
219317041|NCT00390910|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
219317042|NCT04531215|DRUG|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
219317043|NCT04531215|DRUG|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
219317044|NCT02694939|BEHAVIORAL|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
219317045|NCT02694939|BEHAVIORAL|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
219317046|NCT04585776|DRUG|LY900014|Administered SC
219317047|NCT04585776|DRUG|Insulin Degludec|Administered SC
219317048|NCT06976086|DEVICE|Active transcutaneous bone conduction system|The Sentio system consists of the Sentio 1 Mini sound processor (SP) and Sentio Ti implant with fixation band and screws.
219317049|NCT02258165|DEVICE|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
219317050|NCT01620112|DRUG|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
219317051|NCT01620112|DRUG|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
219317052|NCT01620112|DRUG|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
219317053|NCT01620112|DRUG|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
219317054|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
219317055|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
219317056|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
219317057|NCT04421833|BEHAVIORAL|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
219317058|NCT04421833|BEHAVIORAL|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
219317059|NCT03171831|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
219317060|NCT03171831|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
219317061|NCT03171831|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
219317062|NCT03171831|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
219317063|NCT03171831|DRUG|Tacrolimus|Tacrolimus（0.03mg/kg/day）
219317064|NCT03171831|DRUG|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
219317065|NCT03171831|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
219317066|NCT03171831|DRUG|Basiliximab|Basiliximab（10mg on day 0 and +4）
219317067|NCT02762253|DRUG|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
219317068|NCT02902003|BEHAVIORAL|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
219317069|NCT02749656|DRUG|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
219317070|NCT02749656|DRUG|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
219317071|NCT02749656|DRUG|Placebo|apply on the scalp psoriasis lesion twice a day
219317074|NCT05652686|DRUG|Peluntamig (PT217)|A bispecific antibody (bsAb) against DLL3 and CD47.
219317075|NCT05652686|DRUG|Carboplatin + Etoposide|Administered per Standard of Care.
219317076|NCT05652686|DRUG|Paclitaxel.|Administered per Standard of Care.
219317077|NCT05652686|DRUG|Atezolizumab|Administered per Standard of Care.
219317078|NCT02314767|BEHAVIORAL|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
219317079|NCT02314767|BEHAVIORAL|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
219317080|NCT01276431|DRUG|Buprenorphine transdermal patch|
219317081|NCT02612753|PROCEDURE|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
219317082|NCT02612753|DEVICE|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
219317083|NCT02612753|DEVICE|tDCs|
219317084|NCT01389765|DRUG|LY2216684|Administered orally
219317085|NCT01439919|DRUG|SSR411298|"Form: tablet~Route: oral administration with food"
219317086|NCT01439919|DRUG|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
219317087|NCT03565120|RADIATION|Aggressive Thoracic Radiotherapy|The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
219317088|NCT02753140|DRUG|Cetuximab|
219317089|NCT02753140|RADIATION|radiation|
219317090|NCT02753140|DRUG|Docetaxel|
219317091|NCT02753140|DRUG|Cisplatin|
219317092|NCT01216384|DRUG|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
219317093|NCT01216384|DRUG|placebo|Subjects will receive according to the dose group matching number of placebo tablets
219317094|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
219317095|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
219317096|NCT03450967|DRUG|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
219317097|NCT04598048|BEHAVIORAL|Questionnaire|Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
219317098|NCT06223204|OTHER|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
219317099|NCT02292368|BEHAVIORAL|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
219317100|NCT02292368|PROCEDURE|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
219317101|NCT02292368|PROCEDURE|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
219317102|NCT02882087|DRUG|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
219317103|NCT02882087|DRUG|RC18 160 mg plus MTX|
219317104|NCT04497194|OTHER|not applicable (observational study)|not applicable (observational study)
219317105|NCT04727086|DRUG|BP1.3656|BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
219317106|NCT04727086|DRUG|Placebo|Administered once daily in tablet form.
219317107|NCT00516243|OTHER|placebo|Given PO
219317108|NCT00516243|OTHER|quality-of-life assessment|Ancillary studies
219317109|NCT00516243|PROCEDURE|questionnaire administration|Ancillary studies
219317110|NCT00516243|PROCEDURE|laboratory biomarker analysis|Correlative studies
219317111|NCT00516243|DRUG|defined green tea catechin extract|Given PO
219317112|NCT02455219|DEVICE|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
219317113|NCT03877432|DEVICE|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
219317114|NCT06434948|DRUG|Omega-3 Ethyl Esters 4 g|4 grams = 4 capsules, once daily
219317115|NCT06434948|DRUG|Omega-3 Ethyl Esters 2 g|2 grams = 2 capsules, once daily
219317116|NCT06249373|DEVICE|Low intensity pulse ultrasound （LIPUS） intervention for arteriovenous fistula anastomosis|The LIPUS intervention group for arteriovenous fistula should receive forearm wearable portable low-intensity pulse ultrasound （LIPUS） intervention at the anastomotic site no more than 3 days after suture removal two weeks after the fistula surgery. If the ultrasound examination indicates the presence of stenosis in the outflow tract, the intervention should also be performed at the same time. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
219317117|NCT02802709|DEVICE|SB-061|delivered via intra-articular injection
219317118|NCT02802709|OTHER|Placebo|Placebo
219317119|NCT01299987|RADIATION|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
219317120|NCT06151054|DIAGNOSTIC_TEST|Measure of aortic inflammation|Standard Uptake Value (SUV) measures of aortic wall
219317121|NCT04038853|DRUG|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
219317122|NCT04038853|DRUG|Placebo|Placebo identical to the study intervention drug
219317123|NCT01998126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
219317124|NCT01998126|DRUG|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
219317125|NCT01998126|DRUG|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
219317126|NCT01998126|DRUG|Nivolumab|
219317127|NCT04758182|DEVICE|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
219317128|NCT04758182|DEVICE|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
219317129|NCT06378411|DEVICE|Music Game Intervention|Use of music to induce improvements in cognitive and motor outcomes.
219317130|NCT05512637|DIAGNOSTIC_TEST|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
219317131|NCT03365050|OTHER|No Intervention Given|No Intervention to be given
219317132|NCT00174265|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
219317133|NCT00174265|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
219317134|NCT01474863|DRUG|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
219317135|NCT01474863|DRUG|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
219317136|NCT01474863|DRUG|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
219317137|NCT03456531|DEVICE|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
219317138|NCT03456531|DRUG|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
219317139|NCT01473160|DEVICE|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
219317140|NCT01473160|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
219317141|NCT01798277|PROCEDURE|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
219317142|NCT01798277|DRUG|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
219317143|NCT02211352|DRUG|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
219317144|NCT02211352|DRUG|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
219317145|NCT02810899|DRUG|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
219317146|NCT02810899|DRUG|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
219317147|NCT06503562|OTHER|central nervous system focused treatment program|Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery
219317148|NCT06503562|OTHER|Classical Physiotherapy|All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
219317149|NCT05539833|DRUG|KSH01 injection|TCR-T cell injection
219317150|NCT01946841|DIETARY_SUPPLEMENT|RealDiet®Renal|
219317151|NCT02882932|PROCEDURE|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
219317152|NCT00372021|PROCEDURE|optic nerve neurotomy|
219317153|NCT02577601|DRUG|Ulipristal Acetate|
219317154|NCT02577601|DRUG|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
219317155|NCT03728413|BIOLOGICAL|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
219317156|NCT03341351|OTHER|Instructional video|Instructional video using the modified beef tongue model
219317157|NCT03341351|OTHER|Instructional workshop|Instructional workshop using the modified beef tongue model.
219317158|NCT01572922|DEVICE|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
219317159|NCT01572922|DEVICE|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
219317160|NCT01572922|PROCEDURE|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
219317161|NCT03040622|DEVICE|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
219317162|NCT04231266|DRUG|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
219317163|NCT04231266|OTHER|Placebo|Placebo
219317164|NCT06335862|OTHER|Randomisation between the PPT- and no-PPT-group|Randomisation is performed between two possible treatment options for tracheomalacia in OA patients; the PPT or the wait-and-see policy (no-PPT).
219317165|NCT06335862|PROCEDURE|Primary Posterior Tracheopexy|The PPT involves fixating the posterior membrane of the trachea to the spinal ligament with sutures, to prevent the trachea from collapsing.
219317166|NCT06335862|DIAGNOSTIC_TEST|Preoperative tracheobronchoscopy|Prior to OA correction, a flexible and a rigid tracheobronchoscopy will be performed, in addition to a flexible tracheobronchoscopy through the endotracheal tube. Preoperative evaluation of TM through a tracheobronchoscopy is part of standard care for all participating centres.
219317167|NCT06335862|DIAGNOSTIC_TEST|Intraoperative tracheobronchoscopy|After the PPT is performed, or in case of the no-PPT group at the stage of the surgery when the PPT would usually be performed, a flexible tracheobronchoscopy through the endotracheal tube is carried out. This tracheobronchoscopy is routine care for all patients undergoing a PPT, and is additional for patients in the no-PPT-group.
219317168|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy through the endotracheal tube during extubation|A postoperative flexible tracheobronchoscopy is performed in the neonatal or pediatric intensive care unit (ICU), through the endotracheal tube during extubation. This procedure is a study intervention.
219317169|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy after 2-6 months|Two to six months after OA correction, a follow-up flexible and a rigid tracheobronchoscopy will be performed, under general anesthesia in the surgical theatre. This postoperative evaluation of TM through a tracheobronchoscopy is part of standard care for the Karolinska University Hospital and Great Ormond Street Hospital. At the University Medical Centre Utrecht and Erasmus Medical Centre Rotterdam, this tracheobronchoscopy is performed on indication in approximately half of patients. For the other half of patients, this is a study intervention.
219317170|NCT06245642|DRUG|Compound Ciwujia Granules, Guipi Granules|Experimental group: Basic treatment + Compound Ciwujia Granules + Guipi Granules simulator orally for 6 weeks; Positive drug control group: basic treatment + Guipi Granules + Compound Ciwujia Granules simulant orally for 6 weeks.
219317171|NCT05880277|DIAGNOSTIC_TEST|POCUS|Point of Care Ultrasound
219317172|NCT01802489|DRUG|Amiloride|
219317173|NCT01802489|DRUG|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
219317174|NCT00809081|PROCEDURE|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
219317175|NCT00160381|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
219317176|NCT00160381|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
219317177|NCT00160381|DRUG|Placebo|Tablet, oral Daily for 12 months
219317178|NCT00445068|DRUG|LBH589|
219317179|NCT05636891|BIOLOGICAL|Stimus|"* NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
219317180|NCT00447382|DRUG|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
219317181|NCT00447382|DRUG|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
219317182|NCT00447382|DRUG|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
219317183|NCT05651750|DRUG|Montelukast|receiving 2 months treatment with Montelukast once a day
219317184|NCT05651750|DRUG|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
219317185|NCT04119973|OTHER|standard treatment|standard medical treatment
219317186|NCT03861819|BEHAVIORAL|Vigorous-intensity interval training (VIIT)|Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
219317187|NCT05915000|DIAGNOSTIC_TEST|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
219317188|NCT04273698|BEHAVIORAL|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
219317189|NCT05514054|DRUG|Imlunestrant|Administered orally.
219317190|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
219317191|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
219317192|NCT05514054|DRUG|Letrozole|Administered per local approved label.
219317193|NCT05514054|DRUG|Exemestane|Administered per local approved label.
219317194|NCT07118852|DEVICE|Remote Human Milk Sample Collection|"Three commercially available products will be evaluated for their ability to preserve RNA in human milk samples.~* RNAlater (ThermoFisher©) (ratio variable)~* DNA/RNA Shield (Zymo©) (ratio variable)\*~* NucleoProtect RNA (Takara©) (ratio variable)\*~  * Product volume mixed with human milk samples will vary by product and may be titrated as part of protocol development."
219317195|NCT04335383|BIOLOGICAL|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
219317196|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
219317197|NCT04600336|DRUG|Placebo Administration|Given PO
219317198|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
219317199|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
219317200|NCT06809985|PROCEDURE|Hamilton maneuver|The Hamilton maneuver is performed by inserting one or two fingers through the internal cervical os and carefully producing a circumferential rotational movement through the uterine segment in order to separate the fetal membranes from the decidua. This maneuver is recommended in order to reduce the need for formal induction.
219317201|NCT01998009|OTHER|fecal occult blood tests|
219317202|NCT00207805|PROCEDURE|autologous PBSC transplant|optimal timining of a second autologous transplant
219317203|NCT03298685|OTHER|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
219317204|NCT04829929|DEVICE|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
219317205|NCT00308269|DRUG|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
219317206|NCT00308269|DRUG|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
219317207|NCT02561533|OTHER|BRAF detection on fine needle aspiration biopsy (FNAB)|
219317208|NCT05826574|DRUG|Brensocatib|Oral tablets.
219317209|NCT05826574|DRUG|Rifampin|Oral capsules.
219317210|NCT05826574|DRUG|Esomeprazole|Oral capsules.
219317211|NCT06029725|DEVICE|radiofrequency microneedling combined with 1927 nm thulium laser|"1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy"
219317212|NCT06029725|DEVICE|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
219317213|NCT04291261|DRUG|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
219317214|NCT00780754|DRUG|dutasteride|0.5mg
219317215|NCT00780754|PROCEDURE|prostate biopsy|prostate biopsy
219317216|NCT06286007|DIAGNOSTIC_TEST|PCR|Depending on the symptoms presented and date of symptom onset, for pertussis, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 3 weeks For RSV, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 72 hours.
219317217|NCT00091585|DRUG|SNS-595|
219317218|NCT06825338|OTHER|CATCH My Breath|CATCH My Breath (CMB) is a school-based vaping prevention curriculum based on best practices from earlier prevention studies that works by fostering social competence and social influence resistance skills. The curriculum design and content targets two key constructs of Social Cognitive Theory: self-efficacy and behavioural capacity (i.e., knowledge and skills). The curriculum provides students with knowledge of why and how to resist vaping. It is delivered through two 60-minute lessons by a trained Public Health Unit presenter. The curriculum lessons provide information about: 1) the physical, mental, and addiction risks associated with vaping, 2) social norms of vaping (e.g., most youth don't vape), 3) media literacy (e.g., how to recognize and decipher marketing of vapes), 4) strategies to resist and avoid vaping, 5)school and provincial policies about vaping. To solidify the content, in-class activities allow students to discuss what they are learning and practice refusal skills.
219317219|NCT03144804|DRUG|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
219317220|NCT02100397|BIOLOGICAL|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
219355018|NCT01389557|DRUG|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
219317221|NCT06514326|BEHAVIORAL|DPT-TP|"This intervention includes all the ingredients of DPT-STD, but with additional features that correspond to the conceptual model of therapeutic persuasiveness. Each theme in the program comprises a learning phase followed by a 1-2 week focusing phase.~Accordingly, the program utilizes the following features:~1. Call to action: Parents receive timely triggers via text messages that are related to the specific goals and therapeutic activities of the modules they have completed.~2. Monitoring and ongoing feedback of user state: Specific practices currently taught are documented within the system through a brief daily report, on which parents receive feedback.~3. Adaptation to user state: Parents' reports on their activities are used to acknowledge their success and to suggest additional actions based on the specific goals reported by parents. Effort related to desired therapeutic activities is adapted based on graded tasks."
219317222|NCT06514326|BEHAVIORAL|DPT-STD|"This intervention is similar in its features to other programs that deliver DPT, and is suitable for use on computers or on mobile devices. An icon is positioned on the mobile device home screen in order to enable quick access to the program. The DPT-STD comprises seven 10- to 25-minute modules, each corresponding to one of the themes mentioned above. Each module's content includes videos and texts guiding the parent through the training process, and interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials and a questions and answers section that contains frequently asked questions."
219317223|NCT03278730|DRUG|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
219317224|NCT03278730|DRUG|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
219317225|NCT06616324|DEVICE|Virtual Reality|Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
219317226|NCT06993623|DIAGNOSTIC_TEST|heparin binding protien|compare between Heparin binding protien and platelet count and mean platelet volume kinetics in diagnosis and prognosis of VAP
219317227|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
219317228|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
219317229|NCT01786187|BEHAVIORAL|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
219317230|NCT01786187|OTHER|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
219317231|NCT07013708|DEVICE|Laser|High frequency laser device
219317232|NCT07013708|OTHER|Placebo|Same device but without pressing the ON button
219317233|NCT07016633|DRUG|IMM-H014|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
219317234|NCT07016633|DRUG|Placebo|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
219317235|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Solfeggio Frequencies|Music featuring Solfeggio frequencies (174 Hz, 285 Hz, 396 Hz, 528 Hz) is played through standardized speakers in a sound-isolated room during IDT. Duration includes five minutes before and throughout the procedure
219317236|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Traditional Turkish Music|Selected Turkish Classical Music pieces (makams: Rast, Hicaz, Uşşak, Neva, Saba) are played via speakers in a sound-isolated room during IDT. Music begins five minutes prior and continues during the procedure.
219317237|NCT07021092|OTHER|Interventions will be developed in aim 2 of the study.|Person-centred package that connects patients to service delivery, builds rapports and improves engagement in care leading to sustained viral load suppressions
219317238|NCT07020377|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg tab once daily for NAFLD patient
219317239|NCT07020377|DRUG|Placebo|placebo
219317240|NCT07020377|OTHER|Negative control|Baseline sample serum without either drug or placebo
219317241|NCT07020949|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
219317242|NCT07020949|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
219317243|NCT07021183|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria tailored to PSP. The Sleep Course has been slightly adapted for PSP by including relevant statistics and literature pertaining to sleep disturbance in PSP. The Sleep Course has four lessons and includes optional therapist support for up to 8 - 12 weeks. Should clients request support, clients will be contacted by their therapist by secure emails on their designated check-in dates. The therapist also reviews client progress in the Course and emails clients on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
219317244|NCT06901895|COMBINATION_PRODUCT|Hylorunic acid|Hylorunic acid (hylo) eye drop is prescribed and check the curative effect after phacoemulsification after 2nd and 4th week.
219317245|NCT06901895|DIAGNOSTIC_TEST|Lipid coated carbomer gel|Lipid coated carbomer gel (visole)is prescribed and check yhe curative effect after phacoemulsification in diabetic patients post operatively in 2nd and 4th week.
219317246|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
219317247|NCT04091451|DRUG|Placebo|2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
219317248|NCT06733792|BEHAVIORAL|CBT-based intervention|"* 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use).~* 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use).~* 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use).~* 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan."
219317249|NCT06733792|BEHAVIORAL|Self-help guide|Psychoeducation on cannabis.
219317250|NCT06885151|OTHER|Evidence-based IVF website content|The Evidence-based IVF website has been developed through a robust co-design process with IVF patients and clinicians, and the information about effectiveness and safety of add-ons was produced following established systematic review methodology of Cochrane (including risk of bias, GRADE, and TRACT assessment). They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
219317251|NCT06885151|OTHER|Control|Participants will view information that has been generated by combining information from the top 3 websites retrieved on Google search of the add-on name. They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
219317252|NCT06902064|DEVICE|Transcranial temporal interference stimulation|Transcranial temporal interference stimulation (tTIS) is a novel neurostimulation technique that utilizes two or more electric fields of specific frequencies to modulate the oscillations of neurons at the desired spatial location in the brain. The physics of tTIS offers the advantage of non-invasively regulating deep brain structures and minimally stimulating the overlying cortex outside the selected target.
219317253|NCT06902064|DEVICE|sham tTIS|"The sham tTIS is enabled by checking the Pseudo-Stimulation option on the screen. After the rising phase, the current will drop directly to 0mA, imitating the sensation of a real stimulation."
219317254|NCT05671419|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
219317255|NCT06466577|DIAGNOSTIC_TEST|CT 5400 RT System|Computed Tomography X-RAY System is intended to produce images of the head and body by computer reconstruction of x-ray transmission data taken at different angles and planes.
219317256|NCT05772156|DRUG|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
219317257|NCT05772156|DRUG|Placebo|Matching saline placebo
219317258|NCT07178223|PROCEDURE|Arthroplasty CMC-1|Touch Touch® dual-mobility Arthroplasty CMC-1 joint (Kerimed). Dorsal approach. Conical cup. Soft dressing 3 weeks. Loading allowed after 2 months.
219317259|NCT07188350|OTHER|Conventional Physical Therapy|Individualized physical therapy including progressive mobility (e.g., bed exercises, sitting on the edge of the bed, standing, transfers, and ambulation) and respiratory therapy tailored to the patient's clinical condition. Delivered daily by trained professionals.
219317260|NCT07188350|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES will be applied to both lower limbs once or twice daily for 20 consecutive days. Electrodes will be positioned on the vastus lateralis, vastus medialis, tibialis anterior, hamstrings, and gastrocnemius muscles. The stimulation protocol includes progressive parameters to induce visible and effective muscle contractions.
219317261|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine ganlion block with 2ml of 2% lidocaine and 0.5ml of diluted adrenaline after general anesthesia in patients undergoing enoscopic hypophysectomy.
219317262|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine and 0.5ml saline after general anesthesia in patients undergoing enoscopic hypophysectomy.
219317263|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine in addition to 0.5ml of diluted adrenaline. after general anesthesia in patients undergoing enoscopic hypophysectomy.
219317264|NCT07187856|DRUG|PG-102|PG-102 is administered subcutaneously once weekly with a titration regimen.
219317265|NCT07187856|DRUG|Placebo|Placebo is administered subcutaneously once weekly.
219317266|NCT07187856|DRUG|Semaglutide|Open-label semaglutide is administered subcutaneously once weekly with titration regimen.
219317267|NCT07189377|DRUG|Entecavir|Recipients will receive 1mg administered orally, beginning pre-transplant as soon as the patient arrives to the hospital for surgery, and then 1mg post-operatively administered orally or via nasogastric tube once daily for 28 days.
219317268|NCT07189377|BIOLOGICAL|HBIG|Recipients will receive 4500 IU intravenously pre-transplant and then at day 3 and 7 post-transplant (3 doses total).
219317269|NCT07189377|DEVICE|EVLP UV Light Treatment|UV light therapy will be administered to the organ during EVLP prior to transplantation. For minimum 2 hours, maximum 6 hours (duration determined by time clinically required for EVLP based on standard clinical assessment of lung).
219317270|NCT07187609|PROCEDURE|Immediate implant with bovine drived hydroxyapatite xenograft.|patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.
219317271|NCT07187609|PROCEDURE|immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft|patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
219317272|NCT07187687|PROCEDURE|Early Minimally Invasive Surgery with Thrombolysis (eMIST)|Subjects will undergo minimally invasive catheter evacuation in the early stage of intracranial hemorrhage. Up to 10 doses of 50000U of urokinase will be administered through the catheter that was placed directly into the intracerebral hemorrhage.
219317273|NCT07187986|OTHER|Sound acupuncture|Best medical therapy + soundpuncture
219317274|NCT07189013|DEVICE|Mechanical infusion pump|Patients with earlier experience on electronic infusion pumps will crossover to the mechanical infusion pump for three month's period
219317275|NCT01278251|PROCEDURE|Distal Biceps Re-Insertion|
219317276|NCT04286516|DEVICE|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
219317277|NCT02413840|BEHAVIORAL|Baduanjin qigong|
219317278|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
219317279|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
219317280|NCT03620890|DRUG|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
219317281|NCT03620890|DRUG|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
219317282|NCT05976087|DEVICE|SensoExo|combination of sensory feedback and the use of soft exoskeleton
219317283|NCT04358263|DEVICE|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
219317284|NCT04358263|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
219317285|NCT02537418|DRUG|durvalumab|
219317286|NCT02537418|DRUG|tremelimumab|
219317287|NCT06018844|OTHER|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
219317288|NCT05163210|BEHAVIORAL|AO+VR|The experimental treatment will consist of 15 hours (min. 15, max. 20), and will be carried out 4 days/week for a total duration of 5 weeks. During the rehabilitation sessions, the patient will be instructed to carefully watch videos lasting about 1.5 minutes, presented on Liquid Crystal Display (LCD) monitor, consisting in unimanual or bimanual actions performed by an actor, from a lateral perspective. Subsequently, the patient will be asked to imitate the actions presented for at least 3 consecutive times, within a time window of 3 min., using the same objects observed in the video, in a virtual scenario (VR), through the Khymeia Virtual Reality Rehabilitation System (VRRS).
219317289|NCT05163210|BEHAVIORAL|CO+VR|Patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist. Thus, the general setting for carrying out the rehabilitation sessions will be identical to that of the experimental treatment, except for the fact that the control group will not be involved in action observation before preforming the exercises. Thus, the control treatment is not based on action imitation, but on purely motor execution.
219317290|NCT05818436|PROCEDURE|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
219317291|NCT05818436|DEVICE|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
219317292|NCT03633747|DRUG|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
219317293|NCT05995964|DRUG|PF-07275315|subcutaneous injection
219317294|NCT05995964|DRUG|PF-07264660|subcutaneous injection
219317295|NCT05995964|OTHER|Placebo|subcutaneous injection
219317305|NCT03769181|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219317306|NCT03769181|DRUG|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219317307|NCT02087748|DRUG|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
219317308|NCT02087748|DRUG|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
219317309|NCT01674751|OTHER|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
219317310|NCT06493981|DRUG|Eltrombopag|Treatment with eltrombopag in a dose of (50-150mg/d)
219317311|NCT05640466|DEVICE|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
219317312|NCT04260451|OTHER|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1\. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
219317313|NCT01508546|PROCEDURE|axillary dissection|Conservative breast surgery with or without axillary dissection
219317314|NCT01611064|DRUG|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
219317315|NCT01611064|DRUG|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
219317316|NCT00444392|BEHAVIORAL|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
219317317|NCT03078907|DRUG|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
219317318|NCT03078907|DRUG|Placebo|Matching film coated tablets
219317319|NCT06198751|DRUG|6.0 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.
219317320|NCT06198751|DRUG|7.5 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
219317321|NCT05193240|DIAGNOSTIC_TEST|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
219317322|NCT06224309|DIAGNOSTIC_TEST|18F-BL40 PET/CT|Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
219317323|NCT06224309|DIAGNOSTIC_TEST|18F-FDG PET/CT|"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
219317324|NCT06224309|DIAGNOSTIC_TEST|Routine Blood Draw - Phase 1 only|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
219317325|NCT03338192|OTHER|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
219317326|NCT00222573|DRUG|clopidogrel and metoprolol|
219317327|NCT03808688|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
219317328|NCT02991508|DRUG|Placebo|
219317329|NCT02991508|DRUG|Adrecizumab|
219317330|NCT00528983|DRUG|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
219317331|NCT00528983|DRUG|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
219317332|NCT00528983|DRUG|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
219317333|NCT03329196|DRUG|MT-6548|Oral tablet
219317334|NCT03329196|DRUG|Darbepoetin alfa|Subcutaneous
219317335|NCT04401163|DIAGNOSTIC_TEST|Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.
219317336|NCT03974399|DIETARY_SUPPLEMENT|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
219317337|NCT04450836|DRUG|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
219317338|NCT04450836|DRUG|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
219317339|NCT05433675|DRUG|Macitentan|Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
219317340|NCT00278460|DRUG|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
219317341|NCT00278460|DRUG|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
219317342|NCT04536454|DRUG|[18F]FPyGal|Radiotracer for PET-imaging
219317343|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
219317344|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
219317345|NCT06572111|DRUG|BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) formulation 1
219317346|NCT06572111|DRUG|BI 1839100|BI 1839100
219317347|NCT06572111|DRUG|BI 1839100 (C-14) formulation 2|BI 1839100 (C-14) formulation 2
219317348|NCT04450654|DRUG|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
219317349|NCT04450654|DRUG|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
219317350|NCT03685864|OTHER|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
219317351|NCT03685864|OTHER|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
219317352|NCT05028829|DRUG|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
219317353|NCT05028829|DRUG|Placebo|Oral administration of placebo
219317354|NCT00421473|DRUG|Atovaquone / Proguanil|
219317355|NCT04175808|DRUG|Omecamtiv Mecarbil (OM)|Oral solution
219317356|NCT04175808|DRUG|Placebo|Placebo oral solution
219317357|NCT04175808|DRUG|Moxifloxacin|400 mg moxifloxacin oral tablet
219317358|NCT05706896|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
219317359|NCT06284486|DRUG|Venetoclax|Given by PO
219317360|NCT06284486|DRUG|Revumenib|Given by PO
219317361|NCT04883671|OTHER|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
219317362|NCT04883671|RADIATION|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
219317363|NCT05205382|OTHER|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
219317364|NCT05205382|OTHER|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
219317365|NCT05205382|OTHER|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
219317366|NCT03594344|PROCEDURE|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
219317367|NCT04516707|OTHER|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
219317368|NCT04959175|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
219317369|NCT04959175|PROCEDURE|Allogeneic HSCT|Stem cell transplant
219317370|NCT04959175|DRUG|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
219317371|NCT04959175|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
219317372|NCT04959175|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
219317373|NCT04959175|DRUG|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
219317374|NCT04959175|DRUG|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
219317375|NCT04959175|PROCEDURE|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
219317376|NCT05726227|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
219317377|NCT05726227|DRUG|Placebo|Placebo will be administered subcutaneously once-weekly.
219317378|NCT06012149|BEHAVIORAL|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
219317379|NCT06012149|BEHAVIORAL|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
219317380|NCT04171310|DRUG|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
219317381|NCT03263351|BEHAVIORAL|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
219317382|NCT03263351|BEHAVIORAL|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
219317383|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive generic/regular PSAs that address vaping harms more broadly; during the second six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products.
219317384|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products; during the second six months, they will receive generic/regular PSAs that address vaping harms more broadly.
219317385|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (no message exposure)|Participants will not receive any message intervention in this arm.
219317386|NCT04669158|DRUG|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
219317387|NCT04669158|DRUG|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
219317388|NCT05870748|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
219317389|NCT05870748|DRUG|Pegfilgrastim|Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.
219317390|NCT05870748|DRUG|Gemcitabine|Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.
219317391|NCT05870748|DRUG|Paclitaxel|Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.
219317392|NCT05870748|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
219317393|NCT05870748|DRUG|Topotecan|Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
219317394|NCT06334120|DRUG|Darolutamide (Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
219317395|NCT06129864|DRUG|volrustomig|volrustomig
219317396|NCT05598814|BIOLOGICAL|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
219317397|NCT05598814|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
219317398|NCT05499130|DRUG|TEV-48574|Subcutaneous infusion
219317399|NCT05499130|DRUG|Placebo|Matching Placebo
219317400|NCT04033263|OTHER|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
219317401|NCT04033263|OTHER|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
219317402|NCT04033263|OTHER|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
219317403|NCT04033263|OTHER|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
219317404|NCT04733027|COMBINATION_PRODUCT|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
219317405|NCT06635057|DRUG|Tirzepatide|Administered SC
219317406|NCT06625190|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
219317407|NCT06625190|DRUG|Zoledronic acid|"All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion."
219317408|NCT05537740|DRUG|BAY3375968|Intravenous (IV) infusion
219317409|NCT05537740|DRUG|Pembrolizumab|IV infusion
219317410|NCT02076750|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
219317411|NCT06112613|OTHER|Electronic Health Record Review|Ancillary studies
219317412|NCT06112613|OTHER|Health Promotion and Education|Receive access to educational materials
219317413|NCT06112613|PROCEDURE|Health Telemonitoring|Utilize the WiseBag medication dispenser
219317414|NCT06112613|OTHER|Interview|Complete an interview
219317415|NCT06112613|BEHAVIORAL|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
219317416|NCT06112613|OTHER|Survey Administration|Ancillary studies
219317417|NCT06112613|OTHER|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
219317418|NCT03413371|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
219317419|NCT03413371|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
219317420|NCT03413371|DRUG|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
219317421|NCT03413371|DRUG|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
219317422|NCT05531786|DRUG|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
219317423|NCT05907291|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
219317424|NCT00747630|OTHER|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
219317425|NCT04680351|PROCEDURE|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
219317426|NCT01777087|OTHER|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
219317427|NCT05745844|OTHER|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
219317428|NCT01685710|DRUG|GTN patch|
219317429|NCT01685710|DRUG|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
219317430|NCT02415465|PROCEDURE|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
219317431|NCT02415465|PROCEDURE|General|General Intraoperative Anesthesia
219317432|NCT02415465|PROCEDURE|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
219317433|NCT02415465|PROCEDURE|Spinal|Spinal Intraoperative Anesthesia
219317434|NCT06637917|DEVICE|OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System|The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.
219317435|NCT06637917|DEVICE|LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter|The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.
219317436|NCT06637917|DEVICE|1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor|Market-released ECG monitoring system
219317437|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
219317438|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
219317439|NCT05712200|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
219317440|NCT05712200|DRUG|Placebo|"Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab"
219317441|NCT00000913|DRUG|Ritonavir|
219317442|NCT00000913|DRUG|Nelfinavir mesylate|
219317443|NCT00000913|DRUG|Saquinavir|
219317444|NCT05740657|DRUG|Fentanyl|The drugs were administered in the course of a surgery or for pain management.
219317445|NCT03537859|OTHER|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
219317446|NCT03537859|OTHER|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
219317447|NCT04620551|DEVICE|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
219317448|NCT03976349|DRUG|BIIB094|Administered as specified in the treatment arm.
219317449|NCT03976349|DRUG|Placebo|Administered as specified in the treatment arm.
219317450|NCT03997266|DRUG|Ampicillin|Intravenous ampicillin
219317451|NCT03997266|DRUG|Gentamycin|Intravenous gentamycin
219317452|NCT03997266|DRUG|Normal saline|Intravenous normal saline
219317453|NCT04720209|OTHER|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
219317454|NCT04720209|OTHER|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
219317455|NCT04720209|OTHER|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
219317456|NCT06505044|PROCEDURE|aerobic exercise|"aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake."
219317457|NCT06505044|PROCEDURE|resistance exercise|resisted exercise program for 12 weeks
219317458|NCT06378528|DRUG|Ketamine|3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
219317459|NCT06378528|DEVICE|SmartSleep EEG recording headband|Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
219317460|NCT05363280|DRUG|AL8326 low dose group|Taken AL3826 at low dose orally
219317461|NCT05363280|DRUG|AL8326 middle dose group|Taken AL3826 at middle dose orally
219317462|NCT05363280|DRUG|AL8326 high dose group|Taken AL3826 at high dose orally
219317463|NCT05481879|DRUG|DYNE-101|Administered by IV infusion
219317464|NCT05481879|DRUG|Placebo|Administered by IV infusion
219317465|NCT06312358|BEHAVIORAL|Building Capacity for Infant Achievements in Child Care|All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
219317466|NCT06127979|PROCEDURE|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
219317467|NCT06127979|OTHER|blood draw|blood draw
219317468|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
219317469|NCT05796362|DRUG|Azithromycin Oleogel (Oral and Rectal)|"Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)"
219317470|NCT00552201|DRUG|Tacrolimus|Administration Twice a day after adjustment to blood level
219317471|NCT03720262|COMBINATION_PRODUCT|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
219317472|NCT03720262|OTHER|No reinforcement|Suturing the abdominal wall without mesh reinforcement
219317473|NCT06515093|OTHER|PelloGraft|dual layer amnion/chorion-derived allograft
219317474|NCT06515093|OTHER|SanoGraft|single layer amnion-derived allograft
219317475|NCT06510309|DRUG|Venetoclax|B-cell lymphoma inhibitor, tablets taken orally per protocol.
219317476|NCT06510309|DRUG|Rituximab|Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.
219317477|NCT05735730|OTHER|Blood draw|The study intervention consists of a blood draw for genetic analysis.
219317478|NCT04118283|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
219317479|NCT04118283|BEHAVIORAL|Health and Wellness|Health \& Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
219317480|NCT02042430|DRUG|Epacadostat|Given PO
219317481|NCT02042430|OTHER|Laboratory Biomarker Analysis|Correlative studies
219317482|NCT02042430|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219317483|NCT06387966|DRUG|Flonoltinib Maleate Tablets|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
219317484|NCT06387966|DRUG|Flonoltinib Maleate Tablets placebo|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
219317485|NCT02853019|OTHER|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
219317486|NCT02853019|BEHAVIORAL|Cognitive tasks|\- clinical scales and subjective assessments of emotional and motivational stimuli
219317487|NCT02853019|BEHAVIORAL|subjective evaluation scales|\- clinical scales and subjective assessments of emotional and motivational stimuli
219317488|NCT02993523|DRUG|Azacitidine|Solution for subcutaneous or intravenous administration.
219317489|NCT02993523|DRUG|Venetoclax|Tablet
219317490|NCT02993523|DRUG|Placebo|Matching placebo tablet
219317491|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after oncological surgery.|In patients who will undergo oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
219317492|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after non-oncological surgery.|In patients who will undergo non-oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
219317493|NCT06631339|OTHER|Light Intervention|LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
219317494|NCT06631339|BEHAVIORAL|Digital Intervention|Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
219317495|NCT06631339|OTHER|Control Group|Standard Classroom Lighting + Sham LightUP phone application
219317496|NCT03694418|BEHAVIORAL|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.
219317497|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
219317498|NCT06380842|OTHER|Necrotizing Pancreatitis patients' organ dysfunction progression|Study the dynamic nature of organ dysfunction
219317499|NCT06561425|GENETIC|GLPG5101|Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
219317500|NCT06561386|DRUG|Nivolumab|Specified dose on specified days
219317501|NCT06561386|DRUG|Relatlimab|Specified dose on specified days
219317502|NCT06561386|DRUG|Pembrolizumab|Specified dose on specified days
219317503|NCT06561386|DRUG|Carboplatin|Specified dose on specified days
219317504|NCT06561386|DRUG|Pemetrexed|Specified dose on specified days
219317505|NCT06561386|DRUG|Cisplatin|Specified dose on specified days
219317506|NCT05180097|DRUG|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
219317507|NCT05180097|DRUG|Dexamethasone|40mg daily PO, D1-D4
219317508|NCT05180097|DRUG|Cisplatin|75mg/m2 IV, 1 hour, D1
219317509|NCT05180097|DRUG|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
219317510|NCT05180097|DRUG|Pembrolizumab|200mg IV, 30 mins, Q 21 days
219317511|NCT06770452|DRUG|HRS-4642|HRS-4642 is a KRAS G12D inhibitor
219317512|NCT06770452|DRUG|Nimotuzumab|Nimotuzumab is a humanized IgG 1 monoclonal antibody targeting EGFR
219317513|NCT06770452|DRUG|gemcitabine + nab-paclitaxel|Albumin paclitaxel 125mg/m2 intravenous infusion, gemcitabine 1000mg / m2, D1,8, a cycle every 3 weeks
219317514|NCT03258554|BIOLOGICAL|Cetuximab|Given IV
219317515|NCT03258554|BIOLOGICAL|Durvalumab|Given IV
219317516|NCT03258554|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219317517|NCT03258554|OTHER|Laboratory Biomarker Analysis|Correlative studies
219317518|NCT03258554|OTHER|Quality-of-Life Assessment|Ancillary studies
219317519|NCT03258554|OTHER|Questionnaire Administration|Ancillary studies
219317520|NCT06135402|DEVICE|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
219317521|NCT06135402|DRUG|Treatment with Clobetasol|Application of Clobetasol twice per week
219317522|NCT04380649|DEVICE|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
219317523|NCT06629090|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
219317524|NCT06629090|DRUG|Prazosin|A dose of prazosin will be administered based on body weight
219317525|NCT06629090|DRUG|Placebo|Oral placebo
219317526|NCT05645575|DEVICE|Open-label TMS|Customized, Open-Label Transcranial Magnetic Stimulation
219317527|NCT05197881|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
219317528|NCT04782466|BEHAVIORAL|Physical Activity (PA) Intervention|The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
219317529|NCT04782466|BEHAVIORAL|Waitlist attention-control|For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
219317530|NCT00202566|DRUG|Ivabradine|
219317531|NCT06802536|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
219317532|NCT06802536|DEVICE|NeoPutty (calcium silicate-based cement) (Avalon Biomed, Bradenton, USA)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
219317533|NCT03995797|PROCEDURE|Laser therapy|Erbium YAG laser
219317534|NCT02523560|OTHER|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
219317535|NCT01859780|OTHER|Visual distractor|
219317536|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
219317537|NCT03489174|OTHER|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
219317538|NCT03489174|OTHER|Usual Care|Usual care.
219317539|NCT04294563|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
219317540|NCT04294563|OTHER|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
219317541|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Dietary supplement I (WPowDSI)|The WPowDSI group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317542|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Placebo (WPowPl)|The WPowCr group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding placebo, participants were randomly assigned to receive their daily dose.
219317543|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Dietary supplement I (EBPowDSI)|The EBPowDSI group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317544|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Placebo (EBPowPl)|The EBPotPl group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition,) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
219355019|NCT01912209|BEHAVIORAL|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
219317545|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)|The EBEccDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317546|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Placebo (EBEccPl)|The EBEccPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding placebo, participants were randomly assigned to receive their daily dose.
219317547|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)|The EBMaxDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317548|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Placebo (EBMaxPl)|The EBMaxPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
219317549|NCT06620666|DIETARY_SUPPLEMENT|Control + Placebo (CPl)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding placebo, participants were randomly assigned to receive their daily dose.
219317550|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement I (CDSI)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317551|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement (CDSII)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
219317552|NCT06620666|DIETARY_SUPPLEMENT|Active Comparator: Aerobic training + Placebo (AerPl)|The group will perform aerobic exercise for 20-40 minutes with easy execution exercise. Regarding placebo, participants were randomly assigned to receive their daily dose.
219317553|NCT00587353|OTHER|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
219317554|NCT02691260|BEHAVIORAL|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
219317555|NCT02691260|BEHAVIORAL|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
219317556|NCT02691260|BEHAVIORAL|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
219317557|NCT03865823|PROCEDURE|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
219317558|NCT00139087|BEHAVIORAL|Telephone Outreach for Therapy|
219355020|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
219355021|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
219317559|NCT02904434|OTHER|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
219317560|NCT01353625|DRUG|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
219317561|NCT00482924|OTHER|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
219317562|NCT06320613|OTHER|Acupuncture therapy|After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.
219317563|NCT06320613|OTHER|Ginger Acupuncture Point Patch|Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.
219317564|NCT04261023|DRUG|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
219317565|NCT05073237|OTHER|Placebo|Daily placebo tablet
219317566|NCT05073237|DRUG|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
219317567|NCT00528866|DRUG|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
219317568|NCT00528866|DRUG|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
219317569|NCT00528866|DRUG|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
219317570|NCT00528866|DRUG|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
219317571|NCT00528866|RADIATION|3-dimensional conformal radiation therapy|
219317572|NCT00528866|RADIATION|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
219317573|NCT05474586|OTHER|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
219317574|NCT05474586|OTHER|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
219317575|NCT05474586|OTHER|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
219317576|NCT02018367|DRUG|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
219317577|NCT00082303|BEHAVIORAL|Music Imagery|
219317578|NCT02887872|OTHER|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
219317579|NCT01601847|DIETARY_SUPPLEMENT|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
219317580|NCT01601847|DRUG|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
219317581|NCT04589182|DEVICE|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
219317582|NCT04589182|DEVICE|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
219317583|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
219317584|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
219317585|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
219317586|NCT01284062|OTHER|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
219317587|NCT00711256|OTHER|sunscreen MATAS sunlotion SPF 8|
219317588|NCT00711256|RADIATION|UVB light|duration 4 times 1 minute radiation on the trunk.
219317589|NCT05931835|DEVICE|VERAFEYE System|The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.
219317590|NCT06001918|DRUG|Nectero EAST System|Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
219317591|NCT04333654|DRUG|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
219317592|NCT04333654|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
219317593|NCT02234323|BIOLOGICAL|rFVIIIFc|Administered as specified in arm description
219317594|NCT01060826|OTHER|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
219317595|NCT01060826|DRUG|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
219317596|NCT01060826|DRUG|somatostatin|Intravenous bolus 250 micrograms
219317597|NCT02886767|OTHER|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
219317598|NCT00670189|DRUG|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
219317599|NCT06191471|OTHER|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis
219317600|NCT00559585|DRUG|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
219317601|NCT00559585|DRUG|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
219317602|NCT00725634|BIOLOGICAL|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
219317603|NCT00725634|BIOLOGICAL|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
219317604|NCT00019084|BIOLOGICAL|aldesleukin|
219317605|NCT00019084|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
219317606|NCT00019084|BIOLOGICAL|ras peptide cancer vaccine|
219317607|NCT00019084|BIOLOGICAL|sargramostim|
219317608|NCT00019084|BIOLOGICAL|therapeutic autologous lymphocytes|
219317609|NCT00019084|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219317610|NCT02644941|BIOLOGICAL|Human Acellular Vessel (HAV)|HAV-tissue-engineered vascular conduit (6mm diameter)
219317611|NCT02644941|DEVICE|ePTFE graft|One of two commercially available comparators (Bard Impra® and Gore PROPATEN®)
219317612|NCT02047825|OTHER|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
219317613|NCT02047825|OTHER|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
219317614|NCT03506685|OTHER|Dry needling and STM|dry needling and soft tissue mobilization
219317615|NCT00762749|DRUG|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
219317616|NCT04614662|BEHAVIORAL|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
219317617|NCT03027375|DRUG|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
219317618|NCT03027375|DRUG|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
219317619|NCT06113237|DRUG|Epidiolex|Oral solution
219317620|NCT02782546|PROCEDURE|Graft cell infusion|-Day 0
219317621|NCT02782546|DRUG|Tacrolimus|-GVHD prophylaxis
219317622|NCT02782546|DRUG|Mycophenolate mofetil|-GVHD prophylaxis
219317623|NCT02782546|DRUG|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
219317624|NCT02782546|PROCEDURE|CIML NK cell infusion|-Day +7
219317625|NCT02782546|DRUG|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
219317626|NCT02782546|PROCEDURE|Leukapheresis|-Day +6
219317627|NCT04111042|DEVICE|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
219317628|NCT04549025|DRUG|Pimivalimab|Specified dose on specified days
219317629|NCT04549025|DRUG|Vopratelimab|Specified dose on specified days
219317630|NCT02147665|OTHER|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
219317631|NCT05166785|OTHER|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
219317632|NCT05166785|OTHER|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
219317633|NCT06348264|DRUG|Rezvilutamide|Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
219317634|NCT06348264|DRUG|Leuprolide Acetate|The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
219317635|NCT05066477|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
219317636|NCT05066477|OTHER|Placebo|Pure maltodextrin
219317637|NCT03767582|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
219317638|NCT03767582|DRUG|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
219317639|NCT03767582|DRUG|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
219317640|NCT03767582|DRUG|GVAX|Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
219317641|NCT04325308|PROCEDURE|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
219317642|NCT04325308|PROCEDURE|Usual human milk diet|Human-based protein will not be added to the human milk administered.
219317643|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
219317644|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
219317645|NCT06117098|DEVICE|Mobile application|Individual lifestyle intervention via an mobile application
219317646|NCT06117098|BEHAVIORAL|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"
219317647|NCT06117098|BEHAVIORAL|Group-based lifestyle intervention|Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
219317648|NCT05486559|OTHER|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
219317649|NCT05486559|OTHER|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
219317650|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
219317651|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
219317652|NCT05508789|DRUG|Donanemab|Administered IV
219317653|NCT05508789|DRUG|Placebo|Administered IV
219317654|NCT04608669|DRUG|Paracetamol|Give paracetamol or placebo and compare temperature
219317655|NCT01562171|OTHER|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
219317656|NCT01562171|OTHER|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
219317657|NCT00730561|BIOLOGICAL|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
219317658|NCT05532748|DEVICE|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
219317659|NCT05532748|DEVICE|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
219317660|NCT04028908|DIAGNOSTIC_TEST|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
219317661|NCT00279110|BEHAVIORAL|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
219317662|NCT02329665|DEVICE|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
219317663|NCT00286884|PROCEDURE|Monitoring of heart rate variability|
219317664|NCT00842881|DEVICE|Healingstone navel belt|6\~8hours/day for 3months
219317665|NCT05015946|BEHAVIORAL|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
219317666|NCT01633814|DRUG|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
219317667|NCT01633814|DRUG|Placebo|placebo patch.
219317668|NCT04830956|OTHER|FID123238|Lubricant applied to the ocular surface
219317669|NCT04830956|OTHER|Systane Hydration|Drops applied to the ocular surface
219317670|NCT05049746|OTHER|Discussion|Participate in discussion
219317671|NCT05049746|OTHER|Interview|Participate in interview
219317672|NCT05049746|OTHER|Questionnaire Administration|Complete questionnaire
219317673|NCT04706351|OTHER|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
219317674|NCT01717768|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
219317675|NCT05548296|DRUG|ACR-368|ACR-368 is an experimental drug
219317676|NCT05548296|DRUG|Gemcitabine|Sensitization of tumor cells is provided through administration of ULDG
219317677|NCT05548296|DIAGNOSTIC_TEST|OncoSignature|Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy
219317678|NCT00827762|DRUG|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
219317679|NCT02407184|OTHER|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
219317680|NCT00809523|DEVICE|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
219317681|NCT00809523|DEVICE|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
219317682|NCT03417518|DRUG|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
219317683|NCT03417518|DRUG|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
219317684|NCT04195581|DEVICE|comfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
219317685|NCT04195581|DEVICE|fanfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
219317686|NCT01881581|BIOLOGICAL|Saline Solution|Saline Solution is used as control in all arms.
219317687|NCT01881581|BIOLOGICAL|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
219317688|NCT01881581|BIOLOGICAL|M-GPE|M-GPE is used in Arm D,E,F,G and H
219317689|NCT00446238|BEHAVIORAL|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
219317690|NCT00446238|BEHAVIORAL|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
219317691|NCT06107881|BEHAVIORAL|Low Vision Rehabilitation|Evaluation and training with magnification or visual assistive devices for visually-impaired adults
219317692|NCT05506501|PROCEDURE|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
219317693|NCT05506501|PROCEDURE|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
219317694|NCT02646748|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
219317695|NCT02646748|DRUG|itacitinib|Itacitinib tablets administered orally once daily.
219317696|NCT02646748|DRUG|INCB050465|INCB050465 tablets administered orally once daily.
219317697|NCT05175313|RADIATION|transthoracic ultrasonography|"1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound"
219317698|NCT05175313|DEVICE|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
219317699|NCT04693260|DEVICE|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
219317700|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
219317701|NCT03731260|DRUG|Placebo|Placebo tablet
219317702|NCT02576236|OTHER|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
219317703|NCT02576236|OTHER|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
219317704|NCT04721821|DRUG|Tofacitinib|Patients who received Tofacitinib for RA
219317705|NCT01382264|OTHER|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
219317706|NCT03598322|PROCEDURE|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
219317707|NCT03598322|PROCEDURE|Dextrose 2mL injection|Dextrose 2mL injection
219317708|NCT03598322|PROCEDURE|Dextrose 4mL injection|Dextrose 4mL injection
219317709|NCT05160441|BIOLOGICAL|Platelet Rich Plasma Injection|"Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols."
219317710|NCT05160441|BIOLOGICAL|Corticosteroid Injection|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
219317711|NCT05160441|BIOLOGICAL|Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure|Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
219317712|NCT04280536|DRUG|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
219317713|NCT04280536|DRUG|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
219317714|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone"
219317715|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Indian Costus|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements"
219317716|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Quinine pills|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)"
219317717|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Anise seed capsule|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)"
219317718|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg"
219317719|NCT04553705|DRUG|Active Comparator|Standard protocol care of COVID-19 infection
219317720|NCT06425276|DRUG|Melphalan Hydrochloride for Injection|During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
219317721|NCT06254911|BIOLOGICAL|Atezolizumab|Given IV
219317722|NCT06254911|PROCEDURE|Transoral Surgery with cervical lymphadenctomy (neck dissection)|Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck
219317723|NCT06254911|PROCEDURE|Computed Tomography|Undergo CT scan
219317724|NCT06254911|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219317725|NCT05117697|OTHER|lateral subcutaneous sphincterotomy|"Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."
219317726|NCT00183768|BEHAVIORAL|Cognitive Behavioral Therapy|
219317727|NCT00183768|BEHAVIORAL|Psychopharmacology|
219317728|NCT02802930|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
219317729|NCT02802930|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
219317730|NCT02802930|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
219317731|NCT02802930|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
219317732|NCT00472173|DRUG|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
219317733|NCT00472173|DRUG|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
219317734|NCT03088722|OTHER|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
219317735|NCT04549519|OTHER|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
219317736|NCT06374368|PROCEDURE|jejuno-ileal diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
219317737|NCT06374368|PROCEDURE|jejuno-colic diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
219317738|NCT01127945|DRUG|statin|"1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy"
219317739|NCT04394481|DRUG|Dexmedetomidine|IV injection (1 µg/kg - 100 mL) before anesthetic induction
219317740|NCT04394481|DRUG|Ropivacaine|Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
219317741|NCT04394481|DRUG|Dexamethasone|IV injection (0.15 mg/kg) during anesthetic induction
219317742|NCT02371122|DEVICE|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
219317743|NCT02371122|DEVICE|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
219317744|NCT02371122|DEVICE|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
219317745|NCT02371122|DEVICE|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
219317746|NCT02959567|DEVICE|Aqueduct 100 dilation|
219317747|NCT03590015|OTHER|Old invitation letter|Invitation Letter written by researchers/doctors
219317748|NCT03590015|OTHER|New invitation Letter|Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
219317752|NCT01843218|OTHER|Evaluation of erectile dysfunction|Assessment (at night) of erctile dysfunction using R/P recording (RIGISCAN® PLUS / polysomonography)
219317753|NCT01136811|DEVICE|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
219317754|NCT06534411|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219317755|NCT06534411|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219317756|NCT06534411|DRUG|Tirzepatide|Participants will receive once-weekly tirzepatide subcutaneously.
219355022|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
219317757|NCT05062902|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
219317758|NCT05062902|DRUG|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
219355023|NCT03369145|DIETARY_SUPPLEMENT|High-fat diet|The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
219355024|NCT01175902|DRUG|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
219317759|NCT06145282|DRUG|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
219317760|NCT02315599|DRUG|anti-CD19 CAR|
219317761|NCT03015441|OTHER|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
219317762|NCT04026841|DRUG|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
219317763|NCT02981654|DEVICE|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
219317764|NCT02575820|PROCEDURE|Old red blood cells transfusion|Red blood cells (shelf life \> 14 days) transfusion during the operation (total hip replacement arthroplasty)
219317765|NCT02575820|PROCEDURE|New red blood cells transfusion|Red blood cells (shelf life =\< 14 days) transfusion during the operation (total hip replacement arthroplasty)
219317766|NCT04473183|DIAGNOSTIC_TEST|Specimen Collection|"Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container."
219317767|NCT04473183|DIAGNOSTIC_TEST|Surveys|Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
219317768|NCT03628365|DIETARY_SUPPLEMENT|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
219317769|NCT02737839|OTHER|Stepping On Education Program|
219317770|NCT02737839|OTHER|Home visit|
219317771|NCT02737839|OTHER|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
219317772|NCT02737839|OTHER|Mini-Balance Evaluation Systems Test|"* The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes."
219317773|NCT02737839|OTHER|GAITRite|"* Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
219317774|NCT02737839|OTHER|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
219317775|NCT03769012|DIETARY_SUPPLEMENT|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
219317776|NCT03769012|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
219317777|NCT05972629|DRUG|SAR444836|Infusion pump, intravenous infusion (IV)
219317778|NCT03251196|OTHER|No Intervention, and Observational Study|Observational Study
219317779|NCT01068353|BIOLOGICAL|Etanercept|50 mg given as a once weekly subcutaneous injection
219317780|NCT01068353|OTHER|Placebo|Placebo injection given once weekly
219317781|NCT03199937|BEHAVIORAL|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
219317782|NCT03199937|OTHER|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
219317783|NCT06042010|DRUG|Oral zinc supplement|patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
219317784|NCT06042010|DRUG|triamcinolone acetonide Oral paste|patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
219317785|NCT00911794|OTHER|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
219317786|NCT00911794|OTHER|Neutral (Sham) Writing|Patients write about neutral subjects
219317787|NCT06044402|OTHER|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
219317788|NCT06044402|OTHER|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
219317789|NCT01009554|DEVICE|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
219317790|NCT01009554|DRUG|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
219317791|NCT01605253|DRUG|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
219317792|NCT01605253|DRUG|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
219317793|NCT04258436|PROCEDURE|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
219317794|NCT05803590|DRUG|Green tea mouthwash|effictive against caries and periodontal diseases
219317795|NCT05803590|DRUG|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
219317796|NCT01405937|DRUG|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
219317797|NCT01405937|BIOLOGICAL|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
219317798|NCT01405937|DRUG|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
219317799|NCT00177983|BEHAVIORAL|(relapse rate)|
219317800|NCT02949089|DRUG|ACH04|The subjects will receive the study medication in each group
219317801|NCT00243750|DRUG|Methotrexate|
219317802|NCT04888520|DEVICE|Adhesive elastic bandage|"The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist."
219355025|NCT01175902|DRUG|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
219317803|NCT04527120|OTHER|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
219317804|NCT01217268|BEHAVIORAL|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
219317805|NCT03197363|OTHER|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
219317806|NCT00822588|DEVICE|Sangvia® System|Sangvia® Intra- and Post-op System
219317807|NCT00395148|DRUG|rHDL|
219317808|NCT01562951|DRUG|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
219317809|NCT01562951|DRUG|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
219317810|NCT01400789|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
219317811|NCT00014313|DRUG|cisplatin|
219317812|NCT00014313|DRUG|etoposide|
219317813|NCT06220903|OTHER|Complex Decongestive Therapy|"1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
219317814|NCT02519309|OTHER|Virta Program|
219317815|NCT01906346|DRUG|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
219317816|NCT01906346|DRUG|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
219317817|NCT01487356|OTHER|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
219317818|NCT05606133|DIAGNOSTIC_TEST|NavDx(R)|NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
219317819|NCT06075238|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
219317820|NCT04959955|DIAGNOSTIC_TEST||
219317821|NCT00737919|DIETARY_SUPPLEMENT|Plant Stanol|Plant stanols in margarines daily 2 grams
219317822|NCT00737919|DIETARY_SUPPLEMENT|Plant Sterol|Plant sterols in margarines daily 2 grams
219317823|NCT04226833|DRUG|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
219317824|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
219317825|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
219317826|NCT04957550|DRUG|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
219317827|NCT01230853|DRUG|Active Comparator: A|Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
219317828|NCT01230853|DRUG|Placebo Comparator B|Placebo Matching Placebo Infusion
219317829|NCT01230853|DRUG|Active Comparator B|Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
219317830|NCT01230853|DRUG|Placebo Comparator A|Placebo Matching Placebo Infusion
219317831|NCT05452590|PROCEDURE|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
219317832|NCT02774551|BEHAVIORAL|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
219317833|NCT03321487|DEVICE|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
219317834|NCT03510988|DIAGNOSTIC_TEST|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
219317835|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
219317836|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
219317837|NCT03552861|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
219317838|NCT04331041|DEVICE|Adaptive stereotactic body radiation therapy|"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"
219317839|NCT04331041|DRUG|Defactinib|-Oral drug 400 mg twice a day
219317840|NCT04331041|PROCEDURE|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
219317841|NCT04331041|PROCEDURE|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
219317842|NCT01794585|BEHAVIORAL|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
219317843|NCT01794585|BEHAVIORAL|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
219317844|NCT06186245|OTHER|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
219317845|NCT03773822|COMBINATION_PRODUCT|Hydrocortisone + Flucortac|Low dose steroids
219317846|NCT03773822|OTHER|Placebo|Placebo
219317847|NCT00408603|DRUG|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
219317848|NCT01238289|BEHAVIORAL|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
219317849|NCT01238289|BEHAVIORAL|Control|This group continues with standard care at the community health center
219317850|NCT04626817|DEVICE|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
219317851|NCT04612387|BEHAVIORAL|Mind-body therapy|Online yoga, meditation and nutrition tips.
219317852|NCT06124053|BEHAVIORAL|Group Voice Therapy|"The group voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. Each group is composed of three participants. The session durations are planned to be 45-60 minutes each."
219317853|NCT06124053|BEHAVIORAL|Individual Voice Therapy|"The individual voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. The session durations are planned to be 45-60 minutes each."
219317854|NCT06124053|BEHAVIORAL|Vocal Hygiene Education|Regarding vocal hygiene training, information related to voice production and respiratory characteristics will be provided, and guidance on correct and incorrect voice use will be given.
219317855|NCT05583201|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
219317856|NCT04775251|OTHER|Upward rotation exercise|Treatment for correction of depressed scapular Alignment by exercise ( Upward Rotation Exercises) for 6 weeks.
219317857|NCT00324701|BEHAVIORAL|Telepsychology|therapy done at patients house
219317858|NCT00324701|BEHAVIORAL|Face-to-face therapy|therapy delivered at the VAMC
219317859|NCT01561222|DRUG|Calcitriol|0.25 ug per day for one year
219317860|NCT01561222|DRUG|placebo|one pill per day
219317861|NCT06188585|DEVICE|UI-EWD|Hemostatic powder administered at index endoscopy
219317862|NCT06188585|DEVICE|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy
219317863|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
219317864|NCT04742634|DRUG|DEC-C|"* DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant."
219317865|NCT04742634|DEVICE|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
219317866|NCT04338828|DRUG|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
219317867|NCT04338828|OTHER|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
219317868|NCT00003741|BIOLOGICAL|monoclonal antibody HeFi-1|
219317869|NCT05680558|DRUG|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
219317870|NCT05680558|DEVICE|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
219317871|NCT06092554|DIETARY_SUPPLEMENT|LactoLevure|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
219317872|NCT06092554|OTHER|Placebo|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The placebo capsules contain a powdered glucose polymer that is unharmful for the patient and will be provided by the sponsor. The placebo capsules look identical to the probiotic capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
219355026|NCT04482335|OTHER|No intervention|No intervention
219317873|NCT05464030|DRUG|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.
219317874|NCT05464030|DRUG|M9140|M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.
219317875|NCT05464030|DRUG|Bevacizumab|Bevacizumab will be administered intravenously as per standard of care.
219317876|NCT05464030|DRUG|Capecitabine|Capecitabine will be administered orally as per standard of care.
219317877|NCT05464030|DRUG|5-fluorouracil (5-FU)|5-FU will be administered intravenously as per standard of care.
219317878|NCT05464030|DRUG|Folinic acid|Folinic acid will be administered intravenously as per standard of care.
219317879|NCT05532397|DRUG|QPOP category 1|combination regimens with published data in the setting of gliomas
219317880|NCT05532397|DRUG|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
219317881|NCT02500381|DRUG|SRP-4045|SRP-4045 solution for IV infusion
219317882|NCT02500381|DRUG|SRP-4053|SRP-4053 solution for IV infusion
219317883|NCT02500381|DRUG|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
219317884|NCT06392477|DRUG|DR-0201|DR-0201 is a bispecific antibody
219317885|NCT06245889|DRUG|Paclitaxel|chemotherapy
219317886|NCT06245889|DRUG|Carboplatin|chemotherapy
219317887|NCT06245889|DRUG|Pembrolizumab|immunotherapy
219317888|NCT06245889|DRUG|Doxorubicin|additional chemotherapy - neoadjuvant or adjuvant rescue
219317889|NCT06245889|DRUG|Cyclophosphamide|additional chemotherapy - adjuvant rescue
219317890|NCT06245889|DRUG|Olaparib|adjuvant rescue
219317891|NCT06245889|DRUG|Capecitabine|adjuvant rescue
219317892|NCT05326308|DRUG|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
219317893|NCT05326308|DRUG|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
219317894|NCT05514132|DRUG|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
219317895|NCT05514132|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
219317896|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
219317897|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
219317898|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
219317899|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
219317900|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
219317901|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
219317902|NCT06840899|DRUG|CBD|Twice daily 100mg cannabidiol (CBD)
219317903|NCT05827016|DRUG|Iberdomide|Specified dose on specified days
219317904|NCT05827016|DRUG|Lenalidomide|Specified dose on specified days
219317905|NCT06965699|DIETARY_SUPPLEMENT|ProSauce|10g additional protein from ProSauce
219317906|NCT06965699|DIETARY_SUPPLEMENT|low-protein sauce|Commercially available standard low-protein sauce
219317907|NCT06025578|DRUG|BMS-986278|Specified dose on specified days
219317908|NCT06025578|DRUG|BMS-986278 Placebo|Specified dose on specified days
219317909|NCT06122649|DRUG|apremilast|Oral tablet
219317910|NCT06122649|DRUG|Placebo|Oral tablet
219317911|NCT04664829|DRUG|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m\^2
219317912|NCT04664829|DRUG|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m\^2
219317913|NCT04685616|RADIATION|Involved site radiotherapy|"Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.~Recommended dose 30Gy"
219317914|NCT04685616|DRUG|Doxorubicin|See arm description
219317915|NCT04685616|DRUG|Bleomycin|See arm description
219317916|NCT04685616|DRUG|Brentuximab vedotin|See arm description
219317917|NCT04685616|DRUG|Vinblastine|See arm description
219317918|NCT04685616|DRUG|Dacarbazine|See arm description
219317919|NCT04685616|DRUG|Haematopoietic growth factor|See arm description
219317920|NCT06969664|DRUG|SHR7280 Tablet|Oral SHR7280 tablet.
219317921|NCT06969664|DRUG|SHR7280 Placebo Tablet|Oral SHR7280 placebo tablet.
219317922|NCT06039306|DIETARY_SUPPLEMENT|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
219317923|NCT06731335|DRUG|Psilocybin|PSILOCYBIN (PEX010) 25 mg PO single dose
219317924|NCT06731335|DRUG|Active Placebo|Dextromethorphan 400 mg PO single dose
219317925|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
219317926|NCT06390319|DRUG|Vincristine|Given IV.
219317927|NCT06390319|DRUG|Daunorubicin|Given IV.
219317928|NCT06390319|DRUG|Calaspargase pegol|Given IV.
219317929|NCT06390319|DRUG|Dasatinib|Given PO
219317930|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
219317931|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
219317932|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
219317933|NCT06390319|DRUG|Cyclophosphamide|Given IV.
219317934|NCT06390319|DRUG|Cytarabine|Given IV or IT.
219317935|NCT06390319|DRUG|Mercaptopurine|Given PO.
219317936|NCT06390319|DRUG|Nelarabine|Given IV
219317937|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
219317938|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
219317939|NCT05025423|DRUG|Venetoclax Oral Tablet [Venclexta]|Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
219317940|NCT06667609|OTHER|Any treatments regimen|Participants may receive any treatments in accordance with standard clinical practice, based on physicians' recommendations and patients' preferences.
219317941|NCT05483296|OTHER|Dim light condition|"During the Dim light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
219317942|NCT05483296|OTHER|Moderate light condition|"During the Moderate light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
219355027|NCT01019382|DRUG|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
219355028|NCT01232829|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
219317943|NCT05483296|OTHER|Bright light condition|"During the Bright light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
219317944|NCT05632315|DRUG|PMT|Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
219317945|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
219317946|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
219317947|NCT05662241|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
219317948|NCT05662241|OTHER|Placebo|Placebo
219317949|NCT03824483|DRUG|Zanubrutinib|zanubrutinib (160mg by mouth BID)
219317950|NCT03824483|DRUG|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter)."
219317951|NCT03824483|DRUG|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
219317952|NCT02802969|PROCEDURE|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete."
219317953|NCT02802969|RADIATION|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
219317954|NCT02802969|DRUG|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
219317955|NCT02159560|DEVICE|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
219317956|NCT05282615|DEVICE|Emanate Tray|Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
219317957|NCT00713726|DRUG|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
219317958|NCT00713726|DRUG|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
219317959|NCT02960841|OTHER|Intracavitary Manual Lymphatic Drainage|
219317960|NCT02960841|OTHER|Conventional treatment|
219317961|NCT04637477|BEHAVIORAL|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
219317962|NCT02642510|OTHER|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
219317963|NCT02642510|OTHER|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
219317964|NCT05223465|OTHER|Survey|Google form distributed for students and faculties
219317965|NCT01119326|PROCEDURE|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
219317966|NCT03231943|DRUG|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
219317967|NCT03231943|DRUG|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
219317968|NCT04710888|DRUG|use of basil extract gel in treatment of aphthus ulcer|This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
219317969|NCT04710888|OTHER|muco adhesive placebo gel|mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
219317970|NCT04710888|OTHER|no treatment|(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
219317971|NCT04575480|PROCEDURE|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
219317972|NCT02795416|DRUG|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
219317973|NCT05187156|BEHAVIORAL|Behavioral Activation and Social Engagement|brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
219317974|NCT05187156|BEHAVIORAL|Treatment as usual|treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
219317975|NCT04687150|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
219317976|NCT04687150|OTHER|Colored water|Colored water (placebo)
219317977|NCT02944994|OTHER|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
219317978|NCT02944994|OTHER|Routine Care|This arm will reflect typical care received in routine mental health care
219317979|NCT04818424|DEVICE|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
219317980|NCT04818424|BEHAVIORAL|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
219317981|NCT00121693|BEHAVIORAL|Music therapy (listening to specific music)|Listening to Music
219317982|NCT05138991|PROCEDURE|Echocardiogram Recording|Undergo assessment via echo
219317983|NCT05138991|OTHER|Questionnaire Administration|Ancillary Studies
219317984|NCT05138991|PROCEDURE|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
219317985|NCT05138991|DEVICE|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
219317986|NCT05106608|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
219317987|NCT05106608|DEVICE|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
219317988|NCT05106608|DEVICE|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
219317989|NCT00551902|PROCEDURE|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
219317990|NCT00551902|PROCEDURE|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
219317991|NCT05425706|OTHER|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
219317992|NCT05564299|DIAGNOSTIC_TEST|Rapid 30-minute Desktop Assay|"Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols."
219317993|NCT04824521|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
219317994|NCT00523120|DRUG|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
219317995|NCT00523120|DRUG|dexotc|aural drops
219317996|NCT06277908|PROCEDURE|Elective Surgery for gastric cancer|Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
219317997|NCT02537535|OTHER|survey|This is a cross-sectional study without specific intervention
219317998|NCT06096207|DEVICE|Medtronic SenSight Directional DBS lead|At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
219317999|NCT05183750|PROCEDURE|High tibial osteotomy|Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
219318000|NCT06451614|DEVICE|SpaceIT Hydrogel System|"SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque."
219355029|NCT03453983|DEVICE|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
219318001|NCT06451614|DEVICE|Commercially available Boston Scientific Spacer|Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
219318002|NCT05950139|BIOLOGICAL|Peptide vaccine|Peptide vaccine
219318003|NCT05612347|DIAGNOSTIC_TEST|FIT|Annual FIT
219318004|NCT05612347|DIAGNOSTIC_TEST|Colonoscopy|One time surveillance colonoscopy
219318005|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
219318006|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
219318007|NCT06507813|DRUG|ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
219318008|NCT06507813|DRUG|Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
219318009|NCT06507813|DRUG|Placebo of ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
219318010|NCT06507813|DRUG|Placebo of Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.
219318011|NCT06507813|DRUG|ADC189 granules|"For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once."
219318012|NCT06507813|DRUG|Placebo of ADC189 granules|Placebo. Given once only.
219318013|NCT06507813|DRUG|Placebo of Oseltamivir granules|For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).
219318014|NCT06507813|DRUG|Oseltamivir granules|For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
219318015|NCT00396435|DRUG|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
219318016|NCT02989948|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
219318017|NCT06027983|DRUG|Chimeric receptor T-cells + Trastuzumab|Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
219318018|NCT06027983|DRUG|Fludarabine and Cyclophosphosphamide|3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
219318019|NCT02458014|BIOLOGICAL|Blinatumomab|Given IV
219318020|NCT02458014|OTHER|Laboratory Biomarker Analysis|Correlative studies
219318021|NCT05305131|DRUG|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
219318022|NCT05305131|DRUG|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
219318023|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
219318024|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
219318025|NCT04378855|OTHER|Questionnaire|Quality of life assessment
219355030|NCT06258070|OTHER|Abobotulinumtoxin A injection for bruxism|Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
219355031|NCT03090594|PROCEDURE|Biopsy|Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
219318026|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
219318027|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
219318028|NCT05327452|BEHAVIORAL|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
219318029|NCT05327452|BEHAVIORAL|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
219318030|NCT05327452|BEHAVIORAL|Attention Control|Stretching Program
219318031|NCT06655623|BEHAVIORAL|Schema therapy|Schema therapy is a form of psychotherapy invented to address more complex clinical cases. It consists of elements from Cognitive Behavioral Therapy as well as psychodynamic, emotion-focused and gestalt therapies, with a distinct focus on experiential interventions. A therapy manual was developed for use in this study.
219318032|NCT00915733|DRUG|cilostazol|100 mg twice daily for at least 1 month
219318033|NCT00915733|DRUG|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
219318034|NCT00915733|GENETIC|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
219318035|NCT00915733|DRUG|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
219318036|NCT06841536|DRUG|Atorvastatin 80mg|"Daily intake of 80 mg of the approved drug Atorvastatin. Starting at dose 40 mg with 40 mg weekly increment reaching the maintenance dosage of 80 mg on week two, which is the approved maximum dosage of Atorvastatin. Participants who don't tolerate this fast up-titration may have prolonged tritation protocol (up to four weeks).~Under special circumstances, participants with intolerable side-effects may stay at a lower dose (40 mg/day).~The dosage and applied up-tritation is based on recommendations from trained cardiologists at the National Hospital of the Faroe Islands."
219318037|NCT06841536|BEHAVIORAL|Exercise|Exercise will be performed as aerobic interval training sessions on cycling ergometers lasting \~45 min, four times weekly for 12 weeks. All exercise sessions will be supervised. Participants will wear HR monitor system during all sessions (Polar Electro Oy, Kempele, Finland) and the Borg 6-to-20 scale will also be used to assess the rate of perceived exertion during exercise sessions. A 4-week ramp-up phase will be applied, consisting of two sessions in weeks 1 and 2, three sessions in weeks 3 and 4 after which participants will complete 4 sessions a week from weeks 5 to 12.
219318038|NCT06139185|OTHER|Data collection|Data collection
219318039|NCT06340568|DRUG|BNT323/DB-1303|intravenous (IV) infusion
219318040|NCT06340568|DRUG|Doxorubicin|IV bolus or infusion
219318041|NCT06340568|DRUG|Paclitaxel|IV infusion
219318042|NCT06981962|OTHER|Pressure ulcer prevention program|Interventions will consist of proper positioning, frequent change of patients' posture to limit or decrease pressure over the skin, skincare, such as maintaining adequate hydration, keep skin clean, prevent excessive dryness of skin, prevent message over bony prominence, and control moisture.
219318043|NCT06983496|BEHAVIORAL|Post-ICU Telehealth Follow-up|The post-ICU clinic follow-up will be conducted by a pharmacist via a telehealth visit. A collaborating physician (i.e. intensivist) will provide clinical support and oversight as needed. The appointments will be 30-60 minute telephone/video calls. Participants be assessed for PICS and recommended interventions to improve their care.
219318044|NCT01685190|RADIATION|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
219318045|NCT01685190|RADIATION|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
219318046|NCT03834038|DRUG|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
219318047|NCT06656338|OTHER|Higher HEI-2020 diet followed by lower HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
219318048|NCT06656338|OTHER|Lower HEI-2020 diet followed by higher HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
219318049|NCT06629077|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
219318050|NCT06629077|DRUG|Prazosin|A dose of prazosin will be administered based on body weight.
219318051|NCT06629077|DRUG|Placebo|Oral placebo
219318052|NCT06651970|DRUG|Acalabrutinib|Acalabrutinib Monotherapy
219318053|NCT06651970|OTHER|Investigator's choice of treatment|control arm treatment type will be defined by the PI prior to randomisation
219318054|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
219318055|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
219318056|NCT06652113|DRUG|hydroxychloroquine and levothyroxine|Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
219318057|NCT06652113|DRUG|Levothyroxine|Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
219318058|NCT04067375|OTHER|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
219318059|NCT06979453|DRUG|Deucravacitinib|Specified dose on specified days
219318060|NCT06979453|OTHER|Placebo|Specified dose on specified days
219318061|NCT03591302|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
219318062|NCT03591302|RADIATION|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
219318063|NCT00002123|DRUG|Delavirdine mesylate|
219318064|NCT00002123|DRUG|Didanosine|
219318065|NCT00538889|DRUG|Lecozotan SR|
219318066|NCT00538889|DRUG|Citalopram|
219318067|NCT06986798|OTHER|Local standard medical care|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood and of available clinical data are the only activities performed in addition.
219318068|NCT04059016|OTHER|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
219318069|NCT06662292|BEHAVIORAL|Mobile STRIDES app (psychoeducation features)|Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.
219318070|NCT06662292|BEHAVIORAL|Mobile STRIDES app (self-regulation features)|Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.
219318071|NCT06662292|BEHAVIORAL|Mobile STRIDES app (social support training features)|For the experimental group, the Mobile STRIDES app also includes five social support training lessons/modules (during the course of the 3-month intervention) focused on providing guidance related to effective communication when exchanging social support for physical activity within a team. In addition, six team feedback messages will be delivered to respective teams throughout the course of the 3-month intervention to reinforce content taught via the training lessons/modules. A weekly poll will also be administered that complements the social support training lessons, with cumulative results displayed.
219318072|NCT06661122|DRUG|Darolutamide (BAY1841788) + docetaxel + ADT|Follow clinical practice/administration. ADT=androgen deprivation therapy.
219318073|NCT01115790|DRUG|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
219318074|NCT06817382|GENETIC|INS1201|Suspension for IT injection.
219355032|NCT04015895|OTHER|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
219355033|NCT01934088|DRUG|Propofol|
219355034|NCT01934088|DRUG|Midazolam|
219355035|NCT01934088|DRUG|Fentanyl|
219318075|NCT06605391|BEHAVIORAL|Caregiving While Black-LIVE|Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
219318076|NCT06592677|BEHAVIORAL|Condensed internet-delivered prolonged exposure (CIPE)|'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.
219318077|NCT06592677|BEHAVIORAL|Treatment-as-usual (TAU)|There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
219355036|NCT02161211|BEHAVIORAL|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
219355037|NCT02161211|BEHAVIORAL|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
219318078|NCT06601686|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
219318079|NCT06601686|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
219318080|NCT06601686|DEVICE|Sham stimulation|TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current. It will also include periods with no stimulation and a ramping up period followed by no stimulation.
219318081|NCT06602765|OTHER|Tooth brushing, tooth paste containing 1450ppm fluoride|brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
219318082|NCT02132546|DRUG|Chlorhexidine|
219318083|NCT06988124|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
219318084|NCT06988124|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
219355038|NCT02161211|BEHAVIORAL|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
219318085|NCT06655766|PROCEDURE|socket-plug technique with putty bone|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material."
219318086|NCT06655766|PROCEDURE|Ice cream cone technique|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane"
219318087|NCT05573906|COMBINATION_PRODUCT|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
219318088|NCT05573906|COMBINATION_PRODUCT|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
219318089|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
219318090|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
219318091|NCT06352047|OTHER|The effect of positioning on respiratory functions of preterm infants after extubation.|Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
219318092|NCT06991179|DRUG|LY4064809|Administered orally
219355039|NCT00003580|DRUG|amifostine trihydrate|
219355040|NCT00003580|DRUG|cisplatin|
219318093|NCT06990997|BEHAVIORAL|Aphasia identification (ID) card|Participants will view an aphasia ID card for a speaker with aphasia. The card will disclose the speaker's aphasia, define aphasia, and request time to communicate.
219318094|NCT05785767|DRUG|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
219318095|NCT05785767|DRUG|cemiplimab|Q3W as IV co-infusion
219318096|NCT05785767|DRUG|Placebo|Q3W as IV co-infusion
219318097|NCT06346405|OTHER|Subthreshold Micropulse Laser Treatment|Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
219318098|NCT05585853|OTHER|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
219318099|NCT06992544|OTHER|Pistachio-enriched diet|1 packet/day of approximately 1.25 oz (35 g) of dry roasted, unsalted, shelled pistachio kernels
219318100|NCT06992544|OTHER|Usual diet|Usual diet (while abstaining from pistachio consumption and limiting other nut consumption to ≤1 serving/week)
219318101|NCT05215327|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
219318102|NCT05215327|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
219318103|NCT06665685|DEVICE|BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will be the patient wearing the device during their Nursing Home stay for 30-days.
219318104|NCT06665685|DEVICE|Providing Clinical Care with BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will provide care for patients wearing the BioButton device during their Nursing Home stay for 30-days.
219318105|NCT06855537|PROCEDURE|PCI strategy|-In the intervention group, vulnerable plaque lesions (quantitative flow ratio, QFR \>0.8) to be treated at the operator's discretion using second-generation drug eluting stent (DES).
219318106|NCT06855537|DRUG|OMT strategy|"* Lifestyle modifications and intensive medical therapy (based on current guideline-directed secondary prevention).~* Both groups to receive statin or other therapies to achieve LDL-C \<1.4 mmol/L and decrease by 50% compared to the baseline.~* Lifestyle and risk factor management to include smoking cessation, nutritional optimization, physical activity, adherence to prescribed medications, and control of diabetes and hypertension."
219318107|NCT06610110|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
219318108|NCT06610110|DIETARY_SUPPLEMENT|Placebo|Placebo (3 mg/kg maltodextrin)
219318109|NCT02778243|BIOLOGICAL|steroids concentrations determination|
219318110|NCT03459014|OTHER|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
219318111|NCT03459014|OTHER|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
219318112|NCT04369989|OTHER|No intervention|No intervention
219318113|NCT06999239|PROCEDURE|laser therapy in TMD|"In this study patients will receive the Low-level laser therapy with a 635 nm wavelength diode laser (Lasotronix, Diode Laser DiodeLX model SMART M; Zytnia, Piaseczno, Poland) with 200 mW in a continuous mode, using a handpiece with a cylindrical applicator with a diameter of 8 mm in contact mode extra-orally, fiber-optic applicator with a diameter of 8 mm in contact mode intraorally, with a power density of 400 mW/cm2, delivering 10-12 J/cm2 on each application point, over a period of 20 sec.~There are two methods for examination of lateral pterygoid muscle: digital palpation and functional manipulation.~For digital palpation of lateral pterygoid muscle, we place our index finger or tip of our little finger in the vestibular area adjacent to the maxillary third molar.~Functional manipulation of the inferior head of lateral pterygoid muscle: It is best accomplished by having the patient make a protrusive movement against resistance to contract it since this muscle is the primary pro"
219318114|NCT06684613|DEVICE|PrEP Decision Aid|Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.
219318115|NCT06684613|OTHER|Generic Information|"Participants will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid."
219318116|NCT07019415|DRUG|Vitamin D 5000 IU+ placebo|vitamin D 5000 IU + placebo in the experimental group
219318117|NCT07019415|DRUG|Placebo : calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate|this placebo group receive placebo tablet ( calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate )
219318118|NCT06067438|DRUG|Amiodarone Hydrochloride|Given IV and via feeding tube
219318119|NCT06067438|OTHER|Saline|Given IV
219318120|NCT06506448|DIAGNOSTIC_TEST|CT Coronary Angiography|CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
219318121|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
219318122|NCT07179133|PROCEDURE|Craniocervical Flexion Training alone|"10-minute hot pack treatment before starting the protocol. Week 1: Muscle Activation, • Hold for 5-10 seconds.~* Perform in supine with a sphygmomanometer device.~* Nod head gently as if saying yes, aiming for 20-22 mmHg. Week 2: Endurance Training Goal: • Hold for 10-15 seconds. Increase holding time and precision.~Exercise:~• Maintain the contraction at 24-26 mmHg on the device. Week 3: Strength and Postural Training •Hold for 15 seconds.~Exercise:~* Perform CCFT in sitting or standing. Week 4: Functional Integration~* Maintain contraction during functional tasks (e.g., desk work).~* Hold for 15-20 seconds.~* Sets/Reps: 3 sets of 8-12 repetitions."
219318123|NCT07179133|PROCEDURE|Semispinalis Cervicis strengthening with Craniocervical Flexion Training:|"Craniocervical flexion training will be same as given to group A.~Week 1: Semispinalis Cervicis Activation:~* Patient sits upright with neutral spine.~* Therapist applies gentle manual resistance at C2 vertebra while the patient resists backward motion.~* Hold for 3-5 seconds, then relax.~Week 2: Progressive Activation with Increased Resistance:~* Apply moderate manual resistance at C2.~* Hold for 5 seconds, focusing on controlled movement.~Week 3: Strength and Functional Coordination with Dynamic Resistance:~* Introduce light movement (e.g., slight backward head tilt) under resistance.~* Therapist adjusts resistance dynamically.~Week 4: Advanced Endurance and Functional Integration with Functional Movements:~* Combine resistance training with controlled head rotations or slight lateral flexion.~* Maintain resistance and stability.~* Reps/Sets: 3-4 sets of 12 reps."
219318124|NCT07181551|BEHAVIORAL|Forward to Quit (F2Q)|A mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. Delivered via a secure website accessible by smartphone or tablet.
219355041|NCT00003580|RADIATION|radiation therapy|
219355042|NCT01103674|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
219318125|NCT07188363|PROCEDURE|Ligament reconstruction|Retensioning involves restoring the tension in a ligament or soft tissue that has become lax, often due to injury or joint instability. This technique is typically used for ligaments that do not require complete reconstruction but have lost their functional tension. Ligament reconstruction is a surgical procedure to replace or repair a damaged ligament, often using grafts (autografts or allografts). It aims to restore joint stability and function, particularly in cases of significant ligament damage or rupture. Syndesmosis surgery involves repairing or reconstructing the fibrous joint between two bones (e.g., the tibia and fibula). It may involve screw fixation, suture-button devices, or grafts to restore the alignment and stability of the syndesmosis.
219318126|NCT07187895|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
219318127|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|Keep vein open rate
219318128|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements
219318129|NCT07188545|DRUG|Intervention|"GLP-1RA and/or SGLT2i adult users with ≥1 prescription for the intervention GLP-1RA or SGLT2i medications (including combination drugs or mixed therapies with comparator medications).~GLP-1RAs include: Exenatide, Liraglutide, Semaglutide, Dulaglutide, Lixisenatide, Albiglutide, Tirzepatide.~SGLT2is include: Canagliflozin, Dapagliflozin, Bexagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin."
219318130|NCT07188545|DRUG|Active Comparator|"DPP4i or Oral Obesity Agent adult users with ≥1 prescription for the comparator DPP4i or Oral Obesity Agent medications AND no intervention GLP-1RA or SGLT2i prescriptions in first 30 days of follow up.~DPP4is include: Alogliptin, Saxagliptin, Linagliptin, Sitagliptin.~Oral Obesity Agents include: Orlistat, Naltrexone-bupropion, Phentermine-topiramate, Phentermine, Diethylpropion, Bupropion (off-label), Topiramate (off-label)"
219318131|NCT07187427|PROCEDURE|Spinal analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal SPINAL Group: Bupivacaine 0.25% Isobaric 1 ml + Fentanyl 15 mcg, (0,3ml)~STEP 2: Epidural SPINAL group: 0.9% NaCl 2 ml."
219318132|NCT07187427|PROCEDURE|Epidural Analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal EPI Group: Bupivacaine 0.25% Isobaric 1 ml + NaCl 0.9% 0.3 ml~STEP 2: Epidural EPI group: Fentanyl 100 mcg, (2 ml of a concentration of 50 mcg/ml)"
219318133|NCT07187557|OTHER|A self-compassion based birth preparation program|A self-compassion based birth preparation program
219318134|NCT07188129|DEVICE|Test Algorithm and Test Device|Test Algorithm analysis of 24-hour ECG Data collected with a Test Device
219318135|NCT07187440|OTHER|No intervention|This is a non-interventional study
219318136|NCT07187570|DRUG|Dapagliflozin 10 mg once daily|Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.
219318137|NCT07188883|OTHER|Birth Education|The population consisted of all pregnant women between 24-36 weeks of gestation residing in Izmir province, and the study was completed with a total of 80 pregnant women, 40 pregnant women as intervention and 40 as control in line with the snowball sampling method. Ege Birth Perception Scale, Risk Assessment Form, Individual Introduction Form, Prenatal Self-Assessment Scale, Birth Education Evaluation Form were used to collect the data. Pregnant women who agreed to participate in the study were randomly divided into intervention and control groups; the intervention group received nine hours of online training, while the control group did not receive any intervention.
219318138|NCT07188480|DIAGNOSTIC_TEST|bronchial lavage for NGS analysis|NGS analysis conducted on bronchoscopic cytological samples in patients with NSCLC
219318139|NCT07188597|BEHAVIORAL|Cognitive Behavior Therapy for those at risk of first episode psychosis|Participants will receive a culturally adapted manualised Cognitive Behavioural Therapy (CBT) for those at risk of first episode psychosis (FEP). The intervention aims to reduce symptoms, normalise psychosis-like experiences, and prevent catastrophic appraisals that may lead to delusions. It integrates psychoeducation, behavioural experiments, and techniques addressing cognitive biases. By reframing unusual experiences as perceptual or reasoning biases, distress and emotional arousal are reduced, lowering the chance of fixed, frightening beliefs. Homework tasks further support coping. CBT for At-Risk Mental States has shown effectiveness in reducing transition to psychosis and improving recovery. This study will adapt and field test the manual, with potential for remote delivery via phone, video, or AI tools to enhance accessibility.
219318140|NCT07187726|DEVICE|XAINET AI tool|The AI-based prediction of arm lymphedema risk is communicated to the patient and treating physician.
219318141|NCT07186946|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
219318142|NCT07186946|DRUG|Placebo|Placebo
219318143|NCT07187661|DRUG|Intra-articular Bevacizumab|This clinical trial investigates the intra-articular injection of Bevacizumab, a recombinant humanized monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). The intervention functions by binding to and neutralizing VEGF-A, thereby blocking the pathogenic angiogenesis and vascular permeability that characterizes chronic hemophilic synovitis. For administration, the first four patients will receive a dose of 20 mg in 0.8 mL per injection, and if this is well-tolerated without major toxicities, the dose for all subsequent patients will be increased to 40 mg in 1.6 mL. Each injection will be administered directly into the target joint (knee, elbow, or ankle) once every 28 days for a total of four doses. Crucially, all injections will be performed only after appropriate prophylactic factor replacement to mitigate any procedure-related bleeding risk.
219355043|NCT01637233|DRUG|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
219318144|NCT07188662|PROCEDURE|group (B) Prehabilitation care combine with ERAS post-operative care|intervention will includes receiving prehabilitation care combine with ERAS post-operative care.
219318145|NCT07188064|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|Somatic to autonomic nerve grafting procedure which uses a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
219318146|NCT07188272|DIETARY_SUPPLEMENT|DASH diet|Eating vegetables, fruits, and whole grains Including fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils Limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and tropical oils such as coconut, palm kernel, and palm oils Limiting sugar-sweetened beverages and sweets
219318147|NCT07188272|PROCEDURE|High Intensity Interval Training|High Intensity Interval Training
219318148|NCT07188441|DRUG|Teniposide Injection|teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days
219318149|NCT05249426|DRUG|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
219318150|NCT05249426|DRUG|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
219318151|NCT05249426|DRUG|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
219318152|NCT05249426|DRUG|Cetuximab|Cetuximab
219318153|NCT05249426|OTHER|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
219318154|NCT06957756|DRUG|BI 1584862|BI 1584862
219318155|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
219318156|NCT06457997|DRUG|PHN-010|PHN-010 is an ADC
219318157|NCT00210301|DRUG|Provigil (modafinil)|
219318158|NCT06088862|DRUG|Nicoderm|21mg nicotine patch daily; maximum usage 9 weeks
219318159|NCT06088862|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
219318160|NCT06088862|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
219318161|NCT06088862|OTHER|BIDI e-cigarette|BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks
219318162|NCT06088862|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks
219318163|NCT01544699|DEVICE|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
219318164|NCT04593888|BEHAVIORAL|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
219318165|NCT03564743|DIAGNOSTIC_TEST|Evaluation of ASAS criteria|Perform ASAS criteria at the time of physician diagnosis of chronic low back pain in rheumatological practice.
219318166|NCT03122275|OTHER|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
219318167|NCT03122275|OTHER|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
219318168|NCT03122275|OTHER|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
219318169|NCT03122275|OTHER|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
219318170|NCT03122275|OTHER|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
219318171|NCT00000387|BEHAVIORAL|Self-management therapy|Behavioral
219318172|NCT00000387|BEHAVIORAL|Self-management therapy|
219318173|NCT05003713|DRUG|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
219318174|NCT05003713|DRUG|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
219318175|NCT05003713|DRUG|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
219318176|NCT00244127|DRUG|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
219318177|NCT04070755|DRUG|FMX-101|
219318178|NCT01992120|OTHER|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
219318179|NCT01992120|OTHER|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
219318180|NCT01509326|OTHER|chiropractic treatment|12 sessions over 4 weeks
219318181|NCT01509326|DEVICE|Dr. Zaxx pillow|Daily use of an acupressure pillow
219318182|NCT04264429|DEVICE|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
219318183|NCT04264429|OTHER|Elastic band|Orthotic device which is positioned over the patellar tendon
219355044|NCT01637233|DRUG|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
219318184|NCT00627029|BEHAVIORAL|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
219318185|NCT03248583|OTHER|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
219318186|NCT03248583|OTHER|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
219318187|NCT03248583|OTHER|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
219318188|NCT02198625|OTHER|Moderate FiO2 and Protective Lung Ventilation Using|
219318189|NCT01178320|DRUG|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
219318190|NCT04612036|DEVICE|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
219318191|NCT04612036|DEVICE|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
219318192|NCT04612036|DEVICE|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
219318193|NCT01191372|DRUG|placebo control|sterile saline for injection
219318194|NCT01191372|DRUG|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
219318195|NCT01460095|OTHER|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
219318196|NCT02014415|PROCEDURE|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
219318197|NCT02685098|BIOLOGICAL|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
219318198|NCT05299775|DIAGNOSTIC_TEST|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
219318199|NCT04041089|BEHAVIORAL|Recognition of objects|"* Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects"
219318200|NCT04041089|BEHAVIORAL|Location of objects|"* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible"
219318201|NCT04041089|BEHAVIORAL|Manipulation of objects|"* Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)"
219318202|NCT00526409|DRUG|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
219318203|NCT00526409|DRUG|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
219318204|NCT00526409|DRUG|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
219318205|NCT00526409|DRUG|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
219318206|NCT00526409|DRUG|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
219318207|NCT00526409|DRUG|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
219318208|NCT00526409|DRUG|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
219318209|NCT06391554|OTHER|PRT|An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week. The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks. After the 12 weeks, participants will receive 8 booster sessions and are given a membership to a fitness center where they will be encouraged to continue the exercise program on their own.
219318210|NCT06391554|OTHER|EDU|Three EDU sessions provided by a trained physiotherapist involving important disease-specific information. The sessions will address knowledge of OA, treatment options with a specific focus on physical activity recommendations, advice on self-management and more. All three sessions will emphasize on engaging the participants actively and sharing experiences with each other.
219318211|NCT04221763|DEVICE|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
219318212|NCT06178445|DRUG|SOC plus trastuzumab and pembrolizumab|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
219318213|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
219318214|NCT06781801|OTHER|Intervention|"The intervention group follows a structured flowchart for annual health check-ups, focusing on assessing the cardiometabolic profile, considering sex and ethnicity. This assessment includes tracking changes in cardiometabolic parameters, alongside overall cardiometabolic risk using SCORE2 and if the criteria for metabolic syndrome are met.~Lifestyle habits are evaluated based on health status, illness, and benefits of quitting unhealthy behaviors. Education sessions educate participants and families on the link between psychotic disorders, lifestyle choices, and cardiometabolic health.~Gradual lifestyle changes are tailored to individual needs, addressing stress and cognitive challenges, and follow national health guidelines with personalized advice and motivational tools. Regular follow-ups assess progress, while motivational tools body composition analyzer and QRISK3 enhance engagement. Contact with internal and external resources is based on the assessment and motivational work."
219318215|NCT04337177|DRUG|VAL-413|a flavored preparation of orally administered irinotecan
219318216|NCT04337177|DRUG|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
219318217|NCT04104529|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
219318218|NCT04104529|OTHER|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
219318219|NCT01059136|DRUG|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
219355045|NCT01637233|DRUG|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
219355046|NCT03728309|DEVICE|JUVÉDERM VOLITE™ XC|Intradermal, needle in multiple microdepot injections across both cheeks.
219318220|NCT06798454|DRUG|PVT201|"Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor.~PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells.~IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections.~PVT201 will be administered intravenously."
219318221|NCT06798454|OTHER|Placebo|Participants randomized to placebo will be administered normal saline IV.
219318222|NCT02703220|OTHER|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
219318223|NCT02703220|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
219318224|NCT02703220|DRUG|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
219318225|NCT05781152|DRUG|Anti-TNF therapy|Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
219318226|NCT04436237|OTHER|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
219318227|NCT00754143|DRUG|FG-3019|Placebo every 2 weeks IV for all infusions
219318228|NCT00754143|DRUG|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
219318229|NCT00754143|DRUG|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
219318230|NCT02367235|PROCEDURE|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
219318231|NCT02367235|PROCEDURE|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
219318232|NCT05839756|DRUG|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
219318233|NCT05839756|DRUG|normal saline|5 ml normal saline will be nebulized preoperatively
219318234|NCT06316531|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219318235|NCT06316531|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
219318236|NCT00292656|PROCEDURE|NAET|
219318237|NCT04985305|BEHAVIORAL|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
219318238|NCT04985305|BEHAVIORAL|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
219318239|NCT04985305|BEHAVIORAL|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
219355047|NCT03950973|BEHAVIORAL|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
219318240|NCT04985305|BEHAVIORAL|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
219318241|NCT04985305|BEHAVIORAL|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
219318242|NCT02960113|DRUG|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
219318243|NCT02960113|DEVICE|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
219318244|NCT04165590|OTHER|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
219318245|NCT05212454|DRUG|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
219318246|NCT06503029|DEVICE|Invisalign Cleaning Crystals|Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
219318247|NCT06503029|DEVICE|Fittey Dent Cleaning Tablet|Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
219318248|NCT06503029|DRUG|Listeren Mouthwash|Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
219318249|NCT06503029|DEVICE|Toothbrush and Water|Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
219318250|NCT03157232|DEVICE|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
219318251|NCT02090153|DRUG|S-1|40\~60mg bid，d1\~7 q2W
219318252|NCT02090153|DRUG|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
219318253|NCT04202952|DRUG|HEC110114 Tablet|administered orally once daily
219318254|NCT04202952|DRUG|Sofosbuvir Tablet|administered orally once daily
219318255|NCT02513186|DRUG|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
219318256|NCT02513186|DRUG|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
219318257|NCT02513186|DRUG|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
219318258|NCT02513186|DRUG|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
219318259|NCT02513186|DRUG|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
219318260|NCT03638934|OTHER|Videos about ACP|Three videos about advanced care planning are provided for self-education.
219318261|NCT03638934|OTHER|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
219318262|NCT02864420|OTHER|Home hospitalization|
219318263|NCT02864420|OTHER|Inpatient Hospitalization|
219318264|NCT02183532|DRUG|BI 1356 BS|single dose
219318265|NCT02183532|DRUG|BI 1356 BS|multiple doses
219318266|NCT03434353|DRUG|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
219318267|NCT03434353|DRUG|TAF|Administered orally once daily with food
219318268|NCT01572701|DRUG|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
219318269|NCT03665896|DEVICE|intubation with VivaSight double-lumen tube|
219318270|NCT03665896|DEVICE|intubation with standard double-lumen tube|
219318271|NCT03665896|PROCEDURE|fiberoptic bronchoscopy|
219318272|NCT03255837|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
219318273|NCT05092633|DEVICE|Miniscrew|Application of laser on miniscrew
219318274|NCT00551109|DRUG|placebo|placebo, oral administration, once daily for 8 weeks
219318275|NCT00551109|DRUG|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
219318276|NCT00551109|DRUG|SA4503 High|High dose, oral administration, once daily for 8 weeks
219318277|NCT06794996|DRUG|Inaxaplin|Tablets for Oral Administration.
219318278|NCT01538563|DRUG|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
219318279|NCT03932825|DRUG|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
219318280|NCT03932825|DRUG|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
219318281|NCT03138811|DRUG|CSJ117|inhaled once daily dose
219318282|NCT03138811|DRUG|Placebo Comparator|inhaled once daily dose
219318283|NCT00530868|OTHER|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
219318284|NCT00530868|DRUG|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
219318285|NCT01990534|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
219318286|NCT02030756|DEVICE|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
219318287|NCT02030756|DEVICE|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
219318288|NCT01580033|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
219318289|NCT01580033|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
219318290|NCT01580033|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
219318291|NCT01580033|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
219318292|NCT04778969|DEVICE|drug-eluting stent|A group of percutaneous coronary intervention (PCI) using drug-eluting stents (DES)
219318293|NCT04778969|DEVICE|drug-coated balloon|A group of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB)
219318294|NCT05087160|OTHER|mitigation measures against COVID 19|no intervention
219318295|NCT00234494|DRUG|Cisplatin|Cisplatin 70 mg/m2, day 1
219318296|NCT00234494|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
219318297|NCT00234494|DRUG|Bevacizumab|Bevacizumab 15mg/kg, day 1
219318298|NCT01774851|DRUG|MM-111|MM-111 (IV)
219318299|NCT01774851|DRUG|Paclitaxel|Paclitaxel (IV)
219318300|NCT01774851|DRUG|Trastuzumab|Trastuzumab (IV)
219318301|NCT03641053|OTHER|Honey|Substance is given topically after the wound has been sutured
219318302|NCT03641053|OTHER|Povidone-iodine|Substance is given topically after the wound has been sutured
219318303|NCT03641053|OTHER|Paraffin gauze|Substance is given topically after the wound has been sutured
219318304|NCT01831544|DEVICE|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
219318305|NCT04486157|DRUG|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
219318306|NCT04486157|DRUG|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
219318307|NCT04563364|OTHER|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
219318308|NCT04563364|OTHER|Convencional treatment|Control group will receive a conventional treatment given by the institutions
219318309|NCT05539859|PROCEDURE|Endoscopic surgery|Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management
219318310|NCT05539859|OTHER|Medical management|Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
219318311|NCT00609843|OTHER|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
219318312|NCT05114915|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
219318313|NCT00148954|DEVICE|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
219318314|NCT00148954|DEVICE|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
219318315|NCT05388877|DRUG|Dabrafenib|Given PO
219318316|NCT05388877|DRUG|MEK-1/MEKK-1 Inhibitor E6201|Given IV
219318317|NCT05388877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219318318|NCT05388877|PROCEDURE|Computed Tomography|Undergo CT
219318319|NCT05388877|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219318320|NCT04849182|DIETARY_SUPPLEMENT|Vertistop D|Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals
219318321|NCT04849182|DIETARY_SUPPLEMENT|Vertistop L|Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
219318322|NCT01521897|BIOLOGICAL|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
219318323|NCT04090853|DEVICE|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
219318324|NCT00257686|DRUG|Pitavastatin|
219318325|NCT00257686|DRUG|Pravastatin|
219318326|NCT06206512|DRUG|Extended release torsemide|This is an extended-release formulation of torsemide
219318327|NCT06206512|DRUG|Immediate release torsemide|This is the generic, immediate release formulation of torsemide
219318328|NCT06206512|DRUG|Extended release torsemide placebo|Placebo of extended release torsemide
219318329|NCT06206512|DRUG|Immediate release torsemide placebo|Placebo of immediate release torsemide
219318330|NCT05211310|OTHER|High-Activity Arthroplasty Score (HAAS)|The questionnaire developed by Talbot et al. in 2010 consists of 4 sub-dimensions. 0-18 points can be obtained from the survey. High scores are associated with higher functional ability.
219318331|NCT05211310|OTHER|Western Ontario and McMaster Universities osteoarthritis score (WOMAC)|It is used to evaluate disability in patients with hip and knee osteoarthritis. Each sub-dimension is standardized within the range of 0-100 points, with high scores indicating poor health.
219318332|NCT05211310|OTHER|The Knee injury and Osteoarthritis Outcome Score (KOOS)|It is calculated between 0 and 100 points. 0 points indicate severe knee problem, 100 points no knee problem
219318333|NCT05211310|OTHER|The Forgotten Joint Score-12 (FJS-12)|It evaluates how much an individual can forget an artificial joint during activities of daily living. A total of 100 points can be obtained. A high score is associated with the ability to forget.
219318334|NCT05211310|OTHER|EQ-5D-5L|It is a questionnaire evaluating the quality of life. The higher the total score, the higher the quality of life.
219318335|NCT05211310|OTHER|Numerical pain scale (NPS)|It is the numerical expression of perceived pain intensity. It is rated from 0-10 points. 10 points indicate the highest pain intensity, 0 points the absence of pain.
219318336|NCT05843643|DRUG|Upadacitinib|Oral Tablets
219318337|NCT05843643|DRUG|Placebo|Oral Tablet
219318338|NCT04919525|DEVICE|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
219318339|NCT02467348|DRUG|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
219318340|NCT02467348|DRUG|Ascitic fluid|
219318341|NCT04471948|DEVICE|Fractional picosecond 1064 nm laser|The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
219318342|NCT06514235|OTHER|Observational study (Non-interventional study)|This is an observational study.
219318343|NCT04235270|COMBINATION_PRODUCT|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
219318344|NCT04235270|DRUG|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
219318345|NCT04235270|DRUG|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
219318346|NCT03560947|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
219318347|NCT03560947|OTHER|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
219318348|NCT03433495|OTHER|Melodic Intonation Therapy|
219318349|NCT05962047|OTHER|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
219318350|NCT05962047|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
219318351|NCT02194062|DRUG|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
219318352|NCT02194062|DRUG|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
219318353|NCT02194062|DRUG|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
219318354|NCT05599295|DRUG|Orbactiv|Solution for IV infusion
219318355|NCT05599295|DRUG|Kimyrsa|Solution for IV infusion
219318356|NCT06261333|OTHER|Questionnaires|No Intervention
219318357|NCT04434599|DEVICE|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
219318358|NCT04434599|DEVICE|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
219318359|NCT04434599|DEVICE|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
219318360|NCT02704546|DRUG|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
219318361|NCT02704546|DRUG|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
219318362|NCT00719550|DRUG|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
219318363|NCT00719550|DRUG|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
219318364|NCT00719550|DRUG|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
219318365|NCT00719550|DRUG|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
219318366|NCT00719550|DRUG|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
219318367|NCT06583733|BEHAVIORAL|KOKU Bladder|"In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
219318368|NCT06583733|BEHAVIORAL|recommendations|"In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
219318369|NCT04870125|DRUG|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
219318370|NCT04870125|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
219318371|NCT02276872|DRUG|oral treprostinil|
219318372|NCT06847191|DRUG|NE3107|20 mg Capsule
219318373|NCT06847191|DRUG|Placebo|placebo capsule
219318374|NCT05584670|DRUG|SAR445877|Concentrate for solution for infusion
219318375|NCT05584670|DRUG|Cetuximab|Solution for infusion
219318376|NCT05888493|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells taken intravenously (i.v.).
219318377|NCT05888493|DRUG|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
219318378|NCT05888493|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
219318379|NCT05888493|DRUG|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
219318380|NCT05888493|OTHER|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
219318381|NCT06847815|OTHER|Sweet corn|Fresh and processed sweet corn
219318382|NCT06847815|OTHER|Glucose Tolerance Drink|Beverage providing 50 g of glucose
219318383|NCT03588182|OTHER|Virtual Reality Experience|Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
219318384|NCT05249634|DRUG|Jatenzo Pill|oral tablet daily
219318385|NCT06493812|PROCEDURE|Fascia lata|This intervention involves the harvesting of fascia lata from the thigh and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left thigh, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
219355048|NCT03950973|BEHAVIORAL|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
219355049|NCT00397683|DRUG|MK0822|
219355050|NCT03901950|DRUG|XNW7201 tablets|A wnt pathway inhibitor
219355051|NCT01889290|DRUG|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
219355052|NCT04814394|DIAGNOSTIC_TEST|flowcytometry|The study of CD4,CD25,FOXP3 and PD-1 on peripheral blood sample
219355053|NCT04453046|DEVICE|Hemopurifier|Two Hemopurifier treatments on Day 1 and Day 21
219318386|NCT06493812|PROCEDURE|Temporal fascia|This intervention involves the harvesting of temporal muscle fascia from the temporal region of the head and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left temporal region, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
219318387|NCT03912272|BEHAVIORAL|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
219318388|NCT03912272|BEHAVIORAL|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
219318389|NCT01753583|DEVICE|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
219318390|NCT01753583|OTHER|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
219318391|NCT04229472|DIAGNOSTIC_TEST|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
219318392|NCT04229472|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
219318393|NCT02843685|DRUG|Drotrecogin alfa activated|
219318394|NCT01017068|DRUG|OME|4g/100ml) dose: п gutt tid x 1/52
219318395|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
219318396|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
219318397|NCT01017068|DRUG|OME|(4g/100ml) dose: п gutt tid x 1/52
219318398|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
219318399|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
219318400|NCT05577286|OTHER|regular care|the regular medical treatment without change of their daily activity routine
219318401|NCT05577286|OTHER|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
219318402|NCT02021292|DRUG|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
219318403|NCT02021292|DRUG|Placebo|Matching placebo oral tablet, to be taken once daily.
219318404|NCT04147234|DRUG|BI 1387446 50 μg|Participants received 50 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
219318405|NCT04147234|DRUG|BI 754091|Participants received BI 754091 (ezabenlimab) intravenously at a dose of 240 mg once every 21-day cycle.
219318406|NCT04147234|DRUG|BI 1387446 100 μg|Participants received 100 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
219318407|NCT04147234|DRUG|BI 1387446 200 μg|Participants received 200 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
219318408|NCT04147234|DRUG|BI 1387446 400 μg|Participants received 400 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
219318409|NCT06439394|DRUG|Optive MEGA-3 (OM3)|Eye Drops
219318410|NCT00022048|BIOLOGICAL|bevacizumab|
219318411|NCT04464603|DEVICE|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
219318412|NCT04464603|OTHER|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
219318413|NCT06616389|DRUG|ODX (Osteodex)|Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
219318414|NCT05972733|BIOLOGICAL|HIL-214|HIL-214
219318415|NCT04662151|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
219318416|NCT04662151|PROCEDURE|Air-sham|room air for intratracheal administration
219318417|NCT04395118|BEHAVIORAL|Mailed Outreach|The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
219318418|NCT00982215|DRUG|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
219318419|NCT00982215|DRUG|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
219318420|NCT04987658|DRUG|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
219318421|NCT06431880|OTHER|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block
219318422|NCT06431880|OTHER|Thoracic paravertebral block|Patients will receive thoracic paravertebral block
219318423|NCT00601991|BIOLOGICAL|VEGF Trap|Drug under investigation
219318424|NCT00601991|PROCEDURE|Bone marrow biopsy|To determine response to treatment
219318425|NCT00601991|PROCEDURE|bone marrow aspiration|To determine response to treatment
219318426|NCT00601991|PROCEDURE|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
219318427|NCT01157013|OTHER|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
219318428|NCT03492788|OTHER|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
219318429|NCT03492788|OTHER|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
219318430|NCT02869555|OTHER|Data collection|
219318431|NCT02734394|BEHAVIORAL|Exercise|Cardiovascular and resistance exercise training
219318432|NCT05845866|BEHAVIORAL|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
219318433|NCT05845866|BEHAVIORAL|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
219318434|NCT05845866|BEHAVIORAL|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
219318435|NCT04225078|DRUG|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
219318436|NCT04225078|OTHER|Placebo|Matching loperamide placebo capsules will be administered orally.
219318437|NCT04225078|DRUG|Moxifloxacin|Moxifloxacin tablets will be administered orally.
219318438|NCT03865940|DRUG|Lidocaine|6 mL of 1% lidocaine
219318439|NCT03865940|DRUG|Guanfacine|250 mcg
219318440|NCT06338670|DEVICE|Cochlear Osia 3 Sound Processor|Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
219318441|NCT06338670|DEVICE|Cochlear™ Osia® 2 Sound Processor|Osia® 2 Sound Processor
219318442|NCT01205256|DRUG|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
219318443|NCT06345833|DRUG|1%Tranexamic acid with standard local|1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
219318444|NCT06345833|DRUG|3% TXA|3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
219318445|NCT06345833|DRUG|1% TXA with local plus 3% TXA-soaked pledgets|1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
219318446|NCT04982588|DEVICE|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
219318447|NCT01025024|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
219318448|NCT02366728|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
219318449|NCT02366728|BIOLOGICAL|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
219318450|NCT02366728|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
219318451|NCT02366728|BIOLOGICAL|111In-labeled DCs|111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
219318452|NCT02366728|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
219318453|NCT02366728|DRUG|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
219318454|NCT02366728|DRUG|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
219318455|NCT00980681|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
219318456|NCT00980681|OTHER|Time of Flight|Each subject will undergo a TOF MRA
219318457|NCT01704833|BEHAVIORAL|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
219318458|NCT04381455|DEVICE|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
219318459|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
219318460|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
219318461|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
219318462|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
219318463|NCT02091583|DIETARY_SUPPLEMENT|Butter, sunflower and safflower oil|
219318464|NCT02091583|DIETARY_SUPPLEMENT|High Oleic Canola Oil and DHA (HOCO-DHA)|
219318465|NCT02091583|DIETARY_SUPPLEMENT|Barley beta-glucan|
219318466|NCT02091583|DIETARY_SUPPLEMENT|HOCO-DHA and Barley beta-glucan|
219318467|NCT01747304|DEVICE|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
219318468|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
219318469|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
219318470|NCT05030103|DEVICE|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
219318471|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
219318472|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
219318473|NCT03730441|DEVICE|Colonoscopy|Endoscopic examination of large bowel
219318474|NCT00844207|DRUG|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
219318475|NCT00844207|DRUG|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
219318476|NCT03442790|PROCEDURE|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
219318477|NCT03442790|PROCEDURE|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
219318478|NCT03858790|DEVICE|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
219318479|NCT01979224|OTHER|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
219318480|NCT06149390|DRUG|consolidation with ASCT|high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
219318481|NCT04304976|DEVICE|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
219318482|NCT04014036|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
219318483|NCT03499236|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
219318484|NCT03499236|OTHER|Control|Right heart catheterization, invasive echocardiography.
219318485|NCT05317884|BEHAVIORAL|Reminder|Email
219318486|NCT05581667|OTHER|post isometric relaxation|PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
219318487|NCT05581667|OTHER|Swedish Massage|classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
219318488|NCT00182390|PROCEDURE|Red blood cell transfusion|
219318489|NCT05453032|DEVICE|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
219318490|NCT04615247|OTHER|Yoga Program|The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.
219318491|NCT04615247|OTHER|Physical Conditioning Program|The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
219318492|NCT00247377|PROCEDURE|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
219318493|NCT00247377|PROCEDURE|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
219318494|NCT03260231|DIETARY_SUPPLEMENT|Milled seed mix|Dietary intervention with or without seed mix
219318495|NCT04085627|DRUG|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg\& Amlodipine 5mg
219318496|NCT06832306|DEVICE|Phrenic Nerve Stimulation|During controlled MV when patients are not breathing, continuous diaphragm neurostimulation-assisted ventilation (DNAV) will be delivered in synchrony with each ventilator-delivered breath.
219318497|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
219318498|NCT06199466|DRUG|Gemcitabine|Given by IV
219318499|NCT06199466|DRUG|Nab-paclitaxel|Given by IV
219318500|NCT06199466|DRUG|YL-13027|Given by PO
219318501|NCT06076486|DRUG|Elagolix|Elagolix 200 mg tablets administered orally BID
219318502|NCT06076486|DRUG|Elagolix placebo|Elagolix placebo administered orally BID
219318503|NCT05713188|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
219318504|NCT06193863|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|At the discretion of the treating physician, based on the recommendations written in the local product information.
219318505|NCT06834685|DEVICE|Photobiomodulation sessions|The treatment will be administered by an ATP38 device delivering a power of 4 Joules/cm2 at wavelengths of 620 and 820 nm
219318506|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
219318507|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
219318508|NCT01245075|OTHER|Deep brain stimulation|Deep brain stimulation on
219318509|NCT01245075|OTHER|Placebo|deep brain stimulation off
219318510|NCT04500665|DRUG|Colchicine|Colchicine
219318511|NCT04500665|DRUG|Placebo|Placebo
219318512|NCT06390462|BEHAVIORAL|Interpersonal counseling|A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.
219318513|NCT06390462|BEHAVIORAL|Treatment as usual|Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.
219318514|NCT06390462|OTHER|No support, intervention or other treatment|The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
219318515|NCT01621230|DRUG|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
219318516|NCT01621230|DRUG|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
219318517|NCT02596620|DRUG|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
219318518|NCT02596620|DRUG|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
219318519|NCT02596620|DRUG|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
219318520|NCT02596620|DRUG|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
219318521|NCT00411125|DRUG|Oral salmon calcitonin|
219318522|NCT04151264|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
219318523|NCT06511063|DRUG|tenofovir disoproxil/emtricitabine|Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
219318524|NCT06511063|DRUG|Selzentry|Participants will take Selzentry for 90 days.
219318525|NCT06511063|DRUG|Placebo|Matching placebo.
219318526|NCT02039791|BIOLOGICAL|Nimotuzumab|200mg/w,weekly, 6 weeks
219318527|NCT02039791|DRUG|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
219318528|NCT02039791|DRUG|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
219318529|NCT05150652|DRUG|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
219318530|NCT05150652|DRUG|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
219318531|NCT05150652|DRUG|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
219318532|NCT05150652|DRUG|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
219318533|NCT05398887|RADIATION|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
219318534|NCT05398887|RADIATION|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
219318535|NCT05398887|OTHER|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
219318536|NCT06435754|PROCEDURE|Intervention group Vestibular Socket Preservation|After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
219318537|NCT06435754|PROCEDURE|Control Group ice cream cone technique|After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
219318538|NCT00471796|BEHAVIORAL|Biofeedback|
219318539|NCT02209155|DRUG|R-verapamil 75 mg tablet|
219318540|NCT02209155|DRUG|Placebo|
219318541|NCT00132613|PROCEDURE|Observation alone after pericardial drainage|
219318542|NCT00132613|DRUG|Pericardial instillation of bleomycin after drainage|
219318543|NCT01303263|BEHAVIORAL|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
219318544|NCT05247138|DEVICE|BioRootTM RCS|BioRoot™ RCS is a hydrophilic mineral root canal sealer prepared from the mixture of a powder part and a liquid part. BioRoot™ RCS is a class III implantable medical device. This device is intended to be used in dentistry for permanent obturation of root canals of permanent and mature teeth with adjunction of gutta-percha points. Exposure to the sealer BioRootTM RCS starts from the day when the root canal treatment is performed until the end of individual observational period or the removal of the sealer in case of extraction or retreatment, if this event occurs before the end of individual observational period.
219318545|NCT00758056|GENETIC|polymorphism analysis|
219318546|NCT00758056|OTHER|laboratory biomarker analysis|
219318547|NCT00758056|OTHER|questionnaire administration|
219318548|NCT02934022|DRUG|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
219318549|NCT00385372|PROCEDURE|elimination diet|
219318550|NCT00385372|PROCEDURE|provocation diet|
219318551|NCT02906839|OTHER|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
219318552|NCT05103696|DRUG|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
219318553|NCT05103696|DRUG|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
219318554|NCT06226831|OTHER|Structured interview|In-person structured interviews will be performed by the investigators.
219318555|NCT01313403|OTHER|Antidepressant (SSRI)|
219318556|NCT05781568|DIAGNOSTIC_TEST|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
219318557|NCT00448435|DRUG|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
219318558|NCT00448435|DRUG|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
219318559|NCT05339321|GENETIC|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
219318560|NCT05339321|BIOLOGICAL|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
219318561|NCT01387230|DRUG|GSK573719|62.5 mcg
219318562|NCT01387230|DRUG|GSK573719|125mcg
219318563|NCT01387230|OTHER|Placebo|Placebo
219318564|NCT06430944|PROCEDURE|Placing a hip spica cast for patients with femur fractures|Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
219318565|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
219318566|NCT01306422|OTHER|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
219318567|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
219318568|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
219318569|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
219318570|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
219318571|NCT05823025|OTHER|PWV measurement|Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
219318572|NCT03712189|DEVICE|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
219318573|NCT02977117|OTHER|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
219318574|NCT02977117|OTHER|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
219318575|NCT04632472|DEVICE|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
219318576|NCT05189262|OTHER|Blood and urine collection|No intervention - Biological specimen collection
219318577|NCT02066051|DEVICE|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
219318578|NCT02066051|PROCEDURE|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
219318579|NCT02257957|DRUG|PRP injection|
219318580|NCT02257957|DRUG|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
219318581|NCT04561765|DEVICE|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
219318582|NCT04561765|DEVICE|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
219318583|NCT03027557|DRUG|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
219318584|NCT03027557|DRUG|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
219318585|NCT03027557|OTHER|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
219318586|NCT03027557|OTHER|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
219318587|NCT05066698|BIOLOGICAL|ST266|Topical ocular application: one drop four times a day for eight weeks
219318588|NCT05066698|OTHER|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
219318589|NCT05066698|BIOLOGICAL|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
219318590|NCT04289740|BEHAVIORAL|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
219318591|NCT04289740|BEHAVIORAL|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
219318592|NCT02155036|OTHER|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
219318593|NCT01610687|DRUG|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
219318594|NCT00565383|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural
219318595|NCT00565383|PROCEDURE|Intravenous fentanyl (50mcg)|Intravenous fentanyl
219318596|NCT01831830|BEHAVIORAL|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
219318597|NCT06428981|OTHER|degenerative cervical diseases|Including herniation of the intervertebral disc, ossification of the posterior longitudinal ligament, and spinal stenosis, resulting in cervical radiculopathy, or degenerative cervical myelopathy, and were scheduled to undergo anterior discectomy with fusion surgery.
219318598|NCT00486876|DRUG|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
219318599|NCT01615380|BEHAVIORAL|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
219318600|NCT01615380|BEHAVIORAL|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
219318601|NCT03836807|DRUG|OKITASK®|A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
219318602|NCT03836807|OTHER|Placebo|A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
219318603|NCT03951779|DIAGNOSTIC_TEST|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
219318604|NCT00365898|DRUG|Hydromorphone Hydrochloride Extended-Release|
219318605|NCT01012479|DRUG|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
219318606|NCT02765880|OTHER|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
219318607|NCT02765880|OTHER|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
219318608|NCT01019291|OTHER|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
219318609|NCT01019291|OTHER|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
219318610|NCT02430051|BEHAVIORAL|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
219318611|NCT04722250|DEVICE|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
219318612|NCT04722250|DEVICE|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
219318613|NCT00364026|DRUG|darusentan|
219318614|NCT01444209|RADIATION|Iodine Implants|Interstitial Radioactive Iodine Implants
219318615|NCT04962789|DIAGNOSTIC_TEST|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
219318616|NCT00690235|DRUG|Pramlintide|180mg subcutaneous injections, twice daily
219318617|NCT00690235|DRUG|Placebo|180mg subcutaneous injections, twice daily
219318618|NCT00560053|DRUG|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
219318619|NCT00560053|PROCEDURE|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
219318620|NCT00560053|DRUG|Maintenance|"At 3 months of transplantation or with \>1.500 neutrophiles/ \> 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
219318621|NCT00560053|PROCEDURE|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
219318622|NCT00560053|PROCEDURE|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
219318623|NCT05974592|OTHER|Education|Diabetic Foot Self-Management Training Program will be implemented.
219318624|NCT03432286|DRUG|Galcanezumab|Administered SQ
219318625|NCT03432286|DRUG|Placebo|Administered SQ
219318626|NCT05332444|DRUG|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1\. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
219318627|NCT05332444|DRUG|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
219318628|NCT05602142|DRUG|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
219318629|NCT05671874|BEHAVIORAL|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
219318630|NCT05877521|BEHAVIORAL|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
219318631|NCT05877521|OTHER|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
219318632|NCT05556824|DRUG|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
219318633|NCT05556824|OTHER|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
219318634|NCT05183360|DRUG|BI 706321|BI 706321, tablet, oral use
219318635|NCT05183360|DRUG|Placebo|Placebo, tablet, oral use
219318636|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
219318637|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
219318638|NCT01729455|BIOLOGICAL|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
219318639|NCT01729455|OTHER|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
219318640|NCT06253494|BIOLOGICAL|AdHER2DC vaccine|AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12
219318641|NCT06253494|BIOLOGICAL|Pembrolizumab|Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16
219318642|NCT06253494|BIOLOGICAL|N-803|N-803 is given by subcutaneous injections on Day 1 of cycles 1-16
219318643|NCT06253494|DRUG|Lenvatinib|Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16
219318644|NCT06253494|DEVICE|PATHWAY HER2 (4B5) assay|Used during screening to estimate eligibility
219318645|NCT05829031|BEHAVIORAL|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
219318646|NCT06222450|BEHAVIORAL|Vestibular Rehabilitation Therapy (VRT)|customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
219318647|NCT02363400|DRUG|MEP|Adjuvant Chemotherapy
219318648|NCT06852820|DRUG|Lu-PSMA-617|Given IV
219318649|NCT02876302|DRUG|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
219318650|NCT02876302|DRUG|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
219318651|NCT02876302|DRUG|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
219318652|NCT02876302|DRUG|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
219318653|NCT05557331|DEVICE|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
219318654|NCT05579990|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
219318655|NCT02530463|DRUG|Azacitidine|Given IV
219318656|NCT02530463|BIOLOGICAL|Ipilimumab|Given IV
219318657|NCT02530463|OTHER|Laboratory Biomarker Analysis|Correlative studies
219318658|NCT02530463|BIOLOGICAL|Nivolumab|Given IV
219318659|NCT02731716|BEHAVIORAL|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
219318660|NCT02731716|BEHAVIORAL|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
219318661|NCT02731716|BEHAVIORAL|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
219318662|NCT05726864|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
219318663|NCT05423158|BEHAVIORAL|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
219318664|NCT05913973|DRUG|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
219318665|NCT05245851|DEVICE|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
219318666|NCT05718869|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219318667|NCT05718869|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219318668|NCT05718869|PROCEDURE|Computed Tomography|Undergo CT scan
219318669|NCT05718869|BIOLOGICAL|Tafasitamab|Given IV
219318670|NCT05718869|DRUG|Zanubrutinib|Given PO
219318671|NCT04912765|BIOLOGICAL|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
219318672|NCT04912765|DRUG|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
219318673|NCT05704647|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
219318674|NCT05704647|DRUG|Nivolumab|Given by IV (vein)
219318675|NCT05704647|DRUG|Relatlimab|Given by IV (vein)
219318676|NCT06411925|DRUG|Atock Dry Syrup with placebo patch|Atock Dry syrup (TID) with placebo patch (QD)
219318677|NCT06411925|DRUG|Tulobuterol patch with placebo dry syrup|Tulobuterol patch (QD) with placebo dry syrup (TID)
219318678|NCT05317481|BEHAVIORAL|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
219318679|NCT05317481|BEHAVIORAL|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
219318680|NCT06593912|PROCEDURE|Early Functional Training|Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.
219318681|NCT06593912|PROCEDURE|Standard protocol|Cast 6 weeks after peroneal tendon surgery (standard protocol)
219318682|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
219318683|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
219318684|NCT06996756|BIOLOGICAL|AAV8hAAT(AVL)|AAV8hAAT(AVL) gene transfer vector
219318685|NCT06995898|PROCEDURE|Biospecimen Collection|Undergo blood collection
219318686|NCT06995898|DEVICE|Device Usage|Evaluation of MCD tests
219318687|NCT06995898|OTHER|Electronic Health Record Review|Obtain health data
219318688|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Shield MCD test
219318689|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Avantect MCD test
219318690|NCT06995898|OTHER|Questionnaire Administration|Study specific questionnaires
219318691|NCT06997419|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
219318692|NCT06997419|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
219318693|NCT06999122|DIAGNOSTIC_TEST|Brain Scan|"The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.~The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues."
219318694|NCT05903196|DEVICE|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
219318695|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
219318696|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
219318697|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
219318698|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
219318699|NCT06999005|PROCEDURE|Fluoride Varnish Application (Preventive Protocol)|Single application of Duraphat® fluoride varnish on permanent molars and incisors, repeated every 3 months.
219318700|NCT06999005|PROCEDURE|Fluoride Varnish for Active Enamel Lesions|Weekly fluoride varnish applications for 4 weeks, followed by quarterly maintenance applications.
219318701|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART) Sealant|Sealant placement with high-viscosity glass ionomer using the ART technique, with quarterly fluoride varnish.
219318702|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART)|Manual caries removal and cavity restoration with glass ionomer cement, followed by fluoride varnish every 3 months.
219318703|NCT06996496|OTHER|Postpartum educational tool after hypertensive pregnancy|postpartum educational tool for patients having experienced a hypertensive disorder of pregnancy
219318704|NCT04536337|DRUG|ALG-000184|Single or multiple doses of ALG-000184
219318705|NCT04536337|DRUG|Placebo|Single or multiple doses of Placebo
219318706|NCT04536337|DRUG|Entecavir|multiple doses of Entecavir
219318707|NCT05435300|OTHER|PET Scan|Participants will undergo two PET scans throughout the study.
219318708|NCT06364137|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
219318709|NCT06364137|OTHER|Standard videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform
219318710|NCT04480723|OTHER|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
219318711|NCT04480723|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
219318712|NCT07008209|BEHAVIORAL|Reconstrual Strategy Training|"Participants receive training in the reconstrual strategy, which involves recognizing and reinterpreting initial negative appraisals of emotionally challenging situations. The training guides participants to:~Identify the situation and their initial negative interpretation.~Generate alternative, balanced explanations that reduce negative emotional impact.~The goal is to help participants view events from a different, realistic perspective to decrease negative emotions by modifying how they interpret situations."
219318713|NCT07008209|BEHAVIORAL|Repurposing Strategy Training|"Participants receive training in the repurposing strategy, which involves adjusting or replacing personal goals to better align with the current situation. The training guides participants to:~Identify the situation and the original goal that was not met.~Develop alternative, realistic goals or modify existing ones to reduce the emotional impact of unmet expectations.~This approach helps participants manage negative emotions by creating meaningful, adaptable goals that fit the reality of the situation."
219318714|NCT07008209|BEHAVIORAL|Active Control|Participants are asked to carefully copy a neutral descriptive passage without making any changes, focusing solely on transcription accuracy. This task serves as an active control by engaging participants in a cognitive task that requires attention and effort, but does not involve emotion regulation strategies. The task controls for the effects of engagement and time spent on a task without influencing participants' emotional processing.
219318715|NCT05902819|BEHAVIORAL|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
219318716|NCT05902819|DRUG|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
219318717|NCT05902819|DRUG|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
219318718|NCT07008495|PROCEDURE|varicocelectomy|to detect testicular sperm retrieval rate after varicocelectomy in men with non obstructive azoospermia.
219318719|NCT06868628|DRUG|Foralumab Nasal|Foralumab is an anti-CD3 monoclonal antibody administered as a nasal spray. Participants will complete eight 3-week dosing cycles over the study. During each cycle, Foralumab will be administered intranasally three times per week for the first two weeks, with no administration in the third week.
219318720|NCT06866405|BIOLOGICAL|RSVpreF|Single Dose
219318721|NCT06866405|BIOLOGICAL|Placebo|Single Dose
219318722|NCT07010965|DEVICE|NyokAssist™|The NyokAssist™ Ventricular Assist Device can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta .
219318723|NCT07010965|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide coronary flow
219318724|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219318725|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219318726|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
219318727|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
219318728|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
219318729|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219318730|NCT07020806|DRUG|[68Ga]Ga DOTA-5G|Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.
219318731|NCT07020611|DEVICE|Cygnum Aneurysm Sac Management Device (ASMD)|Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks
219318732|NCT07014670|OTHER|Validation and Reability study|Validation and Reability study
219318733|NCT07020533|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219318734|NCT07020533|OTHER|Electronic Health Record Review|Ancillary studies
219318735|NCT07020533|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo HCT
219318736|NCT07020533|DRUG|Letermovir|Given IV or PO
219318737|NCT07020533|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
219318738|NCT07020533|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning
219318739|NCT07020533|PROCEDURE|Pheresis|Undergo apheresis
219318740|NCT07020533|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given G-CSF
219318741|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
219318742|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
219318743|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.
219318744|NCT03716739|DRUG|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
219318745|NCT03716739|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
219318746|NCT06698744|BIOLOGICAL|UF-KURE-BCMA CAR T-cells|"Experimental anti-BCMA CAR T-cells manufactured with a proprietary ultrafast process. Patients will receive a single dose of CAR T-cells at one of three potential doses:~* Dose -1: 3x10\^6 cells~* Dose 1: 10x10\^6 cells~* Dose 2: 15x10\^6 cells"
219318747|NCT06698744|DRUG|Cyclophosphamide|Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
219318748|NCT06698744|DRUG|Fludarabine|Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
219318749|NCT07024979|BEHAVIORAL|Music Therapy Songwriting Intervention|The music therapy songwriting intervention is an active, client-centered music therapy approach in which the participant collaboratively create an original song with a professional music therapist. This evidence-based method combines: 1) lyric writing: the participant can express personal experience/emotions through guided lyric creation; 2) musical composition: the participant will choose or improvise their favorite melody, harmony, and rhythm with a music therapist; 3) therapeutic processing: discussion of song meaning and emotional connections between the participant and music therapist.
219318750|NCT07031245|BEHAVIORAL|Evidence-based quality improvement (EBQI)|Evidence-based quality improvement (EBQI) is a multi-level implementation strategy that aids in the development and implementation of evidence-based interventions to reduce burnout. Preliminary survey, interview, and systematic review data on burnout, turnover intent, burnout drivers, and burnout interventions will be presented to an expert panel for each intervention site. These panels will collectively decide on the top categories of burnout drivers to target and burnout interventions to implement. These top drivers and intervention categories will be presented to site-level providers and staff and proposals will be solicited for quality improvement (QI) interventions to reduce burnout that reflect these categories and address these drivers. The expert panels will then choose one or more of these QI interventions to implement and evaluate at each intervention site.
219318751|NCT06690710|BIOLOGICAL|allogeneic engineered Gingival Fibroblasts (aeGF)|single intra-articular injection of the study drug (aeGF) in the knee joint
219318752|NCT06687395|OTHER|Skill training on different models|Skill training on different models (medium/high fidelity vs. self-made model)
219318753|NCT06711718|OTHER|Qualitative interview (patients)|Qualitative interviews to be carried out by an experienced researcher with patients who have had their diabetes diagnosis reviewed as a result of the running of the tool.
219318754|NCT06711718|OTHER|Qualitative interview (staff)|Qualitative interviews to be carried out by an experienced researcher with practice staff who have run the tool and reviewed patients flagged by the tool.
219318755|NCT06712823|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
219318756|NCT06714357|DRUG|irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes
219318757|NCT06714357|DRUG|panitumumab|Administered as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion at the dosage of 6 mg/kg
219318758|NCT06714357|DRUG|Valproic Acid (VPA)|"VPA will be administered in each patient with a titration strategy to improve the compliance for the treatment, looking for a target serum level between 50 and 100 μg/mL that represents the recommended values for the treatment of epilepsy and also a useful concentration to produce the desired synergistic effect with chemotherapy based on preclinical studies.~Administrated at the dosage of 500 mg/three times a day (after 7 days of gradual dose escalation)."
219318759|NCT07039422|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
219318760|NCT04732273|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
219318761|NCT04732273|OTHER|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
219318762|NCT06925789|DRUG|Ropivacaine|The nerve block is performed when the patients are admitted to the hospital with diagnosed hip fractures. And another nerve block with catheter is performed for post-operative pain control in geriatric population with 0.25% Ropivacaine 30mls.
219318763|NCT07049939|DRUG|MK-3543|Capsule for oral administration
219318764|NCT06787612|DRUG|Ubamatamab|Administered per the protocol
219318765|NCT06787612|DRUG|Bevacizumab|Administered per the protocol
219318766|NCT06787612|DRUG|Cemiplimab|Administered per the protocol
219318767|NCT06787612|DRUG|Fianlimab|Administered per the protocol
219318768|NCT06787612|DRUG|PLD|Administered per the protocol
219318769|NCT06787612|DRUG|Sarilumab|Prophylaxis administered per the protocol
219318770|NCT03989492|OTHER|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
219318771|NCT06344884|PROCEDURE|Early catheter removal|Catheter removal the day after surgery as opposed to standard of care (3 to 4 days after surgery)
219318772|NCT06802549|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material
219318773|NCT06802549|DEVICE|Theracal PT (resin modified calcium silicate-based cement) (Bisco Inc., Schaumburg, IL, USA)|It will be placed on the exposed pulp with the help of its injection tip and the exposed pulp will be covered with material
219318774|NCT06809309|OTHER|Positive pressure ventilation during cardiopulmonary resuscitation|"The primary exposures of interest are the observed ventilation rate, tidal volume and minute ventilation during cardiopulmonary resuscitation.~Ventilation data are obtained by inspiratory and expiratory air flow measurements using the EOlife (Archeon, Besançon, France) to which healthcare providers are blinded."
219318775|NCT07072481|BEHAVIORAL|Activities|"Activities include the implementation of the three main components of 4YBY that include;~1\) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruited youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants."
219318776|NCT07072481|BEHAVIORAL|Benefits|The benefits are conceptualized at the individual, community and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
219318777|NCT07072481|BEHAVIORAL|Capacity|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconferences, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
219318778|NCT07072481|BEHAVIORAL|Activities-S|Activities include the implementation of the three main components of 4YBY that include; 1) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruit youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants.
219318779|NCT07072481|BEHAVIORAL|Benefits-S|The benefits are conceptualized at the individual, community, and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
219318780|NCT07072481|BEHAVIORAL|Capacity-S|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconference, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
219318781|NCT07072481|BEHAVIORAL|People|Sustainability teams will be established in CBOs to lead the implementation of their sustainability blueprint for 4YBY. These teams will train staff, monitor goals, and provide feedback on performance and progress over time
219318782|NCT07072481|BEHAVIORAL|Learning Meetings|CBOs will participate in bi-weekly collaborative meetings to enhance their sustainability efforts, share lessons learned, and support one another. These meetings will focus on creating a supportive learning environment and reinforcing leadership that promotes continuous learning.
219318783|NCT07072481|BEHAVIORAL|Adaptation Monitoring|CBOs will adapt best practices for their sustainability plans using the FRAME-IS framework to ensure that strategies meet local needs while documenting the modifications and maintained elements over time.
219318784|NCT07072481|BEHAVIORAL|Nurturing Coaches|Trained coaches will provide individualized support to CBOs, holding weekly office hours to assist with their sustainability plans, monitor progress, and address site-specific barriers to change.
219318785|NCT05566795|DRUG|Tovorafenib|Oral Tablet Powder for Oral Suspension
219318786|NCT05566795|DRUG|Chemotherapeutic Agent|Intravenous solution for injection
219318787|NCT06788535|DRUG|I-124 evuzamitide|I-124 evuzamitide, single dose imaging agent, administered intravenously.
219318788|NCT04844606|DRUG|Mirikizumab|Administered SC
219318789|NCT04844606|DRUG|Mirikizumab|Administered IV
219318790|NCT06764303|DRUG|NTQ5082 100mg qd|NTQ5082 100mg qd
219318791|NCT06764303|DRUG|NTQ5082 200mg qd|NTQ5082 200mg qd
219318792|NCT07090135|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
219355054|NCT04453046|DRUG|Pembrolizumab 200mg IV|Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
219318793|NCT04135066|OTHER|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
219318794|NCT04135066|OTHER|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
219318795|NCT04135066|OTHER|Oral Glucose Tolerance test (75g 2-hour)|75 g pure glucose with 300 mL water per time per person is applied. In the following 3 hours, participants are advised to rest in a seated position, avoiding unnecessary walking or exercise. Energy-giving food items were still prohibited within this interval.
219318796|NCT05472714|OTHER|Educational Video|Investigators will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
219318797|NCT06689891|DEVICE|Pelvic Floor Muscle Therapy Website|8-week video-based, self-directed PFMT course
219318798|NCT07105098|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
219318799|NCT07105098|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
219318800|NCT07106554|BEHAVIORAL|holotropic breathwork|participants will engage in holotropic breathwork
219318801|NCT07112339|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection.
219318802|NCT07112339|DRUG|Basal insulin analogues|Basal insulin analogues will be administered as subcutaneous injection.
219318803|NCT06914518|OTHER|viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight > 1500 kDa (10 mg/ml, 1%)|At the end of the standardized peri-implant non-surgical therapy a viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight \> 1500 kDa (10 mg/ml, 1%) (REGENFASTe, Mastelli S.r.l., Sanremo, Italy) will be injected in the peri-implant sulcus.
219318804|NCT06914518|PROCEDURE|Non-Surgical Intervention|Standardized peri-implant non-surgical therapy will be performed as follows: local anaesthesia (articaine 4% and adrenaline 1:100,000), debridement of the implant surfaces with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the H3 dental ultrasonic scaler (H3, Satelec Acteon; Olliergues, France), curettage of the bone defect (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) and supra- and submucosally cleaning using an air polisher with sub- gingival tip (EMS Air-flow® with erythritol-based powder containing
219318805|NCT06920043|DRUG|Efimosfermin|Efimosfermin will be administered as a subcutaneous injection.
219318806|NCT06920043|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
219318807|NCT06920004|BIOLOGICAL|empasiprubart|Intravenous infusion of empasiprubart
219318808|NCT06920004|BIOLOGICAL|IVIg|Intravenous infusion of IVIg
219318809|NCT06920004|OTHER|empasiprubart-placebo|A placebo resembling the empasiprubart treatment
219318810|NCT06920004|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
219318811|NCT06919588|BEHAVIORAL|comedy therapy|Before the transplant surgery, the patients were shown 10-minute Turkish comedy films prepared by the researchers.
219318812|NCT04757532|DRUG|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
219318813|NCT04757532|DRUG|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
219318814|NCT04757532|DRUG|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
219318815|NCT04757532|DRUG|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
219318816|NCT04757532|DRUG|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
219318817|NCT07141381|DRUG|VRN110755|VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.
219318818|NCT07141381|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.
219318819|NCT06832189|DRUG|Everolimus|"The starting dose of EVR will be based on the maintenance TAC dose of the subject at study entry:~1. EVR 1 mg PO BID if TAC dose is \<=2 mg BID~2. EVR 2 mg PO BID if TAC dose is 2.5-7 mg BID~3. EVR 3 mg PO BID if TAC dose is \>7 mg BID~The dosage will be adjusted as needed to achieve and maintain EVR trough concentration of 5-8 ng/mL."
219318820|NCT06832189|DRUG|Epoetin alfa|The dose used in this study is 10,000 units SC every 8 weeks (at study weeks 16, 24, 32, 40 and 48) for five doses
219318821|NCT06936670|DEVICE|Inspiratory Muscle Strength Training (IMST)|A novel form of physical training that uses the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device, generating large negative intrathoracic pressures. The device can be set to different levels of resistance, meaning the intervention and sham groups will undergo the same training, but at 75% and 15% of their maximal inspiratory pressure respectively.
219318822|NCT06936670|DEVICE|Sham Training|The same training regiment but at much lower resistance, offering little to strength training impact.
219318823|NCT04124614|DRUG|Brexpiprazole|3 mg pill
219318824|NCT04124614|DRUG|Sertraline|150 mg pill
219318825|NCT04124614|OTHER|Placebo|Pill
219318826|NCT00703898|DRUG|nevirapine|200 mg/day twice a day
219318827|NCT06944626|DEVICE|tDCS|tDCS will be applied to the dorsalateral prefrontal cortex with a current of 2 mA for 30 minutes on 3 consecutive days.
219318828|NCT06944626|DEVICE|Sham tDCS|The tDCS application will be increased to 2 mA for the first 30 seconds and will be reduced to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 min in total).
219318829|NCT06944626|OTHER|Conventional physiotherapy|"Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.~While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises."
219355055|NCT05047276|BIOLOGICAL|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
219355056|NCT02115204|DRUG|Epirubicin|
219355057|NCT02115204|DRUG|Cyclophosphamide|
219355058|NCT02115204|DRUG|Docetaxel|
219355059|NCT02115204|DRUG|Methotrexate|
219355060|NCT02115204|DRUG|5-fluorouracil|
219355061|NCT00953758|DRUG|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
219318830|NCT07147725|DEVICE|AI Stethoscope|"Patients attending routine echocardiography who satisfy the inclusion and exclusion criteria will be approached before their echocardiography appointment to obtain informed consent to participate in the study. On providing informed consent, each patient will receive a non-invasive, external examination with a smart stethoscope that records a 3-lead electrocardiogram (ECG) and phonocardiogram (PCG) waveforms. This examination will require only one study visit (during routine echocardiography) and no additional visits. The stethoscope is a fully CE-marked device.~In addition to echocardiography parameters and smart stethoscope waveforms, baseline demographics, clinical and medication history will be recorded. These data points will be re-examined at 24 months following enrolment (via chart review)."
219318831|NCT07141342|DEVICE|The Fast In-Bed Tracking System (FIT) Weight Scale|It is hypothesized that wheelchair users who are randomized into the FIT Weight Scales group will lose a significantly greater percent of body weight over time (6 months, 12 months) than wheelchair users randomized to the control group.
219318832|NCT07141342|BEHAVIORAL|Group Lifestyle Balance Adapted for Individuals with Impaired Mobility (GLB-AIM) intervention|The GLB-AIM is a direct adaptation of the Diabetes Prevention Program (DPP) - Group Lifestyle Balance (DPP-GLB) which has successfully yielded an average 6 percent weight loss at 12 months and reduced diabetes risk over 2.8 years by 58 percent, which was 39 percent lower than participants randomized to the metformin group. The GLB-AIM which has been proven feasible and effective in a pilot study and a randomized control trial (RCT) with 67 mobility impaired individuals randomized to the intervention group or a waitlist control group. There were significant between group differences in weight loss at 6 months (-1.7 kg loss vs 0.05 kg gain, p \<0.05) and combined results from both groups after receiving the intervention revealed an average weight loss at 12 months of 3.3 percent of their starting weight. Notably, the average loss was lower than the 5 to 7 percent achieved by diverse participants in the DPP-GLB trials.
219318833|NCT06953336|OTHER|Fruit and Vegetable Voucher Support Program|Participants will receive a monthly food voucher in the form of an Electronic Benefit Transfer (EBT) card, mailed to their home and refilled each month for 6 months. The EBT cards are provided and managed by an external community-based organization in partnership with the research team. The intervention is designed to supplement household food purchases, reduce food insecurity, and support nutritional well-being among pediatric and young adult kidney transplant recipients who have recently screened positive for food insecurity. Pre- and post-intervention surveys will be used to assess food security status and dietary quality.
219318834|NCT07147231|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219318835|NCT07147231|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219318836|NCT07147231|BIOLOGICAL|Cemiplimab|Given IV
219318837|NCT07147231|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219318838|NCT07147231|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219318839|NCT07147231|DRUG|Pidnarulex|Given IV
219318840|NCT07147231|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219318841|NCT06954987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
219318842|NCT06954987|PROCEDURE|Biospecimen Collection|Undergo blood, urine and buccal swab collection
219318843|NCT06954987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219318844|NCT06954987|DRUG|Busulfan|Given IV
219318845|NCT06954987|PROCEDURE|Chest Radiography|Undergo chest x-ray
219318846|NCT06954987|PROCEDURE|Computed Tomography|Undergo CT scan
219318847|NCT06954987|PROCEDURE|Echocardiography Test|Undergo echocardiography
219318848|NCT06954987|DRUG|Fludarabine|Given IV
219318849|NCT06954987|DRUG|Melphalan|Given IV
219318850|NCT06954987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219318851|NCT06954987|DRUG|Placebo Administration|Given PO
219318852|NCT06954987|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219318853|NCT06954987|RADIATION|Total-Body Irradiation|Undergo total body irradiation
219318854|NCT06954987|DRUG|Venetoclax|Given PO
219318855|NCT06951269|BEHAVIORAL|Live entrained music therapy|This study will use live, improvised, entrainment-based music. The music will be applied to synchronize with the newborns' breathing patterns, adapting the tempo to the breathing rate, with characteristics that seek to induce a state of relaxation in the patient: moderate volume (below 65 dB; this measure will be validated using the ambient noise indicator of the neonatal intensive care unit), simple harmonic sequences (tonic-subdominant-dominant), melodies that avoid large intervals (beyond a third), medium registers, and a stable pulse. Once the music therapist synchronizes the pulse of the music with the newborn's breathing, the music will be gradually become slower (approximately 10-15%), the volume will be adjusted, and the complexity of the music will be reduced until the patient can transition to a state of greater relaxation. The music therapy session will last 10 minutes, after which the music therapist will leave the room.
219355062|NCT04264247|DIAGNOSTIC_TEST|routine fetal ultrasonography at 11-14 weeks|routine fetal ultrasonography at 11-14 weeks
219355063|NCT05529914|OTHER|Myofascial release|It is a type of physical therapy often used to treat myofascial pain syndrome with pressure.
219318856|NCT07147023|OTHER|LLM SIC Summary Email|"A Large Language Model-based platform is integrated with the Health Vision Platform, a HIPAA-compliant, electronic health record data management system. Real-time summaries of prior SIC with be sent to clinicians caring for participants in the intervention arm.~An email will be sent to the inpatient attending and responding clinician encouraging the team to review the SIC summary, discuss care preferences with the patient and ensure care is aligned with preferences and goals. If no SIC documentation is found, the email will instead encourage the outpatient oncologist to share information regarding undocumented SICs that may have occurred, as well as prompt inpatient and outpatient teams to engage the patient in SIC.~For patients with no SIC documentation who are still admitted 72 hours later, the RA will send an additional email prompting SIC or asking the clinician to indicate that an SIC is not appropriate. Patients will also receive standard of care."
219318857|NCT07146750|COMBINATION_PRODUCT|SAR445229|Single dose
219318858|NCT07151937|DRUG|LAD191|LAD191 subcutaneous injection.
219318859|NCT07151937|OTHER|Placebo|LAD191 Placebo subcutaneous injection.
219318860|NCT07151937|DRUG|Adalimumab|Adalimumab subcutaneous injection.
219318861|NCT07158112|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219318862|NCT07158112|DRUG|Test Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219318863|NCT07158112|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
219318864|NCT07155421|OTHER|Early Cardiopulmonary Rehabilitation|An individualized CPR program including positioning, deep breathing exercises (diaphragmatic and segmental breathing exercises), pursed-lip breathing exercises, breathing exercises using incentive spirometry, and progressive mobilization exercises (in-bed range of motion exercises, sitting, standing, and walking exercises)
219318865|NCT07155421|OTHER|Routine in-hospital care|Routine in-hospital care for acute decompansated heart failure
219318866|NCT07152249|OTHER|AW-D Clinical Decision Support Tool|The AW-D Clinical Decision Support Tool will test the automatic delivery of best practice advisories for antiemetic medications at critical timepoints in the perioperative period.
219318867|NCT07155707|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
219318868|NCT07155707|OTHER|Standard Videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform.
219318869|NCT07161219|DEVICE|inspiratory muscle training|inspiratory muscle training for intervention group
219318870|NCT07162493|BEHAVIORAL|ATTACH|"ATTACH(TM) is a manualized, 10-session, mentalizing/reflective functioning-based parenting program, with one 45-60-minute weekly session. It is conducted individually with one parent focusing on one child throughout the program; however, a co-parent/parental support person will participate in session 7 and session 9. A session includes three components to facilitate parental reflective functioning: 1)Video-review of parent-child interaction, 2) reflection on a hypothetical situation (pre-defined for each session), and 3) reflection on a mildly stressful situation from the parent's everyday life with the child. The parent's reflective process is supported by handouts, e.g., emotion cards. All material used in the sessions have been translated into Danish, and the wording have been modified to fit with the cultural context, based on feedback from two pilot studies. ATTACH is facilitated by professionals employed at the family centers, who have been trained and certified in ATTACH."
219318871|NCT07162493|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual (TAU) consists of the standard services and support typically offered to families by the local social- and healthcare systems within each municipality. These services vary depending on individual needs, risk assessment of the family, and municipal practices, but often include individual and/or group-based parenting support or therapeutic services at the trial site and/or in the parent's home. TAU may also involve referrals to additional resources or interventions deemed necessary by social authorities or healthcare providers (e.g., psychiatric treatment in the region). The control group will not receive the ATTACH™ program but will have access to all relevant standard care options available within their municipality. TAU can be delivered by different professionals, such as health visitors, social workers, family therapists/counsellors or clinical psychologists. For more details on TAU services at each trial site, see the attached project protocol.
219318872|NCT07161713|BEHAVIORAL|Oncology-informed yoga|8 weekly sessions of cancer informed-yoga incorporating light movement, breathing techniques, and some meditation practices
219318873|NCT07161713|BEHAVIORAL|SMART|SMART, developed by the Impact Foundation, is an adaptation of Mindfulness-based Stress Reduction (MBSR) approach that incorporates other elements like mindful self-compassion, emotional literacy, and positive psychology principles to address the unique stressors faced by teachers.
219318874|NCT07167589|PROCEDURE|Cataract surgery with implantation of a single-piece microincisional IOL|
219318875|NCT07168772|DIETARY_SUPPLEMENT|Lactibane Iki|Patients will receive a probiotic sachet twice a day for six months. The probiotic, Lactibiane iki (Pileje; Paris, France), is composed of Bifidobacterium lactis LA 304, Lactobacillus acidophilus LA 201, and Lactobacillus salivarius LA 302 and contains 4x10E10 CFU/sachet.
219318876|NCT07168772|OTHER|Placebo|Patients will receive a placebo (starch) sachet twice a day for six months.
219318877|NCT07162805|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg are titrated if insertion is unsuccessful.
219318878|NCT07164443|BIOLOGICAL|Pasritamig|Pasritamig will be administrated through IV infusion.
219318879|NCT07164443|OTHER|Placebo|Placebo will be administrated through IV infusion.
219318880|NCT07164443|DRUG|Best Supportive Care (BSC)|BSC will be administered as per physician.
219318881|NCT07155148|OTHER|observational study|Observational registry without clinical interventions
219318882|NCT07173660|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
219318883|NCT07174297|DRUG|Acotiamide|Both these drugs are used for the management of PDS type of FD
219318884|NCT07157865|DEVICE|Prism adaptation training combined with TENS|Subjects in the experimental group will receive both prism adaptation training and TENS to identify affects on USN. To date there are no published studies combining these treatments to minimize USN.
219318885|NCT07157865|OTHER|PAT only|Subjects will receive prism adaptation training (PAT) only wearing prism goggles during a functional reaching task during occupational therapy.
219318886|NCT07173205|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
219318887|NCT07175233|DRUG|SIM0278 injection|SIM0278 injection
219318888|NCT07175233|OTHER|Placebo|placebo
219318889|NCT07179003|PROCEDURE|Standard of care breast abscess drainage|All subjects will receive ultrasound-guided percutaneous abscess drainage in a procedure room. The site will be prepared and dressed following standard of care sterile procedure, and a needle/catheter will be advanced under ultrasound guidance into the abscess. The abscess will be drained by syringe aspiration, and the cavity will be flushed with sterile saline. Aspirated abscess fluid will be delivered to the Clinical Microbiology Laboratory for processing, including bacterial identification and antibiotic susceptibility testing.
219318890|NCT07179003|DRUG|Methylene Blue|Following standard of care breast abscess drainage, for subjects randomized to the photodynamic therapy arm, sterile, clinical-grade methylene blue will be infused into the abscess cavity at a concentration of 100 µg/mL via the same needle/catheter used for drainage. The volume introduced will be matched to the amount of abscess material aspirated during the standard of care drainage. After a 10-minute incubation interval, methylene blue will be aspirated and the cavity flushed with sterile saline to remove methylene blue that has not been taken up by microbes.
219318891|NCT07179003|DRUG|Lipid Emulsion|For subjects randomized to the photodynamic therapy arm, immediately prior to illumination a lipid emulsion will be administered directly to the abscess through the drainage needle/catheter at a concentration of 0.1%. This lipid emulsion will be either Intralipid or Nutrilipid. The lipid emulsion serves to gently distend the cavity, and through light scattering, homogenize the light dose to the walls of the cavity. The volume administered will be matched to the amount of abscess material aspirated during the standard of care drainage. Following laser illumination, the lipid emulsion will be aspirated and the cavity flushed with sterile saline.
219318892|NCT07179003|DEVICE|Insertion of optical fiber|For subjects randomized to the photodynamic therapy arm, a sterile, single-use optical fiber will be advanced to the approximate center of the abscess cavity via the same needle/catheter used for abscess drainage under ultrasound guidance. This will be connected to the clinical laser system via SMA connector for delivery of treatment light.
219318893|NCT07179003|DEVICE|Laser illumination|For subjects randomized to the photodynamic therapy arm, laser illumination for photodynamic therapy will be delivered by a laser system operating at 665 nm (ML7710, Modulight, Tampere, Finland) at a fluence rate of 20 mW/cm\^2. The laser power required to achieve this fluence rate will be calculated based on abscess size. Illumination will be delivered for \~20 minutes, resulting in a total delivered fluence of 25 J/cm\^2.
219318894|NCT07179003|PROCEDURE|Photodynamic therapy|For subjects randomized to the photodynamic therapy arm, the photodynamic therapy procedure comprises the methylene blue, lipid emulsion, insertion of optical fiber, and laser illumination interventions.
219318895|NCT07172958|BIOLOGICAL|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
219318896|NCT07179861|OTHER|AI Suggestions (Anonymized 5-tool panel)|"What: Display of AI-generated suggestions for each vignette, aggregated from five large language model tools (names not shown to participants).~When/Who: Shown only in Group 2, after the physician's initial answer and confidence score.~Purpose: Measure AI performance (primary) and quantify the effect of AI suggestions on physicians' answers (secondary).~Applies to: Group 2."
219318897|NCT07179861|OTHER|Confidence Rating Task (1-10 Likert)|"What: Self-rated confidence for the initial answer on a 1-10 scale. When/Who: Group 2 before viewing AI suggestions. Purpose: Quantify confidence changes pre- vs post-AI and relate confidence to correctness.~Applies to: Group 2."
219318898|NCT07179770|DRUG|Belzutifan|120 mg orally daily for 28 days
219318899|NCT07179770|DRUG|89Zr-DFO-girentuximab|10 mg single slow intravenous (IV) administration
219318900|NCT07179770|DEVICE|89Zr-DFO-girentuximab PET|89Zr-DFO-Girentuximab PET before and after 4 weeks of treatment with standard-of-care (SOC) belzutifan.
219318901|NCT07167316|DRUG|DMTN|Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine by inhibiting activity in the locus coeruleus, a key brain region involved in arousal and stress responses. In this study, dexmedetomidine will be administered as an oro-dispersible tablet applied buccally, allowing for rapid absorption through the oral mucosa.
219318902|NCT07167316|OTHER|Auditory Stimulation|Auditory tones will be presented throughout the night at individually calibrated intensities, adjusted to each participant's hearing threshold, in order to induce controlled sleep fragmentation without full awakenings.
219318903|NCT07167316|DRUG|Placbo|Oro-dispersible placebo tablet identical in appearance and packaging to the active Dexmedetomidine tablet.
219318904|NCT07172152|BEHAVIORAL|HRV Biofeedback Training|Participants will be trained to use HRV biofeedback through paced breathing exercises (6 breaths per minute) twice daily over a four-week period.
219318905|NCT07182162|OTHER|Remote supervision + simulation|teacher use remote supervision to assist peer training Hospital-at-Home scenario simulation
219318906|NCT07172594|DRUG|Lactium|Lentra sachet (containing 150 mg Lactium) will be totally dissolved in 100 ml water and 50 ml will be given to cases, 2 hours before surgery.
219318907|NCT07172594|OTHER|Placebo control|50 ml water added to it powdered vanilla flavor will be given to cases 2 hours before surgery.
219355064|NCT05529914|OTHER|Neuromuscular exercises|Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up \& down, Cool-down
219318908|NCT07179354|DEVICE|Rapid Maxillary Expansion with Face Mask (RME/FM)|A tooth- and tissue-borne rapid maxillary expansion appliance with an expansion screw was used to achieve transverse maxillary expansion, followed by Petit-type face mask therapy. Expansion protocol: two quarter-turns per day for 10-14 days, then one quarter-turn per day until cusp-to-cusp relationship was achieved. Face mask elastics applied 16 hours/day at 350-500 g per side, with a 30° downward and forward vector relative to the occlusal plane.
219318909|NCT07179354|DEVICE|Mini Maxillary Protractor (MMP)|An intraoral mini maxillary protraction appliance was used to advance the maxilla. Force was applied through intraoral elastics connected to intraoral anchorage units. The protocol was designed to deliver orthopedic forward traction of the maxilla without an external face mask.
219318910|NCT07179354|DEVICE|Modified Splint with Elastics and Chin Cup (Modified SEC III)|A modified splint appliance combined with intraoral elastics and an orthopedic chin cup was used to achieve skeletal mandibular retrusion and Class III correction. The appliance applied orthopedic forces through combined vertical and horizontal components, promoting backward positioning of the mandible while maintaining transverse maxillary relationships.
219318911|NCT07180472|DRUG|Cilostazol|Oral administration of cilostazol
219318912|NCT07180472|DRUG|Aspirin|Oral administration of Asprin
219318913|NCT07180472|DRUG|Clopidogrel|Oral administration of Clopidogrel
219318914|NCT07182097|DRUG|Fentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia|Patients will receive fentanyl 2 µg/kg IV bolus at induction, followed by a continuous infusion of 1-2 µg/kg/h during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
219318915|NCT07182097|DRUG|Remifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia|Patients will receive remifentanil 1 µg/kg IV bolus at induction, followed by a continuous infusion of 0.1-1 µg/kg/min during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
219318916|NCT07182227|GENETIC|PS-002|Adeno-associated viral vector containing the human Complement Factor I (CFI) gene
219318917|NCT07180810|DRUG|Dexmedetomidine infusion low dose|low dose dexmedetomidine infusion at rate 0.6mcg/kg/hour rate .
219318918|NCT07180810|DRUG|Group B receiving normal saline|Normal saline infusion at rate 0.6mcg/kr/hour rate
219318919|NCT07176767|DEVICE|Positive airway pressure therapy|Initiation of continuous or bilevel positive airway pressure therapy
219318920|NCT07184385|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
219318921|NCT07184385|BIOLOGICAL|Placebo|Normal Saline
219318922|NCT07179367|OTHER|Escape Room-Based Teaching Method on Patient Safety|Intervention Description: This intervention is a patient safety-themed escape room simulation specifically designed for nursing students. The activity consists of three phases structured in accordance with INACSL standards: pre-briefing, escape room simulation, and post-briefing assessment. Working in small groups, students solve knowledge- and skill-based patient safety tasks in three different rooms (patient safety, mother-baby room, and adult intensive care unit). Correct answers ensure progress, while post-briefing assessment using the PEARLS method supports reflection and learning. Unlike traditional teaching, this innovative method emphasizes teamwork, active participation, and experiential learning to increase self-efficacy and satisfaction with patient safety practices.
219318923|NCT07182019|BEHAVIORAL|Connecting Today|Connecting today is a facilitated remote visiting program for people living with moderate to severe dementia in care homes. The program offers residents up to 60 minutes of scheduled contact with a family member, friend or volunteer by video call. An onsite facilitator supports the video calls which are delivered via ipad/zoom.
219355065|NCT05529914|OTHER|Cold pack|Application of cold pack around the patient's body, and covered with dry towel
219355066|NCT00810979|DRUG|SLx-4090|tablet
219355067|NCT00810979|DRUG|SLx-4090|tablet
219355068|NCT00810979|OTHER|Placebo|matching tablet
219318924|NCT07181447|DIAGNOSTIC_TEST|Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy|This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations.
219318925|NCT07187492|DRUG|Bacillus coagulans|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Bacillus coagulans 1050 mg three times daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Bacillus coagulans 1050 mg three times daily."
219318926|NCT07187492|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency)."
219318927|NCT07186270|BEHAVIORAL|Positively framed FOP labels (present versus absent) x Price (high versus low)|"The intervention combines either a front-of-pack (FOP) label that frames high nutrition or no FOP label with price variation. Products are randomly assigned to either receive a positively-framed FOP label or no label, and to either a high or a low price.~This yields four experimental arms:~1. Positively framed FOP label with high price~2. Positively framed FOP label with low price~3. No label with high price~4. No label with low price"
219318928|NCT07186270|BEHAVIORAL|Graded FOP labels (no label vs. high rating (grade A) vs. low rating (grade D)) x Price (average vs. premium)|"The intervention combines either a graded front-of-pack (FOP) labelling or no FOP labelling with price variation. Products are randomly assigned to either receive a graded label or no label, and to either a premium or an average price.~This yields six experimental arms:~1. High grade (A) with premium price~2. Low grade (D) with premium price~3. No label with premium price~4. High grade (A) with average price~5. Low grade (D) with average price~6. No label with average price"
219318929|NCT07188688|DEVICE|Musculoskeletal Ultrasound Device|Musculoskeletal Ultrasound assessment by LOGIQ P10 from General Electric (GE) Healthcare, each patient will be evaluated by grey scale, power doppler MSUS and Shear Wave Elastography (SWE)
219318930|NCT07188701|BEHAVIORAL|Telerehabilitation Exercise Program|"1. Telerehabilitation Exercise Program~   Intervention Description:~   A 6-week structured telerehabilitation exercise program delivered via Zoom under the supervision of a physiotherapist. Sessions were conducted 4 days per week, approximately 20-30 minutes each. Exercises focused on posture correction, cervical stabilization, mobility, and pain management strategies.~2. Home Exercise Program~Intervention Description:~A 6-week home exercise program for chronic non-specific neck pain. Exercises were demonstrated once weekly via Zoom by a physiotherapist, and participants performed them independently at home on the remaining days. Each session lasted 20-30 minutes and included stretching, strengthening, and posture training."
219318931|NCT07188584|RADIATION|Reduced-Target Radiotherapy|Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).
219318932|NCT07188584|RADIATION|Conventional Full-Target Radiotherapy|Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.
219318933|NCT07187804|DRUG|Intravitreal faricimab injection|"* Initial loading injections : every 4 weeks by 12weeks~* Treat and extend injection(\~76 week) : Week 20 - Week 76~TAE is initiated with a minimum injection interval of 8 weeks. If no recurrence is observed, the interval is extended by 2 weeks at a time, up to a maximum of 16 weeks. In the event of recurrence, the injection interval is reduced to 8 weeks, regardless of the previous schedule. The minimum injection interval remains 8 weeks."
219318934|NCT07188610|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.
219318935|NCT07189026|DIAGNOSTIC_TEST|Airway opening pressure|Airway opening pressure will be measured within one hour of intensive care unit admission (using a standardized low-flow insufflation maneuver flow 5-6 LPM). The inflection point on the pressure-time or pressure-volume waveform- depending on ventilator model-will define the airway opening pressure.
219318936|NCT07188168|DEVICE|Miller mobility measurement|Tooth mobility at different levels of mobility was assessed using Miller, Periotest and Osstell, and was evaluated both subjectively and objectively.
219318937|NCT07189325|DRUG|Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)|"Patients randomized in the experimental group will be treated with platform therapies (Dimethyl Fumarate, Diroximel Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) according to treatments' authorization from the day of randomization to M36 described below.~Patients will receive appropriate information and recommendation for the initiation of the chosen platform treatment as mention in the SmPC by treating neurologist or a member of the investigating team. If therapies are not tolerated, a therapeutic switch to other platform therapies will be possible. Any switch to a disease modifying therapy not listed as platform therapy will be considered as a major protocol deviation (see statistics).~Patients are allowed to switch from any platform DMT to another platform DMT."
219318938|NCT07189325|DRUG|Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)|"Patients randomized in the control group will be treated every 6 months (or at previous extended interval dosing) for patients with anti-CD20 (Ocrelizumab, Rituximab) or every 4 weeks for patients with subcutaneous anti-CD20 (Ofatumumab) from the day of randomization to M36. If therapies are not tolerated, a therapeutic switch to other anti-CD20 therapy will be possible. Any switch to a disease modifying therapy not listed as anti-CD20 therapy will be considered as major protocol deviation (see statistics).~Patients are allowed to switch from any anti-CD20 to another anti-CD20."
219355069|NCT00810979|DRUG|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
219318939|NCT07187323|OTHER|Saliva sampling|Unstimulated, whole saliva was collected from all participants across the six study groups following a detailed explanation of the procedure. Initially, individuals were asked to rinse their mouths with filtered water and remain seated in a relaxed position for five minutes. Then, they were instructed to passively drool into a sterile collection tube over a 10-minute period.31 The collected saliva samples were then centrifuged at 3000 ×g for 10 minutes to remove debris and prepare them for storage at -80°C .
219318940|NCT07187323|OTHER|Amino Acid Analysis|Saliva samples were deproteinized by mixing with 6% sulfosalicylic acid in a 1:1 ratio, followed by incubation at room temperature for 5 minutes. The mixtures were then centrifuged at 15,000 rpm for 5 minutes. A 10 µL aliquot of the resulting supernatant was diluted with 800 µL of 2 mM tridecafluoroheptanoic acid containing 0.375 M glucosaminic acid and internal standards. The prepared solutions were transferred into autosampler vials for analysis. Calibration standards were generated by combining known concentrations of amino acid standards.
219318941|NCT07187622|OTHER|examine the impact of education|The mothers in the study group were given education about neonatal jaundice and were trained to increase the mothers' knowledge level and to prevent neonatal jaundice.
219318942|NCT07189234|BEHAVIORAL|Time-restricted eating (TRE) + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hour eating window for the course of the study as well as receive nutritional counseling from the study dietician.
219318943|NCT07189234|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt the 10-hour eating window.
219318944|NCT07188376|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each iTBS session includes 600 pulses delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), in 2 sec on / 8 sec off cycles at 110% resting motor threshold (RMT). Stimulation is ramp-up from 80% to 110% RMT (\~90 pulses). Two iTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
219318945|NCT07188376|DEVICE|Continuous Theta Burst Stimulation|Continuous Theta Burst Stimulation (cTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each cTBS session includes 2 bouts of 1800 pulses separated by a 1 minute rest period. Each bout is delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), continuously for \~120 seconds at 110% resting motor threshold (RMT). Stimulation is ramped up from 80% to 110% RMT over the first 30 seconds. Two cTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
219318946|NCT07188376|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation (TMS) is delivered to the left DLPFC using the sham side of a MagVenture TMS coil, paired with synchronized scalp electrodes to mimic the sensation of real TMS. The sham procedure matches the timing and auditory cues of either iTBS or cTBS protocols, depending on random assignment. Two sham stimulation sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
219318947|NCT07179627|DEVICE|Ankle exoskeleton|The ankle exoskeleton provides bilateral torque assistance at the ankle joints during common functional tasks such as level-ground walking, stair and ramp ascent, and other daily activities, thereby reducing the mechanical workload and supporting more effective community ambulation. In particular, the device is designed to address drop-foot on the paretic side by delivering bidirectional assistance, which helps improve toe clearance during swing as well as push-off during stance. As a wearable assistive device, assistance is applied only while the device is worn.
219318948|NCT07179627|OTHER|Baseline (no ankle exoskeleton)|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing an ankle exoskeleton.
219318949|NCT07187869|DRUG|Cabozantinib|Given by IV
219318950|NCT07187869|DRUG|Nivolumab|Given by IV
219318951|NCT07188389|BEHAVIORAL|Acute exercise-moderate intensity|30 minutes of cycling exercise at moderate (90% of first ventilatory threshold)
219318952|NCT07188389|BEHAVIORAL|Acute effects-heavy intensity|Participants will cycle 30 minutes at heavy (110% of first ventilatory threshold) intensity
219318953|NCT07188090|DRUG|Plerixafor|Plerixafor is an antagonist of chemokine receptor-4 (CXCR4) receptor that can release stem cells from the bone marrow niche into the peripheral blood circulation
219318954|NCT07188090|DRUG|Gcsf|All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.
219318955|NCT07187973|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
219318956|NCT07187505|DRUG|Venetoclax|Venetoclax is a selective BCL-2 inhibitor administered orally once daily. The dose will be adjusted according to the study protocol and patient tolerance.
219318957|NCT07187505|DRUG|All-trans retinoic acid|All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.
219318958|NCT07187505|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide (ATO) is administered intravenously once daily, in combination with ATRA and venetoclax, during induction and consolidation therapy.
219318959|NCT07188246|RADIATION|Radiation|Stereotactic body radiation therapy to the breast
219318960|NCT07188246|DRUG|Pembrolizumab (KEYTRUDA®)|Two injections
219318961|NCT07188792|OTHER|HORTICULTURAL THERAPY|"* Introduction~* Explanation of the training content for horticultural activities using visual materials~* Explanation of the program's scope, duration, and expected participant roles and responsibilities"
219318962|NCT07189221|BEHAVIORAL|Life Style Intervention|"The intervention consists of seven related components:~I. A Bluetooth-enabled weighing scale that syncs with the app to facilitate self-monitoring of weight.~II. Synchronous coaching sessions conducted on a 1:1 basis between the mHealth coach and participants. There will be 2 synchronous sessions, the first at enrolment and the second between 6-8 weeks postpartum. These sessions typically last 45-50 minutes in length with a follow-up summary video message of the goals discussed and, at the beginning of the mother's journey, the establishing of a change agreement. This is mediated through the live-video feature in the B2B\&Me+ mHealth coaching app, but the length and thus number of these sessions is determined by the woman. If the woman is diagnosed with GDM, there will be an opportunity for a third 15-minute synchronous coaching session to review and adjust any lifestyle goals to align with the individual's diabetes management plan.~III. Asynchronous mHealth coaching that uses a combi"
219355070|NCT01698346|BIOLOGICAL|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
219318963|NCT07187674|DRUG|Iparomlimab and tuvonralimab combined with olaparib and paclitaxel|The main objective of this study is to evaluate the tpCR of early high-risk TNBC with HRD positive treated with Iparomlimab and tuvonralimab combined with olaparib and paclitaxel as neoadjuvant therapy
219318964|NCT07189299|DRUG|LSD 10 μg every Day|Participants will receive 10 μg LSD every day during the luteal phase
219318965|NCT07189299|DRUG|LSD 10 μg every other day|Participants receive 10μg LSD every second day during the luteal phase
219318966|NCT07189299|DRUG|Placebo|Participants receive inactive placebo during the luteal phase
219318967|NCT07188805|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 90±3 days
219318968|NCT07188805|DRUG|Placebo|Placebo to finerenone, treatment duration will be 90±3 days
219318969|NCT07189143|DIETARY_SUPPLEMENT|Belinal® (Abies alba branch extract)|Belinal® capsules, 900 mg/day (4 × 225 mg), orally for 14 consecutive days.
219318970|NCT07189078|PROCEDURE|Restrictive intubation strategy|"Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:~1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.~2. SpO₂/FiO₂ \< 88.~3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels."
219318971|NCT07189078|PROCEDURE|Liberal intubation strategy|"Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.~In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes."
219318972|NCT07187934|DEVICE|AI algorithm|iDAScore® is a deep learning-based tool that provides fully automated analysis of embryo time-lapse images. It automatically generates a score (1-9.9) for each embryo in the patient's embryo cohort, which correlates to the likelihood of achieving a fetal heartbeat (clinical pregnancy).
219318973|NCT07189286|BEHAVIORAL|PAVE intervention|The commercial virtual reality app that will be used for the intervention, Supernatural, provides participants a trainer as they use their arms and legs (e.g., seated knee strikes) to smash targets to 500+ musical tracks. In this manner, this study employs fun as a motivator for exercise commencement and adherence while hospitalized. The research assistant will implement the intervention using the four-step approach including: (1) patient mobility screen, (2) orientation to the technology and intervention, (3) goal setting for physical activity, and (4) ongoing assessment, adaptation, and motivation.
219318974|NCT07189286|BEHAVIORAL|Education control|"Education control participants will receive and physical activity education using the NIH Get Fit for Life booklet."
219318975|NCT07189156|OTHER|Immediate Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be immediately weight bearing as tolerated after surgery.
219318976|NCT07189156|OTHER|Delayed Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
219318977|NCT07189156|OTHER|Immediate Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be immediately weight bearing as tolerated after surgery.
219318978|NCT07189156|OTHER|Delayed Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
219318979|NCT07187791|DEVICE|CT scan|All Patients will undergo CT KUB cyst evaluation Qualitatively regarding Gross Picture in Imaging and Quantitavely using Hausfield units then patients will undergo Abdomianl ultrasound
219318980|NCT07188948|DEVICE|Skin conditions|Participants with skin conditions such as AK or participants without any skin conditions (healthy skin)
219318981|NCT07188948|DEVICE|Skin Condition|Participants with Skin conditions or participants without any skin conditions (Healthy)
219318982|NCT07187739|OTHER|Mediterranean diet|All individuals in the intervention group will be instructed to adhere to Mediterranean diet recommendations for a period of three months following the activation of the deep brain stimulation device. Nutritional training sessions focusing on the Mediterranean diet will be provided and reinforced during monthly follow-up interviews. In line with these recommendations, olive oil will be promoted as the primary dietary fat. Participants will be encouraged to consume a minimum of 300-400 grams of vegetables daily and 450 grams of fresh fruit or alternatively, 300 grams of fresh fruit and 30 grams of dried fruit. The consumption of bakery products, sugary snacks, and carbonated beverages will be discouraged. White meat will be favored over red meat in meal planning. Participants will also be advised to include 450 grams of fish, 30 grams of oilseeds, and 180 grams of legumes in their weekly diets. There is no routine Mediterranean diet recommendation after STN DBS.
219318983|NCT07187960|DRUG|TQB2825 Injection|TQB2825 is a Cluster of Differentiation 3 (CD3) × Cluster of Differentiation 20 (CD20) bispecific antibody.
219318984|NCT07187960|DRUG|Rituximab Injection|Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA, Dexamethasone)
219318985|NCT07187375|DRUG|Crinecerfont|Oral solution
219318986|NCT07188740|DRUG|Metformin|Start at 500 mg twice daily, titrate to 2000 mg/day for 6 months
219318987|NCT07188155|BEHAVIORAL|Exposure Therapy for Anorexia (Exp-AN)|"Exp-AN is specifically designed to target anxiety about weight gain. Exp-AN helps participants identify their specific feared consequences of weight gain (e.g., I will permanently hate myself if I gain weight), and combines in vivo (i.e., in real life) and imaginal (i.e., mental) exposure exercises to address these fears."
219318988|NCT07188909|DRUG|Patient-Donor Derived Probiotics|To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
219318989|NCT07187830|DRUG|Semaglutide (1 Mg Dose)|standard of care treatment
219318990|NCT07189065|DRUG|Rocbrutinib|200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc.
219318991|NCT07189065|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 28 days) 90 mg/m2 Bendamustine (IV infusion) on Days 1 and 2 of Cycles 1-6.
219318992|NCT07189065|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 28 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
219318993|NCT07189065|DRUG|Lenalidomide|20mg qd PO day 1-21
219318994|NCT07189182|DEVICE|Origin Intubation System|This device leverages self-deploying geometry to guide intubation.
219318995|NCT07188103|DRUG|Ivonescimab+Radiotherapy|Short-course hypofractionated radiotherapy was administered to progressive lesions after first-line treatment, with a prescribed dose of 20 Gy in 5 fractions (95% PTV). The monoclonal antibody was initiated within 1 week after completing the radiotherapy regimen, at a dose of 20 mg/kg. Ivonescimab was administered every three weeks until disease progression, intolerable toxicity, or patient refusal.
219318996|NCT07188415|DEVICE|Ankle-foot Orthoses|Group 1 will consist of individuals who have CMT and have undergone surgical correction (OP) and Group 2 will be AFO users who have CMT but have not undergone major surgical correction (NonOP).
219318997|NCT07189338|PROCEDURE|Apneic oxygenation|"* Preoxygenation will be performed using NIV for 3-5 min With nasal cannulas placed in standby beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0)~* Rapide sequence induction~* Hypoventilation phase will be continue for 1 min using NIV~* At the time of laryngoscopy :~After removing the facemask, the nasal cannulas of HFNO will be placed in the patient's nares then the laryngoscopy will be performed.~\* Use of capnography to confirm the success of procedure"
219355071|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
219355072|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
219355073|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
219318998|NCT07189338|PROCEDURE|Usual Care|"* Preoxygenation will be performed using NIV for 3-5 min without HFNO~* Rapide sequence induction~* Hypoventilation phase will be continue using NIV for 1min~* At the time of laryngoscopy :~After removing the facemask, laryngoscopy will be performed without oxygen.~\* Use of capnography to confirm the success of procedure"
219355074|NCT00242827|DRUG|Oral CEP-701|
219318999|NCT07188402|OTHER|Prevalence of sleep disturbances in patients with bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
219319000|NCT07188402|OTHER|Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
219319001|NCT07188454|BEHAVIORAL|Mindfulness-Based Digital Intervention (AIZEN Program)|The intervention consisted of a 5-week mindfulness program designed for caregivers. Participants attended one live, instructor-led online class each week (90 minutes per session) delivered via Microsoft Teams. Between classes, they were asked to complete at least 10 minutes of daily guided mindfulness practice using the AIZEN digital platform. To encourage adherence, participants also received automated daily reminders through the LINE messaging service.
219319002|NCT07188233|DEVICE|Transcatheter Mitral Valve Repair|Mitral valve repair with the CathHELIX Transcatheter Mitral Annuloplasty System in subjects with functional Mitral Regurgitation
219319003|NCT07189364|BEHAVIORAL|Peer Comparison Feedback Report|The intervention will be an electronic, individualized, peer-comparison feedback report on the participant's antimicrobial prescribing practices, combined with a knowledge toolkit focused on optimizing antimicrobial use.
219319004|NCT07187713|DRUG|ACE Reno|1 ml sublingual 4 times daily for 12 weeks
219319005|NCT07188519|OTHER|expressive writing|Each of the four rounds consisted of three consecutive days of writing followed by a gap week.
219319006|NCT07187947|DRUG|Feminizing GAHT|Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.
219319007|NCT07187947|DRUG|Masculinizing GAHT|Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)
219355075|NCT06312475|DRUG|KN057|KN057 will be administered subcutaneously once a week.
219355076|NCT00278681|DRUG|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
219319008|NCT05490004|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
219319009|NCT05868811|BEHAVIORAL|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
219319010|NCT05868811|BEHAVIORAL|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
219319011|NCT04697043|PROCEDURE|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
219319012|NCT03855553|BEHAVIORAL|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
219319013|NCT03855553|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
219319014|NCT01486953|DRUG|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
219319015|NCT01486953|DRUG|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
219319016|NCT01708239|OTHER|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
219319017|NCT00561496|DRUG|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
219319018|NCT02872077|OTHER|Auricular acupuncture|
219319019|NCT04358510|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
219319020|NCT06512272|OTHER|Video recorded shared using a mobile application|"The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times"
219319021|NCT06494709|OTHER|photographs|"Standardized photographs presenting 10 control subjects (class I) and patients with dentofacial deformities (10 class II and 10 class III) before and after surgery - from the front and from the side - will be used to form an approximately 10 min video sequence using the Tobii Pro Lab® software (Tobii Pro AB, Danderyd, Sweden). The naive participants will look at the percept during which the faces of the controls and the patients will alternate, with the only instruction being free visual exploration of the percept.~The fixation duration in the defined areas of interest (eyes, nose, mouth, chin) will be recorded with a Tobii® Pro X3-120 eye-tracking device and the results will be processed with the Tobii Pro Lab® software."
219319022|NCT01889303|DRUG|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
219319023|NCT01889303|DRUG|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
219319024|NCT01889303|RADIATION|radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
219319025|NCT02801955|PROCEDURE|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
219319026|NCT02801955|PROCEDURE|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
219319027|NCT01747967|OTHER|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
219319028|NCT03099668|OTHER|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
219319029|NCT04166604|DRUG|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
219319030|NCT05132387|OTHER|ECMO assisted CPR in out-of-hospital cardiac arrest|Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
219319031|NCT05329935|BIOLOGICAL|Cultured Thymus Tissue|Product will be surgically administered into the quadriceps
219319032|NCT02022085|DEVICE|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
219319033|NCT05576350|BEHAVIORAL|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
219319034|NCT05576350|BEHAVIORAL|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.
219319035|NCT05576350|BEHAVIORAL|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
219319036|NCT04012437|DEVICE|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
219319037|NCT04012437|BEHAVIORAL|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
219319038|NCT05467878|OTHER|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
219319039|NCT03111693|OTHER|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
219319040|NCT01939054|DRUG|Nimotuzumab|
219319041|NCT01939054|DRUG|docetaxel|
219319042|NCT01939054|DRUG|capecitabine|
219319043|NCT04864509|DRUG|Melatonin 10 MG|Nightly dose
219319044|NCT04864509|DRUG|Placebo|Nightly dose
219319045|NCT00398970|DEVICE|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
219319046|NCT04356248|BEHAVIORAL|Endurance Training|Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
219319047|NCT04356248|BEHAVIORAL|Education|Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
219319048|NCT03831425|DIETARY_SUPPLEMENT|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
219319049|NCT03831425|OTHER|Placebo|6 week trial of either treatment with Placebo
219319050|NCT05594823|OTHER|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
219319051|NCT05594823|OTHER|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
219319052|NCT05390359|OTHER|High-intensity and short-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
219319053|NCT05390359|OTHER|Low-intensity and long-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds."
219319054|NCT05390359|OTHER|High-intensity, short-duration and 20 Hz|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
219319055|NCT05390359|OTHER|Sham electrolysis|The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
219319056|NCT05334017|DRUG|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
219319057|NCT05334017|DRUG|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
219319058|NCT05766709|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously once weekly.
219319059|NCT05766709|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
219319060|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/3.20 mg/mL)|NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
219319061|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/0.33mg/mL)|NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
219319062|NCT01091597|PROCEDURE|usual PV ablation|usual PV ablation, per above
219319063|NCT01091597|PROCEDURE|Box isolation of pulmonary veins|as above
219319064|NCT05443087|OTHER|Blood sampling to build population pharmacokinetics model|"Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received"
219319065|NCT04844450|DRUG|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
219319066|NCT04844450|DRUG|Placebo|Matching placebo will be administered subcutaneously.
219319067|NCT01119482|BIOLOGICAL|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
219319068|NCT05034536|DRUG|Pembrolizumab|Intravenous infusion
219319069|NCT05034536|DRUG|Infliximab|Intravenous infusion
219319070|NCT05034536|DRUG|Placebo|Intravenous infusion
219319071|NCT05034536|DRUG|Relatlimab|Intravenous infusion
219319072|NCT05034536|DRUG|Nivolumab|Intravenous infusion
219319073|NCT06342284|RADIATION|Proton Beam Radiation with or without concurrent chemotherapy|Curative-intent fractionated proton beam thoracic radiotherapy, with or without concurrent chemotherapy
219319074|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
219319075|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
219319076|NCT02183636|DRUG|Linagliptin tablet|5 mg
219319077|NCT02183636|DRUG|pioglitazone tablet (Actos®)|45 mg
219319078|NCT06371287|BEHAVIORAL|Treinamento Auditivo Musical|Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.
219319079|NCT06371287|BEHAVIORAL|Placebo|"This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009)."
219319080|NCT00409253|DRUG|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
219319081|NCT00409253|DRUG|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
219319082|NCT06027190|DEVICE|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~2. 70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
219319083|NCT06027190|DEVICE|Sham|Placebo coil (Magstim Company, Whitland, UK):
219319084|NCT01054651|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
219319085|NCT01054651|DRUG|Praziquantel|
219319086|NCT06476574|DEVICE|Vacuum-formed retainer|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer)."
219319087|NCT06476574|DEVICE|Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.|"* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0."
219319088|NCT06476574|DEVICE|Lingual bonded retainer from canine-to-canine|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer)."
219319089|NCT01165372|DRUG|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
219319090|NCT02627222|OTHER|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
219319091|NCT02627222|OTHER|White cassava|Conventional white cassava
219319092|NCT06041620|BIOLOGICAL|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
219319093|NCT05385042|DIETARY_SUPPLEMENT|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
219319094|NCT05385042|DIETARY_SUPPLEMENT|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
219319095|NCT01179672|DRUG|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
219319096|NCT01179672|DRUG|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
219319097|NCT01292447|DRUG|2% lidocaine gel|120mg lidocaine x 1
219319098|NCT01292447|DRUG|Placebo gel|Inert gel x 1
219319099|NCT01686009|DRUG|Intra-nasal ketamine|
219319100|NCT01617590|DRUG|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
219319101|NCT01617590|DRUG|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
219319102|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
219319103|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
219319104|NCT00004172|BIOLOGICAL|filgrastim|
219319105|NCT00004172|DRUG|carboplatin|
219319106|NCT00004172|DRUG|cyclophosphamide|
219319107|NCT00004172|DRUG|ifosfamide|
219319108|NCT00004172|DRUG|thiotepa|
219319109|NCT00004172|PROCEDURE|peripheral blood stem cell transplantation|
219319110|NCT00004172|RADIATION|radiation therapy|
219319111|NCT00977457|GENETIC|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319112|NCT00977457|GENETIC|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319113|NCT00977457|GENETIC|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319114|NCT00977457|GENETIC|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319115|NCT00977457|GENETIC|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319116|NCT00977457|OTHER|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
219319117|NCT00977457|PROCEDURE|therapeutic conventional surgery|
219319118|NCT05014893|COMBINATION_PRODUCT|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
219319119|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
219319120|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
219319121|NCT06563583|OTHER|Group 1 will include patients aged 18-40 years|Group 1 will include patients aged 18-40 years.
219319122|NCT06563583|OTHER|Group 2 will include patients aged 40-64 years|Group 2 will include patients aged 40-64 years, and finally.
219319123|NCT06563583|OTHER|Group 3 will include patients aged 65-85 years|Group 3 will include patients aged 65-85 years.
219319124|NCT05518864|DEVICE|IALURIL Prefill|GAG therapy (bladder instillations with glycosaminoglycans)
219319125|NCT06583980|BEHAVIORAL|Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact|A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
219319126|NCT02679339|DRUG|CNTX-2022 (lidocaine gel, 40%)|
219319127|NCT02679339|DRUG|Placebo|
219319128|NCT06027125|OTHER|Action observation Therapy|The patients in the AOT group will be required to observe the upper limb movements or functional actions in video clips and to execute what they had observed to the best of their ability.
219319129|NCT06027125|OTHER|Mirror Therapy|The patients will be seated in front of a mirror box placed at their midsagittal plane to perform the movements. The affected arm of the participants was placed inside of the mirror box, and the unaffected arm was infront ofthe mirror.
219319130|NCT01272947|DRUG|Diclofenac sodium|Topical gel 1%- 4 times daily
219319131|NCT01272947|OTHER|Placebo|Topical gel - 4 times daily
219319132|NCT01961661|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
219319133|NCT01961661|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
219319134|NCT03272763|DEVICE|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
219319135|NCT05803304|BEHAVIORAL|PATH Intervention|The PATH intervention guides participants in making changes in their lifestyle and PA habits to support long-term adherence to the minimum threshold of PA Guidelines (150 MVPA minutes per week). The health coach provides participants with access the PATH website and a detailed orientation on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA by about 10 minutes per week. The PA prescription process begins by identifying a suitable PATH level for each participant. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA).
219319136|NCT05803304|BEHAVIORAL|Attention Control Intervention|"A health coach will have a zoom meeting with each control group participant where they will be provided with an electronic copy of the Be Active Your Way booklet, developed by the Centers for Disease Control and Prevention (CDC) to help individuals integrate PA into their daily lives. The coach will orient the participant to the key strategies used in the booklet and encouraged them to use it regularly and to self-monitor PA using the Fitbit during the entire course of the study. In addition, the group will be introduced to www.health.com, a jargon free website that focuses on general health topics and latest medical news. At the end of the meeting, the participants will be asked to provide a schedule for zoom meetings the study team twice per month during the 6 month study. The meetings will focus on their progress in using the Be Active Your Way handout and the health.com website."
219319137|NCT05803304|OTHER|Physical activity tracker|Participants will be asked to wear Fitbit Charge 5 on their non-dominant hand for the entire duration of the study using a 24hr wear protocol.
219319138|NCT05803304|BEHAVIORAL|Dietary education|Diet quality and barriers to healthy eating will be evaluated at baseline, and then all study participants will be provided with educational materials that are curated to promote diet quality. Participants will receive a monthly email with a brief PDF addressing a diet component focused on improving diet quality to reduce CVD risk and improve general health.
219319139|NCT04315987|BIOLOGICAL|NestaCell®|A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
219319140|NCT04315987|BIOLOGICAL|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
219319141|NCT04193878|DRUG|Inhaled budesonide and formoterol|aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
219319142|NCT04193878|DRUG|Inhaled placebo|aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
219319143|NCT02019420|DRUG|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
219319144|NCT02019420|DRUG|Linezolid|Linezolid IV 600 mg twice daily
219319145|NCT04048265|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
219319146|NCT02510560|DRUG|NTRA-2112|
219319147|NCT02510560|DRUG|Placebo|
219319148|NCT05149365|DRUG|Sitagliptin + Standard Prophylaxis|Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
219319149|NCT05149365|DRUG|Standard Prophylaxis|Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
219319150|NCT02630732|BEHAVIORAL|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
219319151|NCT02630732|BEHAVIORAL|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
219319152|NCT05520541|OTHER|Exercise|Both groups will receive exercise-based training
219319153|NCT04978181|DRUG|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
219319154|NCT02780050|OTHER|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
219319155|NCT00025454|DRUG|tipifarnib|
219319156|NCT01647529|DRUG|Ganciclovir|Treatment with topical ganciclovir ointment
219319157|NCT02592512|OTHER|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
219319158|NCT02592512|OTHER|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
219319159|NCT05913310|DRUG|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
219319160|NCT05913310|DRUG|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
219319161|NCT03521414|DEVICE|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
219319162|NCT03521414|DRUG|Sevoflurane|we used sevoflurane drug at inoperative
219319163|NCT00573599|DRUG|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
219319164|NCT00573599|DRUG|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
219319165|NCT04853355|DRUG|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
219319166|NCT04263012|OTHER|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
219319167|NCT03769064|DRUG|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
219319168|NCT03769064|DRUG|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
219319169|NCT03769064|DRUG|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
219319170|NCT03769064|DRUG|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
219319171|NCT03769064|DRUG|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
219319172|NCT03769064|DRUG|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
219319173|NCT00555490|DIETARY_SUPPLEMENT|Soy protein|35 % of protein from soy protein for 4-years
219319174|NCT02472379|BEHAVIORAL|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
219319175|NCT02472379|OTHER|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
219319176|NCT04614441|DRUG|OFEV®|nintedanib
219319177|NCT02307864|DRUG|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
219319178|NCT02307864|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
219319179|NCT02307864|DRUG|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
219319180|NCT02307864|DRUG|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
219319181|NCT03404284|BEHAVIORAL|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
219319182|NCT03595839|PROCEDURE|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
219319183|NCT03595839|PROCEDURE|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
219319184|NCT02608541|OTHER|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
219319185|NCT04308525|BEHAVIORAL|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
219319186|NCT04308525|BEHAVIORAL|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
219319187|NCT04308525|OTHER|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
219319188|NCT04308525|PROCEDURE|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
219319189|NCT04308525|PROCEDURE|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
219319190|NCT04308525|OTHER|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
219319191|NCT04308525|OTHER|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
219319192|NCT03502954|BIOLOGICAL|ABY-039|ABY-039
219319193|NCT03502954|BIOLOGICAL|Placebo|Placebo
219319194|NCT00186641|PROCEDURE|high dose chemo and auto hematopoietic cell transplant|
219319195|NCT01492530|BEHAVIORAL|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
219319196|NCT01492530|BEHAVIORAL|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
219319197|NCT02554903|DRUG|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
219319198|NCT02554903|DRUG|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
219319199|NCT01210989|DRUG|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
219319200|NCT01210989|DRUG|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
219319201|NCT00800943|BIOLOGICAL|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
219319202|NCT01764048|DRUG|Fix protocol|Please see arm description
219319203|NCT01764048|DRUG|medications following demand protocol|Please see arm description
219319204|NCT05679856|RADIATION|Hypofractionated single vocal cord irradiation|Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
219319205|NCT05679856|RADIATION|Whole laryngeal radiotherapy|The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
219319206|NCT00109720|BEHAVIORAL|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
219319207|NCT00109720|BEHAVIORAL|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
219319208|NCT03700749|DRUG|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
219319209|NCT03700749|DRUG|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
219319210|NCT03700749|DRUG|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
219319211|NCT03700749|DRUG|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
219319212|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care|"Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio."
219319213|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning|The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
219319214|NCT02742766|DRUG|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
219319215|NCT02742766|DRUG|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
219319216|NCT01973946|OTHER|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
219319217|NCT03674125|BIOLOGICAL|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
219319218|NCT02084641|OTHER|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
219319219|NCT01567982|DEVICE|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
219319220|NCT04974515|DEVICE|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
219319221|NCT05275712|OTHER|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
219319222|NCT01482663|BEHAVIORAL|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
219319223|NCT00124371|BEHAVIORAL|a nurse led home-based education and support programme|
219319224|NCT05093725|DEVICE|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
219319225|NCT01677351|DRUG|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
219319226|NCT01677351|DRUG|placebo|
219319227|NCT05285488|OTHER|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
219319228|NCT04936841|DRUG|NKTR-214|Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
219319229|NCT04936841|DRUG|anti-PD-1 therapy|immunotherapy drug, monoclonal antibody
219319230|NCT04936841|RADIATION|Palliative Radiation|radiation to relieve symptoms
219319231|NCT03963752|DRUG|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
219319232|NCT03963752|DRUG|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
219319233|NCT03963752|DRUG|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
219319234|NCT03230656|OTHER|Early cognitive-communication therapy|
219319235|NCT02016833|PROCEDURE|Blood Sampling|Sampling of 80mL of whole blood
219319236|NCT03298321|OTHER|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
219319237|NCT02479334|OTHER|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
219319238|NCT02479334|OTHER|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
219319239|NCT02479334|OTHER|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
219319240|NCT02479334|OTHER|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
219319241|NCT03739437|BEHAVIORAL|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
219319242|NCT03739437|BEHAVIORAL|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
219319243|NCT04586582|DIAGNOSTIC_TEST|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
219319244|NCT02798263|OTHER|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
219319245|NCT02798263|OTHER|Acupuncture|30 minutes of classical acupuncture using predefined points.
219319246|NCT02798263|OTHER|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
219319247|NCT01846325|DIETARY_SUPPLEMENT|vitamin E|
219319248|NCT01846325|DIETARY_SUPPLEMENT|DHA|
219319249|NCT01846325|OTHER|placebo|
219319250|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
219319251|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
219319252|NCT01800422|DRUG|telapristone acetate|Given orally
219319253|NCT01800422|OTHER|placebo|Given orally
219319254|NCT01800422|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
219319255|NCT01800422|OTHER|laboratory biomarker analysis|Correlative studies
219319256|NCT01800422|OTHER|questionnaire administration|Ancillary studies
219319257|NCT04803136|PROCEDURE|spine surgeries|all spine surgeries including stabilization and fusion surgeries
219319258|NCT02618824|DRUG|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
219319259|NCT02618824|OTHER|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
219319260|NCT00086034|DRUG|Motexafin gadolinium|
219319261|NCT04438161|BEHAVIORAL|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
219319262|NCT01052688|OTHER|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
219319263|NCT02138721|PROCEDURE|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
219319264|NCT01172509|DRUG|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
219319265|NCT03600623|DRUG|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
219319266|NCT03600623|DRUG|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
219319267|NCT03056911|DRUG|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
219319268|NCT04221386|BEHAVIORAL|Melodic Intonation Therapy (MIT)|Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
219319269|NCT01143103|DEVICE|Cough assist (Philips,respironics)|
219319270|NCT01143103|OTHER|Usual respiratory therapy|
219319271|NCT00839943|OTHER|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
219319272|NCT00768391|BIOLOGICAL|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
219319273|NCT05295316|OTHER|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
219319274|NCT01395316|DRUG|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
219319275|NCT02750098|OTHER|Glucose measurement|"1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test"
219319276|NCT00569816|DRUG|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
219319277|NCT01868139|DEVICE|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
219319278|NCT02960373|OTHER|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
219319279|NCT02960373|OTHER|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
219319280|NCT02960373|OTHER|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
219319281|NCT02960373|OTHER|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
219319282|NCT03359590|DRUG|Sitagliptin 100 mg|The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
219319283|NCT03359590|DRUG|Placebo|The treatment consists of placebo tablets for up to 24 weeks.
219319284|NCT03425981|OTHER|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
219319285|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
219319286|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
219319287|NCT05399121|BEHAVIORAL|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
219319288|NCT05399121|BEHAVIORAL|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
219319289|NCT02400450|DIETARY_SUPPLEMENT|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
219319290|NCT02400450|DIETARY_SUPPLEMENT|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
219319291|NCT05627206|BEHAVIORAL|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
219319292|NCT04801134|OTHER|Education|as per previous description
219319293|NCT03139825|OTHER|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
219319294|NCT00522912|PROCEDURE|Trichiasis surgery|Posterior lamella tarsal rotation
219319295|NCT00522912|PROCEDURE|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
219319296|NCT06147570|DRUG|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
219319297|NCT02128451|DRUG|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
219319298|NCT02128451|DRUG|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
219319299|NCT04795934|PROCEDURE|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
219319300|NCT02846532|DRUG|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
219319301|NCT02846532|DRUG|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
219319302|NCT05440825|DEVICE|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
219319303|NCT05440825|OTHER|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
219319304|NCT05752123|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
219319305|NCT06238778|DRUG|HDV-Lispro|HDV-L will be used as the mealtime insulin
219319306|NCT06238778|DRUG|Lispro|Lispro will be used as the mealtime insulin
219319307|NCT05121974|DRUG|Tebipenem Pivoxil|Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.
219319308|NCT05121974|DRUG|Azithromycin|Oral Azithromycin antibiotic (Macrolides)
219319309|NCT05121974|DRUG|Ceftriaxon|IV Ceftriaxone (Cephalosporin)
219319310|NCT03951220|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
219319311|NCT03951220|OTHER|DXA scan|Used to assess bone density
219319312|NCT03951220|OTHER|Bloods and urine|Samples will be taken to assess bone biomarkers
219319313|NCT05620901|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
219319314|NCT05620901|DRUG|Pred Forte|To treat perioperative ocular inflammation and pain;
219319315|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
219319316|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
219319317|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
219319318|NCT04598477|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
219319319|NCT04598477|DRUG|prednisone|Oral prednisone tablets
219319320|NCT04468841|DIAGNOSTIC_TEST|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
219319321|NCT04468841|OTHER|sample of saliva or fingernail clipping|collected in clinic one time
219319322|NCT04468841|DIAGNOSTIC_TEST|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
219319323|NCT04468841|DIAGNOSTIC_TEST|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
219319324|NCT02520986|DEVICE|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
219319325|NCT02520986|DEVICE|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
219319326|NCT05512364|DRUG|Elacestrant|400mg QD orally on a continuous dosing schedule
219319327|NCT05512364|DRUG|Tamoxifen|20 mg QD orally on a continuous dosing schedule
219319328|NCT05512364|DRUG|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
219319329|NCT05512364|DRUG|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
219319330|NCT05512364|DRUG|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
219319331|NCT05900037|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
219319332|NCT05900037|DEVICE|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
219319333|NCT05595837|OTHER|Standard organ transplant|Standard organ transplant procedures and follow up care
219319334|NCT06084299|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
219319335|NCT03960840|BIOLOGICAL|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
219319336|NCT03960840|DRUG|Ibrutinib|Tablets or capsules for oral daily use
219319337|NCT06334393|BIOLOGICAL|VLA1601|0.45mL (milliliter), Day 1 and 29
219319338|NCT06334393|BIOLOGICAL|CpG 1018®|CpG 1018® will be investigated in combination with VLA1601 Low dose
219319339|NCT06334393|BIOLOGICAL|3M-052-AF|3M-052-AF will be investigated in combination with VLA1601 Low dose
219319340|NCT05999929|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
219319341|NCT04649229|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
219319342|NCT04649229|DRUG|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
219319343|NCT04649229|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
219319344|NCT04649229|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
219319345|NCT04649229|DRUG|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
219319346|NCT05745883|DRUG|DISC-0974|DISC-0974 is administered subcutaneously
219319347|NCT05745883|DRUG|Placebo|Placebo is administered subcutaneously
219319348|NCT06263582|DRUG|Artesunate pessary|Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
219319349|NCT06263582|DIAGNOSTIC_TEST|blood draws for pharmacokinetics of the study drug|On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
219319351|NCT03021460|DRUG|Ibrutinib|Given PO
219319352|NCT03021460|OTHER|Laboratory Biomarker Analysis|Correlative studies
219319353|NCT03021460|BIOLOGICAL|Pembrolizumab|Given IV
219319354|NCT03376152|BEHAVIORAL|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
219319355|NCT06219356|DRUG|GLB-002|Administered orally according to the assigned treatment schedule.
219319356|NCT06851039|DIETARY_SUPPLEMENT|Potato starch supplementation|Participants will receive potato starch supplement, undergoing gut microbial fermentation and acting as an endogenous source of the short-chain fatty acids, including butyrate. Effects of these compounds on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
219319357|NCT06851039|DIETARY_SUPPLEMENT|Sodium butyrate supplementation|Participants will receive sodium butyrate supplement, acting as an exogenous source of the short-chain fatty acid butyrate. Effects of such compound on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
219319358|NCT06851039|DIETARY_SUPPLEMENT|Accessible starch supplementation|Participants will receive the accessible (digestible) waxy maze starch as placebo.
219319359|NCT06206837|DRUG|vepdegestrant|Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
219319360|NCT06206837|DRUG|PF-07220060|Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
219319361|NCT05413850|DRUG|Lutetium (177Lu) rhPSMA-10.1 Injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
219319362|NCT05413850|DIAGNOSTIC_TEST|18F-rhPSMA-7.3 injection (in phase 1 only)|18F-rhPSMA-7.3 (in phase 1 only) at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
219319363|NCT06315829|DEVICE|Spasm Vision|Machine learning software developed to analyze videos and accurately distinguish infantile spasms from visually similar movements.
219319364|NCT01701596|PROCEDURE|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
219319365|NCT01701596|PROCEDURE|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
219319366|NCT04721132|BIOLOGICAL|Atezolizumab|Given IV
219319367|NCT04721132|BIOLOGICAL|Bevacizumab|Given IV
219319368|NCT04721132|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219319369|NCT04941222|OTHER|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
219319370|NCT03964233|DRUG|BI 907828|Film-coated tablets
219319371|NCT03964233|DRUG|ezabenlimab|Solution for infusion
219319372|NCT03964233|DRUG|BI 754111|Solution for infusion
219319373|NCT05533515|DIAGNOSTIC_TEST|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
219319374|NCT01052922|OTHER|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
219319375|NCT01052922|OTHER|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
219319376|NCT01052922|OTHER|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
219319377|NCT01644110|DRUG|INCB018424/CC-4047|"Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily."
219319378|NCT01202214|DRUG|1440115|
219319379|NCT01202214|DRUG|Placebo|matching placebo
219319380|NCT02020070|DRUG|Degarelix|
219319381|NCT02020070|DRUG|Ipilimumab|
219319382|NCT02020070|PROCEDURE|Radical Prostatectomy|
219319383|NCT03588507|COMBINATION_PRODUCT|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
219319384|NCT02475486|DEVICE|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
219319385|NCT02499770|DRUG|Carboplatin|
219319386|NCT02499770|DRUG|Placebo|
219319387|NCT02499770|DRUG|Trilaciclib|
219319388|NCT02499770|DRUG|Etoposide|
219319389|NCT05742737|OTHER|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
219319390|NCT06079684|DEVICE|Intermittent vacuum therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days."
219319391|NCT05530590|OTHER|Training to Serve (TTS) in person training|Participants receive in person training.
219319392|NCT05530590|OTHER|Training to Serve online training (eTTS)|Participants receive online training.
219319393|NCT04017325|OTHER|no intervention (post study follow up)|No intervention (post study follow up)
219319394|NCT05771909|OTHER|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
219319395|NCT05771909|OTHER|Control|"The Control Group does not receive the NeurodigitX application."
219319396|NCT03193788|DRUG|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
219319397|NCT03193788|DRUG|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
219319398|NCT03193788|DRUG|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
219319399|NCT03193788|DRUG|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
219319400|NCT02564926|DRUG|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
219319401|NCT02564926|DRUG|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
219319402|NCT05052554|DRUG|QR-504a|Intravitreal (IVT) injection
219319403|NCT02089841|DRUG|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
219319404|NCT03267693|DIAGNOSTIC_TEST|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
219319405|NCT03006354|DEVICE|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
219319406|NCT03006354|DEVICE|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
219319407|NCT05750537|BEHAVIORAL|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
219319408|NCT02628301|DIETARY_SUPPLEMENT|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
219319409|NCT02628301|OTHER|Normocaloric diet|Normocaloric diet
219319410|NCT00132223|DRUG|Contrast agent|
219319411|NCT01019980|DRUG|Diclofenac potassium|Diclofenac potassium
219319412|NCT01019980|DRUG|Acetaminophen|Acetaminophen
219319413|NCT05877378|DEVICE|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
219319414|NCT01351753|DRUG|Metformin|
219319415|NCT01351753|DRUG|Orlistat|
219319416|NCT01351753|DRUG|Topiramate|
219319417|NCT01351753|DRUG|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
219319418|NCT06119009|OTHER|non interventions|
219319419|NCT01554488|DRUG|Inhaled Fluticasone Propionate|Inhaled corticosteroid
219319420|NCT00770835|DRUG|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
219319421|NCT00770835|DRUG|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
219319422|NCT04293289|OTHER|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
219319423|NCT00012298|BIOLOGICAL|rituximab|Given IV
219319424|NCT00012298|BIOLOGICAL|yttrium Y 90 ibritumomab tiuxetan|Given IV
219319425|NCT00012298|BIOLOGICAL|indium In 111 ibritumomab tiuxetan|Given IV
219319426|NCT00012298|BIOLOGICAL|oprelvekin|Given subcutaneously
219319427|NCT00012298|BIOLOGICAL|filgrastim|Given subcutaneously
219319428|NCT02038920|DRUG|Vedolizumab|Vedolizumab IV injection
219319429|NCT02038920|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
219319430|NCT00047320|DRUG|carboplatin|Given IV
219319431|NCT00047320|DRUG|etoposide|Given IV
219319432|NCT00047320|DRUG|ifosfamide|Given IV
219319433|NCT00047320|DRUG|thiotepa|Given IV
219319434|NCT00047320|PROCEDURE|adjuvant therapy|
219319435|NCT00047320|PROCEDURE|conventional surgery|
219319436|NCT00047320|PROCEDURE|neoadjuvant therapy|
219319437|NCT00047320|PROCEDURE|peripheral blood stem cell transplantation|
219319438|NCT00047320|RADIATION|radiation therapy|craniospinal irradiation
219319439|NCT02383589|DRUG|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
219319440|NCT02383589|DRUG|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
219319441|NCT02383589|DRUG|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
219319442|NCT02383589|DRUG|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
219319443|NCT00866697|DRUG|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
219319444|NCT00866697|DRUG|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
219319445|NCT04165993|DRUG|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
219319446|NCT04165993|DRUG|KN026 monotherapy|30 mg/kg Q3W KN026
219319447|NCT04165993|DRUG|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
219319448|NCT00450905|DEVICE|PRIMA Device|
219319449|NCT00496795|OTHER|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
219319450|NCT02900534|OTHER|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
219319451|NCT00510523|DEVICE|Whole Body Vibration machine|
219319452|NCT02906787|BEHAVIORAL|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
219319453|NCT02906787|BEHAVIORAL|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
219319454|NCT03050151|DRUG|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
219319455|NCT03050151|DEVICE|Auto-injector Device|Delivery of Dupilumab by auto-injector device
219319456|NCT03050151|DEVICE|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
219319457|NCT03715088|BEHAVIORAL|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
219319458|NCT04396314|BEHAVIORAL|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
219319459|NCT04396314|BEHAVIORAL|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
219319460|NCT04597814|OTHER|No Intervention|No Intervention
219319461|NCT04376060|DEVICE|Gen-Os®; The soft lamina (OsteoBiol®)|"The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects."
219319462|NCT05555667|DRUG|Remimazolam besylate|Sedation drug
219319463|NCT05555667|DRUG|Propofol|Propofol. Sedation drug
219319464|NCT05740020|DEVICE|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
219319465|NCT05740020|OTHER|The traditional exercise program|"The selected physical therapy program:~1. Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~2. Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~3. Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~4. Strengthening exercise: aims to improve the functional ability (figure 7).~5. Spider suspension exercise for 30 minutes (figure 8).~5\. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
219319466|NCT02818920|DRUG|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
219319467|NCT04275297|BEHAVIORAL|Psychosocial Treatment|The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
219319468|NCT04275297|BEHAVIORAL|Attention Control|The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
219319469|NCT04760886|OTHER|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
219319470|NCT03435016|DIAGNOSTIC_TEST|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
219319471|NCT04586062|DRUG|Plasminogen|Human Plasminogen
219319472|NCT06378437|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
219319473|NCT02323763|OTHER|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
219319474|NCT02887027|BEHAVIORAL|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
219319475|NCT02673619|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
219319476|NCT02673619|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
219319477|NCT03002519|BIOLOGICAL|PLX-R18|Intramuscular (IM) administration of PLX-R18
219319478|NCT05145335|DEVICE|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
219319479|NCT05145335|DEVICE|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
219319480|NCT06804226|BEHAVIORAL|Video conversation aid|A video conversation aid which provides information regarding life-sustaining care and encourages further goals of care discussions with a healthcare provider will be shown to patients or their surrogates (for those incapacitated and unable to make their own decisions) on admission or within 48 hours whenever feasible
219319481|NCT06804226|BEHAVIORAL|Usual Care|Participants and/or surrogates will participate in discussions surrounding life-sustaining care at healthcare provider discretion.
219319482|NCT04849624|OTHER|No Intervention|This is an observational study and involved no intervention
219319483|NCT04284293|BIOLOGICAL|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
219319484|NCT06554418|BEHAVIORAL|Communities Care|Communities Care is a violence prevention program targeting social norms and behavioral change
219319485|NCT06510361|DRUG|Epcoritamab|Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
219319486|NCT04833322|DIETARY_SUPPLEMENT|D-Galactose|Galactose supplementation, once per day, up to 1.5g/kg per day
219319487|NCT07130175|DEVICE|Radiofrequency Catheter Ablation|An invasive procedure performed under local anesthesia. An electroanatomic mapping system (CARTO 3) was used to identify the arrhythmogenic substrate of the PMVT. Radiofrequency energy was delivered via an irrigated-tip catheter (30-35 W, 43°C, 17 mL/min saline irrigation) to ablate the target sites. The procedural endpoint was the non-inducibility of the clinical arrhythmia. Post-procedure, patients were prescribed amiodarone.
219319488|NCT07130175|DRUG|Guideline-Directed Medical Therapy (GDMT)|Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily). Doses were titrated according to patient tolerance and clinical guidelines.
219319489|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
219319490|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
219319491|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
219319492|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
219319493|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
219319494|NCT07128758|BEHAVIORAL|Music Group Implementation Before surgery, children were asked whether they enjoyed listening to music and what styles of music they liked.|"All procedures required for developing a music pool to be used for music listening intervention in children undergoing appendectomy were completed and are outlined as follows:~* Children were asked about their music preferences.~* Songs were selected from the Ministry of National Education's music books.~* Music with proven effectiveness was selected from music platforms.~* A music pool was created by the researcher based on these inputs.~* Expert opinions were obtained from 12 academicians and 10 healthy children regarding the music pool.~* Necessary revisions were made in line with expert feedback, and the final version of the music pool was determined.~* A pilot application was conducted (data from the pilot were not included in the main data set).~* Children were randomly assigned to the music and control groups using randomization (https://www.random.org).~* A neutral observer (not the researcher/a blinded observer) was trained to administer the scales after the music intervention"
219319495|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
219319496|NCT00805038|BEHAVIORAL|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
219319497|NCT00805038|BEHAVIORAL|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
219319498|NCT06611267|OTHER|Pain without cream on|Participants will be inflicted with pain without cream on.
219319499|NCT06611267|OTHER|Pain with cream on|Patients are inflicted with pain after getting a cream on, which has previously had pain-relieving effects
219319500|NCT05139069|BEHAVIORAL|Trauma-Informed Toolkit|Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.
219319501|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
219319502|NCT06287502|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB)|Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.
219319503|NCT06287502|BEHAVIORAL|Resistance, aerobic, flexibility and balance exercise training|The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
219319504|NCT07002086|PROCEDURE|Total knee replacement|"* Is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap.~* In the surgical procedure of these surgeries, cement is used to fix the prosthesis."
219319505|NCT07004023|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
219319506|NCT07004023|OTHER|Placebo|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
219319507|NCT06999187|DRUG|DR-0202|DR-0202 is a bispecific antibody
219319508|NCT00528255|DRUG|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
219319509|NCT06917885|BIOLOGICAL|CUE-102|A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.
219319510|NCT06586892|BEHAVIORAL|Radiotherapy followed by chemotherapy|"Researchers would like to test the accuracy of the MRI data being used for this study. If you agree, you will have 2 additional MRI scans within 2 weeks before Visit 1.~The first 90 participants who agree will be selected to have the following scans:~* 35 participants will be scanned 2 times on one MRI device (Device #1).~* 35 participants will be scanned 2 times on another MRI device (Device #2).~* 20 participants will be scanned 1 time on both MRI devices (Device #1 and #2). If you agree and you are chosen, the study doctor will tell you if you will have scans on~  1. or 2 MRI devices."
219319511|NCT07102212|BEHAVIORAL|mHealth Intervention|Participants are randomized to the FOCUS app or Information Control section of the app and will have six weeks to complete the app. Randomization, via the app, is stratified by geographic location (rural vs other), cancer type, and demographics so experimental arms are equivalent. Participants will complete 5 assessments online over a 12-mo period. The participants will have weekly telehealth professional support during the six-week intervention. Participants wear GeneActiv watches for sleep/activity recording for 7 days and provide blood and saliva samples at baseline, 6 and 12 weeks, and 6 and 12 months.
219319512|NCT07129265|OTHER|Working group|Participants will: 1) take a 10-min demographic survey; 2) join 3 x 60-min working group meetings in which they will review preliminary results, collaborate on curriculum design, and provide feedback; and 3) respond to prompts in 3 emails (approx 5-10 mins each).
219319513|NCT07129265|OTHER|Focus group|Participants will take a 10-min demographic survey and join 1 x 30-min focus group meeting in which they will provide feedback on the curriculum in development.
219319514|NCT07130773|DEVICE|Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT|"FARAWAVE Nav without pre-ablation CT (Intervention Group, n = 29)~Description of the investigation-specific intervention:~Participants in the intervention group will undergo pulmonary vein isolation (PVI) using the second-generation FARAWAVE Nav pulsed field ablation (PFA) catheter without the use of pre-ablation CT imaging. The FARAWAVE Nav catheter integrates magnetic navigation and electroanatomical mapping capabilities, allowing real-time visualization of left atrial anatomy and electrical signals. Energy delivery is based on non-thermal pulsed electric fields (irreversible electroporation), specifically targeting myocardial tissue while sparing surrounding structures."
219319515|NCT07130773|DEVICE|FARAPULSE with pre-ablation CT|"FARAPULSE with pre-ablation CT (Control Group, n = 29)~Description of the investigation-specific intervention:~Participants in the control group will undergo pulmonary vein isolation (PVI) using the first-generation FARAPULSE pulsed field ablation (PFA) catheter. All patients in this group will undergo pre-procedural cardiac CT imaging to evaluate pulmonary vein anatomy and assist in procedural planning. The FARAPULSE catheter delivers non-thermal pulsed electric fields for selective myocardial ablation, aiming to achieve electrical isolation of the pulmonary veins."
219319516|NCT07128979|DRUG|Neoven 225 mg capsules|Patients in this group will only use Neoven 225 mg capsules orally. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. A total of 378 mg of total ruscogenin (ruscogenin/neoruscogenin mixture obtained by extraction method) will be taken orally using one Neoven capsule orally with meals twice a day. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
219319517|NCT07128979|DRUG|Placebo|Patients in this group will only receive an oral placebo capsule designed for this study. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. During this period, one placebo capsule will be taken orally twice a day with meals. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
219319518|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
219355077|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
219319519|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
219319520|NCT07003321|DRUG|HRS-4508 tablet|HRS-4508 tablet
219319521|NCT07007533|DRUG|DA-5223-R|once a day
219319522|NCT07007533|DRUG|DA-5223|once a day
219319523|NCT07129863|DIETARY_SUPPLEMENT|Placebo: Mouth rinse with plain water|Placebo: Mouth rinse with plain water, containing no caffeine, serving as the control condition.
219319524|NCT07129863|DIETARY_SUPPLEMENT|Experimental: Low mouth rinse caffeine concentration (1%)|Arm Description: Low caffeine concentration: Mouth rinse containing 1% caffeine solution (based on weight/volume).
219319525|NCT07129863|DIETARY_SUPPLEMENT|Moderate caffeine concentration (2% caffeine solution weight/volume).|Moderate caffeine concentration: Mouth rinse containing 2% caffeine solution (weight/volume).
219319526|NCT07129863|DIETARY_SUPPLEMENT|High caffeine concentration (3% caffeine solution weight/volume).|High caffeine concentration: Mouth rinse containing 3% caffeine solution (weight/volume).
219319527|NCT07130305|OTHER|whole body vibration plus usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this vibration group who will receive vitamin D and their traditional colchicine doses daily for six months. vibration group will also receive three sessions of 20-min whole body vibration in the week for 6 months
219319528|NCT07130305|OTHER|usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this control group who will receive vitamin D and their traditional colchicine doses daily for six months.
219319529|NCT07130851|PROCEDURE|vestibular schwannoma resection|Vestibular schwannoma resection leads to partial or combined acute unilateral peripheral or combined vestibular lesion.The organism responds with the process of central vestibular compensation.
219319530|NCT07130578|DIAGNOSTIC_TEST|urine tumor DNA/RNA testing|The test analyzes DNA and RNA fragments shed by urothelial carcinoma cells into urine, detecting tumor-specific genetic and epigenetic alterations.
219319531|NCT05462951|RADIATION|Standard|Radiation then brachytherapy
219319532|NCT06870383|DRUG|Erector spinae plane block|The block will be done under ultrasound guidance using 20 ml bupivacaine 0.25% that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose.
219319533|NCT06870383|DRUG|Combined Pecto-intercostal and recto-intercostal fascial plane block|The blocks will be done under ultrasound guidance using 10-15 ml of 0.25% bupivacaine that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose..
219319534|NCT06868433|BIOLOGICAL|Autologous Tumor Membrane Vesicles Vaccine|Given intradermally
219319535|NCT06868433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319536|NCT06868433|PROCEDURE|Computed Tomography|Undergo CT
219319537|NCT06868433|PROCEDURE|Echocardiography|Undergo echocardiography
219319538|NCT06868433|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219319539|NCT06868433|BIOLOGICAL|Pembrolizumab|Given IV
219319540|NCT06868433|PROCEDURE|Positron Emission Tomography|Undergo PET
219319541|NCT06868433|PROCEDURE|Surgical Procedure|Provide tissue from standard of care surgery
219319542|NCT07010601|BEHAVIORAL|Experimental Tobacco Marketplace|This study will have three different scenarios in the Experimental Tobacco Marketplace (ETM) for participants who reported being cigarette and/or e-cigarette users. These will consist of hypothetical purchase scenarios where a variety of different tobacco products are available to purchase. The three ETM scenarios will be adjusting price cigarettes, adjusting price e-cigarettes, and both adjusting price cigarettes and e-cigarettes.
219319543|NCT07010601|BEHAVIORAL|Hypothetical Novel Nicotine Product Purchase Tasks|This study will have a set of hypothetical demand tasks for novel nicotine products. These tasks consist of different novel hypothetical products (combusted, oral, and vaporized) of differing nicotine content (high and low), and different flavors (preferred alcoholic flavor, no characterizing flavor) where likelihood to try is assessed at a variety of price points.
219319544|NCT06674109|DRUG|Empagliflozin 10 mg|For the empagliflozin arm, participants will take 10 mg daily.
219319545|NCT06674109|DRUG|Placebo|Participants in the placebo arm will take a placebo daily.
219319546|NCT04469621|DRUG|SAR443122|Pharmaceutical form:capsule Route of administration: oral
219319547|NCT04469621|DRUG|Placebo|Pharmaceutical form:capsule Route of administration: oral
219319548|NCT05731492|DRUG|Macitentan|Macitentan will be administered orally.
219319549|NCT06624462|OTHER|Treatment in the Meta Care Clinic|"* Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention."
219319550|NCT06624462|OTHER|Standard care with general practitioner and/or outpatient clinics|"Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes."
219319551|NCT06625151|BEHAVIORAL|Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI)|The PCPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and coping processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in perceived criticism, self-blame, perceived control, avoidant coping, and event stress are connected to increases negative affect; (b) how changes in perceived social support, positive reinterpretation, perceived control, avoidant coping, and problem-focused coping are linked to increases in positive affect; (c) how self-critical perfectionism and maladaptive stress and coping tendencies explain enduring mood problems; (d) how healthy striving, adaptive appraisal, and coping tendencies can identify personal strengths; and, most important, (e) what the person needs to do to manage and improve his or her mood.
219319552|NCT06625151|BEHAVIORAL|Perfectionism and Emotion Regulation Processes Model - Explanatory Feedback Intervention (PERPM-EFI)|The PERPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and emotion regulation processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in event stress, mindfulness, self-compassion, experiential avoidance, and rumination are connected to increases in negative affect, (b) how changes in event stress, mindfulness, reappraisal, self-compassion, and experiential avoidance are linked to increases in positive affect, (c) how self-critical perfectionism and maladaptive stress and emotion regulation tendencies explain enduring mood problems, (d) how healthy striving, adaptive appraisal, and emotion regulation tendencies can identify personal strengths, and, most important, (e) what the person needs to do to manage and improve his or her mood.
219319553|NCT06173661|DRUG|Fremanezumab|The intervention will be active medication.
219319554|NCT06173661|OTHER|Placebo|The intervention will be placebo injection.
219319555|NCT06685185|DRUG|NNC0363-1063|NNC0363-1063 will be administered subcutaneously.
219319556|NCT06685185|DRUG|Placebo|Placebo will be administered subcutaneously.
219319557|NCT06685185|DRUG|Insulin degludec|Insulin degludec will be administered subcutaneously.
219319558|NCT06685185|DRUG|Insulin detemir|Insulin detemir will be administered subcutaneously.
219319559|NCT06628310|DRUG|ABBV-400|Intravenous (IV) Infusion
219319560|NCT06628310|DRUG|Budigalimab|IV Infusion
219319561|NCT06628310|DRUG|Fluorouracil|IV Infusion; IV Injection
219319562|NCT06628310|DRUG|Leucovorin|IV Infusion; IV Injection
219319563|NCT06628310|DRUG|Oxaliplatin|IV Infusion
219319564|NCT07012031|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219319565|NCT07012031|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319566|NCT07012031|PROCEDURE|Computed Tomography|Undergo CT
219319567|NCT07012031|PROCEDURE|Echocardiography Test|Undergo ECHO
219319568|NCT07012031|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219319569|NCT07012031|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219319570|NCT07012031|DRUG|Sotorasib|Given PO
219319571|NCT07012031|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
219319572|NCT07020026|DRUG|[18F]PI-2620|All participants will undergo PET imaging using the \[18F\]PI-2620 tau-binding tracer.
219319573|NCT07019558|OTHER|Neurological assessment|Collect retrospective and current clinical data and assess motor impairment
219319574|NCT07019558|DIAGNOSTIC_TEST|Ophthalmological assessment|Ophthalmological assessment of possible optic nerve or retinal damage.
219319575|NCT07019961|DEVICE|the GMA-TULIP laryngeal mask|insert GMA-TULIP laryngeal masks after anesthesia induction
219319576|NCT07019961|DEVICE|the i-gel laryngeal mask|insert i-gel laryngeal masks after anesthesia induction
219319577|NCT07021105|PROCEDURE|ESP Plane block|Group E (n=20): Bilateral erector spinae plane (ESP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) at the T12 level, approximately 3-4 cm laterally from the midline, in the neurofascial plane between the transverse processes and the erector spinae muscle.
219319578|NCT07021105|PROCEDURE|QLB plane block|Group Q (n=20): Bilateral quadratus lumborum block (QLB) will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side), placed between the psoas major and quadratus lumborum muscles under US guidance, between the iliac crest and the 12th rib.
219319579|NCT07021105|PROCEDURE|TAP Block|Group T (n=20): Bilateral transversus abdominis plane (TAP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) in the neurofascial plane between the internal oblique and transversus abdominis muscles.
219319580|NCT07021105|OTHER|No intervention|Group C (Control group, n=20): No block will be applied, only the standard intravenous patient-controlled analgesia (PCA) protocol will be used.
219319581|NCT07018401|DRUG|Pomalidomide|Oral pomalidomide up to 4 mg daily
219319582|NCT07020065|DRUG|Cemiplimab|cemiplimab IV 350 mg, day 1
219319583|NCT07020065|DRUG|Carboplatin|carboplatin IV AUC 3 day 1
219319584|NCT07020065|DRUG|Pemetrexed & Gemcitabine|pemetrexed IV 300 mg/m2 day 1 gemcitabine IV 600 mg/m2 day 1, d8
219319585|NCT07020065|DRUG|Paclitaxel|paclitaxel IV 50 mg/m2 day 1, d8
219319586|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 5 g dehydrated nopal powder from highly mature cladodes|Group I received 5 g of dehydrated Opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia.
219319587|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 15 g dehydrated nopal powder from highly mature cladodes|Group II received 15 g plus the diet, and Group III followed only the diet.
219319588|NCT07018908|OTHER|Control Group (only diet)|No dehydrated nopal or placebo. Diet: 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
219319589|NCT07019987|OTHER|PEEP Titration Using Electrical Impedance Tomography (EIT)|"EIT will be used to guide individualized PEEP titration in mechanically ventilated patients with AHRF. Each subject will receive mechanical ventilation at two PEEP levels:~PEEP\_CLIN (set by the treating clinician)~PEEP\_TIT (identified using EIT to minimize alveolar collapse and overdistension)~Both levels will be maintained for 30 minutes in each body position, with continuous physiologic data collected during each phase."
219319590|NCT07019987|PROCEDURE|Body Positioning: Supine and Prone|Each subject will be ventilated in both the supine and prone positions. Positioning will follow institutional protocols and be coordinated with clinical staff to ensure safety. After supine assessments are completed, the patient will be transitioned to prone, followed by a recruitment maneuver to standardize lung volume history. The PEEP titration protocol will then be repeated in the prone position.
219319591|NCT06629779|DRUG|PF-06821497|Oral continuous
219319592|NCT06629779|DRUG|Placebo|Oral continuous
219319593|NCT06629779|DRUG|Enzalutamide|Oral continuous
219319594|NCT06690424|DRUG|Remimazolam|remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
219319595|NCT06690424|DRUG|Propofol|Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
219319596|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
219319597|NCT06112379|DRUG|Dato-DXd|Experimental drug IV infusion
219319598|NCT06112379|DRUG|Durvalumab|Experimental drug IV Infusion
219319599|NCT06112379|DRUG|Pembrolizumab|IV Infusion Active comparator
219319600|NCT06112379|DRUG|Doxorubicin|IV infusion Experimental/Active Comparator
219319601|NCT06112379|DRUG|Epirubicin|IV Infusion Experimental/Active Comparator
219319602|NCT06112379|DRUG|Cyclophosphamide|IV infusion Experimental/Active Comparator
219319603|NCT06112379|DRUG|Paclitaxel|IV infusion Experimental/Active Comparator
219319604|NCT06112379|DRUG|Carboplatin|IV infusion Experimental/Active Comparator
219319605|NCT06112379|DRUG|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
219319606|NCT06112379|DRUG|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
219319607|NCT03425279|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
219319608|NCT03425279|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
219319609|NCT07029581|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
219319610|NCT07029581|DRUG|Placebo|Provided as 1 capsule, to be taken orally once daily
219319611|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
219319612|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
219319613|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
219319614|NCT04915768|BIOLOGICAL|CH505 TF chTrimer|Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
219319615|NCT04915768|BIOLOGICAL|3M-05-AF|Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
219319616|NCT04915768|BIOLOGICAL|Aluminum hydroxide suspension|Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle
219319617|NCT07132645|PROCEDURE|Computed Tomography|Undergo CT scan
219319618|NCT07132645|DRUG|Gallium Ga 68-DOTA-FAPI-04|Given IV
219319619|NCT07132645|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219319620|NCT07131787|DEVICE|Blood flow restriction training (smart-cuff pro device)|This group will undergo low load strength training consisting of calf, thigh, glute and core exercises. A Blood flow restriction cuff will be added during selected exercises in rehabilitation program (targeting quadriceps and calf muscles)
219319621|NCT07131787|OTHER|Standardised strength training|This group will undergo standard, traditional strength training consisting of calf, thigh, glute and core exercises.
219355078|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
219319622|NCT07031531|COMBINATION_PRODUCT|AI-Enabled Stratified Management System|After discharge, participants install SMART-CHD, sync their EHR data, and complete a 10-minute orientation. They then use the app's OCR-assisted surveys to report lifestyle, lab, and event data, while paired wearables stream continuous vitals. AI voice calls and a CRC-managed WeChat group deliver reminders and support. The app's embedded predictive models stratify them into risk tiers and generate tier-specific follow-up schedules. Personalized lifestyle modification guidance, dietary plans, and medication adjustment recommendations are generated by the platform's module. Automated alerts and teleconsultation options are triggered upon detection of high-risk signs or abnormal results, ensuring timely clinical intervention and enhanced secondary prevention.
219319623|NCT07031531|COMBINATION_PRODUCT|Usual Post-Discharge Care|Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.
219319624|NCT07037004|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219319625|NCT07037004|DRUG|Clostridium butyricum CBM588 Strain|Given PO
219319626|NCT07037004|PROCEDURE|Computed Tomography|Undergo CT
219319627|NCT07037004|BIOLOGICAL|Pembrolizumab|Given IV
219319628|NCT05884242|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
219319629|NCT05884242|DRUG|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
219319630|NCT06884332|RADIATION|Sparing irradiation|"For Sparing irradiation arm the Clinical Target Volume (CTV) = Growth Tumor Volume (GTV) + entire vertebra opposite."
219319631|NCT06884332|RADIATION|Conventional spinal irradiation|"For conventional spinal irradiation arm, Clinical Target Volume (CTV ) = Growth Tumor Volume (GTV) + entire vertebra opposite + 1 vertebra above and below."
219319632|NCT07037966|DEVICE|MRI|Standard 3T MRI Scan
219319633|NCT07037966|DEVICE|MRI|Low-field MRI scan using the NextMRI prototype
219319634|NCT06883500|BEHAVIORAL|Energy diary|A prospective observational study is conducted at two German rehabilitation centers in a co-design approach with repeated feedback loops (expert consensus, patient interviews). Daily energy-changes will be analyzed and validated using the Multidimensional Fatigue Inventory-20 (MFI-20).
219319635|NCT06725420|OTHER|Ultrasound-guided local Injection|Ultrasound-Guided steroid injection and splinting in patients with carpal tunnel syndrome
219319636|NCT06725420|OTHER|Intramuscular Steroid Injection|Intramuscular gluteal steroid injection and Splinting in Patients With Carpal Tunnel Syndrome
219319637|NCT06725420|DEVICE|Splinting|wrist night splint
219319638|NCT07042295|DRUG|Amivantamab and Recombinant Human Hyaluronidase|Given SC
219319639|NCT07042295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319640|NCT07042295|BIOLOGICAL|Cetuximab|Given IV
219319641|NCT07042295|PROCEDURE|Computed Tomography|Undergo CT scan
219319642|NCT07042295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219319643|NCT07045766|DIETARY_SUPPLEMENT|FibreGum chewing gum|Chewing gum containing galactooligosaccharides (GOS), delivering a total daily dose of 3 g of dietary fiber.
219319644|NCT06716502|DEVICE|Portable CPAP efficacy|The device will be tested in providing a PEEP comprised between 4-7,5 cmH2O
219319645|NCT06716502|DEVICE|Portable CPAP usability assessment|The device usability will be evaluated in individual's self-experience tests, i.e., in conditions where the volunteer will self-apply the device.
219319646|NCT07045935|DRUG|Cabergoline (Dopamine Agonist)|Cabergoline is available in tablet form, with doses of 0.5 mg per tablet. The standard dosing for hyperprolactinemia typically starts at 0.25 mg to 0.5 mg per week, which can be gradually increased based on the patient's response, with a usual range of 0.25 mg to 2 mg per week. The dose required to achieve the target prolactin levels (pre- defined for each intervention arm) may vary between patients, so a fixed dose is not specified. This allows for individualized treatment based on each patient's response.
219319647|NCT07044596|DEVICE|Functional near-infrared spectroscopy (fNIRS)|fNIRS is a non-invasive imaging technique which takes advantage of the light scattering and absorption differences between oxygenated (HbO) and de-oxygenated hemoglobin (HbDO) to characterize changes in cerebral hemodynamics in response to a given task or stimulus.
219319648|NCT07044596|DEVICE|V1 stimulation electrodes|The V1 electrodes will be placed on the forehead with some gel and held in place with a headband or cap (a conductive adhesive gel may be placed under the electrodes to help with stimulation). Participants will receive short electrical stimulations through these electrodes that will differ in intensity.
219319649|NCT07044596|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo 2 90-minute MRI sessions
219319650|NCT06732323|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
219319651|NCT06732323|DRUG|Investigator's Choice Chemotherapy|Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
219319652|NCT07049926|DRUG|Belzutifan|Oral Tablet
219319653|NCT07049926|DRUG|Zanzalintinib|Oral Tablet
219319654|NCT04012879|COMBINATION_PRODUCT|CD19 CART|CD19 CART
219319655|NCT07052474|BEHAVIORAL|Intensive trauma-focused treatment|"The treatment program includes components of Trauma focused cognitive behavioral therapy (TF-CBT), Eye Movement Desensitization and Reprocessing Therapy (EMDR), physical activity, as well as parent sessions. The intensive treatment largely follows the Dutch intensive trauma treatment program Korte Intensieve Traumabehandeling (KIT) (Albisser et al., 2024).~The intensive treatment incorporates core components from TF-CBT for children and adolescents (Cohen \& Mannarino, 2008) as well as the standard EMDR protocol (Shapiro, 2018)."
219319656|NCT06807086|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia|The Survivorship Sleep Program is a virtual program based on cognitive behavioral therapy for insomnia (CBT-I), which teaches evidence based skills to improve sleep-related behaviors, expectations, and environment, to promote relaxation, and to reduce worry. It also involves reducing the time spent in bed in order to improve the quantity and quality of sleep over time. The Survivorship Sleep Program is delivered in 4 weekly sessions by a trained facilitator and includes considerations specific to managing insomnia after cancer diagnosis and treatment. Additionally, 1 booster session is offered at week 6.
219319657|NCT06807086|BEHAVIORAL|Enhanced Usual Care|A sleep hygiene handout and a referral for CBT-I offered through MGH or community partners.
219319660|NCT06764485|DRUG|BMS-986365|Specified dose on specified days
219319661|NCT06764485|DRUG|Enzalutamide|Specified dose on specified days
219319662|NCT06764485|DRUG|Abiraterone|Specified dose on specified days
219319663|NCT06764485|DRUG|Docetaxel|Specified dose on specified days
219319664|NCT06764485|DRUG|Predinsone/Prednisolone|Specified dose on specified days
219319665|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 1|For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
219319666|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 2|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
219319667|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 3|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
219319668|NCT06550791|BEHAVIORAL|Anticancer Learning Circle|All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
219319671|NCT07067034|BEHAVIORAL|Ridikullus Nursing İntervention|A one-session, nurse-led psychosocial intervention designed to reduce anxiety in university students. Participants identified personal metaphors related to their anxiety and were guided to reconstruct them into less distressing, humorous, or calming mental images. The intervention was delivered in a structured format by an academic nurse trained in therapeutic communication
219319672|NCT07063745|DRUG|BMS-986504|Specified dose on specified days
219319673|NCT07063745|DRUG|Pembrolizumab|Specified dose on specified days
219319674|NCT07063745|OTHER|Placebo|Specified dose on specified days
219319675|NCT07063745|DRUG|Cisplatin|Specified dose on specified days
219319676|NCT07063745|DRUG|Carboplatin|Specified dose on specified days
219319677|NCT07063745|DRUG|Pemetrexed|Specified dose on specified days
219319678|NCT07063745|DRUG|Paclitaxel|Specified dose on specified days
219319679|NCT07063745|DRUG|Nab-paclitaxel|Specified dose on specified days
219319680|NCT06770439|DRUG|IBI343|IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate
219319681|NCT06770439|DRUG|Gemcitabine+Albumin-bound paclitaxel|Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
219319682|NCT06780449|DRUG|Cagrilintide|Participants will receive cagrilintide subcutaneously.
219319683|NCT06780449|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
219319684|NCT06780449|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
219319685|NCT06780449|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
219319686|NCT07069699|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219319687|NCT07069699|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
219319688|NCT07069699|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219319689|NCT07069699|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219319690|NCT07069699|DRUG|Pidnarulex|Given IV
219319691|NCT07069699|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219319692|NCT07070232|DRUG|BNT326|Intravenous (IV) infusion
219319693|NCT07070232|DRUG|BNT327|IV infusion
219319694|NCT07070232|DRUG|Itraconazole|Oral administration
219319695|NCT07070232|DRUG|Paroxetine|Oral administration
219319696|NCT06388083|DRUG|Tinlarebant|5 mg tablet
219319697|NCT06388083|DRUG|Placebo|Placebo tablets
219319698|NCT06759558|DRUG|Zuranolone|Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
219319699|NCT06765434|OTHER|Music ( Dmitri Shostakovich's Jazz Waltz Suite)|Music
219319700|NCT06765434|OTHER|Music( Personalized music)|Music
219319701|NCT07072468|DRUG|VMD-3866 Gel|"Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose).~Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home."
219355079|NCT01164722|OTHER|clinical observation|Patients undergo observation
219355080|NCT01164722|DEVICE|infrared photocoagulation therapy|Anal infrared coagulator ablation
219319702|NCT07072468|DRUG|Placebo Gel|Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose). Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home.
219319703|NCT07130955|DEVICE|Six-channel RF Renal Denervation System|DSA-guided percutaneous renal sympathetic denervation using a six-channel RF renal denervation system-comprising the six-channel radiofrequency generator (specification model: 25D1G, software release version: SRG-V1) and the ultra-guiding radiofrequency denervation catheter (specification model: 25C6W127F115T)
219319704|NCT07130955|PROCEDURE|Parallel controln with sham operation(there is no rade and/or generic name,It is a blank control sham operation)|Sham procedure including femoral artery puncture and selective renal angiography; the six-channel radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
219319705|NCT07130539|OTHER|MIND HIIT|4 week intervention consisting of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in combination with 3 days per week of High-Intensity Interval Training (HIIT) exercise
219319706|NCT03354741|OTHER|laser therapy|stimulation of the acupuncture point P6 by laser therapy
219319707|NCT03773965|DRUG|Baricitinib|Administered orally.
219319708|NCT06832722|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
219319709|NCT06832722|DRUG|Placebo|Application of placebo
219319710|NCT05843864|DEVICE|Photobiomodulation Therapy with Standard Physical Therapy|Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.
219319711|NCT05843864|OTHER|Sham Photobiomodulation Therapy with Standard Physical Therapy|Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
219319712|NCT06659341|DRUG|BAY3498264|Oral
219319713|NCT06468228|DRUG|Lutikizumab|Subcutaneous injection
219319714|NCT06468228|DRUG|Placebo|Subcutaneous injection
219319715|NCT05866419|DEVICE|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
219319716|NCT07078448|OTHER|Foam Roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
219319717|NCT06665399|OTHER|Observation|"In this study, the definition of observation is that participants cannot receive the following treatments currently considered to have a clear efficacy for NL-GLM/PDM, including surgical treatments (minimally invasive excision or open excision, incision and drainage), ultrasound-guided aspiration, oral corticosteroid therapy, antibiotic treatment, anti-tuberculosis therapy, or ductal lavage therapy. As symptomatic management for pain, the use of NSAIDs is permitted. Additionally, for patients with fistulas or skin lesions, routine wound care is also allowed. These two interventions are not considered as receiving treatment intervention in this study."
219319718|NCT06453720|PROCEDURE|Colonoscopy|A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
219319719|NCT03843463|DRUG|Escitalopram 10mg|Escitalopram tablet
219319720|NCT03843463|DRUG|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
219319721|NCT03843463|BEHAVIORAL|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
219319722|NCT04532645|DRUG|Olaparib|Olaparib
219319723|NCT06575192|DEVICE|ARTIA Reconstructive Tissue Matrix|Surgical Implant
219319724|NCT06575192|OTHER|No Intervention|No ADM
219319731|NCT04617834|OTHER|Quality Surveillance Data Collection|Data will be retrospectively collected through EHR queries
219319732|NCT07093307|BEHAVIORAL|Docudrama|Participants at docudrama sites will watch a 30-minute docudrama (two episodes of 15 minutes each) immediately after blood donation while waiting to recover and to be refreshed.
219319733|NCT07093307|BEHAVIORAL|Control|"Participants randomized at control sites will receive the standard NBSG communications for blood donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to when they are due for their next blood donation."
219319734|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1
219319735|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 2
219319736|NCT06908252|DRUG|Pre-Exposure Prophylaxis (PrEP)|Oral Pre-Exposure Prophylaxis (PrEP) pills
219319737|NCT07096362|DRUG|5-Fluorouracil|Participants will be administered 2400 mg/m\^2 of 5-Fluorouracil via continuous intravenous infusion over a 46-hour period beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
219319738|NCT07096362|DRUG|Oxaliplatin|Participants will be administered 85 mg/m\^2 of Oxaliplatin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
219319739|NCT07096362|DRUG|Leucovorin|Participants will be administered 400 mg/m\^2 of Leucovorin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
219319740|NCT07096362|DRUG|Irinotecan|Participants will be administered 150 mg/m\^2 of Irinotecan via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
219319741|NCT07096362|DRUG|Gemcitabine|Participants will be administered 1000 mg/m\^2 of Gemcitabine standard of care (SOC) via intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
219319742|NCT07096362|DRUG|Nab Paclitaxel|Participants will be administered 125 mg/m\^2 of Nab Paclitaxel standard of care (SOC) by intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
219319743|NCT07096362|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* Every weeks 2 beginning at weeks 2, 4, 6 and 8 of standard of care therapy.~* Every 4 weeks beginning at week 10 of standard of care therapy until disease progression.~ctDNA will be measured to obtain participant tumor methylation scores (TMS)."
219319744|NCT07098286|OTHER|high intensity home-based rehabilitation|Whereas standard home healthcare would include 1-3 visits per week of therapy services after a stroke, the HIHR intervention will include at least therapy visits per week. Between occupational, physical, and speech therapy, the frequency for each will match individual patient needs based on the type and severity of their stroke-related deficits.
219319745|NCT06910657|BIOLOGICAL|IDOV-Immune (oncolytic vaccinia virus)|IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
219319746|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
219319747|NCT07091500|BEHAVIORAL|Exercise training|Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.
219319748|NCT07091500|DRUG|Semaglutide|semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling
219319749|NCT07098182|PROCEDURE|Clamping and restauration of arterial blood of the inferior mesenteric artery|"* Injection of Indocynianine green (INFRACYANINE 25mg diluted in 10 mL solvent, IV injection of 3ml at a concentration of 2.5 mg/mL or 7.5 mg), (excluding NaCl), purge 10ml NaCl,~* Camera model (STORZ)~* Camera/target distance: 5cm~* Camera recording time (since Indocynianine green injection): 2 to 5 min with temporal identification of the injection time.~Extracorporeal evaluation (by mini laparatomy extraction in colorectal surgery minimally invasive, by laparotomy in case of ovarian cancer with lights of the room switched off (laparotomy)"
219319750|NCT06880835|DEVICE|Control IQ + sleep activity with TI|TI for meal bolus with Control IQ + sleep activity pump setting
219319751|NCT04776434|DEVICE|SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)|This study will capture data from the use of the SELUTION SLR according to its approved labelling.
219319752|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
219319753|NCT07105111|DRUG|Valbenazine|Valbenazine capsules for oral administration.
219319754|NCT06912867|BEHAVIORAL|Blood Flow Restriction (BFR) Exercise Program|Participants performed supervised low-load resistance training with BFR using KAATSU C3 equipment twice a week for 8 weeks.
219319755|NCT05952167|OTHER|Intensive cervical traction protocol|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
219319756|NCT05952167|OTHER|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
219319757|NCT06488716|DRUG|RO7759065|Specified dose on specified days
219319758|NCT06488716|DRUG|Atezolizumab|Specified dose on specified days
219319759|NCT04880265|DEVICE|Vivalink wearable life sensors|Collection of EKG data
219319760|NCT06915480|BEHAVIORAL|Reminder message and patient navigation|This study will evaluate the combination of pre-appointment messages and patient navigation services.
219319761|NCT07111130|OTHER|12-week Lifestyle Intervention|Eligible participants within the existing ELEGANCE cohort will undergo a structured 12-week lifestyle intervention comprising a low-carbohydrate, high-fibre dietary plan and a prescribed physical activity program targeting at least 150 minutes of moderate-intensity exercise per week. Standardized meal provision and wearable fitness tracking devices will be used to support adherence throughout the intervention period.
219319762|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
219319763|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
219319764|NCT07105605|BEHAVIORAL|Intervention Group|pediatric nursing student
219319765|NCT05845047|BEHAVIORAL|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~1. Single words depicted in the picture, then with written and spoken labels~2. 2-word phrases depicted in the picture and then with written and spoken word~3. Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~4. Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~5. Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
219319766|NCT05845047|BEHAVIORAL|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun, phrase, or sentence. The spoken word, phrase, or sentence either will or will not fit the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
219319767|NCT07113912|DEVICE|counterforce forearm brace|a flexible band that fits around the proximal forearm, applying pressure to underlying tissues during activity to potentially reduce acceleration forces and alleviate pain associated with conditions like lateral epicondylitis.
219319768|NCT07113912|PROCEDURE|thoracic immobilization|the methods and devices used to restrict movement of the thoracic spine, which is the upper and middle part of the back.
219319769|NCT06921200|PROCEDURE|Cryotherapy|Cryotherapy is one of the non-pharmacological pain-relieving techniques, which involves chilling specific body areas with ice packs, ice cubes, ice water, or ethyl chloride sprays. The present study intervention will be conducted on 50 post-partum women to assist in relieve episiotomy pain. The researchers will assess the baseline level of episiotomy pain for each woman then the researchers will instruct women to perform perineal care. After cleaning the perineum, the researchers will ask the women to maintain her knee more flexed and apply ice gel pad against the episiotomy line for about 20 minutes then remove it and keep it in the freezer for reusing and assess the level of episiotomy pain using the Numeric Rating Scale for Pain after two hours from delivery. Ice gel pad will be applied for the second time after the episiotomy.
219319770|NCT05640843|OTHER|Whole Foods Plant-based Diet|The meals will have a low glycemic index and contain legumes, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to education materials. Patients will also receive dietary education and counselling from a research dietitian every 4 weeks for the 12-week intervention period. They will have access to the team for questions and support as needed
219319771|NCT05640843|DIETARY_SUPPLEMENT|Algae Omega 3 + Curcumin|For 52 weeks on the supplement arm, patients will be given algae omega 3 supplements and curcumin supplements (Sabinsa pharmaceuticals) twice daily
219319772|NCT05640843|OTHER|Placebo supplements|For 25 weeks on the placebo arm, patients will be given placebo supplements twice daily (Veggie Doctor/M and M pharmaceuticals and Sabinsa pharmaceuticals).
219319773|NCT07123350|DRUG|Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care|This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.
219319774|NCT07127185|DIAGNOSTIC_TEST|LS/MS|Quantitative determination of ceftobiprole concentrations in plasma and urine was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
219319775|NCT07126990|BIOLOGICAL|Novel oncolytic virus Ad-TD-nsIL12|Ommaya capsule was placed for intratumoral injection at a dose of 1×10\^10vp
219319776|NCT07133139|DEVICE|Dry Needling|"The examiner will use the repeated tapping technique of Travel and Simmons in the active condition in the painful tender points and TPs. In the sham treatment, the needle tip retracts when pushed against the skin (like a ballpoint pen), and the subject feels a pointy object on their skin, which does not penetrate. Prior studies have shown that this is a credible placebo condition. Prior studies have also shown that one dry needling session is effective at least temporarily for 1-2 weeks, AND that US correlates of TPs improve as well"
219319777|NCT07133139|DEVICE|Sham Dry Needling|Half of the subjects will receive a sham needle instead which puts pressure on the skin but does not penetrate the skin (like a ballpoint pen with the tip retracted pushing on the skin). Since manual pressure over myofascial tender and trigger points is also an accepted treatment, the sham procedure could also be therapeutic, although we do not think it will be very effective.
219319778|NCT07133139|OTHER|NUN Biomarker|"A NUN biomarker measurement means checking the level of a certain substance (the NUN biomarker) in your body that can give investigators clues about your condition.~Measuring the NUN biomarker helps investigators see if a treatment is working or if your condition is changing."
219319779|NCT03827460|BEHAVIORAL|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
219319780|NCT03827460|BEHAVIORAL|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
219319781|NCT03827460|DRUG|Intravenous Alcohol|During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
219319782|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
219319783|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
219319784|NCT05670379|COMBINATION_PRODUCT|Exenatide Implant|Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
219319785|NCT05670379|DRUG|Bydureon BCise (exenatide extended release)|glucagon-like peptide-1 (GLP-1) receptor agonist
219319786|NCT05670379|DRUG|Semaglutide, 1.0 mg/mL|glucagon-like peptide-1 (GLP-1) receptor agonist
219319787|NCT04522765|DIAGNOSTIC_TEST|Assessment of 24 hour blood pressure and arterial stiffness|Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device
219319793|NCT07145957|OTHER|Prehabilitation|subjects randomized to the IRTx cohort will also be instructed by a Physical or Occupational Therapist to perform the exercises described in the RSA IR Prehab Exercise Protocol handout, 5-7 times per week for 6 weeks.
219319794|NCT06947031|DEVICE|AHCL|The downloaded data will be analyzed prior to the surgical procedure. In accordance with standard clinical practice, a TBR time-under-range % (\<54 mg/dL) or TBR time-under-range % (\<70 mg/dL) greater than 4% will be identified, and the target glucose will be increased by 10 mg/dL relative to the previously established value. This is intended to reduce the risk of perioperative hypoglycemia.
219319795|NCT04024748|DEVICE|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
219319796|NCT06946355|OTHER|In-hospital food support intervention|The in-hospital food support intervention will provide two meals for up to two parents per day.
219319797|NCT06946355|OTHER|Post-discharge food support intervention|The post-discharge intervention will provide families with grocery gift cards and frozen meals at the time of discharge.
219319798|NCT06951698|DRUG|KarXT|Specified dose on specified days
219319799|NCT06951698|OTHER|Placebo|Specified dose on specified days
219319800|NCT07152197|OTHER|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training Supervised (RET) focusing on lower limbs. Warm-up (5 min cycling), followed by 5 sets of leg press, leg extension, leg curl, and weighted dorsiflexion. Cool-down with flexibility exercises. Load progression from 60% to 80% of 1Repetition Maximum across 8 weeks. Participants must complete ≥80% of sessions. Evaluators of pre- and post-intervention outcomes will be blinded.
219319801|NCT07154654|DRUG|Mexiletine|Non interventional
219319802|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|Low dose
219319803|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.4%|High dose
219319804|NCT07163182|BIOLOGICAL|CHF6467 Part 1 (SAD)|Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts
219319805|NCT07163182|BIOLOGICAL|CHF6467 Part 2 (MAD)|Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts
219319806|NCT07163182|DRUG|Placebo|Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2
219319807|NCT07160244|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
219319808|NCT07160244|BIOLOGICAL|Placebo|Saline Control
219319809|NCT07160244|BIOLOGICAL|Infanrix hexa|Vaccine administered in a subset of infant participants as per the national immunization schedule
219319810|NCT07160244|BIOLOGICAL|Prevenar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
219319811|NCT07160244|BIOLOGICAL|Pediarix|Vaccine administered in a subset of infant participants as per the national immunization schedule
219319812|NCT07160244|BIOLOGICAL|Prevnar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
219319813|NCT07160244|BIOLOGICAL|Infanrix|Vaccine administered in a subset of infant participants as per the national immunization schedule
219319814|NCT07182045|OTHER|Temporary clamping of uterine and ovarian vessels|Surgeon will temporarily clamp uterine and ovarian vessels.
219319815|NCT07179224|DEVICE|Treatment with EXOMIND (BTL-699-2)|Transcranial magnetic stimulation with the EXOMIND (BTL-699-2) device will be delivered across various stimulation locations. The intensity will be carefully adjusted based on subject feedback, but it should not exceed 70% of the motor threshold.
219319816|NCT07174622|DEVICE|Renal Denervation (Symplicity Spyral™)|Symplicity Spyral™ multi-electrode renal denervation system
219319817|NCT07175402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos. The intervention is expected to have the following overall structure: Session 0: Individual videoconference meeting, introduction. Session 1: Creative hopelessness and mindfulness. Session 2: The body, acceptance, and values. Session 3: Compassion. Session 4: Cognitive defusion and committed action. Session 5-7: Personalised content (in-depth material and tasks based on individual difficulties assessed with diary). Session 8: Summary of intervention.
219319818|NCT07175402|OTHER|Psychoeducation|Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company. Session 0: Individual session, introduction. Session 1-8: The content will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS.
219319819|NCT07177430|DEVICE|Inspiratory Muscle Training|"Participants will perform inspiratory muscle training using a respiratory muscle trainer. The initial training load will be set at 30% of PImax.~The intervention will last for 8 weeks and will be carried out 5 days per week, twice daily, in 3 sets of 10 repetitions.~The training load will be increased in the 2nd, 4th, and 6th week of the program, each time by an additional 10% relative to the initial PImax."
219319820|NCT07177430|DEVICE|Inspiratory Muscle Training (Sham)|"The training intervention in the Sham Group will differ from the experimental group only in terms of training load.~This load will remain constant at 15% PImax, which does not cause any changes in the functioning of the inspiratory muscles.~All other training parameters will be identical to those in the IMT group."
219319821|NCT07188636|OTHER|No Intervention: Observational Cohort|Participants underwent non-cardiac surgery and were followed retrospectively without any experimental intervention. Data were collected from electronic medical records and national death registry to assess postoperative mortality outcomes.
219319822|NCT07188714|PROCEDURE|VATs decortication|"A long thoracoscopic instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniportal procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.~Irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura."
219355081|NCT02981680|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
219355082|NCT02981680|PROCEDURE|sham-RIPC|
219319823|NCT07188714|PROCEDURE|VATs debridement|"Removal of pus, debris, granulation tissue is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations.~Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion"
219319824|NCT07188116|OTHER|COVID-19|The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
219319825|NCT03660826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319826|NCT03660826|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspiration and biopsy
219319827|NCT03660826|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219319828|NCT03660826|DRUG|Capivasertib|Given PO
219319829|NCT03660826|DRUG|Cediranib Maleate|Given PO
219319830|NCT03660826|PROCEDURE|Computed Tomography|Undergo CT scan
219319831|NCT03660826|BIOLOGICAL|Durvalumab|Given IV
219319832|NCT03660826|PROCEDURE|Echocardiography|Undergo Echo
219319833|NCT03660826|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219319834|NCT03660826|DRUG|Olaparib|Given PO
219319835|NCT07188051|DIETARY_SUPPLEMENT|Ovolux brand eggshell membrane powder|Unhydrolyzed eggshell membrane powder
219319836|NCT07188051|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
219319837|NCT07187908|DRUG|Efbemalenograstim alfa Injection|The patients with solid tumor who were at high risk for febrile neutropenia or intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia would be injected Efbemalenograstim alfa for primary/secondary prevention.
219319838|NCT07188844|DRUG|Batoclimab|Batoclimab 340 mg SC QW
219319839|NCT07188974|PROCEDURE|Arthrocentesis (lavage only)|A minimally invasive procedure in which the temporomandibular joint (TMJ) space is washed with sterile solution to remove inflammatory mediators and improve joint mobility.
219319840|NCT07188974|PROCEDURE|Arthrocentesis + Injectable Platelet-Rich Fibrin (i-PRF)|Autologous platelet-rich fibrin prepared by centrifugation of the patient's blood and injected intra-articularly into the TMJ following arthrocentesis. i-PRF contains platelets, leukocytes, and growth factors, which may promote tissue regeneration and healing.
219319846|NCT07188779|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
219319847|NCT07188142|DRUG|Drug/Agent: Gluma Desensitizer|Gluma desensitizer applied to prepared tooth surface, followed by universal bonding agent and composite restoration. Application done during the first visit of restorative treatment. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
219319848|NCT07188142|DRUG|Drug/Agent: No desensitizer (Control)|Universal bonding agent applied followed by composite restoration without prior use of Gluma desensitizer. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
219355083|NCT04302532|DRUG|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
219355084|NCT04302532|DRUG|clomiphene citrate|ovulation induction drug
219319849|NCT07187882|PROCEDURE|Autologous Non-cultured Epidermal Cell Suspension transplantation|"1. Thin split thickness skin grafts were taken from the donor site (anterolateral thigh) after application of topical anaesthesia under complete aseptic precautions.~2. The cell suspension was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd).~3. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared.~4. The cell suspension was applied onto the dermabraded recipient area.~5. The recipient site was then fixed firmly with dressings and elastic bandage. The dressings were removed 10 days after transplantation."
219319850|NCT07187635|PROCEDURE|Second Transurethral Resection of Bladder Tumor (re-TURBT)|Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, in accordance with current clinical guidelines.
219319851|NCT07187635|DIAGNOSTIC_TEST|utDNA Testing (Urine Tumor DNA Detection)|"Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing.~If utDNA is positive, the patient will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery.~If utDNA is negative, re-TURBT will be omitted and patients will proceed to guideline-based adjuvant therapy or surveillance."
219319852|NCT07189195|DRUG|TR-002|Weekly intravenous infusion
219319853|NCT07188038|PROCEDURE|Low positive end-expiratory pressure|Low (4 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
219319854|NCT07188038|PROCEDURE|Medium positive end-expiratory pressure|Medium (10 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
219319855|NCT07188038|PROCEDURE|High positive end-expiratory pressure|High(16 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
219319856|NCT07187752|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)
219319857|NCT07187752|DRUG|Pertuzumab|Pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks)
219319858|NCT07187752|DRUG|Chemotherapy|Chemotherapy chosen by the investigators.
219319859|NCT07187752|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
219319860|NCT07189351|OTHER|Bowen Therapy|Participants received a hot pack, followed by Bowen Therapy performed in prone lying position on a plinth. Bowen moves were applied to soft tissues and muscles of the neck and upper back, aiming to reduce muscle tension and pain. Sessions lasted 15-20 minutes, administered on alternate days for 6 weeks. Assessments were conducted at baseline, 3rd week, 6th week, and at 3-week follow-up.
219319861|NCT07189351|OTHER|Muscle Energy Technique (Post-Isometric Relaxation)|Participants received a hot pack applied over the neck and upper back area for 7-10 minutes, followed by Muscle Energy Technique in supine lying position. Post-isometric relaxation was used for upper trapezius, levator scapulae, scalenus, and sternocleidomastoid muscles. A moderate isometric contraction was held for 5 seconds, followed by 3 seconds of relaxation, with 5 repetitions per muscle. Sessions were given on alternate days for 6 weeks. Assessments were performed at baseline, 3rd week, 6th week, and at 3-week follow-up.
219319862|NCT07187778|DRUG|Pembrolizumab|Oral administration
219319863|NCT07187778|DRUG|Belzutifan|Oral administration
219319864|NCT07187401|DRUG|ALN-CFB|Administered as defined in the protocol
219319865|NCT07187401|DRUG|Placebo|Administered as defined in the protocol
219319866|NCT07188558|BIOLOGICAL|rondecabtagene autoleucel|An autologous, dual-targeting CD19/20 CAR T-cell candidate.
219319867|NCT07188558|BIOLOGICAL|axicabtagene ciloleucel|An autologous CD19 CAR T-cell therapy
219319868|NCT07188558|BIOLOGICAL|lisocabtagene maraleucel|An autologous CD19 CAR T-cell therapy
219319869|NCT07187388|DEVICE|Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS|"TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on.~Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place."
219319870|NCT07188831|OTHER|Agarwood Aromatherapy Inhalation|The experimental group will receive agarwood essential oil sachets as the aromatherapy intervention, and participants will place the sachet 60 cm from the nose during sleep for one week.
219319871|NCT07189000|BEHAVIORAL|App-based prehabilitation program|A lightweight mobile/web application delivering a patient-centered prehabilitation program from randomization until surgery. Features include: weekly home six-minute walk tests (6MWT) logged in the app; brief daily check-ins for exercise performed, simple nutrition targets, and mood/stress; push reminders; short educational video/handout content; and CSV export for analysis. The app provides standardized instructions and safety prompts for the home 6MWT and basic validity checks (continuous 6 minutes, pause limits, outlier flags). No additional study-specific clinic visits are required beyond routine preoperative admission and one routine postoperative outpatient visit.
219319872|NCT07189000|OTHER|Usual care (ERAS-standard perioperative care)|Standard perioperative counseling/education and routine mobilization per institutional ERAS practice. No study app is provided and no remote 6MWT logging is required. Outcome assessments are collected at routine preoperative admission (including in-hospital 6MWT per protocol) and at one routine postoperative outpatient visit (≈3 or 6 months per unified site policy). No additional study-specific clinic visits are required.
219319873|NCT07188025|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX). Duration of treatment will be 3 months (12 weeks).
219319874|NCT07189208|DRUG|Benzathine penicillin 2.4 million units|IM injection of BPG
219319875|NCT07189208|BEHAVIORAL|Counseling and intensified testing.|Brazilian Ministry of Health guidelines for the prevention and diagnosis of maternal syphilis consist of counseling about STI prevention and syphilis testing at the first pre-natal consultation, at a subsequent consultation during or after 28 weeks of pregnancy, at delivery, and in case of abortion or stillbirth. In this study, intensified testing refers to treponemal and non-treponemal tests once every four weeks beginning as of the 28th week of pregnancy.
219319876|NCT07188207|DRUG|Oxytocin|"Intravenous oxytocin administered per hospital protocol immediately after delivery of the baby and placenta (example regimen: 10 IU slow IV bolus followed by infusion e.g., 20 IU in 500-1000 mL isotonic crystalloid run over 2-4 hours; actual dosing adjusted per anesthesiologist/obstetrician and hospital policy). Document exact time, dose, and infusion rate in each case.~Single rectal dose of misoprostol 600-1000 µg (select dose based on patient risk profile; e.g., 600 µg for routine prophylaxis, 800-1000 µg for high-risk cases) inserted into the rectum immediately after delivery of the baby and placenta. No dilution required."
219319877|NCT07189169|DRUG|QA108 granules|Take the medication as required for 24 weeks
219319878|NCT07189169|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
219319879|NCT07187544|DRUG|Calcium Chloride|Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.
219319880|NCT07187544|OTHER|Placebo|Intravenous administration of 100ml normal saline, over 10 minutes.
219319881|NCT07187544|DRUG|Carbetocin|50 mcg intravenous carbetocin.
219319882|NCT07187336|PROCEDURE|Shoulder MSAT Group|"Shoulder Motion Style Acupuncture Treatment (MSAT) involves inserting acupuncture needles into specific points around the shoulder joint, then guiding or assisting the patient's shoulder movements while the needles remain in place. This combined technique is intended to maximize acupuncture effects by stimulating both the needles and the joint motion.~In this study, MSAT will be performed once daily for three consecutive days (hospital days 2-4), in addition to standard integrative Korean medicine treatment (acupuncture, pharmacopuncture, Chuna manual therapy, and herbal medicine). Each MSAT session lasts about 10-20 minutes.~This distinguishes the intervention from the comparator arm, which receives integrative Korean medicine treatment only, without MSAT."
219319883|NCT07187336|PROCEDURE|Integrative Korean Medicine Only Group|"Participants in this group receive only standard integrative Korean medicine treatments, without MSAT. Treatments include acupuncture (6-10 points, 15-20 minutes per session), pharmacopuncture (injection of herbal extracts at acupuncture points), Chuna manual therapy (10-15 minutes daily), and herbal medicine (oral decoction extracts taken twice daily).~This arm serves as the comparator to distinguish the additional effects of MSAT, since both groups receive the same integrative Korean medicine but only the experimental arm includes Shoulder MSAT."
219319884|NCT07188532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319885|NCT07188532|DRUG|Chemotherapy|Given chemotherapy
219319886|NCT07188532|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219319887|NCT07188532|PROCEDURE|Conventional Radiotherapy|Undergo conventional radiotherapy
219319888|NCT07188532|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
219319889|NCT07188532|RADIATION|Dose-escalated Radiation Therapy|Undergo hypofractionated or conventional radiotherapy
219319890|NCT07188532|OTHER|Electronic Health Record Review|Ancillary studies
219319891|NCT07188532|RADIATION|External Beam Radiation Therapy|Undergo definitive radiotherapy
219319892|NCT07188532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219319893|NCT07188532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219319894|NCT07188532|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219319895|NCT07188532|OTHER|Questionnaire Administration|Ancillary studies
219319896|NCT07188532|RADIATION|Radiation Therapy|Undergo hypofractionated or conventional standard radiotherapy
219319897|NCT06464562|BEHAVIORAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|An adapted dialectical behavioral therapy skills training intervention
219319898|NCT03462342|DRUG|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
219355085|NCT00999908|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219355086|NCT00999908|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219319899|NCT03462342|DRUG|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
219319900|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
219319901|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
219319902|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
219319903|NCT06957743|BEHAVIORAL|Mindfulness Meditation|The Mindfulness Meditation trainings will teach participants Shamatha Vipassana, which is the specific form of Mindfulness Meditation typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Participants will be invited to lie flat on their back (i.e., to mimic conditions in the MRI scanner) and will listen to the clinician read a standardized Mindfulness Meditation script.
219319904|NCT06957743|BEHAVIORAL|Self-Hypnosis|In the Self-Hypnosis group, participants will relax with their eyes closed and, as with Mindfulness Meditation, will lie flat on their lack and will listen to the clinician read a standardized hypnotic script. The Self-Hypnosis practice will include an induction followed by suggestions for decreased pain and improvement in comorbid symptoms (e.g., mood).
219319905|NCT04700046|DRUG|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
219319906|NCT04700046|DRUG|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
219319907|NCT00238173|BIOLOGICAL|filgrastim|
219319908|NCT00238173|DRUG|acetylcysteine|administered i.v. over 30 to 60 minutes
219319909|NCT00238173|DRUG|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
219319910|NCT00238173|DRUG|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
219319911|NCT00238173|DRUG|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
219319912|NCT00238173|DRUG|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
219319913|NCT00238173|DRUG|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
219319914|NCT01545570|DRUG|GSK2376497|GSK2376497 Active Comparator
219319915|NCT01545570|DRUG|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
219319916|NCT02926131|OTHER|Blood sampling|"* One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
219319917|NCT04721093|DEVICE|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
219319918|NCT03891303|OTHER|Allogenic blood transfusion (ABT)|During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
219319919|NCT05083338|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219319920|NCT05083338|PROCEDURE|Pain Assessment|Undergo pain assessment
219319921|NCT05083338|OTHER|Questionnaire Administration|Complete questionnaires
219319922|NCT00594126|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
219319923|NCT03736161|DRUG|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
219319924|NCT03736161|DRUG|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
219319925|NCT03993197|BEHAVIORAL|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
219319926|NCT05273957|OTHER|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
219319927|NCT05273957|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
219319928|NCT05887453|DEVICE|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
219319929|NCT03837314|DEVICE|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
219319930|NCT04492345|OTHER|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
219319931|NCT04492345|OTHER|Conventional reeducation|Conventional rehabilitation session during 7 weeks
219319932|NCT01377077|PROCEDURE|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
219319933|NCT01377077|PROCEDURE|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
219319934|NCT03811639|PROCEDURE|Radio-frequency ablation|Ablation for atrial fibrillation
219319935|NCT03811639|PROCEDURE|Cryoballoon ablation|Ablation for atrial fibrillation
219319936|NCT05245409|OTHER|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
219319937|NCT03756350|DEVICE|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
219319938|NCT04283981|DEVICE|Control group without use of VSP|The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)
219319939|NCT04283981|DEVICE|Treatment Group with use of VSP|The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
219319940|NCT01099423|PROCEDURE|timing of surgery|
219319941|NCT01099423|GENETIC|gene expression analysis|
219319942|NCT01099423|OTHER|biologic sample preservation procedure|
219319943|NCT01099423|OTHER|laboratory biomarker analysis|
219319944|NCT01099423|PROCEDURE|therapeutic conventional surgery|
219319945|NCT04656509|OTHER|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
219319946|NCT04405700|OTHER|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
219319947|NCT00514761|DRUG|AZD6244|oral vial
219319948|NCT00514761|DRUG|Capecitabine|oral tablet
219319949|NCT00109499|DRUG|AdGVPEDF.11D|
219319950|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
219319951|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
219319952|NCT05428137|DIETARY_SUPPLEMENT|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
219319953|NCT05428137|DIETARY_SUPPLEMENT|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
219319954|NCT05428137|OTHER|Placebo|Placebo in a form of a capsule given for 16 weeks
219319955|NCT04678323|DRUG|Lifestyle Management|Participants in this group will receive lifestyle management.
219319956|NCT05713279|DRUG|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
219319957|NCT01096342|DRUG|dinaciclib|Given IV
219319958|NCT01096342|OTHER|laboratory biomarker analysis|Correlative studies
219319959|NCT02014155|OTHER|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
219319960|NCT02014155|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
219319961|NCT05207735|DRUG|Sintilimab|"* Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
219319962|NCT04317950|OTHER|Vojta|Reflex locomotion stimulus
219319963|NCT04317950|OTHER|Sham|sham stimulus
219319964|NCT03298568|DIETARY_SUPPLEMENT|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
219319965|NCT06402981|OTHER|High risk prediction model for liver injury|Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
219319966|NCT00125879|BIOLOGICAL|Myozyme|20 mg/kg qow or 40 mg/kg qow
219319967|NCT00419718|DRUG|inhaled human insulin|
219319968|NCT01449877|DRUG|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
219319969|NCT01580150|OTHER|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
219319970|NCT01580150|OTHER|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
219319971|NCT04906616|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
219319972|NCT00244972|OTHER|Laboratory Biomarker Analysis|Correlative studies
219319973|NCT00244972|DRUG|Sorafenib Tosylate|Given PO
219319974|NCT00244972|DRUG|Tipifarnib|Given PO
219319975|NCT04774770|BEHAVIORAL|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
219319976|NCT04793269|OTHER|No intervention|no intervention
219319977|NCT03581201|DIAGNOSTIC_TEST|Laboratory measurements|"Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry"
219319978|NCT03581201|DIAGNOSTIC_TEST|Stool samples|For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
219319979|NCT03581201|DIAGNOSTIC_TEST|Bioimpedance analysis|The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
219319980|NCT02464228|DRUG|Tipifarnib|oral
219319981|NCT04560569|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
219319982|NCT04560569|DRUG|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
219319983|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
219319984|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
219319985|NCT04830150|BEHAVIORAL|Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).|This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
219319986|NCT04258371|DRUG|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
219319987|NCT04258371|DRUG|Placebo oral tablet|Placebo once daily for 12 weeks
219319988|NCT03597971|DRUG|HMPL004-6599|For each cohort, 6 subjects will receive HMPL004-6599
219319989|NCT03597971|DRUG|Placebo|For each cohort, 2 subjects will receive placebo
219319990|NCT04159766|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
219319991|NCT04159766|DRUG|Placebo|normal saline
219319992|NCT00003653|DRUG|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319993|NCT00003653|DRUG|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319994|NCT00003653|DRUG|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319995|NCT00003653|DRUG|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219355087|NCT00999908|DRUG|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
219355088|NCT05044156|OTHER|salivary sample|salivary sample
219319996|NCT00003653|DRUG|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319997|NCT00003653|DRUG|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319998|NCT00003653|DRUG|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
219319999|NCT02801903|DRUG|SB204 4%|Topically Once Daily (AM)
219320000|NCT04354805|DRUG|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
219320001|NCT03436706|OTHER|exposure|exposure to chronic stress
219320002|NCT04182503|OTHER|No intervention|This is a multi-city observational cohort study without intervention.
219320003|NCT03579849|DIAGNOSTIC_TEST|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
219320004|NCT05754554|PROCEDURE|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
219320005|NCT00390611|DRUG|Sorafenib|
219320006|NCT00390611|DRUG|Paclitaxel|Paclitaxel
219320007|NCT00390611|DRUG|Carboplatin|Carboplatin
219320008|NCT04691999|BEHAVIORAL|Intermittent Fasting|16-18 hour fasting period four times per week
219320009|NCT02193360|DRUG|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
219320010|NCT06168136|OTHER|protein diet|this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)
219320011|NCT06168136|OTHER|Normal protein diet|this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
219320012|NCT04541056|BEHAVIORAL|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
219320013|NCT04541056|BEHAVIORAL|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
219320014|NCT05500755|DEVICE|Implant Treatment|Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
219320015|NCT00135239|PROCEDURE|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
219320016|NCT00135239|PROCEDURE|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
219320017|NCT05993936|DEVICE|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
219320018|NCT03308942|DRUG|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
219355089|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
219355090|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
219320019|NCT03308942|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
219320020|NCT03308942|BIOLOGICAL|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
219320021|NCT01131351|DRUG|Delamanid|OPC-67683 film-coated tablets
219355091|NCT00685126|DRUG|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
219355092|NCT00003426|DRUG|gemcitabine hydrochloride|
219355093|NCT00003426|RADIATION|radiation therapy|
219355094|NCT00733707|BEHAVIORAL|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
219355095|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as two capsules
219320022|NCT01131351|DRUG|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
219320023|NCT01903070|DRUG|Linagliptin|
219320024|NCT04180748|OTHER|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
219320025|NCT00715195|BEHAVIORAL|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
219320026|NCT05476042|DRUG|Prescription of placebo|Normal saline
219320027|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
219320028|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
219320029|NCT04942795|DEVICE|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
219320030|NCT04202770|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
219320031|NCT01595984|DRUG|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
219320032|NCT01595984|DRUG|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
219320033|NCT04080284|DRUG|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
219320034|NCT00298129|DEVICE|Ambulatory blood pressure monitoring|
219320035|NCT03901573|DRUG|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
219320036|NCT03901573|DRUG|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
219320037|NCT01281007|DRUG|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
219320038|NCT01281007|DRUG|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
219320039|NCT05112198|DEVICE|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
219320040|NCT00347672|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
219320041|NCT04629963|OTHER|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
219320042|NCT04629963|OTHER|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
219320043|NCT02545621|OTHER|RAGE TXNIP Inflammasome axis|
219320044|NCT03981471|BEHAVIORAL|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
219320045|NCT06341608|BEHAVIORAL|Telehealth for opioid use disorder treatment delivery|A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests
219320046|NCT03422172|DRUG|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
219320047|NCT03422172|DRUG|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
219320048|NCT05594199|BEHAVIORAL|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
219320049|NCT05460507|DRUG|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
219320050|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
219320051|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
219320052|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
219320053|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
219320054|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
219320055|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
219320056|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
219320057|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
219355096|NCT06411275|DRUG|Placebo|Matching placebo administered orally BID as two to four capsules
219355097|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as four capsules
219355098|NCT00110565|DEVICE|Pulsed magnetic field pad|
219355099|NCT00868686|DEVICE|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
219320058|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
219320059|NCT06396897|OTHER|Indiana University Health Hospital at Home Program|Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, \& perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.
219320060|NCT03946514|DRUG|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
219320061|NCT03946514|DRUG|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
219320062|NCT04053634|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
219320063|NCT04053634|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
219320064|NCT06170736|PROCEDURE|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
219320065|NCT06170736|PROCEDURE|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
219320066|NCT06293625|DRUG|Folfox|Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
219320067|NCT06293625|PROCEDURE|Surgery|Experimental arm: Surgery should take place 21 days after the last dose of neoadjuvant chemotherapy Control arm: upfront surgery as soon as possible
219320068|NCT05853965|DRUG|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
219320069|NCT03457545|BEHAVIORAL|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
219320070|NCT03457545|OTHER|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
219320071|NCT05039099|DRUG|AP-101|Participants receive AP-101 by intravenous infusion (IV).
219320072|NCT05039099|DRUG|Placebo|Participants receive placebo by IV.
219320073|NCT00140231|DRUG|r-metHuLeptin|recombinant human leptin
219320074|NCT00140231|OTHER|placebo|placebo (no active drug)
219320075|NCT06526351|DEVICE|Early implant placement with immediate provisional restoration|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.
219320076|NCT06526351|DEVICE|Early implant placement with delayed loading|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
219320077|NCT06362798|OTHER|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
219320078|NCT00884338|OTHER|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
219320079|NCT00884338|OTHER|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
219320080|NCT00905138|DRUG|GLPG0259|single ascending doses, oral solution
219320081|NCT00905138|DRUG|placebo|single dose, oral solution
219320082|NCT00905138|DRUG|GLPG0259|multiple dose, oral solution, 5 days
219320083|NCT00905138|DRUG|placebo|oral solution, 5 days
219320084|NCT01753154|DRUG|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
219320085|NCT01753154|DRUG|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
219320086|NCT03304353|OTHER|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
219320087|NCT03304353|OTHER|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
219320088|NCT02858830|OTHER|High fat mixed meal|
219320089|NCT03819010|DRUG|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
219320090|NCT03819010|DRUG|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
219320091|NCT03913975|OTHER|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
219320092|NCT03182166|DRUG|Golimumab (Optimization)|"Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
219320093|NCT03182166|DIAGNOSTIC_TEST|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
219320094|NCT03182166|BIOLOGICAL|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
219320095|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
219320096|NCT06637514|OTHER|Placebo|Placebo Tablet: BID
219320097|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
219320098|NCT06246617|DEVICE|da Vinci SP Surgical System for Single-Port Thoracic Surgeries|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
219320099|NCT03932734|OTHER|survey|Face-Q conversion table
219320100|NCT06412484|BEHAVIORAL|Pain Free Session|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.
219320101|NCT06412484|BEHAVIORAL|Low Back Pain Session (= clinically relevant pain)|On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.
219320102|NCT06412484|BEHAVIORAL|Experimental Pain Session (= clinically irrelevant pain)|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
219320103|NCT03815643|DRUG|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
219320104|NCT06737783|OTHER|Thoracic mobility exercises + Conventional therapy|mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) , Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.
219320105|NCT06737783|OTHER|Self myofascial release with foam roller, T6- T7 Maitland mobilization + Conventional therapy|Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins. Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets).
219320106|NCT04644380|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
219320107|NCT04330846|PROCEDURE|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
219320108|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Sharkskin Forceps|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
219320109|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Standard Forceps|25g Grieshaber Standard ILM Forceps
219320110|NCT02890758|BIOLOGICAL|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
219320111|NCT02890758|BIOLOGICAL|ALT803|given at 6mcg/kg weekly for four weeks
219320112|NCT05716750|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vit D treatment for 8 weeks
219320113|NCT05439434|OTHER|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
219320114|NCT05400642|DEVICE|THRIVE|Apneic ventilation
219320115|NCT05400642|DEVICE|mechanical ventilation|mechanical ventilation in Positive Pressure
219320116|NCT01161901|PROCEDURE|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
219320117|NCT00382603|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
219320118|NCT04027231|OTHER|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
219320119|NCT05138523|COMBINATION_PRODUCT|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
219320120|NCT02479945|OTHER|Obtaining biospecimen|
219320121|NCT04317560|PROCEDURE|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
219320122|NCT04317560|PROCEDURE|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
219320123|NCT00813163|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
219320124|NCT01423812|DRUG|Twice-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
219320125|NCT01423812|DRUG|Once-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
219320126|NCT00799279|BEHAVIORAL|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
219320127|NCT00799279|BEHAVIORAL|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
219320128|NCT04248582|DEVICE|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
219320129|NCT04440787|PROCEDURE|Three point cuff palpation technique|the ETT is finally positioned according to the Three point cuff technique.
219320130|NCT04345081|PROCEDURE|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
219320131|NCT04345081|PROCEDURE|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
219320132|NCT03089242|OTHER|observation of microRNA expression|no intervention
219320133|NCT01755845|DRUG|paclitaxel|
219320134|NCT01755845|DRUG|cisplatin|
219320135|NCT01755845|RADIATION|radiotherapy|
219320136|NCT06235450|DEVICE|iLIDS100|Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
219320137|NCT04315545|DIAGNOSTIC_TEST|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
219320138|NCT06516900|DEVICE|OrthoFeet HandsFree Therapeutic Shoe|Patients with foot pain will be recruited for this study and will go for an intervention of wearing OrthoFeet therapeutic shoes for 6 weeks. Each patient will be evaluated and will participate in data collection before and after intervention.
219320139|NCT05674994|DRUG|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
219320140|NCT05674994|OTHER|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
219320141|NCT05945355|DEVICE|Pro2 - Low Dose - 40% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
219320142|NCT05945355|DEVICE|Pro2 - High Dose - 75% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
219320143|NCT05945355|DEVICE|Pro2 - SHAM - 15% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
219320144|NCT02652455|DRUG|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
219320145|NCT02652455|PROCEDURE|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
219320146|NCT02652455|DRUG|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
219320147|NCT02652455|DRUG|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
219320148|NCT02652455|DRUG|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
219320149|NCT02652455|BIOLOGICAL|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
219320150|NCT02652455|DRUG|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
219320151|NCT02315898|DRUG|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
219320152|NCT05882344|PROCEDURE|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
219320153|NCT05882344|DEVICE|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
219320154|NCT06404086|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
219320155|NCT06404086|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
219355100|NCT00868686|DEVICE|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
219355101|NCT00868686|DEVICE|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
219320156|NCT06404086|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
219320157|NCT06404086|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
219320158|NCT06404086|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
219320159|NCT06404086|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
219320160|NCT06404086|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
219320161|NCT06404086|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
219320162|NCT06309225|RADIATION|Modified dose and fields intensity modulated radiotherapy|Instead of standard bilateral or extensive neck fields, the current radiation fields will cover disease with only 3cm expansion. The clinical target volumes doses are biologically equivalent to the standard but given in a shorter hypofractionated approach.
219320163|NCT05241444|BIOLOGICAL|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood."
219320164|NCT05177107|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
219320165|NCT05177107|OTHER|Placebo|Placebo (normal saline)
219320166|NCT05352048|DEVICE|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
219320167|NCT05352048|DEVICE|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
219320168|NCT06361810|DRUG|Pembrolizumab|"Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase."
219320169|NCT06361810|DRUG|177Lu-PNT2002|"177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles."
219320170|NCT06361810|DRUG|(F-18)-DCFPyL|Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
219320171|NCT02412566|DRUG|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
219320172|NCT01660607|BIOLOGICAL|CD34+ Hematopoietic Progenitor Cells (HSPC)|Purified CD34+ hematopoietic progenitor cells used in transplantation.
219320173|NCT01660607|BIOLOGICAL|Regulatory T-Cells (Treg)|Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.
219320174|NCT01660607|BIOLOGICAL|Conventional T-Cells (Tcon)|Conventional CD3+ T cells used for immune reconstitution and graft enhancement.
219320175|NCT01660607|PROCEDURE|Myeloablative Conditioning Regimen|Chemotherapy or total body irradiation used before hematopoietic cell transplantation.
219320176|NCT03346772|BIOLOGICAL|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
219320177|NCT04526600|OTHER|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
219320178|NCT06773871|OTHER|Exercise|Weekly supervised exercise for 12 weeks followed by 12 weeks of non-supervised exercise
219320179|NCT06773871|OTHER|Control|Remain usual activity level
219320180|NCT02782130|BEHAVIORAL|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
219320181|NCT02782130|BEHAVIORAL|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
219320182|NCT00010972|PROCEDURE|Acupuncture|
219320183|NCT03600857|OTHER|Home administration of misoprostol|First dose of misoprostol administration at home
219320184|NCT01662115|DRUG|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
219320185|NCT01662115|OTHER|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
219320186|NCT00998426|PROCEDURE|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
219320187|NCT00998426|BIOLOGICAL|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
219320188|NCT05641064|DRUG|Placebo|Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
219320189|NCT05641064|DRUG|Dexmedetomidine 0.5mcg/kg/h|Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
219320190|NCT05641064|DRUG|Dexmedetomidine 1 mcg/kg/h|Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
219320191|NCT00312325|DRUG|Prednisolone|
219320192|NCT03383549|OTHER|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
219320193|NCT02967354|RADIATION|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
219320194|NCT05141214|BEHAVIORAL|Virtual Reality Application|In VR application, Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
219320195|NCT05461482|OTHER|Pre-procedural consultation and audiovisual tools|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
219320196|NCT01611753|OTHER|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
219320197|NCT04029350|DRUG|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
219320198|NCT00399386|PROCEDURE|EP|
219320199|NCT00399386|PROCEDURE|ICD|
219320200|NCT00399386|PROCEDURE|Ablation|
219320201|NCT05829707|DRUG|Diclofenac Sodium|"A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4"
219320202|NCT05829707|DRUG|Levobupivacaine bolus analgesia|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4."
219320203|NCT05829707|DRUG|Levobupivacaine PCA group|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4."
219320204|NCT03180749|OTHER|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
219320205|NCT01158651|DRUG|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
219320206|NCT01296035|BIOLOGICAL|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
219320207|NCT00564785|DRUG|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
219320208|NCT00564785|OTHER|Placebo patch|placebo patch applied 20 minutes prior to epidural
219320209|NCT01717963|DRUG|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
219320210|NCT01717963|DRUG|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
219320211|NCT00324129|DRUG|MGCD0103|MGCD0103 given orally three times per week.
219320212|NCT03267953|BEHAVIORAL|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
219320213|NCT03267953|BEHAVIORAL|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
219320214|NCT03267953|BEHAVIORAL|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
219320215|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
219320216|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
219320217|NCT00695851|DRUG|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
219320218|NCT00695851|DRUG|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
219320219|NCT01765868|DRUG|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
219320220|NCT03508258|OTHER|Non-interventional|Non-interventional
219320221|NCT03508258|OTHER|Non-Interventional|Non-Interventional
219320222|NCT05073679|DRUG|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
219320223|NCT05073679|OTHER|Control|Methylcellulose and gelatin capsule only
219320224|NCT05364268|DEVICE|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
219320225|NCT00533468|DRUG|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
219320226|NCT00533468|DRUG|Placebo|inactive placebo without LMX4
219320227|NCT04080791|DEVICE|Virtual Reality (VR) System|The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.
219320228|NCT04080791|PROCEDURE|Standard of care|Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
219320229|NCT06503094|DRUG|CD19&CD20 bispecific CAR-T cells|Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
219320230|NCT00973154|DRUG|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
219320231|NCT02613351|DEVICE|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
219320232|NCT00301158|BEHAVIORAL|exercise intervention|
219320233|NCT00301158|OTHER|counseling intervention|
219320234|NCT00301158|OTHER|educational intervention|
219320235|NCT00301158|PROCEDURE|complementary or alternative medicine procedure|
219320236|NCT05696236|DEVICE|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
219320237|NCT05696236|DEVICE|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
219320238|NCT05341700|BEHAVIORAL|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
219320239|NCT05341700|BEHAVIORAL|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
219320240|NCT05558176|DRUG|Sildenafil citrate|The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
219320241|NCT04876534|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Intravenous administration
219320242|NCT04876534|DRUG|MethylPREDNISolone Injectable Solution|Intravenous administration
219320243|NCT00366483|DRUG|Lecozotan SR|
219320244|NCT00897143|GENETIC|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
219320245|NCT00897143|GENETIC|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
219320246|NCT00897143|OTHER|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
219320247|NCT00897143|OTHER|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
219320248|NCT00867113|DRUG|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
219320249|NCT03327116|DRUG|Methotrexate|oral, 15 mg per week, 24 weeks
219320250|NCT01145495|OTHER|Laboratory Biomarker Analysis|Correlative studies
219320251|NCT01145495|DRUG|Lenalidomide|Given PO
219320252|NCT01145495|BIOLOGICAL|Rituximab|Given IV
219320253|NCT04147325|DRUG|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
219320254|NCT06073236|BEHAVIORAL|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
219320255|NCT06159023|DEVICE|bronchial washing using a thin bronchoscope|For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
219320256|NCT03216421|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
219320257|NCT06400498|BEHAVIORAL|Prompted Palliative Care Consult|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. If the treating clinician feels a palliative care consultation would be indicated for the patient, the clinical decision support tool will facilitate the placement of a palliative care consultation by the treating clinician. If the treating clinician feels that a palliative care consultation would not be indicated, then the clinical decision support will record a reason it is not indicated.
219320258|NCT03426826|BIOLOGICAL|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
219320259|NCT00633165|DRUG|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
219320260|NCT01886313|DRUG|Civamide Nasal Spray|
219320261|NCT01886313|DRUG|Placebo|
219320262|NCT02378220|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
219320263|NCT00578786|DRUG|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
219320264|NCT00697879|DRUG|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
219320265|NCT00593749|BEHAVIORAL|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
219320266|NCT00593749|BEHAVIORAL|Control|control group in study
219320267|NCT04668651|OTHER|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
219320268|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
219320269|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
219320270|NCT00312221|DRUG|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
219320271|NCT04512443|DRUG|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
219320272|NCT06033781|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
219320273|NCT04029220|BEHAVIORAL|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
219320274|NCT05804279|DRUG|BPDO-1603|donepezil/mematine
219320275|NCT01207232|BEHAVIORAL|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
219320276|NCT01207232|BEHAVIORAL|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
219320277|NCT02771314|DRUG|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
219320278|NCT03882905|DRUG|Ezetimibe|10 mg tablet, oral, once daily
219320279|NCT03882905|DRUG|Placebo|one tablet, oral, once daily
219320280|NCT03882905|DRUG|Simivastatin|Once daily administration at dose to be determined
219320281|NCT03882905|DRUG|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
219320282|NCT01805167|OTHER|Electrophysiological study of the interindividual variability of vocal performance|
219320283|NCT04998019|BEHAVIORAL|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
219320284|NCT00193869|DRUG|Dexamethasone|
219320285|NCT04674514|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
219320286|NCT04674514|DRUG|Rd|Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
219320287|NCT04431401|DEVICE|Magstim rTMS|The device is made in London,UK
219320288|NCT01560689|DRUG|Budesonide/formoterol|800 µg/j twice a day, every day
219320289|NCT01560689|DRUG|Placebo|Twice a day, every day
219320290|NCT00006098|DRUG|bortezomib|
219320291|NCT02060721|DRUG|Macitentan|Macitentan 10mg, oral tablet, once daily
219320292|NCT01243697|DRUG|desogestrel|Tablets of 75 µg, once daily during 112 days
219320293|NCT00117507|DRUG|Deferasirox|
219320294|NCT00866723|DRUG|bevacizumab|
219320295|NCT02914691|DRUG|Dapagliflozine 10 mg once daily tablet treatment|
219320296|NCT02914691|DRUG|Placebo identical once daily tablet treatment|
219320297|NCT05105789|DIAGNOSTIC_TEST|BinaxNOW Test|diagnostic test for SARS-CoV-2
219320298|NCT05105789|DIAGNOSTIC_TEST|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
219320299|NCT03024177|DRUG|Vapendavir|Vapendavir Tablets, 264 mg
219320300|NCT03024177|DRUG|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
219320301|NCT04066790|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
219320302|NCT04066790|DRUG|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
219320303|NCT04066790|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
219320304|NCT04066790|DRUG|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
219320305|NCT04066790|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
219320306|NCT05810337|DIETARY_SUPPLEMENT|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
219320307|NCT05810337|DIETARY_SUPPLEMENT|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
219320308|NCT05810337|DIETARY_SUPPLEMENT|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
219320309|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
219320310|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
219320311|NCT05590936|DRUG|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
219320312|NCT05590936|DRUG|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
219320313|NCT00263744|BIOLOGICAL|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
219320314|NCT00263744|OTHER|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
219320315|NCT00389233|DRUG|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
219320316|NCT00389233|DRUG|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
219320317|NCT04072289|DEVICE|Visumax spherocylindrical treatment|treatment of low cylinder (\<0.75D)
219320318|NCT05928130|OTHER|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
219320319|NCT00037791|DRUG|(PN-152,243)/PN-196,444|
219320320|NCT02005081|DEVICE|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
219320321|NCT02005081|DEVICE|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
219320322|NCT00198952|DRUG|DietPro|
219320323|NCT00198952|DRUG|Placebo|
219320324|NCT01222637|DRUG|CetuGEX™|
219320325|NCT03706339|OTHER|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
219320326|NCT03706339|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
219320327|NCT03706339|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
219320328|NCT03613285|DEVICE|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
219320329|NCT03613285|DEVICE|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
219320330|NCT03613285|DEVICE|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
219320331|NCT05029960|DRUG|Brivaracetam|Dose of 50 mg twice daily for 6 months
219320332|NCT05291000|BEHAVIORAL|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
219320333|NCT06522750|OTHER|7-day ambulatory caloric restriction intervention using the Buchinger-Wilhelmi method|Buchinger-Wilhelmi method, will be administered in an ambulatory setting under physician guidance. It involves an initial bowel cleanse followed by 7-day fasting period. The initial bowel cleanse will be performed according to the standard procedure commonly used for colonoscopy preparation. During the fasting period, subjects will be provided with a dietary energy supply of a maximum of 350 kcal per day, primarily consisting of vegetable broths as well as fresh vegetable juices. Patients will only be allowed to consume calorie-free and unsweetened water or tea in addition to the prescribed diet.
219320334|NCT05162638|PROCEDURE|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
219320335|NCT02797067|DRUG|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
219320336|NCT02797067|DRUG|Glycerin Suppository|30min before ESWL
219320337|NCT06191770|PROCEDURE|Morphine,|Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
219320338|NCT00482196|DRUG|MK0493|
219320339|NCT05325697|COMBINATION_PRODUCT|Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement|The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
219320340|NCT01610362|BIOLOGICAL|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
219320341|NCT06057675|DRUG|Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.
219320342|NCT06057675|DRUG|Control (1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
219320343|NCT03943862|BEHAVIORAL|2Share|"The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
219320344|NCT01893892|DIETARY_SUPPLEMENT|levocarnitine|Given PO
219320345|NCT01893892|OTHER|placebo|Given PO
219320346|NCT01893892|OTHER|questionnaire administration|Ancillary studies
219320347|NCT03995901|BIOLOGICAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
219320348|NCT00323297|DRUG|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
219320349|NCT00323297|OTHER|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
219320350|NCT00323297|DRUG|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
219320351|NCT00323297|DRUG|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
219320352|NCT03765411|PROCEDURE|Proctectomy|Resection of the rectum
219320353|NCT03045601|DIAGNOSTIC_TEST|CT-FFR|Invasive FFR and CCTA With CT-FFR
219320354|NCT03045601|DIAGNOSTIC_TEST|Stress echocardiography|Stress echocardiography and invasive FFR
219320355|NCT04910022|DRUG|NMS-03305293|Route of administration: Oral
219320356|NCT04910022|DRUG|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
219320357|NCT02182570|DRUG|WAL 801 CL dry syrup|
219320358|NCT00688831|DRUG|AZD1305|Solution for iv infusion , single dose
219320359|NCT00688831|DRUG|Placebo|NaCl solution for iv infusion, single dose
219320360|NCT01003990|DRUG|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
219320361|NCT01003990|DRUG|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
219320362|NCT01003990|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
219320363|NCT01003990|DRUG|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
219320364|NCT04823715|OTHER|TACE + hypofractionated EBRT|One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
219320365|NCT04823715|PROCEDURE|Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
219320366|NCT02393274|DEVICE|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
219320367|NCT02812901|PROCEDURE|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
219320368|NCT02812901|PROCEDURE|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
219320369|NCT01236105|DRUG|LY2624803|Administered orally (po), once.
219320370|NCT01236105|OTHER|Activated Charcoal|Administered po
219320371|NCT04092062|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
219320372|NCT04092062|DEVICE|powered toothbrush|regular powered toothbrush with no RF
219320373|NCT02302404|DRUG|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
219320374|NCT02302404|DRUG|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
219320375|NCT02302404|DRUG|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
219320376|NCT02302404|DRUG|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
219320377|NCT06246708|OTHER|Self-help app with information for grieving Syrian Refugees|This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.
219320378|NCT06246708|OTHER|Wait-list|Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
219320379|NCT05061784|PROCEDURE|Routine thymectomy, which has been performed|There is no intervention
219320380|NCT03047759|DEVICE|water flosser|Powered
219320381|NCT03047759|DEVICE|air floss|Powered
219320382|NCT03889431|DIETARY_SUPPLEMENT|Iodine capsule|225 µg of iodine daily as a capsule of potassium iodide
219320383|NCT03889431|OTHER|Iodized Salt|450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
219320384|NCT04098965|OTHER|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
219320385|NCT04098965|OTHER|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
219320386|NCT00460057|DRUG|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
219320387|NCT05115604|BEHAVIORAL|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
219320388|NCT05997862|DEVICE|HFFS|This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
219320389|NCT06528639|BEHAVIORAL|HIIT|Three times a week, 10 sets each session, for 24 weeks of high-intensity interval training.
219320390|NCT04086433|DEVICE|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
219320391|NCT01343485|BEHAVIORAL|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
219320392|NCT02129153|BEHAVIORAL|LIFT (Parent Information)|"1. Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~2. Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
219320393|NCT00934804|DEVICE|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
219320394|NCT05798533|BIOLOGICAL|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
219320395|NCT05798533|COMBINATION_PRODUCT|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
219320396|NCT05798533|COMBINATION_PRODUCT|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
219320397|NCT01809184|DRUG|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
219320398|NCT01809184|DRUG|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
219320399|NCT01809184|DRUG|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
219320400|NCT01695915|PROCEDURE|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
219320401|NCT05192304|DRUG|TPN-672|single dose of TPN-672 maleate tablet
219320402|NCT02309060|BEHAVIORAL|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
219320403|NCT00634010|DRUG|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
219320404|NCT00634010|DRUG|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
219320405|NCT04052568|DRUG|Psilocybin|Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
219320406|NCT00114192|DRUG|docetaxel|
219320407|NCT00114192|DRUG|thalidomide|
219320408|NCT04811638|OTHER|Validation of the Chelsea Critical Care Physical Assesment Tools|The validation of the CPAX tools will focus on the validity of constructs, internal consistency reliability and test-retest reliability. PFIT used for criterion validity.
219320409|NCT00151554|BEHAVIORAL|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
219320410|NCT00567216|DRUG|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
219320411|NCT00160355|PROCEDURE|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
219320412|NCT00160355|DEVICE|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
219320413|NCT00160355|DRUG|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
219320414|NCT02185209|DRUG|Placebo|Place capsule to mimic antibiotics
219320415|NCT02185209|DRUG|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
219320416|NCT02185209|DRUG|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
219320417|NCT02185209|DRUG|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
219320418|NCT04890678|DEVICE|22 residentsat risk for PU development|"mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning."
219355102|NCT02121457|DIETARY_SUPPLEMENT|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
219355103|NCT02121457|DIETARY_SUPPLEMENT|selenium|
219320419|NCT04890678|DEVICE|18 residents at least one PU category III-IV in the sacral area|"mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed."
219320420|NCT03030235|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
219320421|NCT03030235|DRUG|Dapagliflozin matching placebo|Dapagliflozin matching placebo
219320422|NCT03690141|DRUG|eFT508|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
219320423|NCT04970043|DRUG|Camrelizumab+ pemetrexed + platinum|"Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years)."
219320424|NCT04649268|DEVICE|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
219320425|NCT04649268|OTHER|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
219320426|NCT01006265|DRUG|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
219320427|NCT01006265|DRUG|Placebo|Matching placebo administered orally once daily
219320428|NCT01006265|DRUG|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
219320429|NCT01006265|DRUG|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
219320430|NCT04611620|BEHAVIORAL|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
219320431|NCT03629743|DEVICE|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
219320432|NCT03629743|DEVICE|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
219320433|NCT04780490|OTHER|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
219320434|NCT04780490|OTHER|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
219320435|NCT03045042|DRUG|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
219320436|NCT03531788|DEVICE|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
219320437|NCT03531788|DEVICE|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
219320438|NCT00132496|DRUG|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
219320439|NCT05743504|DRUG|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
219320440|NCT03645265|BEHAVIORAL|Auditory|Use of auditory cues to improve speech production
219320441|NCT03645265|BEHAVIORAL|Gestures|Use of gestures to improve speech production
219320442|NCT03059927|PROCEDURE|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design
219320443|NCT03059927|PROCEDURE|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design
219320444|NCT03059927|PROCEDURE|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
219320445|NCT00197808|BIOLOGICAL|menjugate|men C conjugate vaccine
219320446|NCT00197808|BIOLOGICAL|Men C conjugate vaccine|men C conjugate vaccine
219320447|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
219320448|NCT00197808|BIOLOGICAL|Men C Conjugate|men C conjugate vaccine
219320449|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
219320450|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
219320451|NCT02238951|OTHER|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
219320452|NCT02238951|OTHER|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
219320453|NCT02374398|DRUG|Tranexamic Acid|see arm/group descriptions
219320454|NCT02374398|DEVICE|Aquamantys System|see arm/group descriptions
219320455|NCT02374398|OTHER|Control|Standard Electro-cautery and Saline
219320456|NCT01093625|DEVICE|Narafilcon B Contact Lens|
219320457|NCT01093625|DEVICE|Spectacles|spectacle wearers
219320458|NCT04567667|DRUG|[14C] BMS-986278|Specified dose on specified days
219320459|NCT04567667|DRUG|Kinevac®|Specified dose on specified days
219320460|NCT02693769|DRUG|fluticasone propionate/formoterol fumarate breath actuated inhaler|
219320461|NCT02693769|DRUG|Indacaterol maleate / glycopyrronium bromide capsules|
219320462|NCT00437671|DRUG|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
219320463|NCT00437671|BIOLOGICAL|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
219320464|NCT06330883|DIAGNOSTIC_TEST|Prognosis|survival/mortalite
219320465|NCT00533026|DRUG|Duloxetine|
219320466|NCT00533026|DRUG|Warfarin|
219320467|NCT00148265|DRUG|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
219320468|NCT02673606|DRUG|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
219320469|NCT02673606|DRUG|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
219320470|NCT02673606|DRUG|Placebo Pills|inactive placebo pills
219320471|NCT05426642|OTHER|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
219320472|NCT05426642|OTHER|Brochure|The brochure contain the information regarding cervical cancer and its screening
219355104|NCT04940910|DIETARY_SUPPLEMENT|Black rice bran extract|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
219320473|NCT02014740|DRUG|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
219320474|NCT02014740|DRUG|Metformin|
219320475|NCT01069250|OTHER|There are no interventions in this study|
219320476|NCT06085027|PROCEDURE|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
219320477|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
219355105|NCT04940910|DIETARY_SUPPLEMENT|Placebo|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
219355106|NCT05501353|OTHER|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
219320478|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
219320479|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
219320480|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
219320481|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
219320482|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
219320483|NCT02992314|DEVICE|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
219320484|NCT02992314|DEVICE|Placebo|Placebo formulation with out the active ingredients
219320485|NCT03173079|OTHER|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
219320486|NCT03234166|OTHER|Non interventional study|Only data will be taken of patient's file.
219320487|NCT04272541|BEHAVIORAL|Psychoeducation program|Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.
219320488|NCT04272541|DRUG|Psychopharmacology intervention|Intervention program consisted of psychopharmacology. This will be executed during 3 months.
219320489|NCT01431534|DRUG|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
219320490|NCT06154213|BEHAVIORAL|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
219320491|NCT06154213|BEHAVIORAL|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
219320492|NCT06497127|DRUG|BW-00112|BW-00112 or volume-matched placebo on Day 1 and Day 90
219320493|NCT05267860|DEVICE|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
219320494|NCT00182351|PROCEDURE|D-dimer|
219320495|NCT00182351|PROCEDURE|Serial Compression Ultrasound|
219320496|NCT03753633|OTHER|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
219320497|NCT03753633|OTHER|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
219320498|NCT02032303|PROCEDURE|Assessment of coronary flow reserve|
219320499|NCT02032303|PROCEDURE|Percutaneous Coronary Intervention|
219320500|NCT02032303|DRUG|Ticagrelor loading|
219320501|NCT02032303|DRUG|Prasugrel loading|
219320502|NCT05100485|DIAGNOSTIC_TEST|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
219320503|NCT05100485|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
219320504|NCT03537950|DRUG|PLC|Single oral dose of PLC.
219320505|NCT03537950|DRUG|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
219320506|NCT03537950|DRUG|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
219320507|NCT00366704|DRUG|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
219320508|NCT00366704|DRUG|risperidone|4mg, QD, 8 week treatment
219320509|NCT03594851|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
219320510|NCT03594851|BEHAVIORAL|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
219320511|NCT03594851|BEHAVIORAL|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
219355107|NCT05850221|OTHER|weight training|weight training
219320512|NCT03594851|BEHAVIORAL|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
219320513|NCT03594851|BEHAVIORAL|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
219320514|NCT03594851|BEHAVIORAL|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
219320515|NCT03594851|BEHAVIORAL|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
219320516|NCT03594851|BEHAVIORAL|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
219320517|NCT03594851|BEHAVIORAL|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses \& includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
219320518|NCT03408782|PROCEDURE|Insertion of drainage|
219320519|NCT02939248|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
219320520|NCT02939248|DRUG|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
219320521|NCT04173065|DRUG|VK2809|Capsule
219320522|NCT04173065|DRUG|Placebos|Capsule
219320523|NCT06061016|OTHER|No intervention|No intervention
219320524|NCT01759212|BIOLOGICAL|Allogeneic stem cells implantation|
219320525|NCT01241097|DRUG|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
219320526|NCT02730364|DRUG|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
219320527|NCT03575455|BEHAVIORAL|Exercise|HR-controlled treadmill walking
219320528|NCT02993653|RADIATION|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
219320529|NCT04561752|DRUG|ZN-c5|ZN-c5 is the study drug.
219320530|NCT01387048|DRUG|skinoren|gel 15%, twice daily, 36 weeks
219320531|NCT01387048|DRUG|differin|0.1% gel, once daily in the evening
219320532|NCT01387048|DRUG|skinoren|12 weeks treatment, the following 24 months only observation
219320533|NCT02628756|PROCEDURE|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
219320534|NCT02518022|DRUG|Insulin|Insulin for beer
219320535|NCT00691886|DRUG|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
219320536|NCT01975818|DRUG|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
219320537|NCT01975818|BIOLOGICAL|Epoetin alfa/beta|
219320538|NCT04427501|DRUG|LY3819253|Administered IV
219320539|NCT04427501|DRUG|LY3832479|Administered IV
219320540|NCT04427501|DRUG|LY3853113|Administered IV
219320541|NCT04427501|DRUG|Placebo|Administered IV
219320542|NCT04144504|DEVICE|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
219320543|NCT04144504|DEVICE|Plastic stenting|Use of plastic stents
219320544|NCT00238667|DRUG|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
219320545|NCT00238667|DRUG|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
219320546|NCT00999713|DRUG|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
219320547|NCT00999713|OTHER|Air placebo|Endotracheal air administration
219320548|NCT04566627|BEHAVIORAL|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
219320549|NCT04427553|DEVICE|Percutaneous Peripheral Nerve Stimulation|Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
219320550|NCT04427553|OTHER|Control Group|No intervention
219320551|NCT00893646|BEHAVIORAL|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
219320552|NCT05612763|DEVICE|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
219320553|NCT03926156|DRUG|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
219320554|NCT03926156|DRUG|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
219320555|NCT00639223|DIETARY_SUPPLEMENT|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
219320556|NCT00639223|DRUG|Pravastatin|One 20mg capsule twice daily for 12 weeks
219320557|NCT00639223|BEHAVIORAL|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
219320558|NCT02873273|DRUG|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
219320559|NCT04910477|DRUG|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
219320560|NCT04910477|DRUG|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
219320561|NCT04910477|OTHER|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
219320562|NCT01236651|DRUG|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
219320563|NCT01236651|DRUG|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
219320564|NCT04640389|OTHER|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
219320565|NCT03228381|DEVICE|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
219320566|NCT00195923|DRUG|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
219320567|NCT00180362|DEVICE|procedure|
219320568|NCT01884233|BEHAVIORAL|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
219320569|NCT01884233|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
219320570|NCT02936128|OTHER|TruSkin|
219320571|NCT02936128|OTHER|Wound Cover|
219320572|NCT04010773|OTHER|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
219320573|NCT03543696|RADIATION|Single Dose Radiotherapy (SDRT)|
219320574|NCT01829399|DRUG|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
219320575|NCT01829399|DRUG|Normal Saline|
219320576|NCT02435589|OTHER|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
219320577|NCT02435589|OTHER|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
219320578|NCT03576703|OTHER|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
219320579|NCT05731414|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
219320580|NCT05731414|BEHAVIORAL|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
219320581|NCT05731414|BEHAVIORAL|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
219320582|NCT05731414|BEHAVIORAL|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
219320583|NCT07129499|DRUG|Shenbai Granules|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
219320584|NCT07129499|DRUG|Placebo|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
219320585|NCT07130045|OTHER|Hybrid Endurance Strength Training|HybEST will be delivered three times weekly over eight weeks, with two supervised sessions at the center and 22 unsupervised sessions at home. The exercise characteristics of supervised HybEST and unsupervised HybEST are described. Monitoring methods for unsupervised HybEST include a wearable tracking device that collects data on patients' health parameters (arterial oxygen saturation (SpO2), heart rate, and blood pressure) and weekly phone calls. The unsupervised sessions will include video material on the home-based exercise program.
219320586|NCT07130045|OTHER|Usual Care|The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
219320587|NCT07130903|DRUG|Fruquintinib|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
219320588|NCT07130903|DEVICE|TheraBionic P1|TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device
219320589|NCT07129551|PROCEDURE|preop virtual 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively
219355108|NCT03552341|OTHER|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
219355109|NCT05697328|DRUG|Pseudoephedrine Pill|One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
219320590|NCT07129551|PROCEDURE|postop 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated
219320591|NCT05371548|DEVICE|SAM mobile application|See description of intervention group
219320592|NCT06716814|DRUG|Efanesoctocog alfa|Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
219320593|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation (SpO₂) Group|FiO₂ adjusted based on pulse oximetry to maintain SpO₂ ≥98%
219320594|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation and Oxygen Reserve Index (SpO₂-ORI) Group|FiO₂ adjusted using both SpO₂ and ORI to maintain ORI between 0-0.3
219320595|NCT07049679|BEHAVIORAL|ActiveHeal Diabetes (AHD) Program|Biweekly phone/Zoom calls to support physical activity and dietary behavior change, focused on history, experience, benefits and adaptation
219320596|NCT07043725|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
219320597|NCT07043725|DRUG|Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection|TCbHP is a commonly used chemotherapy scheme for HER2 positive breast cancer. H represents Trastuzumab injection, P represents Pertuzumab Injection, T represents Docetaxel injection and C represents Carboplatin injection.
219320598|NCT06892197|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
219320599|NCT06892197|DRUG|hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
219320600|NCT06743516|PROCEDURE|Pancreaticojejunostomy with external stent|Inserting ureteric stent at the pancreaticojejunostomy site
219320601|NCT06743516|PROCEDURE|Pancreaticojejunostomy without external stent|Only Pancreaticojejunostomy without inserting external stent
219320602|NCT06894108|DIETARY_SUPPLEMENT|Proprietary Blend of Botanical Extracts|Participants consumed 2.4ml of the supplement each night before bed.
219320603|NCT06894108|DIETARY_SUPPLEMENT|Melatonin|Participants consumed 1mg melatonin each night before bed.
219320604|NCT06894888|OTHER|artifial intelligence education|With the start of the use of artificial intelligence in the field of nursing, we are trying to increase the skills of students by providing them with training in this field.
219320605|NCT07052266|GENETIC|MyRisk Hereditary Cancer Test|Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.
219320606|NCT07052682|DRUG|Ontamalimab|Ontamalimab SC injection.
219320607|NCT07054463|OTHER|FSN Therapy Combined with Rehabilitation Training|"Prior to treatment, blinding will be ensured through the use of eye masks. Based on the affected muscle theory, all forearm muscles within the splint-immobilized area will be considered as an affected muscle group and further subdivided into flexor and extensor subgroups according to functional anatomy.~Two needle insertion points will be selected approximately 5 cm distal to the cubital crease, corresponding to the flexor and extensor muscle groups.~Following standard disinfection of the insertion device and sites, a disposable FSN needle will be inserted subcutaneously into the superficial fascial layer, with the needle tip directed toward the affected muscle group. The needle core will then be retracted into the soft tube, ensuring no tip exposure, and the tube base will be secured within the handle slot. A 30° fan-shaped sweeping motion will be performed bilaterally at a frequency of 100 sweeps/min for 2 minutes."
219320608|NCT07054463|OTHER|Sham FSN Therapy Combined with Rehabilitation Training|"Patients randomized to this group will undergo the sham intervention in the same predetermined anatomical region. Prior to the procedure, eye masks will be applied to ensure blinding. The Sham FSN device, featuring a blunt tip, will generate a pricking sensation upon spring-loaded actuator deployment without actual skin penetration, maintaining parallel alignment to the epidermal surface.~Following standard aseptic preparation, the acupuncturist will stabilize the needle body with the non-dominant hand while simulating insertion motions with the dominant hand, replicating the authentic FSN technique by retracting the stylet to the locking groove. The practitioner will then perform sweeping manipulations (ensuring continuous dermal contact during the procedure). Both the operational protocol and treatment course will be identical to those of the genuine FSN intervention group."
219320609|NCT07053085|PROCEDURE|Lumpectomy or mastectomy|Resection of the primary breast tumor (ie. lumpectomy when possible or mastectomy when breast conservation not possible). Surgical resection of the primary breast tumor is to be performed per standard guidelines as applied to localized disease. Breast conserving surgery (ie. lumpectomy) is allowable per patient preference when supported by standard surgical practice. Mastectomy is preferred when breast conservation is declined by the patient, or if breast conservation would otherwise not be feasible in the early-stage setting (e.g. large tumor:breast volume ratio, inability to achieve negative margins with breast conservation, etc)
219320610|NCT07053085|RADIATION|Radiotherapy|"Radiotherapy will be delivered using external beam radiation per the guidelines.Radiotherapy will be delivered using external beam radiation per the guidelines set forth below, targeting two main compartments:~1. Patients will undergo radiotherapy to the breast/chest wall, and regional nodal basins (including the axilla, supraclavicular fossa and internal mammary chain) per the standard adjuvant approach for locally advanced disease, and~2. Patient will undergo stereotactic body radiotherapy (SBRT) or similarly-ablative approaches to sites of distant disease, including all observable foci and those that may have since resolved radiographically during systemic therapy"
219320611|NCT07053085|DRUG|Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs|Continue to receive the standard treatment you have already started, which includes trastuzumab, pertuzumab, paclitaxel, or a combination of these drugs. This treatment is not part of the study and will be decided by your regular treating physician.
219320612|NCT06895967|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
219320613|NCT06895967|BIOLOGICAL|HyQvia|Participants will receive SC infusion of HyQvia.
219320614|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
219320615|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
219320616|NCT05503797|DRUG|Plixorafenib|Oral tablets
219320617|NCT06750146|DEVICE|Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System|The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
219320618|NCT06891456|DEVICE|RFA Ablation|RFA ablation of VT substrate using FlexAbility or ThermoCool ST catheter
219320619|NCT06891456|DEVICE|PFA Ablation|PFA ablation of VT substrate using FARAPOINT catheter
219320620|NCT07058155|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.
219320621|NCT07058155|PROCEDURE|Sleeve Gastrectomy|Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.
219320622|NCT07058155|DRUG|Anti-Obesity Pharmacotherapy (Class Effect)|Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.
219320623|NCT07058155|BEHAVIORAL|Lifestyle Counseling - Diet & Physical-Activity Program|Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.
219320624|NCT06761677|DRUG|Brincidofovir|Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).
219355110|NCT05697328|DRUG|Placebo|One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
219320625|NCT07054853|DEVICE|Induced rotator cuff fatigue by isokinetic biodex|"Each subject will undergo two separate fatigue protocols from distinct shoulder abduction angles (30° and 90°), referred to as Protocol A and Protocol B, respectively.~Fatigue will be induced using the Biodex System 4 Pro Isokinetic .Participants will be seated with the tested arm positioned at the designated shoulder abduction angle and elbow flexed at 90°. The arm will be secured using a shoulder adapter to ensure standardized positioning. Hand Grip strength will be assessed using a Jamar Plus+ Digital. Participants will perform three maximal grip trials, each lasting 3 seconds, with verbal encouragement provided. The average of the three trials will be used as the maximum voluntary contraction"
219320626|NCT06761976|DRUG|Sevabertinib|Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration
219320627|NCT06861153|BEHAVIORAL|Pulses 1.5 cups Group|Participants will receive 1.5 cup-equivalents of pulses per week.
219320628|NCT06861153|BEHAVIORAL|Pulses 3 cups Group|Participants will receive 3 cup-equivalents of pulses per week.
219320629|NCT06861153|BEHAVIORAL|My Plate Group (Control)|Participants will continue with their usual dietary practices, receiving no additional pulses. They are encouraged to follow My Plate general recommendations.
219320630|NCT06237452|BIOLOGICAL|VE303|VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.
219320631|NCT06237452|BIOLOGICAL|Placebo|Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
219320632|NCT07060235|OTHER|fascial exercise home brochure|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. He/she remembers the exercises from the home brochure.
219320633|NCT07060235|OTHER|Fascial exercise based mobile application|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. Performs the exercises by watching videos on the mobile application. The physiotherapist intervenes in motivation with instant notifications via the mobile application.
219320634|NCT07060235|OTHER|lumbal stabilizasyon home brochure|"Participants assigned to the intervention group will receive a structured home-based lumbar stabilization exercise program designed to improve spinal stability, core muscle control, and functional performance. The program will target deep trunk stabilizer muscles, including the transversus abdominis and multifidus, through low-load, motor control-based exercises.~The intervention will last for 14 days, with exercises to be performed 3 times for everyday, Each session will last approximately 20-30 minutes and consist of:~Warm-up (1 minutes): Breathing exercises and gentle mobility~Core Stabilization (15-20 minutes): Exercises such as abdominal hollowing, bridging, bird-dog, side plank, and dead bug - progressing from static holds to dynamic movements as tolerated~Cool-down (1 minutes): Light stretching and relaxation"
219320635|NCT04047654|DRUG|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
219320636|NCT06770569|DRUG|HRS-3802|HRS-3802
219320637|NCT06739785|OTHER|SCAT6-tr|"Step 1: Initial Translation At this stage, two independent bilingual translators whose native language is Turkish will translate the content into Turkish. Step 2: Integration of Translations~A single translation will be created by comparing the two Turkish versions of SCAT 6.~Step 3: Back-translation The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. These two English versions will be compared, differences will be resolved by consensus and a new combined version will be created. If consensus cannot be reached, a third person will be asked for help. Step 4: Expert Evaluation"
219320638|NCT07071194|PROCEDURE|OMT|Patients in the treatment group will undergo OMT using sub-occipital release, rib raising, doming the diaphragm, thoracic inlet release and myofascial techniques.
219320639|NCT07071194|OTHER|Light touch|Patients in the control group will undergo light touch in similar locations to OMT.
219320640|NCT07071623|DRUG|MK-8527|Oral tablet
219320641|NCT07071623|DRUG|Emtricitabine/tenofovir disoproxil (FTC/TDF)|Oral tablet
219320642|NCT07071623|DRUG|Placebo matched to MK-8527|Placebo oral tablet matched to MK-8527
219320643|NCT07071623|DRUG|Placebo matched to FTC/TDF|Placebo oral tablet matched to FTC/TDF
219320644|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
219320645|NCT04491175|DEVICE|M-Stim|"The casing for the device is a 54 belt with 3-button haptic controller for on-off, therapy cycles(8) and intensity(5) levels."
219320646|NCT04491175|DEVICE|TENS|LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
219320647|NCT07065240|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
219320648|NCT07065240|DRUG|Placebo|Placebo for SPT-300
219320649|NCT05356000|OTHER|Special low-oxalate diet followed by all-day visit to University of Chicago research clinic|"Active participation in this study will last for around one week. For the first two days, participants will be asked to eat a special diet at home. From Days 3-5, they will eat special meals that will be delivered to their home from a research clinic at the University of Chicago. They will also collect urine at home on Days 4 and 5.~On Day 6, subjects will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. They will receive a special liquid that contains oxalate, and will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect their urine and blood throughout the day. We will draw blood 4 separate times."
219320650|NCT06841991|BEHAVIORAL|Teach Back Education|The relatives of patients who will undergo colonoscopy will be trained with the teach-back technique.
219320651|NCT06812377|OTHER|Maitland joint mbilization|Posteroanterior mobilization of the radial head in motion. This method is gliding over the radial head posteriorly to anteriorly while the patient executes (and relaxes) the painful action (e.g., clutching). Repeat the method six to ten times if there is a noticeable increase in your ability to grip without pain
219320652|NCT06812377|OTHER|mulligan mobilization|Using this approach, the patient performs (and relaxes) the painful action (e.g., clutching) while a lateral humeroulnar auxiliary glide is applied and maintained. If you notice a noticeable increase in your ability to grip without pain, repeat the method six to ten times. You can use a belt to help you glide.Three sets of it were performed, with a 30-second break in between
219320653|NCT06812377|OTHER|radial nerve mobilization|The subjects will be placed in a reclining supine position. The arm will be internally rotated, the wrist, thumb, and fingers will be flexed, the shoulder girdle will be depressed, and the elbow will be stretched. Elbow flexion and wrist extension will be used to maintain shoulder depression after the radial nerve will be strained by these motions. Before beginning the gentle elbow extension test, the subject's wrist and fingers will be stabilized. The elbow will be then gently extended for about two seconds, just into the range where the participant felt tension but no pain, and then flexed. In a single session, three sets of six to eight oscillations will be executed
219320654|NCT07128433|PROCEDURE|milk expression|Following one-on-one antenatal manual colostrum expression instruction by a midwife at the breastfeeding clinic, participants will initiate twice-daily practice from 37 weeks gestation onward, performing 3-5 minutes of manual expression per breast per session (total duration ≤10 minutes per session).
219320655|NCT06806150|BEHAVIORAL|INSPIRE Life Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their daily lives. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful moments.
219320656|NCT06806150|BEHAVIORAL|INSPIRE Work Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their work experiences. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful professional interactions.
219320657|NCT06903221|DRUG|Tdap-IPV|intramuscular injection
219320658|NCT06903221|DRUG|Td-IPV|intramuscular injection
219320659|NCT06902753|OTHER|Questionnaire and Physical Exam|"Neuropsychological assessment:~* Phase 1: MMS-LS (overall cognitive efficiency) + fluency tasks (verbal flexibility)~* Phase 2: MMS-LS (if the participant did not take part in phase 1), RL-RI LSF (verbal memory), Rey Complex Figure (visuospatial abilities and visual memory), Progressive Matrices, Symbols and Code (executive functions)"
219320660|NCT07079228|DRUG|QLS31905|QLS31905 will be administered as an IV infusion.
219320661|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion.
219320662|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
219320663|NCT07079228|DRUG|Placebo for QLS31905|Placebo will be administered as an IV infusion.
219320664|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion
219320665|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
219320666|NCT06902831|PROCEDURE|Endoscopic Carpal Tunnel Release|Release of carpal tunnel with endoscopic device
219320667|NCT06902831|PROCEDURE|Open carpal tunnel release|Release of carpal tunnel with open tecnique
219320668|NCT06902831|DRUG|Neurotrophic supplementation|Neurotrophic supplementation after surgery
219320669|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by PSMA PET/CT|The patient will undergo pelvic non-contrast CT imaging. After co-registration of the CT images with 68Ga-PSMA PET/CT data at corresponding anatomical levels, a percutaneous gluteal approach will be utilized for CT-guided prostate biopsy.
219320670|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by mpMRI/US|The patient will undergo transrectal ultrasound (TRUS) prostate scanning. After co-registration and precise image fusion of TRUS findings with multiparametric MRI (mpMRI) data, a transperineal percutaneous approach will be employed to perform TRUS-guided prostate biopsy.
219320671|NCT06901492|DIAGNOSTIC_TEST|Systematic prostate biopsy|The patient will undergo systematic prostate biopsy under TRUS guidance.
219320672|NCT06903676|DEVICE|TRP-2 Urine Dipstick|Urine dipstick testing for Trypsinogen-2
219320673|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using LuminoMark|This group used LuminoMark as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, comparing it to existing methods (charcoal staining, needle targeting, ultrasound-guided skin marking) to assess its safety and effectiveness, with procedural differences based on neoadjuvant chemotherapy status.
219320674|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using conventional method|This group used conventional method (charcoal staining, needle targeting, ultrasound-guided skin marking) as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, with procedural differences based on neoadjuvant chemotherapy status.
219320675|NCT07099001|OTHER|Educational materials on the Alzheimer's disease assay|Between Round 1 and Round 2 virtual patient case administration, Intervention participants will receive educational materials describing the clinical validation and use cases of the Alzheimer's disease assay. These materials will approximate the type of information physicians would receive to introduce them to the Alzheimer's disease assay and may be comprised of a slide deck, fact sheet, sample test report, and/or example case scenarios.
219320676|NCT07099001|OTHER|Alzheimer's disease assay results|Within each of their virtual patient cases in Round 2 of case administration, Intervention participants will receive Alzheimer's disease assay results at the clinically appropriate point for each case.
219320677|NCT05838508|BEHAVIORAL|Exercise intervention|Research participants will be assigned to two exercise conditions.
219320678|NCT06904625|OTHER|Taking blood samples before starting treatment|"For each patient included, a blood sample will be taken (37 mL in total) for the CTCs detection using the 3 techniques (CellSearch®, Parsortix® and SmartCatch®).~For 3 patients only, an additional blood volume (18 mL) will also be collected for tcDNA detection (exploratory analysis of 3 patients)."
219320679|NCT04613206|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
219320680|NCT04613206|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
219320681|NCT04759586|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
219320682|NCT04759586|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219320683|NCT04759586|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219320684|NCT04759586|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219320685|NCT04759586|DRUG|Cyclophosphamide|Given IV
219320686|NCT04759586|DRUG|Doxorubicin Hydrochloride|Given IV
219320687|NCT04759586|PROCEDURE|Echocardiography Test|Undergo ECHO
219320688|NCT04759586|DRUG|Etoposide Phosphate|Given IV
219320689|NCT04759586|BIOLOGICAL|Filgrastim|Given SC
219320690|NCT04759586|PROCEDURE|Lumbar Puncture|Undergo LP
219320691|NCT04759586|BIOLOGICAL|Nivolumab|Given IV
219320692|NCT04759586|BIOLOGICAL|Pegfilgrastim|Given SC
219320693|NCT04759586|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219320694|NCT04759586|DRUG|Prednisolone|Given PO
219320695|NCT04759586|DRUG|Prednisone|Given PO
219320696|NCT04759586|RADIATION|Radiation Therapy|Undergo radiation therapy
219320697|NCT04759586|BIOLOGICAL|Rituximab|Given IV
219320698|NCT04759586|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
219320699|NCT04759586|DRUG|Vincristine Sulfate|Given IV
219320700|NCT07128953|DRUG|Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula|Left Qing San Decoction (25g of Cai Yin + 30g of Eucommia + 25g of Sophora flavescens + 25g of Anemarrhena asphodeloides + 15g of Lithospermum erythrorhizon, prepared in the Pharmacy Department of Anhui University of Traditional Chinese Medicine), add 1000mL of water, boil, then steam and wash the wound surface. The temperature is 40 ± 2℃. Do it once a day, for 15 minutes each time, for 7 consecutive days.
219320701|NCT07128953|OTHER|Equal-volume placebo inhalation rinse|Equal-volume placebo inhalation rinse
219320702|NCT06946225|BIOLOGICAL|IMA203|Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.
219320703|NCT06946225|BIOLOGICAL|mRNA-4203|mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.
219320704|NCT07162428|BEHAVIORAL|Art Therapy|"The art therapy sessions will be conducted by a certified art therapist who has completed a two-year training program, together with a psychiatric nurse who has completed a 4-hour training course on Severe Personality Disorders and Therapeutic Interventions - Art Therapy. A clinical nurse and a psychiatry resident will also participate as observers. The therapist will deliver the intervention through semi-structured sessions, following a predefined content and method. These sessions are referred to as Semi-Structured Art Therapy Sessions."
219320705|NCT07173634|OTHER|Speaking Valve Trial|The speaking valve group ascertains a patient's eligibility for decannulation following the results of the speaking valve test. A patient who can endure a 4-hour trial with a speaking valve, maintaining a pulse oxygen saturation (SpO₂) of at least 95%, a breathing rate (RR) below 20 per minute, and exhibiting no signs of distress throughout the trial, qualifies for decannulation.
219320706|NCT07173634|OTHER|Capping Trial|The capping valve group determines a patient's eligibility for decannulation based on the results of the capping test. A patient who can tolerate 48 hours of capping with a pulse oxygen saturation (SpO₂) of ≥95%, a breathing rate (RR) of \<20/min, and no signs of distress during the 48-hour trial, is eligible for decannulation.
219320707|NCT07182188|DEVICE|Vascular Interventional Robotic System|The cerebral angiography will be performed by using the vascular interventional robotic system
219320708|NCT07188753|OTHER|transcranial magnetic stimulation by accelerated & high-dose theta-burst, functional imaging guided, i|Participants will then be treated with 1,800 pulses of iTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) per session at 90% resting motor threshold and depth-adjustment to the personalized functional target. Each session will last 10 min followed by a 50-minute intersession interval. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 total pulses).
219320709|NCT07188571|DIAGNOSTIC_TEST|Gastric emptying scintigraphy|To assess gastric emptying rates in patients with simple obesity and diagnose the presence of gastric motility abnormalities.
219320710|NCT07189260|DEVICE|positive expiratory pressure|PEP therapy
219320711|NCT07188649|BEHAVIORAL|oxygen deficiency|The aim of this study is to evaluate the effect of the Reverse Trendelenburg position on oxygenation (SpO₂/FiO₂ ratio) in the early postoperative period in patients undergoing laparoscopic surgery. In our study, obesity is considered as a comparative subgroup in terms of variability of this effect; additionally, the STOP-BANG score, which measures the risk of obstructive sleep apnea syndrome, is examined as an auxiliary indicator.
219320712|NCT07187583|DRUG|increased dosing interval of biological therapy|Increasing dosing interval of biological therapy for CRSwNP from every 4 weeks to every 6 weeks and if continued satisfactory response then to every 8 weeks.
219320713|NCT07188012|GENETIC|mRNA|mRNA therapy delivered by extracellular vesicles (EVs)
219320714|NCT07187843|OTHER|Clinical assessments|standardized neurological examination, motor and non-motor symptom scales, cognitive testing, and autonomic symptom questionnaires.
219320715|NCT07187843|OTHER|Phenotypic classification|patients will be stratified into Brain-First and Body-First phenotypes based on the presence of RBD and instrumental findings.
219320716|NCT07187531|DRUG|High Dose SAB-142|High Dose SAB-142
219320717|NCT07187531|DRUG|Low Dose SAB-142|Low Dose SAB-142
219320718|NCT07187531|OTHER|Placebo|Placebo
219320719|NCT07188311|DRUG|Pucotenlimab ,Lenvatinib|A total of 24 cases are planned to be enrolled. All subjects will receive Pucotenlimab (3mg/kg, on Day 1, with a maximum dose not exceeding 200mg) once every 3 weeks (Q3W), in combination with Lenvatinib and Irinotecan. The chemotherapy regimen is fixed: Lenvatinib capsules 7mg/m2 (maximum 12mg) orally from Day 1 to 21 and Irinotecan 50mg/m2 from Day 1 to 5. Chemotherapy will be administered for 2 to 4 cycles, once every 3 weeks (Q3W).
219320720|NCT07188961|OTHER|kinesiologic taping|This intervention is distinguished from other studies by its combined assessment of trunk and extremity kinesiology taping in children with both hemiplegic and diplegic cerebral palsy over a four-week period.
219320721|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
219320722|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
219320723|NCT03188562|OTHER|PET/CT|Positron Emission Tomography (PET/CT)
219320724|NCT03188562|PROCEDURE|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
219320725|NCT03188562|PROCEDURE|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
219320726|NCT06179576|BEHAVIORAL|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
219320727|NCT04890054|OTHER|Fecal Immunochemical Test|Patients due for CRC screening are mailed a FIT test by the clinic or health plan
219320728|NCT04890054|OTHER|Interview|Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations
219320729|NCT04890054|BEHAVIORAL|Patient Navigation|Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
219320730|NCT03531736|DRUG|Antithymocyte globulin (Rabbit)|ATG (2 mg/kg/d IV on days-8 through -7)
219320731|NCT03531736|DRUG|fludarabine|fludarabine (30 mg/m2/d on days -5 through -2)
219320732|NCT03531736|RADIATION|total body irradiation|TBI 200 cGy (days -2 and -1) given post stem cell infusion
219320733|NCT03531736|DRUG|cyclophosphamide|cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
219320734|NCT03531736|DRUG|Rituxan|Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia
219320735|NCT03531736|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
219320736|NCT06018363|BIOLOGICAL|Allogenic B7-H3 CAR-γδT cell(QH104)|"Dose escalation (3+3) : dose 1 (1 × 10\^7 CAR+cells) , dose 2 (3 × 10\^7 CAR+cells), dose 3 (6× 10\^7 CAR+cells), once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 1: dose of RP2D, once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 2: 3 × 10\^7 CAR+cells, every two weeks for three consecutive months, then changed to once every 4 weeks via an Ommaya reservoir or intrathecal administration."
219320737|NCT06261567|DRUG|Biologic treatment|Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
219320738|NCT05333328|DRUG|Ovarian function suppression with endocrine treatments|"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."
219320739|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
219320740|NCT04624126|DEVICE|3D-Erect|3D-printed erectile device for intercourse
219320741|NCT06185530|DIAGNOSTIC_TEST|Detection of obstructive coronary disease|Detection of obstructive coronary disease
219320742|NCT05180578|OTHER|Goat milk diet|Elimination of cow milk from diet . Goat milk containing diet.
219320743|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
219320744|NCT04112654|PROCEDURE|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
219320745|NCT04112654|PROCEDURE|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
219320746|NCT02018757|DRUG|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
219320747|NCT02018757|DRUG|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
219320748|NCT03658746|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
219320749|NCT03658746|DRUG|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
219320750|NCT03658746|DRUG|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
219320751|NCT05061563|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
219320752|NCT05061563|DRUG|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
219320753|NCT01944735|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
219320754|NCT01944735|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
219320755|NCT02296151|OTHER|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
219320756|NCT02296151|OTHER|iliotibial band stretches|Iliotibial band stretches
219320757|NCT05649033|OTHER|data collection|Work-related stress evaluation
219320758|NCT01310803|DRUG|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
219320759|NCT01310803|OTHER|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
219320760|NCT04160143|PROCEDURE|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
219320761|NCT02198612|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
219320762|NCT02378454|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
219320763|NCT04907747|DRUG|Vonoprazan|Potassium-competitive acid blocker
219320764|NCT04907747|DRUG|Esomeprazole|Proton pump inhibitor
219320765|NCT04907747|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
219320766|NCT04907747|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
219320767|NCT04907747|DRUG|Furazolidone|Antibiotic for H. pylori eradication
219320768|NCT01306890|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
219320769|NCT05102084|DEVICE|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
219320770|NCT03219320|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
219320771|NCT03219320|DRUG|Placebo|Matching Placebo capsules.
219320772|NCT03774160|BEHAVIORAL|Generacion Actual|See description in arm description.
219320773|NCT00652392|DRUG|budesonide/formoterol|
219320774|NCT00652392|DRUG|budesonide and placebo|
219320775|NCT06475391|DIETARY_SUPPLEMENT|L-arginine|2 grams iof L-arginine will be ingested before an acute testing bout of exercise tasks in 250 mL of cranberry juice.
219320776|NCT06475391|DIETARY_SUPPLEMENT|Placebo|Placebo
219320777|NCT06104202|OTHER|Early Maladaptive Schemas|"Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory"
219320778|NCT04066803|DRUG|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
219320779|NCT04066803|DRUG|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
219320780|NCT04066803|DRUG|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
219320781|NCT01865396|BEHAVIORAL|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
219320782|NCT01865396|BEHAVIORAL|Standard oncologic care|Patients will receive standard oncologic care.
219320783|NCT00228397|DRUG|CCI-779|
219320784|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
219320785|NCT01135680|DRUG|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
219320786|NCT01135680|DRUG|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
219320787|NCT01135680|DRUG|Moxifloxacin|single oral 400-mg dose on study Day 3
219320788|NCT01135680|DRUG|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
219320789|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
219320790|NCT05137496|DRUG|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
219320791|NCT05137496|DRUG|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
219320792|NCT05222607|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
219320793|NCT04682171|OTHER|Low level laser therapy|"* Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~* Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~* On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
219320794|NCT04682171|OTHER|Conventional Exercise Therapy|"1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
219320795|NCT01940354|DEVICE|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
219320796|NCT01940354|DEVICE|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
219320797|NCT01538953|OTHER|handwashing|participants received weekly in-home handwashing promotion and soap as needed
219320798|NCT01538953|OTHER|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
219320799|NCT01538953|OTHER|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
219320800|NCT00002790|DRUG|cyclosporine|
219320801|NCT00002790|DRUG|methotrexate|
219320802|NCT00002790|DRUG|sirolimus|
219320803|NCT03872453|DRUG|Zavegepant|A single dose of zavegepant
219320804|NCT03872453|DRUG|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
219320805|NCT03872453|DEVICE|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
219320806|NCT00352885|DRUG|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
219320807|NCT00352885|DRUG|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
219320808|NCT00352885|DRUG|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
219320809|NCT03873493|DRUG|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
219320810|NCT03873493|DRUG|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
219320811|NCT00863109|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
219320812|NCT00863109|DRUG|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
219320813|NCT01616433|BEHAVIORAL|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
219320814|NCT01616433|BEHAVIORAL|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
219320815|NCT04123314|DRUG|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
219320816|NCT05185986|BEHAVIORAL|Home-Based Pilates exercise|The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.
219320817|NCT05185986|OTHER|Home-based Cognitive Rehabilitation|Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.
219320818|NCT05185986|OTHER|waiting list group|This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
219320819|NCT00696982|DRUG|sitagliptin|sitagliptin 100 mg once daily for 3 months
219320820|NCT00696982|DRUG|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
219320821|NCT06101953|BEHAVIORAL|Stress management|It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
219320822|NCT00256334|DRUG|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
219320823|NCT05048420|PROCEDURE|surgery|ACL reconstruction and RAMP lesion repair
219320824|NCT03592290|DIAGNOSTIC_TEST|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
219320825|NCT00440700|BEHAVIORAL|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
219320826|NCT00440700|BEHAVIORAL|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
219320827|NCT00440700|BEHAVIORAL|Control 2: Standard of Care|Usual ICU nursing care.
219320828|NCT05584228|DRUG|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
219320829|NCT05584228|PROCEDURE|Intestinal resection|Ileocolonic or small bowel resection
219320830|NCT05906342|OTHER|20% fat meal|Provided to participants once throughout duration of study, contains 20% fat
219320831|NCT05906342|OTHER|40% fat meal|Provided to participants once throughout duration of study, contains 40% fat
219320832|NCT05906342|OTHER|60% fat meal|Provided to participants once throughout duration of study, contains 60% fat
219320833|NCT05906342|OTHER|80% fat meal|Provided to participants once throughout duration of study, contains 80% fat
219320834|NCT00597077|OTHER|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
219320835|NCT00597077|OTHER|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
219320836|NCT02614534|DRUG|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
219320837|NCT02614534|PROCEDURE|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
219320838|NCT04767737|OTHER|Topically Administered Lavender Aromatherapy|3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
219320839|NCT04767737|OTHER|Topically Administered Water|3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
219320840|NCT02284048|DRUG|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
219320841|NCT02350179|DRUG|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
219320842|NCT02350179|DRUG|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
219320843|NCT01834196|DEVICE|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
219320844|NCT00142051|DRUG|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
219320845|NCT00142051|DRUG|oxygen|oxygen fi02 21% (room air)
219320846|NCT02106754|BEHAVIORAL|Brief Intervention|
219320847|NCT02106754|BEHAVIORAL|Brief Intervention with Coaching|
219320848|NCT02106754|BEHAVIORAL|Treatment as Usual|
219320849|NCT06787937|BEHAVIORAL|VLNC messages|Participants will be exposed to messaging about VLNCs and reduced nicotine policy through multiple formats, including inserts placed in cigarette packs, printed advertisements, and video materials presented during their weekly visits.
219320850|NCT06787937|BEHAVIORAL|Control message|Participants will be exposed to control messages, such as advertisements for bottled water, during their weekly visits.
219320851|NCT03739762|BEHAVIORAL|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
219320852|NCT03739762|OTHER|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
219320853|NCT05013853|PROCEDURE|Restoration teeth|Remove caries and restore with resin composite
219320854|NCT05737043|DIAGNOSTIC_TEST|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
219320855|NCT06335992|OTHER|Exercise regime|Exercise
219320856|NCT01695577|OTHER|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
219320857|NCT01695577|OTHER|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
219320858|NCT01873716|DRUG|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
219320859|NCT05925166|DRUG|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
219320860|NCT05925166|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
219320861|NCT06074003|OTHER|Seated Rest (Non-exercise control)|Sitting for 30 minutes
219320862|NCT06074003|OTHER|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
219320863|NCT04103697|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
219320864|NCT04103697|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
219320865|NCT04103697|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
219320866|NCT04103697|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
219320867|NCT04103697|PROCEDURE|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
219320868|NCT00765986|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
219320869|NCT00765986|OTHER|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
219320870|NCT02950402|OTHER|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
219320871|NCT02950402|OTHER|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
219320872|NCT00006036|DRUG|cisplatin|
219320873|NCT00006036|DRUG|lurtotecan liposome|
219320874|NCT06401564|DEVICE|Virtual Reality Therapy|Each participant will receive one or two 20 minute VR sessions during their admission. Participants are able to pause or discontinue at any time. During each VR session, participants will use the REAL Immersive VR system and be equipped with a VR headset and 6 sensors attached to the torso, waist, and upper extremities. Patient will then undergo various virtual challenges guided by the physical or occupational therapist facilitating movements of the upper extremity, core, head, and neck.
219320875|NCT06167603|DIAGNOSTIC_TEST|FDG-PET|Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.
219320876|NCT06167603|DIAGNOSTIC_TEST|Blood test and clinical examination.|baseline, 12-months and 24 months.
219320877|NCT04480060|DIAGNOSTIC_TEST|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
219320878|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid
219320879|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid.
219320880|NCT02080351|BEHAVIORAL|Simple cognitive task|
219320881|NCT02248948|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
219320882|NCT02248948|DIETARY_SUPPLEMENT|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
219320883|NCT02618005|DIETARY_SUPPLEMENT|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
219320884|NCT06603818|BIOLOGICAL|Tiragolumab|Tiragolumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
219320885|NCT06603818|BIOLOGICAL|Atezolizumab|Atezolizumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
219320886|NCT06603818|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will occur on Days 1, 3, and 5 of Cycle 1 only
219320887|NCT05759065|BEHAVIORAL|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
219320888|NCT05759065|BEHAVIORAL|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
219320889|NCT03819881|BIOLOGICAL|STMC-103H|Live bacterial product
219320890|NCT03819881|BIOLOGICAL|Placebo|Inactive placebo substance
219320891|NCT02079090|DRUG|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
219320892|NCT02079090|DRUG|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
219320893|NCT02294682|DRUG|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
219320894|NCT03010306|OTHER|CASITA|
219320895|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
219320896|NCT00162864|DRUG|montelukast sodium|
219320897|NCT05028725|DEVICE|EsophaCap Sponge|Non-invasive strategy to sample esophageal tissue
219320898|NCT05028725|PROCEDURE|Chromoendoscopy|Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus
219320899|NCT05028725|DEVICE|EsoCAN assay|Biomarker Test
219320900|NCT02461030|DRUG|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
219320901|NCT02461030|DRUG|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
219320902|NCT02461030|PROCEDURE|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
219320903|NCT04332224|DEVICE|Blanketrol cooling device and water-perfused blankets|Blanketrol and water-perfused blankets
219320904|NCT04332224|DEVICE|Blanketrol and Kool Kit|Blanketrol cooling device with water-perfused vest, hood and lower body blanket
219320905|NCT04332224|DEVICE|Arctic Sun|Arctic Sun cooling device with gel cooling pads
219320906|NCT00589498|DIETARY_SUPPLEMENT|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
219320907|NCT06548269|DIAGNOSTIC_TEST|Cardiologic work-up|Noninvasive prolonged ECG monitoring with a duration of 7 days measuring AF burden； Echocardiography measuring LA volume or volume index, LA diameter or diameter index； Cardiac CTA measuring LAA morphologies, cardiac thrombus.
219320908|NCT06629441|DIETARY_SUPPLEMENT|Probiotic group|taking 10 billion CFU probiotic one sachet one time, lasting 56 days.
219320909|NCT06629441|DIETARY_SUPPLEMENT|Placebo group|taking maltodaxtrin one sachet one time, lasting 56 days.
219320910|NCT00556153|DRUG|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
219320911|NCT04295980|PROCEDURE|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
219320912|NCT03329443|DRUG|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
219320913|NCT03329443|DRUG|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
219320914|NCT06414681|DRUG|Tagraxofusp|Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
219320915|NCT06414681|DRUG|Pacritinib|Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
219320916|NCT01978860|DEVICE|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
219320917|NCT02612051|DRUG|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
219320918|NCT02612051|DRUG|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
219320919|NCT02612051|RADIATION|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
219320920|NCT04914143|OTHER|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
219320921|NCT04914143|OTHER|placebo|the control group was treated with placebo after chemotherapy
219320922|NCT06267157|DEVICE|virtual reality training|Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
219320923|NCT06267157|OTHER|theoretical breastfeeding training|Classic 2-hour theoretical breastfeeding training with ppt
219320924|NCT02685553|DEVICE|NIR|Laparoscopic use of NIR
219320925|NCT00003181|BIOLOGICAL|aldesleukin|
219320926|NCT00003181|BIOLOGICAL|sargramostim|
219320927|NCT00003181|DRUG|vinblastine sulfate|
219320928|NCT01444014|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
219320929|NCT04866368|PROCEDURE|The ultrasound-guided Sacral Erector spinae plane block|postoperative pain procedure
219320930|NCT04866368|PROCEDURE|The dorsal penile block|postoperative pain procedure
219320931|NCT00005036|DRUG|irinotecan hydrochloride|Given IV
219320932|NCT00005036|DRUG|oxaliplatin|Given IV
219320933|NCT00005036|DRUG|leucovorin calcium|Given IV
219320934|NCT00005036|DRUG|fluorouracil|Given IV
219320935|NCT00005036|PROCEDURE|quality-of-life assessment|Ancillary studies
219320936|NCT03174418|PROCEDURE|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
219320937|NCT05880940|DEVICE|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
219320938|NCT05880940|BEHAVIORAL|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
219320939|NCT02224599|BIOLOGICAL|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
219320940|NCT02224599|DRUG|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
219320941|NCT02224599|DRUG|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
219320942|NCT06007742|OTHER|parent-administered pediatric tuina|"Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention."
219320943|NCT00174590|DRUG|risperidone|
219320944|NCT05197036|PROCEDURE|Total Knee Arthroplasty|A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
219320945|NCT04922463|DEVICE|PLASOMA|Treatment with cold plasma device
219320946|NCT00238550|DRUG|Cannabis based medicine extract (CBME)|
219320947|NCT00868426|DRUG|Budesonide/Formoterol Batch 1|Single, inhaled dose
219320948|NCT00868426|DRUG|Budesonide/Formoterol Batch 2|Single, inhaled dose
219320949|NCT00868426|DRUG|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
219320950|NCT03410849|DIAGNOSTIC_TEST|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
219320951|NCT04973020|DRUG|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
219320952|NCT00733304|DRUG|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
219320953|NCT01187550|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.
219320954|NCT02041260|DRUG|Cabozantinib|
219320955|NCT00129623|DRUG|Placebo|po monthly for 1 year
219320956|NCT00129623|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
219320957|NCT01619111|DRUG|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
219320958|NCT01619111|DRUG|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib~\+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
219320959|NCT03155373|DIAGNOSTIC_TEST|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
219320960|NCT03155373|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
219320961|NCT03155373|DIAGNOSTIC_TEST|Pulmonary function tests|Pre and post-operative pulmonary function tests
219320962|NCT03155373|DIAGNOSTIC_TEST|Cardiac MRI|Pre and post-operative cardiac MRI
219320963|NCT03155373|OTHER|Quality of life survey|Pre and post-operative quality of life survey (SF36)
219320964|NCT03155373|PROCEDURE|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
219320965|NCT03155373|PROCEDURE|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
219320966|NCT01855698|OTHER|Observation|
219320967|NCT05805943|DRUG|IMM0306|IMM0306 is an bi-specific antibody
219320968|NCT04498208|BEHAVIORAL|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome \& Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
219320969|NCT04498208|BEHAVIORAL|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
219320970|NCT04498208|BEHAVIORAL|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
219320971|NCT04498208|BEHAVIORAL|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
219320972|NCT00117546|DRUG|alpha methyldopa|500 mg twice a day
219320973|NCT02616614|DRUG|Onexton|Topical gel for treating acne
219320974|NCT02616614|DRUG|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
219320975|NCT02616614|DRUG|Placebo|Vehicle gel used as a placebo
219320976|NCT01085617|BIOLOGICAL|palifermin|
219320977|NCT01085617|BIOLOGICAL|rituximab|
219320978|NCT01085617|DRUG|cyclophosphamide|
219320979|NCT01085617|DRUG|cytarabine|
219320980|NCT01085617|DRUG|daunorubicin hydrochloride|
219320981|NCT01085617|DRUG|etoposide|
219320982|NCT01085617|DRUG|fludarabine phosphate|
219320983|NCT01085617|DRUG|imatinib mesylate|
219320984|NCT01085617|DRUG|melphalan|
219320985|NCT01085617|DRUG|mercaptopurine|
219320986|NCT01085617|DRUG|methotrexate|
219320987|NCT01085617|DRUG|nelarabine|
219320988|NCT01085617|DRUG|pegaspargase|
219320989|NCT01085617|DRUG|vincristine sulfate|
219320990|NCT01085617|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
219320991|NCT01085617|RADIATION|total-body irradiation|
219320992|NCT06849388|BEHAVIORAL|Heart Math program|Heart Math program is behavior intervention through several sessions
219320993|NCT05258435|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
219320994|NCT03927040|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
219320995|NCT05178134|BIOLOGICAL|Etvax|"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."
219320996|NCT05178134|BIOLOGICAL|Etvax|Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
219320997|NCT00596934|DRUG|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
219320998|NCT01978795|OTHER|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
219320999|NCT01978795|OTHER|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
219321000|NCT04638959|OTHER|collect gastric tissue and stool samples|collect gastric tissue and stool samples
219321001|NCT06411938|OTHER|Self-collection of vaginal swabs|Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
219321002|NCT03008954|DEVICE|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
219321003|NCT03008954|DIETARY_SUPPLEMENT|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
219321004|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
219321005|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
219321006|NCT03239483|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
219321007|NCT03239483|DRUG|Placebo gel|Universal HEC placebo gel; administered rectally
219321008|NCT05090371|DRUG|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
219321009|NCT05090371|DRUG|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
219321010|NCT06000423|DRUG|Tranexamic acid|1300mg TXA taken three times per day for five days
219321011|NCT06000423|OTHER|Placebo|Placebo pills taken three times daily for five days.
219321012|NCT06155331|DRUG|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
219321013|NCT06155331|OTHER|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
219321014|NCT06155331|DRUG|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
219321015|NCT06155331|DRUG|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
219321016|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
219321017|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
219321018|NCT05250908|DEVICE|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
219321019|NCT05250908|DEVICE|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
219321020|NCT04331054|DRUG|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
219321021|NCT04331054|OTHER|1: Usual practice|Usual practice
219321022|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
219321023|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
219321024|NCT05586360|DRUG|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
219321025|NCT06804928|BEHAVIORAL|Virtual Reality Glasses|During the procedure, the patient will wear virtual reality glasses and watch a video. The video will be played through the virtual reality glasses throughout the entire procedure.
219321026|NCT04951154|OTHER|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
219321027|NCT04951154|OTHER|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
219321028|NCT05602948|BEHAVIORAL|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation (see Move \& Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
219321029|NCT05602948|BEHAVIORAL|'Move & Learn' intervention|"The physical activities in Move \& Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
219321030|NCT05466123|BEHAVIORAL|Virtual Reality|Simulated travel destination or activity of the participants choosing that would otherwise be inaccessible
219321031|NCT05538273|OTHER|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
219321032|NCT05538273|OTHER|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
219321033|NCT02885090|PROCEDURE|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
219321034|NCT01214187|DRUG|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
219321035|NCT01214187|OTHER|Oxygen|Room air oxygen concentrations will be administered as placebo
219321036|NCT04011228|DIAGNOSTIC_TEST|Blood sampling|After a fasting period over night blood samples will be taken.
219321037|NCT04011228|DIAGNOSTIC_TEST|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
219321038|NCT04011228|DIAGNOSTIC_TEST|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
219321039|NCT01584154|PROCEDURE|cryoablation|cryoablation with an 8mm-tip catheter
219321040|NCT01584154|PROCEDURE|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
219321041|NCT02724124|OTHER|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
219321042|NCT02724124|OTHER|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
219321043|NCT02724124|OTHER|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
219321044|NCT02724124|OTHER|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
219321045|NCT02724124|OTHER|Control|No intervention
219321046|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 200 mg of bosutinib
219321047|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
219321048|NCT01233869|DRUG|Placebo|Once daily oral dose of placebo
219321049|NCT04287842|DRUG|Desflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
219321050|NCT04287842|DRUG|Sevoflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
219321051|NCT04287842|PROCEDURE|Cardiac arrest|Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
219321052|NCT06494020|OTHER|Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)|Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
219321053|NCT05264428|DIETARY_SUPPLEMENT|Honey|Participants need to drink honey every day for four weeks.
219321054|NCT05264428|DIETARY_SUPPLEMENT|Water|Participants need to drink water every day for four weeks.
219321055|NCT03678103|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
219321056|NCT02887937|DRUG|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
219321057|NCT00537485|DRUG|SPM 962|transdermal application, 1 time per day
219321058|NCT00537485|DRUG|placebo|transdermal application, 1 time per day
219321059|NCT02315677|DEVICE|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
219321060|NCT02315677|DEVICE|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
219321061|NCT00486798|DRUG|Quetiapine|
219321062|NCT00486798|PROCEDURE|Rating Scales|
219321063|NCT00486798|PROCEDURE|Self Assessment Form|
219321064|NCT00486798|PROCEDURE|Blood and urine samples|
219321065|NCT00486798|PROCEDURE|Sleeping pattern|
219321066|NCT00650065|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
219321067|NCT00650065|DRUG|Zyrtec® Tablets 10 mg|10mg, single dose fasting
219321068|NCT05614310|OTHER|Magnetic Resonance Imaging (MRI)|Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.
219321069|NCT05614310|OTHER|Blood Glucose Assessment|A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg/dl (3.9-6 mmol/L). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.
219321070|NCT05614310|OTHER|Positron Emission Tomography (PET)|Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.
219321071|NCT05614310|OTHER|Cognitive Assessment|Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.
219321072|NCT03165539|DEVICE|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
219321073|NCT05645835|BEHAVIORAL|intervention|the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.
219321074|NCT05645835|BEHAVIORAL|waitlist control|Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
219321075|NCT05645835|OTHER|No Interventions|No intervention. Only baseline fMRI and EEG assessment.
219321076|NCT01260727|BIOLOGICAL|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
219321077|NCT01260727|BIOLOGICAL|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
219321078|NCT01260727|BIOLOGICAL|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
219321079|NCT01260727|BIOLOGICAL|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
219321080|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
219321081|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
219321082|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
219321083|NCT00930514|DRUG|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
219321084|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
219321085|NCT01241552|BIOLOGICAL|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
219321086|NCT01241552|BIOLOGICAL|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
219321087|NCT01241552|BIOLOGICAL|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
219321088|NCT01241552|BIOLOGICAL|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
219321089|NCT01241552|DRUG|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
219321090|NCT01264367|DRUG|Clevudine|30mg,QD
219321091|NCT01264367|DRUG|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
219321092|NCT03240913|BEHAVIORAL|Baseline and Follow-up Surveys|(completed online)
219321093|NCT03240913|OTHER|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
219321094|NCT03240913|OTHER|Pamphlet|(usual care)
219321095|NCT02478723|DEVICE|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
219321096|NCT04359875|BEHAVIORAL|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~* How are you doing? (with a Likert scale from 1=very bad to 10=very well)~* Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~* Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
219321097|NCT06227208|DEVICE|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
219321098|NCT04464265|OTHER|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
219321099|NCT04357145|OTHER|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
219321100|NCT04357145|OTHER|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
219321101|NCT02323633|DEVICE|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
219321102|NCT02323633|DEVICE|Sham|No transcranial Pulsed Current Stimulation (tPCS)
219321103|NCT03892512|DRUG|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
219321104|NCT03892512|DRUG|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
219321105|NCT01782079|DIETARY_SUPPLEMENT|L. brevis|
219321106|NCT05882097|OTHER|Transform program|International Care Ministries' (ICM) Transform is a 15-lesson, 15-week long values, health, and livelihood program that targets some of the poorest households in Uganda. The health dimension focuses on increasing health knowledge and behaviours on a range of health topics such as malnutrition, respiratory infection, lifestyle, sanitations, family planning and infant care. The livelihood dimension focuses on increasing the amount and sources of household income. Participants will learn about business ideas and farming techniques to diversify their income sources. Additionally, a savings group will be formed at the end of Transform to promote a sustainable strategy to reduce poverty among the participants. The values dimension will focus on relationships, personal character and decision making aspects of an individual.
219321107|NCT01538797|DRUG|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
219321108|NCT01538797|DRUG|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
219321109|NCT01271803|DRUG|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
219321110|NCT01271803|DRUG|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
219321111|NCT00162890|BEHAVIORAL|Therapeutic exercise|
219321112|NCT03428074|PROCEDURE|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
219321113|NCT03938077|DEVICE|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
219321114|NCT04822623|DIAGNOSTIC_TEST|MRI|MRI examination
219321115|NCT03931733|OTHER|Music Therapy|Single thirty minute receptive music therapy intervention.
219321116|NCT05332405|DRUG|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
219321117|NCT02160704|DRUG|Enclomiphene citrate|25 mg daily for 16 weeks
219321118|NCT02160704|OTHER|Placebo|placebo daily for 16 weeks
219321119|NCT01339741|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
219321120|NCT01339741|DRUG|Placebo|Placebo, oral route, 12 weeks
219321121|NCT02616523|DRUG|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
219321122|NCT02616523|DRUG|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
219321123|NCT02616523|OTHER|placebo|The participants will be given infusion of normal saline intravenously.
219321124|NCT02616523|DRUG|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
219321125|NCT02178553|DRUG|Epidural|
219321126|NCT02178553|DRUG|Intercostal Bupivicaine (Exparel)|
219321127|NCT05089409|DRUG|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
219321128|NCT05089409|DRUG|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
219321129|NCT05089409|DRUG|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
219321130|NCT05089409|DRUG|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
219321131|NCT05089409|DRUG|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
219321132|NCT05089409|OTHER|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
219321133|NCT01394471|DRUG|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
219321134|NCT03283280|OTHER|Ever X Posterior|Resin composite restoration can be made as a direct onlay
219321135|NCT02099903|DEVICE|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
219321136|NCT02583035|OTHER|Nurse telephone contact|Nurse will contact patient 3 days before consultation
219321137|NCT03558022|DIETARY_SUPPLEMENT|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
219321138|NCT03558022|DIETARY_SUPPLEMENT|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
219321139|NCT00154076|DRUG|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
219321140|NCT00154076|DRUG|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
219321141|NCT06137222|DEVICE|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
219321142|NCT06137222|OTHER|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
219321143|NCT05432869|OTHER|ES and lifestyle advices|"The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs."
219321144|NCT05432869|OTHER|Lifestyle advices|The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
219321145|NCT04008758|DIAGNOSTIC_TEST|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
219321146|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with hysterectomy|After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.
219321147|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with cervical amputation|After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
219321148|NCT02512198|BEHAVIORAL|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
219321149|NCT01483833|DRUG|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
219321150|NCT01483833|DRUG|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
219321151|NCT02471950|PROCEDURE|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
219321152|NCT03461874|BEHAVIORAL|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
219321153|NCT03461874|BEHAVIORAL|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
219321154|NCT03461874|DRUG|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
219321155|NCT06360809|BEHAVIORAL|Prehabilitation exercise program|After the allocation, the intervention will consist of a prehabilitation program lasting 4 weeks. Each week, there will be three sessions, with one being face-to-face and the other two being unsupervised sessions but with online video-support. Face-to-face sessions will be organized in small groups, and each patient of the PEP group will have an individualized plan based on data obtained during the initial assessment. Each session will include a combination of strength training and moderate aerobic training in a circuit format with movements especially involving the upper body.
219321156|NCT04423913|OTHER|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
219321157|NCT00201435|DRUG|Paclitaxel weekly in combination with capecitabine|
219321158|NCT00201435|DRUG|Docetaxel every 3 week in combination with capecitabine|
219321159|NCT02642484|DRUG|Gabapentin|Gapapentin twice daily
219321160|NCT02642484|DRUG|Calcium Carbonate|calcium carbonate twice daily
219321161|NCT01463384|DRUG|Minocycline|50mg, twice daily for 6 months.
219321162|NCT01521819|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
219321163|NCT01521819|DRUG|Lucentis|Intravitreal injection of Lucentis as needed.
219321164|NCT04202250|PROCEDURE|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
219321165|NCT04202250|PROCEDURE|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
219321166|NCT01839721|DRUG|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
219321167|NCT01839721|OTHER|placebo|
219321168|NCT01251120|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
219321169|NCT01251120|DRUG|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
219321170|NCT01922479|DRUG|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
219321171|NCT01922479|DRUG|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
219321172|NCT04989699|DRUG|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
219321173|NCT04989699|DRUG|Aflibercept/Sham|Aflibercept administered every 8 weeks
219321174|NCT01822522|DRUG|Cabozantinib S-malate|Given PO
219321175|NCT01822522|OTHER|Laboratory Biomarker Analysis|Correlative studies
219321176|NCT01822522|OTHER|Pharmacological Study|Correlative studies
219321177|NCT04081584|DEVICE|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
219321178|NCT00006159|BEHAVIORAL|lifestyle (exercise, diet, and family and community support)|
219321179|NCT02877940|DEVICE|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
219321180|NCT02877940|DEVICE|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
219321181|NCT02877940|DEVICE|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
219321182|NCT02821468|DRUG|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
219321183|NCT02821468|DRUG|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
219321184|NCT03605563|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
219321185|NCT03605563|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
219321186|NCT00372749|BEHAVIORAL|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
219321187|NCT05212896|DRUG|BC006|BC006 monoclonal antibody injection
219321188|NCT01561781|DRUG|Digoxin|Oral tablets 0.25mg, single dose
219321189|NCT01561781|DRUG|Vandetanib|Oral tablets, 300 mg, single dose
219321190|NCT01807923|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
219321191|NCT01807923|DRUG|Ivacaftor|Film-coated tablet
219321192|NCT01807923|DRUG|Placebo|Matching placebo tablet
219321193|NCT02403622|DRUG|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
219321194|NCT00890929|DRUG|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
219321195|NCT00890929|DRUG|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
219321196|NCT01605981|DRUG|AMN107|
219321197|NCT04231136|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
219321198|NCT04231136|DRUG|EAPA115|EAPA115
219321199|NCT04231136|DRUG|RAPA115|RAPA115
219321200|NCT01473316|DRUG|GDC-0980|Single oral dose
219321201|NCT01473316|DRUG|Ketoconazole|Repeating Oral Dose
219321202|NCT01768988|DRUG|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
219321203|NCT01768988|DRUG|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
219321204|NCT02558231|DRUG|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
219321205|NCT02558231|DRUG|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
219321206|NCT02558231|DRUG|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
219321207|NCT00004239|DRUG|Compound 506U78|
219321208|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
219321209|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
219321210|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
219321211|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
219321212|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
219321213|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
219321214|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
219321215|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
219321216|NCT05757115|BEHAVIORAL|Play Skills Training|"Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised."
219321217|NCT02033603|DRUG|Ropivacaine|30mls of 0.5% ropivacaine
219321218|NCT00565942|PROCEDURE|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
219321219|NCT00565942|PROCEDURE|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
219321220|NCT06396793|OTHER|no intervention because it is an observational study|it is an observational study thus there is no intervention
219321221|NCT05231486|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
219321222|NCT04509960|DEVICE|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
219321223|NCT01464229|DRUG|Iloperidone|Iloperidone 1-8 mg for 4 weeks
219321224|NCT01464229|DRUG|Placebo|Placebo
219321225|NCT01249820|DRUG|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
219321226|NCT01249820|DRUG|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
219321227|NCT04233164|DRUG|Solu-Medrol 1mg/kg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
219321228|NCT04233164|DRUG|Solu-Medrol 250 mg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
219321229|NCT01840605|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
219321230|NCT01840605|DRUG|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
219321231|NCT00399451|DRUG|Polidocanol Sclerotherapy|
219321232|NCT01326195|BEHAVIORAL|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
219321233|NCT01326195|BEHAVIORAL|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
219321234|NCT04561804|PROCEDURE|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
219321235|NCT03553654|DIAGNOSTIC_TEST|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
219321236|NCT01750541|DRUG|Haloperidol|
219321237|NCT01750541|DRUG|Valproate|
219321238|NCT04029961|OTHER|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
219321239|NCT04029961|OTHER|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
219321240|NCT01167751|BIOLOGICAL|MNC|Implantation of BM derived MNC
219321241|NCT01167751|BIOLOGICAL|AC 133|Implantation of BM derived AC133
219321242|NCT01167751|BIOLOGICAL|Control|Injection of cell carrier
219321243|NCT06409585|DIAGNOSTIC_TEST|68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR|200MBq of the above named radiotracer will be administered for PET-MR
219321244|NCT06409585|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 1 year follow-up
219321245|NCT06409585|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
219321246|NCT05739123|DRUG|Relugolix-Containing Product|Any relugolix-containing therapy
219321247|NCT05330455|DRUG|GSK3965193|GSK3965193 will be administered
219321248|NCT05330455|DRUG|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
219321249|NCT05330455|DRUG|Bepirovirsen|Bepirovirsen will be administered
219321250|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_B|Participants received 2 doses of 375\_B vaccine formulation by intramuscular injection in the non-dominant arm.
219321251|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_A|Participants received 2 doses of 375\_A vaccine formulation by intramuscular injection in the non-dominant arm.
219321252|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_B|Participants received 2 doses of 750\_B vaccine formulation by intramuscular injection in the non-dominant arm.
219321253|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_A|Participants received 2 doses of 750\_A vaccine formulation by intramuscular injection in the non-dominant arm.
219321254|NCT06965452|DEVICE|Spinal angiography and embolization/ Embozene Microspheres|"Once consent is obtained the patient will be scheduled for spinal angiography and embolization. The patient will undergo the procedure at North Shore University Hospital. After embolization the patient will be monitored in recovery for 5 hours and then discharged to home.~The primary objective of this study is to examine the safety and feasibility of trans arterial embolization of the facet joint using Embozene Microspheres for the treatment of back pain from facet arthropathy and osteoarthritis."
219321255|NCT06574893|OTHER|physical exercise|physical exercise
219321256|NCT05127434|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
219321257|NCT05127434|DRUG|mRNA-1345|Sterile liquid for injection
219321258|NCT04508478|BEHAVIORAL|Aerobic training|Aerobic training
219321259|NCT04508478|BEHAVIORAL|Resistance training|Resistance training
219321260|NCT04508478|BEHAVIORAL|Control physical exercise|Control physical exercise
219321261|NCT06081283|DRUG|Phenobarbital Sodium Injection|"\*This drug can only be selected as part of the intervention for the subgroup of patients with a Glasgow Coma Score of 8 or less.~Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day."
219321262|NCT06081283|DRUG|Levetiracetam|Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
219321263|NCT06081283|DRUG|Lacosamide Injectable Product|Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.
219321264|NCT06081283|DRUG|Valproate Sodium|Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day
219321265|NCT06081283|DRUG|Phosphenytoin|Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
219321266|NCT04725617|DRUG|Varenicline|Standard smoking cessation treatment.
219321267|NCT04725617|BEHAVIORAL|Smoking Cessation Counseling|Standard smoking cessation treatment
219321268|NCT04725617|BEHAVIORAL|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
219321269|NCT04725617|OTHER|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
219321270|NCT02170090|DRUG|Gemcitabine|Gemcitabine 1000mg/m2
219321271|NCT02170090|DRUG|Cisplatin|Cisplatin 25mg/m2
219321272|NCT02170090|DRUG|Capecitabine|Capecitabine 1250mg/m2
219321273|NCT05932251|DRUG|Metformin|All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
219321274|NCT03189043|DEVICE|Antimicrobial Surface|Antimicrobial Surface
219321275|NCT01507558|PROCEDURE|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
219321276|NCT04543604|BEHAVIORAL|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
219321277|NCT04543604|BEHAVIORAL|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
219321278|NCT02898311|DEVICE|immediate loading of posterior implants with chairside CAD-CAM composite crown|
219321279|NCT02789735|DEVICE|Active laser therapy|Laser therapy at predetermined sites
219321280|NCT02789735|DEVICE|Sham laser therapy|Sham therapy at predetermined sites
219321281|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
219321282|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
219321283|NCT02612025|BEHAVIORAL|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
219321284|NCT02767128|DRUG|Triferic|
219321285|NCT02767128|DRUG|Fer-In-Sol|
219321286|NCT02767128|DRUG|Shohl's solution|
219321287|NCT03398525|OTHER|usual care|usual care following local standard operational procedures
219321288|NCT03398525|OTHER|Musical intervention|Musical intervention using a marketed music program validated for music therapy
219321289|NCT06679205|BEHAVIORAL|Multidisciplinary and multimodal intervention|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of 2 parts: a 2-hour education session called Empowered Relief® and 2 1-hour pain neuroscience education sessions.~* Psychotherapy: The psychotherapy part consists of 1 group session of 1 hour, face-to-face and with groups of up to 15 people.~* Therapeutic exercise: The therapeutic exercise module consists of 3 sessions of 1 hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
219321290|NCT06679205|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
219321291|NCT04252287|DRUG|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
219321292|NCT04252287|DRUG|Placebo|Participants will receive matching placebo capsules orally once daily.
219321293|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
219321294|NCT00632398|BEHAVIORAL|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
219321295|NCT00632398|BEHAVIORAL|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
219321296|NCT01217216|BEHAVIORAL|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
219321297|NCT01217216|BEHAVIORAL|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
219321298|NCT05359965|DEVICE|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
219321299|NCT04612413|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
219321300|NCT04612413|OTHER|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
219321301|NCT06267521|OTHER|Healthy Minds Program|Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.
219321302|NCT06267521|OTHER|Sham Meditation Didactic Material|Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.
219321303|NCT06267521|DEVICE|Sham Stimulation in Lab|On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night
219321304|NCT06267521|DEVICE|Stimulation in Lab|Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
219321305|NCT06267521|DEVICE|MRI Scanner|Imaging protocol will include: structural T1-weighted and T2-weighted images, resting-state functional MRI, task-based functional MRI, and multi-shell diffusion weighted MRI, total scan time will be approximately 2 hours
219321306|NCT04452487|BEHAVIORAL|decisions of limitations and stop processing|Compliance of the modalities of decisions of limitations and stop processing
219321307|NCT05475652|OTHER|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
219321308|NCT05475652|OTHER|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
219321309|NCT01395979|BEHAVIORAL|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
219321310|NCT01395979|BEHAVIORAL|Supportive Psychotherapy|Eight weekly sessions
219321311|NCT01395979|BEHAVIORAL|Sexual Risk Reduction Intervention|Two weekly sessions.
219321312|NCT03523260|DEVICE|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
219321313|NCT01144767|BEHAVIORAL|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
219321314|NCT01144767|BEHAVIORAL|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
219321315|NCT01080677|DRUG|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
219321316|NCT01080677|DRUG|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
219321317|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
219321318|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
219321319|NCT05493085|PROCEDURE|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
219321320|NCT05493085|PROCEDURE|Caudal epidural injection|Single Caudal epidural injection
219321321|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
219321322|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
219321323|NCT01739153|OTHER|Dietary intervention: CHEESE (High cheese intake)|
219321324|NCT01739153|OTHER|Dietary intervention: MEAT (High Meat intake)|
219321325|NCT01739153|OTHER|Dietary intervention: CARB (High Carbohydrate intake)|
219321326|NCT01096134|BIOLOGICAL|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
219321327|NCT03719755|PROCEDURE|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
219321328|NCT03719755|PROCEDURE|Normal Saline|Cystoscopic distention media of normal saline
219321329|NCT05134051|DEVICE|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
219321330|NCT00617188|DRUG|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
219321331|NCT03230526|DRUG|[18F]DPA-714 PET scan|"One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24"
219321332|NCT04805554|OTHER|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
219321333|NCT05541432|OTHER|Supervised strength training (group 1)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of 10-12 repetitions at an intensity of \~70% of estimated 1 repetition maximum.
219321334|NCT05541432|OTHER|Supervised strength training (group 2)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of \~4-6 repetitions at an intensity of 85% of estimated one repetition maximum, with a warm-up set of 8 repetitions at their estimated 70% estimated one repetition maximum to attempt to match the volume performed in the other resistance training group.
219321335|NCT05541432|OTHER|Home exercise|Participants in this arm will complete twice-weekly upper and lower body exercises at home, focused on posture and balance. Participants will meet 1:1 with an exercise physiologist who will select and prescribe exercises. Participants will also be invited to attend twice monthly virtual exercise and education sessions.
219321336|NCT00473421|PROCEDURE|Barium Sulphate and Zirconium Oxide|
219321337|NCT01298518|DRUG|PF-04620110|5 mg of PF-04620110 given once daily
219321338|NCT01298518|DRUG|PF-04620110|2.5 mg of PF-04620110 given twice daily
219321339|NCT01298518|DRUG|Placebo|Matching placebo giving for 4 weeks
219321340|NCT02823808|DRUG|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
219321341|NCT02823808|DRUG|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
219321342|NCT04338555|PROCEDURE|Transcutaneous electrical acupoint stimulation|TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.
219321343|NCT05001854|DRUG|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
219321344|NCT05001854|DRUG|Placebo|100 μg every 6 hours of placebo per os
219321345|NCT00006380|BIOLOGICAL|monoclonal antibody muJ591|
219321346|NCT00006380|RADIATION|iodine I 131 monoclonal antibody muJ591|
219321347|NCT02273726|DRUG|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
219321348|NCT02273726|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
219321349|NCT05197751|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
219321350|NCT01301651|BEHAVIORAL|balance training|30 minute each time, 2 times per week for 6 weeks.
219321351|NCT05608902|OTHER|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
219321352|NCT02921204|OTHER|Vitamin D status|There is no intervention in this study
219321353|NCT01568645|DRUG|Carvedilol|
219321354|NCT01568645|DRUG|Imatinib|
219321355|NCT00628303|BIOLOGICAL|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
219321356|NCT00628303|OTHER|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
219321357|NCT03653533|DEVICE|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
219321358|NCT03653533|DEVICE|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
219321359|NCT03653533|DEVICE|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
219321360|NCT04093427|OTHER|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
219321361|NCT04547673|DIAGNOSTIC_TEST|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
219321362|NCT02129205|DRUG|PF-06650808|Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
219321363|NCT02129205|DRUG|PF-06650808|Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
219321364|NCT00184977|DRUG|N-acetylcysteine|
219321365|NCT00184977|DRUG|fluticasone propionate|
219321366|NCT05196672|BEHAVIORAL|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
219321367|NCT02877927|DRUG|Omadacycline|po tablets
219321368|NCT02877927|DRUG|Linezolid|po tablets
219321369|NCT02079012|BEHAVIORAL|10-week walking program|
219321370|NCT05447533|OTHER|Comprehensive geriatric assessment (CGA)|"Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe)."
219321371|NCT05447533|OTHER|Continued geriatric care|"Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured."
219321372|NCT05447533|OTHER|Faecal microbiota transplantation (FMT)|When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
219321373|NCT05447533|OTHER|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
219321374|NCT05743322|DEVICE|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
219321375|NCT03040310|OTHER|Back Rx program|The Back Rx program can be viewed via a smartphone app.
219321376|NCT05419843|OTHER|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
219321377|NCT03641105|DIAGNOSTIC_TEST|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
219321378|NCT03217149|DRUG|heliox combined with MV|heliox combined with MV is given to infant with ARDS
219321379|NCT03217149|DRUG|MV|MV is given to infant with ARDS
219321380|NCT02257216|OTHER|Vayarin®|Medical Food
219321381|NCT02257216|OTHER|Placebo|Cellulose
219321382|NCT02204566|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
219321383|NCT02626286|OTHER|HIV quarterly global care|
219321384|NCT06044844|DRUG|Tofacitinib|tofacitinib efficacy
219321385|NCT00361491|DRUG|SSR149415|
219321386|NCT00007813|BIOLOGICAL|filgrastim|
219321387|NCT00007813|DRUG|carboplatin|
219321388|NCT00007813|DRUG|cyclophosphamide|
219321389|NCT00007813|DRUG|etoposide|
219321390|NCT00007813|PROCEDURE|autologous bone marrow transplantation|
219321391|NCT00007813|PROCEDURE|peripheral blood stem cell transplantation|
219321392|NCT04411927|OTHER|assessment of postural stability|assessment of postural stability
219321393|NCT05686226|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
219321394|NCT05686226|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
219321395|NCT04312464|OTHER|non|no intervention
219321396|NCT04513704|DRUG|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
219321397|NCT02555696|DRUG|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
219321398|NCT02150330|DRUG|Dehydroepiandrosterone (DHEAS)|
219321399|NCT04237922|DRUG|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
219321400|NCT04237922|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
219321401|NCT04751760|BIOLOGICAL|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
219321402|NCT00851123|BEHAVIORAL|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
219321403|NCT00851123|BEHAVIORAL|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
219321404|NCT00650572|DRUG|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
219321405|NCT05777473|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
219321406|NCT05777473|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
219321407|NCT05777473|BEHAVIORAL|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
219321408|NCT01685424|DRUG|Etoricoxib|As per routine clinical practice in the United Kingdom
219321409|NCT01791647|DRUG|metformin 1500 mg|
219321410|NCT01791647|DRUG|myoinositol 1500 mg|
219321411|NCT03228758|PROCEDURE|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
219321412|NCT03457883|DEVICE|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
219321413|NCT03457883|DEVICE|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
219321414|NCT04118517|OTHER|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing \>50% of the protein.
219321415|NCT00261404|DRUG|TNFerade™|
219321416|NCT01974596|DIETARY_SUPPLEMENT|Probiotic tablets of Lactobacillus reuteri|
219321417|NCT01974596|DIETARY_SUPPLEMENT|Placebo tablets|
219321418|NCT00074022|BIOLOGICAL|GTI-2040|Given IV
219321419|NCT00074022|DRUG|docetaxel|Given IV
219321420|NCT00074022|OTHER|laboratory biomarker analysis|Correlative studies
219321421|NCT00074022|OTHER|pharmacological study|Correlative studies
219321422|NCT03342248|OTHER|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
219321423|NCT05306457|BIOLOGICAL|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
219321424|NCT00411281|DRUG|cytarabine|Given subcutaneously
219321425|NCT00411281|PROCEDURE|observation|No intervention
219321426|NCT02427880|DRUG|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
219321427|NCT02427880|DRUG|Furosemide and Hydrochlorothiazide Followed by Furosemide|
219321428|NCT05619224|OTHER|Neurodevelopmental stimulation + Oral stimulation|"Neurodevelopmental intervention seeks to reduce abnormal postures and movement patterns in premature infants, allowing them to experience physiological postures in flexion and receive sensory stimulation. To this is added oral stimulation.~These stimulations are performed on alternate days."
219321429|NCT05619224|OTHER|Oral stimulation|This intervention consists of performing a sensorimotor stimulation of oral structures: stimulating for 7 minutes perioral structures( cheeks, lips and jaw)intraoral structures for 5 minutes and in the last 3 minutes non-nutritive suction stimulation with pacifier or finger.
219321430|NCT06173193|BEHAVIORAL|Multicomponent exercise regimen|"A multicomponent exercise regimen applied is comprised of the step-aerobic and resistance training programs alternating every two weeks. The trainees participate in supervised training sessions 3 times a week for 8 months. Each session will include a 10-minutes warm-up, 30-minutes of effective training part and a 10-minutes period for cooling down.~Step-aerobic: The program includes accelerating and decelerating through forwards and sideways movements with stops and turns to music. The degree of difficulty of movements and steps as well as training intensity will be gradually increased by increasing the height of the step benches.~Resistance training: The participants will undergo a progressive resistance training program. Resistance training will emphasize training of following muscle groups: Quadriceps and hamstrings, hip abductors, adductors and extensors, and calf muscles. In addition to lower limb exercises, trunk and upper body exercises will be applied at intervals."
219321431|NCT06173193|BEHAVIORAL|Standard rehabilitative management|The treatments that will be provided to the members of a reference group represent the standard rehabilitative management for knee OA patients. The home exercises focus on functional exercises maintaining lower extremity flexibility and muscle function. The home exercises are instructed to be carried out three times a week, each work-out lasting 30 minutes.
219321432|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training via Just-In-Time Training (JITT) implementation strategy|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support."
219321433|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) implemented via usual training|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~Usual training involves (a) a one-day virtual training conducted by an IPT-AST expert prior to the beginning of the intervention, and (b) synchronous evidence-based supervision strategies."
219321434|NCT07128966|OTHER|Observation|This is non-interventional, observational only
219321435|NCT07129707|OTHER|Exercise testing|Each participant performs a constant work-rate exercise test (70% peak work rate) under the 4 experimental conditions (referred as arms).
219321436|NCT05167123|DRUG|Light cured tri-calcium silicate base material|TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
219321437|NCT04025567|DRUG|vancomycin|1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
219321438|NCT04435782|DRUG|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
219321439|NCT06824376|DEVICE|Manual acupuncture|After sterilisation, the sharp needles will be inserted into the deep tissue layers of acupoints. Acupuncturists will tried to elicit acupuncture de-qi sensation by the manual manipulation of needles. Within a 30-minute period, manual manipulation for each acupoint will last at least 10 seconds and wil repeated four times with intervals of 10-minute.
219321440|NCT06824376|DEVICE|Sham acupuncture|After sterilisation, Streitberger placebo needles with blunt tip will be used. It can be fixed on the surface of the sham points without piercing the skin. Within a 30-minute period, each point will undergo a simulated twisting motion of the needle for at least 10 seconds, and this will be repeated four times at 10-minute intervals.
219321441|NCT03672461|OTHER|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
219321442|NCT03672461|OTHER|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
219321443|NCT06744751|BIOLOGICAL|Fecal Microbiota Transplantation|Patients take the capsules twice daily, with a dose of 6 or 10 capsules per day, for a total of 6 days (72 or 120 capsules in total). Select the capsule dosage based on age. For children under 18 years old, take 10 capsules at a time. For adults aged 18 and above, take 6 capsules at a time. Both the FMT and placebo capsules are identical in appearance, size, color, form, weight, and taste, with the placebo containing starch as the main ingredient.
219321444|NCT06744751|DRUG|Placebo|Manufactured by the same company, the placebo capsules contain starch as the main ingredient and are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. They are administered twice daily, 6 or 10 capsules per dose (selected by age), for 6 days.
219321445|NCT06605534|BEHAVIORAL|LungTalk|Tailored lung screening intervention
219321446|NCT06605534|OTHER|Non-tailored lung screening|Non-tailored lung screening. It involves the addition of education to Social Determinants of Health (SDOH) screening and referral with patient navigation. Patients will be identified, and screened for SDOH needs using the UniteUs SDOH screener that is embedded in the Electronic Health Record (EHR), and connected to geographically-tailored resources (as described above under Arm 1). Participants will then be sent a non-tailored lung screening educational brochure via email to review that details lung cancer risk, lung screening facts, benefits, and potential harms. Within 48 hours, the Community Outreach and Engagement (COE) Patient Navigator will contact the patient to answer questions and provide navigation services as described above in Arm 1.
219321447|NCT05386784|DRUG|Raloxifene plus cholecalciferol|Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
219321448|NCT05386784|DRUG|Cholecalciferol|D3 oral base drop, 4 drops once daily (800 IU)
219321449|NCT06615544|DEVICE|Placement of indirect dental restoration|The newly developed dual-cure adhesive will be used for the placement of indirect restorations.
219321450|NCT06672705|PROCEDURE|Biopsy|Undergo biopsy
219321451|NCT06672705|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219321452|NCT06672705|PROCEDURE|Computed Tomography|Undergo PET/CT
219321453|NCT06672705|BIOLOGICAL|Epcoritamab|Given SC
219321454|NCT06672705|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219321455|NCT06673524|PROCEDURE|Group T (Transversus Abmoninis Plane Block)|TAP Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position, the ultrasound (USG) probe is placed in an oblique position lateral to the xiphoid process at the lower border of the rib cage. The rectus abdominis muscle and its posterior sheath are visualized above the transversus abdominis muscle. At this level, only the aponeurosis of the internal oblique muscle can be seen between the transversus and external oblique muscles. By applying some pressure and tilt to the probe, the image of the myofascial planes is better optimized. Using a 22-25G, 50-100 mm block needle, an in-plane technique is applied, advancing either medially to laterally or vice versa. In the fascial plane between the rectus abdominis and transversus abdominis or between the internal oblique and transversus abdominis muscles, 20 ml of 0.25% bupivacaine is injected. The same procedure is then applied to the opposite side.
219321456|NCT06673524|PROCEDURE|Group R (Rectus-Intercostal Fascial Plane Block)|Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
219321457|NCT07001046|OTHER|Mobile app-directed exercise program|The mobile app-guided exercise program initially asks the mother questions to collect information. These questions were about their motivation for exercise, the main exercise goal, and the area of focus in the exercise program
219321458|NCT07001046|OTHER|Traditional Abdominal Exercises|The traditional abdominal exercises program consisted of simple static abdominal exercises, graduated curl-ups, and corrected abdominal crunches with posterior pelvic tilting
219321459|NCT05319028|DRUG|Mivavotinib|oral tablet
219321460|NCT06033911|DEVICE|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information such as calories or the Nutrition Facts table through FoodFlip©
219321461|NCT06033911|DEVICE|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Canada's 'high-in' NS
219321462|NCT02126943|DRUG|Opsumit (macitentan)|10 mg tablets
219321463|NCT07129148|OTHER|Device: No specific devices|Routine doctor-patient interaction.
219321464|NCT07129148|OTHER|Device: CGM,CGM management platform|Wearable monitoring + CGM management platform-assisted administration
219321465|NCT07129148|OTHER|"Device: Professor Tang WeChat Mini-program"|Mini-program-assisted health management
219321466|NCT07129148|OTHER|"Device: CGM, Smart Bracelet, Professor Tang WeChat Mini-program"|Wearable monitoring + mini-program integrated management
219321467|NCT07128680|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219321468|NCT07128680|PROCEDURE|Bone Scan|Undergo bone scan
219321469|NCT07128680|PROCEDURE|Computed Tomography|Undergo CT
219321470|NCT07128680|DIETARY_SUPPLEMENT|Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01|Given PO
219321471|NCT07128680|BIOLOGICAL|Ipilimumab|Given IV
219321472|NCT07128680|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219321473|NCT07128680|BIOLOGICAL|Nivolumab|Given IV
219321474|NCT04693351|DRUG|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
219321475|NCT04693351|DRUG|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
219321476|NCT07130006|PROCEDURE|PENG and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect hyperechogenic iliopsoas notch and psoas tendon, between anterior inferior iliac spine and iliopubic eminence. Then needle needs to be inserted in-plane and 20mL of levobupivacaine 0.25% administered along the fascial plane. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Curvilinear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
219321477|NCT07130006|PROCEDURE|FN and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect both femoral artery and vein medial to it. Then needle needs to be inserted in-plane and 15mL of levobupivacaine 0.5% need to be administered underneath fascia iliaca, lateral to femoral nerve. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles, where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Linear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
219321478|NCT07130006|PROCEDURE|FIC peripheral nerve block with spinal anesthesia|Suprainguinal approach will be performed. At first, one needs to detect anterior inferior iliac spine, sartorius and internal oblique muscles creating a bow-tie. Deep circumflex iliac artery will be seen between transversus abdominis and iliacus muscle. Then needle needs to be inserted in-plane and 40mL of levobupivacaine 0.25% administered along the fascial plane so that fascia separates from iliacus muscle. The needle is inserted from caudal to cranial, to achieve the widest possible spread of local anesthetic under the fascia, to the cranial side, as this reaches both lateral femoral cutaneous nerve and femoral nerve. The spread of anesthetic will appear hypoechoic on ultrasound. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
219321479|NCT07130006|PROCEDURE|Fentanyl (IV) with spinal anesthesia|A total dose of 2 mcg/kg of fentanyl will be given to patients before positioning to spinal. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
219321480|NCT07128836|OTHER|proprioceptive training exercise and receive insole vibrator|The treatment for the participants in the experimental group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with in-sole vibrator, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
219321481|NCT07128836|OTHER|proprioceptive training exercise along with simple insoles without vibration|The treatment for the participants in the control group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with non-vibrating insole, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
219321482|NCT07128654|DRUG|CTL02|FDC tablet, single dose, oral administration
219321483|NCT07128654|DRUG|CTL0201|Nesina, tablet, single dose, oral administration
219321484|NCT07128654|DRUG|CTL0202|Jardiance, tablet, single dose, oral administration
219321485|NCT07130383|DRUG|MHB036C for Injection|Intravenous administration
219321486|NCT07130383|DRUG|MHB039A for Injection|Intravenous administration
219321487|NCT07128511|BEHAVIORAL|Multiple Inhalation Breathing Pattern|"This behavioral intervention involves a breathing pattern characterized by brief, rapid successive inhalations within each breath cycle. The timing of each short inhalation is coordinated with fast, cyclical auditory tones, providing a consistent rhythm for participants to follow. Visual cues are also displayed to reinforce the timing and sequence of breaths.~During training, participants first practice the breathing pattern without any cognitive task, followed by practice while performing the psychomotor vigilance task (PVT). The technique is then applied during the main experimental condition, where participants wear a chest wall force antagonistic device set at 25 cmH₂O to simulate the added work of breathing experienced underwater. The PVT lasts for 10 minutes, requiring participants to respond as quickly as possible to visual stimuli, allowing researchers to measure sustained attention and reaction time."
219321488|NCT07128511|BEHAVIORAL|Tactical Breathing Technique|"This behavioral intervention uses a slow, paced breathing cycle incorporating four distinct phases: inhale, hold, exhale, and hold. Each phase is precisely timed and synchronized with distinct auditory tones for inhalation, hold phase, and exhalation. Participants also receive visual cues to reinforce correct timing and ensure consistency throughout the exercise.~Training begins with participants practicing the breathing pattern without any cognitive task, followed by practice while completing the psychomotor vigilance task (PVT). The full experimental condition involves performing the 10-minute PVT while wearing a chest wall force antagonistic device set at 25 cmH₂O to simulate the restrictive breathing load experienced in underwater environments. The PVT requires quick responses to visual stimuli, allowing measurement of sustained attention and reaction time under load."
219321489|NCT06625697|BEHAVIORAL|Mindfulness Meditation|Participants will be instructed on how to wear the physiological monitoring equipment during the 14-unit mindfulness meditation curriculum. Participants will then complete 2-10 minute guided seated Equa training lessons on a laboratory smartphone device while physiological measures are tracked. After training lessons, a respiration biosignal feedback chart will appear on the smartphone screen. Participants will also complete a brief mindfulness survey before and after training lessons.
219321490|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 200J (® Zoll)|Cardioversion
219321491|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 360J (® Physio-Control)|Cardioversion
219321492|NCT07020507|OTHER|Product gel RV3895A|The product is applied twice a day to the scar(s) under study, avoiding all contact with natural orifices (and avoiding ingestion by children in the case of application to the hands in particular). The product is applied using a specific massage technique developed for the product and which is explained by the investigator at visit 1. The product is applied in sufficient quantity to cover the application area.
219321493|NCT07013383|BEHAVIORAL|"I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy Program"|The training program includes topics such as environmental pollution, recycling behaviors, and the protection of natural resources and ecosystems. In addition, the program incorporates activities such as games, puzzle, brainstorming sessions, and the creation of painted cloth bags.
219321494|NCT06875778|OTHER|Pelvic Floor Exercises|Low intensity Warm Up Pelvic Floor Exercises and Cool down training
219321495|NCT06696430|BEHAVIORAL|Educational Intervention on TENS Usage|"Educational sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management."
219321496|NCT06696430|BEHAVIORAL|Nudging Intervention to Promote TENS Usage|Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
219321497|NCT07023822|DEVICE|Hyaluronic acid (HLA) Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
219321498|NCT07023822|DEVICE|Polycarbophil Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
219321499|NCT07023822|BEHAVIORAL|Hypnotic Relaxation|Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.
219321500|NCT07023822|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Listen to PMR audio file at least 3x/week for weeks 3-8.
219321501|NCT07030699|DRUG|Epcoritamab|Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12
219321502|NCT07030699|DRUG|Lenalidomide|Oral, daily on days 1-21 of a 28-day cycle
219321503|NCT07030699|DRUG|Tafasitamab|Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12
219321504|NCT07130747|OTHER|Myofascial release|The study involves women in both groups receiving myofascial release technique for twenty minutes three times per week for eight weeks. The technique requires the patient's skin to be dry and not oily, and all techniques must be applied at the barrier of tissue resistance. The technique involves gentle, sustained pressure held at the barrier for at least five minutes to allow the patient to respond to the treatment and relax. The technique involves skin stretching and desensitization around the scar, using up and down, side-to-side, and circular maneuvers.
219321505|NCT07130747|OTHER|Deep friction massage|Women in both groups (C) will receive a deep friction massage three times a week for eight weeks, applying a fingertip pad perpendicularly to post-cesarean scar tissue, moving across the band and back-and-forth motion along the scar tissue's length.
219321506|NCT07130747|OTHER|Routine daily scar care advices|Each woman in all groups (A, B, and C) will receive full instructions for daily post-cesarean-section scar care. Weekly revision for post-cesarean-section scar care will conduct by the researcher
219321507|NCT07130890|DEVICE|Health for All Mobile health application|This interventional study is implemented by using Health for All Mobile health application among pregnant women in the intervention group and in the control group pregnant women were those who took the routine ANC contact . The effect of the intervention is mainly depend on the women themselves.
219321508|NCT07035730|DEVICE|Unilateral hip exoskeleton|Unilateral hip exoskeleton assisted gait training. Gait training will consist of overground walking with the exoskeleton SHAJA for 30-40 minutes.
219321509|NCT07035730|BEHAVIORAL|Conventional gait training|Conventional gait training will consist of overground walking without the exoskeleton SHAJA for 30-40 minutes.
219321510|NCT06602076|BEHAVIORAL|ECHO (Empowering Our Community & Health Outcomes)|Additive intervention design wherein study participants receive remotely-delivered standard smoking cessation support (i.e., behavioral support plus nicotine replacement therapy) and engage in community-serving volunteer activities.
219321511|NCT05571735|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
219321512|NCT05571735|BIOLOGICAL|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
219321513|NCT05571735|BIOLOGICAL|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
219321514|NCT06632847|OTHER|IMT based Resistance training|IMT with device group is trained twice daily, with the morning session and afternoon session. The intensity will increase progressively in this group, starting at 60% Maximal Inspiratory Pressure (MIP) and reaching 75% by the end of study. POSITION: Patient will be in sitting position. FREQUENCY: 4 TO 5 times per week. INTENSITY: 60 to 75% of MIP (gradually increment the load by 10%every 2 weeks to reach 75 to 80 %MIP). Time: 15 to 20 minutes.
219321515|NCT06632847|OTHER|Theraband Resistive training|IMT training is form of exercise designed to strengthen the muscle that are involve in inhalation, primarily the diaphragm and intercostal muscles. Thera-band resistive training perform twice daily, with morning and afternoon session. Training will be perform 3 times per week. POSITION: patient will be in standing position. INTENSITY: moderate intensity (black and green thera-band used to provide medium resistance). Time: 15 to 20 minutes
219321516|NCT06738277|DRUG|Bmab 1200 (Biosimilar Ustekinumab)|Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
219321517|NCT06894134|OTHER|Team-based learning|The intervention will include 4 two-hour modules assessing healthy diet, physical activity and screen time, regular sleep, and tobacco and alcohol use. Each module has specific learning objectives (attachment 1). The TBL is a structured active learning approach that fosters collaboration, critical thinking, and accountability. Each module will involve four key steps: (1) Preparation Phase, where students independently will review pre-class materials to build foundational knowledge; (2) Readiness Assurance Process (RAP), which assesses understanding through an individual quiz (iRAT), a team quiz (tRAT), and an instructor-led clarification session; (3) Application Activities
219321518|NCT06773117|DRUG|Susu Xiao'er Zhike Granules|Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
219321519|NCT06773117|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
219321520|NCT07059000|BIOLOGICAL|Kedrion IVIG 10%|(Intravenous) Human Normal Immunoglobulin (IVIg) 10%
219321521|NCT06752356|BIOLOGICAL|Immune globulin (human) 10% solution for intravenous administration|Kedrion intravenous immunoglobulin (IVIg) 10%
219321522|NCT06739356|DEVICE|Fetal Treatment arm (FETO Group)|Participants will undergo FETO surgery at at 27 weeks 0 days - 29 weeks 6 days gestation.Balloon insertion into the fetal trachea will be performed. This will be followed by weekly \\ ultrasound monitoring and MRI at 3 weeks following FETO insertion and removal of the balloon which will be performed at at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age
219321523|NCT06774404|DEVICE|Use of FreeStyle Libre 14 day Flash Glucose Monitoring System|Women with GDM in the intervention arm will use Flash Glucose Monitoring (FGM) from diagnosis until the end of pregnancy
219321524|NCT06774404|OTHER|No intervention|Only using SMBG
219321525|NCT05556954|PROCEDURE|Wound debridement|"Participant that are having usual care visits for management of diabetic foot ulcers will be enrolled into this study. The procedure is done as part of standard of care. Tissue from the samples will be analyzed for this study.~Aliquoting and Deoxyribonucleic acid (DNA) extraction will be done on the specimens. Bacterial DNA from biospecimens will be isolated, quantified, amplified, and sequenced."
219321526|NCT06889389|BEHAVIORAL|Education|The intervention consists of 20 minutes of pain neuroscience education, focused on concepts related to movement-related fear and the benefits of exercise for managing pain. Specific exercises, mentioned in the generic part of the procedure, will be discussed during this session. This intervention aims to modify the subjects' beliefs regarding exercises and their neck pain.
219321527|NCT06889389|OTHER|Excercise|The exercise intervention includes performance tests and variations of these tests used as exercises, such as the Closed Kinetic Chain Upper Extremity Stability Test, Single Arm Military Press, and Seated Medicine Ball Throw. Variations of these performance tests will be implemented, with adjustments made to the load or execution time until the participant reports a perceived fatigue of 4-6 (moderate to strong) on the modified Borg scale.
219321528|NCT06889389|OTHER|Placebo|The placebo intervention involves the application of a TENS device, which will be placed on the participant and kept turned off for 15 minutes. Subjects will be informed that the device is working at a very low intensity, too weak to be perceived. This intervention aims to simulate the experience of treatment without delivering any therapeutic effect.
219321529|NCT06890260|OTHER|Electroacupuncture combined with Microneedle Knife|The patient takes the supine position, the acupoints take bilateral Yingxiang acupoints and upper Yingxiang acupoints, the tip of the needle is stabbed obliquely towards the root of the nose for 5-10mm, to the extent that there is a feeling of soreness and distension in the nose, and perform the flat tonic and flat cathartic method, the waveform of electroacupuncture is selected as sparse and dense wave, the frequency is 2/100Hz, the strength of the current is taken as the degree that the patient can tolerate it, and the time of energizing is 30min; and then the patient takes the seated position, with his head hanging down low on the therapeutic pillow, and the therapeutic point of occipitocervical segment is selected, Then the patient is placed on the therapeutic pillow in a sitting position with the head hanging low, the treatment point of the occipitocervical segment is selected, the treatment point of the cervicothoracic junction is marked, and the micro-needle knife cuts and loose
219321530|NCT06890260|DRUG|Cetirizine hydrochloride tablets combined with nasal budesonide spray.|Cetirizine hydrochloride tablets (specification: 10mg\*24 tablets, Suzhou Sinochem Pharmaceutical Industry Co., Ltd., State Pharmaceutical License: H20030447) shall be given, 1 tablet daily. At the same time, nasal budesonide spray (specification: 64μg\*120 sprays, AstraZeneca Pharmaceuticals Co., Ltd, State Pharmaceutical License: J20090079) shall be used: the starting dose shall be 2 sprays in each nostril twice a day, and after 3 days, it shall be reduced to 1 spray in each nostril twice a day, and then changed to 1 spray once a day after 1 week, which shall be used as the maintenance dose. The dosage will be increased or decreased at the patient's discretion according to the symptomatic condition during the course of treatment for a total of 4 weeks of treatment and observation. No other drugs for allergic rhinitis will be used during the treatment period.
219321531|NCT06854718|BEHAVIORAL|Caregiver-Assisted Pain Coping Skills Training (CG-PCST)|Patient-caregiver dyads will receive five, forty-to-sixty-minute sessions over a six-to-eight-week period with a therapist to learn pain coping skills. These include training caregivers in strategies for assessing patient pain, including nonverbal pain behaviors (e.g., grimacing, bodily tension, labored breathing), which will become increasingly important as the patient's ability to express pain verbally decreases. The therapist will also train the caregiver to coach the patient in the use of the skills during activities that are challenging because of pain. We will focus on increasing positive patient-caregiver interactions and patient engagement in valued activities. Throughout the training, the therapist will help the patient and caregiver learn strategies for fostering regular home practice and application of the skills, identify challenges in using the skills, and find strategies for coping with challenges.
219321532|NCT05546554|DRUG|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
219321533|NCT05546554|DRUG|Placebo|Matching Placebo given orally
219321534|NCT07074392|DEVICE|Electrical Stimulation|Custom stimulator will deliver a 1hour stimulation protocol post-operatively at 20 Hz, with biphasic pulses (100 µs duration, 0-2mA amplitude range).
219321535|NCT07129733|OTHER|Oral hygiene bundle|Implementation of the standardized oral hygiene bundle, which consists of the following key components: Standardization of materials used during the oral hygiene procedure, standardization of oral hygiene frequency, training of nursing staff involved in patient care on proper oral hygiene practices, discontinuation of routine application of chlorhexidine oral solution, and implementation of a standardized oral hygiene technique.
219321536|NCT07128992|OTHER|Control visit interval|Study investigates whether it is safe to extend the interval of routine calendar-based follow-up visits from every 12 to every 24 months in patients with type 1 diabetes.
219321537|NCT07129941|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format
219321538|NCT07128784|OTHER|Aerobic exercise|continuous, moderate intencity aerobic exercise, 3 days a week, 30 minutes per day, 150/min per week for a total of 6 weeks
219321539|NCT07129668|BEHAVIORAL|Condition A|Condition A consists of performing the Finger Kazoo exercise without inducing oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, but without modifying tongue position, soft palate height, or pharyngeal wall expansion to increase the oropharyngeal space.
219321540|NCT07129668|BEHAVIORAL|Condition B|Condition B consists of performing the Finger Kazoo exercise with intentional oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, while simultaneously modifying tongue position, elevating the soft palate, and expanding the pharyngeal walls to increase the oropharyngeal space.
219321541|NCT07130357|DEVICE|Collagen Scaffold|The bioinductive collagen scaffold will be placed over the repair site and secured with soft tissue anchors.
219321542|NCT07130357|PROCEDURE|Achilles tendon repair|Upon diagnosis of an Achilles tendon rupture, the participant will receive a temporary slab and surgical repair will be scheduled, and the operation will be performed under general anaesthesia with the patient lying prone. The ruptured ends of the right Achilles tendon will be marked, and a 3 cm longitudinal skin incision will be made along the medial border of the tendon. A standardized end-to-end direct surgical repair using non-absorbable sutures in a 2-strand core in a krackow locking fashion will be performed. The surgical site will be closed in layers using 3-0 vicryl and 4-0 ethilon.
219321543|NCT07129057|OTHER|MBSR program|The MBSR program lasts eight consecutive weeks (two months), with group sessions lasting two and a half hours each and an intensive 8-hour full-day practice session. At each session, the participants receive audio tracks for daily home practice.
219321544|NCT07130526|DEVICE|Intravascular Lithotripsy (IVL) plus DCB|"The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries.~The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer.~An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue,"
219321545|NCT07130526|DEVICE|POBA plus DCB|Standard of Care
219321546|NCT07078500|DRUG|orelabrutinib combined with the Pola-R-CHP regimen|Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
219321547|NCT06470893|BEHAVIORAL|OCD-NET|OCD-NET is bibliotherapy with coaching and its content is reflective of standard care for OCD. OCD-NET is a self-paced intervention that participants complete entirely online with the support of an assigned individual therapist. Most participants complete this treatment in up to twelve weeks. On average, participants are expected to spend between one to five hours per week during the first half of treatment. In the second half of treatment when participants begin regular exposure and response prevention (ERP) exercises, participants are expected to spend about one hour per day.
219321548|NCT06902948|OTHER|upper limb function training|Intervention selection included stretching and mobilization exercise, strengthening exercise, electrical stimulation, acupuncture, functional or task specific training and mirror therapy.
219321549|NCT06902727|DEVICE|VR-based exercise bike|For the intervention group, participations exercised on an immersive VR-based exercise bike for one hour, twice per week, for 4 weeks. Participants in the control group were asked to maintain their usual routine after the baseline test for 4 weeks. Participants were scheduled separately coming to lab for the post-test after 4 weeks and all participants received the identical assessments in aforementioned physiological and psychological outcomes.
219321550|NCT06902727|OTHER|Usual routine|Participants were asked to maintain their usual activities, without engaging in any other physical activity intervention during the 4-week study period.
219321551|NCT06901843|COMBINATION_PRODUCT|Mobilizations Exercises|Group A was treated with mobilizations exercises for 40 minutes for 3 sessions per week for 6 weeks. Patients received hip mobilizations. Therapist perform anterior posterior glide, caudal glide, posterior anterior glide with abduction, flexion and lateral rotation in 3 sets with 10 repetitions .Mobilization grades were performed according to patients tolerance level with duration 30-second rest .Hip strengthening exercises were performed 3 sets with 10 repetition with hip abduction in side lying, hip extension in prone position, sideway walk, hip abduction in a stand up position.
219321552|NCT06901843|COMBINATION_PRODUCT|Closed Kinetic Chain Exercises|Group B was treated with Closed Kinetic Chain Exercises for 40 minutes for 3 sessions per week for 6 weeks. Closed kinetic chain exercises were performed with 5 minute break between each exercise. Leg press in horizontal position ,Stationary bicycling and Stairmaster climbing.
219321553|NCT06903507|DEVICE|RT-Comfort Mattress|This dedicated RT-Comfort Mattress was newly developed (patent pending) for increasing comfort without compromising radiotherapy treatment quality.
219321554|NCT06901557|COMBINATION_PRODUCT|Jing-Si Herbal Tea|The JSHT group will receive the standard medical treatment along with Jing-Si Herbal Tea, one packet daily for three months.
219321555|NCT06901557|COMBINATION_PRODUCT|Placebo|The UC group will receive standard medical treatment, with one placebo packet daily for three months.
219321556|NCT06901986|DIETARY_SUPPLEMENT|Montmorency tart cherry|Montmorency tart cherry 60ml per day for 6 weeks.
219321557|NCT06901986|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
219321558|NCT06902428|DRUG|HSK44459|HSK44459, bid p.o.
219321559|NCT06902428|DRUG|Placebo|Placebo, bid p.o.
219321560|NCT06902415|DEVICE|QDSA (Quantitative Digital Subtraction Angiography)|QDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.
219321561|NCT06902311|RADIATION|Breast Radiotherapy|The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).
219321562|NCT07092436|DEVICE|Robotic bilateral upper limb rehabilitation training|Bilateral upper limb rehabilitation using PhiCube, a modular robotic end-effector device with two motorized axes that can assist or resist patient movements. Treatment consists of 30 sessions over 3 months (3 sessions/week, 45 minutes each) combining motor training with gaming elements specifically designed for pediatric populations. The device's modular design allows customization for individual patient needs and bilateral coordination training. Sessions focus on improving range of motion, precision, dexterity, and movement fluidity through controlled, repetitive, high-intensity exercises in children aged 4-18 years with neuromotor disorders and developmental coordination disorder.
219321563|NCT00790465|DIETARY_SUPPLEMENT|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
219321564|NCT00790465|DIETARY_SUPPLEMENT|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
219321565|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
219321566|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
219321567|NCT07090642|OTHER|Digital escape room game|"Concurrent with the module training, the intervention group will be given the four-part escape room game M.E.R.C.I. The game's sections will be developed in parallel with the weekly topics of the disaster midwifery module training."
219321568|NCT06901856|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
219321569|NCT06901856|PROCEDURE|mEMR-L procedure|First, install the ligation device (provided by Jiangsu Gerrit) at the front end of the endoscope. After inserting the endoscope into the rectum, suck the lesion into the ligation device, release the ligator to ligate the lesion. Then, use a snare to resect the lesion below the ligator. Finally, uniformly suture the wound surface with metal clips.
219321570|NCT06902493|OTHER|No intervention|No intervention
219321571|NCT06902688|OTHER|ML-based intervention|A ML-based model will predict and identify participants that are at high-risk of receiving a targeted medication within three months after their hospital admission date.
219321572|NCT06901817|DRUG|Intraventricular Pemetrexed|Intraventricular injection of 30 mg pemetrexed via Ommaya reservoir, once every 4 weeks until disease progression.
219321573|NCT06901817|DRUG|Intraventricular Nivolumab|Intraventricular injection of 40 mg nivolumab via Ommaya reservoir, once every 4 weeks until disease progression.
219321574|NCT06901817|DRUG|Intraventricular Dexamethasone|Intraventricular injection of 5mg/2ml pemetrexed via Ommaya reservoir before injection of pemetrexed and nivolumab.
219321575|NCT06901518|DRUG|Galcanezumab-Gnlm|Subcutaneous injection
219321576|NCT07093463|DIETARY_SUPPLEMENT|Colon-delivered riboflavin|10 mg of colon-delivered riboflavin
219321577|NCT07093463|DIETARY_SUPPLEMENT|Conventional riboflavin|10 mg of conventional riboflavin
219321578|NCT07093463|OTHER|Microcrystalline Cellulose|10 mg microcrystalline cellulose
219321579|NCT06730646|BEHAVIORAL|Health effects|Participants in this arm will watch 3 short videos about the smoking-related diseases during the survey data collection.
219321580|NCT06730646|BEHAVIORAL|Tobacco industry manipulation|Participants in this arm will watch 3 short videos about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults during the survey data collection.
219321581|NCT06730646|BEHAVIORAL|Secondhand smoke|Participants in this arm will watch 3 short videos about the risks of secondhand smoke exposure during the survey data collection.
219321582|NCT06730646|BEHAVIORAL|Mentral health|Participants in this arm will watch 3 short videos about the effects of smoking on mental health during the survey data collection.
219321583|NCT06730646|BEHAVIORAL|Social acceptability|Participants in this arm will watch 3 short videos about how smoking is socially unacceptable in China during the survey data collection.
219321584|NCT06730646|BEHAVIORAL|Control|Participants in this arm will watch 3 short videos about drinking bottled water during the survey data collection. These messages display specific water products and describe hydration as a healthy activity.
219321585|NCT06907043|DRUG|EIK1004-001 (IMP1707-001)|PARP1 selective inhibitor
219321586|NCT06163404|DEVICE|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
219321587|NCT04667247|DRUG|FoTv|8 capsules three times a day for 14 consecutive days.
219321588|NCT04419766|OTHER|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
219321589|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
219321590|NCT07109024|DIAGNOSTIC_TEST|Generation of a comprehensive and single-lesion resistance profile|AI-supported image analysis of functional imaging (PET-CT) and previous imaging data and specialized molecular methods (next-generation sequencing) will be combined into a comprehensive resistance profile.
219321591|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
219321592|NCT04900792|DRUG|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
219321593|NCT04900792|DRUG|Pharmacological ascorbate|Intravenous ascorbate
219321594|NCT04900792|RADIATION|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
219321595|NCT04900792|DRUG|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
219321596|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
219321597|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
219321598|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
219321599|NCT05762523|BIOLOGICAL|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
219321600|NCT05867459|DIAGNOSTIC_TEST|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
219321601|NCT05867459|DIAGNOSTIC_TEST|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
219321602|NCT05867459|DIAGNOSTIC_TEST|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
219321603|NCT05867459|DIAGNOSTIC_TEST|Urine analysis|It is mirror of kidney
219321604|NCT05867459|DIAGNOSTIC_TEST|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
219321605|NCT05867459|DIAGNOSTIC_TEST|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
219321606|NCT05867459|OTHER|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm \> 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
219321607|NCT04206995|OTHER|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
219321608|NCT04206995|OTHER|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
219321609|NCT01444651|DRUG|Tadalafil|20 mg Tadalafil taken once a day for 3 months
219321610|NCT01444651|DRUG|Placebo|Placebo tablet taken by mouth once a day for 3 months
219321611|NCT06117371|DRUG|BEBT-607Tablets|"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."
219321612|NCT04727203|BEHAVIORAL|AHAA|Multi-component healthy lifestyle program
219321613|NCT03047551|PROCEDURE|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
219321614|NCT03047551|PROCEDURE|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
219321615|NCT05214417|DRUG|Ketamine Injectable Solution|2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
219321616|NCT05214417|OTHER|Naturalistic Control|Continuation of pre-existing conventional treatment
219321617|NCT00257829|DRUG|Methazolamide|
219321618|NCT00257829|DRUG|Cisplatin|
219321619|NCT06426043|DRUG|Lusutrombopag|Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×109/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
219321620|NCT00726622|PROCEDURE|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
219321621|NCT00726622|PROCEDURE|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
219321622|NCT05653323|DRUG|VX-993|Suspension for oral administration.
219321623|NCT05653323|DRUG|Placebo|Suspension for oral administration.
219321624|NCT05679284|RADIATION|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
219321625|NCT01388231|BEHAVIORAL|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
219321626|NCT01388231|BEHAVIORAL|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
219321627|NCT04311892|DIAGNOSTIC_TEST|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
219321628|NCT01462136|DRUG|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
219321629|NCT00237822|BEHAVIORAL|Adherence Feedback (AF)|
219321630|NCT00237822|BEHAVIORAL|AF + Contingency Management (AF + CM)|
219321631|NCT00237822|BEHAVIORAL|AF + Motivational Enhancement Therapy (AF + MET)|
219321632|NCT02462928|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
219321633|NCT02462928|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
219321634|NCT02462928|OTHER|Sham Procedure|Sham injection.
219321635|NCT02901496|BEHAVIORAL|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
219321636|NCT02901496|BEHAVIORAL|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
219321637|NCT02901496|BEHAVIORAL|No Exercise|Control to exercise
219321638|NCT02901496|DRUG|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
219321639|NCT02901496|DRUG|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
219321640|NCT02954146|BEHAVIORAL|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
219321641|NCT01493557|DRUG|pantoprazole|40 mg q.a.m, p.o.
219321642|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
219321643|NCT01493557|DRUG|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
219321644|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
219321645|NCT00314678|DRUG|Topotecan|
219321646|NCT00314678|DRUG|Cisplatin|
219321647|NCT00314678|DRUG|Paclitaxel|
219321648|NCT02941887|BEHAVIORAL|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
219321649|NCT03998176|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
219321650|NCT02656420|DRUG|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
219321651|NCT02656420|DRUG|Placebos|Placebo as comparison to broccoli sprout-derived beverages
219321652|NCT00335465|DRUG|Insulin glargine|once a daily, sc injection, 100IU/ml
219321653|NCT01640210|DEVICE|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
219321654|NCT01088464|BIOLOGICAL|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
219321655|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, every 2 weeks
219321656|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
219321657|NCT01508104|DRUG|BEZ235|dose escalation 400mg- 1000mg per day
219321658|NCT01508104|DRUG|Everolimus|dose escalation 2.5 to 5 mg per day
219321659|NCT01611948|DRUG|Aprepitant|125mg/day for 8 weeks
219321660|NCT01611948|DRUG|Placebo|125mg/d placebo pill for 8 weeks
219321661|NCT01611948|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
219321662|NCT03629236|OTHER|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
219321663|NCT03629236|OTHER|Control|Debridement, dressing application, standard compression therapy
219321664|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
219321665|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
219321666|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
219321667|NCT05713773|DRUG|coated beads glucose (8 g)|After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
219321668|NCT05713773|DRUG|uncoated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
219321669|NCT03018587|DEVICE|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
219321670|NCT05837182|PROCEDURE|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
219321671|NCT02791282|OTHER|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
219321672|NCT05199675|BEHAVIORAL|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
219321673|NCT03662139|OTHER|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
219321674|NCT04389190|OTHER|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
219321675|NCT06235814|PROCEDURE|Molecular Analysis for Thyroid Resection|"Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care."
219321676|NCT00749879|DRUG|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
219321677|NCT04824638|BIOLOGICAL|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
219321678|NCT04824638|BIOLOGICAL|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
219321679|NCT02967081|PROCEDURE|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
219321680|NCT01249430|DRUG|Azacitidine|Given IV
219321681|NCT01249430|DRUG|Cytarabine|Given IV
219321682|NCT01249430|DRUG|Etoposide Phosphate|Given IV
219321683|NCT01249430|OTHER|Laboratory Biomarker Analysis|Correlative studies
219321684|NCT01249430|DRUG|Mitoxantrone Hydrochloride|Given IV
219321685|NCT01249430|OTHER|Pharmacological Study|Correlative studies
219321686|NCT06359366|PROCEDURE|perineal massage combined hip joint training|pregnant women take the lithotomy position, disinfect the vulva, and wear sterile gloves. Then thumbs, forefingers, and middle fingers dip massage oil to do a 2 minutes pressurized dilatation massage from inside to outside gently to loosen the fascia. Then rest 30s. All steps need to be repeated 2 to 3 times. When the pregnant women feel a slight sense of acidity and tingling sensation disappears, researchers sterilize the perineal body again. left side pelvic floor receives the same intervention as right. The whole process takes 15-20min, 5 times a week until delivery. Additionally, while using the pelvic floor fascia manipulation, pregnant women are instructed to perform specific movements of internal and external hip rotation, adduction and abduction, upward and downward.
219321687|NCT01235559|DRUG|Placebo|Oral doses, once a day for 52 weeks
219321688|NCT01235559|DRUG|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
219321689|NCT01235559|DRUG|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
219321690|NCT02435108|DRUG|crizotinib|crizotinib 250mg bid daily
219321691|NCT00613353|OTHER|Behavioral|Participants will be asked to wear an accelerometer
219321692|NCT05670769|OTHER|Education|The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
219321693|NCT06460883|OTHER|eccentric cable leg curls|The players will undergo eccentric cable leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
219321694|NCT06460883|OTHER|eccentric banded leg curls|The players will undergo eccentric banded leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
219321695|NCT01453777|PROCEDURE|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
219321696|NCT01890148|DRUG|AZD5069|oral BD administration of 45 mg AZD5069
219321697|NCT01215175|BIOLOGICAL|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
219321698|NCT01215175|BIOLOGICAL|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
219321699|NCT01215175|BIOLOGICAL|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
219321700|NCT05732922|DEVICE|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
219321701|NCT06399874|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|A psychotherapy that uses exposure to nightmare images for trauma activation in order to facilitate trauma memory reconsolidation
219321702|NCT06399874|DEVICE|NightWare|Wristband device that detects physiologic signals during sleep that indicate a possible nightmare and gently vibrates to rouse the sleeper without fully waking them.
219321703|NCT01678209|OTHER|fMRI scans|2 fMRI scans 6-8 weeks apart
219321704|NCT01678209|DRUG|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
219321705|NCT01678209|DRUG|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
219321706|NCT05529823|BEHAVIORAL|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
219321707|NCT03840694|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
219321708|NCT03840694|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
219321709|NCT00256880|DRUG|GW786034|
219321710|NCT00350922|BEHAVIORAL|Psychoeducation|
219321711|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
219321712|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
219321713|NCT03527914|OTHER|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
219321714|NCT03527914|OTHER|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
219321715|NCT01882218|DRUG|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
219321716|NCT01882218|DRUG|Standard Treatment|Standard liver surgery.
219321717|NCT00656123|BIOLOGICAL|Colon GVAX|Dose escalation: 1.4x10\^8 to 7x10\^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
219321718|NCT00656123|DRUG|cyclophosphamide|200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
219321719|NCT00702845|DRUG|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
219321720|NCT00702845|DRUG|recFSH (follitropin beta)|150 IU recFSH SC injection
219321721|NCT00702845|DRUG|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
219321722|NCT00702845|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
219321723|NCT00702845|BIOLOGICAL|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
219321724|NCT00702845|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
219321725|NCT00702845|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
219321726|NCT00702845|BIOLOGICAL|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
219321727|NCT02973425|BEHAVIORAL|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience \& Suite of mHealth motivational tools and mini-games.
219321728|NCT02973425|BEHAVIORAL|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
219321729|NCT03538353|OTHER|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
219321730|NCT05276557|COMBINATION_PRODUCT|PyloPlus Urea Breath Test System|System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
219321731|NCT05276557|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patients' stool for H. pylori
219321732|NCT00338663|DEVICE|knee immobilization splint|
219321733|NCT01571765|OTHER|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
219321734|NCT03876171|BEHAVIORAL|Haitian youth family-based intervention study: family functioning|A weekly group therapy with the youth in presence of a parent or caretaker in the family.
219321735|NCT03876171|BEHAVIORAL|Haitian youth intervention study: youth psychoeducational|Weekly one and one psychoeducational module will be delivered to the youth.
219321736|NCT03876171|BEHAVIORAL|Haitian family-based intervention study: psychoeducational|Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.
219321737|NCT03876171|BEHAVIORAL|Diversion Programs|Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
219321738|NCT00459966|PROCEDURE|Preoperative rehabilitation|
219321739|NCT04321980|DRUG|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
219321740|NCT02112435|DEVICE|Somnyx ®|Active mandibular advancement splint
219321741|NCT02112435|DEVICE|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
219321742|NCT03431181|BEHAVIORAL|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
219321743|NCT03431181|BEHAVIORAL|Usual care|Patients in the control arm will receive usual care (as per local practices).
219321744|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
219321745|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
219321746|NCT03207113|BEHAVIORAL|Ned|Prostate cancer survivorship application.
219321747|NCT01170039|DRUG|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
219321748|NCT01170039|DRUG|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
219321749|NCT03763851|RADIATION|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
219321750|NCT03763851|RADIATION|Radiotherapy|Palliative RadioTherapy to the symptomatic site
219321751|NCT04328779|OTHER|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
219321752|NCT04328779|DEVICE|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
219321753|NCT04328779|OTHER|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
219321754|NCT02722876|OTHER|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
219321755|NCT02722876|OTHER|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
219321756|NCT00617136|DEVICE|Intraoperative warming (Bair Hugger)|Intraoperative warming
219321757|NCT00617136|DEVICE|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
219321758|NCT00617136|DEVICE|Intraoperative warming (HotDog)|Intraoperative warming
219321759|NCT06142760|RADIATION|MR-guided radiation|Dayly artifical intelligence-based treatment adaptation under weekly offline MR-guidance
219321760|NCT02338011|DRUG|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
219321761|NCT02338011|RADIATION|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
219321762|NCT00860951|DEVICE|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
219321763|NCT04312373|OTHER|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
219321764|NCT02645929|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
219321765|NCT06178965|PROCEDURE|Incisional Hernia Repair by Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|patients with incisional hernia will be operated by hernia reduction and sac closure followed by placement of onlay mesh after creating suitable flaps.
219321766|NCT00727649|DRUG|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
219321767|NCT00727649|DRUG|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
219321768|NCT01326208|PROCEDURE|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
219321769|NCT02921568|DEVICE|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
219321770|NCT02921568|DEVICE|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
219321771|NCT06198842|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
219321772|NCT03611283|OTHER|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
219321773|NCT03611283|OTHER|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
219321774|NCT03611283|OTHER|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
219321775|NCT03611283|OTHER|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
219321776|NCT01681810|DRUG|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
219321777|NCT05940922|OTHER|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
219321778|NCT01726244|BEHAVIORAL|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
219321779|NCT04558463|DRUG|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
219321780|NCT04558463|DRUG|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
219321781|NCT02931942|OTHER|blood withdrawn|venous blood sampling
219321782|NCT04030039|DRUG|Interferon|chronic hepatitis B patients with interferon therapy
219321783|NCT04030039|DRUG|nucleoside analogues|chronic hepatitis B patients with interferon therapy
219321784|NCT00385203|DRUG|AZD2171|45 mg oral tablet once daily dose
219321785|NCT04296279|DRUG|FMP014|Falciparum Malaria Protein-14
219321786|NCT04296279|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
219321787|NCT06466031|OTHER|MRI & PET fusion|MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.
219321788|NCT06466031|OTHER|MRI+T1C|MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
219321789|NCT03226314|PROCEDURE|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
219321790|NCT03420794|OTHER|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
219321791|NCT03823404|DRUG|COR388 capsule|BID (twice daily)
219321792|NCT03823404|DRUG|Placebo capsule|BID
219321793|NCT03035695|DEVICE|Axiostat®|
219321794|NCT03035695|DEVICE|Cotton Gauze|
219321795|NCT02529267|OTHER|Standard of care|
219321796|NCT05779202|OTHER|No intervention is planned.|No intervention is planned.
219321797|NCT04346498|OTHER|Chest-to-back|
219321798|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
219321799|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
219321800|NCT03383289|OTHER|R-REM training|three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
219321801|NCT02721745|BEHAVIORAL|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
219321802|NCT02721745|DEVICE|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
219321803|NCT02721745|DEVICE|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
219321804|NCT05068518|OTHER|No intervention|no intervention
219321805|NCT04652154|OTHER|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
219321806|NCT06489756|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
219321807|NCT02884726|DRUG|BMS-986148|Specified dose on specified days
219321808|NCT05717478|COMBINATION_PRODUCT|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
219321809|NCT05717478|DEVICE|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
219321810|NCT00832117|DRUG|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
219321811|NCT00832117|DRUG|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
219321812|NCT00832117|DRUG|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
219321813|NCT00832117|DRUG|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
219321814|NCT00264524|PROCEDURE|venipuncture to withdraw patient's blood|
219321815|NCT00498251|DRUG|inhalation of salbutamol (5 mg)|
219321816|NCT00498251|DRUG|ipratropium|
219321817|NCT02241291|PROCEDURE|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
219321818|NCT04008147|DIETARY_SUPPLEMENT|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
219321819|NCT04008147|DIETARY_SUPPLEMENT|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
219321820|NCT00644553|DRUG|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
219321821|NCT00644553|DRUG|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
219321822|NCT01668407|DEVICE|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
219321823|NCT01668407|PROCEDURE|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
219321824|NCT04571827|OTHER|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
219321825|NCT00044551|DRUG|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
219321826|NCT02709590|DRUG|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
219321827|NCT02709590|DRUG|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
219321828|NCT06388681|DEVICE|The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography|The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
219321829|NCT03100799|PROCEDURE|Arthroscopy|Arthroscopy of the target knee
219321830|NCT03100799|PROCEDURE|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
219321831|NCT03100799|DIAGNOSTIC_TEST|MRI|MRI with and without a gadolinium-based contrast agent
219321832|NCT00404066|DRUG|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
219321833|NCT00404066|DRUG|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
219321834|NCT00404066|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
219321835|NCT00404066|DRUG|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
219321836|NCT00404066|DRUG|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
219321837|NCT00404066|DRUG|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
219321838|NCT00404066|DRUG|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
219321839|NCT00404066|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
219321840|NCT03177616|OTHER|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports"
219321841|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
219321842|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
219321843|NCT00303420|DRUG|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
219321844|NCT00303420|DRUG|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
219321845|NCT01426516|DEVICE|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
219321846|NCT05197517|DRUG|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
219321847|NCT01524133|DRUG|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
219321848|NCT01524133|BEHAVIORAL|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
219321849|NCT04323839|OTHER|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
219321850|NCT04323839|OTHER|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
219321851|NCT05054595|BEHAVIORAL|Standard Pain Management|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
219321852|NCT05054595|BEHAVIORAL|Audio-Recorded Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
219321853|NCT05054595|BEHAVIORAL|Nurse-Led Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
219321854|NCT05740085|OTHER|Patient information form|Patients will be asked to fill out a patient information form and an osteoporosis awareness form
219321855|NCT06231576|OTHER|Prehabilitation|"* Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention."
219321856|NCT00862303|BIOLOGICAL|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
219321857|NCT00862303|DRUG|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
219321858|NCT01878643|DRUG|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
219321859|NCT01878643|DRUG|Placebo|normal saline administered to patient via nebulization
219321860|NCT04635683|DRUG|Lenalidomide|Given PO
219321861|NCT04635683|BIOLOGICAL|Ublituximab|Given IV
219321862|NCT04635683|DRUG|Umbralisib|Given PO
219321863|NCT05937633|OTHER|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
219321864|NCT05794750|DRUG|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
219321865|NCT05794750|PROCEDURE|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
219321866|NCT05794750|DRUG|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
219321867|NCT05794750|DRUG|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
219321868|NCT03619538|DRUG|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
219321869|NCT03619538|OTHER|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
219321870|NCT00786825|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
219321871|NCT01920945|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
219321872|NCT04311567|DRUG|Tofacitinib|Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
219321873|NCT04311567|DRUG|Methotrexate|Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
219321874|NCT05861687|DRUG|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
219321875|NCT05861687|DRUG|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg
219321876|NCT05861687|DRUG|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
219321877|NCT05861687|DRUG|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
219321878|NCT01156233|PROCEDURE|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
219321879|NCT01156233|PROCEDURE|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
219321880|NCT02722382|OTHER|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
219321881|NCT00759733|PROCEDURE|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
219321882|NCT00759733|PROCEDURE|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
219321883|NCT01002456|OTHER|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
219321884|NCT01002456|OTHER|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
219321885|NCT03152279|DIAGNOSTIC_TEST|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
219321886|NCT03152279|DIAGNOSTIC_TEST|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
219321887|NCT05821530|DEVICE|HFIT|At least 1 hour daily for 4 weeks
219321888|NCT05821530|DEVICE|TENS|At least 1 hour daily for 4 weeks
219321889|NCT05821530|OTHER|Control|Users will continue to use the digital MSK program as needed
219321890|NCT05050942|DRUG|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
219321891|NCT05050942|DRUG|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
219321892|NCT05050942|DRUG|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
219321893|NCT05802992|DRUG|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
219321894|NCT05802992|DRUG|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
219321895|NCT02136745|BEHAVIORAL|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
219321896|NCT03632109|DRUG|gentamicin 360mg IM|360mg IM of gentamicin
219321897|NCT00963833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
219321898|NCT00966823|DEVICE|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~\- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
219321899|NCT02885948|DRUG|Naloxone|used to block the effects of opioids, especially in overdose
219321900|NCT02885948|DRUG|Placebo|Placebo, ineffective control arm
219321901|NCT05575154|DEVICE|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
219321902|NCT00059839|DRUG|doxorubicin hydrochloride|Given IV
219321903|NCT00059839|DRUG|mercaptopurine|Given by mouth
219321904|NCT00059839|DRUG|methotrexate|Given IV and intrathecally
219321905|NCT00059839|DRUG|prednisone|Given by mouth
219321906|NCT00059839|DRUG|vinblastine sulfate|Given IV
219321907|NCT00059839|DRUG|vincristine sulfate|Given IV
219321908|NCT04888130|GENETIC|Phylogenetic Analysis|The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
219321909|NCT04888130|OTHER|Data collection|Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
219321910|NCT00807963|DRUG|rHuPH20|recombinant human hyaluronidase PH20 injection
219321911|NCT00807963|DRUG|zoledronic acid|subcutaneous injection
219321912|NCT00648089|DRUG|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
219321913|NCT01956734|PROCEDURE|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
219321914|NCT01969097|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
219321915|NCT01969097|BEHAVIORAL|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
219321916|NCT01693081|DRUG|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
219321917|NCT01693081|DRUG|placebo|
219321918|NCT04611438|DRUG|Cannabidiol|"Intervention schedule for each patient is as follows:~1. Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~2. Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~   * Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~  * Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~  * Maintenance: no change in medication dosage"
219321919|NCT03106181|DEVICE|iStent inject®|Insertion of iStent inject®
219321920|NCT03106181|PROCEDURE|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
219321921|NCT05545033|DEVICE|Virtual reality|5 to 15 minutes of virtual reality exposure
219321922|NCT03842163|DIAGNOSTIC_TEST|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
219321923|NCT00158873|DRUG|midazolam|
219321924|NCT00158873|DRUG|lorazepam|
219321925|NCT00158873|DRUG|fentanyl|
219321926|NCT00158873|DRUG|morphine|
219321927|NCT00158873|DRUG|remifentanil|
219321928|NCT00158873|DRUG|propofol|
219321929|NCT02675023|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
219321930|NCT00395551|DRUG|ranibizumab|0.5mg intravitreal injection
219321931|NCT01479114|DRUG|rh-GCSF|10 ug/kg/day intravenously for 3 days
219321932|NCT02575040|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
219321933|NCT04110548|PROCEDURE|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
219321934|NCT04110548|PROCEDURE|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
219321935|NCT02700243|BEHAVIORAL|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
219321936|NCT03415126|DRUG|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
219321937|NCT03415126|DRUG|ASN007 RD|Oral drug for the treatment of advanced solid tumors
219321938|NCT03829241|DRUG|Troriluzole|100 mg capsule
219321939|NCT03829241|DRUG|Placebo|Placebo matched to troriluzole
219321940|NCT01418651|DRUG|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
219321941|NCT00698451|DRUG|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
219321942|NCT06494215|OTHER|Pressure Support Variation and Calculation of Respiratory Mechanics|Patients will be submitted to different levels of pressure support (PS) in a randomly assigned order. First 30 minutes shall be recorded at the clinical PS. Next, blood gas samples shall be collected. Subsequently, three inspiratory pauses of at least 2 seconds shall be performed with an interval of at least 8 respiratory cycles between them. The same shall be performed with three expiratory pauses. Next, the PS shall be varied to 50% less or 50% more than clinical PS (based on randomization) and the same procedures shall be performed after 30 minutes of data recording (blood gas sample collection, inspiratory and expiratory pauses). All data shall be analyzed offline using a software that will be able to compare three different methods to calculate Pendelluft magnitude based on the literature. After completion of the protocol, ventilatory parameters shall be returned to the original settings. If the patient becomes tachypneic during lower PS, the protocol shall be interrupted.
219321943|NCT01924013|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
219321944|NCT01924013|DIETARY_SUPPLEMENT|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
219321945|NCT00469001|PROCEDURE|Treatment according NT Pro BNP level|
219321946|NCT05290922|DIAGNOSTIC_TEST|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
219321947|NCT04752020|DRUG|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
219321948|NCT03525106|BEHAVIORAL|Booklet|Receive positive psychology manual
219321949|NCT03525106|BEHAVIORAL|Exercise Intervention|Complete positive psychology exercises
219321950|NCT03525106|OTHER|Quality-of-Life Assessment|Ancillary studies
219321951|NCT03525106|OTHER|Survey Administration|Ancillary studies
219321952|NCT03525106|BEHAVIORAL|Telephone-Based Intervention|Participate in phone sessions
219321953|NCT01899625|BEHAVIORAL|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
219321954|NCT01899625|BEHAVIORAL|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
219321955|NCT01447368|DRUG|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
219321956|NCT01447368|PROCEDURE|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
219321957|NCT04262050|DEVICE|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
219321958|NCT01627002|BIOLOGICAL|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
219321959|NCT01627002|OTHER|Placebo|Subcutaneous
219321960|NCT00943774|OTHER|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
219321961|NCT00000491|DRUG|aspirin|
219321962|NCT04236882|OTHER|Focus Group|Attend focus group
219321963|NCT04236882|BEHAVIORAL|Health Education|Receive educational material on healthy homes
219321964|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based sleep intervention
219321965|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based health coaching sessions
219321966|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based counseling sessions
219321967|NCT04236882|OTHER|Interview|Complete interview
219321968|NCT04236882|OTHER|Questionnaire Administration|Ancillary studies
219321969|NCT00636688|BEHAVIORAL|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
219321970|NCT00636688|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
219321971|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
219321972|NCT01479933|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
219321973|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
219321974|NCT03509636|DRUG|Fluzoparib|Fluzoparib capsule will be given twice daily orally
219321975|NCT05533242|DRUG|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
219321976|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
219321977|NCT06799338|DRUG|Lenacapavir Injection|"Patients will be included if they initiated LEN from 20 June 2023 to 30 June 2024.~All collected data are routinely reported by clinicians in medical records. All clinical decisions All collected data are routinely reported by clinicians in medical records, and will be collected using a dedicated electronic case report form (eCRF) created on this purpose, to ensure confidentiality of data."
219321978|NCT04504357|BEHAVIORAL|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
219321979|NCT04504357|OTHER|Text messages|Monthly text messages reinforcing intervention content
219321980|NCT05467800|DRUG|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
219321981|NCT06339567|DIAGNOSTIC_TEST|Thrombotic profile|several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
219321982|NCT04778345|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging after 18F-FDG PET/CT scan during 2 days and 1 week.
219321983|NCT04648904|RADIATION|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
219321984|NCT06181266|DRUG|ZH9|ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
219321985|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
219321986|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
219321987|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
219321988|NCT06802523|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
219321989|NCT06802523|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219321990|NCT06802523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219321991|NCT06802523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219321992|NCT06802523|DRUG|Decitabine and Cedazuridine|Given PO
219321993|NCT06802523|DRUG|Venetoclax|Given PO
219321994|NCT01526070|DRUG|Intravitreal injection of Aflibercept|
219321995|NCT04534556|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
219321996|NCT04534556|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
219321997|NCT02308007|DRUG|Terconazole|
219321998|NCT02308007|DRUG|Metronidazole|
219321999|NCT02308007|DRUG|Terconazole/metronidazole|
219322000|NCT05781633|DRUG|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
219322001|NCT03498846|PROCEDURE|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
219322002|NCT03498846|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
219322003|NCT02231125|DRUG|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
219322004|NCT02231125|DRUG|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
219322005|NCT02316184|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
219322006|NCT02316184|BEHAVIORAL|Brief Advice|
219322007|NCT01432834|OTHER|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
219322008|NCT01432834|OTHER|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
219322009|NCT03331653|OTHER|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
219322010|NCT03331653|OTHER|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
219322011|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
219322012|NCT02563093|BIOLOGICAL|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
219322013|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
219322014|NCT02563093|BIOLOGICAL|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
219322015|NCT04622033|BIOLOGICAL|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
219322016|NCT05949151|PROCEDURE|dental implants (K1 line conical connection double thread, OXY, Italy)|Six dental implants inserted on the edentulous mandible
219322017|NCT05949151|DEVICE|Occlusense (Bausch GmbH & Co. KG)|sensor used to evaluate the equilibration of occlusal forces.
219322018|NCT05949151|DEVICE|"electromyography (EMG) (Nemus II)."|EMG recordings were accomplished by a computer electromyography-based data acquisition system
219322019|NCT05949151|OTHER|oral health-related quality of life (OHRQoL)|Oral Health-related Quality of Life (OHRQoL) was estimated by employing the Oral Health Impact Profile questionnaire which comprises nineteen multiple questions that were translated into Arabic.
219322020|NCT05881980|DRUG|Terbinafine Tablets|Terbinafine 250 mg/day
219322021|NCT05881980|DRUG|Itraconazole|Itraconazole 200 mg/day
219322022|NCT03715023|DRUG|PC786|PC786 suspension for inhalation
219322023|NCT03715023|DRUG|Placebo|Placebo solution for inhalation
219322024|NCT03715023|DRUG|SOC|Standard treatment for RSV infection at study site
219322025|NCT05671913|DRUG|Ketamine|Treatment arm
219322026|NCT05671913|DRUG|Placebo|Control arm
219322027|NCT00528567|DRUG|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
219322028|NCT00528567|DRUG|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
219322029|NCT01869257|DEVICE|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
219322030|NCT01869257|DEVICE|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
219322031|NCT00331812|PROCEDURE|Mitochondrial functions and oxidative stress|
219322032|NCT03455192|DRUG|Synbiotic Supplement|
219322033|NCT03455192|DRUG|Placebo Oral Tablet|
219322034|NCT04658459|PROCEDURE|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
219322035|NCT04586998|DEVICE|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
219322036|NCT06005389|PROCEDURE|cryotherapy|Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.
219322037|NCT06005389|DIAGNOSTIC_TEST|serum Galectin-3 assay|From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
219322038|NCT00163423|DRUG|Ciclesonide|
219322039|NCT02970734|BEHAVIORAL|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
219322040|NCT02970734|BEHAVIORAL|Resource Webpage|Static webpage listing anxiety resources.
219322041|NCT03352011|BEHAVIORAL|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
219322042|NCT03352011|BEHAVIORAL|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
219322043|NCT02505581|DRUG|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
219322044|NCT02505581|PROCEDURE|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
219322045|NCT02505581|DRUG|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
219322046|NCT02505581|DRUG|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
219322047|NCT02505581|DRUG|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
219322048|NCT02505581|DRUG|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
219322049|NCT01338129|DIETARY_SUPPLEMENT|vitamin c|1000 mg of vitamin c for 45 days
219322050|NCT01338129|DRUG|placebo|placebo pills
219322051|NCT01233453|DEVICE|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
219322052|NCT01233453|DEVICE|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
219322053|NCT05326425|DRUG|lazertinib(YH25448)|\- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
219322054|NCT02920086|BEHAVIORAL|Nutrition Education Program|"* The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
219322055|NCT02920086|OTHER|Decision Support Program|"* Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care"
219322056|NCT05961280|PROCEDURE|Mastectomy with sentinel lymph node biopsy|
219322057|NCT04825769|DEVICE|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
219322058|NCT05659433|PROCEDURE|CEUS-guided percutaneous biopsy|A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
219322059|NCT05659433|PROCEDURE|B-mode US-guided percutaneous biopsy|Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
219322060|NCT01132066|OTHER|tDCS|tDCS will lead to an increase in cortical excitability
219322061|NCT01132066|OTHER|Sham|Sham will provide identical subjective sensation as tDCS
219322062|NCT00631189|DRUG|Rosuvastatin|5mg oral
219322063|NCT00631189|DRUG|Pravastatin|40mg oral
219322064|NCT00631189|DRUG|Atorvastatin|10mg oral
219322065|NCT01448122|OTHER|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
219322066|NCT01063829|DRUG|60 mg AIC246|Oral administration
219322067|NCT01063829|DRUG|120 mg AIC246|Oral administration
219322068|NCT01063829|DRUG|240 mg AIC246|Oral administration
219322069|NCT01063829|OTHER|Placebo|Oral administration
219322070|NCT03272542|DIETARY_SUPPLEMENT|Prebiotic: soluble corn fiber|prebiotic
219322071|NCT03272542|DIETARY_SUPPLEMENT|Placebo: maltodextrin|placebo
219322072|NCT04580862|OTHER|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
219322073|NCT02423018|DRUG|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
219322074|NCT02423018|DRUG|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
219322075|NCT00974090|DRUG|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
219322076|NCT00974090|DRUG|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
219322077|NCT06449950|BEHAVIORAL|Behavioral: Verbal Oral Hygiene Instructions|OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).
219322078|NCT06449950|BEHAVIORAL|Behavioral: Video-Based Oral Hygiene Instructions|OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
219322079|NCT03189862|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
219322080|NCT05265910|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
219322081|NCT05265910|DRUG|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
219322082|NCT05265910|DRUG|Tears Naturale|Tears Naturale® II (eyedrop)
219322083|NCT05265910|DRUG|Placebo|Placebo tablet (tablet)
219322084|NCT00665743|DRUG|PN400|naproxen 500 mg /esomeprazole 20 mg
219322085|NCT00665743|DRUG|naproxen|naproxen 500 mg tablet
219322086|NCT00665743|DRUG|naproxen|naproxen 500 mg
219322087|NCT06466863|OTHER|Validity and Reliability|"Participants were included in the study after obtaining consent from both the participants and their parents. Participants were informed about the study prior to the survey, and only those who volunteered were included in the study. The data collection process was conducted online via Google Forms. The assessment form was sent to the participants through social media platforms, messages, and emails. Participants completed the YAP-T twice, 7 days apart, and all measurements were taken on weekdays under similar conditions by the same evaluators (4 evaluators) in the same region (Istanbul).~Test-retest reliability will be determined by calculating the Intraclass Correlation Coefficient (ICC) between the total scores obtained from the two assessments."
219322088|NCT02939872|DRUG|aspirin and clopidogrel|at the discretion of investigator
219322089|NCT02939872|DRUG|Clopidogrel only|at the discretion of investigator
219322090|NCT06313073|RADIATION|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
219322091|NCT06313073|RADIATION|adjuvant radiotherapy|The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
219322092|NCT02955576|DEVICE|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
219322093|NCT02955576|DEVICE|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
219322094|NCT02955576|OTHER|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
219322095|NCT00056862|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
219322096|NCT00056862|DRUG|Peginterferon alfa-2a|180 mcg/week
219322097|NCT00056862|DRUG|Ribavirin|800 mg/day
219322098|NCT03902561|DEVICE|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
219322099|NCT03447366|DIAGNOSTIC_TEST|mitral doppler|Mitral doppler before and after vascular filling
219322100|NCT00052039|DRUG|interferon-gamma 1b|This study was terminated prior to enrollment.
219322101|NCT00052039|DRUG|azathioprine|This study was terminated prior to enrollment.
219322102|NCT01829360|BEHAVIORAL|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
219322103|NCT05953779|BEHAVIORAL|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
219322104|NCT01622179|PROCEDURE|sewed indirectly|The epitenon was repaired and sewed indirectly.
219322105|NCT01622179|PROCEDURE|sewed directly|The epitenon was unrepaired and sewed directly.
219322106|NCT03388255|DRUG|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication."
219322107|NCT05987566|OTHER|Morning meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten after 1 hour of waking up in the morning
219322108|NCT05987566|OTHER|Evening meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten within 1 hour of going to bed
219322109|NCT00034450|DRUG|L-carnitine|
219322110|NCT00201838|DRUG|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
219322111|NCT00201838|DRUG|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
219322112|NCT06298812|DEVICE|REFLECT Scoliosis Correction System|The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials.
219322113|NCT06277102|OTHER|music listening|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
219322114|NCT03198598|BEHAVIORAL|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
219322115|NCT03198598|BEHAVIORAL|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
219322116|NCT05532436|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
219322117|NCT02347033|DRUG|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
219322118|NCT02347033|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
219322119|NCT04379336|BIOLOGICAL|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
219322120|NCT04379336|OTHER|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
219322121|NCT00028821|DRUG|2-methoxyestradiol|Given orally
219322122|NCT00028821|OTHER|pharmacological study|Correlative studies
219322123|NCT00028821|OTHER|laboratory biomarker analysis|Correlative studies
219322124|NCT02187614|DRUG|Diclofenac|
219322125|NCT02187614|DRUG|Morphine|
219322126|NCT02187614|DRUG|Paracetamol|
219322127|NCT02187614|DRUG|Placebos|
219322128|NCT04393025|DEVICE|Intracranial Stenting by Intracranial Stent Device|Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted
219322129|NCT04393025|DRUG|Optimum medical treatment|Optimum Medical treatment
219322130|NCT05834686|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC
219322131|NCT04347850|OTHER|blood sample|Collection
219322132|NCT00859950|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
219322133|NCT00847184|DEVICE|Intubation|Intubation using the standard MacIntosh blade
219322134|NCT00847184|DEVICE|Airtraq|Intubation with the use of the Airtraq technique
219322135|NCT00136409|DRUG|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
219322136|NCT03838198|BEHAVIORAL|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
219322137|NCT03838198|BEHAVIORAL|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
219322138|NCT03838198|BEHAVIORAL|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
219322139|NCT01159613|OTHER|Responders|Responders
219322140|NCT01159613|OTHER|Non Responders|Non Responders
219322141|NCT04611854|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
219322142|NCT04611854|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
219322143|NCT00283036|DRUG|Irbesartan|
219322144|NCT05811715|OTHER|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
219322145|NCT05811715|OTHER|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
219322146|NCT05503550|DRUG|Talquetamab|Talquetamab will be administered subcutaneously (SC).
219322147|NCT00320021|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
219322148|NCT02623374|BEHAVIORAL|self-help CBT intervention (SHCBT)|See 'Arms' section
219322149|NCT06226311|OTHER|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
219322150|NCT06226311|OTHER|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
219322151|NCT02042196|DRUG|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
219322152|NCT02042196|DRUG|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
219322153|NCT02042196|DRUG|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
219322154|NCT02042196|DRUG|Climara|0.075mg/d transdermal patch will be placed on skin.
219322155|NCT02042196|DRUG|Placebo transdermal patch|Inactive transdermal patch
219322156|NCT05367180|OTHER|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
219322157|NCT05367180|OTHER|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
219322158|NCT05367180|OTHER|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
219322159|NCT00846885|DRUG|Sumatriptan Succinate|100 mg Tablet
219322160|NCT00846885|DRUG|Imitrex®|100 mg Tablet
219322161|NCT05211739|DEVICE|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
219322162|NCT05211739|DEVICE|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
219322163|NCT05211739|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
219322164|NCT01862640|DRUG|Brexpiprazole, OPC-34712|Once-daily, tablets
219322165|NCT01862640|DRUG|Placebo Oral Tablet|Once-daily, tablets
219322166|NCT01554735|BEHAVIORAL|Exercise and diet|24 weeks of exercise and diet counselling
219322167|NCT02429622|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
219322168|NCT02429622|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
219322169|NCT02429622|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
219322170|NCT02429622|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
219322171|NCT06456996|COMBINATION_PRODUCT|Multi-component intervention package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
219322172|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
219322173|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
219322174|NCT00462189|DRUG|Immunotoxin therapy|
219322175|NCT00462189|DRUG|CAT-8015 Immunotoxin|
219322176|NCT00462189|PROCEDURE|Biological therapy|
219322177|NCT04053530|OTHER|restorative materials|glass ionomer and bulk fill flowable composite
219322178|NCT01975428|DEVICE|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
219322179|NCT01975428|BEHAVIORAL|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
219322180|NCT00003251|DRUG|amifostine trihydrate|
219322181|NCT00003251|DRUG|cisplatin|
219322182|NCT00003251|DRUG|paclitaxel|
219322183|NCT00003251|RADIATION|radiation therapy|
219322184|NCT02187809|DRUG|Clobazam|
219322185|NCT05085665|DRUG|Ivermectin|single dose, 150 ug/kg
219322186|NCT03559920|DRUG|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
219322187|NCT03559920|DRUG|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
219322188|NCT02129920|OTHER|This is an observational study|
219322189|NCT02622880|DIETARY_SUPPLEMENT|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
219322190|NCT02622880|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
219322191|NCT01261754|RADIATION|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
219322192|NCT01261754|RADIATION|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
219322193|NCT01549366|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
219322194|NCT01549366|DEVICE|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
219322195|NCT04069351|DIETARY_SUPPLEMENT|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
219322196|NCT04069351|OTHER|Resistance Training|All participants will complete a 6-week supervised resistance training program.
219322197|NCT04719767|DEVICE|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
219322198|NCT03118349|DRUG|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
219322199|NCT03118349|DRUG|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
219322200|NCT05638893|DRUG|Placebo Tablet|Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
219322201|NCT05638893|DRUG|Metformin Hcl 500Mg Tab|Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
219322202|NCT02927743|BEHAVIORAL|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
219322203|NCT03988322|OTHER|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
219322204|NCT03988322|OTHER|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
219322205|NCT02037646|OTHER|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
219322206|NCT02037646|OTHER|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
219322207|NCT02037646|PROCEDURE|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
219322208|NCT02037646|OTHER|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
219322209|NCT02037646|OTHER|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
219322210|NCT02037646|OTHER|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
219322211|NCT02862860|BIOLOGICAL|blood sample|
219322212|NCT02862860|BIOLOGICAL|urine sample|
219322213|NCT02862860|DEVICE|installation of Holter|
219322214|NCT00270478|DRUG|Erythropoietin and Hydroxyurea|
219322215|NCT00168480|BIOLOGICAL|Botulinum Toxin Type A|100 U, repeated treatments at \> 4 month intervals up to Month 32, over a 36-month study period
219322216|NCT00179725|DRUG|CC-5013|
219322217|NCT00179725|DRUG|liposomal doxorubicin|
219322218|NCT04677699|DIAGNOSTIC_TEST|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
219322219|NCT01641809|DRUG|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
219322220|NCT01641809|DRUG|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
219322221|NCT01641809|DRUG|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
219322222|NCT01641809|DRUG|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
219322223|NCT01641809|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
219322224|NCT01641809|DRUG|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
219322225|NCT01641809|DRUG|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
219322226|NCT00350805|PROCEDURE|EEG|One 20 minutes session
219322227|NCT00146081|BEHAVIORAL|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
219322228|NCT01832363|DRUG|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
219322229|NCT01832363|OTHER|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
219322230|NCT04497909|BEHAVIORAL|Mindfulness|Mindfulness online training
219322231|NCT01243541|PROCEDURE|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
219322232|NCT01243541|OTHER|questionnaire administration|Ancillary studies
219322233|NCT01243541|PROCEDURE|quality-of-life assessment|Ancillary studies
219322234|NCT01243541|PROCEDURE|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
219322235|NCT01243541|PROCEDURE|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
219322236|NCT02749032|OTHER|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
219322237|NCT02749032|DRUG|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
219322238|NCT02749032|DRUG|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
219322239|NCT02749032|DRUG|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
219322240|NCT02749032|DRUG|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
219322241|NCT02749032|OTHER|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
219322242|NCT00778622|DRUG|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
219322243|NCT01460186|OTHER|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
219322244|NCT03067155|GENETIC|CMV-specific T cells|
219322245|NCT03067155|DRUG|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
219322246|NCT00901030|PROCEDURE|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
219322247|NCT03837379|BEHAVIORAL|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
219322248|NCT03837379|COMBINATION_PRODUCT|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
219322249|NCT00626210|DRUG|modafinil|100-400 mg daily for 4 weeks
219322250|NCT04553068|DRUG|EVO100|EVO100 vaginal gel
219322251|NCT04553068|DRUG|Placebo|Placebo vaginal gel
219322252|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
219322253|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
219322254|NCT03367715|DRUG|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
219322255|NCT03367715|DRUG|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
219322256|NCT03367715|RADIATION|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
219322257|NCT00080496|DRUG|Tigecycline|
219322258|NCT00080496|DRUG|Imipenem|
219322259|NCT00080496|DRUG|Cilastatin|
219322260|NCT05191069|OTHER|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
219322261|NCT05191069|OTHER|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
219322262|NCT00076557|GENETIC|Adeno-Associated Viral with Human Factor IX|
219322263|NCT05614973|PROCEDURE|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
219322264|NCT05614973|PROCEDURE|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
219322265|NCT02896179|DEVICE|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
219322266|NCT02896179|DEVICE|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
219322267|NCT06027723|DRUG|Nicotine|Nicotine delivered through a vape
219322268|NCT06027723|OTHER|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
219322269|NCT03200340|DRUG|EC-18|Oral administration of EC-18 twice daily
219322270|NCT03200340|DRUG|Placebo|Placebo to match EC-18 capsule administration
219322271|NCT02301936|DRUG|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
219322272|NCT03065023|DRUG|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
219322273|NCT05315453|BEHAVIORAL|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
219322274|NCT02326714|OTHER|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
219322275|NCT02326714|OTHER|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
219322276|NCT04897269|PROCEDURE|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
219322277|NCT04895072|PROCEDURE|Standard group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a standard injection rate.
219322278|NCT04895072|PROCEDURE|Long group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a long injection rate.
219322279|NCT03427125|DRUG|Tenapanor|Active Drug
219322280|NCT03427125|DRUG|Placebo|Inactive Drug
219322281|NCT03427125|DRUG|Sevelamer Carbonate|Active control
219322282|NCT04779190|DEVICE|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
219322283|NCT04779190|DEVICE|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
219322284|NCT04779190|OTHER|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
219322285|NCT02204384|OTHER|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
219322286|NCT02204384|DIETARY_SUPPLEMENT|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
219322287|NCT02204384|OTHER|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
219322288|NCT04853329|DRUG|CPO107|CD20-CD47 Bispecific Fusion Protein
219322289|NCT05956249|OTHER|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
219322290|NCT05956249|OTHER|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
219322291|NCT05180279|BEHAVIORAL|7-day sleep lab|Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
219322292|NCT04023825|DRUG|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
219322293|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
219322294|NCT05501678|DRUG|Placebo|Matching Placebo given orally
219322295|NCT04014361|DRUG|LY3154885 - Capsule|Administered orally.
219322296|NCT04014361|DRUG|Placebo - Capsule|Administered orally.
219322297|NCT04014361|DRUG|Itraconazole|Administered orally.
219322298|NCT04014361|DRUG|LY3154885 - Tablet|Administered orally.
219322299|NCT04757883|OTHER|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
219322300|NCT05225103|BEHAVIORAL|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
219322301|NCT06604026|DEVICE|BD PosiFlush™ SafeScrub|"Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
219322302|NCT06604026|DEVICE|BD PosiFlush™|"Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
219322303|NCT06163326|DRUG|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
219322304|NCT06163326|DRUG|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
219322305|NCT06163326|DRUG|Placebo|Matching capsule once daily
219322306|NCT03370848|DIETARY_SUPPLEMENT|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
219322307|NCT03370848|DRUG|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
219322308|NCT03998293|DRUG|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
219322309|NCT02632565|DRUG|Lidocaine|
219322310|NCT02632565|DRUG|Saline|
219322311|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
219322312|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
219322313|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
219322314|NCT02715466|DRUG|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
219322315|NCT02715466|DRUG|Balanced electrolyte solution|Sterofundin ISO
219322316|NCT02852486|DRUG|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
219322317|NCT02852486|OTHER|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
219322318|NCT01843868|DRUG|Standard anti-emetics in conjunction with R-CHOP|
219322319|NCT06046755|OTHER|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
219322320|NCT06046755|BEHAVIORAL|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
219322321|NCT00583570|BEHAVIORAL|dietary education|dietary education
219322322|NCT01353456|DRUG|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
219322323|NCT01353456|DRUG|Normal Saline|Same volume as dexmedetomidine given
219322324|NCT03610165|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
219322325|NCT03610165|DEVICE|Control|Arterial waveform and pressures
219322326|NCT05420883|OTHER|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
219322327|NCT05420883|OTHER|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
219322328|NCT05420883|OTHER|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
219322329|NCT03125213|DRUG|AL-3778|AL-3778 tablets
219322330|NCT03125213|DRUG|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
219322331|NCT03125213|DRUG|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
219322332|NCT02764450|DEVICE|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
219322333|NCT02764450|DEVICE|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
219322334|NCT00903656|DRUG|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
219322335|NCT02121496|BEHAVIORAL|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
219322336|NCT03374098|BEHAVIORAL|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
219322337|NCT03374098|BEHAVIORAL|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
219322338|NCT04339114|OTHER|Breakfast: control meal|The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
219322339|NCT04339114|OTHER|Breakfast: Cinnamon meal|The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
219322340|NCT04339114|OTHER|Breakfast: Italian herbs meal|The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
219322341|NCT04339114|OTHER|Breakfast: pumpkin spice|The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
219322342|NCT00781820|DRUG|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
219322343|NCT00781820|DRUG|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
219322344|NCT05880550|OTHER|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
219322345|NCT05880550|OTHER|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
219322346|NCT01810016|BIOLOGICAL|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
219322347|NCT01810016|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
219322348|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
219322349|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
219322350|NCT05150496|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
219322351|NCT05150496|BIOLOGICAL|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
219322352|NCT00708175|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
219322353|NCT00708175|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
219322354|NCT03196232|DRUG|Epacadostat|Given PO
219322355|NCT03196232|DRUG|Pembrolizumab|Given IV
219322356|NCT05110274|PROCEDURE|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
219322357|NCT05110274|PROCEDURE|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
219322358|NCT05906823|OTHER|Detection of pleural effusion|Detection of pleural effusion
219322359|NCT00527254|DEVICE|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
219322360|NCT04744571|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
219322361|NCT04744571|DEVICE|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
219322362|NCT04744571|OTHER|drug-coated balloon|Drug-coated balloon including all sizes and all brands
219322363|NCT04744571|DEVICE|drug-eluting stent|Drug-eluting stent including all sizes and all brands
219322364|NCT01578967|DRUG|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
219322365|NCT01578967|DRUG|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
219322366|NCT03722056|PROCEDURE|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
219322367|NCT05326113|OTHER|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
219322368|NCT05326113|DRUG|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
219322369|NCT00064389|DRUG|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
219322370|NCT00064389|DRUG|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
219322371|NCT02488889|DRUG|Varenicline|
219322372|NCT02488889|DRUG|Placebo pill (for varenicline)|
219322373|NCT02488889|DRUG|Alcohol|
219322374|NCT02488889|DRUG|placebo beverage (for alcohol)|
219322375|NCT05877183|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
219322376|NCT05877183|DEVICE|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
219322377|NCT03165318|DEVICE|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
219322378|NCT03165318|DEVICE|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
219322379|NCT05018260|BEHAVIORAL|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
219322380|NCT05018260|BEHAVIORAL|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
219322381|NCT02978079|DEVICE|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
219322382|NCT03176563|DRUG|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
219322383|NCT03176563|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
219322384|NCT03176563|DRUG|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
219322385|NCT03176563|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
219322386|NCT05574634|BEHAVIORAL|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
219322387|NCT05574634|BEHAVIORAL|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
219322388|NCT05179642|OTHER|OPTIM-EHPAD tool|"This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
219355111|NCT00523588|PROCEDURE|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
219355112|NCT00006089|OTHER|Laboratory Biomarker Analysis|Correlative studies
219355113|NCT00006089|BIOLOGICAL|Trastuzumab|Given IV
219355114|NCT06471270|DIAGNOSTIC_TEST|histologic evaluation|histologic evaluation
219355115|NCT06471270|DIAGNOSTIC_TEST|biochemical analysis|IL-6, IL-8 and sCD44
219355116|NCT06471270|DIAGNOSTIC_TEST|clinical examination|clinical examination
219322389|NCT06162000|OTHER|The group that will use the developed software in case studies|"In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups."
219322390|NCT05201937|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
219322391|NCT01703663|DEVICE|EPAP|
219322392|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
219322393|NCT06666192|OTHER|Cancer Screening|Undergo cancer screening
219322394|NCT06666192|OTHER|Discussion|Participate in discussions
219322395|NCT06666192|OTHER|Educational Activity|Receive coaching calls
219322396|NCT06666192|OTHER|Educational Intervention|Receive educational materials
219322397|NCT06666192|BEHAVIORAL|Focus Group|Participate in focus group
219322398|NCT06666192|OTHER|Health Care Delivery|Integrate new activities into usual clinic processes
219322399|NCT06666192|OTHER|Health Promotion|Promote screening and wellness visits
219322400|NCT06666192|OTHER|Health Promotion and Education|Participate in educational sessions
219322401|NCT06666192|OTHER|Health Promotion and Education|Participate in early wave MLI
219322402|NCT06666192|OTHER|Health Promotion and Education|Participate in late wave MLI
219322403|NCT06666192|BEHAVIORAL|Health Risk Assessment|Incorporate risk assessments
219322404|NCT06666192|PROCEDURE|Implementation|Implement MLI
219322405|NCT06666192|OTHER|Informational Intervention|Review MLI materials
219322406|NCT06666192|OTHER|Internet-Based Intervention|Receive educational online materials
219322407|NCT06666192|OTHER|Interview|Participate in interview
219322408|NCT06666192|BEHAVIORAL|Outreach|Receive outreach activities
219322409|NCT06666192|BEHAVIORAL|Patient Navigation|Receive access to CHW
219322410|NCT06666192|OTHER|Survey Administration|Ancillary studies
219322411|NCT05045040|BEHAVIORAL|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
219322412|NCT07130097|DRUG|PF-07220060|Cyclin-dependent kinase-4 inhibitor
219322413|NCT06809192|BEHAVIORAL|4-session Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, c) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, and autogenic relaxation, and d) goal setting and problem-solving barriers to integrate relaxation practices into daily routine.
219322414|NCT06809192|BEHAVIORAL|4-session Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
219355117|NCT03060070|DRUG|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
219322415|NCT06809192|BEHAVIORAL|4-session Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, c) labeling thoughts as helpful, unhelpful, or neutral, d) using distraction to cope with unhelpful thoughts, e) challenging and changing unhelpful thoughts, f) problem-solving barriers to coping with or changing unhelpful thoughts.
219322416|NCT07129005|OTHER|No intervention (observational study)|No intervention (observational study)
219322417|NCT07128498|BEHAVIORAL|Tinker-Fun|A cognitive flexibility intervention revolves around a hands-on experience where participants design and build a craft or device. The process emphasizes active learning through observing, exploring, t
219322418|NCT06522035|DRUG|Allocetra|Intra-articular injecton of Allocetra into the target joint.
219322419|NCT07130487|BEHAVIORAL|Relational Agent ( RA) Alex|The intervention is an RA (chatbot) integrated into a genetic care delivery portal for primary care patients. The RA provides hereditary cancer education and risk evaluation through an interactive interface. Primary care patients will use the RA to complete questionnaires about their hereditary cancer risk, track their progress through the education component and assessment process, and obtain downloadable summaries of their cancer risk and family tree. Additionally, the chat feature stores past conversations, and a menu guides participants through key steps.
219322420|NCT07118514|BEHAVIORAL|Progressive Resistance Training|A 12-week supervised resistance training program, performed twice weekly for 50 minutes per session. Exercises are based on 1-repetition maximum (1-RM) tests, using fixed machines and progressive loads (50-65% of 1-RM). Exercises include leg press, leg curl, knee extension, chest press, biceps/triceps curls, seated row, and lat pulldown.
219322421|NCT07118514|BEHAVIORAL|Stretching and Relaxation Activities|A 12-week supervised program focused on flexibility and relaxation, performed twice weekly for approximately 50 minutes. Includes static stretching of major muscle groups and guided breathing exercises aimed at reducing muscle tension and promoting mental relaxation.
219322422|NCT02320929|PROCEDURE|Intraoperative flexor tendon sheath irrigation|
219322423|NCT02320929|PROCEDURE|Postoperative flexor tendon sheath irrigation|
219322424|NCT07123740|PROCEDURE|Intrathecal Morphine|"An intrathecal injection of morphine 300μg will be administered at the L3-L4 or L4-L5 level.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219322425|NCT07123740|PROCEDURE|Bi-level Erector Spinae Plane Block|"Bi-level erector spinae plane block will be performed on the patients using a total of 40 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
219322426|NCT07123519|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3E6 STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
219322427|NCT07122011|OTHER|Low-Intensity Resistance Training with BFR|"Warm-up: Five minutes of light-intensity cycling on a stationary bike.~Exercises:~1. Bilateral half squat (0°-90°)~2. Single-leg step-down from a 20 cm step~3. Knee extension (90°-0°) at 30% of one-repetition maximum (1RM)~4. Single-leg shallow squat (0°-45°)~Protocol: One set of 30 repetitions (or until volitional fatigue) followed by three sets of 15 repetitions for each exercise.~Rest periods: One minute between sets and two minutes between exercises.~BFR Application: Pneumatic cuff (The Occlusion Cuff Pro®) placed proximally on the dominant thigh, inflated to 60% of complete arterial occlusion (determined via Doppler ultrasound). The cuff remains inflated during sets and rest periods, and is deflated after completion of each exercise."
219322428|NCT06717854|OTHER|transanal irrigation|The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. the catheter is gently and slowly inserted 7-10 cm through the anus. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
219322429|NCT06717854|OTHER|antegrade enema|The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. Using a disposable catheter, insert it about 20 cm. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
219322430|NCT07125235|BEHAVIORAL|reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention|The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.
219322431|NCT07125235|DEVICE|urine tenofovir point-of-care self-test|urine tenofovir point-of-care self-test
219322432|NCT07128810|OTHER|Parent Child Interaction Therapy|Parent was trained in a structured way during two phases of PCIT that are Phase 1: Child Directed Intervention and Phase 2: Parent Directed Intervention to encourage Language Development with frequency of sessions as 12 sessions; minimum 30 mins each day, 3x per week.
219322433|NCT07128810|OTHER|Conventional Parent Led Therapy|Parent was trained in an unstructured way by using different language development strategies (Imitation, Focused Stimulations, Milieu Teaching, and others) to encourage Language Development with frequency of session as 12 sessions; minimum 30 mins each day, 3x per week.
219322434|NCT07130240|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"Drug: Neoadjuvant Chemotherapy paclitaxel, 135-175mg/m2, q3w, 2-3 cycles~Drug: Neoadjuvant Chemotherapy cisplatin, 75-80mg/m2, q3w, 2-3 cycles~Drug: Immunotherapy Ivonescimab, 20mg/kg, q3w, 2-3cycles~Procedure: Type A hysterectomy After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Type A hysterectomy + sentinel lymph node dissection / pelvic lymphadenectomy"
219322435|NCT07130565|DIAGNOSTIC_TEST|18F-92/AV45/TPZA/FT8, 11CPIB|Each subject receive a single intravenous injection of 18F-92/AV45/TPZA/FT8, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
219322436|NCT07128914|DRUG|GO306|"Part 1: A 3+3 single-dose escalation phase:~Low-dose cohort: 3.0E+07 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Medium-dose cohort: 3.0E+08 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~High-dose cohort: 1.0E+09 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Part 2: A multiple-dose expansion phase at the RP2D level to explore preliminary efficacy in specific tumor type:~RP2D; Intratumoral or intracavitary injection of GO306; Cohort Size: 20 subjects in specific tumor type; Dosing Schedule: QW or Q2W administration."
219322437|NCT07130721|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Test|Blood samples will be collected once from all participants to measure CRP levels
219322438|NCT07130721|DIAGNOSTIC_TEST|D-dimer Test|D-dimer levels will be assessed once to evaluate thrombotic risk.
219322439|NCT07130721|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|A standard 12-lead ECG will be performed once per participant to assess cardiovascular status
219322440|NCT07129564|OTHER|treatment react|Reverse remodeling of the LA was defined as at least a 15% reduction in the max LA volume after electrical or pharmacological cardioversion for 3 months
219322441|NCT07128797|DRUG|B1344|Subcutaneous injection
219322442|NCT07128797|OTHER|Placebo|Subcutaneous injection
219322443|NCT07129031|DRUG|low-titer O-group whole blood|Arm Description: During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.
219322444|NCT07129031|DRUG|1:1:1 component transfusion|"Following the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition), implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets)."
219322445|NCT07129031|DRUG|ABO- and Rh-compatible whole blood|"Administer type-specific whole-blood transfusion in accordance with the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)."
219322446|NCT07129967|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
219322447|NCT04822012|DIAGNOSTIC_TEST|Anti COVID19 IgG Antibodies|Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
219322448|NCT00291811|DRUG|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
219322449|NCT03067012|OTHER|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
219322450|NCT03325478|OTHER|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
219322451|NCT06807203|OTHER|Behavioral observation|Behaviors will be observed in children's natural environment. With a digital health assessment.
219322452|NCT04227951|DEVICE|Avoid drain placement|In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
219322453|NCT04227951|DEVICE|Drain placement|In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
219322454|NCT06153160|DEVICE|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
219322455|NCT06985056|BEHAVIORAL|Supervised 12-week Resistance and Endurance Exercise Program|60 Minute home-based and supervised endurance, resistance and coordination training 2x/week for 12 weeks, self-administered 20 minute home-based multimodal training 1x/week
219322456|NCT03896464|PROCEDURE|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
219322457|NCT03896464|PROCEDURE|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
219322458|NCT06658899|DRUG|CRD-4730|Oral CRD-4730 in tablet form
219322459|NCT06658899|DRUG|Placebo|Placebo to match CRD-4730 in tablet form
219322460|NCT06432946|OTHER|Video|A 7-minute video demonstrating the sensing-glove system, how it can be used to assess manual therapy biomechanics, and its relevance in research and clinical contexts. The video was created by the research team via a voiceover PowerPoint presentation.
219355118|NCT03060070|DRUG|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
219355119|NCT03060070|DRUG|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
219355120|NCT05792878|DRUG|Interferon|The naive treated patients with chronic hepatitis B were given antiviral treatment with interferon according to their condition.
219322461|NCT06432946|OTHER|Practice session|A 20-minute practice session during which participants received verbal information about the sensing-glove system. While wearing the sensing glove, participants performed palpation and manual therapy techniques (palpation, spinal mobilization/manipulation to the cervical and thoracic spine) on a human-sized manikin, guided by the researcher.
219322462|NCT06593470|BEHAVIORAL|MINDS-UP|MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.
219322463|NCT06593470|BEHAVIORAL|Prevention Plus Wellness|PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45-60 minute session between an adolescent and a trained PPW teacher.
219322464|NCT06593470|DIAGNOSTIC_TEST|fMRI|Functional MRI to investigate preliminary neural mechanisms of MINDS-UP
219322465|NCT05838586|BEHAVIORAL|prolonged SB|4 hours of prolonged SB
219322466|NCT05838586|BEHAVIORAL|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
219322467|NCT05838586|BEHAVIORAL|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
219322468|NCT06996353|PROCEDURE|PTK-PRK refractive treatment|The PTK-PRK refractive treatment will be done according to routine clinical practice.
219322469|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
219322470|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
219322471|NCT05524987|BEHAVIORAL|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months
219322472|NCT04542382|DRUG|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
219322473|NCT04542382|DRUG|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
219322474|NCT04542382|DRUG|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
219322475|NCT06102577|DIETARY_SUPPLEMENT|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
219322476|NCT06102577|OTHER|1gr Placebo|ake 1g. of placebo at the end of an osteopathic manual treatment
219322477|NCT06102577|OTHER|control group|control
219322478|NCT01264653|DRUG|adrenalin|adrenalin 0.01%
219322479|NCT05608382|OTHER|sterile Phosphate Buffer Saline|control group
219322480|NCT05608382|OTHER|SGW13|active comparator
219355121|NCT05792878|DRUG|nucleoside analogues|The naive treated patients with chronic hepatitis B were given antiviral treatment with nucleoside analogues according to their condition.
219355122|NCT05808244|BEHAVIORAL|tgCBFI|Six weekly sessions CBT-based family intervention programme
219355123|NCT05808244|BEHAVIORAL|Usual psychiatric care|Integrated community psychiatric care with medical follow-up
219322481|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
219322482|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
219322483|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
219322484|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
219322485|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
219322486|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
219322487|NCT05051345|OTHER|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
219322488|NCT05051345|OTHER|Informational Intervention|Receive tobacco cessation self-help materials
219322489|NCT05051345|OTHER|Informational Intervention|Receive Smoke-Free Homes mailings
219322490|NCT05051345|OTHER|Media Intervention|Download and use the Wellness app
219322491|NCT05051345|OTHER|Questionnaire Administration|Ancillary studies
219322492|NCT05051345|BEHAVIORAL|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
219322493|NCT05051345|OTHER|Survey Administration|Ancillary studies
219322494|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive telephone counseling sessions
219322495|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
219322496|NCT05051345|OTHER|Tobacco Cessation Counseling|Receive telephone counseling sessions
219322497|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
219322498|NCT02430350|DRUG|Compound Edaravone Injection|
219322499|NCT02430350|DRUG|Edaravone Injection|
219322500|NCT05427162|DRUG|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
219322501|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
219322502|NCT06525675|DRUG|Fulvestrant Injectable Product|500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.
219322503|NCT06525675|DRUG|Letrozole 2.5mg|2.5 mg letrozole per day, administered orally (continuous treatment)
219322504|NCT06525675|DRUG|Palbociclib 125mg|orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
219322505|NCT05866770|DEVICE|U8|The U8 Research System
219322506|NCT05866770|DEVICE|N8 sound processor|Nucleus 8 sound processor
219355124|NCT03038425|DRUG|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
219355125|NCT03038425|DRUG|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
219355126|NCT03618511|BEHAVIORAL|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
219355127|NCT03618511|BEHAVIORAL|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
219355128|NCT03618511|BEHAVIORAL|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
219355129|NCT03618511|BEHAVIORAL|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
219355130|NCT03618511|BEHAVIORAL|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
219322507|NCT06956742|DEVICE|Active intermittent intrapulmonary deflation.|"Intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. The device power setting (25%, 50%, 75%, or 100%) will be individualized according to the parameters determined during the familiarization visit by a trained physiotherapist. Patients will be instructed to perform tidal volume inspirations followed by passive expirations into the device through a mouthpiece, up to their maximal tolerance. The device will be activated by the patient during expiration using a manual remote control.~Each device usage cycle consists of 10 expirations, with oscillations generated at 12 Hz during the first 8 cycles and at 6 Hz during the last 2 cycles. Rest periods will be allowed during the session, and a mandatory pause will be imposed every 10 expirations. The session duration is fixed at 20 minutes, with patients performing one session in the"
219322508|NCT06956742|DEVICE|Placebo intermittent intrapulmonary deflation.|"Placebo intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. Due to the physiological mechanism of action of the device (intermittent negative pressure with increasing intensity, inversely proportional to airflow resistance), it is assumed that device use under placebo conditions will be infra-therapeutic.~To ensure this, the device will be set to the same setting as the active intermittent intrapulmonary deflation session but an intentional air leak will be introduced into the circuit at the device's output (not visible to the participant) to prevent the generated negative pressure from exceeding t The validity of this placebo condition will be confirmed through bench tests.~All other conditions will remain identical to the active intermittent intrapulmonary deflation sessions. Patients will be instructed to perform tidal vo"
219322509|NCT04532372|OTHER|Best Practice|Receive standard of care drugs
219322510|NCT04532372|DRUG|Leflunomide|Given PO
219322511|NCT04532372|DRUG|Placebo Administration|Given PO
219322512|NCT06165302|BEHAVIORAL|Exercise Intervention|12 weeks of prescribed exercise intervention.
219322513|NCT03435003|DRUG|Aprepitant 80 mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
219322514|NCT03435003|DRUG|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
219322515|NCT03435003|PROCEDURE|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
219322516|NCT03435003|DRUG|Dexamethasone|Dexamethasone 8 mg intraoperatively
219322517|NCT03435003|DRUG|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
219322518|NCT03435003|DRUG|Reglan|Postoperatively scheduled Reglan
219322519|NCT03435003|DRUG|Ondansetron|Postoperatively scheduled ondansetron
219322520|NCT03435003|DRUG|Compazine|Postoperatively as needed compazine for breakthrough PONV
219322521|NCT03435003|DRUG|Sugammadex|Reversal with sugammadex
219322522|NCT03435003|DRUG|Propofol|Intravenous anesthesia will be maintained through IV propofol
219322523|NCT03435003|DRUG|dexmedetomidine|maintenance of anesthesia in the intervention arm
219322524|NCT03435003|DRUG|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
219322525|NCT03435003|DRUG|Sevoflurane|inhalational anesthesia
219322526|NCT03435003|DRUG|Desflurane|inhalational anesthesia
219322527|NCT04285398|OTHER|Ophthalmic examinations|Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
219322528|NCT04285398|OTHER|Mobility Test|Functional test to evaluate mobility and postural condition of patients
219322529|NCT01153802|DRUG|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
219322530|NCT06955702|DEVICE|cryotherapy for chemotherapy-induced madarosis|Application of temperature-controlled cold devices (-4°C to -7°C) to the supraorbital area (up to 3 cm above the eyelid margin), administered 15 minutes before chemotherapy infusion and maintained for 20 minutes post-infusion.
219322531|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
219322532|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
219322533|NCT04184440|DIETARY_SUPPLEMENT|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
219322534|NCT00222053|DRUG|Thalidomide|Per os thalidomide
219322535|NCT00222053|DRUG|Biphosphonates|Biphosphonates
219322536|NCT04918238|OTHER|Conventional program|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
219322537|NCT04918238|OTHER|Muscle energy technique|The patient was in the lateral recumbent position on the side opposite to his, her side-bending dysfunction while the physiotherapist stood facing the subject. The physiotherapist monitored the lumbar area with one hand while with the other hand flexed the subject's knees and hips until the barrier was engaged at the vertebral segment being treated.
219322538|NCT05470946|DEVICE|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
219322539|NCT02665065|DRUG|Iomab-B|
219322540|NCT02665065|DRUG|Conventional Care|
219322541|NCT02665065|PROCEDURE|HCT|
219322542|NCT01557023|DRUG|barrier methods|
219322543|NCT01557023|DRUG|barrier methods|
219322544|NCT00186862|DRUG|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
219322545|NCT00646061|DRUG|buscopan|
219322546|NCT06476314|DEVICE|Virtual Reality Glasses Group|Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
219322547|NCT06476314|DEVICE|Stress Ball Group|Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
219322548|NCT06267287|DIAGNOSTIC_TEST|Microbiological examination of the patient's biological material and determination of antibiotic resistance|Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
219322549|NCT02410655|DRUG|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
219322550|NCT02410655|DRUG|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
219322551|NCT01436071|DRUG|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
219322552|NCT01436071|DRUG|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
219322553|NCT03839407|DEVICE|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
219322554|NCT04026139|OTHER|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
219322555|NCT04026139|OTHER|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
219322556|NCT00789867|DRUG|pGM169/GL67A|Received a nebulized dose via an breath-actuated nebulizer
219322557|NCT00238628|DRUG|Bexarotene|
219322558|NCT00238628|DRUG|Iressa|
219322559|NCT02774902|DRUG|TAK-438|TAK-438 tablets
219322560|NCT02774902|DRUG|Clarithromycin|Clarithromycin tablets
219322561|NCT05983549|PROCEDURE|fluid balance|patients will receive fluids with the aim to achieve a neutral balance
219322562|NCT03707132|PROCEDURE|Tourniquet: Folley catheter in the low segment of the uterus|
219322563|NCT00512746|OTHER|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
219322564|NCT00512746|OTHER|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
219322565|NCT00512746|PROCEDURE|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
219322566|NCT00512746|PROCEDURE|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
219322567|NCT01283230|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
219322568|NCT00175955|DRUG|Levetiracetam|
219322569|NCT01909648|OTHER|Blood withdrawal|
219322570|NCT01909648|GENETIC|Blood withdrawal|
219322571|NCT00682565|DRUG|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
219322572|NCT00682565|DRUG|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
219322573|NCT00682565|DRUG|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
219322574|NCT00682565|DRUG|CK-1827452 25mg capsule|25mg oral immediate release capsule
219322575|NCT00682565|DRUG|Placebo iv infusion|Matching placebo iv infusion
219322576|NCT00682565|DRUG|Placebo capsule|Matching placebo oral immediate release capsule
219322577|NCT00577850|DRUG|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
219322578|NCT00577850|DRUG|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
219322579|NCT02454335|PROCEDURE|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
219322580|NCT05737134|OTHER|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
219322581|NCT02700204|DEVICE|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
219322582|NCT02700204|DEVICE|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
219322583|NCT05495139|DEVICE|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
219322584|NCT00454532|DRUG|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
219322585|NCT03503513|DRUG|Gentamicin Sulfate|Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
219322586|NCT04495010|BIOLOGICAL|Nivolumab|Specified dose on specified days
219322587|NCT04495010|BIOLOGICAL|Ipilimumab|Specified dose on specified days
219322588|NCT03329222|OTHER|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
219322589|NCT03329222|OTHER|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
219322590|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
219322591|NCT00298168|DRUG|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
219322592|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
219322593|NCT00929656|PROCEDURE|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
219322594|NCT00929656|PROCEDURE|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
219322595|NCT00929656|PROCEDURE|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
219322596|NCT04144751|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
219322597|NCT00607880|PROCEDURE|vascular access device placement|
219322598|NCT02619968|OTHER|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
219322599|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
219322600|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
219322601|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
219322602|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
219322603|NCT00908583|DRUG|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
219322604|NCT00908583|DRUG|Bortezomib|Patients will receive bortezomib as described in protocol
219322605|NCT00908583|DRUG|Rituximab|Patients will receive rituximab as described in protocol
219322606|NCT00908583|DRUG|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
219322607|NCT00993954|PROCEDURE|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
219322608|NCT03234062|OTHER|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219322609|NCT03234062|OTHER|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219322610|NCT03234062|OTHER|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
219322611|NCT06070844|BEHAVIORAL|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
219322612|NCT02041208|PROCEDURE|kidney transplantation|kidney transplantation
219322613|NCT01410682|OTHER|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
219322614|NCT01410682|OTHER|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
219322615|NCT03809455|DRUG|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
219322616|NCT03809455|DRUG|Placebo|one intake of placebo (intranasal or buccal)
219322617|NCT03881228|BEHAVIORAL|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
219322618|NCT05525728|OTHER|Neurosensory|Physiological and neurophysiological investigations
219322619|NCT04032691|DRUG|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
219322620|NCT03496480|DIAGNOSTIC_TEST|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
219322621|NCT03552796|OTHER|Pharmacokinetic Study|Correlative studies
219322622|NCT03552796|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given intravesically
219322623|NCT04785339|BEHAVIORAL|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
219322624|NCT06433804|DIAGNOSTIC_TEST|HER2 IHC|Immunohistochemistry for HER2
219322625|NCT00226187|PROCEDURE|Supplement of fatty acid (DHA and AA)|
219322626|NCT02221232|DRUG|Chloraprep|Apply topically.
219322627|NCT02221232|DRUG|ZuraPrep|Apply topically.
219322628|NCT02221232|DRUG|ZuraPrep Vehicle|Apply topically.
219322629|NCT01839162|PROCEDURE|Coronary angiography|Diagnostic coronary angiography
219322630|NCT01839162|PROCEDURE|PCI|Percutaneous coronary intervention
219322631|NCT01839162|PROCEDURE|Right approach|Right transradial access
219322632|NCT01839162|PROCEDURE|Left approach|Left transradial access
219322633|NCT00908063|DRUG|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
219322634|NCT00908063|DRUG|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
219322635|NCT01764126|DRUG|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
219322636|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
219322637|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
219322638|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
219322639|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
219322640|NCT01191541|DRUG|DNR:|DNR：45mg/m2 d1-3
219322641|NCT01191541|DRUG|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
219322642|NCT02790125|DRUG|BMS-986166|
219322643|NCT02790125|DRUG|Placebo matching BMS-986166|
219322644|NCT00849654|DRUG|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
219322645|NCT03778814|BIOLOGICAL|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
219322646|NCT05029466|DRUG|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
219322647|NCT00564824|DRUG|Caffeine|Caffeine 200 mg tablet
219322648|NCT00564824|DRUG|Placebo|Placebo pills
219322649|NCT03836820|OTHER|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
219322650|NCT03836820|OTHER|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
219322651|NCT03836820|OTHER|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
219322652|NCT06416735|DRUG|Amiloride|administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
219322653|NCT02540863|OTHER|myofascial release protocol and Rocabado exercise therapy|
219322654|NCT02540863|OTHER|exercise therapy|
219322655|NCT04054609|DIAGNOSTIC_TEST|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
219322656|NCT02066623|DEVICE|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
219322657|NCT05564871|OTHER|occupation-based teleintervention|Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.
219322658|NCT00072332|DRUG|cisplatin|
219322659|NCT00072332|DRUG|edotecarin|
219322660|NCT04636866|OTHER|NO intervention|NO intervention
219322661|NCT03471936|DIAGNOSTIC_TEST|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
219322662|NCT02556866|DRUG|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
219322663|NCT02556866|DRUG|Prednisone|
219322664|NCT02556866|DRUG|Placebo|
219322665|NCT03518138|DRUG|Q-122|oral capsule of Q-122
219322666|NCT03518138|DRUG|Placebo|oral capsule of placebo
219322667|NCT00146679|BEHAVIORAL|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
219322668|NCT00146679|BEHAVIORAL|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
219322669|NCT00146679|BEHAVIORAL|Usual Care|Usual Care provided by providers
219322670|NCT00381563|DEVICE|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
219322671|NCT00381563|DEVICE|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
219322672|NCT01248702|OTHER|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
219322673|NCT05040893|BEHAVIORAL|Physiotherapy|"Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
219322674|NCT05128721|BIOLOGICAL|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
219322675|NCT01366261|DEVICE|semirigid thoracoscopy|thoracoscopy with semirigid instrument
219322676|NCT01366261|DEVICE|rigid thoracoscopy|thoracoscopy with rigid instrument
219322677|NCT00364871|DRUG|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
219322678|NCT02693782|DIETARY_SUPPLEMENT|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
219322679|NCT02693782|DIETARY_SUPPLEMENT|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
219322680|NCT00931944|DRUG|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
219322681|NCT03187171|OTHER|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
219322682|NCT03187171|DEVICE|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
219322683|NCT00038584|DRUG|SCH66336|
219322684|NCT02225717|PROCEDURE|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
219322685|NCT01132612|DRUG|AIN457|AIN457A 150 mg powder for solution
219322686|NCT01132612|DRUG|Placebo|Placebo to AIN457A 150 mg powder for solution
219322687|NCT02252536|DRUG|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
219322688|NCT02252536|DRUG|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
219322689|NCT00729781|DEVICE|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
219322690|NCT04608513|DRUG|ACT-1014-6470|Soft capsules for oral administration
219322691|NCT04608513|DRUG|Placebo|Soft capsules for oral administration
219322692|NCT03876990|DIAGNOSTIC_TEST|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
219322693|NCT03876990|DIAGNOSTIC_TEST|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
219322694|NCT02777229|DRUG|Dolutegravir 50 mg|1 tablet once a day
219322695|NCT02777229|DRUG|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
219322696|NCT02777229|DRUG|Efavirenz 400 mg|1 tablets once a day
219322697|NCT02236884|PROCEDURE|no-scar transanal total mesorectal excision(TME)|
219322698|NCT04939519|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
219322699|NCT04939519|BEHAVIORAL|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
219322700|NCT05107804|OTHER|Exercise+CR|Exercise with caloric-restriction
219322701|NCT05107804|OTHER|Light Conditioning|Light Conditioning Exercise
219322702|NCT04044183|BEHAVIORAL|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
219322703|NCT04044183|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
219355131|NCT03618511|BEHAVIORAL|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
219355132|NCT00290966|DRUG|XRP6976|
219322704|NCT01438151|DRUG|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
219322705|NCT01486641|PROCEDURE|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
219322706|NCT05785572|PROCEDURE|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
219322707|NCT05785572|PROCEDURE|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
219322708|NCT02340728|DEVICE|ERCP with SEMS plus radiofrequency ablation|
219322709|NCT02340728|DEVICE|ERCP with SEMS alone (standard of care)|
219322710|NCT04537273|OTHER|Descriptive and analytical|
219322711|NCT00706550|BIOLOGICAL|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
219322712|NCT00706550|BIOLOGICAL|Placebo|Placebo
219322713|NCT00551551|OTHER|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
219322714|NCT00551551|OTHER|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
219322715|NCT05242757|OTHER|Mixed-activated Killer Immune Cells|Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
219322716|NCT03599037|OTHER|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
219355133|NCT01158521|DRUG|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
219355134|NCT01158521|PROCEDURE|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
219355135|NCT03158870|PROCEDURE|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
219355136|NCT01382732|DRUG|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
219355137|NCT01382732|DRUG|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
219322717|NCT05671783|OTHER|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
219322718|NCT00806676|DRUG|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
219322719|NCT02924298|BEHAVIORAL|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
219322720|NCT06313450|RADIATION|de-escalated radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.
219322721|NCT06313450|RADIATION|conventional radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.
219322722|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
219322723|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
219322724|NCT05514704|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
219322725|NCT05514704|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
219322726|NCT05881967|DIAGNOSTIC_TEST|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
219322727|NCT06306287|BEHAVIORAL|ePACE Personalized Intervention|The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.
219322728|NCT06306287|BEHAVIORAL|eFACE Fixed Intervention|The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
219322729|NCT04608760|DRUG|Meksibel|2 ml solution
219322730|NCT03989076|PROCEDURE|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
219322731|NCT01573078|BEHAVIORAL|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
219322732|NCT03406143|PROCEDURE|CGF injection|CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
219322733|NCT03406143|PROCEDURE|Control|Saline will be injected into expanded skin
219322734|NCT03702751|PROCEDURE|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
219322735|NCT03702751|PROCEDURE|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
219322736|NCT02822950|DRUG|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
219322737|NCT00006392|DRUG|Vitamin E|400 IU daily by mouth for 7-12 years
219322738|NCT00006392|DRUG|Selenium|200 mcg daily for 7-12 years
219322739|NCT00006392|OTHER|Vitamin E placebo|daily for 7-12 years
219322740|NCT00006392|OTHER|selenium placebo|daily for 7-12 years
219322741|NCT02068365|DRUG|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
219322742|NCT02594423|DEVICE|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
219322743|NCT02594423|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
219355138|NCT04388995|DIAGNOSTIC_TEST|volume expansion|volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
219355139|NCT04264533|DRUG|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
219322744|NCT06474910|OTHER|Connective tissue massage|In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
219322745|NCT06474910|OTHER|Exercise|Only exercise program will be applied to 15 patients in this group. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
219322746|NCT02933632|OTHER|Physical Therapy-SAP|"* Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date."
219322747|NCT02933632|OTHER|Physical Therapy-ARP|"* Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach."
219322748|NCT04758299|OTHER|decision science-based design|decision science-based design explaining actions to take for a negative or positive COVID-19 test
219322749|NCT00864890|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
219322750|NCT00864890|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
219322751|NCT03579082|DRUG|Decitabine|Given ivgtt
219322752|NCT01186796|DRUG|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
219322753|NCT02459769|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
219322754|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
219322755|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
219322756|NCT00652730|DRUG|Buspar|Tablets, 30 mg, single-dose, fed conditions
219322757|NCT03623594|PROCEDURE|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
219322758|NCT01188473|OTHER|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
219322759|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
219322760|NCT03083704|DRUG|Apixaban 5 MG|factor Xa inhibitor
219322761|NCT03083704|DRUG|Rivaroxaban 20 MG|factor Xa inhibitor
219322762|NCT03083704|DRUG|Enoxaparin sodium|low molecular weight heparin
219322763|NCT03083704|DRUG|Edoxaban 60 MG|factor Xa inhibitor
219322764|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
219322765|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
219322766|NCT03083704|DRUG|Apixaban 10 MG|factor Xa inhibitor
219322767|NCT03083704|DRUG|Rivaroxaban 10 MG|factor Xa inhibitor
219322768|NCT00245310|PROCEDURE|Indocyangreen (ICG) clearance|
219322769|NCT04103489|DRUG|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
219322770|NCT05022394|BIOLOGICAL|Nivolumab|Given IV
219322771|NCT05022394|DRUG|Sapanisertib|Given PO
219322772|NCT00314509|DRUG|Ciclesonide/Formoterol Combination|
219322773|NCT05070039|GENETIC|Expression of Cortactin anti body|assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
219322774|NCT01657474|OTHER|Weekly application of EpiFix plus standard of care|
219322775|NCT01657474|OTHER|Biweekly application of EpiFix plus standard of care|
219322776|NCT00190710|DRUG|Gemcitabine|
219322777|NCT00190710|DRUG|Carboplatin|
219322778|NCT00684450|PROCEDURE|Titration protamine|10\. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
219322779|NCT00684450|DRUG|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
219322780|NCT05067426|OTHER|Exercise|high-intensity interval training sessions
219322781|NCT02807051|DRUG|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
219322782|NCT02807051|DRUG|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
219322783|NCT02807051|DRUG|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
219322784|NCT01049243|DRUG|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
219322785|NCT01294488|BEHAVIORAL|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
219322786|NCT06326892|PROCEDURE|Natural Orifice Specimen Extraction (NOSE)|Low rectal cancer resection with Total Mesorectal Excision (TME) and Natural Orifice Specimen Extraction (NOSE)
219322787|NCT06326892|PROCEDURE|Traditional specimen extraction|Low rectal cancer resection with Total Mesorectal Excision (TME) and specimen extraction through Pfannenstiel incision
219322788|NCT02094833|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
219322789|NCT02094833|BIOLOGICAL|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
219322790|NCT00383357|DRUG|zolpidem|
219322791|NCT04646681|BEHAVIORAL|ConnectCare|increased monitoring between clinical mental health visits
219322792|NCT03808389|OTHER|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
219322793|NCT03808389|OTHER|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
219322794|NCT06439173|BIOLOGICAL|CAR-T cell therapy|Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy at the University Hospital of Salamanca
219322795|NCT05506579|OTHER|Exercises for knees, lower back, hip/groin and pelvic floor muscles in an expanded warm up program|Rhythmic gymnastics clubs allocated to the intervention group will be visited by a physiotherapist (the PhD candidate), which will perform thorough teaching of coaches and gymnasts on how to perform the exercises in the expanded warm up program. During the same visit, before commencing PFMT, the gymnasts will have an individual session were a portable 2D ultrasound machine (GE Healthcare -Logiq e R7, GE\>12L-RS - 5-13 MHz Wideband Linear Probe) will be used to teach and assess ability to perform a correct PFM contraction. The probe is placed suprapubically and provides concurrent visible biofeedback of the PFM contraction. Adherence to the intervention will be registered weekly by the coach in a training diary and asked for as an additional question in the monthly OSTRC-H2 sent to the gymnasts. Reminders will be sent by phone to the coaches every week. To assure proper execution and motivation, the PhD candidate will perform one extra visit midterm.
219322796|NCT05543278|DRUG|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
219322797|NCT02914054|DRUG|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
219322798|NCT02914054|DRUG|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
219322799|NCT05589779|OTHER|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
219322800|NCT03889275|BIOLOGICAL|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
219322801|NCT03889275|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
219322802|NCT00686270|DRUG|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
219355140|NCT04264533|DRUG|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
219322803|NCT00992979|PROCEDURE|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
219355141|NCT02501278|BIOLOGICAL|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~* VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~* INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
219322804|NCT00992979|PROCEDURE|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
219322805|NCT05315050|OTHER|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
219322806|NCT05315050|OTHER|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
219322807|NCT02336841|OTHER|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
219322808|NCT02336841|OTHER|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
219322809|NCT06524583|DRUG|Doxorubicin|60 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
219322810|NCT06524583|DRUG|Trabectedin|1.1 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
219322811|NCT06317818|OTHER|Mesenchymal Stem Cells|Suspension of mesenchymal stromal cells for intratissular injection
219322812|NCT06317818|OTHER|Comparative placebo|Cell-free cell suspension solution devoid of cells for intratissular injection
219322813|NCT06419192|OTHER|dietary advice|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
219322814|NCT06419192|OTHER|dietary advice alone|Advise to eat 7 dates a day from 37SA until delivery. The food will not be provided.
219322815|NCT06419192|OTHER|food supplied|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
219322816|NCT02577744|OTHER|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
219322817|NCT02577744|OTHER|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
219322818|NCT01053442|DIETARY_SUPPLEMENT|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
219322819|NCT01053442|DIETARY_SUPPLEMENT|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
219322820|NCT01316185|DRUG|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
219322821|NCT03612362|DEVICE|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence \& HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements \& suitably short follow-up period to decrease attrition."
219322822|NCT05446428|OTHER|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
219322823|NCT04035226|OTHER|No intervention|No intervention will be administered as a part of this study.
219322824|NCT02104154|DEVICE|Samsung LABGEO PT10 Hepatic Panel|
219322825|NCT00002296|DRUG|Inosine pranobex|
219322826|NCT00440076|DRUG|Velcade|
219322827|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
219322828|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
219322829|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
219322830|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
219322831|NCT01921855|DRUG|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
219322832|NCT01087099|DRUG|Albendazole|Treatment with albendazole
219322833|NCT02679599|OTHER|B-MOBILE-CARDIAC smartphone application|
219322834|NCT02679599|BEHAVIORAL|Cardiac rehabilitation as usual|
219322835|NCT00003757|BIOLOGICAL|rituximab|
219322836|NCT01439542|RADIATION|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
219322837|NCT01439542|DRUG|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
219322838|NCT04098042|DEVICE|Scaffold|implantation of a Magmaris scaffold
219322839|NCT04042870|BEHAVIORAL|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
219322840|NCT00112775|DRUG|dasatinib|
219322841|NCT00112775|DRUG|imatinib mesylate|
219322842|NCT00465946|BEHAVIORAL|Salt Supplementation|
219322843|NCT03966261|OTHER|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
219322844|NCT01543724|DRUG|Lithium|10mg/kg/day for 12 weeks
219322845|NCT00890149|DRUG|Ondansetron|Ondansetron (4ug/kg bid),
219322846|NCT00890149|DRUG|Placebo|Placebo bid
219322847|NCT00890149|BEHAVIORAL|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
219322848|NCT03752099|DRUG|VERU-111|VERU-111
219322849|NCT04656314|DIAGNOSTIC_TEST|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
219322850|NCT03646500|PROCEDURE|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
219322851|NCT03646500|PROCEDURE|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
219322852|NCT01673568|DEVICE|ETO garments|patients wearing abdominal binder for 7 days postoperatively
219322853|NCT03279874|OTHER|Interviews|Semi-structured one-on-one interviews
219322854|NCT05924685|BIOLOGICAL|COVID-19 vaccination|Vaccination
219322855|NCT01993446|DRUG|DRM02|
219322856|NCT01993446|OTHER|Vehicle|
219322857|NCT00952172|BEHAVIORAL|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
219322858|NCT02220309|DRUG|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
219322859|NCT05087355|DIAGNOSTIC_TEST|PCR or antigen test for Covid 19 or Inluenza|PCR or antigen test for Covid 19 or Inluenza
219322860|NCT04866654|DRUG|Nivolumab 10 MG/ML|Nivolumab, 100 mg, 10 mg/ml
219322861|NCT04141254|OTHER|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
219322862|NCT04141254|OTHER|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
219322863|NCT06414915|DRUG|Surufatinib|250 mg, po, qd, q3w
219322864|NCT06414915|DRUG|Tislelizumab|200mg, iv, q3w
219322865|NCT00728481|DRUG|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
219322866|NCT00728481|DRUG|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
219322867|NCT00629655|OTHER|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
219322868|NCT01068925|DRUG|GSK1349572|"1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
219322869|NCT01824680|BEHAVIORAL|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
219322870|NCT00514657|DRUG|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
219322871|NCT00816309|DEVICE|Acapella Physiotherapy|twice daily- around 20 minutes
219322872|NCT02545322|RADIATION|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
219322873|NCT05860023|OTHER|Exercise|Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
219322874|NCT06264778|DRUG|Dabrafenib|"Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery."
219322875|NCT02748837|DRUG|ERY974|
219322876|NCT01071135|DRUG|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
219322877|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
219322878|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
219322879|NCT02183922|DIETARY_SUPPLEMENT|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
219322880|NCT00913250|DRUG|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
219322881|NCT00913250|DRUG|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
219322882|NCT01891435|DRUG|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
219322883|NCT01891435|DRUG|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
219322884|NCT01891435|DRUG|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
219322885|NCT00993135|DRUG|methotrexate|
219322886|NCT00993135|OTHER|medical chart review|
219322887|NCT00993135|PROCEDURE|assessment of therapy complications|
219322888|NCT04249414|DEVICE|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
219322889|NCT04370288|DRUG|MCN (Methylene blue, vitamin C, N-acetyl cysteine)|A mixture of MCN will be injected to covid-19 patients.
219322890|NCT04530461|DIAGNOSTIC_TEST|Serological test|Positive serological test of SARS Cov2
219322891|NCT00698464|DRUG|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
219322892|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
219322893|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
219322894|NCT01505010|PROCEDURE|Renal denervation|Renal denervation in the intervention group
219322895|NCT00270465|DRUG|VRC-HIVDNA016-00-VP|
219322896|NCT00270465|DRUG|VRC-HIVADV014-00-VP|
219322897|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
219322898|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
219322899|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
219322900|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
219322901|NCT03271346|BEHAVIORAL|intensive trauma-focused therapy|
219322902|NCT01722149|GENETIC|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
219322903|NCT02080455|DRUG|lomitapide|20 mg dose
219322904|NCT02080455|DRUG|Atorvastatin|80 mg
219322905|NCT05344768|OTHER|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
219322906|NCT05344768|OTHER|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
219322907|NCT05344768|OTHER|resistance exercise training|resistance exercise training will be applied
219322908|NCT04268043|DEVICE|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
219322909|NCT04268043|DEVICE|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
219322910|NCT02830997|DEVICE|Stereotactic guidance system|
219322911|NCT06493487|OTHER|integrated neuromuscular inhibition technique|integrated neuromuscular inhibition technique for gastrocniemus muscle
219322912|NCT06493487|OTHER|instrument assissted soft tissue mobilization|instrument assissted soft tissue mobilization for calf muscle
219322913|NCT06493487|OTHER|convential treatment|convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
219322914|NCT03051581|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
219322915|NCT00108069|DRUG|Tamoxifen citrate|oral dose 120 mg twice a day, every day
219322916|NCT00108069|DRUG|Bortezomib|intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
219322917|NCT05290688|GENETIC|50 ml blodd sampling|50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
219322918|NCT00995007|DRUG|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
219322919|NCT00995007|DRUG|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
219322920|NCT04696991|BEHAVIORAL|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
219322921|NCT02670681|BEHAVIORAL|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
219322922|NCT04641780|DRUG|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
219322923|NCT01612143|DRUG|setrobuvir|200 mg capsule formulation, single oral dose
219322924|NCT01612143|DRUG|setrobuvir|200 mg tablet formulation, single oral dose
219322925|NCT02370680|DRUG|Aspirin|steady-state run-in prior to Durlaza treatment
219322926|NCT02370680|DRUG|Durlaza™|comparison of different numbers of capsules
219322927|NCT02515578|OTHER|Enhanced practice transformation support|
219322928|NCT02515578|OTHER|Standard practice transformation support|
219322929|NCT04939662|DRUG|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
219322930|NCT03732079|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
219322931|NCT06068660|BEHAVIORAL|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
219322932|NCT06068660|BEHAVIORAL|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
219322933|NCT03956368|DRUG|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
219322934|NCT03956368|DRUG|Placebos|20mg (every evening orally) for 8 weeks.
219322935|NCT06363279|OTHER|Conducting questionnaires|The questionnaires will be administered online or in person.
219322936|NCT01910116|DRUG|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
219322937|NCT01910116|DRUG|Placebo|The study medication and placebo were identical in appearance.
219322938|NCT01037907|DRUG|Pleneva TM BGC20-0134|Placebo or 5 g dose
219322939|NCT01037907|DRUG|Placebo|Placebo or 5 g dose
219322940|NCT01686360|BEHAVIORAL|Decision Aid|
219322941|NCT05384379|DRUG|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
219322942|NCT05206591|BIOLOGICAL|Secukinumab|Secukinumab 300 s.c.
219322943|NCT05206591|OTHER|Placebo|Placebo
219322944|NCT06072560|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
219322945|NCT06072560|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
219322946|NCT03606980|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
219322947|NCT03606980|PROCEDURE|Iontophoresis|Iontophoresis on affected knee
219322948|NCT03606980|PROCEDURE|Physical Therapy|Physical therapy of affected knee
219322949|NCT00194844|BEHAVIORAL|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
219322950|NCT00194844|BEHAVIORAL|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
219322951|NCT00194844|BEHAVIORAL|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
219322952|NCT02218190|DRUG|Alvimopan|
219322953|NCT02218190|DRUG|Placebo|
219322954|NCT02469896|DRUG|Tocilizumab|IV Infusion
219322955|NCT02469896|OTHER|Placebo|IV Infusion
219322956|NCT05709236|DEVICE|Maxillary screw-retained prosthesis|Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
219322957|NCT03937284|OTHER|Patients not treated|
219322958|NCT02839057|PROCEDURE|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
219322959|NCT02839057|PROCEDURE|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
219322960|NCT04862624|BEHAVIORAL|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
219322961|NCT04862624|BEHAVIORAL|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
219322962|NCT01294150|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
219322963|NCT01294150|OTHER|Cystoscopy|The Control Group will undergo cystoscopy.
219322964|NCT01294150|DEVICE|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
219322965|NCT03708120|OTHER|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
219322966|NCT00127920|DRUG|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
219322967|NCT03675776|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
219322968|NCT03675776|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration).
219322969|NCT02368067|PROCEDURE|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
219322970|NCT02368067|PROCEDURE|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
219322971|NCT01519076|DEVICE|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
219322972|NCT03914404|DRUG|γ-linoleic acid and placebo(Thioctic Acid)|"* γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
219322973|NCT03914404|DRUG|Thioctic Acid and placebo(γ-linoleic acid)|"* Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
219322974|NCT01499472|DEVICE|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
219322975|NCT01499472|DEVICE|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
219322976|NCT01499472|PROCEDURE|standard of care|regular care including debridement and bandaging.
219322977|NCT03726762|BEHAVIORAL|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
219322978|NCT03726762|BEHAVIORAL|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
219322979|NCT01351623|DRUG|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
219322980|NCT04273256|DRUG|Myo-inositol|patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
219322981|NCT01959048|DRUG|fecal microbiota transplantation|
219322982|NCT03920813|DRUG|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
219322983|NCT01130974|DEVICE|Bausch & Lomb contact lens|Bausch \& Lomb daily disposable cosmetic tint contact lens
219322984|NCT01130974|DEVICE|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
219322985|NCT01484730|DEVICE|Multi-Spectral and Laser Speckle Imaging|Changes in skin tissue and blood flow.
219322986|NCT06062433|DEVICE|AsthmaTuner|Phone application and spirometer for self-management of asthma
219322987|NCT06062433|OTHER|Asthma-Guidance and Prediction System|Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
219322988|NCT01184053|DRUG|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
219322989|NCT02536573|OTHER|Radlink Surgical Positioning Software|
219322990|NCT02903082|BIOLOGICAL|Residue of blood further to NFS|
219322991|NCT02903082|BIOLOGICAL|Residue of blood further to preoperative workup|
219322992|NCT02903082|BIOLOGICAL|Bone marrow collected during a myelogram carried out for hematological pathology workup|
219322993|NCT02903082|BIOLOGICAL|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
219322994|NCT04418544|DEVICE|Device used to record voice for screening|voice recording
219322995|NCT04399122|DRUG|acetaminophen/codeine vs acetaminophen/oxycodone|pain medications
219322996|NCT00179166|DRUG|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
219322997|NCT01083628|BEHAVIORAL|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
219322998|NCT01083628|BEHAVIORAL|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
219322999|NCT04557085|DRUG|Cenobamate|Cenobamate tablets
219323000|NCT04557085|DRUG|Placebo|Matching placebo tablets
219323001|NCT02536755|DRUG|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
219323002|NCT02086851|BEHAVIORAL|Lifestyle Intervention|
219323003|NCT02086851|BEHAVIORAL|Parent Motivational Interviewing|
219323004|NCT06073379|OTHER|Korean manupuncture|Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
219323005|NCT06073379|OTHER|Placebo session|Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
219323006|NCT00187395|PROCEDURE|Randomized to either a 'less tight' group or a 'tight' group|
219323007|NCT01493258|OTHER|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
219323008|NCT01174238|DRUG|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
219323009|NCT01174238|DRUG|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
219323010|NCT01174238|DRUG|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
219323011|NCT00557583|DRUG|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
219323012|NCT02674191|DEVICE|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
219323013|NCT02674191|PROCEDURE|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
219323014|NCT02674191|PROCEDURE|Administration of , Mepivacaine-l|local anesthesia
219323015|NCT02674191|PROCEDURE|BETADINE povidone-iodine 10%|a local disinfectant
219323016|NCT02674191|DRUG|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
219323017|NCT02674191|DRUG|(Cataflam 25mg), are prescribed post-operatively|an analgesic
219323018|NCT00000268|DRUG|Bupropion|
219323019|NCT01638091|BEHAVIORAL|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
219323020|NCT01638091|BEHAVIORAL|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
219323021|NCT01391585|OTHER|Text Message prompts|In this single armed intervention, patients will receive text message prompts
219323022|NCT01416987|DRUG|Pergoveris®|Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
219323023|NCT01322984|BEHAVIORAL|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
219323024|NCT01322984|BEHAVIORAL|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
219323025|NCT05261971|DRUG|Etodolac 400 MG|Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
219323026|NCT05261971|DRUG|Thiocolchicoside|Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
219323027|NCT01923116|DRUG|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
219323028|NCT01102803|BEHAVIORAL|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
219323029|NCT01102803|DRUG|D-Cycloserine|D-Cycloserine
219323030|NCT01102803|DRUG|Placebo|Sugar Pill
219323031|NCT05487339|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopy device
219323032|NCT05279209|PROCEDURE|catheter-directed sclerotherapy|Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.
219323033|NCT05279209|PROCEDURE|surgical resection|Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
219323034|NCT04688723|DRUG|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
219323035|NCT04688723|DRUG|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
219323036|NCT04356911|OTHER|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
219323037|NCT04356911|OTHER|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
219323038|NCT04356911|OTHER|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
219355142|NCT02501278|RADIATION|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
219355143|NCT02501278|DRUG|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
219355144|NCT01662583|OTHER|Text Message|
219355145|NCT01662583|OTHER|Written reminder|
219355146|NCT03612271|BEHAVIORAL|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
219354763|NCT06242483|OTHER|Elfie Solution|"The Elfie solution was designed to improve knowledge, adherence, and the quality of care for patients with cardiovascular diseases. The Elfie solution comprises a mobile phone app with the following features related to hypertension:~1. Personalized monitoring plan based on health conditions to guide frequency of monitoring of blood pressure, weight, and step count~2. Digital pillbox with daily medication-taking reminders and refill reminders~3. Clinical measurements graphs for BP, weight, medical adherence and step count~4. Newsfeed with short videos and texts related to cardiovascular diseases~5. Digital coach - Artificial intelligence technology that provides information via a chatbox as well as feedback information via personalized videos. This feature does not provide medical advice.~6. Connection with a health app or wearable for step count~7. Possibility of family peer support~8. Gamification through the Elfie rewards scoring system"
219354764|NCT01248351|OTHER|autologous stored platelets|Administration of autologous stored platelets
219354765|NCT01248351|OTHER|administration of autologous stored platelets|administration of autologous stored platelets
219354766|NCT01248351|BIOLOGICAL|autologous stored platelets|transfusion of autologous stored platelets
219354767|NCT04623983|DEVICE|bonding tray|Orthodontic bonding tray
219323039|NCT04356911|OTHER|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
219323040|NCT00067951|DRUG|rosiglitazone/metformin|
219354768|NCT05313061|DRUG|MTX|MTX continuation
219354769|NCT01635114|DIETARY_SUPPLEMENT|resveratrol|150 mg resVida per day for 12 weeks
219354770|NCT01635114|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
219354771|NCT04697407|BIOLOGICAL|Blood sampling|In all groups, 80 ml of blood will be collected. For patients, this will be done during routine cares.
219354772|NCT04697407|BIOLOGICAL|CSF sampling|Only in both patients groups whom will have a CSF sampling in routine care, some CSF will be collected for the study in addition, with a limit of 5 ml for routine care and study.
219354773|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 500mg|Mitopure containing softgels
219354774|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 1000mg|Mitopure containing softgels
219354775|NCT03464500|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
219354776|NCT00142701|BEHAVIORAL|diet|
219354777|NCT00142701|BEHAVIORAL|physical activity|
219354778|NCT00142701|BEHAVIORAL|stress management|
219354779|NCT00142701|BEHAVIORAL|smoking cessation|
219354780|NCT02499432|BEHAVIORAL|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
219354781|NCT02698735|DRUG|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
219323041|NCT00613054|DRUG|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations."
219323042|NCT02877212|DRUG|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
219323043|NCT03976791|PROCEDURE|enlarged internal incision|enlarging the internal incision about 0.4mm
219323044|NCT03976791|PROCEDURE|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
219323045|NCT02022345|PROCEDURE|Percutaneous Coronary Intervention|
219323046|NCT04525339|PROCEDURE|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
219323047|NCT02435342|DRUG|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
219323048|NCT02435342|DRUG|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
219323049|NCT01395251|DRUG|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
219323050|NCT05732662|RADIATION|SBRT|24-50Gy/8-12.5Gy/3-4f
219323051|NCT05732662|DRUG|Cadonilimab|10 mg/kg,q3w
219323052|NCT04964570|BEHAVIORAL|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
219354782|NCT02698735|DRUG|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
219354783|NCT02653768|BEHAVIORAL|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
219323053|NCT06056674|BEHAVIORAL|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
219323054|NCT06056674|BEHAVIORAL|SAU|Participants in this group will continue to receive standard of care within their school clinic.
219323055|NCT02733185|DRUG|disodium EDTA|IV Disodium Ethylene diamine tetra acetic acid in 500 cc
219323056|NCT02733185|DIETARY_SUPPLEMENT|Oral Multi Vitamins/Minerals (OMVM)|6 tablets of Multi-vitamin/Multimineral daily
219323057|NCT02733185|DRUG|Placebo disodium EDTA|IV Placebo comparator- 500 normal saline
219323058|NCT02733185|DIETARY_SUPPLEMENT|Placebo Oral Multi Vitamins/Minerals (OMVM)|6 tablets of a placebo Multi-vitamin/Multimineral daily
219323059|NCT06974916|PROCEDURE|Staged bilateral Exablate thalamotomy|Staged bilateral Exablate thalamotomy in ET patients
219323060|NCT06974916|OTHER|Local standard medical treatment after previous Exablate unilateral thalamotomy.|Local standard medical treatment
219323061|NCT04470609|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219323062|NCT04470609|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219323063|NCT04470609|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219323064|NCT04470609|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
219323065|NCT02593786|DRUG|Nivolumab|
219323066|NCT00188422|PROCEDURE|low dose CT|
219323067|NCT00198627|DRUG|Co-Trimoxazole; TMP-SMZ|
219323068|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
219323069|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
219323070|NCT02659579|BEHAVIORAL|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
219323071|NCT02659579|BEHAVIORAL|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
219323072|NCT00464230|PROCEDURE|Bipolar hemiarthroplasty (Charnley/Hastings)|
219323073|NCT00464230|PROCEDURE|Internal fixation with two parallel screws (Olmed)|
219323074|NCT00835120|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
219323075|NCT01624259|DRUG|LY2189265|Administered SC
219323076|NCT01624259|DRUG|Liraglutide|Administered SC
219323077|NCT01624259|DRUG|Metformin|
219354784|NCT02653768|BEHAVIORAL|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
219323078|NCT03813290|DEVICE|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
219323079|NCT04768270|OTHER|no intervention|It is an observation trial.
219323080|NCT02407366|DRUG|Icotinib|Icotinib (125 mg ,Three times daily)
219323081|NCT02407366|DRUG|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
219323082|NCT02407366|DRUG|Carboplatin|Carboplatin (AUC，5) every 21 days
219323083|NCT02407366|RADIATION|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
219323084|NCT03029169|DRUG|Propafenone i.v.|Treatment
219323085|NCT03029169|DRUG|Amiodarone i.v.|Treatment
219323086|NCT06072287|DIAGNOSTIC_TEST|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
219323087|NCT04689997|BEHAVIORAL|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
219323088|NCT00671554|BIOLOGICAL|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
219323089|NCT01028456|OTHER|Light Therapy|10,000 lux / 30 minutes a day
219323090|NCT01028456|OTHER|100 lux|Placebo light
219323091|NCT04304781|DRUG|KSP/QRH dimer|Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
219323092|NCT02342756|DEVICE|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
219323093|NCT00036894|DRUG|lenalidomide|
219323094|NCT04621929|DRUG|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
219323095|NCT04621929|COMBINATION_PRODUCT|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
219323096|NCT03823768|DRUG|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
219323097|NCT03823768|DRUG|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
219323098|NCT07128745|BEHAVIORAL|Shared Medical Appointment + Self-Management Strategy|Participants assigned to this arm will receive a self-management intervention delivered through shared medical appointments (SMAs). The SMA intervention will be conducted once every two months for a total of three sessions over six months. Each session includes structured medical consultation, health education, behavioral guidance based on the Behavior Change Wheel (BCW) framework, and facilitated peer discussion.
219323099|NCT07128745|BEHAVIORAL|Usual Care + Self-Management Handbook|Participants receive routine one-on-one GP care plus a printed COPD self-management education handbook.
219323100|NCT07130682|RADIATION|Pencil Beam Proton Therapy Treatment Machine|2 fractions will be delivered to treat low- or intermediate- risk prostate cancer
219323101|NCT07130617|DRUG|Low dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.
219323102|NCT07130617|DRUG|Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 625 mg/day, administered once daily (QD) for 7 consecutive days.
219323103|NCT07130617|DRUG|High dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 937.5 mg/day, administered once daily (QD) for 7 consecutive days.
219323104|NCT07130617|DRUG|Megestrol Acetate Oral Suspension Placebo combined with standard therapy|A single dose of 5 mL/day, administered once daily (QD) for 7 consecutive days.
219323105|NCT07128628|DRUG|Lifitegrast/Perfluorohexyloctane Fixed Dose Combination|Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
219323106|NCT07128628|DRUG|Lifitegrast|Topical ocular drop of lifitegrast administered for 4 weeks
219323107|NCT07128628|DRUG|Perfluorohexyloctane|Topical ocular drop of perfluorohexyloctane administered for 4 weeks
219323108|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
219323109|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
219323110|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
219323111|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with tislelizumab|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Tislelizumab，200 mg, iv, d1, Q3W, until disease progression or intolerable toxicity."
219323112|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with anlotinib|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Anlotinib 12mg QD po d1-14，Q3W,until disease progression or intolerable toxicity."
219323113|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 2 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
219323114|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 4 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
219323115|NCT07130149|PROCEDURE|Sonodynamic Therapy (SDT)|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted.
219323116|NCT07130149|OTHER|Standard Treatment|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
219323117|NCT05775510|DEVICE|Commercially available neurostimulation systems|Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
219323118|NCT06827470|BIOLOGICAL|Biological: Bordetella pertussis J820|Intranasal inoculation of Bordetella pertussis J820 in each naris on Day 1 of the study.
219323119|NCT00639210|OTHER|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
219323120|NCT05552209|DEVICE|Elbow MID 500|15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.
219323121|NCT05552209|OTHER|Control group Elbow MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.
219323122|NCT05552209|DEVICE|Elbow STRAP|15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.
219323123|NCT05552209|OTHER|Control group Elbow STRAP|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
219323124|NCT03331016|BEHAVIORAL|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
219323125|NCT06020807|DIAGNOSTIC_TEST|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
219323126|NCT02618954|OTHER|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
219323127|NCT02274168|PROCEDURE|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
219323128|NCT02274168|PROCEDURE|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
219323129|NCT06148857|DIAGNOSTIC_TEST|IOLMaster 700|"The IOLMaster 700, one of the most commonly used optical biometers for IOL power calculation, measures the anterior corneal surface radius using a telecentric keratometry. Additionally, it employs swept-source optical coherence tomography (SS-OCT) technology to simultaneously measures the posterior cornea surface radius and central corneal thickness (CCT).~The AK formula, described by Abulafia et al., is a regression formula that calculates an estimated TCA using K astigmatism.~The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements."
219323130|NCT01768650|BEHAVIORAL|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
219323131|NCT01768650|BEHAVIORAL|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
219323132|NCT03828292|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
219323133|NCT03828292|DRUG|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
219323134|NCT03828292|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally.
219323135|NCT03828292|DRUG|Pomalidomide|Pomalidomide capsules will be administered orally.
219323136|NCT00359151|DRUG|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
219323137|NCT00359151|DRUG|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
219323138|NCT00285077|DRUG|SR57667B|
219323139|NCT05343026|DEVICE|Hearing aids|As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
219323140|NCT05060731|DRUG|Oral iron supplementation|Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
219323141|NCT05060731|DRUG|Intravenous iron supplementation|One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
219323142|NCT04924244|OTHER|Music Therapy|We will play music of the subject's choice of genre during the procedure.
219323143|NCT04924244|OTHER|No Music|No music will be played during the subject's interventional procedure
219323144|NCT02247908|OTHER|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~1. SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~2. SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~3. SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~4. SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
219323145|NCT02247908|OTHER|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~1. Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~2. Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~3. Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~4. Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
219323146|NCT00478101|DRUG|oxycodone fentanyl|
219323147|NCT06658912|OTHER|TOPS Classes|Attend Dietician-Led Sessions
219323148|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
219323149|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
219323150|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
219323151|NCT04159337|OTHER|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
219323152|NCT05553470|DRUG|Miricorilant|600 mg miricorilant
219323153|NCT06586723|BEHAVIORAL|PBIS|Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.
219323154|NCT06586723|OTHER|HELM|Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
219323155|NCT06604741|OTHER|Assigned Interventions for LVIMT|"IMT is a form of exercise designed to strengthen the muscle involved inhalation, primarily the diaphragm and intercostal muscles.~The LVIMT group will perform IMT once daily, 5 days a week, maintaining 60% of maximal inspiratory pressure (MIP) throughout the 6-week intervention.~The intervals are typically longer in duration (e.g., 2-4 minutes) with a work-to-rest ratio of 1:1 or 1:0.5.~POSITION: rested and seated position. FREQUENCY: more frequency, once a day. 2-3 sessions per week. INTENSITY: Low resistance. Only 60%% MIP. TIME: shorter duration of 10-20 mint."
219354785|NCT04036409|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
219323156|NCT06604741|OTHER|Assigned interventions for HVIMT|"The HVIMT group is trained twice daily, with the morning session matching the LV-IMT protocol, and an additional afternoon session. The HVIMT group also experienced a progressive increase in intensity, starting at 60% MIP and reaching 80% by the end of the study. LVIMT works for beginner or individuals with limited respiratory capacity while HVIMT is used for individual with high baseline respiratory fitness.~The intervals are typically shorter in duration (e.g., 30 seconds to 2 minutes) with a work-to-rest ratio of 1:1 or 1:2.~POSITION; Seated upright position. FREQUENCY: more frequency two session per week. 4-5 sessions per week. INTENSITY: high resistance. 60%-80% MIP.~(gradual increment the load by 10% every 2 weeks to reach 80% MIP)~TIME: longer duration 20-30 mint."
219323157|NCT04084964|OTHER|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
219323158|NCT07130435|BEHAVIORAL|Salutogenic Model-Based Healthy Aging Program|The Salutogenic Model-Based Healthy Aging Program is designed to enhance the sense of coherence and promote healthy aging among older adults aged 60-70. The program focuses on strengthening participants' internal resources, building resilience, and improving overall quality of life. It includes educational sessions, group discussions, and practical strategies for managing hypertension and diabetes, all while emphasizing physical, emotional, and mental well-being. The program aims to empower participants to make informed lifestyle choices and cope with the challenges of aging. Participants will receive regular follow-up assessments to track progress and ensure continued support throughout the study period.
219323159|NCT07129083|OTHER|Structured assessment interview|Participants completed a structured, in-person assessment conducted during one to three dialysis sessions. The assessment included validated instruments to measure overall quality of life (ACSA), health-related quality of life (EQ-5D-3L, EORTC QLQ-C30, QLQ-MY20), and various clinical, psychological, functional, and sociodemographic factors.
219323160|NCT07129824|OTHER|Observation|Observe the effect of eating habits and food preferences on symptoms of chronic gastritis
219354786|NCT04036409|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
219323161|NCT07130916|DRUG|Aumolertinib|In Part A, participants will receive aumolertinib 110 mg (2 × 55 mg tablet) once daily, orally administrated under fasted condition (fasting from 2 hours before to 1 hour after dosing) in 21-day treatment cycles. In Part B, participants may continue study intervention (aumolertinib 110 mg once daily) until PD, death, intolerable toxicity, Investigator's decision, lost of follow-up, receiving another anti-cancer therapy, or any other pre-defined discontinuation criteria.
219323162|NCT07129109|DIETARY_SUPPLEMENT|small-quantity lipid-based nutrient supplements (SQ-LNS)|All caregivers will receive 2 months of SQ-LNS in this cross-over design. Half of the participants will be randomized to receive the 7-day packaging first, and half will receive the 1-day packaging first.
219323163|NCT04422756|DIAGNOSTIC_TEST|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."
219354787|NCT01784965|DRUG|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
219323164|NCT04422756|DIAGNOSTIC_TEST|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."
219323165|NCT06283394|BEHAVIORAL|Storefront Choice Architecture|An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
219323166|NCT06283394|BEHAVIORAL|Fresh Funds|The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
219323167|NCT06283394|BEHAVIORAL|Loss Framing|They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
219323168|NCT05488782|BEHAVIORAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
219323169|NCT05488782|OTHER|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
219323170|NCT06902012|DRUG|Infusion of Axicabtagene Ciloleucel|"Drug: Axicabtagene Ciloleucel (CD19 CAR-T cells), 2×106 cells/kg, IV infusion at Day 0 and 30-90 days post-first infusion.~Drug: Cyclophosphamide (500 mg/m²) + Fludarabine (30 mg/m²), IV on Days -5, -4, -3.~Procedure: ctDNA monitoring via liquid biopsy at pre-lymphodepletion and Months 1, 2, 3, 6, 9, 12 post-infusion."
219323171|NCT01744353|DRUG|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
219323172|NCT01744353|DRUG|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
219323173|NCT01744353|DRUG|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
219323174|NCT01608867|BIOLOGICAL|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
219323175|NCT07024940|OTHER|Ethiopian Coffee|Ethiopian Coffee is used as a real-world example of one of the most common drinks in the world.
219323176|NCT07024940|DIETARY_SUPPLEMENT|Supplement|A pre-workout supplement that contains anthocyanins and caffeine as ergogenic aids
219323177|NCT07024940|OTHER|Water (Placebo)|Bottled water acting as the placebo
219323178|NCT07029438|DRUG|Mouthwash|Antiplaque/Antigingivitis Mouthwash
219323179|NCT07029438|DEVICE|Floss|Dental Floss
219323180|NCT07029438|DEVICE|Toothbrush|Soft bristled, manual toothbrush
219323181|NCT07029438|DRUG|Toothpaste|Sodium Monofluorophosphate 0.76 % (0.15% w/v fluoride ion) toothpaste
219323182|NCT07024641|DRUG|GIGA-2339|Administered by intravenous infusion
219323183|NCT07024641|DRUG|Placebo|Administered by intravenous infusion
219354788|NCT01784965|DRUG|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
219354789|NCT04110847|DRUG|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
219354790|NCT00670592|DRUG|HCD122|
219323184|NCT06376643|DEVICE|Augmented reality supportive tool|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario.~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
219355147|NCT06101615|OTHER|IASTM (FAT)|Group-A participants would receive Facial Abrasion Technique (FAT) with an Instrument, FAT-Tool. Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm), to avoid possible confounding circadian effects. The FAT group will receive 2 min application on the quadriceps and hamstring muscles with a FAT-tool Pro Large model, which consists of a handle and 20cm treatment surface. The muscles will be treated in a pre-stretched position, meaning a knee flexion in a supine position for the quadriceps muscle and a hip flexion and knee extension in a side-lying position for the hamstring muscles.
219323185|NCT06376643|OTHER|Conventional method (AHA pocket reference card)|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
219323186|NCT06703879|DRUG|Anesthesia induction with propofol|Establishment of a database of clinical characteristics of propofol-induced loss of consciousness in patients with complete clinical information Acquisition of basic perioperative monitoring data and extended monitoring data: 1,000 patients aged ≥18 years who needed to undergo surgical treatment were included (according to the machine learning diagnosis results, if the poor model fit was due to the small sample size, the necessary number of samples could be continued to be collected), and perioperative monitoring and management of the patients was performed, and a video recorder was used to videotape the whole anesthesia induction process in real time, so as to facilitate the postoperative integration of various data. The basic characteristics of the patients and the perioperative monitoring characteristics were extracted from the surgical anesthesia recording system, including gender, age, height, weight, blood pressure, ASA classification, electroencephalographic parameters, the a
219323187|NCT07130084|OTHER|Virtual Reality Educational Film|The Virtual Reality Educational Film will be viewed during the antenatal appointment, post randomisation. The women will have access to the film at home should they want to watch it more than once.
219323188|NCT07130279|BEHAVIORAL|Postural Exercises + Post-Isometric Relaxation (PIR) Technique|Participants will perform a standardized postural exercise program (strengthening, stretching, and mobility exercises for the cervical and thoracic regions) three times per week for six weeks. In addition, the Post-Isometric Relaxation (PIR) technique will be applied to jaw muscles during each session to reduce muscle tension and improve mandibular mobility.
219323189|NCT07130279|BEHAVIORAL|Postural Exercises|Participants will perform a standardized postural exercise program designed to improve cervical and thoracic mobility and postural alignment. The program will include strengthening, stretching, and mobility exercises targeting the cervical spine, thoracic spine, and related musculature. Each session will last approximately 30-40 minutes and will be conducted three times per week for six weeks under the supervision of a trained therapist.
219323190|NCT07031973|DIETARY_SUPPLEMENT|Active Effervescent Powder|Participants receive a daily sachet of effervescent powder that is Orange flavored, containing multiple vitamins and minerals
219323191|NCT07031973|DIETARY_SUPPLEMENT|Placebo Effervescent powder|Participants receive a daily sachet of effervescent powder that is Orange flavored containing no active ingredients
219323192|NCT07031973|OTHER|Nutrition training and healthy lifestyle coaching|Participants receive Nutrition training and healthy lifestyle coaching
219323193|NCT07042152|OTHER|Smartwatch App for Movement Variability|This app measures movement variability in the upper extremity as described in our previous study (doi:10.3390/s24165266).
219323194|NCT07042152|OTHER|Smartwatch App for Active Time|The other software we are using measures total active time of the upper extremity.
219323195|NCT07042152|BEHAVIORAL|Motivational Interviewing (Within Subjects)|Motivational Interviewing is an established therapeutic technique designed to increase patient adherence to therapy by addressing ambivalence. The motivational Interviewing sessions will include a variety of techniques such as: Open ended questions, Active Listening, Affirmation, Summarization, Questions focused on change talk, and Providing Information.
219323196|NCT06727682|BEHAVIORAL|Stress management|Ten-hour, three-course stress management programme with a psychologist via video conferencing over a 2 month period. The classes will be delivered in small groups of maximum seven care workers. Carers can be brought together in the same room, but the speaker will necessarily be at a distance, via videoconferencing. The formation will adress the following issues: i) Understanding the mechanisms of stress, ii) Identifying sources of stress and triggers, iii) Anticipate stressful situations and use their resources to prevent them, and iv) Use the most appropriate stress-reduction techniques, depending on their sensitivity.
219323197|NCT07128641|BIOLOGICAL|Odronextamab|A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.
219323198|NCT07130032|COMBINATION_PRODUCT|reICB regimen (NSCLC)|"* ICI (one of the following): Atezolizumab 1200 mg every 3 weeks/Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
219323199|NCT07130032|COMBINATION_PRODUCT|reICB regimen (melanoma)|"* ICI (one of the following): Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
219323200|NCT07129902|BEHAVIORAL|Contingency Management|Participants in the active arm will receive payment (monetary incentive) contingent on outpatient MOUD treatment attendance.
219323201|NCT07129902|BEHAVIORAL|Usual care as prescribed by the ED physicians|All participants will receive standard outpatient care at their clinic.
219323202|NCT07129421|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
219323203|NCT07129642|BIOLOGICAL|Allogeneic CAR-T|The participants will receive one dose of allogeneic CAR-T
219323204|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients will be positioned prone on the operation table. Intravenous access is opened. Monitorization for vital signs is performed. Light sedation with midazolam is performed. Under fluoroscopic guidance, medial branch nerve of each lumbar facet joint is found by searching the specific response to the stimulations of the radiofrequency needle. When the tip of the radiofrequency needle is close enough to the corresponding medial branch nerve, ablation with 80 degrees Celsius for 90 seconds is performed. Average 6-10 nerves are ablated in each procedure and the average duration of the procedure is 20-60 minutes.
219323205|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients are positioned prone on the operation table. Intravenous access is opened and monitorization of vital signs is applied. Skin is cleaned by povidone iodine solution. Light sedation is applied by midazolam. Lumbar vertebral region is seen under C-arm fluoroscopic view. Medial branch nerve of the lumbar facet joints is searched by 22 G width, 10-cm length radiofrequency needles. When the needle tip is close enough to the nerve, an 80 Celsius, 90-second radiofrequency ablation is applied. In each procedure, average 5-10 nerves is ablated and the duration of the procedure is 20-60 minutes.
219323206|NCT05784688|DRUG|TU2218 + KEYTRUDA® (Pembrolizumab)|TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered
219323207|NCT06901973|PROCEDURE|Intrafocal pinning|Intrafocal pinning involves the percutaneous insertion of Kirschner wires to stabilize the distal radius fracture, often followed by plaster immobilization.
219323208|NCT06901427|BEHAVIORAL|Mediterranean Diet and exercise|A structured dietary intervention promoting Mediterranean-style eating patterns and regular exercise for 12 weeks.
219323209|NCT06901830|DRUG|YZJ-4729|Loading dose + demand dose
219323210|NCT06901830|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
219323211|NCT06901830|DRUG|Active Comparator: Morphine|Loading dose + demand dose
219323212|NCT06902844|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
219323213|NCT06901622|DRUG|Camrelizumab, anlotinib, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, iv, q3w. Anlotinib: 10 mg, taken orally once a day, day 1\~14, q3w. For patients with intolerance, the dose can be reduced to 8 mg.~Nab-paclitaxel: 200 mg/m\^2, day 1, iv, q3w. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the feasibility of surgery was evaluated. Operable patients: radical surgical resection, followed by 4 cycles of S-1 combined with carrelizumab (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + anlotinib + S-1 were treated until intolerance or disease progression."
219323214|NCT06901622|DRUG|Camrelizumab, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, intravenous drip, 3 weeks as a treatment cycle. Nab-paclitaxel: 200 mg/m\^2, day 1, intravenous drip, 3 weeks as a treatment cycle. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the patient's surgical feasibility was evaluated.~Operable patients: radical surgical resection, followed by S-1 (4 cycles) combined with carrelizumab treatment (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + S-1 treatment until intolerance or disease progression."
219323215|NCT06902090|DRUG|Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)|IV, 30 mg
219323216|NCT06902090|DRUG|Meloxicam Nanocrystal Injection (ANJESO®)|IV, 30 mg
219323217|NCT06901453|PROCEDURE|Low shrinkage Giomer restorative material (Beautifil II LS)|Enamel margins are etched with 37% phosphoric acid for 15 seconds, then the cavity is bonded using FL bond two-step self-etch adhesive. Giomer is applied in increments (maximum 2mm thickness) and light-cured for 20 seconds with a properly calibrated LED curing light.
219323218|NCT06901453|PROCEDURE|RMGI alone - Control|Cavities will be restored with light-cured resin modified glass ionomer (GC Fuji II LC) only. After applying conditioner for 20 seconds, rinsing, and gentle drying, the RMGI will fill the entire cavity and be light-cured
219323219|NCT03904134|OTHER|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
219323220|NCT05756127|OTHER|Observational - no intervention given|Observational - no intervention given
219323221|NCT06902155|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)|Urinary incontinence was assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), a validated instrument with a Cronbach's alpha of 0.88. This tool consists of four items: three scored questions evaluating leakage frequency (0-5), volume (0-6), and impact on quality of life (0-10), summing to a total score of 0-21, and one unscored question identifying situations where incontinence occurs. Two separate analyses were performed: total ICIQ-SF score and responses to question, which identified UI-triggering situations
219323222|NCT06901752|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care,inpatient rehabilitation,outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management, soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive skin
219323223|NCT06901752|BEHAVIORAL|Exercise|Cat Camel Exercise, Bridge Exercise, Lateral Flexion, Cross Walking, Ipsilateral and Contralateral Stretching Exercises
219323224|NCT06913231|DEVICE|Whole body vibration device|Whole-body vibration (WBV) training using the Power Plate Pro 7HC (Northbrook, USA). The vibration frequency was set between 30-40 Hz, with an amplitude of 2-4 mm.
219323225|NCT06913231|OTHER|Sham Whole body vibration|A sham Whole body vibration will be used . participants will stand on the device without actual vibrations.This control condition will be used to isolate the effects of WBV from other potential influences such as standing posture and time spent on the the platform.
219323226|NCT06796660|DRUG|Nephropathy Formula No. 1|On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum, Paeonia lactiflora Pall. , Scutellaria baicalensis Georgi , Pinellia ternata (Thunb.) Breit. , Smilax glabra Roxb. , Oldenlandia diffusa (Willd.) Roxb. , Tussilago farfara L. , Poria cocos (Schw.) Wolf , decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
219323227|NCT06796660|DRUG|integrated basic treatment for chronic kidney disease|"The integrated basic treatment for CKD includes the following:~Dietary Nutrition: α-Keto acid tablets (2.6 g tid) may be used. Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected. β-blockers or α-blockers may be used in combination if necessary.~Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.~Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.~Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.~Regulation of Water, Electrolyte, and Acid-Base Metabolic Balance."
219323228|NCT07105176|DRUG|Cyclophosphamide|Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.
219323229|NCT07105176|DRUG|Fludarabine|Fludarabine is administered once daily via intravenous infusion for 4 consecutive days.
219323230|NCT07105176|DRUG|IL-2 (interleukin 2)|IL-2 administered subcutaneously once daily. Dosing may be adjusted based on subject tolerance, including modifications to dose quantity, administration frequency, or complete treatment discontinuation, with a maximum treatment duration of 3 days.
219323231|NCT07105176|DRUG|HS-IT101 monotherapy|TIL Injection administered by intravenous infusion over 30-60 minutes.
219323232|NCT07110389|BEHAVIORAL|A tele-CR program|"The tele-CR program is divided into three parts: motivational interviewing, app delivery, and self-management and tracking. Motivational interviewing was conducted during hospitalization and involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR app (approximately 30-60 minutes per session).~After discharge, researchers monitored app usage and conducted seven follow-up sessions via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge. These follow-ups, each lasting approximately 5-15 minutes, aimed to assess patients' living conditions, address any issues promptly, and provide encouragement or praise based on their engagement with the app.~After the completion of the 6-month tele-CR intervention, participants could still actively contact the researchers via LINE or the app to seek health-related assistance according to their personal needs, up to 12 months post-discharge."
219323233|NCT07110389|OTHER|Attention-controlled|The researchers conducted face-to-face communication with participants in the control group prior to discharge, aiming to establish a professional relationship and advise them to follow routine health education and adopt an appropriate lifestyle. After discharge, follow-up care was provided regularly via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge-a total of seven sessions, each lasting approximately 3-5 minutes-to inquire about any symptoms of discomfort.
219323234|NCT07110623|DEVICE|LIP device|The LIP device uses polarized Raman spectroscopy to enhance the early detection and diagnosis of oral cancer by facilitating more accurate guiding of biopsies. This non-invasive technology utilizes polarized laser light to generate Raman scattering that can be used to analyze molecular vibrations, which in the future will provide clinicians with insights into tissue composition and structure for identifying cancerous abnormalities.
219323235|NCT07110714|OTHER|Cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), four times daily during the 3-week program and once daily during the 6-month follow-up period. Hydrotherapy interventions are individually tailored to each subject based on their responses and include various washing and pouring techniques.
219323236|NCT07115927|DRUG|Dostarlimab|Arm 1: Patients in the initial cohort will be treated with two doses of dostarlimab prior to surgery, receiving dostarlimab 500mg IV on day 1 and day 22.
219323237|NCT03315975|BIOLOGICAL|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
219323238|NCT07113860|BEHAVIORAL|Views on Aging Intervention|This intervention was developed by Wolff, Warner (47) in 2013-2014; refined by Beyer, Wolff (59) in 2017-2018; and further refined for this project. It will be delivered through three in-person one-hour sessions by two psychologists. it will include homework between sessions two and three. The first session will consist of a quiz on aging with questions about healthy aging and aging in general to detect own negative personal views on aging and misconceptions regarding aging. The second session will provide information on the benefits of more positive views on aging on health, functional and cognitive abilities, and longevity. During the third session participants are thought a technique to modify negative automatic thoughts about aging and asked/invited to put in practice this technique. Finally, the intervention ends with a focus on positive views on aging and their importance for one's health and wellbeing.
219323239|NCT07113860|BEHAVIORAL|Projecte Moviment|The intervention lasts 12 weeks and is based on international guidelines of physical exercise. Participants will be instructed to walk briskly in one continuous bout (45 minutes for 5 days, 225 minutes per week). Intensity, duration, and times per week will be initiated in a stepwise manner to reduce the possibility of injury. During the first week participants will be asked to walk 30 minutes at 9-10 on the Borg Rating of Perceived Exertion Scale (i.e., light intensity). During the second week, participants will be asked to walk 45 minutes with the same intensity. During the remaining weeks, participants will be asked to maintain the duration of 45 minutes and increase the intensity of the activity to a moderate-high effort that corresponds with 12-14 in the Borg Rating of Perceived Exertion Scale.
219323240|NCT07123194|BEHAVIORAL|An Arts-Based Nursing Intervention Program to Help Develop Healthy Digital Habits|Session Time: Arts-Based Nursing Intervention Program Sessions to Help Develop Healthy Digital Habits Week 1, Session 1 - Introductions and Group Agreement Formation (60 minutes) Week 2, Session 2 - Where Am I in the Digital World? (60 minutes) Week 3, Session 3 - Digital Addiction: Are You Connected or Addicted? (90 minutes) Week 4, Session 4 - Digital Addiction and Its Effects (90 minutes) Week 5, Session 5 - Digital Danger: Cyberbullying (90 minutes) Week 6, Session 6 - Discovering Strengths: The Relationship Between Digital Addiction and Self-Efficacy (90 minutes) Week 7, Session 7 - Digital Detox and Alternatives (90 minutes) Week 8, Session 8 - Evaluation and Closing (90 minutes)
219323241|NCT07123259|DIETARY_SUPPLEMENT|WHOLE WHEAT MUFFIN|400g whole wheat flour was used for the development of muffins
219323242|NCT07123259|COMBINATION_PRODUCT|1.5g enriched pomegranate muffins|1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy
219323243|NCT07123259|COMBINATION_PRODUCT|3g enriched pomegranate muffins|3 g of pomegranate peel powder (PPP), alongside conventional medical therapy
219323244|NCT07129681|OTHER|dextrose 5%|Dextrose, is an osmotic proliferant which acts by dehydrating the cells at the injection site which utlimately leads to release of cellular fragments that act as chemo attractants and start the inflammatory cascade leading todeposition of collagen
219323245|NCT07129681|OTHER|Arthrocentesis/Saline|Arthrocentesis , a highly successful, simple and minimally invasive procedure is a safe and simple method for treatment of anterior disc displacement with reduction of TMJ both in short term and long term follow up period, where it is a procedure of removing damaged tissues \&inflammatory mediators.it can be the treatment modality for the for control group
219323246|NCT07129304|COMBINATION_PRODUCT|Collaborative Virtual Reality with Routine Physical Therapy|patients will receive routine Physiotherapy treatment and additional treatment in a Collaborative Virtual Reality Environment for 30 minutes per session 3 times /week for minimum of 8 weeks. There will be a real time interaction in this group between patients and Physiotherapist in the virtual environment. The tasks in the CVE will focus on motor control, balance, coordination, and social engagement while routine Physical Therapy session will consist of performing exercises based on similar goals of improving motor skills, enhanced coordination, functional mobility, muscle strength and stretching exercises.
219323247|NCT07129304|COMBINATION_PRODUCT|Non-Immersive Virtual Reality with Routine Physical Therapy|Patients will receive routine physiotherapy treatment along with the engagement with computer-based virtual rehabilitation content displayed on a standard computer monitor/ LED screen. There will be no real time interaction in this group between patients and Physiotherapist in the virtual environment. Patients will be viewing pre-recorded videos of therapeutic exercises, demonstration, and / or on-screen instructions and cues for performing exercises. This group's patients will be treated with non- immersive virtual reality along with routine physical therapy for 30 minutes session 3 times /week for 8 weeks. Routine Physical Therapy session will consist of performing exercise based on the goal of improving motor skills, enhanced coordination, posture correction, gait efficiency, functional mobility, muscle strength and endurance training, stretching exercises where required.
219323248|NCT07128446|OTHER|Standard physical and occupational therapy|Participants admitted to the Pediatric Intensive Care Unit (PICU) will receive standard occupational therapy as part of routine clinical care. Interventions will be tailored to each patient's medical status and functional needs and may include activities of daily living (ADL) training, positioning, range of motion exercises, sensory stimulation, and caregiver education. No additional experimental treatment will be introduced for study purposes. The primary focus of the study is to evaluate patient-centered outcomes using the Canadian Occupational Performance Measure (COPM), without altering the standard therapeutic approach.
219323249|NCT07128927|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|Web-based, self-administered, and interactive cognitive behavioral therapy for insomnia
219323250|NCT07128927|BEHAVIORAL|Patient education|Website that describes insomnia, including factors that may increase or decrease insomnia symptoms, and provides information about addressing insomnia symptoms.
219323251|NCT07130227|OTHER|Session 1: Preparatory Session|\*Meeting the patients \*Introducing the content of mindfulness-based stress reduction training \*Emphasizing the importance of regular and timely attendance at training \*Determining training dates \*Sharing individuals' experiences and expectations
219323252|NCT07130227|OTHER|Session 2: Mindfulness|\*What is mindfulness? \*Being aware of daily activities. \*Raisin meditation.
219323253|NCT07130227|OTHER|Session 3: Our Perspectives on Ourselves and the World|\*Breathing meditation. \*Habit Breaker: Watching the Sky.
219323254|NCT07130227|OTHER|Session 4: Body Scan *Body scan meditation.|\*Ten-finger gratitude practice. \*Habit Breaker: Spending some time in nature.
219323255|NCT07130227|OTHER|Session 5: Recognizing Schizophrenia|\*What is schizophrenia? \*What are its symptoms? \*What does treatment involve?
219323256|NCT07130227|OTHER|Session 6: Mindful Movement|\*Mindfulness movement meditation practice \*
219323257|NCT07130227|OTHER|Session 7: Mindful Breathing|\*Breathing meditation \*
219323258|NCT07130227|OTHER|Session 8: Treatment Evaluation|\*The importance of medication \*Things to consider when using medication \*Side effects of medication \*What is a flare-up in schizophrenia? \*What are the precursor symptoms?
219323259|NCT07130227|OTHER|Session 9: Mindful Thinking|\*Sounds and thoughts meditation \*Cinema activity.
219323260|NCT07130227|OTHER|Session 10: Coping with Anger|\*What is anger? \*What are its symptoms? \*What are the coping methods?
219323261|NCT07130227|OTHER|Session 11: Coping with Difficult Emotions|\*Facing Difficulties meditation \*
219323262|NCT07130227|OTHER|Session 12: Mindful Communication|\*Communication \& mindful communication \*The importance of communication skills \*Fundamentals of communication, self-language practice \*Ways to prevent communication accidents
219323263|NCT07130227|OTHER|Session 13: Different Connections|\*Breathing meditation. \*Habit Breaker: Thought and Emotional Play.
219323264|NCT07130227|OTHER|Session 14: The Joy of Small Things|\*Treasure of Pleasure Meditation \*Habit Breaker: Letter to Self.
219323265|NCT07130227|OTHER|Session 15: Dwelling on the Past or Living in the Present?|\*Friendship-Building Meditation \*Habit Breaker: Random Acts of Kindness.
219323266|NCT07130227|OTHER|Session 16: Evaluation|\*Reinforcing What Has Been Learned. \*Evaluating the Program. \*Obtaining Feedback.
219323267|NCT07130227|OTHER|Session 1: Group 2, Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
219323268|NCT07130227|OTHER|Session 2: Group 2, Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
219323269|NCT07130227|OTHER|Session 3: Group 2, Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
219323270|NCT07130227|OTHER|Session 4: Group 2, What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
219323271|NCT07130227|OTHER|Session 5: Group 2, Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
219323272|NCT07130227|OTHER|Session 6: Group 2, What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
219323273|NCT07130227|OTHER|Session 7: Group 2, Relaxation|Practicing the relaxation CD with patients
219323274|NCT07130227|OTHER|Session 8: Group 2, Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
219323275|NCT07130994|DEVICE|Mitral Valve Replacement|Implant of SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation
219323276|NCT07129291|COMBINATION_PRODUCT|Experimental: Dual-Language Dysarthria Self-Assessment and Management Software (D-SAMS)|D-SAMS is a bilingual (Urdu and English) digital tool designed for adult dysarthria patients. It enables users to assess their speech through interactive tasks (e.g., repetition, reading, and pronunciation exercises), receive feedback, and track progress over time. The software includes audio-visual prompts, self-rating scales, and progress charts, and is tailored to accommodate varying levels of dysarthria severity. It supports independent practice and helps speech-language pathologists monitor patients remotely
219323277|NCT07128862|OTHER|Heavy-Load Resistance Training with Blood Flow Restriction|"Blood Flow Restriction (BFR) Training (also known as Kaatsu training is an innovative and increasingly popular exercise technique to improve muscle strength and hypertrophy with relatively low loads. Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy."
219323278|NCT07128862|OTHER|Heavy-Load Resistance Training Only|Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy.
219323279|NCT07129629|DRUG|Bedaquiline (B)|Bedaquiline tablets administered orally. Dosing: 400 mg once daily for the first 2 weeks, then 200 mg three times per week for weeks 3-17. Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
219323280|NCT07129629|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally once daily before or after meals throughout the entire treatment period (17 weeks). Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
219323281|NCT07129629|DRUG|Pyrazinamide (PZA)|Pyrazinamide tablets administered orally once daily in the morning during intensive phase (8 weeks). Dosing by weight: 1000 mg for 40.0-49.9 kg, 1500 mg for 50.0-70.9 kg, 2000 mg for ≥75.0 kg. Used in both experimental arms (BZMD and BZMH groups) and control group as part of tuberculosis treatment regimen.
219323282|NCT07129629|DRUG|Delamanid (D)|Delamanid tablets administered orally at 100 mg twice daily (total daily dose 200 mg) throughout the entire treatment period (17 weeks). Used only in the BZMD experimental arm as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
219323283|NCT07129629|DRUG|Isoniazid (H)|Isoniazid tablets administered orally at 300 mg once daily in the morning throughout the entire treatment period. Used in the BZMH experimental arm (17 weeks) and in the standard control group (26 weeks) as part of tuberculosis treatment regimens.
219323284|NCT07129629|DRUG|Rifampicin (R)|Rifampicin tablets administered orally once daily in the morning throughout the entire treatment period (26 weeks). Dosing by weight: 450 mg for 40.0-49.9 kg, 600 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
219323285|NCT07129629|DRUG|Ethambutol (E)|Ethambutol tablets administered orally during the intensive phase (8 weeks). Dosing by weight: 750 mg for 40.0-49.9 kg, 1000 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
219323286|NCT07129889|DRUG|gradual withdrawal of medication|The dose was reduced by one day each month, ultimately reducing atropine treatment from seven days per week to complete withdrawal within six months, with a six-month follow-up.
219323287|NCT07129889|PROCEDURE|Auricular acupressure|First, treat the ear acupoint on one side, then leave the tape in place for 5 days. On the 6th day, remove the tape, rest for 2 days, and on the 8th day, apply new tape to the other side of the ear. Changing the tape aims to minimize adverse event (AE) that may result from prolonged stimulation on one side. Additionally, participants will be instructed to self-administer vertical pressure on the Wangbuluxing seeds 15-20 times to achieve sensation, with a duration of 4-5 times daily. The treatment process will last for 18 months, with a follow-up at 6 months.
219323288|NCT07129889|PROCEDURE|Sham auricular acupressure|Acupuncturists will use a gradual reduction method with 0.01% atropine eye drops, as used in the control group, and apply skin-colored adhesive tape without Wang Bu Liu Xing seeds to the ear acupoints. During treatment, no massage or acupoint pressure will be applied. The SAA group will follow the same protocol as the AA group for compensatory AA treatment at the end of the study.
219323289|NCT07131046|PROCEDURE|Combination of superficial cervical plexus block and supraorbital block|The combined anaesthesia technique involves the use of general anaesthesia and regional block in the superficial cervical plexus and supraorbital areas, with 6 ml of 0.25% bupivacaine injected into the superficial cervical plexus area and 2 ml into the supraorbital area.
219323290|NCT07131046|PROCEDURE|Scalp block with bupivacaine alone|A combination anaesthesia technique is used that involves general anaesthesia and scalp block. Scalp block using 0.25% bupivacaine in the supraorbital area (2 ml), supratrochlear (2 ml), zygomaticotemporal (2 ml), auriculotemporal (2 ml), major occipital (2 ml) and minor occipital (2 ml).
219323291|NCT07130123|PROCEDURE|Suctionning extubation|We will remove the intubation tube with endotracheal suctioning during the extubation procedure and maintain positive end expiratory pressure (PEEP) and pressure support. The PEEP level will be 10 cmH2O and the pressure support 7 cmH2O for 2 minutes prior to extubation. The vacuum level will be the maximum level (standard procedure in the unit), i.e. 450 mmHg. The closed-system suction probe is inserted up to the last mark corresponding to 40cm. The size of our closed system is identical for all patients, i.e. 14 french.
219323292|NCT07130123|PROCEDURE|No suctionning Extubation|In the control group, removal of the intubation tube during the extubation procedure is performed with PEEP maintained, without endotracheal suctioning. The PEEP level will be set at 10 cmH2O and the pressure at 7 cmH2O in the 2 minutes prior to extubation.
219323293|NCT07130708|DEVICE|Telesurgery utilizing Microport Medbot Robotic Platform|A robotic surgery for prostate disease via telesurgery, where a highly trained surgeon performs the operation remotely using a secure internet connection.
219323294|NCT07131033|DRUG|Esketamine|Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
219323295|NCT07131033|DRUG|Magnesium sulfate|Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.
219323296|NCT07131033|DRUG|Esketamine and Magnesium sulfate|Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.
219323297|NCT07131033|DRUG|Saline|Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.
219323298|NCT07130929|OTHER|Functional Electrical Stimulation|Physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb, associated with functional electrical stimulation.
219323299|NCT07130929|OTHER|Conventional physiotherapy|Conventional physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb.
219323300|NCT07130396|DIETARY_SUPPLEMENT|Multivitamin and a Probiotic|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of the study products (PhytoMulti® Multivitamin, 2 tablets/day and UltraFlora® Balance Probiotic, 1 capsule/day) are taken daily with breakfast
219323301|NCT07129200|OTHER|Hot environment|Hot environment of 35 degrees Celsius
219323302|NCT07129200|OTHER|Thermoneutral environment|Thermoneutral environment of 18 degrees Celsius
219323303|NCT07128407|BEHAVIORAL|Protection Motivation Theory-Based Radiation Protection Training|A structured educational program designed according to Protection Motivation Theory (PMT). The program targets both threat appraisal (perceived severity and vulnerability) and coping appraisal (response efficacy, self-efficacy, and response cost) processes to improve nurses' knowledge, awareness, motivation, and safety behaviors regarding radiation protection.
219323304|NCT07130825|OTHER|8 hours simulated mental workday|During a simulated 8-hour mental work day, subjects will complete a set of cognitive tests (ANAM4, version 4; Vista Life Science, Norman, OK, USA) 8 times (1 session approximately 45 minutes), with a break of approximately 10 minutes after each session.
219323305|NCT07130825|OTHER|Moderate intensity aerobic activity|In one of the conditions, subjects will perform moderate intensity aerobic activity (cycle veloergometer) for 30 min before 8 hours simulated mental workday and after.
219323306|NCT07130825|OTHER|Combined work model|In one of the conditions, subjects will perform cognitive test during 8 hours simulated mental workday applying combined work model (they will work standing and sitting on a balance ball).
219323307|NCT07128563|DEVICE|piriform cortex-DBS|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral piriform cortex.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
219323308|NCT07129239|OTHER|Maintenance|Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response
219354791|NCT04407767|BEHAVIORAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
219323309|NCT07128537|PROCEDURE|Scheduled Oropharyngeal Suctioning Every 4 Hours|"The intervention in this study involves scheduled oropharyngeal suctioning every 4 hours, which distinguishes it from other oral care protocols used in clinical practice. In this arm, patients will receive systematic suctioning of the oropharyngeal area using a sterile suction catheter every 4 hours throughout their ICU stay, starting from the first day of mechanical ventilation. This frequent suctioning is designed to remove accumulated secretions that can harbor bacteria, reducing the risk of aspiration into the lungs, which is a major cause of early-onset Ventilator-Associated Pneumonia (VAP).~This intervention is not based on clinical need or visible signs of discomfort (as with traditional on-demand suctioning). Instead, it follows a standardized protocol of proactive, scheduled suctioning. The procedure will be performed by trained ICU staff and will involve suctioning for 10-15 seconds per session, ensuring adequate removal of secretions while minimizing patient discomfort. In"
219323310|NCT07128537|PROCEDURE|Standard Oral Care (Twice-Daily Brushing)|Participants in this group will receive standard oral care as part of ICU routine practice. This includes brushing of teeth, gums, and tongue twice a day to clear accumulated secretions and reduce bacterial growth. Additionally, on-demand suctioning will be performed if clinically indicated (e.g., when visible secretions or discomfort are observed). The control group will not receive the scheduled 4-hourly suctioning intervention, serving as a comparison to evaluate the effectiveness of regular suctioning in preventing VAP.
219323311|NCT07129915|BEHAVIORAL|Linguistic Nudging Training|Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques
219323312|NCT07129915|DEVICE|Medication Preference App|Patients use WeChat-based mini-program to record daily medication preferences and concerns
219323313|NCT07129915|OTHER|Standard Diabetes Care|Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol
219323314|NCT06936722|OTHER|ELDOA + Conventional PT|"ELDOA, the protocol consists of 4 positions. Each position is maintained for 1 min with constant correction of posture throughout with 2 to 4 min rest within each position. The Exercise was performed in 10 to 25 mins. 4 positions of ELDOA are Decoarctation of C0/C1/C2, Decoarctation of C4/C5, Decoarctation of C5/C6, Decoarctation of C6/C7. All positions are attained in lying.~Hot pack 2. isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold."
219323315|NCT06936722|OTHER|McKenzie Protocol + Conventional PT|Extension Dysfunction Retraction Retraction with patient overpressure Retraction with therapist overpressure Retraction with extension Lateral Flexion Dysfunction Lateral flexion: Lateral flexion with patient overpressure Lateral flexion therapist overpressure Rotation Dysfunction Rotation Rotation with patient overpressure Hot pack, isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold Rotation with therapist overpressure
219323316|NCT06940505|OTHER|Telemedicine Follow-up|Oncological follow-up in a general hospital close to the patient, with aid of Telemedicine evaluation of the endoscopy video's by a Head and Neck surgeon in a specialised oncology centre
219323317|NCT06941545|DEVICE|Alimetry|High resolution gastric mapping of electrical gastric activity.
219323318|NCT06941545|DEVICE|tVNS|Transcutaneous Auricular Vagal Nerve Stimulation, electrical stimulation to the ear.
219323319|NCT06941545|DEVICE|Gastroduodenal Manometry|Pressure catheter evaluating gastric and duodenal pressure profiles at rest and with certain stimuli applied
219323320|NCT04708613|DIAGNOSTIC_TEST|Cognitive/Neuropsychological Testing|Comprehensive testing of cognitive function and brain health.
219323321|NCT04708613|DIAGNOSTIC_TEST|Vestibular/Ocular-Motor Testing|A series of tests and questionnaires that asses vestibular function, balance, ocular-motor coordination, and reflexes.
219323322|NCT04708613|DIAGNOSTIC_TEST|Sleep Evaluation|A full assessment of sleep health, including insomnia (duration, frequency, daytime consequences) and other sleep disorders such as obstructive sleep apnea. Overnight sleep study is included.
219323323|NCT04708613|DIAGNOSTIC_TEST|MRI, High-Resolution|A high-resolution MRI to provide qualitative and quantitative assessments of brain structure.
219323324|NCT04708613|DIAGNOSTIC_TEST|Health & Physical Exam|Participants will undergo an executive history and physical exam of all body systems.
219323325|NCT04708613|DIAGNOSTIC_TEST|Physical Function|These assessments will involve a series of tests and questionnaires that focus on physical function.
219323326|NCT04708613|DIAGNOSTIC_TEST|Blood Testing and Biomarker Analysis|"A blood draw will be performed to measure standard clinical labs as part of a full history and physical, as well as additional analysis of biomarkers indicative of brain health.~An optional lumbar puncture will be performed and CSF samples (20-30 mL) stored in the NCTC Biorepository until shipment to the CLIA-certified laboratory.~Both CSF and blood samples will be analyzed for t-tau, p-tau, and Aβ42 and stored for future testing,"
219323327|NCT04708613|DIAGNOSTIC_TEST|Applanation Tonometry|Hearth health is evaluated through testing of arterial stiffness and pulse wave reflections using a high fidelity applanation tonometer.
219323328|NCT04708613|DIAGNOSTIC_TEST|PET brain imaging|PET imaging of the brain using tau and amyloid ligands.
219323329|NCT04708613|DRUG|[C-11]6-OH-BTA-1|PET imaging of the brain using an amyloid ligand.
219323330|NCT04708613|DRUG|[F-18]AV-1451|PET imaging of the brain using a tau ligand.
219323331|NCT06950879|OTHER|Measurement|"A wooden construction was built consisting of two plates with dimensions of 35 x 29 cm: a bottom plate, with a measuring mat glued to it, a movable middle plate and a smaller top plate, allowing to mount a standardized overhead camera.~Participants were seated and placed one hand palm down on the measuring mat on the bottom plate. The hand was aligned with the midline of the body, lay flat with the fingers straight and lightly spread. First the actual landmarks were marked on the computer. Subsequently the participants hand was occluded by adding the middle plate. Participants were verbally cued to mark a certain landmark with their contralateral hand. These indicated points were marked on the computer. Before and after each trial, a picture was taken without the occluding board to ensure that the hand had not moved from its original position by digitally overlaying the images"
219323332|NCT02423551|OTHER|MRE|MRE consumption
219323333|NCT03292289|PROCEDURE|Pre- and post-operative consultation|Before and between the two interventions
219323334|NCT03292289|PROCEDURE|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
219323335|NCT03292289|PROCEDURE|Questionnaires|"* QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
219323336|NCT02047539|DRUG|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
219323337|NCT02047539|DRUG|Placebo|
219323338|NCT04313153|DRUG|Vadadustat|oral tablets
219323339|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
219323340|NCT06789185|DRUG|0.1mg/kg esketamine|Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery
219323341|NCT06789185|DRUG|0.2mg/kg esketamine|Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery
219323342|NCT06789185|DRUG|0.1ml/kg normal saline|Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery
219323343|NCT06830525|COMBINATION_PRODUCT|ACDP® and growth hormone treatment|A cohort of 40 families of children undergoing growth hormone treatment using a connected injector devices that quantifies treatment adherence will be recruited via the ACDP®, to capture additional data that combine Patient Reported Outcomes and Adherence Data.
219323344|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
219323345|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
219323346|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
219323347|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
219323348|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
219323349|NCT06143085|PROCEDURE|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
219323350|NCT02688673|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
219323351|NCT06424470|BIOLOGICAL|Stapokibart|Stapokibart Injection
219323352|NCT06424470|OTHER|Placebo|Placebo
219323353|NCT01277770|DRUG|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
219323354|NCT01277770|OTHER|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
219323355|NCT01277770|DRUG|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
219323356|NCT02753790|RADIATION|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume \[PTV\] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
219323357|NCT02428010|DEVICE|TMVR Implant|Implantation of the Twelve TMVR System
219323358|NCT00893126|PROCEDURE|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
219323359|NCT02952391|OTHER|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol
219323360|NCT02827305|DRUG|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
219323361|NCT02827305|PROCEDURE|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
219323362|NCT00177138|DRUG|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
219323363|NCT00177138|DRUG|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)
219323364|NCT06261086|DIAGNOSTIC_TEST|evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)|2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
219323365|NCT03746951|DRUG|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
219323366|NCT04907110|DIETARY_SUPPLEMENT|Niagen|Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day
219323367|NCT04907110|OTHER|Exercise|During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
219323368|NCT02901873|DEVICE|Electrical Impedance Spectroscopy|
219323369|NCT00182182|BEHAVIORAL|Primary care based disease management strategy|
219323370|NCT02113579|DEVICE|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
219323371|NCT02113579|OTHER|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
219323372|NCT02017041|DEVICE|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
219323373|NCT02017041|DEVICE|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
219323374|NCT03136419|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
219323375|NCT03136419|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
219323376|NCT03765775|BIOLOGICAL|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
219323377|NCT03765775|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
219323378|NCT02871973|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
219323379|NCT02871973|BEHAVIORAL|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
219323380|NCT04283266|DIETARY_SUPPLEMENT|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
219323381|NCT04283266|DIETARY_SUPPLEMENT|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
219323382|NCT00638560|DIETARY_SUPPLEMENT|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
219323383|NCT00638560|DIETARY_SUPPLEMENT|Antioxidant treatment|no treatment
219323384|NCT01194453|DRUG|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
219323385|NCT01194453|DRUG|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
219323386|NCT01877863|OTHER|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
219323387|NCT04035850|DRUG|Vortioxetine Tablets|Strength 5-20 mg
219323388|NCT02567539|RADIATION|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
219323389|NCT02567539|DRUG|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
219323390|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
219323391|NCT00594516|DRUG|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
219323392|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
219323393|NCT03339869|OTHER|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
219323394|NCT04540549|BEHAVIORAL|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
219323395|NCT05935124|DIAGNOSTIC_TEST|WLE first, then B-NBI|
219323396|NCT05747508|COMBINATION_PRODUCT|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
219323397|NCT05747508|COMBINATION_PRODUCT|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
219323398|NCT05747508|COMBINATION_PRODUCT|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
219323399|NCT05060263|DRUG|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
219323400|NCT04828187|DIAGNOSTIC_TEST|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
219323401|NCT04063241|OTHER|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
219323402|NCT04063241|OTHER|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
219323403|NCT00105404|DRUG|Triamcinolone Acetonide|
219323404|NCT02217436|DEVICE|iPad|iPad with age-appropriate applications, videos, and music
219323405|NCT02217436|OTHER|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
219323406|NCT00774280|DRUG|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
219323407|NCT05327374|DIAGNOSTIC_TEST|calculation of the inferior vena cava collapsibility index|the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure
219323408|NCT04662398|DEVICE|JT Device|Shocker giving electrical shocks on testes
219323409|NCT00900354|GENETIC|molecular genetic technique|
219323410|NCT00900354|OTHER|mass spectrometry|
219323411|NCT00900354|OTHER|pharmacological study|
219323412|NCT01974089|OTHER|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
219323413|NCT01098981|DEVICE|Transcranial ultrasound as an adjunctive therapy to tPA|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes"
219323414|NCT01098981|DRUG|Standard of care tPA therapy for acute ischemic stroke|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
219323415|NCT01256151|DRUG|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
219323416|NCT01256151|DRUG|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
219323417|NCT04641299|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
219323418|NCT04641299|DRUG|Placebo|Placebo solution
219323419|NCT05510765|BEHAVIORAL|Transportation service|Improved transportation assets applied to all aspects of subjects life
219323420|NCT00830245|DRUG|Erlotinib|Erlotinib 150mg/day
219323421|NCT05195944|DRUG|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
219323422|NCT05195944|DRUG|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
219323423|NCT02154360|DRUG|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
219323424|NCT05963789|OTHER|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
219323425|NCT05963789|OTHER|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
219323426|NCT04807699|OTHER|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
219323427|NCT04672564|DRUG|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
219323428|NCT04672564|DRUG|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
219323429|NCT04650282|COMBINATION_PRODUCT|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
219323430|NCT04650282|COMBINATION_PRODUCT|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
219323431|NCT04701177|DIAGNOSTIC_TEST|AltoidaML|Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
219323432|NCT00442065|DEVICE|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
219323433|NCT06225635|DRUG|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
219323434|NCT06225635|DRUG|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
219323435|NCT01244243|DEVICE|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
219323436|NCT01332565|DRUG|GSK1349572|50mg tablet
219323437|NCT05370066|DEVICE|CS6BP watches will be used in the study.|CS6BP watches will be used with FDA approved Blood pressure monitors
219323438|NCT04094896|DRUG|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
219323439|NCT02039726|DRUG|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
219323440|NCT02039726|DRUG|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
219323441|NCT03336255|BEHAVIORAL|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
219323442|NCT04100629|BEHAVIORAL|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
219323443|NCT00288977|PROCEDURE|Islet Infusion|
219323444|NCT02460497|DRUG|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
219323445|NCT02598609|BEHAVIORAL|Education program for NICU caregivers|"* standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries"
219323446|NCT01504256|DRUG|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
219323447|NCT01504256|DRUG|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
219323448|NCT03679156|DEVICE|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
219323449|NCT00643669|DRUG|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
219323450|NCT00003108|DRUG|bryostatin 1|
219323451|NCT00003108|DRUG|cisplatin|
219323452|NCT05047783|DRUG|Masitinib Mesylate|3CL-protease inhibitor
219323453|NCT05047783|DRUG|Placebo|Placebo
219323454|NCT01891097|PROCEDURE|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
219323455|NCT01891097|PROCEDURE|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
219323456|NCT04013516|BEHAVIORAL|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
219323457|NCT04013516|BEHAVIORAL|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
219323458|NCT05905510|DRUG|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
219323459|NCT05905510|DRUG|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
219323460|NCT05905510|DRUG|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
219323461|NCT03274609|COMBINATION_PRODUCT|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
219323462|NCT01419353|DRUG|estradiol valerate|2 mg P.O / day for 1-6 days.
219323463|NCT02992886|RADIATION|Preoperative radiation|Radiation treatment before surgery
219323464|NCT02992886|DRUG|Raltitrexed|concurrent chemotherapy
219323465|NCT02992886|PROCEDURE|Pelvic surgery|
219323466|NCT03846739|DRUG|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
219323467|NCT03846739|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
219323468|NCT01556035|DRUG|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
219323469|NCT02393677|DRUG|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
219323470|NCT02393677|DRUG|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
219323471|NCT02607553|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
219323472|NCT05196581|DRUG|Dispersible NaCl powder 10 sessions|Dispersible NaCl powder 10 sessions
219323473|NCT05196581|DRUG|Dispersible NaCl powder 5 sessions|Dispersible NaCl powder 5 sessions
219323474|NCT02838082|BEHAVIORAL|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
219323475|NCT02838082|BEHAVIORAL|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
219323476|NCT00752531|BEHAVIORAL|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
219323477|NCT00813319|BEHAVIORAL|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
219323478|NCT01448213|DRUG|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
219323479|NCT01448213|DRUG|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
219323480|NCT01916863|DRUG|LX4211 400 mg|
219323481|NCT01916863|DRUG|canagliflozin 300 mg|
219323482|NCT01916863|DRUG|LX4211 Placebo|
219323483|NCT05146362|OTHER|Vermont RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
219323484|NCT02012296|DRUG|enzalutamide|Given PO
219323485|NCT02012296|DRUG|mifepristone|Given PO
219323486|NCT02012296|OTHER|laboratory biomarker analysis|Correlative studies
219323487|NCT02012296|OTHER|pharmacological study|Correlative studies
219323488|NCT00919087|DEVICE|Avivo System|Non invasive external monitoring deive
219323489|NCT02485990|DRUG|Tremelimumab|
219323490|NCT02485990|DRUG|Olaparib|
219323491|NCT05452096|BEHAVIORAL|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
219323492|NCT04624880|DEVICE|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
219323493|NCT02917668|OTHER|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
219323494|NCT02917668|OTHER|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %
219323495|NCT03053258|DEVICE|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
219323496|NCT02833480|DRUG|Fluticasone group|
219323497|NCT02833480|DRUG|Budesonide group|
219323498|NCT02833480|DRUG|Formoterol group|
219323499|NCT01096212|DRUG|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
219323500|NCT01096212|DRUG|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
219323501|NCT05315362|DEVICE|solid microneedle skin patch|intradermal vaccination with a skin patch
219323502|NCT05315362|BIOLOGICAL|mRNA-1273|administration of mRNA-1273 vaccine
219323503|NCT05315362|DEVICE|standard needle|intramuscular vaccination with a standard needle
219323504|NCT03511547|DEVICE|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.
219323505|NCT03511547|DEVICE|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
219323506|NCT02608060|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
219323507|NCT00659529|DRUG|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
219323508|NCT04047160|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
219354792|NCT04407767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
219323509|NCT05623397|OTHER|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
219323510|NCT03627767|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
219323511|NCT03627767|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
219323512|NCT03627767|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
219323513|NCT05531487|OTHER|Questionnaire Survey|All students received a 'QR code' link to the survey.
219323514|NCT01873417|DRUG|BG00012 (DMF)|
219323515|NCT00960908|DEVICE|Endeavor Resolute stents|2nd generation ZES
219323516|NCT00960908|DEVICE|Endeavor Sprint stent|1st generation ZES
219323517|NCT03034460|DRUG|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
219323518|NCT03034460|DRUG|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
219323519|NCT03034460|DRUG|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
219323520|NCT03034460|DRUG|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
219323521|NCT00914992|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
219323522|NCT00914992|OTHER|Squatting|Squatting
219323523|NCT00343616|PROCEDURE|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
219323524|NCT00343616|PROCEDURE|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
219323525|NCT00343616|PROCEDURE|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
219323526|NCT00343616|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
219354793|NCT01726348|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
219354794|NCT02458196|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
219323527|NCT01964261|DEVICE|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
219323528|NCT02728661|BEHAVIORAL|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
219323529|NCT02728661|BEHAVIORAL|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
219323530|NCT04863079|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
219323531|NCT05926154|PROCEDURE|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
219323532|NCT01782573|DRUG|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
219323533|NCT01782573|DRUG|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
219323534|NCT00250653|DRUG|Saredutant succinate (SR48968C)|
219323535|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
219323536|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
219323537|NCT00295633|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
219323538|NCT00295633|DRUG|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
219323539|NCT00295633|DRUG|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
219323540|NCT00295633|DRUG|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
219323541|NCT01048749|OTHER|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
219323542|NCT01048749|OTHER|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
219323543|NCT00095082|DRUG|insulin detemir|
219323544|NCT00095082|DRUG|insulin glargine|
219323545|NCT00095082|DRUG|insulin aspart|
219323546|NCT00520455|DRUG|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
219323547|NCT01798992|DRUG|Carvedilol|
219323548|NCT01798992|DRUG|Metoprolol succinate|
219323549|NCT01798992|DRUG|Metoprolol succinate + doxazosin|
219323550|NCT04467944|OTHER|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
219323551|NCT00763971|DRUG|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
219323552|NCT00763971|DRUG|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
219323553|NCT00763971|DRUG|Placebo|Placebo capsule once per day (Overencapsulated)
219323554|NCT04021199|GENETIC|Mody test|"Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test."
219323555|NCT05761054|RADIATION|RT|"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
219323556|NCT04853836|COMBINATION_PRODUCT|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
219323557|NCT04853836|PROCEDURE|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
219323558|NCT04853836|DRUG|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
219323559|NCT04853836|DRUG|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
219323560|NCT06043115|OTHER|covid-19 survival cohort|consists of surviving patients
219323561|NCT06043115|OTHER|covid-19 mortality cohort|consists of deceased patients
219323562|NCT06244979|OTHER|Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)|100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
219323563|NCT00771641|PROCEDURE|conventional surgery|
219323564|NCT00771641|RADIATION|low-LET cobalt-60 gamma ray therapy|
219323565|NCT00771641|RADIATION|low-LET electron therapy|
219323566|NCT00771641|RADIATION|low-LET photon therapy|
219323567|NCT00771641|RADIATION|radiation therapy|
219323568|NCT00853398|PROCEDURE|surgical technique|
219323569|NCT06161662|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
219323570|NCT06161662|OTHER|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
219323571|NCT03653104|BEHAVIORAL|Melodica Intervention|The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
219323572|NCT03653104|BEHAVIORAL|Pulmonary Health Education|A single session including education about COPD and related health topics.
219354795|NCT02458196|DRUG|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
219354796|NCT02343471|DIETARY_SUPPLEMENT|20 g whey protein|
219354797|NCT05904301|OTHER|Usual medical management of patients, additional blood and stool samples for biobanking|"For all systemic diseases the following data will be collected:~Clinical examination, Laboratory data, Current medications, Constitution of biobanking.~For each disease:~Pathology specific Activity score, Global subjective disease activity by patient and by physician."
219323573|NCT06460129|OTHER|Brugger's Exercises|"1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds."
219323574|NCT06460129|OTHER|Kendal Exercise|"1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position."
219323575|NCT00757536|PROCEDURE|Encircling Band|ppVE and encircling band
219323576|NCT00757536|PROCEDURE|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
219323577|NCT01958723|OTHER|Hospitalists|Introduction of Problem Specific Templates
219323578|NCT01997762|DIETARY_SUPPLEMENT|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
219323579|NCT01997762|DIETARY_SUPPLEMENT|Placebo|
219323580|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
219323581|NCT04302584|DRUG|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
219323582|NCT05155787|DEVICE|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
219323583|NCT05155787|DEVICE|Shame neurofeedback|shame neurofeedback
219323584|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the Stereotactic Body Radiation Therapy (SBRT) schedule is completed within 1.5-2 weeks.
219323585|NCT05849480|DRUG|oxaliplatin|Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
219323586|NCT05849480|DRUG|capecitabine|Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
219323587|NCT05849480|BIOLOGICAL|Keytruda|Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
219323588|NCT05849480|BIOLOGICAL|CDX-1140|CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
219323589|NCT05079464|OTHER|tDCS|All participants randomized to tDCS will receive active tDCS
219323590|NCT05079464|OTHER|Exercise|Participants will exercise at Toronto Rehab.
219323591|NCT05079464|OTHER|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
219323592|NCT05079464|OTHER|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
219323593|NCT02496897|BIOLOGICAL|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
219323594|NCT02496897|OTHER|Placebo|Placebo
219323595|NCT02496897|OTHER|IC31® Adjuvant|IC31® Adjuvant
219323596|NCT00931242|DRUG|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
219323597|NCT04322006|DRUG|TJ004309|Antibody to CD73
219323598|NCT04322006|DRUG|Toripalimab|Humanized monoclonal antibody to PD-1
219323599|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
219323600|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
219323601|NCT00519155|DRUG|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
219323602|NCT00519155|PROCEDURE|Open flap debridement|Open flap debridement alone
219323603|NCT03162887|OTHER|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
219323604|NCT03162887|OTHER|Counseling|Undergo a web-based decision counseling session
219323605|NCT03162887|OTHER|Informational Intervention|"Receive a next steps document"
219323606|NCT00346099|DRUG|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
219323607|NCT00346099|DRUG|Panitumumab with capecitabine and radiation|
219323608|NCT03281057|BEHAVIORAL|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
219323609|NCT05977296|DEVICE|CPAP|To use CPAP
219323610|NCT01800357|DRUG|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
219323611|NCT01800357|DRUG|placebo|infusion of plabcebo once a day and for 14 days
219323612|NCT01800357|DRUG|aspirin|infusion of aspirin (100mg) once a day for days
219323613|NCT04439071|DRUG|PTC299|Oral tablets
219323614|NCT04439071|OTHER|SOC|As defined per local written policies or guidelines.
219323615|NCT04439071|DRUG|Placebo|Oral tablets
219323616|NCT06038825|DEVICE|topical vibration|topical vibration (Aprilla brand, giving 6000 vibrations per minute) is a device for pain relief during injection of local anesthetic.
219323617|NCT06447818|OTHER|Change in airway markers|Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
219323618|NCT06228651|DEVICE|Tourniquet|
219323619|NCT06228651|OTHER|The leg without the tourniquet|
219323620|NCT02827123|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
219323621|NCT02827123|DRUG|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
219323622|NCT01679366|DRUG|Placebo|1 tablet 2 times daily
219323623|NCT01679366|DRUG|Probiotics|1 tablet twice daily
219323624|NCT06386640|OTHER|Intervention Development|Phase I: Research to inform intervention design, Phase II: Co-design and production of intervention with relevant stakeholders, Phase IIa: Physical activity accelerometer data collection and analysis to develop an individualised rehabilitation programme, Phase III: Pilot and refine the intervention across to two NHS sites (University Hospitals of Leicester NHS Trust, Portsmouth Hospitals University NHS Trust).
219323625|NCT01434550|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
219323626|NCT01434550|RADIATION|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~1. Necrosis/apoptosis~2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1\. Aposense-PET imaging"
219323627|NCT00179504|BEHAVIORAL|Relaxation Response|Relaxation training
219323628|NCT01062139|DRUG|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
219323629|NCT01062139|DRUG|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
219323630|NCT05495711|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
219323631|NCT05495711|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
219323632|NCT05011682|BEHAVIORAL|Regular diet|participant's usual diet during 2 weeks
219323633|NCT05011682|BEHAVIORAL|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
219323634|NCT03114007|BEHAVIORAL|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
219323635|NCT03114007|BEHAVIORAL|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
219323636|NCT03114007|BEHAVIORAL|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
219323637|NCT00000820|DRUG|Aldesleukin|
219323638|NCT05252156|DEVICE|eXciteOSA|eXciteOSA
219323639|NCT06154551|DIAGNOSTIC_TEST|Paxillin biomarker|Paxillin used as a salivary biomarker
219323640|NCT00001333|DRUG|topotecan|
219323641|NCT05508750|OTHER|New Infant Formula|New infant formula fed daily ad libitum
219323642|NCT05508750|OTHER|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
219323643|NCT03371758|OTHER|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
219323644|NCT04004429|DRUG|50 mg AP1189|50 mg AP1189 powder in bottle
219323645|NCT04004429|DRUG|AP1189|100 mg AP1189 powder in bottle
219323646|NCT04004429|DRUG|Placebo|Placebo powder in bottle
219323647|NCT03085758|BIOLOGICAL|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
219323648|NCT03085758|BIOLOGICAL|Placebo|Single i.v. dose of placebo (control group)
219323649|NCT04579744|OTHER|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
219323650|NCT03601936|DEVICE|Evivo Infant Gut Bifidobacterium Screening Test|Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
219323651|NCT02643160|OTHER|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
219323652|NCT02390817|DRUG|Sugammadex|Administration of Sugammadex
219323653|NCT02390817|DRUG|Neostigmine|Administration of Neostigmine
219323654|NCT02626325|OTHER|High-carbohydrate or High-monounsaturated fat diets|
219323655|NCT03519958|DIAGNOSTIC_TEST|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
219323656|NCT05798078|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
219323657|NCT05798078|BEHAVIORAL|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
219323658|NCT01122576|DEVICE|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
219323659|NCT01122576|DEVICE|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
219323660|NCT01122576|DEVICE|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
219323661|NCT03274583|DIAGNOSTIC_TEST|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
219323662|NCT02740296|OTHER|No intervention|
219323663|NCT03265535|DIAGNOSTIC_TEST|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
219323664|NCT05742503|OTHER|Depo-Provera|Injectable progesterone
219323665|NCT05742503|OTHER|Implanon|Etonogestrel implant
219323666|NCT05742503|OTHER|Norgestrel|Pill containing progesterone
219323667|NCT05742503|OTHER|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
219323668|NCT04281589|OTHER|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
219323669|NCT01550913|BEHAVIORAL|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
219323670|NCT01550913|OTHER|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
219323671|NCT02169817|DRUG|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
219323672|NCT02169817|DRUG|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
219323673|NCT03366051|PROCEDURE|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
219323674|NCT03366051|PROCEDURE|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
219323675|NCT03971656|DIETARY_SUPPLEMENT|Nutritional Supplement|Oral nutritional supplementation
219323676|NCT03971656|BEHAVIORAL|Preoperative Dietitian Consult|Nutritional assessment
219323677|NCT03971656|BEHAVIORAL|Education|Informational materials about nutrition
219323678|NCT03574441|DEVICE|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
219323679|NCT03574441|DEVICE|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
219323680|NCT03574441|DEVICE|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
219323681|NCT00307528|BIOLOGICAL|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
219323682|NCT00307528|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection.
219323683|NCT04259294|BEHAVIORAL|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
219323684|NCT05835089|DIAGNOSTIC_TEST|serum kisspeptin levels|Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
219323685|NCT03068000|BEHAVIORAL|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
219323686|NCT03068000|BEHAVIORAL|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
219323687|NCT02514408|PROCEDURE|Catheter Management|Insertion of venous catheter under ultrasound guidance
219323688|NCT02514408|OTHER|Cytology Specimen Collection Procedure|Collection of blood samples
219323689|NCT02514408|OTHER|Laboratory Biomarker Analysis|Correlative studies
219323690|NCT02613689|BEHAVIORAL|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
219323691|NCT02613689|BEHAVIORAL|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
219354798|NCT01345331|BEHAVIORAL|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
219354799|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^7 CFU in 10 mL phosphate-buffered saline
219323692|NCT04891341|OTHER|Technology Supported Task-Oriented Circuit Training|"Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~1. Sit to stand~2. Standing and trunk training~3. Standing and lower limb training~4. Stepping~5. Walking~6. Walking with object manipulation~7. Climbing and descending stairs~8. Unilateral upper extremity activity training (VR)~9. Bilateral upper extremity activity training (VR)~10. Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching)."
219354800|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^8 CFU in 10 mL phosphate-buffered saline
219323693|NCT04891341|OTHER|Home-based Telerehabilitation|Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
219323694|NCT02906345|DEVICE|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
219354801|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^9 CFU in 10 mL phosphate-buffered saline
219354802|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^10 CFU in 10 mL phosphate-buffered saline
219354803|NCT06201507|DRUG|Brentuximab vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
219354804|NCT06201507|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
219354805|NCT06201507|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
219354806|NCT06201507|DRUG|Vincristine|1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
219354807|NCT06201507|DRUG|Dacarbazine|375 mg/m2 will be administered on days 1 and 15
219354808|NCT04703894|DIETARY_SUPPLEMENT|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
219354809|NCT05001347|DRUG|TJ004309|Antibody to CD73
219354810|NCT01349166|BEHAVIORAL|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
219354811|NCT06540950|DRUG|vinorelbine|Vinorelbine is administered orally at 60mg per square meter per week by body surface area before radiotherapy and continued to be administered at 30mg per square meter per week during radiotherapy until the end of radiotherapy. Within 6 weeks after the end of radiotherapy, there are no serious side effects, and immune checkpoint inhibitors monotherapy can be performed.
219354812|NCT02571010|OTHER|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
219323695|NCT04937244|DIAGNOSTIC_TEST|5ALA exoscopic fluorescence filter|Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
219323696|NCT03326895|DEVICE|Left-sided colon resection|Left-sided colon resection with powered stapler
219323697|NCT03640468|DRUG|Ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg
219323698|NCT03640468|DRUG|Ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
219323699|NCT03640468|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg
219323700|NCT03640468|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
219323701|NCT03640468|DRUG|Normal saline|This group will receive normal saline 10 mL
219354813|NCT02571010|DEVICE|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
219323702|NCT05547282|RADIATION|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
219323703|NCT02785965|DEVICE|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
219323704|NCT02785965|BEHAVIORAL|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
219323705|NCT01558583|OTHER|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
219323706|NCT01558583|OTHER|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
219323707|NCT01558583|OTHER|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
219354814|NCT02571010|DEVICE|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
219354815|NCT02710357|PROCEDURE|Mandibular Overdenture|Placement of an implant in the mandibular midline.
219354816|NCT02710357|PROCEDURE|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
219354817|NCT05854901|DIAGNOSTIC_TEST|Procalcitonin|blood test, measuring the concentration of PCT in ug/L
219354818|NCT05854901|OTHER|Physician's decision|The physician's decided whether the patient will receive antibiotic treatment or not
219354819|NCT01226238|OTHER|Online self-help|Provision of online self-help
219323708|NCT04564144|DRUG|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
219323709|NCT00378833|DRUG|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
219323710|NCT00378833|DRUG|niacin|Duration of Treatment: 18 Weeks
219323711|NCT02690220|DEVICE|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
219323712|NCT00850850|DRUG|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
219323713|NCT00850850|DRUG|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
219323714|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
219323715|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
219323716|NCT01109173|OTHER|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
219323717|NCT01109173|OTHER|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
219323718|NCT03122496|DRUG|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
219323719|NCT03122496|DRUG|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
219323720|NCT03122496|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
219323721|NCT04095078|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
219323722|NCT06111482|DEVICE|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
219323723|NCT06111482|DEVICE|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
219323724|NCT06111482|DEVICE|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
219323725|NCT06111482|DEVICE|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
219354820|NCT01716481|OTHER|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
219323726|NCT05942430|PROCEDURE|Autologous costal osteochondral transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Trim the autograft according to the size of the lesion;~5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
219323727|NCT05942430|PROCEDURE|Autologous iliac osteoperiosteal transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
219323728|NCT00904293|OTHER|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
219323729|NCT00904293|OTHER|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
219323730|NCT05829642|BEHAVIORAL|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
219323731|NCT05869292|DEVICE|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
219323732|NCT05869292|DEVICE|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
219323733|NCT01287364|DRUG|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
219323734|NCT01287364|DRUG|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
219323735|NCT03214133|OTHER|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
219323736|NCT03214133|OTHER|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
219323737|NCT01936909|DRUG|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
219323738|NCT01936909|DRUG|Anakinra (weeks 3-12)|
219323739|NCT01936909|DRUG|Placebo|
219323740|NCT01958788|BEHAVIORAL|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
219323741|NCT03670043|DRUG|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
219323742|NCT03670043|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
219323743|NCT05019157|OTHER|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
219323744|NCT05019157|OTHER|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
219323745|NCT00744211|DRUG|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
219323746|NCT00744211|DRUG|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
219323747|NCT00744211|OTHER|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
219323748|NCT00000125|DRUG|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
219323749|NCT02959749|DRUG|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
219323750|NCT02959749|DRUG|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
219323751|NCT03881384|OTHER|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
219323752|NCT01788657|BEHAVIORAL|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
219323753|NCT01788657|BEHAVIORAL|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
219323754|NCT06094751|BEHAVIORAL|ACT Guide for Insomnia|ACT Guide for Insomnia includes 2 modules. Module 1 will include sleep/insomnia education, ACT skills (acceptance, defusion), and behavioral change. Module 2 will include sleep restriction, sleep hygiene, ACT skills (values, committed action), and behavioral change.
219323755|NCT03570853|BEHAVIORAL|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
219323756|NCT00169520|DRUG|docetaxel|
219323757|NCT00169520|DRUG|SB-715992|
219323758|NCT01026142|DRUG|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
219323759|NCT01026142|DRUG|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
219323760|NCT01026142|DRUG|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
219323761|NCT01026142|DRUG|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
219323762|NCT04663100|OTHER|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
219323763|NCT04663100|OTHER|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
219323764|NCT04663100|OTHER|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
219323765|NCT03210350|DIAGNOSTIC_TEST|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
219323766|NCT03681951|DRUG|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
219323767|NCT03681951|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
219323768|NCT00628251|DRUG|AZD2281|400mg Oral twice daily
219323769|NCT00628251|DRUG|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
219323770|NCT00628251|DRUG|AZD2281|200mg oral twice daily
219323771|NCT02715661|OTHER|exercise|six-month interval of exercise
219323772|NCT01020448|DRUG|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
219323773|NCT00378768|BIOLOGICAL|anti-thymocyte globulin|
219323774|NCT05915897|DIAGNOSTIC_TEST|Specimen Donation|blood donation
219323775|NCT00002951|DRUG|fluorouracil|
219323776|NCT00002951|DRUG|hydroxyurea|
219323777|NCT00002951|PROCEDURE|surgical procedure|
219323778|NCT00002951|RADIATION|radiation therapy|
219323779|NCT02911090|OTHER|Data Registry|Data Registry
219323780|NCT02761746|BEHAVIORAL|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
219323781|NCT01549782|DIETARY_SUPPLEMENT|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
219323782|NCT01549782|DIETARY_SUPPLEMENT|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
219323783|NCT04846374|DEVICE|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
219323784|NCT00041067|BIOLOGICAL|filgrastim|
219323785|NCT00041067|BIOLOGICAL|trastuzumab|
219323786|NCT00041067|DRUG|docetaxel|
219323787|NCT00041067|DRUG|vinorelbine|
219323788|NCT01266525|DRUG|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
219323789|NCT01266525|DRUG|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
219323790|NCT01266525|DRUG|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
219323791|NCT05593874|DIAGNOSTIC_TEST|Histones H3.1 blood levels|Measure of blood concentrations of histone subtype H3.1
219323792|NCT02634203|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
219323793|NCT02634203|DRUG|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
219323794|NCT06159192|DEVICE|Low intensity extracorporeal shock wave|Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.
219323795|NCT00328822|DRUG|Quetiapine|
219323796|NCT00328822|DRUG|placebo|
219323797|NCT02354781|BIOLOGICAL|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
219323798|NCT01033435|OTHER|No intervention|
219323799|NCT00021450|DRUG|bicalutamide|
219323800|NCT00021450|DRUG|goserelin acetate|
219323801|NCT00021450|PROCEDURE|adjuvant therapy|
219323802|NCT00021450|RADIATION|radiation therapy|
219323803|NCT03617965|DIAGNOSTIC_TEST|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
219323804|NCT01968070|DRUG|LY3127760|Administered orally
219323805|NCT01968070|DRUG|Celecoxib|Administered orally
219323806|NCT01968070|DRUG|Placebo|Administered orally
219323807|NCT00497601|DRUG|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
219323808|NCT00497601|DRUG|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
219323809|NCT00497601|DRUG|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
219323810|NCT02883530|PROCEDURE|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
219323811|NCT01449318|DEVICE|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
219323812|NCT02150525|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO (by mouth) daily
219323813|NCT02150525|OTHER|placebo|Given PO(by mouth)daily
219323814|NCT02150525|BEHAVIORAL|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
219323815|NCT00972426|DRUG|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
219323816|NCT03100201|OTHER|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
219323817|NCT03100201|OTHER|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
219323818|NCT00813332|DRUG|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
219323819|NCT00813332|DRUG|Placebo plus Docetaxel|Placebo plus Docetaxel
219323820|NCT00839709|PROCEDURE|blood sampling|peripheral blood draw
219323821|NCT02024451|DEVICE|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
219323822|NCT02024451|DEVICE|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
219323823|NCT02863627|OTHER|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
219323824|NCT01375257|DRUG|Oral treatment with antibiotics for endocarditis|
219323825|NCT01375257|DRUG|Guideline treatment with parenteral antibiotics|
219323826|NCT05750797|DRUG|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
219323827|NCT00836251|DIETARY_SUPPLEMENT|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
219323828|NCT01701076|DRUG|Bendamustine|"Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
219323829|NCT03841695|DEVICE|RMTC finger-hand robot (Mirror Hand)|The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
219323830|NCT03841695|OTHER|Conventional OT|The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
219323831|NCT00120861|DRUG|valopicitabine|
219323832|NCT00120861|DRUG|pegylated interferon|
219323833|NCT00120861|DRUG|ribavirin|
219323834|NCT05788003|DIAGNOSTIC_TEST|self-collected and operator-collected swab followed by molecular analysis|A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples.
219323835|NCT03742635|OTHER|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
219323836|NCT03819036|OTHER|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
219323837|NCT05522049|DEVICE|hyperangulated videolaryngoscope|Intubation using a hyperangulated videolaryngoscope
219323838|NCT05522049|DEVICE|Macintosh videolaryngoscope|Intubation using a Macintosh videolaryngoscope
219323839|NCT05134090|DEVICE|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
219323840|NCT01609751|DIETARY_SUPPLEMENT|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
219323841|NCT03429439|OTHER|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
219323842|NCT03429439|DRUG|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
219323843|NCT02755168|PROCEDURE|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
219323844|NCT02755168|PROCEDURE|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
219323845|NCT06124898|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.
219323846|NCT06124898|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
219323847|NCT06124898|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
219323848|NCT06124898|DEVICE|Higher tech facilitation|Participants will use an app developed during the study that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
219323849|NCT06124898|BEHAVIORAL|Attention control psychoeducation|Brief 25/30-minute psychoeducation on a topic not related to alcohol use that will be developed in the course of the study.
219323850|NCT06124898|DEVICE|Attention control technology|App or other form of technology that will be developed in the course of the study to deliver information not related to alcohol use
219323851|NCT02282566|OTHER|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
219323852|NCT00058474|DRUG|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
219323853|NCT00058474|DRUG|fluorouracil|225 mg/m2 IV daily continuous infusion
219323854|NCT00058474|DRUG|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
219323855|NCT00058474|RADIATION|radiation therapy|Given 5 days a week for 5-6 weeks
219323856|NCT02401412|DEVICE|Test Ostomy Barrier|
219323857|NCT02401412|DEVICE|Control Ostomy Barrier|
219323858|NCT00526396|DRUG|cisplatin|80 mg/m2 on day 1 for 6 cycles
219323859|NCT00526396|DRUG|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
219323860|NCT00526396|DRUG|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
219323861|NCT00526396|DRUG|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
219323862|NCT01585220|DEVICE|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
219323863|NCT00882310|DRUG|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
219323864|NCT00882310|DRUG|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
219323865|NCT00882310|DRUG|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
219323866|NCT03327441|OTHER|Almonds|Almonds will be provided as 15% energy
219323867|NCT03327441|OTHER|Omelette|Omelettes will be provided as 15% energy
219323868|NCT00780819|DEVICE|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
219323869|NCT05106504|DRUG|Medical Cannabis|Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
219323870|NCT01770613|BIOLOGICAL|Stem cells|Allogeneic mesenchymal stem cells
219323871|NCT04119960|DEVICE|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
219323872|NCT01186900|PROCEDURE|ultrasound-guided needle aspiration|one time drainage at time of randomization
219323873|NCT02376608|DIETARY_SUPPLEMENT|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
219323874|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
219323875|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
219323876|NCT02376608|DIETARY_SUPPLEMENT|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
219323877|NCT02756351|DEVICE|CytaCoat Nasal Prong|
219323878|NCT02756351|DEVICE|Inspiration Healthcare Inspire nCPAP Nasal Prong|
219323879|NCT00249210|DRUG|levofloxacin|
219323880|NCT05135221|BIOLOGICAL|dual biological therapy|Simultaneous use of two biologicals.
219323881|NCT03244748|PROCEDURE|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
219323882|NCT05558306|PROCEDURE|Surgery of distal radius fracture|Surgery of distal radius fracture for displaced fractures
219323883|NCT05558306|PROCEDURE|Reduction and cast treatment of distal radius fracture|Reduction and cast treatment of distal radius fracture for minimally displaced fractures
219323884|NCT04275141|OTHER|oral glucose load|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
219323885|NCT04275141|OTHER|exercise test|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
219323886|NCT04246801|DRUG|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
219323887|NCT04246801|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
219323888|NCT03684642|DRUG|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
219323889|NCT03684642|DRUG|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
219323890|NCT03684642|DRUG|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
219323891|NCT05533879|OTHER|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
219323892|NCT06495385|DIAGNOSTIC_TEST|Evolution of renal function|Plasma creatinine levels and glomerular filtration rate estimated using the CKD-Epi formula adjusted for 1.73 m2 body surface area will be measured.
219323893|NCT06495385|DIAGNOSTIC_TEST|Measurement of haemoglobin levels|Haemoglobin levels will be measured.
219323894|NCT06495385|DIAGNOSTIC_TEST|Measurement of biological parameters|Plasma levels of urea, calcium, phosphorus and parathyroid hormone, as well as alkaline reserve, will be measured.
219323895|NCT06495385|DIAGNOSTIC_TEST|Measure sodium and protein consumption|24-hour urine volume, proteinuria, urea and sodium, will be measured.
219323896|NCT06495385|BEHAVIORAL|Quality of life questionnaire EUROQOL 5 dimensions (EQ-5D-5L)|"The descriptive system comprises five dimensions: mobility, personal care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The figures for the five dimensions can be combined into a 5-digit number describing the patient's state of health. Scores close to 1 indicate the best health you can imagine and those close to 0 the worst health you can imagine."
219323897|NCT06010771|OTHER|Listening to fairy tales|Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
219323898|NCT06010771|OTHER|Watching Cartoon Film|The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
219323899|NCT02743351|BIOLOGICAL|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
219323900|NCT02743351|BIOLOGICAL|Control Arm|Untreated mobilized peripheral blood (mPB) cells
219323901|NCT00717054|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
219323902|NCT00717054|DRUG|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
219323903|NCT00161486|DRUG|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
219323904|NCT00161486|DRUG|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
219323905|NCT00161486|DRUG|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
219323906|NCT00161486|DRUG|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
219323907|NCT04556396|DIAGNOSTIC_TEST|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
219323908|NCT01763151|DEVICE|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
219323909|NCT01763151|PROCEDURE|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
219323910|NCT01643525|DEVICE|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
219323911|NCT01522482|DIETARY_SUPPLEMENT|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
219323912|NCT01522482|DIETARY_SUPPLEMENT|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
219323913|NCT01522482|DIETARY_SUPPLEMENT|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
219323914|NCT04445181|DRUG|The physician's prescription in routine clinical practice|This is an Observational study that will not involve prescription of the drugs.
219323915|NCT04713202|DRUG|Telotristat ethyl|Telotristat Ethyl, 250mg
219323916|NCT04713202|DRUG|Peptide Receptor Radionuclide Therapy|Peptide Receptor Radionuclide Therapy
219323917|NCT04713202|OTHER|Placebo|Placebo
219323918|NCT05509985|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
219323919|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
219323920|NCT00521742|DRUG|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
219323921|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
219323922|NCT00521742|DRUG|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
219323923|NCT01087112|BEHAVIORAL|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
219323924|NCT01087112|BEHAVIORAL|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
219323925|NCT05429151|DRUG|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
219323926|NCT04201821|BIOLOGICAL|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
219323927|NCT05564351|OTHER|eye mask and ear plug|black eye mask and silicon ear plug
219323928|NCT05097014|DRUG|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
219323929|NCT05097014|DRUG|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
219323930|NCT05097014|OTHER|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
219323931|NCT02636153|OTHER|normal diet|Diet containing 1500mg of phosphorus
219323932|NCT02636153|OTHER|restricted phosphate diet|Diet containing 500mg of phosphorus
219323933|NCT00387764|DRUG|pazopanib|800 mg daily dosing continously until progression
219323934|NCT02929745|PROCEDURE|Skin biopsy|Four 4-5 mm punch biopsies of the skin
219323935|NCT02929745|PROCEDURE|Blood draw|Blood will be drawn to test for HLA-cw6 status
219323936|NCT04228809|DEVICE|tDCS|transcranial direct current stimulation
219323937|NCT00603655|OTHER|Low glycemic load diet|Low glycemic load diet
219323938|NCT00603655|OTHER|High glycemic load diet|High glycemic load diet
219323939|NCT05511623|DRUG|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
219323940|NCT05511623|OTHER|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
219323941|NCT00094796|PROCEDURE|Exercise cardiopulmonary metabolic testing|
219323942|NCT00094796|PROCEDURE|Skeletal muscle biopsy|
219323943|NCT00094796|PROCEDURE|Brachial artery reactivity testing|
219323944|NCT04379648|OTHER|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
219323945|NCT00528892|DRUG|Raltegravir|switching PI to raltegravir
219323946|NCT00528892|DRUG|boosted PI|continue on boosted-PI
219323947|NCT05861154|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation."
219323948|NCT05861154|DRUG|Benzocaine Gel|a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
219323949|NCT02849158|OTHER|Biopsy|Rectoscopy with biopsy
219323950|NCT02231788|DRUG|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
219323951|NCT02231788|DRUG|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
219323952|NCT04728126|OTHER|Survey|"The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales."
219323953|NCT03624205|DEVICE|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
219323954|NCT03792386|PROCEDURE|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
219323955|NCT03792386|PROCEDURE|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
219323956|NCT01927185|DEVICE|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
219323957|NCT01927185|DEVICE|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
219323958|NCT02374021|DRUG|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
219323959|NCT02374021|DRUG|Sulfasalazine|1 gm bid
219323960|NCT02374021|DRUG|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
219323961|NCT02374021|DRUG|Etanercept|50 mg SC weekly
219323962|NCT02374021|DRUG|Adalimumab|40 mg SQ every other week
219323963|NCT00256425|BEHAVIORAL|Cognitive rehabilitation|
219323964|NCT00002313|DRUG|Nystatin|
219323965|NCT00002313|DRUG|Didanosine|
219323966|NCT03142971|PROCEDURE|focused shock wave therapy|
219323967|NCT03142971|PROCEDURE|ultrasound therapy|
219323968|NCT04872881|PROCEDURE|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
219323969|NCT04872881|PROCEDURE|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
219323970|NCT04872881|PROCEDURE|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
219323971|NCT04872881|PROCEDURE|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
219323972|NCT04872881|DIAGNOSTIC_TEST|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
219323973|NCT04872881|DIAGNOSTIC_TEST|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
219323974|NCT04872881|DRUG|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
219323975|NCT04872881|DRUG|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
219323976|NCT04872881|DRUG|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
219323977|NCT06010069|DIAGNOSTIC_TEST|body temperature measurament|body temperature of every patient was measured with tympanic thermometer during surgical procedure
219323978|NCT00051480|GENETIC|TNFerade|
219323979|NCT00611195|DRUG|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
219323980|NCT00000712|DRUG|Zidovudine|
219323981|NCT00000712|DRUG|Acyclovir|
219323982|NCT05079412|OTHER|Chest ultrasound|Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
219323983|NCT03253939|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
219323984|NCT03253939|PROCEDURE|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
219323985|NCT05408104|DRUG|tolvaptan|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
219323986|NCT01980420|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
219323987|NCT03005951|OTHER|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
219323988|NCT03005951|OTHER|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
219323989|NCT05697731|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
219323990|NCT04692038|DEVICE|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
219323991|NCT04603586|RADIATION|SBRT|SBRT: in 5-6 fractions with CyberKnife
219323992|NCT04603586|DRUG|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
219323993|NCT00824824|DRUG|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
219323994|NCT00824824|DRUG|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
219323995|NCT05235399|OTHER|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
219323996|NCT03359525|DRUG|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
219323997|NCT02684279|DRUG|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
219323998|NCT02448693|DEVICE|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
219323999|NCT02448693|DEVICE|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
219324000|NCT01162239|DRUG|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
219324001|NCT01162239|BEHAVIORAL|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
219324002|NCT01162239|BEHAVIORAL|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
219324003|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
219324004|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
219324005|NCT03410459|DIAGNOSTIC_TEST|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
219324006|NCT00228566|DRUG|Armodafinil|
219324007|NCT04357821|DRUG|Combination Intervention|"1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34"
219324008|NCT05797233|BIOLOGICAL|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
219324009|NCT05797233|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
219324010|NCT05797233|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
219324011|NCT06221553|BIOLOGICAL|B7H3 specific CAR T cell with IL-7Ra signaling domain|Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter
219324012|NCT05251623|OTHER|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
219324013|NCT01012154|DEVICE|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
219324014|NCT00074854|DRUG|CP-547,632|
219324015|NCT05960929|COMBINATION_PRODUCT|Infasurf Aero™|A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
219324016|NCT05705193|OTHER|NeuroFlex (computerized gamified tasks)|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant."
219324017|NCT03585556|DRUG|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
219324018|NCT03585556|BIOLOGICAL|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
219324019|NCT03585556|DRUG|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
219324020|NCT04448756|DRUG|M5049|Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
219324021|NCT04448756|DRUG|M5049|Participants received M5049 100 mg orally twice daily for 14 days.
219324022|NCT04448756|DRUG|Placebo|Participants received placebo tablets matched to M5049 daily for 14 days.
219324023|NCT06606444|DEVICE|Surfactant Administration Through Laryngeal or Supraglottic Airways|While the child is spontaneously breathing on nasal CPAP treatment, the neonatal intensive care (NICU) physician will place the LMA and assess for adequate airway by CO2-detection, chest movement, pulmonary auscultation of bilateral breath sounds, gastric insufflation, oxygen saturation and heart rate. A placement attempt should not last more than 30 seconds. Surfactant will be administered slowly in 1-2 ml aliquots (Curosurf 200 mg/kg) via an appropriate size laryngeal mask airway. The neonate should primarily be spontaneously breathing and if needed receives gentle supportive positive pressure ventilation (PPV). Gentle supportive PPV is given for 30 seconds after surfactant is administered, before LMA is removed.
219324024|NCT06068465|DRUG|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
219324025|NCT06068465|DRUG|placebo|placebo, capsule, once daily by mouth for 6 weeks
219324026|NCT04454437|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
219324027|NCT05359549|DEVICE|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
219324028|NCT03902847|BEHAVIORAL|motor imagery|All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
219324029|NCT03902847|BEHAVIORAL|Action observation|A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
219324030|NCT03902847|BEHAVIORAL|Motor Control Exercises|The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
219324031|NCT02338349|DRUG|Elacestrant|
219324032|NCT04571281|DIAGNOSTIC_TEST|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
219324033|NCT06006338|OTHER|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
219324034|NCT02023255|DRUG|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
219324035|NCT02023255|OTHER|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
219324036|NCT00199433|DRUG|Istradefylline (KW-6002)|
219324037|NCT06292000|BEHAVIORAL|AM Exercise|Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
219324038|NCT06292000|BEHAVIORAL|PM Exercise|Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
219324039|NCT05467475|DRUG|BI 1819479|BI 1819479
219324040|NCT05467475|DRUG|Esomeprazole|Esomeprazole
219324041|NCT00232141|DRUG|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
219324042|NCT00232141|DRUG|Placebo|Placebo
219324043|NCT06031896|OTHER|No interventions|No interventions
219324044|NCT00339170|BEHAVIORAL|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
219324045|NCT00339170|BEHAVIORAL|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
219324046|NCT01088256|DRUG|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
219324047|NCT01088256|DRUG|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
219324048|NCT03474471|BEHAVIORAL|Pulmonary rehabilitation|Following a PR program
219324049|NCT03474471|DEVICE|EBV treatment|Bronchoscopic lung volume reduction using endobronchial valves (EBV)
219324050|NCT00782288|DRUG|digitoxin|0.05mg tabs, once daily for 28 days
219324051|NCT00782288|DRUG|digitoxin|0.1mg pills, once daily for 28 days.
219324052|NCT00782288|OTHER|placebo|pill taken once daily for 28 days
219324053|NCT02307760|OTHER|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
219324054|NCT02307760|OTHER|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
219324055|NCT04775225|DRUG|Lidocaine|denervation of the obturator and femoral genicular branches by Lidocaine 2 %
219324056|NCT04775225|DRUG|Placebo|an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
219324057|NCT04775225|DRUG|Steroid|Intra-articular injection of 80mg of triamcinolone
219324058|NCT05057286|PROCEDURE|Clinical crown lengthening surgery|"* Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection."
219324059|NCT00150332|DRUG|linezolid|
219324060|NCT01479829|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
219324061|NCT01479829|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug
219324062|NCT01479829|DRUG|Placebo|Placebo is a manufactured capsule with no active ingredient
219324063|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
219324064|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
219324065|NCT01116518|PROCEDURE|physiotherapy|
219324066|NCT01116518|PROCEDURE|acromioplasty|
219324067|NCT01116518|PROCEDURE|acromioplasty and rotator cuff reconstruction|
219324068|NCT03759977|OTHER|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
219324069|NCT06129123|BEHAVIORAL|Live Free From E-cigarettes|This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
219324070|NCT04513262|PROCEDURE|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
219324071|NCT04221932|DEVICE|CRRT KPI Reports|This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
219324072|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
219324073|NCT04326647|OTHER|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
219324074|NCT04326647|OTHER|Exercise|Exercises about balance and gait
219324075|NCT01791803|BEHAVIORAL|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
219324076|NCT01791803|DRUG|Nicotine|free one month supply after hospital discharge
219324077|NCT05056324|DEVICE|Online vestibular rehabilitation tool|For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)
219324078|NCT05056324|OTHER|Standard care (written instructions leaflet)|For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
219324079|NCT07130799|OTHER|Immunomonitoring|To analyse monocyte HLA-DR expression (mHLA-DR) and CD4+ T lymphocyte count (CD4) in both group
219324080|NCT07128875|OTHER|Exercise + TENS + Hot Pack|"Therapeutic Exercises with Hot Pack and TENS This intervention focuses on improving physical function and reducing pain through structured therapeutic exercises for knee OA patients. The program includes Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5. Cool Down (5-10 min): Breathing and relaxation. 6. Hot Pack (15 min) + TENS (10 min): Applied pre and post exercises for pain relief and muscle relaxation."
219324081|NCT07128875|OTHER|Exercise|"Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5."
219324082|NCT06421545|BEHAVIORAL|Resilient Together for Dementia|A novel live video dyadic resiliency intervention
219324083|NCT04572854|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
219324084|NCT04279054|DRUG|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
219324085|NCT04279054|DRUG|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
219324086|NCT07130110|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|The c-TBB procedure was performed under general anesthesia with rigid bronchoscopy guidance. The biopsy site was selected based on the area of highest involvement seen on thoracic CT. After evaluating the trachea and main bronchi with a rigid bronchoscope, a flexible bronchoscope was advanced into the target segment. Using a 1.9 mm, 90 cm cryoprobe, tissue was frozen and rapidly retracted with the bronchoscope to obtain the biopsy. The specimen was placed in formalin without damage. Hemorrhage control was achieved with a Fogarty balloon. A chest X-ray was taken two hours later to check for pneumothorax risk.
219324087|NCT07130110|DIAGNOSTIC_TEST|Bronchoalveolar Lavage|The BAL protocol, including pre-procedural preparations and the procedure itself, was performed in accordance with the American Thoracic Society (ATS) guidelines. In cases of diffuse involvement, BAL was performed from the middle lobe or lingula, while in localized involvement, it was done from the affected area. The target segment was occluded with the bronchoscope, and room-temperature 0.9% NaCl solution was instilled in 20 cc portions and gently aspirated to prevent airway collapse. A minimum of 100 mL (maximum 300 mL) saline was used, with at least 30% recovery required. Cellular analysis of BAL fluid was conducted per ATS guidelines. Normal cell distribution: alveolar macrophages \>85%, lymphocytes 10-15%, neutrophils ≤3%, eosinophils ≤1%, squamous/ciliated columnar epithelial cells ≤1%.
219324088|NCT07128940|OTHER|Meat vs fish|Metabolite differences: Meat vs fish
219324089|NCT07128940|OTHER|Meat vs Vegetarian|Metabolite differences: Meat vs Vegetarian
219324090|NCT07128940|OTHER|Fish vs Vegetarian|Metabolite differences: Fish vs Vegetarian
219324091|NCT07128719|DRUG|Modafinil|dose of modafinil preoperatively for for active comparator
219324092|NCT03248674|DIAGNOSTIC_TEST|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
219324093|NCT00846547|DRUG|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
219324094|NCT02750150|DRUG|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
219324095|NCT02750150|DRUG|Fresh-frozen plasma|
219324096|NCT03872232|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
219324097|NCT03872232|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
219324098|NCT01093326|DRUG|Ponesimod 10 mg|Ponesimod 10 mg oral use
219324099|NCT01093326|DRUG|Ponesimod 20 mg|Ponesimod 20 mg oral use
219324100|NCT01093326|DRUG|Ponesimod 40 mg|Ponesimod 40 mg oral use
219324101|NCT04628884|DRUG|Conventional dose|Conventional dose used to calculated the protamine dose
219324102|NCT04628884|DRUG|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
219324103|NCT04260009|DRUG|Brigatinib|Brigatinib tablets
219324104|NCT04260009|DRUG|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
219324105|NCT06812858|DRUG|Nivolumab, Pembrolizumab|"The choice of drug and its dose for maintenance therapy is at the discretion of the study centre (e.g. nivolumab, pembrolizumab). Maintenance therapy should be initiated no later than 60 days after D0, exceptions may be made due to reasonable justification in consultation with the Study PI and will not be considered a protocol deviation.~Nivolumab maintenance therapy regimens:~* Nivolumab (40 mg, fixed dose) IV D1 of each 14-days cycle up to 12 cycles~* Nivolumab (3 mg/kg) IV D1 of each 14-days cycle up to 12 cycles~Pembrolizumab maintenance therapy regimen:~-Pembrolizumab (200 mg, fixed dose) IV D1 of each 21-days cycle up to 8 cycles"
219324106|NCT06820034|OTHER|Empowering Cessation for the ACS South|All participants (N=400) will receive remotely-delivered smoking cessation support comprised of the National Cancer Institute's (NCI) free smoking cessation app and 12 weeks of mailed over-the-counter NRT (nicotine patches, gum or lozenges).. While receiving smoking cessation support, participants in the intervention group (n=200) will also engage in SGM-serving online volunteer activities (≥4 weekly sessions lasting \~1.5 hours each), the protocols for which will be developed in Phase 1 to address the needs of OK, AR, and TX communities. Volunteer sessions will be facilitated by an SGM culturally-competent facilitator employed by the research team (i.e., community partner organizations will not run volunteer sessions). The intervention group will also be added to a digital hub (i.e., a private Reddit group) for 12 weeks to foster social support and exchange of ideas between participants/community partners across the three states.
219324107|NCT03565731|BEHAVIORAL|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
219324108|NCT06987240|PROCEDURE|Ultrasonography-guided combined spinal epidural anesthesia application|patients with BMI\>30
219324109|NCT06987240|PROCEDURE|Combined spinal epidural anesthesia with Landmark|Patients with BMI\>30
219324110|NCT04263896|DRUG|Polyethylene Glycol 3350|Participants will take 1 17g pack per day for 10 days preceding surgery.
219324111|NCT06609213|OTHER|Medical Food|Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.
219324112|NCT07001280|OTHER|No intervention|No intervention will be administered as part of this study.
219324113|NCT07007520|DRUG|DA-5223(Fasting)|once a day
219324114|NCT07007520|DRUG|DA-5223(Fed)|once a day
219324115|NCT07117097|PROCEDURE|Minimally Invasive Non- Surgical Periodontal Therapy (MINST)|The procedure consists of thorough debridement of the root surface through a subpapillary access using exclusively piezoelectric devices with specific thin and delicate tips (EMS, Switzerland) and 4X magnification loupes, taking care to minimize the soft tissue trauma and to stimulate the formation of a stable blood clot
219324116|NCT07117097|PROCEDURE|conventional Non-Surgical Periodontal Treatment (cNSPT)|The intervention consists of thorough debridement of the root surface under local anaesthesia, using conventional piezoelectric devices and hand instruments
219324117|NCT07123246|OTHER|Rigid Tape|Inelastic rigid tape (Strappal) applied to discharge the Achilles tendon
219324118|NCT07123246|OTHER|Placebo Control|A pre-tape and a short piece of rigid tape applied without tension.
219324119|NCT07122479|OTHER|Three-Pronged Approach to Reduce Hospital Acquired Deconditioning|The intervention includes 1) providing and demonstrating a set of daily physical exercises to patient according to their baseline performance status as assessed by physical therapist, 2) maintaining a patient-completed daily log of physical exercise adherence and 3) standardize the monitoring of physical exercise by the healthcare team by its inclusion in daily progress notes.
219324120|NCT07130292|BEHAVIORAL|Abdominal Muscle Strengthening Exercises with Stabilizer Pressure Biofeedback|A supervised exercise program designed to strengthen abdominal and lumbar muscles, incorporating the use of a stabilizer pressure biofeedback device to enhance activation of deep stabilizing muscles such as the transversus abdominis. The program is delivered three times per week for 6 weeks (excluding menstruation weeks) and includes mobility, stretching, and strengthening exercises.
219324121|NCT07130162|DIAGNOSTIC_TEST|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
219324122|NCT07130214|DRUG|Biodentine|Biodentine is used in the treatment of existing dentin damage thanks to active bio-silicate technology.
219324123|NCT07129746|DEVICE|Metallic clip ligation of the appendicular stump|The group A patients will be having the appendicular stump ligated using the metallic clip, and assessed in terms of length of surgery and associated intra operative complications.
219324124|NCT07129746|DEVICE|Suture ligation of appendicular stump|The appendicular stump in the second arm will be ligated using appropriate suture material and assessed in terms of length of surgery and rate of intraoperative complications.
219324125|NCT07130422|PROCEDURE|CABG surgery|CABG surgery
219324126|NCT07130630|OTHER|Completion of Vietnamese Pain Self-Efficacy Questionnaire (PSEQ)|Participants completed the Vietnamese version of the Pain Self-Efficacy Questionnaire (PSEQ) to assess self-efficacy beliefs related to pain management.
219324127|NCT05686187|OTHER|AR's platform for gender empowerment|The intervention of the experimental group is to accept the courses of the gender empowerment platform introduced by AR. The preliminary plan is 50-60 minutes each time. The content of the teaching plan course will adopt the course module design. Group content, and among the three module courses, there must be a core module course unit that is the workplace sexual harassment prevention unit
219324128|NCT06937372|DRUG|Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.|Unlike low molecular weight heparin (LMWH), which requires daily subcutaneous injections, aspirin is taken orally, making it more comfortable and acceptable for patients, particularly the elderly or those with mobility issues. Aspirin is significantly less expensive than injectable anticoagulants like LMWH or newer oral anticoagulants, making it a potentially cost-effective alternative for thromboprophylaxis.
219324129|NCT06937372|DRUG|Low molecular weight heparin (LMWH)|"LMWH is administered via daily subcutaneous injection, typically starting shortly after surgery and continued for a defined period as per each hospital's local policy, often 14 to 28 days. LMWH has a proven track record of reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgery.~However, it carries a risk of bleeding and may be challenging for some frail or elderly patients to tolerate, especially if self-injection is required post-discharge."
219324130|NCT07129954|BEHAVIORAL|Motor rehabilitation|Motor rehabilitation will be characterized by sessions of 45 minutes each with a patient (total sessions 36): physiotherapist ratio of 1:1. The rehabilitation project will be defined by the PM\&R specialist and the physiotherapist who will take charge of the patient. The treatment will focus on the maintenance of active and passive joint ranges, on the training of balance and gait, and on exercises of proprioception and scenic reinforcement. Specific devices (rehabilitation beds, verticalizer, posturography platform) will be used during motor treatment
219324131|NCT07129954|BEHAVIORAL|Motor Rehabilitation and Cognitive Behavioral Therapy|"1 session per week of 45 minutes of cognitive behavioral therapy and 2 sessions per week of 45 minutes of motor rehabilitation. The length of the treatment is the same as the control group: 12 weeks for 12 CBT sessions and 24 motor rehabilitation sessions (a total of 36 sessions).~Motor rehabilitation will be the same as that provided to the control group. In addition, participants will receive Cognitive-Behavioral Therapy (CBT), consisting of individual 45-minute sessions (one psychotherapist per patient).~The sessions will focus on the relationship between cognition, emotions, and behavior. Specifically, the therapist will work with the patient to identify and modify automatic thoughts, cognitive distortions, and underlying beliefs or patterns associated with the fear of falling."
219324132|NCT04256421|DRUG|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
219324133|NCT04256421|DRUG|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
219324134|NCT04256421|DRUG|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
219324135|NCT04256421|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
219324136|NCT04256421|DRUG|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
219324137|NCT06053255|DEVICE|High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR|HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.
219324138|NCT03146468|DRUG|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
219324139|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4|Testmeal with free FeSO4
219324140|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
219324141|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
219324142|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
219324143|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
219324144|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
219324145|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
219324146|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
219324147|NCT03332602|DIETARY_SUPPLEMENT|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
219324148|NCT06472154|OTHER|Experimental|The experimental group intervened based on the midnight-noon ebb-flow theory, listening to music corresponding to the five organs at different time periods.
219324149|NCT06472154|OTHER|Control|The control group listened to Chinese five elements music pieces from 13:00 to 18:00 p.m., each music piece for within 30 minutes for, 5 days per week, 4 weeks for a cycle, 3 cycles in total.
219324150|NCT00494728|BEHAVIORAL|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
219324151|NCT00494728|DRUG|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
219324152|NCT00494728|BEHAVIORAL|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
219324153|NCT05142800|DEVICE|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
219324154|NCT05142800|DEVICE|SOZO device|The machine measures the amount of fluid on the arm(s)
219324155|NCT03040440|DEVICE|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
219324156|NCT03040440|DEVICE|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
219324157|NCT00126633|BIOLOGICAL|bevacizumab|
219324158|NCT00126633|DRUG|cisplatin|
219324159|NCT00126633|DRUG|gemcitabine hydrochloride|
219324160|NCT04198506|OTHER|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.
219324161|NCT04198506|OTHER|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
219324162|NCT01016964|DEVICE|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
219324163|NCT01016964|DEVICE|Sham Device|Sham Device
219324164|NCT01920594|DRUG|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
219324165|NCT01920594|DRUG|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
219324166|NCT06281769|DIAGNOSTIC_TEST|3D multi-parametric ultrasound targeted biopsy pathway using PcaVision|The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.
219324167|NCT06281769|DIAGNOSTIC_TEST|MRI targeted biopsy pathway|MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
219324168|NCT00516620|BEHAVIORAL|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
219324169|NCT00516620|BEHAVIORAL|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
219324170|NCT00516620|BEHAVIORAL|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324171|NCT00516620|BEHAVIORAL|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324172|NCT00516620|BEHAVIORAL|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324173|NCT00516620|BEHAVIORAL|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324174|NCT00516620|BEHAVIORAL|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324175|NCT00516620|BEHAVIORAL|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
219324176|NCT00235820|DRUG|adalimumab|40 mg every other week following an 80 mg dose
219324177|NCT00235820|DRUG|MTX|MTX 7.5 to 25 mg once weekly
219324178|NCT00235820|DRUG|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
219324179|NCT00880035|DEVICE|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
219324180|NCT05571046|DRUG|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
219324181|NCT05571046|OTHER|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
219324182|NCT00016263|BIOLOGICAL|oblimersen sodium|
219324183|NCT00016263|DRUG|dacarbazine|
219324184|NCT04570111|OTHER|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
219324185|NCT04570111|OTHER|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
219324186|NCT03707509|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
219324187|NCT03707509|DRUG|Placebos|Maximum 6 cycles for combined therapy.
219324188|NCT03707509|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
219324189|NCT03707509|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
219324190|NCT03272568|DRUG|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
219324191|NCT03272568|DRUG|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
219324192|NCT03272568|DEVICE|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
219324193|NCT04398511|DRUG|L brevis|Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.
219324194|NCT04398511|DRUG|Placebo|Placebo lozenges after breakfast, lunch and dinner for 21 days.
219324195|NCT00928564|DRUG|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
219324196|NCT00928564|DRUG|Placebo|5ml of saline at each block site.
219324197|NCT04946903|DRUG|RLD2007|Take it once per period.
219324198|NCT04946903|DRUG|RLD2008|Take it once per period.
219324199|NCT04946903|DRUG|HCP1902|Take it once per period.
219324200|NCT03203421|BIOLOGICAL|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
219324201|NCT03203421|BIOLOGICAL|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
219324202|NCT02206165|DRUG|Candesartan 8mg|Once a day, 8 weeks
219324203|NCT02206165|DRUG|Candesartan 16mg|Once a day, 8 weeks
219324204|NCT02206165|DRUG|Amlodipine 5mg|Once a day, 8 weeks
219324205|NCT02206165|DRUG|Amlodipine 10mg|Once a day, 8 weeks
219324206|NCT01569165|PROCEDURE|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
219324207|NCT04218955|COMBINATION_PRODUCT|Silver Diamine Flouride|Material used to arrest caries in children
219324208|NCT06318351|PROCEDURE|transcutaneous acupoint electrical stimulation|This is a safe and non-invasive procedure, similar to an electrode sheet, which applies a weak current to a specific site to achieve the purpose of acupoint stimulation.
219324209|NCT02249754|BEHAVIORAL|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
219324210|NCT02249754|BEHAVIORAL|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
219324211|NCT04147026|DEVICE|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
219324212|NCT04147026|OTHER|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
219324213|NCT03786978|BEHAVIORAL|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
219324214|NCT03786978|BEHAVIORAL|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
219324215|NCT04249323|DRUG|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
219324216|NCT04249323|DRUG|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
219324217|NCT04249323|DRUG|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
219324218|NCT05320562|PROCEDURE|Kinesio taping|"Additionally, they received kinesio taping application for 7 days. Blue color kinesio tape (manufactured by Theraband®, USA) was used. Kinesio taping was done by experienced physiotherapist with 5 years of experience. Two Y shape bands were applied for lymphatic taping and to improve anterior upper leg muscle function (lymphatic correction and muscle correction techniques were integrated together).~Then two I shape bands (75-100% tension) were applied above the patella tendon and medial/lateral collateral ligaments in order to improve mechanoreceptor stimulation, proprioception and knee stability."
219324219|NCT05320562|PROCEDURE|Sham taping|Additionally, they received sham (placebo) taping: usual white patch was applied to the painful knee for 7 days. The technique of taping used was the same as in kinesiotaping group, but without stretching.
219324220|NCT00141895|DRUG|Misoprostol|2 tablets 200 micrograms Vaginal route
219324221|NCT00141895|DRUG|Misoprostol|2 tablets of 200 micrograms Sublingual route
219324222|NCT00220558|DEVICE|Coronary placement of bare metal stent vs. drug eluting stent|
219324223|NCT01326078|DRUG|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
219324224|NCT02611661|DEVICE|PET/MRI|
219324225|NCT02611661|RADIATION|Percutaneous ablation|
219324226|NCT02611661|RADIATION|Stereotactic body radiotherapy|
219324227|NCT03332914|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
219324228|NCT00613444|DEVICE|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
219324229|NCT04309279|BEHAVIORAL|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
219324230|NCT03700151|BEHAVIORAL|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
219324231|NCT01009892|DRUG|Codeine Sulfate|Tablet
219324232|NCT02615470|BEHAVIORAL|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
219324233|NCT02615470|OTHER|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
219324234|NCT02596243|BIOLOGICAL|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
219324235|NCT02596243|BIOLOGICAL|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
219324236|NCT02433171|PROCEDURE|Standard of Care FDG-PET Imaging|\[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
219324237|NCT04121611|DRUG|Unfractionated heparin|"1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
219324238|NCT04121611|DRUG|Acetylsalicylic Acid (ASA)|"1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose"
219324239|NCT02460705|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
219324240|NCT02488187|DEVICE|ABUS|Automated breast ultrasound
219324241|NCT06793033|PROCEDURE|Advanced Cardiac Life Support (ACLS)|Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.
219324242|NCT06793033|DEVICE|Aortic balloon occlusion (ABO)|"Aortic balloon occlusion (ABO) is a technique that diverts blood ﬂow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest.~In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest."
219324243|NCT01817907|DRUG|Placebo pill|Subjects will receive a sugar pill during the placebo arm
219324244|NCT01817907|DRUG|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
219324245|NCT04603365|DRUG|Pamiparib|Given PO
219324246|NCT04603365|DRUG|Temozolomide|Given PO
219324247|NCT05597709|PROCEDURE|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
219324248|NCT04433806|BEHAVIORAL|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
219324249|NCT05125094|DEVICE|TACE,Ablation|Transcatheter arterial chemoembolization
219324250|NCT03420079|DRUG|FCN-411 Dose-escalation|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
219324251|NCT03420079|DRUG|FCN-411 Dose-expansion|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
219324252|NCT02597803|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
219324253|NCT02597803|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
219324254|NCT06165822|DRUG|TQB3909 tablets|TQB3909 100mg/tablet.
219324255|NCT06165822|DRUG|Itraconazole capsule|Itraconazole capsule is a strong inhibitor of CYP3A4.
219324256|NCT06165822|DRUG|Rifampicin capsule|Rifampicin capsule is a strong inducer of CYP3A4.
219324257|NCT02761824|OTHER|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
219324258|NCT03987724|OTHER|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
219324259|NCT04962217|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
219324260|NCT00221650|DRUG|Peginterferon alfa2a|
219324261|NCT00221650|DRUG|Ribavirin|
219324262|NCT03343392|DRUG|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
219324263|NCT03343392|DRUG|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
219324264|NCT00760396|DRUG|VGX-1027|Subjects will
219324265|NCT02809742|DRUG|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
219324266|NCT01650285|DRUG|Cabazitaxel|"Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2"
219324267|NCT00900523|GENETIC|protein expression analysis|protein expression analysis
219324268|NCT00900523|OTHER|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
219324269|NCT03915808|DIETARY_SUPPLEMENT|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
219324270|NCT03915808|DIETARY_SUPPLEMENT|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
219324271|NCT03719638|DEVICE|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
219324272|NCT03719638|OTHER|simulated difficult airway|extension of head will be limited by using collar.
219324273|NCT03719638|DEVICE|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
219324274|NCT03222739|DEVICE|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
219324275|NCT00916539|DEVICE|Cast that immobilizes the thumb|Cast that immobilizes the thumb
219324276|NCT00916539|DEVICE|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
219324277|NCT03161288|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
219324278|NCT03161288|DRUG|Placebo|Matched placebo
219324279|NCT01826851|DRUG|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
219324280|NCT01826851|DRUG|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
219324281|NCT01817283|DRUG|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
219324282|NCT01817283|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
219324283|NCT01817283|DRUG|placebo|Placebo pills produced the same as Triptolide wilfordii.
219324284|NCT02053909|DRUG|Aspirin|
219324285|NCT02053909|DRUG|Ticagrelor|
219324286|NCT04115579|OTHER|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
219324287|NCT04115579|OTHER|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
219324288|NCT02925572|OTHER|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
219324289|NCT04472143|DRUG|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
219324290|NCT04163900|DRUG|NUC-1031|IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes
219324291|NCT04163900|DRUG|Gemcitabine|IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert
219324292|NCT04163900|DRUG|Cisplatin|IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol
219324293|NCT05491252|BEHAVIORAL|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
219324294|NCT02228187|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
219324295|NCT06833255|OTHER|Interview|Ancillary studies
219324296|NCT06833255|OTHER|Questionnaire Administration|Ancillary studies
219324297|NCT06833255|OTHER|Support|Attend 1:1 peer mentoring sessions
219324298|NCT06833255|PROCEDURE|Support Group Therapy|Attend survivorship group support sessions
219324299|NCT00785044|DRUG|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
219324300|NCT04157816|OTHER|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
219354821|NCT03880500|OTHER|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
219355148|NCT06101615|OTHER|Foam Rolling|Group-B participants would receive Foam Rolling (FR). Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm) to avoid possible confounding circadian effects. The Foam Roller group will receive 2x1 min of FR on the quadriceps and the hamstrings on the dominant leg with the opposite leg crossed over the dominant one. During each minute the muscle will be rolled out 4-5 times, with a break of 30s in between sets. They will be instructed to utilize short, kneading like movements in one direction and a quick motion in the other direction. A grid foam roller will be utilized with a length of 33cm, diameter of 14 cm and with a hard hollow core, wrapped in ethylene vinyl acetate foam.
219324301|NCT04157816|OTHER|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
219324302|NCT04157816|OTHER|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
219324303|NCT04841980|DRUG|Rifaximin|Administration route: PO Rifaximin 400mg TDS for 2 weeks
219324304|NCT04841980|OTHER|Low FODMAP diet|Low FODMAP diet under dietitian guidance for 4 weeks
219324305|NCT03746899|BIOLOGICAL|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
219324306|NCT01825642|PROCEDURE|nerve-sparing radical prostatectomy|
219324307|NCT01825642|PROCEDURE|seminal vesicle-sparing radical prostatectomy|
219324308|NCT02507622|OTHER|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
219324309|NCT02507622|OTHER|Parabolic flight|
219324310|NCT01971502|DRUG|Placebo to BI 1060469|single rising doses
219324311|NCT01971502|DRUG|BI 1060469|food effect
219324312|NCT01971502|DRUG|BI 1060469|single rising doses
219324313|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
219324314|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
219324315|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
219324316|NCT01830855|BIOLOGICAL|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
219324317|NCT01830855|BIOLOGICAL|Saline|0.5 mL dose of sterile normal saline for injection.
219324318|NCT00515255|DRUG|Minocycline|Capsules
219324319|NCT02509104|DRUG|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
219324320|NCT02509104|DRUG|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
219324321|NCT06372951|DEVICE|Ultrasound|A device that use ultrasonic waves as a way to image the internal organs and tissues of the body in order to diagnose the different diseases.
219324322|NCT01667081|DRUG|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
219324323|NCT00565591|DRUG|Albuterol sulfate|Single dose dry powder by inhalation
219324324|NCT01840891|BEHAVIORAL|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
219324325|NCT05260853|OTHER|Weaning Board|structured care concept
219324326|NCT03523728|DRUG|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
219324327|NCT03523728|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
219324328|NCT01821833|DIETARY_SUPPLEMENT|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
219324329|NCT01821833|DIETARY_SUPPLEMENT|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
219324330|NCT01821833|DRUG|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
219324331|NCT00621751|DRUG|Carbamazepine|800 mg daily
219324332|NCT00621751|DRUG|Placebo|Placebo
219324333|NCT05136365|DRUG|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
219324334|NCT04918199|DEVICE|Computer based assessment (iBox)|Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
219324335|NCT04918199|OTHER|Physician assessement|Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
219324336|NCT03262454|DRUG|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
219324337|NCT01667536|DRUG|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
219324338|NCT00419120|BIOLOGICAL|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
219324339|NCT03088475|BEHAVIORAL|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
219324340|NCT03088475|BEHAVIORAL|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
219324341|NCT00164047|DRUG|Nitrous Oxide|
219324342|NCT01950247|DRUG|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
219324343|NCT01950247|DRUG|SOC|
219324344|NCT00234936|DRUG|Adalimumab|
219324345|NCT00234936|DRUG|Methotrexate|
219324346|NCT05149898|DRUG|ZYN002|"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."
219324347|NCT03887845|PROCEDURE|Surgery|The respective surgical approach for any gastric and colorectal surgery
219324348|NCT01956149|DRUG|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
219324349|NCT00710879|DEVICE|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
219324350|NCT01043679|DRUG|Utapine|Efficacy and Safety of Utapine
219324351|NCT01043679|DRUG|Seroquel|Efficacy and Safety of Seroquel
219324352|NCT01519804|DRUG|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
219324353|NCT01519804|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
219324354|NCT01519804|DRUG|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
219324355|NCT01519804|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
219324356|NCT01923142|BIOLOGICAL|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
219324357|NCT01923142|BIOLOGICAL|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
219355149|NCT03055975|DIAGNOSTIC_TEST|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
219324358|NCT03486886|DIAGNOSTIC_TEST|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
219324359|NCT01809132|DRUG|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
219324360|NCT01809132|DRUG|Pentoxifylline|Pentoxifylline, generic
219324361|NCT01809132|DRUG|Zinc Sulfate|Zinc Sulfate, nutritional supplement
219324362|NCT01809132|DRUG|Methylprednisolone|Methylprednisolone, corticosteroid
219324363|NCT05526742|DRUG|CKD-510 capsule (reference)|Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
219324364|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
219324365|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fed state.
219324366|NCT03349775|DRUG|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
219324367|NCT03349775|DRUG|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
219324368|NCT01516970|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
219324369|NCT01516970|DRUG|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
219324370|NCT01516970|DRUG|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
219324371|NCT01516970|DRUG|NRTIs|The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
219324372|NCT01516970|DRUG|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
219324373|NCT00612950|DRUG|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
219324374|NCT00612950|DRUG|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
219324375|NCT00612950|DRUG|Saline|continuous infusion of Saline for 120 min
219324376|NCT03066908|DEVICE|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
219324377|NCT06344819|PROCEDURE|Acupuncture|Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
219324378|NCT06344819|OTHER|Sham Acupuncture|During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
219324379|NCT01786200|DRUG|Aspirin|
219324380|NCT01786200|DRUG|Ibuprofen|
219355150|NCT01290692|BIOLOGICAL|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
219355151|NCT01849770|DRUG|Mexiletine|
219324381|NCT00434421|DRUG|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
219324382|NCT00434421|DRUG|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
219324383|NCT02080442|OTHER|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
219355152|NCT01849770|DRUG|Placebo|
219324384|NCT01756040|DRUG|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
219324385|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
219324386|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
219355153|NCT01511770|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
219324387|NCT05168891|PROCEDURE|Surgical therapy|Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
219355154|NCT01511770|DRUG|Fluconazole|Fluconazole 200 mg tablets
219324388|NCT05168891|PROCEDURE|Non-surgical therapy of peri-implantitis|Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
219324389|NCT06248814|DRUG|BMS-986326|Specified dose on specified days
219324390|NCT06248814|OTHER|Placebo|Specified dose on specified days
219324391|NCT04640844|BIOLOGICAL|blood sample|measuring the expression and function of lymphocyte A2A receptors.
219324392|NCT03890991|BEHAVIORAL|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
219355155|NCT00993031|DRUG|Lopinavir/ritonavir|LPV 200mg/r 50mg
219324393|NCT03890991|BEHAVIORAL|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
219324394|NCT03890991|BEHAVIORAL|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
219324395|NCT04055181|DEVICE|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
219324396|NCT04055181|DEVICE|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
219324397|NCT04055181|DEVICE|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
219324398|NCT04055181|DEVICE|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
219324399|NCT04127825|PROCEDURE|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
219324400|NCT00892177|BIOLOGICAL|bevacizumab|Given intravenously
219324401|NCT00892177|DRUG|dasatinib|Given orally
219324402|NCT00892177|OTHER|placebo|Given orally
219324403|NCT00050765|DRUG|MyoCell™ Autologous Myoblasts|
219355156|NCT00993031|DRUG|Efavirenz|600mg
219355157|NCT00993031|DRUG|Zidovudine|Zidovudine 300 mg
219355158|NCT00993031|DRUG|Lamivudine|Lamivudine 150 mg
219324404|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
219324405|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
219324406|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
219324407|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
219355159|NCT04011865|PROCEDURE|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
219324408|NCT04114188|DRUG|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
219324409|NCT02734823|OTHER|Cytology Specimen Collection Procedure|Undergo collection of serum
219324410|NCT02734823|OTHER|Laboratory Biomarker Analysis|Correlative studies
219324411|NCT02734823|OTHER|Questionnaire Administration|Ancillary studies
219324412|NCT02734823|PROCEDURE|Ultrasonography|Undergo transvaginal pelvic ultrasonography
219324413|NCT01758263|DRUG|Metoprolol|Metoprolol, oral administration
219324414|NCT01758263|DRUG|Nebivolol|Nebivolol, oral administration
219324415|NCT02645760|OTHER|Core stabilization exercise|7-weeks of core stabilization exercise
219355160|NCT00270530|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
219324416|NCT02645760|OTHER|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
219324417|NCT00347334|BEHAVIORAL|infant home positioning|
219355161|NCT00875355|DRUG|temozolomide|Given orally
219324418|NCT02163460|PROCEDURE|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
219324419|NCT02163460|PROCEDURE|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
219324420|NCT04549727|OTHER|Organoids creation|Organoids are created from discarded tissue
219324421|NCT00143091|DRUG|CP-316,311|
219324422|NCT00143091|DRUG|Placebo|
219324423|NCT00143091|DRUG|Sertraline|
219324424|NCT02432313|DRUG|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
219324425|NCT06508112|DEVICE|Masimo Radical-7® Pulse CO-Oximeter|Masimo Radical-7® Pulse CO-Oximeter device was attached to the index finger of the patients in the supine position and photoplethysmographic perfusion index and plethysmographic variability index were measured noninvasively, rapidly and continuously.
219324426|NCT01446016|DRUG|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
219324427|NCT01446016|DRUG|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
219324428|NCT01446016|DRUG|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
219324429|NCT01446016|DRUG|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
219324430|NCT01905124|DRUG|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
219324431|NCT01905124|DRUG|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
219324432|NCT02525055|OTHER|Infectious titre 1 (H3N2)|Infectious titre 1: 2.8 x 10\*3 TCID50/mL
219324433|NCT02525055|OTHER|Infectious titre 2 (H3N2)|Infectious titre 2: 2.5 x 10\*4 TCID50/mL
219324434|NCT02525055|OTHER|Infectious titre 3 (H3N2)|Infectious titre 3: 3.6 x 10\*5 TCID50/mL
219324435|NCT02525055|OTHER|Infectious titre 4 (H3N2)|Infectious titre 4: 4.7 x 10\*6 TCID50/mL
219324436|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
219324437|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
219324438|NCT02267603|OTHER|Laboratory Biomarker Analysis|Ancillary studies
219324439|NCT02267603|BIOLOGICAL|Pembrolizumab|Given IV
219324440|NCT00955851|OTHER|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
219324441|NCT01520311|DEVICE|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
219324442|NCT00227487|OTHER|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
219324443|NCT00227487|OTHER|Administration of carbohydrate solution during clinically indicated endoscopy|"* A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
219324444|NCT00227487|OTHER|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
219324445|NCT00049452|DRUG|zoledronic acid|
219324446|NCT06637462|DIAGNOSTIC_TEST|Endoscopy|Standard of care endoscopy
219324447|NCT04621734|DEVICE|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
219324448|NCT04621734|DEVICE|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
219324449|NCT02336789|OTHER|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
219355162|NCT00875355|RADIATION|radiation therapy|Patients undergo radiotherapy
219324450|NCT02336789|OTHER|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
219324451|NCT03517189|PROCEDURE|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
219324452|NCT06494865|DEVICE|MRI device|"Standered breast coils with small field of veiw and thin sections will be used for the examinatio.~MRI breast including Axial T1WI, T2WI Stir contrast DWI and Stir sagittal T1WI with contrast traction and subtraction"
219324453|NCT05436769|DRUG|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
219355163|NCT04515732|DRUG|Apremilast Oral Tablet|As in description
219355164|NCT01075555|DRUG|pravastatin sodium|
219355165|NCT01075555|DRUG|sorafenib tosylate|
219355166|NCT05547178|OTHER|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
219324454|NCT05436769|DRUG|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
219324455|NCT04573751|DRUG|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
219324456|NCT04573751|DRUG|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
219324457|NCT04573751|DRUG|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
219324458|NCT04573751|DRUG|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
219324459|NCT05488210|DIETARY_SUPPLEMENT|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
219324460|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
219324461|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
219324462|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
219324463|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
219324464|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
219324465|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
219324466|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
219324467|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
219324468|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
219324469|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
219324470|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
219324471|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
219324472|NCT02626481|DRUG|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
219324473|NCT02626481|DRUG|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
219324474|NCT00298467|DRUG|MDX-060|
219324475|NCT00943709|BIOLOGICAL|insulin glargine recombinant|Given subcutaneously
219324476|NCT00943709|DRUG|therapeutic insulin|Given subcutaneously
219324477|NCT02091154|BEHAVIORAL|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim"
219324478|NCT02091154|BEHAVIORAL|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
219324479|NCT02091154|BEHAVIORAL|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
219324480|NCT01582022|DRUG|Bupivacaine|local application for 5 minutes
219324481|NCT01582022|DRUG|normal saline|local application for 5 minutes
219324482|NCT00408330|DRUG|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
219324483|NCT00408330|DRUG|Inactive 15% gel base|placebo, topically applied daily for six weeks
219324484|NCT01087957|DEVICE|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
219324485|NCT01087957|OTHER|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
219324486|NCT01291199|DRUG|vardenafil|10 mg p.o. bid for 6 weeks
219324487|NCT01291199|DRUG|Placebo|Placebo p.o. 6 weeks bid
219324488|NCT03743883|DRUG|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
219324489|NCT02313298|RADIATION|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
219324490|NCT03171844|OTHER|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
219324491|NCT02692664|DEVICE|Endovascular aorto-iliac repair|
219324492|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
219324493|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
219324494|NCT04420754|BIOLOGICAL|AIC100 CAR T Cells|Autologous CAR T cells directed against ICAM-1
219324495|NCT00987688|OTHER|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
219324496|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
219324497|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with 5mm suction irrigation blunt dissection starting from fundus
219324498|NCT05559021|OTHER|Myofascial Therapy Treatments|"• Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat"
219324499|NCT05559021|OTHER|Passive Mobilizations Approach|"• Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage"
219324500|NCT00616434|DRUG|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
219324501|NCT00616434|DRUG|Placebo|Placebo IM injection, self-administered per protocol.
219324502|NCT00296179|DRUG|zolpidem tartrate|
219324503|NCT02455934|DIETARY_SUPPLEMENT|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
219324504|NCT03302000|OTHER|Early Visual Stimulation|Early visual stimulation
219324505|NCT03302000|OTHER|standard care|standard care
219324506|NCT04229511|DIAGNOSTIC_TEST|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
219324507|NCT02560064|PROCEDURE|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
219324508|NCT05286983|BEHAVIORAL|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
219324509|NCT01754857|DRUG|Bendamustine|Given IV
219324510|NCT01754857|DRUG|Rituximab|Given IV
219324511|NCT01754857|DRUG|Lenalidomide|Given PO
219324512|NCT01509079|DRUG|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
219324513|NCT01509079|DRUG|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
219324514|NCT01925352|DRUG|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
219324515|NCT03910712|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
219324516|NCT03910712|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
219324517|NCT03910712|DRUG|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
219324518|NCT05788822|DIETARY_SUPPLEMENT|Mevalproic acid|Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
219324519|NCT00328991|DEVICE|duct tape occlusion therapy|
219324520|NCT03938038|DIAGNOSTIC_TEST|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
219324521|NCT03938038|DIAGNOSTIC_TEST|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
219324522|NCT02213432|BIOLOGICAL|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
219324523|NCT01399190|BIOLOGICAL|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
219324524|NCT01399190|BIOLOGICAL|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
219324525|NCT01399190|DRUG|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
219324526|NCT00525889|DRUG|IL-2|Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
219324527|NCT00525889|DRUG|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
219324528|NCT06141044|PROCEDURE|Avoid surgical drainage|Patients who undergo distal pancreatectomy, avoid placing a drain.
219324529|NCT00264225|DRUG|Lamaline® , 3 different doses, Dafalgan codeine|
219324530|NCT06325618|OTHER|No intervention other than obtaining biopsies|Skin, fat, and muscle biopsies will be obtained
219324531|NCT06325618|DRUG|Indocyanine green (ICG)|Indocyanine green will be injected to evaluate the lymphatic system.
219324532|NCT01981239|DEVICE|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
219324533|NCT04353453|DEVICE|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
219355167|NCT05547178|OTHER|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
219355168|NCT05547178|OTHER|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
219355169|NCT02767648|OTHER|proteomic urine analysis|proteomic urine analysis
219355170|NCT03506295|DEVICE|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
219355171|NCT03506295|DEVICE|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
219355172|NCT00868283|DRUG|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
219355173|NCT00868283|DRUG|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
219324534|NCT04353453|DEVICE|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
219324535|NCT04157504|OTHER|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
219324536|NCT02412020|DRUG|PA101|
219324537|NCT02412020|DRUG|Placebo|
219324538|NCT06466811|OTHER|Patients of intensive care unit|Patients of intensive care unit having an EVD
219324539|NCT06466811|OTHER|Patients of surgical intensive care unit|Patients of surgical intensive care unit having an EVD.
219324540|NCT02686021|DRUG|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
219324541|NCT02686021|DRUG|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
219324542|NCT02686021|DRUG|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
219324543|NCT00611962|DRUG|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
219324544|NCT05248451|OTHER|Not an Interventional Study|Not an Interventional Study
219324545|NCT01636414|PROCEDURE|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
219324546|NCT01636414|PROCEDURE|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
219324547|NCT01636414|PROCEDURE|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
219324548|NCT00005920|DRUG|L-743,872|
219324549|NCT04474457|DRUG|Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
219324550|NCT00436618|DRUG|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
219324551|NCT06343012|OTHER|Caring leadership Intervention program|Caring leadership intervention program
219324552|NCT00698204|DRUG|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
219324553|NCT00698204|DRUG|placebo|Subject was asked to take placebo each day that radiation therapy was given.
219324554|NCT03001973|OTHER|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
219324555|NCT00314249|DRUG|Placebo|Placebo, oral administration, twice daily for 12 weeks
219324556|NCT00314249|DRUG|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID \[twice a day\])
219324557|NCT01949155|DRUG|OTO-201|Single, intratympanic injection
219324558|NCT01949155|DRUG|Sham|Simulated single, intratympanic injection
219324559|NCT04292028|OTHER|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
219324560|NCT04292028|OTHER|Home exercises|Control group were given a home-based exercise program.
219324561|NCT00217191|DRUG|Ibuprofen|
219324562|NCT03120806|PROCEDURE|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
219324563|NCT03120806|PROCEDURE|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
219324564|NCT03347981|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
219324565|NCT03347981|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
219324566|NCT04825171|DRUG|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
219324567|NCT05165355|DRUG|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
219324568|NCT00210184|DRUG|Irinotecan associated to fluorouracil and leucovorin|
219324569|NCT04997187|DIETARY_SUPPLEMENT|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
219324570|NCT04997187|DIETARY_SUPPLEMENT|Control group|Placebo 400 mg/day for 12 weeks
219324571|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
219324572|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
219324573|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
219324574|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
219324575|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
219324576|NCT04146428|BEHAVIORAL|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
219324577|NCT04146428|BEHAVIORAL|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
219324578|NCT05988541|DIAGNOSTIC_TEST|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
219355174|NCT03823469|BEHAVIORAL|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
219355175|NCT03823469|BEHAVIORAL|Nutritional counseling|Two 30-minute nutritional counseling sessions
219355176|NCT05779826|OTHER|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
219355177|NCT01622881|DRUG|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
219355178|NCT01622881|DRUG|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
219355179|NCT02762474|DRUG|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
219355180|NCT01543087|PROCEDURE|blood sampling|Blood sample collection at different time points
219355181|NCT01543087|DRUG|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
219355182|NCT01787357|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
219355183|NCT01787357|DRUG|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
219355184|NCT01787357|DRUG|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
219355185|NCT05722665|OTHER|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
219355186|NCT05764486|DEVICE|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
219355187|NCT02167932|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
219355188|NCT04467580|DIAGNOSTIC_TEST|abdominal [18F]FDG PET/CT|Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
219355189|NCT05536661|OTHER|Preservative free hyaluronic acid artificial tear|Ocular lubricant
219324579|NCT05988541|DIAGNOSTIC_TEST|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~1. Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~2. Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~3. Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
219355190|NCT01938144|DRUG|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
219355191|NCT01938144|DRUG|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
219324580|NCT05988541|DIAGNOSTIC_TEST|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
219324581|NCT05988541|DIAGNOSTIC_TEST|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
219324582|NCT06495502|OTHER|semi-structured interview|Semi-structured interviews by qualitative health researchers
219355192|NCT01938144|DRUG|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
219355193|NCT01720537|BIOLOGICAL|PF-05335810 Dose A|Single SC Injection
219355194|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Subcutaneous Injection(s)
219324583|NCT06249204|BEHAVIORAL|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
219324584|NCT05222204|DRUG|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
219324585|NCT06435676|DRUG|HRS9531|Single dose escalation of HRS9531 tablets in healthy subjects
219324586|NCT06435676|DRUG|Placebo|Single dose of placebo in healthy adults
219324587|NCT06435676|DRUG|HRS9531|Multiple dose escalation of HRS9531 tablets in healthy subjects
219324588|NCT06435676|DRUG|Placebo|Multiple dose of placebo in healthy adults
219324589|NCT04607954|BIOLOGICAL|Durvalumab|Given IV
219324590|NCT04607954|DRUG|Lurbinectedin|Given IV
219324591|NCT05003895|DRUG|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
219324592|NCT05003895|BIOLOGICAL|CAR-T cell|Single infusion on Day 0
219324593|NCT05003895|DRUG|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
219324594|NCT01118325|DRUG|ticagrelor|Drug oral treatment
219324595|NCT01118325|DRUG|clopidogrel|Drug oral treatment
219324596|NCT05694520|OTHER|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
219324597|NCT03589690|DIETARY_SUPPLEMENT|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
219324598|NCT03589690|DIETARY_SUPPLEMENT|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
219324599|NCT03532646|PROCEDURE|upper endoscopy|endoscopy of the gastrointestinal tract
219324600|NCT04392453|DEVICE|Robotic therapy|The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
219324601|NCT03258125|GENETIC|real time PCR (rPCR)|A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
219324602|NCT03334409|DRUG|Ascorbic Acid|Given IV
219324603|NCT03334409|DRUG|Pazopanib Hydrochloride|Given PO
219324604|NCT00975715|DRUG|TRI476|TRI476 oral suspension doses, based on body weight twice daily
219324605|NCT00975715|DRUG|Placebo to TRI476|Placebo oral suspension, taken twice daily
219324606|NCT00975715|DRUG|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
219324607|NCT04116424|OTHER|nurse training of the patient|visit + telephone follow-up
219324608|NCT04116424|OTHER|neurologist accompaniement|presentation during consultation by neurologist
219324609|NCT03270566|DEVICE|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
219324610|NCT01245634|DRUG|Placebo|iv infusion every 4 weeks, 32 weeks
219324611|NCT01245634|DRUG|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
219324612|NCT05683587|OTHER|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
219324613|NCT00872664|DIETARY_SUPPLEMENT|carotenoids|beta-carotene, lycopene, lutein
219324614|NCT04214301|DRUG|BLI800|BLI800 Bowel Preparation
219324615|NCT00727233|DRUG|Nexavar (BAY 43-9006) (Sorafenib)|
219324616|NCT00727233|DRUG|Toxicity, Pharmacokinetics|
219324617|NCT00727233|DRUG|Pharmacodynamics|
219324618|NCT00727233|DRUG|Radiographic Evaluation|
219324619|NCT00727233|DRUG|QOL assessment, Neuropsychological|
219324620|NCT00727233|DRUG|Bony Toxicity|
219324621|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
219324622|NCT01674712|DRUG|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
219324623|NCT01674712|DRUG|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
219324624|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
219324625|NCT01674712|DRUG|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
219324626|NCT02279823|DRUG|CB-03-01 solution|Investigational drug solution
219324627|NCT02279823|DRUG|Minoxidil Solution 5%|FDA approved marketed product
219324628|NCT02279823|DRUG|Placebo solution|Vehicle solution
219324629|NCT03686956|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
219324630|NCT01200108|DRUG|Budesonide|
219324631|NCT01200108|DRUG|Budesonide|
219324632|NCT01200108|DRUG|Budesonide|
219355195|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
219355196|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Intravenous Infusion
219355197|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
219355198|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Subcutaneous Injection(s)
219355199|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Intravenous Infusion
219355200|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Subcutaneous Injection(s)
219324633|NCT05573321|OTHER|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
219355201|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
219355202|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Intravenous Infusion
219355203|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
219355204|NCT01720537|BIOLOGICAL|PF-04950615|Single Subcutaneous Injection(s)
219355205|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Subcutaneous Injection(s)
219324634|NCT05573321|OTHER|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
219324635|NCT03096925|BEHAVIORAL|Guided self-help|Web-based guided self-help intervention
219355206|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
219355207|NCT01720537|BIOLOGICAL|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
219355208|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Intravenous Infusion
219324636|NCT00490633|BEHAVIORAL|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
219324637|NCT00490633|BEHAVIORAL|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
219324638|NCT06394596|OTHER|Prognostic factors affecting graft survival|The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation
219324639|NCT01047696|DEVICE|Plancha|locally developed chimney stove
219324640|NCT00445562|OTHER|biologic sample preservation procedure|
219324641|NCT00445562|OTHER|informational intervention|
219324642|NCT04225468|BEHAVIORAL|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
219324643|NCT03623451|DRUG|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
219324644|NCT01617850|OTHER|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
219355209|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
219355210|NCT00706030|DRUG|neratinib|
219355211|NCT00706030|DRUG|vinorelbine|
219355212|NCT03682978|DRUG|Arbaclofen|Arbaclofen tablet.
219355213|NCT03682978|DRUG|Placebo|Placebo tablet.
219355214|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
219355215|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg single dose
219355216|NCT01244880|OTHER|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
219355217|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg tablet single dose
219355218|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
219355219|NCT01244880|OTHER|Placebo|Placebo tablet single dose
219355220|NCT01244880|OTHER|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
219324645|NCT01617850|OTHER|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
219324646|NCT03974334|BEHAVIORAL|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
219324647|NCT06006325|DEVICE|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
219355221|NCT01244880|OTHER|Placebo|Placebo tablet single dose
219355222|NCT04481776|OTHER|Breakfast consumption|Standardised breakfast consumption across seven days
219324648|NCT06006325|DEVICE|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
219324649|NCT03447938|PROCEDURE|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
219324650|NCT03447938|PROCEDURE|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
219324651|NCT05874713|BIOLOGICAL|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
219324652|NCT05874713|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
219324653|NCT05874713|BIOLOGICAL|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
219324654|NCT05874713|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
219324655|NCT05874713|BIOLOGICAL|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
219324656|NCT00024167|DRUG|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
219324657|NCT00024167|DRUG|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
219324658|NCT00024167|DRUG|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
219324659|NCT00024167|DRUG|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
219324660|NCT00024167|DRUG|Prednisone|5 mg orally 2 x daily, weeks 1-14
219324661|NCT00024167|DRUG|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
219324662|NCT00024167|RADIATION|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
219324663|NCT00024167|DRUG|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
219324664|NCT03691090|DRUG|SHR-1210|SHR-1210 200mg
219324665|NCT03691090|DRUG|Placebo|Placebo
219324666|NCT03691090|DRUG|paclitaxel|paclitaxel 175mg/m2
219324667|NCT03691090|DRUG|cisplatin|cisplatin 75mg/m2
219324668|NCT00002016|DRUG|Sevirumab|
219324669|NCT03210103|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
219324670|NCT03210103|PROCEDURE|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
219324671|NCT03610399|DRUG|Primaquine|Different total dose and supervision.
219324672|NCT02764164|DEVICE|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
219324673|NCT04263350|DRUG|Atazanavir/Cobicistat|Specified Dose on Specified Days
219324674|NCT04263350|DRUG|Reyataz Atazanavir|Specified Dose on Specified Days
219324675|NCT04263350|DRUG|Cobicistat|Specified Dose on Specified Days
219324676|NCT01892306|BEHAVIORAL|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
219324677|NCT01892306|DRUG|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
219324678|NCT00120640|DRUG|17 hydroxyprogesterone caproate intramuscular injections|
219324679|NCT04123990|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
219324680|NCT02676388|PROCEDURE|Freeze-dried, Capsulized FMT|
219324681|NCT02676388|PROCEDURE|Fresh FMT|
219324682|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
219324683|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
219324684|NCT02131441|PROCEDURE|laparoscopic hepatectomy|
219324685|NCT02131441|PROCEDURE|open liver resection|
219324686|NCT06417463|PROCEDURE|thyroidectomy opeartion|correlation between TIRADS and Bethesda scoring system (preoperative) and final histopathology (postoperative) in cases of thyroidectomy
219355223|NCT04481776|OTHER|Breakfast omission|No breakfast consumed across seven days
219324687|NCT01534013|DEVICE|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
219324688|NCT01534013|DEVICE|Open loop|glucose sensor and pump
219324689|NCT03341572|OTHER|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
219324690|NCT01379573|DRUG|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
219324691|NCT01138579|DRUG|FBTA05|
219324692|NCT00278850|BEHAVIORAL|Educational|three 1 hour long educational seminars
219324693|NCT00962390|DRUG|S-equol|10mg S-equol 50mg S-equol, \& 150mg S-equol
219324694|NCT00962390|DRUG|Placebo|Placebo
219324695|NCT04582942|DRUG|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
219324696|NCT04582942|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
219324697|NCT02794142|PROCEDURE|renal transplantation|
219324698|NCT02794142|OTHER|No intervention|
219324699|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219324700|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219324701|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219324702|NCT00152282|DRUG|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
219324703|NCT04347070|OTHER|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
219324704|NCT05057260|OTHER|No drug invervention|No clinical trial
219324705|NCT00018850|DRUG|ondansetron|
219324706|NCT00018850|BEHAVIORAL|neuropsychological testing|
219324707|NCT00018850|DRUG|nicotine|
219324708|NCT00018850|DRUG|haloperidol|
219324709|NCT04969445|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
219324710|NCT00470236|RADIATION|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
219324711|NCT00470236|RADIATION|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
219324712|NCT00470236|RADIATION|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
219324713|NCT00470236|RADIATION|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
219324714|NCT02488499|BEHAVIORAL|Coping Power|15 sessions of concurrent parent and child group treatment
219324715|NCT02488499|BEHAVIORAL|Individualized Treatment|15 sessions of individualized child and parent treatment
219324716|NCT05896371|DRUG|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I\&T injected activity
219324717|NCT05896371|DRUG|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I\&T injected activity
219324718|NCT05378997|DRUG|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
219324719|NCT05378997|DRUG|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
219324720|NCT05378997|DRUG|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
219324721|NCT03114865|DRUG|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
219324722|NCT03114865|DRUG|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
219324723|NCT03114865|DRUG|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
219324724|NCT03114865|DRUG|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
219324725|NCT04374643|OTHER|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
219324726|NCT04184492|DRUG|GP-40081|biphasic insulin aspart 30 in doses 0.4 IU/kg
219324727|NCT04184492|DRUG|NovoMix® 30 Penfill®|biphasic insulin aspart 30 in doses 0.4 IU/kg
219324728|NCT00006448|BEHAVIORAL|cognitive therapy|
219324729|NCT00006448|PROCEDURE|Physical Therapy|
219324730|NCT00006448|DRUG|Methadone|
219324731|NCT02179879|OTHER|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
219324732|NCT04338373|COMBINATION_PRODUCT|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
219324733|NCT05668039|PROCEDURE|Enhanced external counterpulsation|15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
219324734|NCT00510081|DEVICE|Calcium Hydroxylapatite injection|filler injection
219324735|NCT00324051|DRUG|olanzapine therapy|
219324736|NCT00888420|OTHER|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
219324737|NCT03725579|DRUG|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
219324738|NCT03725579|DRUG|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
219324739|NCT00113230|DRUG|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
219324740|NCT00113230|DRUG|Capecitabine|900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
219324741|NCT00113230|RADIATION|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
219324742|NCT02307487|DRUG|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
219324743|NCT02307487|DRUG|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
219324744|NCT02307487|DRUG|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
219324745|NCT02307487|DRUG|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
219324746|NCT02307487|DRUG|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
219324747|NCT02307487|DRUG|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
219324748|NCT01657097|DRUG|INCS|
219324749|NCT01657097|DRUG|Placebo|
219324750|NCT01358890|OTHER|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
219324751|NCT01358890|OTHER|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
219324752|NCT03054207|DRUG|Clopidogrel 300Mg Tablet|
219324753|NCT03054207|DRUG|Prasugrel 60Mg|
219324754|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
219324755|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Mini PCNL will be performed.
219324756|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
219324757|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
219324758|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
219324759|NCT02522676|PROCEDURE|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
219324760|NCT04373954|OTHER|Forgiveness Therapy|The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.
219324761|NCT04373954|OTHER|Carey Guides|The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
219324762|NCT03568045|DEVICE|standard light|usual care
219324763|NCT03568045|DEVICE|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
219324764|NCT03568045|DEVICE|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
219324765|NCT00334386|DRUG|Torasemide Prolonged Release (loop diuretic)|
219324766|NCT00334386|DRUG|Torasemide Immediate Release (loop diuretic)|
219324767|NCT00770770|DRUG|Fluocinolone Acetonide|0.2 µg/day
219324768|NCT00770770|DRUG|Fluocinolone Acetonide|0.5 µg/day
219324769|NCT01961375|DRUG|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
219324770|NCT02483559|OTHER|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (\~470 nm) to be worn prior to desired sleep onset time.
219324771|NCT02483559|OTHER|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
219324772|NCT01761279|PROCEDURE|High definition white light endoscopy|
219324773|NCT05407233|DEVICE|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
219355224|NCT04638569|PROCEDURE|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
219355225|NCT06278909|DEVICE|Trigeminal Nerve Stimulation|Active trigeminal nerve stimulation
219355226|NCT00884104|DRUG|Solifenacin|Oral
219324774|NCT05407233|DEVICE|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
219324775|NCT01089920|OTHER|Green tea|Infusion (tea bags) from commercially available green tea
219324776|NCT01089920|OTHER|Coffee|Soluble coffee commercially available
219324777|NCT00572026|DRUG|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
219324778|NCT00797875|PROCEDURE|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
219324779|NCT00797875|PROCEDURE|passive stretching|passive stretching x 5 repetitions continue 3 days
219355227|NCT03188237|BEHAVIORAL|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
219324780|NCT02484976|BEHAVIORAL|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
219324781|NCT03714191|OTHER|Patient Outcomes|The intervention includes different versions of the BPA design and message.
219324782|NCT03714191|OTHER|Billing documentation|The intervention includes different versions of the BPA design and message.
219324783|NCT03714191|OTHER|Regulatory|The intervention includes different versions of the BPA design and message.
219324784|NCT02775084|DIETARY_SUPPLEMENT|Fish Oil|4 capsules twice daily with food for 6 weeks
219324785|NCT02775084|DIETARY_SUPPLEMENT|Olive Oil|4 capsules twice daily with food for 6 weeks
219355228|NCT02337088|PROCEDURE|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
219324786|NCT04124484|DRUG|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
219324787|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
219324788|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
219324789|NCT04124484|DRUG|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
219324790|NCT05372653|DRUG|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
219324791|NCT04328246|DEVICE|IES System|The IES system is composed of a stimulator and self-adhesive surface gel electrodes.
219324792|NCT04328246|OTHER|Standard of Care Therapy|Standard institutional practices for treating pressure injury.
219324793|NCT05090553|PROCEDURE|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
219324794|NCT05090553|BIOLOGICAL|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
219324795|NCT05090553|GENETIC|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
219324796|NCT05090553|GENETIC|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
219324797|NCT00046085|BEHAVIORAL|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
219324798|NCT00046085|BEHAVIORAL|Customary care|Participants received care as usual.
219324799|NCT03991819|DRUG|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
219324800|NCT03991819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
219324801|NCT02271997|DRUG|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
219324802|NCT02271997|DRUG|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
219324803|NCT02271997|DRUG|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
219324804|NCT04894123|DRUG|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
219324805|NCT04894123|DRUG|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
219324806|NCT02428543|DRUG|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
219324807|NCT04808622|DRUG|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
219324808|NCT04808622|DRUG|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
219324809|NCT01381354|OTHER|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
219324810|NCT01381354|DEVICE|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
219324811|NCT01381354|OTHER|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
219324812|NCT01381354|DIETARY_SUPPLEMENT|Omega 3 fatty acids|4 grams daily by mouth.
219324813|NCT01381354|DIETARY_SUPPLEMENT|Full Spectrum vitamin|Two capsules daily.
219324814|NCT01381354|DIETARY_SUPPLEMENT|Essential - hydroxytyrosol|Two capsules twice daily.
219324815|NCT01381354|DIETARY_SUPPLEMENT|Maltodextrin fiber supplement|One scoop daily.
219324816|NCT01381354|DIETARY_SUPPLEMENT|Mineral boost (magnesium)|Two capsules daily
219324817|NCT01381354|DIETARY_SUPPLEMENT|Niacinamide|500 mg daily
219324818|NCT01381354|DIETARY_SUPPLEMENT|Methyl B12|Methyl B12 1000 mcg daily
219324819|NCT01381354|DIETARY_SUPPLEMENT|Taurine|one gram daily
219324820|NCT01381354|DIETARY_SUPPLEMENT|creatine|one teaspoon daily
219324821|NCT01381354|DIETARY_SUPPLEMENT|thiamine|100 mg daily
219324822|NCT01381354|DIETARY_SUPPLEMENT|riboflavin|200 mg daily
219324823|NCT01381354|DIETARY_SUPPLEMENT|N acetylcysteine|1 gram daily
219324824|NCT01381354|DIETARY_SUPPLEMENT|alpha lipoic acid|300 mg twice daily
219324825|NCT01381354|DIETARY_SUPPLEMENT|L acetyl carnitine|500 mg twice daily
219324826|NCT01381354|DIETARY_SUPPLEMENT|methyl folate|1000 mcg one pill four times a week
219324827|NCT01381354|DIETARY_SUPPLEMENT|coenzyme Q|100 mg daily
219324828|NCT01381354|BEHAVIORAL|meditation|meditation 15 minutes daily
219324829|NCT01381354|BEHAVIORAL|self massage|self massage of hands, feet, ears 15 minutes daily
219324830|NCT01381354|BEHAVIORAL|learning|completing puzzles or learning 15 minutes daily
219324831|NCT01381354|DIETARY_SUPPLEMENT|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
219324832|NCT03267160|DIAGNOSTIC_TEST|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
219355229|NCT02337088|PROCEDURE|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
219355230|NCT02772861|DIETARY_SUPPLEMENT|Amino Acid Supplement - One dose|20gr
219355231|NCT02772861|DIETARY_SUPPLEMENT|3-Methylhistidine|120mgr
219355232|NCT02691780|DRUG|Sorafenib|
219324833|NCT00711529|BEHAVIORAL|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
219324834|NCT00711529|DRUG|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
219324835|NCT04128345|DEVICE|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
219324836|NCT02083874|DRUG|CBD|
219324837|NCT03411460|DEVICE|FreeStyle Libre™ system|Measured non-invasively via scanner
219324838|NCT03411460|PROCEDURE|Finger prick|Blood test
219324839|NCT06238674|OTHER|indirect calorimetry and nitrogen balance|"nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance"
219324840|NCT06238674|OTHER|Indirect calorimetry (Standard care nutrition arm)|indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
219324841|NCT00038727|BEHAVIORAL|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
219324842|NCT00038727|DRUG|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
219324843|NCT00038727|BEHAVIORAL|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
219324844|NCT00038727|BEHAVIORAL|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
219324845|NCT06072443|BEHAVIORAL|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
219324846|NCT03740997|DRUG|Optison|Optison is administered intravenously
219324847|NCT04251260|OTHER|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
219324848|NCT02173041|OTHER|Prevention Awareness Groups (PAG)|
219324849|NCT02173041|OTHER|Standard Care|
219324850|NCT00928174|DRUG|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
219324851|NCT02861443|BEHAVIORAL|practice of colonic irrigation|
219324852|NCT00920920|RADIATION|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
219355233|NCT02865330|OTHER|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
219324853|NCT01829425|DRUG|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
219355234|NCT00373035|GENETIC|proteomic profiling|
219355235|NCT00373035|OTHER|immunological diagnostic method|
219355236|NCT00373035|OTHER|laboratory biomarker analysis|
219355237|NCT00373035|OTHER|mass spectrometry|
219355238|NCT00373035|PROCEDURE|biopsy|
219355239|NCT00373035|PROCEDURE|ultrasound imaging|
219355240|NCT04868084|BEHAVIORAL|Physical literacy in the early years|Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
219324854|NCT01829425|BEHAVIORAL|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
219324855|NCT04178967|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
219324856|NCT04178967|OTHER|Placebo|Subcutaneous Injection
219324857|NCT05793177|BEHAVIORAL|Everyday Life is Rehabilitation|Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
219324858|NCT03082950|DIAGNOSTIC_TEST|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
219324859|NCT03750383|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
219324860|NCT03750383|DRUG|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
219324861|NCT03750383|DRUG|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
219324862|NCT03750383|DRUG|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
219324863|NCT02681250|PROCEDURE|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
219324864|NCT02681250|PROCEDURE|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
219324865|NCT02790957|DRUG|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
219324866|NCT02790957|DRUG|Placebo|Single injection of an equal volume of NaCl solution
219324867|NCT01524341|DRUG|KAE609|KAE609 was supplied as capsules for oral use.
219324868|NCT04088383|OTHER|Amnios™ RT|Acellular human allograft
219324869|NCT04088383|OTHER|Saline|Sterile saline
219324870|NCT01481623|OTHER|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
219324871|NCT01481623|OTHER|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
219324872|NCT00814567|RADIATION|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
219324873|NCT04408014|DIAGNOSTIC_TEST|Serological test|IgM and IgG for SARS-CoV-2
219324874|NCT04408014|DIAGNOSTIC_TEST|Nasopharyngeal Swab|PCR for SARS-CoV-2
219324875|NCT04408014|DIAGNOSTIC_TEST|Oropharyngeal Swab|PCR for SARS-CoV-2
219324876|NCT04652713|OTHER|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
219324877|NCT04652713|OTHER|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
219324878|NCT04652713|OTHER|No breakfast|1 glas of water (150 ml)
219355241|NCT04314960|DEVICE|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
219324879|NCT05330403|PROCEDURE|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
219324880|NCT00619905|DRUG|ACZ885|
219324881|NCT00619905|DRUG|ACZ885|
219324882|NCT04869254|OTHER|Lower lymphocyte/ATG ratio|
219324883|NCT04869254|OTHER|Higher lymphocyte/ATG ratio|
219324884|NCT00566917|PROCEDURE|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
219324885|NCT00566917|PROCEDURE|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
219324886|NCT02677376|OTHER|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a second NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
219324887|NCT00685685|DRUG|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
219324888|NCT00685685|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
219355242|NCT04776590|DRUG|Tislelizumab|neoadjuvant immunotherapy
219324889|NCT06494007|DRUG|Sodium chloride|The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.
219324890|NCT06494007|DRUG|90 mg of calcium|The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.
219324891|NCT06494007|DRUG|180 mg Calcium|The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.
219324892|NCT02140333|DRUG|Erlotinib|100mg vs. 150mg
219324893|NCT02710617|DEVICE|Blood glucose monitoring systems for point-of-care-testing|
219324894|NCT06138964|DRUG|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
219324895|NCT06138964|DRUG|siSPARC microneedle patch|siSPARC microneedle patch
219324896|NCT00108914|DRUG|GW685698X|
219324897|NCT06245096|BEHAVIORAL|Cognitive Behavioral Therapy|Sessions will focus on skills such as behavioral activation, mood tracking, identifying and reframing automatic thoughts, assertion training and smart goals.
219324898|NCT06245096|BEHAVIORAL|Acceptance and Commitment Therapy|Sessions will focus on skills such as mindfulness, acceptance and willingness training, values clarification, committed action, defusion, and self-as-context.
219324899|NCT05972382|DIAGNOSTIC_TEST|Quantitative Sensory and Neurophysiological Testing|"Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded."
219355243|NCT03996915|DEVICE|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
219324900|NCT04404322|OTHER|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
219324901|NCT04404322|OTHER|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
219324902|NCT05102578|BEHAVIORAL|Digital Decision Aid Tool|The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
219324903|NCT05549778|DRUG|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
219324904|NCT05549778|DRUG|Control group|Abiraterone, radio- or chemotherapy
219324905|NCT04341168|OTHER|this study is non- interventional|this study is non- interventional
219324906|NCT01791023|OTHER|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
219324907|NCT04236895|DRUG|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
219324908|NCT02650336|DRUG|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
219324909|NCT05511493|DEVICE|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
219324910|NCT05511493|DEVICE|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
219324911|NCT06116227|DEVICE|Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.|Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.
219324912|NCT06116227|OTHER|Conventional Physical Therapy Exercise Program.|The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
219324913|NCT05483205|DRUG|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
219324914|NCT02818166|PROCEDURE|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
219324915|NCT03702803|DIETARY_SUPPLEMENT|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
219324916|NCT03702803|DRUG|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
219324917|NCT03351166|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
219324918|NCT04867889|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
219324919|NCT04867889|DEVICE|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
219324920|NCT03220087|OTHER|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
219324921|NCT04134364|DRUG|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
219324922|NCT00223678|DRUG|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
219324923|NCT05570474|DIETARY_SUPPLEMENT|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
219324924|NCT05570474|DIETARY_SUPPLEMENT|Placebo|Daily placebo drink
219324925|NCT00334555|OTHER|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
219324926|NCT00334555|OTHER|partner delivered meds|patient given meds to give to her partner
219324927|NCT00334555|OTHER|field intervention|health worker finds partners
219324928|NCT04423861|DRUG|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
219324929|NCT04423861|DRUG|Placebo|Patients will receive matching placebo BID for 7 days.
219324930|NCT06558786|OTHER|EORTC QLQ-C30 questionnaire|"The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life."
219324931|NCT06558786|OTHER|QLQ-OGS25 questionnaire|The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
219324932|NCT04720222|DEVICE|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
219324933|NCT05516823|OTHER|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
219324934|NCT00897351|GENETIC|mutation analysis|
219324935|NCT00897351|GENETIC|polymorphism analysis|
219324936|NCT00897351|GENETIC|protein expression analysis|
219324937|NCT00897351|OTHER|immunohistochemistry staining method|
219324938|NCT00897351|OTHER|laboratory biomarker analysis|
219324939|NCT04062253|DIAGNOSTIC_TEST|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
219324940|NCT05033652|OTHER|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR\<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
219355244|NCT03996915|OTHER|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
219355245|NCT00005112|DRUG|Human recombinant growth hormone|
219324941|NCT02542384|DRUG|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
219324942|NCT02542384|DRUG|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
219324943|NCT02542384|DRUG|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
219324944|NCT02966223|RADIATION|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
219324945|NCT01326728|BIOLOGICAL|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
219324946|NCT00674193|OTHER|pharmacological study|Correlative studies
219324947|NCT00674193|OTHER|laboratory biomarker analysis|Correlative studies
219324948|NCT00688012|DRUG|SPC3649|
219324949|NCT01615653|PROCEDURE|EUS|EUS Guided Therapy
219324950|NCT03785678|BIOLOGICAL|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
219324951|NCT03785678|OTHER|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
219324952|NCT05767866|DRUG|YK-029A|Daily dose of YK-029A
219324953|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)
219324954|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
219324955|NCT06441526|DRUG|anti-tumour necrosis factor α antibodies|Biological drug
219324956|NCT06441526|PROCEDURE|Advancement plasty|Surgical closure of the internal opening
219324957|NCT00628173|PROCEDURE|AGV implantation|
219324958|NCT02169180|DRUG|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
219324959|NCT01013766|DRUG|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
219324960|NCT01013766|DRUG|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
219324961|NCT03358511|DIETARY_SUPPLEMENT|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
219324962|NCT05042037|DIETARY_SUPPLEMENT|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
219324963|NCT05042037|OTHER|Placebo|Placebo sachet with no microbial cell preparation
219324964|NCT03620019|DRUG|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
219324965|NCT03620019|DRUG|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
219324966|NCT03620019|DRUG|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
219324967|NCT05973097|DRUG|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
219324968|NCT05973097|OTHER|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
219324969|NCT05973097|OTHER|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
219324970|NCT01883986|BEHAVIORAL|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
219324971|NCT01636791|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
219324972|NCT01636791|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
219324973|NCT02067182|DRUG|Dabigatran|"* Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
219324974|NCT03350776|BEHAVIORAL|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
219324975|NCT03979560|OTHER|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
219324976|NCT00555555|BIOLOGICAL|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
219324977|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
219324978|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
219324979|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
219324980|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
219324981|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
219324982|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
219324983|NCT05109676|OTHER|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
219324984|NCT00020501|DRUG|FOLFIRI regimen|
219324985|NCT00020501|DRUG|floxuridine|
219324986|NCT00020501|DRUG|fluorouracil|
219324987|NCT00020501|DRUG|irinotecan hydrochloride|
219324988|NCT00020501|DRUG|leucovorin calcium|
219324989|NCT00020501|DRUG|melphalan|
219324990|NCT00020501|PROCEDURE|hyperthermia treatment|
219324991|NCT02798822|PROCEDURE|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
219324992|NCT04032730|DEVICE|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
219324993|NCT00805025|DRUG|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
219355246|NCT00791271|DRUG|Decitabine|Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
219355247|NCT00791271|DRUG|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
219324994|NCT00375219|DRUG|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
219324995|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
219324996|NCT00393952|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
219324997|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
219324998|NCT00393952|DRUG|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
219324999|NCT00393952|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
219325000|NCT01667107|DRUG|Posaconazole|
219325001|NCT01667107|DRUG|Calogen®|
219325002|NCT01117584|DRUG|ipragliflozin|oral tablet
219325003|NCT01117584|DRUG|Placebo|oral tablet
219325004|NCT01117584|DRUG|Metformin|oral tablet
219325005|NCT05511896|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
219325006|NCT04203862|DRUG|NPC-22|Single administration of low dose NPC-22
219325007|NCT04203862|DRUG|NPC-22|Single administration of low/middle dose NPC-22
219325008|NCT04203862|DRUG|NPC-22|Single administration of middle dose NPC-22
219325009|NCT04203862|DRUG|NPC-22|Single administration of middle/high dose NPC-22
219325010|NCT04203862|DRUG|NPC-22|Single administration of high dose NPC-22
219325011|NCT04203862|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
219355248|NCT03006939|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
219355249|NCT02682901|DRUG|Cycloset|Cycloset 1.6 -3.2 mg/day
219355250|NCT02682901|DRUG|Placebo|Non-active placebo for cycloset
219325012|NCT05638022|DIAGNOSTIC_TEST|Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test|Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.
219325013|NCT05638022|DIAGNOSTIC_TEST|DNA testing|DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
219325014|NCT03298672|DRUG|NDX-1017|Solution of NDX-1017 for subcutaneous injection
219325015|NCT03298672|DRUG|Placebo|Placebo solution for subcutaneous injection
219325016|NCT00591825|DRUG|D-cycloserine|D-cycloserine
219325017|NCT00591825|DRUG|Placebo|Placebo
219325018|NCT02482766|DRUG|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
219325019|NCT02482766|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
219325020|NCT02482766|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
219325021|NCT03882710|DRUG|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
219325022|NCT07123987|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
219325023|NCT07123987|OTHER|traditional medical treatment for PHN|Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
219325024|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
219325025|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
219325026|NCT06809790|BEHAVIORAL|Therapeutic Exercise Program|Participants in this group will receive a therapeutic exercise program (including cervical range of motion and trapezius stretching) during the study period.
219325027|NCT06809790|PROCEDURE|Dry Needling|Participants in this group will receive dry needling treatment for active trigger points in addition to the therapeutic exercise program. Dry needling treatment will be applied in a total of 3 sessions at 0, 1, and 2. weeks, one week apart.
219325028|NCT07123077|OTHER|Functional Exercises|"Warm-Up Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions.~Strengthening Exercises (40 min):~In a seated position:~Ankle plantar flexion and dorsiflexion exercises, ankle circumduction, knee extension, hip flexion, shoulder joint range of motion exercises in all directions, elbow and hand flexion-extension exercises~In a standing position:~Hip extension, toe raises, mini squats, standing on one leg, 360-degree turning, tandem walking exercises Each exercise was performed for 8 repetitions.~Cool-Down Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions."
219325029|NCT07123077|OTHER|Music Intervention|Slow-paced pieces in the Rast mode were selected for the warm-up and cool-down exercises, while more upbeat pieces in the Mahur mode were chosen for strength and balance exercises and played to the participants throughout the sessions alongside the exercises. To enhance participants' concentration, instrumental compositions in these selected Turkish classical music modes were used. Traditional Turkish instruments such as qanun, ney, kudüm, and oud were preferred in the performance of the compositions.
219325030|NCT07128381|DRUG|Axatilimab (SNDX-6352)|Taken orally
219325031|NCT07128381|DRUG|Ruxolitinib|Taken orally
219325032|NCT07129356|BEHAVIORAL|Combined Exercise|"Participants engaged in a hybrid exercise program that included:~In-field sessions held twice weekly at a local sports facility (45-60 minutes per session, including rest).~Remote sessions delivered via pre-recorded videos through WhatsApp, with ongoing monitoring and feedback.~Exercises included walking, jogging, full-body stretching, and strength training targeting the trunk, limbs, and weak muscle groups (shoulders, back, knees).~The program aimed to reduce joint and muscle pain, improve strength and flexibility, and support daily functional activities.~Pre- and post-intervention assessments included muscle strength (via hand dynamometer), flexibility tests, BMI, and self-reported pain using the NRS-11 scale."
219325033|NCT07130188|DIAGNOSTIC_TEST|PCI|Coronary angiography then SYNTAX score calculation
219325034|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
219325035|NCT06207864|PROCEDURE|Return of Results|Receive results
219325036|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
219325037|NCT02108860|DRUG|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
219325038|NCT02108860|DRUG|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
219325039|NCT04859946|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
219325040|NCT04859946|DRUG|Busulfan|Given IV
219325041|NCT04859946|DRUG|Cyclophosphamide|Given IV
219325042|NCT04859946|DRUG|Fludarabine|Given IV
219325043|NCT04859946|DRUG|Itacitinib|Given PO
219325044|NCT04859946|DRUG|Tacrolimus|Given IV or PO
219325045|NCT04859946|DRUG|Thiotepa|Given IV
219325046|NCT02765087|OTHER|Medical History|Oriented Survey and complete physical exam.
219325047|NCT02765087|DEVICE|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
219325048|NCT02765087|OTHER|Chest CT|
219325049|NCT02765087|OTHER|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
219325050|NCT04661722|OTHER|No intervention|No intervention
219325051|NCT04286087|PROCEDURE|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
219325052|NCT04286087|PROCEDURE|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
219325053|NCT05586269|BEHAVIORAL|Meal Kit Delivery|Dyads (caregiver + child) receive one meal kit delivery per week. One meal kit is designed to include two recipes and ingredients to prepare 10 servings (\~2 meals for a household 5 people). Meal kits come with printed picture-based recipes in English or Spanish and access to online cooking demonstrations.
219325054|NCT05586269|BEHAVIORAL|Newsletter + Food Pantry Referral|Dyads (caregiver + child) receive a printed newsletter in English and Spanish that lists additional local food assistance resources. Dyads receive a referral to the clinic's associated food pantry.
219325055|NCT04491383|DRUG|Tocovid Suprabio (HOV-12020)|Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
219325056|NCT04491383|OTHER|Placebo|Dietary supplement: Placebo. Placebo.
219325057|NCT03507673|DIAGNOSTIC_TEST|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
219325058|NCT00410293|PROCEDURE|NT-proBNP testing|
219325059|NCT06964555|DRUG|Intravenous Ketamine Infusions|Ketamine group received ketamine at 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery.
219325060|NCT06964555|DRUG|Intravenous lignocaine|IV Lignocaine was given at the rate of 1 mg/kg/hr.
219325061|NCT04712825|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
219325062|NCT04712825|DEVICE|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
219325063|NCT00049556|DRUG|gefitinib|
219325064|NCT00049556|OTHER|immunohistochemistry staining method|
219325065|NCT00049556|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
219325066|NCT00049556|PROCEDURE|biopsy|
219325067|NCT00049556|PROCEDURE|sentinel lymph node biopsy|
219325068|NCT06212635|DIAGNOSTIC_TEST|T-TAS|Blood test, laboratory assays
219325069|NCT02944253|OTHER|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
219325070|NCT02944253|OTHER|Low energy diet 100 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
219325071|NCT02944253|OTHER|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
219325072|NCT03404089|DEVICE|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
219325073|NCT03404089|DEVICE|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
219325074|NCT00067392|PROCEDURE|Dental Implant|Dental Implant 4 month time frame
219325075|NCT04056481|DRUG|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
219325076|NCT06274008|DRUG|Exparel|Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
219325077|NCT00332839|DRUG|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
219325078|NCT00332839|DRUG|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
219325079|NCT00332839|DRUG|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
219325080|NCT00332839|DRUG|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
219325081|NCT00332839|DRUG|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
219325082|NCT03452293|DEVICE|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
219325083|NCT00176345|BEHAVIORAL|Exercise Training|
219325084|NCT04885088|DEVICE|Wisdom bracelet|Wisdom bracelet
219325085|NCT01641211|BEHAVIORAL|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
219325086|NCT01641211|OTHER|Nutrition video|Children in this group will watch a 2-minute nutrition video.
219325087|NCT00088907|DRUG|docetaxel|Given IV
219325088|NCT00088907|OTHER|placebo|Given orally
219325089|NCT00088907|DRUG|gefitinib|Given orally
219325090|NCT04946825|DRUG|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
219325091|NCT04946825|DRUG|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
219325092|NCT04946825|BEHAVIORAL|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
219325093|NCT04946825|BEHAVIORAL|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
219325094|NCT03426787|BEHAVIORAL|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
219325095|NCT04564963|OTHER|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
219325096|NCT02791113|OTHER|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
219325097|NCT02476825|DRUG|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
219325098|NCT02476825|DEVICE|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
219325099|NCT02873650|DRUG|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
219325100|NCT06098625|DRUG|Empagliflozin 25 MG|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
219325101|NCT06098625|DRUG|Linagliptin 5 mg Oral Tablet|linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
219325102|NCT02347475|OTHER|Observational Study|Ultrasound and NIRS
219325103|NCT04670497|PROCEDURE|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
219325104|NCT01454245|DRUG|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
219325105|NCT01454245|DRUG|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
219325106|NCT04271007|DRUG|Mometasone Furoate|mometasone furoate
219325107|NCT01361243|BEHAVIORAL|NOURISH+|6 week face-to-face parent intervention.
219325108|NCT01361243|BEHAVIORAL|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
219325109|NCT05510154|BEHAVIORAL|Brief advice|A single, brief advice session on switching to electronic cigarettes.
219325110|NCT05510154|BEHAVIORAL|Single Training|A single, in-depth training session on switching to electronic cigarettes.
219325111|NCT05510154|BEHAVIORAL|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
219325112|NCT05335499|DRUG|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
219325113|NCT05335499|DRUG|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
219325114|NCT05335499|DRUG|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
219325115|NCT05335499|DRUG|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
219325116|NCT05335499|DRUG|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
219325117|NCT05335499|DRUG|Placebo|"* Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD"
219325118|NCT02020863|DEVICE|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
219325119|NCT01491048|PROCEDURE|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
219325120|NCT01491048|PROCEDURE|No physiotherapy after THA|No physiotherapy after THA
219325121|NCT02713035|BEHAVIORAL|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
219325122|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
219325123|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
219325124|NCT01437696|OTHER|placebo|No liquid cholecalciferol will be added to the food.
219325125|NCT04085341|DRUG|GB-102|Intravitreal injection of GB-102
219325126|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
219325127|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
219325128|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Coleman technique
219325129|NCT02677012|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery
219325130|NCT00274404|DRUG|valacyclovir|
219325131|NCT01033656|DRUG|anakinra|100 mg subcutaneous injection daily
219325132|NCT01033656|DRUG|comparators|po drugs, comparators
219325133|NCT00319332|DRUG|Ibritumomab Tiuxetan|
219325134|NCT00319332|DRUG|Iodine I 131 Tositumomab|
219325135|NCT01131949|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
219325136|NCT04764851|DRUG|ecopipam HCl ~2mg/kg/day|oral tablet
219325137|NCT04764851|COMBINATION_PRODUCT|Cohort 1 Probe Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
219325138|NCT04764851|COMBINATION_PRODUCT|Cohort 2 Probe Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
219325139|NCT04764851|COMBINATION_PRODUCT|Cohort 3 Probe Cocktail|bupropion
219325140|NCT03247036|DRUG|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
219325141|NCT01968395|DRUG|Caspofungin 70 mg|Intravenous use
219325142|NCT04110964|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
219325143|NCT04628299|OTHER|Sham Laser|Sham Laser in plantar fascia
219325144|NCT04628299|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
219325145|NCT01025492|DRUG|Trilipix|135 mg po daily
219325146|NCT01025492|DRUG|placebo|one tablet po daily
219325147|NCT03971994|BEHAVIORAL|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
219325148|NCT01145716|PROCEDURE|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
219325149|NCT05024305|DRUG|TWP-102 injection|IV infusion
219325150|NCT03956316|DEVICE|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
219325151|NCT02742597|BEHAVIORAL|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
219325152|NCT01794533|DRUG|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
219325153|NCT01794533|DRUG|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
219325154|NCT05803408|OTHER|gluten-free oats|Early vs late introduction of gluten free oats
219325155|NCT01671020|DRUG|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
219325156|NCT01671020|DRUG|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
219325157|NCT00558155|DRUG|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
219325158|NCT00558155|DRUG|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
219325159|NCT00558155|DRUG|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
219325160|NCT00558155|DRUG|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
219325161|NCT00907257|DRUG|benzoyl peroxide wash|5% benzoyl peroxide wash
219325162|NCT00907257|DRUG|Tretinoin gel|0.04% tretinoin gel
219325163|NCT02616757|DEVICE|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
219325164|NCT05102851|DIAGNOSTIC_TEST|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
219325165|NCT00283049|DRUG|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
219325166|NCT00283049|DRUG|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
219325167|NCT00194181|DRUG|TPA Infusion|
219325168|NCT03269851|RADIATION|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
219325169|NCT05594316|DRUG|Trichloroacetic acid|5\. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
219325170|NCT02675842|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
219325171|NCT02675842|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
219325172|NCT03059095|BEHAVIORAL|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
219325173|NCT00930722|DRUG|quinapril|per label as non interventional study
219325174|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
219325175|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
219325176|NCT02146742|DRUG|ASP1707|oral
219325177|NCT02146742|DRUG|Placebo|oral
219325178|NCT01187069|BEHAVIORAL|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
219325179|NCT02963038|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
219325180|NCT03253757|OTHER|This study is non-interventional.|This study is non-interventional.
219325181|NCT06426251|DEVICE|Photobiomodulation|Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
219325182|NCT00259779|DRUG|budesonide/formoterol|
219325183|NCT00259779|DRUG|Prednisolone|
219325184|NCT05486520|DEVICE|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
219325185|NCT05691231|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
219325186|NCT05492734|DRUG|EDG-5506|single oral dose
219325187|NCT01582542|DRUG|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
219325188|NCT03642756|DEVICE|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
219325190|NCT01205438|DRUG|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
219325191|NCT01205438|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
219325192|NCT01205438|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
219325193|NCT03133806|DEVICE|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
219325194|NCT05020444|DRUG|TriPRIL CAR T Cells|Intravenous infusion
219325195|NCT05020444|DRUG|Cyclophosphamide|Intravenous infusion
219325196|NCT05020444|DRUG|Fludarabine|Intravenous infusion
219325197|NCT03145545|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
219325198|NCT00378469|BEHAVIORAL|45 minute exercise on ergocycle|
219325199|NCT03891342|DRUG|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
219325200|NCT02334787|DRUG|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
219325201|NCT02334787|DRUG|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
219325202|NCT02334787|DRUG|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
219325203|NCT02334787|DRUG|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
219325204|NCT03461172|PROCEDURE|Surgery of breast cancer|Surgery of breast cancer
219325205|NCT03461172|OTHER|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
219325206|NCT06305949|DEVICE|Optimized transcranial Direct Current Stimulation|transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
219325207|NCT06305949|DEVICE|Sham transcranial Direct Current Stimulation|transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
219325208|NCT05560256|OTHER|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
219325209|NCT03631667|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
219325210|NCT03631667|DRUG|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
219325211|NCT04674267|OTHER|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
219325212|NCT05660369|DRUG|CARv3-TEAM-E T cells|Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
219325213|NCT03323476|OTHER|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
219325214|NCT03323476|DRUG|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
219325215|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
219325216|NCT00427232|DRUG|BQ-123 and BQ-788|
219325217|NCT04236648|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
219325218|NCT02398448|DRUG|Zyloprim® 300 mg|
219325219|NCT02398448|DRUG|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
219325220|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
219325221|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 3|
219325222|NCT05679466|BIOLOGICAL|randomized, double-blinded, placebo-controlled|Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
219325223|NCT04699175|DRUG|HR021618|Treatment group A:HR021618; high dose
219325224|NCT04699175|DRUG|HR021618|Treatment group B:HR021618; low dose
219325225|NCT04699175|DRUG|Placebo|Treatment group C: HR021618 blank preparation.
219325226|NCT04830033|OTHER|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
219325227|NCT03173066|DRUG|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
219325228|NCT05046574|OTHER|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
219325229|NCT04613856|OTHER|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
219325230|NCT04613856|OTHER|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
219325231|NCT01580865|DRUG|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
219325232|NCT02321826|BEHAVIORAL|Music|Participants choice among 4 genres of music matched on music characteristics
219325233|NCT02321826|BEHAVIORAL|Audiobook|Participants choice among 4 types of audiobooks
219325234|NCT04290299|OTHER|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
219325235|NCT00005081|DRUG|O6-benzylguanine|
219325236|NCT00005081|DRUG|carmustine|
219325237|NCT01186939|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
219325238|NCT02851420|OTHER|spectroscopy|
219325239|NCT04179747|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
219325240|NCT04179747|DRUG|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
219325241|NCT04695496|DEVICE|Theta bust stimulating|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
219325242|NCT04288830|BEHAVIORAL|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
219325243|NCT04288830|BEHAVIORAL|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
219325244|NCT03664154|BEHAVIORAL|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
219325245|NCT03207711|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
219325246|NCT03207711|BEHAVIORAL|Mindfulness|Mindful eating app-use and instruction
219325247|NCT06837181|OTHER|observational study|This is an observational study.
219325248|NCT04216186|DRUG|Atomoxetine|Atomoxetine once daily
219325249|NCT04216186|DRUG|Coenzyme Q|Coenzyme Q once daily
219355251|NCT02527980|OTHER|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
219325250|NCT05263063|OTHER|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
219325251|NCT03099239|BIOLOGICAL|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
219325252|NCT03355313|RADIATION|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
219325253|NCT00437385|DRUG|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
219325254|NCT00437385|PROCEDURE|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
219325255|NCT00437385|BEHAVIORAL|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
219325256|NCT05682079|OTHER|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
219325257|NCT03341741|DRUG|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
219325258|NCT03341741|DRUG|Colistin|Colistin solution 2 x daily 1 Mega continuously
219325259|NCT03706404|DIAGNOSTIC_TEST|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
219325260|NCT00251381|DRUG|Cetuximab|
219325261|NCT00335894|DRUG|hMG-IBSA|
219325262|NCT03957395|DEVICE|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
219325263|NCT00518414|OTHER|Marketed infant formula with DHA and ARA|
219325264|NCT00518414|OTHER|Milk-based infant formula with DHA and ARA|
219325265|NCT00518414|OTHER|Milk-based formula with DHA, ARA, prebiotics|
219325266|NCT03150316|DRUG|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
219325267|NCT03109548|OTHER|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
219325268|NCT05097729|DEVICE|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
219325269|NCT05489692|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
219325270|NCT00929604|OTHER|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
219325271|NCT03146767|DEVICE|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
219325272|NCT04757441|OTHER|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire|"ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
219325273|NCT04757441|OTHER|Group B: Conventional treatment|"Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
219325274|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFU IM, 1.0 mL
219325275|NCT00376090|BIOLOGICAL|Placebo|1.0 mL IM
219325276|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^6 PFU ID, 0.1 mL
219325277|NCT00376090|BIOLOGICAL|Placebo|0.1 mL ID
219325278|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^8 PFU IM, 1.0 mL
219325279|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFD ID, 0.1 mL
219325280|NCT03714321|DEVICE|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
219325281|NCT03083847|DRUG|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
219325282|NCT03083847|DRUG|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
219325283|NCT03083847|BIOLOGICAL|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
219325284|NCT02941653|DEVICE|Potassium nitrate 2% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
219325285|NCT02941653|DEVICE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
219325286|NCT02290860|PROCEDURE|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
219325287|NCT04216251|DRUG|AMR101|AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
219325288|NCT06121453|BEHAVIORAL|Multicomponent Adherence Intervention|multi-part intervention to reduce barriers to medication use
219325289|NCT06231420|OTHER|Encourage using pedometer|Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
219325290|NCT06231420|DEVICE|pedometer|pedometer
219325291|NCT01887951|DRUG|Penthrox Inhaler|
219325292|NCT01887951|DRUG|Tramadol Injection|
219325293|NCT00184626|DRUG|biphasic insulin aspart|
219325294|NCT00184626|DRUG|insulin glargine|
219325295|NCT00184626|DRUG|metformin|
219325296|NCT02595021|PROCEDURE|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
219325297|NCT02595021|PROCEDURE|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
219325298|NCT03821818|BEHAVIORAL|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise \> 75% max heart rate, 5/day)
219325299|NCT06048692|DRUG|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
219325300|NCT06048692|DRUG|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
219325301|NCT05592067|OTHER|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
219325302|NCT05592067|OTHER|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
219325303|NCT05592067|OTHER|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day
219325304|NCT00418951|DRUG|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
219325305|NCT00418951|DRUG|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
219325306|NCT00418951|DRUG|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
219325307|NCT02717663|BEHAVIORAL|Adaptive Goals|Prescribed goals change daily based on participant's performance
219325308|NCT02717663|BEHAVIORAL|Static Goals|Prescribed goals remain the same throughout study
219325309|NCT02717663|BEHAVIORAL|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
219325310|NCT02717663|BEHAVIORAL|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
219325311|NCT05940610|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
219325312|NCT00467389|DRUG|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
219325313|NCT00467389|OTHER|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
219325314|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
219325315|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
219325316|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
219325317|NCT00874770|DRUG|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
219325318|NCT00874770|DRUG|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
219325319|NCT00874770|DRUG|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
219325320|NCT00325962|DRUG|6R-BH4 (sapropterin dihydrochloride)|
219325321|NCT03255057|DEVICE|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
219325322|NCT03255057|DEVICE|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
219325323|NCT00173745|DRUG|botulinum toxin A injection|
219325324|NCT02294084|DRUG|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
219325325|NCT02294084|DRUG|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
219325326|NCT05395104|DRUG|Midazolam|Syrup for oral administration
219325327|NCT05395104|DRUG|Cefiderocol|Liquid for intravenous infusion
219325328|NCT06237543|OTHER|hypotension|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
219325329|NCT05125068|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
219325330|NCT01313715|BIOLOGICAL|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
219325331|NCT01313715|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
219325332|NCT01313715|BIOLOGICAL|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
219325333|NCT01313715|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
219325334|NCT01805960|BIOLOGICAL|Canakinumab|
219325335|NCT01805960|BIOLOGICAL|Placebo|
219325336|NCT05146804|OTHER|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
219325337|NCT05146804|OTHER|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
219325338|NCT00141804|DRUG|Sirolimus|
219325339|NCT05135026|DIAGNOSTIC_TEST|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
219325340|NCT03457350|PROCEDURE|cervical negotiation|trial to bypass severe cervical stenosis
219325341|NCT03858452|PROCEDURE|Muscles exercises program|
219325342|NCT04635566|DRUG|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
219325343|NCT04635566|DRUG|Placebo|Placebo one time/day at the evening.
219325344|NCT00401739|DRUG|CSL360|Weekly IV Infusion. Dose escalation study.
219325345|NCT01507467|RADIATION|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
219325346|NCT01507467|RADIATION|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
219325347|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
219325348|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
219325349|NCT02257996|BEHAVIORAL|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
219325350|NCT03049787|OTHER|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
219325351|NCT03049787|OTHER|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
219325352|NCT05506826|OTHER|fine motor activities|patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy
219325353|NCT05506826|OTHER|conventional therapy and mirror therapy|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
219325354|NCT01033552|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
219325355|NCT01033552|DRUG|Fludarabine|40 mg/m\^2/day intravenously on Days -6, -5, -4, -3 and -2.
219325356|NCT01033552|DRUG|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
219325357|NCT01033552|DRUG|Myeloablative Busulfan|Targeting AUC 1000 umol/min
219325358|NCT01033552|PROCEDURE|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
219325359|NCT01033552|RADIATION|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
219325360|NCT01033552|PROCEDURE|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
219325361|NCT00789750|DRUG|Colesevelam|Colesevelam 625 mg tablets
219325362|NCT00789750|DRUG|Placebo|Placebo tablets appearing to be colesevelam
219325363|NCT00789750|DRUG|Pioglitazone|30 mg or 45 mg pioglitazone therapy
219325364|NCT04811404|DRUG|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
219325365|NCT02613884|DRUG|Treatment|
219325366|NCT04409899|DIAGNOSTIC_TEST|Blood tests|RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
219325367|NCT02194036|BEHAVIORAL|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
219325368|NCT02194036|BEHAVIORAL|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
219325369|NCT02131675|DIETARY_SUPPLEMENT|Boost shake|Blood draw after mixed-meal consumption
219325370|NCT05131984|DRUG|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
219325371|NCT04565886|DEVICE|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
219325372|NCT04565886|DEVICE|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
219325373|NCT02444481|DRUG|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
219325374|NCT01748409|OTHER|Biopsies of peripheral autonomic nervous system|
219325375|NCT01748409|OTHER|Autonomic dysfunction questionnaires|
219325376|NCT01748409|OTHER|Electrophysiological tests|
219325377|NCT01230554|DEVICE|Daily disposable cosmetic tint lens|Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
219325378|NCT01480921|BEHAVIORAL|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~* 5-10 min warm-up~* 30 min aerobic interval training (walking or stationary bicycle)~* 10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
219325379|NCT01480921|BEHAVIORAL|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~* 5-10 min of warm-up~* 30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~* 10 min of cool down~Exercise will be tracked by the participant in exercise log books."
219325380|NCT00067457|DRUG|alosetron|
219325381|NCT03558256|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
219325382|NCT03558256|DRUG|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
219325383|NCT05542485|DIAGNOSTIC_TEST|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
219325384|NCT02232620|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
219325385|NCT03753009|PROCEDURE|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
219325386|NCT02936934|DRUG|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
219325387|NCT02936934|DRUG|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
219325388|NCT02468596|OTHER|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
219325389|NCT02468596|OTHER|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
219325390|NCT04194853|DEVICE|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
219325391|NCT04194853|OTHER|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
219325392|NCT02414568|DRUG|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
219325393|NCT02414568|DRUG|Prednisone|Prednisone 40 mg/m² PO
219325394|NCT02414568|DRUG|Vinblastine|Vinblastine 6 mg/m² IV
219325395|NCT02414568|DRUG|Doxorubicin|Doxorubicin 40 mg/m² IV
219325396|NCT04199234|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
219325397|NCT04199234|DIETARY_SUPPLEMENT|Comparator product consumption (Iron sulphate)|Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
219325398|NCT03933397|OTHER|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
219325399|NCT03933397|OTHER|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
219325400|NCT03933397|DRUG|Morphine|4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
219325401|NCT03933397|DRUG|Hydromorphone|1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
219325402|NCT03856307|DIAGNOSTIC_TEST|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
219325403|NCT02742467|DRUG|Perindopril plus Amlodipine|Group 1
219325404|NCT02742467|DRUG|Perindopril plus Hydrochlorothiazide|Group 2
219325405|NCT02742467|DRUG|Amlodipine plus Hydrochlorothiazide|Group 3
219325406|NCT03755791|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
219325407|NCT03755791|DRUG|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
219325408|NCT03755791|DRUG|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
219325409|NCT03755791|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
219325410|NCT01558427|PROCEDURE|Surveillance|Active clinical surveillance
219325411|NCT01558427|PROCEDURE|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
219325412|NCT04029181|OTHER|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
219325413|NCT04029116|DRUG|Fluconazole Tablet|150 mg every 72 hours for 3 doses
219325414|NCT04029116|DRUG|IBREXAFUNGERP|300 mg BID (one day) every 4 weeks for a total of 6 dosing days
219325415|NCT04029116|DRUG|Placebo oral tablet|BID (one day) every 4 weeks for a total of 6 dosing days
219325416|NCT03967782|BEHAVIORAL|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219325417|NCT03967782|BEHAVIORAL|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219325418|NCT03967782|BEHAVIORAL|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219325419|NCT02843763|OTHER|Blood sample|Blood sample (28 ml)
219325420|NCT03533413|PROCEDURE|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
219325421|NCT03533413|PROCEDURE|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
219325422|NCT00445523|BIOLOGICAL|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
219325423|NCT00445523|DRUG|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
219325424|NCT00252304|DRUG|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
219325425|NCT00252304|DRUG|Placebo|Placebo
219325426|NCT04349878|DIAGNOSTIC_TEST|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
219325427|NCT04711148|OTHER|placebo|placebo
219325428|NCT04711148|DRUG|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
219325429|NCT05597865|BEHAVIORAL|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
219325430|NCT05597865|BEHAVIORAL|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
219325431|NCT03056950|DEVICE|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
219325432|NCT02739750|OTHER|No intervention|There is no intervention for this study. It is a MRS.
219325433|NCT03661125|DRUG|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
219325434|NCT03661125|DRUG|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
219325435|NCT01552655|RADIATION|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
219325436|NCT02031939|DRUG|Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
219325437|NCT02031939|RADIATION|standard chemoradiotherapy|All rectal patients in this group will receive standard radiotherapy and surgical resection.
219325438|NCT06032338|OTHER|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
219325439|NCT06032338|OTHER|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
219325440|NCT06032338|OTHER|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
219325441|NCT06113484|OTHER|DIET + EXERCISE|At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.
219325442|NCT06113484|OTHER|WITHOUT DIET + EXERCISE|"An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases."
219325443|NCT03686098|DIETARY_SUPPLEMENT|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
219325444|NCT03686098|DIETARY_SUPPLEMENT|Soy Supplement|Soy isoflavones delivered in extracted form
219325445|NCT04766476|DRUG|BMS-963272|Specified dose on specified days
219325446|NCT04766476|OTHER|Placebo matching BMS-963272|Specified dose on specified days
219325447|NCT00549627|DEVICE|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
219325448|NCT03948360|DEVICE|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
219325449|NCT03948360|OTHER|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
219325450|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp CBD|Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.
219325451|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp Placebo Capsule|Vantage Hemp Placebo Capsule Intervention
219325452|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
219325453|NCT03579420|BEHAVIORAL|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
219325454|NCT03579420|BEHAVIORAL|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
219325455|NCT00630851|DRUG|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
219325456|NCT00630851|DRUG|Placebo|Matching placebo tablets orally once daily for 6 months
219325457|NCT05071495|DEVICE|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
219325458|NCT01653964|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
219325459|NCT06470789|BEHAVIORAL|Shoulder blood restriction training|Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
219325460|NCT02608879|PROCEDURE|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
219325461|NCT02608879|PROCEDURE|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
219325462|NCT02608879|PROCEDURE|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
219325463|NCT02608879|OTHER|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
219325464|NCT05035576|DRUG|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
219325465|NCT04588194|DRUG|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
219325466|NCT04588194|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
219325467|NCT04588194|DRUG|Dexamethasone|40 mg IV/PO days 1-4
219325468|NCT00002920|DRUG|medroxyprogesterone|
219325469|NCT00002920|DRUG|tamoxifen citrate|
219325470|NCT00002920|PROCEDURE|adjuvant therapy|
219325471|NCT00002970|DRUG|nelarabine|Given IV
219325472|NCT00002970|DRUG|methotrexate|Given IT
219325473|NCT00002970|DRUG|cytarabine|Given IT
219325474|NCT00002970|DRUG|therapeutic hydrocortisone|Given IT
219325475|NCT02201121|OTHER|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
219325476|NCT01882842|PROCEDURE|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
219325477|NCT01882842|DEVICE|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
219325478|NCT06216184|DIAGNOSTIC_TEST|Vortexing|use combined of vortexing and Maki techniques
219325479|NCT00000604|PROCEDURE|cardiopulmonary bypass|
219325480|NCT00000604|PROCEDURE|heart arrest, induced|
219325481|NCT04919252|DRUG|Vedolizumab|"* Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
219325482|NCT02730052|DEVICE|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
219325483|NCT02730052|DEVICE|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
219325484|NCT00243698|DRUG|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
219325485|NCT05812040|DIAGNOSTIC_TEST|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
219325486|NCT01665547|DRUG|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
219325487|NCT05449626|DIAGNOSTIC_TEST|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
219325488|NCT02846350|BEHAVIORAL|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
219325489|NCT06110260|DIETARY_SUPPLEMENT|AstraGin (Ginseng and Astragalus Saponin Extract)|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
219325490|NCT06110260|DIETARY_SUPPLEMENT|Placebo|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
219325491|NCT06273670|OTHER|screening and data collection|"Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data."
219325492|NCT01811784|BEHAVIORAL|Ask people not to drink raw sap|
219325493|NCT01811784|BEHAVIORAL|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
219325494|NCT01811784|OTHER|No Intervention|
219325495|NCT01811784|OTHER|No Intervention|
219325496|NCT03453658|PROCEDURE|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
219325497|NCT03453658|PROCEDURE|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
219325498|NCT00760669|DRUG|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
219325499|NCT00760669|DRUG|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
219325500|NCT06474975|DEVICE|AURA 10 PET/CT|The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
219325501|NCT02241369|BIOLOGICAL|INO-3106, INO-9012|
219325502|NCT00209365|PROCEDURE|exposure to grass pollen/starch granules|
219325503|NCT04352192|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
219325504|NCT06417112|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|All participants have been referred for a transthoracic echocardiogram by a clinician.
219325505|NCT02113384|OTHER|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
219325506|NCT01572675|DRUG|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
219325507|NCT01572675|DRUG|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
219325508|NCT03618784|BIOLOGICAL|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals"
219325509|NCT03618784|OTHER|sterile saline|"sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
219325510|NCT03476564|DRUG|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
219325511|NCT03476564|DRUG|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
219325512|NCT01910805|BEHAVIORAL|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
219325513|NCT00800423|DRUG|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
219325514|NCT00800423|DRUG|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
219325515|NCT04622189|DEVICE|Action observation training|"Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform."
219325516|NCT03940547|OTHER|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
219325517|NCT03940547|OTHER|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
219325518|NCT02907138|OTHER|Medical Yoga|
219325519|NCT02907138|OTHER|Treatment as Usual (physical therapy)|
219325520|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
219325521|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
219325522|NCT00185250|DRUG|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
219325523|NCT00185250|DRUG|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
219325524|NCT05009186|OTHER|PSA value|We measure PSA value during and after covid-19 infection
219325525|NCT05689723|PROCEDURE|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
219325526|NCT05689723|PROCEDURE|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
219325527|NCT05373524|BIOLOGICAL|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
219325528|NCT01375335|DRUG|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
219325529|NCT02939989|DRUG|Sofosbuvir|Tablet for oral administration
219325530|NCT02939989|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
219325531|NCT02939989|DRUG|Ribavirin|Tablet for oral administration
219325532|NCT02003014|DRUG|Pioglitazone|Pioglitazone Tablets
219325533|NCT01660451|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
219325534|NCT03805009|DEVICE|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
219325535|NCT02690805|DEVICE|MR-compatible scinti-mammography (MRI-SMM) system|
219325536|NCT02052063|DEVICE|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
219325537|NCT02052063|DEVICE|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
219325538|NCT00499954|PROCEDURE|Microdialysis|
219325539|NCT00499954|DEVICE|Guardian RT|
219325540|NCT00499954|DEVICE|Glucoday S|
219325541|NCT05745454|BIOLOGICAL|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
219325542|NCT06188169|PROCEDURE|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
219325543|NCT05245019|BIOLOGICAL|cardamom|cardamom is used as a flavoring agent in foods as well as for treating various cardiovascular, gastrointestinal, and neural problems
219325544|NCT05245019|BIOLOGICAL|fennel|fennel is Known for its anti-inflammatory, anti-spasmodic, and analgesic properties, it is also widely used for treating gastroenteritis and indigestion.
219325545|NCT04515069|PROCEDURE|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
219325546|NCT04515069|PROCEDURE|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
219325547|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
219325548|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
219325549|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
219325550|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
219325551|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
219325552|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
219325553|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
219325554|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
219325555|NCT04561596|DEVICE|OnComfort autohypnosis|"Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
219325556|NCT04561596|OTHER|Treatment as usual, without the OnComfort autohypnosis system|"The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
219325557|NCT04574479|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
219325558|NCT04574479|DRUG|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
219325559|NCT05141123|PROCEDURE|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
219325560|NCT06102603|OTHER|the biobased polyester cast|long arm casting
219325561|NCT06102603|OTHER|the synthetic fiberglass cast|long arm casting
219325562|NCT03426423|OTHER|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB\_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
219325563|NCT03426423|OTHER|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
219325564|NCT05138913|DRUG|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
219325565|NCT05138913|DRUG|Saline|After the arthroscopic operation was completed, a local saline injection was performed
219325566|NCT00716053|DRUG|BLVR|BLVR 20 mL
219325567|NCT06374914|DRUG|Intravesical Solution|Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
219325568|NCT04733339|BEHAVIORAL|Secondary Prevention|behavioral changes in dieting and exercising up to one year after clinical discharge
219325569|NCT00961753|DRUG|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
219325570|NCT00961753|DRUG|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
219325571|NCT00726934|OTHER|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
219325572|NCT00726934|OTHER|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~1. Avoid raw vegetables and fruit (Oranges and bananas are okay.)~2. Avoid take-out foods and fast foods and fountain drinks.~3. Avoid aged cheese (blue, Roquefort, Brie).~4. Cook all produce to well done. Eggs must be hard-boiled.~5. Avoid deli meats.~6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~7. No well water~8. No yogurt"
219325573|NCT00526981|OTHER|Prone position|Prone position during spontaneous breathing.
219325574|NCT03859713|BEHAVIORAL|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
219325575|NCT03859713|BEHAVIORAL|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
219325576|NCT03859713|BEHAVIORAL|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
219325577|NCT05922020|OTHER|Oxygen gas|Administration of Oxygen by inhalation
219325578|NCT02205411|DEVICE|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
219325579|NCT02205411|DEVICE|Control VAD|The HeartMate II® VAD or HVAD®
219325580|NCT05844371|DRUG|tirelizumab|Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.
219325581|NCT05844371|DRUG|chemotherapy with oxaliplatin + heroda|chemotherapy with oxaliplatin + heroda
219325582|NCT03665389|DEVICE|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
219325583|NCT02493894|DRUG|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
219325584|NCT02493894|DRUG|placebo|placebo each 8 hours for 24 hours
219325585|NCT02493894|DRUG|Cefazolin|cefazolin 1gram, every 6hours for 2 days
219325586|NCT06013657|PROCEDURE|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
219325587|NCT02082899|DRUG|Active Comparator EBI-005 5 mg/mL|
219325588|NCT02082899|DRUG|Placebo Comparator|
219325589|NCT03082131|DIETARY_SUPPLEMENT|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
219325590|NCT02281357|BIOLOGICAL|Tralokinumab|Tralokinumab dose
219325591|NCT02281357|OTHER|Placebo|Placebo dose
219325592|NCT00025441|BIOLOGICAL|dactinomycin|
219325593|NCT00025441|BIOLOGICAL|filgrastim|
219325594|NCT00025441|DRUG|carboplatin|
219325595|NCT00025441|DRUG|cyclophosphamide|
219325596|NCT00025441|DRUG|doxorubicin hydrochloride|
219325597|NCT00025441|DRUG|epirubicin hydrochloride|
219325598|NCT00025441|DRUG|etoposide|
219325599|NCT00025441|DRUG|ifosfamide|
219325600|NCT00025441|DRUG|vincristine sulfate|
219325601|NCT00025441|PROCEDURE|peripheral blood stem cell transplantation|
219325602|NCT00025441|RADIATION|radiation therapy|
219325603|NCT05144568|OTHER|Nutrition education|Nutrition education will be given to improve PMS
219325604|NCT01841463|DRUG|P1446A-05|\- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
219325605|NCT01841463|DRUG|Vemurafenib (Zelboraf®)|"* In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
219325606|NCT03344419|DRUG|CI-581a|Medication infusion intravenously over 1 hour.
219325607|NCT03344419|DRUG|CI-581b|Medication infusion intravenously over 1 hour.
219325608|NCT03344419|BEHAVIORAL|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
219325609|NCT03344419|BEHAVIORAL|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
219325610|NCT06325748|BIOLOGICAL|SENTI-202|"SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles to achieve optimal response with the optionality of an additional consolidation cycle thereafter. Additional dosing schedules may be explored depending on study data."
219325611|NCT06295068|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|Replacement of the aortic valve with use of the OpSens SavvyWire
219325612|NCT06295068|DEVICE|Balloon Aortic Valvuloplasty (BAV)|Dilation of the narrowed aortic valve by balloon inflation with use of the OpSens SavvyWire
219325613|NCT01813851|DEVICE|Exercise training in addition to nutritional support|
219325614|NCT03219450|DRUG|NeoVax|It stimulates the immune system to attack cancer cells.
219325615|NCT03219450|DRUG|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
219325616|NCT03219450|DRUG|Pembrolizumab|Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
219325617|NCT05314712|BEHAVIORAL|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
219325618|NCT06235931|DRUG|Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib|"Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day)."
219325619|NCT06012383|DRUG|Bortezomib|Alvocade® was given with a dose of 1.3 mg/m2.
219325620|NCT06493877|OTHER|Retraining program after thoracic surgery|"An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2)."
219325621|NCT06455150|OTHER|Assessment of pelvic floor dysfunctions' symptoms and sings, pelvic floor muscle strength and quality of life|"It will be assessed the presence of urinary incontinence, anal incontinence, pelvic organ prolapse and female sexual dysfunction' symptoms by using the questionaries validated to Spanish population International Consultation on Incontinence Questionnaire-Short Form, Pelvic Floor Distress Inventory Short Form and Female Sexual Function Index; in addition, the sign of stress urinary incontinence and pelvic organ prolapse will be assessed by using the cough stress test and Pelvic Organ Prolapse Quantification System, the pelvic floor muscle strength by using manometry, and quality of life by using SF-12 questionnaire."
219325622|NCT02785679|DIETARY_SUPPLEMENT|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
219325623|NCT01208688|DEVICE|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
219325624|NCT01208688|DEVICE|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
219325625|NCT01208688|OTHER|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
219325626|NCT04417101|DRUG|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
219325627|NCT01499953|DRUG|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
219325628|NCT01499953|DRUG|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
219325629|NCT04800588|DIAGNOSTIC_TEST|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
219325630|NCT06382519|DRUG|Thalidomide|thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
219325631|NCT00482703|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily
219325632|NCT00482703|DRUG|dasatinib|tablets, Oral, 50 mg, twice daily
219325633|NCT06969989|OTHER|10 % water extract of Boswellia Sacra|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant( 10 % water extract of Boswellia sacra) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
219325634|NCT06969989|OTHER|1 % Sodium Hypochlorite|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant ( 1 % NaOCl ) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
219325635|NCT06969989|OTHER|0.9 % Normal Saline|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant (0.9 % saline) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
219325636|NCT04685915|DRUG|Ibrutinib|Capsule, taken by mouth once daily
219325637|NCT04685915|DRUG|Copanlisib|Intravenous Infusion
219325638|NCT04685915|DRUG|Acalabrutinib|Capsule, taken by mouth twice daily
219325639|NCT06541262|DRUG|Silmitasertib|Capsules
219325640|NCT06541262|DRUG|Irinotecan|IV
219325641|NCT06541262|DRUG|Temozolomide|Oral
219325642|NCT06541262|DRUG|Vincristine|IV
219325643|NCT04739072|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
219325644|NCT04739072|OTHER|Electronic Health Record Review|Review of medical records
219325645|NCT04447807|BEHAVIORAL|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
219325646|NCT04447807|OTHER|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
219325647|NCT06447207|BEHAVIORAL|Occupational Therapy Led Social Prescription|The intervention includes encouragement to participate in the co-designed social prescription with 6 monthly sessions with an occupational therapist or occupational therapy doctoral student.
219325648|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
219325649|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
219325650|NCT02270866|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
219325651|NCT06975644|DRUG|nab-paclitaxel, carboplatin, and bemotuzumab|nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W
219325652|NCT06975644|DRUG|epirubicin, cyclophosphamide, and bemotuzumab|epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W
219325653|NCT04777747|OTHER|viral infection|a child is infected by virus only
219325654|NCT04777747|OTHER|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
219325655|NCT05114746|RADIATION|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
219325656|NCT05114746|RADIATION|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 259 MBq (3 - 7 mCi).
219325657|NCT05114746|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
219325658|NCT04887454|BEHAVIORAL|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
219325659|NCT04887454|BEHAVIORAL|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
219325660|NCT04887454|OTHER|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
219325661|NCT03819738|DIAGNOSTIC_TEST|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
219325662|NCT01152762|PROCEDURE|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
219325663|NCT02509897|OTHER|Hypoxic training|Hypoxic training 3 times per week four four weeks
219325664|NCT02509897|OTHER|Normoxic training|Normoxic training 3 times per week four four weeks
219325665|NCT01608542|DRUG|Fostamatinib 100mg|oral tablet
219325666|NCT01608542|DRUG|Fostamatinib 200mg|oral tablet
219325667|NCT02885805|DRUG|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
219325668|NCT02885805|DRUG|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
219325669|NCT00771563|DRUG|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
219325670|NCT00771563|DRUG|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
219325671|NCT02403843|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
219325672|NCT00823303|DRUG|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
219325673|NCT00823303|DRUG|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
219325674|NCT04692454|OTHER|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
219325675|NCT01559194|BEHAVIORAL|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
219325676|NCT01559194|BEHAVIORAL|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
219325677|NCT02710773|OTHER|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
219325678|NCT02710773|OTHER|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
219325679|NCT04817384|OTHER|Graston technique|For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
219325680|NCT04817384|OTHER|Classical Massage|In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
219325681|NCT05503563|PROCEDURE|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
219325682|NCT04765241|BEHAVIORAL|Physical Activity|The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
219325683|NCT04726007|DRUG|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
219325684|NCT01174511|DRUG|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
219325685|NCT04319302|PROCEDURE|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
219325686|NCT05005455|DRUG|bevacizumab with new manufacturing process.|3mg/kg,I.V.,single dose
219325687|NCT05005455|DRUG|bevacizumab with old manufacturing process.|3mg/kg,I.V.,single dose
219325688|NCT04202523|RADIATION|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
219325689|NCT04202523|DEVICE|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
219325690|NCT00186264|DRUG|venlafaxine XR|
219325691|NCT00186264|DRUG|hydrocortisone|
219325692|NCT06197334|DEVICE|Gastro-intestinal biopotentials recording|Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.
219325693|NCT05622825|BIOLOGICAL|DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
219325694|NCT00630461|BIOLOGICAL|Clinical Center Reference Endotoxin|single inhalation challenge
219325695|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219325696|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
219325697|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219325698|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
219325699|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
219325700|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
219325701|NCT04412538|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
219325702|NCT04412538|BIOLOGICAL|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
219325703|NCT05805566|OTHER|Blood collection|Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
219325704|NCT04806139|BEHAVIORAL|Remote Enhance Fitness|The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
219325705|NCT02834416|BEHAVIORAL|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
219325706|NCT02834416|BEHAVIORAL|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
219325707|NCT01306188|BIOLOGICAL|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
219325708|NCT01306188|BIOLOGICAL|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
219325709|NCT05251818|OTHER|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
219325710|NCT05251818|OTHER|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
219325711|NCT00126074|DRUG|Tedisamil sesquifumarate|
219325712|NCT05149664|DEVICE|Therapeutic ultrasound (TUS)|As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
219325713|NCT04248309|DRUG|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
219325714|NCT00506545|DRUG|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
219325715|NCT00506545|DRUG|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
219325716|NCT03197688|OTHER|Notapplicable|Not applicable as non-interventional study
219325717|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
219325718|NCT03491709|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
219325719|NCT03491709|DRUG|Cetuximab injection|Cetuximab injection
219325720|NCT04803110|PROCEDURE|Dental implant placement after tooth extraction|Immediate implant placement after partial or complete tooth extraction.
219325721|NCT06179771|DEVICE|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
219325722|NCT06976567|DEVICE|Telemedicine for urology consultations|The patients that are assigned to the intervention group will receive a virtual urology consultation with urologists from Ahmadu Bello University in Zaria, Nigeria as opposed to physically presenting for the consultation.
219325723|NCT06843174|DRUG|Rectal Methadone administer during spinal surgery|Rectal Methadone administered during spinal surgery for post-operative pain management
219325724|NCT06843174|OTHER|Placebo: Rectal saline solution|Placebo: Rectal saline solution single dose received during surgery
219325725|NCT00972777|DRUG|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
219325726|NCT00972777|DRUG|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
219325727|NCT06985628|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|tVNS will be applied at the cervical level of the vagal nerve.
219325728|NCT06985628|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be applied facially on the trigeminal nerve.
219325729|NCT03850782|DRUG|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
219325730|NCT05334537|OTHER|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
219325731|NCT05334537|OTHER|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
219325732|NCT05619978|OTHER|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
219325733|NCT05619978|OTHER|T315I|Patients with chronic myeloid leukemia with T315I mutation
219325734|NCT06984159|DRUG|Leuprolide Injectable Emulsion (CAMCEVI®)|Leuprolide Injectable Emulsion (CAMCEVI®)，Subcutaneous injection，Once every 24 weeks for a total of 2 doses
219325735|NCT05568602|DIAGNOSTIC_TEST|Dexamethasone suppression test|1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
219325736|NCT03612284|DEVICE|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
219325737|NCT01540383|BEHAVIORAL|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, \>=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
219325738|NCT01540383|BEHAVIORAL|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
219325739|NCT02752750|OTHER|MRI|MR imaging (MRI) at 3 Tesla
219325740|NCT00563667|PROCEDURE|pterygium excision|
219325741|NCT06863155|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|PCI with SupraFlex Cruz® stent in de novo coronary stenosis of patients under chronic oral anticoagulation.
219325742|NCT06607172|DEVICE|oral irrigator|water flosser device
219325743|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
219325744|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
219325745|NCT05835713|DRUG|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
219325746|NCT05835713|DRUG|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
219325747|NCT07130019|PROCEDURE|Fluorescence guided thermal ablation of epidermal tissue|Thermal ablation of epidermal tissue under fluorescence control.
219325748|NCT07130019|PROCEDURE|Thermal ablation of epidermal tissue|Thermal ablation of skin tissue a vue
219325749|NCT06725225|BEHAVIORAL|Symptom cluster-based care intervention|The patient symptoms were surveyed to develop a symptom cluster care intervention plan. The specific steps were as follows: a research team was established, relevant literature was reviewed, and qualitative interviews were conducted. Guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, a draft of the care intervention was created. This draft was then refined through expert consultation to finalize the intervention plan.
219325750|NCT06725225|BEHAVIORAL|Conventional care intervention|Standard nursing intervention. This refers to routine clinical care without a specific care plan tailored to the patient's symptoms. For example, if a patient has symptoms, the nurse assists the patient in notifying the doctor but does not provide any special treatment themselves
219325751|NCT06708611|DRUG|torsemide|Extended release formulation of torsemide
219325752|NCT02247154|BIOLOGICAL|Vigam® (Human Normal Immunoglobulin)|
219325753|NCT06741761|OTHER|12-hour time-restricted feeding (TRF12)|The 12 hour feeding group will receive tube feeding only over a 12 hour period (6:00 AM to 6:00 PM feeding schedule).
219325754|NCT06741761|OTHER|Continuous 24 hour feeding (CONT24).|Patients in this control group will receive the standard of care which is tube feeding continuously over 24 hours.
219325755|NCT06894784|DRUG|Intervention Period 1: Semaglutide + Empagliflozin|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
219325756|NCT06894784|DRUG|Intervention Period 2: Semaglutide + Empagliflozin Placebo|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet, matched in appearance to empagliflozin (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
219325757|NCT06894784|DRUG|Intervention Period 3: Semaglutide Placebo + Empagliflozin|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
219325758|NCT06894784|DRUG|Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet (2.5 mg), matched in appearance to empagliflozin, administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
219325759|NCT07061470|DIETARY_SUPPLEMENT|Ferrous Sulfate|Dosing of the iron supplement will be based on weight.
219325760|NCT07061470|OTHER|Placebo|Placebo pills will be provided to participants in the placebo arm
219325761|NCT02529007|DEVICE|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
219325762|NCT02529007|OTHER|Standard colonoscopy|Standard colonoscopy without end-cuff
219325763|NCT06895291|DIAGNOSTIC_TEST|Whole Body-Magnetic Resonance Imaging (WB-MRI)|"This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed:~* at staging~* at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients."
219325764|NCT07131020|BEHAVIORAL|Yifei moxibustion|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.The Yifei moxibustion is applied from the Dazhui to Yaoshu acupoints along the Governor Vessel. Ginger juice is spread over the treatment area, followed by sprinkling moxa powder and covering with mulberry bark paper. A 2.5 cm thick layer of ginger paste and a 3 cm thick layer of moxa wool are then placed on the mulberry bark paper. The moxa wool is ignited and allowed to burn out naturally, being replaced every 30 minutes. After 90 minutes, the ginger paste is removed. The treatment is performed once every 15 days, with 6 sessions constituting one course of treatment, totaling 3 months.
219325765|NCT07131020|DRUG|Conventional Western medicine treatment|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.
219325766|NCT07131020|DRUG|TCM syndrome differentiation treatment|The conventional Western medicine treatment followes the same protocol as described above. The diagnosis of TCM pattern-based therapy is made in accordance with the TCM Syndrome Diagnostic Criteria for Chronic Obstructive Pulmonary Disease issued by the Pulmonary Disease Committee of the Internal Medicine Branch, China Association of Chinese Medicine and the treatment is based on the 2019 Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease issued by the China Association of Chinese Medicine.
219325767|NCT06927609|OTHER|kendall exercises|Stretching of Cervical Extensors Strengthening Deep Cervical Flexors Strengthening Shoulder Retraction Stretching Pectoralis Muscle
219325768|NCT06927609|OTHER|Conventional therapy group|Cervical Traction Neck Isometric Exercises (Cervical flexors), Static Stretching (Cervical extensors) General Cervical Extension and Flexion Exercises Shoulder Shrugs
219325769|NCT06893237|OTHER|virtual reality goggles and inhalation treatment|Video recording will be started after the consent is obtained. One minute before the procedure, the child's physical parameters (peak heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be fitted with virtual reality goggles and inhalation treatment will be started by watching the aquarium and sea creatures video. Inhalation treatment will last for 10 minutes with the most appropriate air flow rate of 6-8 L/min. Then, the virtual reality goggles will be removed and the child's physiological parameters and anxiety will be measured and recorded again after 1 minute. For participants who want to participate in the study but do not approve the video recording, the evaluations will be made by a nurse independent of the study.
219325770|NCT06893237|OTHER|distraction cards and inhalation therapy|After the consent is obtained, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be shown distraction cards and inhalation therapy will be started simultaneously. Playing with the distraction cards will continue for 10 minutes until the end of the inhalation therapy. Then, the use of the toys will be stopped and the child's physiological parameters and anxiety will be recorded after 1 minute. The video recording will be ended. For participants who want to participate in the study but do not consent to being video recorded, the evaluations will be made by a nurse independent of the study.
219325771|NCT06893237|OTHER|inhalation therapy|After the consent is received, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, inhalation therapy will be started with routine service application. The child will receive inhalation therapy for 10 minutes. 1 minute after the procedure, physiological parameters and anxiety will be measured and recorded again. The video recording will be ended. For participants who want to participate in the study but do not approve of being video recorded, evaluations will be made by a nurse independent of the study.
219325772|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose
219325773|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose
219325774|NCT06903247|OTHER|Neurosonographic Findings of Vitamin D Deficiency in Single Healthy Pregnancies Presenting for Routine Antenatal Care Between 20-30 Weeks of Gestation.|Comparison of Neurosonographic Findings in Patients with and without Vitamin D Deficiency.
219325775|NCT06902675|OTHER|Artificial Intelligence|Artificial Intelligence as a decision making tool
219325776|NCT06902675|OTHER|Retrospective Data Extraction of 10,000 Neurology ER Cases|This intervention involves collecting and de-identifying clinical data from 10,000 patients previously evaluated by neurologists in the Emergency Department. The data are then used retrospectively to refine and fine-tune a large language model (LLM). No real-time clinical decisions or recommendations are made for these patients, as the purpose is to improve the model's accuracy and relevance for future use.
219325777|NCT06903013|OTHER|Non vitalPulp therapy|Pulp therapy deals about management of inflamed vital dental pulp With complete pulp removal and obturation with resorbable materi
219325778|NCT06903013|OTHER|Vital pulp therapy|Pulp therapy through partial root removal and using of regenerative capping material
219325779|NCT07103733|PROCEDURE|Cardiac Magnetic Resonance Imaging|Non-invasive imaging test that uses powerful magnets and radio waves to create detailed pictures of the heart without using radiation.
219325780|NCT07103733|DEVICE|ZioPatch Monitoring|ZioPatch is a small, wearable heart monitor that sticks to the chest and records the heart's electrical activity continuously for up to 14 days. It helps doctors detect irregular heart rhythms (arrhythmias) without the need for bulky wires or equipment.
219325781|NCT07103733|PROCEDURE|Myocardial Tissue Biopsy|During the MVr procedure, surgeons will biopsy approximately 50 μg of tissue from the endocardial and subendocardial myocardium in the inferobasilar and control areas using a surgical rongeur.
219325782|NCT07104539|BEHAVIORAL|Strength Training|Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
219325783|NCT07104539|OTHER|Wait first, then strength training|Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
219325784|NCT03337698|DRUG|Atezolizumab|Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
219325785|NCT03337698|DRUG|Cobimetinib|Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
219325786|NCT03337698|DRUG|RO6958688|"Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle."
219325787|NCT03337698|DRUG|Docetaxel|Docetaxel is administered by IV on Day 1 of each 21 day cycle.
219325788|NCT03337698|DRUG|CPI-444|CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
219325789|NCT03337698|DRUG|Pemetrexed|Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
219325790|NCT03337698|DRUG|Carboplatin|Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
219325791|NCT03337698|DRUG|Gemcitabine|Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
219325792|NCT03337698|DRUG|Linagliptin|Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
219325793|NCT03337698|DRUG|Tocilizumab|Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
219325794|NCT03337698|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
219325795|NCT03337698|DRUG|Bevacizumab|Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
219325796|NCT03337698|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
219325797|NCT03337698|OTHER|Radiation|Radiotherapy up to 21 days
219325798|NCT03337698|DRUG|Evolocumab|Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
219325799|NCT03337698|DRUG|Tiragolumab|Tiragolumab is administered on Day 1 of each 21 day cycle.
219325800|NCT03337698|DRUG|XL092|XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
219325801|NCT03337698|DRUG|Camonsertib|Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
219325802|NCT07104123|OTHER|Social drivers of health screening|Patients will undergo a structured and protocoled screening for social drivers of health and be linked to support services
219325803|NCT07104123|BEHAVIORAL|Patients will undergo a program of contingency management|Patients will enter into a 12 week program of contingency management
219325804|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
219355252|NCT04434144|DRUG|Ivermectin + Doxycycline|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
219325805|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
219325806|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
219325807|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
219325808|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
219325809|NCT07119983|BEHAVIORAL|Stress ball|The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.
219325810|NCT07130604|DRUG|D-2570|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
219325811|NCT07130604|DRUG|Placebo|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
219325812|NCT07130695|DRUG|Olutasidenib Investigational Agent Administration|Twice daily olutasidenib maintenance therapy
219325813|NCT07128472|DRUG|Humira|Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.
219325814|NCT07130669|BEHAVIORAL|Cognitive Remediation|computerized cognitive training with a closed-loop human machine interface that monitor facial expression as engagement status of the person
219325815|NCT07130669|BEHAVIORAL|Cognitive Remediation II|traditional computerized cognitive training
219325816|NCT07129876|OTHER|Simulator Motion|Motion fidelity of the simulator.
219325817|NCT07128394|DRUG|Recombinant Luteinizing Hormone (rLH)|Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.
219325818|NCT07128394|DRUG|Recombinant Follicle-Stimulating Hormone (rFSH)|Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.
219325819|NCT07128394|DRUG|Gonadotropin-Releasing Hormone Agonist (GnRH-a)|Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.
219325820|NCT07128823|OTHER|(High-frequency segmental vibration and ASAP with Routine Physical Therapy)|"A Segmental vibration device was used to provide vibratory stimulation with a frequency of 100 Hz and an amplitude of 1.0 mm. This stimulation was used because vibratory stimulation with a high frequency (80-120 Hz) and low amplitude can elicit strong activity in Ia afferents from the muscle spindles. 100 Hz frequency vibration was applied perpendicularly along the muscle fibers of the forearm extensor muscle (extensor carpi ulnaris (ECU), extensor carpi radialis (ECR), triceps).~The Accelerated Skill Acquisition Programme (ASAP), a structured, taskoriented motor training program for the upper extremities, is a best-practice synthesis implementing neuroscientific evidence regarding motor training approaches and schedules. The Accelerated Skill Acquisition Program (ASAP) for subacute stroke patients focuses on integrating motor training with motivational enhancement and impairment mitigation."
219325821|NCT07128823|OTHER|(Accelerated Skill Acquisition Programme with Routine Physical Therapy)|"Exercises within the ASAP typically include:~Task-Specific Training: Patients engage in activities that mimic daily tasks, such as reaching, grasping, and manipulating objects, to improve their functional abilities Repetitive Practice: Patients perform repetitive movements to strengthen neural pathways and improve motor skills. This can involve tasks like buttoning a shirt, picking up small objects, or pouring water Bilateral Arm Training: This approach involves using both arms simultaneously to perform coordinated tasks, enhancing bimanual skills and improving upper extremity functions Motivational Strategies: The program incorporates motivational techniques to enhance patient engagement and adherence to the exercises, ensuring sustained practice and better outcomes."
219325822|NCT07128589|DEVICE|3MTM FiltekTM Supreme Flowable Composite|"3M ™ Supreme Flowable Restorative contains BisGMA,TEGDMA and Procrylat resins. The fillers are a combination of ytterbium trifluoride filler with a range of particles sizes from 0.1 to 5.0 microns, a non-agglomerated/non-aggregated surface modified 20nm silica filler, a non-agglomerated/non/aggregated surface modified 75nm silica filler, and a surface modified aggregated zirconia/silica cluster filler (comprised of 20 nm silica and 4 to 11nm zirconia particles). The aggregate has an average cluster particle size of 0.6 to 10 microns. The inorganic filler loading is approximately 65% by weight (46% by volume).~3M (TM) Filtek(TM) Supreme Flowable Restorative is a modification of predicate device 3M(TM) Filtek(TM) XT Flowable Restorative (which was a modification of 3M(TM) Filtek(TM) Flow. 3M Filtek Supreme Flowable Composites are used per indication and its approved labeling in this study."
219325823|NCT07129044|BEHAVIORAL|Flipped Classroom Training on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. The training was delivered using a flipped classroom model over 4 weeks. Students were provided with pre-class educational materials, including video lectures, readings, and lecture notes. In-class sessions included interactive activities, discussions, case-based learning, and problem-solving exercises. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
219325824|NCT07129044|BEHAVIORAL|Self-Directed Learning on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. Students were provided with the same pre-class educational materials as the intervention group, including video lectures, readings, and lecture notes, for self-study without any interactive activities or instructor-led sessions. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
219325825|NCT07130942|PROCEDURE|Inhalation using a molecular hydrogen generator|"Hydrogen inhalation will be performed by using a hydrogen gas generator similar in terms of capabilities to the generator Hycellvator ET100 (Helix Japan, Co., Ltd., Tokyo, Japan). The apparatus will be generating 30.0 mL/s gas mixture, consisting of 68.0% hydrogen (hydrogen purity, 99.99%) and 32.0% of oxygen. All gases will be supplied through a nasal cannula connected to the gas generators. Although we could not measure directly the hydrogen and oxygen An average inspiratory flow rate will be adjusted to 500 mL/s at rest, the hydrogen concentration in the inspired gas must have been around 4.08% at most.~Control population will have inhalation with the use of gas generator that has the same outer shape as the used generator to produce Placebo (30.0 mL/s, ambient air 400 m above sea level) consisting of 0.00005% of hydrogen and 20.9% of oxygen."
219325826|NCT07129434|BEHAVIORAL|ECoFam|Mother-infant dyads randomized into the intervention group receive four personal coaching sessions to facilitate emotional connection via multisensory channels including comfort touch and communication of face-to-face affect during holding time.
219325827|NCT07129759|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
219325828|NCT07128459|PROCEDURE|The Five-Step lip reduction surgery|The Five-Step lip reduction surgery: (1) measurement and design; (2) incision and reduction of lip volume; (3) fixation and shape of the dry lip; (4) fixation and shape of the skin (the SMISS approach); (5) shaping of the wet lip mucosa (the SMISS approach).
219325829|NCT07129330|PROCEDURE|RSPO3/SDC-1 pathway profiling assay|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage Subcutaneous Fat: 100-200 mg obtained during elective procedures, preserved in RNAlater at 4 °C for 24 h, then frozen at -80 °C 3D Alveolar Organoid Assay: Lung tissue-derived organoids are cultured in Matrigel and treated ex vivo with recombinant RSPO3 or SDC-1 neutralizing antibody; epithelial repair is assessed over 7 days by Ki-67 immunostaining and wound-closure measurement"
219325830|NCT07129330|PROCEDURE|Blood and Saliva|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage"
219355253|NCT04434144|DRUG|Hydroxychloroquine + Azithromycin|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
219325831|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
219325832|NCT06925451|OTHER|sourdough bread 24|fermentation time=24 hours
219325833|NCT06925451|OTHER|sourdough bread 48|fermentation time=48 hours
219325834|NCT06925451|OTHER|sourdough bread 72|fermentation time=72 hours
219325835|NCT06925451|OTHER|yeast bread|no fermentation
219325836|NCT05294354|BEHAVIORAL|aerobic exercise group (AE)|The participants will ride the cycle ergometer for 35 minutes. The training consisted of a 5-minute warm-up period followed by 25 minutes of moderate exercise and a 5-minute recovery.
219325837|NCT05294354|BEHAVIORAL|aerobic exercise with virtual reality group (AE-VR)|The participants will receive the 3D VR training program and ride the cycle ergometer at the same time. The training protocol is similar to the aerobic exercise group.
219325838|NCT05294354|BEHAVIORAL|combined exercise group (CE)|The intervention consists of 5-minutes aerobic warm-up, 25-minutes bodyweight exercise, and 5-minutes mindfulness meditation for recovery. The participants will follow the video to do the program.
219325839|NCT05294354|BEHAVIORAL|Control group|Participants will watch a 35-min video about exercise science.
219325840|NCT07129343|BIOLOGICAL|VONVENDI|VONVENDI is administered by intravenous injection.
219325841|NCT07129343|BIOLOGICAL|ADVATE|ADVATE is administered by intravenous injection.
219325842|NCT00269165|PROCEDURE|Balloon Aortic Valvuloplasty|
219325843|NCT00269165|PROCEDURE|External Beam Radiation|
219325844|NCT06938386|DIETARY_SUPPLEMENT|Haskap|A whole, frozen Haskap berry puree blended with water in a 2:1 ratio of berry to water.
219325845|NCT02705209|OTHER|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
219325846|NCT02705209|OTHER|Placebo Cataplasm|Poultice of Kaolin and Water
219325847|NCT06954142|OTHER|Fluid restriction|Fluid restriction strategy (fluid target 135 ±5 mL/kg/d)
219325848|NCT06954142|OTHER|Liberal fluid intake|Liberal fluid intake strategy (fluid target 165 ± 5 mL/kg/d)
219325849|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
219325850|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
219325851|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
219325852|NCT01978821|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
219325853|NCT06148987|OTHER|Questionnaire|The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
219325854|NCT00001181|DRUG|Testolactone|
219325855|NCT00729378|OTHER|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
219325856|NCT03683940|DIAGNOSTIC_TEST|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
219325857|NCT01330134|DRUG|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
219325858|NCT01330134|DRUG|lidocaine|1% lidocaine subcutaneous injection alone
219325859|NCT06200844|BIOLOGICAL|ROTAVAC 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.
219325860|NCT06200844|OTHER|Placebo|Placebo is administered as three doses 4 weeks apart
219325861|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
219325862|NCT01606267|OTHER|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
219325863|NCT04790136|DRUG|GLA-015|administration followed by PK blood sampling
219325864|NCT04790136|DRUG|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|administration followed by PK blood sampling
219325865|NCT04389021|DEVICE|Virtual Reality|"The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol."
219325866|NCT02246582|DEVICE|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
219325867|NCT02246582|DEVICE|Guardian Mobile App|
219325868|NCT02246582|DEVICE|640G Insulin Pump|
219325869|NCT02899078|DRUG|Ibrutinib|Given PO
219325870|NCT02899078|DRUG|Nivolumab|Given IV
219325871|NCT05091086|DRUG|Continuous Denosumab|Active comparator: persistent treatment of denosumab.
219325872|NCT05091086|DRUG|Administer zoledronate and denosumab on an alternating schedule|In the experimental group, zoledronic acid was administered for one year, followed by two years of denosumab. This cycle was repeated, with the regimen concluding with one year of zoledronic acid.
219325873|NCT01171352|PROCEDURE|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
219325874|NCT01125943|DRUG|Acetylcholine|Intra-arterial infusion
219325875|NCT01125943|DRUG|Nitroprusside|Intra arterial infusion
219325876|NCT01125943|DRUG|Bevacizumab|Intra arterial infusion
219325877|NCT04184960|DIAGNOSTIC_TEST|Gastroscopy and gastric biopsies|Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
219325878|NCT00523718|DRUG|riluzole|50 mg PO bid, 12 weeks
219325879|NCT00523718|DRUG|placebo|placebo, 1 capsule PO bid, 12 weeks
219325880|NCT04308824|OTHER|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
219325881|NCT04308824|OTHER|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
219325882|NCT04156503|OTHER|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
219325883|NCT06379425|DRUG|Acetaminophen|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
219325884|NCT06379425|DRUG|Celecoxib|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
219325885|NCT06379425|DRUG|Gabapentin|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
219325886|NCT02060383|DRUG|Pasireotide s.c.|Administered to Cushing's disease participants.
219325887|NCT02060383|DRUG|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
219325888|NCT02060383|DRUG|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
219325889|NCT02060383|DRUG|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
219325890|NCT02060383|DRUG|Pasireotide LAR|Administered to Acromegaly participants.
219325891|NCT02060383|DRUG|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
219325892|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
219325893|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
219325894|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
219325895|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
219325896|NCT06177028|DRUG|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
219325897|NCT04139044|PROCEDURE|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
219325898|NCT04139044|PROCEDURE|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
219325899|NCT03311321|DIETARY_SUPPLEMENT|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
219325900|NCT03311321|DIETARY_SUPPLEMENT|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
219325901|NCT00143065|DRUG|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
219325902|NCT00143065|DRUG|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
219325903|NCT00143065|DRUG|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
219325904|NCT05452330|OTHER|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
219325905|NCT05452330|OTHER|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
219325906|NCT05099094|GENETIC|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
219325907|NCT03202823|PROCEDURE|blood samples|3 tubes (5 ml volume) collected during surgery
219325908|NCT03202823|PROCEDURE|recover samples of atheromatous plaque|a carotid sample collected during surgery
219325909|NCT03465631|DEVICE|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
219325910|NCT03465631|DEVICE|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
219325911|NCT01762176|PROCEDURE|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
219325912|NCT01762176|PROCEDURE|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
219325913|NCT03187951|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
219325914|NCT03187951|BEHAVIORAL|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
219325915|NCT03187951|OTHER|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
219325916|NCT03187951|BEHAVIORAL|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
219325917|NCT03187951|BEHAVIORAL|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
219325918|NCT03187951|BEHAVIORAL|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
219325919|NCT04977102|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
219325920|NCT04977102|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
219355254|NCT03087006|OTHER|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
219325921|NCT04450563|DRUG|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
219325922|NCT01109329|BIOLOGICAL|HMPV challenge virus|Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
219325923|NCT01851278|DRUG|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
219325924|NCT01851278|DRUG|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
219325925|NCT03441334|DEVICE|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
219325926|NCT03441334|DEVICE|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
219325927|NCT01999569|DRUG|Letrozole|Letrozole administered daily through the time of ovulation.
219325928|NCT05726539|BEHAVIORAL|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
219325929|NCT05377190|OTHER|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
219325930|NCT05377190|OTHER|Standard of care for the follow-up|No mobile application or digital therapeutics are used
219325931|NCT05377190|OTHER|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
219325932|NCT05831826|BIOLOGICAL|the inactivated COVID-19 vaccines|receive the doses of inactivated COVID-19 vaccines
219325933|NCT00005666|PROCEDURE|PET scan use in radiotherapy planning|
219325934|NCT00395863|DRUG|Multihance|0.5 M at a single injection
219325935|NCT00395863|DRUG|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
219325936|NCT01514487|DRUG|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
219325937|NCT04673227|DIAGNOSTIC_TEST|Blood draw|Blood draw and the analysis of blood in laboratory
219355255|NCT03087006|OTHER|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
219325938|NCT00866450|DIETARY_SUPPLEMENT|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
219325939|NCT00866450|DIETARY_SUPPLEMENT|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
219325940|NCT00024050|DRUG|busulfan|
219325941|NCT00024050|DRUG|cyclophosphamide|
219325942|NCT00024050|DRUG|cyclosporine|
219325943|NCT00024050|DRUG|methotrexate|
219325944|NCT00024050|PROCEDURE|allogeneic bone marrow transplantation|
219325945|NCT00024050|PROCEDURE|peripheral blood stem cell transplantation|
219325946|NCT00316355|BEHAVIORAL|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
219325947|NCT00316355|BEHAVIORAL|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
219355256|NCT01472887|DRUG|SAR3419|"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
219355257|NCT01309035|PROCEDURE|Total Knee Arthroplasty|Surgery for OA knee pains
219355258|NCT05749380|DRUG|AmBisome|Reference, dose of 3 mg/kg.
219325948|NCT03137186|DRUG|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
219325949|NCT03725514|PROCEDURE|Conventional|Conventional Blood Clot Technique
219325950|NCT03725514|PROCEDURE|PRF|Platelet Rich Fibrin Technique
219325951|NCT01406288|OTHER|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
219325952|NCT04485273|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
219355259|NCT05749380|DRUG|DKF-5122|Test, dose of 3 mg/kg
219325953|NCT04485273|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
219325954|NCT04485273|PROCEDURE|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
219325955|NCT04485273|DRUG|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
219325956|NCT04485273|DRUG|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
219325957|NCT03791242|DEVICE|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
219325958|NCT05867082|OTHER|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
219325959|NCT02830672|PROCEDURE|Surgical release A1 pulley for Trigger finger of the hand|
219325960|NCT04072055|DEVICE|MOTO Medial|MOTO medial unicompartmental knee system
219325961|NCT02020057|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
219325962|NCT04703036|DIETARY_SUPPLEMENT|Glycine|Glycine is an amino-acid (protein)
219325963|NCT04703036|DIETARY_SUPPLEMENT|N-acetylcysteine|This is a donor of the amino-acid cysteine (protein)
219325964|NCT04703036|DIETARY_SUPPLEMENT|Alanine|Alanine is an amino-acid (protein)
219325965|NCT00880659|BEHAVIORAL|Soap|Promotion of handwashing with soap
219325966|NCT00182832|BEHAVIORAL|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
219325967|NCT00182832|BEHAVIORAL|Standard Care|Standard care for hospitalized older patients with cognitive impairment
219325968|NCT02768337|DRUG|Afatinib|
219325969|NCT02768337|RADIATION|2 Gy targeted radiotherapy|
219325970|NCT02768337|RADIATION|4 Gy targeted radiotherapy|
219325971|NCT00000225|DRUG|Buprenorphine|
219325972|NCT05952245|BEHAVIORAL|iCBTI-based EMI|Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).
219325973|NCT05952245|BEHAVIORAL|Education-based EMI|Stroke and brief sleep hygiene education with chat-based support on the topics.
219325974|NCT02642770|DEVICE|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
219325975|NCT05052073|DIAGNOSTIC_TEST|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
219325976|NCT05052073|DIAGNOSTIC_TEST|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
219355260|NCT03870555|DRUG|TAK-954|TAK-954 infusion administered intravenously.
219325977|NCT04677673|DRUG|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
219325978|NCT04677673|PROCEDURE|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
219325979|NCT02592551|DRUG|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
219325980|NCT02592551|DRUG|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
219325981|NCT02592551|OTHER|no other name|Neither MEDI4736 nor Tremelimumab will be used.
219325982|NCT02839408|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
219325983|NCT02839408|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn
219325984|NCT02839408|OTHER|Talc powder|Sachet containing talc powder and tablet containing talc powder
219325985|NCT02839408|PROCEDURE|Periodontal treatment Scaling and root planning|
219325986|NCT05151081|OTHER|basicly|Do not repeat information already included in arm/group descriptions.
219325987|NCT01876251|DRUG|PF-03084014|Tablet, 10 mg, twice a day
219325988|NCT01876251|DRUG|PF-03084014|Tablet, 50 mg, twice a day
219325989|NCT01876251|DRUG|PF-03084014|Tablet, 100 mg, twice a day
219325990|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 75 mg/m\^2, every 3 weeks
219325991|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 100 mg/m\^2, every 3 weeks
219325992|NCT00268437|DRUG|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
219325993|NCT00268437|DRUG|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
219325994|NCT00268437|PROCEDURE|conventional surgery|
219325995|NCT00268437|PROCEDURE|neoadjuvant therapy|
219325996|NCT00268437|RADIATION|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
219325997|NCT01355484|DRUG|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
219325998|NCT01355484|DRUG|placebo|subject will receive placebo for the duration of the trial
219355261|NCT03870555|DRUG|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
219355262|NCT04145401|DEVICE|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
219355263|NCT01251783|DIETARY_SUPPLEMENT|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
219325999|NCT05161091|DEVICE|Topical application of Orosol®|Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
219355264|NCT01251783|DIETARY_SUPPLEMENT|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
219355265|NCT01251783|DIETARY_SUPPLEMENT|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
219355266|NCT01251783|DIETARY_SUPPLEMENT|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
219355267|NCT01251783|DIETARY_SUPPLEMENT|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
219355268|NCT01251783|DIETARY_SUPPLEMENT|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
219355269|NCT05730400|DRUG|BMAC loaded on bovine graft|Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
219355270|NCT05730400|DRUG|Bovine graft only|Bovine graft only for sinus floor augmentation
219326000|NCT05161091|DEVICE|Topical application of Placebo comparator|Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
219326001|NCT03715842|OTHER|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
219326002|NCT03715842|OTHER|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
219326003|NCT04339907|OTHER|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
219326004|NCT04339907|OTHER|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
219326005|NCT03667534|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
219326006|NCT00418990|DRUG|Multivitamin/Mineral supplements|
219326007|NCT03013283|OTHER|self questionnaire|"* Interface side effects and degree of satisfaction of the patients~* Technician evaluation and device measures."
219326008|NCT05316402|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
219326009|NCT05316402|OTHER|dosimetry|dosimetry
219326010|NCT01295528|DEVICE|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
219326011|NCT01863940|DEVICE|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
219326012|NCT00222170|DRUG|Rabeprazole|
219326013|NCT01182402|DEVICE|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
219326014|NCT05725070|DRUG|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
219326015|NCT00575627|DRUG|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
219326016|NCT02137512|DEVICE|Closed-Loop Control System|"This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
219326017|NCT02137512|DEVICE|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump"
219326018|NCT05259371|DRUG|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
219326019|NCT01121523|BEHAVIORAL|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
219326020|NCT05516589|DRUG|Nab-paclitaxel|260mg/m\^2 IV Q3W
219326021|NCT05516589|DRUG|Cisplatin|75mg/m\^2 IV Q3W
219326022|NCT05516589|BIOLOGICAL|Tislelizumab|200mg IV Q3W
219326023|NCT05516589|DRUG|Afatinib|30mg PO QD
219326024|NCT06788938|DRUG|Tarlatamab treatment|"* 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle"
219326025|NCT01226823|DRUG|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
219326026|NCT01226823|DRUG|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
219326027|NCT05406388|PROCEDURE|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
219326028|NCT05406388|PROCEDURE|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
219326029|NCT05241509|DRUG|Cymbopogon citratus (lemongrass) oil gel|Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
219326030|NCT00004022|BIOLOGICAL|aldesleukin|
219326031|NCT00004022|BIOLOGICAL|autologous tumor cell vaccine|
219326032|NCT00004022|BIOLOGICAL|muromonab-CD3|
219326033|NCT00004022|BIOLOGICAL|therapeutic autologous lymphocytes|
219326034|NCT00004022|PROCEDURE|surgical procedure|
219326035|NCT05170425|DEVICE|Prospera|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
219326036|NCT01526044|DEVICE|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
219326037|NCT00707850|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
219326038|NCT04900558|PROCEDURE|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
219326039|NCT05244707|BEHAVIORAL|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
219326040|NCT05244707|BEHAVIORAL|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
219326041|NCT02422888|DRUG|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
219326042|NCT02422888|DRUG|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
219326043|NCT05340725|DRUG|DEX-IV|patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
219326044|NCT05340725|DRUG|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
219326045|NCT05340725|DRUG|DEX-Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
219326046|NCT04414371|OTHER|Yoga|Yoga Namaskar and Nadi Shuddhi
219326047|NCT01338623|DRUG|Tansulosine|capsule 0,4 mg
219326048|NCT03712436|COMBINATION_PRODUCT|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
219326049|NCT03712436|COMBINATION_PRODUCT|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
219326050|NCT00237575|DRUG|gemcitabine|
219326051|NCT00237575|DRUG|cisplatin|
219326052|NCT00237575|DRUG|sargramostim|
219326053|NCT00237575|DRUG|filgrastim|
219326054|NCT01068197|BEHAVIORAL|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
219326055|NCT05008536|BIOLOGICAL|Anti-BCMA CAR-NK Cells|1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion
219326056|NCT05008536|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
219326057|NCT05008536|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
219326058|NCT01628107|BIOLOGICAL|Epoetin Hospira|Intravenous (IV) injection
219326059|NCT01086410|DRUG|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
219326060|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
219326061|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
219326062|NCT01086410|DRUG|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
219326063|NCT01086410|DRUG|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
219326064|NCT02256605|DIETARY_SUPPLEMENT|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
219326065|NCT06319313|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.
219326066|NCT06319313|DRUG|docetaxel|50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.
219326067|NCT06319313|DRUG|HB1801|75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.
219326068|NCT02047682|BEHAVIORAL|Biopsychosocial|
219326069|NCT02047682|BEHAVIORAL|Reference|
219326070|NCT00171444|BEHAVIORAL|Medical education|
219326071|NCT02953639|DRUG|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
219326072|NCT02953639|DRUG|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
219326073|NCT04968041|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
219326074|NCT01956825|DIETARY_SUPPLEMENT|"slim water"|
219326075|NCT03569046|DRUG|local anaesthetic injection|ear block by 0.25% bupivacaine
219326076|NCT03569046|DRUG|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
219326077|NCT03569046|DRUG|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
219326078|NCT03569046|DRUG|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
219326079|NCT03921320|PROCEDURE|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
219326080|NCT03921320|PROCEDURE|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
219326081|NCT03921320|PROCEDURE|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
219326082|NCT01145014|DRUG|BI 660848|2 mg oral drinking solution
219326083|NCT01145014|DRUG|BI 660848|10 mg oral drinking solution
219326084|NCT01145014|DRUG|BI 660848|20 mg oral drinking solution
219326085|NCT01145014|DRUG|BI 660848|50 mg oral drinking solution
219326086|NCT01145014|DRUG|BI 660848|100 mg oral drinking solution
219326087|NCT01145014|DRUG|BI 660848|150 mg oral drinking solution
219326088|NCT01145014|DRUG|BI 660848|200 mg oral drinking solution
219326089|NCT01145014|DRUG|BI 660848|400 mg oral drinking solution
219326090|NCT01145014|DRUG|BI 660848|600 mg oral drinking solution
219326091|NCT01145014|DRUG|BI 660848|10,0 mg immediate release tablet
219326092|NCT01145014|DRUG|BI 660848|50,0 mg immediate release tablet
219326093|NCT01145014|DRUG|Placebo|matching placebo (oral drinking solution and IR tablets)
219326094|NCT04196803|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
219326095|NCT04196803|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
219326096|NCT01386918|DEVICE|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
219326097|NCT01033526|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
219326098|NCT01033526|DRUG|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
219326099|NCT06348550|DIETARY_SUPPLEMENT|Berberol® K|Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®
219326100|NCT06348550|DIETARY_SUPPLEMENT|Placebo|Placebo
219326101|NCT04742881|PROCEDURE|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
219326102|NCT04742881|PROCEDURE|Low pressure + standard instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of standard instruments (5mm and 10mm instruments)
219326103|NCT01022996|DRUG|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
219326104|NCT05990751|BIOLOGICAL|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
219326105|NCT03712748|BEHAVIORAL|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
219326106|NCT03832803|BEHAVIORAL|Empty bladder|No drinking protocol.
219326107|NCT03832803|BEHAVIORAL|Full bladder|Followed drinking protocol
219326108|NCT00453648|OTHER|White-fleshed sweet potatoes|
219326109|NCT00453648|OTHER|Orange-fleshed sweet potatoes (boiled)|
219326110|NCT00453648|OTHER|Orange-fleshed sweet potatoes (fried)|
219326111|NCT00453648|OTHER|WFSP and capsule of retinyl palmitate|
219326112|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
219326113|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
219326114|NCT01377025|DRUG|Placebo|two tablets in the morning and two in the evening.
219326115|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
219326116|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
219326117|NCT05242055|OTHER|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
219355271|NCT02171975|PROCEDURE|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
219326118|NCT05353049|BEHAVIORAL|Bathing technique based on Basale Stimulation|"The relaxing somatic modelling technique will be applied, framed within the concept of Basal Stimulation®. To do this, the user remains seated and the parts of the body that are not being washed at that moment are covered with a towel, favouring the preservation of the user's privacy. The user is lathered up with soft mittens previously moistened with lukewarm water and lathered up. This process shall be carried out starting from the shoulder in a proximal to distal direction on the upper limbs, lower limbs and trunk (taking into account the sagittal anatomical plane) and in a cephalic to caudal direction (taking into account the transverse anatomical plane).~Subsequently, rinsing is carried out following the same guidelines as described above, using moistened soft mittens. Finally, intimate hygiene is performed with a disposable soapy sponge and the soap is rinsed off again with moistened soft terrycloth mittens. Throughout the whole process, the activity is explained to the user."
219326119|NCT05166915|DEVICE|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
219326120|NCT05166915|DEVICE|Sham Control Catheter|Sham Control Device
219326121|NCT00575536|PROCEDURE|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
219326122|NCT03228303|DRUG|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
219326123|NCT03228303|DRUG|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
219326124|NCT03040791|DRUG|Nivolumab|Nivolumab
219326125|NCT02075242|DRUG|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
219326126|NCT02075242|DRUG|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
219326127|NCT03582930|COMBINATION_PRODUCT|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
219326128|NCT02791022|DEVICE|SPYDER ECG sensor|
219326129|NCT01831921|BEHAVIORAL|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
219326130|NCT01831921|BEHAVIORAL|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
219326131|NCT02649049|OTHER|there is no intervention|
219326132|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
219326133|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
219326134|NCT01724840|PROCEDURE|GraftJacket|Interposition with GraftJacket
219326135|NCT01724840|PROCEDURE|Tendon Interposition|Tendon Interposition with the FCR tendon
219326136|NCT01069120|DRUG|Proellex|2, 25 mg capsules once per day
219326137|NCT01069120|DRUG|Proellex|1, 25 mg capsule once per day
219326138|NCT00299052|DEVICE|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
219326139|NCT00299052|BIOLOGICAL|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
219326140|NCT04254588|OTHER|Abdominal examination|Examination by in-person physician vs. remote physician.
219326141|NCT05370716|DRUG|Polmacoxib|Polmacoxib
219326142|NCT05370716|DRUG|Pregabalin|Pregabalin
219326143|NCT06337084|DRUG|MNPR-101-DFO*-89Zr|Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans
219326144|NCT06337084|DIAGNOSTIC_TEST|PET/CT Diagnostic Imaging|PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
219326145|NCT04457076|DRUG|LevoCept|Levonorgestrel-Releasing Intrauterine System
219326146|NCT06459596|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
219326147|NCT04683978|OTHER|Position|Neck extension
219326148|NCT00884325|DRUG|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
219326149|NCT00884325|DRUG|placebo|One tablet taken orally at night for 28 days
219326150|NCT01681134|DRUG|Advagraf®|oral
219326151|NCT01681134|DRUG|Prograf®|oral
219326152|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
219326153|NCT04130633|DRUG|THC|Pure THC vapor
219326154|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
219326155|NCT01817855|DRUG|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
219326156|NCT01817855|DRUG|Placebo to match|Multiple doses inhaled placebo via a nebulizer
219326157|NCT05097716|DRUG|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
219326158|NCT05097716|DRUG|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
219326159|NCT01875536|DEVICE|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
219326160|NCT01875536|BEHAVIORAL|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
219326161|NCT02420132|OTHER|Ranibizumab|Ranibizumab administered as part of standard-of-care
219326162|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
219355272|NCT02171975|PROCEDURE|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
219355273|NCT05599997|DRUG|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
219326163|NCT03305939|BEHAVIORAL|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
219326164|NCT03945591|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
219326165|NCT03945591|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
219326166|NCT01464125|DRUG|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
219326167|NCT01464125|DRUG|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
219326168|NCT05378646|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
219326169|NCT00621231|DIETARY_SUPPLEMENT|Placebo|Placebo
219326170|NCT00621231|DIETARY_SUPPLEMENT|Protein|30 E% from protein
219326171|NCT05798234|DEVICE|high flow oxygen device|no intervention
219326172|NCT00741325|DRUG|granulocyte colony-stimulating factor (G-CSF)|
219326173|NCT00741325|DRUG|plerixafor|
219326174|NCT00741325|DRUG|Placebo|
219355274|NCT05599997|DRUG|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
219326175|NCT04122404|DIAGNOSTIC_TEST|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
219326176|NCT05264818|PROCEDURE|Glycocheck|Assessment of the sublingual microvascularization
219326177|NCT05264818|PROCEDURE|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
219326178|NCT01053299|OTHER|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
219355275|NCT04279015|PROCEDURE|Kinesio tape procedure|"Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application."
219355276|NCT01570673|BEHAVIORAL|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
219355277|NCT01570673|BEHAVIORAL|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
219355278|NCT03112239|DEVICE|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
219355279|NCT06471764|DEVICE|FX+ and 12-Lead ECG Recording|While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.
219355280|NCT06549491|BEHAVIORAL|Sleep Wizard|First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.
219326179|NCT06047847|DIETARY_SUPPLEMENT|TOTUM-448|The study is divided in two phases. The first clinical phase of the project is aimed at determining TOTUM-448's metabolites absorption peak (two galenic forms will be tested: capsules and powder). Then, human circulating metabolites from polyphenols will be quantified and characterized by ultra-high performance liquid chromatography hyphenated with tandem mass spectrometry (UPLC-MS/MS). Once the absorption profile is characterized, volunteers will visit once again the clinical center for the collection of serum fractions either naïve (before ingestion) or enriched (containing circulating metabolites following TOTUM-448 ingestion). The enriched fraction (circulating bioactive collection) will be collected at t-max as characterized in the first phase (absorption profil's peak). Finally, biological activity of TOTUM-448 on human hepatocytes will be studied by comparing naïve serum and serum containing circulating metabolites according to an in vitro protocol.
219326180|NCT00287274|DEVICE|computerized physician order entry|
219326181|NCT05119621|DEVICE|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
219326182|NCT01599910|OTHER|Scribes|Scribe
219326183|NCT02603367|OTHER|Communication Intervention|Undergo communication coaching
219326184|NCT02603367|OTHER|Educational Intervention|Receive COMFORT communication curriculum
219326185|NCT02603367|OTHER|Psychosocial Support for Caregiver|Undergo communication coaching
219326186|NCT02603367|OTHER|Questionnaire Administration|Complete questionnaires
219326187|NCT00058552|DRUG|Pertuzumab (rhuMAb 2C4)|
219326188|NCT04587011|DRUG|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
219326189|NCT04587011|DRUG|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
219326190|NCT04587011|DRUG|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
219326191|NCT04587011|DRUG|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
219326192|NCT04290520|OTHER|bioassay|Serum progesterone level (ng/ml)
219326193|NCT04188795|PROCEDURE|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
219326194|NCT03260634|DRUG|Voriconazole|
219326195|NCT00105716|BEHAVIORAL|Telephone behavioral education|
219326196|NCT00105716|BEHAVIORAL|Computer behavioral education|
219326197|NCT04532216|PROCEDURE|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
219326198|NCT04532216|PROCEDURE|Traditional surgery|Tendon transfer
219326199|NCT02319668|DRUG|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
219326200|NCT02319668|DRUG|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
219355281|NCT01828931|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
219355282|NCT01828931|OTHER|Usual Care|Care as usual
219355283|NCT00457327|PROCEDURE|protective ileostomy|
219355284|NCT05103865|BEHAVIORAL|Animal-assisted therapy (AAT)|
219355285|NCT05103865|OTHER|usual treatment|
219355286|NCT04378608|DRUG|OBV/PTV/r) ± ribavirin (RBV)|
219355287|NCT00280007|DRUG|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
219355288|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
219326201|NCT06240000|PROCEDURE|Radiofrequency ablation|Firstly, the posterior superior iliac spine was showed in the transverse plane, and it was gradually moved proximally until gluteus maximus muscle disappears and gluteus medius arises. Medial branch of the SCN is seen between iliac crest and thoracolumbar fascia as an ovoid structure. Radiofrequency device was utilized with 22-gauge 10-cm, 5 mm RF cannulas for all procedures. Cannula was placed thorough the SCN area and Sensory fiber stimulation was started between 0.3 and 0.5 V. The patient was asked for feedback on symptoms such as numbness, paresthesia or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was given up to 1.5 V and it was checked whether there was any contraction or not. If there is no contraction detected, the SCN was ablated at 42° degrees centigrade for 240 seconds.
219326202|NCT05641870|PROCEDURE|Sample collection|Tumor samples will be collected as standard diagnostic procedure at diagnosis. Plasma samples from whole blood extractions will also be collected at diagnosis, after chemoradiotherapy, and every 3 months from there until completing one year of follow-up.
219326203|NCT05641870|DIAGNOSTIC_TEST|Characterization of the tumoral tissue genomic alterations|Genomic alterations of tumor tissue samples will be analyzed locally by next-generation sequencing when material is adequate, as standard diagnostic procedure.
219326204|NCT05641870|DRUG|Chemoradiation treatment regimen and maintenance (if amenable)|Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
219355289|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
219355290|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
219355291|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
219355292|NCT01230957|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
219326205|NCT05641870|DIAGNOSTIC_TEST|Genomic and methylation analysis in liquid biopsy|"Blood samples for ctDNA genomic and methylation analysis (4 mL of plasma for each sample) will be sent to the Guardant Health Laboratories in the US and analyzed after Contractual Agreement signature, using the Guardant Reveal test.~This liquid biopsy test uses ctDNA to detect presence of MRD and monitor for recurrence after definitive surgical/systemic therapy for patients with cancer. It has been validated in early-stage colorectal cancer and integrates assessment of somatic alterations with an epigenomic cancer signature to identify the presence of methylation signatures associated with cancer versus normal DNA."
219326206|NCT00006254|BIOLOGICAL|salmonella VNP20009|
219326207|NCT03427567|PROCEDURE|Sublobar dissection|Sublobar dissection plus lymphadenectomy
219326208|NCT00461344|DRUG|Docetaxel|
219326209|NCT00461344|DRUG|Doxorubicin|
219326210|NCT02783443|OTHER|General anesthesia|General anesthesia
219326211|NCT02783443|OTHER|Regional anesthesia|Regional anesthesia
219326212|NCT04823572|PROCEDURE|A-PRF/OFD|Comparing healing effect of an autologous and open flap debridement
219326213|NCT02640833|DRUG|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
219326214|NCT02640833|DRUG|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
219355293|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
219355294|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
219355295|NCT02989519|DRUG|dydrogesterone|
219355296|NCT02989519|DRUG|Micronized progesterone|
219355297|NCT01337076|DEVICE|cochlear implant|Cochlear implant surgery
219355298|NCT05042310|DRUG|LY3541860|Administered either IV or SC.
219355299|NCT05042310|DRUG|Placebo|Administered either IV or SC.
219355300|NCT05239520|OTHER|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
219326215|NCT03017638|OTHER|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
219326216|NCT02316340|DRUG|Vorinostat|400mg by mouth daily
219326217|NCT02316340|DRUG|Hydroxychloroquine|600mg by mouth daily
219326218|NCT02316340|DRUG|Regorafenib|160 mg by mouth daily
219326219|NCT01794572|DRUG|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
219326220|NCT01794572|BIOLOGICAL|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
219326221|NCT00859599|DEVICE|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
219326222|NCT00859599|DEVICE|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
219326223|NCT06170138|OTHER|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
219326224|NCT00319280|PROCEDURE|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
219326225|NCT00703001|BEHAVIORAL|Educational Intervention|students in this arm will receive several oral health educational modules in class
219326226|NCT00703001|BEHAVIORAL|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
219326227|NCT01986920|DRUG|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
219326228|NCT01986920|DRUG|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
219326229|NCT01986920|DRUG|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
219326230|NCT01986920|DRUG|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
219326231|NCT02238704|DIETARY_SUPPLEMENT|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
219326232|NCT02238704|DIETARY_SUPPLEMENT|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
219326233|NCT06847269|DRUG|Fludarabine|Given IV
219326234|NCT06847269|DRUG|Cyclophosphamide|Given IV
219326235|NCT06847269|DRUG|Mesna|Given IV
219326236|NCT06847269|BIOLOGICAL|CD19-CAR T cell Infusion|Patients will receive the CD19-CAR T cells by vein, through either an IV or a central line.
219326237|NCT05511428|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
219326238|NCT05511428|OTHER|Questionnaire Administration|Ancillary studies
219326239|NCT05511428|OTHER|Quality-of-Life Assessment|Ancillary studies
219326240|NCT05511428|OTHER|Interview|Ancillary studies
219355301|NCT00717600|DIETARY_SUPPLEMENT|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
219355302|NCT06419140|DRUG|Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation|Motivational counseling to perform nutritional, psychological, and exercise inventions
219326241|NCT02091661|PROCEDURE|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
219326242|NCT02091661|RADIATION|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
219326243|NCT04611165|DRUG|Nivolumab|"* Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~* EBRT begins 2-7 days after the first dose of nivolumab.~* The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
219326244|NCT05218785|DRUG|Botox|75 U in medial gastrocbemius head. x 3
219355303|NCT02050269|DRUG|Iohexol|Iohexol, 300 mg/mL
219326245|NCT06169241|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
219326246|NCT06169241|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
219326247|NCT06218901|DRUG|immunotherapy|
219326248|NCT06218901|DRUG|Targeted Therapy Agent|
219326249|NCT04788264|OTHER|Medical Device Usage and Evaluation|Receive Fitbit
219326250|NCT04788264|OTHER|Consultation|Receive consultation from a physical therapist
219326251|NCT04788264|OTHER|Exercise Intervention|Attend exercise training sessions
219326252|NCT04788264|BEHAVIORAL|Behavioral Intervention|Attend sessions with a behavioral therapist
219326253|NCT04788264|OTHER|Questionnaire Administration|Ancillary studies
219326254|NCT04788264|OTHER|Quality of Life Assessment|Ancillary studies
219355304|NCT03227705|DRUG|Prometrium|Intravaginal use, off label, of Prometrium
219355305|NCT03227705|DEVICE|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
219355306|NCT06488157|OTHER|I-HoME|Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
219355307|NCT01732887|OTHER|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
219355308|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally three times a day
219355309|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally twice a day
219326255|NCT05541263|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
219355310|NCT05818657|BIOLOGICAL|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
219355311|NCT05818657|BIOLOGICAL|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
219326256|NCT06962397|DEVICE|Active Touch-Based Sensory Training|This intervention combines functional electrical stimulation with active tactile exploration of virtual textures. Using a touch-sensitive screen and a programmable functional electrical stimulator (MotionStim 8), participants explore two invisible virtual textures by moving their index finger across the screen. Each time the finger crosses a virtual texture line, an electrical pulse is delivered to the finger, simulating tactile sensation. Participants are asked to compare the density of two virtual textures and select the denser one. The stimulation is synchronized with finger movement to ensure real-time sensory feedback. The training consists of 50 trials divided into 5 blocks, and is designed to enhance tactile discrimination and proprioception through sensorimotor integration. The paradigm is interactive, personalized based on individual sensory thresholds, and aims to promote neural plasticity in stroke survivors.
219326257|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
219326258|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
219326259|NCT03575078|DRUG|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
219326260|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
219326261|NCT05720455|DRUG|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
219326262|NCT04872452|PROCEDURE|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
219326263|NCT03508570|BIOLOGICAL|Ipilimumab|Given i.p.
219326264|NCT03508570|OTHER|Laboratory Biomarker Analysis|Correlative studies
219326265|NCT03508570|BIOLOGICAL|Nivolumab|Given i.p.
219326266|NCT03508570|OTHER|Pharmacokinetic Study|Correlative studies
219326267|NCT01338415|DRUG|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
219326268|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
219326269|NCT05109208|DIAGNOSTIC_TEST|Ulrasound Vibroelastography (UVE)|Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).
219326270|NCT02887690|DEVICE|Modular Prosthetic Limb|
219326271|NCT05755074|PROCEDURE|Ablation through left arm|Ablation through left arm
219326272|NCT05755074|PROCEDURE|Ablation through femoral vein|Ablation through femoral vein
219326273|NCT04235023|OTHER|myeloid PTP1B expression analysis|peripheral blood macrophage PTP1B expression
219326274|NCT04092972|OTHER|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
219326275|NCT04092972|OTHER|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
219326276|NCT02150499|DRUG|levalbuterol tartrate HFA inhalation aerosol|
219326277|NCT02150499|DRUG|placebo|
219326278|NCT03990857|OTHER|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
219326279|NCT02087072|OTHER|Collaborative visit with provider and pharmacist|
219326280|NCT00139646|DRUG|Parecoxib|
219326281|NCT00139646|DRUG|Diclofenac|
219326282|NCT03480412|PROCEDURE|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
219326283|NCT03480412|PROCEDURE|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
219326284|NCT00866749|DRUG|Daunorubicin|Starting Dose 25 mg/m\^2 by vein weekly
219326285|NCT00866749|DRUG|Vincristine|Starting Dose 2 mg by vein weekly
219326286|NCT00866749|DRUG|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
219326287|NCT00866749|DRUG|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
219326288|NCT00866749|DRUG|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
219326289|NCT00866749|DRUG|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
219326290|NCT00866749|DRUG|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
219326291|NCT00866749|DRUG|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
219326292|NCT00866749|DRUG|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
219326293|NCT00866749|DRUG|Thioguanine|60 mg/m2 by mouth daily for two weeks
219326294|NCT04880447|BIOLOGICAL|BNT162b2|COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
219326295|NCT03877107|DIAGNOSTIC_TEST|Urinary symptoms profile questionnaire|Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
219326296|NCT03877107|DIAGNOSTIC_TEST|Micturition calendar|Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
219326297|NCT02126449|OTHER|Fasting mimicking diet|
219326298|NCT03659279|BEHAVIORAL|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
219326299|NCT03184324|DRUG|DWP14012|tablet
219326300|NCT03184324|DRUG|Esomeprazole|tablet
219326301|NCT03184324|DRUG|DWP14012 placebo|tablet
219326302|NCT03184324|DRUG|Esomeprazole placebo|tablet
219326303|NCT00432536|OTHER|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
219326304|NCT02952040|DRUG|ASP1517|Oral dose
219326305|NCT02952040|DRUG|Lanthanum carbonate hydrate|Oral dose
219326306|NCT01970488|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
219326307|NCT01970488|BIOLOGICAL|ABP 501|Administered by subcutaneous injection
219326308|NCT02486653|DRUG|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
219326309|NCT02486653|DRUG|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
219326310|NCT01504490|DRUG|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
219326311|NCT03244410|DIAGNOSTIC_TEST|complete blood picture|complete blood picture
219326312|NCT00497783|DRUG|Lactoserum|
219326313|NCT05362383|DEVICE|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
219326314|NCT04495855|DRUG|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
219326315|NCT02365753|DEVICE|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
219326316|NCT01177384|DRUG|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
219326317|NCT01177384|DRUG|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
219326318|NCT01177384|DRUG|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
219326319|NCT01177384|DRUG|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
219326320|NCT01672034|PROCEDURE|Laparoscopic gastric bypass surgery|
219326321|NCT04435379|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
219326322|NCT04435379|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
219326323|NCT03641495|OTHER|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
219326324|NCT03641495|OTHER|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
219326325|NCT04869163|OTHER|Non-red meat|Red meat analogues and alternatives
219326326|NCT03525535|OTHER|data collection|data from patient included will be collected during the study
219326327|NCT00579683|OTHER|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
219326328|NCT01845454|DEVICE|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
219326329|NCT00797836|PROCEDURE|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods"
219326330|NCT04654520|OTHER|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
219326331|NCT01849497|BIOLOGICAL|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
219326332|NCT01849497|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
219326333|NCT04048980|BEHAVIORAL|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
219326334|NCT00951301|DRUG|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
219326335|NCT00951301|DRUG|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
219326336|NCT02897232|OTHER|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
219326337|NCT01398865|PROCEDURE|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
219326338|NCT04841512|BIOLOGICAL|XT-150|non-viral Plasmid DNA encoding an IL-10 variant transgene
219326339|NCT01091688|BEHAVIORAL|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
219326340|NCT02560363|DRUG|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
219326341|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
219326342|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
219326343|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
219326344|NCT01442116|PROCEDURE|stress echocardiography|safety and efficacy of stress echocardiography
219326345|NCT02830763|DIETARY_SUPPLEMENT|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
219326346|NCT00771004|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
219326347|NCT00771004|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
219326348|NCT06290063|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
219326349|NCT06290063|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
219326350|NCT06290063|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
219326351|NCT01514136|DEVICE|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
219326352|NCT00502489|PROCEDURE|Closed-loop sytem for5 weaning from mechanical ventilation|
219326353|NCT05692856|DRUG|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
219326354|NCT05692856|DRUG|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
219326355|NCT02486809|DRUG|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
219326356|NCT05261035|BEHAVIORAL|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos \& pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
219326357|NCT05261035|OTHER|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
219326358|NCT03139708|DRUG|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
219326359|NCT03139708|DRUG|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
219326360|NCT03139708|DRUG|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
219326361|NCT02770443|DRUG|withdrawal|withdrawal of beta blocker and ACE inhibitors
219326362|NCT02770443|DRUG|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
219326363|NCT05125289|OTHER|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
219326364|NCT05125289|OTHER|Active release technique group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~ART steps:~* Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~* Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~* Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
219326365|NCT05125289|OTHER|Proprioceptive Neuromuscular Facilitation stretching group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~PNF technique steps:~* The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~* The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~* Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~* This sequence is repeated 5 times at a 20 second interval."
219326366|NCT02451579|DRUG|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
219326367|NCT02451579|OTHER|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
219326368|NCT01827579|BIOLOGICAL|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
219326369|NCT00809419|DEVICE|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
219326370|NCT05902078|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
219326371|NCT05902078|DRUG|Calcitriol capsules|Oral calcitriol 0.5μg daily
219326372|NCT01852604|DRUG|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
219326373|NCT01852604|DRUG|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
219326374|NCT01852604|DRUG|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
219326375|NCT01852604|DRUG|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
219326376|NCT01852604|DRUG|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
219326377|NCT01852604|BIOLOGICAL|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
219326378|NCT01852604|OTHER|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
219326379|NCT02941926|DRUG|Ribociclib|Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
219326380|NCT02941926|DRUG|Letrozole|Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
219326381|NCT02941926|DRUG|Goserelin|Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
219326382|NCT02941926|DRUG|Leuprolide|Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
219326383|NCT03126526|BEHAVIORAL|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
219326384|NCT03126526|BEHAVIORAL|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
219326385|NCT03126526|BEHAVIORAL|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
219326386|NCT02729740|DEVICE|Penumbra Smart Coil|
219326387|NCT02729740|DEVICE|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
219326388|NCT03217942|DRUG|NGF|Intramuscular injection
219326389|NCT00307333|DEVICE|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
219326390|NCT02537938|DRUG|NGP 555|
219326391|NCT00531882|DRUG|Pioglitazone|30 mg once a day
219326392|NCT00531882|DRUG|Simvastatin|40 mg once a day
219326393|NCT00531882|DRUG|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
219326394|NCT04195035|DEVICE|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.
219326395|NCT04195035|DEVICE|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.
219326396|NCT02768233|BEHAVIORAL|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
219326397|NCT02319291|DEVICE|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
219326398|NCT01318720|OTHER|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
219326399|NCT06469099|OTHER|excercises|exercises for strength and balance
219326400|NCT05646212|OTHER|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
219326401|NCT05646212|OTHER|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
219326402|NCT00601705|DRUG|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
219326403|NCT00601705|DRUG|epirubicin hydrochloride|50 mg/m2 IV bolus
219326404|NCT00601705|DRUG|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
219326405|NCT00601705|DRUG|oxaliplatin|130 mg/m2 IV infusion over 2 hours
219326406|NCT00601705|PROCEDURE|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
219326407|NCT00601705|PROCEDURE|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
219326408|NCT06131333|PROCEDURE|Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation|PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
219326409|NCT03812484|BEHAVIORAL|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
219326410|NCT03812484|BEHAVIORAL|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
219326411|NCT00978835|BEHAVIORAL|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
219326412|NCT00978835|BEHAVIORAL|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
219326413|NCT05017220|OTHER|Nature-based sensory stimuli|A program based on stimulation using nature-based sensory stimuli will be implemented
219326414|NCT05017220|OTHER|Control group intervention|An activity based on a placebo intervention will be implemented
219326415|NCT03254654|DRUG|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
219326416|NCT03254654|DRUG|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
219326417|NCT00077051|DRUG|cisplatin|
219326418|NCT00077051|DRUG|cytochlor|
219326419|NCT00077051|DRUG|tetrahydrouridine|
219326420|NCT00077051|RADIATION|radiation therapy|
219326421|NCT00474734|DEVICE|Intravascular ultrasound of the liver|
219326422|NCT02800070|BIOLOGICAL|Lentivirus Alpha-gal A transduced stem cells|
219326423|NCT02018198|DIAGNOSTIC_TEST|FebriDx|Point of Care Host Immune Response Test
219326424|NCT03197857|BEHAVIORAL|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
219326425|NCT03197857|BEHAVIORAL|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
219326426|NCT03197857|BEHAVIORAL|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
219326427|NCT03197857|BEHAVIORAL|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
219326428|NCT03908320|OTHER|Menstrual Cycle Timing|Quit date is set to menstrual phase.
219326429|NCT03908320|OTHER|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
219326430|NCT03908320|DRUG|NRT Patch|NRT patch is provided
219326431|NCT03908320|BEHAVIORAL|Cessation Counseling|Cessation counseling is provided
219326432|NCT06491082|DRUG|Cisplatin, Carboplatin, Paclitaxel, Docetaxel|Solid cancer Patients receiving any one drug or in combination
219326433|NCT02431897|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
219326434|NCT02431897|DRUG|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
219326435|NCT00560742|PROCEDURE|Control|Coronary artery bypass grafting without bone marrow cells injection
219326436|NCT00560742|PROCEDURE|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
219326437|NCT00560742|PROCEDURE|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
219326438|NCT01758458|BIOLOGICAL|Aldesleukin|Given SC
219326439|NCT01758458|OTHER|Laboratory Biomarker Analysis|Correlative studies
219326440|NCT01758458|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
219326441|NCT01758458|RADIATION|Radiation Therapy|Undergo radiation therapy
219326442|NCT01758458|BIOLOGICAL|Recombinant Interferon Beta|Given intralesionally
219326443|NCT05380011|OTHER|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
219326444|NCT05380011|OTHER|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
219326445|NCT05296642|OTHER|Moderate Cycling|Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
219326446|NCT05296642|OTHER|Personalized Tourniquet System|An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
219326447|NCT02369107|OTHER|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
219326448|NCT02369107|OTHER|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
219326449|NCT01621542|BIOLOGICAL|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
219326450|NCT04533087|OTHER|No intervention|No intervention
219326451|NCT00279019|DRUG|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
219326452|NCT00279019|DRUG|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
219326453|NCT00279019|DRUG|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
219326454|NCT04057534|BEHAVIORAL|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
219326455|NCT04057534|BEHAVIORAL|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
219326456|NCT04057534|BEHAVIORAL|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
219326457|NCT04057534|BEHAVIORAL|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
219326458|NCT00110981|DEVICE|NB-UVB|Three times a week (TIW) for 12 weeks
219326459|NCT00110981|DRUG|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
219326460|NCT00110981|DRUG|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
219326461|NCT03201913|DRUG|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
219326462|NCT05016206|DRUG|Danicopan|Danicopan tablets administered as a single oral dose.
219326463|NCT05016206|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo was administered as a single oral dose.
219326464|NCT05016206|DRUG|Danicopan-matching placebo|Danicopan-matching placebo was administered as a single oral dose.
219326465|NCT05016206|DRUG|Moxifloxacin|Moxifloxacin 400 mg was administered as a single tablet oral dose.
219326466|NCT03694613|OTHER|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
219326467|NCT02221349|DEVICE|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
219326468|NCT02221349|DRUG|Sodium fluoride paste|Toothpaste used by subject
219326469|NCT02221349|DRUG|Stannous fluoride paste|Toothpaste used by subject
219326470|NCT02632721|DRUG|Decitabine|
219326471|NCT02632721|DRUG|BI 836858|
219326472|NCT05380258|OTHER|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
219326473|NCT05380258|OTHER|chewing gum|Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
219326474|NCT05997433|PROCEDURE|7days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days
219326475|NCT05997433|PROCEDURE|14 days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days
219326476|NCT02694770|BIOLOGICAL|Neihulizumab Treatment|Monoclonal antibody
219326477|NCT02694770|BIOLOGICAL|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
219326478|NCT00544648|DRUG|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
219326479|NCT00544648|DRUG|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
219326480|NCT00544648|RADIATION|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
219326481|NCT00003784|DRUG|CHOP regimen|
219326482|NCT00003784|DRUG|cyclophosphamide|
219326483|NCT00003784|DRUG|doxorubicin hydrochloride|
219326484|NCT00003784|DRUG|prednisone|
219326485|NCT00003784|DRUG|vincristine sulfate|
219326486|NCT00003784|RADIATION|tositumomab and iodine I 131 tositumomab|
219326487|NCT02663271|DRUG|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
219326488|NCT02663271|DEVICE|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
219326489|NCT02663271|OTHER|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
219326490|NCT02663271|OTHER|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
219326491|NCT05950295|OTHER|Intranasal lavage with hypochlorous acid solution|intranasal lavage for ten days
219326492|NCT05529849|DRUG|TCMCB07|Subcutaneous injection of TCMCB07
219326493|NCT05529849|DRUG|Placebo|Matching subcutaneous placebo
219326494|NCT05788744|DIAGNOSTIC_TEST|ctDNA|ctDNA guided surveillance
219326495|NCT05798130|OTHER|No intervention group.|No intervention group.
219326496|NCT04204187|BEHAVIORAL|service learning|service learning for university students
219326497|NCT02832700|DIETARY_SUPPLEMENT|Casein glycomacropeptide|
219326498|NCT02832700|DIETARY_SUPPLEMENT|Placebo|
219326499|NCT04437160|DRUG|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
219326500|NCT04437160|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
219326501|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
219326502|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
219326503|NCT00106522|DRUG|Methotrexate|10-25mg weekly
219326504|NCT00106522|DRUG|Placebo|iv every 4 weeks
219326505|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
219326506|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
219326507|NCT01692691|DRUG|Dacarbazine|Dacarbazine IV - Day 1
219326508|NCT01692691|DRUG|Carmustine|Carmustine IV- Day 2
219326509|NCT01692691|DRUG|Neulasta|Neulasta SC - Day 3
219326510|NCT03200964|OTHER|anesthesia given as required for surgical procedure|
219326511|NCT03346057|DRUG|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
219326512|NCT03346057|DRUG|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
219326513|NCT03346057|DRUG|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
219326514|NCT03346057|DRUG|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
219326515|NCT03346057|DRUG|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
219326516|NCT03346057|DRUG|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
219326517|NCT04836663|DRUG|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
219326518|NCT06323122|DEVICE|2.0 miniplates|2.0 miniplates
219326519|NCT06323122|DEVICE|2.3 high profile miniplates|2.3 high profile miniplates
219326520|NCT06323122|DEVICE|3D miniplates|3D miniplates
219326521|NCT03692572|DIETARY_SUPPLEMENT|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
219326522|NCT03692572|DIETARY_SUPPLEMENT|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
219326523|NCT05001451|BIOLOGICAL|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
219326524|NCT04645771|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
219326525|NCT06026683|DEVICE|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
219326526|NCT00916630|DRUG|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
219326527|NCT04998487|DRUG|LY3471851|Administered SC.
219326528|NCT01387919|BEHAVIORAL|Prolonged fasting|48 hours of fasting
219326529|NCT02210377|OTHER|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
219326530|NCT02210377|OTHER|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
219326531|NCT03920722|DRUG|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
219326532|NCT03920722|DRUG|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
219326533|NCT00248846|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
219326534|NCT05426759|DEVICE|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
219326535|NCT05073887|PROCEDURE|Current Targets|blockade and radio frequency stimulation of genicular nerves
219326536|NCT03697434|BEHAVIORAL|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
219326537|NCT02456662|DRUG|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
219326538|NCT02456662|DRUG|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
219326539|NCT00724295|DRUG|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
219326540|NCT00724295|DRUG|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
219326541|NCT00732251|DRUG|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
219326542|NCT00521053|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
219326543|NCT06328998|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
219326544|NCT06328998|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
219326545|NCT06328998|DRUG|Lidocaine Hydrochloride|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
219326546|NCT04243603|BEHAVIORAL|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
219326547|NCT03511404|OTHER|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
219326548|NCT00351416|DRUG|Letrozole|Letrozole 20 mg orally one time
219326549|NCT00351416|DRUG|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
219326550|NCT03663881|DRUG|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
219326551|NCT01353079|BIOLOGICAL|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
219326552|NCT01353079|BIOLOGICAL|Placebo|Placebo: Glycero-COCAs sublingual
219326553|NCT03772470|OTHER|1X airtime incentive|An incentive given in the form of airtime
219326554|NCT03772470|OTHER|2X airtime incentive|An incentive given in the form of airtime
219326555|NCT03772470|OTHER|Lottery airtime incentive|An incentive given in the form of airtime
219326556|NCT02803853|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
219326557|NCT03519867|DRUG|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
219326558|NCT03519867|DRUG|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
219326559|NCT03653221|OTHER|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
219326560|NCT03653221|OTHER|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
219326561|NCT06083831|OTHER|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
219326562|NCT05419401|DRUG|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
219326563|NCT05419401|DRUG|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
219326564|NCT05551767|DRUG|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
219326565|NCT02347488|DEVICE|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
219326566|NCT02347488|PROCEDURE|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
219326567|NCT02693522|DRUG|somatropin|Subcutaneous injection
219326568|NCT02693522|DRUG|Eutropin|Subcutaneous injection
219326569|NCT05723354|PROCEDURE|axillary block guided by ultrasound|axillary block using local anesthetics
219326570|NCT04796922|DRUG|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
219326571|NCT04796922|DRUG|rituximab|rituximab will be administered intravenously on select days as per protocol.
219326572|NCT04796922|DRUG|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
219326573|NCT04582981|DRUG|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
219326574|NCT04582981|DRUG|Fruquintinib|Fruquintinib 5mg qd monotherapy
219326575|NCT00660270|PROCEDURE|Pancreatic Surgery|
219326576|NCT00660270|RADIATION|Radiation therapy|
219326577|NCT00660270|DRUG|Cisplatin|
219326578|NCT00660270|DRUG|5-FU|
219326579|NCT00660270|DRUG|Alpha-interferon|
219326580|NCT00660270|DRUG|Gemcitabine|
219326581|NCT03007979|DRUG|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
219326582|NCT03007979|DRUG|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
219326583|NCT03007979|DRUG|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
219326584|NCT03007979|PROCEDURE|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
219326585|NCT03007979|DRUG|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
219326586|NCT03007979|PROCEDURE|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression"
219326587|NCT03007979|PROCEDURE|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
219326588|NCT03007979|PROCEDURE|Tumor biopsy (optional)|-Baseline and progression
219326589|NCT05565846|COMBINATION_PRODUCT|NTX-001|One-time use surgical product of three solutions and a device
219326590|NCT01553877|DIETARY_SUPPLEMENT|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
219326591|NCT01553877|DIETARY_SUPPLEMENT|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
219326592|NCT01553877|DIETARY_SUPPLEMENT|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
219326593|NCT01428661|DRUG|tasimelteon|20 mg once daily
219326594|NCT01428661|DRUG|placebo|once daily
219326595|NCT01387165|DRUG|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
219326596|NCT02927418|BEHAVIORAL|Strength & Conditioning|
219326597|NCT02927418|BEHAVIORAL|Control|
219326598|NCT07128849|OTHER|upper limb exercise with arm ergometer|upper limb exercise on arm ergometer lasting 5 min at 30 rpm (Rotation per minute) 3 times a day for 7 days and standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
219326599|NCT07128849|OTHER|upper limb exercise with out arm ergometer|standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
219326600|NCT05336253|BEHAVIORAL|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
219326601|NCT05336253|BEHAVIORAL|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
219326602|NCT04631796|DEVICE|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
219326603|NCT04631796|DEVICE|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
219326604|NCT07129538|OTHER|inspiratory muscle retraining|Familial mediterranean fever (FMF adolescents ) will be inspiratory muscle retraining group (IMR group) that will contain 20 FMF adolescents. IMR group will receive two IMR sessions daily, five times weekly, for eight weeks (every IMR session will contain 3 sets of IMR and the set will contain 10 breath cycles).. this group will receive their prescribed colchicine medications daily
219326605|NCT07129538|OTHER|colchicine only|Familial mediterranean fever (FMF adolescents ) will be collected in this group OF FMF that will contain 20 FMF adolescents. this group will receive their prescribed colchicine medications daily for eight weeks
219326606|NCT07130643|DRUG|CDK4/6 inhibitors+Endocrine Therapy|CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib
219326607|NCT07032818|OTHER|Additional post discharge phone call|24-72 hours after hospital discharge, a nurse will call participants to review the written After Visit Summary (AVS) given at discharge, including primary diagnosis, self-care instructions, emergency plan, medication changes, how and why to take medication, and scheduled follow up. These phone calls will take on average 10-15 minutes.
219326608|NCT06736613|DIAGNOSTIC_TEST|Cerebral Spinal Fluid ctDNA|MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
219326609|NCT06885294|BEHAVIORAL|Physiotherapy|Stroke patients will be randomly assigned to join one of the three groups. The first group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
219326610|NCT06885294|BEHAVIORAL|Physiotherapy and Hypnosis|Stroke patients will be randomly assigned to join one of the three groups. The second group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. Patients will continue their standard physiotherapy care during these 4 weeks. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
219326611|NCT06885294|BEHAVIORAL|Control group Physiotherapy and Hypnosis|The control group will be assessed initially and then after 4 weeks. After the second assessment, they will receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. All evaluation sessions will last approximately 1 hour.
219326612|NCT06749444|OTHER|CBT-I|Cognitive therapy tailored for insomnia symptoms.
219326613|NCT06749444|OTHER|CBT|Cognitive behavioral therapy for general psychopathology
219326614|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate consumption (Ilex paraguayensis) A|Yerba mate of the begining of the harvest time
219326615|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate comsuption (ilex paraguayencis) B|Yerba mate of the final time of the harvest
219326616|NCT05228067|DEVICE|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
219326617|NCT05228067|DEVICE|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
219326618|NCT05228067|DEVICE|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
219326619|NCT04223791|DRUG|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
219326620|NCT04223791|DRUG|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
219326621|NCT04223791|DRUG|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
219326622|NCT04223791|DRUG|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
219326623|NCT06773364|DRUG|Levetiracetam|Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH
219326624|NCT06773364|OTHER|Guide-recommended management|To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.
219326625|NCT06773364|OTHER|The lying flat (0°) head position|Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.
219326626|NCT06773364|OTHER|The sitting-up (≥30°) head position|Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.
219326627|NCT07066345|DEVICE|My Pelvic Plan|My Pelvic Plan is comprised of a self-guided program that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring techniques that can help to manage chronic pelvic pain symptoms.
219326628|NCT07066345|BEHAVIORAL|Bend|Bend is a highly rated physical activity application that helps guide users through gentle stretching and yoga poses.
219326629|NCT06897488|RADIATION|Adjuvant Radiotherapy|Participants will receive treatment following Lumpectomy
219326630|NCT05610735|DRUG|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
219326631|NCT05610735|DRUG|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
219326632|NCT05610735|DRUG|Ashwagandha|Administered orally on daily basis twice a day
219326633|NCT05610735|DRUG|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
219326634|NCT06900348|DIAGNOSTIC_TEST|PSA-Activated PSA-PAH1|Intravenous blood sample
219326635|NCT03910621|DRUG|Miglustat|capsule, oral use
219326636|NCT06895707|OTHER|BioFlx crown|NuSmile® BioFlx crown (Group A) will be placed on primary lower second molar.
219326637|NCT06895707|OTHER|Zirconia crown|Zirconia crown (Group B) will be placed on the contralateral primary lower second molar.
219326638|NCT07128420|DEVICE|Application of 3 sessions of microneedle therapy|"Enrolled study participants will receive 3-4 treatments of microneedling to the affected area.~Study participants will microneedling (Fusion Tip Potenza Fractional Radiofrequency Microneedle Electrosurgical Unit, Jeisys Medical Inc, Seoul, KR) at a depth of 2.0 to 2.75mm."
219326639|NCT06771817|BEHAVIORAL|Written Exposure Therapy|WET may be an optimal treatment for pregnant or postpartum adolescents and youth with PTSD in a low resource setting. WET addresses many of the barriers above. It is delivered in just 5 sessions, with no homework, and may promote a sense of self-efficacy in adolescents and youth due to the nature of writing assignments and brief therapist involvement. It is attractive in resource-poor settings because just 10-15 min of direct therapist time per follow-up session is needed.
219326640|NCT07083479|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 (10.0 mg) admixed with ELI-002 Amph-Peptides 7P (4.9 mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing).
219326641|NCT06902974|DRUG|Psilocybin 25 mg|Single dose, 25mg psilocybin, encapsulated, oral administration
219326642|NCT06902025|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 15 years.
219326643|NCT06901804|DIAGNOSTIC_TEST|Experimental Group (training and stabilization)|"Plyometric Shoulder Training \[28\] and Pilates Core Stabilization \[27\]~Exercise 1-2 weeks (rep × kg) 3-4 weeks (rep × kg) 5-6 weeks (rep × kg) Throwing Movements Medicine ball chest pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball step and pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball side throw 8 × 1 kg 10 × 2 kg 12 × 3 kg Tubing Plyos IR/ER 8 × 10 10 × 10 12 × 12 Tubing Plyos Diagonal 8 × 10 10 × 10 12 × 12 Tubing Plyos Biceps 8 × 10 10 × 10 12 × 12 Plyo Push-ups (boxes) 8 × 10 10 × 10 12 × 12 Push-ups (clappers) 8 × 10 10 × 10 12 × 12"
219326644|NCT06901804|COMBINATION_PRODUCT|Control Group (physiotherapy and exercise)|Physiotherapy Care for Low Back Pain \[30\] Exercise Week 1-2 (Sets x Reps/Duration) Week 3-4 (Sets x Reps/Duration) Week 5-6 (Sets x Reps/Duration) Plank 3 x 20 sec 3 x 30 sec 4 x 45 sec Bicycle Crunches 3 x 12 3 x 15 4 x 20-25 Leg Raises 3 x 12 3 x 15 4 x 20-25 Russian Twists 3 x 20 3 x 25 4 x 30-35 Slump Exercise 3 x 10 3 x 12 4 x 15-18 Bridge Exercise with Swiss Ball 3 x 12 3 x 15 4 x 18
219326645|NCT06902649|BEHAVIORAL|Internet-based parenting support|An internet-based parent training program with 5 active modules and a final summarizing module, based on social learning theory/cognitive behavior therapy. All parents participate in this intervention (Step 1) before being randomized to the other three arms of the stepped care model in the randomized controlled trial (Step 2).
219326646|NCT06902649|BEHAVIORAL|"YourSkills for children/youth"|Cognitive behavioral therapy for children/youth with role-plays in virtual reality. A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
219326647|NCT06902649|BEHAVIORAL|Step-by-step parent support|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), including some sessions where virtual reality may be used for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality can be used as an additional way to practice skills.
219326648|NCT06902649|BEHAVIORAL|Intervention/support as usual and prolonged use of internet-based parenting support|Based on other available support, interventions, courses at the units. Parents have access to the internet-based parenting support provided in Step 1 (the first intervention of the study). After 10 weeks with intervention/support as usual, the parents are asked if they want to participate in the CBT-VR-intervention for children (YourSkills) or for parents (Step-by-Step parent support).
219326649|NCT06903325|OTHER|As an observational study, we did not intervene|Interventions
219326650|NCT06902623|RADIATION|Radiation|Radiation only to 66Gy
219326651|NCT06901479|OTHER|Blood was drawn for proteomics testing and Magnetic Resonance Imaging.|The function of the glymphatic system was assessed by MRI before the surgery. Blood was drawn before the surgery. Delirium was assessed on postoperative days 1 to 5. Blood was drawn on the second day after surgery. The function of the glymphatic system was assessed again by MRI on the fifth day after surgery.
219326652|NCT06895109|OTHER|improvement of cognitive functions and psychological aspects|To analyze the neuropsychological, motor and functional profile of a sample of patients with severe acquired brain injury, who underwent craniotomy and subsequent opercular reapposition surgery
219326653|NCT06901609|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.
219326654|NCT06902870|OTHER|Scenario-Based Online Simulation Training Program|"Classroom-Based Teaching and Online Simulation-Assisted Instruction~Classroom-Based Instruction:~Participants were provided with a QR code to access the Moodle platform and download the electronic course materials.~The classroom instruction covered the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Care I Decide! Online Simulation-Assisted Teaching:~A detailed explanation of the operational process for the Care I Decide! online simulation-assisted teaching materials was provided.~The session integrated classroom knowledge with the Care I Decide! online simulation. It presented clinical scenarios involving changes in vital signs and symptoms of chest trauma patients, guiding participants through clinical decision-making processes."
219355312|NCT03959722|DIETARY_SUPPLEMENT|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
219326655|NCT06902870|OTHER|Classroom-Based Teaching|"Classroom-Based Teaching~Delivery of Course Materials:~Participants were provided with a QR code to access the Moodle platform, where they could download the electronic course handouts.~Classroom Instruction Content:~The classroom teaching session included the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Chest Trauma Case Sharing~Case Presentation and Reflection:~Clinical cases involving chest trauma were presented to participants. They were guided to describe the case details, reflect on the management process, and receive constructive feedback.~Discussion and Problem Solving:~During the discussion, questions and uncertainties raised by participants were addressed to enhance understanding and clarify key concepts."
219326656|NCT06808932|DRUG|VK4-116|D3R antagonist
219326657|NCT06808932|DRUG|Placebo|Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.
219326658|NCT06902987|DRUG|Upadacitinib|Enrolled patients received oral upatinib treatment with a conventional induction dose of 45mg/d for 12 weeks, followed by a maintenance dose of 15m/d or 30mg/d
219326659|NCT06902259|OTHER|randomised controlled trial|"Breathing exercise group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group.~Reiki group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group."
219326660|NCT05124080|DRUG|Deucravacitinib|All participants will receive 6 mg of Deucravacitinib daily.
219326661|NCT06660342|DRUG|Vonoprazan|Oral tablet.
219326662|NCT06901934|OTHER|junctional adhesion molecule3 expression by immunhistochemistry|"* Data record of patient will be reviewed for the following:~* Clinical features:~* Age~* Performance status~* Risk factors(smoking,stones or bilharziasis)~* Comorbidities~* Family history~* Pathological features:~* Histological subtype~* Grade~* Muscle invasion~* Carcinoma in situ~* Immunohistochemistry(IHC):~JAM3 expression by IHC~* TNM staging~* Number of chemotherapy cycles received~* Radical surgery or~* CCRT and type of concurrent~* Post treatment histological response~* . Follow-Up and Survival Analysis:~* During treatment: Monitoring for adverse events of chemotherapy and clinical response.~* After treatment: Imaging and clinical examination every 3 months for 2 years.~* Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS).."
219326663|NCT06618807|DEVICE|Active tPBM device|The Neuro RX Gamma (version 2) delivers a synchronized pulse frequency of 40 Hz from all LED clusters. The gamma pulse frequency of 40 Hz has been demonstrated to attenuate amyloid beta proteins production in the hippocampus and modulate microglial activity resulting in increased scavenging of amyloid beta which may lead to improving cognition in MCI. Finally, the Vielight Neuro RX Gamma (version 2) has been designed to target the delivery of NIR energy to particular brain regions; specifically the default mode network (DMN). The active intervention device proceeds to deliver light to each LED at 40 Hz with a 50% duty cycle for 20 minutes and stops automatically. During the 20 minute treatment the power indicator LED on the controller flashes green at 40 Hz. The operator is notified that the treatment is finished when the power indicator LED on the controller stops flashing and the device beeps 2 times.
219326664|NCT06618807|DEVICE|Sham device|The sham device delivers infrared light for only a few seconds before stopping. The controller will still show a green light to maintain the study\&#39;s blinding. If the headset is removed, the device will emit a beep and cease functioning.
219326665|NCT06927206|OTHER|Experimental Group A: Segmental vibrator only on dorsiflexor|"Segmental vibrator only on dorsiflexor:~After standard physiotherapy session this group received the intervention of segmental vibration. Tibialis anterior muscle targeted for dorsiflexor. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
219326666|NCT06927206|OTHER|Experimental Group B: Segmental vibrator + Electrical stimulation on dorsiflexors|"Segmental vibrator + Electrical stimulation on dorsiflexors:~After standard physiotherapy session this group received the intervention of neuromuscular electrical stimulations by means of EMS. Two electrodes were used for this procedure. Tibialis anterior muscle targeted for dorsiflexor. One pad of electrode was placed on anterior of lower leg just below tibial tuberisty and other was 5cm below to it .With a 250-microsecond pulse duration, the EMS device was set up to provide a biphasic current with a symmetrical waveform at 50 Hz for 15 seconds. It was also tuned for a 3-second ramp up time and a 30-second rest period. Each respondent set the intensity to the highest level they could tolerate. Secondly, segmental vibrator was applied for focal vibrations on tibialis anterior. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
219326667|NCT06902363|DEVICE|Macroduct Advanced|Sweat stimulation and collection using the Macroduct Advanced system on two anatomical sites (forearm and thigh) in infants under 6 months of age.
219326668|NCT06827171|COMBINATION_PRODUCT|aerobic exercise + low-level laser therapy|low- level laser parameters: The wavelength: 808 +/- 5nm The power: output is 450 Mw Type of beam: red laser beam. Beam Divergent \>,025 rad+/- ,005rad Nominal Distance of Sight hazard \>8m The duration: is 20 min for each artery. Treatment period: 3 times/week for 3 months.
219326669|NCT06827171|OTHER|Aerobic exercise|Aerobic exercise Frequency = 3sessions/week duration: 10 min warm up and 10 min cool down/ 30 min stance phase Intensity: moderate intensity initiating with 50% HR max to end 75% HR max
219326670|NCT07102264|DEVICE|CPMX1|Compressibility of thyroid nodules using CPMX1 during pre surgery planning visit
219326671|NCT07111013|DRUG|Lifitegrast/perfluorohexyloctane (PFHO)|fixed-dose combination (FDC) (5%/95%)
219326672|NCT07121166|BEHAVIORAL|tgCBFI programme|a six-week online group intervention programme for dyads of service users and caregivers
219326673|NCT07121166|BEHAVIORAL|Treatment as Usual (TAU)|Integrated community psychiatric care with psychiatric outpatient follow-up
219326674|NCT07123064|BEHAVIORAL|Individual Level|A 8-weekly, 1hour telephone-delivered sessions using mindfulness and SOLUS-D program. Key contents include: introduction to mindfulness - Body awareness and present moment experiences, emotional awareness and mind-body labeling, relaxation techniques and sensory discrimination, deepening awareness and accepting feelings, personal values, interconnection between thought patterns and emotions, identifying and analyzing of thought traps, and challenging thoughts and future planning. Booster sessions which focus on embedding mindfulness practices and SOLUS-D program among older adults as a persistent habit will be conducted.
219355313|NCT03959722|DIETARY_SUPPLEMENT|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
219326675|NCT07123064|BEHAVIORAL|Interpersonal Level|A 8 weekly, 1hr sessions through telephone or Zoom using the Group 4 Health and community navigator prgram. Key contents include: understanding the benefits of social connections, exploring self and community, community and action, support and breakthrough, summary and moving forward. Booster sessions which focus on continuous practice of support and community will be conducted.
219326676|NCT07123064|BEHAVIORAL|Community Level|A 4 weekly, 2hour in-person sessions through (1) strengthening collective efficacy via neighbor identification with the community. Key contents include: building neighbourhood connections, getting to know each other, health aging, neighbourhood care, vibrant exploration, thriving community, connecting the dots.
219355314|NCT03167073|OTHER|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
219326677|NCT07123064|BEHAVIORAL|Usual Care Control|Monthly SMS over a period of 6 months will be sent out. Key content includes: healthy diet tips, recognizing warning signs of health, understanding dementia, fall prevention tips, health message, and anti-fraud tips.
219355315|NCT03167073|OTHER|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
219355316|NCT03881397|BEHAVIORAL|Family Media Use Plan|A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
219326678|NCT07129473|DRUG|Metformin Extended Release Oral Tablet|"Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) once daily with the evening meal starting prior to conception. The dosing will begin at 500 mg daily and increase gradually over an eight week period (+500mg every 2 weeks, as tolerated) to a maximum tolerated dose of up to 2,000 mg daily. Treatment at highest tolerated dose will continue (maintenance phase) until either two weeks after a positive pregnancy test or 12 months from treatment initiation, whichever comes first. Participants will attend three clinic visits and provide blood samples at baseline, after dose escalation, and during early pregnancy to assess GDF15 levels. Daily dosing, adherence, and any side effects are recorded via MyCap; clinical visits at baseline, post-escalation (week 8), and after pregnancy confirmation include vital signs, PUQE-24/HELP scores, and blood draws for CBC, creatinine, and GDF15 levels."
219326679|NCT07130838|BEHAVIORAL|MB-EAT program|Phase 2 will include 12 modules, delivered across 12 weeks. The program will contain seated and guided mindfulness practices designed to cultivate better awareness of hunger cues, sensory-specific satiety, as well as external and emotional food-related triggers through body scans, taste satiety and mindful eating practices, self-compassion meditations, and diaphragmatic breathing. The intervention will also include mindful movements. Each session will be focused on a specific theme related to promoting healthy eating behaviours and emotional regulation. Each module will be unlocked as the participant progresses through the program. AmDTx-Epiq also incorporates goal setting, daily feedback, prompts for change, and positive reinforcement in the form of an encouraging text messages from the study coach.
219326680|NCT07130838|BEHAVIORAL|Feasibility study|"Phase 1 will include 4 modules, delivered across 4 weeks. All participants will receive a modified, shortened version of the MB-EAT program through AmDTx-Epiq within the AmDTx app. Participants will also complete the Keep in Balance questionnaire every week on the app, a questionnaire which assesses weekly physically activity and eating habits, as well as associated thoughts and feelings to these. Participants will receive regular check-ins twice per week from a coach (unblinded study coordinator) via text designed to promote engagement and answer questions participants may have during the 4-week intervention period."
219355317|NCT03881397|BEHAVIORAL|Media Use Resources Awareness|Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
219355318|NCT04082585|BEHAVIORAL|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
219355319|NCT03299920|OTHER|Standardized instructions|Specific instructions related to peripheral nerve block.
219355320|NCT03299920|OTHER|Conventional instructions|Usual post-operative instructions.
219355321|NCT02035995|OTHER|Pregnant volunteers with GDM|
219355322|NCT01962051|DEVICE|Amplatzer Cardiac Plug|
219355323|NCT06017596|DEVICE|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
219355324|NCT04113772|DRUG|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
219355325|NCT04113772|DRUG|Orfadin|Orfadin
219326681|NCT07130838|BEHAVIORAL|Psychoeducation|Patients in the control group will receive audio-recorded psychoeducation in the form of standard diet/exercise information. The comparator is publicly available psychoeducational information available on nutrition, physical activity, and weight management through best practice guidelines, clinical guidelines, and public health guidelines. These comparators were chosen as they are easily accessible standard of care practices and interventions available in the community (i.e., the general public have access to it in the community), such as through consultation with a dietician, community care provider, or family physician.
219355326|NCT05089500|OTHER|Endoscopic injection sclerotherapy|Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
219326682|NCT07129369|BEHAVIORAL|PASIM program|The program consists of 5 modules for ROP patients (translated, refined and validated by research team) and 4 group sessions (1.5 hours per session; 8-10 members/group; in-between completion of the 5 modules) facilitated by a peer-support worker over 5 months. The 5 modules include: Module 1-Patient's well-being; Module 2-Getting the best out of support services; Module 3-Acceptance and insight toward psychosis and long-term self-care; Module 4-Dealing with psychosocial effects of the illness- I; and Module 5-Dealing with physical/mental health effects of the illness- II. The 4 group sessions will be conducted at the orientation and after reading the 1st, 3rd and 5th module to introduce the program, encourage to complete the module per month, performing value clarifying and acceptance (psychological flexibility) exercises, and clarify and discuss self-care learning and and challenges.
219326683|NCT07129369|BEHAVIORAL|Psychoeducation|The psychoeducation group (5 subgroups with 12-14 patients per group) will be led by one trained psychiatric nurse experienced in psychiatric rehabilitation and psychoeducation group. The program consists of 12 two-hour sessions held weekly or biweekly (similar to the PASIM) over 5 months with four key components, including introduction and goal setting; an education workshop on psychosis care and community service; learning effective coping and self-care skills with rehearsals/reviews; and skills practices and preparing for future life.
219326684|NCT07129369|BEHAVIORAL|Usual-Care-only|Participants receive usual community mental healthcare services provided by POPCs and ICCMWs.
219326685|NCT07130760|PROCEDURE|Intraligamentary Injection|Intraligamentary local anesthesia will be administered using a standard dental syringe with 2% lidocaine and 1:100,000 epinephrine.
219326686|NCT07130760|PROCEDURE|Inferior Alveolar Nerve Block|Inferior alveolar nerve block will be performed with 2% lidocaine and 1:100,000 epinephrine using the conventional technique.
219326687|NCT07130331|DRUG|Secikinumab|secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks
219326688|NCT07130500|BEHAVIORAL|Financial incentives for adherence to long-acting injectable medication|This intervention is a randomized controlled trial where patients in the treatment group are offered financial incentives for taking long-acting injectable (LAI) versions of the antipsychotic and substance use disorder medications they need and the control group receives the status quo standard of care.
219326689|NCT07130500|BEHAVIORAL|Standard of care with monthly surveys|Receives standard outpatient care and incentives for completing monthly surveys.
219326690|NCT07129525|RADIATION|Radiation therapy|Patients treated with radiotherapy will be evaluated within a period of five to seven weeks, during which time radiation-induced skin toxicities will be assessed.
219326691|NCT07129278|BEHAVIORAL|Breathwork|Participants will complete their single-session, 2-hour training in a small group with the Breathwork instructor.
219326692|NCT04665570|DRUG|BAY81-9783 (Acarbose/Metformin)|Tablet (FDC of 25/50mg acarbose + 500mg metformin), three times daily
219326693|NCT06936202|OTHER|Spirulina capsules|active intervention
219326694|NCT06936202|OTHER|Placebo|no active ingredient
219326695|NCT06936384|BEHAVIORAL|In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form be|White Noise Sleep Mask Group In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form before the surgery and fill out a patient information form.
219355327|NCT05089500|OTHER|Endoscopic Band Ligation|Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
219326696|NCT02296450|BEHAVIORAL|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
219326697|NCT07130253|DRUG|Vonoprazan based ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy
219326698|NCT07130253|DRUG|Vonoprazan based SGT|Susceptibility testing guided therapy Based onsusceptibility test:Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin quadruple therapy
219326699|NCT04266756|DRUG|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
219326700|NCT04266756|DRUG|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
219326701|NCT04266756|DRUG|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
219326702|NCT06291831|DRUG|nirmatrelvir, ritonavir|Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
219326703|NCT06291831|OTHER|Controls|Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
219326704|NCT06433947|DRUG|OPN-6602|orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
219326705|NCT06433947|DRUG|Dexamethasone|Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
219326706|NCT05351775|DEVICE|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
219326707|NCT05351775|DEVICE|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
219326708|NCT05351775|DEVICE|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
219326709|NCT05351775|DEVICE|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
219326710|NCT03907631|OTHER|Standard of care|care decisions driven by local physicians; this is an observational cohort
219326711|NCT00933179|DRUG|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
219326712|NCT00933179|DRUG|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
219326713|NCT06438848|OTHER|Physical therapy program|group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions
219355328|NCT02681237|DRUG|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
219326714|NCT06438848|OTHER|Physical therapy program with lymphedema drainage|physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks
219326715|NCT01903642|OTHER|proteomic analysis|
219326716|NCT05053477|DRUG|mehylprednisolone injection|(40 mg)
219326717|NCT05053477|DEVICE|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
219326718|NCT05053477|BIOLOGICAL|platelet-rich plasma|2 ml of PRP
219326719|NCT01262937|DEVICE|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
219326720|NCT03819062|DEVICE|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
219326721|NCT04170712|OTHER|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
219355329|NCT02681237|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
219326722|NCT03540082|OTHER|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
219326723|NCT03540082|OTHER|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
219326724|NCT02934997|OTHER|Observational study|
219326725|NCT02805049|DRUG|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
219326726|NCT04511832|DRUG|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
219326727|NCT01372150|DRUG|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
219326728|NCT01372150|DRUG|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
219326729|NCT01372150|DRUG|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
219326730|NCT06247436|DIETARY_SUPPLEMENT|Branch Chained Amino Acids|postoperative BCAA consumption
219326731|NCT00277420|BEHAVIORAL|Comprehensive weight management|
219326732|NCT01213875|BEHAVIORAL|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
219355330|NCT00314600|DEVICE|above and below elbow cast|
219355331|NCT02033564|DEVICE|Macintosh/Miller Laryngoscope|
219355332|NCT02033564|DEVICE|Glidescope Laryngoscope|
219326733|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
219326734|NCT06298721|BEHAVIORAL|Standard of Care TKA|\- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
219326735|NCT04679753|DEVICE|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
219326736|NCT04679753|DEVICE|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
219326737|NCT01526551|OTHER|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
219326738|NCT01526551|OTHER|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
219326739|NCT01129726|DEVICE|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
219355333|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
219326740|NCT00164619|BEHAVIORAL|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]
219326741|NCT00164619|BIOLOGICAL|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
219326742|NCT06388304|BEHAVIORAL|THRIVE Online PAT Program|Online program: behavioral intervention based on Positive Affect Training (PAT)
219326743|NCT05215262|BEHAVIORAL|Treat Act Know Engage (T.A.K.E.) Steps|Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.
219326744|NCT05215262|BEHAVIORAL|Standard or Care|S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
219326745|NCT03708172|DEVICE|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
219326746|NCT03708172|OTHER|Cognitive Training|Computer-based cognitive training designed to enhance executive function
219326747|NCT03708172|OTHER|sham Cognitive Training|Computer-based inactive sham training
219326748|NCT01672567|DIETARY_SUPPLEMENT|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
219326749|NCT01672567|DIETARY_SUPPLEMENT|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
219326750|NCT01672567|DIETARY_SUPPLEMENT|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
219326751|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
219326752|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
219326753|NCT03109158|DRUG|NC-6004|NC-6004 provided by NanoCarrier
219326754|NCT03109158|DRUG|Cetuximab|Commercially Available
219326755|NCT03109158|DRUG|5-FU|Commercially Available
219326756|NCT03934255|OTHER|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
219326757|NCT00156351|BEHAVIORAL|Physical activity promotion|
219326758|NCT04227886|RADIATION|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
219326759|NCT04227886|DRUG|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
219326760|NCT00761852|DRUG|Ruboxistaurin|32 mg daily for 2 weeks
219326761|NCT00761852|DRUG|Placebo|1 tab po QD for 2 weeks
219326762|NCT01364623|DRUG|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
219326763|NCT01364623|DRUG|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
219326764|NCT01364623|DRUG|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
219326765|NCT01364623|DRUG|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
219326766|NCT01092975|DRUG|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
219326767|NCT02443649|BEHAVIORAL|Sleep hygiene program|Sleep hygiene program
219326768|NCT02443649|BEHAVIORAL|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
219355334|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
219355335|NCT01791192|DRUG|FTY720|Fingolimod
219355336|NCT01791192|DRUG|Oral Corticosteroid|Oral Corticosteroid
219326769|NCT03505385|BEHAVIORAL|Co-created intervention - Get Ready (GR)|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
219326770|NCT06379308|OTHER|questionaries|"Questionaries will be administered :~* Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI)~* Tegner Activity Scale (TAS)~* Simple Knee Value (SKV)~* International Knee Documentation Commitee (IKDC)"
219326771|NCT06379308|OTHER|datas of medical record|datas of medical record will be collected : epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication.
219326772|NCT00718549|DRUG|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
219326773|NCT00718549|DRUG|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
219326774|NCT00718549|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
219326775|NCT02746666|BEHAVIORAL|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
219326776|NCT01353508|DRUG|LCZ696|200 mg and 400 mg tablets
219326777|NCT01353508|DRUG|Valsartan|160 mg tablets
219326778|NCT05745051|DIAGNOSTIC_TEST|CVAid Flow|CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
219326779|NCT00004152|DRUG|iodinated contrast dye|
219326780|NCT00004152|PROCEDURE|computed tomography|
219326781|NCT00004152|PROCEDURE|positron emission tomography|
219326782|NCT00004152|RADIATION|fludeoxyglucose F 18|
219326783|NCT04924504|OTHER|No interventions|No interventions
219326784|NCT01131026|DRUG|Levofloxacin|tablet, 500 mg, once a day for ten days
219326785|NCT01131026|DRUG|Amoxicillin|tablet, 1000 mg, once a day for ten days
219326786|NCT01131026|DRUG|Lansoprazole|capsule, 30 mg, twice a day for ten days
219326787|NCT06473883|OTHER|Training recommendation|The players in the intervention group are also given specific training recommendations for the prevention of head injuries, which are compiled by experts (sports scientists, physiotherapists and neuroscientists). The exercise selection covers several areas that can be affected after a head injury. Each section contains 8 different exercises with increasing levels of difficulty (3x Basic-3x Intermediate-2x Advanced). The recommendations should be used as a warm-up program throughout the season before each training session. The coach or athletic coach will lead the warm-up program and ensure that each player follows the sequence and completes each phase according to the scheduled weeks. The warm-up program should be conducted as an 8-week cycle.
219326788|NCT02172287|DRUG|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
219326789|NCT02172287|DRUG|Salmeterol|Inhalation aerosol twice daily
219326790|NCT02172287|DRUG|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
219326791|NCT02172287|DRUG|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
219326792|NCT03654014|DEVICE|SofPulse|SofPulse PEMF device treatment of the brain after traumatic injury
219326793|NCT00446524|DRUG|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
219355337|NCT04675866|OTHER|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
219326794|NCT02297360|DIETARY_SUPPLEMENT|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
219326795|NCT02297360|OTHER|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
219326796|NCT02251925|BIOLOGICAL|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
219326797|NCT02251925|DRUG|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
219355338|NCT02573155|DRUG|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219326798|NCT02251925|DRUG|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
219326799|NCT02251925|DRUG|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
219326800|NCT00780013|DRUG|metformin hydrochloride liquid 500 mg per 5 mL|
219326801|NCT03130179|DRUG|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
219326802|NCT03130179|DRUG|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
219326803|NCT03496324|DRUG|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
219326804|NCT03496324|DRUG|Algifor® Junior|Algifor® Junior 400 mg/20 ml
219326805|NCT06209008|DRUG|Intravesical injection of Platlet Rich Plasma (PRP)|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
219326806|NCT05045326|BEHAVIORAL|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
219326807|NCT05045326|BEHAVIORAL|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
219326808|NCT04323826|OTHER|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
219326809|NCT04323826|OTHER|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
219326810|NCT04323826|OTHER|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
219326811|NCT04323826|OTHER|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
219355339|NCT02573155|DRUG|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219355340|NCT02573155|DRUG|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219355341|NCT02573155|DRUG|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219326812|NCT01795300|RADIATION|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
219326813|NCT01795300|RADIATION|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
219355342|NCT02573155|DRUG|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219355343|NCT02573155|DRUG|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219326814|NCT01795300|RADIATION|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
219326815|NCT01795300|RADIATION|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.
219326816|NCT04532736|DRUG|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
219355344|NCT02573155|DRUG|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219326817|NCT04532736|DRUG|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
219326818|NCT04532736|DRUG|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
219326819|NCT04727320|DRUG|Tauroursodeoxycholic acid|Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
219326820|NCT04727320|DRUG|Placebo|Oral placebo, once a day, one tablet at a time for 6 months
219326821|NCT03382015|OTHER|BKR-013 or Placebo|Encapsulated L-glutamine
219326822|NCT06175546|DEVICE|Compression socks|Wearing of compression sock in prescribed regimen
219326823|NCT04323085|BEHAVIORAL|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
219326824|NCT04323085|BEHAVIORAL|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
219326825|NCT00892320|DRUG|ER OROS paliperidone|
219326826|NCT02092350|DRUG|Grazoprevir|Grazoprevir 100 mg tablet
219326827|NCT02092350|DRUG|Elbasvir|Elbasvir 50 mg tablet
219326828|NCT02092350|DRUG|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
219326829|NCT02092350|DRUG|Placebo to Elbasvir|Placebo tablet matched to elbasvir
219326830|NCT00002326|DRUG|Adefovir|
219326831|NCT00002326|DRUG|Zidovudine|
219326832|NCT06411587|DIAGNOSTIC_TEST|Ultrasound imaging and functional assessment|Participants in this study will undergo two types of assessments: capturing muscle images using ultrasound and evaluating their function through clinical scales.
219326833|NCT05361109|DRUG|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
219326834|NCT00239226|PROCEDURE|IAS pacing - study group|site of implant and permanent pacing
219326835|NCT00239226|PROCEDURE|IAS pacing control group|site of implant and permanent pacing
219326836|NCT00239226|PROCEDURE|Pacing RAA study group|site of implant and permanent pacing
219326837|NCT00239226|PROCEDURE|Pacing RAA control group|site of implant and permanent pacing
219326838|NCT01614821|DRUG|PCI-32765|Taken orally, once daily in the morning
219326839|NCT04107883|BIOLOGICAL|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
219326840|NCT04107883|DIAGNOSTIC_TEST|blood sample|get blood samples at several specific points in time during perioperation
219326841|NCT00041301|OTHER|QoL assessment|qol questionnaires
219326842|NCT04559945|DEVICE|Aveir VR Leadless Pacemaker System|Patients will undergo an attempted leadless pacemaker implant
219326843|NCT00005007|DRUG|Etanercept|
219326844|NCT00000138|DRUG|Prednisolone Phosphate|
219326845|NCT00000138|DRUG|Acyclovir|
219326846|NCT05335148|DRUG|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
219326847|NCT04706611|PROCEDURE|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
219326848|NCT03042078|DEVICE|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
219326849|NCT03042078|DEVICE|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
219326850|NCT00646906|DRUG|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
219326851|NCT00646906|DRUG|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
219326852|NCT00646906|DRUG|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
219326853|NCT00646906|DRUG|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
219326854|NCT00646906|DRUG|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
219326855|NCT00161876|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
219355345|NCT02573155|DRUG|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
219326856|NCT02584322|OTHER|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
219326857|NCT01106495|DEVICE|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
219326858|NCT01106495|DRUG|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
219326859|NCT00486772|DRUG|Sevelamer (Renagel), calcium acetate (Phos-ex)|
219326860|NCT05001282|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
219326861|NCT00910195|DEVICE|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
219326862|NCT00910195|DEVICE|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
219326863|NCT02882542|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
219326864|NCT00050648|DRUG|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
219326865|NCT00050648|DRUG|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
219326866|NCT00050648|DRUG|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
219326867|NCT00956657|BEHAVIORAL|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
219326868|NCT00510991|DEVICE|nippv|
219326869|NCT00917527|DRUG|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
219326870|NCT02265861|DRUG|HCG|
219326871|NCT00809211|DRUG|nilotinib|
219326872|NCT00809211|GENETIC|cytogenetic analysis|
219326873|NCT00809211|GENETIC|mutation analysis|
219326874|NCT00809211|GENETIC|polymerase chain reaction|
219326875|NCT00809211|OTHER|pharmacological study|
219326876|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
219326877|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FSPG PET/CT
219326878|NCT02448225|RADIATION|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
219326879|NCT02448225|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
219326880|NCT02448225|OTHER|Laboratory Biomarker Analysis|Correlative studies
219326881|NCT02448225|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
219326882|NCT02448225|PROCEDURE|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
219326883|NCT04858906|DEVICE|McGrath laryngoscope|The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).
219326884|NCT04858906|DEVICE|C-MAC D-blade laryngoscope|The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
219326885|NCT04060563|DEVICE|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
219326886|NCT00851682|DEVICE|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
219326887|NCT06186713|OTHER|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
219326888|NCT04454697|DEVICE|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
219326889|NCT02137122|DEVICE|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
219326890|NCT02137122|DEVICE|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
219326891|NCT03514030|DIAGNOSTIC_TEST|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
219355346|NCT02573155|DRUG|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
219326892|NCT05872490|OTHER|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
219326893|NCT05872490|OTHER|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
219326894|NCT02004951|DEVICE|Misago RX|
219326895|NCT02004951|DEVICE|Zilver PTX|
219326896|NCT06281067|DIAGNOSTIC_TEST|"full-physiology approach arm"|"* All MB patients belonging to the full-physiology arm will undergo functional assessment of the intramural artery with basal Pd/Pa, FFR (after intravenous adenosine), RFR, CFR and IMR.~* In the presence of a negative functional assessment (Pd/Pa\> 0.92, FFR\> 0.80, RFR\> 0.89, CFR≥ 2.0 and IMR\< 25), FFR, CFR and IMR will be measured after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d) to exalt the epicardial hemodynamic significance of MB or its impact on structural microvascular remodelling (impaired endothelium-independent vasodilatation).~* In the absence of epicardial hemodynamic significance (FFR-d\> 0.75) and structural microvascular dysfunction (CFR≥ 2.0 and IMR\< 25), ACH provocative test will be performed to evaluate the presence of epicardial or microvascular spasm (impaired endothelium-dependent vasodilatation)."
219326897|NCT06281067|DIAGNOSTIC_TEST|"standard approach arm"|"In the standard approach arm patients will undergo an angiographic evaluation of the tunnelled artery"
219326898|NCT04354545|DRUG|Xiidra (Lifitegrast ophthalmic solution) 5%|FDA approved lifitegrast opthalmic solution eye drop
219326899|NCT01131416|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
219326900|NCT02551614|PROCEDURE|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
219326901|NCT02551614|PROCEDURE|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
219326902|NCT02551614|PROCEDURE|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
219326903|NCT02112136|OTHER|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
219326904|NCT01105676|PROCEDURE|skin biopsy|Two skin biopsies will be taken one time
219355347|NCT02573155|DRUG|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
219355348|NCT02573155|DRUG|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
219355349|NCT02179333|OTHER|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
219355350|NCT01681433|DRUG|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
219355351|NCT01681433|DRUG|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
219355352|NCT01681433|DRUG|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
219355353|NCT00896376|BIOLOGICAL|trastuzumab|
219355354|NCT00896376|OTHER|laboratory biomarker analysis|
219355355|NCT00896376|OTHER|pharmacological study|
219355356|NCT02301403|DRUG|Nicotine patch|8 weeks of nicotine patch
219326905|NCT04602169|PROCEDURE|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise \>38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
219355357|NCT02301403|BEHAVIORAL|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
219326906|NCT04602169|PROCEDURE|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
219326907|NCT00943891|PROCEDURE|Tumor biopsies|
219326908|NCT06282276|BEHAVIORAL|cross sectional survey|filling out the electronic survey form
219326909|NCT00534820|PROCEDURE|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
219326910|NCT05744622|OTHER|KetacTM Universal AplicapTM|chemically cured conventional GICs
219326911|NCT05744622|OTHER|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
219326912|NCT05349526|OTHER|None, pure observational study|None, pure observational study
219326913|NCT05242731|DEVICE|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
219326914|NCT05242731|DEVICE|"Video calling program Better-close"|Video calling program.
219326915|NCT05242731|DEVICE|Researchmanager program|Case Report Form, Datamanagement program
219326916|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
219326917|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
219326918|NCT00659620|BIOLOGICAL|mesenchymal stem cell|transplantation of mesenchymal stem cell
219326919|NCT00005641|BIOLOGICAL|anti-thymocyte globulin|
219326920|NCT00005641|DRUG|busulfan|
219326921|NCT00005641|DRUG|cyclophosphamide|
219326922|NCT00005641|DRUG|cyclosporine|
219326923|NCT00005641|DRUG|leucovorin calcium|
219326924|NCT00005641|DRUG|methotrexate|
219326925|NCT00005641|DRUG|methylprednisolone|
219326926|NCT00005641|PROCEDURE|allogeneic bone marrow transplantation|
219326927|NCT00005641|PROCEDURE|in vitro-treated bone marrow transplantation|
219326928|NCT00005641|RADIATION|radiation therapy|
219326929|NCT00619970|PROCEDURE|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
219326930|NCT00619970|DRUG|xifaxan|xifaxan 550mg TID x10days
219326931|NCT00619970|DRUG|placebo|placebo TID x 10days
219326932|NCT00619970|PROCEDURE|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
219355358|NCT02301403|DRUG|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
219326933|NCT01436136|OTHER|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
219355359|NCT02301403|DRUG|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
219326934|NCT01436136|OTHER|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
219326935|NCT00433914|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
219326936|NCT00433914|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
219326937|NCT02942914|DRUG|LY3209590|Administered SC
219326938|NCT02942914|DRUG|Placebo|Administered SC
219326939|NCT02942914|DRUG|Insulin Glargine|Administered SC
219355360|NCT02301403|BEHAVIORAL|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
219355361|NCT02301403|BEHAVIORAL|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
219355362|NCT02301403|BEHAVIORAL|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
219326940|NCT04973579|PROCEDURE|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
219326941|NCT00004047|DRUG|exatecan mesylate|
219326942|NCT06317675|OTHER|Osteopathic manipulative treatment (OMT)|Manual therapy on different area of the body.
219326943|NCT05836142|PROCEDURE|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
219326944|NCT02324959|DEVICE|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
219326945|NCT02324959|DEVICE|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
219355363|NCT02884778|DIAGNOSTIC_TEST|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
219326946|NCT06052163|DRUG|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
219326947|NCT06052163|DRUG|Placebo|A placebo has no active properties and is taken orally.
219326948|NCT05836636|OTHER|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
219326949|NCT00441415|DRUG|Adapalene BPO|
219326950|NCT00143663|DRUG|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
219326951|NCT00143663|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
219326952|NCT06002308|OTHER|Age|The retrospective study included 540 patients with primary ACL tears (71 pediatric patients and 469 adults) whose MRI examination and pivot-shift test were conducted within 14 days after injury. To detect concomitant KF and ALL injury in knees with ACL injury using MRI in both adult and pediatric patients and compare the effect of KF injury and multiple risk factors on anterolateral rotatory laxity as measured by the pivot-shift test in a clinical setting.
219326953|NCT04272658|DIAGNOSTIC_TEST|value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI"
219355364|NCT01421550|PROCEDURE|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
219355365|NCT01421550|PROCEDURE|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
219326954|NCT04350385|OTHER|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.
219326955|NCT04350385|OTHER|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week
219326956|NCT02518997|OTHER|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
219326957|NCT05183113|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
219326958|NCT05351047|DRUG|AZD2373 subcutaneous injection|Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
219326959|NCT05351047|DRUG|Placebo|Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
219326960|NCT01050686|PROCEDURE|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
219326961|NCT01050686|PROCEDURE|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
219326962|NCT02945150|DRUG|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
219326963|NCT01134835|OTHER|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
219326964|NCT01134835|DRUG|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
219355366|NCT06463600|DEVICE|Magseed|Tumour localizer
219355367|NCT06463600|DEVICE|Metallic clip and guide wire|Tumour localizers
219355368|NCT05654831|DRUG|Placebo|Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
219355369|NCT05654831|DRUG|ECC5004|ECC5004 will be administered as oral tablet(s) during each dosing day.
219355370|NCT00038350|BEHAVIORAL|Lingual Strengthening|8 week lingual strengthening exercise protocol
219355371|NCT06087354|OTHER|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
219355372|NCT06317480|PROCEDURE|bone resection|patients underwent soft tissue sarcoma excision together with bone resection following either biological or endoprosthesis reconstruction
219355373|NCT06317480|PROCEDURE|subperiosteal excision|patients underwent sub-periosteal tumor excision combining bone and soft tissue ablation without bone excision
219355374|NCT04500327|OTHER|Drive app|The Drive app will be used to monitor sleep metrics for users of CPAP therapy.
219355375|NCT04500327|DEVICE|Non contact motion sensor|The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
219355376|NCT04687501|DEVICE|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
219326965|NCT04900922|DEVICE|isokinetic dynamometer|We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
219326966|NCT03248830|DEVICE|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
219326967|NCT04450511|DEVICE|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
219326968|NCT04450511|OTHER|Bladder Training (BT)|Bladder Training (BT)
219326969|NCT03530917|DRUG|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
219326970|NCT03530917|DRUG|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
219326971|NCT04795726|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
219326972|NCT04795726|DRUG|Placebo|Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
219326973|NCT01581944|DRUG|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
219326974|NCT01581944|DRUG|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
219326975|NCT03920553|BIOLOGICAL|Hyaluronic acid|Topical application of hyaluronic acid following Laser assisted frenectomy
219326976|NCT03407404|COMBINATION_PRODUCT|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
219326977|NCT03407404|COMBINATION_PRODUCT|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
219326978|NCT04039854|DRUG|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
219326979|NCT04039854|DRUG|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
219326980|NCT03312088|DEVICE|Freedom Knee PCK Components|Total Knee Revision
219326981|NCT00409929|DRUG|AEB071|
219326982|NCT02977754|OTHER|This is an observational study|Imaging
219326983|NCT02615704|DEVICE|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
219326984|NCT02615704|DEVICE|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
219326985|NCT02615704|DEVICE|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
219326986|NCT02615704|DEVICE|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
219326987|NCT00048620|DRUG|N-acetylgalactosamine 4-sulfatase|
219326988|NCT01584076|DRUG|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
219326989|NCT01584076|OTHER|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
219326990|NCT03100669|PROCEDURE|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
219326991|NCT01968850|DRUG|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
219326992|NCT02819076|OTHER|pain scale|
219326993|NCT04822610|PROCEDURE|interscalene block|peripheral nerve block
219326994|NCT04822610|PROCEDURE|suprascapular block + axillary block|peripheral nerve block
219326995|NCT05594758|DRUG|Olverembatinib|Oral Olverembatinib
219326996|NCT00409097|DRUG|Rosiglitazone|
219326997|NCT02678416|DRUG|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
219326998|NCT02678416|DRUG|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
219326999|NCT02678416|DRUG|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
219327000|NCT02678416|OTHER|Morphine (Treatment D)|Morphine administered by IV infusion
219327001|NCT04645043|OTHER|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
219327002|NCT01318252|DRUG|AL-54478 0.005%|
219327003|NCT01318252|DRUG|Latanoprost 0.005%|
219327004|NCT01318252|DRUG|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
219327005|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
219327006|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
219327007|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
219327008|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
219327009|NCT01983397|OTHER|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
219327010|NCT01983397|OTHER|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
219327011|NCT01848353|BEHAVIORAL|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
219327012|NCT05807880|DRUG|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
219327013|NCT00935272|DEVICE|Restylane®|Restylane® injections in the lips
219327014|NCT00935272|DEVICE|Non-Treatment|Non- Treatment
219327015|NCT00611338|BEHAVIORAL|HIV Skills-based Prevention|
219327016|NCT00953719|DEVICE|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
219327017|NCT00953719|DEVICE|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
219327018|NCT04085796|OTHER|ICCI|Intentional Compassionate Communication Intervention
219327019|NCT00017121|BIOLOGICAL|sargramostim|
219327020|NCT03483467|OTHER|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
219327021|NCT03483467|OTHER|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
219327022|NCT01170546|OTHER|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
219327023|NCT01170546|OTHER|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
219327024|NCT01170546|OTHER|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
219327025|NCT04046796|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
219327026|NCT05617651|DRUG|IY-NT-T|Ilaprazole 20mg
219327027|NCT05617651|DRUG|IY-NT-R|Ilaprazole 10mg
219327028|NCT04575142|DEVICE|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
219327029|NCT00163462|DRUG|Ciclesonide|
219327030|NCT06473376|PROCEDURE|arthrocentesis|TMJ arthrocentesis and arthroscopy
219327031|NCT03248934|OTHER|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
219327032|NCT03248934|OTHER|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
219327033|NCT00037869|DRUG|I-131 Metaiodobenzylguanidine|
219327034|NCT01639768|DRUG|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
219327035|NCT03492554|OTHER|1-Lead ECG|All participants will record three single-lead ECGs
219327036|NCT03492554|DEVICE|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
219327037|NCT04384393|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight.
219327038|NCT05895162|DRUG|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
219327039|NCT05895162|DRUG|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
219327040|NCT00172653|PROCEDURE|functional tasks|
219327041|NCT06079944|PROCEDURE|Progressive resistance training|"* 6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~* 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~* Speed of movement will be 2 seconds for both the eccentric and concentric phases.~* To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
219327042|NCT06079944|PROCEDURE|Traditional physical therapy|"* TENS+ Hot pack~* Pendulum exercises and stretching exercises"
219327043|NCT01727765|OTHER|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
219327044|NCT00480688|BIOLOGICAL|BCG|
219327045|NCT00331123|DRUG|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
219327046|NCT00331123|DRUG|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
219327047|NCT01478360|DRUG|AIN457 (secukinumab)|Secukinumab intravenous injection
219327048|NCT01478360|DRUG|Placebo|Placebo intravenous injection
219327049|NCT00004639|PROCEDURE|Furlow double z-plasty palatoplasty palate repair|
219327050|NCT00004639|PROCEDURE|Von Langenbeck palatoplasty palate repair|
219327051|NCT02900183|DRUG|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
219327052|NCT02289352|DRUG|Brimonidine|
219327053|NCT02289352|DRUG|placebo|
219327054|NCT01052896|DRUG|Gabapentin|300mg po TID
219327055|NCT01052896|DRUG|Placebo|Look-alike of gabapentin 300mg given po tid
219327056|NCT06310954|DIETARY_SUPPLEMENT|Early ketogenic diet combined with conventional pharmacotherapy.|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
219327057|NCT06310954|DRUG|Common diet combined with conventional pharmacotherapy|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, and inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.We know that drug information for registering clinical information is necessary, but our research design is to add ketogenic diets as a supplementary treatment plan when traditional drug treatment is ineffective. Therefore, in terms of specific drug selection, this is not absolutely the same. Depending on individual differences, the choice of drugs will also vary. Control the number of episodes, time, etc., and everyone uses different drugs. Therefore, we cannot decide on a single drug for comparison like traditional content.
219327058|NCT02671045|GENETIC|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
219327059|NCT02671045|GENETIC|Genomic profile by other methods|Genomic profiling by other testing methods.
219327060|NCT06582316|OTHER|Brain Health Training Programme|"Train Your Brain (TYB) - group-based cognitive intervention programme for mild cognitive impairments. This programme equips participants with knowledge on cognition and brain health, provide cognitive coping strategies and boost their confidence and maintain independence in daily activities."
219327061|NCT02627352|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
219327062|NCT04710953|DEVICE|Continuous positive airway pressure machine|CPAP device set at 6-8cmH2O for several hours
219327063|NCT02663284|DRUG|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
219327064|NCT02649296|OTHER|Skanlab bodywave|The intervention will be done twice a week
219327065|NCT01984944|OTHER|Autistic functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
219327066|NCT01984944|OTHER|Control functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
219327067|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
219327068|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
219327069|NCT04458103|DEVICE|Percutaneous RVAD|ProtekDuo or Impella RP
219327070|NCT06214871|DEVICE|rTMS|Transcranial Magnetic Stimulation
219327071|NCT01772004|DRUG|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
219327072|NCT03948633|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
219327073|NCT01458704|OTHER|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
219327074|NCT00911625|DRUG|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
219327075|NCT00911625|DRUG|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
219327076|NCT04665336|BEHAVIORAL|Circadian Timing Program|"Sleep hygiene training will be provided to the participants. They will be asked to make lifestyle changes according to the Circadian Timing Program created by the researcher."
219327077|NCT04665336|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training will be given by the researcher. There will also be sleep hygiene training sections on the website.
219327078|NCT05342181|OTHER|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~1. supine bridge~2. plank~3. oblique crunch~4. side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
219327079|NCT05342181|OTHER|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~1. bridging~2. straight leg raise in prone lying~3. straight leg raise with hand raise in prone lying~4. pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
219327080|NCT02183155|DRUG|Meloxicam - low|
219327081|NCT02183155|DRUG|Meloxicam - medium|
219327082|NCT02183155|DRUG|Meloxicam - high|
219327083|NCT02183155|DRUG|Placebo|
219327084|NCT02183155|DRUG|Extended-release indomethacin|
219327085|NCT05729295|PROCEDURE|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
219327086|NCT01217151|DEVICE|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
219327087|NCT01217151|OTHER|Usual treatment|Hemodynamic monitoring based on common practice
219327088|NCT02101515|OTHER|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
219327089|NCT00738413|DRUG|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
219327090|NCT00738413|DRUG|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
219327091|NCT01095367|PROCEDURE|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
219327092|NCT00184080|DRUG|Elsamitrusin|
219327093|NCT02884154|DEVICE|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
219327094|NCT02024568|DRUG|Pregabalin|See arm description
219327095|NCT02024568|DRUG|Placebo|See arm description
219327096|NCT02379767|DEVICE|Electroconvulsive therapy|
219327097|NCT02379767|OTHER|Positron emission tomography of the brain using [11C]harmine|
219327098|NCT02379767|OTHER|Structural magnetic resonance imaging|
219327099|NCT00302510|PROCEDURE|immunoadsorption|immunoadsorption
219327100|NCT05440396|DIAGNOSTIC_TEST|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
219327101|NCT05240183|DIAGNOSTIC_TEST|Daily SARS-CoV-2 PCR Testing for 10 days|Each participant will undergo daily SARS-CoV-2 PCR testing to assess viral dynamics
219327102|NCT02478905|OTHER|Influenza|
219327103|NCT00313040|BEHAVIORAL|Brief Consultation with Health Counselor, workbook|
219327104|NCT00313040|BEHAVIORAL|Usual Care wait list|
219327105|NCT03566433|PROCEDURE|Tep surgery for inguinal hernia|TEP surgery
219327106|NCT03566433|PROCEDURE|Lichtenstein|Lichtenstein surgery for inguinal hernia
219327107|NCT04475900|DIAGNOSTIC_TEST|Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)|To measure corneal biomechanics with Scheimpflug based tonometry
219327108|NCT04475900|DIAGNOSTIC_TEST|Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)|To measure corneal topography and tomography with Scheimpflug tomograph
219327109|NCT04475900|DIAGNOSTIC_TEST|Optic nerve head measurement|To measure optic nerve excavation
219327110|NCT02013453|DRUG|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
219327111|NCT02013453|DRUG|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
219327112|NCT02013453|DRUG|5FU|Administered by infusion.
219327113|NCT02013453|DRUG|Paclitaxel|Administered by infusion.
219327114|NCT02013453|DRUG|Pemetrexed|Administered by infusion.
219327115|NCT00518427|DRUG|Insulin Glargine|"Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
219327116|NCT02907710|DRUG|Endostar|intravenous infusion
219327117|NCT02907710|DRUG|DDP|
219327118|NCT03281967|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
219327119|NCT00515957|GENETIC|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2"
219327120|NCT02844621|DRUG|Omeprazole|20mg orally once daily
219327121|NCT01688856|DEVICE|Electrical Stimulator|"The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
219327122|NCT02607449|DRUG|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
219327123|NCT02607449|DRUG|Placebo|Placebo without any active pharmaceutical ingredients
219327124|NCT06301672|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219327125|NCT06301672|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219327126|NCT06301672|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219327127|NCT03945357|DRUG|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
219327128|NCT03945357|DRUG|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
219327129|NCT03966781|PROCEDURE|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
219327130|NCT03966781|PROCEDURE|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
219327131|NCT03966781|PROCEDURE|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
219327132|NCT03966781|PROCEDURE|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
219327133|NCT01648894|PROCEDURE|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
219327134|NCT01648894|PROCEDURE|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
219327135|NCT00356616|DRUG|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
219327136|NCT00356616|DRUG|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
219327137|NCT05110339|DRUG|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
219327138|NCT05110339|DRUG|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
219327139|NCT02463071|DRUG|AZD0585|1g soft capsule
219327140|NCT02463071|DRUG|AZD0585 placebo|1g soft capsule
219327141|NCT01925898|DRUG|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
219327142|NCT01925898|DRUG|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
219327143|NCT00003865|DRUG|toremifene|
219327144|NCT01613495|DRUG|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
219327145|NCT01613495|DRUG|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
219327146|NCT00447486|DRUG|GW842166|
219327147|NCT02765620|OTHER|drug&radiation|"1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
219327148|NCT03364582|OTHER|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
219327149|NCT03039166|DEVICE|MRI 7T|
219327150|NCT03039166|DEVICE|MRI 3 T|
219327151|NCT03039166|BIOLOGICAL|blood sample|
219327152|NCT02019225|OTHER|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
219327153|NCT01930149|BEHAVIORAL|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
219327154|NCT02910765|DRUG|methylene blue|
219327155|NCT02910765|DRUG|ozone|
219327156|NCT02910765|OTHER|saline infusion|
219327157|NCT02910765|OTHER|oxygen|
219327158|NCT06061679|DEVICE|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
219327159|NCT00698932|DRUG|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
219327160|NCT00698932|DRUG|Placebo|oral tablet, once daily for 24 weeks
219327161|NCT01245387|DRUG|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
219327162|NCT00757003|DEVICE|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
219327163|NCT04609332|DIAGNOSTIC_TEST|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
219327164|NCT05440838|DIAGNOSTIC_TEST|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
219327165|NCT02277977|OTHER|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
219327166|NCT06178250|OTHER|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
219327167|NCT00627783|OTHER|a bicycle exercise test|
219327168|NCT01892514|PROCEDURE|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
219327169|NCT00471900|DRUG|dehydroepiandrosterone (DHEA)|
219327170|NCT02445118|OTHER|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
219327171|NCT03723317|PROCEDURE|Liver transplantation|First deceased-donor liver transplantation
219327172|NCT04643080|OTHER|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
219327173|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
219327174|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
219327175|NCT04349982|DIAGNOSTIC_TEST|Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)|Factorial
219327176|NCT02390479|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
219327177|NCT00396994|DEVICE|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
219327178|NCT00396994|DEVICE|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
219327179|NCT02232282|DEVICE|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
219327180|NCT02232282|DEVICE|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
219327181|NCT05144113|BEHAVIORAL|Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.|"The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program."
219327182|NCT03422679|DRUG|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
219327183|NCT02146599|OTHER|Administration of patient self-assessment|
219327184|NCT03391206|DIAGNOSTIC_TEST|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
219327185|NCT00005950|DRUG|nelarabine|Given IV
219327186|NCT06490393|OTHER|Questionnaires|EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department
219327187|NCT05214170|DEVICE|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
219327188|NCT06461182|DRUG|Ga-68-CXCR4|Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
219327189|NCT02426528|OTHER|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
219327190|NCT00905684|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
219327191|NCT00905684|DRUG|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
219327192|NCT05948475|DRUG|Tinengotinib 8 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
219327193|NCT05948475|DRUG|Tinengotinib 10 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
219327194|NCT05948475|DRUG|Physician's Choice|For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
219327195|NCT00000808|DRUG|Nevirapine|
219327196|NCT00908024|DRUG|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
219327197|NCT00908024|DRUG|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
219327198|NCT05708950|DRUG|KVA12123 - Dose Escalation|Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
219327199|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Escalation|Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
219327200|NCT05708950|DRUG|KVA12123 - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
219327201|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
219327202|NCT01799187|PROCEDURE|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
219327203|NCT01799187|PROCEDURE|apexification|apexification uses calcium hydroxide as root medication
219327204|NCT01766271|BEHAVIORAL|Health Coaching|biweekly health coaching for 5 months
219327205|NCT01766271|GENETIC|9p21|Genetic testing results of 9p21
219327206|NCT01766271|OTHER|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
219327207|NCT04267770|DRUG|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
219327208|NCT04267770|DRUG|Insulin (flat rate)|Participant's own insulin set to flat basal rates
219327209|NCT06490341|DRUG|GP Regimen, Nimotuzumab, Sintilimab|gemcitabine,ciplatin, nimotuzumab, sintilimab
219327210|NCT01687140|DRUG|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
219327211|NCT01687140|DRUG|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
219327212|NCT02821923|DIETARY_SUPPLEMENT|E967-Xylitol|24g xylitol/d
219327213|NCT02821923|DIETARY_SUPPLEMENT|E968-Erythritol|36g erythritol/d
219327214|NCT01770470|DIETARY_SUPPLEMENT|Chitosan|The product chitosan is contained in a chewing gum formulation
219327215|NCT02705807|DRUG|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.
219327216|NCT02705807|DRUG|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
219327217|NCT04345770|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
219327218|NCT04345770|DRUG|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
219327219|NCT04345770|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
219327220|NCT03061175|OTHER|Internet-Based Intervention|Receive web-based CPM-DA
219327221|NCT03061175|OTHER|Survey Administration|Ancillary studies
219327222|NCT00995475|DRUG|Fluticasone propionate|
219327223|NCT00995475|DRUG|Placebo|
219327224|NCT01655420|PROCEDURE|LASIK|Laser eye surgery
219327225|NCT02613845|OTHER|no intervention|
219327226|NCT06057584|BEHAVIORAL|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
219327227|NCT06057584|BEHAVIORAL|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
219327228|NCT06057584|BEHAVIORAL|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
219327229|NCT01713270|PROCEDURE|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
219327230|NCT01713270|DRUG|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
219327231|NCT01713270|PROCEDURE|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
219327232|NCT05151120|BIOLOGICAL|blood sample|In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
219327233|NCT05755295|OTHER|horse therapy|equitherapy and hippotherapy once a week during 16 weeks
219327234|NCT03854929|DRUG|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
219327235|NCT03854929|DRUG|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
219327236|NCT02116257|DRUG|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
219327237|NCT02116257|DRUG|PCA regimen|
219327238|NCT02243865|DEVICE|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
219327239|NCT02243865|DEVICE|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
219327240|NCT04173884|OTHER|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
219327241|NCT04173884|OTHER|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
219327242|NCT00440479|DRUG|Bortezomib|dose as determined (observational study) by treating physician
219327243|NCT00546299|DRUG|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
219327244|NCT03044249|DRUG|MP-101|Capsules
219327245|NCT03044249|DRUG|Placebo|Capsules
219327246|NCT03527082|OTHER|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
219327247|NCT00515736|DRUG|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
219327248|NCT00515736|DRUG|Placebo|vehicle
219327249|NCT06373471|OTHER|Comprehensive geriatric assessment (CGA) and treatment|"CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include:~* Assessment of comorbidity and treatments~* Review of medications including potential adjustment~* Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue~* Objective examination including blood tests and electrocardiogram~* Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires~* Assessment of domestic conditions, including need for assistance~* Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required"
219327250|NCT00398671|DEVICE|Application of cool cap after primary successful CPR|
219327251|NCT02101021|DRUG|Momelotinib|Tablet (s) administered orally once or twice daily
219327252|NCT02101021|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
219327253|NCT02101021|DRUG|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
219327254|NCT02101021|DRUG|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
219327255|NCT00955279|DRUG|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
219327256|NCT00955279|DRUG|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
219327257|NCT00955279|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
219327258|NCT03111485|DRUG|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
219327259|NCT03111485|DRUG|Placebo oral capsule|Capsule taken at bedtime
219327260|NCT01166100|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
219327261|NCT02383095|BEHAVIORAL|Art therapy|
219327262|NCT02383095|BEHAVIORAL|metacognitive therapy|
219327263|NCT03078712|OTHER|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
219327264|NCT03078712|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
219327265|NCT04207801|DRUG|AUR101|Inhibitor of RORγ
219327266|NCT04207801|DRUG|Matching Placebo|Drug-Placebo of AUR101 tablet
219327267|NCT01235793|DRUG|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
219327268|NCT00175214|BEHAVIORAL|Multifaceted intervention (patient education, physician guidelines, reminders)|
219327269|NCT00053703|DRUG|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
219327270|NCT00053703|DRUG|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
219327271|NCT00053703|DRUG|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
219327272|NCT01931787|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
219327273|NCT05744570|PROCEDURE|Epidural anesthesia|Regional anesthesia for labor pain
219327274|NCT03277326|PROCEDURE|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
219327275|NCT03277326|PROCEDURE|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
219327276|NCT03277326|PROCEDURE|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
219327277|NCT01947452|BEHAVIORAL|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
219327278|NCT01947452|BEHAVIORAL|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
219327279|NCT01172405|DRUG|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
219327280|NCT01172405|DRUG|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
219327281|NCT03308409|OTHER|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
219327282|NCT05133401|DEVICE|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
219327283|NCT03718663|OTHER|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
219327284|NCT03718663|OTHER|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
219327285|NCT03689647|DEVICE|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
219327286|NCT03602274|DIAGNOSTIC_TEST|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
219327287|NCT03602274|DIAGNOSTIC_TEST|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
219327288|NCT03602274|OTHER|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
219327289|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
219327290|NCT04993833|DEVICE|NPi-200 and NPi-300 pupillometers|Device which measures PLR.
219327291|NCT00267709|DRUG|Visilizumab|
219327292|NCT03698890|DEVICE|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
219327293|NCT05192538|DEVICE|Endoscopic endoloop pre-test treatment|A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
219327294|NCT04787250|BIOLOGICAL|Phage Therapy|Phage will be administered based on patient's matching results.
219327295|NCT04787250|PROCEDURE|Two-Stage Exchange Arthroplasty|Performed per the study center's standard of care. No investigational products are used.
219327296|NCT02209337|DEVICE|SRS|
219327297|NCT04166383|BIOLOGICAL|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
219327298|NCT04166383|DRUG|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
219327299|NCT00460551|BIOLOGICAL|Zalutumumab|8 mg/kg
219327300|NCT00460551|DRUG|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
219327301|NCT00460551|RADIATION|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
219327302|NCT02870413|BEHAVIORAL|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
219327303|NCT00253188|DRUG|galantamine hydrobromide|
219327304|NCT00680563|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
219327305|NCT04997928|OTHER|Serum PAI-1 alpha analysis.|After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
219327306|NCT01543386|DRUG|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
219327307|NCT03044886|DIETARY_SUPPLEMENT|vitamin D|Subjects took vitamin D or placebo
219327308|NCT00576433|DRUG|Methotrexate|As prescribed
219327309|NCT00576433|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
219327310|NCT04001907|BEHAVIORAL|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
219327311|NCT04001907|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate|
219327312|NCT04001907|DIETARY_SUPPLEMENT|placebo|
219327313|NCT03626584|OTHER|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
219327314|NCT03725163|BEHAVIORAL|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
219327315|NCT02921269|DRUG|Atezolizumab|Given IV
219327316|NCT02921269|BIOLOGICAL|Bevacizumab|Given IV
219327317|NCT02921269|OTHER|Laboratory Biomarker Analysis|Correlative studies
219327318|NCT05927922|DRUG|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
219327319|NCT06207357|PROCEDURE|optical trocar to create the pneumoperitoneum for bariatric surgery|The technique involves the use of 4 12 mm trocars. Pneumoperitoneum is induced by a 0° optical trocar and maintained at 15 mmHg. The first trocar is usually inserted along the left mid-clavicular line approximately 2 fingers from the costal arch, another trocar along the left axillary line, a third trocar 1 cm to the right of the midline, and the fourth trocar along the right mid-clavicular line. A 10 mm, 30 ° laparoscope is used.
219327320|NCT06249724|DEVICE|Active stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused low-intensity ultrasound stimulation
219327321|NCT06249724|DEVICE|Sham stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused zero-intensity ultrasound stimulation
219327322|NCT04702282|DIAGNOSTIC_TEST|ropivacain concentration measurements|Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
219327323|NCT00703053|BIOLOGICAL|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
219327324|NCT00703053|BIOLOGICAL|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
219327325|NCT00935545|BIOLOGICAL|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
219327326|NCT00984035|OTHER|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
219327327|NCT00984035|OTHER|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
219327328|NCT00984035|OTHER|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
219327329|NCT01039025|DRUG|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.
219327330|NCT01039025|DRUG|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
219327331|NCT01039025|DRUG|Melphalan|After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.
219327332|NCT01039025|OTHER|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
219327333|NCT00004912|DRUG|megestrol acetate|
219327334|NCT00004912|PROCEDURE|physical therapy|
219327335|NCT01557933|OTHER|No interventions will be used|No interventions will be used
219327336|NCT01159912|DRUG|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
219327337|NCT01159912|DRUG|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
219327338|NCT01159912|DRUG|Placebo|Placebo inhalation powder
219327339|NCT04697121|DIETARY_SUPPLEMENT|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
219327340|NCT04697121|COMBINATION_PRODUCT|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
219327341|NCT00378235|DRUG|IL13-PE38QQR|
219327342|NCT05216757|DRUG|Iguratimod|iguratimod, 25mg bid po.
219327343|NCT05216757|DRUG|placebo|placebo 1 tablet bid po.
219327344|NCT03575286|DIAGNOSTIC_TEST|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
219327345|NCT05099653|OTHER|physical activity|physical activity
219327346|NCT04535180|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
219327347|NCT06174051|BEHAVIORAL|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
219327348|NCT06174051|BEHAVIORAL|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
219327349|NCT03020238|PROCEDURE|BiClamp group|electric energy
219327350|NCT03020238|PROCEDURE|water jet group|water jet energy
219327351|NCT03247426|OTHER|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
219327352|NCT00822354|DRUG|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
219327353|NCT02407522|DIETARY_SUPPLEMENT|Black rice|They asked to keep their normal life style during intervention
219327354|NCT02407522|OTHER|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
219327355|NCT04923048|BIOLOGICAL|GB261|Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
219327356|NCT00594321|DEVICE|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
219327357|NCT00594321|DEVICE|standard vertebroplasty|standard vertebroplasty
219327358|NCT02499081|DRUG|Ixazomib|
219327359|NCT02629471|BEHAVIORAL|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
219327360|NCT04563000|DRUG|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
219327361|NCT04563000|DRUG|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
219327362|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
219327363|NCT00982007|DRUG|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
219327364|NCT00982007|DRUG|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
219327365|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
219327366|NCT06427291|BIOLOGICAL|Herpes virus T3011 injection|T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
219327367|NCT05356468|OTHER|Structured pain neuroscience education|"Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT"
219327368|NCT05356468|OTHER|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)"
219327369|NCT00504153|DRUG|dasatinib|
219327370|NCT00504153|OTHER|laboratory biomarker analysis|Correlative studies
219327371|NCT03445260|OTHER|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
219327372|NCT03445260|OTHER|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
219327373|NCT00407654|DRUG|aflibercept|Given intravenously
219327374|NCT00074581|DRUG|Atazanavir|300 mg taken orally once daily
219327375|NCT00074581|DRUG|Didanosine|400 mg taken orally once daily
219327376|NCT00074581|DRUG|Efavirenz|600 mg taken orally once daily
219327377|NCT00074581|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
219327378|NCT00074581|DRUG|Lamivudine|300 mg taken orally once daily
219327379|NCT00074581|DRUG|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
219327380|NCT00074581|DRUG|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
219327381|NCT00074581|DRUG|Stavudine|Dosage depends on weight
219327382|NCT00074581|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally once daily
219327383|NCT00074581|DRUG|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
219327384|NCT00108992|DRUG|Diclofenac, topical|
219327385|NCT02926469|DEVICE|Virtual Reality|Using Virtual Reality during labor
219327386|NCT00348062|DRUG|Bimatoprost|
219327387|NCT00002355|DRUG|Fomivirsen sodium|
219327388|NCT04733781|DRUG|Tumescent Lidocaine and Epinephrine|Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
219327389|NCT04411953|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
219327390|NCT04411953|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
219327391|NCT04087954|BEHAVIORAL|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
219327392|NCT02322229|DRUG|Ocriplasmin 0.125 mg in a 0.1 mL volume|
219327393|NCT02838095|BEHAVIORAL|Nap|A 1-hour daytime nap opportunity
219327394|NCT02794077|DRUG|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
219327395|NCT01859468|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|
219327396|NCT01859468|OTHER|Placebo|
219327397|NCT03613662|DRUG|SP-102|Injection
219327398|NCT05459285|BIOLOGICAL|14028 injection|14028 injection, single dose, s.c. injection
219327399|NCT05459285|BIOLOGICAL|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
219327400|NCT02176187|DRUG|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
219327401|NCT02176187|DRUG|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
219327402|NCT05355779|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
219327403|NCT03142438|DEVICE|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
219327404|NCT00154336|DRUG|Imatinib|
219327405|NCT00154336|DRUG|Methotrexate|
219327406|NCT00154336|DRUG|Imatinib Placebo|
219327407|NCT06306079|DEVICE|Lateral Wedge insole|Insoles with lateral wedges are placed in patients' shoes to control biomechanical knee loading on the medial side of the knee. Insoles with lateral wedges are designed to be thinner on the inside (medially of the foot) and thicker on the outside (laterally of the foot) to relieve knee biomechanical loading parameters.
219327408|NCT05955404|OTHER|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
219327409|NCT00705432|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
219327410|NCT00705432|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
219327411|NCT00705432|DRUG|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
219327412|NCT00705432|DRUG|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
219327413|NCT01372722|DEVICE|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
219327414|NCT01372722|DEVICE|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
219327415|NCT00598260|PROCEDURE|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
219327416|NCT04411628|DRUG|LY3819253|Administered IV.
219327417|NCT04411628|DRUG|Placebo|Administered IV.
219327418|NCT02827240|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
219327419|NCT01512563|DEVICE|Biliary stent|palliative treatment for malignant patients
219327420|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.
219327421|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with only physiological saline|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
219327422|NCT04286425|OTHER|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
219327423|NCT04286425|OTHER|saline solution|saline solution
219327424|NCT01034540|DRUG|POM3|4 g/day
219327425|NCT01034540|DRUG|Placebo|matching placebo capsule, 4 g/day
219327426|NCT05096351|OTHER|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
219327427|NCT00143481|DRUG|Tolterodine ER 4mg QD|
219327428|NCT01252810|DRUG|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
219327429|NCT02885194|OTHER|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
219327430|NCT02447692|OTHER|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
219327431|NCT02447692|OTHER|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
219327432|NCT01347775|DEVICE|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
219327433|NCT01347775|DEVICE|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
219327434|NCT04468620|BEHAVIORAL|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
219327435|NCT01367353|PROCEDURE|surgery or debulking surgery|surgery or debulking surgery
219327436|NCT05666037|BEHAVIORAL|Mobile health intervention(mHealth)|The intervention group will receive mobile health messaging intervention on behavior change to uptake early postpartum modern contraceptive method.
219327437|NCT04759261|OTHER|SMAD4 expression and methylation|Effect of SMAD4 methylations on smad4 expression
219327438|NCT00636467|OTHER|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
219327439|NCT04379921|DEVICE|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
219327440|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
219327441|NCT02575404|DRUG|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
219327442|NCT02575404|DRUG|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
219327443|NCT04272970|DIAGNOSTIC_TEST|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
219327444|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
219327445|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
219327446|NCT06733935|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
219327447|NCT06733935|DRUG|Fludarabine|Lymphodepletion
219327448|NCT06733935|DRUG|Cyclophosphamide|Lymphodepletion
219327449|NCT06023537|BEHAVIORAL|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
219327450|NCT06752031|BEHAVIORAL|OSCAR-S Care Transition Model|Patients and families in the intervention arm will receive touch points from the surgery nurse coach to support their care transition from hospital to home after surgery.
219327451|NCT03273296|DRUG|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
219327452|NCT03273296|DRUG|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
219327453|NCT03273296|DRUG|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
219327454|NCT06773169|OTHER|IAMABLE web-based app|The Intervention Group will use the IAMABLE app for 4 months. IAMABLE users identify activities that they are having difficulty with because of their health problem and set goals they want to work toward. Self-management (SM) modules help them reach their goals, providing information and rehabilitation strategies about exercise, fall prevention, fatigue management, pain management, physical activity, and stress management. Users complete a self-assessment associated with each module, and receive tailored recommendations that guide them to access relevant module topics. Users create 7-day action plans using the strategies in the module to address their activity goals. Users receive automated notifications when it is time to evaluate action plans and activity goals, as well as weekly messages to remind them to engage with the app. Users have access to therapist support using the Ask a Therapist feature and receive individual consultations in response to queries about SM.
219327455|NCT06773169|OTHER|General health information|The Control Group will receive a monthly email with general health information (not specific to rehabilitation or chronic diseases) for 4 months. Topics will include Nutrition, Vision Care, Foot Care, Hearing, Skin Care and Oral Care. Each email will include an introduction to the topic and links for additional information.
219327456|NCT06895135|OTHER|Amoxicillin|Participants in this group will receive oral amoxicillin at a dosage of 30mg/kg/day. The treatment will be administered in divided doses for the duration of the study, with the aim of resolving symptoms of acute otitis media in children.
219327457|NCT06895135|OTHER|Clavulanic Acid|Participants in this group will receive a combination of oral amoxicillin and clavulanic acid at a dosage of 30mg/kg/day. The medication will be given in divided doses, and participants will be monitored for symptom resolution and any potential side effects.
219327458|NCT05845658|DEVICE|Active VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
219327459|NCT05845658|DEVICE|Sham VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
219327460|NCT07130136|DEVICE|Cochlear™ Osia® System|The Osia System consists of the OSI300 Implant, Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, Osia 2 Sound Processor Magnet Tool, Osia Fitting Software 2 (OFS 2), and Osia Smart App.
219327461|NCT07130136|DEVICE|Cochlear™ Baha® System|The Baha Connect System consists of the BIA300 (BI300 Implant and BA300 Abutment), Baha 7 Sound Processor, and Baha Fitting Software 7 (BFS 7).
219327462|NCT07128732|OTHER|Peer mentoring training|As part of the intervention, a 15-hour peer mentoring training program was implemented, covering topics such as self-management and self-awareness, stress management, coaching and mentoring, critical thinking, problem-solving and decision-making, effective communication and relationship management.
219327463|NCT07130318|BEHAVIORAL|exercise plus diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)
219327464|NCT07130318|BEHAVIORAL|diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.
219327465|NCT07129720|BEHAVIORAL|Educational Program on MIH|"A 30-minute interactive educational session that includes a PowerPoint presentation, clinical images, and case-based discussions on Molar-Incisor Hypomineralization (MIH).~The session covers the definition, eatiology , clinical features, diagnosis and evidence-based treatment options of MIH.~The goal is to improve the participants' knowledge ,attitude and awareness . Evaluation will be conducted through pre- and post-intervention questionnaire."
219327466|NCT05540574|DRUG|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
219327467|NCT05540574|DRUG|Placebo|Matching Placebo given orally
219327468|NCT07075016|DRUG|Venetoclax 400|day 1-28 per cycle
219327469|NCT07075016|DRUG|Placebo|day 1-28 per cycle
219327470|NCT05515861|PROCEDURE|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
219327471|NCT06903156|DRUG|Mexidol|Neuroretinoprotector
219327472|NCT06903156|OTHER|Placebo|Placebo therapy
219327473|NCT06903377|BIOLOGICAL|ZG005 for Injection|intravenous infusion
219327474|NCT06903377|DRUG|Gecacitinib Hydrochloride Tablets|Oral
219327475|NCT07129512|PROCEDURE|Intracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using an ultrasonic scalpel with advanced hemostasis mode.
219327476|NCT07129512|PROCEDURE|Extracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using a monopolar energy device and surgical clips.
219327477|NCT07128901|DEVICE|Ekso Indego Therapy|User-balancing lower Limb exoskeleton
219327478|NCT07128901|DEVICE|Wandercraft Atalante X|Self-balancing lower limb exoskeleton
219327479|NCT01792804|DRUG|Trimethoprim-Sulfamethoxazole|study drug 1
219327480|NCT01792804|DRUG|Clindamycin|study drug 2
219327481|NCT01792804|DRUG|Linezolid|study drug 3
219327482|NCT01792804|DRUG|Flucloxacillin|study drug 4
219327483|NCT01792804|DRUG|Cloxacillin|study drug 5
219327484|NCT01792804|DRUG|Vancomycin|study drug 6
219327485|NCT01792804|DRUG|Daptomycin|study drug 7
219327486|NCT01792804|DRUG|Cefazolin|study drug 8
219327487|NCT05691998|OTHER|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
219327488|NCT00464347|DRUG|Avastin|
219327489|NCT00464347|PROCEDURE|Photodynamic Therapy (PDT)|
219327490|NCT00464347|DRUG|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
219327491|NCT03307434|OTHER|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
219327492|NCT03307434|OTHER|regular training|The regular training will be performed by control group according to the standard practice.
219327493|NCT02008279|BIOLOGICAL|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
219327494|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
219327495|NCT02008279|BIOLOGICAL|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
219327496|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
219327497|NCT02008279|DRUG|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
219327498|NCT03409848|DRUG|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
219327499|NCT03409848|DRUG|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
219327500|NCT03409848|DRUG|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
219327501|NCT01932242|BIOLOGICAL|ETI-204|Monoclonal Antibody
219327502|NCT01932242|OTHER|Placebo|Placebo for ETI-204
219327503|NCT06474416|GENETIC|BD111 Injection (Investigative New Drug)|BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).
219327504|NCT06474416|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
219327505|NCT02349399|DRUG|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
219327506|NCT02549430|DRUG|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
219327507|NCT02549430|DRUG|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
219327508|NCT02549430|DRUG|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
219327509|NCT02549430|DRUG|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
219327510|NCT02549430|DRUG|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
219327511|NCT00372242|BEHAVIORAL|Prospective Longitudinal Interventional Stury|
219327512|NCT02198339|DRUG|BIBN 4096 BS|
219327513|NCT02198339|DRUG|Placebo|
219327514|NCT05732090|OTHER|therapeutic exercise program|therapeutic exercise program (3 sessions/week/two months).
219327515|NCT05732090|OTHER|diaphragmatic myofascial release|therapeutic exercise program in addition to diaphragmatic myofascial release (3 sessions/week/two months).
219327516|NCT01085552|DRUG|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
219327517|NCT01715220|DRUG|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
219327518|NCT00399789|DRUG|Perifosine|Perifosine will be tested in 3 dose forms
219327519|NCT00761306|DRUG|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
219327520|NCT05162027|DRUG|Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
219327521|NCT05162027|DRUG|Placebo|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
219327522|NCT06054191|DRUG|Dabrafenib + Trametinib|Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
219327523|NCT06054191|DRUG|Capmatinib|Capmatinib 400mg BID/（2 cycles）
219327524|NCT04284202|DRUG|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
219327525|NCT02036632|DEVICE|Eye Patching|
219327526|NCT04729673|DEVICE|Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
219327527|NCT03015675|DRUG|ascorbic acid|20g/day, D1-3, every 2 weeks
219327528|NCT03015675|DRUG|mFOLFOX6|"mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
219327529|NCT05574595|OTHER|Music theraphy|In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
219327530|NCT02978534|DRUG|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
219327531|NCT00838214|DRUG|budesonide|3mg capsule, 3x per day for 6 months
219327532|NCT00838214|DRUG|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
219327533|NCT06013592|DIETARY_SUPPLEMENT|0 kcal liquid meal|Flavoured water, given as one meal at one study visit only
219327534|NCT06013592|DIETARY_SUPPLEMENT|600 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
219327535|NCT06013592|DIETARY_SUPPLEMENT|900 kcal liquid meal (only for group without obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
219327536|NCT06013592|DIETARY_SUPPLEMENT|1200 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
219327537|NCT06013592|DIETARY_SUPPLEMENT|1800 kcal liquid meal (only for group with obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
219327538|NCT03713034|OTHER|PlayTest!|Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
219327539|NCT03713034|OTHER|Control games|Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
219327540|NCT02500667|DRUG|N91115|200 mg BID
219327541|NCT02500667|DRUG|Rifampin|600 mg QD
219327542|NCT00713817|DRUG|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
219327543|NCT00713817|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
219327544|NCT02293850|BIOLOGICAL|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
219327545|NCT03846349|DEVICE|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
219327546|NCT03846349|DEVICE|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
219327547|NCT05443230|DIAGNOSTIC_TEST|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
219327548|NCT02982239|BEHAVIORAL|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
219327549|NCT02982239|DEVICE|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
219327550|NCT02982239|DEVICE|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
219327551|NCT02982239|DEVICE|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
219327552|NCT02982239|OTHER|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q\&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
219327553|NCT02982239|BEHAVIORAL|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
219327554|NCT06495528|DEVICE|Pain management with BLISS DTx|Bliss DTx is a Digital Therapeutics (DTx) which uses virtual reality augmented with sound and visual stimuli to reduce pain during Port-A-Cath setting
219327555|NCT06495528|OTHER|Pain Management with site standard of care sedation protocol|Sedation (morphine and/or hypnotics and/or anxiolytics and/or conversational hypnosis) reduces pain during Port-A-Cath setting
219327556|NCT05049980|DRUG|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
219327557|NCT05049980|PROCEDURE|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
219327558|NCT05837520|DEVICE|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
219327559|NCT05837520|BEHAVIORAL|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
219327560|NCT01938131|DEVICE|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
219327561|NCT03561792|OTHER|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
219327562|NCT02475226|OTHER|type of the brain injury|epidural hematoma
219327563|NCT02475226|OTHER|type of the brain injury|subdural hematoma
219327564|NCT02475226|OTHER|type of the brain injury|subarachnoid hematoma
219327565|NCT02475226|OTHER|type of the brain injury|intraparenchymal hematoma
219327566|NCT02475226|OTHER|type of the brain injury|scull fracture
219327567|NCT02475226|OTHER|type of the brain injury|brain contusion
219327568|NCT00452049|PROCEDURE|parathyroidectomy|parathyroidectomy
219327569|NCT06070077|PROCEDURE|Chest compressions|2 minutes of chest compressions
219327570|NCT06227364|DIAGNOSTIC_TEST|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
219327571|NCT06227364|DIAGNOSTIC_TEST|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
219327572|NCT05894174|BEHAVIORAL|Board Game|Food Hunter board game intervention, which includes various nutrient cards and question cards and is played with pawns and dice, will be played with children for approximately 4 weeks, one day a week and one session (40 minutes) with the researcher dietitian. By talking about the nutrients in the game on the game cards, children will be able to recognize the nutrients and important points will be emphasized for the participants with the answers to the cards containing various questions about healthy nutrition.
219327573|NCT04296877|DEVICE|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
219327574|NCT06289322|OTHER|Digital toolkit for assessment|The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
219327575|NCT05331040|DIAGNOSTIC_TEST|MRI|Radiomic analysis of newly diagnosed rectal cancers
219327576|NCT03361150|PROCEDURE|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
219327577|NCT03361150|PROCEDURE|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
219327578|NCT03443505|DIAGNOSTIC_TEST|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
219327579|NCT06302647|OTHER|Questionnaires|Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment
219327580|NCT00886704|DIETARY_SUPPLEMENT|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
219327581|NCT00886704|DIETARY_SUPPLEMENT|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
219327582|NCT03868852|DRUG|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
219327583|NCT03868852|RADIATION|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
219327584|NCT01129050|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
219327585|NCT01129050|DIETARY_SUPPLEMENT|Flaxseed Oil|Flaxseed oil capsule
219327586|NCT01129050|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule
219327587|NCT04183816|OTHER|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
219327588|NCT04183816|OTHER|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
219327589|NCT03846570|DRUG|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
219327590|NCT03846570|DRUG|Placebo|Matching placebo (identically package) administered BID
219327591|NCT02107495|DEVICE|Samsung LABGEO IVD-A20 CHF Test|
219327592|NCT02767323|DEVICE|rTMS|excitatory 5Hz rTMS will be used
219327593|NCT02767323|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
219327594|NCT01865526|DIETARY_SUPPLEMENT|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
219327595|NCT01865526|DIETARY_SUPPLEMENT|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
219327596|NCT05558826|DEVICE|HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software|After induction of anesthesia, intra-arterial catheterization will be done for invasive blood pressure monitoring and blood sampling as routine clinical practice for major laparoscopic surgery. Arterial line will be connected to HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software for arterial pressure waveform analysis. Dynamic indices including pulse pressure variation (PPV), stroke volume variation (SVV), Hypotension Prediction Index (HPI), Dynamic arterial elastance (Eadyn) and dP/dt will be continuously recorded. Changes in levels of intra-abdominal pressure and angles of Trendelenburg position will be recorded. Data analysis and statistics will be particularly performed to explore the effects of levels of intra-abdominal pressure and angles of Trendelenburg position on dynamic indices of arterial pressure waveform.
219327597|NCT05341648|OTHER|Aerobic Exercise Training|Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
219327598|NCT05341648|OTHER|Home Plan|"* Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks."
219327599|NCT05957250|DIAGNOSTIC_TEST|[68Ga]Ga-FAPI-46 PET/CT|one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
219327600|NCT00745199|DRUG|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
219327601|NCT00745199|DRUG|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
219327602|NCT02895620|BIOLOGICAL|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
219327603|NCT01847430|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
219327604|NCT01104038|BEHAVIORAL|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
219327605|NCT01104038|BEHAVIORAL|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
219327606|NCT01104038|BEHAVIORAL|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
219327607|NCT01686776|OTHER|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
219327608|NCT05362422|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
219327609|NCT05362422|DEVICE|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
219327610|NCT04553848|BEHAVIORAL|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
219327611|NCT04553848|BEHAVIORAL|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
219327612|NCT04553848|BEHAVIORAL|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait"
219327613|NCT06396585|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
219327614|NCT06396585|DRUG|Anlotinib|Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
219327615|NCT06396585|DRUG|Oxaliplatin|Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
219327616|NCT06396585|DRUG|Tegafur|Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
219327617|NCT00633711|DEVICE|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
219327618|NCT00633711|DEVICE|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
219327619|NCT05831748|OTHER|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
219327620|NCT05831748|OTHER|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
219327621|NCT02982369|OTHER|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
219327622|NCT02982369|OTHER|Pain Education|Subjects will receive pain education based in biopsychosocial approach
219327623|NCT02982369|OTHER|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
219327624|NCT01187966|DRUG|Safinamide|
219327625|NCT01187966|DRUG|Safinamide|
219327626|NCT01187966|DRUG|Placebo|
219327627|NCT04479436|DRUG|Patritumab Deruxtecan|U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
219327628|NCT02176473|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
219327629|NCT02675816|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
219327630|NCT04311697|DRUG|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
219327631|NCT04311697|DRUG|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
219327632|NCT04782284|OTHER|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
219327633|NCT04782284|OTHER|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
219327634|NCT00012220|DRUG|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
219327635|NCT00012220|DRUG|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
219327636|NCT00012220|DRUG|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle"
219327637|NCT00012220|DRUG|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
219327638|NCT00064220|DRUG|soblidotin|
219327639|NCT04465448|OTHER|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
219327640|NCT04739267|DEVICE|CardioFlux|Not an intervention
219327641|NCT04466644|DIAGNOSTIC_TEST|ELISA|Antibody test (serology) in the blood samples to determine if the subject was previously infected.
219327642|NCT04466644|DIAGNOSTIC_TEST|RT-PCR|For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
219327643|NCT05982093|DRUG|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
219327644|NCT05982093|DRUG|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
219327645|NCT03385720|PROCEDURE|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
219327646|NCT03385720|PROCEDURE|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
219327647|NCT04625842|OTHER|Focus group interview|Group interview with patients who received radiation treatment
219327648|NCT06041399|DRUG|hypoglycemic Agents(metformin)|patients treated with hypoglycemic Agents(metformin)
219327649|NCT06041399|DRUG|lipid-lowering drug(Statin)|patients treated with lipid-lowering drug(Statin)
219327650|NCT00003440|DRUG|paclitaxel|Given IV over 1 hour or 3 hours
219327651|NCT00003440|BIOLOGICAL|trastuzumab|Given IV
219327652|NCT00003440|PROCEDURE|quality-of-life assessment|Ancillary studies
219327653|NCT00003440|OTHER|laboratory biomarker analysis|Correlative studies
219327654|NCT02730273|DEVICE|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
219327655|NCT03754140|DRUG|Polidocanol Injection|Sclerotic agent
219327656|NCT03305289|PROCEDURE|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
219327657|NCT03305289|PROCEDURE|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
219327658|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
219327659|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
219327660|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
219327661|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
219327662|NCT01540825|DRUG|Placebo|Powder for oral solution
219327663|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
219327664|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
219327665|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
219327666|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
219327667|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
219327668|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
219327669|NCT04678596|DEVICE|EonAligner|EonAligner system is one stage system.
219327670|NCT04678596|DEVICE|Clearfix|Clearfix system is three-stage system.
219327671|NCT02247765|DEVICE|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
219327672|NCT02247765|DEVICE|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
219327673|NCT01641237|DRUG|sodium fluoride|fluoride as sodium fluoride
219327674|NCT01641237|DRUG|no added fluoride in a silica base|no added fluoride
219327675|NCT01546974|DEVICE|HME filter Twin Star 55, Drager Medical, Germany|
219327676|NCT01546974|DEVICE|Heated humidification|
219327677|NCT06188819|PROCEDURE|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
219327678|NCT05075837|BIOLOGICAL|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
219327679|NCT00623974|DRUG|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
219327680|NCT00623974|DRUG|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
219327681|NCT00623974|DRUG|Calcitriol|0.25 micrograms PO Every 12 Hours
219327682|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
219327683|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
219327684|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
219327685|NCT00267683|DRUG|insulin aspart|
219327686|NCT00267683|DRUG|glibenclamide|
219327687|NCT00918853|PROCEDURE|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
219327688|NCT00220168|DRUG|Irinotecan, Capecitabine|
219327689|NCT00393796|DRUG|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
219327690|NCT00393796|OTHER|Placebo|
219327691|NCT03504514|DEVICE|speech trials during different ventilation conditions|ventilator parameters are modified
219327692|NCT03504514|OTHER|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
219327693|NCT05368961|BEHAVIORAL|Distraction|Distraction (interactive tablet)
219327694|NCT05368961|OTHER|Usual care|Anxiolytic ordered by anesthesiologist is usual care
219327695|NCT02342366|DRUG|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
219327696|NCT02342366|DRUG|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
219327697|NCT04187300|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
219327698|NCT00164073|PROCEDURE|Liver biopsy|
219327699|NCT03289936|DEVICE|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
219327700|NCT03289936|DEVICE|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
219327701|NCT02508051|BEHAVIORAL|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
219327702|NCT02508051|BEHAVIORAL|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
219327703|NCT02782936|OTHER|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
219327704|NCT02782936|DEVICE|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
219327705|NCT01612468|DRUG|Liraglutide|1.8 mg/day subcutaneous
219327706|NCT01612468|DRUG|Placebo|1.8 mg/day subcutaneous
219327707|NCT03593850|BEHAVIORAL|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
219327708|NCT03593850|BEHAVIORAL|Silence Group|Audio file that contained no sounds.
219327709|NCT02539420|DEVICE|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
219327710|NCT02946242|DEVICE|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
219327711|NCT03357315|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
219327712|NCT01735279|DRUG|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
219327713|NCT01735279|DRUG|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
219327714|NCT05340361|DEVICE|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
219327715|NCT05340361|DEVICE|Optical coherence tomography-guided Onyx family stent expansion|"1. Expansion of 2.25, 3.0, and 4.0 mm Onyx family stent@ nominal pressure~2. OCT pullback~3. Expansion with over 0.5mm sized non-compliant balloon of each stent~4. OCT pullback~5. Expansion with over 1.0mm sized non-compliant balloon of each stent~6. OCT pullback~7. Expansion with over 1.25\~1.5mm sized non-compliant balloon of each stent~8. OCT pullback~9. Evaluation of polymer status with overexpansion assessed by an electric microscope"
219327716|NCT05460611|DEVICE|Sciton HALO 1470nm Non-ablative laser|Patients will be treated with the 1470nm non-ablative laser.
219327717|NCT06033885|DEVICE|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
219327718|NCT00119041|BEHAVIORAL|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
219327719|NCT00119041|BEHAVIORAL|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
219327720|NCT00119041|BEHAVIORAL|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
219327721|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
219327722|NCT04748653|BEHAVIORAL|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
219327723|NCT04170790|DRUG|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
219327724|NCT04170790|DRUG|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
219327725|NCT02790255|OTHER|Cold air|
219327726|NCT02790255|OTHER|Cold water|
219327727|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
219327728|NCT01195090|DRUG|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
219327729|NCT01195090|DRUG|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
219327730|NCT05111041|BEHAVIORAL|#EnufSnuff.TXT- First Responder|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
219327731|NCT05111041|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
219327732|NCT01205230|DRUG|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
219327733|NCT01322503|BIOLOGICAL|Norovirus|Norovirus challenge pool administered to each subject
219327734|NCT02520375|OTHER|Prebiotic|
219327735|NCT02520375|OTHER|Control|
219327736|NCT03770949|DEVICE|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
219327737|NCT02575248|DRUG|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
219327738|NCT02575248|DRUG|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
219327739|NCT00004754|DRUG|epoprostenol|
219327740|NCT01480453|DEVICE|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
219327741|NCT04713423|DIAGNOSTIC_TEST|Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.
219327742|NCT06219070|OTHER|Core straining|The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
219327743|NCT00791258|DRUG|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
219327744|NCT00791258|DRUG|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
219327745|NCT05285709|DIAGNOSTIC_TEST|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
219327746|NCT05285709|DIAGNOSTIC_TEST|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
219327747|NCT00774813|DEVICE|Nexalin 1.3mA Device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant"
219327748|NCT00774813|DEVICE|Nexalin 15mA device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant"
219327749|NCT00774813|DRUG|placebo device and Citalopram|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)"
219327750|NCT02599454|DRUG|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
219327751|NCT02599454|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
219327752|NCT02637115|DIETARY_SUPPLEMENT|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
219327753|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
219327754|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
219327755|NCT02637115|DIETARY_SUPPLEMENT|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
219327756|NCT00805662|DRUG|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
219327757|NCT00156234|BEHAVIORAL|One-knee extension ergometer|
219327758|NCT01698866|BIOLOGICAL|Vaccin GenHevac B Pasteur|
219327759|NCT00922480|DRUG|Fimasartan|Fimasartan 60 \~ 120mg/po take one tablets once a day
219327760|NCT00922480|DRUG|Losartan (Control)|Losartan 50 mg \~ 100 mg/po, take one tablets once a day
219327761|NCT03269643|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219327762|NCT03269643|DEVICE|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219327763|NCT03877978|BIOLOGICAL|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
219327764|NCT02811055|BIOLOGICAL|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
219327765|NCT02811055|PROCEDURE|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
219327766|NCT02811055|DEVICE|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
219327767|NCT02811055|PROCEDURE|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
219327768|NCT02811055|DRUG|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
219327769|NCT02811055|DRUG|Administration of placebo|Administration of placebo once per day during 14 days
219327770|NCT05140122|DRUG|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
219327771|NCT05140122|OTHER|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
219327772|NCT02745366|PROCEDURE|BFPSC+FDBA+PRF|
219327773|NCT02745366|PROCEDURE|FDBA+PRF|
219327774|NCT01017367|DRUG|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
219327775|NCT01017367|DRUG|Placebo|Placebo
219327776|NCT04784897|DRUG|Brilacidin|Brilacidin IV infusion
219327777|NCT04784897|DRUG|Placebo|Placebo IV infusion
219327778|NCT04784897|DRUG|Standard of Care (SoC)|SoC therapies for COVID-19
219327779|NCT01893229|DRUG|Lithium|Lithium is used as a mood stabiliser
219327780|NCT01893229|DRUG|Valproate|Valproate is used as a mood stabiliser
219327781|NCT01893229|DRUG|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
219327782|NCT01893229|DRUG|Quetiapine|Quetiapine is used as a mood stabiliser
219327783|NCT01893229|DRUG|Olanzapine|Olanzapine is used as a mood stabiliser.
219327784|NCT01893229|DRUG|Ziprasidone|Ziprasidone is used as a mood stabiliser
219327785|NCT04918745|DEVICE|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~* A - Baseline stimulation, no modulation stimulation~* B - Baseline stimulation, modulated stimulation~* C - Reduced baseline stimulation, modulated stimulation"
219327786|NCT00502073|DRUG|cyclosporine|
219327787|NCT01200004|DRUG|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
219327788|NCT01200004|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
219327789|NCT01200004|DRUG|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
219327790|NCT04667377|DRUG|BI 456906|BI 456906
219327791|NCT04667377|DRUG|Placebo|Placebo
219327792|NCT04722120|RADIATION|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
219327793|NCT04722120|RADIATION|Conventional CT (radiation)|Underwent liver CT without change of radiation.
219327794|NCT04722120|DRUG|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
219327795|NCT04722120|DRUG|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
219327796|NCT04722120|OTHER|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
219327797|NCT00006345|BIOLOGICAL|denileukin diftitox|
219327798|NCT00006345|DRUG|dexamethasone|
219327799|NCT01312454|DRUG|AL-59412C injectable solution|Concentration 1 and Concentration 2
219327800|NCT01312454|DRUG|Travoprost injectable solution|
219327801|NCT01312454|DRUG|AL-59412C Vehicle|Inactive ingredients used as placebo
219327802|NCT01011439|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
219327803|NCT03687645|DIAGNOSTIC_TEST|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
219327804|NCT03660709|BEHAVIORAL|Intervention|"1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5."
219327805|NCT03660709|BEHAVIORAL|Control|Standard-of-care HIV testing and counseling
219327806|NCT03558165|DIAGNOSTIC_TEST|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
219327807|NCT02302352|OTHER|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
219327808|NCT02302352|OTHER|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
219327809|NCT05931796|OTHER|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
219327810|NCT05931796|OTHER|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
219327811|NCT05781230|BEHAVIORAL|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
219327812|NCT05781230|BEHAVIORAL|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity
219327813|NCT02428855|DRUG|Dasatinib|
219327814|NCT02057796|DEVICE|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
219327815|NCT02057796|DRUG|ART (Atripla, Truvada, Efavirenz, Combivir)|"* ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
219327816|NCT02057796|DRUG|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
219327817|NCT02066311|DRUG|Nelfinavir|
219327818|NCT00006151|BEHAVIORAL|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
219327819|NCT05623930|DEVICE|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
219327820|NCT05623930|OTHER|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
219327821|NCT00702364|DRUG|atomoxetine|
219327822|NCT00702364|DRUG|placebo|
219327823|NCT04624464|OTHER|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
219327824|NCT04624464|OTHER|Examination of patient room|Only performed for cohort 2
219327825|NCT04781231|DEVICE|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
219327826|NCT04781231|DEVICE|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
219327827|NCT04781231|OTHER|Usual management of anxiety|No specific intervention
219327828|NCT00655954|PROCEDURE|Induced sputum|Used Ultrasonic nebuliser
219327829|NCT02607592|DRUG|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
219327830|NCT02607592|DRUG|nedaplatin+pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
219327831|NCT03198520|DEVICE|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
219327832|NCT06340048|DRUG|HiCM-188 therapy|Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
219327833|NCT05223634|OTHER|Collection of oral and/or nasal samples|Collection of oral and/or nasal samples after SOC test performed
219327834|NCT01670539|DEVICE|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
219327835|NCT01444482|BIOLOGICAL|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
219327836|NCT01444482|BIOLOGICAL|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
219327837|NCT01684072|BIOLOGICAL|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
219327838|NCT01684072|BIOLOGICAL|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
219327839|NCT06075342|BEHAVIORAL|exercise|Exercise intervention according to the training program
219327840|NCT01688128|DEVICE|Phase I U-SMART (4 wks)|Intervention\_Control Group, 4-weeks U-SMART(2 session/week); Control\_Intervention Group, no intervention
219327841|NCT01688128|OTHER|Washout (2 wks)|2-weeks wash out period in both arms
219327842|NCT01688128|DEVICE|Phase II U-SMART (4 wks)|Intervention\_Control Group, no intervention; Control\_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
219327843|NCT02558114|DRUG|Ribavirin|
219327844|NCT00536809|DRUG|lapatinib|onced daily Days 1-21
219327845|NCT00536809|DRUG|oxaliplatin|Day one of each cycle
219327846|NCT00536809|DRUG|capecitabine|given BID days 1-14
219327847|NCT00284323|DRUG|Adenosine|
219327848|NCT00164827|DEVICE|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
219327849|NCT01659372|RADIATION|low level laser therapy|
219327850|NCT01659372|DRUG|Naproxen|
219327851|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219327852|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
219327853|NCT04817241|DRUG|Cytarabine|Given IV
219327854|NCT04817241|DRUG|Daunorubicin|Given IV
219327855|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
219327856|NCT04817241|DRUG|Venetoclax|Given PO
219327857|NCT02792179|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
219327858|NCT02905253|DRUG|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
219327859|NCT02905253|DRUG|Placebo|Placebo capsules matching AC-084 capsules
219327860|NCT05986513|BEHAVIORAL|Cold Pressor Gel Test|This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.
219327861|NCT05933486|DRUG|Tongluo-Kaibi tablet plus placebo of pregabalin|Tongluo-Kaibi Tablet 0.93g qd； Placebo of pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
219327862|NCT05933486|DRUG|placebo of Tongluo-Kaibi tablet plus pregabalin|placebo of Tongluo-Kaibi Tablet 0.93g qd； Pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
219327863|NCT02606461|DRUG|Selinexor|Selinexor 60mg
219327864|NCT02606461|DRUG|Placebo|
219327865|NCT03520478|DRUG|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
219327866|NCT03520478|DRUG|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
219327867|NCT03226405|OTHER|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
219327868|NCT03226405|OTHER|Usual Care|the standard of care provided by the institution
219327869|NCT01536236|DEVICE|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
219327870|NCT01536236|DEVICE|Placebo|Placebo
219327871|NCT02320136|BEHAVIORAL|cognitive testing|patients perform simple tasks like watching a video or memorizing items
219327872|NCT04047550|DIAGNOSTIC_TEST|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
219327873|NCT03747978|DRUG|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
219327874|NCT03747978|DRUG|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
219327875|NCT04374409|DIETARY_SUPPLEMENT|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
219327876|NCT04374409|DIETARY_SUPPLEMENT|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
219355377|NCT04405050|DEVICE|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
219327877|NCT02061605|DEVICE|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
219327878|NCT00057356|DRUG|conivaptan|IV
219327879|NCT00057356|DRUG|placebo|IV
219327880|NCT00300287|DRUG|Vildagliptin|
219327881|NCT04714528|OTHER|Physical Exercise|Physical exercise as described before.
219327882|NCT04714528|OTHER|Relaxation Therapy|Relaxation therapy as described before.
219327883|NCT02032602|OTHER|Deep Dry Needling|
219327884|NCT03262792|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
219327885|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 150 mg
219327886|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 300 mg
219327887|NCT03635814|DRUG|YD312 50mg|YD312 50mg \* 1 + placebo 6 tablets
219327888|NCT03635814|DRUG|YD312 150mg|YD312 50mg \* 3 + placebo 6 tablets
219327889|NCT03635814|DRUG|YD312 350mg|YD312 50mg \* 7 tablets
219327890|NCT03635814|DRUG|Placebo|YD312 0mg \* 7 tabets
219327891|NCT06493682|BEHAVIORAL|Experimental (Motivational Interviews)|Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
219327892|NCT01068392|DRUG|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
219327893|NCT06048315|DRUG|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
219327894|NCT06048315|DRUG|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
219327895|NCT00729482|DRUG|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
219327896|NCT01303965|DRUG|Sirolimus|Start on Day -3 and continue for 1 year
219327897|NCT01303965|DRUG|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
219327898|NCT01303965|DRUG|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
219327899|NCT02177890|DEVICE|Transcutaneous vagal nerve stimulation|
219327900|NCT02177890|DEVICE|Sham vagal nerve stimulation|
219327901|NCT02931136|DRUG|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
219327902|NCT02931136|DRUG|Placebo|The participants will treatment by the placebo in 52 weeks.
219327903|NCT01433757|DRUG|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
219327904|NCT01433757|DRUG|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
219327905|NCT03042182|BIOLOGICAL|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
219327906|NCT02941874|OTHER|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
219327907|NCT02111460|RADIATION|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
219327908|NCT00029913|OTHER|Observation|Observation of participants who received HIV preventive vaccine and became infected.
219327909|NCT03178708|DRUG|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
219327910|NCT03178708|OTHER|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
219327911|NCT05971862|DRUG|SKI-G-801|Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
219327912|NCT01797497|BEHAVIORAL|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
219327913|NCT03916887|BEHAVIORAL|Golf instruction|Non-golfers instructed to golf over 10 weeks
219327914|NCT02742064|OTHER|Cogito Companion Mobile Phone Application|
219327915|NCT06374472|PROCEDURE|Osteosynthesis|Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
219327916|NCT04422990|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
219327917|NCT04422990|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
219327918|NCT04422990|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
219327919|NCT03831867|OTHER|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
219327920|NCT03627897|DRUG|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
219327921|NCT03627897|DRUG|saline|No drugs or interventions were administered to the control group.
219327922|NCT00097942|DRUG|memantine HCl|
219327923|NCT02355249|PROCEDURE|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
219327924|NCT02355249|PROCEDURE|OE|Patients will be treated with traditional three incisions esophagectomy.
219327925|NCT04429854|BIOLOGICAL|Convalescent Plasma|"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."
219327926|NCT04429854|DRUG|Standard of care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
219327927|NCT01750320|DEVICE|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
219327928|NCT00713479|DRUG|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
219327929|NCT00713479|DRUG|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
219327930|NCT03789461|PROCEDURE|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
219327931|NCT02648516|COMBINATION_PRODUCT|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
219327932|NCT02844920|DEVICE|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
219327933|NCT01966614|DRUG|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
219327934|NCT01966614|OTHER|Placebo|Single intraprostatic bilateral injection of vehicle only
219327935|NCT02429726|DRUG|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
219327936|NCT02429726|DRUG|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
219327937|NCT02429726|DRUG|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
219327938|NCT02224313|DRUG|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
219327939|NCT02224313|DRUG|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
219327940|NCT00224094|DRUG|Premarin® (oral) vs. Alora® (transdermal)|
219327941|NCT04862533|DRUG|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
219327942|NCT04862533|DRUG|Placebo|Participants will receive matching placebo three times a day
219327943|NCT04862533|PROCEDURE|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
219327944|NCT05281107|DIETARY_SUPPLEMENT|Placebo, 500 mg calcium|Berry flavoured sachet powder (500 mg calcium)
219327945|NCT05281107|DIETARY_SUPPLEMENT|600 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
219327946|NCT05281107|DIETARY_SUPPLEMENT|1200 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
219327947|NCT05281107|DIETARY_SUPPLEMENT|4000 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
219327948|NCT01520233|GENETIC|RNA analysis|
219327949|NCT01520233|GENETIC|gene expression analysis|
219327950|NCT01520233|OTHER|laboratory biomarker analysis|
219327951|NCT04092348|OTHER|complete blood count|"1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
219327952|NCT02193321|BIOLOGICAL|Amniotic Membrane Patch|
219327953|NCT05952674|DEVICE|Vagus Nerve Stimulation (VNS)|The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
219327954|NCT05952674|OTHER|Best Medical Treatment|Best Medical Treatment for resistant depression.
219327955|NCT05005806|DRUG|Omega 3 fatty acid|omega 3 fatty acid soft gel
219327956|NCT05005806|DRUG|Placebo|placebo soft gel
219327957|NCT05963958|COMBINATION_PRODUCT|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
219327958|NCT05963958|COMBINATION_PRODUCT|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
219327959|NCT05339581|RADIATION|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
219327960|NCT05339581|COMBINATION_PRODUCT|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.
219327961|NCT05339581|DRUG|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
219327962|NCT05339581|DRUG|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
219327963|NCT05339581|DRUG|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
219327964|NCT05339581|DRUG|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
219327965|NCT00053950|DRUG|pyrazoloacridine|Given IV
219327966|NCT00053950|BIOLOGICAL|filgrastim|Given IV or SC
219327967|NCT00053950|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
219327968|NCT00053950|PROCEDURE|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
219327969|NCT00053950|OTHER|laboratory biomarker analysis|Correlative studies
219327970|NCT00053950|OTHER|pharmacological study|Correlative studies
219327971|NCT01127659|DRUG|testosterone|intramuscular every 2 weeks
219327972|NCT01127659|DRUG|placebo|saline intramuscular every 2 weeks
219327973|NCT05750875|DRUG|Loratadine|Participants were given loratadine 10mg, oral, daily, for 4 weeks
219327974|NCT05750875|DRUG|Gabapentin|Participants were given gabapentin 100mg, oral, daily, for 4 weeks
219327975|NCT01948336|DRUG|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
219327976|NCT01948336|DRUG|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
219327977|NCT01948336|DRUG|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
219327978|NCT05801328|DEVICE|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
219327979|NCT00721370|DEVICE|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
219327980|NCT04344470|DEVICE|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
219327981|NCT04344470|DEVICE|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
219327982|NCT00047671|DRUG|Citalopram|PDA Approved antidepressant
219327983|NCT04472520|DEVICE|AliveCor Heart Monitor|Records single-channel ECG rhythms
219327984|NCT05244291|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
219327985|NCT05284279|OTHER|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
219327986|NCT00699465|DRUG|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
219327987|NCT00699465|DRUG|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
219327988|NCT00240981|DRUG|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
219327989|NCT00240981|DRUG|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
219327990|NCT00766090|DRUG|GW685698X|Inhaled Corticosteroid
219327991|NCT00800436|DRUG|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
219327992|NCT00021320|DRUG|cisplatin|
219327993|NCT00021320|DRUG|fluorouracil|
219327994|NCT00021320|DRUG|paclitaxel|
219327995|NCT00021320|PROCEDURE|conventional surgery|
219327996|NCT00021320|PROCEDURE|neoadjuvant therapy|
219327997|NCT00021320|RADIATION|radiation therapy|
219327998|NCT03331770|DRUG|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
219327999|NCT05172414|OTHER|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
219328000|NCT03331861|DRUG|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
219328001|NCT03331861|DRUG|Placebo|Similar dosing regime as active comparator
219328002|NCT04858763|OTHER|No Intervention|There will be no intervention during this study.
219328003|NCT03250260|OTHER|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
219328004|NCT03250260|OTHER|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
219328005|NCT01578408|PROCEDURE|Total Hip Arthroplasty|
219328006|NCT01578408|DEVICE|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
219328007|NCT01578408|DEVICE|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
219328008|NCT04195854|DEVICE|P4HB product|Retrospective use of P4HB in various anatomies
219328009|NCT01750931|DRUG|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
219328010|NCT01750931|DRUG|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
219328011|NCT00528580|DRUG|Simvastatin|80 mg once daily PO/NG x 4 days
219328012|NCT00528580|DRUG|Identical-appearing placebo|once daily x 4 days
219328013|NCT06170112|OTHER|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
219328014|NCT02855671|DEVICE|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
219328015|NCT00587392|DEVICE|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
219328016|NCT02198092|OTHER|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
219328017|NCT01106027|DRUG|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
219328018|NCT03875989|PROCEDURE|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
219328019|NCT03875989|PROCEDURE|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
219328020|NCT02115425|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
219328021|NCT02115425|OTHER|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
219328022|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
219328023|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
219328024|NCT02115425|OTHER|add name here|
219328025|NCT02871778|DRUG|VX-371|
219328026|NCT02871778|DRUG|Hypertonic Saline|
219328027|NCT02871778|DRUG|Placebo (0.17% saline)|
219328028|NCT02871778|DRUG|VX-371 + HS|
219328029|NCT02871778|DRUG|Ivacaftor|
219328030|NCT03149614|OTHER|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
219328031|NCT03149614|OTHER|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
219328032|NCT02078635|BEHAVIORAL|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
219328033|NCT02078635|BEHAVIORAL|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
219328034|NCT01568398|DRUG|TAK-438|
219328035|NCT05217563|BEHAVIORAL|Memory-reframing intervention (Reframe the Pain)|Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
219328036|NCT02653300|BIOLOGICAL|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
219328037|NCT02927587|DRUG|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
219328038|NCT04646070|PROCEDURE|Reduction mammaplasty|Breast reduction surgery
219328039|NCT02761486|DRUG|Aspirin|325mg aspirin per day
219328040|NCT02761486|DRUG|Placebo|placebo in matching capsules
219328041|NCT04554238|DEVICE|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
219328042|NCT04554238|OTHER|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
219328043|NCT00427089|DRUG|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
219328044|NCT00427089|DRUG|Sodium Phosphate solution (NaP)|45 ml solution; BID
219328045|NCT00842738|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
219328046|NCT00842738|OTHER|No meditation|Health care services as usual
219328047|NCT00842738|OTHER|Controls|No intervention
219328048|NCT01106820|OTHER|Supervised progressive resistance training|Supervised progressive resistance training
219328049|NCT01106820|OTHER|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
219328050|NCT00189189|BEHAVIORAL|parent management training|
219328051|NCT02170779|BEHAVIORAL|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
219328052|NCT02170779|OTHER|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
219328053|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
219328054|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
219328055|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
219328056|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
219328057|NCT01286454|DRUG|fesoterodine|single dose of tablet
219328058|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
219328059|NCT00369785|DRUG|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
219328060|NCT00369785|DRUG|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
219328061|NCT02946632|DRUG|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
219328062|NCT02946632|DRUG|Stepwise add-on therapy|metformin -\> glimepirde -\> sitagliptin
219328063|NCT00800683|DRUG|BI 1356|BI 1356 dosed once daily
219328064|NCT00800683|DRUG|placebo|placebo matching BI 1356 taken once daily
219328065|NCT03623581|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
219328066|NCT05182996|BEHAVIORAL|smoking education|Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
219328067|NCT01883479|BEHAVIORAL|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
219328068|NCT01883479|BEHAVIORAL|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
219328069|NCT01636479|DRUG|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
219328070|NCT03244514|OTHER|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
219328071|NCT00457873|DRUG|0.9% saline in 5% dextrose (intravenous)|
219328072|NCT00457873|DRUG|0.45% saline in 5% dextrose (intravenous)|
219328073|NCT02367066|DRUG|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
219328074|NCT02367066|OTHER|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
219328075|NCT02827669|BEHAVIORAL|One Drop Experts Program|
219328076|NCT02827669|BEHAVIORAL|One Drop Experts Program + Apple Watch|
219328077|NCT02231021|DRUG|alogliptin|alogliptin 25 mg add-on background medication metformin
219328078|NCT02231021|DRUG|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
219328079|NCT02231021|DRUG|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
219328080|NCT01898689|DRUG|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
219328081|NCT01898689|DRUG|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
219328082|NCT00627302|DRUG|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
219328083|NCT00627302|DRUG|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
219328084|NCT00570817|OTHER|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
219328085|NCT03788395|DEVICE|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
219328086|NCT03788395|DRUG|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
219328087|NCT04556136|DEVICE|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
219328088|NCT04556136|DIETARY_SUPPLEMENT|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
219328089|NCT04465097|DRUG|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
219328090|NCT04465097|DRUG|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
219328091|NCT04465097|DRUG|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
219328092|NCT01182766|DRUG|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
219328093|NCT01182766|DRUG|Placebo with brief behavioral enhancement therapy|placebo
219328094|NCT00662350|DEVICE|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
219328095|NCT05803434|DRUG|Cannabidiol oral solution|"Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks."
219328096|NCT01678482|DEVICE|light based device for treatment of acne|
219328097|NCT06125379|BEHAVIORAL|brief mindfulness|The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
219328098|NCT06232928|DEVICE|Early Class II elastics|Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
219328099|NCT06232928|DEVICE|Conventional Class II elastics|patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
219328100|NCT01221727|DRUG|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
219328101|NCT01221727|DRUG|Midazolam|All subjects will receive two oral dose administrations of midazolam.
219328102|NCT01196533|DEVICE|Non invasive peripheral blood monitoring|non invasive monitoring
219328103|NCT03595319|DRUG|Sevoflurane|Inhaled sevoflurane until allocated dose (see adaptive protocol)
219328104|NCT00529451|DRUG|Aliskiren|Aliskiren
219328105|NCT00529451|DRUG|Ramipril|comparator
219328106|NCT01549626|DIETARY_SUPPLEMENT|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
219328107|NCT01549626|DIETARY_SUPPLEMENT|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
219328108|NCT01549626|DIETARY_SUPPLEMENT|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
219328109|NCT00481897|BEHAVIORAL|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
219328110|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
219328111|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
219328112|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
219328113|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
219328114|NCT03923751|OTHER|Invitation to regional anesthesia survey|An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
219328115|NCT01329887|DRUG|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
219328116|NCT02955420|DRUG|BC 007|
219328117|NCT02955420|DRUG|NaCl 0.9 %|
219328118|NCT04006340|COMBINATION_PRODUCT|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
219328119|NCT04006340|COMBINATION_PRODUCT|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
219328120|NCT04006340|DIAGNOSTIC_TEST|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
219328121|NCT00909233|DRUG|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
219328122|NCT00572962|PROCEDURE|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
219328123|NCT05586750|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
219328124|NCT05586750|DRUG|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
219328125|NCT03750578|BEHAVIORAL|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
219328126|NCT00053924|DRUG|perifosine|
219328127|NCT01054950|BEHAVIORAL|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
219328128|NCT01054950|BEHAVIORAL|Placebo phone call|Phone call w/ no behavioral counseling
219328129|NCT03015519|DRUG|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
219328130|NCT03015519|DRUG|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
219328131|NCT02437617|PROCEDURE|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
219328132|NCT01974388|PROCEDURE|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
219328133|NCT01974388|PROCEDURE|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
219328134|NCT00773136|DRUG|Bimatoprost Suspension|see prior
219328135|NCT01929239|DRUG|Anti-PSMA Designer T Cells|
219328136|NCT01561495|RADIATION|Proton Therapy|
219328137|NCT04711798|OTHER|passive leg raising maneuver (PLR)|Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
219328138|NCT04711798|OTHER|lung recruitment maneuver (LRM)|lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
219328139|NCT04711798|OTHER|echographic evaluation of the right cardiac function|echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
219328140|NCT04650724|DRUG|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
219328141|NCT04666350|OTHER|Direct Skin Feeding Assay (DSFA)|In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.
219328142|NCT04666350|DRUG|Primaquine|Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.
219328143|NCT04666350|DRUG|Artemether/Lumefantrine|Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
219328144|NCT04353479|DRUG|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
219328145|NCT04353479|DRUG|Decitabine|A DNA methyltransferase inhibitor
219328146|NCT02629796|OTHER|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
219328147|NCT01891708|OTHER|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
219328148|NCT00211848|DRUG|Polyenylphosphatidylcholine (PPC)|
219328149|NCT00211848|DRUG|Pegylated Interferon|
219328150|NCT00211848|DRUG|Ribavirin|
219328151|NCT06143150|OTHER|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
219328152|NCT00910572|DEVICE|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
219328153|NCT02937194|BEHAVIORAL|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
219328154|NCT02937194|BEHAVIORAL|Pamphlets distribution|Oral health pamphlets distribution
219328155|NCT04387955|DIAGNOSTIC_TEST|Biological Sample Collection|"* Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2"
219328156|NCT00298025|DRUG|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
219328157|NCT00298025|DRUG|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
219328158|NCT00298025|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
219328159|NCT00298025|DRUG|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
219328160|NCT00298025|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
219328161|NCT05662696|OTHER|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
219328162|NCT00888381|BIOLOGICAL|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
219328163|NCT04635410|OTHER|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
219328164|NCT01961401|BEHAVIORAL|exercise|
219328165|NCT00097773|DRUG|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
219328166|NCT00097773|DRUG|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
219328167|NCT00097773|DRUG|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
219328168|NCT04637893|OTHER|Colonoscopy|Pt. underwent colonoscopy
219328169|NCT00003702|BIOLOGICAL|Dactinomycin|Given IV
219328170|NCT00003702|DRUG|Methotrexate|Given intramuscularly
219328171|NCT04695067|BEHAVIORAL|Central fatigue group|a fatigue protocol that pitchers need to pitch 80 trials in a simulated game
219328172|NCT00362349|DRUG|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
219328173|NCT01009034|OTHER|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
219328174|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
219328175|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
219328176|NCT02427230|DRUG|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
219328177|NCT04943003|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
219328178|NCT03763669|DIETARY_SUPPLEMENT|Myoinositol|myo-inositol (2 g. twice a day)
219328179|NCT03763669|DIETARY_SUPPLEMENT|Placebo (for myoinositol)|(twice a day)
219328180|NCT02180620|OTHER|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
219328181|NCT02180620|OTHER|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
219328182|NCT02180620|OTHER|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
219328183|NCT04577729|PROCEDURE|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
219328184|NCT04577729|PROCEDURE|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
219328185|NCT05656625|OTHER|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
219328186|NCT04521829|OTHER|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
219328187|NCT01761825|DRUG|ivabradine|
219328188|NCT04119141|DIAGNOSTIC_TEST|X ray imaging|"Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions."
219328189|NCT02654249|DEVICE|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
219328190|NCT02654249|PROCEDURE|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
219328191|NCT02654249|DEVICE|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
219328192|NCT02654249|DEVICE|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
219328193|NCT04016831|BEHAVIORAL|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
219328194|NCT04016831|OTHER|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
219328195|NCT04077541|BEHAVIORAL|internet platform|The trauma care bundles combined with the internet platform.
219328196|NCT01494350|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
219328197|NCT00714467|BEHAVIORAL|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
219328198|NCT00714467|BEHAVIORAL|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
219328199|NCT06395233|DEVICE|BetterPoints App|The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
219328200|NCT04771585|OTHER|Community Mask|Fabric mask, no medical device
219328201|NCT04771585|OTHER|Surgical Mask|Medical face mask (personal protective equipment), CE-certified
219328202|NCT04771585|OTHER|FFP2 respirator|Filtering Face Piece with no less than 94% filtering capacity, CE-certified
219328203|NCT04771585|OTHER|FFP3 respirator|Filtering Face Piece with no less than 99% filtering capacity, CE-certified
219328204|NCT05169216|BEHAVIORAL|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided."
219328205|NCT00683566|PROCEDURE|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
219328206|NCT02494466|DRUG|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
219328207|NCT01995578|DRUG|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
219328208|NCT02054325|DRUG|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
219328209|NCT02054325|DRUG|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
219328210|NCT00115791|DRUG|RSD1235|IV
219328211|NCT00115791|DRUG|placebo|IV
219328212|NCT00617604|DRUG|Alefacept|IV and subcutaneous injection
219328213|NCT00617604|DRUG|placebo|IV and subcutaneous injection
219328214|NCT00617604|DRUG|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
219328215|NCT00617604|DRUG|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
219328216|NCT00617604|DRUG|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
219328217|NCT03250832|DRUG|TSR-033|TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
219328218|NCT03250832|DRUG|Dostarlimab|Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
219328219|NCT03250832|DRUG|mFOLFOX6|mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
219328220|NCT03250832|DRUG|FOLFIRI|FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
219328221|NCT03250832|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
219328222|NCT03410836|DRUG|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
219328223|NCT03410836|OTHER|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
219328224|NCT02303704|PROCEDURE|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
219328225|NCT02303704|PROCEDURE|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
219328226|NCT02862405|OTHER|vision tests|
219328227|NCT05880017|PROCEDURE|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
219355378|NCT04405050|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
219355379|NCT03434977|DRUG|TAK-536|TAK-536 granule formulation
219328228|NCT05880017|PROCEDURE|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
219328229|NCT05880017|DRUG|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
219328230|NCT05880017|DRUG|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
219328231|NCT05629429|DRUG|Olaparib|Olaparib 300mg BID PO
219328232|NCT05629429|DRUG|Chemotherapy drug|Continue platinum based chemotherapy
219328233|NCT03407651|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
219328234|NCT01518283|DRUG|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
219328235|NCT04181944|OTHER|Exercise Treatment Group|be specific
219328236|NCT00355979|DEVICE|intragastric balloon|
219328237|NCT01984164|DRUG|Candesartan|blinded
219328238|NCT01984164|DRUG|Lisinopril|Blinded
219328239|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with novel Dynamic Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.
219328240|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with Standard Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
219328241|NCT00584883|DRUG|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
219328242|NCT03031379|OTHER|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
219328243|NCT05187624|DRUG|RO7428731|Participants will receive RO7428731 as described.
219328244|NCT06970496|DRUG|B019|B019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg
219328245|NCT00667823|DRUG|Macitentan|Tablet, oral administration, 10 mg dose once daily
219328246|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
219328247|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
219328248|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
219328249|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
219328250|NCT06985420|OTHER|Resistance exercise|Resistance Exercise Protocols: Participants will perform exercises, including belt squats, hex bar deadlifts, and plyometric drop jumps. The load and intensity will be standardized based on each participant's 1-repetition maximum (1RM) to ensure uniformity across trials.
219328251|NCT06985420|OTHER|Menstrual Cycle Phases|Menstrual Cycle Phases: The key exposure variable is the phase of the menstrual cycle, with participants being assessed during the early follicular, late follicular, and mid-luteal phases.
219328252|NCT04711668|DRUG|Ketamine|intraoperative ketamine bolus and infusion
219328253|NCT04711668|DRUG|Lidocain|intraoperative lidocain bolus and infusion
219328254|NCT04711668|DRUG|Saline|intraoperative saline bolus and infusion
219328255|NCT03732651|PROCEDURE|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
219328256|NCT00583024|BIOLOGICAL|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
219328257|NCT05953272|OTHER|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
219355380|NCT03064841|DRUG|No Treatment|No treatment
219328258|NCT05953272|OTHER|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
219328259|NCT00271778|PROCEDURE|mastoidotympanoplasty and tympanoplasty|
219328260|NCT02684513|DIETARY_SUPPLEMENT|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
219328261|NCT02684513|DIETARY_SUPPLEMENT|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
219328262|NCT05733273|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
219328263|NCT05733273|OTHER|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
219328264|NCT05733273|OTHER|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
219328265|NCT02564107|DRUG|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
219328266|NCT06487832|OTHER|Subcutaneous GLP1-RA|Subcutaneous administration of semaglutide
219328267|NCT06487832|OTHER|Subcutaneous placebo|Subcutaneous administration of NaCl
219328268|NCT07129590|OTHER|Expired carbon monoxide (CO)|Expired CO will be measured using a non-investigational device
219328269|NCT07129590|OTHER|Interviews|Participants will be interviewed via video conference or in person
219328270|NCT07129590|OTHER|Questionnaires|Participants will receive questionnaires to complete through the course of the study
219328271|NCT07130864|PROCEDURE|Early cholecystectomy|Early cholecystectomy is performed within 72 hours of ERCP.
219328272|NCT07130864|PROCEDURE|Late cholecystectomy|Late cholecystectomy is performed after 72 hours of ERCP
219328273|NCT03045783|DRUG|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
219328274|NCT06902467|DRUG|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrong 8 and modified by GEICO 18: IV paclitaxel 175 mg /m2 (day 1) + IP cisplatin 100 mg/m2 (day 2) + IP paclitaxel 60 mg/m2 (day 8).
219328275|NCT06901921|DIAGNOSTIC_TEST|PT-intervention|60 participants undergoing PT-intervention for about 3 months will be taken and questionnaire (KOOS-12) will be filled by them at regular intervals of baseline, 4, 8 and 12 weeks respectively while global rating of change questionnaire will be filled by them at start and end of intervention and these values will be compared to see if patients' condition has improved or not.
219328276|NCT06902116|PROCEDURE|No Mechanical Bowel Preparation|In this group patients will not receive any mechanical bowel preparation prior to undergoing colostomy reversal.
219328277|NCT06902116|PROCEDURE|Mechanical Bowel Preparation|In this group patients will receive 3 days mechanical bowel preparation prior to undergoing colostomy reversal.
219328278|NCT06902038|DRUG|PD-1 inhibitor|100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2
219328279|NCT06902038|DRUG|Sidarbenamide|Sidarbenamide 10mg biw orally for 2 weeks
219328280|NCT06902038|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline 50ml Q3W ×2
219328281|NCT05469269|BEHAVIORAL|Passive Education|Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
219328282|NCT05469269|BEHAVIORAL|Education by Community Navigator|A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
219328283|NCT05469269|BEHAVIORAL|Education at Community Outreach Screening Event|The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
219328284|NCT03543098|PROCEDURE|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
219328285|NCT03543098|PROCEDURE|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
219328286|NCT03543098|PROCEDURE|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
219328287|NCT03543098|PROCEDURE|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
219355381|NCT02055066|DRUG|ARGX-111|
219328288|NCT06903390|BEHAVIORAL|QPL-based Communication Intervention|"This QPL-based communication intervention stands out with the following key features:~Patient-Centered \& Cancer-Specific QPL: The intervention uses a QPL tailored for cancer patients, culturally adapted to enhance empowerment and manage anxiety.~Structured Training \& Support: Patients receive training before consultations, with additional guidance for effective QPL use at subsequent visits.~Multiple Assessment Points: The QPL's impact is measured after the first, second, and third consultations, allowing for longitudinal evaluation.~RCT Design: This study is a randomized controlled trial (RCT), comparing the intervention group (QPL) to a control group receiving standard care.~Focus on Empowerment \& Anxiety: Unlike prior studies, this intervention focuses on empowering patients and reducing anxiety, with outcomes measured through validated scales (Patient Empowerment Scale and HADS).~These features differentiate this intervention by offering a structured, culturally relevant approach."
219328289|NCT06901791|DIETARY_SUPPLEMENT|Conventional treatment and Probiotic|Participants will continuously take Lactobacillus rhamnosus LRa05 from the time of enrollment until delivery.
219328290|NCT06902792|DRUG|treated group|This study marks the first application of Adebrelimab in pediatric patients with Langerhans Cell Histiocytosis (LCH). The initial dose is 20 mg/kg, delivered via a 60-minute intravenous infusion. If no Dose-Limiting Toxicity (DLT) occurs, the second dose of 20 mg/kg will be administered in the second cycle. Treatment cycles consist of dosing every 4 weeks, up to a maximum of 6 cycles.
219328291|NCT06902935|DIAGNOSTIC_TEST|Diagnosis of Breast Cancer by Traditional Chinese Medicine Four Examinations|The Daosheng TCM Four-Diagnostic Instrument (DS01-A) comprehensively collects patients' TCM four-diagnostic information, covering tongue (e.g., overall color, coating color/thickness/greasiness, tooth marks, etc.), pulse (e.g., position, force, rhythm, etc.), face (e.g., overall color, luster, lip color/dryness, etc.) and constitution scores (quantifying 9 constitutions via the TCM Constitution Classification Table).
219328292|NCT06902935|DIAGNOSTIC_TEST|Ultrasound diagnosis of breast cancer|Professional ultrasound physicians use B - ultrasound equipment of the same model to accurately collect detailed parameters of breast masses according to a standardized process. These parameters include shape (oval, round, irregular), orientation (parallel, non - parallel), margin (smooth, non - smooth, with non - smooth including blurred, angular, microlobulated, spiculated, etc.), echo pattern (anechoic, hyperechoic, complex cystic - solid echo, hypoechoic, isoechoic, heterogeneous echo), posterior echo characteristics (no change, enhancement, shadowing, mixed), calcification (microcalcification and coarse calcification within the mass, calcification outside the mass, intraductal), and vascular supply (no blood supply, internal blood supply, marginal blood supply), etc.
219328293|NCT06901661|BEHAVIORAL|Telerehabilitation|Exercise program include Warm-up, Targeted muscle Strengthening, Joint mobilization, and Proprioception
219328294|NCT06901661|BEHAVIORAL|Standard care|Education session on their pain, disability, and functional activities
219328295|NCT06902298|DEVICE|LTFUS to SCC|Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
219328296|NCT06902298|DEVICE|LTFUS to ALIC|Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule
219328297|NCT06901999|DRUG|Orelabrutinib|150 mg qd po. D1-21, 6 cycles, 21 days per cycle For patients continue transplant, maitaining for 1 year follow-up; otherwise maintaining during 2 years of follow-up，unless disease progression or intolerable toxicity occurs.
219328298|NCT06901999|DRUG|RCHOP+MTX or Thiotepa|rituximab: 375 mg/m2, D0; cyclophosphamide: 750 mg/m2, D1; doxorubicin: 50 mg/m2, D1; vincristine: 1.4 mg/m2, D1; prednisone: 100 mg, D1-5; MTX: 3.5 g/m2, D0; Thiotepa: 40 mg/m2, D3; Induction therapy, 6 cycles, 21 days a cycle
219328299|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
219328300|NCT06108648|OTHER|Control|Standard care according to national standards.
219328301|NCT02706561|BEHAVIORAL|questionnaires|
219328302|NCT02706561|BEHAVIORAL|three in-person sessions|
219328303|NCT02706561|BEHAVIORAL|monthly phone calls|
219328304|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
219328305|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
219328306|NCT00537498|DRUG|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l"
219328307|NCT01839253|DRUG|b-blocker(Atenolol)|
219328308|NCT01839253|DRUG|ACE inhibitor(Enapril)|
219328309|NCT01839253|OTHER|control|
219328310|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
219328311|NCT04890314|OTHER|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
219328312|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
219328313|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
219328314|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
219328315|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
219328316|NCT01148706|DEVICE|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
219328317|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
219328318|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
219328319|NCT05473910|DRUG|SOC + TSC-100|HA-1 positive
219328320|NCT05473910|DRUG|SOC + TSC-101|HA-2 positive or HA-1 negative
219328321|NCT05473910|OTHER|Control|SOC alone
219328322|NCT00522054|OTHER|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
219328323|NCT01095406|DEVICE|S1 ventilation|Ventilation with a O2 and CO2 controller
219328324|NCT03377842|DRUG|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
219328325|NCT03377842|DRUG|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
219328326|NCT01819649|DIETARY_SUPPLEMENT|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
219328327|NCT03419039|DIETARY_SUPPLEMENT|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
219328328|NCT03419039|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules.
219328329|NCT04778982|DRUG|KN026 combined with Palbociclib and Fulvestrant|HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
219328330|NCT05988450|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
219328331|NCT03173131|BEHAVIORAL|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
219328332|NCT02245438|DRUG|Tipranavir low dose|
219328333|NCT02245438|DRUG|Tipranavir high dose|
219328334|NCT02245438|DRUG|Ritonavir low dose|
219328335|NCT02245438|DRUG|Ritonavir high dose|
219328336|NCT02245438|DRUG|Norethindrone-Ethinyl Estradiol|
219328337|NCT03317470|OTHER|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
219328338|NCT03317470|BEHAVIORAL|Life Navigator|"* The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
219328339|NCT03317470|OTHER|Follow-up survey|-5 questions about the acceptability of the basic needs survey
219328340|NCT03317470|OTHER|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
219328341|NCT01687075|DEVICE|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
219328342|NCT03335163|DRUG|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
219328343|NCT01689675|BEHAVIORAL|Computer based pain management|
219328344|NCT05497596|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
219328345|NCT05497596|OTHER|Placebo|Placebo
219328346|NCT05596682|DEVICE|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
219328347|NCT01745250|DEVICE|Emervel Lips|Lip treatment of both upper and lower lip
219328348|NCT01745250|DEVICE|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
219328349|NCT01131533|PROCEDURE|Vitrectomy|vitrectomy following intravitreal erythropoietin
219328350|NCT03426371|DRUG|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
219328351|NCT03426371|DRUG|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
219328352|NCT00483561|DRUG|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
219328353|NCT02623127|DRUG|Sunitinib|
219328354|NCT02553265|DRUG|Carbidopa Low-Dose|300 mg/day
219328355|NCT02553265|OTHER|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
219328356|NCT02553265|DRUG|Carbidopa High-Dose|600 mg/day
219328357|NCT01653288|BEHAVIORAL|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
219328358|NCT00635037|DRUG|bupivacaine and acupuncture|"* trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week"
219328359|NCT03471039|DRUG|PACAP27|Infusion of PACAP27 over 20 minutes.
219328360|NCT03471039|DRUG|Saline|Infusion of Saline over 20 minutes.
219328361|NCT04042740|DRUG|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
219328362|NCT03868969|DRUG|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
219328363|NCT06426485|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablets|orally once a day
219328364|NCT06426485|DRUG|placebo|orally once a day
219328365|NCT03764163|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
219328366|NCT03764163|DIAGNOSTIC_TEST|CT Scans|volume scans, perfusion scan, ventilation scan
219328367|NCT03764163|BEHAVIORAL|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
219328368|NCT03764163|DIAGNOSTIC_TEST|MRI|proton scans, hyperpolarized 3-Helium scan
219328369|NCT03764163|BIOLOGICAL|Xenon gas|ventilation CT scans
219328370|NCT03380351|BEHAVIORAL|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
219328371|NCT00668070|DRUG|ASP9831|Oral
219328372|NCT00668070|DRUG|Placebo|Oral
219328373|NCT04415658|DRUG|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
219328374|NCT04415658|DRUG|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
219328375|NCT03042780|DRUG|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
219328376|NCT03042780|DRUG|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
219328377|NCT03580239|DRUG|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
219328378|NCT03580239|DRUG|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
219328379|NCT02581293|PROCEDURE|Group 1: Only visceral peritoneum will be closed|
219328380|NCT02581293|PROCEDURE|Group 2 : Only parietal peritoneum will be closed|
219328381|NCT02581293|PROCEDURE|Group 3 : Both of them will be closed|
219328382|NCT02581293|PROCEDURE|Group 4: None of them will be closed|
219328383|NCT02465983|BIOLOGICAL|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
219328384|NCT02465983|DRUG|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
219328385|NCT06074991|OTHER|musıc therapy|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
219328386|NCT04741386|BIOLOGICAL|SARS-CoV-2 vaccination|All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
219328387|NCT03528278|BEHAVIORAL|Motivational interviewing and environmental interventions|"* Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~* Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~* Training equipment~* Motivational Interviewing (MI) techniques applied by staff~* Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
219328388|NCT02114775|DRUG|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
219328389|NCT02114775|DRUG|Sildenafil|50 mg by mouth daily
219328390|NCT02114775|DRUG|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
219328391|NCT02000596|DRUG|Trastuzumab plus Pertuzumab|
219328392|NCT02000596|DRUG|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
219328393|NCT02000596|DRUG|Chemotherapy with Eribulin|
219328394|NCT03767036|DRUG|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
219328395|NCT03767036|DRUG|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
219328396|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
219328397|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
219328398|NCT02960178|BEHAVIORAL|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
219328399|NCT02960178|BEHAVIORAL|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
219328400|NCT01764971|OTHER|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
219328401|NCT01764971|OTHER|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
219328402|NCT03662672|PROCEDURE|Rib raising and lumbar release|Rib raising per protocol described in arm description.
219328403|NCT03662672|PROCEDURE|Sham procedure|Sham procedure per protocol described in arm description
219328404|NCT04634981|PROCEDURE|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
219328405|NCT02419326|BEHAVIORAL|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
219328406|NCT02530372|DEVICE|UriCap-F|non-invasive urine collection device for women
219328407|NCT01971983|OTHER|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
219328408|NCT01971983|OTHER|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
219328409|NCT01971983|OTHER|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
219328410|NCT02276664|BEHAVIORAL|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
219328411|NCT02276664|BEHAVIORAL|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
219328412|NCT03405805|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
219328413|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
219328414|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
219328415|NCT03294226|DEVICE|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
219328416|NCT03294226|DEVICE|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
219328417|NCT01587378|DRUG|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
219328418|NCT01587378|DRUG|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
219328419|NCT03029741|DRUG|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
219328420|NCT03029741|DRUG|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
219328421|NCT05948007|DEVICE|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
219328422|NCT05948007|DEVICE|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
219328423|NCT05948007|BEHAVIORAL|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
219328424|NCT01651104|BIOLOGICAL|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
219328425|NCT02794818|BEHAVIORAL|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
219328426|NCT03453073|BEHAVIORAL|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
219328427|NCT03453073|OTHER|physician diagnosis of first occurrence of serious chronic disease|
219328428|NCT01421927|DRUG|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~\- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~\- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant"
219328429|NCT02718599|DRUG|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
219328430|NCT02718599|DRUG|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
219328431|NCT06171620|DEVICE|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
219328432|NCT06171620|OTHER|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
219328433|NCT06417320|DRUG|ACEI, SGLT-2i|"Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)"
219328434|NCT02614391|OTHER|Active distraction using a tablet|Playing a videogame using a computer tablet
219328435|NCT02614391|OTHER|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
219328436|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
219328437|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
219328438|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
219328439|NCT02982590|DRUG|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
219328440|NCT02982590|DRUG|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
219328441|NCT03340649|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
219328442|NCT02744300|BEHAVIORAL|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
219328443|NCT00350584|BEHAVIORAL|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
219328444|NCT00350584|BEHAVIORAL|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
219328445|NCT02676999|PROCEDURE|Implantation of a Scheker total distal radioulnar joint prosthesis|
219328446|NCT00087347|DRUG|ferumoxytol|
219328447|NCT00087347|PROCEDURE|magnetic resonance imaging|
219328448|NCT03975270|DRUG|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
219328449|NCT04860375|PROCEDURE|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
219328450|NCT04860375|OTHER|Standard care|Standard care in Sweden
219328451|NCT05500820|DRUG|CIN-107|A repeat oral dose of CIN-107 once daily for 10 days.
219328452|NCT05500820|DRUG|Matching Placebo|A repeat oral dose of matching placebo once daily for 10 days.
219328453|NCT00906893|PROCEDURE|18F]-FMISO PET-CT|pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.
219328454|NCT00827684|DRUG|Irinotecan|
219328455|NCT00827684|DRUG|Temsirolimus|
219328456|NCT00349167|DRUG|PR-104|
219328457|NCT00349167|OTHER|laboratory biomarker analysis|
219328458|NCT00349167|OTHER|pharmacological study|
219328459|NCT04485143|DEVICE|Wisdom bracelet|routine medical
219328460|NCT02408705|DRUG|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
219328461|NCT02408705|DRUG|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
219328462|NCT02408705|DRUG|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
219328463|NCT00699803|DRUG|T-PRED|T-PRED sterile ophthalmic solution
219328464|NCT00699803|DRUG|Pred Forte|Pred Forte sterile ophthalmic solution
219328465|NCT04688151|DRUG|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
219328466|NCT03505047|DEVICE|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
219328467|NCT06387654|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
219328468|NCT06387654|BIOLOGICAL|Remainders of samples taken as part of the treatment|blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
219328469|NCT01161602|DRUG|Pumosetrag|
219328470|NCT01161602|DRUG|Pumosetrag|
219328471|NCT01161602|OTHER|Placebo|
219328472|NCT01161602|DRUG|Pumosetrag|
219328473|NCT00151970|DRUG|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
219328474|NCT00151970|DRUG|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
219328475|NCT00151970|DRUG|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
219328476|NCT00415506|DRUG|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
219328477|NCT06208384|DRUG|Statin eye drop|Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
219328478|NCT06208384|DRUG|Placebo|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
219328479|NCT04666467|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
219328480|NCT00492830|DRUG|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
219328481|NCT01389167|DRUG|Vivitrol|An extended release naltrexone formulation for intramuscular injection
219328482|NCT01389167|DRUG|Naltrexone (oral)|Naltrexone 50 mg pills, daily
219328483|NCT01389167|BEHAVIORAL|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
219328484|NCT01389167|BEHAVIORAL|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
219328485|NCT02019576|RADIATION|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
219328486|NCT04327765|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
219328487|NCT04327765|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
219328488|NCT04327765|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
219328489|NCT02991742|OTHER|contrast media|Compare 2 contrast media
219328490|NCT00653042|DRUG|Nesiritide|
219328491|NCT03932656|BEHAVIORAL|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
219328492|NCT03932656|DRUG|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
219328493|NCT00139347|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
219328494|NCT05349851|OTHER|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
219328495|NCT00773721|DEVICE|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
219328496|NCT01434420|GENETIC|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
219328497|NCT04891094|DIAGNOSTIC_TEST|Ultrasound|daily ultrasound of the lung and the diaphragm
219328498|NCT02596477|DRUG|Vepoloxamer|
219328499|NCT02596477|OTHER|5% dextrose in water|
219328500|NCT01375842|DRUG|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
219328501|NCT01796587|DEVICE|LoFric Origo|
219328502|NCT04026347|DEVICE|Vesair Balloon|Indwelling, intravesical balloon
219328503|NCT04026347|OTHER|Sham balloon placement|Sham balloon placement procedure
219328504|NCT00542464|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
219328505|NCT03449498|OTHER|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
219328506|NCT03449498|OTHER|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
219328507|NCT03339388|DEVICE|Enhanced Lithotripsy System|Stone treatment with the Enhanced Lithotripsy System
219328508|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in PD|Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).
219328509|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in PD|STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).
219328510|NCT06323564|DEVICE|International Affective Picture System (IAPS)|Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).
219328511|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in AN|Verbal Fluencies, Tower of London, TMT-A \& B
219328512|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in AN|STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).
219328513|NCT06323564|DIAGNOSTIC_TEST|Analysis of bio-humoral parameters|the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1
219328514|NCT05287971|BEHAVIORAL|Lifestyle advice|Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.
219328515|NCT04449770|DEVICE|double lumen tube|prospective cohort study
219328516|NCT00625989|DRUG|Aeroallergen|
219328517|NCT02106286|DRUG|Bisoprolol|
219328518|NCT00215995|DRUG|Cisplatin|As outlined in Detailed Description
219328519|NCT00215995|DRUG|Irinotecan|As outlined in Detailed Description
219328520|NCT00215995|DRUG|ZD 1839|As outlined in Detailed Description
219328521|NCT02361450|DEVICE|Retrograde Colonic Irrigation|
219328522|NCT02361450|OTHER|Usual Care|
219328523|NCT03228472|DEVICE|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
219328524|NCT03228472|DEVICE|sham stimulation|Placebo treatment
219328525|NCT00376116|DEVICE|Cardiac resynchronisation therapy|
219328526|NCT00376116|DEVICE|Implantable cardioverter-defibrillator|
219328527|NCT02921191|DRUG|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
219328528|NCT04405154|BIOLOGICAL|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
219328529|NCT04405154|DRUG|Cisplatin|75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
219328530|NCT04405154|RADIATION|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
219328531|NCT03129087|BEHAVIORAL|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
219328532|NCT06473675|PROCEDURE|Hysterectomy with adnexal surgery|Robotic-assisted and laparoscopic hysterectomy with adnexal surgery for benign disease.
219328533|NCT02285920|DRUG|Spironolactone|The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
219328534|NCT04942717|BEHAVIORAL|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
219328535|NCT06256315|PROCEDURE|Hyper-ERAS Program|Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.
219328536|NCT01102348|OTHER|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
219328537|NCT04195048|OTHER|Risk factors|Risk factors: modifiable and unmodifiable risk factors
219328538|NCT05401799|DEVICE|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
219328539|NCT05401799|PROCEDURE|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
219328540|NCT06016465|DRUG|Dexamethasone Oral|Two 4mg pills
219328541|NCT06016465|DRUG|Placebo|2 placebo pills
219328542|NCT03055754|PROCEDURE|Argon randomized arm|Endoscopic argon plasma coagulation
219328543|NCT03055754|PROCEDURE|Control arm|No Endoscopic procedure
219328544|NCT05444842|OTHER|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor\_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
219328545|NCT05444842|OTHER|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
219328546|NCT05444842|OTHER|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
219328547|NCT06046222|DRUG|NS-229|Experimental
219328548|NCT06046222|DRUG|Placebo|Placebo comparator
219328549|NCT05002569|BIOLOGICAL|Nivolumab|Specified dose on specified days
219328550|NCT05002569|BIOLOGICAL|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
219328551|NCT00003765|DRUG|O6-benzylguanine|
219328552|NCT00003765|DRUG|carmustine|
219328553|NCT02424942|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
219328554|NCT02424942|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
219328555|NCT05224908|DEVICE|EOS|pelvimetry by EOS in standing and sitting position
219328556|NCT05321914|BEHAVIORAL|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
219328557|NCT01480284|DRUG|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
219328558|NCT01480284|DRUG|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
219328559|NCT00709111|DRUG|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
219328560|NCT02716675|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
219328561|NCT02716675|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
219328562|NCT03138187|BEHAVIORAL|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
219328563|NCT03138187|BEHAVIORAL|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
219328564|NCT05337579|OTHER|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
219328565|NCT05337579|PROCEDURE|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
219328566|NCT04256460|BEHAVIORAL|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
219328567|NCT00915772|DRUG|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
219328568|NCT00915772|DRUG|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
219328569|NCT00915772|DRUG|Metformin|Metformin 1000 mg tablet bid
219328570|NCT04745013|BEHAVIORAL|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
219328571|NCT04745013|BEHAVIORAL|Usual care|Only a written personalized exercise prescription will be provided.
219328572|NCT05023863|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
219328573|NCT05023863|OTHER|Placebo tablets|placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
219328574|NCT05023863|RADIATION|radiation or concurrent chemoradiation|radiation or concurrent radiotherapy plus platinum-based chemotherapy
219328575|NCT02202291|GENETIC|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
219328576|NCT01194713|BEHAVIORAL|Sleep deprivation|subjects will undergo one night of full sleep deprivation
219328577|NCT04012034|DEVICE|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
219328578|NCT04012034|DEVICE|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
219328579|NCT02783716|PROCEDURE|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
219328580|NCT02783716|DIAGNOSTIC_TEST|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
219328581|NCT04559191|DEVICE|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
219328582|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
219328583|NCT01383096|DRUG|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
219328584|NCT01383096|DRUG|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
219328585|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
219328586|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
219328587|NCT04679779|OTHER|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
219328588|NCT04679779|OTHER|Wii virtual reality games|"1. Bowling~2. Frisbee~3. Basketball~4. Boxing"
219328589|NCT03288870|DRUG|BCD-100|monoclonal antibody to PD-1 receptor
219328590|NCT03288870|DRUG|Docetaxel|Chemotherapy drug (taxane)
219328591|NCT01211535|DEVICE|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
219328592|NCT01211535|DEVICE|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
219328593|NCT01211535|DEVICE|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
219328594|NCT04747834|DEVICE|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
219328595|NCT03485248|DIETARY_SUPPLEMENT|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
219328596|NCT03485248|DIETARY_SUPPLEMENT|Placebo|140ml of Beetroot Juice (nitrate free)
219328597|NCT02781142|OTHER|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
219328598|NCT01411020|PROCEDURE|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
219328599|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
219328600|NCT05582395|OTHER|Placebo|Specified dose on specified days
219328601|NCT01111942|OTHER|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)"
219328602|NCT01111942|PROCEDURE|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
219328603|NCT00068211|DRUG|ILX651|
219328604|NCT03268434|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
219328605|NCT03268434|BEHAVIORAL|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
219328606|NCT05925556|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
219328607|NCT03157141|PROCEDURE|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
219328608|NCT03157141|PROCEDURE|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
219328609|NCT00697450|DRUG|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
219328610|NCT00610545|DRUG|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
219328611|NCT00610545|DRUG|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
219328612|NCT02383290|OTHER|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
219328613|NCT00625352|DRUG|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
219328614|NCT03883191|OTHER|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
219328615|NCT03883191|OTHER|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
219328616|NCT00467779|DRUG|cobimetinib|Repeating oral dose
219328617|NCT00467779|DRUG|dextromethorphan|In Stage III only: single dose of dextromethorphan
219328618|NCT00467779|DRUG|midazolam|In Stage III only: single dose of midazolam
219328619|NCT01701999|BIOLOGICAL|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
219328620|NCT04217304|DRUG|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
219328621|NCT05851742|DEVICE|TENS|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
219328622|NCT05851742|OTHER|Myofascial trigger point release|Release of trigger points
219328623|NCT03979222|DEVICE|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
219328624|NCT02678338|DRUG|Hu5F9-G4|
219328625|NCT05439668|OTHER|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
219328626|NCT05439668|OTHER|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
219328627|NCT04841824|OTHER|Observational study|Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
219328628|NCT03878173|OTHER|No intervention|No intervention
219328629|NCT03528759|DIAGNOSTIC_TEST||phenotypic and genotypic Method
219328630|NCT01887067|PROCEDURE|Renal denervation therapy|
219328631|NCT06462300|BEHAVIORAL|A meaning-centered intervention for young women with weight and shape concerns|"* adapted version of the manualized meaning-centered psychotherapy for cancer patients developed by van der Spek et al. (2017)~* six weekly individual online sessions, each lasting one hour~* sessions led by a certified trainer~* four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
219328632|NCT02116504|PROCEDURE|Sampling of blood|Sampling of blood for dosage of antibodies
219328633|NCT01312038|DRUG|Simethicone|single 125 mg chewable tablet
219328634|NCT01312038|DRUG|Placebo|chewable calcium tablet
219328635|NCT03487809|DRUG|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
219328636|NCT03099642|RADIATION|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
219328637|NCT05784779|DRUG|GH509|Orally, once daily before bedtime (qhs)
219328638|NCT05784779|DRUG|Placebo|Orally, once daily before bedtime (qhs)
219328639|NCT01599520|BEHAVIORAL|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
219328640|NCT01599520|BEHAVIORAL|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
219328641|NCT04353596|DRUG|ACE inhibitor, angiotensin receptor blocker|In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
219328642|NCT05088642|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet
219328643|NCT02603770|DRUG|XueZhiKang|
219328644|NCT02603770|DRUG|Lovastatin|
219328645|NCT01141114|OTHER|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
219328646|NCT01141114|OTHER|Usual care|Usual care
219328647|NCT02463721|OTHER|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
219328648|NCT05488600|BEHAVIORAL|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
219328649|NCT00490178|DRUG|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
219328650|NCT05224063|DEVICE|Individualized CEN-targeted rTMS|Delivers patterned magnetic stimulation based on individualized CEN targeting
219328651|NCT05224063|DEVICE|Neuronavigated rTMS|Delivers patterned magnetic stimulation based on MRI images
219328652|NCT05224063|DEVICE|Scalp-targeted rTMS|Delivers patterned magnetic stimulation based on BEAM F3 targeting
219328653|NCT05224063|DEVICE|Sham rTMS|Delivers placebo magnetic stimulation
219355382|NCT06617520|OTHER|Cigarillo flavor type|Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor
219355383|NCT00217087|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
219355384|NCT00217087|PROCEDURE|Photodynamic Therapy|Porfimer sodium 2mg/kg
219328654|NCT04492098|DIAGNOSTIC_TEST|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
219328655|NCT04717518|OTHER|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
219328656|NCT00659568|DRUG|metformin hydrochloride|
219328657|NCT00659568|DRUG|temsirolimus|
219328658|NCT03568474|DRUG|Silver Diamine Fluoride|Indirect pulp capping material
219328659|NCT03568474|DRUG|Glass Ionomer|Indirect pulp capping material
219328660|NCT02475070|DRUG|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
219328661|NCT02475070|DRUG|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
219328662|NCT02665052|DEVICE|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
219328663|NCT02665052|DEVICE|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
219328664|NCT02665052|BEHAVIORAL|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
219328665|NCT00823823|OTHER|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
219328666|NCT00823823|OTHER|Circumferential cast|Circumferential cast will be applied following closed reduction
219328667|NCT00082524|DRUG|caspofungin acetate|Duration of Treatment - 7-90 days
219328668|NCT02234284|BEHAVIORAL|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
219328669|NCT03044938|DRUG|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
219328670|NCT03044938|DRUG|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
219328671|NCT04973982|DRUG|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
219328672|NCT04973982|DRUG|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
219328673|NCT06290349|DRUG|DA5221-T1|DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
219328674|NCT06290349|DRUG|DA5221-T2|DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
219328675|NCT06290349|DRUG|Placebo|DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
219328676|NCT06290349|DRUG|DA5221-B1|DA5221-B1, orally, daily for background therapy
219328677|NCT06290349|DRUG|DA5221-B2|DA5221-B2, orally, daily for background therapy
219328678|NCT03923556|DRUG|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
219328679|NCT03923556|DRUG|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
219328680|NCT02887664|PROCEDURE|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
219355385|NCT03920670|DEVICE|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
219328681|NCT06261073|DIAGNOSTIC_TEST|blood sample and tissue biopsy|Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
219328682|NCT05840926|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12|Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
219328683|NCT05840926|OTHER|No probiotic supplementation|Children who did not receive any probiotic supplementation
219328684|NCT00097747|DRUG|Placebo|
219328685|NCT00097747|DRUG|peginesatide|
219328686|NCT00352287|DRUG|Recombinant human growth hormone; pioglitazone|
219328687|NCT06396091|DRUG|zolbetuximab|Zolbetuximab will be administered intravenously on day 1 then every two weeks.
219328688|NCT06396091|DRUG|mFOLFIRINOX|Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
219328689|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
219328690|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
219328691|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
219328692|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
219328693|NCT00215124|DRUG|Filgrastim|
219328694|NCT03469583|DRUG|EYP001|EYP001 self administered capsules, morning, with non carbonated water
219328695|NCT03469583|DRUG|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
219328696|NCT06330350|OTHER|Qualitative interview|Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
219328697|NCT03884712|DEVICE|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
219328698|NCT05362929|DEVICE|Sciton Halo|Laser treatment
219328699|NCT05827653|DRUG|NX210c|3 times a week, for 28 days
219328700|NCT05827653|DRUG|Placebo|3 times a week, for 28 days
219328701|NCT00190827|DRUG|duloxetine|
219328702|NCT00190827|DRUG|placebo|
219328703|NCT05119218|OTHER|No Intervention|No Intervention
219328704|NCT04992962|DRUG|CBD/CBN|A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
219328705|NCT04992962|DRUG|CBD/THC|A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
219328706|NCT04992962|DRUG|Placebo|An inactive compound.
219328707|NCT02441673|DRUG|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
219328708|NCT02441673|DRUG|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
219328709|NCT02441673|DRUG|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
219328710|NCT02441673|DRUG|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
219328711|NCT02441673|DRUG|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
219328712|NCT02441673|DRUG|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
219328713|NCT02441673|DRUG|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
219328714|NCT06399848|OTHER|Skip one day of peritoneal dialysis treatment|Skip one day of peritoneal dialysis treatment
219328715|NCT04956042|DRUG|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
219328716|NCT04956042|DRUG|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
219328717|NCT05857540|PROCEDURE|Plyometric and strengthening exercises|Each session includes 2 upper-extremity plyometric exercises in bodyweight or with weight ball for 15-20 minutes and 4-5 strengthening exercises with band, dumbbell or barbell for 30-35 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
219328718|NCT05857540|PROCEDURE|Strengthening exercise|Each session includes 5 upper-extremity strengthening exercises with band, dumbbell or barbell for 50 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
219328719|NCT02912299|PROCEDURE|Skin biopsies|2 3mm skin biopsies will be taken
219328720|NCT02912299|OTHER|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
219328721|NCT02912299|OTHER|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
219328722|NCT00217529|BIOLOGICAL|pegfilgrastim|
219328723|NCT00217529|DRUG|carboplatin|
219328724|NCT00217529|DRUG|docetaxel|
219328725|NCT00217529|DRUG|erlotinib hydrochloride|
219328726|NCT01219647|BEHAVIORAL|exercise|subjects will participate in one of two forms of exercise
219328727|NCT01219647|BEHAVIORAL|stretching|subjects will particiopate in supervised stretching as described in arm description.
219328728|NCT04638582|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
219328729|NCT04638582|DRUG|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
219328730|NCT04638582|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
219328731|NCT04638582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
219328732|NCT04005651|DEVICE|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
219328733|NCT04005651|DEVICE|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
219328734|NCT04005651|DEVICE|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
219328735|NCT03166163|DRUG|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
219328736|NCT03166163|DRUG|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
219328737|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 1|2 doses of study intervention are administered to participants intramuscularly.
219328738|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 2|2 doses of study intervention are administered to participants intramuscularly.
219328739|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 3.|2 doses of study intervention are administered to participants intramuscularly.
219328740|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 4|2 doses of study intervention are administered to participants intramuscularly.
219328741|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 5|2 doses of study intervention are administered to participants intramuscularly.
219328742|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 6|2 dose of study intervention is administered to participants intramuscularly.
219328743|NCT06382311|BIOLOGICAL|Influenza virus vaccine|2 doses of Influenza virus vaccine are administered to participants intramuscularly.
219328744|NCT06382311|DRUG|Placebo|2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 2 dose is administered to participants in Phase 2 Part B.
219328745|NCT02868177|DIETARY_SUPPLEMENT|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
219328746|NCT02868177|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
219328747|NCT03607123|OTHER|programing of pacemaker|Different programing parameters will be set in different group/stage
219328748|NCT03607123|PROCEDURE|AF ablation|AF ablation can only be performed in Step 3
219328749|NCT03607123|DRUG|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
219328750|NCT01495858|DRUG|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
219328751|NCT01495858|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
219328752|NCT01495858|DRUG|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
219328753|NCT00233363|DRUG|Rebamipide|
219328754|NCT00000180|DRUG|AIT-082|
219328755|NCT01561625|OTHER|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
219328756|NCT04092517|OTHER|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
219328757|NCT04092517|OTHER|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
219328758|NCT06155747|OTHER|Epidemiologic investigation|"Identification of:~1. overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~2. environmental NTM isolates that are highly related to respiratory isolates.~3. common water source exposure among subjects with clustered NTM infections via shared home of residence watershed."
219328759|NCT01541579|OTHER|Cx601|120 million cells administered by intralesional injection.
219328760|NCT01541579|OTHER|Saline solution|24 mL saline solution by intralesional injection
219328761|NCT02334124|OTHER|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
219328762|NCT02334124|OTHER|Ward|Admission to a hospital based ward
219328763|NCT02334124|DRUG|ceftriaxone|50mg/kg once daily
219328764|NCT02334124|DRUG|flucloxacillin|50mg/kg 6 hourly
219328765|NCT02493504|DRUG|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
219328766|NCT04743479|DIAGNOSTIC_TEST|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
219328767|NCT00752687|DRUG|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
219328768|NCT00752687|DRUG|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
219328769|NCT04668053|OTHER|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
219328770|NCT04668053|OTHER|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
219328771|NCT01576172|DRUG|Abiraterone Acetate|Given PO
219328772|NCT01576172|OTHER|Laboratory Biomarker Analysis|Correlative studies
219328773|NCT01576172|DRUG|Prednisone|Given PO
219328774|NCT01576172|DRUG|Veliparib|Given PO
219328775|NCT01731314|BEHAVIORAL|Learning and Memory of Pain|
219328776|NCT03706495|BEHAVIORAL|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
219328777|NCT03706495|BEHAVIORAL|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
219328778|NCT00344565|DRUG|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
219328779|NCT00344565|BEHAVIORAL|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
219328780|NCT04731038|DRUG|Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin|This is a single-arm study with all patients receiving these four drugs.
219328781|NCT04597957|DIETARY_SUPPLEMENT|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
219328782|NCT01274936|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
219328783|NCT01274936|DRUG|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
219328784|NCT00646594|DRUG|budesonide/formoterol (Symbicort)|
219328785|NCT00646594|DRUG|fluticasone/salmeterol (Advair)|
219328786|NCT01756469|BEHAVIORAL|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
219328787|NCT05885867|BEHAVIORAL|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
219328788|NCT05553483|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
219328789|NCT05553483|OTHER|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
219328790|NCT04048590|OTHER|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
219328791|NCT02439996|DRUG|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
219328792|NCT02439996|DRUG|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
219328793|NCT02439996|DRUG|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
219328794|NCT00463268|DRUG|alendronate|alendronate 70 mg every 2 weeks
219328795|NCT00463268|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
219328796|NCT00463268|DRUG|placebo|identical placebo every 2 weeks
219328797|NCT00473551|DRUG|Rituximab|375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.
219328798|NCT00473551|DRUG|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
219328799|NCT00473551|DRUG|Fludarabine|40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
219328800|NCT00473551|DRUG|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
219328801|NCT00473551|RADIATION|Radiation Treatment|2Gy Total body radiation day before transplantation
219328802|NCT00473551|PROCEDURE|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
219328803|NCT00473551|DRUG|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
219328804|NCT00473551|PROCEDURE|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
219328805|NCT04351763|DRUG|Amiodarone|Ion channel blocker
219328806|NCT04351763|DRUG|Verapamil|Ion channel blocker
219328807|NCT01460953|BEHAVIORAL|health literacy training video|participants will watch a training video
219328808|NCT02902081|DRUG|Cannabidiol|
219328809|NCT02902081|DRUG|Placebo|
219328810|NCT03390543|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
219328811|NCT03390543|DEVICE|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
219328812|NCT04307160|PROCEDURE|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
219328813|NCT03512639|DRUG|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
219328814|NCT03512639|DRUG|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
219328815|NCT00073151|DRUG|ABT-751|
219328816|NCT01937533|PROCEDURE|Magnetic Resonance Imaging using an endovaginal receiver coil|
219328817|NCT04702776|DRUG|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
219328818|NCT04702776|DRUG|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
219328819|NCT04702776|DRUG|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
219328820|NCT06156436|DEVICE|ResAppDx v.20|Software application used to aid diagnosis of respiratory disorders
219328821|NCT05662475|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
219328822|NCT05662475|PROCEDURE|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
219328823|NCT05662475|DIAGNOSTIC_TEST|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
219328824|NCT01723215|BEHAVIORAL|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
219328825|NCT01723215|BEHAVIORAL|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
219328826|NCT01723215|BEHAVIORAL|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
219328827|NCT00196638|DRUG|Antiretroviral combination (drugs)|
219328828|NCT00196638|DRUG|Pegylated Interferon alpha (drug)|
219328829|NCT05275348|BEHAVIORAL|Tele-Enhance Fitness|"Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode."
219328830|NCT05275348|BEHAVIORAL|In-person Enhance Fitness|Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
219328831|NCT01490814|PROCEDURE|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
219328832|NCT01490814|PROCEDURE|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
219328833|NCT03092206|DRUG|F/TAF|antiretroviral therapy
219328834|NCT03092206|DRUG|E/C/F/TAF|antiretroviral therapy
219328835|NCT03092206|DRUG|R/F/TAF|antiretroviral therapy
219328836|NCT02386748|DIETARY_SUPPLEMENT|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
219328837|NCT02386748|DIETARY_SUPPLEMENT|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
219328838|NCT02386748|OTHER|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
219328839|NCT05417607|BEHAVIORAL|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
219328840|NCT05929560|OTHER|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
219328841|NCT05929560|OTHER|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
219328842|NCT03024970|DEVICE|stenfilcon A lens with solution additive (test)|silicone hydrogel lens
219328843|NCT03024970|DEVICE|stenfilcon A lens (control)|contact lens
219328844|NCT04457466|DRUG|Nerve Growth Factor|Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
219328845|NCT00277251|DRUG|Alendronate|
219328846|NCT02119754|DRUG|Plurogel PN|
219328847|NCT03299634|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
219328848|NCT05221723|BEHAVIORAL|High Intensity Interval Exercise Training Group|Participants will participate in a maximum of twice weekly exercise classes (90 minutes each class) for a total of 6 months. While participants will be encouraged to attend as many classes as able, there is no minimum requirement for class attendance. During the exercise classes, participants will participate in a 10-minute warm up, followed by 30-60 minutes of aerobic, resistance and/or balance training up to a maximum intensity of 8/10 on the rating of perceived exertion scale. Participants will finish each class with a 10-minute cool-down consisting of lower intensity exercise.
219328849|NCT04616391|DEVICE|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
219328850|NCT03628937|DIETARY_SUPPLEMENT|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
219328851|NCT03628937|OTHER|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
219328852|NCT00814671|DRUG|Rifapentine 450|rifapentine 450 mg
219328853|NCT00814671|DRUG|Rifapentine 600|rifapentine 600 mg
219328854|NCT00814671|DRUG|Rifampin|rifampin 600 mg
219328855|NCT00786123|DIETARY_SUPPLEMENT|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
219328856|NCT00786123|DIETARY_SUPPLEMENT|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
219328857|NCT04749966|OTHER|This is an observational study, there are no interventions|This is an observational study, there are no interventions
219328858|NCT02017379|DRUG|Erythromycin|
219328859|NCT02017379|DRUG|Metoclopromide|
219328860|NCT02612740|BIOLOGICAL|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
219328861|NCT02612740|DEVICE|granules of deproteinized bovine bone (Bio-Oss)|
219328862|NCT05967117|DRUG|Iohexol (320mgI/mL) with 120kVp|Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
219328863|NCT05967117|DRUG|Iohexol (320mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
219328864|NCT05967117|DRUG|Iohexol (270mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
219328865|NCT05967117|DRUG|Iohexol (240mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
219328866|NCT02556125|DEVICE|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
219328867|NCT00268307|DRUG|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
219328868|NCT04340557|DRUG|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
219328869|NCT02794467|DRUG|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
219328870|NCT02794467|DRUG|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
219328871|NCT04557319|BIOLOGICAL|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
219328872|NCT04557319|BIOLOGICAL|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
219328873|NCT04557319|BIOLOGICAL|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
219328874|NCT00219050|DRUG|aliskiren|
219328875|NCT01289821|DRUG|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
219328876|NCT01289821|DRUG|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
219328877|NCT01289821|DRUG|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
219328878|NCT01289821|DRUG|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
219328879|NCT03591354|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.
219328880|NCT03591354|DEVICE|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
219328881|NCT05132270|DRUG|hydroxyurea and thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
219328882|NCT00590044|DRUG|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
219328883|NCT00590044|DRUG|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
219328884|NCT02231463|OTHER|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
219328885|NCT02231463|OTHER|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
219328886|NCT02231463|OTHER|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
219328887|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
219328888|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
219328889|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
219328890|NCT00273936|DRUG|AVN-944 capsules for oral administration|
219328891|NCT06035991|PROCEDURE|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
219328892|NCT02218957|PROCEDURE|Extended Pouch RYGB|
219328893|NCT02218957|PROCEDURE|Standard RYGB|
219328894|NCT01937572|OTHER|Visionaire system (Knee MRI)|
219328895|NCT01937572|OTHER|No Knee MRI|
219328896|NCT02901574|DEVICE|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
219328897|NCT02901574|DEVICE|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
219328898|NCT02901574|BEHAVIORAL|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
219328899|NCT01475929|DIETARY_SUPPLEMENT|Probiotic supplement|A single strain probiotic supplement given at two doses
219328900|NCT01010633|DRUG|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
219328901|NCT01010633|DRUG|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
219328902|NCT03241199|DRUG|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
219328903|NCT01040065|PROCEDURE|distal clavicle resection|Presence of tenderness at 2 years after surgery
219328904|NCT04980950|DIETARY_SUPPLEMENT|Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science|Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
219328905|NCT01881945|OTHER|Non-invasive physiological signal recording on healthy volunteer|
219328906|NCT03084406|OTHER|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
219328907|NCT01759004|OTHER|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
219328908|NCT05060705|DRUG|Efesovir|Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
219328909|NCT01116141|DRUG|CH-4051|Different doses CH-4051 to be compared
219328910|NCT01116141|DRUG|Methotrexate (MTX)|20 mg MTX weekly
219328911|NCT01116141|DRUG|Folic Acid|1 mg folic acid daily
219328912|NCT03428022|DRUG|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
219328913|NCT03965936|PROCEDURE|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
219328914|NCT03965936|PROCEDURE|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
219328915|NCT03975101|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
219328916|NCT03707613|PROCEDURE|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
219328917|NCT00535275|DRUG|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
219328918|NCT00535275|DRUG|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
219328919|NCT04160169|OTHER|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
219328920|NCT00000626|DRUG|Vinblastine sulfate|
219328921|NCT00000626|DRUG|Dacarbazine|
219328922|NCT00000626|DRUG|Filgrastim|
219328923|NCT00000626|DRUG|Bleomycin sulfate|
219328924|NCT00000626|DRUG|Doxorubicin hydrochloride|
219328925|NCT02670941|DRUG|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
219328926|NCT02670941|DRUG|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
219328927|NCT02670941|DRUG|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
219328928|NCT02670941|DRUG|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
219328929|NCT03621527|OTHER|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
219328930|NCT03621527|OTHER|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
219328931|NCT01923350|BEHAVIORAL|Weight Reduction Intervention|"The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
219328932|NCT01923350|BEHAVIORAL|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
219328933|NCT01923350|BEHAVIORAL|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
219328934|NCT01923350|BEHAVIORAL|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
219328935|NCT02654366|BEHAVIORAL|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
219328936|NCT05638451|DRUG|Sintilimab plus Bevacizumab and Temozolomide|200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
219328937|NCT02753660|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
219328938|NCT02753660|PROCEDURE|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
219328939|NCT05421962|DRUG|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
219328940|NCT01408433|OTHER|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
219328941|NCT01408433|OTHER|Double embryo transfer|two (2) embryo transfer of untested embryos
219328942|NCT02806154|OTHER|DEXA|The appendicular muscle mass measured by DEXA
219328943|NCT05010954|DRUG|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
219328944|NCT05010954|DRUG|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
219328945|NCT05274802|DRUG|ALS-4|Single dose of ALS-4 before Breakfast
219328946|NCT05274802|DRUG|Placebo|Single dose of placebo before Breakfast
219328947|NCT05274802|DRUG|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
219328948|NCT05274802|DRUG|ALS-4|Multiple dose of ALS-4 up to two times daily
219328949|NCT05274802|DRUG|Placebo|Multiple dose of placebo up to two times daily
219328950|NCT00225979|DRUG|Octreotide LAR|
219328951|NCT00189618|DRUG|Aspirin|100mg p.o. OD
219328952|NCT00189618|DRUG|Clopidogrel|75mg p.o. OD
219328953|NCT05864742|DRUG|Ibrutinib|560 mg daily continuously
219328954|NCT05864742|DRUG|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
219328955|NCT05864742|DRUG|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
219328956|NCT05864742|DRUG|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
219328957|NCT02616744|DRUG|Ibandronic acid|150 mg per month oral ibandronate
219328958|NCT02616744|DRUG|Placebo|1 oral capsule of placebo per month
219328959|NCT02790138|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
219328960|NCT02790138|DRUG|Ciprofloxacin|Ciprofloxacin tablets
219328961|NCT02790138|DRUG|Vedolizumab|Vedolizumab IV infusion
219328962|NCT04360499|OTHER|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
219328963|NCT04360499|OTHER|Pilates training|Pilates style exercise training
219328964|NCT02903251|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
219328965|NCT02903251|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
219328966|NCT06343935|DRUG|Linperlisib|Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
219328967|NCT02408107|BEHAVIORAL|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
219328968|NCT05300321|DEVICE|frame lens|The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
219328969|NCT02985099|DRUG|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
219328970|NCT02985099|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
219328971|NCT01786603|DRUG|Rasagiline|Rasagiline 2mg once a day for 12 months.
219328972|NCT01786603|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
219328973|NCT01226459|DRUG|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
219328974|NCT01226459|DRUG|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
219328975|NCT03848754|DRUG|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
219328976|NCT03848754|DRUG|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
219328977|NCT03848754|DRUG|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
219328978|NCT03848754|DRUG|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
219328979|NCT01059110|DRUG|Salicylate ointment|cream, one application every night, for 90 days
219328980|NCT01059110|DRUG|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
219328981|NCT01059110|DRUG|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
219328982|NCT01059110|DRUG|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
219328983|NCT01030159|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
219328984|NCT00474708|DRUG|Effexor|
219328985|NCT00474708|DRUG|SSRI|
219328986|NCT01112176|PROCEDURE|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
219328987|NCT00187213|DEVICE|Cardiac Resynchronization Therapy|
219328988|NCT00625495|DRUG|Esomeprazole|40mg Intravenous infusion over 3 minutes
219328989|NCT00625495|DRUG|Esomeprazole|40mg Oral
219328990|NCT03700320|DRUG|Standard of Care (SOC) Migraine Preventive Medication|Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
219328991|NCT03700320|DRUG|Atogepant|Atogepant tablets taken orally, once daily for 52 weeks.
219328992|NCT00480181|DRUG|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
219328993|NCT00480181|OTHER|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
219328994|NCT03770091|DRUG|Theraworx|Theraworx foam applied to skin and/or compression wrap
219328995|NCT03770091|DRUG|Placebo|Placebo foam
219328996|NCT00136526|DRUG|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
219328997|NCT03193762|OTHER|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
219328998|NCT03951051|DRUG|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
219328999|NCT03951051|DRUG|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
219329000|NCT03039231|DEVICE|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
219329001|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
219329002|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
219329003|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
219329004|NCT01504165|DRUG|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
219329005|NCT01504165|DRUG|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
219329006|NCT01391403|DRUG|Artemisinin|400 mg/day
219329007|NCT01391403|OTHER|Placebo|400mg/day
219329008|NCT02841202|DRUG|oral contraceptive pills|
219329009|NCT01083524|DRUG|Dichloroacetate Sodium|3 mg po bid for 28 weeks
219329010|NCT01083524|DRUG|Dichloroacetate Sodium|6.25 mg po bid
219329011|NCT01083524|DRUG|Dichloroacetate Sodium|12.5 mg po bid
219329012|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Consult
219329013|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Control - Standard of Care
219329014|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Newsletter
219329015|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Parent Letter
219329016|NCT04970550|OTHER|Non intervention|Non intervention
219329017|NCT00838292|DIETARY_SUPPLEMENT|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
219329018|NCT00838292|OTHER|nutrition counseling|
219329019|NCT00175877|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
219329020|NCT05311670|BEHAVIORAL|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
219329021|NCT01978535|DRUG|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
219329022|NCT01978535|DRUG|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
219329023|NCT03306355|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
219329024|NCT03306355|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
219329025|NCT03456648|DRUG|apixaban|non-vitamin K oral anticoagulant (NOAC)
219329026|NCT04961268|DRUG|TraMADol 50 Mg Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
219329027|NCT04961268|DRUG|Tramadol 100 MG Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
219329028|NCT04961268|DRUG|Ibuprofen 600Mg Tab|The patients were randomly given the medication by mouth 60 min before administering IANB.
219329029|NCT04961268|DRUG|ibuprofen 600 mg/acetaminophen 1000 mg|The patients were randomly given the medication by mouth 60 min before administering IANB.
219329030|NCT04961268|DRUG|Placebo|The patients were randomly given the medication by mouth 60 min before administering IANB.
219329031|NCT02042651|DEVICE|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
219329032|NCT02042651|DEVICE|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
219329033|NCT04278300|BIOLOGICAL|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
219329034|NCT04278300|BIOLOGICAL|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
219329035|NCT05520437|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
219329036|NCT05520437|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
219329037|NCT05680571|DEVICE|BulbiCam|BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
219329038|NCT05511974|DIAGNOSTIC_TEST|BASET score|The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
219329039|NCT04514120|OTHER|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
219329040|NCT03171766|DIAGNOSTIC_TEST|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
219329041|NCT03171766|DIAGNOSTIC_TEST|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
219329042|NCT03171766|DIAGNOSTIC_TEST|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
219329043|NCT04961151|OTHER|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
219329044|NCT04961151|OTHER|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
219329045|NCT02407470|DRUG|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
219329046|NCT02407470|PROCEDURE|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
219329047|NCT02407470|PROCEDURE|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
219329048|NCT05117255|BEHAVIORAL|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
219329049|NCT05117255|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
219329050|NCT05538520|OTHER|Traditional Pilates|This group will perform a traditional Pilates session, which consists of stretching exercises, followed by exercises to strengthen the core (trunk flexors and extensors), lower limbs and upper limbs. The total duration of the intervention in this group should be approximately 50 minutes.
219329051|NCT05538520|OTHER|Pilates without stretching|This group will conduct a non-traditional Pilates session. This is because stretching exercises will be excluded. The muscle strengthening exercises will be the same as in the TP group, so that it is possible to discuss the influence of the inclusion/exclusion of stretching for the considered outcomes. The total duration of the intervention in this group should be approximately 35 minutes.
219329052|NCT01092143|DRUG|BI 671800|BI 671800
219329053|NCT01092143|DRUG|Fluticasone propionate placebo|Placebo matching Fluticasone propionate
219329054|NCT01092143|DRUG|Fluticasone propionate|Fluticasone propionate
219329055|NCT01092143|DRUG|BI 671800 Placebo|Placebo matching BI 671800
219329056|NCT05189613|BIOLOGICAL|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
219329057|NCT05406843|OTHER|Preoperative cognitive functions of participants undergoing open heart surgery|Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
219329058|NCT05406843|OTHER|Postoperative cognitive functions of particiants undergoing open heart surgery|Changes in mini mental test scores were recorded in the postoperative period.
219329059|NCT00932984|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
219329060|NCT04326699|PROCEDURE|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
219329061|NCT06306885|BEHAVIORAL|Action observation plus motor imagery followed by sleep|Participants will be asked to observe video-clips showing motor contents immediately before sleeping
219329062|NCT06306885|BEHAVIORAL|Action observation plus motor imagery|Participants will be asked to observe video-clips showing motor contents at least 12 hours before sleeping
219329063|NCT06306885|BEHAVIORAL|Control|Participants will be asked to observe video-clips showing landscapes before sleeping
219329064|NCT03536975|OTHER|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
219329065|NCT03986866|OTHER|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
219329066|NCT05738811|OTHER|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
219329067|NCT05738811|OTHER|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
219329068|NCT05738811|OTHER|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
219329069|NCT04820374|PROCEDURE|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
219329070|NCT04295096|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
219329071|NCT00024414|DRUG|DHA-paclitaxel|
219329072|NCT01560923|BIOLOGICAL|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
219329073|NCT01560923|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
219329074|NCT01560923|OTHER|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
219329075|NCT00201669|DRUG|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
219329076|NCT04158921|OTHER|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. \> 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
219329077|NCT05093322|DRUG|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
219329078|NCT05710926|BEHAVIORAL|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
219329079|NCT05710926|BEHAVIORAL|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
219329080|NCT02452281|DRUG|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
219329081|NCT02452281|DRUG|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
219329082|NCT01079897|DEVICE|Atopiclair|topical applied cream, twice daily
219329083|NCT01079897|DEVICE|EHK02-01|topical applied cream containing 7% ectoine
219329084|NCT01033253|BEHAVIORAL|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
219329085|NCT04643314|OTHER|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
219329086|NCT00786812|DRUG|Nilotinib|
219329087|NCT00919555|DRUG|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
219329088|NCT00919555|DRUG|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
219329089|NCT00919555|DRUG|Placebo|Placebo
219329090|NCT02743416|OTHER|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
219329091|NCT01380639|OTHER|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
219329092|NCT01491295|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
219329093|NCT01491295|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
219329094|NCT01528813|DEVICE|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
219329095|NCT01528813|DRUG|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
219329096|NCT05831553|DIAGNOSTIC_TEST|Tissue Immune Profile|Tissue samples of the patients will be analized for the presence of TILs, CD73 and PDL1 (\>=1%)
219329097|NCT00103428|BIOLOGICAL|CG7870|
219329098|NCT02495350|OTHER|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
219329099|NCT03920150|DRUG|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
219329100|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
219329101|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
219329102|NCT04115826|PROCEDURE|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
219329103|NCT04115826|PROCEDURE|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
219329104|NCT04295616|DEVICE|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
219329105|NCT04295616|BEHAVIORAL|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
219329106|NCT01400581|BEHAVIORAL|Collaborative Care Intervention|See description of Intervention arm
219329107|NCT00620568|DRUG|SLV-313 SR|sustained release tablets taken once daily for 14 days
219329108|NCT01542268|DRUG|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
219329109|NCT01542268|DRUG|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
219329110|NCT04682704|DEVICE|Parasym|Tragus stimulation
219329111|NCT02774616|DEVICE|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
219329112|NCT02774616|DEVICE|Plexa ICD lead|predefined follow-up schedule
219329113|NCT02149212|DRUG|Phlebotonic|Aminaftone -- 75 mg BID
219329114|NCT02149212|DEVICE|Stent|Iliac Vein Stenting
219329115|NCT02149212|PROCEDURE|Limb elastic compression support|CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages
219329116|NCT02149212|PROCEDURE|Unna boot dressing|CEAP 6 \> Unna boot dressing
219329117|NCT00137163|DEVICE|Dermafill Dressing|
219329118|NCT05614687|BEHAVIORAL|Community-informed art-based programme|The Community-informed art-based programme is an intervention incorporating art in the form of for example poetry and drawings in addressing trauma and encouraging community attitudes towards the positive reintegration of ex-offenders.
219329119|NCT05614687|OTHER|Government Media Intervention|Government Media Intervention involving media content from the National Orientation Agency and other media sources
219329120|NCT03050996|PROCEDURE|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
219329121|NCT04420650|DEVICE|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
219329122|NCT00397033|DRUG|Paliperidone ER|6mg/day paliperidone er for 6 weeks
219329123|NCT00397033|DRUG|Paliperidone ER|12mg/day paliperidone er for 6 weeks
219329124|NCT00397033|DRUG|Placebo|Placebo for 6 weeks
219329125|NCT05173142|DRUG|HMPL-453|HMPL-453 administered orally.
219329126|NCT05173142|DRUG|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
219329127|NCT05173142|DRUG|toripalimab|Toripalimab administered intravenously.
219329128|NCT05173142|DRUG|Docetaxel|Docetaxel administered intravenously.
219329129|NCT00514163|DRUG|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
219329130|NCT00514163|DRUG|gemcitabine|gemcitabine DIV on day one , 8th and 15th
219329131|NCT02630446|OTHER|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
219329132|NCT00502346|DRUG|PM10|
219329133|NCT03533595|DEVICE|Barbed|Barbed Suture
219329134|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
219329135|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
219329136|NCT00067860|DRUG|recombinant human growth hormone|
219329137|NCT00067860|BEHAVIORAL|diet modification|
219329138|NCT04344340|DIAGNOSTIC_TEST|clinical examination|clinical examination
219329139|NCT00992940|PROCEDURE|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
219329140|NCT00992940|PROCEDURE|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
219329141|NCT01969487|OTHER|Preoperative warm-up on simulator|
219329142|NCT02670824|DRUG|CN-105|Single and multiple intravenous (IV) doses of CN-105
219329143|NCT02670824|DRUG|Placebo|Normal Saline
219329144|NCT06206564|DRUG|Artesunate ointment|Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
219329145|NCT06206564|DRUG|Placebo|Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
219329146|NCT05323188|OTHER|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
219329147|NCT06510205|DEVICE|Mentor Breast implants|"Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form."
219329148|NCT04882098|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
219329149|NCT04882098|DRUG|Placebo|Participants will receive matching placebo as SC injection.
219329150|NCT04045795|DRUG|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
219329151|NCT04045795|DRUG|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
219329152|NCT04045795|DRUG|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
219329153|NCT04045795|DRUG|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
219329154|NCT04045795|DEVICE|Investigational injector device|Subcutaneous administration
219329155|NCT01360541|PROCEDURE|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
219329156|NCT01360541|OTHER|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
219329157|NCT03022318|DRUG|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
219329158|NCT04675931|DRUG|KAE609|"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."
219329159|NCT04675931|DRUG|IV Artesunate|Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
219329160|NCT04675931|DRUG|Coartem|Oral Standard of Care
219329161|NCT02229539|DRUG|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
219329162|NCT02229539|DRUG|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
219329163|NCT02229539|OTHER|Placebo|2.5 mL placebo and 2.5 mL water administered orally
219329164|NCT04244916|BIOLOGICAL|AUC of MPA measure|"Plasmatic AUC determination of MPA requires 3 blood punctures at H0, H30 and H2.~These punctures will be made at inclusion after 6 weeks, 12 weeks, 6 months and one year."
219329165|NCT05748171|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
219329166|NCT05748171|DRUG|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
219329167|NCT00246909|DRUG|Pantoprazole|
219329168|NCT01688284|DEVICE|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14\_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
219329169|NCT01864187|DRUG|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
219329170|NCT02823795|BEHAVIORAL|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
219329171|NCT05767554|BEHAVIORAL|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can begin a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
219329172|NCT04516317|OTHER|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
219329173|NCT04516317|OTHER|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
219329174|NCT02777697|OTHER|chronic pain|
219329175|NCT02525393|DEVICE|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
219329176|NCT02525393|DEVICE|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
219329177|NCT02525393|DEVICE|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
219329178|NCT00682448|DRUG|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
219329179|NCT00682448|DRUG|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
219329180|NCT04714242|DRUG|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
219329181|NCT00311376|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
219329182|NCT00311376|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval
219329183|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
219329184|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval
219329185|NCT00257166|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
219329186|NCT00257166|DRUG|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
219329187|NCT00829049|DRUG|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
219329188|NCT00829049|DRUG|Adapalene|1 pea-size amount, QD x 16 weeks
219329189|NCT02737852|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
219329190|NCT04223895|DRUG|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
219329191|NCT04223895|DRUG|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
219329192|NCT04223895|DRUG|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
219329193|NCT00364520|OTHER|Shanghai workers|
219329194|NCT05865444|BEHAVIORAL|Values alignment wise intervention|"The intervention includes: (1) reading materials, such as recent journalistic works that expose the deceptive and manipulative marketing practices of food companies and the harmful effects of these practices on society, with particular emphasis on harm to young children and the economically disadvantaged. Stories from other young people will also be included in order to contribute to the perception of widespread outrage and to suggest how that outrage can be channeled into taking a stand against the injustice perpetrated by food companies by eating less unhealthy or healthier food; (2) writing exercises, such as a story with a brief statement of what the participants would tell a younger child about the ads; and (3) an interactive activity, called Make It Real in which they are shown pictures of food ads and allowed to write and draw about them, making whatever changes (e.g., crossing out and substituting words) they feel necessary to make the ad real (i.e., no longer misleading)."
219329195|NCT05865444|BEHAVIORAL|Educational traditional intervention|The educational intervention includes information on nutrition and physical exercise. It includes reading and writing exercises.
219329196|NCT03193645|DRUG|Degarelix|Injection
219329197|NCT00077532|BIOLOGICAL|gp100 antigen|
219329198|NCT00077532|BIOLOGICAL|incomplete Freund's adjuvant|
219329199|NCT00077532|BIOLOGICAL|ipilimumab|
219329200|NCT03862144|DRUG|Netupitant/Palonosetron|
219329201|NCT00521924|BIOLOGICAL|infliximab|infliximab 3 mg/kg and basic treatment
219329202|NCT00521924|DRUG|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
219329203|NCT04050670|DRUG|Tirzepatide|Tirzepatide administered SC
219329204|NCT05564975|OTHER||
219329205|NCT04146194|OTHER|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
219329206|NCT00982865|DRUG|MSC1936369B|
219329207|NCT00982865|DRUG|MSC1936369B|
219329208|NCT00982865|DRUG|MSC1936369B|
219329209|NCT00982865|DRUG|MSC1936369B|
219329210|NCT03882138|PROCEDURE|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
219329211|NCT05560542|DRUG|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
219329212|NCT02225470|DRUG|E7389 (Eribulin Mesylate)|
219329213|NCT02225470|DRUG|Vinorelbine injection|
219329214|NCT02348775|DIETARY_SUPPLEMENT|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
219329215|NCT00714675|DIETARY_SUPPLEMENT|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
219329216|NCT00714675|DIETARY_SUPPLEMENT|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
219329217|NCT03251742|DEVICE|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
219329218|NCT00525044|DRUG|Ambroxol|
219329219|NCT00525044|DRUG|Placebo|
219329220|NCT04125550|DRUG|Propofol|2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
219329221|NCT04125550|DRUG|Sevoflurane|sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
219329222|NCT03652038|DRUG|TD-8236|Study drug to be administered via inhaler device
219329223|NCT03652038|DRUG|Placebo|Placebo to be administered via inhaler device
219329224|NCT02125227|DRUG|Rosuvastatin, Metformin, YH14755|single dose
219329225|NCT02125227|DRUG|YH14755|single dose
219329226|NCT03286062|COMBINATION_PRODUCT|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
219329227|NCT05251740|DEVICE|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
219329228|NCT03333720|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
219329229|NCT04758442|OTHER|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
219329230|NCT06331442|OTHER|Photodynamic therapy|Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
219329231|NCT06331442|OTHER|Tricalcium phosphate (TCP) varnish with 5% NaF|Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
219329232|NCT06331442|OTHER|Chlorhexidine varnish|Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
219329233|NCT06466629|BIOLOGICAL|Triaxis, Sanofi Pasteur|tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine
219329234|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
219329235|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
219329236|NCT01458912|DRUG|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
219329237|NCT01458912|DRUG|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
219329238|NCT02220842|DRUG|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
219329239|NCT02220842|DRUG|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
219329240|NCT02220842|DRUG|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
219329241|NCT01164774|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
219329242|NCT01164774|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
219329243|NCT04750759|DRUG|Niclosamide + Camostat|Niclosamide will be applied in combination with camostat.
219329244|NCT04750759|OTHER|Placebo|Placebo to interventional drug
219329245|NCT00443807|DEVICE|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
219329246|NCT00443807|DEVICE|EEGo vs BIS|comparison of two processed EEG monitors.
219329247|NCT00000761|DRUG|Interferon gamma-1b|
219329248|NCT01908985|PROCEDURE|high intensity focused ultrasound for cyclodestruction in the eye|
219329249|NCT01810185|DRUG|Low dose naltrexone|4.5 mg daily for 12 weeeks
219329250|NCT01810185|DRUG|Placebo|
219329251|NCT04265846|DEVICE|bifocal IOL|The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
219329252|NCT04265846|DEVICE|mix bifocal IOL|The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
219329253|NCT04265846|DEVICE|trifocal IOL|The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
219329254|NCT04265846|DEVICE|EDOF IOL|The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
219329255|NCT04265846|DEVICE|different IOLs|The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
219329256|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
219329257|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
219329258|NCT02688491|DRUG|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
219329259|NCT04533282|DIAGNOSTIC_TEST|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
219329260|NCT04533282|DIAGNOSTIC_TEST|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
219329261|NCT04533282|DIAGNOSTIC_TEST|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
219329262|NCT04533282|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
219329263|NCT01168973|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
219329264|NCT01168973|DRUG|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
219329265|NCT01168973|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
219329266|NCT06021899|OTHER|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
219329267|NCT05902377|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
219329268|NCT02975193|BEHAVIORAL|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
219329269|NCT02975193|BEHAVIORAL|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
219329270|NCT02975193|PROCEDURE|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
219329271|NCT06414928|OTHER|Acute Heart Failure|Consecutive patients presented at Emergency Departement with Acute Heart Failure
219329272|NCT02230254|DEVICE|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
219329273|NCT06236295|DRUG|SHR6508|SHR6508 will be administered to all the eligible subjects
219329274|NCT00647153|OTHER|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
219329275|NCT00647153|PROCEDURE|single photon emission computed tomography|One day post infusion
219329276|NCT00647153|RADIATION|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
219329277|NCT05291442|OTHER|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
219329278|NCT03995732|DRUG|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
219329279|NCT03995732|DRUG|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
219329280|NCT02023242|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
219329281|NCT02023242|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
219329282|NCT03358199|PROCEDURE|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
219329283|NCT02375152|PROCEDURE|Anterior Capsulotomy|
219329284|NCT04512053|DRUG|TAS-303 18 mg/day|Oral administration for 12 weeks, once daily
219329285|NCT04512053|DRUG|Placebo|Oral administration for 12 weeks, once daily
219329286|NCT06466785|DRUG|Efepoetin Alfa|Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
219329287|NCT06466785|DRUG|Darbepoetin Alfa|Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
219329288|NCT05327413|OTHER|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
219329289|NCT00003370|DRUG|irofulven|
219329290|NCT03805997|DEVICE|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
219329291|NCT03805997|OTHER|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
219329292|NCT03805997|OTHER|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
219329293|NCT03805997|BIOLOGICAL|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
219329294|NCT03805997|OTHER|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
219329295|NCT03805997|OTHER|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
219329296|NCT03805997|OTHER|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
219329297|NCT03805997|OTHER|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
219329298|NCT02528370|DEVICE|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
219329299|NCT05689970|DIAGNOSTIC_TEST|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
219329300|NCT00979706|DRUG|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
219329301|NCT00979706|DRUG|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
219329302|NCT02995486|OTHER|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
219329303|NCT02847455|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
219329304|NCT02847455|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
219329305|NCT02847455|DRUG|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
219329306|NCT04671277|OTHER|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
219329307|NCT03108547|OTHER|Determination of scalp hair steroids|
219329308|NCT04540146|DIAGNOSTIC_TEST|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
219329309|NCT03988348|PROCEDURE|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
219329310|NCT03988348|PROCEDURE|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
219329311|NCT00069927|DRUG|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
219329312|NCT00069927|DRUG|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
219329313|NCT05507775|DRUG|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
219329314|NCT03010124|PROCEDURE|Blood sample|
219329315|NCT05326945|OTHER|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
219329316|NCT02679014|DRUG|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
219329317|NCT02679014|DRUG|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
219329318|NCT06354582|DRUG|Vitamin C Injection|Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.
219329319|NCT06354582|OTHER|Normal saline|The placebo comparator will receive normal saline with the same volume and be administered after the induction of epidural labor anesthesia.
219329320|NCT02326454|DRUG|talaporfin sodium|1 mg/kg
219329321|NCT02326454|DRUG|Saline|
219329322|NCT02326454|DEVICE|Drug Activator 100 J/cm|Light Dose: 100 J/cm
219329323|NCT02326454|DEVICE|Drug Activator 200 J/cm|Light Dose: 200 J/cm
219329324|NCT00388505|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
219329325|NCT00388505|DRUG|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
219329326|NCT02650999|DRUG|Pembrolizumab|200mg intravenously (IV)
219329327|NCT03556553|DEVICE|Vertise Flow|Composite resin
219329328|NCT03556553|DEVICE|LuxaFlow|Composite resin
219329329|NCT03556553|DEVICE|Teco Adhesive|Adhesive system
219329330|NCT03886753|OTHER|Registry|Collect data on subjects
219329331|NCT03886753|OTHER|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
219329332|NCT01414699|BEHAVIORAL|Variety|These conditions will have snack served with an increase of fruit variety.
219329333|NCT01414699|BEHAVIORAL|Non-Variety|These conditions will receive a snack without a variety of fruit.
219329334|NCT02018406|DRUG|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
219329335|NCT02018406|DRUG|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
219329336|NCT00094692|DEVICE|Eye patch|
219329337|NCT00094692|DEVICE|spectacles|
219329338|NCT00094692|DRUG|atropine|
219329339|NCT03195751|DEVICE|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
219329340|NCT03195751|DEVICE|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
219329341|NCT02251379|DRUG|Flovent Diskus|Inhaled corticosteroids
219329342|NCT02251379|OTHER|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
219329343|NCT02251379|DRUG|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
219329344|NCT02258789|OTHER|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
219329345|NCT00618436|DRUG|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
219329346|NCT00618436|DRUG|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
219329347|NCT03897907|OTHER|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
219329348|NCT03897907|OTHER|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
219329349|NCT00299962|BIOLOGICAL|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
219329350|NCT00299962|BIOLOGICAL|SCH 721015|Comparison of different doses and frequency of investigational agent
219329351|NCT01471314|BEHAVIORAL|Headache day versus non-headache day|
219329352|NCT05092178|BEHAVIORAL|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
219329353|NCT05092178|BEHAVIORAL|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
219329354|NCT03094351|PROCEDURE|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
219329355|NCT03094351|PROCEDURE|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
219329356|NCT05503784|OTHER|BITE Deodorant|BITE natural Deodorant
219329357|NCT05435170|DRUG|linerixibat|linerixibat will be administered per the treatment sequence
219329358|NCT00370227|BIOLOGICAL|10 valent pneumococcal conjugate (vaccine)|
219329359|NCT03439436|DRUG|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
219329360|NCT03439436|DRUG|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
219329361|NCT04854434|DRUG|Selinexor|Participants will receive selinexor oral tablets.
219329362|NCT04854434|DRUG|Pembrolizumab|Participants will receive pembrolizumab intravenously.
219329363|NCT04854434|DRUG|Trifluridine|Participants will receive trifluridine oral tablets as SOC.
219329364|NCT04854434|DRUG|Tipiracil|Participants will receive tipiracil oral tablets as SOC.
219329365|NCT01974492|PROCEDURE|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
219329366|NCT01974492|PROCEDURE|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
219329367|NCT04424160|BIOLOGICAL|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
219329368|NCT01586884|PROCEDURE|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
219329369|NCT02218281|BEHAVIORAL|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
219329370|NCT02218281|BEHAVIORAL|NCI's QuitSTART app|NCI's smoking cessation app
219329371|NCT02218281|BEHAVIORAL|Written smoking cessation materials only|Receipt of written smoking cessation materials
219329372|NCT04458662|PROCEDURE|Interval running protocol / eccentric-based resistance exercise protocol|
219329373|NCT03832491|OTHER|Home based therapy|Airway clearence techniques
219329374|NCT03832491|OTHER|Game and home based therapy|Game based approach programme and airway clearence techniques
219329375|NCT01975740|OTHER|Sham manual diaphragm release technique|
219329376|NCT01975740|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
219329377|NCT00693914|BEHAVIORAL|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
219329378|NCT02667275|DRUG|A-101 Solution|
219329379|NCT02667275|OTHER|Vehicle Solution|Placebo
219329380|NCT00932204|DEVICE|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
219329381|NCT01487642|DEVICE|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
219329382|NCT01487642|DEVICE|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
219329383|NCT01487642|DEVICE|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
219329384|NCT01487642|DEVICE|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
219329385|NCT06388850|BEHAVIORAL|Healthy Relationships Project|The Healthy Relationships Project (HRP), created by the community-based organization Prevent Child Abuse Vermont (PCAVT), will be the focus of this rigorous evaluation study. The program is fully manualized with a widely accepted curriculum designed for Pre-K to 2nd graders (Care for Kids) and 3rd to 6th graders (We Care Elementary, though implementation will stop at 5th grade for this study). The HRP uses an upstream universal public health approach for the primary prevention of child and youth perpetration of child sexual abuse with developmentally appropriate intervention elements for children, faculty and staff at their schools, and for their caregivers.
219329386|NCT05681000|DRUG|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
219329387|NCT05700305|OTHER|12-week, low threshold physical rehabilitation intervention with protein supplementation|12 week, low threshold, rolling exercise intervention with protein supplementation
219329388|NCT02318862|PROCEDURE|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
219329389|NCT04816929|OTHER|Bobath Method|Neurodevelopmental Treatment
219329390|NCT04816929|OTHER|Task-Oriented Approach|Task-Oriented Treatment
219329391|NCT01274715|BEHAVIORAL|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
219329392|NCT00338039|DRUG|Cetuximab|500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
219329393|NCT00338039|DRUG|Gemcitabine|"Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off."
219329394|NCT00338039|DRUG|Oxaliplatin|Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
219329395|NCT00338039|DRUG|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
219329396|NCT00338039|RADIATION|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
219329397|NCT04248101|PROCEDURE|Double Ligation|
219329398|NCT04248101|DRUG|Topical Silver Nitrate|
219329399|NCT05578859|DRUG|AMG 510|Single oral dose of AMG510.
219329400|NCT00363324|PROCEDURE|intracoronary injection of bone marrow cells|
219329401|NCT03075813|OTHER|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
219329402|NCT04169750|BEHAVIORAL|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
219329403|NCT04169750|BEHAVIORAL|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
219329404|NCT04169750|BEHAVIORAL|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
219329405|NCT05694351|BEHAVIORAL|Healthy meals and physical activity in families with type 2 diabetes|Families will participate in telehealth family education on diabetes management and prevention through lifestyle modifications in their everyday occupations regarding current recommendations for physical activity, grocery shopping, meal preparation, and family meal routines. Each family will be assisted in setting tailored goals for the family as a whole and individually regarding physical activity and dieting habits. The goals will be incorporated into family daily routines, to secure manageability and sustainability of the new lifestyle habits. Local facilities and communy networks will be engaged in this process to empower and motivate the participants. Working with the goals will be monitored and facilitated throughout the intervention period of 3 months. Before discharge, each family will co-produce a maintenance plan for physical activity and healthy dieting.
219329406|NCT05893979|DEVICE|Spectacle Lenses|Standard Spectacle Lenses
219329407|NCT03199820|DEVICE|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
219329408|NCT03199820|DRUG|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
219329409|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
219329410|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
219329411|NCT05546164|OTHER|Assessment of hand grip strength|Assessment of hand grip strength
219329412|NCT05546164|OTHER|Assessment of pinch strength|Assessment of pinch strength
219329413|NCT05546164|OTHER|Assessment of upper limb dexterity|Assessment of upper limb dexterity
219329414|NCT06196645|BEHAVIORAL|Physical Activity Intervention Based on Theory of Planned Behavior|The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in.
219329415|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow oxygen
219329416|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow air
219329417|NCT02357134|OTHER|Quality-of-Life Assessment|Ancillary studies
219329418|NCT02357134|OTHER|Questionnaire Administration|Ancillary studies
219329419|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow oxygen
219329420|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow air
219329421|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
219329422|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329423|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329424|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329425|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
219329426|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329427|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329428|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
219329429|NCT01301456|BIOLOGICAL|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
219329430|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
219329431|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
219329432|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
219329433|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
219329434|NCT05704686|DEVICE|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
219329435|NCT04442191|BIOLOGICAL|Convalescent plasma|This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
219329436|NCT04442191|BIOLOGICAL|Placebo|The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
219329437|NCT03583450|DEVICE|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
219329438|NCT03374995|OTHER|Best Practice|Receive standard of care
219329439|NCT03374995|OTHER|Quality-of-Life Assessment|Ancillary studies
219329440|NCT03374995|DEVICE|Topical Keratin|Given topically
219329441|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
219329442|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
219329443|NCT00564005|OTHER|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
219329444|NCT00564005|OTHER|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
219329445|NCT00564005|OTHER|Combined therapy (CT)|combined different treatment approaches
219329446|NCT00564005|BEHAVIORAL|Control intervention|Conventional treatment program
219329447|NCT00670501|DRUG|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
219329448|NCT00670501|DRUG|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
219329449|NCT00670501|DRUG|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
219329450|NCT00670501|DRUG|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
219329451|NCT00670501|DRUG|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
219329452|NCT03974087|DEVICE|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
219329453|NCT01380730|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219329454|NCT01380730|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
219329455|NCT03413852|DEVICE|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
219329456|NCT02712151|PROCEDURE|Abdominal Wall Block|bilateral TAP and RS blocks.
219329457|NCT02712151|PROCEDURE|Surgical infiltration|distributed between the 4 laparoscopic port sites.
219329458|NCT02712151|DRUG|Sterile saline|Placebo injection
219329459|NCT02712151|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
219329460|NCT02712151|DEVICE|Ultrasound|For nerve localization
219329461|NCT02712151|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
219329462|NCT00041080|DRUG|tamoxifen citrate|Given orally
219329463|NCT00041080|DRUG|thalidomide|Given orally
219329464|NCT00041080|OTHER|laboratory biomarker analysis|Correlative studies
219329465|NCT02879227|DRUG|Cisplatin|Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
219329466|NCT02879227|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
219329467|NCT05418673|DRUG|BIIB122|Administered as specified in the treatment arm.
219329468|NCT05418673|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
219329469|NCT06005337|BEHAVIORAL|Blogshots 1-3|"1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection"
219329470|NCT06005337|BEHAVIORAL|Blogshots 4-6|"1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media"
219329471|NCT01202851|OTHER|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
219329472|NCT01202851|BEHAVIORAL|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
219329473|NCT01202851|OTHER|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
219329474|NCT00550654|OTHER|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
219329475|NCT00550654|RADIATION|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
219329476|NCT00550654|RADIATION|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
219329477|NCT00550654|RADIATION|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
219329478|NCT00550654|RADIATION|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
219329479|NCT06016179|DRUG|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
219329480|NCT03406299|DRUG|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
219329481|NCT03406299|DRUG|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
219329482|NCT03406299|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
219329483|NCT03406299|DRUG|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
219329484|NCT03406299|DRUG|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
219329485|NCT04762316|DRUG|SB-UF|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
219329486|NCT04762316|DEVICE|SB-UF Placebo|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
219329487|NCT03128567|DEVICE|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
219329488|NCT05955391|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
219329489|NCT05133440|DRUG|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
219329490|NCT05133440|DIAGNOSTIC_TEST|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
219329491|NCT04329351|PROCEDURE|Guided Bone regeneration|Guided bone regeneration to ridge preservation
219329492|NCT06155110|DRUG|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
219329493|NCT04328948|RADIATION|Chemoradiotherapy|Chemoradiotherapy
219329494|NCT05451563|DEVICE|Double-S|Wearable device for intercourse
219329495|NCT02180971|PROCEDURE|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
219329496|NCT02180971|PROCEDURE|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
219329497|NCT04563780|DEVICE|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
219329498|NCT00041925|DRUG|CGT003 (E2F Duplex Decoy)|
219329499|NCT06038240|BEHAVIORAL|Savoring Meditation|Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).
219329500|NCT06038240|BEHAVIORAL|Pain Self-Management and Education|Participants will learn about the biopsychosocial drivers of chronic pain.
219329501|NCT03199040|DRUG|Durvalumab|-Human monoclonal antibody
219329502|NCT03199040|BIOLOGICAL|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
219329503|NCT03199040|DEVICE|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
219329504|NCT03199040|PROCEDURE|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
219329505|NCT03882203|DRUG|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
219329506|NCT02580942|DEVICE|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
219329507|NCT02580942|DEVICE|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
219329508|NCT02580942|DRUG|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
219329509|NCT04290338|OTHER|PIOMI|Intraoral and extraoral stimulation.
219329510|NCT03778567|DRUG|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
219329511|NCT06059924|OTHER|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
219329512|NCT05838079|OTHER|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
219329513|NCT05168748|DRUG|IMJ995 single agent|Single intravenous administration of IMJ995
219329514|NCT00588510|OTHER|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
219329515|NCT01089998|DRUG|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
219329516|NCT01089998|DRUG|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
219329517|NCT01089998|DRUG|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
219329518|NCT01089998|DRUG|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
219329519|NCT01652742|DRUG|BI 135585 XX|one single dose
219329520|NCT04541979|DRUG|aerosolized DNase|DNase
219329521|NCT04541979|DRUG|NaCl|NaCl 0.9%, isotonic saline
219329522|NCT02566291|DEVICE|Success|Success rate and time for insertion
219329523|NCT02984579|DEVICE|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
219329524|NCT02984579|DEVICE|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
219329525|NCT02984579|DEVICE|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
219329526|NCT02951286|DEVICE|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
219329527|NCT02951286|DEVICE|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
219329528|NCT00199836|BIOLOGICAL|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
219329529|NCT02301663|OTHER|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
219329530|NCT02301663|OTHER|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
219329531|NCT02301663|OTHER|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
219329532|NCT00449384|BEHAVIORAL|Diagnostic Screening|
219329533|NCT00940381|DRUG|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
219329534|NCT00940381|DRUG|Cetuximab|Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
219329535|NCT02582320|DRUG|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
219329536|NCT02967705|BEHAVIORAL|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
219329537|NCT01114282|DRUG|velcade|
219329538|NCT01114282|DRUG|Pralatrexate|
219329539|NCT05353400|OTHER|Early urinary catheter removal|Early catheter removal
219329540|NCT05353400|OTHER|Urinary catheter removal on POD 3|Catheter removal on POD 3
219329541|NCT02237404|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
219329542|NCT04267718|OTHER|Application of Padua and IMPROVE Bleeding scores|Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
219329543|NCT02400034|OTHER|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
219329544|NCT03392272|DEVICE|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
219329545|NCT03392272|OTHER|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
219329546|NCT04301362|DIAGNOSTIC_TEST|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
219329547|NCT04575103|DRUG|Antipsychotic|Antipsychotic treatment \>0.5 DDD
219329548|NCT00503243|DRUG|Delayed and extended release mesalazine|
219329549|NCT06375434|OTHER|No intervention|No intervention
219329550|NCT04254744|DRUG|Sevoflurane|Sevoflurane inhalation for anesthesia
219329551|NCT03228069|PROCEDURE|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
219329552|NCT03870516|PROCEDURE|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
219329553|NCT03870516|DEVICE|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
219329554|NCT04215614|DRUG|Lidocaine and Bupivacaine solution|1:1 ratio 2% lidocaine, and 0.5% bupivacaine
219329555|NCT04215614|DEVICE|Costoclavicular block|Ultrasound-guided costoclavicular brachial plexus block
219329556|NCT04215614|DEVICE|Lateral Sagittal block|Ultrasound-guided lateral sagittal brachial plexus block
219329557|NCT02336763|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219329558|NCT02336763|OTHER|Laboratory Biomarker Analysis|Correlative studies
219329559|NCT00286351|DRUG|Combined treatment with Arimidex and Zoladex before IVF|
219329560|NCT02232126|OTHER|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
219329561|NCT01515293|PROCEDURE|Single Incision Laparoscopic Appendectomy|
219329562|NCT01515293|PROCEDURE|Conventional appendectomy|
219329563|NCT04257565|DEVICE|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
219329564|NCT04257565|OTHER|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
219329565|NCT00041054|DRUG|carboplatin|
219329566|NCT00041054|DRUG|etoposide|
219329567|NCT00041054|DRUG|exisulind|
219329568|NCT02980120|OTHER|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig \& Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
219329569|NCT02980120|OTHER|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner \& Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
219329570|NCT02980120|OTHER|EDI-2|The Eating Disorder Inventory 2 (Paul \& Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
219329571|NCT02980120|OTHER|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig \& Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
219329572|NCT02980120|OTHER|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke \& Krischer, 2011).
219329573|NCT02980120|OTHER|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann \& Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
219329574|NCT02980120|DEVICE|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
219329575|NCT05425069|DRUG|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
219329576|NCT00000551|BEHAVIORAL|health education|
219329577|NCT02465385|DRUG|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
219329578|NCT01212978|BEHAVIORAL|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
219329579|NCT00518388|BEHAVIORAL|Focus Group|Focus groups each lasting about 2 hours.
219329580|NCT00518388|BEHAVIORAL|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
219329581|NCT04297501|DRUG|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
219329582|NCT00024401|DRUG|DHA-paclitaxel|
219329583|NCT03982342|DEVICE|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
219329584|NCT03982342|OTHER|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
219329585|NCT02627755|DEVICE|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
219329586|NCT02627755|DEVICE|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
219329587|NCT03171727|DRUG|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
219329588|NCT01854645|DRUG|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
219329589|NCT01854645|DRUG|GP MDI|GP MDI administered as two puffs BID
219329590|NCT01854645|DRUG|FF MDI|FF MDI administered as two puffs BID
219329591|NCT01854645|DRUG|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
219329592|NCT01854645|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID
219329593|NCT03517384|BEHAVIORAL|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
219329594|NCT01903291|DRUG|dimethyl fumarate|As described in the treatment arm
219329595|NCT02748850|BIOLOGICAL|blood sample|a blood sample 20 milliliter
219329596|NCT02748850|BIOLOGICAL|Stem cell donation|The volume of stem cells remained in the tube is recovered
219329597|NCT04553510|DRUG|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
219329598|NCT04553510|DRUG|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
219329599|NCT01223521|DEVICE|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
219329600|NCT02975492|DRUG|Cholecalciferol sequential dose|sequential dose administration of the treatment
219329601|NCT02975492|DRUG|Cholecalciferol daily dose|daily dose administration of the treatment
219329602|NCT04253535|OTHER|questionnaries|Study on questionnaries
219329603|NCT05147064|PROCEDURE|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
219329604|NCT05147064|PROCEDURE|conventional open surgery|open interlaminar lumbar decompression
219329605|NCT00430482|BEHAVIORAL|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
219329606|NCT00430482|BEHAVIORAL|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
219329607|NCT01898897|PROCEDURE|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
219329608|NCT01898897|PROCEDURE|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
219329609|NCT01910350|BEHAVIORAL|Kin KeeperSM Cancer Prevention Intervention|
219329610|NCT01910350|OTHER|Standard of care|
219329611|NCT04915651|DEVICE|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
219329612|NCT00555477|DRUG|anastrozole|1 mg tablet by mouth once a day
219329613|NCT00545402|DRUG|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
219329614|NCT00545402|DRUG|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
219329615|NCT00545402|DRUG|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
219329616|NCT00545402|DRUG|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
219329617|NCT00545402|DRUG|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
219329618|NCT01486797|DRUG|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~* 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
219329619|NCT01773642|BEHAVIORAL|Cognitive behavioral intervention to support pediatric HIV disclosure|
219329620|NCT01721876|DRUG|Placebo|Placebo matching Volasertib
219329621|NCT01721876|DRUG|Volasertib|Volasertib
219329622|NCT01721876|DRUG|Cytarabine|Cytarabine
219329623|NCT01714778|OTHER|e-Cigarette|
219329624|NCT05354076|DRUG|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
219329625|NCT03862365|GENETIC|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
219329626|NCT06280222|DEVICE|The VR instrument - Oculus Quest 2|Patients in the interventional group will watch 20-minute scenery movies in the VR instrument before entering the oocyte retrieval procedure.
219329627|NCT05757336|DRUG|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
219329628|NCT03086265|DEVICE|THRIVE|active nasal oxygen delivery system
219329629|NCT03086265|DEVICE|Endotracheal tube|Plastic tube for supporting ventilation during surgery
219329630|NCT01001468|DRUG|VB-201|Single daily dose of oral VB-201 20 mg
219329631|NCT01001468|DRUG|VB-201|Single daily dose or oral VB-201 80 mg
219329632|NCT01001468|OTHER|Placebo|Single daily dose of oral placebo
219329633|NCT01848886|PROCEDURE|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
219329634|NCT01848886|PROCEDURE|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
219329635|NCT01848886|PROCEDURE|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
219329636|NCT01848886|PROCEDURE|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
219329637|NCT01721057|DRUG|Placebo|Administered orally
219329638|NCT01721057|DRUG|Baricitinib|Administered orally
219329639|NCT01721057|DRUG|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
219329640|NCT05407597|DRUG|Icatibant|"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
219329641|NCT05407597|DRUG|0.9% Sodium Chloride Injection|"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
219329642|NCT05487898|DEVICE|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
219329643|NCT01202279|DRUG|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
219329644|NCT01202279|DEVICE|Placebo|Placebo bid for 7 days
219329645|NCT05877222|DRUG|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
219329646|NCT05877222|DRUG|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
219329647|NCT05881889|DEVICE|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
219329648|NCT05881889|DEVICE|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
219329649|NCT04054089|DRUG|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
219329650|NCT04054089|DRUG|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
219329651|NCT03970850|DIAGNOSTIC_TEST|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
219329652|NCT03970850|DIAGNOSTIC_TEST|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
219329653|NCT00514774|DRUG|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
219329654|NCT00514774|DRUG|placebo|placebo 600mg twice daily for study days 0 through 28
219329655|NCT02041754|DEVICE|IQP-AK-102|
219329656|NCT02041754|DEVICE|Placebo|
219329657|NCT05802394|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
219329658|NCT05923749|DEVICE|Biatain Ag|Biatain with silver
219329659|NCT05923749|DEVICE|Cutimed Siltec Sorbact|comparator device
219329660|NCT00686296|OTHER|Taliderm™|taliderm™ dressing application once
219329661|NCT00686296|OTHER|Taliderm™|Taliderm™ dressing application up to three applications
219329662|NCT00686296|OTHER|standard wet to dry dressing with gauze|wet to dry dressing standard of care
219329663|NCT03516890|PROCEDURE|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
219329664|NCT06387849|OTHER|Aromatherapy|women enrolled in the experimental group received aromatherapy with lavender essential oil (EO) through dry inhalation (inhalation via a cotton support soaked in a few drops of EO)
219329665|NCT06387849|OTHER|Placebo|women enrolled in the placebo group received ihaled a cotton support soaked in a few drops of distilled water
219329666|NCT04353466|PROCEDURE|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
219329667|NCT04353466|DRUG|Elelyso|intravenous (IV) infusions of Elelyso
219329668|NCT00000420|DRUG|Ortho-Novum 777|
219329669|NCT04687332|OTHER|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
219329670|NCT05852041|PROCEDURE|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
219329671|NCT05852041|GENETIC|Decipher Prostate Cancer Test|Undergo decipher
219329672|NCT05852041|OTHER|Flotufolastat F-18 Gallium|Given IV
219329673|NCT05852041|PROCEDURE|Magnetic Resonance Imaging|Undergo PET-MRI
219329674|NCT05852041|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
219329675|NCT05852041|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
219329676|NCT05852041|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219329677|NCT01908972|DRUG|Prednisolone|2mg/kg/day for 16weeks
219329678|NCT01908972|DRUG|Propranolol|2mg/kg/day for 16weeks
219329679|NCT04747093|BIOLOGICAL|CAR-ITNK cells|CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
219329680|NCT02366975|DRUG|Testosterone gel 2%|testosterone gel 2% (50mg/die).
219329681|NCT02366975|OTHER|Placebo|placebo gel
219329682|NCT02546765|DRUG|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
219329683|NCT02546765|DRUG|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
219329684|NCT02546765|DRUG|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
219329685|NCT02546765|DRUG|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
219329686|NCT01640912|DRUG|RXI-109|Single intradermal injection of RXI-109 at incision sites
219329687|NCT01640912|DRUG|Placebo|Single intradermal injection of placebo at incision sites
219329688|NCT05197413|DIETARY_SUPPLEMENT|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
219329689|NCT01710995|DRUG|Zegerid|
219329690|NCT01710995|DRUG|Losec|
219329691|NCT02026921|DRUG|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
219329692|NCT02026921|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
219329693|NCT02380950|BEHAVIORAL|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
219329694|NCT02763228|BEHAVIORAL|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
219329695|NCT02763228|BEHAVIORAL|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
219329696|NCT02763228|BEHAVIORAL|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
219329697|NCT02763228|BEHAVIORAL|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
219329698|NCT02763228|BEHAVIORAL|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
219329699|NCT02763228|BEHAVIORAL|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
219329700|NCT02763228|BEHAVIORAL|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
219329701|NCT02698748|DRUG|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
219329702|NCT02698748|DRUG|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
219329703|NCT05327621|DRUG|Pamiparib|40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
219329704|NCT00475722|BEHAVIORAL|1 Healthy Eating|6 months telephone counseling
219329705|NCT00475722|BEHAVIORAL|2 Mediterranean|6 months telephone counseling
219329706|NCT03182985|BEHAVIORAL|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
219329707|NCT03687073|DRUG|Indole-3-Carbinol|Cohorts 2, 3, \& 4: 400 mg PO BID
219329708|NCT03687073|DRUG|Silibinin|Cohorts 1 \& 4: 720mg
219329709|NCT03687073|DRUG|Silibin|Cohort 3: 360mg
219329710|NCT04291248|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
219329711|NCT04291248|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
219329712|NCT06039462|BEHAVIORAL|Application of a virtual reality headset|Use of a headset to experience a different reality
219329713|NCT03001960|DRUG|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
219329714|NCT03001960|DRUG|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
219329715|NCT05201027|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
219329716|NCT00086970|DRUG|ifosfamide|Given IV
219329717|NCT00086970|DRUG|O6-benzylguanine|Given IV
219329718|NCT03128970|OTHER|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
219329719|NCT02495220|DRUG|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
219329720|NCT02495220|DRUG|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
219329721|NCT01377064|BEHAVIORAL|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
219329722|NCT01377064|OTHER|Standard Care Group|No intervention, the group will be followed under their standard medical care.
219329723|NCT04765475|BEHAVIORAL|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
219329724|NCT04765475|BEHAVIORAL|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
219329725|NCT04765475|BEHAVIORAL|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
219329726|NCT04765475|OTHER|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
219329727|NCT05799599|BEHAVIORAL|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
219329728|NCT05799599|BEHAVIORAL|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
219329729|NCT05799599|BEHAVIORAL|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
219329730|NCT01298583|BEHAVIORAL|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
219329731|NCT04095728|DIETARY_SUPPLEMENT|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
219329732|NCT04095728|OTHER|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
219329733|NCT01021787|DRUG|Titanium dioxide|Topical cream
219329734|NCT00865397|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
219329735|NCT00916279|DEVICE|Lutonix Paclitaxel-Coated Balloon|PTCA
219329736|NCT02064920|DRUG|Placebo|Placebo for donepezil hydrochloride capsule
219329737|NCT02064920|DRUG|Donepezil|5 mg donepezil hydrochloride capsule.
219329738|NCT02064920|DRUG|Donepezil|10 mg donepezil hydrochloride capsule.
219329739|NCT02109562|DRUG|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
219329740|NCT02109562|DRUG|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
219329741|NCT02109562|DRUG|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
219329742|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
219329743|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
219329744|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
219329745|NCT00310804|BIOLOGICAL|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
219329746|NCT02441465|DRUG|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
219329747|NCT02441465|DRUG|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
219329748|NCT03877536|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
219329749|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
219329750|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
219329751|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
219329752|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
219329753|NCT04700384|BEHAVIORAL|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
219329754|NCT04700384|BEHAVIORAL|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
219329755|NCT03598647|BEHAVIORAL|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
219329756|NCT03598647|BEHAVIORAL|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
219329757|NCT00688155|BEHAVIORAL|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
219329758|NCT00688155|BEHAVIORAL|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
219329759|NCT00688155|BEHAVIORAL|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
219329760|NCT05744336|OTHER|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
219329761|NCT05744336|OTHER|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
219329762|NCT04310085|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
219329763|NCT04310085|BIOLOGICAL|PfSPZ-DVI Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
219329764|NCT06456528|DRUG|QL0911|QL0911
219329765|NCT06456528|DRUG|QL0911 plus Placebo|QL0911 plus Placebo
219329766|NCT06456528|DRUG|Placebo|Placebo
219329767|NCT05492695|DRUG|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
219329768|NCT05492695|OTHER|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
219329769|NCT03543111|BEHAVIORAL|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
219329770|NCT02366559|DEVICE|Hyfrecator|
219329771|NCT02366559|DEVICE|532 nm Q-switched Nd:YAG laser|
219329772|NCT03044782|OTHER|53-Item Survey|
219329773|NCT04334707|PROCEDURE|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
219329774|NCT01248286|OTHER|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
219329775|NCT01248286|OTHER|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
219329776|NCT02484833|DRUG|Cetuximab|
219329777|NCT02484833|DRUG|FOLFIRI|
219329778|NCT05520099|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
219329779|NCT01043341|BEHAVIORAL|educative folder|folder about HPV infection and vaccines
219329780|NCT00745693|DRUG|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
219329781|NCT00745693|DRUG|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
219329782|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
219329783|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
219329784|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
219329785|NCT05112627|PROCEDURE|Biospecimen Collection|Undergo blood collection
219329786|NCT06073990|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
219329787|NCT00215800|DRUG|Ampligen|
219329788|NCT06315738|BIOLOGICAL|ST266|Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
219329789|NCT06598241|DEVICE|Borate-base Bioactive Glass Fiber Matrix (BBGFM)|Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
219329790|NCT05744908|OTHER|Pentosan Polysulphate|300mg 3 times a day
219329791|NCT06043674|DRUG|Glofitamab|"2:1 T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol."
219329792|NCT06043674|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, administered via intravenous infusion per protocol.
219329793|NCT06043674|DRUG|Polatuzumab Vedotin|Antibody-drug conjugate, administered via intravenous infusion per protocol.
219329794|NCT06043674|DRUG|Atezolizumab|Humanized immunoglobulin monoclonal antibody, administered via intravenous infusion per protocol.
219329795|NCT06043674|DRUG|Tocilizumab|For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, administered via intravenous infusion per protocol.
219329796|NCT06043674|DRUG|Pirtobrutinib|Selective inhibitor of BTK, 50 mg or 100 mg tablet, via oral administration per protocol.
219329797|NCT05425914|DRUG|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
219329798|NCT05425914|DRUG|Artificial tear|Conventional dry eye treatment
219329799|NCT05566613|RADIATION|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
219329800|NCT06537778|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 45 h.
219329801|NCT06537778|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
219329802|NCT05296837|DRUG|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
219329803|NCT05296837|DRUG|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
219329804|NCT05296837|DRUG|Placebo|Placebo to be administered in tablet form twice daily
219329805|NCT04085315|DRUG|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
219329806|NCT04085315|DRUG|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
219329807|NCT01292798|DRUG|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
219329808|NCT04629352|DEVICE|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
219329809|NCT04629352|DEVICE|Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
219329810|NCT03573609|DEVICE|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
219329811|NCT00997451|BEHAVIORAL|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
219329812|NCT00997451|BEHAVIORAL|Symptom monitoring|Daily symptom via web diary
219329813|NCT00000353|DRUG|Buprenorphine/naloxone|
219329814|NCT04453293|BIOLOGICAL|BCG (Tokyo 172) vaccine|Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
219329815|NCT04453293|DRUG|Placebo|Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
219329816|NCT04451850|OTHER|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
219329817|NCT05054738|BEHAVIORAL|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
219329818|NCT05054738|BEHAVIORAL|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
219329819|NCT03613753|DRUG|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
219329820|NCT03613753|DRUG|irinotecan|irinotecan chemotherapy alone
219329821|NCT04749342|OTHER|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
219329822|NCT01200238|DRUG|STA-9090|
219329823|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
219329824|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
219329825|NCT02823249|DIETARY_SUPPLEMENT|50 g Xylitol|
219329826|NCT02823249|DIETARY_SUPPLEMENT|75 g Erythritol|
219329827|NCT02823249|DIETARY_SUPPLEMENT|75 g Glucose|
219329828|NCT02823249|DIETARY_SUPPLEMENT|Tap water|
219329829|NCT02823249|DIETARY_SUPPLEMENT|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
219329830|NCT02823249|DEVICE|Nasogastric Tube|
219329831|NCT02717754|DRUG|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
219329832|NCT02717754|DRUG|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
219329833|NCT03447951|DRUG|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
219329834|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
219329835|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
219329836|NCT03548285|RADIATION|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
219329837|NCT06970704|OTHER|Erector Spinae Plane Block using 0.25 % bupivacaine|After induction of anesthesia and prone positioning and before surgery, Erector Spinae Plane Block was performed bilaterally using a low-frequency curved ultrasound transducer placed in a longitudinal orientation 3 cm lateral to the spinous process one vertebral level above a predetermined marked surgical incision. An 8-cm 22-gauge block needle was inserted in a cephalad to caudad direction until the tip lay in the interfascial plane below the erector spinae muscle, the block was performed by injection of 20 ml of 0.25% bupivacaine. Fentanyl 1 µg/kg as a rescue analgesia was given based on hemodynamic parameters.
219329838|NCT06966596|DRUG|Ketamine only|Group A received ketamineat 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery. W
219329839|NCT06966596|OTHER|Placebo Normal Saline (NS)|Control group received normal saline to maintain double blinding
219329840|NCT06970886|BEHAVIORAL|Rhythm-Based Music Intervention|The rhythm-based music intervention is designed to reduce anxiety and improve emotional well-being in pregnant women with gestational diabetes. This intervention involves structured music sessions, utilizing rhythm as a therapeutic tool to engage participants in either active creation or passive listening. The intervention aims to promote relaxation, reduce stress, and support overall psychological health by leveraging the emotional and cognitive effects of rhythm and music.
219329841|NCT06646354|DRUG|Ezetimibe/Rosuvastatin/Candesartan/Amlodipine|PO, QD, 8 weeks
219329842|NCT06646354|DRUG|Candesartan/Amlodipine|PO, QD, 8 weeks
219329843|NCT06646354|DRUG|Candesartan/Rosuvastatin/Ezetimibe|PO, QD, 8 weeks
219329844|NCT05834348|DRUG|lorlatinib|As provided in real world practice
219329845|NCT05834348|DRUG|crizotinib|As provided in real world practice
219329846|NCT05834348|DRUG|brigatinib|As provided in real world practice
219329847|NCT05834348|DRUG|ceritinib|As provided in real world practice
219329848|NCT05834348|DRUG|alectinib|As provided in real world practice
219329849|NCT05834348|DRUG|atezolizumab|As provided in real world practice
219329850|NCT05834348|DRUG|bevacizumab|As provided in real world practice
219329851|NCT05834348|DRUG|paclitaxel|As provided in real world practice
219329852|NCT05834348|DRUG|carboplatin|As provided in real world practice
219329853|NCT05834348|DRUG|docetaxel|As provided in real world practice
219329854|NCT05834348|DRUG|erlotinib|As provided in real world practice
219329855|NCT05834348|DRUG|gefitinib|As provided in real world practice
219329856|NCT05834348|DRUG|afatinib|As provided in real world practice
219329857|NCT05834348|DRUG|dacomitinib|As provided in real world practice
219329858|NCT05834348|DRUG|osimertinib|As provided in real world practice
219329859|NCT05834348|DRUG|pembrolizumab|As provided in real world practice
219329860|NCT05834348|DRUG|nivolumab|As provided in real world practice
219329861|NCT05834348|DRUG|entrectinib|As provided in real world practice
219329862|NCT05992025|BEHAVIORAL|Physical activity|Intervention with physical activity more than 150 minutes of medium to high intensity per week.
219329863|NCT05992025|BEHAVIORAL|Sleep hygiene|Intervention with sleep hygiene to optimize sleep duration and quality.
219329864|NCT04154917|OTHER|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
219329865|NCT05257941|DRUG|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
219329866|NCT05257941|DRUG|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
219329867|NCT06972888|DRUG|AC-201|AC-201 tablets will be administered orally
219329868|NCT06972888|DRUG|Placebo|Matching placebo tablets will be administered orally.
219329869|NCT03933670|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
219329870|NCT03933670|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
219329871|NCT03933670|PROCEDURE|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
219329872|NCT05770102|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
219329873|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
219329874|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
219329875|NCT03188393|PROCEDURE|Biopsy of Breast|Undergo stereotactic biopsy
219329876|NCT02620267|DEVICE|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
219329877|NCT06241807|DRUG|Camrelizumab Plus Chemotherapy|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
219329878|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
219329879|NCT02420860|DRUG|Lenalidomide|Given PO
219329880|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
219329881|NCT05051150|DRUG|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
219329882|NCT05051150|DRUG|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
219329883|NCT05051150|DRUG|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
219329884|NCT05234554|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
219329885|NCT05234554|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
219329886|NCT00794443|DRUG|YM529 / ONO-5920|Oral
219329887|NCT01320787|DRUG|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
219329888|NCT03608982|OTHER|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
219329889|NCT03608982|OTHER|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
219329890|NCT01979835|DEVICE|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
219329891|NCT04063254|RADIATION|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
219329892|NCT04623372|PROCEDURE|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
219329893|NCT04623372|PROCEDURE|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
219329894|NCT01777412|DRUG|Bevacizumab|
219329895|NCT01710592|DRUG|Epirubicin|
219329896|NCT01710592|DRUG|Oxaliplatin|
219329897|NCT01710592|DRUG|Capecitabine|
219329898|NCT01710592|DRUG|Docetaxel|
219329899|NCT01879787|OTHER|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
219329900|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
219329901|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
219329902|NCT02807649|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|Two tablets consume daily with meal.
219329903|NCT00021151|BIOLOGICAL|alemtuzumab|
219329904|NCT00376584|DRUG|MK-0524A|
219329905|NCT00376584|DRUG|ER Niacin|
219329906|NCT00376584|DRUG|Placebo|
219329907|NCT00567684|DEVICE|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
219329908|NCT00567684|OTHER|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
219329909|NCT00878852|BEHAVIORAL|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
219329910|NCT00878852|BEHAVIORAL|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
219329911|NCT04633174|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
219329912|NCT02903069|DRUG|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
219329913|NCT02903069|DRUG|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
219329914|NCT02903069|RADIATION|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
219329915|NCT02903069|DEVICE|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
219329916|NCT05031988|OTHER|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
219329917|NCT00890253|DRUG|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
219329918|NCT00890253|DRUG|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
219329919|NCT00890253|DRUG|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
219329920|NCT00890253|DRUG|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
219329921|NCT02747953|DRUG|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
219329922|NCT02592018|DRUG|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
219329923|NCT02638350|DEVICE|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
219329924|NCT02422407|PROCEDURE|Biopsy|Salivary Gland
219329925|NCT04230707|OTHER|Endogenous Melatonin Levels|High Endogenous Melatonin Levels is Group 1 Low Endogenous Melatonin Levels is group 2
219329926|NCT00314353|DRUG|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
219329927|NCT00314353|DRUG|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
219329928|NCT00314353|DRUG|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
219329929|NCT00314353|DRUG|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
219329930|NCT06363669|DIETARY_SUPPLEMENT|multi-ingredient pre-workout dietary supplement (caffeine-based)|The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
219329931|NCT02964299|DEVICE|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
219329932|NCT03599895|PROCEDURE|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
219329933|NCT03599895|PROCEDURE|non 3D printing model|da Vinci robot assisted radical gastrectomy
219329934|NCT04416061|DIAGNOSTIC_TEST|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
219329935|NCT01255969|OTHER|Exercise|Personalized exercise program
219329936|NCT03800290|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
219329937|NCT03800290|DRUG|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
219329938|NCT02558478|GENETIC|blood sampling|
219329939|NCT02710136|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
219329940|NCT00418665|BIOLOGICAL|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
219329941|NCT00418665|DRUG|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
219329942|NCT02483377|OTHER|Quality-of-Life Assessment|Ancillary studies
219329943|NCT02483377|OTHER|Questionnaire Administration|Complete questionnaires
219329944|NCT00891319|DEVICE|Electrical stimulator|"• 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
219329945|NCT03662217|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
219329946|NCT03662217|OTHER|ADA- based diet|The American standard of care dietary guidelines for diabetes.
219329947|NCT01177436|BIOLOGICAL|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
219329948|NCT03926845|OTHER|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
219329949|NCT03926845|OTHER|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
219329950|NCT01129921|DEVICE|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
219329951|NCT01129921|DEVICE|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
219329952|NCT05785390|DRUG|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
219329953|NCT05785390|OTHER|Placebo|Identical placebo
219329954|NCT02672098|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
219329955|NCT02672098|DRUG|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
219329956|NCT04194281|OTHER|Action Observation Training [AOT]|Parents are instructed to show their child repetitive arm, hand and finger movements in a playful and age-appropriate way for about 20 minutes a day, divided into several short sequences. AOT is to be carried out for four weeks at home by the parents and, if necessary, other caregivers. The parents receive instructions which contain background information on the possible importance of AOT for improving the functions of the upper limb, information about positions, promoting motivation, attention and interest as well as tips for promoting movement observation in everyday life.
219329957|NCT06980519|BIOLOGICAL|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.
219329958|NCT01794364|DRUG|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
219329959|NCT01794364|OTHER|placebo|Correspondingly, placebo doses will be administered as suspension.
219329960|NCT06986252|OTHER|Consultation|Consultations at a specialist surgical nurse-led clinic
219329961|NCT06986018|DRUG|RD06-04 Cell Injection Infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
219329962|NCT06984198|BEHAVIORAL|Sandplay Therapy|Sandplay Therapy - The objects involved in this form of therapy are: sandtray, sand, multiple figurines in all categories (people, animals, buildings, vehicles, vegetation, structures, natural objects and symbolic objects). The subject engaging in this therapy is instructed to build a sand picture with the minatures present. There is no time limit to these sessions; however, they tend to be 20-30 minutes long. Upon completion of their sand picture the child, if comfortable, may elaborate on their creation.
219329963|NCT06984198|BEHAVIORAL|Art Therapy|"Art Therapy - The instruments used in this form of therapy are: a blank 8 x 11 paper and coloring utensils (markers, crayons, and color pencils). During each 30-minute session, the subject is informed to draw whatever they feel with the coloring utensils provided. Possible drawing topics may include: their family, a memory of their life back in their country of origin, or something from their imagination."
219329964|NCT06986044|DIAGNOSTIC_TEST|Serum Total Oxidant Status|Serum total oxidant status
219329965|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Oxidant Status|Salivary Total Oxidant Status
219329966|NCT06986044|DIAGNOSTIC_TEST|Serum Total Antioxidant Status|Serum Total Antioxidant Status
219329967|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Antioxidant Status|Salivary Total Antioxidant Status
219329968|NCT06986044|DIAGNOSTIC_TEST|Serum Oxidative Stress Index|Serum Oxidative Stress Index
219329969|NCT06986044|DIAGNOSTIC_TEST|Salivary Oxidative Stress Index|Salivary Oxidative Stress Index
219329970|NCT06986044|DIAGNOSTIC_TEST|Serum Arylesterase|Serum Arylesterase
219329971|NCT06986044|DIAGNOSTIC_TEST|Salivary Arylesterase|Salivary Arylesterase
219329972|NCT06986044|DIAGNOSTIC_TEST|Serum Heme Oxygenase|Serum Heme Oxygenase
219329973|NCT06986044|DIAGNOSTIC_TEST|Salivary Heme Oxygenase|Salivary Heme Oxygenase
219329974|NCT06986044|DIAGNOSTIC_TEST|Serum Nuclear Factor Erythroid 2 Related Factor 2|Serum Nuclear Factor Erythroid 2 Related Factor 2
219329975|NCT06986044|DIAGNOSTIC_TEST|Salivary Nuclear Factor Erythroid 2 Related Factor 2|Salivary Nuclear Factor Erythroid 2 Related Factor 2
219329976|NCT06986044|DIAGNOSTIC_TEST|Gingival Index|Gingival Index
219329977|NCT06986044|DIAGNOSTIC_TEST|Plaque Index|Plaque Index
219329978|NCT06986044|DIAGNOSTIC_TEST|Bleeding on Probing Index|Bleeding on Probing Index
219329979|NCT06986044|DIAGNOSTIC_TEST|Clinical Attachment Loss|Clinical Attachment Loss
219329980|NCT06986044|DIAGNOSTIC_TEST|Pocket Deep|Pocket Deep
219329981|NCT06984016|OTHER|Work-related Musculoskeletal Disorders Risk Among Physical Therapists|217 Males and females Egyptian physical therapists at will be included in the study.
219329982|NCT06984458|BEHAVIORAL|Robot Dementia Prevention Course|"It is expected that through the eight-week course design activities, the cognitive functions, social activities, emotional management (such as alleviating depression), well-being, reduce loneliness and can be achieved, thereby preventing or delaying cognitive decline.~The experimental group conducted a two-month Robot Dementia Prevention Course intervention. The research subjects were 40 people. Each group of 5 people was assigned a Kebbi robot. The course intervention was divided into 8 groups. The Kebbi robot mainly taught and communicated with the elderly interactively. There is a well-trained teaching assistant in the class to enhance the learning effect of the elderly. The two classes per week are about 2 hours long, with 50 minutes of course knowledge introduction, 10 minutes of rest, 50 minutes of interaction with Kebbi Artificial Intelligence-based board games, and 10 minutes of prize-based quizzes after class."
219329983|NCT01467453|DEVICE|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
219329984|NCT06985537|DRUG|Ultrasound guided intralesional Steroids injection (Triamicinolone)|Radiological guided steroid injection of IGM
219329985|NCT06984588|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,
219329986|NCT06984588|DRUG|Toripalimab|240 mg on Day 1, once every 3 weeks (Q3W)
219329987|NCT06984588|DRUG|Pembrolizumab|200 mg on Day 1, once every 3 weeks (Q3W)
219329988|NCT06985160|OTHER|Specific single nucleotide polymorphisms|Next-generation sequencing was performed to analyze the TLR4, LTA, and RFP175 genes, with a focus on specific single nucleotide polymorphisms
219329989|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
219329990|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
219329991|NCT00640484|DRUG|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
219329992|NCT00640484|DRUG|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
219329993|NCT06599476|DEVICE|BioProtect Balloon Implant™ System|The BioProtect Balloon Implant System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, and by creating this space, to reduce the radiation dose delivered to the anterior rectum. The balloon is inserted into the perirectal space and inflated to its pre-defined size. The Balloon is made of biodegradable materials that maintain the space for the entire course of prostate radiation treatment and are absorbed by the patient's body over time
219329994|NCT05694819|DRUG|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
219329995|NCT05694819|DRUG|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
219329996|NCT06099210|DIAGNOSTIC_TEST|Glasgow coma scale|Closed tach brain injury due to external force was included according to the GCS score
219329997|NCT03779919|DEVICE|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
219329998|NCT06902220|DEVICE|continuous high-frequency oscillation therapy|Once patients' CPOT score reaches 0, intubated patients will receive continuous high-frequency oscillation (CHFO) therapy three times daily, with 8-hour intervals and 10-minute sessions. Extubated patients will receive CHFO and continuous positive expiratory pressure (CPEP) therapy twice daily, with 12-hour intervals and 10-minute sessions.
219329999|NCT06903273|DRUG|Tislelizumab|"Tislelizumab plus chemotherapy (14 days as one cycle) 3 cycles every 2 weeks as neoadjuvant therapy and followed by a curative surgery.~Tislelizumab 200 mg fixed-dose IVD on day 1. Gemcitabine 800 mg/m2 on day 1 with a fixed-infusion rate of 80 mins. Cisplatin 25 mg/m2 on day 1. S-1 70 mg/m2 daily as a BID dosing per oral on day 1 to 7. (daily total dose determined by body surface area (BSA): \<1.25 m2, 80 mg; 1.25-1.50 m2, 100 mg; ≥1.50 m2, 120 mg)"
219330000|NCT06902597|PROCEDURE|Dual energy X-ray absorptiometry|Very low radiation dose technique to show fat mass (FM) and lean mass (LM)
219330001|NCT06729905|DIETARY_SUPPLEMENT|Yerba mate tea|Consumption of three cups per day of a beverage prepared with yerba mate
219330002|NCT06729905|DIETARY_SUPPLEMENT|Control drink|Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
219330003|NCT06903260|COMBINATION_PRODUCT|Mixed Reality|Virtual reality (VR) is defined as an artificial 3D visual environment and augmented reality (AR), as virtual objects superimposed on the real world; mixed reality is the association between VR and AR. The images were exported from CT image in DICOM (Digital Imaging and Communications in Medicine) and applied in Brainlab Elements software (Brainlab AG, Munich, Germany), where the images and 3D drawing were rendered in partnership with the collaborating bioengineer of this work to obtain the VR. AG was obtained during the intraoperative through the Magic Leap 1 goggle (Magic Leap Inc., Plantation, FL, USA)
219330004|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
219330005|NCT06749899|DRUG|QL1706|QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
219330006|NCT06749899|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
219330007|NCT06749899|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
219330008|NCT06749899|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
219330009|NCT06901674|PROCEDURE|Modified surgical approach|An electrode typically placed under the temporalis muscle will be placed into the cochlear helicotrema instead.
219330010|NCT06901674|DEVICE|Cochlear Nucleus CI632 cochlear implant|Cochlear implant (CI) system where stimulation from one of the intracochear electrodes is grounded via one of two (or both) extra cochlear electrodes in the device.
219330011|NCT06901765|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care, inpatient rehabilitation, outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management\[5\], soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive
219330012|NCT06901765|BEHAVIORAL|Exercise|Range of Motion Exercise, Stretching Exercises
219330013|NCT02522507|BEHAVIORAL|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
219330014|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
219330015|NCT06290193|BIOLOGICAL|Acute Normovolemic Hemodilution/ANH|For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
219330016|NCT06934720|BEHAVIORAL|aPAVRCT|"* We offered a system integrated with an indoor bike (for physical activity) and a multisensory VR environment (for cognitive training, such as reminiscence).~* Participants will actively navigate the virtual environment by pedaling and steering the handlebar.~* Care professionals will deliver the intervention using this system."
219330017|NCT00137228|PROCEDURE|figure-of-eight hand measurements|
219330018|NCT00137228|PROCEDURE|water volumetry hand measurements|
219330019|NCT04968977|PROCEDURE|PCI vs. CABG|PCI vs. CABG
219330020|NCT04492462|OTHER|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
219330021|NCT04492462|OTHER|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
219330022|NCT01925924|OTHER|Resin-modified glass ionomer cement|This material contains fluoride
219330023|NCT01925924|OTHER|Composite resin|This material does not include fluoride
219330024|NCT04133818|BEHAVIORAL|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation"
219330025|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
219330026|NCT03706417|DIAGNOSTIC_TEST|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
219330027|NCT04590950|OTHER|Non interventional study|Non interventional study
219330028|NCT03200327|PROCEDURE|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
219330029|NCT03200327|PROCEDURE|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
219330030|NCT05938998|BEHAVIORAL|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
219330031|NCT06159621|DRUG|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg. Commercially available PD-1 inhibitor may be substituted.
219330032|NCT06159621|DRUG|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
219330033|NCT05263739|DRUG|ESG206|Administered via intravenous (IV) infusion
219330034|NCT05450367|OTHER|Data collection|Data collection
219330035|NCT06833983|DRUG|GS1191-0445 injection|A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg
219330036|NCT04969770|OTHER|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
219330037|NCT04230278|BEHAVIORAL|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
219330038|NCT04230278|BEHAVIORAL|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
219330039|NCT05050318|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
219330040|NCT05050318|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
219330041|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
219330042|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
219330043|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
219330044|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
219330045|NCT01198860|DRUG|CTH Chronic Hepatitis B|"Drug:~* Tenofovir/ 300mg daily~* Phyllanthus Urinaria/300mg daily~* Adenosma Glutinosum/150mg daily~* Eclipta Prostrata/150mg daily~* Ascorbic Acid / 500mg daily"
219330046|NCT06293430|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.
219330047|NCT05045066|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
219330048|NCT05045066|OTHER|Quality-of-Life Assessment|Ancillary studies
219330049|NCT05045066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219330050|NCT04750798|DEVICE|BWI Medical Device|Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
219330051|NCT04750798|DEVICE|Varipulse Catheter|Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
219330052|NCT06131840|DRUG|PF-08046050|Given into the vein (IV; intravenous)
219330053|NCT06131840|DRUG|bevacizumab|Given into the vein (IV; intravenous)
219330054|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
219330055|NCT04586426|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
219330056|NCT04586426|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
219330057|NCT04586426|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
219330058|NCT05546450|BEHAVIORAL|Diet|"Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician."
219330059|NCT05546450|DIETARY_SUPPLEMENT|Cornus mas L.(Cornelian Cherry)|"Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement."
219330060|NCT01907542|PROCEDURE|stapled skin closure|as above
219330061|NCT01907542|PROCEDURE|monocryl skin suture|as above
219330062|NCT00574145|PROCEDURE|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
219330063|NCT00574145|PROCEDURE|fatigue assessment and management|duration
219330064|NCT00574145|PROCEDURE|psychosocial assessment and care|duration
219330065|NCT00574145|PROCEDURE|quality-of-life assessment|duration
219330066|NCT00574145|PROCEDURE|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
219330067|NCT01944293|DRUG|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
219330068|NCT01944293|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
219330069|NCT06083441|DIAGNOSTIC_TEST|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
219330070|NCT06083441|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score \>2, or an arousal score \> 0 means that a subject is responding to commands
219330071|NCT00121836|DRUG|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
219330072|NCT00121836|DRUG|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
219330073|NCT03227471|DRUG|IVA|IVA tablet for oral administration
219330074|NCT03227471|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
219330075|NCT03227471|DRUG|VX-445|VX-445 tablet for oral administration.
219330076|NCT03227471|DRUG|Matched Placebo|Matched placebo.
219330077|NCT03227471|DRUG|TEZ|Tablet for oral administration.
219330078|NCT03227471|DRUG|VX-561|Tablet for oral administration.
219330079|NCT03227471|DRUG|VX-445|VX-445 IV injection
219330080|NCT00345189|DRUG|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
219330081|NCT04494230|BEHAVIORAL|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
219330082|NCT02536768|BEHAVIORAL|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
219330083|NCT05571748|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
219330084|NCT05571748|OTHER|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
219330085|NCT01855763|DRUG|Metformin|
219330086|NCT01855763|DRUG|Insulin|
219330087|NCT00382720|DRUG|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
219330088|NCT00382720|DRUG|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
219330089|NCT00382720|DRUG|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
219330090|NCT01740960|DRUG|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
219330091|NCT01740960|DRUG|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
219330092|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
219330093|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
219330094|NCT02171845|OTHER|surgical biopsies|
219330095|NCT00993642|DRUG|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
219330096|NCT05570942|DIETARY_SUPPLEMENT|Oral Lactobacillus rhamnosus TCELL-1|A kind of probiotics which was isolated from the intestinal mucosa of health Taiwanese people
219330097|NCT04175106|OTHER|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
219330098|NCT04175106|OTHER|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
219330099|NCT04175106|OTHER|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
219330100|NCT04175106|OTHER|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
219330101|NCT04788251|OTHER|Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)|"The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31)."
219330102|NCT04788251|OTHER|Wait-list control|To receive fall prevention resources while waiting for their programme to start
219330103|NCT04193020|OTHER|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
219330104|NCT01454375|BEHAVIORAL|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
219330105|NCT05026281|DEVICE|Quantra analyzer|one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
219330106|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
219330107|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
219330108|NCT03999723|DIETARY_SUPPLEMENT|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
219330109|NCT03999723|DIETARY_SUPPLEMENT|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
219330110|NCT05140655|DRUG|Fulvestrant|Medicine for Advanced breast cancer
219330111|NCT01440842|OTHER|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
219330112|NCT01440842|OTHER|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
219330113|NCT02389023|OTHER|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
219330114|NCT02389023|OTHER|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
219330115|NCT00161187|BIOLOGICAL|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
219330116|NCT00737256|DRUG|Aripiprazole|15-30 mg
219330117|NCT00737256|DRUG|Perphenazine|8-16 mg
219330118|NCT01931748|DRUG|MELSMON|
219330119|NCT01931748|DRUG|UNCNT|
219330120|NCT05066321|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
219330121|NCT04935892|BEHAVIORAL|Slippers|Patients in the intervention group wear slippers when out of bed
219330122|NCT05548348|DRUG|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
219330123|NCT03529721|OTHER|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
219330124|NCT03529721|OTHER|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
219330125|NCT02071212|DRUG|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
219330126|NCT00844155|DRUG|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
219330127|NCT03621865|DIETARY_SUPPLEMENT|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
219330128|NCT03621865|DIETARY_SUPPLEMENT|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
219330129|NCT03621865|DIETARY_SUPPLEMENT|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
219330130|NCT03621865|DIETARY_SUPPLEMENT|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
219330131|NCT03621865|DIETARY_SUPPLEMENT|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
219330132|NCT04680728|OTHER|collection of biological parameters|haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
219330133|NCT04680728|OTHER|collection of echographic parameters|echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
219330134|NCT04680728|OTHER|collection of clinical parameters|eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
219330135|NCT00654914|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
219330136|NCT02709694|OTHER|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
219330137|NCT06289244|DIAGNOSTIC_TEST|Ultrasound|"The thickness of the diaphragm and quadriceps will be assessed using bedside ultrasound, utilizing a 13-6 MHz cm linear probe. The measurement of the right hemidiaphragm's end-expiratory thickness will be conducted via diaphragm ultrasound. For accurate positioning, the ultrasound probe will be placed along the right anterior axillary line, specifically between the ninth and tenth intercostal spaces, in a sagittal oblique orientation. To enhance measurement consistency, the probe's position on the skin will be marked.~To ascertain accuracy, the operator will conduct each measurement three times, and the mean of these three values will be used for analysis. Similarly, for diaphragmatic assessment and peripheral assessments (Qthick and CSA) of the lower limbs, the examination areas will be demarcated on the skin with a dermatographic pen, ensuring measurement reproducibility over different timepoints."
219330138|NCT06289244|DIAGNOSTIC_TEST|Muscle strength measurement|"The assessment of limb muscle strength in this study will be conducted using the Medical Research Council (MRC) Score. For a more precise evaluation of quadriceps strength, a dynamometer will be employed.~Furthermore, the study will incorporate an invasive method for gauging inspiratory muscle strength, utilizing the negative inspiratory force (NIF) metric. Post-extubation, the maximum inspiratory pressure (MIP) will be determined using an electronic manometer. Three separate MIP measurements will be executed, and the highest reading among these will be recorded as the definitive measurement."
219330139|NCT05347186|OTHER|Systematic corrective exercises and non-biomechanical functional exercises|"1. Restraint exercise or self-release: will involve the gastrocnemius muscle, soleus muscle, fibula, knee compressor muscles, adductors of the thighs, the short head of the biceps femoris, and iliotibial band for 30 seconds, using a foam roller.~2. Static stretching drills: involving the soleus and gastrocnemius muscles on an inclined plane, tensor fasciae latae muscle, short head of the biceps femoris, and ilio- psoas muscle;~3. Resistance exercises: will consist of strengthening the eccentric muscles of the feet including dorsiflexion and knee inversion, adduction, and extension, external rotation of the hip joint with TheraBand exercise band, and strengthening the intrinsic muscles of the foot.~4. Integrative exercises: including the star balance test on all planes and resistive exercises."
219330140|NCT05347186|OTHER|Non biomechanical functional exercises|Conventional treatment involved Non biomechanical Functional exercises (NBF), these exercises indicated for the control group consists of dorsal and plantar flexion of the metatarsophalangeal joints in unloading of the subject in a long sitting position on a chair or couch with the knee at 90◦ for a period of eight weeks. Feet will be in hanging position to allow plantar flexion smoothly. The exercises will carry out daily without any kind of resistance for a period of 30s. A total of five series will be completed for each foot. These exercises will be considered as non-therapeutic which might have affected the foot's posture.
219330141|NCT04857801|DRUG|Teduglutide|effect of teduglutide on intestinal rehabilitation
219330142|NCT02999542|OTHER|Music|Children will be randomised to receive either music via headphones or silence via headphones
219330143|NCT02999542|OTHER|No music|Children will be randomised to receive either music via headphones or silence via headphones
219330144|NCT02925702|DRUG|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
219330145|NCT04308070|DEVICE|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
219330146|NCT04308070|DEVICE|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
219330147|NCT06069336|DRUG|Hypertonic saline|Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
219330148|NCT06069336|DRUG|Normal saline|0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
219330149|NCT02834169|OTHER|Non interventional|Data collection
219330150|NCT02302508|DRUG|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
219330151|NCT03242265|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
219330152|NCT00130702|DRUG|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
219330153|NCT02713542|DEVICE|ACP|Autologous Conditioned Plasma
219330154|NCT02713542|OTHER|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
219330155|NCT06489639|BEHAVIORAL|DOCT-SAD|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder is a 10-session, combined individual/group clinical intervention for treating social anxiety in adolescents. It consists of four individual and six group sessions during ten weeks. DOCT-SAD groups are formed for 4-6 adolescnts. One parent or both parents attend two of the individual sessions.
219330156|NCT06489639|BEHAVIORAL|SC|Standard Counseling (SC) is a intervention consisting of counseling sessions delivered by a school health and welfare (SHWS) professional (i.e., school nurse, school social worker, or school psychologist) to support a student with social anxiety. The defined length of intervention is ten weeks, and number of sessions will be according to what is routinely agreed between the professional and the adolescent. In SC, routine professional working methods and procedures available to the SHWS professional delivering the intervention are used.
219330157|NCT00066742|DRUG|tirapazamine|Given IV
219330158|NCT00066742|DRUG|cisplatin|Given IV
219330159|NCT00066742|DRUG|etoposide|Given IV
219330160|NCT00066742|RADIATION|radiation therapy|Undergo radiation therapy
219330161|NCT00066742|OTHER|laboratory biomarker analysis|Correlative studies
219330162|NCT01490853|DRUG|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
219330163|NCT02558920|OTHER|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
219330164|NCT04860986|DEVICE|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
219330165|NCT03203499|DRUG|ANS-6637 Oral Tablet|Ascending single doses administered orally.
219330166|NCT03203499|DRUG|Placebo Oral Tablet|Placebo administered orally.
219330167|NCT00791336|DRUG|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
219330168|NCT00127868|DRUG|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
219330169|NCT01488279|DRUG|Dexamethasone 2.5 mg and Sitagliptin 100 mg|Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
219330170|NCT01488279|DRUG|Dexamethasone 2.5 mg and placebo tablet|Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
219330171|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
219330172|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
219330173|NCT00929877|DRUG|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
219330174|NCT01172197|DRUG|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
219330175|NCT01172197|DRUG|Ropivacaine|Bolus and infusion
219330176|NCT01518881|DRUG|TKM-100201|IV Infusion
219330177|NCT01518881|DRUG|Placebo|IV infusion
219330178|NCT04103905|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
219330179|NCT06330961|OTHER|Isometric exercise|Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.
219330180|NCT06330961|OTHER|Aerobic exercise|After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.
219330181|NCT06330961|OTHER|Placebo intervention|A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
219330182|NCT02429297|OTHER|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
219330183|NCT02429297|OTHER|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
219330184|NCT00314626|DRUG|efavirenz|Efavirenz
219330185|NCT00314626|DRUG|Abacavir+lamivudine|Abacavir+lamivudine
219330186|NCT00051675|DRUG|ING-1(heMAb)|
219330187|NCT04972981|DRUG|ADCT-901|Intravenous infusion
219330188|NCT00163267|DRUG|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
219330189|NCT02877862|BEHAVIORAL|mAGIC app|7-day app to encourage uptake of genetic counseling
219330190|NCT00233688|DEVICE|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
219330191|NCT00233688|PROCEDURE|Open surgical repair|Open surgical repair
219330192|NCT01994382|DRUG|Cerdulatinib|Oral capsule
219330193|NCT01994382|BIOLOGICAL|Rituximab|IV infusion
219330194|NCT05947994|PROCEDURE|Intracranial stenting with Credo® stent|Symptomatic ischemic stroke patients were treated with Credo® Stent
219330195|NCT05415475|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
219330196|NCT02793440|OTHER|cortivazol treatment|
219330197|NCT02793440|OTHER|lumbar traction|
219330198|NCT05599542|OTHER|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
219330199|NCT05599542|OTHER|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
219330200|NCT06189846|DEVICE|International Cohort|"Assessing tumour response following neoadjuvant treatment in rectal cancer include :~* Digital rectal examination~* Rectal MRI~* Rectoscopy ( Lumeneye device)~The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment."
219330201|NCT03000088|DEVICE|intubate with 60° angled stylet|
219330202|NCT03000088|DEVICE|intubate with 60° angled stylet|
219330203|NCT04615468|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
219330204|NCT00873366|DRUG|dextromethorphan hydrobromide|
219330205|NCT00873366|DRUG|tamoxifen citrate|
219330206|NCT00873366|OTHER|high performance liquid chromatography|
219330207|NCT00873366|OTHER|laboratory biomarker analysis|
219330208|NCT00873366|OTHER|pharmacogenomic studies|
219330209|NCT00873366|OTHER|pharmacological study|
219330210|NCT00873366|PROCEDURE|fluorescence imaging|
219330211|NCT00473577|DRUG|CRA-24781|
219330212|NCT00648804|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
219330213|NCT00648804|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fed
219330214|NCT00343876|DRUG|aspirin|
219330215|NCT00343876|DRUG|clopidogrel|
219330216|NCT00328744|BEHAVIORAL|Standard|18-month standard behavioral weight loss intervention
219330217|NCT00328744|BEHAVIORAL|Limited Variety|Two chosen snack foods
219330218|NCT01820936|DRUG|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
219330219|NCT01820936|DRUG|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
219330220|NCT01820936|DRUG|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
219330221|NCT01820936|DRUG|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
219330222|NCT01820936|DRUG|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
219330223|NCT02237963|PROCEDURE|Posterolateral thoracotomy|
219330224|NCT02237963|PROCEDURE|Axillary thoracotomy|
219330225|NCT03076931|PROCEDURE|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
219330226|NCT03076931|PROCEDURE|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
219330227|NCT03076931|PROCEDURE|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
219330228|NCT03512691|BEHAVIORAL|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
219330229|NCT03512691|BEHAVIORAL|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
219330230|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
219330231|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
219330232|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
219330233|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
219330234|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
219330235|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
219330236|NCT02274181|DRUG|Androxal|
219330237|NCT01086020|DRUG|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
219330238|NCT01086020|DRUG|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
219330239|NCT00050141|DRUG|ZARNESTRA, tipifarnib, R115777|
219330240|NCT02489643|PROCEDURE|Individualized practical training|
219330241|NCT01792349|BEHAVIORAL|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
219330242|NCT05175573|DEVICE|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
219330243|NCT05175573|DEVICE|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
219330244|NCT00006469|DRUG|carboplatin|
219330245|NCT00006469|DRUG|paclitaxel|
219330246|NCT00006469|PROCEDURE|conventional surgery|
219330247|NCT00006469|PROCEDURE|neoadjuvant therapy|
219330248|NCT00006469|RADIATION|radiation therapy|
219330249|NCT00656240|DRUG|DE-104 ophthalmic solution|
219330250|NCT00656240|DRUG|DE-104 vehicle|
219330251|NCT04420611|OTHER|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
219330252|NCT04420611|OTHER|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
219330253|NCT04420611|OTHER|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
219330254|NCT04420611|OTHER|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
219330255|NCT04234672|DRUG|TAK-831 Oral Tablet|TAK-831 tablet.
219330256|NCT04234672|DRUG|[14C]TAK-831 IV Infusion|\[14C\]TAK-831 IV infusion.
219330257|NCT04234672|DRUG|[14C]TAK-831 Oral Suspension|\[14C\]TAK-831 oral suspension.
219330258|NCT00779792|DRUG|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
219330259|NCT00779792|DRUG|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
219330260|NCT00779792|DRUG|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
219330261|NCT00779792|DRUG|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
219330262|NCT00779792|DRUG|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
219330263|NCT02153554|BEHAVIORAL|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
219330264|NCT04366050|DRUG|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
219330265|NCT04366050|DRUG|Placebo oral capsule|Placebo
219330266|NCT04792567|DRUG|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
219330267|NCT04792567|DRUG|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
219330268|NCT04792567|BIOLOGICAL|BNT162|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
219330269|NCT04792567|BIOLOGICAL|mRNA-1273|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
219330270|NCT03533972|DRUG|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
219330271|NCT03533972|OTHER|Placebo|placebo capsules given twice daily after meals for 1 month
219330272|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
219330273|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
219330274|NCT01516840|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
219330275|NCT01516840|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
219330276|NCT00239811|DRUG|FTY720|
219330277|NCT00005798|DRUG|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
219330278|NCT00005798|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
219330279|NCT00005798|DRUG|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
219330280|NCT03163251|BEHAVIORAL|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
219330281|NCT04049955|PROCEDURE|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
219330282|NCT01231659|DRUG|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
219330283|NCT01231659|DRUG|Letrozole|Letrozole 2.5 mg once daily
219330284|NCT03526770|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
219330285|NCT03526770|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
219330286|NCT03526770|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
219330287|NCT03526770|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
219330288|NCT03526770|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
219330289|NCT03526770|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
219330290|NCT01010698|DRUG|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
219330291|NCT04216745|DIAGNOSTIC_TEST|bile culture|Bile samples will be collected for microbial cultures and antimicrobial susceptibility testing using COMPACT-15 automated system (Bio Merieux, Marcy I'Etoile, France) for bacteria and saboroud's agar for fungal culture.
219330292|NCT04091490|DRUG|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
219330293|NCT02504359|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219330294|NCT02504359|DRUG|Carmustine|Given BEAM chemotherapy
219330295|NCT02504359|DRUG|Cytarabine|Given BEAM chemotherapy
219330296|NCT02504359|DRUG|Etoposide|Given BEAM chemotherapy
219330297|NCT02504359|DRUG|Ixazomib Citrate|Given PO
219330298|NCT02504359|DRUG|Melphalan|Given BEAM chemotherapy
219330299|NCT02504359|DRUG|Methotrexate|Given IV
219330300|NCT02504359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
219330301|NCT02504359|OTHER|Quality-of-Life Assessment|Ancillary studies
219330302|NCT02504359|DRUG|Tacrolimus|Given IV or PO
219330303|NCT03295877|DRUG|RO7171009|Patients will receive RO7171009 via ITV injection.
219330304|NCT02651051|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
219330305|NCT02651051|OTHER|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
219330306|NCT00530283|OTHER|PET-CT|
219330307|NCT03926754|DRUG|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
219330308|NCT04494139|BEHAVIORAL|Behavioral and Canteen intervention|Behavioral intervention: 16 weeks
219330309|NCT04494139|OTHER|Canteen|Canteen changes to introduce health foods
219330310|NCT06227273|DIETARY_SUPPLEMENT|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
219330311|NCT00990054|DRUG|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
219330312|NCT02700568|DRUG|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
219330313|NCT06072989|BIOLOGICAL|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
219330314|NCT00356889|DRUG|erlotinib hydrochloride|Given orally, 150 mg, once daily.
219330315|NCT00356889|BIOLOGICAL|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
219330316|NCT06006663|DRUG|Ibuprofen 400 mg.|synthetic intracanal medicament
219330317|NCT06006663|DRUG|modified triple antibiotic paste|synthetic intracanal medicament
219330318|NCT06006663|DIETARY_SUPPLEMENT|curcumin|herbal intracanal medicament
219330319|NCT06006663|DIETARY_SUPPLEMENT|olive leaves extract|herbal intracanal medicament
219330320|NCT02247960|DRUG|Ciprofloxacin|
219330321|NCT02131909|PROCEDURE|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
219330322|NCT02131909|PROCEDURE|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
219330323|NCT00702325|DRUG|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
219330324|NCT00702325|DRUG|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
219330325|NCT04756037|DRUG|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
219330326|NCT01990092|OTHER|Metanx|Metanx is a prescription medical food.
219330327|NCT01990092|OTHER|Placebo|
219330328|NCT05141162|BEHAVIORAL|case and control group|randomized controlled experimental study
219330329|NCT03910426|OTHER|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
219330330|NCT03910426|OTHER|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
219330331|NCT03910426|OTHER|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
219330332|NCT03910426|OTHER|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
219330333|NCT03910426|OTHER|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
219330334|NCT05744765|OTHER|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
219330335|NCT06023316|DEVICE|mGain system|passive, noninvasive surface electromyography measurement device and gaming mobile application
219330336|NCT03038750|OTHER|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
219330337|NCT03038750|OTHER|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
219330338|NCT03038750|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
219330339|NCT03038750|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
219330340|NCT03038750|OTHER|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
219330341|NCT03038750|OTHER|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
219330342|NCT03038750|OTHER|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
219330343|NCT03038750|OTHER|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
219330344|NCT03038750|OTHER|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
219330345|NCT03038750|OTHER|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
219330346|NCT03038750|OTHER|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
219330347|NCT03038750|OTHER|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
219330348|NCT03038750|OTHER|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
219330349|NCT03038750|OTHER|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
219330350|NCT03038750|OTHER|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
219330351|NCT03038750|OTHER|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
219330352|NCT03038750|OTHER|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
219330353|NCT03038750|OTHER|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
219330354|NCT03038750|OTHER|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
219330355|NCT03038750|OTHER|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
219330356|NCT02417155|BEHAVIORAL|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
219330357|NCT02417155|BEHAVIORAL|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
219330358|NCT00395889|PROCEDURE|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
219330359|NCT00395889|PROCEDURE|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
219330360|NCT01624987|BEHAVIORAL|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
219330361|NCT01624987|OTHER|Control group|The control group receives no intervention.
219330362|NCT00936403|DRUG|NNC126-0083|One single dose administered in four dose levels in an escalating order
219330363|NCT00936403|DRUG|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
219330364|NCT05924737|OTHER|Sleep deprivatin|40 hours of continuous awakening
219330365|NCT05924737|OTHER|Sleep recovery|sleep recovery after 40 hours of continuous awakening
219330366|NCT01456689|DRUG|LGH447|
219330367|NCT01456689|DRUG|midazolam|
219330368|NCT03368950|OTHER|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
219330369|NCT02049268|DRUG|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
219330370|NCT02049268|DRUG|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
219330371|NCT02049268|DRUG|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
219330372|NCT01118416|BEHAVIORAL|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
219330373|NCT00143195|DRUG|Amlodipine|
219330374|NCT00143195|DRUG|iso- 5 - mononitrate|
219330375|NCT00143195|PROCEDURE|Blood tests|
219330376|NCT00143195|PROCEDURE|Exercise Stress Test|
219330377|NCT00736034|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
219330378|NCT05889455|DRUG|Sildenafil|Oral administration of 100mg
219330379|NCT05889455|OTHER|Placebo|Placebo
219330380|NCT01591317|DRUG|Prasugrel|Tablets orally
219330381|NCT06493539|PROCEDURE|Standard of Care group|The control group will receive standard of care wound treatment
219330382|NCT06493539|DEVICE|CINPWT|Subject will receive CINPWT until discharged
219330383|NCT01022502|DRUG|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
219330384|NCT01022502|DRUG|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
219330385|NCT05479279|OTHER|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
219330386|NCT05479279|OTHER|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
219330387|NCT01073241|PROCEDURE|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
219330388|NCT01073241|PROCEDURE|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
219330389|NCT00003172|BIOLOGICAL|filgrastim|
219330390|NCT00003172|BIOLOGICAL|recombinant interferon alfa|
219330391|NCT00003172|DRUG|docetaxel|
219330392|NCT00003172|DRUG|doxorubicin hydrochloride|
219330393|NCT00003172|DRUG|fluorouracil|
219330394|NCT00003172|DRUG|hydroxyurea|
219330395|NCT03716050|DRUG|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
219330396|NCT03716050|DEVICE|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
219330397|NCT03716050|OTHER|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
219330398|NCT03716050|OTHER|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
219330399|NCT03229421|OTHER|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
219330400|NCT01587339|DRUG|retigabine/ezogabine|oral - all doses
219330401|NCT01587339|DRUG|lacosamide|oral - all doses
219330402|NCT01587339|DRUG|zonisamide|oral - all doses
219330403|NCT01587339|DRUG|pregabalin|oral - all doses
219330404|NCT01587339|DRUG|eslicarbazepine|oral - all doses
219330405|NCT01812889|DRUG|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
219330406|NCT01812889|DRUG|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
219330407|NCT03123250|DEVICE|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
219330408|NCT04135339|OTHER|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
219330409|NCT04135339|OTHER|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
219330410|NCT04135339|OTHER|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
219330411|NCT06200649|OTHER|massage|Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
219330412|NCT03963414|COMBINATION_PRODUCT|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
219330413|NCT03963414|COMBINATION_PRODUCT|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
219330414|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
219330415|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
219330416|NCT01390272|BEHAVIORAL|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
219330417|NCT01390272|BEHAVIORAL|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
219330418|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
219330419|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
219330420|NCT05973552|OTHER|CO-rebreathing|In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
219330421|NCT05973552|OTHER|Oral iron isotope administration (54Fe)|Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
219330422|NCT05973552|OTHER|Intravenous iron isotope administration (58Fe)|Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
219330423|NCT05893602|OTHER|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
219355386|NCT03920670|DEVICE|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
219355387|NCT03436615|DRUG|SB206 4%|Twice daily
219355388|NCT03436615|DRUG|SB206 8%|Twice daily
219355389|NCT03436615|DRUG|SB206 12%|Once or twice daily
219355390|NCT03436615|DRUG|Placebo|Once or twice daily
219330424|NCT01958190|DRUG|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
219330425|NCT01958190|DRUG|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
219330426|NCT02910960|DEVICE|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
219330427|NCT02910960|DEVICE|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
219330428|NCT05053516|OTHER|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
219330429|NCT00087750|DRUG|Quetiapine|
219330430|NCT03931967|DIAGNOSTIC_TEST|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
219330431|NCT01466530|DRUG|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
219330432|NCT01466530|DRUG|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
219330433|NCT00051285|DRUG|Enoximone|Participants receive oral enoximone
219330434|NCT00051285|DRUG|Enoximone placebo|Participants receive placebo to match enoximone
219330435|NCT03342313|OTHER|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
219330436|NCT00300768|DRUG|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
219330437|NCT00300768|DRUG|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
219330438|NCT00300768|DRUG|4 mg moxidectin|Single dose, tablets encapsulated for blinding
219330439|NCT00300768|DRUG|8 mg moxidectin|single dose, tablets encapsulated for blinding
219330440|NCT05232006|DRUG|Niraparib|Niraparib, once daily
219330441|NCT01982721|DEVICE|Locking mechanism for prosthetic knee|
219330442|NCT01600976|DRUG|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
219330443|NCT00496236|DRUG|TNFerade biologic|
219330444|NCT00524849|BIOLOGICAL|Zoledronic acid|Zometa 1 mg weekly (intravenous)
219330445|NCT00524849|DRUG|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
219330446|NCT04190433|DRUG|Carvedilol|Given PO
219330447|NCT04190433|DRUG|Lisinopril|Given PO
219330448|NCT04190433|DRUG|Pravastatin|Given PO
219330449|NCT04190433|DRUG|Spironolactone|Given PO
219330450|NCT04143360|DEVICE|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
219330451|NCT04143360|DEVICE|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
219330452|NCT01214863|DEVICE|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
219330453|NCT01214863|DEVICE|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
219330454|NCT01214863|DEVICE|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
219330455|NCT02566577|BIOLOGICAL|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
219330456|NCT02566577|BIOLOGICAL|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
219330457|NCT02566577|DEVICE|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
219330458|NCT06154655|OTHER|E-zine|Health education will be delivered through an electronic magazine
219330459|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
219330460|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
219330461|NCT00354081|DRUG|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
219330462|NCT00354081|DRUG|placebo|placebo, in a capsule, taken orally once a day
219355391|NCT02271412|DRUG|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
219330463|NCT03300167|DEVICE|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
219330464|NCT00861913|OTHER|Laboratory Biomarker Analysis|Correlative studies
219330465|NCT00861913|DRUG|Pazopanib Hydrochloride|Given orally
219330466|NCT00861913|OTHER|Pharmacological Study|Correlative studies
219330467|NCT03851003|PROCEDURE|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
219330468|NCT03851003|PROCEDURE|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
219330469|NCT03851003|DEVICE|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
219330470|NCT03851003|OTHER|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
219330471|NCT00350168|DRUG|valsartan + amlodipine|
219330472|NCT04812067|DRUG|TTHX1114|engineered FGF-1
219330473|NCT03200054|OTHER|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
219330474|NCT04651543|OTHER|X-Ray|X-ray obtained at one-week of the fracture
219330475|NCT00596661|DEVICE|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
219330476|NCT03612011|OTHER|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
219330477|NCT04239105|DEVICE|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
219330478|NCT01210170|DRUG|placebo|placebo inhalation before albuterol.
219330479|NCT01210170|DRUG|mometasone 400 mcg|mometasone inhalation before albuterol.
219330480|NCT01210170|DRUG|mometasone 200 mcg|200ug mometasone before albuterol.
219355392|NCT02271412|DRUG|Placebo|Placebo
219330481|NCT04046081|DRUG|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
219330482|NCT04760951|DIETARY_SUPPLEMENT|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
219330483|NCT04760951|DIETARY_SUPPLEMENT|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
219330484|NCT01751399|DRUG|LY2605541|
219330485|NCT03052504|OTHER|Registration of complications|Prospective registration
219330486|NCT00606450|DRUG|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
219330487|NCT00606450|DRUG|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
219330488|NCT00606450|DRUG|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
219330489|NCT02032550|OTHER|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
219330490|NCT02558387|DRUG|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
219330491|NCT05301920|DEVICE|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
219330492|NCT01866397|OTHER|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
219330493|NCT02630342|BEHAVIORAL|Mock MRI scanner|Using a mock scanner for preparation for MRI
219330494|NCT02630342|BEHAVIORAL|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
219330495|NCT02630342|BEHAVIORAL|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
219330496|NCT02630342|BEHAVIORAL|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
219330497|NCT00073528|DRUG|Lapatinib|1500 mg orally once a day
219330498|NCT00073528|DRUG|Letrozole|2.5 mg orally once a day
219330499|NCT00073528|DRUG|Placebo|Placebo (which matched with lapatinib tablet)
219330500|NCT02284620|PROCEDURE|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
219330501|NCT02284620|PROCEDURE|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
219330502|NCT05855057|PROCEDURE|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
219330503|NCT05855057|PROCEDURE|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
219330504|NCT05855057|PROCEDURE|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
219330505|NCT02467283|GENETIC|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
219330506|NCT05891184|DEVICE|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
219330507|NCT02207998|DRUG|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
219330508|NCT02207998|DRUG|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
219330509|NCT03086057|BEHAVIORAL|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
219330510|NCT03086057|BEHAVIORAL|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
219330511|NCT06011564|DEVICE|Reminder function on Android computer tablet|Computer tablet with reminder function
219330512|NCT03979690|DEVICE|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
219330513|NCT00195312|BIOLOGICAL|HIV-1 gag DNA (formulated with bupivacaine)|
219330514|NCT00195312|BIOLOGICAL|IL-15 DNA (formulated with bupivacaine)|
219330515|NCT00195312|BIOLOGICAL|IL-12 DNA (formulated with bupivacaine)|
219330516|NCT00195312|BIOLOGICAL|Sodium chloride injection USP (0.9%)|
219330517|NCT00943020|DIETARY_SUPPLEMENT|Nutricia PreOp nutritional supplement|nutritional supplement
219330518|NCT00943020|DIETARY_SUPPLEMENT|Lipid|Drink
219330519|NCT00943020|DIETARY_SUPPLEMENT|Glutamine|Drink
219330520|NCT03924336|PROCEDURE|Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
219330521|NCT03924336|PROCEDURE|Open flap debridement (OFD) alone|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
219330522|NCT02341703|DRUG|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
219330523|NCT02341703|DRUG|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
219330524|NCT02341703|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
219330525|NCT02341703|OTHER|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
219330526|NCT02887404|OTHER|Spine surgery analgesic pathway|Enhanced pain management care
219330527|NCT02887404|OTHER|Usual Care|Standard of pain management care
219330528|NCT01485341|DIETARY_SUPPLEMENT|gluten|gluten is administered once a day at 10g/day for 15 days
219330529|NCT01485341|DIETARY_SUPPLEMENT|rice starch|rice starch is administered once a day at 10 g/day for 15 days
219330530|NCT01033617|PROCEDURE|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
219330531|NCT00775736|DRUG|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
219330532|NCT00775736|DRUG|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
219330533|NCT00775736|DRUG|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
219330534|NCT01406236|PROCEDURE|Transradial PCI|Transradial PCI
219330535|NCT01406236|PROCEDURE|Transfemoral PCI|Transfemoral PCI
219330536|NCT03180164|OTHER|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
219330537|NCT04088825|OTHER|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
219330538|NCT03196986|DRUG|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
219330539|NCT03196986|DRUG|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
219330540|NCT00247936|PROCEDURE|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
219330541|NCT06027736|OTHER|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
219330542|NCT01244295|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
219330543|NCT01244295|BEHAVIORAL|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
219330544|NCT00000580|DRUG|immunoglobulins, intravenous|
219330545|NCT03126396|DEVICE|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
219330546|NCT04874519|BEHAVIORAL|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
219330547|NCT05496179|DRUG|Prucalopride|Prokinetic
219330548|NCT05496179|DRUG|Metoclopramide|Prokinetic
219330549|NCT03459118|BEHAVIORAL|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
219330550|NCT01622192|DEVICE|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
219330551|NCT03838055|PROCEDURE|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
219330552|NCT05712135|OTHER|supine position|The patient group whose cuff pressure was measured in the supine position
219330553|NCT05712135|OTHER|prone position|The patient group whose cuff pressure was measured in the prone position
219330554|NCT05712135|OTHER|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
219330555|NCT04843046|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
219330556|NCT04843046|DRUG|Pioglitazone|Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.
219330557|NCT04843046|DRUG|Placebo|Placebo capsules will be filled with corn starch and riboflavin.
219330558|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II hemispherical cup
219330559|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II Tritanium cup
219330560|NCT01129830|DIETARY_SUPPLEMENT|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
219330561|NCT04305275|DRUG|SAGE-324|SAGE-324 oral tablet
219330562|NCT04305275|DRUG|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
219330563|NCT01728415|OTHER|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
219330564|NCT02867124|DRUG|XR-NTX|Vivitrol
219330565|NCT02867124|OTHER|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
219330566|NCT02867124|OTHER|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
219330567|NCT00348920|PROCEDURE|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
219330568|NCT05360173|BEHAVIORAL|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
219330569|NCT05360173|BEHAVIORAL|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
219330570|NCT02433197|DEVICE|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
219330571|NCT02801136|BEHAVIORAL|ReACT|
219330572|NCT02801136|BEHAVIORAL|Supportive Therapy|
219330573|NCT02525250|PROCEDURE|Realization of 3 Blood samples during study during treatment with lenalidomide|
219330574|NCT03978221|OTHER|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
219330575|NCT05881174|PROCEDURE|acupuncture|acupuncture
219330576|NCT02524548|OTHER|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
219330577|NCT05604820|BEHAVIORAL|Progressive Muscle Relaxation Exercise|Training on progressive muscle relaxation exercises will be given to the experimental group in the chemotherapy unit. Before going to sleep in the evening and during the day, they will be asked to do progressive muscle relaxation exercises in line with the instruction of the video. They will be asked to do the application every day for 8 weeks. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. Only routine care will be applied to the control group and no intervention will be made. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. After the evaluations, information about progressive muscle relaxation exercises will be given.
219330578|NCT03163784|BIOLOGICAL|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
219330579|NCT03163784|BIOLOGICAL|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
219330580|NCT03163784|DRUG|Antibiotic|Antibiotic pre-treatment
219330581|NCT03163784|DRUG|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
219330582|NCT01236664|BEHAVIORAL|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
219330583|NCT01236664|BEHAVIORAL|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
219330584|NCT03959124|DEVICE|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz
219330585|NCT03959124|DRUG|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
219330586|NCT00458796|DRUG|zoledronic acid|
219330587|NCT00458796|PROCEDURE|quality-of-life assessment|
219330588|NCT01067755|DEVICE|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
219330589|NCT00749476|BIOLOGICAL|Factor IX recovery|
219330590|NCT01937598|DRUG|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
219330591|NCT01937598|OTHER|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
219330592|NCT01937598|DRUG|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
219330593|NCT01937598|DRUG|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
219330594|NCT01022242|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
219330595|NCT01022242|DRUG|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
219330596|NCT03566355|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
219330597|NCT01700270|DRUG|dovitinib (TKI258)|
219330598|NCT01700270|DRUG|fluvoxamine|perpetrator drug; 7 days of dosing
219330599|NCT00069732|BEHAVIORAL|qigong|
219330600|NCT00069732|BEHAVIORAL|acupressure-TAT|
219330601|NCT03648008|DRUG|Hydromorphone|0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
219330602|NCT03648008|DRUG|Morphine|0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
219330603|NCT01037491|DRUG|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
219330604|NCT05520151|DIETARY_SUPPLEMENT|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
219330605|NCT05520151|OTHER|control|no intervention
219330606|NCT03502291|BIOLOGICAL|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
219330607|NCT03502291|BIOLOGICAL|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
219330608|NCT03502291|BIOLOGICAL|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
219330609|NCT03502291|BIOLOGICAL|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
219330610|NCT00545727|BEHAVIORAL|Diet|Whole-foods, low glycemic index diet
219330611|NCT00545727|OTHER|Standard diet|Standard diet meeting American Diabetes Association guidelines
219330612|NCT01390766|DRUG|Azathioprine|
219330613|NCT05340894|PROCEDURE|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
219330614|NCT05340894|PROCEDURE|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
219330615|NCT00745407|DRUG|fenofibrate|
219330616|NCT02674698|OTHER|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
219330617|NCT02674698|OTHER|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
219330618|NCT02674698|OTHER|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
219330619|NCT02674698|OTHER|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
219330620|NCT05344794|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-6 and NE levels were detected.
219330621|NCT05839275|DRUG|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
219330622|NCT05839275|DRUG|Sintilimab|200mg, d1, q3w
219330623|NCT05839275|RADIATION|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
219330624|NCT01762215|BEHAVIORAL|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
219330625|NCT01638078|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
219330626|NCT01638078|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
219330627|NCT00956397|DRUG|Rifaximin|rifaximin 550 mg TID PO x 10 days
219330628|NCT00956397|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
219330629|NCT00956397|DRUG|Placebo|placebo TID x 10 days
219330630|NCT00002400|DRUG|Indinavir sulfate|
219330631|NCT00002400|DRUG|Delavirdine mesylate|
219330632|NCT00002400|DRUG|Lamivudine|
219330633|NCT00002400|DRUG|Zidovudine|
219330634|NCT01640652|BIOLOGICAL|MenPF-1.|A new vaccine against meningococcal disease.
219330635|NCT02032563|DRUG|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
219330636|NCT05069506|OTHER|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219330637|NCT05069506|OTHER|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219330638|NCT05069506|OTHER|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219330639|NCT05069506|OTHER|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219330640|NCT05069506|OTHER|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
219330641|NCT05069506|OTHER|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
219330642|NCT05069506|OTHER|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
219330643|NCT05992103|PROCEDURE|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
219330644|NCT05992103|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
219330645|NCT05992103|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
219330646|NCT04040075|DRUG|Biktarvy Tab|Antiretroviral drug
219330647|NCT01702714|DRUG|RO5083945|multiple ascending doses
219330648|NCT01702714|DRUG|carboplatin|up to 6 cycles
219330649|NCT01702714|DRUG|cisplatin|up to 6 cycles
219330650|NCT01702714|DRUG|gemcitabine|up to 6 cycles
219330651|NCT01702714|DRUG|paclitaxel|up to 6 cycles
219330652|NCT00788281|PROCEDURE|laparoscopic surgery|surgery would be performed by laparoscope
219330653|NCT00788281|PROCEDURE|open surgery|surgery would be performed by traditional surgery.
219330654|NCT03470038|DRUG|NGF|Intramuscular injection
219330655|NCT03470038|DRUG|Isotonic saline|Intramuscular injection
219330656|NCT00839670|OTHER|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
219330657|NCT00839670|OTHER|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
219330658|NCT06492616|DRUG|Elacestrant|Administered as oral tablets
219330659|NCT06492616|DRUG|Anastrozole|Administered as oral tablets
219330660|NCT06492616|DRUG|Letrozole|Administered as oral tablets
219330661|NCT06492616|DRUG|Exemestane|Administered as oral tablets
219330662|NCT06492616|DRUG|Tamoxifen|Administered as oral tablets
219330663|NCT00449683|DRUG|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
219330664|NCT04173689|DEVICE|Threshold IMT|7 days a week, 2 times a day 15 min each
219330665|NCT04173689|OTHER|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
219330666|NCT04144374|DRUG|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
219330667|NCT04144374|PROCEDURE|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
219330668|NCT03295370|PROCEDURE|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
219330669|NCT00525993|DRUG|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
219330670|NCT00525993|DRUG|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
219330671|NCT02179671|DRUG|Gefitinib|Gefitinib once daily followed by MEDI4736
219330672|NCT02179671|DRUG|AZD9291|AZD9291 once daily followed by MEDI4736
219330673|NCT02179671|DRUG|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
219330674|NCT02179671|DRUG|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
219355393|NCT03341169|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|:Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
219355394|NCT03341169|DRUG|placebo (0.9% NaCl (normal saline))|Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
219355395|NCT02849366|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
219330675|NCT04820400|OTHER|Immersive VR Video|"The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft."
219330676|NCT05421312|DRUG|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
219330677|NCT05421312|DRUG|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
219330678|NCT05421312|DRUG|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
219330679|NCT02247895|DEVICE|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
219330680|NCT02247895|DEVICE|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
219330681|NCT01909427|DRUG|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
219330682|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
219330683|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
219330684|NCT01909427|DRUG|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
219330685|NCT01909427|DRUG|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
219330686|NCT01909427|DRUG|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
219330687|NCT01909427|DRUG|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
219330688|NCT05355025|BEHAVIORAL|WiserAD|"See Arms"
219330689|NCT05355025|BEHAVIORAL|Attention control|"See Arms"
219330690|NCT01431326|DRUG|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
219330691|NCT05298982|BEHAVIORAL|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
219330692|NCT01708291|BEHAVIORAL|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
219330693|NCT01708291|BEHAVIORAL|only pre and post evaluation measures|
219330694|NCT02543827|BIOLOGICAL|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
219330695|NCT02543827|BIOLOGICAL|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
219330696|NCT00096668|DRUG|TOCOSOL(R) Paclitaxel|
219330697|NCT02290626|DRUG|Elmental diet|elemental diet is administered using PEG.
219330698|NCT02290626|DRUG|Semi-solid diet|Semi-solid diet is administered using PEG.
219330699|NCT02357823|OTHER|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
219330700|NCT02357823|OTHER|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
219330701|NCT04382196|OTHER|Online survey|An online survey will be administered
219330702|NCT06211465|PROCEDURE|Total joint arthroplasty|Hip or knee total joint arthroplasty
219330703|NCT05613166|DRUG|Everolimus|Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.
219330704|NCT05613166|DRUG|Placebo|Vitamin C
219330705|NCT01536951|DRUG|LY3009104|administered orally
219330706|NCT01536951|DRUG|Placebo|Administered orally
219330707|NCT01536951|DRUG|moxifloxacin|Administered orally
219330708|NCT04169490|OTHER|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
219330709|NCT04169490|OTHER|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
219330710|NCT04169490|OTHER|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
219330711|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
219330712|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
219330713|NCT05033665|BEHAVIORAL|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
219330714|NCT05033665|BEHAVIORAL|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
219330715|NCT02345304|DRUG|Omeprazole|
219330716|NCT02345304|DRUG|Warfarin|
219330717|NCT02345304|DRUG|BI 1181181|
219330718|NCT02345304|DRUG|Midazolam|
219330719|NCT02345304|DRUG|Omeprazole|
219330720|NCT02345304|DRUG|BI 1181181|
219330721|NCT02345304|DRUG|Midazolam|
219330722|NCT02345304|DRUG|Midazolam|
219330723|NCT02345304|DRUG|Warfarin|
219330724|NCT02345304|DRUG|BI 1181181|
219330725|NCT02345304|DRUG|Digoxin|
219330726|NCT02345304|DRUG|Digoxin|
219330727|NCT03093779|OTHER|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
219330728|NCT00189072|DRUG|gabapentin|
219330729|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 6
219330730|NCT01843972|DRUG|BI 691751|oral solution
219330731|NCT01843972|DRUG|Placebo|placebo solution
219330732|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 2
219330733|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 5
219330734|NCT01843972|DRUG|BI 691751|1 tablet
219330735|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 3
219330736|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 4
219330737|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 7
219330738|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 1
219330739|NCT05584254|DIETARY_SUPPLEMENT|yeast-beta glucan|
219330740|NCT01961206|OTHER|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
219330741|NCT03817866|DIAGNOSTIC_TEST|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
219330742|NCT06178237|DEVICE|Purabond|Application of Purabond to surgical field
219330743|NCT00393809|DRUG|DTA-H19|
219330744|NCT05116150|DIETARY_SUPPLEMENT|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
219330745|NCT05116150|DIETARY_SUPPLEMENT|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
219355396|NCT02849366|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
219355397|NCT05531669|BEHAVIORAL|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
219330746|NCT05378854|OTHER|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
219330747|NCT02154542|DEVICE|Neurovent Monitor XIII|
219330748|NCT00932425|DEVICE|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
219330749|NCT03410017|OTHER|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
219330750|NCT05218681|OTHER|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
219330751|NCT05218681|OTHER|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
219330752|NCT05916781|DRUG|Mycophenolate Mofetil|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
219330753|NCT05916781|DRUG|Tacrolimus|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
219330754|NCT05916781|DRUG|Glucocorticoid|"Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare."
219330755|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
219330756|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
219330757|NCT01028326|BIOLOGICAL|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
219330758|NCT03759483|DIAGNOSTIC_TEST|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
219330759|NCT04403750|PROCEDURE|Combined laser-surgical technology of RRD treatment|"1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
219330760|NCT00334126|DRUG|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
219355398|NCT05531669|BEHAVIORAL|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
219355399|NCT03436186|OTHER||no intervention
219330761|NCT03061461|DEVICE|rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
219330762|NCT03061461|DEVICE|Sham rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
219330763|NCT02896829|BEHAVIORAL|Interruption of the treatment by Imatinib|
219330764|NCT02422342|DEVICE|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
219330765|NCT03827772|OTHER|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
219330766|NCT03827772|OTHER|Standard of care treatment|Nutritional supplementation, supportive management.
219330767|NCT04164576|GENETIC|Transplant patients|Study the specific immunity against Polyomavirus
219330768|NCT01669967|DRUG|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
219330769|NCT01669967|DRUG|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
219330770|NCT04607928|DRUG|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
219330771|NCT04607928|DRUG|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
219330772|NCT01765842|BIOLOGICAL|Rituximab|Only one cycle of rituximab will be administered in this arm.
219330773|NCT01881893|BEHAVIORAL|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
219330774|NCT00010920|DRUG|Ginkgo Biloba Extract|
219330775|NCT03178968|OTHER|Orange juice|3 immersion times in orange juice were investigated
219330776|NCT05443893|DEVICE|Application Research of key points detection technology|"Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis"
219330777|NCT03805750|DRUG|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
219330778|NCT03805750|DRUG|Placebo oral capsule|Matched Placebo
219330779|NCT01177683|DRUG|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
219330780|NCT01177683|DRUG|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
219330781|NCT01177683|DRUG|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
219330782|NCT01177683|DRUG|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
219330783|NCT01177683|DRUG|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000"
219330784|NCT02859376|DIETARY_SUPPLEMENT|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
219330785|NCT03745833|DEVICE|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
219330786|NCT04416347|OTHER|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
219330787|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219330788|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219355400|NCT06250322|DEVICE|Intervention|No study treatments will be administered during this study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
219330789|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219330790|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219330791|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219330792|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
219355401|NCT00401063|DEVICE|Acupuncture|Acupuncture treatment twice a day for eight weeks
219330793|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
219330794|NCT00946504|DRUG|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
219330795|NCT00946504|DRUG|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
219330796|NCT06035796|DEVICE|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
219355402|NCT03797469|DIETARY_SUPPLEMENT|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
219355403|NCT03797469|DIETARY_SUPPLEMENT|Pyruvate|2 tablets of 1500 mg each will be administered orally.
219355404|NCT03797469|DIETARY_SUPPLEMENT|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
219355405|NCT04610528|DRUG|U3 1402|6.4 mg/kg dose
219355406|NCT04610528|DRUG|U3 1402|5.6 mg/kg dose
219355407|NCT00691431|DEVICE|LASIK|
219355408|NCT05403125|DEVICE|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
219330797|NCT05546294|DEVICE|Aerobic and home exercise|"A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
219330798|NCT05546294|OTHER|Home exercise|"The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
219330799|NCT05546294|OTHER|Healthy control group|Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
219330800|NCT03057613|DRUG|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
219330801|NCT03057613|RADIATION|IMRT 60-66Gy|60-66Gy for 6 weeks
219330802|NCT00493090|BEHAVIORAL|modification of an interactive seminar|
219330803|NCT06346184|DRUG|HCP2303|Take 1 tablet once per period
219330804|NCT06346184|DRUG|RLD2302|Take 1 tablet once per period
219330805|NCT06346184|DRUG|RLD2102|Take 1 tablet once per period
219330806|NCT02762279|OTHER|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
219330807|NCT02580851|OTHER|diagnostic test - cardiac magnetic resonance imaging|
219330808|NCT02580851|OTHER|diagnostic test - coronary angiography|
219330809|NCT02453373|DEVICE|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
219330810|NCT02453373|DRUG|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
219330811|NCT02453373|DRUG|tPA|tPA will be administered intravenously if indicated
219330812|NCT02453373|DRUG|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
219330813|NCT02453373|DRUG|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
219330814|NCT02453373|PROCEDURE|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
219330815|NCT02198443|DRUG|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
219330816|NCT02198443|DRUG|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
219330817|NCT03631030|DEVICE|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
219330818|NCT04549870|DRUG|Roflumilast|Treatment according to national roflumilast guidelines
219330819|NCT00068575|BIOLOGICAL|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
219330820|NCT00068575|DRUG|Cisplatin|30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
219330821|NCT00068575|DRUG|Fluorouracil|175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
219330822|NCT00068575|RADIATION|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
219330823|NCT05149222|DEVICE|Digital ACT|This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
219330824|NCT01241799|PROCEDURE|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
219330825|NCT01241799|PROCEDURE|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
219330826|NCT05132374|OTHER|I-T CHILD|This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
219330827|NCT05432882|BIOLOGICAL|bi-4SCAR CD19/22 T cells|Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
219330828|NCT00052351|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
219330829|NCT00052351|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
219330830|NCT00052351|BIOLOGICAL|sargramostim|
219330831|NCT00052351|DRUG|cyclophosphamide|
219330832|NCT00052351|DRUG|doxorubicin hydrochloride|
219330833|NCT00052351|DRUG|paclitaxel|
219330834|NCT00052351|RADIATION|radiation therapy|
219330835|NCT01316094|DRUG|ASP1941|oral
219330836|NCT01316094|DRUG|placebo|oral
219330837|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
219330838|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
219330839|NCT04887155|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
219330840|NCT03318978|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
219330841|NCT02844816|DRUG|Atezolizumab|Given IV
219330842|NCT00918047|DRUG|SPN-804O|Open Label study
219330843|NCT01871636|PROCEDURE|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
219330844|NCT01871636|PROCEDURE|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
219330845|NCT01871636|DEVICE|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
219330846|NCT00246597|DRUG|epoetin alfa|
219330847|NCT04084106|DRUG|Phenoxymethylpenicillin|Oral administration
219330848|NCT04084106|DRUG|Amoxicillin|Oral administration
219330849|NCT04084106|DRUG|Amoxicillin-clavulanic acid|Oral administration
219330850|NCT04952740|PROCEDURE|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
219330851|NCT04952740|PROCEDURE|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
219330852|NCT04180150|DRUG|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
219330853|NCT04180150|DRUG|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
219330854|NCT04180150|DRUG|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
219330855|NCT01557179|DEVICE|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
219330856|NCT01557179|DEVICE|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
219330857|NCT01133379|DEVICE|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
219330858|NCT01133379|DEVICE|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
219330859|NCT01133379|DEVICE|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
219330860|NCT04363073|DEVICE|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
219330861|NCT04363073|DEVICE|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
219330862|NCT00407589|DRUG|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
219330863|NCT02795533|BEHAVIORAL|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
219330864|NCT04280965|DRUG|Quetiapine Fumarate|Atypical antipsychotic
219330865|NCT04280965|OTHER|Standard of care meducations|SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
219330866|NCT00591214|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
219330867|NCT00841204|DRUG|sulindac|Given orally
219330868|NCT00841204|OTHER|placebo|Inactive agent
219330869|NCT00841204|OTHER|laboratory biomarker analysis|Correlative studies
219330870|NCT00161460|BEHAVIORAL|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
219330871|NCT06505239|DIETARY_SUPPLEMENT|FSD-F2R6-A-CP|FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
219330872|NCT06505239|DIETARY_SUPPLEMENT|Placebo|Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
219330873|NCT03585218|BIOLOGICAL|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
219330874|NCT00130195|DRUG|imatinib|
219330875|NCT00130195|DRUG|cyclophosphamide|
219330876|NCT00130195|DRUG|daunorubicin|
219330877|NCT00130195|DRUG|vincristine|
219330878|NCT00130195|DRUG|prednisolone|
219330879|NCT00130195|DRUG|methotrexate|
219330880|NCT00130195|DRUG|cytarabine|
219330881|NCT00130195|DRUG|dexamethasone|
219330882|NCT00282178|DRUG|Hydrochlorothiazide|25-50 mg once daily
219330883|NCT00282178|DRUG|Placebo|Once daily
219330884|NCT00282178|DRUG|Candesartan|16-32 mg once daily 12 weeks
219330885|NCT03800888|OTHER|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
219330886|NCT03800888|OTHER|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
219330887|NCT03800888|OTHER|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
219330888|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
219330889|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
219330890|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
219330891|NCT01516151|DRUG|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
219330892|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|4 capsules of 1 g total per day for 8 weeks.
219330893|NCT01166503|PROCEDURE|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
219330894|NCT01166503|PROCEDURE|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
219330895|NCT01166503|PROCEDURE|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
219330896|NCT01166503|PROCEDURE|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
219330897|NCT01166503|PROCEDURE|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
219330898|NCT03587714|DIAGNOSTIC_TEST|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
219330899|NCT02786134|RADIATION|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
219330900|NCT02786134|RADIATION|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
219330901|NCT05957952|PROCEDURE|Motor control exercise with dynamic taping|Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape
219330902|NCT05957952|PROCEDURE|Motor control exercise|Subjects will learn how to control their scapula during motor control exercise without taping
219330903|NCT05470465|DRUG|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
219330904|NCT05470465|DRUG|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
219330905|NCT05470465|DRUG|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
219330906|NCT05906576|DRUG|Infliximab|Infliximab in the treatment of Crohn's disease in children
219330907|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
219330908|NCT06653426|DIETARY_SUPPLEMENT|Sodium Butyrate (NaBu)|Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
219355409|NCT05403125|DEVICE|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
219355410|NCT03861143|DRUG|BT-11 (440 mg)|Oral, once daily tablet
219355411|NCT03861143|DRUG|BT-11 (880 mg)|Oral, once daily tablet
219355412|NCT03861143|DRUG|Placebo|Oral, once daily tablet
219355413|NCT00281879|BIOLOGICAL|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
219330909|NCT06973252|BEHAVIORAL|Eye masks|The intervention group patients were fitted with an eye mask designed by the researcher by placing a black fabric in the size of the mask between two three-layer surgical masks with Asfor brand soft elastic earphones and stapling the edges. The designed eye mask was cut with scissors according to the shape of the nose so that the mask would fit the eye exactly and prevent the light from entering the eye. A separate mask was used for each patient in the intervention group. Patients who were admitted to the NICU after surgery were evaluated for agitation-pain-delirium at 23:00 on postoperative days 0, 1, and 2, were told to wear their eye masks after the scale application, and the patients were allowed to sleep at 23:00 at the latest. Patients were allowed to remove the eye patch for short periods of time (10 minutes or less at a time) and then put it back on when uncomfortable and when necessary.
219330910|NCT06978855|DEVICE|Wrist band acupressure application to P6 point|"The intervention group received standardized instructions for applying the wristband to the P6 acupressure point on their wrist, with daily application scheduled from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift the intervention was applied for 30 days.~At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over."
219330911|NCT06978855|DEVICE|Wrist band acupressure application to sham point|the control group will receive standardized instructions to apply the wristband to a sham point, with daily application from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift. This will occur for 30 days. At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over.
219330912|NCT06854913|OTHER|Post-Operative monitoring using wearable biosensor|The protocol involves the use of the Medtronic Zephyr BioPatch™, a wearable biosensor, to monitor sleep quality and patterns in patients recovering from shoulder surgery. The device tracks physiological signals (ECG, HRV, respiratory rate) and postural changes, providing objective data on sleep profiles. Patients are assessed at three key time points: before surgery (baseline), two weeks after surgery (early recovery phase), and 30 days post-surgery (mid-recovery phase). The primary goal is to evaluate changes in sleep quality and patterns during the post-operative period, while also monitoring improvements in shoulder functionality and pain levels. This approach aims to provide insights into the relationship between sleep quality and recovery outcomes following shoulder surgery.
219330913|NCT06854913|OTHER|Usability Assessment and Patient Willingness to Use Technology Description|The usability of the Medtronic Zephyr BioPatch™ is evaluated through patient feedback and questionnaires, focusing on comfort, ease of use, and reliability. Additionally, patient willingness to continue using the wearable sensor for sleep monitoring is assessed. This evaluation helps determine the practicality and acceptance of the technology in real-world rehabilitation settings, providing insights into its potential for long-term use in clinical practice.
219330914|NCT06593249|OTHER|No Intervention: Observational Cohort|no intervention, observational study
219330915|NCT01978353|BEHAVIORAL|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
219330916|NCT01978353|BEHAVIORAL|Psychoeducation|Participants receive information about memory functioning and aging
219330917|NCT06655909|OTHER|consumption of maize porridge containing stable iron isotope|consumption of maize porridge containing stable iron isotope
219330918|NCT05470322|DEVICE|Er: YAG laser|Patients will be treated with laser for their HS scarring.
219330919|NCT06985810|OTHER|Accentuated Eccentric Loading training|18 particpants will train in AEL group for three days a week for eight weeks and each session will take about 60-75 minutes, focusing on eccentric exercises like back squats, leg press, and hip thrusts at 90% 1RM intensity. Sessions, supervised by coaches, include free weight and weight machine exercises. Performance tests (20m sprint, T-agility, broad jump, 1RM assessments) will evaluate progress at the study's start and end.
219330920|NCT06985810|OTHER|Flywheel exercises|18 particpants will train in FW group for three days a week for eight weeks and each session will take about 60-75 minutes, incorporating compound movements, Flywheel exercises (squats, sprints, jumps), and relevant free weight and weight machine exercises. Supervised sessions maintain consistent parameters. Performance tests (20m speed, T-agility, broad jump, 1RM assessments) will measure improvements at study start and end for evaluation.
219330921|NCT06985602|COMBINATION_PRODUCT|Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery|"* Adebrelimab: Given concurrently with chemotherapy, 1200mg by intravenous infusion every three weeks for four cycles.~* Chemotherapy: Oxaliplatin 130mg/m² on day 1 + Capecitabine 1000mg/m² bid (XELOX regimen), from day 1 to day 14, repeated every three weeks for four cycles;~* Radiotherapy: Unresectable limited metastatic lesions with SBRT; Potentially resectable lesions with low-dose radiotherapy.~* Surgery: Performed 3-5 weeks after the completion of conversion therapy."
219330922|NCT06984237|DIAGNOSTIC_TEST|TNF-α Analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be instructed to refrain from eating, drinking, brushing, or chewing gum for at least one hour before collection. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
219330923|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be asked to avoid eating, drinking, brushing their teeth, or chewing gum for at least one hour prior to sampling. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. IL-17A levels will be determined using ELISA.
219330924|NCT06984237|DIAGNOSTIC_TEST|YKL-40 Analysis in saliva|Unstimulated whole saliva samples will be obtained from participants in the morning, at least one day after the periodontal clinical assessment. They will be instructed not to eat, drink, chew gum, or brush their teeth for at least one hour before collection. Samples will be centrifuged at 1500 rpm for 10 minutes, and the clear supernatants will be stored at -80°C until the time of analysis. YKL-40 levels will be measured using ELISA.
219330925|NCT06984237|DIAGNOSTIC_TEST|TNF-α analysis in serum|A total of 8 mL of venous blood will be collected from the antecubital fossa of seated participants. Samples will be transferred into BD Vacutainer® SST™ II Advance serum separator tubes containing acrylic gel and will be allowed to clot for 30 minutes at room temperature. The samples will then be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The resulting serum will be transferred into Eppendorf tubes using a Pasteur pipette and will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
219330926|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in serum|A total of 8 mL of venous blood will be obtained from the antecubital fossa of participants in a seated position. After collection, the blood will be placed into BD Vacutainer® SST™ II Advance tubes with acrylic gel and will rest for 30 minutes to allow clotting. The samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The serum will be extracted using a Pasteur pipette and stored in Eppendorf tubes at -80°C until analysis. IL-17A levels will be analyzed using ELISA.
219330927|NCT06984237|DIAGNOSTIC_TEST|YKL-40 analysis in serum|Venous blood (8 mL) will be drawn from the antecubital fossa of seated participants. The samples will be placed in BD Vacutainer® SST™ II Advance tubes containing acrylic gel and will be left to clot for 30 minutes at room temperature. Following this, the samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The supernatant serum will be separated with a Pasteur pipette and transferred into Eppendorf tubes. All samples will be stored at -80°C until analysis. YKL-40 levels will be measured using ELISA.
219330928|NCT06984237|DIAGNOSTIC_TEST|Clinical periodontal evaluation|Clinical periodontal parameters will be recorded from participants who meet the inclusion criteria. The following indices will be measured from all teeth present in the oral cavity: Plaque Index (PI; Silness \& Löe, 1964), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), and Bleeding on Probing (BOP). Radiographic evaluations will also be performed. All measurements will be conducted by the same calibrated clinician (HD) using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA).
219330929|NCT06984393|OTHER|home tele-rehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. The sessions will be organised as follows: one session will be conducted via tele-rehabilitation with the support of a physiotherapist in small groups of up to 5 patients; in the remaining two sessions, the patient will perform the exercises independently at home. BTS TELEREHAB is the platform that will allow the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. Before starting the rehabilitation program, the patient will receive training with the technology in the hospital, in the presence of the physiotherapist. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device.
219330930|NCT06984393|OTHER|Usual care|Participants will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
219330931|NCT06985511|PROCEDURE|Immediate implant placement|Tooth extraction was performed atraumatically on one side, followed by immediate implant placement, right after extraction.
219330932|NCT06985511|PROCEDURE|Early implant placement|The tooth was extracted, and the implant was placed four weeks later (early placement).
219330933|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein level prior to IUT|One milliliter of cord blood will be collected before each IUT procedure to measure S100B protein concentration. The sample will be labeled with the mother's name, date of birth, collection date, and IUT indication, then sent to the laboratory for centrifugation.
219330934|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis prior to IUT|Half a milliliter of cord blood will be collected before each IUT procedure for immediate umbilical cord blood gas analysis, including pH, base excess (BE), and lactate levels.
219330935|NCT06984445|DIAGNOSTIC_TEST|Fetal blood count evaluation prior to IUT|Fetal blood count data, including hemoglobin and hematocrit levels, will be collected before each IUT procedure.
219330936|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein concentration at birth|After delivery, one milliliter of blood will be collected from the severed umbilical cord to measure the concentration of S100B protein. The sample will be labeled with the mother's name, the child's birth date and sex, and the collection date, before being sent to the laboratory for centrifugation.
219330937|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis at birth|After birth, 0.5 mL of blood will be collected from the severed umbilical cord to assess pH, base excess (BE), and lactate levels in an umbilical cord blood gas analysis.
219330938|NCT06984445|DIAGNOSTIC_TEST|Complete blood count after birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured within six hours after birth.
219330939|NCT06984445|DIAGNOSTIC_TEST|Ultrasound evaluation of fetal blood flow|Fetal cerebral blood flow will be routinely assessed via ultrasound, including measurements of MCA-PSV values.
219330940|NCT06984445|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination will. be performed to assess for any abnormalities in the newborn.
219330941|NCT06984445|DIAGNOSTIC_TEST|Complete blood count analysis in cord blood at birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured in cord blood samples collected at birth.
219330942|NCT06984471|OTHER|Palliative care consult|A palliative care (PC) consult involves a specialized palliative care team to provide symptom management, psychosocial support, and assistance with goals-of-care discussions for patients with serious or life-limiting illnesses.
219330943|NCT06984809|BEHAVIORAL|Intervention|The intervention group will receive Invest in Play (iiP), a 12 session group-based parent program, which is led by two trained group leaders.
219330944|NCT06986005|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.|All participants will receive neoadjuvant chemotherapy appropriate to the characteristics of their breast cancer as part of their standard care.
219330945|NCT06984978|COMBINATION_PRODUCT|AI-assisted, village doctors and express services-involved personalized fall prevention strategy|"The EXPRESS trial implements a pragmatic, community-based, AI-assisted fall prevention strategy tailored to the needs of older adults in rural China. The intervention is structured around five core components-SAFER:~1. Screening: multidimensional fall risk screening and assessment tailored to rural older adults;~2. AI-assisted recommendations: AI-assisted personalized fall prevention recommendations;~3. Fitness: Tailored balance and strength training via Health Intervention Cartoon Brochure and Action Demonstration Video;~4. Events-based engagement: culturally integrated seasonal intervention packages following the traditional Chinese calendar;~5. Reach-home delivery: home delivery of fall prevention services through local couriers."
219330946|NCT06984146|DRUG|Nivolumab|40 mg day 1 and 15
219330947|NCT06984146|DRUG|Doxorubicin|25 mg/m2 day 1 and 15
219330948|NCT06984146|DRUG|Vinblastine|6 mg/m2 (not exceeding 10 mg) day 1 and 15
219330949|NCT06984146|DRUG|Dacarbazine|375 mg/m2 day 1 and 15
219330950|NCT06986057|DRUG|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy
219330951|NCT06984640|DIETARY_SUPPLEMENT|Curcumin|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin. Longvida® is a trademark of Vendure Sciences, Noblesville, IN, USA.
219330952|NCT06984640|DIETARY_SUPPLEMENT|Placebo|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin.
219330953|NCT06985030|DEVICE|gyroscope embedded eye-sheild|Small pcb with gyroscope and lithium polymer battery embedded eyeshield will be distributed right after surgery
219330954|NCT06985316|DRUG|Tunlametinib combined with Fruquintinib|Tunlametinib combined with Fruquintinib
219330955|NCT06985017|BEHAVIORAL|Playing Playfully to Overcome Adversity|This training is provided via virtual group sessions (Telehealth) and consists of five 45-minute-long weekly sessions addressing ways to promote children's play and playfulness in the classroom and techniques to reduce teacher/caregiver burnout.
219330956|NCT06985524|DRUG|Weipi Formula（Wu SiSi Formula）|take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
219330957|NCT06985524|OTHER|Placebo|Take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
219330958|NCT06985693|PROCEDURE|Medipixel XA-Assisted Percutaneous Coronary Intervention|"Medipixel XA-Assisted Percutaneous Coronary Intervention (MPXA-PCI) is an AI-assisted coronary intervention procedure utilizing Medipixel XA (MPXA), an artificial intelligence-based quantitative coronary analysis (AI-QCA) software. MPXA analyzes angiographic images in real-time to assist in lesion assessment, optimal balloon and stent selection, and procedural decision-making during percutaneous coronary intervention (PCI).~In this study, all participants will undergo MPXA-assisted PCI, where the software provides automated vessel segmentation, diameter measurement, and lesion quantification to optimize procedural outcomes. Operators will follow a predefined protocol incorporating MPXA measurements for balloon sizing, stent selection, and post-dilation strategies.~The study evaluates the safety, feasibility, and clinical impact of MPXA-assisted PCI in real-world coronary artery disease patients."
219330959|NCT06984770|BEHAVIORAL|Virtual peer support group intervention|The virtual peer support group aims to improve emotional well-being, reduce isolation, and help caregivers cope by offering a safe space to share experiences and receive support from others facing similar caregiving demands.
219330960|NCT06984770|BEHAVIORAL|Caregiver Support intervention|The caregiver support intervention is a personalized program designed to improve quality of life, reduce fatigue and caregiver burden, and build resilience.
219330961|NCT06984770|OTHER|Resources|Participants will be given a list of resources to contact in case of emotional or psychological distress.
219330962|NCT04437537|DEVICE|Bioresorbable 3D electrospun synthetic matrix|All participants in this study will receive PHOENIX Wound Matrix® in addition to the SOC treatment for their chronic DFU.
219330963|NCT06097962|DRUG|NK510|Intravenous infusion
219330964|NCT06097962|DRUG|Tislelizumab，atezolizumab or sugemalimab|Administer according to the instructions
219330965|NCT06785012|DRUG|JNJ-89495120|JNJ-89495120 will be administered.
219330966|NCT06785012|DRUG|Placebo|Placebo will be administered.
219330967|NCT05740735|OTHER|"Use of expressive sounds"|"Use of expressive sounds, that is to say the own first name pronounced by the voice of the relative to generate the P300 and a sound with an approaching character of the subject to generate the MMN.~The investigators will thus be able to compare:~* MMN: present/absent for each modality (neutral vs approaching sounds)~* Wave P3a: latencies and amplitudes for each modality (own first name voice of the near vs unfamiliar)."
219330968|NCT05740735|OTHER|Having benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)|"Retrospective inclusion Have already had an assessment with event related potentials without emotional modalities (VF and similar sounds) as part of their care between April 2022 and December 2022 in intensive care at Cochin hospital."
219330969|NCT06790693|DRUG|Inavolisib|Participants will receive oral inavolisib once daily (QD).
219330970|NCT06790693|DRUG|Placebo|Participants will receive oral placebo QD.
219330971|NCT06790693|DRUG|CDK4/6i|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
219330972|NCT06790693|DRUG|Letrozole|Participants will receive oral letrozole QD.
219330973|NCT03730636|PROCEDURE|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
219330974|NCT05532904|BEHAVIORAL|Personalized multidisciplinary day-hospital intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
219330975|NCT06963125|DIETARY_SUPPLEMENT|Low-Dose Prune Juice|Intervention Name: Prune Juice 100 mL/day Description: 100 mL prune juice daily (1.07 g dietary fiber), administered once each morning for 4 weeks.
219330976|NCT06963125|DIETARY_SUPPLEMENT|Medium-Dose Prune Juice|Intervention Name: Prune Juice 150 mL/day Description: 150 mL prune juice daily (1.61 g dietary fiber), administered once each morning for 4 weeks.
219330977|NCT06963125|DIETARY_SUPPLEMENT|High-Dose Prune Juice|Intervention Name: Prune Juice 200 mL/day Description: 200 mL prune juice daily (3.22 g dietary fiber), administered once each morning for 4 weeks.
219330978|NCT02142738|DRUG|Pembrolizumab|Pembrolizumab IV solution
219330979|NCT02142738|DRUG|Paclitaxel|Paclitaxel IV solution
219330980|NCT02142738|DRUG|Carboplatin|Carboplatin IV solution
219330981|NCT02142738|DRUG|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
219330982|NCT02142738|DRUG|Cisplatin|Cisplatin IV solution
219330983|NCT02142738|DRUG|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
219330984|NCT02110368|DRUG|Testosterone Topical Gel, 1.62% Metered Pump|
219330985|NCT02110368|DRUG|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
219330986|NCT03688880|DEVICE|MAR-CUTIS|MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds \>8 cm, 2 syringes were required.
219330987|NCT03688880|DEVICE|Dermabond Advanced|Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
219330988|NCT06100887|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
219330989|NCT06100887|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
219330990|NCT06100887|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
219330991|NCT06100887|DRUG|Placebo|Placebo is administered orally once per day
219330992|NCT06336720|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The active PoNS device delivers amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes.
219330993|NCT00836628|DRUG|Busulfan|
219330994|NCT00645814|DRUG|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
219330995|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
219330996|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
219330997|NCT04490395|BEHAVIORAL|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
219330998|NCT04490395|OTHER|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
219330999|NCT05014360|DRUG|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
219331000|NCT03128398|DRUG|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
219331001|NCT04383379|BEHAVIORAL|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
219331002|NCT00022867|DRUG|Nondigestible oligosaccharide (NDO)|
219331003|NCT03215550|PROCEDURE|CEA|Carotid Endarterectomy
219331004|NCT03215550|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
219331005|NCT03215550|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
219331006|NCT00330395|DRUG|caspofungin acetate|Duration of Treatment 28 Days
219331007|NCT03277742|BEHAVIORAL|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
219331008|NCT03277742|DRUG|Standard of care|DOTS plus standard DM2 care
219331009|NCT00268632|DRUG|risedronate|
219331010|NCT06433609|DRUG|SHR-A1811|Via intravenous infusion
219331011|NCT06433609|DRUG|SHR-A1921|Via intravenous infusion
219331012|NCT06433609|DRUG|Adebrelimab|Via intravenous infusion
219331013|NCT00011908|DRUG|hLL2 (Epratuzumab)|
219331014|NCT03371979|DRUG|Pegzilarginase|Administered IV
219331015|NCT03371979|DRUG|Pembrolizumab|Administered IV
219331016|NCT01942148|DRUG|Aripiprazole|
219331017|NCT03143010|DRUG|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
219331018|NCT03143010|DRUG|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
219331019|NCT03143010|DRUG|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
219331020|NCT03143010|DRUG|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
219331021|NCT02644564|OTHER|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
219331022|NCT06353828|DRUG|CBD, synthetic form|Cannabidiol enema
219331023|NCT06353828|DRUG|Placebo|placebo enema
219331024|NCT04591730|OTHER|First time father questionnaire self-administration|The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
219331025|NCT02965521|BEHAVIORAL|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
219331026|NCT01309542|DRUG|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
219331027|NCT01231256|BEHAVIORAL|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
219331028|NCT05371977|PROCEDURE|Trabeculectomy|trabeculectomy glaucoma surgery
219331029|NCT05371977|PROCEDURE|Deep Sclerectomy|deep sclerectomy glaucoma surgery
219331030|NCT01262768|BEHAVIORAL|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
219331031|NCT01775332|OTHER|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
219331032|NCT04106882|DRUG|Ketones|Supplement administered mid-scan.
219331033|NCT04106882|DRUG|Glucose|Supplement administered mid-scan.
219331034|NCT02418780|OTHER|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
219331035|NCT00857532|DRUG|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
219331036|NCT00284206|DRUG|long-acting injectable risperidone|
219331037|NCT03134742|OTHER|Control Group|No interventions this is the control group-no additional scans
219331038|NCT03134742|DIAGNOSTIC_TEST|CT Scan|CT Scan of affected and contralateral limb
219331039|NCT03134742|DIAGNOSTIC_TEST|DEXA Scans|DEXA Scan of affected and contralateral limb
219331040|NCT03134742|DIAGNOSTIC_TEST|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
219331041|NCT04368572|BEHAVIORAL|Hypnosis|"An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase"
219331042|NCT03119961|DEVICE|SONOCLOUD®|BBB opening by ultrasound
219331043|NCT00257725|DRUG|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
219331044|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
219331045|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
219331046|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
219331047|NCT05002270|DRUG|Cetuximab (EGFR inhibitor)|Administered IV
219331048|NCT01858532|DRUG|Atrasentan|Film-coated tablet
219331049|NCT01858532|DRUG|Placebo|Film-coated tablet
219331050|NCT00514514|DRUG|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
219331051|NCT00514514|DRUG|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
219331052|NCT00514514|DRUG|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
219331053|NCT00514514|DRUG|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
219331054|NCT03271814|BIOLOGICAL|LPS|0.6 by/kg LPS single dose iv
219331055|NCT03271814|OTHER|Placebo|Sterile Water
219331056|NCT00366275|PROCEDURE|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes \>1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
219331057|NCT00333671|DRUG|Glycerol|
219331058|NCT02753322|OTHER|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
219331059|NCT02753322|OTHER|Single-task training|Balance and walking exercises and and attention demanding task performed separately
219331060|NCT02753322|OTHER|Limbs exercise|Stretching and strengthening exercises
219331061|NCT03785925|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
219331062|NCT03785925|BIOLOGICAL|Nivolumab|Specified dose on specified days
219331063|NCT00954720|OTHER|No Intervention|There is no intervention on this trial
219331064|NCT03370536|DEVICE|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
219331065|NCT03370536|PROCEDURE|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
219331066|NCT03370536|DRUG|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
219331067|NCT03164057|DRUG|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
219331068|NCT03164057|DRUG|Decitabine|Administered intravenously (IV) over approximately one hour.
219331069|NCT03164057|DRUG|Cytarabine|Given IV or intrathecally (IT).
219331070|NCT03164057|DRUG|Daunorubicin|Given IV.
219331071|NCT03164057|DRUG|Etoposide|Given IV.
219331072|NCT03164057|COMBINATION_PRODUCT|ITMHA|Given IT.
219331073|NCT03164057|DRUG|Idarubicin|Given IV.
219331074|NCT03164057|DRUG|Fludarabine|Given IV over approximately 30 minutes.
219331075|NCT03164057|DRUG|Mitoxantrone|Given IV.
219331076|NCT03164057|DRUG|Erwinia asparaginase|Given IV or intramuscularly (IM).
219331077|NCT03164057|DRUG|Sorafenib|Given PO.
219331078|NCT03164057|DRUG|G-CSF|Given IV.
219331079|NCT03164057|DRUG|Dexrazoxane|Given IV immediately before idarubicin administration.
219331080|NCT03164057|BIOLOGICAL|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
219331081|NCT03164057|DRUG|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
219355414|NCT00281879|BIOLOGICAL|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
219331082|NCT06389864|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
219355415|NCT00281879|DRUG|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
219355416|NCT00281879|DRUG|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
219331083|NCT02205203|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
219331084|NCT02205203|OTHER|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
219331085|NCT03422562|DIETARY_SUPPLEMENT|Florababy|Probiotic supplement
219331086|NCT03506711|DIAGNOSTIC_TEST|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
219331087|NCT05410613|COMBINATION_PRODUCT|electromagnetic field and a plantar resistance exercise|"Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening)."
219331088|NCT05410613|DEVICE|Pulsed electromagnetic field|Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
219331089|NCT05410613|OTHER|usual care|standard general advice according to hospital protocol
219331090|NCT06210698|DIAGNOSTIC_TEST|Venipuncture|venipuncture
219331091|NCT06239337|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra in stools and urine|All children with presumptive TB had at least 1 sample collected of respiratory or extrapulmonary specimen (considered as gold standard) and 1 sample of stools and 1 sample of urine. All of them were analyzed with Xpert MTB/RIF Ultra.
219331092|NCT06398899|DRUG|Group S: sugammadex injection|Reversal agent: sugammadex
219331093|NCT06398899|DRUG|Group N: neostigmine/glycopyrrolate|Reversal agent: glycopyrrolate and neostigmine
219331094|NCT02809131|DRUG|polymixin/bacitracin|Antibacterial irrigation
219331095|NCT02809131|DRUG|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
219331096|NCT02809131|DRUG|Saline|Saline irrigation
219331097|NCT02438891|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
219331098|NCT01456650|DRUG|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
219331099|NCT02244320|DRUG|Tamsulosin|
219331100|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
219331101|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
219331102|NCT03585985|PROCEDURE|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
219331103|NCT03585985|PROCEDURE|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
219331104|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
219331105|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
219331106|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
219331107|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
219331108|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
219331109|NCT00188565|DRUG|Celecoxib|
219331110|NCT00774865|PROCEDURE|MIBI and CTA|Rest and Stress MIBI and CT Angiography
219331111|NCT02088814|BEHAVIORAL|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
219331112|NCT06455592|BEHAVIORAL|practice adapted physical activity|practice daily adapted physical activity during 4 days
219331113|NCT06455592|OTHER|control arm|practice once adapted physical activity during 4 days
219331114|NCT05841030|OTHER|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
219331115|NCT00689702|DRUG|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
219331116|NCT03073668|PROCEDURE|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
219331117|NCT03073668|DRUG|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
219331118|NCT04601623|OTHER|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
219331119|NCT04244526|OTHER|Talking a urine sample|Just taking a urine sample
219331120|NCT02617186|PROCEDURE|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
219331121|NCT02617186|PROCEDURE|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
219331122|NCT02177396|DRUG|Telmisartan|
219331123|NCT02177396|DRUG|Valsartan|
219331124|NCT02177396|DRUG|Placebo|
219331125|NCT06584942|DRUG|Suvorexant|Subjects will titrate up to 20 mg of suvorexant daily. Subjects will follow a titration schedule with 10 mg once daily on days 1-3, 15 mg once daily on days 4-6, then 20 mg on day seven and for the remainder of the study. If participants report AEs (worsening depression/suicidal ideation, complex sleep behaviors, sleep paralysis, etc.) dose may be decreased to the previous dose taken. Participants will be treated for 14 days in total; however, due to scanner availability, the second scan may occur more than 14 days after the first scan. In this case, participants will be allowed to continue taking this dose for up to 14 additional days until the final scan occurs (28 days total).
219331126|NCT00036439|DRUG|Infliximab|
219331127|NCT03794583|DRUG|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
219331128|NCT04457180|DRUG|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
219331129|NCT04457180|DRUG|Repaglinide|Repaglinide will be administered daily on D1 and D12
219331130|NCT04457180|DRUG|Bupropion|Bupropion will be administered daily on D2 and D13
219331131|NCT01440868|PROCEDURE|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
219331132|NCT05342662|DEVICE|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
219331133|NCT05342662|DEVICE|Glasses with clear lenses|Non-blue light-blocking glasses
219331134|NCT05568108|PROCEDURE|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
219331135|NCT05568108|PROCEDURE|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
219331136|NCT03936621|DRUG|Omega 3 fatty acid|To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
219331137|NCT00003895|BIOLOGICAL|HPV 16 E7:12-20|Given SC
219331138|NCT00003895|BIOLOGICAL|gp100:209-217(210M)|Given SC
219331139|NCT00003895|OTHER|laboratory biomarker analysis|Correlative studies
219331140|NCT03182647|PROCEDURE|Surgically treatment of the ACL|Surgical initial ACL treatment
219331141|NCT03182647|OTHER|Non surgical initial ACL treatment|Non surgical initial ACL treatment
219331142|NCT00415857|BIOLOGICAL|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
219331143|NCT00415857|DRUG|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
219331144|NCT00415857|DRUG|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
219331145|NCT00415857|DRUG|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
219331146|NCT06132165|DRUG|Deoxycholic Acid|Injection into the cutaneous Neurofibromas lesion.
219331147|NCT06132165|DRUG|Polidocanol|Injection into the cutaneous Neurofibromas lesion.
219331148|NCT06132165|DEVICE|1064nm Nd:YAG laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.
219331149|NCT06132165|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
219331150|NCT04897022|DRUG|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
219331151|NCT04897022|RADIATION|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
219331152|NCT00806195|BIOLOGICAL|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
219331153|NCT00806195|BIOLOGICAL|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
219331154|NCT00806195|BIOLOGICAL|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
219331155|NCT00806195|BIOLOGICAL|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
219331156|NCT00806195|BIOLOGICAL|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
219331157|NCT00806195|BIOLOGICAL|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
219331158|NCT00806195|BIOLOGICAL|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
219331159|NCT00806195|BIOLOGICAL|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
219331160|NCT04192851|PROCEDURE|Tent Pole Technique|"* All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material"
219331161|NCT02490475|DRUG|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
219331162|NCT02490475|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
219355417|NCT00281879|DRUG|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
219331163|NCT02075489|OTHER|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
219331164|NCT02075489|OTHER|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
219331165|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
219331166|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
219331167|NCT05316532|DEVICE|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
219331168|NCT02953353|DEVICE|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
219331169|NCT02953353|OTHER|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
219331170|NCT02953353|OTHER|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
219331171|NCT02994277|DEVICE|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
219331172|NCT06228820|DRUG|Aspirin 81Mg Ec Tab|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
219331173|NCT03761381|DEVICE|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
219331174|NCT03761381|DEVICE|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
219331175|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
219331176|NCT02825004|BEHAVIORAL|Psychological Intervention|
219331177|NCT04024150|BIOLOGICAL|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
219331178|NCT01288222|OTHER|KIR genotype|KIR genotype data from unrelated donor are collected
219331179|NCT03399981|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
219331180|NCT04697810|DRUG|Namodenoson|25 mg q12hours x 36 weeks
219331181|NCT04697810|DRUG|Placebo|Matching capsules q12hours x 36 weeks
219331182|NCT04375579|OTHER|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
219331183|NCT00674583|BIOLOGICAL|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
219331184|NCT00674583|BIOLOGICAL|Menjugate|Intramuscular administration, 1 dose
219331185|NCT05563519|PROCEDURE|I-PRF with collagen|The products will be applied to the sockets after tooth extractions
219331186|NCT05563519|PROCEDURE|L-PRF|The products will be applied to the sockets after tooth extractions
219331187|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
219331188|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
219331189|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
219355418|NCT00281879|DRUG|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
219355419|NCT00281879|DRUG|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
219331190|NCT04912245|BEHAVIORAL|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
219331191|NCT05784636|DEVICE|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
219331192|NCT05784636|DEVICE|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
219331193|NCT02751593|DRUG|Dexamethasone|dexamethasone 40mg/d for 4 days
219331194|NCT04675164|DEVICE|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
219331195|NCT04675164|PROCEDURE|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
219331196|NCT01369420|DEVICE|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
219331197|NCT06540976|BEHAVIORAL|Cognitive testing|Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
219331198|NCT01150175|PROCEDURE|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
219331199|NCT01150175|PROCEDURE|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
219331200|NCT04186975|DEVICE|Non-Invasive fetal ECG|Non-Invasive fetal ECG
219331201|NCT04186975|DEVICE|Fetal heart rate monitor|Fetal heart rate monitor
219331202|NCT04227314|DRUG|Apremilast|Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
219331203|NCT04227314|DRUG|Placebo oral tablet|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
219331204|NCT06506812|BIOLOGICAL|High-Dose Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
219331205|NCT06506812|BIOLOGICAL|Standard-Dose Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the governmental influenza vaccine programs may be used.
219331206|NCT05198726|DEVICE|alpha tACS|2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
219355420|NCT00281879|DRUG|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
219331207|NCT05198726|BEHAVIORAL|Speed of Processing Training|SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
219331208|NCT02510092|DEVICE|Percutaneous coronary intervention with new generation fully resorbable scaffold|
219331209|NCT01472770|DRUG|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
219331210|NCT03520543|DRUG|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of \[11C\]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of \[11C\]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of \[11C\]Yohimbine.
219331211|NCT03520543|DRUG|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following \[11C\]Yohimbine PET scan (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after \[11C\]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of \[11C\]Yohimbine (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of \[11C\]Yohimbine obtained at baseline (part A)."
219331212|NCT02240979|DEVICE|cardiac MRI|cardiac MRI
219355421|NCT00281879|DRUG|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
219355422|NCT00281879|DRUG|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
219331213|NCT01512836|BEHAVIORAL|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching"
219331214|NCT05150600|PROCEDURE|Inverse Ratio Ventilation|The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
219331215|NCT02910947|PROCEDURE|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
219331216|NCT06324006|DRUG|LIB-01|LIB-01 oral suspension
219331217|NCT06324006|OTHER|Placebo|Placebo oral suspension
219331218|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
219331219|NCT01119742|DRUG|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
219331220|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
219331221|NCT01119742|DRUG|Vehicle A|Twice daily application for 7 days
219331222|NCT01119742|DRUG|Vehicle B|Twice daily application for 7 days
219331223|NCT06537440|OTHER|Electroacupuncture|Electroacupuncture TE6 Zhigou (double), ST36 Zusanli (double), ST25 Tianshu (double), CV12 Zhongwan
219331224|NCT01134614|BIOLOGICAL|Ipilimumab|Given IV
219331225|NCT01134614|BIOLOGICAL|Sargramostim|Given SC
219331226|NCT00428909|DRUG|Imatinib/Acetaminophen|
219331227|NCT06577025|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
219331228|NCT06577025|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219355423|NCT00281879|DRUG|methotrexate|Administered on days +1, +3, and +7.
219331229|NCT06577025|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
219331230|NCT06577025|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
219331231|NCT06577025|DRUG|Bortezomib|Bortezomib will be administered subcutaneously as a part of induction.
219331232|NCT06577025|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of induction.
219331233|NCT06577025|DRUG|Dexamethasone|Dexamethasone will be administered orally as a part of induction.
219331234|NCT06577025|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
219331235|NCT06577025|DRUG|Fludarabine|Fludarabine will be administered intravenously as a part of conditioning regimen.
219331236|NCT02752035|DRUG|gilteritinib|Tablet, oral
219331237|NCT02752035|DRUG|azacitidine|Subcutaneous injection or intravenous infusion
219331238|NCT06116786|DRUG|JNJ-86974680|JNJ-86974680 will be administered.
219331239|NCT06116786|DRUG|Cetrelimab|Cetrelimab will be administered.
219331240|NCT06116786|RADIATION|Radiation Therapy|Radiation therapy will be administered.
219331241|NCT02275585|OTHER|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
219331242|NCT06425484|OTHER|Bilateral US TAP block|epidural plus bilateral US guided TAP block
219331243|NCT04289480|DEVICE|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
219331244|NCT03869281|PROCEDURE|Pancreas transplantation alone|Pancreas transplantation
219331245|NCT00357214|DIETARY_SUPPLEMENT|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
219331246|NCT00357214|DIETARY_SUPPLEMENT|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
219331247|NCT00357214|DIETARY_SUPPLEMENT|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
219331248|NCT00357214|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
219331249|NCT06461767|DEVICE|transcranial magnetic stimulation device|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30"
219331250|NCT06820853|DEVICE|Diaphragmatic excursion evaluation|They will receive 10 ml of 0.5% bupivacaine over 10 minutes
219331251|NCT00657865|DRUG|ramipril|oral intake
219331252|NCT00657865|DRUG|placebo|placebo
219331253|NCT06182150|BEHAVIORAL|Moderate-Intensity Indoor Cycling Exercise|The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
219331254|NCT00544050|DRUG|Levetiracetam|
219331255|NCT01009827|OTHER|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
219331256|NCT04062019|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
219331257|NCT06465251|DEVICE|Home-based CIMT|Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.
219331258|NCT06465251|DEVICE|Clinic-based CIMT|Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour. Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day
219331259|NCT06465251|DEVICE|Control|Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
219331260|NCT05788887|OTHER|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
219331261|NCT05788887|OTHER|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
219355424|NCT00281879|DRUG|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
219355425|NCT00281879|DRUG|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
219331262|NCT05606250|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
219331263|NCT00955812|DRUG|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
219331264|NCT02509182|DRUG|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
219331265|NCT02509182|DRUG|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
219331266|NCT05919654|DEVICE|MyoCare|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
219331267|NCT05919654|DEVICE|ClearView|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
219331268|NCT00897806|GENETIC|Microarray analysis|
219331269|NCT00897806|OTHER|Laboratory biomarker analysis|
219331270|NCT03175354|DRUG|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
219331271|NCT03175354|DRUG|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
219331272|NCT03801954|BEHAVIORAL|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
219331273|NCT02472041|DEVICE|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
219331274|NCT02472041|DEVICE|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
219331275|NCT01186120|DEVICE|Biolimus A9-eluting stent|drug-eluting stent
219331276|NCT01186120|DEVICE|Everolimus-eluting stent|drug-eluting stent
219331277|NCT04701385|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
219331278|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 200 mg"|"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
219331279|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 400 mg"|Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
219331280|NCT00587002|PROCEDURE|IVUS|Intravascular ultrasound with virtual histology
219331281|NCT01429818|DRUG|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
219331282|NCT01429818|DRUG|Metformin|1000 mg tablets once daily for eight weeks
219331283|NCT01368536|DRUG|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
219331284|NCT01368536|DRUG|Amlodipine|Amlodipine 5 mg and 10 mg capsule
219331285|NCT01368536|DRUG|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
219331286|NCT01368536|DRUG|Placebo of Valturna Tablet|Matching placebo of valturna tablet
219331287|NCT01368536|DRUG|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
219331288|NCT03804736|BIOLOGICAL|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
219331289|NCT03804736|BIOLOGICAL|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
219331290|NCT03010969|PROCEDURE|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
219331291|NCT00139282|DRUG|Squalamine Lactate|
219355426|NCT00281879|DRUG|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
219331292|NCT06372938|DIAGNOSTIC_TEST|Ultrasound measurement|The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).
219331293|NCT06372938|DIAGNOSTIC_TEST|Laboratory Tests and Inflammatory Markers|"The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL)."
219331294|NCT03802279|OTHER|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
219331295|NCT03802279|OTHER|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
219331296|NCT05260905|BEHAVIORAL|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
219331297|NCT02436564|GENETIC|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
219331298|NCT01553175|GENETIC|DNA analysis|
219331299|NCT01553175|GENETIC|gene expression analysis|
219331300|NCT01553175|GENETIC|mutation analysis|
219331301|NCT01553175|GENETIC|protein expression analysis|
219331302|NCT01553175|OTHER|immunohistochemistry staining method|
219331303|NCT01553175|OTHER|laboratory biomarker analysis|
219331304|NCT06245876|OTHER|Blood collection|Blood collection
219331305|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
219331306|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
219331307|NCT00659399|DRUG|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
219331308|NCT03861936|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
219331309|NCT03861936|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
219331310|NCT00359021|DRUG|TMC125|200 mg twice daily until commercially available
219331311|NCT04530903|DRUG|Clonidine|75 µg (0.5mL) per injection site
219331312|NCT04530903|DRUG|Levobupivacaine|0.25% (10 ml) per injection site
219331313|NCT04530903|DRUG|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
219331314|NCT05863975|DRUG|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
219331315|NCT00698724|DRUG|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
219331316|NCT00698724|DRUG|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
219331317|NCT00587548|OTHER|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
219331318|NCT01442194|DRUG|other disease-modifying therapy|
219331319|NCT01442194|DRUG|Fingolimod|
219331320|NCT01247636|OTHER|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
219331321|NCT01247636|OTHER|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
219331322|NCT03941678|DIETARY_SUPPLEMENT|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
219331323|NCT03941678|DIETARY_SUPPLEMENT|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
219331324|NCT04654442|DIAGNOSTIC_TEST|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
219355427|NCT00281879|PROCEDURE|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
219355428|NCT00281879|PROCEDURE|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
219355429|NCT00281879|RADIATION|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
219355430|NCT02228863|OTHER|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
219331325|NCT01534104|PROCEDURE|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI \& DSI, neurological/physical testing \& brain MRI showing tumor \&/or edema located in or near (\<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), \&/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately \<48 hours before surgery\*) fMRI to localize gray matter DTI, DSI \& tractography to localize white matter, DSI \& updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray \&/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (\<48 hours after surgery)
219331326|NCT05322928|BEHAVIORAL|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
219331327|NCT03280654|OTHER|overactive bladder|Association between groups and over active bladder symptoms
219331328|NCT06153875|OTHER|Sensory Thresold, Burst High Frecuency|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 5 trains of 5 seconds, 55 seconds apart, at a frequency of 100Hz, making 5 minutes of total treatment. The intensity will be set 200 microamperes (μA) above the detection threshold for each patient, guaranteeing a sensitive but not painful perception.
219331329|NCT06153875|OTHER|Theta-Burst Stimulation|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 40 trains separated by 7 seconds from each other, where each train contains 5 trains separated by 200ms, at a frequency of 5Hz, resulting in 6 minutes and 45 seconds of total treatment. The intensity will be set at the motor threshold of the patient, ensuring a non-painful stimulation.
219331330|NCT06153875|OTHER|Transcutaneous Electrical Nerve Stimulation|The transcutaneous electrical nerve stimulation will be applied on the trapezius or low back and internal calf muscles at a frequency of 80Hz and a pulse width of 250 microseconds, for 15 minutes. The intensity will be set at the detection threshold of each patient generating a sensitive but non-painful perception.
219331331|NCT01236573|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
219331332|NCT01236573|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
219331333|NCT01236573|BIOLOGICAL|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
219331334|NCT00330876|DRUG|Pitavastatin|
219331335|NCT01232543|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
219331336|NCT04578860|OTHER|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
219331337|NCT04578860|OTHER|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
219331338|NCT04578860|OTHER|Treatment as usual for sleep disorders|No intervention
219331339|NCT03496220|DEVICE|Angulus|Feedback on patient recumbency
219331340|NCT01846728|DRUG|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
219331341|NCT02614365|BEHAVIORAL|Aerobic exercise|Cardiovascular fitness
219331342|NCT02614365|BEHAVIORAL|Stretch exercise|Muscle stretch
219331343|NCT02700152|DEVICE|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
219331344|NCT02161575|DRUG|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
219331345|NCT00374686|DRUG|Valganciclovir|
219331346|NCT03735927|OTHER|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
219331347|NCT05281133|OTHER|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
219331348|NCT02150148|BEHAVIORAL|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
219331349|NCT02909075|DEVICE|PET/CT scans|
219331350|NCT02909075|DEVICE|MRI|
219331351|NCT05753072|OTHER|Carer Support Nurse|Specialist community nursing role to support unpaid family/carers with complex health-related support needs or unresolved health-related support needs that cannot be met by their usual health care team
219331352|NCT00066768|DRUG|suramin|Given IV
219331353|NCT00066768|DRUG|docetaxel|Given IV
219331354|NCT00066768|DRUG|gemcitabine hydrochloride|Given IV
219331355|NCT00066768|OTHER|laboratory biomarker analysis|Correlative studies
219331356|NCT00066768|OTHER|pharmacological study|Correlative studies
219331357|NCT01659242|DRUG|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
219331358|NCT01659242|DRUG|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
219331359|NCT05240911|DRUG|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
219331360|NCT01835015|DRUG|CLG561|Administered by intravitreal injection, Day 1
219331361|NCT02330887|OTHER|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
219331362|NCT02330887|OTHER|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
219331363|NCT02242084|DRUG|Intravenuse Alteplase|
219331364|NCT01667770|PROCEDURE|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
219331365|NCT01257815|DRUG|Ranibizumab|
219331366|NCT06387511|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax|"1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm.~2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions.~3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward.~4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth.~5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first.~6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program."
219331367|NCT06387511|BEHAVIORAL|Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices|"1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages."
219331368|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler|
219331369|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
219331370|NCT03060044|DRUG|Seretide Diskus|
219331371|NCT03060044|DRUG|Seretide Diskus with charcoal|
219331372|NCT04107415|OTHER|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
219331373|NCT03753646|OTHER|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
219331374|NCT01879995|PROCEDURE||
219331375|NCT00938808|DIETARY_SUPPLEMENT|day formula diet|The Cambridge Programme. Formula diet
219331376|NCT02446314|DIETARY_SUPPLEMENT|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
219331377|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
219331378|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
219331379|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
219331380|NCT00182312|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
219331381|NCT04670185|BEHAVIORAL|BIP SAMBA|Behavioral parent management training
219331382|NCT01610180|DRUG|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
219331383|NCT02036242|DRUG|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
219331384|NCT02036242|DRUG|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
219331385|NCT02036242|DRUG|Ropivacaine|
219331386|NCT06850077|BEHAVIORAL|Cognitive-Balance dual task|"The cognitive-balance dual task consists of three levels of difficulty and is performed simultaneously.~The cognitive tasks include the N-back test, while the balance tasks consist of static balance tasks."
219331387|NCT04117776|OTHER|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
219331388|NCT04117776|OTHER|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
219331389|NCT04109222|BIOLOGICAL|Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219331390|NCT04109222|BIOLOGICAL|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219331391|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
219331392|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
219355431|NCT02228863|OTHER|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
219355432|NCT02228863|OTHER|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
219355433|NCT02228863|OTHER|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
219331393|NCT04785768|DRUG|Morphine Sulfate Sustained-release Tablets|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;"
219331394|NCT06067971|DEVICE|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
219331395|NCT03738969|PROCEDURE|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
219331396|NCT03738969|PROCEDURE|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
219331397|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.
219331398|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.
219331399|NCT02676856|DRUG|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
219331400|NCT02676856|DRUG|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
219331401|NCT04637698|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
219331402|NCT01410435|DRUG|Monofer|Infusion according to current HB level
219331403|NCT02442726|DEVICE|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
219331404|NCT01187849|DRUG|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
219331405|NCT01187849|DRUG|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
219331406|NCT00034190|DRUG|S-8184 Paclitaxel Injectable Emulsion|
219331407|NCT04569032|DRUG|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
219331408|NCT04569032|DRUG|cyclophosphamide|750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
219331409|NCT04569032|DRUG|doxorubicin|50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
219331410|NCT04569032|DRUG|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
219331411|NCT00588536|DRUG|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
219331412|NCT00588536|DRUG|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
219331413|NCT00588536|DRUG|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
219331414|NCT00701090|DRUG|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
219331415|NCT00701090|DRUG|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
219331416|NCT00701090|DRUG|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
219331417|NCT06321926|DEVICE|ActiveWaiting App|"The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field."
219331418|NCT03899363|PROCEDURE|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
219331419|NCT03056560|BEHAVIORAL|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
219331420|NCT05970497|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
219331421|NCT05970497|DRUG|Opdualag|Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
219331422|NCT05970497|DRUG|KEYTRUDA ®( Pembrolizumab)|Immunotherapy (PD-1 immune checkpoint inhibitor)
219331423|NCT00324753|BEHAVIORAL|Communication|Communication sheet
219331424|NCT00324753|BEHAVIORAL|Standard of care|Standard of care brochures
219331425|NCT03090087|BIOLOGICAL|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
219331426|NCT03090087|DRUG|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
219331427|NCT05923021|OTHER|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
219331428|NCT04450667|DIETARY_SUPPLEMENT|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
219331429|NCT01085786|DRUG|14-day sequential treatment|"* 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
219331430|NCT01085786|DRUG|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
219331431|NCT03633526|DRUG|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
219331432|NCT03633526|DRUG|IVA|IVA mono tablet.
219331433|NCT02147366|BEHAVIORAL|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
219331434|NCT02147366|BEHAVIORAL|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
219331435|NCT00105144|DRUG|Micafungin|IV
219331436|NCT00105144|DRUG|Caspofungin|IV
219331437|NCT03320928|OTHER|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
219331438|NCT03856853|DRUG|Pirfenidone|pirfenidone for SSc-ILD treatment
219331439|NCT03856853|OTHER|placebo|as control
219331440|NCT02201420|DRUG|Tc 99m tilmanocept|
219331441|NCT00001096|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
219331442|NCT00001096|BIOLOGICAL|QS-21|
219331443|NCT00001096|BIOLOGICAL|rgp120/HIV-1MN|
219331444|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
219331445|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
219331446|NCT04935398|OTHER|Physiotherapy|The aim is to test two treatment techniques against each other to see how effective they are.
219331447|NCT00227292|DRUG|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
219331448|NCT00227292|DRUG|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
219331449|NCT05728931|BIOLOGICAL|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
219331450|NCT06091085|DRUG|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
219331451|NCT06091085|DRUG|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
219331452|NCT01214694|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
219331453|NCT01214694|BEHAVIORAL|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
219331454|NCT01214694|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
219331455|NCT02831192|BIOLOGICAL|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
219331456|NCT04497896|OTHER|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
219331457|NCT04534491|DRUG|Oxybutynin (Oxytrol, BAY839380)|Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
219331458|NCT03366675|DRUG|AZD2811|AZD2811 100mg/vial
219331459|NCT05501938|PROCEDURE|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
219331460|NCT03708549|DRUG|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
219331461|NCT03708549|DRUG|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
219331462|NCT01219049|DRUG|Tyrosine|1000 mg / day
219331463|NCT01219049|DRUG|Tyrosine|2000 mg / day
219331464|NCT01219049|DRUG|Placebo|Placebo daily
219331465|NCT03936283|BEHAVIORAL|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
219331466|NCT02355899|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
219331467|NCT06432829|BEHAVIORAL|Unified Protocol for the transdiagnostic treatment of emotional disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
219331468|NCT05040802|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
219331469|NCT04785170|DRUG|Amino Acid|"A novel non-protein amino acid secreted by skeletal muscles which aids the cross-talk between skeletal muscles, liver, and adipose tissue at molecular levels. amino acid is generated by catabolism of the branched-chain amino acid valine. Existing literature states, amino acid induces body fat loss by increasing energy expenditure, stimulating free fatty acid (FFA) oxidation in the liver and skeletal muscle cell, and by enhancing oxygen consumption by adipose tissue and hepatocytes. It was observed that amino acid stimulated differentiation of energy storing white adipose tissue preadipocytes to an energy burning beige (brown to white) phenotype."
219331470|NCT05837442|OTHER|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
219331471|NCT05063721|BIOLOGICAL|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
219331472|NCT02197338|OTHER|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
219331473|NCT03920189|DIAGNOSTIC_TEST|echocariographic ultrasound|left ventricular diastolic function description
219331474|NCT02162524|BEHAVIORAL|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
219331475|NCT02851381|DRUG|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~* Dose: 35 mg/kg~* Route: IV over one hour following completion of gemcitabine infusion~* Schedule:~  * Days 1, 8, and 15~ * Please note that Day 8 infusion will on be completed during the first treatment cycle"
219331476|NCT04637607|OTHER|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
219331477|NCT04383873|DEVICE|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
219331478|NCT04383873|OTHER|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
219331479|NCT04383873|OTHER|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
219331480|NCT03863600|BEHAVIORAL|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
219331481|NCT01314963|DEVICE|Prototype intraoperative handheld gamma camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
219331482|NCT01314963|DEVICE|Lymphoscintigraphy with intraoperative gamma probes (GP)|Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
219331483|NCT01314963|RADIATION|radioactive Tc99M|Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
219331484|NCT04898920|DRUG|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
219331485|NCT04898920|DRUG|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
219331486|NCT01147328|OTHER|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
219331487|NCT00113074|DRUG|Nicotine Replacement Therapy|Nicotine replacement therapy program
219331488|NCT00113074|BEHAVIORAL|Diet|Diet program
219331489|NCT05377268|PROCEDURE|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy
219331490|NCT03705637|DRUG|Exparel|"* Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
219331491|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
219331492|NCT02114268|DRUG|Placebo|Participants received placebo on Day 1.
219331493|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
219331494|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
219331495|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
219331496|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
219331497|NCT02741804|DIETARY_SUPPLEMENT|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
219331498|NCT02741804|OTHER|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
219331499|NCT02741804|DIETARY_SUPPLEMENT|Brain Health Placebo|Treatment with placebo consisting of soybean oil
219331500|NCT04981314|DRUG|Equinacea Arkopharma|Echinacea hard caplets
219331501|NCT04981314|OTHER|Placebo|Placebo hard caplets
219331502|NCT03988231|DRUG|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
219331503|NCT03988231|DRUG|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
219331504|NCT03875209|BIOLOGICAL|10E8.4/iMab|bispecific monoclonal antibody
219331505|NCT01737385|PROCEDURE|Measurement with O2C|Measurement of microcirculation using O2C light probes.
219331506|NCT01997736|DEVICE|Ablation|
219331507|NCT03962738|DRUG|Lasmiditan|Administered orally
219331508|NCT03962738|DRUG|Placebo|Administered orally
219331509|NCT03764891|PROCEDURE|Uphold|Uphold system in treating women with cystocele
219331510|NCT03764891|PROCEDURE|Perigee|Perigee system in treating women with cystocele
219331511|NCT05541822|DRUG|Vabametkib|"Tablets~Route of Administration: Oral"
219331512|NCT05541822|DRUG|Lazertinib|"Tablets~Route of Administration: Oral"
219331513|NCT05348148|DRUG|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
219331514|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
219331515|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
219331516|NCT00509067|DRUG|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
219331517|NCT00509067|DRUG|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
219331518|NCT00509067|DRUG|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
219331519|NCT00509067|DRUG|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
219331520|NCT00016380|DRUG|dexamethasone|
219331521|NCT00016380|DRUG|ondansetron|
219331522|NCT00016380|PROCEDURE|quality-of-life assessment|
219331523|NCT02520323|OTHER|Blood draw|
219331524|NCT02520323|PROCEDURE|Bronchoscopy|
219331525|NCT02520323|BEHAVIORAL|Questionnaires|
219331526|NCT00131469|DRUG|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
219331527|NCT00131469|DRUG|Placebos|
219331528|NCT02094963|DRUG|Ticagrelor|180mg loading and 90mg bid
219331529|NCT02094963|DRUG|Clopidogrel|600mg loading and 75mg qd
219331530|NCT02577614|DRUG|FEIBA|Administration of FEIBA after cardiopulmonary bypass
219331531|NCT02577614|DRUG|Normal Saline|Administration of placebo after cardiopulmonary bypass
219331532|NCT01479179|DRUG|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
219331533|NCT01479179|DRUG|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
219331534|NCT04087278|DIETARY_SUPPLEMENT|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
219331535|NCT04087278|DIETARY_SUPPLEMENT|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
219331536|NCT02923089|OTHER|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331537|NCT02923089|OTHER|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331538|NCT02923089|OTHER|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331539|NCT02923089|OTHER|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331540|NCT02923089|OTHER|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331541|NCT02923089|OTHER|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331542|NCT02923089|OTHER|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331543|NCT02923089|OTHER|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331544|NCT02923089|OTHER|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
219331545|NCT05489835|BEHAVIORAL|Nutritional counseling|Nutritional counseling
219331546|NCT03255707|DEVICE|eye patch|Occluding the better seeing eye for a given number of hours daily
219331547|NCT03255707|DEVICE|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
219331548|NCT06288945|OTHER|Educational Program|The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
219331549|NCT00204971|DIETARY_SUPPLEMENT|Enteral glutamine powder|nutritional supplement
219331550|NCT00204971|OTHER|placebo|placebo control
219331551|NCT02695433|DIETARY_SUPPLEMENT|Active|Active Treatment Diet Plan
219331552|NCT02695433|DIETARY_SUPPLEMENT|Control|Control Diet Plan
219331553|NCT02575768|OTHER|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
219331554|NCT00152555|BEHAVIORAL|Physical Therapy or Relaxation Therapy|
219331555|NCT05731570|BEHAVIORAL|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
219331556|NCT06097117|DIAGNOSTIC_TEST|MultiplexPCR|PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.
219331557|NCT02261779|DRUG|Tranylcypromine|
219331558|NCT02261779|DRUG|Tretinoin|
219331559|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
219331560|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
219331561|NCT00807326|DRUG|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
219331562|NCT06115941|DEVICE|Pre-Op Incentive Spirometer|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
219331563|NCT01365585|DRUG|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
219331564|NCT01419782|OTHER|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
219331565|NCT03202784|DRUG|BCX7353|BCX7353
219331566|NCT00750971|PROCEDURE|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
219331567|NCT01507779|BIOLOGICAL|IVACFLU|IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
219331568|NCT01507779|OTHER|Placebo|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
219331569|NCT04621396|OTHER|Observational screening study|
219331570|NCT04810182|DRUG|Regorafenib 40 MG Oral Tablet [STIVARGA]|As per the treating physicians discretion
219331571|NCT04053647|OTHER|Non-interventional study|Non-interventional study
219331572|NCT03654976|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
219331573|NCT03654976|OTHER|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
219331574|NCT02782520|DRUG|Ringer Lactate (10ml/kg) fluid expansion|
219331575|NCT02782520|DRUG|Hypertonic saline (3ml/kg) fluid expansion|
219331576|NCT00771134|DRUG|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
219331577|NCT00771134|DRUG|Placebo|B.I.D. for 8 weeks
219331578|NCT00771134|DRUG|Quetiapine|300mg/day for 8 weeks
219331579|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
219331580|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
219331581|NCT00117598|DRUG|Investigator's choice|"Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
219331582|NCT04451577|OTHER|No intervention|No intervention, analysis of biological samples
219331583|NCT05095870|OTHER|No intervention|Pure observational study
219331584|NCT01616420|OTHER|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
219331585|NCT02198703|DIETARY_SUPPLEMENT|Probiotics bacterial strains|
219331586|NCT02198703|DIETARY_SUPPLEMENT|Placebo|
219331587|NCT00595322|OTHER|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
219331588|NCT03853681|DIAGNOSTIC_TEST|additional blood sampling|additional blood sampling
219331589|NCT03648775|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
219331590|NCT00236925|DRUG|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
219331591|NCT00236925|DRUG|Placebo|Placebo
219331592|NCT02887287|DRUG|EEN|
219331593|NCT03098836|DRUG|ARN-509|240 mg orally daily
219331594|NCT03098836|DRUG|Abiraterone Acetate|1000 mg orally daily
219331595|NCT03098836|DRUG|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
219331596|NCT01775735|DEVICE|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
219331597|NCT00617500|OTHER|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
219331598|NCT00617500|OTHER|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
219331599|NCT00617500|OTHER|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
219331600|NCT00617500|DRUG|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
219331601|NCT03521375|PROCEDURE|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
219331602|NCT03521375|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
219331603|NCT01053390|DRUG|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
219331604|NCT01053390|DRUG|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
219331605|NCT04688775|DRUG|Eptinezumab|Eptinezumab - concentrate for solution for infusion, intravenously
219331606|NCT04688775|DRUG|Placebo|Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
219331607|NCT05573659|OTHER|time of cutaneous recoloration|In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
219331608|NCT05573659|OTHER|video assisted cutaneous recoloration|"Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second."
219331609|NCT05159154|DEVICE|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
219331610|NCT03156127|DRUG|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
219331611|NCT05198479|RADIATION|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
219331612|NCT00433342|DRUG|Flucloxacillin|500 mg QD oral
219331613|NCT02483624|DRUG|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
219331614|NCT02483624|DRUG|Placebo|Placebo
219331615|NCT02017639|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
219331616|NCT02017639|DRUG|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
219331617|NCT04824781|OTHER|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
219331618|NCT03724734|DEVICE|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
219331619|NCT03724734|DEVICE|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
219331620|NCT00002860|PROCEDURE|Surgery|Complete surgical resection of metastatic melanoma
219331621|NCT01770912|DRUG|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
219331622|NCT01770912|DRUG|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
219331623|NCT03644654|PROCEDURE|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
219331624|NCT03644654|PROCEDURE|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
219331625|NCT00581685|DRUG|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
219331626|NCT00391664|BEHAVIORAL|Psychosocial|
219331627|NCT01918423|BEHAVIORAL|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
219331628|NCT01864772|DRUG|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
219331629|NCT01193881|DRUG|Erlotinib Hydrochloride|Given PO
219331630|NCT01193881|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
219331631|NCT01193881|OTHER|Laboratory Biomarker Analysis|Correlative studies
219331632|NCT01193881|OTHER|Pharmacological Study|Correlative studies
219331633|NCT03378323|DRUG|Multiple injection local anesthetic|Multiple injection local anesthetic
219331634|NCT03378323|DRUG|Single injection local anesthetic|Single injection local anesthetic
219331635|NCT05259579|PROCEDURE|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
219331636|NCT00615472|DRUG|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
219331637|NCT00615472|DRUG|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
219331638|NCT00615472|DRUG|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
219331639|NCT03128476|DIETARY_SUPPLEMENT|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
219331640|NCT03128476|DIETARY_SUPPLEMENT|Placebo (Energy matched)|
219331641|NCT06292572|PROCEDURE|Retinal Detachment Surgery|Retinal Detachment Surgery that consists in either Pars Plana Vitrectomy or Scleral Buckling or a combination of both techniques, and with or without use of intraocular tamponade
219331642|NCT04261504|BEHAVIORAL|IBMT|mindful presence in a non-judgmental way
219331643|NCT04261504|BEHAVIORAL|RT|progressive muscle relaxation
219331644|NCT05149703|OTHER|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
219331645|NCT03765242|OTHER|Non-Interventional|Non-Interventional
219331646|NCT06098898|DRUG|NK510|NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.
219331647|NCT06098898|DRUG|Tislelizumab，atezolizumab or Trastuzumab|Administer according to the instructions.
219331648|NCT04426604|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
219331649|NCT04426604|DIAGNOSTIC_TEST|Laser-induced fluorescence device|Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
219331650|NCT04426604|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
219331651|NCT05218590|DEVICE|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
219331652|NCT05392504|OTHER|Core stability exercise|The core stability training consist of three phases
219331653|NCT05392504|OTHER|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
219331654|NCT01817751|DRUG|sorafenib tosylate|Given by mouth
219331655|NCT01817751|DRUG|valproic acid|Given by mouth
219331656|NCT01817751|DRUG|sildenafil citrate|Given by mouth
219331657|NCT02946593|BEHAVIORAL|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
219331658|NCT02946593|BEHAVIORAL|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
219331659|NCT02193048|OTHER|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
219331660|NCT03617250|OTHER|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
219331661|NCT02849197|PROCEDURE|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
219331662|NCT00382018|DRUG|chemotherapy|No administration details available
219331663|NCT01852682|DRUG|PA21|
219331664|NCT03898492|OTHER|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
219331665|NCT02073071|OTHER|Preterm infant formula per standard of care|Commercially available preterm infant formula
219331666|NCT03752008|BEHAVIORAL|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
219331667|NCT03752008|BEHAVIORAL|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
219331668|NCT06272786|PROCEDURE|conventional physiotherapy program.|It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.
219331669|NCT06272786|PROCEDURE|Suprascapular nerve block|Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
219331670|NCT02611804|DRUG|Diclofenac sodium|
219331671|NCT02611804|DRUG|Diclofenac sodium|
219331672|NCT02611804|DRUG|Placebo|
219331673|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
219331674|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
219331675|NCT01537536|DRUG|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
219331676|NCT06270342|OTHER|dual task assessment|The Minnesota Manual Dexterity Test was used to evaluate the upper extremity function of the participants in single and dual task conditions, and the Dual Task Questionnaire was used to evaluate the difficulties experienced during dual tasks. In the dual-task turning test, in addition to the single-task turning test, they were given a cognitive task, the task of counting the months of the year backwards from December to January. The dual-task turning test was continued by changing hands at the end of each turn until the last disk was turned. Meanwhile, verbal fluency and hand errors made while spinning the disc were recorded.
219331677|NCT00789880|DRUG|Vitamin D3|Administration of oral vitamin D3 at 4000IU
219331678|NCT00789880|DRUG|Placebo|Administration of oral Vitamin D3 placebo
219331679|NCT00217243|OTHER|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
219331680|NCT00003111|DRUG|carboplatin|
219331681|NCT00003111|DRUG|cisplatin|
219331682|NCT00003111|DRUG|irinotecan hydrochloride|
219331683|NCT00003111|DRUG|paclitaxel|
219331684|NCT00003111|PROCEDURE|neoadjuvant therapy|
219331685|NCT00003111|PROCEDURE|surgical procedure|
219331686|NCT00003111|RADIATION|radiation therapy|
219331687|NCT01112020|DEVICE|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
219331688|NCT01112020|DEVICE|Biopatch|Biopatch applied to 7 sites
219331689|NCT01112020|DEVICE|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
219331690|NCT05995015|BIOLOGICAL|Universal CD19-specific CAR gene-engineered T cells|Infusion of 4SCAR19U cells
219331691|NCT02219321|DRUG|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
219331692|NCT02219321|DRUG|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
219331693|NCT00617539|DRUG|irinotecan hydrochloride|
219331694|NCT00617539|DRUG|temozolomide|
219331695|NCT04538872|BEHAVIORAL|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
219331696|NCT04538872|BEHAVIORAL|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
219331697|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
219331698|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
219331699|NCT02098642|OTHER|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
219331700|NCT02098642|OTHER|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
219331701|NCT01977820|DRUG|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
219331702|NCT01977820|DRUG|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
219331703|NCT02081404|DRUG|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
219331704|NCT02081404|DRUG|Placebo|placebo
219331705|NCT00123292|DRUG|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
219331706|NCT00123292|DRUG|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
219331707|NCT00123292|DRUG|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
219331708|NCT03043521|DRUG|Dexlansoprazole 60 MG|
219331709|NCT03043521|DRUG|CJ-12420 50mg|
219331710|NCT03043521|DRUG|CJ-12420 100mg|
219331711|NCT03043521|DRUG|CJ-12420 200mg|
219331712|NCT03860675|DIAGNOSTIC_TEST|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
219331713|NCT02568475|BEHAVIORAL|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
219331714|NCT04468789|OTHER|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
219331715|NCT00493220|DRUG|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
219331716|NCT00493220|DRUG|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
219331717|NCT00493220|DRUG|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
219331718|NCT05659784|OTHER|Telerehabilitation|Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
219331719|NCT02743884|DEVICE|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
219331720|NCT02743884|DEVICE|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
219331721|NCT02324855|OTHER|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
219331722|NCT02625233|DEVICE|senofilcon C|
219331723|NCT02625233|DEVICE|comfilcon A|
219331724|NCT04190979|DEVICE|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
219331725|NCT06491108|DRUG|Vardenafil 5 Mg Oral Tablet|Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
219331726|NCT02426476|BEHAVIORAL|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
219331727|NCT02426476|BEHAVIORAL|sham HRVB training|passive relaxation
219331728|NCT05184673|OTHER|Behavioral and environmental|These are all active comparator yoga sequences
219331729|NCT02866799|OTHER|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
219331730|NCT02866799|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
219331731|NCT05273879|PROCEDURE|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
219331732|NCT05273879|PROCEDURE|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
219331733|NCT02691208|OTHER|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
219331734|NCT02691208|OTHER|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
219331735|NCT02254577|DRUG|Endometrin® plus Progesterone in Oil (PIO)|
219331736|NCT02254577|DRUG|Progesterone in Oil (PIO) Only|
219331737|NCT02072928|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
219331738|NCT05741281|BEHAVIORAL|Physical exercises program|\- Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
219331739|NCT05466812|DRUG|Sr-89|"1. strontium-89 chloride treatment~2. periodical evaluation and follow-up"
219331740|NCT05529056|DRUG|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
219331741|NCT05529056|DRUG|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
219331742|NCT05529056|DRUG|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
219331743|NCT05529056|DRUG|Placebo|Placebo ophthalmic solution
219331744|NCT02937012|DRUG|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
219331745|NCT02937012|DRUG|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
219331746|NCT02937012|DRUG|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
219331747|NCT00331695|DRUG|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
219331748|NCT02724384|DEVICE|MOE Plasma Delivery System A|Plasma treatment
219331749|NCT02724384|DEVICE|MOE Plasma Delivery System B|Plasma treatment
219331750|NCT02000076|BEHAVIORAL|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
219331751|NCT02000076|BEHAVIORAL|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
219331752|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) at baseline|Detailed imaging of coronary arteries
219331753|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) after 1 year|Detailed imaging of coronary arteries
219331754|NCT00049803|DRUG|sodium oxybate|
219331755|NCT06656455|DRUG|sevoflurane via LMA|In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
219331756|NCT06656455|DRUG|Propofol with oxygen via simple mask|"In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min."
219331757|NCT06985823|OTHER|Rotational exercises|14 participants will be in experimental group A, giving them rotational exercises (Rotational Crunch exercise, Single leg romanian deadlift with rotation, rotational medicine ball throws for six weeks. Measure all values before giving them protocol and after protocol.
219331758|NCT06985823|OTHER|Anti-Rotational exercises|14 participants will be in experimental group B, giving them anti-rotational exercises (Quadruped exercise 3 sets of 15 repetition, planks 3 sets of 60 second hold, pallof press 3 sets of 15 repetition) for six weeks. Measure all values before giving them protocol and after protocol.
219331759|NCT06985225|COMBINATION_PRODUCT|Hyperpolarized 129 Xenon|Xenon gas contrast agent for MRI
219331760|NCT06985290|DRUG|Dexmedetomidine Infusion|Dexmedetomidine infusion given for sedation during therapeutic hypothermia. Dexmedetomidine infusion at a starting dose of 0.2 μg/kg/h, with titration in 0.1 μg/kg/h increments with a maximum of 0.5 μg/kg/h based on objective assessment of sedation.
219331761|NCT06985290|DRUG|Morphine Infusion|Morphine infusion given for sedation during therapeutic hypothermia. Morphine infusion at a starting dose of 4 μg/kg/h, with titration in 2 μg/kg/h increments with a maximum of 10 μg/kg/h based on objective assessment of sedation.
219331762|NCT06655454|DRUG|Supplemental Postoperative Bupivacaine|This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention.
219331763|NCT06655454|DRUG|Placebo Injection|This intervention will appear to give patients an additional injection, but no additional drug will be given.
219331764|NCT03122717|DRUG|Gefitinib|gefitinib is a EGFR inhibitor
219331765|NCT03122717|DRUG|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
219331766|NCT06984887|DIAGNOSTIC_TEST|Diagnostic procedures|This study will be evaluated by conducting a non-inferiority diagnostic trial within routine ACF settings by comparing the New Diagnostic tests (NAT) to the reference standard test (Xpert MTB/Rif Assay) to determine how well it can detect and diagnose TB. All samples will be tested for MTB using cultures.
219331767|NCT00232583|DRUG|Metformin|Metformin 1000mg/BID
219331768|NCT00232583|DRUG|Insulin|Insulin Novolg 70/30 per protocol titration
219331769|NCT00232583|DRUG|Metfomin|Metformin 1000mg/BID
219331770|NCT00232583|DRUG|Pioglitazone|Pioglitazone 45mg
219331771|NCT00232583|DRUG|glyburide|Glyburide per protocol titration
219331772|NCT06984757|DEVICE|Deep-brain Stimulation|a neurosurgical procedure that uses implanted electrodes and electrical stimulation to treat movement disorders and certain neuropsychiatric conditions when medications are ineffective or cause significant side effects.
219331773|NCT06984757|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive treatment that uses magnetic fields to stimulate specific areas of the brain.
219331774|NCT06984757|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive brain stimulation technique that uses weak, alternating electrical currents applied to the scalp to modulate brain activity and potentially influence cognitive processes by entraining brain oscillations.
219331775|NCT06984081|PROCEDURE|CAPA IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
219331776|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
219331777|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
219331778|NCT06681467|OTHER|Respiratory monitoring band|The only intervention in this study is the application of two CE marked study approved chest bands- the Go direct respiratory sensor and a biosignal respiration belt
219331779|NCT06249711|DEVICE|Active stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation
219331780|NCT06249711|DEVICE|Sham stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation
219331781|NCT05804643|PROCEDURE|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
219331782|NCT01255852|DRUG|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
219331783|NCT06850883|OTHER|A person-centered dementia home care scenario-based training program|"The training program primarily consists of three major themes in dementia care scenario-based training: Empathy, Challenging Behavior Management, and Interactive Activity Design."
219331784|NCT06850883|OTHER|Routine Treatment|Routine Treatment
219331785|NCT00291798|PROCEDURE|rate of remission|
219331786|NCT06902207|DRUG|Faricimab Injection [Vabysmo]|The procedures followed local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of an eye speculum, topical 5% povidone-iodine disinfection, 33G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in the supertemporal or the inferotemporal quadrant, sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
219331787|NCT06906796|OTHER|Diaphragmatic breathing exercise and posture exercises|"Diaphragmatic breathing exercise: Before starting the exercise protocol, individuals in the exercise group will be given training on diaphragmatic breathing exercises. During the exercise sessions, individuals will be advised to place one hand on their abdomen and the other on their chest while lying on their back and to increase abdominal movement by breathing slowly through the nose, thus decreasing rib cage movement. The diaphragmatic breathing exercise will be performed for 5 minutes.~Posture exercises: Individuals will be given posture exercise training before starting the exercise protocol. The smoothness of the movements will be checked throughout the exercise. Chin tuck, shoulder rotation, neck extension with exercise rubber and right-left lateral flexion, pectoral stretching with hands behind, pectoral stretching in the corner and head rib cage extension exercises will be applied as posture exercises. Each exercise will be done with 10 repetitions."
219331788|NCT06044714|PROCEDURE|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
219331789|NCT06044714|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
219331790|NCT00546767|BEHAVIORAL|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
219331791|NCT00546767|BEHAVIORAL|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
219331792|NCT00546767|BEHAVIORAL|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
219331793|NCT00546767|BEHAVIORAL|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
219331794|NCT05910502|BEHAVIORAL|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
219331795|NCT00003398|BIOLOGICAL|anti-thymocyte globulin|
219331796|NCT00003398|BIOLOGICAL|filgrastim|
219331797|NCT00003398|DRUG|cyclophosphamide|
219331798|NCT00003398|DRUG|thiotepa|
219331799|NCT00003398|PROCEDURE|allogeneic bone marrow transplantation|
219331800|NCT00003398|PROCEDURE|bone marrow ablation with stem cell support|
219331801|NCT00003398|RADIATION|radiation therapy|
219331802|NCT04396002|DIAGNOSTIC_TEST|Life Space Questionnaire|This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
219331803|NCT04396002|DIAGNOSTIC_TEST|Low Luminance Questionnaire|This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
219331804|NCT04396002|DIAGNOSTIC_TEST|Contrast sensitivity under dim illumination|Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
219331805|NCT04396002|DIAGNOSTIC_TEST|Visual field under dim illumination (MAIA)|Sensitivity in the central visual area will be assessed under dim illumination
219331806|NCT04396002|DIAGNOSTIC_TEST|Macular Pigment Optical Density (MPOD)|Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
219331807|NCT04396002|DIAGNOSTIC_TEST|Dark Adaptation|After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
219331808|NCT02946658|PROCEDURE|lipoaspiration|Closed syringe harvesting subdermal fat
219331809|NCT02946658|PROCEDURE|ADcSVF|Isolation of AD-cSVF
219331810|NCT02946658|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
219331811|NCT03788772|OTHER|Multiple blood sampling|ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
219331812|NCT03788772|OTHER|Simple blood sampling|Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
219331813|NCT03831659|OTHER|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
219331814|NCT05704387|PROCEDURE|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
219331815|NCT05704387|PROCEDURE|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
219331816|NCT03096041|DEVICE|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
219331817|NCT03096041|DEVICE|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
219331818|NCT06149559|DRUG|rozanolixizumab|rozanolixizumab solution for injection
219331819|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
219331820|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
219331821|NCT06316102|BEHAVIORAL|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|Multilevel intervention with 4 components
219331822|NCT05961085|PROCEDURE|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
219331823|NCT05338515|DRUG|Selpercatinib|Administered orally.
219331824|NCT05714969|BIOLOGICAL|TAK-755|TAK-755 IV infusion
219331825|NCT05036603|OTHER|chest physiotherapy|diffferent chest physiotherapy methods
219331826|NCT01315639|BIOLOGICAL|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
219331827|NCT05405803|BEHAVIORAL|Web-App based Lifestyle Physical Activity Promotion Program|"WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences.~The program includes 3 components in 2 languages (English and Korean):~1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers.~2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity.~3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.).~Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls."
219331828|NCT05405803|BEHAVIORAL|The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines|A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.
219331829|NCT05977959|BEHAVIORAL|Mentoring Program|Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.
219331830|NCT05977959|BEHAVIORAL|Enhanced Resources|Schools in this group will receive extra resources such as program incentives to aid in program implementation.
219331831|NCT05977959|BEHAVIORAL|Enhanced Engagement|Schools in this group will participate in program contests to aid program implementation.
219331832|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
219331833|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
219331834|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
219331835|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
219331836|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
219331837|NCT05848089|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
219331838|NCT05848089|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
219331839|NCT05848089|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
219331840|NCT02414399|DRUG|Azithromycin|oral administration of Azithromycin
219331841|NCT02414399|DRUG|Placebo|5 days of taste/appearance/bottle-matched inactive substance
219331842|NCT03755128|OTHER|No intervention|No investigational drugs will be administered as part of the study
219331843|NCT06361290|OTHER|Data collection from hospital medical records|Data collection from hospital medical records of patients concerning the 5 years following the resection of the tumor.
219331844|NCT02088112|DRUG|Gefitinib|Gefitinib QD
219331845|NCT02088112|DRUG|MEDI4736|MEDI4736 IV Q2W
219331846|NCT01490099|DRUG|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
219331847|NCT01987206|DEVICE|MPC control algorithm|
219331848|NCT01987206|DEVICE|PID control algorithm|
219331849|NCT06302348|DRUG|Sepiapterin|Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
219331850|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
219331851|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
219331852|NCT04856787|DRUG|placebo、 BP102、 XELOX|"Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
219331853|NCT00985803|OTHER|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
219331854|NCT00985803|OTHER|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
219331855|NCT00732511|DRUG|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
219331856|NCT00732511|DRUG|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
219331857|NCT00177775|DRUG|MucoMilk product|
219331858|NCT05745675|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
219331859|NCT01529177|DRUG|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
219331860|NCT01529177|DRUG|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
219331861|NCT03110926|DRUG|mFOLFOX6|Induction Chemotherapy
219331862|NCT03110926|COMBINATION_PRODUCT|Chemoradiation|Chemoradiation
219331863|NCT06138522|BEHAVIORAL|Semi-structured interviews|Semi-structured interviews
219331864|NCT06138522|BEHAVIORAL|Child Post-Traumatic Stress Response Index (CPTS-RI) scale|Child Post-Traumatic Stress Response Index (CPTS-RI) scale
219331865|NCT06138522|BEHAVIORAL|- Therapeutic Alliance Questionnaire (HAQ-CP)|\- Therapeutic Alliance Questionnaire (HAQ-CP)
219331866|NCT01704287|BIOLOGICAL|Pembrolizumab|IV infusion
219331867|NCT01704287|DRUG|Carboplatin|Carboplatin per institutional standard
219331868|NCT01704287|DRUG|Paclitaxel|Paclitaxel per institutional standard
219331869|NCT01704287|DRUG|Dacarbazine|Dacarbazine per institutional standard
219331870|NCT01704287|DRUG|Temozolomide|Temozolomide per institutional standard
219331871|NCT04356664|DRUG|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
219331872|NCT06790641|BEHAVIORAL|Program in Support of Moms (PRISM)|Program in Support of Moms (PRISM): a practice-level intervention with implementation support that helps obstetric practices integrate mental health care for perinatal individuals. To help obstetric practices implement pathways for screening, assessment, and a stepped intervention response for mental health problems and social determinants of health. PRISM offers training in trauma informed and equitable care, technical assistance, and implementation and change management support.
219331873|NCT06790641|BEHAVIORAL|PSI Peer Support|Postpartum Support International (PSI) Peer Support: a service administered by PSI that pairs perinatal individuals with a volunteer peer mentor who provides support, psychoeducation, behavioral activation, and navigation services, which includes planning, goal setting, and practical tools to manage parenting and mental health symptoms.
219331874|NCT06157957|DIAGNOSTIC_TEST|Lung cancer screening with low dose CT scan|Low dose CT scan in active smokers or ex-smokers with an age between 50 and 75 years old
219331875|NCT03776474|BIOLOGICAL|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
219331876|NCT00532181|BEHAVIORAL|Savings Behavior and Consumer's Approach to Risk|
219331877|NCT04175665|DRUG|Semaglutide|Prescription for semaglutide as part of usual clinical practice
219331878|NCT02214602|DRUG|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
219331879|NCT06051513|DRUG|treatment with or without colistin|For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
219331880|NCT01094587|PROCEDURE|Gastroschisis closure with suture|
219331881|NCT01094587|PROCEDURE|Gastroschisis closure without suture|
219331882|NCT02524522|DEVICE|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
219331883|NCT02524522|DEVICE|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
219331884|NCT00297635|DEVICE|GlucoDYNAMIX™ intervention system|
219331885|NCT00297635|DEVICE|GlucoMON™ telemetry device|
219331886|NCT04024228|BIOLOGICAL|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219331887|NCT04024228|BIOLOGICAL|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
219331888|NCT01570764|DRUG|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
219331889|NCT01570764|DRUG|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
219331890|NCT02875249|OTHER|patients stool collection|patients stool collection
219331891|NCT03053700|DRUG|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
219331892|NCT03053700|DEVICE|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
219331893|NCT02456597|DRUG|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
219331894|NCT02456597|DRUG|Isotonic Saline|Isotonic saline injected through the novel Catheter
219331895|NCT02809014|OTHER|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
219331896|NCT02809014|OTHER|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
219331897|NCT02809014|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
219331898|NCT02809014|OTHER|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
219331899|NCT03553914|DRUG|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
219331900|NCT06386211|DRUG|MAGNE-B6 Oral Solution|Oral solution.
219331901|NCT06386211|DRUG|MAGNE-B6 New Formulation Tablet|New formulation tablet.
219331902|NCT00938717|DRUG|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
219331903|NCT02800434|PROCEDURE|hand allograft|
219331904|NCT00998049|DRUG|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
219331905|NCT00998049|DRUG|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
219331906|NCT06074406|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
219331907|NCT02897492|OTHER|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
219331908|NCT04660513|PROCEDURE|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
219331909|NCT04144270|OTHER|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
219331910|NCT00170612|BIOLOGICAL|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
219331911|NCT00170612|BIOLOGICAL|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
219331912|NCT06226909|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
219331913|NCT03853811|DEVICE|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
219331914|NCT03156348|OTHER|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
219331915|NCT05926388|OTHER|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
219331916|NCT04829357|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
219331917|NCT01462435|DRUG|Diclofenac Test (lower dose)|Capsules
219331918|NCT01462435|DRUG|Diclofenac Test (upper dose)|Capsules
219331919|NCT01462435|DRUG|Celecoxib|200 mg Capsules
219331920|NCT01462435|DRUG|Placebo|Capsules
219331921|NCT05860075|DRUG|IMM01|IMM01 will be administered once a week for 4 weeks.
219331922|NCT05438043|DRUG|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
219331923|NCT05438043|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
219331924|NCT05438043|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
219331925|NCT05438043|DRUG|Lenalidomide|Lenalidomide will be administered orally.
219331926|NCT05438043|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219331927|NCT03239366|OTHER|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
219331928|NCT03239366|OTHER|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
219331929|NCT05092919|OTHER|Flavor|Sweet flavored vs. non-flavored cigarillos.
219331930|NCT05899244|OTHER|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
219331931|NCT05899244|OTHER|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
219331932|NCT05899244|OTHER|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
219331933|NCT05075070|BIOLOGICAL|Inactivated COVID-19 vaccine|two doses inactivated COVID-19 vaccine
219331934|NCT01161355|DRUG|AZD9668|Tablets of AZD9668 and IV dose of \[C14\]AZD9668
219331935|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
219331936|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
219331937|NCT00063141|DRUG|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
219331938|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
219331939|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
219331940|NCT02821611|BEHAVIORAL|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
219331941|NCT02248259|DRUG|BI 409306|Oral single dose of BI 409306
219331942|NCT02248259|DRUG|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
219331943|NCT04950179|OTHER|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
219331944|NCT04452045|DEVICE|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
219331945|NCT04162496|DEVICE|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
219331946|NCT02114411|PROCEDURE|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
219331947|NCT02114411|PROCEDURE|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
219331948|NCT02470468|BIOLOGICAL|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
219331949|NCT02470468|BIOLOGICAL|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
219331950|NCT02470468|OTHER|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
219331951|NCT00739011|DEVICE|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
219331952|NCT03145181|DRUG|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
219331953|NCT03145181|DRUG|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
219331954|NCT06098365|OTHER|segmental cervical stabilization exercises|Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
219331955|NCT06098365|OTHER|cervical isometric exercises|Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
219331956|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
219331957|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
219331958|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
219331959|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
219331960|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
219331961|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
219331962|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
219331963|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
219331964|NCT01329250|DRUG|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
219331965|NCT06433830|DRUG|Hetrombopag Olamine|The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
219331966|NCT02556502|DEVICE|18F-Florbetaben PET|
219331967|NCT00258336|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
219331968|NCT00258336|BIOLOGICAL|rituximab|
219331969|NCT00258336|BIOLOGICAL|sargramostim|
219331970|NCT04956003|BEHAVIORAL|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
219331971|NCT05439486|DEVICE|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
219331972|NCT00792194|OTHER|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
219331973|NCT05972200|DEVICE|Active HD-tDCS over V5/MT|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V5/MT, whereas the other 4 electrodes return electrical currents that flow away from that area. V5/MT will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
219331974|NCT05972200|DEVICE|Active HD-tDCS over V1|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V1, whereas the other 4 electrodes return electrical currents that flow away from that area. V1 will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
219331975|NCT05972200|DEVICE|Sham HD-tDCS over V5/MT or V1|Sham HD-tDCS will be delivered over left V5/MT or left V1. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. .
219331976|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
219331977|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
219331978|NCT00319150|DRUG|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
219331979|NCT04425603|DEVICE|Anthology Hip Replacement System|
219331980|NCT04501068|DEVICE|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
219331981|NCT00029874|DRUG|Minocycline|
219331982|NCT02656459|OTHER|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
219331983|NCT02905370|BEHAVIORAL|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
219331984|NCT02905370|BEHAVIORAL|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
219331985|NCT03479996|DRUG|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
219331986|NCT01719315|OTHER|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
219331987|NCT01035775|PROCEDURE|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
219331988|NCT01035775|PROCEDURE|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
219331989|NCT04391348|RADIATION|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
219331990|NCT02573870|DRUG|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
219331991|NCT02573870|DRUG|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
219331992|NCT02573870|DRUG|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
219331993|NCT00002142|DRUG|Cidofovir|
219331994|NCT00002142|DRUG|Probenecid|
219331995|NCT06427408|OTHER|Non applicable|Placental transcriptomic analysis
219331996|NCT01575106|DEVICE|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
219331997|NCT01414881|DRUG|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
219331998|NCT01414881|DRUG|Placebo|Placebo administered subcutaneously (SC) once weekly
219331999|NCT01206062|DRUG|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
219332000|NCT01206062|DRUG|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
219332001|NCT04229433|DRUG|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
219332002|NCT04229433|DRUG|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
219332003|NCT05270837|DRUG|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
219332004|NCT05270837|OTHER|Diet Only|Diet Control
219332005|NCT06449066|OTHER|Non applicable|Non applicable (data collection)
219332006|NCT02407262|DIETARY_SUPPLEMENT|Black seed oil|
219332007|NCT02407262|OTHER|Placebo|vegetable oil
219332008|NCT05005026|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
219332009|NCT05005026|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
219332010|NCT03947983|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
219332011|NCT03947983|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
219332012|NCT00245544|DRUG|MK0759|
219332013|NCT03537144|DRUG|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
219332014|NCT03537144|DRUG|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
219332015|NCT05506956|DRUG|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
219332016|NCT02097524|DRUG|Sarilumab|
219332017|NCT02097524|DRUG|Tocilizumab|
219332018|NCT01305642|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
219332019|NCT04092712|DRUG|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
219332020|NCT05429970|BEHAVIORAL|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
219332021|NCT05429970|BEHAVIORAL|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
219332022|NCT05429970|DRUG|Propranolol|Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
219332023|NCT05429970|DRUG|Etodolac|Etodolac 400 mg PO BID (for 21 consecutive days)
219332024|NCT01848288|DEVICE|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
219332025|NCT01848288|DEVICE|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
219332026|NCT02091778|DEVICE|Fast gelling dressing|
219332027|NCT04110457|PROCEDURE|spinal decompression|spinal surgery by decompression or fixation
219332028|NCT05237232|OTHER|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
219332029|NCT05237232|OTHER|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure"
219332030|NCT05895006|DEVICE|Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219332031|NCT05895006|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219332032|NCT05895006|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219332033|NCT01007032|BIOLOGICAL|Cixutumumab|Cixutumumab intravenously
219332034|NCT04292808|DRUG|Methoxyflurane|Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
219332035|NCT01025960|PROCEDURE|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
219332036|NCT01025960|PROCEDURE|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
219332037|NCT05843721|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
219332038|NCT01737918|PROCEDURE|TOT|
219332039|NCT01737918|DRUG|solifenacin|
219332040|NCT00677820|BIOLOGICAL|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
219332041|NCT00677820|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
219332042|NCT05252429|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
219332043|NCT05252429|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
219332044|NCT04253184|DEVICE|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
219332045|NCT05322018|DIAGNOSTIC_TEST|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
219332046|NCT04653636|OTHER|Arthrographic distension|"The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance"
219332047|NCT04653636|OTHER|Immediate joint mobilization|"This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period."
219332048|NCT01554644|DEVICE|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
219332049|NCT01554644|DEVICE|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
219332050|NCT06254495|DRUG|PF-08046044/SGN-35C|Given into the vein (IV; intravenously)
219332051|NCT04774250|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
219332052|NCT04774250|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
219332053|NCT06211517|OTHER|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
219332054|NCT06211517|OTHER|Semi-structured interviews|Semi-structured interviews
219332055|NCT01673919|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
219332056|NCT05534347|BIOLOGICAL|Blood sample|Addtional tube of blood needed for follow up of patients
219332057|NCT05534347|BIOLOGICAL|Joint puncture|Joint puncture if needed according to routine care of the patients
219332058|NCT03776487|DRUG|Fluorouracil|Given IV
219332059|NCT03776487|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219332060|NCT03776487|BIOLOGICAL|Ipilimumab|Given IV
219332061|NCT03776487|BIOLOGICAL|Nivolumab|Given IV
219332062|NCT03776487|DRUG|Oxaliplatin|Given IV
219332063|NCT03776487|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
219332070|NCT01101438|DRUG|metformin hydrochloride|Given orally
219332071|NCT01101438|OTHER|placebo|Given orally
219332072|NCT00001520|DRUG|neostigmine|
219332073|NCT06361693|OTHER|Auto-preoxygenation|"Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%."
219332074|NCT06361693|OTHER|APAIS scale|APAIS scale
219332075|NCT06361693|OTHER|Visual analog anxiety scale (VAS-A)|Visual analog anxiety scale (VAS-A)
219332076|NCT06361693|OTHER|Visual analog comfort scale (VAS-C)|Visual analog comfort scale (VAS-C)
219332077|NCT02722538|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
219332078|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .
219332079|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
219332080|NCT04237649|DRUG|KAZ954|KAZ954 will be administered in every arm.
219332081|NCT04237649|DRUG|PDR001|KAZ954 + PDR001
219332082|NCT04237649|DRUG|NIR178|KAZ954 + NIR178
219332083|NCT04237649|DRUG|NZV930|KAZ954 + NZV930
219332084|NCT00986544|PROCEDURE|no drain|drain positioned on the skin
219332085|NCT00986544|PROCEDURE|drain positioned|drain positioned in the subhepatic space
219332086|NCT00986544|PROCEDURE|drain not positioned|Drain positioned in the abdominal wall
219332087|NCT06536023|DRUG|IBI362|IBI362 SA.QW
219332088|NCT06536023|DRUG|IBI362 placebo|IBI362 placebo SA.QW
219332089|NCT05990439|BEHAVIORAL|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
219332090|NCT05990439|BEHAVIORAL|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
219332091|NCT06477341|DIETARY_SUPPLEMENT|various available nutrition as those contain high protein content as ensure milk|note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
219332092|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, on day 1.
219332093|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
219332094|NCT05069064|OTHER|music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
219332095|NCT05069064|OTHER|no music|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
219332096|NCT05217199|OTHER|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
219332097|NCT03194282|OTHER|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
219332098|NCT04594382|DIAGNOSTIC_TEST|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
219332099|NCT04594382|DIAGNOSTIC_TEST|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
219332100|NCT05988658|DEVICE|ESTOP - AKI 2.0|Medical software as a Noninvasive medical device, which at the time of the project will not implement directly into subject/clinical care.
219332101|NCT03515798|DRUG|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
219332102|NCT03515798|DRUG|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
219332103|NCT03333642|PROCEDURE|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
219332104|NCT06527625|BEHAVIORAL|Cultural Arts Program|9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression
219332105|NCT06527625|BEHAVIORAL|Treatment as usual|Treatment as usual provided in local community aged care centres
219332106|NCT05757869|DRUG|Milvexian|Milvexian will be administered orally.
219332107|NCT05757869|DRUG|Apixaban|Apixaban will be administered orally.
219332108|NCT05757869|DRUG|Placebo|Milvexian matching milvexian placebo will be administered orally.
219332109|NCT05757869|DRUG|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
219332110|NCT05772572|OTHER|Questionnaires|"Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life"
219332111|NCT06543290|DRUG|Azithromycin Pill|Azithromycin 2 grams to be administered prior to start of induction for those randomized to intervention group
219332112|NCT06543290|DRUG|Placebo|4 magnesium oxide tablets prior to the start of induction for those randomized to placebo
219332113|NCT00616915|DRUG|Wellbutrin XL|Wellbutrin XL 300mg daily
219332114|NCT05316155|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
219332115|NCT04827719|DRUG|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
219332116|NCT03778528|PROCEDURE|cataract surgery|tissue collection.
219332117|NCT04814342|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
219332118|NCT01864499|PROCEDURE|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
219332119|NCT01871220|DEVICE|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
219332120|NCT01871220|DEVICE|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
219332121|NCT02508142|DRUG|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
219332122|NCT03896542|DEVICE|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
219332123|NCT03896542|DEVICE|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
219332124|NCT05542407|DRUG|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
219332125|NCT05542407|DRUG|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
219332126|NCT05102344|BEHAVIORAL|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
219332127|NCT05102344|BEHAVIORAL|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
219332128|NCT06144632|DEVICE|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
219332129|NCT06144632|DEVICE|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
219332130|NCT06268171|OTHER|ultrasound measurement of the cross-sectional area of the rectus femoris|ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
219332131|NCT01825057|BEHAVIORAL|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
219332132|NCT01825057|BEHAVIORAL|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
219332133|NCT01825057|BEHAVIORAL|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
219332134|NCT01688596|DRUG|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
219332135|NCT06552338|OTHER|Observational|No intervention. Study is observational
219332136|NCT00794599|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
219332137|NCT00794599|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
219332138|NCT03023020|DRUG|Aspirin|Dosing per current guidelines and local practice
219332139|NCT03023020|DRUG|P2Y12 inhibitor|Dosing per current guidelines and local practice
219332140|NCT03831061|OTHER|Cognitive stimulation|
219332141|NCT00975299|DRUG|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
219332142|NCT00975299|DRUG|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
219332143|NCT05865379|DEVICE|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
219332144|NCT05865379|DEVICE|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
219332145|NCT02075372|OTHER|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
219332146|NCT00547872|PROCEDURE|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
219332147|NCT04746833|BEHAVIORAL|SUMMIT|multicomponent web-based application focused on pain self-management skills
219332148|NCT04746833|BEHAVIORAL|control|My Pain Diary app
219332149|NCT03380455|DRUG|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
219332150|NCT03380455|DRUG|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
219332151|NCT03968614|OTHER|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
219332152|NCT03968614|OTHER|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
219332153|NCT04925167|DRUG|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
219332154|NCT04925167|DRUG|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
219332155|NCT00541320|DRUG|GW813893|
219332156|NCT05570812|DRUG|Placebo|(4-week ramp, 4-week steady dosing)
219332157|NCT05570812|DRUG|Pregnenolone|(4-week ramp, 4-week steady dosing)
219332158|NCT06490549|OTHER|RSV infection observation cohort|No intervention; Epidemiological Study. Participants will receive standard care based on local clinical practice
219332159|NCT05075525|OTHER|High Intensity Laser Therapy Group|High Intensity Laser Therapy (HILT) and exercises will be used.
219332160|NCT05075525|OTHER|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Transcutaneous electrical nerve stimulation(TENS), ultrasound (US) will be applied.
219332161|NCT05075525|OTHER|Ultrasound and Interferential Current Stimulation Group|Ultrasound (US) ,interferential current stimulation and exercise will be used.
219332162|NCT04906356|GENETIC|Genetic sub-study|One time saliva sample collection
219332163|NCT05109286|BEHAVIORAL|CrossFit|CrossFit training
219332164|NCT03450291|OTHER|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
219332165|NCT04942652|DRUG|Itraconazole 200 mg|Itraconazole 100 mg capsule x 2
219332166|NCT04942652|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet x 1
219332167|NCT05250973|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
219332168|NCT05250973|DRUG|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
219332169|NCT05250973|DRUG|Bortezomib|Bortezomib will be administered by SC injection or IV.
219332170|NCT05250973|DRUG|Dexamethasone|Dexamethasone will be administered orally or IV.
219332171|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
219332172|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
219332173|NCT03503409|DRUG|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
219332174|NCT00290290|DRUG|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
219332175|NCT00290290|DRUG|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
219332176|NCT06473311|DEVICE|whole bady vibration and virtual reality|study group I received a whole body vibration program in addition to a conventional physical therapy program, and study group II received a Wii-fit therapy program (a virtual reality treatment program) in addition to the same. A two-month treatment program was implemented for both groups. Every child in both groups had the same evaluation processes, which included using the Physical Self Maintenance Scale (PSMS) for daily living activities and a dynamometer to measure quadriceps muscular strength. Evaluation was done prior to the start of treatment and was done again after one month (post I) and two months (post II).
219332177|NCT04603885|BEHAVIORAL|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
219332178|NCT04603885|BEHAVIORAL|Stretching exercise|stretching exercise
219332179|NCT05317507|DRUG|CBD oil|50 mg
219332180|NCT05317507|DRUG|CBD oil|100 mg CBD
219332181|NCT05317507|DRUG|Placebo|Placebo
219332182|NCT05149027|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
219332183|NCT04013789|DEVICE|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
219332184|NCT04013789|DEVICE|DACP contact lenses|Nelfilcon A soft contact lenses
219332185|NCT01482585|OTHER|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
219332186|NCT03399799|DRUG|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
219332187|NCT06538584|DRUG|Caffeine citrate 15mg/kg|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 15mg/kg Caffeine citrate 15 minutes post surgery.
219332188|NCT06538584|DRUG|0.9% Sodium Citrate|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
219332189|NCT00192387|BIOLOGICAL|CAIV-T, Liquid|
219332190|NCT01247987|PROCEDURE|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
219332191|NCT01247987|PROCEDURE|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
219332192|NCT03319407|DEVICE|EPAD monitoring system|EPAD system will be used as part of routine care
219332193|NCT04092296|OTHER|resin infiltration|using infiltrant resin intervene proximal caries
219332194|NCT04092296|OTHER|remineralization|using fluoride to remineralize proximal caries
219332195|NCT04092296|OTHER|sham|replace resin with water
219332196|NCT02342496|DIETARY_SUPPLEMENT|Placebo|Powder
219332197|NCT02342496|DIETARY_SUPPLEMENT|Active, only probiotics|Powder
219332198|NCT02342496|DIETARY_SUPPLEMENT|Active, blend of berries and probiotics|Powder
219332199|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
219332200|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
219332201|NCT05567185|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
219332202|NCT03685383|DEVICE|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
219332203|NCT03685383|DEVICE|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
219332204|NCT05257083|DRUG|Daratumumab|Daratumumab will be administered SC.
219332205|NCT05257083|DRUG|Bortezomib|Bortezomib will be administered SC.
219332206|NCT05257083|DRUG|Lenalidomide|Lenalidomide will be administered orally.
219332207|NCT05257083|DRUG|Dexamethasone|Dexamethasone will be administered orally.
219332208|NCT05257083|DRUG|Cilta-cel|Cilta-cel will be administered intravenously
219332209|NCT05257083|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
219332210|NCT05257083|DRUG|Fludarabine|Fludarabine will be administered intravenously.
219332211|NCT01345136|DRUG|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
219332212|NCT06108713|OTHER|Addition of juggling|Participants will not change ther daily activities, and participate in juggling intervention lasted 4 weeks and consisted of 12 meetings (3 trainings per week), each lasting 45 minutes.
219332213|NCT05179876|DRUG|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
219332214|NCT05179876|DRUG|Selexipag|Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
219332215|NCT05179876|DRUG|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
219332216|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
219332217|NCT04372108|DRUG|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
219332218|NCT04372108|DRUG|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
219332219|NCT00768326|DRUG|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
219332220|NCT00768326|DRUG|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
219332221|NCT00768326|DRUG|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
219332222|NCT00768326|DRUG|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
219332223|NCT00768326|DRUG|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
219332224|NCT00768326|DRUG|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
219332225|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
219332226|NCT03023059|DRUG|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
219332227|NCT06055257|DRUG|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
219332228|NCT06055257|DRUG|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
219332229|NCT05628727|OTHER|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
219332230|NCT05628727|OTHER|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
219332231|NCT05660083|DRUG|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
219332232|NCT02609776|DRUG|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
219332233|NCT02609776|DRUG|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
219332234|NCT02609776|DRUG|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
219332235|NCT02609776|DRUG|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
219332236|NCT02609776|DRUG|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
219332237|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
219332238|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
219332239|NCT06106945|DRUG|AZD0305|AZD0305
219332240|NCT06150417|DRUG|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
219332241|NCT06150417|DRUG|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
219332242|NCT06150417|OTHER|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection"
219332243|NCT06150417|RADIATION|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
219332244|NCT06435858|DRUG|Empagliflozin|Empagliflozin 10mg
219332245|NCT06435858|DRUG|Placebo|Placebo capsule
219332246|NCT05788042|DEVICE|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
219332247|NCT05788042|DEVICE|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
219332248|NCT02686125|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
219332249|NCT05083182|DRUG|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
219332250|NCT05083182|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219332251|NCT06961968|DRUG|iloperidone|iloperidone LAI
219332252|NCT06961968|DRUG|placebo|matching placebo
219332253|NCT06550895|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
219332254|NCT06550895|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219332255|NCT04153344|OTHER|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
219332256|NCT04153344|OTHER|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
219332257|NCT05957276|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
219332258|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
219332259|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
219332260|NCT06452238|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
219332261|NCT06452238|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound-guided transversus abdominis plane block.
219332262|NCT00606346|BIOLOGICAL|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
219332263|NCT00606346|DRUG|No Biologics|Treatments will be prescribed according to investigator judgement.
219332264|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
219332265|NCT06129591|DRUG|Vantage Hemp CBD Isolate + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
219332266|NCT06129591|DRUG|Silicone patch|"Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
219332267|NCT06351020|DRUG|LM-302|LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
219332268|NCT06351020|DRUG|Apatinib|The subjects will receive Apatinib orally,qd
219332269|NCT06351020|DRUG|Irinotecan|The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
219332270|NCT00125762|DEVICE|FibroScan|
219332271|NCT05343897|BEHAVIORAL|Low intensity exercise - Ping-Shuai Gong (PSG)|Participants were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
219332272|NCT05343897|BEHAVIORAL|Low intensity exercise - Arm-Swing Exercise (ASE)|Participants were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
219332273|NCT06166979|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)
219332274|NCT06166979|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
219332275|NCT05888324|OTHER|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
219332276|NCT05486026|DRUG|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
219332277|NCT05486026|DRUG|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
219332278|NCT04689659|BIOLOGICAL|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
219332279|NCT03648359|PROCEDURE|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
219332280|NCT05911750|DIAGNOSTIC_TEST|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
219332281|NCT03372109|DIETARY_SUPPLEMENT|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
219332282|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral capsules|Multivitamin/mineral supplement
219332283|NCT03372109|DIETARY_SUPPLEMENT|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
219332284|NCT03372109|DIETARY_SUPPLEMENT|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
219332285|NCT03372109|DIETARY_SUPPLEMENT|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
219332286|NCT03372109|DIETARY_SUPPLEMENT|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
219332287|NCT03372109|DIETARY_SUPPLEMENT|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
219332288|NCT03372109|DIETARY_SUPPLEMENT|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
219332289|NCT03372109|DIETARY_SUPPLEMENT|Saffron extract capsule|Saffron extract 88.25mg/capsule
219332290|NCT03372109|DIETARY_SUPPLEMENT|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
219332291|NCT03372109|DIETARY_SUPPLEMENT|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
219332292|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
219332293|NCT01951079|DRUG|Intra-amniotic injection of DIGOXIN|
219332294|NCT03373981|DEVICE|rTMS|repetitive transcranial magnetic stimulation
219332295|NCT04434196|DRUG|CC-99282|CC-99282
219332296|NCT04434196|DRUG|Obinutuzumab|Obinutuzumab
219332297|NCT01017588|DEVICE|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
219332298|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
219332299|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
219332300|NCT03021148|OTHER|Questionnaire|Administration of questionnaire.
219332301|NCT02015325|BEHAVIORAL|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
219332302|NCT03019250|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
219332303|NCT03019250|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
219332304|NCT04301232|OTHER|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg \> preanesthetic level, 20 - 50 mm Hg \> preanesthetic level, 50 mm Hg \> preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 \> 92% on room air, Supplemental O2 required to maintain SpO2 \> 90%,SpO2 \< 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
219332305|NCT04301232|OTHER|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)\<15%, Blood pressure 15-30%, Blood pressure\>30%, Level of consciousness,(Awake\&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value\>90% on room air, Requires supplemental oxygen, Saturation\<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea\&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score\<1 in any individual category)would be required for a patient after general anesthesia
219332306|NCT04301232|OTHER|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in room air Y/N, Pain Control (VAS \< 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
219332307|NCT04095780|OTHER|Advanced oral hygiene care programme|"1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education"
219332308|NCT04095780|OTHER|Oral hygiene instruction|Oral hygiene education
219332309|NCT04431336|BEHAVIORAL|movement|movement
219332310|NCT04537546|DEVICE|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
219332311|NCT05573776|OTHER|Exercise Therapy, High Protein supplement|patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
219332312|NCT05394220|DIAGNOSTIC_TEST|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
219332313|NCT00779922|DRUG|lenalidomide|
219332314|NCT01039077|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
219332315|NCT00702754|BIOLOGICAL|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
219332316|NCT05374382|BEHAVIORAL|Strengthening|3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery
219332317|NCT05374382|BEHAVIORAL|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
219332318|NCT03165435|BIOLOGICAL|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
219332319|NCT03165435|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
219332320|NCT05534906|OTHER|Blood & Urine Samples|Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
219332321|NCT05534906|OTHER|Imaging|MRI \& MRE Scans
219332322|NCT03172832|PROCEDURE|PTBD|Percutaneous access and tube placement into the bile duct
219332323|NCT03172832|PROCEDURE|ERC|Endoscopic access and stent placement in the bile duct
219332324|NCT04994197|OTHER|Observational study only - no intervention|Observational study only - no intervention
219332325|NCT02432222|BEHAVIORAL|Visual Arts Training|Visual arts training
219332326|NCT02432222|BEHAVIORAL|Music Training|Music training
219332327|NCT06397417|OTHER|Data collection|The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
219332328|NCT00006090|DRUG|arsenic trioxide|
219332329|NCT00520728|BEHAVIORAL|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
219332330|NCT04094753|DIAGNOSTIC_TEST|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
219332331|NCT04094753|DIAGNOSTIC_TEST|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
219332332|NCT04094753|DIAGNOSTIC_TEST|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
219332333|NCT04094753|DIAGNOSTIC_TEST|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
219332334|NCT04094753|DIAGNOSTIC_TEST|Questionaires|"Patients have to fulfill the following questionaires~* ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~* TILBURG FRAILTY INDICATOR~* SF-36 Quality of Life score~* N- QOL"
219332335|NCT04094753|DIAGNOSTIC_TEST|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
219332336|NCT04094753|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
219332337|NCT06267170|DRUG|Adebrelimab|Treatment with adbelizumab
219332338|NCT02295345|OTHER|Cognitive Behavioural Therapy for Insomnia|
219332339|NCT00894062|DEVICE|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
219332340|NCT00894062|DEVICE|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
219332341|NCT02403362|DRUG|EPO-018B|
219332342|NCT04269148|OTHER|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
219332343|NCT00596947|DRUG|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
219332344|NCT00596947|DRUG|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
219332345|NCT00596947|DRUG|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
219332346|NCT00596947|DRUG|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
219332347|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
219332348|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
219332349|NCT02427451|DRUG|Bcl-2 Inhibitor GDC-0199|Given PO
219332350|NCT02427451|BIOLOGICAL|Obinutuzumab|Given IV
219332351|NCT02427451|DRUG|Ibrutinib|Given PO
219332352|NCT02427451|OTHER|Pharmacological Study|Correlative studies
219332353|NCT02427451|OTHER|Laboratory Biomarker Analysis|Correlative studies
219332354|NCT02427451|OTHER|Quality-of-Life Assessment|Ancillary studies
219332355|NCT02884063|PROCEDURE|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
219332356|NCT00496730|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
219332357|NCT00496730|DRUG|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
219332358|NCT01984372|DRUG|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
219332359|NCT03556436|DRUG|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
219332360|NCT06042777|BEHAVIORAL|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
219332361|NCT06044064|PROCEDURE|A blood sample for CA 19-9 (cancer detection test)|"* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline.~* Contrast CT abdomen - Pancreas protocol will be done at baseline.~* EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you.~* If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done."
219332362|NCT04646785|BEHAVIORAL|Mindfulness-based cognitive therapy + TAU|The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).
219332363|NCT04646785|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
219332364|NCT04782271|DRUG|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
219332365|NCT04782271|DRUG|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
219332366|NCT04782271|DRUG|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
219332367|NCT04782271|DRUG|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
219332368|NCT03463733|DRUG|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
219332369|NCT03463733|DRUG|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
219332370|NCT00574288|DRUG|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
219332371|NCT00574288|DRUG|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
219332372|NCT00574288|OTHER|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
219332373|NCT00574288|OTHER|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
219332374|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
219332375|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
219332376|NCT01025596|DRUG|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
219332377|NCT02361944|DRUG|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
219332378|NCT02361944|DRUG|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
219332379|NCT03960073|DIETARY_SUPPLEMENT|MitoQ|4 week 20mg oral daily dose of Mito Q
219332380|NCT03960073|DIETARY_SUPPLEMENT|Placebo|4 week oral daily dose of TTP placebo
219332381|NCT02769663|BEHAVIORAL|questionnaires and neuropsychological assessments|
219332382|NCT01733966|DRUG|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
219332383|NCT01733966|DRUG|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
219332384|NCT06115187|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
219332385|NCT06115187|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
219332386|NCT00255762|DRUG|carboplatin|Given IV
219332387|NCT00255762|DRUG|paclitaxel|Given IV
219332388|NCT00255762|BIOLOGICAL|bevacizumab|Given IV
219332389|NCT00255762|OTHER|laboratory biomarker analysis|Correlative studies
219332390|NCT04237727|DEVICE|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
219332391|NCT05404399|BEHAVIORAL|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
219332392|NCT05404399|BEHAVIORAL|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
219332393|NCT02354014|DRUG|Bedaquiline (TMC207)|Bedaquiline (TMC207) oral tablet adult formulation (containing 100 mg bedaquiline (TMC207) per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg bedaquiline . Bedaquiline tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of bedaquiline 8 mg/kg qd for the first 2 weeks, followed by bedaquiline 4 mg/kg times weekly (TIW) with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, bedaquiline (TMC207) qd for the first 2 weeks, followed by bedaquiline TIW with intakes at least 2 days (48 hours) apart for 22 weeks.
219332394|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
219332395|NCT03956914|OTHER|Placebo|Placeob water 440 ml/day for 8 weeks
219332396|NCT03956914|OTHER|Deep sea water|Deep sea water 440 ml/day for 8 weeks
219332397|NCT00901771|DEVICE|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
219332398|NCT04118296|DRUG|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
219332399|NCT04227262|OTHER|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
219332400|NCT03929081|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
219332401|NCT03929081|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
219332402|NCT02871804|PROCEDURE|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
219332403|NCT02871804|PROCEDURE|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
219332404|NCT06308432|OTHER|Low intensity|The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
219332405|NCT06308432|OTHER|Low temperature|The performance test will be carried out in a room conditioned to a temperature of 22º.
219332406|NCT06308432|OTHER|Low Humidity|The performance test will be carried out in a room conditioned to 40% humidity.
219332407|NCT06308432|OTHER|High intensity|The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
219332408|NCT06308432|OTHER|High temperature|The performance test will be carried out in a room conditioned to a temperature of 35º.
219332409|NCT06308432|OTHER|High humidity|The performance test will be carried out in a room conditioned to 65% humidity.
219332410|NCT00121784|DRUG|mycophenolate mofetil [CellCept]|1
219332411|NCT02811549|DEVICE|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
219332412|NCT00580372|DRUG|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
219332413|NCT00580372|DRUG|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
219332414|NCT00580372|PROCEDURE|Hemopoietic stem cell procurement|Collection target = 10 x 10\^6 cells/kg
219332415|NCT00580372|DRUG|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
219332416|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
219332417|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
219332418|NCT00580372|DRUG|Maintenance|3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
219332419|NCT00236769|DRUG|norelgestromin + ethinyl estradiol|
219332420|NCT03472924|DEVICE|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
219332421|NCT02685579|OTHER|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
219332422|NCT05484479|BEHAVIORAL|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
219332423|NCT00241995|DRUG|Anticonvulsants|
219332424|NCT03911973|DRUG|Gedatolisib|Gedatolisib, 150-180MG IV
219332425|NCT03911973|DRUG|Talazoparib|.75-1.00mg
219332426|NCT02741869|DEVICE|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
219332427|NCT04123236|OTHER|Age 0-18|Patients under 18 years of age
219332428|NCT04123236|OTHER|Age 18-26|Patients over18 years of age
219332429|NCT04123236|OTHER|Girls|Girls
219332430|NCT04123236|OTHER|Boys|Boys
219332431|NCT04743921|DEVICE|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
219332432|NCT00427349|DRUG|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
219332433|NCT00427349|DRUG|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
219332434|NCT00924105|DRUG|CYT013-IL1bQb|s.c. injection
219332435|NCT00924105|DRUG|Placebo|s.c. injection
219332436|NCT01660321|DRUG|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
219332437|NCT00441181|DRUG|Travoprost|
219332438|NCT00278759|PROCEDURE|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
219332439|NCT02720770|DRUG|norditropine simplex|
219332440|NCT03041350|OTHER|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
219332441|NCT03130062|OTHER|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
219332442|NCT05082376|DRUG|CLM Original|Sunscreen lip balm.
219332443|NCT06198803|DRUG|L Carnitine|The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
219332444|NCT00360906|DRUG|Triomar™ (omega-3 fatty acids)|
219332445|NCT05453903|DRUG|Bleximenib|Participants will receive bleximenib.
219332446|NCT05453903|DRUG|Venetoclax (VEN)|Participants will receive VEN.
219332447|NCT05453903|DRUG|Azacitidine (AZA)|Participants will receive AZA.
219332448|NCT05453903|DRUG|Cytarabine|Participants will receive cytarabine.
219332449|NCT05453903|DRUG|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin.
219332450|NCT00649259|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
219332451|NCT00649259|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
219332452|NCT02478970|DEVICE|Konan SP4000|current standard of care at Kellogg Eye Center
219332453|NCT02478970|DEVICE|NIDEK CEM-350|newly marketed device
219332454|NCT05911659|DRUG|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
219332455|NCT00538330|DRUG|Tamoxifen|Tamoxifen
219332456|NCT01398020|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
219332457|NCT01398020|DRUG|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
219332458|NCT00162760|DRUG|Thalidomide|
219332459|NCT05403320|DEVICE|Continuous cuff pressure regulation|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)
219332460|NCT05403320|DEVICE|Intermittent cuff pressure regulation|ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O
219332461|NCT05403320|DEVICE|Automatic subglottic secretion drainage|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)
219332462|NCT05403320|DEVICE|Manual subglottic secretion drainage|Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen
219332463|NCT05403320|DIAGNOSTIC_TEST|Tracheobronchial colonization assessment|Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture
219332464|NCT05403320|DIAGNOSTIC_TEST|Microaspiration assessment|Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase
219332465|NCT05403320|DIAGNOSTIC_TEST|VAP assessment|Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
219332466|NCT01415128|DRUG|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
219332467|NCT01415128|DRUG|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
219332468|NCT01415128|DRUG|Desipramine|Single dose of Desipramine (50 mg) for 1 day
219332469|NCT05442255|OTHER|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
219332470|NCT05561361|PROCEDURE|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
219332471|NCT05561361|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
219332472|NCT01906775|OTHER|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
219332473|NCT06243406|OTHER|Intravitreal injection of anti-VEGF|Intravitreal injection of anti- vascular endothelial growth factor (VEGF) treatment
219332474|NCT02043821|DRUG|Capecitabine|14days
219332475|NCT02043821|OTHER|placebo|14 days
219332476|NCT03023930|OTHER|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
219332477|NCT03023930|OTHER|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
219332478|NCT00199446|DRUG|Istradefylline (KW-6002)|
219332479|NCT01379469|DRUG|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
219332480|NCT01379469|DRUG|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
219332481|NCT04712877|DIAGNOSTIC_TEST|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
219332482|NCT04425720|DEVICE|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.
219332483|NCT04425720|OTHER|Standard of Care|This group will be treated based on standard of care at our institution.
219332484|NCT00947700|BEHAVIORAL|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
219332485|NCT03778853|DRUG|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
219332486|NCT02703415|DRUG|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
219332487|NCT02703415|DRUG|Tramadol|caudal block with tramadol 1 mg/kg
219332488|NCT05517928|DRUG|Omeprazole|40 MG oral capsules daily
219332489|NCT05517928|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
219332490|NCT05517928|DRUG|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
219332491|NCT01614938|DRUG|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
219332492|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
219332493|NCT01614938|DRUG|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
219332494|NCT01614938|RADIATION|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
219332495|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
219332496|NCT00290186|DEVICE|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
219332497|NCT00290186|DEVICE|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
219332498|NCT00253396|DRUG|Unfractionated heparin|
219332499|NCT00253396|DRUG|Enoxaparin|
219332500|NCT00445224|OTHER|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
219332501|NCT00445224|OTHER|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
219332502|NCT04752176|DEVICE|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
219332503|NCT02882490|BEHAVIORAL|Parent Training|
219332504|NCT02882490|OTHER|Supportive Therapy|
219332505|NCT02895503|BEHAVIORAL|Yoga|Participate in yoga
219332506|NCT02895503|BEHAVIORAL|Support Group Therapy|Participate in emotional support group therapy
219332507|NCT02895503|OTHER|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
219332508|NCT02895503|OTHER|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
219332509|NCT00075595|DRUG|FOLFIRI regimen|
219332510|NCT00075595|DRUG|fluorouracil|
219332511|NCT00075595|DRUG|irinotecan hydrochloride|
219332512|NCT00075595|DRUG|leucovorin calcium|
219332513|NCT01157754|DRUG|levonorgestrel and ethynilestradiol|
219332514|NCT00833950|DEVICE|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
219332515|NCT04247958|PROCEDURE|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
219332516|NCT05500001|BEHAVIORAL|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
219332517|NCT01431196|BIOLOGICAL|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
219332518|NCT01771055|PROCEDURE|Galactose|Galactose dripped into the abdomen after surgery
219332519|NCT01771055|PROCEDURE|Standard surgical methods|
219332520|NCT04391036|DEVICE|High Eudragit® Content Vaginal Film|High (12.8%) Eudragit® Content Vaginal Film
219332521|NCT04391036|DEVICE|Low Eudragit® Content Vaginal Film|Low (6.4%) Eudragit® Content Vaginal Film
219332522|NCT04801875|OTHER|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
219332523|NCT01856244|BEHAVIORAL|treadmill walking|
219332524|NCT01856244|DEVICE|Treadmill|
219332525|NCT06633367|OTHER|Increasing time in nature|This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.
219332526|NCT04557059|RADIATION|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
219332527|NCT04557059|DRUG|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
219332528|NCT04557059|DRUG|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
219332529|NCT06280482|DRUG|Nicotinamide riboside (NR)|Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
219332530|NCT03388632|DRUG|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
219332531|NCT03388632|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
219332532|NCT03388632|DRUG|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
219332533|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
219332534|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
219332535|NCT05912517|DRUG|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
219332536|NCT05912517|DRUG|Placebo|Placebo will be administered as an intravenous infusion.
219332537|NCT06218472|OTHER|Day Hospital Treatment|Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).
219332538|NCT06218472|OTHER|"Multidisciplinary follow-up as usual within the service"|"Multidisciplinary follow-up as usual within the service"
219332539|NCT06218472|OTHER|Conduct semi-structured qualitative interviews|Conduct semi-structured qualitative interviews
219332540|NCT03661307|DRUG|Decitabine|Given IV
219332541|NCT03661307|DRUG|Quizartinib|Given PO
219332542|NCT03661307|DRUG|Venetoclax|Given PO
219332543|NCT05741307|BEHAVIORAL|Self-hypnosis application|"The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment."
219332544|NCT05741307|OTHER|Questionnaires|"Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2"
219332545|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
219332546|NCT06083844|DRUG|Pembrolizumab|Given by IV (vein)
219332547|NCT06083844|DRUG|Bevacizumab|Given by IV (vein)
219332548|NCT06083844|DRUG|Cyclophosphamide|Given by mouth
219332549|NCT06852222|DRUG|Bleximenib|Bleximenib will be administered orally.
219332550|NCT06852222|DRUG|Venetoclax (VEN)|VEN will be administered orally.
219332551|NCT06852222|DRUG|Azacitidine (AZA)|AZA will be administered intravenously or subcutaneously.
219332552|NCT06852222|DRUG|Placebo|Placebo will be administered orally.
219332553|NCT03706482|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
219332554|NCT05635669|DEVICE|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
219332555|NCT05635669|DEVICE|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
219332556|NCT05635669|DEVICE|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
219332557|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
219332558|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
219332559|NCT06284902|DRUG|Fexofenadine HCl Coated tablet|Film-coated tablet.
219332560|NCT06284902|DRUG|Fexofenadine HCl New Formulation Tablet|New formulation tablet.
219332561|NCT06557122|DEVICE|SOC and Advanced Bioengineered Skin Substitute|SOC primary dressing with Helicoll®
219332562|NCT06557122|OTHER|SOC and Active Comparator|SOC primary dressing with Epifix® or Grafix®
219332563|NCT03977402|OTHER|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
219332564|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
219332565|NCT02479438|OTHER|Diagnosed with GERD|Recording of patient outcomes
219332566|NCT01877915|DRUG|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
219332567|NCT01877915|DRUG|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
219332568|NCT01877915|OTHER|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
219332569|NCT06968052|OTHER|Strength and Feldenkrais Exercise|This is a behavioral, non-drug and non-device-based intervention combining somatic awareness through Feldenkrais principles with neuromuscular re-education. Movements emphasize minimal effort, reduced muscle tension, and improved self-perception of posture. The approach supports individualized progression and complements conventional physiotherapy without the use of pharmacological agents or medical equipment.
219332570|NCT06968052|OTHER|Strength Exercise|This is a non-drug, non-device corrective exercise program tailored for adults with forward head posture. It includes postural muscle strengthening and stretching, such as deep neck flexor activation, scapular retraction, and pectoral stretching. Additionally, participants perform diaphragmatic and thoracic breathing exercises.
219332571|NCT05505682|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
219332572|NCT02373215|DRUG|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
219332573|NCT03659851|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
219332574|NCT01350830|PROCEDURE|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
219332575|NCT01350830|PROCEDURE|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
219332576|NCT05469555|PROCEDURE|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
219332577|NCT04248387|DRUG|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
219332578|NCT03520959|BIOLOGICAL|LV305|Administered via subcutaneous (SC) injection.
219332579|NCT03520959|BIOLOGICAL|G305|Administered via intramuscular (IM) injection.
219332580|NCT03520959|OTHER|LV305-matching placebo|Administered via SC injection.
219332581|NCT03520959|OTHER|G305-matching placebo|Administered via IM injection.
219332582|NCT06970470|DEVICE|Triple-Adjustable Posture Corrector Manufacturer: Mercur®, Santa Cruz do Sul, Brazil|"The Triple-Adjustable Posture Corrector is a thoracic spinal orthosis designed to provide biomechanical support and postural correction in individuals with excessive thoracic kyphosis. It consists of elastic and adjustable non-rigid bands positioned around the shoulders and thorax, allowing individualized tension regulation. The brace promotes scapular retraction and axial alignment by increasing proprioceptive feedback and limiting thoracic flexion.~Participants randomized to this intervention will be instructed to wear the orthosis for a minimum of four consecutive hours per day, during waking hours, for 16 weeks. The orthosis is to be removed during bathing, aquatic activities, and sleep. Individualized fitting will be provided at baseline by trained personnel, following the manufacturer's guidelines. Adherence will be monitored through self-reported daily logbooks. Participants will be advised to report discomfort, adverse effects, or perceived benefits.~The primary clinical obje"
219332583|NCT06970470|DEVICE|Generation Dynamic Osteoporosis Brace Manufacturer: Bort®, Weinstadt, Germany|"The Generation Dynamic Osteoporosis Brace is a semi-rigid thoracic orthosis designed to stabilize the spine and counteract the progression of hyperkyphosis, especially in populations at risk for vertebral fragility. The brace is composed of lightweight, breathable material, with anterior and posterior structural support and adjustable tension straps. It is intended to reduce spinal flexion, improve sagittal alignment, and facilitate back extensor activation.~Participants assigned to this group will wear the orthosis for a minimum of four hours daily during waking hours, excluding sleep and aquatic activities, over a 16-week period. The orthosis will be individually fitted at the initial session by a trained physical therapist, following manufacturer protocols to ensure comfort, stability, and effectiveness. Participants will receive a daily logbook to record usage duration, comfort level, and perceived effects. Adherence will be monitored weekly.~The brace is intended to improve trun"
219332584|NCT01449461|DRUG|Brigatinib|Brigatinib tablets and capsules.
219332585|NCT04610021|BIOLOGICAL|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
219332586|NCT06970990|PROCEDURE|HFNC:50L/min|Under high-flow oxygen therapy at a flow rate of 50 L/min, record/monitor for 5 minutes
219332587|NCT06970990|PROCEDURE|HFNC:flow=40L/min|Under high-flow oxygen therapy at a flow rate of 40 L/min, record/monitor for 5 minutes.
219332588|NCT06970990|PROCEDURE|HFNC:flow=30L/min|Under high-flow oxygen therapy at a flow rate of 30 L/min, record/monitor for 5 minutes.
219332589|NCT06970990|PROCEDURE|Face mask oxygen:8L/min|Under face mask oxygen at a flow rate of 8 L/min, record/monitor for 5 minutes.
219332590|NCT06970990|PROCEDURE|Face mask oxygen:5L/min|Under face mask oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
219332591|NCT06970990|PROCEDURE|Nasal cannula oxygen:5L/min|Under nasal cannula oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
219332592|NCT06970990|PROCEDURE|Nasal cannula oxygen:3L/min|Under nasal cannula oxygen at a flow rate of 3 L/min, record/monitor for 5 minutes.
219332593|NCT02470299|DRUG|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
219332594|NCT02470299|OTHER|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
219332595|NCT04187105|DEVICE|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
219332596|NCT04187105|DRUG|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
219332597|NCT04187105|DRUG|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
219332598|NCT04187105|DEVICE|Arm 1|Total body irradiation 2Gy on day -1.
219332599|NCT04187105|OTHER|Arm1|Stem cell infusion on day 0.
219332600|NCT04187105|DRUG|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
219332601|NCT04187105|DRUG|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
219332602|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
219332603|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
219332604|NCT00389792|DRUG|ATI-2042|no intervention
219332605|NCT00389792|DRUG|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
219332606|NCT02484326|OTHER|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
219332607|NCT03947125|DRUG|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
219332608|NCT02878551|OTHER|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
219332609|NCT03203551|OTHER|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
219332610|NCT02624466|OTHER|CKD progress|CKD progress
219332611|NCT00605592|PROCEDURE|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
219332612|NCT02416752|DRUG|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
219332613|NCT02416752|DRUG|choice of intra-operative opioids were left to the discretion of anesthesiologist|
219332614|NCT02848950|DRUG|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
219332615|NCT00612261|PROCEDURE|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
219332616|NCT00612261|PROCEDURE|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
219332617|NCT04609813|DIAGNOSTIC_TEST|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
219332618|NCT00971763|BIOLOGICAL|rituximab|
219332619|NCT00971763|DRUG|cyclophosphamide|
219332620|NCT00971763|DRUG|gemcitabine hydrochloride|
219332621|NCT00971763|DRUG|prednisolone|
219332622|NCT00971763|DRUG|vincristine sulfate|
219332623|NCT01038804|DRUG|YM155|intravenous infusion
219332624|NCT01038804|DRUG|Docetaxel|intravenous infusion
219332625|NCT06807619|DRUG|Sotorasib|Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care
219332626|NCT02524470|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
219332627|NCT02524470|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
219332628|NCT01766128|DRUG|Zonisamide|The first arm will be treated by zonisamide
219332629|NCT01766128|DRUG|Placebo|The second arm will receive placebo
219332630|NCT04972240|OTHER|customization of abutment|we will customize abutment for every patient not ready made
219332631|NCT05667948|DRUG|Chemotherapy|different treatments based on the molecular analysis
219332632|NCT01708070|BEHAVIORAL|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
219332633|NCT05179226|DRUG|Ferric Derisomaltose|All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
219332634|NCT06980506|DIAGNOSTIC_TEST|MNPR-101-DFO*-89Zr|MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.
219332635|NCT01357577|BEHAVIORAL|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
219332636|NCT03372850|DRUG|HIP1601|Test Drug
219332637|NCT03372850|DRUG|HGP1705|Reference Drug
219332638|NCT06985797|OTHER|Funfitness program with no music|Group A will undergo FunFitness program without music (Control Group)
219332639|NCT06985797|OTHER|funfitness program with slow music|Group B will undergo FunFitness program with slow music (Experimental Group)
219332640|NCT06985797|OTHER|Funfitness program with fast music|Group C will undergo FunFitness program with fast music (Experimental Group)
219332641|NCT06984991|DIAGNOSTIC_TEST|fine needle aspiration|Different needle sizes will be used in FNA sampling ; 5ml syringe with 21G needle, 3ml syringe with 23G needle or 22G Quincke tip spinal needle will be used for FNA. Needle insertion will be directed either trans-isthmic or lateral cervical approach. Aspirations will be conducted at different angles and within different nodule regions using a to-and-fro motion till getting blood stain in the needle hub to obtain representative samples. Maximum number of four passes will be performed within the nodule in a single session. Samples will be primarily obtained without suction via the capillary method. However, aspiration with suction will be applied if no aspirates could be obtained in the needle hub after routine capillary method. For mixed cystic solid lesions; FNA will be done from the solid component after aspiration of the cystic component
219332642|NCT06984796|DEVICE|Photobiomodulation|The irradiated region will cover the lumbar and thoracic spine, specifically from T10 to L4, using the Light Emitting Diode panel in a vertical orientation. Photobiomodulation in the experimental group will be administered using 132 Light Emitting Diodes with wavelengths of 660 nm and 850 nm, applied in contact mode. Each Light Emitting Diode has an emission area of 0.5 cm², with an application time of 20 minutes, an irradiance of 16 mW/cm², and an energy delivery of 4.8 J per Light Emitting Diode, resulting in a radiant exposure of 9.6 J/cm².
219332643|NCT06984796|OTHER|Simulation of Photobiomodulation|"The researcher responsible for the photobiomodulation application will simulate irradiation by positioning the device in the exact location as in the Photobiomodulation Group; however, the equipment will remain turned off.~To prevent participants from identifying the group to which they belong, the device's activation sound (beep) will be pre-recorded and played during the application."
219332644|NCT06986239|BIOLOGICAL|PCV-LITE|Fractional dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
219332645|NCT06986239|BIOLOGICAL|PCV-LITE+LVA|Fractional dose of pneumococcal polysaccharide conjugate vaccine with 1 mg of LiteVax Adjuvant (LVA)
219332646|NCT06986239|BIOLOGICAL|PCV20|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
219332647|NCT06986239|BIOLOGICAL|PCV20+LVA|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine with LiteVax Adjuvant (LVA)
219332648|NCT06986213|BEHAVIORAL|Heart Pillow Intervention|"Self-Care:~Teach techniques to perform diminished or dependent self-care. Demonstrate assistive devices for self-care. Teach and train techniques and the use of assistive devices.~Scare Tissue:~Perform massage techniques on scar tissue: gliding and friction. Teach and train massage technique."
219332649|NCT06985615|DRUG|Single dose of HDM1002 on Day 1|Single dose of HDM1002 will be administered on Day 1
219332650|NCT06984575|OTHER|No interventions|No interventions
219332651|NCT06986265|OTHER|Collection of clinical data and biological sampling|Multiple measures relevant to cachexia, such as body weight, body mass index (BMI), muscle mass (handgrip strength using a Jamar hand dynamometer, mid-upper arm muscle circumference), appetite (Functional Assessment of Anorexia/Cachexia Therapy \[FAACT\], Simplified Nutritional Appetite Questionnaire \[SNAQ\], Automated Self- Administered Dietary Assessment Tool \[ASA24\]) will be recorded at inclusion (T0), after 6 months (T6) and after one year of follow-up (T12). Body composition will be assessed by bioelectrical impedance analysis at T0, T6 and T12, and by CT-scan at T0 and T12. In parallel, gut microbiota composition on feces collection will be determined at the two time points (T0 and T12). Markers of systemic and intestinal inflammation will be assessed at T0 and T12. Serum levels of uremic toxins will be measured at T0 and T12. Human muscle biopsies will be performed at the time of a surgical intervention.
219332652|NCT06985082|OTHER|THERE IS NOT A INTERVENTION|THERE IS NOT A INTERVENTION
219332653|NCT06985680|BEHAVIORAL|LINE@ Diabetes Health Education Chatbot|"Upon opening the LINE application, the research subjects need to enter Diabetes Smart Helper in the LINE@ Diabetes Health Education Chatbot. Once added to the program, the LINE interface will directly display six small windows for diabetes symptoms/complications, diet, medication, exercise, mental health, and others, facilitating self-selection by users."
219332654|NCT06984614|OTHER|Snoezelen room|'Snoezelen room' is a meaning a room designed to stimulate people's senses. The history of the Snoezelen room dates back to people with mild or severe disabilities. It provides muscle relaxation for people with severe pain. This has become part of complementary medicine that promotes effective comfort and relaxation, which causes the release of endorphins and alleviates a person's capacity to cope with pain. The Snoezelen environment can be used to distract from pain by focusing on various senses, including visual and auditory. Describing multi-sensory therapeutic activity in a special room filled with stimuli that aim to stimulate all senses provides participants with feelings of relaxation and self-control (Nielsen, Overgaard, 2020; Jamshidi Manesh et. al., 2015; Anderson et. al.2011). In the study, the Snoezelen room was designed and the pregnant women in the intervention group will complete their labor in this room, while the control group will complete their labor in the
219332655|NCT06687356|PROCEDURE|Surgery with Intraoperative Optical Coherence Tomography application|Surgery with the application of intraoperative optical coherence tomography technique. Intraoperative optical coherence tomography technique can provide intraocular images and show changes in intraocular structures, assisting in analyzing the correlation between preoperative, intraoperative anterior segment structural changes and postoperative surgical effects in patients with lens diseases.
219332656|NCT06687356|PROCEDURE|Conventional surgery|Conventional lens surgery, without the application of intraoperative optical coherence tomography technique.
219332657|NCT06734741|DIAGNOSTIC_TEST|COVID/Flu Detect™ Rapid Self-Test|The COVID/Flu Detect™ Rapid Self-Test is an investigational qualitative lateral flow immunoassay designed for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. It is intended for non-prescription over-the-counter (OTC) use.
219332658|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
219332659|NCT01798368|DEVICE|PBASE system 2.0|
219332660|NCT03690076|OTHER|Endocarditis|Comparison : Endocarditis vs. control
219332661|NCT03690076|OTHER|Obese vs. control|Comparisons : Obese vs. control
219332662|NCT01155362|BIOLOGICAL|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
219332663|NCT01155362|DRUG|Vehice Control|
219332664|NCT04086394|PROCEDURE|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
219332665|NCT04086394|PROCEDURE|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
219332666|NCT03697720|DRUG|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
219332667|NCT03919279|DEVICE|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
219332668|NCT05396079|OTHER|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
219332669|NCT05396079|OTHER|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
219332670|NCT03045445|DIAGNOSTIC_TEST|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
219332671|NCT03045445|DIAGNOSTIC_TEST|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
219332672|NCT00645957|PROCEDURE|penrose drain|incision and drainage of the infection with placement of a penrose drain
219332673|NCT00645957|PROCEDURE|red rubber drain|incision and drainage of infection and placement of a red rubber drain
219332674|NCT03433014|PROCEDURE|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
219332675|NCT03433014|OTHER|Control|No infiltration
219332676|NCT03464994|DIAGNOSTIC_TEST|ophthalmological examination|"* Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis"
219332677|NCT03235648|PROCEDURE|cardiophrenic lymph nodes resection|surgical resection
219332678|NCT01027611|DRUG|proparacaine HCL 0.5%|
219332679|NCT01027611|DRUG|proparacaine HCL 0.5% + 4% lidocaine solution|
219332680|NCT01027611|DRUG|3.5% viscous lidocaine gel|
219332681|NCT05488587|DIAGNOSTIC_TEST|magnesium and zinc levels|measuring magnesium and zinc levels
219332682|NCT02025868|BEHAVIORAL|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
219332683|NCT02025868|DRUG|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
219332684|NCT05048368|DRUG|Larotinib|Capsules, Oral, 350 mg, single dose, one day
219332685|NCT06781632|DRUG|ropivacaine|Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)
219332686|NCT04456764|BEHAVIORAL|SaFTiE|A multi-modal fatigue risk management program.
219332687|NCT04456764|BEHAVIORAL|Attention Placebo Control|A multi-modal teamwork assessment program.
219332688|NCT03140358|DRUG|Atropine sulfate 0.01%|Atropine 0.01%
219332689|NCT03140358|DRUG|Placebo|placebo
219332690|NCT05431595|DRUG|Haloperidol|Given by Vein (IV)
219332691|NCT05431595|DRUG|Chlorpromazine|Given by Vein (IV)
219332692|NCT05431595|DRUG|Valproate|Given by Vein (IV)
219332693|NCT05431595|DRUG|Placebo|Given by Vein (IV)
219332694|NCT03116997|DRUG|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
219332695|NCT03116997|DRUG|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
219332696|NCT05876221|DRUG|Cablivi|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
219332697|NCT03496012|GENETIC|BIIB111|Administered as specified in the treatment arm.
219332698|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
219332699|NCT05925803|DRUG|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
219332700|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
219332701|NCT04116086|DIAGNOSTIC_TEST|Prostate Biopsy Test|see earlier information
219332702|NCT04429906|DEVICE|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
219332703|NCT06195982|DIETARY_SUPPLEMENT|ketone ester|500 mg/kg of ketone ester administered approximately 1 hour prior to the maximal exercise testing and 250 mg/kg administered approximately 30 minutes prior to submaximal exercise testing
219332704|NCT06195982|DIETARY_SUPPLEMENT|placebo|ketone-free placebo administered approximately 1 hour prior to the maximal exercise testing and ketone-free placebo administered approximately 30 minutes prior to submaximal exercise testing
219332705|NCT03085979|PROCEDURE|Burch Colposuspension|Anti-incontinent surgery
219332706|NCT03085979|PROCEDURE|trans obturator tape|Anti-incontinent surgery
219332707|NCT03085979|PROCEDURE|tension free vaginal tape|Anti-incontinent surgery
219332708|NCT04336670|DEVICE|Immersive Virtual Reality exercise program|Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
219332709|NCT04336670|OTHER|Usual care|Usual center therapies (Physical therapy, occupational therapy..)
219332710|NCT05996159|DEVICE|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
219332711|NCT05996159|DEVICE|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
219332712|NCT02034942|OTHER|Non-sedation|
219332713|NCT02034942|OTHER|Sedation, control|
219332714|NCT01395199|DRUG|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
219332715|NCT05045898|OTHER|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
219332716|NCT05045898|OTHER|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
219332717|NCT01720342|PROCEDURE|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
219332718|NCT03395548|DRUG|Macrogol|Used drug: Macrogol (osmotic laxative)
219332719|NCT00665873|DEVICE|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
219332720|NCT00665873|DRUG|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
219332721|NCT05261958|OTHER|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
219332722|NCT04507542|BEHAVIORAL|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
219332723|NCT04507542|BEHAVIORAL|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
219332724|NCT02308631|PROCEDURE|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
219332725|NCT03805945|DRUG|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
219332726|NCT03805945|DRUG|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
219332727|NCT04436536|OTHER|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
219332728|NCT04436536|OTHER|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
219332729|NCT00169455|BIOLOGICAL|Live attenuated human rotavirus vaccine|
219332730|NCT06087796|DRUG|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
219332731|NCT06087796|DRUG|Pentoxifylline|Topical treatment modality for alopecia areata.
219332732|NCT06087796|DRUG|Metformin|Topical treatment modality for alopecia areata.
219332733|NCT01156272|DEVICE|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
219332734|NCT03852251|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
219332735|NCT03852251|DRUG|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
219332736|NCT03852251|DRUG|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
219332737|NCT00861120|DRUG|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
219332738|NCT00861120|DRUG|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
219332739|NCT01593293|DRUG|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
219332740|NCT01593293|DRUG|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
219332741|NCT01439282|DRUG|eribulin mesylate|Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
219332742|NCT01439282|DRUG|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
219332743|NCT00751777|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
219332744|NCT00751777|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
219332745|NCT02715375|DEVICE|CREON2000A|
219332746|NCT02834221|DEVICE|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
219332747|NCT02834221|OTHER|Anatomical landmark guided puncture|Anatomical landmark puncture
219332748|NCT01502709|DEVICE|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
219332749|NCT01502709|DEVICE|placebo|Matching placebo device
219332750|NCT04096274|BEHAVIORAL|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
219332751|NCT04096274|BEHAVIORAL|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
219332752|NCT03638154|PROCEDURE|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
219332753|NCT03638154|PROCEDURE|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
219332754|NCT02756728|BIOLOGICAL|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
219332755|NCT02756728|OTHER|High dose melphalan|High dose melphalan (HDM)
219332756|NCT02756728|OTHER|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
219332757|NCT04739514|OTHER|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
219332758|NCT03724071|BIOLOGICAL|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
219332759|NCT03724071|DRUG|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
219332760|NCT00959036|DRUG|ATN-103|10 mg every 4 weeks until week 12
219332761|NCT00959036|DRUG|ATN-103|10 mg every 8 weeks until week 12
219332762|NCT00959036|DRUG|ATN-103|30 mg every 4 weeks until week 12
219332763|NCT00959036|DRUG|ATN-103|80 mg every 4 weeks until week 12
219332764|NCT00959036|DRUG|ATN-103|80 mg every 8 weeks until week 12
219332765|NCT00959036|DRUG|Placebo|Placebo every 4 weeks
219332766|NCT00959036|DRUG|Methotrexate|
219332767|NCT04745871|DIAGNOSTIC_TEST|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA or 1,8-2,2 MBq/kg of 68Ga-PSMA-11 will be performed to patient by a single intravenous injection.
219332768|NCT04617938|BEHAVIORAL|TACUNA plus Wellness Circle|TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.
219332769|NCT04617938|BEHAVIORAL|Opioid Education Workshop|The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
219332770|NCT06777641|OTHER|remote supervision|teacher use remote supervision to assist peer training
219332771|NCT00937937|DRUG|Dinaciclib|Given IV
219332772|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
219332773|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
219332774|NCT02715921|OTHER|Tele-exercise|
219332775|NCT04221815|DEVICE|Eagle Eye Platinum digital IVUS catheter with optional SyncVision|IVUS catheter
219332776|NCT04221815|DEVICE|Resolute Onyx Drug Eluting Stent|Stent
219332777|NCT04221815|DEVICE|Onyx Frontier Drug Eluting Stent|Stent
219332778|NCT04221815|DEVICE|Onyx TruStar Drug Eluting Stent|Stent
219332779|NCT04221815|DEVICE|Onyx TruCor Drug Eluting Stent|Stent
219332780|NCT06208787|BEHAVIORAL|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
219332781|NCT06208787|BEHAVIORAL|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
219332782|NCT06837129|DRUG|A single dose of 4 mg iv nalbuphine|prevention of nausea vomiting
219332783|NCT04712396|DRUG|Capivasertib|Subects will be administered single doses of capiversatib on Day 1 and Day 6.
219332784|NCT04712396|DRUG|Itraconazole|Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
219332785|NCT05238129|OTHER|No intervention - standard care is assessed|No intervention - standard care is assessed
219332786|NCT02863731|OTHER|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
219332787|NCT02863731|OTHER|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
219332788|NCT04615221|OTHER|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
219332789|NCT00984490|DRUG|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
219332790|NCT00984490|OTHER|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
219332791|NCT05114395|OTHER|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
219332792|NCT05114395|OTHER|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
219332793|NCT00941161|DRUG|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
219332794|NCT00941161|DRUG|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
219332795|NCT00941161|DRUG|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
219332796|NCT01704040|DRUG|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
219332797|NCT01704040|DRUG|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
219332798|NCT01704040|DRUG|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
219332799|NCT01704040|DRUG|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
219332800|NCT01704040|OTHER|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
219332801|NCT04384484|DRUG|Loncastuximab Tesirine|Intravenous Infusion
219332802|NCT04384484|DRUG|Rituximab|Intravenous Infusion
219332803|NCT04384484|DRUG|Gemcitabine|Intravenous Infusion
219332804|NCT04384484|DRUG|Oxaliplatin|Intravenous Infusion
219332805|NCT05262699|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
219332806|NCT05262699|OTHER|Placebo Control|Devices mounted, no stimulation
219332807|NCT01573871|OTHER|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
219332808|NCT00099996|DRUG|SCH-58235|
219332809|NCT00099996|DRUG|Ezetimibe|
219332810|NCT00210808|DRUG|topiramate|
219332811|NCT05341479|PROCEDURE|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
219332812|NCT05341479|RADIATION|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
219332813|NCT05341479|RADIATION|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
219332814|NCT05341479|OTHER|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
219332815|NCT05341479|PROCEDURE|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
219332816|NCT05610904|DIAGNOSTIC_TEST|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
219332817|NCT05358171|OTHER|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
219332818|NCT05358171|OTHER|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
219332819|NCT06220604|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
219332820|NCT06220604|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
219332821|NCT06220604|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
219332822|NCT06220604|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
219332823|NCT04154670|BIOLOGICAL|MGTA-145|MGTA-145 will be given intravenously
219332824|NCT00842426|BEHAVIORAL|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
219332825|NCT00842426|BEHAVIORAL|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
219332826|NCT06243042|DIAGNOSTIC_TEST|serum vitamin D|blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.
219332827|NCT06243042|DIAGNOSTIC_TEST|urine osmolality|"nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg."
219332828|NCT06243042|OTHER|Frequency volume chart|volume and frequency from time of sleep till 8 am
219332829|NCT02956954|DRUG|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
219332830|NCT02956954|PROCEDURE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
219332831|NCT06244355|OTHER|Extra blood tubes|Extra blood tubes
219332832|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
219332833|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
219332834|NCT05328726|DRUG|GZR-18|As previously described in Arms
219332835|NCT05328726|OTHER|Placebo|Placebo will be dosed in an identical manner to active study drug.
219332836|NCT02807480|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy
219332837|NCT02807480|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
219332838|NCT02807480|BEHAVIORAL|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
219332839|NCT02807480|BEHAVIORAL|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
219332840|NCT02807480|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
219332841|NCT02807480|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
219332842|NCT02163187|DEVICE|Implantation of the InterStimTM|
219332843|NCT02163187|BEHAVIORAL|MSK BFI questionnaires|
219332844|NCT02163187|BEHAVIORAL|The Low Anterior Resection Score (LARS) questionnaires|
219332845|NCT02163187|BEHAVIORAL|The EuroQOL5D questionnaires|
219332846|NCT02163187|BEHAVIORAL|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
219332847|NCT05104645|OTHER|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
219332848|NCT05104645|OTHER|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
219332849|NCT05104645|OTHER|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
219332850|NCT00641550|OTHER|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
219332851|NCT02369848|DEVICE|Shockwave Lithoplasty System|
219332852|NCT04594590|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
219332853|NCT01188200|OTHER|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
219332854|NCT01188200|OTHER|Standard food|Standard meal prior to test time
219332855|NCT00366964|DEVICE|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
219332856|NCT00366964|DEVICE|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
219332857|NCT05073497|OTHER|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
219332858|NCT01979159|BEHAVIORAL|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
219332859|NCT00906802|PROCEDURE|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
219332860|NCT03281668|BEHAVIORAL|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
219332861|NCT02718781|BEHAVIORAL|Health talk|Health talk on zero-time exercise.
219332862|NCT02718781|BEHAVIORAL|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
219332863|NCT02718781|DEVICE|Handgrip|This is a home-based equipment
219332864|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
219332865|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
219332866|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
219332867|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
219332868|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
219332869|NCT02932410|DRUG|Macitentan|Dispersible tablet; Oral use
219332870|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
219332871|NCT00760019|DRUG|salsalate|1.5 grams orally 3 times daily
219332872|NCT00760019|DRUG|placebo|matching placebo
219332873|NCT02471703|DEVICE|Total hip arthroplasty|Total hip arthroplasty
219332874|NCT03870542|PROCEDURE|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
219332875|NCT02541279|PROCEDURE|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
219332876|NCT04193046|OTHER|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
219332877|NCT04425291|BIOLOGICAL|4-valent HPV Vaccine|Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
219332878|NCT04425291|BIOLOGICAL|9-valent HPV Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
219332879|NCT04425291|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
219332880|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
219332881|NCT00949832|DIETARY_SUPPLEMENT|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
219332882|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D2|50,000 IU given orally once
219332883|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU given orally once
219332884|NCT06220539|OTHER|Casting and supervised rehabilitation|casting (8 weeks) followed by supervised rehabilitation
219332885|NCT03785158|OTHER|Liquid Melatonin|Melatonin is a natural supplement.
219332886|NCT03785158|OTHER|Placebo|Similar looking/tasting placebo syrup
219332887|NCT00540137|DRUG|nevirapine|400mg once daily
219332888|NCT00540137|DRUG|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
219332889|NCT01901575|DRUG|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
219332890|NCT05021107|OTHER|FDM with isometrics|FDM with isometrics will be done
219332891|NCT05021107|OTHER|FDM without isometrics|FDM without isometrics will be done
219332892|NCT06090214|DIAGNOSTIC_TEST|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
219332893|NCT04347707|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
219332894|NCT03717909|DRUG|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
219332895|NCT03717909|DRUG|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
219332896|NCT00762892|DRUG|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
219332897|NCT00762892|DRUG|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
219332898|NCT01378507|BEHAVIORAL|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
219332899|NCT03514537|PROCEDURE|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
219332900|NCT03514537|DEVICE|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
219332901|NCT03514537|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
219332902|NCT03514537|DRUG|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
219332903|NCT03514537|DRUG|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
219332904|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
219332905|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
219332906|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
219332907|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
219332908|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
219332909|NCT02466711|DRUG|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
219332910|NCT02466711|DRUG|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
219332911|NCT06151912|OTHER|Postoperative Nausea and Vomiting scala|The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
219332912|NCT06151912|OTHER|Quality of life|The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
219332913|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
219332914|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
219332915|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
219332916|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
219332917|NCT05714982|OTHER|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
219332918|NCT05714982|OTHER|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
219332919|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
219332920|NCT00549939|DRUG|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
219332921|NCT00549939|DRUG|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
219332922|NCT03677596|DRUG|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
219332923|NCT03677596|DRUG|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
219332924|NCT04726384|DEVICE|Assessment of physical activity level|Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (\>3MET) and moderate ( \>6MET) exercise.
219332925|NCT00305968|BEHAVIORAL|patient education|Patient education group
219332926|NCT04932850|BIOLOGICAL|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
219332927|NCT04932850|OTHER|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
219332928|NCT05201781|DRUG|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
219332929|NCT06216379|DIAGNOSTIC_TEST|Assessment|Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
219332930|NCT04520048|OTHER|Determination of the UEMP levels|Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.
219332931|NCT04520048|PROCEDURE|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical) and/or Popmetre.
219332932|NCT04520048|OTHER|Vascular biomarker assay|Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.
219332933|NCT04520048|PROCEDURE|Measurement of the uterine artery diameter|This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
219332934|NCT05140512|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
219332935|NCT05140512|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
219332936|NCT04632303|OTHER|Early Palliative Care|Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
219332937|NCT06581471|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
219332938|NCT01279577|DRUG|Low dose TSO|Low dose TSO suspension
219332939|NCT01279577|DRUG|Medium dose TSO|Medium dose TSO suspension
219332940|NCT01279577|DRUG|High dose TSO|High dose TSO suspension
219332941|NCT01279577|DRUG|Placebo|Placebo solution
219332942|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
219332943|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
219332944|NCT03127267|DRUG|Placebo|treatment per os
219332945|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
219332946|NCT03634397|BEHAVIORAL|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
219332947|NCT03634397|BEHAVIORAL|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
219332948|NCT02123758|DRUG|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
219332949|NCT02123758|DRUG|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
219332950|NCT02123758|DRUG|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
219332951|NCT00861250|DRUG|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
219332952|NCT06429280|DEVICE|N/A this is an observational study of Standard of Care|Medical Device which treats unilateral amblyopia through therapeutic software which stimulate vision
219332953|NCT06380660|DRUG|ACE-86225106 tablet|ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
219332954|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
219332955|NCT05822843|DRUG|ESG206|Administered via intravenous (IV) infusion
219332956|NCT03364153|DRUG|avacincaptad pegol|Intravitreal Injection
219332957|NCT03364153|DRUG|Sham|Intravitreal Injection
219332958|NCT00015054|DRUG|Methylphenidate|
219332959|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
219332960|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
219332961|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
219332962|NCT06169475|DRUG|Dexmedetomidine Hydrochloride|The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
219332963|NCT06169475|DRUG|Esmolol Hydrochloride|The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
219332964|NCT06959511|DRUG|Zanzalintinib|Given by po
219332965|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
219332966|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
219332967|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
219332968|NCT06407648|OTHER|Personalized Assessments|Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
219332969|NCT06407648|OTHER|Standard of Care|The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
219332970|NCT02849470|PROCEDURE|Intradermal Injection in hair loss|Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss
219332971|NCT02849470|PROCEDURE|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
219332972|NCT02849470|PROCEDURE|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
219332973|NCT02849470|PROCEDURE|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
219332974|NCT02849470|PROCEDURE|MatriStem Matrix (ACell) - Current Standard of Care|
219332975|NCT02849470|PROCEDURE|HD-PRP (High Density Platelet Rich Plasma)|
219332976|NCT02849470|PROCEDURE|Emulsified AD-tSVF|
219332977|NCT02849470|PROCEDURE|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
219332978|NCT00533143|OTHER|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
219332979|NCT04858984|DEVICE|Virtual Reality|A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
219332980|NCT05160584|OTHER|No intervention|There is no interventional treatment component for participants with RRMM in this study.
219332981|NCT06075576|DIAGNOSTIC_TEST|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
219332982|NCT05455320|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219332983|NCT05455320|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
219332984|NCT05455320|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219332985|NCT05455320|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
219332986|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
219332987|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
219332988|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
219332989|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
219332990|NCT04769050|DRUG|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
219332991|NCT04769050|DRUG|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
219332992|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
219332993|NCT05648058|DRUG|Nefopam ampule|nefopam ampule 50 mg
219332994|NCT05648058|DRUG|diphenhydramine ampule|diphenhydramine ampule 10 mg
219332995|NCT05097521|OTHER|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
219332996|NCT05097521|OTHER|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
219332997|NCT05097521|OTHER|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
219332998|NCT02677948|DRUG|Pacritinib|
219332999|NCT02677948|DRUG|Ibrutinib|
219333000|NCT00786747|BEHAVIORAL|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
219333001|NCT00786747|BEHAVIORAL|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
219333002|NCT05636189|PROCEDURE|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
219333003|NCT05636189|PROCEDURE|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
219333004|NCT04344795|DRUG|TPST-1495 twice daily|TPST-1495 administered orally twice daily
219333005|NCT04344795|DRUG|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
219333006|NCT04344795|DRUG|Pembrolizumab|Pembrolizumab dosed per label recommendations
219333007|NCT04263064|DRUG|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
219333008|NCT04263064|DRUG|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
219333009|NCT05242042|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
219333010|NCT05242042|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
219333011|NCT04886648|BEHAVIORAL|Music Therapy|
219333012|NCT03442036|DEVICE|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
219333013|NCT03442036|DEVICE|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
219333014|NCT01161043|DEVICE|Sensor wear|All subjects to wear sensors
219333015|NCT02200354|DRUG|pemetrexed with bevacizumab|
219333016|NCT01612182|OTHER|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
219333017|NCT02999867|DIETARY_SUPPLEMENT|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
219333018|NCT02999867|DIETARY_SUPPLEMENT|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
219333019|NCT00309465|DRUG|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
219333020|NCT00309465|OTHER|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
219333021|NCT00309465|DRUG|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
219333022|NCT02902354|OTHER|Nifedipine for tocolysis|observational
219333023|NCT06127927|DEVICE|Interventional Left Ventricular Assist System|Interventional left ventricular assist system for cardiogenic shock patients
219333024|NCT05279144|OTHER|Ventroguleal|Vastus Lateralis
219333025|NCT06402175|OTHER|follow up|follow up
219333026|NCT02164929|PROCEDURE|TAP block|
219333027|NCT02164929|PROCEDURE|Epidural|
219333028|NCT02164929|PROCEDURE|Paravertebral block|
219333029|NCT02164929|DRUG|Acetaminophen 1g IV|
219333030|NCT02164929|DRUG|Dexamethasone 4mg|
219333031|NCT02164929|DRUG|Midazolam up to 2mg|
219333032|NCT02164929|DRUG|Propofol 1-2.5 mg/kg|
219333033|NCT02164929|DRUG|Sevoflurane to keep a bispectral index of between 40-60|
219333034|NCT02164929|DRUG|Local infiltration with 10 mL of plain ropivacaine 0.25%|
219333035|NCT02164929|DRUG|Lidocaine|1.5% lidocaine
219333036|NCT02164929|DRUG|Epinephrine|1:200,000 epinephrine
219333037|NCT02164929|DRUG|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
219333038|NCT05794386|PROCEDURE|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
219333039|NCT06482736|DEVICE|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy could reduce the pain of myofascial pain syndrome by pain signal alteration, promoting angiogenesis and increasing perfusion in ischemic tissues induced by sensitization of nociceptors and muscle ischemia.
219333040|NCT00971178|DRUG|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
219333041|NCT00971178|DRUG|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
219333042|NCT00971178|DRUG|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
219333043|NCT03364244|DRUG|Sildenafil|"\[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
219333044|NCT01418807|PROCEDURE|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
219333045|NCT01418807|PROCEDURE|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
219333046|NCT03101228|BEHAVIORAL|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
219333047|NCT01925573|DEVICE|Optune(NOVOTTF-100A)|
219333048|NCT04404387|DRUG|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
219333049|NCT04404387|DRUG|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
219333050|NCT00424749|DRUG|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m\^2.
219333051|NCT00424749|DRUG|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
219333052|NCT00530114|DRUG|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
219333053|NCT00530114|DRUG|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
219333054|NCT04212455|OTHER|Non-interventional study|This is an observational, non-interventional study
219333055|NCT06559306|DRUG|Seltorexant|Seltorexant will be administered orally.
219333056|NCT06559306|DRUG|Placebo|Matching Placebo tablets will be administered orally.
219333057|NCT06559306|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|SSRI/SNRI will be administered orally.
219333058|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 3mg/0.5ml
219333059|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 1mg/0.5ml
219333060|NCT05138809|BEHAVIORAL|Exercise|Use online exercise platform
219333061|NCT01540253|DRUG|PI3K inhibitor BKM120|Given PO
219333062|NCT01540253|DRUG|docetaxel|Given IV
219333063|NCT01540253|OTHER|pharmacological study|Correlative studies
219333064|NCT01540253|OTHER|questionnaire administration|Ancillary studies
219333065|NCT01540253|OTHER|laboratory biomarker analysis|Correlative studies
219333066|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
219333067|NCT04183829|PROCEDURE|induced termination of pregnancy|Medically, induced termination of pregnancy (I-TOP) is defined as an intervention to voluntarily terminate a pregnancy (ie, induced abortion) by either surgical or medical means so it does not result in a live birth.
219333068|NCT01990638|OTHER|exercise capacity test|
219333069|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-8mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
219333070|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-8mmHg), and use standard room temperature with dry insufflation.
219333071|NCT06449651|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
219333072|NCT06449651|DRUG|Placebo|Placebo will be administered intravenously.
219333073|NCT05644652|OTHER|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training."
219333074|NCT05644652|OTHER|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
219333075|NCT02577406|DRUG|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
219333076|NCT02577406|OTHER|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
219333077|NCT02577406|DRUG|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
219333078|NCT02577406|DRUG|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
219333079|NCT02577406|DRUG|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
219333080|NCT04696809|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
219333081|NCT03742349|BIOLOGICAL|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
219333082|NCT03742349|BIOLOGICAL|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
219333083|NCT03742349|DRUG|NIR178|Capsule
219333084|NCT03742349|DRUG|capmatinib|Tablet
219333085|NCT03742349|BIOLOGICAL|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
219333086|NCT03742349|BIOLOGICAL|canakinumab|LIVI (Liquid in vial) Solution for injection
219333087|NCT02138617|DRUG|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
219333088|NCT02138617|DRUG|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
219333089|NCT02138617|DRUG|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
219333090|NCT02138617|DRUG|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
219333091|NCT05884398|DRUG|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
219333092|NCT05884398|DRUG|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
219333093|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
219333094|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered intravenously.
219333095|NCT06323980|DEVICE|Reverse Total Shoulder|Uncemented Reverse Total Shoulder
219333096|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
219333097|NCT04829058|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
219333098|NCT04397276|DRUG|JNJ-70218902|JNJ-70218902 will be administered.
219333099|NCT03006172|DRUG|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
219333100|NCT03006172|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
219333101|NCT03006172|DRUG|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
219333102|NCT03006172|DRUG|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
219333103|NCT03006172|DRUG|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
219333104|NCT03006172|DRUG|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
219333105|NCT03006172|DRUG|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
219333106|NCT04611568|OTHER|Educational Intervention|Receive educational and training material
219333107|NCT04611568|OTHER|Educational Intervention|Receive educational lecture
219333108|NCT04611568|BEHAVIORAL|Health Education|Receive melanoma curriculum
219333109|NCT04611568|BEHAVIORAL|Media Campaign|View digital media strategies
219333110|NCT04611568|OTHER|Survey Administration|Complete survey
219333111|NCT04175600|DRUG|Selexipag|Selexipag tablet will be administered orally.
219333112|NCT04175600|DRUG|Placebo|Matching placebo tablets will be administered orally.
219333113|NCT06091488|OTHER|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
219333114|NCT04033445|DRUG|Placebo|Participants will receive matching placebo IV or SC.
219333115|NCT04033445|DRUG|Guselkumab|Participants will receive guselkumab IV or SC.
219333116|NCT06639659|PROCEDURE|Sphenopalatine Ganglion Block|patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
219333117|NCT06639659|DRUG|Dexmedetomidine|patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
219333118|NCT06639659|OTHER|General Anesthesia (control group)|patients will be operated under general anesthesia including routine protocol for these cases
219333119|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
219333120|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
219333121|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
219333122|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
219333123|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
219333124|NCT01648478|OTHER|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)"
219333125|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
219333126|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
219333127|NCT05272631|DEVICE|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
219333128|NCT05272631|DEVICE|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
219333129|NCT05702034|DRUG|Milvexian|Milvexian will be administered orally.
219333130|NCT05702034|DRUG|Placebo|Placebo will be administered orally
219333131|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
219333132|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
219333133|NCT06408935|DRUG|Guselkumab|Guselkumab will be administered IV and SC.
219333134|NCT05851066|DRUG|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
219333135|NCT05851066|DRUG|0.9% NaCl|placebo
219333136|NCT02531516|DRUG|Apalutamide|
219333137|NCT02531516|DRUG|Bicalutamide|
219333138|NCT02531516|DRUG|Bicalutamide Placebo|
219333139|NCT02531516|DRUG|Apalutamide Placebo|
219333140|NCT02531516|DRUG|GnRH (agonist)|
219333141|NCT02531516|RADIATION|74-80 Grays (units of radiation)|
219333142|NCT06521762|DRUG|Etrasimod|2 mg/day oral tablet
219333143|NCT06521762|DRUG|Placebo|matching placebo oral tablet
219333144|NCT06521762|DRUG|Corticosteroids|Corticosteroids will be given in conjunction with study drug or placebo
219333145|NCT04630171|DEVICE|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
219333146|NCT04630171|DEVICE|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
219333147|NCT04630171|OTHER|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
219333148|NCT00647166|DRUG|corticosteroid and azathioprine|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
219333149|NCT00647166|DRUG|corticosteroid and placebo|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
219333150|NCT04550715|BEHAVIORAL|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
219333151|NCT04550715|BEHAVIORAL|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
219333152|NCT04550715|BEHAVIORAL|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
219333153|NCT04057976|DIAGNOSTIC_TEST|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
219333154|NCT04162015|DRUG|Nivolumab|nivolumab 360 mg
219333155|NCT04162015|DRUG|Pemetrexed|500 mg/m\^2
219333156|NCT04162015|DRUG|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
219333157|NCT05368038|DIAGNOSTIC_TEST|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
219333158|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
219333159|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
219333160|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
219333161|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
219333162|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
219333163|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
219333164|NCT04077463|DRUG|Lazertinib|Lazertinib will be administered orally.
219333165|NCT04077463|DRUG|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
219333166|NCT04077463|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
219333167|NCT04077463|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
219333168|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
219333169|NCT06807424|DRUG|Icotrokinra|Icotrokinra will be administered.
219333170|NCT06807424|DRUG|Placebo|Placebo will be administered.
219333171|NCT05678010|DRUG|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
219333172|NCT05678010|RADIATION|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
219333173|NCT05074810|DRUG|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
219333174|NCT05074810|DRUG|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
219333175|NCT04133636|DRUG|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
219333176|NCT04133636|DRUG|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
219333177|NCT04133636|DRUG|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
219333178|NCT04133636|DRUG|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
219333179|NCT04133636|DRUG|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
219333180|NCT05734391|DIAGNOSTIC_TEST|Routine Infection control|routine part of hospital IPC activities
219333181|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
219333182|NCT05467150|DIETARY_SUPPLEMENT|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
219333183|NCT06008093|DRUG|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles as induction treatment. Durvalumab will also be given during the maintenance treatment period q4w until disease progression or unacceptable toxicity.
219333184|NCT06008093|DRUG|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-days cycles as induction treatment. Tremelimumab will also be given during the maintenance therapy phase at week 16 and week 104 (at the investigators discretion).
219333185|NCT06008093|DRUG|Pemetrexed|Participants in Arm A and Arm B will receive IV pemetrexed q3w for four 21-day cycles as induction treatment. In the maintenance therapy phase, Treatment Arm A will receive Pemetrexed q4w, Treatment Arm B will receive Pemetrexed q3w until disease progression or unacceptable toxicity.
219333186|NCT06008093|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-days cycles as induction treatment. Pembrolizumab will also be given in the maintenance treatment phase q3w until disease progression or unacceptable toxicity or up to 24 months.
219333187|NCT06008093|DRUG|Carboplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
219333188|NCT06008093|DRUG|Cisplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
219333189|NCT05836987|DEVICE|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
219333190|NCT05836987|DRUG|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
219333191|NCT05380141|BEHAVIORAL|Individual patient interviews|"Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview."
219333192|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
219333193|NCT06799819|BEHAVIORAL|Mobility group|Free mobility between FDG injection and scanning (without exiting the Nuclear Medicine Department)
219333194|NCT02113930|BIOLOGICAL|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
219333195|NCT02113930|GENETIC|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
219333196|NCT04754802|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
219333197|NCT04754802|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
219333198|NCT05064579|OTHER|Questionnaires|Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
219333199|NCT05400941|BEHAVIORAL|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
219333200|NCT03653247|BIOLOGICAL|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
219333201|NCT03653247|DRUG|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
219333202|NCT03653247|GENETIC|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
219333203|NCT04451161|BEHAVIORAL|Beliefs and Attitudes for Successful Implementation in Schools (BASIS)|BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.
219333204|NCT04451161|BEHAVIORAL|Trauma-Focused Cognitive-Behavioral Therapy|TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.
219333205|NCT04451161|BEHAVIORAL|Treatment as Usual|Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
219333206|NCT04451161|BEHAVIORAL|Attention Control|Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
219333207|NCT06029660|DEVICE|IMPEDE-FX RapidFill Implants|Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
219333208|NCT06029660|PROCEDURE|EndoVascular Aneurysm Repair|Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
219333209|NCT02344433|BEHAVIORAL|VICKY|Relational agent/virtual counselor
219333210|NCT02344433|BEHAVIORAL|MFHP|US Surgeon General's family history tool
219333211|NCT02246725|OTHER|Contact with palliative care unit.|
219333212|NCT06366074|DEVICE|Watch-TEA group|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
219333213|NCT06366074|DEVICE|Tethered TEA device|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
219333214|NCT04105907|DEVICE|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
219333215|NCT06406855|OTHER|BCI-TSCS|BCI-TSCS therapy, completed 3-4 times per week, that will include activity-based training, with TSCS activated by BCI system detecting movement attempt.
219333216|NCT00144612|DRUG|MRA(Tocilizumab)|8mg/kg/2weeks
219333217|NCT05629234|DRUG|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
219333218|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
219333219|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
219333220|NCT05525689|BEHAVIORAL|IntelliCare|Application with patient-facing tools for depression symptom monitoring, self-management, and care manager communication as well as care manager dashboards for workflow optimization
219333221|NCT05525689|OTHER|COMPASS-Care|Website with content specific to perinatal depression and standard EHR-based tools for patient communication
219333222|NCT00122811|DRUG|Indapamide SR 1.5mg; Perindopril 2-4mg|
219333223|NCT05098392|BEHAVIORAL|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
219333224|NCT03725124|OTHER|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
219333225|NCT03042104|DEVICE|Edwards SAPIEN 3 / SAPIEN 3 Ultra THV|Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
219333226|NCT05696275|BEHAVIORAL|exercise|20-30 minutes of walking and elastic band exercise per day
219333227|NCT02056197|OTHER|Placebo|Shortwave
219333228|NCT02056197|OTHER|Stable surface exercises|Stable surface exercises
219333229|NCT02056197|OTHER|Unstable surface exercises|
219333230|NCT05554796|PROCEDURE|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
219333231|NCT05554796|PROCEDURE|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
219333232|NCT01671111|DRUG|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
219333233|NCT05774925|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
219333234|NCT06079983|DRUG|JSKN003|Administered intravenously according to protocol.
219333235|NCT06079983|DRUG|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333236|NCT06079983|DRUG|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333237|NCT06079983|DRUG|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333238|NCT06079983|DRUG|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333239|NCT06079983|DRUG|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333240|NCT06079983|DRUG|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
219333241|NCT04032470|DEVICE|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
219333242|NCT05312424|DIETARY_SUPPLEMENT|Placebo|300 mg olive oil
219333243|NCT05312424|DIETARY_SUPPLEMENT|Low GG|150 mg GG
219333244|NCT05312424|DIETARY_SUPPLEMENT|High GG|300 mg GG
219333245|NCT02938130|OTHER|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
219333246|NCT06526195|DEVICE|CardioMEMS HF System|The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
219333247|NCT06526195|DEVICE|HeartMate 3 Left Ventricular Assist System|The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
219333248|NCT06526195|OTHER|Guideline Medical Directed Therapy|Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
219333249|NCT00578110|DEVICE|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
219333250|NCT04923893|DRUG|Bortezomib|Bortezomib will be administered SC.
219333251|NCT04923893|DRUG|Dexamethasone|Dexamethasone will be administered orally.
219333252|NCT04923893|DRUG|Lenalidomide|Lenalidomide will be administered orally.
219333253|NCT04923893|DRUG|Cilta-cel|Cilta-cel infusion will be administered.
219333254|NCT04923893|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
219333255|NCT04923893|DRUG|Fludarabine|Fludarabine will be administered intravenously.
219333256|NCT03680911|DRUG|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
219333257|NCT03680911|DRUG|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
219333258|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219333259|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
219333260|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
219333261|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
219333262|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
219333263|NCT00889226|DRUG|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
219333264|NCT00889226|DRUG|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
219333265|NCT04154410|OTHER|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
219333266|NCT04154410|OTHER|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
219333267|NCT04991467|BEHAVIORAL|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
219333268|NCT04991467|BEHAVIORAL|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
219333269|NCT04991467|BEHAVIORAL|CARE Program|Participant will take part in 12 week CARE program.
219333270|NCT04991467|BEHAVIORAL|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
219333271|NCT04991467|BEHAVIORAL|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
219333272|NCT04829175|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
219333273|NCT03434171|BEHAVIORAL|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
219333274|NCT03434171|DIETARY_SUPPLEMENT|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
219333275|NCT06493149|OTHER|Massage therapy|Participants receive a Swedish massage based on the tensegrity principle.
219333276|NCT04634552|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression.
219333277|NCT01862068|OTHER|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
219333278|NCT01862068|OTHER|Blood sample|Blood sample will be performed at inclusion from all healthy patients
219333279|NCT05627557|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
219333280|NCT05627557|DRUG|MMF|MMF will be administered as per schedule specified in the respective arm.
219333281|NCT05627557|DRUG|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
219333282|NCT05627557|DRUG|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
219333283|NCT05627557|DRUG|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
219333284|NCT05627557|DRUG|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
219333285|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
219333286|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
219333287|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
219333288|NCT01135862|DRUG|platelets|6 packs of platelets will be administered
219333289|NCT05829356|BIOLOGICAL|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
219333290|NCT05829356|BIOLOGICAL|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
219333291|NCT02132884|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
219333292|NCT02132884|PROCEDURE|therapeutic procedure|Receive standard of care treatment
219333293|NCT02132884|DRUG|targeted therapy|Receive specific targeted therapy
219333294|NCT02132884|OTHER|laboratory biomarker analysis|Correlative studies
219333295|NCT05597475|DIAGNOSTIC_TEST|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
219333296|NCT05347095|DRUG|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
219333297|NCT05347095|DRUG|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
219333298|NCT04838665|DRUG|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
219333299|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
219333300|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
219333301|NCT04510688|DRUG|Cabozantinib|Observation of treatment with Cabozantinib
219333302|NCT01586351|DEVICE|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
219333303|NCT04970225|OTHER|1 blood sample|4 tubes of 7 ml per sample (a single sample)
219333304|NCT04970225|OTHER|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
219333305|NCT06284265|DRUG|Raphamin|Tablet for oral use.
219333306|NCT06284265|DRUG|Placebo|Tablet for oral use.
219333307|NCT05834309|OTHER|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
219333308|NCT03843281|DRUG|Paracetamol|s. above
219333309|NCT03843281|DRUG|Placebo|s. above
219333310|NCT03843281|DRUG|Morphine|s. above
219333311|NCT03208751|BEHAVIORAL|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
219333312|NCT05088408|DIETARY_SUPPLEMENT|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
219333313|NCT05088408|OTHER|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
219333314|NCT01965977|DRUG|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
219333315|NCT02803528|DRUG|Biodentine|Biodentine is going to be used as the direct pulp capping material
219333316|NCT02803528|DRUG|MTA|MTA is going to be used as the direct pulp capping material in the second group
219333317|NCT00631501|DRUG|Placebo|
219333318|NCT00631501|DRUG|Doxycycline|
219333319|NCT00898443|OTHER|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
219333320|NCT00898443|OTHER|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
219333321|NCT01028950|DRUG|YM150|oral
219333322|NCT05998083|OTHER|exercise|"In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations."
219333323|NCT05998083|OTHER|control|The control group continued only the individual support education program.
219333324|NCT00656773|DRUG|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
219333325|NCT00656773|DRUG|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
219333326|NCT05022849|DRUG|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
219333327|NCT05022849|DRUG|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
219333328|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
219333329|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
219333330|NCT06001112|OTHER|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
219333331|NCT06001112|DRUG|Etoricoxib|etoricoxib 120mg
219333332|NCT05330247|OTHER|Carbohydrate-reduced high-protein (CRHP) Diet|Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.
219333333|NCT05330247|OTHER|Conventional diabetes (CD) Diet|Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
219333334|NCT05784441|DRUG|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
219333335|NCT03591848|BEHAVIORAL|Online support decision tool|Online support decision tool, in addition of the standard oral information
219333336|NCT03591848|BEHAVIORAL|standard oral information|standard oral information
219333337|NCT06235840|BEHAVIORAL|working memory adaptive training|The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each
219333338|NCT06235840|BEHAVIORAL|multi-domain non-adaptive control training|The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
219333339|NCT04695392|OTHER|R2 Bundle|"During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries."
219333340|NCT00422526|DRUG|Micronised progesterone (Utrogestan)|
219333341|NCT04444960|PROCEDURE|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
219333342|NCT00691990|PROCEDURE|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
219333343|NCT05370885|BIOLOGICAL|VE202|VE202 is a rationally defined, live biotherapeutic product for oral administration.
219333344|NCT05370885|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection
219333345|NCT05370885|OTHER|VE202 Placebo|VE202 Placebo
219333346|NCT05370885|OTHER|Vancomycin Placebo|Vancomycin Placebo
219333347|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
219333348|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
219333349|NCT02715336|DRUG|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
219333350|NCT02019823|BEHAVIORAL|Informational SMS-text|
219333351|NCT02019823|BEHAVIORAL|Interactive SMS-text|
219333352|NCT02019823|BEHAVIORAL|Enhanced usual care|
219333353|NCT04045704|PROCEDURE|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
219333354|NCT06075160|DIAGNOSTIC_TEST|Resting full-cycle ratio (RFR)-guided revascularization|The decision of coronary intervention is based on an RFR cut-value of 0.89. If RFR ≤ 0.89, target lesion will be revascularized, and if RFR \> 0.89, PCI will be deferred. However, even if RFR ≤ 0.89, PCI can be deferred if the RFR gradient of the lesion ≤ 0.02, or if the diffused type of stenosis, because physiological gain is expected to be very low.
219333355|NCT06075160|DIAGNOSTIC_TEST|Fractional flow ratio (FFR)-guided revascularization|Study participants of FFR-guided PCI arm will be selected from a large-scaled, ongoing FFR registry. The decision of coronary intervention is based on an FFR cut-value of 0.80. If FFR ≤ 0.80, target lesion will be revascularized, and if RFR \> 0.80, PCI will be deferred.
219333356|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
219333357|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
219333358|NCT02867176|DRUG|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
219333359|NCT02867176|DRUG|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
219333360|NCT02510781|DRUG|Epirubicin|75mg/m2 d1 evry 21days
219333361|NCT02510781|DRUG|Docetaxel|75mg/m2 d1 evry 21days
219333362|NCT02510781|DRUG|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
219333363|NCT02510781|DRUG|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
219333364|NCT03412279|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
219333365|NCT03412279|BEHAVIORAL|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
219333366|NCT05643612|DIAGNOSTIC_TEST|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
219333367|NCT05138666|BIOLOGICAL|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
219333368|NCT05138666|BIOLOGICAL|blood sample|Blood sampling drawn from an existing arterial line twice a week
219333369|NCT02492477|PROCEDURE|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
219333370|NCT02492477|DRUG|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
219333371|NCT02492477|DRUG|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
219333372|NCT05868551|PROCEDURE|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
219333373|NCT03947840|BEHAVIORAL|Physical activity|Se their physical activity level
219333374|NCT05222529|DRUG|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
219333375|NCT05222529|DRUG|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
219333376|NCT05222529|DRUG|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
219333377|NCT01120548|OTHER|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
219333378|NCT02187679|DRUG|Abobotulinum toxin A|
219333379|NCT02504554|DRUG|oral Vancomycin|an antibiotic
219333380|NCT02504554|DRUG|MoviPrep|a bowel cleanse
219333381|NCT02504554|DRUG|Prilosec|a stomach acid suppressan
219333382|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
219333383|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
219333384|NCT03364361|PROCEDURE|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
219333385|NCT01806857|DRUG|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
219333386|NCT01806857|DRUG|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
219333387|NCT04754750|DRUG|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
219333388|NCT04754750|DRUG|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
219333389|NCT05963074|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
219333390|NCT05963074|DRUG|Venetoclax|Venetoclax tablets will be administered orally.
219333391|NCT01020591|OTHER|Osteopathic evaluation|evaluation of movement and tissue mobility
219333392|NCT01020591|OTHER|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
219333393|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
219333394|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
219333395|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
219333396|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
219333397|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
219333398|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
219333399|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
219333400|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
219333401|NCT04702737|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
219333402|NCT03517787|OTHER|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
219333403|NCT03517787|OTHER|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
219333404|NCT03517787|OTHER|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
219333405|NCT03517787|OTHER|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
219333406|NCT04620850|DEVICE|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
219333407|NCT05897814|OTHER|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
219333408|NCT03726606|DEVICE|Intraocular lens|Bilateral implantation of the same intraocular lens.
219333409|NCT03713749|DEVICE|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
219333410|NCT03389295|RADIATION|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
219333411|NCT03484286|DEVICE|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
219333412|NCT03484286|OTHER|Standard care|Patients in the control group will be subject to standard heart failure care.
219333413|NCT06004648|PROCEDURE|Upper extremity surgery|Comparison of 2 different peripheral nerve blocks
219333414|NCT05009927|DRUG|Imatinib tablets|Imatinib interruption
219333415|NCT05651555|BEHAVIORAL|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
219333416|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
219333417|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
219333418|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
219333419|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
219333420|NCT03591822|BEHAVIORAL|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
219333421|NCT03591822|BEHAVIORAL|B : Systemic evaluation of the pain|A systematic evaluation of the pain
219333422|NCT01651858|DRUG|Nurigra Chewable tablet|1 tablet of 100mg, once a day
219333423|NCT06087887|OTHER|no interventions|no interventions
219333424|NCT00036751|DRUG|imatinib mesylate|Given orally
219333425|NCT00036751|OTHER|laboratory biomarker analysis|Correlative studies
219333426|NCT06378671|PROCEDURE|General treatment|routine bronchoscopy examination, lavage, and mucosal biopsy
219333427|NCT06378671|PROCEDURE|Cryotherapy Treatment|local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
219333428|NCT04860271|PROCEDURE|Manual Acupuncture|Manual acupuncture treatment using different types of needle
219333429|NCT00978549|DRUG|docetaxel|
219333430|NCT00978549|DRUG|steroid therapy|
219333431|NCT00978549|OTHER|questionnaire administration|
219333432|NCT00978549|PROCEDURE|nausea and vomiting therapy|
219333433|NCT00978549|PROCEDURE|pain therapy|
219333434|NCT00978549|PROCEDURE|quality-of-life assessment|
219333435|NCT00978549|PROCEDURE|standard follow-up care|
219333436|NCT00978549|RADIATION|radiation therapy|
219333437|NCT00698997|BEHAVIORAL|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
219333438|NCT00698997|BEHAVIORAL|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
219333439|NCT00002128|DRUG|Adefovir dipivoxil|
219333440|NCT03256955|DEVICE|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
219333441|NCT03256955|DEVICE|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
219333442|NCT03491007|DRUG|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
219333443|NCT01350921|DRUG|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
219333444|NCT01350921|DRUG|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
219333445|NCT02513849|DRUG|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
219333446|NCT04722770|DEVICE|PhotoniCare OtoSight Middle Ear Scope|PhotoniCare OtoSight imaging using a near-infrared laser
219333447|NCT02802748|DRUG|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
219333448|NCT02802748|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
219333449|NCT06015139|DEVICE|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
219333450|NCT06015139|DEVICE|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
219333451|NCT00417040|OTHER|internet-based intervention|Use the STAR database system
219333452|NCT00417040|OTHER|assessment of therapy complications|Use the STAR database system
219333453|NCT00417040|OTHER|Questionnaire Administration|Ancillary studies
219333454|NCT01436084|DRUG|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
219333455|NCT05664542|OTHER|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
219333456|NCT05664542|DRUG|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
219333457|NCT01898936|PROCEDURE|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
219333458|NCT01898936|DEVICE|Only photodynamic therapy|
219333459|NCT04319848|OTHER|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
219333460|NCT04784728|DRUG|Lidocaine topical system 1.8%|lidocaine patch
219333461|NCT02447055|BIOLOGICAL|Tocilizumab|
219333462|NCT02447055|DRUG|Melphalan|
219333463|NCT02447055|DRUG|Fludarabine|
219333464|NCT02447055|DRUG|Cyclophosphamide|
219333465|NCT02447055|DRUG|Tacrolimus|
219333466|NCT02447055|DRUG|Mycophenolate mofetil|
219333467|NCT02447055|DRUG|Filgrastim|
219333468|NCT04021836|OTHER|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
219333469|NCT04221698|OTHER|Gait retraining|5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
219333470|NCT01550861|PROCEDURE|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
219333471|NCT01550861|PROCEDURE|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
219333472|NCT04952103|OTHER|no intervention|The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
219333473|NCT02124278|DRUG|PUL-042 Inhalation Solution|
219333474|NCT03327012|DRUG|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
219333475|NCT03327012|DRUG|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
219333476|NCT02639611|OTHER|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
219333477|NCT02639611|OTHER|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
219333478|NCT04825795|DRUG|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
219333479|NCT04825795|DRUG|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
219333480|NCT04354220|DIAGNOSTIC_TEST|capnography monitoring|routinely used capnography monitoring
219333481|NCT04354220|DIAGNOSTIC_TEST|arterial blood gas|Routinely taken arterial blood gas values
219333482|NCT03388918|DEVICE|Telerehabilitation|Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
219333483|NCT05167682|OTHER|Prehabilitation program|Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
219333484|NCT00071942|BIOLOGICAL|recombinant vaccinia-MUC1 vaccine|Given intradermally
219333485|NCT00071942|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|Given intradermally
219333486|NCT00071942|OTHER|laboratory biomarker analysis|Correlative studies
219333487|NCT00071942|PROCEDURE|quality-of-life assessment|Ancillary studies
219333488|NCT02911506|OTHER|Polysomnography|
219333489|NCT04194359|DRUG|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
219333490|NCT06273267|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
219333491|NCT00912002|DRUG|MK-0941|A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
219333492|NCT02509806|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
219333493|NCT06362252|DRUG|Ifinatamab deruxtecan|Intravenous administration
219333494|NCT06362252|DRUG|Atezolizumab|Intravenous administration
219333495|NCT06362252|DRUG|Carboplatin|Intravenous administration
219333496|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
219333497|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
219333498|NCT05865535|BIOLOGICAL|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
219333499|NCT04687787|OTHER|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
219333500|NCT04687787|OTHER|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
219333501|NCT06436066|OTHER|Self-Acupressure|"Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)"
219333502|NCT04814823|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
219333503|NCT02798549|OTHER|blood draw|blood draw of 150ml, twice
219333504|NCT06683937|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file
219333505|NCT06228352|OTHER|Feces collection|"A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers."
219333506|NCT06532032|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
219333507|NCT06532032|DRUG|Docetaxel|Docetaxel will be administered as IV infusion.
219333508|NCT03461419|PROCEDURE|Microcannula Harvest Adipose Stroma|Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
219333509|NCT03461419|DEVICE|Centricyte 1000|Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
219333510|NCT03461419|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
219333511|NCT05488314|DRUG|Capmatinib|Capmatinib will be administered orally.
219333512|NCT05488314|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
219333513|NCT05908734|DRUG|Cetrelimab|Cetrelimab will be administered as IV infusion.
219333514|NCT05908734|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
219333515|NCT04119050|DRUG|M281|M281 injection administered as intravenous infusion
219333516|NCT04119050|DRUG|Placebo|Placebo administered as intravenous infusion
219333517|NCT06851507|DRUG|Fluorouracil 5-FU|Participants in the fluorouracil arm will apply fluorouracil twice daily for 2-3 weeks (depending on body area).
219333518|NCT06851507|DRUG|Fluorouracil/Calcipotriene|Participants in the fluorouracil/calcipotriene will apply fluorouracil/calcipotriene twice daily for 4 days to the affected area.
219333519|NCT04815044|OTHER|Pregnancy|Experiences from being pregnant when having a history of eating disorder
219333520|NCT04815044|OTHER|Post-Partum|Experiences from the post-partum period when having a history of eating disorder
219333521|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
219333522|NCT04272892|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
219333523|NCT04272892|BEHAVIORAL|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
219333524|NCT05424822|DRUG|JNJ-80948543|JNJ-80948543 will be administered as SC or IV injection.
219333525|NCT04540796|DRUG|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
219333526|NCT06012435|DRUG|sigvotatug vedotin|Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
219333527|NCT06012435|DRUG|docetaxel|75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
219333528|NCT01208792|PROCEDURE|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
219333529|NCT01208792|OTHER|Blood Sample|a blood sample will be collected
219333530|NCT05359679|BEHAVIORAL|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
219333531|NCT05359679|OTHER|No Intervention|Usual clinical care - no value champion present at this clinical setting
219333532|NCT05269342|BEHAVIORAL|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
219333533|NCT06393127|DRUG|BI 1015550 Formulation C2|BI 1015550 Formulation C2
219333534|NCT06393127|DRUG|BI 1015550 Formulation C1|BI 1015550 Formulation C1
219333535|NCT06404125|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities. Flexion, extension, abduction, adduction, internal and external rotation angles of the shoulder complex will be evaluated in the measurement.
219333536|NCT06404125|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 10 seconds. The test will be repeated for both upper extremities separately.
219333537|NCT06404125|DIAGNOSTIC_TEST|Numeric Rating Scale|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
219333538|NCT06404125|DIAGNOSTIC_TEST|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point"
219333539|NCT06404125|DIAGNOSTIC_TEST|Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH)|The arm, shoulder and hand problems rapid questionnaire is a shortened version of a questionnaire designed to detect symptoms and loss of function secondary to musculoskeletal problems of the upper extremity. The questionnaire will be used to assess quality of life related to upper extremity function.
219333540|NCT06404125|DIAGNOSTIC_TEST|Short Form-36|The scale was developed by Ware in 1987 and consists of 36 questions in which 8 sub-parameters related to the health status of the person are questioned. These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception. The Turkish validity and reliability of the scale was performed by Pınar et al. It is one of the leading methods used in the evaluation of quality of life in our country as well as all over the world.
219333541|NCT06404125|DIAGNOSTIC_TEST|Central Sensitization Scale|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization are questioned. In part B, the presence of diseases with a well-defined relationship with central sensitization is questioned without participating in the scoring. Patients who score 40 points or more out of a total of 100 points are considered to have central sensitization. Düzce et al. stated that the Central Sensitization Scale can be used as a valid method in the Turkish population to screen the presence of central sensitization in patients presenting with chronic pain.
219333542|NCT06404125|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
219333543|NCT05983133|DRUG|PF-08046052|Given into the vein (IV; intravenously)
219333544|NCT06012786|DIAGNOSTIC_TEST|Diagnostic Criteria of Myofascial Pain Syndrome|"Major criteria:~1. The patient's complaint of regional pain~2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point~3. Presence of palpable taut band~4. Presence of palpable and tender points along the length of the taut band~5. Restriction of ROM in the area of the affected muscle~Minor criteria:~1. Pain/sensory change with pressure palpation of the trigger point~2. Local twitch response with palpation/injection of the trigger point in the taut band~3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis"
219333545|NCT06012786|DIAGNOSTIC_TEST|The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer|Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
219333546|NCT06012786|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
219333547|NCT06012786|DIAGNOSTIC_TEST|VAS|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
219333548|NCT06012786|DIAGNOSTIC_TEST|Quick DASH|The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
219333549|NCT06012786|DIAGNOSTIC_TEST|Lymqol-Arm|Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
219333550|NCT06012786|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
219333551|NCT06118268|DEVICE|iTBS (Active)|"The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands)."
219333552|NCT06118268|DEVICE|iTBS (Sham)|DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
219333553|NCT00943579|DRUG|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
219333554|NCT01164566|PROCEDURE|endoscopic procedure|
219333555|NCT01164566|OTHER|questionnaire administration|Ancillary studies
219333556|NCT02486848|DRUG|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
219333557|NCT02486848|DRUG|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
219333558|NCT05204823|OTHER|Experimental product|Chocolate milk shakes
219333559|NCT05204823|OTHER|Control product|Glucose
219333560|NCT03427333|DEVICE|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
219333561|NCT04142528|DEVICE|ParkinPal|Wear and periodic recording of motion data during daily wear
219333562|NCT06986135|OTHER|Box Breathing|Box breathing consisted of a 4 second inhale, 4 second hold, 4 second exhale, 4 second hold; for 4 minutes.
219333563|NCT06986135|OTHER|Prolonged Exhalation|Prolonged Exhalation consisted of a deep, 3 second inhale, followed by a slow 6 second exhale through pursed lips, once every 30 seconds for 4 minutes.
219333564|NCT06986135|OTHER|Normal Breathing|This was the placebo, normal breathing group was instructed to breath as they normally would for the entirety of the 4 minute period.
219333565|NCT06903416|OTHER|Transcutaneous Cervical Spinal Cord Stimulation|"Cervical transcutaneous spinal cord stimulation will be delivered following previously reported guidelines. Circular (1.25) electrodes will be placed over the cervical spinal cord between the C3 and C4 vertebral level, with rectangular return electrodes placed either over the clavicles or iliac crests. Biphasic stimulation will be delivered continuously at 30Hz, with a 1ms pulse width, and overlapping 10kHz carrier frequency (Gelenitis et al 2024; Moritz et al 2024). Stimulation will be delivered at a current intensity below motor threshold, that is below the intensity required to elicit a muscle twitch. Cervical tSCS will be delivered for at least 60 minutes during each training session, and FTP will occur during the active stimulation."
219333566|NCT06903416|OTHER|Paired Corticospinal Motoneuronal Stimulation|Paired transcranial magnetic stimulation and nerve stimulation will be implemented following a previously-published protocol for individuals with SCI (Jo et al 2023). Two figure-eight coils will be used to deliver bilateral magnetic stimulation of the motor cortex and will be combined with synchronous electrical stimulation of the brachial plexus and ulnar nerves, bilaterally. The timing of stimuli will be determined to ensure that electrical volleys arrive at the corticospinal motoneuronal synapse at an appropriate interval to induce long term potentiation. During each session, 360 paired stimuli will be delivered at a frequency of 0.2 Hz. The stimulation paradigm should take approximately 30 minutes. Following this, participants will then complete 60 minutes of FTP.
219333567|NCT06903416|OTHER|Functional Task Practice|A typical rehabilitation program will be defined and delivered in consultation with physical and occupational therapists. The program will consist of functional tasks including repetitive activities of gross upper extremity movement, isolated finger movements, simple and complex pinch, and grasping activities. For each category, 4-10 activities with various difficulty levels will be identified. Each participant will perform at least 1-2 exercises within each category during each treatment session. Activities in each category will be chosen according to the participants' ability and adjusted based on the evolution of the ability to perform the functional task over time (graded training).
219333568|NCT06754462|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection.
219333569|NCT06754462|DRUG|Placebo|Administered once weekly by subcutaneous injection.
219333570|NCT07138937|PROCEDURE|Root canal treatment in primary molars with irreversible pulpitis|Root canal treatment in primary molars with irreversible pulpitis followed by coronal restoration with stainless-steel crowns in a single visit.
219333571|NCT07138937|DEVICE|EDDY system for sonic activation of irrigation|sonic activation of irrigation with EDDY system during root canal treatment in primary molars
219333572|NCT07138937|DEVICE|side-vented needle|conventional irrigation with side-vented needle without activation during root canal treatment in primary molars
219333573|NCT07138807|BEHAVIORAL|Muscle Energy Technique|Participants in this group received Muscle Energy Techniques targeting the upper trapezius trigger points. Treatment was provided 3 sessions per week for 4 weeks. Each session included post-isometric relaxation techniques with stretching, along with baseline TENS therapy.Participants performed Neck Calliet Exercises focusing on cervical flexion, extension, rotation, and lateral flexion. Exercises were done under supervision, 3 times per week for 4 weeks. All participants also received baseline TENS therapy.
219333574|NCT07138807|OTHER|Neck Calliet exercise|Neck Calliet exercise
219333575|NCT07140211|DRUG|Low-dose low-molecular-weight heparin|"Low-molecular-weight heparin given for 7-10 days after delivery:~* enoxaparin 4000-6000IU o.d.~* nadroparin 3800-5700IU o.d.~* dalteparin 5000-7500IU o.d.~* tinzaparin 4500-7000IU o.d."
219333576|NCT02231151|BEHAVIORAL|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
219333577|NCT06039124|OTHER|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
219333578|NCT06272461|DRUG|Lidocaine IV|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
219333579|NCT06272461|DRUG|Ketamine Injectable Solution|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
219333580|NCT04031144|PROCEDURE|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
219333581|NCT00683163|DRUG|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
219333582|NCT00683163|DRUG|Ibandronate|150mg by mouth once monthly
219333583|NCT00683163|OTHER|Placebo injection|Daily injections as placebo for PTS 1-84
219333584|NCT00683163|OTHER|Placebo pills|Monthly pills as placebo for oral ibandronate
219333585|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
219333586|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
219333587|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
219333588|NCT05696483|DRUG|OLX-07010 Active|25 and 75 mg capsules
219333589|NCT05696483|DRUG|OLX-07010 Placebo|25 and 75 mg capsules
219333590|NCT04635800|DRUG|MHU650|MHU650 powder for solution for injection
219333591|NCT05854316|DIAGNOSTIC_TEST|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
219333592|NCT05281666|DEVICE|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
219333593|NCT05281666|DEVICE|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
219333594|NCT04753853|PROCEDURE|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
219333595|NCT02671357|PROCEDURE|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
219333596|NCT02322125|DEVICE|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
219333597|NCT01199588|DRUG|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
219333598|NCT01199588|DRUG|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
219333599|NCT01199588|DRUG|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
219333600|NCT01815047|DIETARY_SUPPLEMENT|Vitamin D3 Supplementation|
219333601|NCT01463670|DRUG|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
219333602|NCT05502042|BEHAVIORAL|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
219333603|NCT00565253|DRUG|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
219333604|NCT02055651|BEHAVIORAL|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
219333605|NCT02280395|DRUG|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
219333606|NCT02280395|DRUG|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
219333607|NCT05288218|DEVICE|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
219333608|NCT05288218|DEVICE|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
219333609|NCT01841944|DRUG|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
219333610|NCT01841944|OTHER|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
219333611|NCT03388359|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
219333612|NCT03388359|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
219333613|NCT03388359|OTHER|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
219333614|NCT03388359|OTHER|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
219333615|NCT03388359|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
219333616|NCT03388359|DEVICE|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
219333617|NCT03388359|BIOLOGICAL|Eosinophils|Eosinophils are isolated from peripheral blood
219333618|NCT03388359|BIOLOGICAL|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
219333619|NCT03388359|BIOLOGICAL|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
219333620|NCT04203732|PROCEDURE|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
219333621|NCT04024033|DIETARY_SUPPLEMENT|pine cone extract|pine cone extract capsule
219333622|NCT04024033|OTHER|placebo|placebo capsule
219333623|NCT00971165|DRUG|losartan|Oral losartan up to 100 mg daily fo 18 months
219333624|NCT00971165|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
219333625|NCT05490173|OTHER|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
219333626|NCT00929175|DEVICE|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
219333627|NCT00929175|DEVICE|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
219333628|NCT02227732|DEVICE|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
219333629|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
219333630|NCT00449670|BIOLOGICAL|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
219333631|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
219333632|NCT00234468|DRUG|Iressa (Gefitinib)|
219333633|NCT03059238|DRUG|Celecoxib 200mg oral capsule|
219333634|NCT03059238|DRUG|parecoxib sodium|
219333635|NCT03059238|DRUG|controlled-release oxycodone|
219333636|NCT04183790|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
219333637|NCT04183790|DRUG|IVA|Mono tablet for oral administration.
219333638|NCT03716271|DEVICE|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
219333639|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
219333640|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
219333641|NCT01251653|DRUG|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
219333642|NCT01251653|DRUG|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
219333643|NCT01825291|PROCEDURE|CPAP treatment|
219333644|NCT03410433|DEVICE|Silk 4.0|Silk suture 4.0
219333645|NCT03410433|DEVICE|PG 910 4.0|PG 910 4.0
219333646|NCT03410433|DEVICE|PP 4.0|PP 4.0
219333647|NCT03410433|DEVICE|Silk 5.0|Silk 5.0
219333648|NCT03410433|DEVICE|PG910 5.0|PG910 5.0
219333649|NCT03410433|DEVICE|PP 5.0|PP 5.0
219333650|NCT03410433|DEVICE|APG 5.0|APG 5.0
219333651|NCT03410433|DEVICE|ePTFE 5.0|ePTFE 5.0
219333652|NCT02268279|DRUG|solithromycin|
219333653|NCT04268251|DIAGNOSTIC_TEST|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
219333654|NCT06156683|OTHER|Multiple sclerosis disease modifying drug|There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.
219333655|NCT03075800|BEHAVIORAL|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
219333656|NCT01798589|DRUG|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
219333657|NCT05068570|OTHER|ARMEROMTERY|ARMERGOMTERY TRAINING FOR UPPERLIMB
219333658|NCT01781715|DEVICE|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
219333659|NCT03906097|OTHER|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
219333660|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
219333661|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
219333662|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
219333663|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
219333664|NCT04289337|DIETARY_SUPPLEMENT|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
219333665|NCT04289337|DIETARY_SUPPLEMENT|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
219333666|NCT04058340|DIETARY_SUPPLEMENT|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
219333667|NCT04058340|OTHER|Placebo|0.9% NaCl solution in nebulization
219333668|NCT01739985|DRUG|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
219333669|NCT01739985|DRUG|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
219333670|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
219333671|NCT04305522|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
219333672|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
219333673|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
219333674|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
219333675|NCT03380260|BEHAVIORAL|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
219333676|NCT00790686|PROCEDURE|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
219333677|NCT00634634|DRUG|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
219333678|NCT00634634|DRUG|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
219333679|NCT00885703|DRUG|Fluconazole|"Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
219333680|NCT00885703|DRUG|Amphotericin B|Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
219333681|NCT01183143|DRUG|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
219333682|NCT00689468|PROCEDURE|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
219333683|NCT00689468|DIETARY_SUPPLEMENT|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
219333684|NCT00689468|PROCEDURE|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
219333685|NCT00689468|DIETARY_SUPPLEMENT|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
219333686|NCT03045770|DRUG|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
219333687|NCT03045770|DRUG|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
219333688|NCT03045770|DRUG|Irinotecan|Irinotecan was used as first line treatment with AGC.
219333689|NCT03045770|DRUG|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
219333690|NCT03045770|DRUG|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
219333691|NCT00001764|DRUG|Mycophenolate Mofetil|
219333692|NCT05023356|DEVICE|Non-contact vital signs monitoring with camera|Monitor patients face image by non-contact vital signs monitoring with camera
219333693|NCT01365260|DEVICE|MM-II|Single intraarticular (knee) injection of MM-II
219333694|NCT01365260|DEVICE|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
219333695|NCT04584528|OTHER|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
219333696|NCT02270619|BIOLOGICAL|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
219333697|NCT02270619|BEHAVIORAL|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
219333698|NCT02270619|OTHER|Placebo|0.9% saline as IV bolus
219333699|NCT02270619|OTHER|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
219333700|NCT02726087|PROCEDURE|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
219333701|NCT02726087|PROCEDURE|Full sternotomy|Conventional full median sternotomy
219333702|NCT03223480|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
219333703|NCT05348512|OTHER|spectral imaging|non-contact, non-invasive hyperspectral and multispectral imaging without a diagnostic test
219333704|NCT05348512|OTHER|photoplethysmography|non-invasive pulse oximetry without a diagnostic test
219333705|NCT05343286|PROCEDURE|blood sample|blood sample before and after 12 weeks of physical activity
219333706|NCT05343286|OTHER|physical assessement|"physical assessement before and after 12 weeks of physical activity~* Standardized geriatric assessment (physician visit)~* ICOPE Monitor Assessment~* Sit-to-stand Test~* Quantified Gait Analysis (QAM)~* Bone densitometer measurement of body composition"
219333707|NCT05343286|BEHAVIORAL|psychometric assessment|"Psychometric questionnaires~* Cognitive tests (MMSE)~* The long questionnaire of personality traits: Big Five Inventory~* Perceived health and subjective age~* Age group identification~* Attitudes towards aging: French version of the Attitudes Toward Own Aging scale~* Physical self-perception: French version of the Physical Self-Perception Profile~* MOTIVATION SCALE FOR PA FOR HEALTH PURPOSES: Motivation Scale for Physical Activity in a Health Context~* Aging Stereotypes and Exercise Scale"
219333708|NCT03698942|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
219333709|NCT05251714|DRUG|CFI-402257|Oral once daily in 28 day cycles
219333710|NCT05251714|DRUG|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
219333711|NCT06959680|OTHER|Exercise and Kinesiotaping|Exercise and Kinesiotaping
219333712|NCT06959680|OTHER|Exercise|only exercise will be performed without any band treatment
219333713|NCT06959680|OTHER|exercise and sham taping|exercise and sham banding (banding without tension with plaster)
219333714|NCT00794495|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
219333715|NCT00794495|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
219333716|NCT06104982|DEVICE|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
219333717|NCT06104982|OTHER|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
219333721|NCT04989426|OTHER|the state of health of newly arrived migrant patients in the year following their arrival in France|the state of health of newly arrived migrant patients in the year following their arrival in France
219333722|NCT03584828|BEHAVIORAL|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
219333723|NCT00201968|DEVICE|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
219333724|NCT00201968|DEVICE|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
219333725|NCT00201968|OTHER|Conventional Exercise|An aerobic and resistance training program.
219333726|NCT03926715|OTHER|Nutritional status|
219333727|NCT01490450|BIOLOGICAL|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
219333728|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
219333729|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
219333730|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
219333731|NCT02712476|DRUG|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
219333732|NCT02712476|DRUG|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
219333733|NCT02712476|DRUG|placebo|mannitol alone is compared with placebo
219333734|NCT04316377|DRUG|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
219333735|NCT02800408|OTHER|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
219333736|NCT02800408|OTHER|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
219333737|NCT02800408|OTHER|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
219333738|NCT01814020|DRUG|MOB015B|
219333739|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
219333740|NCT00182195|PROCEDURE|Control Ventilation Strategy|
219333741|NCT04133532|DRUG|Metoprolol|metoprolol 50 mg daily for three months
219333742|NCT03947489|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
219333743|NCT03210389|DRUG|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
219333744|NCT01086462|DRUG|GSK2239633|100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
219333745|NCT04933331|DRUG|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
219333746|NCT04933331|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
219333747|NCT04933331|DEVICE|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
219333748|NCT04933331|DEVICE|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
219333749|NCT04933331|DRUG|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
219333750|NCT05865327|PROCEDURE|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
219333751|NCT05865327|PROCEDURE|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
219333755|NCT01407640|PROCEDURE|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
219333756|NCT06580340|OTHER|AFA (Adapted Physical Activity)|An exercise program to improve joint mobility, muscle strength, static and dynamic balance, motor coordination will be performed 2 times/week for 6 months.
219333757|NCT01888120|DRUG|Ziconotide|
219333758|NCT03420014|DRUG|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
219333759|NCT03420014|COMBINATION_PRODUCT|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
219333760|NCT06631638|DEVICE|EMPHASYS Cup with VHN|Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
219333761|NCT03576599|DRUG|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
219333762|NCT03576599|DRUG|Placebo|Placebo
219333763|NCT01489670|DRUG|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
219333764|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
219333765|NCT06455098|DEVICE|OMNYPULSE™ Catheter with the TRUPULSE Generator|OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
219333766|NCT04788654|DRUG|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
219333767|NCT04788654|PROCEDURE|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
219333768|NCT01129362|BIOLOGICAL|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
219333769|NCT01129362|BIOLOGICAL|Other Pertussis Vaccines|0.5 mL, Intramuscular
219333770|NCT01776762|DIETARY_SUPPLEMENT|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
219333771|NCT06549816|DRUG|sigvotatug vedotin|Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
219333772|NCT03965676|OTHER|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
219333773|NCT03662165|BEHAVIORAL|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
219333774|NCT03662165|BEHAVIORAL|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
219333775|NCT03662165|BEHAVIORAL|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
219333776|NCT02865018|DRUG|cetirizine|
219333777|NCT01163812|PROCEDURE|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
219333778|NCT05336916|BEHAVIORAL|Buddy|Mindfulness-based Cognitive Behavioural Therapy
219333779|NCT02015442|DIETARY_SUPPLEMENT|Sucrose|
219333780|NCT06491056|DEVICE|Focal Therapy for Prostate Cancer|Ablation of \<75% of the prostate gland for limited volume prostate cancer
219333781|NCT04067479|DIETARY_SUPPLEMENT|Amino Acids|Oral bolus of essential amino acids
219333782|NCT01062633|DIETARY_SUPPLEMENT|A, erythritol|2,5 g 3 times a day
219333783|NCT01062633|DIETARY_SUPPLEMENT|xylitol|2,5 g 3 times a day
219333784|NCT01062633|DIETARY_SUPPLEMENT|C, sorbitol|2,5 g 3 times aday
219333785|NCT02124395|OTHER|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
219333786|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
219333787|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
219333788|NCT00286481|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
219333789|NCT05843435|BEHAVIORAL|Go-Nogo-task during functional magnetic resonance imaging|Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.
219333790|NCT05843435|OTHER|Resting-state functional magnetic resonance imaging|An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.
219333791|NCT00744133|BIOLOGICAL|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
219333792|NCT06243198|DRUG|Lebrikizumab|Administered subcutaneously (SC)
219333793|NCT06243198|DRUG|Placebo|Administered subcutaneously (SC)
219333794|NCT04878770|DRUG|Topical corticosteroids|Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
219333795|NCT04878770|DRUG|Systemic cyclosporine|"Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months."
219333796|NCT04878770|DRUG|Systemic dupilumab|Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
219333797|NCT00665899|BEHAVIORAL|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
219333798|NCT00665899|BEHAVIORAL|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
219333799|NCT06127160|DRUG|Cephalexin|Cephalexin 1000 mg by mouth 3 times daily for 10 days
219333800|NCT06127160|DRUG|Cephalexin or placebo|Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
219333801|NCT06471829|DRUG|Lu AG13909|Solution for injection/infusion
219333802|NCT03561870|DRUG|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
219333803|NCT05500274|OTHER|Education|Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.
219333804|NCT05500274|OTHER|Motivational|This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content
219333809|NCT06616285|BEHAVIORAL|Self-Guided Multidomain Lifestyle Intervention|Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
219333810|NCT06616285|BEHAVIORAL|Folk Dance Multidomain Lifestyle Intervention|"Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored."
219333811|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
219333812|NCT06798532|OTHER|Collection of data from the patient's medical file.|Collection of data from the patient's medical file.
219333813|NCT04577833|DRUG|Niraparib|Niraparib will be administered orally.
219333814|NCT04577833|DRUG|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
219333815|NCT04577833|DRUG|Prednisone|Prednisone will be administered orally.
219333816|NCT00993408|DEVICE|ACT-293987 (NS-304)|
219333817|NCT01555151|DRUG|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
219333818|NCT01555151|DEVICE|Concept 1|A single dose dry powder inhaler (SDDPI)
219333819|NCT01555151|DEVICE|Twisthaler|A single dose dry powder inhaler (SDDPI)
219333820|NCT03596866|DRUG|Brigatinib|Brigatinib Tablets.
219333821|NCT03596866|DRUG|Alectinib|Alectinib Capsules.
219333822|NCT06440109|OTHER|Emotional freedom technique (EFT)|İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.
219333823|NCT06440109|OTHER|Therapeutic touch (TD)|İntervention groups will be followed for six weeks and one of the six TD therapies will be applied, one session every week.
219333824|NCT05796375|PROCEDURE|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
219333825|NCT05796375|DIAGNOSTIC_TEST|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
219333826|NCT05796375|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
219333827|NCT00454285|DRUG|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
219333828|NCT01886339|OTHER|SNIF test (Sniff Nasal Inspiratory Force)|
219333829|NCT02957591|DIETARY_SUPPLEMENT|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
219333830|NCT02957591|OTHER|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
219333831|NCT04647877|DRUG|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
219333832|NCT04647877|OTHER|Placebo cream|Placebo cream to be applied on the neuropathic pain area
219333833|NCT00873340|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
219333834|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
219333835|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
219333836|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
219333837|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
219333838|NCT04266184|OTHER|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
219333839|NCT04266184|OTHER|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
219333840|NCT04266184|OTHER|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
219333841|NCT05390112|BIOLOGICAL|DNA|ctDNA; cfDNA
219333842|NCT01675635|DRUG|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
219333843|NCT01675635|OTHER|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
219333844|NCT05050708|OTHER|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
219333845|NCT03241953|PROCEDURE|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
219333846|NCT02904915|DRUG|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
219333847|NCT02904915|OTHER|No analgesia|IUD placement without analgesia.
219333848|NCT02904915|DEVICE|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
219333849|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
219333850|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
219333851|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
219333852|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
219333853|NCT03159091|DRUG|Rengalin|Oral administration.
219333854|NCT03159091|DRUG|Placebo|Oral administration.
219333855|NCT03929666|DRUG|ZW25 (Zanidatamab)|"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
219333856|NCT03929666|DRUG|Capecitabine|Administered orally twice daily (PO bid)
219333857|NCT03929666|DRUG|Cisplatin|Administered IV
219333858|NCT03929666|DRUG|Fluorouracil|Administered IV
219333859|NCT03929666|DRUG|Leucovorin|Administered IV
219333860|NCT03929666|DRUG|Oxaliplatin|Administered IV
219333861|NCT03929666|DRUG|Bevacizumab|Administered IV
219333862|NCT03929666|DRUG|Gemcitabine|Administered IV
219333863|NCT04875715|OTHER|Almond Oil|Almond oil
219333864|NCT04875715|DRUG|Hydroquinone Topical|Hydroquinone 2% cream
219333865|NCT04592744|DRUG|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
219333866|NCT04592744|DRUG|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
219333867|NCT05253651|DRUG|tucatinib|300mg given by mouth (orally) twice daily
219333868|NCT05253651|DRUG|trastuzumab|8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
219333869|NCT05253651|DRUG|bevacizumab|5mg/kg given by IV every 2 weeks
219333870|NCT05253651|DRUG|cetuximab|400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
219333871|NCT05253651|DRUG|oxaliplatin|85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
219333872|NCT05253651|DRUG|leucovorin|400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
219333873|NCT05253651|DRUG|levoleucovorin|200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
219333874|NCT05253651|DRUG|fluorouracil|400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
219333875|NCT04769856|OTHER|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
219333876|NCT04769856|OTHER|Satisfaction scale|Satisfaction scale
219333877|NCT06264752|OTHER|Level A|Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
219333878|NCT06264752|OTHER|Level B|The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
219333879|NCT06264752|OTHER|Passive Alert|Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
219333880|NCT06211569|OTHER|Usual follow-up|Usual follow-up
219333881|NCT05620719|BEHAVIORAL|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
219333882|NCT05620719|OTHER|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
219333883|NCT05620719|OTHER|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
219333884|NCT04722146|DRUG|Teclistamab|Participants will receive teclistamab.
219333885|NCT04722146|DRUG|Daratumumab|Participants will receive daratumumab.
219333886|NCT04722146|DRUG|Pomalidomide|Participants will receive pomalidomide.
219333887|NCT04722146|DRUG|Lenalidomide|Participants will receive lenalidomide.
219333888|NCT04722146|DRUG|Bortezomib|Participants will receive bortezomib.
219333889|NCT04722146|DRUG|Nirogacestat|Participants will receive nirogacestat.
219333890|NCT05652335|DRUG|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
219333891|NCT03740165|BIOLOGICAL|Pembrolizumab|IV infusion
219333892|NCT03740165|DRUG|Placebo for pembrolizumab|IV infusion
219333893|NCT03740165|DRUG|Carboplatin|IV infusion
219333894|NCT03740165|DRUG|Paclitaxel|IV infusion
219333895|NCT03740165|DRUG|Olaparib|Oral tablet
219333896|NCT03740165|DRUG|Placebo for olaparib|Oral tablet
219333897|NCT03740165|BIOLOGICAL|Bevacizumab|IV infusion
219333898|NCT03740165|DRUG|Docetaxel|IV infusion
219333899|NCT03523442|DRUG|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
219333900|NCT04936308|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
219333901|NCT04936308|DRUG|Placebo|Participants will receive matching placebo as SC injection.
219333902|NCT02044133|OTHER|Dosage Vitamine D|
219333903|NCT04157985|DRUG|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
219333904|NCT04157985|OTHER|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
219333905|NCT05901649|DRUG|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
219333906|NCT05901649|DRUG|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
219333907|NCT05327114|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
219333908|NCT05327114|DRUG|Placebo|Placebo will be administered intravenously.
219333909|NCT04883619|OTHER|Placebo|Placebo will be administered intravenously.
219333910|NCT04883619|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
219333911|NCT04883619|DRUG|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
219333912|NCT06598059|DEVICE|Cochlear implant|CI632D cochlear implant
219333913|NCT06598059|DRUG|Dexamethasone|CI632D, dexamethasone-eluting cochlear implant
219333914|NCT06582173|OTHER|Face-to-face interviews assisted by a biographical grid|"Face-to-face interviews assisted by a biographical grid.~Healthcare event of the adolescent :~* medical specialist appointment~* general practitioner appointment~* emergency services use~* hospital admission~* diagnostic test~* medication use~* non-pharmacological treatment~* nursing or physical therapy~* alternative care~Biographical of the adolescent :~* Education event~  * Class/level~ * School~ * Attendance~ * Special arrangements~ * Grades~ * Off school education~* Family event~  * Separation/union~ * Birth/death~ * Leave/Arrival~ * Location/Moving~ * Disease/accident~* Peer events~  * Friendships~ * Love interests~ * Bullying~* Leisure \& interests events~  * Activity~ * Frequency"
219333915|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
219333916|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
219333917|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
219333918|NCT06150157|DRUG|JNJ-88549968|JNJ-88549968 will be administered.
219333919|NCT06553625|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
219333920|NCT05754957|DRUG|Milvexian|Milvexian will be administered orally.
219333921|NCT05754957|OTHER|Placebo|Placebo will be administered orally.
219333922|NCT05089799|BEHAVIORAL|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~1. welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~2. providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~3. providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~4. providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~5. Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
219333923|NCT06275048|OTHER|Wrist/hand immobilization|Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
219333924|NCT05318937|DRUG|SAGE-718-matching placebo|Oral capsules
219333925|NCT05318937|DRUG|SAGE-718|Oral capsules
219333926|NCT05272150|DRUG|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
219333927|NCT05272150|DRUG|Placebo|Participants will receive placebo as subcutaneous injection.
219333928|NCT05441488|DRUG|Placebo|treatment per os
219333929|NCT05441488|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
219333930|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
219333931|NCT06295692|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
219333932|NCT04209153|OTHER|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
219333933|NCT06965881|DRUG|Radiprodil with Carbamazepine|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 30mg along with oral doses of Carbamazepine in the range of 100mg to 300mg twice daily over a period of 27 days.
219333934|NCT06965881|DRUG|Radiprodil with Itraconazole|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 15mg along with oral doses of Itraconazole 200mg twice daily over a period of 21 days.
219333935|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active|The study will utilize the H4 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the bilateral insula, a core salience network node.
219333936|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham|The study will utilize an identical protocol using the H4 coil to administer a sham condition.
219333937|NCT03320902|BEHAVIORAL|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
219333938|NCT04221854|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|Stool-based SDC2 DNA methylation test
219333939|NCT04221854|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test
219333940|NCT04149015|DRUG|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
219333941|NCT06312943|OTHER|Collection of joint fluid or tissue sample|During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
219333942|NCT06275789|PROCEDURE|Alveolar ridge preservation|Premolar tooth will be extracted flapless and ridge preservation procedure with bone grafting material will be done.
219333943|NCT06948591|DEVICE|Anterior cruciate ligament reconstruction with BioBrace® augmentation|An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.
219333944|NCT06948591|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction|An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.
219333945|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
219333946|NCT03970096|DRUG|Thiotepa|Given IV
219333947|NCT03970096|DRUG|Fludarabine|Given IV
219333948|NCT03970096|DRUG|Tacrolimus|Given IV
219333949|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
219333950|NCT03970096|DRUG|Methotrexate|Given IV
219333951|NCT03970096|DRUG|Cyclophosphamide|Given IV
219333952|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
219333953|NCT03970096|DRUG|Cyclosporine|Given IV
219333954|NCT03970096|DRUG|Sirolimus|Given IV
219333955|NCT03970096|DRUG|Busulfan|Given IV
219333956|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
219333957|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
219333958|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219333959|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219333960|NCT03521024|OTHER|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
219333961|NCT03521024|OTHER|lithium disilicate|well documented in the literatures as successful restoration modality.
219333962|NCT03339011|BEHAVIORAL|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
219333963|NCT00881218|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
219333964|NCT05981209|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219333965|NCT05981209|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219333966|NCT05981209|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219333967|NCT05981209|PROCEDURE|Computed Tomography|Undergo CT
219333968|NCT05981209|DRUG|Dexamethasone|Given IV or PO
219333969|NCT05981209|PROCEDURE|Echocardiography|Undergo ECHO
219333970|NCT05981209|BIOLOGICAL|Elotuzumab|Given IV
219333971|NCT05981209|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219333972|NCT05981209|BIOLOGICAL|Mezigdomide|Given PO
219333973|NCT05981209|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
219333974|NCT03232411|OTHER|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
219333975|NCT03232411|OTHER|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
219333976|NCT03232411|OTHER|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
219333977|NCT05678257|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
219333978|NCT05678257|DRUG|Leucovorin|Intravenous infusion
219333979|NCT05678257|DRUG|Irinotecan|Intravenous infusion
219333980|NCT05678257|BIOLOGICAL|Bevacizumab|Intravenous infusion
219333981|NCT05678257|DRUG|5-FU|Intravenous infusion
219333982|NCT03583983|BEHAVIORAL|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
219333983|NCT03583983|BEHAVIORAL|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
219333984|NCT06518954|OTHER|Interview|The athletes contributes with experience exchange through individual interviews, following a interview template
219333985|NCT05145998|DIETARY_SUPPLEMENT|Glucola|50 grams of Glucola sugar beverage
219333986|NCT05145998|DIETARY_SUPPLEMENT|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
219333987|NCT05145998|DIETARY_SUPPLEMENT|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
219333988|NCT05145998|DIETARY_SUPPLEMENT|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
219333989|NCT05145998|DIETARY_SUPPLEMENT|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
219333990|NCT04996823|DRUG|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
219333991|NCT04996823|DRUG|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
219333992|NCT00806247|DRUG|tapentadol HCl|
219333993|NCT06065462|DRUG|Dostarlimab|Given by vein (IV)
219333994|NCT06065462|DRUG|LB-100|GIven by vein (IV)
219333995|NCT06970314|DEVICE|Lokomat|Exoelectric walking aid for patients who have suffered a stroke
219333996|NCT06970314|DEVICE|C-Mill|Exoelectric walking aid for patients who have suffered a stroke
219333997|NCT04445675|OTHER|Support for breastfeeding and the feeding of infants' with breast milk|The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
219333998|NCT06970756|BIOLOGICAL|26-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.
219333999|NCT06970756|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.
219334000|NCT05835843|OTHER|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
219334001|NCT06647511|DEVICE|Nokia-Withings BPM Connect Blood Pressure Monitor|At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.
219334002|NCT06647511|DEVICE|Smartwatch Devices|Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
219334003|NCT06233799|DRUG|extended-release naltrexone (XR-NTX)|Once per three weeks injections of extended-release naltrexone
219334004|NCT06233799|DRUG|extended release bupropion (BUP-XL) tablets (BUP-XL)|Daily oral extended release bupropion tablets
219334005|NCT06233799|DRUG|iPLB|Once per three weeks injections of placebo
219334006|NCT06233799|DRUG|oPLB|Daily oral placebo tablets
219334007|NCT06437717|OTHER|application of different topical nasal solutions|each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients
219334008|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
219334009|NCT06046339|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
219334010|NCT06138509|OTHER|Dosage of serotonin and metabolites|The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.
219334011|NCT06138509|OTHER|Blood parameters|The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
219334012|NCT05002816|DRUG|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
219334013|NCT05002816|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
219334014|NCT04590170|BEHAVIORAL|Post-intensive Care unit syndrome|Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19
219334015|NCT04590170|OTHER|Spatiotemporal measurements of walking|Spatiotemporal measurements of walking in asymptomatic participants from the general population.
219334016|NCT04389632|DRUG|sigvotatug vedotin|Administered into the vein (IV; intravenously)
219334017|NCT04389632|DRUG|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
219334018|NCT04389632|DRUG|cisplatin|75 mg/m2 every 3 weeks, given by IV
219334019|NCT04389632|DRUG|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
219334020|NCT02822846|OTHER|lung ultrasound|
219334021|NCT05314517|DRUG|Namilumab|Namilumab administered subcutaneously
219334022|NCT05314517|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
219334023|NCT06168942|DEVICE|Experimental: Laminar Left Atrial Appendage Closure System|Treatment with the Laminar Left Atrial Appendage Closure System.
219334024|NCT06168942|DEVICE|Active Comparator: WATCHMAN / Amulet|Treatment with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder.
219334025|NCT04969276|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
219334026|NCT04969276|BIOLOGICAL|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
219334027|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
219334028|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
219334029|NCT05424926|OTHER|collection of clinical parameters and blood sample|"* A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
219334030|NCT05285566|DRUG|Exparel|106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
219334031|NCT05285566|DRUG|Xylocaine|8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
219334032|NCT04839601|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
219334033|NCT05721846|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
219334034|NCT05721846|DRUG|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
219334035|NCT05721846|RADIATION|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
219334036|NCT05721846|BIOLOGICAL|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
219334037|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
219334038|NCT04312672|BIOLOGICAL|AAV5-hRKp.RPGR|Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
219334039|NCT04551677|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"
219334040|NCT04551677|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"
219334041|NCT03289923|DEVICE|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
219334042|NCT03289923|DEVICE|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
219334043|NCT06976008|OTHER|blood sampling|Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
219334044|NCT06804538|PROCEDURE|Insemination between 42 and 43 hours post hCG|Patients will be stimulated by gonadotropins, ovulation will be blocked by a GnRH antagonist then triggered by hCG allowing IU to occur between 42 and 43 hours post hCG
219334045|NCT06804538|PROCEDURE|Insemination between 36 and 37 hours post hCG|Patients will be stimulated with gonadotropin and GnRH antagonist whose ovulation will be triggered and for which intrauterine insemination will be carried out between 36 and 37 hours post hCG
219334046|NCT05316311|DEVICE|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
219334047|NCT04808427|DEVICE|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
219334048|NCT04655144|DRUG|Dexamethasone|Dexamethasone delivered to the uterine arterial bed, prior to embolization.
219334049|NCT04655144|DRUG|Saline|Saline delivered to the uterine arterial bed, prior to embolization.
219334050|NCT03470584|OTHER|Diet Exposure|Vegetarian diet vs nonvegetarian diet
219334051|NCT06545071|BEHAVIORAL|NEAT-O program|NEAT-O's curriculum is designed to interrupt the cycle of negative emotions and opioid use through a multifaceted approach encompassing physiological, psychological, and behavioral strategies. The program includes interactive modules that capture the core therapeutic components of CBT and teach skills to support OUD recovery.
219334052|NCT01430286|BEHAVIORAL|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
219334053|NCT01430286|BEHAVIORAL|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
219334054|NCT03543865|BEHAVIORAL|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
219334055|NCT03543865|BEHAVIORAL|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
219334056|NCT03543865|OTHER|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
219334057|NCT06057181|GENETIC|Exome sequencing|Exome sequencing will be completed on each sample submitted.
219334065|NCT06967753|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Enrolled participants will be switched to a dual therapy regimen consisting of 50-mg DTG plus 300-mg 3TC tablet (as a single pill fixed dose combination) orally administered once daily with or without food. No dose reductions, modifications in dosage, or changes in the frequency of dosing will be allowed in this study.
219334066|NCT06311188|BEHAVIORAL|ITR Healing intervention|This is a nonrandomized test of the culturally adapted ITR healing intervention that is based on the ITR framework. The ITR Healing intervention comprises six 60-minute sessions based on Intersectionality theoretical framework, Healing Centered Engagement (HCE) activities that were integrated into the intervention, as well as participant's feedback about the intervention. Also, the participants' behavioral experiences per the Theoretical Domains Framework targets was used to adapt the intervention activities. HCE focuses on building a holistic approach and empathy for each session, i.e., using music, dance/movement, meditation, breathing and journaling.
219334067|NCT04413331|OTHER|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
219334068|NCT04413331|OTHER|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
219334069|NCT04490018|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
219334070|NCT04490018|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
219334071|NCT04490018|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219334072|NCT04490018|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219334073|NCT06227884|OTHER|APN intervention|"Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
219334074|NCT06227884|OTHER|No APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months)
219334075|NCT04714073|DRUG|BI 706321|Treatment period 1: Single oral dose of 1 film-coated tablet administered with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) Treatment period 2: On day 1 of period 2 (1 h after the itraconazole administration) a single oral dose of 1 film-coated tablet administered with 240 mL of water after an overnight fast of at least 10 h.
219334076|NCT04714073|DRUG|Itraconazole|Treatment period 2: Administered as an oral solution formulation once daily for 14 days orally with 240 mL of water after an overnight fast of at least 9 h, starting from day -3 up to day 11 of period 2.
219334077|NCT05091983|OTHER|Sensory Processing Scale Inventory (SPSI)|The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire
219334078|NCT05091983|OTHER|Autism Spectrum Screening Quotient (ASSQ)|"The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents."
219334079|NCT05091983|OTHER|GAD 7|"The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire."
219334080|NCT05091983|OTHER|Conners abridged|"The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents."
219334081|NCT05091983|OTHER|EAT 26|"The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire."
219334082|NCT02678143|DRUG|Alemtuzumab|
219334083|NCT02678143|DRUG|Cyclophosphamide|
219334084|NCT02678143|DRUG|Mycophenolate mofetil|
219334085|NCT02678143|DRUG|Sirolimus|
219334086|NCT02678143|DRUG|Fludarabine|
219334087|NCT02678143|RADIATION|Total body irradiation|
219334088|NCT02678143|PROCEDURE|Hematopoietic stem cell transplant|
219334089|NCT04829994|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
219334090|NCT04672265|OTHER|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
219334091|NCT06376968|DEVICE|BioLogic Fusion|Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
219334092|NCT06099158|OTHER|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
219334093|NCT00784290|DRUG|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
219334094|NCT01212653|DRUG|Simponi|Golimumab 50mg monthly
219334095|NCT01212653|OTHER|0.9ml sodium chloride|0.9ml sodium chloride
219334096|NCT04636424|OTHER|assesment of gait|speed and weight distribution during gait
219334097|NCT00937261|DRUG|Risperidone|2mg - 8mg per day, for the duration of participation in the study
219334098|NCT00937261|DRUG|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
219334099|NCT00002243|DRUG|Calanolide A|
219334100|NCT03181230|OTHER|No intervention|No intervention
219334101|NCT03653130|BEHAVIORAL|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
219334102|NCT02760979|DRUG|Denosumab|Denosumab treatment one year after surgery
219334103|NCT02760979|DRUG|Placebo|Serum one year after surgery
219334104|NCT04416399|DRUG|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
219334105|NCT05023408|DRUG|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
219334106|NCT05023408|PROCEDURE|Cryotherapy|Cryotherapy used for comparison of efficacy.
219334107|NCT00887120|DRUG|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"* BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
219334108|NCT00887120|DRUG|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"* BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
219334109|NCT05584982|DEVICE|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
219334110|NCT04755348|OTHER|Product A|A 4mg nicotine pouch product
219334111|NCT04755348|OTHER|Product B|A 4mg nicotine pouch product
219334112|NCT04755348|OTHER|Product C|A 2mg nicotine lozenge product
219334113|NCT04755348|OTHER|Product D|A 2mg nicotine lozenge product
219334114|NCT04755348|OTHER|Product E|A 2mg nicotine lozenge product
219334115|NCT04755348|OTHER|Product F|A 2mg nicotine lozenge product
219334116|NCT01362361|DRUG|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
219334117|NCT01362361|DRUG|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
219334118|NCT00282295|BIOLOGICAL|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
219334119|NCT00282295|BIOLOGICAL|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
219334120|NCT03337542|BIOLOGICAL|AR101|AR101
219334121|NCT02876120|OTHER|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
219334122|NCT01630655|DRUG|Torrent's Felodipine Extended-Release Tablets|
219334123|NCT02351479|BEHAVIORAL|Hula|
219334124|NCT05013190|OTHER|No intervention|This is a non-interventional study.
219334125|NCT00121108|BIOLOGICAL|Motavizumab|Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
219334126|NCT00121108|OTHER|Placebo|Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
219334127|NCT04861181|BIOLOGICAL|Pharmacokinetics, Dosage of Niraparib|The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
219334128|NCT01380379|BEHAVIORAL|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
219334129|NCT00904800|DRUG|AZD0837|tablet, oral, once daily, 1+5 days
219334130|NCT00904800|DRUG|Placebo|Placebo
219334131|NCT04943081|PROCEDURE|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
219334132|NCT06385080|BIOLOGICAL|Amivantamab|Amivantamab will be administered subcutaneously.
219334133|NCT06385080|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously.
219334134|NCT06385080|DRUG|Paclitaxel|Paclitaxel will be administered intravenously.
219334135|NCT06385080|DRUG|Carboplatin|Carboplatin will be administered intravenously.
219334136|NCT03208764|DRUG|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
219334137|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
219334138|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
219334139|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
219334140|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219334141|NCT05261763|OTHER|Dry Needling|abc
219334142|NCT05261763|OTHER|Sham Dry Needing|xyz
219334143|NCT05789082|DRUG|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
219334144|NCT05789082|DRUG|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
219334145|NCT05789082|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
219334146|NCT05789082|DRUG|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
219334147|NCT05789082|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W.
219334148|NCT05199753|DRUG|LM-108|Administered intravenously
219334149|NCT05199753|DRUG|An Anti-PD-1 Antibody|Administered intravenously
219334150|NCT05911295|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
219334151|NCT05911295|DRUG|pembrolizumab|400mg given by IV every 6 weeks
219334152|NCT05911295|DRUG|gemcitabine|1000 mg/m\^2 given by IV on days 1 and 8 of every 3-week cycle
219334153|NCT05911295|DRUG|cisplatin|70 mg\^2 given by IV on day 1 of every 3-week cycle
219334154|NCT05911295|DRUG|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
219334155|NCT04335669|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
219334156|NCT04335669|DRUG|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
219334157|NCT03603912|DRUG|Metformin|Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.
219334158|NCT03603912|BEHAVIORAL|Lifestyle/Risk Factor Modification|Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
219334159|NCT06031714|OTHER|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
219334160|NCT06031714|OTHER|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
219334161|NCT06031714|OTHER|Interviews|V2 and/or V3
219334162|NCT06031714|OTHER|Clinical examination|V2 and/or V3
219334163|NCT04707885|DEVICE|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
219334164|NCT05640193|BIOLOGICAL|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
219334165|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
219334166|NCT04300192|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
219334167|NCT01734122|OTHER|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
219334168|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219334169|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
219334170|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
219334171|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
219334172|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
219334173|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
219334174|NCT07116837|BEHAVIORAL|Vaping prevention video ads|Participants will view and rate 5 vaping prevention video ads. The vaping prevention video ads cover a variety of different topics and were identified in a previous study activity.
219334175|NCT06977360|OTHER|Routine care|Routine care provided by NCCS
219334176|NCT06977360|OTHER|Routine care + iCareBreast+ mobile app|Routine care provided by NCCS (identical to the control group) along with access to the iCareBreast+ mobile app
219334177|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
219334178|NCT07128329|DRUG|Nicotine Pouches|Nicotine pouches
219334179|NCT05123339|OTHER|Questionnaire|Questionnaire
219334180|NCT06319820|COMBINATION_PRODUCT|TAR-210|TAR-210 will be administered intravesically.
219334181|NCT06319820|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
219334182|NCT06319820|DRUG|MMC|MMC will be administered intravesically.
219334183|NCT06155032|PROCEDURE|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
219334184|NCT06155032|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
219334185|NCT01071850|DRUG|ipragliflozin|oral tablet
219334186|NCT01071850|DRUG|Metformin|oral tablet
219334187|NCT01071850|DRUG|Placebo|oral tablet
219334188|NCT00878111|DRUG|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
219334189|NCT03372928|DIETARY_SUPPLEMENT|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
219334190|NCT03372928|DIETARY_SUPPLEMENT|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
219334191|NCT06979674|DRUG|ESG406|Administered via intravenous (IV) infusion.
219334192|NCT05962853|OTHER|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
219334193|NCT06979544|DRUG|LPCN 1154A|Oral LPCN 1154A tablets for 48 hours
219334194|NCT06979544|DRUG|Placebo|Oral Placebo Tablets for 48 hours
219334195|NCT06979804|DEVICE|Semiconducting fabric sleeves|This intervention includes semiconductor embedded sleeves that patients will wear for 4 months post-operatively.
219334196|NCT06979804|DEVICE|Non-semiconducting fabric sleeves|This intervention includes sleeves absent of semiconductors that will be worn for 4 months post-operatively.
219334197|NCT06983899|OTHER|Aerobic Exercise|Complete virtual home-based aerobic interval training sessions
219334198|NCT06983899|OTHER|Exercise Intervention|Receive stationary bike, HR monitor, BP monitor, SPO2 monitor
219334199|NCT06983899|OTHER|Educational Intervention|Receive general healthy lifestyle guidebook
219334200|NCT06983899|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
219334201|NCT06983899|OTHER|Electronic Health Record Review|Ancillary studies
219334202|NCT06983899|OTHER|Cardiopulmonary Exercise Testing|Ancillary studies
219334203|NCT06983899|OTHER|Physical Performance Testing|Ancillary studies
219334204|NCT06983899|OTHER|Questionnaire Administration|Ancillary studies
219334205|NCT06983899|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219334206|NCT06983899|PROCEDURE|Pulmonary Function Test|Undergo PFT
219334207|NCT05088902|DIAGNOSTIC_TEST|TERABio Ltd.|Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).
219334208|NCT03347331|DRUG|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~\*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
219334209|NCT03347331|DRUG|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min
219334210|NCT04354909|OTHER|s-CD95-L|levels of s-CD95-L (ELISA test)
219334211|NCT06651229|DRUG|JNJ-90189892|JNJ-90189892 will be administered.
219334212|NCT06984718|BIOLOGICAL|AK104+lenvatinib|Subjects will receive AK104+lenvatinib until disease progression
219334213|NCT06984718|DRUG|lenvatinib|Subjects will receive lenvatinib until disease progression
219334214|NCT06984549|OTHER|DED diagnosis using PAOSID|A non-invasive diagnostic approach using the Portable Automatic Ocular Surface Imaging Device (PAOSID) to capture anterior segment images and videos for the assessment of dry eye disease (DED).
219334215|NCT06984549|OTHER|DED diagnosis using slit lamp|A non-invasive diagnostic approach using the slit lamp to capture anterior segment images and videos for the assessment of dry eye disease (DED).
219334216|NCT06985771|OTHER|Observational study, with no intervention.|Observational study, with no intervention.
219334217|NCT06984068|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
219334218|NCT06984068|DRUG|Placebo|Placebo will be used for 6 months
219334219|NCT06985394|DIETARY_SUPPLEMENT|Antioxidant cocktail|"Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of the following concentrations of antioxidants:~600 mg of α-lipoic acid, 1,000 mg of vitamin C, and 600 IU of vitamin E."
219334220|NCT06985394|DIETARY_SUPPLEMENT|Placebo|Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of placebo pills made from microcrystalline cellulose, designed to match the antioxidants in taste, color, and appearance.
219334221|NCT06984874|OTHER|Erector spinae plane block|Patients will receive bilateral erector spinae plane block after the induction of general anesthesia as a study group.
219334222|NCT06984874|OTHER|General anesthesia|Patients will not receive the block after the induction of general anesthesia as a control group.
219334223|NCT06985004|OTHER|PIODO Questionnaire|An original PIODO Questionnaire is a structured protocol that has been developed by the investigators of this study for the preoperative assessment of patients undergoing RARP. It evaluates not only clinical data on the prostate cancer, but also patient characteristics, including anthropometric measurements of the pelvis. The aim is to develope a tool that can be used to predict the risk of operational difficulties and possible outcomes of RARP.
219334224|NCT06985589|PROCEDURE|Fire needle|At the beginning of the fire needle therapy, the patient was instructed to exposure the lesion in a comfortable position. And the Ashi point (lesion area) was disinfected with iodophor. The 95% alcohol lamp was lit and held by the left hand. Then the needle was held by the right hand in the outer flame of the alcohol lamp to heat the needle body, making the tip of the needle whiten. Subsequently, the needle was quickly and accurately puncted into the base of the herpes at a depth of about 2-5 mm, straight in and out. According to the number of herpes, the early-onset herpes was puncted first, and about 5 to 10 blisters were selected for each puncture. The acupuncture was performed 1-5 times according to the size of the herpes. The treatment was performed once every other day for total 5 sessions.
219334225|NCT06985589|DRUG|Cortex Phellodendri compound fluid wet compress|For the Chinese herbal wet compress treatment, CPCF (Shandong Hanfang Pharmaceutical Co., LTD.) was decocted using forsythia, honeysuckle, phellodendron, dandelion, and centipede. Appropriate amount of liquid was diluted with 5 times the volume of water. Then according to the area of skin lesions, several pieces of medical fat-free cotton gauze with thickness of 8 layers were put into the liquid completely wet. After wringing out to a semi-dry state, the gauze was applied to the lesion for 15 minutes/time, 3 times a day, for 10 days.
219334226|NCT06985589|DRUG|basic treatment|The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
219334227|NCT06984666|BEHAVIORAL|language|Language cues are used to provide participants with psychological suggestions in order to achieve the goal of shifting their focus in gaze patterns.
219334228|NCT06985563|COMBINATION_PRODUCT|HMME-PDT|Prior to treatment, patients or their guardians provided written informed consent. Then patients were then prepared for the procedure by fully exposing the treatment area and shielding the surrounding normal skin with a black cloth. Hemoporfin (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) was administrated intravenously at a dosage of 5.0 mg/kg. Subsequently, patients underwent light radiation at 532 nm (Wuhan Yage Optic and Electronic Technique, Wuhan, China) for 18 to 25 minutes, with a power density randing form 75 to 110 mW/cm2.
219334229|NCT06985563|DEVICE|Ultrasound examinations|Ultrasound examinations were performed using three types of devices: a Paragon XHD equipped with a L38-22 probe operating at a frequency of 20-30 MHz (Kolo Medical Co., Ltd, Suzhou, China), a DUB Skin Scanner with a 22 MHz probe (Taberna Pro Medicum, German), or a Mindray Resona 7 featuring an L14-5WU linear probe set to a frequency range of 11-12 MHz frequency (Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, China).
219334230|NCT06588621|OTHER|Questionnaire on physical and mental health among healthcare professionnals|Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting
219334231|NCT05533034|OTHER|Rehabilitation|"* 1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs.~* 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence."
219334232|NCT06985836|OTHER|Mulligan Mobilization and Niel Asher technique|"* Mulligan mobilization technique for shoulder external rotation and abduction as described by Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets, 3 times a week for 4 weeks are performed~* Niel Asher technique provided for 3 sessions a week for 4 weeks"
219334233|NCT06985836|OTHER|Mulligan Mobilization and Conventional physiotherapy.|"* Modalities i.e. heating pad and TENS for ten Minutes~* Postural correction exercises / Scapular retraction~* Therapeutic Exercise : Codman' s, finger ladder, wand exercises~* End Range Gleno-humeral joint stretching Both groups will come four times per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed."
219334234|NCT06985849|OTHER|Feldenkrais method|"Activating flexors The pelvic clocktwisting).Side lying lesson for improving the integration of arms, shoulders and spine (reaching motion of shoulders in different directions).Transitioning from supine to side lying to sitting (lying supine involving flexion, extension, and twisting).Twisting on the side Twisting from supine with head fixed to the side (by limiting the movement of the head, the rib cage is forced to participate in the twisting motion) Lengthening the hamstrings Arm circles (lying on side, circling arms in different directions). Rolling from supine to prone via hip rotation"
219334235|NCT06985849|OTHER|Otago exercise protocol.|The study began by completing all 3-outcome measures by first asking about their pain intensity then by checking their balance through Berg Balance Scale and then checking the level of function through ODI questionere. The OEP included the following exercises: knee extension and knee flexion, hip abduction, calf raises, toe raises, sit to stand, semi squats from a standing position, tandem stand, tandem walk, sideways walking, backwards walking, heel walking, toe walking, one leg stand, and walking and turning around. All exercises will be performed with 10-20 repetitions, which will be progressed after 2 week.(12)
219334236|NCT06984185|DIAGNOSTIC_TEST|combined assay on capillary blotting paper|combined assay on capillary blotting paper
219334237|NCT05613517|OTHER|Eye examination|"* orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition"
219334238|NCT06663332|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219334239|NCT06660563|DRUG|JNJ-80948543|JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
219334240|NCT06660563|DRUG|JNJ-75348780|JNJ-75348780 will be administered as SC injection.
219334241|NCT06662786|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
219334242|NCT06662786|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
219334243|NCT06662786|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
219334244|NCT06662786|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
219334245|NCT06662786|DRUG|Oxaliplatin|Oxaliplatin will be administered as chemotherapy regimen.
219334246|NCT06662786|DRUG|Irinotecan Hydrochloride|Irinotecan hydrochloride will be administered as chemotherapy regimen.
219334247|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
219334248|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
219334249|NCT04870411|BIOLOGICAL|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
219334250|NCT06608485|DEVICE|HARMONIC 700 Shears|There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
219334251|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule]|1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.
219334252|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]|"1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months."
219334253|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
219334254|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
219334255|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
219334256|NCT06985095|OTHER|Nutrition educational program|"Participants in the intervention group will attend a structured nutrition education program consisting of four monthly sessions, each lasting approximately 40 to 60 minutes. These sessions will be conducted in small groups by the researcher.~Each session includes: A 20-30 minute presentation delivered by the researcher using visual aids, such as slides and educational images. A 20-30 minute interactive discussion to address participants' questions, clarify concepts.~Session Topics:~Treatment Goals in Diabetes Care: Overview of blood glucose targets and the importance of achieving glycemic control.~Key Nutritional Components of Food: Roles of carbohydrates, proteins, fats, fiber, and their impact on blood glucose.~Principles of Meal Planning: Adjusting energy intake based on physical activity levels and BMI.~Understanding the Food Exchange System: Introduction to food exchange lists; selecting the appropriate number of food exchanges to meet individual energy needs."
219334257|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
219334258|NCT06984341|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.
219334259|NCT06984341|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
219334260|NCT06984341|DRUG|Fludarabine|Fludarabine will be administered intravenously.
219334261|NCT06984341|DRUG|Rimiducid|Rimiducid will be used as a rescue therapy in the event of the occurrence of severe or life-threatening adverse events. It will be administered intravenously.
219334262|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
219334263|NCT01410019|OTHER|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
219334264|NCT06864858|DEVICE|etafilcon A with PVP with cosmetic pattern contact lens|Test Lens
219334265|NCT06864858|DEVICE|1-DAY ACUVUE® DEFINE® with LACREON®, FRESH Honey|Control Lens
219334266|NCT05572515|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
219334267|NCT05572515|DRUG|Pomalidomide|Pomalidomide will be administered orally.
219334268|NCT05572515|DRUG|Bortezomib|Bortezomib will be administered subcutaneously.
219334269|NCT05572515|DRUG|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
219334270|NCT05572515|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
219334271|NCT00733915|DEVICE|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
219334272|NCT06647615|DEVICE|VR headset|The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
219334273|NCT04892342|DRUG|ESG401|Administered via intravenous (IV) infusion
219334274|NCT06857175|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219334275|NCT06857175|DRUG|Docetaxel or Paclitaxel|Administration by intravenous infusion for a cycle of 3 weeks.
219334276|NCT07002034|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
219334277|NCT06349733|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
219334278|NCT06868199|DRUG|LM-168|Q3W,Intravenous Drip
219334279|NCT06868199|DRUG|Toripalimab|Q3W,Intravenous
219334280|NCT06675123|PROCEDURE|Biopsy|Undergo optional tissue biopsy
219334281|NCT06675123|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219334282|NCT06675123|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219334283|NCT06675123|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219334284|NCT06675123|DRUG|BTK Inhibitor|Given BTK inhibitor
219334285|NCT06675123|PROCEDURE|Computed Tomography|Undergo PET/CT
219334286|NCT06675123|DRUG|Pacritinib|Given PO
219334287|NCT06675123|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219334288|NCT06043141|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
219334289|NCT06043141|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
219334290|NCT06043141|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
219334291|NCT03969953|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban is an orally administered selective direct factor Xa inhibitor.
219334292|NCT03969953|OTHER|Placebo|Rivaroxaban matched placebo
219334293|NCT05027919|DRUG|Hydromorphone|Up to 120mg oral per day in q4 dosing to manage withdrawal
219334294|NCT05027919|DRUG|Naloxone + lofexidine pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
219334295|NCT05027919|DRUG|Naloxone + placebo pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge
219334296|NCT05027919|DRUG|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
219334297|NCT05875129|DEVICE|VAVA prototype|Cognitive behavioral therapy for insomnia
219334298|NCT03424460|BIOLOGICAL|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
219334299|NCT03424460|BIOLOGICAL|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
219334300|NCT03424460|GENETIC|RNA extraction|RNA extraction from liver tissue
219334301|NCT06862869|DRUG|Alectinib|"Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice.~NOTE: No intervention will be provided in this study as the study is observational."
219334302|NCT03977974|DRUG|LY3526318|Administered orally
219334303|NCT03977974|DRUG|Placebo|Administered orally
219334304|NCT06618001|DRUG|JNJ-89853413|JNJ-89853413 will be administered.
219334305|NCT05556096|COMBINATION_PRODUCT|ALXN1720|Combination product consisting of syringe prefilled with ALXN1720.
219334306|NCT05556096|COMBINATION_PRODUCT|Placebo|Combination product consisting of syringe prefilled with placebo.
219334307|NCT07017335|DRUG|R1_PBK_M2301(Levocloperastine 60mg)|R1\_PBK\_M2301 is a test drug containing 60mg of levocloperastine per tablet. It is administered orally to evaluate pharmacokinetic characteristics and potential drug-drug interactions with R2\_PBK\_M2301 in healthy adult volunteers.
219334308|NCT07017335|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|R2\_PBK\_M2301 is an oral tablet containing 20 mg of Pelargonium sidoides 11% ethanol extract, used as a comparator to evaluate potential pharmacokinetic interactions with R1\_PBK\_M2301.
219334309|NCT06051617|DRUG|Seladelpar|"* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis."
219334310|NCT06051617|DRUG|Placebo|One capsule daily for up to 36 months.
219334311|NCT06128824|OTHER|MR Imaging|Serial magnetic resonance imaging (MRI)
219334312|NCT06731478|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
219334313|NCT06731478|DRUG|pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg IV Q3W
219334314|NCT06731478|DRUG|Trastuzumab|Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W
219334315|NCT06731478|DRUG|Chemotherapy|"For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered."
219334316|NCT07049848|DRUG|Atezolizumab|Given by IV
219334317|NCT07049848|DRUG|Doxorubicin Hydrochloride|Given by IV
219334318|NCT06778005|DIAGNOSTIC_TEST|Ultrasonography|Measurements will be performed using a 7-12 MHz Sonosite M-Turbo device (Fujifilm, USA) with a linear probe by an operator trained in peripheral nervous system ultrasonography. Cross-sectional area (CSA) and echogenicity measurements of the bilateral tibial, common peroneal, and sural nerves will be conducted using the ultrasound device. Tibial nerve assessment will be performed 3 cm proximal to the level of the medial malleolus. Common peroneal nerve assessment will be performed by identifying the nerve at the fibular head and tracking it proximally to image it at the level of the popliteal fossa. Sural nerve assessment will be conducted 10 cm proximal to the upper level of the lateral malleolus. All nerve measurements will be conducted twice in the transverse plane, and the obtained images will be recorded and uploaded into the ImageJ programming system.
219334319|NCT06778005|DIAGNOSTIC_TEST|Biodex Balance System|"The Biodex is a computer-assisted device with a movement system capable of providing surface inclinations ranging from 360 degrees to 20 degrees. It allows movement in anterior/posterior and mediolateral planes. The device has 12 levels of difficulty, where level 12 represents the highest stability and level 1 represents the lowest stability. It can be used for balance training with different therapy protocols and includes standardized programming systems for evaluating both static and dynamic balance. It provides numerical data for key parameters such as balance, fall risk, and proprioception. In this study, patients will be assessed using the fall risk test and postural stability evaluation test protocols on the Biodex balance system. All participants will be trained and familiarized with the system before the test.~Postural Stability Test: The difficulty level will be set to 8. Fall Risk Test: The difficulty level will progressively decrease from 6 to 2."
219334320|NCT06778005|DIAGNOSTIC_TEST|Douleur Neuropathique 4 (DN4) Pain Scale|"The Douleur Neuropathique 4 (DN4) pain scale score will be used to screen for diabetic peripheral neuropathic pain. The DN4 scale consists of 10 questions, 7 of which inquire about symptoms, and 3 that assess the patient's clinical examination for neuropathy. The symptoms assessed include a burning sensation, pain from cold, electric shock sensations, tingling, pins and needles, numbness, and itching. The sensory exams assess touch hypoesthesia, pin-prick hypoesthesia, and brush allodynia. Each yes response to a question receives 1 point. To calculate the total score, points obtained from the symptom inquiry and clinical examination are added together. The maximum total score is 10, and a score of 4 or higher is considered indicative of neuropathic pain"
219334321|NCT06778005|DIAGNOSTIC_TEST|Numeric Rating Scale|The numeric pain scale will be used to assess the intensity of neuropathic pain. The patient is asked to provide a value between 0 and 10 to indicate the intensity of their pain. Higher scores are associated with an increase in pain severity.
219334322|NCT06778005|DIAGNOSTIC_TEST|Toronto Clinical Neuropathy Score|The Toronto Clinical Neuropathy Score (TCNS) will be used to assess the severity of Diabetic Peripheral Polyneuropathy (DPPN). The Turkish version of the Toronto clinical scoring system is a reliable and valid tool for assessing polyneuropathy in Turkish-speaking patients. The TCNS is preferred in clinical studies because of its ease of use, patient acceptability, ability to classify the severity of DPPN, and its representation of clinical changes related to the progression of DPPN. The scale consists of three sections: symptom scores, sensory test scores, and reflex scores.The first section includes scoring symptoms in the upper and lower extremities .The second section includes scoring the bilateral Achilles and patellar reflexes. The third section involves scoring the sensation in the toe. The total score ranges from a minimum of 0 (no neuropathy) to a maximum of 19 points.
219334323|NCT06778005|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test (6MWT) is a commonly used test to assess functional capacity. The test area should be a corridor with a minimum length of 30 meters, flat, and firm surface. The corridor should be marked every 3 meters. Turnaround points are indicated with objects such as orange traffic cones. A line is drawn for the start and end of the test. Recommended materials for the test include a stopwatch, a device to count laps, cones to mark turning points, a chair placed within easy reach, oxygen support (to be given if necessary), and a blood pressure cuff. The patient should wear comfortable clothing and shoes suitable for walking. They can use any walking aids such as crutches or a walker. Medications or treatments should be taken as usual. The patient should have had a light meal before the test and should not have engaged in heavy physical activity within the 2 hours preceding the test. There should be no warm-up period before the test.
219334324|NCT06778005|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale will be calculated using an online calculator tool, providing two types of scores: physical and mental scores.
219334325|NCT06778005|COMBINATION_PRODUCT|International Physical Activity Questionnaire-Short Form (IPAQ)|The IPAQ scale was developed to address the general health problem of insufficient physical activity, which necessitates large population studies and allows for cross-country comparisons. Validity studies conducted across multiple countries have proven that this questionnaire is valid and reliable. This survey assesses individuals based on the types of physical activities they perform in their daily lives. The questions asked pertain to the time spent physically active over the past 7 days.
219334326|NCT06778005|DIAGNOSTIC_TEST|Tuning Fork Vibration Sense|"Vibration sense will be assessed using a traditional 128 Hz tuning fork. When the stem of a 128 Hz tuning fork is placed on the dorsal aspect of the interphalangeal joint of the hallux, a healthy person can feel the vibration as long as it continues (15-20 seconds). In conditions leading to peripheral nerve damage (such as polyneuropathy), vibration sense is impaired. The examiner holds the proximal end of the tuning fork with one hand, while the distal end is struck strongly against the palm of the examiner's other hand. The examiner should try to strike the tuning fork with consistent force for each assessment. After striking, the tuning fork is placed just proximal to the nail bed, on the dorsal aspect of the distal phalanx of the hallux.Before applying the tuning fork, the participant is instructed to verbally respond with yes if they can initially feel the vibration, and they should also indicate now when they stop feeling the vibration."
219334327|NCT06778005|DIAGNOSTIC_TEST|Timed Up and Go Test|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for patients to stand up and walk, providing quantitative results. The patient starts the test by sitting on a standardized chair (46 cm high). During the test, the patient is instructed to stand up from the chair, walk 3 meters away, turn around, and then return to sit back down on the chair. The duration of this process is measured. Lower values indicate better stability. A cutoff value of 13.5 seconds has been used to identify high fall risk in the TUG test.
219334328|NCT06778005|DIAGNOSTIC_TEST|Physical Examination|"Manual Muscle Test: Muscle strength is evaluated using the MRC (Medical Research Council) muscle strength scale.~Reflexes:Patellar reflex: The reflex hammer is struck on the patella, and extension of the leg is observed. Achilles reflex: With one hand, the patient's foot is lightly dorsiflexed, and the Achilles tendon is struck; plantar flexion is observed in the ankle."
219334329|NCT00804531|DRUG|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
219334330|NCT00804531|DRUG|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
219334331|NCT07053345|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
219334332|NCT07053345|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
219334333|NCT06812078|DRUG|TAK-360|TAK-360 tablet.
219334334|NCT06812078|OTHER|Placebo|TAK-360 matching placebo tablet.
219334335|NCT04000282|DRUG|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
219334336|NCT07059065|DEVICE|FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute|"FIBERGRAFT™ Aeridyan Matrix is a next generation synthetic bone graft that is resorbable, bioactive, and osteoconductive. FIBERGRAFT Aeridyan Matrix is composed of ultra-porous 45S5 bioactive glass granules, boron-based bioactive glass microspheres, and bovine type 1 collagen. The granules are made entirely of 45S5 bioactive glass fibers and feature a porous outer shell encasing an intricate nest of micro- and nano- fibers and microspheres. The nonporous microspheres are made entirely of boron-based bioactive glass and feature essential metallic ions such as zinc, copper, magnesium, and potassium. The highly biocompatible type 1 collagen5 serves as a carrier for the bioactive glass components.~FIBERGRAFT Aeridyan Matrix is designed to have an adequate structural integrity for its application as a bone graft substitute material, while optimizing radiopacity and resorption."
219334337|NCT07059065|DEVICE|Demineralized Bone Matrix|Demineralized Bone Matrix is to be used with bone marrow aspirate and mixed with autograft bone in accordance with approved indications per the IFU
219334338|NCT03084523|DRUG|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
219334339|NCT06735833|DEVICE|Middle Meningeal Artery embolization|Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system
219334340|NCT06757712|OTHER|non linear periodization exercise|The non-linear periodized resistance training program follows a 12-week schedule with varying intensity levels across three training days per week. The intensity fluctuates between very light (VL), light (L), moderate (M), heavy (H), and very heavy (VH) workouts, distributed strategically throughout the week. Each training day implements different intensity levels, and an active rest day follows any workout session.
219334341|NCT06757712|OTHER|linear periodization exercise|The linear periodization exercise program spans 12 weeks with systematically varied training parameters. During weeks 1-2, participants perform 3 sets of 10 repetitions, followed by 3 sets of 8 repetitions in weeks 3-4. The program progresses to 4 sets of 6 repetitions in weeks 5-6, then 3 sets of 6 repetitions during weeks 7-8. The final phases consist of 4 sets of 4 repetitions in weeks 9-10, concluding with 3 sets of 4 repetitions in weeks 11-12. Training loads advance through autoregulatory progression, where participants progress at their individual pace under supervision. While sets and repetitions remain fixed within each phase, load progression is determined by performance in the final set of each exercise, ensuring safe and effective advancement.
219334342|NCT06757712|DRUG|medical treatment|The medical treatment will be received for 12 weeks.
219334343|NCT06312553|BEHAVIORAL|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring described in study arm
219334344|NCT06312553|BEHAVIORAL|Standard Diabetes Self Management Education|Standard Diabetes Self Management Education described in study arm
219334345|NCT05238116|DRUG|PC945|Sterile aqueous liquid for Nebulization
219334346|NCT05238116|DRUG|Placebo|Sterile aqueous liquid for Nebulization
219334347|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
219334348|NCT06600490|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
219334349|NCT06714123|DRUG|Senicapoc|administering 30 mg senicapoc a day, in addition to standard of care.
219334350|NCT06714123|DRUG|Placebo|Tablets similar in size and color
219334351|NCT07065552|DRUG|Tirzepatide|Tirzepatide will be administered once weekly, subcutaneously, and patients will be taught how to administer this drug at home. Patients will be started on a dose of 5 mg tirzepatide weekly for four weeks prior to surgical staging. .
219334352|NCT06748417|DEVICE|Acute Cognitive Training|Participants will receive the intervention in person once within in the study for 30 minutes. During the intervention, participants will receive a cognitive training session consisting of an upper extremity, lower extremity, and whole-body reaction time task. The device (5 LED) will be placed in front of participants in all tasks, and participants will be asked to deactivate lights that illuminate for a period of 30 seconds with 30 seconds of rest. For the upper and lower extremity tasks, these will be repeated on both limbs. The purpose of the tasks are to pre-train reaction time in an isolated fashion, requiring participants to use either hands or feet to deactivate the lights, as well as incorporate whole-body movement in the third task along with a decision-making (color-matching) component.
219334353|NCT06748417|OTHER|Non-stimulating Rest|Participants will receive the intervention in person once within the study for 30 minutes. During the intervention, participants will watch, while seated, a 30-minute segment of a nature documentary. The purpose of this intervention is to ensure no additional cognitive or movement training that would improve performance on the dual-task test occurs during the intended rest period.
219334354|NCT05198674|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
219334355|NCT07078682|DIETARY_SUPPLEMENT|Elix Daily Harmony|"Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:~Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)"
219334356|NCT07072910|DRUG|Cabergoline 0.5 MG|Participants will receive cabergoline 0.5 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 0.5 mg during the double-blind phase will continue with the same 0.5 mg dose in the open-label phase.
219334357|NCT07072910|DRUG|Placebo|Participants will receive placebo as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. In the open-label phase, these participants will transition to active cabergoline treatment, receiving either 0.5 mg or 1.0 mg once weekly, depending on their randomized allocation at the start of the open-label phase. The placebo tablets will be formulated to match the cabergoline tablets in size, shape, and color, and should be taken under the same conditions.
219334358|NCT07072910|DRUG|Cabergoline 1 MG|Participants will receive cabergoline 1.0 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 1.0 mg during the double-blind phase will continue with the same 1.0 mg dose in the open-label phase.
219334359|NCT06635148|DRUG|JNJ-81201887|No study intervention will be administered as part of this LTE study.
219334360|NCT06635148|OTHER|Sham Procedure|No study intervention will be administered as part of this LTE study.
219334361|NCT07079904|OTHER|Ultrasound Guided Peripheral Vein Catheterization With or Without Laser-Assisted.|In group T, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique. In group L, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique with laser-assisted.
219334362|NCT07079839|DEVICE|Transcranial Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219334363|NCT07079839|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219334364|NCT07079839|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
219334365|NCT07080177|PROCEDURE|Free gingival graft simultaneous with delayed implant placement|XCM grafts (of bovine origin)
219334366|NCT07080177|PROCEDURE|Xenogeneic collagen matrix simultaneous with delayed implant placement|A FGG will be harvested from the palate between first premolar and first molar
219334367|NCT06893302|BIOLOGICAL|Bone Marrow Aspirate (BMA)|Bone marrow aspirate (BMA) is being investigated as an augmentation to arthroscopic debridement surgery of the knee to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
219334368|NCT06893302|PROCEDURE|Arthroscopic Debridement Surgery|Arthroscopic debridement surgery of the knee is performed to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
219334369|NCT06893302|OTHER|Saline|Patients in the control arm of the study will receive arthroscopic debridement surgery along with a saline injection. This will be compared to the experimental arm, in which patients will receive arthroscopic debridement surgery along with a bone marrow aspirate injection.
219334370|NCT06746064|DRUG|CHF10073 (Part 1 - SAD)|Single doses of CHF10073 for each cohort
219334371|NCT06746064|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF10073 for each cohort
219334372|NCT06746064|DRUG|CHF10073 (Part 2 - MAD)|Multiple doses of CHF10073 for each cohort
219334373|NCT06746064|DRUG|CHF10073 (Part 3)|Single dose of CHF10073
219334374|NCT06746064|DRUG|Placebo (Part 2 - MAD)|Multiple doses of placebo matching CHF10073 for each cohort
219334375|NCT06746064|DRUG|itraconazole (Part 4)|Multiple dose of itraconazole in treatment period 2
219334376|NCT06746064|DRUG|CHF10073 (Part 4)|Single dose of CHF10073 in Treatment Period 1 and 2
219334377|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 1 )
219334378|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 2 )
219334379|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given intravenously (dose level 3)
219334380|NCT07076160|DEVICE|INFUSE® One Day Multifocal|Test Lens
219334381|NCT07076160|DEVICE|ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens|Control Lens
219334382|NCT05450354|OTHER|Questionnaires|"Questionnaires will be completed only once :~* Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~* Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~* Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~* Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects."
219334383|NCT05450354|OTHER|Questionnaire|Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
219334384|NCT06929572|PROCEDURE|Autologous umbilical cord patch|Surgery will occur from birth to 24 hours of age. The autologous umbilical cord patch is harvested at time of delivery and immediately processed in a sterile setting in order to create a dural patch as a spinal cord cover to close the developmental defect within a few hours after birth.
219334385|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
219334386|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
219334387|NCT06549595|DRUG|AZD0486|a fully human bispecific monoclonal IgG4 antibody
219334388|NCT06549595|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
219334389|NCT06549595|DRUG|R-CVP|Rituximab, Cyclophosphamide, Vincristine and Prednisone
219334390|NCT06549595|DRUG|BR|Bendamustine, Rituximab
219334391|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
219334392|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
219334393|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
219334394|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
219334395|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
219334396|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
219334397|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
219334398|NCT06647745|DRUG|THP-00101|Dapagliflozin 10 mg
219334399|NCT06647745|DRUG|THP-00102|Telmisartan 80 mg
219334400|NCT06647745|DRUG|THP-00103|Telmisartan 40 mg
219334401|NCT06647745|DRUG|THP-00104|Placebo of Dapagliflozin 10mg
219334402|NCT06647745|DRUG|THP-00105|Placebo of Telmisartan 80mg
219334403|NCT06647745|DRUG|THP-00106|Placebo of Telmisartan 40mg
219334404|NCT06914141|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
219334405|NCT06914141|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the reference.
219334406|NCT07116525|DEVICE|Paddle-Shaped, High-Density, Multi-Electrode Mapping Catheter|High-density, multi-electrode mapping catheter will be used for the procedure.
219334408|NCT07117266|OTHER|radiologists reference AI reports|Radiologists generate reports with reference to AI reports
219334409|NCT05629546|BIOLOGICAL|Cytokine-induced memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
219334410|NCT05629546|BIOLOGICAL|Relatilmab|Standard of care
219334411|NCT05629546|BIOLOGICAL|Nivolumab|Standard of care
219334412|NCT05642507|DRUG|AC01|AC01 microtablets
219334413|NCT07127471|DEVICE|Water exchange with AI-assisted detection|The study employs standard high-definition colonoscopy video processors with integrated CADe system (CAD-EYE, EW10-EC02, Fujifilm) The ELUXEO 7000 system (Fujifilm) will be used in this study. During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe device will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe systems, ensuring readiness before study initiation.
219334414|NCT07127471|DEVICE|Water exchange with AI-assisted detection and LCI|The study employs high-definition colonoscopy video processors with integrated CADe (CAD-EYE, EW10-EC02, Fujifilm) and LCI systems (Fujifilm).The ELUXEO 7000 system will be used . During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe and LCI devices will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe and LCI systems, ensuring readiness before study initiation.
219334415|NCT07133191|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration.~A single dose of 16 mg selatogrel will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system."
219334416|NCT07133191|COMBINATION_PRODUCT|Matching placebo|A single dose of placebo will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.
219334417|NCT07140705|OTHER|Transformative Virtual Reality Experience and ACT for General Practitioners|"This intervention consists of an individual, in-person session in which each participant engages in a 10-minute transformative Virtual Reality (VR) experience entitled The River and the Leaf, delivered through the Meta Quest 3 headset. Drawing on Acceptance and Commitment Therapy (ACT) metaphors, participants are guided to reflect on key aspects of the experience, their professional challenges, and the personal resources available to them. Following the VR session, participants are supported in clarifying the values that guide their everyday actions. After the in-person session, all participants are encouraged to identify and implement committed actions aligned with their values over the subsequent two weeks, supported by two dedicated audio tracks."
219334418|NCT06934226|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
219334419|NCT06934226|DRUG|Matching Placebo to JNJ-77242113|Matching placebo will be administered orally.
219334420|NCT06934226|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously.
219334421|NCT06934226|DRUG|Matching Placebo to Ustekinumab|Matching placebo will be administered subcutaneously.
219334422|NCT07141888|DIETARY_SUPPLEMENT|Placebo (no active ingredient)|Placebo product containing the same ingredients as the active intervention but without the active compounds
219334423|NCT07141888|DIETARY_SUPPLEMENT|Probiotics|Product contains two probiotic strains
219334424|NCT07141888|DIETARY_SUPPLEMENT|Probiotics plus fibre|Product contains two probiotic strains plus a fibre (beta-glucan)
219334425|NCT06936657|OTHER|optimized carbohydrate diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 15-20% of daily starch intake (around 40 g/day), slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 75-80%, with dietary fiber at 20-40g per 1000 kcal and free sugars contributing less than 5% of total energy.
219334426|NCT06936657|OTHER|conventional diabetes diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 5% of daily starch intake, slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 90%, with dietary fiber at 14g per 1000 kcal and free sugars contributing less than 5% of total energy.
219334427|NCT06935656|OTHER|Tablet-based executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented in a gamified environment, and each executive function is stimulated for an equal amount of time through activities that children complete on a tablet.
219334428|NCT06935656|OTHER|Traditional executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time through activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks.
219334429|NCT06935656|OTHER|Mixed executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time. Half of the intervention sessions utilize activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks, and the other half are activities that are completed on a tablet.
219334430|NCT07143578|DEVICE|Operative hysteroscopy using tissue removal device|Operative hysteroscopy using tissue removal device
219334431|NCT07143578|DEVICE|suction curettage|suction curettage using plastic scution curette
219334432|NCT01719055|DEVICE|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
219334433|NCT05934331|DRUG|LM-302|Q2W/Q3W，Administered intravenously
219334434|NCT05934331|DRUG|Toripalimab|Q2W/Q3W,Administered intravenously
219334435|NCT05934331|DRUG|Capecitabine|BID,Oral Administration
219334436|NCT05934331|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules|BID,Oral Administration
219334437|NCT05934331|DRUG|Nivolumab|Q4W,Administered intravenously
219334438|NCT05934331|DRUG|Apatinib|QD,Oral Administration
219334439|NCT05934331|DRUG|Gemcitabine|Q4W,Administered intravenously
219334440|NCT06161571|DRUG|Efruxifermin|Administered by subcutaneous (SC) injection
219334441|NCT06161571|DRUG|Placebo|Administered by SC injection
219334442|NCT05517174|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
219334443|NCT05517174|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
219334444|NCT07145827|DRUG|Metfomin|Metformin Tab. 500mg twice daily for 12 months (titrated to tolerance if needed).
219334445|NCT07145827|DRUG|tamoxifen|Standard prescribed oncological dose.
219334446|NCT07145827|DRUG|Placebo matching Metformin|"An inert, film-coated tablet identical in appearance and packaging to metformin 500 mg (same size, shape, color, coating, weight, and dosing schedule), manufactured without active ingredient using standard excipients (e.g., microcrystalline cellulose, starch/croscarmellose, povidone, magnesium stearate) and identical film coat (e.g., hypromellose, polyethylene glycol, titanium dioxide). Packaged in sealed blisters to minimize odor/taste cues. Dispensed by the investigational pharmacy per randomization; to be taken twice daily"
219334447|NCT07171385|OTHER|Nordic Hamstring Curl (NHC)|Knee-dominant eccentric hamstring strengthening exercise performed on a padded surface. Participants control the descent of the torso while knees remain fixed, emphasizing eccentric activation of hamstring muscles.
219334448|NCT07171385|OTHER|Kettlebell Swing (KS)|Hip-dominant ballistic movement involving rapid hip flexion-extension using a kettlebell (16-20 kg depending on participant's ability). Each repetition includes concentric, isometric, and eccentric phases standardized by metronome pacing.
219334449|NCT07171385|OTHER|Supine Sliding Single-Leg Curl (SSLC)|Closed-chain exercise performed in supine position with heels placed on sliding discs. One leg is extended while the other leg performs concentric-eccentric sliding curl.
219334450|NCT07171697|BEHAVIORAL|Mindfulness and psycho-education|4 week tailored mindfulness and psychoeducation programme for medical interns
219334451|NCT07170111|PROCEDURE|Greater Occipital Nerve (GON) Blockade|The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions
219334452|NCT07171034|DRUG|KLA318-2 Nanocrystal Injection|Intravenous injection, single dose
219334453|NCT07171034|DRUG|Celebrex Capsule|P.O., single dose
219334454|NCT07170839|OTHER|ESWT Aplication|All three groups received a total of five ESWT sessions, once a week for five weeks. All ESWT sessions were administered by the same physiotherapist, and the patients were positioned with their elbows flexed to 90 degrees and supported. ESWT was applied to sensitive points on the lateral epicondyle using a shock wave dose of 2000 pulses/session, with an intensity of 1.6 bar, a frequency of 10 Hz, and 1.6 bar. No analgesics or local anesthetics were administered before, during, or after the treatment.
219334455|NCT07170839|OTHER|ECCENTRIC EXERCISE|Patients in the eccentric exercise group underwent a protocol consisting of slow-progressive eccentric wrist extensor exercises combined with static stretching exercises three times a week for 5 weeks. Eccentric exercises were performed without any resistance to eliminate gravity in the first week, and the intensity of the resistance was gradually increased using yellow elastic resistance bands in weeks 2-3 and red elastic resistance bands in weeks 4-5. Eccentric exercises were performed with the elbow extended, the forearm pronated, the wrist extended, and hanging down from the support surface. Patients were asked to slowly bend the wrist downward, count to 30, and then return to the starting position. Eccentric contractions were then performed in the same manner, and so on. Patients were instructed to continue the exercise if mild pain occurred but to stop the exercise if the pain increased to the point of preventing movement. Once patients tolerated the exercise, the lo
219334456|NCT07170839|OTHER|COMBINED ISOTONIC EXERCISE|Patients in the combined isotonic exercise group underwent an eccentric-concentric exercise protocol combined with wrist isometric exercises three days a week for 5 weeks. Similar to the eccentric training group, this group completed the training with resistance applied in the first week and elastic bands in subsequent weeks. In the first week, exercise training began with the patients' elbows in full extension, forearms in pronation, wrists in extension, and hanging from the support surface. Participants were asked to slowly bend their wrists for a count of 30, and the wrist extensors were eccentrically exercised. Immediately afterward, patients performed a concentric contraction while returning to the starting position (extension). Then, isometric contraction of the wrist extensors was maintained in the starting position for 30-45 seconds. Once the isometric contraction was achieved, concentric contraction continued, completing the exercise protocol.
219334457|NCT07171151|OTHER|cyst fluid examination|Participants will not undergo any procedures outside of the routine for the study. The cyst fluid obtained during the puncture will be collected in a tube and centrifuged at 3000 rpm for 20 minutes at 4 degrees Celsius. The Eppendorf tubes will be stored at -80 °C until the clear liquid remaining above is taken and examined, without removing the particles that have settled at the bottom of the tube. The biochemical parameters of the cyst fluid obtained from the study participants will be analyzed using the ELISA method. MMP-8, MMP-9, RANKL, and MIP1alpha will be analyzed using commercially available ELISA kits, following the manufacturer's instructions.
219334458|NCT07171606|DRUG|SSGJ-706|PD-1/PD-L1 bispecific antibody
219334459|NCT07171606|DRUG|pemetrexed /carboplatin|chemotherapy
219334460|NCT07171606|DRUG|Carboplatin/Paclitaxel|chemotherapy
219334461|NCT07171606|DRUG|PD-1 Inhibitor + Chemotherapy|control group
219334462|NCT07170254|GENETIC|BD114VLP, or BD114|"CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion."
219334463|NCT07170254|GENETIC|BD114VLP or BD114 plus Gel|"Genetic: BD114VLP or BD114 plus Gel CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~Multiple dosing BD114 gel (BD114 injection :Gel, 1:1) topical application on HSIL, one time every other day, total 5 times (D0, D2, D4, D6, and D8) ."
219334464|NCT07171632|OTHER|monitoring of clinical and ventilatory variables|Monitoring clinical data
219334465|NCT07170033|OTHER|Dietary Approach to Stop Hypertension (DASH) Diet|"Dietary intervention: DASH diet Participants in the intervention group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for 12 weeks. The diet plan will be personalized based on each participant's 24-hour physical activity level and basal metabolic rate. Dietary adherence will be monitored through 3-day dietary intake records and DASH diet scores calculated using the Nutrition Information System (BeBiS). The intervention aims to assess the effect of the DASH diet on inflammatory markers, disease activity scores, functional status, and quality of life in adults diagnosed with seropositive rheumatoid arthritis."
219334466|NCT07171489|DEVICE|TNM at a sham-point (AccelBand) - randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
219334467|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
219334468|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- open-label|After 4 weeks of blinded treatment sham participants will be given the option to continue open-label TNM treatment at a leg point acupoint. Participants that agree to this will be re-trained and allowed to keep the AccelBand for another 2 weeks. During this stage, participants will be asked to complete daily home-based TNM treatment and complete the daily online symptom questionnaires. Participants will complete a visit following this additional treatment.
219334469|NCT07170176|DEVICE|Percutaneous Patent Foramen Ovale Closure|Percutaneous transcatheter closure of patent foramen ovale (PFO) is a minimally invasive procedure. Under local anesthesia, a closure device is delivered via a catheter through the femoral vein to the heart to seal the PFO tunnel. The procedure is performed under fluoroscopic and echocardiographic guidance. This intervention aims to eliminate right-to-left shunt, which is hypothesized to improve migraine symptoms and glymphatic function.
219334470|NCT07170176|OTHER|No Intervention|This arm does not receive the PFO closure procedure. Patients in this control group are observed under their standard care regimen without any study-specific intervention.
219334471|NCT07170618|DEVICE|balloon microcatheter|The balloon microcatheter simultaneously possesses both balloon dilatation and device delivery functions.
219334472|NCT07171255|BEHAVIORAL|RemoteEx+ Programming|The exercise program will include video instruction for all exercises, motivational cues, and ADRD risk education throughout the 16-week exercise program to encourage exercise adherence. RemoteEx+ is optimized to enhance exercise knowledge surrounding dementia risk factors to facilitate ADRD risk reduction and overall health improvement. The purpose of this study is to investigate the efficacy of RemoteEx+ on health outcomes associated with dementia risk in underactive rural adults.
219334473|NCT07170436|BEHAVIORAL|Short version of cognitive testing during surgery|Cognitive testing in 3 blocks of 3 minutes during awake surgery
219334474|NCT07170904|OTHER|Not applicable- observational study|This is an observational study; no interventions are administered to participants.
219334475|NCT07170007|OTHER|Physiotherapeutic protocol|"The women randomized to the Intervention Group will receive the following interventions:~During hospitalization: Pelvic Floor Muscle Contraction, observing the participant's ability to contract and advising on how to perform it, associated with cryotherapy and information on physiotherapy in women's health, pelvic floor muscles and its dysfunctions, as well as guidance on the care to be taken during hospitalization and after discharge, including guidance on postures to be adopted or avoided, breathing control, load management, intimate hygiene and the use of cryotherapy at home for pain relief.~After hospitalization, up to 3 months after delivery: Pelvic Floor Muscle Training in weekly online sessions and guidance to carry out the training daily at home, with the same protocols and without supervision. A total of 12 individual online sessions."
219334476|NCT07170007|OTHER|Usual maternity care|Participants in the control group will receive standard postpartum care for perineal trauma from the maternity hospital, which includes suturing the injury and oral analgesic medication.
219334477|NCT07171008|OTHER|Ney music|Ney music concert
219334478|NCT07171359|DEVICE|TMS Low-Dose|one 3-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
219334479|NCT07171359|DEVICE|TMS High-Dose|One 9-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
219334480|NCT07169760|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
219334481|NCT07170943|OTHER|Blueberry|Daily consumption of blueberries
219334482|NCT07170943|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder|Daily consumption of a freeze-dried blueberry powder
219334483|NCT07170943|DIETARY_SUPPLEMENT|Placebo powder|Daily consumption of a placebo powder
219334484|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein + Collagen|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.
219334485|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.
219334486|NCT07171411|DIETARY_SUPPLEMENT|Collagen Peptides|Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.
219334487|NCT07171411|OTHER|Maltodextrin (Placebo)|Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.
219334488|NCT07171671|OTHER|exercises|manuel therapy and exercises
219334489|NCT07171112|DRUG|Standard Varenicline Dosing (1 mg BID)|Varenicline PO (oral) 1mg twice daily
219334490|NCT07171112|DRUG|Bupropion 150 mg twice daily|Bupropion 150 mg PO twice daily
219334491|NCT07171112|DRUG|Increased Varenicline Dosing (1mg TID)|Varenicline 1mg PO (oral) three times daily
219334492|NCT07170605|BEHAVIORAL|Mental health, positive coping strategies promoting self-regulation and adaptive skills|"The BRP manual includes eight modules delivered over eight weeks: introduction to resilience, identifying and communicating emotions, emotional regulation, coping strategies for self-regulation (2 parts), breath awareness/meditation, applying positive coping strategies, and review/group session with caregiver. Sessions utilize play as the primary occupation, introducing resiliency concepts through 40-60 minute sessions three times each week to provide repetition and application of concepts with multiple opportunities to review, repeat and apply.~Each BRP session will be implemented by two occupational therapists, one occupational therapy student, and one YWCA staff member. Group size has been determined to approach therapeutic limits with 8-10 students, requiring this staffing ratio for optimal intervention delivery."
219334493|NCT07170605|OTHER|Standard care/School Readiness Condition|The School Readiness protocol supplements existing preschool curriculum while mitigating positive researcher interaction effects. Sessions start with a song and warm-up, including active listening, sharing and turn-taking while targeting different domains each week: perceptual motor, fine motor (tool use), fine motor (coloring), problem solving, teamwork, coordination and motor planning, problem solving (teams), and gross and fine motor (teams). These skills were selected based on feasibility study observations and designed not to overlap with social-emotional skills embedded in the BRP.
219334494|NCT07171567|DEVICE|Vacuum erection device|"A vacuum erection device (VED) is a mechanical device designed to enhance blood flow to the corpora cavernosa by creating a vacuum environment. When combined with a constriction ring at the base of the penis, VEDs can promote and sustain an erection.~This is a prospective, uncontrolled, hypothesis-generating pilot study. Eight adult male participants with penile insensitivity will be enrolled and asked to use a VED daily for six months. Monthly self-reported questionnaire data and biweekly follow-up calls will be used to assess feasibility and to collect exploratory outcome data."
219334495|NCT07170657|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.
219334496|NCT07169981|DRUG|Empagliflozin 10 MG [Jardiance]|This intervention consists of Empagliflozin 10 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
219334497|NCT07169981|DRUG|empagliflozin (Jardiance) 25 mg|This intervention consists of Empagliflozin 25 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
219334498|NCT07171268|BEHAVIORAL|Yoga Asana Chandra Harmoni|"Description: Participants randomized to the intervention group will receive the Yoga Asana Chandra Harmoni program. This program is designed to improve psychological well-being, sleep quality, and self-directed learning readiness.~Components:~Initial Face-to-Face Session: Participants will attend one in-person session led by a qualified yoga instructor. This session will introduce the principles of Yoga Asana Chandra Harmoni and provide instruction on the core asana sequence, breathing techniques (pranayama), and meditation.~Weekly Yoga Sessions: Participants will engage in three 45-minute yoga sessions per week for four weeks, practicing the Yoga Asana Chandra Harmoni sequence.~Video Support: Participants will be provided with a video demonstrating the Yoga Asana Chandra Harmoni sequence to support their home practice. The video will be shared individually via Whatsapp.~Home Practice: Participants are expected to practice the Yoga Asana Chandra Harmoni sequence independently at home,"
219334499|NCT07171294|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
219334500|NCT07169799|OTHER|trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)|This treatment consists of performing a diagnostic EGD to identify GAVE lesions. A catheter advances through the therapeutic channel to treat target areas with cryotherapy.
219334501|NCT07170293|DRUG|Tunlametinib|Do not chew, dissolve or open the capsule. If you miss a dose of medication, you can take the missed dose 8 hours before the next dose. If the time until the next medication is less than 8 hours, it is not recommended to take it again. Every 21 days for one cycle, subjects will use the investigational drug until the treatment termination criteria specified in the protocol are met. The recommended dosage for the first dose reduction is 9mg, twice daily. The recommended second dose reduction is 6mg, twice daily.
219334502|NCT07169643|DRUG|Darbepoetin (DP)|Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)
219334503|NCT07160413|DEVICE|Electric and electromagnetic stimulation|Application of electromagnetic and electric stimulation using coils of different designs and electrodes to assess peripheral nerve sensitivity. The stimulation is momentary, non-therapeutic, and performed for basic science research purposes
219334504|NCT07170995|DRUG|SHR-8068，adebelizumab and platinum-based chemotherapy|SHR-8068，adebelizumab and platinum-based chemotherapy
219334505|NCT07170995|DRUG|tislelizumab, and platinum-based chemotherapy|tislelizumab, and platinum-based chemotherapy
219334506|NCT07169955|OTHER|Motivational Interviewing|Implementation of the Research in the Experimental Group Since the patients in the experimental group come from many different cities and regions, the interviews will be conducted online. It was planned to conduct weekly online individual motivational interviews with the patients for 40 minutes on one day of the week for 6 weeks. In the last session of the motivational interview (6th week), Oswetry Low Back Pain Disability Index and World Health Organization Quality of Life Scale - Short Form will be administered. Post-tests will be administered 6 weeks after these forms are administered. Three months (12 weeks) after the first interview, the tests will be administered again.
219334507|NCT07170462|DRUG|Cranberry powder|Cranberry whole powder equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols), and approximately 3.6 g of fiber.
219334508|NCT07170462|DIETARY_SUPPLEMENT|Placebo|placebo powder (9 g powder, no (poly)phenols, no fibers
219334509|NCT07170813|OTHER|Spinal hyperextension brace|The Jewett brace is a hyperextension spinal orthosis designed to limit spinal flexion and promote proper posture by applying anterior and posterior forces to the thoracolumbar spine. It is commonly used for spinal fractures, postural disorders, and to reduce spinal load. Participants will wear the Jewett brace during the intervention phase, and spinal mobility and posture will be assessed.
219334510|NCT07170098|DEVICE|EDDY sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
219334511|NCT07170098|DEVICE|EndoActivator (EA) sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
219334512|NCT07170098|DEVICE|980-nm diode laser|Diode laser irradiation during endodontic treatment.
219334513|NCT07171177|DEVICE|Foot Orthoses|To compare the use of handmade plantar orthoses versus the use of splints in the management of low back pain.
219334514|NCT07171047|DIETARY_SUPPLEMENT|Placebo then Verum|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
219334515|NCT07171047|DIETARY_SUPPLEMENT|Verum then Placebo|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
219334516|NCT07170722|DEVICE|Subtreshhold DRG-S|Continuous electrical stimulation delivered through an implanted DRG neurostimulator. Amplitude is set individually to 80% of each participant's perception threshold, ensuring no paresthesia is produced. Frequency and pulse width remain unchanged from the participant's established therapeutic settings. This sub-threshold programming distinguishes the intervention from suprathreshold (paresthesia-based) DRG stimulation used in earlier studies.
219334517|NCT07170722|OTHER|Sham|The implanted DRG stimulator remains switched off for the entire 5-day period. Device interrogation logs are masked to maintain blinding. No electrical stimulation is delivered, allowing a placebo-controlled comparison with active sub-threshold stimulation.
219334518|NCT07170345|DIAGNOSTIC_TEST|Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC|This intervention is an artificial intelligence-based computer-aided diagnosis (CAD) system developed to predict microvascular invasion (MVI) in patients with hepatocellular carcinoma using preoperative multiphase CT imaging. The system integrates deep learning, radiomics, and expert-defined imaging features to provide risk assessment and visualization of MVI prior to surgery. In this study, the CAD system will be evaluated retrospectively and prospectively in an observational manner only. The results will not influence clinical decision-making or patient management, and all treatments will follow standard of care.
219334519|NCT01509495|DEVICE|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
219334520|NCT06789198|DRUG|Vaccination of Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).~A total of two vaccinations are planned, 4 weeks apart from each other. If no sufficient T cell response is achieved at the end of treatment visit (28 days after last vaccination) a booster vaccination at day 56 (+7 days) after the second vaccination can be applied"
219334521|NCT06956651|OTHER|FIT SA|Self Adhesive Flowable giomer restorative material
219334522|NCT06956651|OTHER|Beautifil Flow Plus F00|Conventional Flowable giomer composite
219334523|NCT02861768|BIOLOGICAL|Pharyngeal swab|
219334524|NCT03029715|DRUG|Propofol|Total intravenous anaesthesia.
219334525|NCT03029715|DRUG|Remifentanil|Narcotics
219334526|NCT03029715|DRUG|Dexmedetomidine|Total intravenous anaesthesia
219334527|NCT03029715|DRUG|Desflurane|Inhalation anaesthesia.
219334528|NCT01270308|DRUG|Lansoprazole|Lansoprazole DR Capsules 30 mg
219334529|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
219334530|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
219334531|NCT00349375|DRUG|Simvastatin|Simvastatin 40 mg
219334532|NCT00095875|DRUG|carboplatin|Given IV
219334533|NCT00095875|DRUG|cisplatin|Given IV
219334534|NCT00095875|DRUG|docetaxel|Given IV
219334535|NCT00095875|DRUG|fluorouracil|Given IV
219334536|NCT05679128|DIAGNOSTIC_TEST|identification of the cricothyroid membrane using Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
219334537|NCT05679128|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane using ultrasonography|identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
219334538|NCT05049096|DEVICE|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
219334539|NCT05049096|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
219334540|NCT05651165|DEVICE|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
219334541|NCT05651165|DEVICE|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
219334542|NCT05566951|OTHER|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
219334543|NCT05566951|OTHER|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
219334544|NCT02998775|DRUG|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
219334545|NCT04701138|DIETARY_SUPPLEMENT|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
219334546|NCT04678570|OTHER|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
219334547|NCT04678570|OTHER|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
219334548|NCT03682679|DIAGNOSTIC_TEST|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
219334549|NCT05549700|OTHER|Neuromodulation|Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
219334550|NCT00003281|DRUG|paclitaxel|
219334551|NCT00003281|DRUG|topotecan hydrochloride|
219334552|NCT00003281|RADIATION|radiation therapy|
219334553|NCT03151863|DRUG|Opioids|The usual opioid treatment used for nursing care
219334554|NCT03151863|DRUG|Dexmedetomidine|Dexmedetomidine is provided intranasally
219334555|NCT03151863|DRUG|Placebo|Normal saline is either given subcutaneously or intranasally
219334556|NCT03743311|PROCEDURE|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
219334557|NCT03743311|DRUG|Detralex|Conservative treatment of Hemorhoid
219334558|NCT03743311|OTHER|Combined therapy|Surgical + conservative treatment of Hemorhoid
219334559|NCT03731650|PROCEDURE|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
219334560|NCT06206174|DRUG|TGRX-814|Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
219334561|NCT05554484|BIOLOGICAL|Autologous peripheral blood-derived tolerogenic dendritic cells|AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1\~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
219334562|NCT04161820|BEHAVIORAL|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
219334563|NCT06379386|PROCEDURE|Transcatheter aortic valve replacement|A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
219334564|NCT01524198|DRUG|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
219334565|NCT01524198|DRUG|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
219334566|NCT04419610|BIOLOGICAL|TRV027|peptide for infusion
219334567|NCT04419610|OTHER|sodium chloride 0.9%|placebo comparator for infusion
219334568|NCT04870242|OTHER|Observational study, non-interventional|observational study for the ERAS protocols in pediatric surgery
219334569|NCT00675922|DRUG|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
219334570|NCT05030454|DEVICE|ETHOS|Ring-gantry CT-guided radiotherapy unit, pairing a linear accelerator within a ring-gantry imaging unit.
219334571|NCT05030454|RADIATION|CT-guided stereotactic adaptive radiotherapy|All participants will be initially planned to at least 35 Gy in 5 fractions, subject to hard constraints based on the treatment site.
219334572|NCT06794164|PROCEDURE|skin to skin care|skin to skin care of preterm infants with their parents immediately after birth
219334573|NCT06794164|PROCEDURE|Standard Care (in control arm)|skin to skin care within 24 hours after birth
219334574|NCT01998620|DRUG|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
219334575|NCT01998620|DRUG|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
219334576|NCT01998620|DRUG|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
219334577|NCT00916253|DRUG|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
219334578|NCT00916253|DRUG|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
219334579|NCT04620044|OTHER|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
219334580|NCT04620044|OTHER|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
219334581|NCT04620044|OTHER|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
219334582|NCT01180478|DEVICE|White Light|White Light Cystoscopy
219334583|NCT01180478|DEVICE|Narrow Band Imaging|Narrow Band Imaging
219334584|NCT03012087|BEHAVIORAL|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
219334585|NCT03012087|OTHER|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
219334586|NCT00054704|DRUG|Riluzole|Riluzole
219334587|NCT00054704|DRUG|Placebo|Placebo
219334588|NCT00362414|DRUG|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
219334589|NCT04238975|BIOLOGICAL|GC3111 vaccine|0.5mL, Intramuscular
219334590|NCT04238975|BIOLOGICAL|Boostrix® vaccine|0.5mL, Intramuscular
219334591|NCT00007839|DRUG|beta alethine|
219334592|NCT05060822|DRUG|HEC585|HEC585 Tablets，once daily
219334593|NCT05060822|DRUG|Pirfenidone|Pirfenidone，three times a day
219334594|NCT05060822|DRUG|Placebo|Placebo，once daily
219334595|NCT01505270|OTHER|Retrospective case study|Retrospective case study
219334596|NCT00019708|DRUG|tanespimycin|Given IV
219334597|NCT03527134|DRUG|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
219334598|NCT00000570|DRUG|pulmonary surfactant|
219334599|NCT05283759|OTHER|No intervention because it is a patient registry|
219334600|NCT01806350|OTHER|questionnaire administration|Ancillary studies
219334601|NCT01806350|PROCEDURE|standard follow-up care|Receive usual care
219334602|NCT01806350|OTHER|educational intervention|Undergo PFMT
219334603|NCT04272671|OTHER|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
219334604|NCT06397755|PROCEDURE|Prostate Biopsy and/or Radical Prostatectomy|Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
219334605|NCT03118700|OTHER|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
219334606|NCT03118700|OTHER|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
219334607|NCT00575198|OTHER|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
219334608|NCT00575198|OTHER|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
219334609|NCT02053168|DEVICE|Resorbable Mesh|Phasix Mesh
219334610|NCT02853448|DEVICE|Novel Blood Drawing Apparatus|
219334611|NCT00636675|BEHAVIORAL|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets."
219334612|NCT00636675|BEHAVIORAL|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
219334613|NCT04053868|OTHER|JUUL|Electronic Cigarette
219334614|NCT04053868|OTHER|Tobacco|Tobacco Cigarette
219334615|NCT00956774|PROCEDURE|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
219334616|NCT00956774|PROCEDURE|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
219334617|NCT00956774|PROCEDURE|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
219334618|NCT01912742|BEHAVIORAL|Very-low calorie diet (VLCD)|
219334619|NCT01912742|BEHAVIORAL|Low calorie diet (LCD)|
219334620|NCT01133899|DIETARY_SUPPLEMENT|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
219334621|NCT01133899|DIETARY_SUPPLEMENT|GAA-4|4.8 grams of guanidinoacetic acid
219334622|NCT01133899|DIETARY_SUPPLEMENT|GAA-1|1.2 grams of guanidinoacetic acid
219334623|NCT01133899|DIETARY_SUPPLEMENT|PLACEBO|celulose
219334624|NCT03545763|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
219334625|NCT02774512|DRUG|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
219334626|NCT01424111|DRUG|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
219334627|NCT01424111|OTHER|Healthy Control|No Treatment
219334628|NCT04729985|DEVICE|CGM device with diabetic education, CGM education and a follow up protocol.|Blind CGM placed and recorded for 14 days after discharge and data downloaded
219334629|NCT03677830|DRUG|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
219334630|NCT03677830|DRUG|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
219334631|NCT05313451|OTHER|Soluble fiber|15g/day during 2 months
219334632|NCT05313451|OTHER|Placebo|Maltodextrin 15g/day during 2 months
219334633|NCT00833053|DRUG|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
219334634|NCT00833053|DRUG|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
219334635|NCT04483674|DRUG|50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide|"Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL"
219334636|NCT02828553|OTHER|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
219334637|NCT03707067|DEVICE|Compression garments|Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)
219334638|NCT03707067|OTHER|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
219334639|NCT01408992|PROCEDURE|Audiometry|Standard hearing test performed by audiologists
219334640|NCT01408992|OTHER|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
219334641|NCT00522145|DRUG|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
219334642|NCT04064502|DIAGNOSTIC_TEST|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
219334643|NCT02187471|DRUG|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
219334644|NCT02187471|DRUG|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
219334645|NCT02187471|DRUG|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
219334646|NCT02187471|DRUG|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
219334647|NCT02651168|BIOLOGICAL|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
219334648|NCT02236520|DRUG|Spironolactone|
219334649|NCT02236520|DRUG|Chlorthalidone|
219334650|NCT02236520|DIETARY_SUPPLEMENT|Diet|
219334651|NCT02236520|DRUG|Placebo|
219334652|NCT01785160|DRUG|Raltegravir|low dose oral administration
219334653|NCT01785160|DRUG|Raltegravir|low dose oral administration
219334654|NCT01785160|DRUG|Faldaprevir|medium dose oral administration
219334655|NCT00820677|BEHAVIORAL|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
219334656|NCT04096209|DEVICE|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
219334657|NCT06022731|DIAGNOSTIC_TEST|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
219334658|NCT01370720|DIETARY_SUPPLEMENT|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
219334659|NCT01370720|OTHER|Placebo|tablets, 2tablets/day, 12 weeks
219334660|NCT05754385|BEHAVIORAL|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
219334661|NCT05754385|BEHAVIORAL|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
219334662|NCT00957528|DRUG|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
219334663|NCT00957528|DRUG|Placebo|Weekly IM injections of sesame oil.
219334664|NCT05823415|PROCEDURE|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
219334665|NCT05823415|PROCEDURE|CAF with CTG|Gold standard surgical technique
219334666|NCT06119867|PROCEDURE|Japanese pathological investigation|Japanese pathological investigation
219334667|NCT06119867|PROCEDURE|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
219334668|NCT02440360|BEHAVIORAL|PSH|Please see arm description.
219334669|NCT02440360|BEHAVIORAL|Usual Care|Please see arm description.
219334670|NCT04776733|OTHER|prepackaged semisolid nutritional formulations|"The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast."
219334671|NCT04776733|OTHER|restricted diet|"The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast."
219334672|NCT05141760|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
219334673|NCT06003114|DRUG|Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment.
219334674|NCT01021956|DRUG|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
219334675|NCT02116556|DRUG|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
219334676|NCT02116556|DRUG|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
219334677|NCT05793671|DEVICE|PPCI in heavy thrombus burden STEMI patients|minimally invasive procedures used to open clogged coronary arteries
219334678|NCT04090008|DRUG|PRP gel|The PRP gel is applied on the ulcer twice per week
219334679|NCT04090008|DRUG|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
219334680|NCT03553043|BEHAVIORAL|Intervention|Energy label condition.
219334681|NCT03553043|BEHAVIORAL|Control|No label
219334682|NCT02345954|PROCEDURE|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
219334683|NCT02345954|PROCEDURE|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
219334684|NCT03114176|DIETARY_SUPPLEMENT|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
219334685|NCT03269071|DRUG|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
219334686|NCT00837941|DRUG|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
219334687|NCT00837941|DRUG|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
219334688|NCT00837941|DRUG|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
219334689|NCT04182373|DRUG|Antithrombin gamma|Intravenous infusion, once a day, 7 days
219334690|NCT04182373|DRUG|physiological saline|Intravenous infusion, once a day, 7 days
219334691|NCT00483301|DRUG|Sorafenib (BAY 43-9006)|dosage
219334692|NCT00483301|DRUG|ABI-007(Abraxane)|dosage
219334693|NCT02250820|DRUG|Dexmedetomidine|Nasal administration
219334694|NCT02250820|DRUG|Pentobarbital|Oral administration
219334695|NCT02250820|OTHER|Oral Placebo|Oral placebo will be cherry syrup
219334696|NCT02250820|OTHER|Nasal Placebo|Nasal placebo will be nasally atomized saline
219334697|NCT04539340|BIOLOGICAL|GNR-055|Single intravenous administration
219334698|NCT05289635|PROCEDURE|different suture types|For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
219334699|NCT02234479|BIOLOGICAL|Hydrophor (Group A)|"* Rehydrates dry, chapped or chafed skin~* May be used alone as a skin lubricant or protectant"
219334700|NCT02234479|BIOLOGICAL|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~* Maintain a balanced environment for healing.~* Aids in reducing dermatitis.~* Reduce affected area pH.2-3"
219334701|NCT02318667|BIOLOGICAL|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
219334702|NCT01423409|DEVICE|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
219334703|NCT01423409|DEVICE|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
219334704|NCT00343421|BIOLOGICAL|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
219334705|NCT00343421|BIOLOGICAL|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
219334706|NCT02177968|OTHER|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
219334707|NCT02151955|BEHAVIORAL|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
219334708|NCT04882592|DEVICE|SCiP|Noninvasive spinal cord neuromodulator
219334709|NCT06548919|DRUG|Endocrine therapy|All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
219334710|NCT06548919|DRUG|Chemotherapy Prednisone|All chemotherapy treatment regimens approved for advanced breast cancer
219334711|NCT02947672|DRUG|Intravenous Dexamethasone|
219334712|NCT02947672|DRUG|Intraperitoneal Dexamesathone|
219334713|NCT00820911|DRUG|cyclosporine (reduced exposure) / everolimus|twice daily
219334714|NCT00820911|DRUG|AEB071 300 mg b.i.d. / everolimus|twice daily
219334715|NCT00820911|DRUG|AEB071 200 mg b.i.d. / everolimus|twice daily
219334716|NCT05376865|DIETARY_SUPPLEMENT|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
219334717|NCT00309634|BIOLOGICAL|4 adjuvanted pandemic influenza candidate vaccines|
219334718|NCT00309634|BIOLOGICAL|4 non-adjuvanted pandemic influenza candidate vaccines|
219334719|NCT06116617|DRUG|SRSD107|SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
219334720|NCT06116617|DRUG|Placebo|Sodium chloride
219334721|NCT03066128|DIAGNOSTIC_TEST|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
219334722|NCT03066128|OTHER|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
219334723|NCT02672436|DRUG|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
219334724|NCT02672436|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
219334725|NCT04774731|OTHER|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
219334726|NCT02289742|DEVICE|Nelfilcon A multifocal contact lenses|
219334727|NCT02289742|DEVICE|Nelfilcon A toric contact lenses|
219334728|NCT02289742|DEVICE|Nelfilcon A sphere contact lenses|
219334729|NCT05802654|RADIATION|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
219334730|NCT00445874|DRUG|Ketotifen with a Contact Lens (no generic name)|
219334731|NCT03483909|DEVICE|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
219334732|NCT03483909|DEVICE|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
219334733|NCT03483909|DEVICE|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
219334734|NCT06037798|OTHER|cranio-cervical flexion test with NOD|testing the anterior neck muscles during a nodding movement and by using a dynamometer
219334735|NCT01365039|DEVICE|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
219334736|NCT01365039|DEVICE|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
219334737|NCT04871165|DIAGNOSTIC_TEST|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
219334738|NCT04871165|DIAGNOSTIC_TEST|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
219334739|NCT04871165|DIAGNOSTIC_TEST|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
219334740|NCT00169689|PROCEDURE|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
219334741|NCT00169689|OTHER|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
219334742|NCT01203540|DRUG|NAABAK eyedrops|
219334743|NCT01203540|DRUG|Saline eyedrops|
219334744|NCT05379634|DRUG|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
219334745|NCT05379634|OTHER|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
219334746|NCT05379634|DRUG|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
219334747|NCT00159757|DRUG|ziprazidone|
219334748|NCT05354557|DRUG|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
219334749|NCT04557098|DRUG|Teclistamab|Teclistamab will be administered SC.
219334750|NCT04319575|DRUG|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
219334751|NCT05099341|OTHER|HDRS-17 depression scale|Measuring the severity of depression
219334752|NCT05099341|BIOLOGICAL|Blood sampling|3 tubes of 5 ml
219334753|NCT05939674|DRUG|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
219334754|NCT05939674|DRUG|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
219334755|NCT04442295|DRUG|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
219334756|NCT04442295|DRUG|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
219334757|NCT00853320|DRUG|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
219334758|NCT00853320|DRUG|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
219334759|NCT05726851|DRUG|E2025|E2025 IV infusion.
219334760|NCT05726851|DRUG|Placebo|E2025 matched placebo IV infusion.
219334761|NCT04223843|DRUG|Tiotropium + olodaterol|Oral Inhalation
219334762|NCT04223843|DRUG|Placebo|Oral Inhalation
219334763|NCT01473342|BEHAVIORAL|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
219334764|NCT03707548|BEHAVIORAL|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
219334765|NCT03707548|BEHAVIORAL|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
219334766|NCT03707548|BEHAVIORAL|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
219334767|NCT05470751|DEVICE|Intermittent self-catheterisation|Self-catheterising with GC Male and Glide Male with Feelclean technology
219334768|NCT00253643|DIETARY_SUPPLEMENT|green tea catechin extract|Given orally 2 times/day
219334769|NCT00253643|DIETARY_SUPPLEMENT|fish oil|Given orally 3 times/day
219334770|NCT00253643|OTHER|placebo|Given olive oil placebo orally 3 times/day
219334771|NCT00253643|OTHER|placebo|Given green tea placebo orally 2 times/day
219334772|NCT04035070|COMBINATION_PRODUCT|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
219334773|NCT04035070|COMBINATION_PRODUCT|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
219334774|NCT04035070|COMBINATION_PRODUCT|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
219334775|NCT05926700|DRUG|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
219334776|NCT06959043|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants will follow the same strict vegetarian diet and regular physical exercise as in Intervention 1. Additionally, they will receive a probiotic supplement, taken twice daily for four weeks. This aims to evaluate the metabolic impact of probiotics in type 2 diabetes.
219334777|NCT06959043|DIETARY_SUPPLEMENT|Placebo Administration|Participants will follow a strictly plant-based diet rich in fiber and bioactive compounds, with controlled macronutrient distribution. Regular physical exercise includes supervised aerobic and resistance training sessions. The intervention lasts four weeks. Instead of probiotic supplementation, participants will receive a placebo, administered in the same manner as the probiotic group to maintain blinding.
219334778|NCT06836661|BEHAVIORAL|FDC and TLC and medication adherance|Level 1: Patient 1. Rational FDCs 2. NPHWs and PMs mediated therapeutic lifestyle changes 3. Texts/ WhatsApp reminders Level 2:Physician 1. Reinforcing task sharing 2. Providing evidence on FDCs 3. Theory based behavior modification Level 3: Health administrators 1. Pharmacy - Update drug formulary FDCs 2. CV health days 3. Facility strengthening
219334779|NCT06836661|BEHAVIORAL|Patients will Enhanced Usual Care (EUC)|Patients will Enhanced Usual Care (EUC) with periodic follow ups
219334780|NCT01789762|BIOLOGICAL|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
219334781|NCT01789762|BIOLOGICAL|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
219334782|NCT01789762|BIOLOGICAL|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
219334783|NCT04606381|DRUG|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
219334784|NCT04606381|DRUG|Ami-LC|Participants will receive amivantamab SC infusion.
219334785|NCT04606381|DRUG|Ami-HC|Participants will receive amivantamab SC infusion.
219334786|NCT04606381|DRUG|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
219334787|NCT04606381|DRUG|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
219334788|NCT01154244|OTHER|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
219334789|NCT01978782|DRUG|raltegravir|
219334790|NCT01978782|DRUG|citalopram|
219334791|NCT03270189|DEVICE|prism glasses|orthoptic treatment by wearing prisms when writing
219334792|NCT00383084|BEHAVIORAL|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
219334793|NCT00383084|BEHAVIORAL|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
219334794|NCT06848387|DIAGNOSTIC_TEST|Unbound cloxacillin concentration|Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
219334795|NCT04729036|PROCEDURE|open reduction and internal fixation|The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
219334796|NCT06185829|DRUG|Neurloeptanalgesic treatment|Usual neuroleptanalgesic treatment
219334797|NCT06185829|OTHER|Hypnoanalgesia|Hypnoanalgesia
219334798|NCT02636582|OTHER|Laboratory Biomarker Analysis|Correlative studies
219334799|NCT02636582|DRUG|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
219334800|NCT02636582|BIOLOGICAL|Sargramostim|Given ID
219334801|NCT02636582|PROCEDURE|Surgical Procedure|Undergo surgery
219334802|NCT03260504|BIOLOGICAL|Aldesleukin|Given SC or IV
219334803|NCT03260504|BIOLOGICAL|Pembrolizumab|Given IV
219334804|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
219334805|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
219334806|NCT01263483|DRUG|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
219334807|NCT00326209|DRUG|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
219334808|NCT00714285|BIOLOGICAL|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
219334809|NCT00714285|BIOLOGICAL|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
219334810|NCT01372384|DRUG|erlotinib [Tarceva]|150 mg orally daily
219334811|NCT01621633|DRUG|LCZ696|
219334812|NCT01131676|DRUG|BI 10773 low dose|BI 10773 tablets once daily
219334813|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
219334814|NCT01131676|DRUG|BI 10773 high dose|BI 10773 tablets once daily
219334815|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
219334816|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
219334817|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
219334818|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
219334819|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
219334820|NCT05920616|OTHER|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
219334821|NCT05920616|OTHER|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
219334822|NCT04537494|DIETARY_SUPPLEMENT|L. reuteri|Probiotic
219334823|NCT02556996|BIOLOGICAL|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
219334824|NCT02556996|OTHER|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
219334825|NCT04506814|DEVICE|Endocardial PVI|Catheter based PVI
219334826|NCT04506814|DEVICE|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
219334827|NCT03512795|BIOLOGICAL|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
219334828|NCT02576444|DRUG|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
219334829|NCT02576444|DRUG|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
219334830|NCT02576444|DRUG|AZD1775|The recommended dose will be available no earlier than March 2016.
219334831|NCT02576444|DRUG|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
219334832|NCT00896779|DRUG|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
219334833|NCT00771823|DRUG|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
219334834|NCT00771823|DRUG|Maraviroc|"* Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study."
219334835|NCT03953430|OTHER|Gait analysis|
219334836|NCT06476236|DIETARY_SUPPLEMENT|M4C|Nutraceutical designed to enhance novel metabolic pathway activity.
219334837|NCT03606993|OTHER|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one \~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
219334838|NCT04526743|BEHAVIORAL|Questionnaire|Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
219334839|NCT04798937|OTHER|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
219334840|NCT00507299|BEHAVIORAL|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
219334841|NCT00507299|BEHAVIORAL|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
219334842|NCT01239095|DRUG|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
219334843|NCT00112671|DRUG|sorafenib tosylate|Given orally 400mg orally twice daily
219334844|NCT00112671|OTHER|laboratory biomarker analysis|Correlative studies
219334845|NCT05354583|DRUG|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
219334846|NCT00829179|DRUG|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
219334847|NCT01541189|DRUG|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
219334848|NCT03098849|OTHER|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
219334849|NCT00464321|BIOLOGICAL|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
219334850|NCT00464321|BIOLOGICAL|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
219334851|NCT00464321|BIOLOGICAL|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
219334852|NCT00464321|BIOLOGICAL|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
219334853|NCT03419338|PROCEDURE|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
219334854|NCT03419338|PROCEDURE|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
219334855|NCT03419338|PROCEDURE|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
219334856|NCT03419338|PROCEDURE|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
219334857|NCT03419338|DEVICE|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
219334858|NCT02685423|BEHAVIORAL|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
219334859|NCT02685423|BEHAVIORAL|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
219334860|NCT03000179|DRUG|Avelumab|Avelumab through a vein once every 2 weeks
219334861|NCT06461975|DRUG|Benoxinate Hydrochloride|"The first group had the first examination done using the tear substitute Polyfresh ® eye drops and the second using the Benoxinate HCL drops Benox ® given just before the ROP screening."
219334862|NCT06461975|DRUG|artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.|"The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening."
219334863|NCT03413111|PROCEDURE|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
219334864|NCT00381199|DRUG|Amitriptyline Hydrochloride|
219334865|NCT00381199|DRUG|Nabilone|
219334866|NCT02410668|DIETARY_SUPPLEMENT|flaxseed|
219334867|NCT02410668|DIETARY_SUPPLEMENT|Placebo|
219334868|NCT02410668|BEHAVIORAL|Exercise recommendation|
219334869|NCT02738970|DRUG|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
219334870|NCT02738970|DRUG|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
219334871|NCT00217048|DRUG|Yohimbine, oral|
219334872|NCT04015453|PROCEDURE|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
219334873|NCT03351920|OTHER|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
219334874|NCT02343159|DRUG|dimethyl fumarate|120 mg and 240 mg delayed release capsules
219334875|NCT02343159|DEVICE|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
219334876|NCT02343159|BEHAVIORAL|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
219334877|NCT05467514|DRUG|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
219334878|NCT03769246|DEVICE|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
219334879|NCT03769246|OTHER|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
219334880|NCT05142475|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219334881|NCT02512471|DRUG|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
219334882|NCT00825279|DEVICE|Bare Metal Stent|Stainless steel stent
219334883|NCT00825279|DEVICE|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
219334884|NCT00002300|DRUG|Megestrol acetate|
219334885|NCT03076385|BIOLOGICAL|VAL-506440|Escalating dose levels
219334886|NCT03076385|OTHER|Placebo|
219334887|NCT00914251|DRUG|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
219334888|NCT00914251|DRUG|Placebo|Administration of oral Placebo, 500 mg/daily
219334889|NCT00502814|PROCEDURE|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
219334890|NCT00502814|PROCEDURE|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
219334891|NCT00502814|PROCEDURE|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
219334892|NCT00502814|PROCEDURE|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
219334893|NCT01353027|DRUG|Placebo|Normal saline
219334894|NCT01353027|DRUG|AVI-6002|Single intravenous administration
219334895|NCT06417359|PROCEDURE|Mesh Fixation|That mesh will be fixation with three tackers.
219334896|NCT06417359|PROCEDURE|No Mesh Fixation|That mesh will not be fixation
219334897|NCT04168944|DRUG|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
219334898|NCT04168944|DRUG|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
219334899|NCT04168944|DRUG|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
219334900|NCT00635479|DEVICE|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
219334901|NCT00635479|OTHER|Gauze dressing|Gauze dressing for surgical incision
219334902|NCT03387436|BEHAVIORAL|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
219334903|NCT03387436|BEHAVIORAL|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
219334904|NCT00258011|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
219334905|NCT05479214|DRUG|Metformin|1gm tablet with the 2 main meals
219334906|NCT05479214|DRUG|Insulin|subcutaneous insulin daily administration
219334907|NCT01075412|DRUG|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
219334908|NCT00501371|DRUG|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
219334909|NCT00501371|DRUG|Placebo|soft-gel capsule, Qd, 12 weeks
219334910|NCT03959332|DRUG|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
219334911|NCT04278209|OTHER|Breakfast 1|Participant will receive Breakfast 1
219334912|NCT04278209|OTHER|Breakfast 2|Participant will receive Breakfast 2
219334913|NCT04278209|OTHER|Water|Participant will receive water
219334914|NCT00554359|DRUG|I5NP (a small interfering RNA)|Single IV injection of experimental drug
219334915|NCT00554359|DRUG|placebo|Single IV injection of saline
219334916|NCT02816307|OTHER|blood samples|
219334917|NCT02431091|OTHER|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
219334918|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
219334919|NCT01954186|DRUG|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
219334920|NCT01954186|PROCEDURE|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
219334921|NCT04619420|DRUG|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
219334922|NCT04619420|DRUG|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
219334923|NCT03394144|DRUG|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
219334924|NCT01179464|DRUG|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
219334925|NCT01179464|DRUG|Simvastatin|40 mg once daily
219334926|NCT05239533|DRUG|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
219334927|NCT05239533|DRUG|Nivolumab|Nivolumab 240mg q2wk
219334928|NCT05239533|DIAGNOSTIC_TEST|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
219334929|NCT05239533|DIAGNOSTIC_TEST|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
219334930|NCT03506035|DIAGNOSTIC_TEST|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
219334931|NCT02772640|DRUG|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -\> evening evening -\> morning"
219334932|NCT04782011|BEHAVIORAL|ATC/DDD|The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
219334933|NCT04579562|OTHER|No intervention|This is observational, non-interventional study
219334934|NCT04961853|RADIATION|Ultrasound and MRI|Ultrasound examination and magnetic resonance imaging on the hand
219334935|NCT04787094|OTHER|Yoga|Yoga
219334936|NCT04787094|OTHER|Spinal Stabilization Exercise|Spinal Stabilization Exercise
219334937|NCT02692365|PROCEDURE|Magnetic Resonance + hemodynamic + infusion of gadolinium|
219334938|NCT00812799|DRUG|Oralgen|19.000 BU daily
219334939|NCT00812799|OTHER|placebo control|placebo control
219334940|NCT05837351|BEHAVIORAL|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
219334941|NCT03980834|BEHAVIORAL|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
219334942|NCT03980834|BEHAVIORAL|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
219334943|NCT03980834|BEHAVIORAL|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
219334944|NCT03980834|BEHAVIORAL|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
219334945|NCT05885438|BEHAVIORAL|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
219334946|NCT04042168|DIAGNOSTIC_TEST|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
219334947|NCT06234150|OTHER|Aerobic dance|Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
219334948|NCT06234150|OTHER|Fast-walking|Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
219334949|NCT00237848|DRUG|D-serine|
219334950|NCT00237848|BEHAVIORAL|Cognitive retraining|
219334951|NCT05139849|DRUG|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
219334952|NCT05139849|DRUG|Sodium chloride|Sodium chloride 9 mg/ml
219334953|NCT02056054|OTHER|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
219334954|NCT02056054|OTHER|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
219334955|NCT02056054|OTHER|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
219334956|NCT02056054|OTHER|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
219334957|NCT02056054|OTHER|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
219334958|NCT02056054|OTHER|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
219334959|NCT02056054|OTHER|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
219334960|NCT03482687|BEHAVIORAL|Me & You: Building Healthy Relationships|Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
219334961|NCT05304650|DEVICE|iTEAR100|Controlled Stimulation External Nasal Nerve to stimulate tear production
219334962|NCT00865904|DRUG|VX-809|Capsules
219334963|NCT00865904|DRUG|Placebo|Placebo matched to VX-809 capsules.
219334964|NCT01963429|PROCEDURE|radiofrequency ablation|"\* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min."
219334965|NCT01963429|RADIATION|Proton beam therapy|"\* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)"
219334966|NCT00517322|DRUG|ramipril|ramipril 2.5- 5 mg once daily
219334967|NCT00517322|DRUG|irbesartan|irbesartan 150-300 mg once daily
219334968|NCT03625687|DRUG|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
219334969|NCT00454038|DEVICE|HYPRO SORB F|resorbable, double layered, collagen membrane
219334970|NCT02372916|DRUG|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
219334971|NCT00941668|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
219334972|NCT00941668|DRUG|sodium monofluorophosphate toothpaste|Twice daily usage
219334973|NCT04593667|DEVICE|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
219334974|NCT01396226|DRUG|AZD2927|A single dose of AZD2927 administered as an iv infusion
219334975|NCT01396226|DRUG|Placebo|A single dose of placebo administered as an iv infusion
219334976|NCT05217121|OTHER|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
219334977|NCT05217121|OTHER|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
219334978|NCT00321750|DRUG|1% pimecrolimus cream|
219334979|NCT00711425|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
219334980|NCT01023867|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
219334981|NCT02485457|PROCEDURE|Volume loading|Volume loading with Ringer Lactate
219334982|NCT02485457|DRUG|Ringer solution|
219334983|NCT01473979|PROCEDURE|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
219334984|NCT01421940|DRUG|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
219334985|NCT01421940|DRUG|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
219334986|NCT05786079|BEHAVIORAL|Footstrike modification|
219334987|NCT05786079|BEHAVIORAL|Control|
219334988|NCT03522051|OTHER|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
219334989|NCT03351790|OTHER|Questionniare only|A pre-procedure questionnaire will be completed by all participants
219334990|NCT00681174|DRUG|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
219334991|NCT00681174|DRUG|oxycodone|20 mg p.o. 1 h before the start of anesthesia
219334992|NCT00681174|PROCEDURE|Paravertebral block|"* Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
219334993|NCT00681174|DRUG|Propofol|"* Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
219334994|NCT00681174|DRUG|Remifentanil|"* 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
219334995|NCT00681174|DRUG|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
219334996|NCT00681174|DRUG|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none"
219334997|NCT06466538|DRUG|Calcium hydroxide|intracanal medicament
219334998|NCT06466538|DRUG|Leddermix|Leddermix
219334999|NCT06466538|DRUG|Boswellia|Boswellia
219335000|NCT04607148|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
219335001|NCT03366090|PROCEDURE|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
219335002|NCT00151983|DRUG|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
219335003|NCT00916149|DRUG|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
219335004|NCT00916149|DRUG|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
219335005|NCT06441045|DRUG|Double Dose of Third-generation EGFR-TKI|Double Dose of Third-generation EGFR-TKI
219335006|NCT06441045|DRUG|Intrathecal Pemetrexed|Intrathecal Pemetrexed
219335007|NCT00907751|DRUG|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
219335008|NCT01965639|OTHER|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
219335009|NCT05712148|BIOLOGICAL|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
219335010|NCT06119490|DRUG|Abrocitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks
219335011|NCT06119490|DRUG|Tofacitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
219335012|NCT00589420|DRUG|docetaxel|
219335013|NCT00589420|DRUG|sorafenib tosylate|
219335014|NCT03025230|OTHER|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
219335015|NCT03025230|OTHER|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
219335016|NCT02761395|PROCEDURE|Al-hijamah|"* Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
219335017|NCT02761395|DRUG|Deferasirox|20-40 mg/kg/day orally
219335018|NCT04475575|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
219335019|NCT06508918|DRUG|Betametasona|pressure pain threshold values of the most painful area will be recorded with a manual algometer
219335020|NCT00912028|DEVICE|senofilcon A|contact lens
219335021|NCT00912028|DEVICE|lotrafilcon B|contact lens
219335022|NCT00912028|DEVICE|balafilcon A|contact lens
219335023|NCT00912028|DEVICE|methafilcon A|contact lens
219335024|NCT00912028|DEVICE|vifilcon A|contact lens
219335025|NCT06448702|PROCEDURE|wet wrap therapy|Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect
219335026|NCT06448702|DEVICE|External compression counter-pulsation (EECP)|External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
219335027|NCT01214928|DRUG|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
219335028|NCT00585000|DRUG|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
219335029|NCT04378530|BEHAVIORAL|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
219335030|NCT04378530|BEHAVIORAL|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
219335031|NCT04378530|BEHAVIORAL|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
219335032|NCT01940471|DRUG|TAF|25 mg tablet administered orally once daily
219335033|NCT01940471|DRUG|TDF|300 mg tablet administered orally once daily
219335034|NCT01940471|DRUG|TAF Placebo|Tablet administered orally once daily
219335035|NCT01940471|DRUG|TDF Placebo|Tablet administered orally once daily
219335036|NCT03296085|PROCEDURE|Exam for quantity of edema|There is no intervention
219335037|NCT02123316|BIOLOGICAL|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
219335038|NCT02123316|BIOLOGICAL|Placebo|Placebo for subcutaneous injection
219335039|NCT00353834|DRUG|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
219335040|NCT00353834|DRUG|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
219335041|NCT03216811|DRUG|nutraceutical|8-week administration of nutraceutical compound
219335042|NCT03675035|DEVICE|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
219335043|NCT04311216|OTHER|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
219335044|NCT04941066|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
219335045|NCT04941066|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
219335046|NCT06090526|DIAGNOSTIC_TEST|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
219335047|NCT01191866|BEHAVIORAL|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
219335048|NCT01846624|DRUG|Decitabine|Given IV
219335049|NCT01846624|DRUG|Midostaurin|Given PO
219335050|NCT03574753|DRUG|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
219335051|NCT00832520|DRUG|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None"
219335052|NCT05365555|PROCEDURE|Fascia Iliaca Compartment Block|Blind technique.
219335053|NCT05365555|PROCEDURE|Femoral Nerve Block|Ultrasound guided.
219335054|NCT05365555|DRUG|Ropivacaine|Ropivacaine dosed according to local guidelines.
219335055|NCT04930809|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
219335056|NCT03853720|PROCEDURE|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
219335057|NCT05039333|DEVICE|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
219335058|NCT02218242|DEVICE|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
219335059|NCT04529681|DEVICE|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
219335060|NCT04529681|OTHER|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
219335061|NCT06165250|DRUG|BR1018A|One tablet administered alone
219335062|NCT06165250|DRUG|BR1018A-1|One tablet administered alone
219335063|NCT06165250|DRUG|BR1018B|One tablet administered alone
219335064|NCT06165250|DRUG|BR1018B-1|One tablet administered alone
219335065|NCT06165250|DRUG|BR1018C|One tablet administered alone
219335066|NCT06165250|DRUG|BR1018C-1|One tablet administered alone
219335067|NCT02559297|DRUG|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
219335068|NCT02559297|DRUG|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
219335069|NCT06148571|DEVICE|left bundle branch area pacing|left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
219335070|NCT04000789|DRUG|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
219335071|NCT03762720|DEVICE|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
219335072|NCT06185621|DRUG|100mg aspirin|Patients received oral 100mg aspirin, one tablet daily for 2 years
219335073|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
219335074|NCT01733979|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
219335075|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron|Heme-Iron (1g/day)
219335076|NCT01733979|DIETARY_SUPPLEMENT|Organic Iron|Organic Iron (1g/day)
219335077|NCT01744665|DRUG|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
219335078|NCT04844684|OTHER|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
219335079|NCT02411162|DRUG|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
219335080|NCT02411162|DRUG|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
219335081|NCT04986306|PROCEDURE|SLNB + ALND|Patients who received neoadjuvant chemotherapy will undergo SLNB+ALND to evaluate the feasibility of SLNB
219335082|NCT05126186|OTHER|haplo-SCT with PTCy|"Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic."
219335083|NCT03625050|PROCEDURE|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
219335084|NCT03625050|DRUG|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
219335085|NCT01590550|PROCEDURE|Use of citrate based dialysate|Use of heparin free citrate based dialysate
219335086|NCT03184077|PROCEDURE|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
219335087|NCT03184077|PROCEDURE|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
219335088|NCT03998111|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
219335089|NCT03062592|DIETARY_SUPPLEMENT|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
219335090|NCT04170439|DRUG|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
219335091|NCT04170439|DRUG|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
219335092|NCT04170439|DRUG|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
219335093|NCT00478582|PROCEDURE|Estimation of Hb concentrations with the HemoHue card|
219335094|NCT04209751|DIAGNOSTIC_TEST|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
219335095|NCT03193151|PROCEDURE|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
219335096|NCT06285318|OTHER|Teclistamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
219335097|NCT06285318|OTHER|Talquetamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
219335098|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
219335099|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
219335100|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
219335101|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
219335102|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
219335103|NCT06162676|BEHAVIORAL|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
219335106|NCT06293040|DRUG|Cannabis|Cannabis will be vaporized using the Mighty Medic
219335107|NCT06293040|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
219335108|NCT06293040|DRUG|Placebo Cannabis|Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
219335109|NCT06293040|DRUG|Placebo Alcohol|A non-alcoholic, placebo, flavored drink will be orally ingested.
219335110|NCT05432323|BEHAVIORAL|Multi-family therapy|8 sessions of Multi-family therapy of 3 hours each during 24 weeks
219335111|NCT06337357|BEHAVIORAL|Progressive Resistance Training|"Progressive resistance training includes face-to-face education on resistance training:~Resistance exercises with elastic bands include 9 exercises for 1 course. During the first 4 weeks, the patient exercises twice a week with a level of exertion according to Borg's category-ratio 10 (CR10) scale of 4-5 points. For the next 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 6-7 points. In the last 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 8-9 points.~The three-month intervention involves twelve weekly calls, with a focus on building rapport (e.g. providing feedback on the baseline assessment); education reinforcement on resistance training; and skill-building (e.g. self-monitoring and resistance training diary). The emphasis is on helping participants to gain the knowledge and skills necessary to achieve targeted intensity. Every 4 weeks, all patients are re-visited by investigators in the hospital."
219335112|NCT06368921|BIOLOGICAL|VRT106|intratumoral injection
219335113|NCT05208762|DRUG|PF-08046054|Given into the vein (IV; intravenously)
219335114|NCT05208762|DRUG|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
219335115|NCT02699645|DRUG|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 pill taken orally once daily for average of 72 months
219335116|NCT02699645|DRUG|Placebo|1 pill taken orally once daily for average of 72 months
219335117|NCT06851091|DIAGNOSTIC_TEST|Biodex Balance System|Biodex Balance System \[Biodex Balance System SD (Biodex, Inc, Shirley, NY) (BBS)\]:The Biodex Balance System is a computer-assisted device that assesses postural stability. It measures static and dynamic balance, fall risk, and proprioception through different difficulty levels and test protocols. In our study, this system will be used to investigate the relationship between balance and central sensitization. Participants will be evaluated using the postural stability test, fall risk test, athlete single leg test, and limits of stability test protocols, and they will be trained before the testing process.
219335118|NCT06851091|DIAGNOSTIC_TEST|Pressure Pain Threshold (PPT) Measurement with Algometer|Pressure pain threshold (PPT) is defined as the minimum force applied that causes pain. This measurement is commonly used for assessing tender points and has been shown to be useful.
219335119|NCT06851091|DIAGNOSTIC_TEST|Conditioned Pain Modulation (CPM)|According to this protocol, a pressure stimulus, referred to as the test stimulus, will first be applied to the trapezius muscle to induce a pain intensity of 4 on a 10-point Numeric Rating Scale (NRS). Subsequently, a conditioning stimulus will be introduced by immersing the participant's right hand in 7°C water for 20 seconds. Following this conditioning stimulus, the same test stimulus will be reapplied to the trapezius muscle, and participants will be asked to rate their pain using the NRS. If participants are unable to keep their hands in the water for the full 20 seconds, the test stimulus will be applied immediately after hand removal. The CPM score will be calculated as the ratio of the initial NRS score to the second NRS score, multiplied by 100. Scores above 100 are considered indicative of a normal CPM response, with higher scores reflecting greater descending pain inhibition.
219335120|NCT06851091|DIAGNOSTIC_TEST|Slowly Repeated Evoked Pain Assessment Protocol (SREP)|"Responses to induced pain indicate the presence of allodynia and hyperalgesia in FMS patients. The Slow Repetitive Evoked Pain (SREP) protocol consists of nine suprathreshold painful stimuli applied to the nail bed for five seconds each, with 30-second intervals. Painful stimulation will be administered using a pressure algometer with a 1 cm² stimulation surface. Nailbed pain stimuli are commonly used to assess pain sensitivity.~The intensity of pain perception from each SREP stimulus will be evaluated using a 10-point Numerical Rating Scale (NRS) (0 = no pain, 10 = extremely painful). The SREP sensitization index will be calculated as the difference between the final and initial pain scores.~Higher positive SREP sensitization index values indicate a greater increase in perceived pain intensity across the nine stimuli, reflecting higher pain sensitization."
219335121|NCT06851091|DIAGNOSTIC_TEST|Central Sensitization Inventory (CSI)|"The Central Sensitization Inventory (CSI) is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization.~The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.~This scale has been shown to be a reliable and valid tool in the Turkish population with chronic pain (test-retest reliability = 0.92, Cronbach's alpha = 0.93)"
219335122|NCT06851091|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Numeric Rating Scale (NRS) will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
219335123|NCT06851091|DIAGNOSTIC_TEST|Revised Fibromyalgia Impact Questionnaire (FIQ)|Revised Fibromyalgia Impact Questionnaire (FIQ) consists of three sections: function, general, and symptoms, with a total of 21 questions. It evaluates the limitations and functional disability that occur in patients with fibromyalgia. All questions are scored on the Numeric Rating Scale (NRS), ranging from 0 to 10. As the score from the questionnaire increases, it indicates a higher level of disability related to fibromyalgia. In our study, the Turkish version of the questionnaire, which has been validated and shown to be reliable, will be used.
219335124|NCT06851091|DIAGNOSTIC_TEST|S-LANSS Pain Score (Self-administered Leeds Assessment of Neuropathic Symptoms and Signs)|The S-LANSS pain score is a 7-item self-administered scale developed and validated to recognize neuropathic pain in chronic pain patients and distinguish it from nociceptive pain. It evaluates neuropathic symptoms and signs through a series of questions that help identify features like hyperalgesia, allodynia, and paresthesia, which characterize the chronic pain sensation associated with neuropathic pain. These features are often seen in fibromyalgia (FMS) pain. In our study, the Turkish version of the questionnaire, which has undergone validity and reliability testing, will be used.
219355434|NCT05634395|DEVICE|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
219335125|NCT06851091|DIAGNOSTIC_TEST|Tampa Kinesiophobia Scale (TKS)|"The Tampa Kinesiophobia Scale is a 17-item measure designed to assess fear of movement/re-injury. The scale evaluates fear-avoidance behaviors related to work activities, injury/re-injury concerns, and fear-avoidance parameters. It is used in the context of acute and chronic low back pain, fibromyalgia (FMS), musculoskeletal injuries, and whiplash-associated disorders.~The scale uses a 4-point Likert scoring system (1 = Strongly disagree, 4 = Strongly agree). After reversing the scores for items 4, 8, 12, and 16 (for example, if a participant selects 1 for these items, it is counted as 4; 2 is counted as 3, etc.), the total score is calculated. The participant receives a score between 17 and 68. A higher score on the scale indicates a higher level of kinesiophobia. In our study, the Turkish version of the scale, which has undergone validity and reliability testing, will be used."
219335126|NCT06851091|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale (HAD)|"This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21:~* 0-7 points: No symptoms or very mild symptoms~* 8-10 points: Moderate symptoms~* 11 points or higher: Symptoms likely corresponding to a clinical diagnosis of anxiety and depression According to the 2016 diagnostic criteria for Fibromyalgia Syndrome (FMS), the presence of depression contributes to the diagnosis of FMS. The HAD scale has been shown to be a suitable tool for assessing FMS and related patient education programs.~In our study, the Turkish version of the HAD scale, which has been validated and shown to be reliable, will be used."
219335127|NCT06851091|DIAGNOSTIC_TEST|SF-12 Health Survey (SF-12 Quality of Life Scale)|The SF-12 Health Survey is one of the most widely used scales for assessing health-related quality of life. In our study, the Turkish version of the SF-12, which has been validated and shown to be reliable, will be used. The scores will be calculated using an online calculation tool, and two types of scores-Physical Component Summary (PCS) and Mental Component Summary (MCS)-will be obtained.
219335128|NCT06851091|DIAGNOSTIC_TEST|Fatigue Severity Scale (FSS)|The Fatigue Severity Scale (FSS) is a 9-item questionnaire used to assess the severity, frequency, and impact of fatigue on daily life. Each item is rated on a scale from 1 to 7. A lower score indicates a decrease in fatigue severity. In our study, the Turkish version of the scale, which has been validated and shown to be reliable, will be used.
219335129|NCT06851091|DIAGNOSTIC_TEST|Timed Up and Go Test (TUG)|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for participants to stand up and walk. The patient begins by sitting on a standardized chair (height of 46 cm). During the test, the patient is asked to stand up from the chair, walk 3 meters, turn around, and return to sit back on the chair. The time taken to complete this process is measured. Lower values indicate better stability. A cut-off value of 13.5 seconds is used to identify individuals at higher risk of falling.
219335130|NCT03970954|DRUG|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
219335131|NCT04289402|OTHER|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
219335132|NCT04289402|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
219335133|NCT04297085|BIOLOGICAL|Biologic sample|Biological samples will be taken from the subjects included
219335134|NCT04354298|BEHAVIORAL|Improvisational Dance Class|Hour long movement classes that meet weekly for 12 weeks.
219335135|NCT02258503|OTHER|pain in elderly patients|
219335136|NCT03761875|OTHER|blood sample CHB patients|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 1 dry tube per patient"
219335137|NCT03761875|OTHER|boold sample Control group|"* 2 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 1 dry tube"
219335138|NCT02046096|DEVICE|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
219335139|NCT02046096|DEVICE|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
219335140|NCT01693354|DEVICE|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
219335141|NCT01693354|DEVICE|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
219335142|NCT00626249|DRUG|Technosphere Inhalation Powder|Technosphere Inhalation Powder
219335143|NCT05338775|DRUG|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
219335144|NCT05338775|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
219335145|NCT05338775|DRUG|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
219335146|NCT06972225|DEVICE|DEB|Use of DEB to treat coronary lesions
219335148|NCT03832179|DRUG|Bevacizumab|Bevacizumab
219335149|NCT03832179|DRUG|Ranibizumab|Ranibizumab
219335150|NCT03832179|DRUG|Aflibercept|Aflibercept
219335151|NCT03832179|DRUG|Ozurdex|Ozurdex
219335152|NCT01608152|BEHAVIORAL|Focus Group|Attend a focus group
219335153|NCT01608152|OTHER|Internet-Based Intervention|Have access to the game
219335154|NCT01608152|BEHAVIORAL|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
219335155|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
219335156|NCT04678882|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
219335157|NCT04678882|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
219335158|NCT04898933|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
219335159|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
219335160|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
219335161|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
219335162|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
219335163|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
219335164|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
219335165|NCT06973629|BIOLOGICAL|Debamestrocel - MSC-NTF (NurOwn)|MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).
219335166|NCT06973629|BIOLOGICAL|Placebo|Dulbecco Modified Eagle Medium (DMEM).
219335167|NCT06501820|DEVICE|Transcranial direct current stimulation|2mA transcranial direct current stimulation, applied bilaterally on the scalp, over the brain vestibular cortex
219335168|NCT05092269|DRUG|Ustekinumab|Ustekinumab will be administered as a SC injection.
219335169|NCT06255496|DIAGNOSTIC_TEST|Quantra Hemostasis Analyzer with the QStat Cartridge|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219335170|NCT01656148|DRUG|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
219335171|NCT06082635|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
219335172|NCT06082635|DRUG|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
219335173|NCT05599672|BEHAVIORAL|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
219335174|NCT05599672|BEHAVIORAL|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
219335175|NCT05125601|OTHER|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
219335176|NCT04863664|DEVICE|Defibrillation (RV Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
219335177|NCT04863664|DEVICE|Defibrillation (LBBAP Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
219335178|NCT04287218|BEHAVIORAL|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
219335179|NCT04287218|BEHAVIORAL|aTAU|Active control group
219335180|NCT05161390|DRUG|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
219335181|NCT00193089|DRUG|Docetaxel|Docetaxel
219335182|NCT00193089|DRUG|Vinorelbine|Vinorelbine
219335183|NCT00193089|DRUG|Trastuzumab|Trastuzumab
219335184|NCT02919592|DEVICE|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
219335185|NCT02919592|DEVICE|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
219335186|NCT02919592|PROCEDURE|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
219335187|NCT05552222|DRUG|Teclistamab|Teclistamab will be administered as SC injection.
219335188|NCT05552222|DRUG|Daratumumab|Daratumumab will be administered as SC injection.
219335189|NCT05552222|DRUG|Lenalidomide|Lenalidomide will be administered orally.
219335190|NCT05552222|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
219335191|NCT05552222|DRUG|Talquetamab|Talquetamab will be administered as SC injection.
219335192|NCT00000536|BEHAVIORAL|sodium, dietary|
219335193|NCT01401842|OTHER|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
219335194|NCT01401842|OTHER|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
219335195|NCT04616534|PROCEDURE|Biopsy Procedure|Undergo biopsy (dose expansion cohort only)
219335196|NCT04616534|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219335197|NCT04616534|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
219335198|NCT04616534|DRUG|Elimusertib|Given PO
219335199|NCT04616534|DRUG|Gemcitabine|Given IV
219335200|NCT01181076|DIETARY_SUPPLEMENT|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
219335201|NCT02971631|OTHER|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
219335202|NCT02971631|OTHER|Placebo|Infusion of 1% human albumin in normal saline
219335203|NCT06005610|DRUG|Estradiol|Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
219335204|NCT07122167|DEVICE|Peripheral Drug-eluting Stent System|Drug-eluting stents (DES) are increasingly used in the treatment of PAD. These stentsare coated with antiproliferative drugs designed to provide mechanical support within the artery while releasing the drug gradually to reduce the risk of restenosis. Commonly used drugs include paclitaxel, sirolimus, and everolimus, which inhibit vascular smooth muscle cell proliferation, thereby reducing the likelihood of re-occlusion.
219335205|NCT05070988|OTHER|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
219335206|NCT06602219|DRUG|LY4100511|Administered orally
219335207|NCT06602219|DRUG|Placebo|Administered orally
219335208|NCT06985407|DIETARY_SUPPLEMENT|Grape extract (VinteraTM Premium Red Grape)|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
219335209|NCT06985407|DIETARY_SUPPLEMENT|Control (placebo) group|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
219335210|NCT02489136|OTHER|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
219335211|NCT06985251|OTHER|gamified mHealth lifestyle app|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard.
219335212|NCT06985251|OTHER|Attention Control|Standard of care healthy lifestyle handouts were emailed monthly to control families.
219335213|NCT06985251|OTHER|gamified mHealth app with financial incentives|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard. CommitFit$ adolescents received an extra $0.05 for each point they earned in the app.
219335214|NCT06984133|BEHAVIORAL|Structured education program|"A structured group educational program culturally adapted from a UK model for adolescents with type 1 diabetes. The program aims to empower adolescents by providing knowledge and tools needed for effective diabetes management.~It is delivered by dietitians, diabetes educators, and a pediatric endocrinologist in small groups. The curriculum targets both caregivers and adolescents: the first day is for parents and covers diabetes basics, management of hypoglycemia and hyperglycemia, insulin dosing, sick day management, and exercise considerations. The following three days focus on adolescents and include interactive sessions on the role of food in diabetes management, the effect of different nutrients on blood glucose levels, carbohydrate sources, reading food labels, advanced carbohydrate counting, and insulin dose adjustment."
219335215|NCT04702451|PROCEDURE|Dispersion ablation + PVI|Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
219335216|NCT04702451|DEVICE|VX1|VX1-based dispersion mapping
219335217|NCT04702451|PROCEDURE|PVI|Pulmonary vein antrum isolation
219335218|NCT06051006|OTHER|ESR and ECAP measurements|"Measurement of electrically evoked stapedial reflexes (ESRT) by stimulation via the cochlear implant. Measurement of the Electric compound action potentials (ECAPs) on the electrodes where the ESRT were performed.~The measurements and tests will be performed during a routine visit to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
219335219|NCT06051006|OTHER|Device setting|"The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
219355435|NCT05043467|DRUG|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
219355436|NCT04024267|OTHER|Eurythmy therapy|Mind-body therapy
219335220|NCT06051006|OTHER|Speech audiometry|"This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
219335221|NCT06051006|OTHER|Intelligibility in noise test|"The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
219335222|NCT06051006|OTHER|Cochlear implant datalogging, speech audiometry test, FraSimat test|"The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR."
219335223|NCT06600542|DEVICE|Inari Medical Commercially Available Devices|Commercially approved Inari Medical devices
219335224|NCT06590493|DRUG|doxecitine and doxribtimine|TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.
219335225|NCT06981806|DRUG|Balixafortide|Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly
219335226|NCT06981806|DRUG|Balixafortide|Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly
219335227|NCT06981806|DRUG|Cosibelimab|Dose: 800 mg Route: IV (60 min) Frequency: Weekly
219335228|NCT06981806|DRUG|Balixafortide|Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly
219335229|NCT06985550|BEHAVIORAL|Multicomponent Exercise|Participants in this group will engage in a 12-week supervised multicomponent exercise program, performed 3 times per week, 90 minutes per session. Each session includes a 10-minute warm-up, 40 minutes of Waltz dance (learning and practicing routines), 30 minutes of resistance band exercises (1-3 sets of 8-12 repetitions, using 10-20RM), and a 10-minute cool-down with stretching. Exercise intensity progresses from 50% to 75% of HRmax (RPE 10-13, 2.0-6.0 METs). The program is designed to improve lipid profile, body composition, cardiovascular fitness, balance, mental health, and cognitive function in postmenopausal women aged ≤65 years with dyslipidemia.
219335230|NCT06985550|OTHER|daily activity|Only daily activities are included.
219335231|NCT06481098|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
219335232|NCT06481098|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
219335233|NCT04276389|DEVICE|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
219335234|NCT04276389|DEVICE|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
219335235|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
219335236|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
219335237|NCT06984224|DEVICE|Neubie Direct Current Stimulation Device|Pulsed Direct Current Electrical Stimulation Device
219335238|NCT05816356|DRUG|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
219335239|NCT05816356|DRUG|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
219335240|NCT03350711|OTHER|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
219335241|NCT06996080|DRUG|KSI-101|Intravitreal injection
219335242|NCT06996080|OTHER|Sham Comparator|Sham injections
219335243|NCT03996980|DEVICE|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
219335244|NCT06667076|DRUG|Amivantamab|Amivantamab will be administered.
219335245|NCT06667076|DRUG|Lazertinib|Lazertinib tablet will be administered.
219355437|NCT04024267|OTHER|CoordiFit|Fitness training
219335246|NCT06667076|DRUG|Chemotherapy: Pemetrexed|Pemetrexed will be administered.
219335247|NCT06667076|DRUG|Chemotherapy: Carboplatin|Carboplatin will be administered.
219335248|NCT02724371|DEVICE|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
219335249|NCT06862986|OTHER|Ear massage|At least one Intervention must be specified for an Interventional study. Patients included in the study group will receive ear massage in addition to the routine treatment and care practices of the clinic. Ear massage application will be started in the evening of the first day after surgical intervention (at 19:30) and will be applied twice a day at least 30 minutes after morning and evening meals (07:30 am, 19:30 pm) for 3 minutes each, similar to the literature (8,9,12). The bowel sounds of the patients will be re-evaluated before and 10 minutes after the ear massage application, and the excretory activities form will be filled out. Ear massage application will be terminated when the patient defecates or when the patient is given an enema.
219335250|NCT05585983|BIOLOGICAL|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
219335251|NCT07001111|OTHER|kinesio taping|Kinesio taping at the level of the cubital tunnel on the elbow
219335252|NCT07001111|OTHER|Ulnar nerve mobilization exercise|All patients will be provided with information and an exercise sheet containing pictures on ulnar nerve gliding exercises. To monitor whether patients are performing the exercises correctly, they will be asked to come to the hospital once a week, where they will perform the exercises under the supervision of a physiotherapist. In the exercise program, different positions will be held for 30 seconds, with a 1-minute rest between them, and the exercises will be performed twice a day .
219335253|NCT07001111|OTHER|Sham (No Treatment)|It will be applied in the same way as kinesiological taping with adhesive tape.
219335254|NCT07001111|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Description: To demonstrate that kinesiological taping will result in a reduction of pain intensity associated with Cubital Tunnel Syndrome, as measured by the Numeric Rating Scale (NRS) ranging from 0 to 10.
219335255|NCT07001111|DIAGNOSTIC_TEST|the ulnar nerve cross-sectional area measured by ultrasound|The measurements will be taken with the patient in a supine position, the affected arm in shoulder abduction and external rotation, and the elbow flexed at 70°-90°. After applying a generous amount of gel, the lateral edge of the ultrasound probe will be placed on the medial epicondyle, and the medial edge of the probe will be positioned on the olecranon; the ulnar nerve will be directly examined in the retroepicondylar groove. Once the nerve is visualized, the widest point will be identified, and cross-sectional area (CSA) measurements will be taken with the probe perpendicular to the nerve at the center of the screen . The measurements will be repeated twice, and the average will be calculated.
219335256|NCT07001111|DIAGNOSTIC_TEST|Neuropathic pain scale (measured using the DN-4 scale)|"The DN4 questionnaire consists of two main sections and a total of ten questions. The first section includes seven questions related to pain characteristics and sensory information obtained through patient interview. These questions are about burning, electric shocks, coldness, tingling, pricking, numbness, and itching. The second section contains three statements related to physical examination (touch hypoesthesia, pinprick hypoesthesia, and allodynia). For each statement, yes or no responses are given. A score of 1 is assigned for yes answers and 0 for no answers, and the scores are summed. A total score of 4 or more out of 12 is interpreted as neuropathic pain."
219335257|NCT07001111|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale is a short form of the SF-36 Quality of Life Scale. While the SF-36 is used for chronic conditions (states), the SF-12 is used for short-term assessments (clinical findings). Similarly, it is also used to gather information about the patient's general health status. The SF-12 provides the same summary component scores as the SF-36, but with fewer items, making it a significant advantage due to its shorter application time. The scale asks the patient about their health opinions, how they feel, and how easily they can perform their usual activities. Scores range from 0 to 100, with higher scores indicating better quality of life.
219335258|NCT07001111|DIAGNOSTIC_TEST|QUICK-DASH|"QUICK-DASH (Shoulder, Arm, and Hand Problems Questionnaire):~This questionnaire assesses both the ability to perform certain physical activities as well as the symptoms of the disease. Each question is answered based on the condition of the past week, and the appropriate score is marked. The answer is given based solely on the ability to perform the physical activity, without considering which hand or arm is injured.~Scoring:~1. = No difficulty~2. = Mild difficulty~3. = Moderate difficulty~4. = Severe difficulty~5. = Unable to perform~QUICK DASH DISABILITY/SYMPTOM SCORE:~(\[(n total score\] - 1) x 25; where n represents the number of questions answered. If more than one question is unanswered, the Quick DASH score cannot be calculated.~SCORE FOR OPTIONAL MODELS:~For each model, divide the total score by 4, subtract 1, and multiply by 25. If more than one question is unanswered, the score for optional models cannot be calculated.~Based on the results of the questionnaire, a score b"
219335259|NCT07001111|DIAGNOSTIC_TEST|Grip strength measured with a hand dynamometer|Grip strength will be measured using a hand dynamometer, with the average of three measurements taken, each followed by a 30-second rest period.
219335260|NCT07001059|DIAGNOSTIC_TEST|orbital ultrasound|orbital ultrasound at the beginning of the participation, and at 6 months after the inclusion.
219335261|NCT04117646|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|Subjects respond to the translated questionnaire twice at 15 days apart.
219335262|NCT04347226|DRUG|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
219335263|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
219335264|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
219335265|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
219335266|NCT07003282|BEHAVIORAL|"The intervention includes 1) the First Breath app, 2) reminders during the follow-up period and 3) only for women- cotinine concentration measurement (a biomarker of secondhand smoke exposure)"|"The intervention focus on raising knowledge about the health consequences of prenatal secondhand smoke exposure, proposing strategies to avoid exposure at home and in the car, and raising motivation to implement a smoke-free home and car. An exposure score of each participant is calculated, based on his perception of secondhand smoke exposure, smoking rules within the home and strategies used to reduce exposure. Participants are guided in setting specific goals, with a detailed action plan, and receive ongoing feedback throughout follow up. In addition, for pregnant women, urine cotinine measurements at baseline, 4-weeks and 12-weeks study visit are integrated into the intervention and personalized biofeedback provided to them . Participants of the intervention arm also receive remiders (by WhatsApp) to re-use the App during all the follow-up period (3 times during the first week, 2 times/week during the 2nd, 3th and 4th weeks, and then once a week until the end of follow-up)."
219335267|NCT05077904|DRUG|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
219335268|NCT05077904|OTHER|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
219335269|NCT06707935|BEHAVIORAL|Descriptive social norm nudges|A set of messages with descriptive social norm nudges sent to participants.
219335270|NCT06707935|BEHAVIORAL|Pictorial social norm nudges|A set of messages with pictorial social norm nudges sent to participants.
219335271|NCT06707935|BEHAVIORAL|Service as usual|Traditional mental health education information disseminated to participants.
219335272|NCT06710418|OTHER|Activity Tracking|Ancillary studies
219335273|NCT06710418|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219335274|NCT06710418|PROCEDURE|Cognitive Assessment|Ancillary studies
219335275|NCT06710418|OTHER|Electronic Health Record Review|Ancillary studies
219335276|NCT06710418|OTHER|Packed Red Blood Cell Transfusion|Undergo PRBC transfusion
219335277|NCT06710418|OTHER|Quality-of-Life Assessment|Ancillary studies
219335278|NCT06717074|DRUG|RBD4059|RBD4059, active drug.
219335279|NCT06717074|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
219335280|NCT07047144|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
219335281|NCT07047144|DRUG|Nusinersen|Nusinersen is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered intrathecally per the prescribing information.
219335282|NCT07047144|DRUG|Risdiplam|Risdiplam is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered orally per the prescribing information.
219335283|NCT06715943|DRUG|HRS-5965 capsule|HRS-5965 capsule treatment
219335284|NCT06740968|DEVICE|transcranial alternating current stimulation (tACS)|During each of the 3 stimulation visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).
219335285|NCT06749496|DEVICE|Test Lens|ACUVUE® OASYS MAX 1-Day for ASTIGMATISM (AOM1DfA).
219335286|NCT06749496|DEVICE|Control Lens|Alcon DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA).
219335287|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
219335288|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
219335289|NCT05645523|DRUG|Indocyanine Green|Given in to the vein (IV)
219335290|NCT07071324|BEHAVIORAL|CF Wellness Program|Intervention modules are 1) Introduction \& Fatigue Explained, 2) Finding Balance between Activity \& Rest, 3) Physical Activity, Self-Review \& Planning, 4) Improving Your Sleep, 5) Managing Emotions, 6) Changing Less Helpful Thoughts, 7) Learning to Relax \& Manage Stress, and 8) Accessing Social Support and Preparing for the Future.
219335291|NCT07069712|DRUG|AZD0901|AZD0901 will be administered as an IV infusion.
219335292|NCT07069712|DRUG|Rilvegostomig|Rilvegostomig will be administered as an IV infusion.
219335293|NCT07069712|DRUG|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered as an IV infusion.
219335294|NCT07069712|DRUG|Capecitabine|Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.
219335295|NCT07069712|DRUG|5-Fluorouracil (5-FU)|5-FU (Fluoropyrimidine) will be administered as an IV infusion as chemotherapy standard of care.
219335296|NCT07069712|DRUG|FLOT Chemotherapy|FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.
219335297|NCT06773962|DRUG|TB006|IV infusion.
219335298|NCT06773962|DRUG|Placebo|IV infusion.
219335299|NCT04670965|BIOLOGICAL|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
219355438|NCT04666272|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
219335300|NCT04670965|BIOLOGICAL|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
219335301|NCT04670965|BIOLOGICAL|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
219335302|NCT04670965|BIOLOGICAL|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
219335303|NCT06663319|DRUG|JNJ-89402638|JNJ-89402638 will be administered.
219335304|NCT06863610|OTHER|Extension Deficit (>5 degrees)|Patients who had a knee extension ROM deficit of more than 5 degrees will included
219335305|NCT06863610|OTHER|Extension Deficit (<5 degrees)|Patients who had a knee extension ROM deficit of less than 5 degrees will included
219335306|NCT06120140|DRUG|Amivantamab IV|Amivantamab will be administered.
219335307|NCT06120140|DRUG|Amivantamab SC|Amivantamab will be administered as SC injection.
219335308|NCT06120140|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
219335309|NCT06120140|DRUG|Doxycycline|Doxycycline tablet will be administered orally.
219335310|NCT06120140|DRUG|Minocycline|Minocycline capsule will be administered orally.
219335311|NCT06120140|DRUG|Clindamycin|Clindamycin lotion will be used as topical application on the scalp.
219335312|NCT06120140|DRUG|Chlorhexidine|Chlorhexidine solution will be used as topical application on hands and feet.
219335313|NCT06120140|OTHER|Noncomedogenic skin moisturizer|Noncomedogenic skin moisturizer will be used as topical application.
219335314|NCT06120140|OTHER|Ruxolitinib|Ruxolitinib will be used to the affected skin area.
219335315|NCT06120140|OTHER|Tacrolimus|Tacrolimus will be used as topical application to the affected skin area.
219335316|NCT06120140|DRUG|Zinc gluconate|Zinc gluconate tablet will be administered.
219335317|NCT06120140|DRUG|Propranolol|Propranolol tablet will be administered.
219335318|NCT06120140|DRUG|Timolol|Timolol will be used to the affected skin area.
219335319|NCT06120140|DRUG|Clobetasol|Clobetasol shampoo will be used on the scalp.
219335320|NCT07072819|BEHAVIORAL|Crisis Ready Training|Crisis Ready Training combines Crisis Line Facilitation with Take Home Naloxone training. The intervention is delivered in a group format.
219335321|NCT04168827|BEHAVIORAL|Questionnaire|Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
219335322|NCT06821698|DRUG|KP-001|KP-001 100 mg dry syrup
219335323|NCT06821698|DRUG|Rosuvastatin calcium10mg|A oral dose of 10 mg tablet
219335324|NCT06821698|DRUG|Caffeine citrate|100 mg oral solution
219335325|NCT06821698|DRUG|Fluvoxamine|50 mg tablet
219335326|NCT06895187|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing PAF ablation.
219335327|NCT01740076|OTHER|soy nuts|
219335328|NCT07088640|PROCEDURE|Single-step warming protocol by thawing solution only|Potentially eligible patients' vitrified blastocysts will be thawed by a single-step thawing protocol. For the warming phase, vitrified blastocysts are exposed to the thawing solution of a commercial embryo thawing kit (Irvine Scientific Inc., USA) at 37°C for one minute. Immediately following this, embryos will be rinsed in a 35mm diameter dish of 2ml of pre-equilibrated thawing solution before being placed in culture media in the incubator for at least 2 hours before transfer.
219335329|NCT07088640|PROCEDURE|Standard warming protocol|"For the MS protocol, thawing kits were equilibrated overnight in a 37°C incubator. Warming procedures utilized the kits (Cryotech RtU, Japan). To remove the cryoprotectants, blastocysts were warmed, and cryoprotectants were diluted in a three-step process.~The warming process starts with the exposure of blastocysts to thaw solution (TS) with 1M trehalose for one minute at 37°C. Subsequently, the blastocyst will be transferred to a second well containing a dilution solution (DS) of 0.5M trehalose for a two-minute rinse at room temperature. This is followed by two additional three-minute and 30-second rinses in the wash solution (WS) at room temperature. The timeline for standard warming of blastocysts requires a total of 6.5 min. After thawing, embryo will be placed in the incubator at least 2 hours before transfer."
219335330|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
219335331|NCT06878404|DRUG|Icotrokinra|Icotrokinra will be administered.
219335332|NCT06878404|DRUG|Placebo|Placebo will be administered.
219335333|NCT06878404|DRUG|Active reference comparator|Active reference drug will be administered.
219335334|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
219335335|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
219335336|NCT07109817|DRUG|Desloratodine|Desloratadine 5mg PO daily for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.
219335337|NCT07109817|DRUG|Placebo|Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.
219335338|NCT07107659|DRUG|ONT01 is a small molecule CD11b modulator.|ONT01 will be administered orally twice daily (in the morning and in the evening at approximately 12 hours apart and approximately the same time each day) and should be taken as whole tablets (not crushed) under fasted conditions (2 hours before and 1 hour after each dose) with 8 oz/240 mL of water.
219335339|NCT06948799|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 1 following protocol requirements
219335340|NCT06948799|DRUG|Placebo|Subjects will receive the administration dose on Day 1 following protocol requirements
219335341|NCT06945887|PROCEDURE|embolization therapy|Identification of the main vessels afferent to the tumor to be treated. -Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters. - Injection of embolizing material (hydrogel microspheres) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
219335342|NCT07143513|DRUG|Sotorasib|Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.
219335343|NCT06948903|DIAGNOSTIC_TEST|Central Sensitization Inventory|The Central Sensitization Inventory is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization. The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.
219335344|NCT06948903|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment|The Montreal Cognitive Assessment was initially developed as a test for mild cognitive impairment, but has also been determined to match qualities of the mini mental state examination 80. It assesses seven areas of cognition for a total possible score of 30 points. A score of 21 or less is indicative of cognitive impairment in Turkish population.
219335345|NCT06948903|DIAGNOSTIC_TEST|Cognitive Symptom Severity Scale-Extended|The Cognitive Symptom Severity Scale extends the scale of the original cognitive symptom severity scale. Participants are asked to rate their cognitive symptoms related to concentration and memory on a single scale ranging from 1-5, rather than the original 1-3, where higher scores indicate greater severity.
219335346|NCT06948903|OTHER|Fibromyalgia Impact Questionnaire|The Fibromyalgia Impact Questionnaire is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression. The maximum scale score is 100, with higher scores associated with increasing disability.
219335347|NCT06948903|OTHER|Numeric rating scale|Numeric Rating Scale will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
219335348|NCT06948903|OTHER|Hospital Anxiety and Depression Scale|This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21: • 0-7 points: No symptoms or very mild symptoms • 8-10 points: Moderate symptoms • 11 points or higher
219335349|NCT07141199|DRUG|ABBV-8736|Intravenous (IV) Infusion
219335350|NCT07141199|DRUG|Placebo|IV Infusion
219335351|NCT07101510|BEHAVIORAL|sV-CPR|In the sV-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone. To simulate challenging conditions, they must carry out the task in near-total darkness, with the phone's flashlight as the only light source.
219335352|NCT07101510|BEHAVIORAL|V-CPR|In the V-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone.
219335353|NCT07101510|BEHAVIORAL|T-CPR|In the T-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only).
219335354|NCT07101510|BEHAVIORAL|sT-CPR|In the sT-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only). To simulate challenging conditions, they must carry out the task in higher environmental noises (traffic), generated by a loudspeaker.
219335355|NCT07154433|DRUG|Opioid Analgesic Regimen|Participants will take 5 mg/325 mg of oxycodone - acetaminophen every 6 hours as needed for pain, with a maximum of 4 doses per day. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
219335356|NCT07154433|DRUG|Non-opioid analgesic regimen|Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
219335357|NCT07154979|DRUG|Oliceridine Injection|"Adult participants receive a single IV bolus of oliceridine (initial dose 45 µg/kg for ages 18-65 y or 40 µg/kg for ≥65 y). Two minutes later, propofol 2 mg/kg IV is administered. Upon loss of consciousness (MOAA/S ≤ 1), rocuronium 0.6 mg/kg IV is given. Direct laryngoscopic tracheal intubation is performed after full muscle relaxation. Blood pressure and heart rate are recorded at baseline, 2 min post-oliceridine, immediately pre-intubation, and for 3 min post-intubation. A positive hemodynamic response is defined as ≥ 20% increase in MAP or HR, HR ≥ 120 bpm, or SBP ≥ 180 mmHg. Subsequent oliceridine doses are adjusted ± 3 µg/kg based on the prior patient's response until seven response crossovers are observed, allowing estimation of ED₅₀ and ED₉₅."
219355439|NCT04666272|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
219355440|NCT01865331|DRUG|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
219355441|NCT01865331|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
219355442|NCT01865331|DRUG|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
219355443|NCT06390332|BEHAVIORAL|Giving Information for Trauma Support and Safety (GIFTSS) Training|Training for college health center staff and clinicians on GIFTSS intervention which is a universal education and brief counseling to address sexual violence prevention and intervention.
219335358|NCT07153029|BEHAVIORAL|Smartphone based cognitive tasks|"15 days Smartphone/Cellphone tasks: Using NeuroUX smartphone testing software, Cognitive games/tasks lasting approximately 3-4 minutes each will be administered through the a smartphone application and will be prompted via text message twice per day across 15 consecutive days in the morning (8-11am) and evening (5-8). Tasks were chosen to measure aspects of diverse aspects of cognitive that are impaired among patients taking methadone, including N-back task (working memory), the Stroop Task (executive function/cognitive control), and the Variable Difficulty List Memory Test (learning and memory). The 15 days will include two types of task administration: a) Testing Phase: tasks administered at a consistent, fixed difficulty level (days 1-5) b) Remediation Phase: increasing task difficulty in response to participant performance (days 6-15). To encourage adherence, researchers will contact participants to remind them of task completion."
219335359|NCT07151105|DIETARY_SUPPLEMENT|Vitamin C|Participants will receive a vitamin C supplement while following a low vitamin C diet to achieve adequate vitamin C status in a blinded manner. This will be compared to participants receiving a placebo while following a low vitamin C diet that is expected to maintain inadequate vitamin C status.
219335360|NCT07151105|DIETARY_SUPPLEMENT|Placebo + Low Vitamin C Diet|Participants will receive a placebo while following a low vitamin C diet to achieve inadequate vitamin C status in a blinded manner. This will be compared to participants receiving a vitamin C supplement while following a low vitamin C diet that is expected to maintain adequate vitamin C status.
219335361|NCT07155967|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
219335362|NCT07162675|DEVICE|Huawei Fit 2 Smartwatch|Participants will receive a Huawei Fit 2 smartwatch within the first week of initiating neoadjuvant systemic therapy. The device will be worn throughout the treatment period to continuously monitor step counts, physical activity intensity, sleep duration, and heart rate. It is used solely for non-invasive monitoring and does not alter the standard oncological treatment.
219335363|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with extracoronal adhesive attachments|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the extracoronal adhesive attachment and the RPD.~* Evaluation of the attachment's condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
219335364|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with conventional clasps|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the clasps and the RPD.~* Evaluation of the clasps' condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
219335365|NCT07171580|OTHER|Remote Home Monitoring - Education|A virtual platform will be used to provide education to ACS patients post discharge.
219335366|NCT07171580|OTHER|Remote Home Monitoring - Education and Support|A virtual platform will be used to provide education and support to ACS patients post discharge.
219335367|NCT07171736|BEHAVIORAL|Virtual Reality chairwork exercise|A chairwork exercise from schema therapy, executed in Virtual Reality
219335368|NCT07171736|BEHAVIORAL|Imagination exercise|A regular schema therapy imagination exercise
219335369|NCT07170163|BEHAVIORAL|¡Iniciando! mHealth App|Participants will undergo 12 weekly, 1-hour virtual group sessions (separate for young adults and parents) and weekly, 30-minute individual virtual coaching sessions for young adults (which parents may attend as appropriate). Participants will also engage with the ¡Iniciando! app modules before and after their virtual group meetings. Throughout the approximately three-month study period, participants will complete (e.g., usability, satisfaction, adherence, app usage data).
219335370|NCT07171437|DEVICE|Doppler ultra sound|\- Doppler Ultrasound (DUS) To evaluate the abdominal aorta and the 3 main splanchnic vessels: Celiac Trunk (CT) Superior Mesenteric Artery (SMA) Inferior Mesenteric Artery (IMA) An ultrasound examination will be performed after a fasting period of at least 8 hours by a single operator blinded to clinical features. For abdominal vessels, the following parameters were measured: caliber, thickness, echogenicity, peak systolic velocity (PSV), end diastolic velocity (EDV), reverse velocity (RV), mean velocity (MV), resistive index (RI), and pulsatility index (PI).
219335371|NCT07170423|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive automated text messages instructing them to obtain hearing aids. The messages will also include basic information on the prevalence and negative effects of hearing loss.
219335372|NCT07171658|BEHAVIORAL|Sensitization to Cervical Cancer (CC) screening|Women will receive an awareness letter explaining the importance of cervical cancer screening, the Swiss recommendations and an invitation to schedule an appointment.
219335373|NCT07171658|BEHAVIORAL|Home-based HPV self-sampling|Women will receive a free-of-charge vaginal self-sampling kit for HPV infection.
219335374|NCT07171450|OTHER|Computerized Cognitive Remediation|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Importantly, NeuroFlex personalizes gameplay with adaptive algorithms that adjust difficulty on a trial-by-trial basis. Participants are prescribed a 30-hour dose distributed across 6 weeks. The treatment is completed remotely by the participant within their own home or other private location that is most convenient for the participant."
219335375|NCT07171450|OTHER|Alternative Computer Activities|The active control condition is carefully matched to the experimental condition in duration, computer tablet use, audiovisual stimulation, reward presentation, and interaction with study staff. It involves playing visuospatially-oriented computerized games that do not load on executive functions and watching stimulating educational videos.
219335376|NCT07165483|DRUG|Dexmedetomidine|Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
219335377|NCT07165483|DRUG|Dexmedetomidine|Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
219335378|NCT07165483|DRUG|Saline|Patients will receive saline before induction of anesthesia as a control group.
219335379|NCT07169578|DRUG|Trontinemab|Participants will receive IV trontinemab.
219335380|NCT07169578|OTHER|Placebo|Participants will receive IV placebo.
219335381|NCT07170852|DRUG|Bempedoic acid film coated tablet|1 tablet of 180 mg Bempedoic Acid
219335382|NCT07170852|DRUG|Nilemdo® Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
219335383|NCT05659576|DRUG|Sucralfate|"1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
219335384|NCT05659576|OTHER|Usual Care|Standard supportive care by using opioids.
219335385|NCT05659576|OTHER|One consent|Patient will sign one consent form.
219335386|NCT05659576|OTHER|Two consent|Patient will sign two consent forms.
219335387|NCT03218488|DRUG|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
219335388|NCT06104150|OTHER|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
219335389|NCT05611346|BEHAVIORAL|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
219335390|NCT05712278|DRUG|SAR445419|Cell suspension, by intraveneous (IV) injection
219335391|NCT05712278|DRUG|fludarabine|Solution for injection , by IV injection
219335392|NCT05712278|DRUG|cytarabine|Solution for injection, by IV injection
219335393|NCT05798221|BEHAVIORAL|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
219335394|NCT05798221|OTHER|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
219335395|NCT02554747|DEVICE|Navigated laser|Aflibercept, Navilas®
219335396|NCT02554747|DEVICE|Conventional laser|Aflibercept, Pascal
219335397|NCT00766038|DRUG|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
219335398|NCT00766038|DRUG|Placebo|SC injection daily
219335399|NCT02681536|DRUG|Triptorelin|
219335400|NCT02681536|DRUG|Combined oral contraceptive pills|
219335401|NCT02681536|DRUG|HMG|
219335402|NCT03284671|OTHER|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
219335403|NCT06080828|DEVICE|Percutaneous Posterior Tibial Nerve Stimulation|20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
219335404|NCT06080828|DEVICE|Placebo Percutaneous Posterior Tibial Nerve Stimulation|placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
219335405|NCT06080828|BEHAVIORAL|Home instructions|they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
219335406|NCT00767052|DRUG|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
219335407|NCT00767052|DRUG|Placebo|Placebo tablet matching to the active in multiple dose part.
219335408|NCT00767052|DRUG|AZD1236|75mg single dose will be administered in relative bioavailability part.
219335409|NCT00767052|DRUG|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
219335410|NCT01973712|PROCEDURE|Locked Compression Plating|
219335411|NCT01973712|PROCEDURE|Retrograde Intramedullary Nailing (RIMN)|
219335412|NCT04163796|DEVICE|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
219335413|NCT01258244|OTHER|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
219335414|NCT02950090|BEHAVIORAL|MobilWise|see arm description for MobilWise above
219335415|NCT02950090|BEHAVIORAL|Fitbit Only|see arm description for Fitbit above
219335416|NCT00748280|PROCEDURE|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
219335417|NCT00748280|PROCEDURE|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
219335418|NCT04272840|BEHAVIORAL|Low Glycemic Index Education|Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
219335419|NCT04876170|OTHER|Brain-computer-interface: EEG-based musical Neurofeedback task|Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.
219335420|NCT00847145|BIOLOGICAL|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
219335421|NCT00847145|BIOLOGICAL|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
219335422|NCT00847145|BIOLOGICAL|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
219335423|NCT00847145|BIOLOGICAL|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
219335424|NCT00847145|BIOLOGICAL|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
219335425|NCT00847145|BIOLOGICAL|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
219335426|NCT00847145|BIOLOGICAL|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
219335427|NCT00847145|BIOLOGICAL|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
219335428|NCT01012791|OTHER|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
219335429|NCT02833974|DRUG|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
219335430|NCT02833974|DRUG|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
219335431|NCT06236477|BEHAVIORAL|Personalized Music|Music that is familiar to the child will be played via bluetooth speaker throughout their immediate perioperative care
219335432|NCT06236477|BEHAVIORAL|No Music|Participants will receive standard care without music.
219335433|NCT04225130|BEHAVIORAL|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
219335434|NCT04225130|BEHAVIORAL|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
219335435|NCT00350948|DRUG|Telcyta|Day 1 of 28 day Cycle.
219335436|NCT00350948|DRUG|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
219335437|NCT03592706|BIOLOGICAL|IKC (Immune Killer Cells)|
219335438|NCT03592706|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization)|
219335439|NCT03775954|DIAGNOSTIC_TEST|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
219335440|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
219335441|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
219335442|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
219335443|NCT01199029|DRUG|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
219335444|NCT01199029|DRUG|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
219335445|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
219335446|NCT01199029|DRUG|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
219335447|NCT02761304|PROCEDURE|Ultrasound|
219335448|NCT01973777|DEVICE|IUB|intrauterine contraceptive device
219335449|NCT01188889|DRUG|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
219335450|NCT01188889|DRUG|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
219335451|NCT00307151|DRUG|Lamivudine|4 mg/kg twice daily
219335452|NCT00307151|DRUG|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
219335453|NCT00307151|DRUG|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
219335454|NCT00307151|DRUG|Zidovudine|180 mg/m\^2 twice daily
219335455|NCT06439212|DRUG|Ginger powder capsule|Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
219335456|NCT06439212|DRUG|Placebo|Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
219335457|NCT00209014|DRUG|Thalidomide|
219335458|NCT04818203|BIOLOGICAL|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10\^7 cells/1 mL/vial
219335459|NCT04818203|OTHER|Placebo|The injection solution without clusters of autologous dermal fibroblasts
219335460|NCT04737408|DRUG|Rosuvastatin 40mg|Rosuvastatin 40 mg
219335461|NCT00356083|DRUG|Methadone|
219335462|NCT03874663|DEVICE|Directly assisted oral HIV self-testing (HIVST)|"1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
219335463|NCT05745662|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
219335464|NCT06838676|DRUG|ACT001|PO BID at 875 mg/m2 for 28 days
219335465|NCT06788587|DRUG|LDX-01 plus TAU|"Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
219335466|NCT06788587|DRUG|Placebo plus TAU|"Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
219335467|NCT04885868|OTHER|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.
219335468|NCT00504907|DRUG|BTA9881|Single oral escalating doses
219335469|NCT00504907|DRUG|Placebo|
219335470|NCT05508009|DRUG|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
219335471|NCT05508009|DRUG|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
219335472|NCT05508009|DRUG|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
219335473|NCT05508009|RADIATION|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
219335474|NCT05508009|DRUG|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
219335475|NCT05508009|DRUG|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
219335476|NCT05508009|DRUG|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
219335477|NCT05508009|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
219335478|NCT05508009|PROCEDURE|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with \> 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI \>18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
219335479|NCT06201897|DRUG|ACTH/Oral Steroids|Injection ACTH or Oral Steroids in children with West Syndrome
219335480|NCT00478465|DRUG|valganciclovir|
219335481|NCT06401122|PROCEDURE|haemodialysis|process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
219335482|NCT02466867|DRUG|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
219335483|NCT02466867|DRUG|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
219335484|NCT00692484|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
219335485|NCT00692484|DRUG|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
219335486|NCT02520895|BIOLOGICAL|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
219335487|NCT04363528|OTHER|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
219335488|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
219335489|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
219335490|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
219335491|NCT00382239|DRUG|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
219335492|NCT05542550|BEHAVIORAL|Voice Rest|Voice rest restricting patient phonation
219335493|NCT05542550|BEHAVIORAL|No Voice Rest|No Voice rest
219335494|NCT03435848|DRUG|BST-236|1 to 4 courses
219335495|NCT03869359|OTHER|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
219335496|NCT03869359|OTHER|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
219335497|NCT01357096|BEHAVIORAL|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
219335498|NCT01357096|OTHER|Traditional group|CAD education fryers
219335499|NCT03600142|BEHAVIORAL|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
219335500|NCT03662880|RADIATION|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
219335501|NCT03662880|RADIATION|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
219335502|NCT00516048|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
219335503|NCT06470113|DEVICE|simultaneous cognitive training with transcranial magnetic stimulation|simultaneous cognitive training with transcranial magnetic stimulation can enhance the therapeutic effect and improve brain function non-invasively.
219335504|NCT02080247|DRUG|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
219335505|NCT02080247|DRUG|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
219335506|NCT00639691|BIOLOGICAL|omalizumab|sc
219335507|NCT05414981|DRUG|ABI-H3733|25 mg or 100 mg tablets for oral administration
219335508|NCT05414981|DRUG|Placebo|25 mg or 100 mg tablets for oral administration
219335509|NCT04415957|OTHER|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
219335510|NCT02430142|OTHER|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
219335511|NCT00883662|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
219335512|NCT01841502|DRUG|Paroxetine|paroxetine 20 mg once daily
219335513|NCT01841502|DRUG|telaprevir|telaprevir 1125 mg twice daily
219335514|NCT01262378|PROCEDURE|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
219335515|NCT04155255|OTHER|MyBFF@school|
219335516|NCT05755841|OTHER|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~* Twice weekly fetal cardiotocography.~* Complete blood count once a week.~* A weekly clinical and ultrasound examination."
219335517|NCT05755841|OTHER|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
219335518|NCT03722342|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
219335519|NCT01511276|BEHAVIORAL|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
219335520|NCT01511276|BEHAVIORAL|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
219335521|NCT01451008|DEVICE|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
219335522|NCT05837156|DRUG|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
219335523|NCT05837156|DRUG|Heptaflurane|Heptaflurane only
219335524|NCT05837156|DRUG|Cyclophenol|Cyclophenol only
219335525|NCT04026698|BEHAVIORAL|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months."
219335526|NCT02808754|PROCEDURE|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic \> 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
219335527|NCT00337909|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
219335528|NCT00337909|OTHER|Educational DVDs|
219335529|NCT06323603|OTHER|Micro and nanoplastic|Biological samples will be obtained to evaluate the different biomarkers selected
219335530|NCT00096785|DRUG|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
219335531|NCT00096785|DRUG|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
219335532|NCT03023527|DRUG|Nivolumab|
219335533|NCT03023527|DRUG|Pomalidomide|
219335534|NCT03023527|DRUG|Dexamethasone|
219335535|NCT03023527|DRUG|Elotuzumab|
219335536|NCT02877693|RADIATION|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
219335537|NCT02751203|BEHAVIORAL|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
219335538|NCT06243874|PROCEDURE|greater occipital nerve block|greater occipital nerve block
219335539|NCT06243874|PROCEDURE|transnasal sphenopalatine ganglion block|transnasal sphenopalatine ganglion block
219335540|NCT02829307|DRUG|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
219335541|NCT04411485|OTHER|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
219335542|NCT06496282|DRUG|Lemborexant|The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
219335543|NCT06496282|DRUG|Placebo|The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
219335544|NCT00637884|DRUG|Fexofenadine HCl|
219335545|NCT04082871|OTHER|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
219335546|NCT01539681|DRUG|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
219335547|NCT02154282|BEHAVIORAL|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
219335548|NCT06361732|OTHER|No intervention|No intervention
219335549|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
219335550|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
219335551|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
219335552|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
219335553|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
219335554|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
219335555|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
219335556|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
219335557|NCT02593162|DRUG|Faldaprevir|
219335558|NCT02593162|DRUG|TD-6450|
219335559|NCT02593162|DRUG|Ribavirin|
219335560|NCT03854864|OTHER|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
219335561|NCT05908682|OTHER|Non-interventional study|This is not an interventional study
219335562|NCT03027362|OTHER|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
219335563|NCT03027362|OTHER|Psychoeducation and medication|
219335564|NCT04911036|OTHER|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
219335565|NCT02081534|DRUG|AZD1722|AZD1722, oral tablet
219335566|NCT02081534|DRUG|Placebo|Placebo bid, double dummy technique
219335567|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
219335568|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
219335569|NCT00670319|DRUG|Placebo|Placebo one tab orally per day
219335570|NCT03611855|DEVICE|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
219335571|NCT03611855|OTHER|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
219335572|NCT00518037|BEHAVIORAL|surveys|anxiety surveys
219335573|NCT05040724|DRUG|Ivermectin|ivermectin placebo
219335574|NCT01652183|DRUG|intravenous paracetamol|
219335575|NCT01652183|DRUG|Placebo|
219335576|NCT06004414|BEHAVIORAL|App-based Cognitive Behavioral Therapy (CBT)|SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
219335577|NCT06004414|BEHAVIORAL|Psychotherapy|Psychotherapy with a licensed clinician at one of the study sites.
219335578|NCT04638972|DEVICE|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
219355444|NCT06390332|BEHAVIORAL|Centering gender Affirming Resources in higher Education (CARE) Learning Modules|Training for college health center clinicians and staff on trans and gender diverse (TGD) affirming clinical practices in addition to sexual violence and alcohol abuse prevention that is inclusive of TGD service users
219355445|NCT02065752|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
219355446|NCT02065752|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
219355447|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
219335579|NCT05760443|BEHAVIORAL|Learning to BREATHE|"Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
219335580|NCT04042779|OTHER|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
219335581|NCT04042779|OTHER|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
219335582|NCT04042779|OTHER|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
219335583|NCT04042779|OTHER|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
219335584|NCT00003535|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
219335585|NCT01607736|BEHAVIORAL|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
219335586|NCT05604495|DIAGNOSTIC_TEST|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
219335587|NCT06075589|BEHAVIORAL|Education for Intervention|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
219335588|NCT06075589|BEHAVIORAL|Best Practice|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
219335589|NCT05675943|BIOLOGICAL|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
219335590|NCT01868256|OTHER|early discharge (<72 h)|
219335591|NCT01868256|OTHER|Conventional discharge|
219335592|NCT01715753|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
219335593|NCT01715753|BEHAVIORAL|Diet counseling and group education lessons|Individual and group diet counseling to achieve a \>10% weight loss
219335594|NCT04266262|BEHAVIORAL|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
219335595|NCT04266262|BEHAVIORAL|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
219335596|NCT02181816|DRUG|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD \& HD
219335597|NCT05650814|DEVICE|ButterfLife|On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.
219335598|NCT05650814|OTHER|Control|Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
219335599|NCT04345289|BIOLOGICAL|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
219335600|NCT04345289|OTHER|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
219335601|NCT00867789|DRUG|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
219335602|NCT00867789|DRUG|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
219335603|NCT05843851|DIAGNOSTIC_TEST|Diagnostic test|Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
219335604|NCT02705521|DEVICE|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
219335605|NCT03807349|DEVICE|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
219335606|NCT01399554|BEHAVIORAL|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
219335607|NCT00474396|BEHAVIORAL|Low fat dairy diet|
219335608|NCT01505348|OTHER|Overnight fast|Overnight fast from 21:00 h
219335609|NCT05666336|BIOLOGICAL|Telitacicept|It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
219335610|NCT05666336|DRUG|Hydroxychloroquine|It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
219335611|NCT05666336|DRUG|Prednisone|It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
219335612|NCT05666336|DRUG|Methylprednisolone|It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
219335613|NCT05666336|DRUG|Cyclophosphamide|It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
219335614|NCT05666336|DRUG|Mycophenolate Mofetil|It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
219335615|NCT05666336|DRUG|Tacrolimus|It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
219335616|NCT06399887|OTHER|Exercise|All patients in these groups are taught diaphragmatic breathing, which is the basis for DNS, and are asked to maintain it throughout the exercises. The DNS protocol includes a 5-minute warm-up, 40 minutes of DNS exercises (10 minutes for each of the 4 different body parts) and breathing exercises. The DNS exercises included diaphragmatic breathing, Baby Rock, Roll Over, Lying on the Side, Sitting Down, Sitting Upright, Tripod, Kneeling, Squatting, Prone, and Pull Up (CGU). The focus of the first week is to teach and practice basic DNS exercises.
219335617|NCT06399887|OTHER|Biofeedback|Patients in Group II and Group III will be trained in animated CP using the Aymed Medical Locum Wireless System v.2.69.0.12 device. During CP, 10-second contraction and 30-second relaxation cycles are maintained throughout the animated game. Each session will last approximately 20 minutes. The training protocol will consist of a total of 12 sessions of 20 minutes per week for 3 months.
219335618|NCT06475066|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|"After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline."
219335619|NCT05138042|OTHER|Cryotherapy (frozen glove)|"In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes."
219335620|NCT01366547|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
219335621|NCT01366547|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
219335622|NCT01366547|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
219335623|NCT06210074|DEVICE|Daye Diagnostic Tampon|"The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746).~The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. The DDT needs to be worn for 20 minutes then when removed should be placed immediately in the sterile container."
219335624|NCT02538874|DRUG|BMS-986171|
219335625|NCT02538874|OTHER|Placebo|
219335626|NCT02861209|OTHER|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
219335627|NCT03549156|DIETARY_SUPPLEMENT|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
219335628|NCT03549156|DIETARY_SUPPLEMENT|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
219335629|NCT00603460|BIOLOGICAL|DCVax-L and T Cells|"Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit"
219335630|NCT01914380|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
219335631|NCT01360554|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
219335632|NCT01360554|DRUG|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
219335633|NCT01360554|DRUG|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
219335634|NCT01360554|DRUG|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
219335635|NCT02210065|BIOLOGICAL|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
219335636|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
219335637|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
219335638|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
219335639|NCT05258409|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
219335640|NCT05258409|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
219335641|NCT06464107|DEVICE|PadKit™ from Preprogen|"The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval.~The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis."
219335642|NCT05954923|OTHER|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
219335643|NCT00187096|DRUG|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
219335644|NCT00187096|PROCEDURE|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
219335645|NCT00187096|DEVICE|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
219335646|NCT03958227|OTHER|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
219335647|NCT03958227|OTHER|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
219335648|NCT02170883|OTHER|Interactive SMS|
219335649|NCT02170883|OTHER|Usual care|
219335650|NCT01397370|DRUG|GLPG0492|Oral solution
219335651|NCT01397370|DRUG|Placebo|Oral solution
219335652|NCT02422420|BEHAVIORAL|Financial Incentives|Use of financial incentives to promote health behaviors.
219335653|NCT05726799|PROCEDURE|Cryo myectomy|Extended septal myecotmy using cryo energy
219335654|NCT05726799|PROCEDURE|Myectomy|Classic surgical myectomy
219335655|NCT01534247|DRUG|CAZ-AVI|Infusion
219335656|NCT01534247|DRUG|metronidazole|Infusion
219335657|NCT01534247|DRUG|CAZ-AVI + metronidazole|Infusion
219335658|NCT00226109|DRUG|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
219335659|NCT04663789|PROCEDURE|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
219335660|NCT04663789|PROCEDURE|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
219335661|NCT05995288|DRUG|Homeopathic Globule|Homeopathic globules were administered after careful anamnesis
219335662|NCT06493344|OTHER|Applying additional weight|Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
219335663|NCT05645614|OTHER|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
219335664|NCT03651453|BEHAVIORAL|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
219335665|NCT03651453|BEHAVIORAL|Standard care|Standard harm reduction information
219335666|NCT01989403|OTHER|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
219335667|NCT02113436|DRUG|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
219335668|NCT02113436|DRUG|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
219335669|NCT02159729|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
219335670|NCT02159729|DRUG|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
219335671|NCT02159729|DRUG|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
219335672|NCT02159729|DRUG|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
219335673|NCT05454371|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
219335674|NCT02106052|OTHER|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
219335675|NCT02106052|OTHER|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
219335676|NCT04122014|OTHER|Progressive balance training|Progressive balance training program
219335677|NCT04122014|OTHER|Normal daily activities|Usual daily activities
219335678|NCT03799250|DRUG|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
219335679|NCT03799250|OTHER|standard care|standard care
219335680|NCT00777010|OTHER|Ketogenic diet|carbohydrate restricted diet
219335681|NCT00777010|OTHER|Healthy high carbohydrate diet|higher carbohydrate diet
219335682|NCT04044131|DRUG|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
219335683|NCT04044131|DRUG|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
219335684|NCT03121911|OTHER|Interval Training (IT)|"Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
219335685|NCT03121911|OTHER|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
219335686|NCT00272909|DRUG|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
219335687|NCT00272909|DRUG|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
219335688|NCT00272909|DRUG|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
219335689|NCT06545968|BEHAVIORAL|A social media based intervention|WatsApp-based modules to influence retention in care behaviour
219335690|NCT04821544|BEHAVIORAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
219335691|NCT04821544|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at 2,000 IU/day for 8 weeks.
219335692|NCT00390754|BEHAVIORAL|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
219335693|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
219335694|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
219335695|NCT05845645|DRUG|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
219335696|NCT05845645|OTHER|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
219335697|NCT05845645|OTHER|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
219335698|NCT06069934|DRUG|Pridopidine|Pridopidine 45 mg hard gelatin capsules once daily p.o. (or via feeding tube)
219335699|NCT05590143|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
219335700|NCT05590143|DRUG|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
219335701|NCT05362968|DRUG|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
219335702|NCT01816061|BEHAVIORAL|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
219335703|NCT01816061|BEHAVIORAL|Control - COMPASS|Increased hours of patient-provider interactions Group.
219335704|NCT01961349|DRUG|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
219335705|NCT01961349|DRUG|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
219335706|NCT01961349|DRUG|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
219335707|NCT04524702|DRUG|Gemcitabine|Given IV
219335708|NCT04524702|DRUG|Hydroxychloroquine|Given PO
219335709|NCT04524702|DRUG|Nab-paclitaxel|Given IV
219335710|NCT04524702|DRUG|Paricalcitol|Given IV
219335711|NCT03677050|OTHER|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
219335712|NCT04673591|DRUG|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
219335713|NCT04673591|OTHER|Placebo|Matched Placebo
219335714|NCT03668886|OTHER|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
219335715|NCT03151642|RADIATION|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
219335716|NCT03151642|RADIATION|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
219335717|NCT03151642|PROCEDURE|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
219335718|NCT03151642|DEVICE|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
219335719|NCT03151642|OTHER|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
219335720|NCT03007368|OTHER|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335721|NCT03007368|OTHER|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
219335722|NCT03007368|OTHER|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335723|NCT03007368|OTHER|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335724|NCT03007368|OTHER|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335725|NCT03007368|OTHER|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335726|NCT03007368|OTHER|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335727|NCT03007368|OTHER|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
219335728|NCT03991000|DRUG|Ferric carboxymaltose|Intravenous iron
219335729|NCT03991000|DRUG|Saline|Saline application according to dosing rules of iron.
219335730|NCT00612170|DRUG|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
219335731|NCT00612170|DRUG|Placebo|0 mg oral tablet once a day dosing
219335732|NCT00612170|DRUG|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
219335733|NCT00612170|DRUG|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
219335734|NCT01299376|DRUG|L50/H12.5/A5|
219335735|NCT01299376|DRUG|L50/H12.5|
219335736|NCT01299376|DRUG|Placebo to L50/H12.5/A5|
219335737|NCT01299376|DRUG|Placebo to L50/H12.5|
219335738|NCT04142775|OTHER|complication versus no complication|development of ICH
219335739|NCT03429881|PROCEDURE|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
219335740|NCT04315181|DRUG|Opioid Agonist|Abuse liability evaluation.
219335741|NCT04315181|DRUG|Sedatives|Abuse liability evaluation.
219335742|NCT00585611|DRUG|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
219335743|NCT00585611|OTHER|placebo|placebo
219335744|NCT05879107|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
219335745|NCT05879107|BIOLOGICAL|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
219335746|NCT05800340|BIOLOGICAL|Toripalimab|240mg Q3W
219335747|NCT05800340|DRUG|Nab paclitaxel|135 mg/m2, d1, 8 Q3W
219335748|NCT05800340|DRUG|Pemetrexed|500mg/m2, d1 Q3W
219335749|NCT05800340|DRUG|Carboplatin|AUC 5, d1 Q3W
219335750|NCT02398708|OTHER|Questionnaires|Both groups will have questionnaires collected and compared.
219335751|NCT02398708|OTHER|Blood Sample|Both groups will have a blood sample collected and compared.
219335752|NCT02398708|OTHER|Stool Sample|Both groups will have a stool sample collected and compared.
219335753|NCT02398708|OTHER|Clinical data|Both groups will have clinical data collected and compared.
219335754|NCT03213964|BIOLOGICAL|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)"
219335755|NCT03213964|DRUG|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
219335756|NCT00376337|DRUG|Micafungin|IV
219335757|NCT00376337|DRUG|Systemic antifungal therapy|IV
219335758|NCT05106673|BEHAVIORAL|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
219335759|NCT05106673|BEHAVIORAL|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
219335760|NCT05106673|BEHAVIORAL|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
219335761|NCT05106673|OTHER|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
219335762|NCT01217398|BIOLOGICAL|bevacizumab|
219335763|NCT01217398|DRUG|temozolomide|
219335764|NCT01217398|GENETIC|polymorphism analysis|
219335765|NCT01217398|OTHER|pharmacogenomic studies|
219335766|NCT00708149|DRUG|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
219335767|NCT00708149|DRUG|placebo|takepron placebo
219335768|NCT05956730|OTHER|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
219335769|NCT05956730|OTHER|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
219335770|NCT00408395|BIOLOGICAL|Influenza vaccine|Seasonal Influenza Vaccine
219355448|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
219355449|NCT04770779|DRUG|Placebo Matching Mitapivat|Tablets
219335771|NCT03975621|BEHAVIORAL|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
219335772|NCT05532449|DRUG|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
219335773|NCT05259813|GENETIC|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
219335774|NCT00843518|DRUG|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
219335775|NCT00843518|DRUG|Placebo|Placebo orally twice daily for 12 weeks
219335776|NCT01943513|BIOLOGICAL|BIIB023|Intravenous (IV) infusions
219335777|NCT01943513|BIOLOGICAL|Placebo|Matched placebo
219335778|NCT00602095|DRUG|misoprostol|0.025mg tablet vaginally every 4 hour until progress
219335779|NCT00602095|DRUG|dinoprostone|2mg vaginal gel every 6 hours until progress
219335780|NCT00602095|DEVICE|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
219335781|NCT00754351|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
219335782|NCT00754351|DRUG|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
219335783|NCT00754351|DRUG|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
219335784|NCT00247741|DRUG|spinal administration of articaine|
219335785|NCT00247741|DRUG|spinal administration of lidocaine|
219335786|NCT05146245|OTHER|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
219335787|NCT05146245|OTHER|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
219335788|NCT02674542|OTHER|In-depth interviews|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
219335789|NCT02674542|OTHER|Focus Group|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
219335790|NCT01811745|BEHAVIORAL|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
219335791|NCT01811745|BEHAVIORAL|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
219335792|NCT03120221|DIAGNOSTIC_TEST|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
219335793|NCT04417179|PROCEDURE|transversus abdominis block|transversus abdominis block
219335794|NCT04417179|PROCEDURE|Erector spinae block|Erector spinae block
219335795|NCT04417179|DRUG|Bupivacaine 0.25% Injectable Solution|Local Anesthetic used in both blocks
219335796|NCT04417179|DEVICE|Siemens Acuson x300 3-5MHz Ultrasound|Ultrasound used to aid in the blocks
219335797|NCT00962442|DRUG|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
219335798|NCT00962442|DRUG|placebo|Glucosé 5% perfusion for 14 days, intravenously
219335799|NCT04071743|DEVICE|gammaCore Sapphire|non-invasive vagus nerve stimulator
219335800|NCT04071743|DEVICE|sham gammaCore Sapphire|sham gammaCore Sapphire
219335801|NCT00827606|DRUG|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
219335802|NCT00445484|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
219335803|NCT00445484|DRUG|lenalidomide|Given orally
219335804|NCT01748942|DRUG|Dexamethasone|Given IV
219335805|NCT01748942|DRUG|Dexamethasone|Given PO
219335806|NCT01748942|OTHER|Placebo|Given PO
219335807|NCT01748942|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
219335808|NCT01748942|OTHER|Questionnaire Administration|Ancillary studies
219335809|NCT01748942|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
219335810|NCT01772901|OTHER|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
219335811|NCT03636620|DEVICE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
219335812|NCT03636620|DEVICE|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
219335813|NCT00571844|BEHAVIORAL|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
219355450|NCT04770779|DRUG|Mitapivat|Tablets
219355451|NCT06403761|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219355452|NCT06403761|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219355453|NCT06403761|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
219335814|NCT00571844|BEHAVIORAL|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
219335815|NCT00110292|BEHAVIORAL|Age-specific parenting newsletters and developmental toys|
219335816|NCT00110292|BEHAVIORAL|Parent-completed Ages & Stages Questionnaires|
219335817|NCT00110292|BEHAVIORAL|Clinic-based distribution of children's books|
219335818|NCT00817882|OTHER|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
219335819|NCT00817882|OTHER|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
219335820|NCT02933099|DRUG|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
219335821|NCT02933099|DRUG|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
219335822|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline and at follow up|Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
219335823|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline|Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
219335824|NCT02553122|DRUG|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
219335825|NCT02553122|DEVICE|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
219335826|NCT03437564|DRUG|Vortioxetine|Vortioxetine tablet
219335827|NCT02098720|DRUG|Conbercept|
219335828|NCT00998270|PROCEDURE|Autologous bone marrow transplantation|"Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
219335829|NCT00998270|PROCEDURE|Allogeneic bone marrow transplantation|"Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
219335830|NCT03574857|DRUG|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
219335831|NCT03574857|DRUG|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
219335832|NCT06428084|DRUG|Ondansetron|4 mg of ondansetron intravenously
219335833|NCT06428084|DRUG|Haloperidol|1 mg of Haloperidol intravenously
219335834|NCT05231499|OTHER|nasal irrigation|regular saline nasal rinse
219335835|NCT02748330|DRUG|Ticagrelor|Ticagrelor
219335836|NCT02748330|DRUG|Clopidogrel|Clopidogrel
219335837|NCT02748330|DRUG|Aspirin|Acetylsalicylic acid
219335838|NCT04689581|OTHER|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
219335839|NCT04689581|OTHER|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
219335840|NCT05895682|DEVICE|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70\~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
219335841|NCT04037748|DRUG|Puran T4®|Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
219335842|NCT04037748|DRUG|Eutirox®|Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
219335843|NCT05454436|PROCEDURE|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
219335844|NCT00927654|DRUG|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
219335845|NCT00927654|DRUG|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
219335846|NCT02937025|DEVICE|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
219335847|NCT06159387|DRUG|Cannabis Extract Oil SR Capsule|"After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model"
219335848|NCT00163202|PROCEDURE|Blood samples|
219335849|NCT00163202|DRUG|Atorvastatin|
219335850|NCT02069470|BEHAVIORAL|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
219335851|NCT00573989|DRUG|erlotinib hydrochloride|
219335852|NCT00573989|DRUG|pemetrexed disodium|
219335853|NCT00573989|PROCEDURE|quality-of-life assessment|
219335854|NCT00573989|RADIATION|intensity-modulated radiation therapy|
219335855|NCT04544475|DEVICE|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
219335856|NCT04544475|DRUG|Estrace|Vaginal estrogen cream, estradiol: 100mcg
219335857|NCT04530942|DEVICE|Deep brain stimulation(Active)|DBS On with the optiomal parameters
219335858|NCT04530942|DEVICE|Deep brain stimulation(Sham)|DBS On with 0V Amplitude
219335859|NCT03507920|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
219335860|NCT03507920|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
219335861|NCT06158542|PROCEDURE|Spinal Anesthesia|After standard monitoring, the patient is placed in a sitting position for site marking and administration of anesthesia. The line connecting the upper border of the right and left iliac crests through conventional palpation of anatomical landmarks (Tuffier line) is identified as the entry point at the L3-L4 interspinous space or L2-L3 interspace. For patients in whom spinal entry is successful, spinal anesthesia is provided with the appropriate dose and types of local anesthetics (intrathecal 10-12 mg bupivacaine with the addition of 15-25 mcg fentanyl). After completing the procedure and placing the patient in the supine position, the block level is determined 10 minutes post-procedure using the ice test/pinprick test. Blocks reaching the T4-T6 level are considered successful.
219335862|NCT06158542|DIAGNOSTIC_TEST|Blood Sampling|Preoperatively, syndecan-1 serum levels will be investigated from the blood sample taken before cesarean section.
219335863|NCT03710174|RADIATION|Infrared LED photobiomodulation|Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
219335864|NCT03710174|DEVICE|Occlusal splint|After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
219335865|NCT03710174|RADIATION|Placebo LED photobiomodulation|The same procedure as LED group with the device turned off.
219335866|NCT03715699|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
219335867|NCT03715699|DRUG|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
219335868|NCT05891925|OTHER|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~* older adult id,~* date, hour and time that the older adult listened to each poem,~* poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
219335869|NCT03089775|DRUG|BBI-2000|Experimental
219335870|NCT03089775|DRUG|Vehicle|Vehicle Comparator
219335871|NCT03089775|OTHER|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
219335872|NCT01826110|DRUG|[11C]PIB|Approximately 15 mCI \[11C\]PIB IV x1
219335873|NCT01378858|DRUG|Varenicline|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
219335874|NCT00942175|DRUG|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
219335875|NCT00942175|DRUG|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
219335876|NCT00942175|DRUG|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
219335877|NCT00942175|DRUG|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
219335878|NCT00942175|DRUG|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
219335879|NCT02431936|DRUG|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
219335880|NCT02431936|DRUG|Placebo|Sugar pill made to look identical to Prazosin intervention.
219335881|NCT04452474|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL
219335882|NCT04452474|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
219335883|NCT03581266|OTHER|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
219335884|NCT02664272|PROCEDURE|Total Hip Arthroplasty|
219335885|NCT02527525|BEHAVIORAL|Stepped Care|
219335886|NCT04534478|DRUG|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
219335887|NCT03436459|DEVICE|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
219335888|NCT03436459|DEVICE|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
219335889|NCT06044207|DIAGNOSTIC_TEST|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
219335890|NCT06044207|DIAGNOSTIC_TEST|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
219335891|NCT06044207|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
219335892|NCT04629820|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
219335893|NCT04001075|DRUG|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
219335894|NCT02173860|PROCEDURE|FFR-guided surgical revascularization|
219335895|NCT02173860|PROCEDURE|Angio-guided surgical revascularization|
219335896|NCT03991806|OTHER|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
219335897|NCT03263962|DRUG|Canrenone|Evaluation of canrenone therapy in patients with CHF
219335898|NCT02505503|DEVICE|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
219335899|NCT02505503|DEVICE|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
219335900|NCT03073980|DRUG|IV Acetaminophen|IV Acetaminophen for pain control during procedure
219335901|NCT03073980|DRUG|PO Acetaminophen|PO Acetaminophen for pain control during procedure
219335902|NCT03073980|OTHER|Placebo IV Acetaminophen|Placebo IV Acetaminophen
219335903|NCT03073980|OTHER|Placebo PO Acetaminophen|Placebo PO Acetaminophen
219335904|NCT00812058|DRUG|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
219335905|NCT00812058|DRUG|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
219335906|NCT06338904|BEHAVIORAL|Problem-solving-based psychological intervention|The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).
219335907|NCT02895880|BEHAVIORAL|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
219335908|NCT02895880|BEHAVIORAL|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
219335909|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
219335910|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
219335911|NCT00545064|DRUG|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
219335912|NCT05345535|OTHER|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
219335913|NCT05345535|OTHER|Walking|45 minutes of moderate tempo walking
219335914|NCT03113656|OTHER|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
219335915|NCT03113656|OTHER|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
219335916|NCT05606367|DEVICE|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
219335917|NCT05606367|DEVICE|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
219335918|NCT00868062|OTHER|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
219335919|NCT05787873|DRUG|SIPS-2209-1|QD, PO
219335920|NCT05787873|DRUG|SIPS-2209-2, SIPS-2209-3|QD, PO
219335921|NCT00081237|DRUG|OSI-7904L|
219335922|NCT00081237|DRUG|oxaliplatin|
219335923|NCT01392911|DRUG|Rifampicin|High dose rifampicin
219335924|NCT04001621|DRUG|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
219335925|NCT00113828|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
219335926|NCT00113828|PROCEDURE|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
219335927|NCT00258674|OTHER|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
219335928|NCT00258674|OTHER|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
219335929|NCT00258674|OTHER|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
219335930|NCT03886051|PROCEDURE|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
219335931|NCT03886051|PROCEDURE|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
219335932|NCT04342000|OTHER|Movement education workshop|"30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form."
219335933|NCT04342000|OTHER|Sham Education Workshop|"30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)"
219335934|NCT01035554|OTHER|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
219335935|NCT01035554|OTHER|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
219335936|NCT01035554|OTHER|Usual Care|Standard care
219335937|NCT01035554|OTHER|Printed Materials|National Institutes of Health Printed Materials on hypertension
219335938|NCT05953558|DEVICE|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
219335939|NCT00949546|DRUG|etanercept|etanercept 50 mg sc twice weekly
219335940|NCT00002117|DRUG|Zidovudine|
219335941|NCT00002117|DRUG|Zalcitabine|
219335942|NCT02934308|DEVICE|Skin Conductance Monitor|
219335943|NCT03715153|DRUG|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
219335944|NCT03715153|DRUG|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
219335945|NCT03715153|DRUG|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
219335946|NCT01699854|DRUG|capsaicin patch (qutenza)|
219335947|NCT01699854|DRUG|Placebo|
219335948|NCT00150293|DRUG|Pregabalin|
219335949|NCT00075088|DEVICE|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
219335950|NCT00075088|OTHER|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
219335951|NCT03880032|BEHAVIORAL|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
219335952|NCT01358760|DRUG|Placebo|Placebo vaginal suppository
219335953|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
219335954|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
219335955|NCT05556278|DIAGNOSTIC_TEST|Ultrasound study|based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
219335956|NCT05556278|DIAGNOSTIC_TEST|Neurophysiological test|ultrasound protocol described by Chen et al. (2)
219335957|NCT05619302|DRUG|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
219335958|NCT04876755|DRUG|MBM-02|MBM-02 is an HIF-1 and HIF-2 inhibitor.
219335959|NCT00904631|DEVICE|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
219335960|NCT06044935|OTHER|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
219335961|NCT06044935|OTHER|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
219335962|NCT06044935|DIETARY_SUPPLEMENT|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
219335963|NCT06044935|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
219335964|NCT06875128|DRUG|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
219335965|NCT06875128|DRUG|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
219335966|NCT05796427|BEHAVIORAL|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
219335967|NCT03979846|OTHER|Best Practice|Receive usual care
219335968|NCT03979846|OTHER|Computer Application|Use computer-based symptom reporting system
219335969|NCT03979846|OTHER|Questionnaire Administration|Ancillary studies
219335970|NCT03979846|OTHER|Quality-of-Life Assessment|Ancillary studies
219335971|NCT07010224|OTHER|Retrospective Medical Record Review|Review of archived medical, surgical, and radiological records of patients diagnosed with elastofibroma dorsi and treated surgically. No active intervention was administered as part of the study.
219335972|NCT07010939|PROCEDURE|blood sampling|At baseline, participants will undergo peripheral blood collection using EDTA tubes. A total of 10 mL of venous blood will be collected and processed into plasma and peripheral blood mononuclear cells (PBMCs). Plasma samples will be stored at -80°C, and PBMCs will be cryopreserved in liquid nitrogen. These samples will be used for future biomarker discovery, multi-omics analysis, and studies of biological mechanisms underlying treatment-related toxicities.
219335973|NCT04090580|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks or 2000 mg metformin. Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
219335974|NCT07013006|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
219335975|NCT07016321|DRUG|Emetine Hydrochloride 6mg|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
219335976|NCT07016321|DRUG|Placebo|Participant take a placebo for 10 consecutive days.
219335977|NCT07016321|DRUG|Emetine Hydrochloride 12mg|To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
219355454|NCT06403761|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
219335978|NCT06694428|OTHER|Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed|"The CMV serology results of the patients will have been previously interpreted as part of the care on the basis of the entire virological file according to the reference method.~These results will be reinterpreted using the MyCMV tool on the basis of the serology results performed (IgM, IgG, avidity), CMV PCR, the date of sampling and the date of the start of pregnancy (or last period). This reinterpretation by the tool will be carried out as part of the study and will not be communicated to the patient or to the doctor prescribing the virological analyses."
219335979|NCT02812290|PROCEDURE|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
219335980|NCT07023367|BEHAVIORAL|Parent Navigator Program|Participants in this group will be connected with a parent with lived experience to help get them obtain developmental follow up services and early intervention.
219335981|NCT07023367|BEHAVIORAL|Standard of Care|The families in the standard care group will have their connections to neurodevelopmental (ND) follow-up and support delivered in the standard fashion which consists of a referral to high-risk infant follow-up (HRIF) by discharge coordinator.
219335982|NCT07025044|DRUG|onabotulinum toxin type a|All subjects will be scheduled to undergo Onabotulinum toxin type A intradetrusor injection for management of OAB. On Day 0, subjects will undergo Onabotulinum toxin type A injection by a licensed clinical provider and receive a one-time dose of Nitrofurantoin for infection prevention per standard clinic protocol.
219335983|NCT07029204|DRUG|CycloSPORINE Injectable Product|Intralesional 0.5-2 mL injections of cyclosporine (2.5 mg/ml)
219335984|NCT07029204|DRUG|Saline Solution|Intralesional 0.5-2 mL injections of Saline Solution
219335985|NCT07025187|DRUG|Muscle relaxants tizanidine|All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day for one month .
219335986|NCT07025187|OTHER|integrated neuromuscular inhibition technique|Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month .
219335987|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
219335988|NCT07028697|DRUG|Daridorexant|Daridorexant will be taken orally, once daily in the evening as indicated by investigator.
219335989|NCT07028697|DRUG|Placebo|Placebo will be taken orally, once daily in the evening as indicated by investigator.
219335990|NCT06694402|DEVICE|focal muscle vibration combined with exercise|The treatment group will receive a 30-minute intervention in each session. Focal muscle vibration will be applied to the anterior and lateral parts of shoulder to give a sensory stimulation while participants are doing eaercise.
219335991|NCT06694402|OTHER|exercise|The control group will receive 30-minute exercise without focal muslce vibration.
219335992|NCT00597753|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
219335993|NCT00597753|DRUG|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
219335994|NCT05133271|OTHER|Clinical hemodynamic and echocardiographic evaluation|"Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~1. T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~2. T2: clinico-ultrasound evaluation after performing the PLR.~   Then, clinical hemodynamic evaluation during two periods T3 and T4:~3. T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~4. T4: period after performing spinal anesthesia until clamping of the umbilical cord."
219335995|NCT07030517|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
219355455|NCT03705728|DRUG|Propofol|"Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
219355456|NCT03705728|DRUG|Sevoflurane|Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval
219355457|NCT03705728|DRUG|Remifentanil automatic|"Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
219335996|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"Relaxing Acupressure entails applying pressure with either a finger, pencil, or similar object to acupressure points. For the relaxing protocol, there is a total of 9 acupoints (1 unilateral and 4 bilateral). Each point will be stimulated for 3 minutes, yielding a total treatment time of 27 minutes each day. The acupoints are:~1. Yin Tang (Unilaterally): Located on the forehead, between the eyebrows.~2. Anmian (Right and Left/bilaterally): Located on the posterior aspect of the neck, in a slight depression along the bone directly behind the ear.~3. Heart 7 (HT7) (Right and Left/bilaterally): Located on the palmer surface of the hands on the wrist crease; in line with the pinky.~4. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~5. Liver 3 (LIV3) (Right and Left/bilaterally): This point is located on the foot, near the big and second toes."
219335997|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"There is a total of 10 acupoints (2 unilateral and 4 bilateral). Each point is stimulated for 3 minutes, yielding a total treatment time of 30 minutes each day. The acupoints are:~1. Du 20 (Unilaterally): Located at the top of the head.~2. Large Intestine 4 (LI4) (Right and Left/bilaterally): Located on the back of the hand, between your thumb and index finger.~3. Conception Vessel 6 (CV6) (Unilaterally): Located two finger widths below the navel on the centerline.~4. Stomach 36 (ST36) (Right and Left/bilaterally): Located on the lower leg below the knee on the outside of the leg.~5. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~6. Kidney 3 (K3) (Right and Left/bilaterally): Located on the inside of the ankle."
219335998|NCT05482516|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
219335999|NCT05482516|DRUG|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
219336000|NCT06881251|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
219336001|NCT06881251|DRUG|JNJ-95475939|JNJ-95475939 will be administered subcutaneously.
219336002|NCT06881251|DRUG|Placebo|Placebo will be administered subcutaneously.
219336003|NCT07045155|DRUG|The rHuEPO Monotherapy Group (Control Group)|The rHuEPO Monotherapy Group (Control Group) will be treated with rHuEPO for the first 16 weeks and then switch to Pegmolesatide treatment for the subsequent 8 weeks.
219336004|NCT07045155|DRUG|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group)|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group) will receive a combination of Pegmolesatide and roxadustat throughout the entire 24-week treatment period.
219336005|NCT07045155|DRUG|The Pegmolesatide Monotherapy Group (Experimental group)|The Pegmolesatide Monotherapy Group (Experimental Group) will receive Pegmolesatide treatment throughout the entire 24-week period.
219336006|NCT06926036|BEHAVIORAL|Wake training + TMR|"In this within-participant design, all participants will undergo the same intervention of waking training and TMR.~Waking training - waking training will associate an auditory cue with a specific learned behavioral response (a tongue protrusion and inhalation) during daily sessions for approximately one week, with home sleep monitoring.~TMR - Targeted memory reactivation (TMR) refers to the process of playing learning-associated audio cues quietly during sleep in order to reactivate memories associated with the cue. After completion of waking training, TMR occurs in a laboratory setting, with PSG recording, during a single night."
219336007|NCT06728904|BEHAVIORAL|Tai Chi intervention|40-90 minutes per session, 3-5 sessions per week. 6. Each practice mainly includes basic theoretical knowledge, warm-up exercises, standing exercises, Chen style Tai Chi, and relaxation techniques. This study expects to divide the Tai Chi intervention program into three stages: the first stage is the introductory learning of simple high-intensity Chen style Tai Chi, the second stage is the combination of strength training and Chen style Tai Chi courses, and the third stage uses optional high-intensity competitive Chen style Tai Chi or Tai Chi Sword as advanced content to consolidate learning outcomes, such as the 32 style Tai Chi Sword (HR of about 120 times/minute). The intervention plan will be combined with high-intensity interval training (HIIT) to adapt Chen style Tai Chi.
219336008|NCT06889012|DRUG|BR1018|One tablet administered alone
219336009|NCT06889012|DRUG|BR1018A|One tablet administered alone
219336010|NCT06889012|DRUG|BR1018B|One tablet administered alone
219336011|NCT06778057|DEVICE|Test Lens 1|Acuvue® Oasys MAX 1-Day daily disposable contact lenses
219336012|NCT06778057|DEVICE|Test Lens 2|Dailies Total 1 daily disposable contact lenses
219336013|NCT06778057|DEVICE|Test Lens 3|Clariti 1-Day daily disposable contact lenses
219336014|NCT06734585|DRUG|Gilteritinib|tablet, oral
219336015|NCT06737562|PROCEDURE|Immediatly sequential bilateral cataract surgery|Immediatly sequential bilateral cataract surgery
219336016|NCT06737562|PROCEDURE|Delayed sequential bilateral cataract surgery|Delayed sequential bilateral cataract surgery : 3 weeks +/-1 week between the two procedures
219336017|NCT06735404|OTHER|Hybrid care|"The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online"
219336018|NCT06743022|DIAGNOSTIC_TEST|Chest CT|Repeated chest CT for automated ILD quantification
219355458|NCT03705728|DRUG|Remifentanil manual|Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
219336019|NCT06737484|OTHER|APPLYING TOPICAL OLIVE OIL|"1. Preparation phase: Before the application, hand hygiene will be provided, materials will be prepared, and the application will be carried out wearing gloves. The patient bed will be prepared, a stretcher cover and a bed protector will be laid. A screen will be used for patient privacy and only the areas to be applied will be opened in order. Itchy areas will be identified. Before starting the application, olive oil will be tested by applying it to a small area on the inside of the patient's arm in case of any allergic reaction.~2. Application of olive oil: 3 drops of olive oil will be dropped on the itchy areas (excluding the scalp and private areas) for every 25 cm square area and gently spread over the area for 30-60 seconds. Since there is a 5-7 minute absorption period from the skin, the area will be kept open and then a VAS score will be taken.~3. After the application: The procedure will be marked on the patient follow-up form."
219336020|NCT05114876|OTHER|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses."
219336021|NCT06474793|OTHER|Aromatherapy Intervention Group-1|For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
219336022|NCT06474793|OTHER|Aromatherapy Intervention Group-2|For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
219336023|NCT06474793|OTHER|Aromatherapy Placebo Control Group|For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
219336024|NCT06774846|DRUG|Acetylsalicylic acid/Aspirin (100 mg)|Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
219336025|NCT06774846|DRUG|Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride|patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
219336026|NCT06449222|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
219336027|NCT06449222|DRUG|BNT327 Dose Level 1 (DL2)|IV infusion
219336028|NCT06449222|DRUG|Nab-placlitaxel|IV infusion
219336029|NCT06449222|DRUG|Carboplatin|IV infusion
219336030|NCT06449222|DRUG|Gemcitabine|IV infusion
219336031|NCT06449222|DRUG|Paclitaxel|IV infusion
219336032|NCT06449222|DRUG|Eribulin|IV infusion
219336033|NCT06449222|DRUG|BNT327 Optimized Dose|IV infusion
219336034|NCT06449222|DRUG|BNT327 Equivalent Q3W Dose|IV infusion
219336035|NCT06741969|DRUG|Nipocalimab|Nipocalimab SC.
219336036|NCT06741969|DRUG|Placebo|Placebo SC.
219336037|NCT06741969|DRUG|Standard of care treatment|Protocol-defined topical and systemic standard of care background treatments.
219336038|NCT04117620|OTHER|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
219355459|NCT01283165|BEHAVIORAL|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
219355460|NCT03271372|DRUG|Avelumab|Given IV
219355461|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
219336039|NCT06905925|OTHER|The group receiving counseling|Patients in the experimental group will receive pre-operative stoma care education from the researcher. This training is expected to last approximately 15 minutes. After the training, a brochure will be provided to the patients, which they can use if they need additional information. During the training process, patients will be informed that the researcher will contact them by phone during the 1st, 2nd, 3rd, and 4th weeks after discharge. During these calls, patients will be asked weekly (during weeks 1, 2, 3, and 4) about the color, odor, texture of the wound area, the function of the colostomy, and any complications. Additionally, at the end of the 2nd week, if there are no issues around the wound or sutures, patients will be called to the hospital for suture removal and dressing changes. In other weeks, dietary habits and the condition of the wound will also be inquired. During this four-week period, patients or their relatives will be informed that they can contact the researcher
219336040|NCT05242471|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219336041|NCT05242471|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
219336042|NCT05242471|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
219336043|NCT05242471|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
219336044|NCT07089134|PROCEDURE|reabilitação fisioterapêutica tradicional|Active and passive exercises, and walking
219336045|NCT07089134|PROCEDURE|fisioterapia utilizando realidade virtual imersiva|Use of immersive virtual reality headset for rehabilitation sessions
219336046|NCT06461247|OTHER|Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals|Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
219336047|NCT06461247|OTHER|Standard Care Group|Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
219336048|NCT06764875|DRUG|Rilvegostomig|Q3W, intravenous infusion
219336049|NCT06764875|DRUG|Trastuzumab deruxtecan|Q3W, intravenous infusion
219336050|NCT06764875|DRUG|Trastuzumab|Q3W, intravenous infusion
219336051|NCT06764875|DRUG|Pembrolizumab|Q3W, intravenous infusion
219336052|NCT06764875|DRUG|5-fluorouracil|Q3W, intravenous infusion
219336053|NCT06764875|DRUG|Capecitabine|BID, oral administration
219336054|NCT06764875|DRUG|Cisplatin|Q3W, intravenous infusion
219336055|NCT06764875|DRUG|Oxaliplatin|Q3W, intravenous infusion
219336056|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
219336057|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
219336058|NCT06681324|DRUG|AZD7798|AZD7798
219336059|NCT06681324|OTHER|Placebo|Placebo
219336060|NCT04207892|PROCEDURE|Conservative (non-surgical) treatment|Cast Sling Splint Collar
219336061|NCT04207892|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
219336062|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
219336063|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
219336064|NCT07099716|DEVICE|Wearing Hilo band, Ambulatory Blood Pressure Monitor, and Hydrostatic Pressure monitor|During study Visit 1, participants are equipped with tthree devices- the Device Under Test (Hilo band), the reference device (Ambulatory Blood Pressure Monitor), worn on the opposite arm, and a Hydrostatic pressure monitor on the chest. Subjects are instructed to wear the three devices for the next 24 hours to collect blood pressure (BP) and heart rate (HR) data as well as hydrostatic pressure measurements. After Visit 1, subjects return home with the devices in place. Visit 2 takes place at least 24.5 hours later, when participants return to the site to hand back the equipment.
219336065|NCT03777722|DEVICE|Tailored Lighting Intervention|Lighting Intervention - active or placebo
219336066|NCT06888050|DRUG|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ)|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention
219336067|NCT06888050|DRUG|Metformin|Metformin (500mg, twice a day) plus lifestyle intervention
219336068|NCT06760208|BIOLOGICAL|Pneumococcal 20-valent conjugate vaccine|For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be administered intramuscularly, preferably in the deltoid muscle, with care to avoid injection into or near nerves and blood vessels.
219336069|NCT06905119|OTHER|Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters|The application is offered to all patients at the time of PICC placement. If they accept, they go to the intervention group. If they do not accept, they go to the control group.
219336070|NCT07097779|BEHAVIORAL|Visual Aids(Photos, Videos, and Pictograms)|Participants will be presented with three types of visual instructional aids: photographs, videos, and pictograms, via a laptop or tablet. Each participant will perform three motor tasks, each paired with a different visual aid, assigned in random order using a Latin Square design. Each task takes approximately 3 minutes, followed by 1 minute of rest. After completing all tasks, participants will complete a 5-minute survey about their understanding, preference, and perceived cognitive load. The total session lasts about 20 minutes.
219336071|NCT04481165|OTHER|Survey|Oral interview and written questions
219336072|NCT07107230|DRUG|JNJ-95437446|JNJ-95437446 will be administered.
219336073|NCT05384392|OTHER|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
219355462|NCT03271372|OTHER|Placebo|Given IV
219336074|NCT05384392|OTHER|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
219336075|NCT05384392|BIOLOGICAL|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
219336076|NCT04939610|DRUG|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
219336077|NCT04939610|DRUG|177Lu-FAP-2286|"Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose."
219336078|NCT06500884|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
219336079|NCT06500884|DRUG|Prophylaxis A|Prophylaxis A will be administered orally.
219336080|NCT06500884|DRUG|Prophylaxis B|Prophylaxis B will be administered orally.
219336081|NCT06500884|DRUG|Prophylaxis C|Prophylaxis C will be administered orally.
219336082|NCT05251259|DRUG|Atuliflapon|Randomised participants will receive Atuliflapon
219336083|NCT05251259|DRUG|Placebo|Randomised participants will receive matching placebo to Atuliflapon.
219336084|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
219336085|NCT02500407|DRUG|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
219336086|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
219336087|NCT07109349|DEVICE|Sparrow Link|Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. Participants will self-administer daily active tAN sessions on Days 1 - 28.
219336088|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
219336089|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
219336090|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 1|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
219336091|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 2|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
219336092|NCT06430905|OTHER|Placebo|Administration of placebo to 5 participants.
219336093|NCT07102394|DRUG|Imlygic|intralesional administration of IMLYGIC administered on Days 1 and 21 of each cycle for 4 cycles (8 treatments).
219336094|NCT07106229|BIOLOGICAL|allogeneic human adipose-derived mesenchymal stem cells|The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs).
219336095|NCT07106229|OTHER|Placebo|Placebo is commercially available injectable normal saline (0.9% Sodium Chloride in Water for Injection)
219336096|NCT07108166|OTHER|Cigarette|COPD patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
219336097|NCT07108166|OTHER|THS|COPD patients will switch from cigarette smoking to ad libitum THS use, with no flavor variant restrictions.
219336098|NCT07112911|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20 sessions of robot-assisted upper limb training combined with central-to-peripheral electrical stimulation, delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of NMES and tsES-assisted robotic training. After a 10-minute break, the session will continue with an additional 20 minutes of robotic-assisted training combined with NMES alone, with tsES turned off during this phase. During the training, patients will perform repeated wrist and finger flexion-extension tasks. The training protocol is designed to activate wrist extension voluntarily (exceeding 10% of their initial MVC), which then triggers NMES and inflation of the robotic hand to assist finger opening.
219336099|NCT07112911|BEHAVIORAL|Occupational Therapy with Electrical Stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the OT training, the stroke participants will perform functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
219355463|NCT05326542|PROCEDURE|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
219336100|NCT07112911|BEHAVIORAL|occupational therapy with sham electrical stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with sham trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with 0mA-intensity tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the training, the stroke participants will repeatedly practice functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
219336101|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
219336102|NCT06918834|OTHER|Immediate HSCT Group|Patients undergo direct allogeneic HSCT.
219336103|NCT06918834|OTHER|Bridging Therapy Group|"Patients receive one to two cycles of bridging therapy before undergoing allogeneic HSCT.~o Bridging Therapy Regimen: Hypomethylating agents (HMA) alone or HMA-based combination chemotherapy, e.g., azacitidine (AZA) 100 mg/day + venetoclax (VEN) 400 mg/day for 7 days. Targeted therapies (e.g., IDH1 inhibitors) will be used for eligible patients."
219336104|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
219336105|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
219336106|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
219336107|NCT05765474|BEHAVIORAL|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
219336108|NCT05765474|BEHAVIORAL|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
219336109|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0.5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
219336110|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0.5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
219336111|NCT07145190|DRUG|SL-APO|"Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an ON response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better ON response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode."
219336112|NCT07144683|PROCEDURE|Patients Undergoing Colorectal Resection with Anastomosis|All eligible patients undergoing elective/emergency colorectal surgery with primary anastomosis (e.g., ileocolic, colocolic, colorectal, or coloanal)
219336113|NCT07143227|DRUG|XW003 injection|Subcutaneous injection
219336114|NCT07143227|DRUG|placebo with matching volume|Subcutaneous injection
219336115|NCT06946524|DRUG|Risankizumab|Subcutaneous Injection
219336116|NCT06946797|DRUG|Nivolumab|Specified dose on specified days
219336117|NCT06946797|DRUG|Ipilimumab|Specified dose on specified days
219336118|NCT06946797|DRUG|Carboplatin|Specified dose on specified days
219336119|NCT06946797|DRUG|Paclitaxel|Specified dose on specified days
219336120|NCT06946797|DRUG|Pemetrexed|Specified dose on specified days
219336121|NCT06946797|DRUG|Cisplatin|Specified dose on specified days
219336122|NCT06951919|BEHAVIORAL|Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program specifically for people who have multiple sclerosis. It incorporates education about these conditions and cognition into the education module.
219336123|NCT06948500|OTHER|Immersive Virtual Reality|"Participants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback.~To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events."
219336124|NCT06948500|OTHER|Physical Activity|Participants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload.
219336125|NCT06955806|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
219336126|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
219336127|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
219336128|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine Only|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care. No additional regional block is performed. Postoperative analgesia is maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs as per institutional protocol.
219336129|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine plus Bilateral TAP Block|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care, plus bilateral ultrasound-guided transversus abdominis plane (TAP) block performed at the end of surgery. The TAP block will be performed in-plane with a high-frequency linear probe, using 0.25% bupivacaine, 20 mL per side, injected between the internal oblique and transversus abdominis muscles. Postoperative analgesia will be maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs.
219336130|NCT07147816|DEVICE|Transcutaneous electrical stimulation of the cervical spinal cord (tSCS)|All participants enrolled in this group will receive non-invasive transcutaneous electrical stimulation of the cervical spinal cord (tSCS) while performing strength, spasticity and motor control assessment tasks. Researchers will assess the immediate effects of tSCS (within the same experimental session) on arm and hand movements in individuals with motor impairments caused by traumatic brain injury.
219336131|NCT07158229|OTHER|Questionnaires|Complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.
219336132|NCT07154992|DIETARY_SUPPLEMENT|Probiotic - Lacticaseibacillus rhamnosus CRL1505|The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU/g, with corn starch and maltodextrin as excipients.
219336133|NCT07154992|DIETARY_SUPPLEMENT|Placebo|The placebo product is provided in 2g sticks of corn starch and maltodextrin.
219336134|NCT07149324|BEHAVIORAL|Single Session for Overevaluation|A single session informed by the principles of Cognitive Behavioural Therapy-Enhanced and motivational intervening.
219336135|NCT07154784|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) will be performed at weeks 0 and 4 of study enrollment by administering approximately 250-300 cc of a multi-donor fecal suspension into the colon via sigmoidoscopy, colonoscopy, or by oral administration of an equivalent amount (4 capsules).
219336136|NCT07155122|DRUG|Drug: Serplulimab|serplulimab Serplulimab , 300mg, D1, intravenous drip , Q3W.
219336137|NCT07155122|DRUG|Drug: Etoposide|Etoposide, 60-100 mg/m², D1-3 or D1-5, intravenous drip, Q3W
219336138|NCT07155122|DRUG|Drug: Chemotherapy|Cisplatin, 50-75 mg/m², D2, intravenous drip, Q3W. Or Carboplatin, AUC 5, D2, intravenous drip, Q3W.
219336139|NCT07159503|PROCEDURE|Vortex Intelligence Stone Optimized Removal|Vortex Intelligence Stone Optimized Removal integrates irrigation-suction, pressure monitoring-control, and lithotripsy-stone removal functions, aiming to improve stone clearance efficiency, stabilize intrapelvic pressure, and reduce complications.
219336140|NCT07159503|PROCEDURE|Percutaneous Nephrolithotomy (PCNL)|A standard PCNL technique will be performed according to institutional practice guidelines.
219336141|NCT07161648|OTHER|neuromuscular electrical stimulation|The study participants will engage in 100-minutes of neuromuscular electrical stimulation (NMES). NMES pads are sticky pieces of plastic, similar in size to a 25-cent coin. The pads will be placed on the bellies of thigh muscles (the vastus lateralis, vastus medialis), and calf muscles (the long and short head of the gastrocnemius). These skeletal muscles are selected due to their size (thereby promoting a bigger increase for metabolic rate compared with a small muscle), because they are relatively superficial, and because previous published studies of NMES used these anatomical locations.
219336142|NCT07158476|DRUG|Meloxicam 15 mg|PO once/day for 1 week
219336143|NCT07158476|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|PO 6 day taper
219336144|NCT07158476|DRUG|Gabapentin 300 mg|PO every 8 hours for 1 week
219336145|NCT07158476|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|PO 1-2 tabs every 4 hours as needed (total of 28 pills)
219336146|NCT07158476|DRUG|Ketorolac 10 Mg Oral Tablet|PO every 6 hours for 5 days
219336147|NCT07157852|DRUG|Mirogabalin|For the mirogabalin group, therapy will begin at 5mg twice daily. If the pain will remain inadequately controlled after one week without significant adverse effects, the dose will be escalated in 5 mg per day increments at weekly intervals, with a maximum allowable dose of 15mg twice daily.
219336148|NCT07157852|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
219336149|NCT07165444|DRUG|Potassium-Competitive Acid Blocker|Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.
219336150|NCT07165444|DRUG|Proton Pump Inhibitor|Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.
219336151|NCT07160673|DEVICE|VR-based Respite|Caregivers and homebound older adults will receive 4 weeks of VR-based respite sessions. 4 weeks (1 session/week; 30 min/session) of immersive VR sessions using SilVR Adventures platform. Sessions include virtual travel destinations (e.g., cities, natural wonders) and social activities (e.g., group tours). Facilitated by trained research staff, with 5-10 minutes viewing and 20 minutes reflection/discussion.
219336152|NCT07160673|DEVICE|Video-based Respite|Caregivers and homebound older adults will receive 4 weeks of video-based respite sessions. 4 weeks (1 session/week; 30 min/session) of non-immersive video sessions with content similar to VR themes (e.g., landscapes, cultural events). Facilitated by trained research staff, with post-video discussion. EEG data collected during viewing to assess emotional states.
219336153|NCT07171281|BEHAVIORAL|Early Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
219336154|NCT07171281|BEHAVIORAL|Late Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
219336155|NCT07170735|DIAGNOSTIC_TEST|Plasma MTB cfDNA assay|Quantitative measurement of MTB cfDNA level in the plasma
219336156|NCT07171684|DRUG|Insulin glargine alone|Once daily dosing of insulin glargine
219336157|NCT07171684|DRUG|Insulin glargine + insulin lispro|Once daily dosing of insulin glargine + three times daily dosing of insulin lispro with meals
219336158|NCT07170644|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
219336159|NCT07171060|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
219336160|NCT07169916|DRUG|Yueju Pill + Standard Anti-tumor Therapy|Group A (Intervention): Standard therapy + Yueju Pill (6-9 g per dose, twice daily, orally until disease progression or intolerable toxicity).
219336161|NCT07169916|DRUG|Placebo + Standard anti-tumor therapy|Group B (Control): Standard therapy + placebo (identical in appearance, packaging, dosage, and administration frequency to Yueju Pill).
219336162|NCT07169656|DRUG|ETV,TDF,TAF,TMF|treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)
219336163|NCT07169656|DRUG|Peginterferon α-2b injection|treated with Peginterferon α-2b injection
219336164|NCT07171229|PROCEDURE|Pulpotomy|"* Local anesthesia will be administered, and the tooth will be isolated with a rubber dam.~* To minimize further bacterial contamination, carious tissues will be removed progressively, starting from the cavity periphery and then over the pulp chamber roof.~* Before managing the pulpal hemorrhage, a sterile cotton pellet will be placed over the pulp tissue for 30-45 s.~* A fresh sterile bur will be used to remove all coronal pulp tissue down to the root canal orifices, with copious water irrigation~* MTA will be used as medicament of choice for pulpotomy.~* The pulpotomy-treated tooth will be prepared to receive a full-coverage stainless steel crown (SSC) after the procedure."
219336165|NCT07171229|OTHER|Measuring Cytokines level|measuring cytokines level as an indicator for pulp inflammation
219336166|NCT07170683|OTHER|MAIA Microperimetry|Microperimetry (MP) is not performed as part of the current NHS patient pathway. We plan testing 2 MP strategies ('standard' vrs 'fast') to determine whether the fast testing strategy is as robust as the standard test strategy. Adopting the fast strategy will reduce time spent on the MP machine to obtain relevant test results. Healthy volunteers (with no retinal disease) are necessary for comparison, and to establish validity of any new findings.
219336167|NCT07170683|DEVICE|Microperimetry|Two fully automatic MAIA MP (CenterVue, spa; Padova, Italy) examinations (to obtain retinal sensitivity) shall be performed over the 10° diameter central retinal area for the recruited study participants. The first one will be performed with a fast projection, and the second one with the standard full 4-2 staircase projection strategy. Identification of the PRL area will be automatically calculated at the end of each examination. All patient groups will have identical assessment, at all time points. Healthy volunteers will only have assessments at baseline (one examination only)..
219336168|NCT07170683|OTHER|Visual Acuity Measurement (logMAR)|Visual acuity will be measured with the ETDRS chart, and with the participant habitual distance correction, and recorded in logMAR notation
219336169|NCT07170683|DEVICE|OCT-A|OCT and OCT-A examination, as well FAF will be undertaken with the Topcon Triton Plus OCT
219336170|NCT07171476|PROCEDURE|Guided bone regeneration|traditional guided bone regeneration will be done in which a flap will be raised under local anesthesia, followed by atraumatic extraction of the tooth, after which a 3D guided osteotomy will be done and the implant will be inserted, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing
219355464|NCT05326542|PROCEDURE|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
219336171|NCT07171476|PROCEDURE|bone ring technique|bone ring technique will be applied in which the same procedure as group A will be followed till tooth extraction, after which a trephine bure will be inserted through a 3D guide to prepare the site to receive the bone ring. The osteotomy will be done through the bone ring and the implant will be inserted to fix the implant in place, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
219336172|NCT07171476|PROCEDURE|Tent pole technique|tent pole technique will be applied in which the same procedure same as group A will be followed till implant insertion. Two monocortical screws will then be inserted using 3D guide, mesial and distal to the implant and extending 3 mm outside the bone, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
219336173|NCT07170488|BEHAVIORAL|Yoga|The LoveYourBrain (LYB) Yoga program is a six-week, evidence-based, light intensity Yoga and meditation curriculum developed for individuals living with TBI. It is delivered online and synchronously, the program is led by experienced instructors with more than a decade of teaching experience in Yoga. Each weekly session is 75 minutes and combines gentle postures, guided breathing exercises (pranayama), Yoga nidra (deep relaxation), and meditation practices. Before each of the Yoga sessions, participants are e-mailed prerecorded tools that focused on a specific theme for the week (resilience, mindfulness etc.)
219336174|NCT07170488|BEHAVIORAL|Yoga for wait list control|After the active Yoga group received the intervention, the wait list control was then assigned to the intervention.
219336175|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
219336176|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
219336177|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
219336178|NCT07170449|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
219336179|NCT07170449|DIAGNOSTIC_TEST|Median nerve ultrasonography|Median nerve sonographic cross-sectional area and echogenicity measurements
219336180|NCT07170449|DIAGNOSTIC_TEST|Sensory testing|tactile sensory tests
219336181|NCT07171190|OTHER|Lung Cancer Screening Invitation Intervention|Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message
219336182|NCT07171190|DIAGNOSTIC_TEST|Abdominal scan intervention|Receiving an abdominal CT scan at the same time as the lung scan.
219336183|NCT07170358|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
219336184|NCT07170514|PROCEDURE|EIT-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O.~On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the EIT-GROUP optimal PEEP is considered as the intersect between the lower percentage of overdistension and collapse, based on the diagnostic tool of the EIT device."
219336185|NCT07170514|PROCEDURE|Cdyn-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O. On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the Cdyn-GROUP optimal PEEP is considered as the PEEP value resulting the highest possible Cdyn measured by the ventilator."
219336186|NCT07160452|DRUG|Levocarnitine Injection|1,000 mg levocarnitine IV (slow IV push or infusion per unit policy) post-hemodialysis, three times weekly for 6 months (\~72 doses). Administered in the dialysis unit in addition to usual ESA-based anemia care.
219336187|NCT07160452|OTHER|Usual ESA-Based Anemia Care|Standard-of-care anemia management using recombinant human erythropoietin (ESA) per unit protocol. Typical initial dosing: 50-100 U/kg/week if Hb \<10 g/dL (in 2-3 doses/week); 50 U/kg/week if Hb 10-11 g/dL; 25-50 U/kg/week as maintenance if Hb 11-12 g/dL. ESA dose adjusted monthly using ERI and Hb/Hct targets (generally Hb 10-12 g/dL).
219336188|NCT07158749|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
219355465|NCT03198052|BIOLOGICAL|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
219336189|NCT07158749|BEHAVIORAL|Episodic Recent Thinking (ERT)|Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
219336190|NCT07158749|BEHAVIORAL|Domain-specific episodic thinking|Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).
219336191|NCT07158749|BEHAVIORAL|Generalized episodic thinking|Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).
219336192|NCT07160062|BEHAVIORAL|Mandala painting|Each mandala painting process took a total of 35 to 50 minutes, consisting of 30 to 40 minutes for mandala painting and drawing and 5 to 10 minutes for explaining the painted mandala.
219336193|NCT07165860|BEHAVIORAL|Doula Thrive|The intervention will be pairing intimate partner violence survivors with a trained doula
219336194|NCT07165860|BEHAVIORAL|Thrive|The active control arm will include pairing intimate partner violence survivors with IPV advocates
219336195|NCT07171502|DEVICE|AI Annotation|Use the AI model to assist in annotating the target images.
219336196|NCT07171502|OTHER|manual annotation|Use the manual to annotate the target images.
219336197|NCT07170371|OTHER|patient education|A culturally adapted patient education program designed for individuals with rheumatoid arthritis. The program was developed through a structured needs assessment and based on established health behavior theories. It includes five core modules delivered over six months: understanding rheumatoid arthritis, monitoring disease activity, treatment strategies, nutrition, and stress management. Sessions combine group workshops and individual support, with interactive materials and practical exercises. The program aims to strengthen patients' knowledge, self-management skills, and quality of life compared to usual care.
219336198|NCT07170371|OTHER|Usual Care|patients will receive usual care only
219336199|NCT07171541|DIAGNOSTIC_TEST|OCT ,mFERG,VA test|retinal photography by OCT, VA measurement, and mfERG test
219336200|NCT07170917|DRUG|Brivekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
219336201|NCT07170917|DRUG|Placebo|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
219336202|NCT07170696|BEHAVIORAL|nutrition education|dialogic reading-based nutrition education
219336203|NCT07170059|BIOLOGICAL|herpes zoster vaccine|Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
219336204|NCT07171086|DEVICE|AI-POCUS (BabyChecker, Delft Imaging)|A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
219336205|NCT07171086|DEVICE|AI-POCUS (Edan, China)|An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
219336206|NCT07171138|DEVICE|Positioning and positioning devices|"Different positioning strategies and positional devices. Measurement of skin interface pressure at key anatomical pressure points (occiput, elbows, sacrum, heels) under different patient positioning strategies and positional devices.~The positions that produce the least amount of pressure are identified and will be implemented and compared with pre-intervention hospital acquired pressure injuries (HAPI)"
219336207|NCT07169968|DEVICE|clear aligners group|patients with lower anterior crowding, after randomization and allocation, will receive intraoral scanning to create a digital model. using computer software, teeth segmentation, setup and stagging of tooth movement will be carried out. models for each stage of tooth movement will be three-dimentionally printed and the aligners will be thermoformed over each model. patients are instructed to wear each aligner for a week then continue to the next aligner till treatment is finished
219336208|NCT07169968|DEVICE|micro-osteoperforations group|patients having lower anteriro crowding, after randomization and allocation, aligners will be produced for them. patients in this group will receive micro-osteoperforation using mini-implants before wearing the first aligner and after one month from starting treatment.
219336209|NCT07171554|DIAGNOSTIC_TEST|µCAN drug screen test|µCAN guided therapy is based on drug screening of patient-derived tumoroids. The patient might be treated with clinically relevant on-label or off-label drugs
219336210|NCT07171554|OTHER|Standard-of-Care Therapy|trifluridine/tipiracil/bevacizumab combination, 28 day cycles
219336211|NCT07170280|PROCEDURE|Direct Infrapectineal Plating in Quadrilateral Plate Acetabular Fractures: A Prospective Cohort Study|This study aims to evaluate the outcomes of direct infrapectineal plate fixation in patients with quadrilateral plate acetabular fractures. A total of 25 adult patients with acute fractures were enrolled between 2021 and 2024 at a university-affiliated hospital. All patients underwent surgical fixation through the ilioinguinal approach. Radiological results were assessed using the Matta scoring system, and functional outcomes were evaluated using the Merle d'Aubigné and Postel scoring system. The study further assessed complication rates, operative time, intraoperative blood loss, and hospital stay.
219355466|NCT02321436|BIOLOGICAL|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
219336212|NCT07170553|BEHAVIORAL|Digital Game|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will engage with a digital game prototype. The game involves brief relationship enhancing activities focused on different domains of attachment with the purpose of facilitating appropriate and healthy playful interaction between parents and children.
219336213|NCT07170553|BEHAVIORAL|Control|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will receive pamphlets with information regarding play based attachment activities and be given the chance to engage in said activities.
219336214|NCT07169994|DRUG|YL202 for injection; Toripalimab injection|"Part 1: YL202 and Toripalimab will be administered intravenously.~Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined.~Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab"
219336215|NCT07169994|DRUG|YL202 for injection; Furmonertinib Mesilate Tablets|"Part 2: YL202 will be administered intravenously，Furmonertinib Mesilate Tablets will be administered orally.~Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined.~Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate."
219336216|NCT07161557|OTHER|No Intervention: Observational Cohort|No intervention involved, participants will fill out some questionnaires and blood samples will drawn for test and analysis.
219336217|NCT07159061|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
219336218|NCT07159061|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
219336219|NCT07170215|DEVICE|antigravity treadmill (ALTERG VIA, Lifeward CA, Inc., Milmont Drive, Fremont, CA, U-SA)|Antigravity treadmill training in the experimental group (EG) involved walking in a straight line at a self-selected, com-fortable pace-without running, shortness of breath, or pain. The treadmill's chamber was set to reduce the participant's effective body weight to 20% of their actual body weight (slight unloading was applied to reduce the need for handrail support and to prevent the use of compensatory mechanisms).
219336220|NCT07169773|DEVICE|Rezum|Rezum procedure in Rezum group
219336221|NCT07169773|DRUG|Tamsulosin|Tamsulosin were given to Tamsulosin group
219336222|NCT07170319|DRUG|IBI3032|IBI3032. Method of administration: oral, fasted administration.
219336223|NCT07170319|DRUG|placebo|Placebo (without active ingredients). Method of administration: oral, fasted administration.
219336224|NCT07171645|OTHER|Assessment regarding gender-affirming care|No comparison
219336225|NCT07171203|DRUG|Imatinib|Tyrosine kinase inhibitor. Imatinib will be dosed at 400 mg once a day. Dose can be reduced by 100 mg per dose reduction step if clinically indicated.
219336226|NCT07171203|DRUG|Fampridine|Voltage-gated potassium channel (VGKC) blocker. Fampridine will be dosed in a 3+3 design at 10 mg given either every 2 days, or every day, or twice a day.
219336227|NCT07171398|OTHER|Functional Performance Testing Battery|"Participants performed a standardized battery of sport-specific performance tests during a single laboratory session, including:~Countermovement Jump (height, power, flight time)~5-10-5 Pro-Agility Shuttle Test~Acceleration-Deceleration-Acceleration (ADA) Test~Side Jump Test~6-Meter Timed Hop Test~Single-Leg Hop Test~Triple Crossover Hop Test~Lateral Hop Test Performance was assessed using the Deepsport AI program and standard timing/distance protocols. Results compared between CAI and control cohorts."
219336228|NCT07169682|DRUG|interleukin 17 inhibitor|52 weeks
219336229|NCT07169682|DRUG|interleukin-23 inhibitor|52 weeks
219336230|NCT07169682|DRUG|conventional systemic agent or apremilast|52 weeks
219336231|NCT07171710|DRUG|0.05% Cyclosporine Eye Drops|Cyclosporin A 0.05% eye drops were administered twice daily to both eyes
219336232|NCT07171710|DEVICE|Smart plug absorbable lacrimal duct plugs|The lacrimal duct embolization implant is performed by partially sealing the tear discharge duct to increase the lubrication of natural tears on the eye surface.
219336233|NCT07170826|OTHER|Self questionnaire|Rosenberg Scale, SF36, MBRSQ
219336234|NCT07170826|OTHER|interview|Semi-structured individual interviews
219336235|NCT07171346|DEVICE|Zynex NexWave Electrotherapy Device|All participants will use the NMES device in addition to standard rehabilitation
219336236|NCT07171333|DEVICE|Colonoscopy with CADe system|Patients in the CADe+ arm underwent colonoscopy with CADe DISCOVERY™ (PENTAX Medical, Tokyo, Japan), an AI-driven tool highlighting suspected lesions in real-time, through a light-blue box. The final lesion characterization remained the endoscopist's responsibility.
219336237|NCT07171216|OTHER|Treat to target|"Participants will receive treatment from a toolbox depending on the situation to reach the PTH target. Available medication is mirroring what is used in the outpatient clinic setting already (native vitamin D, activated vitamin D, phosphate binders, calcimetics)."
219355467|NCT02321436|DRUG|Placebo|Placebo administered intramuscularly in the targeted upper limb.
219355468|NCT03801655|DIETARY_SUPPLEMENT|Bio-Kult|4 capsules/day
219355469|NCT03801655|OTHER|Placebo|4 capsules/day
219336238|NCT07170124|OTHER|Obstetric exercises|"The intervention will consist of a structured obstetric exercise program administered by a physiotherapist who is permanently employed at the hospital's prenatal education center, ensuring the reliability and standardization of the intervention. The program will be based on the Pregnancy and Exercise Guide (2012) published by the Turkish Ministry of Health and will be delivered in the pregnancy school of a public hospital in eastern Türkiye.~The exercises will be provided at weekly intervals and will include:~Active joint movements to improve mobility and maintain functional range of motion,~Stretching exercises to enhance flexibility and alleviate musculoskeletal discomfort,~Calisthenic bodyweight exercises to promote muscle strength and endurance,~Relaxation and breathing techniques to reduce stress and improve maternal well-being."
219336239|NCT07169825|DRUG|Lu-177|Given by IV
219336240|NCT07169825|OTHER|SPECT|SPECT/CT
219336241|NCT07171528|PROCEDURE|Secondary Cytoreductive Surgery|"Surgery will only be performed in patients assigned to the experimental arm of the study.~The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority."
219336242|NCT07169838|OTHER|Perinatal Tissue Collection|Collection of perinatal medical waste (amniotic fluid, amniotic membrane, umbilical cord, placenta) at the time of term delivery for laboratory-based mesenchymal stem cell isolation and analysis. No therapeutic or interventional procedure was performed on participants.
219336243|NCT07169617|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219336244|NCT07169617|DRUG|Montanide ISA 51 VG|Given SC
219336245|NCT07169617|OTHER|Questionnaire Administration|Ancillary studies
219336246|NCT07169617|BIOLOGICAL|Sargramostim|Given SC
219336247|NCT07169617|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
219336248|NCT07171372|OTHER|Device&behavioral|The IoT-HFActive intervention is a 12-month personalized program delivered via a mobile app, integrating patient-centered goal setting, real-time monitoring, and behavioral support. Intervention group participants will first attend two structured education sessions on exercise in HF and the use of the app and smart wristbands. They will then complete 12 supervised group-based sessions (3×50 min/week for 4 weeks) including warm-up, moderate aerobic exercise, and cool-down. Personalized activity goals will be calculated using heart rate reserve (HRR) via the Karvonen formula and exponential weighted moving average (EWMA) based on wristband data. Continuous remote monitoring will display target HR, achieved minutes, calories, and steps, and include daily confirmation prompts. Behavioral support features of the app will provide personalized feedback, motivational messages, visualizations, and monthly goal re-planning to promote adherence and reduce sedentary behavior.
219336249|NCT07169942|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally Drug: placebo administered orally
219336250|NCT07170787|BIOLOGICAL|IMM2510|IMM2510 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM2510 (e.g., 10 mg/kg, 20 mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
219336251|NCT07170787|BIOLOGICAL|IMM01|IMM01 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM01 (e.g., 1 mg/kg, 2 mg/kg, 3mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
219336252|NCT07170982|DRUG|Fruquintinib|This study aims to confirm the safety and efficacy of fruquintinib combined with standard chemotherapy, further compare whether first-line standard chemotherapy has superiority, bring better survival benefits to patients with pMMR endometrial cancer, and provide more options for patients with late recurrent and metastatic endometrial cancer.
219336253|NCT07170306|PROCEDURE|transcatheter aortic valve replacement|Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).
219336254|NCT07170384|BEHAVIORAL|Mediterranean Diet|"A structured Mediterranean diet program designed and supervised by a dietitian. The program emphasizes high consumption of olive oil, vegetables, fruits, legumes, whole grains, and fish; moderate intake of dairy and poultry; and low intake of red meat and processed foods. Adherence will be monitored through 10-day interval follow-up phone calls. Assessments will be conducted at baseline and 3 months"
219336255|NCT07170384|BEHAVIORAL|Healthy Eating Advice|Participants will continue their standard medical treatment and will receive general healthy eating advice, as routinely recommended in clinical practice. No additional structured dietary program will be provided. Assessments will be performed at baseline and at 3 months.
219336256|NCT02516787|OTHER|Parabolic flight|
219336257|NCT02516787|OTHER|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
219336258|NCT02516787|OTHER|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
219336259|NCT00268489|BIOLOGICAL|bevacizumab|
219336260|NCT00268489|DRUG|pemetrexed disodium|
219336261|NCT00128479|DRUG|mifepristone|mifepristone 300 mg daily for 7 dats
219336262|NCT00128479|DRUG|mifepristone matched placebo|daily for 7 days
219336263|NCT00128479|DRUG|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
219336264|NCT00128479|DRUG|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
219336265|NCT06365866|DEVICE|"BRAXX Esophageal Brachytherapy Applicator."|The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.
219336266|NCT06365866|RADIATION|Add-on of intraluminal brachytherapy|Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
219336267|NCT05377788|DRUG|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
219336268|NCT05498350|PROCEDURE|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
219336269|NCT03820414|BIOLOGICAL|CRV 101|(Different formulations)
219336270|NCT03820414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
219336271|NCT03516526|DRUG|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
219336272|NCT03870438|DRUG|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
219336273|NCT01329445|OTHER|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
219336274|NCT03488173|DRUG|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
219336275|NCT02386436|DRUG|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
219336276|NCT02386436|DRUG|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
219336277|NCT00736255|DRUG|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
219336278|NCT00736255|DRUG|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
219336279|NCT00736255|DRUG|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
219336280|NCT00960336|DRUG|pegylated liposomal doxorubicin hydrochloride|
219336281|NCT03427047|DEVICE|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
219336282|NCT03427047|DEVICE|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
219336283|NCT00822731|DRUG|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
219336284|NCT03278184|DEVICE|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
219336285|NCT03278184|DEVICE|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
219336286|NCT03278184|DEVICE|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
219336287|NCT04481984|OTHER|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
219336288|NCT04481984|OTHER|Care advice|Patients received care advice including avoiding cold exposure and trauma.
219336289|NCT04617951|DIETARY_SUPPLEMENT|Ishige Okamurae extracts group|Ishige Okamurae extracts 300 mg/day for 12 weeks
219336290|NCT04617951|DIETARY_SUPPLEMENT|Placebo group|Placebo 300 mg/day for 12 weeks
219336291|NCT06320691|PROCEDURE|Total Hip Arthroplasty|Patients that underwent direct anterior approach total hip arthroplasty
219336292|NCT06320691|PROCEDURE|General Anesthesia|Patients that underwent general/systemic anesthesia before surgery
219336293|NCT06320691|PROCEDURE|Spinal Anesthesia|Patients that underwent spinal/neuraxial anesthesia before surgery
219336294|NCT04012554|PROCEDURE|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
219336295|NCT04012554|PROCEDURE|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
219336296|NCT02145286|RADIATION|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
219336297|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
219336298|NCT01141504|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
219336299|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
219336300|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
219336301|NCT03650842|DEVICE|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
219336302|NCT00950508|PROCEDURE|High volume plasma exchange|3 high volume plasma exchanges over 3 days
219336303|NCT00950508|PROCEDURE|Standard medical treatment|Standard medical treatment
219336304|NCT04599777|DRUG|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
219336305|NCT05988060|OTHER|Experimental Intervention|"Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week."
219336306|NCT02656095|DRUG|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
219336307|NCT02966509|BEHAVIORAL|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
219336308|NCT02170675|DRUG|Dabigatran etexilate|
219336309|NCT02170675|DRUG|Ketoconazole|
219336310|NCT04169087|OTHER|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
219336311|NCT04327830|OTHER|Decisional needs assessment|Assessment of decision-making needs
219336312|NCT03540225|DRUG|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
219336313|NCT00404820|DRUG|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
219336314|NCT00404820|DRUG|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
219336315|NCT00404820|DRUG|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
219336316|NCT04541290|DRUG|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
219336317|NCT01976520|BIOLOGICAL|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
219336318|NCT03960775|DRUG|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
219336319|NCT03960775|DRUG|saline|Saline infusion during same time period.
219336320|NCT05472467|DRUG|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
219336321|NCT05472467|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
219336322|NCT05472467|DRUG|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
219336323|NCT02013947|OTHER|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
219336324|NCT00351832|DRUG|Vildagliptin|
219336325|NCT02443363|OTHER|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
219336326|NCT02443363|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
219355470|NCT01348997|BEHAVIORAL|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
219336327|NCT01833637|OTHER|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
219336328|NCT00907348|DRUG|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
219336329|NCT03887533|DRUG|VTS-270|Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
219336330|NCT01993212|DRUG|Androxal 12.5 mg or 25 mg|
219336331|NCT01993212|DRUG|AndroGel 1.62%|
219336332|NCT01993212|DRUG|Placebo Capsules|
219336333|NCT01993212|DRUG|Placebo Gel|
219336334|NCT01018433|BEHAVIORAL|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
219336335|NCT01018433|OTHER|Treatment as usual|Can include other psychotherapy and pharmacotherapy
219336336|NCT02329964|DRUG|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
219336337|NCT02329964|DRUG|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
219336338|NCT00124059|DRUG|Seroquel|400mg/day quetiapine
219336339|NCT00124059|DRUG|Placebo|400mg/day placebo
219336340|NCT05137548|DRUG|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
219336341|NCT05137548|DRUG|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
219336342|NCT01469182|BIOLOGICAL|SCH 39641|Rapidly dissolving tablet sublingually once daily
219336343|NCT01469182|DRUG|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
219336344|NCT02613650|DRUG|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
219336345|NCT02114164|DEVICE|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
219336346|NCT02114164|DEVICE|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
219336347|NCT04798599|OTHER|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
219336348|NCT04798599|OTHER|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
219336349|NCT02687542|DRUG|Placebo|Placebo
219336350|NCT02687542|DRUG|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
219336351|NCT02687542|DRUG|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
219336352|NCT02687542|DRUG|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
219336353|NCT02687542|DRUG|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
219336354|NCT01838616|DRUG|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
219336355|NCT01838616|DRUG|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
219336356|NCT02021084|DIETARY_SUPPLEMENT|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
219336357|NCT02021084|DIETARY_SUPPLEMENT|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
219336358|NCT01349868|DRUG|PT005 MDI|PT005 MDI taken as two inhalations
219336359|NCT01349868|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
219336360|NCT01349868|DRUG|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
219336361|NCT01349868|OTHER|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
219336362|NCT04272684|OTHER|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
219336363|NCT00309543|DRUG|Fluorouracil|
219336364|NCT00309543|DRUG|Leucovorin|
219336365|NCT00829075|DRUG|r-FSH|
219336366|NCT00829075|DRUG|HP-hMG|
219336367|NCT00829075|DRUG|r-FSH plus HP-hMG|
219336368|NCT00379652|BEHAVIORAL|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
219336369|NCT00379652|BEHAVIORAL|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
219336370|NCT00379652|OTHER|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
219336371|NCT05435651|BEHAVIORAL|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
219336372|NCT05435651|BEHAVIORAL|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
219336373|NCT01566773|DRUG|PT001 MDI|Administered as two puffs BID for 14 days
219336374|NCT01566773|DRUG|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
219336375|NCT01566773|DRUG|PT001 Placebo MDI|
219336376|NCT03033537|DRUG|Verapamil|Local treatment of erectile dysfunction
219336377|NCT05778058|DEVICE|Unilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
219336378|NCT05778058|DEVICE|Bilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
219336379|NCT05778058|DEVICE|Bilateral Sham Stimulation|Participants were shown that the device was working, but no current was given.
219336380|NCT05778058|DIAGNOSTIC_TEST|Bicycle Ergometer Test|Participants in this group were asked to perform bicycle exercise with maximum performance under 30 watts for 30 minutes.
219336381|NCT05778058|DIAGNOSTIC_TEST|Lactat Scout|For lactic acid analysis measurement, the middle fingertip of the athlete is disinfected with an alcohol swab and a blood sample is taken by puncturing the finger.The measuring range is 0.5 - 0.25 mmol/L.
219336382|NCT05778058|DIAGNOSTIC_TEST|Polar H10|RR times transferred to computer with Polar H10 are used in heart rate variability analysis. Heart rate data will be transferred to the Kubios program and heart rate variability parameters will be calculated and data on the autonomic nervous system (RMSSD, PNS index, Stress index, SNS index, pNN50, Power LF, Power HF and LF/HF ratio) will be obtained.
219336383|NCT05778058|DEVICE|Vagustim Device|Vagustim Health Technologies Vagus stimulator device is used for this experiment.
219336384|NCT04940104|DRUG|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
219336385|NCT00103974|BIOLOGICAL|BHT-3009-01|
219336386|NCT05639127|DRUG|Prednisolone|Nebulization of prednisolone
219336387|NCT00136422|BIOLOGICAL|autologous tumor cells|
219336388|NCT01033734|DRUG|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
219336389|NCT00286273|DRUG|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
219336390|NCT00286273|DRUG|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
219336391|NCT01577901|OTHER|Clearblue Advanced|Pregnancy test
219336392|NCT04451915|OTHER|late management strategy|late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
219336393|NCT04451915|OTHER|early management strategy|early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
219336394|NCT03089593|OTHER|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
219336395|NCT03089593|OTHER|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
219336396|NCT01347424|DRUG|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
219336397|NCT01347424|DRUG|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
219336398|NCT03351751|DRUG|Placebo|Placebo
219336399|NCT03351751|DRUG|PF-06372865|PF-06372865
219336400|NCT00657813|DRUG|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
219336401|NCT01409733|DEVICE|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
219336402|NCT01441830|DEVICE|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
219336403|NCT03976011|DEVICE|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
219336404|NCT03785990|OTHER|adipose tissue|taking a sample of the adipose tissue during operation
219336405|NCT03785990|OTHER|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
219336406|NCT03785990|DIAGNOSTIC_TEST|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
219336407|NCT06571279|OTHER|Plant-based diet|Standard plant-based meals will be provided directly to participants. The dietary intervention will begin with a one-week Western diet run-in; hereafter, participants will consume plant-based meals for approximately 5 weeks. Total energy provided will be equal to REE X 1.4 to account for light physical activity to support weight maintenance. High-inositol snacks will be provided to meet energy needs. Meals and snacks combined will provide a minimum of 20mg total inositol/kg body weight. For example, a 200lb participant will consume 1.8g daily, which is consistent with doses used in prior studies.
219336408|NCT04184687|PROCEDURE|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
219336409|NCT04184687|PROCEDURE|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
219336410|NCT02724254|DRUG|AP611074 5% gel|
219336411|NCT02724254|DRUG|AP611074 matching placebo|
219336412|NCT06490588|OTHER|sevoflurane|No intervention
219336413|NCT02366442|OTHER|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
219336414|NCT04022187|OTHER|Observational study : no intervention|Observational study : no intervention, only exporting data
219336415|NCT05915689|OTHER|Myofascial arm pull technique|patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.
219336416|NCT05915689|OTHER|post isometric relaxation technique|The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
219336417|NCT06136377|RADIATION|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
219336418|NCT00111800|DRUG|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336419|NCT00111800|DRUG|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336420|NCT00111800|DRUG|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336421|NCT00111800|DRUG|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336422|NCT00111800|DRUG|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336423|NCT00111800|DRUG|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
219336424|NCT02211729|DRUG|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
219336425|NCT02211729|DRUG|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
219336426|NCT02548325|OTHER|Not apply|None. Just registration epidemiology dates
219336427|NCT01273051|DRUG|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
219336428|NCT01273051|RADIATION|radiotherapy|radiation 25x2 Gy
219336429|NCT01273051|PROCEDURE|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
219336430|NCT01273051|PROCEDURE|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (\<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
219336431|NCT03609138|DEVICE|Spinal Hardware|Pedicle screws and patient specific rods
219336432|NCT04660461|DRUG|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
219336433|NCT04660461|DRUG|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
219336434|NCT04152577|DRUG|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
219336435|NCT04152577|DRUG|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
219336436|NCT00524602|PROCEDURE|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
219336437|NCT03448068|DRUG|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
219336438|NCT03448068|DRUG|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
219336439|NCT01704586|RADIATION|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
219336440|NCT01704586|RADIATION|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
219336441|NCT01735253|PROCEDURE|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
219336442|NCT00873977|DEVICE|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
219336443|NCT02560376|DRUG|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
219336444|NCT03445871|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
219336445|NCT03445871|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
219336446|NCT05959395|DEVICE|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
219336447|NCT03353571|DEVICE|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
219336448|NCT03086733|DRUG|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
219336449|NCT01094769|DRUG|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
219336450|NCT01094769|DRUG|Placebo|lactose capsule taken once daily
219336451|NCT05100472|BIOLOGICAL|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
219336452|NCT05100472|RADIATION|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
219336453|NCT05100472|RADIATION|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
219336454|NCT04730258|DRUG|CFI-400945|The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
219336455|NCT04730258|DRUG|Azacitidine|Azacitidine will be given at its labeled dose and schedule
219336456|NCT04104243|OTHER|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
219336457|NCT02977650|PROCEDURE|Endoscopic ultrasonography-guided fine needle aspiration|
219336458|NCT01111851|DRUG|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
219336459|NCT01111851|DRUG|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
219336460|NCT01111851|DRUG|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
219336461|NCT01111851|DRUG|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
219336462|NCT01111851|DRUG|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
219336463|NCT01111851|DRUG|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
219336464|NCT01111851|DRUG|MK0999|I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
219336465|NCT05264545|DEVICE|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
219336466|NCT06048094|DRUG|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
219336467|NCT00843388|DRUG|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
219336468|NCT00843388|DRUG|placebo tablet|placebo tablet 25 mg OD
219336469|NCT00239616|DRUG|Iron Sucrose injection|Iron sucrose 100 mg dose
219336470|NCT02263521|OTHER|No intervention employed. Study is based on a cross-sectional observational design.|
219336473|NCT00731055|DRUG|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
219336474|NCT00731055|DRUG|Placebo|1 dose of placebo
219336475|NCT04427683|BEHAVIORAL|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
219336476|NCT03589495|DRUG|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
219336477|NCT03589495|OTHER|dextrose 5%|
219336478|NCT04654481|DEVICE|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
219336479|NCT04654481|OTHER|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
219336480|NCT00795249|BEHAVIORAL|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
219336481|NCT05212506|BIOLOGICAL|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
219336482|NCT05916105|DRUG|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
219336483|NCT03889665|OTHER|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
219336484|NCT01471015|DRUG|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
219336485|NCT01471015|DRUG|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
219336486|NCT01471015|DRUG|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
219336487|NCT05735808|BEHAVIORAL|Physician based education|Regular education provided by physician
219336488|NCT05735808|BEHAVIORAL|VR based education|VR based education
219336489|NCT02589899|OTHER|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
219336490|NCT01843842|DRUG|Ergoferon|Safety and Efficiency of liquid dosage form
219336491|NCT01843842|DRUG|Placebo|Safety and Efficiency of liquid dosage form
219336492|NCT04429165|OTHER|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
219336493|NCT04429165|OTHER|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
219336494|NCT04429165|OTHER|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
219336495|NCT06400173|BEHAVIORAL|Cognitive screening|The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
219336496|NCT06400173|BEHAVIORAL|Audiological Assessment|"Four audiological tests are included in the audiological assessment~1. Tympanometry to assss the middle ear status~2. Pure-tone audiometry with headphone to evaluate the hearing thresholds~3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise~4. The hAVICOP questionnaire to assess the hearing-related quality of life"
219336497|NCT02953340|DRUG|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
219336498|NCT02953340|DRUG|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
219336499|NCT02953340|DRUG|Docetaxel|75mg/m\^2 IV infusion administered on Day 1 of each cycle
219336500|NCT02953340|DRUG|Cyclophosphamide|600mg/m\^2 IV infusion administered on Day 1 of each cycle
219336501|NCT02512406|OTHER|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
219336502|NCT02512406|OTHER|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
219336503|NCT02512406|OTHER|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
219336504|NCT02512406|OTHER|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
219336505|NCT02512406|OTHER|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
219336506|NCT02512406|OTHER|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
219336507|NCT01376778|DRUG|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
219336508|NCT01376778|OTHER|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
219336509|NCT00928889|DRUG|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
219336510|NCT00928889|DRUG|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
219336511|NCT02363348|DIETARY_SUPPLEMENT|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
219336512|NCT02363348|OTHER|Placebo|calcined magnesia
219336513|NCT02615483|OTHER|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
219336514|NCT04664361|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
219336515|NCT04664361|OTHER|Placebo|Daily supplementation with placebo for 38 days in total
219336516|NCT03141554|DRUG|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
219336517|NCT03141554|DRUG|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
219336518|NCT03141554|DRUG|Normal saline gargle|Normal saline gargle
219336519|NCT04898270|DRUG|Flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."
219336520|NCT04898270|DRUG|Multi-acting receptor-targeted antipsychotics (MARTAs)|Multi-acting receptor-targeted antipsychotics (MARTAs)
219336521|NCT01989312|PROCEDURE|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
219336522|NCT01989312|PROCEDURE|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
219336523|NCT01989312|DEVICE|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
219336524|NCT01989312|DEVICE|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
219336525|NCT01989312|DRUG|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
219336526|NCT01989312|DRUG|Lidocaine|
219336527|NCT01989312|DRUG|Epinephrine|
219336528|NCT01989312|DRUG|Levobupivacaine|
219336529|NCT01547585|OTHER|Standardized soy containing muffin|Standardized muffin containing two levels of soy
219336530|NCT01676675|BIOLOGICAL|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
219336531|NCT01676675|BIOLOGICAL|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
219336532|NCT01676675|BIOLOGICAL|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
219336533|NCT01676675|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
219336534|NCT03804333|RADIATION|standard treatment|3000 cGy in 10 daily fractions
219336535|NCT03804333|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
219336536|NCT00820651|DIETARY_SUPPLEMENT|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
219336537|NCT00820651|OTHER|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
219336538|NCT04384562|DRUG|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
219336539|NCT04384562|DRUG|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
219336540|NCT04384562|DRUG|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
219336541|NCT04384562|DRUG|Placebo pill|A placebo pill is administered only once.
219336542|NCT04384562|DRUG|Placebo gum|A placebo gum is administered only once.
219336543|NCT02068742|OTHER|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
219336544|NCT02735395|PROCEDURE|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
219336545|NCT02735395|DRUG|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
219336546|NCT02735395|DRUG|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
219336547|NCT02735395|DRUG|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
219336548|NCT02735395|DRUG|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
219336549|NCT02735395|DRUG|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
219336550|NCT02735395|OTHER|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
219336551|NCT02735395|OTHER|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
219336552|NCT02735395|OTHER|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
219336553|NCT02735395|OTHER|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
219336554|NCT02058030|DEVICE|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
219336555|NCT03800784|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
219336556|NCT04878003|DRUG|KRT-232|KRT-232, administration by mouth
219336557|NCT04878003|DRUG|TL-895|TL-895, administration by mouth
219336558|NCT04712110|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
219336559|NCT04712110|BIOLOGICAL|Placebo|Placebo intramuscular injection
219336560|NCT03997435|DRUG|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
219336561|NCT03997435|DRUG|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
219336562|NCT02111161|DRUG|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
219336563|NCT02111161|DRUG|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
219336564|NCT04585464|DRUG|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
219336565|NCT04585464|DRUG|Placebo|Placebo is administered orally as a single dose or once daily
219336566|NCT04417036|DRUG|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
219336567|NCT04417036|OTHER|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
219336568|NCT04417036|DRUG|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
219336569|NCT04993235|BEHAVIORAL|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
219336570|NCT04993235|BEHAVIORAL|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
219336571|NCT04993235|BEHAVIORAL|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
219336572|NCT03332823|BEHAVIORAL|SME Ambassadors training & program|"* Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
219336573|NCT01517893|DRUG|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
219336574|NCT01517893|DRUG|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
219336575|NCT06275763|DRUG|Phase C: Eplerenone|Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
219336576|NCT06275763|DRUG|Phase C: Spironolactone|Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
219336577|NCT06275763|DRUG|Phase C: Torasemide|Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
219336578|NCT06275763|DRUG|Phase B: Triplixam / Elestar HCT|Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
219336579|NCT06275763|DIAGNOSTIC_TEST|Phase A: Confirmation of uncontrolled hypertension|Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
219336580|NCT01309659|DRUG|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
219336581|NCT01309659|DRUG|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
219336582|NCT03462576|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
219336583|NCT03462576|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
219336584|NCT03462576|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
219336585|NCT01921751|RADIATION|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
219336586|NCT01921751|DRUG|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
219336587|NCT01921751|DRUG|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]
219336588|NCT01921751|RADIATION|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
219336589|NCT01921751|DRUG|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]
219336590|NCT01059669|OTHER|diagnostic test|
219336591|NCT04095650|BEHAVIORAL|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
219336592|NCT02285777|BIOLOGICAL|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
219336593|NCT02285777|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
219336594|NCT02667210|OTHER|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
219336595|NCT04502251|DRUG|Low-Dose Naltrexone|4.5mg daily dose, orally, during 26 days
219336596|NCT04502251|DEVICE|Transcranial Direct Current Stimulation|An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
219336597|NCT04502251|DRUG|Placebo|The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
219336598|NCT04502251|DEVICE|Sham Transcranial Direct Current Stimulation|Sham-tDCS stimulation consists of an active current during 30 seconds
219336599|NCT05627414|DRUG|Disitamab Vedotin|2.5mg/kg，IV，Q3W
219336600|NCT05627414|DRUG|Sintilimab|200 mg，IV，Q3W
219336601|NCT05627414|DRUG|S-1|40\~60mg / m2, bid, d1-14, repeated every 3 weeks.
219336602|NCT05627414|PROCEDURE|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
219336603|NCT02092012|DRUG|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
219336604|NCT02092012|DRUG|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
219336605|NCT05129059|OTHER|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
219336606|NCT06148376|OTHER|Personalized treatment|Discontinue prandial insulin treatment
219336607|NCT01083004|PROCEDURE|Indocyanine green|Using indocyanine green as intraoperative dye
219336608|NCT01083004|PROCEDURE|Brilliant blue arm|Using brilliant blue as intraoperative dye
219336609|NCT03269435|PROCEDURE|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
219336610|NCT03269435|DRUG|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
219336611|NCT00295711|DRUG|Bicifadine|
219336612|NCT00300664|DRUG|Human Growth hormone|
219336613|NCT04178759|PROCEDURE|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
219336614|NCT04252053|OTHER|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
219336615|NCT04252053|OTHER|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
219336616|NCT04490863|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
219336617|NCT01496131|RADIATION|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
219336618|NCT01496131|DRUG|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
219336619|NCT01496131|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
219336620|NCT01496131|DRUG|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
219336621|NCT03199664|RADIATION|NB-UVB|NB-UVB given twice weekly for 6 months
219336622|NCT03199664|COMBINATION_PRODUCT|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
219336623|NCT00662402|OTHER|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
219336624|NCT00271596|DRUG|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
219336625|NCT00271596|DRUG|Placebo|a daily matching placebo administered over 16 weeks
219336626|NCT05993559|RADIATION|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
219336627|NCT05993559|RADIATION|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
219336628|NCT01555047|PROCEDURE|IUI|intrauterine insemination
219336629|NCT01555047|PROCEDURE|IUI|intrauterine insemination
219336630|NCT01329679|DIETARY_SUPPLEMENT|Energy Drink|Energy drink, 2oz twice daily for 7 days
219336631|NCT01329679|OTHER|Placebo|Water, lime juice and cherry flavoring
219336632|NCT00870766|PROCEDURE|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
219336633|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
219336634|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
219336635|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
219336636|NCT02512809|DRUG|Isoflurane|
219336637|NCT02512809|DRUG|Dexmedetomidine|
219336638|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
219336639|NCT01431274|DRUG|tiotropium|low dose
219336640|NCT01431274|DRUG|olodaterol|one dose only
219336641|NCT01431274|DRUG|tiotropium|high dose
219336642|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
219336643|NCT01431274|DEVICE|Respimat|Respimat inhaler
219336644|NCT01069172|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
219336645|NCT01069172|PROCEDURE|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
219336646|NCT05119608|BEHAVIORAL|CBT/ACT|10-session ACT-re-enforced CBT intervention.
219336647|NCT06000995|OTHER|Survey Questions|Thirty questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure.
219336648|NCT01944683|OTHER|Placebo|
219336649|NCT01944683|DRUG|GGF2|
219336650|NCT01944683|DRUG|Midazolam|
219336651|NCT03944226|DIETARY_SUPPLEMENT|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
219336652|NCT00003004|DRUG|alvocidib|
219336653|NCT00003004|DRUG|cisplatin|
219336654|NCT00003004|DRUG|paclitaxel|
219336655|NCT04967560|DEVICE|deep brain stimulation|Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
219336656|NCT03948100|OTHER|Educational Intervention|Undergo dyadic education program
219336657|NCT03948100|OTHER|Quality-of-Life Assessment|Ancillary studies
219336658|NCT03948100|OTHER|Questionnaire Administration|Ancillary studies
219336659|NCT03948100|PROCEDURE|Yoga|Undergo dyadic yoga
219336660|NCT03388242|OTHER|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
219336661|NCT03901079|OTHER|single-arm study|single-arm study
219336662|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks"
219336663|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks"
219336664|NCT03764371|DIAGNOSTIC_TEST|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
219336665|NCT02773030|DRUG|CC-220|Specified dose on specified days
219336666|NCT02773030|DRUG|Dexamethasone|Specified dose on specified days
219336667|NCT02773030|DRUG|Daratumumab|Specified dose on specified days
219336668|NCT02773030|DRUG|Bortezomib|Specified dose on specified days
219336669|NCT02773030|DRUG|Carfilzomib|Specified dose on specified days
219336670|NCT03655808|BIOLOGICAL|Bronchial basal cells (BBCs)|Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
219336671|NCT03655808|PROCEDURE|Bronchoscopic airway clearance treatment （B-ACT）|The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
219336672|NCT05223660|DRUG|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
219336673|NCT05223660|DRUG|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
219336674|NCT05223660|DRUG|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
219336675|NCT05223660|DRUG|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
219336676|NCT00488722|DRUG|Zoladex|
219336677|NCT01345396|BEHAVIORAL|Health education about asthma|Three face-to-face appointments (\<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
219336678|NCT02973087|BIOLOGICAL|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
219336679|NCT02973087|BIOLOGICAL|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
219336680|NCT05520645|DRUG|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
219336681|NCT05520645|DRUG|propofol|use propofol for anesthesia induction in hysteroscopic surgery
219336682|NCT00020579|DRUG|entinostat|
219336683|NCT01637909|DRUG|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
219336684|NCT01637909|DIETARY_SUPPLEMENT|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
219336685|NCT01637909|OTHER|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
219336686|NCT02975427|OTHER|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
219336687|NCT02607683|DRUG|XAF5 (concentration A: 0.1%)|
219336688|NCT02607683|DRUG|XAF5 (concentration B: 0.035%)|
219336689|NCT02607683|DRUG|Matching placebo|
219336690|NCT01565915|DEVICE|Perlane-L|Perlane-L Injection in the midface
219336691|NCT01565915|OTHER|Non-treatment|Non-treatment Arm
219336692|NCT05449990|OTHER|Participation in PFCC-IR|Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
219336693|NCT01506960|DEVICE|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
219336694|NCT03093753|OTHER|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
219336695|NCT03093753|OTHER|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
219336696|NCT03093753|OTHER|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
219336697|NCT03093753|DIETARY_SUPPLEMENT|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
219336698|NCT03093753|OTHER|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
219336699|NCT03093753|DIETARY_SUPPLEMENT|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
219336700|NCT03093753|OTHER|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
219336701|NCT03093753|DIETARY_SUPPLEMENT|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
219336702|NCT03093753|OTHER|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
219336703|NCT03093753|OTHER|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
219336704|NCT03093753|OTHER|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
219336705|NCT03093753|OTHER|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
219336706|NCT03093753|OTHER|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
219336707|NCT03093753|OTHER|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
219336708|NCT00450723|DRUG|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
219336709|NCT00450723|PROCEDURE|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
219336710|NCT00450723|PROCEDURE|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
219336711|NCT00450723|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
219336712|NCT00450723|PROCEDURE|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
219336713|NCT00450723|RADIATION|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
219336714|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions|Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.
219336715|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions using intraoral scanners|Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
219336716|NCT04572880|PROCEDURE|Trabeculectomy|Trabeculectomy is performed
219336717|NCT04572880|DEVICE|XEN®|Microinvasive Surgery with XEN® is performed
219336718|NCT04572880|DEVICE|Preserflo®|Microinvasive Surgery with Preserflo® is performed
219336719|NCT01905163|PROCEDURE|Tumor Debulking Surgery by laparoscopy|
219336720|NCT02163083|PROCEDURE|ICG|Improvement of detection of positive lymphnodes
219336721|NCT01713751|OTHER|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
219336722|NCT01713751|OTHER|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\]
219336723|NCT02047136|OTHER|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
219336724|NCT02047136|OTHER|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
219336725|NCT05281796|DIAGNOSTIC_TEST|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
219336726|NCT05281796|DIAGNOSTIC_TEST|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
219336727|NCT06034171|DEVICE|dental implant|Dental implant surgery in the lower jawbone.
219336728|NCT02660203|PROCEDURE|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
219355471|NCT01348997|BEHAVIORAL|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
219355472|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
219336729|NCT01500122|DRUG|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
219336730|NCT00932360|DEVICE|TENS|Active TENS, Placebo TENS and No Treatment TENS
219336731|NCT06368167|DRUG|SHR2554|SHR2554
219336732|NCT05126108|PROCEDURE|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
219336733|NCT05126108|OTHER|Recurrent nerves monitoring|Recurrent nerves monitoring
219336734|NCT01753128|DRUG|imipramine|
219336735|NCT04417764|PROCEDURE|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
219336736|NCT04417764|BIOLOGICAL|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10\^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
219336737|NCT04296214|DRUG|5-azacitidine|Cycles of 28 days
219336738|NCT05381142|DRUG|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
219336739|NCT05381142|DRUG|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
219336740|NCT00627653|DRUG|fenofibrate|148mg daily for 30 days
219336741|NCT04143009|BEHAVIORAL|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
219336742|NCT04143009|OTHER|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
219336743|NCT04143009|BEHAVIORAL|Adapted Friendship Bench|Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
219336744|NCT00787462|DRUG|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
219336745|NCT00787462|DRUG|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
219355473|NCT06649942|DRUG|KP-001|KP-001 400 mg
219355474|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
219355475|NCT06649942|DRUG|Placebo|Placebo
219355476|NCT06856473|OTHER|Traditional Physical Therapy|Traditional Physical Therapy based on neurodevelopmental technique
219355477|NCT06856473|OTHER|Dry Needling|Dry Needling in addition to the same traditional physical therapy program
219336746|NCT06504537|OTHER|THERAGUN PERCUSSION THERAPY|In Group A, Patients will receive Theragun Percussion therapy along with routine Physical Therapy Treatment. The range of motion of lateral flexion and forward flexion will take by using a bubble inclinometer. Then the patient will place in a sitting position with the shoulder area exposed. Percussion therapy by using the Theragun device will give by a specific order. Treatment will start with the percussion head applied at the origin and insertion heads of the trapezius, Rhomboid and scalene muscle for 3-4 minutes each. Following this the percussive Theragun applicator will applied with circular strokes along the length of the muscle for 3 minutes. The pressure of application will adjust to the subject's tolerance.
219336747|NCT06504537|OTHER|COMPRESSION THERAPY|In Group B, Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks. The cap will store in a freezer (15-18°C). At the onset of the migraine attacks, patients wore the cap and used it. We will choose 25 minutes as the time for application of the gel cap based on the results of two published studies.(23) Headache severity will measured by Visual Analogue Scale and pain relief will measured on a similar scale. Analgesic treatment will not take within 25 minutes after the onset of cold therapy. If patients did not experience adequate relief from the headache, we will allow them to use analgesics 25 minutes after the onset of cold therapy. The routine physical treatment will be same as in group A.
219336748|NCT00846300|BEHAVIORAL|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
219336749|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
219336750|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
219336751|NCT02384902|OTHER|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
219336752|NCT01268358|DRUG|Lamazym|Lamazym, ERT, infusion weekly
219336753|NCT03755570|DIAGNOSTIC_TEST|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
219336754|NCT03755570|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
219336755|NCT03755570|DIAGNOSTIC_TEST|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
219336756|NCT03755570|DIAGNOSTIC_TEST|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
219336757|NCT03755570|DIAGNOSTIC_TEST|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
219336758|NCT01064674|OTHER|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
219336759|NCT05003622|DRUG|Encorafenib|oral capsule
219336760|NCT05193253|PROCEDURE|Radiofrequency ablation|Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
219336761|NCT05193253|PROCEDURE|Liver resection|Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
219336762|NCT05193253|PROCEDURE|Liver transplantation|Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
219336763|NCT04086082|DEVICE|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
219336764|NCT06241092|OTHER||
219336765|NCT01271192|PROCEDURE|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
219336766|NCT01271192|PROCEDURE|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
219336767|NCT06265857|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
219336768|NCT06265857|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
219355478|NCT07006714|DRUG|Vitamin D3|Patients with a Vitamin D3 level of less than 30 nanograms per milliliter will receive a single oral (pill) dose of 300,000 international units of vitamin D3.
219355479|NCT07028788|OTHER|Health Education Material|Weekly electronic health education handbooks covering nutrition, sleep, shift work, stress awareness, and digital device use.
219355480|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness|Guided mindfulness practice via mobile app using pre-recorded 360° natural environment video.
219355481|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness combined with Breathing|Mindfulness training combined with brief structured breathing exercises via mobile app using 360° nature video.
219336769|NCT06265857|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219336770|NCT06040242|OTHER|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
219336771|NCT05571228|BEHAVIORAL|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
219336772|NCT02921074|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
219336773|NCT02921074|OTHER|Commercially available computerized training|
219336774|NCT02384668|DIETARY_SUPPLEMENT|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
219336775|NCT02384668|DIETARY_SUPPLEMENT|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
219336776|NCT00013208|BEHAVIORAL|Case Management|
219336777|NCT03008850|DRUG|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
219336778|NCT03008850|DRUG|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
219336779|NCT02381405|DIETARY_SUPPLEMENT|Enterade beverage|
219336780|NCT00890032|BIOLOGICAL|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
219336781|NCT02301182|DEVICE|ADM X3-MoP Cup|
219336782|NCT02301182|DEVICE|CoC Cup|
219336783|NCT00382746|DEVICE|EarlySense monitoring device|
219336784|NCT06430853|BEHAVIORAL|Step count goal|The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive weekly reminders that are tailored for their intervention arm. Intervention group participants will also receive a step count diary with motivational ideas of how to obtain step goals, which will be reviewed with a study team member every 2 weeks.
219336785|NCT06430853|DEVICE|Actigraph watch|Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
219336786|NCT06641999|DEVICE|Tinnitus Implant System|Implanted with Tinnitus Implant System: Active Implantable Medical Device
219336787|NCT04917848|OTHER|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
219336788|NCT03318380|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
219336789|NCT03775330|RADIATION|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm"
219336790|NCT03775330|RADIATION|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
219336791|NCT05057949|DRUG|Larotinib|Larotinib Capsules
219336792|NCT05057949|DRUG|Rifampin|Rifampin Capsules
219336793|NCT05057949|DRUG|Itraconazole|Itraconazole Capsules
219336794|NCT06278935|BEHAVIORAL|Lifestyle-based intervention by an occupational therapist|Participants with diabetic foot ulcers will be offered lifestyle-based treatment sessions virtually for up to 8 sessions (\~8 weeks) with a licensed occupational therapist.
219336795|NCT01031550|DRUG|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
219336796|NCT01031550|DRUG|propofol|standard of care
219336797|NCT06424951|BEHAVIORAL|LKCM(Loving-kindness and Compassion Meditations)|Loving-kindness and Compassion Meditations
219336798|NCT00050154|DRUG|ZARNESTRA, tipifarnib, R115777|
219336799|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
219336800|NCT05510700|DEVICE|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
219355482|NCT07028788|BEHAVIORAL|VR-Based Mindfulness combined with Breathing|Virtual reality-delivered mindfulness and structured breathing training using immersive 360° natural environment video.
219336801|NCT05510700|DEVICE|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
219336802|NCT03497806|BIOLOGICAL|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
219336803|NCT02247245|DRUG|Ivabradine|Ivabradine 7.5mg
219336804|NCT02247245|OTHER|Atrial fibrillation|Pacemaker base rate alteration
219336805|NCT02247245|DRUG|Placebo|Placebo
219336806|NCT01045798|DRUG|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
219336807|NCT01045798|DRUG|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
219336808|NCT01529099|DEVICE|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
219336809|NCT05424484|DEVICE|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
219336810|NCT06464692|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
219336811|NCT06966726|BEHAVIORAL|Positive Dental Imagery|Children were shown four A4-sized laminated color images depicting positive dental scenes (e.g., children interacting happily with the dentist, smiling after treatment) for 2 minutes prior to the procedure.
219336812|NCT06966726|BEHAVIORAL|Neutral Nature Imagery|Children were shown four A4-sized laminated color images depicting neutral nature scenes (e.g., a beach, sunset, flowers) for 2 minutes prior to the procedure.
219336813|NCT06968793|PROCEDURE|Pressure support 15|Pressure support of 15 cm H2O will be applied for 5 minutes.
219336814|NCT06968793|PROCEDURE|Pressure support 13|Pressure support of 13 cm H2O will be applied for 5 minutes.
219336815|NCT06968793|PROCEDURE|Pressure support 11|Pressure support of 11 cm H2O will be applied for 5 minutes.
219336816|NCT06968793|PROCEDURE|Pressure support 9|Pressure support of 9 cm H2O will be applied for 5 minutes.
219336817|NCT06968793|PROCEDURE|Pressure support 7|Pressure support of 7 cm H2O will be applied for 5 minutes.
219336818|NCT06968793|PROCEDURE|Pressure support 5|Pressure support of 5 cm H2O will be applied for 5 minutes.
219336819|NCT06971484|DIETARY_SUPPLEMENT|Crystalline glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in a caplet.
219336820|NCT06971484|DIETARY_SUPPLEMENT|Regular glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in hard gel capsules.
219336821|NCT06344351|DRUG|TQB3006 tablets|TQB3006 is an inhibitor protein.
219336822|NCT01651715|DRUG|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
219336823|NCT00411359|BEHAVIORAL|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
219336824|NCT05680922|BIOLOGICAL|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
219336825|NCT05555862|DRUG|Artesunate|artesunate formulated as intra-anal suppositories
219336826|NCT05555862|DRUG|Placebo|placebo intra-anal suppository
219336827|NCT00761618|PROCEDURE|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
219336828|NCT00761618|PROCEDURE|IPC Placement|IPC placed in chest cavity to drain excess fluid
219336829|NCT00761618|RADIATION|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
219336830|NCT04929210|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219336831|NCT04929210|DRUG|Placebo|Matching placebo will be administered as subcutaneous injection.
219336832|NCT06805630|DIAGNOSTIC_TEST|Femto Human DNA Quantification Kit|Urine methylation biomarker test
219336833|NCT01739569|OTHER|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
219336834|NCT03779971|OTHER|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
219336835|NCT03779971|OTHER|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
219336836|NCT03779971|OTHER|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
219336837|NCT00498160|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
219336838|NCT06026748|DRUG|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
219336839|NCT06026748|DRUG|Placebo|Placebo contains only excipients.
219336840|NCT02988180|OTHER|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
219336841|NCT02988180|OTHER|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
219336842|NCT03715894|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
219336843|NCT05166629|BEHAVIORAL|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
219336844|NCT05166629|BEHAVIORAL|Usual Care|Please see above description of usual care.
219336845|NCT00625209|DRUG|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
219336846|NCT00625209|DRUG|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
219336847|NCT00625209|DRUG|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
219336848|NCT00625209|DRUG|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
219336849|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
219336850|NCT05425004|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
219336851|NCT05102370|DRUG|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
219336852|NCT03255252|DRUG|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
219336853|NCT03255252|COMBINATION_PRODUCT|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
219336854|NCT06975163|BEHAVIORAL|Mindfulness-Based Stigma Stress Reduction (MBSSR) program|The MBSSR program was developed by modifying elements from the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) programs to create a distinct mindfulness intervention targeted at alleviating stigma stress among parents of autistic children. This program consisted of four group sessions, each incorporating mindfulness practices, group discussions, and activities that helped participants apply mindfulness principles to their daily lives.
219336855|NCT05496543|DEVICE|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
219336856|NCT05496543|DEVICE|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
219336857|NCT03392792|DRUG|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
219336858|NCT03392792|PROCEDURE|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
219336859|NCT04837001|DRUG|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
219336860|NCT04837001|OTHER|Placebo|Placebo will be administered as a single bolus injection.
219336861|NCT02639572|BIOLOGICAL|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
219336862|NCT02639572|BIOLOGICAL|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
219336863|NCT04694664|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
219336864|NCT05097144|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
219336865|NCT05097144|DEVICE|Lens B (asmofilcon A)|Daily wear for one month
219336866|NCT03100071|DRUG|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
219336867|NCT01530412|OTHER|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
219336868|NCT02130739|PROCEDURE|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
219336869|NCT02130739|PROCEDURE|mastectomy|mastectomy with/without breast reconstruction
219336870|NCT02130739|DRUG|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
219336871|NCT02130739|DRUG|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
219336872|NCT02130739|DRUG|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
219336873|NCT05321069|DRUG|BI 1015550|Participants received film-coated nerandomilast tablets orally twice daily at doses of either 9 mg or 18 mg, with each dose administered at least 12 hours apart and taken with 250 mL of water.
219336874|NCT05321069|DRUG|Placebo|Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally twice daily, with doses given at least 12 hours apart and each taken with 250 mL of water.
219336875|NCT03817554|DRUG|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
219336876|NCT03817554|OTHER|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
219336877|NCT04422548|PROCEDURE|AI-assisted Colonoscopy|This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
219336878|NCT04422548|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
219336879|NCT02603471|OTHER|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
219336880|NCT02603471|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
219336881|NCT01816412|DEVICE|MD02-LDCB Paclitaxel coated balloon catheter|
219336882|NCT01816412|PROCEDURE|Standard Uncoated Balloon Angioplasty Catheter|
219336883|NCT04224844|OTHER|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
219336884|NCT04224844|OTHER|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
219336885|NCT03999658|BIOLOGICAL|STI-3031|anti-PD-L1 antibody
219336886|NCT00199602|DRUG|warfarine - low molecular heparin|
219336887|NCT02806128|DRUG|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
219336888|NCT02441413|RADIATION|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
219336889|NCT03275220|DIAGNOSTIC_TEST|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
219336890|NCT06317025|DIAGNOSTIC_TEST|Multi-modal Intelligent Anesthesia Monitoring System|To evaluate the sensitivity and specificity of self-developed anesthesia monitoring systems in diagnosing the depth of anesthesia (too deep or too shallow)
219336891|NCT02113943|DRUG|Citalopram 30mg|
219336892|NCT02401321|BEHAVIORAL|Telephone-Based Intervention|Complete Taking Care of Her program
219336893|NCT02401321|OTHER|Caregiver-Assisted Training|Complete Taking Care of Her program
219336894|NCT02401321|OTHER|Questionnaire Administration|Ancillary studies
219336895|NCT02401321|OTHER|Quality-of-Life Assessment|Ancillary studies
219336896|NCT00450242|DRUG|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
219336897|NCT00450242|DRUG|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
219336898|NCT06475313|BEHAVIORAL|plaque index assessment, periodontal probing, Bleeding on probing (BOP), Prosthetic adjacency check, initial occlusal contact, maximum occlusal contact, and filling of the cusps.|oral panoramic radiograph
219336899|NCT05691049|DEVICE|HCC_45|"Dosage form: HCC\_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
219336900|NCT04881071|DEVICE|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
219336901|NCT04881071|OTHER|Usual clinical practice|Participants will receive the usual clinical practice
219336902|NCT03236220|DRUG|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
219336903|NCT00447512|DRUG|ghrelin|acylated ghrelin
219336904|NCT04260412|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
219336905|NCT04260412|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
219336906|NCT04260412|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
219336907|NCT01803321|DRUG|rilonacept (IL-1 Trap)|
219336908|NCT01803321|OTHER|Placebo|
219336909|NCT05407909|DRUG|SYHX2001|SYHX2001 tablets, oral
219336910|NCT04169022|OTHER|Sample collection|Sample collection blood and/or bone marrow
219336911|NCT04170803|DEVICE|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
219336912|NCT04170803|OTHER|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
219336913|NCT06125912|OTHER|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
219336914|NCT06125912|OTHER|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
219336915|NCT05886712|OTHER|Naloxone|Naloxone
219336916|NCT05886712|OTHER|Usual intervention|usual administered drug for overdose
219336917|NCT04644939|OTHER|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
219336918|NCT04644939|OTHER|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
219336919|NCT04644939|OTHER|Colonoscopy|Patients will undergo colonoscopy
219336920|NCT00687440|DRUG|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
219336921|NCT00687440|DRUG|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
219336922|NCT00687440|DRUG|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
219336923|NCT00290199|DEVICE|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
219336924|NCT02829242|DEVICE|NIRS Monitoring (SenSmart Monitor)|
219336925|NCT03352700|DRUG|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
219336926|NCT03352700|DRUG|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
219336927|NCT02817971|BEHAVIORAL|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
219336928|NCT02817971|BEHAVIORAL|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
219336929|NCT00577109|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
219336930|NCT00577109|DRUG|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
219336931|NCT00577109|DRUG|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
219336932|NCT00577109|DRUG|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
219336933|NCT00577109|DRUG|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
219336934|NCT01837030|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
219336935|NCT01837030|DEVICE|Capsule Endoscopy|GIVEN capsule
219336936|NCT00278642|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
219336937|NCT03072784|PROCEDURE|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
219336938|NCT04127253|DEVICE|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
219336939|NCT04127253|DEVICE|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
219336940|NCT04127253|BEHAVIORAL|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
219336941|NCT03180099|DRUG|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
219336942|NCT03180099|DRUG|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
219336943|NCT02324075|BEHAVIORAL|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
219336944|NCT03321227|OTHER|Snack skipping|No snack provided
219336945|NCT03321227|OTHER|Whole eggs|2 whole large eggs scrambled, provided as a snack
219336946|NCT03321227|OTHER|Egg whites|2 egg whites scrambled, provided as a snack
219336947|NCT03321227|OTHER|Egg yolks|2 egg yolks scrambled, provided as a snack
219336948|NCT03321227|OTHER|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
219336949|NCT04623203|OTHER|No intervention|No intervention
219336950|NCT00474110|DRUG|Ketamine & hydromorphone|See Detailed Description
219336951|NCT03588988|DRUG|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
219336952|NCT03588988|DRUG|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
219336953|NCT01660360|BIOLOGICAL|Tanibirumab|
219336954|NCT04084067|DRUG|Indocyanine Green|IV
219336955|NCT00000421|DRUG|Prednisone|
219336956|NCT00000421|DRUG|Placebo|
219336957|NCT04609735|OTHER|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
219336958|NCT04609735|OTHER|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
219336959|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
219336960|NCT05820633|RADIATION|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
219336961|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
219336962|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
219336963|NCT05820633|RADIATION|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
219336964|NCT05820633|RADIATION|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
219336965|NCT05820633|RADIATION|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
219336966|NCT05820633|RADIATION|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
219336967|NCT03592966|DIETARY_SUPPLEMENT|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
219336968|NCT03592966|DIETARY_SUPPLEMENT|Placebo|Freeze-dried placebo powder
219336969|NCT03865212|DRUG|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
219336970|NCT03321370|DIAGNOSTIC_TEST|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
219336971|NCT05264740|BEHAVIORAL|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
219336972|NCT05264740|BEHAVIORAL|Educational materials|The control group will receive educational material only.
219336973|NCT06977165|DIAGNOSTIC_TEST|Antibiotic quantification|Piperacillin/tazobactam quantification using liquid chromatography-tandem mass spectrometry
219336974|NCT06978322|PROCEDURE|Immediate surgery|Patients will undergo upfront surgery, then adjuvant chemotherapy.
219336975|NCT06978322|PROCEDURE|Neoadjuvant chemotherapy|Patients will undergo neoadjuvant chemotherapy, then surgery.
219336976|NCT06979024|GENETIC|Triplet-primed PCR or Long-read sequencing|This study involves long-read sequencing in patients with Myotonic Dystrophy Type 1 (DM1) to identify specific motifs, determine the range of repeat numbers, and assess the presence of interruptions in the CTG repeat sequence. The aim is to gain insights into the genetic variability and its clinical implications in DM1.
219336977|NCT06977659|DRUG|Norepinephrine|Norepinephrine bitartrate (LEVOPHEDR, Pfizer inc.) 4 mg/4ml + 5% Dextrose in water 246 ml (total volume 250 ml, final concentration 16 mcg/ml) infuses intravenously via a central catheter or peripheral line with the rate of 10 ml/h (equivalent to 0.05 mcg/kg/min for a 50-kg patient). The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
219336978|NCT06977659|DRUG|Placebo|5% Dextrose in water 250 ml infused intravenously at a rate of 10 ml/h. The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
219336979|NCT06978699|DRUG|XH-S003 Capsule|25mg \& 100mg
219336980|NCT06978075|DEVICE|Chest wall tumor resection by the artificial intelgent assistent|we plan to carry out of the research on the application of artificial intelligence (AI) assisted chest wall tumor research combined with a personalized 3D preformed chest wall defect reconstruction system in chest wall tumor surgery. Data will be imported into a computer to draw a 3D model of the tumor and construct an ideal resection range to ensuring sufficient surgical margins while avoiding damage to important nerve and vascular tissues in the chest. Preformed titanium plates will be prepared based on the calculated resection range and the titanium plates will be detachable assembly components through screws, which can be adjusted at any time according to the surgical situation.
219336981|NCT06978478|PROCEDURE|Unlabelled PET CT Scan|\[18F\]-FDG-PET CT
219336982|NCT06978478|PROCEDURE|Labelled PET CT Scan|\[18F\]-FBA-A20FMDV2 -PET CT
219336983|NCT06978777|DRUG|Caffeine (200 mg)|single dose of 200mg caffeine orally in study visit A
219336984|NCT06978777|DRUG|Placebo|single dose of 1 tablet Placebo in study visit B
219336985|NCT06978023|COMBINATION_PRODUCT|JM-LD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix Lonicerae Japonicae Flos (CAL) plus low dose extract of Ophiopogonis Radix
219336986|NCT06978023|COMBINATION_PRODUCT|JM-HD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix, Lonicerae Japonicae Flos (CAL) plus high dose extract of Ophiopogonis Radix
219336987|NCT06978023|COMBINATION_PRODUCT|Placebo|Placebo consisting of excipients, coloring and food ingredients to provide a powder mixture of same weight with similar color, texture and odour
219336988|NCT06977919|BEHAVIORAL|NASM OPT Program|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included bench presses, chest flyes, and push-ups.
219336989|NCT06977919|BEHAVIORAL|General Exercise|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
219336990|NCT06977412|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of breast cancer|The CT scan is part of the standard treatment protocol.
219336991|NCT06977932|DRUG|Carbarmazepine|If patients were on carbamazepine (CBZ) prior to enrollment, the CBZ dose remained unchanged after enrollment; if patients were on oxcarbazepine (OXC) prior to enrollment, they received half of their pre-enrollment OXC dose as CBZ after enrollment. Orally administered for four consecutive weeks.
219336992|NCT06977932|PROCEDURE|Sham Electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent + GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent + ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
219336993|NCT06977932|DRUG|Carbarmazepine Placebo|CBZ placebo is a tablet with identical packaging and appearance to CBZ but lacks therapeutic effects. If patients were receiving CBZ prior to enrollment, they were transitioned to a CBZ placebo at an equivalent daily dose post-enrollment. For patients previously treated with oxcarbazepine, the post-enrollment regimen consisted of a CBZ placebo administered at half the pre-enrollment oxcarbazepine dose. Orally administered for four consecutive weeks.
219336994|NCT06977932|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
219336995|NCT06978205|DEVICE|Urethral Balloon Dilation|Urethral balloon dilation + conventional rehabilitation therapy. 1.A 14-Fr urethral catheter will be prefilled with sterile saline to check for balloon integrity. If intact, the saline will be completely withdrawn. 2.Ultrasound imaging will be used to precisely locate the external urethral sphincter. 3.The catheter will be fully lubricated and gently inserted into the urethra. 4.Under real-time ultrasound guidance, 2-4 mL of sterile saline will be gradually injected into the balloon to expand the external urethral sphincter. 5.Patients will be instructed to attempt urination during the procedure, and changes in voiding patterns will be observed. This procedure will be performed three times per participant. The expansion volume will increase by 0.5-1 mL per session, depending on urethral outlet resistance (urodynamic results) and degree of urethral narrowing (ultrasound assessment）Each session lasts 5 minutes. Strict aseptic techniques will be followed.
219336996|NCT06978205|DEVICE|intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine.
219336997|NCT06978205|DEVICE|Acupuncture treatment|Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints.
219336998|NCT06978205|BEHAVIORAL|Pelvic floor function training|The pelvic floor therapist assesses the patient's pelvic floor muscle condition and guides the patient to perform effective pelvic floor muscle contractions and relaxations.
219336999|NCT06340451|DEVICE|iovera° system|subjects will receive ultrasound-guided iovera° system treatment
219337000|NCT06340451|DEVICE|sham iovera° system treatment|subjects will receive ultrasound-guided iovera° sham system treatment
219337001|NCT06316297|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: Liquid suspension for injection Route of administration: intramuscular
219337002|NCT06316297|OTHER|Placebo|Pharmaceutical form: Liquid solution for injection Route of administration: intramuscular
219337003|NCT05229926|DEVICE|CareCube|modular, disposable, negative pressure, isolation patient care system
219337004|NCT01538628|DEVICE|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
219337005|NCT04086004|OTHER|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
219337006|NCT04086004|OTHER|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
219337007|NCT02410304|DEVICE|Xrays|Clinical evaluation
219337008|NCT02410304|DEVICE|Ultrasound (B mode )|
219337009|NCT02410304|DEVICE|Ultrasound (D mode)|
219337010|NCT06978569|DEVICE|Injectable Acellular dermal matrix hydrogel|An injectable, sterile acellular dermal matrix (ADM) gel derived from processed biological tissue, designed to promote healing in chronic wounds. The gel is injected directly onto the wound bed following standard debridement and serves as a biocompatible scaffold to support granulation tissue formation, epithelialization, and wound closure. After application, the wound is covered with a standard secondary dressing. Dressing changes are performed every 2 to 3 days or as clinically indicated.
219337011|NCT06978569|DEVICE|Alginate dressing|A sterile, absorbent alginate wound dressing composed of natural polysaccharide fibers derived from seaweed. Following standard debridement, the alginate dressing is applied directly to the wound bed to manage exudate and maintain a moist wound environment conducive to healing. The dressing is covered with a secondary dressing and changed according to the manufacturer's instructions and clinical protocol.
219337012|NCT06978790|OTHER|Generative Artificial Intelligence Nurse Staffing (GAINS) Intervention|The Generative Artificial Intelligence intervention is an industrial engineering and nursing-informed innovation developed to optimize team-based staffing of registered nurses and nursing assistants. We anticipate that the GAINS intervention will enhance staffing efficiency, reduces reliance on travel nurses, minimizes overtime costs, and supports nurse well-being by proactively managing workload distribution and reducing burnout. At the core of GAINS is a generative AI model that predicts future unit-level staffing needs using historical staffing patterns, patient turnover (admissions and discharges), and patient acuity scores (based on ICU versus medical/surgical status, physician orders, charge nurse input, and other clinical factors) reflective of workload. Based on the prediction, the intervention dynamically recommends float pool assignments by evaluating staffing gaps across units and optimally deploying available nurses and nursing assistants to where they are most needed.
219337013|NCT06977295|DEVICE|Diagnostic Software Application for CAD Assessment|A novel on-premises diagnostic software integrating automated coronary stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification for evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) datasets.
219337014|NCT06587243|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
219337015|NCT06587243|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
219337016|NCT01147198|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
219337017|NCT01147198|DIETARY_SUPPLEMENT|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
219337018|NCT06985173|DEVICE|Occlusal splints manufactured with fully digital workflow.|The intervention involves the fabrication of 3D printed occlusal splint with fully digitalization technique by the aid of Jaw Tracing Device. The acquisition and scanning of the patients are done by using an intra oral scanner and designing them using a designing software. This device will be printed with a 3D printer utilizing printable resin material
219337019|NCT06985173|DEVICE|Occlusal splints manufactured with Conventional workflow|For the comparator group, maxillary and mandibular impressions will be made with Cavex CA37 alginate impression material (Cavex Holland B.V, Holland), models will be poured with gypsum (Kimberlit, Type IV Dental Stone, Protechno Spain), facebow (Bio-art) record and interocclusal registrations will be recorded at centric by using bite registration material after patient deprogramming with Lucia jig. The models will be mounted in a semi-adjustable articulator (Bio-art, A7Plus, Brazil), wax pattern fabrication on surveyed and mounted casts to be invested finally to form a clear, heated-cured acrylic resin splint
219337020|NCT06195488|PROCEDURE|Gastric ultrasound|performing gastric ultrasound to determine gastric contents
219337021|NCT06439082|BIOLOGICAL|Crizanlizumab|Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
219337022|NCT06439082|DRUG|Placebo|Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
219337023|NCT02494258|DRUG|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
219337024|NCT06985134|DRUG|Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh|The present study included patients aged \>18 years with inflammatory low back pain fulfilling the Modified New York criteria \[12\], 2014 for moderate to severe ankylosing spondylitis. The criteria include radiographic sacroiliitis (at least grade II bilaterally or grade III unilaterally) along with clinical signs, such as inflammatory back pain for at least 3 months' duration, limitation of lumbar spine in sagittal and frontal planes, or chest expansion decreased relative to normal values for age and sex. Exclusion criteria were non-inflammatory back pain or back pain due to inflammatory causes other than AS, failure to confirm a washout period of four weeks, those who were on DMARDs, allergy to thalidomide, Sulfasalazine, and NSAIDs, known to have kidney diseases or cardiac disease, active peptic ulcer disease, and pregnancy.
219337025|NCT06680934|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
219337026|NCT06930781|DEVICE|Ponto implantation|Ponto implantation is a surgical procedure to implant a bone-anchored hearing device, improving hearing by transmitting sound directly to the inner ear through bone conduction.
219337027|NCT04497844|DRUG|Niraparib|Participants will receive Niraparib 200 mg once daily.
219337028|NCT04497844|DRUG|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
219337029|NCT04497844|DRUG|Prednisone|Participants will receive prednisone 5 mg once daily.
219337030|NCT04497844|DRUG|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
219337031|NCT06936904|PROCEDURE|injection speed|Patients undergoing CT-guided lung nodule localization were selected for the study, and ultrasound-guided erector spinae plane block was performed before surgery with different injection speed.
219337032|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
219337033|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
219337034|NCT07149844|DRUG|tea tree oil ointment|Petrolatum (petroleum jelly) was sterilized in the oven at 160°C for 90 min, then The ointment was prepared as 10% .
219337035|NCT07157917|OTHER|Protocol based|Apply a thirst safety management protocol
219337036|NCT07157917|OTHER|Control|Room air water
219337037|NCT07161063|BEHAVIORAL|Brief Family Therapy Program|The Lausanne Family Play - Brief is a video-feedback intervention adapted for families seeking support for a child two to nine years old with a mental health challenge. Feedback focuses on engagement, teamwork, conflict, and child-focused issues.
219337038|NCT07161479|PROCEDURE|Argon Plasma Coagulation (APC)|Ablation of gastric adenoma using argon plasma coagulation.
219337039|NCT07161479|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic resection of gastric adenoma by mucosal resection technique.
219337040|NCT07159789|DEVICE|Repetitive Transcranial Magnetic Stimulation|Treatment with the rTMS or sham rTMS will be scheduled daily 5x per week for a total of 6 consecutive weeks followed, after a 6 week pause, by another treatment session of 6 weeks where all patients will receive active rTMS treatment
219337041|NCT07161336|DRUG|Methotrexate (MTX)|One group will receive MTX, starting with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated. another group will receive placebo
219337042|NCT07161336|DRUG|Placebo|The investigational drug and the placebo will be formulated to be identical in appearance, packaging, labeling. Blinded study medications will be prepared, packaged, and labeled by the sponsor according to Good Manufacturing Practice (GMP) standards. All packaging will use neutral labeling with unique subject numbers only.
219337043|NCT07161180|DRUG|PBK_M2301 (levodropropizine + Pelargonium sidoides extract)|A single oral tablet containing levodropropizine 60 mg and Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
219337044|NCT07161180|DRUG|R1_PBK_M2301 (levodropropizine)|A single oral tablet containing levodropropizine 60 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
219337045|NCT07161180|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|A single oral tablet containing Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
219337046|NCT07159958|OTHER|Simulation-Based Vulvar Cancer and Self-Vulvar Examination Training|The topics covered include the definition of vulvar cancer, risk factors, symptoms, preventive measures to protect against cancer, the definition of KKVM, and the steps involved in performing an examination. The inspection phase of the examination was demonstrated using a light source and mirror on a simulated model of the external genitalia. In addition, the topic was reiterated by explaining on the model how palpation examination is performed, when it should be performed, what signs and symptoms to look for, and in which cases a doctor should be consulted.
219337047|NCT07160998|OTHER|Digital Lifestyle Therapeutic|Personalized real-time lifestyle recommendations delivered via smartphone/tablet, integrating CGM and wearable data.
219337048|NCT07160998|BEHAVIORAL|Standard Care|Participants receive standard diabetes management including medications and lifestyle recommendations based on guidelines.
219337049|NCT07146880|DRUG|Empagliflozin (EMPA)|Participants will take Empagliflozin once daily, starting at 10 mg. The dose will be increased to 25 mg at monthly follow-ups if participants are non-responders based on ECG ST-segment morphology. The total treatment period is three months.
219337050|NCT07161310|DIETARY_SUPPLEMENT|Urolithin A|Patients will receive urolithin A (UA) 1,000mg QD on from day -7 until day 60 (±7) of first-line ICI-based SACT.
219337051|NCT07161310|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo (PBO) on from day -7 until day 60 (±7) of first-line ICI-based SACT.
219337052|NCT07161310|OTHER|Bio specimens|Bio specimens (PBMC, plasma, stool) will be collected during screening and on days 1, 26 (±7) and 60 (±7) of ICI.
219337053|NCT07170020|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen has been shown in several case studies and retrospective studies to possibly improve mortality and morbidity in this patient population. One limitation of prior studies is many of them are retrospective. This study will be prospective.
219337054|NCT07170579|OTHER|Exercise|Participants engaged in High-Intensity Interval Training (HIIT) sessions three times per week, each lasting 60 minutes. Sessions included a 10-minute warm-up, a central HIIT block with cycles of aerobic exercises performed at high intensity (30-60 seconds) alternated with active recovery (60-90 seconds), followed by a 10-minute aerobic functional segment and a 10-minute cool-down with stretching. Exercises included modified jumping jacks, stationary marching, high knees, squats, and functional movements tailored to the participants' physical capacity. Training intensity was monitored using the Borg Rating of Perceived Exertion scale, targeting 13-17 during effort phases and 9-11 during recovery.
219337055|NCT07171021|DRUG|Theophylline 200 mg|taking theophylline (400 mg twice a day) and performing olfactory training for 6 months
219337056|NCT07171021|BEHAVIORAL|olfactory training|performing olfactory training for 6 months
219337057|NCT07171593|DIETARY_SUPPLEMENT|HMB|EEN+HMB
219337058|NCT07170228|DIETARY_SUPPLEMENT|Micellar Casein|"Participants consumed 30 g of micellar casein powder dissolved in 300 mL of water.~Supplement timing varied by group:~Post-Exercise Casein Ingestion Group (PECIG): Taken 10-15 minutes after completing the standardized high-intensity resistance training session.~Pre-Sleep Casein Ingestion Group (PSCIG): Taken 30-60 minutes before bedtime on the same day as the training session.~The control group received no supplementation. All supplements were prepared and monitored by the research team to ensure dosage accuracy and participant compliance."
219337059|NCT07171619|DRUG|Nirogacestat|oral dose of 150 mg nirogacestat
219337060|NCT07171619|DRUG|Nirogacestat and Famotidine|oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine
219337061|NCT07171619|DRUG|Nirogacestat and Rabeprazole|oral dose of 150 mg nirogacestat and oral dose of 20 mg rabeprazole
219337062|NCT07169903|PROCEDURE|Pulmonary segmentectomy|Segmentectomy is applied to lung adenocarcinomas with a diameter of 2-3 cm, in which intraoperative frozen pathology confirms a new pathological grade of 1-2.
219337063|NCT07171463|PROCEDURE|Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation|Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter
219337064|NCT07171463|PROCEDURE|Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion|Targeted application of radiofrequency energy at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical location of the superior paraseptal parasympathetic ganglion.
219337065|NCT07169695|DIAGNOSTIC_TEST|Slit Lamp Examination|The participant will have a slit lamp examination
219337066|NCT07169695|DIAGNOSTIC_TEST|Far Best Corrected Visual Acuity (BCVA)|The participant 's BCVA will be evaluated.
219337067|NCT07169695|DRUG|T1695|The participant should instill T1695.
219337068|NCT07169695|DRUG|Ciclosporin|The participant should instill Ciclosporin.
219337069|NCT07169695|DIAGNOSTIC_TEST|Corneal fluorescein staining score on modified Oxford scale|One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
219337070|NCT07170475|DRUG|Febuxostat|Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
219337071|NCT07170475|DRUG|Inosine|Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
219337072|NCT07169864|PROCEDURE|Simple Surgical Glove Compression Technique|Patients will wear surgical gloves of smaller size than the patient's hand, on the dominant hand from 15 minutes before the start of each neoadjuvant chemotherapy infusion until 15 minutes after the end of infusion (total of 90 minutes). The non-dominant hand will serve as the untreated control.
219337073|NCT07171073|DEVICE|RecoveriX|RecoveriX is a brain-computer interface (BCI) system designed for motor rehabilitation after stroke. It records brain activity using EEG and provides real-time feedback through virtual reality and functional electrical stimulation (FES). Participants imagine hand movements, and the system activates corresponding virtual movements and stimulates the muscles to support motor recovery.
219337074|NCT07171073|DEVICE|Gloreha Aria|Gloreha Aria is a robotic therapy system for upper limb rehabilitation. It combines mechanical assistance with virtual reality tasks to restore hand and finger movements. The device can be used in passive, assistive, or active modes, depending on the patient's abilities, and provides interactive exercises to improve motor function and neuroplasticity.
219337075|NCT07171073|DEVICE|E-Link System|E-Link is an interactive computer-based system for hand and finger rehabilitation. It uses sensors to capture movements and provides individualized motor training through interactive tasks. The system allows both active motor practice and objective assessment of fine motor skills and functional abilities.
219337076|NCT07171073|OTHER|Standard Occupational Therapy|The control group will receive conventional occupational therapy as part of standard rehabilitation. Therapy will include individualized exercises to improve motor, cognitive, and functional abilities, consistent with usual clinical practice.
219337077|NCT07170774|DEVICE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
219337078|NCT07170774|DEVICE|Sham|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
219337079|NCT00285129|DEVICE|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
219337080|NCT05767593|DEVICE|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
219337081|NCT02455570|OTHER|No intervention|No intervention
219337082|NCT04171375|DEVICE|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
219337083|NCT00764595|DRUG|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
219337084|NCT04046107|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
219337085|NCT05314608|COMBINATION_PRODUCT|IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee|Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
219337086|NCT00900458|BEHAVIORAL|Aerobic Exercise training|aerobic exercise training (cycling)
219337087|NCT00586261|DRUG|Pioglitazone|Pioglitazone 30 mg daily for 6 months
219337088|NCT00586261|DRUG|Placebo|Placebo 30 mg daily for 6 months
219337089|NCT00586261|DRUG|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
219337090|NCT03471702|DEVICE|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
219337091|NCT06001996|PROCEDURE|Pericapsular nerve group (PENG) block|Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
219337092|NCT06001996|PROCEDURE|Suprainguinal fascia iliaca plane block|Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
219337093|NCT01717287|DRUG|Raltegravir Film-coated Tablet|
219337094|NCT01717287|DRUG|Raltegravir Chewable Tablet|
219337095|NCT01717287|DRUG|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
219337096|NCT03700281|BEHAVIORAL|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
219337097|NCT03700281|BEHAVIORAL|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
219337098|NCT05827159|DRUG|Naltrexone Pill|In the MAUD component, some participants will receive oral Naltrexone in the ED.
219337099|NCT05827159|DRUG|Naltrexone Injection|In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
219337100|NCT05827159|BEHAVIORAL|Brief Negotiation Interview|Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
219337101|NCT05827159|DRUG|Gabapentin Pill|In the MAUD component, ancillary treatment with gabapentin will be provided.
219355483|NCT06746415|OTHER|Conventional Gait Training|onventional walking training group will be given 20 minutes of NMES, 20 minutes of weight transfer, stretching, mobilization, bobath exercises and 20 minutes of parallel bar walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks.
219337102|NCT01310790|PROCEDURE|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was \>30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
219337103|NCT03870984|DIETARY_SUPPLEMENT|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
219337104|NCT03870984|OTHER|w/oNUTS, low-caloric diet without nuts|low caloric diet
219337105|NCT03095794|OTHER|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
219337106|NCT03095794|OTHER|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
219337107|NCT03095794|OTHER|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
219337108|NCT03095794|OTHER|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
219337109|NCT02227628|DIETARY_SUPPLEMENT|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
219337110|NCT02227628|DIETARY_SUPPLEMENT|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
219337111|NCT01432249|DRUG|Enbrel group|will be decided by treating physicians
219337112|NCT05807360|DEVICE|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
219337113|NCT04340375|DIETARY_SUPPLEMENT|AP green tea extracts|AP green tea extracts
219337114|NCT05449197|OTHER|HEMOPHAR e-learning program|training on professional practice by following HEMOPHAR e-learning program
219337115|NCT02970214|OTHER|no intervention, only observational|no intervention, only observational
219337116|NCT00003283|DRUG|octreotide acetate|
219337117|NCT00003283|DRUG|prednisone|
219337118|NCT00658476|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 fatty acid supplements.
219337119|NCT00658476|BEHAVIORAL|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
219337120|NCT00658476|OTHER|Placebo|
219337121|NCT06536660|PROCEDURE|Magnesium bone plate and screw fixation in jaw surgery|Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.
219337122|NCT04066582|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
219337123|NCT00236834|DRUG|levofloxacin; imipenem/cilastitin|
219337124|NCT01110616|DRUG|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
219337125|NCT01110616|DRUG|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
219337126|NCT01110616|DRUG|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
219337127|NCT01417598|OTHER|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
219337128|NCT01417598|OTHER|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
219337129|NCT02889406|BEHAVIORAL|Motivational intervention|motivational interviewing schema
219337130|NCT05800548|OTHER|survey application|In data collection; Socio-demographic and obstetric characteristics of puerperant women, descriptive information form including questions about current birth, Postpartum Family Planning Attitude Scale The Health Literacy Scale was used.
219337131|NCT03218098|PROCEDURE|Lobectomy via UVATS|lobectomy with small skin access 4 cm
219337132|NCT05941325|DRUG|fruquintinib|VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
219337133|NCT05941325|DRUG|Envafolimab|anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
219337134|NCT03974776|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
219337135|NCT03974776|OTHER|Placebo|Placebo administered subcutaneously
219337136|NCT01865630|DRUG|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
219337137|NCT04146779|BEHAVIORAL|Yoga Video|A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
219337138|NCT04146779|BEHAVIORAL|Posture and Strengthening Video|The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
219337139|NCT04146779|BEHAVIORAL|Relaxation Video|The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
219337140|NCT04146779|BEHAVIORAL|Breath Work Video|The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
219337141|NCT04146779|BEHAVIORAL|Satisfaction Survey|Participants will complete a questionnaire addressing satisfaction with the yoga program.
219337142|NCT04146779|BEHAVIORAL|Guided Yoga Session|Instructor guided yoga session twice a week
219337143|NCT04146779|BEHAVIORAL|Written Yoga Instructions|Introduction to Yoga and Yoga poses
219337144|NCT04311736|BEHAVIORAL|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
219337145|NCT04311736|BEHAVIORAL|Cycling|Cycling on a recumbent cycle ergometer
219337146|NCT04311736|BEHAVIORAL|Stretching|Stretching exercises
219337147|NCT05246020|PROCEDURE|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
219337148|NCT05246020|PROCEDURE|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
219337149|NCT01764542|PROCEDURE|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
219337150|NCT03649282|OTHER|HFNC|HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
219337151|NCT03649282|OTHER|NCPAP|NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
219337152|NCT04812431|BIOLOGICAL|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
219337153|NCT05187546|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
219337154|NCT02590120|DIETARY_SUPPLEMENT|Enteral nutrition|
219337155|NCT03858842|OTHER|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
219337156|NCT02385981|DEVICE|Stivax|
219337157|NCT03494751|DEVICE|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
219337158|NCT03494751|DEVICE|No heart monitor|Standard monitoring by nurses.
219337159|NCT03739398|DEVICE|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1\. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
219337160|NCT03739398|DEVICE|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2\. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
219337161|NCT02535715|DRUG|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
219337162|NCT02535715|DRUG|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
219337163|NCT02535715|DRUG|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
219337164|NCT00909181|DRUG|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
219337165|NCT00909181|DRUG|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
219337166|NCT00177749|DRUG|Posaconazole|
219337167|NCT05601648|DRUG|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
219337168|NCT01227486|DEVICE|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
219337169|NCT05536310|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|TAVI with the JenaValve Trilogy Heart Valve System
219337170|NCT01030770|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
219337171|NCT01030770|DRUG|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
219337172|NCT00086203|DRUG|Talabostat mesylate (PT-100) tablets|
219337173|NCT00086203|DRUG|Rituximab|
219337174|NCT05087290|OTHER|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
219337175|NCT05087290|OTHER|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
219337176|NCT05950984|OTHER|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
219337177|NCT01767454|DRUG|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
219337178|NCT01767454|DRUG|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
219337179|NCT01767454|DRUG|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
219337180|NCT02933034|DRUG|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
219337181|NCT02933034|DRUG|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
219337182|NCT05241457|DEVICE|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
219337183|NCT05241457|PROCEDURE|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
219337184|NCT02506595|BEHAVIORAL|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
219337185|NCT03126942|DEVICE|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
219337186|NCT03126942|DEVICE|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
219337187|NCT01713842|DRUG|TCZ|Tocilizumab at week 0, 4 and 8.
219337188|NCT02349048|DRUG|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
219337189|NCT02349048|DRUG|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
219337190|NCT02349048|DRUG|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
219337191|NCT02219282|OTHER|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
219337192|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
219337193|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
219337194|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
219337195|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
219337196|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
219337197|NCT00653614|DRUG|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
219337198|NCT00653614|DRUG|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
219337199|NCT00653614|DRUG|Placebo|Placebo administration in each arm
219337200|NCT04070027|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
219337201|NCT04070027|OTHER|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
219337202|NCT02286414|DRUG|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
219337203|NCT02286414|DRUG|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
219337204|NCT01322464|DRUG|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
219337205|NCT01322464|DRUG|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
219337206|NCT01322464|DRUG|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
219337207|NCT01322464|DRUG|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
219337208|NCT03152903|BIOLOGICAL|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
219337209|NCT03152903|OTHER|Placebo|Single dose of Placebo is administered intradermally.
219337210|NCT00094770|DRUG|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
219337211|NCT00094770|DRUG|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
219337212|NCT06414811|OTHER|HYPOTENSİON|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
219337213|NCT00475683|OTHER|Mouth wash|Mouth wash with chlorehexidin, three times a day
219337214|NCT00475683|DIETARY_SUPPLEMENT|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
219337215|NCT02771704|OTHER|Silver Diamine fluoride|
219337216|NCT02771704|OTHER|Potassium iodide|
219337217|NCT02771704|OTHER|Chlorhexidine|
219337218|NCT02771704|OTHER|Silver diamine fluoride and potassium iodide|
219337219|NCT02771704|OTHER|Physiological saline|
219337220|NCT05698082|DIAGNOSTIC_TEST|Immunohistochemical staining with anti-FOS|The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
219355484|NCT06746415|OTHER|Robotic Gait Training|The robot-assisted walking group will receive 20 minutes of NMES, 20 minutes of weight transfer, stretching,mobilization, bobath exercises and 20 minutes of robot-assisted walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks
219337221|NCT04911803|BEHAVIORAL|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
219337222|NCT04911803|BEHAVIORAL|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
219337223|NCT05479942|OTHER|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~1. Left/right discrimination (Implicit motor imagery):~2. Explicit motor imagery~3. Mirror Therapy"
219337224|NCT05479942|OTHER|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
219337225|NCT03187938|DIAGNOSTIC_TEST|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
219337226|NCT02070029|PROCEDURE|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~\- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
219337227|NCT06480916|PROCEDURE|Maternal-fetal transfers|Prospective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for.
219337228|NCT05244759|DRUG|[14C]-BLU-5937|Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
219337229|NCT03057236|BEHAVIORAL|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
219337230|NCT04282395|BEHAVIORAL|Resilience-Based Diabetes Self-Management Education|"During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~* the location in community-based church settings,~* recognition of cultural dietary preferences, and~* emphasis on cultural/historical significance of resilience in AAs."
219337231|NCT04282395|BEHAVIORAL|Standard Diabetes Self-Management Education|"Control group sessions, led by professional nurses, cover topics such as:~* causes and symptoms of type 2 diabetes,~* glucose self-monitoring,~* models for and principles of healthy eating, grocery shopping and dining out,~* physical activity,~* diabetes medications,~* managing sick days and stress, and~* community resources."
219337232|NCT03901105|DRUG|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
219337233|NCT03901105|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
219337234|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
219337235|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
219337236|NCT00914927|DRUG|Placebo|Placebo or inactive substance once a day for up to 7 days
219337237|NCT00822965|OTHER|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
219337238|NCT00822965|OTHER|Phone Interviews|2 follow-up phone interviews.
219337239|NCT00822965|BEHAVIORAL|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
219337240|NCT04347915|DRUG|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
219337241|NCT04347915|DRUG|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
219337242|NCT00779480|DRUG|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
219337243|NCT04773106|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally implanted during routine local intraocular pressure lowering procedures in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
219337244|NCT02877368|OTHER|Computed tomography|
219337245|NCT04335994|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
219337246|NCT04335994|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
219337247|NCT00053092|BIOLOGICAL|rituximab|
219337248|NCT00053092|DRUG|cyclophosphamide|
219337249|NCT00053092|DRUG|fludarabine phosphate|
219337250|NCT01274819|OTHER|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
219337251|NCT04468542|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
219337252|NCT04468542|DRUG|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
219337253|NCT03597230|OTHER|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
219337254|NCT01349465|DRUG|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
219337255|NCT03081442|DRUG|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
219337256|NCT03081442|DEVICE|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
219337257|NCT00073489|DRUG|OSI-461|
219337258|NCT06399523|DEVICE|VR therapy|Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.
219337259|NCT06399523|DEVICE|VR sham|Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
219337260|NCT01388660|DRUG|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)
219337261|NCT01388660|DRUG|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
219337262|NCT00934570|DRUG|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
219337263|NCT00934570|DRUG|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
219337264|NCT00934570|BEHAVIORAL|Placebo Standard exercise|Standard exercise
219337265|NCT00934570|BEHAVIORAL|Intensive exercise|Placebo Intensive exercise
219337266|NCT00003073|DRUG|liposomal cytarabine|
219337267|NCT00000270|DRUG|Cocaine|
219337268|NCT00025051|DRUG|celecoxib|
219337269|NCT00025051|PROCEDURE|anti-cytokine therapy|
219337270|NCT00025051|PROCEDURE|antiangiogenesis therapy|
219337271|NCT00025051|PROCEDURE|biological therapy|
219337272|NCT00025051|PROCEDURE|cancer prevention intervention|
219337273|NCT00025051|PROCEDURE|chemoprevention of cancer|
219337274|NCT00025051|PROCEDURE|growth factor antagonist therapy|
219337275|NCT04343625|BEHAVIORAL|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
219337276|NCT02571296|DRUG|micronized progesterone|Oral
219337277|NCT02571296|DRUG|Placebo|Oral
219337278|NCT04508400|DRUG|Fosaprepitant,ondansetron, dexamethasone|Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.
219337279|NCT04508400|DRUG|placebo ondansetron with dexamethasone|placebo plus ondansetron with dexamethasone
219337280|NCT02970604|DRUG|Aspirin|Non enteric coated aspirin
219337281|NCT04831489|RADIATION|Imaging|pre and postoperative CT scan of lung
219337282|NCT02835001|PROCEDURE|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
219337283|NCT02835001|DEVICE|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
219337284|NCT02604316|OTHER|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
219337285|NCT02604316|OTHER|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
219337286|NCT06073015|DRUG|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
219337287|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
219337288|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
219337289|NCT03844984|DRUG|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
219337290|NCT03844984|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
219337291|NCT03844984|DRUG|Normal saline|This group will receive normal saline 10 mL
219337292|NCT03844984|DRUG|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
219337293|NCT03844984|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
219337294|NCT05645497|PROCEDURE|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
219337295|NCT05645497|PROCEDURE|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
219337296|NCT03283124|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
219337297|NCT03002584|OTHER|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
219337298|NCT03329911|DRUG|EU Avastin®|100 mg/4 mL
219337299|NCT03329911|DRUG|BAT1706|100 mg/4 mL
219337300|NCT03329911|DRUG|Paclitaxel|200 mg/m²
219337301|NCT03329911|DRUG|carboplatin|target area under the curve \[AUC\] 6 mg/mL•minute
219337302|NCT01648790|DRUG|Prasugrel ODT1 - Tablet|Administered orally as tablet.
219337303|NCT01648790|DRUG|Prasugrel ODT2 - Tablet|Administered orally as tablet.
219337304|NCT01648790|DRUG|Prasugrel ODT2 - Suspension|Administered orally as suspension.
219337305|NCT02969187|DRUG|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
219337306|NCT02969187|DRUG|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
219337307|NCT02969187|DRUG|Saline|
219337308|NCT05177120|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
219337309|NCT05177120|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients
219337310|NCT05177120|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
219337311|NCT05177120|OTHER|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
219337312|NCT05177120|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
219337313|NCT05177120|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
219337314|NCT05177120|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
219337315|NCT01486927|BIOLOGICAL|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
219337316|NCT01486927|BIOLOGICAL|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
219337317|NCT00365456|DRUG|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
219337318|NCT00365456|DRUG|Risedronate|Orally once weekly as one 35 mg tablet.
219337319|NCT03668600|DRUG|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
219337320|NCT03686436|DEVICE|ocular coherence tomography|imaging by ocular coherence tomography
219337321|NCT03451786|DEVICE|IOL|Intraocular lens
219337322|NCT01476475|DRUG|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
219337323|NCT01476475|DRUG|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
219337324|NCT01476475|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
219337325|NCT01908764|DRUG|AL-60371 otic suspension|
219337326|NCT02954367|DIETARY_SUPPLEMENT|PROTEIN|Immediately (\<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
219337327|NCT02954367|DIETARY_SUPPLEMENT|CARBOHYDRATE|Immediately (\<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
219337328|NCT01278745|BIOLOGICAL|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
219337329|NCT01278745|DRUG|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
219337330|NCT04608227|DEVICE|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
219337331|NCT00004340|DRUG|calcitriol|
219337332|NCT00004340|DRUG|growth hormone|
219337333|NCT00859378|DEVICE|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)
219337334|NCT00859378|DEVICE|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
219337335|NCT03627221|BEHAVIORAL|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
219337336|NCT04327583|BEHAVIORAL|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
219337337|NCT03458390|DEVICE|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
219337338|NCT02789904|OTHER|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
219337339|NCT05798091|BEHAVIORAL|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
219337340|NCT05798091|OTHER|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
219337341|NCT03594630|DRUG|Chemotherapy|Receive chemotherapy
219337342|NCT03594630|OTHER|Patient Observation|Receive active surveillance
219337343|NCT03594630|OTHER|Questionnaire Administration|Ancillary studies
219337344|NCT03594630|PROCEDURE|Resection of Rectum|Undergo surgical resection
219337345|NCT02214966|DRUG|Telmisartan/Ramipril, fixed dose combination tablet|
219337346|NCT02214966|OTHER|high fat, high caloric meal|
219337347|NCT02719392|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
219337348|NCT02719392|DRUG|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
219337349|NCT02719392|OTHER|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
219337350|NCT05085951|DEVICE|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
219337351|NCT05085951|DIAGNOSTIC_TEST|OGD|OGD (No dilatation)
219337352|NCT01265615|DRUG|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
219337353|NCT01265615|DRUG|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
219337354|NCT01265615|DRUG|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
219337355|NCT01265615|DIETARY_SUPPLEMENT|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
219337356|NCT04236063|OTHER|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
219337357|NCT03243383|OTHER|DiaTOHC Program|"1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support"
219337358|NCT03891290|OTHER|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
219337359|NCT00338754|DRUG|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
219337360|NCT00988143|BIOLOGICAL|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
219337361|NCT00988143|BIOLOGICAL|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
219337362|NCT00988143|BIOLOGICAL|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
219337363|NCT00842231|OTHER|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
219337364|NCT00304200|DRUG|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
219337365|NCT02486978|OTHER|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
219337366|NCT02486978|DIETARY_SUPPLEMENT|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
219337367|NCT02486978|DIETARY_SUPPLEMENT|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
219337368|NCT02562079|BIOLOGICAL|Blood samples|"* biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)"
219337369|NCT02562079|BIOLOGICAL|Biopsy|Skin biopsies
219337370|NCT03434340|BIOLOGICAL|Peppermint essential oil|2 drops applied on a nasal strip
219337371|NCT03434340|DRUG|Granisetron|1mg intravenous injection
219337372|NCT03434340|DRUG|Dexamethasone|4mg intravenous injection
219337373|NCT00454857|OTHER|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
219337374|NCT00454857|OTHER|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
219337375|NCT00454857|OTHER|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
219337376|NCT01886573|DRUG|Azacitidine|Given SC
219337377|NCT01886573|DRUG|Entinostat|Given PO
219337378|NCT01886573|OTHER|Laboratory Biomarker Analysis|Correlative studies
219337379|NCT01886573|OTHER|Pharmacological Study|Correlative studies
219337380|NCT01886573|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219337381|NCT01977599|OTHER|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
219337382|NCT04503304|OTHER|Exercises|already included in arm/group descriptions.
219337383|NCT04278963|DRUG|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
219337384|NCT04278963|DRUG|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
219337385|NCT04278963|OTHER|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
219337386|NCT04278963|OTHER|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
219337387|NCT04302194|DIETARY_SUPPLEMENT|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
219337388|NCT01743924|OTHER|raw broccoli|To eat this plant material
219337389|NCT00061165|BEHAVIORAL|School + family changes promoting healthy eating + activity|
219337390|NCT06303284|DRUG|subcutaneous Teriparatide injection|20 µg subcutaneous (SC) Teriparatide injection
219337391|NCT06303284|OTHER|placebo|placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
219337392|NCT01605279|DRUG|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
219337393|NCT01605279|DRUG|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
219337394|NCT00108394|DRUG|pamidronate|
219337395|NCT03078075|DRUG|Naltrexone: Vivitrol®|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
219337396|NCT03078075|DRUG|Placebo (PLB) Injectable|Placebo: 4 intramuscular injections administered every 3 weeks
219337397|NCT03078075|DRUG|Bupropion: Wellbutrin XL®|Bupropion: 450 mg oral dose daily
219337398|NCT03078075|DRUG|Placebo (PLB) Oral|Placebo: once-daily oral placebo tablets
219337399|NCT01722175|PROCEDURE|ALPPS surgery|
219337400|NCT01722175|PROCEDURE|PVO surgery|
219337401|NCT03880487|DRUG|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
219337402|NCT03880487|DRUG|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
219337403|NCT03880487|DRUG|Oxycodone oral capsule|10 mg Oxycodone Capsules
219337404|NCT02375724|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
219337405|NCT02375724|DRUG|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
219337406|NCT03489408|DEVICE|Conventus Cage™ PH|Proximal humeral fracture fixation
219337407|NCT04334980|BIOLOGICAL|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
219355485|NCT06895941|DIAGNOSTIC_TEST|PET|Exploring the predictive value of PET/CT metabolic parameters for the efficacy of neoadjuvant immunotherapy in non-small cell lung cancer.
219337408|NCT06255704|DRUG|Zanubrutinib and RCHOP/RDHAP|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。"
219337409|NCT05415995|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
219337410|NCT00073216|BIOLOGICAL|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
219337411|NCT00073216|BIOLOGICAL|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
219337412|NCT01982032|PROCEDURE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
219337413|NCT01982032|DEVICE|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
219337414|NCT01982032|DEVICE|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
219337415|NCT03483142|DRUG|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
219337416|NCT03483142|DRUG|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
219337417|NCT04217187|DEVICE|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
219337418|NCT04217187|DEVICE|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
219337419|NCT05246436|PROCEDURE|warming saline media|use warm saline as a distention media in office hysteroscopy
219337420|NCT05246436|PROCEDURE|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
219337421|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily
219337422|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
219337423|NCT01197521|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
219337424|NCT00562952|DRUG|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
219337425|NCT00562952|DRUG|placebo|no intervention
219337426|NCT01489566|DRUG|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
219337427|NCT01489566|DRUG|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
219337428|NCT02300948|DRUG|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
219337429|NCT02300948|DRUG|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
219337430|NCT00543075|DRUG|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
219337431|NCT03481114|COMBINATION_PRODUCT|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
219337432|NCT03481114|COMBINATION_PRODUCT|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
219337433|NCT03155581|BEHAVIORAL|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
219337434|NCT03155581|BEHAVIORAL|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
219337435|NCT02820792|PROCEDURE|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
219337436|NCT02820792|DEVICE|LMA ProtectorTM|
219337437|NCT02820792|DEVICE|Ambu AuraGainTM|
219337438|NCT05827939|OTHER|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
219337439|NCT00433108|DRUG|Mitoquinone mesylate (MitoQ)|
219337440|NCT05896085|OTHER|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
219337441|NCT01903707|OTHER|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
219337442|NCT01903707|OTHER|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
219337443|NCT03962101|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
219337444|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
219337445|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
219337446|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
219337447|NCT00761007|DRUG|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
219337448|NCT05298891|OTHER|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~* energy equal to daily energy expenditure (estimated by indirect calorimetry \* physical activity factor)~* fats 28-35%~* carbohydrates 50-60%~* proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
219337449|NCT05085639|BIOLOGICAL|GLS-5130|GLS-5310 DNA plasmid vaccine
219337450|NCT05085639|BIOLOGICAL|Placebo|Placebo
219337451|NCT03302715|GENETIC|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
219337452|NCT03569709|BEHAVIORAL|Aerobic Exercise|Progressive sub-threshold aerobic exercise
219337453|NCT03569709|BEHAVIORAL|Rest|No structured exercise.
219337454|NCT03569709|BEHAVIORAL|Stretching|Gentle progressive upper and lower extremity stretching program
219337455|NCT00431340|DRUG|PXD101|
219337456|NCT02713958|OTHER|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
219337457|NCT02713958|OTHER|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
219337458|NCT02921620|BIOLOGICAL|PRX-102|Intravenous
219337459|NCT02921620|OTHER|Placebo|Intravenous
219337460|NCT05874323|GENETIC|Detection of RAGE gene polymorphism (rs1800625)|Detection of RAGE gene polymorphism (rs1800625) By Molecular analysis (real time PCR)
219337461|NCT01743755|DRUG|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
219337462|NCT01743755|DRUG|Placebo|Placebo tablet, once daily for four consecutive days
219337463|NCT01956513|OTHER|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
219337464|NCT04533490|DRUG|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
219337465|NCT04528862|BEHAVIORAL|Nature slides|participants will view a presentation of nature slides
219337466|NCT04528862|BEHAVIORAL|Urban slides|participants will view a presentation of urban slides
219337467|NCT03535714|BEHAVIORAL|MANTR-a treatment|MANTR-a treatment
219337468|NCT05024799|DRUG|Fentanyl, propofol|The patients in this group will be administered with fentanyl and propofol
219337469|NCT05024799|DRUG|fentanyl and dexmedetomindine|The patients in this group will be administered with fentanyl and dexmedetomindine
219337470|NCT05024799|DRUG|Butorphanol and propofol|The patients in this group will be administered with butorphanol and propofol
219337471|NCT05024799|DRUG|Butorphanol and dexmedetomindine|The patients in this group will be administered with butorphanol and dexmedetomindine
219337472|NCT02053324|COMBINATION_PRODUCT|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
219337473|NCT04903925|PROCEDURE|Impacted tooth extraction|All patients will undergo a surgical tooth extraction
219337474|NCT00419146|DRUG|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
219337475|NCT00419146|DRUG|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
219337476|NCT00419146|OTHER|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
219337477|NCT00419146|OTHER|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
219337478|NCT03353974|DEVICE|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
219337479|NCT03353974|DEVICE|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
219337480|NCT00505596|BEHAVIORAL|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
219337481|NCT00433680|BEHAVIORAL|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
219337482|NCT05658016|DRUG|TK-112690|TK112690 treatment Pre \& Post Radiation
219337483|NCT05658016|DRUG|Placebo|TK112690 Placebo treatment Pre \& Post Radiation
219337484|NCT05661227|DRUG|Dexmedetomidine|Whether apply DEX or not
219337485|NCT05661227|DRUG|0.9% Sodium chloride|Whether apply DEX or not
219337486|NCT05661227|DEVICE|Tourniquet(Early)|Timing of tourniquet application
219337487|NCT05661227|DEVICE|Tourniquet(Late)|Timing of tourniquet application
219337488|NCT00332254|DRUG|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
219337489|NCT04206605|OTHER|Placebo|Placebo-matching lanadelumab SC injection.
219337490|NCT04206605|DRUG|Lanadelumab|Lanadelumab solution in a PFS for injection.
219337491|NCT01651351|BIOLOGICAL|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
219337492|NCT01651351|BIOLOGICAL|Placebo: Human albumin 2.5%|Intravenous administration
219337493|NCT03082105|OTHER|Breathing in snow|Breathing in snow with different physical properties
219337494|NCT00679510|DRUG|rosuvastatin|tablet 10 mgs once daily
219337495|NCT00679510|DRUG|placebo|placebo
219337496|NCT03641872|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
219337497|NCT02964026|DEVICE|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
219337498|NCT02403336|OTHER|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
219337499|NCT02403336|BEHAVIORAL|Behavioral group intervention|Intervention on patients (educational workshop).
219337500|NCT02403336|OTHER|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
219337501|NCT03890783|OTHER|Evaluation of phonation quality|"Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
219337502|NCT03890783|OTHER|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
219337503|NCT03890783|OTHER|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
219337504|NCT00113776|DRUG|ABX-EGF|
219337505|NCT01218464|DRUG|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
219337506|NCT01218464|DRUG|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
219337507|NCT04662944|DRUG|brolucizumab|There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
219337508|NCT04662944|DRUG|ranibizumab|There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
219337509|NCT04662944|DRUG|aflibercept|There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
219337510|NCT00316251|DEVICE|Vibration Plate Therapy|
219337511|NCT00707928|DRUG|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
219337512|NCT00707928|OTHER|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
219337513|NCT02529982|DIETARY_SUPPLEMENT|Curcumin|
219337514|NCT02529982|DIETARY_SUPPLEMENT|Placebo|
219337515|NCT02336659|DRUG|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
219337516|NCT02336659|DRUG|sitagliptin|DPP-4 Inhibition
219337517|NCT02336659|OTHER|Placebo|Saline
219337518|NCT05932940|PROCEDURE|Gonioscopy-Assisted Transluminal Trabeculotomy|Ab interno angle surgery one of MIGS to lower IOP
219337519|NCT00329667|DEVICE|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
219337520|NCT00078325|DRUG|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
219337521|NCT00078325|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
219337522|NCT00078325|DRUG|Placebo|Matching placebo tablets once daily in the morning
219337523|NCT04719494|OTHER|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
219337524|NCT02713165|OTHER|Raisins|Participants will consume 84g of raisins per day for 14 days.
219337525|NCT00710736|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
219337526|NCT00710736|DRUG|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
219337527|NCT00578136|DRUG|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
219337528|NCT01677156|DIAGNOSTIC_TEST|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
219337529|NCT03700580|DRUG|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
219337530|NCT03700580|DRUG|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
219337531|NCT02047253|DRUG|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
219337532|NCT02047253|DRUG|Dexamethasone|Administered prior to administration of Study drug
219337533|NCT02047253|DRUG|Acyclovir|Administered orally twice daily
219337534|NCT02680132|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
219337535|NCT02680132|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
219337536|NCT01037660|DRUG|Metformin|Metformin 1 gram per day
219337537|NCT01034592|DRUG|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
219337538|NCT01987960|DRUG|Placebo|Once daily, tablets, orally
219337539|NCT01987960|DRUG|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
219337540|NCT00121433|DRUG|leptin|
219337541|NCT02575053|PROCEDURE|assessment of a new latex protocol|"1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol."
219337542|NCT00966420|DEVICE|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
219337543|NCT02065167|BIOLOGICAL|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
219337544|NCT02241382|DEVICE|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
219337545|NCT02241382|DEVICE|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
219337546|NCT04374760|BEHAVIORAL|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
219337547|NCT03422419|DRUG|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
219337548|NCT03422419|DEVICE|TIPS|transjugular intrahepatic portosystemic shunt deployment
219337549|NCT00527436|DIETARY_SUPPLEMENT|fish oil|Fish oil pills will be taken daily for 12 weeks
219337550|NCT00527436|DIETARY_SUPPLEMENT|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
219337551|NCT04066036|OTHER|This is an observational study only.|This is an observational study only.
219337552|NCT03371433|OTHER|Soft drinks|Caffeine and Caffeine free soft drinks
219337553|NCT04118270|DEVICE|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
219337554|NCT01304095|DRUG|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
219337555|NCT05896514|DEVICE|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
219337556|NCT05627544|PROCEDURE|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
219337557|NCT05627544|PROCEDURE|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
219337558|NCT05627544|PROCEDURE|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
219337559|NCT05627544|PROCEDURE|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
219337560|NCT04586543|DRUG|Selegiline|10 mg selegiline tablet per day
219337561|NCT04586543|DRUG|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
219337562|NCT03223870|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
219337563|NCT00281645|DRUG|Bicifadine|
219337564|NCT00281645|DRUG|Standard of Care (pharmacological analgesic treatment)|
219337565|NCT02209298|DEVICE|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
219337566|NCT05197348|BEHAVIORAL|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
219337567|NCT05197348|BEHAVIORAL|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
219337568|NCT05273476|PROCEDURE|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
219337569|NCT04662658|DRUG|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
219337570|NCT03163589|DRUG|Erythropoietin|injection
219337571|NCT03163589|DRUG|normal saline|injection
219337572|NCT01439672|DIETARY_SUPPLEMENT|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \~100mg/dl at 1100.
219337573|NCT04843215|PROCEDURE|Type of omentectomy|Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
219337574|NCT05602662|BEHAVIORAL|Music|Music therapy during mechanical ventilation
219337575|NCT01607424|BEHAVIORAL|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
219337576|NCT02034630|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
219337577|NCT05824286|OTHER|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
219337578|NCT01251848|DRUG|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
219337579|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
219337580|NCT01251848|DRUG|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
219337581|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
219337582|NCT01854320|BEHAVIORAL|Acceptance-based treatment|
219337583|NCT01854320|BEHAVIORAL|Standard behavioral treatment|
219337584|NCT05147467|DRUG|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
219337585|NCT02602912|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
219337586|NCT05653622|PROCEDURE|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
219337587|NCT01058070|DEVICE|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
219337588|NCT06089148|DIAGNOSTIC_TEST|contrast enhanced digital mammography, tomosyntheis and MRI|
219337589|NCT00542295|DRUG|alverine citrate and simeticone|
219337590|NCT00542295|DRUG|placebo|
219337591|NCT01924182|DEVICE|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
219337592|NCT01924182|OTHER|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
219337593|NCT04018794|DEVICE|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
219337594|NCT00856960|DRUG|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
219337595|NCT00856960|DRUG|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
219337596|NCT00856960|DRUG|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
219337597|NCT00856960|DRUG|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
219337598|NCT00856960|DRUG|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
219337599|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression.
219337600|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression and perinatal extra support.|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression. Additionally, up to three supportive contacts with a midwife or perinatal mental health nurse to support ICBT treatment and adress general pregnancy related health problems.
219337601|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by chance|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation by chance.
219337602|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by choice|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation based on patient preference.
219337603|NCT04007575|DIAGNOSTIC_TEST|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
219337604|NCT03350295|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
219337605|NCT05945186|DEVICE|Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)|External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
219337606|NCT00993265|DRUG|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
219337607|NCT00993265|DRUG|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
219337608|NCT05337787|OTHER|flipped classroom approach|The students in the experimental group were trained using the flipped learning model.
219337609|NCT01853995|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
219337610|NCT00821080|DRUG|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
219337611|NCT00821080|DRUG|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
219337612|NCT04455763|PROCEDURE|SVF|Adipose-derived stromal vascular fraction
219337613|NCT04455763|OTHER|Splint|Thumb brace (Actimove® Rhizo Forte)
219337614|NCT03497585|BEHAVIORAL|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
219337615|NCT06148688|OTHER|Digital Story|"Digital storytelling; It is used in education and training, business marketing, non-profit organizations such as libraries, community centers and museums, and health sciences education. Digital storytelling in health sciences can be a tool for patients and health science professionals to share their experiences, cope with diseases, and add a human element to health problems.~In the study, digital stories were created to increase the self-management of pregnant women with gestational diabetes. In creating a digital story; Qualitative studies involving the self-management experiences of women with gestational diabetes have been examined in the literature. Using the results of the studies, scenarios were created that included factors that facilitate and complicate diabetes self-management. The created scenarios were used in the digital storytelling initiative. A total of four long and four short digital story videos were prepared."
219337616|NCT03688399|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
219337617|NCT03688399|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
219337618|NCT01357655|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
219337619|NCT01357655|DRUG|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
219337620|NCT04935099|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
219337621|NCT04935099|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
219337622|NCT00609986|DRUG|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
219337623|NCT00609986|DRUG|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
219337624|NCT02098512|DRUG|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
219337625|NCT02098512|PROCEDURE|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
219337626|NCT02098512|DRUG|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
219337627|NCT03173859|DRUG|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
219337628|NCT03173859|DRUG|Apalutamide|apalutamide 240mg qD orally
219337629|NCT04355741|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
219337630|NCT01982474|BIOLOGICAL|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
219337631|NCT01982474|OTHER|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
219337632|NCT04076514|PROCEDURE|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
219337633|NCT04643951|BEHAVIORAL|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
219337634|NCT05066789|DEVICE|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
219337635|NCT05066789|DRUG|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
219337636|NCT06552312|OTHER|Delphi Questionnaire|"Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion."
219337637|NCT06061250|DIETARY_SUPPLEMENT|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
219337638|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
219337639|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
219337640|NCT06383936|PROCEDURE|intensive rehabilitation after uncemented TKA|patients undergoing an intensive rehabilitation protocol after uncemented tka
219337641|NCT03514108|DRUG|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
219337642|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 3 daily
219337643|NCT03514108|DRUG|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
219337644|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
219337645|NCT02943057|DRUG|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
219337646|NCT04722042|OTHER|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
219337647|NCT04722042|OTHER|default mapping|Default frequency filter assignments
219337648|NCT03972787|DEVICE|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
219337649|NCT05742997|DEVICE|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
219337650|NCT05742997|DEVICE|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
219337651|NCT01992133|DIETARY_SUPPLEMENT|Vitamin D3|
219337652|NCT01992133|DIETARY_SUPPLEMENT|Placebo|
219337653|NCT06852274|DIETARY_SUPPLEMENT|Clostridium butyricum CBM588® (Butirrisan®)|Probiotic
219337654|NCT06852274|DRUG|Rifaximin 400 mg Oral Tablet|Antibiotic
219337655|NCT02090413|DRUG|dimethyl fumarate|
219337656|NCT02090413|DRUG|acetylsalicylic acid|enteric-coated capsule
219337657|NCT02090413|DRUG|ASA-Placebo|matched placebo
219337658|NCT03912142|DIAGNOSTIC_TEST|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
219337659|NCT04165226|DEVICE|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
219337660|NCT04165226|DEVICE|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
219337661|NCT04165226|DEVICE|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
219337662|NCT05467956|OTHER|Covid-19|Covid-19 disease
219337663|NCT05155202|DRUG|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
219337664|NCT02902250|PROCEDURE|Decompression|vertebral body decompression in compression fracture
219337665|NCT02902250|PROCEDURE|Conservative Treatment|Conservative Treatment in vertebral compression fracture
219337666|NCT06971705|DEVICE|repetitive transcranial magnetic stimulation, rTMS|Participants underwent rTMS intervention prior to daily ankle stability training. The interventional targets were the key cortical brain regions identified in preliminary studies, with stimulation applied to the contralateral cortical areas corresponding to the affected ankle joint. Parameters included a figure-of-8 coil, 10 Hz frequency, 2-second stimulation duration, 8-second inter-train intervals, 60 repetitions, totaling 1,200 pulses per session, with each session lasting 10 minutes. Ankle stability training commenced within 10 minutes post-rTMS, following the same duration and intensity as the Ankle Stability Training Group + Sham rTMS Group. The treatment was conducted three times per week for a total of 4 weeks.
219337667|NCT06971705|BEHAVIORAL|ankle stability training|The ankle stability training protocol comprised three modalities: neuromuscular training, balance training, and proprioceptive training. Specific exercises included single-leg stance, balance pad training, heel raises, resistive ankle inversion/eversion exercises, MOBO board balance exercises, alphabet tracing (toe-writing), lateral walking, heel walking, toe walking, and jump and landing control drills. The training progressed from stable to unstable surfaces, starting at low intensity and gradually increasing in difficulty and intensity. The training was conducted three times per week for a total of four weeks.
219337668|NCT06971705|DEVICE|Sham repetitive transcranial magnetic stimulation, SrTMS|Before each session of ankle stability training, participants received sham rTMS intervention. The sham stimulation mimicked the sensory experience of real rTMS but did not produce any physiological effects.
219337669|NCT05366933|DRUG|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
219337670|NCT04001751|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
219337671|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
219337672|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
219337673|NCT05082285|COMBINATION_PRODUCT|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
219337674|NCT05082285|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
219337675|NCT05082285|COMBINATION_PRODUCT|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
219337676|NCT00487396|DEVICE|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
219337677|NCT02920424|DRUG|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
219337678|NCT02920424|DRUG|Placebo|Subjects will receive matching placebo.
219337679|NCT02515383|OTHER|Interview|Complete cognitive debriefing interview
219337680|NCT02515383|OTHER|Quality-of-Life Assessment|Ancillary studies
219337681|NCT02515383|OTHER|Questionnaire Administration|Complete MDASI questionnaire
219337682|NCT06460064|BIOLOGICAL|fH1 2 ug|2 administrations at 3-week intervals.
219337683|NCT06460064|BIOLOGICAL|fH1 8 ug|2 administrations at 3-week intervals.
219337684|NCT06460064|BIOLOGICAL|DSP-0546LP 2.5 ug|2 administrations at 3-week intervals.
219337685|NCT06460064|BIOLOGICAL|DSP-0546LP 5 ug|2 administrations at 3-week intervals.
219337686|NCT06460064|BIOLOGICAL|DSP-0546LP 10 ug|2 administrations at 3-week intervals.
219337687|NCT06460064|BIOLOGICAL|Placebo|2 administrations at 3-week intervals.
219337688|NCT06614465|OTHER|Multimodal Rehabilitation|The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
219337689|NCT05496868|DRUG|Reparixin 600mg|Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
219337690|NCT05496868|OTHER|Matching Placebo|"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
219337691|NCT06619522|DRUG|Ruxolitinib|Given orally
219337692|NCT06619522|DRUG|INCB57643|Given orally
219337693|NCT06490731|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine
219337694|NCT06490731|DRUG|Ketamine|patients Will receive ketamine
219337695|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
219337696|NCT05399888|DRUG|BIIB080|Administered as specified in the treatment arm.
219337697|NCT05399888|DRUG|BIIB080-matching placebo|Administered as specified in the treatment arm.
219337698|NCT06965569|DRUG|ALA-3000|Subcutaneous injection
219337699|NCT06965569|DRUG|Placebo|Subcutaneous injection
219337700|NCT06965569|DRUG|escitalopram, sertraline, duloxetine or venlafaxine XR|Newly initiated oral AD selected from SSRI (escitalopram or sertraline) or SNRI (duloxetine or venlafaxine XR) will be given daily
219337701|NCT05696548|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
219337702|NCT05696548|DRUG|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
219337703|NCT01357421|DRUG|TT301|Single iv dose of TT301
219337704|NCT01357421|DRUG|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
219337705|NCT05103878|DRUG|BT051 100mg|Single oral dose of 100mg BT051
219337706|NCT05103878|DRUG|BT051 300mg|Single oral dose of 300mg BT051
219337707|NCT05103878|DRUG|BT051 700mg|Single oral dose of 700mg BT051
219337708|NCT05103878|DRUG|BT051 1500mg|Single oral dose of 1500mg BT051
219337709|NCT05103878|DRUG|BT051 3500mg|Single oral dose of 3500mg BT051
219337710|NCT05103878|DRUG|Matching Placebo|Placebo Matching BT051
219337711|NCT01591967|DEVICE|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
219337712|NCT06144775|OTHER|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
219337713|NCT02652338|DIETARY_SUPPLEMENT|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
219337714|NCT02652338|DIETARY_SUPPLEMENT|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
219337715|NCT01641328|BEHAVIORAL|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
219337716|NCT01641328|BEHAVIORAL|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
219337717|NCT00074321|DRUG|irinotecan hydrochloride|Given IV
219337718|NCT00074321|DRUG|oxaliplatin|Given IV
219337719|NCT00074321|DRUG|capecitabine|Given PO
219337720|NCT00074321|OTHER|laboratory biomarker analysis|Correlative studies
219337721|NCT00074321|OTHER|pharmacological study|Correlative studies
219337722|NCT05445401|BEHAVIORAL|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
219337723|NCT05445401|BEHAVIORAL|Standard medical care|Traditional care
219337724|NCT04405687|PROCEDURE|Severe head and face deformity reconstructive surgery|Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
219337725|NCT01245504|OTHER|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
219337726|NCT04052451|BIOLOGICAL|MET-2|Subjects will take study medication once daily for the duration of the study
219337727|NCT04587167|OTHER|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
219337728|NCT04587167|OTHER|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
219337729|NCT04587167|OTHER|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
219337730|NCT01671423|DRUG|Prednisone|"See Prednisone arm description"
219337731|NCT01671423|DRUG|Placebo|"See Placebo arm description"
219337732|NCT00981513|BIOLOGICAL|Trivalent live attenuated seasonal influenza vaccine|One dose
219337733|NCT00981513|BIOLOGICAL|Monovalent live attenuated pandemic influenza vaccine|One dose
219337734|NCT00981513|BIOLOGICAL|Saline|One dose
219337735|NCT02237781|DRUG|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
219337736|NCT01839396|DEVICE|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
219337737|NCT03600064|DRUG|Misoprostol|the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
219337738|NCT01519596|PROCEDURE|quality-of-life assessment|Ancillary studies
219337739|NCT01519596|OTHER|counseling intervention|Receive lifestyle-related counseling
219337740|NCT01519596|BEHAVIORAL|exercise intervention|Undergo physical activity intervention
219337741|NCT01519596|OTHER|educational intervention|Receive educational materials
219337742|NCT01519596|PROCEDURE|standard follow-up care|Undergo usual care
219337743|NCT04201990|DRUG|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
219337744|NCT00545597|DRUG|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
219337745|NCT02321930|DRUG|tofacitinib 5mg po bid|
219337746|NCT03129451|DIAGNOSTIC_TEST|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
219337747|NCT05071365|OTHER|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
219337748|NCT03883594|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
219337749|NCT00664495|BEHAVIORAL|Diet Weight Loss|
219337750|NCT00664495|BEHAVIORAL|Exercise Weight Loss|
219337751|NCT00664495|BEHAVIORAL|Exercise Without Weight Loss|
219337752|NCT01293968|DRUG|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
219337753|NCT01293968|DRUG|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
219337754|NCT02594969|OTHER|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
219337755|NCT04196738|OTHER|ventilation strategy|Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
219337756|NCT02987179|OTHER|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
219337757|NCT05843682|DEVICE|Using the Avatr App|The patients will use the mobile application called Avatr, which will monitor their health data, as well as provide individualized care and early intervention through alerts generated for the multidisciplinary team.
219337758|NCT01483742|DRUG|RO5024048|1000 mg orally bid, 24 weeks
219337759|NCT01483742|DRUG|danoprevir|100 mg orally bid, 24 weeks
219337760|NCT01483742|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
219337761|NCT01483742|DRUG|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
219337762|NCT01483742|DRUG|ritonavir|100 mg orally bid, 24 weeks
219337763|NCT00956267|DRUG|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
219337764|NCT00956267|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
219337765|NCT02449681|DRUG|TH-4000 (Tarloxotinib)|
219337766|NCT01484977|DRUG|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
219337767|NCT03480568|DRUG|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
219337768|NCT00853749|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
219337769|NCT00853749|PROCEDURE|Blood draw|Collection of 10 mL of blood
219337770|NCT00930839|DRUG|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
219337771|NCT03276312|DEVICE|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
219337772|NCT01081457|DEVICE|Deep brain stimulation|Comparison ON vs OFF
219337773|NCT00848133|PROCEDURE|mini-midvastus surgical approach for total knee arthroplasty|
219337774|NCT00848133|PROCEDURE|mini-subvastus surgical approach for total knee arthroplasty|
219337775|NCT02450604|GENETIC|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
219337776|NCT04020939|DEVICE|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
219337777|NCT04020939|DRUG|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
219337778|NCT03919929|DRUG|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
219337779|NCT03919929|OTHER|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
219337780|NCT03760341|PROCEDURE|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
219337781|NCT03760341|PROCEDURE|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
219337782|NCT04224675|DRUG|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
219337783|NCT03294525|DRUG|Escitalopram Pill|escitalopram 10\~20mg/day
219337784|NCT03294525|DRUG|Duloxetine|duloxetine 30\~120mg/day
219337785|NCT03294525|DRUG|Mirtazapine Pill|Mirtazapine 15\~45mg/day
219337786|NCT03294525|DRUG|Other Antidepressants|
219337787|NCT05482074|DRUG|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
219337788|NCT01671813|DRUG|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
219337789|NCT04100681|DEVICE|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
219337790|NCT04100681|DEVICE|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
219337791|NCT01583933|DEVICE|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
219337792|NCT01583933|DEVICE|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
219337793|NCT04857996|DRUG|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
219337794|NCT04857996|OTHER|Sham|Sham procedure
219337795|NCT02269787|BEHAVIORAL|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
219337796|NCT02917681|OTHER|Two intrathecal MSC injections|
219337797|NCT05163470|OTHER|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
219337798|NCT05163470|OTHER|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
219337799|NCT06118151|BIOLOGICAL|Influenza Hemagglutinin mRNA vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
219337800|NCT06118151|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
219337801|NCT04262635|DRUG|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
219337802|NCT04262635|DRUG|Cetuximab|Maintenance treatment ( ArmB )
219337803|NCT00798135|DRUG|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
219337804|NCT03972579|BEHAVIORAL|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
219337805|NCT03972579|BEHAVIORAL|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
219337806|NCT00777621|OTHER|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
219337807|NCT00777621|OTHER|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
219337808|NCT00777621|OTHER|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
219337809|NCT06547658|OTHER|Mouth closure|Closing the mouth during sleep by applying pressure to the mentum until the teeth were in occlusion, without altering the head position.
219337810|NCT04822051|OTHER|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
219337811|NCT04967079|DRUG|Trametinib|Trametinib 2 mg given orally, once daily
219337812|NCT04967079|DRUG|Anlotinib|Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle
219337813|NCT03778411|DEVICE|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
219337814|NCT02670070|DRUG|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
219337815|NCT04720781|DRUG|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
219337816|NCT04720781|DRUG|Esomeprazole|esomeprazole (20mg/day)
219337817|NCT05899881|BEHAVIORAL|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
219337818|NCT01892592|BEHAVIORAL|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
219337819|NCT02228720|DEVICE|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
219337820|NCT04563273|BIOLOGICAL|BCG vaccine 1（0.025mg/0.1ml/person）|Intradermal injection of 0.025mg/0.1ml/person dose BCG.
219337821|NCT04563273|BIOLOGICAL|BCG vaccine 2 （0.05mg/0.1ml/person）|Intradermal injection of 0.05mg/0.1ml/person dose BCG.
219337822|NCT04563273|BIOLOGICAL|BCG vaccine 3（0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
219337823|NCT04563273|BIOLOGICAL|BCG vaccine 4 （0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
219337824|NCT04563273|BIOLOGICAL|Placebo of BCG vaccine （0.1ml/person）|Intradermal injection of 0.1ml/person dose Placebo.
219337825|NCT05192356|DRUG|CKD-348(3)|QD, PO
219337826|NCT05192356|DRUG|CKD-828, D097, D337|QD, PO
219337827|NCT03086395|DRUG|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
219337828|NCT00254748|DRUG|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
219337829|NCT00254748|DRUG|Placebo|placebo
219337830|NCT00255970|OTHER|DFDBA|Demineralized Freeze Dried Allograft bone
219337831|NCT00255970|DEVICE|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
219337832|NCT03101774|DEVICE|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
219337833|NCT03101774|DEVICE|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
219337834|NCT03101774|OTHER|Control group|Conventional therapy without any inspiratory muscle training program
219337835|NCT03926689|BEHAVIORAL|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
219337836|NCT03926689|BEHAVIORAL|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
219337837|NCT01969994|OTHER|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
219337838|NCT01969994|OTHER|(-)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.
219337839|NCT03779308|DEVICE|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
219337840|NCT01392677|DRUG|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
219337841|NCT01392677|DRUG|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
219337842|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
219337843|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
219337844|NCT02726971|DRUG|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
219337845|NCT05206409|DIAGNOSTIC_TEST|Ultrasound|Fetal head position determination using ultrasound
219337846|NCT02170402|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|"* Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen"
219337847|NCT01326182|BEHAVIORAL|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
219337848|NCT01326182|BEHAVIORAL|MAAS|Group-based intervention including asthma education and education regarding general child health
219337849|NCT06977906|PROCEDURE|conventional Robotic-assisted radical prostatectomy group|Robotic-assisted radical prostatectomy uses a standard anterior approach with transabdominal or extraperitoneal access. After establishing pneumoperitoneum, the Retzius space is dissected to expose the prostate. The deep dorsal venous complex is ligated to control bleeding, and the bladder neck is carefully dissected while preserving the ureters. Seminal vesicles, vas deferens, and neurovascular bundles are selectively preserved based on tumor characteristics. A tension-free anastomosis of the bladder and urethra is performed using absorbable sutures. Lymph node dissection is done if necessary. The robotic system ensures precise dissection, hemostasis, and suturing, optimizing oncological control while preserving urinary continence and sexual function with reduced bleeding and complications.
219337850|NCT06977906|PROCEDURE|Improved Robotic-assisted radical prostatectomy group|The procedure is performed in a head-down, feet-up supine position with an abdominal or extraperitoneal approach. The right peritoneum is opened along the right external iliac vein to clear the obturator nerve, vessels, and lymph nodes. The external and internal iliac lymph nodes are also cleared. The right pelvic fascia is incised to remove prostate fat while preserving the bladder's anterior wall peritoneum. The same approach is used on the left side. The peritoneum is retracted to clear anterior prostate fat, and the deep venous complex is ligated to expose the prostate. Prostatectomy is performed, followed by urethra and bladder anastomosis, and peritoneal suturing with drainage tube placement.
219337851|NCT06979271|DRUG|Telitacicept Tofacitinib|One group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment
219337852|NCT06979115|DRUG|Indocyanine green (ICG)|Indocyanine green (ICG; National Drug Approval No. H20213567, Ruida Pharmaceuticals) is administered intravenously 24 hours preoperatively at a dose of 2 mg/kg. The drug is dissolved in 250 mL of normal saline using a light-protected infusion set and infused at a constant rate over 60 minutes. Alternatively, a 0.5 mg/kg dose may be administered via IV infusion 1-3 hours before surgery.
219337853|NCT06977087|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
219337854|NCT06977087|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
219337855|NCT06977087|BEHAVIORAL|Verbal Reasoning|Participants are asked to reflect on the pros and cons of facing the socially feared situation
219337856|NCT05351151|PROCEDURE|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
219337857|NCT05351151|PROCEDURE|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
219337858|NCT02681679|DRUG|0.1% bromfenac ophthalmic solution|
219337859|NCT02681679|PROCEDURE|femtosecond laser cataract surgery|
219337860|NCT06977776|BEHAVIORAL|Web-Based Osteoporosis Awareness Training Based on Health Belief Model|This study presents a web-based osteoporosis awareness training based on the health belief model. The training is designed to provide information about the risks of osteoporosis, ways of prevention and healthy lifestyle habits. Participants will be taught about the importance of calcium intake, the benefits of exercise and osteoporosis prevention methods. The training process will be supported by interactive content and individual counseling sessions offered through the website and participants will be provided with the opportunity to consolidate their knowledge.
219337861|NCT06977789|DEVICE|S Patch3-Cardio/S-Patch Ex|S Patch3-Cardio/S-Patch Ex for 72 hours
219337862|NCT06977789|DEVICE|Holter|Holter for 24 hours
219337863|NCT06813677|OTHER|In-person health promotion|The results from the initial pre-baseline examination are reviewed during the baseline visit to identify potential risk factors related to the Life's Essential 8 (LE8). Based on these findings, participants receive personalized recommendations to enhance their vascular health and information on local vascular health promotion resources. Additionally, participants receive bi-monthly motivational newsletters designed to support ongoing vascular health improvements.
219337864|NCT06977685|DRUG|Non-selective beta-blockers|Non-selective beta-blockers (NSBB) prescribed at discharge for patients hospitalized with hepatic complications. The study will analyze two types of NSBB: propranolol and carvedilol. The study will also examine potential dosage effects by categorizing NSBB use into low-dose and middle-high dose groups. NSBB use is defined as a prescription for at least 2 days at discharge.
219337865|NCT06984601|PROCEDURE|Lateral Internal Sphincterotomy (LIS)|This is a routinely performed surgical procedure for chronic anal fissure. The study is observational and does not assign this procedure to participants.
219337866|NCT06985667|BEHAVIORAL|Cognitive-Based Behavior Change Training Program|"Parents will be given an 8-session parent training program.~Session 1: Establishing a trusting relationship and informing them about the study Session 2: Informing parents about the cognitive development of 3-6 year old children Theme: Children learn with 'numbers/scales/amounts' Session 3: Parents being consistent in their approach to children Theme: Children learn with the all/or nothing rule Session 4: Reinforcing positive behaviors in children Theme: Children Learn Laterally Session 5: Parents being positive models Theme: Children Learn by Imitation Session 6: Guidance of parents on the principle of 'learning by doing and experiencing' Theme: Children Learn by Action Session 7: This is the last session. Session 8: Application of final tests and saying goodbye."
219337867|NCT02963545|OTHER|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
219337868|NCT02963545|BIOLOGICAL|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
219337869|NCT02963545|PROCEDURE|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
219337870|NCT02524821|DEVICE|Gelesis100|3 capsules each containing 0.75 mg
219337871|NCT02524821|DRUG|Metformin|1 tablet of 850 mg
219337872|NCT04404998|OTHER|Lower Energy Density|Test meal with lower energy density
219337873|NCT04404998|OTHER|Higher Energy Density|Test meal with higher energy density
219337874|NCT04404998|OTHER|Lower Satiation|Information on lower satiation
219337875|NCT04404998|OTHER|Higher Satiation|Information on higher satiation
219337876|NCT01637220|BIOLOGICAL|Blood volume collected specifically for this study|"* case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection"
219337877|NCT01213420|OTHER|Nivea Cream for scar hydration|3 applications per day during 6 months
219337878|NCT01213420|OTHER|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
219337879|NCT01213420|OTHER|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
219337880|NCT01213420|OTHER|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
219337881|NCT06984835|DEVICE|Ellanse S|Ellanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe
219337882|NCT06984835|DEVICE|Calcium Hydroxylapatite-based filler|Calcium Hydroxylapatite and carboxymethylcellulose based filler
219337883|NCT03739476|DRUG|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
219337884|NCT03739476|DRUG|Placebo oral capsule|Compare the incidence of postoperative delirium.
219337885|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
219337886|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
219337887|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
219337888|NCT06240624|OTHER|No intervention|No intervention will be given.
219337889|NCT03841097|DRUG|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
219337890|NCT03841097|DRUG|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
219337891|NCT06903611|DRUG|CAM-101|fibrinogen depleted human platelet lysate
219337892|NCT06903611|OTHER|Vehicle Control|Plasmalyte-A
219337893|NCT03080883|DRUG|Apixaban|Given PO
219337894|NCT05950360|DEVICE|Electromagnetic tracking system, surface electromyography|arm elevation in the scapular plane, overhead reaching to the target 15° backward to the frontal plane, pull-up with overhead reaching forward and backward.
219337895|NCT06928480|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders|"This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7).~In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows:~* Module 1 (session 1): Setting goals and maintaining motivation.~* Module 2 (sessions 2 and 3): Understanding your emotions.~* Module 3 (sessions 4 and 5): Mindful Emotions Awareness.~* Module 4 (sessions 6 and 7): Flexible thinking.~* Module 5 (session 8): Emotional baheviors.~* Module 6 (session 9): Facing physical sensations.~* Module 7 (sessions 10 and 11): Emotionl exposures.~* Module 8 (Session 12): Relapse prevention."
219337896|NCT06928480|OTHER|Treatment as Usual (TAU)|"This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19.~After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition."
219337897|NCT06939920|OTHER|Non-invasive ventilation mask with airway washout|Non-invasive ventilation mask with airway washout for dual limb ventilators
219337898|NCT06939920|OTHER|non-invasive ventilation|standard state of the art non-invasive ventilation
219337899|NCT06947954|BEHAVIORAL|Nourish intervention then no intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 9 weeks, participants crossover into the No Intervention group.
219337900|NCT06947954|BEHAVIORAL|no intervention then Nourish intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
219337901|NCT06275022|PROCEDURE|Inflow occlusion with perforation of septation and sclerotherapy|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
219337902|NCT06275022|PROCEDURE|Perforation of septation and sclerotherapy|Perforation of septation and sclerotherapy
219337903|NCT06275022|PROCEDURE|Indocyanine green-guided partial resection and sclerotherapy|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
219337904|NCT06275022|PROCEDURE|Partial resection and sclerotherapy|Partial resection and sclerotherapy
219337905|NCT04162821|DRUG|Hydronidone|Take hydroxynitone capsule
219337906|NCT01054742|DRUG|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
219337907|NCT01054742|DRUG|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
219337908|NCT03366298|COMBINATION_PRODUCT|Epipen 0.3mg|Epipen 0.3mg auto-injector
219337909|NCT03366298|COMBINATION_PRODUCT|Emerade 300mcg|Emerade 300mcg auto-injector
219337910|NCT03366298|COMBINATION_PRODUCT|Emerade 500mcg|Emerade 500mcg auto-injector
219337911|NCT02481921|BEHAVIORAL|Group medical visits|Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
219337912|NCT04360551|DRUG|Telmisartan 40mg|Angiotensin Receptor Blocker (ARB)
219337913|NCT04360551|DRUG|Placebo|Placebo once daily
219337914|NCT01443520|DRUG|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
219337915|NCT01443520|DRUG|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
219337916|NCT01443520|DRUG|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
219337917|NCT04640337|OTHER|IPE applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
219337918|NCT04640337|OTHER|IPE applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
219337919|NCT04640337|OTHER|IPE not applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
219337920|NCT04640337|OTHER|IPE not applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
219337921|NCT02916849|OTHER|Safe Step|Strength and balance exercise-digital version
219337922|NCT02916849|OTHER|OEP|Strength and balance exercise -paper version
219337923|NCT02230059|OTHER|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
219337924|NCT01887236|BEHAVIORAL|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
219337925|NCT01887236|BEHAVIORAL|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
219337926|NCT03849417|OTHER|ECT|ECT administered as part of normal clinical management
219337927|NCT00520884|DRUG|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
219337928|NCT00520884|DRUG|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
219337929|NCT00520884|OTHER|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
219337930|NCT00520884|OTHER|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
219337931|NCT02459327|BEHAVIORAL|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
219337932|NCT02459327|BEHAVIORAL|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
219337933|NCT05029206|PROCEDURE|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~1. In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~2. A minimum of 2 × 10\^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~3. Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~4. After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
219337934|NCT01149889|PROCEDURE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
219337935|NCT02894853|GENETIC|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
219337936|NCT03193697|DEVICE|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
219337937|NCT03193697|DEVICE|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
219337938|NCT00130585|BEHAVIORAL|Controlled diet|
219337939|NCT00130585|BEHAVIORAL|folic acid supplement|
219337940|NCT00130585|BEHAVIORAL|13C11-labelled folic acid supplement|
219337941|NCT02448602|OTHER|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
219337942|NCT02448602|OTHER|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
219337943|NCT02448602|OTHER|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
219337944|NCT02522702|OTHER|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
219337945|NCT00388973|DRUG|Quetiapine|
219337946|NCT01497470|DRUG|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
219337947|NCT03138538|DRUG|Part 1: M8891|Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
219337948|NCT03829930|DRUG|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
219337949|NCT03829930|DRUG|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
219337950|NCT00000742|DRUG|Atevirdine mesylate|
219337951|NCT00000742|DRUG|Zidovudine|
219337952|NCT00000742|DRUG|Didanosine|
219337953|NCT02458755|DRUG|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
219337954|NCT01116908|DEVICE|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
219337955|NCT01469338|DRUG|cabazitaxel|Given IV
219337956|NCT01469338|DRUG|prednisone|Given PO
219337957|NCT01469338|DRUG|octreotide pamoate|Given IM
219337958|NCT01469338|OTHER|questionnaire administration|Ancillary studies
219337959|NCT01469338|DRUG|octreotide acetate|Given SC
219337960|NCT02530528|DRUG|CHG|Varied application times
219337961|NCT00705211|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets,
219337962|NCT00705211|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
219337963|NCT03370783|DRUG|Ethanol|Moderate alcohol consumption
219337964|NCT01202331|DRUG|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
219337965|NCT00239798|DRUG|FTY720|
219337966|NCT01417715|DEVICE|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
219337967|NCT00515801|DRUG|glibenclamide|glibenclamide 15 mg single dose
219337968|NCT00515801|DRUG|placebo|placebo capsules, single dose
219337969|NCT00006476|DRUG|suramin|
219337970|NCT00006476|PROCEDURE|conventional surgery|
219337971|NCT04551937|OTHER|Lactose Free 1% Milk|8 oz of study beverage daily
219337972|NCT04551937|OTHER|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
219337973|NCT00603109|DRUG|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
219337974|NCT00603109|DRUG|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
219337975|NCT00119535|BEHAVIORAL|Implementation of Proactive Diabetes Eye Care Program|
219337976|NCT04661709|DRUG|Wen Xin granule|one dose daily, two times per day.
219337977|NCT04661709|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
219337978|NCT04661709|DRUG|Atorvastatin Calcium|20 mg tablet, one tablet each night.
219337979|NCT04661709|DRUG|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
219337980|NCT04661709|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
219337981|NCT04661709|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
219337982|NCT04661709|DRUG|WXG placebo|one dose daily, two times per day.
219337983|NCT04661709|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
219337984|NCT04661709|DRUG|glyceryl trinitrate|be taken when angina pectoris attacks.
219337985|NCT03053297|OTHER|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
219337986|NCT05936450|BIOLOGICAL|delivery of placentrex gel after open flap debridement|placentrex gel is placed after open flap debridement only in the test group
219337987|NCT05936450|PROCEDURE|Open Flap Debridement|Open Flap Debridement done in both test and control groups
219337988|NCT06197828|OTHER|This study is an observational studie which have no intervention|This study is an observational studie which have no intervention
219337989|NCT00017862|DRUG|SCH55700|
219337990|NCT01535573|DRUG|Citalopram|20 mg once per day for 9 weeks
219337991|NCT01535573|DRUG|Citalopram|40 mg per day for 9 weeks
219337992|NCT01535573|DRUG|Placebo|0 mg per day for 9 weeks
219337993|NCT04795232|OTHER|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
219337994|NCT04795232|OTHER|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
219337995|NCT06073496|OTHER|Electroacupuncture|Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator
219337996|NCT04438473|DIETARY_SUPPLEMENT|pectin-supplemented enteral nutrition feeding|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
219337997|NCT04438473|OTHER|enteral nutrition feeding|standard formula enteral nutrition feeding without pectin for 7 days
219337998|NCT04179734|DRUG|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
219337999|NCT04179734|DRUG|Placebo|Placebo subcutaenous injection.
219338000|NCT04503954|OTHER|Chronic disease self-management program|The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
219338001|NCT04503954|OTHER|General psychiatric intervention|General psychiatric intervention contains the activities in psychiatric center.
219338002|NCT01078831|OTHER|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
219338003|NCT04395339|DRUG|Monosialotetrahexosyl ganglioside (GM1)|Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
219338004|NCT04395339|DRUG|Control|250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
219338005|NCT01683201|PROCEDURE|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
219338006|NCT01683201|PROCEDURE|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
219338007|NCT00290615|BIOLOGICAL|bevacizumab|
219338008|NCT00290615|BIOLOGICAL|cetuximab|
219338009|NCT00290615|DRUG|capecitabine|
219338010|NCT00290615|DRUG|oxaliplatin|
219338011|NCT04027114|BEHAVIORAL|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
219338012|NCT04262687|DRUG|Capecitabine|2000 mg/m²/day, from day 1 to 14 of each cycle
219338013|NCT04262687|DRUG|Oxaliplatin|130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle
219338014|NCT04262687|DRUG|Bevacizumab|7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle
219338015|NCT04262687|DRUG|Pembrolizumab|200 mg by IV infusion over 30 minutes, on day 1 of each cycle
219338016|NCT02900079|DEVICE|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
219338017|NCT05058755|DRUG|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
219338018|NCT05058755|DRUG|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
219338019|NCT04944511|DRUG|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
219338020|NCT05086328|BEHAVIORAL|Nonviolent Resistance|Six two weekly sessions of two hours, based on nonviolent resistance Questionnaires pre and post intervention
219338021|NCT04216459|DRUG|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
219338022|NCT04216459|DRUG|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
219338023|NCT03343587|DRUG|LY3375880 IV|administered IV
219338024|NCT03343587|DRUG|LY3375880 SC|administered SC
219338025|NCT03343587|DRUG|Placebo IV|administered IV
219338026|NCT03343587|DRUG|Placebo SC|administered SC
219338027|NCT01645189|BIOLOGICAL|Hunterase|once weekly, 0.5mg/kg IV infusion
219338028|NCT06156982|DRUG|Evusheld|Administration of Evusheld 600 mg
219338029|NCT03317041|OTHER|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
219338030|NCT01628445|DRUG|liraglutide|liraglutide titrated to 1.8 mg sc daily
219338031|NCT01628445|DRUG|placebo injection|placebo injected sc daily volume equal to active comparator
219338032|NCT04031911|DEVICE|Hydroposturotherapy|"Hydroposturotherapy combines:~* posturotherapy (patient placed upside down with water jets sent to the kidneys)~* lumbar percussion~* hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
219338033|NCT04031911|DEVICE|Standard support in urology|Dispensing of AFU plugs Dietary advice
219338034|NCT00677651|PROCEDURE|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
219338035|NCT00677651|PROCEDURE|Blood sample|Blood will be sampled from an IV line
219338036|NCT00677651|RADIATION|CT Scan|Single image at the level of the liver
219338037|NCT00677651|RADIATION|DEXA|Whole body scan
219338038|NCT01973374|BEHAVIORAL|Text Message Intervention|
219338039|NCT01572116|DRUG|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
219338040|NCT01572116|DRUG|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
219338041|NCT05091463|DEVICE|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
219338042|NCT01748175|DRUG|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
219338043|NCT01035385|DRUG|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
219338044|NCT04609228|OTHER|Non-acceptance of blood-transfusions|Patients who do not accept blood products transfusions
219338045|NCT04609228|OTHER|Acceptance of blood-transfusions|Patients who accept blood products transfusions
219338046|NCT00983177|DRUG|Colchicine|0.5 mg twice daily for 4 months
219338047|NCT00983177|DRUG|lactose|lactose capsules twice daily
219338048|NCT02288936|DRUG|Enzalutamide|Enzalutamide 160 mg/day
219338049|NCT04552275|DIAGNOSTIC_TEST|Proteomics Analysis|Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
219338050|NCT03709238|BEHAVIORAL|Thermal stimulation|Thermal stimulation
219338051|NCT05913661|DRUG|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
219338052|NCT05913661|DRUG|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
219338053|NCT05744089|DEVICE|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
219338054|NCT01761292|DRUG|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
219338055|NCT00840086|DRUG|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
219338056|NCT01916837|OTHER|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
219338057|NCT01916837|OTHER|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
219338058|NCT01916837|PROCEDURE|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
219338059|NCT03332498|DRUG|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
219338060|NCT03332498|DRUG|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
219338061|NCT05953142|DRUG|Dobutamine|Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
219338062|NCT01750385|DRUG|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
219338063|NCT01750385|DRUG|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
219338064|NCT01492608|DRUG|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
219338065|NCT04036708|BEHAVIORAL|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
219338066|NCT04036708|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
219338067|NCT06501404|DIETARY_SUPPLEMENT|High dose group|A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
219338068|NCT06501404|DIETARY_SUPPLEMENT|Low dose group|A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
219338069|NCT01263171|DRUG|Leucovorin|
219338070|NCT01263171|DRUG|fluorouracil|
219338071|NCT01263171|DRUG|leucovorin calcium|
219338072|NCT01263171|DRUG|oxaliplatin|
219338073|NCT01263171|PROCEDURE|adjuvant therapy|
219338074|NCT01263171|PROCEDURE|neoadjuvant therapy|
219338075|NCT01263171|PROCEDURE|therapeutic conventional surgery|
219338076|NCT01263171|RADIATION|radiation therapy|
219338077|NCT02538016|DRUG|Tolvaptan|
219338078|NCT00000787|BEHAVIORAL|Pre- and post-test counseling|
219338079|NCT05080023|DEVICE|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
219338080|NCT04203745|DEVICE|Nonablative Fractional Diode Laser|The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
219338081|NCT05764382|BEHAVIORAL|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.
219338082|NCT05764382|OTHER|Usual care|Usual care as per primary care physican, physical therapist.
219338083|NCT01444742|DRUG|Clofarabine|"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
219338084|NCT01444742|DRUG|Cytarabine|"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"
219338085|NCT03151720|DRUG|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
219338086|NCT03151720|DRUG|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
219338087|NCT06159920|DIAGNOSTIC_TEST|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
219338088|NCT02690870|DRUG|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
219338089|NCT02690870|DRUG|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
219338090|NCT00527475|DRUG|ranibizumab|0.5 mg. given as an intraocular injection
219338091|NCT00527475|DRUG|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
219338092|NCT00004887|DRUG|carboplatin|
219338093|NCT00004887|DRUG|cisplatin|
219338094|NCT00004887|DRUG|ifosfamide|
219338095|NCT00004887|DRUG|mitomycin C|
219338096|NCT00004887|DRUG|paclitaxel|
219338097|NCT00004887|DRUG|vinblastine sulfate|
219338098|NCT01589471|DRUG|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
219338099|NCT01859832|OTHER|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
219338100|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
219338101|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
219338102|NCT00381342|DRUG|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
219338103|NCT01394042|DEVICE|Proxiscan device|All patients will be imaged with the device
219338104|NCT05288738|DRUG|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
219338105|NCT05288738|DRUG|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
219338106|NCT03744351|OTHER|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
219338107|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
219338108|NCT03744351|OTHER|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
219338109|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
219338110|NCT04892264|BIOLOGICAL|Belantamab Mafodotin|Given IV
219338111|NCT04892264|BIOLOGICAL|Daratumumab|Given IV
219338112|NCT04892264|DRUG|Dexamethasone|Given PO
219338113|NCT04892264|DRUG|Lenalidomide|Given PO
219338114|NCT04892264|OTHER|Quality-of-Life Assessment|Ancillary studies
219338115|NCT04892264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219338116|NCT04892264|PROCEDURE|Skeletal Survey X-Ray|Undergo X-ray skeletal survey
219338117|NCT04892264|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo whole body low dose CT
219338118|NCT04892264|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219338119|NCT04892264|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219338120|NCT01141036|DRUG|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
219338121|NCT01141036|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
219338122|NCT06414525|OTHER|abdominal massage|It will include patients that will receive abdominal massage; the frequency and duration of the massage will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
219338123|NCT06414525|OTHER|visceral manipulation|It will include patients that will receive visceral manipulation; the frequency and duration of the technique will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
219338124|NCT06414525|OTHER|instructions on daily, dietary , toilet , and physical activity habits|It will include patients that will receive behavioral therapy: defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advice (diet, water consumption, fiber food, etc.), teaching effective defecation posture, and timed toilet training.
219338125|NCT03370120|DRUG|Padsevonil|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
219338126|NCT03185364|DRUG|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
219338127|NCT03185364|DRUG|Placebo Oral Tablet|placebos treatment for 12 weeks
219338128|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation|Oral, encapsulated FMT
219338129|NCT02801656|DRUG|Vancomycin|Vancomycin po 125 mg qid x 10 days
219338130|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
219338131|NCT02801656|DRUG|Vancomycin Placebo|Matching placebo to Vancomycin
219338132|NCT03533647|OTHER|Observational|none (observational study)
219338133|NCT04206020|DRUG|SkQ1 Vehicle Solution|SkQ1 Ophthalmic Solution Vehicle
219338134|NCT04206020|DRUG|SkQ1 Ophthalmic Solution|SkQ1 Ophthalmic Solution
219338135|NCT04745039|DEVICE|Endopatch System|The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
219338136|NCT02700412|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
219338137|NCT01835925|GENETIC|Tissue specimen|
219338138|NCT05915520|BEHAVIORAL|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
219338139|NCT05915520|OTHER|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
219338140|NCT05780775|OTHER|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
219338141|NCT02462356|PROCEDURE|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
219338142|NCT02462356|PROCEDURE|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
219338143|NCT03924349|DEVICE|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
219338144|NCT00632099|DRUG|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
219338145|NCT00632099|DRUG|Placebo|matched placebo
219338146|NCT02330575|BEHAVIORAL|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
219338147|NCT02330575|BEHAVIORAL|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
219338148|NCT03399136|BEHAVIORAL|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
219338149|NCT00159991|PROCEDURE|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
219338150|NCT00159991|PROCEDURE|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
219338151|NCT02840695|DRUG|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
219338152|NCT04426877|BEHAVIORAL|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
219338153|NCT04426877|BEHAVIORAL|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
219338154|NCT04989114|DEVICE|nasal continuous positive airway pressure|positive end expiratory pressure will be applied by nasal continuous positive airway pressure
219338155|NCT00080028|DRUG|Motexafin Gadolinium Injection|
219338156|NCT01550250|BEHAVIORAL|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
219338157|NCT01550250|BEHAVIORAL|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
219338158|NCT02011282|OTHER|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
219338159|NCT00962572|BEHAVIORAL|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
219338160|NCT02543463|DEVICE|Trident X3 Insert with Navigation system|
219338161|NCT02543463|DEVICE|Trident X3 Insert with conventional instrumentation|
219338162|NCT06272474|OTHER|CAD-CAM zirconia crowns using buccal interocclusal record.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record.~First, scanning the buccal interocclusal record for each patient with the two arches in maximum intercuspation position (MIP) will be performed. The IOS will immediately reproduce the occlusal state of the digital casts; this method is called the buccal bite registration method (BBR)."
219338163|NCT06272474|OTHER|CAD-CAM zirconia crowns using lateral interocclusal records.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using lateral interocclusal record.~A second scan will be performed for each patient to record lateral mandibular excursion. Then, three STL files will be exported; maxillary arch, mandibular arch at MIP and lateral mandibular excursion"
219338164|NCT03374189|DEVICE|EZ close|EZ close used.
219338165|NCT03374189|DEVICE|Carter Thomason|Carter Thomason used.
219338166|NCT05401084|OTHER|Diet|Macronutrient diet changes.
219338167|NCT01244555|OTHER|ultrasound|Twice weekly ultrasound sessions for 6 weeks
219338168|NCT01244555|OTHER|massage|Twice weekly massage sessions for 6 weeks
219338169|NCT00127725|DEVICE|Pulsed electromagnetic field stimulation|
219338170|NCT02162836|DRUG|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
219338171|NCT05931237|DIETARY_SUPPLEMENT|Cranberry extract capsules|Cranberry extract capsules (Prebiocran(TM))
219338172|NCT02289170|DEVICE|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
219338173|NCT02289170|DEVICE|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
219338174|NCT05775185|RADIATION|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
219338175|NCT04512040|BEHAVIORAL|At-Home Yoga|At-home yoga practice over 12 weeks.
219338176|NCT00494611|DRUG|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
219338177|NCT00709982|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
219338178|NCT06098612|DRUG|C11-SY08|a PET imaging agent
219338179|NCT00552175|DRUG|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
219338180|NCT00552175|DRUG|placebo|placebo taken orally every day
219338181|NCT00552175|DRUG|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
219338182|NCT06493773|BEHAVIORAL|Offer of referral to specialized alcohol use disorder treatment|Patients are offered referral to specialized alcohol use disorder treatment.
219338183|NCT05112536|DRUG|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
219338184|NCT05112536|DRUG|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
219338185|NCT05112536|DRUG|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
219338186|NCT05112536|DRUG|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
219338187|NCT05112536|DRUG|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
219338188|NCT05112536|BIOLOGICAL|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
219338189|NCT03591640|DIAGNOSTIC_TEST|Blood test|Standard blood test
219338190|NCT00522353|DIETARY_SUPPLEMENT|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
219338191|NCT00522353|DIETARY_SUPPLEMENT|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
219338192|NCT04338503|DIAGNOSTIC_TEST|Partial IVC occlusion|Partial balloon occlusion of the inferior vena cava.
219338193|NCT04739254|DIAGNOSTIC_TEST|CardioFlux|Magnetocardiography
219338194|NCT03899766|OTHER|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
219338195|NCT03899766|OTHER|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
219338196|NCT03899766|OTHER|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
219338197|NCT01779973|BEHAVIORAL|Remote Observed Dosing|
219338198|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
219338199|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
219338200|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
219338201|NCT04746352|PROCEDURE|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
219338202|NCT04746352|PROCEDURE|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
219338203|NCT01830504|DRUG|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
219338204|NCT04971291|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks
219338205|NCT04971291|DRUG|Bupropion SR|Bupropion taken twice daily for 6 weeks
219338206|NCT04521036|BIOLOGICAL|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
219338207|NCT04185753|DIAGNOSTIC_TEST|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
219338208|NCT05560282|DRUG|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
219338209|NCT03789851|DEVICE|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
219338210|NCT01543828|DRUG|indacaterol|delivered via single-dose dry-powder inhaler
219338211|NCT01543828|DRUG|placebo|delivered via single-dose dry-powder inhaler
219338212|NCT04807855|DEVICE|The cMLP device|There is only one medical device we are testing, so only one intervention.
219338213|NCT01072305|DEVICE|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
219338214|NCT01072305|DEVICE|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
219338215|NCT05111665|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|
219338216|NCT05111665|BEHAVIORAL|Relaxation Group Therapy (RGT)|
219338217|NCT05111665|BEHAVIORAL|Treatment as usual (TAU)|
219338218|NCT02746133|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
219338219|NCT05188820|PROCEDURE|PRP - platelet rich plasma injection|Facet block using PRP
219338220|NCT05188820|PROCEDURE|Cortisone injection|Facet block using cortisone
219338221|NCT05104021|DEVICE|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
219338222|NCT03975920|DEVICE|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
219338223|NCT04824820|BEHAVIORAL|Vibrator|Clitoral stimulation
219338224|NCT00874445|DEVICE|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
219338225|NCT03469765|OTHER|does not apply|biological sample taking: urine, blood
219338226|NCT00228995|DRUG|epoetin alfa|
219338227|NCT04493021|DEVICE|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
219338228|NCT00029692|DRUG|Ginseng|
219338229|NCT00029692|DRUG|Ginkgo|
219338230|NCT05279248|BIOLOGICAL|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
219338231|NCT05279248|BIOLOGICAL|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
219338232|NCT05279248|BIOLOGICAL|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
219338233|NCT04265716|OTHER|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
219338234|NCT04300699|OTHER|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
219338235|NCT00738153|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219338236|NCT03436381|OTHER|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
219338237|NCT03702764|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
219338238|NCT01824992|DRUG|Yallaferon®|
219338239|NCT00927290|DRUG|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
219338240|NCT00927290|DRUG|Placebo|Placebo 45 mg QD (30 mg QD the first month)
219338241|NCT05018039|OTHER|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
219338242|NCT02285998|BIOLOGICAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
219338243|NCT02285998|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
219338244|NCT04209036|OTHER|0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)|total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
219338245|NCT04998838|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
219338246|NCT04998838|DRUG|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
219338247|NCT04796051|DEVICE|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
219338248|NCT04796051|OTHER|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
219338249|NCT00468520|DRUG|low dose oxytocin|
219338250|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
219338251|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
219338252|NCT00333398|BIOLOGICAL|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
219338253|NCT06470256|PROCEDURE|Palliative Hepatectomy|"Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection."
219338254|NCT06470256|DRUG|Durvalumab|Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
219338255|NCT06470256|DRUG|Lenvatinib|Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
219338256|NCT04669340|OTHER|E-learning patient education|"The intervention implies patient education through an e-learning program. The program consists of three learning modules covering knowledge of rheumatoid arthritis, medication, examinations, complications and daily living with RA. Module 1 consists of 'need to know' information about disease management, symptoms and medication. Thus, it is mandatory and must be completed before entering module 2 and 3. In module 2 and 3, patients can move around on the basis of their individual needs.~The duration of the full program is approximately two hours, but may vary dependent on the individual user needs. The program may be used as much as needed throughout the study period."
219338257|NCT04669340|OTHER|Standard face-to-face patient education|The intervention implies usual care, i.e. face-to-face patient education in a one-hour session with a nurse at the hospital. This form of patient education is based on the patients individual need for information and guidance in relation to rheumatoid arthritis and medication. Thus, aspects of daily life with the disease is discussed at the beginning and forms the conversation. However, as a standard, information of the disease, disease management, symptoms and medication must be discussed with the patient and relatives.
219338258|NCT04080947|DRUG|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
219338259|NCT04080947|DRUG|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
219338260|NCT01450449|RADIATION|Radiotherapy|25 Gy in 5 daily fractions over 1 week
219338261|NCT01450449|RADIATION|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
219338262|NCT02512133|DEVICE|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
219338263|NCT02512133|PROCEDURE|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
219338264|NCT03624933|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
219338265|NCT03624933|BEHAVIORAL|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
219338266|NCT00213187|BEHAVIORAL|Aerobic and Qi gong Exercise|
219338267|NCT02242578|DEVICE|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
219338268|NCT02242578|DEVICE|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
219338269|NCT01820364|DRUG|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
219338270|NCT00685880|DRUG|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
219338271|NCT00685880|DRUG|Betamethasone|CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
219338272|NCT00966342|DRUG|Fluviral 2009/10|single dose given IM .05 mL
219338273|NCT03451084|DRUG|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
219338274|NCT03339206|BEHAVIORAL|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
219338275|NCT03339206|BEHAVIORAL|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
219338276|NCT03339206|BEHAVIORAL|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
219338277|NCT02662036|DRUG|Bupivicaine HCL|
219338278|NCT02662036|DRUG|Liposomal bupivacaine|
219338279|NCT04995055|DEVICE|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
219338280|NCT04995055|DEVICE|ACUVUE® OASYS Multifocal|CONTROL Lens
219338281|NCT00836043|DRUG|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
219338282|NCT02668874|DEVICE|Isolite System|
219338283|NCT02668874|OTHER|Cotton Roll Technique|
219338284|NCT05421936|DRUG|Osimertinib|Treatment as the first EGFR-TKI
219338285|NCT01845922|DIETARY_SUPPLEMENT|Low sodium diet|Low sodium diet
219338286|NCT00810004|DRUG|Ferinject|Intravenous infusion of iron
219338287|NCT01384227|DRUG|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
219338288|NCT03418129|DEVICE|Mindfulness|Neuromodulatory intervention for pain management
219338289|NCT03418129|DEVICE|Neurofeedback|Neuromodulatory intervention for pain management
219338290|NCT03418129|DEVICE|Relaxation|Neuromodulatory intervention for pain management
219338291|NCT00454103|DRUG|123I-Iodometomidate|
219338292|NCT03230552|OTHER|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
219338293|NCT04267341|OTHER|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
219338294|NCT04267341|OTHER|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
219338295|NCT04267341|OTHER|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
219338296|NCT04532476|DEVICE|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
219338297|NCT05014334|DRUG|Berberine|berberine 500 mg, twice daily for 14 days
219338298|NCT05014334|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
219338299|NCT05014334|DRUG|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
219338300|NCT05014334|DRUG|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
219338301|NCT05014334|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
219338302|NCT05014334|DRUG|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
219338303|NCT04521023|DRUG|Cantabell Tab|Patients assigned to experimental group are treated with Cantabell Tab
219338304|NCT04521023|DRUG|Candemore Plus Tab|Patients assigned to experimental group are treated with Candemore Plus Tab
219338305|NCT03300674|DRUG|Hydromorphone|Hydromorphone intravenous infusion
219338306|NCT03300674|DRUG|Lidocaine|Lidocaine intravenous infusion
219338307|NCT03426956|DIETARY_SUPPLEMENT|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
219338308|NCT03426956|DIETARY_SUPPLEMENT|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
219338309|NCT02349594|DRUG|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
219338310|NCT02349594|DRUG|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
219338311|NCT04267419|DIAGNOSTIC_TEST|salivary biomarker|MDA and NO as salivary biomarkers
219338312|NCT02035085|DRUG|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
219338313|NCT03096730|DRUG|Normal saline|Normal saline is intravenously administrated before anesthesia induction
219338314|NCT03096730|DRUG|Remifentanil|Remifentanil is intravenously administrated
219338315|NCT03096730|DRUG|Sufentanil|Sufentanil is intravenously administrated
219338316|NCT03096730|DRUG|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
219338317|NCT03096730|DRUG|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
219338318|NCT04298775|PROCEDURE|spinal anesthesia with morphine|
219338319|NCT04298775|PROCEDURE|spinal anesthesia without morphine + peripheral nerve block|
219338320|NCT00058812|BIOLOGICAL|EBV specific T cells|One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
219338321|NCT02797340|OTHER|Blood draws and urine samples for metformin concentration measurements|
219338322|NCT02797340|DRUG|Metformin|
219338323|NCT03166566|DEVICE|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
219338324|NCT00314184|DRUG|quetiapine fumarate|
219338325|NCT03231046|DEVICE|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
219338326|NCT03231046|PROCEDURE|Hepatic Biopsy or Ablation|Standard of Care
219338327|NCT03913052|PROCEDURE|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
219338328|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
219338329|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
219338330|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
219338331|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
219338332|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
219338333|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
219338334|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
219338335|NCT05843734|PROCEDURE|Equia forte HT|Restoration of anterior class III caries lesions
219338336|NCT06264427|GENETIC|Whole genome sequencing|Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
219338337|NCT06264427|DIAGNOSTIC_TEST|VAGUS|To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
219338338|NCT06264427|DIAGNOSTIC_TEST|NightOwl|Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
219338339|NCT06264427|DEVICE|CPAP|Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
219338340|NCT00000475|BEHAVIORAL|health education|
219338341|NCT04927286|BEHAVIORAL|Learning to Breathe|Learning to Breathe is an evidence-based mindfulness curriculum for adolescents
219338342|NCT04927286|BEHAVIORAL|Campus Connections|Campus Connections is a mentoring program for at-risk adolescents
219338343|NCT01066585|DRUG|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
219338344|NCT01066585|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
219338345|NCT03259750|OTHER|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
219338346|NCT01071538|DRUG|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
219338347|NCT04080570|OTHER|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
219338348|NCT04697238|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
219338349|NCT01784770|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
219338350|NCT02221531|DRUG|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
219338351|NCT02221531|DRUG|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
219338352|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
219338353|NCT05007951|BIOLOGICAL|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
219338354|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
219338355|NCT03046485|BEHAVIORAL|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
219338356|NCT02238873|DRUG|Pegfilgrastim|
219338357|NCT04597983|DIETARY_SUPPLEMENT|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
219338358|NCT04597983|DIETARY_SUPPLEMENT|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
219338359|NCT04441268|PROCEDURE|primary IOL implantation|implant IOL in capsular bag after cataract extraction
219338360|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
219338361|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
219338362|NCT00884273|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
219338363|NCT00884273|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
219338364|NCT00884273|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
219338365|NCT05032625|PROCEDURE|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
219338366|NCT02742753|OTHER|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
219338367|NCT02912416|DIETARY_SUPPLEMENT|Probiotics|
219338368|NCT02912416|DIETARY_SUPPLEMENT|Placebo|
219338369|NCT03462420|OTHER|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
219338370|NCT05693168|DEVICE|ANNE Limb Sensor|Pulse Oximeter
219338371|NCT02591381|PROCEDURE|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
219338372|NCT04255446|DEVICE|Thora3DiTM|Not international
219338373|NCT04502004|DEVICE|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
219338374|NCT04967781|BEHAVIORAL|autoimmunity|autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
219338375|NCT01444768|OTHER|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
219338376|NCT03216096|DRUG|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
219338377|NCT03495258|PROCEDURE|Clarion Evolve Laser Vaporization System|
219338378|NCT03495258|PROCEDURE|Olympus TURis Plasma Vaporization|
219338379|NCT02512224|DEVICE|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
219338380|NCT02512224|DEVICE|Enteral nutrition|Participants are retrospectively selected with propensity score matching
219338381|NCT01184222|DEVICE|great occipital nerve stimulation|"* Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
219338382|NCT02699957|PROCEDURE|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
219338383|NCT04993534|BEHAVIORAL|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
219338384|NCT04993534|OTHER|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
219338385|NCT03492528|BIOLOGICAL|blood samples|blood samples
219338386|NCT05221801|BEHAVIORAL|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
219338387|NCT05221801|OTHER|food type|the swallowing was tested with 3 food types
219338388|NCT03961217|RADIATION|Radiotherapy|Radiotherapy as part of cancer treatment
219338389|NCT00482443|OTHER|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
219338390|NCT00482443|OTHER|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
219338391|NCT01195753|BIOLOGICAL|HHLivC|multiple infusion of liver cells
219338392|NCT02371239|BEHAVIORAL|Physical activity intervention|
219338393|NCT05795686|OTHER|"Evaluation of program AVanCer"|Evaluation of program AVanCer with quantitative and qualitative approaches
219338394|NCT05530720|OTHER|Cross-sectional survey|No intervention.
219338395|NCT01050452|DRUG|albendazole|albendazole (400 mg on dose)
219338396|NCT01050452|DRUG|mebendazole|mebendazole (500 mg one dose)
219338397|NCT01050452|DRUG|ivermectin|ivermectin (200 microgram/kg body weight)
219338398|NCT01050452|DRUG|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
219338399|NCT01050452|DRUG|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
219338400|NCT01776736|DEVICE|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
219338401|NCT04960020|OTHER|Retrospective Data Review|Retrospective Data Review
219338402|NCT04275505|OTHER|shortwave diathermy treatment|shortwave diathermy is a deep heating physical therapy agent. It was found efficiaous in carpal tunnel syndrome which is an entrapment neuropathy like ulnar nerve entrapment so it was hypothesised that shortwave diathermy could be an effective treatment method in ulnar nerve entrapment.
219338403|NCT04275505|OTHER|placebo shortwave diathermy treatment|shortwave device was not turned on while participants were asked to put their elbow into the device
219338404|NCT05198336|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
219338405|NCT01535495|DRUG|Propranolol|Propranolol XL 120mg by mouth once daily
219338406|NCT00037011|BIOLOGICAL|beta-glucan|
219338407|NCT00037011|BIOLOGICAL|monoclonal antibody 3F8|
219338408|NCT04126083|DRUG|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
219338409|NCT03054922|DRUG|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
219338410|NCT03054922|DRUG|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
219338411|NCT03054922|DRUG|Normosol-R Inj|IV infusion of Normosol throughout surgery.
219338412|NCT02840110|OTHER|ACTR T Cell Product|
219338413|NCT03858036|DRUG|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
219338414|NCT03858036|DEVICE|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
219338415|NCT04133454|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
219338416|NCT05247814|GENETIC|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
219338417|NCT05247814|OTHER|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
219338418|NCT05247814|OTHER|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
219338419|NCT00959998|OTHER|Self-administered Acupressure|
219338420|NCT02841098|OTHER|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
219338421|NCT02841098|DRUG|Optimal medical therapy alone|Optimal medical therapy alone
219338422|NCT01434589|BEHAVIORAL|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
219338423|NCT00020618|DRUG|morphine sulfate|
219338424|NCT00020618|PROCEDURE|quality-of-life assessment|
219338425|NCT00445705|DRUG|placebo|Part A: Placebo every 12 hours for 4 weeks
219338426|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
219338427|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
219338428|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
219338429|NCT01582295|DRUG|Cabozantinib|Starting dose 40 mg daily
219338430|NCT02887014|PROCEDURE|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
219338431|NCT01295476|GENETIC|gene expression analysis|
219338432|NCT01295476|GENETIC|microarray analysis|
219338433|NCT01295476|OTHER|laboratory biomarker analysis|
219338434|NCT02330822|DRUG|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
219338435|NCT04613154|DIETARY_SUPPLEMENT|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
219338436|NCT04613154|DIETARY_SUPPLEMENT|Placebo|Ester-c
219338437|NCT05731258|DRUG|Liposomal doxorubicin containing regimen|Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
219338438|NCT01279850|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
219338439|NCT01752660|BEHAVIORAL|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
219338440|NCT01752660|BEHAVIORAL|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
219338441|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
219338442|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
219338443|NCT01131520|BEHAVIORAL|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
219338444|NCT01131520|BEHAVIORAL|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
219338445|NCT01761045|DIETARY_SUPPLEMENT|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
219338446|NCT01761045|DIETARY_SUPPLEMENT|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
219338447|NCT01761045|DIETARY_SUPPLEMENT|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
219338448|NCT03762369|DRUG|CKD-351|twice a day
219338449|NCT03762369|DRUG|Latanoprost|once a day
219338450|NCT03762369|DRUG|D930|three times a day
219338451|NCT03762369|DRUG|Placebo of CKD-351|once a day
219338452|NCT03762369|DRUG|Placebo of CKD-351|twice a day
219338453|NCT03762369|DRUG|Placebo of D930|three times a day
219338454|NCT01499784|BEHAVIORAL|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
219338455|NCT02372565|BEHAVIORAL|Facebook and text Message|Culturally-relevant physical activity promotion program
219338456|NCT02372565|BEHAVIORAL|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
219338457|NCT04515225|OTHER|Blood Sample|Blood Sample
219338458|NCT04960540|OTHER|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
219338459|NCT02293447|DRUG|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
219338460|NCT02293447|DRUG|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
219338461|NCT02810847|DEVICE|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
219338462|NCT01147744|DRUG|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
219338463|NCT01147744|DRUG|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
219338464|NCT01147744|DRUG|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
219338465|NCT01147744|DRUG|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
219338466|NCT01147744|DRUG|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
219338467|NCT01147744|DRUG|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
219338468|NCT01147744|DRUG|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
219338469|NCT01147744|DRUG|Placebo montelukast|Placebo capsule once daily in the evening
219338470|NCT01147744|DRUG|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
219338471|NCT01147744|DRUG|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
219338472|NCT01788033|DRUG|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
219338473|NCT01788033|DRUG|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
219338474|NCT00089050|DRUG|cyclosporine|
219338475|NCT00089050|DRUG|gemtuzumab ozogamicin|
219338476|NCT05369104|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
219338477|NCT04879667|PROCEDURE|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
219338478|NCT04489251|DIAGNOSTIC_TEST|Protein Elisa analysis, microRNA analysis, whole exome sequencing|"ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing."
219338479|NCT01555567|DEVICE|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
219338480|NCT01555567|OTHER|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
219338481|NCT03555513|PROCEDURE|living kidney transplantation|receiving kidney transplantation from living donor
219338482|NCT02536313|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
219338483|NCT02536313|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219338484|NCT05672511|BEHAVIORAL|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
219338485|NCT02941705|BIOLOGICAL|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
219338486|NCT02941705|BIOLOGICAL|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
219338487|NCT01252745|DRUG|10.0 mg of Testosterone, 4.0% TID|
219338488|NCT01252745|DRUG|13.5 mg of Testosterone, 4.5% B.I.D|
219338489|NCT01252745|DRUG|11.25 mg of Testosterone, 4.5% T.I.D|
219338490|NCT01878942|DRUG|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
219338491|NCT01878942|DRUG|LSD|200µg per os, single dose
219338492|NCT03506737|OTHER|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
219338493|NCT03506737|OTHER|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
219338494|NCT02669966|PROCEDURE|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
219338495|NCT01208584|OTHER|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
219338496|NCT01460199|DRUG|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
219338497|NCT01460199|DRUG|placebo|tablets
219338498|NCT03946137|OTHER|Chest Therapy|The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
219338499|NCT03946137|OTHER|Postural Hygiene|Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
219338500|NCT01457391|BEHAVIORAL|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
219338501|NCT01457391|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
219338502|NCT01457391|BEHAVIORAL|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
219338503|NCT06460675|PROCEDURE|Autogenic Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
219338504|NCT06460675|PROCEDURE|Reciprocal Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
219338505|NCT06186076|DRUG|TRX-221|TRX-221 oral dose as defined
219338506|NCT04754360|OTHER|Evaluation of functional impairment|Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test
219338507|NCT04754360|OTHER|Evaluation of pulmonary function|Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.
219338508|NCT04754360|OTHER|Evaluation of quality of life|Quality of life will be evaluated using Short Form-36 Questionnaire.
219338509|NCT04754360|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form
219338510|NCT05586048|DRUG|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
219338511|NCT02437864|DEVICE|Supplemental oxygen via nasal cannula|
219338512|NCT01833442|BEHAVIORAL|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
219338513|NCT01833442|BEHAVIORAL|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
219338514|NCT00480818|DRUG|SAM-531|
219338515|NCT04350528|DRUG|Chlorpromazine or Pentobarbital|Sedation
219338516|NCT04315194|DRUG|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
219338517|NCT05780255|DEVICE|VV-ECMO|veno-venous extracorporeal membrane oxygenation
219338518|NCT05410444|DEVICE|Clean Intermittent Catheterization|Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.
219338519|NCT05410444|DEVICE|Indwelling catheterization|A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
219338520|NCT01829971|DRUG|MRX34|micro RNA therapy
219338521|NCT01671540|DEVICE|intrapulmonary percussive ventilation|
219338522|NCT01671540|OTHER|standard treatment|breathing control exercises
219338523|NCT01892163|DEVICE|Ozurdex|Dexamethasone implant (Ozurdex)
219338524|NCT04919291|DEVICE|Topoguided LASIK|Topoguided ablation profile on dominant eye
219338525|NCT04919291|DEVICE|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
219338526|NCT02361541|PROCEDURE|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
219338527|NCT05787080|OTHER|Massage|In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
219338528|NCT01289236|DRUG|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
219338529|NCT01289236|DRUG|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
219338530|NCT01289236|DRUG|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
219338531|NCT00262210|DRUG|Cyclophosphamide Epirubicin Etoposide Prednisolone|
219338532|NCT04651621|DEVICE|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
219338533|NCT04651621|DEVICE|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
219338534|NCT01014325|BIOLOGICAL|Allergen extract|sublingual application
219338535|NCT01014325|BIOLOGICAL|Placebo|sublingual application
219338536|NCT03302975|DEVICE|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
219338537|NCT05842369|DEVICE|ADVOS|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
219338538|NCT05842369|DEVICE|CVVHD|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
219338539|NCT03493087|DIETARY_SUPPLEMENT|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
219338540|NCT03493087|DIETARY_SUPPLEMENT|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
219338541|NCT03939845|RADIATION|RT|external- beam radiotherapy (EBRT)
219338542|NCT03939845|PROCEDURE|TACE|transarterial chemoembolization (TACE)
219338543|NCT01552291|DIETARY_SUPPLEMENT|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
219338544|NCT01552291|DRUG|Placebo|30g oral maltodextrin / day for 5 days before surgery
219338545|NCT02754895|OTHER|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
219338546|NCT02754895|OTHER|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
219338547|NCT01080248|DRUG|Gemcitabine|
219338548|NCT01080248|DRUG|Pazopanib|
219338549|NCT00037570|DRUG|Pantoprazole|
219338550|NCT04191330|DEVICE|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
219338551|NCT06220370|OTHER|Observational|There is no clinical intervention as part of this study. Participants will receive treatment as per their clinical treating team.
219338552|NCT04993040|DRUG|Oraxol|"* HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules"
219338553|NCT02287389|DEVICE|balloon dilation|
219338554|NCT02287389|PROCEDURE|cryotherapy|
219338555|NCT02287389|PROCEDURE|spiculiform electrosurgery|
219338556|NCT02287389|DRUG|mitomycin C|
219338557|NCT01824511|BEHAVIORAL|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
219338558|NCT05606081|DEVICE|Logistic regression risk model|Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
219338559|NCT05645874|DIAGNOSTIC_TEST|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
219338560|NCT05547880|DRUG|[11C]ER176|Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
219338561|NCT03454802|DIAGNOSTIC_TEST|Passive Leg Raising|See above
219338562|NCT02009436|DRUG|Azacitidine|Given via nebulizer
219338563|NCT02009436|OTHER|Laboratory Biomarker Analysis|Correlative studies
219338564|NCT02009436|OTHER|Pharmacological Study|Correlative studies
219338565|NCT02073175|DRUG|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
219338566|NCT01294202|DRUG|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
219338567|NCT05636592|DRUG|immunotherapy|statin combined with immunotherapy
219338568|NCT06226350|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
219338569|NCT05883462|COMBINATION_PRODUCT|Airiver Nasal Drug Coated Balloon (DCB) Catheter.|The balloon is coated with a paclitaxel drug (3.5ug/mm2).
219338570|NCT01922687|DRUG|amlodipine plus atorvastatin (Caduet)|
219338571|NCT01922687|DRUG|amlodipine (Norvasc)|
219338572|NCT00642395|DRUG|Bortezomib|bortezomib-Melphalan
219338573|NCT01124903|PROCEDURE|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
219338574|NCT04979689|OTHER|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
219338575|NCT04979689|OTHER|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
219338576|NCT04945668|PROCEDURE|Modified technique for pericapsular nerve group block|with the patient in the supine position, ultrasound probe in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus. In this view, the ilio pubic eminence (IPE), the iliopsoas muscle and tendon will be observed. A spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip between the psoas tendon and the pubic ramus. Fluoroscopic image will be taken to confirm the needle tip position in the target site. Following negative aspiration, 15 ml dye will be injected in 5-mL increments while observing for adequate spread using fluoroscopy followed by 15ml local anesthetic
219338577|NCT01043276|DRUG|Treatment A|PF-00258210 220 µg using inhaler A
219338578|NCT01043276|DRUG|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
219338579|NCT01043276|DRUG|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
219338580|NCT01043276|DRUG|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
219338581|NCT01043276|DRUG|Treatment E|PF-00258210 220 µg using inhaler B
219338582|NCT02458521|DEVICE|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
219338583|NCT02458521|DEVICE|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
219338584|NCT01787682|DIETARY_SUPPLEMENT|BOOST High Protein|
219338585|NCT02779959|DRUG|Prochlorperazine|
219338586|NCT02479100|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
219338587|NCT00807742|DRUG|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
219338588|NCT00807742|BEHAVIORAL|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
219338589|NCT00807742|BEHAVIORAL|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
219338590|NCT00807742|BEHAVIORAL|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
219338591|NCT04918030|PROCEDURE|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
219338592|NCT04918030|PROCEDURE|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
219338593|NCT00492752|DRUG|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
219338594|NCT00492752|DRUG|Placebo|Matching placebo (orally) twice daily
219338595|NCT00219284|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
219338596|NCT00004414|DRUG|sincalide|
219338597|NCT02705924|BEHAVIORAL|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
219338598|NCT06262958|BEHAVIORAL|ASSIST|Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.
219338599|NCT06262958|OTHER|Treatment as usual|Psychotherapy and/or psychotropic drug treatment
219338600|NCT02258451|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
219338601|NCT02258451|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
219338602|NCT02258451|DRUG|Exemestane|One 25 mg tablet once daily after a meal.
219338603|NCT02258451|DRUG|Everolimus|"The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice."
219338604|NCT03129490|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219338605|NCT03129490|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219338606|NCT03129490|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219338607|NCT03129490|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
219338608|NCT05771220|OTHER|radial extracorporeal shockwave therapy+ evidence-based physical therapy|The experimental group received six sessions of rESWT over six weeks in addition to an EBPT program. The rESWT procedure involved applying shockwaves to the affected area using a radial probe, with sessions lasting 10-15 minutes and consisting of up to 2000 impulses delivered at a frequency of 3-6 pulses per second and an energy intensity level of 1.8 bar, based on patient tolerance. Patients were seated or lying down during the rESWT procedure, with gel or oil applied to facilitate shockwave transmission through the skin. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
219338609|NCT05771220|OTHER|sham radial extracorporeal shockwave therapy+ evidence-based physical therapy|The participants in the control group received six weeks of sham rESWT (radial extracorporeal shock wave therapy) combined with the EBPT (evidence-based physical therapy) program. The sham rESWT involved six sessions with a maximum of 200 impulses delivered at a low intensity, with the applicator placed on the affected area for the same duration as the experimental group. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
219338610|NCT04738786|PROCEDURE|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
219338611|NCT04738786|PROCEDURE|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
219338612|NCT05375994|DRUG|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
219338613|NCT04991025|DRUG|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
219338614|NCT04991025|DRUG|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
219338615|NCT04991025|DRUG|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
219338616|NCT04991025|DRUG|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
219338617|NCT04991025|DRUG|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
219338618|NCT04991025|DRUG|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
219338619|NCT02390635|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
219338620|NCT02390635|PROCEDURE|Diffusion Weighted Imaging|Undergo whole body PET/MRI
219338621|NCT02390635|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
219338622|NCT02390635|DRUG|Gadolinium|Given IV
219338623|NCT02390635|PROCEDURE|Magnetic Resonance Imaging|Undergo whole body PET/MRI
219338624|NCT02390635|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
219338625|NCT02390635|PROCEDURE|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
219338626|NCT06216756|PROCEDURE|osteochondral transplant on the femoral condyle|Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
219338627|NCT06321432|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
219338628|NCT06321432|BEHAVIORAL|Usual care|Usual care
219338629|NCT05236556|BEHAVIORAL|Best practice advisory (BPA)|"For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider."
219338630|NCT05944926|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
219338631|NCT05944926|DRUG|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
219338632|NCT05914766|BEHAVIORAL|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of four behavioral coaching sessions and a patient education guidebook.
219338633|NCT05914766|OTHER|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
219338634|NCT06850766|OTHER|Morning administration of TMZ|Administration of TMZ within 2 hours of waking
219338635|NCT06850766|OTHER|Evening administration of TMZ|Administration of TMZ within 2 hours of bedtime
219338636|NCT03674229|OTHER|Informational Intervention|Receive information about weight management programs
219338637|NCT03674229|OTHER|Questionnaire Administration|Ancillary studies
219338638|NCT03674229|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
219338639|NCT02289651|DEVICE|Venner|Video-laryngoscopy
219338640|NCT02289651|DEVICE|Miller|Direct-Laryngoscopy
219338641|NCT04630587|PROCEDURE|Indirect restorations|see the Arm description
219338642|NCT05803200|DRUG|No intervention|No intervention was given as this is an observational study.
219338643|NCT03067571|BIOLOGICAL|Daratumumab|Given IV
219338644|NCT02836028|DRUG|Talazoparib|Talazoparib monotherapy 1mg/day orally
219338645|NCT02836028|DRUG|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
219338646|NCT06967142|DEVICE|Correcte Carotid flow measurement by USG Doppler|Aim of this study is to investigate the usability of changes in corrected carotid flow time induced by lung recruitment maneuvers during protective lung ventilation (6 ml/kg tidal volume) in patients undergoing elective Coronary Artery Bypass Graft Surgery (CABG) to evaluate fluid responsiveness. The secondary objective is to determine the correlation between measurements taken before and after sternotomy. This study aims to reduce invasive procedures used for assessing fluid responsiveness and develop an alternative method to the use of hard-to-access devices for measurements.
219338647|NCT03087188|OTHER|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
219338648|NCT01440270|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
219338649|NCT02281032|OTHER|interRAI PC|"PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results"
219338650|NCT03598816|DRUG|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
219338651|NCT03598816|DRUG|Tremelimumab|-Tremelimumab will be administered first
219338652|NCT03598816|DEVICE|TDS-IM v1.0 System|-Integrated electroporation device
219338653|NCT03598816|BIOLOGICAL|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
219338654|NCT03598816|PROCEDURE|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
219338655|NCT03375398|DIETARY_SUPPLEMENT|Rice|Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water
219338656|NCT03375398|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
219338657|NCT05693636|PROCEDURE|Total wrist arthroplasty|Two different surgical interventions for treatment of end-stage arthritis are compared
219338658|NCT06304805|DRUG|cycle 1: treatment drug|for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
219338659|NCT06304805|DRUG|cycle 1: reference drug|for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
219338660|NCT06304805|BEHAVIORAL|cycle 1: fasted|for cycle 1 treatment: participants are asked to take the drug fasted
219338661|NCT06304805|BEHAVIORAL|cycle 1: food|for cycle 1 treatment: participants are asked to take the drug after food intake
219338662|NCT06304805|DRUG|cycle 2: treatment drug|for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
219338663|NCT06304805|DRUG|cycle 2: reference drug|for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
219338664|NCT06304805|BEHAVIORAL|cycle 2: fasted|for cycle 2 treatment: participants are asked to take the drug fasted
219338665|NCT06304805|BEHAVIORAL|cycle 2: food|for cycle 2 treatment: participants are asked to take the drug after food intake
219338666|NCT06304805|DRUG|cycle 3: treatment drug|for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
219338667|NCT06304805|DRUG|cycle 3: reference drug|for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
219338668|NCT06304805|BEHAVIORAL|cycle 3: fasted|for cycle 3 treatment: participants are asked to take the drug fasted
219338669|NCT06304805|BEHAVIORAL|cycle 3: food|for cycle 3 treatment: participants are asked to take the drug after food intake
219338670|NCT05081479|DRUG|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.
219338671|NCT06228326|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
219338672|NCT06228326|DRUG|Pembrolizumab (KEYTRUDA®)|PD-1 immune checkpoint inhibitor
219338673|NCT06228326|DRUG|Chemotherapy|SOC chemotherapy
219338674|NCT04730622|DIAGNOSTIC_TEST|SARC-F questionnaire|Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
219338675|NCT04730622|DIAGNOSTIC_TEST|Bone tissue histology|Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
219338676|NCT04730622|DIAGNOSTIC_TEST|Muscle tissue histology|Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
219338677|NCT04730622|DIAGNOSTIC_TEST|Myostatin serum levels|Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
219338678|NCT04730622|DIAGNOSTIC_TEST|Insulin-like growth factor 1 (IGF-1) serum levels|Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
219338679|NCT04730622|OTHER|Frequency food questionnaire|Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
219338680|NCT04730622|OTHER|Gut microbiota profiling|Assessment of gut microbiome composition on stool samples.
219338681|NCT04473690|BIOLOGICAL|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
219338682|NCT04473690|BIOLOGICAL|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
219338683|NCT04473690|BIOLOGICAL|Placebo|Buffered saline solution
219338684|NCT00118391|BEHAVIORAL|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
219338685|NCT00118391|BEHAVIORAL|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
219338686|NCT06268444|DEVICE|7-day actimetry sleep recording|7-day actimetry sleep recording
219338687|NCT06268444|OTHER|Determination of environmental pollutants in breast milk|Determination of environmental pollutants in breast milk
219338688|NCT06268444|OTHER|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
219338689|NCT06268444|OTHER|Continuous recording of the child&#39;s temperature for 7 days|Continuous recording of the child\&#39;s temperature for 7 days
219338690|NCT06268444|OTHER|Use of a sleep diary for 7 days|Use of a sleep diary for 7 days
219338691|NCT06268444|OTHER|Parental questionnaire of environmental exposure|Parental questionnaire of environmental exposure
219338692|NCT06131775|BIOLOGICAL|Blood sampling|One blood sample of 10mL is realized before initiation of immunotherapy
219338693|NCT06131775|BIOLOGICAL|Blood sampling|Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
219338694|NCT04415853|DRUG|Lerotinib|Specification: 50 mg/capsule and 150 mg/capsule
219338695|NCT04415853|DRUG|Irinotecan/Tegafur|Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule
219338696|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the PartnerCHESS app but not in ACHESS:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between identified patient and concerned significant other to follow key principles.~Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
219338697|NCT05419128|BEHAVIORAL|ACHESS|ACHESS offers the following, which are also available in PartnerCHESS: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
219338698|NCT04977791|DRUG|Anti-PD-1/PD-L1 monoclonal antibody|Observe a situation before and after immunotherapy
219338699|NCT03834519|BIOLOGICAL|Pembrolizumab|IV infusion
219338700|NCT03834519|DRUG|Olaparib|Oral tablets
219338701|NCT03834519|DRUG|Abiraterone acetate|Oral tablets
219338702|NCT03834519|DRUG|Prednisone|Oral tablets
219338703|NCT03834519|DRUG|Enzalutamide|Oral tablets or oral capsules
219338704|NCT03834519|DRUG|Prednisolone|Oral tablets
219338705|NCT06972485|PROCEDURE|spinal anesthesia|spinal anesthesia with hypobaric and hyperbaric bupivacaine
219338706|NCT06976411|DRUG|MTA|Perforation repair using MTA repair material
219338707|NCT06976411|DRUG|Bioceramic putty|Perforation repair using Bioceramic repair material
219338708|NCT00488111|OTHER|Ringer's Lactate|Ringer's Lactate was used 15min before operation
219338709|NCT00488111|OTHER|6% Starch|6% Starch was used 15min before operation
219338710|NCT01485939|OTHER|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
219338711|NCT01485939|OTHER|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
219338712|NCT05957666|DRUG|Misoprostol Oral Tablet|oral misoprostol 50 microgram repeated after 6 hours if required
219338713|NCT05957666|DRUG|vaginal misoprostol|vaginal misoprostol 50 microgram repeated after 6 hours if required
219338714|NCT06972134|DIETARY_SUPPLEMENT|Sesame Oil (SO) at 100 mg/mL in dissolving fluid.|Pure Sesamum indicum oil (cold-pressed, unrefined) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by homogenization (30 min, 37°C). Used as monotherapy.
219338715|NCT06972134|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO) at 100 mg/mL in dissolving fluid.|Pure Olea europaea oil (first cold-pressed, acidity ≤0.8%) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by vortex mixing (15 min, 25°C). Used as monotherapy.
219338716|NCT06972134|DIETARY_SUPPLEMENT|50% Sesame Oil (SO) + 50% Extra Virgin Olive Oil (EVOO).|A 1:1 (v/v) blend of Sesamum indicum oil (AIU-BC-618-1) and Olea europaea oil (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by mechanical stirring (1 hr, 40°C).
219338717|NCT06972134|DIETARY_SUPPLEMENT|50% Psyllium Extract (PE) + 50% Oil Blend (50% SO + 50% EVOO).|50% Plantago ovata mucilage extract (aqueous extraction, 65°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by sonication (20 min).
219338718|NCT06972134|DIETARY_SUPPLEMENT|Plantago ovata extract (AIU-BC-618-4) + AIU-BC-618-3|50% Taraxacum officinale root extract (ethanol-water extraction, 70°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by magnetic stirring (30 min, 50°C).
219338719|NCT06972134|DIETARY_SUPPLEMENT|50% Herbal Extract (25% PE + 25% DE) + 50% Oil Blend (25% SO + 25% EVOO).|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
219338720|NCT06972134|DRUG|Drug: Rowachol® (terpene extract) at 100 mg/mL in dissolving fluid.|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
219338721|NCT03524885|PROCEDURE|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
219338722|NCT03524885|PROCEDURE|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
219338723|NCT00517751|DEVICE|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
219338724|NCT02604953|DIAGNOSTIC_TEST|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
219338725|NCT02604953|DIAGNOSTIC_TEST|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
219338726|NCT01188720|BEHAVIORAL|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
219338727|NCT04888299|DEVICE|Raman spectroscopy (SPECTRA IMDx)|The SPECTRA IMDx comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx probe is connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal for diagnostic classification.
219338728|NCT01741675|BEHAVIORAL|Questionnaire and monetary incentive|
219338729|NCT01741675|BEHAVIORAL|Questionnaire only|
219338730|NCT06978933|DRUG|ABSK-011|"Drug: ABSK-011 RP2D according to the results of Phase I trial~Other Names:~• FGFR4 inhibitor Drug: ABSK043 RP2D according to the results of Phase I trial~Other Names:~• Oral PD-L1 inhibitor"
219338731|NCT00095355|DRUG|Lithium|
219338732|NCT00095355|DRUG|Divalproex|
219338733|NCT01169220|DRUG|Go-Lytely|Bowel cleansing agent
219338734|NCT01169220|DRUG|Go Lytely|Bowel cleansing agent
219338735|NCT06891950|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Each 0.5 mL dose of the lyophilized formulation of Dengue 1,2,3,4 (attenuated) presents an approximate concentration of 103.0 PFU of each vaccine virus rDEN1Δ30-1545, rDEN2/4Δ30(ME)-1495,7163, rDEN3Δ30/31-7164, rDEN4Δ30-7132,7163,8308.
219338736|NCT06410300|RADIATION|Curative Radiotherapy|Radiation dose of 45 Gy or higher
219338737|NCT06410300|DRUG|Immunotherapy|checkpoint inhibitor per PI discretion
219338738|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
219338739|NCT01605526|DRUG|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
219338740|NCT01605526|DRUG|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
219338741|NCT04754698|BIOLOGICAL|CoronaVac|CoronaVac (Sinovac Biotech Ltd., Beijing, China)
219338742|NCT00633906|BEHAVIORAL|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
219338743|NCT00633906|BEHAVIORAL|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
219338744|NCT04010500|DEVICE|no mouthguard|Control (not using mouthguard)
219338745|NCT04010500|DEVICE|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
219338746|NCT04010500|DEVICE|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
219338747|NCT00407095|DRUG|Pardoprunox|12-42 mg/day
219338748|NCT01497639|DEVICE|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
219338749|NCT01497639|DEVICE|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
219338750|NCT03729674|DRUG|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
219338751|NCT03729674|DRUG|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
219338752|NCT00346073|BIOLOGICAL|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
219338753|NCT00346073|BIOLOGICAL|ADACEL®|Sanofi Pasteur
219338754|NCT02204150|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
219338755|NCT04350853|PROCEDURE|Surgical extrusion|Surgically coronal reposition of the tooth
219338756|NCT00001003|DRUG|Pentamidine isethionate|
219338757|NCT00001003|DRUG|Zidovudine|
219338758|NCT05914168|DEVICE|Breast Tomosynthesis|Three dimensional mammography
219338759|NCT02728193|PROCEDURE|RFA|
219338760|NCT02728193|PROCEDURE|MWV|
219338761|NCT02728193|PROCEDURE|PEI|Percutaneous ethanol injection
219338762|NCT06035900|DRUG|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
219338763|NCT03703882|DRUG|Edasalonexent|100 mg/kg/day
219338764|NCT03703882|DRUG|Placebo|Placebo
219338765|NCT01617460|DRUG|Aripiprazole|Flexibly dose administered orally once daily
219338766|NCT03711656|DEVICE|isCGM (intermittently scanned Continuous Glucose Monitoring)|Data collection
219338767|NCT03711656|DEVICE|Physical exercise tracker|Data collection
219338768|NCT05183607|OTHER|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
219338769|NCT02079571|DIETARY_SUPPLEMENT|Coconut water|250 ml Coconut water for each subject
219338770|NCT02079571|DIETARY_SUPPLEMENT|ginger tea|250 ml for each subject
219338771|NCT04359303|OTHER|Systemic indirect endovenous ozone therapy|200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
219338772|NCT01140360|DRUG|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
219338773|NCT01006421|DIETARY_SUPPLEMENT|GINGKO BILOBA|MEMOREX 60 MG BID
219338774|NCT05280678|PROCEDURE|Orthodontic miniscrew insertion in the mandibular buccal shelf|"Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion."
219338775|NCT02708953|PROCEDURE|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
219338776|NCT02708953|PROCEDURE|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
219338777|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
219338778|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
219338779|NCT03773042|DRUG|HSK3486|For induction and maintenance of sedation.
219338780|NCT03773042|DRUG|Propofol|For induction and maintenance of sedation.
219338781|NCT03415295|OTHER|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
219338782|NCT03762759|PROCEDURE|Computed Tomography|Undergo PET/CT
219338783|NCT03762759|DRUG|Fluciclovine F18|Given IV
219338784|NCT03762759|RADIATION|Gallium Ga68-labeled PSMA-11|Given IV
219338785|NCT03762759|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219338786|NCT00625833|DRUG|Placebo|Oral tablet once a day dosing for 10 weeks.
219338787|NCT00625833|DRUG|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
219338788|NCT02834468|DRUG|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
219338789|NCT06081556|DIAGNOSTIC_TEST|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
219338790|NCT01123863|OTHER|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
219338791|NCT01123863|OTHER|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
219338792|NCT04098770|BIOLOGICAL|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
219338793|NCT03339661|DRUG|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
219338794|NCT03339661|DRUG|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
219338795|NCT03339661|DRUG|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
219338796|NCT03313427|OTHER|Physical Therapy Early Intervention|"At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
219338797|NCT03313427|OTHER|Usual Care|NICU usual care
219338798|NCT05716880|DRUG|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
219338799|NCT05716880|OTHER|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
219338800|NCT06355765|DIETARY_SUPPLEMENT|Citicoline blackcurrant supplement|Citicoline, Vitamins A, B, C and E, and Blackcurrant
219338801|NCT00355433|PROCEDURE|Urodymanics|
219338802|NCT06302907|PROCEDURE|Buffered Local anaesthesia|A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
219338803|NCT06302907|PROCEDURE|Unbuffered Local anaesthesia|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
219338804|NCT05453058|DIAGNOSTIC_TEST|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
219338805|NCT02275078|BEHAVIORAL|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
219338806|NCT02275078|DEVICE|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
219338807|NCT02275078|OTHER|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
219338808|NCT01388673|PROCEDURE|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
219338809|NCT00466466|DRUG|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
219338810|NCT00075023|DRUG|Thalidomide Gel|
219338811|NCT00075023|DRUG|Placebo Gel|
219338812|NCT04458142|OTHER|Single buccal infiltration|painless technique for palatal anesthesia,single injection,single puncture given
219338813|NCT03670953|DRUG|IR CD-LD|Active comparator - IR CD-LD
219338814|NCT03670953|DRUG|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
219338815|NCT03670953|OTHER|Placebo Matching IPX203|Double dummy placebo capsules
219338816|NCT03670953|OTHER|Placebo Matching IR CD-LD|Double dummy placebo tablets
219338817|NCT04268485|DIAGNOSTIC_TEST|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
219338818|NCT00899184|GENETIC|polymorphism analysis|
219338819|NCT00899184|OTHER|laboratory biomarker analysis|
219338820|NCT03094234|DEVICE|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
219338821|NCT03094234|PROCEDURE|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
219338822|NCT03094234|DRUG|Propranolol|Appropriate dose of propranolol was administered to the patients.
219338823|NCT02603120|DRUG|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
219338824|NCT02603120|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
219338825|NCT02603120|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
219338826|NCT02603120|DRUG|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
219338827|NCT06379737|BEHAVIORAL|Multi-systemic Rehabilitation|"Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit"
219338828|NCT06434194|DEVICE|Serranator PTA Serration Catheter|The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
219338829|NCT06434194|DRUG|PTA (Standard of Care)|A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
219338830|NCT04639973|DIAGNOSTIC_TEST|Group 1 (First trimester ultrasound)|A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
219338831|NCT04639973|DIAGNOSTIC_TEST|Group 2 (Second trimester anatomy ultrasound)|Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
219338832|NCT03171220|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
219338833|NCT03171220|BIOLOGICAL|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
219338834|NCT03171220|DRUG|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
219338835|NCT03171220|DRUG|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
219338836|NCT03171220|BIOLOGICAL|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
219338837|NCT00838773|BEHAVIORAL|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
219338838|NCT00838773|BEHAVIORAL|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
219338839|NCT00838773|BEHAVIORAL|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
219338840|NCT02281643|DRUG|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
219338841|NCT00529997|DEVICE|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
219338842|NCT04056572|DRUG|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
219338843|NCT00176605|DRUG|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
219338844|NCT00176605|DRUG|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
219338845|NCT01321710|BEHAVIORAL|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
219338846|NCT01321710|BEHAVIORAL|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
219338847|NCT01321710|DRUG|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
219338848|NCT01234974|DRUG|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
219338849|NCT01234974|DRUG|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
219338850|NCT01227187|DRUG|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
219338851|NCT01880671|DEVICE|Inactive Migraine Medical Device|
219338852|NCT01880671|DEVICE|Migraine Medical Device|
219338853|NCT01407770|GENETIC|DNA analysis|Genetic
219338854|NCT01407770|GENETIC|gene expression analysis|Genetic
219338855|NCT01407770|OTHER|enzyme-linked immunosorbent assay|Genetic
219338856|NCT01407770|OTHER|flow cytometry|Genetic
219338857|NCT01407770|OTHER|laboratory biomarker analysis|Genetic
219338858|NCT01407770|OTHER|questionnaire administration|Genetic
219338859|NCT01407770|PROCEDURE|adjuvant therapy|Genetic
219338860|NCT01407770|PROCEDURE|assessment of therapy complications|Genetic
219338861|NCT01407770|PROCEDURE|quality-of-life assessment|Genetic
219338862|NCT01407770|RADIATION|3-dimensional conformal radiation therapy|Genetic
219338863|NCT01407770|RADIATION|breast irradiation|Genetic
219338864|NCT01407770|RADIATION|external beam radiation therapy|Genetic
219338865|NCT01407770|RADIATION|hypofractionated radiation therapy|Genetic
219338866|NCT01407770|RADIATION|intensity-modulated radiation therapy|Genetic
219338867|NCT01407770|RADIATION|whole breast irradiation|Genetic
219338868|NCT05311124|DEVICE|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
219338869|NCT03889314|DRUG|Rosuvastatin 20mg|Statin Therapy
219338870|NCT03889314|OTHER|Placebo|Placebo
219338871|NCT02361502|DRUG|mirabegron|
219338872|NCT02361502|DRUG|placebo|
219338873|NCT01908023|BEHAVIORAL|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
219338874|NCT03603860|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
219338875|NCT02463409|DRUG|Theophylline|24 hour infusion of IV theophylline
219338876|NCT05627284|PROCEDURE|Stoma reversal with bio-mesh placement|Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.
219338877|NCT05285241|OTHER|Multidirectional stepping exercises|These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).
219338878|NCT05285241|OTHER|Conventional physiotherapy group|Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)
219338879|NCT01433237|GENETIC|RNA analysis|
219338880|NCT01433237|GENETIC|gene expression analysis|
219338881|NCT01433237|OTHER|laboratory biomarker analysis|
219338882|NCT03656679|PROCEDURE|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
219338883|NCT03656679|PROCEDURE|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
219338884|NCT03303950|DRUG|Busulfan|Given IV
219338885|NCT03303950|DRUG|Cyclophosphamide|Given IV
219338886|NCT03303950|DRUG|Fludarabine|Given IV
219338887|NCT03303950|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
219338888|NCT03303950|OTHER|Laboratory Biomarker Analysis|Correlative studies
219338889|NCT00639483|DRUG|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
219338890|NCT00639483|DRUG|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
219338891|NCT02131558|PROCEDURE|ICG Dye|ICG Dye injections
219338892|NCT04134962|DIAGNOSTIC_TEST|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
219338893|NCT03577730|DRUG|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
219338894|NCT03577730|DRUG|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
219338895|NCT05874973|OTHER|Time-controlled adaptative ventilation (TCAV)|Ventilation with TCAV set on the APRV mode on the ventilator.
219338896|NCT05874973|OTHER|Volume-controlled ventilation (VCV)|Ventilation with the VCV mode set on the ventilator.
219338897|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage survival cohort|consists of surviving patients
219338898|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage mortality cohort|consists of deceased patients
219338899|NCT02203825|BIOLOGICAL|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
219338900|NCT02146508|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
219338901|NCT02146508|DEVICE|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
219338902|NCT01911442|DRUG|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
219338903|NCT01911442|DRUG|Lurasidone|Lurasidone 60 mg once daily
219338904|NCT01911442|DRUG|Placebo|Placebo
219338905|NCT00825500|DRUG|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
219338906|NCT00825500|DRUG|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
219338907|NCT00825500|DRUG|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
219338908|NCT00003437|DRUG|asparaginase|
219338909|NCT00003437|DRUG|cyclophosphamide|
219338910|NCT00003437|DRUG|cytarabine|
219338911|NCT00003437|DRUG|daunorubicin hydrochloride|
219338912|NCT00003437|DRUG|dexamethasone|
219338913|NCT00003437|DRUG|doxorubicin hydrochloride|
219338914|NCT00003437|DRUG|mercaptopurine|
219338915|NCT00003437|DRUG|methotrexate|
219338916|NCT00003437|DRUG|pegaspargase|
219338917|NCT00003437|DRUG|prednisolone|
219338918|NCT00003437|DRUG|thioguanine|
219338919|NCT00003437|DRUG|vincristine sulfate|
219338920|NCT00003437|RADIATION|radiation therapy|
219338921|NCT00122681|BIOLOGICAL|Cervarix™|Intramuscular injection, 3 doses
219338922|NCT00122681|BIOLOGICAL|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
219338923|NCT02819635|DRUG|Placebo|Film-coated tablet for oral administration
219338924|NCT02819635|DRUG|Upadacitinib|Film-coated tablet for oral administration
219338925|NCT03179891|DRUG|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
219338926|NCT02833922|BEHAVIORAL|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
219338927|NCT02938884|DEVICE|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
219338928|NCT05233020|DEVICE|robotic|fifteen patients undergo robotic operation
219338929|NCT05233020|DEVICE|hybrid|fifteen patients undergo hybrid operation
219338930|NCT04058925|DEVICE|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
219338931|NCT00018655|BEHAVIORAL|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
219338932|NCT00018655|BEHAVIORAL|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
219338933|NCT02771509|DRUG|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
219338934|NCT02771509|DRUG|Placebo|Normal saline
219338935|NCT02456844|DRUG|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12."
219338936|NCT02456844|DRUG|Methotrexate, Leucovorin and BMS-986142|"1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10."
219338937|NCT03137589|OTHER|Telemedical support|Participating sites will be advised by telemedicine support.
219338938|NCT03078374|DRUG|Warfarin|Reduced dosage to obtain lower INR range
219338939|NCT03559855|BEHAVIORAL|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
219338940|NCT03219242|DEVICE|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
219338941|NCT06171438|DIAGNOSTIC_TEST|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
219338942|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
219338943|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
219338944|NCT04417634|DIAGNOSTIC_TEST|RFR|Measurement of resting flow ratio
219338945|NCT04417634|DIAGNOSTIC_TEST|FFR|Measurement of fractional flow reserve
219338946|NCT02167750|OTHER|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
219338947|NCT04026724|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
219338948|NCT03840512|DRUG|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
219338949|NCT00609193|DRUG|lithium|standard clinical care
219338950|NCT00609193|DRUG|quetiapine|standard clinical care
219338951|NCT04349163|OTHER|Questionnaire|CD-RISC 25 questionnaire
219338952|NCT05141370|DEVICE|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
219338953|NCT04291443|PROCEDURE|Heavy Force (225g)|Orthodontic Force
219338954|NCT04291443|PROCEDURE|Light Force (25g)|Orthodontic Force
219338955|NCT01568775|DRUG|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
219338956|NCT04416555|DEVICE|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
219338957|NCT04416555|DEVICE|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
219338958|NCT02723695|OTHER|Evaluation of postural performances|Postural tests
219338959|NCT02537886|DEVICE|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
219338960|NCT00250250|DRUG|ZOMACTON|
219338961|NCT02006342|DRUG|Insulin Glargine|
219338962|NCT02006342|DRUG|Regular Insulin|
219338963|NCT06490835|BEHAVIORAL|High-quality palliative care through consultation-based palliative care services in the ICU|"Family Counseling: Social workers implement a supportive process for families, assessing the individualized psychosocial and decisional support needs of patients and families to provide foundational data for palliative care consultations.~Family Meeting Support: In cases of high medical complexity, uncertainty, value conflicts, or communication issues, the palliative care consultation team supports the facilitation of family meetings.~Consultation: The palliative care team provides consultations to the attending physician based on the palliative care needs assessed during family counseling. Topics include symptom management, understanding treatment options, decisional conflict, emotional and practical support, goal of care setting, resources, and bereavement support.~Palliative Care by attending Physician: The attending physician incorporates the consultations received from the palliative care consultation team to provide high-quality palliative care to patients and their families."
219338964|NCT00737191|DRUG|olanzapine|Given orally
219338965|NCT00737191|OTHER|placebo|Given orally
219338966|NCT04670614|PROCEDURE|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
219338967|NCT04670614|PROCEDURE|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
219338968|NCT06466447|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
219338969|NCT01972620|DRUG|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
219338970|NCT04134182|DRUG|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
219338971|NCT04134182|DRUG|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
219338972|NCT04828070|OTHER|Observation|all participants followed for clinical data for one year, vital status check at 5 years
219338973|NCT02691975|DRUG|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
219338974|NCT06004843|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
219338975|NCT06004843|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
219338976|NCT03528343|DRUG|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
219338977|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
219338978|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
219338979|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
219338980|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
219338981|NCT01118273|DRUG|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
219338982|NCT01118273|DRUG|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
219338983|NCT03360097|PROCEDURE|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
219338984|NCT04592640|OTHER|Human amniotic mesenchymal stem cells|"1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
219338985|NCT05790382|DRUG|NM-101|"In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts)."
219338986|NCT05790382|DRUG|Placebo|Placebo solution for infusion
219338987|NCT03574675|DEVICE|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219338988|NCT03574675|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219338989|NCT01392534|DRUG|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
219338990|NCT03014778|DRUG|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
219338991|NCT03014778|DRUG|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
219338992|NCT00754832|DRUG|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
219338993|NCT00754832|DRUG|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
219338994|NCT05998421|PROCEDURE|acupuncture|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle. Seirin 0.2-×30-mm acupuncture needles were used. First, needles were inserted into Shenting (GV 24) and bilateral Benshen (G 13) to relieve uneasiness of mind. Then, they were inserted into Chung wan (cv 12), Qihai (CV6), Guan yuan, chung chi (cv 3), bilateral Guiai (S 29) and Zigong (Extra 16) to recuperate energy. Finally, bilateral Tsusanli (st 36), Yinlingch'uan (sp 9) and San yin chiao (sp 6) were used to soothe the liver and tonify the spleen and kidney. Each acupuncture treatment session lasted 30 minutes, with mostly bilateral needle retention over 20-30 minutes for evens techniques.
219338995|NCT05998421|DRUG|routine aspirin and heparin treatment|The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
219338996|NCT02004262|BIOLOGICAL|GVAX Pancreas Vaccine|
219338997|NCT02004262|BIOLOGICAL|CRS-207|
219338998|NCT02004262|DRUG|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
219338999|NCT02004262|DRUG|cyclophosphamide|
219339000|NCT02888015|OTHER|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
219339001|NCT04200053|OTHER|Reflexology massage|Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.
219339002|NCT04200053|OTHER|Reflexology massage and passive music|Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
219339003|NCT01923285|DEVICE|AXIUM Neurostimulator System|
219339004|NCT01923285|DEVICE|Control Spinal Cord Stimulation Device|
219339005|NCT05501561|BIOLOGICAL|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219339006|NCT05501561|BIOLOGICAL|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219339007|NCT05501561|BIOLOGICAL|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219339008|NCT05501561|BIOLOGICAL|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
219339009|NCT04945070|DRUG|IGlarLixi|Switching T2DM subjects from MDI to iGlarLixi
219339010|NCT04945070|DRUG|MDI - Multiple dose insulin injection|Continuing with established MDI regimen
219339011|NCT00711984|DEVICE|Herkulink renal artery Stent|renal artery stent
219339012|NCT00711984|OTHER|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
219339013|NCT01209650|DRUG|BIBW 2992|tablets
219339014|NCT00039585|DRUG|imatinib mesylate|
219339015|NCT03978507|BEHAVIORAL|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
219339016|NCT03978507|BEHAVIORAL|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
219339017|NCT02583906|DEVICE|CPAP|Treatment with CPAP for six months in the CPAP arm.
219339018|NCT04863846|OTHER|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
219339019|NCT01041482|DRUG|sorafenib|sorafenib 400mg twice daily
219339020|NCT00428142|BIOLOGICAL|rituximab|375mg/m2 day 1
219339021|NCT00428142|DRUG|bortezomib|1.3mg/m2 days 1 \& 8
219339022|NCT00428142|DRUG|cyclophosphamide|750mg/m2 day 1
219339023|NCT00428142|DRUG|prednisone|40mg/m2 days 1-5
219339024|NCT00428142|DRUG|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
219339025|NCT00330382|DRUG|Bowman-Birk inhibitor concentrate|Given orally
219339026|NCT00330382|OTHER|placebo|Given orally
219339027|NCT00330382|OTHER|laboratory biomarker analysis|Correlative studies
219339028|NCT04188574|DRUG|BB2603-1|Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
219339029|NCT04188574|DRUG|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
219339030|NCT04188574|DRUG|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
219339031|NCT04188574|OTHER|Vehicle|Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
219339032|NCT03823066|DEVICE|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
219339033|NCT05067322|DEVICE|Minecraft|A game played within the videogame Minecraft
219339034|NCT05511272|BIOLOGICAL|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
219339035|NCT03633175|DRUG|Vaginal progesterone|400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
219339036|NCT03045679|OTHER|RYGB|laparoscopic RYGB
219339037|NCT03045679|OTHER|OAGB/MGB|laparoscopic OAGB/MGB
219339038|NCT04542759|DRUG|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
219339039|NCT04542759|DRUG|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
219339040|NCT03172845|PROCEDURE|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
219339041|NCT03814486|OTHER|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
219339042|NCT02987036|DEVICE|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
219339043|NCT02987036|DEVICE|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
219339044|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
219339045|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
219339046|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
219339047|NCT04603131|BIOLOGICAL|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
219339048|NCT03628053|BIOLOGICAL|Tisagenlecleucel|autologous cellular immunotherapy product
219339049|NCT03628053|DRUG|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
219339050|NCT03628053|DRUG|Inotuzumab|CD22-directed antibody-drug conjugate
219339051|NCT01699477|DEVICE|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
219339052|NCT02483663|DEVICE|Functional Magnetic Resonance Imaging|Measure brain activity.
219339053|NCT02483663|RADIATION|Dual Energy X-ray absorptiometry|Body composition measurements.
219339054|NCT02483663|OTHER|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
219339055|NCT02483663|OTHER|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
219339056|NCT02483663|OTHER|Test Meals|Breakfast, a snack, and lunch provided during study visit.
219339057|NCT02483663|OTHER|Computer Tests|Perform a series of computer tests to determine reaction time.
219339058|NCT02483663|PROCEDURE|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
219339059|NCT01245582|DRUG|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
219339060|NCT01245582|DRUG|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
219339061|NCT01245582|DRUG|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
219339062|NCT02810756|DRUG|New Pazopanib formulation|
219339063|NCT00711620|DRUG|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
219339064|NCT03839173|OTHER|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
219339065|NCT04006886|DIETARY_SUPPLEMENT|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
219339066|NCT02221453|DRUG|Triamcinolone Acetonide|
219339067|NCT00871520|OTHER|no specific interventions|There are no specific interventions in this observational study
219339068|NCT01732497|DEVICE|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
219339069|NCT03200366|BEHAVIORAL|Tailored DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
219339070|NCT03200366|BEHAVIORAL|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
219339071|NCT04004637|DRUG|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg."
219339072|NCT04459182|DIAGNOSTIC_TEST|ENDOPAT|digital plethysmography
219339073|NCT03827824|DEVICE|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
219339074|NCT03827824|DEVICE|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
219339075|NCT02820311|DRUG|TD-4208 175 mcg|via nebulizer
219339076|NCT02820311|DRUG|TD-4208 700 mcg|via nebulizer
219339077|NCT02820311|DRUG|Placebo for TD-4208|via nebulizer
219339078|NCT02820311|DRUG|Moxifloxacin 400 mg|oral
219339079|NCT05397626|BEHAVIORAL|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome
219339080|NCT05397626|DIETARY_SUPPLEMENT|Hydrogen Water|Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome
219339081|NCT05397626|COMBINATION_PRODUCT|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
219339082|NCT02192203|DRUG|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
219339083|NCT02192203|DRUG|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
219339084|NCT02192203|DRUG|Menthol Only Gel|3% menthol
219339085|NCT02192203|DRUG|Placebo Only Gel|0.09% menthol
219339086|NCT05704894|BIOLOGICAL|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between \<12g/dL
219339087|NCT04075474|DEVICE|silver diamine fluoride|38% SDF on primary upper anterior teeth
219339088|NCT04075474|DEVICE|sodium fluoride|5% NaF on primary upper anterior teeth
219339089|NCT06281470|DRUG|WS016 Single Dose(6g)|WS016 6g, to be administered orally as a single dose.
219339090|NCT06281470|DRUG|WS016 Single Dose(12g)|WS016 12g, to be administered orally as a single dose.
219339091|NCT06281470|DRUG|WS016 Single Dose(24g)|WS016 24g, to be administered orally as a single dose.
219339092|NCT06281470|DRUG|WS016 Single Dose(36g)|WS016 36g, to be administered orally as a single dose.
219339093|NCT06281470|DRUG|WS016 Single Dose(48g)|WS016 48g, to be administered orally as a single dose.
219339094|NCT06281470|DRUG|SAD matching placebo|Matching placebo, to be administered orally as a single dose.
219339095|NCT06281470|DRUG|WS016 Multiple Dose(12g)|WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
219339096|NCT06281470|DRUG|WS016 Multiple Dose(24g)|WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
219339097|NCT06281470|DRUG|WS016 Multiple Dose(48g)|WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
219339098|NCT06281470|DRUG|MAD matching placebo|Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
219339099|NCT04032600|PROCEDURE|Paracentesis|Full versus partial paracentesis (3 liters)
219339100|NCT03590730|DEVICE|ICD implantation|ICD will be implanted according to current guidelines recommendations.
219339101|NCT02018822|DEVICE|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
219339102|NCT02018822|DEVICE|TPH3|light-cured resin composite for teeth
219339103|NCT02018822|DEVICE|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
219339104|NCT02690155|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
219339105|NCT02690155|DRUG|VKA (Vitamin K antagonist)|As prescribed by treating physicians
219339106|NCT04622332|DRUG|SIR1-365|Route of administration: oral
219339107|NCT04622332|DRUG|Matching Placebo|Route of administration: oral
219339108|NCT05758519|DRUG|QLS1128|QLS1128
219339109|NCT05758519|DRUG|Placebo|Placebo
219339110|NCT03201458|DRUG|Atezolizumab|Given IV
219339111|NCT03201458|PROCEDURE|Biopsy|Undergo tumor biopsy
219339112|NCT03201458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219339113|NCT03201458|DRUG|Cobimetinib|Given PO
219339114|NCT03201458|PROCEDURE|Computed Tomography|Undergo CT
219339115|NCT03201458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219339116|NCT02963116|DRUG|AZD5718 IR tablet|
219339117|NCT02963116|DRUG|AZD5718 oral suspension|
219339118|NCT02963116|DRUG|Rosuvastatin tablet|
219339119|NCT01785459|DRUG|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
219339120|NCT01785459|DRUG|Standard Care|10 mg Intravenous injection of Prochlorperazine
219339121|NCT00715026|DEVICE|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
219339122|NCT01263821|PROCEDURE|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
219339123|NCT01263821|PROCEDURE|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
219339124|NCT01263821|PROCEDURE|Functional magnetic resonance imaging|Undergo functional MRI
219339125|NCT01263821|PROCEDURE|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
219339126|NCT01263821|PROCEDURE|Therapeutic conventional surgery|Undergo maximal surgical resection
219339127|NCT01263821|PROCEDURE|Quality-of-life assessment|Ancillary studies
219339128|NCT01263821|PROCEDURE|Radiation therapy treatment planning/simulation|Undergo IMRT planning
219339129|NCT01263821|PROCEDURE|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
219339130|NCT01263821|OTHER|Questionnaire administration|Ancillary studies
219339131|NCT00442780|DRUG|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
219339132|NCT00442780|DRUG|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
219339133|NCT05768451|OTHER|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
219339134|NCT00750737|DRUG|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
219339135|NCT00750737|DRUG|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
219339136|NCT01826253|DRUG|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
219339137|NCT03399877|BIOLOGICAL|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
219339138|NCT03399877|BIOLOGICAL|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
219339139|NCT03399877|BIOLOGICAL|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
219339140|NCT06116500|DEVICE|Modified twin block appliance with expander|These appliances are myofunctional appliance used for treating class II division growing adolescents.
219339141|NCT06116500|DEVICE|Conventional twin block appliance with expander|These appliances are myofunctional appliances used for treating class II division growing adolescents.
219339142|NCT05479253|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
219339143|NCT00068744|DRUG|cisplatin|
219339144|NCT00068744|DRUG|fluorouracil|
219339145|NCT00068744|DRUG|mitomycin C|
219339146|NCT00068744|RADIATION|radiation therapy|
219339147|NCT01161264|BIOLOGICAL|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
219339148|NCT03694496|BEHAVIORAL|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
219339149|NCT04652323|DRUG|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
219339150|NCT04707157|DRUG|LY3556050|given orally
219339151|NCT04707157|DRUG|Placebo|given orally
219339152|NCT02636088|DRUG|Cetuximab|
219339153|NCT04539561|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
219339154|NCT00502138|DRUG|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
219339155|NCT04784182|DIETARY_SUPPLEMENT|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
219339156|NCT04784182|DIETARY_SUPPLEMENT|placebo|Daily consumption of visually similar placebo pills
219339157|NCT02069405|OTHER|Relaxation Music|
219339158|NCT03098823|DRUG|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
219339159|NCT03098823|DRUG|Prednisone|FDA approved corticosteroid frequently used for SLE.
219339160|NCT03007056|OTHER|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
219339161|NCT01389752|DRUG|LY2216684|Administered orally
219339162|NCT01389752|DRUG|Activated Charcoal|Administered orally
219339163|NCT01401725|BEHAVIORAL|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
219339164|NCT01401725|BEHAVIORAL|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
219339165|NCT01401725|OTHER|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
219339166|NCT05142527|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
219339167|NCT05142527|OTHER|Placebo|Placebo
219339168|NCT04193163|DEVICE|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
219339169|NCT03001050|DEVICE|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
219339170|NCT01063075|DRUG|Cetuximab|Administered Intravenously
219339171|NCT01063075|DRUG|Carboplatin|Administered Intravenously
219339172|NCT01063075|DRUG|5 - FU|Administered Intravenously
219339173|NCT04643756|OTHER|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
219339174|NCT04643756|OTHER|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
219339175|NCT03716401|DIAGNOSTIC_TEST|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
219339176|NCT03716401|DIAGNOSTIC_TEST|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
219339177|NCT03716401|PROCEDURE|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
219339178|NCT03716401|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
219339179|NCT03716401|DIAGNOSTIC_TEST|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
219339180|NCT01195129|DEVICE|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
219339181|NCT01195129|DEVICE|Non-hydrogel coils|Cerecyte or bare platinum coils
219339182|NCT04327687|DEVICE|Remote ischaemic conditioning|5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
219339183|NCT04327687|OTHER|conventional therapy|conventional therapy
219339184|NCT03568591|PROCEDURE|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
219339185|NCT04085679|OTHER|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
219339186|NCT01730508|DRUG|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
219339187|NCT05338177|OTHER|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
219339188|NCT05338177|OTHER|No immunosuppression reduction|participants do not alter immunosuppresion
219339189|NCT00643526|DEVICE|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
219339190|NCT03957265|PROCEDURE|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
219339191|NCT05768945|DRUG|Semaglutide|Semaglutide claim is used as the exposure group.
219339192|NCT05768945|DRUG|DPP-4 inhibitor|DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
219339193|NCT06386965|OTHER|taking blood sample|A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
219339194|NCT06273007|OTHER|PartoMa intervention(Locally achievable intrapartum care guideline), in house LDHF trainings|We will implement PartoMa interventions: seminars, LDHF training, and supportive supervision
219339195|NCT03048539|PROCEDURE|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
219339196|NCT00303147|BEHAVIORAL|Expressive Writing|
219339197|NCT01371136|PROCEDURE|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
219339198|NCT00321347|DRUG|Lidocaine|
219339199|NCT04035018|PROCEDURE|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
219339200|NCT04035018|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
219339201|NCT03885791|DEVICE|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
219339202|NCT04340713|OTHER|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
219339203|NCT04251910|DRUG|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
219339204|NCT04251910|DRUG|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
219339205|NCT03559036|PROCEDURE|Locomotor Training|Body-weight supported stepping on a treadmill.
219339206|NCT01722604|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
219339207|NCT01722604|DRUG|Azopt 1%|Azopt 1%, RLD
219339208|NCT06174844|OTHER|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
219339209|NCT04519359|OTHER|Stop NAs therapy|Stop NAs therapy
219339210|NCT03880942|OTHER|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
219339211|NCT03880942|OTHER|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
219339212|NCT00804570|DRUG|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
219339213|NCT00804570|DRUG|placebo|once daily, orally, 16 weeks
219339214|NCT06033742|DRUG|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
219339215|NCT06033742|DRUG|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
219339216|NCT03467464|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
219339217|NCT05214612|COMBINATION_PRODUCT|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
219339218|NCT03837782|PROCEDURE|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
219339219|NCT03135275|PROCEDURE|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
219339220|NCT03135275|PROCEDURE|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
219339221|NCT03135275|DEVICE|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
219339222|NCT04312685|DEVICE|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
219339223|NCT00487136|DRUG|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
219339224|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
219339225|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
219339226|NCT03870659|RADIATION|Breast MRI|Magnetic resonance imaging to the breast
219339227|NCT03173729|DIAGNOSTIC_TEST|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
219339228|NCT06405711|DEVICE|frame lens|A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
219339229|NCT00290342|BIOLOGICAL|DTPa-IPV|3 intramuscular injections
219339230|NCT00290342|BIOLOGICAL|DTPa|3 intramuscular injections
219339231|NCT00290342|BIOLOGICAL|IMOVAX Polio®|3 intramuscular injections
219339232|NCT05171348|DRUG|CM326|a humanized monoclonal antibody
219339233|NCT05171348|DRUG|Placebo|Placebo
219339234|NCT01045980|DRUG|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
219339235|NCT01045980|DRUG|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
219339236|NCT01045980|DRUG|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
219339237|NCT01045980|DEVICE|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
219339238|NCT06064942|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
219339239|NCT06064942|BEHAVIORAL|School services for families of children with ADHD|Selected school social personnel will deliver services as usual for the control group.
219339240|NCT03221491|DEVICE|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
219339241|NCT03096951|BEHAVIORAL|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
219339242|NCT03096951|OTHER|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
219339243|NCT05054647|OTHER|psychometric questionnaires|Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
219339244|NCT02535884|DEVICE|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
219339245|NCT01936636|DRUG|Fentanyl|
219339246|NCT06474949|DRUG|Bupivacaine injection|Injection at end of Open Reduction Internal Fixation
219339247|NCT06474949|OTHER|Saline|Injection at end of Open Reduction Internal Fixation
219339248|NCT03341975|BEHAVIORAL|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
219339249|NCT01664988|BEHAVIORAL|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
219339250|NCT01664988|BEHAVIORAL|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
219339251|NCT01664988|OTHER|control (routine care)|received routine care of clinic or health center and use drugs if necessary
219339252|NCT01056510|DRUG|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
219339253|NCT01056510|DRUG|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
219339254|NCT01056510|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
219339255|NCT01898871|DIETARY_SUPPLEMENT|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
219339256|NCT03275571|BEHAVIORAL|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
219339257|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
219339258|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
219339259|NCT01034735|BIOLOGICAL|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
219339260|NCT01269762|DRUG|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
219339261|NCT04137120|DRUG|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
219339262|NCT02798055|DRUG|Bosentan group|
219339263|NCT06385730|DRUG|neoadjuvant anti-PD-1|PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
219339264|NCT06385730|DRUG|neoadjuvant anti-PD-1 with LDRT|"Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators"
219339265|NCT04776473|PROCEDURE|Open treatment|Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
219339266|NCT04776473|OTHER|Closed treatment|Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
219339267|NCT04944654|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
219339268|NCT05148039|BEHAVIORAL|Dietician advice|Personalised dietetic advice
219339269|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
219339270|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
219339271|NCT00489814|BEHAVIORAL|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
219339272|NCT05352152|DIAGNOSTIC_TEST|Next generation sequence|Next generation sequence will be used to detect the pathogens in ascites.
219339273|NCT02707380|OTHER|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
219339274|NCT02707380|OTHER|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
219339275|NCT04006496|BEHAVIORAL|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
219339276|NCT00803699|DIETARY_SUPPLEMENT|placebo|daily placebo capsules for 12 months
219339277|NCT00803699|DIETARY_SUPPLEMENT|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
219339278|NCT00724997|BIOLOGICAL|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
219339279|NCT00133991|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
219339280|NCT00133991|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
219339281|NCT00133991|DRUG|Cyclophosphamide|1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
219339282|NCT00133991|DRUG|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
219339283|NCT00133991|DRUG|Methotrexate|3 g/m\^2 on Day 8 of each cycle of R-CVP.
219339284|NCT00133991|DRUG|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
219339285|NCT00133991|DRUG|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
219339286|NCT00133991|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
219339287|NCT00133991|DRUG|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
219339288|NCT03002155|OTHER|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
219339289|NCT03271398|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing (intensive format)
219339290|NCT03271398|BEHAVIORAL|PC|Progressive counting (intensive format)
219339291|NCT00871182|DRUG|Inhaled PT001|single dose, inhaled
219339292|NCT00871182|DRUG|Inhaled Placebo|single dose, inhaled
219339293|NCT00871182|DRUG|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
219339294|NCT00545298|DRUG|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
219339295|NCT00545298|DRUG|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
219339296|NCT00978029|DRUG|Placebo|Placebo sublingual tablet, once daily
219339297|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
219339298|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
219339299|NCT03819348|OTHER|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
219339300|NCT01498198|PROCEDURE|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
219339301|NCT01498198|OTHER|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
219339302|NCT04972474|OTHER|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
219339303|NCT00259155|DRUG|Rifaximin|
219339304|NCT05912777|RADIATION|Scanner|Scanner to be performed by patients
219339305|NCT01953575|DEVICE|Mucosal Impedance|A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
219339306|NCT01953575|PROCEDURE|Upper Endoscopy|Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
219339307|NCT01931657|DRUG|Mifepristone prior to Mirena|
219339308|NCT01931657|DRUG|Placebo prior to Mirena insertion|
219339309|NCT02088970|DEVICE|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
219339310|NCT02088970|DRUG|antibiotic treatment|"If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone"
219339311|NCT01793142|DRUG|Viviant|Viviant (Bazedoxifene) 20mg once daily
219339312|NCT00326742|BEHAVIORAL|Trier Social Stress Test|
219339313|NCT01866384|PROCEDURE|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
219339314|NCT01866384|OTHER|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
219339315|NCT04960982|DIAGNOSTIC_TEST|blood test|blood sample is taken in first, second and third trimester of pregnancy
219339316|NCT05326984|DRUG|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
219339317|NCT02820155|DRUG|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
219339318|NCT02820155|DRUG|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
219339319|NCT01553188|DRUG|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
219339320|NCT01553188|DRUG|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
219339321|NCT01553188|DRUG|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
219339322|NCT00061542|DRUG|BETOPTIC S (betaxolol HCl)|betaxolol HC)
219339323|NCT00061542|DRUG|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
219339324|NCT02445625|DEVICE|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
219339325|NCT00547846|DRUG|PDC-748|
219339326|NCT02087956|BEHAVIORAL|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
219339327|NCT02087956|BEHAVIORAL|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
219339328|NCT04744207|DRUG|GS-248|120 mg, capsule, once daily for 4 weeks
219339329|NCT04744207|DRUG|Placebo|capsule, once daily for 4 weeks
219339330|NCT03069885|DEVICE|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
219339331|NCT03069885|OTHER|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
219339332|NCT05462964|BEHAVIORAL|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
219339333|NCT05462964|BEHAVIORAL|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
219339334|NCT02718742|OTHER|Laboratory Biomarker Analysis|Correlative studies
219339335|NCT02718742|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
219339336|NCT02718742|OTHER|Quality-of-Life Assessment|Ancillary studies
219339337|NCT00344721|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
219339338|NCT00344721|DIETARY_SUPPLEMENT|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
219339339|NCT03117075|DEVICE|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
219339340|NCT04066491|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
219339341|NCT04066491|DRUG|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
219339342|NCT04066491|DRUG|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
219339343|NCT04066491|DRUG|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
219339344|NCT03650816|OTHER|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
219339345|NCT03650816|OTHER|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
219339346|NCT04506086|DRUG|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
219339347|NCT04506086|DEVICE|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
219339348|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
219339349|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
219339350|NCT06648980|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
219339351|NCT06648980|DIETARY_SUPPLEMENT|Phytoglycogen|Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
219339352|NCT05570539|DRUG|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
219339353|NCT05570539|DRUG|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
219339354|NCT05827250|DEVICE|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
219339355|NCT04687813|DRUG|Placebo|Placebo is a tablet with the same appearance as FTP-198
219339356|NCT04173715|BEHAVIORAL|Older Adults Group.|Physical activity and energy expenditure quantification
219339357|NCT04173715|BEHAVIORAL|Low Physical Function Status Group|Physical activity and energy expenditure quantification
219339358|NCT04173715|BEHAVIORAL|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
219339359|NCT04173715|BEHAVIORAL|High Physical Function Status Group|Physical activity and energy expenditure quantification
219339360|NCT02958007|BEHAVIORAL|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
219339361|NCT02958007|BEHAVIORAL|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
219339362|NCT02495155|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
219339363|NCT01441856|PROCEDURE|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
219339364|NCT01441856|PROCEDURE|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
219339365|NCT05896449|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
219339366|NCT06025890|OTHER|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
219339367|NCT06025890|OTHER|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
219339368|NCT00668031|DRUG|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
219339369|NCT00668031|DRUG|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
219339370|NCT06048107|DRUG|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
219339371|NCT01415011|DRUG|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
219339372|NCT00361426|DEVICE|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
219339373|NCT01855451|DRUG|Cetuximab|
219339374|NCT01855451|RADIATION|RT (70 Gy in 35 fractions)|
219339375|NCT01855451|DRUG|Cisplatin|
219339376|NCT04097613|DRUG|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
219339377|NCT04097613|DRUG|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
219339378|NCT00041275|DRUG|megestrol acetate|
219339379|NCT02462213|OTHER|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
219339380|NCT02462213|OTHER|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
219339381|NCT04373681|OTHER|patient-administered questionnaires|patient-administered questionnaires
219339382|NCT05539768|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
219339383|NCT04858750|DEVICE|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
219339384|NCT00495820|DRUG|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
219339385|NCT00495820|OTHER|Placebo|Standard inactive pill.
219339386|NCT01161290|BEHAVIORAL|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
219339387|NCT05903729|OTHER|Neurodevelopmental therapy treatment|The group will receive NDT therapy
219339388|NCT05903729|OTHER|conventional physiotherapy|conventional physiotherapy
219339389|NCT00741247|PROCEDURE|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
219339390|NCT02470026|DRUG|yohimbine|single low dose treatment
219339391|NCT02470026|DRUG|placebo|single control treatment
219339392|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
219339393|NCT00820950|DRUG|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
219339394|NCT00820950|DRUG|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
219339395|NCT00820950|DRUG|Placebo cream|Cream applied once or twice daily for 56 days
219339396|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
219339397|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
219339398|NCT03497481|BIOLOGICAL|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
219339399|NCT03314077|OTHER|GOLD 2017|Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
219339400|NCT05901493|BEHAVIORAL|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
219339401|NCT06037642|BEHAVIORAL|ABC 0-2 years|Four 1 hour meetings and homework
219339402|NCT06037642|OTHER|waiting list|Will be put on hold for four weeks
219339403|NCT00538798|DRUG|[18F]SP203|
219339404|NCT04543058|DEVICE|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
219339405|NCT04543058|OTHER|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
219339406|NCT04543058|OTHER|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
219339407|NCT04207450|OTHER|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
219339408|NCT04207450|OTHER|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
219339409|NCT04207450|OTHER|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
219339410|NCT05222256|DRUG|Levosimendan|Patients in this group will receive levosimendan
219339411|NCT05222256|DRUG|Adrenaline|Patients in this group will receive Adrenaline
219339412|NCT00503594|DRUG|Methotrexate and temozolomide|Methotrexate and temozolomide
219339413|NCT00503594|DRUG|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
219339414|NCT04465721|BEHAVIORAL|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
219339415|NCT04465721|BEHAVIORAL|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
219339416|NCT00199914|DEVICE|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
219339417|NCT02186847|RADIATION|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
219339418|NCT02186847|DRUG|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
219339419|NCT02186847|DRUG|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
219339420|NCT02186847|DRUG|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
219339421|NCT06977529|BEHAVIORAL|Algorithm; Algorithm-based maintenance created by researchers:such as falls training, early mobilization|"The Fall Prevention Algorithm prepared by the researchers was applied to the experimental group patients."
219339422|NCT06977126|DRUG|PORPHYSOMES|Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension
219339423|NCT06977126|DRUG|64Cu-PORPHYSOMES|Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension
219339424|NCT06978426|OTHER|Pain Group|Professional e-sports athletes who report wrist pain rated at 3 or higher on a 10-point Visual Analog Scale during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
219339425|NCT06978426|OTHER|No-Pain Group|Professional e-sports athletes who report minimal to no wrist pain (less than 3 on a 10-point Visual Analog Scale) during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
219339426|NCT06977945|DIAGNOSTIC_TEST|Specific positron imaging agents targeting NTRS-1(FL-091)|This study is diagnostic. Oncologists screen patients with malignant tumors such as head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma who are clinically suspected or confirmed; investigators talk to patients who meet the inclusion criteria, explain the study purpose and study process, sign informed consent forms, and patients can complete 68Ga-FL-091PET imaging and 111In-FL-091SPECT imaging respectively in outpatient or inpatient periods. General information, clinical data, blood routine, urine routine, liver and kidney function and other biochemical indicators, electrocardiogram, radionuclide imaging results and other imaging data of the patients participating in the study were collected and compared with histopathology to evaluate the value of both imaging in the diagnosis of head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma.
219339427|NCT06977893|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
219339428|NCT06977893|DRUG|Neoadjuvant Chemotherapy|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.
219339429|NCT06977217|PROCEDURE|CRT-D implantation|Cardiac resynchronization therapy with a defibrillator (CRT-D). This combination device uses a pacemaker and an implantable cardioverter-defibrillator (ICD). It may be recommended for people with heart failure who also have a risk of sudden cardiac death. It can find dangerous heart rhythms and correct them. It can pace the heartbeat or shock the heart out of a dangerous heart rhythm.
219339430|NCT06977464|DEVICE|Wearable Technology and Information Software-Based Psychological Stress Monitoring|The intervention group will additionally use a smartwatch for physiological monitoring and a mobile app for daily to weekly psychological assessments.
219339431|NCT06978387|DEVICE|Minimed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
219339432|NCT06977607|PROCEDURE|Platelets Rich Fibrin|Repair of facial nerve injury plus Platelets Rich Fibrin will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Nano-fat stem cells)
219339433|NCT06977607|PROCEDURE|Nano-fat stem cells (NFSCs)|Repair of facial nerve injury plus Nano fat derived stem cells will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Platelets Rich Fibrin).
219339434|NCT06977607|PROCEDURE|Repair only|facial nerve neurorrhaphy only (repair only) after acute facial nerve trauma and measure the out come in comparison with (Repair plus Nano- fat Stem Cells) and (Repair Plus Platelets Rich Fibrin).
219339435|NCT00085956|DRUG|Arzoxifene|
219339436|NCT00085956|DRUG|Placebo|
219339437|NCT06979063|OTHER|Remote Infertility Education and Counseling|"Patients receive video call counseling covering infertility investigation, non-pharmacological fertility enhancement strategies, and healthcare navigation guidance.~Health professionals review patient records and request missing infertility-related exams according to local protocol.~Additional follow-ups occur approximately every 30 days to assist with pending investigations.~If significant findings arise, patients will receive an explanation and assistance in scheduling primary care consultations."
219339438|NCT06979063|OTHER|Standard Care Arm|Referrals from patients will be avaluated following local protocols in the electronic referral system. Incomplete data will be requested through this system. There will be no direct contact with patients.
219339439|NCT05567575|BEHAVIORAL|Cognitive Behavioral Therapy,|TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
219339440|NCT05016115|BEHAVIORAL|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
219339441|NCT06985641|BEHAVIORAL|Khanya-Ekhaya|The Khanya Ekhaya intervention includes an integration of several evidence-based treatment components, including motivational interviewing (MI), problem solving therapy (PST), and behavioral activation (BA), previously tested and adapted for this context in clinic settings, as well as cognitive-behavioral and mindfulness strategies that target rumination and negative thinking patterns. Aims 1-2 will inform Khanya-Ekhaya adaptation, including intervention length, but it is likely to include 3-6 sessions of CHW home visits based on formative work with ongoing supervision and support for CHWs.
219339442|NCT06985264|PROCEDURE|Upper Eyelid Blepharoplasty surgery|Orbicularis oculi excision
219339443|NCT06984406|DIETARY_SUPPLEMENT|Beet-Derived Inorganic Nitrate-Based Food Product|This intervention consists of an orally administered food product enriched with inorganic nitrates derived from beetroot. Participants in the intervention group will consume a standardized dose of 12 mmol of nitrate per day for 5 days (starting 24 hours before PCI and continuing for 4 days post-procedure). The product is designed to enhance nitric oxide bioavailability, improve renal perfusion, reduce oxidative stress, and lower the risk of contrast-induced nephropathy (CIN).
219339444|NCT04634396|BEHAVIORAL|ACT Acceptance and Commitment Therapy|6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
219339445|NCT06984731|PROCEDURE|left atrial appendage closure|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
219339446|NCT06984731|PROCEDURE|radiofrequency ablation|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
219339447|NCT06984289|OTHER|Radiomic Analysis of Ultrasound Images|Quantitative analysis of pre-treatment ultrasound images of the primary cervical tumor to extract radiomic features. These features will be used to develop and validate machine learning models for predicting treatment response and disease relapse in patients with locally advanced cervical cancer (LACC).
219339448|NCT06984250|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost
219339449|NCT06442865|DEVICE|AMNIODERM+|"A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC."
219339450|NCT05065931|OTHER|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
219339451|NCT04076254|DRUG|Albumins|albumin 5%
219339452|NCT04076254|DRUG|Fluid|Ringer Lactate
219339453|NCT05060120|DIAGNOSTIC_TEST|biomakers for ovarian torsion|Blood biomarkers analysis using multiplex ELISA: The Luminex system is a magnetic bead-based multiplex ELISA that enable to measure simultaneously multiple proteins within the same sample. Human magnetic Luminex assay will be used for the following analytes: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml). Plasma samples stored at -70°C will be sent to accredited lab at BioTest (Israel) for performing the multiplex ELISA readout assay test using MagPix system.
219339454|NCT05060120|DIAGNOSTIC_TEST|peritoneal fluid proteins analysis|"Western blot for peritoneal fluid proteins analysis~We will look for the relative abundance of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS) using western blot. Superoxide dismutase 1 (SOD1, 16kDa) scavenges superoxides (O-2) within cells. Catalase (60kDa) is hydrogen peroxide (H2O2) scavenging enzyme regulate ROS concentrations within cells by reducing H202 into O2 and water. Thioredoxin (12kDa) facilitates the reduction of proteins via cysteine thiol-disulfide exchange. Alpha smooth muscle actin (42kDa) will be used as a loading control. These four proteins will be resolved by western blot given their different molecular weights using western blot cocktail antibodies (abcam # ab179843)."
219339455|NCT03602092|OTHER|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
219339456|NCT00940979|PROCEDURE|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
219339457|NCT00670436|DEVICE|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
219339458|NCT00670436|DEVICE|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
219339459|NCT05015920|GENETIC|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
219339460|NCT05440656|DRUG|Cohort|Participants with Severe Eosinophilic Asthma
219339461|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
219339462|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
219339463|NCT06676592|DIAGNOSTIC_TEST|Preoperative imaging|Preoperative imaging will be performed as part of the standard of care. Imaging data from US, CT, MRI, and/or PET performed for routine care will be used for this study.
219339464|NCT06676592|DIAGNOSTIC_TEST|3D framework|3D images of surface landmarks will be acquired by use of US and the Scaniverse app before surgery, in conjunction with the participant's standard-of-care US or US-guided biopsy procedure
219339465|NCT06984822|DRUG|Anti-VEGF treatment|Intravitreal anti-VEGF treatment
219339466|NCT06984822|DEVICE|Dexamethasone implant|Intravitreal Dexamethasone implant
219339467|NCT06984822|OTHER|Anti-VEGF treatment or Dexamethasone implant|Intravitreal anti-VEGF treatment or Intravitreal Dexamethasone implant
219339468|NCT03332329|DRUG|Entecavir|Entecavir is used for 96 weeks
219339469|NCT03332329|DRUG|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
219339470|NCT03332329|DRUG|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
219339471|NCT03332329|DRUG|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
219339472|NCT03109379|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
219339473|NCT04178174|RADIATION|SABR boost and de-escalated chemoradiation|Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
219339474|NCT04178174|RADIATION|Standard chemoradiation|Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
219339475|NCT05672472|DRUG|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
219339476|NCT03246139|BEHAVIORAL|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
219339477|NCT03246139|BEHAVIORAL|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
219339478|NCT03246139|BEHAVIORAL|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
219339479|NCT03565575|BEHAVIORAL|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~1. Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~2. Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
219339480|NCT06324448|DEVICE|Transcranial direct current stimulation|tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).
219339481|NCT06869161|DEVICE|Stabilization splint|Measurements will be taken from the patients with intraoral scans, transferred to the design program and a stabilization splint will be digitally designed. The designed splint will be produced from 3D printers.
219339482|NCT06869161|OTHER|Muscle exercises|Muscle exercises prepared by physical therapists will be planned to relieve trigger points in the masticatory muscles.
219339483|NCT06042725|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood samples
219339484|NCT06042725|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219339485|NCT06042725|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219339486|NCT06042725|PROCEDURE|Chest Radiography|Undergo chest x-ray
219339487|NCT06042725|PROCEDURE|Computed Tomography|Undergo PET/CT
219339488|NCT06042725|BIOLOGICAL|Daratumumab|Given SC
219339489|NCT06042725|DRUG|Dexamethasone|Given PO
219339490|NCT06042725|DRUG|Lenalidomide|Given PO
219339491|NCT06042725|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
219339492|NCT06042725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219339493|NCT06042725|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219339494|NCT06042725|DRUG|Venetoclax|Given PO
219339495|NCT06042725|PROCEDURE|X-Ray Imaging|Undergo x-rays
219339496|NCT06042725|OTHER|Questionnaire Administration|Ancillary studies
219339497|NCT06872866|DRUG|ASP-001.1|Oral liquid suspension of sildenafil
219339498|NCT06872866|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
219339499|NCT00184236|BEHAVIORAL|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
219339500|NCT00184236|BEHAVIORAL|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
219339501|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice|Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.
219339502|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.
219339503|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
219339504|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
219339505|NCT06611540|PROCEDURE|Biospecimen Collection|Undergo collection of a cervical sample by clinician
219339506|NCT06611540|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy
219339507|NCT06611540|PROCEDURE|Colposcopy|Undergo colposcopy
219339508|NCT06611540|OTHER|Electronic Health Record Review|Ancillary studies
219339509|NCT06611540|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage
219339510|NCT06611540|PROCEDURE|Excision|Undergo cervical excisional procedure
219339511|NCT06611540|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
219339512|NCT06611540|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
219339513|NCT06611540|OTHER|Questionnaire Administration|Ancillary studies
219339514|NCT01383980|DIETARY_SUPPLEMENT|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
219339515|NCT04819256|OTHER|PACE-It mobile application|Care co-ordination platform
219339516|NCT06693856|DRUG|High-Dose Methylprednisolone|Methylprednisolone 500mg, administered intravenously once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
219339517|NCT06693856|DRUG|Low-Dose Methylprednisolone|Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
219339518|NCT06712602|DRUG|alcohol|During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.
219339519|NCT06712602|BEHAVIORAL|Stress-Induction|The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.
219339520|NCT06712602|DRUG|PT150|Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.
219339521|NCT06882642|PROCEDURE|Sensory integration therapy|Autistic patients will undergo sensory integration therapy
219339522|NCT05458050|DEVICE|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
219339523|NCT06708312|PROCEDURE|press needle acupuncture|Placement of press needle on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
219339524|NCT06708312|PROCEDURE|sham press needle acupuncture|Placement of adhesive plaster on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
219339525|NCT06727331|DRUG|Tirzepatide|This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.
219339526|NCT06727331|OTHER|Saline Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
219339527|NCT06736509|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
219339528|NCT03298425|DEVICE|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
219339529|NCT03298425|DEVICE|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
219339530|NCT06889480|DEVICE|New Target DBS|Participants in this arm will receive active DBS targeting a novel brain region identified via electrophysiological brain mapping. A DBS electrode will be implanted at the new target, and stimulation parameters (including frequency, voltage, and pulse width) are individually optimized based on mapping and 24-hour testing. The procedure is performed using a robotic system for precise electrode placement, and the device is provided by Beijing PINS Medical Co., Ltd.
219339531|NCT06889480|DEVICE|CM-DBS|This intervention involves active DBS at the central medial thalamic nucleus (CM) -a widely used target in TS treatment. A DBS electrode is implanted at the CM target, with stimulation settings determined through electrophysiological brain mapping and subsequent 24-hour stimulation. This arm serves as an active comparator, with stimulation administered during a 1-month period in the crossover phase. The same device and robotic-assisted implantation are used to ensure consistency and precision.
219339532|NCT06889480|DEVICE|Sham Stimulation|Participants assigned to the sham stimulation arm undergo the identical surgical procedure and electrode implantation as those in the active arms. However, during the stimulation periods, the device is programmed to deliver no active stimulation. This sham intervention is designed to control for placebo effects and ensure that any observed improvements in TS symptoms are attributable to the active DBS interventions.
219339533|NCT06747260|BIOLOGICAL|Intranasal breast milk|Neonates with hypoxic-ischemic encephalopathy receive their own-mother's fresh breast milk intranasally, starting from the first 48 hours of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart).
219339534|NCT05957861|BEHAVIORAL|web-based aerobic exercise|Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
219339535|NCT06733155|OTHER|Financial intervention|Participants completing the mammogram within the study end date will receive a $10 voucher.
219339536|NCT06733155|OTHER|Lottery intervention|Participants completing the mammogram within the study end date will receive achance to win a $5000 lottery.
219339537|NCT06733155|OTHER|Health Messages|Participants will receive a less than 5 minute long video from an influential person. The video will be available in four languages (English, Chinese, Malay, Tamil).
219339538|NCT06733155|OTHER|Personal Health Concierge|Participants will be able to call a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks of receive the the mailer.
219339539|NCT06733155|OTHER|Only reminder mailer|Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram.
219339540|NCT06763744|DRUG|P2Y12 antagonist monotherapy|CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.
219339541|NCT06763744|DRUG|clopidogrel + aspirin|In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
219339542|NCT06756581|OTHER|baked milk product diet|Elimination of none baked cow milk from diet . Baked cow milk containing diet.
219339543|NCT04192344|DRUG|ABSK021|ABSK021 oral capsule
219339544|NCT02984761|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
219339545|NCT02984761|PROCEDURE|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
219339546|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
219339547|NCT03416153|DRUG|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
219339548|NCT03416153|RADIATION|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
219339549|NCT03416153|DRUG|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
219339550|NCT06176638|BEHAVIORAL|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
219339551|NCT02113085|BEHAVIORAL|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
219339552|NCT04106700|DRUG|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
219339553|NCT02085603|DRUG|Saracatinib|
219339554|NCT02085603|DRUG|Placebo|
219339555|NCT04342871|BEHAVIORAL|FACT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
219339556|NCT05378438|OTHER|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
219339557|NCT02229071|DRUG|Donafenib(200mg)|Donafenib 200mg,bid,po
219339558|NCT02229071|DRUG|Donafenib(300mg)|Donafenib 300mg,bid,po
219339559|NCT03957837|DIAGNOSTIC_TEST|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
219339560|NCT04509310|DEVICE|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
219339561|NCT00666458|DRUG|saxagliptin|tablet, per oral, once daily
219339562|NCT00666458|DRUG|sitagliptin|capsule, per oral, once daily
219339563|NCT03740750|DEVICE|Thermacare heat wraps|low level continuous heat wrap
219339564|NCT03740750|DEVICE|TENS|electrical stimulation
219339565|NCT03740750|DEVICE|sham heat|expended heat wrap
219339566|NCT03740750|DEVICE|sham Tens|tens applied but unit not turned on
219339567|NCT02222207|DRUG|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
219339568|NCT02222207|PROCEDURE|Sham IVT|Sham injections
219339569|NCT02222207|DRUG|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
219339570|NCT02222207|DRUG|Placebo|Placebo eye drops
219339571|NCT03162770|BEHAVIORAL|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
219339572|NCT05556499|DIAGNOSTIC_TEST|Biomarker assays|Circulating bone biomarkers assays
219339573|NCT03105687|BEHAVIORAL|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
219339574|NCT01847482|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
219339575|NCT02878538|DRUG|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
219339576|NCT02878538|OTHER|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
219339577|NCT02982954|DRUG|Nivolumab|Specified dose on specified day
219339578|NCT02982954|DRUG|Ipilimumab|Specified Dose on Specified Day
219339579|NCT05407259|BEHAVIORAL|Resistance exercise|There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
219339580|NCT01272310|BIOLOGICAL|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is \< 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is \>= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
219339581|NCT04858945|BEHAVIORAL|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
219339582|NCT04772261|DIAGNOSTIC_TEST|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
219339583|NCT05194462|DEVICE|Pericoach® by Analytica|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback .
219339584|NCT05194462|OTHER|Pelvic Floor Physical Therapy|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of PFPT.
219339585|NCT01093274|DRUG|Sodium Picosulphate|2 Sachets
219339586|NCT01093274|DRUG|Polyethylene Glycol|3 Liters solution
219339587|NCT06407635|DRUG|Psilocybin|The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.
219339588|NCT06407635|OTHER|Trauma-focused psychotherapy|Components of trauma-focused psychotherapy will include Cognitive Processing Therapy and in vivo exposure. Such components of evidence-based psychotherapy may lower the safety risk profile for this vulnerable population and enhance the effect size and maintenance of psilocybin therapy.
219339589|NCT06407635|OTHER|Standard psychological support|Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.
219339590|NCT03366688|DRUG|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
219339591|NCT03366688|DRUG|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
219339592|NCT03691233|DRUG|Clinical audit on diagnosis and management of neonatal shock|intervenous
219339593|NCT03614754|DIAGNOSTIC_TEST|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
219339594|NCT04002037|DRUG|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
219339595|NCT04002037|DRUG|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
219339596|NCT04002037|DRUG|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
219339597|NCT01429584|DRUG|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
219339598|NCT01429584|DRUG|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
219339599|NCT00747643|DRUG|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
219339600|NCT00747643|DRUG|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
219339601|NCT04114292|DRUG|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
219339602|NCT01987687|BEHAVIORAL|Exercise|Exercise at 55% of maximum power output for 30 min.
219339603|NCT01987687|BEHAVIORAL|Rest|Rest for 30 min
219339604|NCT01987687|BEHAVIORAL|Delay|Delay between exercise and OGTT
219339605|NCT03588351|DRUG|chitosan nanoparticles gel|intracanal medicament
219339606|NCT03588351|DRUG|chitosan gel|intracanal medicament
219339607|NCT03588351|DRUG|chlorhexidine gluconate|intracanal medicament
219339608|NCT00750698|DRUG|Entinostat|Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
219339609|NCT00750698|DRUG|Erlotinib|Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
219339610|NCT01636973|PROCEDURE|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
219339611|NCT04715061|OTHER|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
219339612|NCT04715061|OTHER|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
219339613|NCT04715061|OTHER|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
219339614|NCT05947487|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"
219339615|NCT01426139|DEVICE|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
219339616|NCT03522870|DEVICE|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
219339617|NCT03522870|DEVICE|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
219339618|NCT02452905|DRUG|Nitazoxanide|
219339619|NCT02452905|DRUG|Placebo (for Nitazoxanide)|
219339620|NCT02365220|BEHAVIORAL|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
219339621|NCT02365220|BEHAVIORAL|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
219339622|NCT02365220|BEHAVIORAL|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
219339623|NCT02365220|BEHAVIORAL|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
219339624|NCT06219265|BEHAVIORAL|Dance Therapy|"A single-centre prospective randomised controlled trial will be conducted with a minimum of 48 patients with severe mental disorder (SMD) who will be randomised into two groups, 1 intervention group receiving dance therapy (n=24) and 1 control group receiving no intervention or treatment (n=24).~In addition, there will be an intervention group of healthy people who will receive dance therapy (n=20).~All the tests, will be carried out with patients with SMD and only the EEG for healthy people, in order to determine their baseline state. The dance therapy program will last for 20 sessions over 10 weeks.~The 44 people in the two experimental groups will participate in a 10-week intervention program with 2 sessions per week in which they will work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.~The 24 people in the control group will not receive any type of intervention."
219339625|NCT03378804|PROCEDURE|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
219339626|NCT03378804|PROCEDURE|Continous epidural analgesia|
219339627|NCT02263079|DRUG|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
219339628|NCT02263079|DRUG|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
219339629|NCT02263079|DRUG|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
219339630|NCT05905120|DRUG|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
219339631|NCT04298736|PROCEDURE|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
219339632|NCT04298736|BEHAVIORAL|Lifestyle modification|guided low-calorie diet and physical activity.
219339633|NCT00210392|DRUG|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
219339634|NCT01473238|OTHER|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
219339635|NCT06011148|DEVICE|Perceval S sutureless heart valve|Aortic Valve Replacement with Perceval S sutureless heart valve
219339636|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with web-based support|Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
219339637|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with standard support|Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
219339638|NCT00199550|PROCEDURE|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
219339639|NCT00199550|PROCEDURE|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
219339640|NCT05823675|DRUG|Itolizumab|Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
219339641|NCT05823675|DRUG|Methylprednisolone|Methylprednisolone will be taperred as required
219339642|NCT05895942|DRUG|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
219339643|NCT02031562|OTHER|chiropractic|chiropractic
219339644|NCT02031562|OTHER|physical therapy|physical therapy
219339645|NCT05426889|PROCEDURE|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
219339646|NCT05426889|DRUG|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
219339647|NCT01157221|OTHER|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
219339648|NCT01157221|OTHER|EMSMTA|end-range mobilization/scapular mobilization treatment approach
219339649|NCT02004496|DEVICE|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
219339650|NCT04802993|OTHER|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
219339651|NCT02700724|OTHER|Immediate Surgery|
219339652|NCT02700724|OTHER|Observation|
219339653|NCT02700724|PROCEDURE|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
219339654|NCT01467843|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
219339655|NCT01467843|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
219339656|NCT03970694|RADIATION|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
219339657|NCT03970694|DRUG|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
219339658|NCT00529074|DEVICE|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
219339659|NCT04930055|BIOLOGICAL|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
219339660|NCT02665169|BEHAVIORAL|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
219339661|NCT02665169|OTHER|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
219339662|NCT00402649|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
219339663|NCT04467424|DRUG|ketamine, propofol|anesthesia with ketofol in pediatric surgery
219339664|NCT04467424|DRUG|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
219339665|NCT01199042|DEVICE|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
219339666|NCT01999465|DEVICE|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)"
219339667|NCT01999465|DEVICE|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)"
219339668|NCT01439464|DEVICE|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
219339669|NCT01439464|DEVICE|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
219339670|NCT05030012|DEVICE|Automated Control|The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
219339671|NCT05030012|DEVICE|Manual Control|The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
219339672|NCT00809666|DEVICE|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
219339673|NCT01114503|DRUG|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
219339674|NCT01114503|DRUG|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
219339675|NCT01114503|DRUG|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
219339676|NCT01114503|DRUG|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
219339677|NCT01114503|DRUG|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
219339678|NCT01114503|DRUG|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
219339679|NCT03328546|OTHER|Dietary intake|Dietary intake converted into dietary pattern scores.
219339680|NCT01867060|DEVICE|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
219339681|NCT01867060|DEVICE|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
219339682|NCT01602770|DRUG|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
219339683|NCT05365503|OTHER|Shamiri Intervention|The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
219339684|NCT05798442|OTHER|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
219339685|NCT06050174|DRUG|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
219339686|NCT06050174|PROCEDURE|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
219339687|NCT01423162|OTHER|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
219339688|NCT01423162|OTHER|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
219339689|NCT02157675|DIETARY_SUPPLEMENT|Polyherbal capsule|
219339690|NCT02157675|DIETARY_SUPPLEMENT|Placebo capsule|
219339691|NCT02951715|DRUG|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
219339692|NCT02180555|OTHER|Oral glucose tolerance test|
219339693|NCT06320561|OTHER|Longitudinal prospective cohort study|Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
219339694|NCT02853942|BIOLOGICAL|Autologous adipose stem cell therapy|
219339695|NCT02853942|DRUG|Mecobalamin|
219339696|NCT01756534|DEVICE|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
219339697|NCT05722119|DIAGNOSTIC_TEST|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
219339698|NCT02791984|DEVICE|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
219339699|NCT05418400|OTHER|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
219339700|NCT02029859|PROCEDURE|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
219339701|NCT02657395|DEVICE|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
219339702|NCT02554019|BIOLOGICAL|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
219339703|NCT02554019|BIOLOGICAL|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
219339704|NCT05745220|OTHER|Device: silicone hydrogel contact lens|Silicone hydrogel contact lens
219339705|NCT01465100|RADIATION|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
219339706|NCT01465100|PROCEDURE|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
219339707|NCT01465100|DRUG|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
219339708|NCT01465100|OTHER|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
219339709|NCT01465100|BEHAVIORAL|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
219339710|NCT01465100|DIAGNOSTIC_TEST|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
219339711|NCT01465100|PROCEDURE|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
219339712|NCT06232070|DEVICE|Lunit INSIGHT MMG|In the Lunit Assisted arm, the radiographers will also be seeing the Lunit INSIGHT MMG reports while reading the mammograms. The standard of care will be followed in all the cases
219339713|NCT04639856|PROCEDURE|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
219339714|NCT03978455|BEHAVIORAL|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
219339715|NCT04411264|DEVICE|virtual reality|Use of a virtual reality headset while caring for chronic wound dressings
219339716|NCT00004231|BIOLOGICAL|aldesleukin|
219339717|NCT00004231|BIOLOGICAL|filgrastim|
219339718|NCT00004231|BIOLOGICAL|recombinant interferon alfa|
219339719|NCT00004231|DRUG|busulfan|
219339720|NCT00004231|DRUG|cyclophosphamide|
219339721|NCT00004231|DRUG|cytarabine|
219339722|NCT00004231|DRUG|doxorubicin hydrochloride|
219339723|NCT00004231|DRUG|leucovorin calcium|
219339724|NCT00004231|DRUG|methotrexate|
219339725|NCT00004231|DRUG|prednisone|
219339726|NCT00004231|DRUG|teniposide|
219339727|NCT00004231|DRUG|vincristine sulfate|
219339728|NCT00004231|PROCEDURE|allogeneic bone marrow transplantation|
219339729|NCT00004231|PROCEDURE|autologous bone marrow transplantation|
219339730|NCT00004231|PROCEDURE|peripheral blood stem cell transplantation|
219339731|NCT06047340|DEVICE|G:DATA, dementia screen videogame|A videogame for screening
219339732|NCT02500680|BIOLOGICAL|MER4101|
219339733|NCT02500680|BIOLOGICAL|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
219339734|NCT04749823|OTHER|Blended treatment program|A combined treatment program with specific active neck exercises and general aerobic training in counteractive amount will be executed during 12 weeks. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
219339735|NCT04749823|OTHER|Specific strength exercise program|This program includes an individual, patient-tailored exercise program with the aim of retraining the neck musculature. A detailed exercise programme will be constructed in which all exercises are listed with the amount of repetitions and series of each exercise. Strength exercises will be performed by means of dumbbells with different weights and elastic bands with different degrees of resistance. The amount of weight or resistance, and the amount of series and repetitions will be evaluated during the first session. This exercise programme will be re-evaluated repeatedly during the course of the program. Specific strength neck exercises will be performed for 30 minutes. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
219339736|NCT04749823|OTHER|General aerobic exercise program|This control group will receive a general aerobic exercise program. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
219339737|NCT02281370|DRUG|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
219339738|NCT02281370|DRUG|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
219339739|NCT04170361|OTHER|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
219339740|NCT04170361|OTHER|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
219339741|NCT06450652|DRUG|Chinese Herbal Medicine granules|The intervention will be a 4 weeks of Chinese Herbal Medicine (CHM) granules, which will consist of six Chinese herbs. Subjects will take one sachet orally, twice daily after meals for 4 weeks. Way of taking CHM granules is as follow: Add 100ml boiling water into a cup, then pour one pack of granules into the cup and soap it for 2-3 mins. Stir until the granules completely dissolve before drinking.
219339742|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
219339743|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
219339744|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
219339745|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
219339746|NCT02268721|DEVICE|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
219339747|NCT02603874|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
219339748|NCT02388438|DEVICE|Bongener|
219339749|NCT03842423|PROCEDURE|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
219339750|NCT02266992|BIOLOGICAL|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
219339751|NCT00733148|DRUG|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
219339752|NCT05940792|OTHER|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
219339753|NCT05940792|OTHER|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
219339754|NCT00756145|PROCEDURE|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
219339755|NCT00756145|PROCEDURE|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
219339756|NCT00756145|PROCEDURE|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
219339757|NCT00316680|BIOLOGICAL|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
219339758|NCT02089399|DRUG|Sevikar(amlodipne/olmesartan)|Treatment AB
219339759|NCT02089399|DRUG|crestor(Rosuvastatin)|Treatment AB/Treatment C
219339760|NCT00880399|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
219339761|NCT00880399|OTHER|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
219339762|NCT06008444|OTHER|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
219339763|NCT06008444|OTHER|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
219339764|NCT04353284|DRUG|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
219339765|NCT04353284|OTHER|Placebo|Placebo taken orally, 4 times daily, for 7 days.
219339766|NCT00521261|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
219339767|NCT04778098|OTHER|Received SMS reminder|telenursing
219339768|NCT03443076|DIETARY_SUPPLEMENT|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
219339769|NCT03443076|OTHER|Lovaza (active comparator; already FDA approved)|A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
219339770|NCT04548726|DEVICE|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
219339771|NCT04548726|DEVICE|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
219339772|NCT02997527|DEVICE|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
219339773|NCT04715750|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
219339774|NCT00871845|BEHAVIORAL|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
219339775|NCT05138016|DEVICE|Soft exosuit|Progressive cardiovascular exercise testing with soft exosuit assistance.
219339776|NCT05138016|BEHAVIORAL|No Soft exosuit|Progressive cardiovascular exercise testing.
219339777|NCT02094456|PROCEDURE|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
219339778|NCT02094456|PROCEDURE|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
219339779|NCT04866693|OTHER|None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.|Qualitative study
219339780|NCT06152445|OTHER|Wheat bread|Different wheat breads
219339781|NCT05175833|COMBINATION_PRODUCT|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
219339782|NCT05175833|OTHER|Oral placebo|Oral gel containing placebo
219339783|NCT01306448|DEVICE|Vibrant capsule|vibrating capsule
219339784|NCT02568813|BEHAVIORAL|Multiscore Depression Inventory for Children scale|
219339785|NCT05312177|OTHER|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
219339786|NCT05312177|OTHER|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
219339787|NCT05312177|OTHER|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
219339788|NCT05312177|OTHER|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
219339789|NCT05312177|OTHER|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
219339790|NCT05312177|OTHER|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
219339791|NCT05312177|OTHER|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
219339792|NCT05312177|OTHER|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
219339793|NCT03211221|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
219339794|NCT03079206|DIAGNOSTIC_TEST|Food challenge|food challenge with hazelnut
219339795|NCT03079206|DIAGNOSTIC_TEST|skin testing|Skin testing with hazelnut extract
219339796|NCT03079206|DIAGNOSTIC_TEST|blood sampling|blood sampling to perform basophile activation tests
219339797|NCT00101751|DRUG|biphasic insulin aspart|
219339798|NCT00101751|BEHAVIORAL|dietary regimen|
219339799|NCT04214379|PROCEDURE|Ptosis surgery|Frontalis sling surgery using pose-up and Wright's fascia-lata needle
219339800|NCT01795885|BEHAVIORAL|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
219339801|NCT00530751|OTHER|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool \[GREAT\]) are explored.
219339802|NCT06372548|DEVICE|Find You! Cure My Animal Friends|Introduced cognitive evaluation theory combined with masking therapy to develop a gamified product that guides amblyopic children to develop habits for the purpose of rehabilitation training.
219339803|NCT06372548|DEVICE|DuoBao Vision Training System|This is a visual training app where participants are required to complete several training tasks.
219339804|NCT04428463|PROCEDURE|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
219339805|NCT04428463|PROCEDURE|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
219339806|NCT03677258|DEVICE|Collagen for injections 7%|Injection of medical device
219339807|NCT03677258|DEVICE|Hyaluronic acid for injections 2%|Injection of medical device
219339808|NCT00621699|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
219339809|NCT00621699|DRUG|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
219339810|NCT00621699|DRUG|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
219339811|NCT01590940|PROCEDURE|Open inguinal hernia repair with mesh|
219339812|NCT04967300|PROCEDURE|Dental treatment|bilateral restorative treatment on the mandibular primary first molars
219339813|NCT06460402|OTHER|Ice packing|For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.
219339814|NCT06460402|OTHER|Warm sitz bath|Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
219339815|NCT04777487|DIAGNOSTIC_TEST|GCF obtaining|4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
219339816|NCT00751400|DRUG|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
219339817|NCT00676676|DRUG|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
219339818|NCT06171451|DIAGNOSTIC_TEST|PET with 11C-Fe-CIT|Use of the PET11C-Fe\_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
219339819|NCT00643266|BEHAVIORAL|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
219339820|NCT00643266|BEHAVIORAL|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
219339821|NCT01334151|DRUG|Insulin LISPRO|Single doses of: 0.15 U/kg
219339822|NCT01334151|DRUG|recombinant human insulin|Single doses of: 0.15 U/kg
219339823|NCT01609946|DEVICE|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
219339824|NCT01609946|PROCEDURE|Cytology (FNAB) or Surgery|
219339825|NCT01930136|BEHAVIORAL|Calorie restriction (25%)|
219339826|NCT01930136|BEHAVIORAL|Ad libitum health diet|
219339827|NCT06494852|DIAGNOSTIC_TEST|investigations|laboratory assesment Kidney function test, Urine analysis, Arterial blood gases ,Electrolytes (Na,K,Cl,Ca,phosphorus) and Calcium/creatinine ratio , Total serum IgE Radiological assessment Abdominal ultrasonography
219339828|NCT01222546|DRUG|CH5132799|
219339829|NCT01048762|OTHER|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
219339830|NCT01048762|OTHER|home training|one instruction in home based exercise training
219339831|NCT06247943|PROCEDURE|Lung Protective Ventilation Strategy|After 10 minutes of pneumoperitoneum, VT 7 ml/kg was used, PEEP 6 cmH2O, FiO2 was 40%, and plateau pressure \<30 cmH2O was maintained throughout.
219339832|NCT06247943|PROCEDURE|regular ventilation|VT 9ml /kg without PEEP, FiO2 of 60%
219339833|NCT03129321|DRUG|Econazole Nitrate Cream, 1%|
219339834|NCT03129321|DRUG|Placebo|
219339835|NCT04165707|DEVICE|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
219339836|NCT04165707|OTHER|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
219339837|NCT05373654|OTHER|F-SUS Questionnaire|"This F-SUS questionnaire uses a Likert scale including 5 possible responses ranging from  I do not agree at all to  I completely agree  (Celenza A 2011, Croasmun JT 2011). The F-SUS is a short questionnaire with 10 questions (Brooke J 2013). In its original version half of the questions express strong agreement and the other half disagreement. Thus, all the even-numbered items (2, 4, 6, 8, 10) allow the participant to express a very negative opinion (disagreement). On the other hand, the odd-numbered items allow the participant to express a very positive opinion (strong agreement)."
219339838|NCT05373654|OTHER|Interview (only for dissatisfied patients)|"Patients that are dissatisfied with the recharge procedure (Score F-SUS \< 70/100) will be invited to a so-called complementary information interview (an interview after the questionnaire has been completed).~The corpus (the study group that will be interviewed) will naturally be diverse men/women, patients who were improved or not by stimulation, implanted with a rechargeable stimulator directly/replacing a stimulator, different brands of stimulator… The patient must agree to the interview and the way it will be performed (signature of consent form). The interview may be face-to -face at the site or by remote videoconference depending on the wishes and availability of the patient. There is no payment for these interviews but travelling or videoconference expenses are reimbursed All interviews will be audio- taped for further qualitative analysis."
219339839|NCT00441974|DRUG|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
219339840|NCT02770547|DEVICE|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
219339841|NCT02770547|DEVICE|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
219339842|NCT01148537|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.
219339843|NCT01148537|DRUG|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
219339844|NCT01148537|DRUG|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
219339845|NCT03561909|OTHER|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
219339846|NCT03051555|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
219339847|NCT01309074|DRUG|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
219339848|NCT01309074|DRUG|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
219339849|NCT03553342|DRUG|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
219339850|NCT03553342|OTHER|Placebo|Patients will receive placebo for seven days.
219339851|NCT00393887|DEVICE|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
219339852|NCT00393887|DEVICE|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
219339853|NCT05526690|DRUG|Metformin|1000 mg dose of immediate-release metformin
219339854|NCT05526690|DRUG|CIN-107|10 mg dose of CIN-107
219339855|NCT03016208|DRUG|Misoprostol vaginal insert|
219339856|NCT01966328|DRUG|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
219339857|NCT01966328|DRUG|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
219339858|NCT03385811|OTHER|no intervention, only questionnaires survey|questionnaires survey
219339859|NCT00224614|PROCEDURE|Allogenic transplantation|
219339860|NCT00492323|DRUG|placebo|twice daily for 4 weeks
219339861|NCT00492323|DRUG|carisbamate|200 mg tablet twice daily for 4 weeks
219339862|NCT02600104|DEVICE|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
219339863|NCT04513886|PROCEDURE|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
219339864|NCT02171962|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
219339865|NCT02887235|OTHER|Home Delivered, Medically Tailored Meals (HDTM)|
219339866|NCT04069195|DIETARY_SUPPLEMENT|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
219339867|NCT04069195|DIETARY_SUPPLEMENT|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
219339868|NCT05973929|OTHER|Screen for movement disorder and correlates it with MRI findings.|"* To determine the prevalence of movement disorders in MS patients.~* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~* To find the correlation between the movement disorder and the different types of MS."
219339869|NCT02403570|OTHER|Brain MRI|
219339870|NCT01617070|DRUG|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
219339871|NCT01617070|DIETARY_SUPPLEMENT|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
219339872|NCT00077363|DRUG|tipifarnib|Given PO
219339873|NCT00077363|DRUG|capecitabine|Given PO
219339874|NCT01336582|DRUG|taxotere|70 mg/m2 for age of ≥ 65
219339875|NCT02111642|OTHER|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
219339876|NCT01967355|OTHER|lipid apheresis|
219339877|NCT03906383|OTHER|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
219339878|NCT05675878|BEHAVIORAL|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
219339879|NCT00244387|DRUG|SPM 962|
219339880|NCT05125055|DRUG|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
219339881|NCT05125055|DRUG|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
219339882|NCT05125055|DRUG|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
219339883|NCT05125055|DRUG|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
219339884|NCT05125055|DRUG|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
219339885|NCT04638348|DEVICE|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
219339886|NCT05341362|PROCEDURE|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
219339887|NCT05122884|DRUG|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
219339888|NCT00481286|BEHAVIORAL|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
219339889|NCT00481286|BEHAVIORAL|Standard of Care|Standard of care for diabetes patients
219339890|NCT01301443|DRUG|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
219339891|NCT02348892|OTHER|Coordinator|Patients in complex situation taken care by coordinator
219339892|NCT02348892|OTHER|Classic plan|Patients in complex situation taken care by classic plan
219339893|NCT04279275|OTHER|SURVEY|QUESTIONAIRRE
219339894|NCT04944212|DIAGNOSTIC_TEST|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
219339895|NCT02618655|OTHER|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
219339896|NCT06476210|DRUG|BDL regimen|"Drug:bedaquiline 100mg tablets~Other Names:~Bdq TMC-207 bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week~Drug:delamanid 50mg tablets~Other Names:~Dlm OPC-67683 delamanid 100mg 2 times daily~Drug:linezolid Scored 600mg tablets~Other Names:~Lzd linezolid 600mg once daily"
219339897|NCT02582606|OTHER|Regular meal pattern|a 14-day period of eating 6 meal per day
219339898|NCT02582606|OTHER|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
219339899|NCT00777101|DRUG|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
219339900|NCT00777101|DRUG|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
219339901|NCT00777101|DRUG|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
219339902|NCT02230384|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
219339903|NCT02230384|DRUG|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
219339904|NCT00808236|DEVICE|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
219339905|NCT00808236|OTHER|Control|Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
219339906|NCT04928859|DRUG|Albumin|"At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group."
219339907|NCT06422975|DRUG|Vasopressin|Patients treated with vasopressin
219339908|NCT05752877|BIOLOGICAL|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
219339909|NCT05752877|BIOLOGICAL|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
219339910|NCT00961220|DRUG|Carmustine|Applied topically
219339911|NCT00961220|OTHER|Laboratory Biomarker Analysis|Correlative studies
219339912|NCT00961220|DRUG|O6-Benzylguanine|Given IV
219339913|NCT03280875|OTHER|pedalling exercises|pedalling exercises on a bicycle ergometer
219339914|NCT04732741|DIAGNOSTIC_TEST|Salivary Gamma-synuclein|Gamma-synuclein salivary levels measured using ELISA assay
219339915|NCT04732741|DIAGNOSTIC_TEST|Incisional biopsy|"A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region."
219339916|NCT04732741|DIAGNOSTIC_TEST|Conventional visual and tactile examination|Conventional visual and tactile examination using light and mirror
219339917|NCT00881127|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
219339918|NCT00881127|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
219339919|NCT00888550|PROCEDURE|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
219339920|NCT00888550|PROCEDURE|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
219339921|NCT03379272|DEVICE|GOLDSTANDARD|RECORDING WITH EEG GOLDSTANDARD
219339922|NCT03379272|DEVICE|NEURONAUTE|RECORDING WITH NEURONAUTE
219339923|NCT03666455|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
219339924|NCT05376215|DEVICE|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
219339925|NCT02153528|DRUG|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
219339926|NCT02153528|DRUG|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
219339927|NCT02031770|DRUG|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
219339928|NCT02031770|OTHER|Control|subjects will receive no treatment
219339929|NCT05354011|OTHER|Kinesiotape|Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain
219339930|NCT05354011|OTHER|Active Release Technique|This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
219339931|NCT03666832|DRUG|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
219339932|NCT00471705|DRUG|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
219339933|NCT00471705|DEVICE|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
219339934|NCT00471705|DRUG|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
219339935|NCT01301950|OTHER|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
219339936|NCT01301950|OTHER|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
219339937|NCT00593944|BIOLOGICAL|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
219339938|NCT00426257|PROCEDURE|Secondary debulking|Secondary debulking
219339939|NCT00426257|PROCEDURE|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
219339940|NCT01068691|PROCEDURE|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"* Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~* Blood pressure~* Obstructive sleep apnea syndrome (OSAS)~* Carotid-to-femoral pulse wave velocity (PWV)~* Biological parameters"
219339941|NCT01908270|BEHAVIORAL|Yoga|
219339942|NCT01908270|OTHER|Usual care|
219339943|NCT05023759|DIETARY_SUPPLEMENT|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
219339944|NCT02651584|DRUG|CAM2038 SC injection|
219339945|NCT02651584|DRUG|SL BPN/NX tabs|
219339946|NCT02651584|DRUG|placebo SC injections|
219339947|NCT02651584|DRUG|SL placebo tablets|
219339948|NCT01711411|DEVICE|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
219339949|NCT06029621|PROCEDURE|RATS for Thymectomy|a minimally invasive surgical type for Thymoma: RATS
219339950|NCT06029621|PROCEDURE|VATS for Thymectomy|a minimally invasive surgical type for Thymoma: VATS
219339951|NCT05523037|DRUG|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
219339952|NCT05523037|DRUG|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
219339953|NCT01651624|OTHER|Invitation to screening|
219339954|NCT02742428|DEVICE|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
219339955|NCT02742428|PROCEDURE|Acute paracentesis.|Evacuation of a large (\>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
219339956|NCT02742428|BEHAVIORAL|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
219339957|NCT02742428|BEHAVIORAL|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
219339958|NCT02742428|BEHAVIORAL|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
219339959|NCT04802525|OTHER|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
219339960|NCT00007085|DEVICE|Tomography, X-ray Computed|
219339961|NCT03621332|OTHER|Questionnaire|Online/paper questionnaires
219339962|NCT01592253|DRUG|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
219339963|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
219339964|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
219339965|NCT00141024|BIOLOGICAL|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
219339966|NCT00141024|BIOLOGICAL|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
219339967|NCT01024010|DRUG|Cyclophosphamide|Given IV
219339968|NCT01024010|OTHER|Laboratory Biomarker Analysis|Correlative studies
219339969|NCT01024010|BIOLOGICAL|Ofatumumab|Given IV
219339970|NCT01024010|DRUG|Pentostatin|Given IV
219339971|NCT03215420|DIAGNOSTIC_TEST|MRI 3T|
219339972|NCT03573427|DEVICE|Trans-atrial septal placement LV lead for CRT|
219339973|NCT01055600|DRUG|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
219339974|NCT03407638|OTHER|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
219339975|NCT03425214|OTHER|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
219339976|NCT03425214|OTHER|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
219339977|NCT03425214|OTHER|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
219339978|NCT05591118|DRUG|Anticoagulant Therapy|All subjects will receive anticoagulation for a minimum of 3 months.
219339979|NCT05591118|DEVICE|Catheter-Directed Therapy|The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
219339980|NCT00452751|PROCEDURE|laparoscopy-assisted distal gastrectomy|
219339981|NCT00452751|PROCEDURE|open distal gastrectomy|
219339982|NCT02642445|DEVICE|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
219339983|NCT05809414|DEVICE|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
219339984|NCT05809414|DRUG|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
219339985|NCT04075838|OTHER|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
219339986|NCT03009032|DIETARY_SUPPLEMENT|PMT25341|
219339987|NCT03009032|DIETARY_SUPPLEMENT|Placebo|Lactose
219339988|NCT01478035|DRUG|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
219339989|NCT01478035|DRUG|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
219339990|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
219339991|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
219339992|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
219339993|NCT03454022|BEHAVIORAL|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
219339994|NCT03454022|BEHAVIORAL|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
219339995|NCT02263898|DRUG|Raf kinase inhibitor LGX818|Given PO
219339996|NCT02263898|DRUG|binimetinib|Given PO
219339997|NCT02263898|OTHER|laboratory biomarker analysis|Correlative studies
219339998|NCT03514342|PROCEDURE|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
219339999|NCT03514342|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
219340000|NCT00964743|DRUG|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
219340001|NCT00964743|DRUG|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
219340002|NCT03455491|DRUG|XC221 100 mg|once daily during 3 days.
219340003|NCT03455491|DRUG|XC221 200 mg|once daily during 3 days.
219340004|NCT03455491|DRUG|Placebo|once daily during 3 days.
219340005|NCT05505136|DEVICE|Arrhythmia Management System (AMS)|Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
219340006|NCT04219176|DIAGNOSTIC_TEST|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
219340007|NCT06416904|DEVICE|archwire stopper mesial to the maxillary first molar group|canine retraction after the extraction of the maxillary first premolars with archwire stoppers is mesial to the maxillary first molars.
219340008|NCT06416904|DEVICE|inter-radicular mini-screw|canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
219340009|NCT03212053|BIOLOGICAL|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
219340010|NCT05815407|OTHER|No intervention|No intervention
219340011|NCT00236860|DRUG|topiramate|
219340012|NCT03424785|OTHER|drug, stent, surgical treatment|drug, stent, surgical treatment
219340013|NCT01391286|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
219340014|NCT01391286|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
219340015|NCT04049838|PROCEDURE|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
219340016|NCT01530204|PROCEDURE|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
219340017|NCT01530204|BEHAVIORAL|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
219340018|NCT01530204|OTHER|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
219340019|NCT05790109|DEVICE|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
219340020|NCT02918383|DIAGNOSTIC_TEST|Indocyanin Green Dye (ICG)|
219340021|NCT03317795|DRUG|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
219340022|NCT03317795|DRUG|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
219340023|NCT06495034|DEVICE|airwave compression therapy|Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb
219340024|NCT06495034|OTHER|standard care: health education and routine functional exercise|standard care: health education and routine functional exercise
219340025|NCT06174623|DEVICE|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
219340026|NCT06360991|DEVICE|Deep brain stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (vALIC, BNST, amSTN, VC/VS, or NAc) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
219340027|NCT01628471|DRUG|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
219340028|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
219340029|NCT03015571|DEVICE|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
219340030|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
219340031|NCT03015571|DEVICE|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
219340032|NCT06183840|DEVICE|Glutack|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
219340033|NCT06183840|DEVICE|Conventional|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
219340034|NCT00479284|PROCEDURE|Average volume assured pressure support (AVAPS)|
219340035|NCT02386280|BEHAVIORAL|Motivational Interviewing for Change of Parenting Styles|
219340036|NCT02386280|BEHAVIORAL|Psicoeducation|
219340037|NCT06295939|OTHER|social support program|"Group 2, the experimental group, will receive routine nursing care from the assigned nurse and a social support program provided by the researcher, as follows:~Phase 1 (Before Pregnancy Termination)~Phase 2 (After Pregnancy Termination, Before Returning Home):"
219340038|NCT06295939|OTHER|Routine nursing care|The sample group will receive routine nursing care from the assigned nurse.
219340039|NCT00896207|DRUG|Akt inhibitor SR13668|Given orally as a single dose
219340040|NCT04141332|DIAGNOSTIC_TEST|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
219340041|NCT04655443|OTHER|Standard Care|Standard cardiovascular care
219340042|NCT01549002|DRUG|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
219340043|NCT01549002|DRUG|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
219340044|NCT01891500|DRUG|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
219340045|NCT01891500|DRUG|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
219340046|NCT01891500|DRUG|Crossover iNO|Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
219340047|NCT01918839|DEVICE|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
219340048|NCT01918839|DEVICE|Restylane-L|Restylane-L injected into wrinkle treatment area
219340049|NCT05872802|OTHER|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
219340050|NCT05872802|OTHER|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
219340051|NCT01141088|PROCEDURE|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
219340052|NCT01141088|PROCEDURE|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
219340053|NCT04320732|BEHAVIORAL|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
219340054|NCT03821025|DEVICE|Biliary stent|Palliation of malignant biliary obstruction
219340055|NCT05928195|DIETARY_SUPPLEMENT|Acute Moderate-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
219340056|NCT05928195|DIETARY_SUPPLEMENT|Acute High-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
219340057|NCT05928195|DIETARY_SUPPLEMENT|Placebo|Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
219340058|NCT01732809|DRUG|AbobotulinumtoxinA (ABO)|Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
219340059|NCT01732809|DRUG|OnabotulinumtoxinA (ONA)|Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
219340060|NCT02424253|DRUG|ZPL-3893787|ZPL-3893787
219340061|NCT02424253|DRUG|Placebo|Matched Placebo
219340062|NCT03998046|BEHAVIORAL|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
219340063|NCT03998046|BEHAVIORAL|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
219340064|NCT03998046|BEHAVIORAL|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
219340065|NCT04509141|OTHER|acupuncture|acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
219340066|NCT03080246|BEHAVIORAL|Strength Training Exercise|
219340067|NCT01378104|DRUG|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
219340068|NCT01378104|DRUG|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
219340069|NCT00885274|DRUG|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
219340070|NCT00885274|DRUG|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
219340071|NCT05929716|DRUG|Magrolimab|Given by IV (vein)
219340072|NCT05929716|DRUG|Rituximab|Given by IV (vein)
219340073|NCT05929716|DRUG|CAR T leukapheresis|Given by IV (vein)
219340074|NCT05929716|DRUG|Radiation|Given by IV (vein)
219340075|NCT05161533|DRUG|Carboplatin|Given IV
219340076|NCT05161533|DRUG|Cisplatin|Given IV
219340077|NCT05161533|BIOLOGICAL|Durvalumab|Given IV
219340078|NCT05161533|DRUG|Etoposide|Given IV
219340079|NCT05161533|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219340080|NCT05161533|OTHER|Quality-of-Life Assessment|Ancillary studies
219340081|NCT05161533|OTHER|Questionnaire Administration|Ancillary studies
219340082|NCT05501145|PROCEDURE|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
219340083|NCT03610724|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel was infused once as an intravenous infustion at a dose of either 0.2 to 5 x 106 CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 108 CAR-positive viable T cells for subjects \> 50 kg.
219340084|NCT03610724|DRUG|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
219340085|NCT03610724|DRUG|Bridging Therapy|Pre-treatment phase could also include bridging therapy of investigator's choice
219340086|NCT05544188|DIAGNOSTIC_TEST|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
219340087|NCT02354222|DRUG|Canagliflozin|
219340088|NCT02354222|DRUG|Teneligliptin|
219340089|NCT02354222|DRUG|Placebo|
219340090|NCT00786565|DEVICE|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
219340091|NCT00786565|DEVICE|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
219340092|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
219340093|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
219340094|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
219340095|NCT03632590|DRUG|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
219340096|NCT05289050|DRUG|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
219340097|NCT05289050|DRUG|S-ketamine|For patients in the s-ketamine group,anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
219340098|NCT00753831|PROCEDURE|Aurosling|Silicon rod to be used in frontalis suspension surgery
219340099|NCT00805272|OTHER|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
219340100|NCT05395611|OTHER|EBPcollected using the PExA device.|The PExA device is a non invasive device that collect particles in exhaled air
219340101|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
219340102|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
219340103|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
219340104|NCT04719650|DRUG|Placebo|Infusion normal saline once.
219340105|NCT06443918|BEHAVIORAL|A Just-in-Time Adaptive Intervention for Child and Family Mental Health|Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
219340106|NCT06648668|DRUG|TMP-301|Once daily \[QD\] × 14 days
219340107|NCT06648668|DRUG|Placebo|Once daily \[QD\] × 14 days
219340108|NCT03777540|PROCEDURE|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
219340109|NCT00248755|PROCEDURE|mucociliary clearance scan|
219340110|NCT04721470|PROCEDURE|Combined therapy|Patients undergoing combined therapy
219340111|NCT04721470|PROCEDURE|Microwave ablation|Patients undergoing Microwave ablation
219340112|NCT04721470|PROCEDURE|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
219340113|NCT05302752|OTHER|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
219340114|NCT03471975|PROCEDURE|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
219340115|NCT03471975|PROCEDURE|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
219340116|NCT01342484|DRUG|placebo|comparison of different dosages of drug (low vs high) vs placebo
219340117|NCT01342484|DRUG|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
219340118|NCT01342484|DRUG|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
219340119|NCT02067195|DRUG|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
219340120|NCT02067195|DRUG|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
219340121|NCT04402970|DRUG|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
219340122|NCT04171479|DEVICE|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
219340123|NCT01840579|BIOLOGICAL|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
219340124|NCT01840579|BIOLOGICAL|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
219340125|NCT01840579|BIOLOGICAL|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
219340126|NCT01840579|DRUG|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
219340127|NCT01840579|DRUG|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
219340128|NCT01840579|DRUG|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
219340129|NCT01840579|DRUG|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
219340130|NCT01840579|DRUG|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
219340131|NCT01840579|DRUG|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
219340132|NCT01840579|BIOLOGICAL|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
219340133|NCT01840579|DRUG|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
219340134|NCT01840579|DRUG|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
219340135|NCT03499509|OTHER|Low Glycemic Diet|Low Glycemic (LG) diet: The LG diet was made up of foods that do not stimulate insulin secretion and was composed of 20% CHO, 55% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
219340136|NCT03499509|OTHER|High Glycemic Diet|High Glycemic (HG) diet: The HG diet aligned with the United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/) and was composed of 55% CHO, 20% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
219340137|NCT01475175|DEVICE|CRT pacing at rest and during exercise|CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
219340138|NCT02171273|BEHAVIORAL|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
219340139|NCT02171273|BEHAVIORAL|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
219340140|NCT02171273|BEHAVIORAL|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
219340141|NCT05352126|OTHER|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
219340142|NCT02768090|DEVICE|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
219340143|NCT01889082|BEHAVIORAL|Behavioral Weight Loss Intervention for Young Adults|
219340144|NCT00554567|BEHAVIORAL|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
219340145|NCT05560373|DRUG|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
219340146|NCT05560373|OTHER|operational treatment, the best basic treatment|other
219340147|NCT05560373|DRUG|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
219340148|NCT05560373|OTHER|Interventional treatment, the best basic treatment|other
219340149|NCT05860842|OTHER|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
219340150|NCT04288986|BEHAVIORAL|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
219340151|NCT01446406|DEVICE|MONARCA|Monitoring affective symptoms entered by the patient every day.
219340152|NCT01446406|DEVICE|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
219340153|NCT00725881|DRUG|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
219340154|NCT00725881|DRUG|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
219340155|NCT03105167|PROCEDURE|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
219340156|NCT03105167|PROCEDURE|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
219340157|NCT05060653|OTHER|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
219340158|NCT02648802|PROCEDURE|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
219340159|NCT02648802|PROCEDURE|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
219340160|NCT01971021|DEVICE|PICC or subcutaneous venous port|
219340161|NCT00277186|OTHER|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
219340162|NCT06006234|OTHER|questionnaire survey|questionnaire survey
219340163|NCT02822885|RADIATION|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
219340164|NCT05517395|BEHAVIORAL|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
219340165|NCT05517395|BEHAVIORAL|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
219340166|NCT01496729|PROCEDURE|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
219340167|NCT01496729|PROCEDURE|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
219340168|NCT02710838|DEVICE|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
219340169|NCT04444999|PROCEDURE|Carbon Dioxide Angiography|• Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
219340170|NCT03034564|DRUG|Northera|
219340171|NCT03034564|DRUG|Placebo Oral Tablet|
219340172|NCT01159028|DRUG|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
219340173|NCT01159028|DRUG|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
219340174|NCT02428842|PROCEDURE|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
219340175|NCT02428842|PROCEDURE|Blood sampling|Blood sampling will be performed before and after treatment.
219340176|NCT01238016|DEVICE|experimental|
219340177|NCT04247633|DRUG|Palbociclib|Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
219340178|NCT04600245|PROCEDURE|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
219340179|NCT02745587|RADIATION|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
219340180|NCT06348485|OTHER|Patients without massive nasal bleeding|No event of massive nasal bleeding after curative radiotherapy
219340181|NCT06348485|OTHER|Patients with massive nasal bleeding|Any event of massive nasal bleeding after curative radiotherapy
219340182|NCT05462015|BEHAVIORAL|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
219340183|NCT05462015|BEHAVIORAL|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
219340184|NCT01231594|DRUG|GSK2118436|Study Drug
219340185|NCT01231594|DRUG|GSK1120212|Study Drug
219340186|NCT01231594|DRUG|Other approved anti-cancer agent|Study Drug
219340187|NCT01325922|PROCEDURE|DFT Testing with a 50/50% tilt|
219340188|NCT05071976|DIAGNOSTIC_TEST|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
219340189|NCT06046872|BEHAVIORAL|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
219340190|NCT06965140|DEVICE|flat 1-piece open ostomy device|OCT scan and skin measurements of peristomal and abdominal skin
219340191|NCT05962138|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
219340192|NCT04963556|DIETARY_SUPPLEMENT|Red Bull|Drinking of Red Bull before exercise
219340193|NCT06968663|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
219340194|NCT06968663|BEHAVIORAL|Modified Constraint Induced Language Therapy (mCILT)|Constraint-induced language therapy (CILT) is a treatment approach for aphasia that focuses on forcing the patient to use their impaired language skills, while restricting the use of compensatory strategies like gestures or writing. All participants will receive mCILT.
219340195|NCT06526585|BEHAVIORAL|Cyclic Sighing Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes."
219340196|NCT06526585|BEHAVIORAL|Box Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes."
219340197|NCT06526585|BEHAVIORAL|Hypnosis|Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
219340198|NCT06526585|BEHAVIORAL|Audiobook|Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
219340199|NCT05918575|DEVICE|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
219340200|NCT05918575|DEVICE|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
219340201|NCT00887237|DEVICE|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
219340202|NCT00887237|DEVICE|Conventional cardiac resynchronization|Conventional cardiac resynchronization
219340203|NCT06543823|DEVICE|SupraTHEL 250|the membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures
219340204|NCT06543823|OTHER|Comparator|no membrane is placed onto the wound bed , left bare to heal
219340205|NCT05485155|DRUG|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.
219340206|NCT02389751|DRUG|Carboplatin|Given IV
219340207|NCT02389751|DRUG|Ganetespib|Given IV
219340208|NCT02389751|DRUG|Paclitaxel|Given IV
219340209|NCT02389751|RADIATION|Radiation Therapy|Undergo radiation therapy
219340210|NCT05020171|DEVICE|Group of strength training|2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
219340211|NCT05020171|OTHER|Group of physiotherapy not focus on strength training|2x a week during 5 weeks, active physical therapy treatment based on movement
219340212|NCT02306109|PROCEDURE|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
219340213|NCT02306109|PROCEDURE|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
219340214|NCT01018628|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
219340215|NCT01018628|DRUG|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
219340216|NCT05546125|OTHER|as per Physician's prescription|Participants need to take the Revatio as per Physician's prescription
219340217|NCT03558984|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
219340218|NCT03558984|OTHER|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
219340219|NCT05248295|BEHAVIORAL|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
219340220|NCT05248295|BEHAVIORAL|Metrical timing (vs. conversational)|This is the secondary contrast in the 2x2 design described above.
219340221|NCT01053871|DRUG|propofol|conscious sedation using propofol
219340222|NCT01053871|DRUG|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
219340223|NCT02874456|OTHER|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
219340224|NCT04543799|DEVICE|polysomnography, actigraphy, questionnaires|sleep quality recording
219340225|NCT03091075|DRUG|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
219340226|NCT03091075|DRUG|Placebo|Placebo group will receive placebo for 12 weeks postoperative
219340227|NCT05909397|DRUG|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
219340228|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
219340229|NCT05909397|DRUG|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
219340230|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
219340231|NCT03021499|DRUG|Voclosporin|calcineurin inhibitor
219340232|NCT03021499|DRUG|Placebo Oral Capsule|matching placebo capsule
219340233|NCT04410588|DRUG|Fentanyl + Topical Levobupivacaine|in nasal packing
219340234|NCT04410588|DRUG|levobupivacaine|in nasal packing
219340235|NCT04329481|DIETARY_SUPPLEMENT|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
219340236|NCT06350734|OTHER|Non-Interventional Study|Non-Interventional Study
219340237|NCT02959528|OTHER|Working memory training|n-back training program
219340238|NCT02959528|OTHER|perceptual training|visual-perceptual training program
219340239|NCT00470054|DRUG|dasatinib|Given PO
219340240|NCT04993794|DRUG|XueBiJing Injection|XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.
219340241|NCT04993794|DRUG|Normal saline|Same saline dose as XueBiJing injection is taken intravenously.
219340242|NCT00870220|DRUG|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
219340243|NCT03739905|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
219340244|NCT04519411|DIAGNOSTIC_TEST|Transpulmonary pressure measurements|Transpulmonary pressure measurements
219340245|NCT03459911|DRUG|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)
219340246|NCT03459911|DRUG|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
219340247|NCT04093843|DEVICE|TMS|NeuroStar TMS Therapy
219340248|NCT01666509|DEVICE|Rossoseq™|
219340249|NCT01666509|DEVICE|Placebo|
219340250|NCT02680925|PROCEDURE|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
219340251|NCT02680925|PROCEDURE|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
219340252|NCT01878526|DRUG|Alginic acid|Algycon 1 tab chew tid after meal
219340253|NCT01878526|DRUG|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
219340254|NCT01878526|DRUG|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
219340255|NCT01878526|DRUG|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
219340256|NCT02947152|DRUG|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
219340257|NCT03310450|OTHER|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
219340258|NCT00754481|OTHER|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
219340259|NCT00754481|OTHER|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
219340260|NCT01787942|DEVICE|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
219340261|NCT03639103|PROCEDURE|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
219340262|NCT05046847|DRUG|TQB3811|TQB3811 is a second-generation TrkA inhibitor.
219340263|NCT04869345|BEHAVIORAL|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
219340264|NCT00359138|DRUG|desloratadine|5 mg tablet once daily
219340265|NCT00359138|DRUG|levocetirizine|5 mg capsule once daily
219340266|NCT00359138|DRUG|Desloratadine placebo tablet|once daily
219340267|NCT00359138|DRUG|Levocetirizine placebo capsule|once daily
219340268|NCT03854136|PROCEDURE|Excision of tumor|Wide margin excision of tumors +/- limb preservation
219340269|NCT02716051|DEVICE|MRI|Whole body MRI with cardiac and pulmonary synchronization
219340270|NCT02716051|DEVICE|PET|
219340271|NCT04526236|DRUG|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
219340272|NCT05303116|DIAGNOSTIC_TEST|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
219340273|NCT00626756|DEVICE|LiDCO technology|non invasive monitoring of cardiac output
219340274|NCT00001075|DRUG|Ritonavir|
219340275|NCT00001075|DRUG|Lamivudine|
219340276|NCT00001075|DRUG|Zidovudine|
219340277|NCT02781909|DRUG|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
219340278|NCT02781909|DRUG|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
219340279|NCT01128127|BEHAVIORAL|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
219340280|NCT01128127|BEHAVIORAL|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
219340281|NCT01128127|BEHAVIORAL|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
219340282|NCT05743738|DIAGNOSTIC_TEST|Doppler ultrasound|Control venous Doppler ultrasound
219340283|NCT00528021|DRUG|Placebo|Vehicle Only
219340284|NCT00528021|DRUG|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
219340285|NCT05094791|DEVICE|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
219340286|NCT05094791|DEVICE|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
219340287|NCT05094791|DEVICE|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
219340288|NCT04226690|DRUG|Active CBD/THC Dose 1|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
219340289|NCT04226690|DRUG|Active CBD/THC Dose 2|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
219340290|NCT04226690|DRUG|matched placebo comparator|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
219340291|NCT04050982|DEVICE|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
219340292|NCT04050982|BEHAVIORAL|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
219340293|NCT05144035|DRUG|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
219340294|NCT00449501|DRUG|Budesonide/formoterol pMDI|
219340295|NCT00449501|DRUG|Budesonide HFA pMDI|
219340296|NCT05054114|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
219340297|NCT06199609|PROCEDURE|Hemodialysis pathway|AVF and TCC are two different vascular pathways for hemodialysis
219340298|NCT06199609|PROCEDURE|AVF|Left atrial changes caused by AVF establishment
219340299|NCT06199609|PROCEDURE|AVF|New onset atrial fibrillation caused by AVF establishment
219340300|NCT00413647|DRUG|CardioPET|
219340301|NCT00751595|BIOLOGICAL|Tat protein|Biologically active recombinant Tat protein
219340302|NCT01791348|OTHER|d2 test of attention|
219340303|NCT06216431|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
219340304|NCT06978374|OTHER|Sonographic examination of thoracolumbar fascia, manual examination of MTrP|"Patients were positioned in the prone position, with a cushion placed under the abdomen to flatten the lumbar lordosis.~A 14-18 MHz linear transducer was used for ultrasonographic (USG) evaluation, performed with a GE Logiq P5 ultrasound device (Serial No: GE-114118SU3).~The USG probe was placed longitudinally at the L2-L3 intervertebral level, 2 cm lateral to the vertical line connecting the spinous processes on both sides, in order to assess the thoracolumbar fascia (TLF)."
219340305|NCT06978816|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|Intravenous infusion of 50 mg dexketoprofen trometamol injection
219340306|NCT06978816|OTHER|Auricular Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, verum auricular acupoint embedding was performed using disposable sterile press needles at three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), with needle retention for 60 minutes
219340307|NCT06978816|OTHER|Sham Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, sham auricular stimulation was administered using non-penetrating adhesive patches applied to three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), maintaining the application for 60 minutes.
219340308|NCT06978517|PROCEDURE|Biodex balance system|Participants assigned to the Biodex balance training group underwent balance rehabilitation using the Biodex Balance System SD, a computerized platform designed to assess and train postural stability. Each participant engaged in training sessions three times per week, with each session lasting approximately 30 minutes, over a total period of six weeks. The intervention began with exercises conducted on a higher stability level (e.g., Level 8), gradually progressing to lower stability levels (e.g., Level 2) to increase the challenge as participants' balance improved. The training included both static and dynamic tasks aimed at enhancing weight shifting, center-of-gravity control, and response to instability. Real-time visual biofeedback was provided via the system's screen, enabling participants to monitor their performance and maintain motivation. All sessions were conducted under the supervision of a qualified physiotherapist to ensure proper technique and safety.
219340309|NCT06978517|PROCEDURE|nintendo Wii fit balance training|Participants in the Nintendo Wii Fit training group engaged in balance exercises using the Nintendo Wii console and Wii Fit balance board. This interactive system includes a variety of balance-focused activities and games that simulate real-life balance challenges in a virtual environment. The training was conducted three times per week, with each session lasting approximately 30 minutes, over a six-week period. Exercises included selected Wii Fit balance games (such as Ski Slalom, Table Tilt, and Tightrope Walk) and yoga-based poses (such as Tree Pose and Warrior), which encouraged participants to engage their core and lower limb muscles while maintaining postural alignment. The difficulty level was gradually increased by introducing more complex tasks and longer balance durations as participants progressed. The system provided immediate visual and auditory feedback, allowing users to track their scores and improvements in real time. All sessions were performed under supervision.
219340310|NCT06979284|PROCEDURE|IVUS-guided strategy|Percutaneous revascularization will be performed using intravascular ultrasound. The operators will follow instructions to modify arteries hardened by calcium and use IVUS to optimize the equipment (balloon and stents) used to unblock the artery.
219340311|NCT06977672|OTHER|Down Dog Yoga|In this study, a period of 10 weeks, commencing with a preliminary assessment during the first week, followed by an 8-week intervention phase, and concluding with a final assessment in the last week of the study period. The frequency-intensity-time-type principle will be implemented as follows: sessions will occur 4 times per week, consisting of 2 sessions led by experts and 2 sessions involving parents. The intensity will be 40 to 45 minutes for expert-led sessions and 20 to 25 minutes for parent-led sessions. These sessions will take place 3 or 4 times per week over an 8-week period, focusing on a type of intervention known as dog down yoga
219340312|NCT06977672|OTHER|Traditional|The children took part in group sessions four days a week over a span of 10 weeks, totaling 40 sessions. Each session, lasting around 20 minutes, involved small groups of four to seven children. The aim will be to evaluate the children's writing across four stages of development: pre-phonemic, semi-phonemic, phonemic, and conventional
219340313|NCT06977243|BEHAVIORAL|Online MedEd Intern Bootcamp|7 weeks, online training program
219340314|NCT06979167|DEVICE|midline catheter insertion during general anesthesia|This intervention involves the ultrasound-guided insertion of a midline catheter into a peripheral vein (basilic, cephalic, or brachial vein) during general anesthesia in pediatric patients.
219340315|NCT06978738|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
219340316|NCT01345747|DEVICE|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
219340317|NCT00592033|OTHER|oxygen from a portable concentrator|2 l/minute during exercise
219340318|NCT00801645|BEHAVIORAL|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
219340319|NCT05472012|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
219340320|NCT01423851|DRUG|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
219340321|NCT06929195|DRUG|TQB2210 Injection|TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
219340322|NCT06904339|BEHAVIORAL|Starting the Conversation|Starting the Conversation includes a 25-minute video with information about sexual health and gynecologic cancer and tips about how to talk to their cancer care team about sexual health concerns. Participants will also fill out a workbook with activities to help them practice communication skills.
219340323|NCT06904339|BEHAVIORAL|Sexual Health Resources|The sexual health resource guide includes institutional resources for patients with sexual concerns (for example, the Women's Survivorship Clinic) and links to reputable websites with information about sexual health after gynecologic cancer.
219340324|NCT05118802|OTHER|Interview|Attends Interviews
219340325|NCT05118802|OTHER|Survey Administration|Complete Survey
219340326|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
219340327|NCT06927466|BIOLOGICAL|B019|B019： Intravenous infusion, 1.0×10\^6 CAR T cell/kg-10.0×10\^6 CAR T cell/kg
219340328|NCT00733954|DRUG|clobetasol propionate spray|Apply twice daily
219340329|NCT00733954|DRUG|clobetasol propionate ointment|Apply twice daily
219340330|NCT02663453|DRUG|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
219340331|NCT02663453|DRUG|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
219340332|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
219340333|NCT00350051|DRUG|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
219340334|NCT00916357|DRUG|Humalog|
219340335|NCT00916357|DRUG|Humulin-R|
219340336|NCT00916357|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
219340337|NCT02835183|DEVICE|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
219340338|NCT02835183|DEVICE|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
219340339|NCT04167046|PROCEDURE|Erector spinae block|Preoperative erector spinae block.
219340340|NCT01308008|BEHAVIORAL|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
219340341|NCT01308008|BEHAVIORAL|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
219340342|NCT01417195|DRUG|Bravelle|
219340343|NCT01417195|DRUG|Menopur|
219340344|NCT03357731|DRUG|HNO Donor|Infusion
219340345|NCT03357731|DRUG|Nitroglycerin (NTG)|Infusion
219340346|NCT03357731|OTHER|Placebo|Infusion
219340347|NCT05196126|PROCEDURE|Permament pacemaker implantation|PM implantation
219340348|NCT05196126|PROCEDURE|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
219340349|NCT05382351|DRUG|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
219340350|NCT05382351|DRUG|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
219340351|NCT01570504|DRUG|Ivermectin|oral formulation
219340352|NCT03069430|BEHAVIORAL|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
219340353|NCT00772954|BIOLOGICAL|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
219340354|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
219340355|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
219340356|NCT00535561|DRUG|Ferrous sulfate tablets 325 mg, po, TID|
219340357|NCT00535561|DRUG|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
219340358|NCT04989283|BIOLOGICAL|Atezolizumab|Given IV
219340359|NCT04989283|PROCEDURE|Biopsy|Undergo tumor biopsy
219340360|NCT04989283|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219340361|NCT04989283|DRUG|Carboplatin|Given IV
219340362|NCT04989283|DRUG|Cisplatin|Given IV
219340363|NCT04989283|PROCEDURE|Computed Tomography|Undergo PET/CT scan
219340364|NCT04989283|DRUG|Etoposide|Given IV
219340365|NCT04989283|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
219340366|NCT04989283|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219340367|NCT04989283|DRUG|Paclitaxel|Given IV
219340368|NCT04989283|DRUG|Pemetrexed|Given IV
219340369|NCT04989283|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219340370|NCT04989283|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219340371|NCT00000414|BEHAVIORAL|Arthritis Self-Management Program|
219340372|NCT00000414|BEHAVIORAL|SMART Program|
219340373|NCT01773109|DRUG|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
219340374|NCT01815307|DRUG|Gemcitabine|1000mg/m2, day 1 every 2 weeks
219340375|NCT01815307|DRUG|S-1|80mg/m2/day, day 1-28, every 6 weeks
219340376|NCT04155138|DEVICE|Naida Hearing Aid|hearing aid
219340377|NCT04155138|DEVICE|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
219340378|NCT01239342|DRUG|Akt Inhibitor MK2206|Given PO
219340379|NCT01239342|DRUG|Everolimus|Given PO
219340380|NCT01239342|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
219340381|NCT00406510|DRUG|Optive, Systane|
219340382|NCT04799392|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
219340383|NCT03628014|OTHER|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities"
219340384|NCT02892474|PROCEDURE|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
219340385|NCT02892474|PROCEDURE|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
219340386|NCT02011321|DRUG|clevidipine|clevidipine infusion x4 hours
219340387|NCT04956380|OTHER|Self-administered Triage|Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
219340388|NCT04156971|DIETARY_SUPPLEMENT|Omega 3|
219340389|NCT04156971|BEHAVIORAL|stage-based lifestyle modification intervention|
219340390|NCT00360594|DRUG|Acamprosate|3 pills (666 mg) for 1998mg/day
219340391|NCT00360594|DRUG|Placebo|3 pills (666mg) for 1998mg/day
219340392|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
219340393|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
219340394|NCT02495844|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
219340395|NCT03118232|DRUG|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
219340396|NCT03118232|DRUG|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
219340397|NCT01136135|OTHER|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
219340398|NCT02325219|DRUG|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
219340399|NCT02325219|DRUG|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
219340400|NCT02325219|DRUG|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
219340401|NCT02325219|DRUG|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
219340402|NCT02655432|DEVICE|Spot photoscreener|Screening of vision problem through an automated device
219340403|NCT02655432|PROCEDURE|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
219340404|NCT02655432|PROCEDURE|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
219340405|NCT05705609|OTHER|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
219340406|NCT03426085|DRUG|Liraglutide 6 mg Solution for Injection|
219340407|NCT03426085|OTHER|Placebo|
219340408|NCT03986489|BEHAVIORAL|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
219340409|NCT03986489|BEHAVIORAL|Chronic pain social support group|"The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session."
219340410|NCT01099852|OTHER|biological sample collection|blood sample collection urine sample cerebrospinal fluid sample
219340411|NCT01099852|OTHER|Quality of life Questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
219340412|NCT01099852|OTHER|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
219340413|NCT01099852|OTHER|Neuropathic Pain Questionnaire (DN4)|Questionnaire used during the follow up
219340414|NCT00798850|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.
219340415|NCT00798850|PROCEDURE|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
219340416|NCT00798850|PROCEDURE|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
219340417|NCT02918864|DRUG|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
219340418|NCT02918864|BEHAVIORAL|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
219340419|NCT02918864|BEHAVIORAL|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
219340420|NCT04667351|DRUG|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
219340421|NCT04667351|DRUG|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
219340422|NCT00198380|DRUG|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
219340423|NCT03841071|OTHER|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
219340424|NCT03344315|DEVICE|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
219340425|NCT03344315|OTHER|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
219340426|NCT04766021|DRUG|Mirabegron|Dose-response effect on thermogenesis
219340427|NCT04766021|DRUG|Placebo|Placebo control condition
219340428|NCT02645357|OTHER|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
219340429|NCT02645357|OTHER|Control group|control group
219340430|NCT02750540|DRUG|Tenofovir enema|
219340431|NCT02750540|OTHER|Saline enema|
219340432|NCT02979665|DRUG|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
219340433|NCT04595903|DEVICE|Hemopurifier|Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
219340434|NCT04464395|DRUG|CPI-006|Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
219340435|NCT04464395|OTHER|Standard of Care|Participants will receive standard of care treatment only.
219340436|NCT05198271|OTHER|Management of risk factors|"* For all patients:~  * Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~ * Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~ * Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~* Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
219340437|NCT05198271|BEHAVIORAL|Smoking cessation|"\- For active smoking patients:~* Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~* Nicotine substitutes +/- varenicline according to tobacco consumption~* Online notebook to record tobacco consumption and triggers"
219340438|NCT05198271|BEHAVIORAL|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
219340439|NCT05198271|OTHER|periodontal disease treatment|\- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
219340440|NCT05198271|BEHAVIORAL|increased physical activity|\- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
219340441|NCT05198271|BEHAVIORAL|Decreased anxiety|"\- For anxious patients:~* Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~* Delivery of connected equipment for the practice of cardiac coherence"
219340442|NCT00709215|DRUG|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
219340443|NCT03289650|DRUG|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
219340444|NCT03289650|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
219340445|NCT01677533|OTHER|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
219340446|NCT01677533|OTHER|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
219340447|NCT01677533|OTHER|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
219340448|NCT01656031|DRUG|clofarabine|
219340449|NCT01656031|DRUG|cytarabine|
219340450|NCT05668624|OTHER|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
219340451|NCT00079404|DRUG|tanespimycin|Given IV
219340452|NCT05999188|OTHER|Observational|No interventions will be given to patients.
219340453|NCT02634151|DRUG|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
219340454|NCT02634151|DRUG|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
219340455|NCT02289430|DRUG|Crestor+Ezetrol|rosuvastatin+ezetimibe
219340456|NCT02289430|DRUG|Ezetrol|ezetimibe
219340457|NCT02289430|DRUG|Crestor|rosuvastatin
219340458|NCT05143892|DRUG|Avatrombopag|Avatrombopag administered at the described frequency to achieve a target platelet count
219340459|NCT05143892|OTHER|Supportive care|Supportive care other than TPO-RAs or recombinant human thrombopoietin.
219340460|NCT05008107|OTHER|Virtual reality|Using VR goggles to watch peri-operative instructional video.
219340461|NCT04392115|BEHAVIORAL|The PREPARE program|"A home-based exercise program guided by paper materials, weekly phone calls, and a DVD.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
219340462|NCT03156920|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219340463|NCT03156920|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
219340464|NCT02347098|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
219340465|NCT02347098|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
219340466|NCT02187172|DRUG|Ustekinumab|
219340467|NCT02187172|DRUG|Placebo|
219340468|NCT04550091|DEVICE|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
219340469|NCT04782362|OTHER|Brace Treatment|Body image and quality of life of individuals who have used brace will be evaluated
219340470|NCT04640272|DRUG|RBM-007|Intravitreal injection
219340471|NCT04412850|DRUG|Magnesium Sulfate|"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge."
219340472|NCT05710120|OTHER|Hepatitis C Screening Alerts in CHORUS™|"ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test."
219340473|NCT05710120|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
219340474|NCT01523496|DRUG|Vitamin D control dose|18,000 IU per month
219340475|NCT01523496|DRUG|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
219340476|NCT01792921|BEHAVIORAL|COG - FUN|
219340477|NCT06469996|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.
219340478|NCT06469996|OTHER|Self myofascial relaxation|Self myofascial relaxation will be practiced with foam roller in patients with Fibromyalgia.
219340479|NCT00145028|DRUG|Carboplatin|
219340480|NCT04096027|DRUG|Cabergoline Pill|0.5 mg cabergoline pill taken orally
219340481|NCT01389375|DEVICE|FemoSeal®|Closure device for femoral artery access closure
219340482|NCT01389375|DEVICE|ExoSeal®|Closure device for femoral artery access closure
219340483|NCT01389375|OTHER|Manual compression|Conventional manual compression
219340484|NCT01875783|DEVICE|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
219340485|NCT00128856|DRUG|Gemcitabine|
219340486|NCT00128856|DRUG|Adriamycine|
219340487|NCT00128856|DRUG|Paclitaxel|
219340488|NCT05785156|OTHER|quick tests|"New quick tests are~* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
219340489|NCT02678481|DEVICE|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
219340490|NCT02678481|DEVICE|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
219340491|NCT00351013|OTHER|Malaria Tropica Nosode D200|5 pellets every four months
219340492|NCT02464384|PROCEDURE|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
219340493|NCT05911542|BEHAVIORAL|Survey|Participants complete survey about pain management practices
219340494|NCT01647451|DRUG|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
219340495|NCT01647451|DRUG|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
219340496|NCT05080465|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
219340497|NCT04636827|BIOLOGICAL|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
219340498|NCT04636827|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
219340499|NCT04636827|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
219340500|NCT04636827|BIOLOGICAL|HepA|HepA at the age of 18 month old
219340501|NCT04172714|DEVICE|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
219340502|NCT01035099|DRUG|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;"
219340503|NCT01035099|DRUG|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
219340504|NCT05018247|PROCEDURE|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
219340505|NCT00146315|BEHAVIORAL|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
219340506|NCT00146315|BEHAVIORAL|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
219340507|NCT05988268|OTHER|Vibration Foam Rolling|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
219340508|NCT05988268|OTHER|Non-Vibration Foam Rolling|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
219340509|NCT00889148|DRUG|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
219340510|NCT00889148|OTHER|Placebo|Half the patients will be randomized to placebo
219340511|NCT05440162|DIAGNOSTIC_TEST|electrolyte|follow up NA
219340512|NCT01710384|DRUG|betamethasone|
219340513|NCT02572726|DEVICE|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
219340514|NCT02572726|DEVICE|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
219340515|NCT01170520|DEVICE|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
219340516|NCT01528111|DRUG|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
219340517|NCT01528111|DRUG|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
219340518|NCT01528111|DRUG|LX7101 Vehicle|Subjects will receive vehicle
219340519|NCT04790877|OTHER|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
219340520|NCT04790877|OTHER|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
219340521|NCT04075721|DRUG|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
219340522|NCT04075721|DRUG|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
219340523|NCT05352204|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
219340524|NCT01630473|PROCEDURE|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
219340525|NCT01630473|PROCEDURE|Conventional orthodontics|Conventional orthodontic treatment
219340526|NCT00766532|DRUG|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
219340527|NCT01438489|BIOLOGICAL|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
219340528|NCT01438489|BIOLOGICAL|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
219340529|NCT01438489|OTHER|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
219340530|NCT00533832|DEVICE|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
219340531|NCT04659265|OTHER|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
219340532|NCT05099627|OTHER|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
219340533|NCT05099627|OTHER|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
219340534|NCT05099627|OTHER|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
219340535|NCT06477874|PROCEDURE|Dental implants placement|implants placed in consolidated bone grafts
219340536|NCT00429403|DRUG|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
219340537|NCT00573430|DRUG|Candesartan Cilexetil|8 mg oral once daily dose
219340538|NCT00573430|DRUG|Candesartan Cilexetil|16 mg oral once daily dose
219340539|NCT00573430|DRUG|Candesartan Cilexetil 32mg|32 mg oral once daily dose
219340540|NCT05699889|OTHER|Data collection|acute kidney injury and tubular dysfunction
219340541|NCT02194751|BIOLOGICAL|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
219340542|NCT03437382|DEVICE|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
219340543|NCT00004998|DRUG|Lamivudine/Zidovudine|
219340544|NCT00004998|DRUG|Capravirine|
219340545|NCT00004998|DRUG|Nelfinavir mesylate|
219340546|NCT00099970|DRUG|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
219340547|NCT05491928|DRUG|Tempol|Tempol will be given as an adjunct to chemotherapy.
219340548|NCT05630079|DEVICE|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
219340549|NCT05630079|DEVICE|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% \[-\] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
219340550|NCT00129324|PROCEDURE|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
219340551|NCT00129324|PROCEDURE|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
219340552|NCT01262521|DIETARY_SUPPLEMENT|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
219340553|NCT01262521|DIETARY_SUPPLEMENT|Water|150 ml Chapelle mineral water
219340554|NCT06096402|PROCEDURE|no intervention, but surgical practice as usual is continued. Its a pragmatic study|no intervention
219340555|NCT05266937|COMBINATION_PRODUCT|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
219340556|NCT06033573|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
219340557|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
219340558|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
219340559|NCT00865059|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
219340560|NCT00865059|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
219340561|NCT03005795|DEVICE|Headphones|Music can be heard through headphones
219340562|NCT03005795|OTHER|No Headphones|No Headphones will be used.
219340563|NCT01191073|DEVICE|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
219340564|NCT01191073|DEVICE|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
219340565|NCT04808531|DRUG|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
219340566|NCT04808531|DRUG|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
219340567|NCT04808531|DRUG|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
219340568|NCT04808531|DRUG|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
219340569|NCT04808531|DRUG|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
219340570|NCT02037295|DRUG|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
219340571|NCT02037295|DRUG|Placebo oral tablet|Placebo pills orally four times per day for 12 days
219340572|NCT02037295|OTHER|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
219340573|NCT02037295|OTHER|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
219340574|NCT04989920|BEHAVIORAL|Experimental group: CIMT group (Constraint-Induced Movement Therapy)|2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
219340575|NCT04575558|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
219340576|NCT05433506|DRUG|HU6 Tablet|Six subjects will receive a tablet formulation.
219340577|NCT05433506|DRUG|HU6 Capsule|Six subjects will receive the capsule formulation
219340578|NCT01255527|DRUG|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
219340579|NCT01505621|OTHER|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine
219340580|NCT00073723|DRUG|ABI-007|
219340581|NCT00984971|DRUG|Tenofovir|Topical gel applied rectally
219340582|NCT00984971|DRUG|HEC Placebo|Placebo gel applied rectally
219340583|NCT00984971|DRUG|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
219340584|NCT05363475|DEVICE|ForeSite Intelligent Surface|The ForeSite IS is a continuous bedside pressure mapping system with machine learning and artificial intelligence (ML/AI). It consists of an overlay with over 1500 undetectable integrated sensors and a medical-grade bedside touchscreen monitor. The monitor displays a real-time coloured body pressure image, a turn timer, and a history of previous turns. The ML/AI software tracks 17 body locations and the patient's body position. The system has a centralized dashboard that shows the pressure injury risk and turn history, which can be transmitted to the nursing station. In addition, data is stored in an Amazon Web Services (AWS) secured cloud database, enabling access to individual reports on turn history and compliance and pressure exposure. Data is stored as both, raw pressure data files and real time event information on pressure exposure and turn data.
219340585|NCT03991351|OTHER|Exposure to images|Exposure to images
219340586|NCT02152085|DEVICE|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
219340587|NCT02152085|DEVICE|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
219340588|NCT00872105|PROCEDURE|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
219340589|NCT00872105|PROCEDURE|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
219340590|NCT03391271|OTHER|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
219340591|NCT03391271|OTHER|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
219340592|NCT05279547|OTHER|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
219340593|NCT05279547|OTHER|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
219340594|NCT02534402|DRUG|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
219340595|NCT05341271|OTHER|Experimental: digital reminiscence group (DRG)|Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
219340596|NCT05341271|OTHER|Experimental: general reminiscence group (GRG)|"Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences"
219340597|NCT01157312|DRUG|clomiphene citrate +highly purified uFSH|
219340598|NCT01157312|DRUG|clomiphene citrate|
219340599|NCT05733871|DIETARY_SUPPLEMENT|meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
219340600|NCT05733871|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
219340601|NCT04003233|DEVICE|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
219340602|NCT04003233|DEVICE|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
219340603|NCT04563429|DIETARY_SUPPLEMENT|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
219340604|NCT02879565|OTHER|Semi structured interviews + EEG exams|
219340605|NCT02858674|OTHER|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
219340606|NCT02858674|OTHER|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
219340607|NCT01686620|DRUG|BIOD-123|
219340608|NCT01686620|DRUG|Lispro (Humalog)|
219340609|NCT05059496|OTHER|Hamstring stretching with Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
219340610|NCT05059496|OTHER|Hamstring stretching with out Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
219340611|NCT05562375|DEVICE|GOCCLES|"Inspection using GOCCLES®. An UV light source will be administered, with polymerization lamp sdi radii xpert, with a potency of 1500 mW/cm2 and a wavelength of 440-480nm, applied at 20cm of the injury.~Notes will be taken on the location and size of the injury observed with the device.~Image register using the GOCCLES® photographic filter for mobile devices. The same light source will be used."
219340612|NCT05562375|DIAGNOSTIC_TEST|Toluidine blue stain|"To value the toluidine blue diagnosis capacity, the sequence described by Mashberg will be followed: The patient will realize a mouthwash with acetic acid at 1% for 20 seconds. Two using water for 20 seconds. Toluidine blue at 1% will be applied for 20 seconds. New mouthwash with acetic acid for 60 seconds and a final mouthwash with water.~Notes on the and pictures will be taken on the location and size of the injury."
219340613|NCT05562375|PROCEDURE|Biopsy|The area to biopsy will be chosen, and, using local anaesthesia, it will be resected. The specimens will be sent to the oral and maxillofacial pathology diagnostic service of the University of Basque Country for anatomopathological study
219340614|NCT01168661|BEHAVIORAL|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) \>= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
219340615|NCT01168661|BEHAVIORAL|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
219340616|NCT01168661|BEHAVIORAL|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
219340617|NCT01324232|DRUG|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
219340618|NCT01324232|DRUG|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
219340619|NCT01324232|DRUG|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
219340620|NCT01324232|DRUG|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
219340621|NCT01527474|DRUG|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
219340622|NCT04564586|BEHAVIORAL|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
219340623|NCT05325905|DIAGNOSTIC_TEST|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
219340624|NCT03840538|DRUG|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
219340625|NCT03627845|DRUG|PHP-303|Investigational drug
219340626|NCT03627845|OTHER|Placebo|Matching placebo
219340627|NCT00661531|DRUG|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
219340628|NCT00661531|DRUG|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
219340629|NCT02869386|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
219340630|NCT02869386|PROCEDURE|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
219340631|NCT05493943|DEVICE|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
219340632|NCT05493943|OTHER|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
219340633|NCT00060346|BIOLOGICAL|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
219340634|NCT00060346|DRUG|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
219340635|NCT00060346|DRUG|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
219340636|NCT00060346|DRUG|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
219340637|NCT00060346|DRUG|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
219340638|NCT04118816|DIAGNOSTIC_TEST|Polysomnography|overnight polysomnography recording at least six hours
219340639|NCT04118816|DIAGNOSTIC_TEST|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
219340640|NCT04118816|OTHER|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
219340641|NCT03134599|DEVICE|etafilcon A|contact lens
219340642|NCT03134599|DEVICE|methafilcon A - Interozzo|contact lens
219340643|NCT03134599|DEVICE|methafilcon A - CVI (CooperVision)|contact lens
219340644|NCT00916188|DIETARY_SUPPLEMENT|Black Tea Extract|Amount/dose depends on Arm assignment.
219340645|NCT02021045|DEVICE|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
219340646|NCT06426355|DIETARY_SUPPLEMENT|NMN|NMN capsules (total of 600mg/day) for 2-5 months
219340647|NCT06426355|OTHER|Placebo|NMN-free placebo capsules for 2-5 months
219340648|NCT02350556|OTHER|Dynamic Avoidance Task|
219340649|NCT02350556|PROCEDURE|physical therapy|
219340650|NCT02350556|DEVICE|3D motion on optoelectronic device|
219340651|NCT04001361|PROCEDURE|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
219340652|NCT03333083|DRUG|Raltegravir|Raltegravir (1200 mg once a day)
219340653|NCT03333083|DRUG|Lamivudine|Lamivudine (300 mg once a day)
219340654|NCT05873881|DRUG|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
219340655|NCT05873881|DRUG|Colchicine placebo|Placebo colchicine daily
219340656|NCT05873881|DRUG|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
219340657|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
219340658|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
219340659|NCT00312624|PROCEDURE|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
219340660|NCT03503877|DEVICE|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
219340661|NCT03503877|OTHER|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
219340662|NCT03503877|OTHER|SAGE MEDIA|Embryos will be cultured in SAGE media
219340663|NCT00002284|DRUG|Zidovudine|
219340664|NCT00865683|DIETARY_SUPPLEMENT|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
219340665|NCT00865683|DIETARY_SUPPLEMENT|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
219340666|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
219340667|NCT04962022|DRUG|Itraconazole|Administered orally once daily for 8 days from Days 1 through 8
219340668|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
219340669|NCT03546530|DRUG|Interferon|Interferon
219340670|NCT03546530|DRUG|Interferon+resveratrol|Interferon+resveratrol
219340671|NCT00006451|DRUG|anti-thymocyte globulin|
219340672|NCT00006451|DRUG|cyclophosphamide|
219340673|NCT00006451|DRUG|cyclosporine|
219340674|NCT00006451|DRUG|methotrexate|
219340675|NCT00006451|DRUG|methylprednisolone|
219340676|NCT00006451|PROCEDURE|allogeneic bone marrow transplantation|
219340677|NCT00006451|PROCEDURE|in vitro-treated bone marrow transplantation|
219340678|NCT00006451|PROCEDURE|radiation therapy|
219340679|NCT00071695|DRUG|Duloxetine Hydrochloride|
219340680|NCT00071695|DRUG|Venlafaxine Extended Release|
219340681|NCT02690857|DRUG|Docosahexaenoic acid|
219340682|NCT02690857|DRUG|Sunflower Oil|
219340683|NCT03782402|DRUG|Cannabinoids|Cannabinoids with THC and CBD versus placebo cannabinoids
219340684|NCT04240015|OTHER|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
219340685|NCT01146873|DRUG|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
219340686|NCT01146873|DRUG|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
219340687|NCT01146873|DRUG|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
219340688|NCT01146873|DRUG|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
219340689|NCT06398548|OTHER|Control Group|Participants continue with their lifestyle as usual, with no modification to lifestyle, or exercise habits.
219340690|NCT06398548|OTHER|Moderate Intensity Continuous Training|This group cycles at 70% of the resistance associated with their first lactate threshold.
219340691|NCT06398548|OTHER|Heavy Intensity Continuous Training|This group cycles at 10% of the difference between the resistance associated with their lactate threshold, and maximal achieved watts, added to the resistance associated with their lactate threshold.
219340692|NCT01967628|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
219340693|NCT01967628|DIETARY_SUPPLEMENT|Placebo Sugar Pill|
219340694|NCT01356407|DRUG|PICOPREP|
219340695|NCT01356407|DRUG|PEG-ELS|
219340696|NCT01545479|DRUG|captopril 25mg|renal blood oxygenation after captopril
219340697|NCT01826279|DIETARY_SUPPLEMENT|Resveratrol|500mg 3 times daily for 1 month
219340698|NCT01826279|OTHER|Placebo|1 placebo tablet 3 times daily for 1 month
219340699|NCT04439604|OTHER|regional ventilation monitoring|regional ventilation monitoring
219340700|NCT04496622|OTHER|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
219340701|NCT04496622|OTHER|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
219340702|NCT03331055|DEVICE|PENS|percutaneous electrical nerve stimulation
219340703|NCT03331055|DEVICE|TENS|transcutaneous electrical nerve stimulation
219340704|NCT04331795|DRUG|Tocilizumab|"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
219340705|NCT04331795|DRUG|Tocilizumab|"Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
219340706|NCT03544372|OTHER|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
219340707|NCT02970825|OTHER|Exercise|Moderate to high intensity physical training
219340708|NCT02970825|OTHER|Relaxation|Low intensity physical activity and relaxation
219340709|NCT05011929|BEHAVIORAL|Cognitive behavioral therapy|refer to the arm description
219340710|NCT03532594|PROCEDURE|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
219340711|NCT03532594|PROCEDURE|Standard Care|Protamine administered according to Standard Care
219340712|NCT00120991|PROCEDURE|Coronary artery bypass grafting|
219340713|NCT01396174|BEHAVIORAL|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
219340714|NCT01396174|BEHAVIORAL|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
219340715|NCT04312035|PROCEDURE|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
219340716|NCT04312035|PROCEDURE|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
219340717|NCT04312035|PROCEDURE|Control|hands-on cutaneous technique
219340718|NCT02936583|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
219340719|NCT02317861|DRUG|RDEA3170|Oral Treatment
219340720|NCT02317861|DRUG|Febuxostat|Oral Treatment
219340721|NCT02317861|DRUG|Benzbromarone|Oral Treatment
219340722|NCT02055820|DRUG|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
219340723|NCT02055820|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
219340724|NCT02055820|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
219340725|NCT02055820|DRUG|Rituximab|Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
219340726|NCT02055820|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
219340727|NCT02055820|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
219340728|NCT02055820|DRUG|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
219340729|NCT02107638|PROCEDURE|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
219340730|NCT02107638|OTHER|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
219340731|NCT02947035|PROCEDURE|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
219340732|NCT02947035|PROCEDURE|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
219340733|NCT03962374|DEVICE|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
219340734|NCT03962374|DEVICE|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
219340735|NCT04428021|DRUG|Standard Therapy Protocol (STP)|Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee
219340736|NCT04428021|OTHER|STP + Standard Plasma (SP)|Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP
219340737|NCT04428021|OTHER|STP + COVID-19 Convalescent Plasma (CP)|Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
219340738|NCT05386901|PROCEDURE|Conventional positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.
219340739|NCT05386901|PROCEDURE|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
219340740|NCT01106170|DRUG|Provex CV|dietary supplement, 2 capsules per day by mouth
219340741|NCT01106170|OTHER|placebo|corn starch, 2 capsules per day by mouth
219340742|NCT04624711|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
219340743|NCT04624711|DRUG|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
219340744|NCT03917173|PROCEDURE|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
219340745|NCT03917173|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
219340746|NCT03884738|OTHER|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
219340747|NCT03884738|OTHER|Nordic Eccentric exercise|"1. st week - 1 day - 2 sets of 5 repeats.~2. nd week - 2 days - 2 sets of 6 repeats.~3. rd week - 3 days - 3 sets of 6-8 repeats.~4. th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
219340748|NCT03884738|OTHER|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
219340749|NCT00507390|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
219340750|NCT00507390|DIETARY_SUPPLEMENT|olive oil|1 capsule day
219340751|NCT00913900|BIOLOGICAL|autologous CD133+ cells|Intramuscular injection
219340752|NCT05382975|BEHAVIORAL|CSPAP-T|"Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning"
219340753|NCT02362958|DRUG|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
219340754|NCT00877812|DIETARY_SUPPLEMENT|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
219340755|NCT00877812|DIETARY_SUPPLEMENT|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
219340756|NCT05583929|OTHER|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
219340757|NCT00315744|DRUG|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
219340758|NCT00315744|DRUG|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
219340759|NCT00315744|DRUG|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
219340760|NCT02949180|DEVICE|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
219340761|NCT04153721|BEHAVIORAL|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
219340762|NCT04986462|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
219340763|NCT04435509|DIETARY_SUPPLEMENT|1000+ Greek Mountain Tea|Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month
219340764|NCT04435509|OTHER|Mediterranean Diet|a Mediterranean dietary protocol
219340765|NCT04243850|DRUG|Empagliflozin 10 MG|Jardiance
219340766|NCT04243850|DRUG|Placebo oral tablet|Placebo
219340767|NCT04243850|DIAGNOSTIC_TEST|Caffeine|caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
219340768|NCT03624699|DEVICE|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
219340769|NCT01157364|DRUG|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
219340770|NCT01157364|DRUG|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
219340771|NCT01157364|DRUG|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
219340772|NCT01157364|DRUG|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
219340773|NCT01157364|DRUG|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
219340774|NCT01157364|DRUG|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
219340775|NCT01157364|DRUG|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
219340776|NCT03720431|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
219340777|NCT02243254|DRUG|high dose remifentanil|high dose remifentanil
219340778|NCT02243254|DRUG|Ibuprofen|intravenous ibuprofen
219340779|NCT02243254|DRUG|low dose remifentanil|low dose remifentanil
219340780|NCT00482430|DRUG|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
219340781|NCT00482430|DRUG|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
219340782|NCT02410135|DRUG|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
219340783|NCT00541554|DRUG|Abilify (aripiprazole)|
219340784|NCT02891304|OTHER|Quarterly Feedback|Learning curves received quarterly vs. annually
219340785|NCT01594515|DRUG|BI 1015550|High dose powder for oral solution
219340786|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
219340787|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
219340788|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
219340789|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
219340790|NCT01594515|DRUG|Placebo|Solution for oral administration
219340791|NCT01594515|DRUG|BI 101550|High dose powder for oral solution
219340792|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
219340793|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
219340794|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
219340795|NCT02529787|DRUG|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
219340796|NCT02529787|DRUG|Dexilant|1 capsule contains 60 mg Dexlansoprazole
219340797|NCT02170285|DEVICE|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
219340798|NCT02170285|DEVICE|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
219340799|NCT04362280|BEHAVIORAL|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
219340800|NCT04362280|BEHAVIORAL|TAU|PE class as usual led by PE teacher.
219340801|NCT04756700|DIAGNOSTIC_TEST|DigiCog (BCCAMS app)|Administered as specified in the treatment arm.
219340802|NCT04756700|DIAGNOSTIC_TEST|Konectom Application|Administered as specified in the treatment arm.
219340803|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
219340804|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
219340805|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
219340806|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
219340807|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
219340808|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
219340809|NCT01079273|BIOLOGICAL|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
219340810|NCT01713621|DRUG|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
219340811|NCT00570973|PROCEDURE|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
219340812|NCT00570973|PROCEDURE|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
219340813|NCT04277520|PROCEDURE|Root canal therapy|Different types of instrumentation motions during root canal therapy
219340814|NCT00528515|DRUG|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
219340815|NCT00528515|DRUG|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
219340816|NCT04303130|DRUG|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
219340817|NCT00006047|DRUG|Oral Etoposide|
219340818|NCT00006047|DRUG|Oral 9-Nitrocamptothecin|
219340819|NCT06466304|BEHAVIORAL|inspiratory muscle training|children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
219340820|NCT06490016|DEVICE|web based education|"The web page will be prepared with professional support in line with the guidelines of the Web Content Accessibility Guide (WCAG / WIEK 2.1) developed by W3C.~1. st meeting: online Informed Consent will be obtained. After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out online.~2. nd interview: Module 1-2.~3. rd interview: Module 3 -4.~4. th meeting: Module 5.They will be asked to fill out the System Usability Scale.~5. th interview: During the first menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online.~6. th interview: During the second menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online."
219340821|NCT06490016|BEHAVIORAL|Face to face|"In face-to-face training, female internal reproductive organ models, female external reproductive organ models, training content prepared with Braille alphabet, menstrual hygiene management kit (underwear, pads, napkins, calendar) materials will be used. Pictures and audio descriptions will be used in web-based training.~1. st interview: Informed Consent . After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out.~2. nd meeting: Module 1-2~3. rd meeting: Module 3- 4~4. th meeting: Module 5.~5. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed.~6. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed."
219340822|NCT01547169|DRUG|Placebo Comparator|saline, taken twice per day for a 3 week duration
219340823|NCT01547169|DRUG|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
219340824|NCT01547169|DRUG|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
219340825|NCT00841568|DRUG|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
219340826|NCT00763230|DEVICE|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
219340827|NCT01230281|OTHER|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
219340828|NCT01830751|OTHER|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
219340829|NCT04341220|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
219340830|NCT04341220|OTHER|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
219340831|NCT04178694|DEVICE|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
219340832|NCT00002364|DRUG|Abacavir sulfate|
219340833|NCT01556139|DEVICE|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
219340834|NCT05774379|DEVICE|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
219340835|NCT05774379|BEHAVIORAL|fatigue education|fatigue education for children
219340836|NCT06489496|DIAGNOSTIC_TEST|18F-1007 PSMA PSMA PET/CT|"Each patient will receive an IV injection 18F-PSMA-1007 PET/CT.~PET/CT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq/kg (max 400 MBq +/- 15%) 18F-PSMA-1007 in patients."
219340837|NCT01483716|BEHAVIORAL|Rehabilitation|
219340838|NCT01087775|BEHAVIORAL|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
219340839|NCT00454259|DRUG|Fentanyl/Placebo injection|Ultra low dose intravenous injection
219340840|NCT01017003|DRUG|colchicine tablets|0.6mg colchicine tablet
219340841|NCT01017003|DRUG|colchicine tablets|0.6mg q12 hours for 10 days
219340842|NCT04146740|OTHER|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
219340843|NCT04146740|BEHAVIORAL|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
219340844|NCT04699019|OTHER|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
219340845|NCT04699019|OTHER|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
219340846|NCT04346589|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
219340847|NCT04536428|DEVICE|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops."
219340848|NCT00891982|DRUG|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
219340849|NCT00891982|DRUG|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
219340850|NCT00974246|DRUG|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
219340851|NCT05289570|DRUG|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
219340852|NCT03669432|RADIATION|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
219340853|NCT03669432|PROCEDURE|Surgery alone|This intervention is of no interest
219340854|NCT03458221|DRUG|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
219340855|NCT03458221|DRUG|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
219340856|NCT03458221|DRUG|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
219340857|NCT03458221|DRUG|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
219340858|NCT03043716|OTHER|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
219340859|NCT02227602|DRUG|Mango polyphenolics|Frozen mango pack will be provided (200\~400g per day).
219340860|NCT02777268|DRUG|Infacort|Multi-particulate granules
219340861|NCT02777268|DRUG|Hydrocortisone|Tablet
219340862|NCT04562207|DIAGNOSTIC_TEST|Screening for respiratory virus infection|Nasopharyngeal swab for screening for respiratory virus infection before surgery
219340863|NCT02061670|BIOLOGICAL|Ragweed-SPIRE|Intradermal injection
219340864|NCT02061670|BIOLOGICAL|Placebo|
219340865|NCT04159220|PROCEDURE|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
219340866|NCT00272064|DRUG|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
219340867|NCT00272064|DRUG|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
219340868|NCT00272064|DRUG|Metformin|1000 mg b.i.d, since the qualification phase, oral
219340869|NCT04948775|OTHER|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
219340870|NCT00841789|DRUG|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
219340871|NCT00841789|DRUG|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
219340872|NCT05458765|DRUG|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
219340873|NCT05458765|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
219340874|NCT00784381|DEVICE|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
219340875|NCT01452763|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
219340876|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
219340877|NCT01452763|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
219340878|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
219340879|NCT01452763|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
219340880|NCT01452763|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
219340881|NCT03983577|OTHER|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
219340882|NCT05650801|OTHER|Music Therapy|Therapy using a traditional music originally from Indonesian culture
219340883|NCT04933175|DRUG|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
219340884|NCT04933175|DRUG|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
219340885|NCT01803984|DEVICE|MRI|
219340886|NCT01803984|DEVICE|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
219340887|NCT01803984|OTHER|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
219340888|NCT06282042|PROCEDURE|Early transcatheter edge-to-edge mitral valve repair (TEER).|TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.
219340889|NCT06282042|DEVICE|MitraClip|MitraClip
219340890|NCT06282042|OTHER|Optimal medical treatment|Optimal medical treatment
219340891|NCT02725723|DEVICE|Therm-AppTM TH, thermographic camera|
219340892|NCT02725723|DRUG|epidural injection|
219340893|NCT05984342|DRUG|Tislelizumab|Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
219340894|NCT01748279|DRUG|Atorvastatin|
219340895|NCT01748279|DRUG|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
219340896|NCT01748279|DRUG|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
219340897|NCT04294875|DRUG|MPT0B640|PO, every 3 days. dose escalation per MTD
219340898|NCT00534339|DEVICE|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
219340899|NCT04227509|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
219340900|NCT04227509|DRUG|Placebo|normal saline will be administered as a 30 minute IV infusion every 3 weeks.
219340901|NCT04443543|DRUG|Capecitabine (Xeloda) Pharmacogenetic Test Reagents|CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
219340902|NCT04443543|DRUG|irinotecan|CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
219340903|NCT04443543|RADIATION|IMRT|Pelvic Radiation: 50Gy/25Fx
219340904|NCT04443543|DRUG|Oxaliplatin|FOLFIRINOX: 85mg/m2 d1
219340905|NCT04443543|DRUG|5Fluorouracil|FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
219340906|NCT04443543|DRUG|Tislelizumab|200mg iv
219340907|NCT06306521|GENETIC|BeginNGS Test|Genomic sequencing that screens for over 400 genetic diseases.
219340908|NCT00319774|DEVICE|Hemocontrol Biofeedback System|
219340909|NCT03778619|DRUG|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
219340910|NCT03778619|DRUG|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
219340911|NCT03778619|DRUG|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
219340912|NCT03778619|BIOLOGICAL|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
219340913|NCT03778619|DRUG|Interleukin-2|1 x 10\^6 IU/m2, together with MG4101
219340914|NCT00277511|DRUG|Levofloxacin|
219340915|NCT05650489|OTHER|assessment|correlation between Autistic features, motor function and quality of life
219340916|NCT04966546|DRUG|Memantine Hydrochloride|Active drug arm
219340917|NCT04966546|DRUG|Placebo|Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
219340918|NCT00781911|BIOLOGICAL|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
219340919|NCT00781911|DRUG|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
219340920|NCT02698670|DEVICE|Rhythmia mapping system|A 3-D Cardiac Mapping system
219340921|NCT02698670|DEVICE|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
219340922|NCT01274975|OTHER|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
219340923|NCT00651417|DIETARY_SUPPLEMENT|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
219340924|NCT00651417|DIETARY_SUPPLEMENT|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
219340925|NCT05858021|DIAGNOSTIC_TEST|Physical examination|"Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA."
219340926|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg"
219340927|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg"
219340928|NCT02373059|OTHER|Diabetes Issue Cards Decision Aids|
219340929|NCT02373059|OTHER|Usual Pharmaceutical Care|
219340930|NCT05754502|DRUG|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
219340931|NCT04811456|OTHER|multisystem inflammatory syndrome in children (MIS-C)|as in group description
219340932|NCT01298752|DRUG|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
219340933|NCT01298752|DRUG|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
219340934|NCT02438514|OTHER|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
219340935|NCT00111280|DRUG|TMC125|
219340936|NCT03569800|OTHER|self completed questionnaire|self completed questionnaire
219340937|NCT03741114|PROCEDURE|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
219340938|NCT03741114|DRUG|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
219340939|NCT03741114|DRUG|Placebo|patients received 100 ml saline just before skin incision
219340940|NCT00091104|BIOLOGICAL|MART-1:27-35 peptide vaccine|
219340941|NCT00091104|BIOLOGICAL|aldesleukin|
219340942|NCT00091104|BIOLOGICAL|filgrastim|
219340943|NCT00091104|BIOLOGICAL|incomplete Freund's adjuvant|
219340944|NCT00091104|BIOLOGICAL|therapeutic autologous lymphocytes|
219340945|NCT00091104|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219340946|NCT00091104|DRUG|cyclophosphamide|
219340947|NCT00091104|DRUG|fludarabine phosphate|
219340948|NCT00091104|PROCEDURE|autologous hematopoietic stem cell transplantation|
219340949|NCT00091104|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
219340950|NCT00091104|RADIATION|total-body irradiation|
219340951|NCT05782621|OTHER|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
219340952|NCT05782621|OTHER|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
219340953|NCT05782621|OTHER|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
219340954|NCT02989831|DEVICE|Vibrating insoles 'on'|Duration: 30-60 seconds
219340955|NCT02055105|PROCEDURE|miRNA in Sepsis|miRNA in Sepsis
219340956|NCT02290873|DRUG|Remimazolam|For induction and maintenance of sedation
219340957|NCT02290873|DRUG|Midazolam|For induction of maintenance and sedation
219340958|NCT02290873|DRUG|Placebo|Inactive control arm
219340959|NCT00267033|PROCEDURE|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
219340960|NCT03045562|DRUG|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
219340961|NCT03045562|DRUG|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
219340962|NCT03186690|OTHER|Biodentine|
219340963|NCT03186690|OTHER|Mineral Trioxide Aggregate|
219340964|NCT04714736|DEVICE|Coronary angiography using DyeVert system|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
219340965|NCT04714736|PROCEDURE|Coronary angiography using conventional manual injection syringe.|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
219340966|NCT05875051|OTHER|Reduced-exertion high intensity training|The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
219340967|NCT05875051|OTHER|Short moderate intensity training|The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
219340968|NCT05382247|DEVICE|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
219340969|NCT01473563|DRUG|Pemetrexed|Administered intravenously
219340970|NCT01519765|DRUG|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
219340971|NCT01519765|DRUG|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
219340972|NCT05301868|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
219340973|NCT01699542|DEVICE|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
219340974|NCT01699542|DEVICE|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
219340975|NCT01091584|DEVICE|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
219340976|NCT05280028|DRUG|Tibolone 2.5 mg|Tibolone 2.5 mg per day
219340977|NCT05280028|DRUG|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
219340978|NCT06099899|OTHER|interview|conduct in-depth interviews
219340979|NCT06345521|OTHER|No intervention|No intervention
219340980|NCT06388044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
219340981|NCT01395875|DRUG|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
219340982|NCT01395875|DRUG|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
219340983|NCT00576017|DRUG|Fentanyl-TTS|
219340984|NCT04474665|DEVICE|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
219340985|NCT04360980|DRUG|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
219340986|NCT02282150|DRUG|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
219340987|NCT02282150|DRUG|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
219340988|NCT02341638|DRUG|BMS-986141|
219340989|NCT02341638|DRUG|Placebo|
219340990|NCT02341638|DRUG|Aspirin|
219340991|NCT02341638|DRUG|Itraconazole|
219340992|NCT00432042|BIOLOGICAL|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
219340993|NCT00432042|BIOLOGICAL|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
219340994|NCT00455390|PROCEDURE|Post-immediate Psychotherapeutic Intervention|
219340995|NCT00548015|BEHAVIORAL|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
219340996|NCT01737476|PROCEDURE|Transcranial Magnetic Stimulation. PFC|
219340997|NCT02908256|DRUG|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
219340998|NCT02908256|DRUG|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
219340999|NCT04400370|DEVICE|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~1. At the entrance of the operating room before induction of anesthesia~2. 1 hour after surgery~3. 24 hours after surgery"
219341000|NCT01718561|PROCEDURE|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
219341001|NCT06341530|DRUG|anlotinib combined with penpulimab|single arm
219341002|NCT03990064|OTHER|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
219341003|NCT02577146|DEVICE|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
219341004|NCT03765138|COMBINATION_PRODUCT|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
219341005|NCT05964374|DEVICE|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
219341006|NCT00164112|DRUG|Cooperstown 5+1 alone|
219341007|NCT00164112|DRUG|Azithromycin plus Cooperstown 5+1|
219341008|NCT00164112|DRUG|Telithromycin plus Cooperstown 5+1|
219341009|NCT00164112|DRUG|Levofloxacin plus Cooperstown 5+1|
219341010|NCT05798676|OTHER|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
219341011|NCT00530985|BEHAVIORAL|Benefits Counseling|Help deciding whether to work
219341012|NCT00530985|BEHAVIORAL|VA Orientation|Orientation to services available at VA
219341013|NCT01970501|DRUG|bucindolol hydrochloride|
219341014|NCT01970501|DRUG|metoprolol succinate|
219341015|NCT01970501|OTHER|Placebo oral capsule|
219341016|NCT02701452|OTHER|COAGO|blood samples for haemostasis and hormonal data
219341017|NCT03924752|DEVICE|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
219341018|NCT02676089|DRUG|CHF 5993 200/6/12.5 µg|
219341019|NCT02676089|DRUG|CHF 1535 200/6 µg|
219341020|NCT02676089|DRUG|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
219341021|NCT03803059|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
219341022|NCT06497348|OTHER|manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder|They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
219341023|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
219341024|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC)|See above in arm/group description
219341025|NCT05675540|DEVICE|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
219341026|NCT04818736|BIOLOGICAL|COVID-19 Vaccination|Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28
219341027|NCT04818736|OTHER|Usual care|Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
219341028|NCT01027819|DEVICE|Mobile bearing|Mobile bearing in total knee arthroplasty
219341029|NCT01027819|DEVICE|Fixed bearing|Fixed bearing in total knee arthroplasty
219341030|NCT06170424|PROCEDURE|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
219341031|NCT06170424|PROCEDURE|Control group|The patients who used skin grafting.
219341032|NCT04013529|BEHAVIORAL|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
219341033|NCT04013529|BEHAVIORAL|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
219341034|NCT00554242|DIETARY_SUPPLEMENT|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
219341035|NCT04398875|OTHER|Acupuncture and standard care (ASC)|A semi-standardized treatment protocol and standard care will be employed.
219341036|NCT04398875|OTHER|Sham acupuncture and standard care (SSC)|Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.
219341037|NCT04398875|OTHER|Standard care (SC)|Standard care will be employed.
219341038|NCT01763619|DEVICE|Freedom Cervical Disc|
219341039|NCT04884321|OTHER|Complementary And Alternative Medicine|No intervention was done in the cross-sectional study
219341040|NCT03019042|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
219341041|NCT03019042|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
219341042|NCT04020601|DRUG|Ropivacaine|Local anesthetic injection
219341043|NCT04020601|DRUG|Dextrose|Sham injection
219341044|NCT05041751|PROCEDURE|Acupuncture Point Injection|Receive trigger point injections
219341045|NCT05041751|PROCEDURE|Massage Therapy|Perform myofascial release
219341046|NCT05041751|OTHER|Quality-of-Life Assessment|Ancillary studies
219341047|NCT05041751|OTHER|Questionnaire Administration|Ancillary studies
219341048|NCT03116698|DRUG|Low dose DFD07 once daily|Low dose DFD07 once daily
219341049|NCT03116698|DRUG|High dose DFD07 once daily|High dose DFD07 once daily
219341050|NCT03116698|DRUG|High dose DFD07 twice daily|High dose DFD07 twice daily
219341051|NCT03116698|DRUG|Placebo twice daily|Placebo twice daily
219341052|NCT00788372|DRUG|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
219341053|NCT06494696|DIAGNOSTIC_TEST|Ga-68 PSMA PET/MRI|The participant will undergo a Ga-68 PSMA PET/MRI scan, and then be followed up for 2 years to see if prostate cancer is diagnosed.
219341054|NCT06317909|OTHER|allergen challenge|Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
219341055|NCT00817232|DEVICE|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
219341056|NCT04841421|DRUG|89Zr-CD147|The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
219341057|NCT05335174|DEVICE|Device: HemoSphere monitor and Acumen IQ sensor.|Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
219341058|NCT05815719|DRUG|Corifollitropin Alfa|150 micrograms per dose
219341059|NCT05815719|DRUG|Follitropin Alfa|Variable dose.
219341060|NCT05815719|DRUG|Follitropin Alfa Biosimilar|Variable dose.
219341061|NCT05815719|DRUG|Urinary Human follicle stimulating hormone|Variable dose.
219341062|NCT05402475|BEHAVIORAL|CBT + Mindfulness|Eight weeks of online CBT intervention combined with mindfulness
219341063|NCT06972173|OTHER|DEEP BREATHING AND PROGRESSIVE MUSCLE RELAXATION EXERCISES|"For deep breathing exercises, students were asked to place their dominant hand on their abdomen and non-dominant hand on their chest in the semi-fowler position. Afterwards, they were instructed to breath deeply through their nose for 4 seconds and exhale through their mouth for 8 seconds. These exercises were performed as 4 repetitions with 2 minutes rest time between the exercises. When the deep breathing exercises were finished, the students lay on their backs and rested for 1 minute and then progressive muscle relaxation exercise was started (10,11).~For the progressive muscle relaxation exercise, the students were asked to contract and then relax the right foot, left foot, right leg, left leg, hip, abdominal muscles, chest muscles and back muscles, right hand, left hand, right arm, left arm, neck and shoulders, and facial muscles respectively. Respectively, from bottom to top, all the major muscles are contracted while inhaling deeply and slowly, and relaxed and r"
219341064|NCT05619510|BEHAVIORAL|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
219341065|NCT06025669|BEHAVIORAL|Nap restriction|There are 2 interventions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of nap intervention followed randomization.
219341066|NCT06135649|PROCEDURE|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
219341067|NCT03988530|DRUG|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
219341068|NCT03988530|OTHER|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
219341069|NCT01403818|DRUG|ASP1941|oral
219341070|NCT01403818|DRUG|Mitiglinide calcium hydrate|oral
219341071|NCT00025220|DRUG|Thalidomide|Given PO
219341072|NCT00025220|OTHER|Laboratory Biomarker Analysis|Correlative studies
219341073|NCT02589691|DRUG|Rocuronium|
219341074|NCT02589691|OTHER|Sodium chloride 0.9%|
219341075|NCT02277015|DEVICE|Miller Laryngoscope|Direct Laryngoscopy
219341076|NCT02277015|DEVICE|The Berci-Kaplan DCI|Videolaryngoscope-1
219341077|NCT02277015|DEVICE|The AirTraq|Videolaryngoscope-2
219341078|NCT02277015|DEVICE|GlideScope GVL|Videolaryngoscope-3
219341079|NCT02277015|DEVICE|The Pentax AWS|Videolaryngoscope-4
219341080|NCT05970874|DEVICE|Hand grip strength measureme|Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).
219341081|NCT06978504|OTHER|DASH diet|Prospective, single-arm, unblinded clinical trial lasting 90 days. The study population will consist of menopausal women aged between 40 and 60 years who are obese (BMI \> 30) and diagnosed with metabolic syndrome. Volunteers will have an in-person consultation with a nutritionist at t0 to assess their previous habitual food intake and will receive a DASH diet. To minimize losses during the study, in-person consultations with a nutritionist will be held at t0, t30, t60, t90 and online consultations (teleconsultation) at t15, t45 and t75 to answer a questionnaire to assess nutritional adherence that will be applied by the nutritionist. Saliva samples will be collected for genetic panel analysis only at t90. Serum samples for analysis of lipid profile, blood glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), follicle stimulating hormone (FSH), C-reactive protein (CRP) and tumor necrosis factor (TNF) and profile of medications used will be collected at t0 and t90.
219341082|NCT06977386|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of gastric cancer|CT scan of the abdomen outside of standard treatment options
219341083|NCT06977763|DRUG|succinylated gelatin injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
219341084|NCT06977763|DRUG|succinylated gelatin injection|Gelofusine
219341085|NCT06977399|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of liver cancer|The CT scan is part of the standard treatment protocol.
219341086|NCT06978283|BEHAVIORAL|AI-assisted case analysis|Nursing students will perform visual case analyses of pressure injuries using an AI-based platform. The AI system will provide students with case-based feedback.
219341087|NCT06978283|BEHAVIORAL|Traditional case analysis|Participants will be present with written case scenarios and a case analysis will conduct with the instructor. The training process will be carried out with group discussions and the instructor's guidance. No technological or artificial intelligence support will be used.
219341088|NCT06977997|OTHER|KAP survey|33 questions to assess knowledge, attitude, and practice of dentists in Egypt regarding TMD
219341089|NCT04070859|PROCEDURE|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes \& Screws, Tension bands. etc)
219341090|NCT02116777|OTHER|Laboratory Biomarker Analysis|Correlative studies
219341091|NCT02116777|OTHER|Pharmacological Study|Correlative studies
219341092|NCT02116777|DRUG|Talazoparib|Given PO
219341093|NCT02116777|DRUG|Temozolomide|Given PO
219341094|NCT02569814|DRUG|Fimasartan/Amlodipine/Rosuvastatin|
219341095|NCT02569814|DRUG|Fimasartan/Amlodipine|
219341096|NCT02569814|DRUG|Rosuvastatin|
219341097|NCT04558866|DRUG|Testosterone Cypionate|One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
219341098|NCT04558866|DRUG|Darolutamide|During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
219341099|NCT06978244|DRUG|BL1332 ophthalmic solution|Both arms taken four times a day for 1 day
219341100|NCT06978244|DRUG|BL1332 ophthalmic vehicle|Both arms taken four times a day for 1 day
219341101|NCT06978712|PROCEDURE|Sub-gingival instrumentation|All patients will undergo dental biofilm control through patient motivation, oral hygiene instructions and supragingival professional mechanical plaque removal followed by sub-gingival instrumentation.
219341102|NCT06978543|DEVICE|A Prototype Device Developed for Flat or Inverted Nipples (DFIN)|This is a non-commercial, researchers-developed prototype breastfeeding aid (DFIN) designed for mothers with flat or inverted nipples. Produced using 3D printing, the device is made of biocompatible material and is not commercially registered. Prior to its application in patients, official approval for use was obtained from the Turkish Medicines and Medical Devices Agency (TITCK). DFIN was developed based on clinical experience and literature. Previous studies showed that warming the breast increases nipple temperature and enhances milk production. DFIN contains a 150-200 mL reservoir of warm water (39-41°C) to apply heat directly. It is anatomically designed to fit the breast and is kept in place for 10 minutes. Then the piston in the DFIN is pulled, with the mother's maximum comfort.
219341103|NCT06978543|DEVICE|Modified injector|The syringe method used routinely in the unit was applied by the researcher to mothers immediately after delivery. In this method, the thin part to which the needle is attached is cut with a sharp knife, the plunger is placed in this area and the syringe is applied to the flat or inverted nipple to create a vacuum
219341104|NCT06977438|DRUG|Semaglutide|All participants in this study will receive treatment with Semaglutide
219341105|NCT06601660|BEHAVIORAL|Morning Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 7 am to 10 am, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
219341106|NCT06601660|BEHAVIORAL|Night Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 6 pm to 9 pm, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
219341107|NCT06601660|OTHER|No intervention|Group of women who will not receive intervention with combined physical training, but will be evaluated before and after 8 weeks, and monitored, without any intervention with physical exercise.
219341108|NCT06978049|DRUG|Topical Lactic Acid Gel (BAYER)|Lactic acid gel, applied topically once daily to the episiotomy site, starting on postpartum day 7 for a total of seven consecutive days. Commercial product: BAYER (Bucharest, Romania).
219341109|NCT06978101|OTHER|POAG group|Patients had intraocular pressure (IOP)\>21 mmHg.
219341110|NCT06978101|OTHER|Control group|Patients without family history of primary open-angle glaucoma (POAG), IOP ˂21mm Hg.
219341111|NCT06977308|DRUG|Methylphenidate (MPH)|Each participate will receive one oral dose of 60mg methylphenidate.
219341112|NCT01810653|DRUG|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
219341113|NCT01810653|DRUG|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
219341114|NCT06345963|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
219341115|NCT01650961|DRUG|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
219341116|NCT01650961|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
219341117|NCT01352832|OTHER|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
219341118|NCT01352832|OTHER|Usual Care|Usual Care
219341119|NCT02682628|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219341120|NCT06977854|OTHER|Removal from study. In case of adverse event, subject treated for the AE.|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
219341121|NCT06977854|OTHER|removal from study|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
219341122|NCT06978764|PROCEDURE|Thalamic LIFUP|Patients will receive intervention in Thalamus region by LIFUP
219341123|NCT06985472|DRUG|ZO|Orelabrutinib 150mg, po, gd, D1-D28, every 28 days, cycle 1-12; Zuberitamab: intravenously administered on day 1 of the cycle at a dose of 375mg/m2 every 28 days, once every cycle for cycles 1-6 and once every 2 cycles for cycles 7-12.
219341124|NCT06986031|DRUG|Vaginal product|Intravaginal application of gel PKB171 with a single-use applicator (syringe)
219341125|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
219341126|NCT06655051|DEVICE|endoscopic retrograde biliary drainage (single plastic stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A single plastic stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
219341127|NCT06655051|DEVICE|endoscopic retrograde biliary drainage ( fully covered self-expanding metal stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A fully covered self-expanding metal stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
219341128|NCT01088776|DIETARY_SUPPLEMENT|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
219341129|NCT01088776|DIETARY_SUPPLEMENT|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
219341130|NCT05847101|PROCEDURE|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
219341131|NCT02544711|DEVICE|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
219341132|NCT02544711|PROCEDURE|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
219341133|NCT03640598|PROCEDURE|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
219341134|NCT03640598|PROCEDURE|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
219341135|NCT03066648|DRUG|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
219341136|NCT03066648|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
219341137|NCT03066648|DRUG|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
219341138|NCT03066648|DRUG|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
219341139|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
219341140|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
219341141|NCT04641455|DRUG|Water|Administration of water before upper endoscopy
219341142|NCT05367362|DRUG|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
219341143|NCT06872112|DRUG|Artesunate|Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
219341144|NCT06640491|DRUG|IO Administration of Cefazolin|Intraosseous injection of cefazolin to guard against infection.
219341145|NCT06640491|DRUG|IO Administration of Vancomycin|Intraosseous injection of vancomycin to guard against infection.
219341146|NCT06640491|DRUG|IV Administration of Cefazolin|Intravenous dose of cefazolin to guard against infection.
219341147|NCT06640491|DRUG|IV Administration of Vancomycin|Intravenous dose of vancomycin to guard against infection.
219341148|NCT04705168|DIAGNOSTIC_TEST|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter
219341149|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
219341150|NCT04342754|DEVICE|Deep Brain Stimulation (DBS)|The device will be ON
219341151|NCT04342754|DEVICE|Sham Stimulation|The device will be OFF
219341152|NCT02014350|DEVICE|DePuy Delta Xtend Reverse TSA|
219341153|NCT03832062|OTHER|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
219341154|NCT06438978|BIOLOGICAL|Tuberculosis Vaccine|"1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain~2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate~3. Lyophilized pellet in vials (10doses)~4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)"
219341155|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
219341156|NCT00115609|DRUG|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
219341157|NCT00115609|DRUG|tenofovir DF|300mg once a day
219341158|NCT00115609|DRUG|emtricitabine|one pill of 200mg once a day
219341159|NCT03994939|BEHAVIORAL|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
219341160|NCT01183559|DRUG|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
219341161|NCT01183559|DRUG|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
219341162|NCT01183559|DRUG|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
219341163|NCT01183559|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
219341164|NCT01183559|RADIATION|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
219341165|NCT04720235|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
219341166|NCT02474433|DRUG|Misoprostol (Cytotec)|
219341167|NCT00937300|BIOLOGICAL|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
219341168|NCT06391671|OTHER|Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)|Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
219341169|NCT00290485|DRUG|Imatinib mesylate|
219341170|NCT01705600|BEHAVIORAL|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
219341171|NCT00641251|OTHER|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
219341172|NCT00641251|OTHER|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
219341173|NCT05160259|RADIATION|Radial visualization of the foramen arcuale atlantis|In patients with diagnosed Kimmerle's anomaly, using transcranial Doppler sonography to determine the degree of changes in blood flow in the vertebral arteries
219341174|NCT00897663|GENETIC|gene expression analysis|
219341175|NCT00897663|GENETIC|microarray analysis|
219341176|NCT00897663|GENETIC|protein expression analysis|
219341177|NCT00897663|OTHER|diagnostic laboratory biomarker analysis|
219341178|NCT00897663|OTHER|immunohistochemistry staining method|
219341179|NCT01556607|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
219341180|NCT01556607|DRUG|Placebo|
219341181|NCT01050309|DRUG|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
219341182|NCT04193007|DRUG|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
219341183|NCT04193007|RADIATION|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
219341184|NCT00980200|DRUG|Dose 4 QD|QD once daily
219341185|NCT00980200|DRUG|Dose 3 QD|QD once daily
219341186|NCT00980200|DRUG|placebo|placebo
219341187|NCT00980200|DRUG|Dose 2 QD|QD once daily
219341188|NCT00980200|DRUG|Dose 1 BD|BD twice daily
219341189|NCT00985062|PROCEDURE|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
219341190|NCT00985062|PROCEDURE|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
219341191|NCT00457015|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
219341192|NCT00457015|DRUG|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
219341193|NCT01700933|OTHER|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
219341194|NCT01700933|OTHER|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
219341195|NCT00247754|BEHAVIORAL|Cognitive Behaviour Treatment|
219341196|NCT01084070|OTHER|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
219341197|NCT01084070|OTHER|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
219341198|NCT05461911|DIETARY_SUPPLEMENT|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
219341199|NCT02288585|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols
219341200|NCT02288585|DIETARY_SUPPLEMENT|Placebo product|Placebo product
219341201|NCT05618665|OTHER|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
219341202|NCT05618665|OTHER|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
219341203|NCT05438316|DRUG|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
219341204|NCT05438316|DRUG|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
219341205|NCT06114173|DRUG|Cardunilizumab|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
219341206|NCT02969057|OTHER|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
219341207|NCT02969057|OTHER|Breakfast with rice bran oil|25 grams of rice bran oil
219341208|NCT02969057|OTHER|Breakfast with palm oil gel|25 grams of palm oil gel
219341209|NCT02969057|OTHER|Breakfast with palm oil|25 grams of palm oil
219341210|NCT05888727|BEHAVIORAL|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
219341211|NCT05888727|BEHAVIORAL|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
219341212|NCT01568684|OTHER|Citalopram|Treatment
219341213|NCT04964427|DRUG|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
219341214|NCT04964427|DEVICE|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
219341215|NCT04964427|DEVICE|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
219341216|NCT03321136|DRUG|LSD|0.025 mg LSD per os, single dose
219341217|NCT03321136|DRUG|LSD|0.05 mg LSD per os, single dose
219341218|NCT03321136|DRUG|LSD|0.1 mg LSD per os, single dose
219341219|NCT03321136|DRUG|LSD|0.2 mg LSD per os, single dose
219341220|NCT03321136|DRUG|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
219341221|NCT03321136|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
219341222|NCT03557281|DRUG|GSK3036656|GSK3036656 will be administered
219341223|NCT03557281|DRUG|Rifafour e-275|Rifafour e-275 will be administered
219341224|NCT04216277|DIAGNOSTIC_TEST|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
219341225|NCT02628236|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
219341226|NCT02628236|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
219341227|NCT00143715|DRUG|Phytonadione (Vitamin K1)|1.25 mg given orally
219341228|NCT03446222|PROCEDURE|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
219341229|NCT03446222|PROCEDURE|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
219341230|NCT03872986|DEVICE|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
219341231|NCT03872986|DEVICE|Giomer|Beautifil II dental restorative material
219341232|NCT03872986|DEVICE|GIC|Equia forte dental restorative material
219341233|NCT03284684|OTHER|Blood test|plasma concentration of circulating DNA of specific genes
219341234|NCT01845012|OTHER|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
219341235|NCT02140697|DIETARY_SUPPLEMENT|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
219341236|NCT02140697|DIETARY_SUPPLEMENT|Placebo (3g/day)|Placebo (3g/day), parallel design
219341237|NCT05073614|GENETIC|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
219341238|NCT06082141|PROCEDURE|Transversus thoracis plane block combined with serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance
219341239|NCT06082141|PROCEDURE|Serratus anterior plan block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
219341240|NCT01611974|DRUG|Maribavir|Tablet for oral administration
219341241|NCT01534312|DRUG|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
219341242|NCT01534312|DRUG|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
219341243|NCT04185103|DRUG|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
219341244|NCT01351935|DRUG|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
219341245|NCT04040894|BIOLOGICAL|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
219341246|NCT00867373|BEHAVIORAL|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
219341247|NCT03067883|DRUG|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
219341248|NCT03258112|PROCEDURE|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
219341249|NCT03846752|PROCEDURE|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
219341250|NCT03846752|PROCEDURE|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
219341251|NCT06394713|DRUG|QLF31907|intravenous administration, once every 3 weeks
219341252|NCT06394713|DRUG|Irinotecan|intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
219341253|NCT06394713|DRUG|Docetaxel|intravenous administration, 75mg/m2, d1, every 3 weeks
219341254|NCT05407584|DRUG|Orevogomab+PLD|"PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
219341255|NCT05407584|DRUG|Orevogomab+Paclitaxel|"paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
219341256|NCT01500109|DRUG|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
219341257|NCT01500109|DRUG|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
219341258|NCT01500109|DRUG|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
219341259|NCT00084123|BEHAVIORAL|Healing Touch Therapy|
219341260|NCT00084123|BEHAVIORAL|Relaxation Therapy|
219341261|NCT00084123|BEHAVIORAL|Standard Care|Standard Care
219341262|NCT00234611|PROCEDURE|Echocardiogram guided left ventricular lead placement|
219341263|NCT04704232|DRUG|ACD440|Double blind, parallel within subject comparison
219341264|NCT04704232|DRUG|PLAC|Double blind, parallel within subject comparison
219341265|NCT06188156|PROCEDURE|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
219341266|NCT05517642|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
219341267|NCT05517642|BIOLOGICAL|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
219341268|NCT05447494|DRUG|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
219341269|NCT05447494|DRUG|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
219341270|NCT02244216|DRUG|Berotec® N 100 µg Metered-dose Inhaler|
219341271|NCT02872740|PROCEDURE|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
219341272|NCT02872740|PROCEDURE|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
219341273|NCT06288087|OTHER|VR Based Training with Machine Guidance (MG Group)|The members of both groups will undertake a VR based basic training for ALS. Afterwards MG group were trained with VR based Advanced Training Module, which provides training with full machine guidance. The knowledge level will then be evaluated by the exam mode of the VR based training module
219341274|NCT06288087|OTHER|VR Based Training with Educator Guidance in Metaverse (EG Group)|The members of both groupswill undertake a VR based basic training for ALS. Afterwards EG group will attend at VR based Educator guided training in metaverse. The knowledge level will then be evaluated by the exam mode of the VR based training module
219341275|NCT06410560|OTHER|Training about storytelling and creative writing: 12 hours|Participants in training courses on creative writing and storytelling.
219341276|NCT06410560|OTHER|Training only about theoretical narrative medicine: 4 hours|Participants in training courses on only theoretical narrative medicine.
219341277|NCT03551444|DRUG|Administration of DAA-based treatment|"* Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered."
219341278|NCT03820622|DEVICE|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
219341279|NCT03820622|DEVICE|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
219341280|NCT04022915|DRUG|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
219341281|NCT04022915|DIAGNOSTIC_TEST|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
219341282|NCT04640688|PROCEDURE|Bariatric procedures|510(k) summary K081853 dated June 26, 2008, Endoscopic Sleeve Gastroplasty lecture, Methodist Dallas Medical Center Endobariatric Pathway \& Endoscopic Sleeve Gastroplasty Procedure Description
219341283|NCT02732769|DEVICE|GammaKnifePerfexion®|neurosurgery
219341284|NCT02732769|DEVICE|GammaKnifeIcon®|neurosurgery
219341285|NCT02732769|DEVICE|Efficast®|Thermoformed mask
219341286|NCT02732769|DEVICE|MRI|
219341287|NCT01958801|OTHER|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
219341288|NCT01958801|OTHER|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
219341289|NCT04870528|DEVICE|pulsed electromagnetic field device|the pulsed electromagnetic field device treatment parameters will be set as 15 Hz frequency, 20 gauss amplitude, and 20 minutes as total treatment duration.
219341290|NCT04870528|OTHER|Free weights for Strengthening Exercise|"• Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks"
219341291|NCT06145295|BEHAVIORAL|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
219341292|NCT06145295|BEHAVIORAL|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
219341293|NCT03563469|OTHER|Salivary bacterial and pH level|"1. Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~2. The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
219341294|NCT03238859|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
219341295|NCT03238859|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
219341296|NCT03428893|DEVICE|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
219341297|NCT01032304|DRUG|Erdosteine|One 300 mg capsule twice a day
219341298|NCT01032304|DRUG|Placebo|One capsule twice a day
219341299|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341300|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341301|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341302|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341303|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341304|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
219341305|NCT04535479|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
219341306|NCT02859935|BEHAVIORAL|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
219341307|NCT02872623|RADIATION|Enterography-MRI without enteroclysis|
219341308|NCT02872623|RADIATION|enteroCT with enteroclysis|
219341309|NCT06151171|DIETARY_SUPPLEMENT|CoQ10|"Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day."
219341310|NCT03116646|DIAGNOSTIC_TEST|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
219341311|NCT05865678|OTHER|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
219341312|NCT06177756|BEHAVIORAL|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
219341313|NCT04824508|BEHAVIORAL|position|teamleaders are instructed to allocated position
219341314|NCT04187885|BEHAVIORAL|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
219341315|NCT04753073|PROCEDURE|Non-invasive physical plasma|Treatment with non invasive physical low-temperature plasma
219341316|NCT05651295|BEHAVIORAL|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
219341317|NCT05651295|BEHAVIORAL|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
219341318|NCT05651295|BEHAVIORAL|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
219341319|NCT02034890|DRUG|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
219341320|NCT01733472|DRUG|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
219341321|NCT01733472|DRUG|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
219341322|NCT02257372|DRUG|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
219341323|NCT02257372|DRUG|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
219341324|NCT02257372|DRUG|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
219341325|NCT02257372|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
219341326|NCT04490733|BEHAVIORAL|dual-task walking|Participants in the experimental group will receive 3 times interventions during chemotherapy and 12 weekly phone calls or via LINE to assess barriers of dual-task walking.
219341327|NCT00789529|DEVICE|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
219341328|NCT00789529|DEVICE|ReNu MultiPlus®|soft contact lens disinfecting solution
219341329|NCT01419951|BEHAVIORAL|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
219341330|NCT01419951|OTHER|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
219341331|NCT01419951|BEHAVIORAL|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
219341332|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
219341333|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
219341334|NCT06318910|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
219341335|NCT06318910|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
219341336|NCT06465797|DIAGNOSTIC_TEST|Bronchoscopy|No intervention will take place in this study, only image material will be captured from the standard-of-care bronchoscopy
219341337|NCT00034372|DRUG|oregovomab|
219341338|NCT02390011|PROCEDURE|MRI|
219341339|NCT04192487|DRUG|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
219341340|NCT04325542|DIAGNOSTIC_TEST|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
219341341|NCT03431155|OTHER|Nursing intervention|Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
219341342|NCT04065555|DRUG|TAK-981|Intratumoral microdose injection by the CIVO device.
219341343|NCT04065555|BIOLOGICAL|Cetuximab|Intratumoral microdose injection by the CIVO device.
219341344|NCT04065555|BIOLOGICAL|Avelumab|Intratumoral microdose injection by the CIVO device.
219341345|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
219341346|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
219341347|NCT01849874|DRUG|MEK162, MEK inhibitor; oral|multiple dose, single schedule
219341348|NCT01849874|DRUG|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
219341349|NCT00928551|DRUG|vabicaserin|
219341350|NCT02618304|DRUG|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
219341351|NCT02363140|OTHER|Will undergo a single MRI assessment with intravenous dye|
219341352|NCT02363140|OTHER|pre and post surgery MRI scan|
219341353|NCT04673292|BEHAVIORAL|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
219341354|NCT04673292|BEHAVIORAL|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
219341355|NCT04673292|BEHAVIORAL|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
219341356|NCT01922817|DRUG|Saxagliptin|5mg saxagliptin
219341357|NCT03324906|DEVICE|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
219341358|NCT03687151|OTHER|non intervention / observationnal|non intervention / observationnal
219341359|NCT06475417|DRUG|Adebrelimab combined with DOS|After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR
219341360|NCT00823628|DRUG|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
219341361|NCT00823628|DRUG|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
219341362|NCT01427998|DIETARY_SUPPLEMENT|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
219341363|NCT01427998|OTHER|placebo|placebo
219341364|NCT05939310|PROCEDURE|Fluorescence guided detection of tumor positive margins.|Intraoperative fluorescence imaging detection of tumor positive margins using the targeted tracer bevacizumab-IRDye800CW.
219341365|NCT03239574|DEVICE|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
219341366|NCT03865173|OTHER|Telephone Interview|Telephone Interview
219341367|NCT02831413|BEHAVIORAL|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
219341368|NCT02831413|BEHAVIORAL|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
219341369|NCT02409589|DEVICE|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
219341370|NCT02409589|PROCEDURE|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
219341371|NCT02960828|PROCEDURE|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
219341372|NCT02960828|DRUG|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
219341373|NCT02960828|DEVICE|Subthreshold Laser|
219341374|NCT01916876|OTHER|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice"
219341375|NCT05097703|BEHAVIORAL|Sleep Resource|The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
219341376|NCT05427409|DIETARY_SUPPLEMENT|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
219341377|NCT03914807|OTHER|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
219341378|NCT03914807|OTHER|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
219341379|NCT02744443|DIETARY_SUPPLEMENT|Leucine|
219341380|NCT02744443|DIETARY_SUPPLEMENT|Placebo|
219341381|NCT02064530|DRUG|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
219341382|NCT02064530|DRUG|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
219341383|NCT02064530|DRUG|serum physiologic|21 ml serum physiologic is applied interfasially
219355486|NCT07089654|BEHAVIORAL|A PMT rehabilitation nursing plan|Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving 2 phases of relaxation and breathing exercises, face exercises, hand exercises and mind exercises to promote cognitive health. Phase 1 (Weeks 1-6): Includes relaxation and breathing exercises (10 minutes), facial exercises (10 minutes), bead maze activities (10 minutes), geometric shape puzzles (10 minutes), and finger exercises (20 minutes). Phase 2 (Weeks 7-12): Includes relaxation and breathing exercises (10 minutes), Tai Chi ball exercises (10 minutes), screw and nut assembly activities (10 minutes), tangram puzzles (10 minutes), and upper limb music exercises (20 minutes). The experimental group will be given interventions, twice a week every Tuesday and Thursday 9-10 am along with the study intervention.
219355487|NCT07089654|BEHAVIORAL|General rehabilitation nursing|The control group will be given a standard health education on cognitive health.
219355488|NCT07143409|OTHER|epidemiology and medical treatment strategies|Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023
219341384|NCT06036862|PROCEDURE|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
219341385|NCT00019409|DRUG|asparaginase|
219341386|NCT00019409|DRUG|cyclophosphamide|
219341387|NCT00019409|DRUG|cytarabine|
219341388|NCT00019409|DRUG|daunorubicin hydrochloride|
219341389|NCT00019409|DRUG|mercaptopurine|
219341390|NCT00019409|DRUG|methotrexate|
219341391|NCT00019409|DRUG|prednisone|
219341392|NCT00019409|DRUG|therapeutic hydrocortisone|
219341393|NCT00019409|DRUG|vincristine sulfate|
219341394|NCT00019409|RADIATION|radiation therapy|
219341395|NCT04382170|DRUG|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
219355489|NCT07142967|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered with a prescription dose of 8 Gy x 5 fractions prescribed to the 95% isodose line encompassing the dominant recurrent intraprostatic lesion (DRIL) as seen on MRI and/or PET PSMA imaging plus 4mm (GTV+4mm=CTV\_40). Remainder of the prostate gland minus CTV\_40 (CTV\_25) will be prescribed to 5 Gy x 5 fractions at the 95% isodose line.
219355490|NCT07142967|DRUG|Androgen Deprivation Therapy (ADT)|ADT would be given 0-1 months prior to planned SBRT to the prostate for total of 4-6 months. ADT will be administered via Leuprolide or Degarelix monthly injections or daily Relugolix pills.
219355491|NCT07143851|OTHER|Not applicable- observational study|There is no special intervention method
219355492|NCT07144709|DRUG|Phytotherapy|Phytotherapy or alphablockers
219355493|NCT07143097|DRUG|capecitabine|capecitabine 650 mg / m2 twice per day for one year
219355494|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy|The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.
219355495|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy|The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.
219341396|NCT05019898|DIAGNOSTIC_TEST|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~* The quantification of their anxiety~* An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
219341397|NCT05587855|OTHER|E-group|Participants with Hypertension will be assigned to eCulinary medicine
219341398|NCT05015075|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
219341399|NCT01512602|BEHAVIORAL|DBT|16 weeks DBT treatment
219341400|NCT01512602|BEHAVIORAL|CAMS|CAMS-informed psychotherapy
219341401|NCT01439321|BIOLOGICAL|Eltrombopag|Switched to Eltrombopag
219341402|NCT01439321|BIOLOGICAL|Romiplostim|Switched to Romiplostim
219341403|NCT04082403|PROCEDURE|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
219341404|NCT04082403|PROCEDURE|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
219341405|NCT03144245|BIOLOGICAL|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
219341406|NCT03144245|COMBINATION_PRODUCT|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
219355496|NCT07143266|OTHER|This is an observational study. No drugs will be administered|Data from objective sleep evaluation (actigraphy, polisomnography and MLST), subjective sleep evaluation (questionnaires), neuroimaging (MRI and PET-CT), ophthalmological evaluation and hormone evaluation (urine and blood) will be collected in a cross-sectional manner, without performing any additional intervention.
219355497|NCT07144345|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
219355498|NCT07144345|OTHER|Vehicle containing excipients only (VEH) without active ingredient|Solution for topical use
219355499|NCT07144345|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E|BLU-U® blue light Photodynamic Therapy (PDT) illuminator
219355500|NCT07144462|DRUG|Fludarabine|Specified dose on specified days
219355501|NCT07144462|DRUG|Cyclophosphamide (C)|Specified dose on specified days
219355502|NCT07144462|GENETIC|NEUK203-215 Injection|Specified dose on specified days
219355503|NCT07143162|BEHAVIORAL|LoveYourBrain Yoga|The LoveYourBrain Yoga program consists of various techniques, including: breathing, Yoga postures, meditation, and psychoeducation as well as a group discussion.
219355504|NCT07143786|DRUG|iNSC-EV01|Intravenous induced neural stem cell-derived exosome
219355505|NCT07143786|DRUG|Placebo|iNSC-EV01 mimics
219355506|NCT07142954|OTHER|P-tau217 Test|A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
219355507|NCT06846515|DRUG|AR882 50 mg|Solid Oral Capsule
219355508|NCT06846515|DRUG|AR882 75 mg|Solid Oral Capsule
219355509|NCT06846515|DRUG|Placebo|Matching Solid Oral Capsule Placebo
219355510|NCT04137887|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
219341407|NCT02328651|DRUG|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg,iv, Bid\~tid）"
219341408|NCT02328651|DRUG|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）"
219341409|NCT02332499|DRUG|Anlotinib|Anlotinib p.o. qd
219341410|NCT02332499|DRUG|Placebo|Placebo p.o. qd
219341411|NCT05513248|PROCEDURE|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
219341412|NCT01230242|DEVICE|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
219341413|NCT04164836|DIAGNOSTIC_TEST|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
219341414|NCT04315675|BEHAVIORAL|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
219341415|NCT04315675|BEHAVIORAL|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
219341416|NCT04315675|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
219341417|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with muscle stretching
219341418|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
219341419|NCT00087828|DRUG|Cranberry juice cocktail|
219341420|NCT01601028|DRUG|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
219341421|NCT01601028|DRUG|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
219341422|NCT04329702|BEHAVIORAL|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
219341423|NCT04329702|BEHAVIORAL|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
219341424|NCT00597480|DRUG|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
219341425|NCT00597480|DRUG|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
219341426|NCT03923543|DIAGNOSTIC_TEST|Neutrophil to lymphosit ratio|
219355511|NCT04137887|BIOLOGICAL|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
219355512|NCT02040298|DRUG|Clemastine|4mg tablet twice daily
219355513|NCT02040298|DRUG|Placebo|Placebo tablet twice daily
219341427|NCT01761084|BEHAVIORAL|Exercise and behaviour change strategies|"1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
219341428|NCT03915015|DIAGNOSTIC_TEST|MRI|MRI
219355514|NCT06211231|BEHAVIORAL|Digitally delivered mindfulness- and acceptance-based psychological intervention|MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
219355515|NCT01790503|DRUG|PLX3397|
219355516|NCT01790503|RADIATION|Radiation Therapy|
219355517|NCT01790503|DRUG|Temozolomide|
219341429|NCT02330159|PROCEDURE|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
219341430|NCT02749773|DEVICE|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
219341431|NCT00323232|DEVICE|2 Versus 4 Hole DHS|See Detailed Description.
219341432|NCT06155370|OTHER|construction of organoids from gynecological tumor|organoids construction
219341433|NCT02838498|DEVICE|ERCP Mechanical Simulator (EMS)|Hands on EMS training
219341434|NCT04185090|COMBINATION_PRODUCT|ID1803|Amlodipine 10mg/Valsartan 160mg
219341435|NCT04185090|COMBINATION_PRODUCT|ID1801|Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
219341436|NCT04185090|COMBINATION_PRODUCT|ID1803+ID1801|Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
219341437|NCT04066270|DIAGNOSTIC_TEST|video nystagmography|routine test battery applied to all cochlear implant candidates
219341438|NCT00159900|DRUG|Sildenafil Citrate|
219341439|NCT02891655|OTHER|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
219341440|NCT01140451|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
219341441|NCT00695448|DRUG|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
219341442|NCT01971073|DEVICE|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
219341443|NCT01971073|DEVICE|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
219341444|NCT04608812|DRUG|OS2966|OS2966 is a humanized monoclonal antibody antagonizing CD29 (Beta 1 integrin)
219341445|NCT04608812|DRUG|Gadoteridol|Gadoteridol is a contrast agent which will be added to OS2966 to allow investigators to observe how OS2966 distributes within the brain tumor. Gadoteridol is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
219341446|NCT04245007|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
219341447|NCT01236690|DRUG|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
219341448|NCT02031497|DIETARY_SUPPLEMENT|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
219341449|NCT02031497|DIETARY_SUPPLEMENT|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
219341450|NCT02698267|DRUG|BIIB074|Administered as specified in the treatment arm
219341451|NCT02698267|DRUG|Itraconazole|200 mg twice daily \[BID\] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
219341452|NCT04531696|PROCEDURE|Blood draw|Blood draw at inclusion
219341453|NCT04531696|PROCEDURE|Post-mortem tissue collection|Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
219341454|NCT04623684|DRUG|Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
219341455|NCT04623684|DRUG|Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]|1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
219341456|NCT05988775|BEHAVIORAL|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
219341457|NCT05988775|BEHAVIORAL|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
219341458|NCT05988775|OTHER|Nature movie watching|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
219341459|NCT05914636|BIOLOGICAL|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
219341460|NCT02841397|DEVICE|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
219341461|NCT01152320|BEHAVIORAL|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
219341462|NCT04647591|OTHER|Questionnaires|Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
219341463|NCT03433872|OTHER|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
219341464|NCT02616549|BEHAVIORAL|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
219341465|NCT00841802|DRUG|Prednisone|Prednisone 30mg once daily x 5 days
219341466|NCT03851900|OTHER|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
219341467|NCT03851900|OTHER|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
219341468|NCT03851900|OTHER|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
219341469|NCT02614859|DRUG|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
219341470|NCT02614859|DRUG|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
219341471|NCT00001014|DRUG|Trimetrexate glucuronate|
219341472|NCT00001014|DRUG|Sulfamethoxazole-Trimethoprim|
219341473|NCT00001014|DRUG|Leucovorin calcium|
219341474|NCT04066972|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
219341475|NCT02983682|DRUG|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
219341476|NCT01432873|DRUG|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
219341477|NCT01432873|DRUG|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
219341478|NCT01628588|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
219341479|NCT00959868|DRUG|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
219341480|NCT01399788|DRUG|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
219341481|NCT01399788|DRUG|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
219341482|NCT04778254|OTHER|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
219341483|NCT04778254|OTHER|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
219341484|NCT04778254|OTHER|conventional obturator|clasp retained obturator for management of hemi maxillectomy
219341485|NCT01441037|DRUG|Danazol|Danazol, 800 mg daily by mouth for 2 years
219341486|NCT00911352|DEVICE|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for \> 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
219341487|NCT02383732|BEHAVIORAL|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
219341488|NCT02383732|BEHAVIORAL|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
219341489|NCT02383732|BEHAVIORAL|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
219341490|NCT05076383|OTHER|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
219341491|NCT05076383|OTHER|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
219341492|NCT04990466|DRUG|IIBR-100|Administration of IIBR-100 vaccine
219341493|NCT04990466|DRUG|Active Comparator|Administration of a currently-approved vaccine for COVID-19
219341494|NCT05808400|BIOLOGICAL|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.
219355518|NCT04906434|DRUG|ABSK-011|"During the escalation part, the administration of oral ABSK-011 will be guided by 3+3design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level."
219355519|NCT01577485|DIETARY_SUPPLEMENT|Probiotics in an pastille|Test group
219355520|NCT01577485|DIETARY_SUPPLEMENT|Control pastille|Control group
219341495|NCT00734799|BEHAVIORAL|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
219341496|NCT00921232|BEHAVIORAL|Questionnaires|"During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data"
219341497|NCT04599556|BIOLOGICAL|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
219355521|NCT06425627|PROCEDURE|spinal anesthesia|An intrathecal anesthetic technique.
219355522|NCT06425627|PROCEDURE|general anesthesia|An intravenous (combined with inhalation) anesthetic technique.
219355523|NCT02944630|BEHAVIORAL|Psychotherapy|Individual psychotherapy
219355524|NCT04201483|OTHER|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
219355525|NCT04201483|OTHER|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
219341498|NCT04718974|OTHER|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
219341499|NCT04643912|DIAGNOSTIC_TEST|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
219341500|NCT01923597|DRUG|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
219341501|NCT00002788|BIOLOGICAL|filgrastim|
219341502|NCT00002788|DRUG|cyclophosphamide|
219341503|NCT00002788|DRUG|dexamethasone|
219341504|NCT00002788|DRUG|etoposide|
219341505|NCT00002788|PROCEDURE|peripheral blood stem cell transplantation|
219341506|NCT00002788|RADIATION|radiation therapy|
219341507|NCT04220957|OTHER|Digital Impression Technique|Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
219341508|NCT04220957|OTHER|Conventional Impression Technique|Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
219341509|NCT01233973|OTHER|video decision aid|video
219341510|NCT01653548|BEHAVIORAL|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
219341511|NCT01653548|BEHAVIORAL|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
219341512|NCT01653548|BEHAVIORAL|Habituation|Participants will habituate to personally-relevant stressor.
219341513|NCT03294785|PROCEDURE|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
219341514|NCT03294785|DRUG|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
219341515|NCT03294785|PROCEDURE|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
219341516|NCT05883891|DIAGNOSTIC_TEST|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
219341517|NCT03496246|DIAGNOSTIC_TEST|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
219341518|NCT03496246|DIAGNOSTIC_TEST|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
219341519|NCT03496246|DIAGNOSTIC_TEST|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
219341520|NCT03496246|DIAGNOSTIC_TEST|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
219341521|NCT03496246|DIAGNOSTIC_TEST|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
219341522|NCT03496246|DIAGNOSTIC_TEST|serum creatinine|for assessment of renal function
219341523|NCT03496246|DIAGNOSTIC_TEST|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
219341524|NCT03496246|DIAGNOSTIC_TEST|seum alanine aminotransferase|for assessment of liver function
219341525|NCT03496246|DIAGNOSTIC_TEST|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
219341526|NCT03496246|DIAGNOSTIC_TEST|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
219341527|NCT00097344|DRUG|Atamestane|
219341528|NCT00097344|DRUG|Toremifene|
219341529|NCT00097344|DRUG|Letrozole|
219341530|NCT00097344|DRUG|Aromatase inhibition|
219341531|NCT00097344|DRUG|Estrogen receptor blocker|
219341532|NCT00097344|PROCEDURE|Hormone therapy|
219341533|NCT00097344|PROCEDURE|Endocrine therapy|
219341534|NCT00097344|PROCEDURE|Antiestrogen therapy|
219341535|NCT05015088|OTHER|No interventions will be performed in this study|This study will not include any intervention
219341536|NCT05329376|DEVICE|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine"
219341537|NCT05329376|OTHER|Usual Care|Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
219341538|NCT02723500|DEVICE|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
219341539|NCT03719274|DIETARY_SUPPLEMENT|vitamin c depigementation|locally injected vitamin c depigementation
219341540|NCT00281398|BEHAVIORAL|Questionnaire|
219341541|NCT00868777|PROCEDURE|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
219341542|NCT01741649|PROCEDURE|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
219341543|NCT01741649|PROCEDURE|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
219341544|NCT04780620|OTHER|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
219341545|NCT05741255|BEHAVIORAL|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
219341546|NCT00704782|DRUG|dimebon|
219341547|NCT03473496|BIOLOGICAL|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
219341548|NCT05069857|DRUG|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
219341549|NCT05069857|DRUG|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
219341550|NCT05032612|DEVICE|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
219341551|NCT05032612|DEVICE|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
219341552|NCT04368156|DEVICE|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
219341553|NCT04950257|DEVICE|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
219341554|NCT05217745|DIETARY_SUPPLEMENT|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
219341555|NCT05217745|DIETARY_SUPPLEMENT|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
219341556|NCT00575809|OTHER|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
219341557|NCT00183274|DRUG|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
219341558|NCT00183274|DRUG|Placebo|six month intervention with placebo drug
219341559|NCT01538654|PROCEDURE|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
219355526|NCT05101018|DRUG|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
219341560|NCT04345744|PROCEDURE|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
219341561|NCT04345744|DEVICE|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
219341562|NCT04345744|DEVICE|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
219341563|NCT05848154|DIAGNOSTIC_TEST|ctDNA detection|Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
219341564|NCT04111029|DIAGNOSTIC_TEST|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
219341565|NCT00188643|DRUG|Venlafaxine and Lamotrigine|
219341566|NCT02370875|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
219341567|NCT02370875|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
219341568|NCT04868721|PROCEDURE|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
219341569|NCT05598918|PROCEDURE|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
219341570|NCT05598918|PROCEDURE|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
219341571|NCT03048929|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
219341572|NCT03048929|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
219341573|NCT03847675|BEHAVIORAL|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
219341574|NCT05530226|DRUG|Traditional Chinese medicine|Traditional Chinese medicine, oral administration, twice daily
219341575|NCT04712929|OTHER|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
219341576|NCT00641589|DRUG|epoetin alfa|
219341577|NCT00015288|DRUG|Buprenorphine/naloxone|
219341578|NCT04081363|DRUG|Centanafadine|Extended-release and immediate-release capsules.
219341579|NCT01805622|BEHAVIORAL|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
219341580|NCT02409654|OTHER|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
219341581|NCT02409654|OTHER|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
219341582|NCT00077792|DRUG|Enoxaparin sodium (XRP4563)|
219341583|NCT03673774|DEVICE|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
219341584|NCT02409290|DRUG|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
219341585|NCT02409290|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
219341586|NCT02409290|DRUG|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
219341587|NCT02409290|DRUG|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
219341588|NCT02409290|DRUG|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
219355527|NCT05101018|DRUG|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
219355528|NCT02326805|OTHER|Laboratory Biomarker Analysis|Correlative studies
219341589|NCT02409290|DRUG|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
219341590|NCT02409290|DRUG|Prothionamide|Prothionamide has a bacteriostatic action.
219341591|NCT02409290|DRUG|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
219341592|NCT02409290|DRUG|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
219341593|NCT02409290|DRUG|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
219341594|NCT02389803|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
219341595|NCT02389803|DIETARY_SUPPLEMENT|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
219341596|NCT04971304|DRUG|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
219341597|NCT05021250|PROCEDURE|Lipiodol marking|HCC patients treated with TACE and the tumor marked with lipiodol.
219341598|NCT03401528|DRUG|AVB-S6-500|AVB-S6-500 is an investigational drug.
219341599|NCT03401528|OTHER|Placebo|Matching placebo
219341600|NCT00320008|BEHAVIORAL|Diet|
219341601|NCT00320008|BEHAVIORAL|Exercise|
219341602|NCT00320008|BEHAVIORAL|Stop smoking|
219341603|NCT00320008|DRUG|Glucose lowering therapy|
219341604|NCT00320008|DRUG|Blood pressure lowering therapy|
219341605|NCT00320008|DRUG|Lipid lowering therapy|
219341606|NCT05679336|DRUG|Rituximab, Cyclophosphamide, and Corticosteroids|"1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count \>5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7)."
219341607|NCT00708500|DRUG|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
219341608|NCT00708500|BIOLOGICAL|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
219341609|NCT00708500|DRUG|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
219341610|NCT00708500|DRUG|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
219341611|NCT04363775|DEVICE|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
219341612|NCT04363775|DEVICE|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
219341613|NCT05111444|DRUG|Camrelizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion
219341614|NCT05111444|DRUG|Pyrotinib|320mg as continuous oral once daily on every 21 days
219341615|NCT05111444|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
219341616|NCT05111444|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
219341617|NCT05111444|DRUG|Paclitaxel|80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
219341618|NCT05111444|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
219341619|NCT03583151|BIOLOGICAL|Amniotic fluid injection|Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
219341620|NCT03583151|BIOLOGICAL|Steroid injection|Solu-medrol
219341621|NCT03440099|OTHER|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
219341622|NCT01219010|BIOLOGICAL|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
219341623|NCT01242267|DRUG|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
219341624|NCT00896922|GENETIC|microarray analysis|
219341625|NCT00896922|OTHER|immunohistochemistry staining method|
219341626|NCT00896922|OTHER|laboratory biomarker analysis|
219341627|NCT00202735|PROCEDURE|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
219341628|NCT00202735|PROCEDURE|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
219341629|NCT00618410|DEVICE|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
219341630|NCT00618410|OTHER|Placebo|Nasal placebo
219341631|NCT05699161|GENETIC|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
219341632|NCT01758796|PROCEDURE|Non-operative treatment|Below-the-knee cast for six weeks.
219341633|NCT01758796|PROCEDURE|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
219341634|NCT05068466|DRUG|INCB054707|Administered Orally
219341635|NCT05068466|DRUG|Placebo|Administered Orally
219341636|NCT00403676|OTHER|Follow up bu a nurse|Follow up bu a nurse
219341637|NCT00403676|OTHER|Follow up by a medical doctor|Follow up by a medical doctor
219341638|NCT06360250|DRUG|Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation|Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.
219341639|NCT06360250|DRUG|Tetanus human immunoglobulin (HTIG)|Tetanus human immunoglobulin (HTIG)
219341640|NCT06360250|DRUG|Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo|There were no active ingredients, and other ingredients were the same
219341641|NCT06360250|BIOLOGICAL|Adsorbed tetanus vaccine (TT)|containing tetanus toxoid titer not less than 40 IU
219341642|NCT03525717|DIETARY_SUPPLEMENT|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
219341643|NCT03525717|DIETARY_SUPPLEMENT|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
219341644|NCT03747211|BEHAVIORAL|Aerobic exercise|High Intensity Interval Training (HIIT)
219341645|NCT00705783|DRUG|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
219341646|NCT00705783|DRUG|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
219341647|NCT05826756|OTHER|There are no interventions in this study. All participants complete online surveys.|There are no interventions in this study. All participants complete online surveys.
219341648|NCT02184195|DRUG|Olaparib|Tablet -100mg
219341649|NCT02184195|DRUG|Olaparib|Tablet-150mg
219341650|NCT02184195|DRUG|Placebo|Match Olaparib 100mg placebo
219341651|NCT02184195|DRUG|Placebo|Match Olaparib 150mg placebo
219341652|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - active|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
219341653|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - sham|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
219341654|NCT03849378|DIETARY_SUPPLEMENT|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
219341655|NCT03849378|DIETARY_SUPPLEMENT|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
219341656|NCT03300895|OTHER|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
219341657|NCT03300895|OTHER|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
219341658|NCT05891340|OTHER|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
219341659|NCT05891340|OTHER|Endurance exercise|walking exercise 5000 steps/day
219341660|NCT02997735|BEHAVIORAL|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
219341661|NCT06512012|BEHAVIORAL|yoga and exercise|Technology-Assisted Yoga and Exercise Intervention during 6 months
219341662|NCT00563628|DEVICE|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
219341663|NCT03658265|OTHER|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
219341664|NCT03658265|OTHER|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
219341665|NCT03658265|OTHER|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
219341666|NCT03658265|OTHER|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
219341667|NCT02336490|OTHER|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
219341668|NCT02189161|DEVICE|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
219341669|NCT00939783|DRUG|Dimebon|Tablet for oral administration
219341670|NCT03187431|BIOLOGICAL|autologous bone marrow mesenchymal stem cells|intravenous infusion
219341671|NCT05939024|OTHER|Muscle Energy Technique plus Conventional Physical Therapy|Post-Isometric Relaxation of the Muscle Energy Techniques will be applied to Spinal Stabilizers and Mechanoreceptors. Hold time will be 7 seconds with 5 seconds rest between two performance x 3 times /session. Whereas, Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
219341672|NCT05939024|OTHER|Conventional Physical Therapy|Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
219341673|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
219341674|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
219341675|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
219341676|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
219341677|NCT01425827|DRUG|duloxetine HCL|60 mg/day duloxetine for 16 weeks
219341678|NCT01425827|DRUG|placebo|similar looking tablets to the active agent for 16 weeks
219341679|NCT00409084|PROCEDURE|endoscopic variceal band ligation|endoscopic variceal band ligation
219341680|NCT01783275|BEHAVIORAL|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
219341681|NCT00435838|DRUG|No Intervention -- Observational study|
219341682|NCT04489745|RADIATION|SBRT|
219341683|NCT04489745|DRUG|Androgen deprivation therapy (ADT)|
219341684|NCT02718755|DRUG|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
219341685|NCT02718755|DRUG|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
219341686|NCT02718755|DRUG|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
219341687|NCT04897477|DRUG|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
219341688|NCT00905736|PROCEDURE|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
219341689|NCT00905736|PROCEDURE|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
219341690|NCT04004650|PROCEDURE|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7\_vH2\_1ZZc
219341691|NCT06022952|OTHER|Stone MD stent radar|Mobile app
219341692|NCT03672409|BEHAVIORAL|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
219341693|NCT00713427|DEVICE|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
219341694|NCT00455689|DRUG|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
219341695|NCT03297736|DEVICE|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
219341696|NCT03297736|DEVICE|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
219341697|NCT03969121|DRUG|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
219341698|NCT03969121|DRUG|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
219341699|NCT00638001|DEVICE|custom-molded insoles and custom-molded shoes|"* custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~* custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
219341700|NCT01824277|OTHER|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
219341701|NCT00663988|PROCEDURE|human transplantation|Allograft composite tissue transplantation. procedure. medication
219341702|NCT04113200|DIETARY_SUPPLEMENT|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
219341703|NCT04113200|DIETARY_SUPPLEMENT|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
219341704|NCT06290206|BEHAVIORAL|PREVENT - BCT|"Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings)."
219341705|NCT01664559|DRUG|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
219341706|NCT01664559|DRUG|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
219341707|NCT05885100|DRUG|Eleveld Model|Target plasma propofol
219341708|NCT04168073|OTHER|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
219341709|NCT04168073|OTHER|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
219341710|NCT00864643|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
219341711|NCT00864643|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
219341712|NCT01509963|OTHER|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
219341713|NCT00083031|DRUG|bevacizumab|
219341714|NCT00083031|DRUG|cyclophosphamide|
219341715|NCT00083031|DRUG|methotrexate|
219341716|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
219341717|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
219341718|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
219341719|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
219341720|NCT01880931|DRUG|Remifentanil|The effect site concentration of remifentanil
219341721|NCT01251367|BIOLOGICAL|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
219341722|NCT02255409|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
219341723|NCT02255409|BIOLOGICAL|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
219341724|NCT05505162|DRUG|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
219341725|NCT05505162|DRUG|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
219341726|NCT04839731|DRUG|Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream|Apply twice per day for allotted time
219341727|NCT04839731|DRUG|Nourivan Base Cream|Apply twice per day for allotted time
219341728|NCT04067570|RADIATION|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
219341729|NCT02114437|DEVICE|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
219341730|NCT02114437|DEVICE|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
219341731|NCT01353820|DIETARY_SUPPLEMENT|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( \>10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )
219341732|NCT01353820|DIETARY_SUPPLEMENT|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
219341733|NCT02189213|DRUG|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
219341734|NCT04457050|DRUG|Sofosbuvir 400 milligram|single daily dose of 400 milligrams
219341735|NCT04457050|DRUG|Daclatasvir 60 milligram|single daily dose of 60 milligrams for 12 weeks
219341736|NCT04457050|DRUG|Ribavirin 400 milligram|weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks
219341737|NCT04457050|DRUG|Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab|single daily dose for 12 weeks
219341738|NCT02016820|DRUG|Omeprazole (suspension)|1 mg/kg/day
219341739|NCT02016820|OTHER|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
219341740|NCT01227044|DRUG|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
219341741|NCT01227044|OTHER|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
219355529|NCT02326805|OTHER|Placebo Administration|Given SC
219341742|NCT01342835|DRUG|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
219341743|NCT04474756|DEVICE|custom-made adjustable mandibular advancement device|a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
219341744|NCT02343172|DRUG|HDM201|
219341745|NCT02343172|DRUG|LEE011|
219341746|NCT02134483|BIOLOGICAL|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
219341747|NCT05773521|PROCEDURE|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
219341748|NCT00583362|BIOLOGICAL|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
219341749|NCT00473343|DRUG|Metvix® cream|
219341750|NCT06156956|PROCEDURE|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14"
219341751|NCT02261194|BEHAVIORAL|Self-Care Tools|
219341752|NCT00400673|BEHAVIORAL|Two-step remission induction and risk-oriented consolidation|
219341753|NCT02982135|OTHER|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
219341754|NCT04247061|OTHER|Educational video|One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
219341755|NCT04247061|OTHER|Text-message program|A one-month text message program to motivate and facilitate contact with smoking cessation resources.
219341756|NCT05858619|DRUG|Dupilumab|dupilumab 600 mg injection initially and then 300 mg every other week
219341757|NCT03961503|DRUG|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
219341758|NCT03961503|DRUG|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
219341759|NCT05107856|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
219341760|NCT05107856|DRUG|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
219341761|NCT05107856|DRUG|Venetoclax|Venetoclax will be administered orally
219341762|NCT01886365|DEVICE|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
219341763|NCT01886365|OTHER|Conventional therapy with a fixed insulin dosing scheme|Routine care
219341764|NCT00345176|DIETARY_SUPPLEMENT|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
219341765|NCT00345176|DIETARY_SUPPLEMENT|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
219341766|NCT00345176|DRUG|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
219341767|NCT03621514|PROCEDURE|painless indwelling catheter|Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).
219341768|NCT03621514|PROCEDURE|indwelling catheter|The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
219341769|NCT04452903|BEHAVIORAL|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
219341770|NCT00935480|DRUG|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
219341771|NCT00935480|DRUG|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
219341772|NCT03359512|DEVICE|qCON monitor|supervision by qCON monitor of the depth of anesthesia
219341773|NCT00500630|DEVICE|Body fixed 3D sensors|
219341774|NCT02370615|DRUG|TAK-272|TAK-272 tablet.
219341775|NCT02370615|DRUG|Digoxin|Digoxin tablet.
219341776|NCT02370615|DRUG|Itraconazole|Itraconazole oral solution
219341777|NCT02370615|DRUG|Midazolam|Midazolam syrup.
219341778|NCT02431572|OTHER|PBR PET|
219341779|NCT02431572|BIOLOGICAL|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
219341780|NCT02431572|RADIATION|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
219341781|NCT01136655|DRUG|80/2.25 μg Symbicort pMDI|inhalation
219341782|NCT01136655|DRUG|80/4.5 μg Symbicort pMDI|inhalation
219341783|NCT01136655|DRUG|Foradil Aerolizer 12 μg|inhalation
219341784|NCT01136655|DRUG|40 μg budesonide HFA pMDI|inhalation
219341785|NCT01136655|DRUG|placebo HFA pMDI|inhalation
219341786|NCT05435456|OTHER|Exercise|Strengthening and Relaxation Exercises
219355530|NCT02326805|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
219341787|NCT02491957|OTHER|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
219341788|NCT02031783|DIETARY_SUPPLEMENT|Mixture of glucose and fructose|
219341789|NCT02031783|DIETARY_SUPPLEMENT|glucose|
219341790|NCT02633410|PROCEDURE|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
219341791|NCT04077450|BEHAVIORAL|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
219341792|NCT01115530|OTHER|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
219341793|NCT01115530|DIETARY_SUPPLEMENT|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
219341794|NCT06036342|DIAGNOSTIC_TEST|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
219341795|NCT04455880|OTHER|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
219341796|NCT03938779|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
219341797|NCT03938779|DIAGNOSTIC_TEST|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
219341798|NCT05761028|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
219341799|NCT05761028|OTHER|Placebo|Placebo
219341800|NCT05880446|OTHER|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
219341801|NCT00685503|DRUG|Ranibizumab|
219341802|NCT00627887|PROCEDURE|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
219341803|NCT00627887|DRUG|venlafaxine|extended release target dose of 300mg/day duration of one year
219341804|NCT00627887|DRUG|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
219341805|NCT02555943|DRUG|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
219341806|NCT02555943|DRUG|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
219341807|NCT02555943|DRUG|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
219341808|NCT02555943|DRUG|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
219341809|NCT02555943|DRUG|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
219341810|NCT03953066|OTHER|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
219341811|NCT02752516|DRUG|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
219355531|NCT04835012|OTHER|Medical debt forgiveness|A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
219355532|NCT01772615|DRUG|Ciprofloxacin|Antibiotic
219355533|NCT01772615|DIETARY_SUPPLEMENT|E. coli Nissle|Probiotic
219341812|NCT04360759|DRUG|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
219341813|NCT02663388|PROCEDURE|gastric bypass, sleeve, gastric banding|
219341814|NCT02278900|OTHER|Communication aids|Question Prompt list Audiofile
219341815|NCT04496401|DRUG|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
219341816|NCT03518593|OTHER|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
219341817|NCT06476522|OTHER|Physiotherapy Program|In the first evaluation, 5 different exercises were shown and the patients were asked to do home exercises in accordance with the given program. The physiotherapist suggested starting with a 10-minute walk 5 times a week and then gradually increasing the walking time. The patients were given a program for balance and sensory training. They were asked to apply the physiotherapy program at least 3 days a week for 12 weeks. Weekly follow-up of the patients was carried out by the physiotherapist over the phone or face to face when they underwent routine treatment.
219341818|NCT06476522|OTHER|To Inform|The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.
219341819|NCT06036251|OTHER|Questionnaires|Self-reported quality of life (QOL) measures completed online
219341820|NCT03786562|DRUG|Intrathecal Morphine|Group 1
219341821|NCT03786562|DRUG|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
219341822|NCT02847195|DEVICE|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
219341823|NCT01102075|DEVICE|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
219341824|NCT01102075|DEVICE|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
219341825|NCT02287623|DRUG|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
219341826|NCT02287623|DRUG|bupivacaine|patients will receive a tap with bupivacaine
219341827|NCT01189188|PROCEDURE|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
219341828|NCT01189188|PROCEDURE|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
219341829|NCT01303042|DRUG|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
219341830|NCT05796908|DEVICE|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
219341831|NCT02755311|PROCEDURE|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
219341832|NCT02755311|PROCEDURE|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
219341833|NCT02755311|DRUG|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
219341834|NCT02755311|DRUG|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
219341835|NCT02755311|DRUG|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
219341836|NCT02755311|OTHER|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
219341837|NCT04739085|DIAGNOSTIC_TEST|Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
219341838|NCT04739085|DIAGNOSTIC_TEST|wDDART - Monocular near visual acuity using the best correction for distance|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
219341839|NCT03645993|GENETIC|Genetic Testing|A one time blood sample will be taken.
219341840|NCT02700997|DEVICE|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
219341841|NCT01120392|OTHER|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
219341842|NCT01120392|OTHER|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
219341843|NCT00442052|DRUG|aspirin|
219341844|NCT00442052|DRUG|omeprazole|
219341845|NCT06471400|OTHER|interview|patient relatives or legal authorized representatives will be interviewed
219341846|NCT02048618|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
219341847|NCT02048618|DRUG|Placebo|placebo oral tablets, intake once daily for 20 weeks
219341848|NCT04570501|DRUG|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
219341849|NCT04570501|DRUG|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
219341850|NCT06104852|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
219341851|NCT06104852|OTHER|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
219341852|NCT03563378|DRUG|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
219341853|NCT03563378|DRUG|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
219341854|NCT02126033|PROCEDURE|take blood samples|
219341855|NCT02227680|OTHER|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
219341856|NCT02227680|OTHER|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
219341857|NCT01505790|DRUG|PRASUGREL|60 mg the first day then 10 mg per day during one month
219341858|NCT01505790|DRUG|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
219341859|NCT00492427|DRUG|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.
219341860|NCT00492427|DRUG|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
219341861|NCT05295004|BEHAVIORAL|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
219341862|NCT03792815|DRUG|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
219341863|NCT03792815|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
219341864|NCT03792815|DRUG|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
219341865|NCT03463798|DEVICE|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
219341866|NCT03463798|DEVICE|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
219341867|NCT02527369|DEVICE|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
219341868|NCT03852862|DRUG|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
219341869|NCT03852862|DRUG|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
219341870|NCT01585272|DRUG|ENA713|
219341871|NCT00645593|DRUG|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
219341872|NCT00645593|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
219341873|NCT00645593|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
219341874|NCT02268903|DRUG|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
219341875|NCT02268903|DRUG|Placebo|Placebo in one single direct intra venous injection
219341876|NCT00404690|PROCEDURE|Bedside Silo|silo placed at bedside on admission
219341877|NCT00404690|PROCEDURE|Operative attempt at closure|go the operating room to attempt closure
219341878|NCT05217485|DEVICE|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
219341879|NCT03189823|DEVICE|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
219341880|NCT01579448|BIOLOGICAL|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
219341881|NCT01579448|BIOLOGICAL|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
219341882|NCT01579448|OTHER|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
219341883|NCT03650920|PROCEDURE|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
219341884|NCT03704142|DEVICE|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
219341885|NCT03704142|DEVICE|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
219341886|NCT03704142|DEVICE|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
219341887|NCT03704142|DEVICE|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
219341888|NCT01187186|DRUG|ASP1941|oral
219341889|NCT00996268|DRUG|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
219341890|NCT00996268|DRUG|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
219341891|NCT00732277|DRUG|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
219341892|NCT05270590|PROCEDURE|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
219341893|NCT00427076|DRUG|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
219341894|NCT00427076|DRUG|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
219341895|NCT02905929|DEVICE|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
219341896|NCT02905929|BEHAVIORAL|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
219341897|NCT02905929|BEHAVIORAL|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
219341898|NCT02905929|BEHAVIORAL|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
219341899|NCT02905929|OTHER|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
219341900|NCT02905929|BEHAVIORAL|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
219341901|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
219341902|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
219341903|NCT03309085|PROCEDURE|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
219341904|NCT03309085|DEVICE|CT scan|CT scan
219341905|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
219341906|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.25mL dose for intramuscular injection
219341907|NCT04111640|OTHER|CoRe software|Computer-supported cognitive training (CT)
219341908|NCT04111640|OTHER|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
219341909|NCT06356298|OTHER|Airway Management: Flexible Reinforced Laryngeal Mask Airway|In the FLMA group, a FLMA was applied according to the manufacturer's recommendations. After lubrication of the posterior surface with oxybuprocaine hydrochloride gel, the FLMA was inserted after propping the shoulders. Its cuff was fully deflated before insertion, and the pressure was adjusted to 40 cm H2O with a manometer after insertion.
219341910|NCT06356298|OTHER|Airway Management: Endotracheal Tube|In the ETT group, guided by a visual laryngoscope, a ETT was intubated after lubrication of the surface with oxybuprocaine hydrochloride gel: endotracheal tube size = (16+ age) /4. The cuff pressure of ETT was adjusted to 20 cm H2O with a handheld manometer after inflation.
219341911|NCT01981655|DRUG|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
219341912|NCT01981655|DRUG|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
219341913|NCT06535841|BIOLOGICAL|MTX-474|MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
219341914|NCT06535841|OTHER|Placebo|Matching Placebo - Normal Saline
219341915|NCT04914325|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
219341916|NCT03885427|DRUG|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
219341917|NCT05378776|DIETARY_SUPPLEMENT|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
219341918|NCT05378776|DIETARY_SUPPLEMENT|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
219341919|NCT06874010|DRUG|DT-216P2|Active
219341920|NCT03789942|PROCEDURE|Oral surgery|Oral surgery procedures
219341921|NCT06809530|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every 2 weeks for 6 weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
219341922|NCT06809530|DRUG|Pemetrexed (Alimta)|Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
219341923|NCT04153773|DIAGNOSTIC_TEST|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
219341924|NCT06870799|DEVICE|Surface guided radiation therapy|Radiation therapy will be delivered using no immobilization mask, but a surface guided system with infrared light
219341925|NCT06870799|DEVICE|Closed face mask|Radiotherapy with closed face mask for immobilization
219341926|NCT06911242|DRUG|ARN-75039|An oral therapy for the treatment of Lassa infection
219341927|NCT04532385|DIETARY_SUPPLEMENT|Green tea extract|400 mg capsule
219341928|NCT04532385|DIETARY_SUPPLEMENT|Placebo|400 mg capsule
219341929|NCT02523066|DEVICE|Magna Ease|This study is non-intervention
219341930|NCT06907849|DRUG|124I-evuzamitide|124I-evuzamitide is an iodine-124 (124I) labeled 45 L-amino acid peptide (also known as p5+14) suitable for single dose PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and with the ubiquitous amyloid-associated hypersulfated heparan sulfate proteoglycans.
219341931|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
219341932|NCT06949618|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)
219341933|NCT03900273|OTHER|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
219341934|NCT03900273|OTHER|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
219341935|NCT01677806|PROCEDURE|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
219341936|NCT01677806|OTHER|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
219341937|NCT03581227|OTHER|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
219341938|NCT00113542|DRUG|Tetrathiomolybdate (TM)|
219341939|NCT01531920|DRUG|alcohol + placebo|Part A alcohol + placebo
219341940|NCT01531920|DRUG|alcohol + perampanel|Part A: alcohol + perampanel
219341941|NCT01531920|DRUG|perampanel + alcohol|Part B: perampanel + alcohol
219341942|NCT01531920|DRUG|placebo + alcohol|Part B: placebo + alcohol
219341943|NCT02195024|PROCEDURE|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
219341944|NCT03723707|BEHAVIORAL|EQUIPED-ADRD Intervention|(10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
219341945|NCT03723707|BEHAVIORAL|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
219341946|NCT04027400|BEHAVIORAL|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
219341947|NCT01409135|DRUG|AGS-22M6E|IV Infusion
219341948|NCT01409135|DRUG|ASG-22CE|IV Infusion
219341949|NCT01208350|BEHAVIORAL|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
219341950|NCT01208350|BEHAVIORAL|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
219341951|NCT01208350|BEHAVIORAL|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
219341952|NCT00037609|DRUG|Capecitabine|1000 mg/m\^2 taken by mouth twice daily.
219341953|NCT00037609|DRUG|Exisulind|125 mg taken by mouth twice daily.
219341954|NCT01028664|DEVICE|SENSIMED Triggerfish|2-hour continuous IOP monitoring
219341955|NCT05121480|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
219341956|NCT05121480|DRUG|Placebo|Placebo oral capsule
219341957|NCT02366611|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
219341958|NCT02658123|OTHER|Pre-operative education (standard of care)|
219341959|NCT02658123|OTHER|Home health care visits (standard of care)|
219341960|NCT02658123|OTHER|Follow-up post-operative visits|
219341961|NCT02658123|OTHER|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
219341962|NCT02658123|OTHER|Healthcare Utilization Form|"* Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit"
219341963|NCT02658123|OTHER|The City of Hope QOL Survey for Ostomy Patients|"* Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
219341964|NCT02658123|OTHER|Phone call with CWOCN or PA|
219341965|NCT05541809|OTHER|Aromatherapy|Peppermint aroma inhalation
219341966|NCT05541809|OTHER|Placebo|Water inhalation
219341967|NCT06205888|OTHER|18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT|Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
219341968|NCT04864730|OTHER|No intervention|No intervention
219341969|NCT02822066|PROCEDURE|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
219341970|NCT04124146|RADIATION|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
219341971|NCT00001550|DRUG|IVIg|
219341972|NCT04851951|PROCEDURE|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
219341973|NCT02831673|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
219341974|NCT02831673|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
219341975|NCT02831673|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
219341976|NCT01411748|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
219341977|NCT01411748|DRUG|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
219341978|NCT00919035|DRUG|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
219341979|NCT02356562|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
219341980|NCT02356562|DRUG|Sofosbuvir|tablet
219341981|NCT02356562|DRUG|Ribavirin|tablet
219341982|NCT01469858|DEVICE|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
219341983|NCT03278132|BIOLOGICAL|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
219341984|NCT05453617|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
219341985|NCT05453617|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
219341986|NCT06457386|PROCEDURE|systematic echocardiography|"transthoracic echocardiography (TTE) will be performed as soon as possible within 14 days following the first blood sample collection for SAB diagnosis, completed, if required, by a transoesophageal (TEE) echocardiography based on the judgment of the echocardiographist.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
219341987|NCT06457386|PROCEDURE|no echocardiography arm|"no echocardiography will be performed unless occurrence of new events evocating IE (extra-cardiac events or positive Staphylococcus aureus blood culture), based on the clinical judgment of the investigator.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
219341988|NCT00126087|DRUG|dopamine|
219341989|NCT00294307|BEHAVIORAL|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];
219341990|NCT00294307|BEHAVIORAL|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.
219341991|NCT00294307|BEHAVIORAL|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
219341992|NCT04760665|BIOLOGICAL|Fecal microbiota transplantation|Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
219341993|NCT04760665|OTHER|Placebo|Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
219341994|NCT03610061|DRUG|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
219341995|NCT03610061|RADIATION|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
219341996|NCT03610061|RADIATION|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
219341997|NCT03772626|DEVICE|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
219341998|NCT04083482|PROCEDURE|continous venovenous hemofiltraion|CVVH
219341999|NCT03615183|DRUG|MK-8527|Single oral capsule
219342000|NCT01977781|DRUG|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
219342001|NCT01977781|DRUG|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
219342002|NCT02263183|DIETARY_SUPPLEMENT|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
219342003|NCT02263183|DIETARY_SUPPLEMENT|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
219342004|NCT03368651|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
219342005|NCT04706039|DIAGNOSTIC_TEST|Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process|"Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.~A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms."
219342006|NCT06407180|DRUG|Triamcinolone Acetonide|receive intraarticular triamcinolone injection
219342007|NCT06407180|DRUG|Normal saline|receive intraarticular normal saline injection
219342008|NCT00099190|DRUG|ARQ 501|
219342009|NCT03762070|DEVICE|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
219342010|NCT01477385|PROCEDURE|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
219342011|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
219342012|NCT01477385|PROCEDURE|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
219342013|NCT01477385|PROCEDURE|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
219342014|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
219342015|NCT01042860|DIETARY_SUPPLEMENT|Lutein|Lutein supplement, 10 mg daily
219342016|NCT01042860|DIETARY_SUPPLEMENT|Placebo|Placebo
219342017|NCT00365521|PROCEDURE|Photodynamic Therapy|
219342018|NCT02531581|DRUG|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc
219342019|NCT02531581|DRUG|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
219342020|NCT01082432|OTHER|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
219342021|NCT02913937|DEVICE|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
219342022|NCT02913937|DEVICE|Endodontic needle|Endodontic irrigation
219342023|NCT02952157|DRUG|Lidocaine jelly application|
219342024|NCT02952157|DRUG|Normal saline application|
219342025|NCT04546477|DEVICE|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
219342026|NCT02217605|DIETARY_SUPPLEMENT|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
219342027|NCT02830880|DRUG|FACBC PET-CT|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
219342028|NCT02830880|OTHER|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
219342029|NCT01671852|DRUG|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
219342030|NCT01671852|DRUG|Placebo|
219342031|NCT03045861|DRUG|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
219342032|NCT03045861|DRUG|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
219342033|NCT04048915|BEHAVIORAL|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
219342034|NCT04048915|BEHAVIORAL|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
219342035|NCT01412593|BIOLOGICAL|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
219342036|NCT05400213|DEVICE|Vallos (DCP)|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
219342037|NCT05400213|DEVICE|Vallomix (DCF)|A combination of cow-derived xenograft and human-derived DFDBA particulate
219342038|NCT05400213|DEVICE|Vallos-F (DPX)|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
219342039|NCT05400213|DEVICE|Vallomix-F (DFX)|A combination of cow-derived xenograft and human-derived DFDBA fibers
219342040|NCT06047041|BEHAVIORAL|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation."
219342041|NCT06047041|BEHAVIORAL|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
219342042|NCT05571787|DRUG|HMPL-523|700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
219342043|NCT05571787|DRUG|Rabeprazole|40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
219342044|NCT04096911|DRUG|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
219342045|NCT04096911|DRUG|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
219342046|NCT06292936|BEHAVIORAL|Acceptance-Based Behavioral Intervention|"Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs)."
219342047|NCT03551509|PROCEDURE|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
219342048|NCT03551509|PROCEDURE|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
219342049|NCT03551509|BIOLOGICAL|Alternative Treatment Group|Patients who meet pre-op inclusion criteria where a repair cannot be accomplished due to intraoperative findings will remain in the study. This group will be analyzed separately and still follow study procedures.
219342050|NCT04461262|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
219342051|NCT04461262|DEVICE|Standard Care|Uncoated Foley catheter
219342052|NCT01972048|BEHAVIORAL|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
219342053|NCT01972048|OTHER|Print brochure|Mailed print brochure about breast cancer screening and community resources.
219342054|NCT00806936|DRUG|human insulin|Any kind of human insulin administered at the discretion of the physician
219342055|NCT00806936|DRUG|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
219342056|NCT03891940|PROCEDURE|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
219342057|NCT04052685|PROCEDURE|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
219342058|NCT04052685|PROCEDURE|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
219342059|NCT03443908|DEVICE|CPAP|CPAP therapy 3-4 weeks
219342060|NCT04515693|OTHER|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
219342061|NCT04720482|DIAGNOSTIC_TEST|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
219342062|NCT04720482|DIAGNOSTIC_TEST|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
219342063|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
219342064|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
219342065|NCT01700556|OTHER|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
219342066|NCT01700556|OTHER|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
219342067|NCT01700556|OTHER|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
219355534|NCT03280004|DRUG|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
219355535|NCT02244710|DRUG|Ticagrelor vs Clopidogrel|
219342068|NCT01700556|OTHER|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
219342069|NCT04252846|DRUG|Perampanel|Perampanel oral tablets or oral suspension.
219342070|NCT00770614|DRUG|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
219342071|NCT00770614|DRUG|Isotonic saline|0.9% sodium chloride
219342072|NCT00770614|DRUG|Placebo|Placebo
219342073|NCT01040351|PROCEDURE|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
219342074|NCT04071821|DRUG|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
219342075|NCT04071821|DRUG|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
219342076|NCT01230307|DRUG|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
219342077|NCT01230307|DRUG|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
219342078|NCT04631575|DRUG|SHR6390|SHR6390, PO,single-dose
219342079|NCT02634853|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
219342080|NCT02634853|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
219342081|NCT04243590|BEHAVIORAL|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
219342082|NCT04243590|BEHAVIORAL|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
219342083|NCT04243590|BEHAVIORAL|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study."
219342084|NCT00567970|PROCEDURE|quality-of-life assessment|
219342085|NCT00567970|RADIATION|stereotactic body radiation therapy|
219342086|NCT04527302|COMBINATION_PRODUCT|ERP combined with high-definition active tDCS|"The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4)."
219342087|NCT04527302|COMBINATION_PRODUCT|ERP combined with sham tDCS|Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
219342088|NCT06126432|DIETARY_SUPPLEMENT|Yugart|Yugart 2 bottles per day for 1 month
219342089|NCT00577785|OTHER|tissue procurement|No intervention. Tissue procurement study.
219342090|NCT02027142|OTHER|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality."
219342091|NCT02027142|OTHER|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
219342092|NCT02027142|OTHER|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
219342093|NCT02027142|OTHER|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
219342094|NCT03500432|PROCEDURE|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
219342095|NCT00004262|PROCEDURE|conventional surgery|
219342096|NCT00004262|RADIATION|3-dimensional conformal radiation therapy|
219342097|NCT00004262|RADIATION|stereotactic radiosurgery|
219342098|NCT00004262|DRUG|motexafin gadolinium|Given IV
219342099|NCT00004262|PROCEDURE|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
219342100|NCT00004262|PROCEDURE|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
219342101|NCT01523379|DRUG|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
219342102|NCT01523379|DRUG|Placebo|NaCl i.v. two times a day, two days in an row
219342103|NCT00115154|DRUG|Aldara (imiquimod) cream, 5%|
219342104|NCT00185081|DRUG|Indium labeled IMP-205xm734|
219342105|NCT02387359|DRUG|Plecanatide|
219342106|NCT02387359|DRUG|Placebo|
219342107|NCT02511652|DEVICE|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
219342108|NCT02511652|DEVICE|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
219342109|NCT02511652|PROCEDURE|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
219342110|NCT00291447|BIOLOGICAL|ch806|ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
219342111|NCT03877562|DRUG|Olanzapine|Olanzapine 10 mg oral tablet
219342112|NCT03877562|DRUG|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
219342113|NCT03877562|DRUG|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
219342114|NCT03203044|OTHER|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
219342115|NCT00244270|DEVICE|totally implantable vascular access device|totally implantable vascular access device
219342116|NCT03411720|OTHER|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
219342117|NCT01361035|OTHER|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
219342118|NCT02774447|PROCEDURE|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
219342119|NCT01323725|BEHAVIORAL|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
219342120|NCT00530894|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|
219342121|NCT00530894|DEVICE|Surgical Valve Replacement|
219342122|NCT00530894|OTHER|medical management and/or balloon aortic valvuloplasty|
219342123|NCT00933673|DRUG|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
219342124|NCT01788384|DRUG|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
219342125|NCT01788384|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
219342126|NCT01788384|DRUG|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
219342127|NCT01077648|DRUG|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
219342128|NCT04776382|OTHER|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
219342129|NCT05319184|OTHER|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
219342130|NCT02859181|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
219342131|NCT02936427|DRUG|Dexamethasone|perineural infiltration of dexamethasone
219342132|NCT02256540|DRUG|Climara|
219342133|NCT02256540|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
219342134|NCT02256540|DIETARY_SUPPLEMENT|Resveratrol|
219342135|NCT02256540|DIETARY_SUPPLEMENT|Placebo|Placebo tablets designed to match active resveratrol tablets.
219342136|NCT03578471|DEVICE|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
219342137|NCT03578471|DEVICE|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
219342138|NCT03578471|DEVICE|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
219342139|NCT00114582|PROCEDURE|family style dinner|
219342140|NCT02605187|OTHER|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
219342141|NCT02605187|OTHER|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
219342142|NCT02605187|DRUG|Ibuprofen|Ibuprofen 600mg po q6h
219342143|NCT02605187|DRUG|Acetaminophen|Acetaminophen 650mg po q6h
219342144|NCT02605187|DRUG|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
219342145|NCT02605187|DRUG|Morphine (low)|Intrathecal morphine dose 50mcg
219342146|NCT02605187|DRUG|Morphine (med)|Intrathecal morphine dose 150mcg
219342147|NCT02605187|DRUG|Morphine (high)|Intrathecal morphine 300mcg
219342148|NCT05917561|DRUG|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
219342149|NCT05917561|DRUG|Placebo|Placebo once a month, infusion for 36 weeks
219342150|NCT05433571|DEVICE|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
219342151|NCT02562560|BEHAVIORAL|Neuropsychological tests|
219342152|NCT02562560|DEVICE|Cerebral imaging (MRI, PET-FDG)|
219342153|NCT01520935|OTHER|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
219342154|NCT05203497|DRUG|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
219342155|NCT02431065|PROCEDURE|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
219342156|NCT02431065|DRUG|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
219342157|NCT02431065|OTHER|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
219342158|NCT04462562|DIAGNOSTIC_TEST|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
219342159|NCT06478069|DIAGNOSTIC_TEST|Group A|Group A was treated with Ibuprofen Dosage After breakfast and after dinner for 6 weeks.
219342160|NCT06478069|BEHAVIORAL|Group B|Group B was treated with physical therapy; (Upper limb: The stroke patient warmed up with some gentle stretches for the wrist and fingers to get the muscles ready. They subsequently engaged in resistance training using dumbbells or resistance bands to increase the strength of their upper limbs. Bicep curls, tricep extensions, and shoulder presses were some of these exercises. They tried to complete two to three sets of ten to fifteen repetitions for each exercise, progressively increasing the resistance as their strength increased. Then, to improve dexterity and coordination in daily tasks, functional exercises were included.
219342161|NCT02808000|DEVICE|BIP Foley (latex) or BIP Foley -silicone|
219342162|NCT02808000|DEVICE|Standard catheter|
219342163|NCT03586128|DRUG|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
219342164|NCT03586128|DRUG|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
219342165|NCT01910259|DRUG|Amiloride|Comparison with placebo
219342166|NCT01910259|DRUG|Riluzole|Comparison with placebo
219342167|NCT01910259|DRUG|Fluoxetine|Comparison with placebo
219342168|NCT01910259|DRUG|Placebo|Placebo comparator
219342169|NCT02238275|DRUG|Micardis® plus|
219342170|NCT06359873|DIAGNOSTIC_TEST|CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)|"CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\].~C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\].~LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database."
219342171|NCT03834467|OTHER|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
219342172|NCT03834467|OTHER|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
219342173|NCT02907294|DRUG|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
219342174|NCT02907294|DRUG|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
219342175|NCT02907294|DRUG|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
219342176|NCT05927051|OTHER|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
219342177|NCT05927051|OTHER|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
219342178|NCT05927051|OTHER|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
219342179|NCT00940589|DRUG|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
219342180|NCT00940589|DRUG|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
219342181|NCT02291120|PROCEDURE|Pulpotomy|
219342182|NCT03719690|DRUG|Tipifarnib|Tablet for oral administration
219342183|NCT03719690|DEVICE|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
219342184|NCT06011343|DRUG|Oral tofacitinib|Association of tofacitinib and meglumine antimoniate
219342185|NCT06011343|DRUG|Parenteral meglumine antimoniate|Meglumine antimoniate
219342186|NCT01918007|PROCEDURE|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
219342187|NCT05070975|OTHER|Epidemiology|Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
219342188|NCT02448030|OTHER|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
219342189|NCT02448030|OTHER|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
219342190|NCT03695575|DEVICE|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
219342191|NCT05778500|DEVICE|COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines
219342192|NCT02150577|BEHAVIORAL|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
219342193|NCT00631774|DIETARY_SUPPLEMENT|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
219342194|NCT02830100|OTHER|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
219342195|NCT02830100|DEVICE|MRI|
219342196|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
219342197|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
219342198|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
219342199|NCT01028092|DRUG|Thymoglobulin + Everolimus|"* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
219342200|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine then Everolimus|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
219342201|NCT02191254|DRUG|Antistax®|
219342202|NCT02191254|DRUG|Placebo|
219342203|NCT03298581|DRUG|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
219342204|NCT04006964|DEVICE|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
219342205|NCT02085382|PROCEDURE|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
219342206|NCT02085382|PROCEDURE|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
219342207|NCT04565964|OTHER|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
219342208|NCT03420690|OTHER|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (\>1) and the death of patients (\> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
219342209|NCT01713023|DIETARY_SUPPLEMENT|Glucose|The same described in Arm description
219342210|NCT01713023|DIETARY_SUPPLEMENT|Fructose|The same described in Arm description
219342211|NCT02466152|DRUG|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
219342212|NCT03410173|DRUG|Taurine|
219342213|NCT03410173|DRUG|Placebo|
219342214|NCT05710471|DRUG|Brolucizumab|Intravitreal injection
219342215|NCT05710471|DRUG|Aflibercept|Intravitreal injection
219342216|NCT03688932|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
219342217|NCT03688932|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
219342218|NCT03688932|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
219342219|NCT04174781|DRUG|Sintilimab|Sintilimab: 200mg iv Q3W D1
219342220|NCT04174781|DRUG|DEB-TACE|DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
219342221|NCT06548256|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|probiotics
219342222|NCT03241914|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
219342223|NCT03241914|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
219342224|NCT06500143|DIAGNOSTIC_TEST|Gastric ultrasound|"Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create ring-down artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value."
219342225|NCT01499420|BIOLOGICAL|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
219342226|NCT01499420|BIOLOGICAL|Placebo|Single intravenous doses of normal saline (0.9%)
219342227|NCT03958162|DIAGNOSTIC_TEST|lung biopsy|transbronchial lung cryobiopsy
219342228|NCT02701543|DEVICE|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
219342229|NCT02701543|DEVICE|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
219342230|NCT00114049|DRUG|GW406381|
219342231|NCT02666339|OTHER|Usual care|Usual care : drug therapy, nurse and physician consultations.
219342232|NCT02666339|BEHAVIORAL|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
219342233|NCT03629457|BEHAVIORAL|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
219342234|NCT00003362|BIOLOGICAL|QS21|
219342235|NCT00003362|BIOLOGICAL|gp100 antigen|
219342236|NCT00003362|BIOLOGICAL|incomplete Freund's adjuvant|
219342237|NCT00003362|BIOLOGICAL|sargramostim|
219342238|NCT00003362|BIOLOGICAL|tyrosinase peptide|
219342239|NCT03551223|BIOLOGICAL|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
219342240|NCT02353156|OTHER|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
219342241|NCT02353156|OTHER|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
219342242|NCT00014456|BIOLOGICAL|filgrastim|
219342243|NCT00014456|DRUG|docetaxel|
219342244|NCT00014456|DRUG|gemcitabine hydrochloride|
219342245|NCT03077347|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
219342246|NCT00960661|DRUG|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
219342247|NCT00960661|DRUG|insulin lispro|titrated based on pre-meal glucose level; three times a day
219342248|NCT00960661|DRUG|Metformin|
219342249|NCT00960661|DRUG|Insulin/ Glargine|
219342250|NCT02699892|DRUG|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
219342251|NCT02287974|DRUG|Stem cell infusion|Unique stem cell infusion of the randomized group
219342252|NCT02989558|DRUG|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
219342253|NCT02989558|DRUG|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
219342254|NCT00067028|DRUG|Clofarabine 40mg/m^2|40 mg/m\^2 by vein over 1 hour daily for 5 days.
219342255|NCT00067028|DRUG|Idarubicin 10mg/m^2|"10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
219342256|NCT00067028|DRUG|Ara-C 0.75 g/m^2|0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
219342257|NCT00067028|DRUG|Clofarabine 22.5mg/m^2|22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
219342258|NCT00067028|DRUG|Ara-C 1 g/m^2|1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
219342259|NCT00067028|DRUG|Idarubicin 6 mg/m^2|6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
219342260|NCT05178238|OTHER|Fecal sample|Fecal sample taken to investigate intestinal microbiota
219342261|NCT03303742|OTHER|deep chamfer|finish line marginal design of a full coverage crown preparation
219342262|NCT03303742|OTHER|feather edge|finish line marginal design of a full coverage crown preparation
219342263|NCT05220527|DRUG|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
219342264|NCT05220527|DRUG|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
219342265|NCT05220527|DRUG|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
219342266|NCT06392646|BEHAVIORAL|self-management education program|Intervention through a self-management education program constructed through evidence summarization and expert correspondence.
219342267|NCT02226107|BEHAVIORAL|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
219342268|NCT02226107|BEHAVIORAL|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
219342269|NCT02519933|PROCEDURE|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
219342270|NCT02519933|PROCEDURE|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
219342271|NCT04485520|OTHER|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
219342272|NCT04485520|OTHER|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
219342273|NCT00630266|DEVICE|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
219342274|NCT06413862|DRUG|Ciprofol|The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).
219342275|NCT06413862|DRUG|Propofol|The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
219342276|NCT03047070|DRUG|Lidocaine|IV Lidocaine infusion
219342277|NCT03047070|DRUG|Normal saline|IV normal saline infusion
219342278|NCT06377826|OTHER|aerobic exercises|group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
219342279|NCT06377826|OTHER|resistance training|this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
219342280|NCT06377826|DRUG|medication|This group will be just on medication and no exercise will be given to this group
219342281|NCT00637260|DEVICE|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
219342282|NCT00637260|DEVICE|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
219342283|NCT01256073|DRUG|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
219342284|NCT04596475|DRUG|glecaprevir/pibrentasvir (GLE/PIB)|The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
219342285|NCT03490305|PROCEDURE|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
219342286|NCT05469971|GENETIC|KIR genotyping|DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).
219342287|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
219342288|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
219342289|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
219342290|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
219342291|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
219342292|NCT02517775|DIETARY_SUPPLEMENT|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
219342293|NCT03645928|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.
219342294|NCT03645928|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
219342295|NCT03645928|DRUG|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
219342296|NCT03645928|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
219342297|NCT03645928|DRUG|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
219342298|NCT03645928|DRUG|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
219342299|NCT03645928|DRUG|Nivolumab-relatlimab|Nivolumab-relatlimab will be administered following tumor resection and will continue every 4 weeks thereafter for up to 2 years.
219342300|NCT03645928|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219342301|NCT03645928|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219342302|NCT03645928|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219342303|NCT03645928|DRUG|Nab-Paclitaxel|Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
219342304|NCT03645928|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.
219342305|NCT06276283|DRUG|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
219342306|NCT00142350|DRUG|continuous infusion of 5-fluorouracil|
219342307|NCT00142350|DRUG|combination of irinotecan and cisplatin|
219342308|NCT00142350|DRUG|oral administration of S-1|
219342309|NCT03070470|DRUG|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
219342310|NCT03070470|DRUG|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
219342311|NCT03070470|DRUG|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
219342312|NCT03070470|DRUG|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
219342313|NCT03070470|DRUG|Placebo|Placebo (administered orally)
219342314|NCT03070470|DRUG|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
219342315|NCT00800293|DRUG|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
219342316|NCT02709499|DEVICE|0J LLLT|perform with the machine off
219342317|NCT02709499|DEVICE|6J LLLT|irradiation will be perform with 4J
219342318|NCT02371226|DRUG|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
219342319|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE NEO/TF|Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation
219342320|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro|Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
219342321|NCT06265675|DRUG|Phenol|Chemical neurolysis
219342322|NCT06265675|DRUG|Celestone|Chemical neurolysis with corticosteroid
219342323|NCT06265675|DRUG|Lidocain|Chemical neurolysis with local anesthetic
219342324|NCT05307484|OTHER|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
219342325|NCT05307484|OTHER|Dengue prevention website|This is a website containing information regarding dengue prevention.
219342326|NCT03234387|OTHER|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
219342327|NCT00280306|OTHER|No interventions|No intervention
219342328|NCT05267275|PROCEDURE|extended resection with splenic flexure mobilization|During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
219342329|NCT02854514|PROCEDURE|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
219342330|NCT05970198|RADIATION|Total Marrow irradiation，TMI|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min."
219342331|NCT05970198|PROCEDURE|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation;Porting method melphalan
219342332|NCT02888093|DEVICE|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
219342333|NCT02389127|DEVICE|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
219342334|NCT02104986|DRUG|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
219342335|NCT02104986|DRUG|Vepeside-ifosfamide-Cisplatin|
219342336|NCT01397799|DRUG|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
219342337|NCT00530270|DRUG|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
219342338|NCT00530270|DRUG|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
219342339|NCT01858077|DEVICE|ABSORB BVS™|Bioresorbable scaffold
219342340|NCT01858077|DEVICE|XIENCE™|Drug eluting metallic stent
219342341|NCT02975895|DEVICE|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
219342342|NCT02975895|DEVICE|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
219342343|NCT00354770|DRUG|Placebo|daily
219342344|NCT00354770|DRUG|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
219342345|NCT02963389|DRUG|Tripegfilgrastim|
219342346|NCT02093806|OTHER|measurment|
219342347|NCT02474212|DRUG|Enoxaparin|
219342348|NCT02757599|OTHER|Ultrasound training|Training on the transvaginal ultrasound simulator.
219342349|NCT00283114|DRUG|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
219342350|NCT02324920|DEVICE|DDD-CLS|
219342351|NCT02324920|DEVICE|ODO|
219342352|NCT01483391|BEHAVIORAL|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
219342353|NCT01483391|BEHAVIORAL|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
219342354|NCT06190067|DRUG|Azacitidine Plus PD-1 therapy|Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
219342355|NCT01870102|DRUG|Pelubiprofen IR (Pelubiprofen 30mg) TID|
219342356|NCT01870102|DRUG|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
219342357|NCT02164175|DEVICE|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
219342358|NCT01109875|OTHER|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
219342359|NCT04945603|OTHER|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
219342360|NCT05988476|OTHER|Exercise|5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
219342361|NCT05988476|DEVICE|Pulsed Electromagnetic Field Therapy|5 day/week, two week,two sessions consisting of 180 minutes
219342362|NCT01468584|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
219342363|NCT01468584|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
219342364|NCT01468584|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
219342365|NCT00892385|DRUG|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
219342366|NCT00892385|DRUG|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
219342367|NCT04998435|PROCEDURE|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
219342368|NCT04998435|PROCEDURE|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
219342369|NCT00142467|DRUG|Gemcitabine|
219342370|NCT00142467|DRUG|Oxaliplatin|
219342371|NCT00142467|DRUG|Bevacizumab|
219342372|NCT00238251|DRUG|gefitinib|Once daily during days 1-28
219342373|NCT00238251|DRUG|temozolomide|Once daily on days 1-21
219342374|NCT00238251|RADIATION|radiation therapy|Whole brain radiotherapy
219342375|NCT03927001|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
219342376|NCT05413382|DIETARY_SUPPLEMENT|Biofresh® 4plus|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
219342377|NCT05413382|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
219342378|NCT03024554|DEVICE|Implantation of the Bifurcated Multilayer Flow Modulator|
219342379|NCT01155804|BEHAVIORAL|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
219342380|NCT03971279|DRUG|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
219342381|NCT06493968|DRUG|oxytocin|Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
219342382|NCT06493968|OTHER|placebo|IV bolus of normal saline immediately with the uterine incision
219342383|NCT02734160|DRUG|Galunisertib|Administered orally
219342384|NCT02734160|DRUG|Durvalumab|Administered IV
219342385|NCT01381432|DRUG|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
219342386|NCT00779649|OTHER|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
219342387|NCT00779649|OTHER|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
219342388|NCT00976222|DRUG|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
219342389|NCT02919436|DRUG|Tamsulosin|Active drug
219342390|NCT02919436|DRUG|Placebo|Lactose-filled capsules identical to active drug
219342391|NCT03699007|BEHAVIORAL|Graded Exposure Therapy (GET Living)|The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
219342392|NCT03699007|BEHAVIORAL|Multidisciplinary Pain Management (MPM)|The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
219342393|NCT03259074|BIOLOGICAL|Placebo|Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes
219342394|NCT03259074|BIOLOGICAL|GP2017 (adalimumab biosimilar)|40 mg in pre-filled syringes was administered subcutaneously
219342395|NCT03259074|BIOLOGICAL|AIN457 150 mg|150 mg in pre-filled syringes was administered subcutaneously
219342396|NCT01780662|DRUG|Brentuximab Vedotin|Given IV
219342397|NCT01780662|DRUG|Gemcitabine Hydrochloride|Given IV
219342398|NCT01755715|PROCEDURE|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
219342399|NCT01490437|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
219342400|NCT01490437|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
219342401|NCT01490437|DRUG|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
219342402|NCT01490437|DRUG|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
219342403|NCT00053417|DRUG|Placebo|Placebo for 15 weeks
219342404|NCT00053417|DRUG|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
219342405|NCT00053417|DRUG|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
219342406|NCT00053417|DRUG|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
219342407|NCT02779374|OTHER|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
219342408|NCT02360020|DEVICE|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
219342409|NCT03445455|DEVICE|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
219342410|NCT02597569|BEHAVIORAL|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
219342411|NCT04026178|DRUG|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
219342412|NCT05494021|OTHER|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
219342413|NCT05494021|DEVICE|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
219342414|NCT05616936|BIOLOGICAL|injectable platelet rich fibrin|injectable platelet rich fibrin
219342415|NCT03404011|OTHER|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
219342416|NCT03404011|DEVICE|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
219342417|NCT02043535|DEVICE|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
219342418|NCT02043535|DEVICE|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
219342419|NCT06254365|BIOLOGICAL|Exogenous LEAP2 hormone|This intervention has never been examined in this type of study before.
219342420|NCT04196075|DRUG|Andrographis Paniculata|AP as palliative treatment
219342421|NCT00595556|DRUG|zonisamide|flexible dosages of 100-500mg/day
219342422|NCT00595556|DRUG|Placebo|Placebo
219342423|NCT02988570|BEHAVIORAL|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
219342424|NCT00371293|BEHAVIORAL|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
219342425|NCT00371293|DEVICE|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
219342426|NCT01121133|DRUG|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
219342427|NCT01121133|DRUG|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
219342428|NCT02234154|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
219342429|NCT02182687|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
219342430|NCT02182687|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
219342431|NCT02182687|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
219342432|NCT02327052|OTHER|No intervention was performed.|No intervention was performed.
219342433|NCT05365542|OTHER|Hemodialyzer scanning|After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.
219342434|NCT05365542|OTHER|Bleeding Questionnaires|The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked
219342435|NCT05365542|OTHER|Quality of life questionnaire|The EQ5D questionnaire is asked.
219342436|NCT05365542|OTHER|Visual inspection of the limbs|Visual inspection is done of the patient's limbs in order to quantify bruising.
219342437|NCT06475014|PROCEDURE|Total knee replacement|Mechanical Alignment Using PSI Pre and post-operative CT Scan
219342438|NCT01029132|DRUG|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
219342439|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
219342440|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
219342441|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
219342442|NCT02788097|PROCEDURE|Progesterone supplementation|artificial frozen embryo transfers
219342443|NCT00718276|DRUG|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
219342444|NCT00718276|DIETARY_SUPPLEMENT|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
219342445|NCT04523506|BIOLOGICAL|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
219342446|NCT00121212|PROCEDURE|carbon-11 acetate PET scan|
219342447|NCT02514616|PROCEDURE|Laparoscopic IPG and lead implant procedure|EST placement
219342448|NCT02514616|DEVICE|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
219342449|NCT02514616|DEVICE|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
219342450|NCT04213105|DRUG|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
219342451|NCT04213105|DRUG|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
219342452|NCT03070925|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
219342453|NCT04509375|DEVICE|Cranial Doppler Ultrasonography|Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.
219342454|NCT04509375|DEVICE|Near-Infrared Spectroscopy|Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
219342455|NCT00670670|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
219342456|NCT00670670|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
219342457|NCT04162184|BEHAVIORAL|Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention|a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
219342458|NCT02385149|OTHER|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
219342459|NCT02385149|OTHER|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
219342460|NCT02334449|DRUG|LML134|LML134 will be administered first as single doses and then as multiple doses
219342461|NCT02334449|DRUG|Placebo|All study cohorts (except food effect cohort) are placebo controlled
219342462|NCT00336219|DRUG|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
219342463|NCT05726344|DRUG|Lactulose|4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
219342464|NCT05726344|DRUG|Polyethylene Glycol 3350|4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
219342465|NCT00543426|DRUG|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
219342466|NCT00543426|DRUG|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
219342467|NCT05170906|OTHER|Reflex locomotion stimulus|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
219342468|NCT05170906|OTHER|sham stimulus|The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
219342469|NCT03615196|DRUG|USB005 (aclerastide) Ophthalmic Solution|Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
219342470|NCT03615196|DRUG|USB005 Ophthalmic Solution Placebo|A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
219342471|NCT05464706|DIETARY_SUPPLEMENT|Synchrolevels|Supplement therapy to model the recovery after liver surgery
219342472|NCT03029143|DRUG|Vedolizumab IV|Vedolizumab intravenous infusion.
219342473|NCT04572984|PROCEDURE|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
219342474|NCT01662674|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
219342475|NCT01662674|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
219342476|NCT03203057|OTHER|coronary occlusion|percutaneous coronary intervention
219342477|NCT00851539|BEHAVIORAL|Video|Behavioral Intervention Video
219342478|NCT05738473|DRUG|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
219342479|NCT03752775|DEVICE|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
219342480|NCT00619255|BEHAVIORAL|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
219342481|NCT00974675|BIOLOGICAL|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
219342482|NCT00974675|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
219342483|NCT00974675|BIOLOGICAL|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
219342484|NCT00974675|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
219342485|NCT04123782|DEVICE|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
219342486|NCT04123782|DEVICE|Placebo F-ESW Treatment|Very low concentration of F-ESW.
219342487|NCT02695992|DRUG|Metoprolol|Dosage 100 mg o.d.
219342488|NCT02695992|DRUG|Diltiazem|Dosage 360 mg o.d.
219342489|NCT05227521|BEHAVIORAL|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
219342490|NCT01669070|DRUG|FF, 50 mcg|Novel dry powder inhaler
219342491|NCT01669070|DRUG|FF, 100 mcg|Novel dry powder inhaler
219342492|NCT01669070|DRUG|FF, 200 mcg|Novel dry powder inhaler
219342493|NCT01669070|DRUG|FF, 250 mcg|Intravenous
219342494|NCT01250340|DRUG|Aspirin|100 mg/day for 30 days
219342495|NCT01250340|DRUG|Placebo|1 cp day for 30 days
219342496|NCT02121262|DRUG|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
219342497|NCT02121262|PROCEDURE|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
219342498|NCT04422860|DRUG|Gum Arabic varnish|Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
219342499|NCT04422860|DRUG|Proflourid Varnish,VOCO|5% NaF varnish
219342500|NCT04422860|DRUG|MI Varnish,GC Japan Inc.|CPP-ACP with fluoride based varnish
219342501|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
219342502|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
219342503|NCT01898572|OTHER|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
219342504|NCT04160702|BEHAVIORAL|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
219342505|NCT05298189|BEHAVIORAL|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
219342506|NCT05298189|BEHAVIORAL|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
219342507|NCT05298189|BEHAVIORAL|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
219342508|NCT05933369|BEHAVIORAL|Clincal pharmacist intervention|Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
219342509|NCT00851201|BEHAVIORAL|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
219342510|NCT00851201|BEHAVIORAL|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
219342511|NCT00033410|DRUG|carboplatin|
219342512|NCT00033410|DRUG|paclitaxel|
219342513|NCT00033410|DRUG|tirapazamine|
219342514|NCT00033410|RADIATION|radiation therapy|
219342515|NCT02992340|DRUG|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
219342516|NCT02992340|DRUG|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
219342517|NCT02992340|DRUG|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
219342518|NCT02601677|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
219342519|NCT02601677|DRUG|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
219342520|NCT06410365|DRUG|Dexmedetomidine injection|Comparison of intravenous and intrathecal route of dexmedetomidine
219342521|NCT04914689|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
219342522|NCT04914689|OTHER|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
219342523|NCT04914689|OTHER|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
219342524|NCT02588976|DEVICE|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
219342525|NCT00091715|DRUG|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
219342526|NCT00091715|DRUG|placebo|placebo for 6 months followed by an open-label period
219342527|NCT01394627|DRUG|Eplerenone|100mg x 2
219342528|NCT01394627|DRUG|Placebo|
219342529|NCT03602079|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
219342530|NCT06009003|DRUG|REL-1017|REL-1017 tablet
219342531|NCT01991990|DRUG|placebo|Single i.v. infusion
219342532|NCT01991990|DRUG|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
219342533|NCT00547170|DRUG|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
219342534|NCT00547170|DRUG|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
219342535|NCT03292809|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
219342536|NCT03292809|DRUG|Vehicle topical ocular, eye drops|Vehicle
219342537|NCT05598099|BEHAVIORAL|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
219342538|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
219342539|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
219342540|NCT01765920|DRUG|Ergoferon|5 ml 3 times a day
219342541|NCT01765920|DRUG|Placebo|5 ml 3 times a day
219342542|NCT04335942|OTHER|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
219342543|NCT04335942|OTHER|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
219342544|NCT03383445|PROCEDURE|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
219342545|NCT03383445|PROCEDURE|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
219342546|NCT03383445|PROCEDURE|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
219342547|NCT03383445|PROCEDURE|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
219342548|NCT04103684|DRUG|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
219342549|NCT04103684|DRUG|Dexamethasone|0.6mg per kg perday for 5 days
219342550|NCT01081249|DRUG|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
219342551|NCT01081249|DRUG|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
219342552|NCT03844165|BEHAVIORAL|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
219342553|NCT03844165|BEHAVIORAL|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
219342554|NCT02025907|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
219342555|NCT02025907|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
219342556|NCT02025907|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily.
219342557|NCT01544946|DRUG|88% sucrose po|88% sucrose solution (Syrup B.P.)
219342558|NCT01544946|DRUG|placebo po|sterile water
219342559|NCT03424252|DRUG|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
219342560|NCT05514626|DEVICE|3D Holographic Display|3D holographic visualization of the anatomy during the planned interventional procedure. The HOLOSCOPE-i will be used in addition to and will not replace conventional displays that are currently being used during the procedure.
219342561|NCT01073332|DIETARY_SUPPLEMENT|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
219342562|NCT01073332|DIETARY_SUPPLEMENT|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
219342563|NCT04187638|DIETARY_SUPPLEMENT|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
219342564|NCT04187638|DIETARY_SUPPLEMENT|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
219342565|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
219342566|NCT02395926|DRUG|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
219342567|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
219342568|NCT00282334|DEVICE|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
219342569|NCT03681119|BEHAVIORAL|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
219342570|NCT03681119|BEHAVIORAL|Education and Training|Education and training
219342571|NCT06294886|DIAGNOSTIC_TEST|Screening test to detect endometrial cancer and precancer|The device is designed to detect DNA biomarkers for cancer in cells shed from the lining of the uterus into vaginal fluid
219342572|NCT03332563|BEHAVIORAL|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
219342573|NCT01857284|DRUG|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
219342574|NCT01857284|DRUG|Ursodeoxycholic Acid Capsules|250mg.tid.po
219342575|NCT01236300|DEVICE|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
219342576|NCT01704352|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
219342577|NCT03146000|DRUG|lidocaine-prilocaine cream|topical cream
219342578|NCT03146000|DRUG|meloxicam rectal suppository|suppository
219342579|NCT06392568|OTHER|epidemiological records|Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
219342580|NCT02305095|DRUG|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
219342581|NCT03009214|DRUG|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
219342582|NCT02657161|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
219342583|NCT02657161|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
219342584|NCT02657161|BIOLOGICAL|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
219342585|NCT00878371|DRUG|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
219342586|NCT05981170|OTHER|Adapted physical activity at home|"The programme will take place over 6 months and will include :~1 consultation with the oncologist who will first assess the need for Adapted Physical Activity and then prescribe the APA with a certificate of no physical contraindication~1 consultation with the ICO's APA coach who will present the APA programme and assess the patient's physical capacity using the Short Physical Performance Battery (SPPB) test in order to adapt the programme to their needs.~13 home-based APA sessions (ideally one session per week) with the EAPA from Departmental Committee for Sport for All in 49~1 telephone call with the EAPA of the ICO to evaluate the programme 3 months after the last session.~Patients will also be asked to complete questionnaires at the first session (S1), halfway through the sessions (S6) and at the last session (S13).~These are FACIT-F 5Functional Assessment of Chronic Illness Therapy - Fatigue ; Ricci and L. Gagnon ; P-GIC (Patients' Global Impression of Change (PGIC) scale)"
219342587|NCT02086786|DRUG|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
219342588|NCT00625469|DRUG|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
219342589|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.
219342590|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
219342591|NCT05970900|DRUG|Imatinib Mesylate|"1. For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~2. For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd."
219342592|NCT05970900|PROCEDURE|Local resection|"According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach"
219342593|NCT01530984|DRUG|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
219342594|NCT01530984|DRUG|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
219342595|NCT02595671|OTHER|Digital Super Coach|Receive Digital Super Coach during 12 weeks
219342596|NCT02595671|OTHER|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
219342597|NCT02595671|OTHER|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
219342598|NCT02595671|OTHER|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
219342599|NCT06005727|DEVICE|Transanal ice pack|A condom is filled with 100ml of water and frozen to serve as a transanal ice pack. It is covered by sterile plastic dressing and applied to the hemorrhoidectomy wound for 1 minute after surgery is completed.
219342600|NCT01923129|DRUG|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
219342601|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
219342602|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
219342603|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
219342604|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
219342605|NCT00054067|DRUG|cisplatin|
219342606|NCT00054067|PROCEDURE|adjuvant therapy|
219342607|NCT00054067|PROCEDURE|conventional surgery|
219342608|NCT00054067|RADIATION|brachytherapy|
219342609|NCT00054067|RADIATION|radiation therapy|
219342610|NCT02477059|DRUG|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
219342611|NCT02477059|DRUG|saline solution|La saline solution is administered by intravenous infusion.
219342612|NCT03512600|DIETARY_SUPPLEMENT|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
219342613|NCT03512600|DIETARY_SUPPLEMENT|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
219342614|NCT03512600|DIETARY_SUPPLEMENT|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
219342615|NCT03512600|DIETARY_SUPPLEMENT|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
219342616|NCT01166737|PROCEDURE|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
219342617|NCT03631732|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
219342618|NCT03631732|DRUG|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
219342619|NCT03631732|DRUG|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
219342620|NCT00330902|DRUG|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
219342621|NCT00330902|DRUG|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
219342622|NCT04827784|PROCEDURE|local anaesthetic injection|The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
219342623|NCT03334890|DIAGNOSTIC_TEST|plasma mSEPT9 level|the plasma level of methylated SEPT9
219342624|NCT04046432|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
219342625|NCT04046432|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo.
219342626|NCT04288154|DEVICE|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
219342627|NCT04288154|OTHER|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
219342628|NCT00005832|DRUG|R115777|300mg/dose BID, PO, Days 1-21, q 28days
219342629|NCT01457209|OTHER|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
219342630|NCT02149940|OTHER|heart-failure related pharmaceutical intervention|
219342631|NCT03051360|DRUG|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
219342632|NCT03051360|DRUG|Placebos|Patients will receive Placebo by a biweekly injection
219342633|NCT03784976|OTHER|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
219342634|NCT01833286|PROCEDURE|TACE+RFA|TACE first, followed by RFA within 2 months
219342635|NCT01833286|PROCEDURE|re-resection|repeat hepatectomy for recurrent small HCC
219342636|NCT05944315|BEHAVIORAL|Education session|Classroom Education session appropriate for elementary school children
219342637|NCT04936295|DRUG|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
219342638|NCT00768521|DRUG|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
219342639|NCT00768521|DRUG|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
219342640|NCT03982004|DEVICE|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
219342641|NCT03982004|DRUG|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
219342642|NCT03982004|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
219342643|NCT03982004|OTHER|Dermatologic Quality of Life Index|"* 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
219342644|NCT03982004|OTHER|Functional Assessment of Cancer Therapy|"* 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
219342645|NCT03982004|DRUG|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
219342646|NCT03982004|DEVICE|Cry-AC|-Device used to give the cryoimmunotherapy
219342647|NCT03982004|PROCEDURE|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
219342648|NCT03982004|PROCEDURE|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
219342649|NCT01131377|DRUG|acetazolamide|"If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
219342650|NCT01131377|DRUG|Saline|They will receive saline 50ml via IV q 24h.
219342651|NCT04599283|DEVICE|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
219342652|NCT03182270|DIAGNOSTIC_TEST|nCLE|Procedure: EUS-FNA Device: nCLE
219342653|NCT02870309|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
219342654|NCT00793260|BEHAVIORAL|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
219342655|NCT00793260|BEHAVIORAL|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
219342656|NCT05252364|DRUG|HP518 - Dose Escalation|"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."
219342657|NCT05252364|DRUG|HP518 - Dose expansion|"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."
219342658|NCT06086093|DIETARY_SUPPLEMENT|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
219342659|NCT02873936|DRUG|Filgotinib|Tablet(s) administered orally once daily
219342660|NCT02873936|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
219342661|NCT02873936|DRUG|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
219342662|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
219342663|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
219342664|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
219342665|NCT00917150|DRUG|placebo|oral administration of placebo, once daily for 24months
219342666|NCT03978195|DEVICE|Non-invasive device for middle ear ventilation|Daily use of the device
219342667|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 30|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
219342668|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 90|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
219342669|NCT01859728|DRUG|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
219342670|NCT01859728|DRUG|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
219342671|NCT01859728|DRUG|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
219342672|NCT01859728|DRUG|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
219342673|NCT05648994|BIOLOGICAL|TCR-T cells|patients will be administration of TCR-T cells
219342674|NCT05648994|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
219342675|NCT05648994|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
219342676|NCT05648994|DRUG|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
219342677|NCT05648994|DRUG|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
219342678|NCT04041986|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
219342679|NCT04605302|DEVICE|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
219342680|NCT04605302|DEVICE|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
219342681|NCT05229302|BEHAVIORAL|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
219342682|NCT05229302|BEHAVIORAL|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
219342683|NCT01624662|DRUG|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
219342684|NCT05818592|OTHER|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
219342685|NCT01361776|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 4 arms
219342686|NCT03115736|DRUG|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
219342687|NCT02354066|DEVICE|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
219342688|NCT02354066|DEVICE|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
219342689|NCT02354066|DEVICE|Retail Shoe|Brake response time measurement before surgery (control run)
219342690|NCT01972867|DEVICE|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
219342691|NCT02971462|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
219342692|NCT04938583|BIOLOGICAL|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
219342693|NCT04938583|DRUG|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
219342694|NCT04938583|DRUG|Paclitaxel|175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
219342695|NCT04938583|DRUG|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
219342696|NCT05512546|DRUG|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
219342697|NCT03853603|DIETARY_SUPPLEMENT|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
219342698|NCT03853603|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
219342699|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
219342700|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
219342701|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
219342702|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
219342703|NCT01848184|DEVICE|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
219342704|NCT04071847|DEVICE|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
219342705|NCT04206748|DEVICE|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
219342706|NCT04206748|DEVICE|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
219342707|NCT03099187|DRUG|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
219342708|NCT03099187|DRUG|Placebo|Matching placebo capsules three times in a day.
219342709|NCT06972641|DRUG|Decitabine|Decitabine 3.5 mg/m2 1-5d for 28 days for 6 cycles of dosing
219342710|NCT06972641|DRUG|Sorafenib (BAY-43-9006)，giritinib|Sorafenib 0.2g 2/day or giritinib 40mg 2/day orally for 2 years
219342711|NCT06972641|DRUG|Avastinib|100 mg 1/day
219342712|NCT06972641|DRUG|Venetoclax;Selenisol|Vinaclat: 50-100mg 1/day orally, d1-14 1/day per month (adjust drug dosage based on blood levels), 28-day cycle; Selenisol: 20mg qw orally (weeks 1 and 2), 28-day cycle If the above treatment is not tolerated, adjust the regimen to decitabine 3.5 mg/m2 1-5 d; 28 days as a cycle of 6 cycles of medication; Vinaclat: 50-100 mg 1/day orally, d1-14 1/day per month orally (adjust the dose of the drug according to the blood concentration), 28 days as a cycle of medication
219342713|NCT05478798|OTHER|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
219342714|NCT05478798|OTHER|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
219342715|NCT05478798|OTHER|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
219342716|NCT04918277|DEVICE|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
219342717|NCT01439555|DRUG|Simvastatin|Simvastatin, 40 mg per day orally
219342718|NCT01439555|DRUG|L-Arginine|L-Arginine, 2 Gm four times per day orally;
219342719|NCT01439555|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
219342720|NCT00134264|DRUG|torcetrapib/atorvastatin|
219342721|NCT00134264|DRUG|atorvastatin|
219342722|NCT04326712|OTHER|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
219342723|NCT04326712|OTHER|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
219342724|NCT06369103|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
219342725|NCT06369103|DRUG|Propofol|Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
219342726|NCT00777777|DEVICE|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
219342727|NCT00553709|DRUG|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
219342728|NCT01246583|DRUG|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
219342729|NCT01246583|DRUG|Vehicle 1|Vehicle 1 twice daily for 4 weeks
219342730|NCT01246583|DRUG|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
219342731|NCT01246583|DRUG|Vehicle 2|Vehicle 2 twice daily for 4 weeks
219342732|NCT06977178|BEHAVIORAL|Trier Social Stress Test|Psychosocial stress procedure; 5 minutes of public speaking (preceded by 5 minutes of preparation) and 5 minutes of mental arithmetic.
219342733|NCT06977698|DIAGNOSTIC_TEST|OCT-Raman|a machine to detect positive margins in lumpectomy specimens
219342734|NCT04609709|OTHER|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
219342735|NCT04609709|OTHER|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
219342736|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
219342737|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
219342738|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
219342739|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
219342740|NCT04943575|DIETARY_SUPPLEMENT|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
219342741|NCT03194386|OTHER|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
219342742|NCT03194386|OTHER|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
219342743|NCT06978868|OTHER|Sauna Intervention in Clinically Stable Outpatients with HFpEF|Patients were accompanied by study physicians for two sessions weekly, each between 8-15 minutes. We started the first 2 weeks with 8 minutes. Week 3-4: 10 minutes, week 5-6: 12 minutes, week 7-10: 12-15 minutes. Patients were given the freedom to leave the sauna session at any time if they experienced discomfort or were unable to tolerate it. Sessions were done in groups of 5 patients of men or women. The temperature of the sauna was 60°C. After each session, patients were asked to shower with moderate temperature of water and then rest for 20 minutes. Blood pressure and heart rate were measured prior to each session as well as directly after the sauna session and at the end of the rest time.
219342744|NCT06978361|PROCEDURE|Microneedling with autologous Platelet Rich Plasma|Patients in group A will undergo Microneedling with autologous PRP
219342745|NCT06978361|PROCEDURE|Microneedling with topical insulin|Patients in group B will undergo Microneedling with Topical insulin ( regular).
219342746|NCT06979310|OTHER|text-based education messages only|Participants will receive text-based education messages
219342747|NCT06979310|OTHER|in-clinic tablet-based multimedia education|Participants will receive tablet-based multimedia education in clinic
219342748|NCT06979310|OTHER|standard of care provider led education|Participants will receive standard of care education from their provider
219342749|NCT06978400|DRUG|mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy|Dabrafenib 150 mg twice orally daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks, Сalcium folinate 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks.
219342750|NCT06977373|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer|The CT scan is part of the standard treatment protocol.
219342751|NCT03401515|DRUG|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
219342752|NCT03401515|OTHER|Normal saline|Normal Saline 1 ml every 6 hrs
219342753|NCT06978725|DRUG|Oral Brepocitinib|Drug: Oral Brepocitinib
219342754|NCT06978725|DRUG|Oral Placebo|Drug: Oral Placebo
219342755|NCT06984172|PROCEDURE|Remote cardiac rehabilitation|"The patient, following heart valve surgery, is undergoing home-based cardiovascular rehabilitation during the late recovery phase. The rehabilitation is remotely supervised by a therapist through the Open TeleRehab software and includes aerobic exercises, breathing exercises, and lower limb resistance training.~* Aerobic exercise: Performed 3 times per week, each session lasting 20-40 minutes. Activities include walking, stair climbing, or cycling. Exercise intensity is determined based on:~  1. Target heart rate: Set at the anaerobic threshold identified through Cardiopulmonary Exercise Testing (CPET) prior to hospital discharge; heart rate is monitored using a handheld pulse oximeter.~ 2. Borg Rating of Perceived Exertion (RPE) scale for dyspnea: maintained at 12-13 out of 20.~* Lower limb resistance training: Performed 3 times per week, each session lasting 30-40 minutes. Intensity is based on the one-repetition maximum (1RM).~* Breathing exercises: Performed 3 times per week"
219342756|NCT06984172|PROCEDURE|Facility-based cardiac rehabilitation|"After completing inpatient rehabilitation, patients are discharged and continue supervised outpatient rehabilitation three times per week. The program includes aerobic exercise, lower limb resistance training, and breathing exercises.~Aerobic exercise: Each session lasts 20-40 minutes, depending on the patient's condition, and is performed using a Cardiopulmonary Exercise Testing (CPET) device. Exercise intensity is determined based on the target heart rate and the Borg Rating of Perceived Exertion (RPE) scale for dyspnea and fatigue, in accordance with the 2021 guidelines of the Japanese Circulation Society.~Lower limb resistance training: Each session lasts 30-40 minutes.~Breathing exercises: Each session lasts 15-20 minutes"
219342757|NCT02589496|DRUG|pembrolizumab|200 mg every 3 weeks
219342758|NCT05791500|BEHAVIORAL|lifestyle intervention|dietary behavior interventions:through a couple of dietary health education lectures physical activity interventions:through at least an offline teaching and jump rope or jog regularly and quantitatively life schedule and habits intervention group: live in a regular and healthy life habit and last at least 4 months
219342759|NCT02193399|OTHER|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
219342760|NCT01127685|DEVICE|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
219342761|NCT00870051|DEVICE|Endurant Stent Graft|Endurant Stent Graft implantation
219342762|NCT04128488|OTHER|Abdominal MR Imaging|Imaging to evaluate visceral adipose tissue and hepatic lipid content
219342763|NCT04128488|OTHER|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
219342764|NCT04128488|OTHER|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
219342765|NCT04128488|OTHER|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
219342766|NCT06586528|OTHER|NGAGE tool|Access to NGAGE tool
219342767|NCT05376475|DEVICE|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
219342768|NCT05376475|DEVICE|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
219342769|NCT05376475|DEVICE|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
219342770|NCT05376475|DEVICE|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
219342771|NCT00139945|DRUG|Human acylated ghrelin|5 pmol/kg body weight per min
219342772|NCT00102960|DRUG|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
219342773|NCT00102960|DRUG|Didanosine|Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
219342774|NCT00102960|DRUG|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
219342775|NCT00102960|DRUG|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
219342776|NCT00102960|DRUG|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
219342777|NCT00102960|DRUG|Nevirapine|Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
219342778|NCT00102960|DRUG|Zidovudine|First Line Regimen: 240 mg/m\^2 taken orally twice daily
219342779|NCT05904977|PROCEDURE|Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)|The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
219342780|NCT02017353|DIETARY_SUPPLEMENT|Curcuphyt|
219342781|NCT06494670|OTHER|No intervention|This study was a cross-sectional study with no intervention for participants
219342782|NCT06214247|DEVICE|Wedge NC Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
219342783|NCT06214247|DEVICE|Scoreflex Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
219342784|NCT07028112|OTHER|Cohort|Participants undergo one routine visit blood draw and non invasive liver stiffness measurement. Retrospective data are abstracted from medical records.
219342785|NCT05307939|DIAGNOSTIC_TEST|HPV ctDNA Assay|HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
219342786|NCT05307939|DIAGNOSTIC_TEST|MRI Studies|Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
219342787|NCT05307939|BEHAVIORAL|EORTC QLQ H&N 35 and C30|The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
219342788|NCT05307939|BEHAVIORAL|MDADI-HN|The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
219342789|NCT05307939|BEHAVIORAL|COST-FACIT|Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
219342790|NCT05307939|RADIATION|Intensity-Modulated Radiation Therapy (Arm A)|59.4-60 Gy in 1.8-2 Gy fractions: CTV\_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
219342791|NCT05307939|COMBINATION_PRODUCT|Chemoradiation (Arm B)|30 Gy in 2 Gy fractions: CTV\_primary, CTV\_node-positive neck, CTV\_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
219342792|NCT06666621|DRUG|Normal saline infusion|"After assessment of response to lumbar medial branch block, 8 ml normal saline will be infused through IV over several minutes. 10 minutes will pass, and response to lumbar medial branch block procedure will be re-assessed.~After this step, naloxone infusion will occur (see next intervention)"
219342793|NCT06666621|DRUG|Naloxone infusion|After infusion of normal saline and re-assessment of response to lumbar medial branch block procedure, 8 milligrams of naloxone will be infused over several minutes. Then after 10 minutes, response to lumbar medial branch block procedure will be re-reassessed for the final time.
219342794|NCT05406063|RADIATION|SBRT|Stereotactic multiple fraction radiotherapy
219342795|NCT04218201|BEHAVIORAL|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
219342796|NCT04218201|BEHAVIORAL|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
219342797|NCT04218201|BEHAVIORAL|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
219342798|NCT04218201|BEHAVIORAL|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
219342799|NCT03631836|DRUG|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
219342800|NCT03631836|DRUG|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
219342801|NCT03631836|BIOLOGICAL|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
219342802|NCT03631836|DEVICE|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
219342803|NCT00218491|DRUG|N-Acetylcysteine|1200mg N-Acetylcysteine
219342804|NCT00218491|DRUG|N-Acetylcysteine|2400mg N-Acetylcysteine
219342805|NCT00218491|DRUG|Matching Placebo|Matching Placebo
219342806|NCT02562924|DEVICE|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
219342807|NCT02562924|DRUG|Budesonide|Topical steroid
219342808|NCT02562924|DRUG|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
219342809|NCT02562924|DRUG|Prednisone|Post-operatively, 40 mg daily for 7 days
219342810|NCT02562924|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
219342811|NCT02562924|DRUG|nasal saline spray|saline nasal mist every hour while awake
219342812|NCT01553630|PROCEDURE|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
219342813|NCT01553630|PROCEDURE|Surgery without bone graft|Plating of fracture without bone graft
219342814|NCT04523077|DIAGNOSTIC_TEST|determination of thyroid hormones and antibodies|TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
219342815|NCT01834092|OTHER|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
219342816|NCT00633659|DRUG|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
219342817|NCT00633659|DRUG|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
219342818|NCT01579188|DRUG|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
219342819|NCT01579188|DRUG|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
219342820|NCT01317342|DEVICE|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
219342821|NCT01860924|BEHAVIORAL|exercise|vigorous intensity exercise
219342822|NCT01860924|BEHAVIORAL|health education|education
219342823|NCT05266235|DEVICE|Validation of the Withings bodyscan scale WBS08|Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
219342824|NCT03189875|OTHER|Standard of Care|Participants will be followed as per local routine clinical practice
219342825|NCT00991523|DIETARY_SUPPLEMENT|protein|protein
219342826|NCT00991523|DIETARY_SUPPLEMENT|placebo|placebo control
219342827|NCT00127907|DRUG|epinephrine (1 mg/1 mL)|
219342828|NCT00127907|DRUG|arginine-vasopressin (40 UI/2 mL)|
219342829|NCT01221064|PROCEDURE|Early drainage removal|Drainage will be removed in postoperative day 1
219342830|NCT01221064|PROCEDURE|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
219342831|NCT02019407|PROCEDURE|PVI, CTI block|"* PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
219342832|NCT02019407|PROCEDURE|PVI|PVI (pulmonary isolation)
219342833|NCT00412750|DRUG|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
219342834|NCT00412750|DRUG|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
219342835|NCT01526512|DRUG|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
219342836|NCT02611154|DRUG|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
219342837|NCT00089908|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
219342838|NCT00089908|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
219342839|NCT04711772|OTHER|whole-genome sequencing|Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
219342840|NCT01243710|DEVICE|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
219342841|NCT05208151|OTHER|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
219342842|NCT01490658|DRUG|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
219342843|NCT01490658|DRUG|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
219342844|NCT01490658|DRUG|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
219342845|NCT00848861|DRUG|propofol (sedation for outpatient colonoscopy)|
219342846|NCT00848861|DRUG|midazolam plus meperidine (sedation for outpatient colonoscopy)|
219342847|NCT03031275|RADIATION|High-resolution computed tomography|HRCT of the thorax
219342848|NCT03031275|RADIATION|Magnetic resonance imaging|MRI of the brain
219342849|NCT03031275|BEHAVIORAL|Cognitive testing|Neuropsychological testing
219342850|NCT05120479|PROCEDURE|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
219342851|NCT05120479|PROCEDURE|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
219342852|NCT04135430|OTHER|Survey|practice of an updated questionnaire at D0, D2 and D7
219342853|NCT03139812|DRUG|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
219342854|NCT03139812|DEVICE|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
219342855|NCT00896675|OTHER|proteomic profiles|blood samples analysis
219342856|NCT00896675|OTHER|proteomic profiles|blood samples analysis
219342857|NCT06042400|BEHAVIORAL|Written Exposure Therapy|An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
219342858|NCT05069246|OTHER|Nigella Sativa oil|5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
219342859|NCT05069246|DRUG|Chlorhexidine mouthwash|10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
219342860|NCT05957289|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
219342861|NCT04019132|DIAGNOSTIC_TEST|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
219342862|NCT06297746|PROCEDURE|Subvastus approach|Subvastus approach
219342863|NCT06297746|PROCEDURE|Medial Parapatellar approach|Medial Parapatellar approach
219342864|NCT04479163|BIOLOGICAL|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
219342865|NCT04479163|OTHER|Placebo|Normal Saline 0.9%
219342866|NCT02887391|OTHER|No intervention - observational study|No intervention - observational study
219342867|NCT06194890|OTHER|Distraction technique with comedy video|Women in the intervention group will watch an average of 6 minutes of comedy videos during the active phase, transition phase and latent phase of labor.
219342868|NCT06090942|OTHER|Smartphone-based cognitive training|Smartphone-based cognitive training
219342869|NCT04176263|BEHAVIORAL|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
219342870|NCT04176263|BEHAVIORAL|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
219342871|NCT00716105|OTHER|Standard infant formula|From 3 to 12 months of age. As per standard requirement
219342872|NCT00716105|OTHER|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
219342873|NCT03724565|PROCEDURE|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
219342874|NCT05660720|DRUG|Orelabrutinib and placebo (orelabrutinib tablet simulator)|Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
219342875|NCT05660720|DRUG|Orelabrutinib|Orelabrutinib will be administered as 8 tablets (400mg)
219342876|NCT05660720|DRUG|Placebo (orelabrutinib tablet simulator)|Placebo will be administered as 8 tablets (400mg).
219342877|NCT05660720|DRUG|Moxifloxacin hydrochloride|Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
219342878|NCT01725555|DRUG|Fasted treatment: AXL1717|
219342879|NCT01725555|DRUG|Fed treatment: AXL1717|
219342880|NCT01135498|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
219342881|NCT01135498|DRUG|eloxatin|Intravenous repeating dose
219342882|NCT01135498|DRUG|capecitabine [Xeloda]|Oral repeating dose
219342883|NCT01135498|DRUG|erlotinib [Tarceva]|Oral repeating dose
219342884|NCT04734912|OTHER|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
219342885|NCT02104583|DRUG|Eleclazine|Eleclazine tablets administered orally
219342886|NCT02104583|DRUG|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
219342887|NCT01726751|DEVICE|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
219342888|NCT01726751|DEVICE|Spinal cord nerve stimulation|
219342889|NCT01908647|BEHAVIORAL|RT fMRI|Real-time fMRI with neurofeedback.
219342890|NCT01908647|BEHAVIORAL|Cognitive Training|Computer based attention training.
219342891|NCT01908647|BEHAVIORAL|Control RT fMRI|Control condition for real-time fMRI.
219342892|NCT01908647|BEHAVIORAL|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
219342893|NCT02326870|DEVICE|AutoLap|
219342894|NCT03726645|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation
219342895|NCT00236015|DRUG|Gabitril|
219342896|NCT05265403|DRUG|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
219342897|NCT05265403|DEVICE|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
219342898|NCT02471547|OTHER|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
219342899|NCT01385020|DRUG|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
219342900|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
219342901|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
219342902|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
219342903|NCT03095742|DIAGNOSTIC_TEST|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
219342904|NCT03095742|DIAGNOSTIC_TEST|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
219342905|NCT01351389|BEHAVIORAL|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
219342906|NCT01351389|BEHAVIORAL|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
219342907|NCT04136873|DRUG|CVL-231|CVL-231
219342908|NCT04136873|DRUG|Matching Placebo|Placebo matching CVL-231
219342909|NCT06490458|COMBINATION_PRODUCT|Balance Training|Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.
219342910|NCT03539744|DRUG|Pomalidomide|capsule, oral
219342911|NCT03539744|DRUG|Dexamethasone|oral, locally available form
219342912|NCT03539744|DRUG|Venetoclax|tablet; oral
219342913|NCT06312748|DRUG|L-Citrulline|100 mg tablet
219342914|NCT06312748|DRUG|Placebo for L-Citrulline|L-Citrulline-matched Placebo tablet
219342915|NCT06312748|DRUG|BH4|10mg/kg
219342916|NCT06312748|DRUG|Placebo for BH4|BH4-matched Placebo
219342917|NCT06312748|DRUG|Atorvastatin|10 mg tablet
219342918|NCT06312748|DRUG|Placebo for Atorvastatin|Atorvastatin-matched Placebo
219342919|NCT01160757|DEVICE|ultrasound|ultrasound exposure on acute acne lesions
219342920|NCT05950087|OTHER|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy
219342921|NCT05735691|PROCEDURE|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
219342922|NCT05735691|PROCEDURE|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
219342923|NCT05735691|PROCEDURE|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
219342924|NCT04577950|PROCEDURE|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
219342925|NCT03113240|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
219342926|NCT03113240|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
219342927|NCT02799407|OTHER|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
219342928|NCT06153251|DRUG|BMS-986453|Specified dose on specified days
219342929|NCT06153251|DRUG|Fludarabine|Specified dose on specified days
219342930|NCT06153251|DRUG|Cyclophosphamide|Specified dose on specified days
219342931|NCT02693561|BEHAVIORAL|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
219342932|NCT02693561|BEHAVIORAL|Self-Help Book|Reading the self-help book.
219342933|NCT02185950|DEVICE|ultrasound|
219342934|NCT02185950|DEVICE|paraffin|
219342935|NCT02185950|DEVICE|endermotherapy|
219342936|NCT03784547|DRUG|Ocrelizumab|already described
219342937|NCT00933075|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
219342938|NCT04474769|OTHER|Educational intervention for preceptors|
219342939|NCT03487575|BEHAVIORAL|Open trial|Integrated electronic support and care support manager contact
219342940|NCT03024489|DRUG|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
219342941|NCT03024489|DRUG|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
219342942|NCT03024489|DRUG|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
219342943|NCT03024489|DRUG|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
219342944|NCT03024489|DRUG|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
219342945|NCT03024489|RADIATION|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
219342946|NCT00252343|DRUG|SR58611A|
219342947|NCT02239276|DRUG|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
219342948|NCT06113900|DRUG|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
219342949|NCT02646982|DRUG|Placebo|A matched placebo will be given once daily for 12 months.
219342950|NCT02646982|DRUG|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
219342951|NCT00750958|PROCEDURE|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
219342952|NCT01077843|DRUG|Etoricoxib|Cox-2 inhibitor
219342953|NCT01077843|DRUG|Other Cox-2 inhibitors|Cox-2 inhibitor
219342954|NCT01077843|DRUG|Other Non-selective NSAIDs|Non-selective NSAID
219342955|NCT01077843|OTHER|No anti-inflammatory treatment|No anti-inflammatory prescription
219342956|NCT00713700|DEVICE|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
219342957|NCT00527579|DRUG|[F-18]FBR|
219342958|NCT01251809|DRUG|Oncaspar|2000 U/m2 BSA, single infusion
219342959|NCT01251809|DRUG|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
219342960|NCT00528762|BEHAVIORAL|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
219342961|NCT05336071|DRUG|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
219342962|NCT05336071|DRUG|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
219342963|NCT05231148|PROCEDURE|local debridement and local calcium sulfate loaded by antibiotics|debridement of infected non united fractures and placement of local calcium sulfate loaded by antibiotic then follow up at regular intervals
219342964|NCT06076577|BEHAVIORAL|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
219342965|NCT01464476|DRUG|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
219342966|NCT01464476|DRUG|Placebo|Dose-matched placebo. Once daily, oral administration
219342967|NCT05453331|PROCEDURE|bilateral STN deep brain stimulation|bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
219342968|NCT05580029|DEVICE|Triamcinolone Topical|The treatments will consist of fractional ablative CO2 laser therapies followed by topical application of triamcinolone dosed at 40 mg/ml.
219342969|NCT05580029|PROCEDURE|Fractional Ablative CO2 Therapy|1st pass: 30-40 mJ at 5% density. 2nd pass: 120 mJ at 1% density
219342970|NCT05580029|DRUG|EMLA 5% cream|2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
219342971|NCT02518009|OTHER|Genetic men treated with estrogen|Observational during estrogen treatment
219342972|NCT02518009|OTHER|Genetic women treated with androgen|Observational during androgen treatment
219342973|NCT06137274|RADIATION|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
219342974|NCT06137274|OTHER|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
219342975|NCT00253175|DRUG|topiramate|
219342976|NCT05942027|DRUG|Placebo|Placebo match Coenzyme Q10 capsules once per day .
219342977|NCT05942027|DRUG|Co-Enzyme Q10|Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
219342978|NCT01337856|OTHER|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
219342979|NCT04697459|OTHER|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
219342980|NCT04697459|OTHER|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
219342981|NCT06087653|DRUG|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
219342982|NCT06087653|DRUG|Lenalidomide 25 MG Oral Capsule|Oral lenalidomide for active control
219342983|NCT03966742|PROCEDURE|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
219342984|NCT05001321|RADIATION|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
219342985|NCT05001321|OTHER|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
219342986|NCT02874807|DRUG|Empagliflozin|
219342987|NCT02874807|OTHER|Placebo|
219342988|NCT05815589|OTHER|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
219342989|NCT02340585|DEVICE|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
219342990|NCT01563770|DIETARY_SUPPLEMENT|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
219342991|NCT01563770|DIETARY_SUPPLEMENT|Placebo|3 placebo capsules, twice daily for four consecutive weeks
219342992|NCT03923426|OTHER|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
219342993|NCT04543071|DRUG|Motixafortide|1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
219342994|NCT04543071|DRUG|Cemiplimab|350 mg intravenous (IV) once every 21 days
219342995|NCT04543071|DRUG|Gemcitabine|1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
219342996|NCT04543071|DRUG|Nab paclitaxel|125 mg/m2 IV on days 1, 8, 14 (every 28 days)
219342997|NCT00769002|BIOLOGICAL|FluShield|Flu vaccine
219342998|NCT00769002|BIOLOGICAL|FluShield - same arm|Flu vaccine
219342999|NCT00769002|BIOLOGICAL|FluShield - opposite arm|Flu vaccine
219343000|NCT00769002|PROCEDURE|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
219343001|NCT00769002|PROCEDURE|FDG PET-CT Scan|PET scan
219343002|NCT00769002|GENETIC|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
219343003|NCT02316535|DRUG|Capecitabine|adjuvant chemotherapy;
219343004|NCT03381235|OTHER|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
219343005|NCT04697875|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219343006|NCT04697875|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
219343007|NCT04456179|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
219343008|NCT04456179|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
219343009|NCT03623607|OTHER|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
219343010|NCT04983407|DRUG|batiraxcept|Batiraxcept is experimental drug
219343011|NCT04983407|DRUG|Nab paclitaxel|Nab paclitaxel is active comparator
219343012|NCT04983407|DRUG|Gemcitabine|Gemcitabine is active comparator
219343013|NCT05779462|OTHER|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
219343014|NCT00971451|OTHER|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
219343015|NCT00971451|OTHER|TENS|continuous use of TENS during the exercise session
219343016|NCT05298007|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
219343017|NCT05298007|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219343018|NCT05059314|OTHER|Brisk walking (moderate physical activity)|"1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6"
219343019|NCT04291950|PROCEDURE|Needle core biopsy|"Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab."
219343020|NCT00952497|DRUG|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
219343021|NCT02965495|DRUG|YYD302 2ml|YYD302 2ml
219343022|NCT02965495|DRUG|YYD302 3ml|YYD302 3ml
219343023|NCT02965495|DRUG|Placebo 3ml|phosphate buffered saline 3ml
219343024|NCT05666427|BEHAVIORAL|Pelvic floor muscle training combined with stabilization exercises|While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
219343025|NCT05666427|BEHAVIORAL|Pelvic floor muscle training|Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
219343026|NCT00556452|DRUG|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
219343027|NCT00556452|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
219343028|NCT00556452|RADIATION|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
219343029|NCT02005809|PROCEDURE|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
219343030|NCT05389163|DEVICE|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
219343031|NCT05389163|DEVICE|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
219343032|NCT02442973|PROCEDURE|Control group (CG): standard practice|Standard practice group
219343033|NCT02442973|PROCEDURE|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
219343034|NCT02442973|DEVICE|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
219343035|NCT05455853|OTHER|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
219343036|NCT04423809|OTHER|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
219343037|NCT01836432|DRUG|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
219343038|NCT01836432|BIOLOGICAL|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
219343039|NCT01836432|RADIATION|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
219343040|NCT01836432|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
219343041|NCT01836432|DRUG|Capecitabine|Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
219343042|NCT01836432|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
219343043|NCT03951623|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
219343044|NCT03951623|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
219343045|NCT02554123|DRUG|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
219343046|NCT02554123|DRUG|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
219343047|NCT01143753|DRUG|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
219343048|NCT04091529|DEVICE|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
219343049|NCT01981590|DEVICE|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
219343050|NCT06077266|OTHER|Change of weight class to normal weight|The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
219343051|NCT04309240|DRUG|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
219343052|NCT00421668|DRUG|Zinc|zinc
219343053|NCT00421668|DRUG|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
219343054|NCT00421668|DRUG|Placebo|Placebo
219343055|NCT05396742|DRUG|Ravulizumab|Solution for infusion or injection, as applicable
219343056|NCT05396742|DRUG|rHuPH20|Solution for infusion
219343057|NCT05917574|OTHER|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
219343058|NCT00847912|DRUG|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
219343059|NCT00847912|DRUG|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
219343060|NCT03306732|DRUG|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
219343061|NCT03306732|DRUG|Normal saline (100ml)|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
219343062|NCT06149234|BEHAVIORAL|Fruit leather on the tongue|The patient holds a fruit leather strip on the tongue while being exposed.
219343063|NCT06149234|BEHAVIORAL|Chewing gum strip|The patient holds a banana-tasting gum strip on the tongue while being exposed.
219343064|NCT06149234|BEHAVIORAL|Celluloid matrix group|The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
219343065|NCT00117468|DRUG|DR-2011|Administered vaginally from Day 14 to Day 31
219343066|NCT00117468|DRUG|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
219343067|NCT05251402|BEHAVIORAL|Group A - Patient Education|"If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice."
219343068|NCT05251402|BEHAVIORAL|Group B - Patient Education with Nutrition Counseling|"If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term."
219343069|NCT03646851|DIAGNOSTIC_TEST|Questionnaries|patients will have to do a sputum and to complete some questionnaries
219343070|NCT06544161|DEVICE|CPMX2|The CPMX2 is a point-of-care device for non-invasive, real-time, and intermittent monitoring of vascular occlusion pressure.
219343071|NCT01838109|DIETARY_SUPPLEMENT|oral nutritional supplement|
219343072|NCT03969849|DRUG|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
219343073|NCT03969849|DRUG|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
219343074|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
219343075|NCT01732796|DRUG|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
219343076|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
219343077|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
219343078|NCT01732796|DRUG|BI 201335 (Faldaprevir)|24 weeks of BI 201335
219343079|NCT01732796|DRUG|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
219343080|NCT01732796|DRUG|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
219343081|NCT01732796|DRUG|Faldaprevir (BI 201335)|24 weeks of 201335
219343082|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
219343083|NCT00630656|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
219343084|NCT00630656|DRUG|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
219343085|NCT02806089|DEVICE|Handheld dynamometer|Evaluation of muscle strength
219343086|NCT02806089|BIOLOGICAL|Creatinine index|Evaluation of muscle mass using plasma creatinine level
219343087|NCT02806089|DEVICE|Electrical bioimpedance analysis|Evaluation of lean body mass
219343088|NCT02806089|OTHER|"Voorrips score questionnaire"|Evaluation of physical activity
219343089|NCT02806089|BIOLOGICAL|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
219343090|NCT01422148|DRUG|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
219343091|NCT01422148|DRUG|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
219343092|NCT05626270|DEVICE|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
219343093|NCT02441049|BEHAVIORAL|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
219343094|NCT03639870|DEVICE|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
219343095|NCT03147716|OTHER|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
219343096|NCT03147716|OTHER|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
219343097|NCT03147716|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
219343098|NCT03147716|OTHER|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
219343099|NCT01023633|DRUG|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
219343100|NCT01089348|DRUG|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
219343101|NCT01089348|DRUG|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
219343102|NCT02376270|DIETARY_SUPPLEMENT|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
219343103|NCT02376270|DIETARY_SUPPLEMENT|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
219343104|NCT05774730|OTHER|Emphysema quantitative analysis software based on chest image AI technology|The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.
219343105|NCT05774730|OTHER|artificial analysis of chest image|The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.
219343106|NCT05774730|PROCEDURE|imported Chartis detection system|The participants would undergo imported Chartis detection system.
219343107|NCT05087550|PROCEDURE|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
219343108|NCT06125769|PROCEDURE|Liver transplantation|Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
219343109|NCT00932347|DRUG|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
219343110|NCT00932347|DRUG|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
219343111|NCT02310776|DEVICE|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
219343112|NCT02310776|DEVICE|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
219343113|NCT03257670|DRUG|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
219343114|NCT03257670|DEVICE|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
219343115|NCT06211894|PROCEDURE|transobturator tape|transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
219343116|NCT05144750|BEHAVIORAL|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
219343117|NCT00117429|BIOLOGICAL|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
219343118|NCT02443896|PROCEDURE|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
219343119|NCT02443896|PROCEDURE|No sealant of permanent molars|No sealant applied to permanent molars.
219343120|NCT01169298|DRUG|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
219343121|NCT01823042|DRUG|azathioprine+enteral nutrition|
219343122|NCT01823042|DRUG|Azathioprine|
219343123|NCT06264895|BEHAVIORAL|Exercise|three times weekly exercise intervention with protein supplementation
219343124|NCT00861068|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
219343125|NCT00861068|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
219343126|NCT04240444|DEVICE|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
219343127|NCT01757678|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
219343128|NCT01757678|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
219343129|NCT01757678|PROCEDURE|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
219343130|NCT01757678|OTHER|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
219343131|NCT03589599|OTHER|Flavored tobacco|Effects of flavored tobacco
219343132|NCT03589599|OTHER|Non-flavored tobacco|Effects of non-flavored tobacco
219343133|NCT05514379|BEHAVIORAL|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
219343134|NCT01487252|BEHAVIORAL|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
219343135|NCT00150657|DRUG|bevacizumab|
219343136|NCT00150657|DRUG|carboplatin|
219343137|NCT00150657|DRUG|gemcitabine|
219343138|NCT06501651|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
219343139|NCT06501651|DRUG|Valsartan|Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
219343140|NCT02767440|BEHAVIORAL|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
219343141|NCT02458963|PROCEDURE|IVF|Women will undergo one IVF cycle
219343142|NCT02458963|DRUG|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
219343143|NCT00234689|DRUG|Naltrexone|
219343144|NCT04431570|DEVICE|rTMS|The device is made in London, United Kingdom
219343145|NCT04431570|DEVICE|sham stimulation|the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
219343146|NCT00838331|BIOLOGICAL|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
219343147|NCT00838331|BIOLOGICAL|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions."
219343148|NCT03096964|OTHER|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
219343149|NCT03096964|OTHER|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
219343150|NCT02641145|RADIATION|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
219343151|NCT02641145|DEVICE|MRI|Cardiac MRI with gadolinium contrast.
219343152|NCT02641145|RADIATION|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
219343153|NCT01314677|PROCEDURE|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
219343154|NCT01314677|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
219343155|NCT04071574|DRUG|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
219343156|NCT04071574|DRUG|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
219343157|NCT04071574|DRUG|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
219343158|NCT04071574|DRUG|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
219343159|NCT04484298|DIAGNOSTIC_TEST|Reference position patient is put in a 30 degree supine position during 5 minutes|Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
219343160|NCT04484298|DIAGNOSTIC_TEST|nitroglucerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
219343161|NCT00576459|DRUG|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
219343162|NCT00576459|DRUG|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
219343163|NCT00576459|PROCEDURE|standard of care laser photocoagulation|standard of care laser photocoagulation
219343164|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice1|Apple Juice1
219343165|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
219343166|NCT03846986|DIETARY_SUPPLEMENT|Raw Apple|Raw Apple
219343167|NCT03972969|BEHAVIORAL|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
219343168|NCT03972969|BEHAVIORAL|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
219343169|NCT03972969|BEHAVIORAL|Health education|Provision of general information about a variety of topics
219343170|NCT01339806|BEHAVIORAL|Cognitive Rehab|APT-III, Other standard individual and group interventions.
219343171|NCT01339806|BEHAVIORAL|Brainworks|POSIT
219343172|NCT01339806|BEHAVIORAL|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
219343173|NCT03326076|DIAGNOSTIC_TEST|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
219343174|NCT03326076|OTHER|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
219343175|NCT03326076|DIAGNOSTIC_TEST|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
219343176|NCT03326076|DIAGNOSTIC_TEST|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
219343177|NCT00732303|DRUG|Pemetrexed|Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
219343178|NCT00732303|RADIATION|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
219343179|NCT01074190|DRUG|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
219343180|NCT01074190|DRUG|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
219343181|NCT01074190|DRUG|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
219343182|NCT00264875|DRUG|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
219343183|NCT02474732|DEVICE|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
219343184|NCT00397813|DRUG|Cyclosporine|Given PO
219343185|NCT00397813|DRUG|Fludarabine Phosphate|Given IV
219343186|NCT00397813|OTHER|Laboratory Biomarker Analysis|Correlative studies
219343187|NCT00397813|DRUG|Mycophenolate Mofetil|Given PO
219343188|NCT00397813|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
219343189|NCT00397813|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
219343190|NCT00397813|RADIATION|Total-Body Irradiation|Undergo TBI
219343191|NCT01614314|OTHER|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
219343192|NCT01614314|OTHER|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
219343193|NCT05882448|PROCEDURE|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
219343194|NCT05882448|PROCEDURE|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
219343195|NCT05632185|BEHAVIORAL|Equine-assisted Therapy|An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
219343196|NCT06460090|BEHAVIORAL|Happy Talk|A targeted selective speech language and communication programme embedded in the community, designed for people livling in social disadvantage.
219343197|NCT03267121|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
219343198|NCT03267121|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
219343199|NCT06330389|PROCEDURE|Burn Injuries Graft Surgery|Burn Injuries Graft Surgery
219343200|NCT03488875|BEHAVIORAL|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
219343201|NCT01974544|DRUG|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
219343202|NCT01974544|PROCEDURE|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
219343203|NCT01974544|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
219343204|NCT01974544|DRUG|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
219343205|NCT01974544|DRUG|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
219343206|NCT01974544|BEHAVIORAL|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
219343207|NCT05862181|PROCEDURE|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
219343208|NCT04568278|OTHER|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
219343209|NCT01674101|OTHER|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
219343210|NCT01674101|OTHER|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
219343211|NCT01674101|OTHER|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
219343212|NCT01674101|OTHER|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
219343213|NCT03600662|OTHER|TriRec|Trileaflet Reconstruction of the Aortic Valve
219343214|NCT03600662|OTHER|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
219343215|NCT04944160|OTHER|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
219343216|NCT04944160|OTHER|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
219343217|NCT02766738|OTHER|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
219343218|NCT02766738|OTHER|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
219343219|NCT01500278|BIOLOGICAL|Certolizumab Pegol (CZP)|"* Active substance: an injectable volume of 1 ml solution for injection CZP~* Pharmaceutical form: prefilled syringes CZP~* Concentration: 200 mg/ml CZP~* Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
219343220|NCT01500278|BIOLOGICAL|Adalimumab (ADA)|"* Active substance: an injectable volume of 0.8 ml solution for injection ADA~* Pharmaceutical form: prefilled syringes ADA~* Concentration: 40 mg/0.8 ml ADA~* Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
219343221|NCT01500278|DRUG|Methotrexate (MTX)|"* Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally"
219343222|NCT05590260|DRUG|IV iron infusion|single-dose IV iron infusion
219343223|NCT05590260|DRUG|Oral iron tablets|60 mg of elemental iron
219343224|NCT02459795|DRUG|Ingenol Mebutate (Perrigo)|
219343225|NCT02459795|DRUG|Ingenol Mebutate (Reference)|
219343226|NCT02459795|DRUG|Placebo gel|
219343227|NCT03362021|PROCEDURE|transvaginal oocyte retrieval|sedation for oocyte retrieval
219343228|NCT02854423|DEVICE|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
219343229|NCT04013035|PROCEDURE|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
219343230|NCT01709435|DRUG|Cabozantinib S-malate|Given PO
219343231|NCT01709435|OTHER|Laboratory Biomarker Analysis|Correlative studies
219343232|NCT01709435|OTHER|Pharmacological Study|Correlative studies
219343233|NCT02981875|OTHER|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
219343234|NCT02981875|OTHER|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
219343235|NCT00730938|DRUG|cefuroxime|intracameral cefuroxime 0.1 ml
219343236|NCT00730938|DRUG|Saline placebo|0.1 ml of Ringers lactate
219343237|NCT04452981|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
219343238|NCT01319695|DRUG|corifollitropin alfa|100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg
219343239|NCT01319695|DRUG|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
219343240|NCT05914909|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
219343241|NCT05914909|OTHER|Placebo|Placebo
219343242|NCT04881825|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
219343243|NCT00951847|DRUG|oxcarbazepine 300 mg/5 mL oral suspension|
219343244|NCT02798536|DRUG|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
219343245|NCT02798536|DRUG|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
219343246|NCT01297270|DRUG|BI201335|QD BI 201335
219343247|NCT01297270|DRUG|PegIFN/RBV|
219343248|NCT01297270|DRUG|BI201335|QD (once daily) BI 201335
219343249|NCT01297270|DRUG|Placebo|
219343250|NCT05468554|DRUG|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
219343251|NCT05468554|RADIATION|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
219343252|NCT01384578|DRUG|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
219343253|NCT01384578|DRUG|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
219343254|NCT02060578|OTHER|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
219343255|NCT04793542|PROCEDURE|lower-limb hot water immersion|For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
219343256|NCT02265770|DRUG|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
219343257|NCT02265770|DRUG|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
219343258|NCT02265770|DRUG|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
219343259|NCT02265770|RADIATION|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
219343260|NCT02265770|DRUG|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
219343261|NCT02265770|DRUG|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
219343262|NCT02265770|RADIATION|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
219343263|NCT01707043|DRUG|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
219343264|NCT00105248|BEHAVIORAL|patient-centered communication training|
219343265|NCT00019188|DRUG|interleukin-12|
219343266|NCT00006507|BEHAVIORAL|Occupational Therapy|
219343267|NCT05043571|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
219343268|NCT02477657|PROCEDURE|Paracentesis|Paracentesis
219343269|NCT02477657|DEVICE|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
219343270|NCT02477657|DEVICE|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
219343271|NCT05709964|OTHER|Self-reported|Self-reported height, weight, and neck circumference
219343272|NCT05709964|OTHER|Measured|Height, weight, and neck circumference measured by the investigator.
219343273|NCT03013673|OTHER|No intervention|No intervention
219343274|NCT03882970|DRUG|Tirzepatide|Administered SC
219343275|NCT03882970|DRUG|Insulin Degludec|Administered SC
219343276|NCT03820648|DEVICE|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
219343277|NCT03820648|DEVICE|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
219343278|NCT03831971|DRUG|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
219343279|NCT02526342|DEVICE|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
219343280|NCT03653273|OTHER|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
219343281|NCT03653273|DRUG|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
219343282|NCT02567253|PROCEDURE|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
219343283|NCT02567253|DRUG|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
219343284|NCT02567253|DRUG|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
219343285|NCT02567253|DRUG|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
219343286|NCT02567253|DRUG|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
219343287|NCT04555824|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
219343288|NCT04555824|OTHER|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
219343289|NCT05358756|DRUG|SACT-1|Single administartion of 150mg SACT-1
219343290|NCT05358756|DRUG|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
219343291|NCT05292105|DEVICE|NC Xperience|Coronary dilatation balloon catheter (non compliant)
219343292|NCT06268743|OTHER|High intensity|High intensity exercise
219343293|NCT06268743|OTHER|Moderate intensity|Moderate intensity exercise
219343294|NCT04861675|PROCEDURE|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
219343295|NCT04707742|DRUG|Betadine© bucal 100 mg/ml|15 ml 2% povidone-iodine, one minute rinse.
219343296|NCT04707742|DRUG|Oximen® 3%|15 ml 1% hydrogen peroxide, one minute rinse.
219343297|NCT04707742|DRUG|Clorhexidine Dental PHB©|15 ml 0,12% clorhexidine, one minute rinse.
219343298|NCT04707742|DRUG|Vitis Xtra Forte©|15 ml 0,07% cetylpyridinium chloride, one minute rinse.
219343299|NCT04707742|DRUG|Distilled Water|15 ml distilled water, one minute rinse.
219343300|NCT05140538|OTHER|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
219343301|NCT05140538|OTHER|SRP + toothpaste|Use of domiciliary products twice a day
219343302|NCT01112046|PROCEDURE|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
219343303|NCT01112046|PROCEDURE|Laparoscopic resection|Surgical treatment performed under general anesthesia
219343304|NCT00522587|DRUG|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
219343305|NCT00522587|DRUG|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
219343306|NCT00522587|DRUG|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
219343307|NCT00522587|DRUG|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
219343308|NCT00522587|DRUG|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
219343309|NCT00522587|DRUG|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
219343310|NCT00522587|DRUG|Fixed remifentanil dose 1|Dose 1 of remifentanil
219343311|NCT00522587|DRUG|Fixed remifentanil dose 2|Dose 2 of remifentanil
219343312|NCT00522587|DRUG|Fixed remifentanil dose 3|Dose 3 of remifentanil
219343313|NCT00522587|DRUG|Fixed remifentanil dose 4|Dose 4 of remifentanil
219343314|NCT00522587|DRUG|Fixed remifentanil dose 5|Dose 5 of remifentanil
219343315|NCT00522587|DRUG|Fixed remifentanil dose 6|Dose 6 of remifentanil
219343316|NCT03183193|OTHER|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
219343317|NCT03183193|OTHER|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
219343318|NCT03540784|OTHER|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
219343319|NCT03540784|OTHER|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
219343320|NCT00634309|DRUG|Candesartan|
219343321|NCT00634309|DRUG|Placebo|
219343322|NCT03643874|DRUG|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
219343323|NCT03643874|DRUG|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
219343324|NCT06489587|DIETARY_SUPPLEMENT|Placebo|Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
219343325|NCT06489587|DIETARY_SUPPLEMENT|Creatine|Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
219343326|NCT03724188|PROCEDURE|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
219343327|NCT02424032|BEHAVIORAL|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
219343328|NCT02424032|BEHAVIORAL|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
219343329|NCT02709564|DRUG|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
219343330|NCT02709564|DRUG|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
219343331|NCT02863809|DRUG|Riboflavin|Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
219343332|NCT02863809|DRUG|Dextran|Dextran is used to increase the viscosity of the solution.
219343333|NCT02863809|DEVICE|UVA Light Source|Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
219343334|NCT05106322|OTHER|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
219343335|NCT02810665|BEHAVIORAL|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
219343336|NCT05429788|DRUG|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
219343337|NCT05429788|DRUG|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
219343338|NCT05429788|DRUG|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
219343339|NCT04558411|BEHAVIORAL|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
219343340|NCT00001990|DRUG|Atovaquone|
219343341|NCT02830776|DRUG|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
219343342|NCT04848558|DRUG|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
219343343|NCT04848558|OTHER|Placebo|Participants will receive IV infusion or SC injection of placebo.
219343344|NCT04804787|DIAGNOSTIC_TEST|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
219343345|NCT02829138|GENETIC|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
219343346|NCT02829138|BEHAVIORAL|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
219343347|NCT05114200|PROCEDURE|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
219343348|NCT04891315|DIAGNOSTIC_TEST|Blood test for soluble VAP-1 (sVAP-1).|\~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
219343349|NCT00362934|DRUG|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
219343350|NCT00362934|DRUG|Atorvastatin|Atorvastatin 10 mg and 20mg
219343351|NCT02319421|OTHER|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
219343352|NCT02411539|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
219343353|NCT02411539|BIOLOGICAL|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
219343354|NCT01486849|DRUG|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
219343355|NCT01486849|DRUG|Placebo|Matching placebo tablets BID for 21 days
219343356|NCT01486849|DRUG|Riluzole 50 MG|
219343357|NCT00524342|DRUG|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
219343358|NCT04481542|DIAGNOSTIC_TEST|MRI|check MRI quality in aorta
219343359|NCT05676359|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
219343360|NCT05676359|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
219343361|NCT05676359|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
219343362|NCT05676359|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
219343363|NCT05676359|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
219343364|NCT05676359|OTHER|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
219343365|NCT05676359|OTHER|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
219343366|NCT05676359|OTHER|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
219343367|NCT02794324|PROCEDURE|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v\_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
219343368|NCT02794324|PROCEDURE|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC\_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC\_DIBH, CT images will be obtained.
219343369|NCT02794324|PROCEDURE|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
219343370|NCT02794324|DEVICE|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
219343371|NCT06294457|DEVICE|Non-Invasive Neuromodulation NESA|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
219343372|NCT04245475|BEHAVIORAL|Virtual Reality psychological pain reduction|attention distraction
219343373|NCT04828395|BIOLOGICAL|Camrelizumab|200mg iv Q3W
219343374|NCT04828395|DRUG|Fluzoparib|150mg bid
219343375|NCT04828395|DRUG|Cisplatin，Pemetrexed|Cisplatin 75mg/m2 IV and Pemetrexed 500mg/m2 IV Q3W (Day 1 of each cycle of cycles 1-3) (non-squamous cell carcinoma only)
219343376|NCT04828395|DRUG|Cisplatin，Etoposide|Cisplatin 50mg/m2 IV (the 1st and 8th days of the 1st cycle and the 2nd cycle; the 8th and 15th days of the 3rd cycle); Etoposide 50mg/m2 IV (the 1st cycle And the 1st to the 5th day of the 2nd cycle; the 8th to the 12th day of the 3rd cycle).
219343377|NCT04828395|DRUG|Carboplatin, Albumin Paclitaxel|Carboplatin AUC=6, Albumin Paclitaxel 100mg/m2 IV; Days 1, 8 and 15 of cycles 1, 2, and 3.
219343378|NCT04828395|RADIATION|Radiotherapy|60 Gy (total 6 weeks)
219343379|NCT06254729|OTHER|Observational study|Our study does not have any exposure factors.
219343380|NCT04474795|BEHAVIORAL|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
219343381|NCT00413426|DRUG|Darifenacin (DAR328)|
219343382|NCT06171321|DRUG|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
219343383|NCT04041284|DRUG|Fremanezumab|Monthly 225 mg subcutaneous
219343384|NCT04041284|DRUG|Placebo|Matching Placebo
219343385|NCT01148199|DEVICE|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
219343386|NCT01148199|DEVICE|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
219343387|NCT01576770|DEVICE|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
219343388|NCT01576770|DRUG|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
219343389|NCT00829907|DRUG|ORM-12741|Single dose as a capsule, oral administration
219343390|NCT00872651|DRUG|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
219343391|NCT00872651|DRUG|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
219343392|NCT01833611|DRUG|Entecavir|entecavir 0.5mg qd
219343393|NCT01833611|DRUG|placebo|placebo qd
219343394|NCT03478111|DRUG|CMAB008|the study drug
219343395|NCT03478111|DRUG|MTX|basic therapy drug
219343396|NCT03478111|DRUG|Remicade|active comparator
219343397|NCT04253275|GENETIC|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
219343398|NCT04253275|DIAGNOSTIC_TEST|MRI without injection|MRI at inclusion for controls
219343399|NCT04030923|DEVICE|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
219343400|NCT04081636|PROCEDURE|Systematic Transrectal biopsy (TR-Bx)|Through the rectum
219343401|NCT04081636|PROCEDURE|Targeted Transrectal biopsy (TR-Bx)|Through the rectum
219343402|NCT04081636|PROCEDURE|Systematic Transperineal biopsy (TP-Bx)|Through the perineal skin
219343403|NCT04081636|PROCEDURE|Targeted Transperineal biopsy (TP-Bx)|Through the perineal skin
219343404|NCT06395831|DIAGNOSTIC_TEST|BREF,ADL,AIS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
219343405|NCT00841594|DRUG|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
219343406|NCT00841594|DRUG|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
219343407|NCT00563186|OTHER|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
219343408|NCT05618821|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
219343409|NCT03812640|DEVICE|Vicryl suture|Corneal suture with Vicryl suture
219343410|NCT03812640|DEVICE|Nylon suture|Corneal suture with Nylon suture
219343411|NCT02776189|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
219343412|NCT02776189|DRUG|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
219343413|NCT02776189|DRUG|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
219343414|NCT03412175|BEHAVIORAL|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
219343415|NCT01661907|PROCEDURE|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
219343416|NCT01661907|PROCEDURE|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
219343417|NCT05561660|DEVICE|PFO device closure|Participants randomized into this group will take PFO device closure.
219343418|NCT05561660|DRUG|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
219343419|NCT00882609|DEVICE|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
219343420|NCT01142102|RADIATION|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
219343421|NCT03620227|OTHER|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
219343422|NCT03620227|DIETARY_SUPPLEMENT|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
219343423|NCT03620227|DIETARY_SUPPLEMENT|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
219343424|NCT02567149|DRUG|Cidofovir|Cidofovir
219343425|NCT00886600|DRUG|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
219343426|NCT00886600|DRUG|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
219343427|NCT00886600|DRUG|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
219343428|NCT00573573|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
219343429|NCT01439204|BIOLOGICAL|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
219343430|NCT01358409|DRUG|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
219343431|NCT00047060|OTHER|A matched peripheral donor stem cells|A matched peripheral donor stem cells
219343432|NCT00047060|DRUG|cyclosporine|cyclosporine
219343433|NCT00047060|DRUG|fludarabine|fludarabine
219343434|NCT00047060|DRUG|Campath|Campath
219343435|NCT01972750|DRUG|Dovitinib|daily oral intake of capsule
219343436|NCT00336973|DRUG|efalizumab|Subcutaneous repeating dose
219343437|NCT03115307|DRUG|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
219343438|NCT04045288|BEHAVIORAL|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
219343439|NCT04045288|BEHAVIORAL|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
219343440|NCT03917823|DEVICE|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
219343441|NCT03917823|DEVICE|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
219343442|NCT03775421|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
219343443|NCT01246440|DRUG|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
219343444|NCT02679898|OTHER|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
219343445|NCT02679898|OTHER|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
219343446|NCT03257007|BEHAVIORAL|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
219343447|NCT04703556|DEVICE|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
219343448|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
219343449|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
219343450|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
219343451|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
219343452|NCT02445807|DRUG|DFD06-Cream|Twice daily topical application for 14 days.
219343453|NCT02445807|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
219343454|NCT04304716|DRUG|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
219343455|NCT01531309|DRUG|AGO178|AGO178 is administered as a sublingual tablet.
219343456|NCT02199938|OTHER|Identification and characterization of molecular markers in musculoskeletal tumors|
219343457|NCT06240832|OTHER|Physical therapy exercise|Endurance, strength and stretching training in Chronic liver disease children
219343458|NCT00094978|DRUG|Depsipeptide|
219343459|NCT00094978|DRUG|Flavopiridol (alvocidib)|
219343460|NCT01455688|DRUG|early HAART|Initiation of HAART within 5 days of ICU admission
219343461|NCT01455688|DRUG|Late HAART|Initiation of HAART after ICU discharge
219343462|NCT02008682|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
219343463|NCT02008682|DRUG|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
219343464|NCT05234606|DRUG|SBT6290|Escalating doses by subcutaneous (SC) injection in 21-day cycles
219343465|NCT05234606|DRUG|SBT6290|Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
219343466|NCT05234606|DRUG|pembrolizumab|200 mg via intravenous (IV) injection in 21-day cycles
219343467|NCT04631146|DRUG|Camrelizumab|PD-1 inhibitors
219343468|NCT04650373|PROCEDURE|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
219343469|NCT03685539|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
219343470|NCT00455013|DRUG|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
219343471|NCT00455013|DRUG|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
219343472|NCT00455013|DRUG|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
219343473|NCT00455013|DRUG|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
219343474|NCT00455013|DRUG|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
219343475|NCT00263029|DRUG|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
219343476|NCT00263029|DRUG|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
219343477|NCT00263029|RADIATION|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
219343478|NCT04901481|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
219343479|NCT00503646|OTHER|communication intervention|
219343480|NCT00503646|OTHER|counseling intervention|
219343481|NCT00503646|OTHER|questionnaire administration|
219343482|NCT00503646|PROCEDURE|psychosocial assessment and care|
219343483|NCT01271283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
219343484|NCT01271283|DRUG|Lenalidomide|Given orally
219343485|NCT03521050|DEVICE|defibrillator lead|observation of long-term performance of defibrillator leads
219343486|NCT02739620|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
219343487|NCT05069883|DRUG|Steroid Drug|In this group Oral steroid medication after Direct Vision Internal Urethrotomy
219343488|NCT05069883|DRUG|No steroid|In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
219343489|NCT03476941|DRUG|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
219343490|NCT03476941|DRUG|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
219343491|NCT03476941|OTHER|Placebo|The placebo group will receive drain irrigation twice/day
219343492|NCT06358222|PROCEDURE|Blood ctDNA + methylation + PET-CT and Postoperative pathology|A highly sensitive tumor-naïve MRD panel of ctDNA will be employed to detect preoperative blood. Some patients will undergo methylation profiling to prospectively establish LNMs-specific ctDNA methylation signatures.
219343493|NCT06358222|PROCEDURE|MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA|A certain number (depending on the Results of Stage 1) of patients requiring invasive mediastinoscopy or EBUS-TBNA, based on the clinical guidelines, will be included for blood ctDNA mutation/methylation profile (or combined PET-CT), and the detection rate of LNMs will be assessed in patients with negative preoperative blood ctDNA mutation/methylation (or combined PET-CT). The accuracy of predicting LNMs will be compared with that of patients with negative or positive preoperative blood ctDNA mutation/methylation (or combined PET-CT).
219343494|NCT06358222|PROCEDURE|Intraoperative lymph node dissection|For patients with negative preoperative blood negative testing (ctDNA mutation/methylation profiles alone or in combination with PET-CT), systematic lymph node sampling/dissection and no lymph node dissection will be grouped and compared. Regular follow-up is performed to investigate the impact on long-term MRD negative duration and prognosis.
219343495|NCT05772754|GENETIC|study of molecular and protein pathways|42 ml peripheral venous blood sample.
219343496|NCT00730964|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
219343497|NCT04568395|OTHER|TCIG|Use a TCIG
219343498|NCT04568395|OTHER|ECIG|Use an ECIG
219343499|NCT04568395|OTHER|sham control|Use a sham control (empty ECIG)
219343500|NCT01561950|DRUG|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
219343501|NCT01561950|DRUG|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
219343502|NCT01561950|DRUG|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
219343503|NCT02860195|OTHER|oral dose of alcohol|
219343504|NCT02860195|DEVICE|alcotest|
219343505|NCT02860195|BIOLOGICAL|blood samples|
219343506|NCT02860195|DEVICE|Transdermal monitor|
219343507|NCT04234165|DEVICE|TURBT|different power sources ( bipolar vs monopolar)
219343508|NCT00754793|DRUG|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
219343509|NCT00754793|DRUG|placebo|inactive comparator; titrated as per protocol over 12 weeks
219343510|NCT05164107|DEVICE|Globe Mapping and Pulsed Field Ablation System (Globe PF System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
219343511|NCT02079857|OTHER|Standard protocol|Subjects will receive a standard treatment
219343512|NCT02079857|OTHER|Individualized protocol|Subjects will receive an individualized treatment
219343513|NCT02079857|OTHER|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
219343514|NCT05563922|COMBINATION_PRODUCT|Total Neoadjuvant Chemoradiotherapy|"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"
219343515|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
219343516|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
219343517|NCT00456105|BEHAVIORAL|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
219343518|NCT00742248|DRUG|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
219343519|NCT00742248|DRUG|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
219343520|NCT00742248|DRUG|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
219343521|NCT04060420|OTHER|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
219343522|NCT02166164|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
219343523|NCT02166164|OTHER|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
219343524|NCT02166164|OTHER|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
219343525|NCT01669161|DEVICE|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
219343526|NCT01669161|OTHER|Rehab Only|Rehabilitation without device implant and VNS
219343527|NCT00018551|DRUG|Folic Acid|
219343528|NCT00318214|DRUG|MRE0094|Gel, 500 mcg/g once each day
219343529|NCT00318214|DRUG|Vehicle gel|Gel administered once per day
219343530|NCT03517891|BEHAVIORAL|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
219343531|NCT02943564|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
219343532|NCT02943564|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
219343533|NCT05775640|BEHAVIORAL|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
219343534|NCT04700839|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
219343535|NCT04700839|DRUG|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
219343536|NCT02461550|DEVICE|Irreversible Electroporation Ablation|
219343537|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
219343538|NCT00063570|DRUG|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
219343539|NCT00063570|DRUG|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
219343540|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
219343541|NCT01943526|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
219343542|NCT01073267|RADIATION|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
219343543|NCT00034710|DRUG|Capsaicin Patch|
219343544|NCT01225731|BIOLOGICAL|tildrakizumab|SC administration of tildrakizumab at assigned dose
219343545|NCT01225731|DRUG|Placebo|SC administration of Placebo
219343546|NCT01367535|DRUG|SC Methylnaltrexone (MNTX)|
219343547|NCT01367535|DRUG|IV Methylnaltrexone (MNTX)|
219343548|NCT01367535|DRUG|Oral Paroxetine|
219343549|NCT01367535|DRUG|SC Placebo|
219343550|NCT00513110|GENETIC|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
219343551|NCT00513110|DRUG|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
219343552|NCT00513110|DRUG|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
219343553|NCT04027699|PROCEDURE|Mini-bolus|"* First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)"
219343554|NCT01567657|DRUG|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
219343555|NCT01567657|DRUG|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
219343556|NCT05080049|DRUG|Erythropoietin|"Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
219343557|NCT05080049|DRUG|Placebo|"In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
219343558|NCT00577642|DRUG|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
219343559|NCT00977236|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
219343560|NCT00977236|DEVICE|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
219343561|NCT04341441|DRUG|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
219343562|NCT04341441|DRUG|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
219343563|NCT04341441|OTHER|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
219343564|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
219343565|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
219343566|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
219343567|NCT04341441|OTHER|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 \&7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
219343568|NCT05219942|DRUG|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
219343569|NCT05219942|OTHER|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
219343570|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
219343571|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
219343572|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
219343573|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
219343574|NCT03300999|DIETARY_SUPPLEMENT|ginger tea|"1\. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
219343575|NCT00185952|DRUG|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
219343576|NCT05913570|DRUG|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
219343577|NCT06017570|DIAGNOSTIC_TEST|Radiologic examination on orthopantomogram|Caries examination on the distal side of the adjacent second molar in the orthopantomogram of patients with an appointment for the extraction of mesioangular or horizontal partially impacted third molars
219343578|NCT06017570|DIAGNOSTIC_TEST|Clinical examination after surgery|İnspectional caries examination on the distal side of the adjacent second molar after surgery of patients with mesioangular or horizontal partially impacted third molars
219343579|NCT05873582|DEVICE|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
219343580|NCT01587911|OTHER|Whey|Preload containing complete whey protein.
219343581|NCT01587911|OTHER|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
219343582|NCT01587911|OTHER|Control|Preload control matched for energy to the other 5 preloads.
219343583|NCT01587911|OTHER|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
219343584|NCT01587911|OTHER|MPI|Preload containing whole milk protein.
219343585|NCT01587911|OTHER|CPI|Preload containing sodium caseinate.
219343586|NCT05123833|PROCEDURE|Hypospadias repair|surgical repair of hypospadias
219343587|NCT00001545|DEVICE|Magstim Super Rapid Magnetic Stimulator|
219343588|NCT00001545|DEVICE|Cadwell MES-10|
219343589|NCT00554502|DRUG|supportive therapy with: ACE-inhibitor / ARB / Statin|"* Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
219343590|NCT00554502|DRUG|supportive and immunosuppressive therapy|"* supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice"
219343591|NCT03737383|BEHAVIORAL|Narrative Exposure Therapy|brief, trauma-focused treatment.
219343592|NCT03184961|DIAGNOSTIC_TEST|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
219343593|NCT06427200|DRUG|oral Iron|oral iron once daily during or after meals as add-on therapy for 12 weeks.
219343594|NCT06427200|DRUG|Lactoferrin|lactoferrin twice daily before meals as add-on therapy for 12 weeks.
219343595|NCT06427200|DRUG|lactoferrin and oral iron|lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
219343596|NCT01102647|DIETARY_SUPPLEMENT|phytosterol ester|1.6 g phytosterols/day for 29 days
219343597|NCT04973475|DRUG|Indocyanine Green|Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer
219343598|NCT01747642|DIETARY_SUPPLEMENT|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
219343599|NCT01747642|DRUG|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
219343600|NCT01535456|PROCEDURE|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
219343601|NCT05520697|BEHAVIORAL|Nutritional intervention|Nutritional treatment with caloric restriction.
219343602|NCT05520697|BEHAVIORAL|Mental exercise.|Mental exercise.
219343603|NCT05520697|BEHAVIORAL|Physical training.|Exercise.
219343604|NCT03891264|DRUG|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
219343605|NCT04597736|BIOLOGICAL|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
219343606|NCT06210750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219343607|NCT06210750|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219343608|NCT06210750|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219343609|NCT06210750|DRUG|Calaspargase Pegol|Given IV
219343610|NCT06210750|PROCEDURE|Computed Tomography|Undergo CT
219343611|NCT06210750|DRUG|Cyclophosphamide|Given IV
219343612|NCT06210750|DRUG|Cytarabine|Given IT, IV or SC
219343613|NCT06210750|DRUG|Daunorubicin|Given IV
219343614|NCT06210750|DRUG|Dexamethasone|Given PO
219343615|NCT06210750|DRUG|Doxorubicin|Given IV
219343616|NCT06210750|PROCEDURE|Echocardiography|Undergo echocardiography
219343617|NCT06210750|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
219343618|NCT06210750|DRUG|Mercaptopurine|Given PO
219343619|NCT06210750|DRUG|Methotrexate|Given IT
219343620|NCT06210750|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219343621|NCT06210750|BIOLOGICAL|Navitoclax|Given PO
219343622|NCT06210750|DRUG|Nelarabine|Given IV
219343623|NCT06210750|DRUG|Pegaspargase|Given IV
219343624|NCT06210750|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219343625|NCT06210750|DRUG|Thioguanine|Given PO
219343626|NCT06210750|DRUG|Venetoclax|Given PO
219343627|NCT06210750|DRUG|Vincristine|Given IV
219343628|NCT06210750|PROCEDURE|X-Ray Imaging|Undergo X-ray
219343629|NCT01112540|DRUG|Morphine|0.1 mg/kg Intravenous bolus
219343630|NCT05105464|DRUG|SYHA1815|Subjects will receive SYHA1815 orally.
219343631|NCT02308982|DRUG|Immunoglobulins, Intravenous (Privigen)|
219343632|NCT02308982|DRUG|Placebo|
219343633|NCT01806363|DRUG|Telmisartan 80mg|
219343634|NCT01806363|DRUG|Chlorthalidone 25mg|
219343635|NCT00036075|DRUG|CP-461|
219343636|NCT04808570|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
219343637|NCT00000299|DRUG|Buprenorphine|
219343638|NCT00002375|DRUG|Indinavir sulfate|
219343639|NCT00002375|DRUG|Nelfinavir mesylate|
219343640|NCT06926010|OTHER|predictive approach to hemodynamic management|vasoactive drugs and fluids will be given based on the hypotension prediction index
219343641|NCT06894433|PROCEDURE|neuroendoscopic surgery|Subjects will receive Neuroendoscopic Surgery followed by standard medical management
219343642|NCT06894433|PROCEDURE|craniotomy|Subjects will receive Craniotomy followed by standard medical management
219343643|NCT03748446|DRUG|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
219343644|NCT03748446|DRUG|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
219343645|NCT02209077|DEVICE|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
219343646|NCT00910793|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
219343647|NCT02821871|DRUG|SP2086|
219343648|NCT02821871|DIETARY_SUPPLEMENT|high fat diet|
219343649|NCT05982405|OTHER|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
219343650|NCT05982405|OTHER|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
219343651|NCT06766916|DRUG|Crisugabalin|"Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
219343652|NCT06766916|DRUG|Pregabalin|"Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
219343653|NCT06938607|DEVICE|Drain|Participants assigned to the drain group will have a surgical drain placed on the surface of the wound during closure. The drain will be removed within 24 hours.
219343654|NCT06938763|DRUG|J4|dry powder capsule
219343655|NCT06938763|DRUG|Placebo|Placebo dry powder capsule
219343656|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
219343657|NCT06944041|OTHER|STO3 sensor (Structure Inc., Boulder, CO)|The advent of Apple iPad based 3D scanner opens a new avenue for measuring limb volume. The latest ambient light scanner model was utilized for the current study. 3D scanning technology has gained broad industrial use, including the manufacturing of high-precision tools. A commercially available software package was used for limb volumetry.
219343658|NCT03087630|BEHAVIORAL|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
219343659|NCT03087630|BEHAVIORAL|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
219343660|NCT03087630|BEHAVIORAL|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
219343661|NCT03087630|BEHAVIORAL|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
219343662|NCT05598593|DRUG|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
219343663|NCT06953388|DEVICE|transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Active stimulation will consist of direct electrical stimulation to the inner side of the left tragus (anode on the cymba concha, cathode on the surface of the tragus), thereby stimulating the ABVN. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
219343664|NCT06953388|DEVICE|sham transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Sham will be delivered to the ear lobe. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
219343665|NCT05870267|DEVICE|Power Knee with bone anchored suspension|Motor powered microprocessor controlled prosthetic knee joint
219343666|NCT05870267|DEVICE|C-Leg|Passive hydraulic microprocessor controlled prosthetic knee joint
219343667|NCT05870267|DEVICE|Rheo Knee XC|Passive magneto-rheologic microprocessor controlled knee joint
219343668|NCT06446440|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis
219343669|NCT06446440|PROCEDURE|Open adhesiolysis|Open adhesiolysis
219343670|NCT05645406|DRUG|Divigel 0.1% Topical Gel|estradiol topical products
219343671|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
219343672|NCT00006142|BEHAVIORAL|phenylalanine restricted diet|
219343673|NCT01689298|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219343674|NCT01689298|DRUG|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
219343675|NCT02883946|OTHER|Data collection|
219343676|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
219343677|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
219343678|NCT05233137|BEHAVIORAL|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
219343679|NCT05233137|OTHER|Exercise training|"Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
219343680|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
219343681|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
219343682|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
219343683|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
219343684|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
219343685|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
219343686|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
219343687|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
219343688|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
219343689|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
219343690|NCT06834451|DRUG|Revolade®|Tableta 50 mg Reference
219343691|NCT06834451|DRUG|Eltrombopag (EPAG)|Tableta 50 mg
219343692|NCT05711446|OTHER|Double Voiding|Participant will be instructed to void twice.
219343693|NCT05711446|OTHER|Regular Voiding|Participant will void as usual
219343694|NCT02432378|BIOLOGICAL|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
219343695|NCT02432378|BIOLOGICAL|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
219343696|NCT04138017|DEVICE|ViviGen|A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
219343697|NCT01292642|BEHAVIORAL|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
219343698|NCT01292642|DRUG|Nicotine Replacement Therapy|"1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
219343699|NCT05682027|DIAGNOSTIC_TEST|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
219343700|NCT01851681|DRUG|Amoxicillin|
219343701|NCT00706251|DEVICE|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
219343702|NCT06534450|DEVICE|Sham|The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.
219343703|NCT06534450|DEVICE|Therapeutic Plasma Exchange|Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.
219343704|NCT06534450|DRUG|IVIG|Intravenous Immunoglobulin
219343705|NCT03312660|DIETARY_SUPPLEMENT|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
219343706|NCT03312660|DIETARY_SUPPLEMENT|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
219343707|NCT01040052|BIOLOGICAL|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
219343708|NCT04043546|BEHAVIORAL|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
219343709|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
219343710|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
219343711|NCT05054972|PROCEDURE|Exclusion of the aortic aneurysm.|Surgical procedure in which an aortic aneurysm is excluded.
219343712|NCT05628220|OTHER|physiotherapy|rehabilitation through using session of virtual reality desensitization
219343713|NCT04071184|DRUG|Alofanib|Five dose cohorts and expanded cohort will be included
219343714|NCT05492929|OTHER|The deep breathing group|The deep breathing group
219343715|NCT05492929|OTHER|4-7-8 breathing technique|4-7-8 breathing technique Group
219343716|NCT04882306|DEVICE|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
219343717|NCT04922840|BEHAVIORAL|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
219343718|NCT03465189|DEVICE|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
219343719|NCT06082700|DIAGNOSTIC_TEST|imaging|clinical examination to see missing posterior teeth \& vertical measurements by lateral cephalometric x-ray
219343720|NCT01379274|DRUG|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
219343721|NCT06464250|OTHER|Bundla care group|A care package consisting of foot examination, correct foot care behaviours, and regular blood glucose monitoring was used.
219343722|NCT06458803|DRUG|Eltrombopag|patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
219343723|NCT04219345|DEVICE|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
219343724|NCT03443674|DRUG|SCB-313|Lyophilized powder in a single-use vial
219343725|NCT06042218|BEHAVIORAL|Xiaxi intervention program|The Xiaxi sessions will follow the same structure in both intervention groups. First of all, 8-minute warm-up where the participants will work on: postural awareness; active static stretching of the pectoral, hamstring and psoas muscles; and mobility. The main part will include the following blocks of content during the 12 weeks of intervention (46 minutes will be spent on this part in each session): breathing; mobility; active and dynamic static stretching of the tonic muscles with effects on the spine dynamic; strength of the phasic muscles with effects on the spine dynamic, alternating upper limb, lower limb and core; postural awareness; and passive static stretching of the tonic muscles with effects on the spine dynamic. The cool down will be similar in each session (6 minutes) and will focus on: postural awareness and passive static stretching of the pectoral, hamstring and psoas muscles.
219343726|NCT03767075|DRUG|Atezolizumab|1200 mg, administered IV, once every 3 weeks
219343727|NCT03767075|DRUG|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
219343728|NCT03767075|DRUG|Amivantamab|1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
219343729|NCT00004873|DRUG|cisplatin|
219343730|NCT00004873|DRUG|docetaxel|
219343731|NCT00004873|DRUG|epirubicin hydrochloride|
219343732|NCT00004873|DRUG|fluorouracil|
219343733|NCT00631020|BEHAVIORAL|CBME|6 weeks of once a week one-on-one CBME
219343734|NCT00631020|DRUG|Optional NRT|NicoDerm CQ nicotine transdermal patch
219343735|NCT02409849|DRUG|Octreotide lar|
219343736|NCT03223064|DIAGNOSTIC_TEST|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
219343737|NCT03223064|DIAGNOSTIC_TEST|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
219343738|NCT04070742|DRUG|FMX101|
219343739|NCT06279767|DRUG|6-mercaptopurine|6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
219343740|NCT03500900|DRUG|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
219343741|NCT03500900|DRUG|Placebo Oral Tablet|Acute administration of placebo tablet
219343742|NCT03627260|BEHAVIORAL|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
219343743|NCT03548935|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
219343744|NCT03548935|DRUG|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
219343745|NCT01756131|DRUG|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
219343746|NCT01756131|OTHER|Placebo to match injectable suspension|placebo
219343747|NCT03698435|DRUG|Ganciclovir|Intravenous ganciclovir + TDM
219343748|NCT03698435|DRUG|Valganciclovir|Oral valganciclovir + TDM
219343749|NCT00283595|DRUG|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
219343750|NCT00283595|DRUG|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
219343751|NCT01362036|DRUG|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
219343752|NCT01250600|BEHAVIORAL|Home exercise|Daily home exercise for 3 months
219343753|NCT01263639|OTHER|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
219343754|NCT01263639|OTHER|Standard of care - No biosketch card|Standard of care
219343755|NCT01576549|DRUG|LY2127399|Administered subcutaneously
219343756|NCT00492167|BIOLOGICAL|beta-glucan|
219343757|NCT00492167|BIOLOGICAL|monoclonal antibody 3F8|
219343758|NCT00492167|OTHER|immunohistochemistry staining method|
219343759|NCT00492167|OTHER|laboratory biomarker analysis|
219343760|NCT02103998|DRUG|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
219343761|NCT02103998|DRUG|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
219343762|NCT05514314|DRUG|Icotinib|Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
219343763|NCT06308042|OTHER|30 second sit and stand test|The individual sits in the middle of the chair with his back upright, his feet on the ground, and his arms crossed in front of his chest. The individual starts the test with the start command while in this position and takes off as fully as he can for 30 seconds.
219343764|NCT03247270|BEHAVIORAL|Intervention I|Low intensive physical exercise
219343765|NCT03247270|BEHAVIORAL|Intervention II|High intensive physical exercise
219343766|NCT04043325|DIAGNOSTIC_TEST|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
219343767|NCT00607386|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
219343768|NCT03459209|OTHER|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
219343769|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
219343770|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
219343771|NCT04938128|DEVICE|CPAP|Gold standard treatment for obstructive sleep apnea. In this group, patients will be prescribed CPAP treatment according to local policy.
219343772|NCT04860570|DEVICE|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
219343773|NCT04233697|DRUG|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
219343774|NCT04233697|DRUG|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
219343775|NCT06082388|DRUG|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
219343776|NCT02716987|DRUG|TAK-831|TAK-831 oral suspension.
219343777|NCT02716987|DRUG|[18F]PGM299|\[18F\]PGM299 injection
219343778|NCT05576389|DRUG|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
219343779|NCT02705651|DRUG|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
219343780|NCT03838302|PROCEDURE|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
219343781|NCT03838302|PROCEDURE|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
219343782|NCT02670863|OTHER|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
219343783|NCT02670863|OTHER|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
219343784|NCT05115838|DRUG|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
219343785|NCT05115838|DRUG|Placebo|Placebo implantable rod placed subdermally on the upper arm.
219343786|NCT00520364|OTHER|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
219343787|NCT03322189|GENETIC|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
219343788|NCT00153114|DRUG|polyethyleneglycol3350|
219343789|NCT02681172|DRUG|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
219343790|NCT02681172|PROCEDURE|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
219343791|NCT03622463|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
219343792|NCT03622463|OTHER|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
219343793|NCT01850485|DEVICE|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
219343794|NCT04265885|OTHER|collection of testimonies from transgender people|guided interview
219343795|NCT02820285|OTHER|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
219343796|NCT02820285|OTHER|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
219343797|NCT02820285|OTHER|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
219343798|NCT03417908|PROCEDURE|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
219343799|NCT03417908|PROCEDURE|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
219343800|NCT05882955|BEHAVIORAL|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
219343801|NCT05882955|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
219343802|NCT02988453|OTHER|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
219343803|NCT04424654|DRUG|Testosterone cypionate|Testosterone cypionate 400 mg IM
219343804|NCT05151003|OTHER|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
219343805|NCT00436800|DRUG|Gemcitabine|1000mg/m² over 10mg/m²/min
219343806|NCT00436800|DRUG|Oxaliplatin|100 mg/m² over 2 hours.
219343807|NCT00767091|DRUG|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
219343808|NCT00767091|DRUG|placebo|transdermal patch of placebo
219343809|NCT04615754|DIETARY_SUPPLEMENT|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
219343810|NCT04615754|DIETARY_SUPPLEMENT|Placebo - use of saline infusion|Saline is infused as an comparator
219343811|NCT03580252|OTHER|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
219343812|NCT04510233|DRUG|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
219343813|NCT04510233|DRUG|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
219343814|NCT04510233|OTHER|standard care|oxygen via masks or ventilators
219343815|NCT01193855|DRUG|dutasteride|
219343816|NCT01193855|DRUG|gadolinium-chelate|
219343817|NCT01193855|OTHER|active surveillance|
219343818|NCT01193855|PROCEDURE|diffusion-weighted magnetic resonance imaging|
219343819|NCT01193855|PROCEDURE|functional magnetic resonance imaging|
219343820|NCT01193855|PROCEDURE|prostate biopsy|
219343821|NCT01193855|PROCEDURE|ultrasound imaging|
219343822|NCT05877482|OTHER|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
219343823|NCT05877482|OTHER|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
219343824|NCT03569579|DRUG|Memantine Tab. 10mg|Memantine Tab. 10mg\* 2T/day, QD, PO
219343825|NCT03569579|DRUG|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
219343826|NCT05687331|PROCEDURE|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
219343827|NCT05687331|PROCEDURE|venipuncture|Peripheral venipuncture to gather a blood sample
219343828|NCT05687331|DIAGNOSTIC_TEST|MRI-scan|MRI-scan of the knee
219343829|NCT05687331|DIAGNOSTIC_TEST|Physical examination|Physical examination of the injured knee
219343830|NCT05687331|OTHER|KOOS questionnaire|KOOS questionnaire of the injured knee
219343831|NCT04317495|OTHER|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
219343832|NCT01963312|PROCEDURE|Transarterial Supraselective Embolization of the prostate|
219343833|NCT01963312|PROCEDURE|Transurethral Resection of the prostate|
219343834|NCT02228291|DIETARY_SUPPLEMENT|Capsule containing citrus flavonoid|
219343835|NCT02228291|DIETARY_SUPPLEMENT|Placebo|
219343836|NCT03223428|DRUG|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
219343837|NCT01834274|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
219343838|NCT01834274|DRUG|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
219343839|NCT01834274|DRUG|Sitagliptin|Sitagliptin tablets
219343840|NCT01834274|DRUG|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
219343841|NCT01834274|DRUG|Metformin|Metformin tablets
219343842|NCT06012370|PROCEDURE|PRP injection|Injection of PRP and hyaluronic acid
219343843|NCT03119714|DRUG|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
219343844|NCT03119714|DRUG|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
219343845|NCT01142401|DRUG|Bortezomib|Given IV
219343846|NCT01142401|DRUG|Fulvestrant|Given IM
219343847|NCT01142401|OTHER|Laboratory Biomarker Analysis|Correlative studies
219343848|NCT05973604|DIAGNOSTIC_TEST|Screening and Confirmatory diagnostic test for primary aldosteronism|Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is \>30, accompanied by elevated aldosterone values (\>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are \>5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are \>8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (\>6ng/dl) are found at the end of the test).
219343849|NCT02017327|DRUG|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
219343850|NCT02017327|DRUG|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
219343851|NCT02017327|DRUG|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
219343852|NCT02422212|OTHER|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
219343853|NCT05872750|DEVICE|theta burst stimulation|Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)
219343854|NCT05872750|DEVICE|sham stimulation|sham stimulation
219343855|NCT06180200|DIAGNOSTIC_TEST|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
219343856|NCT01537562|OTHER|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
219343857|NCT03362970|DEVICE|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
219343858|NCT03362970|OTHER|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
219343859|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
219343860|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
219343861|NCT03880175|BEHAVIORAL|Anti Stigma Information|Adults in the households are provided anti-stigma information
219343862|NCT03880175|BEHAVIORAL|HIV/AIDS Information|The households receive information about HIV infection and AIDS
219343863|NCT03880175|BEHAVIORAL|ART Information|The households receive information about antiretroviral therapy.
219343864|NCT03880175|BEHAVIORAL|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
219343865|NCT03880175|BEHAVIORAL|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
219343866|NCT00106275|BEHAVIORAL|Mindfulness Based Stress Reduction|
219343867|NCT03592940|DIETARY_SUPPLEMENT|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
219343868|NCT01956903|GENETIC|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
219343869|NCT02739607|BEHAVIORAL|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
219343870|NCT01529437|DRUG|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
219343871|NCT01529437|DRUG|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
219343872|NCT00491699|DRUG|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
219343873|NCT02813694|DRUG|lefamulin|antibacterial agent
219343874|NCT02813694|DRUG|Moxifloxacin|antibacterial agent
219343875|NCT00549172|PROCEDURE|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
219343876|NCT00549172|PROCEDURE|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
219343877|NCT01265797|DEVICE|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
219343878|NCT01265797|DEVICE|Sham Device|participant wears sham device for 20 minutes daily for 28 days
219343879|NCT06290375|DRUG|HSK21542 tablet|once-daily
219343880|NCT06290375|DRUG|Placebo|once-daily
219343881|NCT05711004|BEHAVIORAL|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
219343882|NCT00731575|DRUG|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
219343883|NCT02942745|BEHAVIORAL|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
219343884|NCT02942745|BEHAVIORAL|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
219343885|NCT02980224|DRUG|OmegaD|OmegaD Softgels
219343886|NCT02980224|DRUG|Placebo|Placebo Softgels
219343887|NCT02331433|DRUG|APN1125|APN1125 orally at ascending doses
219343888|NCT02331433|DRUG|Placebo|Matching Placebo
219343889|NCT03930719|DIAGNOSTIC_TEST|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
219343890|NCT00606320|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
219343891|NCT01428284|DRUG|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
219343892|NCT04009863|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
219343893|NCT04009863|RADIATION|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
219343894|NCT03516682|BEHAVIORAL|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
219343895|NCT04952298|PROCEDURE|Mesial temporal lobe epilepsy surgery|"Medial temporal lobe epilepsy surgery including~* selective Amygdalohippocempectomy (SAH) including anterior parahippocampal gyrus / entorhinal cortex~* anteromedial temporal lobe resection including amygdalohippocampectomy~* anterior temporal lobe resection"
219343896|NCT04839380|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
219343897|NCT03336021|OTHER|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
219343898|NCT01087905|DRUG|Nicotine patch|"If \> 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day"
219343899|NCT01087905|DRUG|Nicotine gum|"If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
219343900|NCT01087905|BEHAVIORAL|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
219343901|NCT01347554|DEVICE|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
219343902|NCT01347554|DEVICE|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
219343903|NCT01865409|BEHAVIORAL|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
219343904|NCT03228355|DRUG|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
219343905|NCT03228355|DRUG|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
219343906|NCT03027531|BEHAVIORAL|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
219343907|NCT02223260|DRUG|dabigatran|Experimental dose chosen based on age and weight
219343908|NCT01179009|DRUG|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
219343909|NCT01179009|DRUG|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
219343910|NCT01179009|DRUG|placebo|IV saline (i.e. placebo ketamine)
219343911|NCT04325841|BIOLOGICAL|Murine autologous anti-CD19 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
219343912|NCT05266378|PROCEDURE|PECs block|The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
219343913|NCT05266378|OTHER|Not receiving PECs Block|In this group, the PECs block was not implemented.
219343914|NCT05780307|DRUG|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
219343915|NCT02937818|DRUG|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
219343916|NCT02937818|DRUG|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
219343917|NCT02937818|DRUG|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
219343918|NCT03371615|OTHER|Anti-regurgitation infant formula|Anti regurgitation infant formula
219343919|NCT06006793|DRUG|SY-5933|KRAS p.G12C inhibitor
219343920|NCT04377711|DRUG|Ciclesonide|160mcg Inhaler
219343921|NCT04377711|DRUG|Placebo|Matching Placebo Inhaler
219343922|NCT01748539|DRUG|KHK4827|
219343923|NCT01748539|DRUG|Placebo|
219343924|NCT02534701|DEVICE|ERIC® and SOFIA™|a self-expanding clot retrieval system
219343925|NCT02702765|PROCEDURE|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
219343926|NCT02702765|PROCEDURE|Ultrasound|Ultrasound is a non-invasive procedure
219343927|NCT02702765|DRUG|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
219343928|NCT02702765|PROCEDURE|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
219343929|NCT02702765|PROCEDURE|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
219343930|NCT06150235|OTHER|Data collection|Data collection
219343931|NCT03518788|PROCEDURE|Pleur-X|Permanent drainage
219343932|NCT03518788|PROCEDURE|Pleurodesis|Pleurodesis with talc in permanent VATS
219343933|NCT02231554|OTHER|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
219343934|NCT02231554|OTHER|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
219343935|NCT00002278|DRUG|Diclazuril|
219343936|NCT00205855|DEVICE|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
219343937|NCT06209554|DEVICE|ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser|diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
219343938|NCT03518879|OTHER|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
219343939|NCT03428178|DRUG|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
219343940|NCT03147729|RADIATION|Radiofrequency non ablation|Use of radiofrequency
219343941|NCT03747250|DEVICE|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
219343942|NCT03747250|DEVICE|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
219343943|NCT06429267|DEVICE|Bioabsorbable Screw|Bioabsorbable screw that redissolves into the bone. Mineral fibers are composed of Silicon Dioxide (SiO2), Sodium Oxide, Calcium Oxide, Magnesium Oxide, Boron Trioxide, and Phosphorous Pentoxide
219343944|NCT06429267|DEVICE|Metal/Titanium Screw|Traditional metal screw used in fracture fixation that requires hardware removal
219343945|NCT05246137|BIOLOGICAL|COVID-19 Vaccine 40 ug/dose|Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
219343946|NCT05513625|DRUG|Pritelivir|oral administration
219343947|NCT05513625|DRUG|ESO and pritelivir|oral administration
219343948|NCT02717884|DRUG|tranylcypromine|"TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
219343949|NCT02717884|DRUG|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
219343950|NCT02717884|DRUG|cytarabine|40mg s.c. (days 1-10)
219343951|NCT04596020|OTHER|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
219343952|NCT01015768|DEVICE|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
219343953|NCT01015768|DEVICE|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
219343954|NCT04778436|DIETARY_SUPPLEMENT|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
219343955|NCT00004138|PROCEDURE|positron emission tomography|
219343956|NCT00004138|PROCEDURE|radionuclide imaging|
219343957|NCT00004138|RADIATION|fludeoxyglucose F 18|
219343958|NCT00923403|DIETARY_SUPPLEMENT|plant sterol enriched soymilk|plant sterol enriched soymilk
219343959|NCT00923403|DIETARY_SUPPLEMENT|control dairy milk|control dairy milk
219343960|NCT05248568|DEVICE|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
219343961|NCT00676390|OTHER|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
219343962|NCT01556425|DRUG|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
219343963|NCT01556425|BEHAVIORAL|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
219343964|NCT01556425|OTHER|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
219343965|NCT03126695|DRUG|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
219343966|NCT03126695|DRUG|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
219343967|NCT03126695|DRUG|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
219343968|NCT03126695|DRUG|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
219343969|NCT04518215|PROCEDURE|Erector Spinae Plain Block|Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.
219343970|NCT04518215|PROCEDURE|Intra-Venous Analgesia|Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.
219343971|NCT05649085|DEVICE|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
219343972|NCT05654597|OTHER|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
219343973|NCT05654597|OTHER|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
219343974|NCT04800562|DRUG|PCS499|PCS499 900mg twice a day with food
219343975|NCT04800562|OTHER|placebo|placebo comparator
219343976|NCT03344952|DRUG|Botulinum toxin type A|Repeated injections to hypertonic muscles
219343977|NCT03344952|OTHER|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
219343978|NCT05635799|OTHER|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
219343979|NCT05635799|OTHER|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
219343980|NCT05635799|OTHER|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
219343981|NCT05635799|OTHER|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
219343982|NCT01505634|DRUG|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
219343983|NCT01505634|DRUG|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
219343984|NCT01505634|DRUG|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
219343985|NCT01505634|DRUG|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
219343986|NCT01505634|DRUG|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
219343987|NCT02054897|DRUG|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
219343988|NCT02054897|DRUG|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
219343989|NCT00472264|PROCEDURE|PET imaging|Medical imaging assessment
219343990|NCT04261075|BIOLOGICAL|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
219343991|NCT04261075|BIOLOGICAL|durvalumab|Durvalumab Q3W for a maximum of 2 years
219343992|NCT04261075|BIOLOGICAL|oleclumab|Oleclumab Q3W for a maximum of 2 years
219343993|NCT01173224|DRUG|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
219343994|NCT01173224|DRUG|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
219343995|NCT04309942|OTHER|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
219343996|NCT06538948|PROCEDURE|Bariatric Surgery|The intervention is not assigned to the participant after recruitment in the study, rather the intervention is an inclusion criteria for participation in the study.
219343997|NCT03611192|OTHER|Multicomponent exercise|Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins
219343998|NCT03611192|OTHER|Home-program exercise|60 mins exercise
219343999|NCT00794157|DRUG|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219344000|NCT00794157|DRUG|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219344001|NCT00794157|DRUG|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
219344002|NCT01673711|DRUG|deuterated phenanthrene tetraol|Given PO
219344003|NCT01673711|DRUG|pharmacological study|Correlative studies
219344004|NCT01673711|DRUG|laboratory biomarker analysis|Correlative studies
219344005|NCT01692275|OTHER|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
219344006|NCT01692275|OTHER|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
219344007|NCT02854644|OTHER|additional blood sample|
219344008|NCT02600832|BEHAVIORAL|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
219344009|NCT02600832|BEHAVIORAL|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
219344010|NCT01300169|BEHAVIORAL|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
219344011|NCT01300169|BEHAVIORAL|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
219344012|NCT03446950|PROCEDURE|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
219344013|NCT02961621|BEHAVIORAL|Stress Reduction Training for 9-1-1 Telecommunicators|
219344014|NCT03734835|DIETARY_SUPPLEMENT|hesperidin|1000 mg hesperidin as two capsules
219344015|NCT03734835|DIETARY_SUPPLEMENT|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
219344016|NCT03734835|DIETARY_SUPPLEMENT|flaxseed|30 grams flaxseed
219344017|NCT03734835|OTHER|control|no supplementation
219344018|NCT05602038|PROCEDURE|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
219344019|NCT05602038|DRUG|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
219344020|NCT05602038|DRUG|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
219344021|NCT02364089|PROCEDURE|Laparoscopic surgical removal of the adrenal tumor|
219344022|NCT02364089|DRUG|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day."
219344023|NCT00002152|DRUG|WF10|
219344024|NCT06087744|BEHAVIORAL|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
219344025|NCT06087744|BEHAVIORAL|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
219344026|NCT04588779|OTHER|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
219344027|NCT04588779|OTHER|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
219344028|NCT03816930|PROCEDURE|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
219344029|NCT03111784|OTHER|Fish consumption and lipid profiles|
219344030|NCT05160961|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
219344031|NCT05160961|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
219344032|NCT01811875|BIOLOGICAL|Optivate 500IU|
219344033|NCT01632995|DRUG|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
219344034|NCT03885310|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
219344035|NCT01012375|DRUG|AZD1446|10 mg capsule, oral dose
219344036|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
219344037|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
219344038|NCT01012375|DRUG|Placebo|Matching capsule, oral dose
219344039|NCT02849561|OTHER|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
219344040|NCT02849561|DEVICE|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
219344041|NCT02849561|OTHER|Electroencephalography|
219344042|NCT02849561|DEVICE|Pupillary light reflex surveillance|With Neurolight® device.
219344043|NCT02849561|DEVICE|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
219344044|NCT03814070|PROCEDURE|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
219344045|NCT03814070|PROCEDURE|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
219344046|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
219344047|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
219344048|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
219344049|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
219344050|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
219344051|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
219344052|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
219344053|NCT00361270|BEHAVIORAL|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
219344054|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
219344055|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
219344056|NCT03691129|BEHAVIORAL|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
219344057|NCT05447468|OTHER|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
219344058|NCT05447468|OTHER|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
219344059|NCT05447468|OTHER|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
219344060|NCT05447468|OTHER|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
219344061|NCT05447468|OTHER|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
219344062|NCT05447468|OTHER|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
219344063|NCT04599322|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
219344064|NCT02351505|DRUG|Selinexor|Given PO
219344065|NCT02351505|OTHER|Laboratory Biomarker Analysis|Correlative studies
219344066|NCT02351505|OTHER|Pharmacological Study|Correlative studies
219344067|NCT04899700|DEVICE|Linked Color Imaging|Inspection of the postpolypectomy scar will be made with Linked Color Imaging
219344068|NCT04899700|OTHER|White light endoscopy|Inspection of the postpolypectomy scar will be made with White light Endoscopy
219344069|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
219344070|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
219344071|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
219344072|NCT02427074|PROCEDURE|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
219344073|NCT02427074|PROCEDURE|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
219344074|NCT00640328|DRUG|Ofatumumab 100|100mg
219344075|NCT00640328|DRUG|Ofatumumab 300|300mg
219344076|NCT00640328|DRUG|Ofatumumab 700|700mg
219344077|NCT00640328|DRUG|Placebo|matching placebo
219344078|NCT04686721|DIAGNOSTIC_TEST|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
219344079|NCT03761095|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
219344080|NCT03761095|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
219344081|NCT04338035|BEHAVIORAL|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
219344082|NCT02079103|DEVICE|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
219344083|NCT02079103|BEHAVIORAL|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
219344084|NCT00669058|DRUG|Lactic acid (Dermacid)|
219344085|NCT02374099|DRUG|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
219344086|NCT02374099|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
219344087|NCT03898375|OTHER|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
219344088|NCT01550146|DRUG|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
219344089|NCT01550146|DRUG|Placebo|iv. Normal Saline 0.1 ml/kg
219344090|NCT01433575|DRUG|RO4917838|10 mg single oral dose
219344091|NCT01433575|DRUG|RO4917838|20 mg single oral dose
219344092|NCT01326546|BIOLOGICAL|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
219344093|NCT01326546|DRUG|entecavir|0.5mg,per day,oral intake.
219344094|NCT01326546|OTHER|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
219344095|NCT04039893|DIAGNOSTIC_TEST|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
219344096|NCT04039893|DIAGNOSTIC_TEST|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
219344097|NCT04039893|PROCEDURE|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
219344098|NCT04039893|PROCEDURE|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
219344099|NCT02913690|DIETARY_SUPPLEMENT|Placebo|2 x 150mg capsules daily
219344100|NCT02913690|DIETARY_SUPPLEMENT|TRF|2 x 150mg capsules daily
219344101|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
219344102|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
219344103|NCT01033825|DRUG|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
219344104|NCT01033825|DRUG|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
219344105|NCT01033825|DRUG|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
219344106|NCT01033825|DRUG|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
219344107|NCT01033825|DRUG|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
219344108|NCT01057407|DRUG|ASP1585|oral
219344109|NCT01057407|DRUG|Sevelamer hydrochloride|oral
219344110|NCT03065907|OTHER|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
219344111|NCT04294719|OTHER|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
219344112|NCT02211027|BIOLOGICAL|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
219344113|NCT05088486|GENETIC|DNA analysis|GWAS
219344114|NCT04503239|DEVICE|G6|Wear 9 wear periods of the 10-day CGM
219344115|NCT01868880|DRUG|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
219344116|NCT01868880|DRUG|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
219344117|NCT00081159|DRUG|Doxorubicin hydrochloride|Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
219344118|NCT00081159|DRUG|Goserelin acetate|
219344119|NCT00081159|DRUG|Leuprolide acetate|
219344120|NCT00081159|DRUG|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
219344121|NCT00081159|PROCEDURE|orchiectomy|
219344122|NCT00081159|RADIATION|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
219344123|NCT03276000|PROCEDURE|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
219344124|NCT00388700|DRUG|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
219344125|NCT00388700|DRUG|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
219344126|NCT05297942|OTHER|Expansion of Abbreviations and Acronyms|Expansion of Abbreviations and Acronyms
219344127|NCT01513421|PROCEDURE|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
219344128|NCT02237521|OTHER|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
219344129|NCT02237521|OTHER|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
219344130|NCT00272142|DRUG|Zinc|
219344131|NCT00272142|DRUG|Placebo|
219344132|NCT01548339|PROCEDURE|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
219344133|NCT01714687|DEVICE|balloon sinus dilation|
219344134|NCT01714687|OTHER|medical therapy|
219344135|NCT04322851|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
219344136|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
219344137|NCT04988412|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
219344138|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
219344139|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
219344140|NCT02731261|OTHER|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
219344141|NCT06402708|DRUG|Chemotherapy|paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
219344142|NCT06402708|RADIATION|Radiotherapy|IMRT, 50Gy/25f
219344143|NCT03177421|OTHER|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
219344144|NCT03177421|OTHER|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
219344145|NCT04124913|DRUG|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
219344146|NCT04124913|DRUG|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
219344147|NCT01553981|DRUG|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
219344148|NCT01553981|DRUG|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
219344149|NCT03449095|DRUG|Alcohol|Alcohol Target BAC .08%
219344150|NCT01986413|DEVICE|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
219344151|NCT01986413|DEVICE|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
219344152|NCT01986413|DEVICE|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
219344153|NCT00203853|DEVICE|pillbox, wristwatch|
219344154|NCT02812277|OTHER||This is a Non-Interventional Study, so there are no drug or devices included.
219344155|NCT03270865|DEVICE|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
219344156|NCT03578224|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
219344157|NCT03578224|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
219344158|NCT03578224|PROCEDURE|Fine-Needle Aspiration|Undergo FNA
219344159|NCT03578224|DRUG|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
219344160|NCT05177653|OTHER|Intravenous infusion|GIP receptor antagonist (GIP(3-30)NH2)
219344161|NCT05177653|OTHER|Intravenous infusion|GLP-1 receptor antagonist (exendin(9-39)NH2)
219344162|NCT05177653|OTHER|Intravenous infusion|GIP(3-30)NH2 and exendin(9-39)NH2
219344163|NCT05177653|OTHER|Intravenous infusion|Saline
219344164|NCT01285115|DRUG|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
219344165|NCT01285115|DRUG|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
219344166|NCT01285115|DRUG|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
219344167|NCT04171518|DEVICE|Catalys Precision Laser System|Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
219344168|NCT01553136|DRUG|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
219344169|NCT04342286|GENETIC|Organoid culture|Organoid culture
219344170|NCT06047652|DEVICE|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
219344171|NCT03001089|DRUG|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
219344172|NCT03001089|DRUG|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
219344173|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
219344174|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
219344175|NCT06973031|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
219344176|NCT00214370|DRUG|Propofol-Fentanyl|
219344177|NCT00214370|DRUG|Propofol alone|
219344178|NCT01964014|DRUG|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
219344179|NCT01515761|PROCEDURE|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
219344180|NCT01515761|PROCEDURE|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
219344181|NCT03381716|DRUG|drug|Application bracket
219344182|NCT03381716|PROCEDURE|Surgery|Surgery
219344183|NCT01070472|DRUG|Misoprostol|titrated oral misoprostol solution
219354822|NCT05651035|OTHER|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
219344184|NCT01127568|DRUG|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
219344185|NCT04505618|DEVICE|Swept-Source (SS) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
219344186|NCT04505618|DEVICE|Spectral-Domain (SD) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
219344187|NCT04505618|DEVICE|Fundus Imaging|Non-invasive, minimal risk, ocular imaging study
219344188|NCT04505618|DEVICE|Axial Length Measurement Device|Non-invasive, minimal risk, ocular imaging study
219344189|NCT03542006|DRUG|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
219344190|NCT02704338|BIOLOGICAL|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
219344191|NCT02632396|DRUG|Ixazomib|Given PO
219344192|NCT02632396|BIOLOGICAL|Rituximab|Given IV
219344193|NCT02899689|DEVICE|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
219344194|NCT02899689|DEVICE|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
219344195|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
219344196|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
219344197|NCT04750876|OTHER|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
219344198|NCT04750876|OTHER|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~* consultations with a psychologist~* The patient will also be cared for on a daily basis by a physical therapist."
219344199|NCT00217204|DRUG|Pancrelipase microtablets|
219344200|NCT00516542|DRUG|letrozole|A daily dose of 2.5 mg will be used throughout the study.
219344201|NCT00516542|DRUG|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
219344202|NCT00516542|OTHER|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
219344203|NCT04264403|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
219344204|NCT00894556|DRUG|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
219344205|NCT00894556|DRUG|Comparator: Placebo|Placebo to Rizatriptan
219344206|NCT00894556|DRUG|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
219344207|NCT02994433|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
219344208|NCT02994433|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
219344209|NCT02994433|DEVICE|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
219344210|NCT05617976|PROCEDURE|caudal block|caudal block
219344211|NCT02284789|OTHER|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
219344212|NCT03209206|DRUG|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
219344213|NCT03209206|DRUG|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
219344214|NCT03926975|DEVICE|Scleral Lens|The contact lens will be worn on one eye.
219344215|NCT03926975|OTHER|No lens|No lens worn on the contralateral control eye
219344216|NCT01223170|BEHAVIORAL|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
219344217|NCT01223170|BEHAVIORAL|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
219344218|NCT01223170|BEHAVIORAL|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
219344219|NCT01223170|BEHAVIORAL|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
219344220|NCT00294359|DRUG|Mitomycin C; Capecitabine; Bevacizumab|
219344221|NCT04763642|PROCEDURE|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
219344222|NCT00868348|DRUG|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
219344223|NCT00868348|DRUG|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
219344224|NCT02993874|DIETARY_SUPPLEMENT|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
219344225|NCT02993874|DIETARY_SUPPLEMENT|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
219344226|NCT03269370|BEHAVIORAL|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
219344227|NCT03269370|BEHAVIORAL|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
219344228|NCT03269370|BEHAVIORAL|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)"
219344229|NCT00150826|DRUG|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
219344230|NCT00150826|DRUG|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
219344231|NCT03402984|DRUG|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
219344232|NCT03402984|DRUG|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
219344233|NCT00003351|DRUG|irinotecan hydrochloride|
219344234|NCT01884259|DRUG|Docetaxel|75 mg/m² on day 1 of 21-days cycle
219344235|NCT01884259|DRUG|Cisplatin|75 mg/m² on day 1 of 21-days cycle
219344236|NCT01884259|DRUG|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
219344237|NCT01884259|BIOLOGICAL|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
219344238|NCT01884259|BIOLOGICAL|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
219344239|NCT01884259|RADIATION|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
219344240|NCT01979536|DRUG|Brentuximab Vedotin|Given IV
219344241|NCT01979536|DRUG|Crizotinib|Given PO
219344242|NCT01979536|DRUG|Cyclophosphamide|Given IV
219344243|NCT01979536|DRUG|Cytarabine|Given IT and IV
219344244|NCT01979536|DRUG|Dexamethasone|Given PO or IV
219344245|NCT01979536|DRUG|Doxorubicin Hydrochloride|Given IV
219344246|NCT01979536|DRUG|Etoposide|Given IV
219344247|NCT01979536|DRUG|Ifosfamide|Given IV
219344248|NCT01979536|DRUG|Methotrexate|Given IT and IV
219344249|NCT03077685|DRUG|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
219344250|NCT00573209|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
219344251|NCT06320587|OTHER|Kangaroo care practice by both mother and father|In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.
219344252|NCT06320587|OTHER|Kangaroo care practice only mother|In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
219344253|NCT00396201|DRUG|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
219344254|NCT03767023|OTHER|cross sectional|
219344255|NCT03745274|BIOLOGICAL|GHB04L1|Solution
219344256|NCT03745274|OTHER|Placebo|Buffer solution
219344257|NCT02594306|DEVICE|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
219344258|NCT02594306|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
219344259|NCT02594306|PROCEDURE|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
219344260|NCT02594306|PROCEDURE|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
219344261|NCT04885803|DIETARY_SUPPLEMENT|Softgel Vitamin D3|5000IU vitamin D3 taken as single oral softgel once daily for 30 days
219344262|NCT04885803|DIETARY_SUPPLEMENT|Nano Liquid Vitamin D3|5000IU vitamin D3 taken as liquid oral spray once daily for 30 days
219354823|NCT03889041|OTHER|Quality of life assessment|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
219344263|NCT04885803|DIAGNOSTIC_TEST|25(OH)D Blood Serum Test|A sample of blood is drawn off and processed for 25(OH)D levels at baseline, after 15 days of supplementation, and after 30 days of supplementation
219344264|NCT04885803|OTHER|Placebo Control|Liquid oral spray once daily for 30 days. Solution identical in smell, taste, color, and production process to Nano Liquid D3, but containing no Vitamin D3.
219344265|NCT04158076|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
219344266|NCT04158076|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
219344267|NCT04158076|DRUG|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
219344268|NCT01933633|BEHAVIORAL|Exercise|
219344269|NCT03685266|OTHER|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
219344270|NCT01378234|BEHAVIORAL|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~1. Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~2. Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~3. Supporting caregivers to reduce stress and burden"
219344271|NCT02232373|BEHAVIORAL|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
219344272|NCT02232373|DIETARY_SUPPLEMENT|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
219344273|NCT02232373|DIETARY_SUPPLEMENT|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
219344274|NCT05413486|OTHER|Observational|"Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups."
219344275|NCT00058786|BIOLOGICAL|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
219344276|NCT00476411|BIOLOGICAL|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
219344277|NCT01353040|DRUG|AVI-6003|Single intravenous administration
219344278|NCT01353040|DRUG|Placebo|Single intravenous administration
219344279|NCT02404623|DIETARY_SUPPLEMENT|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
219344280|NCT00507949|DRUG|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
219344281|NCT00507949|DRUG|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
219344282|NCT03080844|BEHAVIORAL|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
219344283|NCT03080844|BEHAVIORAL|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
219344284|NCT00616122|DRUG|cyclophosphamide|
219344285|NCT00616122|DRUG|methotrexate|
219344286|NCT00616122|DRUG|sunitinib malate|
219344287|NCT00616122|OTHER|laboratory biomarker analysis|
219344288|NCT06496815|DRUG|Donafenib|Donafenib will be taken orally twice a day, 0.2g each time.
219344289|NCT06496815|PROCEDURE|transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy|Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).
219344290|NCT06496815|DRUG|PD-1,PD-L1|PD-1/PD-L1 will be used as previous (if have).
219344291|NCT00356850|DRUG|Azithromycin|
219344292|NCT05004636|DRUG|Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
219344293|NCT03921424|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
219344294|NCT03921424|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
219344295|NCT03921424|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
219344296|NCT00867321|BIOLOGICAL|bevacizumab|Given IV
219344297|NCT00867321|DRUG|sorafenib tosylate|Given orally
219344298|NCT06137924|DRUG|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
219344299|NCT06137924|DRUG|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
219344300|NCT06137924|DRUG|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
219344301|NCT02159703|PROCEDURE|TORS|
219344302|NCT02159703|RADIATION|Adjuvant Radiation Therapy|
219344303|NCT03599128|OTHER|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
219344304|NCT03599128|OTHER|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
219344305|NCT03599128|OTHER|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
219344306|NCT03599128|OTHER|Placebo|Reconstituted in water and given to subjects
219344307|NCT02883023|OTHER|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
219344308|NCT02883023|DRUG|Intralesional bleomycin injection|Local intralesional injections with bleomycin
219344309|NCT05063227|DIAGNOSTIC_TEST|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
219344310|NCT02122198|DRUG|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
219344311|NCT02122198|DRUG|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
219344312|NCT02122198|DRUG|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
219344313|NCT02122198|DRUG|Placebo|placebo
219344314|NCT04772495|GENETIC|miRNA|miRNA effect on Multiple sclerosis pathology
219344315|NCT02581202|DRUG|lopinavir/ritonavir|tablet
219344316|NCT02581202|DRUG|lamivudine|tablet
219344317|NCT05489731|DRUG|VIC-1911|VIC-1911 tablets for oral administration
219344318|NCT05489731|DRUG|Osimertinib Mesylate Tablets|Osimertinib tablets for oral administration
219344319|NCT01143727|DRUG|Santyl|Apply one 24-hr period sufficient to cover the wound.
219344320|NCT01143727|DRUG|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
219344321|NCT03205462|DRUG|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
219344322|NCT03205462|DRUG|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
219344323|NCT03205462|DRUG|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
219344324|NCT00005039|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|Given IM
219344325|NCT00005039|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
219344326|NCT00005039|OTHER|laboratory biomarker analysis|Correlative studies
219344327|NCT05884931|DEVICE|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
219344328|NCT05884931|PROCEDURE|Conventional Treatment|Standard hemostatic procedure
219344329|NCT03295162|DRUG|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
219344330|NCT03295162|COMBINATION_PRODUCT|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
219344331|NCT04719143|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Subjects receive 6-8 CBT-I sessions in an individual format.
219344332|NCT05062876|DRUG|AD-214|1 tablet administered before the breakfast during 7 days
219344333|NCT05062876|DRUG|AD-2141|1 tablet administered before the breakfast during 7 days
219344334|NCT02898532|BEHAVIORAL|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
219344335|NCT05412056|DRUG|Metformin|as in arm/group description
219344336|NCT05412056|DRUG|Placebo oral tablet|as in arm/group description
219344337|NCT06387407|DRUG|Dabigatran Etexilate 150mg|Oral dabigatran etexilate capsules, 150 mg twice a day.
219344338|NCT04141384|DEVICE|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
219344339|NCT05169151|OTHER|Smartphone Application|Utilize smartphone application
219344340|NCT02132481|OTHER|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
219344341|NCT02132481|OTHER|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
219344342|NCT02132481|OTHER|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
219344343|NCT02132481|OTHER|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
219344344|NCT03473574|BIOLOGICAL|Durvalumab|immune checkpoint inhibitor
219344345|NCT03473574|DRUG|Gemcitabine|standard chemotherapy
219344346|NCT03473574|DRUG|Cisplatin|standard chemotherapy
219344347|NCT03473574|BIOLOGICAL|Tremelimumab|immune checkpoint inhibitor
219344348|NCT02488369|DEVICE|PET / CT|
219344349|NCT04936360|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
219344350|NCT03707600|DEVICE|TMS|MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
219344351|NCT06403527|OTHER|Ultrasound guided venous access during AF ablation|Ultrasound guided venous access during AF ablation
219344352|NCT04030221|OTHER|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
219344353|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
219344354|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
219344355|NCT01076049|DEVICE|Standard of Care (SoC)|The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.
219344356|NCT01076049|DEVICE|Irrisept Delivery System|"Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression.~Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits."
219344357|NCT00621478|DRUG|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
219344358|NCT04894500|DIAGNOSTIC_TEST|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
219344359|NCT06248281|OTHER|combination of different rehabilitation strategies|"The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos."
219344360|NCT03412656|DEVICE|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
219344361|NCT01806779|DRUG|Chantix|
219344362|NCT01806779|DRUG|Zyban|
219344363|NCT01806779|DRUG|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
219344364|NCT01779024|DRUG|Ghrelin|
219344365|NCT01779024|DRUG|Placebo|
219344366|NCT01779024|PROCEDURE|fMRI|
219344367|NCT01779024|DRUG|Alcohol|
219344368|NCT02595450|DRUG|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
219344369|NCT00391573|PROCEDURE|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
219344370|NCT00391573|PROCEDURE|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
219344371|NCT02613390|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
219344372|NCT02613390|BEHAVIORAL|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
219344373|NCT02330978|PROCEDURE|Intravitreal transplantation of mesenchymal stem cell|
219344374|NCT02330978|BIOLOGICAL|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
219344375|NCT05110703|DIETARY_SUPPLEMENT|Supergut|Meal replacement shake
219344376|NCT05110703|DIETARY_SUPPLEMENT|Placebo|Placebo
219344377|NCT05110703|OTHER|Dietary guidelines|Dietary guidelines
219344378|NCT05531175|OTHER|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
219344379|NCT06474442|GENETIC|BD111 Injection (investigational new drug)|BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.
219344380|NCT06474442|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
219344381|NCT06978829|DRUG|TP + Cetuximab + Tislelizumab|"Conversion therapy stage:~TP regimen: Albumin-bound paclitaxel+Platinum (Cisplatin or Carboplatin) Albumin-bound paclitaxel: 100 mg/m² by IV infusion, D1/D8, every 3 weeks (Q3W) Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W Cetuximab: The initial dose is 400 mg/m² by IV infusion for 1 week. Subsequently followed by 250 mg/m² IV infusion, D1/D8, Q3W.~Tislelizumab: 200 mg by IV infusion, Q3W. 3 weeks/cycle, 3 cycles in total.~Patients who have completed conversion therapy undergo efficacy evaluation.~Radical therapy stage:~Evaluated as operable: Undergo surgery, followed by one cycle of adjuvant chemotherapy according to the preoperative regimen.~Evaluated as inoperable: Receive radical radiotherapy.~Maintenance therapy stage:~Tislelizumab for 1 year or until disease progression, intolerable toxicity, or patient refusal to continue treatment."
219344382|NCT06979349|OTHER|Physical Evaluations in Players|Respiratory muscle strength, respiratory muscle endurance, cough strength or balance will be evaluated in adolescent volleyball players.
219344383|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
219344384|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
219344385|NCT06977542|DRUG|Ivonescimab|"a PD-1/ VEGF Bispecific Antibody, 20mg/kg, every 2 weeks;~Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide"
219344386|NCT06978192|DRUG|dexmedetomidine nasal spray group|Experimental group: Long duration high voltage pulse RF therapy plus dexmedetomidine nasal spray group
219344387|NCT06978192|OTHER|long duration high voltage pulse RF therapy group|Experimental group: long duration high voltage pulse RF therapy group
219344388|NCT06978634|OTHER|SBAR training with cases|"The researcher will hold a face-to-face meeting with the students in the intervention group and provide information about the purpose of the study, the content of the training, the Student Guidelines for the SBAR Role Playing Application and the research process. Then, SBAR Training with Cases will be given. In addition, a group will be established via Whatsapp and communication during the process will be provided through this channel. The days and times of the training will be determined by looking at the students' course schedules. The training will be carried out in the Skills Laboratory of the Faculty of Health Sciences at Yüzüncü Yıl University."
219344389|NCT06978036|PROCEDURE|Flapless periodontal regeneration with EMD + EASD|Periodontal regneration with EMD in conjuction with Endoscope-assisted subgingival debridement
219344390|NCT06978036|PROCEDURE|Periodontal regeneration with EMD + PPT|Periodontal regneration with EMD in conjunction with periodontal surgery using Papilla Presevation Technique
219344391|NCT06979258|OTHER|Cooling intervention|Infrastructure and/or equipment that cools the house in the hot season
219344392|NCT06977425|DRUG|Magnesium sulphate|Patients received an initial intravenous loading dose of 30 mg/kg of 10% magnesium sulfate solution over 10 min. This will be followed by a continuous infusion of (10mg/kg/hr) for the entire duration of surgery.
219344393|NCT06977425|DRUG|Dexmedetomidine|Patients received dexmedetomidine infusion 0.5 μg/kg over 10 min as a bolus dose, followed by 0.2 μg/kg/h all over the operation.
219344394|NCT06977958|BEHAVIORAL|NASM OPT Group|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included hip thrusts, squats, and glute bridges.
219344395|NCT06977958|BEHAVIORAL|General Exercise Group|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
219344396|NCT06978179|PROCEDURE|Ultrasound-Guided Quadratus Lumborum Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|"Group ( 1 ) QLB Type III: Patients will receive QLB performedwith20ml of diluted bupivacaine 0.25% on each side."
219344397|NCT06978179|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|Group ( 2 ) TAP: Patients will receive TAP block performed with 20ml of diluted bupivacaine 0.25% on each side.
219344398|NCT06978985|DRUG|Risdiplam|Risdiplam
219344399|NCT06978985|DRUG|Nusinersen Injectable Product|Nusinersen
219344400|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
219344401|NCT03501667|OTHER|Use of decision support tool|use of a decision support software during clinical assessment of a case
219354824|NCT06221982|OTHER|No intervention, observational study|Observational study, no intervention
219354825|NCT01491178|DRUG|Prazaxa|Dabigatran etexilate
219354826|NCT02257047|DIETARY_SUPPLEMENT|Tea|
219344402|NCT03501667|OTHER|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
219344403|NCT03040375|BEHAVIORAL|Peer counselling|
219344404|NCT02800889|DRUG|Pixantrone|Pixantrone
219344405|NCT02393638|OTHER|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
219344406|NCT02393638|OTHER|Lecture|Lecture
219344407|NCT06978153|DRUG|benmelstobart combined with chemotherapy and anlotinib|Cohort 1: Neoadjuvant therapy (benmelstobart combined with chemotherapy and anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day 1. Anlotinib, 10 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Etoposide, 100mg/m2, day 1\~3. Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 10 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
219344408|NCT06978153|DRUG|benmelstobart combined with chemotherapy|Cohort 2: Neoadjuvant therapy (benmelstobart combined with chemotherapy, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; Etoposide, 100mg/m2, day 1\~3; Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
219344409|NCT06977477|OTHER|Remote Monitoring for Congestion Management in HFpEF Patients|All patients will undergo baseline tests, including echocardiography (left ventricular ejection fraction, E/e', left atrial volume index, left atrial strain analysis, left ventricular mass index, tricuspid annular plane systolic excursion, right ventricular strain, inferior vena cava index) and blood tests (NT-proBNP, creatinine, GFR, sST2, CA 125, bio-ADM, ALAT, ASAT, complete blood count, and hsCRP). Evaluation of extracellular and total body water volumes in the arms, legs, and trunk will be conducted using the Body Water Scale InBody (South Korea) and daily monitoring of pulmonary pressure through CardioMEMSTM. Bioelectrical impedance analysis (BIA) will be used to assess volume. Additional blood tests will be conducted at weeks 2, 6, 12, and at the final visit, with a focus on NT-proBNP, creatinine, GFR, ALAT, ASAT, hemoglobin, hematocrit, hsCRP, sST2, CA 125, and bio-ADM. At the final visit, a complete set of tests will be repeated to assess overall health and response to the int
219344410|NCT06977347|DRUG|Piperacillin/Tazobactam|Piperacillin/tazobactam: 4.5g IV q6h (over 3h)
219344411|NCT06977347|DRUG|Piperacillin/tazobactam + Levofloxacin|"Piperacillin/tazobactam: 4.5g IV q6h (over 3h)~\+ Levofloxacin 750mg IV q24h (over 30min)"
219344412|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
219344413|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection|Gelaspan
219344414|NCT03092102|DRUG|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
219344415|NCT00349856|DEVICE|Biofinity|Soft contact lens
219344416|NCT03100045|DRUG|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
219344417|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 1|Soft gel capsule
219344418|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 2|Soft gel chewable
219344419|NCT02284126|DRUG|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
219344420|NCT01934556|DRUG|Ranibizumab 0.3 mg intravitreal injection|
219344421|NCT01934556|DEVICE|Guided Laser Photocoagulation|
219344422|NCT02813551|DRUG|Torsemide|
219344423|NCT02813551|DRUG|Placebo|
219344424|NCT04375787|DRUG|Atorvastatin|Patients received 80 mg atorvastatin before elective coronary angiography
219344425|NCT06141369|BIOLOGICAL|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
219344426|NCT06862557|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
219344427|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
219344428|NCT06659042|DRUG|Cisplatin|administered via IV infusion
219344429|NCT06659042|DRUG|Carboplatin|administered via IV infusion
219344430|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
219344431|NCT05039632|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
219344432|NCT05039632|RADIATION|Radiation Therapy|Undergo Abscopal radiation therapy
219344433|NCT05039632|RADIATION|Radiation Therapy|Undergo RadScopal radiation therapy
219344434|NCT04478292|DRUG|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
219344435|NCT04478292|PROCEDURE|Primary surgery resection|Resection of the primary tumor up-front
219344436|NCT04478292|DRUG|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
219344437|NCT04478292|DRUG|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
219344438|NCT04478292|PROCEDURE|Biopsy|Tumors are deemed unresectable at diagnosis.
219344439|NCT04478292|PROCEDURE|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
219344440|NCT04478292|PROCEDURE|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
219344441|NCT04478292|DRUG|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
219344442|NCT04478292|DRUG|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
219344443|NCT04478292|DRUG|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
219344444|NCT04478292|DRUG|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
219344445|NCT06338553|DRUG|Semaglutide (Rybelsus®)|7 mg single dose of Rybelsus® by mouth once before each MMTT
219344446|NCT06338553|DRUG|Placebo|placebo capsule or tablet once before each MMTT.
219344447|NCT03845712|DRUG|doxecitine and doxribtimine|Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
219344448|NCT07004894|PROCEDURE|Neuromuscular re-education(experimental)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by neuromuscular reeducation technique (5-10 minutes duration) which includes for the 1st two weeks; cross friction massage with active movement and for the last two weeks longitudinal friction massage with active movement will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
219344449|NCT07004894|PROCEDURE|Friction massage(standard protocol)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by friction massage technique(5-10 minutes duration) which includes for the 1st two weeks; cross friction massage alone and for the last two weeks longitudinal friction massage alone will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
219344450|NCT02450175|DRUG|Everolimus|10 mg of Everolimus daily (by mouth)
219344451|NCT02450175|DRUG|Letrozole|2.5mg taken daily (by mouth)
219344452|NCT06869265|DRUG|Thiotepa ;busulfan;fludarabine|Eligible patients will receive the following conditioning regimen: thiotepa 5 mg/kg/day on Days -10 to -9; busulfan 3.2 mg/kg/day on Days -8 to -6; fludarabine 30 mg/m²/day on Days -6 to -2; and rabbit anti-thymocyte globulin (rATG) 1.5-2.5 mg/kg/day on Days -5 to -2. Hematopoietic stem cell infusion will be performed on Day 0. Graft-versus-host disease (GVHD) prophylaxis will include cyclosporine A (CsA), mycophenolate mofetil (MMF), and methotrexate (MTX).
219344453|NCT02922374|DRUG|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
219344454|NCT05106309|DRUG|10 mg CVL-231 as IR formulation|Tablets
219344455|NCT05106309|DRUG|30 mg CVL-231 as slow-release MR formulation|Capsules
219344456|NCT05106309|DRUG|30 mg CVL-231 as medium release MR formulation|Capsules
219344457|NCT05106309|DRUG|30 mg CVL-231 as fast release MR formulation|Capsules
219344458|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fasted|Capsules
219344459|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fed|Capsules
219344460|NCT05622344|BEHAVIORAL|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
219344461|NCT05622344|DEVICE|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
219344462|NCT06872437|DRUG|Lidocaine Injectable Solution|Infiltration by injections of 6mL of lidocaine (10 mg/mL) per injection site (left ischioanal fossa, right ischioanal fossa right ischioanal fossa, coccyx),
219344463|NCT06872437|DRUG|Saline Solution for Block|Infiltration by injections of 6mL of saline solution per injection site (left ischio-anal fossa, right ischio-anal fossa right ischio-anal fossa, coccyx)
219344464|NCT03471065|DEVICE|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
219344465|NCT06112067|DEVICE|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
219344466|NCT06695429|DIETARY_SUPPLEMENT|Beetroot juice|Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
219344467|NCT06869499|PROCEDURE|Blood sampling for dosage|4ml blood sample to measure acid sphingomyelinase enzyme activity and LysoSM, if required.
219344468|NCT06698939|DRUG|ORKA-001|ORKA-001 is supplied as sterile solution to be administered by SC injection
219344469|NCT06698939|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
219354827|NCT02257047|DIETARY_SUPPLEMENT|RYR|red yeast rice
219354828|NCT04520178|DRUG|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
219354829|NCT04520178|DRUG|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
219344470|NCT07029269|PROCEDURE|ERAS-tubeless group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; No abdominal drainage and nasojejunal feeding tubes were placed intraoperatively; None of these 3 tubes were present postoperatively.
219344471|NCT07029269|PROCEDURE|ERAS-tube group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; Nasojejunal feeding tube is not placed intraoperatively; 1 prophylactic abdominal drainage tube is placed at the duodenal stump for LDG and retained postoperatively.
219344472|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
219344473|NCT03085524|DIAGNOSTIC_TEST|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
219344474|NCT03085524|DIAGNOSTIC_TEST|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
219344475|NCT06776692|DRUG|Qdenga|Administration of Dengue vaccine and blood sample collection
219344476|NCT04507685|OTHER|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
219344477|NCT02558673|OTHER|TMAO dietary precursors|
219344478|NCT02558673|OTHER|Control (or active comparator)|
219344479|NCT06901882|BEHAVIORAL|CONECTEM, Communication based in BCS (basic communication skills) and AAC ( aumentative alternative communicatiton)|"It consists of applying basic and assisted communication techniques, already validated by experts (Happ, et al., 2008) to the critical patient admitted to the ICU. The intervention is divided into 3 strategies according to the level of patient awareness. Each strategy presents both verbal and non-verbal communication skills~Estratègia 3. Glasgow (≤8). Very ill patient, with indications for intubation, sedation and analgesia. We will basically use non-verbal communication, taking into account all external factors that may predispose to a change in the patient's condition.~Modulate your voice, speak softly and slowly, respecting an atmosphere of silence, without intense lights or loud noises. Adjust the temperature of the ICU according to the needs of the patient.~Achieve a relaxing atmosphere, playing calm music during the journey.Make comforting movements for the patient, avoiding abruptness and trying to establish non-verbal communication."
219344480|NCT06897501|DEVICE|bronchial blocker|Lung isolation for robot-assisted esophagectomy will be performed using bronchial blocker in this group.
219344481|NCT06897501|DEVICE|double-lumen endobronchial tube|Lung isolation for robot-assisted esophagectomy will be performed using double-lumen endobronchial tube in this group.
219344482|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
219344483|NCT06820671|OTHER|Recording voice samples|"Voice recording with~* reading the standard text~* repeating the test words~* vowel elicitation of 'a' and 'o' vowels for 5-10 seconds"
219344484|NCT06498713|DRUG|Acetaminophen 650 mg Oral Tablet|650 mg pills
219344485|NCT06498713|DRUG|Acetaminophen 650mg Liquid|650 mg liquid
219344486|NCT06498713|DEVICE|CADD pump|Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.
219344487|NCT06774859|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).
219344488|NCT06774859|DRUG|Oseltamivir|Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
219344489|NCT00377377|DRUG|EP1572 (ghrelin agonist) oral and duodenal application|
219344490|NCT05213208|DRUG|Propofol|Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
219344491|NCT05695950|DRUG|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
219344492|NCT05695950|DRUG|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
219344493|NCT06829251|BEHAVIORAL|Effective Ear Massage|The intervention consists of a structured ear massage technique administered daily for 2 weeks. Parents will receive training on how to target specific pressure points on the ear to reduce stress and anxiety, and improve sleep quality. This training will be conducted via WhatsApp (What's up Application) for 20 minutes, followed by daily massage practice. The massage will be performed using varying pressure over a 3-minute period on the entire ear, focusing on stress and sleep points.
219354830|NCT04520178|DRUG|Carbidopa|50mg
219354831|NCT04520178|DRUG|Placebo|Placebo
219344494|NCT06829251|BEHAVIORAL|Sham Ear Massage|The sham intervention involves a 1-minute ear massage on the outer helix rim, helix crest, and helix points 1, 2, and 3, without applying any pressure. The goal of the sham massage is to mimic the process of ear massage while ensuring no physiological effect on stress, anxiety, or sleep quality.
219344495|NCT04161833|DIETARY_SUPPLEMENT|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
219354832|NCT05689047|DRUG|M5717 330 mg|Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
219354833|NCT05689047|DRUG|M5717 500 mg|Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
219354834|NCT05689047|DRUG|M5717 660 mg|Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
219354835|NCT05689047|DRUG|Pyronaridine 360 mg|Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
219354836|NCT05689047|DRUG|Pyronaridine 360 mg|Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
219354837|NCT05689047|DRUG|Pyronaridine 540 mg|Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
219354838|NCT05689047|DRUG|Pyronaridine 720 mg|Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
219354839|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
219354840|NCT00612443|BEHAVIORAL|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
219354841|NCT00612443|BEHAVIORAL|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
219354842|NCT06487624|DRUG|HCB301|HCB301 administered via. intravenous (IV) infusion.
219354843|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
219354844|NCT03207672|DRUG|E7389-LF|intravenous infusion
219354845|NCT05206838|PROCEDURE|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
219354846|NCT02174055|BEHAVIORAL|Patient Interviews|participate in a brief interview
219354847|NCT02174055|BEHAVIORAL|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
219354848|NCT02174055|BEHAVIORAL|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
219354849|NCT04175626|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
219354850|NCT05622110|PROCEDURE|Adhesive glue closure|Incision closure with adhesive glue
219354851|NCT05622110|PROCEDURE|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
219354852|NCT04481204|DRUG|Cisplatin|Given IV
219354853|NCT04481204|DRUG|Fluorouracil|Given IV
219354854|NCT04481204|DRUG|Gemcitabine|Given IV
219354855|NCT04481204|DRUG|Irinotecan|Given IV
219354856|NCT04481204|DRUG|Leucovorin|Given IV
219354857|NCT04481204|DRUG|Nab-paclitaxel|Given IV
219354858|NCT04481204|DRUG|Oxaliplatin|Given IV
219354859|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
219344496|NCT06830499|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.
219344497|NCT03770260|DRUG|Ixazomib Citrate|Given PO
219344498|NCT03770260|DRUG|Pevonedistat|Given IV
219344499|NCT05386992|DIAGNOSTIC_TEST|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
219344500|NCT04649255|DEVICE|Liquid Embolic|Lava Liquid Embolic System (LES)
219344501|NCT03529266|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
219344502|NCT03529266|PROCEDURE|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
219344503|NCT01225484|PROCEDURE|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
219344504|NCT01225484|PROCEDURE|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
219344505|NCT00414102|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
219344506|NCT00414102|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
219344507|NCT01981915|PROCEDURE|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
219344508|NCT01981915|PROCEDURE|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
219344509|NCT01652885|DRUG|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
219344510|NCT00075400|DRUG|imatinib mesylate|Given PO
219344511|NCT00075400|OTHER|laboratory biomarker analysis|Correlative studies
219344512|NCT06130267|OTHER|Endocare|Virtual paradigm (calming environnement)
219344513|NCT00490568|DRUG|Rosiglitazone XR|Experimental drug
219344514|NCT01066364|DRUG|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
219344515|NCT02849795|OTHER|bone densitometry|
219344516|NCT02849795|OTHER|questionnaires|
219344517|NCT02849795|OTHER|biological analyses|
219344518|NCT03574090|DRUG|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
219344519|NCT03574090|DRUG|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
219344520|NCT05347888|OTHER|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
219344521|NCT03451773|DRUG|M7824|1,200 or 500mg every 2 weeks by intravenous (IV) infusion
219344522|NCT03451773|DRUG|Gemcitabine|Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
219344523|NCT02316405|OTHER|Arm and Leg Cycling Exercise for Walking after Stroke|
219344524|NCT06053515|BEHAVIORAL|Rosie the Chatbot|"Participants in the intervention group will be using the chatbot to ask questions related to the mom and baby's health, provide feedback selecting thumbs up or thumbs down on the questions' response, and use the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus). In addition, participants will be taking a pre-test health survey, mid-test health survey, and post-test health survey."
219344525|NCT05558956|DRUG|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
219344526|NCT06519019|PROCEDURE|Dental Implant Surgery - Hydrophilic group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
219344527|NCT06519019|PROCEDURE|Dental Implant Surgery - Conventional group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
219344528|NCT05073809|DIAGNOSTIC_TEST|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
219344529|NCT03283189|OTHER|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
219344530|NCT03468855|DRUG|ATI-50002 topical solution|Topical Solution administered twice daily
219344531|NCT02400788|DRUG|Resminostat|
219344532|NCT02400788|DRUG|Sorafenib|
219344533|NCT00371878|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (Prevnar)|
219344534|NCT05097807|BEHAVIORAL|smartphone related behaviors|Participants are required to watch specific contents on their own smartphones.
219344535|NCT01908101|DRUG|Eribulin Mesylate|Given IV
219344536|NCT01908101|OTHER|Laboratory Biomarker Analysis|Correlative studies
219344537|NCT03838679|DIAGNOSTIC_TEST|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
219344538|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
219344539|NCT03838679|DIAGNOSTIC_TEST|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
219344540|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
219344541|NCT03838679|DIAGNOSTIC_TEST|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
219344542|NCT03838679|DIAGNOSTIC_TEST|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
219344543|NCT03838679|DIAGNOSTIC_TEST|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
219344544|NCT03838679|DIAGNOSTIC_TEST|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
219344545|NCT00464412|BEHAVIORAL|Education|
219344546|NCT04245020|OTHER|Text message follow up|A text message will be sent to the patient 6-8 weeks following discharge
219344547|NCT04245020|OTHER|Telephone follow up|The patient will be followed up at 6-8 weeks following discharge with a telephone call
219344548|NCT04245020|OTHER|In person follow up|The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
219344549|NCT04957771|OTHER|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
219344550|NCT03854708|DRUG|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
219344551|NCT03854708|DRUG|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
219344552|NCT03854708|DRUG|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
219344553|NCT06539013|DRUG|Remifentanil|remifentanil infusion
219344554|NCT06539013|DRUG|N2O|Use of N2O for analgesia
219344555|NCT06539013|DRUG|Fentanyl|Use of Fentanylfor analgesia
219344556|NCT04806607|PROCEDURE|19G FNB|Biopsy specimen adequacy using the 19G FNB
219344557|NCT04806607|PROCEDURE|22G FNB|Biopsy specimen adequacy using the 22G FNB.
219344558|NCT06543108|DIAGNOSTIC_TEST|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
219344559|NCT03269760|DRUG|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
219344560|NCT02146612|OTHER|Amino Acid Supplement Group|Group receiving nutritional supplement
219344561|NCT04489966|BEHAVIORAL|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
219344562|NCT00166205|DEVICE|Swedish Adjustable Gastric Band|Long term implantable device.
219344563|NCT05712044|DRUG|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
219344564|NCT02205749|BEHAVIORAL|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
219344565|NCT02205749|BEHAVIORAL|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
219344566|NCT02205749|BEHAVIORAL|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
219344567|NCT03496090|OTHER|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
219344568|NCT03496090|OTHER|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
219344569|NCT04609189|DRUG|Pearlium/EffectiCal|Oral administration of Pearlium/EffectiCal.
219344570|NCT04609189|DRUG|Calcium carbonate/vitamin D3|Oral administration of Calcium Carbonate/Vitamin D3
219344571|NCT04223960|DRUG|EA1080|EA1080 Formulation A.
219344572|NCT04223960|DRUG|EA1080|EA1080 Formulation B.
219344573|NCT04223960|DRUG|EA1080|EA1080 Formulation C.
219344574|NCT04223960|DRUG|EA1080|EA1080 Formulation D.
219344575|NCT04223960|DRUG|EA1080-matching placebo|EA1080-matching placebo.
219344576|NCT04223960|DRUG|EA1080|EA1080 Formulation E.
219344577|NCT04223960|DRUG|EA1080|EA1080 Formulation F.
219344578|NCT01610765|DRUG|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
219344579|NCT01610765|DRUG|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
219344580|NCT03442543|DEVICE|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
219344581|NCT04278612|OTHER|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
219344582|NCT03616678|DEVICE|VenTouch System|"The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester."
219344583|NCT00846014|DRUG|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
219344584|NCT03351257|OTHER|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
219344585|NCT01864278|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
219344586|NCT02135692|BIOLOGICAL|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
219344587|NCT02135692|DRUG|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
219344588|NCT01056250|PROCEDURE|SILS cholangiography|intraoperative
219344589|NCT00144898|PROCEDURE|Sentinel Node Resection|Sentinel Node Resection
219344590|NCT00144898|PROCEDURE|Conventional Axillary Dissection|Conventional Axillary Dissection
219344591|NCT03976037|DRUG|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
219344592|NCT01099072|DRUG|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo
219344593|NCT01099072|DRUG|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
219344594|NCT05069987|OTHER|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax \& Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
219344595|NCT05689411|DEVICE|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
219344596|NCT03187769|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
219344597|NCT03187769|DRUG|Olanzapine|Daily oral dosing
219344598|NCT04378283|DRUG|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)|The study is designed to evaluate topical anesthetics
219344599|NCT04378283|DRUG|EMLA plus infiltration as anesthetic for wound repair.|EMLA plus infiltration as anesthetic for wound repair.
219344600|NCT06364449|OTHER|No intervention|No intervention
219344601|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
219344602|NCT06167785|DRUG|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks
219344603|NCT06167785|DRUG|Zanubrutinib|Zanubrutinib 160 mg oral twice daily
219344604|NCT06167785|DRUG|Tislelizumab + Zanubrutinib|Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
219344605|NCT01793155|OTHER|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
219344606|NCT01793155|OTHER|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
219344607|NCT02597738|OTHER|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
219344608|NCT02597738|OTHER|Blood/Urine Sample Collection|A one time blood sample will be collected.
219344609|NCT02198807|DRUG|Fosmidomycin-Piperaquine|
219344610|NCT05495893|DRUG|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
219344611|NCT05495893|DRUG|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
219344612|NCT04429061|BEHAVIORAL|SKILLZ-Girl curriculum|Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
219344613|NCT04314921|OTHER|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
219344614|NCT03103802|DEVICE|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
219344615|NCT00622648|DRUG|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
219344616|NCT00622648|DRUG|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
219344617|NCT05464303|DRUG|Intravenous Antibodies|Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
219344618|NCT03964961|OTHER|Functional massage|It's a massage combined with a stretching of the muscles.
219344619|NCT03964961|OTHER|Conventional massage|It's a regular massage made with the therapist's hands.
219344620|NCT03186677|BIOLOGICAL|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous
219344621|NCT03186677|BIOLOGICAL|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
219344622|NCT03108313|DRUG|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
219344623|NCT03108313|DRUG|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
219344624|NCT03766048|PROCEDURE|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
219344625|NCT03766048|PROCEDURE|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
219344626|NCT05317520|PROCEDURE|Cold vapor|"The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated."
219344627|NCT00879229|DRUG|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
219344628|NCT00879229|DRUG|Placebo|Placebo to match ambrisentan administered orally once daily.
219344629|NCT02085889|OTHER|no intervention: observational study|observational
219344630|NCT05094700|OTHER|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
219344631|NCT01097746|BIOLOGICAL|Bevacizumab|Given IV
219344632|NCT01097746|DRUG|Carboplatin|Given IV
219344633|NCT01097746|DRUG|Paclitaxel|Given IV
219344634|NCT01227733|OTHER|Breast Tumor Blocks|
219344635|NCT05071950|OTHER|Control period|"* first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal"
219354860|NCT05944432|DEVICE|FreeStyle Libre 3 Continuous Glucose Monitoring System.|Subjects will be randomised to use the FreeStyle Libre 3 system
219354861|NCT05944432|DEVICE|Self monitoring of blood glucose|Subjects will be randomised to continue with their current glucose monitoring system
219344636|NCT05071950|DIETARY_SUPPLEMENT|D-allulose period|"* \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose"
219344637|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
219344638|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
219344639|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
219344640|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
219344641|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
219344642|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
219344643|NCT04762537|OTHER|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
219344644|NCT04762537|OTHER|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
219344645|NCT00208221|DRUG|ramipril|
219344646|NCT00208221|DRUG|ramipril-telmisartan|
219344647|NCT00549458|BEHAVIORAL|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
219344648|NCT00549458|PROCEDURE|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
219344649|NCT04628637|OTHER|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
219344650|NCT03791788|DIAGNOSTIC_TEST|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
219344651|NCT03924609|DIAGNOSTIC_TEST|Intensive screening / routine screening|Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
219344652|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
219344653|NCT00631371|DRUG|Temsirolimus|Temsirolimus 25 mg IV weekly
219344654|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
219344655|NCT00631371|DRUG|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
219344656|NCT04179383|OTHER|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
219344657|NCT00390546|DRUG|Digoxin|
219344658|NCT00390546|DRUG|Propranolol|
219344659|NCT03670212|DRUG|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
219344660|NCT03670212|DRUG|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
219344661|NCT03670212|DRUG|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
219344662|NCT02241759|DRUG|TA-8995|
219344663|NCT02241759|DRUG|Moxifloxacin|
219344664|NCT02241759|DRUG|Placebo|
219344665|NCT04313127|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
219344666|NCT04893642|PROCEDURE|Suture rectopexy|
219344667|NCT04893642|PROCEDURE|resection rectopexy|
219344668|NCT04893642|PROCEDURE|Delorme's operation|
219344669|NCT04893642|PROCEDURE|Altemeier's operation|
219344670|NCT00489567|PROCEDURE|Blood sample collection|
219344671|NCT04117464|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
219344672|NCT04117464|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
219344673|NCT04117464|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
219344674|NCT04117464|OTHER|Wait List Group|No psychological intervention
219344675|NCT05007275|BIOLOGICAL|1x10^9 vp AZD1222|A single dose of 1x 10\^9 vp AZD1222
219344676|NCT05007275|BIOLOGICAL|5x10^9 vp AZD1222|A single dose of 5x 10\^9 vp AZD1222
219344677|NCT05007275|BIOLOGICAL|1x10^10 vp AZD1222|A single dose of 1x10\^10 vp AZD1222
219344678|NCT02836067|BEHAVIORAL|Counseling|Smoking cessation counseling
219344679|NCT02836067|OTHER|Smoking Cessation drugs|Medication to aid smoking cessation
219344680|NCT02836067|PROCEDURE|Bronchoscopy|Bronchoscopy
219344681|NCT02836067|PROCEDURE|Blood Draw|Screening and research blood draws
219344682|NCT02836067|BEHAVIORAL|Questionnaires|Behavioral questionnaires
219344683|NCT01093027|OTHER|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
219344684|NCT01093027|OTHER|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
219344685|NCT05088304|OTHER|no intervention|
219344686|NCT02526706|OTHER|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
219344687|NCT05558839|BEHAVIORAL|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
219344688|NCT00665457|BIOLOGICAL|filgrastim|
219344689|NCT00665457|DRUG|capecitabine|
219344690|NCT00665457|DRUG|celecoxib|
219344691|NCT00665457|DRUG|cyclophosphamide|
219344692|NCT00665457|DRUG|docetaxel|
219344693|NCT00665457|DRUG|doxorubicin hydrochloride|
219344694|NCT00665457|GENETIC|gene expression analysis|
219344695|NCT00665457|GENETIC|polymorphism analysis|
219344696|NCT00665457|GENETIC|protein expression analysis|
219344697|NCT00665457|GENETIC|reverse transcriptase-polymerase chain reaction|
219344698|NCT00665457|OTHER|imaging biomarker analysis|
219344699|NCT00665457|OTHER|immunohistochemistry staining method|
219344700|NCT00665457|OTHER|laboratory biomarker analysis|
219344701|NCT00665457|OTHER|pharmacogenomic studies|
219344702|NCT00665457|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
219344703|NCT00665457|PROCEDURE|needle biopsy|
219344704|NCT00665457|PROCEDURE|neoadjuvant therapy|
219344705|NCT00665457|PROCEDURE|radiomammography|
219344706|NCT00665457|PROCEDURE|ultrasound imaging|
219344707|NCT01554280|DEVICE|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
219344708|NCT04195321|DRUG|Norepinephrine|infusion will be started after induction of spinal anesthesia
219344709|NCT04195321|DRUG|phenylephrine|infusion will be started after induction of spinal anesthesia
219344710|NCT00291408|PROCEDURE|Skin Prick Test|
219344711|NCT00291408|PROCEDURE|Impulse Oscillometry|
219344712|NCT00291408|PROCEDURE|Exhaled Nitric Oxide|
219344713|NCT00291408|PROCEDURE|Spirometry|
219344714|NCT00291408|PROCEDURE|Reversibility|
219344715|NCT00291408|PROCEDURE|Exhaled Breath Condensate|
219344716|NCT00291408|PROCEDURE|Sputum Induction|
219344717|NCT05348655|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease
219344718|NCT05348655|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
219344719|NCT01526902|DEVICE|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
219344720|NCT01526902|DEVICE|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
219344721|NCT00812214|DRUG|eszopiclone|3 mg tablet every night at bedtime
219344722|NCT00812214|DRUG|placebo|1 tablet every night at bedtime
219344723|NCT04578795|DEVICE|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
219344724|NCT01091701|BIOLOGICAL|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
219344725|NCT01091701|OTHER|Plasmalyte-A|Single IV dose of Plasmalyte-A
219344726|NCT00046774|DRUG|MRA 003 US|
219344727|NCT04603573|DEVICE|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
219344728|NCT04603573|DEVICE|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
219344729|NCT06118684|DRUG|EP395 (Part A and B)|"EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg."
219344730|NCT06118684|DRUG|Verapamil (Part A)|Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
219344731|NCT06118684|DRUG|Midazolam (Part B)|Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
219344732|NCT06118684|DRUG|Digoxin (Part B)|Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
219344733|NCT03080298|DRUG|BP101|
219344734|NCT03080298|DRUG|Placebo|
219344735|NCT02145741|DRUG|750 milligram Xentuzumab|750 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
219344736|NCT02145741|DRUG|1000 milligram Xentuzumab|1000 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
219344737|NCT02145741|DRUG|1400 milligram Xentuzumab|1400 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
219344738|NCT01692964|DEVICE|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
219344739|NCT00129766|BIOLOGICAL|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
219344740|NCT00129766|BIOLOGICAL|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
219344741|NCT02181829|RADIATION|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
219344742|NCT03044340|OTHER|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
219344743|NCT02148380|DRUG|pemetrexed plus carboplatin|
219344744|NCT02148380|DRUG|gefitinib|
219344745|NCT02598843|OTHER|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
219344746|NCT02598843|OTHER|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
219344747|NCT04852107|OTHER|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
219344748|NCT04737577|PROCEDURE|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
219344749|NCT04737577|PROCEDURE|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
219344750|NCT04091087|DRUG|crisaborole ointment|crisaborole ointment
219344751|NCT04091087|OTHER|vehicle ointment|vehicle ointment
219344752|NCT03425032|DEVICE|CT scanner|Regular CT imaging of the abdomen and pelvis
219344753|NCT06425575|BIOLOGICAL|Amniotic suspension allograft|the amniotic suspension allograft consists of fresh amniotic fluid into which micronized amniotic membrane has been added as a suspension.
219344754|NCT05217771|OTHER|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
219344755|NCT03872804|PROCEDURE|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
219344756|NCT03872804|PROCEDURE|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
219344757|NCT03872804|PROCEDURE|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
219344758|NCT03872804|OTHER|Oral pulse steroid with narrow band|"* A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~* All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
219344759|NCT00041093|DRUG|Docetaxel|Given IV
219344760|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.
219344761|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.
219344762|NCT04507659|DRUG|Placebo|Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
219344763|NCT01019447|OTHER|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
219344764|NCT01019447|OTHER|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
219344765|NCT05043415|PROCEDURE|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
219344766|NCT05043415|PROCEDURE|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
219344767|NCT04277845|DRUG|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
219344768|NCT02505399|DRUG|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:~* 180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 90 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 90 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
219344769|NCT02505399|DRUG|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:~* 300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 75 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 0 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
219344770|NCT04869085|BEHAVIORAL|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
219344771|NCT06447610|PROCEDURE|Lateral arm free flap|In this study, we present a case series of 8 patients operated for a maxillo-facial defect with a lateral arm free flap.
219344772|NCT05150379|OTHER|Different exercises with their shoulders|"* Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test"
219344773|NCT05150379|BEHAVIORAL|SI-RSI questionnaire|French version of Shoulder Instability Return-to-Sport after Injury
219344774|NCT04997018|RADIATION|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
219344775|NCT05554614|BEHAVIORAL|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
219344776|NCT05554614|BEHAVIORAL|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
219344777|NCT05554614|BEHAVIORAL|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
219344778|NCT04814251|OTHER|Observationnal cohort|data collection
219344779|NCT04527900|DRUG|carboplatin and paclitaxel|carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
219344780|NCT04527900|RADIATION|pelvic IMPT (Intensity Modulated Proton Therapy)|whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions
219344781|NCT00003345|DRUG|cisplatin|
219344782|NCT00003345|DRUG|irinotecan hydrochloride|
219344783|NCT05440539|OTHER|Written Handouts|The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
219344784|NCT05440539|OTHER|Interactive Workshop|Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
219344785|NCT03808077|DRUG|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.003 mg/kg/min or 0.18mg/kg/hr).
219344786|NCT03808077|DRUG|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.006mg/kg/min or 0.35mg/kg/hr).
219344787|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
219344788|NCT04152161|BIOLOGICAL|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
219344789|NCT04152161|BIOLOGICAL|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
219344790|NCT01409200|DRUG|Antiandrogen Therapy|Given per standard of care
219344791|NCT01409200|DRUG|Axitinib|Given PO
219344792|NCT01409200|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219344793|NCT01409200|PROCEDURE|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
219344794|NCT05704933|DRUG|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
219344795|NCT05704933|DRUG|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.\[18-20\] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
219344796|NCT05704933|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.\[6\] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
219344797|NCT05704933|PROCEDURE|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
219344798|NCT05701358|PROCEDURE|Physiology-guided NCL PCI|For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
219344799|NCT05701358|PROCEDURE|Angiography-guided NCL PCI|PCI will be performed as per local practice
219344800|NCT05937672|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
219344801|NCT06668714|COMBINATION_PRODUCT|Placebo + mixed meal|Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR
219344802|NCT06668714|COMBINATION_PRODUCT|Lactate + mixed meal|Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.
219344803|NCT06668714|RADIATION|PET-scan|Dynamic whole-body PET scan.
219344804|NCT06668714|COMBINATION_PRODUCT|Mixed meal with 18F-FTHA|Mixed meal test with the addition of 70 MBq 18F-FTHA
219344805|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
219344806|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
219344807|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
219344808|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
219344809|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
219344810|NCT06280209|DRUG|BMN 351|Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
219344811|NCT05841043|DRUG|SHR8028 eye drops|SHR8028 eye drops
219344812|NCT05841043|DRUG|Vehicle eye drops.|Vehicle eye drops.
219344813|NCT01527864|DRUG|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
219344814|NCT01527864|DRUG|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
219344815|NCT05569707|DEVICE|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with SPIO particles (Magtrace®).
219344816|NCT02510027|OTHER|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
219344817|NCT03703102|DRUG|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
219344818|NCT03703102|DRUG|Placebo|Matching placebo
219344819|NCT00808795|DRUG|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
219344820|NCT00808795|DRUG|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
219344821|NCT01220895|BIOLOGICAL|CMV-specific T-cells, single infusion following single positive CMV PCR result|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
219344822|NCT01186575|OTHER|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
219344823|NCT04503499|OTHER|Manuel Therapy|"The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times."
219344824|NCT05392686|DRUG|PD-1 inhibitor|Tirelizumab
219344825|NCT05392686|DRUG|PARP inhibitor|Fluzopari capsule
219344826|NCT00816426|DRUG|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
219344827|NCT00816426|DRUG|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
219344828|NCT00816426|DRUG|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
219344829|NCT00816426|DRUG|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
219344830|NCT00816426|DRUG|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
219344831|NCT05241730|OTHER|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
219344832|NCT05241730|OTHER|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
219344833|NCT05241730|OTHER|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
219344834|NCT05241730|OTHER|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
219344835|NCT00945776|BEHAVIORAL|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
219344836|NCT00945776|BEHAVIORAL|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
219344837|NCT00945776|BEHAVIORAL|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
219344838|NCT02676492|OTHER|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
219344839|NCT02676492|OTHER|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
219344840|NCT01599403|PROCEDURE|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
219344841|NCT01599403|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
219344842|NCT01599403|PROCEDURE|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
219344843|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
219344844|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
219344845|NCT01224626|DRUG|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
219344846|NCT01577186|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
219344847|NCT03363321|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous injection
219344848|NCT05074251|DIAGNOSTIC_TEST|HIV self test|For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).
219344849|NCT05074251|BEHAVIORAL|Counseling and referral for partner testing|Counseling and refer participant's partner for facility based HIV testing
219344850|NCT02783703|DIETARY_SUPPLEMENT|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
219344851|NCT04352959|DEVICE|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
219344852|NCT04352959|DEVICE|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
219344853|NCT05886790|BIOLOGICAL|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
219344854|NCT05886790|BIOLOGICAL|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
219344855|NCT05886790|BIOLOGICAL|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
219344856|NCT02915523|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACi).
219344857|NCT02915523|DRUG|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
219344858|NCT02915523|DRUG|Placebo|A pill containing no active drug ingredient.
219344859|NCT03287219|DRUG|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
219344860|NCT03742180|DRUG|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
219344861|NCT03742180|DRUG|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
219344862|NCT00930761|BEHAVIORAL|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
219344863|NCT00957008|BEHAVIORAL|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
219344864|NCT00957008|OTHER|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
219344865|NCT00957008|DEVICE|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
219344866|NCT00518154|DRUG|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
219344867|NCT03220542|DRUG|Probiotics|Saccharomyces boulardii
219344868|NCT03220542|DIETARY_SUPPLEMENT|Broccoli|Broccoli sprouts extract
219344869|NCT03220542|DRUG|Esomeprazole|Esomeprazole
219344870|NCT03220542|DRUG|Amoxicillin|Amoxicillin
219344871|NCT03220542|DRUG|Clarithromycin|Clarithromycin
219344872|NCT06168032|BIOLOGICAL|Any Chinese government-recommended COVID-19 booster vaccine|Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.
219344873|NCT00002000|DRUG|Valacyclovir hydrochloride|
219344874|NCT00002000|DRUG|Acyclovir|
219344875|NCT02498015|DRUG|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
219344876|NCT02498015|DRUG|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
219344877|NCT03724864|DIETARY_SUPPLEMENT|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
219344878|NCT00823407|DRUG|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
219344879|NCT00823407|DRUG|Placebo|Subjects will receive a single oral dose of placebo
219344880|NCT02824705|PROCEDURE|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
219344881|NCT03949920|DRUG|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
219344882|NCT06495086|DEVICE|NIV|The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.
219344883|NCT06495086|DEVICE|HFNC-30|The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
219344884|NCT06495086|DEVICE|HFNC-50|The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
219344885|NCT05879042|OTHER|Static Stretching|Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.
219344886|NCT05879042|OTHER|Dynamic Stretching|Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.
219344887|NCT05879042|OTHER|PNF Stretching|For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.
219344888|NCT05879042|OTHER|Sham stretching|Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
219344889|NCT02731209|DEVICE|urinary catheter|
219344890|NCT04523311|BEHAVIORAL|Hypnosis.|Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
219344891|NCT04523311|OTHER|Usual care|Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
219344892|NCT02601521|BEHAVIORAL|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
219344893|NCT02601521|BEHAVIORAL|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
219344894|NCT05284942|DRUG|Mycophenolate mofetil combined with oral prednisone|Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108
219344895|NCT05959135|DEVICE|Gastric ultrasonography|"It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies"
219344896|NCT00721474|DRUG|Bosutinib|Bosutinib fasting
219344897|NCT00721474|DRUG|Bosutinib|Bosutinib fed
219344898|NCT03221751|DRUG|prazosin hydrochloride|Prazosin is an oral capsule. It is an alpha-1 antagonists.
219344899|NCT03221751|DRUG|placebo|Placebo is an inert oral capsule identical in appearance to prazosin capsules.
219344900|NCT06308276|OTHER|Aerobic Training|Aerobic Training: Brisk walking, jogging, cycling, or low-impact aerobics
219344901|NCT06308276|OTHER|Resistance Training|Resistance Training: Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
219344902|NCT02757560|OTHER|SFA diet|SFA versus control diet
219344903|NCT02757560|OTHER|MUFA diet|MUFA versus control diet
219344904|NCT02757560|OTHER|CARB diet|CARB versus control diet
219344905|NCT03571646|BEHAVIORAL|Capnostream 20 monitoring|Continuous monitoring on a general ward
219344906|NCT03571646|DEVICE|PM1000N-RR monitoring|Continuous monitoring on a general ward
219344907|NCT04413253|DRUG|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
219344908|NCT04413253|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
219344909|NCT02086539|OTHER|Large Envelope|
219344910|NCT02086539|OTHER|Priority Mail|
219344911|NCT02086539|OTHER|Amazon|
219344912|NCT00801879|DRUG|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
219344913|NCT00801879|DRUG|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
219344914|NCT04677959|DRUG|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
219344915|NCT04677959|DRUG|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
219344916|NCT04677959|DRUG|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
219344917|NCT04677959|DRUG|Standard of Care Rescue Medication|Current rescue medication
219344918|NCT06098768|BEHAVIORAL|VR Social Skills|The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
219344919|NCT03227900|DRUG|Lidocaine|Intragastric infusion of lidocain
219344920|NCT03227900|DRUG|Placebos|Intragastric infusion of water for injections
219344921|NCT01253655|DRUG|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
219344922|NCT04529759|OTHER|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
219344923|NCT04529759|OTHER|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
219344924|NCT03403114|BEHAVIORAL|Questionnaire|a 15min questionnaire
219344925|NCT04774835|DIAGNOSTIC_TEST|HIVST|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
219344926|NCT04774835|DIAGNOSTIC_TEST|Standard aPS|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
219344927|NCT02057315|DRUG|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
219344928|NCT02057315|DRUG|Placebo|One dose of matching placebo over 3 bilateral applications.
219344929|NCT00763815|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219344930|NCT00763815|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
219344931|NCT00763815|DEVICE|Pen auto-injector|
219344932|NCT00763815|DRUG|Pioglitazone|Dose to be kept stable.
219344933|NCT00763815|DRUG|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
219344934|NCT00166608|PROCEDURE|Blood sampling|
219344935|NCT06044688|DEVICE|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
219344936|NCT06044688|DEVICE|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
219344937|NCT04395664|DEVICE|C3+ Holter Monitor|ECG monitoring
219344938|NCT01970995|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
219344939|NCT01970995|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
219344940|NCT01970995|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
219344941|NCT05559489|DRUG|Oral Rehydration Solution|Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
219344942|NCT05559489|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
219344943|NCT03535467|OTHER|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
219344944|NCT04309227|OTHER|Strength Training|"Strength training traditionally requires use of high intensity loads to stimulate muscle growth and strength improvements. Some participants will be randomized to a traditional strength training program.~Blood Flow Restriction (BFR) training is used to stimulate muscle hypertrophy and strength improvements in a variety of populations. Results of BFR training are comparable to traditional high intensity training (HIT) despite using weight that are at a low intensity (low percent of 1 repetition maximum). This intervention has not been extensively studies in the rheumatoid or osteoarthritis populations, nor the myositis populations despite idealogical benefit for each group of low-load strengthening."
219344945|NCT00886301|PROCEDURE|liver biopsy|liver biopsy
219344946|NCT00678405|BEHAVIORAL|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
219344947|NCT00678405|BEHAVIORAL|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
219344948|NCT06044480|DRUG|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
219344949|NCT06044480|OTHER|Placebo|Administration of the same amount of saline solution instead of dexamethasone
219344950|NCT00003715|BIOLOGICAL|BCG vaccine|
219344951|NCT00003715|BIOLOGICAL|autologous tumor cell vaccine|
219344952|NCT00003715|BIOLOGICAL|recombinant interferon alfa|
219344953|NCT00003715|DRUG|chemotherapy|
219344954|NCT00003715|DRUG|cyclophosphamide|
219344955|NCT00199563|DRUG|Viagra|Sildenafil 100mg daily for 12 weeks
219344956|NCT01485757|DRUG|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
219344957|NCT05012956|PROCEDURE|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
219344958|NCT05012956|PROCEDURE|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
219344959|NCT03594188|PROCEDURE|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
219344960|NCT01056627|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
219344961|NCT05969509|OTHER|progressive relaxation exercise|applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
219344962|NCT05561517|OTHER|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
219344963|NCT01639677|PROCEDURE|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
219344964|NCT01639677|PROCEDURE|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
219344965|NCT05558878|DRUG|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
219344966|NCT03825770|BEHAVIORAL|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
219344967|NCT03825770|BEHAVIORAL|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
219344968|NCT03167996|BEHAVIORAL|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
219344969|NCT04254068|BEHAVIORAL|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
219344970|NCT05395065|DEVICE|Silver Diamine Fluoride/Sodium Fluoride Varnish|Application of dental caries arresting topical medication
219344971|NCT04742088|DEVICE|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
219344972|NCT06310980|DEVICE|smartpen|use of a smartpen connected with glucose sensor by an digital application
219344973|NCT00586495|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
219344974|NCT02354937|DRUG|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
219344975|NCT01252212|BEHAVIORAL|SMS medication adherence|SMS messages to cell phones.
219344976|NCT01252212|BEHAVIORAL|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
219344977|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg once daily
219344978|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg bid
219344979|NCT03891173|DRUG|L-DOS47|L-DOS47 lyophilized powder reconstituted and diluted for iv injection
219344980|NCT03891173|DRUG|Cisplatin|Cisplatin concentrate for solution for iv infusion
219344981|NCT03891173|DRUG|Vinorelbine|Vinorelbine concentrate for solution for iv infusion
219344982|NCT03679533|DIETARY_SUPPLEMENT|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
219344983|NCT03679533|DIETARY_SUPPLEMENT|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
219344984|NCT01382797|DRUG|ALKS 37|Capsules for oral administration
219344985|NCT01382797|DRUG|Placebo|Capsules for oral administration
219344986|NCT03480100|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
219344987|NCT03480100|DEVICE|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
219344988|NCT04361591|OTHER|Observational only|Observational Study
219344989|NCT05284760|DRUG|Soticlestat|Soticlestat T4 tablets.
219344990|NCT05284760|DRUG|Soticlestat|Soticlestat T3 mini-tablets.
219344991|NCT05284760|DRUG|Soticlestat|Soticlestat commercial tablets.
219344992|NCT04082754|BIOLOGICAL|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
219344993|NCT04082754|DRUG|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
219344994|NCT02965807|DEVICE|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
219344995|NCT00356928|DRUG|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
219344996|NCT00356928|BIOLOGICAL|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
219344997|NCT06090370|DEVICE|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
219344998|NCT06090370|DEVICE|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
219344999|NCT06090370|OTHER|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
219345000|NCT06090370|OTHER|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
219345001|NCT06090370|OTHER|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
219345002|NCT00823355|DRUG|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
219345003|NCT00823355|DRUG|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
219345004|NCT00823355|DRUG|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
219345005|NCT00823355|DRUG|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
219345006|NCT01311037|OTHER|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
219345007|NCT01090466|DRUG|cisplatin|
219345008|NCT01090466|DRUG|gemcitabine hydrochloride|
219345009|NCT01090466|DRUG|temsirolimus|
219345010|NCT01090466|OTHER|pharmacological study|
219345011|NCT01870427|DRUG|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
219345012|NCT05259865|DIAGNOSTIC_TEST|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
219345013|NCT05422807|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
219345014|NCT03068442|DRUG|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
219345015|NCT00177333|DRUG|Doxycycline|
219345016|NCT02821507|DRUG|sirolimus and cyclophosphamide|
219345017|NCT02595723|DRUG|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
219345018|NCT02595723|DRUG|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
219345019|NCT02595723|DRUG|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
219345020|NCT02595723|DRUG|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
219345021|NCT01197404|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
219345022|NCT01197404|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
219345023|NCT02897700|DRUG|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
219345024|NCT02897700|DRUG|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
219345025|NCT02897700|DRUG|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
219345026|NCT03570931|DRUG|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
219345027|NCT00096707|DRUG|2-deoxy-D-glucose (2DG)|
219345028|NCT06182982|DEVICE|auricolotherapy|Magnetic bal plasters are applied on the ear surface
219345029|NCT00000522|BEHAVIORAL|diet, sodium-restricted|
219345030|NCT00000522|BEHAVIORAL|diet, reducing|
219345031|NCT00000522|BEHAVIORAL|exercise|
219345032|NCT00000522|BEHAVIORAL|alcohol restriction|
219345033|NCT00000522|DRUG|chlorthalidone|
219345034|NCT00000522|DRUG|acebutolol|
219345035|NCT00000522|DRUG|doxazosin|
219345036|NCT00000522|DRUG|amlodipine|
219345037|NCT00000522|DRUG|enalapril|
219345038|NCT04502485|PROCEDURE|Gastric water exchange|Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
219345039|NCT04502485|PROCEDURE|traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
219345040|NCT00004259|DRUG|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
219345041|NCT00004259|DRUG|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
219345042|NCT00004259|RADIATION|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
219345043|NCT00004259|DRUG|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
219345044|NCT00004259|DRUG|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
219345045|NCT00004259|DRUG|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
219345046|NCT00004259|DRUG|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
219345047|NCT00004259|DRUG|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
219345048|NCT05821764|OTHER|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~* Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~* The cord blood sample (10 mL) immediately after delivery.~Data collection :~* A data collection sheet for the attention of the investigator (doctor or midwife) ;~* Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
219345049|NCT00996944|DRUG|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
219345050|NCT00996944|DRUG|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
219345051|NCT01688154|DIETARY_SUPPLEMENT|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
219345052|NCT01688154|OTHER|2 empty capsules|
219345053|NCT03910907|DRUG|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
219345054|NCT00769184|DRUG|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
219345055|NCT00769184|OTHER|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
219345056|NCT00769184|DRUG|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
219345057|NCT01119300|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
219345058|NCT01119300|OTHER|Standard care|Standard care
219345059|NCT02381639|BEHAVIORAL|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
219345060|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 3 mg/kg
219345061|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 15 mg/kg
219345062|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 30 mg/kg
219345063|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 0.3 mg/kg
219345064|NCT00385255|BIOLOGICAL|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
219345065|NCT00385255|BIOLOGICAL|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
219345066|NCT02443883|DRUG|Ramucirumab|Administered IV
219345067|NCT01643629|BIOLOGICAL|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
219345068|NCT01643629|OTHER|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
219345069|NCT04788121|DRUG|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
219345070|NCT04788121|OTHER|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
219345071|NCT00860210|DEVICE|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
219345072|NCT02337374|DEVICE|Midurethral sling mesh|
219345073|NCT01297335|DRUG|clonidine|Intrathecal Clonidine
219345074|NCT06373809|BIOLOGICAL|Transplantation of Placenta Derived Stem Cells|Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
219345075|NCT01997411|DRUG|Nasal Glucagon|
219345076|NCT01997411|DRUG|Intramuscular Glucagon|
219345077|NCT03358888|DRUG|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
219345078|NCT03358888|DRUG|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
219345079|NCT03358888|DRUG|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
219345080|NCT04793295|DRUG|MT-7117|MT-7117
219345081|NCT02573363|DRUG|Cytarabine|Given per standard of care
219345082|NCT02573363|DRUG|Mitoxantrone Hydrochloride|Given per standard of care
219345083|NCT02573363|DRUG|Selinexor|Given PO
219345084|NCT03119792|OTHER|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
219345085|NCT03119792|OTHER|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
219345086|NCT00091806|DRUG|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
219345087|NCT00091806|DRUG|Panitumumab|9 mg/kg once every 3 weeks
219345088|NCT03811457|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
219345089|NCT03729063|OTHER|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
219345090|NCT03729063|OTHER|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
219345091|NCT04922476|DIETARY_SUPPLEMENT|Alflorex®|Each probiotic capsule contains 1 x 10\^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
219345092|NCT01724658|DRUG|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
219345093|NCT01724658|DRUG|placebo|placebo orally twice a week with progynova 1 mg oral daily
219345094|NCT01868048|DRUG|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
219345095|NCT01868048|DRUG|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
219345096|NCT03604965|DRUG|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
219345097|NCT03604965|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
219345098|NCT00303914|PROCEDURE|assessment of therapy complications|
219345099|NCT00303914|PROCEDURE|cognitive assessment|
219345100|NCT00303914|PROCEDURE|psychosocial assessment and care|
219345101|NCT00393107|DRUG|rituximab|
219345102|NCT00393107|DRUG|rituximab,fludarabine, cyclophosphamide|
219345103|NCT00775632|DRUG|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
219345104|NCT00775632|DRUG|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
219345105|NCT00663065|DRUG|PAZ-417|
219345106|NCT02079987|BEHAVIORAL|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
219345107|NCT02079987|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
219345108|NCT01617330|PROCEDURE|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
219345109|NCT02911480|DRUG|Oxytocin|
219345110|NCT01206205|DRUG|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
219345111|NCT02757664|DEVICE|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
219345112|NCT02757664|OTHER|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
219345113|NCT02757664|DEVICE|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
219345114|NCT02940509|DRUG|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)"
219345115|NCT02940509|DRUG|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
219345116|NCT00823290|DRUG|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
219345117|NCT00506883|DRUG|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
219345118|NCT00506883|DRUG|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
219345119|NCT00506883|OTHER|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
219345120|NCT02224378|PROCEDURE|peep induced CVP|
219345121|NCT02224378|PROCEDURE|passive leg raising(PLR)|
219345122|NCT02626195|DIETARY_SUPPLEMENT|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse"
219345123|NCT03429192|PROCEDURE|Surgery|Surgeries plus dissection of lymph nodes
219345124|NCT04173676|DRUG|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
219345125|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
219345126|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
219345127|NCT00399165|DRUG|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
219345128|NCT00399165|OTHER|placebo sesame oil|placebo sesame oil
219345129|NCT00399165|DRUG|Dutasteride|24.5 mg po once (Day 0)
219345130|NCT03777150|OTHER|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
219345131|NCT03777150|OTHER|Postoperative care in standard ward|Postoperative care in standard ward
219345132|NCT03636139|DEVICE|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
219345133|NCT03636139|DEVICE|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
219345134|NCT03999762|DEVICE|sample prep|Effectiveness of a sample preparation protocol
219345135|NCT03104894|PROCEDURE|Meibomian Glands Massage|Meibomian gland expression
219345136|NCT03104894|PROCEDURE|Sham Meibomian Glands Massage|Touching the eyelids gently
219345137|NCT03104894|DEVICE|Meibomian Massage device|Meibomian glands expression with applicator
219345138|NCT01445951|DRUG|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
219345139|NCT01445951|DRUG|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
219345140|NCT01445951|DRUG|Insulin Aspart in combination with a basal insulin|Injectable insulin
219345141|NCT03857204|DEVICE|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
219345142|NCT06539572|PROCEDURE|Cleft lip repair; palatoplasty; alveolar bone grafting|cleft surgical treatment based on Chang Gung Craniofacial Center Protocol for cleft treatment
219345143|NCT06181942|DEVICE|SP|English name: da Vinci SP Surgical System Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
219345144|NCT03238105|DRUG|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
219345145|NCT03238105|DEVICE|Intense Pulsed Light|Monthly sessions for 3 months.
219345146|NCT00538395|DRUG|Adriamycin, Taxol and Cytoxan|Chemotherapy
219345147|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
219345148|NCT04735445|DIAGNOSTIC_TEST|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
219345149|NCT04735445|DIAGNOSTIC_TEST|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
219345150|NCT04735445|DIAGNOSTIC_TEST|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
219345151|NCT04735445|DIAGNOSTIC_TEST|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
219345152|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
219345153|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~* Asian male\> 40 years old~* Asian woman\> 50 years old~* African man or woman~* HCC family history"
219345154|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
219345155|NCT04735445|DIAGNOSTIC_TEST|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
219345156|NCT04735445|DIAGNOSTIC_TEST|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
219345157|NCT04735445|DIAGNOSTIC_TEST|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
219345158|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
219345159|NCT04735445|DIAGNOSTIC_TEST|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
219345160|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~* Age \> 40 years~* Active smoker or former smoker\<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~* No contraindications for thoracic surgery~* No lung infection in the last 2 months"
219345161|NCT04735445|DIAGNOSTIC_TEST|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
219345162|NCT02923661|DEVICE|CM LOC|
219345163|NCT02923661|DEVICE|ball attachment|
219345164|NCT06194513|OTHER|Intervention 1: Twice a day for 1 week PIOMI|Preterm babies will receive two sessions of treatment every day for a week, for a total of 14 sessions. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
219345165|NCT06194513|OTHER|Intervention 2: Once a day for 2 weeks PIOMI|Preterm babies will receive a total of 14 sessions of treatment, one every day for two weeks. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
219345166|NCT02663050|OTHER|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
219345167|NCT02663050|DRUG|NSAID's|twice a daily
219345168|NCT03803072|BEHAVIORAL|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
219345169|NCT03154814|DRUG|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
219345170|NCT03154814|DRUG|control|conventional CPB was applied without ulinastatin treatment
219345171|NCT05270070|OTHER|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
219345172|NCT04674475|DEVICE|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
219345173|NCT03112889|DRUG|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
219345174|NCT04442945|DRUG|ANAVEX3-71|Active oral dose of ANAVEX3-71
219345175|NCT04442945|DRUG|Placebo|Oral placebo
219345176|NCT01786096|DRUG|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
219345177|NCT02076997|DRUG|Methotrexate|"Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
219345178|NCT04376320|DEVICE|customised ceramic sheets (Group 1)|guided bone regeneration
219345179|NCT04376320|COMBINATION_PRODUCT|modified sausage technique (Group 2)|guided bone regeneration
219345180|NCT02215876|DRUG|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
219345181|NCT02215876|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
219345182|NCT02215876|DRUG|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
219345183|NCT04055792|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
219345184|NCT03817775|OTHER|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
219345185|NCT03955302|BEHAVIORAL|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
219345186|NCT03439202|OTHER|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
219345187|NCT02572674|OTHER|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
219345188|NCT02572674|GENETIC|Genetic sample|Blood samples
219345189|NCT05145907|BIOLOGICAL|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
219345190|NCT01888029|DEVICE|transcranial direct current stimulation|
219345191|NCT01888029|DEVICE|sham stimulation|
219345192|NCT03804203|RADIATION|standard treatment|3000 cGy in 10 daily fractions
219345193|NCT03804203|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
219345194|NCT03116074|BEHAVIORAL|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
219345195|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
219345196|NCT00531752|DRUG|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
219345197|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
219345198|NCT00385957|DRUG|AZT+3TC+IDV+RTV|
219345199|NCT00385957|DRUG|AZT+3TC+EFV|
219345200|NCT00401375|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
219345201|NCT00401375|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
219345202|NCT04540042|DRUG|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
219345203|NCT04540042|DRUG|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
219345204|NCT04540042|DRUG|SelK2 (Part 2)|I.V., single-dose (Day 1)
219345205|NCT04540042|DRUG|Placebo (Part 2)|I.V., single-dose (Day 1)
219345206|NCT00950664|DRUG|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
219345207|NCT00950664|DRUG|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
219345208|NCT02821715|DRUG|Active comparator: Modafinil + placebo|
219345209|NCT02821715|DRUG|THN102 300/3|
219345210|NCT02821715|DRUG|THN102 300/27|
219345211|NCT02526459|BEHAVIORAL|Birth plan|Patient will receive a birth plan
219345212|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using locator attachment|
219345213|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using ball attachment|
219345214|NCT03461328|DRUG|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
219345215|NCT00950768|PROCEDURE|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
219345216|NCT04116385|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219345217|NCT05417724|OTHER|Battlefield Acupuncture|Battlefield Acupuncture
219345218|NCT03152019|DRUG|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
219345219|NCT03152019|DRUG|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
219345220|NCT00350142|RADIATION|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
219345221|NCT00350142|DRUG|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
219345222|NCT00350142|OTHER|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
219345223|NCT00350142|RADIATION|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
219345224|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
219345225|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
219345226|NCT03763071|OTHER|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
219345227|NCT04286204|OTHER|Basic Life Support training based on ICTs|This intervention is defined as a self-training course consisting of a 5-minute educational video in basic life support and a Kit with the elements to build the home dummy and the home DEA allowing integrally students to develop the steps as the video. The Kit will be delivered at the beginning of the study and every month the necessary materials will be complemented. The strategy will be carried out by the students every month and supervised by their teachers. Students will have constant access to an educational platform based on ICTs.
219345228|NCT04286204|OTHER|Classic Basic Life Support training|It is defined as a module carried out by trained personnel in basic resuscitation (pre-hospital care program staff of the UdeA medical school), which includes two subcomponents of the conventional BLS course that are basic resuscitation and DEA in adults. The duration of the subcomponents is a theoretical part of 30 minutes and a practical part in a low fidelity simulator with 1.5 hours duration.
219345229|NCT06220331|DEVICE|Intra Ocular Lens|Intensity SL Intra Ocular Lens
219345230|NCT03757286|PROCEDURE|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
219345231|NCT03757286|PROCEDURE|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
219345232|NCT02721680|OTHER|Internal Awareness Training Program|
219345233|NCT02721680|OTHER|External Awareness Training Program|
219345234|NCT00610987|DRUG|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
219345235|NCT00610987|DRUG|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
219345236|NCT01743911|OTHER|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
219345237|NCT01743911|DRUG|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
219345238|NCT00424424|DRUG|MK0719|
219345239|NCT00385502|DRUG|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
219345240|NCT03060135|BEHAVIORAL|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
219345241|NCT03060135|BEHAVIORAL|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
219345242|NCT03022695|DEVICE|High Intensity Focused Ultrasound|
219345243|NCT00254501|BEHAVIORAL|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
219345244|NCT00254501|BEHAVIORAL|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
219345245|NCT01317862|DEVICE|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
219345246|NCT01509196|DRUG|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
219345247|NCT06060964|OTHER|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
219345248|NCT00923130|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
219345249|NCT00923130|DRUG|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
219345250|NCT01402609|DEVICE|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
219345251|NCT01402609|DEVICE|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
219345252|NCT04919642|DRUG|TT-00420|TT-00420 tablet, administered orally once daily
219345253|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
219345254|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
219345255|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
219345256|NCT03063710|DRUG|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
219345257|NCT03921021|DRUG|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
219345258|NCT04594967|OTHER|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
219345259|NCT04523636|DEVICE|Splinting|Pre-fabricated or custom resting hand splints
219345260|NCT00003936|DRUG|bryostatin 1|
219345261|NCT05543577|OTHER|Questionnaire|Questionnaire
219345262|NCT02094690|DEVICE|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
219345263|NCT02094690|DEVICE|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
219345264|NCT04926051|DRUG|BMS-986172|Specified dose on specified days
219345265|NCT04926051|OTHER|Placebo|Specified dose on specified days
219345266|NCT04227366|BIOLOGICAL|BCD-089|BCD-089 162 mg SC
219345267|NCT04227366|BIOLOGICAL|Placebo|Placebo
219345268|NCT04227366|DRUG|Methotrexat|15 to 25 mg/week
219345269|NCT01934686|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
219345270|NCT03853239|PROCEDURE|face mask ventilation crossover nasal ventilation|Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.
219345271|NCT03853239|PROCEDURE|nasal ventilation crossover face mask ventilation|Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
219345272|NCT02587650|DRUG|Capmatinib|Given PO
219345273|NCT02587650|DRUG|Ceritinib|Given PO
219345274|NCT02587650|DRUG|Entrectinib|Given PO
219345275|NCT02587650|OTHER|Laboratory Biomarker Analysis|Correlative studies
219345276|NCT02587650|DRUG|Regorafenib|Given PO
219345277|NCT05785468|DRUG|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
219345278|NCT01766960|OTHER|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
219345279|NCT01766960|DRUG|Morphine|Five milligrams of intravenous morphine will be administered.
219345280|NCT01473082|DEVICE|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
219345281|NCT01473082|DEVICE|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
219345282|NCT06978959|BEHAVIORAL|FN+ Intervention|Participants will attend 5 one-on-one sessions over the course of 5 weeks; they will meet with a family navigator over video conferencing software (e.g., Zoom). The purpose of each sessions are as follows: 1) Provide an overview of the program and help parents understand their perceptions of child behaviors, 2) Train parents to find, access, and overcome barriers to mental health services, 3) Build parent capacity in understanding how mental health treatment works and how to communicate with providers, 4) Help parents understand the common function of child behaviors, and 5) Train parents to find, evaluate, and use online mental health tools. Participants will complete measures of child symptoms, parent activation, barriers to treatment, and/or satisfaction with the program before the intervention, immediately after the intervention, and 3 months after completing the intervention.
219345283|NCT04769960|DIAGNOSTIC_TEST|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
219345284|NCT04769960|BEHAVIORAL|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
219345285|NCT06675617|DEVICE|Allay Aortic Stent|Endovascular treatment of an aortic dissection
219345286|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
219345287|NCT01260012|OTHER|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
219345288|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
219345289|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
219345290|NCT07006454|PROCEDURE|Ventro-Cephalic Translatoric Glide|"Participants of group A will receive ventro-cephalic translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's right side.~2. Therapist's stable hand: with the thumb and index finger of left hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her right hand on left side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in ventro-cranial direction in the right angle of the treatment plane of the facet joint."
219345291|NCT07006454|PROCEDURE|Dorso-Caudal Translatoric Glide|"Participants of group B will receive Dorso-caudal translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's left side.~2. Therapist's stable hand: with the thumb and index finger of right hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her left hand on right side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in dorso-caudal direction in the right angle of the treatment plane of the facet joint."
219345292|NCT06099964|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
219345293|NCT06099964|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
219345294|NCT06692075|PROCEDURE|extracorporeal life support|ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA
219345295|NCT06692075|PROCEDURE|standard ACLS|Standard ACLS in cardioplumonary resuscitation of refractory OHCA
219345296|NCT05038020|DRUG|AKST4290|Oral AKST4290
219345297|NCT05038020|DRUG|Placebo|Oral Placebo
219345298|NCT07028879|PROCEDURE|Fatigue management program|Combination of Occupational Therapy and Physiotherapy strategies and sessions.
219345299|NCT07029607|DIETARY_SUPPLEMENT|Placebo|Placebo
219345300|NCT07029607|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium
219345301|NCT07023315|DRUG|Cadonilimab|Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
219345302|NCT07023315|DRUG|SOX chemotherapy|A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium
219345303|NCT05309187|BIOLOGICAL|IO-202|IO-202 given as monotherapy
219345304|NCT05309187|BIOLOGICAL|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
219345305|NCT05309187|BIOLOGICAL|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
219345306|NCT07028437|PROCEDURE|Endoscopic-assisted transoral approach for parotid tumor resection|The buccal mucosa was incised in front of the mandibular ligament of the inner wing of the mouth, the submucosal tissue was separated, and important structures such as the buccal nerve, parotid duct, and facial nerve were protected. The tumor was completely resected while preserving the parotid gland.
219345307|NCT07028437|PROCEDURE|Blair S-shaped incision for parotid tumor|The Blair S-shaped incision was made through an anterior auricular incision. After cutting the skin, the flap was reflapped. The greater auricular nerve and facial nerve were separated and protected, and the tumor was completely resected.
219345308|NCT07027930|OTHER|Eye movement desensitization and reprocessing therapy integrative group treatment protocol for Ongoing traumatic stress|EMDR-IGTP-OTS is a group intervention based on EMDR 8-phased protocols with the integration of the Butterfly hug technique.
219345309|NCT07028450|BEHAVIORAL|Proactive call|The proactive call will be based on the principles of motivational interviewing. The content of the call comprises: 1) Asking the gambler/recipient to reflect on their gambling behavior, 2) providing to the gambler/recipient an overview of their gambling account and financial history, 3) offering to the gambler/recipient information about responsible gambling tools, such as setting lower limits, locking limits, taking a break, or self-exclusion, and 4) providing to the gambler/recipient information about relevant support services and the Gamban tool in cases where a need is expressed.
219345310|NCT06699342|PROCEDURE|Pacemaker implantation with Left bundle branch area pacing (LBBAP)|"Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients.~The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice."
219345311|NCT06699342|PROCEDURE|Atrioventricular node ablation (AVNA)|Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
219345312|NCT06699342|DRUG|Pharmacologic therapy optimized for Atrial Fibrillation management|"Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy."
219345313|NCT06001333|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
219345314|NCT07027943|DIETARY_SUPPLEMENT|DAO supplement|Gastro-resistant DAO tablets of porcine kidney protein extract. Posology: 3 tablets per day (total 12.6mg of DAO extract/day).
219345315|NCT07027943|DIETARY_SUPPLEMENT|Placebo|Tablets containing microcrystalline cellulose and hydroxypropyl cellulose, with the same shape, size, and color as the DAO-containing tablets. Posology: 3 tablets per day.
219345316|NCT07028476|PROCEDURE|Automated Dynamic Laximetry|Patients are prescribed a Zimmer splint to immobilize the injured limb, and referred to a referring sports physician at the investigating center to perform the LDA as a confirmatory examination (complementary test). Patients arrange their appointment with the sports physician as soon as possible.
219345317|NCT07028476|PROCEDURE|MRI|In the control arm, and in line with standard practice, patients with a suspected ACL injury are prescribed a Zimmer splint to immobilize the injured limb, an MRI as a confirmatory examination, and a consultation with the doctor of their choice. Following the MRI, patients arrange their appointments according to the usual care pathway for their pathology.
219345318|NCT01125150|DRUG|Metformin|Dosage to be determined by Endocrinologist
219345319|NCT01125150|BEHAVIORAL|Dietary Modification|To be determined by Endocrinologist
219345320|NCT06718361|OTHER|Oxygen levels measurement (%)|Measuring levels of oxygen in the environment around the patient in %.
219345321|NCT06744296|OTHER|Blood Draws and Tissue Sample(s)|All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.
219345322|NCT06895993|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 2 mL: 100 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 1 min, with a speed of 2 mL/min.
219345323|NCT06895993|DRUG|Ferric Carboxymaltose Injection [Injectafer®]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Injectafer®) (R, 2 mL: 100 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 1 min, with a speed of 2 mL/min.
219345324|NCT02433652|BIOLOGICAL|Recombinant live attenuated trivalent dengue vaccine|Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.
219345325|NCT02433652|BIOLOGICAL|Placebo|
219345326|NCT02433652|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
219345327|NCT06862752|PROCEDURE|erector spine plane (ESP) block|Bilateral ultrasound guided erector spine plane (ESP) block will be performe preoperatively at T5 level. 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL serum physiologic % l) will be injected deep to the erector spinae muscle.
219345328|NCT06862752|PROCEDURE|Serratus Anterior Plane Block|Bilateral ultrasound guided serratus plane block with 20 ml %0,25 bupivacaine at the midaxillary 5. Rib
219345329|NCT06883747|DRUG|BMS-986504|MTA cooperative PRMT5 inhibitor
219345330|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
219345331|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
219345332|NCT06845423|DRUG|Low molecular weight heparin|"Pharmacological thromboprophylaxis using LMWH at preventive dosage. The choice of subcutaneous LMWH depends on the practice of each center:~* Enoxaparine 4000 UI (weight \> 90 kg 6000 UI)~* Tinzaparine 3500 UI (weight \> 90 kg 4500 UI)~* Dalteparine 5000 UI (weight \> 90 kg 7500 UI)~* Nadroparine 2850 UI (weight \> 90 kg 3800 UI)."
219345333|NCT03744390|DRUG|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
219345334|NCT00202787|DRUG|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
219345335|NCT00202787|DRUG|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
219345336|NCT00240409|DRUG|Pramipexole|
219345337|NCT00240409|DRUG|Bromocriptine|
219345338|NCT03837639|OTHER|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
219345339|NCT03837639|OTHER|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
219345340|NCT03837639|OTHER|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
219345341|NCT04044300|PROCEDURE|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
219345342|NCT04044300|OTHER|Conservative|Continued pain management and physical therapy.
219345343|NCT05626998|DRUG|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
219345344|NCT05626998|DRUG|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
219345345|NCT05912842|BEHAVIORAL|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
219345346|NCT05912842|BEHAVIORAL|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
219345347|NCT05332158|BEHAVIORAL|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
219345348|NCT00782951|DRUG|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
219345349|NCT00782951|DRUG|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
219345350|NCT00782951|DRUG|Placebo|single IV dose of placebo after dental impaction surgery
219345351|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
219345352|NCT06192264|DRUG|ASC40|ASC 40 tablets orally once daily
219345353|NCT04758611|DEVICE|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
219345354|NCT05926830|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
219345355|NCT06039722|DEVICE|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
219345356|NCT04563078|DEVICE|Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
219345357|NCT04563078|PROCEDURE|Sham Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
219345358|NCT06047171|BIOLOGICAL|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
219345359|NCT06047171|DRUG|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
219345360|NCT06047171|DRUG|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
219345361|NCT06047171|DRUG|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
219345362|NCT06047171|DRUG|Placebo|Drug product that will contain no active ingredient
219345363|NCT06047171|DRUG|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
219345364|NCT05863572|OTHER|Primary care health worker training|Training primary care workers to detect and treat psychosis.
219345365|NCT05863572|OTHER|Community Health Workers Training|training community health workers in detection and referral
219345366|NCT05863572|OTHER|Home visits|home visits conducted by people with lived experience of psychosis
219345367|NCT06547840|DRUG|MOv18 IgE|MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
219345368|NCT06790602|DRUG|Cemiplimab Plus Gemcitabine|Cemiplimab Plus Gemcitabine
219345369|NCT05804318|DEVICE|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
219345370|NCT05368571|OTHER|CHOICES-TEEN|This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
219345371|NCT05368571|OTHER|Health and Life Skills Education|This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
219345372|NCT05522608|PROCEDURE|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
219345373|NCT06087926|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
219345374|NCT05376228|DRUG|Oral Vancomycin|As part of standard of care
219345375|NCT04017481|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
219345376|NCT04017481|OTHER|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
219345377|NCT01560000|DIETARY_SUPPLEMENT|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
219345378|NCT06785324|BEHAVIORAL|Nutrition Intervention|"The nutrition intervention will target a 10% caloric deficit calculated from each patient's Basal Metabolic Rate (WHO/Schofield) utilizing a high protein (\>25%), low fat (\<25%), low glycemic index/high fiber (45-55%) diet.~The study registered dietician (RD) will meet with the patient on day of enrollment to go over the menu of dietary options and will re-assess the patient every two days (excluding weekends) for adherence.~My Plate (USDA) will control portion size and eating habits."
219345379|NCT06785324|BEHAVIORAL|Exercise intervention|"The exercise intervention will target 200 minutes of moderate physical activity weekly, as defined by Metabolic Equivalents (METs) of 3-6, made up of aerobic and resistance training activities tailored to the patient's preference by working with the study physical therapist (PT).~Physical Therapist to evaluate patient every 48 hours, excluding weekends."
219345380|NCT02484911|DRUG|Olanzapine|5mg,twice a day orally on day 1 to day 4
219345381|NCT02484911|DRUG|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
219345382|NCT02484911|DRUG|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
219345383|NCT02484911|DRUG|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
219345384|NCT02387255|DEVICE|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
219345385|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
219345386|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
219345387|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
219345388|NCT04129528|DRUG|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
219345389|NCT04129528|OTHER|Placebo|Placebo for active drug
219345390|NCT04185688|OTHER|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
219345391|NCT01316861|DRUG|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
219345392|NCT01316861|DRUG|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
219345393|NCT04194099|DEVICE|20 Hz rTMS (Brain)|Higher frequency (\>5 Hz) trains increase cortical excitability.
219345394|NCT04194099|DEVICE|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
219345395|NCT04194099|DEVICE|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
219345396|NCT04194099|DEVICE|20 Hz current square-wave pulses (Spinal)|Higher frequency (\>5 Hz) of current increase cortical excitability.
219345397|NCT04194099|DEVICE|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
219345398|NCT04194099|DEVICE|sham|with sham stimulation on brain and spinal.
219345399|NCT04753827|OTHER|Drug eluting stent|Put a Drug eluting stent in the blood vessel
219345400|NCT04753827|OTHER|Durg coated balloon|Put a Durg coated balloon in the blood vessel
219345401|NCT03670875|DIETARY_SUPPLEMENT|Agave inulin|Will be provided in dehydrated apple cubes
219345402|NCT03670875|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
219345403|NCT03670875|DIETARY_SUPPLEMENT|O3FA|Will be provided in capsules
219345404|NCT03670875|BEHAVIORAL|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
219345405|NCT03008356|DIETARY_SUPPLEMENT|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
219345406|NCT03008356|BEHAVIORAL|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
219345407|NCT03008356|DIETARY_SUPPLEMENT|Placebo capsules|
219345408|NCT01156584|BIOLOGICAL|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
219345409|NCT01156584|DRUG|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
219345410|NCT03801850|DEVICE|3D surface scan|measurement of inter fractional deformations by surface scanning
219345411|NCT05149690|OTHER|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
219345412|NCT05149690|OTHER|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
219345413|NCT05182957|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
219345414|NCT05182957|DRUG|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
219345415|NCT05182957|DRUG|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
219345416|NCT05361772|DRUG|colchicine|colchicine 0.5mg per day for 24 months
219345417|NCT05361772|DRUG|Placebo|placebo 0.5mg per day for 24 months
219345418|NCT01258504|DRUG|St. Johns Wort|"* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
219345419|NCT04315519|OTHER|Exercise|Aerobic Exercise
219345420|NCT01682135|BIOLOGICAL|Ramucirumab|Administered IV.
219345421|NCT02372474|BIOLOGICAL|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
219345422|NCT03632421|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219345423|NCT03632421|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
219345424|NCT06519786|DRUG|Metformin|Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
219345425|NCT04956159|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
219345426|NCT04956159|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
219345427|NCT05196659|BEHAVIORAL|Integrated comprehensive cardiovascular disease management|"1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   \- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team"
219345428|NCT03065348|DIETARY_SUPPLEMENT|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
219345429|NCT03065348|DIETARY_SUPPLEMENT|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
219345430|NCT03065348|DIETARY_SUPPLEMENT|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal"
219345431|NCT03065348|OTHER|Preoperative hydration|If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
219345432|NCT03065348|OTHER|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
219345433|NCT00187421|PROCEDURE|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
219345434|NCT01395394|DRUG|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
219345435|NCT01395394|OTHER|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
219345436|NCT04559958|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
219345437|NCT01876407|DEVICE|Low intensity laser for oral mucositis|
219345438|NCT01876407|DEVICE|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
219345439|NCT00044577|DRUG|abacavir/lamivudine|
219345440|NCT00044577|DRUG|abacavir|
219345441|NCT00044577|DRUG|lamivudine|
219345442|NCT00044577|DRUG|tenofovir|
219345443|NCT06309459|DIAGNOSTIC_TEST|Carbonic anhydrase staining levels|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
219345444|NCT01964352|DRUG|tiotropium|fixed dose combination
219345445|NCT01964352|DRUG|placebo|
219345446|NCT01964352|DRUG|olodaterol|fixed dose combination
219345447|NCT01964352|DRUG|tiotropium|fixed dose combination
219345448|NCT01964352|DRUG|tiotropium|
219345449|NCT01964352|DRUG|olodaterol|fixed dose combination
219345450|NCT03746704|DRUG|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
219345451|NCT01457742|DEVICE|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
219345452|NCT01457742|DEVICE|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
219345453|NCT00890565|DRUG|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
219345454|NCT04090112|DRUG|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
219345455|NCT04090112|DRUG|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
219345456|NCT04546685|OTHER|Usual Care|Participants who are randomized to the Usual Care group (waitlist for cross-over to ER) will be instructed to continue with their normal pain care. They will receive only study surveys (baseline, 2 weeks, and 1 month). Upon completion of the 1-month study, UC participants will be invited to cross-over and receive ER. Post-class treatment appraisal/satisfaction data only will be collected.
219345457|NCT04546685|BEHAVIORAL|Empowered Relief|The participants will attend an online Spanish Empowered Relief class. The two hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a Spanish binaural relaxation audio file for daily use.
219345458|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
219345459|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens2|TEST
219345460|NCT05640778|DRUG|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
219345461|NCT04220996|DRUG|Vortioxetine|Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
219345462|NCT00477165|DRUG|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
219345463|NCT00477165|DRUG|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
219345464|NCT03159858|DEVICE|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
219345465|NCT00105443|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
219345466|NCT00105443|DRUG|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
219345467|NCT05842187|PROCEDURE|Biopsy of tumor tissue for organoid culture|By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
219345468|NCT06367881|DRUG|Alveofact|Intratracheal High-dose Alveofact versus Low-dose Alveofact with or without Budesonide
219345469|NCT06367881|DRUG|Budesonide|Budesonide
219345470|NCT01157078|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
219345471|NCT01157078|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
219345472|NCT00250614|DRUG|Saredutant succinate (SR48968C)|
219345473|NCT01175785|PROCEDURE|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood transplant
219345474|NCT01175785|DRUG|fludarabine phosphate|Given IV
219345475|NCT01175785|DRUG|cyclophosphamide|Given IV
219345476|NCT01175785|BIOLOGICAL|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
219345477|NCT01175785|RADIATION|total-body irradiation|Undergo TBI
219345478|NCT01175785|DRUG|cyclosporine|Given IV
219345479|NCT01175785|DRUG|mycophenolate mofetil|Given IV and PO
219345480|NCT01175785|OTHER|laboratory biomarker analysis|Correlative studies
219345481|NCT06443970|DEVICE|Exsalta Suction Device|Low flow endotracheal suction device
219345482|NCT06845163|DRUG|Dapagliflozin|Dapagliflozin 10 mg will be given orally once daily for three months.
219345483|NCT06845163|DRUG|Anti-VEGF drug|Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.
219345484|NCT02586675|DRUG|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
219345485|NCT02586675|DRUG|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
219345486|NCT02586675|DRUG|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
219345487|NCT04500977|BEHAVIORAL|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
219345488|NCT00000859|DRUG|Indinavir sulfate|
219345489|NCT00000859|DRUG|Ritonavir|
219345490|NCT00000859|DRUG|Nelfinavir mesylate|
219345491|NCT03992508|DEVICE|intermittent pneumatic compression|
219345492|NCT03992508|PROCEDURE|complex decongestive therapy|
219345493|NCT04286061|OTHER|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
219345494|NCT06073600|DRUG|Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
219345495|NCT06073600|DRUG|Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
219345496|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
219345497|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
219345498|NCT03962439|BEHAVIORAL|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
219345499|NCT03962439|BEHAVIORAL|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
219345500|NCT03962439|BEHAVIORAL|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
219345501|NCT00513409|BIOLOGICAL|Synflorix|Intramuscular injection, 1 or 2 doses
219345502|NCT00513409|BIOLOGICAL|Infanrix Hexa|1 Intramuscular injection
219345503|NCT00513409|BIOLOGICAL|Havrix|1 Intramuscular injection
219345504|NCT05736900|DIAGNOSTIC_TEST|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
219345505|NCT06307912|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
219345506|NCT06307912|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
219345507|NCT01735487|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
219345508|NCT01735487|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
219345509|NCT01735487|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
219345510|NCT01735487|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
219345511|NCT01735487|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
219345512|NCT01088074|DEVICE|Histoacryl Tissue Adhesive|
219345513|NCT01088074|DEVICE|Dermabond|
219345514|NCT01088074|DEVICE|Staples|
219345515|NCT01088074|DEVICE|Monocryl 4-0|
219345516|NCT01564355|DEVICE|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
219345517|NCT01564355|DRUG|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
219345518|NCT03066427|DRUG|Sunitinib|Sunitinib 50 mg/d
219345519|NCT02289222|DRUG|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
219345520|NCT02289222|DRUG|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
219345521|NCT02289222|DRUG|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
219345522|NCT04462952|DRUG|Adavosertib (AZD1775)|Adavosertib taken orally
219345523|NCT00636766|DRUG|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
219345524|NCT00636766|DRUG|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
219345525|NCT00636766|DRUG|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
219345526|NCT00636766|DRUG|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
219345527|NCT03189446|RADIATION|Vaginal Cuff Brachytherapy|Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
219345528|NCT03189446|DRUG|Carboplatin|Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
219345529|NCT03189446|DRUG|Paclitaxel|Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
219345530|NCT05931809|BEHAVIORAL|Serqual tool|The SERVQUAL scale will be applied with the questionnaire of expectations in the first 24 hours after admission and perception questionnaire within the first 24 hours after discharge.
219345531|NCT06124482|DEVICE|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
219345532|NCT05634577|DRUG|Mitotane|Given by PO
219345533|NCT05634577|DRUG|Pembrolizumab|Given by vein (IV)
219345534|NCT06406192|DIAGNOSTIC_TEST|Height, Weight, and Blood Pressure Measurement Procedures Improvement|"In the intervention group, the investigators improve the process of measuring blood pressure, height, and weight, requiring timely recording of these measurements. The intervention includes:~i. Enlisting the assistance of nurses and volunteers to improve the accessibility of measurement environments and provide guidance on instrument operation.~ii. Using paper reminders at check-in stations to prompt patients to complete blood pressure and weight recordings before entering examination rooms; providing paper for recording if patients forget their health insurance cards.~iii. Providing alcohol and hand wipes outside examination rooms for disinfecting measurement instruments.~iv. Promoting the recording mode outside the check-in station.~v. Ensuring that physicians or nurses in examination rooms accurately record measurements in the medical order system.~vi. Encouraging patients to ask physicians during consultations, Is my blood pressure and weight okay?"
219345535|NCT01192022|BIOLOGICAL|TachoSil®|Intraoperative application as secondary hemostatic treatment
219345536|NCT01192022|DEVICE|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
219345537|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
219345538|NCT06168292|PROCEDURE|ID-RFA and Radiotherapy|The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
219345539|NCT06246565|DRUG|HS-10383|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
219345540|NCT06246565|DRUG|HS-10383 Placebo|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
219345541|NCT06081803|DRUG|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
219345542|NCT06490913|DRUG|Capecitabine|1000mg/m2, bid, d1-d14，q3w，1cycle
219345543|NCT06490913|DRUG|oxaliplatin|130mg/m2, ivgtt, d1，q3w，1cycle
219345544|NCT06490913|DRUG|Cetuximab|cetuximab 500mg/m2, q2w
219345545|NCT06490913|DRUG|Oxaliplatin|85mg/m2, d1,q2w
219345546|NCT06490913|DRUG|Leucovorin|400mg/m2, d1,q2w
219345547|NCT06490913|DRUG|5-FU|400mg/m2，d1,q2w
219345548|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drug free norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
219345549|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. Trainings and tools will be provided, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
219345550|NCT03865706|DRUG|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
219345551|NCT03865706|DRUG|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
219345552|NCT03865706|DRUG|Broad-spectrum antibiotics|Standard of care treatment for infections
219345553|NCT00278421|BIOLOGICAL|rituximab|
219345554|NCT00278421|DRUG|cyclophosphamide|
219345555|NCT00278421|DRUG|doxorubicin hydrochloride|
219345556|NCT00278421|DRUG|prednisone|
219345557|NCT00278421|DRUG|vincristine sulfate|
219345558|NCT04459780|BIOLOGICAL|Skin biopsies|3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
219345559|NCT04459780|BIOLOGICAL|Blood sample|One blood sample for the group 1 only.
219354862|NCT05768633|BEHAVIORAL|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
219345560|NCT05075356|DEVICE|The intelligent total body scanner (iToBoS)|"The intelligent total body scanner (iToBoS) device will be an AI diagnostic platform for early detection for melanoma, which includes a novel total-body high-resolution scanner and a Computer Aided Diagnostics (CAD) tool. The prototype iToBoS imaging device used in this study, will not have the integrated CAD system.~The device consists of a horizontal bed on which the participant would lie on. The bed will slide under a series of 5 arc shaped rails that have a total of 15 vision units mounted on rails (3 vision units per arc). The vision units incorporate high-resolution cameras and LED lighting system. When imaging is initiated by an operator, the vision units systematically move along the arch rails taking numerous images capturing majority of the skin surface. The imaging process will take approx. 10 minutes.~Purpose built software will be used to stitch images together to create a body avatar on which skin lesions can be viewed and monitored with."
219345561|NCT04522674|BIOLOGICAL|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
219345562|NCT00781456|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
219345563|NCT00781456|DRUG|Placebo|1 tablet daily to match experimental arm
219345564|NCT03496909|BEHAVIORAL|Standard OT|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
219345565|NCT03496909|BEHAVIORAL|PhysioTouch|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
219345566|NCT04989582|OTHER|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
219345567|NCT02631330|OTHER|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
219345568|NCT06010966|DEVICE|rTMS|intermittent theta-burst stimulation (iTBS)
219345569|NCT04803838|OTHER|No intervention|No intervention
219345570|NCT05456477|OTHER|Beef|Beef entrees
219345571|NCT05456477|OTHER|Poultry|Poultry entrees
219345572|NCT04677348|PROCEDURE|Pericapsular nerve group (PENG) block|ultrasound-guided PENG block with 0.3% ropivacaine 20cc
219345573|NCT04677348|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
219345574|NCT04229745|DEVICE|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
219345575|NCT02805777|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
219345576|NCT06229795|DRUG|Green Tea Leaf Extract Decaffeinated|300 mg film coated tablet
219345577|NCT06229795|DRUG|Metformin Hydrochloride 500 MG|500 mg tablet
219345578|NCT04842084|BIOLOGICAL|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
219345579|NCT04986709|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
219345580|NCT01594853|BEHAVIORAL|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
219345581|NCT03628170|OTHER|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
219345582|NCT03628170|OTHER|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
219345583|NCT02916355|DRUG|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
219345584|NCT02916355|DRUG|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
219345585|NCT02027103|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
219345586|NCT02027103|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
219345587|NCT00003625|DRUG|cyclosporine|
219345588|NCT00003625|DRUG|etoposide|
219345589|NCT00003625|DRUG|vincristine sulfate|
219345590|NCT00003625|RADIATION|radiation therapy|
219345591|NCT03226145|PROCEDURE|MRI Motility|MRI sequence to assess colonic motility
219345592|NCT03226145|PROCEDURE|High Resolution Manometry|HRM of colon to assess motility
219345593|NCT03226145|DRUG|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
219345594|NCT03226145|DRUG|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
219345595|NCT04835636|BEHAVIORAL|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
219345596|NCT05681507|DRUG|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
219345597|NCT05681507|PROCEDURE|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
219354863|NCT05553704|DRUG|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
219345598|NCT02642133|PROCEDURE|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
219345599|NCT02321254|DEVICE|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
219345600|NCT02321254|BEHAVIORAL|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
219345601|NCT03741998|DEVICE|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
219345602|NCT03174132|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
219345603|NCT03174132|DEVICE|Restylane Perlane|Intradermal injection
219345604|NCT04583098|OTHER|fecal microbiota transplantation|frozen or capsulized stool from donors who had already finished recommended blood \& stool screening for stool donors
219345605|NCT05939843|BEHAVIORAL|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
219345606|NCT05939843|BEHAVIORAL|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
219345607|NCT05939843|BEHAVIORAL|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
219345608|NCT05939843|BEHAVIORAL|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
219345609|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
219345610|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
219345611|NCT05974631|BEHAVIORAL|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
219345612|NCT05974631|BEHAVIORAL|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
219345613|NCT02750033|DEVICE|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
219345614|NCT05564143|PROCEDURE|EUS-guided gastroenterostomy (EUS-GE)|Treatment
219345615|NCT05564143|PROCEDURE|Laparoscopic gastroenterostomy (LGE)|Treatment
219345616|NCT01166022|OTHER|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
219345617|NCT06849076|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
219345618|NCT06849076|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
219345619|NCT03175900|DRUG|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
219345620|NCT03175900|DRUG|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
219345621|NCT03875898|OTHER|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
219345622|NCT03875898|OTHER|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
219345623|NCT00920673|PROCEDURE|MRI|MRI during 35 to 65 minutes
219345624|NCT01920880|OTHER|Quantitative Sensory Testing analysis|
219345625|NCT03655613|BIOLOGICAL|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
219345626|NCT03655613|DRUG|APL-101|Oral specific c-Met inhibitor
219345627|NCT03655613|BIOLOGICAL|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
219345628|NCT03413280|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
219345629|NCT03413280|DRUG|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
219345630|NCT05319171|DEVICE|TAVR|TAVR
219345631|NCT01457807|DRUG|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
219345632|NCT01457807|DRUG|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
219345633|NCT01457807|DRUG|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
219345634|NCT04639622|DIAGNOSTIC_TEST|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
219345635|NCT01493453|GENETIC|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10\*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
219345636|NCT01854619|DEVICE|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
219345637|NCT01854619|DEVICE|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
219345638|NCT03867578|DIAGNOSTIC_TEST|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
219345639|NCT03867578|DIAGNOSTIC_TEST|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
219345640|NCT03867578|DIAGNOSTIC_TEST|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
219345641|NCT04020250|DEVICE|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
219345642|NCT06849245|BEHAVIORAL|A digital social intervention by primary care clinicians|"* Signposting to the online health community by explaining different sections of the website.~* Introducing norms and values for passive (just reading) and active (writing posts) participation.~* Motivation for engagement with the online health community, emphasising that it could be used ad hoc (e.g. when feeling unwell, or when they need information or emotional support).~* Problem solving with respect to any difficulties/concerns.~* Signing patients up to the online health community, by explaining terms and conditions.~* Explaining the differences between posting publicly and privately (public posts are shared with third parties whereas private messages to other users are not shared).~* Collection of baseline measures. Data will be entered into the study's online database.~Patients will leave the consultation with a leaflet summarising all procedural matters in relation to signing up with the online health community and a reminder of their username and password."
219345643|NCT02344888|DRUG|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
219345644|NCT02344888|DRUG|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
219345645|NCT04105374|DRUG|Extended Release Flucytosine|Given PO
219345646|NCT04105374|DEVICE|NovoTTF-100A Device|Receive Optune device
219345647|NCT04105374|OTHER|Quality-of-Life Assessment|Ancillary studies
219345648|NCT04105374|OTHER|Questionnaire Administration|Ancillary studies
219345649|NCT04105374|RADIATION|Radiation Therapy|Undergo radiation
219345650|NCT04105374|DRUG|Temozolomide|Given PO
219345651|NCT04105374|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
219345652|NCT04105374|BIOLOGICAL|Vocimagene Amiretrorepvec|Given via intracranial injection
219345653|NCT02098174|DRUG|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219345654|NCT02098174|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
219345655|NCT00715832|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
219345656|NCT00405197|BEHAVIORAL|Isocaloric diet high in MUFA or Mediterranean diet|
219345657|NCT01148446|DRUG|Cyclophosphamide|750 mg/mq IV, day 1
219345658|NCT01148446|DRUG|Cyclophosphamide|50 mg/mq IV, day 1
219345659|NCT01148446|DRUG|Doxorubicin|50 mg/mq IV, day1
219345660|NCT01148446|DRUG|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
219345661|NCT01148446|DRUG|Prednisone|75 mg/mq IV, days 1-5
219345662|NCT01148446|DRUG|Prednisone|60 mg/mq IV/PO, days 1-5
219345663|NCT01148446|DRUG|Epirubicin|50 mg/mq IV, day 1
219345664|NCT01148446|DRUG|Vinblastine|5 mg/mq IV, day 1
219345665|NCT01148446|DRUG|Rituximab|375 mg/mq IV, day 1
219345666|NCT01148446|DRUG|G-CSF|300 µg tot., SC; days 7-11
219345667|NCT01312597|OTHER|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
219345668|NCT04434274|DRUG|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
219345669|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 1|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
219354864|NCT04827355|DEVICE|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
219354865|NCT04827355|DEVICE|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
219345670|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 2|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
219345671|NCT02229500|DIETARY_SUPPLEMENT|Inulin|
219345672|NCT02229500|DIETARY_SUPPLEMENT|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
219345673|NCT02229500|DIETARY_SUPPLEMENT|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
219345674|NCT03608943|OTHER|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
219345675|NCT04677712|DRUG|CCH-aaes|Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
219345676|NCT04677712|OTHER|Compression|Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.
219345677|NCT04677712|OTHER|Cold Packs|Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.
219345678|NCT04677712|DRUG|Arnica Gel|Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
219345679|NCT04677712|DRUG|INhance®|Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
219345680|NCT04677712|OTHER|PDL|Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
219345681|NCT00711100|OTHER|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
219345682|NCT00711100|OTHER|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
219345683|NCT00711100|OTHER|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
219345684|NCT00711100|OTHER|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
219345685|NCT00711100|OTHER|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
219345686|NCT05815303|DRUG|Cadonilimab|10mg/kg iv on day 1, every 21 day
219345687|NCT05815303|DRUG|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
219345688|NCT05815303|DRUG|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
219345689|NCT01117636|DRUG|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
219345690|NCT01117636|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
219345691|NCT01117636|DRUG|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
219345692|NCT04519892|OTHER|PDRC|Personalized depression risk communication.
219345693|NCT04519892|OTHER|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
219345694|NCT01065688|PROCEDURE|Roux-en Y reconstruction|surgical procedure
219345695|NCT01065688|PROCEDURE|Billroth-I reconstruction|surgical procedure
219345696|NCT04479566|DRUG|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
219345697|NCT04479566|DRUG|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
219345698|NCT00783094|DRUG|Tadalafil 2.5 mg|oral, daily
219345699|NCT00783094|DRUG|Tadalafil 5 mg|oral, daily
219345700|NCT00783094|DRUG|Placebo|oral, daily
219345701|NCT04322773|DRUG|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
219345702|NCT04322773|DRUG|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
219345703|NCT04322773|DRUG|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
219345704|NCT04322773|OTHER|Standard medical care|management as usual
219345705|NCT05241080|OTHER|Survey|It is a survey based on questionnaire
219345706|NCT02513329|DRUG|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
219345707|NCT02513329|DRUG|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
219345708|NCT01123252|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
219345709|NCT01123252|DIETARY_SUPPLEMENT|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
219345710|NCT03317756|OTHER|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
219345711|NCT03317756|OTHER|Patient Control|Patients will receive an attention control
219345712|NCT03962205|BEHAVIORAL|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
219345713|NCT03962205|BEHAVIORAL|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
219345714|NCT03962205|OTHER|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
219345715|NCT02121366|PROCEDURE|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
219345716|NCT01294670|DRUG|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
219345717|NCT05707091|OTHER|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
219345718|NCT05707091|PROCEDURE|Conventional therapy|Group B treated with ems and exercises
219345719|NCT02290795|OTHER|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
219345720|NCT03714529|BIOLOGICAL|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
219345721|NCT00186550|BEHAVIORAL|Supportive Expressive Group Psychotherapy|
219345722|NCT00186550|BEHAVIORAL|Education|
219345723|NCT01871974|DRUG|FK949E|oral
219345724|NCT04852848|BEHAVIORAL|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
219345725|NCT02042937|OTHER|Exercise|Exercise to improve gluteus maximus recruitment
219345726|NCT00517595|DRUG|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
219345727|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
219345728|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
219345729|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
219345730|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
219345731|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
219345732|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
219345733|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
219345734|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
219345735|NCT01365663|DRUG|Saline 0.9%|3 Weekly SC injections
219345736|NCT05576402|PROCEDURE|colonoscopy|endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis
219345737|NCT00001379|BIOLOGICAL|Interferon|For lymphomatoid granulomatosis (LYG) Grade 1 and 2: Interferon starting at 7.5 million Units subcutaneous (subQ) 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond complete remission (CR).
219345738|NCT00001379|DRUG|Rituxan and EPOCH|For lymphomatoid granulomatosis (LYG) Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) every 3 weeks for 6 cycles.
219345739|NCT00001379|PROCEDURE|Tumor biopsy|Baseline (optional).
219345740|NCT00001379|PROCEDURE|Bone marrow biopsy|Baseline.
219345741|NCT00001379|BIOLOGICAL|Bone marrow aspirate|Baseline.
219345742|NCT00001379|PROCEDURE|Lumber puncture|Baseline.
219354866|NCT05852704|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
219345743|NCT00001379|DIAGNOSTIC_TEST|CT|Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years. Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years.
219345744|NCT00001379|DIAGNOSTIC_TEST|Brain MRI|"Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with central nervous system (CNS) disease only).~Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with CNS disease only)."
219345745|NCT00001379|DIAGNOSTIC_TEST|Echocardiogram|For participants receiving \> 450 mg/m\^2 doxorubicin.
219345746|NCT00001379|DIAGNOSTIC_TEST|FDG-PET|Arm 1: Baseline and following completion of interferon. Arm 2: Baseline and following completion of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R).
219345747|NCT03299348|BEHAVIORAL|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
219345748|NCT03299348|BEHAVIORAL|Active Control Group|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) four major health conditions that affect the lives of many middle-aged and older adults (e.g., cardiovascular disease, cancer, type 2 diabetes; clinical depression); and (b) how these conditions can be managed successfully.
219345749|NCT03930654|BEHAVIORAL|iPrEP|"* iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women"
219345750|NCT03930654|BEHAVIORAL|Usual Care|"* Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies"
219345751|NCT05427552|DEVICE|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 \* (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8\*6=16.8(%) were added to the normal intensity.
219345752|NCT00918034|DRUG|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
219345753|NCT00918034|DEVICE|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
219345754|NCT00918034|PROCEDURE|Placement|Placement of device in prostate urethra
219345755|NCT03405259|DEVICE|Super Seal® Desensitizer|Single dose professional application.
219345756|NCT03405259|DEVICE|Acclean® Fluoride Varnish|Single dose professional application.
219345757|NCT05033470|DEVICE|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
219345758|NCT00876187|BIOLOGICAL|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
219345759|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
219345760|NCT00876187|BIOLOGICAL|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
219345761|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
219345762|NCT00876187|BIOLOGICAL|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
219345763|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
219345764|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
219345765|NCT00876187|DRUG|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
219345766|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
219345767|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
219345768|NCT02742038|OTHER|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
219345769|NCT01068028|DRUG|ORM-12741|Ascending multiple doses to sequential panels
219345770|NCT01068028|DRUG|Placebo for ORM-12741|
219345771|NCT05349929|DRUG|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
219345772|NCT05349929|DRUG|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
219345773|NCT05349929|PROCEDURE|Root Canal Therapy|all the participants go under RCT.
219345774|NCT00893724|DRUG|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
219345775|NCT00893724|DIETARY_SUPPLEMENT|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
219345776|NCT00893724|DRUG|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
219345777|NCT00404014|DRUG|AL-208|1 dose of 300 mg
219345778|NCT00404014|DRUG|Placebo|1 dose of placebo
219345779|NCT00405067|DRUG|BMS-201038 (AEGR-733)|
219345780|NCT00405067|DRUG|Ezetimibe|
219345781|NCT02081040|OTHER|Not applicable (observational study with no active intervention)|
219345782|NCT00334022|DRUG|enfuvirtide|1ml BID
219345783|NCT01560780|DRUG|Prasugrel|one 10 mg tablet by mouth daily
219345784|NCT01560780|DRUG|Placebo|placebo similar in appearance to prasugrel
219345785|NCT03992976|OTHER|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
219345786|NCT06027359|OTHER|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~* Therapeutic play activities will not be performed with the children in the control group.~* One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
219345787|NCT05200078|DEVICE|Deep inspiration breath-hold technique|Selective application of deep inspiration breath-hold technique
219345788|NCT03798964|OTHER|Placental analysis|Analysis of placenta to determine expression of heparanase
219345789|NCT03676621|DRUG|Misoprostol|buccal tablets
219345790|NCT03676621|DRUG|Oxytocin|intravenous drip
219345791|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
219345792|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
219345793|NCT01032915|BIOLOGICAL|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
219345794|NCT01032915|DRUG|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
219345795|NCT06424782|OTHER|medicinal water|Medicinal water treatment in bath tub once daily.
219345796|NCT01897285|DEVICE|AQUACEL® foam adhesive dressing|
219345797|NCT00883207|BEHAVIORAL|Psychotherapy|Narrative and dialogical approach for couples
219345798|NCT04658901|DEVICE|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
219345799|NCT04658901|DEVICE|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
219345800|NCT03882814|DRUG|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
219345801|NCT03882814|DRUG|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
219345802|NCT00005648|DRUG|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
219345803|NCT00005648|DRUG|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
219345804|NCT01535170|DIETARY_SUPPLEMENT|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
219345805|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345806|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345807|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345808|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345809|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345810|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345811|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
219345812|NCT00848055|DRUG|AbGn168 subcutaneous injection|single dose subcutaneous injection
219345813|NCT02550886|OTHER|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
219345814|NCT05623579|BEHAVIORAL|Pain Neuroscience Education|8 Sessions of different pain education interventions
219345815|NCT05623579|BEHAVIORAL|Exercise|12 Sessions of Aerobic Exercise
219345816|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
219345817|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
219345818|NCT00977951|DRUG|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
219345819|NCT00977951|DRUG|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
219345820|NCT03141736|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
219345821|NCT03141736|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
219345822|NCT03141736|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
219345823|NCT03141736|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
219345824|NCT03255681|PROCEDURE|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
219345825|NCT00915681|DRUG|Silibinin|20 mg/kg continuous IV is over 24 hours
219345826|NCT00811135|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
219345827|NCT00811135|DRUG|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
219345828|NCT00811135|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
219345829|NCT04016480|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
219345830|NCT04016480|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
219345831|NCT05910866|DEVICE|Left bundle branch area pacing (LBBAP)|Pacing of the conduction system of the heart to obtain physiological activation
219345832|NCT05910866|DEVICE|Right ventricular pacing (RVP)|Conventional ventricular pacing
219345833|NCT01118351|DRUG|sunitinib malate|Given orally
219345834|NCT01118351|OTHER|immunohistochemistry staining method|Correlative studies
219345835|NCT01118351|OTHER|TdT-mediated dUTP nick end labeling assay|Correlative studies
219345836|NCT01118351|OTHER|light microscopy|Correlative studies
219345837|NCT01118351|OTHER|laboratory biomarker analysis|Correlative studies
219345838|NCT02413112|BEHAVIORAL|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
219345839|NCT03147781|DEVICE|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
219345840|NCT03147781|DEVICE|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
219345841|NCT01515137|DRUG|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
219345842|NCT01515137|DRUG|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
219345843|NCT01515137|DRUG|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
219345844|NCT02817321|PROCEDURE|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
219345845|NCT02817321|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
219345846|NCT02817321|DEVICE|PAJUNK Contiplex S Catheter|
219345847|NCT02817321|DRUG|single dose ropivacaine|"* 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed"
219345848|NCT02817321|DRUG|continuously infusion of ropivacaine|"* 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose"
219345849|NCT02817321|DRUG|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
219345850|NCT04158622|PROCEDURE|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
219345851|NCT04158622|PROCEDURE|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
219345852|NCT01226550|PROCEDURE|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
219345853|NCT01685463|DEVICE|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
219345854|NCT01685463|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
219345855|NCT04931784|DRUG|Nitrate|Administration of intra-coronary nitrate before percutaneous coronary intervention
219345856|NCT00746980|DRUG|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
219345857|NCT05654389|OTHER|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
219345858|NCT00919100|DEVICE|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
219345859|NCT00919100|OTHER|vapocoolant|venipuncture with vapocoolant spray offered
219345860|NCT04200261|DRUG|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
219345861|NCT04200261|DRUG|sodium chloride|sodium chloride
219345862|NCT04052659|DRUG|Sintilimab|200 mg IV, every 3 weeks, d1
219345863|NCT04052659|DRUG|Chidamide|30 mg PO, 2 times every week, d1 and d4
219345864|NCT04052659|DRUG|Azacidine|100 mg SC, every 3 weeks, d1 to d7
219345865|NCT06076421|OTHER|Fact box|Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
219345866|NCT01536600|DRUG|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
219345867|NCT02785250|OTHER|DPX-Survivac|SubQ injection
219345868|NCT02785250|DRUG|Cyclophosphamide|PO BID
219345869|NCT02785250|DRUG|Epacadostat (INCB024360)|PO BID
219345870|NCT03345108|DEVICE|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
219345871|NCT03345108|DEVICE|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
219345872|NCT03345108|OTHER|No Adhesive|No adhesive applied.
219345873|NCT01849302|DIETARY_SUPPLEMENT|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
219345874|NCT02317120|GENETIC|NGS BRCA 1 and BRCA 2 full sequencing|
219345875|NCT02317120|GENETIC|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
219345876|NCT02868697|DRUG|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
219345877|NCT02868697|DRUG|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
219345878|NCT01867281|DRUG|aspirin|
219345879|NCT05000385|OTHER|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
219345880|NCT05000385|DIAGNOSTIC_TEST|body mass index|as an indication of nutritional status
219345881|NCT05160155|PROCEDURE|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
219345882|NCT05160155|PROCEDURE|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
219345883|NCT02712567|DRUG|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
219345884|NCT05104580|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
219345885|NCT03853785|BIOLOGICAL|MMR vaccine|Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
219345886|NCT03853785|BIOLOGICAL|Candida antigen|Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
219345887|NCT03853785|DRUG|Topical Podophyllin|It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
219345888|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
219345889|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally(once daily) on Day 1
219345890|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
219345891|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
219345892|NCT05345964|DRUG|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
219345893|NCT05345964|DRUG|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
219345894|NCT01437852|BIOLOGICAL|StrataGraft Skin Tissue|
219345895|NCT04408690|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
219345896|NCT04408690|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
219345897|NCT04408690|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
219345898|NCT03114514|BIOLOGICAL|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
219345899|NCT06378814|PROCEDURE|Selective Caries Removal (No Pulp Exposure)|Caries excavation technique where clinician leaves carious tissue so close to pulp
219345900|NCT06378814|PROCEDURE|Non-Selective Caries Removal (No Pulp exposure)|Complete caries removal even in areas so close to pulp
219345901|NCT06378814|PROCEDURE|Partial Pulpotomy (Pulp Exposed)|In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
219345902|NCT04853784|PROCEDURE|intracorporeal anastomosis|intracorporeal anastomosis
219345903|NCT04648384|DIETARY_SUPPLEMENT|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
219345904|NCT04648384|DIETARY_SUPPLEMENT|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
219345905|NCT04648384|OTHER|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
219345906|NCT04517747|DRUG|Ramucirumab|chemotherapy i.v.
219345907|NCT04517747|DRUG|TAS 102|p.o. twice daily
219345908|NCT04962360|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
219345909|NCT04962360|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
219345910|NCT04131335|DRUG|AEONTM Repair|Lubricating eye drops
219345911|NCT04131335|OTHER|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
219345912|NCT00601068|OTHER|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
219345913|NCT04971876|DEVICE|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
219345914|NCT04971876|DEVICE|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
219345915|NCT04971876|DEVICE|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
219345916|NCT03986385|DRUG|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
219345917|NCT03986385|DRUG|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
219345918|NCT04536688|DRUG|RGLS4326|Solution for subcutaneous injection
219345919|NCT04833088|OTHER|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
219345920|NCT00655031|DIETARY_SUPPLEMENT|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
219345921|NCT00655031|DIETARY_SUPPLEMENT|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
219345922|NCT00919503|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infused IV
219345923|NCT00919503|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219345924|NCT00919503|DRUG|Cyclosporine|Given IV or PO
219345925|NCT00919503|DRUG|Fludarabine Phosphate|Given IV
219345926|NCT00919503|OTHER|Laboratory Biomarker Analysis|Correlative studies
219345927|NCT00919503|DRUG|Methotrexate|Given IV
219345928|NCT00919503|DRUG|Mycophenolate Mofetil|Given IV or PO
219345929|NCT00919503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infused IV
219345930|NCT00919503|DRUG|Tacrolimus|Given IV or PO
219345931|NCT00919503|RADIATION|Total-Body Irradiation|Undergo total body irradiation
219345932|NCT00919503|DRUG|Treosulfan|Given IV
219345933|NCT00919503|PROCEDURE|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
219345934|NCT01324258|DRUG|GSK1120212|Part1 and Part2
219345935|NCT01324258|DRUG|Gemcitabine|Part2
219345936|NCT00649532|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fasting
219345937|NCT00649532|DRUG|Zofran® Tablets 24 mg|24mg, single dose fasting
219345938|NCT03659682|DRUG|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
219345939|NCT05945953|OTHER|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
219345940|NCT05945953|OTHER|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
219345941|NCT04654494|PROCEDURE|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
219345942|NCT04654494|PROCEDURE|Total colectomy|excision of the colon with preservation of the rectum
219345943|NCT04654494|PROCEDURE|Segmental colectomy|excision of a segment of colon
219345944|NCT04925232|DEVICE|Transcranial Magnetic Stimulation device|Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
219345945|NCT03094871|BEHAVIORAL|FACE-PC|
219345946|NCT04921735|DRUG|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
219345947|NCT02305355|DRUG|Omega-3-acids ethylesters 90 4g|
219345948|NCT02305355|DRUG|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
219345949|NCT00072735|PROCEDURE|Electrocardiogram|
219345950|NCT05224583|PROCEDURE|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
219345951|NCT02120014|PROCEDURE|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
219345952|NCT02120014|PROCEDURE|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
219345953|NCT00845728|DRUG|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
219345954|NCT00845728|DRUG|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
219354867|NCT05852704|DRUG|Placebo Tab|Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
219354868|NCT05882058|DRUG|BI 764532, dose 1|BI 764532, dose 1
219354869|NCT05882058|DRUG|BI 764532, dose 2|BI 764532, dose 2
219354870|NCT06328686|DIETARY_SUPPLEMENT|Arginine|Given IV or PO
219354871|NCT06328686|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219354872|NCT06328686|PROCEDURE|Computed Tomography|Undergo CT
219354873|NCT06328686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219354874|NCT06328686|PROCEDURE|Spectroscopy|Undergo spectroscopy
219345955|NCT05837637|DIAGNOSTIC_TEST|The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)|"* The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12"
219345956|NCT02907385|DEVICE|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
219345957|NCT02206646|DRUG|Metalyse|
219345958|NCT02919878|DRUG|Gemcitabine|Nucleoside analog- Chemotherapy
219345959|NCT02919878|RADIATION|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
219345960|NCT02919878|DRUG|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
219345961|NCT00941876|BEHAVIORAL|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
219345962|NCT00822757|BIOLOGICAL|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
219345963|NCT00822757|BIOLOGICAL|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
219345964|NCT06537960|PROCEDURE|18FDG PET-CT|"18FDG PET-CT will be performed in 2 phases:~1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer~2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection."
219345965|NCT05990673|DRUG|Remimazolam|remimazolam is given intravenously
219345966|NCT04457804|BEHAVIORAL|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
219345967|NCT05697601|DIAGNOSTIC_TEST|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
219345968|NCT05697601|DIAGNOSTIC_TEST|Pathology analysis|Pathology assessment of cells and tissues from respective organs
219345969|NCT02419560|DRUG|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
219345970|NCT03166033|OTHER|the disease|Observation the patients and non-patients
219345971|NCT04646759|DRUG|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
219345972|NCT04646759|DRUG|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
219345973|NCT06359509|BIOLOGICAL|BCMA Targeted CAR T-cells|Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.
219345974|NCT02562456|PROCEDURE|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
219345975|NCT02562456|PROCEDURE|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
219345976|NCT03150771|DRUG|Aripiprazole|Injection
219345977|NCT05725616|PROCEDURE|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
219345978|NCT04951037|BEHAVIORAL|Fully Asynchronous Online Savvy Program|"The intervention is a fully online, self-administered psychoeducational program designed to enhance caregiver mastery for family and friends providing unpaid care for living with Alzheimer's and similar dementia disorders. Participants will be asked to engage with a fully online version of Tele-Savvy for 42 days.~Participants will receive a series of daily video lessons related to caregiving. These lessons are generally 8-15 minutes in length and are emailed to participants. Participants can watch the lessons whenever and as often as they wish over the course of the study. There will also be self-guided learning strategies and exercises to accomplish skill and mastery related to the caregiving role. The lessons cover a variety of topics including:~* Facts about dementing Illnesses~* Caregiving Strategies - guiding the person through days that are as safe, calm, and pleasant as possible~* Self-Care for the Caregiver"
219345979|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
219345980|NCT05949905|BEHAVIORAL|Stage-matched interventions|The intervention would be using the Processes of Change that match each Stage of Change.
219345981|NCT05137327|BEHAVIORAL|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
219354875|NCT06328686|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
219345982|NCT05137327|BEHAVIORAL|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
219345983|NCT00500084|DRUG|Liprotamase|Administered orally
219345984|NCT04677244|PROCEDURE|Blood sample in portal vein|A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
219345985|NCT04319978|DRUG|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
219345986|NCT02500524|DRUG|Cocamide diethanolamine|Topical lotion
219345987|NCT02500524|DRUG|Permethrin|Topical creme rinse
219345988|NCT03946709|OTHER|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
219345989|NCT00331474|BIOLOGICAL|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
219345990|NCT00003460|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
219345991|NCT04719182|OTHER|Adjunctive therapies|Determine and compare practice of adjunctive and supportive treatments for COVID-19
219345992|NCT03616938|PROCEDURE|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
219345993|NCT03389035|BIOLOGICAL|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
219345994|NCT02214238|DEVICE|PAP device|
219345995|NCT05985031|DIAGNOSTIC_TEST|Tendon tap|While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
219345996|NCT05985031|DIAGNOSTIC_TEST|Tibial nerve stimulation|H-reflex responses were examined by tibial nerve stimulation
219345997|NCT00849732|BIOLOGICAL|V520|Intentionally Blank
219345998|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26
219345999|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26
219346000|NCT00849732|BIOLOGICAL|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
219346001|NCT03432078|OTHER|Hypnotherapy|Non-pharmacological treatment
219346002|NCT00397826|DRUG|MK0733|Duration of Treatment: 12 Weeks
219346003|NCT01173991|BEHAVIORAL|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
219346004|NCT00273975|DRUG|Nevirapine|
219346005|NCT00273975|DRUG|Lamivudine|
219346006|NCT00273975|DRUG|Zidovudine|
219346007|NCT02833012|DRUG|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
219346008|NCT02833012|DRUG|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
219346009|NCT02833012|DRUG|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
219346010|NCT02833012|DRUG|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
219346011|NCT01717209|DRUG|Nitric Oxide|inhaled nitric oxide
219346012|NCT01717209|DRUG|Prostacyclin|inhaled prostacyclin
219346013|NCT04583033|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
219346014|NCT04442230|BIOLOGICAL|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
219346015|NCT04442230|OTHER|Placebo|Normal saline
219346016|NCT01604265|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
219346017|NCT01604265|DRUG|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
219346018|NCT05026307|PROCEDURE|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
219346019|NCT01821651|DEVICE|HeartNavigator|Procedure with software
219346020|NCT01821651|DEVICE|EchoNav|Procedure with software
219346021|NCT01821651|OTHER|Control-Group EN|Procedure without software
219346022|NCT01821651|OTHER|Control-group HN|Procedure without software
219346023|NCT05984238|DEVICE|ReCET|Investigational product.
219346024|NCT05984238|DRUG|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
219346025|NCT05984238|OTHER|Sham procedure|The sham control for the ReCET procedure.
219346026|NCT04492683|COMBINATION_PRODUCT|DBV1605|"Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation."
219346027|NCT03807804|BIOLOGICAL|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
219346028|NCT06072521|DRUG|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
219346029|NCT01578733|DIETARY_SUPPLEMENT|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
219346030|NCT05300191|DIAGNOSTIC_TEST|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
219346031|NCT02706873|DRUG|Placebo to Upadacitinib|Tablet; Oral
219346032|NCT02706873|DRUG|Methotrexate|Capsule or Tablet; Oral
219346033|NCT02706873|DRUG|Placebo to Methotrexate|Capsule or Tablet; Oral
219346034|NCT02706873|DRUG|Upadacitinib|Tablet; Oral
219346035|NCT04242082|DIAGNOSTIC_TEST|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
219346036|NCT00657891|DRUG|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
219346037|NCT00657891|DRUG|Placebo|Placebo Injection
219346038|NCT05086536|OTHER|no intervention|This is a retrospective and observational study.
219346039|NCT02599961|DRUG|UX007|UX007 is a liquid intended for oral (PO) administration.
219346040|NCT02630758|BEHAVIORAL|Mindfulness-based Yoga|See study arm description.
219346041|NCT02630758|BEHAVIORAL|Walking Control Condition|See study arm description.
219346042|NCT00210093|DRUG|denufosol tetrasodium (INS37217)|
219346043|NCT05028400|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
219346044|NCT03187665|DEVICE|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
219346045|NCT03187665|DEVICE|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
219346046|NCT05875675|DRUG|Drug: Pioglitazone Oral Tablet|Dietary Supplement: Pioglitazone 30 mg by mouth daily
219346047|NCT05875675|DIETARY_SUPPLEMENT|Placebo|Dietary: Supplement: Placebo
219346048|NCT03824808|DRUG|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
219346049|NCT03824808|DRUG|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
219346050|NCT05461950|PROCEDURE|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
219346051|NCT05461950|PROCEDURE|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
219346052|NCT05461950|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
219346053|NCT05138081|OTHER|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
219346054|NCT05138081|OTHER|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
219346055|NCT00000848|DRUG|Indinavir sulfate|
219346056|NCT00000848|DRUG|Saquinavir|
219346057|NCT00464334|BIOLOGICAL|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
219346058|NCT00464334|BIOLOGICAL|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
219346059|NCT00464334|BIOLOGICAL|Placebo to V950|
219346060|NCT04232579|OTHER|Therapeutic strategy|Therapeutic strategy compatible with the guidelines and development of predictive biomarkers of the response to treatment.
219346061|NCT02467933|OTHER|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
219346062|NCT02467933|OTHER|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
219346063|NCT02467933|OTHER|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
219346064|NCT02569762|DIETARY_SUPPLEMENT|Sucralose-Aspartame|Sucralose or aspartame
219346065|NCT02569762|DIETARY_SUPPLEMENT|Aspartame-Sucralose|Aspartame or sucralose
219346066|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 without adjuvant
219346067|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 with adjuvant
219346068|NCT05903183|BIOLOGICAL|Placebo|Diluent
219346069|NCT02173574|DRUG|DEB025|
219346070|NCT02173574|DRUG|EDP239|
219346071|NCT04821037|BEHAVIORAL|ACT|Acceptance and Commitment Therapy
219346072|NCT04321759|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
219346073|NCT04321759|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
219346074|NCT00855985|PROCEDURE|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
219346075|NCT04019730|OTHER|diet|low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)
219346076|NCT03127371|DRUG|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
219346077|NCT03127371|DRUG|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
219346078|NCT02941016|DRUG|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
219346079|NCT03196076|DRUG|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
219346080|NCT02631525|DRUG|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
219346081|NCT02631525|DRUG|Propofol|Total intravenous anesthesia based on propofol
219346082|NCT00820495|BEHAVIORAL|Web + Phone|Web + Phone
219346083|NCT00820495|BEHAVIORAL|Web Only|Web Only
219346084|NCT00820495|BEHAVIORAL|Phone Only|Phone Only
219346085|NCT00820495|BEHAVIORAL|Usual Care|Usual Care
219346086|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
219346087|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
219346088|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
219346089|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
219346090|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
219346091|NCT01418183|PROCEDURE|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
219346092|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
219346093|NCT02424526|OTHER|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
219346094|NCT02424526|DEVICE|Treadmill|
219346095|NCT02461992|DRUG|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
219346096|NCT00794677|DRUG|ezetimibe|Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
219346097|NCT00794677|DRUG|placebo|Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
219346098|NCT02151474|DRUG|INCB047986|
219346099|NCT02151474|DRUG|Placebo|
219346100|NCT03302845|DRUG|Omeprazole 40 MG|Omeprazole 40 mg capsule
219346101|NCT03302845|DRUG|Famotidine 40 mg|Famotidine 40 mg tablet
219346102|NCT03302845|DRUG|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
219346103|NCT04684446|BIOLOGICAL|AZD1222|Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
219346104|NCT04684446|BIOLOGICAL|rAd26-S|Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
219346105|NCT04411355|DIETARY_SUPPLEMENT|control by dietitian|
219346106|NCT04411355|OTHER|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
219346107|NCT04411355|BEHAVIORAL|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
219346108|NCT05377047|RADIATION|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
219346109|NCT02555670|OTHER|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
219346110|NCT03413189|OTHER|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
219346111|NCT03413189|OTHER|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
219346112|NCT03413189|OTHER|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
219346113|NCT00626691|BEHAVIORAL|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
219346114|NCT03961815|DRUG|Brazikumab Induction Dose|Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
219346115|NCT03961815|DRUG|Brazikumab Maintenance Dose|Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
219346116|NCT04906174|OTHER|Electronic Health Record Review|Medical records are reviewed
219346117|NCT05752253|OTHER|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
219346118|NCT05213377|PROCEDURE|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
219346119|NCT05532774|DEVICE|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
219346120|NCT05937178|DRUG|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
219346121|NCT05937178|DRUG|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
219346122|NCT03237104|OTHER|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
219346123|NCT02662257|DRUG|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
219354876|NCT01996800|PROCEDURE|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
219346124|NCT02662257|DRUG|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
219346125|NCT01774578|DRUG|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
219346126|NCT01774578|BIOLOGICAL|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
219346127|NCT01774578|DRUG|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
219346128|NCT01774578|DRUG|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
219346129|NCT01100515|OTHER|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
219346130|NCT01100515|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
219346131|NCT04241211|DRUG|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
219346132|NCT04241211|DRUG|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
219346133|NCT01422915|DRUG|Colestipol|2 grams morning and bedtime for 90 days.
219346134|NCT03761615|DEVICE|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
219346135|NCT04682886|DIAGNOSTIC_TEST|diagnosis|there is no intervention diagnosis or treatment for patients
219346136|NCT01152021|DRUG|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
219346137|NCT01152021|DRUG|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
219346138|NCT04586283|OTHER|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
219346139|NCT01982929|PROCEDURE|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
219346140|NCT01982929|PROCEDURE|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
219346141|NCT05013762|BEHAVIORAL|Fast intervention|This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.
219346142|NCT05013762|BEHAVIORAL|Active Monitoring|This is an observation-only group. The training received in this group will be dose equivalent to the active group.
219346143|NCT05209633|DRUG|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
219346144|NCT05209633|DRUG|Placebo|placebo
219346145|NCT02534688|DRUG|LNG-IUS|
219346146|NCT02534688|DRUG|DMPA|
219346147|NCT04893772|DIETARY_SUPPLEMENT|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
219346148|NCT00034658|DRUG|Posaconazole|
219346149|NCT04522089|BIOLOGICAL|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
219346150|NCT01825707|DRUG|[14C]-YH4808 200 mg|\[14C\]-YH4808 200 mg (oral) on day1
219346151|NCT04160130|PROCEDURE|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
219346152|NCT01885611|OTHER|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
219346153|NCT01885611|DIETARY_SUPPLEMENT|Virgin Coconut Oil|cold-processed VCO
219346154|NCT02243215|OTHER|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
219346155|NCT00909558|BIOLOGICAL|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
219346156|NCT01441570|DRUG|Nebivolol|Subject will take nebivolol daily for 12 weeks.
219346157|NCT01441570|DRUG|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
219346158|NCT05318391|DIAGNOSTIC_TEST|Gene expression profile|"Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)"
219346159|NCT05747911|OTHER||Groups will not be intervened. Only observational data will be used.
219346160|NCT04027998|DIAGNOSTIC_TEST|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
219346161|NCT00826124|PROCEDURE|Epidural steroid injection|Injection based solely on history and physical exam
219346162|NCT00826124|PROCEDURE|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
219346163|NCT00826124|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
219346164|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
219346165|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
219346166|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
219346167|NCT04994119|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
219346168|NCT04994119|DRUG|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
219346169|NCT05462847|DRUG|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
219346170|NCT04197115|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
219346171|NCT04197115|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
219346172|NCT04197115|DRUG|Complex B|Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
219346173|NCT06512974|BEHAVIORAL|NeuroTrainer|Virtual reality based cognitive training
219346174|NCT06982469|RADIATION|Brachytherapy|HDR brachytherapy
219346175|NCT07020858|DIAGNOSTIC_TEST|FAPl lmaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPl) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPl imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
219346176|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
219346177|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） High Dose|
219346178|NCT01411254|DRUG|Sham|
219346179|NCT06629753|BEHAVIORAL|Differentiated service delivery model|The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
219346180|NCT07027904|DEVICE|Implant|The immediate implant was placed, and the surrounding cavity was filled with xenograft bone material, along with the application of hyaluronic acid or platelet-rich fibrin (PRF) to enhance healing and bone integration.
219346181|NCT07029867|DRUG|Yishen Daluo Yin granuls|The patient takes YSDLY granules or placebo twice a day.
219346182|NCT07029867|DRUG|Placebo|The patient takes placebo (YSDL mimetic granules) twice a day.
219346183|NCT07028892|DEVICE|A gamified mobile learning|There will be a gamified environment in a mobile application with case scenarios on pressure injury prevention designed by researchers.
219346184|NCT07028892|OTHER|Booklet training|Nurses will receive training via a booklet about prevention of pressure injuries.
219346185|NCT07030023|OTHER|Non intervention|Non intervention
219346186|NCT07029893|BEHAVIORAL|Independent Life Skills Program (ILSP)|The ILSP runs for 14 weeks, covering six areas of independent living skills and 14 weekly sessions lasting 2 hours each. The program will run in a group format with 4 participants in each group. The ILSP will be run by occupational therapists who are trained in the program delivery.
219346187|NCT07029893|OTHER|Wait-list control|Participants do not receive the experimental treatment and will be put on a waiting list to receive the intervention after the active treatment group does.
219346188|NCT07028203|DEVICE|Treatment with BTL-785 with the applicator BTL-785-7-11|The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes.
219346189|NCT07029243|BEHAVIORAL|HEAL-ME digital app|HEAL-ME is a digital prehabilitation app that provides semi-guided nutrition/exercise prehabilitation
219346190|NCT07029243|DIETARY_SUPPLEMENT|Creatine supplementation|Patients will take 5g creatine supplementation daily for 13 weeks
219346191|NCT07029243|DIETARY_SUPPLEMENT|Whey protein supplementation|Patients will take 35g whey protein supplementation daily
219346192|NCT07029243|DIETARY_SUPPLEMENT|Placebo|Patients will be administered daily placebo supplementation.
219346193|NCT07029477|DEVICE|Incentive Spirometry|Participants received incentive spirometry therapy using a standard device beginning within 2 hours post-laparoscopic cholecystectomy. They were instructed to take 10 deep breaths every 2 hours for 12 hours.
219346194|NCT07029477|BEHAVIORAL|Massage Therapy|Participants received manual massage therapy at regular intervals of 4, 8, and 12 hours after laparoscopic cholecystectomy.
219346195|NCT07029074|DEVICE|Sham inspiratory muscle training (MIP 0%)|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
219346196|NCT07029074|DEVICE|MIP 30% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
219346197|NCT07029074|OTHER|MIP 70% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
219346198|NCT07028580|OTHER|Diet based on animal proteins|Ιntervention with a diet based on animal proteins.
219346199|NCT07028580|OTHER|Diet based on plant proteins.|Ιntervention with a diet based on animal proteins.
219346200|NCT07028580|OTHER|General instructions for patients with liver disease.|Α brochure with general instructions was designed for patients with liver disease.
219346201|NCT07029880|OTHER|full veneered metal ceramic dental prosthesis cemented with resin cement|full veneered metal ceramic dental prosthesis cemented with resin cement
219346202|NCT07028216|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
219346203|NCT07029958|DRUG|recombinant humanized anti-CD25 monoclonal antibody|"For children at high risk of GVHD, one of the following conditions must be met (haploidentical donors must meet one condition, while unrelated donors must meet two conditions):~1. The donor is ≥40 years old;~2. The donor is an unrelated donor with ≥1 locus mismatch, a haploidentical female donor, or collateral consanguinity (e.g., cousin, uncle/aunt);~3. Pre-transplant CD3 count ≥4 x 10\^8/kg;~4. The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase;~5. ATG (or biologically equivalent doses of ATLG \[1:2\] or ALG \[1:20\]) \<10mg/kg. Combining recombinant anti-CD25 humanized monoclonal antibody with conventional pretreatment regimen, before peripheral blood stem cell transfusion (i.e. 0d) and+3d, 1mg/kg，\<40kg the maximum dose should not exceed25mg/dose, ≥40kg 1mg/kg, and the maximum dose should not exceed 50mg/dose."
219346204|NCT07029386|DEVICE|tES|"his study employs a randomized controlled trial (RCT) design, randomly dividing eligible participants into a neuromodulation group and a sham neuromodulation group.~Neuromodulation Group:~Receive individualized transcranial electrical stimulation (tES) treatment Combined with cognitive training~Stimulation parameters:~Total current: approximately 2mA Duration: 21 minutes Electroencephalogram (EEG) and functional MRI (fMRI) monitoring before and after electrical stimulation"
219346205|NCT07029386|DEVICE|tES|Use the same device and procedure as the neuromodulation group Stimulation device automatically turns off after 30 seconds Maintain device connection Design creates similar initial sensations to actual stimulation Maintains the double-blind nature of the study
219346206|NCT07029256|OTHER|Non-Interventional Study|Non-interventional study
219346207|NCT07027852|BEHAVIORAL|My Lung Health Coach|Virtual education and self-management program with companion application
219346208|NCT07029191|OTHER|Progressive standing test|Progressive raising test in successive steps in a healthy subject
219346209|NCT07028255|DIETARY_SUPPLEMENT|Qualia Testosterone|Qualia Testosterone manufactured by Qualia Life Sciences
219346210|NCT07028255|DIETARY_SUPPLEMENT|Placebo|Rice Flour
219346211|NCT07028814|OTHER|Risk-informed obesity care plan|A risk-informed obesity care plan, implemented through pediatric primary care provider training via a Virtual Learning Collaborative (VLC) will be deployed.
219346212|NCT06706245|BEHAVIORAL|SET-VR (computer)|Low-immersive version of the SET-VR program
219346213|NCT06706245|BEHAVIORAL|SET-VR (headset)|High-immersive version of the SET-VR program
219346214|NCT07028931|BEHAVIORAL|Visualization technique|In GROUP A, i.e., visualization technique Athletes will be shown a video of stretching protocols and then will be asked to visualize those exercises, the total session time will be approximately 20 minutes which will be divided into three phases: pre-Session visualization (5-10 minutes) which will begin with 1-2 minutes of deep breathing and mental preparation to start visualization technique then players will be asked to visualize dynamic stretching (leg swings, arm circles, and lunges) and static stretching (hamstring and shoulder stretch) for 2-3 minutes each. Then begins the during session visualization phase (1-2 minutes per stretch) the players will be asked to pause before each stretch to visualize the movements, muscle engagement and the feeling of stretch and the transit between the stretches and then last comes the post session phase of visualization (5 minutes) this will involve visualization of cool down exercises like spinal twist, bicep stretch, triceps and hip stretch.
219346215|NCT07028931|OTHER|Combined Stretching Protocol|GROUP B will receive Combined stretching training protocol. The overall duration will be 20 minutes starting from warm up (5-7 minutes) which will include light jogging arm swings, leg swings and lunges, hamstring and shoulder stretches then followed by combined stretching movements (8-10 minutes) this will include hip flexor and hamstring combo, calf and Achilles stretch and spinal twist and arm extension movements and ending with a cool down protocol (5-7 minutes) which will include hip flexor stretch, quadriceps stretch and calf stretch, bicep and triceps stretch.
219346216|NCT07028060|DEVICE|PulseNmore MC™|novel mobile Self-scan ultrasound device, Pulsenmore MC™
219346217|NCT07027891|DEVICE|AI-ECG|The patients in AI-ECG group would be managed with the information of the myocardial infarction risk score in AI-ECG in addition to the usual care.
219346218|NCT07028307|OTHER|Breathing Exercises|"Ujjai: While the mouth is closed, a hissing sound is made until the space between the throat and lungs is filled with breath, and a slow and deep inhalation is made. Then, without holding the breath, a long and full exhalation is made through a partially closed glottis and a slight laryngeal muscle contraction, and the same sound is made. In each session, two sets of ujjayi technique were applied, with an inhalation:exhalation ratio of 1:2 and 10 respiratory cycles, with a 1-minute rest period between sets.~Sukha Pranayama: Applied for 5 minutes with a 5:5 inhalation:exhalation ratio of 6 breaths per minute.~Nadi Shodhana: After closing the right nostril with the thumb of the right hand, a slow and deep inhalation is performed through the left nostril. After maximum inhalation, without holding the breath, the left nostril is closed with the fourth finger of the right hand and a full exhalation is performed through the right nostril. Maintaining the closed position of the left nostr"
219346219|NCT07028307|OTHER|Breathing Exercises + Kinesio Taping Group|The tape was not removed for 5 days from the day of the procedure, but was removed after the 5th day, allowing the skin to rest for 2 days, and then repeated for 4 weeks with a new kinesio tape application. The tapes of those who stated that there was wear or tear on the tape were renewed within a week. After the skin was cleaned with alcohol, the kinesio tape application was applied bilaterally as an I tape with 25-50% tension on the paraspinal muscles from the 7th cervical vertebra to the 12th thoracic vertebra. The I tape was applied horizontally with 50% tension to the point where the kyphotic area was clearly observed. All strips were rubbed to increase adhesion to the skin and activate the tape.
219346220|NCT07029165|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
219346221|NCT07029165|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
219346222|NCT07029165|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
219346223|NCT06737627|OTHER|no intervention|no intervention
219346224|NCT06833502|OTHER|CT Scan|Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
219346225|NCT05696522|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
219346226|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
219346227|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
219346228|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
219346229|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
219346230|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
219346231|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
219346232|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
219346233|NCT00274027|DRUG|tiotropium bromide|
219346234|NCT04226820|OTHER|examination: blood pressure assessment|blood pressure measurement for 30 minutes, dominant side
219346235|NCT04226820|OTHER|examination: Flow Mediated Dilatation (FMD)-test|Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality
219346236|NCT04226820|OTHER|examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring|participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation
219346237|NCT04226820|OTHER|examination: measurement of glucose by a finger prick|follow-up of blood sugar (glucose) during examinations by a finger prick
219346238|NCT01347151|DEVICE|The glidescope video laryngoscopy|
219346239|NCT01347151|DEVICE|The Pentax airwayscope|
219346240|NCT01920204|DRUG|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
219346241|NCT02098564|OTHER|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
219346242|NCT02098564|OTHER|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
219346243|NCT04979507|OTHER|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
219346244|NCT01394939|BIOLOGICAL|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
219346245|NCT01394939|DRUG|Irinotecan|180 mg/m2 IV every 2 weeks.
219346246|NCT03379662|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
219346247|NCT03379662|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
219346248|NCT05928455|BIOLOGICAL|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
219346249|NCT05928455|BIOLOGICAL|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
219346250|NCT01871961|DRUG|Methotrexate (Metoject® prefilled pen)|
219346251|NCT02806323|OTHER|Yoga practice|
219346252|NCT05118256|DRUG|Pirfenidone Oral Tablet|Patients will be treated with pirfenidone (oral tablets) during 6 months
219346253|NCT00246532|DRUG|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
219346254|NCT00246532|DRUG|Placebo|Patients will receive placebo tablets.
219346255|NCT04448587|DRUG|Sitagliptin 100mg|Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
219346256|NCT00446602|DRUG|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
219346257|NCT00659204|DRUG|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
219346258|NCT00659204|DRUG|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
219346259|NCT05227638|OTHER|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
219346260|NCT04210609|DEVICE|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
219346261|NCT03373305|DRUG|Brentuximab Vedotin|Given IV
219346262|NCT03373305|DRUG|Lenalidomide|Given PO
219346263|NCT03373305|OTHER|Laboratory Biomarker Analysis|Correlative studies
219346264|NCT05578729|BEHAVIORAL|Single surgical mask group, Double surgical mask group, N95 mask group|Masks were given to the resting pregnant women 30 minutes before the NST, and they were provided to wear masks. After 30 minutes, the vital signs of the pregnant women were measured just before and after the NST, and the images of the NST traces were taken.
219346265|NCT03637933|PROCEDURE|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
219346266|NCT01495442|DEVICE|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
219346267|NCT01495442|DEVICE|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
219346268|NCT04238390|DRUG|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
219346269|NCT04238390|DRUG|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
219346270|NCT05331014|DRUG|LivaloVA|For 8 weeks(PO, QD)
219346271|NCT05331014|DRUG|LivaloV|For 8 weeks(PO, QD)
219346272|NCT05331014|DRUG|VA|For 8 weeks(PO, QD)
219346273|NCT02823691|DRUG|Lanreotide and Metformin|Lanreotide and Metformin
219346274|NCT00216411|BIOLOGICAL|Botulinum toxin type A|
219346275|NCT00216411|DRUG|Placebo|
219346276|NCT04690400|OTHER|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
219346277|NCT04690400|OTHER|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
219346278|NCT00774462|DRUG|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
219346279|NCT04842201|DRUG|CM326|subcutaneous injection
219346280|NCT04842201|DRUG|Placebo|subcutaneous injection
219346281|NCT03489382|OTHER|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
219346282|NCT01049035|BIOLOGICAL|Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate|0.5 milliliter (mL), Intramuscular (IM) injection
219346283|NCT01049035|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)|0.5 mL, IM injection
219346284|NCT01049035|BIOLOGICAL|M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live|0.5 mL, Subcutaneous (SC) injection
219346285|NCT01049035|BIOLOGICAL|Varicella Virus Vaccine Live|0.5 mL, SC injection
219346286|NCT01049035|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
219346287|NCT01049035|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
219346288|NCT01049035|BIOLOGICAL|Rotavirus Vaccine|oral
219346289|NCT01049035|BIOLOGICAL|Hepatitis B Vaccine|0.5 mL, IM injection
219346290|NCT04716790|PROCEDURE|Ultrasound Debridement|Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
219346291|NCT04716790|PROCEDURE|Conventional Treatment|Conventional Treatment based on international guidelines for diabetic foot
219346292|NCT01312246|DEVICE|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
219346293|NCT00180310|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
219346294|NCT00180310|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
219346295|NCT02491814|OTHER|1% M.F. Milk|
219346296|NCT02491814|OTHER|Yogurt Beverage|
219346297|NCT02491814|OTHER|Soy Beverage|
219346298|NCT02491814|OTHER|Almond Beverage|
219346299|NCT02491814|OTHER|Water|
219346300|NCT02491814|OTHER|Breakfast cereal|
219346301|NCT03315767|DIAGNOSTIC_TEST|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
219346302|NCT03315767|DIAGNOSTIC_TEST|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
219346303|NCT06046261|OTHER|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
219346304|NCT02095535|DRUG|Chlorhexidine gluconate|antiseptic
219346305|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
219346306|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
219346307|NCT00288093|RADIATION|3-Dimensional Conformal Radiation Therapy|
219346308|NCT00288093|DRUG|Triapine|
219346309|NCT00568646|DRUG|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
219346310|NCT06247709|OTHER|Immunohistochemical expression in pitNET cells of KLHL14|Lab essay evaluating the expression of KLHL 14
219346311|NCT00658554|DRUG|ARQ 197|Treatment with ARQ 197
219346312|NCT01330238|DRUG|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
219346313|NCT02056483|OTHER|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
219346314|NCT03709654|BIOLOGICAL|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
219346315|NCT03709654|OTHER|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
219346316|NCT03801668|DRUG|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
219346317|NCT03801668|DRUG|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
219346318|NCT01902966|DRUG|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
219346319|NCT01902966|BEHAVIORAL|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
219346320|NCT01902966|BEHAVIORAL|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
219346321|NCT01902966|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
219346322|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
219346323|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
219346324|NCT04543994|OTHER|Placebo|Normal saline
219346325|NCT01515787|DRUG|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
219346326|NCT01515787|OTHER|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
219346327|NCT01515787|PROCEDURE|surgery|low anterior resection with total mesorectal excision
219346328|NCT01515787|PROCEDURE|magnetic resonance imaging or endorectal ultrasound|
219346329|NCT02631200|BEHAVIORAL|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
219346330|NCT05086471|DEVICE|NaviCam SB|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
219346331|NCT05086471|DEVICE|PillCam SB3|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
219346332|NCT00948870|DRUG|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
219346333|NCT01081912|DRUG|Placebo|Capsules, no active substance, shells identical to active comparator capsules
219346334|NCT01081912|DRUG|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
219346335|NCT05374252|DRUG|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
219346336|NCT05374252|RADIATION|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
219346337|NCT02868242|DRUG|LDV/SOF|Tablet(s) administered orally once daily
219346338|NCT03669302|OTHER|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219346339|NCT03669302|DEVICE|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219346340|NCT03669302|DEVICE|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
219346341|NCT03776175|DRUG|PF-05221304 Monotherapy|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
219346342|NCT03776175|DRUG|PF-06865571 Monotherapy|Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
219346343|NCT03776175|DRUG|Placebo|Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
219346344|NCT03776175|DRUG|PF-05221304 and PF-06865571 Combination|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
219346345|NCT03124823|DEVICE|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
219346346|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2 in orange juice|1000 IU dose
219346347|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3 in orange juice|1000 IU
219346348|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2|capsule, 1000 IU
219346349|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3|capsule, 1000 IU
219346350|NCT01778114|OTHER|Placebo|Placebo
219346351|NCT05261022|BEHAVIORAL|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
219346352|NCT02486198|DRUG|placebo|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
219346353|NCT02486198|DRUG|GM|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
219346354|NCT02486198|DRUG|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
219346355|NCT00773812|DRUG|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
219346356|NCT00773812|DRUG|placebo|One pill is taken once daily.
219346357|NCT04464161|DIETARY_SUPPLEMENT|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
219346358|NCT02475798|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
219346359|NCT03981783|BEHAVIORAL|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
219346360|NCT03981783|BEHAVIORAL|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
219346361|NCT06888830|DRUG|JS212 for Injection|JS212 for Injection is administered on the first day of the first cycle and every 3 weeks thereafter.
219346362|NCT02412787|DRUG|Idursulfase-IT|Participants received 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who were younger than 3 years of age received an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).
219346363|NCT02412787|DRUG|Elaprase|Participants received intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
219346364|NCT05836103|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
219346365|NCT06786936|DRUG|Secukinumab|Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.
219346366|NCT06786936|DRUG|Bimekizumab|Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.
219346367|NCT06786936|DRUG|Ixekizumab|Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.
219346368|NCT06786936|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
219346369|NCT02852031|OTHER|Collaborative Learning Network|
219346370|NCT05829135|DEVICE|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
219346371|NCT06223828|DRUG|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
219346372|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
219346373|NCT04278859|BIOLOGICAL|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
219346374|NCT06145724|BEHAVIORAL|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
219346375|NCT02339064|DRUG|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
219346376|NCT05930548|OTHER|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
219346377|NCT00622674|BIOLOGICAL|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
219346378|NCT00622674|DRUG|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
219346379|NCT03945526|DRUG|Astaxanthine|
219346380|NCT03945526|DRUG|Placebo Oral Tablet|
219346381|NCT00455234|DRUG|Intramuscular Olanzepine 10 mg|
219346382|NCT00455234|DRUG|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
219346383|NCT02788942|PROCEDURE|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
219346384|NCT05702528|DEVICE|Apollo Neuro|The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
219346385|NCT02730585|BIOLOGICAL|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
219346386|NCT05044208|DIAGNOSTIC_TEST|ECG monitoring|After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
219346387|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
219346388|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
219346389|NCT02311153|DEVICE|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
219346390|NCT02311153|DEVICE|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
219346391|NCT05194085|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
219346392|NCT05194085|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
219346393|NCT01303094|DRUG|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
219346394|NCT01303094|OTHER|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
219346395|NCT02855528|DEVICE|Tin Filter|
219346396|NCT04086823|DRUG|RZL-012|Subcutaneous injection to the submental fat area
219346397|NCT04086823|DRUG|Placebo|Placebo
219346398|NCT06535243|BEHAVIORAL|Lifespan Integration Therapy (LI)|same as above
219346399|NCT02414386|OTHER|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
219346400|NCT04351984|DEVICE|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
219346401|NCT06377787|OTHER|ELDOA and conventional therapy|hot pack and TENS for10 min, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4rep with 6 sec hold once a day) and ELDOA method C0-C1-C2, C2 \& C3 positions for cervical spine (2 sets of five repetitions with 45 sec hold and 15sec rest between each set once a day).
219346402|NCT06377787|OTHER|conventional therapy|include hot pack and TENS for 10 minutes, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4 reps with 6 seconds hold once a day).
219346403|NCT05234970|OTHER|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
219346404|NCT05234970|OTHER|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
219346405|NCT01816009|OTHER|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
219346406|NCT03923569|DIAGNOSTIC_TEST|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
219346407|NCT03923569|DIAGNOSTIC_TEST|blood sample|blood sample for genetic testing of the Apolipoprotein E
219346408|NCT03923569|DIAGNOSTIC_TEST|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
219346409|NCT03923569|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
219346410|NCT01072214|DRUG|pazopanib|gw786034
219346411|NCT01072214|DRUG|pazopanib|gw786034
219346412|NCT01072214|DRUG|pazopanib|gw786034
219346413|NCT01072214|DRUG|Placebo|placebo
219346414|NCT04840160|DIETARY_SUPPLEMENT|Cherry juice|A tart cherry juice intervention
219346415|NCT04840160|DIETARY_SUPPLEMENT|Placebo|A tart cherry juice placebo
219346416|NCT03641066|DEVICE|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
219346417|NCT02368054|DRUG|Bupivacaine|Infiltration anesthesia
219346418|NCT02368054|DRUG|Adrenaline|Infiltration anesthesia
219346419|NCT01018498|BEHAVIORAL|Restricted FODMAPs diet|Restricted fermentable substrate diet
219346420|NCT05070221|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
219346421|NCT05070221|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
219346422|NCT05070221|DRUG|Axitinib|5mg，bid，p.o.；
219346423|NCT00414453|DRUG|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
219346424|NCT00414453|DRUG|Extended-release oxycodone|extended-release oxycodone titrating schedule
219346425|NCT00414453|DRUG|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
219346426|NCT00414453|DRUG|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
219346427|NCT06079450|OTHER|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
219346428|NCT01803360|DRUG|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
219346429|NCT03934450|DRUG|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
219346430|NCT03934450|DRUG|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
219346431|NCT03934450|DRUG|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
219346432|NCT03934450|DRUG|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
219346433|NCT05679635|DEVICE|Evone|The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
219346434|NCT05679635|DEVICE|Evita Infinity V500|Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
219346435|NCT03285737|DIETARY_SUPPLEMENT|Whey|Supplement provided twice daily in 30g doses
219346436|NCT03285737|DIETARY_SUPPLEMENT|Collagen|Supplement provided twice daily in 30g doses
219346437|NCT00001287|DRUG|intravenous immunoglobulin (IVIg)|
219346438|NCT02281695|OTHER|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
219346439|NCT00514865|DRUG|ONO-2333Ms Experimental 2|5-10 mg QD(once a day) for 8 weeks
219346440|NCT00514865|DRUG|Placebo|0 mg QD(once a day) for 8 weeks
219346441|NCT00514865|DRUG|ONO-2333Ms Experimental 1|1-2 mg QD(once a day) for 8 weeks
219346442|NCT02549768|DRUG|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
219346443|NCT02549768|DRUG|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
219346444|NCT02429414|DEVICE|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
219346445|NCT02429414|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
219346446|NCT02429414|DEVICE|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
219346447|NCT03155594|DEVICE|Freestyle Libre|Continuous glucose monitoring patch
219346448|NCT00969449|DRUG|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
219346449|NCT00969449|DRUG|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
219346450|NCT00000511|DIETARY_SUPPLEMENT|mineral supplements|
219346451|NCT00000511|DIETARY_SUPPLEMENT|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
219346452|NCT00000511|BEHAVIORAL|dietary supplements|
219346453|NCT04769011|DIAGNOSTIC_TEST|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
219346454|NCT04769011|DIAGNOSTIC_TEST|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
219346455|NCT04769011|DIAGNOSTIC_TEST|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
219346456|NCT04769011|DIAGNOSTIC_TEST|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
219346457|NCT04499261|PROCEDURE|laparoscopic surgery|Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
219346458|NCT04499261|PROCEDURE|Open surgery|Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
219346459|NCT01784861|DRUG|X-82|
219346460|NCT01784861|DRUG|Everolimus|
219346461|NCT04901143|DEVICE|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
219346462|NCT03948178|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
219346463|NCT04234711|PROCEDURE|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
219346464|NCT03597932|DEVICE|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
219346465|NCT03178227|BEHAVIORAL|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
219346466|NCT05628714|OTHER|Patient decision aid for patients with superficial basal cell carcinoma|An online WebApp
219346467|NCT04370080|DEVICE|Silver Diamine Fluoride 38%|Dental caries arrest medication
219346468|NCT03788720|PROCEDURE|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
219346469|NCT03788720|PROCEDURE|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
219346470|NCT01699945|OTHER|This is an observational study being conducted as a substudy of antoher trial.|
219346471|NCT06443866|DIAGNOSTIC_TEST|Disease status detection|RAI dose determination
219346472|NCT06443866|DIAGNOSTIC_TEST|Theranostic dosimetry|Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer
219346473|NCT06443866|DRUG|I-124 PET/CT imaging|Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer
219346474|NCT06438484|BEHAVIORAL|multimodal prehabilitation program|"Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience). The physical exercise training consisted of high-intensity interval training (HIIT) three times a week and functional strengthening exercises. Patients visited the hospital two times a week and performed home exercise training five times a week on a stationary cycle ergometer (Corival Home+, Lode BV, Groningen, The Netherlands).~The dietary intervention consisted of optimization of energy and protein intake, optimization of timing of eating protein-rich products, and if necessary additional protein and vitamin supplements. Individual protein requirements were set at 1.5-1.9 g/kg fat free mass. Patients used the eiFIT-application or a food diary to track their protein intake."
219346475|NCT05437003|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients
219346476|NCT05515250|DEVICE|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
219346477|NCT03015259|DRUG|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
219346478|NCT03015259|DRUG|Symbicort|Active Comparator: Treatment 2
219346479|NCT03015259|DRUG|Placebo|Placebo Comparator: Treatment 3
219346480|NCT01305538|DRUG|BMS-954561|
219346481|NCT01305538|DRUG|BMS-954561|
219346482|NCT01305538|DRUG|Placebo|
219346483|NCT00385645|DRUG|Combivir+Kaletra|
219346484|NCT00385645|DRUG|Combivir+Reyataz|
219346485|NCT04149067|DRUG|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
219346486|NCT04149067|DRUG|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
219346487|NCT03232086|OTHER|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219346488|NCT03232086|OTHER|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
219346489|NCT02371447|DRUG|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
219346490|NCT06364085|DEVICE|Neuromodulation programming|"Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up."
219346491|NCT04499872|OTHER|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
219346492|NCT00362089|DIETARY_SUPPLEMENT|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
219346493|NCT04400474|DRUG|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
219346494|NCT01965262|DEVICE|Hema-copolymer Lens|contact lens
219346495|NCT01965262|DEVICE|etafilcon A Lens|contact lens
219346496|NCT03173794|OTHER|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
219346497|NCT00143312|DRUG|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
219346498|NCT03048903|DRUG|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
219346499|NCT03048903|DRUG|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
219346500|NCT03444285|OTHER|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
219346501|NCT03444285|OTHER|Hot Pack|20 minutes of hot-pack on both hamstring
219346502|NCT02911532|PROCEDURE|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
219346503|NCT05210530|COMBINATION_PRODUCT|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
219346504|NCT02244567|DRUG|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
219346505|NCT02244567|PROCEDURE|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
219346506|NCT02244567|OTHER|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
219346507|NCT01029366|BIOLOGICAL|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
219346508|NCT05387811|COMBINATION_PRODUCT|Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy|Adherence to International Club of Ascites recommendations for the management of AKI
219346509|NCT05428787|PROCEDURE|Left Bundle Branch Area Pacing|The patients will be allocated by randomization to receive the intervention of Left Bundle Branch Area Pacing
219346510|NCT05428787|PROCEDURE|CRT|The patients will be allocated by randomization to receive the intervention of CRT.
219346511|NCT05428787|PROCEDURE|AV node ablation|AV node ablation after 4 weeks of CRT implant or LBBAP implant.
219346512|NCT01479543|OTHER|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
219346513|NCT01479543|OTHER|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
219346514|NCT01479543|OTHER|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
219346515|NCT01479543|OTHER|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
219346516|NCT01479543|OTHER|Placebo|Placebo capsule for 28 days.
219346517|NCT06212245|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg
219346518|NCT00906087|DRUG|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
219346519|NCT02127190|DRUG|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
219346520|NCT02127190|DRUG|Placebo|
219346521|NCT00370279|PROCEDURE|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
219346522|NCT01109784|DRUG|prasugrel|prasugrel 10 mg/day
219346523|NCT01109784|DRUG|clopidogrel|clopidogrel per os 150mg/day
219346524|NCT03341962|DRUG|IMU-838|IMU-838 tablet
219346525|NCT03341962|DRUG|Placebo|Tablets manufactured to mimic IMU-838 tablets
219346526|NCT01576692|BIOLOGICAL|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once"
219346527|NCT01576692|DRUG|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3"
219346528|NCT01576692|OTHER|Cytokines|"Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC \>2,000/mm\^3"
219346529|NCT01576692|BIOLOGICAL|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.
219346530|NCT01576692|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
219346531|NCT02936700|BEHAVIORAL|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
219346532|NCT02936700|BEHAVIORAL|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions"
219346533|NCT00001133|DRUG|Indinavir sulfate|
219346534|NCT00001133|DRUG|Ritonavir|
219346535|NCT03831594|DEVICE|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
219346536|NCT03831594|OTHER|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
219346537|NCT02866474|DIETARY_SUPPLEMENT|population living at home with meals on wheels|
219346538|NCT02866474|DIETARY_SUPPLEMENT|population living in an EHPAD|
219346539|NCT04280900|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
219346540|NCT04280900|BEHAVIORAL|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
219346541|NCT06466226|PROCEDURE|Multiple central venous lines in two sites separately|Patients with two central venous lines in two sites separately (two central venous sites).
219346542|NCT06466226|PROCEDURE|Multiple central venous lines in one site (internal jugular vein)|Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).
219346543|NCT05209503|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
219346544|NCT05209503|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
219346545|NCT05020873|OTHER|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
219346546|NCT05965284|DRUG|Azathioprine|All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
219346547|NCT05965284|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
219346548|NCT05828693|BEHAVIORAL|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
219346549|NCT05828693|BEHAVIORAL|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
219346550|NCT03350217|DRUG|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
219346551|NCT03350217|DRUG|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
219346552|NCT00800332|DRUG|CYT003-QbG10|subcutaneous injection
219346553|NCT00800332|DRUG|Placebo|subcutaneous injection
219346554|NCT03027986|BEHAVIORAL|postural rehabilitation program|This program is based on sensory-motor control
219346555|NCT04267874|PROCEDURE|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
219346556|NCT04267874|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given black raspberry nectar PO
219346557|NCT04267874|DRUG|Placebo Administration|Given PO
219346558|NCT04267874|OTHER|Questionnaire Administration|Ancillary studies
219346559|NCT05473403|OTHER|Corticosteroid therapy|Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
219346560|NCT00947180|BEHAVIORAL|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
219346561|NCT00947180|OTHER|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
219346562|NCT00947180|BEHAVIORAL|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
219346563|NCT04096196|BEHAVIORAL|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
219346564|NCT04096196|OTHER|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
219346565|NCT03464656|DRUG|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)"
219346566|NCT03464656|DIAGNOSTIC_TEST|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
219346567|NCT03464656|DIAGNOSTIC_TEST|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
219346568|NCT03464656|DIAGNOSTIC_TEST|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
219346569|NCT03617991|OTHER|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
219346570|NCT00757250|DRUG|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
219346571|NCT02012985|BIOLOGICAL|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
219346572|NCT02012985|DRUG|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
219346573|NCT01811251|DRUG|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
219346574|NCT04759651|OTHER|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
219346575|NCT04759651|OTHER|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
219346576|NCT04759651|OTHER|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
219346577|NCT04759651|OTHER|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
219346578|NCT04759651|OTHER|Insomnia Questionnaire|Subjective evaluation of insomnia.
219346579|NCT04759651|OTHER|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
219346580|NCT04759651|OTHER|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
219346581|NCT04759651|OTHER|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
219346582|NCT03353870|OTHER|qualitative interview|individual qualitative interview
219346583|NCT03579784|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
219346584|NCT03579784|DRUG|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
219346585|NCT03579784|DRUG|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
219346586|NCT02820129|DEVICE|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
219346587|NCT02820129|DEVICE|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
219346588|NCT02671136|DEVICE|Hyperbaric Oxygen therapy|
219346589|NCT02671136|OTHER|Conventional Wound Therapies|
219346590|NCT03643380|DEVICE|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
219346591|NCT02327637|BEHAVIORAL|Moderate Activity|Ambulation 150 feet, two times per day
219346592|NCT02547350|DRUG|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
219346593|NCT04572477|DRUG|[18F]THK-5351|F-18 THK PET Imaging
219346594|NCT04572477|DRUG|[18F]AV-45|F-18 AV45 PET Imaging
219346595|NCT01565070|DRUG|Biofreeze|Use of Biofreeze ointment
219346596|NCT01565070|OTHER|Placebo|Use of placebo ointment
219346597|NCT04937556|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
219346598|NCT04937556|DIETARY_SUPPLEMENT|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
219346599|NCT00806559|OTHER|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
219346600|NCT00806559|OTHER|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
219346601|NCT05409261|BIOLOGICAL|Ad26.COV2.S|Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
219346602|NCT02982343|BEHAVIORAL|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
219346603|NCT02982343|BEHAVIORAL|Falls management only|Participants will undergo a session of falls management and education.
219346604|NCT03766529|PROCEDURE|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
219346605|NCT04251637|OTHER|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
219346606|NCT03730155|OTHER|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
219346607|NCT00513500|DRUG|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
219346608|NCT00513500|DRUG|Coartem|Give Coartem without RDT and refer fast breathing
219346609|NCT06494137|OTHER|inulin|inulin from chicory root
219346610|NCT02248727|DEVICE|somofilcon A|somofilcon A lens
219346611|NCT02585505|PROCEDURE|stem cells|stem cell will be injected
219346612|NCT05852535|PROCEDURE|Exploration|abdominal exploration
219346613|NCT04639583|DEVICE|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
219346614|NCT04326335|OTHER|Felt-tip marking|Marking the location of the future stoma with a felt pen
219346615|NCT04326335|OTHER|Felt-tip marking + 3D printed ostomy button|Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
219346616|NCT03216356|BEHAVIORAL|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
219346617|NCT03216356|BEHAVIORAL|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
219346618|NCT03216356|DRUG|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
219346619|NCT03216356|DRUG|Placebo|polyethylene glycol 3350 powder
219346620|NCT03216356|DRUG|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
219346621|NCT02613598|DRUG|Bortezomib|
219346622|NCT02613598|DRUG|Ruxolitinib|
219346623|NCT04687579|OTHER|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
219346624|NCT04687579|PROCEDURE|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
219346625|NCT04687579|PROCEDURE|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
219346626|NCT00749996|DEVICE|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
219346627|NCT00749996|PROCEDURE|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
219346628|NCT06293612|OTHER|No intervention was administrated to the two cohorts.|
219346629|NCT03134872|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
219346630|NCT03134872|DRUG|Carboplatin|Carboplatin
219346631|NCT03134872|DRUG|Pemetrexed|Pemetrexed
219346632|NCT04996121|DRUG|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
219346633|NCT05595083|DRUG|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
219346634|NCT05595083|DRUG|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
219346635|NCT00251940|DRUG|Tesaglitazar 0.5 or 1 mg|
219346636|NCT00251940|DRUG|Glibenclamide 2.5, 5, 10 or 15 mg|
219346637|NCT00517829|DRUG|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
219346638|NCT00517829|DRUG|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
219346639|NCT00517829|DRUG|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
219346640|NCT00223028|DRUG|sirolimus, mycophenolat mofetil, fluvastatin|
219346641|NCT02194127|DRUG|Anthocyan capsules|
219346642|NCT02194127|DRUG|Placebo|
219346643|NCT03410888|PROCEDURE|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
219346644|NCT03410888|PROCEDURE|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
219346645|NCT02184078|DRUG|Nevirapine|
219346646|NCT02184078|DRUG|Rifabutin|
219346647|NCT04793425|BEHAVIORAL|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
219346648|NCT02672670|BEHAVIORAL|Experimental: Intervention group---coping-oriented supportive programme|
219346649|NCT02672670|BEHAVIORAL|Active Comparator: Comparison group---a didactic talk (usual care)|
219346650|NCT02267694|DRUG|Freeze-dried black raspberry powder|
219346651|NCT02688595|DEVICE|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
219346652|NCT02688595|OTHER|General anesthesia|Scheduled operation under general anesthesia
219346653|NCT05979298|DRUG|Gemcitabine|Chemotherapeutics
219346654|NCT05979298|BIOLOGICAL|ELENAGEN|DNA plasmid
219346655|NCT01178450|PROCEDURE|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
219346656|NCT01178450|DRUG|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
219346657|NCT01329393|BEHAVIORAL|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
219346658|NCT01329393|BEHAVIORAL|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
219346659|NCT00793481|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
219346660|NCT00674050|DRUG|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
219346661|NCT00674050|DRUG|Albuterol (Salbutamol)|2 puff= 200ug total dose
219346662|NCT00674050|DRUG|Fluticasone|2 puffs= 500ug total dose
219346663|NCT00006456|RADIATION|stereotactic radiosurgery|
219346664|NCT02970890|DEVICE|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
219346665|NCT00978315|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
219346666|NCT00978315|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
219346667|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
219346668|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
219346669|NCT04450121|DEVICE|Patients will be intubated using Air-Q airway|"Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)"
219346670|NCT01606111|DRUG|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
219346671|NCT01606111|DRUG|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
219346672|NCT02881632|DEVICE|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
219346673|NCT03460782|BIOLOGICAL|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
219346674|NCT00606086|DRUG|GI-5005|40YU, subcutaneous
219346675|NCT00606086|DRUG|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
219346676|NCT00436371|DRUG|Amisulpride|Oral tablets
219346677|NCT02620696|DRUG|netazepide|
219346678|NCT02432768|DRUG|Triheptanoin|Anaplerotic dietary oil
219346679|NCT02432768|OTHER|Placebo oil|Safflower oil
219346680|NCT00548496|DRUG|SB-751689|SB-751689
219346681|NCT00548496|OTHER|Placebo|Placebo to match
219346682|NCT02500628|DRUG|Metformin|500 mg orally after baseline testing of heart rate
219346683|NCT04212676|OTHER|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
219346684|NCT04212676|OTHER|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
219346685|NCT04640883|BEHAVIORAL|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (\>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.
219346686|NCT04640883|BEHAVIORAL|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (\>four hours per session), distance-matched to sprint group.
219346687|NCT04640883|BEHAVIORAL|Recovery for 10 days (low training load)|Habitual low-intensity cycling (\>0.5-2 hours per session)
219346688|NCT03934983|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
219346689|NCT02381665|DEVICE|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
219346690|NCT02381665|DEVICE|Flexstim IF faked|Patient enrolled will receive a sham device.
219346691|NCT01710449|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
219346692|NCT05190003|OTHER|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
219346693|NCT01471457|DRUG|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
219346694|NCT00708578|DRUG|Glimepiride|Once a day before breakfast
219346695|NCT00708578|DRUG|Metformin|After breakfast and supper
219346696|NCT00708578|DRUG|Insulin Glargine|Injection in the morning
219346697|NCT04858165|PROCEDURE|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
219346698|NCT00641498|BEHAVIORAL|Psychotherapy|Individual supportive
219346699|NCT06074874|OTHER|Intestinal tissue analysis|Intestinal tissue analysis
219346700|NCT02905565|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
219346701|NCT02905565|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
219346702|NCT03840655|PROCEDURE|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
219346703|NCT03891511|DEVICE|MRI scann|MRI will be performed in the TMJ of participants affected with TMD
219346704|NCT06089642|DEVICE|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
219346705|NCT02958488|DEVICE|High Flow Nasal Cannula|
219346706|NCT03759626|BEHAVIORAL|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
219346707|NCT03759626|BEHAVIORAL|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
219346708|NCT02504021|BEHAVIORAL|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
219346709|NCT00428532|DRUG|Licorice root extract or Pomegranate juice|
219346710|NCT04440995|PROCEDURE|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
219346711|NCT00092430|BIOLOGICAL|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
219346712|NCT04840680|OTHER|No Intervention|This is a non-interventional study.
219346713|NCT05383027|BEHAVIORAL|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
219346714|NCT05383027|BEHAVIORAL|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
219346715|NCT05472727|OTHER|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
219346716|NCT05472727|OTHER|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
219346717|NCT04847973|OTHER|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
219346718|NCT04847973|DIETARY_SUPPLEMENT|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
219346719|NCT02135718|DEVICE|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
219346720|NCT02135718|DEVICE|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
219346721|NCT04476888|BIOLOGICAL|Convalescent Plasma (CP)|500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.
219346722|NCT04476888|OTHER|Drugs and supportive care|This will include drugs like steroids, tocilizumab, azithromycin and supportive care
219346723|NCT04952064|DRUG|Monosialoganglioside GM1|Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
219346724|NCT05458076|DRUG|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
219346725|NCT05458076|DRUG|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
219346726|NCT05458076|DRUG|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
219346727|NCT02342002|DRUG|Mifepristone|Mifepristone for treatment of missed abortion
219346728|NCT02342002|DRUG|Misoprostol|Misoprostol for treatment of missed abortion
219346729|NCT00194545|BEHAVIORAL|Medication diaries|Caregivers expected to complete medication diaries daily
219346730|NCT04516928|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
219346731|NCT04516928|OTHER|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
219346732|NCT00796315|DRUG|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
219346733|NCT01975012|DRUG|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
219346734|NCT00802243|DRUG|leflunomide|
219346735|NCT04689776|BEHAVIORAL|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
219346736|NCT04015154|DEVICE|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
219346737|NCT02072031|DRUG|Anlotinib|Anlotinib p.o. qd
219346738|NCT02072031|DRUG|Sunitinib maleate|Sunitinib 50 mg p.o. qd
219346739|NCT02223572|RADIATION|hip Xray|
219346740|NCT03937583|DRUG|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
219346741|NCT04017143|BEHAVIORAL|HPV app intervention|Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
219346742|NCT00037479|DRUG|ceftriaxone|
219346743|NCT00782548|DRUG|KADIAN (morphine sulfate sustained-release) capsules|Capsules, 30 mg
219346744|NCT00782548|DRUG|Avinza (morphine sulfate sustained-release) capsules|Capsules, 30 mg
219346745|NCT06517134|DRUG|Antihypertensive Agents|use of antihypertensive drugs
219346746|NCT05634863|DEVICE|Implantable Doppler probe manufactured by COOK Medical Company.|The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
219346747|NCT04126382|PROCEDURE|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
219346748|NCT04126382|PROCEDURE|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
219346749|NCT02359630|DEVICE|EasyTube|Insertion for ventilation
219346750|NCT02359630|DEVICE|Endotracheal tube|Insertion for ventilation
219346751|NCT01638780|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
219346752|NCT01638780|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
219346753|NCT03663426|PROCEDURE|study group|"1. High dose corticoids pre-operative and 24h postoperative~2. Opioid free general anesthesia~3. Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
219346754|NCT03663426|PROCEDURE|control|"1. No corticoids pre-operative.~2. Opioid anesthesia~3. Opioids post-operative after NSAID and paracetamol."
219346755|NCT05508555|PROCEDURE|hyperthermic intrathoracic chemotherapy|application of chemotherapeutic agent intrathoracic under hyperthermic conditions
219346756|NCT02924662|OTHER|There is no intervention.|
219346757|NCT00604604|BEHAVIORAL|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
219346758|NCT01627860|DRUG|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
219346759|NCT01627860|DRUG|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
219346760|NCT03385603|DEVICE|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
219346761|NCT03385603|BEHAVIORAL|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
219346762|NCT03260088|DIAGNOSTIC_TEST|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
219346763|NCT05530265|DEVICE|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
219346764|NCT00035022|DRUG|BCX-1777|
219346765|NCT00453726|PROCEDURE|Non invasive mechanical ventilation|
219346766|NCT01356082|DEVICE|CNAP|Non-invasive blood pressure monitor
219346767|NCT03234244|DRUG|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
219346768|NCT03234244|DRUG|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
219346769|NCT03234244|DRUG|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
219346770|NCT01794611|DEVICE|laryngoscopy|
219346771|NCT01778439|DRUG|OMP-52M51|
219346772|NCT03278470|DRUG|HL237|Experimental
219346773|NCT03278470|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
219346774|NCT01962571|DRUG|Erythropoietin alfa|
219346775|NCT01962571|DRUG|Placebo|
219346776|NCT02613936|DEVICE|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
219346777|NCT02613936|BEHAVIORAL|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
219346778|NCT00309309|DRUG|Rosiglitazone|
219346779|NCT01157975|DRUG|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
219346780|NCT01157975|DRUG|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
219346781|NCT02249143|DEVICE|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
219346782|NCT01555528|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
219346783|NCT00689871|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
219346784|NCT02084303|OTHER|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
219346785|NCT03388411|DIAGNOSTIC_TEST|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
219346786|NCT01783080|BEHAVIORAL|Behavioral Activation for return to work|See Arm Description
219346787|NCT06365203|PROCEDURE|Through knee amputation|Amputation Technique
219346788|NCT06365203|PROCEDURE|Above knee Amputation|Amputation Technique
219346789|NCT05273034|PROCEDURE|1-hour sepsis bundle|"The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate \> 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (\> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation."
219346790|NCT02185404|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
219346791|NCT02533063|DEVICE|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
219346792|NCT06051682|DEVICE|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
219346793|NCT06051682|PROCEDURE|Emergency physician|the emergency physician analyzes the x-rays
219346794|NCT02845570|OTHER|68Ga-DOTANOC PET/MRI|
219346795|NCT02845570|OTHER|18F-FDG PET/MRI|
219346796|NCT00889265|DEVICE|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
219346797|NCT06364111|DEVICE|Vibrabot capsule|Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.
219346798|NCT06364111|DRUG|polyethylene glycol|Subjects in the control group received polyethylene glycol for 6 weeks
219346799|NCT04618159|OTHER|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
219346800|NCT02075099|OTHER|tensing exercises|Donors will do tensing exercises during blood donation
219346801|NCT02075099|OTHER|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
219346802|NCT01228370|DRUG|silodosin|silodosin 8mg once a day for 12 weeks
219346803|NCT01732302|OTHER|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
219346804|NCT03357679|PROCEDURE|Tracheal intubation|Intubation of the trachea with endotracheal tube
219346805|NCT03357679|DEVICE|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
219346806|NCT03357679|DEVICE|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
219346807|NCT04455646|BEHAVIORAL|CBT-based, mobile-delivered, intervention platform|App of this platform have been shown to be associated with reduced psychopathology symptoms,including depressive symptoms, following treatment (i.e., relapse prevention). GGDE, which was specifically designed to address MDD related maladaptive beliefs and symptoms,includes different CBT-based intervention modules (nine active and one sham), as well as means for data collection and response monitoring. The active treatment modules will differ in the proportion of adaptive vs. maladaptive statements and the emphasis on particular content (e.g loneliness vs. hopelessness).
219346808|NCT02404259|DRUG|TDF (Tenofovir)|
219346809|NCT02404259|DRUG|Efavirenz|
219346810|NCT02404259|DRUG|lopinavir/ritonavir, atazanavir/ritonavir|
219346811|NCT02135211|BEHAVIORAL|Lifestyle counseling|
219346812|NCT04350775|OTHER|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
219346813|NCT04350775|OTHER|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
219346814|NCT05656677|BEHAVIORAL|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
219346815|NCT05656677|RADIATION|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
219346816|NCT00127738|PROCEDURE|Angiographic renal revascularization|
219346817|NCT06190652|DRUG|Chemotherapy combined with immunotherapy|chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
219346818|NCT06190652|RADIATION|radiotherapy|Intensity-modulated radiation therapy
219346819|NCT04648605|OTHER|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
219346820|NCT02690662|BEHAVIORAL|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
219346821|NCT04514523|OTHER|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
219346822|NCT04777136|OTHER|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
219346823|NCT04777136|OTHER|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
219346824|NCT03275194|PROCEDURE|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
219346825|NCT04879043|DRUG|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
219346826|NCT05690529|PROCEDURE|Ablation|Radiofrequency AF ablatoon
219346827|NCT01422122|DRUG|Vitamin D3|4000 mg per day, one tablespoon syrup per day
219346828|NCT01422122|DRUG|Placebo|one table spoon Syrup per day
219346829|NCT03054376|OTHER|Immobilization|Full length cast of one leg R/L randomized
219346830|NCT03054376|OTHER|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
219346831|NCT03054376|OTHER|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
219346832|NCT03609307|DRUG|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
219346833|NCT03609307|DRUG|Intravitreal bevacizumab|these patients receive only Bevacizumab
219346834|NCT04967937|OTHER|Strengthening, resistance exercise, plyometric and dynamic movement training|(1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
219346835|NCT00250835|OTHER|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
219346836|NCT02302482|OTHER|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
219346837|NCT04155671|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
219346838|NCT04155671|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
219346839|NCT00256737|DRUG|Omeprazole|
219346840|NCT03793712|DRUG|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
219346841|NCT03793712|DRUG|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
219346842|NCT03793712|DRUG|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
219346843|NCT05182151|DRUG|Istradefylline 40 mg|adenosine A2A receptor antagonist
219346844|NCT05303545|OTHER|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
219354877|NCT01996800|PROCEDURE|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
219346845|NCT06339528|PROCEDURE|Vojta's Reflex Locomotion|"Reflex locomotion according to Vojta's therapy is a neurorehabilitative concept originally used for diagnostics and treatment of infants who were at risk of non-physiological psychomotor development, especially spastic cerebral palsy. This concept utilizes stimulation of specific zones described by Vojta to evoke global motor and non-motor response.~Trigger zones are specific body zones that are stimulated with pressure during reflex locomotion stimulation. They are pressure stimulated in order to induce reflex response. Variations of stimulation of different trigger zones (spatial summation) causes multiplication of afferent impulses. Sufficiently long stimulation of trigger zones (temporal summation) induces isometric contraction in muscle groups described by Vojta."
219346846|NCT06339528|PROCEDURE|Sham stimulation|Control group received sham stimulation by physicians at zones outside of the pressure zones, specifically 4-5 cm above the patella and on the lateral malleolus.
219346847|NCT05022797|DRUG|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
219346848|NCT02222259|PROCEDURE|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
219346849|NCT04797065|PROCEDURE|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
219346850|NCT04797065|PROCEDURE|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
219346851|NCT00159861|DRUG|Sildenafil citrate|
219346852|NCT05954442|DRUG|Everolimus|Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .
219346853|NCT05954442|DRUG|Investigator's Choice of Chemotherapy|Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
219346854|NCT02463175|DRUG|Plasmalyte|Boluses of 5ml/kg of plasmalyte
219346855|NCT02463175|PROCEDURE|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
219346856|NCT00418353|DRUG|Betamethasone(Celestone soluspan) and Dexamethasone|
219346857|NCT05799456|DIAGNOSTIC_TEST|Free glycosaminoglycan profiling|Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
219346858|NCT05266066|OTHER|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.
219346859|NCT05266066|OTHER|7 day antibiotic course for VAT|Patients will receive standard care plus 7 day course of antibiotic.
219346860|NCT02735369|DRUG|2% OC-10X|2% OC-10X
219346861|NCT02735369|DRUG|Placebo Comparator|Placebo
219346862|NCT02319187|DRUG|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
219346863|NCT02319187|DRUG|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
219346864|NCT02319187|DRUG|irinotecan|irinotecan 160mg/m2 d1, every 14 days
219346865|NCT04319133|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
219346866|NCT02401828|DRUG|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
219346867|NCT01650025|DIETARY_SUPPLEMENT|VSL#3 active probiotic|
219346868|NCT01650025|OTHER|VSL#3 placebo|
219346869|NCT02260115|DEVICE|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
219346870|NCT02260115|PROCEDURE|Surgical Control|Surgery only
219346871|NCT00823498|BEHAVIORAL|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
219346872|NCT00823498|BEHAVIORAL|Interview|Interview with a member of study staff at housing development site.
219346873|NCT00823498|OTHER|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
219346874|NCT00288756|PROCEDURE|lv injection of contrast|
219346875|NCT06632184|DRUG|Ondansetron Intraperitoneal Lavage|A single dose of 8 mg of ondansetron diluted in 500 mL of 0.9% saline solution will be administered as an intraperitoneal lavage at the end of elective laparoscopic cholecystectomy. The solution will remain in the abdominal cavity for 5 minutes and then be fully aspirated before surgical closure. This intervention aims to evaluate the local analgesic and antiemetic effects of ondansetron when used via the peritoneal route.
219346876|NCT06632184|DRUG|Saline Intraperitoneal Lavage|At the end of elective laparoscopic cholecystectomy, a peritoneal lavage will be performed using 500 mL of 0.9% saline solution (normal saline). The solution will be maintained in the peritoneal cavity for 5 minutes and then fully aspirated before surgical closure. This intervention serves as the comparator to assess the added effect of ondansetron in the experimental group.
219346877|NCT04841707|DEVICE|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
219346878|NCT01744600|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
219346879|NCT04499443|DRUG|GST-HG131 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
219346880|NCT04499443|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
219346881|NCT05232838|DEVICE|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
219346882|NCT04489888|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
219346883|NCT04489888|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
219346884|NCT04489888|DRUG|Paclitaxel|At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
219346885|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators"
219346886|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
219346887|NCT06047600|OTHER|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
219346888|NCT03349099|DEVICE|Cook Flexor|ureteral access sheath
219346889|NCT03349099|DEVICE|Boston Scientific Navigator|ureteral access sheath
219346890|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
219346891|NCT02775396|DEVICE|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
219346892|NCT02727985|PROCEDURE|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
219346893|NCT05422820|DIAGNOSTIC_TEST|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (\>150-400 or \>400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
219346894|NCT03641963|DEVICE|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
219346895|NCT01070732|DRUG|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
219346896|NCT05428891|PROCEDURE|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
219346897|NCT02967874|PROCEDURE|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
219346898|NCT02967874|DRUG|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
219346899|NCT02258828|DRUG|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
219346900|NCT02258828|DRUG|Placebo|Matched placebo
219346901|NCT02285621|OTHER|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
219346902|NCT01685827|DRUG|Fexinidazole|
219346903|NCT01685827|DRUG|Nifurtimox|
219346904|NCT01685827|DRUG|Eflornithine|
219346905|NCT00872807|BEHAVIORAL|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
219346906|NCT00872807|BEHAVIORAL|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
219346907|NCT06493474|OTHER|Education|PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM
219346908|NCT06493474|OTHER|Routine Care|Non education program only routine care
219346909|NCT05941078|BEHAVIORAL|ICF-based post-stroke rehabilitation program|Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
219346910|NCT01750112|DEVICE|Macrolane VRF20|Injection treatment with Macrolane VRF20
219346911|NCT04080193|BEHAVIORAL|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
219346912|NCT00278993|DRUG|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
219346913|NCT00986700|DIETARY_SUPPLEMENT|late night meal|Three different kinds of late night meal each for 2 days.
219346914|NCT04828057|DRUG|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
219346915|NCT02062788|DIETARY_SUPPLEMENT|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
219346916|NCT06333834|DRUG|Traditional scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)
219346917|NCT06333834|DRUG|Serial dose of scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
219346918|NCT03071614|OTHER|News items with spin|Interpretation of news items with spin
219346919|NCT03071614|OTHER|News items without spin|Interpretation of news items without spin
219346920|NCT04933604|PROCEDURE|laparoscopic partial nephrectomy|Nephron sparing minimally invasive surgery
219346921|NCT04933604|PROCEDURE|Laparoscopic radical nephrectomy|Completely removal of kidney by using laparoscopic surgery
219346922|NCT00389428|DRUG|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
219346923|NCT06503575|OTHER|Assesment|All assessments will be made
219346924|NCT02317211|DIETARY_SUPPLEMENT|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
219346925|NCT02317211|DIETARY_SUPPLEMENT|placebo|starch
219346926|NCT04674020|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
219346927|NCT06037733|RADIATION|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
219346928|NCT05677555|DRUG|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
219346929|NCT05677555|DRUG|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
219346930|NCT04010214|OTHER|No intervention|No intervention
219346931|NCT02114320|DEVICE|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
219346932|NCT04234906|DRUG|Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
219346933|NCT04234906|DRUG|Magnesium Sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
219346934|NCT04234906|DRUG|Amiodarone|I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
219346935|NCT04234906|DRUG|Procainamide|IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
219346936|NCT02838966|DIETARY_SUPPLEMENT|Nestle IMPACT Advanced Recovery|
219346937|NCT02838966|DIETARY_SUPPLEMENT|Nestle Boost High Protein Drink|
219346938|NCT00456989|DRUG|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
219346939|NCT00456989|DRUG|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
219346940|NCT04666779|OTHER|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
219346941|NCT01290874|DRUG|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
219346942|NCT01290874|DRUG|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
219346943|NCT01290874|DRUG|Formoterol|Formoterol 12 mcg twice daily for one year
219346944|NCT05796102|PROCEDURE|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
219346945|NCT04501185|DEVICE|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
219346946|NCT04194528|DRUG|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
219346947|NCT04194528|DEVICE|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
219346948|NCT04571411|OTHER|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
219346949|NCT02304107|DRUG|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
219346950|NCT02304107|DRUG|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
219346951|NCT02325284|DEVICE|Pressure Algometer Testing|
219346952|NCT02589444|DIETARY_SUPPLEMENT|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
219346953|NCT02589444|OTHER|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
219346954|NCT02589444|OTHER|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
219346955|NCT02589444|OTHER|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
219346956|NCT02589444|PROCEDURE|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
219346957|NCT06043232|BIOLOGICAL|DC vaccine|DC vaccine produced by the Team
219346958|NCT02188875|BEHAVIORAL|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
219346959|NCT02188875|BEHAVIORAL|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
219346960|NCT01255644|DRUG|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
219346961|NCT01311050|DRUG|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
219346962|NCT05559190|OTHER|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
219346963|NCT05559190|OTHER|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
219346964|NCT00485602|PROCEDURE|"orthodontic treatment with Rafenalign appliance"|
219346965|NCT03587220|DRUG|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
219346966|NCT03587220|RADIATION|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
219346967|NCT03587220|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
219346968|NCT03587220|DRUG|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
219346969|NCT03200132|DIAGNOSTIC_TEST|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
219346970|NCT04867473|BEHAVIORAL|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
219346971|NCT06020586|OTHER|hair lotion|ECOHAIR
219346972|NCT00432614|DRUG|SR58611A|oral administration
219346973|NCT00432614|DRUG|escitalopram|oral administration
219346974|NCT00432614|DRUG|placebo|oral administration
219346975|NCT03283826|BIOLOGICAL|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
219346976|NCT03283826|DRUG|Placebo|Placebo matching to ATA188
219346977|NCT05422560|PROCEDURE|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
219346978|NCT00003462|DRUG|busulfan|
219346979|NCT01632462|DRUG|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
219346980|NCT05468268|DEVICE|20 Hz rTMS|rTMS stimulation
219346981|NCT05468268|DEVICE|Sham rTMS|Sham stimulation
219346982|NCT01996475|DRUG|Escitalopram Oxalate Tablets|
219346983|NCT05353699|OTHER|Implementation strategies|We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
219346984|NCT01547455|DRUG|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
219346985|NCT01547455|DRUG|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
219346986|NCT03565627|DEVICE|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
219346987|NCT03565627|DEVICE|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
219346988|NCT00544609|DRUG|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
219346989|NCT00544609|PROCEDURE|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
219346990|NCT00718783|OTHER|Tissue samples taken from retinoblastoma|Tissue banking
219346991|NCT00718783|OTHER|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
219346992|NCT03813537|OTHER|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
219346993|NCT01696526|OTHER|vitamin D fortified fish|fish containing vitamin D3
219346994|NCT01696526|OTHER|conventional fish|fish containing low concentrations of vitamin D3
219346995|NCT00362011|BEHAVIORAL|Salba diet|
219346996|NCT00333359|DRUG|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
219346997|NCT00584155|DRUG|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
219346998|NCT00584155|DRUG|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
219346999|NCT02282644|BIOLOGICAL|Bone marrow sampling|
219347000|NCT00941265|DRUG|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
219347001|NCT00941265|DRUG|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
219347002|NCT02148965|BEHAVIORAL|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
219347003|NCT03955133|OTHER|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
219347004|NCT00650910|DRUG|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
219347005|NCT00650910|DRUG|Digoxin|0.5mg on Days 1 and 9
219347006|NCT03667066|DRUG|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
219347007|NCT04682405|DRUG|Uproleselan|Provided by study
219347008|NCT04682405|DRUG|Placebo|Provided by study
219347009|NCT04682405|DRUG|Melphalan|-Standard of care
219347010|NCT03777644|PROCEDURE|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
219347011|NCT03777644|PROCEDURE|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
219347012|NCT03777644|DRUG|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
219347013|NCT03536455|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
219347014|NCT03536455|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
219347015|NCT04987138|DEVICE|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
219347016|NCT04987138|DEVICE|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
219347017|NCT03007173|PROCEDURE|umbilicus preserving surgery|excision of umbilical complex
219347018|NCT05771610|BEHAVIORAL|Activity pattern in CVD|Only individuals who have had a cardiac event within the past twelve months upon recruitment will be included in this study.
219347019|NCT02294513|DEVICE|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
219347020|NCT04513002|DIETARY_SUPPLEMENT|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
219347021|NCT05186207|OTHER|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
219347022|NCT05461612|DEVICE|Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device|Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
219347023|NCT01178775|BEHAVIORAL|walking|use a pedometer for records steps.
219347024|NCT05619198|BEHAVIORAL|High Intensity Interval Exercise|"High Intensity Interval Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~* 5 minutes resting phase @ 0 watts."
219347025|NCT05619198|BEHAVIORAL|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of MICE 65% VO2max.~* 5 minutes resting phase @ 0 watts."
219347026|NCT03157427|DEVICE|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
219347027|NCT00522431|DRUG|Testosterone|2% gel
219347028|NCT00643695|BEHAVIORAL|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
219347029|NCT00643695|OTHER|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
219347030|NCT03378076|DRUG|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
219347031|NCT03378076|DRUG|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
219347032|NCT02249650|DRUG|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
219347033|NCT02342795|OTHER|e-cigarette|
219347034|NCT02342795|OTHER|cigarette substitute|
219347035|NCT04743102|PROCEDURE|multi-points and full-thickness Biopsy|Four points around the tumor site and center of the tumor site full-thickness Biopsy
219347036|NCT04743102|DIAGNOSTIC_TEST|traditional cCR|diginal examination, endoscopy test, rectal MRI, and serum CEA level
219347037|NCT01339559|DRUG|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
219347038|NCT06552169|DRUG|Arm 1: SOC (mTOR + CNI)|Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
219347039|NCT06552169|BIOLOGICAL|Arm 2A: TRACT/MONO mTOR|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
219347040|NCT06552169|BIOLOGICAL|Arm 2B: TRACT/MONO CNI|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
219347041|NCT03483480|PROCEDURE|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
219347042|NCT03483480|PROCEDURE|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
219347043|NCT01107678|OTHER|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
219347044|NCT01137773|DRUG|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
219347045|NCT01137773|DRUG|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
219347046|NCT04342221|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
219347047|NCT04342221|DRUG|Placebo|Placebo capsules
219347048|NCT06273332|OTHER|AI-assisted registration|We will use artificial intelligence to register 3d model on intra-oral scan
219347049|NCT06273332|OTHER|Point-based registration|We will use five references points or more to perform model registration
219347050|NCT03891589|BEHAVIORAL|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
219347051|NCT03891589|DIETARY_SUPPLEMENT|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
219347052|NCT00529256|BEHAVIORAL|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
219347053|NCT01133587|OTHER|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
219347054|NCT01133587|BEHAVIORAL|admissions contract|"contract regarding patient-guided admissions starting immediately"
219347055|NCT04569721|DEVICE|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
219347056|NCT03640039|PROCEDURE|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
219347057|NCT00976066|DRUG|Part A Assessing GSK1521498|"Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
219347058|NCT00976066|DRUG|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
219347059|NCT00976066|DRUG|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
219347060|NCT02755857|DRUG|Lozanoc|65 mg
219347061|NCT05677074|DIETARY_SUPPLEMENT|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
219347062|NCT05677074|DIETARY_SUPPLEMENT|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
219347063|NCT05677074|DIETARY_SUPPLEMENT|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
219347064|NCT03113643|DRUG|Azacitidine|Chemotherapy
219347065|NCT03113643|DRUG|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
219347066|NCT03113643|DRUG|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
219347067|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
219347068|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
219347069|NCT03940859|DEVICE|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
219347070|NCT04010396|OTHER|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
219347071|NCT02738983|DRUG|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
219347072|NCT02738983|RADIATION|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
219347073|NCT05372523|DIAGNOSTIC_TEST|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
219347074|NCT05372523|DIAGNOSTIC_TEST|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
219347075|NCT00123006|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
219347076|NCT00123006|BEHAVIORAL|Control Diet|4 week feeding intervention
219347077|NCT05093738|OTHER|Cognitive Rehabilitation|In the content of the person-centered intervention program, attention, memory, orientation, praxis (motor planning) training; metacognition (metacognition) training; visual perception; There will be cognitive training for executive functions. The intervention will consist of play activities (games, computer-assisted games) for cognitive skills; The games will be applied in a way that suits the child from simple to complex. Visual perception applications (designing blocks, recognizing and sorting the shapes in the picture, matching opposite shapes etc.); attention practices, memory practices, strategy development, space-time orientation, motor planning, games and metacognitive strategies aimed at developing skills such as planning, organization, working memory, impulse control, time management and awareness, abstract thinking, cognitive flexibility will form our intervention program.
219347078|NCT02329769|DRUG|PRO044 SC 6 mg/kg|
219347079|NCT02329769|DRUG|PRO044 IV 6 mg/kg|
219347080|NCT02329769|DRUG|PRO044 IV 9 mg/kg|
219347081|NCT02878954|OTHER|No intervention (Observational study)|"160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed."
219347082|NCT02878954|OTHER|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
219347083|NCT02878954|OTHER|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
219347084|NCT03725748|OTHER|irrigation|irrigation the edges of the cs scar before closure
219347085|NCT03177772|BEHAVIORAL|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
219347086|NCT05097456|DEVICE|carbon dioxide laser|carbon dioxide laser
219347087|NCT05097456|DEVICE|sham laser|sham laser
219347088|NCT01950351|OTHER|Laboratory Biomarker Analysis|Correlative studies
219347089|NCT01950351|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
219347090|NCT01950351|OTHER|Quality-of-Life Assessment|Ancillary studies
219347091|NCT04889300|BEHAVIORAL|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
219347092|NCT04889300|BEHAVIORAL|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
219347093|NCT04429178|OTHER|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
219347094|NCT06333509|BIOLOGICAL|CT071|a single CAR-T infusion of CT071
219347095|NCT01231100|OTHER|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
219347096|NCT03422315|DRUG|Propofol|injection;2mg/kg;single-dose
219347097|NCT04418700|DEVICE|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
219347098|NCT02918773|DEVICE|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
219347099|NCT02918773|DEVICE|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
219347100|NCT01829256|BEHAVIORAL|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
219347101|NCT03046875|OTHER|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
219347102|NCT03046875|OTHER|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
219347103|NCT00290433|DRUG|Cyclophosphamide|Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
219347104|NCT00290433|DRUG|Mesna|Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
219347105|NCT00290433|DRUG|Vincristine|Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
219347106|NCT00290433|DRUG|Methotrexate|Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
219347107|NCT00290433|DRUG|Ara-C|Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
219347108|NCT00290433|DRUG|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
219347109|NCT00290433|DRUG|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
219347110|NCT00290433|DRUG|Doxil|Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
219347111|NCT02559687|BIOLOGICAL|pembrolizumab|IV Q3W
219347112|NCT01554137|OTHER|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
219347113|NCT01554137|OTHER|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
219347114|NCT03245073|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
219347115|NCT03245073|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
219347116|NCT03001674|DEVICE|Conductance catheterization|CD Leycom Conductance Catheter
219347117|NCT03224273|OTHER|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
219347118|NCT01702610|RADIATION|IMRT Technique|
219347119|NCT01702610|RADIATION|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
219347120|NCT01702610|RADIATION|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
219347121|NCT01702610|DRUG|Temozolomide and Accelerated Hypofractionation RT|
219347122|NCT05204966|DIAGNOSTIC_TEST|AI analysis|"1. Bottle feeding filming~   \- With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
219347123|NCT04344587|OTHER|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
219347124|NCT04344587|OTHER|Usual care|"The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
219347125|NCT03971201|PROCEDURE|hepatic resection|removal of portion of liver containing cancer
219347126|NCT03971201|DRUG|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
219347127|NCT05324046|DIAGNOSTIC_TEST|contrast-enhanced abdomen CT|"contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation).~* full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional)~* low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software.~* images are reconstructed using full dose (A- \& B- tubes) and smaller dose (A-tube only, B-tube only)"
219347128|NCT00620412|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.
219347129|NCT00620412|DIETARY_SUPPLEMENT|placebo control|2 capsules by mouth twice a day for 28 days
219347130|NCT00620412|BIOLOGICAL|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
219347131|NCT03919708|DEVICE|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
219347132|NCT00940407|DEVICE|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
219347133|NCT03760900|COMBINATION_PRODUCT|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
219347134|NCT05006469|DRUG|Bendamustine|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
219347135|NCT02742285|DRUG|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
219347136|NCT04472585|DRUG|Ivermectin Injectable Solution|Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
219347137|NCT04472585|OTHER|Injectable Placebo|0.9% normal saline
219347138|NCT04472585|DRUG|Zinc|Zinc Sulphate 20mg 3 times a day
219347139|NCT04472585|DRUG|Placebo empty capsule|Placebo empty capsule
219347140|NCT04472585|DRUG|Oral Ivermectin|0.2mg/kg/day
219347141|NCT03668483|OTHER|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
219347142|NCT00222183|DRUG|Elidel (pimecrolimus)|
219347143|NCT03072056|DRUG|MIN-101|
219347144|NCT05101603|DEVICE|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
219347145|NCT05101603|DEVICE|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
219347146|NCT05101603|PROCEDURE|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
219347147|NCT04612010|DEVICE|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
219347148|NCT04749459|DRUG|ChapStick Moisturizer, Strawberry Flavor|A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.
219347149|NCT04749459|DRUG|ChapStick Moisturizer, Classic Flavor|A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
219347150|NCT04749459|DRUG|ISO 24444:2010 P2 Standard Reference Sunscreen|A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
219347151|NCT00097760|DRUG|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
219347152|NCT00097760|DRUG|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
219347153|NCT00097760|DRUG|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
219347154|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|iPACK block + Adductor Canal Block
219347155|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|Erector Spinae Plane Block
219347156|NCT06302218|DRUG|control group|only spinal anesthesia
219347157|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
219347158|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
219347159|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
219347160|NCT01356914|DRUG|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
219347161|NCT02991092|PROCEDURE|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
219347162|NCT06023979|OTHER|Full weight bearing|Full weight bearing monitored with a bio-feedback insole
219347163|NCT06023979|OTHER|Partial weight bearing|Partial weight bearing monitored with a bio-feedback insole
219347164|NCT05152550|OTHER|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
219347165|NCT01936545|DRUG|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
219347166|NCT01936545|DRUG|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
219347167|NCT03031301|DEVICE|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
219347168|NCT03031301|DEVICE|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
219347169|NCT05532410|DEVICE|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
219347170|NCT01859442|PROCEDURE|Structured responsive interval exercise training programme|
219347171|NCT01859442|OTHER|Sham group|NO intervention in this group, only standard care (no exercise programme)
219347172|NCT03245450|DRUG|Eribulin mesilate|IV infusion
219347173|NCT03245450|DRUG|Irinotecan hydrochloride|IV infusion
219347174|NCT02326558|PROCEDURE|laparoscopic microwave ablation-assisted enucleation|
219347175|NCT02326558|PROCEDURE|conventional laparoscopic partial nephrectomy|
219347176|NCT05477290|PROCEDURE|Trigger Finger Release through Transverse Incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
219347177|NCT05477290|PROCEDURE|Trigger Finger Release through Oblique Incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
219347178|NCT05477290|PROCEDURE|Trigger Finger Release through Vertical Incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
219347179|NCT03959280|OTHER|Tailored intervention|"* The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions."
219347180|NCT03959280|OTHER|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
219347181|NCT06260280|DIAGNOSTIC_TEST|Cerebral Nuclear Magnetic Resonance|Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
219347182|NCT06033820|DRUG|ZR2-ICE|"* Drug: zanubrutinib Oral Capsule~* Drug: lenalidomide Oral Capsule~* Drug: R-ICE chemotherapy"
219347183|NCT01731652|DRUG|TMX-101|
219347184|NCT03729492|DIAGNOSTIC_TEST|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
219347185|NCT04381910|DRUG|LY01610( Irinotecan hydrochloride liposome injection )|LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
219347186|NCT03283176|DIAGNOSTIC_TEST|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
219347187|NCT03961087|DRUG|Coenzyme Q10|Coenzyme Q10 will be given twice
219347188|NCT03961087|DRUG|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
219347189|NCT00983983|DIETARY_SUPPLEMENT|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
219347190|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
219347191|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
219347192|NCT01826682|OTHER|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
219347193|NCT01826682|OTHER|Medical treatment|Standard medical treatment without physiotherapy.
219347194|NCT02041377|DEVICE|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
219347195|NCT05376826|BEHAVIORAL|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
219347196|NCT06349395|OTHER|MBSR surgical nursing care|This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
219347197|NCT02122237|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
219347198|NCT05009719|BIOLOGICAL|Prophylactic Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
219347199|NCT05009719|BIOLOGICAL|Preventive Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
219347200|NCT01120496|DRUG|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
219347201|NCT01120496|DRUG|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
219347202|NCT03504410|DRUG|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
219347203|NCT03504410|DRUG|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
219347204|NCT03504410|DRUG|Mitoxantrone, Etoposide and Cytarabine|"Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6"
219347205|NCT03504410|DRUG|Fludarabine, Cytarabine, Filgrastim|"Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
219347206|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
219347207|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
219347208|NCT04213612|DRUG|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
219347209|NCT03375450|OTHER|Standard of Care|Participants will be followed as per local routine primary healthcare practice
219347210|NCT03784066|DRUG|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
219347211|NCT03784066|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
219347212|NCT02661425|OTHER|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
219347213|NCT00645983|DIETARY_SUPPLEMENT|Chamomile Extract|220 mg - 1100 mg daily
219347214|NCT00645983|OTHER|Placebo|1 to 5 capsules daily
219347215|NCT02114580|OTHER|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
219347216|NCT00525395|GENETIC|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
219347217|NCT00525395|PROCEDURE|Continuous phototherapy|Group B: 6 months non-stop treatment.
219347218|NCT03413020|DRUG|esomeprazole|proton pump inhibitor
219347219|NCT03413020|DRUG|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
219347220|NCT03413020|DRUG|amoxicillin|antibiotic for H. pylori eradication
219347221|NCT03413020|DRUG|clarithromycin|antibiotic for H. pylori eradication
219347222|NCT03413020|DRUG|metronidazole|antibiotic for H. pylori eradication
219347223|NCT03413020|DRUG|levofloxacin|antibiotic for H. pylori eradication
219347224|NCT03729388|OTHER|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
219347225|NCT03665402|DRUG|Isoniazid|One of the first line anti-tubercolosis drug
219347226|NCT01797900|DRUG|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
219347227|NCT01797900|DRUG|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
219347228|NCT01797900|RADIATION|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
219347229|NCT04064775|BEHAVIORAL|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
219347230|NCT03098329|OTHER|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
219347231|NCT02973737|DRUG|pyrotinib|400 mg once daily
219347232|NCT02973737|DRUG|placebo|400 mg once daily
219347233|NCT02973737|DRUG|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
219347234|NCT03089073|DRUG|Desmopressin|60μg or 120μg once daily at bedtime
219347235|NCT00018265|BEHAVIORAL|Task specific endurance training|
219347236|NCT00018265|BEHAVIORAL|Tai Chi|
219347237|NCT04283695|DRUG|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
219347238|NCT01598038|OTHER|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
219347239|NCT04699487|DEVICE|Photobiomodulation|"Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session."
219347240|NCT04592783|DRUG|Antihypertensive Agents|Antihypertensive medications will be initialed once BP is at predetermined threshold
219347241|NCT00909311|DRUG|ABT-450|capsules, QD, 1 dose in each cross-over period
219347242|NCT00909311|DRUG|ritonavir|capsule, QD, 1 dose in each cross-over period
219347243|NCT06106854|BEHAVIORAL|Behavioral: SystemCHANGE|six-month SystemCHANGE™ intervention
219347244|NCT06106854|OTHER|Education|Six patient education booklets
219347245|NCT05099861|OTHER|No intervention|this is an observational study
219347246|NCT00138736|DRUG|Mannan Binding Lectin (MBL)|
219347247|NCT00138736|DRUG|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
219347248|NCT02009527|DRUG|N-hydroxy-nor-arginine|
219347249|NCT02009527|DRUG|NaCl|
219347250|NCT02357498|PROCEDURE|transsphenoidal surgery|
219347251|NCT03190200|DEVICE|MRI|No intervention - observational trial using MRI
219347252|NCT05771298|DEVICE|532nm KTP|one to three treatment sessions
219347253|NCT05771298|DEVICE|585nm PDL|one to three treatment sessions
219347254|NCT03783390|BEHAVIORAL|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
219347255|NCT03783390|BEHAVIORAL|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
219347256|NCT05178732|DIETARY_SUPPLEMENT|Dose of protein|One of three protein doses provided
219347257|NCT05178732|OTHER|Menstrual cycle phase|Different phase of the menstrual cycle
219347258|NCT02432235|DRUG|Camidanlumab tesirine|Intravenous (IV) infusion.
219347259|NCT00282503|DRUG|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
219347260|NCT00282503|PROCEDURE|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
219347261|NCT02148237|BEHAVIORAL|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
219347262|NCT03535259|RADIATION|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
219347263|NCT01399580|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
219347264|NCT01399580|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
219347265|NCT05134961|PROCEDURE|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
219347266|NCT06277895|DIAGNOSTIC_TEST|VOCs|test the end-expiratory gas
219347267|NCT03721094|OTHER|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
219347268|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
219347269|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
219347270|NCT00331045|DRUG|alvimopan|0.25 mg/day
219347271|NCT00331045|DRUG|Placebo|
219347272|NCT00331045|DRUG|Alvimopan 0.5 mg/day|
219347273|NCT00331045|DRUG|Alvimopan 1 mg/day|
219347274|NCT01515384|DRUG|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
219347275|NCT02970292|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
219347276|NCT02970292|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
219347277|NCT03757208|DIETARY_SUPPLEMENT|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
219347278|NCT06549569|PROCEDURE|TFS|burn coverage with TFS
219347279|NCT04383860|PROCEDURE|5-0 suture|5-0 suture administration during surgery
219347280|NCT04383860|PROCEDURE|4-0 suture|4-0 suture administration during surgery
219347281|NCT00279825|DRUG|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
219347282|NCT00279825|DRUG|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
219347283|NCT00279825|DRUG|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
219347284|NCT00279825|DRUG|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
219347285|NCT00279825|DRUG|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
219347286|NCT00279825|DRUG|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
219347287|NCT00279825|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
219347288|NCT00279825|DRUG|CD-LD CR Placebo|Placebo to match CD-LD CR
219347289|NCT00865826|OTHER|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
219347290|NCT02765568|BEHAVIORAL|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
219347291|NCT02765568|BEHAVIORAL|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
219347292|NCT02765568|BEHAVIORAL|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
219347293|NCT04038788|DEVICE|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
219347294|NCT03061981|DRUG|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
219347295|NCT03061981|DRUG|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
219347296|NCT03061981|DRUG|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
219347297|NCT02171585|DRUG|Dabigatran etexilate|
219347298|NCT02171585|DRUG|Clarithromycin|
219347299|NCT04356560|DIAGNOSTIC_TEST|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
219347300|NCT02821702|DEVICE|Vaginal ultrasound|
219347301|NCT02821702|BIOLOGICAL|Blood sample|
219347302|NCT02626897|DEVICE|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
219347303|NCT02626897|DEVICE|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
219347304|NCT02905474|OTHER|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
219347305|NCT02905474|DEVICE|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
219347306|NCT02905474|DEVICE|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
219347307|NCT02883751|RADIATION|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
219347308|NCT02883751|PROCEDURE|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
219347309|NCT05211479|BEHAVIORAL|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
219347310|NCT01514227|DRUG|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
219347311|NCT01514227|DRUG|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
219347312|NCT00037180|DRUG|Celecoxib|
219347313|NCT00037180|DRUG|Irinotecan|
219347314|NCT00037180|DRUG|5-fluorouracil|
219347315|NCT00037180|DRUG|Leucovorin|
219347316|NCT04707898|DEVICE|Single Bond Universal|Adhesive system
219347317|NCT04707898|DEVICE|G-Premio Bond|Adhesive system
219347318|NCT04538794|DRUG|CDX-0159|Administered intravenously
219347319|NCT04538794|DRUG|Normal Saline|Administered intravenously
219347320|NCT00062335|RADIATION|radiation therapy|
219347321|NCT04609852|DRUG|E8001|Intravenous infusion.
219347322|NCT04609852|DRUG|Placebo|Intravenous infusion.
219347323|NCT00796276|DRUG|IR OROS paliperidone and ER OROS paliperidone|
219347324|NCT00004420|DRUG|gamma-Linolenic acid|
219347325|NCT03256500|DEVICE|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
219347326|NCT04683965|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
219347327|NCT04683965|DRUG|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
219347328|NCT04683965|DRUG|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
219347329|NCT01508728|DEVICE|ORTHOSENS orthosis|with active vibration
219347330|NCT01508728|DEVICE|ORTHOSENS orthosis|with placebo vibration
219347331|NCT00285727|DRUG|Ropinirole CR|
219347332|NCT03393767|DRUG|Ranibizumab|Intravitreal injection
219347333|NCT01501305|DIETARY_SUPPLEMENT|Mineral solution|Rehydration mineral solution
219347334|NCT01501305|DIETARY_SUPPLEMENT|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
219347335|NCT02563847|DIETARY_SUPPLEMENT|0.52 g L-Tryptophan|
219347336|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
219347337|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
219347338|NCT02563847|DIETARY_SUPPLEMENT|50 g Xylitol|
219347339|NCT02563847|DIETARY_SUPPLEMENT|75 g Erythritol|
219347340|NCT02563847|DIETARY_SUPPLEMENT|75 g Glucose|
219347341|NCT02563847|DIETARY_SUPPLEMENT|300 mL tap water|
219347342|NCT02563847|OTHER|50 mg 13C-sodium acetate|
219347343|NCT05940779|OTHER|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
219347344|NCT02971579|PROCEDURE|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
219347345|NCT03658382|OTHER|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
219347346|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
219347347|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
219347348|NCT05915572|OTHER|Mulligan Mobilization Technique|The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation
219347349|NCT05915572|OTHER|Traditional Physical Therapy Program|Myofascial release and ROM ex. 3 sessions per week for 6 weeks.
219347350|NCT03743870|DRUG|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
219347351|NCT03743870|DRUG|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
219347352|NCT00887393|OTHER|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (\< 15% of total kcaloric intake)
219347353|NCT00887393|OTHER|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
219347354|NCT02997579|PROCEDURE|patellar resurfacing|patellar component insert with cement
219347355|NCT01656863|OTHER|Questionnaire|
219347356|NCT03428165|OTHER|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
219347357|NCT05182554|BEHAVIORAL|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
219347358|NCT05182554|BEHAVIORAL|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
219347359|NCT05182554|BEHAVIORAL|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
219347360|NCT05182554|BEHAVIORAL|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
219347361|NCT05182554|BEHAVIORAL|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
219347362|NCT05182554|BEHAVIORAL|Video order|The order in which videos appear on the vaccine content website will be randomized.
219347363|NCT05603715|DRUG|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
219347364|NCT05195697|OTHER|Observational study of different treatments and time to treatment|Different treatment based on the clinical decision
219347365|NCT00259883|DRUG|paroxetine|1 or 2 tablets once a day
219347366|NCT06452966|OTHER|traditional Chinese medicine|"patients in the group will receive one of or a combination of the following interventions:~Oral Chinese medicine decoction:~The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs."
219347367|NCT06452966|OTHER|Routine ICU care|Patients will receive ICU care
219347368|NCT06452966|OTHER|historical Routine ICU care|Patients had received ICU care
219347369|NCT01230541|DRUG|Placebo|Daily, oral tablet
219347370|NCT01230541|DRUG|Udenafil|Daily tablet
219347371|NCT03672279|DIAGNOSTIC_TEST|CogCheck|Novel self-administered cognitive assessment tool
219347372|NCT03705585|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
219347373|NCT03705585|DRUG|Vaxchora|One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
219347374|NCT02524574|PROCEDURE|cardiac Rehabilitation|
219347375|NCT02524574|OTHER|Tomography Positron Emission|
219347376|NCT03215771|DEVICE|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
219354878|NCT02072655|PROCEDURE|socio-aesthetic care|"* care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
219354879|NCT03286842|DRUG|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
219347377|NCT03215771|OTHER|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
219347378|NCT02039375|OTHER|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
219347379|NCT01588795|PROCEDURE|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
219347380|NCT01588795|DRUG|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
219347381|NCT03134170|OTHER|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
219347382|NCT02462668|PROCEDURE|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
219347383|NCT02462668|PROCEDURE|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
219347384|NCT02462668|PROCEDURE|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
219347385|NCT00002106|DRUG|Ranitidine hydrochloride|
219347386|NCT03519763|DIAGNOSTIC_TEST|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
219347387|NCT04770389|DRUG|Obicetrapib 5mg|tablet
219347388|NCT04770389|DRUG|Ezetimibe 10mg|tablet
219347389|NCT04770389|OTHER|Placebo|tablet
219347390|NCT04296370|DRUG|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
219347391|NCT04296370|DRUG|Fluzoparib|Fluzoparib Orally twice daily
219347392|NCT04296370|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
219347393|NCT01666431|DRUG|Lapatinib|
219347394|NCT03831074|DEVICE|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
219347395|NCT03949933|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
219347396|NCT05893407|DIAGNOSTIC_TEST|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
219347397|NCT04169880|DEVICE|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
219347398|NCT04169880|COMBINATION_PRODUCT|HILT & EXERCISE|HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
219347399|NCT00363948|DRUG|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
219347400|NCT00363948|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
219347401|NCT00956670|OTHER|Quality-of-Life Assessment|Ancillary studies
219347402|NCT00956670|OTHER|Questionnaire Administration|Ancillary studies
219347403|NCT00956670|PROCEDURE|Study of High Risk Factors|Undergo lymphedema assessment
219347404|NCT00956670|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
219347405|NCT00956670|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo surgery
219347406|NCT00956670|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
219347407|NCT01734577|PROCEDURE|Dry needling|Sterile monofilament needles
219347408|NCT01734577|PROCEDURE|Sham needling|Applicator tubes from the sterile monofilament needles
219347409|NCT00326807|DRUG|Naltrexone|
219347410|NCT00542269|DRUG|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
219347411|NCT00542269|DRUG|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
219347412|NCT00542269|DRUG|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
219347413|NCT00867399|DRUG|ABT-126|See arm for details
219347414|NCT04450680|OTHER|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
219347415|NCT03873714|DEVICE|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
219347416|NCT03363750|BEHAVIORAL|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
219347417|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
219347418|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
219347419|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
219347420|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
219347421|NCT04455529|OTHER|ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
219347422|NCT00012779|BEHAVIORAL|Health Education Program|
219347423|NCT03028870|DRUG|V120083|Capsules
219347424|NCT03028870|DRUG|Naproxen|Capsules
219347425|NCT03028870|DRUG|Placebo|Capsules to match V120083 and/or naproxen
219347426|NCT00524407|DRUG|Epoetin alfa|
219347427|NCT02799823|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
219347428|NCT01445821|BIOLOGICAL|Peripheral Blood Stem Cells|Mobilized leukapheresis product
219347429|NCT01445821|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
219347430|NCT01445821|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
219347431|NCT01445821|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
219347432|NCT01445821|DRUG|Methylprednisolone|Steroid
219347433|NCT01445821|DRUG|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
219347434|NCT01445821|DRUG|Fludarabine|Purine analog which inhibits DNA synthesis or repair
219347435|NCT03574870|DEVICE|wearable sensor|A commercially-available wearable fitness sensor
219347436|NCT00708123|DRUG|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
219347437|NCT00708123|DRUG|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
219347438|NCT04821466|DEVICE|Virtual Reality Headset to provide a Virtual Reality Experience|Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
219347439|NCT06264882|DRUG|Degarelix|After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.
219347440|NCT06264882|DRUG|Transdermal Estradiol Patch|Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
219347441|NCT06264882|DRUG|Transdermal Placebo Patch|Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
219347442|NCT00845650|BIOLOGICAL|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
219347443|NCT00845650|BIOLOGICAL|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
219347444|NCT00845650|BIOLOGICAL|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
219347445|NCT00845650|BIOLOGICAL|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
219347446|NCT00845650|BIOLOGICAL|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
219347447|NCT00845650|BIOLOGICAL|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
219347448|NCT00814892|BIOLOGICAL|allogeneic tumor cell vaccine|Given intradermally
219347449|NCT00814892|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
219347450|NCT00776607|DRUG|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
219354880|NCT03036137|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
219354881|NCT03036137|DEVICE|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
219354882|NCT05744739|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219354883|NCT05744739|DRUG|Tomivosertib|Given PO
219354884|NCT03783520|DEVICE|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
219354885|NCT03783520|OTHER|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
219347451|NCT00776607|DRUG|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
219347452|NCT05630248|DIAGNOSTIC_TEST|Recurrent Neural Network|it is to classify pulse types by using specialized pulse measuring instruments.
219347453|NCT02350972|BIOLOGICAL|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
219347454|NCT01731379|PROCEDURE|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
219347455|NCT05277545|BEHAVIORAL|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
219347456|NCT01541475|DRUG|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
219347457|NCT01541475|DRUG|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
219347458|NCT05339295|DRUG|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
219347459|NCT04486950|DRUG|TAK-951|TAK-951 intravenous infusion.
219347460|NCT04486950|DRUG|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
219347461|NCT01914874|BEHAVIORAL|Mindfulness Meditation|
219347462|NCT00710476|PROCEDURE|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
219347463|NCT03651284|BEHAVIORAL|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
219347464|NCT03651284|BEHAVIORAL|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
219347465|NCT00533442|DRUG|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
219347466|NCT00533442|DRUG|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
219347467|NCT00533442|DRUG|Tacrolimus|Part of standard maintenance.
219347468|NCT00533442|DRUG|Steroids|Part of standard maintenance
219347469|NCT03186170|OTHER|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
219347470|NCT02745275|BEHAVIORAL|Peer-led Health Education|Peer-led health education
219347471|NCT06095661|OTHER|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
219347472|NCT03808727|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
219347473|NCT01251107|DRUG|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
219347474|NCT01251107|DRUG|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
219347475|NCT01251107|DRUG|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
219347476|NCT01251107|DRUG|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
219347477|NCT01251107|DRUG|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
219347478|NCT01251107|DRUG|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
219347479|NCT01251107|DRUG|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
219347480|NCT01251107|DRUG|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
219347481|NCT01251107|DRUG|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
219347482|NCT01251107|DRUG|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
219347483|NCT01251107|DRUG|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
219347484|NCT03115567|DRUG|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
219347485|NCT03362424|BIOLOGICAL|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
219347486|NCT03362424|PROCEDURE|Rotator cuff repair|Rotator cuff repair
219347487|NCT04403581|OTHER|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
219347488|NCT02090322|PROCEDURE|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
219347489|NCT05065502|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.\[practice\]."
219347490|NCT05065502|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
219347491|NCT00606203|DRUG|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
219347492|NCT00606203|DRUG|placebo|placebo
219347493|NCT05061173|OTHER|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
219347494|NCT05061173|OTHER|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
219347495|NCT05061173|OTHER|Combined Exercise Training Group|"Combined Exercise training includes \[Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction\] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
219347496|NCT03371446|GENETIC|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
219347497|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5421|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
219347498|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5424|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
219347499|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5429|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
219347500|NCT06361875|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
219347501|NCT06361875|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
219347502|NCT06361875|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
219347503|NCT02312635|DRUG|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
219347504|NCT02312635|BEHAVIORAL|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
219347505|NCT01849471|OTHER|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
219347506|NCT02544685|DIETARY_SUPPLEMENT|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
219347507|NCT02544685|DIETARY_SUPPLEMENT|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
219347508|NCT02544685|OTHER|Placebo|Same dosage regimen as active drugs
219347509|NCT03319875|DEVICE|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
219347510|NCT00236808|DRUG|levofloxacin|
219347511|NCT04156880|OTHER|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
219347512|NCT00947336|DRUG|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
219347513|NCT00947336|DRUG|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
219347514|NCT01119248|OTHER|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
219347515|NCT03098784|OTHER|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
219347516|NCT03098784|OTHER|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
219347517|NCT01545856|DRUG|levodopa|levodopa use
219347518|NCT03397407|OTHER|No intervention|
219347519|NCT00550680|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
219347520|NCT02757183|DEVICE|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
219347521|NCT06066827|DRUG|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
219347522|NCT06066827|OTHER|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
219347523|NCT06066827|COMBINATION_PRODUCT|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
219347524|NCT03000907|OTHER|Intervention|Diet and physical exercises
219347525|NCT02060682|DEVICE|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
219347526|NCT00138788|PROCEDURE|Radiotherapy, dose fractionation|
219347527|NCT05446545|OTHER|ND-EOC or platinum-sensitive rEOC|platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
219347528|NCT00505440|BEHAVIORAL|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
219347529|NCT00505440|BEHAVIORAL|Usual care|Usual care with mailed screening results
219347530|NCT03456752|DRUG|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
219347531|NCT03456752|DRUG|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
219347532|NCT01981642|OTHER|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
219347533|NCT01981642|OTHER|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
219347534|NCT00456352|PROCEDURE|duodenal exclusion|
219347535|NCT05047757|DIETARY_SUPPLEMENT|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
219347536|NCT05017207|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
219347537|NCT00562354|BIOLOGICAL|13vPnC|13vPnC for both stratum
219347538|NCT04257825|DEVICE|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
219347539|NCT06002399|DEVICE|cataract surgery|cataract surgery
219347540|NCT00317109|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
219347541|NCT00317109|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
219347542|NCT00317109|BIOLOGICAL|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
219347543|NCT04687800|DRUG|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
219347544|NCT04687800|DRUG|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
219347545|NCT01315860|OTHER|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
219347546|NCT03693625|DRUG|GDC-0853|Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
219347547|NCT01464502|PROCEDURE|Standard CRT Implant|
219347548|NCT01464502|PROCEDURE|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
219347549|NCT01883635|BEHAVIORAL|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
219347550|NCT01883635|BEHAVIORAL|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
219347551|NCT02072811|DRUG|DAC|"* DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
219347552|NCT02072811|DRUG|CLAG|"* G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
219347553|NCT02072811|DRUG|Consolidation, I HAM cycle|"* Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
219347554|NCT02072811|DRUG|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
219347555|NCT02072811|DRUG|Consolidation, III HiDAraC cycle|"* Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~* 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
219347556|NCT01187953|DRUG|Prograf (tacrolimus)|Administered per current product labeling
219347557|NCT01187953|DRUG|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
219347558|NCT03536988|PROCEDURE|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
219347559|NCT03536988|PROCEDURE|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
219347560|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
219347561|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
219347562|NCT02105402|BEHAVIORAL|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
219347563|NCT01505842|PROCEDURE|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
219347564|NCT01505842|PROCEDURE|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
219347565|NCT05537597|PROCEDURE|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
219347566|NCT05537597|PROCEDURE|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
219347567|NCT01464307|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
219347568|NCT01464307|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
219347569|NCT00964327|DRUG|TMC114|
219347570|NCT02714920|OTHER|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
219347571|NCT01335763|DRUG|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
219347572|NCT02911922|DEVICE|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
219347573|NCT02911922|DEVICE|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
219347574|NCT02911922|RADIATION|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
219347575|NCT01217021|DRUG|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
219347576|NCT00338871|PROCEDURE|home exercise|
219347577|NCT06537713|DIAGNOSTIC_TEST|Testican-1|Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
219347578|NCT06123065|BEHAVIORAL|Yoga|8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
219347579|NCT02457637|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
219347580|NCT00916266|PROCEDURE|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
219354886|NCT05398315|BEHAVIORAL|Empathic Statements/Reflections|Presence of Empathic Statements
219354887|NCT05398315|BEHAVIORAL|Narrator Backstory|Presence of a narrator backstory
219354888|NCT05398315|BEHAVIORAL|Male Narrator|Presence of a male narrator
219354889|NCT05398315|BEHAVIORAL|Female Narrator|Presence of a female narrator
219354890|NCT05398315|BEHAVIORAL|MI Techniques|Presence of MI techniques
219347581|NCT05185271|BEHAVIORAL|Dyad-focused strategy training|"Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
219347582|NCT00042861|DRUG|7-hydroxystaurosporine|
219347583|NCT00042861|DRUG|fluorouracil|
219347584|NCT00042861|DRUG|leucovorin calcium|
219347585|NCT01359709|DRUG|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
219347586|NCT04916509|DRUG|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
219347587|NCT04916509|DRUG|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
219347588|NCT01588717|DRUG|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
219347589|NCT04011280|DRUG|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
219347590|NCT05558280|DRUG|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
219347591|NCT00934986|OTHER|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~* Stage A patient who does not require a treatment: one sample the day of enrollment.~* Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
219347592|NCT03027700|DEVICE|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
219347593|NCT06168838|DRUG|Anticoagulant|Know the casuistry of spontaneous intracranial hemorrhages and secondary to the use of both oral and parenteral anticoagulants
219347594|NCT04942925|DEVICE|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
219347595|NCT04942925|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
219347596|NCT01273883|DIETARY_SUPPLEMENT|Magnesium|Magnesium 532 mg a day
219347597|NCT01273883|OTHER|Placebo|matching form/dosage
219347598|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
219347599|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
219347600|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
219347601|NCT01052298|DRUG|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
219347602|NCT02215720|DRUG|Cetuximab|
219347603|NCT02215720|DRUG|Temsirolimus|
219347604|NCT05170243|DRUG|9MW1911 Injection|Single dose intravenously on day 1
219347605|NCT05170243|DRUG|9MW1911 Injection Placebo|Single dose of matching placebo intravenously on day 1
219347606|NCT02686515|DEVICE|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
219347607|NCT02686515|DEVICE|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
219347608|NCT06086132|COMBINATION_PRODUCT|Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy|Follow-up visits at baseline, 3-months, and 1-year
219347609|NCT05942300|DRUG|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
219347610|NCT05942300|DRUG|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
219347611|NCT05388461|OTHER|electroconvulsive therapy|electroconvulsive therapy
219347612|NCT03221738|BEHAVIORAL|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
219354891|NCT03178487|DRUG|Upadacitinib|Tablet
219354892|NCT03178487|DRUG|Placebo|Tablet
219347613|NCT05404464|OTHER|Different baseline characteristics and clinical management|Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
219347614|NCT00802204|RADIATION|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
219347615|NCT00802204|PROCEDURE|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
219347616|NCT00802204|PROCEDURE|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
219347617|NCT00802204|BEHAVIORAL|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
219347618|NCT00802204|OTHER|Caloric Restriction|Obese participants only complete a short-term (\~10days) very low calorie diet
219347619|NCT01805531|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
219347620|NCT02385630|OTHER|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
219347621|NCT06539910|PROCEDURE|General Anesthesia|All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
219347622|NCT06539910|PROCEDURE|TIPS block|Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection. Distal adductor canal block via another needle puncture.Ten mL of a mixture of 0.25 % bupivacaine and 8 mg dexamethasone will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane lateral to medial approach just lateral to the superficial femoral artery
219347623|NCT06539910|PROCEDURE|Modified TIPS block|Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane.Both groups will receive a mixture of 0.25 % bupivacaine and 8 mg dexamethasone. Ten mL will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA anaesthetic mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane medial to lateral approach just lateral to the superficial femoral artery. Then, the needle will be redirected just underneath the ALM and 10 mL of the LA mixture will be injected in the plane between the ALM and the adductor magnus muscle (AMM).Total volume of LA will be 50 mL.
219347624|NCT06539910|PROCEDURE|Mutimodal analgesia|Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes
219347625|NCT01003275|DRUG|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
219347626|NCT01003275|DRUG|Placebo|Two soft gels by mouth daily for 8 weeks
219347627|NCT06293469|PROCEDURE|Accelerated Flap Coverage Surgery|Timing of the flap surgery is with a goal of 72 hours from injury
219347628|NCT06293469|PROCEDURE|Standard of Care Flap Timing|Timing of the flap surgery is the standard of care flap timing for the participating institution.
219347629|NCT02701387|DEVICE|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
219347630|NCT02701387|DEVICE|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
219347631|NCT02043548|DRUG|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
219347632|NCT02043548|DRUG|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
219347633|NCT05699265|DIAGNOSTIC_TEST|Measures of arterial stiffness and endothelial function|baseline cMRI, vascular reactivity studies, and CPET
219347634|NCT05699265|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).
219347635|NCT05699265|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.
219347636|NCT05699265|DIAGNOSTIC_TEST|Serum and urine biomarkers|Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
219347637|NCT05613764|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
219347638|NCT05678036|DRUG|Opioid maintenance treatment|A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
219347639|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
219347640|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
219347641|NCT03871322|DIETARY_SUPPLEMENT|Placebo|Placebo control group
219347642|NCT00254462|DRUG|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
219347643|NCT00254462|DRUG|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
219347644|NCT00254462|BEHAVIORAL|Parent Training|All children will receive parent training for the duration of the study.
219347645|NCT06068712|BEHAVIORAL|Attentional Cue Type|Positive cue (target), negative cue (distractor), or neutral cue (baseline)
219347646|NCT02136030|DRUG|Liposomal amphotericin B|4mg/kg/day, IV infusion
219347647|NCT02136030|DRUG|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
219347648|NCT01430455|DRUG|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
219347649|NCT02598375|OTHER|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
219347650|NCT02386228|GENETIC|collection of CSF and blood|collection of CSF and blood
219347651|NCT05035615|DIAGNOSTIC_TEST|IUO Acute Leukemia Panel|This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
219347652|NCT02408471|DEVICE|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
219347653|NCT05216679|DEVICE|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
219347654|NCT05216679|DEVICE|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
219347655|NCT03829657|DRUG|ampreloxetine|Oral tablet, QD (Daily)
219347656|NCT03829657|DRUG|Placebo|Oral tablet, QD
219347657|NCT00948363|OTHER|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
219347658|NCT00948363|OTHER|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
219347659|NCT02121600|OTHER|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.
219347660|NCT02121600|RADIATION|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
219347661|NCT02121600|RADIATION|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
219347662|NCT01195727|DRUG|Apixaban|
219347663|NCT00116350|DRUG|Misoprostol|800 mcg sublingual misoprostol
219347664|NCT00116350|DRUG|Oxytocin|40 IU Oxytocin IV
219347665|NCT01014689|DRUG|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
219347666|NCT01014689|DRUG|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
219347667|NCT05075811|DRUG|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
219347668|NCT05075811|OTHER|Placebo|Normal Saline
219347669|NCT02549209|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
219347670|NCT02549209|DRUG|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
219347671|NCT02549209|DRUG|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
219347672|NCT05686200|BEHAVIORAL|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
219347673|NCT00322283|DRUG|Oglemilast|Oglemilast, 15mg once per day, oral administration
219347674|NCT00322283|DRUG|Placebo|Dose-marched placebo, once per day, oral administration
219347675|NCT06285591|DRUG|Lactobacillus reuteri Tablets|Lactobacillus reuteri lozenges (NOW Foods, Sweden) contained 2×10\^8 CFU viable cells of Lactobacillus reuteri as the active ingredient.
219347676|NCT06285591|DRUG|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus reuteri.
219347677|NCT06285591|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
219347678|NCT04793178|DEVICE|Oxygen Reserve Index, Masimo Corporation, USA.|The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
219347679|NCT01217671|BIOLOGICAL|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
219347680|NCT01217671|OTHER|Placebo|Placebo
219347681|NCT02030743|OTHER|Visual training|6 training sessions with computerised visual attention paradigm
219347682|NCT06363214|PROCEDURE|Patient blood management|Perioperative optimization of hemoglobin level, perioperative minimization of blood loss, increase of anemia tolerance
219347683|NCT01770132|DRUG|porfimer sodium|Given IV
219347684|NCT01770132|PROCEDURE|endoscopic ultrasonography|Undergo EUS-PDT
219347685|NCT01770132|PROCEDURE|photodynamic therapy|Undergo EUS-PDT
219347686|NCT01770132|DRUG|gemcitabine hydrochloride|Given IV
219347687|NCT06841913|BIOLOGICAL|LAIV nasal vaccine is chosen as a model viral infection|Inoculation with LAIV
219347688|NCT06841913|OTHER|Wood smoke|Wood smoke exposure concentrations at 500 ug/m3 for two hours.
219347689|NCT06841913|BIOLOGICAL|Placebo for LAIV nasal vaccine is chosen as a model viral infection|Placebo for LAIV inoculation. Nasal administration of normal saline.
219347690|NCT06841913|OTHER|Placebo for Wood Smoke (clean Air Exposure)|Clean Air Exposure for 2 hours
219347691|NCT06568692|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
219347692|NCT06568692|DRUG|Capecitabine|Commercially available capecitabine is a commonly used oral fluoropyrimidine.
219347693|NCT04061421|DRUG|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
219347694|NCT04061421|DRUG|Itacitinib|Taken by mouth daily during each 28-day cycle
219347695|NCT02956603|OTHER|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
219347696|NCT00612638|DRUG|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
219347697|NCT05571514|DIETARY_SUPPLEMENT|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
219347698|NCT05571514|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate is a source of calcium.
219347699|NCT06816017|DRUG|Eciskafusp Alfa|Participants will receive eciskafusp alfa via intravesical instillation.
219347700|NCT06816017|DRUG|BCG Medac Strain|Participants will receive BCG via intravesical instillation.
219347701|NCT02072408|DRUG|aflibercept|"1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~   * Loss of five ETDRS letters or one Snellen line of vision from baseline~  * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~  * Presence of active polyp on indocyanine green angiography"
219347702|NCT02380716|DEVICE|GORE® Ascending Stent Graft|
219347703|NCT02867995|DEVICE|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
219347704|NCT00502762|DRUG|topotecan|
219347705|NCT02548104|OTHER|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
219347706|NCT02548104|OTHER|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
219347707|NCT05618327|DRUG|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
219347708|NCT07001540|DRUG|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx)
219347709|NCT07008170|PROCEDURE|Laparoendoscopic rendezvous|"The main principles of LERV technique consists of~1. An antegrade trans cystic cannulation of the bile duct during laparoscopic cholecystectomy, with a guidewire that can be retrieved with a duodenoscope, thus facilitating retrograde bile duct cannulation.~2. An over-the-wire sphincterotome is then inserted and standard maneuvers of endoscopic common bile duct stones clearance are performed.~3. The procedure is then completed by cholecystectomy in one procedure"
219347710|NCT06868446|DEVICE|Digital Therapeutic (Version 1)|Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD
219347711|NCT06868446|DEVICE|Digital Therapeutic (Version 2)|Prescription digital therapeutic (increased dose) designed to overcome existing barriers and deliver evidence-based treatment for PTSD
219347712|NCT06868446|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual may include psychotherapy and/or pharmacological interventions.
219347713|NCT07014176|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
219347714|NCT07014176|PROCEDURE|Standard of Care (SOC)|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
219347715|NCT06871462|BEHAVIORAL|BP monitor use training and app training|Patients will be taught how to use a BP monitor, along with the accompanying mobile app to view their readings.
219347716|NCT06871462|BEHAVIORAL|Online patient portal enrollment and training|Patients will receive training on how to use an online patient portal. If they are not yet enrolled in an online patient portal and would like to be, they will also be enrolled into one.
219347717|NCT06871462|BEHAVIORAL|SMS reminders to take blood pressure|Patients will receive reminders via SMS to take their blood pressure.
219354893|NCT01018875|DRUG|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
219347718|NCT06871462|BEHAVIORAL|Education about self-management of hypertension|One-time training with action planning, access to website with language concordant patient education, and educational text messages
219347719|NCT06871462|BEHAVIORAL|Educational text messages that encourage seeking support from a support person|Educational text messages about behavioral changes that explicitly encourage seeking support from a support person
219347720|NCT06871462|BEHAVIORAL|Involvement of caregiver or support person|Patients will be asked to involve a caregiver or support person for all activities above, including patient portal proxy access.
219347721|NCT06871462|BEHAVIORAL|Group classes|Patients will be asked to attend in-person or online group education classes on hypertension management
219347722|NCT03894670|OTHER|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
219347723|NCT03894670|OTHER|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
219347724|NCT06691672|DIAGNOSTIC_TEST|Robotic Tomographic ultrasound imaging of the arm vasculature.|Semi-autonomous robotic tomographic ultrasound imaging of the arm vasculature for vascular access creation mapping in CKD patients.
219347725|NCT07019636|PROCEDURE|Weaning strategy with direct extubation (no spontaneous breathing trial)|Patients will be extubated within the 60 minutes following randomization
219347726|NCT07019636|PROCEDURE|Weaning strategy with extubation only after a successful spontaneous breathing|Patients will undergo a spontaneous breathing trial and will be extubated only in case of successful spontaneous breathing
219347727|NCT05132101|DRUG|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
219347728|NCT07029594|OTHER|balneotherapy|"Specific procedures performed during the 3-week spa therapy~Thermal Treatments (Number of sessions)~Individual nasal irrigation (18) Sonic aerosol therapy (18) Simple aerosol therapy (18) Individual inhalation therapy (18)~Administered by a licensed physiotherapist~Individual respiratory rehabilitation and bronchial drainage (18)~Administered by a spa physician Tubo-tympanic insufflation (9) Sinus lavage using the Proëtz displacement method 9"
219347729|NCT07028567|DRUG|Calcium hydroxylapatite filler|Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
219347730|NCT07028567|DRUG|Painting chemical reconstruction of skin scars trichloroacetic acid technique|Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
219347731|NCT07029802|OTHER|No intervention|This is an observational study
219347732|NCT07027787|BEHAVIORAL|Standard Physical Therapy for Hand Dexterity in Stroke Patients|Standard physical therapy program for stroke patients targeting hand dexterity. Conducted 3 times/week for 8 weeks (60 min/session), exercises included wrist and forearm movements, object manipulation, ball gripping, and putty-based hand strengthening.
219347733|NCT07027787|BEHAVIORAL|Rehacom Attention Training + Physical Therapy|Combined intervention: 30 minutes of computerized attention training using the Rehacom system, followed by 30 minutes of standard hand dexterity physical therapy. Conducted 3 times/week for 8 weeks. Rehacom provided task-based cognitive training with visual, auditory, and performance feedback in a controlled lab setting.
219347734|NCT07028333|BEHAVIORAL|Motor-Motor Dual Task Exercise Group|Participants in this group will perform motor tasks (such as ball handling, throwing, holding) accompanied by physiotherapist. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
219347735|NCT07028333|BEHAVIORAL|Motor-Cognitive Dual Task Exercise Group|This group will also do walking and balance exercises with the physiotherapist, while simultaneously doing cognitive tasks (rhythmic counting, saying color names, finding words, etc.). The exercises will last approximately 40 minutes, 2 days a week, for 6 weeks.
219347736|NCT07028333|BEHAVIORAL|Control Group|Standard walking and balance exercises will be given to the control group at home and followed by parents. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
219347737|NCT07029906|DRUG|Bisoprolol 2.5 mg|Active bisoprolol 2.5mg tablets
219347738|NCT07029906|DRUG|Placebo|Blinded placebo for a total of 3 weeks
219347739|NCT07029100|OTHER|Ex-vivo organoid culture|ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection
219347740|NCT07028970|OTHER|No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )|This study is observational study and all participants will be obsreved with no intervention.
219347741|NCT07028242|PROCEDURE|Hysteroscopic fertility-sparing surgery and hormonal treatment|"Patients undergo hysteroscopic endometrial resection using the Mazzon three-step technique or tissue removal device (TRD), depending on the lesion type. Following surgery, hormonal treatment is administered either via intrauterine device (IUD) or oral progestin. Monitoring includes serial endometrial biopsies and transvaginal ultrasounds at 3, 6, and 12 months."
219347742|NCT07029659|DIAGNOSTIC_TEST|Ovarian Cancer Score|Preoperatively, 5 ml blood samples were collected for OCS testing to determine the benign or malignant nature of ovarian endometriotic tissues. The OCS results were statistically analyzed against the gold standard of histopathological diagnosis.
219347743|NCT07029061|DEVICE|Air splints|Application of CPPS (Urias splints) + physiotherapy
219347744|NCT07029997|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|insertion of eartubes
219347745|NCT07027917|DEVICE|Virtual Reality Goggles|VR
219347746|NCT07028736|OTHER|Dry eye assessment|Dry eye assessment was performed using the Mediworks Dry Eye Diagnostic System.
219354894|NCT01018875|DRUG|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
219347747|NCT07028918|RADIATION|Low dose radiotherapy regimen|On the first and second day of chemotherapy and immunotherapy, low-dose radiotherapy of 1 Gy/1f was administered to the primary tumor lesion and metastatic lymph nodes, respectively, for a total of 4 Gy/4f.
219347748|NCT07028918|DRUG|New adjuvant immunotherapy regimen|Terriptylimab: fixed dose 240 mg, q30000, intravenous infusion, each infusion lasting 30 minutes (not less than 20 minutes, not more than 60 minutes); Chemotherapy regimen: Albumin bound paclitaxel: 175-260 mg/m2, d1, q3w; Platinum class: Cisplatin: 75mg/m2, d1-3, q3w; Carboplatin: AUC=5, d1, q3w (for patients with cisplatin allergy, intolerance, hearing impairment, creatinine clearance rate\<50ml/min, or grade 1 neuropathy that are not suitable for cisplatin use).
219347749|NCT07028918|PROCEDURE|Surgical treatment|Surgery begins around 4 weeks after the first day of the second cycle of neoadjuvant therapy. The surgical plan is developed and evaluated by oral surgeons with years of clinical surgical experience. The determination of surgical margins is mainly based on baseline standards before neoadjuvant therapy for tumors, and can be appropriately reduced by oral surgeons depending on the situation.
219347750|NCT07028918|DRUG|Postoperative adjuvant therapy plan|"* Patients with postoperative pathological progression of pCR were given maintenance treatment with Triprolizumab Q3W for 1 year.~  * Patients with postoperative pathology not reaching pCR should receive adjuvant radiotherapy (60-66Gy/30-33f) ③ Patients with high-risk recurrence factors in postoperative pathology (positive tumor margin or insufficient safe margin, presence of lymph node extracellular invasion) are given adjuvant radiotherapy and chemotherapy."
219347751|NCT07028918|RADIATION|Radical radiotherapy plan|"① Radical radiotherapy for the primary lesion and cervical lymphatic drainage area.~② Synchronous cisplatin during radiotherapy: 75mg/m2, d1-3, q3w."
219347752|NCT07029815|PROCEDURE|irradiation with Er:YAG laser|An Er:YAG laser (LightTouch, LightInstruments, Yokneam, Israel) was used with the following parameters: 400mJ (millijoules), 6W (Watt), 15Hz (Hertz), 5/8 water cooling, laser tip with a diameter of 800 microns. Tissue debridement continued until hard, healthy, lively bleeding bone was exposed, indicative of normal bone.
219347753|NCT07029815|PROCEDURE|Tissue preparation|Rose-shaped rotary drills (8 mm diameter) were used with water cooling at a speed not exceeding 40.000 rpm. Tissue preparation limits were consistent with those used for the Er:YAG laser group.
219347754|NCT07028593|DRUG|Propofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in propofol group.
219347755|NCT07028593|DRUG|ciprofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in ciprofol group.
219347756|NCT07027878|DEVICE|JETi lower extremity venous thrombosis|The JETi System is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
219347757|NCT07028138|OTHER|electrical stimulation with mime therapy|"A total of 38 Bell's palsy patients will be randomly selected and divided into two equal groups at Shalamar Hospital.~Group A will receive mime therapy with electrical stimulation, including facial massage, relaxation, stretching, and facial movement exercises.~Group B will undergo electrical stimulation followed by proprioceptive neuromuscular facilitation (PNF) with resisted facial and tongue exercises.~Each group will receive 30-minute sessions, three times per week, for six weeks.~Outcomes will be assessed using the Facial Disability Index (FDI), Sunnybrook Facial Grading System, and SF-12 quality of life scale.~Evaluations will be conducted at baseline, after one month, and at a 2-3 month follow-up."
219347758|NCT07028229|BEHAVIORAL|Training Group|A structured educational and practical training program in gynecologic oncology ultrasound designed for residents. The intervention includes lectures, clinical case discussions, supervised and independent ultrasound examinations, and performance assessments to evaluate learning progression and diagnostic concordance with experts.
219347759|NCT07028047|BIOLOGICAL|WGc-043 Injection|WGc-043 Injection, intramuscular injection
219347760|NCT07029854|OTHER|Medical treatment|They will receive oral chemotherapy, based on the cancer stage, and will also undergo radiotherapy.
219347761|NCT07029854|OTHER|LASER acupoints therapy|LASER acupoints therapy will use the Pointer Pulse device (GMT2000 s.r.l., Italy), emitting 650 nm red light with an audio trimmer for acupoint detection. Treatment parameters include 5 mW power, 120 s irradiation per point over a 3.14 mm² area (fluence: 19.2 J/cm², power density: 0.16 W/cm², total dose: 0.6 J). Continuous red laser will be applied for effective stimulation. Sessions will occur once weekly for five weeks. Bilateral stimulation will follow this order: left hand, left face, trunk, right face, and right hand. Targeted acupoints: LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
219347762|NCT07029854|OTHER|Pseudo-LASER acupoints therapy|For the pseudo-LASER acupoints therapy, the same procedures and sequence of acupoint application will be followed as in the active treatment. However, the Pointer Pulse device (GMT2000 s.r.l., Italy) will be deactivated to emit no therapeutic laser light while maintaining visual and audio cues to mimic real stimulation. The device will appear active to ensure blinding. Sessions will be conducted once weekly for five weeks, applying the probe to the same bilateral acupoints in the following order: left hand, left face, trunk, right face, and right hand. The targeted points will be LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
219347763|NCT07028827|DRUG|0.05% atropine eye drops|One drop of 0.05% atropine in each eye once a day before bedtime
219347764|NCT07028827|DRUG|0.025% atropine eye drops|One drop of 0.025% atropine in each eye once a day before bedtime
219347765|NCT07028827|DRUG|placebo eye drops|One drop of placebo in each eye once a day before bedtime
219347766|NCT06877845|OTHER|Activity Tracker & Postural Corrector|"Use of Activity Tracker \& Postural Corrector along with following baseline treatment.~* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
219354895|NCT01018875|DRUG|placebo|Subjects will take 4 capsules once daily for 12 weeks.
219347767|NCT06877845|OTHER|Conventional Therapy|"* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
219347768|NCT06203561|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
219347769|NCT06203561|BEHAVIORAL|comprehensive rehabilitation therapy|including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.
219347770|NCT06203561|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
219347771|NCT06203561|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
219347772|NCT00481650|DRUG|Leios/Alesse|
219347773|NCT01307215|DRUG|Ropivacaine|20mLs of 0.5%
219347774|NCT01307215|DRUG|Ropivacaine|30mLs of 0.33%
219347775|NCT01307215|DRUG|Ropivacaine|40mLs of 0.25%
219347776|NCT06758362|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|A structured psychotherapy approach focused on reducing PTSD symptoms through guided eye movements and trauma processing.
219347777|NCT06758362|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A psychotherapy approach focused on identifying and modifying maladaptive thought patterns and behaviors to reduce PTSD symptoms.
219347778|NCT06673277|DEVICE|Prolonged (2-hour) cryocompression therapy|The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.
219347779|NCT06067555|DEVICE|MicronJet|MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
219347780|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intradermal injections of 0.3mL
219347781|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intramuscular injection of 0.3mL
219347782|NCT06067555|OTHER|Bacteriostatic Saline|Intradermal injection of 0.3mL (control)
219347783|NCT05952557|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
219347784|NCT05952557|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered orally
219347785|NCT05952557|DRUG|Anastrozole|Anastrozole. Comparator. Administered orally
219347786|NCT05952557|DRUG|Letrozole|Letrozole. Comparator. Administered orally
219347787|NCT05952557|DRUG|Exemestane|Exemestane. Comparator. Administered orally
219347788|NCT05952557|DRUG|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
219347789|NCT06781814|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, specification: 3g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
219347790|NCT02907398|DEVICE|Inspire therapy|
219347791|NCT02907398|OTHER|No intervention|
219347792|NCT04305795|BIOLOGICAL|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
219347793|NCT04305795|BIOLOGICAL|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
219347794|NCT04305795|COMBINATION_PRODUCT|ASP-1929 PIT|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
219347795|NCT06298474|BEHAVIORAL|The BRAIN App|The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
219347796|NCT06789601|OTHER|Informatics system for eligibility monitoring|A daily automated data query of eligible subjects will collect EHR data, and our informatics system will be run on these data behind our institution's secure firewall. The daily list of subjects identified by the informatics system as having a new irAE will be accessed by the Alliance irAE biorespository study team at Dana-Farber/Brigham Cancer Center for review.
219347797|NCT06789601|OTHER|Standard eligibility monitoring|Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.
219347798|NCT04068376|OTHER|Control excercise|Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).
219347799|NCT04068376|OTHER|"Mind and Movement for Cognitive Health in the Older Adult"|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).
219347800|NCT04068376|OTHER|Double-task exercise by older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
219347801|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
219347802|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
219347803|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
219347804|NCT00085761|DRUG|Capsaicin Dermal Patch|
219347805|NCT03317938|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
219347806|NCT05692037|COMBINATION_PRODUCT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
219347807|NCT06931600|PROCEDURE|Sham adjustment|Two manual high velocity, low amplitude (HVLA) simulated/sham chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
219347808|NCT06931600|PROCEDURE|Chiropractic adjustment|Two manual high velocity, low amplitude (HVLA) genuine/real chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
219347809|NCT00729456|OTHER|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
219347810|NCT02091570|OTHER|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
219347811|NCT06116825|OTHER|1450ppm Fluoride toothpaste|1450ppm Fluoride toothpaste
219347812|NCT06116825|OTHER|1000Pppm Fluoride toothpaste|1000Pppm Fluoride toothpaste
219347813|NCT04201925|PROCEDURE|upper blepharoplasty|excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
219347814|NCT04652271|PROCEDURE|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
219347815|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
219347816|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
219347817|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
219347818|NCT00938314|DRUG|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
219347819|NCT01826552|DEVICE|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
219347820|NCT01826552|DEVICE|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
219347821|NCT06263569|PROCEDURE|Total hip arthroplasty|Unilateral primary total hip arthroplasty procedure.
219347822|NCT00150592|DRUG|SPD503 (Guanfacine HCl)|
219347823|NCT00150592|DRUG|Placebo|
219347824|NCT02288507|DRUG|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
219347825|NCT02288507|RADIATION|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
219347826|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
219347827|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
219347828|NCT01281462|DRUG|Doripenem|500 mg doripenem IV q8h;
219347829|NCT01281462|DRUG|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
219347830|NCT00002350|BIOLOGICAL|APL 400-003|
219347831|NCT02227693|DRUG|avatrombopag|E5501 (avatrombopag) 20-mg tablets
219347832|NCT02227693|DRUG|Placebo|Placebo matching 20-mg tablets
219347833|NCT05686174|DIETARY_SUPPLEMENT|MBS217|Soybean Fermented Extract (MBS217)
219347834|NCT05686174|DIETARY_SUPPLEMENT|Placebo|Without active ingredient
219347835|NCT03504878|PROCEDURE|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
219347836|NCT03504878|PROCEDURE|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
219347837|NCT00874120|DRUG|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
219347838|NCT00874120|DRUG|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
219347839|NCT01096563|DRUG|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
219347840|NCT01096563|DRUG|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
219347841|NCT05299437|DRUG|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
219347842|NCT01823679|DRUG|Capecitabine|Given orally
219347843|NCT03706287|DRUG|anlotinib 8mg + AP/PC|anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
219347844|NCT03706287|DRUG|anlotinib 10mg + AP/PC|anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
219347845|NCT03706287|DRUG|anlotinib 12mg + AP/PC|anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
219347846|NCT03706287|DRUG|anlotinib + AP/PC|anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
219347847|NCT00225511|DRUG|Effexor XR|
219347848|NCT00225511|DRUG|Milnacipran|
219347849|NCT05185609|OTHER|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
219347850|NCT05185609|OTHER|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
219347851|NCT05230186|PROCEDURE|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
219347852|NCT01072370|BIOLOGICAL|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
219347853|NCT01072370|BIOLOGICAL|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
219347854|NCT02164981|DRUG|sodium nitroprusside|intravenous
219347855|NCT02164981|OTHER|Placebo|Placebo
219347856|NCT04395261|DIAGNOSTIC_TEST|Wideband Tympanometry|
219347857|NCT04710095|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
219347858|NCT04710095|BEHAVIORAL|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
219347859|NCT04590092|DEVICE|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
219347860|NCT00809770|BEHAVIORAL|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
219347861|NCT00809770|BEHAVIORAL|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
219347862|NCT01465906|DRUG|tulobuterol|patch, 2mg, qN, 3 months
219347863|NCT01465906|DRUG|Tiotropium Bromide|18ug, inhale, qD, 3 months
219347864|NCT01465906|DRUG|tiotropium bromide|18ug, inhale, qD, 3 months
219347865|NCT04886687|PROCEDURE|mechanical thrombectomy|mechanical thrombectomy
219347866|NCT00651092|PROCEDURE|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
219347867|NCT00651092|PROCEDURE|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
219347868|NCT02469766|PROCEDURE|SWL|Patients in this arm will undergo SWL
219347869|NCT02469766|PROCEDURE|Semirigid URS|Patients in this arm will undergo semirigid URS
219347870|NCT02469766|PROCEDURE|Flexible URS|Patients in this arm will undergo Flexible URS
219347871|NCT00006388|DRUG|tamoxifen citrate|
219347872|NCT00006388|RADIATION|radiation therapy|
219347873|NCT02404103|DRUG|Flunisolide HFA|
219347874|NCT01039337|OTHER|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
219347875|NCT01039337|OTHER|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
219347876|NCT01039337|OTHER|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
219347877|NCT05328037|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for dosage of vitamin C
219347878|NCT04275622|BEHAVIORAL|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
219347879|NCT01277094|DRUG|Placebo|Oral daily doses for 12 weeks
219347880|NCT01277094|DRUG|RO5093151|Oral daily doses for 12 weeks
219347881|NCT02652897|PROCEDURE|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
219347882|NCT02652897|PROCEDURE|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
219347883|NCT00328627|DRUG|Alogliptin|Alogliptin tablets.
219347884|NCT00328627|DRUG|Alogliptin placebo|Alogliptin placebo-matching tablets.
219347885|NCT00328627|DRUG|Pioglitazone|Pioglitazone tablets.
219347886|NCT00328627|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
219347887|NCT05903287|DEVICE|Chang Gung Pleural Effusion Detection Software|"The Chang Gung Pleural Effusion Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pleural effusion. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pleural effusion.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
219347888|NCT02258360|OTHER|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
219347889|NCT05443841|OTHER|pleural lavage|pleural lavages before tumor resection and after tumor resecion, respectively
219347890|NCT02544308|DRUG|Lenalidomide|Experimental Arm
219347891|NCT02544308|DRUG|Dexamethasone|Experimental Arm
219347892|NCT02544308|OTHER|No further treatment|Comparator Arm
219347893|NCT03311711|BEHAVIORAL|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
219347894|NCT03311711|BEHAVIORAL|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
219347895|NCT03311711|BEHAVIORAL|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
219347896|NCT05896982|OTHER|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
219347897|NCT05896982|OTHER|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
219347898|NCT05896982|OTHER|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
219347899|NCT01451710|DRUG|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
219347900|NCT04188184|DRUG|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
219347901|NCT04188184|DRUG|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
219347902|NCT01632514|DRUG|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
219347903|NCT04349423|BEHAVIORAL|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
219347904|NCT02730884|DRUG|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
219347905|NCT02730884|BEHAVIORAL|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
219347906|NCT05787262|PROCEDURE|upper endoscopy|Upper endoscopy , biopsy and histopathological examination of taken biopsies.
219347907|NCT03405623|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
219347908|NCT03405623|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
219347909|NCT00963001|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
219347910|NCT00963001|OTHER|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
219347911|NCT03922009|DEVICE|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
219347912|NCT04821427|BEHAVIORAL|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
219347913|NCT04728685|PROCEDURE|Mechanical Traction|Mechanical Traction will be applied to the lumbar region using a traction unit.
219347914|NCT04584580|DRUG|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
219347915|NCT03981237|DEVICE|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
219347916|NCT03981237|DEVICE|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).
219347917|NCT03981237|PROCEDURE|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
219347918|NCT01525004|DRUG|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
219347919|NCT01525004|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
219347920|NCT03548051|PROCEDURE|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
219347921|NCT03548051|DRUG|Saline|250 ml of saline delivered by retention enema
219347922|NCT05581914|OTHER|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
219347923|NCT05581914|OTHER|Care as Usual|The care as usual the adolescents receives
219347924|NCT03927105|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
219347925|NCT03927105|DRUG|cabiralizumab|Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
219347926|NCT03402607|PROCEDURE|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
219347927|NCT03402607|RADIATION|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
219347928|NCT01657409|DRUG|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
219347929|NCT01657409|DRUG|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
219347930|NCT01657409|DRUG|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
219347931|NCT06268691|OTHER|Insecticide Coating INESFLY|The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
219347932|NCT05941598|DEVICE|Electroacupuncture|Participants in the electroacupuncture group will receive electroacupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
219347933|NCT05941598|DEVICE|Sham acupuncture|Participants in the sham acupuncture group will receive minimal acupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
219347934|NCT01378312|BIOLOGICAL|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
219347935|NCT01378312|BIOLOGICAL|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
219347936|NCT05748093|DRUG|Cobicistat|Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
219347937|NCT05931146|OTHER|MyNetDiary app group|MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
219347938|NCT05931146|OTHER|Paper diary group|Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
219347939|NCT01768455|DRUG|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
219347940|NCT01768455|DRUG|Glimepiride|Glimepiride 4mg (qd) on Day1
219347941|NCT06100341|OTHER|Virtual reality|A role-playing game set in a spaceship in outer space where a user will need to accomplish three activities to complete the game. These activities were designed based on typical therapy goals for children with cerebral palsy of improving balance, gross motor performance, walking speed, and functional mobility.
219347942|NCT04623476|PROCEDURE|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
219347943|NCT03470493|DIAGNOSTIC_TEST|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
219347944|NCT01745146|BEHAVIORAL|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
219347945|NCT01745146|BEHAVIORAL|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
219347946|NCT04816812|BEHAVIORAL|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
219347947|NCT04816812|BEHAVIORAL|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
219347948|NCT02289183|PROCEDURE|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
219347949|NCT02289183|PROCEDURE|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
219347950|NCT02510768|DEVICE|ELAPR002f|Intradermal implant
219347951|NCT02510768|DEVICE|ELAPR002g|Intradermal implant
219347952|NCT02510768|DEVICE|Saline|Intradermal implant
219347953|NCT04660162|DEVICE|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
219347954|NCT04660162|OTHER|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
219347955|NCT00316563|DRUG|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
219347956|NCT00316563|OTHER|Placebo|
219347957|NCT05655338|DEVICE|antimicrobial photodynamic therapy|
219347958|NCT05655338|DRUG|systemic antibiotics|
219347959|NCT05493020|OTHER|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
219347960|NCT01858181|BIOLOGICAL|ocaratuzumab|
219347961|NCT02454166|OTHER|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
219347962|NCT02454166|OTHER|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
219347963|NCT02346760|DRUG|UB-621|100 mg/ml, subcutaneous injection
219347964|NCT05594173|OTHER|Food texture modification|Food prepared in three different consistencies: minced and moist, soft and bite-sized and regular, as defined by the International Dysphagia Diet Standardisation Initiative
219347965|NCT00647556|DRUG|adapalene gel, 0.3%|applied topically once daily in the evening
219347966|NCT00647556|DRUG|tretinoin 0.05% emollient cream|applied topically once daily in the evening
219347967|NCT00369187|DRUG|large protein molecule|
219347968|NCT05319392|DIAGNOSTIC_TEST|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
219347969|NCT05403983|BEHAVIORAL|Yoga movement intervention|Mixture of yoga, tai chi, pilates. Will be delivered in person (experimental) and online (active comparator)
219347970|NCT05403983|OTHER|Education booklet|Recently published postpartum physical activity guidebook through the Sport Information Resource Center of Canada
219347971|NCT04834531|DRUG|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
219347972|NCT04834531|DRUG|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
219347973|NCT04834531|OTHER|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
219347974|NCT01480297|DRUG|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
219347975|NCT03126760|DRUG|Acthar Gel|Acthar Gel 1 mL (80U) for subcutaneous injection
219347976|NCT03126760|DRUG|Placebo|Placebo for subcutaneous injection
219347977|NCT06550154|OTHER|Data collection|Participants were identified by reviewing electronic medical records. Medical history information of thyroid disease and associated medication were collected in both groups, as well as a history of other comorbidities such as diabetes mellitus type 2, arterial hypertension, dyslipidemia, anxiety, and depression. Cases and controls were matched by age and sex.
219347978|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension/Tamiflu|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
219347979|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
219347980|NCT01334034|DRUG|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
219347981|NCT01334034|DRUG|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
219347982|NCT01334034|DRUG|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
219347983|NCT05744999|PROCEDURE|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
219347984|NCT03538509|OTHER|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
219347985|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
219347986|NCT03714945|OTHER|No intervention|No intervention is required as this study is observational.
219347987|NCT02823977|DRUG|Ketamine|Blinded study drug administered to experimental arm
219347988|NCT02823977|DRUG|Dexmedetomidine|Open-label study drug administered to both arms
219347989|NCT02823977|DRUG|Normal saline|Blinded comparator administered to control arm
219347990|NCT06786520|DRUG|CAB LA|CAB LA injection will be administered
219347991|NCT06786520|DRUG|CAB ULA|CAB ULA injection will be administered
219347992|NCT00999414|DRUG|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
219347993|NCT01877187|DRUG|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
219347994|NCT04711707|OTHER|Community navigator|All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.
219347995|NCT04711707|OTHER|Self-Navigation|The control group will receive an electronic or paper copy of community resources that address the identified social needs.
219347996|NCT01489839|OTHER|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
219347997|NCT04141709|RADIATION|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~* Scheme A 3\*10 Gy (once a day, 2-3 days a week)~* Scheme B 25\*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3\*10 Gy or 25\*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
219347998|NCT04788355|DRUG|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
219347999|NCT04788355|DRUG|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
219348000|NCT04788355|DRUG|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
219348001|NCT04788355|DRUG|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
219348002|NCT05291494|BEHAVIORAL|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
219348003|NCT05291494|BEHAVIORAL|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
219348004|NCT03232476|DEVICE|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
219348005|NCT04457427|DEVICE|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
219348006|NCT04682080|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
219348007|NCT04407559|OTHER|Serological analyses to be lead on a pre-existing biobank|"3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~* WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~* Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~* Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime."
219348008|NCT00003338|PROCEDURE|immunoscintigraphy|
219348009|NCT00003338|RADIATION|technetium Tc 99m epratuzumab|
219348010|NCT04473456|PROCEDURE|Simultaneous EGD and colonoscopy|Patients are examined simultaneously by EGD and colonoscopy
219348011|NCT00589446|DEVICE|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
219348012|NCT03372031|BEHAVIORAL|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
219348013|NCT03372031|BEHAVIORAL|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
219348014|NCT04804254|DRUG|ABBV-623|Oral Tablets
219348015|NCT04804254|DRUG|ABBV-992|Oral Tablets
219348016|NCT06187376|DRUG|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
219348017|NCT06187376|DRUG|Placebo|Matching placebo tincture.
219348018|NCT03393273|DRUG|Elotuzumab|"* Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
219348019|NCT00923390|GENETIC|2G-1 TCR Retroviral Vector-Transduced lyn|
219348020|NCT00923390|DRUG|Aldesleukin|
219348021|NCT00923390|DRUG|Cyclophosphamide|
219348022|NCT00923390|DRUG|Fludarabine|
219348023|NCT00923390|DRUG|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
219348024|NCT00006130|PROCEDURE|Core decompression|
219348025|NCT05972811|OTHER|Cold application|In the experimental group, cold application will be made until the skin temperature of the drain exit area reaches 13.6 °C. And before drain removal, immediately after drain removal and 15 minutes later, pain levels will be measured with VAS and analgesic needs will be questioned
219348026|NCT01068171|OTHER|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
219348027|NCT01068171|OTHER|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
219348028|NCT05362409|DRUG|5 Aminolevulinic Acid|5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
219348029|NCT05362409|DEVICE|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
219348030|NCT03102905|OTHER|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
219348031|NCT01641614|PROCEDURE|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
219348032|NCT01641614|PROCEDURE|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
219348033|NCT03548558|BEHAVIORAL|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
219348034|NCT03548558|BEHAVIORAL|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
219348035|NCT03548558|BEHAVIORAL|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
219348036|NCT03548558|BEHAVIORAL|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
219348037|NCT02350270|OTHER|gait and cognitive testing|
219348038|NCT03584867|OTHER|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
219348039|NCT04491656|OTHER|WALANT Technique|A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
219348040|NCT03756038|DRUG|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
219348041|NCT03756038|DRUG|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
219348042|NCT03431571|PROCEDURE|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
219348043|NCT05449678|BEHAVIORAL|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
219348044|NCT00413361|DRUG|versus hydroxychloroquine|versus hydroxychloroquine
219348045|NCT05526833|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
219348046|NCT01789814|DRUG|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
219348047|NCT01789814|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
219348048|NCT01090401|DEVICE|Linox smart S DX|ICD lead
219348049|NCT03273166|DEVICE|INVSENSOR00001|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
219348050|NCT03273166|DEVICE|Control SpHb sensor|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
219348051|NCT03273166|PROCEDURE|Hemodilution|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
219348052|NCT01317589|DRUG|fentanyl|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
219348053|NCT01317589|DRUG|methadone|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
219348054|NCT04329195|DRUG|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
219348055|NCT04329195|DRUG|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
219348056|NCT01898182|OTHER|Kinetin, N6-furfuryladenine, 0.1%|
219348057|NCT02669017|DRUG|ADCT-402|intravenous infusion
219348058|NCT01289015|DRUG|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
219348059|NCT01289015|DRUG|Placebo|Topical; applied once daily for two weeks
219348060|NCT06639984|DRUG|Psyllium (0.7 g/year of age per day)|Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
219348061|NCT06639984|DRUG|Psyllium (0.5 g/year of age per day)|Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
219348062|NCT06639984|DRUG|Placebo|Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
219348063|NCT06639984|OTHER|fructans|Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
219348064|NCT03382795|DRUG|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
219348065|NCT00428974|DRUG|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
219348066|NCT00428974|DRUG|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
219348067|NCT00428974|DRUG|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
219348068|NCT00428974|DRUG|Placebo|Placebo tablets q12 hours for 12 weeks
219348069|NCT04775329|DRUG|Rifaximin|Rifaximin 1000mg OM
219348070|NCT01714427|DRUG|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
219348071|NCT01714427|DRUG|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
219348072|NCT01217632|DRUG|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
219348073|NCT01217632|DRUG|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
219348074|NCT01217632|DRUG|Entecavir|
219348075|NCT04089007|DEVICE|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
219348076|NCT04089007|OTHER|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
219348077|NCT01857661|DEVICE|sound generator|hearing aid with an integrated sound generator
219348078|NCT01857661|DEVICE|hearing aids with only amplification|
219348079|NCT01175109|DRUG|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
219348080|NCT05506189|OTHER|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
219348081|NCT06279156|DEVICE|Bioelectrical Impedance Analysis (BIA)|"Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition."
219348082|NCT04807907|BEHAVIORAL|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
219348083|NCT02277509|BEHAVIORAL|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
219348084|NCT02277509|BEHAVIORAL|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
219348085|NCT03509350|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
219348086|NCT03509350|DRUG|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
219348087|NCT03509350|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
219348088|NCT03509350|DRUG|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
219348089|NCT03509350|DRUG|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
219348090|NCT03509350|DRUG|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
219348091|NCT04338815|OTHER|Exoskeleton Optimization|Participants will walk 10-minute trials while an optimization algorithm changes the assistance profile of the exoskeleton.
219348092|NCT04338815|OTHER|Endurance Evaluation|Participants will walk 2 trials at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes, which ever comes first.
219348093|NCT05773196|OTHER|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~* 10 mL EDTA Vial (Box 1; Frozen)~  o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~* 10 mL EDTA Vial (Box 2; Ambient)~  * Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
219348094|NCT01425203|DRUG|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
219348095|NCT01425203|DRUG|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
219348096|NCT01425203|BIOLOGICAL|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
219348097|NCT01425203|DRUG|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
219348098|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
219348099|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
219348100|NCT03700307|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
219348101|NCT00261430|BEHAVIORAL|GAIN Acceptance Approach|
219348102|NCT00006121|DRUG|oxaliplatin|
219348103|NCT01456676|DRUG|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
219348104|NCT01780025|BEHAVIORAL|Auditory evoked potentials and audiometry|
219348105|NCT01780025|BEHAVIORAL|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
219348106|NCT04674592|OTHER|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
219348107|NCT01109888|DRUG|Cetrotide|
219348108|NCT00662103|BEHAVIORAL|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
219348109|NCT00662103|OTHER|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health \& Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
219348110|NCT00662103|OTHER|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
219348111|NCT00662103|OTHER|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
219348112|NCT00662103|PROCEDURE|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
219348113|NCT00662103|PROCEDURE|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
219348114|NCT00662103|PROCEDURE|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
219348115|NCT00662103|PROCEDURE|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
219348116|NCT05667714|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
219348117|NCT05667714|DRUG|Placebo|Placebo was provided by Sinovac Life Sciences Co. , Ltd.
219348118|NCT02567890|BEHAVIORAL|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
219348119|NCT02567890|BEHAVIORAL|Expressive writing|Participants will be asked to reflect upon issues related to body image.
219348120|NCT05269758|BEHAVIORAL|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
219348121|NCT05865236|PROCEDURE|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
219348122|NCT05865236|PROCEDURE|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
219348123|NCT00015977|BIOLOGICAL|PSA prostate cancer vaccine|
219348124|NCT00015977|BIOLOGICAL|recombinant interleukin-12|
219348125|NCT01050270|DRUG|Ondansetron|4mgs iv bolus
219348126|NCT01050270|DRUG|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
219348127|NCT01050270|DRUG|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
219348128|NCT00813423|DRUG|Hydroxychloroquine|Given PO
219348129|NCT00813423|OTHER|Laboratory Biomarker Analysis|Correlative studies
219348130|NCT00813423|OTHER|Pharmacological Study|Correlative studies
219348131|NCT00813423|DRUG|Sunitinib Malate|Given PO
219348132|NCT01751308|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
219348133|NCT00181181|DRUG|atorvastatin|Atorvastatin 80 mg daily for 3 months
219348134|NCT00181181|OTHER|placebo|placebo daily
219348135|NCT03938805|BEHAVIORAL|Internet-based cognitive behavioral therapy for insomnia|Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
219348136|NCT03938805|OTHER|Control group|Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
219348137|NCT01960621|DRUG|cyclodextrin|intravenous
219348138|NCT04993365|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
219348139|NCT04993365|BIOLOGICAL|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
219348140|NCT03330886|DRUG|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
219348141|NCT04995393|PROCEDURE|Heating with a disposable glove containing water|Heating of the infants heel with a glove before blood sampling.
219348142|NCT04995393|PROCEDURE|Heating with a blanket|Heating of the infants heel with a blanket before blood sampling.
219348143|NCT04995393|PROCEDURE|Heating with a gel pack|Heating of the infants heel with a gel pack before blood sampling.
219348144|NCT02585011|DRUG|Ropivacaine|
219348145|NCT02585011|DRUG|Epinephrine|
219348146|NCT02585011|DRUG|Saline|
219348147|NCT06437678|DRUG|Liposomal Irinotecan Hydrochloride|Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
219348148|NCT06339879|OTHER|High Whole Grain, Low Sugar|6 servings of whole grain and \<13% energy from added sugars.
219348149|NCT06339879|OTHER|Low Whole Grain, Low Sugar|3 servings of whole grain and \<13% energy from added sugars.
219348150|NCT06339879|OTHER|High Whole Grain, High Sugar|6 servings of whole grain and \>13% energy from added sugars.
219348151|NCT06339879|OTHER|Low Whole Grain, High Sugar|3 servings of whole grain and \>13% energy from added sugars.
219348152|NCT03534700|PROCEDURE|parasacral flap reconstruction|parasacral flap reconstruction
219348153|NCT03534700|PROCEDURE|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
219348154|NCT02355782|BIOLOGICAL|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
219348155|NCT00209378|OTHER|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
219348156|NCT00209378|OTHER|HfCitPre|regional anticoagulation with citrate containing replacement solution
219348157|NCT00938756|OTHER|diagnostic laboratory biomarker analysis|
219348158|NCT00938756|OTHER|immunoenzyme technique|
219348159|NCT00938756|PROCEDURE|magnetic resonance imaging|
219348160|NCT03177083|DRUG|peginterferon beta-1a|SC every 2 weeks
219348161|NCT03177083|DRUG|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
219348162|NCT03177083|DRUG|interferon beta-1b|Per SMPC
219348163|NCT03865693|DEVICE|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
219348164|NCT02925130|DRUG|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
219348165|NCT02925130|DRUG|Placebo|Acute oral intake of a placebo drug
219348166|NCT00382993|DRUG|Placebo|Matching placebo tablet
219348167|NCT00382993|DRUG|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
219348168|NCT05872776|DEVICE|Neuromodulation with RR2 device|non-invasive neuromodulation with RR2 device
219348169|NCT05872776|DEVICE|Mock sham neuromodulation with sham RR2 device|Mock sham stimulation with RR2 device
219348170|NCT01052311|DRUG|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
219348171|NCT01052311|DRUG|Placebo|Placebo tablets once daily
219348172|NCT01052311|DRUG|Tredaptive|Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
219348173|NCT02826109|DEVICE|PeriAcryl®90 HV|
219348174|NCT06131879|DEVICE|Laser acupuncture|Biostimulation of temporalis and masseter muscles
219348175|NCT06131879|BEHAVIORAL|Modified physical therapy|Progressive muscle relaxation of temporalis and masseter muscles
219348176|NCT00252707|DRUG|Gefitinib or Docetaxel|
219348177|NCT05956106|DIETARY_SUPPLEMENT|Black Mulberry Fruit Powder|Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
219348178|NCT01785212|DEVICE|Stapler|stapler hepatectomy
219348179|NCT01785212|DEVICE|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
219348180|NCT00491348|DRUG|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
219348181|NCT03837470|DRUG|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
219348182|NCT03837470|DRUG|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
219348183|NCT05892809|OTHER|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
219348184|NCT01957358|BEHAVIORAL|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
219348185|NCT02898259|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
219348186|NCT02898259|DRUG|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~* Starting lenalidomide Dose (20mg)~* Calculated Creatinine Clearance: \>=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~* Calculated Creatinine Clearance: \>= 30 and \< 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
219348187|NCT02898259|DRUG|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
219348188|NCT01856881|DRUG|AMG 876|Ascending multiple doses of study drug administered SC
219348189|NCT03442634|OTHER|Early Hydration|this group will start oral hydration within 1 hour after cesarean section
219348190|NCT03442634|OTHER|Traditional Oral Hydration|this group will start oral hydration 6 hours after cesarean section
219348191|NCT01225679|DEVICE|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
219348192|NCT03099889|BEHAVIORAL|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
219348193|NCT01796327|DRUG|dacomitinib oral|Dacomitinib 45 mg oral tablet
219348194|NCT01796327|DRUG|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
219348195|NCT01046877|DEVICE|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
219348196|NCT00084201|DRUG|Cranberry juice|
219348197|NCT00084201|DRUG|Amoxicillin|
219348198|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem \& Delta-TT cup with a polyethylene insert
219348199|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert
219348200|NCT03093038|DEVICE|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
219348201|NCT01108146|DRUG|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
219348202|NCT01108146|DRUG|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
219348203|NCT03869528|DRUG|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
219348204|NCT03869528|DRUG|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
219348205|NCT01888042|DRUG|Everolimus|10 mg (1 tablet of 10 mg)
219348206|NCT00712699|DRUG|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
219348207|NCT00712699|DRUG|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
219348208|NCT03836391|BEHAVIORAL|Nudge|Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
219348209|NCT01040559|DRUG|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
219348210|NCT01323426|PROCEDURE|Periurethral injection|Periurethral injection of autologous muscle fibers
219348211|NCT03016325|DRUG|HNO Donor|Infusion
219348212|NCT03016325|DRUG|Placebo|Infusion
219348213|NCT04162574|OTHER|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
219348214|NCT00814775|DEVICE|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
219348215|NCT00814775|DEVICE|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
219348216|NCT06475833|DIAGNOSTIC_TEST|Prone plank test, Side plank test, The Awareness of Sports Injuries Scales|"Prone Plank Test: For the prone bridge test, athletes will position themselves in a plank position with their elbows shoulder-width apart and directly under their shoulders. Using a stopwatch, the duration for which they can maintain this position without breaking form will be recorded.~Side Plank Tests: For the side bridge test, athletes will position themselves in a side plank position, ensuring that the shoulder is directly above the elbow. The duration for which they can maintain this position will be recorded using a stopwatch.~The Injury Prevention Awareness Scale for Athletes will be used to evaluate athletes' awareness and attitudes towards preventing sports injuries. A high score indicates a good level of awareness of injury prevention in sports."
219348217|NCT00599482|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
219348218|NCT01003496|BEHAVIORAL|Treatment as Usual (TAU)|Outpatient substance abuse treatment
219348219|NCT01003496|BEHAVIORAL|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
219348220|NCT03711500|DRUG|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
219348221|NCT03711500|DRUG|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
219348222|NCT01310894|DRUG|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
219348223|NCT01902290|BIOLOGICAL|Placebo|Placebo administered subcutaneously
219348224|NCT01902290|BIOLOGICAL|Brodalumab|Brodalumab administered subcutaneously
219348225|NCT03043248|DRUG|TRK-700|repeated oral administration
219348226|NCT03043248|DRUG|Digoxin|single oral administration with/without TRK-700
219348227|NCT03043248|DRUG|Midazolam|single oral administration with/without TRK-700
219348228|NCT02666573|DEVICE|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
219348229|NCT02666573|OTHER|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
219348230|NCT02486055|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
219348231|NCT00805831|DEVICE|HDH|sutureless vascular anastomosis
219348232|NCT00505999|BEHAVIORAL|Questionnaire|Questionnaire taking 30-40 minutes to complete.
219348233|NCT03042715|BEHAVIORAL|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
219348234|NCT00001288|DRUG|15 O Water|
219348235|NCT00001288|DRUG|FDG|
219348236|NCT04807348|DRUG|Chiglitazar 32mg|Administrated once daily
219348237|NCT04807348|DRUG|Chiglitazar 48mg|Administrated once daily
219348238|NCT04807348|DRUG|Placebo|Placebo of Chiglitazar
219348239|NCT04807348|DRUG|Metformin Hydrochloride|most tolerable dose
219348240|NCT02250274|BIOLOGICAL|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
219348241|NCT02250274|BIOLOGICAL|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]"
219348242|NCT02556398|BEHAVIORAL|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
219348243|NCT01277549|DEVICE|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
219348244|NCT03166293|BEHAVIORAL|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
219348245|NCT04395911|DEVICE|SCD|cytopheretic device
219348246|NCT03344302|DRUG|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
219348247|NCT00446511|DRUG|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
219348248|NCT00446511|DRUG|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
219348249|NCT00446511|DRUG|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
219348250|NCT00446511|DRUG|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
219348251|NCT01618214|DRUG|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
219348252|NCT01312935|DRUG|PMX-60056|investigational drug
219348253|NCT03245931|OTHER|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
219348254|NCT01617980|OTHER|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
219348255|NCT02204696|PROCEDURE|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
219348256|NCT02756507|BEHAVIORAL|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
219348257|NCT02756507|BEHAVIORAL|Wait list|Delayed intervention
219348258|NCT03106038|DRUG|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
219348259|NCT04744337|PROCEDURE|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
219348260|NCT00870402|DRUG|Spironolactone|25 mg per day for 9 months
219348261|NCT00870402|DRUG|Placebo|Placebo 1 tablet per day for nine months
219348262|NCT04170322|DEVICE|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
219348263|NCT04170322|DEVICE|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
219348264|NCT01890642|DEVICE|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
219348265|NCT01890642|OTHER|Pain Ease Spray|Cold Spray used to anesthetize the skin
219348266|NCT01890642|DRUG|1% buffered lidocaine|Lidocaine placed using Jet Injection
219348267|NCT01890642|OTHER|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
219348268|NCT01890642|OTHER|Sucrose|Oral Sucrose used for children \< 1 year
219348269|NCT03383484|OTHER|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
219348270|NCT03383484|OTHER|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
219348271|NCT02599701|DRUG|Gabapentin|A single dose Gabapentin 300mg at bedtime.
219348272|NCT02599701|DRUG|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
219348273|NCT02175732|BEHAVIORAL|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
219348274|NCT02175732|BEHAVIORAL|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
219348275|NCT02813278|DIETARY_SUPPLEMENT|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
219348276|NCT02813278|OTHER|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
219348277|NCT00407524|DRUG|AKL 1|
219348278|NCT00579852|PROCEDURE|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
219348279|NCT01083303|BEHAVIORAL|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
219348280|NCT01582425|DRUG|Isavuconazole|oral
219348281|NCT01582425|DRUG|Methadone|oral
219348282|NCT03269045|DRUG|ORL-1B|Oral ORL-1B
219348283|NCT04703075|DRUG|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
219348284|NCT04703075|DRUG|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
219348285|NCT05622526|DRUG|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
219348286|NCT05622526|OTHER|Group 2 or Control group|capsules of placebo
219348287|NCT04423497|OTHER|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
219348288|NCT00050609|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
219348289|NCT00050609|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
219348290|NCT00050609|DRUG|placebo|Placebo tablet taken by mouth once a day for 8 weeks
219348291|NCT02247323|OTHER|Risk of malignancy index|Calculation of RMI before sugery.
219348292|NCT04462094|DRUG|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
219348293|NCT04462094|DRUG|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
219348294|NCT03124771|DEVICE|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
219348295|NCT01508702|DRUG|lesinurad|Tablets, 400 mg QD
219348296|NCT01508702|DRUG|Placebo|Tablets, Placebo QD
219348297|NCT04632758|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, QD
219348298|NCT04632758|DRUG|crizotinib|Capsules, 250mg, BID
219348299|NCT03991689|BEHAVIORAL|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
219348300|NCT05482685|BEHAVIORAL|Questionnaire|Conduct a 10-minute survey
219348301|NCT00684255|PROCEDURE|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
219348302|NCT00684255|DRUG|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
219348303|NCT00684255|DRUG|Busulfan|Busulfan 3.2 mg/kg Days \_8, -7, -6, -5
219348304|NCT00684255|DRUG|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
219348305|NCT03402529|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammography|Pilot study
219348306|NCT03847129|OTHER|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
219348307|NCT03847129|OTHER|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
219348308|NCT02572752|DRUG|Nintedanib|1 soft gelatine capsule, single dose, oral
219348309|NCT02572752|DRUG|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
219348310|NCT02572752|DRUG|Nintedanib|
219348311|NCT01648127|DRUG|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
219348312|NCT05480748|DEVICE|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
219348313|NCT04253795|OTHER|Laryngeal mask|After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
219348314|NCT04253795|OTHER|double lumen tube|After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
219348315|NCT02152852|BEHAVIORAL|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
219348316|NCT04289844|OTHER|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
219348317|NCT04289844|OTHER|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
219348318|NCT00761514|DRUG|Humira (adalimumab)|40 mg eow
219348319|NCT01040455|DRUG|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
219348320|NCT01040455|DRUG|placebo|placebo once daily for eight weeks
219348321|NCT03937180|BEHAVIORAL|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
219348322|NCT03937180|BEHAVIORAL|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
219348323|NCT02955615|DRUG|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
219348324|NCT02955615|DRUG|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
219348325|NCT04195152|OTHER|Observational|No intervention
219348326|NCT01505569|DRUG|Ifosfamide|"* Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
219348327|NCT01505569|DRUG|Etoposide|"* Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age \>36 mos.) approx. hour 75 on days -5, -4, and -3"
219348328|NCT01505569|DRUG|Mesna|"* Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
219348329|NCT01505569|BIOLOGICAL|G-CSF|"* Arms A\&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (\>) 1,000/mm\^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3~* Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~* Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~* Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference"
219348330|NCT01505569|DRUG|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
219348331|NCT01505569|DRUG|Melphalan|Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
219348332|NCT01505569|DRUG|Thiotepa|Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age \>36 mos.) approx. hour 72 on days -5, -4, and -3
219348333|NCT01505569|BIOLOGICAL|Autologous stem cell infusion|"Arms A, B \& C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard."
219348334|NCT01505569|RADIATION|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
219348335|NCT01505569|DRUG|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
219348336|NCT01505569|DRUG|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
219348337|NCT01505569|PROCEDURE|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
219348338|NCT01505569|DRUG|Anti-seizure prophylaxis|"Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg."
219348339|NCT01505569|DRUG|Ursodiol|Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
219348340|NCT02902952|BEHAVIORAL|Physical Exercise|An eight week physical exercise intervention
219348341|NCT02902952|BEHAVIORAL|Control Intervention|An eight week sedentary control intervention
219348342|NCT04840043|OTHER|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
219348343|NCT04840043|OTHER|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
219348344|NCT01836783|OTHER|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
219348345|NCT01836783|OTHER|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
219348346|NCT00853671|OTHER|Adenosine Stress Dual-source CTP|"Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure."
219348347|NCT01966133|DRUG|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
219348348|NCT02565979|DIETARY_SUPPLEMENT|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
219348349|NCT02565979|DIETARY_SUPPLEMENT|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
219348350|NCT04845828|PROCEDURE|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3\. Sentinel lymph node is excised"
219348351|NCT04845828|PROCEDURE|Routine lymph node dissection|"1. Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~2. Lymph node detection is performed."
219348352|NCT05805722|BEHAVIORAL|Behavioral counseling for tobacco cessation|"Participants can choose to receive behavioral counseling in group v. individual format:~Group Sessions: Participants will be offered the opportunity to attend 6 weekly 60-90 minute sessions Individual Sessions: Participants will be offered the opportunity to attend up to 12 30-45 minute sessions on a schedule mutually agreed upon between interventionist and participant"
219348353|NCT06584929|DRUG|Nicoderm CQ nicotine patch|Two week supply provided to participants on study.
219348354|NCT06584929|DRUG|Nicorette Nicotine Lozenges|Two week supply provided to participants on study.
219348355|NCT01803243|OTHER|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
219348356|NCT01803243|OTHER|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
219348357|NCT01803243|OTHER|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
219348358|NCT00005870|DRUG|fluorouracil|
219348359|NCT00005870|DRUG|gemcitabine hydrochloride|
219348360|NCT00005870|DRUG|mitomycin C|
219348361|NCT00005870|DRUG|rubitecan|
219348362|NCT02852512|PROCEDURE|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
219348363|NCT05021783|DIAGNOSTIC_TEST|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
219348364|NCT05021783|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
219348365|NCT05021783|OTHER|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
219348366|NCT05021783|DIAGNOSTIC_TEST|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
219348367|NCT05021783|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
219348368|NCT04978207|BEHAVIORAL|A Faithful Response to COVID-19|See previous description
219348369|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
219348370|NCT03441178|DEVICE|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
219348371|NCT02328430|DEVICE|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
219348372|NCT04358835|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio enteral ketogenic formula within 48 hours of intubation
219348373|NCT04358835|OTHER|standard of care|standard of care/supportive therapy
219348374|NCT01988610|DRUG|28 days treatment with Mifepristone.|
219348375|NCT02931058|OTHER|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
219348376|NCT02931058|OTHER|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
219348377|NCT02931058|OTHER|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
219348378|NCT00642915|DRUG|Lantus, Amaryl|
219348379|NCT01665183|DRUG|ADI-PEG 20|
219348380|NCT04875546|BEHAVIORAL|Standard treatment|Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
219348381|NCT04875546|BEHAVIORAL|Integrated Intervention|In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
219348382|NCT04875546|OTHER|Control|The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
219348383|NCT01056146|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
219348384|NCT01056146|BEHAVIORAL|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
219348385|NCT06241040|OTHER|Aerobic Exercises with core Muscle strengthening|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
219348386|NCT06241040|OTHER|Aerobic Exercise without Core Muscle Strengthening|Aerobic Exercise without Core Muscle Strengthening
219348387|NCT01452399|PROCEDURE|Shave margins|Partial mastectomy with shave margins.
219348388|NCT01452399|PROCEDURE|No Shave Margins|Partial mastectomy without shave margins.
219348389|NCT01107431|DIETARY_SUPPLEMENT|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
219348390|NCT01107431|DIETARY_SUPPLEMENT|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
219348391|NCT03070847|DRUG|Tranexamic Acid|Dose: 5mg/kg
219348392|NCT03070847|DRUG|Tranexamic Acid|Dose: 10mg/kg
219348393|NCT03070847|DRUG|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
219348394|NCT00385632|DRUG|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
219348395|NCT04756505|DRUG|Bintrafusp Alfa|Given IV
219348396|NCT04756505|BIOLOGICAL|Immunocytokine NHS-IL12|Given SC
219348397|NCT04756505|RADIATION|Radiation Therapy|Undergo radiation therapy
219348398|NCT05817877|OTHER|phone use|There is no intervention.
219348399|NCT05673551|OTHER|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
219348400|NCT01698164|DRUG|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
219348401|NCT01698164|DRUG|Ximingting Tablet|Participants are given phytoestrogen.
219348402|NCT01698164|DRUG|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
219348403|NCT02124564|DRUG|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
219348404|NCT01647971|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
219348405|NCT01317433|DRUG|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
219348406|NCT01317433|DRUG|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
219348407|NCT03885089|DRUG|Infliximab [infliximab biosimilar 3]|\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
219348408|NCT05367817|OTHER|Neuromuscular exercise therapy|Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
219348409|NCT05367817|OTHER|Training program|Participants perform range of motion exercises for the wrist.
219348410|NCT06975891|DRUG|Systane PRO|Lubricating Eyedrops
219348411|NCT06975891|DRUG|Refresh Optive MEGA-3|Lubricating Eyedrops
219348412|NCT01383577|PROCEDURE|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
219348413|NCT01383577|PROCEDURE|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
219348414|NCT05062863|DEVICE|T3 dental implant system|This clinical study will evaluate patients being treated with the T3 dental implant to confirm its safety and performance (effect of treatment of edentulism). The patients treated will experience a benefit from treatment of edentulism with the T3 dental implant system. The patients will be followed prospectively from the time of exposure (dental implant placement surgery) to outcome (implant survival at 2 years).
219348415|NCT01518218|BEHAVIORAL|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
219348416|NCT03834415|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10\>8 CFU
219348417|NCT03834415|OTHER|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
219348418|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
219348419|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
219348420|NCT04703673|DRUG|Cineole|self administration according to directions for use
219348421|NCT04703673|DRUG|Nasal Decongestant|self administration according to directions for use
219348422|NCT04571216|DRUG|NFL-101 dose 1|Subcutaneous injections
219348423|NCT04571216|DRUG|NFL-101 dose 2|Subcutaneous injections
219348424|NCT04571216|DRUG|Placebo|Subcutaneous injections
219348425|NCT04378816|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
219348426|NCT03050242|DRUG|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
219348427|NCT00507559|DEVICE|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
219348428|NCT04986397|DEVICE|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
219348429|NCT04986397|OTHER|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
219348430|NCT04132791|OTHER|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
219348431|NCT04132791|OTHER|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
219348432|NCT05146921|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
219348433|NCT05146921|OTHER|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
219348434|NCT05863104|DRUG|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
219348435|NCT01952561|DRUG|dapivirine ring|
219348436|NCT02346032|DRUG|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
219348437|NCT00631748|DRUG|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
219348438|NCT00631748|DRUG|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
219348439|NCT00631748|BEHAVIORAL|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
219348440|NCT05914142|DEVICE|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
219348441|NCT05287945|DRUG|Orellanine|Orellanine administered intravenously
219348442|NCT05685875|OTHER|diabetes|Diabetes and metabolic syndrome defined using criteria by IDF. Obesity defined as BMI\>=30
219348443|NCT00400881|OTHER|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
219348444|NCT02528903|DRUG|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
219348445|NCT02528903|DRUG|Matching placebo|Single intravenous dose
219348446|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
219348447|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
219348448|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
219348449|NCT02100436|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
219348450|NCT02431351|DRUG|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
219348451|NCT02532894|DEVICE|Electronic cigarette|Inhaling e-cigarette vapor
219348452|NCT00863200|BEHAVIORAL|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
219348453|NCT00863200|BEHAVIORAL|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
219348454|NCT02292030|DRUG|HTEA|usually high thoracic epidural anesthesia
219348455|NCT05506176|DRUG|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
219348456|NCT05506176|DRUG|Placebo|Placebo (tablet)
219348457|NCT01481051|DRUG|Latanoprost-PPDS|Sustained delivery for 12 weeks
219348458|NCT01222455|DRUG|Fostamatinib|Oral tablets, single dose
219348459|NCT05437120|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
219348460|NCT04375202|DRUG|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
219348461|NCT03319485|DEVICE|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
219348462|NCT03319485|DEVICE|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
219348463|NCT00858858|DRUG|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
219348464|NCT03803462|OTHER|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
219348465|NCT06329037|DRUG|Vasopressin|Administration of Vasopressin (20 IU) (oral spray)
219348466|NCT06329037|DRUG|Placebo|Administration of Placebo (oral spray)
219348467|NCT04314856|DRUG|18F-FTC-146|18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
219348468|NCT01425008|DRUG|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
219348469|NCT03216473|DRUG|Neuronox|Clostridium Botulinum Toxin A 100 U
219348470|NCT03216473|DRUG|Botox|Clostridium Botulinum Toxin A 100 U
219348471|NCT02097914|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
219348472|NCT04770051|PROCEDURE|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
219348473|NCT05269485|RADIATION|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
219348474|NCT05269485|RADIATION|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
219348475|NCT00312988|DRUG|Hycamtin|
219348476|NCT00312988|DRUG|Gemcitabine|
219348477|NCT03718286|DRUG|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
219348478|NCT03718286|OTHER|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
219348479|NCT01808300|DRUG|Pregabalin 300mg, Thioctic acid 600mg|"* A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
219348480|NCT06061549|BIOLOGICAL|AAV1/SERCA2a|3E13 viral genomes fixed dose
219348481|NCT02706808|DIETARY_SUPPLEMENT|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
219348482|NCT02706808|DIETARY_SUPPLEMENT|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
219348483|NCT04468165|DRUG|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
219348484|NCT04368728|BIOLOGICAL|BNT162b1|Intramuscular injection
219348485|NCT04368728|BIOLOGICAL|BNT162b2|Intramuscular injection
219348486|NCT04368728|OTHER|Placebo|Intramuscular injection
219348487|NCT04368728|BIOLOGICAL|BNT162b2SA|Intramuscular injection
219348488|NCT05314205|PROCEDURE|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
219348489|NCT04069065|DRUG|Conversion to Once-daily Tacrolimus|"* Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml."
219348490|NCT00939900|DRUG|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
219348491|NCT03294031|OTHER|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
219348492|NCT03294031|OTHER|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
219348493|NCT05711290|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
219348494|NCT05711290|OTHER|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
219348495|NCT00805480|DRUG|AIN457|AIN457 was administered intravenously.
219348496|NCT00805480|DRUG|Placebo|Matching placebo to AIN457 was administered intravenously.
219348497|NCT01234272|DRUG|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
219348498|NCT01234272|DRUG|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
219348499|NCT05536765|PROCEDURE|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
219348500|NCT00865072|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
219348501|NCT00865072|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
219348502|NCT05580133|PROCEDURE|anterior cruciate ligament reconstruction|Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
219348503|NCT05026398|DRUG|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
219348504|NCT05026398|OTHER|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
219348505|NCT03544827|DRUG|Atropine|Atropine 0.01% then atropine 0.1%
219348506|NCT03544827|DRUG|Atropine|Atropine 0.1% then atropine 0.01%
219348507|NCT02295527|OTHER|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
219348508|NCT02295527|OTHER|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
219348509|NCT01430039|PROCEDURE|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
219348510|NCT01430039|PROCEDURE|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
219348511|NCT04091997|DIAGNOSTIC_TEST|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
219348512|NCT03156088|DEVICE|"Sacral Neuromodulator InterStim"|
219348513|NCT00105651|BEHAVIORAL|Combined nursing invention|
219348514|NCT06682468|BEHAVIORAL|Population level patient portal based substance involvement screening|Participants 18 years or older, with an active patient portal account, who have attended an HIV care clinic visit in the HIV clinic in the last two years and have not completed the validated National Institute for Drug Abuse (NIDA) Quick Screen V1.0 in the previous year will be eligible for intervention randomization. Those randomized into the intervention group will receive the validated NIDA Quick Screen V1.0 over their patient portal account. Participants randomized to this group can complete the screener over the patient portal without a scheduled appointment with their HIV clinician.
219348515|NCT06682468|BEHAVIORAL|Usual Care Substance Use Involvement Screening|Participants randomized to the usual care group will receive the validated NIDA Quick Screen V1.0 during routine in-clinic visits if they attend their scheduled visit. The medical assistant will ask participants to complete the NIDA Quick Screen V1.0. Participants who endorse the use of illegal drugs or prescription drugs for non-medical reasons, tobacco use, or heavy drinking will be referred to SUD treatment.
219348516|NCT06654414|BEHAVIORAL|PRIDE QUIT|"This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will likely receive 6-10 weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session."
219348517|NCT06654414|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|Brief counseling, the option of nicotine replacement therapy, and referral to the Quit Line.
219348518|NCT03798158|OTHER|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
219348519|NCT00562588|DRUG|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
219348520|NCT00562588|DRUG|ASA 100 mg qd|
219348521|NCT02191943|DEVICE|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
219348522|NCT02191943|DEVICE|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
219348523|NCT06594354|OTHER|ICE|"The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent. During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later. The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive chemotherapy, and to record their applications on the "
219348524|NCT00337870|BEHAVIORAL|PAT|Cognitive-Behavioral/Relaxation Intervention
219348525|NCT00698243|DRUG|OSI-027|Administered orally
219348526|NCT06126237|BIOLOGICAL|CM313 injection|CM313, subcutaneous injection
219348527|NCT00893321|PROCEDURE|Inferior Oblique Muscle Recession and Myectomy|
219348528|NCT00313209|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
219348529|NCT00313209|DRUG|Placebo|once daily
219348530|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
219348531|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
219348532|NCT00484653|PROCEDURE|cervical smear|biological analysis
219348533|NCT04434391|OTHER|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
219348534|NCT03828591|PROCEDURE|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
219348535|NCT03828591|PROCEDURE|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
219348536|NCT00163787|BEHAVIORAL|outcome measures and self report|
219348537|NCT06539923|OTHER|retrieving data|Data will be retrieved retrospectively
219348538|NCT01819051|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
219348539|NCT02997761|BIOLOGICAL|Blinatumomab|Given IV
219348540|NCT02997761|DRUG|Ibrutinib|Given PO
219348541|NCT02011659|DRUG|Ramosetron|
219348542|NCT04451356|DEVICE|Bioimpedance Spectroscopy|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device (BCM®Body Composition Monitor - Fresenius Medical Care D GmbH). The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. In addition, this analysis will provide the LTI and FTI for the included patients.
219348543|NCT04451356|DEVICE|Arterial Stiffness|Arterial stiffness assessment will be performed by applanation tonometry (SphygmoCorTM; PWV Inc., Westmead, Sydney, Australia) with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
219348544|NCT04451356|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic evaluations will be made in each patient at baseline. All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
219348545|NCT04451356|DIAGNOSTIC_TEST|Lung ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
219348546|NCT03701828|PROCEDURE|Weight loss surgery|All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
219348547|NCT04505098|DRUG|Icosapent ethyl|2 g by mouth twice daily for at least 6 months
219348548|NCT03784079|DRUG|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
219348549|NCT03784079|DRUG|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
219348550|NCT07003490|PROCEDURE|Radical Resection with Bilateral Lymph Node Dissection|The patient will be positioned in a contralateral decubitus position based on the location of the primary tumor, with the axillary region on the side of the primary tumor exposed. For example, if the patient is diagnosed with left-sided primary lung cancer with right-sided lymph node metastasis, investigators perform left axillary incision to resect the tumor. And then investigators change the patient's position to perform right axillary incision to resect the lymph nodes. Thoracoscopy surgery will be used to access and resect the primary lesion and lymph node metastasis.
219348551|NCT06459154|OTHER|Mixed Reality|The experimental group MR will use the mixed reality project involving activities in a supermarket. MR HoloLens2 glasses will be used to conduct the program. The technological equipment that will be used will allow the provision of visual and auditory stimuli. The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment. This program offers coordination activities, posture, cognitive activities and balance exercises. The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
219348552|NCT06459154|OTHER|Traditional Physiotherapy|The group of traditional physiotherapy follows the guidelines of EPDA. Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks. The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
219348553|NCT07009964|OTHER|ContextWell Educational Programme|ContextWell Educational Programme
219348554|NCT07016022|OTHER|CardioPulmonary Variability Assessment|The Preoperative CardioPulmonary Variability Assessment (CPVA) will assess baseline HRV \& RRV and the ability to tolerate mild physiologic stress. The assessment will involve a a Philips MP50 monitor that will collect continuous ECG (Lead II) and CO2-based respiratory waveform data with intermittent blood pressure (BP) measurements over a test of less than 60 minutes. We will measure the response to mild physiological stress which reflects adaptability, autonomic function and functional mobility by having the participant perform certain tasks such as sitting, standing, deep breathing, valsalva manoeuvres, and marching.
219348555|NCT04994951|DRUG|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
219348556|NCT04994951|DRUG|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
219348557|NCT07021079|DEVICE|Focal muscle vibration|focal muscle vibration sessions, using small and portable vibrator devices.
219348558|NCT07021079|DEVICE|NO Focal muscle vibration|The control group will not receive any intervention.
219348559|NCT07028944|OTHER|Gravity assisted stress|Patients have a post 7-10 day ankle fracture x-ray taken under gravity assisted stress
219348560|NCT07028944|OTHER|Manual external rotation stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual external rotation stress
219348561|NCT07028944|OTHER|Weight-bearing stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual weigh-bearing stress
219348562|NCT07030101|DRUG|TCA108|TCA108
219348563|NCT07030101|DRUG|Bramicar HCT|Bramicar HCT
219348564|NCT07029984|OTHER|Baylor Continence Scale|This study may be one of the first to test the Turkish adaptation and validity of the scale in Turkish children with anorectal malformations.
219348565|NCT07028502|PROCEDURE|J Wire|The movement of the puncture needle was monitored using intracardiac echocardiography rather than fluoroscopy. All other steps followed the conventional approach.
219348566|NCT07028502|PROCEDURE|3D mapping system|Guided by the ablation catheter image on the 3D mapping system, the long sheath was advanced to the puncture site and then exchanged for a puncture needle. The entire procedure was monitored with intracardiac echocardiography.
219348567|NCT07029087|PROCEDURE|Pudendal Nerve Block|Pudendal nerve blocks are often preferred as an initial diagnostic and therapeutic method for chronic pelvic pain caused by pudendal neuralgia due to nerve entrapment. Additionally, the pudendal nerve block is a widely used regional anesthesia technique in gynecologic, obstetric, and anorectal procedures . It is particularly applied to provide perineal anesthesia during the second stage of vaginal delivery, vaginal repairs, and obstetric procedures including anorectal surgeries such as hemorrhoidectomy . Pudendal nerve blocks can effectively anesthetize the posterior perineum, anus, lower vagina, vulva/scrotum, and penis.
219348568|NCT07028606|PROCEDURE|Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft.~Osteotomy for implant will be carried out with advanced kit of roott\_system Switzerland brand, sandwich osteotomy technique will be carried out with three full thickness cuts using the tungsten carbide disc were performed in the form of two vertical cuts away from the neighboring teeth by 3 mm and one horizontal bony cut on the labial surface of alveolar ridge. Bone splitting chisels were used in sequential width (2 mm, 3 mm) and lightweight mallet to complete splitting of the bony segment, the surgical sites will be irrigated with sterile saline. Surgical flaps will be sutured to the pre-surgical level."
219348569|NCT07028606|BIOLOGICAL|Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft with and with RGD.~Injectable RGD-bioconjugate Mussel Adhesive Proteins (RGD-MAPs) composite hydroxypropyl methylcellulose (HPMC) hydrogels . Previously we developed a novel type of injectable self-supported hydrogel (2 mg/ml of RGD-MAPs/HPMC) based porcine nano hydroxyapatite (MPH) for dental graft, which could good handling property, biodegradation or biocompatibility with the hydrogel disassembly and provided efficient cell adhesion activity and no inflammatory responses. Surgical flaps will be sutured to the pre-surgical level with 4-0 polyproline non resorbable suture utilizing a single interrupted suturing technique."
219348570|NCT07029126|DRUG|Fremanezumab|subcutaneous injection 225 mg monthly or 675 mg quarterly
219348571|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-V|Recombinant vaccinia virus vector antigen direct immunotherapy of the genus Orthopoxvirus. Administered by subcutaneous injection.
219348572|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-F|Recombinant fowlpox virus vector Antigen direct immunotherapy of the genus Avipoxvirus. Administered by subcutaneous injection.
219348573|NCT03315871|DRUG|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines immunoglobulin G1 (IgG1) anti-programmed death-ligand 1 (PD-L1) and Transforming growth factor, beta receptor II (TGFbetaRII) as a monoclonal antibody. Administered via intravenous (IV) infusion over 1 hour.
219348574|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: CV301|Recombinant vaccinia virus Antigen direct immunotherapy of the genus Avipoxvirus. Administered subcutaneously.
219348575|NCT03315871|DIAGNOSTIC_TEST|CT scan of chest|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
219348576|NCT03315871|DIAGNOSTIC_TEST|CT scan of abdomen/pelvis|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
219348577|NCT03315871|DIAGNOSTIC_TEST|MRI|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
219348578|NCT03315871|DIAGNOSTIC_TEST|PSMA|Biochemical recurrence group only. Screening, prior to Antigen direct immunotherapy therapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
219348579|NCT03315871|DIAGNOSTIC_TEST|Bone scan|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
219348580|NCT06900777|DRUG|Tacrolimus|Participants receive oral tacrolimus capsules at a dosage of 0.1 ± 0.05 mg/kg per day, divided into two administrations. The treatment duration is 24 weeks. Blood drug concentration is monitored to maintain trough levels between 7-15 ng/mL. Safety assessments include regular blood tests (hematology, liver/kidney function, blood glucose) and adverse event tracking.
219348581|NCT06900777|DRUG|Dexamethasone|Participants receive oral dexamethasone tablets at a dosage of 0.05 ± 0.025 mg/kg per day, administered as a single dose on weekends (Saturday and Sunday). The treatment duration is 24 weeks. Safety evaluations include monitoring of blood parameters (hematology, liver/kidney function, blood glucose), weight, and adrenal function (cortisol, ACTH levels).
219348582|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
219348583|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
219348584|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
219348585|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
219348586|NCT05388773|DRUG|Cisplatin|Given IV.
219348587|NCT05388773|DRUG|Carboplatin|Given IV
219348588|NCT03424707|DRUG|DW340(pelubiprofen/eperisone)|DW340
219348589|NCT03424707|DRUG|Pelubi(pelubiprofen)|pelubiprofen
219348590|NCT03424707|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
219348591|NCT06923761|DRUG|Module 1 (GRWD5769 on its own as monotherapy)|"Module 1 will initially be conducted in 4 study parts:~Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review committee)~Part B: (Optional) Monotherapy dose expansion part (to look at the effect of GRWD5769 on the body, and of the body on GRWD5769, at particular dose levels to include evaluation of biopsies of tumour tissue)~Part C: (Optional) Intra-patient dose escalation (where a patient may receive three different GRWD5769 doses so that blood levels at each dose can be measured in an individual)~Part D: Monotherapy dose expansion group(s) (where a dose of GRWD5769 may be chosen to be evaluated in specific types of cancer)"
219348592|NCT06923761|DRUG|Module 2 (GRWD5769 in combination with cemiplimab, administered IV)|"Module 2 will initially be conducted as 3 study parts, similar to those above, but looking at GRWD5769 when given in combination with cemiplimab:~Part A: Combination therapy dose escalation (like Module 1 Part A)~Part B: (Optional) Combination therapy dose expansion part (like Module 1 Part B)~Part C: Combination therapy dose expansion group(s) (where a dose of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer)"
219348593|NCT06945653|OTHER|Survey using a questionnaire.|The survey questions are aimed to assess the current state of diversity training in anesthesiology education. This survey serves as a needs assessment and will help gather information on the current state of DEI education within the specialty.
219348594|NCT06945900|OTHER|Telehealth|Paramedics will utilize Telehealth for STEMI patients during transport to determine appropriate care steps.
219348595|NCT00001498|DRUG|methotrexate|
219348596|NCT00001498|DRUG|leucovorin|
219348597|NCT00001498|DRUG|5-fluorouracil|
219348598|NCT00001498|DRUG|cyclophosphamide|
219348599|NCT00001498|PROCEDURE|peripheral blood progenitor cell|
219348600|NCT00001498|DRUG|paclitaxel|
219348601|NCT00001498|DRUG|doxorubicin|
219348602|NCT06213155|DEVICE|Cryoneurolysis|Cryoneurolysis
219348603|NCT06213155|DEVICE|Stimulation|Stimulation
219348604|NCT03713164|DIETARY_SUPPLEMENT|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
219348605|NCT03713164|DIETARY_SUPPLEMENT|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
219348606|NCT04421248|DRUG|Methylphenidate|In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
219348607|NCT04421248|DRUG|Placebo|In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
219348608|NCT02023333|DRUG|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
219348609|NCT04274998|DRUG|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
219348610|NCT04274998|DRUG|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
219348611|NCT06568601|GENETIC|Pharmacogenetic and polygenic risk testing|The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
219348612|NCT06568601|OTHER|Active control|The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
219348613|NCT04099251|BIOLOGICAL|Nivolumab|Specified dose on specified days
219348614|NCT04099251|OTHER|Placebo|Specified dose on specified days
219348615|NCT03094026|BEHAVIORAL|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
219348616|NCT03094026|BEHAVIORAL|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
219348617|NCT03727971|DRUG|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
219348618|NCT03727971|DRUG|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
219348619|NCT06957405|BEHAVIORAL|MPPG (Mental and Physical Practice Group)|Participants in this group will undergo 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of: (1) two blocks of first-person kinesthetic MP, conducted while seated with eyes closed and guided using DNI principles; and (2) two blocks of corresponding PP, involving simulated gait components such as ankle mobility, postural weight shifts, and short-distance walking under real-time supervision. Each block lasts approximately 10 minutes. The MP emphasizes attentional focus, sensory detail, and task-specific goals. Sessions are conducted synchronously via video call by trained physiotherapists.
219348620|NCT06957405|BEHAVIORAL|PPG (Physical Practice Group)|Participants in the control group will receive 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of the same PP as the experimental group but replaces motor imagery with two 10-minute seated stretching block, focusing on the upper limbs and trunk. The PP follows the same structure and duration as in the experimental group. All sessions are delivered remotely via live video by physiotherapists trained in both protocols. Volume, frequency, and interaction levels are matched between groups to ensure equivalence.
219348621|NCT05032157|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
219348622|NCT05032157|DRUG|Placebo|Placebo
219348623|NCT05032157|DRUG|LOU064 (open-label)|LOU064 (open-label) active treatment
219348624|NCT04392518|OTHER|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
219348625|NCT04495738|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
219348626|NCT04495738|OTHER|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
219348627|NCT04495738|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
219348628|NCT04495738|OTHER|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
219348629|NCT04495738|OTHER|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
219348630|NCT04495738|OTHER|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
219348631|NCT00480610|DRUG|tacrolimus ointment|Topical application
219348632|NCT00480610|DRUG|Placebo ointment|Topical application
219348633|NCT03047980|DRUG|Sirolimus|Low dose oral sirolimus
219348634|NCT04411550|DRUG|HLX11|healthy volunteers receive HLX11 (420mg) once
219348635|NCT04411550|DRUG|CN-Perjeta(Pertuzumab)|healthy volunteers receive CN-Perjeta (420mg) once
219348636|NCT04411550|DRUG|EU-Perjeta(Pertuzumab)|healthy volunteers receive EU-Perjeta (420mg) once
219348637|NCT04411550|DRUG|US-Perjeta(Pertuzumab)|healthy volunteers receive US-Perjeta (420mg) once
219348638|NCT06246760|OTHER|Exercise|Incremental exercise test until volitional exhaustion
219348639|NCT03331809|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.
219348640|NCT03331809|PROCEDURE|Conventional intubation|The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
219348641|NCT00006565|DEVICE|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
219348642|NCT00006565|DEVICE|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
219348643|NCT05650983|BEHAVIORAL|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
219348644|NCT02930993|BIOLOGICAL|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
219348645|NCT00913029|DEVICE|iStent|iStent
219348646|NCT00913029|DRUG|latanoprost/timolol|Combination latanoprost/timolol
219348647|NCT01783678|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
219348648|NCT01783678|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
219348649|NCT01995071|DRUG|ABT-493|Tablet
219348650|NCT01995071|DRUG|ABT-530|Tablet
219348651|NCT01995071|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
219348652|NCT01995071|DRUG|Ribavirin (RBV)|Tablet
219348653|NCT05546892|PROCEDURE|Full bowel preparation prior to colon resection for cancer|Mechanical bowel preparation and oral antibiotics
219348654|NCT05546892|PROCEDURE|No bowel preparation|Omission of any bowel preparation
219348655|NCT00112905|DRUG|sorafenib tosylate|Given PO
219348656|NCT00112905|OTHER|laboratory biomarker analysis|Optional correlative studies
219348657|NCT03999424|BIOLOGICAL|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
219348658|NCT06473909|DRUG|CD25 antibody combined glucocorticoid as first-line treatment|CD25 antibody combined glucocorticoid as first-line treatment
219348659|NCT01932957|PROCEDURE|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
219348660|NCT01932957|PROCEDURE|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
219348661|NCT02844387|DIETARY_SUPPLEMENT|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
219348662|NCT02844387|OTHER|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
219348663|NCT05898035|PROCEDURE|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
219348664|NCT01979523|OTHER|Laboratory Biomarker Analysis|Correlative studies
219348665|NCT01979523|OTHER|Pharmacological Study|Correlative studies
219348666|NCT01979523|DRUG|Trametinib|Given PO
219348667|NCT01979523|DRUG|Uprosertib|Given PO
219348668|NCT01946607|DRUG|Citalopram|
219348669|NCT01946607|DRUG|Placebo|
219348670|NCT01573715|DRUG|NIMBEX|
219348671|NCT01573715|DRUG|NIMBEX|
219348672|NCT01573715|OTHER|WITHOUT NIMBEX|
219348673|NCT01614132|DRUG|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
219348674|NCT01614132|RADIATION|Radiotherapy|Radiotherapy of the partial brain
219348675|NCT06537843|DRUG|Venetoclax|Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
219348676|NCT06537843|DRUG|Cytarabine Injection|Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
219348677|NCT06537843|DRUG|Metformin|Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
219348678|NCT06375109|DRUG|Tislelizumab|administered via Intravenous (IV) injection
219348679|NCT06375109|DRUG|Carboplatin injection|administered via IV injection
219348680|NCT06375109|DRUG|Cisplatin injection|administered via IV injection
219348681|NCT06375109|DRUG|Etoposide injection|administered via IV injection
219348682|NCT03290235|DRUG|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
219348683|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
219348684|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
219348685|NCT05729412|OTHER|Mentioned|If prescription is properly filled for specific details than it is compliance
219348686|NCT05017740|PROCEDURE|ICSI|In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.
219348687|NCT05017740|PROCEDURE|PICSI|In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
219348688|NCT00609479|PROCEDURE|Osteosynthesis|"1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
219348689|NCT01481311|DEVICE|medical Body Composition Analyzer seca 514/515|Current of 100 µA
219348690|NCT01481311|PROCEDURE|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
219348691|NCT03640923|OTHER|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
219348692|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
219348693|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
219348694|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD."
219348695|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD."
219348696|NCT06081907|DRUG|IBI363|The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
219348697|NCT04947488|DIETARY_SUPPLEMENT|Bioarginina C|Dietary supplement vials
219348698|NCT00488982|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days
219348699|NCT00488982|DRUG|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
219348700|NCT01626898|BEHAVIORAL|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
219348701|NCT01626898|BEHAVIORAL|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
219348702|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal powder
219348703|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intramuscular injection
219348704|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal spray
219348705|NCT02368717|DRUG|Mesalazine Enema|
219348706|NCT02368717|DRUG|Placebo Enema|
219348707|NCT01659645|DRUG|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
219348708|NCT04813471|DRUG|Endothelial Protocol|Endothelial Protocol
219348709|NCT03716869|OTHER|Universal Screening Arm|"Students with PHQ-9 score \>10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
219348710|NCT03868683|OTHER|Glucose Reference 1|30 g of glucose dissolved in 250 ml of water
219348711|NCT03868683|OTHER|Glucose Reference 2|30 g of glucose dissolved in 250 ml of water
219348712|NCT03868683|OTHER|Glucose reference 3|30 g of glucose dissolved in 250 ml of water
219348713|NCT03868683|OTHER|Sucrose|30 g of Sucrose dissolved in 250 ml of water
219348714|NCT03868683|OTHER|Regular Bake beans in tomato sauce|Bake beans in tomato sauce containing 14 g of sugar
219348715|NCT03868683|OTHER|Bake beans in tomato sauce, reduced sugar|Bake beans in tomato sauce containing 12.2 g of sugar
219348716|NCT03868683|OTHER|Bake beans in tomato sauce, low GI|Bake beans in tomato sauce containing 7.2 g of sugar
219348717|NCT02008656|DRUG|Oxaliplatin (OXAL)|
219348718|NCT02008656|DRUG|5-Fluorouracil (5-FU)|
219348719|NCT02008656|DRUG|Leucovorin|
219348720|NCT02008656|DRUG|Capecitabine (Xeloda®)|
219348721|NCT02008656|RADIATION|intensity modulated radiotherapy (IMRT)|
219348722|NCT02008656|BEHAVIORAL|Quality of Life Questionnaires|
219348723|NCT02008656|PROCEDURE|DRE-Endoscopy|
219348724|NCT06477276|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
219348725|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
219348726|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
219348727|NCT03621280|DRUG|Levoketoconazole|Levoketoconazole up to 1200 mg daily
219348728|NCT03757533|BEHAVIORAL|Health Coaching|10 phone calls with a trained health coach
219348729|NCT03757533|OTHER|Surveys|Surveys to assess Behavioural and Psychosocial measures
219348730|NCT04621370|DRUG|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
219348731|NCT04621370|DRUG|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
219348732|NCT04621370|RADIATION|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
219348733|NCT04621370|RADIATION|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
219348734|NCT04621370|DRUG|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
219348735|NCT01709149|DRUG|CK-2017357|CK-2017357 125 mg tablets twice daily
219348736|NCT01709149|OTHER|Placebo tablets|Tablets
219348737|NCT01709149|DRUG|Riluzole|Tablets
219348738|NCT06179758|DEVICE|icompanion app|use of the icompanion app as a digital telemonitoring solution
219348739|NCT03279614|DRUG|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
219348740|NCT00343668|DRUG|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
219348741|NCT03335332|BEHAVIORAL|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
219348742|NCT03335332|BEHAVIORAL|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
219348743|NCT01266863|OTHER|E test method|E test strips directly applied to BAL
219348744|NCT02192827|DRUG|Dexamethasone Sodium Phosphate Injection|
219348745|NCT03269123|DEVICE|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
219348746|NCT00535132|DRUG|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
219348747|NCT00535132|DRUG|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
219348748|NCT02590588|DRUG|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
219348749|NCT02917889|DRUG|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
219348750|NCT02917889|DRUG|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
219348751|NCT02917889|OTHER|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
219348752|NCT02917889|OTHER|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
219348753|NCT00793650|DRUG|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
219348754|NCT00793650|DRUG|Melphalan|"All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2."
219348755|NCT00793650|PROCEDURE|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
219348756|NCT01357486|DRUG|sorafenib|patients receiving sorafenib 400 mg - twice a day
219348757|NCT01357486|DRUG|Pravastatin|patients receiving pravastatin 40 mg - once a day
219348758|NCT01357486|DRUG|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
219348759|NCT01357486|OTHER|patients receiving best supportive care|palliative management
219348760|NCT01409720|OTHER|exercise|tailored isometric physical exercise
219348761|NCT01857713|DEVICE|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
219348762|NCT03759665|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
219348763|NCT02037737|DRUG|Abatacept|
219348764|NCT02776488|DRUG|Sodium Lactate|Infusion of exogenous sodium lactate
219348765|NCT02776488|DRUG|Placebo|Infusion of normal saline
219348766|NCT04429620|DIAGNOSTIC_TEST|Immunfluorescence|Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
219348767|NCT00006366|DRUG|fluorouracil|
219348768|NCT00006366|DRUG|irinotecan hydrochloride|
219348769|NCT00006366|PROCEDURE|conventional surgery|
219348770|NCT00006366|RADIATION|radiation therapy|
219348771|NCT02825095|PROCEDURE|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
219348772|NCT02825095|PROCEDURE|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
219348773|NCT02825095|PROCEDURE|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
219348774|NCT02825095|DRUG|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
219348775|NCT02825095|PROCEDURE|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
219348776|NCT05304507|BEHAVIORAL|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
219348777|NCT05304507|BEHAVIORAL|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
219348778|NCT03006510|OTHER|Hypoglycemia prediction alert|"In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is \>35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
219348779|NCT03236558|PROCEDURE|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
219348780|NCT05102955|OTHER|Observational questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
219348781|NCT04606459|DEVICE|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
219348782|NCT04606459|OTHER|Optimal medical therapy|Guideline-directed medical therapy
219348783|NCT04992819|PROCEDURE|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
219348784|NCT00488384|DRUG|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
219348785|NCT01531114|DRUG|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
219348786|NCT01531114|DRUG|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
219348787|NCT05148975|DIAGNOSTIC_TEST|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
219348788|NCT04746768|COMBINATION_PRODUCT|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
219348789|NCT04092127|OTHER|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
219348790|NCT01857869|BIOLOGICAL|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
219348791|NCT01857869|BIOLOGICAL|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
219348792|NCT01857869|PROCEDURE|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
219348793|NCT00731250|DRUG|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
219348794|NCT00731250|DRUG|Placebo|Subjects will be administered SB-705498 matching placebo tablets
219348795|NCT00731250|OTHER|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
219348796|NCT00181194|DEVICE|Asthma Control and Communication Instrument|
219348797|NCT03527563|BEHAVIORAL|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
219348798|NCT02296398|DRUG|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
219348799|NCT02465073|DEVICE|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
219348800|NCT02465073|DEVICE|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
219348801|NCT02465073|DEVICE|Standard of Care Group|Subjects will receive Standard of Care only.
219348802|NCT05037110|BEHAVIORAL|Physical activity|For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
219348803|NCT05037110|OTHER|Smell training|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
219348804|NCT03988335|DRUG|RIST4721|RIST4721 oral solution
219348805|NCT03988335|DRUG|Placebo|Placebo oral solution
219348806|NCT01517477|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
219348807|NCT01517477|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
219348808|NCT01517477|DEVICE|iStent|Implantation of Three iStents through a small temporal clear corneal incision
219348809|NCT02150590|DRUG|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
219348810|NCT02150590|DRUG|sham oxygen (room air)|
219348811|NCT00881777|PROCEDURE|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
219348812|NCT00881777|PROCEDURE|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
219348813|NCT03420950|OTHER|Rapid sequence intubation: sedative first|Sedative first
219348814|NCT03420950|OTHER|Rapid sequence intubation: paralytic first|Paralytic first
219348815|NCT02971878|BIOLOGICAL|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
219348816|NCT04517188|DRUG|Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP|Single topical administration
219348817|NCT04607733|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
219348818|NCT04607733|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
219348819|NCT04283136|DRUG|Padsevonil type 1 Tablet 200 mg|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
219348820|NCT04283136|DRUG|Padsevonil type 2 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
219348821|NCT04283136|DRUG|Padsevonil type 3 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
219348822|NCT04283136|DRUG|Padsevonil type 4 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
219348823|NCT04283136|DRUG|Padsevonil type 5 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
219348824|NCT05601375|OTHER|Echocardiography|Fetal echocardiography (ultrasound)
219348825|NCT03238820|PROCEDURE|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
219348826|NCT05847088|DRUG|Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:|Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
219348827|NCT02482675|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
219348828|NCT02482675|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
219348829|NCT02482675|OTHER|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
219348830|NCT02482675|OTHER|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
219348831|NCT00985205|DIETARY_SUPPLEMENT|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
219348832|NCT00985205|DIETARY_SUPPLEMENT|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
219348833|NCT04754100|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
219348834|NCT00754910|DRUG|porfimer sodium|Given IV
219348835|NCT00754910|PROCEDURE|bronchoscopy|Patients undergo bronchoscopy
219348836|NCT05429294|DRUG|Pyrotinib|Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
219348837|NCT00743379|DRUG|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
219348838|NCT01272700|PROCEDURE|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
219348839|NCT01272700|PROCEDURE|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
219348840|NCT00239876|DRUG|FTY720|
219348841|NCT02215356|DRUG|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
219348842|NCT02215356|DRUG|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
219348843|NCT04479579|DRUG|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
219348844|NCT01425151|DEVICE|i-Gel|Oropharyngeal leak pressure Insertion success
219348845|NCT01425151|DEVICE|ProSeal|Oropharyngeal leak pressure Insertion success
219348846|NCT01827670|DRUG|Stannous fluoride|Test dentifrice containing 0.454% SnF
219348847|NCT01827670|DRUG|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
219348848|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
219348849|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
219348850|NCT04819152|BEHAVIORAL|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
219348851|NCT03900403|OTHER|Walnut Intake|40g of daily walnut intake for 12 weeks
219348852|NCT01127724|DRUG|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
219348853|NCT05726500|DIAGNOSTIC_TEST|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
219348854|NCT05726500|DIAGNOSTIC_TEST|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
219348855|NCT05726500|DIAGNOSTIC_TEST|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
219348856|NCT05726500|DIAGNOSTIC_TEST|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
219348857|NCT05726500|DIAGNOSTIC_TEST|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
219348858|NCT00832559|BIOLOGICAL|CVA21|1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
219348859|NCT04307992|DEVICE|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
219348860|NCT00083993|DRUG|Temsirolimus (CCI-779) for 34 months|
219348861|NCT00083993|DRUG|Letrozole for 34 months|
219348862|NCT01797575|DRUG|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
219348863|NCT01797575|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
219348864|NCT01797575|DRUG|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
219348865|NCT03704870|DIAGNOSTIC_TEST|Chest Xray|Daily chest xray
219348866|NCT03704870|DIAGNOSTIC_TEST|No daily chest xray|Chest xray will be done post chest tube removal only
219348867|NCT04723121|DIAGNOSTIC_TEST|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
219348868|NCT04723121|DIAGNOSTIC_TEST|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
219348869|NCT02941627|DEVICE|Neuro Zti|Cochlear implant
219348870|NCT02941627|DEVICE|Neuro One|Sound processor
219348871|NCT06470269|BEHAVIORAL|Eye tracking|Recording the eye movement of participants while they read medical cases.
219348872|NCT01419912|DIETARY_SUPPLEMENT|soy milk|
219348873|NCT01419912|DIETARY_SUPPLEMENT|cow's milk|
219348874|NCT02237300|BEHAVIORAL|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
219348875|NCT02237300|BEHAVIORAL|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
219348876|NCT06320769|DEVICE|Plate Technique|Using Plates, non-absorbable sutures or cerclage wires to guide the distal femoral physis towards rotational growth to correct deformity
219348877|NCT02286700|DRUG|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
219348878|NCT02286700|OTHER|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
219348879|NCT03428971|PROCEDURE|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
219348880|NCT03132337|OTHER|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
219348881|NCT03058042|OTHER|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
219348882|NCT03058042|OTHER|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
219348883|NCT04888273|BEHAVIORAL|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
219348884|NCT02777671|DRUG|BIA 2-093|
219348885|NCT02777671|DRUG|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
219348886|NCT04319328|DRUG|Cefazolin|Non-interventional pharmacokinetic evaluation
219348887|NCT04319328|DRUG|Ceftazidime|Non-interventional pharmacokinetic evaluation
219348888|NCT02763202|OTHER|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
219348889|NCT04640467|DIAGNOSTIC_TEST|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
219348890|NCT04640467|DIAGNOSTIC_TEST|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
219348891|NCT01708642|DRUG|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
219348892|NCT01708642|DRUG|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
219348893|NCT06057779|OTHER|Slow and heavy exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
219348894|NCT06057779|OTHER|Slow and light exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
219348895|NCT06057779|OTHER|Fast and heavy exercise therapy|6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
219348896|NCT04925609|DRUG|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
219348897|NCT00997100|DRUG|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
219348898|NCT02832973|DRUG|Spironolactone|Spironolactone 25 mg
219348899|NCT02832973|DRUG|Furosemide,|Furosemide 20-40 mg
219348900|NCT02832973|DRUG|Amiloride|Amiloride 5 mg
219348901|NCT02832973|DRUG|Ramipril|Ramipril 5-10 mg
219348902|NCT02832973|DRUG|Bisoprolol|Bisoprolol 5-10 mg
219348903|NCT04755361|BEHAVIORAL|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
219348904|NCT05070767|DEVICE|Neurolens spectacle lens|spectacle lens
219348905|NCT05070767|DEVICE|Placebo spectacle lens|spectacle lens for refractive error correction
219348906|NCT01696240|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
219348907|NCT01696240|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
219348908|NCT00689715|PROCEDURE|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
219348909|NCT05555537|DIAGNOSTIC_TEST|MiRNA223 and High mobility group box1(HMGB1)|Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
219348910|NCT00368511|PROCEDURE|Music Listening|Listen to music and posture measurements
219348911|NCT03594227|DRUG|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
219348912|NCT03594227|DRUG|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
219348913|NCT03594227|DRUG|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
219348914|NCT03594227|DRUG|Placebo|Placebo - oral administration
219348915|NCT01801956|BEHAVIORAL|physical activity|free membership of a sport club
219348916|NCT01801956|OTHER|Motivational interview|Four motivational interviews by instructors of the local sport club
219348917|NCT01801956|OTHER|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
219348918|NCT00790907|DRUG|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
219348919|NCT00790907|DRUG|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
219348920|NCT00790907|DRUG|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
219348921|NCT01888640|DEVICE|TENS|"TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
219348922|NCT04434495|BIOLOGICAL|PRP|PRP injection into uterine cavity
219348923|NCT06199388|OTHER|Survival state|We recorded clinically relevant information and survival status of pediatric glioma patients
219348924|NCT06518577|BIOLOGICAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4)
219348925|NCT06518577|BIOLOGICAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV)
219348926|NCT03389854|DEVICE|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
219348927|NCT03389854|DEVICE|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
219348928|NCT00907101|DRUG|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
219348929|NCT00576043|PROCEDURE|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
219348930|NCT00109707|DRUG|Nilotinib|
219348931|NCT00586209|DRUG|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
219348932|NCT00586209|DRUG|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
219348933|NCT02199080|OTHER|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
219348934|NCT02018627|DRUG|Xeris glucagon|The subject is given an injection of xeris glucagon
219348935|NCT02018627|DRUG|Lilly glucagon|The subject is given an injection of lilly glucagon
219348936|NCT01437020|DRUG|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
219348937|NCT01437020|DRUG|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
219348938|NCT05084911|DRUG|Pyramax|Pyronaridine-Artesunate(180/60mg) tablet for 3days.
219348939|NCT05084911|DRUG|Placebo|Placebo tablet for 3days.
219348940|NCT01365559|DRUG|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
219348941|NCT01365559|DRUG|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
219348942|NCT00514956|BEHAVIORAL|Emotional Freedom Techniques (EFT)|
219348943|NCT03030430|BIOLOGICAL|BAT1706 injection|1mg/kg, IV on day 1
219348944|NCT03030430|BIOLOGICAL|EU-sourced Avastin|1mg/kg, IV on day 1
219348945|NCT03030430|BIOLOGICAL|US-sourced Avastin|1mg/kg, IV on day 1
219348946|NCT05785143|PROCEDURE|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
219348947|NCT04394533|DRUG|Prilocaine (Hyperbaric 2%)|2 ml hyperbaric prilocaine
219348948|NCT04394533|DRUG|Bupivacaine (Hyperbaric 0.5%)|2 ml hyperbaric bupivacaine
219348949|NCT00599040|BEHAVIORAL|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
219348950|NCT00599040|BEHAVIORAL|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
219348951|NCT00599040|BEHAVIORAL|Dairy diet|participants are given a high dairy, reduced calorie diet
219348952|NCT01758250|OTHER|Acoustic Radiation Force Impulse (ARFI)|
219348953|NCT01758250|OTHER|Laser Doppler Flowmetry (LDF)|
219348954|NCT01758250|OTHER|Laser Doppler Perfusion Imaging (LDI)|
219348955|NCT01758250|OTHER|Optical Coherence Tomography (OCT)|
219348956|NCT01758250|OTHER|Orthogonal Polarization Spectral Imaging (OPSI)|
219348957|NCT01758250|OTHER|Nail fold video capillaroscopy (NVC)|
219348958|NCT04051437|PROCEDURE|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
219348959|NCT04051437|DRUG|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
219348960|NCT01595776|OTHER|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
219348961|NCT05468632|DRUG|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
219348962|NCT00725400|OTHER|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
219348963|NCT00725400|PROCEDURE|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
219348964|NCT02875639|DRUG|Yiqi prescription|
219348965|NCT02875639|DRUG|Huoxue prescription|
219348966|NCT02875639|DRUG|Buyang huanwu decoction|
219348967|NCT02875639|DRUG|QISHEN YIQI DRIPPING PILLS|
219348968|NCT02875639|DRUG|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
219348969|NCT02875639|DRUG|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
219348970|NCT06542055|OTHER|Preoperative and postoperative pulmonary rehabilitation exercise|Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.
219348971|NCT06542055|OTHER|Preoperative education and postoperative exercise|Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises
219348972|NCT04467307|DEVICE|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
219348973|NCT00736346|BEHAVIORAL|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
219348974|NCT00736346|BEHAVIORAL|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
219348975|NCT00736346|DRUG|paroxetine|40 mg die, for 6 months
219348976|NCT03339921|DRUG|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
219348977|NCT03339921|PROCEDURE|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
219348978|NCT01438580|DRUG|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
219348979|NCT01438580|DRUG|aspirin|100mg aspirin was administrated every day
219348980|NCT03472157|OTHER|Lifestyle therapy|Lifestyle habits (caloric intake and exercise) + pedometer
219348981|NCT03472157|PROCEDURE|Bariatric surgery|Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
219348982|NCT03579355|BEHAVIORAL|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
219348983|NCT02109900|OTHER|Serum Progesterone Levels|
219348984|NCT05934500|DRUG|Cannabidiol Oil|Subjects will self administer CBD sublingually
219348985|NCT03436862|DRUG|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
219348986|NCT00571350|PROCEDURE|tvt-o operation|transvaginal tention free obturator tape
219348987|NCT00571350|PROCEDURE|tvt o operation|transobturator vaginal tape insertion
219348988|NCT01109914|BIOLOGICAL|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
219348989|NCT05455112|BIOLOGICAL|RUTI® Vaccine|One subcutaneous injection of RUTI 25µg FCMtb
219348990|NCT05455112|BIOLOGICAL|Placebo|One subcutaneous injection of saline
219348991|NCT06288620|PROCEDURE|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
219348992|NCT02398591|DRUG|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
219348993|NCT02398591|DRUG|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
219348994|NCT02961335|PROCEDURE|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
219348995|NCT02961335|PROCEDURE|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
219348996|NCT02961335|PROCEDURE|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
219348997|NCT02733666|PROCEDURE|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
219348998|NCT04580381|DRUG|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
219348999|NCT04352439|DRUG|Aspirin|81 mg aspirin daily
219349000|NCT04931004|DRUG|Mouthwash Product|Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
219349001|NCT04931004|OTHER|Water rinse|30-second water rinse will occur in the control group. Viral load will be measured prior to and after water rinse using serial face mask and saliva samples.
219349002|NCT01839864|BEHAVIORAL|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
219349003|NCT03386175|DEVICE|therapy with negative pression and instillation|therapy with negative pression and instillation
219349004|NCT04732182|DEVICE|BrightGo cognitive training|Training on the BrightGo experimental device in the home
219349005|NCT04732182|DRUG|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
219349006|NCT00278278|DRUG|cisplatin|Given IV
219349007|NCT00278278|DRUG|etoposide|Given IV
219349008|NCT00278278|DRUG|ifosfamide|Given IV
219349009|NCT00278278|DRUG|lomustine|Given IV
219349010|NCT00278278|DRUG|methotrexate|Given IV
219349011|NCT00278278|DRUG|prednisone|Given IV
219349012|NCT00278278|DRUG|vincristine sulfate|Given IV
219349013|NCT04393922|BEHAVIORAL|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
219349014|NCT00634829|DRUG|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
219349015|NCT00634829|DRUG|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
219349016|NCT00634829|DRUG|Placebo-HFA|Placebo containing HFA propellant without active drug substance
219349017|NCT02228590|DRUG|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
219349018|NCT05113836|BIOLOGICAL|Deep nasopharyngeal swab|On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
219349019|NCT05113836|BIOLOGICAL|Blood sample at D1, D3 and D7|"Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total)."
219349020|NCT00450476|DEVICE|Hi-Lo Evac Endotracheal Tube|
219349021|NCT00391222|DRUG|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
219349022|NCT00391222|DRUG|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
219349023|NCT00391222|DRUG|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
219349024|NCT02702037|DIETARY_SUPPLEMENT|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
219349025|NCT02702037|OTHER|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
219349026|NCT05700162|BEHAVIORAL|Photograph|As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.
219349027|NCT05700162|BEHAVIORAL|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
219349028|NCT05700162|BEHAVIORAL|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
219349029|NCT05700162|BEHAVIORAL|Control Group|She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
219349030|NCT00337064|PROCEDURE|Radiation Therapy|
219349031|NCT05279846|DRUG|MOB015B|Applied topically for 48 weeks
219349032|NCT05279846|DRUG|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
219349033|NCT04576598|OTHER|Self-management program to increase physical activity levels|Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.
219349034|NCT04576598|OTHER|Education information|Education on the importance of active lifestyle habits post-stroke.
219349035|NCT04009044|DRUG|Afimoxifene|Apply topically
219349036|NCT04009044|PROCEDURE|Core Biopsy|Undergo core needle biopsy
219349037|NCT04009044|OTHER|Questionnaire Administration|Ancillary studies
219349038|NCT03144466|COMBINATION_PRODUCT|Pembrolizumab|antiPD1 monoclonal antibody
219349039|NCT02447315|DRUG|Pilocarpine|oral
219349040|NCT02447315|DRUG|Placebo|oral
219349041|NCT00847366|DRUG|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
219349042|NCT00847366|DRUG|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
219349043|NCT00847366|DRUG|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
219349044|NCT01097863|DEVICE|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
219349045|NCT01097863|DEVICE|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
219349046|NCT01097863|DEVICE|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
219349047|NCT02996188|PROCEDURE|routine therapeutic paracentesis|
219349048|NCT03993366|COMBINATION_PRODUCT|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
219349049|NCT03993366|DEVICE|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
219349050|NCT01908660|DRUG|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
219349051|NCT05458388|PROCEDURE|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
219349052|NCT05458388|PROCEDURE|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
219349053|NCT01214785|BEHAVIORAL|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
219349054|NCT03915873|DIAGNOSTIC_TEST|The von Willebrand Antigen level|blood sample
219349055|NCT01871584|DEVICE|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
219349056|NCT04568226|OTHER|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
219349057|NCT04568226|OTHER|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
219349058|NCT04307290|DRUG|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
219349059|NCT00005070|DRUG|irofulven|
219349060|NCT00772486|BIOLOGICAL|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
219349061|NCT02023645|DIETARY_SUPPLEMENT|active supplement|tablet
219349062|NCT02023645|OTHER|placebo|tablet
219349063|NCT00745563|DEVICE|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
219349064|NCT04966377|BEHAVIORAL|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS), increasing awareness of Syrian women under temporary protection against breast cancer, decreasing their perception of barriers to screening tests, developing early diagnosis behaviors (such as BSE, CBE and mammography), increasing their self-efficacy and breast cancer fears are expected to be reduced.
219349065|NCT06350838|DRUG|BCG for Therapeutic Use|Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
219349066|NCT00574275|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
219349067|NCT00574275|DRUG|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
219349068|NCT00574275|DRUG|Gemcitabine|1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
219349069|NCT00763750|DRUG|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
219349070|NCT00644774|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
219349071|NCT00644774|DRUG|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
219349072|NCT01959711|PROCEDURE|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
219349073|NCT01959711|PROCEDURE|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
219349074|NCT02703311|DEVICE|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
219349075|NCT02734836|DEVICE|Balloon Angioplasty|
219349076|NCT02734836|OTHER|Optical Coherence Tomography|
219349077|NCT03692728|OTHER|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
219349078|NCT05595824|DRUG|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
219349079|NCT05595824|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
219349080|NCT03278600|GENETIC|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
219349081|NCT01620242|DRUG|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
219349082|NCT00960843|DEVICE|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
219349083|NCT00960843|OTHER|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
219349084|NCT03957564|DRUG|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
219349085|NCT03957564|OTHER|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
219349086|NCT03957564|OTHER|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
219349087|NCT03957564|OTHER|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
219349088|NCT04276428|DRUG|LY3209590|Administered SC.
219349089|NCT04276428|DRUG|Insulin Degludec|Administered SC.
219349090|NCT03009266|DRUG|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
219349091|NCT00652366|DRUG|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
219349092|NCT00652366|DRUG|Erlotinib, standard dose|100mg, PO, once daily
219349093|NCT00652366|DRUG|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
219349094|NCT03377530|DIAGNOSTIC_TEST|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
219349095|NCT04905121|DRUG|Psilocybin|Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
219349096|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
219349097|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Hard Capsule-Route of administration:Oral
219349098|NCT01618942|DEVICE|pressure algometer|
219349099|NCT01788254|DRUG|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
219349100|NCT01788254|DRUG|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
219349101|NCT01788254|DRUG|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
219349102|NCT01788254|DRUG|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
219349103|NCT01788254|DRUG|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
219349104|NCT03664999|DIAGNOSTIC_TEST|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
219349105|NCT04896554|BEHAVIORAL|Health literacy scale|"The Turkish version of The European Health Literacy Survey (HLS-EU) Health Literacy Questionnaire scale (ASOY-TR) was used to measure health literacy. This scale consists of 47 questions. Each item has 4 degrees such that 1 = Very difficult, 2 = Difficult, 3 = Easy, 4 = Very easy. Code 5 is used for the expression I don't know. The total score that can be obtained from the scale is between 47-188. For the sake of ease of calculation, the total score is standardized with the following formula to take a value between 0-50.~Formula = Index = (arithmetic mean-1) x \[50/3\] High score means better health literacy."
219349106|NCT01411436|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
219349107|NCT00558870|DRUG|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
219349108|NCT00558870|DRUG|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
219349109|NCT03632733|DRUG|Tetracycline|Tetracycline cream
219349110|NCT03632733|DRUG|Clotrimazole|Clotrimazole cream
219349111|NCT03632733|DRUG|Tetracycline and Clotrimazole|Combination cream
219349112|NCT03632733|OTHER|Placebo|Placebo cream without active drug ingredients
219349113|NCT03609697|BEHAVIORAL|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
219349114|NCT03609697|BEHAVIORAL|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
219349115|NCT03728075|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
219349116|NCT05193110|OTHER|Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis|Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
219349117|NCT05949775|BIOLOGICAL|Neoantigen mRNA Personalised Cancer vaccine|Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection
219349118|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
219349119|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
219349120|NCT02069899|DRUG|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
219349121|NCT04344938|OTHER|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality|Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
219349122|NCT02511730|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
219349123|NCT02511730|DEVICE|FFDM|FujiFilm Aspire Cristalle System
219349124|NCT02550184|OTHER|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
219349125|NCT00153686|PROCEDURE|capsule endoscopy|capsule endoscopy of small intestine
219349126|NCT00153686|PROCEDURE|Mesenteric Angiogram|Mesenteric Angiogram
219349127|NCT03456921|OTHER|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
219349128|NCT03413501|BEHAVIORAL|MUD-PI|
219349129|NCT00090194|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
219349130|NCT00490451|DRUG|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
219349131|NCT01181011|DRUG|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
219349132|NCT05220826|PROCEDURE|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
219349133|NCT05607875|BEHAVIORAL|The Grow to Recovery Train-the-Trainer program|"Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training."
219349134|NCT05607875|OTHER|Control group|Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
219349135|NCT04235556|BEHAVIORAL|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
219349136|NCT02559440|DRUG|mometasone furoate|50μg, 1 puff in each nostril every evening
219349137|NCT02559440|DRUG|Placebo|1 puff in each nostril every evening
219349138|NCT02559440|DRUG|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
219349139|NCT02559440|DRUG|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
219349140|NCT02559440|DRUG|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
219349141|NCT02559440|DRUG|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
219349142|NCT03268044|OTHER|Hospital admission and surgery|Hospital admission and noncardiac surgery
219349143|NCT03997955|OTHER|Myofascial induction|Myofascial induction in plantar fascia
219349144|NCT03997955|OTHER|Sham myofascial induction|Sham myofascial induction in plantar fascia
219349145|NCT04772040|DIETARY_SUPPLEMENT|Fish oil supplementation|Fish oil capsules.
219349146|NCT06402266|DEVICE|tDCS|"The STM task will be combined with respectively two times active tDCS and one sham tDCS. The 3 conditions will be randomised, and both scientific staff and participants will be blinded.~Participants will perform the STM task on a tablet for 45 min. Headsets will deliver the tDCS. Two different placements will be used for the active stimulations: 1) F3 and PZ, and 2) F4 and PZ. The current output range will be 1.6mA and the stimulation will last for 30 min. The sham stimulation will function as a control condition. During the sham stimulation, the current density will be ramped up for 15 sec until the current reaches a density of 1.6mA for 60 sec and then again ramped down for 15 sec.~After the session, participants will fill out a brief questionnaire regarding their experience.~The time interval between sessions will be 1-3 weeks."
219349147|NCT00137111|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
219349148|NCT00137111|DRUG|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
219349149|NCT00137111|DRUG|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
219349150|NCT00137111|DRUG|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
219349151|NCT00137111|PROCEDURE|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
219349152|NCT00137111|PROCEDURE|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
219349153|NCT04081350|DRUG|LY3471851|Administered SC
219349154|NCT04081350|DRUG|Placebo|Administered SC
219349155|NCT00232102|DRUG|Tegaserod|
219349156|NCT00892307|RADIATION|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
219349157|NCT04577235|OTHER|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
219349158|NCT04186741|DRUG|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
219349159|NCT03699176|DRUG|Vilaprisan (BAY1002670)|2 mg, once daily, oral
219349160|NCT03699176|DRUG|Placebo|Once daily, oral
219349161|NCT05486351|OTHER|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
219349162|NCT03682523|BEHAVIORAL|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
219349163|NCT03325725|DEVICE|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
219349164|NCT02970448|PROCEDURE|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
219349165|NCT02970448|RADIATION|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
219349166|NCT02970448|DRUG|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
219349167|NCT02788747|DRUG|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
219349168|NCT02788747|DRUG|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
219349169|NCT02788747|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
219349170|NCT03028571|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
219349171|NCT03028571|OTHER|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
219349172|NCT02054026|BEHAVIORAL|Reducing the Risk|
219349173|NCT05941975|DEVICE|Visual Evoked Potential (VEP)|To assess the integrity of visual pathways through the optic nerves to the visual cortex, latencies and amplitudes of P100 will be measured after pattern-reversal stimuli.
219349174|NCT05941975|DEVICE|Somatosensory evoked potential (SSEP)|To assess the integrity of sensitive pathways through the peripheral nerves and dorsal spinal cord to the somatosensory cortex. For the upper limbs, latencies and amplitudes of N9, N13, P14, N20 and P25 will be measured after median nerve stimulation. For the lower limbs, latency and amplitude of P40 will be measured after tibial nerve stimulation.
219349175|NCT05941975|DEVICE|Transcranial magnetic motor evoked potentials (TCmMEP)|To measure the integrity of motor pathways, the central conduction times will be measured for upper and lower limbs through magnetic stimulations of the primary motor cortex and the spinal cord, at cervical and lumbar levels.
219349176|NCT05941975|DEVICE|Tesla Brain MRI|All patients will undergo a single brain MRI on a 3T scanner. The acquisition protocol will include high-resolution three-dimensional (3D) T2\*-weighted echo-planar imaging and 3D T2-FLAIR images acquired, respectively, during or after intravenous injection of a single dose (0.1mmol/kg) of gadolinium-based contrast material.
219349177|NCT05941975|DIAGNOSTIC_TEST|Blood test - Neurofilament light chain (NfL)|\- Neurofilament light chain (NfL) will be tested (Quanterix's Simoa® Technology) in the serum of patients. To evaluate their variation over time, 3 time-point tests will be obtained at 6 months apart (at baseline, at 6- and 12-month follow-up).
219349178|NCT05941975|DIAGNOSTIC_TEST|Blood test - EBV serology|EBV serology will be assessed (VCA IgG) in the serum of patients to evaluate the variation of antibody titers over time (at baseline, at 6- and 12-month follow-up), and compare to titers at the time of diagnosis (when available in their medical record).
219349179|NCT01967550|DRUG|diclofenac diethylamine, DDEA 2.32% gel|
219349180|NCT01967550|DRUG|Placebo|
219349181|NCT05309798|BEHAVIORAL|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
219349182|NCT05309798|BEHAVIORAL|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
219349183|NCT05309798|BEHAVIORAL|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
219349184|NCT01223703|DRUG|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
219349185|NCT01223703|DRUG|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
219349186|NCT00295984|DRUG|nicotine|
219349187|NCT04091633|BEHAVIORAL|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
219349188|NCT04091633|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
219349189|NCT00784654|DRUG|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
219349190|NCT00784654|DRUG|Placebo|Placebo capsule once per day (double-blind period)
219349191|NCT04163250|DIAGNOSTIC_TEST|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
219349192|NCT04589273|DIETARY_SUPPLEMENT|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
219349193|NCT04589273|OTHER|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
219349194|NCT03458208|DRUG|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
219349195|NCT03458208|DRUG|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
219349196|NCT03458208|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
219349197|NCT03458208|DRUG|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
219349198|NCT04002635|DRUG|Letrozole|Letrozole ovulation induction
219349199|NCT04002635|DRUG|estradiol valerate|hormonal replacement therapy
219349200|NCT00273104|PROCEDURE|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
219349201|NCT00273104|BEHAVIORAL|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
219349202|NCT01640509|RADIATION|treated by synchrotron radiation|treated by synchrotron radiation
219349203|NCT03740971|DEVICE|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
219349204|NCT03740971|DRUG|Guideline-based therapy|Guideline-based therapy
219349205|NCT06147479|BEHAVIORAL|CS-ADL (Cognitive stimulation in Activities of Daily Living)|CS-ADL sessions are delivered once weekly, for seven weeks. Sessions last approximately 2 hours. Sessions are themed around domains of everyday activities, for example 'Morning routine', ' Domestic Activities', 'Leisure'. Activities in each session follow this theme. A typical session begins with introductions, reality orientation, a group song and discussion of the news of the week. This is followed by a physical activity/game and ADL-focused cognitive stimulation activities. These activities include the identification and categorization of everyday items, discussion, reminiscence, planning and sequencing of ADLs and the completion of everyday writing/calculation tasks. This is followed by practice of an ADL. Examples of activities include making a breakfast, a simple gardening activity or sorting laundry. The session then ends with a summary and repeat of the group song, and a plan for the next session.
219349206|NCT03831841|BEHAVIORAL|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
219349207|NCT05139186|DEVICE|Artificial Intelligence|Artificial intelligence
219349208|NCT02989064|GENETIC|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
219349209|NCT04249687|BIOLOGICAL|botulinum toxin|neuromodulator
219349210|NCT04249687|BIOLOGICAL|Placebo|placebo
219349211|NCT01202929|PROCEDURE|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
219349212|NCT02698488|PROCEDURE|Morphology|
219349213|NCT02698488|PROCEDURE|Morphology and Mass Spectroscopy|
219349214|NCT04845100|OTHER|Animal Assisted Activity Program|"Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)"
219349215|NCT03963635|DIAGNOSTIC_TEST|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
219349216|NCT01962233|BIOLOGICAL|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
219349217|NCT00262873|DRUG|bortezomib|
219349218|NCT06383273|DRUG|MELT-300 sublingual tablet|Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
219349219|NCT06383273|DRUG|Midalozam sublingual tablet|Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
219349220|NCT06383273|DRUG|Placebo sublingual tablet|Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
219349221|NCT03014401|PROCEDURE|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
219349222|NCT03014401|PROCEDURE|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
219349223|NCT04169360|DRUG|ANS-6637|White, oblong 300 mg tablet
219349224|NCT04169360|DRUG|Placebo oral tablet|White, oblong 300 mg tablet
219349225|NCT03448250|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
219349226|NCT03448250|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
219349227|NCT00634153|OTHER|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
219349228|NCT04218253|DIETARY_SUPPLEMENT|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
219349229|NCT04218253|BEHAVIORAL|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
219349230|NCT03826550|DRUG|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
219349231|NCT03826550|DRUG|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
219349232|NCT03826550|OTHER|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
219349233|NCT00844753|DRUG|atomoxetine|atomoxetine
219349234|NCT00844753|DRUG|Placebo|Placebo + parent management treatment
219349235|NCT00844753|BEHAVIORAL|Parent Management Training|
219349236|NCT05909956|OTHER|KinesioTape|The kinesio tape technique, one of the physiotherapy techniques, is an elastic thin band, water-resistant, air-permeable framework to stimulate muscle movements, assist weak muscles (fascia and soft tissue), reduce discomfort and muscle cramps, facilitate proprioceptive input, boost lymph and blood flow, and relieve pain. Participants in the KT group will receive therapeutic tape on the sacral and suprapubic regions with the Star shape and ligament technique (From initial 4 h to 72 h of the menstruation cycle)
219349237|NCT05909956|OTHER|Sham Tape|This group will receive KT tapping without stretch on the sacral and suprapubic region.
219349238|NCT05909956|OTHER|General Physio session|General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck \& upper trapezius, arm \& shoulder girdle, triceps brachii, teres major \& minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
219349239|NCT00549367|BEHAVIORAL|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
219349240|NCT03452696|DIETARY_SUPPLEMENT|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
219349241|NCT00005071|PROCEDURE|biopsy|
219349242|NCT00005071|PROCEDURE|bronchoscopy|
219349243|NCT00005071|PROCEDURE|computed tomography|
219349244|NCT00005071|PROCEDURE|quality-of-life assessment|
219349245|NCT03143140|OTHER|PAFA|percutaneous ablation of tumor feeding artery
219349246|NCT03143140|OTHER|tumor ablation|ablation of tumor area directly
219349247|NCT01852994|DRUG|Testosterone replacement|Application quarterly of Testosterone Undecylate
219349248|NCT01852994|OTHER|Exercise training|Aerobic and strength exercise training
219349249|NCT00510926|DRUG|Imatinib Mesilate (Glivec)|
219349250|NCT02425826|DRUG|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
219349251|NCT02425826|DRUG|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
219349252|NCT02425826|DRUG|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
219349253|NCT04874987|OTHER|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
219349254|NCT00525655|BEHAVIORAL|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
219349255|NCT00525655|BEHAVIORAL|Questionnaire|Questionnaires taking 10-15 minutes to complete.
219349256|NCT02725983|BEHAVIORAL|SPT consultation|
219349257|NCT02725983|DEVICE|SOPROCARE®|
219349258|NCT03912675|PROCEDURE|Integra® dermal substitute and RigeneraTM protocol|Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
219349259|NCT04634500|DRUG|Dapagliflozin|Dapagliflozin Tablet
219349260|NCT04676997|BIOLOGICAL|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
219349261|NCT04676997|DRUG|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
219349262|NCT04676997|DRUG|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
219349263|NCT04676997|DRUG|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
219349264|NCT05667896|DRUG|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
219349265|NCT02707783|DEVICE|Bioresorbable vascular scaffold (BVS) implantation|
219349266|NCT02202629|OTHER|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
219349267|NCT04554160|DEVICE|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
219349268|NCT04554160|DEVICE|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
219349269|NCT05184608|OTHER|Cycling exercise|20 minutes of cycling (90 rpm).
219349270|NCT05184608|OTHER|Cognitive tasks|20 minutes of cognitive tasks based on the different domains of the UPDRS scale.
219349271|NCT02337400|BEHAVIORAL|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
219349272|NCT02337400|BEHAVIORAL|15 minute counseling interview|
219349273|NCT01950000|DRUG|Fentanyl|
219349274|NCT01950000|OTHER|Placebo|
219349275|NCT02446431|DRUG|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
219349276|NCT02446431|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
219349277|NCT02446431|DRUG|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
219349278|NCT02446431|DRUG|Temsirolimus|Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
219349279|NCT02683200|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
219349280|NCT02683200|RADIATION|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
219349281|NCT03270735|DRUG|Snake venom thrombin (Treatment)|Snake venom thrombin
219349282|NCT03270735|DRUG|Placebo|No snake venom thrombin
219349283|NCT04036968|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
219349284|NCT04180293|BEHAVIORAL|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot virtual psychoeducation program and its evaluation. Two six-week sessions will be implemented over a virtual care platform (Zoom for healthcare) based out of OSI Clinic in Atlantic Canada - the first in January/February of 2021 and the second in the spring of 2021. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place virtually and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
219349285|NCT04180293|OTHER|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
219349286|NCT02997904|DEVICE|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
219349287|NCT01308970|BEHAVIORAL|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
219349288|NCT01308970|BEHAVIORAL|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
219349289|NCT01308970|BEHAVIORAL|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
219349290|NCT05637918|OTHER|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
219349291|NCT05637918|OTHER|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
219349292|NCT01246570|BEHAVIORAL|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
219349293|NCT01246570|OTHER|Control|The patients will receive the usual care provided by the hospitals and the community health services
219349294|NCT04724564|DIAGNOSTIC_TEST|THE SURGICAL PLETH INDEX|CORRELATION OF DIFFERENT TIME MEASUREMENTS OF THE SURGICAL PLETH INDEX WITH POSTOPERATIVE PAIN
219349295|NCT03171207|DEVICE|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
219349296|NCT03171207|DEVICE|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
219349297|NCT02814630|BIOLOGICAL|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
219349298|NCT04840108|BEHAVIORAL|Support Person Coaching Intervention|The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.
219349299|NCT04840108|BEHAVIORAL|Support Person Written Materials|Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
219349300|NCT02690311|DEVICE|smartphone display|
219349301|NCT02595151|DEVICE|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
219349302|NCT01208714|DRUG|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%)."
219349303|NCT01208714|PROCEDURE|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
219349304|NCT02813200|DRUG|Seretide® Diskus® 500/550 μg|Every day during 7 days
219349305|NCT02813200|DRUG|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
219349306|NCT02813200|DRUG|Spiriva® Respimat® 2,5 μg|Every day during 7 days
219349307|NCT02500121|OTHER|Placebo|Normal saline
219349308|NCT02500121|DRUG|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
219349309|NCT05500209|BEHAVIORAL|Personal resources' enhancement: self-efficacy|Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
219349310|NCT03730116|DRUG|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
219349311|NCT00852995|BIOLOGICAL|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
219349312|NCT00852995|BIOLOGICAL|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
219349313|NCT03111446|PROCEDURE|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
219349314|NCT03111446|PROCEDURE|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
219349315|NCT02133989|DRUG|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
219349316|NCT02133989|DRUG|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
219349317|NCT00445419|BIOLOGICAL|PEV2A PEV2B|
219349318|NCT05256407|OTHER|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
219349319|NCT05260619|DRUG|lenalidomide|Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
219349320|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
219349321|NCT04539639|DRUG|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
219349322|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
219349323|NCT04539639|DRUG|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
219349324|NCT03380689|DRUG|S-1|\- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
219349325|NCT03380689|DRUG|Irinotecan|\- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
219349326|NCT03380689|DRUG|Bevacizumab|\- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
219349327|NCT02868008|PROCEDURE|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
219349328|NCT04031651|DRUG|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
219349329|NCT00118014|DRUG|Sertraline|
219349330|NCT00118014|BEHAVIORAL|Habit Reversal Training|
219349331|NCT00661115|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
219349332|NCT00661115|DRUG|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
219349333|NCT00150254|DRUG|CP-526,555 (varenicline)|
219349334|NCT04336631|BEHAVIORAL|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
219349335|NCT02565407|BEHAVIORAL|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
219349336|NCT02565407|BEHAVIORAL|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
219349337|NCT02537171|DRUG|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
219349338|NCT00717171|DEVICE|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
219349339|NCT00717171|DEVICE|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
219349340|NCT02567487|DRUG|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
219349341|NCT05551832|DRUG|Arm I (Placebo),|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
219349342|NCT05551832|DRUG|Arm II (ESMESOL)|SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
219349343|NCT03799393|BEHAVIORAL|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
219349344|NCT03799393|BEHAVIORAL|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
219349345|NCT04986800|BEHAVIORAL|PROACTIVE Parent|PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
219349346|NCT03284736|PROCEDURE|Resorbable membrane|
219349347|NCT03284736|PROCEDURE|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
219349348|NCT02858414|OTHER|additional blood sample|
219349349|NCT00418197|DEVICE|Total Facet Arthroplasty System® (TFAS®)|
219349350|NCT06505109|BEHAVIORAL|RESST|Subjects randomized to the RESST intervention will receive on top of standard rehabilitation a behavioural group intervention focussing on improving sleep and stress. This intervention will consist of 5 till 6 meetings of 90 till 120 minutes in the local rehabilitation centre during a time period of 3 till 4 months.
219349351|NCT03615677|DRUG|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
219349352|NCT03615677|DRUG|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
219349353|NCT03649061|DRUG|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
219349354|NCT03649061|DRUG|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
219349355|NCT06394011|DRUG|venetoclax, azacitidine and HAAG regimen|Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
219349356|NCT05595187|DEVICE|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
219349357|NCT00247000|DEVICE|Routine Care in a HF clinic vs Home Telehealth Care for HF|
219349358|NCT00579371|DRUG|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
219349359|NCT04109820|DIETARY_SUPPLEMENT|MitoQ|Oral; 20mg once a day for 14 days
219349360|NCT05163119|BEHAVIORAL|Commercial Cellphone-Blocking App (Active)|The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.
219349361|NCT05163119|BEHAVIORAL|Driving Mode|"Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider)."
219349362|NCT01441479|DEVICE|In Vitro Diagnostic Device aid in diagnosing|
219349363|NCT04818684|OTHER|questionnaire|a questionnaire consisting of a list of support practices
219349364|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
219349365|NCT00247026|DRUG|curcumin; coenzyme q10|
219349366|NCT01222676|DRUG|cisplatin|
219349367|NCT01222676|DRUG|gemcitabine hydrochloride|
219349368|NCT01222676|DRUG|sorafenib tosylate|
219349369|NCT01222676|OTHER|imaging biomarker analysis|
219349370|NCT01222676|OTHER|laboratory biomarker analysis|
219349371|NCT01222676|PROCEDURE|computed tomography|
219349372|NCT01222676|PROCEDURE|neoadjuvant therapy|
219349373|NCT01222676|RADIATION|fludeoxyglucose F 18|
219349374|NCT02323269|DRUG|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
219349375|NCT04518462|DRUG|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
219349376|NCT04518462|DRUG|Bupivacaine Hydrochloride|0.25% bupivacaine
219349377|NCT02866279|DEVICE|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
219349378|NCT05723705|OTHER|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
219349379|NCT06267196|OTHER|The use of a stress ball|The effect of the stress ball used during spinal anesthesia on pain and anxiety
219349380|NCT04133467|OTHER|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
219349381|NCT04418076|DEVICE|Group A_No feedback|In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
219349382|NCT04418076|DEVICE|Group B_Automated feedback|For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
219349383|NCT04418076|DEVICE|Group C_Automated feedback + Clinician feedback|For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
219349384|NCT04418076|DEVICE|Group D_Automated feedback + Social Network feedback|For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
219349385|NCT05424653|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
219349386|NCT02554097|PROCEDURE|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
219349387|NCT02554097|PROCEDURE|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
219349388|NCT02554097|PROCEDURE|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
219349389|NCT02554097|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
219349390|NCT02844556|PROCEDURE|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
219349391|NCT02844556|OTHER|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
219349392|NCT00978211|DRUG|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment."
219349393|NCT04338750|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers|Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.
219349394|NCT04338750|BEHAVIORAL|minimally-Enhanced Usual Care|Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
219349395|NCT04689529|DIAGNOSTIC_TEST|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
219349396|NCT05378451|PROCEDURE|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
219349397|NCT00999531|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
219349398|NCT00999531|DRUG|Placebo|Inhaled Placebo, sterile saline
219349399|NCT03080909|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
219349400|NCT03080909|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
219349401|NCT00429208|DRUG|Nicotine|
219349402|NCT04292509|DEVICE|SAP with stop before low|cross-over comparison from stop on low to stop before low
219349403|NCT04292509|DEVICE|SAP with stop on low|cross-over comparison from stop before low to stop on low
219349404|NCT04372277|DRUG|Enstilar|topical Enstilar foam
219349405|NCT05288270|DEVICE|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~* 1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~* 5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
219349406|NCT05288270|OTHER|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
219349407|NCT01697735|DRUG|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
219349408|NCT01697735|DRUG|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
219349409|NCT01950871|DEVICE|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
219349410|NCT01471782|BIOLOGICAL|Blinatumomab|Administered by continuous intravenous infusion
219349411|NCT00309231|PROCEDURE|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
219349412|NCT02164695|PROCEDURE|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
219349413|NCT02164695|PROCEDURE|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
219349414|NCT03363815|DRUG|CC-90001|CC-90001
219349415|NCT03363815|DRUG|Omeprazole|Omeprazole
219349416|NCT03363815|DRUG|Midazolam|Midazolam
219349417|NCT03363815|DRUG|Warfarin|Warfarin
219349418|NCT03363815|DIETARY_SUPPLEMENT|Vitamin K|Vitamin K
219349419|NCT03363815|DRUG|Rosuvastatin|Rosuvastatin
219349420|NCT03363815|DRUG|Metformin|Metformin
219349421|NCT03363815|DRUG|Digoxin|Digoxin
219349422|NCT03363815|DRUG|Nintedanib|Nintedanib
219349423|NCT02586168|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
219349424|NCT02586168|DRUG|Placebo|Placebo
219349425|NCT03473288|BEHAVIORAL|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
219349426|NCT03473288|BEHAVIORAL|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
219349427|NCT04117971|OTHER|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
219349428|NCT03976973|DRUG|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
219349429|NCT03976973|DRUG|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
219349430|NCT03976973|PROCEDURE|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
219349431|NCT05779137|BEHAVIORAL|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
219349432|NCT05567237|OTHER|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
219349433|NCT05567237|OTHER|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
219349434|NCT05567237|OTHER|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
219349435|NCT05567237|OTHER|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
219349436|NCT01403012|OTHER|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
219349437|NCT03927274|DRUG|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
219349438|NCT00716651|DRUG|mepolizumab|750 mg mepolizumab iv q4wk until week 32
219349439|NCT01314716|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
219349440|NCT01314716|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
219349441|NCT02479009|DEVICE|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
219349442|NCT06330038|DRUG|Propofol|Propofol will be used for the induction and maintenance of general anesthesia.
219349443|NCT06330038|DRUG|Inhaled anesthetics|Inhaled anesthetics will be used for the maintenance of general anesthesia.
219349444|NCT04290832|BEHAVIORAL|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
219349445|NCT02922062|OTHER|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
219349446|NCT02922062|OTHER|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
219349447|NCT02922062|OTHER|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
219349448|NCT04454190|DIAGNOSTIC_TEST|Collection of genetic material|Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
219349449|NCT01452152|DRUG|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
219349450|NCT01452152|DRUG|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
219349451|NCT07029841|DEVICE|catheter-based therapy|catheter-based therapy
219349452|NCT07028658|OTHER|Speechreading training|The patient will undergo 16 lip reading training sessions. By developing functional lip reading skills, they will be able to fill in the gaps in auditory information they miss, especially in loud or noisy settings
219349453|NCT07029685|OTHER|Physical|They will carry out a physical activity intervention based on the ecological model
219349454|NCT04875884|DEVICE|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
219349455|NCT04151199|OTHER|EE Training|Participants randomized to EE training engage in three school-based or center-based (PERC) EE training sessions each week for approximately 12 weeks; each session lasting roughly 70 min with a 45-50 minutes of a stimulus phase and the remaining time being used to warm-up and cool down.
219349456|NCT05292781|OTHER|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
219349457|NCT05292781|OTHER|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
219349458|NCT03711214|PROCEDURE|Periodontal scaling|Periodontal scaling and root planing
219349459|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
219349460|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
219349461|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
219349462|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
219349463|NCT06191185|BEHAVIORAL|BPB, No PIN|"Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
219349464|NCT06191185|BEHAVIORAL|BPB, PIN|"Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
219349465|NCT06191185|BEHAVIORAL|No BPB, PIN|Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.
219349466|NCT06191185|BEHAVIORAL|No BPB, No PIN|Patient-level: standard communication from their care team.
219349467|NCT06407934|DRUG|Amlitelimab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection"
219349468|NCT06407934|DRUG|Placebo|"Pharmaceutical form: Injection solution~Route of administration: SC injection"
219349469|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
219349470|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
219349471|NCT06425003|DRUG|[14C] ABBV-CLS-7262|Oral Solution
219349472|NCT01197326|DEVICE|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
219349473|NCT01497015|BEHAVIORAL|memory training|10 1-hour sessions over 6-8 weeks
219349474|NCT01497015|BEHAVIORAL|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
219349475|NCT01497015|BEHAVIORAL|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
219349476|NCT02627495|DEVICE|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
219349477|NCT02364128|BEHAVIORAL|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
219349478|NCT03314545|PROCEDURE|laminate veneer with coronal post|laminate veneer with coronal post
219349479|NCT03314545|PROCEDURE|post,core and crown|post,core and crown
219349480|NCT00880893|BIOLOGICAL|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
219349481|NCT00880893|BIOLOGICAL|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
219349482|NCT02187952|BEHAVIORAL|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
219349483|NCT05738850|DRUG|ABBV-932|Oral Capsule
219349484|NCT05738850|DRUG|Placebo|Oral Capsule
219349485|NCT01489514|OTHER|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~1. Histamine control purchased from Greer.~2. Saline control purchased from Greer.~3. Standard Peanut Extract purchased from Greer.~4. Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A \& T.~5. Sterile extract prepared from roasted \& blanched but untreated peanuts. This is prepared by North Carolina A \& T.~6. Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A \& T. This is not classified as a drug and is~7. Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~8. Sterile extracts containing peanuts that have been treated with alcalase"
219349486|NCT01612429|DIETARY_SUPPLEMENT|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
219349487|NCT03329235|DRUG|PRP|platelet rich plasma
219349488|NCT03329235|DRUG|HA|hyaluronic acid
219349489|NCT02561091|OTHER|Placebo|
219349490|NCT02561091|DRUG|AM-111 0.4 mg/ml|
219349491|NCT02561091|DRUG|AM-111 0.8 mg/ml|
219349492|NCT00479154|DRUG|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
219349493|NCT05745935|DRUG|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
219349494|NCT01317680|DEVICE|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
219349495|NCT01317680|DEVICE|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
219349496|NCT02543528|DEVICE|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
219349497|NCT02543528|DEVICE|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
219349498|NCT02543528|DEVICE|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
219349499|NCT02543528|DEVICE|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
219349500|NCT02543528|DEVICE|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
219349501|NCT06390085|OTHER|Soft tissue manipulation|The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
219349502|NCT04506697|PROCEDURE|Uroflowmetry|The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
219349503|NCT04437212|DRUG|Toripalimab|Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
219349504|NCT00650754|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
219349505|NCT00650754|OTHER|Placebo|Placebo
219349506|NCT01531283|DRUG|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
219349507|NCT01531283|DRUG|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
219349508|NCT01531283|DRUG|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
219349509|NCT01531283|DRUG|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
219349510|NCT06277752|DRUG|dose-5 group|IBI128 300mg po. QD(Quaque Die)
219349511|NCT06277752|DRUG|dose-1 group|IBI128 25mg po. QD(Quaque Die)
219349512|NCT06277752|DRUG|dose-2 group|IBI128 50mg po. QD(Quaque Die)
219349513|NCT06277752|DRUG|dose-4 group|IBI128 200mg po. QD(Quaque Die)
219349514|NCT06277752|DRUG|dose-3 group|IBI128 100mg po. QD(Quaque Die)
219349515|NCT05808036|OTHER|Dietary intervention: DOMINO app|Life style intervention and diet low in FODMAPs.
219349516|NCT05808036|OTHER|Dietary intervention: low FODMAP diet|Strict low FODMAP diet.
219349517|NCT04943705|DEVICE|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
219349518|NCT00364312|BEHAVIORAL|diet and physical activity|
219349519|NCT06500832|OTHER|Survey-based Data Collection Tool|"The data collection tool to be presented to the participants is planned as a three-part survey. The first part of this form asked 9 questions about the demographic characteristics of the participants consisted of age, gender, marital status, duration in the profession, specialization in dentistry, type of workplace, and off-the-clock work.~The second part of the data collection tool consisted of the 'Defensive Dentistry Practice Survey,'(DDPS) DDPS which is the original language of which is Turkish, is a 5-point Likert-type scale. A total of 12 statements about DDPS which measure the opinions, attitudes, or behaviors of the participants in terms of DDP, the following options are used: strongly disagreed, disagreed, neither disagreed nor agreed, agreed and strongly agreed, each expressing groups of 20%.~The last part of the survey had 3 close-ended questions with yes-no options expressing 50% groups is used."
219349520|NCT06220734|PROCEDURE|transurethral resection of the prostate|transurethral resection of the prostate for indicated patients then US was done for early detection of fluid accumulation in the lungs
219349521|NCT02049944|DRUG|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
219349522|NCT00004941|DRUG|monoclonal antibody cA2|
219349523|NCT06341673|DEVICE|Active Transcutaneous Electrical Nerve Stimulation (TENS)|For active group: TENS is to be used to stimulate tibial Nerve at medial aspect of the foot. The stimulation is proved by flexion of the big toe (motor response) and/or tingling sensation of ipsilateral sole of foot (sensory response) by raising the current amplitude, mA, intensity. Increasing the intensity above sensory threshold is recommended but should not be painful
219349524|NCT06341673|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|TENS on the lateral side of the foot, the negative electrode on the top of the foot just above the small toe for conduction and the positive electrode on the bottom of below the smallest toe to avoid the tibial nerve and relevant cutaneous nerves. Participants will be instructed to raise up the intensity until the first and slight tingling sensation on the sole of the foot or toe
219349525|NCT05926310|DEVICE|TWIICE Rise|"TWIICE Rise is a lower-limb overground robotic exoskeleton intended for patients with spinal cord injury (SCI).~TWIICE Rise is intended to perform ambulatory functions in rehabilitation institutions, home, or community environment under the supervision of a specially trained coach."
219349526|NCT06391138|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
219349527|NCT03678597|OTHER|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
219349528|NCT00916240|BEHAVIORAL|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
219349529|NCT00916240|BEHAVIORAL|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
219349530|NCT01272466|BIOLOGICAL|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
219349531|NCT01311947|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
219349532|NCT05881187|DRUG|Riboflavin|topical application of riboflavin followed by cross linking
219349533|NCT05881187|DRUG|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
219349534|NCT05881187|DEVICE|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
219349535|NCT05273580|DEVICE|Garmin VivoSmart 4|Wearable sensor to record; sleep, stress, heart rate etc.
219349536|NCT05273580|DEVICE|mema - ilumivu|mEMA is the a self-service platform running on both iOS and Android that is specifically designed for the administration of mobile Ecological Momentary Assessment or Experience Sampling research studies.
219349537|NCT05174000|DRUG|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
219349538|NCT05174000|DRUG|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
219349539|NCT01765673|DEVICE|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
219349540|NCT06548204|DRUG|Fexofenadine Hydrochloride 60mg bid|Fexofenadine hydrochloride 60mg bid treatment for 6 months.
219349541|NCT06548204|OTHER|Placebo|Placebo administration for 6 months.
219349542|NCT06548204|DRUG|Fexofenadine Hydrochloride 120mg bid|Fexofenadine hydrochloride 120mg bid treatment for 6 months.
219349543|NCT01042600|DEVICE|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
219349544|NCT01042600|DEVICE|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
219349545|NCT00000873|DRUG|Infant Formula|
219349546|NCT02205684|OTHER|Computer game skills training|Playing Nintendo Wii Sports
219349547|NCT02205684|OTHER|Physical activity|Aerobic High Intensity Training (HIT)
219349548|NCT03678480|DRUG|HTD1801|HTD1801 capsules, 250mg
219349549|NCT03678480|DRUG|Ursodeoxycholic Acid|UDCA capsules, 125mg
219349550|NCT02600507|DRUG|Lumateperone (ITI-007)|
219349551|NCT02600507|DRUG|Placebo|
219349552|NCT05392348|DIETARY_SUPPLEMENT|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
219349553|NCT05392348|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
219349554|NCT04771533|PROCEDURE|hand motor coordination in a sitting position|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
219349555|NCT04771533|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
219349556|NCT02643004|DEVICE|Senofilcon A|contact lens
219349557|NCT02643004|DEVICE|Stenfilcon A|contact lens
219349558|NCT01975922|BEHAVIORAL|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
219349559|NCT02485145|DRUG|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
219349560|NCT02485145|DRUG|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
219349561|NCT02485145|DRUG|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
219349562|NCT01082185|DEVICE|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
219349563|NCT00742339|DRUG|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
219349564|NCT00742339|DRUG|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
219349565|NCT06326242|OTHER|Solid Tumor|The study focuses on defining the problem of geographical accessibility of patients to the Phase 1 facility of the European Institute of Oncology, based on anonymized data extraction from the enrolled patient database, to evaluate national territorial disparities in access to innovative experimental therapies, in relation to various socioeconomic determinants. Finally, relevant information on psychological factors for participation in clinical trials will also be collected.
219349566|NCT04632355|OTHER|Interview|This interview will be conducted to collecting all outcomes about musculoskeletal pain in COVID-19 survivors
219349567|NCT04917211|PROCEDURE|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
219349568|NCT04970004|OTHER|No intervention|No study intervention will be administered as part of this study.
219349569|NCT03536351|BEHAVIORAL|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
219349570|NCT01013987|DRUG|maraviroc|maraviroc: one 150 mg pill twice daily
219349571|NCT01013987|DRUG|Raltegravir|raltegravir : one 400 mg pill twice daily
219349572|NCT01013987|DRUG|Darunavir/ritonavir|"* darunavir : two 300 mg pills twice daily with meal~* ritonavir: one 100 mg pill twice daily with meal"
219349573|NCT04484532|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
219349574|NCT00141765|PROCEDURE|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
219349575|NCT00141765|PROCEDURE|Stem Cell Rescue|autologous stem cell transplantation
219349576|NCT05054452|DEVICE|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
219349577|NCT05396274|DEVICE|High Flow Nasal Cannula|high flow nasale cannula
219349578|NCT00605085|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
219349579|NCT00605085|BIOLOGICAL|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
219349580|NCT00190593|DRUG|raloxifene|
219349581|NCT00190593|DRUG|placebo|
219349582|NCT01179074|PROCEDURE|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
219349583|NCT01179074|PROCEDURE|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
219349584|NCT00621504|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
219349585|NCT00621504|DRUG|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
219349586|NCT00621504|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
219349587|NCT00621504|DRUG|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
219349588|NCT02132104|PROCEDURE|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
219349589|NCT02132104|DEVICE|Foley balloon|Uterine application of Foley balloon
219349590|NCT02132104|DRUG|Femoston|Hormones treatment after surgery.
219349591|NCT01952587|BIOLOGICAL|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
219349592|NCT05836298|OTHER|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
219349593|NCT02514967|DRUG|Blisibimod|Administered via subcutaneous injection once per week
219349594|NCT02514967|DRUG|Placebo|Administered via subcutaneous injection once per week
219349595|NCT00600015|DRUG|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
219349596|NCT00600015|DRUG|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
219349597|NCT03980366|DEVICE|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
219349598|NCT05662267|OTHER|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
219349599|NCT00731874|DRUG|Tacrolimus|Dosed to achieve target trough concentrations.
219349600|NCT04999189|OTHER|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
219349601|NCT00936624|DRUG|SOTB07|SOTB07 100mg
219349602|NCT00936624|DRUG|SOTB07|SOTB07 200mg
219349603|NCT00936624|DRUG|placebo|placebo
219349604|NCT00936624|DRUG|montelukast|montelukast 10mg po, bid, 12week
219349605|NCT02934009|DEVICE|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
219349606|NCT05130307|BEHAVIORAL|virtual reality game|participants interact with a computer generated world
219349607|NCT03110055|DRUG|Grazoprevir/Elbasvir|anti-viral treatment for HCV
219349608|NCT03110055|OTHER|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
219349609|NCT03110055|PROCEDURE|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
219354896|NCT06465589|OTHER|JOURNeY anonymous|"The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
219349610|NCT03206723|DEVICE|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
219349611|NCT03206723|DRUG|Eyedrop|Fluoroquinolone eyedrops 4x/day
219349612|NCT03206723|DRUG|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
219349613|NCT06796309|OTHER|Trak Telerehabilitation Platform|The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.
219349614|NCT06796309|OTHER|Conventional Rehabilitation Program|Exercise protocol with the methodology of conventional clinical practice.
219349615|NCT06399276|BEHAVIORAL|Weight Loss|Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
219349616|NCT05490745|BEHAVIORAL|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
219349617|NCT05490745|OTHER|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
219349618|NCT06630793|RADIATION|IMPT (Intensity Modulated Proton Therapy)|Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.
219349619|NCT06630793|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
219349620|NCT03257267|DRUG|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
219349621|NCT03257267|DRUG|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
219349622|NCT01508871|OTHER|Observational study, no intervention|No intervention
219349623|NCT03308656|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
219349624|NCT04012047|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
219349625|NCT04012047|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
219349626|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
219349627|NCT01926483|OTHER|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
219349628|NCT04509778|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
219349629|NCT06022263|DRUG|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
219349630|NCT06022263|DRUG|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
219349631|NCT05173454|BEHAVIORAL|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
219349632|NCT00292825|DEVICE|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
219349633|NCT00292825|DEVICE|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
219349634|NCT00184678|DRUG|somatropin|
219349635|NCT02077088|OTHER|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
219349636|NCT01442883|DEVICE|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
219349637|NCT02457871|BEHAVIORAL|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
219349638|NCT04231383|OTHER|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
219349639|NCT05298137|PROCEDURE|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
219349640|NCT03657368|PROCEDURE|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
219349641|NCT03657368|PROCEDURE|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
219349642|NCT03657368|PROCEDURE|Low PEEP|PEEP = 5 cm H2O
219349643|NCT03657368|PROCEDURE|High PEEP|PEEP = 8 cm H2O
219349644|NCT01623271|DRUG|Gabapentin|
219349645|NCT00706134|DRUG|Placebo|Placebo tablet taken once daily in the morning with a light meal.
219349646|NCT00706134|DRUG|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
219349647|NCT00706134|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
219349648|NCT00706134|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
219349649|NCT04747171|DRUG|intrathecal Magnesium|intrathecal adjuvants to bupivacaine
219349650|NCT04747171|DRUG|intrathecal dexamthasone|intrathecal adjuvants to bupivacaine
219349651|NCT04747171|DRUG|intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
219349652|NCT03224897|DEVICE|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
219349653|NCT03224897|DEVICE|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
219349654|NCT03224897|DEVICE|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
219349655|NCT02738658|DEVICE|Bioresorbable vascular scaffold|
219349656|NCT02738658|DEVICE|Everolimus-eluting stent|
219349657|NCT01972893|DRUG|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
219349658|NCT01972893|DRUG|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
219349659|NCT03715283|OTHER|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
219349660|NCT03715283|OTHER|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
219349661|NCT01982292|DRUG|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
219349662|NCT01982292|DRUG|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
219349663|NCT00720603|DRUG|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
219349664|NCT02195752|OTHER|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
219349665|NCT00891605|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
219349666|NCT00891605|DRUG|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
219349667|NCT04320238|DRUG|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
219349668|NCT04320238|DRUG|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
219349669|NCT00011921|BIOLOGICAL|filgrastim|
219349670|NCT00011921|DRUG|carboplatin|
219349671|NCT00011921|DRUG|epirubicin hydrochloride|
219349672|NCT00011921|DRUG|etoposide|
219349673|NCT00011921|DRUG|etoposide phosphate|
219349674|NCT00011921|DRUG|ifosfamide|
219349675|NCT00011921|DRUG|paclitaxel|
219349676|NCT00011921|PROCEDURE|autologous bone marrow transplantation|
219349677|NCT00011921|PROCEDURE|bone marrow ablation with stem cell support|
219349678|NCT00011921|PROCEDURE|peripheral blood stem cell transplantation|
219349679|NCT00011921|RADIATION|radiation therapy|
219349680|NCT01069822|DRUG|AZD6765|IV solution
219349681|NCT01069822|DRUG|midazolam|
219349682|NCT02700490|BEHAVIORAL|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
219349683|NCT02915081|OTHER|Blue light|"Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
219349684|NCT05459831|DEVICE|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
219349685|NCT01372904|DRUG|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
219349686|NCT06471556|DRUG|IV Methylprednisolone pulses|Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
219349687|NCT06265766|DEVICE|Active cTBS|10 sessions of active cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
219349688|NCT06265766|DEVICE|Sham cTBS|10 sessions of sham cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
219349689|NCT03718507|DRUG|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
219349690|NCT03718507|DRUG|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
219349691|NCT03354754|DRUG|LYS228|LYS228 IV infusion every 6 hours
219349692|NCT03354754|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
219349693|NCT02837315|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
219349694|NCT02837315|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
219349695|NCT02837315|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
219349696|NCT05791656|DEVICE|Mectascrew-C|reconstruction of ACL or PCL rupture
219349697|NCT00746252|DRUG|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
219349698|NCT00746252|DRUG|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
219349699|NCT02242955|DRUG|Diazepam|40 mg per day.
219349700|NCT01240642|DRUG|ASA404|
219349701|NCT00935168|DRUG|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
219349702|NCT00935168|DRUG|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
219349703|NCT00082888|OTHER|Laboratory Biomarker Analysis|Correlative studies
219349704|NCT00082888|DRUG|Tipifarnib|Given PO
219349705|NCT01549236|DRUG|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~\- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
219349706|NCT03874377|BEHAVIORAL|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
219349707|NCT03874377|BEHAVIORAL|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
219349708|NCT00317798|BIOLOGICAL|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
219349709|NCT00317798|DRUG|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
219349710|NCT02716610|DRUG|INH 69 U (low)|inhaled human insulin
219349711|NCT02716610|DRUG|INH 69 U (high)|inhaled human insulin
219349712|NCT02716610|DRUG|INH 139 U|inhaled human insulin
219349713|NCT02716610|DRUG|INH 208 U|inhaled human insulin
219349714|NCT02716610|DRUG|LIS 18 U|subcutaneous insulin lispro
219349715|NCT04033835|OTHER|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
219349716|NCT04033835|OTHER|Treatment as usual|Treatment as usual
219349717|NCT05448872|DRUG|Sacubitril/Valsartan|HF patients treated with Sac/Val
219349718|NCT06299527|OTHER|Exercise Program|Exercise Program In our study, the telerehabilitation program was applied for both synchronous and asynchronous groups, 3 days a week, 1 session per day, for 8 weeks. The exercises were combined individually according to the person's capacity, and the intensity and duration of the exercise will gradually increase according to the patient's tolerance.
219349719|NCT04582578|DEVICE|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
219349720|NCT01659320|DRUG|Minocycline|Minocycline 100 mg twice daily for 8 weeks
219349721|NCT01871454|RADIATION|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
219349722|NCT01871454|DRUG|Pentoxifylline|pentoxifylline
219349723|NCT02436850|PROCEDURE|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
219349724|NCT06038786|BEHAVIORAL|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
219349725|NCT01870401|DEVICE|Lutonix DCB|
219349726|NCT01870401|DEVICE|Uncoated PTA Catheter|
219349727|NCT04623242|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
219349728|NCT04623242|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
219349729|NCT04623242|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
219349730|NCT04623242|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
219349731|NCT00820898|DRUG|Gemcitabine Hydrochloride|Given IV
219349732|NCT01826747|DRUG|crinone (progesterone 8%, vaginal application)|
219349733|NCT01000662|RADIATION|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
219349734|NCT01000662|RADIATION|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
219349735|NCT01667471|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
219349736|NCT00753870|BIOLOGICAL|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
219349737|NCT02503904|PROCEDURE|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
219349738|NCT02503904|DEVICE|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
219349739|NCT02503904|DRUG|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
219349740|NCT01863511|DRUG|loop diuretic|
219349741|NCT01863511|DRUG|tolvaptan|
219349742|NCT01863511|PROCEDURE|ultrafiltration|
219349743|NCT00493870|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
219349744|NCT00493870|DRUG|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
219349745|NCT00493870|DRUG|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
219349746|NCT03605680|DRUG|Centanafadine SR|100 mg, BID, oral tablets
219349747|NCT03605680|OTHER|Placebo|BID, oral tablet.
219349748|NCT03605680|DRUG|Centanafadine SR|200 mg, BID, oral tablets
219349749|NCT05552911|PROCEDURE|Pretreatment strategies before drug balloon therapy|Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
219349750|NCT05552911|PROCEDURE|Different types of in-stent restenosis were treated with drug-coated balloons|A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
219349751|NCT04222595|OTHER|Fluenz Tetra nasal spray suspension|Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
219349752|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
219349753|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
219349754|NCT06538883|DRUG|Sedation with Ciprofol|During the drug administration period, ciprofol were IV infused at loading doses of 0.1 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
219349755|NCT06538883|DRUG|Sedation with Propofol|During the drug administration period, propofol were IV infused at loading doses of 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Propofol were then immediately administered at an initial maintenance dose of 1.5 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
219349756|NCT03943212|OTHER|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
219349757|NCT03943212|OTHER|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
219349758|NCT01120665|DRUG|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
219349759|NCT01120665|OTHER|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
219349760|NCT01120665|DRUG|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
219349761|NCT01120665|OTHER|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
219349762|NCT04170517|DIAGNOSTIC_TEST|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
219349763|NCT03136315|OTHER|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
219349764|NCT05284682|DIAGNOSTIC_TEST|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
219349765|NCT01652287|DRUG|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
219349766|NCT01652287|OTHER|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
219349767|NCT02106312|RADIATION|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
219349768|NCT00527605|DRUG|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
219349769|NCT00527605|DRUG|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
219349770|NCT03697187|DRUG|rhC1INH|Recombinant human C1 inhibitor
219349771|NCT03365466|DRUG|Low dose aspirin|LDA 25mg tid
219349772|NCT03365466|DRUG|Low molecular weight heparin|LMWH 5000u IH qd
219349773|NCT03365466|DRUG|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
219349774|NCT03365466|DRUG|no treatment|Patients who did not receive any treatment.
219349775|NCT02838849|DIETARY_SUPPLEMENT|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
219349776|NCT02838849|DIETARY_SUPPLEMENT|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
219349777|NCT00763139|DRUG|Pioglitazone|45 mg by mouth once a day for 8 weeks
219349778|NCT00763139|DRUG|Placebo|By mouth once a day for 8 weeks
219349779|NCT03282760|BIOLOGICAL|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
219349780|NCT04789356|BIOLOGICAL|Adsorbed SARS-CoV-2 (inactivated) vaccine|600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.
219349781|NCT03556930|DEVICE|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
219349782|NCT01592760|DEVICE|air-Q SP|air-Q SP placement for airway maintenance.
219349783|NCT01592760|DEVICE|air-Q|air-Q placement for airway maintenance.
219349784|NCT01592760|DEVICE|i-gel|i-gel placement for airway maintenance.
219349785|NCT04312009|DRUG|Losartan|Losartan; 50 mg daily; oral administration
219349786|NCT04312009|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
219349787|NCT01008280|DRUG|baclofen|baclofen 10 mg tid
219349788|NCT01008280|DRUG|placebo|placebo pill tid
219349789|NCT05216965|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
219349790|NCT05466214|BEHAVIORAL|Conjoint Behavioral Consultation (CBC)|Within the treatment group, CBC will be integrated into how a school-based specialist works with families and teachers of children with or at risk of severe emotional disturbance.
219349791|NCT04930575|OTHER|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
219349792|NCT04930575|OTHER|Mulligan Technique|"* The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~* Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
219349793|NCT02490085|OTHER|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
219349794|NCT02490085|OTHER|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
219349795|NCT02490085|DRUG|Insulin|Subject's usual insulin analog will be used.
219349796|NCT02490085|DEVICE|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
219349797|NCT02490085|DEVICE|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
219349798|NCT01315379|BEHAVIORAL|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
219349799|NCT01146678|DRUG|Insulin glargine HOE901|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
219349800|NCT01146678|DRUG|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
219349801|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
219349802|NCT01968460|DRUG|Placebo|placebo
219349803|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
219349804|NCT00711633|DIETARY_SUPPLEMENT|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
219349805|NCT00711633|DIETARY_SUPPLEMENT|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
219349806|NCT05855512|OTHER|Nursing Educational Intervention|Nursing Educational Intervention
219349807|NCT05729373|DRUG|SEP-363856|once daily tablet
219349808|NCT05729373|DRUG|Placebo|once daily tablet
219349809|NCT05550311|OTHER|Robot-assisted rehabilitation|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program. Range of motion exercises will display on the monitor as a game form. There are 4 games available on the computer (airplane game, rabbit shooting game, ball game, and shopping game) and these games can provide exercises for three joints (shoulder, elbow wrist). There are also 3 different levels of resistance apparatus for each joint. People with a full range of motion can do these exercises with resistance. Before starting the rehabilitation, which joint and which movement to do is determined. To the person; After explaining the desired movement and how to play the game shown on the monitor, the exercises are started. The exercises last 45 minutes, during which exercises are performed for the shoulder, elbow, and wrist.
219349810|NCT05550311|OTHER|Conventional rehabilitation|The conventional Rehabilitation Program consists of; range of motion exercises, strengthening exercises, stretching exercises, balance, and walking exercises and Bobath based neurophysiological approaches.
219349811|NCT03825874|OTHER|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
219349812|NCT03825874|OTHER|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
219349813|NCT05802719|OTHER|Blood sampling|"The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy"
219349814|NCT05909202|DEVICE|Sham VR|Nature-based non-immersive VR program
219349815|NCT05909202|DEVICE|Active VR|Nature-based immersive VR program
219349816|NCT05151107|DIAGNOSTIC_TEST|"The radiographic images were collected through a software called PACS which combined with a viewer for image processing, that allows the calculation of the residual stomach area (RSA)."|Upper gastrointestinal radiographie
219349817|NCT00179309|DRUG|Docetaxel|35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
219349818|NCT00179309|BIOLOGICAL|PANVAC-V|2 x 10\^8 PFU
219349819|NCT00179309|BIOLOGICAL|PANVAC-F|1 x 10\^9 PFU
219349820|NCT00179309|BIOLOGICAL|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
219349821|NCT02072473|PROCEDURE|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~1. coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~2. left-sided slow pathway ablation, using trans-septal approach."
219349822|NCT03907852|BIOLOGICAL|gavo-cel|gavo-cel
219349823|NCT03907852|DRUG|fludarabine|lymphodepletion chemotherapy
219349824|NCT03907852|DRUG|cyclophosphamide|lymphodepletion chemotherapy
219349825|NCT03907852|DRUG|Nivolumab|immuno-oncology agent
219349826|NCT03907852|DRUG|Ipilimumab|immuno-oncology agent
219349827|NCT04369365|DRUG|Azithromycin 500 milligram (mg) oral Tablet|weekly oral use
219349828|NCT04369365|DRUG|Placebo|weekly oral use
219349829|NCT06156579|DRUG|Decitabine|Decitabine 20 mg/m\^2, i.v., once daily, 10 days
219349830|NCT06156579|DRUG|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
219349831|NCT06351995|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
219349832|NCT06351995|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
219349833|NCT06063109|DRUG|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
219349834|NCT06063109|DRUG|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
219349835|NCT05355142|BEHAVIORAL|PM+|"1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
219349836|NCT06208020|OTHER|Functional near-infrared spectroscopy (fNIRS) detection|fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
219349837|NCT05525117|BEHAVIORAL|covivio (additional to treatment as usual)|Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
219349838|NCT05525117|OTHER|treatment as usual|Participants may continue with any treatment that they require (treatment as usual)
219349839|NCT01941407|DRUG|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
219349840|NCT00085371|DRUG|triapine|Given IV
219349841|NCT00539695|BIOLOGICAL|IL-2|"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed \>grade I side effects to IL-2 and has not developed \>grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
219349842|NCT05493475|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
219349843|NCT05879419|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
219349844|NCT05879419|OTHER|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
219349845|NCT05879419|OTHER|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
219349846|NCT05879419|OTHER|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
219349847|NCT05879419|OTHER|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
219349848|NCT05879419|OTHER|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
219349849|NCT06797869|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
219349850|NCT06797869|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
219349851|NCT06193486|BIOLOGICAL|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
219349852|NCT06193486|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
219349853|NCT06193486|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
219349854|NCT03910829|BEHAVIORAL|Action Observation|Action observation training
219349855|NCT03910829|BEHAVIORAL|Motor Imagery|Motor imagery protocol
219349856|NCT03910829|BEHAVIORAL|Placebo Action Observation|Placebo Action Observation
219349857|NCT04622007|DRUG|Tomivosertib|Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
219349858|NCT04622007|BIOLOGICAL|Pembrolizumab|Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
219349859|NCT04622007|DRUG|Pemetrexed|Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
219349860|NCT02616289|OTHER|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
219349861|NCT02797808|DRUG|Sertraline|Impact of sertraline on functional brain connectivity
219349862|NCT02797808|OTHER|No Intervention|Healthy control non-intervention
219349863|NCT04469413|DRUG|Paracetamol Infusion|Continuous and Standard Intermittent Boluses Paracetamol Infusion
219349864|NCT01423799|DIETARY_SUPPLEMENT|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
219349865|NCT01423799|DIETARY_SUPPLEMENT|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
219349866|NCT00003022|RADIATION|iodine I 131 monoclonal antibody 3F8|
219349867|NCT04601948|BEHAVIORAL|mHealth Activity Intervention|Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
219349868|NCT02140814|DIETARY_SUPPLEMENT|Niacinamide|
219349869|NCT00160459|DRUG|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
219349870|NCT00160459|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
219349871|NCT00160459|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
219349872|NCT00160459|DRUG|Placebo|Tablet, oral Daily for 12 weeks
219349873|NCT06239987|BEHAVIORAL|Care-oriented Practical Training|The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
219349874|NCT05797324|OTHER|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
219349875|NCT05797324|OTHER|Sham|Sham protocol (white light \<100 lux equivalent).
219349876|NCT05785312|DEVICE|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
219349877|NCT05785312|OTHER|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
219349878|NCT04163445|DEVICE|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
219349879|NCT04163445|DEVICE|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
219349880|NCT04388150|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
219349881|NCT02764827|BIOLOGICAL|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
219349882|NCT00871312|DEVICE|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
219349883|NCT00871312|DEVICE|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
219349884|NCT05051774|BEHAVIORAL|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
219349885|NCT05051774|BEHAVIORAL|2. Exercise|"The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
219349886|NCT05051774|BEHAVIORAL|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
219349887|NCT00881400|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
219349888|NCT00881400|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
219349889|NCT01791907|BEHAVIORAL|Structured education in carbohydrate counting|
219349890|NCT01791907|BEHAVIORAL|Structured education in healthy food choices and low glycemic index|
219349891|NCT06276803|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.
219349892|NCT04025827|OTHER|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
219349893|NCT02469285|DIETARY_SUPPLEMENT|Modified pork|Pork with modified fatty acid composition
219349894|NCT02469285|DIETARY_SUPPLEMENT|Pork|Pork with normal fat composition
219349895|NCT02469285|DIETARY_SUPPLEMENT|Pork and berries|Pork with normal fat composition and Finnish berries
219349896|NCT01968135|DRUG|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
219349897|NCT01968135|DRUG|Placebo Sugar Pill|Placebo Sugar Pill
219349898|NCT05133635|DRUG|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
219349899|NCT05133635|DRUG|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
219349900|NCT04377451|DRUG|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
219349901|NCT04481529|OTHER|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
219349902|NCT01780831|DRUG|Raltegravir|RAL was given as oral granules for suspension.
219349903|NCT05300178|PROCEDURE|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
219349904|NCT03027583|DIETARY_SUPPLEMENT|Probiotic|6 weeks daily oral intake of a probiotic strain.
219349905|NCT03027583|DIETARY_SUPPLEMENT|Placebo|6 weeks daily oral intake of placebo.
219349906|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
219349907|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
219349908|NCT00723970|DRUG|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
219349909|NCT02559466|DEVICE|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
219349910|NCT02559466|DEVICE|Positon Emission Tomography (PET) - Discovery 710®|Class IB
219349911|NCT06409312|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports the therapeutic training of people with musculoskeletal conditions. It provides two therapeutic training programs for patients, one for each specific indication. Patients have continuous access to these programs through Akina Cloud, allowing them to independently complete nine training sessions without supervision. A minimum of three sessions per week is recommended, but patients have the option to engage in daily sessions if preferred. These therapy programs are based on current treatment guidelines and supported by relevant scientific research. They include customizable physical exercises tailored to individual needs and difficulty levels. Patients receive audio-visual guidance during these exercise sessions to ensure proper execution. Exercise therapy has demonstrated its ability to reduce pain, improve physical function, and enhance the overall quality of life for patients suffering from back pain and hip osteoarthritis.
219349912|NCT04057274|OTHER|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
219349913|NCT01200901|DRUG|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
219349914|NCT02128230|DEVICE|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
219349915|NCT02128230|DRUG|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, \& 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
219349916|NCT02128230|DRUG|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
219349917|NCT02128230|DRUG|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
219349918|NCT02128230|DRUG|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
219349919|NCT02128230|DRUG|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
219349920|NCT02128230|DRUG|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
219349921|NCT03887897|PROCEDURE|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
219349922|NCT04901299|DRUG|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
219349923|NCT04901299|DRUG|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
219349924|NCT05913414|DRUG|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
219349925|NCT05913414|DRUG|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
219349926|NCT05913414|RADIATION|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
219349927|NCT03524339|DRUG|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
219349928|NCT03524339|DRUG|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
219354897|NCT06465589|OTHER|JOURNeY standard|"The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
219349929|NCT04466800|OTHER|Intervention group_rehabilitation program|"Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate."
219349930|NCT02995616|DEVICE|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
219349931|NCT02995616|DEVICE|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
219349932|NCT02995616|DEVICE|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
219349933|NCT01976598|OTHER|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
219349934|NCT06221163|OTHER|collection of biographical and sociological data|collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
219349935|NCT02956668|OTHER|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
219349936|NCT02956668|OTHER|Blindsight Training alone|The patient undergo visual rehabilitation
219349937|NCT04687696|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
219349938|NCT04687696|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
219349939|NCT04687696|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
219349940|NCT05066256|DIAGNOSTIC_TEST|Left ventricular diastolic function|Transthoracic echocardiography Mitral E/e'
219349941|NCT05066256|DIAGNOSTIC_TEST|Inferior vena cava variation|Inferior vena cava variation from ultrasound
219349942|NCT03127033|OTHER|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
219349943|NCT06020456|DRUG|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
219349944|NCT02645175|DIETARY_SUPPLEMENT|TW1025|20ml, 3 times per day (daily dose: 60 ml)
219349945|NCT02645175|DIETARY_SUPPLEMENT|Placebo|20ml, 3 times per day (daily dose: 60 ml)
219349946|NCT05337332|DRUG|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
219349947|NCT04864665|DIETARY_SUPPLEMENT|a formula with prebiotics and milk fat|Provided in a formula added with prebiotics and milk fat for 1 month
219349948|NCT00267748|DRUG|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
219349949|NCT00267748|DRUG|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
219349950|NCT00907400|DRUG|PN400|oral tablet
219349951|NCT00907400|DRUG|Naproxen|oral tablet
219349952|NCT00513032|DRUG|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
219349953|NCT03992937|DRUG|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
219349954|NCT03992937|DEVICE|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
219349955|NCT04833283|DEVICE|ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)|Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
219349956|NCT04833283|DEVICE|ReOxy Cardio device|Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
219349957|NCT02163018|DRUG|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
219349958|NCT02163018|DRUG|Placebo|Subcutaneous administration of increasing doses of placebo
219349959|NCT05179317|DRUG|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
219349960|NCT00896311|DRUG|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
219349961|NCT00896311|DRUG|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
219349962|NCT01294800|DRUG|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
219349963|NCT01294800|DRUG|Placebo tablet to match Preladenant|tablets taken orally BID
219349964|NCT00381771|BEHAVIORAL|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
219349965|NCT00958204|PROCEDURE|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
219349966|NCT00958204|PROCEDURE|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
219349967|NCT00958204|DRUG|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
219349968|NCT00958204|DRUG|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
219349969|NCT03130088|OTHER|no intervention planed|no intervention planed
219349970|NCT00225472|DEVICE|Modified Viaspan|
219349971|NCT02499068|DEVICE|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
219349972|NCT00014183|DRUG|gefitinib|
219349973|NCT02491255|DEVICE|Lotus Valve System|Device: Lotus Valve System
219349974|NCT00864955|RADIATION|UVA and UVB irradiation|"* 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
219349975|NCT00000559|DRUG|estrogen replacement therapy|
219349976|NCT00000559|DRUG|hormone replacement therapy|
219349977|NCT00000559|DRUG|estradiol|
219349978|NCT00000559|DRUG|medroxyprogesterone|
219349979|NCT00673166|PROCEDURE|Staff incentive & supervision|Control \& management of funds for incentive of staff; supervision
219349980|NCT00673166|BEHAVIORAL|Staff motivation|Supervision, control of funds
219349981|NCT00003683|DRUG|doxorubicin hydrochloride|
219349982|NCT00003683|DRUG|ifosfamide|
219349983|NCT05800249|DRUG|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
219349984|NCT06095765|DRUG|Colchicine 0.5 MG Oral Tablet|Oral intake of 0.5 mg colchicine once daily
219349985|NCT06095765|DRUG|Placebo|Oral intake of matching placebo once daily
219349986|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
219349987|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 4) \& matching placebo administered orally once daily
219349988|NCT01241214|DRUG|Cetirizine|Ceterizine administered once daily
219349989|NCT01241214|DRUG|Placebo|Matching placebo administered twice daily.
219349990|NCT05098041|DRUG|Soticlestat|Soticlestat tablets.
219349991|NCT05098041|DRUG|Rifampin|Rifampin capsules.
219349992|NCT00244023|DRUG|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
219349993|NCT00244023|DRUG|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
219349994|NCT00244023|OTHER|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
219349995|NCT01595152|DRUG|solifenacin succinate|8 mg once daily for 60 days
219349996|NCT01595152|DRUG|fesoterodine|8 mg, once daily for 60 dyas
219349997|NCT03554915|OTHER|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
219349998|NCT03554915|OTHER|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
219349999|NCT00000896|DRUG|Indinavir sulfate|
219350000|NCT00000896|DRUG|Lamivudine/Zidovudine|
219350001|NCT00000896|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
219350002|NCT00000896|DRUG|Interleukin-12|
219350003|NCT00000896|DRUG|Nevirapine|
219350004|NCT00000896|DRUG|Stavudine|
219350005|NCT00000896|DRUG|Sargramostim|
219350006|NCT05458414|DEVICE|Intra-operative Navigation System|In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
219350007|NCT02997995|DRUG|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
219350008|NCT02997995|DRUG|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
219350009|NCT02997995|PROCEDURE|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
219350010|NCT03246737|OTHER|monitoring|
219350011|NCT05930262|DEVICE|TCM acupuncture therapy|TCM acupuncture therapy: Zusanli, Quchi, Hegu, Taichong, Feishu and Fenglong were selected as the main acupoints, and the auxiliary acupoints were selected according to the symptoms, including Fengchi, Dazhui, Lieque, Tiantu, Shenshu, Zhongfu, etc.
219350012|NCT05930262|DRUG|Conventional drug therapy|Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
219350013|NCT05930262|BEHAVIORAL|Rehabilitation therapy|Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.
219350014|NCT05930262|BEHAVIORAL|Breathing training|Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.
219350015|NCT00961883|BIOLOGICAL|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU
219350016|NCT00961883|BIOLOGICAL|Placebo|Sodium Chloride for injection, delivered intramuscularly
219350017|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU
219350018|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU
219350019|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
219350020|NCT02905786|DEVICE|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
219350021|NCT02905786|OTHER|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
219350022|NCT02905786|OTHER|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
219350023|NCT02373280|DRUG|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
219350024|NCT02373280|DRUG|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]
219350025|NCT02373280|DRUG|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].
219350026|NCT02373280|DRUG|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
219350027|NCT01515657|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
219350028|NCT01515657|DRUG|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
219350029|NCT01515657|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
219350030|NCT00797732|DEVICE|Acupuncture|
219350031|NCT03958552|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
219350032|NCT05102643|BIOLOGICAL|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
219350033|NCT05102643|BIOLOGICAL|Matching placebo|Solution for intramuscular injection
219350034|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg orally twice daily for three months
219350035|NCT00915200|DIETARY_SUPPLEMENT|silibin|480 mg orally twice daily for three months
219350036|NCT00915200|DIETARY_SUPPLEMENT|high-dose silibin|960 mg orally twice daily for three months
219350037|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine placebo|excipient orally twice daily for three months
219350038|NCT00915200|DIETARY_SUPPLEMENT|silibin placebo|excipient orally twice daily for three months
219350039|NCT03239717|OTHER|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
219350040|NCT03239717|OTHER|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
219350041|NCT02849132|DRUG|Entecavir|oral entecavir 0.5mg daily for 8 years
219350042|NCT02393729|BEHAVIORAL|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour"
219350043|NCT02393729|OTHER|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
219350044|NCT04555122|BEHAVIORAL|Social Distancing Advertisements|Participants will receive 3 types of advertisements to increase social distancing/staying at home.
219350045|NCT01763450|DRUG|bevacizumab plus chemotherapy|"1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
219350046|NCT04830670|PROCEDURE|sinus floor elevation with lateral approach|sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
219350047|NCT01679210|BEHAVIORAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
219350048|NCT00401752|DRUG|Esomeprazole|
219350049|NCT00401752|DRUG|Ranitidine|
219350050|NCT00689949|DIETARY_SUPPLEMENT|folic acid|0.4 mg of folic acid per day
219350051|NCT02275338|DRUG|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
219350052|NCT02011165|PROCEDURE|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
219350053|NCT04136431|OTHER|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
219350054|NCT04136431|OTHER|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
219350055|NCT02870855|DRUG|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
219350056|NCT01061450|DRUG|Simvastatin|80 mg once a day
219350057|NCT01061450|DRUG|Placebo|1 pill once a day
219350058|NCT02154386|DEVICE|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
219350059|NCT00564811|DIETARY_SUPPLEMENT|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
219350060|NCT04505228|DRUG|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
219350061|NCT04505228|DRUG|Atropine Sulfate|The basic treatment for heart disease
219350062|NCT03149081|DRUG|Boswellia|Boswellia is an extract from frankincense
219350063|NCT00388908|BEHAVIORAL|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
219350064|NCT00388908|OTHER|Usual Care|
219350065|NCT03723629|OTHER|No intercention|No intercention
219350066|NCT03187600|PROCEDURE|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
219350067|NCT03187600|PROCEDURE|Standard of Care Pharyngeal Flap|Included in study arm description
219350068|NCT00785330|DRUG|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
219350069|NCT00785330|DRUG|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
219350070|NCT02882295|OTHER|Validation of a handwriting scale|
219350071|NCT01472497|DRUG|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
219350072|NCT00453271|DRUG|NB-002|
219350073|NCT00453271|DRUG|Vehicle control|
219350074|NCT04370327|OTHER|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
219350075|NCT04370327|OTHER|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
219350076|NCT04370327|OTHER|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
219350077|NCT06170515|DIAGNOSTIC_TEST|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
219350078|NCT06170515|DIAGNOSTIC_TEST|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
219350079|NCT02488395|OTHER|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
219350080|NCT02488395|OTHER|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
219350081|NCT02488395|OTHER|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
219350082|NCT02164656|BEHAVIORAL|mindfulness for smokers|
219350083|NCT02491294|BEHAVIORAL|School|students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
219350084|NCT02491294|BEHAVIORAL|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
219350085|NCT02491294|BEHAVIORAL|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
219350086|NCT03473431|DRUG|Ketamine|single infusion of 0.5 mg / kg ketamine
219350087|NCT03473431|OTHER|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
219350088|NCT06392880|OTHER|Floss Band|A floss band will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
219350089|NCT06392880|OTHER|Mulligan Mobilization|Mulligan mobilization will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
219350090|NCT06392880|OTHER|Control|Participants will practice various weight-bearing active ankle motions simultaneously.
219350091|NCT03877887|DIAGNOSTIC_TEST|echo cardiogram|Assessment of left ventricular systolic and diastolic function
219350092|NCT01914562|DRUG|OCA 10 mg|OCA 10 mg tablet oral
219350093|NCT01914562|DRUG|OCA 25 mg|OCA 25 mg tablet oral
219350094|NCT01999283|OTHER|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
219350095|NCT01999283|OTHER|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
219350096|NCT02560610|DRUG|OC000459|
219350097|NCT02560610|DRUG|Placebo|
219350098|NCT02215603|BEHAVIORAL|Breaking prolonged sitting with physical activity|
219350099|NCT00540878|DRUG|SB-751689 oral tablets (400 mg)|
219350100|NCT02452580|OTHER|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
219350101|NCT03936374|DRUG|BMS-986205|Participants will receive BMS-986205 on Days 1 and 15
219350102|NCT03936374|DRUG|omeprazole|Participants will receive omeprazole on Days 10 to 15
219350103|NCT00739414|DRUG|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
219350104|NCT05112783|DEVICE|Henan Tuoren Endotracheal Tube|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
219350105|NCT05112783|DEVICE|Smiths Portex Tracheal Tubes|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
219350106|NCT01378286|DRUG|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:~Route of administration:"
219350107|NCT01378286|DRUG|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
219350108|NCT01281566|DRUG|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
219350109|NCT01281566|DRUG|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
219350110|NCT00300638|PROCEDURE|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
219350111|NCT00300638|BEHAVIORAL|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
219350112|NCT03439709|RADIATION|Gamma knife radiosurgery|Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
219350113|NCT03439709|DRUG|Lanreotide 60Mg Solution for Injection|Lanreotide injection.
219350114|NCT05598892|DEVICE|Training with Robotic Hand Exoskeleton|The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
219350115|NCT02096341|DRUG|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
219350116|NCT02298829|DRUG|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
219350117|NCT03053479|PROCEDURE|Laparoscopic sacrocolpopexy|see arm/group descriptions
219350118|NCT03053479|PROCEDURE|Transvaginal mesh procedure|see arm/group descriptions
219350119|NCT03053479|PROCEDURE|Amreich-Richter procedure|see arm/group descriptions
219350120|NCT03979157|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
219350121|NCT00080782|DRUG|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
219350122|NCT00080782|DRUG|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
219350123|NCT00080782|RADIATION|Strontium chloride Sr 89|IV on day 1
219350124|NCT05993624|DEVICE|virtual reality|The BeCure Balance Assessment System protocol used in this study; It was planned to determine the amount of change in the center of gravity in the x and y axes and the position of the center of gravity of the body with images during standing and balancing for 15 seconds on the board with eyes open. In order to support the balanced development of the participants with the Becure system; Balance surfing, balance adventure, balance bowling and traffic games were played. uBall, gates, smartclean and SmartBubblePop games with Kinect for the upper extremity; KneeUp game was played on the lower extremity.
219350125|NCT01443104|DEVICE|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
219350126|NCT01443104|DEVICE|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
219350127|NCT02826642|DRUG|IDH305|
219350128|NCT03413930|PROCEDURE|Transanal total mesorectal excision|Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
219350129|NCT03413930|PROCEDURE|Laparoscopic total mesorectal excision|Patients undergo Laparoscopic total mesorectal excision.
219350130|NCT05521230|DRUG|Placebo Mouthwash|Application of mouthwashes
219350131|NCT05521230|DRUG|Cymenol mouthwash|Application of mouthwashes
219350132|NCT01764074|BEHAVIORAL|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
219350133|NCT05344521|DEVICE|Integra®|A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
219350134|NCT05344521|DEVICE|Integra®-SC|A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
219350135|NCT01441531|DRUG|gabapentin 600 mg po|Given one hour before surgery
219350136|NCT01441531|DRUG|Placebo pill given one hour before surgery|Placebo pill given
219350137|NCT02026609|OTHER|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
219350138|NCT02026609|OTHER|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
219350139|NCT02806297|PROCEDURE|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
219350140|NCT02806297|PROCEDURE|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
219350141|NCT03669458|DEVICE|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
219350142|NCT03893968|BEHAVIORAL|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
219350143|NCT03893968|BEHAVIORAL|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
219350144|NCT00977821|OTHER|IVF|
219350145|NCT00977821|OTHER|Oocyte Vitrification|
219350146|NCT04933929|BEHAVIORAL|Post-hospitalization nutritional monitoring|Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
219350147|NCT01097278|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
219350148|NCT01097278|OTHER|placebo|Given orally
219350149|NCT03732300|OTHER|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
219350150|NCT00841685|DEVICE|Goldlock|Insertion of Goldlock marker
219350151|NCT00841685|DEVICE|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
219350152|NCT00841685|DEVICE|Visicoil larger size|Insertion of Visicoil, larger size, marker
219350153|NCT00841685|DEVICE|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
219350154|NCT00841685|DEVICE|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
219350155|NCT03889977|OTHER|Resistance exercise|2 major muscle groups (lower extremity, chest)
219350156|NCT03017170|DRUG|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
219350157|NCT03017170|DRUG|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
219350158|NCT01600443|DEVICE|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
219350159|NCT01600443|DEVICE|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
219350160|NCT01600443|DEVICE|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
219350161|NCT05151055|DIETARY_SUPPLEMENT|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
219350162|NCT05151055|DIETARY_SUPPLEMENT|Placebo|starch
219350163|NCT04705194|PROCEDURE|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
219350164|NCT04705194|PROCEDURE|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
219350165|NCT02497859|BEHAVIORAL|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
219350166|NCT02497859|BEHAVIORAL|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
219350167|NCT02497859|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
219350168|NCT02497859|BEHAVIORAL|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
219350169|NCT00835237|BIOLOGICAL|Boostrix®|Intramuscular, single dose.
219350170|NCT00835237|BIOLOGICAL|Decavac™|Intramuscular, single dose.
219350171|NCT05574205|OTHER|Resistance Exercise|Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
219350172|NCT05574205|DIETARY_SUPPLEMENT|Protein supplementation|Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
219350173|NCT00092846|DRUG|MK0803, lovastatin|
219350174|NCT00092846|BEHAVIORAL|Self-Management System|
219350175|NCT02102321|DRUG|albendazole|
219350176|NCT02102321|DRUG|placebo|
219350177|NCT06281860|DRUG|Cisplatine Teva®|PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C
219350178|NCT03108950|BEHAVIORAL|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
219350179|NCT01926184|BEHAVIORAL|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
219350180|NCT01926184|BEHAVIORAL|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
219350181|NCT01265550|DEVICE|Nissen fundoplication|laparoscopic antireflux surgery
219350182|NCT01265550|DRUG|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
219350183|NCT01265550|DRUG|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
219350184|NCT00684788|COMBINATION_PRODUCT|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
219350185|NCT00003737|DRUG|becatecarin|
219350186|NCT06373289|DEVICE|higher oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the higher oxygen saturation target.
219350187|NCT06373289|DEVICE|lower oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the lower oxygen saturation target.
219350188|NCT04558814|DIAGNOSTIC_TEST|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
219350189|NCT02639000|PROCEDURE|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
219350190|NCT04460976|BEHAVIORAL|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
219350191|NCT04460976|BEHAVIORAL|Treatment as usual/standard care|Standard care at disability/habilitation services.
219350192|NCT00623428|DRUG|peginterferon alfa-2a|
219350193|NCT00623428|DRUG|Ribavirin|
219350194|NCT03948828|BIOLOGICAL|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
219350195|NCT03948828|DRUG|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
219350196|NCT03592095|DEVICE|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
219350197|NCT03592095|DEVICE|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
219350198|NCT04519385|DRUG|Tocilizumab|Tocilizumab therapy
219350199|NCT04519385|DRUG|Dexamethasone|dexamethsone pulse therapy
219350200|NCT04791774|DIETARY_SUPPLEMENT|Milk protein (food grade protein)|Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
219350201|NCT04791774|DIETARY_SUPPLEMENT|Fee amino acids (food grade amino acids)|Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
219350202|NCT01948843|DRUG|ADI-PEG 20|
219350203|NCT00343174|DRUG|Ancrod|
219350204|NCT00479791|BEHAVIORAL|Test meals rich in different fatty acids|
219350205|NCT03333031|DRUG|HS-196|HS-196 will be administered intravenously as a single dose
219350206|NCT00864435|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
219350207|NCT00864435|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
219350208|NCT01212302|DRUG|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
219350209|NCT04336995|DIAGNOSTIC_TEST|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
219350210|NCT01188083|DIETARY_SUPPLEMENT|Fructose Drink|Fructose Based beverage 8 oz
219350211|NCT01188083|DIETARY_SUPPLEMENT|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
219350212|NCT02318472|DEVICE|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
219350213|NCT02318472|DEVICE|Plaster cast|Lower limb plaster cast
219350214|NCT00540189|PROCEDURE|Initial appendectomy|
219350215|NCT00540189|PROCEDURE|Interval appendectomy|
219350216|NCT06252272|DIAGNOSTIC_TEST|Biopsy from patients undergoing surgery abdominal.|A small portion (about 10 mm in diameter) of liver tissue was collected macroscopically free from alterations of the parenchyma obtained in the open at the site surgery for primary or secondary liver tumors, for the preparation of cultures of organotypic liver slices.
219350217|NCT03608176|OTHER|PASO diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
219350218|NCT03608176|OTHER|Low-fat diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
219350219|NCT03608176|OTHER|Waiting list group|This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
219350220|NCT05143073|BEHAVIORAL|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
219350221|NCT05143073|BEHAVIORAL|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
219350222|NCT01727609|DIETARY_SUPPLEMENT|Milk feed (breast milk or formula milk)|
219350223|NCT04739046|DRUG|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
219350224|NCT04755049|DIAGNOSTIC_TEST|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire
219350225|NCT00006112|DRUG|chemotherapy|
219350226|NCT00006112|DRUG|fluorouracil|
219350227|NCT00006112|DRUG|leucovorin calcium|
219350228|NCT00006112|DRUG|mitomycin C|
219350229|NCT00023374|DRUG|Rifampin|6mos REZ intermittent
219350230|NCT00023374|DRUG|Pyrazinamide|6mos REZ intermittent
219350231|NCT00023374|DRUG|Ethambutol|6mos REZ intermittent
219350232|NCT00023374|DRUG|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
219350233|NCT00293579|DRUG|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
219350234|NCT02538068|BEHAVIORAL|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
219350235|NCT02538068|BEHAVIORAL|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
219350236|NCT03993184|BEHAVIORAL|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
219350237|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with hamstrings|Anatomical ACL reconstruction with quadruple-bundle hamstrings graft
219350238|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with patellar tendon|Anatomical single bundle ACL reconstruction with patellar tendon
219350239|NCT05088278|PROCEDURE|ACL reconstruction with over the top plus lateral plasty technique|Non-anatomical ACL reconstruction, the hamstrings' tibial insertion is preserved; a double-bundle hamstring graft is passed intra-articularly, fixed in over the top position on the lateral femoral condyle, and then passed extra-articularly deeply to ileo-tibial band up to the tibia, where it is fixed at the level of Gerdy's tubercle.
219350240|NCT01701570|BEHAVIORAL|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
219350241|NCT01701570|OTHER|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
219350242|NCT06417619|BEHAVIORAL|Mindfulness-Based Psychoeducation|The Effect of Mindfulness-Based Psychoeducation on Depression Level of Depression Patients
219350243|NCT04161430|DRUG|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
219350244|NCT04161430|DRUG|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
219350245|NCT04161430|DRUG|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
219350246|NCT02394873|BIOLOGICAL|ALLO-ASC-DFU|Dressing for second-degree burn wound.
219354898|NCT05373147|BIOLOGICAL|αPD1-MSLN-CAR T cells|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
219354899|NCT00004900|BIOLOGICAL|filgrastim|
219354900|NCT00004900|DRUG|anastrozole|
219354901|NCT00004900|DRUG|carboplatin|
219354902|NCT00004900|DRUG|cisplatin|
219354903|NCT00004900|DRUG|cyclophosphamide|
219354904|NCT00004900|DRUG|etoposide|
219354905|NCT00004900|DRUG|thiotepa|
219354906|NCT00004900|PROCEDURE|peripheral blood stem cell transplantation|
219350247|NCT02331082|OTHER|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
219350248|NCT02331082|OTHER|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
219350249|NCT02331082|DEVICE|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
219350250|NCT02331082|DEVICE|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
219350251|NCT02331082|BEHAVIORAL|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
219350252|NCT02331082|OTHER|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
219350253|NCT00332995|DRUG|dapivirine (TMC120) vaginal ring|
219350254|NCT01001000|PROCEDURE|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
219350255|NCT01180660|DRUG|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
219350256|NCT01180660|DRUG|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
219350257|NCT02790151|BEHAVIORAL|Standard Therapy|Learning and practicing Memory strategies
219350258|NCT02790151|BEHAVIORAL|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
219350259|NCT04983914|DEVICE|Transcorneal Electrostimulation via OkuStim System|Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).
219350260|NCT03222206|DRUG|Salsalate|"1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
219350261|NCT03222206|OTHER|Placebo|"1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
219350262|NCT03505229|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
219350263|NCT06046144|DIAGNOSTIC_TEST|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
219350264|NCT06046144|DIAGNOSTIC_TEST|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
219350265|NCT06046144|DIAGNOSTIC_TEST|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
219350266|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
219350267|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
219350268|NCT05091398|OTHER|Regional analgesia of thoracic surgical patients|ultrasound-guided erector spinae block on T4 and T6 levels ,paravertebral block or intercostal nerve block after the anesthesia induction and turning the patient in the lateral position with 30 mL 0.5% bupivacaine +50 µ adrenaline will be injected by the surgeon through the thoracoscope .
219354907|NCT00004900|RADIATION|radiation therapy|
219354908|NCT03375190|OTHER|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
219354909|NCT03375190|OTHER|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
219350269|NCT02890810|OTHER|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
219350270|NCT02890810|OTHER|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
219350271|NCT01550562|DEVICE|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
219350272|NCT01477242|DRUG|Ondansetron|2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
219350273|NCT03119909|OTHER|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
219350274|NCT03119909|OTHER|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
219350275|NCT03119909|OTHER|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
219350276|NCT03119909|OTHER|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
219350277|NCT03119909|OTHER|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
219350278|NCT03119909|OTHER|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
219350279|NCT05543564|PROCEDURE|PRP|Single session prophylactic early Pan-retinal Photocoagulation
219350280|NCT04414800|DRUG|Placebo|Distilled water
219350281|NCT04414800|DRUG|Ketamine|1 mg/kg intranasal ketamine
219350282|NCT04414800|DRUG|Fentanyl|1μg/kg intranasal fentanyl
219350283|NCT00449462|PROCEDURE|consumption of CLA enriched food|
219350284|NCT02282943|DEVICE|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
219350285|NCT02282943|DEVICE|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
219350286|NCT00366587|DEVICE|Cataract surgery and IOL implantation|
219350287|NCT00953368|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
219350288|NCT00406302|DRUG|Docetaxel|75mg/m², day 1,22
219350289|NCT00406302|DRUG|oxaliplatin|40mg/m², d1,2,22,23
219350290|NCT00406302|DRUG|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
219350291|NCT00406302|PROCEDURE|surgery|28 days after end of induction chemotherapy
219350292|NCT07028359|BEHAVIORAL|Printed Instructions with Phone Reminders|Participants received paper-based instructions for perioperative care, including medication, fasting, and follow-up logistics. Automated phone calls were sent before surgery to reinforce preparation. Participants used a printed checklist to self-report eye drop adherence.
219350293|NCT07028359|BEHAVIORAL|Sharp Health Companion App (CareKit)|The Sharp Health Companion App delivered interactive digital perioperative checklists, medication adherence prompts, COVID-19 protocol reminders, symptom tracking, and educational videos via iPhone. Participants logged their medication use in real time on the Sharp Health Companion App. Printed instructions were provided as a backup.
219350294|NCT05354505|DEVICE|Placement of the GOLDBAL2 balloon|The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
219350295|NCT06926972|OTHER|NOURISH|Culinary medicine demonstrations and nutritional education focused on balanced eating.
219350296|NCT02956551|BIOLOGICAL|DC vaccine|subcutaneous administration
219350297|NCT06296329|OTHER|Rubber Hand Illusion|The traditional behavioural illusion of the Rubber Hand will be applied
219350298|NCT06776419|DIAGNOSTIC_TEST|Cardiac Magnetic Ressonance Imaging|CMR-protocol with gadolinium contrast
219350299|NCT06776419|DIAGNOSTIC_TEST|82Rubidium-positron emission tomography and computer-tomography|cardiac Rb-PET protocol
219350300|NCT02491164|OTHER|BAC TWO|BAC TWO administration
219350301|NCT02491164|DEVICE|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
219350302|NCT04766307|DRUG|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
219354910|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
219350303|NCT05269407|DEVICE|Peripheral perfusion index|"The study aimed to generate a model relating pre-spinal perfusion index to the likelihood and severity of the reduction in blood pressure in the first 20 min after spinal injection.~A correlation between the delta PI and the delta SBP (the difference between the baseline maternal systolic blood pressure and the lowest blood pressure)will be investigated to establish a predictive model to define cut-off values at which perfusion index variation indicated a low risk (no or mild hypotension groups) or a high risk (moderate, severe groups) of reduction in blood pressure.. The incremental change of a measure PI, the ΔPI will be calculated as the absolute change in PI between supine and sitting positions, ΔPI=PIsupine-sitting. The relative change in PI the rPI, will be expressed as the percentage of change in PI, rPI=ΔPI/PIsitting× 100."
219350304|NCT01047774|DIETARY_SUPPLEMENT|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
219350305|NCT01047774|DIETARY_SUPPLEMENT|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
219350306|NCT00276172|DRUG|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
219350307|NCT04901910|BEHAVIORAL|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
219350308|NCT04901910|BEHAVIORAL|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
219350309|NCT06461260|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
219350310|NCT03790254|OTHER|systematic review|
219350311|NCT04121442|BIOLOGICAL|Isunakinra|Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
219350312|NCT04121442|BIOLOGICAL|PD-(L)1 Inhibitor|Monoclonal antibody targeting PD-1 or PD-L1
219350313|NCT03232515|COMBINATION_PRODUCT|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
219350314|NCT01583621|DIETARY_SUPPLEMENT|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
219350315|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
219350316|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
219350317|NCT02579980|PROCEDURE|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
219350318|NCT02579980|PROCEDURE|Surgery|Standard of care procedure for sarcoma patients
219350319|NCT03143231|OTHER|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
219350320|NCT03143231|OTHER|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
219350321|NCT02416284|OTHER|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
219350322|NCT01150539|OTHER|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
219350323|NCT01150539|OTHER|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
219350324|NCT03011346|DEVICE|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
219350325|NCT03011346|DEVICE|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
219350326|NCT03657043|DRUG|tisotumab vedotin|Intravenous (IV) infusion
219350327|NCT06193785|OTHER|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
219350328|NCT05011188|BIOLOGICAL|FOR46|Given intravenously (IV)
219350329|NCT05011188|BIOLOGICAL|Enzalutamide|Given orally (PO)
219350330|NCT05011188|DRUG|Pegfilgrastim|Given subcutaneously (subQ)
219350331|NCT05011188|PROCEDURE|Blood Samples|Blood samples will be taken for correlative studies
219350332|NCT05256498|DEVICE|Picostim Amber|Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
219350333|NCT04864431|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
219350334|NCT04864431|OTHER|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
219350335|NCT04455555|DRUG|LY03003( the name of rotigotine)|LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
219350336|NCT04455555|OTHER|Placebo|Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
219350337|NCT01736579|DRUG|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
219350338|NCT02542475|DEVICE|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
219350339|NCT02650037|PROCEDURE|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
219350340|NCT06045338|BEHAVIORAL|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
219350341|NCT05786625|DEVICE|Ablation|Bronchoscopy and microwave ablation of lung nodule
219350342|NCT03754244|DRUG|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
219350343|NCT05088707|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
219350344|NCT05088707|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
219350345|NCT03090126|OTHER|Therapeutic education|Questionnaires
219350346|NCT05896020|DRUG|SHR- A1811|Subjects with gynaecological malignancies
219350347|NCT04710342|DEVICE|CapBuster|Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
219350348|NCT04170595|BIOLOGICAL|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
219350349|NCT04170595|BIOLOGICAL|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
219350350|NCT04170595|BIOLOGICAL|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
219350351|NCT04170595|BIOLOGICAL|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
219350352|NCT04170595|BIOLOGICAL|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
219350353|NCT04170595|BIOLOGICAL|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
219350354|NCT04647955|DRUG|Itopride|Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
219350355|NCT04647955|DRUG|Placebo|Patients were treated for 8 weeks.
219350356|NCT05568342|BEHAVIORAL|The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study|Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
219350357|NCT05048719|DRUG|LY3502970|Administered orally
219350358|NCT05048719|DRUG|Dulaglutide|Administered subcutaneously
219350359|NCT05048719|DRUG|Placebo|Administered orally
219350360|NCT05048719|DRUG|Placebo|Administered subcutaneously
219350361|NCT04541004|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
219350362|NCT04818515|DRUG|Atogepant|Oral; Tablet
219350363|NCT04818515|DRUG|Ubrogepant|Oral; Tablet
219350364|NCT00501982|DRUG|Poractant alfa (Curosurf®)|
219350365|NCT05332119|DEVICE|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
219350366|NCT05332119|OTHER|Control group|Patients will not receive distraction during chest drain removal
219350367|NCT04088344|DIETARY_SUPPLEMENT|isocaloric diet|a 7-day isocaloric diet
219350368|NCT04088344|DIETARY_SUPPLEMENT|Hypercaloric diet|A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
219350369|NCT04088344|OTHER|Liquid meal|
219350370|NCT04088344|RADIATION|PET imaging|
219350371|NCT04088344|OTHER|perfusions of stable tracers|
219350372|NCT04088344|DEVICE|Indirect calorimetry|
219350373|NCT06763913|DEVICE|taVNS|Set the pulse width to 200 microseconds, frequency to 30 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
219350374|NCT06763913|DEVICE|sham taVNS|Set the pulse width to 200 microseconds, frequency to 1 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
219350375|NCT00616109|DRUG|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
219350376|NCT05829525|OTHER|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
219350377|NCT04480281|DRUG|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
219350378|NCT04480281|DRUG|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
219350379|NCT05762328|BEHAVIORAL|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
219350380|NCT06840028|OTHER|mHealth/sFitRx|Experimental Group - Will receive a personalized mHealth application and fitness tracker. Specifically, Experimental Group participants will receive the sFitRx smartphone application that provides weekly personalized PA interventions informed by big data analysis. They will also receive a Fitbit Inspire 3 to track real-time PA, with PA data uploaded to Fitabase. Importantly, the PA data from the Fitbit Inspire 3 will inform the big data analyses used to generate the personalized PA intervention provided by the sFitRx application.
219350381|NCT06840028|OTHER|Fitness Tracker|Comparison Group - Will receive the Fitbit Inspire 3 only.
219350382|NCT06343194|DEVICE|Bruxoff ®|Bruxoff ® is a holter that measures the masseter muscle contraction and heart rate.
219350383|NCT03723382|OTHER|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
219350384|NCT00110773|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
219350385|NCT00110773|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
219350386|NCT02229552|OTHER|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
219350387|NCT04872101|DRUG|Delgocitinib cream|Cream for topical application
219350388|NCT04872101|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
219350389|NCT02269527|OTHER|Live music|Providing 1-hour live music 5 days/ week.
219350390|NCT02029287|OTHER|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
219350391|NCT02029287|OTHER|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
219350392|NCT02115464|DRUG|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
219350393|NCT02115464|RADIATION|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
219350394|NCT03907332|OTHER|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
219350395|NCT04057625|DEVICE|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
219350396|NCT04349527|PROCEDURE|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
219350397|NCT04349527|PROCEDURE|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
219350398|NCT03807713|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
219350399|NCT00971945|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
219350400|NCT01998828|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
219350401|NCT03354663|DEVICE|TactiCath SE|Ablation to achieve pulmonary vein isolation.
219350402|NCT03691974|DRUG|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
219350403|NCT03691974|OTHER|Placebo|Subcutaneous (SC) every four weeks (Q4W)
219350404|NCT01482364|DEVICE|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
219350405|NCT01482364|DEVICE|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
219350406|NCT00554125|DRUG|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
219350407|NCT02706821|DIETARY_SUPPLEMENT|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
219350408|NCT02706821|DIETARY_SUPPLEMENT|Placebo|Placebo, crossover design
219350409|NCT02670642|DRUG|Esomeprazole|Proton pump inhibitor
219350410|NCT04255056|DRUG|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
219350411|NCT06223282|OTHER|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
219350412|NCT06223282|OTHER|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
219350413|NCT06223282|OTHER|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
219350414|NCT06223282|OTHER|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
219350415|NCT00157976|DRUG|Photrex (rostaporfin)|
219350416|NCT02279680|DEVICE|Electroencephalography|
219350417|NCT02279680|BEHAVIORAL|Neuropsychological assesments|
219350418|NCT02239939|BEHAVIORAL|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
219350419|NCT02239939|BEHAVIORAL|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
219354911|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
219350420|NCT05572762|DEVICE|Cannula plastic part while applying peribulbar block|Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
219350421|NCT05572762|PROCEDURE|traditional technique|the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
219350422|NCT00272974|BEHAVIORAL|Clinic-based counseling|
219350423|NCT02323698|DRUG|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
219350424|NCT02323698|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
219350425|NCT02323698|OTHER|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
219350426|NCT02323698|OTHER|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
219350427|NCT02482454|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
219350428|NCT02482454|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
219350429|NCT01069562|OTHER|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
219350430|NCT01069562|OTHER|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
219350431|NCT06244238|OTHER|Observational study|Observational study
219350432|NCT02564315|DRUG|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
219350433|NCT02564315|BEHAVIORAL|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
219350434|NCT02564315|BEHAVIORAL|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
219350435|NCT02564315|BEHAVIORAL|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
219350436|NCT02564315|BEHAVIORAL|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
219350437|NCT02564315|BEHAVIORAL|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
219350438|NCT02564315|BEHAVIORAL|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
219354912|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
219350439|NCT02564315|DRUG|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke \>10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke \<=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
219350440|NCT03325673|DEVICE|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
219350441|NCT03325673|DEVICE|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
219350442|NCT03678805|PROCEDURE|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
219350443|NCT03678805|PROCEDURE|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
219350444|NCT04002011|DRUG|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
219350445|NCT04002011|DRUG|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
219350446|NCT04002011|DRUG|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
219350447|NCT04002011|DRUG|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
219350448|NCT04002011|DRUG|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
219350449|NCT03652532|BEHAVIORAL|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
219350450|NCT03652532|BEHAVIORAL|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
219350451|NCT01751217|BEHAVIORAL|Functional Family Tx|
219350452|NCT01751217|BEHAVIORAL|Services as Usual|
219350453|NCT06457581|OTHER|Dry Needling|Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.
219350454|NCT06457581|PROCEDURE|Trigger points injections|Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.
219350455|NCT06457581|DRUG|serotonin reuptake inhibitor (SSRI)|serotonin reuptake inhibitor (SSRI)
219350456|NCT00782457|PROCEDURE|RECTAL CANCER RESECTION|
219350457|NCT01759758|OTHER|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
219350458|NCT01759758|OTHER|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
219350459|NCT04572269|OTHER|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
219350460|NCT03698006|DRUG|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
219350461|NCT03698006|DRUG|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
219350462|NCT03673683|BEHAVIORAL|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
219350463|NCT03673683|BEHAVIORAL|Usual care|Usual sedation and weaning management that is not protocol based
219350464|NCT05162482|BIOLOGICAL|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
219350465|NCT05162482|BIOLOGICAL|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
219350466|NCT05162482|BIOLOGICAL|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
219350467|NCT01514682|DRUG|Anti-inflammatory Combination Therapy|"1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
219350468|NCT01514682|DRUG|Placebo|Non-medication pills; To be taken in morning and evening intervals.
219350469|NCT00590590|DRUG|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
219350470|NCT00590590|DRUG|lidocaine|semi solid, twice weekly for 4 months
219350471|NCT00590590|DRUG|placebo|semi solid, twice weekly for 4 months
219350472|NCT00406770|DEVICE|Light therapy|
219350473|NCT01210339|DRUG|Clopidogrel|Clopidogrel
219350474|NCT01210339|DRUG|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
219350475|NCT05381064|DEVICE|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
219350476|NCT05562986|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
219350477|NCT02684214|BEHAVIORAL|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
219350478|NCT02684214|BEHAVIORAL|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
219350479|NCT03023943|OTHER|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
219350480|NCT03826693|DRUG|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
219350481|NCT03826693|DRUG|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
219350482|NCT00992316|DRUG|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
219350483|NCT03878511|DIETARY_SUPPLEMENT|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
219350484|NCT03878511|DIETARY_SUPPLEMENT|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
219350485|NCT00951730|OTHER|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
219350486|NCT03506542|DEVICE|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
219350487|NCT03506542|PROCEDURE|Phacotrabeculectomy|Trabeculectomy with cataract extraction
219350488|NCT03506542|DRUG|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
219350489|NCT00699517|DRUG|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
219350490|NCT00699517|DRUG|Placebo|I.V. infusion followed by administration of cisplatin
219350491|NCT05096988|DIETARY_SUPPLEMENT|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
219350492|NCT00505466|BEHAVIORAL|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
219350493|NCT04651387|DIETARY_SUPPLEMENT|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
219350494|NCT00625092|DRUG|fluorouracil|Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
219350495|NCT00625092|DRUG|leucovorin calcium|Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
219350496|NCT00625092|DRUG|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2
219350497|NCT00625092|PROCEDURE|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
219350498|NCT01602692|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
219350499|NCT01602692|DRUG|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
219350500|NCT02105454|DRUG|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
219350501|NCT02105454|DRUG|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
219350502|NCT02105454|DRUG|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
219350503|NCT00272038|DRUG|Tarceva|150mg QD
219354913|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
219354914|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.003%|
219354915|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.004%|
219354916|NCT00634491|DRUG|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
219350504|NCT02211274|OTHER|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
219350505|NCT03368261|OTHER|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
219350506|NCT04940143|DRUG|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
219350507|NCT04940143|OTHER|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
219350508|NCT03294018|OTHER|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
219350509|NCT02721355|DIETARY_SUPPLEMENT|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
219350510|NCT02535182|OTHER|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
219350511|NCT01002807|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
219350512|NCT01002807|DRUG|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
219350513|NCT01002807|DRUG|Glucophage|Tablets, Oral, 1000 mg, Single Dose
219350514|NCT00356278|DRUG|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
219350515|NCT00356278|DRUG|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
219350516|NCT00356278|BEHAVIORAL|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
219350517|NCT00356278|DRUG|Placebo|Placebo will be administered in the same manner as the active drugs.
219350518|NCT02341092|BEHAVIORAL|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
219350519|NCT05453643|BEHAVIORAL|sleep deprivation patterns|Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
219350520|NCT06344078|PROCEDURE|sigmoid resection and anastomosis / stoma|intestinal resection and recostruction or creation of stoma
219350521|NCT04395794|DIAGNOSTIC_TEST|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
219350522|NCT04395794|OTHER|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
219350523|NCT00883337|DRUG|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
219350524|NCT00883337|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
219350525|NCT02230631|OTHER|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
219350526|NCT03253146|DIAGNOSTIC_TEST|VIM detection|VIM expression in serum and lymphocytes detection
219350527|NCT00242008|DRUG|Rotigotine|
219350528|NCT00280410|DRUG|E7337|
219350529|NCT04469478|OTHER|Survey and interview|Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
219350530|NCT01780610|DRUG|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5\~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
219350531|NCT01780610|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
219350532|NCT02177760|DRUG|Sirolimus|
219350533|NCT01748344|DRUG|Cetirizine|10mg tablets
219350534|NCT01748344|DRUG|High dose ONO-4053|Experimental
219350535|NCT01748344|DRUG|Low dose ONO-4053|Experimental
219350536|NCT01748344|DRUG|Placebo|None active
219350537|NCT03340844|PROCEDURE|No Touch (NT)|Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.
219350538|NCT03340844|PROCEDURE|Superior Mesenteric Artery First (SMA)|Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
219350539|NCT03146572|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
219350540|NCT03146572|OTHER|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
219350541|NCT03177733|PROCEDURE|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
219350542|NCT01582438|DRUG|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
219350543|NCT01004757|OTHER|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
219350544|NCT01004757|OTHER|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
219350545|NCT01864408|OTHER|"Usual practice counseling"|
219350546|NCT01864408|OTHER|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
219350547|NCT03347877|PROCEDURE|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
219350548|NCT03347877|PROCEDURE|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
219350549|NCT03347877|DEVICE|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
219350550|NCT04720820|OTHER|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
219350551|NCT04720820|OTHER|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
219350552|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
219350553|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
219350554|NCT03258567|BIOLOGICAL|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
219350555|NCT01707472|BIOLOGICAL|Simtuzumab|700 mg intravenously for a total of 12 infusions.
219350556|NCT00416962|DRUG|amantadine hydrochloride|
219350557|NCT00416962|DRUG|oseltamivir phosphate|
219354917|NCT00634491|DRUG|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
219350558|NCT05768672|BEHAVIORAL|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
219350559|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
219350560|NCT01892358|BEHAVIORAL|SKIN Intervention|
219350561|NCT01892358|OTHER|Treatment as Usual|
219350562|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
219350563|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
219350564|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
219350565|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
219350566|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
219350567|NCT00814229|BIOLOGICAL|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
219350568|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
219350569|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
219350570|NCT00814229|BIOLOGICAL|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
219350571|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
219350572|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
219350573|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
219350574|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
219350575|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
219350576|NCT04358679|OTHER|Conventional Treatment|"Conventional Treatment:~* Deep breathing: 10-15 reps, twice a day (BD)~* Assisted coughing 10-15 reps, BD~* range of motion (ROM)+ stretching 10 reps, BD~* Tilt table standing"
219350577|NCT04358679|OTHER|Upper Limb ergometer training|Conventional Treatment + upper limb (UL) ergometry exercise UL ergometry exercise 15 to 20 mints , 2 times ,five days per week for 6 weeks.
219350578|NCT03790683|DEVICE|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
219350579|NCT03790683|DEVICE|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
219350580|NCT01678144|DEVICE|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
219350581|NCT02438709|DRUG|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
219350582|NCT03185390|PROCEDURE|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
219350583|NCT04671849|DRUG|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
219350584|NCT03687216|PROCEDURE|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
219350585|NCT03687216|PROCEDURE|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
219350586|NCT05779982|PROCEDURE|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
219350587|NCT02363686|PROCEDURE|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
219350588|NCT02363686|PROCEDURE|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
219354918|NCT00634491|DRUG|normal salin|1 cc/kg/hr 6 hour before and after angiography
219354919|NCT06301880|DRUG|The topical application of a vasodilator on the LIMA graft|Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
219350589|NCT02952222|DRUG|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
219350590|NCT02952222|DRUG|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
219350591|NCT02952222|DRUG|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
219350592|NCT00562549|DRUG|SLx-2101|
219350593|NCT00057473|DRUG|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
219350594|NCT00057473|DRUG|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
219350595|NCT06422741|DIETARY_SUPPLEMENT|grape seed proanthocyanidin extract|250 mg of product presented in capsule form will be given.
219350596|NCT06422741|DIETARY_SUPPLEMENT|Placebo|165 mg of cellulose will be given presented in capsule form.
219350597|NCT05371886|OTHER|Dose-effect relationship of morphine +/- midazolam administration|Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
219350598|NCT01485627|BEHAVIORAL|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
219350599|NCT06126302|OTHER|Birth year|we divided the patients according to patients' birth year
219350600|NCT03587454|DIAGNOSTIC_TEST|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
219350601|NCT02335827|PROCEDURE|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
219350602|NCT00274521|DRUG|Tiotropium|
219350603|NCT00832728|OTHER|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
219350604|NCT00832728|DEVICE|ELAD®|ELAD therapy
219350605|NCT01687764|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
219350606|NCT01687764|OTHER|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
219350607|NCT01687764|BEHAVIORAL|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
219350608|NCT01687764|BEHAVIORAL|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
219350609|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
219350610|NCT03239821|DRUG|Codeine Phosphate|58.8 mg codeïne phosphate
219350611|NCT03239821|DRUG|Placebo|Sirupus Simplex
219350612|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
219350613|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
219350614|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
219350615|NCT03798821|DIETARY_SUPPLEMENT|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
219350616|NCT02246062|BEHAVIORAL|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
219350617|NCT02246062|BEHAVIORAL|smartphone|the child received smartphone application immediately before entering the operating room
219350618|NCT02575521|DRUG|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
219350619|NCT02575521|DRUG|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
219350620|NCT06475144|OTHER|online escape room teaching|here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.
219350621|NCT06475144|OTHER|online video-based teaching|"The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay."
219350622|NCT02264990|DRUG|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
219350623|NCT02264990|DRUG|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
219350624|NCT02264990|DRUG|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
219350625|NCT02264990|DRUG|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
219350626|NCT02264990|DRUG|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
219350627|NCT01134965|DRUG|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
219350628|NCT01134965|DRUG|Digoxin|Digoxin 0.5 mg as single dose
219350629|NCT01452334|BIOLOGICAL|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
219350630|NCT01849172|OTHER|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
219350631|NCT01849172|OTHER|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
219350632|NCT01662895|DRUG|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
219350633|NCT01662895|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
219350634|NCT02112370|DRUG|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
219350635|NCT02112370|OTHER|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
219350636|NCT02962050|PROCEDURE|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
219350637|NCT02962050|DEVICE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
219350638|NCT02962050|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
219350639|NCT02962050|DRUG|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
219350640|NCT02962050|DEVICE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
219350641|NCT02962050|OTHER|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
219350642|NCT02962050|OTHER|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
219350643|NCT03214484|OTHER|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
219350644|NCT03214484|OTHER|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
219350645|NCT04004884|DRUG|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
219350646|NCT03995615|PROCEDURE|scaling and root planing|"* After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
219350647|NCT06267833|BEHAVIORAL|exercise|In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
219350648|NCT02481973|OTHER|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
219350649|NCT00087009|BIOLOGICAL|beta-glucan|Given orally
219350650|NCT00087009|BIOLOGICAL|rituximab|Given IV
219350651|NCT01895322|DRUG|OPC-41061|
219350652|NCT06118060|OTHER|Acupressure|In this study, the frequency of acupressure was twice a day (the interval between each acupressure was more than 6 hours, 6:00 to 9:00 in the morning and 1:00 to 4:00 in the afternoon); the acupressure was applied from the first day after surgery for a total of 5 days, that is, each patient received a total of 10 acupressure; the duration was 5 minutes, and the bilateral acupressure required 10 minutes.
219350653|NCT06282120|DRUG|Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy|The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
219350654|NCT05836337|DEVICE|Tattoo- Black Eye|Device name: Black eye Manufacturer: The Standard Co., Ltd
219350655|NCT05836337|DEVICE|clip- HydroMARK|Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
219350656|NCT03516760|DRUG|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
219350657|NCT02433600|OTHER|Cow's milk-based infant formula|
219350658|NCT02433600|OTHER|Cow milk-based infant formula with enriched protein fractions|
219350659|NCT00002279|DRUG|Zalcitabine|
219350660|NCT00271323|DRUG|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
219350661|NCT00271323|RADIATION|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
219350662|NCT01612260|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
219350663|NCT01612260|DRUG|placebo Capsule|4 granules t.i.d. po for 12 weeks
219350664|NCT05146570|DIAGNOSTIC_TEST|D-lactate test|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
219350665|NCT05146570|DIAGNOSTIC_TEST|Standard diagnostic tests|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
219350666|NCT02230280|OTHER|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
219350667|NCT05231382|PROCEDURE|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
219350668|NCT05231382|PROCEDURE|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
219350669|NCT02610595|DRUG|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
219350670|NCT02302898|BEHAVIORAL|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
219350671|NCT02302898|OTHER|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
219350672|NCT02302898|OTHER|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
219350673|NCT05411419|PROCEDURE|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
219350674|NCT04276714|OTHER|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
219350675|NCT04276714|OTHER|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
219350676|NCT02501265|BEHAVIORAL|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
219350677|NCT02501265|BEHAVIORAL|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
219350678|NCT02501265|DRUG|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
219350679|NCT02501265|DRUG|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
219350680|NCT04856553|OTHER|Acute effects of handgrip exercise|The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
219350681|NCT01216436|BIOLOGICAL|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
219350682|NCT06005870|DRUG|Zanubrutinib plus RCHOP|Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21
219350683|NCT00689572|DRUG|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
219350684|NCT00689572|DRUG|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
219350685|NCT06195722|OTHER|simulation|parenteral drug simulation
219350686|NCT00283075|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
219350687|NCT03303794|DRUG|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
219350688|NCT03303794|DRUG|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
219350689|NCT03070158|BEHAVIORAL|Attachment Promotion|"Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up."
219350690|NCT05739786|DRUG|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
219350691|NCT05739786|DRUG|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
219350692|NCT06076915|BEHAVIORAL|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
219350693|NCT02365714|RADIATION|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
219350694|NCT00870961|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
219350695|NCT00870961|OTHER|placebo|Given orally
219350696|NCT03603821|DIAGNOSTIC_TEST|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
219350697|NCT05030870|DEVICE|Capnography monitoring|Standard monitoring and capnographic monitoring.
219350698|NCT05030870|DEVICE|Standard monitoring|Standard monitoring but no capnographic monitoring
219350699|NCT00707070|DRUG|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
219350700|NCT00707070|DRUG|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
219350701|NCT03099486|DRUG|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
219350702|NCT03099486|DRUG|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
219350703|NCT03099486|DRUG|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
219350704|NCT03490643|OTHER|Postural Analysis|posture and plantar pressure analysis
219350705|NCT03490643|OTHER|plantar pressure analysis|posture and plantar pressure analysis
219350706|NCT04312490|DIAGNOSTIC_TEST|endomyocardial biopsy|Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
219350707|NCT03603496|BEHAVIORAL|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
219350708|NCT03603496|BEHAVIORAL|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
219350709|NCT03603496|DRUG|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
219350710|NCT01681420|BEHAVIORAL|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
219350711|NCT01681420|BEHAVIORAL|Blood Donation|Blood donation without HIV counseling
219350712|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-experimental treatment
219350713|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-placebo
219350714|NCT00261872|DRUG|Methylphenidate|
219350715|NCT00352651|DRUG|Pregabalin|
219350716|NCT03419715|DRUG|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
219350717|NCT03419715|DRUG|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
219350718|NCT02022488|DRUG|midazolam|Group M
219350719|NCT02022488|DRUG|alfentanil|Group MA
219350720|NCT02022488|DRUG|ketamine|Group MK
219350721|NCT04505241|BEHAVIORAL|Remotely-delivered physical activity promotion|Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
219350722|NCT00774345|DRUG|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
219350723|NCT00774345|DRUG|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
219350724|NCT05841823|BEHAVIORAL|Virtual reality exposure therapy (VRET)|The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
219350725|NCT05841823|BEHAVIORAL|Acceptance and commitment therapy (ACT)|The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
219350726|NCT00891579|DRUG|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
219350727|NCT00891579|DRUG|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
219350728|NCT00484497|DRUG|cyclamax|
219350729|NCT00024115|DRUG|BL22 immunotoxin|
219350730|NCT00024115|PROCEDURE|antibody therapy|
219350731|NCT00024115|PROCEDURE|biological response modifier therapy|
219350732|NCT00024115|PROCEDURE|immunotoxin therapy|
219350733|NCT02014064|DRUG|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)"
219350734|NCT02014064|OTHER|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
219350735|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the Turin group|Fracture classification annotations provided by the Turin group: fracture vs non-fracture, and, if fracture, the Arbeitsgemeinschaft für Osteosynthesefragen (AO, in English, Association for the Study of Internal Fixation)/Orthopedic Trauma Association (OTA) classification.
219350736|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the AO expert surgeon group|Fracture classification annotations provided by the AO expert surgeon group: fracture vs non-fracture, and, if fracture, the AO/OTA classification.
219350737|NCT03482414|OTHER|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
219350738|NCT03482414|OTHER|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
219350739|NCT03482414|OTHER|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
219350740|NCT01527214|RADIATION|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
219350741|NCT02202876|OTHER|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
219350742|NCT02202876|OTHER|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
219350743|NCT02202876|OTHER|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
219350744|NCT02202876|OTHER|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
219350745|NCT02202876|OTHER|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
219350746|NCT00416247|BEHAVIORAL|Hypnosis|Hypnosis
219350747|NCT05230888|OTHER|Questionnaires about symptoms|The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
219350748|NCT00193895|DRUG|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
219350749|NCT00193895|RADIATION|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
219350750|NCT00075504|DRUG|triapine|Given IV
219350751|NCT00075504|DRUG|gemcitabine|Given IV
219350752|NCT03202966|OTHER|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
219350753|NCT05318456|DIETARY_SUPPLEMENT|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
219350754|NCT05318456|DIETARY_SUPPLEMENT|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
219350755|NCT05318456|OTHER|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
219350756|NCT02260843|OTHER|Generic Fitness|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
219350757|NCT02260843|OTHER|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
219350758|NCT03757910|DRUG|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
219350759|NCT03757910|DRUG|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
219350760|NCT00944164|BEHAVIORAL|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
219350761|NCT00944164|BEHAVIORAL|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
219350762|NCT03179332|DRUG|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
219350763|NCT03179332|DRUG|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
219350764|NCT03179332|DRUG|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
219350765|NCT02640417|DRUG|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
219350766|NCT02640417|DRUG|B Vitamins|Oral treatment with vitamins B1, B6, and B12
219350767|NCT02686593|DRUG|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
219350768|NCT04441229|BEHAVIORAL|ABMT mobile application|"After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required."
219350769|NCT02342015|DRUG|Atorvastatin|Atorvastatin 40mg/day for three months
219350770|NCT02789865|DRUG|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
219350771|NCT02789865|PROCEDURE|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
219350772|NCT02789865|PROCEDURE|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
219350773|NCT02274103|BEHAVIORAL|BFST|Family-based skills training.
219350774|NCT01692301|DRUG|LCZ696|200 mg tablet
219350775|NCT01692301|DRUG|Olmesartan|20 mg and 40 mg capsules
219350776|NCT01692301|DRUG|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
219350777|NCT01692301|DRUG|Olmesartan matching placebo|Olmesartan matching placebo capsule
219350778|NCT01692301|DRUG|amlodipine|amlodipine 2.5 mg or 5 mg tablets
219350779|NCT01692301|DRUG|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
219350780|NCT04073771|DEVICE|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
219350781|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
219350782|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
219350783|NCT06252064|OTHER|Rehabilitation + Drug therapy|Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.
219350784|NCT06252064|OTHER|Rehabilitation|Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.
219350785|NCT06252064|OTHER|Drug therapy|The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
219350786|NCT01052584|DRUG|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
219350787|NCT01052584|DRUG|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
219350788|NCT01052584|DRUG|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
219350789|NCT02474966|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
219350790|NCT01227330|BEHAVIORAL|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
219350791|NCT01227330|BEHAVIORAL|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
219350792|NCT03501030|BEHAVIORAL|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
219350793|NCT00459992|DRUG|Betahistine Hydrochloride|
219350794|NCT02592239|DEVICE|Functional brain MRI|Functional brain MRI before and after test meal ingestion
219350795|NCT02592239|DIETARY_SUPPLEMENT|A warm ham and cheese sandwich and a 200 ml fruit juice|
219350796|NCT01401634|OTHER|Oral water|2 Liters of water given orally
219350797|NCT01401634|OTHER|Intravenous normal saline|2 Liters Intravenous normal saline
219350798|NCT01142726|DRUG|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
219350799|NCT01142726|DRUG|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
219350800|NCT01142726|DRUG|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
219350801|NCT01142726|DRUG|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
219350802|NCT01070264|DIETARY_SUPPLEMENT|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
219350803|NCT04360902|OTHER|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
219350804|NCT01568593|DEVICE|T2750|1 drop in each eye 3 to 6 times daily during 84 days
219350805|NCT01568593|DEVICE|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
219350806|NCT03304015|BEHAVIORAL|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
219350807|NCT00865865|PROCEDURE|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
219350808|NCT00865865|PROCEDURE|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
219350809|NCT03212833|DIAGNOSTIC_TEST|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
219350810|NCT06398041|OTHER|Blood flow restriction training|standard physiotherapy 45 minutes per day, 5 day a week (GAPP) + 2 extra sessions of blood flow restriction training
219350811|NCT06398041|OTHER|Opinions|Healthcare workers in the geriatric rehabilitation ward and patients will be asked on their opinions on GAPP+Care concerning blood flow restriction training
219350812|NCT03242837|BEHAVIORAL|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
219350813|NCT03242837|OTHER|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
219350814|NCT04422249|PROCEDURE|laparoscopic middle hepatic vein guidance anatomic hemihepatectomy|95 patients with primary HCC were divided into the middle hepatic vein guidance group(n=45) and the traditional group(n=45) according to the odd and even Numbers, and sealed into envelopes.Outcomes were monitored and evaluated during the 3-year follow-up period
219350815|NCT04854837|DRUG|Remdesivir|Remdesivir treatment
219350816|NCT02138032|BEHAVIORAL|Gains Framed Message|
219350817|NCT02138032|BEHAVIORAL|Loss Framed Message|
219350818|NCT04659460|DEVICE|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
219350819|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 10mcg|10 mcg
219350820|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
219350821|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 60mcg|60 mcg
219350822|NCT02109484|OTHER|Placebo|
219350823|NCT05186142|OTHER|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
219350824|NCT04204733|BEHAVIORAL|Mobile application|Mobile application that incorporates biosensor feedback, teleconsultation, and online group physical activity classes
219350825|NCT03003208|OTHER|Pulmonary rehabilitation|An exercise and education program
219350826|NCT00265538|BEHAVIORAL|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
219350827|NCT00265538|BEHAVIORAL|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
219350828|NCT05559229|PROCEDURE|laparoscopic whole-layer cholecystectomy|laparoscopic whole-layer cholecystectomy.
219350829|NCT05821803|OTHER|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
219350830|NCT05821803|OTHER|Foot Core Exercises|4 weeks including
219350831|NCT06428578|OTHER|FBM-In person|Participants will receive two home visits by a CHW. Each home visit will last about 30 minutes, during which the CHW will assist the woman with community resources and help with enrolling in any state or federal nutrition and medical programs. Furthermore, the participants will be given access to a private Facebook group for nutrition, health education, and social support. Home visits will occur during the second and fifth weeks of the study.
219350832|NCT06428578|OTHER|FBM-Virtual|Participants will receive access to a virtual platform which will have information on national, state, and local food and medical resources, as well as local community resources, and will have access to a private Facebook group for nutrition, health education, and social support.
219350833|NCT06428578|OTHER|home delivered food boxes|Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
219350834|NCT00892632|PROCEDURE|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
219350835|NCT03445091|DEVICE|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
219350836|NCT03020732|PROCEDURE|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
219350837|NCT03020732|PROCEDURE|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
219350838|NCT04735094|DIAGNOSTIC_TEST|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
219350839|NCT03651596|BEHAVIORAL|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
219350840|NCT03651596|BEHAVIORAL|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
219350841|NCT02111993|DEVICE|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
219350842|NCT02111993|DEVICE|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
219350843|NCT03671031|PROCEDURE|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
219350844|NCT03671031|PROCEDURE|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
219350845|NCT05797701|DRUG|SAR443820|Tablet by oral administration
219350846|NCT05797701|DRUG|SAR443820|Capsule by oral administration
219350847|NCT05987111|BEHAVIORAL|Pilates|Pilates exercises were applied twice a week for 4 weeks in both groups. The sessions were supervised by an Australian Physiotherapy and Pilates Institute (APPI) certified physiotherapist as 5 minutes of warm-up, 45 minutes of exercise and 5 minutes of cool-down periods.
219350848|NCT03223545|BEHAVIORAL|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
219350849|NCT03223545|BEHAVIORAL|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
219350850|NCT04074928|BIOLOGICAL|QIVc|Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.
219350851|NCT04074928|BIOLOGICAL|Comparator QIV|Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
219350852|NCT00427609|DRUG|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
219350853|NCT02014636|DRUG|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
219350854|NCT02014636|DRUG|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
219350855|NCT02950220|DRUG|Ibrutinib|Given PO
219350856|NCT02950220|OTHER|Laboratory Biomarker Analysis|Correlative studies
219350857|NCT02950220|BIOLOGICAL|Pembrolizumab|Given IV
219350858|NCT01311700|DRUG|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
219350859|NCT02685709|DRUG|Octreotide capsules|
219350860|NCT00821639|BEHAVIORAL|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
219350861|NCT02656602|OTHER|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
219350862|NCT01903499|OTHER|Other: Bean patty|
219350863|NCT01903499|OTHER|Other: Beef patty|
219350864|NCT04400812|OTHER|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
219350865|NCT05218512|OTHER|WB-EMS|"The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS."
219350866|NCT03127384|DEVICE|Restylane Lidocaine|Hyaluronic acid based filler
219350867|NCT03127384|OTHER|No-treatment control|No-treatment control
219350868|NCT06287970|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.
219350869|NCT06287970|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
219350870|NCT01063374|DIETARY_SUPPLEMENT|low glycemic diet instruction|
219350871|NCT01063374|DIETARY_SUPPLEMENT|high cereal fibre diet instruction|
219350872|NCT00355173|DEVICE|Lubo cervical collar|
219350873|NCT00715585|BEHAVIORAL|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
219350874|NCT00715585|BEHAVIORAL|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
219350875|NCT00715585|BEHAVIORAL|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
219350876|NCT03926663|DRUG|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
219350877|NCT03926663|DRUG|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
219350878|NCT01168648|BEHAVIORAL|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
219350879|NCT01168648|OTHER|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
219350880|NCT00163774|DEVICE|Brain oxygenation and microdialysis catheters|
219350881|NCT03496428|DEVICE|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
219350882|NCT01664728|DRUG|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
219350883|NCT01664728|DRUG|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
219354920|NCT04103437|DIAGNOSTIC_TEST|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
219350884|NCT05925296|DEVICE|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
219350885|NCT03233555|OTHER|Informational Intervention|Receive brochure
219350886|NCT03233555|OTHER|Internet-Based Intervention|Have access to EXCELS
219350887|NCT03233555|OTHER|Quality-of-Life Assessment|Ancillary studies
219350888|NCT03233555|OTHER|Questionnaire Administration|Ancillary studies
219350889|NCT03233555|BEHAVIORAL|Telephone-Based Intervention|Receive quarterly calls
219350890|NCT02691442|DRUG|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
219350891|NCT02691442|DRUG|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
219350892|NCT02691442|DRUG|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
219350893|NCT04812132|PROCEDURE|One-anastomosis gastric bypass|One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)
219350894|NCT04812132|PROCEDURE|Long biliary limb Roux gastric bypass|Other group is planned to receive a long biliary limb Roux gastric bypass
219350895|NCT00002753|RADIATION|iodine I 131 monoclonal antibody 81C6|
219350896|NCT06216639|DRUG|Bismuth Subcitrate|Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
219350897|NCT06216639|DRUG|Esomeprazole|Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
219350898|NCT06216639|DRUG|Metronidazole|Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
219350899|NCT06216639|DRUG|Amoxicillin|Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
219350900|NCT06216639|DRUG|Clarithromycin|Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
219350901|NCT06216639|DRUG|Levofloxacin|Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
219350902|NCT05223946|DIAGNOSTIC_TEST|Microwave Radiometry|The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
219350903|NCT05223946|DEVICE|SCENAR-CHENS-01|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
219350904|NCT05223946|COMBINATION_PRODUCT|Traditional Combination Therapy|ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
219350905|NCT04055714|DEVICE|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
219350906|NCT06424028|OTHER|Right Ventricular Infarct|Consecutive patients presented with isolated inferior, infero-posterior and inferolateral wall MI with or without acute right ventricular infarction.
219350907|NCT00326352|DRUG|Sedation with propofol and remifentanil|
219350908|NCT04199637|OTHER|TVG|Therapeutic video game
219350909|NCT05171257|DRUG|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
219350910|NCT05171257|DRUG|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
219350911|NCT04458298|DRUG|OP-101|OP-101 infusion will be administered intravenously.
219350912|NCT04458298|DRUG|Placebo|Matching placebo infusion will be administered intravenously.
219350913|NCT05517941|OTHER|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
219350914|NCT05517941|OTHER|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
219350915|NCT03957772|PROCEDURE|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
219350916|NCT03957772|PROCEDURE|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
219350917|NCT05284123|OTHER|Self-compassion workshop|The self-compassion workshop instructs participants to reflect on a source of shame, connect with their suffering related to it, and then direct feelings of support and understanding towards their suffering via a few brief writing tasks. This workshop also provides participants with basic information about mental health resources.
219350918|NCT05284123|OTHER|Mental health literacy workshop|The mental health literacy workshop provides participants with information about the symptoms and treatment of common mental disorders, and asks participants to reflect on what they learned through a couple brief writing tasks. This workshop also provides participants with basic information about mental health resources.
219350919|NCT05284123|OTHER|Control workshop|The control workshop provides participants with basic information about mental health resources.
219350920|NCT05290025|DRUG|Nicotine patch|\> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
219350921|NCT05290025|DRUG|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
219350922|NCT05290025|DRUG|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
219350923|NCT05290025|BEHAVIORAL|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
219350924|NCT05290025|OTHER|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
219350925|NCT05290025|OTHER|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
219350926|NCT03709173|BEHAVIORAL|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
219350927|NCT01026831|DRUG|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
219350928|NCT01026831|DRUG|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
219350929|NCT04417894|DRUG|dupilumab|Solution for subcutaneous (SC) injection administration
219350930|NCT04417894|DRUG|Placebo|Solution for SC injection administration
219350931|NCT03916211|BIOLOGICAL|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
219350932|NCT06454253|DEVICE|Da Vinci Robot Surgical System|Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system
219350933|NCT03576937|DIAGNOSTIC_TEST|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
219350934|NCT04401176|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
219350935|NCT04401176|DRUG|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
219350936|NCT02505880|OTHER|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
219350937|NCT02505880|DRUG|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
219350938|NCT03440814|DRUG|DCCR|Once daily oral administration
219350939|NCT03440814|DRUG|Placebo for DCCR|Once daily oral administration
219350940|NCT03477760|BIOLOGICAL|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
219350941|NCT00879697|BEHAVIORAL|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
219350942|NCT00879697|BEHAVIORAL|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
219350943|NCT06421558|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
219350944|NCT06421558|DEVICE|Transcutaneous Electrical Stimulation|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
219350945|NCT02774837|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
219350946|NCT02774837|DRUG|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
219350947|NCT04885725|DEVICE|All group|All the participants performed the isokinetic proprioception and strength tests and the functional tests, on the same visit.
219350948|NCT06241846|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
219350949|NCT01201161|DRUG|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
219350950|NCT01201161|OTHER|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
219350951|NCT00756873|DRUG|Administration of placebo|Placebo qd orally day 0-14
219350952|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
219350953|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
219350954|NCT00501787|DRUG|Metformin|
219350955|NCT00002689|DRUG|dexamethasone|
219350956|NCT00002689|DRUG|fluorouracil|
219350957|NCT00002689|RADIATION|brachytherapy|
219350958|NCT00002689|RADIATION|phosphorus P32|
219350959|NCT00002689|RADIATION|radiation therapy|
219350960|NCT03593252|DRUG|Senna|Laxative,used for bowel preparation
219350961|NCT03593252|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
219350962|NCT03593252|DRUG|Metronidazole Oral|Oral antibiotic
219350963|NCT03593252|DRUG|Neomycin|Oral non-absorbable antibiotic
219350964|NCT03593252|DRUG|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
219350965|NCT03593252|DRUG|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
219350966|NCT03593252|OTHER|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for \>=8 hours, no formula milk/full liquids \>= 4hours; no breast milk or clear fluids \>=2hours.
219350967|NCT03593252|OTHER|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
219350968|NCT04456309|OTHER|No intervention,|pure observational study
219350969|NCT03527121|OTHER|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
219350970|NCT03527121|OTHER|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
219350971|NCT01905280|PROCEDURE|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
219350972|NCT01905280|PROCEDURE|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
219350973|NCT04647500|DRUG|Concerta|Evaluation of a treatment of Concerta over a period of 13 days.
219350974|NCT02751502|DEVICE|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
219350975|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
219350976|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
219350977|NCT03064737|OTHER|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
219350978|NCT00088374|DRUG|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
219350979|NCT00088374|DRUG|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
219350980|NCT00088374|DRUG|[15-O] H2O|\[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
219350981|NCT00088374|DRUG|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
219350982|NCT02984046|DRUG|Protein CC16|
219350983|NCT02678390|DIETARY_SUPPLEMENT|MCT|A 5 day consecutive MCT intake of 30 g/day.
219350984|NCT02678390|DIETARY_SUPPLEMENT|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
219350985|NCT02678390|DIETARY_SUPPLEMENT|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
219350986|NCT02678390|DIETARY_SUPPLEMENT|Control day|No MCT or aerobic exercise
219350987|NCT02300701|DRUG|Xolair|According to manufacturer's instructions
219350988|NCT02300701|DRUG|Placebo|Placebo
219350989|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
219350990|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
219350991|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
219350992|NCT04194255|DIETARY_SUPPLEMENT|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
219350993|NCT00498173|DRUG|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
219350994|NCT00498173|DRUG|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
219350995|NCT00750633|DRUG|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
219350996|NCT00750633|DRUG|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
219350997|NCT00750633|DRUG|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
219350998|NCT00750633|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
219350999|NCT01681264|DRUG|Morphine|
219351000|NCT01681264|DRUG|Guanfacine 1mg|
219351001|NCT01681264|DRUG|Guanfacine 2mg|
219351002|NCT01681264|DRUG|Placebo|
219351003|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
219351004|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
219351005|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
219351006|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
219351007|NCT01110200|DRUG|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
219351008|NCT01110200|DRUG|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
219351009|NCT04011020|COMBINATION_PRODUCT|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
219351010|NCT03268915|DIAGNOSTIC_TEST|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
219351011|NCT01616407|DRUG|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
219351012|NCT01616407|DRUG|Methylphenidate|40 mg per os, single dose
219351013|NCT01616407|DRUG|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
219351014|NCT00903175|DRUG|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
219351015|NCT00903175|DRUG|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
219351016|NCT04865068|DIAGNOSTIC_TEST|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
219351017|NCT03466177|DIAGNOSTIC_TEST|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
219351018|NCT05903846|OTHER|Oketani massage|"The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless."
219351019|NCT04017260|PROCEDURE|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
219351020|NCT04017260|PROCEDURE|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
219351021|NCT04017260|PROCEDURE|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
219354921|NCT04103437|DIAGNOSTIC_TEST|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
219354922|NCT04103437|OTHER|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
219351022|NCT04017260|PROCEDURE|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
219351023|NCT00106171|DRUG|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
219351024|NCT01785134|PROCEDURE|Omentectomy|
219351025|NCT01785134|PROCEDURE|Gastric bypass operation|
219351026|NCT03074474|DEVICE|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
219351027|NCT02987621|DEVICE|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
219351028|NCT04755634|DEVICE|Hyaluronic Acid|Injectable
219351029|NCT02882659|BIOLOGICAL|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
219351030|NCT03539250|RADIATION|IMRT|IMRT with and without chemotherapy
219351031|NCT02963532|OTHER|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
219351032|NCT04817111|DRUG|MIB-626|Two (2) 500 mg Tablets, By Mouth, Daily
219351033|NCT02615444|DIETARY_SUPPLEMENT|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
219351034|NCT02615444|DIETARY_SUPPLEMENT|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
219351035|NCT05307029|PROCEDURE|rehabilitation with fixed full-arch prosthesis|
219351036|NCT05594043|DRUG|MK-6598|Oral tablet
219351037|NCT05594043|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
219351038|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
219351039|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
219351040|NCT01318109|DRUG|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
219351041|NCT05346705|BEHAVIORAL|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
219351042|NCT05504733|DEVICE|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
219351043|NCT05504733|DEVICE|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
219351044|NCT06127251|BEHAVIORAL|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
219351045|NCT06127251|BEHAVIORAL|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using ScanWatch. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
219351046|NCT06127251|DEVICE|Physical activity tracker|Participants will be asked to wear a ScanWatch tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
219351047|NCT06127251|BEHAVIORAL|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
219351048|NCT05502575|BEHAVIORAL|Self-monitoring and personalized stress management|Self-monitoring and personalized stress management education and materials.
219351049|NCT05502575|BEHAVIORAL|Self-monitoring and general stress management|Self-monitoring and general stress management education and materials.
219351050|NCT01708109|OTHER|no measures taken to clear bile ductus|biliary calculus remain
219351051|NCT01708109|PROCEDURE|clearance of bile ductus|biliary calculus removed at surgery
219351052|NCT04500782|OTHER|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
219351053|NCT04042103|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
219351054|NCT06108895|OTHER|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
219351055|NCT06108895|OTHER|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
219351056|NCT06122480|PROCEDURE|Surgery|All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
219351057|NCT02193074|DRUG|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
219351058|NCT02193074|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
219351059|NCT02727283|DRUG|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
219351060|NCT02727283|DRUG|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
219351061|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
219351062|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
219351063|NCT04486755|RADIATION|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
219351064|NCT05898958|PROCEDURE|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
219351065|NCT05898958|PROCEDURE|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
219351066|NCT02540486|OTHER|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
219351067|NCT02540486|OTHER|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
219351068|NCT07009353|DRUG|PF-07054894|"Cohort 1 Period 1 - Oral \[cyclobutenyl-14C\]PF-07054894 under fasted state. Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose.~Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose."
219351069|NCT07009353|DRUG|PF-07054894|Cohort 2 Period 1 - Oral \[Methyl-14C\]PF-07054894 under fasted state.
219351070|NCT02071407|DRUG|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
219351071|NCT02071407|DRUG|Placebo|
219351072|NCT00004471|GENETIC|pGT-1 gene lipid complex|
219351073|NCT06877221|PROCEDURE|ultrasound renal denervation|Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device
219351074|NCT07011550|DRUG|Nivolumab|Given by IV
219351075|NCT07011550|DRUG|Bevacizumab|Given by IV
219351076|NCT07011550|DRUG|BMS-986340|Given by IV
219351077|NCT07011550|DRUG|Trifluridine + Tipiracil|Given by PO
219351078|NCT03124563|BEHAVIORAL|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
219351079|NCT03124563|BEHAVIORAL|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
219351080|NCT01534533|DIETARY_SUPPLEMENT|Placebo|one gelatine capsule containing starch per day, for 12 months
219351081|NCT01534533|DIETARY_SUPPLEMENT|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
219351082|NCT01534533|DIETARY_SUPPLEMENT|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
219351083|NCT01534533|DIETARY_SUPPLEMENT|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
219351084|NCT07015528|DRUG|Droperidol|Medication administered as a single intravenous dose.
219351085|NCT07015528|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration.
219351086|NCT07023211|BEHAVIORAL|Neo-Functional diaphragmatic breathing|This technique, rooted in the Neo-Functionalist orientation which actively utilizes body contact, involves direct manual assistance from the therapist during different respiratory movements. This hands-on guidance is specifically aimed at promoting and facilitating congruent movements across the thoracic, diaphragmatic, and abdominal regions throughout the breathing cycle, enhancing the targeted respiratory pattern. The intervention will be delivered by a psychotherapist specialized in Neo-Functional techniques.
219351087|NCT07023211|BEHAVIORAL|Social touch|Participants will receive occasional physical contact applied by the therapist specifically to the right arm. This contact is deliberately non-specific to the breathing process and contrasts with the targeted manual respiratory assistance provided to the experimental group. Participants in this group will not receive breathing instructions.
219351088|NCT07028099|DEVICE|Expandable OLIF cage with posterior bone grafting|This intervention involves the use of a novel expandable OLIF cage that allows intraoperative height adjustment and posterior bone grafting through a dedicated channel. The device is designed to restore intervertebral height and lumbar lordosis while minimizing endplate injury. Bone grafts (autologous or synthetic) are delivered after expansion to enhance fusion. This design aims to reduce cage subsidence, improve fusion rates, and simplify the surgical workflow compared to conventional OLIF cages with fixed heights.
219351089|NCT07028099|DEVICE|Conventional OLIF cage|Participants in the control group will undergo oblique lateral interbody fusion (OLIF) using a standard non-expandable interbody fusion cage. The cage has a fixed height and is inserted via the retroperitoneal approach. Bone grafts are packed into the cage prior to insertion through the anterior or lateral window. This represents the current standard practice for OLIF procedures and does not allow intraoperative height adjustment or posterior graft delivery. The procedure follows conventional OLIF surgical protocols without additional design modifications.
219351090|NCT07029698|DRUG|Vitamin B12, Vitamin B6, Folic acid|A solution for intramuscular injection of fixed vitamin combination (5 mg vitamin B6, 1 mg B12 and 1,05 mg folic acid )
219351091|NCT07029698|DRUG|Vitamin B12 (Cyanocobalamin)|oral tablets of 1mg Vitamin B12
219351092|NCT07029750|PROCEDURE|Lipoabdominoplasty|Combination of liposuction and abdominoplasty under general anesthesia. Klein solution used for tumescent liposuction. Muscle plication performed with 0 loop polydioxanone suture. Umbilicus preserved and repositioned. Postoperative compression corset used for 1 month.
219351093|NCT07027969|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
219351094|NCT07027969|DRUG|Anti-Obesity Medication (AOM) treatment|Implementation of obesity pharmacotherapy in the nonsurgical group includes initial assessment of side effects and response, followed by achieving a clinically meaningful weight loss (5% weight loss) after three months. Once this goal is reached, AOMs will be continued throughout the study. If a weight plateau is reached within the first AOM, then another AOM may be added in combination in a stepwise fashion. The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.
219351095|NCT07029620|DEVICE|Balance and postural rehabilitation using sensor-based stabilometric platform (GEAMASTER) under static and dynamic conditions|This intervention consists of a structured postural rehabilitation program supported by the GEAMASTER stabilometric platform. The device provides real-time feedback on center-of-pressure shifts and enables both static and dynamic balance training through interactive visual tasks. Exercises include multi-directional weight shifting, stability control, and task-specific balance strategies. The platform integrates sensor-based tracking and allows fine-grained analysis of postural parameters, distinguishing it from conventional physiotherapy by its precision, adaptability, and real-time feedback mechanisms.
219354923|NCT01797211|DIETARY_SUPPLEMENT|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
219354924|NCT02127437|DRUG|Lanreotide|120 mg, subcutaneously, once every 4 weeks
219354925|NCT02127437|DRUG|saline|0,5 ml, subcutaneously, once every 4 weeks
219351096|NCT07029620|OTHER|Conventional balance and gait rehabilitation program|This intervention consists of a standardized physiotherapy program aimed at improving postural control and gait in patients with peripheral neuropathy. The rehabilitation protocol includes stretching, weight-shifting exercises, balance training on foam or unstable surfaces, and obstacle navigation. Unlike the experimental intervention, this program does not use any technological or sensor-based feedback systems. The content, frequency, and duration of the sessions are matched to those of the experimental arm to allow for comparative analysis of clinical outcomes.
219351097|NCT07029620|OTHER|Stabilometric assessment in healthy volunteers|This intervention involves a non-interventional assessment of healthy adult volunteers using the GEAMASTER stabilometric platform. The objective is to generate normative data for stabilometric parameters and to assess test-retest reliability of the device under static and dynamic conditions. Participants do not undergo any rehabilitation program or therapeutic intervention. The data collected will serve as a reference for interpreting pathological findings in patients with peripheral neuropathy.
219351098|NCT07028073|DRUG|Group A (FIT): Avapritinib + IA regimen|Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)
219351099|NCT07028073|DRUG|Group B (UNFIT): Avapritinib + VA regimen|Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)
219351100|NCT07039396|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219351101|NCT06715124|DRUG|QTX3544|QTX3544 will be administered at protocol defined dose.
219351102|NCT06715124|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
219351103|NCT06926621|DRUG|VX-670|Solution for intravenous administration.
219351104|NCT07049692|OTHER|Hyperbaric Oxygen Therapy|1.6 atmosphere absolute (1.6 ATA), HBO treatment administrated via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
219351105|NCT07049692|OTHER|High-flow oxygen therapy|1 atmosphere absolute (1 ATA), high-flow oxygen delieved at 10L/min (100%) via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
219351106|NCT06744673|OTHER|No Intervention|This is a non-interventional study.
219351107|NCT06742957|DRUG|Tapinarof Cream 1%|Cream
219351108|NCT06742957|DRUG|VTAMA®|Cream
219351109|NCT06742957|DRUG|Placebo|Cream
219351110|NCT06740435|OTHER|Enhanced Telemedicine for Type 2 Diabetes|Telemedicine-based endocrinology specialty care for type 2 diabetes with multidisciplinary diabetes care team support including pre-visit preparation, in-visit support and self-management education, and post-visit follow-up.
219351111|NCT06740435|OTHER|Usual Telemedicine Endocrinology Care for T2D|Routine telemedicine-based endocrinology specialty care for type 2 diabetes, generally consisting of synchronous virtual visit with an endocrinologist and additional support including self-management education on an individualized basis.
219351112|NCT06763328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219351113|NCT06763328|OTHER|Educational Intervention|Receive standard of care healthy diet and exercise handouts
219351114|NCT06763328|DRUG|Extended Release Metformin Hydrochloride|Given PO
219351115|NCT06763328|OTHER|Questionnaire Administration|Ancillary studies
219351116|NCT07058376|PROCEDURE|Herbal Medicine Strategy|A pragmatic intervention involving tailored herbal prescriptions created by Korean medicine doctors. The specific composition, dose, and duration of herbal medicine vary per patient, and prescriptions are adjusted according to clinical response.
219351117|NCT07058376|PROCEDURE|Standard Korean Medicine Treatment|"This includes the application of Korean medical procedures widely used for chronic low back pain:~Acupuncture: Insertion of needles at 10-20 selected acupoints for 10-15 minutes.~Electroacupuncture: Electrical stimulation at 3 Hz to 4 acupoints for 10-15 minutes.~Infrared Therapy: Application of infrared rays from 30 cm for 10-15 minutes.~Cupping: Wet or dry cupping at 2-4 points on the lower back.~Moxibustion: Applied to two points near the painful area at 43±1°C for 10-15 minutes.~Physical Therapy (ICT or TENS): Applied for 10-15 minutes focusing on the quadratus lumborum.~Treatment frequency is 2 times/week for 5 weeks, but may be adjusted to 1-3 times/week depending on symptoms. Total number of sessions is limited to 10."
219351118|NCT02390297|GENETIC|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
219351120|NCT05865301|OTHER|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
219351121|NCT05149573|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
219351122|NCT05149573|DEVICE|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
219354926|NCT01445028|DRUG|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
219354927|NCT03915223|PROCEDURE|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
219354928|NCT00153582|BIOLOGICAL|WT1 126-134 peptide|
219354929|NCT01716910|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus NCFM and cellobiose|
219351123|NCT06534827|BEHAVIORAL|Great Life Mentoring|The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
219351124|NCT07102095|DRUG|Sevabertinib|Single oral dose of 20 mg sevabertinib administered as 2 x 10 mg film-coated tablets
219351125|NCT03448237|OTHER|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
219351126|NCT03448237|OTHER|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~* Proprioceptive stimulation of oculomotor muscles (active prisms).~* Oral somatosensory stimulation (ALPH).~* Proprioceptive antigravity stimulation (proprioceptive sole).~* Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
219351127|NCT06942741|DRUG|MK-1084 OCT|Oral tablet
219351128|NCT06942741|DRUG|MK-1084 FCT|Oral tablet
219351129|NCT07143955|BEHAVIORAL|Structured Dietary Intervention|A comprehensive dietary program consisting of dietary modification (high-fiber, lean protein), daily probiotic supplementation capsule (Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus), and encouraged intake of prebiotics and unsaturated fatty acids.
219351130|NCT07143955|BEHAVIORAL|Routine Dietary Care|Standard institutional dietary counseling for patients with HCC, providing general advice on nutrition.
219351131|NCT07142798|DRUG|Bismuth amoxilillin potassium|vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days
219351132|NCT07143331|DRUG|Part 1 KS101|Six doses of oral KS101 will be administered to participants.
219351133|NCT07143331|DRUG|Part 1 Placebo|Six doses of oral matching placebo will be administered to participants.
219351134|NCT07143331|DRUG|Part 2 with Food|KS101 administered with food
219351135|NCT07143331|DRUG|Part 2 without food|KS101 administered without food
219351136|NCT07143331|DRUG|Part 3 KS101|3 multiple doses of KS101
219351137|NCT07144046|OTHER|Micropore covering of the medial half of the scar|3 months of micropore covering of the medial half of the scar
219351138|NCT07143526|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCT-A)|Two Optical Coherence Tomography Angiography swept source devices are compared for the detection of large pigment epithelium detachments in age related macular degeneration. The sensitivity of the devices is compared in both the automatic segmentation done by the device and the manual segmentation done by a retina specialist.
219351139|NCT07143071|PROCEDURE|Acute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in acute phase (2-14days)
219351140|NCT07143071|PROCEDURE|Subacute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in subacute phase (≥14days)
219351141|NCT07144735|DRUG|Allogeneic γδ T (ABOUT) cells|Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.
219351142|NCT07143669|OTHER|Screening|After providing informed consent and relevant medical history data, samples will be collected from participants with suspected clonal mast cell disease.
219351143|NCT07142928|OTHER|light-blocking lenses|The eye with higher hyperopia will be fitted with light-blocking lenses for full-time wear, while the fellow eye with lower hyperopia will be fitted with conventional single-vision lenses for full-time wear, over 12 months
219351144|NCT07142928|OTHER|single-vision lenses|Both eyes of the subjects will be fitted with conventional single-vision lenses for full-time wear over 12 months.
219351145|NCT07143279|DRUG|Sustanon 250|Sustanon 250® (1 ml, IM) every 10 days
219351146|NCT07144189|DIAGNOSTIC_TEST|AI diagnostic test for severe low-gradient aortic stenosis|All participants will undergo standard transthoracic echocardiography performed for clinical indications. Echocardiographic images will be analyzed both by experienced physicians and by the investigational AI model. Additional diagnostic tests (such as cardiac CT, low-dose dobutamine stress echocardiography or transesophageal echocardiography) may be performed if clinically indicated, according to current guideline recommendations. The AI-derived results will not influence clinical decision-making.
219351147|NCT07144280|DRUG|PF-08046054|"Antibody Drug Conjugate~Participants will receive PF-08046054, administered as an IV infusion."
219351148|NCT07144280|DRUG|Docetaxel monotherapy|Participants will receive Docetaxel, administered as an IV infusion.
219351149|NCT07144761|DEVICE|Ziplyft|Ziplyft™ is a Class 1, 510(k) Exempt device for removing excess unwanted eyelid skin using a novel surgical device called Ziplyft™.
219351150|NCT05276960|DRUG|Cholecalciferol Pill|Dose increments according to serum levels determined every 2 months
219351151|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
219351152|NCT02255383|DEVICE|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
219351153|NCT06048835|DEVICE|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
219351154|NCT05774600|BEHAVIORAL|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
219351155|NCT05774600|BEHAVIORAL|Minimal Information Control|Provision of online materials for skin cancer prevention.
219351156|NCT03624010|DRUG|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
219351157|NCT06454903|BEHAVIORAL|ACT to RECOVER|During Phase 3 (Stage 1b RCT), the treatment condition will employ ACT to RECOVER. ACT to RECOVER will be a smartphone app designed to act as a flexible, semi-structured, user-friendly adjunct to standard medication treatment for opioid use disorder. Content will include components appropriate for either self-management and/or use with providers. ACT to RECOVER will be designed to have major ACT-focused modules completable within 1 month.
219351158|NCT06454903|BEHAVIORAL|Smartphone-based Symptom-Monitoring|During Phase 3 (Stage 1b RCT), the control condition will employ a smartphone-based symptom monitoring program in an effort to provide a balanced alternative to the treatment condition with respect to attention, time using a mobile application, and nonspecific intervention effects. This condition will not, however, include any content or components from the Prototype Digital Intervention hypothesized to produce active clinical effects.
219351159|NCT06202066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219351160|NCT06202066|PROCEDURE|Computed Tomography|Undergo CT scan
219351161|NCT06202066|BIOLOGICAL|Incomplete Freund''s Adjuvant|Given SC
219351162|NCT06202066|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219351163|NCT06202066|BIOLOGICAL|Sargramostim|Given SC
219351164|NCT06202066|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
219351165|NCT06202066|DRUG|Temozolomide|Given PO
219351166|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
219351167|NCT05380063|DRUG|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
219351168|NCT05380063|DRUG|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
219351169|NCT03596905|DRUG|Plecanatide|Taken orally daily for 4 weeks
219351170|NCT03596905|DRUG|Matching placebo|Taken orally daily for 4 weeks
219351171|NCT05980169|DEVICE|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
219351172|NCT04311502|DRUG|Rifapentine|1200 mg once daily
219351173|NCT04311502|DRUG|Rifampicin|600 mg once daily
219351174|NCT04311502|DRUG|Isoniazid|300 mg once daily
219351175|NCT04311502|DRUG|Pyrazinamide|1000mg once daily if weight is 40 to \<55kg; 1500mg once daily if weight is 55 to \<71kg; 2000mg once if weight is ≥71kg
219351176|NCT04311502|DRUG|Ethambutol|800 mg once daily if weight is 40 to \<55kg; 1200 mg once daily if weight is 55 to \<71kg; 1600mg once if weight is ≥71kg
219351177|NCT04311502|DRUG|Clofazimine loading dose|300 mg once daily for 2 weeks (loading dose), then 100 mg once daily
219351178|NCT04311502|DRUG|Clofazimine 100 MG|100 mg once daily
219351179|NCT04707274|OTHER|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
219351180|NCT03833700|DRUG|E7386|E7386 doses.
219351181|NCT06963346|DRUG|Romidepsin|Administered as intravesical treatment.
219351182|NCT06963346|DRUG|Durvalumab|Administered as intravenous treatment.
219351183|NCT05279755|DRUG|prosetin|oral solution
219351184|NCT05279755|DRUG|placebo|oral solution
219351185|NCT06963359|DEVICE|HD-sEMG|High definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair rises, depending on the patient's functional state
219351186|NCT06963359|DEVICE|Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed
219351187|NCT06963359|OTHER|IPAQ Physical Activity Questionnaire|Physical activity assessment questionnaire/adapted version for seniors
219351188|NCT03040999|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
219351189|NCT03040999|DRUG|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
219351190|NCT03040999|DRUG|Cisplatin|100 mg/m\^2 administered as an IV infusion Q3W
219351191|NCT03040999|RADIATION|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
219351192|NCT03040999|RADIATION|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
219351193|NCT05779774|BEHAVIORAL|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
219351194|NCT05779774|BEHAVIORAL|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
219351198|NCT03802851|PROCEDURE|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
219351199|NCT06373861|OTHER|no intervention|This study is an observational study without treatment intervention.
219351200|NCT01408147|BEHAVIORAL|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
219351201|NCT01564927|DEVICE|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
219351202|NCT01564927|DEVICE|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
219351203|NCT01564927|DEVICE|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
219351204|NCT00176280|DRUG|Leukine|
219351205|NCT00176280|DRUG|Dexamethasone|
219351206|NCT01661140|DRUG|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
219351207|NCT01661140|DRUG|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
219351208|NCT01661140|DRUG|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
219351209|NCT03639714|BIOLOGICAL|GRT-C901|a patient-specific neoantigen cancer vaccine prime
219351210|NCT03639714|BIOLOGICAL|GRT-R902|a patient-specific neoantigen cancer vaccine boost
219351211|NCT03639714|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
219351212|NCT03639714|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
219351213|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
219351214|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
219351215|NCT01946321|OTHER|Post-amputation functional rehabilitation (normal clinical practice)|
219351216|NCT04295161|DRUG|Abiraterone Acetate|Abiraterone acetate immediate release formulations
219351217|NCT01391000|PROCEDURE|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
219351218|NCT01391000|PROCEDURE|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
219351219|NCT05772260|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
219351220|NCT01991782|OTHER|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
219351221|NCT03766880|PROCEDURE|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
219351222|NCT03766880|PROCEDURE|MR imaging|MR images for the post-processing analysis
219351223|NCT04783636|DRUG|leuprorelin acetate 3.75mg|PT105, PT105R
219351224|NCT04880200|DIAGNOSTIC_TEST|POC NAT & Adherence Intervention|The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
219351225|NCT00488891|DRUG|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
219351226|NCT00488891|DRUG|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
219351227|NCT04740047|DIAGNOSTIC_TEST|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
219351228|NCT03535753|DRUG|Decitabine and R-GDP|Decitabine and R-GDP
219351229|NCT01436539|DRUG|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
219351230|NCT01436539|DRUG|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
219351231|NCT04872114|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
219351232|NCT05344456|DEVICE|Change in the device PVC algorithm to ''Off''|PVC algorithm change from Atrial Pace mode to Off
219351233|NCT02303379|OTHER|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
219351234|NCT02303379|OTHER|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
219351235|NCT02303379|OTHER|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
219351236|NCT00817531|DRUG|Dasatinib|pill form, 100 mg daily
219351237|NCT02896595|DEVICE|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
219351238|NCT02896595|DEVICE|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
219351239|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,"
219351240|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike"
219351241|NCT02103569|DRUG|FDC of Daclatasvir, Asunaprevir and BMS-791325|
219351242|NCT02103569|DRUG|FDC of Norethindrone and Ethinyl Estradiol|
219351243|NCT02103569|DRUG|BMS-791325|
219351244|NCT04991766|DRUG|[¹⁴C]-LY3484356|Administered orally.
219351245|NCT04991766|DRUG|LY3484356|Administered orally.
219351246|NCT04991766|DRUG|[¹⁴C]-LY3484356 (IV)|Administered IV.
219351247|NCT03678402|DEVICE|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
219351248|NCT03485833|DIAGNOSTIC_TEST|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
219351249|NCT04926974|BEHAVIORAL|Low Vision Rehabilitation|Smart phone App
219351250|NCT00251537|DRUG|LTB4|
219351251|NCT05661773|DEVICE|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
219351252|NCT01961700|OTHER|Physiotherapy|Physiotherapy treatment
219351253|NCT06445868|OTHER|Sedentary behaviour intervention|COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
219351254|NCT03206697|OTHER|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
219351255|NCT02872766|DEVICE|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
219351256|NCT01450033|BEHAVIORAL|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
219351257|NCT01450033|BEHAVIORAL|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
219351258|NCT03607864|DEVICE|coral bone graft and xenograft|"ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures."
219351259|NCT01536054|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
219351260|NCT01536054|DRUG|sirolimus|Given PO
219351261|NCT01536054|OTHER|laboratory biomarker analysis|Correlative studies
219351262|NCT01536054|BIOLOGICAL|sargramostim|Given SC
219351263|NCT04001816|OTHER|Orthodontic Brackets|Self ligating and Conventional brackets
219351264|NCT05766995|DEVICE|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
219351265|NCT05766995|DEVICE|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
219351266|NCT05766995|DEVICE|Waxed Dental Floss|Nylon string used to clean between the teeth manually
219351267|NCT00132132|BEHAVIORAL|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
219351268|NCT02025426|DRUG|Phenylephrine|
219351269|NCT02025426|DRUG|Ephedrine|
219351270|NCT04421274|BIOLOGICAL|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
219351271|NCT04421274|DRUG|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
219351272|NCT04421274|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
219351273|NCT02200315|OTHER|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
219351274|NCT05136937|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
219351275|NCT02235532|OTHER|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
219351276|NCT02235532|OTHER|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
219351277|NCT03889561|BEHAVIORAL|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
219351278|NCT01770925|DEVICE|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
219351279|NCT01770925|DEVICE|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
219351280|NCT01770925|DEVICE|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
219351281|NCT04273178|DRUG|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
219351282|NCT03939507|OTHER|AEP score available to the treating physician|the treating physician knew the AEP score results
219351283|NCT05500625|PROCEDURE|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
219351284|NCT05500625|PROCEDURE|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
219351285|NCT05875870|BEHAVIORAL|Daylight exposure combine walking|"1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
219351286|NCT05875870|BEHAVIORAL|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
219351287|NCT05134272|DEVICE|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
219351288|NCT05134272|BEHAVIORAL|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
219351289|NCT05134272|BEHAVIORAL|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
219351290|NCT01916265|DRUG|Glucagon|
219351291|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
219351292|NCT00737867|DRUG|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
219351293|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
219351294|NCT00737867|DRUG|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
219351295|NCT03695003|DIETARY_SUPPLEMENT|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
219351296|NCT03695003|DIETARY_SUPPLEMENT|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
219351297|NCT00432978|DRUG|Bosentan administration|
219351298|NCT00494091|DRUG|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
219351299|NCT00494091|DRUG|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
219351300|NCT05796635|OTHER|Herpecin L|Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
219351301|NCT03300466|DEVICE|GP0045|Hyaluronic acid gel
219351302|NCT03300466|DEVICE|Comparator|Hyaluronic acid gel
219351303|NCT03343132|BEHAVIORAL|Standard locomotor therapy|Typical clinical therapy.
219351304|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine|
219351305|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine + adjuvant|
219351306|NCT02797236|BIOLOGICAL|Placebo|
219351307|NCT02797236|BIOLOGICAL|Placebo + adjuvant|
219351308|NCT00003385|DRUG|carboplatin|
219351309|NCT00003385|DRUG|paclitaxel|
219351310|NCT00003385|DRUG|pegylated liposomal doxorubicin hydrochloride|
219351311|NCT04248413|DEVICE|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
219351312|NCT04248413|OTHER|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
219351313|NCT00452699|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
219351314|NCT00452699|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
219351315|NCT00807755|DRUG|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
219351316|NCT00807755|DRUG|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
219351317|NCT00807755|DRUG|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
219351318|NCT00428649|DIETARY_SUPPLEMENT|20 µg selenium|20 µg selenium as selenomethionine
219351319|NCT00428649|DIETARY_SUPPLEMENT|40 µg selenium|40 µg selenium as selenomethionine
219351320|NCT00428649|DIETARY_SUPPLEMENT|60 µg selenium|60 µg selenium as selenomethionine
219351321|NCT00428649|DIETARY_SUPPLEMENT|80 µg selenium|80 µg selenium as selenomethionine
219351322|NCT00428649|DIETARY_SUPPLEMENT|100 µg selenium|100 µg selenium as selenomethionine
219351323|NCT00428649|DIETARY_SUPPLEMENT|120 µg selenium|120 µg selenium as selenomethionine
219351324|NCT00428649|DIETARY_SUPPLEMENT|placebo|placebo
219351325|NCT02953535|DRUG|Magicbuvir|1 tablet contains 400 mg sofosbuvir
219351326|NCT02953535|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
219351327|NCT02953535|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
219351328|NCT03847987|DRUG|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
219351329|NCT03847987|DRUG|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
219351330|NCT03847987|DRUG|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
219351331|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
219351332|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
219351333|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
219351334|NCT00648375|DRUG|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
219351335|NCT00648375|DRUG|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
219351336|NCT00648375|BEHAVIORAL|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
219351337|NCT04788979|DRUG|Melatonin 5Mg Oral Tablet|"1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
219351338|NCT01965132|DRUG|Biologic or targeted synthetic DMARD|
219351339|NCT02236455|BEHAVIORAL|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
219351340|NCT02236455|BEHAVIORAL|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
219351341|NCT02236455|BEHAVIORAL|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
219351342|NCT02236455|BEHAVIORAL|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
219351343|NCT02012478|BEHAVIORAL|MI- informed SMS program|
219351344|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center);~Camrelizumab at a fixed dose of 200mg, administered via intravenous drip, with each infusion lasting no less than 30 min and no more than 60 min. Administered on day 1 of every 2-week cycle (d1, q2w).~Each treatment cycle is 14 days, and all drugs are administered on day 1."
219351345|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center); Each treatment cycle is 14 days, and all drugs are administered on day 1."
219351346|NCT00002553|DRUG|cyclophosphamide|
219351347|NCT00002553|PROCEDURE|allogeneic bone marrow transplantation|
219351348|NCT00002553|RADIATION|low-LET cobalt-60 gamma ray therapy|
219351349|NCT05087069|DRUG|BV100|Rifabutin for Infusion
219351350|NCT05087069|DRUG|Placebo|Saline intravenous infusion
219351351|NCT03582670|BEHAVIORAL|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
219351352|NCT03582670|BEHAVIORAL|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
219351353|NCT03582670|BEHAVIORAL|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
219351354|NCT04813029|PROCEDURE|Straight leg raise maneuver|With the patient in supine position, one leg is raised to form an angle of at least 45 degrees with the bed. The patient will be asked to keep that position for at least 5 seconds. The maneuver will be repeated after 20-30 seconds. The first adequate maneuver will be considered for the study. Intra-esophageal and intra-abdominal pressure will be analyzed both during baseline and SLR maneuver. Intra-esophageal pressure is measured as peak and mean over 5 seconds, 1 cm and 5 cm above the proximal margin of the LES. Intra-abdominal pressure will be measured as peak and mean over 5 seconds 1 cm below the distal margin of the diaphragm notch.
219351355|NCT01531036|DEVICE|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
219351356|NCT02111564|DRUG|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
219351357|NCT02111564|DRUG|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
219351358|NCT02111564|DRUG|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
219351359|NCT00918814|DRUG|LIPO-102|Subcutaneous Injection
219351360|NCT00918814|DRUG|Placebo|Placebo
219351361|NCT00687362|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
219351362|NCT02852382|DRUG|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
219351363|NCT02852382|DRUG|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
219351364|NCT02950519|OTHER|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
219351365|NCT02354703|DRUG|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
219351366|NCT02354703|DRUG|Placebo|Placebo + BBCET counseling
219351367|NCT01014845|BIOLOGICAL|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
219351368|NCT01014845|BIOLOGICAL|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
219351369|NCT02276092|OTHER|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
219351370|NCT04415073|DRUG|SNDX-6352|SNDX-6352
219351371|NCT04415073|DRUG|Placebo|Placebo comparator
219351372|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
219351373|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
219351374|NCT06126991|DRUG|Cetirizine|Oral administration of cetirizine at 10mg once daily will be used.
219351375|NCT06126991|DRUG|Midazolam and Fentanyl|Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
219351376|NCT03468309|GENETIC|Genecept Assay and G-DIG decision tool|Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
219351377|NCT06137118|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
219351378|NCT05966298|OTHER|Core stabilization training|First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.
219351379|NCT05966298|OTHER|Standart Rehabilitation|This treatment includes shoulder exercises and conventional therapy (Infrared, TENS).
219351380|NCT01075061|OTHER|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
219351381|NCT01075061|OTHER|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
219351382|NCT01075061|OTHER|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
219351383|NCT06205121|DRUG|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
219351384|NCT06205121|DRUG|Placebo|Matching placebo tablets
219351385|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
219351386|NCT04188418|DRUG|Morphine|Given PO
219351387|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
219351388|NCT04188418|OTHER|Placebo Administration|Given PO
219351389|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
219351390|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
219351391|NCT06353451|BEHAVIORAL|Digital Detox|In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
219351392|NCT02396732|DRUG|Aspirin|Daily dose is 81 mg oral tablet
219351393|NCT02396732|DRUG|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
219351394|NCT05144607|OTHER|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
219351395|NCT01259609|PROCEDURE|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
219351396|NCT05195008|DRUG|BIIB113|Administered as specified in the treatment arm.
219351397|NCT05195008|DRUG|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
219351398|NCT05195008|DRUG|11^C]BIO-1819578|Administered as specified in the treatment arm.
219351399|NCT04230174|DRUG|11C-PBR28|This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
219351400|NCT00963274|DRUG|Bortezomib|Starting dose: 1.3 mg/sq m
219351401|NCT00963274|DRUG|Romidepsin|Starting dose: 8 mg/sq m
219351402|NCT04934761|PROCEDURE|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV\< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV \<10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV\<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
219351403|NCT04934761|PROCEDURE|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
219351404|NCT05409339|DRUG|Caffeine|150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
219351405|NCT05409339|DRUG|Placebo|Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
219351406|NCT02750462|OTHER|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
219351407|NCT02750462|OTHER|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
219351408|NCT06296862|OTHER|Dietary Approaches to Stop Hypertension Diet|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
219351409|NCT02981771|BEHAVIORAL|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
219351410|NCT02981771|BEHAVIORAL|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
219351411|NCT00586573|DRUG|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
219351412|NCT06401161|OTHER|3T Pu'er tea|Two types of Pu-erh tea with different levels of theabrownin content.
219351413|NCT00556660|DRUG|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
219351414|NCT01496885|OTHER|Observational study|This was an observational study and no study drug was administered.
219351415|NCT03657901|BEHAVIORAL|Music listening|Guided music listening for 30 minutes before sleep onset
219351416|NCT03657901|BEHAVIORAL|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
219351417|NCT03434405|BEHAVIORAL|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
219351418|NCT03434405|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
219351419|NCT03434405|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
219351420|NCT05011708|DEVICE|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
219351421|NCT05011708|DEVICE|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
219351422|NCT01404299|DIETARY_SUPPLEMENT|Nutritional Supplementation|\- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
219351423|NCT01404299|OTHER|Control|\- No intervention, except monthly home visits
219351424|NCT03164382|DRUG|FOLFOX regimen|Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
219351425|NCT03164382|DRUG|Sorafenib 200Mg Tab|Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
219351426|NCT03833830|DIAGNOSTIC_TEST|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).
219351427|NCT05075538|BIOLOGICAL|Spikevax|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351428|NCT05075538|BIOLOGICAL|Comirnaty|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351429|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351430|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351431|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351432|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351433|NCT05075538|BIOLOGICAL|Comirnaty Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351434|NCT05075538|BIOLOGICAL|Spikevax Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
219351435|NCT05439499|DRUG|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
219351436|NCT05439499|DRUG|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
219351437|NCT03380910|BEHAVIORAL|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
219351438|NCT03380910|BEHAVIORAL|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
219351439|NCT00215384|DRUG|Formoterol Fumarate|
219351440|NCT04378803|BEHAVIORAL|Mindfulness training (MT) Connect|MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.
219351441|NCT05168358|PROCEDURE|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
219351442|NCT00845442|DEVICE|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
219351443|NCT00170430|DRUG|Fluconazole|
219351444|NCT00170430|DRUG|Metronizadole|
219351445|NCT04882397|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
219351446|NCT04882397|OTHER|Sham|Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
219351447|NCT02005757|DRUG|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
219351448|NCT02005757|DRUG|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
219351449|NCT05798260|DIAGNOSTIC_TEST|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
219351450|NCT01608412|DRUG|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
219351451|NCT01608412|DRUG|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
219351452|NCT03446885|DRUG|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
219351453|NCT03446885|DRUG|Placebo|Placebo capsule administered orally
219351454|NCT03826927|OTHER|treatment with NOACs or VKAs|treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
219351455|NCT02801214|OTHER|fMRI|
219351456|NCT06541223|OTHER|Standard informed consent procedure|Face-to-face informed consent procedure supported by informational brochure
219351457|NCT06541223|OTHER|Multimedia video|Multimedia presentation on implant-based reconstruction
219351458|NCT02672566|DRUG|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
219351459|NCT02672566|OTHER|Usual care|Patients will all benefit from the usual care
219351460|NCT01124487|DIETARY_SUPPLEMENT|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
219351461|NCT05388539|PROCEDURE|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
219351462|NCT05388539|PROCEDURE|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
219351463|NCT01070160|DRUG|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
219351464|NCT01070160|DRUG|Metformin|per clinical care guidelines
219351465|NCT04276584|DEVICE|Positive expiratory pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
219351466|NCT04276584|OTHER|Speaking loudly during about 3 minutes|A specified swedish text
219351467|NCT06962787|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
219351468|NCT06962787|DRUG|axitinib|Oral administration, and twice daily with an interval of 12 hours.
219351469|NCT06962787|DRUG|pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
219351470|NCT05726318|DRUG|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
219351471|NCT06075095|DRUG|BGF MDI HFO 320/14.4/9.6μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
219351472|NCT06075095|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
219351473|NCT06075095|DRUG|Placebo MDI HFA|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
219351474|NCT01707407|DRUG|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
219351475|NCT01707407|DRUG|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
219351476|NCT01707407|DRUG|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
219351477|NCT01707407|DRUG|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
219351478|NCT05956041|DRUG|Pembrolizumab|400mg Intravenously
219351479|NCT05956041|DRUG|Mogamulizumab|1mg/kg Intravenously
219351480|NCT05215340|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219351481|NCT05215340|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
219351482|NCT05468697|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
219351483|NCT05468697|DRUG|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
219351484|NCT06076408|OTHER|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
219351485|NCT06076408|OTHER|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
219351486|NCT06451913|DRUG|Amoxicillin + Saccharomyces boulardii CNCM I-745|At inclusion visit (V1), the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + Saccharomyces boulardii 250 mg x 2 twice a day for 21 days
219351487|NCT06451913|DRUG|Amoxicillin + Placebo|At inclusion visit (V1),the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + a matching placebo bid for 21 days
219351488|NCT06451913|OTHER|Stool samples|"The subject will be asked to collect thanks to four OMNIgene® •GUT OMR-200 kits :~* an initial stool collection when returning home at D1 (in any case before any intake of amoxicillin and of the investigational medication and up to 1 day after D1).~* a stool collection at home after the phone call 1, Day 7 (stool collection up to Day 7 + 1 day)~* a stool collection at home after the phone call 2, Day 14 (stool collection up to Day 14 + 1 day)~* at home the day of the Visit 2, Day 21 (stool collection up to Day 21 + 1 day)"
219351489|NCT06451913|OTHER|BSFS : Bristol Stool Form Scale|All included subjects will have to complete a stool diary BSFS (Bristol Stool Form Scale) daily and at each bowel movement, from Day 1 until the end of study treatment (Day 21). The patient will fill the form with the date, the time, and the stool texture.
219351490|NCT06451913|OTHER|GSRS : Gastrointestinal Symptom Rating Scale|All included subjects will have to complete a GSRS (Gastrointestinal Symptom Response Score) questionnaire weekly from Day 1 until the end of the study treatment (Day 21).
219351491|NCT06395324|OTHER|High arabinose diet|Participants will consume a high arabinose diet for 18 consecutive days.
219351492|NCT06798597|BEHAVIORAL|Health4Life app|Health4Life is a program based on the anticipatory guidance approach aiming to support parents create healthy lifestyle behaviours starting in early infancy. The intervention consists of ten themes over a 16 month period and incorporates interactive features such as quizzes.
219354930|NCT04655664|DIAGNOSTIC_TEST|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
219351493|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
219351494|NCT05098197|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
219351495|NCT06570304|PROCEDURE|iCount Device|"Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory."
219351496|NCT05010005|DRUG|Ruxolitinib|Ruxolitinib 20mg BID
219351497|NCT05010005|DRUG|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
219351498|NCT03988439|DRUG|IDP-118 Lotion|Topical
219351499|NCT04303858|DRUG|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
219351500|NCT04303858|DRUG|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
219351501|NCT05667753|BEHAVIORAL|MINISTOP 3.0|MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
219351502|NCT06472011|OTHER|lean steak and potatoes|Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351503|NCT06472011|OTHER|lentil and sweet potato chili|Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351504|NCT06472011|OTHER|macaroni and cheese|Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351505|NCT06472011|OTHER|fish tacos|Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351506|NCT06472011|OTHER|chicken and pea fried rice|Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351507|NCT06472011|OTHER|pita and hummus|Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351508|NCT06472011|OTHER|creamy pork pasta|Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
219351509|NCT06381388|DEVICE|cTBS|A single cTBS session delivered to the contralesional primary motor cortex.
219351510|NCT04734106|DRUG|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
219351511|NCT04734106|OTHER|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
219351512|NCT06388187|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219351513|NCT06388187|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219351514|NCT06388187|DRUG|Placebo|Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
219351515|NCT04589988|BEHAVIORAL|Removing Environmental Barriers to Independent Living (REBIL)|REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.
219351516|NCT04589988|BEHAVIORAL|Waitlist Attentional Control|The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
219351517|NCT05857241|DIETARY_SUPPLEMENT|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
219351518|NCT02498639|PROCEDURE|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
219351519|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
219351520|NCT03685786|BIOLOGICAL|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
219351521|NCT02476721|OTHER|detection of pulmonary embolism|
219351522|NCT06275503|BEHAVIORAL|Screening invitation mode|Cluster randomized study to compare mode of invitation
219351523|NCT03760926|DEVICE|May Health Kit|The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
219351524|NCT04672759|DRUG|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
219351525|NCT04672759|DRUG|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
219351526|NCT02989415|OTHER|Mechanical Ventilation|Mechanical ventilation during robotic surgery
219351527|NCT05535348|BEHAVIORAL|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
219351528|NCT02736669|BEHAVIORAL|Energy Reduction|
219351529|NCT06117319|OTHER|Individual assistance Virtual reality training sessions|5 virtual reality training sessions where feedback will be provided to each individual by the research team
219351530|NCT06117319|OTHER|Collective assistance Virtual reality training sessions|4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual. No participant was ever assigned to this intervention.
219351531|NCT00252057|BEHAVIORAL|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
219351532|NCT05648435|DIAGNOSTIC_TEST|Lithium measures|Measurements of lithium levels in blood and urine
219351533|NCT03248401|DRUG|Cilostazol|Cilostazol 200 mg/day
219351534|NCT03248401|DRUG|Aspirin|Aspirin 100 mg/day
219351535|NCT00928538|OTHER|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
219351536|NCT03662425|DRUG|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
219351537|NCT03662425|DRUG|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
219351538|NCT03449823|DIAGNOSTIC_TEST|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
219351539|NCT05287009|PROCEDURE|ILM nonpeeling|ILM is not peeled after ERM removal
219351540|NCT05287009|PROCEDURE|ILM peeling|ILM is peeled after ERM removal
219351541|NCT01660932|DRUG|placebo|
219351542|NCT01660932|DRUG|omega|
219351543|NCT03041285|DRUG|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
219351544|NCT03041285|RADIATION|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
219351545|NCT05412680|PROCEDURE|TOETVA|TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH
219351546|NCT05412680|PROCEDURE|conventional thyroidectomy|conventional open thyroidectomy by cervical approach
219351547|NCT02592850|OTHER|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
219351548|NCT02592850|OTHER|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
219351549|NCT01084265|DRUG|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units \[IU\]) injection s.c. once daily.
219351550|NCT01084265|DRUG|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
219351551|NCT01084265|DRUG|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
219351552|NCT02743832|PROCEDURE|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
219351553|NCT02743832|PROCEDURE|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
219351554|NCT06198673|DRUG|Antiplatelet Agents|Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
219351555|NCT00832507|DRUG|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
219351556|NCT00832507|DRUG|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
219351557|NCT06345677|COMBINATION_PRODUCT|ViXe Xombination|Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure
219351558|NCT06345677|COMBINATION_PRODUCT|Placebo + Sham|Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
219351559|NCT00876993|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
219351560|NCT00876993|DRUG|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
219351561|NCT00876993|DRUG|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
219351562|NCT04884230|PROCEDURE|Oversewing|Oversewing of the gastric remnant
219351563|NCT05332483|DRUG|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
219351564|NCT02972255|DRUG|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
219351565|NCT02972255|DRUG|Meropenem|Meropenem will be administered as per schedule described in individual arm.
219351566|NCT02972255|OTHER|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
219351567|NCT02972255|OTHER|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
219351568|NCT01098071|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
219351569|NCT06281639|DEVICE|RAPID|test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
219351570|NCT00940355|BEHAVIORAL|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
219351571|NCT06093139|DIETARY_SUPPLEMENT|Probiotic capsule|probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules
219351572|NCT06093139|DIETARY_SUPPLEMENT|Placebo|placebo consisted of the same capsules filled with potato starch
219351573|NCT06063421|DEVICE|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
219351574|NCT06063421|DRUG|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
219351575|NCT03648697|BIOLOGICAL|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
219351576|NCT01507272|DRUG|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
219351577|NCT01507272|DRUG|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
219351578|NCT01507272|DRUG|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
219351579|NCT01507272|DRUG|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
219351580|NCT03326843|DRUG|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
219351581|NCT00942474|DEVICE|Facilitate nerve stimulation lead placement with the nerve access tool|
219351582|NCT03703973|DIAGNOSTIC_TEST|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
219351583|NCT03324997|DRUG|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
219351584|NCT03324997|DRUG|Saline|Saline as placebo
219351585|NCT03324997|DEVICE|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
219351586|NCT00312910|DRUG|Probiotics-Bio-plus|
219351587|NCT02510287|DRUG|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
219351588|NCT02510287|DRUG|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
219351589|NCT02510287|DRUG|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
219351590|NCT02510287|DRUG|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
219351591|NCT02510287|DRUG|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
219351592|NCT01555203|BEHAVIORAL|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
219351593|NCT05069181|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
219351594|NCT05069181|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
219351595|NCT05069181|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
219351596|NCT03025958|DRUG|Nimotuzumab|Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.
219351597|NCT03025958|RADIATION|Radiation|Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
219351598|NCT01081795|DRUG|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
219351599|NCT01081795|DRUG|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
219351600|NCT01358656|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith \& Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
219354931|NCT04655664|DIAGNOSTIC_TEST|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
219354932|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
219354933|NCT03779113|DRUG|HMPL-523|Oral HMPL-523
219354934|NCT05357300|DEVICE|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
219351601|NCT01358656|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
219351602|NCT05823597|BEHAVIORAL|Sugar Intensive Treatment|see arm description
219351603|NCT05823597|BEHAVIORAL|General Health Control|see arm description
219351604|NCT04509921|OTHER|asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness|Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
219351605|NCT00661271|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
219351606|NCT00661271|BEHAVIORAL|Healthy topics|8 week health education program with one retreat session
219351607|NCT06164379|DRUG|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
219351608|NCT06164379|DRUG|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
219351609|NCT05244850|OTHER|Test|Measurements
219351610|NCT03398577|DRUG|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
219351611|NCT03398577|DRUG|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
219351612|NCT00136591|DRUG|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
219351613|NCT00136591|DRUG|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
219351614|NCT00683033|BEHAVIORAL|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
219351615|NCT00683033|BEHAVIORAL|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
219351616|NCT05758259|DRUG|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
219351617|NCT05758259|DRUG|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
219351618|NCT05758259|DRUG|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
219351619|NCT06299254|OTHER|Placebo-Natural History|"Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts."
219351620|NCT01707693|BEHAVIORAL|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing \& follow-up
219351621|NCT01707693|BEHAVIORAL|Information / Attention Comparison|Physical Activity information given \& follow-up, no behavioral counseling
219351622|NCT04223310|DRUG|Virtual AAD TEST group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design."
219351623|NCT04223310|DRUG|Empirical AAD group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design."
219351624|NCT00781716|DEVICE|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
219351625|NCT00302965|DRUG|Frozen Plasma|
219351626|NCT06076655|OTHER|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
219351627|NCT01146106|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
219351628|NCT02895061|DRUG|Alfacalcidol|Alfacalcidol 1 microgram/capsule
219354935|NCT04269226|PROCEDURE|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
219354936|NCT04269226|PROCEDURE|No recruitment maneuver|Usual ventilation procedures will be applied.
219354937|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
219354938|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
219351629|NCT04760561|PROCEDURE|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
219351630|NCT00143455|DRUG|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
219351631|NCT00143455|DRUG|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
219351632|NCT00123214|DRUG|Controlled Dietary Intervention|
219351633|NCT05268926|DRUG|Dapagliflozin 10Mg Tab|dapagliflozin 10 mg/d or matched placebo
219351634|NCT05268926|DRUG|Placebo|Placebo
219351635|NCT05484960|OTHER|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
219351636|NCT03537027|DIETARY_SUPPLEMENT|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
219351637|NCT04593654|DRUG|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
219351638|NCT00022529|DRUG|BMS-214662|Given IV
219351639|NCT00022529|BIOLOGICAL|trastuzumab|Given IV
219351640|NCT00022529|OTHER|pharmacological study|Correlative studies
219351641|NCT03665142|OTHER|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
219351642|NCT03665142|OTHER|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
219351643|NCT02335996|BIOLOGICAL|Blood samples for measuring adiponectin, leptin and omentin plasma|
219351644|NCT02335996|DEVICE|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
219351645|NCT03713944|DRUG|Carboplatin|Carboplatin, AUC 5
219351646|NCT03713944|DRUG|Pemetrexed|Pemetrexed 500mg/m2
219351647|NCT03713944|DRUG|Atezolizumab|Atezolizumab 1200mg
219351648|NCT03713944|DRUG|Bevacizumab|Bevacizumab 15mg/kg
219351649|NCT01242449|DRUG|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
219351650|NCT01242449|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
219351651|NCT02184871|OTHER|exposure to different risk factors and molecular assessment|
219351652|NCT03768947|OTHER|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of \~12-15 visits (45 min each) of immersion in to a hot tub.
219351653|NCT03801369|PROCEDURE|Biopsy|Undergo biopsy
219351654|NCT03801369|DRUG|Capivasertib|Given PO (orally)
219351655|NCT03801369|DRUG|Ceralasertib|Given PO (orally)
219351656|NCT03801369|BIOLOGICAL|Durvalumab|Given IV (infusion)
219351657|NCT03801369|DRUG|Olaparib|Given PO (orally)
219351658|NCT03801369|OTHER|Quality-of-Life Assessment|Ancillary studies
219351659|NCT03801369|DRUG|Selumetinib|Given PO (orally)
219351660|NCT04509466|DRUG|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
219351661|NCT04509466|DRUG|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
219351662|NCT04509466|DRUG|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
219351663|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
219351664|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
219351665|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
219351666|NCT03557892|DEVICE|CGM+CSII|Animas Vibe Platinum insulin pump and Dexcom G4 CGM
219351667|NCT03557892|DEVICE|MDI with degludec|Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
219354939|NCT04427215|OTHER|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
219351668|NCT06420973|DRUG|RC48+carboplatin±bevacizumab|RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
219351669|NCT00985400|BEHAVIORAL|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
219354940|NCT05979571|OTHER|Mobile health app|Breastfeeding knowledge and promotion information will be delivered through the AmiBreastfeed app platform
219351670|NCT00985400|BEHAVIORAL|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
219351671|NCT00985400|OTHER|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
219351672|NCT00985400|OTHER|Questionnaire administration|
219351673|NCT00985400|BEHAVIORAL|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
219351674|NCT01714986|BEHAVIORAL|Affect School|
219351675|NCT01714986|BEHAVIORAL|Body Awareness Therapy|
219351676|NCT00066898|DRUG|AGI-1067|
219351677|NCT04196868|DRUG|Metformin treatment|1500 mg once a day, per os, during six months
219351678|NCT04196868|OTHER|Placebo|per os, during six months
219351679|NCT04196868|DRUG|Methotrexate treatment|per os
219351680|NCT03657251|GENETIC|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
219351681|NCT05688878|DEVICE|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
219351682|NCT02577861|PROCEDURE|Biopsy from donor eye|Corneal biopsy from undamaged limbus
219351683|NCT02577861|PROCEDURE|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
219351684|NCT02577861|PROCEDURE|Ophtalmologic examination|"The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
219351685|NCT02577861|PROCEDURE|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
219351686|NCT02577861|PROCEDURE|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
219351687|NCT02577861|PROCEDURE|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
219351688|NCT02577861|BEHAVIORAL|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
219351689|NCT02577861|PROCEDURE|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
219351690|NCT04639180|DRUG|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
219351691|NCT04639180|DRUG|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
219351692|NCT05533983|OTHER|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
219351693|NCT03730337|DRUG|ONO-7475|ONO-7475 specified dose on specified days
219351694|NCT03730337|DRUG|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
219351695|NCT03134352|DRUG|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
219351696|NCT03134352|DRUG|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
219351697|NCT00419380|DRUG|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
219351698|NCT01325012|PROCEDURE|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
219351699|NCT01325012|PROCEDURE|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
219351700|NCT02236052|BIOLOGICAL|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
219351701|NCT02236052|BIOLOGICAL|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
219351702|NCT02236052|BIOLOGICAL|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
219351703|NCT02236052|BIOLOGICAL|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
219351704|NCT02236052|BIOLOGICAL|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
219351705|NCT02236052|BIOLOGICAL|Placebo|A single dose of placebo
219351706|NCT01861405|BEHAVIORAL|neuropsychological testing and quality of life assessments|
219351707|NCT01861405|RADIATION|Standard of Care WBRT or SRS|
219351708|NCT01861405|DEVICE|Functional magnetic resonance imaging|
219351709|NCT03099707|BEHAVIORAL|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
219351710|NCT00440505|DRUG|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
219351711|NCT00440505|DRUG|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
219351712|NCT00440505|DRUG|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
219351713|NCT05725356|OTHER|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
219351714|NCT01090882|DRUG|Bupivocaine|20ml 0.25% at beginning of operation
219351715|NCT01090882|DRUG|0.9% normal saline solution|20ml 0.9% NaCl
219351716|NCT03945708|DEVICE|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
219351717|NCT00962832|DRUG|Placebo|Placebo was supplied as a sterile liquid solution.
219351718|NCT00962832|DRUG|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
219351719|NCT01309178|DRUG|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
219351720|NCT01309178|DRUG|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
219351721|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
219351722|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
219351723|NCT01024998|BIOLOGICAL|AAV2-sFLT01|6 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
219351724|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
219351725|NCT00144482|DRUG|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
219351726|NCT00144482|DRUG|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
219351727|NCT02525159|DIETARY_SUPPLEMENT|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
219351728|NCT02525159|OTHER|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
219351729|NCT00758745|DEVICE|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
219351730|NCT00758745|DEVICE|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
219351731|NCT01130571|PROCEDURE|Xenografts and cell cultures|
219351732|NCT03039842|DRUG|Dextromethorphan|
219351733|NCT03039842|DRUG|Memantine|
219351734|NCT03039842|DRUG|dextromethorphan+memantine|
219351735|NCT03039842|DRUG|placebo+valproate|
219351736|NCT03721666|OTHER|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
219351737|NCT06374823|DRUG|Multiple Electrolyte|Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
219351738|NCT06374823|DRUG|Normal Saline|Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
219351739|NCT03861559|DRUG|mometasone furoate nasal spray|intranasal administration
219351740|NCT03861559|DRUG|placebo nasal spray|intranasal administration
219351741|NCT00671021|OTHER|Platelet aggregation|Platelet aggregation TxA2 formation
219351742|NCT03652662|DEVICE|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
219351743|NCT03652662|BEHAVIORAL|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
219351744|NCT00861952|OTHER|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
219351745|NCT00861952|OTHER|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
219351746|NCT01725009|DRUG|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
219351747|NCT01988064|OTHER|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
219351748|NCT01988064|OTHER|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
219351749|NCT03841929|OTHER|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
219351750|NCT00487539|BIOLOGICAL|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
219351751|NCT00487539|BIOLOGICAL|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.
219351752|NCT00487539|BIOLOGICAL|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.
219351753|NCT00487539|BIOLOGICAL|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.
219351754|NCT00487539|BIOLOGICAL|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
219351755|NCT01659008|DRUG|Estradiol|
219351756|NCT01659008|DRUG|Lysteda|
219351757|NCT01926288|DRUG|Entecavir maleate tablets|
219351758|NCT01926288|DRUG|blank Baraclude tablets|
219351759|NCT01926288|DRUG|Blank maleate entecavir tablets|
219351760|NCT01926288|DRUG|Baraclude tablets|
219351761|NCT01394588|DEVICE|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
219351762|NCT05706389|DIETARY_SUPPLEMENT|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
219351763|NCT00847483|DRUG|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
219351764|NCT00847483|DRUG|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
219351765|NCT00847483|DRUG|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
219351766|NCT00005613|DRUG|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
219351767|NCT00005613|DRUG|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
219351768|NCT00005613|DRUG|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
219351769|NCT03910556|DRUG|Propofol|intraoperative factors
219351770|NCT03462407|BEHAVIORAL|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
219351771|NCT03462407|BEHAVIORAL|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
219351772|NCT02877342|OTHER|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
219351773|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
219351774|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
219351775|NCT01437397|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
219351776|NCT01437397|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
219351777|NCT01437397|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
219351778|NCT03318146|DEVICE|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
219351779|NCT03318146|DRUG|XALATAN®|one drop in the affected eye(s) once daily in the evening
219351780|NCT01596998|DRUG|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
219351781|NCT01596998|DRUG|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
219354941|NCT01562548|DRUG|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
219354942|NCT01562548|DRUG|Placebo|no active ingredient
219354943|NCT00798746|BEHAVIORAL|Telephone Questionnaire|Ten questions regarding symptoms of reflux
219354944|NCT02163473|PROCEDURE|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
219351782|NCT01596998|OTHER|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
219351783|NCT01596998|OTHER|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
219351784|NCT00001386|DRUG|PCLUS 3-18 MN|
219351785|NCT00001386|DRUG|PCLUS 6.1 MN|
219351786|NCT01776073|BEHAVIORAL|Patient Navigation|
219351787|NCT01594021|DRUG|Gelatin 500 mL|intravenous administration
219351788|NCT01594021|DRUG|Gelatin 50 mL|intravenous administration
219351789|NCT05543473|OTHER|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
219354945|NCT02163473|PROCEDURE|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
219351790|NCT02678858|BEHAVIORAL|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
219351791|NCT02678858|BEHAVIORAL|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
219351792|NCT03881150|OTHER|Comprehensive assessment|Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
219351793|NCT03881150|OTHER|Counseling|Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
219351794|NCT03881150|OTHER|Group education|Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
219351795|NCT03881150|OTHER|Exercise sessions in hybrid program|"10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate."
219351796|NCT03881150|OTHER|Exercise sessions in standard program|"18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate."
219351797|NCT03881150|OTHER|Transition to unsupervised phase|After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
219351798|NCT00710528|DRUG|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
219351799|NCT03770585|PROCEDURE|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
219351800|NCT03770585|PROCEDURE|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
219351801|NCT00987038|DRUG|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
219351802|NCT00987038|DRUG|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
219351803|NCT00964977|RADIATION|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
219351804|NCT01687712|DRUG|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
219351805|NCT01687712|DRUG|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
219351806|NCT00722150|DRUG|Artesunate|2 mg/kg/day x 7 days
219351807|NCT00722150|DRUG|Artesunate|4 mg/kg/day x 7 days
219351808|NCT00722150|DRUG|Artesunate|6 mg/kg/day x 7 days
219351809|NCT02751840|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine capsule before RMR measurement
219351810|NCT02751840|DIETARY_SUPPLEMENT|Placebo|Placebo capsule (starch) before RMR measurement
219351811|NCT02751840|OTHER|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
219351812|NCT02751840|OTHER|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
219351813|NCT02179229|DIETARY_SUPPLEMENT|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
219351814|NCT02179229|DIETARY_SUPPLEMENT|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
219351815|NCT04947670|PROCEDURE|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
219351816|NCT04947670|PROCEDURE|Sham Renal arteriography|Renal arteriography only
219351817|NCT00371865|BEHAVIORAL|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
219351818|NCT00371865|BEHAVIORAL|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
219351819|NCT00245362|BIOLOGICAL|CG 8020 and CG 2505|
219351820|NCT01088581|DRUG|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
219351821|NCT00710073|DEVICE|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
219351822|NCT01632566|DRUG|Placebo|Capsules administered orally
219351823|NCT01632566|DRUG|LY3031207|Administered orally
219351824|NCT01632566|DRUG|Celecoxib|Administered orally
219351825|NCT01632566|DRUG|Simvastatin|Administered orally
219351826|NCT01328951|DRUG|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
219351827|NCT01328951|DRUG|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
219351828|NCT01328951|DRUG|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
219351829|NCT00912249|BEHAVIORAL|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
219351830|NCT04607200|DRUG|AGEN2034|Anti-PD-1 Monoclonal Antibody
219351831|NCT04607200|DRUG|AGEN1884|Anti-CTLA-4 Monoclonal Antibody
219351832|NCT03268928|BEHAVIORAL|Story Starters Intervention|Shared reading intervention
219351833|NCT03268928|BEHAVIORAL|Wait-list Control|Wait-list control
219351834|NCT00970853|BEHAVIORAL|MOM Program home visiting|Mixed professional home visiting program.
219351835|NCT00970853|OTHER|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
219351836|NCT06849440|BEHAVIORAL|Training|Participants will be divided into groups of ten and the training is planned in 4 sessions. Session contents are prepared as sharing general information on preparation for birth, explanation of frequently applied interventions in labor, explanation of non-drug pain relieving methods, teaching and practicing active birth positions that help the labor progress. The duration of the sessions is planned as 2 hours on average.
219351837|NCT06412497|DRUG|Rituximab|For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.
219351838|NCT06412497|DRUG|Rabbit ATG|Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.
219351839|NCT06412497|DRUG|Cyclophosphamide|"Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines."
219351840|NCT06412497|DRUG|Fludarabine|For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.
219351841|NCT06412497|RADIATION|Total Body Irradiation|"For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.~Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus."
219351842|NCT06412497|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines.
219351843|NCT06412497|DRUG|Post-Transplant G-CSF|Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.
219351844|NCT06412497|DRUG|Tacrolimus|Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
219351845|NCT06412497|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
219351846|NCT01631136|DRUG|Cisplatin|75 mg/m²
219351847|NCT01631136|DRUG|Pemetrexed|500 mg/m²
219351848|NCT01631136|DRUG|Cisplatin|80 mg/m²
219351849|NCT01631136|DRUG|Gemcitabine|1250 mg/m²
219351850|NCT02051543|BEHAVIORAL|Brief Behavioral Treatment of Insomnia -Military Version|
219351851|NCT05656352|DEVICE|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
219351852|NCT05656352|DIAGNOSTIC_TEST|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
219351853|NCT05491226|DRUG|Pembrolizumab|Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
219351854|NCT05491226|RADIATION|Radiation Therapy|Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
219351855|NCT05491226|DRUG|Axatilimab|Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
219351856|NCT03627403|DRUG|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
219351857|NCT05024864|DIAGNOSTIC_TEST|Urea breath test (UBT)|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection.~In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician.~During the period without H. pylori screening, the study´s UBT equipment will not be available."
219351858|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
219351859|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
219351860|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
219351861|NCT04263337|DRUG|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
219354946|NCT01355939|PROCEDURE|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
219351862|NCT04263337|DRUG|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
219351863|NCT04263337|DRUG|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
219351864|NCT04539210|DEVICE|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
219351865|NCT01483781|DRUG|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
219351866|NCT01483781|DRUG|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
219351867|NCT00325026|DRUG|Misoprostol|
219351868|NCT00325026|DEVICE|Foley bulb|
219351869|NCT04186494|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
219351870|NCT04186494|DEVICE|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
219351871|NCT04186494|COMBINATION_PRODUCT|Liraglutide and CPAP|Combination of both treatments
219351872|NCT01762852|DRUG|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
219351873|NCT01762852|DRUG|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
219351874|NCT03787498|DRUG|PLX2853|Tablets
219351875|NCT04553120|BEHAVIORAL|Alternating single stimulus and multiple stimuli|"P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation)."
219351876|NCT03476499|DEVICE|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
219351877|NCT06354114|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
219351878|NCT02244502|DEVICE|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
219351879|NCT02244502|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
219351880|NCT01003210|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
219351881|NCT00376870|DRUG|Pioglitazone|pioglitazone 30 mg/d
219351882|NCT00376870|DRUG|Placebo|Placebo 30 mg/d
219351883|NCT00089362|DRUG|alvespimycin hydrochloride|Given IV
219351884|NCT00089362|OTHER|laboratory biomarker analysis|Correlative studies
219351885|NCT00089362|OTHER|pharmacological study|Correlative studies
219351886|NCT03861754|BEHAVIORAL|Lifestyle modification|
219351887|NCT00601536|DRUG|Lithium|
219351888|NCT02256514|BIOLOGICAL|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
219351889|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
219351890|NCT00271817|DRUG|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
219351891|NCT00271817|DRUG|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
219351892|NCT00271817|DRUG|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
219351893|NCT00271817|DRUG|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
219351894|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
219351895|NCT00271817|DRUG|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
219351896|NCT00271817|DRUG|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
219351897|NCT00542256|DEVICE|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
219351898|NCT00542256|DEVICE|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
219351899|NCT02037932|DEVICE|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
219351900|NCT03754075|PROCEDURE|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
219351901|NCT03754075|PROCEDURE|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
219351902|NCT01302951|DRUG|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
219351903|NCT01740375|PROCEDURE|esophagectomy|esophagectomy
219351904|NCT03919526|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
219351905|NCT03919526|DRUG|Fludarabine|30mg/m2/d
219351906|NCT03919526|DRUG|Cyclophosphamide|300mg/m2/d
219351907|NCT05590286|DRUG|Vonoprazan Tablets|Vonoprazan 20 mg, tablets, orally，QD
219351908|NCT05590286|DRUG|Amoxicillin Capsules|Amoxicillin 750mg, Capsules ,orally，QID
219351909|NCT05590286|DRUG|Esomeprazole|Esomeprazole 20mg, Capsules ,orally，BID
219351910|NCT01049685|DRUG|First-line Antiretroviral Therapy|"* Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background"
219351911|NCT01319409|PROCEDURE|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
219351912|NCT01319409|PROCEDURE|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
219351913|NCT00017342|DRUG|bryostatin 1|
219351914|NCT00017342|DRUG|cytarabine|
219351915|NCT05073107|OTHER|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
219351916|NCT00931359|DEVICE|DTS-G2 System|Treatment with microwave energy
219351917|NCT00931359|DEVICE|DTS System (Sham treatment)|Sham treatment - no energy is delivered
219351918|NCT04153188|DEVICE|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
219351919|NCT04153188|DRUG|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
219351920|NCT01480336|DRUG|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
219351921|NCT01480336|DRUG|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
219351922|NCT02613962|PROCEDURE|biopsy or surgical resection of tumor and blood sampling|
219351923|NCT03711578|DRUG|Tenalisib,|BID, Orally
219351924|NCT03834428|BEHAVIORAL|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
219351925|NCT03834428|BEHAVIORAL|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
219351926|NCT03560856|DRUG|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
219351927|NCT00264238|DRUG|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
219351928|NCT00000879|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
219351929|NCT00000879|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
219351930|NCT00000879|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
219351931|NCT00185978|BEHAVIORAL|diet, physical activity, reduced sedentary behavior|
219351932|NCT05687461|OTHER|Build a national diagnosis and treatment quality control platform for major respiratory diseases|"1. Build a national diagnosis and treatment quality control platform for major respiratory diseases~2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases~3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases"
219351933|NCT04943991|DIAGNOSTIC_TEST|blood sampling (alpha-Galactosidase & LysoGb3)|"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"
219351934|NCT02004080|OTHER|Intensive Care treatment|intensive care treatment
219351935|NCT00700271|DRUG|Amlodipine|5 mg or 10 mg tablets.
219351936|NCT00700271|DRUG|Valsartan|160 mg capsules.
219351937|NCT05138835|DRUG|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
219351938|NCT06162910|DIAGNOSTIC_TEST|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
219351939|NCT06162910|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
219351940|NCT00861744|BIOLOGICAL|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
219351941|NCT00861744|BIOLOGICAL|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
219351942|NCT00861744|BIOLOGICAL|Varivax®|Subcutaneous injection, one dose
219351943|NCT00861744|BIOLOGICAL|Havrix®|Intramuscular injection, one dose
219351944|NCT00861744|BIOLOGICAL|Prevnar®|Intramuscular injection, one dose
219351945|NCT00862264|DRUG|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
219351946|NCT00716755|DRUG|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
219351947|NCT03042208|OTHER|Self guided handout|Written handout with basic weight management strategies
219351948|NCT03042208|BEHAVIORAL|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
219351949|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
219351950|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
219351951|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent totally covers the deep femoral artery
219351952|NCT05259982|PROCEDURE|Vital root resection|Vital resection of root with attachment loss exceeding 2/3 of the root with the use of calcium silicate cement in the pulpal wound
219351953|NCT06129266|OTHER|oral care with breastmilk|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
219351954|NCT01490619|BEHAVIORAL|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
219351955|NCT01490619|OTHER|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
219351956|NCT05107765|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
219351957|NCT05107765|DRUG|Placebo|Pill capsules will look same as that of active drug.
219351958|NCT02542709|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
219351959|NCT02542709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
219351960|NCT06092073|PROCEDURE|recto-intercostal fascial plane block|Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.
219351961|NCT06092073|DRUG|bupivacaine|bupivacaine 0.25%
219351962|NCT04391699|DEVICE|heated humidification|heated humidification system
219351963|NCT01295216|BEHAVIORAL|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
219351964|NCT04726878|PROCEDURE|Erector spinae plane block|Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
219351965|NCT04726878|PROCEDURE|Sham block|Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
219351966|NCT04726878|PROCEDURE|General anesthesia|"Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl."
219351967|NCT04726878|PROCEDURE|Patient-controlled analgesia|All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
219351968|NCT04726878|DRUG|Oxycodone|Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
219351969|NCT04726878|DRUG|paracetamol|intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
219351970|NCT05416853|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
219351971|NCT02135887|DRUG|MB-6|6# TID with meal
219351972|NCT02135887|DRUG|Placebo|6# TID with meal
219351973|NCT00128544|DRUG|telbivudine|
219351974|NCT00128544|DRUG|valtorcitabine|
219351975|NCT04794712|DEVICE|Venous reflux tools (Ultrasound and Photo plethysmography (PPG))|Venous reflux tools Pain assessment tools
219354947|NCT03406221|BEHAVIORAL|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
219351976|NCT03343496|PROCEDURE|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I\~II, aged 18\~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
219351977|NCT03258658|BIOLOGICAL|Autologous Engineered Urethral Construct|urethral construct
219351978|NCT01411085|DRUG|Risperidone + Desipramine|
219351979|NCT01547325|DRUG|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
219351980|NCT01547325|DRUG|placebo hydrogel|placebo hydrogel
219351981|NCT00147524|DRUG|quinapril|
219351982|NCT00147524|PROCEDURE|Laser Doppler imaging|
219351983|NCT07132840|PROCEDURE|Kinesio tape application followed by single session of balance training on various unstable surfaces.|Participants with functional ankle instability received balance training on various unstable surfaces after kinesio tape application.
219351984|NCT06855251|BEHAVIORAL|The crossmodal dual-task|"Two main sensory tasks performed together:~1\. the visual task, in which participants are requested to monitor visual stimuli presented on a computer screen and to detect the deviant target as soon as possible. The target changes across blocks: in half of the trials, participants will have to respond to food stimuli presented together with irrelevant non-food stimuli (food target condition); in the other half conditions, participants will have to respond to non-food stimuli presented together with irrelevant food stimuli (non-food target condition). For each participant, we will collect the Reaction Time in milliseconds only for the valid responses, and the level of Accuracy in percentage.~2\) The interoceptive task, in which participants are requested to monitor their heartbeat presented through headphones and registered through pulse oximetry. Participants will judge the level of asynchrony between their heartbeat and the auditory cue."
219351985|NCT06654271|DEVICE|Robotic assisted bronchoscopy (RAB)|Participants allocated to the robotic assisted bronchoscopy arm will undergo robotic assisted bronchoscopy with integrated cone beam computed tomography
219351986|NCT06654271|DEVICE|Electromagnetic navigation bronchoscopy (ENB)|Participants allocated to the electromagnetic navigation bronchoscopy arm will undergo electromagnetic navigation bronchoscopy with integrated digital tomosynthesis
219351987|NCT02200185|DRUG|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~* SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
219351988|NCT02200185|DRUG|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
219351989|NCT02200185|DRUG|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
219351990|NCT01262690|DRUG|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
219351991|NCT01262690|DRUG|PF-05230901|Single dose SC
219351992|NCT02093013|OTHER|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
219351993|NCT03809611|DRUG|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
219351994|NCT03809611|DRUG|Placebo|placebo
219351995|NCT03116932|BEHAVIORAL|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
219351996|NCT05442307|BEHAVIORAL|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
219351997|NCT05442307|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
219351998|NCT00387400|DRUG|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
219351999|NCT00387400|DRUG|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
219352000|NCT00387400|GENETIC|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
219352001|NCT00387400|OTHER|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
219352002|NCT06107062|DRUG|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
219352003|NCT06107062|DRUG|Placebo|Placebo arm
219352004|NCT06107062|DRUG|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
219352005|NCT01493934|DRUG|injection of 6-DIG|Unique injection dose of 92.5 MBq
219352006|NCT06989671|DRUG|JMT101|JMT101 Q2W or Q3W, intravenous injection
219352007|NCT06989671|DRUG|SYS6002|SYS6002 Q2W or Q3W, intravenous injection
219352008|NCT06989671|DRUG|SG001|SG001 Q2W or Q3W, intravenous injection
219352009|NCT02926950|DRUG|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
219352010|NCT02926950|DRUG|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
219352011|NCT02926950|DRUG|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
219352012|NCT06801015|DRUG|Semaglutide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
219352013|NCT06801015|DRUG|Tirzepatide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
219352014|NCT06801015|DRUG|Placebo|Placebo administered by subcutaneous injection once per week.
219352015|NCT02905578|DRUG|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
219352016|NCT02905578|DRUG|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
219352017|NCT02905578|DRUG|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
219352018|NCT06918561|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
219352019|NCT06918561|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219352020|NCT07132632|BEHAVIORAL|12-week multicomponent therapeutic exercise program including supervised and home-based sessions focused on strength, balance, mobility, and aerobic capacity|This intervention consists of a 12-week multicomponent therapeutic exercise program for older adults with mild to moderate frailty. Participants will complete 12 sessions (8 supervised in primary care and 4 home-based), each lasting approximately 60 minutes. Sessions include warm-up, strength exercises (using body weight or elastic bands), moderate aerobic activity (e.g., walking or pedaling), balance and coordination training (including dual tasks), and a cool-down phase. The program follows FITT-VP principles and is tailored to functional capacity. Intensity is monitored using the Borg scale (CR10 and RPE), estimated 1RM (20-80%), and 64-76% HRmax. Exercises are progressively adjusted in volume, intensity, and complexity. Home sessions are guided by an illustrated manual and reinforced by biweekly follow-up phone calls to promote adherence and safety. The intervention is aligned with international guidelines and aims to improve physical performance, reduce frailty and sarcopenia.
219352021|NCT07132632|BEHAVIORAL|Placebo Pre-Treat|The pre-intervention period (Month 0 to Month 3) will serve as the control phase, during which participants will receive no specific exercise program. From Month 3 to Month 6, the intervention phase will begin. Participants act as their own control.
219352022|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7, 14 and 28, total 5 doses"
219352023|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 14, total 4 doses"
219352024|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 28, total 4 doses"
219352025|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 2 dose on day 0, 1 dose on day 7 and 21, total 4 doses"
219352026|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Chengdu Kanghua Biological Products Co., LTD Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection~Receive 1 dose on day 0, 3, 7, 14and 28, total 5 doses"
219352027|NCT02447588|OTHER|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
219352028|NCT02447588|OTHER|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
219352029|NCT07135453|BIOLOGICAL|Pneumococcal Vaccine|PCV
219352030|NCT06909201|DRUG|HP 129Xe MRI|Gas delivery will be from a Tedlar bag
219352031|NCT07102433|OTHER|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.
219352032|NCT06057090|BEHAVIORAL|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
219354948|NCT03406221|OTHER|Control Condition|Standard of care
219354949|NCT01496066|DEVICE|LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|LAL implanted and adjusted with LDD
219354950|NCT01496066|DEVICE|Monofocal control IOL|Commercially available monofocal intraocular lens (IOL)
219352033|NCT07110064|DRUG|QL1706+Lenvatinib+AG Regimen|Participants will receive QL1706 combination with Lenvatinib and AG regimen for 8 cycles. Subsequently, the enrolled patients will continue to receive maintenance therapy with QL1706 and Lenvatinib until disease progression (PD) is observed, intolerable adverse events occur, or the investigator deems it inappropriate for the subject to continue treatment.
219352034|NCT07111936|BEHAVIORAL|CONNECT Intervention for multilingual populations|The program includes interactive Video Doctor visits to provide participants with information tailored to their individual responses and outreach via brief telephone calls and text messaging to follow-up and connect smokers with evidence-based resources for smoking cessation.
219352035|NCT07111936|OTHER|Saliva Sample|Undergo saliva collection
219352036|NCT07111936|OTHER|Interview|Attend a focus group
219352037|NCT06934395|BEHAVIORAL|Healthy Choices|Healthy Choices is an adapted and developmentally tailored intervention designed to address self-management of risk behaviors and HIV from Motivational Enhancement Therapy, a brief alcohol intervention in SAMHSA's registry of evidenced-based programs. For the purposes of this project, this intervention will be delivered as a combination approach, with all participants receiving an initial session via CIAS, and randomized to either receiving a telehealth session with a trained interventionist at week 2, with additional randomizations for telehealth sessions at weeks 4 and 6. The goal is to test if delivering (vs. not delivering) a coaching session increases the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3
219352038|NCT06934395|BEHAVIORAL|Text Message Prompts|This within-participant micro-randomization will test whether, on average, delivering (vs. not delivering) a text messaged prompt focused on medication adherence or stress increases the likelihood of medication adherence by the end of the current day .
219352039|NCT07143760|DEVICE|Gengigel|Free gingival graft (FGG) surgery leaves an open wound at the palatal donor site, which heals by secondary intention and can cause patient discomfort. Various adjunctive materials, such as stents, collagen sponges, platelet-rich fibrin, and hyaluronic acid (HA), have been explored to improve healing. HA is a naturally occurring glycosaminoglycan with hydrating, anti-inflammatory, and pro-regenerative properties that support fibroblast and keratinocyte activity and promote angiogenesis. These qualities make HA a promising adjunct for enhancing wound healing in periodontal surgery. However, few studies have assessed its clinical impact on palatal donor site healing after FGG, and in existing studies HA was applied only once by the operator rather than used consistently by patients. This study evaluates daily, patient-applied HA gel to address this gap and compare outcomes in smokers and non-smokers.
219352040|NCT05458284|PROCEDURE|Real Acupuncture|Real Acupuncture weekly till taxane completion
219352041|NCT05458284|OTHER|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
219352042|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
219352043|NCT05850598|DEVICE|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
219352044|NCT05850598|DEVICE|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
219352045|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
219352046|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
219352047|NCT04306588|OTHER|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
219352048|NCT01777802|RADIATION|SBRT|
219352049|NCT01777802|RADIATION|IMRT|
219352050|NCT01777802|RADIATION|Brachytherapy|
219352051|NCT06829459|DRUG|Glumetinib|Patients will be administered glumetinib 300 mg/dose once daily once daily under fasting conditions in each 21-day treatment cycle.
219352052|NCT06829459|DRUG|Osimertinib mesylate|Patients will be administered osimertinib mesylate 80 mg/dose once daily under fasting conditions in each 21-day treatment cycle.
219352053|NCT06829459|DRUG|Pemetrexed|Patients will be administered pemetrexed 500 mg/m\^2 via intravenous infusion on the first day of each 3-week cycle.
219352054|NCT06829459|DRUG|Cisplatin or carboplatin|Patients will be administered cisplatin 75 mg/m\^2 or carboplatin AUC=5 via intravenous infusion on the first day of each 3-week cycle
219352055|NCT04909125|RADIATION|Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy|The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes
219352056|NCT04748094|DEVICE|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
219352057|NCT04748094|OTHER|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
219352058|NCT05772832|DRUG|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
219352059|NCT05772832|DRUG|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
219352060|NCT06963411|DRUG|KP001|Epinephrine Inhalation Aerosol (0.125 mg per inhalation)
219352061|NCT06963411|DRUG|Placebo|Matched Placebo control (KP001 vehicle only)
219352062|NCT05763745|DIAGNOSTIC_TEST|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
219352063|NCT03004378|BEHAVIORAL|Activity Tracker|Fitbit Alta
219352064|NCT01203384|DRUG|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
219352065|NCT01203384|DRUG|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
219352066|NCT01203384|DRUG|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
219352067|NCT01203384|DRUG|Placebo|oral tablet, placebo, once a day in the morning for 14 days
219352068|NCT04752995|PROCEDURE|osteotomy|osteotomy osteoclasis of upper tibia
219352069|NCT00107237|DRUG|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
219352070|NCT00107237|DRUG|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
219352071|NCT05723614|BEHAVIORAL|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
219352072|NCT01850056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|
219352073|NCT01850056|DEVICE|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
219352074|NCT03368170|DRUG|Mesdopetam (IRL790)|Mesdopetam (IRL790) capsule
219352075|NCT00193765|PROCEDURE|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
219352076|NCT00193765|PROCEDURE|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
219352077|NCT02587533|OTHER|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
219352078|NCT02587533|OTHER|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
219352079|NCT02587533|OTHER|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
219352080|NCT02587533|OTHER|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
219352081|NCT05672342|DRUG|Cannabidiol|Given PO
219352082|NCT05672342|DRUG|Delta-8-Tetrahydrocannabinol|Given PO
219352083|NCT05672342|DRUG|Placebo Administration|Given PO
219352084|NCT05672342|OTHER|Questionnaire Administration|Ancillary studies
219352085|NCT02589262|DRUG|AUT00206|
219352086|NCT02068547|BIOLOGICAL|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
219352087|NCT02068547|BIOLOGICAL|Bone Marrow Aspirate|
219352088|NCT00959816|DRUG|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
219352089|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
219352090|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
219352091|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
219352092|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
219352093|NCT01055158|BEHAVIORAL|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
219352094|NCT01055158|BEHAVIORAL|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
219352095|NCT02355288|PROCEDURE|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
219352096|NCT02355288|PROCEDURE|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
219352097|NCT04365465|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
219352098|NCT04365465|DEVICE|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
219352099|NCT04365465|OTHER|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
219352100|NCT00465959|DRUG|trospium chloride inhalation powder (TrIP)|
219352101|NCT00465959|DRUG|Placebo|
219352102|NCT05955625|OTHER|TIMELY|The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
219352103|NCT03036293|DRUG|Tenoten|Tablet for oral use.
219352104|NCT03036293|DRUG|Placebo|Tablet for oral use.
219352105|NCT03591081|OTHER|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
219352106|NCT02562742|DRUG|SOF|SOF 400 mg tablets administered orally once daily
219352107|NCT02562742|DRUG|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
219352108|NCT04032210|OTHER|dual Zinc plus Arginine based toothpaste (Colgate total)|Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
219352109|NCT04032210|OTHER|Zinc based toothpaste (Crest complete)|Regimen using Zinc based toothpaste (Crest complete)
219352110|NCT04032210|OTHER|Fluoride based toothpaste (Signal)|Fluoride based toothpaste (Signal)
219354951|NCT02010164|DIETARY_SUPPLEMENT|Co-enzyme Q10|600mg for 3 months
219352111|NCT04780269|DEVICE|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
219352112|NCT04780269|DRUG|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
219352113|NCT04647292|OTHER|anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration|"A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly."
219352114|NCT04647292|OTHER|Standard of Care Blood Pressure Management with Antihypertensives|Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.
219352115|NCT02977169|RADIATION|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
219352116|NCT02977169|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
219352117|NCT06541405|DRUG|NK520|The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.
219352118|NCT04669834|OTHER|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
219352119|NCT04669834|OTHER|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
219352120|NCT06407310|DRUG|Pembrolizumab|I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
219352121|NCT06407310|DRUG|Carboplatin|I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
219352122|NCT06407310|DRUG|Paclitaxel|I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
219352123|NCT05814289|OTHER|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
219352124|NCT03447158|PROCEDURE|15% Dextrose|inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
219352125|NCT03447158|PROCEDURE|Normal saline|inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
219352126|NCT01662440|BIOLOGICAL|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
219352127|NCT01662440|BIOLOGICAL|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
219352128|NCT01662440|OTHER|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
219352129|NCT01084187|DRUG|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
219352130|NCT03012373|PROCEDURE|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
219352131|NCT03012373|PROCEDURE|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
219352132|NCT05314244|PROCEDURE|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
219352133|NCT02116010|DRUG|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
219352134|NCT02116010|DRUG|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
219352135|NCT02116010|DRUG|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
219352136|NCT02766829|PROCEDURE|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
219352137|NCT02766829|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
219352138|NCT06025266|DEVICE|Evaluation of Viscoelastic and mechanical properties with MyotonPRO|MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
219352139|NCT03595540|OTHER|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
219352140|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
219354952|NCT04226404|OTHER|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
219352141|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
219352142|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
219352143|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
219352144|NCT01620541|PROCEDURE|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
219352145|NCT01620541|PROCEDURE|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
219352146|NCT00264004|DRUG|AZD2171|30 mg \& 45 mg oral tablet
219352147|NCT01535781|DRUG|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
219352148|NCT01535781|DRUG|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
219352149|NCT00691483|DRUG|placebo|placebo tablet taken orally twice daily for 12 weeks
219352150|NCT00691483|DRUG|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
219352151|NCT01891487|DRUG|Track A|Bimatoprost 0.03% solution applied to eyebrow
219352152|NCT01891487|DRUG|Track B|Refresh Tears applied to eyebrows
219352153|NCT06282003|PROCEDURE|The procedure of protective lung ventilation|The procedure of protective lung ventilation in the PV group of patients included preoxygenation with 60% oxygen in a mixture with air for 3 min, which maintained the target peripheral oxygen saturation at values above 94%, endotracheal intubation, volume-controlled mechanical ventilation, a tidal volume of 6 ml per kg of body weight. Normocarbia during the protective ventilation procedure was maintained by adjusting the minute ventilation, which is the product of the respiratory rate (12-14 breaths per minute) and the tidal volume set to 6 ml/kg of body weight. The most critical variable for the adjustment was the inhalation-exhalation ratio of 1:2, which ensured adequate oxygenation and removal of carbon dioxide during anesthesia. Identically as in the PV group, the target peripheral saturation was kept above 94% with an inspiratory oxygen concentration of 50% and peak airway pressure values of up to 40 kPa.
219352154|NCT00439946|DRUG|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
219352155|NCT00439946|DEVICE|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
219352156|NCT00049673|DRUG|prednisone|Given orally
219352157|NCT00049673|DRUG|thalidomide|Given orally
219352158|NCT02365168|OTHER|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
219352159|NCT02365168|OTHER|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
219352160|NCT02365168|OTHER|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
219352161|NCT02365168|OTHER|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
219352162|NCT02475681|DRUG|Acalabrutinib|
219352163|NCT02475681|DRUG|Obinutuzumab|
219352164|NCT02475681|DRUG|Chlorambucil|
219352165|NCT06471868|DRUG|IY-HCR21|Betanechol 50mg
219352166|NCT06471868|DRUG|IY-MIC|Betanechol 25mg
219352167|NCT04077658|BEHAVIORAL|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
219352168|NCT04077658|BEHAVIORAL|Waitlist Control|Standard of Care Migraine Treatment
219352169|NCT05244265|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).
219352170|NCT05244265|BEHAVIORAL|Treatment as usual (TAU)|Different interventions and support in outpatient and other services.
219352171|NCT01030510|DRUG|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
219352172|NCT04731935|DEVICE|Sparrow Therapy System|Transcutaneous auricular neurostimulation
219352173|NCT00595712|PROCEDURE|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
219352174|NCT00595712|PROCEDURE|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
219352175|NCT05415449|DEVICE|Gus gear protective wearable device|Gus gear protective wearable device for central line.
219352176|NCT01262365|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
219352177|NCT01262365|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
219352178|NCT01262365|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
219352179|NCT01817309|OTHER|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
219352180|NCT04864444|DRUG|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
219352181|NCT04864444|DRUG|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
219352182|NCT00326898|OTHER|Laboratory Biomarker Analysis|Correlative studies
219352183|NCT00326898|OTHER|Placebo|Given PO
219352184|NCT00326898|OTHER|Quality-of-Life Assessment|Ancillary studies
219352185|NCT00326898|DRUG|Sorafenib Tosylate|Given PO
219352186|NCT00326898|DRUG|Sunitinib Malate|Given PO
219352187|NCT04918329|OTHER|Observational study|Non interventional study
219352188|NCT01265459|DEVICE|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
219352189|NCT03960281|OTHER|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
219352190|NCT00883714|OTHER|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
219352191|NCT00883714|OTHER|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
219352192|NCT01017393|DRUG|Ketamine|
219352193|NCT01017393|DRUG|ketamine free|
219352194|NCT03733392|DEVICE|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
219352195|NCT04046679|DRUG|Bleomycin|Skin bleomycin infusion through tattoo machine
219352196|NCT04046679|OTHER|Saline Solution|Saline solution infusion through tattoo machine
219352197|NCT03824860|BEHAVIORAL|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~* guided breathing exercises,~* upper and lower extremity stretching~* structured postures and movements to improve balance and strength"
219352198|NCT03083340|BEHAVIORAL|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
219352199|NCT00679952|PROCEDURE|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
219352200|NCT00679952|PROCEDURE|natural drainage of pancreatic duct|Natural drainage group
219352201|NCT03638505|OTHER|PSP-QoL|"PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings."
219352202|NCT01578980|DEVICE|Outpatient Control-to-Range|Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
219352203|NCT03451188|DEVICE|Cerecare compression garments|all Cerecare compression garments
219352204|NCT01280136|BEHAVIORAL|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
219352205|NCT01535365|OTHER|Heat|Application of heat pack to the back or neck sprain.
219352206|NCT01535365|OTHER|Cold|Application of ice pack to the back or neck sprain.
219352207|NCT02615990|DEVICE|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
219352208|NCT02615990|OTHER|Standard Physical Therapy|Patients receive standard physical therapy.
219352209|NCT00036179|DRUG|FK463|
219352210|NCT02397928|DEVICE|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
219352211|NCT02397928|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
219352212|NCT02397928|DRUG|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
219352213|NCT05079503|DRUG|GEN-001|GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
219352214|NCT04135898|DRUG|SIBP-04|3mg/kg, infusion in 90 minutes
219352215|NCT04135898|DRUG|Bevacizumab|3mg/kg, infusion in 90 minutes
219352216|NCT01256437|DRUG|Threolone ointment|ointment once daily for 1 month
219352217|NCT01256437|DRUG|ointment Synthomycine|ointment once daily for 1 month
219352218|NCT01256437|DRUG|Aqua cream|ointment once daily for 1 month
219352219|NCT01363986|DRUG|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
219352220|NCT01637142|DRUG|LY2140023|Administered orally.
219352221|NCT01637142|DRUG|14C-LY2140023|Administered IV.
219352222|NCT01637142|DRUG|14C-LY404039|Administered IV.
219352223|NCT05572034|PROCEDURE|Electrophysiological study|Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.
219352224|NCT05572034|PROCEDURE|Electrophysiological study and Right side Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works (anatomic mapping):~In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and, the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
219352225|NCT05572034|PROCEDURE|Electrophysiological study and bi-atrial Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works(anatomic mapping):~In the LA: the inferior right GP (septal aspect of the right pulmonary veins \[PV\]) antra, and LA posterior wall. In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
219352226|NCT02881268|OTHER|blood sample|
219352227|NCT05135715|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
219352228|NCT01989000|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
219352229|NCT01989000|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
219352230|NCT01989000|DRUG|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
219352231|NCT01989000|RADIATION|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
219352232|NCT01989000|PROCEDURE|Pancreaticoduodenectomy|
219352233|NCT01300182|OTHER|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
219352234|NCT01300182|OTHER|Control|Conventional post-operative physical therapy exercises and rehabilitation.
219352235|NCT03049904|BEHAVIORAL|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
219352236|NCT03767322|DRUG|Allopurinol|Eligible patients will receive allopurinol 300 mg before and after coronary intervention
219352237|NCT03767322|DRUG|Febuxostat|Eligible patients will receive febuxostat 80 mg before and after coronary intervention
219352238|NCT03767322|DRUG|Placebo|Eligible patients will receive before and after coronary intervention
219352239|NCT05654844|RADIATION|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
219352240|NCT05654844|RADIATION|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
219352241|NCT06565156|OTHER|BR-AM|BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
219352242|NCT06565156|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
219352243|NCT02070861|OTHER|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
219352244|NCT03546855|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
219352245|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
219352246|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
219352247|NCT00639249|DRUG|placebo|Oral administration
219352248|NCT00639249|DRUG|SA4503 Low|Oral administration
219352249|NCT00639249|DRUG|SA4503 High|Oral administration
219352250|NCT00925015|BIOLOGICAL|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
219352251|NCT00925015|BIOLOGICAL|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
219352252|NCT00925015|DRUG|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
219352253|NCT00925015|BIOLOGICAL|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
219352254|NCT05685433|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
219352255|NCT03261622|DEVICE|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
219352256|NCT06134232|DRUG|Sipuleucel-T Injection|Single Infusion
219352257|NCT05967663|DEVICE|PCI-immediate complete revascularisation|In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.
219352258|NCT05967663|DEVICE|PCI-staged complete revascularisation|In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.
219352259|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
219352260|NCT04986202|DRUG|AZD4831|AZD4831
219352261|NCT04986202|OTHER|Placebo|Placebo
219352262|NCT02493348|DEVICE|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
219352263|NCT02787863|BIOLOGICAL|Prevenar-13|Conjugate 13 serotype pneumococcal vaccine
219352264|NCT02787863|BIOLOGICAL|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
219352265|NCT01049841|DRUG|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
219352266|NCT04644809|DRUG|LY3561774|Administered SC.
219352267|NCT04644809|DRUG|Placebo|Administered SC.
219352268|NCT05911906|DRUG|Remdesivir|"Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.~Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes."
219352269|NCT02777216|DEVICE|ConfidenHT system|ConfidenHT Medical system
219352270|NCT00963898|DEVICE|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
219352271|NCT04550130|DEVICE|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
219352272|NCT04120155|PROCEDURE|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
219352273|NCT04120155|PROCEDURE|Preservation of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
219352274|NCT02754726|DRUG|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
219352275|NCT02754726|DRUG|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
219352276|NCT02754726|DRUG|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
219352277|NCT02754726|DRUG|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
219352278|NCT02754726|DRUG|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
219352279|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
219352280|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
219352281|NCT01885000|DRUG|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
219352282|NCT01885000|DRUG|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
219352283|NCT00497211|PROCEDURE|Intracoronary mononuclear cell infusion|
219354953|NCT04226404|OTHER|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
219354954|NCT04226404|OTHER|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
219354955|NCT04226404|OTHER|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
219354956|NCT04226404|OTHER|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
219352284|NCT06092281|BEHAVIORAL|Questionnaire|"Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information:~1. General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)~2. Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.)~3. Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)"
219352285|NCT06092281|BEHAVIORAL|Questionnaire without compliance-related education|Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)
219352286|NCT03124784|DEVICE|RD Disposable Sensors|Noninvasive pulse oximeter sensor
219352287|NCT00837109|BEHAVIORAL|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
219352288|NCT00837109|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
219352289|NCT02969798|DRUG|Dapagliflozin|10mg/day
219352290|NCT02969798|DRUG|Saxagliptin|5mg/day
219352291|NCT02969798|DRUG|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
219352292|NCT02969798|DRUG|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
219352293|NCT05143840|DRUG|Single Agent Asciminib|taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase. Asciminib is a potent allosteric inhibitor of BCR::ABL1.
219352294|NCT05143840|COMBINATION_PRODUCT|Low TKI|"Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion, may be added to asciminib in the following situations:~* Patients who have treatment failure at any time based on ELN criteria (Appendix 7)~* Patients who have a warning response after 12 months of single agent asciminib based on ELN criteria (Appendix 7)~* Patients who have not achieved MR4.5 after 24 months, but no later than 36 months, of single agent asciminib."
219352295|NCT05143840|OTHER|Elective Free Treatment|Once central eligibility has been obtained the patient should discontinue asciminib and if applicable lowTKI within 14 days.
219352296|NCT00719927|BEHAVIORAL|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
219352297|NCT00875745|DRUG|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
219352298|NCT01514032|PROCEDURE|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
219352299|NCT01514032|PROCEDURE|Retrograde intrarenal surgery|Retrograde intrarenal surgery
219352300|NCT04674631|OTHER|The effect of neuropathic pain on quality of life, depression and sleep quality|The effect of neuropathic pain on quality of life, depression and sleep quality
219352301|NCT05912465|OTHER|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
219352302|NCT02009644|DEVICE|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
219352303|NCT00646542|DRUG|Vildagliptin|
219352304|NCT00646542|DRUG|Placebo|
219352305|NCT01564615|DEVICE|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
219352306|NCT01564615|DEVICE|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
219352307|NCT01695473|DRUG|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
219352308|NCT05929690|OTHER|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
219352309|NCT04754451|DRUG|Group L|Attach two lidocaine patches for 12 hours, one above and below the incision site.
219352310|NCT02137564|DRUG|gamma secretase inhibitor PF-03084014|Given PO
219352311|NCT02137564|OTHER|pharmacological study|Correlative studies
219352312|NCT02137564|OTHER|laboratory biomarker analysis|Correlative studies
219352313|NCT01484626|DRUG|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m\^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m\^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m\^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m\^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
219352314|NCT03824847|DRUG|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
219352315|NCT03824847|DRUG|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
219352316|NCT05730465|BEHAVIORAL|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
219354957|NCT04226404|OTHER|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
219354958|NCT04226404|OTHER|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
219352317|NCT05493319|OTHER|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
219352318|NCT00557219|DRUG|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
219352319|NCT00557219|DRUG|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
219352320|NCT00557219|DRUG|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
219352321|NCT03931278|OTHER|learning and recall of a sequence of body movements|The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
219352322|NCT02534259|OTHER|Force monitoring of external fixator struts|
219352323|NCT05056025|DIETARY_SUPPLEMENT|Postbotics and Vitamins|2 capsule 3 times a day, before meals
219352324|NCT05056025|DIETARY_SUPPLEMENT|Vitamins|2 capsule 3 times a day, before meals
219352325|NCT00874978|DRUG|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
219352326|NCT05053295|DRUG|autologous activated T lymphocyte|"Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV"
219352327|NCT01617278|DEVICE|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
219352328|NCT01617278|DEVICE|HD Colon|High definition white light
219352329|NCT01617278|DEVICE|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
219352330|NCT05991856|PROCEDURE|radiofrequency ablation|The subjects is placed in a prone or lateral position under local anesthesia, and the electrodes are placed in the adrenal nodules under ultrasound guidance. A rapidly alternating radiofrequency current (300-500khz) generated around the electrode propagates through the adrenal nodules, causing resistance heating (Joule effect) and inducing cell death through coagulation necrosis. The choice of ablation time and frequency depends on the size, shape and location of the nodules within the adrenal gland.
219352331|NCT05991856|PROCEDURE|laparoscopic adrenalectomy|The subjects was placed in a lateral position under general anesthesia. Using harmonic scalpel carefully separates the adrenal vessels and lates them. The adipose tissue around the adrenal gland is dissected carefully, the surrounding tissue is bluntly separated, and the adrenal gland is fully exposed and dissected. After adrenalectomy was completed, hemostasis was rechecked and specimens were removed.
219352332|NCT05991856|DRUG|Hypotensive Drugs|All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
219352333|NCT00005012|DRUG|Peginterferon alfa-2b|
219352334|NCT02078076|DEVICE|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
219352335|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
219352336|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
219352337|NCT01405261|DRUG|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
219352338|NCT01405261|DRUG|oral placebo|Subjects will be randomised to receive a single dose of placebo.
219352339|NCT02266693|BEHAVIORAL|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
219352340|NCT01660074|OTHER|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
219352341|NCT01406834|BEHAVIORAL|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
219352342|NCT04852120|OTHER|No intervention|Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
219352343|NCT02163434|DRUG|Gabapentin|
219352344|NCT02163434|DRUG|Metoclopramide|
219352345|NCT04549701|OTHER|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
219352346|NCT04549701|OTHER|Standard of care|Standard of care will be provided.
219352347|NCT02652884|DRUG|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
219352348|NCT02652884|DRUG|saline 0.9% NaCl|single dose of intramuscular placebo
219352349|NCT02350803|DEVICE|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
219352350|NCT03012074|BEHAVIORAL|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
219352351|NCT00554203|DRUG|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
219352352|NCT05381129|OTHER|Detection of Pain, Quality of Life, Sleep and Functioning|All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.
219352353|NCT05381129|OTHER|Temporomandibular joint dysfunction|Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
219352354|NCT06500091|DRUG|TQB2916 injection + doxorubicin hydrochloride for injection|"TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells."
219352355|NCT06500091|DRUG|TQB2916 injection+penpulimab injection|TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
219352356|NCT06112106|BEHAVIORAL|Intelligent Physical Exercise Training (IPET)|The intervention group will follow an Intelligent Physical Exercise training (IPET) program delivered via a mobile phone app. The scope of the physical exercise program is 50 minutes per week, and it is individually tailored according to questionnaire responses about work profile, physical capacity, health status and extent of musculoskeletal pain.
219352357|NCT06550167|DIETARY_SUPPLEMENT|Nano-PSO, Pomegranate seed oil (omega-5)|"During the intervention, Nano-PSO dietary supplement will be administered to the participants in the assigned group.~Participants will be followed before and after treatment to assess the effects of Nano-PSO on cognitive status, serum concentrations of trophic factors, and other relevant parameters . This randomized, double-blind, controlled clinical trial design allows for a rigorous evaluation of the potential benefits of Nano-PSO in patients with substance use disorders. The study aims to provide valuable insights into the neuroprotective and cognitive-enhancing properties of Nano-PSO in this population."
219352358|NCT06550167|OTHER|PLACEBO|In this arm of the study the participants will receive a placebo as a control treatment . The placebo is essential in clinical trials to compare the effects of the active intervention (Nano-PSO) with those of an inert substance.
219352359|NCT02665429|BEHAVIORAL|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
219352360|NCT02740088|OTHER|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
219352361|NCT05916404|OTHER|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (\<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
219352362|NCT05916404|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
219352363|NCT00575562|DRUG|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
219352364|NCT05075980|DRUG|Cisplatin|Given IV
219352365|NCT05075980|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
219352366|NCT05075980|OTHER|Quality-of-Life Assessment|Ancillary studies
219352367|NCT05075980|OTHER|Questionnaire Administration|Ancillary studies
219352368|NCT05075980|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219352369|NCT05075980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
219352370|NCT05075980|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
219352371|NCT05075980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219352372|NCT05075980|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219352373|NCT02290314|PROCEDURE|minimally invasive MID-line Lumbar Fusion (MIDLF)|
219352374|NCT02290314|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|
219352375|NCT00483860|DRUG|Topotecan|once a day
219352376|NCT02085291|DRUG|Norepinephrine|Norepinephrine infusion to titrate MAP to usual level
219352377|NCT02085291|DRUG|Crystalloid|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
219352378|NCT02792803|DRUG|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
219352379|NCT02792803|DRUG|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
219352380|NCT02792803|DRUG|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
219352381|NCT03822975|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
219352382|NCT03822975|DRUG|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
219352383|NCT01833130|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
219352384|NCT01833130|DRUG|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
219352385|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
219352386|NCT04514029|DRUG|Simvastatin|Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
219352387|NCT04514029|DRUG|Dexamethasone|Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
219352388|NCT02959463|OTHER|Laboratory Biomarker Analysis|Correlative studies
219352389|NCT02959463|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
219352390|NCT02959463|BIOLOGICAL|Pembrolizumab|Given IV
219352391|NCT02959463|RADIATION|Radiation Therapy|Undergo hemithoracic radiation therapy
219352392|NCT02118688|DRUG|Risperidone|
219352393|NCT02118688|DRUG|Trazodone|
219352394|NCT02118688|DRUG|Placebo|
219352395|NCT06963216|BIOLOGICAL|Coagadex(R)|Coagulation Factor X (Human)
219352396|NCT04283669|DRUG|Crizotinib|Oral
219352397|NCT03987763|DRUG|IDP-122 Lotion|Topical
219352398|NCT04283123|BEHAVIORAL|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
219352399|NCT04283123|OTHER|No Intervention|Waitlist control
219352400|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
219352401|NCT05768659|BEHAVIORAL|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
219352402|NCT06802380|DEVICE|Low-level tragus stimulation|Low-level tragus stimulation will recruit the fibers from the inner part of the tragus of the external ear and sent afferent signals through the greater auricular branch of the vagus nerve. Ultimately the stimulation is transmitted to the dorsal vagal complex and the brainstem thereby modulating the neuronal activity in the vehicle output. Sham stimulation will be performed by clipping the electrode to the ear lobule which will not relay any afferent signals through the greater auricular branch of the vagus nerve.
219352403|NCT06802380|DEVICE|Sham stimulation|In the sham stimulation the electrodes will be attached to the ear lobule which are devoid of any afferent nerves traveling to the greater auricular branch of the vagus nerve.
219352404|NCT03494881|DRUG|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
219352405|NCT05466422|BIOLOGICAL|MK-2214|MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57
219352406|NCT05466422|DRUG|Placebo|Placebo as an IV infusion on Days 1, 29, and 57
219352407|NCT05313464|OTHER|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
219352408|NCT05313464|OTHER|syringe-push enteral feeding|skin to skin nutrition with syringe pump
219352409|NCT05838287|DRUG|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
219352410|NCT05838287|DRUG|Placebo|Placebo for Pioglitazone
219352411|NCT05635968|RADIATION|Low-dose whole brain irradiation|In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
219352412|NCT01415752|BIOLOGICAL|rituximab|Given IV
219352413|NCT01415752|DRUG|Bendamustine|Given IV
219352414|NCT01415752|DRUG|bortezomib|Given IV or SC
219352415|NCT01415752|DRUG|lenalidomide|Given PO
219352416|NCT01240460|DRUG|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
219352417|NCT01240460|DRUG|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
219352418|NCT01022190|DRUG|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
219352419|NCT05244681|OTHER|Semi-structured interview|Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
219352420|NCT04192578|DEVICE|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
219352421|NCT01903837|DRUG|Samidorphan (Low Dose)|Tablets taken once daily
219352422|NCT01903837|DRUG|Samidorphan (Medium Dose)|Tablets taken once daily
219352423|NCT01903837|DRUG|Samidorphan (High Dose)|Tablets taken once daily
219352424|NCT01903837|DRUG|Placebo|Tablets taken once daily
219352425|NCT01903837|DRUG|Olanzapine|Tablets taken once daily
219352426|NCT03979092|BEHAVIORAL|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
219352427|NCT03979092|BEHAVIORAL|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
219352428|NCT01992783|DIETARY_SUPPLEMENT|Hi-maize resistant starch|13.5 g/day
219352429|NCT01992783|DIETARY_SUPPLEMENT|Maltodextrin|13.5 g/day
219352430|NCT00825565|DRUG|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
219352431|NCT02188316|DEVICE|Jumbo forceps|comparison of different polypectomy devices
219352432|NCT02188316|DEVICE|Hot biopsy forceps|comparison of different polypectomy devices
219352433|NCT01898065|DRUG|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
219352434|NCT02750163|DRUG|paracetamol|Paracetamol will be given to febrile septic patients
219352435|NCT03755648|OTHER|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
219352436|NCT03755648|OTHER|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
219352437|NCT03755648|OTHER|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
219352438|NCT03105570|PROCEDURE|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
219352439|NCT00369356|DRUG|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
219352440|NCT00369356|DEVICE|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
219352441|NCT00369356|DEVICE|Bare metal coronary stent|Stenting with BMS only
219352442|NCT00705939|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
219352443|NCT02498626|OTHER|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
219352444|NCT04612998|OTHER|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
219352445|NCT04612998|OTHER|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
219352446|NCT04612998|DRUG|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
219352447|NCT04612998|DRUG|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.
219352448|NCT04612998|DRUG|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
219352449|NCT05048342|DRUG|LOU064|Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
219352450|NCT01441063|DRUG|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
219352451|NCT01441063|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
219352452|NCT01441063|DRUG|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
219352453|NCT01937650|DRUG|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
219352454|NCT03313674|DEVICE|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
219352455|NCT01119170|OTHER|Starter formula|standard starter formula given from birth to 6 months of age
219352456|NCT01119170|OTHER|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
219352457|NCT06096558|DIETARY_SUPPLEMENT|Melatonin|5 mg Melatonin in one tablet, 30 minutes before night sleep
219352458|NCT06096558|OTHER|placebo|1 tablet of placebo (starch)
219352459|NCT01851850|DRUG|Opicapone|25mg or 50mg once per day
219352460|NCT03353727|OTHER|Orthoptic rehabilitation|Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
219352461|NCT02164422|DRUG|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
219352462|NCT02164422|DRUG|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
219352463|NCT02164422|DRUG|Placebo|
219352464|NCT04951687|DIETARY_SUPPLEMENT|Ecologic Barrier©|5x10\^9 CFU/ 2g per day of Ecologic Barrier©
219352465|NCT04951687|DIETARY_SUPPLEMENT|Placebo powder|matched placebo
219352466|NCT03249571|DIETARY_SUPPLEMENT|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
219352467|NCT03249571|DIETARY_SUPPLEMENT|Placebo|2-week ingestion of placebo supplement
219352468|NCT01207622|DRUG|Atomoxetine|
219352469|NCT01207622|DRUG|Placebo|
219352470|NCT01441752|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
219352471|NCT01441752|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
219352472|NCT03064477|BEHAVIORAL|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
219352473|NCT03064477|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
219352474|NCT03988595|OTHER|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
219352475|NCT00902785|OTHER|no drug|observational no drug
219352476|NCT04372927|DRUG|Cisplatin|Given IV
219352477|NCT04372927|BIOLOGICAL|Durvalumab|Given IV
219352478|NCT04372927|DRUG|Etoposide|Given IV
219352479|NCT04372927|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219352480|NCT04372927|DRUG|Pemetrexed|Given IV
219352481|NCT06501417|OTHER|mainstreaming|mainstreaming in EC patients
219352482|NCT01665807|BIOLOGICAL|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
219352483|NCT01665807|BIOLOGICAL|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
219352484|NCT06053424|DRUG|AZD7798|Participants will receive IV infusion of AZD7798 as stated in arm description.
219352485|NCT06053424|DRUG|[11C]AZ14132516|Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.
219352486|NCT04393610|DRUG|Lidocaine|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
219352487|NCT04393610|DRUG|Magnesium Sulphate|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
219352488|NCT04393610|DRUG|Fentanyl|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
219352489|NCT01014832|DRUG|Intensive insulin therapy|Intensive insulin therapy
219352490|NCT06467890|BEHAVIORAL|Educational programme about vital pulp therapy|An awareness educational material based on the recent AAPD and AAE guidelines on vital pulp therapy will be sent to the participants right after they answer the questionnaire for the first time
219352491|NCT05248438|BEHAVIORAL|Questionnaire|Questionnaire
219352492|NCT05968729|OTHER|Active Comparator: 0.25 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.
219352493|NCT05968729|OTHER|Active Comparator: 0.50 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
219352494|NCT02059200|BEHAVIORAL|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
219352495|NCT02728830|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
219352496|NCT01707615|DRUG|GSPE|GSPE 240 mg/day (120mg bid)
219352497|NCT01707615|OTHER|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
219352498|NCT04795557|DIETARY_SUPPLEMENT|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
219352499|NCT04795557|OTHER|Placebo oral solution|Excipients
219352500|NCT06500416|DEVICE|Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL|Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts.
219352501|NCT00632801|OTHER|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
219352502|NCT01701739|DRUG|aleglitazar|Multiple doses of aleglitazar
219352503|NCT01701739|DRUG|digoxin|Single dose of digoxin
219352504|NCT03578120|BIOLOGICAL|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
219352505|NCT02462473|DRUG|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
219352506|NCT02462473|DRUG|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
219352507|NCT02462473|DRUG|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
219352508|NCT02462473|DRUG|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
219352509|NCT02462473|DRUG|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
219352510|NCT00299832|DRUG|Aliskiren|
219352511|NCT01243320|DRUG|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
219352512|NCT01243320|DRUG|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
219352513|NCT04779203|DEVICE|Osseodensification Densah Bur|Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
219352514|NCT01899235|DEVICE|drug eluting balloon|
219352515|NCT01899235|DEVICE|drug eluting stent|
219352516|NCT02254889|DRUG|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
219352517|NCT04989101|DRUG|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
219352518|NCT00973076|DRUG|AZD8055|Tablets, orally administered, twice daily
219352519|NCT02480127|PROCEDURE|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
219352520|NCT00375726|BIOLOGICAL|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
219352521|NCT00375726|BIOLOGICAL|Placebo|Placebo for rDEN3/4delta30(ME)
219352522|NCT03638232|OTHER|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
219352523|NCT03638232|OTHER|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
219352524|NCT03638232|OTHER|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
219352525|NCT03987854|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
219352526|NCT05559827|DRUG|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
219352527|NCT02575287|DEVICE|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
219352528|NCT02575287|DEVICE|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
219352529|NCT02575287|DEVICE|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
219352530|NCT02833103|DRUG|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
219352531|NCT02833103|DRUG|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
219352532|NCT02956993|DRUG|vonapanitase|
219352533|NCT02956993|DRUG|Placebo|
219352534|NCT03217838|DRUG|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
219352535|NCT03217838|DRUG|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
219352536|NCT03217838|DRUG|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
219352537|NCT04577443|DRUG|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
219352538|NCT04577443|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
219352539|NCT06128460|DRUG|Zimberelimab|240mg, q3w，8 cycles
219352540|NCT06128460|DRUG|Platinum|cisplatin 40mg/m2 for 5-6 cycles
219352541|NCT06128460|RADIATION|radiotherapy|45-50Gy/1.8Gy/25-28f
219352542|NCT02758340|DRUG|Misoprostol|Women would be given misoprostol tablet by mouth
219352543|NCT02758340|DEVICE|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
219352544|NCT04099303|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
219352545|NCT04099303|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
219352546|NCT04099303|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
219352547|NCT04099303|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
219352548|NCT00866138|DRUG|masitinib (AB1010)|masitinib 9 mg/kg/day per os
219352549|NCT04029012|DRUG|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
219352550|NCT03852394|OTHER|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
219352551|NCT01325428|DRUG|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
219352552|NCT01325428|DRUG|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
219352553|NCT05972460|DRUG|IMM2510|IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
219352554|NCT02141711|DRUG|TAK-438|TAK-438 tablets
219352555|NCT02141711|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
219352556|NCT03017053|RADIATION|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
219352557|NCT03017053|PROCEDURE|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
219352558|NCT01990287|DEVICE|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
219352559|NCT01990287|DEVICE|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
219352560|NCT01827033|BEHAVIORAL|meditation training|
219352561|NCT04375774|DEVICE|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
219352562|NCT04375774|DEVICE|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
219352563|NCT04375774|DEVICE|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
219352564|NCT02090400|DRUG|Bazedoxifene|20 mg Oral daily for 12 months
219352565|NCT02090400|DRUG|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
219352566|NCT04437355|DIAGNOSTIC_TEST|Specific provocation test|To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (\<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
219352567|NCT05034965|DRUG|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
219352568|NCT05920876|DRUG|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
219352569|NCT01739179|PROCEDURE|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
219352570|NCT01739179|PROCEDURE|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
219352571|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using dehydrated corneas
219352572|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using standard organ culture stored corneas
219352573|NCT04593069|BEHAVIORAL|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
219352574|NCT05181527|DRUG|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
219352575|NCT05181527|DRUG|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
219352576|NCT05181527|DRUG|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
219352577|NCT04094220|PROCEDURE|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
219352578|NCT02723123|OTHER|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
219352579|NCT03198208|DRUG|Fentanyl dose administration|
219352580|NCT00248183|DRUG|PRX-00023|
219352581|NCT02889432|DRUG|Oral Melatonin 10mg|
219352582|NCT02889432|DRUG|Placebo|
219352583|NCT03847610|DRUG|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
219352584|NCT03847610|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
219352585|NCT05753956|DRUG|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
219352586|NCT05753956|DRUG|Placebo|GH002 placebo administered via i.v. bolus injection
219352587|NCT01074138|DRUG|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
219352588|NCT04110665|DRUG|Tramadol|Tramadol 100 mg tablet
219352589|NCT04110665|DRUG|Nefopam 20 MG/ML|120 mg for 24 hours
219352590|NCT04110665|DRUG|Morphine Sulfate|Tablet 10mg
219352591|NCT04110665|DRUG|Oxycodone 20mg|release
219352592|NCT02421237|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|
219352593|NCT02421237|BEHAVIORAL|Supportive Group Therapy|
219352594|NCT01254279|DRUG|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
219352595|NCT05988801|OTHER|Glass ionomer sealant|glass ionomer-based sealant material
219352596|NCT05988801|OTHER|Resin based sealant|resin-based sealant material
219352597|NCT06170398|DIAGNOSTIC_TEST|Wideband tympanometry|Wideband tympanometry
219352598|NCT06170398|DIAGNOSTIC_TEST|Electrocochleography|Electrocochleography
219352599|NCT06170398|DIAGNOSTIC_TEST|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
219352600|NCT02313779|BEHAVIORAL|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
219352601|NCT02313779|BEHAVIORAL|Mindfulness Meditation|
219352602|NCT03298022|BIOLOGICAL|ALTB-168|monoclonal antibody
219352603|NCT05769179|OTHER|Massage group|Massage group will be applied classic massage and cervical stabilisation exercises 3 days a week for 4 weeks
219352604|NCT05769179|OTHER|Connective tissue massage group|Connective tissue massage group will be applied connective tissue massage and cervical stabilisation exercises 3 days a week for 4 weeks
219352605|NCT05769179|OTHER|Mobilization group|Mobilization group will be applied cervical mobilization techniques and cervical stabilisation exercises 3 days a week for 4 weeks
219352606|NCT03313245|OTHER|No Intervention/Observational Study|No Intervention/Observational Study
219352607|NCT01029067|BEHAVIORAL|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
219352608|NCT01029067|BEHAVIORAL|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
219352609|NCT00096863|DRUG|Ziprasidone|
219352610|NCT00096863|DRUG|Haloperidol|
219352611|NCT00096863|OTHER|Placebo|
219352612|NCT01787916|DRUG|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
219352613|NCT01787916|DRUG|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
219352614|NCT01445769|DRUG|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
219352615|NCT03056118|DRUG|6-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
219352616|NCT03056118|DRUG|12-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
219352617|NCT03056118|DEVICE|Zotarolimus eluting stent|Zotarolimus eluting stent is applied to coronary stenotic lesion
219352618|NCT03056118|DEVICE|Biolimus eluting stent|Biolimus eluting stent is applied to coronary stenotic lesion
219352619|NCT01552044|DRUG|Spironolactone|25mg tablet once a day for 1 month
219352620|NCT01552044|DRUG|Placebo|one tablet once a day for 1 month
219352621|NCT00016666|DRUG|Propranolol|
219352622|NCT00205478|DRUG|VX-702|
219352623|NCT01843855|DRUG|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
219352624|NCT01843855|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
219352625|NCT04534777|OTHER|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
219352626|NCT02624037|OTHER|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
219354959|NCT05323435|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
219354960|NCT05323435|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
219354961|NCT00039988|DRUG|Glatiramer acetate|20 mg administered subcutaneously daily
219354962|NCT00039988|DRUG|Albuterol|2 mg or 4 mg oral capsules taken daily
219354963|NCT00039988|DRUG|Albuterol placebo|Oral placebo capsules will be taken daily
219354964|NCT02824744|DEVICE|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
219352627|NCT05167019|BEHAVIORAL|CODE intervention|The CODE intervention consists of 1) One interactive session of 2 to 3 hrs focusing on the concepts of medical-ethical decision-making, the psychological challenge of dealing with ethically sensitive medical topics, and empowering leadership. 2) Observation and debrief of the interdisciplinary meeting to enhance self-reflection on empowering leadership and managing group dynamics. 3) Individual coaching on the spot in self-reflective and empowering leadership and in managing groups dynamics with regard to ethical decision-making about patients who are perceived to receive excessive treatment during the intervention period, and in absence of such patients, every item with regard to ethical decision-making that is important for the coachee. 4) During the intervention coaches and doctors in charge will be informed of the presence of a patient potentially receiving excessive treatment in their ward by an electronic alert.
219352628|NCT05167019|OTHER|Usual care|The control group will receive usual care in which the quality of the ethical decision-making is determined by the clinical team according to their usual practice. Except from a treatment-limitation-decisions guideline which focuses on the legal and deontological framework, no other guideline with regard to ethical decision-making has been implemented at the Ghent University Hospital. In one ward (geriatrics), there is a ongoing project in which a clinical nurse specialist stimulates and performes advance care planning conversations with patient and/or relatives at request of the team and who organizes debriefings when needed based on the ethical concerns of the nurses.
219352629|NCT05220605|DRUG|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
219352630|NCT01459705|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
219352631|NCT01459705|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
219352632|NCT01459705|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
219352633|NCT03658486|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
219352634|NCT05926726|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
219352635|NCT01400451|DRUG|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
219352636|NCT01400451|DRUG|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
219352637|NCT03021902|DRUG|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
219352638|NCT03021902|DEVICE|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
219352639|NCT01428817|DRUG|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219352640|NCT01428817|DRUG|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219352641|NCT01428817|DRUG|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219352642|NCT01428817|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219352643|NCT01428817|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
219352644|NCT05199324|DRUG|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
219352645|NCT05199324|DRUG|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
219352646|NCT02886416|OTHER|Non interventional study|
219352647|NCT04425187|DRUG|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
219352648|NCT04425187|DRUG|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
219352649|NCT00042887|DRUG|mitomycin C|
219352650|NCT00042887|PROCEDURE|conventional surgery|
219352651|NCT02499861|DRUG|Decitabine and Genistein|intravenous Decitabine with oral genistein
219352652|NCT05957991|DRUG|Metformin Hydrochloride tablet|Treatment with metformin
219352653|NCT05957991|DRUG|Placebo|Treatment with placebo
219352654|NCT05957991|BEHAVIORAL|Lifestyle intervention|Changing behaviour on diet and excersise
219352655|NCT05957991|BEHAVIORAL|No lifestyle intervention|No changes in behaviou on diet and excersise
219352656|NCT03862352|DEVICE|Covered coronary stent|Insertion of covered coronary stent as part of standard care
219352657|NCT04891289|DRUG|Gemcitabine|See arm for details.
219352658|NCT04891289|DRUG|Oxaliplatin|See arm for details.
219352659|NCT04891289|DRUG|Dexamethasone|See arm for details.
219352660|NCT04891289|DRUG|Floxuridine (FUDR)|See arm for details.
219352661|NCT04891289|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
219352662|NCT00129168|DRUG|Zosuquidar|
219352663|NCT00129168|DRUG|Daunorubicin|
219352664|NCT00129168|DRUG|Cytarabine|
219352665|NCT02171611|DRUG|Dabigatran etexilate pellets|
219352666|NCT02171611|DRUG|Dabigatran etexilate powder|
219352667|NCT02171611|DRUG|Dabigatran etexilate capsule|
219352668|NCT00610831|DEVICE|DIRECTVIEW CR Mammography|4 views screening mammogram
219352669|NCT04643028|OTHER|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
219352670|NCT04643028|OTHER|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
219352671|NCT04643028|OTHER|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
219352672|NCT02487420|BEHAVIORAL|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
219352673|NCT02340338|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
219352674|NCT04906980|DRUG|JNJ-64281802|JNJ-64281802 will be administered orally.
219352675|NCT04906980|DRUG|Placebo|Matching placebo (PEG400) will be administered orally.
219352676|NCT01169155|OTHER|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
219352677|NCT02774382|DRUG|Vancomycin|Already incl. in arm description
219352678|NCT02774382|DRUG|Fecal microbiota transplantation|Already incl. in arm description
219352679|NCT02774382|DRUG|Rectal bacteriotherapy|Already incl. in arm description
219352680|NCT06218095|OTHER|Simulation application|Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
219352681|NCT00343889|BIOLOGICAL|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
219352682|NCT00343889|BIOLOGICAL|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
219352683|NCT00343889|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine
219352684|NCT02595476|DRUG|Remifentanil|
219352685|NCT02595476|DRUG|propofol|
219352686|NCT02595476|DEVICE|TCI|
219352687|NCT02595476|PROCEDURE|Tetanic stimulation|
219352688|NCT02595476|DEVICE|Algiscan|Pupillometry
219352689|NCT02396186|DEVICE|PTCA Balloon Angioplasty|
219352690|NCT06084520|DIAGNOSTIC_TEST|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
219352691|NCT06084520|DIAGNOSTIC_TEST|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
219352692|NCT06084520|DIAGNOSTIC_TEST|PETh|Alcohol use detection
219352693|NCT06084520|DIAGNOSTIC_TEST|ASI-SR|Cross-validation form
219352694|NCT06084520|DIAGNOSTIC_TEST|AUDIT|Cross-validation form
219352695|NCT06084520|DIAGNOSTIC_TEST|DUDIT|Cross-validation form
219352696|NCT06084520|DIAGNOSTIC_TEST|Brief Pain Inventory - BPI|Cross-validation form
219352697|NCT06084520|DIAGNOSTIC_TEST|Patient Global Impression of Change PGIC|Cross-validation form
219352698|NCT06084520|DIAGNOSTIC_TEST|GAD-7|Cross-validation form
219352699|NCT06084520|DIAGNOSTIC_TEST|Patient Health questionnaire (PHQ9)|Cross-validation form
219352700|NCT06084520|DIAGNOSTIC_TEST|DBS - cannabis test|cross-validation form
219352701|NCT06084520|OTHER|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
219352702|NCT01951820|DRUG|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
219352703|NCT01951820|DRUG|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
219352704|NCT01951820|DRUG|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
219352705|NCT02829840|DRUG|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
219352706|NCT02829840|DRUG|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
219354965|NCT02824744|DEVICE|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
219354966|NCT01339546|OTHER|no intervention|
219352707|NCT02829840|BEHAVIORAL|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
219352708|NCT03506243|BIOLOGICAL|Follitrope PFS|Follitrope PFS
219352709|NCT03506243|BIOLOGICAL|Gonal-f pen|Gonal-f pen
219352710|NCT01294579|BIOLOGICAL|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
219352711|NCT01294579|DRUG|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
219352712|NCT05671432|BIOLOGICAL|CM326|CM326 injection
219352713|NCT05671432|OTHER|Placebo|Placebo
219352714|NCT05499949|DIAGNOSTIC_TEST|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
219352715|NCT05499949|DIAGNOSTIC_TEST|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
219352716|NCT05499949|DIAGNOSTIC_TEST|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
219352717|NCT04349774|DRUG|Control Group - ESP block with SAP block|None - Control Group
219352718|NCT04349774|DRUG|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
219352719|NCT05243264|BEHAVIORAL|Empower@Home|The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
219352720|NCT03081520|BEHAVIORAL|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
219352721|NCT03081520|BEHAVIORAL|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
219352722|NCT03081520|BEHAVIORAL|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
219352723|NCT00619073|DRUG|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
219352724|NCT00619073|DRUG|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
219352725|NCT00619073|DRUG|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
219352726|NCT04543643|DRUG|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
219352727|NCT04543643|DRUG|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
219352728|NCT01967537|DRUG|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
219352729|NCT01967537|PROCEDURE|Radio-guided surgery|Using 68Gallium DOTATATE
219352730|NCT04985903|BEHAVIORAL|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
219352731|NCT04985903|OTHER|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
219352732|NCT02827864|BEHAVIORAL|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
219352733|NCT02827864|BEHAVIORAL|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
219352734|NCT02827864|BEHAVIORAL|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
219352735|NCT06411626|OTHER|PNH-relevant therapies|This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
219352736|NCT04324372|DRUG|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
219352737|NCT02517164|OTHER|Measurement of serum 25-hydroxyvitamin D|
219352738|NCT02517164|OTHER|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
219352739|NCT03263507|DRUG|Placebo|Saline .9%
219352740|NCT03263507|DRUG|Donidalorsen|Donidalorsen administered subcutaneously
219354967|NCT00001193|PROCEDURE|high dose melphalan and autologous bone marrow transplantation|
219354968|NCT00493038|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
219352741|NCT01783327|BEHAVIORAL|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
219352742|NCT01783327|BEHAVIORAL|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
219352743|NCT05093400|OTHER|no intervention|saliva collection
219352744|NCT06106464|OTHER|Aerobic exercise+6.5 h of prolonged sitting|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
219352745|NCT06106464|OTHER|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
219352746|NCT06106464|OTHER|Aerobic exercise+4 minutes of walking breaks every 1-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
219352747|NCT06106464|OTHER|Aerobic exercise+8 minutes of walking breaks every 2-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
219352748|NCT04829851|DEVICE|PROTEIN Mobile App|All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
219352749|NCT04829851|DEVICE|Expert Dashboard|Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
219352750|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
219352751|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
219352752|NCT02611388|DEVICE|fake stimulation|Patients were only attached electrodes without electric current
219352753|NCT03140137|DRUG|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
219352754|NCT04354714|DRUG|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
219352755|NCT04354714|PROCEDURE|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
219352756|NCT04737655|DRUG|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
219352757|NCT05130463|DRUG|Empagliflozin/Linagliptin|Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.
219352758|NCT03461757|DRUG|Rimegepant|75 mg ODT QD
219352759|NCT03461757|DRUG|Placebo|Placebo ODT to match rimegepant dose QD
219352760|NCT02142777|DRUG|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
219352761|NCT02142777|DRUG|Placebo|The placebo has no active ingredients but is made to look like the study drug.
219352762|NCT03514628|OTHER|Standard Care|The Valsalva strain will be produced using Standard Care techniques
219352763|NCT03514628|DEVICE|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
219352764|NCT01258764|DRUG|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
219352765|NCT01258764|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
219352766|NCT04754880|DIAGNOSTIC_TEST|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
219352767|NCT02984527|DEVICE|wet wipes|intimate hygiene with disposable wet wipes
219352768|NCT02984527|DEVICE|water and soap|Intimate hygiene with water and soap
219352769|NCT03260959|BEHAVIORAL|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
219352770|NCT02864368|DRUG|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
219352771|NCT02864368|DRUG|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
219352772|NCT02864368|BIOLOGICAL|PEP-CMV: Component A|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
219352773|NCT02864368|DRUG|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
219352774|NCT02864368|DRUG|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
219352775|NCT02864368|BIOLOGICAL|PEP-CMV: Component B|500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
219352776|NCT05235035|BEHAVIORAL|Night shift work|Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
219352777|NCT01565733|DRUG|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
219352778|NCT01386359|DRUG|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
219352779|NCT03506555|PROCEDURE|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
219352780|NCT00301951|BIOLOGICAL|anti-thymocyte globulin|
219352781|NCT00301951|BIOLOGICAL|sargramostim|
219352782|NCT00301951|DRUG|busulfan|
219352783|NCT00301951|DRUG|fludarabine phosphate|
219352784|NCT00301951|DRUG|mycophenolate mofetil|
219352785|NCT00301951|DRUG|tacrolimus|
219352786|NCT00301951|PROCEDURE|umbilical cord blood transplantation|
219352787|NCT03499028|OTHER|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
219352788|NCT06548984|OTHER|diaphragmatic exercises|Perform controlled and supervised diaphragmatic exercises
219352789|NCT06548984|OTHER|Respiratory muscle training|Perform respiratory muscle training with controlled and supervised devices
219352790|NCT00299208|DRUG|Artesunate|
219352791|NCT00299208|DRUG|Azithromycin|
219352792|NCT00299208|DRUG|Quinine|
219352793|NCT03595553|DRUG|Ridinilazole|ridinilazole (200 mg bid)
219352794|NCT03595553|DRUG|Vancomycin|vancomycin (125 mg qid)
219352795|NCT02355561|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
219352796|NCT02355561|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
219352797|NCT02355561|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
219352798|NCT03826732|BEHAVIORAL|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
219352799|NCT05334186|BEHAVIORAL|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
219352800|NCT03612986|DIETARY_SUPPLEMENT|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
219352801|NCT03612986|DIETARY_SUPPLEMENT|Placebo|Placebo comparator. No chemical effect expected
219352802|NCT02058680|BIOLOGICAL|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
219352803|NCT00066079|PROCEDURE|massage|
219352804|NCT00066079|BEHAVIORAL|relaxation|
219352805|NCT01035905|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219352806|NCT01035905|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
219352807|NCT04385654|DRUG|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
219352808|NCT04385654|DRUG|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
219352809|NCT02508194|BIOLOGICAL|MEDI7510|RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
219352810|NCT02508194|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
219352811|NCT02508194|OTHER|Placebo|Sterile Saline
219354969|NCT00493038|DRUG|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
219352812|NCT00393874|BEHAVIORAL|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
219352813|NCT00393874|DRUG|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
219352814|NCT00393874|DRUG|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
219352815|NCT02415738|PROCEDURE|Prone positioning|
219352816|NCT01031914|DEVICE|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
219352817|NCT03800875|DRUG|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
219352818|NCT01479712|PROCEDURE|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
219352819|NCT02126085|PROCEDURE|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
219352820|NCT00291005|DRUG|ARD6562, Docetaxel|
219352821|NCT01150266|DRUG|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
219352822|NCT01227551|BIOLOGICAL|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
219352823|NCT02677155|RADIATION|Radiotherapy|Radiotherapy 8 Gy single dose
219352824|NCT02677155|BIOLOGICAL|Rituximab|Intranodal injection 5 mg
219352825|NCT02677155|BIOLOGICAL|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
219352826|NCT02677155|BIOLOGICAL|GM-CSF|Subcutaneous injection of 50 ug
219352827|NCT02677155|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
219352828|NCT02158091|DRUG|IPI-145|oral PI3K delta/gamma inhibitor
219352829|NCT02158091|DRUG|Fludarabine|intravenous chemotherapy
219352830|NCT02158091|DRUG|Cyclophosphamide|intravenous chemotherapy
219352831|NCT02158091|DRUG|Rituximab|intravenous immunotherapy
219352832|NCT04404062|DIAGNOSTIC_TEST|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
219352833|NCT04404062|DIAGNOSTIC_TEST|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
219352834|NCT04404062|DIAGNOSTIC_TEST|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
219352835|NCT02001233|BIOLOGICAL|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
219352836|NCT04722172|DRUG|Acalabrutinib|Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
219352837|NCT04722172|DRUG|Obinutuzumab|Obinutuzumab will be administered during Cycles 2-7.
219352838|NCT03977467|DRUG|Atezolizumab|Atezolizumab at a flat dose of 1200 mg IV every 3 weeks
219352839|NCT03977467|DRUG|Standard of Care Chemotherapy|Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
219352840|NCT03977467|DRUG|Tiragolumab|Tiragolumab at a flat dose of 600 mg IV every 3 weeks
219352841|NCT05530798|DEVICE|Definity Perflutren Lipid Microsphere Ultrasound Contrast|"1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had."
219352842|NCT01696734|DRUG|Domperidone|Given PO
219352843|NCT01696734|OTHER|Questionnaire Administration|Ancillary studies
219352844|NCT05913232|DRUG|H-1337 0.6%|ophthalmic solution
219352845|NCT05913232|DRUG|H-1337 1.0%|ophthalmic solution
219352846|NCT05913232|DRUG|H-1337 Placebo|ophthalmic solution
219352847|NCT05913232|DRUG|Timolol 0.5%|ophthalmic solution
219352848|NCT05161377|PROCEDURE|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
219352849|NCT05161377|PROCEDURE|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
219352850|NCT06851312|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
219352851|NCT06504459|DRUG|Azacitidine|Given IV or SC
219352852|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219352853|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219352854|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219352855|NCT06504459|DRUG|Cladribine|Given IV
219352856|NCT06504459|DRUG|Cytarabine|Given SC
219352857|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
219352858|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
219352859|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219352860|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
219352861|NCT06504459|DRUG|Venetoclax|Given PO
219352862|NCT00472433|DRUG|Alemtuzumab|
219352863|NCT05176119|DRUG|Nalbuphine Injection|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
219352864|NCT05176119|DRUG|Ketamine|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
219352865|NCT05176119|DRUG|Saline|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
219352866|NCT01627899|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
219352867|NCT05693896|BEHAVIORAL|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
219352868|NCT06967519|DRUG|Artemether-lumefantrine (AL)|Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine
219352869|NCT06967519|DRUG|artesunate-amodiaquine (AS-AQ)|Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing
219352870|NCT02579070|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
219352871|NCT00039793|PROCEDURE|Moderate-intensity and low-intensity bodywork therapy|
219352872|NCT06576583|BIOLOGICAL|Engineered cartilage graft (N-TEC)|Nasal chondrocytes based tissue engineered cartilage
219352873|NCT06576583|PROCEDURE|Autologous Matrix Induced Chondrogenesis (AMIC)|Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells
219352874|NCT06576583|PROCEDURE|Patellofemoral Arthroplasty (PFA)|Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.
219352875|NCT04533659|BEHAVIORAL|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
219352876|NCT04533659|BEHAVIORAL|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
219352877|NCT05348057|DRUG|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
219352878|NCT05404620|OTHER|Schroth exercises|9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.
219352879|NCT05404620|OTHER|PNF technique|9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
219352880|NCT04449055|DEVICE|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
219352881|NCT06368713|BEHAVIORAL|Exercise|"* Frequency: Exercise sessions will occur no less than three times per week.~* Intensity: The intensity will be based on a rating of perceived exertion score ranging from 12 to 16 on a scale of 6 to 20.~* Exercise duration: Each exercise session will last approximately 30 minutes.~* Exercise Type:The exercise regimen will include aerobic exercise, resistance exercise, and flexibility training."
219352882|NCT04563494|DRUG|dexamethasone|Prevention of post op nausea and vomiting
219352883|NCT02901288|DRUG|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
219352884|NCT02901288|DRUG|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
219352885|NCT02901288|DRUG|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
219352886|NCT02901288|DRUG|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
219352887|NCT02901288|DRUG|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
219352888|NCT00002827|BIOLOGICAL|bleomycin sulfate|Given IV
219352889|NCT00002827|BIOLOGICAL|filgrastim|Given IV
219352890|NCT00002827|DRUG|dexrazoxane hydrochloride|Given IV
219352891|NCT00002827|DRUG|doxorubicin hydrochloride|Given IV
219352892|NCT00002827|DRUG|etoposide|Given IV
219352893|NCT00002827|DRUG|vincristine sulfate|Given IV
219352894|NCT00002827|RADIATION|low-LET cobalt-60 gamma ray therapy|
219352895|NCT00002827|RADIATION|low-LET electron therapy|
219352896|NCT00002827|RADIATION|low-LET photon therapy|
219352897|NCT07131982|OTHER|Informative Animated Video to be Viewed with Virtual Reality Glasses|No study has been found in the literature evaluating the effect of animated videos shown to children through virtual reality glasses on mothers and children. The aim of this study was to determine the effect of animated videos shown through virtual reality glasses before surgery on perioperative anxiety and fear in children and their mothers.
219352898|NCT07144397|PROCEDURE|TOLS|"Standard AC plus bilateral lateral suspension using non-absorbable sutures passed through the obturator foramen to support lateral vaginal wall."
219352899|NCT07143344|OTHER|Fermented lingonberry juice sprey|Patented fermented lingonberry juice sprey
219352900|NCT07144085|DRUG|68Ga-FXX489|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
219352901|NCT07144085|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes.
219352902|NCT07144085|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
219352903|NCT07142746|PROCEDURE|Digital intra oral scanning|One groups prepared teeth will be scanned by a digital intra oral scanner.
219352904|NCT07142746|PROCEDURE|Conventional impression|One group will recieve impressions conventionally in a tray with dental impression polyvinly siloxane.
219352905|NCT06687746|DEVICE|Bili-ruler|The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.
219352906|NCT06516913|DEVICE|Harvard Apparatus syringe pump|Used to administer buffer solution with hyaluronic acid SC.
219352907|NCT05938673|OTHER|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
219352908|NCT05938673|OTHER|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
219352909|NCT06438432|OTHER|RAIT|The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
219352910|NCT04341948|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
219352911|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
219352912|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
219352913|NCT03983850|DRUG|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
219352914|NCT03983850|DRUG|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
219352915|NCT03983850|DRUG|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
219352916|NCT03983850|DRUG|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
219352917|NCT03983850|DRUG|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
219352918|NCT06356909|OTHER|Survey of sedo-analgesia practices before laryngoscopy|The survey will evaluate adequation to the French best practice guidelines to improve their dissemination and to identify current practices of premedication before laryngoscopy in neonates in French units (agents, dosing, efficacy, safety)
219352919|NCT04475055|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen (DIPS)|The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
219352920|NCT03041558|BEHAVIORAL|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
219352921|NCT03041558|BEHAVIORAL|SafeCare (SC)|SafeCare intervention as usual
219352922|NCT01469910|DRUG|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
219352923|NCT01469910|DRUG|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
219352924|NCT01972230|DRUG|Sevoflurane|
219352925|NCT01972230|DRUG|Diprivan + Remifentanil TCI|
219352926|NCT02686229|OTHER|no interventions|
219352927|NCT02787850|DEVICE|CoolSculpting Treatment|The CoolSculpting device will be used to perform treatments.
219352928|NCT04018911|DEVICE|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
219352929|NCT04018911|DEVICE|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
219352930|NCT04018911|DEVICE|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
219352931|NCT04018911|DRUG|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
219352932|NCT00767377|DRUG|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
219352933|NCT03598166|DIAGNOSTIC_TEST|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
219352934|NCT02466061|BEHAVIORAL|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
219352935|NCT02466061|BEHAVIORAL|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
219352936|NCT02466061|BEHAVIORAL|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
219352937|NCT00917449|DRUG|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
219352938|NCT00917449|DRUG|Placebo|Oral Placebo BID for 18 months
219352939|NCT02921971|DRUG|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
219352940|NCT02921971|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
219352941|NCT00274131|DRUG|Pramipexole 0.125 mg tablets|
219352942|NCT00274131|DRUG|Pramipexole 0.5 mg tablets|
219352943|NCT02322710|DEVICE|Urgotul: Low-adherent dressing|
219352944|NCT02322710|DEVICE|TulleGras M.S.: Vaseline gauze|
219352945|NCT05576571|DIAGNOSTIC_TEST|Met-score|methylation analysis
219352946|NCT02158780|PROCEDURE|Scrotal Orchidopexy|Single incision
219352947|NCT02158780|PROCEDURE|Inguinal Orchidopexy|Double Incision (Standard)
219352948|NCT03351777|DRUG|PR022|Topical Gel
219352949|NCT01708980|OTHER|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
219352950|NCT04619485|DEVICE|CO2 LASER|5 SESSIONS OF CO2 VAGINAL LASER
219352951|NCT04619485|DEVICE|CO2 SHAM LASER|5 SESSIONS OF CO2 VAGINAL SHAM LASER
219352952|NCT00143585|PROCEDURE|intramyocardial delivery of either VEGF165 or placebo|
219352953|NCT04161131|BEHAVIORAL|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
219352954|NCT06239129|DRUG|Initiation of specific medications|multiple therapies studied within this database
219352955|NCT06239129|PROCEDURE|Undertaking of specific procedures|multiple procedures/surgeries studied within this database
219352956|NCT06239129|DIAGNOSTIC_TEST|Abnormalities in specific laboratory tests|multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database
219352957|NCT02472132|DEVICE|POC US|Use of point of care ultrasound in insertion of CVC
219352958|NCT00703638|DRUG|cisplatin|Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
219352959|NCT00703638|DRUG|pemetrexed disodium|Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
219352960|NCT00703638|DRUG|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
219352961|NCT02816918|DEVICE|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
219352962|NCT02816918|DEVICE|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
219352963|NCT05119712|DRUG|Terbinafine Tablets|500mg oral terbinafine or placebo daily
219352964|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
219352965|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
219352966|NCT04536597|OTHER|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
219352967|NCT04536597|OTHER|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
219352968|NCT04536597|OTHER|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
219352969|NCT03165097|DRUG|ACT-709478|Hard gelatine capsules for oral administration
219352970|NCT03165097|DRUG|Placebo|Placebo capsules matching ACT-709478 capsules
219352971|NCT03165097|DRUG|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
219352972|NCT03165097|DRUG|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
219352973|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Psycho-educational group
219352974|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Spiritual-Existential Group
219352975|NCT01185405|OTHER|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
219352976|NCT06213727|DRUG|lowe-dose ZKY001 eye drops|eye drops
219352977|NCT06213727|DRUG|Medium-dose ZKY001 eye drops|eye drops
219352978|NCT06213727|DRUG|ZKY001 simulated eye drops|eye drops
219352979|NCT04209803|DRUG|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
219352980|NCT05058183|DIAGNOSTIC_TEST|ctDNA|Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
219352981|NCT05980715|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
219352982|NCT05980715|RADIATION|concurrent chemoradiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
219352983|NCT01243905|OTHER|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
219352984|NCT01243905|OTHER|Treatment as usual|Treatment as usual administered by physicians
219352985|NCT01592981|DRUG|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
219352986|NCT01592981|DRUG|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
219352987|NCT01592981|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
219352988|NCT01592981|DRUG|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
219352989|NCT05402644|PROCEDURE|hepatectomy|Liver resection
219352990|NCT03936504|BEHAVIORAL|Control Group ：conventional exercise rehabilitation programs (CERP)|The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
219352991|NCT03936504|BEHAVIORAL|Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)|Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
219352992|NCT00505258|DRUG|ceftobiprole medocaril|
219352993|NCT03883880|OTHER|Epigallocatechin gallate|Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
219352994|NCT03883880|OTHER|Epigallocatechin gallate control|Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
219352995|NCT03883880|OTHER|Linoleic acid|Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
219352996|NCT03883880|OTHER|Linoleic acid control|Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
219352997|NCT03883880|OTHER|Capsaicin solution|Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
219352998|NCT03883880|OTHER|Capsaicin control|Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
219352999|NCT02073773|DRUG|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
219353000|NCT02073773|OTHER|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
219353001|NCT04316585|DRUG|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
219353002|NCT04316585|DRUG|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
219353003|NCT01897246|PROCEDURE|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
219353004|NCT01897246|PROCEDURE|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
219353005|NCT00023530|DRUG|fluconazole|
219353006|NCT00023530|DRUG|voriconazole|
219353007|NCT00023530|PROCEDURE|bone marrow transplant|
219353008|NCT00023530|DRUG|thalidomide|
219353009|NCT00023530|DRUG|dexamethasone|
219353010|NCT02439125|DRUG|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
219353011|NCT02439125|DRUG|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
219353012|NCT02439125|DRUG|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
219353013|NCT02439125|DRUG|Placebo|b.i.d. orally for 3 weeks
219353014|NCT05350826|OTHER|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
219353015|NCT00130832|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
219353016|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
219353017|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
219353018|NCT03905863|DEVICE|Natrox® Oxygen Wound Therapy|A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
219353019|NCT04634175|BEHAVIORAL|Yoga intervention|The yoga intervention is composed of kundalini yoga techniques.
219353020|NCT04634175|BEHAVIORAL|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
219353021|NCT01207973|DRUG|BI 113823|5 dose-groups of multiple oral doses of BI 113823
219353022|NCT00532480|DRUG|Duloxetine|60 mg capsules
219353023|NCT00545701|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
219353024|NCT02213601|BEHAVIORAL|Yoga|
219353025|NCT01977235|DRUG|Irinotecan|
219353026|NCT01977235|DRUG|Cisplatin|
219353027|NCT01471080|PROCEDURE|RFA|using RFA to treat cavernous hemangiomas
219353028|NCT01471080|PROCEDURE|hepatectomy|using hepatectomy to treat cavernous hemangiomas
219353029|NCT00477126|DRUG|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
219353030|NCT04176185|BIOLOGICAL|Sublingual allergy immunological tablet|For daily administration (1 tablet per day)
219353031|NCT04176185|OTHER|Placebo|For daily administration (1 tablet per day)
219353032|NCT03842930|PROCEDURE|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
219353033|NCT03408795|PROCEDURE|Laparoscopic distal gastrectomy|Longitudinal testing of The Japanese Operative Rating Scale for Laparoscopic Distal Gastrectomy
219353034|NCT01155115|PROCEDURE|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
219353035|NCT01155115|PROCEDURE|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
219353036|NCT01155115|PROCEDURE|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
219353037|NCT01675986|DRUG|hydroxyzine|75 mg
219353038|NCT01675986|DRUG|Pregabalin|150 mg
219353039|NCT01675986|DRUG|Lactose|4 g
219353040|NCT05222217|DEVICE|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
219353041|NCT00794209|DRUG|i.v fentanyl, AeroLEF|"* i.v fentanyl~* 5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~* 5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~* 5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~* 3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
219353042|NCT06268379|PROCEDURE|Surgery|Not an interventional study, it is an observational, longitudinal study.
219353043|NCT05026788|OTHER|type of treatment|pathway of management for conservative treatment, operative treatment and type of anaesthesia used
219353044|NCT04775511|OTHER|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
219353045|NCT04775511|OTHER|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
219353046|NCT04775511|OTHER|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
219353047|NCT03828279|DIAGNOSTIC_TEST|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
219353048|NCT02601924|DRUG|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
219353049|NCT02601924|OTHER|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
219353050|NCT04240977|BEHAVIORAL|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
219353051|NCT02584491|BEHAVIORAL|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
219353052|NCT04789733|OTHER|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
219353053|NCT04789733|OTHER|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
219353054|NCT04622176|DIAGNOSTIC_TEST|MMUS|MMUS will be used to perform diagnostics, we will compare with MRI and histology
219353055|NCT02996747|PROCEDURE|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
219353056|NCT03573453|OTHER|enteral nutrition|administration of enteral nutrition
219353057|NCT01492998|OTHER|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
219353058|NCT05618743|PROCEDURE|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
219353059|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
219353060|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
219353061|NCT05948280|OTHER|Virtual reality-supported mindfulness|A single mindful stretching exercise provides a conscious stretch of VR scenario. The implementation of VR exercises will be performed by the interventionist who have received training in the application of VR scenarios and have extensive experience in VR research.
219353062|NCT05948280|OTHER|Mindfulness|The interventionist will guide the participant to do a mindful stretching exercise in the first week. During the second week, the interventionist will send participants an audio recording on how to do mindful stretching exercise via WeChat/WhatsApp.
219353063|NCT05730179|OTHER|Mechanical Conditioning stimulus|Painful mechanical stimulus
219353064|NCT05439187|PROCEDURE|hernia repair|Open or laparoscopic hernia repair with mesh placement.
219353065|NCT02135731|OTHER|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
219353066|NCT04390087|OTHER|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
219353067|NCT00397722|DRUG|GW876008|
219353068|NCT00397722|DRUG|paroxetine|
219353069|NCT01872728|DRUG|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
219353070|NCT01817738|BIOLOGICAL|CV9104|Intradermal injection of CV9104
219353071|NCT01817738|BIOLOGICAL|Placebo|Intradermal injection of placebo
219353072|NCT00526682|DIETARY_SUPPLEMENT|Irvingia/cissus combo|
219353073|NCT05684380|DRUG|MAZ-101association|Experimental drug
219353074|NCT05684380|DRUG|DYMISTA®|Active comparator
219353075|NCT02944448|DRUG|CR845 tablet 1 mg|CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
219353076|NCT02944448|DRUG|CR845 tablet 2.5 mg|CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
219353077|NCT02944448|DRUG|CR845 tablet 5 mg|CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
219353078|NCT02944448|DRUG|Placebo tablet|Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
219353079|NCT03871855|DRUG|SHR-1702|Administered IV
219353080|NCT03871855|DRUG|Camrelizumab|Administered IV
219353081|NCT06334094|DRUG|Ozanimod|A hard capsule that is taken daily for one year.
219353082|NCT01098890|DRUG|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
219353083|NCT01098890|DRUG|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
219353084|NCT04086251|OTHER|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
219353085|NCT00091910|DRUG|Epoetin alfa|
219353086|NCT00652353|OTHER|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
219353087|NCT00652353|OTHER|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
219353088|NCT02117726|DRUG|Dexmedetomidine,midazolam|
219353089|NCT02117726|DRUG|Propofol,midazolam|
219353090|NCT01135589|DRUG|Micafungin|i.v.
219353091|NCT06147557|PROCEDURE|Heat therapy|14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
219353092|NCT02070107|OTHER|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
219353093|NCT06068972|DEVICE|MolecuLight|Point-of-care fluorescence imaging of high bacterial loads
219353094|NCT05627076|DEVICE|Blood Sampling|Blood samples will be collected for the PSP measurement using the abioSCOPE.
219353095|NCT04527198|DIAGNOSTIC_TEST|Brainstem Responses Assessment Sedation Score (BRASS)|"It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning."
219353096|NCT04527198|DIAGNOSTIC_TEST|Electroencephalogram with EKG lead|"A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity)."
219353097|NCT03644433|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
219353098|NCT03644433|PROCEDURE|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
219353099|NCT06064344|DRUG|Rituximab|Intralesional Rituximab Injection
219353100|NCT06064344|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
219353101|NCT04357106|BIOLOGICAL|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
219353102|NCT01980472|BIOLOGICAL|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
219353103|NCT00521521|DRUG|docetaxel and cisplatin|
219353104|NCT00521521|DRUG|docetaxel|
219353105|NCT00870337|DRUG|everolimus|
219353106|NCT04858893|DIAGNOSTIC_TEST|CoMDA associated with Neural Net 91 classificator|
219353107|NCT01144585|PROCEDURE|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
219353108|NCT01144585|PROCEDURE|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
219353109|NCT03253263|DRUG|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
219353110|NCT04022382|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
219353111|NCT02392013|OTHER|Home Modification|Removal of home barriers or hazards.
219353112|NCT06539598|OTHER|Respiratory Strength Training (RST)|Respiratory Strength training involves inhaling/exhaling against a fix resistant to potentially increase respiratory strength
219354970|NCT03440827|BEHAVIORAL|Focus Group|First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
219353113|NCT02524353|OTHER|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
219353114|NCT03491384|DRUG|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
219353115|NCT04252430|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
219353116|NCT05499559|BEHAVIORAL|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
219353117|NCT06582745|DRUG|Trametinib|Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
219353118|NCT04381390|DIETARY_SUPPLEMENT|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
219353119|NCT04381390|DIETARY_SUPPLEMENT|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
219353120|NCT02386488|DRUG|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
219353121|NCT02386488|DRUG|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
219353122|NCT02386488|DRUG|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
219353123|NCT02386488|DRUG|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
219353124|NCT02317666|PROCEDURE|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
219353125|NCT01617837|DEVICE|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
219353126|NCT01617837|OTHER|Placebo band|Comparison between groups 0-48 hours postoperatively
219353127|NCT02800200|PROCEDURE|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
219353128|NCT02800200|DEVICE|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
219353129|NCT03389971|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
219353130|NCT02200380|DRUG|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
219353131|NCT02200380|DRUG|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
219353132|NCT04539730|DRUG|Liposomal bupivacaine|266 mg or 20 ml Liposomal Bupivacaine injectable solution
219353133|NCT04539730|PROCEDURE|Drug: SoC Ropivacaine|0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
219353134|NCT04681170|DRUG|Lomitapide|2mg,5mg, 10mg and 20mg capsules
219353135|NCT05942092|PROCEDURE|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
219353136|NCT02468648|DRUG|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
219353137|NCT02468648|DRUG|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
219353138|NCT02118792|DRUG|AN2728 Topical Ointment, 2%|
219353139|NCT02118792|DRUG|Matching vehicle control|
219353140|NCT05131204|DRUG|Cemdisiran|Administered per protocol
219353141|NCT05131204|DRUG|Eculizumab|Administered per protocol
219353142|NCT05131204|DRUG|Pozelimab|Administered per protocol
219353143|NCT05131204|DRUG|Ravulizumab|Administered per protocol
219353144|NCT05055180|DIAGNOSTIC_TEST|Invasive hemodynamics and myocardial biopsies|Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies
219353145|NCT06333015|DEVICE|enVista EY Beyond IOL|enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
219353146|NCT06333015|DEVICE|enVista MX60E monofocal IOL|enVista MX60E monofocal IOL
219353147|NCT05451849|BIOLOGICAL|TC-510|TC-510
219353148|NCT05451849|DRUG|Fludarabine|Fludarabine
219353149|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
219353150|NCT01368835|DEVICE|Ulthera treatment|treatment of cheeks and upper neck area of face
219353151|NCT03118297|DRUG|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
219353152|NCT03118297|DRUG|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
219353153|NCT03733223|DRUG|Ateptidase|Treatment of ischemic stroke with Ateptidase
219353154|NCT05474300|OTHER|mechanical ventilation|Pressure controlled ventilation mode on mechanical ventilation
219353155|NCT02870231|DRUG|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
219353156|NCT02870231|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
219353157|NCT02870231|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration
219353158|NCT01495494|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
219353159|NCT01495494|DEVICE|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
219353160|NCT01859377|DRUG|V0498 - A mg|Single oromucosal administration
219353161|NCT01859377|DRUG|Ibuprofen|Single oral administration
219353162|NCT01228123|OTHER|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
219353163|NCT01228123|OTHER|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
219353164|NCT05243927|OTHER|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
219353165|NCT05243927|OTHER|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
219353166|NCT01676714|DRUG|Dovitinib|
219353167|NCT04034160|OTHER|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
219353168|NCT04034160|OTHER|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
219353169|NCT01954693|DRUG|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
219353170|NCT01954693|DRUG|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
219353171|NCT05202522|BEHAVIORAL|Virtual GERAS DANCE|Dance is a form of aerobic exercise that involves multicomponent training with physical, cognitive, and social dimensions and may have synergetic benefits when delivered in combination. GERAS DANcing for Cognition and Exercise (DANCE), a community-based rehabilitation program for older adults with cognitive decline and/or mobility impairments, has been adapted for virtual delivery through videoconferencing systems. Participants will receive twice-weekly (one hour per session) virtual dance sessions for a total of 6 weeks.
219353172|NCT01272999|OTHER|No intervention|Non interventional
219353173|NCT04204174|DIETARY_SUPPLEMENT|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
219353174|NCT01888458|DRUG|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
219353175|NCT02554539|PROCEDURE|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
219353176|NCT01777152|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
219353177|NCT01777152|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
219353178|NCT01777152|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
219353179|NCT01777152|DRUG|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
219353180|NCT01777152|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
219353181|NCT02022982|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
219353182|NCT02022982|DRUG|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
219353183|NCT02792842|DRUG|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
219353184|NCT02792842|DRUG|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
219353185|NCT02792842|DRUG|Placebo|Placebo infusion once daily on days 1-3 in each cycle
219353186|NCT03096509|OTHER|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
219353187|NCT02085499|OTHER|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.~NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
219353188|NCT02085499|OTHER|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.~S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
219353189|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
219353190|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
219353191|NCT02258880|DRUG|SUN13837|
219353192|NCT02258880|DRUG|placebo|
219353193|NCT03581851|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219353194|NCT03581851|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219353195|NCT02498873|BEHAVIORAL|Linear Periodization|Linear Intensity Periodization Running
219353196|NCT02498873|BEHAVIORAL|Non Linear Periodization|Non Linear Periodization Running
219353197|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
219353198|NCT04761055|OTHER|Clinical Breast exam (CBE)|The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.
219353199|NCT04761055|DEVICE|iBreastExam device|The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.
219353200|NCT04761055|DIAGNOSTIC_TEST|mammogram|All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
219353201|NCT05044065|OTHER|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
219353202|NCT05337423|DEVICE|Photobiomodulation|Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.
219353203|NCT05337423|OTHER|Moisturizer|Both groups will receive moisturizer.
219353204|NCT05625321|BEHAVIORAL|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
219353205|NCT05625321|BEHAVIORAL|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
219353206|NCT00152542|DRUG|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
219353207|NCT00152542|DRUG|Placebo|No iNO given for days 1-7
219353208|NCT03530371|DRUG|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
219353209|NCT02261727|DRUG|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
219353210|NCT02261727|DRUG|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
219353211|NCT02261727|DRUG|Placebo (for prednisone)|"* Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
219353212|NCT02261727|DRUG|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
219353213|NCT02419287|DRUG|crizotinib|
219353214|NCT02113735|DRUG|H.P. Acthar® Gel (repository corticotropin injection)|
219353215|NCT02113735|DRUG|Placebo|
219353216|NCT02705638|DRUG|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
219353217|NCT02705638|DRUG|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
219353218|NCT04208477|PROCEDURE|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
219353219|NCT00516347|GENETIC|comparative genomic hybridization|
219353220|NCT00516347|GENETIC|genetic linkage analysis|
219353221|NCT00516347|OTHER|laboratory biomarker analysis|
219353222|NCT00516347|OTHER|questionnaire administration|
219353223|NCT00516347|PROCEDURE|study of high risk factors|
219353224|NCT02490514|OTHER|No intervention|No intervention was administered in this study.
219353225|NCT02092194|PROCEDURE|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
219353226|NCT02092194|PROCEDURE|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
219353227|NCT03066102|OTHER|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
219353228|NCT02926209|DEVICE|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
219353229|NCT02926209|PROCEDURE|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
219353230|NCT06078969|DRUG|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
219353231|NCT06253156|BEHAVIORAL|virtual reality|It is planned to provide 4 sessions of standard disaster preparedness training to nursing students in the intervention group. After the standard training sessions are completed, nursing students will be shown disaster simulation videos and visuals using virtual reality glasses within the scope of the virtual reality-based disaster preparedness training program.
219353232|NCT00540254|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
219353233|NCT00540254|OTHER|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
219353234|NCT05354986|OTHER|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
219353235|NCT05354986|OTHER|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
219353236|NCT03345472|DEVICE|Spinal Cord Stimulation System|Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
219353237|NCT01926782|DRUG|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
219353238|NCT01926782|DRUG|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
219353239|NCT01926782|DRUG|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
219353240|NCT02615743|BEHAVIORAL|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
219353241|NCT02615743|DEVICE|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
219353242|NCT05581732|DIETARY_SUPPLEMENT|Nutrinidrink with Dietary Fiber|Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
219353243|NCT03334331|OTHER|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
219353244|NCT03334331|OTHER|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
219353245|NCT04624165|OTHER|Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
219353246|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
219353247|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
219353248|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
219353249|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
219353250|NCT00703664|DRUG|Bortezomib|Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.
219353251|NCT00703664|OTHER|Laboratory Biomarker Analysis|Correlative studies
219353252|NCT00703664|DRUG|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
219353253|NCT04211207|OTHER|non invasive monitoring value|heart's respiratory quotient as non invasive monitoring value
219353254|NCT03138876|DEVICE|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
219353255|NCT03138876|DRUG|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
219353256|NCT03138876|PROCEDURE|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
219353257|NCT04854681|DRUG|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
219353258|NCT05946369|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient
219353259|NCT04673786|BIOLOGICAL|CT-P43|45mg or 90mg dose subcutaneous administration
219353260|NCT04673786|BIOLOGICAL|Stelara|45mg or 90mg dose subcutaneous administration
219353261|NCT02025387|BEHAVIORAL|Physical activity feedback|
219353262|NCT02025387|BEHAVIORAL|Usual care except physical activity measurement|
219353263|NCT04632498|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
219353264|NCT01422239|BEHAVIORAL|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
219353265|NCT01422239|BEHAVIORAL|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
219353266|NCT00384020|DRUG|Paroxetine (Seroxat)|
219353267|NCT00384020|DRUG|Escitalopram (Lexapro)|
219353268|NCT01120119|DRUG|Calcitriol|
219353269|NCT01051141|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
219353270|NCT01051141|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
219353271|NCT01051141|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (\~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
219353272|NCT04538391|DRUG|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
219353273|NCT03712397|DRUG|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
219353274|NCT00102206|DRUG|Abacavir sulfate|
219353275|NCT00102206|DRUG|Emtricitabine|
219353276|NCT00102206|DRUG|Lamivudine|
219353277|NCT00102206|DRUG|Lopinavir/ritonavir|
219353278|NCT00102206|DRUG|Saquinavir|
219353279|NCT00102206|DRUG|Tenofovir disoproxil fumarate|
219353280|NCT00102206|DRUG|Zidovudine|
219353281|NCT03195907|OTHER|Pulmonary physiotherapy|
219353282|NCT02195388|OTHER|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
219353283|NCT04627272|DEVICE|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
219353284|NCT05448911|PROCEDURE|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
219353285|NCT05448911|PROCEDURE|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
219353286|NCT05566756|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
219353287|NCT00720109|DRUG|Asparaginase|Given IT
219353288|NCT00720109|DRUG|Cyclophosphamide|Given IV
219353289|NCT00720109|DRUG|Cytarabine|Given IT or IV
219353290|NCT00720109|DRUG|Dasatinib|Given PO
219353291|NCT00720109|DRUG|Daunorubicin Hydrochloride|Given IV
219353292|NCT00720109|DRUG|Dexamethasone|Given IV or PO
219353293|NCT00720109|DRUG|Etoposide|Given IV
219353294|NCT00720109|BIOLOGICAL|Filgrastim|Given IV or SC
219353295|NCT00720109|DRUG|Hydrocortisone Sodium Succinate|Given IT
219353296|NCT00720109|DRUG|Ifosfamide|Given IV
219353297|NCT00720109|OTHER|Laboratory Biomarker Analysis|Correlative studies
219353298|NCT00720109|DRUG|Leucovorin Calcium|Given IV or PO
219353299|NCT00720109|DRUG|Mercaptopurine|Given PO
219353300|NCT00720109|DRUG|Methotrexate|Given IT, PO, or IV
219353301|NCT00720109|DRUG|Methylprednisolone|Given IV
219353302|NCT00720109|DRUG|Pegaspargase|Given IM
219353303|NCT00720109|DRUG|Prednisone|Given PO or IV
219353304|NCT00720109|RADIATION|Radiation Therapy|Some patients undergo cranial RT
219353305|NCT00720109|DRUG|Vincristine Sulfate|Given IV
219353306|NCT02590380|DEVICE|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
219353307|NCT02590380|DEVICE|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
219353308|NCT03759535|DIAGNOSTIC_TEST|Acute rejection|Donor derived cell free DNA
219353309|NCT03057925|DEVICE|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
219353310|NCT00179582|DRUG|VSL#3|
219353311|NCT02173743|OTHER|PRP|platelet enriched autologous blood plasma
219353312|NCT02173743|OTHER|Control|Regular barbotage/care as usual
219353313|NCT04963257|DRUG|sertraline fluvoxamine|the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
219353314|NCT04963257|DRUG|sertraline|The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
219353315|NCT01148277|DRUG|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
219353316|NCT01148277|DRUG|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
219353317|NCT01148277|DRUG|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
219353318|NCT00903929|DRUG|Eltrombopag|dose escalation
219353319|NCT04397094|DRUG|Theracal LC|pulpotomy
219353320|NCT04397094|DRUG|Formocresol|Pulpotomy
219353321|NCT05427266|OTHER|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
219353322|NCT01716572|DRUG|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
219353323|NCT01716572|PROCEDURE|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
219353324|NCT03150225|OTHER|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
219353325|NCT03150225|DIETARY_SUPPLEMENT|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
219353326|NCT05051007|DRUG|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
219353327|NCT05051007|DRUG|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
219353328|NCT03933865|DRUG|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
219353329|NCT03933865|DRUG|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
219353330|NCT03933865|DRUG|Placebos|Placebo will be normal saline solution given via intramuscular injection.
219353331|NCT05998629|DEVICE|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
219353332|NCT05998629|OTHER|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
219353333|NCT06667752|DEVICE|Advanced Antibacterial Wound Dressing|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
219353334|NCT06667752|DEVICE|Aquacel Ag+ Extra|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
219353335|NCT02471495|DEVICE|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
219353336|NCT04595214|OTHER|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
219353337|NCT01477931|DRUG|Bupropion extended release|300mg once a daily, PO, 8weeks
219353338|NCT05066490|OTHER|Endurance exercise|Treadmill training at moderate intensity.
219353339|NCT05066490|OTHER|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
219353340|NCT00955630|DRUG|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
219353341|NCT00955630|DRUG|ranibizumab|prn injections of ranibizumab throughout the study
219353342|NCT04938258|BEHAVIORAL|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
219353343|NCT04904458|OTHER|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
219353344|NCT04904458|OTHER|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
219353345|NCT01903512|PROCEDURE|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
219353346|NCT02757170|DEVICE|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
219353347|NCT05072132|OTHER|Personal information on genetic susceptibility to arsenic toxicity|The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
219353348|NCT05072132|OTHER|standard information on arsenic exposure reduction|In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
219353349|NCT03252483|OTHER|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
219353350|NCT03252483|OTHER|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
219353351|NCT01537757|DRUG|MK-8931|Single dose, administered as oral capsules
219353352|NCT01902550|DRUG|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
219353353|NCT01902550|DRUG|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
219353354|NCT01902550|DRUG|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
219353355|NCT04495309|RADIATION|Metastases-directed Radiotherapy|Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
219353356|NCT00394459|DEVICE|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
219353357|NCT00394459|DEVICE|Perifix Standard|Perifix Standard
219353358|NCT00394459|DEVICE|Perifix New|Perifix New
219353359|NCT00512798|DRUG|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2"
219353360|NCT00512798|DRUG|temozolomide|"Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2"
219353361|NCT00512798|OTHER|immunoenzyme technique|Not noted
219353362|NCT00512798|DRUG|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
219353363|NCT00512798|DRUG|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
219353364|NCT05701332|BIOLOGICAL|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
219353365|NCT03900871|DRUG|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
219353366|NCT06245551|DRUG|Budesonide/albuterol metered-dose inhaler 160/180 μg|Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
219353367|NCT06245551|DRUG|Placebo metered-dose inhaler|Placebo aerosol for inhalation, single dose (given as 2 actuations)
219353368|NCT04476238|DIETARY_SUPPLEMENT|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
219353369|NCT04476238|OTHER|Placebo|250 ml water taken by mouth
219353370|NCT00968851|DRUG|EVP-6124|Arms: 1
219353371|NCT00968851|DRUG|Placebo|Arm: 3
219353372|NCT00968851|DRUG|EVP-6124|Arms: 2
219353373|NCT06194396|OTHER|chlorhexidine|chlorhexidine will be used as skin disinfectant before insertion of CVC, PICC line, and umbilical catheter
219353374|NCT06194396|OTHER|alcohol|alcohol will be used as skin disinfectant before insertion of CVC ,PICC line and umbilical catheter
219353375|NCT01061814|DRUG|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
219353376|NCT01061814|DRUG|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
219353377|NCT02235194|DIETARY_SUPPLEMENT|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
219353378|NCT02235194|DIETARY_SUPPLEMENT|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
219353379|NCT05820425|OTHER|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
219353380|NCT04067063|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
219353381|NCT03228966|DIAGNOSTIC_TEST|Echocardiogram|Screening echocardiogram
219353382|NCT04654208|DRUG|palbociclib|patients on palbociclib combination treatment
219353383|NCT06383767|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
219353384|NCT06383767|DRUG|Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)|Eribulin, capecitabine, gemcitabine or vinorelbine
219353385|NCT04464980|DRUG|SL-BUP|Daily dosing of sublingual buprenorphine-naloxone
219353386|NCT04464980|DRUG|XR-BUP|Weekly/monthly dosing of extended-release injectable buprenorphine
219353387|NCT04464980|DRUG|XR-NTX|Monthly dosing of extended-release injectable naltrexone
219353388|NCT04464980|BEHAVIORAL|MM|MM consists of standard Medical Management and the usual counseling at the treatment program.
219353389|NCT04464980|BEHAVIORAL|MMR|MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
219353390|NCT04464980|BEHAVIORAL|MMD|MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
219353391|NCT03847701|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
219353392|NCT03847701|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
219353393|NCT04002544|DRUG|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
219353394|NCT04002544|OTHER|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
219353395|NCT00476879|DRUG|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
219353396|NCT00538720|DRUG|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
219353397|NCT00538720|DEVICE|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
219353398|NCT06057363|OTHER|volumetric evaluation of gingival augmentation around dental implants|objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
219353399|NCT04641442|BIOLOGICAL|MAS825|Experimental drug
219353400|NCT04641442|BIOLOGICAL|Placebo|matching placebo
219353401|NCT05142826|BEHAVIORAL|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
219353402|NCT05142826|OTHER|School as Usual|Interventions and supports as provided through usual care
219353403|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )|repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
219353404|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation|sham trans-spinal magnetic stimulation
219353405|NCT01489592|DRUG|curcuma longa|oral administration of 6 grams of curcumin
219353406|NCT04519801|OTHER|Blood Flow Restriction (BFR) therapy|BFR therapy beginning after first MD follow up appointment after ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion.
219353407|NCT04519801|OTHER|Standard REHAB|Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion
219353408|NCT05024097|DRUG|Etrumadenant (AB928)|Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
219353409|NCT05024097|RADIATION|Radiation therapy|Patients will receive a radiation therapy dose of 25Gy in 5fx
219353410|NCT05024097|DRUG|FOLFOX regimen|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
219354971|NCT06222125|DRUG|HB0025|HB0025 IV every 2 weeks (q2w)
219353411|NCT05024097|DRUG|Zimberelimab (AB122)|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
219353412|NCT06329661|DRUG|Cyclosporine ophthalmic solution, 0.1%|Colorless and clear opthalmic solution containing 0.1% Cyclosporine
219353413|NCT06329661|DRUG|Saline solution, 0.6%|Colorless and clear sodium chloride solution (0.6%)
219353414|NCT05432856|BEHAVIORAL|Time restricted eating, nutrition education, and sedentary time reduction strategies|"1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
219353415|NCT06310499|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
219353416|NCT06142643|DEVICE|Dermal Filler Device|Injection of the device by investigators according to the IFU
219353417|NCT03485820|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
219353418|NCT03485820|BEHAVIORAL|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
219353419|NCT05700435|BEHAVIORAL|Stress Management and Resilience Training|The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
219353420|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
219353421|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
219353422|NCT02959021|BEHAVIORAL|weight loss intervention - self directed|
219353423|NCT02959021|BEHAVIORAL|weight loss intervention - peer coach|
219353424|NCT04907760|OTHER|Personalized care program|It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
219353425|NCT04868604|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
219353426|NCT04868604|DRUG|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
219353427|NCT06545084|PROCEDURE|Leukocyte and Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin (L-PRF) is a collection of growth factors rich in proinflammatory cells that promote healing after dental surgery. A L-PRF clot is obtained by collecting blood from the subject, similar to a phlebotomist drawing blood via venipuncture. The blood samples are spun in a centrifuge using the recommended settings by the manufacture(1). The resultant product has separated the red blood cells from the L-PRF clot which is placed back into the subject to promote healing of the surgical site.
219353428|NCT04886089|DEVICE|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
219353429|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
219353430|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
219353431|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
219353432|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
219353433|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
219353434|NCT04685876|DRUG|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
219353435|NCT04685876|DRUG|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
219353436|NCT04685876|DRUG|Normal saline|placebo (normal saline).
219353437|NCT06503172|BIOLOGICAL|Taiwanese whole grain job's tear (red job's tear)|300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
219353438|NCT06503172|BIOLOGICAL|White job's tear|300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
219353439|NCT01358864|DRUG|BI 201335|BI 201335 once a day (QD) for 24 weeks
219353440|NCT01358864|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
219353441|NCT01358864|DRUG|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
219353442|NCT01358864|DRUG|Placebo|Placebo to BI201335 for 24 weeks
219353443|NCT06640036|OTHER|Rapeseed oil|During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
219353444|NCT06640036|OTHER|Butter|During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
219353445|NCT06640036|OTHER|Coconut oil|During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
219353446|NCT04479111|PROCEDURE|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
219353447|NCT02656485|DRUG|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
219353448|NCT02656485|DRUG|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
219353449|NCT01986543|DRUG|drug administration|
219353450|NCT03194373|DRUG|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
219353451|NCT03194373|DRUG|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
219353452|NCT00679705|DRUG|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
219353453|NCT00679705|DRUG|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
219353454|NCT00679705|DRUG|Placebo|Glucose 5%, IV
219353455|NCT02386150|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
219353456|NCT02428257|PROCEDURE|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
219353457|NCT02428257|DRUG|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
219353458|NCT02428257|DRUG|isobaric bupivacaine|0.5% isobaric bupivacaine
219353459|NCT02428257|DRUG|ephedrine|
219353460|NCT01526161|DRUG|inhaled fluticasone propionate|100 micrograms
219353461|NCT01526161|DRUG|salmeterol|50 m
219353462|NCT01526161|DRUG|Montelukast|Double blind double dummy
219353463|NCT02177201|OTHER|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
219353464|NCT02177201|OTHER|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
219353465|NCT01238458|DRUG|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
219353466|NCT05563506|BEHAVIORAL|Healthy Kids +|Three times a week for 30 weeks.
219353467|NCT02847130|OTHER|Informational Intervention|Participate in focus group
219353468|NCT02847130|OTHER|Interview|Undergo one-on-one interviews
219353469|NCT02847130|OTHER|Medical Chart Review|Review of medical chart
219353470|NCT02847130|OTHER|Questionnaire Administration|Ancillary studies
219353471|NCT06502171|DRUG|Cabozantinib Oral Tablet|"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."
219353472|NCT06502171|DRUG|Selumetinib Oral Capsule|"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."
219353473|NCT04261127|GENETIC|Genetic diagnosis (PMDA panel)|Blood samples for DNA study
219353474|NCT04261127|DIAGNOSTIC_TEST|Use of RADIAL algorithm|RADIAL card filling (contains clinical and biological data)
219353475|NCT04158648|DRUG|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
219353476|NCT04209855|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
219353477|NCT04209855|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
219353478|NCT04209855|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
219353479|NCT04209855|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
219353480|NCT04203615|DEVICE|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
219353481|NCT04203615|DEVICE|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
219353482|NCT06479681|BEHAVIORAL|Peer recovery coaching (PRC)|The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.
219353483|NCT06479681|BEHAVIORAL|Brief Intervention (SBIRT)|The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
219353484|NCT03528694|BIOLOGICAL|Durvalumab (MEDI4736)|Investigational product
219353485|NCT03528694|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Standard of care
219353486|NCT05442099|BEHAVIORAL|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
219353487|NCT05442099|BEHAVIORAL|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
219353488|NCT02860312|BEHAVIORAL|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
219353489|NCT02860312|BEHAVIORAL|Non-exercising group|Patients are having their usual physical activity
219353490|NCT02655965|DRUG|Ropivacaine|Ropivacaine 3.5 mg/ml
219353491|NCT02655965|DRUG|Clonidine|Clonidine 5µg/ml
219353492|NCT02655965|DRUG|Sodium Chloride|Sodium Chloride 0.9 %
219353493|NCT04338009|OTHER|Discontinuation of ARB/ACEI|The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
219353494|NCT04338009|OTHER|Continuation of ARB/ACEI|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
219353495|NCT01250379|DRUG|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
219353496|NCT01250379|DRUG|Chemotherapy|Standard chemotherapy (doublets not allowed)
219353497|NCT02358642|DRUG|Angiotensin converting enzyme inhibitor (Lisinopril)|
219353498|NCT02358642|DRUG|Placebo|
219353499|NCT05902364|OTHER|Systane Ultra PF lubricant eye drops|Commercially available preservative free eye drops
219353500|NCT02954497|DEVICE|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
219353501|NCT02954497|PROCEDURE|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
219353502|NCT02626507|DRUG|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
219353503|NCT02626507|DRUG|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
219353504|NCT02626507|DRUG|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
219353505|NCT02626507|DRUG|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
219353506|NCT02553512|OTHER|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
219353507|NCT00000625|DRUG|Zidovudine|
219353508|NCT00000625|DRUG|Zalcitabine|
219353509|NCT00000625|DRUG|Didanosine|
219353510|NCT03042507|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
219353511|NCT01489527|BIOLOGICAL|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
219353512|NCT01489527|OTHER|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
219353513|NCT01984268|DRUG|ACTHAR|
219353514|NCT04589104|BEHAVIORAL|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth"
219353515|NCT02566746|DEVICE|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
219353516|NCT02566746|DRUG|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
219353517|NCT06222840|OTHER|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
219353518|NCT06222840|OTHER|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
219353519|NCT06222840|OTHER|Clinical datas analysis|Clinical datas analysis
219353520|NCT06222840|OTHER|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
219353521|NCT05405283|BIOLOGICAL|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
219353522|NCT05405283|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
219353523|NCT04485312|BEHAVIORAL|preventive protocol|preventive protocol
219353524|NCT04485312|BEHAVIORAL|chlorhexidine added to the preventive protocol|chlorhexidine varnish added to the preventive protocol
219353525|NCT02922140|BEHAVIORAL|pharmaceutical care service|
219353526|NCT00800501|DRUG|sNN0029|Continuous ICV infusion at one of three dose levels
219353527|NCT00800501|DRUG|Placebo|Continuous ICV infusion
219353528|NCT04053738|DEVICE|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
219353529|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
219353530|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
219353531|NCT01394146|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
219353532|NCT04899232|DRUG|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
219353533|NCT00485212|DEVICE|compression bandage|
219353534|NCT03312959|DRUG|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
219353535|NCT03312959|DRUG|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
219353536|NCT00898560|DRUG|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
219353537|NCT00898560|DRUG|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
219353538|NCT04800536|OTHER|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
219353539|NCT04800536|OTHER|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
219353540|NCT01327157|PROCEDURE|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
219353541|NCT01327157|BEHAVIORAL|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
219353542|NCT04248439|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
219353543|NCT00248248|DRUG|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
219353544|NCT01380431|DRUG|Lisinopril|Tablets, 40 mg, single oral dose
219353545|NCT01380431|DRUG|lisinopril|Tablets, 40 mg, single, oral dose
219353546|NCT01380431|DRUG|Lisinopril|50% of subjects received the Par formulated product.
219353547|NCT05558540|DEVICE|spinal cord stimulator|By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
219353548|NCT02201407|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
219353549|NCT01344876|DRUG|OPB-51602|once daily during the treatment period
219353550|NCT04428424|DRUG|Enbrel|As provided in real world practice
219353551|NCT00381264|DRUG|Cesamet™ (nabilone)|
219353552|NCT04760925|DEVICE|CascadeTM, Non-Occlusive Remodeling Net|Temporary assistance device for coil embolization of intracranial aneurysms
219353553|NCT01781494|PROCEDURE|Immobilization followed by protected range of motion|
219353554|NCT01781494|PROCEDURE|Immediate range of motion|
219353555|NCT06287034|PROCEDURE|Primary suture|The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
219353556|NCT00441597|DRUG|atorvastatin|atorvastatine 80mg, during 3 days
219353557|NCT06269133|DRUG|REGN2810|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
219353558|NCT06269133|OTHER|Platinum-doublet chemotherapy|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
219353559|NCT06094257|DIAGNOSTIC_TEST|Sensory testing|Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
219353560|NCT07115043|DRUG|AZD6750|AZD6750- CD8 guided IL-2
219353561|NCT07115043|DRUG|rilvegostomig|Rilvegostomig- PD1-TIGIT bispecific antibody
219353562|NCT03110224|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
219353563|NCT07132970|DEVICE|Monoplus Suture Material|Ileocolic Anastomosis Construction using Monoplus Suture Material after open or laparoscopic surgery
219353564|NCT02180360|OTHER|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
219354972|NCT03315832|DRUG|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
219353565|NCT04818593|DEVICE|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
219353566|NCT04818593|OTHER|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
219353567|NCT04147104|DEVICE|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
219353568|NCT04147104|DEVICE|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
219353569|NCT04265183|OTHER|Placing preformed metal crowns using Hall technique.|Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
219353570|NCT01564862|DRUG|vortioxetine (Lu AA21004)|Lu AA21004 capsules
219353571|NCT01564862|DRUG|Duloxetine|Duloxetine capsules
219353572|NCT01564862|DRUG|Placebo|Placebo matching capsules
219353573|NCT06981780|DEVICE|Femoral artery Doppler|An experienced operator will conduct femoral artery examination for the change in Doppler indices namely pulsatility index, resisitive index, and waveform morphology
219353574|NCT06809179|DRUG|Fasedienol Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.
219353575|NCT06809179|DRUG|Fasedienol Nasal Spray - Fasedienol Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.
219353576|NCT06809179|DRUG|Placebo Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.
219353577|NCT02343354|BEHAVIORAL|Nutrition/physical activity intervention|Please see arm description
219353578|NCT01767675|PROCEDURE|Secondary Cytoreductive Surgery|
219353579|NCT01767675|DRUG|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
219353580|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|5 cycles
219353581|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|6 cycles
219353582|NCT06818734|OTHER|Clinical Decision Support Tool|The CDS in and AI algorithm that will alert clinicians only if patients have high risk of developing PPD, and provide clinicians with risk score, risk factors, and anticipatory actions with an order set to assist with ordering. Clinicians will make the ultimate clinical judgement after receiving CDS aid, including taking no actions towards PPD prevention. Clinicians will manage patients per usual care, including initiating PPD prevention such as conducting referrals to nutrition and behavioral health, suggest educational readings through patient portals, or no actions. Clinicians in the intervention arm will refer patients based on the CDS.
219353583|NCT06817499|OTHER|Nasal Insert + VNS|Participants will complete olfactory training with scented nose plugs along with VNS
219353584|NCT06817499|OTHER|Nasal Insert|Participants will complete olfactory training with scented nose plugs
219353585|NCT05798338|DIAGNOSTIC_TEST|Blood sample|Analysis of plasma in order to quantify and characterize EVs
219353586|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
219353587|NCT04319107|OTHER|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
219353588|NCT00603759|DRUG|celecoxib|100 mg qid
219353589|NCT00603759|DRUG|placebo|1 cap qid
219353590|NCT06299293|OTHER|Facial Emotion Recognition Test|In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
219353591|NCT06984744|DEVICE|MIIP-E2 containing gum|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit. MIIP-E2 is an ultrapure (\>99%) fully native and completely active form of bovine lactoferrin purified directly from raw milk.
219353592|NCT06984744|DEVICE|placebo gum without MIIP-E2|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit.
219353593|NCT04526665|DRUG|Elafibranor 80mg|Elafibranor 80mg daily
219353594|NCT04526665|DRUG|Placebo|Placebo daily
219353595|NCT06746831|DRUG|S-(+)-methamphetamine|15 mg
219353596|NCT06746831|DRUG|R-(-)-methamphetamine|15 mg
219353597|NCT06746831|DRUG|1:1 racemic mixture of two isomers|15 mg R-Meth + 15 mg S-Meth
219353598|NCT06538480|DRUG|PRGN-2012|PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
219353599|NCT06527391|DRUG|choline bitartrate|Daily supplementation for 9 months with 200 mg choline bitartrate
219353600|NCT06527391|OTHER|placebo drug|Daily supplementation for 9 months with identical placebo
219353601|NCT07000045|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy device used for calcium modification in coronary lesions, using either operator-determined or maximum pulsed numbers for lesion preparation prior to stenting.
219353602|NCT07000045|DEVICE|Rotational atherectomy|Rotational atherectomy device used to debulk calcified nodules before IVL and stent implantation.
219353603|NCT07001748|DRUG|Standard of Care Chemotherapy|The most common regimens are FOLFOX, CAPOX, FLOT, CF, and CX. Other local institutional standard of care regimens as well as targeted agents for gastric/GEJ adenocarcinoma are allowed.
219353604|NCT07001748|PROCEDURE|Biospecimen Collection|Plasma is to be submitted at baseline and every three months for the first year or until progression, whichever comes first. For patients who have progression, their last plasma sample should be at time of progression.
219353605|NCT07001748|PROCEDURE|Computed Tomography|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
219353606|NCT07001748|PROCEDURE|Diagnostic Laparoscopy|After induction of general anesthesia, administration of preoperative antibiotics and placement of appropriate laparoscopic ports, peritoneal lavage will be performed by instillation of 200 ml of normal saline in the left upper quadrant and allowed to dwell for 5 minutes after which it will be aspirated for cytology. Extent of peritoneal disease burden will be ascertained as per the Peritoneal Cancer Index (PCI) scoring system as outlined in Appendix V.
219353607|NCT07001748|PROCEDURE|Intraperitoneal Port Placement|Patients assigned to Arm B will undergo placement of indwelling tunneled intraperitoneal port with Teflon cuff following Step 1 randomization and during the diagnostic laparoscopy procedure.
219353608|NCT07001748|PROCEDURE|Magnetic Resonance Imaging|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
219353609|NCT07001748|DRUG|Intraperitoneal Paclitaxel|"Patients on Arm B will start systemic therapy + intraperitoneal paclitaxel as early as the day after Step 1 randomization and must start within 30 calendar days (including holidays) after Step 1 randomization as per the schedule shown in the table below.~Therapy will be administered on Days 1 and 8 of a 21-day cycle for 4 cycles."
219353610|NCT06617143|OTHER|mindfulness-based cognitive therapy|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
219353611|NCT06617143|OTHER|routine treatment and care|routine treatment and care
219353612|NCT06547021|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
219353613|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
219353614|NCT06547021|DEVICE|Theta Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
219354973|NCT03315832|DRUG|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
219353615|NCT06547021|DEVICE|Sham|"Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
219353616|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)-Precuneus|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
219353617|NCT07006441|OTHER|Preoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
219353618|NCT07006441|OTHER|Postoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
219353619|NCT06679101|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
219353620|NCT06679101|DRUG|Lenalidomide|Lenalidomide will be administered.
219353621|NCT06679101|DRUG|Dexamethasone|Dexamethasone will be administered.
219353622|NCT06679101|DRUG|Daratumumab|Daratumumab will be administered.
219353623|NCT07133880|DRUG|umeclidinium 62.5 µg and vilanterol 25 µg|DPI Treatment
219353624|NCT07133880|DRUG|Revefenacin 175 µg, Formoterol 20 µg|Nebulizer Treatment
219353625|NCT07133880|DRUG|Placebo ( Revefenacin and Formoterol )|Placebo Nebulizer Treatment
219353626|NCT07133880|DRUG|Placebo DPI|Placebo DPI Treatment
219353627|NCT07134114|PROCEDURE|Hall Technique|"Procedure: Hall Technique A preformed stainless-steel crown will be placed on a primary molar using the Hall Technique. This approach does not require local anesthesia, caries removal, or tooth preparation.~Digital Scan and Bite Registration Schedule:~* T0 (Baseline): Immediately before crown placement~* T1 (Immediate): Immediately after crown placement~* T2 (Two Weeks): Two weeks after crown placement~* T3 (One Month): One month after crown placement At each time point (T0-T3), digital scans of both the upper and lower arches will be obtained, and a bite registration will be recorded. These records will be used to generate three-dimensional digital models, which will be analyzed to assess occlusal relationships and monitor changes over time."
219353628|NCT07127380|PROCEDURE|Midline Lumbar Interbody Fusion (MIDLIF)|Midline Lumbar Interbody Fusion (MIDLIF) is a procedure utilizes a medial approach to the spine, involving the retraction of the segmental back muscles to expose the lamine and articular processes. Screw placement is medialized, with entry to a point along the pars intercularis or joint surface. It places the screw through potentially more cortical and stronger bone. Decompression is achieved by resecting the inferior articular process and lamina marginalis, followed by a discectomy. Subsequently, a transforaminal lumbar interbody fusion (TLIF) is performed to place an interbody cage and promote fusion.
219353629|NCT07127380|PROCEDURE|Minimally Invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF)|Minimally invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF) is a procedure that employs a percutaneous approach for pedicle screw placement through the pedicles. Decompression is performed using a lateral approach, with 2-3 cm lateral to the ipsilateral borders. This is followed by resection of the inferior articular process and removal of the ligamentum flavum, facilitating discectomy. An interbody cage is then inserted to achieve fusion.
219353630|NCT07008989|BEHAVIORAL|Memory replay|"Within the HippoCamera application, half of all recorded events will be categorized as baseline memories, and half will be categorized as replay memories.~Baseline memories are recorded, but never viewed by the participant again until the Early HippoCamera test at the end of the 12-week intervention.~Replay memories are recorded, and then placed into a memory gallery. HippoCamera uses a research-based algorithm to select 5 memories from this gallery for participants to replay each day. Prior research has shown that this replay is associated with significant memory enhancements for replayed v. baseline memories for HippoCamera users from other populations."
219353631|NCT07004205|OTHER|The ARCS Motivation Model Education|The ARCS Motivation Model Education-focused on Attention, Relevance, Confidence, and Satisfaction
219353632|NCT07005505|OTHER|Pressure Support Ventilation (PSV)|Spontaneous breathing trials will be conducted using the mode pressure support ventilation (PSV) with settings of a pressure support of 5 cmH2O and positive end expiratory pressure (PEEP) 5 cmH2O.
219353633|NCT07005505|OTHER|Automatic tube compensation (ATC)|Spontaneous breathing trials will be conducted using the mode automatic tube compensation (ATC) with settings of 100% tube compensation and a positive end expiratory pressure (PEEP) of 5 cmH2O.
219353634|NCT04586010|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
219353635|NCT04586010|DRUG|Teriflunomide|Participants will receive teriflunomide.
219353636|NCT04586010|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
219353637|NCT06310525|OTHER|Drowning incident|"Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid."
219353638|NCT07025343|OTHER|Lipid emulsion|Patients (\>70kg will receive 100 ml, \<70 will receive 1.5ml/kg) of 20% intravenous lipid emulsion at the end of surgery as a study group.
219353639|NCT07029646|DEVICE|EndoScell™ intraoperative handheld microscope|The research instrument used is the EndoScell™ intraoperative handheld microscope, which employs the principle of epifluorescence. It is a miniaturized microscope that reduces the size of a traditional large optical microscope by approximately a thousand times. It is the world's first handheld micrometer-level intraoperative real-time cell imaging probe microscope. This microscope is equipped with high-definition, real-time, anti-shake, and full-coverage scanning features. It can rapidly investigate the structure and cell morphology of tissues in real-time.
219353640|NCT07029295|OTHER|Sending a link to the video|Sending a link to the educational video (3 min, 34 sec.) prepared as part of the study, explaining the importance of proper preparation and the diet to follow.
219353641|NCT07029295|BEHAVIORAL|Compliance questionnaire|Patient completes a questionnaire on compliance with preparation instructions on the day of the imaging test.
219353642|NCT07029295|BIOLOGICAL|Determination of beta-hydroxybutyrate (BHB) in capillary blood|Determination of beta-hydroxybutyrate (BHB) in capillary blood prior to imaging examination.
219353643|NCT07029113|OTHER|Task-oriented trainig|In addition to MCP, PIP, DIP joint mobilisation and isometric exercises, the task-oriented training group will perform 30 repetitions of face washing, using a fork, drinking water with a glass, sitting and wearing a t-shirt exercises.
219353644|NCT07029113|OTHER|Mulligan mobilization|In patients included in the Mulligan mobilisation group, the therapist will apply a dorsal shift from the distal radius to the carpal bones and the patient simultaneously extends the wrist. It is essential that the movement is painless; if any pain occurs during mobilisation, the direction or technique is re-evaluated. This application is performed in 8-10 repetitions and the frequency of the session is planned according to the patient's symptoms.
219353645|NCT07029113|OTHER|Conventional treatment|Passive range of motion exercises, metacarpopalangeal, proximal interphalangeal and distal interphalangeal joint mobilisation and isometric exercises will be applied. Isometric exercises will be performed as 30 repetitions, while joint mobilisations will be performed by the therapist as moderate anteroposterior and mediolateral shifts.
219353646|NCT03895866|OTHER|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
219353647|NCT07028151|OTHER|manual therapy|"Participants who meet the inclusion criteria will be evaluated following the acquisition of written informed consent. Treatment will be administered with participants in the supine position. Initially, soft tissue mobilization will be applied to the cervical extensor muscle group, followed by gentle cervical vertebral traction. Subsequently, a classical facial massage will be performed. The massage will include the suprahyoid muscles and the medial pterygoid. Intramuscular stretching and friction massage techniques will be applied to the masseter and anterior temporalis muscles. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions."
219353648|NCT07028151|OTHER|Conventional Therapy|Participants who meet the inclusion criteria will be evaluated after providing written informed consent. Treatment will be administered with participants in the supine position. Protective goggles will be placed on the participants' eyes prior to the infrared therapy application. Following 20 minutes of infrared treatment, ultrasound (1 MHz) will be applied to the masseter muscle using the full-contact method for 3 minutes. Finally, transcutaneous electrical nerve stimulation (TENS) will be applied to the masseter and anterior temporalis muscles for 15 to 20 minutes. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions.
219353649|NCT07029139|DRUG|JMT601 Injection|In accordance with the protocol
219353650|NCT07029139|DRUG|Rituximab|In accordance with the protocol
219353651|NCT07029139|DRUG|Cyclosporin Capsules|In accordance with the protocol
219353652|NCT07028411|BEHAVIORAL|Educational board game|The educational board game will be administered once for a duration of 90 minutes, consisting of a gameplay session followed by a debriefing.
219353653|NCT07028411|BEHAVIORAL|Lecture|The lecture will be administered once for a duration of 90 minutes, consisting of video lecture followed by question and answer (QnA) session.
219353654|NCT07029009|DRUG|Liraglutide|Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.
219353655|NCT06876935|OTHER|Daily avocado|Infants in the daily avocado group will receive a daily exposure amount of avocado ranging from 1/4 (\~37.5 g or 1.25 oz) to 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado. At 6-8 months, infants will be provided 1/4 (\~37.5 g or 1.25 oz) of a medium-sized avocado for daily consumption. Then from 9-12 months, they will begin receiving 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado for daily consumption.
219353656|NCT07137143|OTHER|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.
219353657|NCT07027995|BEHAVIORAL|Exercise is Medicine (EIM)|During Phase 1 (Weeks 1-12), participants are enrolled in a comprehensive 12-week fitness education and training program.
219353658|NCT07027995|BEHAVIORAL|Culinary Education|During Phase 1 \& 2, participants receive monthly hybrid cooking demonstrations with culinary training.
219353659|NCT07027995|BEHAVIORAL|Food is Medicine|During Phase 1 (Weeks 1-12), participants receive bi-weekly medically tailored grocery vouchers.
219353660|NCT07027995|BEHAVIORAL|Nutrition Counseling|During Phase 1 (Weeks 1-12), participants engage in weekly behavioral nutrition counseling.
219353661|NCT07027995|BEHAVIORAL|Participant Website|During Phases 1 and 2, participants will receive digital behavioral reinforcers and access to a secure web portal that provides evidence-based resources.
219353662|NCT07028541|DEVICE|Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children|This is a first-in-child clinical investigation of a bioresorbable magnesium alloy DrillPin (RemeOs™) for fixation of distal radius fractures in children aged 5 to \<14 years. The implant is investigational, not CE-marked or FDA-approved, and represents a novel alternative to traditional metallic implants. It gradually degrades in vivo, eliminating the need for removal. The study focuses on safety and feasibility in a pediatric population, supported by preclinical data from a similar Mg-based RemeOs™ Screw. The DrillPin's material and design are intended to support bone healing without growth disturbances, offering a state-of-the-art, bioresorbable solution tailored for growing patients.
219353663|NCT06768463|PROCEDURE|Cytoreductive Gastrectomy|The patients undergo gastrectomy after 4 cycles of systemic therapy
219353664|NCT07132073|RADIATION|Brachytherapy + SBRT|Brachytherapy + SBRT
219353665|NCT07078760|PROCEDURE|CTI radiofrequency ablation.|Cavotricuspid Isthmus ablation
219353666|NCT05077137|BIOLOGICAL|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
219353667|NCT05077137|BIOLOGICAL|Polio Boost Immunization|trivalent inactivated polio vaccine
219353668|NCT06863480|DRUG|tocilizumab-aazg (TYENNE)|A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.
219353669|NCT05043012|DEVICE|flexible AIR coil|mpMRI scan
219353670|NCT05043012|DEVICE|endorectal coi|mpMRI scan
219353671|NCT02028455|BIOLOGICAL|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
219353672|NCT00648635|BEHAVIORAL|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
219353673|NCT07078461|DEVICE|1927-nm Thulium Laser therapy|The investigators will use the LaseMD LEO Laser System (1927-nm Thulium laser) to create controlled, localized microscopic treatment zones (MTZs) of thermal injury to treatment area (unilateral upper arm). The investigators will utilize the random mode using the C1 tip (spot size 200 micrometers), which involves irradiation of the entire upper arm until diffuse erythema and edema appear. Additionally, the investigators may use the C5 tip (350 micrometers spot size) for focused treatment, up to five passes, until coagulation becomes evident. The maximum fluence for all C1 tip is 3-60 J/cm2 and 1-20 J/cm2 for C5 tips. The maximum pulse energy is 20 J with a pulse duration of 20 ms.
219353674|NCT06902584|DEVICE|comfilcon A Sphere lens|2 hours of wear
219353675|NCT06902584|DEVICE|comfilcon A Toric lens|2 hours of wear
219353676|NCT06902584|DEVICE|comfilcon A Multifocal lens|2 hours of wear
219353677|NCT06902584|DEVICE|comfilcon A Multifocal Toric lens|2 hours of wear
219353678|NCT06902584|DEVICE|comfilcon A Energys lens|2 hours of wear
219353679|NCT07093580|DRUG|S-892216-LAI|S-892216-LAI injection will be administered per schedule specified in the arm description.
219353680|NCT07093580|DRUG|Placebo|Physiological saline will be administered per schedule specified in the arm description.
219353681|NCT07097545|BEHAVIORAL|Mindfulness|15 minute daily guided meditation
219353682|NCT07097545|BEHAVIORAL|Social Media Reduction|Reduce social media use at least 30 minutes daily and exercise instead
219353683|NCT07097545|BEHAVIORAL|Exercise|Participants will exercise at least 30 minutes daily. Participants are given examples of common exercises (walking, yoga, strength training, etc.), but are allowed to choose any type, although dissuaded from activities with high potential for injury.
219353684|NCT07135427|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Administration of PCV20
219353685|NCT05554133|DEVICE|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
219353686|NCT05554133|DEVICE|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
219353687|NCT05554133|DRUG|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
219353688|NCT06918548|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
219353689|NCT06918548|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
219353690|NCT06916702|DRUG|BI 3031185|BI 3031185
219353691|NCT06916702|DRUG|Midazolam|Midazolam
219353692|NCT06916702|DRUG|Placebo|Placebo matching BI 3031185
219353693|NCT06922539|DRUG|Fenretinide|Intravenous administration
219353694|NCT06922539|DRUG|Fenretinide|Intravenous administration
219353695|NCT07110636|DIAGNOSTIC_TEST|Metagenomic plasma-based test for agnostic pathogen detection|Karius Spectrum metagenomic plasma-based test.
219353696|NCT06923462|OTHER|Communication Application|Participants will receive the VoiceLove intervention versus the standard care which does not utilize VoiceLove.
219353697|NCT06931301|DEVICE|Hyperbaric Oxygen Therapy|Sechrist Monoplace Hyperbaric Chamber Model 3600, Chamber will be used to supply patients with 100% oxygen to breathe at 2-2.4 ATA (the equivalent of diving to 33 - 45 feet of sea water) for two hours, 5 treatments per week
219353698|NCT07123285|DEVICE|Photobiomodulation plus Compression Therapy|This intervention uses a low-level laser device with 8 emitters, including 4 red emitters at 660 nm and 4 infrared emitters at 808 nm. Each emitter delivers 6 Joules of energy at 100 mW power, with a total power output of 800 mW. Treatment is administered twice weekly over 16 weeks, totaling 32 sessions per participant. The device is used in combination with standard compression therapy for venous leg ulcer management.
219353699|NCT07123285|DEVICE|Compression Therapy plus Sham Photobiomodulation|This intervention uses a sham photobiomodulation therapy with the same laser device used in the active group but without emission of therapeutic laser light (inactive device). The device appears identical and the treatment sessions are conducted twice weekly over 16 weeks, totaling 32 sessions per participant. Participants also receive standard compression therapy for venous leg ulcer management. This sham procedure is designed to mimic the active treatment without delivering any laser energy, serving as a placebo control.
219353700|NCT07132060|RADIATION|MR-guided Irradiation|MR-guided Irradiation
219353701|NCT07132034|PROCEDURE|Acupuncture|8 sessions of acupuncture treatment (body and auricular acupuncture) will be given once a week after randomization.
219353702|NCT07132034|OTHER|Standard supportive care|Supportive care according to local standards will be given which may also include face-to-face psychosocial support or the participation of support groups
219353703|NCT07137273|BEHAVIORAL|Operant Conditioning Tasks with Reinforcement Manipulations|This behavioral intervention involves structured operant conditioning tasks. Reinforcement parameters (e.g., schedule arrangement, magnitude, and probability) are systematically manipulated to evaluate their effects on behavioral allocation. The primary objective is to assess how variations in reinforcement contingencies influence choice patterns. The procedures are designed to examine fundamental behavioral processes rather than to provide therapeutic benefit.
219353704|NCT07143058|PROCEDURE|Flaps reconstruction in head and neck in oral cance|Follow up and quality of life of reconstruction flaps in head and neck
219353705|NCT07143058|PROCEDURE|Flap of head and neck|All types of flaps in oral cancer reconstruction
219353706|NCT07142993|BEHAVIORAL|Social Media-Based Nursing Intervention|A structured nursing follow-up program delivered through a WeChat group. The program included regular sharing of educational content (articles, videos), personalized care advice, remote photo-based monitoring by medical staff, and peer support within the group. The intervention was managed by a dedicated team of dermatologists and nurses.
219353707|NCT07142993|BEHAVIORAL|Conventional Nursing Care|A standard care follow-up protocol involving verbal education at discharge, provision of printed health materials, and proactive weekly telephone calls to monitor the patient's condition, correct improper self-care actions, and encourage clinic visits if necessary.
219353708|NCT07142876|PROCEDURE|Liver resection Cavitron Ultrasonic Surgical Aspirator (CUSA)|In-group A Cavitron Ultrasonic Surgical Settings Aspirator (CUSA) with standard tip was used for parenchymal transection with the following Settings; 23 kHz, 70 Watt, and continuous irrigation at rate of 4-6 ml/min with normal saline and the vessel coagulation was performed by the bipolar sealer (Valleylab force FX electrosurgical generator, Medtronic, Minneapolis, USA), the power was used at 50 Watt coagulation.
219353709|NCT07142876|PROCEDURE|Liver resection with the harmonic scalpel|In group B the harmonic scalpel (Ethicon EndoSurgery, Johnson \& Johnson, New Jersey, USA) was set at a high power, and blood vessels or bile ducts up to 3-4 mm in diameter were coagulated for 5-6 seconds.
219353710|NCT07144384|PROCEDURE|Biopsy Procedure|Undergo SOC biopsy
219353711|NCT07144384|BIOLOGICAL|Natural Killer Cell Therapy|Given UD expanded NK cells intratumorally
219353712|NCT07144384|PROCEDURE|Surgical Procedure|Undergo SOC excision
219353713|NCT07144384|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given intratumorally
219353714|NCT07142694|DIETARY_SUPPLEMENT|Plant Based pudding|Will consume one high protein plant based pudding daily for 7-days per week for 12 weeks
219353715|NCT07143539|OTHER|Exercise-based rehabilitation program|Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.
219353716|NCT07143916|PROCEDURE|bonded anterior bite turbos|Sixty patients with anterior deep bite malocclusion were treated with composite bite turbos bonded to the maxillary central incisors. A questionnaire form using the Likert scale with 5 responses (very unpleasant, unpleasant, acceptable, pleasant and very pleasant) was used by patients to document their satisfaction and feedback regarding the bite turbos after 1 week and 1 month.
219353717|NCT07142889|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
219353718|NCT07142889|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
219353719|NCT07142889|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
219353720|NCT07143149|DEVICE|the Intelligent Lipid Management Decision-support System|Doctor's Side: Long-term lipid management support based on guidelines/consensus• Provides lipid management pathways based on guidelines/consensus to ensure clinical decisions align with the latest standards.• Combines individualized patient data to offer intelligent lipid management and medication suggestions.• Provides medical education support to enhance doctors' awareness of guidelines, consensus, and management strategies.Patient's Side: Personalized lipid risk assessment and regular reminders• Based on the lipid test reports uploaded by patients via photos, provides lipid test reports tailored to the patient's risk stratification.• Uses digital tools to regularly remind patients, optimizing follow-up adherence and medication compliance.
219353721|NCT07142759|OTHER|Precision Bred Provitamin D-rich Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
219353722|NCT07142759|OTHER|Precision Bred Vitamin D-rich Tomato Soup|Participants will consume one tomato soup everyday for 21-days as part of their normal diet.
219353723|NCT07142759|OTHER|Wild-type (store-bought) Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
219353724|NCT07142759|OTHER|Wild-type (store-bought) Tomato with vitamin D supplementation Soup|Participants will consume one tomato soup everyday for 21 days as part of their normal diet.
219353725|NCT07144124|DIETARY_SUPPLEMENT|Biopro-max 8 Billion Probiotics (Bioserv Healthcare)|Participants in the intervention arm will receive Biopro-Max 8 Billion Probiotics (Bioserv Healthcare). The supplement will be administered as one bottle per day for 15 consecutive days in addition to standard ICU care. The intervention is intended to evaluate whether daily probiotic supplementation reduces the incidence of ICU-acquired infections and improves related clinical outcomes, including inflammatory and immune markers, feeding tolerance, muscle changes, and mortality.
219353726|NCT07143136|DRUG|Colchicine|Administration of Colchicine 1 day before and 90 days after PCI in Non-STEMI Patients
219353727|NCT07143136|DRUG|Placebo|Matching Placebo Regimen
219353728|NCT07144098|DRUG|GZR18 injection|3 mg-Control group
219353729|NCT07144098|DRUG|GZR18 injection|3 mg-mild liver insufficiency
219353730|NCT07144098|DRUG|GZR18 injection|3 mg-moderate liver insufficiency
219353731|NCT07144098|DRUG|GZR18 injection|3 mg-severe liver insufficiency
219353732|NCT07143318|DRUG|KLA578-1 for injection|Intravenous injection, single dose
219353733|NCT07143318|DRUG|Etopcoxib Tablets|P.O., single dose
219353734|NCT07143292|DRUG|Famitinib + Camrelizumab|Famitinib + Camrelizumab
219353735|NCT07143799|DRUG|Cisatracurium|Induction of general anesthesia will be done by IV propofol 2-2.5 mg / kg and IV fentanyl lug/kg. After IV Cis-atracurium 0.15mg/kg, endotracheal intubation will be done.
219353736|NCT07143799|OTHER|scalp block|The scalp block will target six pairs of sensory nerves that innervate the scalp: the supraorbital nerve, supratrochlear nerve, auriculotemporal nerve, zygomaticotemporal nerve, greater occipital nerve, and lesser occipital nerve. Local anesthetic (2% lidocaine and bupivacaine) will be infiltrated at specific anatomical landmarks corresponding to the course of each nerve.
219353737|NCT07142915|OTHER|light-blocking lenses|Subjects will be instructed to wear light-blocking lenses full-time for 12 months.
219353738|NCT07142915|OTHER|single-vision lenses|Subjects will be instructed to wear single-vision lenses full-time for 12 months.
219353739|NCT07144449|BEHAVIORAL|Nurse-Led ePRO System|A nurse-designed electronic patient-reported outcome (ePRO) system for chemotherapy patients. Participants complete weekly symptom assessments for 12 weeks through an electronic platform. The system provides automated feedback, evidence-based self-care advice, and alerts to oncology nurses. Nurses follow up with weekly phone calls if severe symptoms are reported. This intervention is intended to improve symptom self-management, quality of life, and health literacy.
219353740|NCT07144449|BEHAVIORAL|Usual Care|Participants will receive standard oncology care without the use of an ePRO system. Symptom monitoring and management will be provided according to routine clinical practice by the treating oncology team, typically during scheduled visits or when patients proactively report problems.
219353741|NCT07144774|DEVICE|Fitbit wrist-worn Inspire 2® activity tracker (Fitbit Inc., San Francisco, CA, USA)|Visual feedback of the physical activity level
219353742|NCT07143175|OTHER|Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation|"The CARE-D-FOOT-Nav (Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation) program is a patient navigator intervention that aims to increase access to guideline-concordant multidisciplinary DFU care to improve DFU healing.~CARE-D-Foot-Nav is a diabetes educator who will serve as a dedicated Diabetic Foot Ulcer (DFU) patient navigator. The navigator will assist the subjects with diabetic foot ulcer care.~Based on community input, navigators will conduct 30-to 60-minute encounters, either by phone or in person, at least once a week during the 20-week program. Additional contact may be warranted to coordinate appointments and transportation. Participants can call the navigator with DFU-related concerns at any time during the navigator's working hours. The overarching goal of the navigator is to help patients access the four key pillars of DFU care, thereby optimizing the chances of DFU healing."
219353743|NCT07142941|DIETARY_SUPPLEMENT|HMB|Participants were instructed to take active products including 3000 mg calcium-HMB per day
219353744|NCT07142941|BEHAVIORAL|Exercise|Participants allocated to the exercise programs were provided 45 min of supervised sessions on 2 nonconsecutive days per week
219353745|NCT07142941|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to take active products including equal in quality resistant dextrin per day
219353746|NCT07142941|OTHER|Education|Participants were given health education and educational manuals
219353747|NCT00380328|DRUG|neratinib|HKI-272
219353748|NCT02396589|BEHAVIORAL|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
219353749|NCT02396589|BEHAVIORAL|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
219353750|NCT03899987|DRUG|EC Aspirin|Given PO
219353751|NCT03899987|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
219353752|NCT03899987|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
219353753|NCT03899987|DRUG|Rintatolimod|Given IV
219353754|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
219353755|NCT05406635|DIAGNOSTIC_TEST|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
219353756|NCT06800014|OTHER|Telerehabilitation|Participants in the telerehabilitation group will receive weekly home exercise instructions through a mobile application installed on their or their caregivers' smartphones, in addition to their standard rehabilitation program. These instructions will include videos, reminders, and directives for the exercises, with compliance monitored through mini-surveys delivered via the app.
219353757|NCT06800014|OTHER|Conventional exercise|Participants in the conventional exercise group will continue their standard rehabilitation program supplemented with printed home exercise instructions, including visuals and text, similar to the content provided to the TG.
219353758|NCT00836134|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
219353759|NCT00836134|PROCEDURE|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
219353760|NCT05570123|DIETARY_SUPPLEMENT|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
219353761|NCT05570123|DIETARY_SUPPLEMENT|Placebo|2 tablets a day, one in the morning, one in the evening
219353762|NCT00510627|DEVICE|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
219353763|NCT00510627|DRUG|Chemotherapy|Standard of care chemotherapy regimen
219353764|NCT01461174|DRUG|Modafinil|200 mg tablet, single dose
219353765|NCT01461174|DRUG|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
219353766|NCT01461174|DRUG|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
219353767|NCT04381442|RADIATION|Low Level Laser Therapy|
219353768|NCT04156555|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
219353769|NCT02381431|DEVICE|FLIR ONE|
219353770|NCT03508492|OTHER|Surgical tinted Chloraprep® applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
219353771|NCT03508492|OTHER|Surgical tinted Nex Clorex 2% applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
219353772|NCT05689931|BIOLOGICAL|Mepolizumab|"Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)"
219353773|NCT05689931|DRUG|Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)|Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
219353774|NCT01761266|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
219353775|NCT01761266|DRUG|Sorafenib|400 mg twice daily (BID) oral dosing.
219353776|NCT02802605|DRUG|Bemiparin|Bemiparin subcutaneus administration
219353777|NCT05313997|DRUG|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
219353778|NCT01540799|DEVICE|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
219353779|NCT03283631|BIOLOGICAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
219353780|NCT01284114|DRUG|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
219353781|NCT01984255|DRUG|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
219353782|NCT01984255|DRUG|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
219353783|NCT03936387|DRUG|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
219353784|NCT01418547|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
219353785|NCT06840808|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
219353786|NCT06840808|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
219353787|NCT02007551|BEHAVIORAL|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
219353788|NCT03445000|DRUG|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
219353789|NCT03409744|DRUG|evinacumab|Intravenous (IV) administration
219353790|NCT02532231|OTHER|Laboratory Biomarker Analysis|Correlative studies
219353791|NCT02532231|BIOLOGICAL|Nivolumab|Given IV
219353792|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
219353793|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
219353794|NCT05819866|DRUG|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
219353795|NCT05819866|DRUG|Placebo|Placebo will match the study drug visually and by taste
219353796|NCT05951608|DRUG|AK127 in combination with AK112|AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years
219353797|NCT04693000|DRUG|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
219353798|NCT04035317|DRUG|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
219353799|NCT04035317|DRUG|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
219353800|NCT00748579|DRUG|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
219353801|NCT00748579|DRUG|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
219353802|NCT03707535|BIOLOGICAL|CT-P13|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
219353803|NCT03707535|BIOLOGICAL|Remicade|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
219353804|NCT04994106|DRUG|AZD5462|Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
219353805|NCT04994106|DRUG|Placebo|Participants will receive Placebo matched to AZD5462.
219353806|NCT04756375|DEVICE|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
219353807|NCT04756375|OTHER|Usual Care|Usual management of sickle cell patients with VOS
219353808|NCT02977195|DRUG|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
219353809|NCT02700737|OTHER|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
219353810|NCT02700737|OTHER|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
219353811|NCT03770065|DEVICE|VML-0001|Medical device
219353812|NCT00142883|DRUG|Pregabalin|pregabalin compared to placebo
219353813|NCT00142883|DRUG|placebo|sugar pill compared to pregabalin
219353814|NCT03591380|DRUG|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
219353815|NCT06109480|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
219353816|NCT06109480|DEVICE|Sham High definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
219353817|NCT06109480|DEVICE|electroconvulsive therapy device|ECT induces brief generalized epileptic seizures by electric current to stimulate the forehead under general anesthesia
219353818|NCT00145405|DRUG|Lanreotide Autogel and Octreotide LAR|
219353819|NCT06501755|DEVICE|transcranial alternating current stimulation (tACS)|Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
219353820|NCT01935843|BIOLOGICAL|CART-HER-2|
219353821|NCT01014117|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
219353822|NCT01014117|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
219353823|NCT05150366|PROCEDURE|Trans thoracic echocardiography|trans thoracic echocardiography at the beggining and at the end of the placement of the Saint Jude Medical AMULET type prosthesis
219353824|NCT03412773|DRUG|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
219353825|NCT03412773|DRUG|Sorafenib|400 mg twice daily (BID), oral dosing
219353826|NCT01348646|BEHAVIORAL|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
219353827|NCT01175746|DRUG|Nicardipine|
219353828|NCT01175746|DRUG|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
219353829|NCT04244929|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
219353830|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
219353831|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
219353832|NCT01869647|RADIATION|Ultra low dose CT scan|Ultra low dose CT scan
219353833|NCT01869647|RADIATION|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
219353834|NCT01869647|RADIATION|No imaging|No imaging
219353835|NCT04922411|DEVICE|STN DBS|PD patients with DBS STN will be scanned and tested with DBS ON and OFF
219353836|NCT00775580|DRUG|Atenolol 100mg Tablets|
219353837|NCT03917602|PROCEDURE|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
219353838|NCT00694057|DRUG|HE3286|HE3286 10 mg per day (5 mg BID)
219353839|NCT00694057|DRUG|Placebo|Placebo capsules BID
219353840|NCT04357457|DRUG|Almitrine|Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
219353841|NCT04357457|DRUG|Placebo|Intravenous glucose 5% during 5 days
219353842|NCT02574533|BIOLOGICAL|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
219353843|NCT02574533|DRUG|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
219353844|NCT04508660|DRUG|CGB-400|BID application
219353845|NCT01961479|BEHAVIORAL|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
219353846|NCT01961479|OTHER|Waiting list|During the waiting period, participants receive no treatment.
219353847|NCT03716089|PROCEDURE|Laparoscopic resection|Laparoscopic surgery under general anesthesia
219353848|NCT00388050|BEHAVIORAL|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
219353849|NCT00388050|BEHAVIORAL|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
219353850|NCT02212132|OTHER|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
219353851|NCT00002800|BIOLOGICAL|filgrastim|
219353852|NCT00002800|BIOLOGICAL|lintuzumab|
219353853|NCT00002800|DRUG|cytarabine|
219353854|NCT00002800|DRUG|etoposide|
219353855|NCT00002800|DRUG|idarubicin|
219353856|NCT00865384|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
219353857|NCT00865384|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
219353858|NCT02828072|OTHER|SKY therapy|slow breathing
219353859|NCT02828072|DRUG|usual drug therapy|
219353860|NCT01076465|OTHER|Disease management program|1\. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
219353861|NCT01076465|BEHAVIORAL|Usual care|Usual care
219353862|NCT03394560|DEVICE|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
219353863|NCT03394560|DEVICE|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
219353864|NCT03390413|PROCEDURE|Robot|Renal cancer treated with robotic surgery
219353865|NCT03390413|PROCEDURE|Cryoablation|Renal cancer treated with cryoablation
219353866|NCT00859365|PROCEDURE|Real Acupuncture|Real acupuncture treatment in real acupuncture points
219353867|NCT00859365|PROCEDURE|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
219353868|NCT00859365|PROCEDURE|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
219353869|NCT01976923|DRUG|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
219353870|NCT01976923|PROCEDURE|Small-gauge pars plana vitrectomy|
219353871|NCT00699348|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
219353872|NCT05410548|OTHER|Standard-of-Care|Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
219353873|NCT05410548|OTHER|Clinical Screening|Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
219353874|NCT03509220|DRUG|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
219353875|NCT03509220|DRUG|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
219353876|NCT02599584|BEHAVIORAL|precritical staff|free pre critical scenario team staff
219353877|NCT05233657|DRUG|JX11502MA|Oral capsule
219353878|NCT05233657|DRUG|Placebo|Oral capsule
219353879|NCT00135304|DRUG|Sensipar®|Cinacalcet hydrochloride
219353880|NCT00135304|DRUG|Vitamin D|Vitamin D administered IV
219353881|NCT03269344|DRUG|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
219353882|NCT03269344|DRUG|Placebo Oral Capsule|Placebo
219353883|NCT01099202|DRUG|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
219353884|NCT02597855|DRUG|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
219353885|NCT02597855|DRUG|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
219353886|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
219353887|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
219353888|NCT03660878|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
219353889|NCT01282073|DRUG|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
219353890|NCT01282073|DRUG|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
219353891|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
219353892|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
219353893|NCT06492954|PROCEDURE|Surgical Resection|Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
219353894|NCT06492954|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
219353895|NCT06492954|DRUG|Atezolizumab|For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
219353896|NCT05565950|BIOLOGICAL|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
219353897|NCT05565950|BIOLOGICAL|Vehicle|Vehicle Formulation
219353898|NCT02375230|PROCEDURE|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
219353899|NCT02375230|PROCEDURE|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
219353900|NCT05743452|DEVICE|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
219353901|NCT01931800|BIOLOGICAL|Sampling of blood|
219353902|NCT01931358|BIOLOGICAL|ALVAC-HIV|1 mL intramuscular injection containing 10\^6 CCID50/dose
219353903|NCT01931358|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
219353904|NCT01931358|BIOLOGICAL|ALVAC-HIV Placebo|1 mL per injection
219353905|NCT01931358|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
219353906|NCT06362239|OTHER|Study Surveys|Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
219353907|NCT06186687|BEHAVIORAL|Myofunctional therapy exercise|Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
219353908|NCT03424447|PROCEDURE|efferent limb stimulation|
219353909|NCT03305107|OTHER|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
219353910|NCT03305107|OTHER|Exercise and Water|High intensity interval exercise Water
219353911|NCT03305107|OTHER|Sitting and Chocolate Milk|Sitting Chocolate Milk
219353912|NCT03305107|OTHER|Sitting and Water|Sitting Water
219353913|NCT00358787|PROCEDURE|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
219353914|NCT00358787|PROCEDURE|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
219353915|NCT03340610|DRUG|Alflibercept|Intravitreal Injection
219353916|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
219353917|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
219353918|NCT02101723|DIETARY_SUPPLEMENT|Placebo|Placebo powder without micronutrients
219353919|NCT04079270|OTHER|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
219353920|NCT04313829|BEHAVIORAL|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
219353921|NCT04580290|DEVICE|JewelACL|The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
219353922|NCT05359978|BEHAVIORAL|To with significance activities|activities with purpose with people who are diagnosed of dementia 2 days at week during 30 minutes
219353923|NCT02469090|DRUG|APL-130277|"Use to treat up to 5 OFF episodes per day"
219353924|NCT02469090|DRUG|Placebo|placebo
219353925|NCT04405375|DRUG|gemcitabin|1.25g/㎡ d1, repeated every 21 days
219353926|NCT04405375|DRUG|Pegaspargase|2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days
219353927|NCT04405375|DRUG|Etoposide|75mg/㎡ d1-3, repeated every 21 days
219353928|NCT04405375|DRUG|Dexamethasone|20mg d1-4
219353929|NCT04710329|DRUG|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
219353930|NCT00000645|DRUG|Hypericin|
219353931|NCT03725618|BIOLOGICAL|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
219353932|NCT05272800|DEVICE|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
219353933|NCT05272800|OTHER|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
219353934|NCT04293861|DEVICE|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
219353935|NCT01391507|DRUG|0.9 % sodium chloride|Monthly intravenous injection for 6 months
219353936|NCT01391507|DRUG|COR-1|Monthly intravenous injection for 6 months
219353937|NCT01391507|DRUG|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
219353938|NCT02961556|DRUG|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
219353939|NCT00857727|DRUG|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
219353940|NCT00857727|DRUG|Saline|Given by a continuous infusion
219353941|NCT01202656|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
219353942|NCT01202656|DRUG|Saline|intrauterine saline infusion 1 cc
219353943|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
219353944|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
219353945|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
219353946|NCT01131000|OTHER|Normal Saline|Normal Saline, 100 ml, Single-dose
219353947|NCT02070042|DRUG|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
219353948|NCT02070042|DRUG|Placebo|Placebo capsules (olive oil) twice a day
219353949|NCT02507011|DRUG|Carvedilol|Beta-adrenergic receptor blocker
219353950|NCT02507011|DRUG|Placebo|Placebo
219353951|NCT05459623|OTHER|Manual myofascial release|will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
219353952|NCT05459623|OTHER|Emmett intervention|"will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute."
219353953|NCT02630238|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet \& exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
219353954|NCT02630238|OTHER|Placebo|All participants will partake in the same diet \& exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
219353955|NCT02630238|OTHER|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
219353956|NCT02630238|OTHER|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
219353957|NCT00010361|DRUG|cyclosporine|
219353958|NCT00010361|DRUG|fludarabine|
219353959|NCT00010361|DRUG|mycophenolate mofetil|
219353960|NCT02639780|OTHER|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
219353961|NCT05148923|PROCEDURE|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
219353962|NCT01028807|OTHER|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
219353963|NCT01028807|OTHER|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
219353964|NCT06437808|COMBINATION_PRODUCT|Training with Portable Force Plates Integration|This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.
219353965|NCT06437808|OTHER|Standard Training|This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
219353966|NCT00682266|BEHAVIORAL|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
219353967|NCT00682266|BEHAVIORAL|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
219353968|NCT02011191|DIETARY_SUPPLEMENT|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
219353969|NCT02011191|DIETARY_SUPPLEMENT|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
219353970|NCT06492044|OTHER|Transthoracic echocardiography (TTE)|"In this pilot study, all included patients will undergo a TTE before (TTEt0) and after (TTEt1) the PLR maneuver, then before (TTEt2) and after the FC (TTEt3).~Passive leg raising is PLR. FC is fluid challenge. TTE, PLR and FC are routine care procedures in patient in septic shock. In this study the patient will undergo repeated image acquisition with TTE at different times as part of the study, resulting in a longer TTE procedure. The advantage of TTE is that it is a non-invasive, painless, non-irradiating procedure that can be easily performed at the patient's bedside and has no known side effects to date. TTE is a non-invasive procedure that poses no infectious or psychological risk to the patient. No additional follow-up or telephone contact will be necessary for the study. The study concludes once TTEt3 is completed."
219353971|NCT00355394|DRUG|Metoclopramide|Intravenous bolus administration.
219353972|NCT00355394|OTHER|Placebo|Standard care including intravenous fluid, but no metoclopramide.
219353973|NCT05883098|PROCEDURE|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
219353974|NCT05883098|DEVICE|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
219353975|NCT00070941|DRUG|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
219353976|NCT00070941|DRUG|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
219353977|NCT00070941|DRUG|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
219353978|NCT01691469|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
219353979|NCT00094055|DRUG|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
219353980|NCT04765280|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
219353981|NCT04765280|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
219353982|NCT04765280|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.
219353983|NCT04765280|OTHER|Disabilities of the Arm, Shoulder and Hand (DASH)|Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.
219353984|NCT04765280|OTHER|Neck Pain and Disability scale|Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.
219353985|NCT04765280|OTHER|Knee Injury and Osteoarthritis Outcome Score|Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.
219353986|NCT04765280|OTHER|Western Ontario and McMaster Universities Arthritis Index|Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.
219353987|NCT04765280|OTHER|Visual analogue scale|global pain score on a 0 to 10
219353988|NCT02803021|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
219353989|NCT04861220|BEHAVIORAL|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
219353990|NCT00226551|DRUG|Isoproterenol|
219353991|NCT01307475|OTHER|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
219353992|NCT01307475|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
219353993|NCT01307475|OTHER|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
219353994|NCT01307475|OTHER|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
219353995|NCT01307475|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
219353996|NCT01307475|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
219353997|NCT01307475|OTHER|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
219353998|NCT01307475|OTHER|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
219353999|NCT01307475|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
219354000|NCT04821804|DRUG|Hyaluronic Acid (HYADENT BG)|"the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures"
219354001|NCT00411554|DRUG|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
219354002|NCT00411554|DRUG|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
219354003|NCT00080509|DRUG|KOS-862|
219354004|NCT03247894|OTHER|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
219354005|NCT02955745|OTHER|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
219354006|NCT00699907|DRUG|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
219354007|NCT02087787|BEHAVIORAL|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
219354008|NCT02680379|DRUG|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
219354009|NCT02680379|DRUG|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
219354010|NCT05430100|OTHER|The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
219354011|NCT05430100|OTHER|The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
219354012|NCT05430100|OTHER|The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
219354013|NCT02948803|BEHAVIORAL|smartphone based intervention with Active Coach app|
219354014|NCT03390062|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
219354015|NCT06016426|OTHER|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
219354016|NCT04280432|PROCEDURE|CESAREAN|Women hospitalized for cesarean section
219354017|NCT01924208|BIOLOGICAL|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
219354018|NCT01924208|BIOLOGICAL|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
219354019|NCT01924208|PROCEDURE|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
219354020|NCT03971110|DRUG|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
219354021|NCT02097147|DRUG|Vilazodone 20 mg|Oral administration, once per day.
219354022|NCT02097147|DRUG|Vilazodone 40 mg|Oral administration, once per day.
219354023|NCT02097147|DRUG|Paroxetine 20 mg|Oral administration, once per day.
219354024|NCT02097147|DRUG|Placebo|Oral administration, once per day.
219354025|NCT00001570|DRUG|PSC 833|
219354026|NCT00001570|DRUG|vinblastine|
219354027|NCT00257803|DRUG|Oxytocin|See detailed description
219354028|NCT00257803|DRUG|Saline solution|See detailed description
219354029|NCT04676737|DRUG|TTHX1114(NM141)|TTHX1114
219354030|NCT02693587|DRUG|Misodel and Angusta|
219354031|NCT04313907|COMBINATION_PRODUCT|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
219354032|NCT04313907|DRUG|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
219354033|NCT04313907|RADIATION|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
219354034|NCT01487915|DRUG|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
219354035|NCT01487915|DRUG|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
219354036|NCT03104725|DRUG|N-Acetylcysteine|Oral
219354037|NCT03104725|PROCEDURE|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
219354038|NCT03104725|RADIATION|Fluoroscopy|If needed for lumbar puncture
219354039|NCT04511728|DRUG|HSK3486|The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h
219354040|NCT04511728|DRUG|Propofol|The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h
219354041|NCT00423163|DRUG|micafungin|
219354042|NCT00423163|DRUG|voriconazole|
219354043|NCT01532531|DEVICE|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
219354044|NCT01925690|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
219354045|NCT01925690|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
219354046|NCT01276236|DRUG|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
219354047|NCT05828511|DRUG|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
219354048|NCT00044512|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
219354049|NCT02673645|OTHER|SAGA Innovations|An intensive math tutoring program.
219354050|NCT01097304|DRUG|Ursodiol|Given PO
219354051|NCT01097304|OTHER|Laboratory Biomarker Analysis|Correlative studies
219354052|NCT00035282|DRUG|aprepitant|
219354053|NCT00035282|DRUG|Comparator: placebo (unspecified)|
219354054|NCT05046405|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
219354055|NCT00130403|DRUG|risedronate sodium|
219354056|NCT06309056|DEVICE|VitalStim|VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
219354057|NCT04486092|DRUG|Valproic Acid|
219354058|NCT03821740|OTHER|Kinesiotaping|Mc Connel taping and another kinesiotaping technique
219354059|NCT06238167|DRUG|Tislelizumab|Tislelizumab, 200mg Q3W, max 16 cycles.
219354060|NCT06238167|DRUG|S-1 therapy|S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).
219354061|NCT06238167|DRUG|low dose SOX therapy|Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
219354062|NCT02302976|DRUG|cocaine hydrochloride|
219354063|NCT02302976|DRUG|exenatide|
219354064|NCT02302976|DRUG|placebo|
219354065|NCT03222791|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
219354066|NCT03222791|OTHER|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
219354067|NCT04360070|DRUG|Ketamine Hydrochloride|Parenteral General Anesthetic
219354068|NCT03858673|PROCEDURE|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
219354069|NCT03290833|DEVICE|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
219354070|NCT03290833|OTHER|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
219354071|NCT05476159|DRUG|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
219354072|NCT05476159|DEVICE|Gastric bypass|Roux and Y Gastric bypass
219354073|NCT01512303|BEHAVIORAL|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
219354074|NCT01512303|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
219354075|NCT03850912|OTHER|Stakeholder Survey (Control Period)|Before eSyM go-live, study team members from each site will solicit input via emailed survey, remote meetings and/or in-person meeting on the use of ePROs in oncology from stakeholders to obtain input regarding adaptation, anticipated challenges, and implementation.
219354076|NCT03850912|OTHER|Stakeholder Survey (Intervention Period)|After eSyM go-live and on an ongoing basis, we will evaluate the implementation process at each of the sites with a focus on adoption, appropriateness, acceptability, sustainability, penetration, and scalability. We will do so through emailed surveys and/or discussions with health system leadership, clinicians, clinic support staff, and informatics/IT staff.
219354077|NCT03850912|OTHER|Qualitative Interview|A small subset of patients and stakeholders were invited to take part in qualitative interviews after the eSyM trial rollout.
219354078|NCT03850912|OTHER|SASS Questionnaire|"A subset of control and intervention patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care."
219354079|NCT03850912|OTHER|eSyM|The electronic symptom management (eSyM) program is the EHR-integrated ePRO program being evaluated through this trial.
219354080|NCT01539590|DRUG|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
219354081|NCT01539590|DRUG|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
219354082|NCT02278172|DIETARY_SUPPLEMENT|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
219354083|NCT02278172|DIETARY_SUPPLEMENT|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
219354084|NCT04857255|BEHAVIORAL|Technology assisted language intervention|speech language therapy that has integrated technology delivered through specific software on an iPad
219354085|NCT04857255|BEHAVIORAL|Treatment as usual|No change will occur to the current ongoing speech-language therapy being delivered.
219354086|NCT03569527|DIETARY_SUPPLEMENT|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
219354087|NCT03569527|DIETARY_SUPPLEMENT|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
219354088|NCT03569527|DIETARY_SUPPLEMENT|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
219354089|NCT00803075|DEVICE|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
219354090|NCT02627820|DRUG|Isis 420915/GSK 299872|Open label study in comparison to historic control.
219354091|NCT06194591|DEVICE|NephrospecTM, low-intensity extracorporal shockwave therapy device|"Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter."
219354092|NCT06194591|DEVICE|Sham-Device|The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
219354093|NCT01290380|DRUG|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
219354094|NCT02966691|OTHER|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
219354095|NCT06239311|DRUG|Methotrexate|Solution for injection in prefilled pen
219354096|NCT06239311|DRUG|Placebo|Solution for injection in prefilled pen
219354097|NCT00301340|DRUG|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
219354098|NCT04406909|OTHER|Access to training facility|Access to training facility under national regulations for COVID control
219354099|NCT01666327|DRUG|MT-1303|
219354100|NCT05347160|PROCEDURE|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
219354101|NCT05572775|PROCEDURE|Quadratus lumborum (QL) block|bilateral anterior subcostal quadratus lumborum block
219354102|NCT05572775|PROCEDURE|Erector Spinae Plane (ESP) Block|bilateral erector spinae plane block
219354103|NCT00336947|DRUG|tegafur-gimeracil-oteracil potassium|
219354104|NCT00336947|DRUG|tegafur-uracil|
219354105|NCT00336947|PROCEDURE|adjuvant therapy|
219354106|NCT01520571|PROCEDURE|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
219354107|NCT01520571|PROCEDURE|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
219354108|NCT05024955|PROCEDURE|Discussion|Attend a focus group
219354109|NCT05024955|OTHER|Interview|Attend interview
219354110|NCT00470600|DRUG|Caldolor|800 milligrams intravenous
219354111|NCT00470600|OTHER|Normal Saline|Placebo comparator
219354112|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
219354113|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
219354114|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
219354115|NCT01432691|PROCEDURE|Hemi (hemialloplastik)|THA vs hemi
219354116|NCT00678873|PROCEDURE|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
219354117|NCT00270517|DRUG|EDP-420 / Duration of Treatment - 3 days|
219354118|NCT00270517|DRUG|Telithromycin / Duration of Treatment - 7 days|
219354119|NCT02126709|DRUG|Repigel|Repigel will be used as the intervention in the treatment group
219354120|NCT03550482|DIETARY_SUPPLEMENT|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
219354121|NCT00357500|DRUG|celecoxib|
219354122|NCT00357500|DRUG|cyclophosphamide|
219354123|NCT00357500|DRUG|etoposide|
219354124|NCT00357500|DRUG|fenofibrate|
219354125|NCT00357500|DRUG|thalidomide|
219354126|NCT00985335|OTHER|Neem Based External Application Cream|Apply externally 3-4 times per day
219354127|NCT02107586|PROCEDURE|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
219354128|NCT02107586|PROCEDURE|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
219354129|NCT06017804|OTHER|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
219354130|NCT06017804|OTHER|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
219354131|NCT01972555|PROCEDURE|Minimally invasive aortic valve replacement|
219354132|NCT01972555|PROCEDURE|Conventional aortic valve replacement|
219354133|NCT00473707|PROCEDURE|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
219354134|NCT00473707|PROCEDURE|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
219354135|NCT00473707|DRUG|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
219354136|NCT00473707|DRUG|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
219354137|NCT00176995|DRUG|15% Eflornithine Hdyrochloride|
219354138|NCT03132181|DRUG|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
219354139|NCT03132181|OTHER|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
219354140|NCT01431664|DRUG|multikinase inhibitor AT9283|
219354141|NCT01431664|OTHER|laboratory biomarker analysis|
219354142|NCT01431664|OTHER|pharmacological study|
219354143|NCT05789030|DRUG|Diprospan plus iguratimod|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
219354144|NCT05789030|DRUG|Diprospan plus leflunomide|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
219354145|NCT05789030|DRUG|Prednisone plus leflunomide|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
219354146|NCT02197676|DRUG|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
219354147|NCT05853614|BEHAVIORAL|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
219354148|NCT00746135|DEVICE|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
219354149|NCT02948621|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
219354150|NCT04434521|BEHAVIORAL|Questionnaire|Questionnaire about habits in terms of near vision activities
219354151|NCT04434521|OTHER|Eye examination|"The eye examination involves the following measurements:~* Distant vision phoria with Thorington method~* Close vision with Thorington method~* Objective eye-to-eye refraction with self-refractometer~* Binocular objective refraction with autorefractometer~* Monocular/biocular/binocular refraction with Nidek TS610~* SiView automatic refraction~* Humphriss binocular refraction~* MOU Binocular refraction"
219354152|NCT01816581|DRUG|Targin|
219354153|NCT01816581|DRUG|Oxynorm|
219354154|NCT01816581|DRUG|Morphine|
219354155|NCT06146725|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
219354156|NCT06146725|PROCEDURE|Tumor biopsy|Biopsy of the tumor
219354157|NCT01730235|OTHER|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
219354158|NCT02175056|BIOLOGICAL|HL2351|Dose-escalation For 5 level dose groups A \~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
219354159|NCT02175056|BIOLOGICAL|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A\~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
219354160|NCT02695628|DRUG|18F-Fluoromisonidazole|Undergo \[18F\] FMISO PET/CT
219354161|NCT02695628|PROCEDURE|Arterial Embolization|Undergo transcatheter arterial embolization
219354162|NCT02695628|DIAGNOSTIC_TEST|Computed Tomography|Undergo \[18F\] FMISO PET/CT
219354163|NCT02695628|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo \[18F\] FMISO PET/CT
219354164|NCT02520232|BEHAVIORAL|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
219354165|NCT02520232|BEHAVIORAL|Stretching and balance exercise program|Stretching and balance exercise program
219354166|NCT00679497|BIOLOGICAL|MVA-B|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
219354167|NCT00679497|BIOLOGICAL|Placebo|-3 immunisations at week 0, 4 and 16
219354168|NCT05068336|DIAGNOSTIC_TEST|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
219354169|NCT05068336|DIAGNOSTIC_TEST|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
219354170|NCT02085434|BEHAVIORAL|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
219354171|NCT00356941|DRUG|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
219354172|NCT00356941|DRUG|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
219354173|NCT00356941|PROCEDURE|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
219354174|NCT04326608|OTHER|physiotherapy|manual therapy and sef-care exercises
219354175|NCT01440621|DRUG|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
219354176|NCT01440621|DRUG|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
219354177|NCT04772729|DRUG|Insulin faster aspart (Fiasp, Novo Nordisk)|"Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent."
219354178|NCT04914208|DEVICE|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
219354179|NCT04914208|DEVICE|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
219354180|NCT04914208|DEVICE|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
219354181|NCT04914208|OTHER|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
219354182|NCT04914208|OTHER|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
219354183|NCT03027739|BIOLOGICAL|CART-19|CART-19 cells treated
219354184|NCT02189850|DRUG|BLI800 - Dose 1|BLI800 oral solution
219354185|NCT02189850|DRUG|BLI800 - Dose 2|BLI800 oral solution
219354186|NCT03958448|PROCEDURE|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
219354187|NCT03958448|PROCEDURE|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
219354188|NCT03958448|PROCEDURE|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
219354189|NCT01076582|DRUG|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
219354190|NCT01076582|DRUG|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
219354191|NCT01141595|DRUG|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
219354192|NCT03290495|DRUG|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
219354193|NCT03290495|DRUG|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
219354194|NCT04082000|DRUG|BOL-DP-o-04|BOL-DP-o-04
219354195|NCT04082000|DRUG|Placebo|Placebo
219354196|NCT03347071|BEHAVIORAL|Prevention Course Group|The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
219354197|NCT03580421|PROCEDURE|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
219354198|NCT03580421|PROCEDURE|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
219354199|NCT02820428|OTHER|Healthy participants|Semi-structured interview
219354200|NCT02147483|BEHAVIORAL|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
219354201|NCT02147483|BEHAVIORAL|Treatment as usual|Treatment usually provided by clinician
219354202|NCT04850209|OTHER|oral and written education|oral and written education
219354203|NCT04850209|OTHER|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
219354204|NCT03183882|BEHAVIORAL|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
219354205|NCT03183882|BEHAVIORAL|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
219354206|NCT06062862|DEVICE|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
219354207|NCT06062862|DEVICE|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
219354208|NCT03405948|DRUG|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
219354209|NCT03911765|BEHAVIORAL|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
219354210|NCT00971386|BEHAVIORAL|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
219354211|NCT00516737|DRUG|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
219354212|NCT00516737|DRUG|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
219354213|NCT06107075|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
219354214|NCT06107075|DIETARY_SUPPLEMENT|Placebo|around 40g pea protein powder not containing phospholipids
219354215|NCT02448732|DRUG|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
219354216|NCT05578742|PROCEDURE|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
219354217|NCT05578742|PROCEDURE|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
219354218|NCT02423915|DRUG|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
219354219|NCT02423915|DRUG|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
219354220|NCT02423915|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -8.
219354221|NCT02423915|RADIATION|Total Body Radiation|2 Gy delivered on Day -4.
219354222|NCT02423915|PROCEDURE|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Fucosylated T-reg cells on Day -1."
219354223|NCT02423915|PROCEDURE|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
219354224|NCT02423915|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
219354225|NCT02423915|DRUG|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
219354226|NCT02423915|PROCEDURE|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
219354227|NCT02423915|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
219354228|NCT02423915|PROCEDURE|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1."
219354229|NCT02173795|DRUG|Berodual® Respimat®|
219354230|NCT02173795|DRUG|Berodual® MA HFA|
219354231|NCT05565469|OTHER|Adjustment of neurostimulator settings|"This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation."
219354232|NCT01844895|DRUG|Abatacept|
219354233|NCT02122978|BEHAVIORAL|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
219354234|NCT02122978|BEHAVIORAL|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
219354235|NCT02122978|BEHAVIORAL|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
219354236|NCT04868812|DEVICE|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
219354237|NCT05079607|OTHER|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
219354238|NCT05079607|OTHER|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
219354239|NCT03286855|DEVICE|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
219354240|NCT03286855|DEVICE|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
219354241|NCT00425386|DRUG|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily"
219354242|NCT00425386|DRUG|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
219354243|NCT00425386|PROCEDURE|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
219354244|NCT01387243|DRUG|Orlistat|60 mg
219354245|NCT03597048|BEHAVIORAL|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
219354246|NCT03597048|BEHAVIORAL|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
219354247|NCT03597048|BEHAVIORAL|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
219354248|NCT00511355|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
219354249|NCT00511355|DRUG|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
219354250|NCT01708460|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
219354251|NCT00713583|DRUG|levodopa|800mg levodopa and 200mg carbidopa per day
219354252|NCT00713583|DRUG|Placebo|Placebo
219354253|NCT00713583|BEHAVIORAL|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
219354254|NCT00713583|BEHAVIORAL|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
219354255|NCT02803944|DRUG|Azithromycin|
219354256|NCT00454805|DRUG|AZD2171|Oral tablet
219354257|NCT00454805|DRUG|Fulvestrant|intramuscular injection
219354258|NCT02868346|OTHER|Anal swab|
219354259|NCT03967548|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
219354260|NCT04870879|PROCEDURE|Liver Transplant|Liver Transplant from cadaveric donors
219354261|NCT04870879|DRUG|Chemotherapy|Chemotherapy
219354262|NCT00767897|DRUG|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
219354263|NCT00802685|DRUG|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
219354264|NCT00802685|OTHER|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV."
219354265|NCT05199259|DIAGNOSTIC_TEST|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
219354266|NCT01487512|DRUG|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
219354267|NCT01487512|DRUG|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
219354268|NCT01487512|DRUG|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
219354269|NCT01487512|DRUG|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
219354270|NCT00040755|DRUG|rebimastat|Given orally
219354271|NCT00040755|OTHER|laboratory biomarker analysis|Correlative studies
219354272|NCT02772432|BEHAVIORAL|Relaxation Response Resiliency Training for Parents of SPLD|
219354273|NCT01450423|BEHAVIORAL|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
219354274|NCT01545700|DRUG|Control-saline|Patients are randomized to receive saline 2 cc
219354275|NCT01545700|DRUG|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
219354276|NCT01545700|DRUG|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
219354277|NCT01545700|DRUG|Control saline|Patients are randomized to receive saline 2 cc
219354278|NCT01545700|DRUG|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
219354279|NCT01545700|DRUG|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
219354280|NCT03208231|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered by subcutaneous injection.
219354281|NCT03208231|DRUG|Combination Antiretroviral Therapy (cART)|All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
219354282|NCT01563887|BEHAVIORAL|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
219354283|NCT01563887|BEHAVIORAL|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
219354284|NCT03321097|DEVICE|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
219354285|NCT03321097|DEVICE|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
219354286|NCT04442841|BIOLOGICAL|Hepatitis B vaccine|It may be GSk or MSD vaccine
219354287|NCT04679831|DIETARY_SUPPLEMENT|Ujiplus®|Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
219354288|NCT04679831|DRUG|Praziquantel 400mg|400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
219354289|NCT03188445|DRUG|Iron Isomaltoside 1000|Administered iv
219354290|NCT03188445|DRUG|ferrous fumarate with ascorbic acid|Oral administration
219354291|NCT02080793|OTHER|Questionnaire|
219354292|NCT04347239|DRUG|Placebo|Placebo
219354293|NCT04347239|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
219354294|NCT06558838|DRUG|acyclovir-penciclovir cream|Patients will treat their cold sore with active study drug based upon their randomization
219354295|NCT06558838|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
219354296|NCT04899687|DRUG|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
219354297|NCT04899687|DRUG|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
219354298|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
219354299|NCT05513456|BEHAVIORAL|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
219354300|NCT06384001|BEHAVIORAL|Active MBM|The MBM is designed to be applied for 20 minutes per session daily for two weeks. The recording will instruct participants to close their eyes, connect to the openness of one's minds, and mindfully maintain and deepen the connection through breathing with more openness and awareness. The MBM intervention will include three recordings that gradually take the participant into a more profound meditation practice. Participants will be instructed to listen to Meditation 1 for the first three days of the intervention, then switch to Meditation 2 for days 4-6 and Meditation 3 for the remainder of the 2-week intervention. The participants will be asked to practice meditation for eight weeks (6 weeks after the initial two weeks of MBM practice).
219354301|NCT06384001|BEHAVIORAL|Sham MBM|The sham MBM intervention was also recorded. The sham recording will instruct participants to relax and take deep breaths every 3 minutes without the specific mindfulness-based instructions (e.g., practicing mindful attention to the breath in a non-evaluative manner). All other aspects of the sham MBM intervention (e.g., body position, time spent listening to instructions, eyes closed) will match the active MBM.
219354302|NCT06492070|OTHER|Best Practice|Undergo standard of care
219354303|NCT06492070|DRUG|Cilostazol|Given PO
219354304|NCT06492070|DEVICE|Cryocompression Therapy|Undergo cryocompression therapy
219354305|NCT06492070|DRUG|Paclitaxel|Given by infusion
219354306|NCT06492070|OTHER|Quality-of-Life Assessment|Ancillary studies
219354307|NCT05099107|DRUG|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
219354308|NCT05099107|DRUG|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
219354309|NCT02626260|OTHER|adhesive strip|Adhesive strip with a standard adhesive base
219354310|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
219354311|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
219354312|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
219354313|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
219354314|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
219354315|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
219354316|NCT03430921|DEVICE|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
219354317|NCT06240884|PROCEDURE|Infraspinatus-teres minor interfascial block|After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
219354318|NCT06240884|PROCEDURE|interscalene block|The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
219354319|NCT04892836|OTHER|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
219354320|NCT02224859|DEVICE|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
219354321|NCT02224859|OTHER|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
219354322|NCT05790265|DEVICE|ANNE One|Chest sensor for single lead ECG and finger sensor for pulse oximetry.
219354323|NCT06351527|DRUG|ICP-248|ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).
219354324|NCT06351527|DRUG|Obinutuzumab (G)|Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.
219354325|NCT06351527|DRUG|Rituximab (R)|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.
219354326|NCT06443606|DRUG|Bezafibrate 400 mg in addition to UDCA therapy|"* Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
219354327|NCT06443606|DRUG|Bezafibrate 200 mg in addition to UDCA therapy|"* Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
219354328|NCT06443606|DRUG|Placebo in addition to UDCA therapy|"* Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks placebo /UDCA = daily oral dose."
219354329|NCT03639025|DEVICE|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
219354330|NCT05653752|DRUG|YL202|"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."
219354331|NCT00069498|DRUG|5-aminosalicylic acid|
219354332|NCT02289950|DRUG|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
219354333|NCT02289950|DRUG|Placebo|Placebo will be administered intravenously (IV) weekly
219354334|NCT02270242|DRUG|Aspirin|
219354335|NCT02270242|DRUG|Placebo|
219354336|NCT02270242|DRUG|ticagrelor|
219354337|NCT04800289|OTHER|questionnaires|questionnaires about disease and satisfaction of patient
219354338|NCT03963011|DIAGNOSTIC_TEST|Bowel Ultrasound|Ultrasound imaging of the bowel
219354339|NCT02294240|DIETARY_SUPPLEMENT|Energy dense biscuits|Energy dense biscuits will be provided
219354340|NCT02294240|OTHER|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
219354341|NCT06062186|DIETARY_SUPPLEMENT|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
219354342|NCT06062186|DIETARY_SUPPLEMENT|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
219354343|NCT06062186|DIETARY_SUPPLEMENT|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
219354344|NCT04876014|OTHER|Guided Mobile-Based Perinatal Mindfulness Intervention|GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.
219354345|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
219354346|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
219354347|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
219354348|NCT00664833|OTHER|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
219354349|NCT04926272|DRUG|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
219354350|NCT02369614|OTHER|Active Comparator: 1 Hz rTMS|1 Hz rTMS
219354351|NCT02369614|OTHER|Active Comparator: 10 Hz rTMS|10 Hz rTMS
219354352|NCT02369614|OTHER|Sham Comparator:|Sham rTMS
219354353|NCT03225053|DEVICE|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
219354354|NCT00105937|DRUG|OraVescent fentanyl citrate|
219354355|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
219354356|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
219354357|NCT00644787|DRUG|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
219354358|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
219354359|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
219354360|NCT03355300|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
219354361|NCT04901208|DRUG|Nicotine pod|Nicotine pods administered to individuals who use Juul
219354362|NCT04901208|DRUG|Placebo pod|Nicotine-free pods administered to individuals who use Juul
219354363|NCT05056532|DIAGNOSTIC_TEST|patient assessment|subjective and objective measurement will be performed in patients with PAH
219354364|NCT05517876|DEVICE|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
219354365|NCT02097615|PROCEDURE|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
219354366|NCT02097615|OTHER|deionized water|application every 24 hours six weeks
219354367|NCT01051427|DEVICE|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
219354368|NCT01051427|DEVICE|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
219354369|NCT03048422|DRUG|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
219354370|NCT03048422|DRUG|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
219354371|NCT03048422|DRUG|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
219354372|NCT03048422|DRUG|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
219354373|NCT04797832|DRUG|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
219354374|NCT03922698|OTHER|No interventions|No interventions - observational study
219354375|NCT02796248|OTHER|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
219354376|NCT06235099|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
219354377|NCT02975544|BEHAVIORAL|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
219354378|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
219354379|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
219354380|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
219354381|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
219354382|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
219354383|NCT06986993|DRUG|Semaglutide|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
219354384|NCT06986993|DRUG|Placebo|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
219354385|NCT05237128|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
219354386|NCT05237128|BEHAVIORAL|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
219354387|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
219354388|NCT02868073|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
219354389|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
219354390|NCT04451421|BEHAVIORAL|Change of standing Angle|Change the patient's standing Angle by using an electric bed
219354391|NCT03443154|DIAGNOSTIC_TEST|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
219354392|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
219354393|NCT06824363|DRUG|Tremelimumab|single dose, 300mg IV, day 1
219354394|NCT06824363|DRUG|Durvalumab|single dose, 1500 mg IV, day 1
219354395|NCT06989112|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
219354396|NCT06989112|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
219354397|NCT06989112|DRUG|Pembrolizumab|Immunotherapy by intravenous infusion
219354398|NCT06989112|DRUG|Carboplatin|Standard of Care (SoC) chemotherapy by intravenous infusion
219354399|NCT06989112|DRUG|Paclitaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
219354400|NCT06989112|DRUG|Docetaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
219354401|NCT06607627|COMBINATION_PRODUCT|Gefurulimab|Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
219354402|NCT06588894|BEHAVIORAL|Questionnaire and Physical Exam|Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
219354403|NCT06588894|BEHAVIORAL|Motor Imagery Ability|Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
219354404|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
219354405|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
219354406|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
219354407|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
219354408|NCT07128355|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Starting on Day 1 participants will have 2-4 treatments per week for about 2 weeks, with no more than 2 days in a row. This is expected to last about 2 weeks but could last up to 3 weeks.
219354409|NCT07128355|DRUG|Botensilimab|Administered once every 6 weeks by intravenous infusion over about 30 minutes, on Day 1 of Cycles 1-4 (six-week cycles). Administered 30 minutes after balstilimab.
219354410|NCT07128355|DRUG|Balstilimab|Administered once every 2 weeks by intravenous infusion over about 30 minutes, starting on Day 1 of Cycle 1 and continuing for 4 six-week cycles (with botensilimab) followed by up to 14 six-week cycles of balstilimab alone. Participants will receive balstilimab for a total of 18 six-week cycles.
219354411|NCT06675799|BEHAVIORAL|Sleep Extension|Weekly educational material about sleep health and weekly brief phone coaching calls for a total of 6 weeks.
219354412|NCT06675799|BEHAVIORAL|Healthy Living Psychoeducation|Weekly educational materials about healthy habits and weekly brief phone calls to clarify terms or concepts.
219354413|NCT07006233|BEHAVIORAL|Whole Food Ketogenic Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This group will focus on the consumption of low-energy, nutrient dense whole foods with a targeted carbohydrate intake of 30-50g per day to achieve nutritional ketosis. The WFKD will adjust carbohydrate level for the individual participant to achieve average blood/urinary ketone levels of between 0.5 and 3.0 mmol/L (tested for objective feedback using a mix of urinary ketone sticks and finger prick blood measures).
219354414|NCT07006233|BEHAVIORAL|Whole Food Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This diet is high carbohydrate (45-65% of total energy coming from carbohydrate, 20-35% from fat and 15-25% from protein) based on the Australian dietary guidelines focusing on the consumption of low-energy, nutrient dense whole foods. The higher carbohydrate diet reflects current contemporary 'standard care' dietary recommendations as outlined by the National Health and Medical Research Council's Australian Dietary Guidelines, and therefore represents the most appropriate control diet to compare to the effects of the proposed intervention.
219354415|NCT07009483|BEHAVIORAL|Patient education modules providing information on the psychological aspects of atopic dermatitis treatment and management.|Provision of online patient educational modules (in addition to patients receiving regular clinical action/ appointments at the Kaye Edmonton Clinic, the Stollery Children's Hospital, and the Rao Dermatology Clinic for Atopic Dermatitis).
219354416|NCT05049343|DRUG|SAGE-904|SAGE-904 oral solution.
219354417|NCT05049343|DRUG|Placebo|Placebo oral solution.
219354418|NCT05049343|DRUG|Ketamine|Ketamine intravenous (IV) infusion.
219354419|NCT05469386|DRUG|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
219354420|NCT05469386|BEHAVIORAL|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
219354421|NCT05469386|DRUG|Placebo|Placebo capsule
219354422|NCT05469386|BEHAVIORAL|General Classroom|General education classroom procedures
219354423|NCT05469386|BEHAVIORAL|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
219354424|NCT07010315|BEHAVIORAL|Cognitive Testing|Given by Survey and one-on one interviews
219354425|NCT07010315|BEHAVIORAL|Usability Testing|Given by surveys and one-on-one interview.
219354426|NCT03377907|DRUG|ketamine in hematoma block|ketamine used in local hematoma block only
219354427|NCT03377907|DRUG|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
219354428|NCT03377907|DRUG|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
219354429|NCT07015853|DRUG|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
219354430|NCT07015853|RADIATION|Radiotherapy|RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2;
219354431|NCT07015853|DRUG|Axatilimab|Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
219354432|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
219354433|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
219354434|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
219354435|NCT07019376|OTHER|Visual biofeedback supported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be followed visually with the help of a laser.
219354436|NCT07019376|OTHER|visual biofeedback unsupported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be the same exercises as the group with laser support, but no visual support will be provided.
219354437|NCT06245603|DEVICE|Hydeal Cyst®|"BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation."
219354438|NCT07018661|DIAGNOSTIC_TEST|[18F]FAPI-74 PET/CT|Patients included in the study will undergo FAPI-PET/CT after initial staging with gastroscopy and a contrast-enhanced CT of thorax and abdomen, but before undergoing a staging laparoscopy. Based on the results of the FAPI-PET/CT, the MDT and/or treating physician will decide on the next step: confirming possible malignant lesions on PET/CT by biopsies (either percutaneous of by staging laparoscopy), or in case of negative PET/CT, diagnostic laparoscopy.
219354439|NCT07018661|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 will be administered intravenously 60 minutes before PET/CT-scanning to be able to detect (metastases of) gastric cancer
219354440|NCT06627517|DEVICE|Episodic overnight patch pump|Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.
219354441|NCT06631872|BEHAVIORAL|Tele-prehabilitation education session: Surgery School|Online telehealth education program using videos and a live clinician facilitator
219354442|NCT06631872|BEHAVIORAL|Individualised Inspiratory Muscle Training and Walking Program|An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.
219354443|NCT06631872|OTHER|Usual Care|Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
219354444|NCT07023003|DRUG|Enalapril 10mg QD|Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
219354445|NCT07023003|DRUG|Nifedipine 30mg XL BID|Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
219354446|NCT07023705|DIAGNOSTIC_TEST|Monocyte to Large Platelet Ratio (MLPR)|Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.
219354447|NCT07018245|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
219354448|NCT07018245|DRUG|Placebo|Capsule, Once Daily
219354449|NCT07018466|OTHER|Tele-exercise|Exercise training 3x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
219354450|NCT07018466|OTHER|Standard of Care|Health education discussions and lectures 3x/week led remotely.
219354451|NCT07025720|DEVICE|TMS|"The protocol involves delivering sessions of intermittent theta burst stimulation (iTBS) of 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation sessions will be delivered hourly. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation will be delivered at 90% resting motor threshold (rMT) adjusted for cortical depth.~MR brain imaging will be used with the Localite Neuronavigation System (Localite GmbH, Sankt Augustin, Germany) to position the TMS coil over the individualized stimulation target."
219354452|NCT07024966|DIETARY_SUPPLEMENT|Pterostilbene-silybin-nicotinamide riboside|Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.
219354453|NCT07024966|DIETARY_SUPPLEMENT|Control Group|Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.
219354454|NCT07023614|DRUG|Ninerafaxstat 200mg MR|Ninerafaxstat 200mg Modified Release tablet administered BID
219354455|NCT07023614|DRUG|Placebo|Matching placebo tablet administered BID
219354456|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
219354457|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22. Fenofibrate 160 mg tablets orally once daily during the period of the 6 cycles of the(VRd) regimen."
219354458|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22."
219354459|NCT04647253|DEVICE|AGENT DCB|Drug coated PTCA balloon catheter
219354460|NCT04647253|DEVICE|PTCA balloon catheter|PTCA balloon catheter
219354461|NCT07028554|DEVICE|Cartridges of Disposable Endoscopic Linear Cutting Staplers, Disposable Powered|Investigational devices encompassing all models of the Cartridges for Disposable Endoscopic Linear Cutting Staplers, as well as Staplers utilized in conjunction with the Cartridges specified in the Study Plan (Plan number: WEKD-QS-PMCF).
219354462|NCT04312113|DRUG|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
219354463|NCT06712407|DRUG|TARPEYO®|6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
219354464|NCT06877234|PROCEDURE|Ultrasonic Nerve Ablation System|Treatment of patients with essential hypertension using the ultrasonic nerve ablation system
219354465|NCT02956161|DEVICE|Stimulation of up-phase of sleep slow oscillation|
219354466|NCT02956161|DEVICE|Random stimulation of up phase of sleep slow oscillation|
219354467|NCT02956161|DEVICE|No stimulation|
219354468|NCT07032844|BEHAVIORAL|Digital Health Coaching|This program will be developed using existing, evidence-based curricula for chronic disease self-management, with emphasis on diabetes, hypertension, and obesity. Prior to initiating health coaching with participants, coaches will review data collected related to SDoH to further tailor the intervention as appropriate for housing stability, access to food and transportation, and interpersonal safety. All coaches will have access to participants' EMRs such that they can view medical information throughout the intervention. Coaches will be trained using a curriculum developed by Family and Community Medicine's inter-professional care team and our partners at NCHPAD, making the coaching inclusive of people with physical disabilities, such that the coaches are proficient in motivating behavior change related to resilience, physical activity, nutrition, mindfulness, and relationship-building, among others.
219354469|NCT07032844|BEHAVIORAL|Phone Based Coaching|Weekly coaching calls that address topics related to goal setting, creating supportive environments for behavior change, physical activity, and nutrition.
219354470|NCT07032844|BEHAVIORAL|Combination of Digital Health coaching + Remote Patient Monitoring|Combination of both digital health coaching and remote patient monitoring
219354471|NCT06716307|DRUG|CagriSema (cagrilintide B and semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.
219354472|NCT06716307|DRUG|CagriSema A|Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.
219354473|NCT01934283|DEVICE|urine folly catheter|
219354474|NCT05907629|OTHER|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
219354475|NCT06728410|DRUG|Pemigatinib|Pemigatinib 13.5 mg
219354476|NCT06728410|DRUG|Durvalumab|Durvalumab 1500 mg IV
219354477|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
219354478|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days.
219354479|NCT06738303|DRUG|Cabazitaxel and carboplatin|Given IV
219354480|NCT06738303|DRUG|Lu-PSMA-617|Given IV
219354481|NCT07046624|BEHAVIORAL|Infusion monitoring system developed for use by nurses in patient care|In the experimental group, the frequency of complications will first be determined and an infusion monitoring system will be developed and used by nurses in patient care.
219354482|NCT06736704|DRUG|SNV4818|SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
219354483|NCT06736704|DRUG|Fulvestrant|Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
219354484|NCT06744374|DRUG|BGF|Budesonide/glycopyrrolate/formoterol fumarate
219354485|NCT06744374|DRUG|MITT|Multiple-inhaler triple therapy
219354486|NCT07127081|BEHAVIORAL|Stress ball|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
219354487|NCT07127081|BEHAVIORAL|Cartoons|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
219354488|NCT03961945|DEVICE|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
219354489|NCT06742723|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
219354490|NCT06742723|DRUG|Placebo/dapagliflozin|"dapagliflozin tablet~placebo tablet"
219354491|NCT07061522|OTHER|Behavioral/Physical Assessment|This study will not include any therapeutic or clinical intervention. Instead, participants will undergo a series of structured physical and questionnaire-based assessments to evaluate lower extremity motor performance. These include the Fagerström Test for Nicotine Dependence and DSM-IV-TR criteria to classify smoking addiction. Anthropometric measurements such as Body Mass Index (BMI) and bimalleolar diameter/circumference will be recorded to assess potential confounding structural factors. Lower extremity coordination will be evaluated using the Lower Extremity Motor Coordination Test (LEMOCOT), and movement speed will be assessed with a 30-meter sprint test. All assessments will be conducted once in a controlled laboratory setting and are intended solely for comparative analysis between smokers and non-smokers.
219354492|NCT06898814|DRUG|Ferric Derisomaltose|The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%
219354493|NCT06898814|DRUG|Saline (NaCl 0,9 %) (placebo)|Single dose of 100 mL isotonic sodium chloride 0.9%
219354494|NCT06774547|OTHER|Heavy-slow resistance training|Heavy-slow resistance training consists of a progressive protocol of dynamic exercises where the relative load increases over time from a weight that can only be lifted 15 times (i.e., 15 repetition maximum) during the first week to a relative load of 6 repetition maximum from Week 9 to 12. The exercises are performed unsupervised three days per week separated by a minimum of 48 hours. There are two exercises that are performed for four sets separated by a 2-minute rest. Participants with Achilles tendinopathy or plantar fasciopathy perform seated and standing weighted heel raises and participants with patellar tendinopathy perform a free-standing squat and a seated leg press. Tolerable pain during the exercises is allowed.
219354495|NCT06774547|OTHER|Plyometric exercise|The progressive plyometric programme consists of three different levels and is performed unsupervised three times per week separated by a minimum of 48 hours. Each level consists of several exercise sets that are separated by 2-minute rest intervals. Participants' self-evaluated readiness to progress to a higher level will guide the progression. Level 1 includes free-standing double-legged plyometric exercises where they push off the ground and lift their heels while maintaining contact with it. If the participant feels they can do more, they will progress to Level 2, where participants increase the relative load during the dynamic exercises and start performing plyometric double-legged jumps. At the highest level, Level 3, the relative load during the exercises is further increased, and the plyometric exercises are to be performed as single-legged hops. Tolerable pain during the exercises is allowed.
219354496|NCT07070076|PROCEDURE|Yttrium-90|Step 1: The MDT team conducts a routine preoperative assessment. Step 2: The interventional team performed tumor vascularity distribution and 99mTc simulation surgery. Step 3: Nuclear Medicine performs SPECT validation and yttrium-90 treatment activity calculation. Step 4: Infusion of yttrium-90 microspheres in the interventional department. Step 5: Nuclear Medicine uses PET/CT or SPECT to determine the distribution of nuclides. If the patient is unwell, he or she can be discharged after 24 hours without special protection. Follow-up examination 1 month after surgery, and then every 2 months, a total of 1 course of treatment. After yttrium-90 treatment, rest for 3-4 months, and arrange hepatectomy after excluding surgical contraindications. The patients in both groups were consulted and discussed by multidisciplinary experts in liver cancer, and elective hepatectomy was arranged after excluding surgical contraindications according to the standardized process.
219354497|NCT07070076|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriography and hepatic arteriography are performed, and after the hepatic artery is cannulated to a predetermined position, the patient is returned to the ward with an indwelling catheter. In the ward, a catheter syringe pump is continuously pumped into the following chemotherapy drugs: oxaliplatin 135mg/m2 over 3hrs, leucovorin 400mg/m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs. After the chemotherapy is completed, the catheter is removed, and the patient can be discharged after 12 hours of compression bandaging to stop the bleeding. Repeat at intervals of 3\~4 weeks, a total of 2 or 4 strokes. For details, see 3.3.1.4 Grouping and Treatment Flow Chart. After the end of HAIC, rest for 3\~4 weeks for re-examination, and arrange liver resection after excluding surgical contraindications.
219354498|NCT07063251|GENETIC|HG005|Once subretinal injection; The duration of the study is about 52 weeks for each subject, including a 4 weeks screening period, enrollment visit, treatment visit, and 56 weeks follow-up period.
219354499|NCT06898905|OTHER|Bridging Radiation Therapy|Study seeks to compare the hypofractionated radiation therapy with hyperfractionated treatment within the same tumor. Each participant will be serving as their own control; half their tumor will receive once daily hypofractionated (QD) bridging radiotherapy, and the other half of their tumor will receive twice daily hyperfractionated (BID) bridging radiotherapy. Either schedule is considered standard of care and this study aims to determine which schedule may prove superior between the two standards.
219354500|NCT07072598|DEVICE|ClearPETRA suction access sheath|Ureteroscopy utilizing the ClearPETRA suction access sheath.
219354501|NCT07072598|DEVICE|ClearPETRA suction access sheath|Mini-PCNL utilizing the ClearPETRA suction access sheath
219354502|NCT02494869|BEHAVIORAL|Nonlinear Aerobic Training|
219354503|NCT02494869|OTHER|Height, Weight, BMI measure|
219354504|NCT02494869|OTHER|Blood draw|
219354505|NCT02494869|OTHER|Cardiopulmonary exercise test|
219354506|NCT06844500|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
219354507|NCT06844500|BIOLOGICAL|MVA-BN standard regimen (Administered as PEP)|"MVA-BN. Post Exposure Prophylaxis (PEP)~The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.~For Maternal Group 3, MVA-Bn will be administered as PEP as soon as possible after exposure, preferably within 4 days after exposure. However, as per WHO guidelines, PEP will be offered up to 14 days after exposure if the pregnant woman has not yet developed symptoms."
219354508|NCT01844986|DRUG|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
219354509|NCT06887218|DRUG|Regorafenib (BAY 73-4506)|Regorafenib will be administered a starting dose of 80 mg per day with weekly 40 mg per day increases to a maximum of 120 mg per day for 3 weeks on / 1 week off continued until disease progression or unacceptable toxic effects occurred or consent was withdrawn, up to 12 cycles of treatment.
219354510|NCT06887218|DRUG|5FU/LV|5FU/LV administered as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m² IV bolus then 2400 mg/m² IV infusion over 46 hours\] in 2-week cycles)
219354511|NCT06887218|DRUG|Bevacizumab|Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered intravenously on days 1 and 15.
219354512|NCT06887218|DRUG|Trifluridine-tipiracil|FTD-TPI, administered orally, BID, at a starting dose of 35 mg/m2 of body-surface area, on days 1 through 5 and on days 8 through 12 every 28 days.
219354513|NCT05624268|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
219354515|NCT07126548|OTHER|Best Practice|Receive standard care
219354516|NCT07126548|OTHER|Discussion|Ancillary studies
219354517|NCT07126548|OTHER|Survey Administration|Ancillary studies
219354518|NCT07126548|PROCEDURE|Virtual Reality|Receive access to ViRA application
219354519|NCT07131891|OTHER|Fatigue Severity Scale|"Individuals' fatigue severity will be assessed using the Fatigue Severity Scale (FSS). The scale consists of nine questions, and participants are asked about their fatigue level over the past week. Questions are scored from 1 to 7 using a Likert-type scale, where 1 corresponds to strongly disagree and 7 to strongly agree, with higher scores indicating greater agreement. The total score is calculated by taking the arithmetic mean of all items, with the highest possible score being 7. Scores of 4 and above indicate pathological fatigue. The validity and reliability of the FSS in Turkish have been previously established."
219354520|NCT07131891|OTHER|Depression, Anxiety and Stress Scale-21|"The 21-item Depression, Anxiety, and Stress Scale (DASS-21) will be administered to assess individuals' levels of depression, anxiety, and stress. The original scale was developed by Lovibond with 42 items. Subsequently, Brown et al. validated a shorter form for the same purpose and created the 21-item DASS-21. The Turkish adaptation of the DASS-21 was conducted by Yılmaz et al. The scale measures three subscales-depression, anxiety, and stress-consisting of seven items each. It is a 4-point Likert-type scale, with 0 indicating Does not apply to me, 1 Applies to me somewhat, 2 Generally applies to me, and 3 Applies to me completely. All items are scored positively, and each subscale is categorized as normal, mild, moderate, severe, or very severe."
219354521|NCT07131891|OTHER|Jenkins Sleep Scale|The Jenkins Sleep Scale consists of four questions that assess sleep problems over a four-week period. Each question is scored from 0 to 5, resulting in a total score ranging from 0 to 20, with higher scores indicating greater sleep disturbances.
219354522|NCT07131891|OTHER|Epworth Sleepiness Scale|The Epworth Sleepiness Scale (ESS) was developed to assess daytime sleepiness. It consists of eight items, each scored from 0 to 3, yielding a total score ranging from 0 to 24. Higher scores indicate greater daytime sleepiness. The Turkish version of the scale was validated for reliability and accuracy by İzci et al. in 2008..
219354523|NCT07131891|OTHER|Short Form-36|Quality of life will be assessed using the Turkish version of the Short Form-36 (SF-36). The SF-36 assesses quality of life under eight subscales: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for each subscale are calculated separately, ranging from 0 to 100, with higher scores indicating better health status. A total score is not calculated.
219354524|NCT06929143|DRUG|Aflibercept (Eylea, BAY86-5321)|8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).
219354525|NCT07141745|PROCEDURE|Pulsed field ablation of reccurent atrial arrythmia|Substrate modification strategy based ablation of reccurent atrial arrythmia following pulmonary viens isolation employing pulsed field ablation with 3D guidance and high density mapping
219354526|NCT07141745|PROCEDURE|Radiofrequency ablation of reccurent atrial arrythmia (standard of care)|Standard radiofrequncy ablation of reccurent atrial arrythmia following pulmonary vien isolation employing substrate modification strategy
219354527|NCT07130266|PROCEDURE|Procedure/Surgery: Hyaluronic acid gel application|After root surface cleaning and infected cement removal, 0.8% HA gel was applied to the root surface, bone, and inner surface of the flap and left for 2 minutes.
219354528|NCT07130266|PROCEDURE|giving an impression of the application|In the control group, instead of HA gel, the area was irrigated with physiological saline solution.
219354529|NCT03723083|DRUG|CC-2001|CC-2001 will be administered orally
219354530|NCT00376610|DEVICE|ASR/Re-cap|
219354531|NCT06943573|DRUG|psilocybin (25 mg)|Single-dose psilocybin (25 mg)-assisted therapy (PAT)
219354532|NCT06943573|DRUG|psilocybin 1mg micro-dose|Single dose active placebo psilocybin-assisted therapy
219354533|NCT07142902|OTHER|Data processing only, treatment is not part of the registry|Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.
219354534|NCT07142785|PROCEDURE|Epiretinal membrane peeling|All patients will receive standard pars plana vitrectomy, followed by only epiretinal membrane peeling.
219354535|NCT07142785|PROCEDURE|Epiretinal membrane peeling combined with internal limiting membrane peeling|All patients will receive standard pars plana vitrectomy, followed by epiretinal membrane peeling and internal limiting membrane peeling.
219354536|NCT07144020|BIOLOGICAL|CD117 CAR T-cells|Each subject receive CD117 CAR T-cells by intravenous infusion
219354537|NCT07143747|OTHER|Hyperpolarized 129Xe MRI|Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.
219354538|NCT07143747|OTHER|Tc-99m Technegas Ventilation Imaging|Inhalation of Tc-99m-labeled carbon aerosol (Technegas) followed by SPECT imaging to assess lung ventilation.
219354539|NCT07144059|OTHER|ECG by the SMUR after medical interrogation by the SAMU|Patients who had the qualifying ECG by the SMUR after medical interrogation by the SAMU
219354540|NCT07144059|OTHER|ECG performed by a non-medical vector|Patients who have called the emergency services with either an ECG performed by a non-medical vector (SP or ambulance), or a decision to reinforce SMUR during the first aid assessment
219354541|NCT07143968|DRUG|Resmetirom|Resmetirom - 80mg or 100mg based on participant weight
219354542|NCT07143968|DRUG|Placebo Control|Placebo - an identical looking tablet with no medicinal properties
219354543|NCT07144605|OTHER|CAD-CAM, indirect restorations|Indirect restorations that we think will last longer than traditional filling materials in teeth with molar hypomineralization.
219354544|NCT07144644|DEVICE|Adjusting intraocular pressure (IOP) settings|Investigating whether adjusting IOP settings near physiologic levels during cataract surgery could potentially lead to better surgical outcomes
219354545|NCT07144657|DRUG|Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole|"1. Frontline antibiotics treatment (two weeks of quadruple HPE regimens followed by 4 weeks of clarithromycin).~2. If no response to frontline antibiotics treatment, second line immune-modulator regimens (CAMC, clarithromycin (CAM) and low-dose cyclophosphamide) will be prescribed"
219354546|NCT07143890|OTHER|Meal A|Iron chlorophyllin + water
219354547|NCT07143890|OTHER|Meal B|Soy hemoglobin + water
219354548|NCT07143890|OTHER|Meal C|FeSO4 (negative control) + water
219354549|NCT07143890|OTHER|Meal D|Porcine hemoglobin (positive control) + water
219354550|NCT07143890|OTHER|Meal E|Iron chlorophyllin + maize porridge
219354551|NCT07143890|OTHER|Meal F|Soy hemoglobin + maize porridge
219354552|NCT07143890|OTHER|Meal G|FeSO4 (negative control) + maize porridge
219354553|NCT07143890|OTHER|Meal H|Porcine hemoglobin (positive control) + maize porridge
219354554|NCT07144254|DRUG|Tegavivint|Tegavivint will be administered second, IV over 4 hours, on days 1, 8, and 15 at the dose level assigned at study entry Cycle length will be 21 days. A cycle may be repeated for a total of 17 cycles, up to a total duration of therapy of approximately 12 months.
219354555|NCT07144254|DRUG|Gemcitabine|Gemcitabine will be administered first, intravenously (IV) over 60 minutes, on days 1 and 8 at a fixed dose of 1000 mg/m2
219354556|NCT07144501|DIAGNOSTIC_TEST|Ultrasonography|Ultrasound, also known as sonography or ultrasonography, is a medical imaging technique that uses high-frequency sound waves to create real-time images of internal body structures
219354557|NCT07144501|PROCEDURE|Blood Sampling|"To assess hepatic function in congenital heart disease (CHD) patients, blood samples will be collected from all patients in our study for:~* Alanine Transferase (ALT).~* Aspartate Aminotransferase (AST).~* Gamma Glutamyl Transferase (GGT).~* Alkaline Phosphatase (ALP).~* Total/direct bilirubin.~* Albumin.~* Prothrombin time.~* International Normalized Ratio (INR).~* Platelet count."
219354558|NCT07143500|OTHER|Selected physical therapy program|Passive stretching, active range of motion exercises, isometric strengthening, and functional gripping practice for the hand
219354559|NCT07143500|OTHER|Task Oriented Training for Upper limb|Seated in chair with arm and back support, with forearms resting on a table 73 cm high. Functional movements were trained through task-oriented exercises involving simple activities of daily living(ADL), such as eating (using a plate and spoon), personal hygiene (combing hair, brushing teeth), and tasks using household items (e.g., handling a cup and spoon, or opening a bottle and cap). Each task was repeated five times. Patients were allowed rest periods of five minutes as needed during the exercise sessions.
219354560|NCT07143500|OTHER|Action Observation Training Program|sat comfortably in a chair or wheelchair with both arms resting on a table (73 cm high) positioned 50 cm from a 15.6-inch colored laptop screen. They were instructed to attentively observe action videos displayed on the screen and then imitate the observed movements using their affected upper limb. A total of 30 action videos were used, each lasting approximately 50 seconds and demonstrating specific upper limb movements, such as wrist flexion/extension, abduction/adduction, pronation/supination, ulnar/radial deviation, and various grasping and manipulation tasks (e.g., handling coins, pens, a computer mouse, jar lids, bottle caps, typewriting, dialing a phone, and feeding).
219354561|NCT07142837|DRUG|ZG005|ZG005 20mg/kg; once every 3 weeks；IV infusion
219354562|NCT07142837|DRUG|Gecacitinib|Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
219354563|NCT07143032|PROCEDURE|Extropia squint surgery|patients with large angle exotropia will be treated by three different surgical techniques including: 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation ,to compare the surgical outcomes between them.
219354564|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
219354565|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
219354566|NCT07143682|DRUG|Letrozol step up dose|Tablet letrozole 2.5mg one, two, three, and four tablets once daily from 2nd/3rd day of the menstrual cycle for 4 days
219354567|NCT07143682|DRUG|Conventional fixed dose letrozole|Tab letrozole 5mg once daily for 5 days started from the 2nd/3rd day of the menstrual cycle
219354568|NCT07143240|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, clinical data relating to neuropathy, and tedizolid prescription modalities (dose, duration).
219354569|NCT07144488|DIETARY_SUPPLEMENT|Olive Oil Polyphenol Supplement (OOPs, OLEOPROTECT®, Thousand Olives®)|Participants receive two capsules daily (total 10 mg/day) of a standardized olive oil polyphenol extract. Each capsule contains 5 mg of aldehydic phenols: 75% oleocanthal/oleacein and 25% oleuropein aglycon/ligstroside aglycon. Formulated with PEG400, cellulose, silicon dioxide, and magnesium stearate. Duration: 12 weeks.
219354570|NCT07144488|DIETARY_SUPPLEMENT|Placebo capsules|Two capsules taken daily for 12 weeks. Identical in weight, appearance, and taste to the active OOPs capsules. Contain PEG400, cellulose, silicon dioxide, and magnesium stearate, but no active olive oil polyphenols.
219354571|NCT07143188|DIETARY_SUPPLEMENT|elemental diet (ED)|mBIOTA is a palatable elemental diet formulation
219354572|NCT07143812|DRUG|MSC11FCD|Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery.
219354573|NCT07142980|DRUG|HRS-7172 Tablets|HRS-7172 tablets.
219354574|NCT07144423|PROCEDURE|Endoscope-assisted hematoma drainage|The procedure of endoscope-assisted hematoma drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as shown on CT scan. A bone flap measuring 2.0 cm × 2.0 cm is then created using a milling cutter. Under the guidance of a visualized neuroendoscope, the hematoma is thoroughly irrigated and evacuated. A subdural drainage tube is inserted, and postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
219354575|NCT07144423|PROCEDURE|Burr hole hematoma drainage|The procedure of burr hole drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as indicated by CT scan. A subdural drainage tube is then inserted. The hematoma cavity is irrigated intraoperatively until the drainage fluid becomes clear. Postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
219354576|NCT07142720|DIETARY_SUPPLEMENT|A seaweed extract from brown seaweed, containing fucoidan, laminarin, and the antioxidant phlorotannin.|Portions of the seaweed extract were dissolved in rice milk to help camouflage the strong algae-taste. Plain rice milk served as placebo.
219354577|NCT07143357|BEHAVIORAL|Recovering Together after Cardiac Arrest 1|The intervention will teach resiliency skills (mindfulness and coping) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person until the survivor is discharged; remaining sessions will occur over Zoom.
219354578|NCT07143357|OTHER|Recovering Together after Cardiac Arrest 2|In this minimally enhanced usual care control, dyads will participate in one 30-minute session with a clinician at beside to review a pamphlet of available psychosocial resources for cardiac arrest survivors and their caregivers.
219354579|NCT07143565|BEHAVIORAL|Online platform hub and mHealth Text Messaging|The treatment package includes both optional and mandatory treatments. The mandatory treatments consist of mHealth text messaging and an online platform hub. We have developed a game which educates teenagers about alcohol reduction and promotes awareness of alcohol-related harm. Designed to be both engaging and informative, the game uses real-life scenarios, interactive storytelling, and decision-based gameplay to help young people understand the risks of excessive drinking. Also, participants with Audit Score \> 7 will receive individualized chat-based instant text messages from WhatsApp for 8 weeks. They will have real-time and one-to-one interaction. The conversation intensity depends on the participants' need.
219354580|NCT07143565|BEHAVIORAL|Self-help material|Self-help material like leaflet is a common method used in preventing teenage Drinking.
219354581|NCT07143773|DRUG|SGLT-2 inhibitor|The intervention in this clinical trial will be treatment with an SGLT2 inhibitor (Forxiga, 10 mg tablet once daily) compared with a matching placebo. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either Forxiga or placebo as an add-on to standard immunosuppressive therapy. This intervention differs from other studies by specifically targeting non-diabetic kidney transplant recipients, a population in which the efficacy and safety of SGLT2 inhibitors have not yet been established.
219354582|NCT07143773|DRUG|Placebo|The control intervention in this clinical trial will be a matching placebo tablet, identical in appearance to Forxiga (10 mg), administered once daily as an add-on to standard immunosuppressive therapy. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either placebo or Forxiga. This placebo intervention ensures blinding of both participants and investigators and allows a direct comparison of the safety and efficacy of SGLT2 inhibition versus no active treatment in this unique patient population.
219354583|NCT07143929|DRUG|CAR-T|autologous CD7-targeted CAR-T cells, single injection
219354584|NCT07144358|BEHAVIORAL|Biological Feeding Position|Biological Feeding Position
219354585|NCT07144540|OTHER|NeuroBot|NeuroBot is an artificial intelligence online accessible chatbot that used machine learning and generative pretrained transformer model for supporting patients undergoing neurovascular surgery during perioperative period
219354586|NCT07144540|OTHER|Standard Care (in control arm)|Standard care include face-to-face consultation in preoperative nurse clinic and provision of leaflet
219354587|NCT07144592|BEHAVIORAL|solution-oriented approach program|The solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment.
219354588|NCT07144371|OTHER|Virtual Reality Training Group|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
219354589|NCT07144371|OTHER|Standard Football Training|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
219354590|NCT07143214|BEHAVIORAL|online dialectical behavior therapy|"Enrolled participants will be provided with credentials to access the mobile application for a 28-day therapist-supported DBT self-help intervention. Participants are required to engage with the application at least once daily throughout the 4-week intervention period, with each session requiring approximately 30 minutes of engagement. The application delivers automated daily reminders at user-configurable timepoints. Additionally, participants receive asynchronous text-based guidance via WeChat during the treatment phase, wherein therapists provide support, feedback, and clinical direction during predetermined response windows. Each participant's cumulative weekly guidance duration is capped at 15 minutes.~The application's therapeutic framework integrates core components from The Dialectical Behavior Therapy Skills for Emotional Eating and standardized DBT treatment manuals, structured across four evidence-based modules: (1) Mindfulness, (2) Distress Tolerance, (3) Interpersonal Eff"
219354591|NCT07143214|BEHAVIORAL|Waitlist and psychoeducation|The active control group serves as a rigorous placebo comparator condition. Participants allocated to this arm will receive daily psychoeducational communications regarding binge-eating pathology, encompassing epidemiological data, biopsychosocial determinants, clinical manifestations, and therapeutic approaches. Crucially, all disseminated content remains devoid of Dialectical Behavior Therapy (DBT)-related components or skill-building elements.
219354592|NCT07144566|OTHER|Nurse Led Sexual Health Clinical Program Intervention|In person visit with Advanced Practice Provider (APP) whom is an Advanced Practice Nurse Practitioner in Oncology. Visit will include a focused pelvic exam, sexual health treatment plan, sexual health education, and referrals that follow the current Sexual Health Survivorship NCCN guidelines. A post visit telephone will be provided by the APP 8 weeks after APP visit for follow up questions and further education if needed.
219354593|NCT07144475|BIOLOGICAL|Lactobacillus casei Shirota|Consumption of Lactobacillus casei Shirota three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
219354594|NCT07144475|BIOLOGICAL|Lactobacillus acidophilus|Consumption of Lactobacillus acidophilus three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
219354595|NCT07143864|BIOLOGICAL|Stapokibart|A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha
219354596|NCT07143864|OTHER|Placebo drug|Placebo drugs without Stapokibart
219354597|NCT07143201|DRUG|Standard Dose - Ibuprofen oral suspension|Standard dosing administers ibuprofen without adjustments, starting with an initial loading dose followed by two maintenance doses at 24-hour intervals: 10/5/5 mg/kg for infants aged ≤72 hours, and 20/10/10 mg/kg for those \>72 hours old.
219354598|NCT07143201|DRUG|Precision Dose - Ibuprofen oral suspension|Precision Dosing (Model-Informed Precision Dosing - MIPD): Begins with the same initial loading dose as the Standard Dosing arm, with subsequent doses adjusted based on a Bayesian forecasting model that integrates real-time PK and echocardiographic data.
219354599|NCT05901818|DRUG|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
219354600|NCT04370301|DRUG|Cyclophosphamide|Given IV
219354601|NCT04370301|DRUG|JAK Inhibitor|Given PO
219354602|NCT04370301|DRUG|Fludarabine|Given IV
219354603|NCT04370301|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
219354604|NCT04370301|DRUG|Melphalan|Given IV
219354605|NCT04370301|DRUG|Mycophenolate Mofetil|Given PO
219354606|NCT04370301|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
219354607|NCT04370301|DRUG|Tacrolimus|Given IV and PO
219354608|NCT04370301|RADIATION|Total-Body Irradiation|Undergo TBI
219354609|NCT04370301|PROCEDURE|Computed Tomography|Undergo CT
219354610|NCT04370301|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219354611|NCT04370301|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219354612|NCT04370301|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219354613|NCT04370301|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219354614|NCT04370301|PROCEDURE|Echocardiography|Undergo ECHO
219354615|NCT04370301|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219354616|NCT05744921|DRUG|Pozelimab|Administered per the protocol
219354617|NCT05744921|DRUG|Cemdisiran|Administered per the protocol
219354618|NCT05752279|DRUG|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
219354619|NCT05752279|DRUG|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
219354620|NCT04319510|PROCEDURE|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
219354621|NCT04319510|PROCEDURE|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
219354622|NCT04319510|PROCEDURE|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered self-selection to 1:1 CST or participation in the CST self-help group training.
219354623|NCT04062318|DEVICE|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
219354624|NCT05861531|BEHAVIORAL|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
219354625|NCT05861531|BEHAVIORAL|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
219354626|NCT05861531|BEHAVIORAL|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
219354627|NCT05861531|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
219354628|NCT05861531|BEHAVIORAL|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
219354629|NCT01149265|BEHAVIORAL|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
219354630|NCT01149265|BEHAVIORAL|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
219354631|NCT04705051|DRUG|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
219354632|NCT04532710|DRUG|Eye Drops, Solution in Single-Dose Container|Application of eye drops
219354633|NCT06267027|BEHAVIORAL|Exercise|The aim of exercise therapy is to stretch and strengthen the wrist extensor and flexor muscles. All study groups were given a home exercise program including stretching and eccentric strengthening exercises. The patient was instructed to start with stretching, and the patient was informed to stretch for 30s by flexing the wrist with the other hand while the shoulder was flexed 90 degrees, the elbow was in extension and the forearm was pronated. When stretching exercises could be performed painlessly, the patient was instructed to move on to strengthening exercises. Eccentric strengthening exercises for wrist extensors and flexors were explained with a support under the forearm and each patient was given a written program supported with visuals. It was emphasized that the exercises should be performed within the pain limit and patients were told to stop if they had severe pain. The exercise program was told to be performed 2 times a day, in 3 sets, 10 repetitions.
219354634|NCT06267027|DEVICE|Kinesiotaping|Area where the tape would be applied was clean and dry. If there is excessive hair in the application area, patients were asked to shave this area. It was explained that cream and similar substances should not be used. Muscle inhibition technique and fascia correction technique were used as the application technique. An X strip of approximately 25 cm and a Y strip of 10 cm in length are prepared as long as the distance between the lateral epicondyle and the wrist. The short arms of the X strip are adhered to the dorsal side of the hand without stretching and the crossed part of the strip is placed on the wrist with maximal stretching. The long arms of the X strip are adhered along the extensor carpi ulnaris and extensor carpi radialis to the lateral epicondyle without stretching. The Y strip was applied using the fascia correction method. The tails of the Y band were applied using an oscillating motion. The taping procedure was applied 2 times a week for 3 weeks for a total of 6 times.
219354635|NCT06267027|DEVICE|High intensity laser therapy|The elbow area was marked and then the epicondylitis protocol was selected. The epicondylitis protocol consists of 3 phases. Phase 1 and 2 consist of analgesic treatment and phase 3 consists of anti-inflammatory treatment. In phase 1 and phase 2 treatment protocol, 8 W was applied to a circular area with a radius of 1.0 cm for 3 min. In Phase 3 protocol, a dose of 80 J/cm2 at 8 W power was applied and the patient's treatment was completed.
219354636|NCT00004575|DRUG|Miconazole, L-NMMA, Bradykinin|
219354637|NCT06181162|OTHER|Social and/or physical environmental interventions|To be determined in the co-creation groups at the four sites (Denmark, the Netherlands, Nigeria, South Africa)
219354638|NCT04784221|RADIATION|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
219354639|NCT02968810|PROCEDURE|Biospecimen Collection|Undergo collection of blood
219354640|NCT02968810|PROCEDURE|Computed Tomography|Undergo CT
219354641|NCT02968810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219354642|NCT02968810|OTHER|Placebo Administration|Given PO
219354643|NCT02968810|OTHER|Questionnaire Administration|Ancillary studies
219354644|NCT02968810|DRUG|Simvastatin|Given PO
219354645|NCT06248957|COMBINATION_PRODUCT|Immunomodulation|Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
219354646|NCT00883883|DRUG|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
219354647|NCT00883883|DRUG|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
219354648|NCT05273684|OTHER|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
219354649|NCT05446493|DRUG|Tadalafil 5mg|"* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~* Penile color Doppler ultrasound examination before and after treatment"
219354650|NCT05995392|DRUG|Topical spironolactone ophthalmic solution, 0.005 mg/cc|Used four times a day in both eyes for 4 weeks.
219354651|NCT05995392|DRUG|Placebo|Used four times a day in both eyes for 4 weeks.
219354652|NCT01236456|DRUG|Cyclophosphamide|
219354653|NCT00002944|DRUG|carboplatin|Given IV
219354654|NCT00002944|DRUG|lomustine|Given IV
219354655|NCT00002944|DRUG|procarbazine hydrochloride|Given PO
219354656|NCT00002944|DRUG|thioguanine|Given PO
219354657|NCT00002944|DRUG|vincristine sulfate|Given PO and IV
219354658|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
219354659|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
219354660|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
219354661|NCT05220592|BEHAVIORAL|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
219354662|NCT02977923|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
219354663|NCT02977923|OTHER|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
219354664|NCT01449708|DRUG|TIVA NoNarc|"* patients in both groups receive antiemetic prophylaxis~* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~* postop management in both groups is similar in both groups"
219354665|NCT01231165|DRUG|Amiloride|5mg/daily for 12th months
219354666|NCT01231165|DRUG|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
219354667|NCT04505683|DRUG|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
219354668|NCT04505683|DRUG|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
219354669|NCT05753722|BIOLOGICAL|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
219354670|NCT05753722|BIOLOGICAL|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
219354671|NCT06401018|PROCEDURE|No noise cancellation and no music playing|In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.
219354672|NCT06401018|PROCEDURE|Noise cancelled but not allowed to listen to music|In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.
219354673|NCT06401018|PROCEDURE|Music is played but noise is not cancelled|In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
219354674|NCT04880577|DRUG|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
219354675|NCT04880577|DRUG|Placebo|Placebo arm
219354676|NCT05022641|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
219354677|NCT05022641|OTHER|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
219354678|NCT00223496|DRUG|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
219354679|NCT05982262|OTHER|Naturopathic-pharmacological consultation|The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
219354680|NCT01894204|OTHER|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
219354681|NCT00559507|DRUG|saracatinib|
219354682|NCT00559507|OTHER|laboratory biomarker analysis|Correlative studies
219354683|NCT01548001|DRUG|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
219354684|NCT01548001|DRUG|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
219354685|NCT02250014|PROCEDURE|cryotherapy|Undergo cryotherapy
219354686|NCT02250014|BIOLOGICAL|sargramostim|Given subcutaneously
219354687|NCT06335550|PROCEDURE|Robotic mastectomy|Robotic mastectomy with or without reconstruction
219354688|NCT02889796|DRUG|Filgotinib|200 mg or 100 mg tablet(s) administered orally once daily
219354689|NCT02889796|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
219354690|NCT02889796|DRUG|Adalimumab|40 mg administered via subcutaneous injection once every two weeks
219354691|NCT02889796|DRUG|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
219354692|NCT02889796|DRUG|MTX|Commercially sourced tablet(s) administered orally
219354693|NCT00360659|DEVICE|Continuous Positive Airway Pressure|
219354694|NCT04418687|DEVICE|Orthoglide|Knee rehabilitation device.
219354695|NCT04418687|OTHER|Physiotherapy only|Physiotherapy only.
219354696|NCT01629797|BEHAVIORAL|Educational script on Acne|An educational script on Acne will be presented by investigator
219354697|NCT03346460|OTHER|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
219360222|NCT04217265|DRUG|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
219360223|NCT03222427|DRUG|LY3314814|Administered orally
219360224|NCT03222427|DRUG|[13C415N3] LY3314814|Administered as an IV infusion
219360225|NCT04184817|OTHER|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
219360226|NCT02922387|DRUG|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
219360227|NCT02922387|BEHAVIORAL|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
219363857|NCT03357393|DRUG|Propofol-Lipuro|Propofol is given as sedation to both intervention arms.
219363858|NCT03357393|DRUG|morphine-scopolamine|Given as premedication for the Control arm and one of the interventions arms.
219363859|NCT03357393|DRUG|Glycopyrrolate|Given as premedication for one of the intervention arms..
219364357|NCT01483430|DRUG|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
219364358|NCT01483430|DRUG|Placebo|1 capsule/day (starch), Duration: 8 weeks
219360228|NCT03646084|OTHER|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
219360229|NCT03646084|OTHER|Rehabilitation program|Rehabilitation program current clinical practice
219360230|NCT01970176|DRUG|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
219364359|NCT05495204|DRUG|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
219360231|NCT01970176|DRUG|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
219360232|NCT05336084|BEHAVIORAL|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
219360233|NCT06231758|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
219364360|NCT01171820|DEVICE|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
219360234|NCT06231758|DRUG|Metformin|Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
219360235|NCT04931134|DEVICE|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
219360236|NCT04931134|DEVICE|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
219360237|NCT03106779|DRUG|Asciminib|40 mg tablets was taken orally twice a day (BID)
219360238|NCT03106779|DRUG|Bosutinib|500 mg tablets was taken orally once daily (QD)
219360239|NCT05867667|OTHER|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
219360240|NCT04001647|DRUG|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
219360241|NCT04001647|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
219364361|NCT01171820|DEVICE|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
219364362|NCT04285385|OTHER|Lavender aromatherapy|0.10 ml of lavender essential oil
219364363|NCT04285385|OTHER|Sham aromatherapy|0.10 ml of mineral oil
219366201|NCT00439582|DIETARY_SUPPLEMENT|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
219360242|NCT04001647|DRUG|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
219366202|NCT03310970|DRUG|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
219360243|NCT05188703|BEHAVIORAL|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
219360244|NCT05622097|OTHER|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
219360245|NCT05622097|OTHER|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
219360246|NCT06507566|DEVICE|Tasso+™|The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.
219360247|NCT05003934|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219360248|NCT02288247|DRUG|Enzalutamide|Oral
219360249|NCT02288247|DRUG|Docetaxel|intravenous infusion
219360250|NCT02288247|DRUG|Prednisolone|Oral
219360251|NCT02288247|DRUG|Placebo|Oral
219360252|NCT06395090|BIOLOGICAL|Pembrolizumab|IV infusion
219360253|NCT06395090|BIOLOGICAL|Favezelimab|IV infusion
219360254|NCT06395090|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
219360255|NCT06395090|BIOLOGICAL|Vibostolimab|IV infusion
219360256|NCT06395090|BIOLOGICAL|Pembrolizumab/Vibostolimab|IV infusion
219360257|NCT05269290|DRUG|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
219360258|NCT05269290|DRUG|Placebo|Placebo will be administered once a day on top of standard therapy.
219366203|NCT03310970|DRUG|Lidocaine hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
219355536|NCT04109495|OTHER|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
219360926|NCT02617810|DRUG|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
219360927|NCT02617810|DRUG|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
219360928|NCT02456350|DRUG|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
219366204|NCT03310970|DRUG|Lidoderm 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
219360929|NCT02456350|DRUG|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
219366205|NCT00028990|DRUG|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
219366206|NCT00028990|DRUG|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
219360930|NCT02456350|BIOLOGICAL|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
219364364|NCT06207266|BEHAVIORAL|emotion intelligence program|The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
219361426|NCT07160231|DRUG|JAKi disease activity guided continuation of same dose strategy|JAKi disease activity guided continuation of same dose strategy
219361427|NCT07179198|DEVICE|KIO021|KIO021 is used as a device product for dry skin and dull complexion
219361428|NCT07177599|BIOLOGICAL|Natural history|Natural history of pancreatic diseases
219355537|NCT04109495|OTHER|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
219355538|NCT02270203|RADIATION|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
219355539|NCT04525716|OTHER|COVID-19 infection status|We will compare patients with/without confirmed COVID-19 infection
219355540|NCT00741156|DRUG|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
219355541|NCT01316172|BEHAVIORAL|5 Cs|education on consultation
219355542|NCT03388463|DRUG|Omeprazole|Omeprazole 80 mg continues infusion
219355543|NCT03388463|DRUG|Placebo group|Omeprazole 40 mg single daily dose.
219355544|NCT03879564|DRUG|Ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
219355545|NCT03879564|DRUG|Normal saline|NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
219355546|NCT01951469|DRUG|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
219355547|NCT01951469|DRUG|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
219355548|NCT02463955|DEVICE|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
219355549|NCT02463955|DEVICE|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
219355550|NCT00734669|DRUG|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
219355551|NCT02165384|DEVICE|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
219355552|NCT02762513|DRUG|Axitinib|
219364648|NCT02814149|PROCEDURE|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
219364649|NCT03729947|DEVICE|Subfascial closed suction drain|Ch 14 closed suction drain
219364650|NCT00524160|DRUG|Fentanyl transdermal patch|
219364651|NCT00123565|DRUG|Hexadecasaccharide (SR123781A)|
219364652|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
219364653|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
219355553|NCT01390909|DRUG|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
219355554|NCT00984204|DEVICE|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
219355555|NCT03844906|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
219355556|NCT03844906|DRUG|Placebo|Placebo in combination with Ketamine
219355557|NCT02848079|DRUG|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
219355558|NCT04290702|PROCEDURE|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
219355559|NCT04313556|PROCEDURE|Lateral patellar release|Arthroscopic lateral patellar reticular release
219364654|NCT03175341|DRUG|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
219364655|NCT03175341|DRUG|Placebos|100 ml normal saline 0.9%
219355560|NCT05093101|OTHER|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
219355561|NCT00004493|DRUG|sodium dichloroacetate|
219364656|NCT03881969|BEHAVIORAL|Financial Payment of £100|No financial payment
219364918|NCT05422066|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
219364657|NCT04305015|DEVICE|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
219364658|NCT04305015|OTHER|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
219355562|NCT01268293|DRUG|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
219362043|NCT01725750|DEVICE|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
219364659|NCT00173862|DRUG|Gemcitabine, Ifosfamide|
219355563|NCT06173557|PROCEDURE|entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic i|technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports
219355564|NCT04788082|DIAGNOSTIC_TEST|3D Printed Heart Model|Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
219355565|NCT04390867|DEVICE|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
219355566|NCT04390867|DEVICE|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
219355567|NCT04390867|DEVICE|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
219362044|NCT04291755|DRUG|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
219355568|NCT04390867|DEVICE|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
219362045|NCT02542072|DEVICE|comfilcon A|contact lens
219355569|NCT03592979|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219355570|NCT03592979|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
219355571|NCT03812809|DRUG|BPI-7711|BPI-7711: 180mg, QD, oral
219355572|NCT06164405|DEVICE|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
219362046|NCT02542072|DEVICE|samfilcon A|contact lens
219355573|NCT06638892|BEHAVIORAL|Using PrEP, Doing it for Ourselves (UPDOs)|An e-Health intervention that considers women's lived experiences and uses three components: beauty salons and stylists as opinion leaders (trusted gatekeepers who share health information in the community), theory driven edutainment videos and blogs, and a secure online platform for accessing pre-exposure prophylaxis (PrEP).
219355574|NCT06638892|OTHER|Standard of Care|CDC standard of care, e.g., CDC videos and website.
219355575|NCT05111262|DRUG|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
219364660|NCT00140894|DRUG|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
219355576|NCT06175234|DEVICE|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
219355577|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
219355578|NCT06501274|DEVICE|capsule sponge|capsule sponge sampling device of the oesophagus
219355579|NCT06576427|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
219355580|NCT00360581|BEHAVIORAL|Yoga|
219355581|NCT00360581|BEHAVIORAL|Yoga and Cognitive Behavioral Therapy|
219355582|NCT00317148|DRUG|Placebos|Placebo capsule
219355583|NCT00317148|DRUG|DHEA capsule|One capsule of DHEA
219362280|NCT03631706|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
219362281|NCT03631706|DRUG|Pembrolizumab|Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
219364661|NCT00140894|DRUG|Comparator: placebo / Duration of Treatment: 24 weeks|
219364662|NCT00234039|DRUG|gemcitabine hydrochloride|
219364663|NCT01284504|DRUG|Celecoxib|200 mg tablet oral
219355588|NCT04040569|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
219364664|NCT01284504|OTHER|placebo|Placebo, tab
219361429|NCT07178873|BEHAVIORAL|Psychosocial teleassistance intervention|The teleassistance psychosocial intervention involves 10 weekly 90-minute group sessions, with each group comprising 6 to 7 participants. These sessions are designed to enhance self-concept, self-esteem and social skills, reduce symptoms, and improve overall psychological well-being. Two follow-up sessions will be provided three months after the main program concludes.
219361430|NCT07179055|DRUG|VSJ-110|ophthalmic solution
219361431|NCT07179055|DRUG|Placebo|ophthalmic solution
219364665|NCT03558347|DEVICE|short implants with splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
219361536|NCT00804687|DRUG|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
219361537|NCT00334503|DRUG|Miglitol|
219361538|NCT02550158|PROCEDURE|Educational program EDU-MICI|
219361539|NCT05042427|OTHER|Pregnancy Weight Management Health Literacy Questionnaire|Give questionnaires to check the weight management health literacy level of primigravida women.
219361540|NCT01864785|PROCEDURE|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
219361541|NCT01864785|PROCEDURE|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
219361542|NCT02008825|DEVICE|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
219361543|NCT02008825|DEVICE|Usual non suction Bougie|Usual non suction Bougie
219361544|NCT03329456|DRUG|Ropivacaine|Minimum effective volume
219361545|NCT03569202|DEVICE|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
219361546|NCT03569202|DEVICE|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
219361547|NCT02439580|DIETARY_SUPPLEMENT|Annona muricata extract|ethanol-soluble fraction of water extract
219361548|NCT02439580|DIETARY_SUPPLEMENT|Placebo|maltose
219361549|NCT00337233|PROCEDURE|yoga therapy|10 week yoga class
219361550|NCT00727363|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
219361551|NCT00727363|DIETARY_SUPPLEMENT|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
219361552|NCT01283932|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
219361553|NCT01145937|PROCEDURE|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
219361554|NCT01145937|PROCEDURE|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
219361555|NCT00890838|DIETARY_SUPPLEMENT|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
219361556|NCT00420511|DRUG|Sitagliptin|sitagliptin 100 mg once a day
219361557|NCT00420511|DRUG|Placebo|placebo once a day
219361558|NCT00420511|DRUG|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
219361937|NCT00903279|DRUG|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
219366207|NCT05993637|OTHER|Examination of propriception|application of the tests used in proprioception assessment to patients by a physiotherapist
219361938|NCT00903279|DRUG|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
219361939|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
219361940|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
219361941|NCT01463813|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
219355589|NCT06298071|DRUG|SIBP-R002|Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
219361942|NCT04408807|OTHER|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
219361943|NCT04408807|OTHER|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
219364666|NCT03558347|DEVICE|short implants with non-splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
219366208|NCT01964235|DRUG|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
219355590|NCT06298071|DRUG|SIBP-R002|Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
219361944|NCT03543085|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
219364788|NCT02526550|BIOLOGICAL|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
219361945|NCT04428606|DIETARY_SUPPLEMENT|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
219366209|NCT01964235|DRUG|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
219366262|NCT05558150|DRUG|Aceclofenac|Aceclofenac 100mg
219355591|NCT06298071|DRUG|SIBP-R002|Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
219355592|NCT06298071|DRUG|Methotrexate|Combination drugs: Methotrexate, dose15 mg, oral.
219355593|NCT05702515|OTHER|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
219355594|NCT06845813|DRUG|AZD6234|Dose 1
219364919|NCT05422066|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
219355595|NCT04970251|DRUG|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
219355596|NCT01396005|DRUG|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
219355597|NCT01396005|DRUG|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
219355598|NCT01396005|DRUG|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
219361946|NCT04428606|DIETARY_SUPPLEMENT|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
219361947|NCT04428606|DIETARY_SUPPLEMENT|Placebo|Placebo
219361948|NCT01099969|DEVICE|Glidescope videolaryngoscope|
219361949|NCT01099969|DEVICE|McGrath videolaryngoscope|
219355599|NCT03027752|PROCEDURE|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
219361950|NCT01099969|DEVICE|Non-styletted Endotrol endotracheal tube (ETT)|
219361951|NCT01099969|DEVICE|Regular endotracheal tube (ETT) with Gliderite stylet|
219364920|NCT06133660|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy and Silicone oil removal to distinguish subjects
219366263|NCT04955561|OTHER|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
219359835|NCT07179289|OTHER|Provision of the MSProgress quality approach support tool|"The MSProgress tool is composed of 43 quantitative indicators identified by field teams and queried in health insurance databases. It is presented in a 20-page document organized by theme, allowing simplified access to the team's data, easily understandable by all. It allows the MSP to choose the indicators that make sense at the level of their patient base. Updated annually, the results make it possible to observe the team's progress and to position itself in relation to the regional average of MSPs in the Auvergne-Rhône-Alpes region, promoting collective reflection on the implementation of corrective actions.~The MSProgress tool will be made available for 12, 24 or 36 months depending on the randomization group."
219359836|NCT07178236|DEVICE|MARIE|Portable capnoghraphy
219359837|NCT07177859|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
219359838|NCT07177859|DRUG|Eculizumab Injection|Eculizumab
219359839|NCT07177651|PROCEDURE|Laminoplasty|Is a posterior approach that involves the surgical widening of the spinal canal by reshaping or repositioning the lamina. However, some patients with cervical stenosis
219359840|NCT07177651|PROCEDURE|Laminectomy with lateral mass fixation|Posterior cervical decompression with lateral mass screw insertion
219359841|NCT07178964|OTHER|Potassium-enriched salt-substitute|The patients in the experimental group will use potassium-enriched salt-substitutes for cooking and seasoning food in their home environment. Potassium-enriched salt-substitutes will contain 25% potassium chloride nad 75% sodium chloride.
219359842|NCT07178964|OTHER|Regular table salt|Patients in this arm will use regular table salt (100 % sodium chloride) for cooking and seasoning food in their home environment.
219359843|NCT07179380|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
219359844|NCT07179380|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
219359845|NCT07177469|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
219359846|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
219359847|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
219359848|NCT07177469|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
219360093|NCT01340521|DRUG|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
219359812|NCT07164677|PROCEDURE|Bilateral ultrasound guided Sham Block|"Bilateral ultrasound-guided needle placement will be performed in the same anatomical plane as in the SPSIP group, but instead of local anesthetic, an equivalent volume of normal saline (30 mL per side) will be injected.~Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis."
219178229|NCT06798116|PROCEDURE|Experimental: open flap debridement and demineralized freeze-dried bone allograft and mixed with liquid (PRF|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement and DFDBA and mixed with liquid (PRF)"
219178230|NCT06798116|PROCEDURE|defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects."
219178231|NCT06798116|PROCEDURE|defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane"
219178232|NCT06798116|PROCEDURE|open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane.|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane."
219178233|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
219178234|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
219178235|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
219178236|NCT06254807|DRUG|CT-0525|Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
219178237|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
219178238|NCT05540860|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
219178239|NCT05540860|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
219178240|NCT05540860|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
219178241|NCT05540860|DRUG|Sevasemten Dose 4|Sevasemten is administered orally once per day
219178242|NCT05540860|DRUG|Sevasemten Dose 5|Sevasemten is administered orally once per day
219178243|NCT05540860|DRUG|Placebo|Placebo is administered orally once per day
219178244|NCT04683744|OTHER|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
219178245|NCT04683744|OTHER|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
219178246|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
219178247|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
219178248|NCT04472598|DRUG|Navitoclax|Tablet; Oral
219178249|NCT04472598|DRUG|Ruxolitinib|Tablet; Oral
219178250|NCT04472598|DRUG|Placebo for Navitoclax|Tablet; Oral
219178251|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
219178252|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
219178253|NCT05182398|OTHER|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
219178254|NCT05464160|DEVICE|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
219178255|NCT05464160|OTHER|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
219178256|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
219178257|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
219178258|NCT02432404|DRUG|NuvaRing|
219178259|NCT05987735|BEHAVIORAL|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
219178260|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
219178261|NCT06100900|DRUG|BCX10013|Multiple dose levels may be tested in this study.
219178262|NCT04101851|PROCEDURE|omission of SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
219178263|NCT03315806|OTHER|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
219178264|NCT03315806|OTHER|Placebo|140 mL of beetroot juice isent of nitrate
219178265|NCT05761366|DRUG|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
219178266|NCT04963270|DRUG|Satralizumab|Satralizumab will be administered as a subcutaneous injection
219178267|NCT04963270|OTHER|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
219178268|NCT05136417|DEVICE|intra-procedural intracardiac echocardiography (ICE) probe|placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
219178269|NCT06289647|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
219178270|NCT04026555|OTHER|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
219178271|NCT04026555|OTHER|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
219178272|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
219178273|NCT04859530|DIAGNOSTIC_TEST|AVC test|The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
219178275|NCT06800222|OTHER|modern agents rehab|rehabilitation interventions containing modern physical agents together with classical interventions
219178276|NCT06800222|OTHER|classical rehab|classical rehabilitation interventions
219178277|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
219178278|NCT06213298|DRUG|Kava|75 mg kavalactones
219178279|NCT06213298|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
219178280|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
219178281|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
219178282|NCT06415942|OTHER|Maternal Outcome Monitoring and Support system|The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
219178283|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
219178284|NCT06475521|OTHER|Infant Formula|Test group
219178285|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
219178286|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
219178287|NCT06797986|BIOLOGICAL|BVAC-E6E7 (low level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
219178288|NCT06797986|BIOLOGICAL|BVAC-E6E7 (high level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
219178289|NCT06797986|BIOLOGICAL|BVAC-E6E7 (RP2D)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
219178290|NCT05842265|OTHER|Self acupressure|patients will do self acupressure
219178291|NCT03737643|DRUG|Bevacizumab|Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
219178292|NCT03737643|DRUG|Durvalumab|Durvalumab by intravenous infusion
219178293|NCT03737643|DRUG|Olaparib|Olaparib tablets
219178294|NCT03737643|DRUG|Placebo olaparib|Placebo tablets to match olaparib
219178295|NCT03737643|DRUG|Durvalumab placebo|Matching placebo for intravenous infusion
219178296|NCT03737643|DRUG|Carboplatin+Paclitaxel|Standard of care chemotherapy
219178297|NCT04150900|DRUG|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
219178298|NCT04150900|DRUG|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
219178299|NCT06543537|BEHAVIORAL|Collaborative Agenda-Setting Intervention|A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
219178300|NCT05689684|DIETARY_SUPPLEMENT|AG+XOS+AXOS|4-month parallel randomized controlled study
219178301|NCT05689684|DIETARY_SUPPLEMENT|Placebo Maltodextrin|4-month parallel randomized controlled study
219178302|NCT05871905|DRUG|TY-9591|C14 TY-9591
219178303|NCT01521039|PROCEDURE|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
219178304|NCT05462353|DRUG|2mg of ASC41|ASC41 tablet administered orally once daily.
219178305|NCT05462353|DRUG|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
219178306|NCT05462353|DRUG|Placebo|Placebo tablets administered orally once daily.
219178307|NCT05950841|DRUG|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
219178308|NCT05950841|DRUG|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
219178309|NCT05950841|DRUG|Carob flour|Twice daily dose of 1 capsule (carob flour)
219178310|NCT05255965|DIAGNOSTIC_TEST|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
219178311|NCT04284865|OTHER|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
219178312|NCT05569122|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
219178313|NCT05569122|DEVICE|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
219178314|NCT05569122|DEVICE|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
219178315|NCT05569122|DEVICE|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
219178316|NCT05569122|DRUG|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
219178317|NCT06799468|PROCEDURE|liver transplantation|Liver transplantation or hepatic transplantation is the replacement of a diseased liver with the healthy liver from another person (allograft). Liver transplantation is a treatment option for end-stage liver disease and acute liver failure, although availability of donor organs is a major limitation. Liver transplantation is highly regulated, and only performed at designated transplant medical centers by highly trained transplant physicians. Favorable outcomes require careful screening for eligible recipients, as well as a well-calibrated live or deceased donor match.
219178318|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
219178319|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 1.1|Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
219178320|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
219178321|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 2.1|Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
219178322|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
219178323|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 3.1|Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.
219178324|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
219178325|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.1|Participants will use their Radicle Relaxation Active Study Product 4.1 as directed for a period of 6 weeks.
219178326|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.2|Participants will use their Radicle Relaxation Active Study Product 4.2 as directed for a period of 6 weeks.
219178327|NCT06771401|DIAGNOSTIC_TEST|cervical mucus sampling|Monitoring of menstrual cycle will be conducted in the follicular, ovulatory and luteal phases during which cervical mucus, serum and urine samples will be collected and pelvic ultrasound scans performed (3-5 ultrasound scans/samples within the cycle).
219178328|NCT05910749|DEVICE|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
219178329|NCT06547268|DEVICE|Wireless sensor and platform|Skin-mounted sensor that pairs with tablet platform
219178330|NCT05376579|OTHER|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
219178331|NCT01724580|DRUG|Baricitinib|Administered orally
219178332|NCT06414018|DRUG|Alfentanil|alfentanil 10ug/kg is used for anesthesia induction
219178333|NCT06381713|BEHAVIORAL|High intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks."
219178334|NCT06381713|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks."
219178335|NCT06798376|DRUG|≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
219178336|NCT06798376|DRUG|≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
219178337|NCT06798376|PROCEDURE|Gastrectomy|Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed
219178338|NCT06433245|PROCEDURE|effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
219178339|NCT04856982|DRUG|Tofersen|Administered as specified in the treatment arm
219178340|NCT04856982|DRUG|Placebo|Administered as specified in the treatment arm
219178341|NCT06461845|OTHER|Whole Body Vibration group|This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
219178342|NCT06461845|OTHER|conventional therapy|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
219178343|NCT02994160|OTHER|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
219178344|NCT04624633|DRUG|Acalabrutinib|Oral, twice a day, predetermined dosage
219178345|NCT04624633|DRUG|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
219178346|NCT04624633|DRUG|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
219366264|NCT04955561|OTHER|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
219178347|NCT01667952|GENETIC|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
219178348|NCT01667952|GENETIC|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
219178349|NCT01667952|OTHER|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
219178350|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
219178351|NCT04316871|DRUG|1.5 mg of Morphine Sulfate|1.5 mg of Morphine Sulphate will be given epidurally.
219178352|NCT04316871|DRUG|Normal saline|Normal saline will be given epidurally.
219178353|NCT04316871|DRUG|3 mg of Morphine Sulfate|3 mg of Morphine Sulphate will be given epidurally.
219178354|NCT04316871|DRUG|4.5 mg of Morphine Sulfate|4.5 mg of Morphine Sulphate will be given epidurally.
219178355|NCT05366075|OTHER|Intervention 1 (simple exercise program)|Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
219178356|NCT05366075|OTHER|Intervention 2 (comprehensive exercise program)|Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
219178357|NCT05087992|DRUG|BI 905711|BI 905711
219178358|NCT05087992|DRUG|FOLFIRI|FOLFIRI
219178359|NCT05087992|DRUG|Bevacizumab|Bevacizumab
219178360|NCT05758922|DRUG|AZ-3102 (Dose 1)|"Pharmaceutical form: capsule~Route of administration: oral"
219178361|NCT05758922|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
219178362|NCT05758922|DRUG|AZ-3102 (Dose 2)|"Pharmaceutical form: capsule~Route of administration: oral"
219178363|NCT06773273|PROCEDURE|CapsuLaser-Assisted Capsulorhexis and Flanged Prolene Suture|CapsuLaser-Assisted Capsulorhexis and Flanged 6-0 Prolene Suture for Cionni Ring Scleral Fixation
219178364|NCT06545682|DRUG|Alpelisib + Pembrolizumab|Given by mouth (PO) Given by vein (IV)
219178365|NCT04900818|DRUG|TJ033721 (givastomig)|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
219178366|NCT04900818|DRUG|TJ033721 (givastomig) , nivolumab, chemotherapy|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
219178367|NCT06114940|DRUG|Toripalimab|"Preoperative: Toripalimab 240mg, IV on day 1 in a 3-week cycle. Preoperative Toripalimab contains 4-5 cycles.~Postoperative: Toripalimab 240mg, IV on day 1 of a 3-week cycle. Postoperative Toripalimab following surgery within 4 weeks for patients mentioned above in cohort 1, 2 and 3."
219178368|NCT06114940|DRUG|Lenvatinib|"Preoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Preoperative Lenvatinib contains 4-5 cycles.~Postoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Postoperative Lenvatinib following surgery within 4 weeks for patients in cohort 3.~Adjustment of dose: For patients with intolerable adverse reactions (CTCAE v5.0 grade 3 or grater), the dose could be reduced to 12mg for those who were suitable to continue taking the drug after systematic evaluation by the investigator. Patients who are assessed as intolerable and not suitable for continued medication will discontinue and undergo nephrectomy within 4 weeks."
219178369|NCT01842542|DEVICE|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
219178370|NCT01192464|DRUG|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
219178371|NCT06774209|DIAGNOSTIC_TEST|three kinds of examinations|Following the enrollment of patients, both Gallium-68 labeled Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography (68Ga-FAPI-04 PET/CT) and Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) scans are carried out. Additionally, within a one-week interval before and after the aforementioned examinations, Fluorine-18 labeled Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is performed on the same cohort of patients.
219178372|NCT06381284|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
219178373|NCT06381284|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
219178374|NCT06381284|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
219178375|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
219178376|NCT06807814|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT))|A well-defined and structured rehabilitation program that restricts the use of the unaffected limb to promote the functional recovery of the affected limb in chronic stroke patients(Franck et al., 2019). Sit-to-stand transitions, Indoor overground walking (forward, backward, and sideways), Weight-bearing movements in different directions: Stepping over obstacles and climbing stairs, Ideally, specific tasks to involve the paretic limb according to the activity of stroke survivors. This task was repeated ten times as part of the therapy sessions. Dynamic strengthening exercises like squats and lunges are integrated, progressively increasing intensity as patients gain confidence and strength. Balance and core stability exercises, including single-leg stances and seated weight shifts on therapy balls, address postural control and stability.(Cabanas-Valdés \& Boix-Sala, 2021)
219178377|NCT06807814|BEHAVIORAL|Mirror Therapy|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. The MT protocol included 10 minutes of warm-up, 1 hour of mirror box training, and 50 minutes of functional task practice. The warm-up activities included stretching and passive range of motion exercises. During the mirror box training, a mirror box that reflected the image of the unaffected arm was placed in the participant's midsagittal plane. Participants were required to symmetrically move both hands as simultaneously as possible while watching the reflection of the unaffected arm in the mirror as if it were the affected one. To ensure that the participants focused on the reflection, the unaffected arm was placed in the mirror box, and vision of the affected arm was occluded by a vertical board placed beside the mirror box. The activities consisted of transitive (eg, gross motor tasks, such as reaching
219178378|NCT04002518|DEVICE|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
219178379|NCT05119491|DEVICE|uitrasonography and spirometry|chest uitrasonography and spirometry
219178380|NCT03696225|BEHAVIORAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
219178381|NCT03696225|BEHAVIORAL|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
219178382|NCT06577090|BIOLOGICAL|Nimacimab injection|Nimacimab injection 200 mg
219178383|NCT06577090|BIOLOGICAL|Nimacimab placebo injection|matching nimacimab placebo injection
219178384|NCT06577090|COMBINATION_PRODUCT|semaglutide injection|semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
219178385|NCT06321809|BEHAVIORAL|intensive lifestyle|INTENSIVE LIFESTYLE INTERVENTIONS
219178386|NCT05759156|DRUG|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
219178387|NCT06529796|DRUG|IXP|Tablet for oral administration.
219178388|NCT02436096|DRUG|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
219178389|NCT02436096|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
219178390|NCT06185101|BEHAVIORAL|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
219178391|NCT05211635|DIETARY_SUPPLEMENT|Vitamin D|One capsule daily for 84 days
219178392|NCT05211635|OTHER|Placebo|One capsule daily for 84 days
219178393|NCT05339451|DIAGNOSTIC_TEST|Blood biomarkers|Blood biomarkers in plasma and serum.
219178394|NCT06311565|BEHAVIORAL|Education|Individuals in this group will be trained on acquiring healthy lifestyle behaviors to protect against colorectal cancer. Training will be individual, face-to-face and in the form of question and answer. At the end of the training, training brochures prepared by the researchers after taking expert opinions will be distributed to the participants. The training will take approximately 25-30 minutes. The training will take place in the training hall at the family health center.
219178395|NCT05145309|DRUG|KMgCit|Supplement that provide K, Mg, and citrate
219178396|NCT05145309|DRUG|Placebo|Power with identical appearance to KMgCit
219178397|NCT01824394|DEVICE|nMARQ Navigation Catheters|
219178398|NCT01824394|DEVICE|NaviStar ThermoCool Catheters|
219178399|NCT06639503|DRUG|Bupivacain|5mL 0.25% bupivacain
219178400|NCT03787693|BEHAVIORAL|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
219178401|NCT04485104|DRUG|GWP42003-P|Oral Solution
219178402|NCT05871385|DEVICE|rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
219178403|NCT05871385|DEVICE|placebo rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
219178404|NCT06129682|OTHER|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
219360094|NCT00122135|OTHER|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
219178405|NCT05222451|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
219178406|NCT05222451|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
219178407|NCT05222451|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
219178408|NCT05869760|OTHER|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
219178409|NCT05869760|OTHER|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
219178410|NCT06545214|PROCEDURE|Video-EEG monitoring|Video-EEG monitoring
219178411|NCT06545214|PROCEDURE|Respiratory monitoring and polysomnography|heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)
219178412|NCT06545214|PROCEDURE|1 Hypercapnic challenge while participant is awake|The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
219178413|NCT06545214|PROCEDURE|2 Hypercapnic challenges while participant is sleeping|"In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance."
219178414|NCT06545214|PROCEDURE|Auditory stimulus|Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.
219178415|NCT06545214|OTHER|Questionnaires|Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS
219178416|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
219178417|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
219178418|NCT00179829|PROCEDURE|WT 1 Testing|
219178419|NCT06479486|DIAGNOSTIC_TEST|Assigned Interventions|warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
219178420|NCT04057638|PROCEDURE|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
219178421|NCT04152655|DRUG|Idebenone|30mg tablets three times a day
219178422|NCT04152655|DRUG|Placebo oral tablet|placebo tablets three times a day
219178423|NCT06107010|DEVICE|Use of the Atalante exoskeleton|Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
219178424|NCT01987895|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
219178425|NCT01987895|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
219178426|NCT01987895|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
219178427|NCT01987895|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
219178428|NCT04696185|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 mg (daily oral dose)
219178429|NCT04325035|DRUG|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
219178430|NCT04325035|DRUG|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
219178431|NCT06807788|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
219178432|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
219178433|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
219178434|NCT05956756|BEHAVIORAL|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
219178435|NCT05081999|OTHER|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
219178436|NCT05081999|OTHER|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
219178437|NCT06807398|GENETIC|Data will be used to develop a novel predictive model assessing the risk of LNI.|The epigenetic signature will be tested on DNA extracted from PCa tissue obtained at prostate biopsy. For each patient, 2 positive cores will be analysed. The 2 cores will be selected as follows: (i) one core from the index lesion; the core with the highest Gleason Score will be selected. In case of two or more cores with the same Gleason Score, the one with the highest percentage of cancer involvement will be selected; (ii) one core with the highest Gleason score outside the index lesion. In case of two or more cores with the same Gleason score, the one with the highest percentage of cancer involvement will be selected. The epigenetic signature will be tested on DNA extracted from prostate cancer tissue obtained from the two positive cores. In particular, the epigenetic score will be calculated on the prostatic tissue using the epigenetic signatures previously identified \[8\].In patients diagnosed with PCa who will be treated with RP, ePLND will be performed when the predicted LNI risk
219178438|NCT04682691|DRUG|Erythromycin (400mg)|oral Erythromycin (400mg)
219178439|NCT04682691|DRUG|metoclopramide (10mg)|oral metoclopramide (10mg)
219178440|NCT04682691|DIETARY_SUPPLEMENT|naturally flavored water|naturally flavored water
219178441|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
219178442|NCT05317611|DRUG|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
219178443|NCT05317611|DRUG|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
219178444|NCT05317611|DRUG|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
219178445|NCT05364671|DRUG|Raphamin|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
219178446|NCT05364671|DRUG|Placebo|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
219178447|NCT03511846|DRUG|Oral capsaicin|Subjects will drink a solution with capsaicin
219178448|NCT03511846|DRUG|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
219178449|NCT03511846|DRUG|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
219178450|NCT03511846|OTHER|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
219178451|NCT03511846|OTHER|Medical Air|Subjects will be exposed to medical air
219178452|NCT03511846|DRUG|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
219178453|NCT03511846|DRUG|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
219178454|NCT06059339|OTHER|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
219178455|NCT04755517|OTHER|Frequent information of cytological/ HPV DNA screening results|"All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end."
219178456|NCT05090033|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
219178457|NCT06772870|DRUG|DT-216P2|DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
219178458|NCT06772870|DRUG|Saline|Normal saline solution will be used as placebo control.
219178459|NCT05256017|DRUG|Acoziborole|Single dose administration of acoziborole (3 tablets of 320 mg) on Day 1
219178460|NCT05256017|DRUG|Placebo|Single dose administration of placebo (3 tablets of 320 mg) on Day 1
219178461|NCT05757778|PROCEDURE|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
219178462|NCT06770530|DRUG|Fluconazole|400 mg inravenous Fluconazole, single dose 200 ml
219178463|NCT06770530|DRUG|Isotonic saline solution|Intravenous saline solution, single dose 200 ml
219178464|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
219178465|NCT06766487|BEHAVIORAL|Tongue resistance exercises|"The TRE program consisted of the following exercises:~Exercise 1: Tongue Protrusion and Retraction Against Resistance, Exercise 2: Anterior Tongue Protrusion and Retraction Against Resistance, Exercise 3: Middle Tongue Protrusion and Retraction Against Resistance, Exercise 4: Middle Tongue Elevation with Pharyngeal Sound Production, Exercise 5: Tongue Elevation and Posterior Sweeping, and Exercise 6: Saliva Swallowing with Lip Closure."
219178466|NCT06766487|BEHAVIORAL|cheek bulging exercises|Cheek bulging exercises involved a series of movements: Lip Closure: Participants began by closing their lips. Unilateral Cheek Bulging: They then bulged their right cheek, followed by relaxation and return to the initial position. This was repeated on the left side. Bilateral Cheek Bulging: Finally, participants bulged both cheeks simultaneously.
219178467|NCT05465928|DEVICE|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
219178468|NCT05465928|DEVICE|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
219178469|NCT04018859|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
219178470|NCT04018859|DRUG|Saline|intradermal injections to the eyebrows
219178471|NCT06807658|BEHAVIORAL|Experimental: Cardiac tele-rehabilitation|Patients will connect to their health care provider via a tele-call
219178472|NCT06807658|BEHAVIORAL|Other: Control, in person cardiac rehabilitation|Patients will attend an ambulatory cardiac rehabilitation unit
219360095|NCT06547476|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib|Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w
219360096|NCT01944085|DRUG|Acetaminophen|Syrup
219178473|NCT05368402|DRUG|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) were administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules were swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
219178474|NCT05368402|OTHER|Placebo|Placebo was administered with the same ladarixin schedule.
219178475|NCT04500613|PROCEDURE|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
219178476|NCT04500613|OTHER|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
219178477|NCT03947190|BIOLOGICAL|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
219178478|NCT03947190|BIOLOGICAL|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
219178479|NCT03947190|BIOLOGICAL|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
219178480|NCT03092635|DRUG|OPC|OPC is a derivative of grape seed extract
219178481|NCT05564221|DRUG|YH35324|Subcutaneous injection of YH35324
219178482|NCT05564221|DRUG|Placebo|Subcutaneous injection of None of active ingredient
219178483|NCT05564221|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
219178484|NCT04493645|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
219178485|NCT04493645|BEHAVIORAL|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
219178486|NCT03536754|OTHER|Placebo|Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
219178487|NCT03536754|DRUG|CCX140-B|One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
219178488|NCT03536754|DRUG|CCX140-B|Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
219178489|NCT03536754|DRUG|CCX140-B|Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
219178490|NCT05300464|DEVICE|Clinical investigation medical device class IIa marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
219178491|NCT06758752|DIETARY_SUPPLEMENT|ZAX.1400.EC.02|ZAX.1400.EC.02, applied twice daily for 3 weeks after enrolment
219178492|NCT06758752|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
219178493|NCT06109194|OTHER|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
219178494|NCT04832282|DEVICE|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
219178495|NCT04832282|OTHER|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
219178496|NCT02658565|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
219178497|NCT06451549|DEVICE|Syndi recommender system for mental health apps|Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
219178498|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
219178499|NCT04919057|DEVICE|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
219178500|NCT04858321|PROCEDURE|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
219178501|NCT06780371|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels.~Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
219178502|NCT05057247|DRUG|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
219178503|NCT05057247|DRUG|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
219360097|NCT01944085|DRUG|Ibuprofen|Syrup
219360098|NCT01944085|OTHER|Vitamin C|Syrup
219178504|NCT06803160|PROCEDURE|Laparoscopic Extravesical Fistula Excision of Uterovesical Fistula|• In extravesical approach, the posterior bladder wall and the anterior uterine wall around the fistula will be dissected. Scar tissue around the orifice of the fistula will be removed and trimmed. After suturing uterine and bladder wall, intervening omentum will be placed in-between.
219178505|NCT06803160|PROCEDURE|Laparoscopic Combined Fistula Excision of Uterovesical Fistula|• In the combined approach, bladder will be opened bivalved till the site of the fistula. Scar tissue around the orifice of the fistula will be removed and trimmed. Careful dissection around the bladder and uterus will be done to suture both walls and place an intervening omentum in-between.
219178506|NCT06803394|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
219178507|NCT06803394|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
219178508|NCT02774421|DRUG|Trastuzumab after SubQ GM-CSF|Administration of trastuzumab following subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Trastuzumab is a monoclonal antibody targeting HER2-positive cancers, commonly used in breast and gastric cancer treatment.
219178509|NCT02774421|DRUG|Trastuzumab in combination with SubQ GM-CSF|Combine trastuzumab, a monoclonal antibody targeting HER2-positive cancers, with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF functions as an immune system modulator, promoting the activation and proliferation of dendritic cells, macrophages, and granulocytes.
219178510|NCT06760403|DRUG|Hypochlorous acid|Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
219178511|NCT06804044|BEHAVIORAL|Intermittent Fasting|A 16:8 intermittent fasting with a daytime eating window model was applied.
219178512|NCT06804044|BEHAVIORAL|Standart Diet Therapy|Meal plan with 3 main meals and 3 snacks was applied.
219178513|NCT05024734|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
219178514|NCT05024734|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
219178515|NCT05024734|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
219178516|NCT05024734|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
219178517|NCT04987723|OTHER|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
219178518|NCT04987723|OTHER|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
219178519|NCT04987723|OTHER|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
219178520|NCT04987723|OTHER|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
219178521|NCT06803199|DRUG|FSH and LH|In the study group, participants receive FSH and LH in IVF cycle
219178522|NCT06803199|DRUG|FSH|In the control group, participants receive FSH alone in IVF cycle
219178523|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
219178524|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
219178525|NCT06345157|DRUG|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
219178526|NCT02907554|DRUG|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
219178527|NCT02907554|DRUG|Placebo|control group receives a placebo
219178528|NCT04652700|DRUG|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
219178529|NCT04652700|DRUG|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
219178530|NCT04652700|DRUG|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
219178531|NCT04652700|DRUG|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
219178532|NCT04652700|DRUG|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
219178533|NCT04652700|DRUG|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
219178534|NCT04187833|DRUG|Nivolumab|480mg intravenously every 4 weeks (28 days)
219178535|NCT04187833|DRUG|Talazoparib|1mg orally daily
219178536|NCT04513639|DRUG|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
219178537|NCT04513639|DRUG|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
219178538|NCT02381353|DRUG|Bupivacaine|Intraoperative orbital injection of local pain medication
219178539|NCT03097549|DEVICE|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
219178540|NCT03097549|DEVICE|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
219178541|NCT05647304|DEVICE|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
219178542|NCT05647304|DEVICE|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
219178543|NCT04148560|OTHER|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
219178544|NCT04605770|DRUG|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
219178545|NCT06332326|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.
219178546|NCT06332326|BEHAVIORAL|vestibular rehabilitation|vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
219178547|NCT05903807|DRUG|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
219178548|NCT04008355|DRUG|AZP2006 oral solution|Once daily intake in the morning
219178549|NCT04008355|DRUG|Placebo oral solution|Once daily intake in the morning
219178550|NCT04906447|BEHAVIORAL|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
219178551|NCT04906447|OTHER|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
219178552|NCT05437055|DEVICE|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
219178553|NCT04517149|BIOLOGICAL|4D-125 IVT Injection|4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
219178554|NCT04517149|OTHER|Observational|Natural History
219178555|NCT04594278|BEHAVIORAL|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
219178556|NCT04282148|DEVICE|ABT NG DES 48 EECSS|Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
219178557|NCT06144086|DRUG|Foscenvivint|Administered by intravenous (IV) infusion over 3-4 hours
219178558|NCT06559332|DIAGNOSTIC_TEST|Risk-based CAD management|Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.
219178559|NCT06559332|DIAGNOSTIC_TEST|Invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
219178560|NCT02146378|DRUG|Vyndaqel|20mg/day
219178561|NCT03490201|DEVICE|Market Approved RF Ablation System|Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
219178562|NCT03490201|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment using an ablation system that is not FDA approved.
219178563|NCT06647160|DEVICE|Blue star MAX-5 spectacle lens|The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
219178564|NCT06647160|DEVICE|Single-vision spectacle lens|The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
219178565|NCT06647225|DEVICE|Artificial intelligence augmented ultrasound|"The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan)."
219178566|NCT04838288|DRUG|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
219178567|NCT06083948|DRUG|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
219178568|NCT06083948|DRUG|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
219178569|NCT04612699|DRUG|Jaktinib|Administered orally
219178570|NCT04612699|DRUG|Placebo|Administered orally
219178571|NCT06381258|PROCEDURE|Ultrasound|Fetal echocardiography using ultrasound device
219178572|NCT06340282|DEVICE|Virtual reality|Immersive virtual reality
219178573|NCT06340282|BEHAVIORAL|multicomponent exercise|individualized exercise
219178574|NCT04529044|PROCEDURE|Biopsy|Undergo biopsy
219178575|NCT04529044|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219178576|NCT04529044|PROCEDURE|Computed Tomography|Undergo PET/CT
219178577|NCT04529044|RADIATION|Gallium Ga 68-DOTATATE|Receive 68Ga
219178578|NCT04529044|DRUG|Lutetium Lu 177 Dotatate|Given IV
219178579|NCT04529044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219178580|NCT05646589|BEHAVIORAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
219178581|NCT05646589|BEHAVIORAL|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
219178582|NCT06041568|DRUG|Imvotamab|Administered intravenously
219178583|NCT05265546|DRUG|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
219178584|NCT06313892|BEHAVIORAL|Home based Exercise|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
219178585|NCT02683447|OTHER|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
219178586|NCT05436600|OTHER|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
219178587|NCT03448107|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
219178588|NCT03448107|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
219178589|NCT03448107|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
219178590|NCT04883463|DEVICE|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
219178591|NCT04851340|OTHER|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
219178592|NCT04851340|OTHER|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
219178593|NCT06005987|BEHAVIORAL|OneTouch Reveal application|Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
219178594|NCT04025554|DRUG|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
219178595|NCT03115476|DRUG|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
219178596|NCT03115476|DRUG|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
219178597|NCT03115476|OTHER|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
219178598|NCT06279780|DIETARY_SUPPLEMENT|very low-calorie diet|Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
219178599|NCT05559931|DRUG|N,N-Dimethyltryptamine|IV infusion over 6 hours
219178600|NCT05559931|DRUG|Placebo|Placebo infusion over 6 hours
219178601|NCT05266495|OTHER|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
219178602|NCT04980248|BIOLOGICAL|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
219178603|NCT02933736|DRUG|Ribociclib|
219178604|NCT04852783|DEVICE|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
219178605|NCT00613106|DRUG|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
219178606|NCT00613106|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
219178607|NCT05574387|DRUG|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
219178608|NCT03142568|DRUG|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
219178609|NCT03142568|OTHER|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
219178610|NCT03906331|DRUG|Selpercatinib|Open-label expanded access
219178611|NCT06283498|DEVICE|Device Morpheus8V|Assigned to be treated using the modified Morpheus8V
219178612|NCT02396134|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Given SC
219178613|NCT02396134|OTHER|Placebo|Given SC
219178614|NCT02396134|OTHER|Laboratory Biomarker Analysis|Correlative studies
219178615|NCT06129019|BEHAVIORAL|Reiki|Reiki application will be done
219178616|NCT06122142|DEVICE|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
219178617|NCT06122142|DEVICE|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
219178618|NCT06122142|DEVICE|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
219178619|NCT00742482|DRUG|HL 10|Freeze dried HL 10
219178620|NCT03596788|DIETARY_SUPPLEMENT|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
219178621|NCT03596788|DIETARY_SUPPLEMENT|Placebo Beverage|The placebo beverage will contain aspartame.
219178622|NCT06424223|PROCEDURE|Horizontal Ridge augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
219178623|NCT01424150|OTHER|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
219178624|NCT01424150|OTHER|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
219178625|NCT05732805|BIOLOGICAL|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
219178626|NCT05732805|BIOLOGICAL|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
219178627|NCT05732805|BIOLOGICAL|Placebo|Placebo
219178628|NCT06330233|OTHER|Moxibustion|The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control. The drug treatment group received mecobalamin tablets and epalrestat orally for four weeks along with their daily treatment. Moxibustion 15-minute group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11), and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment. The moxibustion 30-minute group except for the operating time will use the same intervention as above.
219178629|NCT06517264|DRUG|Antibiotic|antibiotic treatment, analgesics and hygienic-dietetic measures
219178630|NCT06517264|OTHER|Non antibiotic|Analgesics and hygienic-dietetic measures
219178631|NCT04158804|DIAGNOSTIC_TEST|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
219178632|NCT02423603|DRUG|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
219178633|NCT02423603|DRUG|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
219178634|NCT02423603|DRUG|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
219178635|NCT06020677|OTHER|L-WebTIPS|This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
219178636|NCT06139458|BEHAVIORAL|Cryotherapy|Participants will receive cryotherapy on both hands and feet
219178637|NCT06139458|BEHAVIORAL|Compression|Participants will receive compression on both hands and feet
219178638|NCT05296525|DRUG|GDA-201|NAM-expanded allogeneic NK cells
219178639|NCT04536857|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
219178640|NCT06815835|BIOLOGICAL|Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd|Live attenuated vaccine
219178641|NCT06815835|BIOLOGICAL|Yellow fever Vaccine (WHO prequalified)|Live attenuated vaccine
219178642|NCT06072807|DIAGNOSTIC_TEST|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
219178643|NCT02918890|OTHER|Constraint-induced Movement Therapy|
219178644|NCT02918890|OTHER|Hand-arm Bimanual Intensive Therapy|
219178645|NCT05758688|RADIATION|Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
219366265|NCT04955561|OTHER|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
219178646|NCT04898413|BEHAVIORAL|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
219178647|NCT04898413|BEHAVIORAL|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
219178648|NCT03138863|DEVICE|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio-opaque inclusion
219178649|NCT03138863|DEVICE|Catheter System|100 cm tapered micro-catheter
219178650|NCT05479578|DRUG|Cyclophosphamide|Given PO
219178651|NCT05479578|DRUG|Dexamethasone|Given PO
219178652|NCT06207227|DEVICE|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
219178653|NCT04065841|DRUG|Tropifexor|100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
219178654|NCT04065841|DRUG|Licogliflozin|30mg tablet of licoglifozin taken orally every day
219178655|NCT04065841|OTHER|Placebo|licogliflozin placebo + tropifexor placebo
219178656|NCT03651414|OTHER|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
219178657|NCT05601687|PROCEDURE|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
219178658|NCT05601687|PROCEDURE|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
219178659|NCT01420237|DEVICE|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
219178660|NCT04222972|DRUG|Pralsetinib|Administered orally
219178661|NCT04222972|DRUG|Carboplatin|Administered IV
219178662|NCT04222972|DRUG|Cisplatin|Administered IV
219178663|NCT04222972|DRUG|Pemetrexed|Administered IV
219178664|NCT04222972|DRUG|Pembrolizumab|Administered IV
219178665|NCT04222972|DRUG|Gemcitabine|Administered IV
219178666|NCT04222972|DRUG|Paclitaxel|Administered IV
219178667|NCT04222972|DRUG|Nab-Paclitaxel|Administered IV
219178668|NCT06065176|BIOLOGICAL|Novavax COVID-19 vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Novavax vaccine.
219178669|NCT06065176|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Pfizer vaccine.
219178670|NCT04793737|RADIATION|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
219178671|NCT05804136|DEVICE|Duramesh|Laparotomy closure with Duramesh
219178672|NCT05804136|DEVICE|Polydioxanone suture|Laparotomy closure with standard PDS
219178673|NCT06539104|PROCEDURE|arteficial inteligence evaluation of oocyte and embryo development|apply AI to find out the complex oocyte quality, embryo development, embryo ploidy and pregnancy success probability from the sequence of the data starting from the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse record of early embryo development.
219178674|NCT05981833|DEVICE|Repair with DAA (dermal allograft augmentation)|Patients undergo rotator cuff repair with dermal allograft augmentation.
219178675|NCT06243016|BEHAVIORAL|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
219178676|NCT06243016|BEHAVIORAL|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
219178677|NCT04492722|DRUG|AZD5718|Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
219178678|NCT04492722|DRUG|Dapagliflozin 10 mg|Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
219178679|NCT04492722|DRUG|Placebo|Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
219178680|NCT02923570|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
219178681|NCT02923570|RADIATION|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
219178682|NCT03286699|BEHAVIORAL|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
219178683|NCT03286699|BEHAVIORAL|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
219178684|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
219178685|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
219178686|NCT06275945|DEVICE|Voro Urologic Scaffold|radical prostatectomy
219178687|NCT04946253|BEHAVIORAL|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
219178688|NCT04946253|BEHAVIORAL|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
219178689|NCT04946253|BEHAVIORAL|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
219178690|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
219178691|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
219178692|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
219178693|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
219178694|NCT03631784|DRUG|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
219178695|NCT03631784|DRUG|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
219178696|NCT03631784|DRUG|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
219178697|NCT03631784|DRUG|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
219178698|NCT03631784|DRUG|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
219178699|NCT03631784|RADIATION|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
219178700|NCT03631784|DRUG|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
219178701|NCT03631784|DRUG|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
219178702|NCT03373695|DEVICE|Dissolve™|Dissolve™ are to be used in the trial
219178703|NCT03373695|DEVICE|SeQuent®Please|SeQuent®Please are to be used in the trial
219178704|NCT05494411|DRUG|Mitomycin for pyelocalyceal solution|
219178705|NCT06423482|OTHER|PEEK bar|The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
219360099|NCT05145621|DRUG|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
219178706|NCT06423482|OTHER|Titanium bar|The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
219178707|NCT03848689|OTHER|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
219178708|NCT03848689|OTHER|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
219178709|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
219178710|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
219178711|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
219178712|NCT04589026|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
219178713|NCT04589026|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
219178714|NCT04484012|DRUG|Acalabrutinib|Given PO
219178715|NCT04484012|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
219178716|NCT00597805|BEHAVIORAL|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
219178717|NCT02876588|OTHER|Unrestricted|Users may open up to 4 patient records at a time.
219178718|NCT02876588|OTHER|Restricted|Users are restricted to open 1 patient record at a time.
219178719|NCT01956084|DRUG|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
219178720|NCT01956084|DRUG|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
219178721|NCT04722575|DRUG|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
219178722|NCT04722575|DRUG|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
219178723|NCT04722575|DRUG|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
219178724|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
219178725|NCT06822803|BEHAVIORAL|Gardening Nutrition Education Program|This intervention was a 6-week Social Cognitive Theory based, urban gardening, cooking and nutrition education program designed to change health behavior mediators, fruit and vegetable intake, stress, and life satisfaction in food insecure college students.
219178726|NCT05147701|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219178727|NCT04921917|OTHER|neoadjuvant exercise therapy|brief exercise regimen completed immediately prior to neoadjuvant radiation therapy. Rubber bands will be used for the exercise training of patients with lower extremity tumors while an electronic hand-held dynamometer will be used for the exercise training for patients with upper extremity tumors.
219178728|NCT06918925|DRUG|JUV-161, Placebo|Single-Ascending, Placebo-Controlled
219178729|NCT05144529|DRUG|Nivolumab|Nivolumab IV 240 mg
219178730|NCT05144529|DRUG|Ipilimumab|Ipilimumab IV 1 mg/kg
219178731|NCT05144529|DRUG|Evolocumab|Evolocumab 14 mg subcutaneous injection
219178732|NCT02251548|DRUG|Ibrutinib|Oral BTK inhibitor
219178733|NCT02251548|DRUG|Fludarabine|IV purine analogue chemotherapy agent
219178734|NCT02251548|DRUG|Cyclophosphamide|IV alkylator chemotherapy agent
219178735|NCT02251548|DRUG|Rituximab|IV anti-CD20 monoclonal antibody
219178736|NCT06837324|DEVICE|home-based Neofect Smart Glove|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart Glove, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeks.
219178737|NCT06837324|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
219178738|NCT05639478|OTHER|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
219178739|NCT05030233|BEHAVIORAL|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
219178740|NCT06930183|DRUG|Awake thoracic epidural anesthesia|Patients will preoperatively receive awake thoracic epidural anesthesia.
219178741|NCT06930183|DRUG|General anesthesia|Patients will receive general anesthesia.
219178742|NCT06931184|OTHER|self-sampling|increase screening coverage by self-sampling
219364921|NCT02658422|DRUG|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
219355600|NCT03027752|PROCEDURE|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
219355601|NCT03156400|OTHER|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
219355602|NCT04593784|DRUG|Ciraparantag|Ciraparantag: 180 mg, intravenous
219355603|NCT04593784|DRUG|Placebo|Placebo: 0.9% sodium chloride, intravenous
219355604|NCT04593784|DEVICE|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
219355605|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
219355606|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
219355607|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 1 mg/kg IV on Day 1
219355608|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 5 mg/kg IV on Day 1
219355609|NCT00607308|DRUG|Placebo|Single dose of placebo IV on Day 1
219355610|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 10 mg/kg IV on Day 1
219355611|NCT03622099|DRUG|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
219355612|NCT00424827|DRUG|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
219355613|NCT03264430|DRUG|Ketamine|an antagonist of the NMDA receptor
219355614|NCT03264430|DRUG|bupivacaine|local anaesthetic
219355615|NCT02697383|DRUG|Ixazomib (MLN9708)|
219355616|NCT02697383|DRUG|Dexamethasone|
219355617|NCT03757988|BEHAVIORAL|Exercise Intervention- PACE-Life|Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
219355618|NCT06286033|DRUG|AG-181|AG-181 tablets
219355619|NCT06286033|DRUG|Placebo|AG-181 matched-placebo tablets
219355620|NCT02093442|PROCEDURE|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
219355621|NCT02580500|PROCEDURE|epidural catheter|epidural anaesthesia application for spinal catheter will be used
219355622|NCT02580500|PROCEDURE|spinal catheter|spinal anesthesia application for spinal catheter will be used
219355623|NCT02401737|DRUG|NVR 3-778|
219355624|NCT02401737|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
219355625|NCT02401737|DRUG|Pegasys|
219355626|NCT00769145|DRUG|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
219355627|NCT00053248|DRUG|arsenic trioxide|
219355628|NCT00053248|DRUG|imatinib mesylate|
219355629|NCT01627587|DRUG|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
219355630|NCT01627587|DRUG|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
219355631|NCT01627587|DRUG|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
219355632|NCT01627587|DRUG|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
219355633|NCT01627587|DRUG|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
219355634|NCT02829021|DEVICE|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
219355635|NCT06237517|BEHAVIORAL|Assessment of Vasomotion of People With Idiopathic Chilblains|Investigation of vasomotion of people with and without idiopathic chilblains
219355636|NCT01390259|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
219355637|NCT01390259|DEVICE|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
219365459|NCT01551693|DRUG|STA-9090|
219355638|NCT02981836|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
219355639|NCT02981836|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
219355640|NCT04385563|DRUG|TQ-B211|Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
219355641|NCT04385563|DRUG|Herceptin®|Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
219355642|NCT04385563|DRUG|docetaxel|Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
219355643|NCT03237065|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
219355644|NCT03237065|DRUG|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
219355645|NCT00209339|DEVICE|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
219355646|NCT02188030|OTHER|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
219355647|NCT02188030|OTHER|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
219355648|NCT05449600|DEVICE|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
219355649|NCT05449600|DEVICE|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
219355650|NCT05449600|DEVICE|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
219355651|NCT01692548|OTHER|Neurofeedback|
219355652|NCT03529292|DEVICE|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
219355653|NCT01764633|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219355654|NCT01764633|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
219355655|NCT01913392|PROCEDURE|laparoscopic sleeve gastrectomy|
219355656|NCT02268058|DRUG|Acetaminophen|routine administration of medication for a 72 hour period
219355657|NCT02268058|DRUG|Ibuprofen|routine administration of medication for a 72 hour period
219355658|NCT02288338|DRUG|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355659|NCT02288338|DRUG|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355660|NCT02288338|DRUG|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355661|NCT02288338|DRUG|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355662|NCT02288338|DRUG|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355663|NCT02288338|DRUG|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355664|NCT02288338|DRUG|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355665|NCT02288338|DRUG|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355666|NCT02288338|DRUG|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355667|NCT02288338|DRUG|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355668|NCT02288338|DRUG|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355669|NCT02288338|DRUG|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355670|NCT02288338|DRUG|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355671|NCT02288338|DRUG|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355672|NCT02288338|DRUG|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355673|NCT02288338|DRUG|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355674|NCT02288338|DRUG|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
219355675|NCT02288338|DRUG|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
219355676|NCT04421625|DIAGNOSTIC_TEST|Diagnostic test for SARS-Cov2 for patients and health staff|"Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)"
219355677|NCT05055193|DRUG|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
219355678|NCT01503255|BEHAVIORAL|cognitive behavioral group therapy|6 weekly 90-minute group sessions
219355679|NCT01503255|BEHAVIORAL|health education group|6 weekly 90-minute group sessions
219355680|NCT02011009|OTHER|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
219355681|NCT03639090|DIAGNOSTIC_TEST|mass spectrometry|mass spectrometry for bladder cancer cells
219355682|NCT00128869|PROCEDURE|spine mobilizations|
219355683|NCT00128869|PROCEDURE|spine manipulations|
219355684|NCT03302754|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
219355685|NCT06303609|DEVICE|nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.
219355686|NCT06303609|DEVICE|Vaginal dilator|Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.
219355687|NCT06303609|DEVICE|Sham nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.
219355688|NCT02741102|PROCEDURE|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
219355689|NCT00144183|DRUG|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
219355690|NCT00144183|DRUG|Zidovudine (ZCV)|
219355691|NCT00144183|DRUG|3TC|
219355692|NCT04418765|DRUG|Eptinezumab|Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
219355693|NCT04418765|DRUG|Placebo|concentrate for solution for infusion, intravenously
219355694|NCT00104897|DRUG|tanespimycin|
219355695|NCT01065974|BEHAVIORAL|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
219355696|NCT01065974|DIETARY_SUPPLEMENT|Meal Replacements|Weight loss using CBT and meal replacements.
219355697|NCT01065974|BEHAVIORAL|Nutritrol|To make widespread nutritional changes to participants personal food environments.
219355698|NCT00927771|DRUG|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
219355699|NCT00927771|DRUG|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
219355700|NCT01121393|DRUG|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
219355701|NCT01121393|DRUG|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
219359813|NCT07171866|PROCEDURE|Immediate Implant Placement with SST|Participants underwent extraction and socket shield preparation, followed by immediate implant placement in the esthetic maxillary zone. The implant was inserted at the same surgical session using a flapless or minimally invasive approach. CBCT was used to guide planning and assess ridge dimensions. Healing and follow-up assessments were conducted at 1 year and 6 years post-placement.
219355702|NCT01100944|DRUG|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
219355703|NCT00778037|DRUG|Cyclobenzaprine hydrochloride 10 mg tablet|
219355704|NCT02105532|OTHER|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
219355705|NCT02105532|OTHER|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
219355706|NCT02467530|OTHER|AGE|
219355707|NCT06195020|OTHER|Metaverse|"The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months."
219355708|NCT06195020|OTHER|Polyclinic information|This group will be informed only at the outpatient clinic. The intervention will last 3 months.
219355709|NCT03736512|DEVICE|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
219355710|NCT04741724|DEVICE|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
219355711|NCT06446245|DRUG|Doxycycline|adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy
219355712|NCT06446245|DRUG|Placebo|Placebo
219355713|NCT06446245|DRUG|Anti Tuberculosis Drug|Standard anti-tuberculous therapy
219355714|NCT06446245|DRUG|Adjunctive corticosteroid|Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
219355715|NCT04755946|DRUG|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
219355716|NCT04755946|DRUG|Placebo|Placebo
219355717|NCT06311474|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a dyadic therapy that focuses on enhancing the parent-child relationship and improving child behavior through positive parenting and limit setting skills. All PCIT sessions are delivered remotely via Zoom once per week for up to 20 weeks. Session length is about 1 hour. There are two distinct phases of PCIT, the Child Directed Interaction and the Parent Directed Interaction. Each phase begins with a Teach session, where parents learn about the skills they will practice during that portion of PCIT, and is followed by Coach sessions, in which the PCIT therapist provides direct feedback and live coaching on the use of the skills. An additional component is Daily Play practice. Parents are instructed to spend five minutes per day playing with their child, during which they practice skills learned during sessions. Adaptations have been made to the standard approach to increase suitability for the TSC population.
219355718|NCT01848535|DIETARY_SUPPLEMENT|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
219355719|NCT01848535|DIETARY_SUPPLEMENT|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
219355720|NCT00341250|DRUG|AMA1-C1/Alhydrogel Malaria Vaccine|
219355721|NCT01183273|PROCEDURE|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
219355722|NCT01183273|PROCEDURE|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
219355723|NCT00577993|DRUG|Fludarabine|Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
219355724|NCT00577993|DRUG|Novantrone|Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
219355725|NCT00577993|DRUG|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
219355726|NCT00577993|DRUG|Rituximab|Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
219355727|NCT00577993|DRUG|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
219355728|NCT00577993|DRUG|Doxorubicin|25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
219355729|NCT00577993|DRUG|Vincristine|.7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
219355730|NCT00577993|DRUG|Bleomycin|5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
219355731|NCT00577993|DRUG|Cyclophosphamide|750 mg/m\^2 IV Day 2 of 1st Sequence.
219355732|NCT00577993|DRUG|Etoposide|40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
219355733|NCT00577993|DRUG|Cisplatin|25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
219355734|NCT00577993|DRUG|Ara-C|1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
219355735|NCT00577993|DRUG|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
219355736|NCT00577993|DRUG|Procarbazine|100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
219355737|NCT00577993|DRUG|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
219355738|NCT04668352|DRUG|Dactolisib|TORC1 inhibitor
219355739|NCT04668352|OTHER|Placebo|Placebo
219355740|NCT02296242|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
219355741|NCT02217566|DRUG|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
219355742|NCT02217566|DRUG|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
219355743|NCT02217566|DRUG|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
219355744|NCT01077973|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
219355745|NCT01077973|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
219355746|NCT01077973|DRUG|Placebo|Single-dose of placebo
219355747|NCT00883246|DEVICE|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
219355748|NCT00415779|DRUG|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
219355749|NCT00415779|DRUG|zoledronic acid|2 mg IV every 2 weeks
219355750|NCT02679469|DRUG|nalmefene hydrochloride 10 mg|
219355751|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid|Readily available marketed open label ascorbic acid
219355752|NCT04342728|DIETARY_SUPPLEMENT|Zinc Gluconate|Readily available marketed open label zinc gluconate
219355753|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
219355754|NCT04342728|OTHER|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
219355755|NCT00328146|OTHER|Observation of sternal reentry|Observation of sternal reentry
219355756|NCT00803504|PROCEDURE|ocular blood flow measurement|
219355757|NCT04358783|BIOLOGICAL|Plasma|The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.
219355758|NCT04358783|OTHER|Best Available Therapy|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
219355759|NCT00157612|PROCEDURE|a clinical pathway nursing home acquired pneumonia|treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
219355760|NCT02618447|DEVICE|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
219355761|NCT02618447|PROCEDURE|Portal vein embolization|
219355762|NCT06436885|DRUG|Iruplinalkib tablets|Iruplinalkib tablets should be administered orally at a roughly fixed time each day. Once daily, on an empty stomach or with food, 60mg per dose for days 1 to 7, 180 mg per dose from day 8 if tolerated. Swallow the tablet whole, do not crush, divide or chew the tablet
219355763|NCT00119158|DRUG|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
219355764|NCT00119158|DRUG|pimecrolimus|apply daily with fluticasone cream for flares
219355765|NCT03786549|OTHER|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients"
219355766|NCT00133380|DRUG|PPAR alpha|
219355767|NCT00133380|DRUG|atorvastatin|
219355768|NCT00133380|DRUG|placebo|
219355769|NCT01726946|DRUG|VX-135|12 weeks of VX-135
219355770|NCT01726946|DRUG|ribavirin|12 weeks of ribavirin
219355771|NCT04975061|DRUG|YY-20394|YY-20394 is a small molecule inhibitor.
219355772|NCT03052452|OTHER|My Nutritional Health App|The My Nutritional Health app built in LifeData will be used as the data collection platform for this study. We will use the data collected in the app testing to develop population-level FAST scores.
219355773|NCT06182488|OTHER|ERAS protocols|ERAS protocols for emergency abdominal surgery
219355774|NCT06182488|OTHER|Conventional protocols|Conventional protocols for emergency abdominal surgery
219355775|NCT05156827|DRUG|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
219355776|NCT05156827|DRUG|Placebo|Normal saline administered through IV infusion over an hour
219355777|NCT04291937|DRUG|Lurbinectedin|Powder for concentrate for solution for infusion in 4 mg vials
219355778|NCT05450679|PROCEDURE|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at \> 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
219355779|NCT02574637|DRUG|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
219355780|NCT02574637|DRUG|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
219355781|NCT02574637|DRUG|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
219355782|NCT05582642|DEVICE|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
219355783|NCT04714541|DRUG|Ketamine Hcl 50Mg/Ml Inj|Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
219355784|NCT04016311|BEHAVIORAL|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
219355785|NCT01568606|DEVICE|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
219355786|NCT04311086|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
219355787|NCT04674566|DRUG|COR-101|Administered intravenously (IV) single dose
219355788|NCT04674566|DRUG|Placebo|Administered intravenously (IV) single dose
219355789|NCT04029519|DEVICE|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
219355790|NCT02653222|PROCEDURE|Renal sympathicolysis|
219355791|NCT02653222|PROCEDURE|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
219355792|NCT02653222|RADIATION|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
219355793|NCT02653222|BIOLOGICAL|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
219355794|NCT02548026|BEHAVIORAL|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
219355795|NCT02548026|BEHAVIORAL|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
219355796|NCT05152797|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
219355797|NCT02064387|DRUG|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
219355798|NCT02706730|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
219355799|NCT05875259|DRUG|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
219355800|NCT05875259|DRUG|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
219355801|NCT05875259|DRUG|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
219355802|NCT04429815|DIAGNOSTIC_TEST|Serological test for COVID-19.|Serological test for COVID-19 performed as part of standard of care.
219355803|NCT02499029|DRUG|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
219355804|NCT02499029|DRUG|Placebo|Identical looking placebo pills were administered each week.
219355805|NCT02266030|DRUG|Cilostazol|Pletaal as an active drug
219355806|NCT02266030|DRUG|Aspirin|Aspirin as an active comparator
219355807|NCT04851600|DEVICE|prosthesis|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
219355808|NCT02681016|DEVICE|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
219355809|NCT02681016|DEVICE|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
219355810|NCT02681016|PROCEDURE|Coronary angioplasty|
219355811|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
219355812|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
219355813|NCT05082103|OTHER|Enzyme lozenge 1|Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
219355814|NCT05082103|OTHER|Enzyme lozenge 2|Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
219355815|NCT05082103|OTHER|Placebo lozenge|Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
219355816|NCT02237430|DEVICE|MynxGrip|Closure device for femoral artery access closure
219355817|NCT02237430|OTHER|Manual compression|Conventional manual compression
219355818|NCT02841215|DRUG|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
219355819|NCT02841215|DRUG|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
219355820|NCT03075566|BIOLOGICAL|Healthy subjects|\- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
219355821|NCT03075566|BIOLOGICAL|Patients|\- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
219355822|NCT03639844|BIOLOGICAL|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
219355823|NCT03639844|DRUG|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
219355824|NCT01679041|DRUG|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
219355825|NCT01679041|DRUG|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
219355826|NCT01679041|DRUG|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
219355827|NCT03489798|PROCEDURE|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
219355828|NCT03489798|PROCEDURE|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
219355829|NCT03607760|DEVICE|ECMO|the patients with severe respiratory failure were supported by ECMO
219355830|NCT03607760|DEVICE|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
219355831|NCT03153449|DEVICE|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
219355832|NCT03452566|DRUG|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
219355833|NCT00731172|DRUG|glatiramer acetate|20 mg daily subcutaneous injection through week 12
219355834|NCT00731172|DRUG|placebo|subcutaneous daiky injection through week 12
219355835|NCT06319105|OTHER|Standard intervention: Offer PrEP choice|This hybrid observational-implementation study will observe the implementation of a choice of oral pre-exposure prophylaxis or long-acting injectable cabotegravir for pre-exposure prophylaxis for all participants.
219355836|NCT03106623|DRUG|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
219355837|NCT03106623|DRUG|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
219355838|NCT03106623|DRUG|Placebo|Oral administration of Placebo once a daily for 4 weeks
219355839|NCT03572556|BIOLOGICAL|Blood samples|"* 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
219355840|NCT03572556|OTHER|Epistaxis charts|Three monthly epistaxis charts to be completed
219355841|NCT02776800|DEVICE|Allevyn Life|
219355842|NCT02776800|DEVICE|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
219355843|NCT02076542|BEHAVIORAL|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
219355844|NCT02702648|DRUG|AC-082|Hard gelatin capsules for oral administration
219355845|NCT02702648|DRUG|Placebo|Matched placebo capsules for oral administration
219355846|NCT04444622|BIOLOGICAL|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
219355847|NCT05528510|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
219355848|NCT05528510|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
219355849|NCT05528510|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
219355850|NCT05528510|OTHER|Placebo|Placebo will be administered as SC injection.
219355851|NCT00486408|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5x10\^10 Ad vg
219355852|NCT06501287|DIAGNOSTIC_TEST|Postprandial triglyceride|impact of postprandial triglyceride level on coronary atherosclerosis
219355853|NCT04951258|OTHER|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
219355854|NCT04951258|OTHER|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
219355855|NCT01675960|DRUG|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
219355856|NCT01675960|DRUG|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
219355857|NCT03889639|DRUG|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
219355858|NCT03889639|DRUG|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
219355859|NCT03889639|DRUG|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
219355860|NCT06345456|DEVICE|End-tidal capnography|The value of end-tidal capnography
219355861|NCT01789450|PROCEDURE|Section of Periareolar Dermis in Breast Reduction.|
219355862|NCT01703858|DRUG|BI 113608 PIB|powder for oral solution
219355863|NCT01703858|DRUG|BI 113608|conventional tablet formulation
219355864|NCT01703858|DRUG|BI 113608|conventional tablet formulation
219355865|NCT01703858|DRUG|BI 113608|conventional tablet formulation
219355866|NCT01703858|DRUG|pantoprazole 40 mg STADA|film-coated tablet
219355867|NCT01703858|DRUG|BI 113608|conventional tablet formulation
219355868|NCT01993693|DEVICE|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
219355869|NCT01993693|DEVICE|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
219355870|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
219355871|NCT04080895|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
219355872|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
219355873|NCT04080895|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
219355874|NCT04828408|PROCEDURE|Bariatric surgery|Patients with a body mass index (BMI) ˃35, age interval of 18-65, and ASA score II-III undergoing laparoscopic bariatric surgery were included in the study. Patients with neuromuscular, cardiopulmonary, and cerebrovascular diseases, phrenic nerve damage or diaphragm paralysis, those who have undergone thoracic surgery, who could not communicate, who did not want to participate in the study, who used alcohol, those who needed postoperative intensive care, those who had surgical complications during surgery, and those who were switched to open surgery were not included in the study.
219355875|NCT00927095|DRUG|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
219355876|NCT00927095|DRUG|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
219355877|NCT00927095|DRUG|placebo|daily placebo
219355878|NCT04894929|OTHER|multi component exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
219355879|NCT04894929|OTHER|vestibular exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
219355880|NCT04894929|OTHER|vestibular exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
219355881|NCT04894929|OTHER|multi component exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
219355882|NCT04931992|OTHER|No intervention|Retrospective analysis
219355883|NCT05462509|DEVICE|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
219355884|NCT06202300|OTHER|Inflammation burden|Coronary artery disease patients undergone multimodality imaging with different level inflammation burden
219355885|NCT00467454|DRUG|Naltrexone|daily
219355886|NCT00467454|DRUG|Placebo|daily
219355887|NCT02556255|DEVICE|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
219355888|NCT02475811|RADIATION|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
219355889|NCT06352294|OTHER|Core stability training|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult
219355890|NCT06352294|OTHER|Core stability training and myofascial relase|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
219355891|NCT04799886|OTHER|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
219355892|NCT04087525|DRUG|HIP1701|Vildagliptin
219355893|NCT04087525|DRUG|HGP1809|Vildagliptin
219355894|NCT00598416|BEHAVIORAL|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
219355895|NCT03115151|DRUG|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
219355896|NCT03115151|DRUG|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
219355897|NCT03115151|DRUG|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
219355898|NCT04471727|BIOLOGICAL|Gocatamig|IV infusion
219355899|NCT04471727|BIOLOGICAL|Atezolizumab|IV infusion
219355900|NCT04471727|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
219355901|NCT00005059|DRUG|carboplatin|
219355902|NCT00005059|DRUG|paclitaxel|
219355903|NCT00465595|DRUG|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
219355904|NCT03279003|DEVICE|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
219355905|NCT00027339|DRUG|lopinavir/ritonavir|
219355906|NCT00027339|DRUG|indinavir sulfate|
219355907|NCT00027339|DRUG|tenofovir disoproxil fumarate|
219355908|NCT00027339|DRUG|ritonavir|
219355909|NCT00027339|DRUG|fosamprenavir|
219355910|NCT04600895|DRUG|Favipiravir|Favipiravir
219355911|NCT04600895|DRUG|Placebo|Placebo
219355912|NCT01665118|DEVICE|Trusculpt (Radio Frequency) Device|
219355913|NCT05779072|DEVICE|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
219355914|NCT03640871|DEVICE|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC\_019 dressing 10x10 cm (AWC=Advanced Wound Care)
219355915|NCT03353857|DRUG|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
219355916|NCT03353857|DRUG|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
219355917|NCT03353857|DRUG|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
219355918|NCT03353857|DRUG|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
219355919|NCT03353857|DRUG|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
219355920|NCT03353857|DRUG|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
219355921|NCT03353857|DRUG|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
219355922|NCT06099587|DIAGNOSTIC_TEST|high-resolution diffusion MRI|The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
219355923|NCT02397850|BEHAVIORAL|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
219355924|NCT02397850|BEHAVIORAL|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
219355925|NCT04961606|OTHER|interview|semi-structured individual interview
219355926|NCT03046355|PROCEDURE|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
219355927|NCT03046355|PROCEDURE|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
219355928|NCT01765101|OTHER|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
219355929|NCT01765101|OTHER|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
219355930|NCT05044052|BEHAVIORAL|Emphasis on the Choosing Wisely Viral Prescription Pad|We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
219355931|NCT02695511|OTHER|Caloric restriction|25% caloric restriction below baseline energy requirement
219355932|NCT00020540|BIOLOGICAL|recombinant CD40-ligand|
219355933|NCT00020540|BIOLOGICAL|recombinant flt3 ligand|
219355934|NCT02326779|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
219355935|NCT05788679|DRUG|Azacitidine|Azacitidine
219355936|NCT05788679|OTHER|Donor lymphocytes|Donor lymphocytes in patients without immune suppression
219355937|NCT05788679|OTHER|Tapering of immune suppression|Tapering of immune suppression in patients who are on immune suppressive drugs
219355938|NCT05519735|DIAGNOSTIC_TEST|Multimodality Imaging|Patients receive CXCR4-targeted PET/CT, CMR and Echo
219355939|NCT00941460|DRUG|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
219355940|NCT00941460|DRUG|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
219355941|NCT03395379|PROCEDURE|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
219355942|NCT03694925|DIAGNOSTIC_TEST|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
219355943|NCT01639872|DRUG|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
219355944|NCT01639872|DRUG|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
219355945|NCT03954600|DRUG|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
219355946|NCT03954600|DRUG|Placebos (125 mg)|Placebo, 125 mg oral capsules
219355947|NCT01475201|BEHAVIORAL|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
219355948|NCT01475201|BEHAVIORAL|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
219355949|NCT02799069|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
219355950|NCT02799069|DRUG|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
219355951|NCT02799069|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
219355952|NCT01307969|DRUG|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
219355953|NCT01265680|DRUG|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
219355954|NCT01277640|DRUG|dapivirine|"* dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
219355955|NCT01277640|DRUG|matched placebo|"* dosage form: gel, no api~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
219355956|NCT01277640|DRUG|universal placebo|"* dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
219355957|NCT05513989|DEVICE|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
219355958|NCT05513989|DEVICE|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
219355959|NCT00972673|DRUG|Placebo|comparator
219355960|NCT00972673|DRUG|GW685698X|Inhaled steroid
219355961|NCT05207007|PROCEDURE|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
219355962|NCT03173833|OTHER|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
219355963|NCT00372502|PROCEDURE|Modified EGDT|Early goal directed therapy with lactate clearance
219355964|NCT00372502|PROCEDURE|Standard EGDT|Early goal directed therapy
219355965|NCT03659019|OTHER|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
219355966|NCT03536871|DIETARY_SUPPLEMENT|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
219355967|NCT03536871|OTHER|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
219355968|NCT00820521|DRUG|active|
219355969|NCT00820521|DRUG|placebo|
219355970|NCT01112098|BEHAVIORAL|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
219355971|NCT03677700|OTHER|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
219355972|NCT05479500|OTHER|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
219355973|NCT05479500|OTHER|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
219355974|NCT02092571|DRUG|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
219355975|NCT04145011|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
219355976|NCT04145011|DEVICE|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
219355977|NCT01383837|BEHAVIORAL|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
219355978|NCT01383837|BEHAVIORAL|Health Promotion|Health Promotion Intervention
219355979|NCT01738334|BEHAVIORAL|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
219355980|NCT01738334|BEHAVIORAL|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
219355981|NCT02715037|OTHER|Throat swabbing|
219355982|NCT01533376|DRUG|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
219355983|NCT01533376|DRUG|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
219355984|NCT00653822|DRUG|alefacept|IC and SC
219355985|NCT00653822|DRUG|placebo|IV and SC
219355986|NCT04993404|DRUG|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
219355987|NCT04865328|OTHER|Overactive Bladder-Validated 8-question Screener (OAB-V8)|OAB-V8 is an eight-item, self-reported questionnaire that assesses the burden of OAB and the degree of bother caused by the symptoms. Since its development as a subscale of the overactive bladder questionnaire (OAB-q), the OAB-V8 questionnaire has been used to screen for OAB and to assess OAB symptom burden and severity.
219355988|NCT02178488|DRUG|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
219355989|NCT02178488|OTHER|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
219355990|NCT03033875|BEHAVIORAL|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
219355991|NCT03033875|BEHAVIORAL|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
219355992|NCT03754426|DEVICE|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
219355993|NCT04000685|OTHER|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
219355994|NCT04000685|OTHER|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
219355995|NCT04000685|OTHER|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
219355996|NCT02065154|DRUG|Cyclophosphamide|
219355997|NCT02271503|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
219355998|NCT02271503|DRUG|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
219355999|NCT02271503|DRUG|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
219356000|NCT02271503|DRUG|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
219356001|NCT02271503|DRUG|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
219356002|NCT02841969|OTHER|Electrolysed water|Irrigation of wound using electrolysed water
219356003|NCT02841969|OTHER|Prontosan|Irrigation of wound using Prontosan
219356004|NCT00630955|DRUG|memantine|Memantine 20 mg once per day for 7 days
219356005|NCT00630955|DRUG|Memantine|Memantine 40 mg once per day for 7 days
219356006|NCT00630955|DRUG|Placebo|Placebo once per day for 7 days
219356007|NCT03739632|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
219356008|NCT03739632|OTHER|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
219356009|NCT04897464|OTHER|BGaze therapy Alzheimer|BGaze Therapy is an interactive eye tracking game
219356010|NCT03655964|DRUG|Olmesartan|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
219356011|NCT03655964|DRUG|Nebivolol|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
219356012|NCT03655964|OTHER|No antihypertensive treatment|Patients will be left without treatment
219356013|NCT01201239|DRUG|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
219356014|NCT04427631|DEVICE|Bone conduction headphones|Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
219356015|NCT00500526|OTHER|Singing practice|
219356016|NCT00500526|OTHER|Singing classes|
219356017|NCT00500526|OTHER|Hand craft classes|
219356018|NCT02018731|DRUG|Metformin and Metformin & L-Citrulline|
219356019|NCT02018731|DRUG|L-Citrulline and Metformin & L-Citrulline|
219356020|NCT02519166|BIOLOGICAL|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
219356021|NCT02601339|PROCEDURE|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
219356022|NCT04086550|DEVICE|LIQOSEAL|Adjunctive bioresorbable patch
219356023|NCT04086550|DEVICE|DuraSeal, Adherus|synthetic absorbable sealants
219356024|NCT02108431|DEVICE|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
219356025|NCT02108431|DEVICE|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
219356026|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
219356027|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
219356028|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
219356029|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
219356030|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
219356031|NCT01819909|PROCEDURE|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
219356032|NCT01819909|PROCEDURE|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
219356033|NCT02665286|DRUG|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
219356034|NCT02665286|DRUG|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
219356035|NCT02665286|DRUG|Naproxen|Naproxen 500mg PO BID x 7 days
219356036|NCT02665286|DRUG|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
219356037|NCT03308396|DRUG|Guadecitabine|Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2
219356038|NCT03308396|DRUG|Durvalumab|Day 8 Durvalumab (1500 mg IV)
219356039|NCT06037330|DRUG|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.
219356040|NCT06037330|DRUG|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
219356041|NCT06488131|PROCEDURE|MTA Pulpotomy|Complete coronal MTA pulpotomy.
219356042|NCT06488131|PROCEDURE|Root Canal Treatment|Conventional root canal treatment.
219356043|NCT00361595|DRUG|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
219356044|NCT05654129|OTHER|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
219356045|NCT05654129|OTHER|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
219356046|NCT03528512|DRUG|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
219356047|NCT03528512|DRUG|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
219356048|NCT00940264|PROCEDURE|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
219356049|NCT02611986|DEVICE|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
219356050|NCT02611986|DEVICE|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
219356051|NCT02689830|DEVICE|Bead Block|Prostate embolization
219356052|NCT00002356|DRUG|Fomivirsen sodium|
219366266|NCT01635790|DRUG|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
219356053|NCT06257030|DEVICE|Transarterial Radioembolization|(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
219356054|NCT03602872|BIOLOGICAL|Human allogeneic mesenchymal bone marrow derived stem cells|Intraarticular administration of 20x10\^6 MSCs
219356055|NCT04797845|OTHER|teleconsultation|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
219356056|NCT01047657|BEHAVIORAL|Low caloric diet plus orlistat and sibutramine|All subjetcs
219356057|NCT03790280|DIAGNOSTIC_TEST|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
219356058|NCT02797886|OTHER|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
219356059|NCT02797886|OTHER|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
219356060|NCT02797886|OTHER|VOL|The subject initiates and completes the movement without electrical stimulation.
219356061|NCT00164294|BEHAVIORAL|Brief intervention|
219356062|NCT01147146|DRUG|propofol, fentanyl, atracurium|general anesthesia
219356063|NCT01147146|DRUG|bupivacaine|spinal anesthesia
219356064|NCT01147146|DRUG|bupivacaine, Midazolam|spinal anesthesia \& sedation
219356065|NCT02216461|DRUG|Low dose of BIBW 2948 BS for oral inhalation|
219356066|NCT02216461|DRUG|Medium dose of BIBW 2948 BS for oral inhalation|
219356067|NCT02216461|DRUG|High dose of BIBW 2948 BS for oral inhalation|
219356068|NCT02216461|DRUG|Placebo|
219356069|NCT05450146|OTHER|Partner in Balance|"The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals."
219356070|NCT06420505|DEVICE|Percutaneous Coronary Intervention|The Vivo ISAR is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
219356071|NCT04729777|PROCEDURE|Combined Cardiovascular Magnetic Resonance and Cardiopulmonary Exercise Testing|Clinical Cardiac MRI scan at rest with routine administration of gadolinium contrast agent. Participants then undergo the research component of the test which requires them to perform exercise, using a recumbent, MRI-compatible cycle ergometer, whilst their breathing is simultaneously analysed using a mask connected to a CPET machine, until they are limited by symptoms and they stop pedalling. Most participants will undergo only one scan. Some participants will be asked to have two or three such scans over 3 months to assess changes over time, and in response to standard treatment of pulmonary hypertension.
219356072|NCT03186235|OTHER|Flow cytometry|Isolation of T regulatory cells from blood
219356073|NCT00740350|PROCEDURE|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
219356074|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
219356075|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
219356076|NCT01233778|DIETARY_SUPPLEMENT|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
219356077|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
219356078|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
219356079|NCT01233778|DIETARY_SUPPLEMENT|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
219356080|NCT01233778|DIETARY_SUPPLEMENT|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
219356081|NCT00897078|OTHER|laboratory biomarker analysis|
219356082|NCT00897078|OTHER|medical chart review|
219356083|NCT00897078|OTHER|metabolic assessment|
219356084|NCT00897078|OTHER|questionnaire administration|will be obtained at a single clinic visit
219356085|NCT00897078|PROCEDURE|assessment of therapy complications|
219356086|NCT04979754|OTHER|standard of care|retrospective study : standard of care
219356087|NCT04565678|DRUG|Mitapivat tablets|Oral tablets
219356088|NCT04565678|DRUG|Mitapivat coated granules|Oral coated granules
219356089|NCT00002693|BIOLOGICAL|filgrastim|
219356090|NCT00002693|DRUG|carboplatin|
219356091|NCT00002693|DRUG|topotecan hydrochloride|
219356092|NCT01918670|PROCEDURE|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
219356093|NCT01353742|DRUG|Lamivudine|100mg tablet
219356094|NCT01353742|DRUG|Adefovir dipivoxil|10mg tablet
219356095|NCT01353742|DRUG|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
219356096|NCT04490837|DIAGNOSTIC_TEST|ELISA and Rapid test to detect antibodies against COVID-19|Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
219356097|NCT03711643|PROCEDURE|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
219356098|NCT03711643|DEVICE|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
219356099|NCT02067039|DEVICE|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home \& Sure Check HIV tests
219356100|NCT01972074|DRUG|Memantine|Capsule
219356101|NCT01972074|OTHER|Placebo|Capsule
219366267|NCT01635790|DRUG|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
219356102|NCT05595044|DRUG|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
219356103|NCT05595044|OTHER|Habilitation|Habilitation
219356104|NCT04916405|OTHER|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
219356105|NCT06537115|BEHAVIORAL|exercise|progressive resistance exercise
219356106|NCT06537115|DIETARY_SUPPLEMENT|whey protein powder|The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
219356107|NCT06537115|DRUG|Eldecalcitol|Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
219356108|NCT00051155|DRUG|Travoprost (0.004%)|
219356109|NCT00051155|DRUG|Latanoprost (0.005%)/Timolol (0.5%)|
219356110|NCT04791046|DRUG|antihypertensive therapy|Personalized evidence-based antihypertensive therapy in patients with comorbidities
219356111|NCT03899662|OTHER|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
219356112|NCT03899662|OTHER|Physical Training|Physical training included aerobic, strength, flexibility and balance.
219356113|NCT04761211|DEVICE|smart bra|This is a patented infrared breast examination bra
219356114|NCT05537805|PROCEDURE|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
219356115|NCT01009476|DRUG|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
219356116|NCT01009476|DRUG|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
219356117|NCT06355232|BIOLOGICAL|Covid-19 vaccine|Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant
219356118|NCT06355232|BIOLOGICAL|Influenza vaccine|Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
219356119|NCT04001868|PROCEDURE|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
219356120|NCT04001868|PROCEDURE|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
219356121|NCT01699555|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
219356122|NCT01699555|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
219356123|NCT02734251|DIETARY_SUPPLEMENT|Relora|750 mg/day
219356124|NCT02734251|DIETARY_SUPPLEMENT|Placebo|
219356125|NCT06962839|DRUG|BI 1815368|BI 1815368
219356126|NCT06962839|DRUG|Placebo|Placebo matching BI 1815368
219356127|NCT06413511|BIOLOGICAL|Belantamab|Belantamab will be administered
219356128|NCT05237895|DIAGNOSTIC_TEST|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
219356129|NCT03757104|BEHAVIORAL|micro-incentive|Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
219356130|NCT03757104|BEHAVIORAL|EPIC-HIV|Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
219356131|NCT03757104|BEHAVIORAL|micro-incentive and EPIC-HIV|"micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care."
219356132|NCT05518604|BEHAVIORAL|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
219356133|NCT01211379|BEHAVIORAL|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
219356134|NCT01502904|DEVICE|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219356135|NCT01502904|DEVICE|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219366678|NCT04610476|DRUG|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
219356136|NCT01502904|DRUG|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219356137|NCT01502904|DRUG|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219356138|NCT01502904|DRUG|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219356139|NCT01502904|DRUG|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
219356140|NCT02813772|DIETARY_SUPPLEMENT|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
219356141|NCT02813772|DIETARY_SUPPLEMENT|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
219356142|NCT05506059|DIAGNOSTIC_TEST|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
219356143|NCT06450197|DRUG|AZD7798|AZD7798
219356144|NCT06450197|OTHER|Placebo|Placebo
219356145|NCT05574062|DEVICE|MiniMed 780G Auto Mode with G4S sensor|MiniMed™ 780G system in Auto Mode with G4S sensor.
219356146|NCT05574062|DEVICE|MiniMed 780G Manual Mode with G4S sensor|MiniMed™ 780G system in Manual Mode.
219356147|NCT05574062|DEVICE|MiniMed 780G Auto Mode with DS5 sensor|MiniMed 780G Auto Mode with DS5 sensor
219356148|NCT00368576|DRUG|SB 480848, tablets|
219356149|NCT04999579|DEVICE|T scan|Occlusal load analysis
219356150|NCT06529536|DIAGNOSTIC_TEST|Genotyping for CYP3A4 and CYP3A5 genes|"Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array). Pre-transplant genotyping will test for CYP3A5 \*3, \*6, \*7, \*8 and \*9 alleles, and will test for CYP3A4\*22 only (with CYP3A4\*1 reported if no variant corresponding to \*22 was present).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus. In addition, influence of CYP3A4 will be incorporated based on recent literature and interventional trials. Initial dose in BRUNO-PIC will use allometric size scaling from adult dose, with adjustment based on genotype (CYP3A4 \& CYP3A5)"
219356151|NCT06529536|DEVICE|Use of NextDose platform|NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.
219356152|NCT06529536|DRUG|Tacrolimus|Tacrolimus is administered to all patients post SOT at The Royal Children's Hospital (RCH)
219356153|NCT05752214|OTHER|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
219356154|NCT05615636|DRUG|Mosunetuzumab|Given by IV (vein)
219356155|NCT05615636|DRUG|Polatuzumab vedotin|Given by IV (vein)
219356156|NCT05615636|DRUG|Tafasitamab|Given by IV (vein)
219356157|NCT05615636|DRUG|Lenalidomide|Given by PO
219356158|NCT03356184|DEVICE|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219356159|NCT03356184|DEVICE|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
219356160|NCT05986097|BEHAVIORAL|Breakfast|We will provide participants recipes and information to support this dietary change.
219356161|NCT06351852|DRUG|Combination of Neostigmine and Glycopyrrolate|Transcutaneous
219356162|NCT06351852|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
219356163|NCT04403165|PROCEDURE|Nocturnal polysomnography (NPSG)|Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
219356164|NCT04403165|PROCEDURE|Lumbar Puncture (LP)|Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
219356165|NCT04403165|OTHER|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
219356166|NCT04403165|BEHAVIORAL|Psychomotor Vigilance Task (PVT)|Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
219356167|NCT04278131|DRUG|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
219356168|NCT06186141|DRUG|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
219356169|NCT06186141|DRUG|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
219356170|NCT06269679|DIAGNOSTIC_TEST|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
219356171|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
219356172|NCT06282575|DRUG|Zanidatamab|Administered intravenously (IV)
219356173|NCT06282575|DRUG|Cisplatin|Administered intravenously (IV)
219356174|NCT06282575|DRUG|Gemcitabine|Administered intravenously (IV)
219356175|NCT06282575|DRUG|Pembrolizumab|Administered intravenously (IV)
219356176|NCT06282575|DRUG|Durvalumab|Administered intravenously (IV)
219356177|NCT06839287|OTHER|Interpersonal psychotherapy-based counseling|The first data from the individuals in the experimental and control groups will be collected after the first interview. Data will be collected from the individuals to whom interpersonal relationship therapy techniques are applied after the 8th session by face-to-face interviews. In addition, if the individuals in the experimental group have questions about psychotherapy, they will be answered. The control group will be verbally informed with the data collection form and chronic disease adaptation and depression scales and will continue to receive routine care. Data will be collected by face-to-face interviews with the control group after the first interview and 8 weeks later when they come to the dialysis center. Follow-up data of the participants will be collected again at the 3rd month after the last interview.
219356178|NCT06263491|DRUG|Rituximab|Given by PO
219356179|NCT06263491|DRUG|Pirtobrutinib|Given by PO
219356180|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
219356181|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
219356182|NCT02611089|PROCEDURE|Tissue biopsy|Sampling of tissue as described.
219356183|NCT03320759|BEHAVIORAL|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
219356184|NCT00455598|DRUG|ISIS 113715|doses of 100 and 200 mg per week
219356185|NCT05226624|BEHAVIORAL|Rooming-in care|Implementation of Rooming-in model of care
219356186|NCT05226624|BEHAVIORAL|Baseline standard of care|Baseline standard of care
219356187|NCT06428357|DIETARY_SUPPLEMENT|Recombinant Bovine Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
219356188|NCT06428357|DIETARY_SUPPLEMENT|Bovine Milk-Derived Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
219356189|NCT06428357|DIETARY_SUPPLEMENT|Placebo|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
219356190|NCT04938661|OTHER|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
219356191|NCT04938661|OTHER|mHealth|Mobile Health Platform
219356192|NCT04938661|OTHER|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
219356193|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
219356194|NCT04507737|OTHER|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
219356195|NCT04906668|PROCEDURE|Cryoballoon pulmonary-vein isolation|Electrical isolation of the pulmonary-veins using cryoenergy
219356196|NCT04906668|PROCEDURE|Pacemaker implantation and ablation of atrioventricular-node|Pacemaker implantation and ablation of atrioventricular-node
219356197|NCT04253483|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR
219356198|NCT04253483|OTHER|Quality-of-Life Assessment|Ancillary studies
219356199|NCT04253483|OTHER|Questionnaire Administration|Ancillary studies
219356200|NCT04253483|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
219356201|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
219356202|NCT06386887|BEHAVIORAL|Intermittent Fasting|Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).
219356203|NCT06386887|DRUG|Neoadjuvant chemotherapy|Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
219356204|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
219356205|NCT06182579|DRUG|RiMO-401|• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
219356206|NCT06152731|GENETIC|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
219356207|NCT06289985|DEVICE|Endovascular thrombectomy with any FDA-approved category POL or NRY device|Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)
219356208|NCT06289985|OTHER|Medical Management|Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.
219356209|NCT04417478|OTHER|Scaling and root planning|Periodontal debridement was performed in all patients.
219356210|NCT06235151|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
219356211|NCT05560958|DEVICE|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
219356212|NCT01870154|BEHAVIORAL|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
219356213|NCT04621695|PROCEDURE|RBL|Both arms are standard care procedures in the Netherlands
219356214|NCT04621695|PROCEDURE|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
219356215|NCT01352806|PROCEDURE|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
219356216|NCT04312698|DRUG|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
219356217|NCT04312698|DRUG|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
219356218|NCT04312698|DRUG|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
219356219|NCT06179888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219356220|NCT06179888|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219356221|NCT06179888|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219356222|NCT06179888|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
219356223|NCT06179888|DRUG|Iberdomide|Given PO
219356224|NCT06179888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219356225|NCT06179888|PROCEDURE|Patient Monitoring|Undergo disease monitoring
219356226|NCT06179888|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219356227|NCT06179888|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
219356228|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
219356229|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
219356230|NCT04820309|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
219356231|NCT06297291|DEVICE|Paradise Ultrasound Renal Denervation Treatment|"The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight."
219356232|NCT03692052|DRUG|AG-348|AG-348 tablet orally BID
219356233|NCT05766059|DEVICE|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
219356234|NCT00223899|GENETIC|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
219356235|NCT05632770|BEHAVIORAL|Stepped Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
219356236|NCT05632770|BEHAVIORAL|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
219356237|NCT06261294|DIAGNOSTIC_TEST|OncoSweep Lung Spotligh|This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
219356238|NCT04969081|BEHAVIORAL|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
219356239|NCT04969081|OTHER|treatment as usual|usual treatment
219356240|NCT06232317|OTHER|Virtual Reality Software|The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
219356241|NCT06232317|OTHER|Traditional Orientation Methods|Standard-of-care methods to orient patients after surgery
219356242|NCT05600309|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
219356243|NCT05600309|DRUG|regorafenib|Oral
219356244|NCT05600309|DRUG|TAS-102|Oral
219356245|NCT06195839|BEHAVIORAL|Remote Patient Monitoring|Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study. Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol. Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
219356246|NCT06195839|BEHAVIORAL|Self-monitoring of hypertension-related factors|As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity. Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
219356247|NCT06195839|BEHAVIORAL|Immediate financial incentives|Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)
219356248|NCT06195839|BEHAVIORAL|Delayed financial incentives|Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)
219356249|NCT02967289|DRUG|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
219356250|NCT02967289|DRUG|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
219356251|NCT06085963|DRUG|ITULAZAX 12 SQ-Bet|Active ingredients: Birch (Betula verrucosa) extracts Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Dose/strength: 12 SQ-Bet Excipients: Gelatine (fish source), mannitol and sodium hydroxide
219356252|NCT06085963|DRUG|Placebo tablet|Active ingredients: None Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Excipients: Gelatine (fish source), mannitol and sodium hydroxide
219356253|NCT06085963|DRUG|Nacl|Sodium chloride solution 9mg/ml
219356254|NCT04579588|BIOLOGICAL|Flu shot|All participants will receive a single shot of the flu vaccine
219356255|NCT05098210|BIOLOGICAL|Neoantigen Peptide Vaccine|Given IM
219356256|NCT05098210|BIOLOGICAL|Nivolumab|Given IV
219356257|NCT05098210|DRUG|Poly ICLC|Given IM
219356258|NCT05098210|PROCEDURE|Echocardiography|Undergo ECHO
219356259|NCT05098210|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219356260|NCT05098210|PROCEDURE|Biopsy|Undergo tumor biopsy
219356261|NCT05098210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219356262|NCT05098210|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219356263|NCT05098210|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
219356264|NCT05853497|BEHAVIORAL|Multi-Component Weight Loss Intervention|The intervention group will receive weekly 1-on-1 health coaching with a very-low calorie nutrition plan prior to total knee replacement and a conventional weight maintenance nutrition plan after surgery.
219356265|NCT04951778|DRUG|CC-91633|Administered orally according to the assigned treatment schedule
219356266|NCT05245500|DRUG|MRTX1719|"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
219356267|NCT06577116|DRUG|AK006 IV|Formulation for intravenous infusion
219356268|NCT03032601|DIETARY_SUPPLEMENT|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
219356269|NCT05165654|DEVICE|Transcranial Electrical Stimulation|Transcranial electrical stimulation
219356270|NCT04342975|DRUG|Nicotinamide Riboside + Pterostilbene|It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
219356271|NCT04342975|DRUG|Placebo|The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
219356272|NCT02886143|PROCEDURE|Active Voiding Trial|"Nursing protocol:~1. Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~2. Clamp the Foley~3. Deflate the catheter balloon and remove the catheter from the bladder.~4. Record the amount of saline that was instilled into the bladder.~5. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7\. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
219359814|NCT07171866|PROCEDURE|Delayed Implant Placement with SST|Participants underwent extraction and socket shield preparation. Implant placement was delayed for 6 months to allow soft and hard tissue healing. The implant was placed after verifying shield stability and ridge preservation via CBCT. Follow-up assessments were conducted at 1 year and 6 years post-placement.
219366679|NCT04610476|DRUG|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
219356273|NCT02886143|PROCEDURE|Passive Voiding Trial|"Nursing protocol:~1. Deflate the catheter balloon and remove the catheter from the bladder.~2. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~3. 5\. If the patient has not voided within 5 hours, assist the patient to try to void.~6\. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7\. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
219356274|NCT05196035|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
219356275|NCT05196035|DRUG|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
219356276|NCT06033079|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
219356277|NCT05783596|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
219356278|NCT05783596|DRUG|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
219356279|NCT06529120|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
219356280|NCT05689983|DRUG|Maintenance ICS and Symptom Driven SABA|In this intervention, patients will be assigned to a standard therapy with a maintenance inhaled corticosteroid (Flovent) and an as needed short-acting beta-agonist and their adherence to this regimen will be assessed and compared to patients taking a regimen with an as needed inhaled corticosteroid and long-acting beta-agonist.
219356281|NCT05689983|DRUG|Symptom-driven budesonide/formoterol combination|In this intervention, patients will be assigned to a symptom-driven budesonide/formoterol combination therapy (Symbicort) and their adherence to this regimen will be assessed and compared to patients taking a standard therapy with a maintenance inhaled corticosteroid and as needed short-acting beta-agonist.
219356282|NCT04201119|DEVICE|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
219356283|NCT05505552|DIETARY_SUPPLEMENT|Vitamin K|1 mg/day phylloquinone (vitamin K1)
219356284|NCT05505552|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
219356285|NCT05242484|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219356286|NCT05242484|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
219356287|NCT05242484|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
219356288|NCT05242484|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
219356289|NCT06211764|DRUG|TAR-200|Participants will receive TAR-200 intravesically.
219356290|NCT06211764|DRUG|Mitomycin C|Participants will receive MMC intravesically.
219356291|NCT06211764|DRUG|Gemcitabine|Participants will receive gemcitabine intravesically.
219356292|NCT06388655|DEVICE|mobile neurofeedback|The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.
219356293|NCT06388655|DEVICE|sham mobile neurofeedback|The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
219356294|NCT00980538|DRUG|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
219356295|NCT01745770|DRUG|Mesalazine - TID 1000 mg|
219356296|NCT01745770|DRUG|Mesalazine - TID 2x 500 mg|
219356297|NCT01034007|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
219356298|NCT05125237|DRUG|Amiloride|Amiloride claim is used as the exposure group.
219356299|NCT05125237|DRUG|Triamterene|Triamterene claim is used as the reference group.
219356300|NCT06163612|BEHAVIORAL|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
219356301|NCT06163612|BEHAVIORAL|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
219356302|NCT06163612|OTHER|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
219356303|NCT06163612|BEHAVIORAL|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
219356304|NCT02482129|DRUG|LME636 60 mg/mL ophthalmic solution|
219356305|NCT02482129|DRUG|Dexamethasone 0.1% ophthalmic solution|
219356306|NCT02482129|DRUG|LME636 Vehicle|Inactive ingredients used for masking purposes
219359815|NCT07171879|PROCEDURE|Tooth Extraction only|Conventional atraumatic extraction of the non-restorable maxillary tooth in the esthetic zone without socket preservation procedures.
219356307|NCT04955392|OTHER|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~1. Inhibition of the suboccipital muscles.~2. Parietal Lift.~3. Sutherland Technique of Sphenobasilar Synchondrosis.~4. Compression technique of the fourth ventricle (CV4)."
219356308|NCT04955392|OTHER|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
219356309|NCT00602108|PROCEDURE|adjuvant therapy|
219356310|NCT00602108|PROCEDURE|conventional surgery|
219356311|NCT00602108|RADIATION|hypofractionated radiation therapy|
219356312|NCT00602108|RADIATION|intraoperative radiation therapy|
219356313|NCT03413150|DRUG|Amiodarone|Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
219356314|NCT05855447|OTHER|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (\> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
219356315|NCT05855447|OTHER|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
219356316|NCT05855447|OTHER|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
219356317|NCT05583266|DRUG|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
219356318|NCT05583266|DRUG|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
219356319|NCT00653003|DRUG|Leflunomide|tablets, 20mg, single-dose
219356320|NCT00653003|DRUG|ARAVA|Tablets, 20mg, single-dose
219356321|NCT04314440|BEHAVIORAL|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
219356322|NCT07121894|BEHAVIORAL|Ketogenic Diet|Participants will initiate a modified ketogenic diet under structured, intensive guidance. Simultaneously, participants will attend weekly behavioral support interviews with a psychiatrist to monitor mental health and mood stability.
219356323|NCT06564207|DRUG|Placebo|Placebo to be given twice daily for 14 days
219356324|NCT06564207|DRUG|Fostamatinib|Fostamatinib 150mg to be given twice daily for 14 days
219356325|NCT06130293|DEVICE|VR game intervention|Using self-paced VR game to train.
219356326|NCT07029633|OTHER|storytelling|to distract telling a story
219356327|NCT07029633|OTHER|cartoon|to distract watching a cartoon
219356328|NCT04049045|DRUG|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
219356329|NCT04049045|DRUG|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
219356330|NCT03505021|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
219356331|NCT03505021|DRUG|Placebo for levosimendan|Placebo capsule for oral administration
219356332|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot A|Sterile liquid for injection
219356333|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot B|Sterile liquid for injection
219356334|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose B|Sterile liquid for injection
219356335|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose C|Sterile liquid for injection
219356336|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose A|Sterile liquid for injection
219356337|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose B|Sterile liquid for injection
219356338|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose A|Sterile liquid for injection
219356339|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose B|Sterile liquid for injection
219356340|NCT06864143|BIOLOGICAL|Influenza Vaccine|Sterile liquid for injection
219356341|NCT06864143|BIOLOGICAL|COVID-19 Vaccine|Sterile liquid for injection
219356342|NCT06864143|BIOLOGICAL|Investigational Influenza Vaccine|Sterile liquid for injection
219356343|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot A|Sterile liquid for injection
219356344|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot B|Sterile liquid for injection
219356345|NCT05100641|BIOLOGICAL|AV-GBM-1|Therapeutic autologous dendritic cell vaccine
219356346|NCT05100641|BIOLOGICAL|Autologous monocytes|Autologous monocyte control
219356347|NCT06609005|DRUG|INV-9956|INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
219356348|NCT03226704|PROCEDURE|Leukapheresis|Leukapheresis
219356349|NCT06909825|DRUG|FPI-2265|PSMA ligand radiolabeled with Ac225
219356350|NCT06909825|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor
219356351|NCT06911229|DEVICE|Deep Brain Stimulation (DBS)|Patients will receive DBS in the clinically-optimized setting.
219356352|NCT06917664|DRUG|sacubitril/valsartan|Sacubitril/valsartan therapy after isolated CABG
219356353|NCT07143994|OTHER|eccentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
219356354|NCT07143994|OTHER|concentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
219356355|NCT07142824|PROCEDURE|burn dressing using Tilapia-Fish Skin|we use tilapia fish skin as a healing dressing in burn patients
219356356|NCT07142824|PROCEDURE|burn dressing using regular dressing|we use regular dressing in burn patients
219356357|NCT07144228|DEVICE|HeLP TM|lab test for prostate cancer
219356358|NCT07143708|OTHER|Glaucoma Surgery with Amniotic Membrane|Arm 2: Glaucoma Surgery with Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. In this group, the implanted stent is covered with an amniotic membrane patch to reduce postoperative scarring and improve long-term outcomes. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
219356359|NCT07143708|OTHER|Glaucoma Surgery without Amniotic Membrane|Arm 1: Glaucoma Surgery without Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. No modifications are made to the procedure. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
219356360|NCT07143448|BIOLOGICAL|HS235|Subcutaneous Injection
219356361|NCT07143448|OTHER|Placebo|Subcutaneous Injection
219356362|NCT07143045|DRUG|zorifertinib|Cohort A and B will receive zorifertinib as first line treatment
219356363|NCT07143123|BEHAVIORAL|Cloud-based learning platform|"The SimCapture system is the technological backbone of the intervention, transforming the way clinical skills are taught and learned.~1. System Access and Structure:Both faculty and students are provided with individual accounts to access the SimCapture platform.~2. The system facilitates the organization of students into groups, enabling collaborative learning and peer feedback.~3. Digital Evaluation Tools:Faculty develop standardized, digital tools within SimCapture to assess student performance of clinical skills.These tools ensure consistent and objective evaluation.~4. Recording and Feedback:Students record their practice sessions using personal devices (e.g., smartphones).These recordings are uploaded to the SimCapture cloud, creating a repository of learning resources.~5. Faculty use tablets to provide specific, time-stamped feedback on student performance directly within the SimCapture system."
219356364|NCT07143253|PROCEDURE|Preventive pit and fissure sealant application|"Preventive pit and fissure sealant application is a preventive procedure involving the use of flowable resin-based or glass ionomer-based materials to physically cover the occlusal surfaces of teeth, particularly in pits and fissures at high risk of caries development. This barrier prevents plaque accumulation and protects the enamel surface.~In this study, no procedures beyond the routine clinical application of the materials will be performed. However, partially erupted permanent teeth with challenging isolation will be specifically selected. Both materials will be applied using a split-mouth design to the teeth of the same participant. This approach will allow for an effective and comparative evaluation of the clinical retention of the material."
219356365|NCT07142863|DRUG|Envafolimab and neoadjuvant chemotherapy|"\* PD-L1 inhibitor envafolimab Paediatric (\<18 years): 2.5 mg/kg (maximum 200 mg) by subcutaneous injection on Day 1 of every week (q1w).~Adult (≥18 years): 200 mg flat dose by subcutaneous injection on Day 1 of every week (q1w).~* Neoadjuvant chemotherapy--MAP regimen (paediatric patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Methotrexate 8-12 g/m² intravenously on Day 1 of weeks 3 and 4 of each 6-week cycle.~* Neoadjuvant chemotherapy--DIA regimen (adult patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Ifosfamide 12-15 g/m² total dose intravenously on Days 1-5 of week 3 of each 6-week cycle."
219356366|NCT07135583|OTHER|Active Comparator: Single Intervention 1|Acute intermittent hypercapnic-hypoxia (15 episodes of 1.5 minute O2= 9%, CO2=4% and balance N2, interspaced with 1.5 min room air
219356367|NCT07135583|OTHER|Active Comparator: Single Intervention 2|An open-loop continuous tSCS stimulation \[30 min duration, low frequency (30 Hz), tolerable intensity (\~10-15 mA), 400 µsec pulse width, biphasic symmetric waveform\] will be delivered using 2 channels: Channel 1- C4-C5 spine; Channel 2- T4 spine; returning electrodes at ASIS.
219356368|NCT07135583|BEHAVIORAL|Respiratory Resistance Exercise|Respiratory strength training will be conducted using a standard, spring-loaded threshold device while the participant is receiving either tSCS or Sham tSCS. Participants will complete one warm-up set at a pressure threshold approximately 40% of their pre-test outcomes (obtained on day 1 of the corresponding intervention block) for maximal inspiratory and expiratory pressure generation. Following the warm-up, participants will train at a pressure threshold approximately 70% of their pre-test outcomes and will complete three sets of 6-12 repetitions for both inspiratory and expiratory strength training. A training breath will consist of a \~1-2-second sustained effort through the device, separated by 5-10 seconds of quiet breathing. The order of the three sets each of inspiratory or expiratory training will alternate for each of the five daily sessions; the order on day 1 of training will be randomly determined.
219356369|NCT07144631|DEVICE|Peroneal Nerve Stimulation (PNS) Device|The TOMAC™ system is a non-invasive, wearable peroneal nerve stimulator that delivers high-frequency electrical stimulation to the common peroneal nerves at the fibular head. It is FDA-cleared for the treatment of moderate-to-severe Restless Legs Syndrome (RLS) in adults but has not been studied in pregnancy. In this trial, pregnant participants will undergo an in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation to determine comfortable therapeutic intensity. They will then use the device at home for 8 weeks, up to four 30-minute sessions daily, prioritizing periods of high symptom burden or before bedtime. Outcomes will assess feasibility, acceptability, adherence, symptom improvement, sleep quality, and maternal-fetal safety.
219359816|NCT07171879|PROCEDURE|Extraction + MPM|Tooth extraction followed by socket grafting using MPM, prepared from autologous blood combined with xenograft bone particles.
219366680|NCT04610476|DRUG|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
219356370|NCT07159828|BIOLOGICAL|AXN-2510|AXN-2510 is an antibody with PD-L1 blocking and VEGF inhibition activity in one drug. This is called a bispecific antibody, because it has 2 activities. This immuno-oncology treatment is in development for the treatment of solid tumors. AXN-2510 is differentiated from other PD-L1 and VEGF bispecific antibodies by its ability to inhibit multiple VEGF molecules and also increased antibody-dependent cellular cytotoxicity (ADCC) that can directly kill PD-L1-positive tumor cells.
219356371|NCT07160478|OTHER|School Health Program|Health education interventions of approximately 60 minutes that include a conceptual presentation and a practical component.
219356372|NCT07166133|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Lesions in aortic arch in Zone 0 or Zone 1
219356373|NCT03087955|DRUG|Acoziborole|Acoziborole 3 x 320 mg tablets (fasted state)
219356374|NCT06285097|DRUG|PF-07820435|immune agonist
219356375|NCT06285097|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
219356376|NCT05279456|BIOLOGICAL|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
219356377|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
219356378|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
219356379|NCT06257966|DRUG|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
219356380|NCT06257966|DRUG|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
219356381|NCT01841723|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219356382|NCT01841723|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
219356383|NCT01841723|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
219356384|NCT01841723|PROCEDURE|Computed Tomography|Undergo CT
219356385|NCT01841723|DRUG|Ibrutinib|Given PO
219356386|NCT01841723|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
219356387|NCT05379946|DRUG|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
219356388|NCT05379946|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day
219356389|NCT02392429|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219356390|NCT02392429|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
219356391|NCT02392429|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
219356392|NCT02392429|DRUG|Chemotherapy|Given anthracycline IV
219356393|NCT02392429|PROCEDURE|Computed Tomography|Undergo FLT PET/CT
219356394|NCT02392429|DRUG|Cytarabine|Given IV
219356395|NCT02392429|OTHER|Fluorothymidine F-18|Undergo FLT PET/CT
219356396|NCT02392429|OTHER|Laboratory Biomarker Analysis|Correlative studies
219356397|NCT02392429|PROCEDURE|Positron Emission Tomography|Undergo FLT PET/CT
219356398|NCT06484322|BEHAVIORAL|Strategies Empowering Activities in Everyday life (SEE 2.0)|SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
219356399|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
219356400|NCT06569108|DRUG|KN057|KN057 will be administered subcutaneously once a week.
219356401|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
219356402|NCT05392608|DRUG|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
219356403|NCT05392608|DRUG|Fulvestrant|Fulvestrant 300mg 1x/four weeks
219356404|NCT04880031|DRUG|Efimosfermin|Efimosfermin will be administered by subcutaneous injection
219356405|NCT04880031|DRUG|Placebo|Placebo will be administered by subcutaneous injection
219356406|NCT06952660|DRUG|TIVDAK|2 mg/kg once every 3 weeks (Q3W)
219356407|NCT06707090|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
219356408|NCT06707090|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
219356409|NCT03266016|OTHER|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
219356410|NCT03266016|DIAGNOSTIC_TEST|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
219366681|NCT05770128|PROCEDURE|laparoscope|subserosal manipulation of gallbladder with laparoscope .
219356411|NCT03266016|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
219356412|NCT03266016|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
219356413|NCT03266016|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
219356414|NCT06467084|DRUG|KVD900 150 mg|KVD900 Tablet 150 mg (2 x 75 mg)
219356415|NCT06467084|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
219356416|NCT06467084|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
219356417|NCT04519489|DEVICE|PAP therapy with telemonitoring|This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
219356418|NCT04519489|OTHER|AF standard management and OSA general care|Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
219356419|NCT04101838|DRUG|Fluzone|inactivated seasonal influenza vaccine
219356420|NCT04101838|DRUG|Flucelvax|inactivated seasonal influenza vaccine
219356421|NCT04101838|DRUG|Fluzone High-Dose|inactivated seasonal influenza vaccine
219356422|NCT04101838|DRUG|Fluad|inactivated seasonal influenza vaccine
219356423|NCT02869282|OTHER|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
219356424|NCT02869282|OTHER|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
219356425|NCT04229160|DEVICE|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
219356426|NCT04229160|DEVICE|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
219356427|NCT04229160|PROCEDURE|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
219356428|NCT06139523|DEVICE|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
219356429|NCT06139523|DEVICE|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
219356430|NCT03771586|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
219356431|NCT03771586|DRUG|Placebo|Placebo in combination with Ketamine
219356432|NCT06390592|DEVICE|PD cycler|"Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
219356433|NCT05099471|DRUG|Venetoclax; Rituximab|Combination of venetoclax and rituximab
219356434|NCT05099471|DRUG|DRC|Combination of Dexamethasone / Rituximab / Cyclophosphamide
219356435|NCT04027972|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
219356436|NCT04027972|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
219356437|NCT05553080|GENETIC|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
219356438|NCT04938973|PROCEDURE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
219356439|NCT04938973|PROCEDURE|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
219356440|NCT04938973|DEVICE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
219356441|NCT00482014|DRUG|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
219366682|NCT02130414|DRUG|Sandimmun® IV|2 mg/kg IV
219356442|NCT00482014|DRUG|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
219356443|NCT00482014|DRUG|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles"
219356444|NCT00482014|RADIATION|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
219356445|NCT03213301|DRUG|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
219356446|NCT03343275|COMBINATION_PRODUCT|Lit control pHDown|Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
219356447|NCT06158165|DEVICE|Mostcare (Vytech, Vygon, Padua, Italy)|Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
219356448|NCT03686397|DRUG|SVT-15652|1 vial twice daily
219356449|NCT03686397|DRUG|Placebo|1 vial twice daily
219356450|NCT05181995|DRUG|NYX-783|NYX-783
219356451|NCT05181995|DRUG|Placebo|Placebo for 50 mg NYX-783
219356452|NCT04310046|PROCEDURE|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
219356453|NCT04310046|PROCEDURE|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
219356454|NCT03402776|DRUG|4th dose of hexavalent vaccine 1 month after the 3rd dose|4th dose of hexavalent vaccine 1 month after the 3rd dose
219356455|NCT02257580|DRUG|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
219356456|NCT01178138|DRUG|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
219356457|NCT05902169|DEVICE|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
219356458|NCT05902169|DRUG|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\]."
219356459|NCT05902169|DRUG|Lomustine|Dosed and administered per labelling.
219356460|NCT05902169|DRUG|Temozolomide|Dosed and administered per labelling.
219356461|NCT06763484|DRUG|Paroxetine|20 mg PO daily
219356462|NCT06763484|DIETARY_SUPPLEMENT|Placebo|1 capsule starch
219356463|NCT02381561|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219356464|NCT02381561|OTHER|Laboratory Biomarker Analysis|Correlative studies
219356465|NCT02381561|OTHER|Pharmacological Study|Correlative studies
219356466|NCT02381561|DRUG|Ropidoxuridine|Given PO
219356467|NCT03269214|DRUG|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
219356468|NCT05728866|PROCEDURE|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
219356469|NCT03225365|BIOLOGICAL|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
219356470|NCT01241708|DRUG|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
219356471|NCT04640623|DRUG|TAR-200|TAR-200 will be administered transuretherally.
219356472|NCT04640623|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
219356473|NCT01273545|DRUG|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
219356474|NCT03787758|DRUG|SAGE-718|SAGE-718
219356475|NCT03735537|DRUG|Teriparatide Pen Injector|
219356476|NCT03735537|DRUG|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
219356477|NCT04183335|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219356478|NCT04183335|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219356479|NCT04183335|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
219356480|NCT04183335|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
219356481|NCT04183335|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
219356482|NCT06569329|DEVICE|GentleWave System Root Canal Therapy|This device has 510k market approval for its intended use within this study.
219356483|NCT06569329|DEVICE|EdgePro Laser Root Canal Therapy|This device has 510k market approval for its intended use within this study.
219366683|NCT02130414|DRUG|CyCol® capsules|37.5 mg CyCol® capsules
219356484|NCT06569329|DEVICE|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|This device has 510k market approval for its intended use within this study.
219356485|NCT02605642|DRUG|CT-P13|biosimilar infliximab
219356486|NCT03459027|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g) acutely
219356487|NCT03459027|DIETARY_SUPPLEMENT|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
219356488|NCT04724161|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
219356489|NCT06399497|OTHER|spinal manipulation|A high-velocity low-amplitude spinal manipulation at the L5 level will be performance by means of the lumbar roll technique, with the subject in right lateral decubitus.
219356490|NCT06399497|OTHER|simulated manipulation|Simulated manipulation intervention, in the same position as in the Intervention Group, performance in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
219356491|NCT03632395|DIAGNOSTIC_TEST|computed tomography|computed tomography
219356492|NCT05873348|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
219356493|NCT03438045|BEHAVIORAL|Partnered intervention|CHWs will provide dental education and counseling, lead interactive demonstrations of brushing with fluoride toothpaste and flossing, and improve access to dental care through dental coverage enrollment and linkage to local dentists.
219356494|NCT00391404|DRUG|Alendronate|Alendronate 70 mg weekly (oral)
219356495|NCT00391404|DRUG|Placebo|Placebo
219356496|NCT04363372|DRUG|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
219356497|NCT04363372|DRUG|Placebo|Placebo capsules will be identical in appearance to active product.
219356498|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
219356499|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
219356500|NCT01294384|DRUG|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
219356501|NCT05850208|BIOLOGICAL|Transplantation of self BMSCs|Bone marrow was collected, cultured in vitro and injected back into the body
219356502|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
219356503|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
219356504|NCT01062360|DRUG|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
219356505|NCT01062360|DRUG|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
219356506|NCT05129397|BEHAVIORAL|Mom Power|Virtual Mom Power is a manualized multi-family group intervention consisting of 10 virtual group + 2 individual sessions led by two masters-level co-facilitators. Virtual groups are 90 minutes, following a structured format via secure HIPAA compatible video platform. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice (4) Social Support; \& (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs.
219356507|NCT05129397|BEHAVIORAL|Mom Power Informational Mailing|This active comparison condition intervention includes two individual sessions along with 10 weeks of informational mailing with content related to Mom Power core concepts.
219356508|NCT02168686|GENETIC|ADVM-043|Gene transfer vector administration
219356509|NCT04295070|BIOLOGICAL|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
219356510|NCT04295070|BIOLOGICAL|Normal saline|Saline (0.9%) administered via dropper
219356511|NCT00786877|OTHER|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
219356512|NCT00786877|OTHER|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
219356513|NCT02803164|DEVICE|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
219356514|NCT02803164|OTHER|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
219356515|NCT00618748|DRUG|Olanzapine|5-20 mg/day, oral, daily
219356516|NCT03870802|OTHER|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
219359817|NCT07171879|PROCEDURE|Pontic Shield Only|Partial extraction therapy using the pontic shield technique, in which the buccal root fragment is preserved to maintain ridge contour, without additional grafting.
219356517|NCT05282823|DEVICE|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
219356518|NCT04288570|PROCEDURE|suture anchor socket creation with punch|suture anchor socket creation with punch
219356519|NCT04288570|PROCEDURE|suture anchor socket creation with drill|suture anchor socket creation with drill
219356520|NCT05273827|DRUG|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
219356521|NCT05273827|DRUG|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
219356522|NCT06180889|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
219356523|NCT06180889|DRUG|KN060 Low|Single dose of KN060 administered as intravenous infusion
219356524|NCT06180889|DRUG|KN060 Middle|Single dose of KN060 administered as intravenous infusion
219356525|NCT06180889|DRUG|KN060 Hight|Single dose of KN060 administered as intravenous infusion
219356526|NCT01693315|DRUG|AMA0076|
219356527|NCT01693315|DRUG|Placebo|
219356528|NCT05321836|OTHER|Glucosamine Chondroitin|control group
219356529|NCT05321836|COMBINATION_PRODUCT|glucosamine chondritin & Physiotherapy|experimental group
219356530|NCT06959810|OTHER|Adapted Onco-Esthetics sessions|Patient will received three sessions of Adapted Onco-Esthetics
219356531|NCT02657135|BEHAVIORAL|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
219356532|NCT02657135|OTHER|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
219356533|NCT02657135|OTHER|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
219356534|NCT02657135|OTHER|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
219356535|NCT02657135|OTHER|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
219356536|NCT02657135|OTHER|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
219356537|NCT02657135|OTHER|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
219356538|NCT02789813|DRUG|Valproic Acid|Once oral administration of 500mg before exposure therapy.
219356539|NCT02789813|DRUG|Placebo|Once oral administration of 500mg before exposure therapy.
219356540|NCT02789813|BEHAVIORAL|Fear reactivation|Fear reactivation before exposure therapy.
219356541|NCT02789813|BEHAVIORAL|No fear reactivation|No fear reactivation before exposure therapy.
219356542|NCT02074852|OTHER|Foley urethral catheter|
219356543|NCT01266486|DRUG|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
219356544|NCT05878652|DEVICE|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
219356545|NCT05878652|OTHER|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
219356546|NCT03193398|DRUG|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
219356547|NCT03193398|DRUG|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
219356548|NCT01394445|DRUG|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
219356549|NCT01394445|DRUG|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
219356550|NCT03279380|OTHER|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
219356551|NCT03279380|OTHER|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
219356552|NCT03279380|OTHER|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
219356553|NCT01178060|OTHER|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
219356554|NCT01178060|OTHER|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
219359818|NCT07171879|PROCEDURE|Pontic Shield + MPM|Pontic shield technique combined with grafting using mineralized plasmatic matrix (MPM) for enhanced ridge preservation and healing.
219356555|NCT02963805|BEHAVIORAL|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (\~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
219356556|NCT02963805|BEHAVIORAL|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
219356557|NCT02963805|BEHAVIORAL|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
219356558|NCT02440815|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
219356559|NCT03109171|OTHER|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
219356560|NCT00274365|PROCEDURE|videoconference|
219356561|NCT00777569|DRUG|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
219356562|NCT00777569|DRUG|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
219356563|NCT00777569|DRUG|Nicotine Lozenge|4 mg nicotine lozenge
219356564|NCT00159289|PROCEDURE|Inhalation of LPS|
219356565|NCT00159289|PROCEDURE|Placebo|
219356566|NCT01820325|DRUG|Buparlisib|
219356567|NCT01820325|DRUG|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
219356568|NCT01820325|DRUG|Carboplatin|
219356569|NCT01820325|DRUG|Paclitaxel|
219356570|NCT00003793|GENETIC|clonality analysis|
219356571|NCT00003793|GENETIC|microsatellite instability analysis|
219356572|NCT00003793|GENETIC|mutation analysis|
219356573|NCT03806127|DRUG|Vibegron|oral administration
219356574|NCT03806127|DRUG|Placebo|oral administration
219356575|NCT02170662|DRUG|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
219356576|NCT02170662|DRUG|Placebo|
219356577|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
219356578|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
219356579|NCT00133523|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
219356580|NCT00133523|OTHER|Placebo|Physiological saline administered as an intramuscular injection.
219356581|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
219356582|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
219356583|NCT00133523|OTHER|Placebo|Normal allantoic fluid administered annually as an internasal spray.
219356584|NCT06423079|PROCEDURE|Siepser knots|Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation
219356585|NCT01467492|DRUG|Telaprevir|Tablet
219356586|NCT01467492|DRUG|Ribavirin|Tablet
219356587|NCT01467492|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
219356588|NCT04436146|OTHER|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
219356589|NCT00167635|BEHAVIORAL|cognitive-behavioral|Cognitive-behavioral over 9 weeks
219356590|NCT00485641|DEVICE|SaeboFlex Dynamic Hand Orthosis|
219356591|NCT00485641|PROCEDURE|Saebo F.T.M. Arm Training Program|
219356592|NCT02950233|DRUG|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).
219356593|NCT02950233|DRUG|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
219356594|NCT02950233|DRUG|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
219356595|NCT02950233|DRUG|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
219356596|NCT05461079|DIAGNOSTIC_TEST|obtention of up to three semen samples|sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.
219356597|NCT06502093|OTHER|Observational Malnutrition Screening and Foodservice Satisfaction|Patients asked Acute Care Hospital Foodservice Patient Satisfaction Questionnaire and malnutrition risk assessed with NRS-2002 screening tool.
219356598|NCT00235079|DRUG|Colchicine|Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
219356599|NCT00235079|DRUG|Placebo|Placebo comparator
219356600|NCT05280977|OTHER|POST ISOMETRIC RELAXATION|Group A (Post Isometric Relaxation + Conventional Physiotherapy): This group will receive Muscle Energy Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session.
219356601|NCT05280977|OTHER|POST FACILITATION STRETCHING|"Group B (Post Facilitation Stretching + Conventional Physiotherapy):~This group will receive Post Facilitation Stretching Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session."
219356602|NCT04929171|OTHER|Physical Therapy|Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
219356603|NCT04408495|PROCEDURE|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
219356604|NCT04408495|PROCEDURE|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
219356605|NCT01164085|DRUG|Intravitreal Ketorolac|4mg of intravitreal ketorolac
219356606|NCT02361645|DRUG|Ketorolac 0.5% eyedrops|
219356607|NCT02361645|DRUG|Indomethacin 0.5% eyedrops|
219356608|NCT02361645|DRUG|Bromfenac 0.09% eyedrops|
219356609|NCT02361645|DRUG|Nepafenac 0.1% eyedrops|
219356610|NCT03390179|DRUG|Steroid Drug|mesure of the glucose concentration
219356611|NCT00522795|DRUG|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
219356612|NCT03823391|DRUG|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
219356613|NCT03823391|DRUG|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
219356614|NCT03823391|DRUG|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
219356615|NCT03823391|DRUG|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
219356616|NCT03489733|OTHER|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
219356617|NCT03489733|OTHER|Control formula|Infant formula with intact proteins and pre- and probiotics.
219356618|NCT02913157|DRUG|Hydroxychloroquine|Orally administered Hydroxychloroquine
219356619|NCT02770937|OTHER|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
219356620|NCT02770937|OTHER|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
219356621|NCT02770937|DEVICE|Simbionix|
219356622|NCT02450487|DRUG|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
219356623|NCT06427551|DRUG|Ropivacaine|The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
219356624|NCT04635306|DIAGNOSTIC_TEST|Approved GEBT test meal|FDA-approve GEBT test meal
219356625|NCT01790048|DIETARY_SUPPLEMENT|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
219356626|NCT01790048|DIETARY_SUPPLEMENT|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
219356627|NCT03609372|BEHAVIORAL|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
219356628|NCT00159432|DRUG|Oxaliplatin|
219356629|NCT00159432|DRUG|Bevacizumab|
219356630|NCT00159432|DRUG|Capecitabine|
219356631|NCT05736588|BEHAVIORAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
219359819|NCT07168824|DIETARY_SUPPLEMENT|Lacticaseibacillus paracasei|one capsule daily for 12 weeks
219356632|NCT01677247|DRUG|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
219356633|NCT01677247|DRUG|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
219356634|NCT05079490|BEHAVIORAL|motor intervention|gross motor skill intervention combined with fitness training
219356635|NCT03248726|DRUG|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
219356636|NCT03248726|DRUG|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
219356637|NCT01200784|DRUG|Nicotinamide|dosage
219356638|NCT05366699|PROCEDURE|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
219356639|NCT05366699|PROCEDURE|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
219356640|NCT05366699|PROCEDURE|axillary lymphadenectomy with soft tissue reinforcement|axillary lymphadenectomy with soft tissue reinforcement(STR)
219356641|NCT06222944|DRUG|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
219356642|NCT06222944|DRUG|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
219356643|NCT06222944|DRUG|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
219356644|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
219356645|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
219356646|NCT05489237|DRUG|IDRX-42|Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
219356647|NCT01842503|DRUG|GET 73|300 mg tid on 3 days cycle
219356648|NCT01842503|DRUG|inactive ingredients capsule|3 capsules tid on 3 days cycle
219356649|NCT06282458|DRUG|Enobosarm|Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
219356650|NCT06282458|DRUG|Semaglutide|Semaglutide for Chronic Weight Management
219356651|NCT05159596|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
219356652|NCT05159596|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
219356653|NCT05218499|DRUG|Brigimadlin|Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).
219356654|NCT05218499|DRUG|Doxorubicin|Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).
219356655|NCT06121401|DRUG|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
219356656|NCT06121401|DRUG|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
219356657|NCT00796471|DRUG|Paliperidone ER|
219356658|NCT06047561|RADIATION|PET-CT|PET combined with CT or MRI
219356659|NCT05754918|DEVICE|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
219356660|NCT05754918|DEVICE|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
219356661|NCT03403699|BIOLOGICAL|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
219356662|NCT05029921|DRUG|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
219356663|NCT05072483|DEVICE|MRI|Research pulse sequences.
219356664|NCT06397833|DEVICE|Acorai ICPM system|Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
219356665|NCT04500275|DRUG|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
219356666|NCT04500275|OTHER|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
219356667|NCT06181240|DEVICE|Intravascular lithotripsy|Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
219356668|NCT00517972|DRUG|Omacor (omega-3-acid ethyl esters)|
219356669|NCT06553612|OTHER|Multidisciplinary assessment|Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
219356670|NCT06553612|OTHER|Standard assesment|Delivery of a personalized post-cancer plan without a day hospital
219366684|NCT03611439|DIETARY_SUPPLEMENT|ReBuilder|8-component botanical dietary supplement
219356671|NCT06553612|OTHER|Observational cohort|Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort
219356672|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
219356673|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
219356674|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
219356675|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
219356676|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
219356677|NCT06674863|OTHER|Educational Intervention|Receive a low literacy educational supplement
219356678|NCT06674863|OTHER|Interview|Undergo a structured interview
219356679|NCT06674863|OTHER|Questionnaire Administration|Ancillary studies
219356680|NCT06674863|OTHER|Supportive Care|Receive standard SCP
219356681|NCT06674863|OTHER|Supportive Care|Receive a tailored SCP
219356682|NCT01804686|DRUG|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
219356683|NCT05487599|GENETIC|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
219356684|NCT06801275|OTHER|1 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering once with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
219356685|NCT06801275|OTHER|2 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering twice with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
219356686|NCT03508310|OTHER|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
219356687|NCT05851677|DRUG|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
219356688|NCT04468126|OTHER|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
219356689|NCT04468126|OTHER|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
219356690|NCT05286801|BIOLOGICAL|Atezolizumab|Given IV
219356691|NCT05286801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219356692|NCT05286801|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
219356693|NCT05286801|PROCEDURE|Echocardiography Test|Undergo ECHO
219356694|NCT05286801|OTHER|Fludeoxyglucose F-18|Given FDG
219356695|NCT05286801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219356696|NCT05286801|PROCEDURE|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
219356697|NCT05286801|BIOLOGICAL|Tiragolumab|Given IV
219356698|NCT05286801|PROCEDURE|X-Ray Imaging|Undergo x-rays
219356699|NCT03132636|DRUG|cemiplimab|Regimen as per protocol
219356700|NCT02129751|DRUG|bupropion hydrobromide|study drug
219356701|NCT02129751|DRUG|Placebo|placebo arm
219356702|NCT03461445|DRUG|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
219356703|NCT03461445|DRUG|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
219356704|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
219356705|NCT06378346|OTHER|Observation|Participants will not receive glycyrrhizin
219356706|NCT06378346|DRUG|Glycyrrhizin - 75 mg|Participants will either receive 75 mg orally daily
219356707|NCT06378346|DRUG|Glycyrrhizin - 150 mg|Participants will receive 150 mg orally daily
219356708|NCT05607823|OTHER|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
219356709|NCT05607823|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
219356710|NCT05607823|OTHER|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
219356711|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356712|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356713|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356714|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356715|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356716|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
219356717|NCT05807035|BIOLOGICAL|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
219356718|NCT06323616|PROCEDURE|MAC adjustment to PSI between 25 and 50|According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
219356719|NCT06233656|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing.
219356720|NCT05869773|DRUG|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
219356721|NCT05105100|PROCEDURE|Biopsy|Tumor tissue collection
219356722|NCT05105100|PROCEDURE|Biospecimen Collection|Intravenously Blood draw
219356723|NCT05206357|DRUG|Epcoritamab|Subcutaneous Injection (SC)
219356724|NCT05030311|DRUG|LOU064 25 mg (b.i.d)|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.
219356725|NCT05030311|DRUG|Placebo|Placebo
219356726|NCT05030311|DRUG|LOU064 25 mg (b.i.d) as a tablet.|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
219356727|NCT06136234|BEHAVIORAL|Caring Contacts|Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern
219356728|NCT06136234|BEHAVIORAL|Best Available Resources Alone|Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
219356729|NCT02484417|BIOLOGICAL|RSV A2|Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
219356730|NCT03142321|DRUG|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
219356731|NCT03042468|DRUG|177Lu-PSMA-617|177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
219356732|NCT03042468|DRUG|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
219356733|NCT06278207|DRUG|Finerenone (BAY 94-8862)|10 mg or 20 mg daily
219356734|NCT05746767|BEHAVIORAL|Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
219356735|NCT05746767|BEHAVIORAL|Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
219356736|NCT05647226|COMBINATION_PRODUCT|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
219356737|NCT05647226|OTHER|Standard of care|Standard of care.
219356738|NCT06367920|DIAGNOSTIC_TEST|Magnetic Resonance Imaging, Behavioral assessments|Magnetic Resonance Imaging, Behavioral assessments
219356739|NCT04748874|PROCEDURE|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
219356740|NCT06408077|OTHER|Water administration|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
219356741|NCT06408077|OTHER|NaCl-Administration|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
219356742|NCT06420245|DEVICE|Orion TM Amniotic Membrane Allograft|The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
219356743|NCT06420245|PROCEDURE|Standard of Care (SOC)|Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
219356744|NCT04298658|DIAGNOSTIC_TEST|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
219356745|NCT04298658|DIAGNOSTIC_TEST|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
219356746|NCT04298658|OTHER|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
219356747|NCT04298658|DIAGNOSTIC_TEST|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
219356748|NCT04298658|DIAGNOSTIC_TEST|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
219356749|NCT05183568|BEHAVIORAL|Mindful Self-Compassion|Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
219356750|NCT06307106|DRUG|ketorolac and light marcaine|local injection at surgical site of 30 mg ketorolac and 7-1.5 mg\\kg\\dose light marcaine
219356751|NCT06307106|DRUG|light marcaine|local injection at surgical site of 7-1.5 mg\\kg\\dose light marcaine
219356752|NCT06307106|DRUG|Corticosteroids injection|local injection at surgical site of 40 mg\\ dose of dexamethasone
219356753|NCT06307106|DRUG|Diclofenac Sodium Gel|topical application of Diclofenac Sodium Gel
219356754|NCT06307106|OTHER|the standard analgesic protocol|the routine analgesia was given without local analgesia application
219356755|NCT05140499|DRUG|Liposomal bupivacaine|Popliteal nerve block
219356756|NCT05140499|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
219356757|NCT06560021|OTHER|Biopsy strategy|Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
219356758|NCT04666155|DEVICE|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
219356759|NCT04666155|DEVICE|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
219356760|NCT05880368|OTHER|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
219356761|NCT05723653|BEHAVIORAL|Social Network Support Intervention|The Social Network Support Intervention is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV. The intervention consists of (1) selection and invitation of a Support Confidant, (2) a face-to-face intervention between the Intervention Case Manager and the Index and Support Confidant, and (3) quarterly interactive mini-booster sessions delivered to the Index and Support Confidant via text or telephone, based on participant preference.
219356762|NCT06414473|DRUG|Cannabidiol (CBD) Extract|Administered thrice daily (with food) using a sublingual route of administration
219356763|NCT06414473|DRUG|Placebo|Administered thrice daily (with food) using a sublingual route of administration
219356764|NCT04608110|DRUG|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
219356765|NCT05238714|DRUG|venglustat|Powder for Oral solution
219356766|NCT06431425|BEHAVIORAL|eCG Family Clinic|The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
219356767|NCT03212742|DRUG|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
219356768|NCT03212742|DRUG|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
219356769|NCT03212742|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
219356770|NCT03083886|OTHER|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
219356771|NCT03083886|OTHER|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
219356772|NCT03083886|OTHER|Usual PCP led care|Primary care provider will direct patients' care pathway.
219356773|NCT05333341|BEHAVIORAL|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
219362282|NCT06915909|DEVICE|surgery|40 patients randomised to two arms will undergo robotic prostatectomies using either the control AirSeal® Insufflation System (AIS) or the intervention Stryker PneumoClear Insufflator. Intra-operative and post-operative pain will be compared between the two arms of the trial.
219356774|NCT05333341|BEHAVIORAL|TCM plus COPES|The COPES program will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
219356775|NCT05405179|PROCEDURE|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized bone flaps for jaw reconstruction using patient-specific surgical guides and titanium plates
219356776|NCT00083083|DRUG|carboplatin|
219356777|NCT00083083|DRUG|cisplatin|
219356778|NCT00083083|DRUG|docetaxel|
219356779|NCT00083083|DRUG|etoposide|
219356780|NCT00083083|DRUG|paclitaxel|
219356781|NCT00083083|DRUG|vinblastine sulfate|
219356782|NCT00083083|DRUG|vinorelbine tartrate|
219356783|NCT00083083|GENETIC|gene expression analysis|
219356784|NCT00083083|PROCEDURE|positron emission tomography|
219356785|NCT00083083|RADIATION|fludeoxyglucose F 18|
219356786|NCT00083083|RADIATION|radiation therapy|
219356787|NCT04163068|OTHER|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
219356788|NCT04532060|DRUG|Nystatin|
219356789|NCT04532060|PROCEDURE|Antimicrobial Photodynamic Therapy|
219356790|NCT05511168|PROCEDURE|Craniostnostosis surgery|Surgery of craniosynostosis
219356791|NCT04161495|BIOLOGICAL|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV injection
219356792|NCT00211146|DRUG|epoetin alfa|
219356793|NCT03655756|BIOLOGICAL|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
219356794|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356795|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356796|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356797|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356798|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356799|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
219356800|NCT05409547|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
219356801|NCT01476657|DRUG|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
219356802|NCT04623450|OTHER|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
219356803|NCT03894930|BEHAVIORAL|Metta meditation|Administered 5 days per week for 8 weeks.
219356804|NCT03656861|OTHER|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
219356805|NCT02117765|DRUG|Ustekinumab|
219356806|NCT00253630|OTHER|Laboratory Biomarker Analysis|Correlative studies
219356807|NCT00253630|DRUG|Vorinostat|Given PO
219356808|NCT05364242|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
219356809|NCT01169077|DRUG|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
219356810|NCT01169077|BIOLOGICAL|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
219356811|NCT03771365|PROCEDURE|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
219356812|NCT03771365|PROCEDURE|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
219356813|NCT03771365|PROCEDURE|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
219356814|NCT03589378|PROCEDURE|PEAF|PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
219356815|NCT05172739|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
219360100|NCT01873755|BEHAVIORAL|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
219356816|NCT05172739|DRUG|Opioid-free Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
219356817|NCT00429858|DRUG|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
219356818|NCT00429858|DRUG|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
219356819|NCT02555423|DRUG|Local anaesthetic - chirocaine|
219356820|NCT00161629|DRUG|rhBMP-2/CPM|
219356821|NCT01587079|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
219356822|NCT01587079|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
219356823|NCT01587079|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
219356824|NCT01587079|DRUG|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
219356825|NCT01184482|DRUG|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~1. 750 mg (3 tabs)~2. 1000 mg (4 tabs)~3. 1250 mg (5 tabs)"
219356826|NCT02796378|DRUG|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
219356827|NCT02796378|DRUG|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
219356828|NCT02796378|DRUG|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
219356829|NCT01654510|BEHAVIORAL|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
219356830|NCT01654510|OTHER|Vocational Services as Usual|
219356831|NCT00555100|DRUG|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
219356832|NCT00555100|DRUG|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
219356833|NCT03005054|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
219356834|NCT03005054|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
219356835|NCT03257787|OTHER|new adhesive strip|This is a strip made of a newly developed adhesive
219356836|NCT02213809|BEHAVIORAL|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
219356837|NCT02213809|BEHAVIORAL|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
219356838|NCT01239160|DEVICE|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
219356839|NCT01239160|DEVICE|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
219356840|NCT05339672|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
219356841|NCT03995264|PROCEDURE|Ultrasound -guided cannulation|radial artery cannulation using the ultrasound
219356842|NCT03995264|PROCEDURE|Palpation -guided cannulation|radial artery cannulation using the palpation
219356843|NCT04567550|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
219356844|NCT04567550|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
219356845|NCT04567550|GENETIC|ABBV-RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
219356846|NCT04567550|DRUG|Topical Steroid|Topical Steroid
219356847|NCT04567550|GENETIC|ABBV-RGX-314 Dose 4|AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
219356848|NCT04567550|BIOLOGICAL|Aflibercept|Aflibercept
219356849|NCT04146610|DRUG|an antibody drug conjugate|Multiple dose grouping
219356850|NCT02263833|DRUG|Mircera|Participants received Mircera according to individualized physician-prescribed regimen.
219356851|NCT01415427|DRUG|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
219356852|NCT01415427|DRUG|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
219356853|NCT02929264|DRUG|ABX-1431|Capsules, 40 mg, single dose
219356854|NCT02929264|DRUG|Placebo|Capsules, single dose
219356855|NCT05506761|PROCEDURE|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
219356856|NCT05506761|PROCEDURE|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
219356857|NCT03912129|GENETIC|blood sample|"A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants."
219356858|NCT03355183|OTHER|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
219356859|NCT00704964|BIOLOGICAL|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
219356860|NCT00704964|DRUG|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
219356861|NCT04781816|DRUG|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
219356862|NCT04781816|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
219356863|NCT03174483|DRUG|Hypertonic saline|nasal spray
219356864|NCT03174483|DRUG|Fluticasone Nasal|nasal spray
219356865|NCT01882283|DIETARY_SUPPLEMENT|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
219356866|NCT01882283|DIETARY_SUPPLEMENT|Placebo|
219356867|NCT01571583|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
219356868|NCT01571583|DRUG|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
219356869|NCT01571583|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.
219356870|NCT02062658|DRUG|Ketamine|0.5mg/kg IV
219356871|NCT02062658|BEHAVIORAL|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
219356872|NCT03322059|BEHAVIORAL|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
219356873|NCT03322059|BEHAVIORAL|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
219356874|NCT01789970|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
219356875|NCT01789970|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
219356876|NCT05090293|BEHAVIORAL|Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)|A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
219356877|NCT05090293|BEHAVIORAL|Lifestyle Intervention (LI)|A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
219356878|NCT04904289|OTHER|All intervention of real world|We analyzed all data we can obtain from our databases
219356879|NCT02161562|DRUG|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
219356880|NCT02161562|DRUG|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
219356881|NCT06221020|DIAGNOSTIC_TEST|Malnutrition Universal Screening Tool|"The Malnutrition Universal Screening Tool (MUST) is a commonly used tool for assessing the nutritional status of adult patients. It is designed to identify early whether a patient is at risk of malnutrition or is already malnourished, enabling timely intervention and treatment. MUST includes three main assessment criteria:~Body Mass Index (BMI):~Degree of Weight Loss: This assesses the patient's weight change over the past three months, with grading based on the extent of weight loss.~Effect of Illness on Dietary Intake: This evaluates the impact of illness on the patient's dietary intake, with grading based on the reduction in dietary intake.~By combining the grades from these three assessment indicators, a final MUST score is obtained to determine the patient's nutritional status and level of risk. Based on the MUST score, patients can be categorized as low risk, medium risk, or high risk for malnutrition."
219356882|NCT06221020|DEVICE|TIB Olfactory Test Device|Olfactory testing is conducted on patients undergoing pituitary tumor surgery via nasal endoscopy using the TIB Olfactory Test Device (TIBSIT). This testing aims to compare olfactory (sense of smell) outcomes before and after the surgery. The olfactory tests are performed preoperatively and then again at the 3-month postoperative mark to assess any changes or impacts on the sense of smell due to the surgery.
219356883|NCT06221020|DIAGNOSTIC_TEST|Apfel Score for Postoperative nausea and vomiting|"Nausea and Vomiting Risk Scale: Apfel Score~Risk Factors: Female; Smoking habit; History of postoperative nausea and vomiting or motion sickness; Use of opioid painkillers post-surgery (Each risk factor scores 1 point; minimum score is 0; maximum score is 4)~Score Probability of Postoperative Nausea and Vomiting~0 - 10%~1. \- 21%~2. \- 39%~3. \- 61%~4. \- 79%"
219356884|NCT06221020|DIAGNOSTIC_TEST|The American Society of Anesthesiologists (ASA) Physical Status Classification|"ASA I: A normal, healthy patient with no systemic disease. ASA II: A patient with mild systemic disease. ASA III: A patient with severe systemic disease that limits activity but is not incapacitating.~ASA IV: A patient with severe systemic disease that is a constant threat to life.~ASA V: A moribund patient not expected to survive without the operation. This project involves collecting data from adult patients aged 20 to 75 years old who are classified as ASA I to III grade."
219356885|NCT06221020|BEHAVIORAL|Short Form-36|The Short Form-36 (SF-36) is a widely used health assessment tool, extensively applied in both research and clinical practice. It is a concise yet comprehensive questionnaire designed to evaluate individuals' health status and quality of life. The SF-36 covers eight different dimensions of health, including physical functioning, bodily pain, general health, vitality, social functioning, emotional health, mental health, and health change. Each dimension is assessed through a series of questions that address aspects such as an individual's capabilities in daily life, symptoms, and emotional states. The SF-36 allows healthcare professionals and researchers to gain insights into a person's health and quality of life across these varied aspects. Additionally, SF-36 has undergone extensive testing and validation, proving to have good reliability and validity.
219356886|NCT06221020|BEHAVIORAL|World Health Organization Quality of Life questionnaire (WHOQOL-BREF)|The World Health Organization Quality of Life questionnaire (WHOQOL-BREF) is a health-related quality of life assessment tool developed by the World Health Organization (WHO). It is designed to evaluate an individual's satisfaction with their life and overall health status. The WHOQOL-BREF is a condensed version of the original WHOQOL-100 questionnaire, intended to reduce the time required to complete it and enhance its applicability.
219356887|NCT06221020|BEHAVIORAL|BDI-II(Beck Depression Inventory-II)|"The BDI-II consists of 21 questions that assess the degree of depression by asking respondents about various depressive symptoms they have experienced. These symptoms include sadness, insomnia or oversleeping, changes in appetite, self-blame, self-disdain, loss of interest in daily activities, and more. Each question has four possible response options, allowing respondents to choose the answer that best fits their feelings.~Scoring on the BDI-II ranges from 0 to 63, with higher scores indicating more severe depression. Based on the scores, the severity of a respondent's depression can be classified into different levels, ranging from mild to severe. The purpose of using this scale is to help healthcare professionals assess a patient's depressive symptoms, monitor changes in condition, and evaluate the effectiveness of treatments."
219356888|NCT06221020|BEHAVIORAL|ERAS Patient Satisfaction Questionnaire(ERAS-PSQ)|The ERAS Patient Satisfaction Questionnaire (ERAS-PSQ) is a satisfaction survey specifically designed for patients who have undergone treatment following the Enhanced Recovery After Surgery (ERAS) protocols. This questionnaire aims to evaluate the patients' satisfaction and experience with the ERAS approach. Typically, it includes questions about various aspects of their treatment and care, such as pain management, the recovery process, the quality of nursing care, and communication with the medical team. The ERAS-PSQ is an important tool for assessing how well the ERAS protocols are received by patients and for identifying areas for improvement in patient care within the ERAS framework.
219356889|NCT06221020|BEHAVIORAL|Quality of Recovery-40(QoR-40)|The Quality of Recovery-40 (QoR-40) is a widely used questionnaire designed to assess the quality of recovery after surgery. It comprises 40 questions that cover both physical and psychological aspects of a patient's recovery, such as pain, nausea, anxiety, dietary habits, and social functioning. The QoR-40 provides a comprehensive view of a patient's postoperative recovery, encompassing a range of factors crucial to understanding the effectiveness of surgical procedures and the overall patient experience during the recovery phase. This tool is instrumental in evaluating and improving post-surgical care and patient outcomes.
219356890|NCT00207415|BEHAVIORAL|ASHC and CDSMP|
219356891|NCT02668718|RADIATION|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
219356892|NCT05528627|OTHER|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
219356893|NCT03382847|COMBINATION_PRODUCT|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
219356894|NCT05946473|DIETARY_SUPPLEMENT|Gum base containing xylitol and essencial oils|Participants will be asked to chew 2 pieces of chewing gum containing additives for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
219356895|NCT05946473|DIETARY_SUPPLEMENT|Gum base with no additives|Participants will be asked to chew 2 pieces of pure gum base for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
219356896|NCT02123485|DEVICE|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
219356897|NCT02123485|DEVICE|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
219356898|NCT03423342|DIETARY_SUPPLEMENT|nicotinamide riboside|nicotinamide riboside capsule
219356899|NCT03423342|DRUG|Placebo|matching placebo capsule
219356900|NCT06437873|PROCEDURE|Total Thyroidectomy (TT)|TT:Surgical removal of the entire thyroid gland.
219356901|NCT06437873|RADIATION|Radioactive iodine treatment(RAIT)|RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
219366685|NCT03611439|DIETARY_SUPPLEMENT|Placebo|Inactive Placebo Capsule
219366686|NCT00531960|DRUG|Erlotinib|150 mg, PO, daily
219356902|NCT02933697|DRUG|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
219356903|NCT02933697|DRUG|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
219356904|NCT03243994|DIAGNOSTIC_TEST|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
219356905|NCT01639833|DEVICE|Veriset Hemostatic Patch|Topical hemostat
219356906|NCT01639833|DEVICE|TachoSil®|Topical Hemostat
219356907|NCT04453579|BEHAVIORAL|Telephonic interview during the Italian lockdown.|The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
219356908|NCT03541005|DIETARY_SUPPLEMENT|Obex|After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
219356909|NCT03541005|DIETARY_SUPPLEMENT|Placebo|After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
219356910|NCT04516473|PROCEDURE|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
219356911|NCT01999803|DRUG|sNN0029|
219356912|NCT01999803|DRUG|Placebo|
219356913|NCT04976894|OTHER|open|open
219356914|NCT01179958|BEHAVIORAL|aerobic training|24 weeks of aerobic training, 4X/week
219356915|NCT01179958|BEHAVIORAL|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
219356916|NCT00584480|OTHER|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
219356917|NCT02656628|DEVICE|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
219356918|NCT00794560|BEHAVIORAL|patient education|"Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist"
219356919|NCT01584245|OTHER|Amino Acid formula|
219356920|NCT02481388|OTHER|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
219356921|NCT03511131|BEHAVIORAL|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
219356922|NCT03511131|BEHAVIORAL|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
219356923|NCT03511131|BEHAVIORAL|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
219356924|NCT03511131|BEHAVIORAL|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
219356925|NCT01014741|DRUG|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
219356926|NCT01014741|DRUG|Placebo|Placebo after PV isolation prior to CFE ablation.
219356927|NCT01887977|OTHER|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
219356928|NCT03326141|BEHAVIORAL|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
219356929|NCT03326141|DEVICE|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
219356930|NCT03326141|BEHAVIORAL|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
219356931|NCT03326141|BEHAVIORAL|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
219356932|NCT03326141|OTHER|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
219356933|NCT00180960|DRUG|Oxaliplatin and irinotecan|
219356934|NCT05966285|OTHER|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
219356935|NCT05966285|OTHER|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
219356936|NCT02436876|DRUG|MBN-101|MBN-101 is a locally administered, anti-infective drug product
219356937|NCT02436876|OTHER|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
219356938|NCT04455373|PROCEDURE|pediatric vascular bypass grafting|pediatric vascular bypass grafting
219356939|NCT04534660|DEVICE|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
219356940|NCT03403205|DRUG|ALXN1840|ALXN1840 administered orally in 15 mg tablets
219356941|NCT03403205|DRUG|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
219356942|NCT03396965|OTHER|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
219356943|NCT03285243|DEVICE|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
219356944|NCT05018234|DEVICE|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
219356945|NCT01834729|DRUG|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
219356946|NCT01834729|OTHER|Placebo|placebo capsule identical to the study drug
219356947|NCT02326415|OTHER|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
219356948|NCT02326415|OTHER|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
219356949|NCT06533475|DRUG|Minzasolmin tablet formulation under fasting condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
219356950|NCT06533475|DRUG|Minzasolmin Granules in capsule under fasting condition|Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition
219356951|NCT06533475|DRUG|Minzasolmin tablet formulation under fed condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition
219356952|NCT03431987|DRUG|One day with a dose of placebo cannabis paired with alcohol|Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%
219356953|NCT03431987|DRUG|One day with a dose of active THC cannabis paired with alcohol|Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
219356954|NCT02971670|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
219356955|NCT03664414|DRUG|pentoxifylline|Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
219356956|NCT01258959|PROCEDURE|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
219356957|NCT00288080|DRUG|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
219356958|NCT00288080|DRUG|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
219356959|NCT00288080|DRUG|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
219356960|NCT00288080|DRUG|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
219356961|NCT00288080|RADIATION|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
219356962|NCT00288080|DRUG|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
219356963|NCT03437239|DEVICE|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
219366687|NCT00531960|DRUG|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
219356964|NCT03524261|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
219356965|NCT03524261|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
219356966|NCT03166332|BEHAVIORAL|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
219356967|NCT03166332|BEHAVIORAL|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
219356968|NCT04459455|BEHAVIORAL|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
219356969|NCT04459455|BEHAVIORAL|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
219356970|NCT05275062|DRUG|IM92 CAR-T cells|2.5×10\^8 CAR-T cells
219356971|NCT00853697|OTHER|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
219356972|NCT02576743|DEVICE|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
219356973|NCT04347083|DIAGNOSTIC_TEST|Electrodiagnostic test|Muscle spindle- based reflex latency will be measured
219356974|NCT04438174|DRUG|Processed Amniotic Fluid|Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
219356975|NCT04438174|OTHER|Standard of Care Wound Treatment Regimen|ointment-based dressing and non-ointment-based dressings
219356976|NCT05116124|OTHER|dosing of inflammatory parameters|View and register the dosing of inflammatory parameters
219356977|NCT05480813|DEVICE|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
219356978|NCT05480813|OTHER|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
219356979|NCT02387580|DRUG|OZ439 + TPGS|
219356980|NCT02387580|DRUG|OZ439 Prototype 1|
219356981|NCT02387580|DRUG|OZ439 Prototype 3|
219356982|NCT02387580|DRUG|PQP|
219356983|NCT02949752|DRUG|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
219356984|NCT03201185|DRUG|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
219356985|NCT05358379|DRUG|CYC140|CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
219356986|NCT05416294|DEVICE|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
219356987|NCT05416294|DEVICE|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
219356988|NCT00002655|PROCEDURE|cryosurgery|
219356989|NCT06500806|OTHER|Scroth and brace|Participants in this group will wear a brace and follow a 12-month Schroth exercise program three times a week. Sessions will be supervised by a physiotherapist and last 60 minutes, using equipment like foam blocks, exercise balls, and rods. Exercise intensity will gradually increase based on progress. The individualized Schroth exercises will aim to correct spinal deformity and include elongation, rotational correction, stretches, strengthening, and breathing exercises. These exercises will help patients maintain proper posture in daily activities and will be adapted to each participant's abilities, with varying difficulty and positions.
219356990|NCT06500806|DEVICE|Brace|Participants in this group will follow only the brace treatment
219356991|NCT04172558|BIOLOGICAL|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
219356992|NCT04172558|DRUG|Trimix|on demand ICI of Trimix
219356993|NCT06303934|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
219356994|NCT06303934|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
219356995|NCT06303934|DEVICE|Persistent Nasogastric Tube Feeding|After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
219356996|NCT02199197|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
219356997|NCT02199197|DRUG|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
219356998|NCT01881464|DEVICE|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
219356999|NCT01881464|DRUG|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
219357000|NCT02882633|DRUG|30ml bolus of bupivacaine|Local anesthetic
219357001|NCT04943328|DEVICE|Total Hip Arthroplasty|cemented hip arthroplasty
219357002|NCT04620460|DEVICE|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
219357003|NCT06098729|BEHAVIORAL|Digital Exercise|A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
219357004|NCT04662580|DRUG|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
219357005|NCT04662580|DRUG|Apalutamide|Oral tablet and will be given once daily by mouth.
219357006|NCT04662580|DRUG|Abiraterone acetate|Oral tablet and will be given once daily by mouth.
219357007|NCT04662580|DRUG|Prednisone|Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
219357008|NCT04179643|BIOLOGICAL|3 x 10e13vg AB-1002|There are 2 components to AB-1002. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
219357009|NCT02129660|DRUG|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
219357010|NCT02129660|DRUG|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
219357011|NCT02129660|DRUG|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
219357012|NCT02129660|DRUG|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
219357013|NCT02129660|OTHER|Vehicle|Vehicle Topical Wipes
219357014|NCT03433222|DEVICE|HF-LED-RL Phototherapy|"The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
219357015|NCT03433222|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
219357016|NCT03475459|DRUG|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
219357017|NCT06208592|DEVICE|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
219357018|NCT05057169|BIOLOGICAL|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
219357019|NCT05057169|BIOLOGICAL|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
219357020|NCT02555735|DRUG|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
219357021|NCT04884048|DIAGNOSTIC_TEST|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
219357022|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
219357023|NCT06087055|DRUG|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
219357024|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
219357025|NCT03592446|DEVICE|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
219357026|NCT03592446|DEVICE|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
219357027|NCT02418416|OTHER|Oocyte double chemical activation|Oocyte double chemical activation
219357028|NCT03912077|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
219357029|NCT02448407|BIOLOGICAL|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
219357030|NCT02448407|DRUG|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
219357031|NCT00303251|DRUG|TKI258|
219357032|NCT04223934|OTHER|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
219357033|NCT04222166|BIOLOGICAL|CAM|Cryopreserved Amniotic Membrane
219357034|NCT03296046|BIOLOGICAL|Blood test|30 ml
219357035|NCT02189135|DEVICE|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
219357036|NCT06426069|OTHER|Masticatory efficiency assessment|Masticatory efficiency will be assessed for each group.
219357037|NCT02634723|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|
219357038|NCT02238444|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
219357039|NCT02238444|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
219357040|NCT02238444|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
219357041|NCT02238444|DRUG|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
219357042|NCT04925752|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
219357043|NCT04925752|DRUG|F/TDF|Tablets administered orally
219357044|NCT04925752|DRUG|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
219357045|NCT04925752|DRUG|Placebo SC LEN|Administered via SC injections
219357046|NCT04925752|DRUG|PTM F/TDF|Tablets administered orally
219357047|NCT04925752|DRUG|PTM Oral LEN|Tablets administered orally
219357048|NCT04925752|DRUG|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
219357049|NCT06323161|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219357050|NCT06323161|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219357051|NCT06323161|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
219357052|NCT06434519|DRUG|Metronidazole cream|After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
219357053|NCT06434519|OTHER|Cetaphil moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
219357054|NCT06434519|OTHER|CeraVe moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
219357055|NCT06434519|OTHER|Eucerin Healing Lotion moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
219357056|NCT06434519|OTHER|Aveeno Calm and Restore Oat Gel moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
219357057|NCT06970405|DRUG|Garetosmab|Administered per the protocol
219357058|NCT06970405|DRUG|Matching Placebo|Administered per the protocol
219357059|NCT03512418|BEHAVIORAL|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
219357060|NCT03512418|DEVICE|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
219357061|NCT03512418|DRUG|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
219359820|NCT07178041|PROCEDURE|Remote Ischaemic Conditioning|Brief episodes of reversible ischaemia are applied to a particular tissue or organ by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg). This procedure is performed for periods that avoid physical injury to the limbs, but induce neurohormonal, systemic or vascular changes in the body. In this study, the treatment will be delivered on the upper arm or unaffected leg.
219359821|NCT07178301|PROCEDURE|Computed Tomography|Undergo CT
219357062|NCT06027905|OTHER|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
219357063|NCT03864653|BEHAVIORAL|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
219357064|NCT04069845|DRUG|liposomal doxorubicin|intravenous liposomal doxorubicin
219357065|NCT06026332|DRUG|ADSTILADRIN|Non-interventional
219357066|NCT00546052|DRUG|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
219357067|NCT01680900|DRUG|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
219357068|NCT01680900|DRUG|placebo capsules|placebo capsules matched to drug capsules.
219357069|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
219357070|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
219357071|NCT00015223|DRUG|Methylphenidate|
219357072|NCT03583190|OTHER|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
219357073|NCT03583190|OTHER|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
219357074|NCT03583190|OTHER|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
219357075|NCT03583190|OTHER|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
219357076|NCT03583190|OTHER|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
219357077|NCT06975046|DEVICE|Complete airflow interruption|Participants will produce a sustained vowel into a mouthpiece (with nose-clip) connected to a PVC tube, with a balloon valve
219357078|NCT06975046|DEVICE|Incomplete airflow interruption|Incomplete airflow interruption uses a Y-shaped device. The participant produces a sustained /a/ into a mouthpiece and air filter connected to the tube. The tube splits into two tubes distally.
219357079|NCT06975046|DEVICE|Airflow redirection|Participant phonates through a mouthpiece into a PVC tube that splits into two paths. One path is connected to an open balloon valve. When the balloon is inflated and blocks the path, air is redirected into the other path which is gated by a one-way valve.
219357080|NCT01261156|DRUG|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
219357081|NCT01261156|DRUG|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
219357082|NCT05481372|OTHER|Imaging|Trans-perineal ultrasound and Magnetic resonance image acquisition
219357083|NCT05713097|DIAGNOSTIC_TEST|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
219357084|NCT01060358|PROCEDURE|method (non-surgical) to measure neuromuscular neutral zones|
219357085|NCT01928381|DRUG|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
219357086|NCT01928381|DRUG|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
219357087|NCT01928381|DRUG|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
219357088|NCT05816980|RADIATION|Hyperfractionated external beam radiation|40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
219357089|NCT01209026|DRUG|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
219357090|NCT01209026|DRUG|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
219357091|NCT01209026|DRUG|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
219357092|NCT01209026|DRUG|Moxifloxacin 400mg|Film coated oral tablet
219357093|NCT01209026|DRUG|Moxifloxacin placebo|Film coated oral tablet
219357094|NCT05434637|OTHER|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
219357095|NCT05434637|OTHER|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
219359822|NCT07178301|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo nasopharyngolaryngoscopy
219357096|NCT05434637|OTHER|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
219357097|NCT07120425|DRUG|IBI3032|"IBI3032:~Method of administration: oral, fasted administration."
219357098|NCT07120425|DRUG|placebo|Placebo (without active ingredients) Method of administration: oral, fasted administration.
219357099|NCT07120386|DEVICE|Negative Pressure Wound Therapy|NPWT creates a vacuum seal over your wound to promote healing
219357100|NCT07120386|DEVICE|Negative Pressure Wound Therapy with Instillation|NPWTi creates a vacuum seal over your wound and infuses the wound with hypochlorous acid (medical grade dilute bleach) to clean it.
219357101|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
219357102|NCT06269783|BEHAVIORAL|sipIT|Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
219357103|NCT03939481|DRUG|Chemotherapy|Given chemotherapy regimen
219357104|NCT03939481|OTHER|Functional Assessment|Functional and sensory clinician assessments
219357105|NCT03939481|OTHER|Questionnaire Administration|Patient and physician reported responses
219357106|NCT06812260|DRUG|HLX10+chemo|Treatment arm
219357107|NCT06977503|PROCEDURE|Cranial Electrical Stimulation|Use Alpha-Stim® device
219357108|NCT06977503|OTHER|Discussion|Participate in discussions
219357109|NCT06977503|BEHAVIORAL|Health and Wellness Coach|Undergo coaching sessions
219357110|NCT06977503|OTHER|Informational Intervention|View video assignments
219357111|NCT06977503|PROCEDURE|Sham Intervention|Undergo sham intervention
219357112|NCT06977503|OTHER|Survey Administration|Ancillary studies
219357113|NCT03676647|OTHER|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
219357114|NCT05618158|BEHAVIORAL|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
219357115|NCT06814262|DEVICE|Corresponding treatment order in the prescription with Align Technology|Treating orthodontist placing the corresponding order in the prescription with Align Technology.
219357116|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Predicted model|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model will be superimposed with the predicted final model to establish the predicted movement of the maxillary lateral incisors
219357117|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x3mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x3mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
219357118|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x4mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x4mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
219357119|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x5mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x5mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
219357120|NCT06443060|BEHAVIORAL|Virtual Reality Group|Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
219357121|NCT06443060|BEHAVIORAL|Buzzy Application Group|Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
219357122|NCT06443060|OTHER|Control Group|Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
219357123|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
219357124|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
219357125|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
219357126|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
219357127|NCT06990841|DEVICE|sperm separation device|comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates
219357128|NCT06599762|DRUG|Tranexamic acid|Tranexamic acid 1000mg orally two or three times daily
219357129|NCT06599762|DRUG|Placebo|Placebo orally two or three times daily
219357130|NCT06995820|DRUG|AZD1613|AZD1613 will be administered as either SC injection or IV infusion on Day 1 in Part A and on Days 1, 29 and 57 in Part B of the study.
219357131|NCT06995820|DRUG|Placebo|Placebo will be administered as either SC injection or IV infusion on Day 1 in Part A and Days 1, 29 and 57 in Part B fo the study.
219357132|NCT06670859|OTHER|Intervention-Control:|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the mobilization coverall they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the coverall-mobilization-sitting in the wheelchair and moving-taking off the coverall) with the overall.Than,will be asked to evaluate the indicator level that they think the coverall they wear protects physical privacy and the levels of comfort and satisfaction they feel about the coverall with the VAS.During the next mobilization,patients will be asked to perform the same application protocol with a traditional hospital gown.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.Than interview,participants will have completed the study by filling out the QUEST 2.0.
219357133|NCT06670859|OTHER|Control-Intervention|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the traditional hospital gown they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the gown-mobilization-sitting in the wheelchair and moving-taking off the gown) with the gown.Than,will be asked to evaluate the indicator level that they think the gown they wear protects physical privacy, and the levels of comfort and satisfaction they feel about the gown with the VAS.During the next mobilization, patients will be asked to perform the same application protocol with the mobilization coverall.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.At the end of the interview, participants will have completed the study by filling out the QUEST 2.0.
219357134|NCT06672224|PROCEDURE|Fluid Therapy|Given IV
219357135|NCT06672224|DRUG|Indocyanine Green|Given subcutaneously
219357136|NCT06672224|OTHER|Questionnaire Administration|Ancillary studies
219357137|NCT06672224|OTHER|Research or Clinical Assessment Tool|Undergo lymphedema assessment
219357138|NCT06672224|PROCEDURE|SPY Elite Fluorescence Imaging|Undergo SPY imaging
219357139|NCT06672224|OTHER|Survey Administration|Ancillary studies
219357140|NCT05527210|DIETARY_SUPPLEMENT|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
219357141|NCT05527210|DIETARY_SUPPLEMENT|Placebo Prebiotic|Placebo prebiotic mixed into water
219357142|NCT06204848|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
219357143|NCT06865781|OTHER|Forgone overnight vital signs|No vital signs (temp, heart rate, respiratory rate, blood pressure, oxygen saturation) taken at 0000 or 0400
219357144|NCT06400537|BIOLOGICAL|A-319|A-319 will be dosed according to the assigned group.
219357145|NCT06258200|BEHAVIORAL|Gender and immunization activities|Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.
219357146|NCT06258200|OTHER|No intervention|Participants in the comparison group will not receive any intervention
219357147|NCT07010692|DRUG|Tirbanibulin ointment 1%|Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.
219357148|NCT07010692|DEVICE|non-ablative fractional laser|Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.
219357149|NCT06869447|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219357150|NCT06869447|OTHER|Electronic Health Record Review|Ancillary studies
219357151|NCT06869447|OTHER|Medical Device Usage and Evaluation|Use Power Lung breathing device
219357152|NCT06869447|OTHER|Questionnaire Administration|Ancillary studies
219357153|NCT06869447|PROCEDURE|Respiratory Muscle Training|Participate in RMT sessions
219357154|NCT06869447|PROCEDURE|Sham Intervention|Participate in sham sessions
219357155|NCT06860724|OTHER|NG-nitro-L-arginine methyl ester (L-NAME)|Acute local perfusion of L-NAME (15 mM) directly to the microvasculature will be used to inhibit NO synthase.
219357156|NCT07012863|BIOLOGICAL|Dry plasma|Patient that fulfil the inclusion criteria for this study and are randomized for active treatment will get dry plasma as intervention.
219357157|NCT05016245|COMBINATION_PRODUCT|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
219357158|NCT05016245|PROCEDURE|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
219357159|NCT03532191|OTHER|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
219357160|NCT03206060|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
219357161|NCT03206060|DRUG|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
219357162|NCT03206060|DRUG|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
219357163|NCT03206060|DRUG|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
219357164|NCT07013396|OTHER|TCD measurement|TCD measurement will be collected with TCD low frequency MHz probes. All TCD operations will be performed by a trained sonographer to assess bilateral MCA, ACA, PCA, Siph, and OA. TCD examinations will be performed as soon as possible after EVT, daily for 3 days and, when possible, as close to any reported neurological deterioration or CT brain scan performed within 72 hours of EVT.
219359823|NCT07178301|PROCEDURE|Positron Emission Tomography|Undergo PET
219359824|NCT07178301|OTHER|Questionnaire Administration|Ancillary studies
219359825|NCT07178301|RADIATION|Radiation Therapy|Undergo radiation therapy
219360101|NCT01846455|DRUG|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
219366688|NCT00531960|DRUG|Standard platinum-based chemotherapy|At the discretion of the investigator
219357165|NCT07013396|OTHER|TCD parameters|"TCD parameters are PSV, EDV, MFV, and PI. Sampling volume will be 5-10 mm, and the monitoring depth on transtemporal windows will be adjusted to gather appropriate vessel segment, e.g. 20-30 mm in the leptomeningeal flow, 40-50 mm in the distal MCA, 50-60 mm in the proximal MCA, 70-75 mm in the ACA, 62-70 mm in PCA, and transorbital, including 60-64 mm in the Siph and 50-60 mm in the OA. TAMMV and PI will be automatically derived from preset.~Additionally, flow diversion will be assessed as an indirect indicator of arterial occlusion or severe stenosis in the middle cerebral artery (M1). It will be identified by TCD based on the following criteria: (1) low-resistance flow pattern in the anterior or posterior cerebral artery, and (2) mean flow velocity in the ACA or PCA greater than or equal to that in the MCA."
219357166|NCT07013396|OTHER|Baseline characteristics|Baseline characteristics will be collected, including age, sex, ethnicity, history of HTN, DM, DLP, CHF, AF, CA, CKD, previous CAD, cirrhosis, mRS, previous stroke or TIA, current antiplatelet usage, current anticoagulant usage, smoking, and alcohol status. This data will be collected through a combination of verbal interviews with participants/LAR legally authorized representatives and a review of their medical history charts.
219357167|NCT07013396|OTHER|Clinical data will be collected|Clinical data will be collected, including blood pressure values before, during, and after TCD as well as, Door to needle, Door to groin, Groin to first pass, time from recanalization to TCD, baseline NIHSS, site of occlusion, infarct core volume, mismatch volume, mismatch ratio, and IVT treatment status. Classification of stroke etiologies will be collected based on widely accepted TOAST criteria categorized in large vessel atherosclerosis (LAA), cardio-embolism (CE), small vessel occlusion (SAO), Stroke of other determined etiology (SOC), and stroke of undetermined etiology (SUC) \[30\]. This data will be collected by reviewing medical charts from EHR coded as part of standard care.
219357168|NCT07013396|OTHER|All follow-up patients receive a phone call|All follow-up patients receive a phone call as part of standard post thrombectomy care from the stroke nurses to gather modified Rankin Scale at 7 days and 90 days since hospital discharge.
219357169|NCT06874699|BEHAVIORAL|Physical activity programme|"The physical activity programme will have the following features:~* 6-week programme~* 1-2 supervised physical activity sessions per week~* 60 minutes per session, including a mixture of physical activities (e.g. walking, other aerobic physical activity, resistance, balance and stretching exercises)~* Self-selected physical activity intensity~* Group-based (maximum of 10 students per session)~* Sessions supervised by a qualified exercise instructor. A member of the University's Wellbeing team will also be present to offer students mental health support, if needed.~* Physical activity behavioral strategies incorporated into the 6-week programme (e.g., goal setting, action planning, exploring barriers and enablers, setting cues or prompts for self-directed PA)~* Encouragement to be physically active away from the supervised sessions"
219357170|NCT04372641|DRUG|p97 Inhibitor CB-5339 Tosylate|Given PO
219357171|NCT06880198|DIETARY_SUPPLEMENT|Oral Impact®|One Arm: 2 Impact brick/d for 21 days + 1 brick/d for 14 days, starting exactly one week before Anti PD-1 treatment in patients with inoperable locally advanced or metastatic melanoma Treatment duration: 35 days
219357172|NCT07137923|BEHAVIORAL|Clinical decision support + education (CDS+)|Intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
219357173|NCT07137923|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
219357174|NCT07037641|OTHER|Lumbar Spine Manipulation|Painful lumbar segments will be identified through palpation of the spinous and transverse processes. Patients will be positioned side-lying with head supported by a pillow. The lower arm will rest across the chest, and the lower leg will be extended while the upper leg will be flexed, with the foot placed in the popliteal space. The practitioner will assume a 45-degree angled stance, stabilizing the patient's pelvis between their thighs. The hypothenar eminence will contact the mammillary process of the dysfunctional vertebra, while the opposite hand stabilizes the upper shoulder. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction toward the patient's umbilicus. This technique will be performed twice per week for two weeks (4 sessions total), alongside conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
219357175|NCT07037641|OTHER|Sacroiliac Joint Manipulation|The side for sacroiliac joint manipulation will be determined using the Derifield leg length test. Based on functional leg length differences, a PI (posterior-inferior) ilium will be identified. Patients will be positioned side-lying with appropriate limb and trunk alignment. The practitioner's hypothenar eminence will be placed on the PSIS of the dysfunctional side. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction from the PSIS toward the patient's umbilicus to correct the joint dysfunction. The manipulation will be performed twice a week over two weeks (4 sessions in total), combined with conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
219357176|NCT07037641|OTHER|Conventional Physiotherapy|Conventional physiotherapy will consist of hot pack, TENS, therapeutic ultrasound, and supervised exercises applied over two weeks (6 sessions/week). Hot packs filled with silicate gel will be wrapped in four towel layers and applied for 20 minutes with the patient prone and a pillow under the abdomen. TENS will be delivered via Chattanooga Intelect device with a symmetrical biphasic program for 30 minutes using four electrodes placed on the treatment area. Ultrasound will be applied continuously for 3 minutes with the same device. Patients will be instructed on lumbar mobility and strengthening exercises, performed twice daily with 15 repetitions each. No spinal or sacroiliac manipulation will be performed in this group.
219357177|NCT06701370|OTHER|Task Oriented Training|Task oriented training consists of opening the bottlecap, stacking cubes on different sizes, buttoning,screwing, wearing a coat.
219357178|NCT06701370|OTHER|Conventional Rehabilitation|Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.
219357179|NCT06701370|OTHER|Upper arm ergometer|The patients will be rode 5 minutes forwardly and 5 minutes backwardly
219357180|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive enhanced delivery half-price food boxes delivered by a community health worker
219357181|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive the standard half-price produce box delivery delivered by FreshFix staff
219357182|NCT07039630|OTHER|Health Promotion and Education|Receive nutritional education materials and resources
219357183|NCT07039630|OTHER|Questionnaire Administration|Ancillary studies
219357184|NCT07039630|OTHER|Survey Administration|Ancillary studies
219357185|NCT07039630|BEHAVIORAL|Telephone-Based Intervention|Receive a dietary recall phone call
219357186|NCT06717919|PROCEDURE|Hypothermic oxygenated perfusion|All study centres will use either VitaSmart, Liver assist or Perlife devices for machine liver perfusion, with a pressure controlled hypothermic oxygenated liver perfusion through the portal vein (HOPE) or through the portal vein and the hepatic artery (DHOPE), targeting a flow rate between 200-250 ml/min at a pressure of 3 mmHg, and a perfusate temperature between 8-12°C. The perfusate consists of 3L re-circulating Belzer MPS® (Bridge to Life Ltd.) with an active oxygenation (70-110 kPa). The minimum perfusion duration is defined at 2 hours, while perfusion is generally continued until the recipient hepatectomy is completed. The perfusion will exclusively be performed in the recipient centre after initial cold storage and bench preparation of the liver for implantation. The perfusion devices are routinely used in all participating centres.
219357187|NCT06717919|PROCEDURE|Conventional cold storage|Conventional cold storage at 4°C will be performed with precooled preservation solution according to local standard of care. For cold storage at the Swiss centres, IGL-1 (Institute George Lopez) is used for cold storage. Liver transplant centres in other European countries, use mainly three other storage solutions (Histidine trypophan-ketoglutarat, HTK and University of Wisconsin, UW solution, Celsior) in accordance to their national guidelines.
219357188|NCT01355705|DRUG|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
219357189|NCT01355705|DRUG|Lenalidomide|15 mg daily by mouth
219357190|NCT01355705|DRUG|Dexamethasone|40 mg weekly by mouth
219357191|NCT01355705|DRUG|Aspirin|81 or 325 mg daily by mouth
219357192|NCT01355705|DRUG|Pegfilgrastim|6 mg subcutaneous on Day 2
219357193|NCT06730945|DRUG|Oral isosorbide mononitrate 4+ amlodipine|Oral isosorbide mononitrate 40mg (if unable to tolerate, 20mg) once daily + amlodipine 5mg (if unable to tolerate, 2.5mg) once daily for 24 weeks after CABG
219357194|NCT06888960|BIOLOGICAL|CC312|After a 28-day screening period, subjects who meet the inclusion and exclusion criteria will be enrolled for baseline assessments and biological sample collection prior to the guided administration period. The guided dose of CC312 will be administered via IV infusion on Day -3, followed by safety and tolerability assessments on the third day after the initial administration (i.e., Day -1). The therapeutic dose of CC312 will be administered via IV infusion on Day 1, with subsequent infusions scheduled on Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25. Comprehensive safety and tolerability assessments will be conducted at each of these time points.
219357195|NCT07042243|BEHAVIORAL|MyCarePulse and ASCENT PN|The combination of a digital platform and patient navigators assisting the process. Also, taking a multi-level approach engaging community members, patients, and providers in phase one through qualitative interviews. Then using the findings to adapt MyCarePulse for the clincial trial in phase two.
219357196|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
219357197|NCT06026371|DRUG|Placebo|Given PO
219357198|NCT06889298|DEVICE|Treatment with BTL-699|Four to six transcranial magnetic stimulation treatments with the BTL-699 device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 3 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
219357199|NCT02791061|OTHER|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
219357200|NCT02791061|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
219357201|NCT02791061|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
219357202|NCT06333899|DRUG|Lorlatinib|Continue maintenance monotherapy for total 12 cycles
219357203|NCT06333899|DRUG|Lorlatinib with chemotherapy1|Continue lorlatinib with BABY-POG chemotherapy backbone for 72 weeks
219357204|NCT06333899|DRUG|Lorlatinib with chemotherapy 2|Continue lorlatinib with HIT-SKK chemotherapy backbone for 42 weeks
219357205|NCT06333899|DRUG|Lorlatinib post Radiation|Continue lorlatinib monotherapy 28 days post completion of radiation therapy for 12 cycles
219357206|NCT07062887|BEHAVIORAL|Mindfulness app|Mindfulness app called Calm Health. It has mindfulness guidance modules related to different aspects of physical and mental health, including type 1 diabetes. It also provides a final report to help you track the relationship between mindfulness and your blood sugar, stress, and sleep.
219357207|NCT07065721|DEVICE|Continuous glucose monitor|Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.
219357208|NCT03803098|DEVICE|reference measure|measure of a physiological parameter performed with the gold standard medical device
219357209|NCT03803098|DEVICE|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
219357210|NCT07071350|OTHER|HRV Coherence Ratio|Evaluates autonomic function and the intervention process's efficacy, specifically resonance frequency breathing. The HRV Coherence Ratio will be quantified using a non-invasive procedure during resonance frequency breathing conditions and a standardized definition.
219357211|NCT07071350|BEHAVIORAL|NSI|This inventory assesses the overall symptom burden, including post-concussion symptoms, on a 5-point scale. It is a well-established measure used by the Department of Defense (DoD) and VA and in mTBI outcome research at large, and includes 27 items that capture vestibular, somatosensory, cognitive, and affective symptoms.
219357212|NCT07071350|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|It includes seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Higher PSQI scores indicate poorer sleep quality.
219357213|NCT07071350|BEHAVIORAL|Quantitative Sleep Measures|Measured using wrist actigraphy, which provides objective data on sleep parameters such as sleep latency, duration, efficiency, fragmentation, and wake time after sleep onset (WASO). Participants will wear the actigraphy monitors at baseline, post-training, and follow-up assessments.
219357214|NCT07071350|BEHAVIORAL|Patient Global Impression of Change (PGIC)|It evaluates patients' perceptions of clinically meaningful changes in their condition following the intervention. It is considered the gold standard for such assessments.
219357215|NCT07071350|BEHAVIORAL|Cognitive Performance/NIH Toolbox Cognitive Battery|Assessed using the NIH Toolbox Cognitive Battery, which measures executive function, episodic memory, working memory, processing speed, language, attention, and reading through a brief, computer-based test
219357216|NCT07071350|OTHER|Pain Interference/TBI-QoL Pain Interference Short-Form|"Evaluated using the TBI-QoL Pain Interference Short-Form, a 10-item questionnaire that measures the extent to which pain interferes with daily activities and overall quality of life. Each BPI-I item is scored from 0=Does not interfere to 10=Completely interferes, and the scale score is the mean of the 7 items. Scores range from 0 to 10 with higher scores indicating greater pain interference."
219357217|NCT07071350|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|Assesses the severity of depressive symptoms over the past two weeks. Scores less than 5 almost always signified the absence of a depressive disorder; scores of 5 to 9 predominantly represented patients with either no depression or subthreshold (i.e., other) depression; scores of 10 to 14 represented a spectrum of patients; and scores of 15 or greater usually indicated major depression.
219357218|NCT07071350|BEHAVIORAL|PTSD Checklist for DSM-5 (PCL-5)|The PCL-5 (PTSD Checklist for DSM-5) is a screening tool that assesses the presence and severity of PTSD symptoms according to DSM-5 criteria. It's not a diagnostic tool itself but helps clinicians determine if further evaluation is needed. Scores range from 0 to 80, with higher scores indicating more severe symptoms.
219357219|NCT07071350|OTHER|HRV Biofeedback (HRV-B)|participants will receive weekly biofeedback training over a six-week period. Each session includes approximately 30-40 minutes of biofeedback training where participants are affixed with HRV monitoring equipment. They will be guided to synchronize their heart rate variability (HRV) through slow diaphragmatic breathing and focusing on positive emotions. This process involves viewing real-time HRV patterns on a computer monitor, with coaching to help participants achieve resonant frequency breathing.
219357220|NCT07071350|OTHER|Psychoeducational (Edu) Comparator Intervention|Six weekly meetings 30-40 minutes, viewing standardized educational content on concussion recovery. No information on breathing will be provided to participants in the Edu group.
219357221|NCT06778135|PROCEDURE|Temporary implatation of large-scale intracranial electrode.|The Neuropixels probe (imec, Leuven, Belgium) is a new high resolution multi electrode technology that uses custom 130-nm complementary metal-oxide-semiconductor fabrication with high surface area but low-impedance titanium nitride recordings to produce high site count devices with extreme electrode density in a small package.
219357222|NCT06778135|DEVICE|brain electrode|Show that Neuropixels can safely and effectively record from large populations of neurons.
219357223|NCT01707849|DRUG|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
219357224|NCT01707849|DRUG|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
219357225|NCT03892447|DRUG|Alprostadil|Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d
219357226|NCT03892447|DRUG|Sodium Ferulate|Sodium Ferulate 2\~6mg/kg.d,iv,14d
219357227|NCT03892447|DRUG|Dopamine|Dopamine3～5 ug/kg·min,iv,3 h/d,14d
219357228|NCT06844487|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
219357229|NCT06844487|BIOLOGICAL|MVA-BN half-dose regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as two half doses of the standard regimen; meaning infants/children allocated to Child Group 2 will receive 0.25 mL of the 0.5 mL. 1x10\^8 TCID50 Inf.U./0.5 mL standard regimen. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm. Only one vial will be used per infant/child.
219357230|NCT07082686|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol
219357231|NCT07085442|PROCEDURE|Targeted Sentinel Node Biopsy (TSNB)|Targeted Sentinel Node Biopsy will be performed according to routine local practice. The procedure has been standardised for the post-NACT setting as part of the ongoing ATNEC trial. Sites are advised to follow the ATNEC protocol in the primary surgery setting, using either a dual- or single-tracer sentinel node biopsy technique, with localisation and removal of the marked biopsy proven positive node, and removal of at least 3 nodes.
219357232|NCT00931398|DRUG|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
219357233|NCT00931398|DRUG|Placebo|Matched placebo for all Concerta doses.
219357234|NCT05807139|OTHER|Placebo|Placebo
219357235|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
219357236|NCT07107204|DRUG|BT02|BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks
219357237|NCT07108621|DRUG|Choriongonadotropin alfa (hCG)|hCG 260 IU once daily for two menstrual cycles (aproximately 8 weeks) prior til standard IVF/ICSI.
219357238|NCT07108621|DRUG|Isotonic NaCl (Placebo)|Placebo priming (isotone NaCl) once daily for two menstrual cycles (approximately 8 weeks) prior to standard IVF/ICSI.
219357239|NCT07113561|OTHER|High-protein diet and resistance training|Participants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise.
219357240|NCT07113561|OTHER|Balanced control diet|Participants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention.
219357241|NCT07104318|DRUG|Bismuth quadruple therapy with optimized PPI|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.
219357242|NCT07104318|DRUG|Bismuth quadruple therapy with standard PPI|"Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days.~\*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding"
219357243|NCT07104318|DRUG|Clarithromycin triple therapy with optimized PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg QID for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
219357244|NCT07104318|DRUG|Clarithromycin triple therapy with standard PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
219357245|NCT07104318|DRUG|Standard bismuth quadruple therapy|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
219357246|NCT06922318|DRUG|ZEN-3694|One ZEN-3694 pill (48 mg) will be taken each day of each BATZEN cycle.
219357247|NCT06922318|DRUG|Testosterone cypionate|On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.
219357248|NCT06922318|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken daily by mouth on each ZENZA cycle.
219357249|NCT06922318|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.
219357250|NCT07124403|DIAGNOSTIC_TEST|blood sampling|DPD Activity wil be assessed from blood samples
219357251|NCT07124403|DIAGNOSTIC_TEST|Blood sampling|Measurement of uracilemia and assessment of renal function
219357252|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
219357253|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
219357254|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
219357255|NCT06937203|DRUG|ARO-ALK7|SC injection
219357256|NCT06937203|DRUG|Placebo|calculated volume to match active treatment by SC injection
219357257|NCT06943664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219357258|NCT06943664|BIOLOGICAL|Cemiplimab|Given IV
219357259|NCT06943664|BIOLOGICAL|Cetuximab Sarotalocan Sodium|Given IV
219357260|NCT06943664|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
219357261|NCT06943664|OTHER|Electronic Health Record Review|Ancillary studies
219357262|NCT06943664|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
219357263|NCT06943664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219357264|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo EB-PIT
219357265|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo I-PIT
219357266|NCT06943664|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219357267|NCT06943664|PROCEDURE|Robotic Bronchoscopy|Undergo robotic bronchoscopy
219357268|NCT06943664|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
219357269|NCT07144410|DRUG|fentanyl + morphine|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
219357270|NCT07144410|DRUG|fentanyl|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
219357271|NCT06942351|OTHER|Walnuts|Daily consumption of 1.5 ounces of plain walnuts for 12 weeks
219357272|NCT06942351|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
219357273|NCT06944340|OTHER|WHO Trauma Care Checklist|"A standardized checklist developed by the WHO for trauma care, designed to reduce errors and ensure compliance with critical steps in trauma management.~Implemented by trained clinicians during patient assessment and treatment phases. Components include verification of patient identity, assessment of airway/breathing/circulation, pain management, monitoring for missed injuries, and post-resuscitation care. Checklist use is documented in medical records."
219357274|NCT06942286|DIAGNOSTIC_TEST|HPV Self-Collection|Participants will perform HPV self-collection.
219357275|NCT07146438|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered with the MagPro X100 system equipped with a Cool-DB80 coil and a Localite neuronavigation system. Neuronavigation will be performed for anatomical landmarking and co-registration of the brain to Talairach stereotaxic space, with the co-registered coil vertex coordinate (x0, y+60, z+60) as performed in previously published work on dmPFC-rTMS and which represents \~25% of the nasion-inion distance. Posterior coil handle orientation will be used with stimulation parameters of 20Hz repetition rate, 2 second stimulation duration, 20 second inter-train interval, and 50 trains, for a total of 2000 pulses per day. Stimulation will be delivered at 100% of extensor hallucis longus muscle resting motor threshold (MT), as determined by the PI. rTMS will be delivered 5 days per week (Monday through Friday) for 6 weeks for a total of 30 treatment sessions, in keeping with established protocols. Trained research staff will perform daily rTMS treatments and monitor participants.
219357276|NCT07146438|BEHAVIORAL|Supportive Therapy (ST)|"Supportive therapy (ST) is a nondirective talk therapy focused on enhancing coping skills, strengthening existing resources, and improving daily functioning. Core techniques will include active listening, encouragement, validation, reframing, clarification (summarizing and paraphrasing), and naming problems. Participants will receive two ST sessions per week during the 6-week rTMS course. General goals include using the therapeutic relationship to foster adaptation, improve self-esteem, and support overall well-being. Each session will last 53-60 minutes and take place concurrently with rTMS, with the participant remaining in the TMS treatment room throughout."
219365675|NCT03371797|DRUG|Valsartan, Amlodipine -|"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."
219357277|NCT07146438|BEHAVIORAL|Exposure and Response Prevention (ERP) Therapy|ERP is a form of cognitive-behavioral therapy designed to reduce obsessive-compulsive symptoms by weakening the association between feared stimuli and maladaptive responses. It promotes the formation and recall of non-threatening associations to counter fear-based learning. The participant and therapist will collaboratively create a hierarchy of OCD triggers, rated using the Subjective Units of Distress Scale (SUDS). ERP will begin with exposures rated 4-7 on the SUDS, while participants refrain from engaging in compulsions. Each trigger will be repeated until the SUDS rating decreases by at least 50% before progressing to the next item. Between-session ERP homework will be assigned, and participants will be provided self-monitoring homework rating forms to complete for subsequent review with the therapist. Each ERP session will last 53-60 minutes and will be conducted concurrently with rTMS, with the participant remaining in the TMS treatment room throughout.
219357278|NCT07144007|DRUG|Dexmedetomidine|In rhinoplasty, 10 minute infusion of 0,5 mcg/kg dexmedetomidine will be administered after nasal packing
219357279|NCT07144007|DRUG|Propofol|In rhinoplasty, 0,5 mg/kg propofol IV bolus will be administered after nasal packing
219357280|NCT06947473|DRUG|umbilical cord blood CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to umbilical cord blood CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
219357281|NCT06947083|DRUG|Elranatamab|Maintenance therapy
219357282|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-EDF+I Taping method: flex the knee 60° and apply two mesh Kinesio tape strips with natural tension to the painful area of the patellar tendon. Use a jellyfish-shaped Kinesio tape strip with natural tension to the center of the knee joint, aligning the center hole with the treatment area. Apply a thin KT strip clockwise around the tape strip. Then, stretch the center of an I-type tape strip to 50%-75% tension and apply it horizontally to the painful area of the patellar tendon, covering 1/3 to 1/2 the width of the inferior pole of the patella. Secure the ends without tension., and a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-EDF+I taping intervention was continued for 8 weeks."
219357283|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-I taping method: bend the knee joint 30°, use an I-shaped muscle tape to apply horizontally to the painful area of the patellar tendon (from the middle to the sides) with 50%-75% tension, and then use a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-I taping intervention was continued for 8 weeks."
219357284|NCT07143942|BEHAVIORAL|exercise therapy|"Phase 1 aims to control load and reduce pain. This includes quadriceps isometric exercises, double-legged squats with the knees bent 90 degrees against a wall, Spanish squats, vastus medialis exercises, single-leg hip bridges with the affected leg supported, and stretches for the quadriceps, hamstrings, and calf triceps.~Phase 2 aims to gradually increase load and strengthen the training. This includes eccentric and progressive loading exercises. This includes single-leg squats on a 25° incline, lunges, vastus medialis exercises, step-ups, and gluteus resistance exercises.~Phase 3 aims to strengthen function and gradually return to sports. Energy-conserving exercises such as jumping, box jumps, and interval running are performed, gradually increasing jump height, running distance, and speed. After completing all of these exercises and experiencing no knee discomfort for 24 hours, specific exercises can be gradually introduced."
219357285|NCT07144579|BEHAVIORAL|Mozart music group|The experimental group was played Mozart - Sonata for Two Pianos in D, K. 448 on the clinic computer.
219357286|NCT07144579|BEHAVIORAL|preferred music group|The experimental group was made to listen to their preferred music in the clinic.
219357287|NCT07144722|OTHER|Exercise|What distinguishes this intervention from others is its hybrid delivery model, combining virtual more than in-person sessions to increase accessibility and adherence. Additionally, it incorporates specific inspiratory muscle training, which is often overlooked in standard prehabilitation programs, and emphasizes a personalized progression based on each participant's functional capacity and feedback. This tailored approach aims to optimize physical readiness before surgery while minimizing patient burden and travel requirements.
219357288|NCT07158944|BEHAVIORAL|More and Less|Dose: 10 group sessions + 6 individual booster sessions Frequency: 10 weekly group sessions (10 weeks) 6 booster sessions every 6th week
219357289|NCT04496739|BEHAVIORAL|Cancer Educational Materials|Receive educational materials about breast cancer risk and chemoprevention via RealRisk
219357290|NCT04496739|OTHER|Decision Aid|Given patient-centered decision support via an action plan
219357291|NCT04496739|OTHER|Decision Aid|Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
219357292|NCT04496739|OTHER|Interview|Participate in audio-recorded interview via telephone or video conference
219357293|NCT04496739|OTHER|Questionnaire Administration|Ancillary studies
219357294|NCT01061515|DRUG|Intraperitoneal Oxaliplatin|
219357295|NCT01061515|DRUG|Bevacizumab|
219357296|NCT01061515|DRUG|Capecitabine|
219357297|NCT06776367|OTHER|Remote study participation and self-collection of specimens|Participants in Group B will complete all study procedures remotely and will not physically visit any clinical research site. This will include telehealth (videoconference) visits with study personnel, self-collection of specimens, shipping of specimens using pre-labeled packaging, and completion of electronic diaries for data collection.
219357298|NCT06776367|OTHER|Traditional clinical trial participation with clinician-collected specimens|Participants in Group A will attend study visits in person at a clinical research site and will have the majority of specimens collected by a clinician at the clinic. Group A participants will have some electronic diary usage.
219357299|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
219360102|NCT01846455|DRUG|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
219357300|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity and healthy eating|"Behavioural Experimental: guidelines-based physical activity:~Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.~Behavioural Experimental: guidelines-based healthy eating:~One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide."
219357301|NCT06345937|BEHAVIORAL|Behavioural: Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
219357302|NCT06362369|DRUG|Alintegimod|Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
219357303|NCT06362369|DRUG|Ipilimumab|Ipilimumab (Yervoy) will be administered via IV
219357304|NCT06362369|DRUG|Nivolumab|Nivolumab (Opdivo) will be administered via IV
219357305|NCT04441905|OTHER|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
219357306|NCT04441905|BIOLOGICAL|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
219357307|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
219357308|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
219357309|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
219357310|NCT04770753|DRUG|Placebo Matching Mitapivat|Tablets
219357311|NCT04770753|DRUG|Mitapivat|Tablets
219357312|NCT02775851|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
219357313|NCT02775851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219357314|NCT02775851|PROCEDURE|Computed Tomography|Undergo CT scan
219357315|NCT02775851|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
219357316|NCT02775851|BIOLOGICAL|Pembrolizumab|Given IV
219357317|NCT02775851|PROCEDURE|Positron Emission Tomography|Undergo PET scan
219357318|NCT02775851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
219357319|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention|Receive active EFT stimulus
219357320|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention (control)|Receive control EFT stimulus
219357321|NCT05825001|OTHER|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
219357322|NCT06420531|DIETARY_SUPPLEMENT|Human milk|maternal breastmilk or donor breastmilk
219357323|NCT06533579|GENETIC|Dose Level 1, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
219357324|NCT06533579|GENETIC|Dose Level 2, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
219357325|NCT06533579|GENETIC|Dose Level 3, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
219357326|NCT06533579|GENETIC|Dose Level 4, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
219357327|NCT02170181|RADIATION|SBRT|SBRT to Oligometastases
219357328|NCT05643131|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
219357329|NCT04862663|DRUG|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
219357330|NCT04862663|DRUG|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
219357331|NCT04862663|DRUG|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
219357332|NCT04862663|DRUG|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
219357333|NCT04862663|DRUG|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
219357334|NCT06416371|DIAGNOSTIC_TEST|Fundus fluorescein angiography, with ultrawide field retinal imaging|Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
219357335|NCT04570423|DRUG|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
219357336|NCT04570423|DRUG|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
219357337|NCT06487247|BEHAVIORAL|HEME-Hospice Program|A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.
219357338|NCT05593029|DRUG|SEP-363856|Tablet
219357339|NCT05593029|OTHER|Placebo|Placebo
219357340|NCT05036681|DRUG|Futibatinib|tablets by mouth 1 time every day
219357341|NCT05036681|DRUG|Pembrolizumab|Given by vein over about 30-60 minutes on Day 1 of all cycles
219357342|NCT04292847|OTHER|Referrals Recommendations|All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
219365676|NCT00865020|DRUG|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
219357343|NCT05159557|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
219357344|NCT05159557|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
219357345|NCT05421663|BIOLOGICAL|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
219357346|NCT00898222|DRUG|aspirin|81 mg orally daily for two weeks
219357347|NCT00185393|BIOLOGICAL|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
219357348|NCT00185393|OTHER|no treatment|no treatment
219357349|NCT03718143|DRUG|Combination AZD1775 with AraC|AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
219357350|NCT03718143|DRUG|AZD1775 only|AZD1775 days 1-5 \& 8-12
219357351|NCT05064059|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
219357352|NCT05064059|DRUG|regorafenib|Oral
219357353|NCT05064059|DRUG|TAS-102|Oral
219357354|NCT04450485|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
219357355|NCT04424069|PROCEDURE|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
219357356|NCT02172157|DRUG|BI 1744 CL i.v.|
219357357|NCT02172157|DRUG|BI 1744 CL oral|
219357358|NCT01934140|BIOLOGICAL|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
219357359|NCT05134571|DRUG|Laronidase|Solution for injection; Intravenous
219357360|NCT00664248|DRUG|IDP-110|Topical application for 12 weeks
219357361|NCT00664248|DRUG|Clindamycin|Topical application for 12 weeks
219357362|NCT00664248|DRUG|Benzoyl peroxide|Topical application for 12 weeks
219357363|NCT00664248|DRUG|Vehicle|Topical application for 12 weeks
219357364|NCT00805740|DRUG|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
219357365|NCT00805740|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
219357366|NCT00200850|BIOLOGICAL|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
219357367|NCT00200850|BIOLOGICAL|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
219357368|NCT00200850|BIOLOGICAL|Placebo SLIT|Placebo SLIT daily
219357369|NCT02595879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219357370|NCT02595879|RADIATION|Brachytherapy|Undergo LDR brachytherapy
219357371|NCT02595879|DRUG|Cisplatin|Given IV
219357372|NCT02595879|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
219357373|NCT02595879|RADIATION|External Beam Radiation Therapy|Undergo pelvic EBRT
219357374|NCT02595879|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
219357375|NCT02595879|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
219357376|NCT02595879|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219357377|NCT02595879|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219357378|NCT02595879|OTHER|Pharmacological Study|Correlative studies
219357379|NCT02595879|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
219357380|NCT02595879|DRUG|Triapine|Given IV and PO
219357381|NCT06375135|BEHAVIORAL|TXTXT|Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.
219357382|NCT06375135|BEHAVIORAL|e-Navigation|"Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support."
219357383|NCT06375135|BEHAVIORAL|Ecological Momentary Assessment (EMA) supported e-Navigation.|Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
219357384|NCT03293563|PROCEDURE|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
219360103|NCT03120169|OTHER|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
219357385|NCT05578690|BEHAVIORAL|Diet|An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
219357386|NCT05578690|BEHAVIORAL|Exercise|After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
219357387|NCT05578690|BEHAVIORAL|Mentorship|"Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups."
219357388|NCT06580964|BEHAVIORAL|Heat therapy|Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 6d/wk (5 at-home and 1 in-lab).
219357389|NCT06580964|BEHAVIORAL|High-intensity interval training|High-intensity interval training will be performed 3 days per week for 12 weeks.
219357390|NCT06547775|DRUG|KN069|Solution for SC injection
219357391|NCT06636071|BIOLOGICAL|setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
219357392|NCT06429475|DRUG|Budesonide/formoterol|"The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years."
219357393|NCT06429475|DRUG|standard of care|Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
219357394|NCT06089603|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
219357395|NCT06089603|DRUG|Conventional pharmacological treatment|Usual treatment of the patient
219357396|NCT06089603|OTHER|Sleep ,diet and life style recomendations|Daily recomendatios
219357397|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
219357398|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
219357399|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
219357400|NCT06799520|DRUG|VIS171|VIS171 will be administered as a SC injection.
219357401|NCT06461156|DRUG|HS-10504|HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
219357402|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
219357403|NCT01475123|DRUG|Nicorandil|15mg per day
219357404|NCT03631043|PROCEDURE|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
219357405|NCT03631043|DRUG|Lenalidomide|Given PO
219357406|NCT03631043|BIOLOGICAL|Vaccine Therapy|Given personalized vaccine SC
219357407|NCT05116449|BEHAVIORAL|Quality of life questionnaires|Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
219360104|NCT03120169|OTHER|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
219365677|NCT00865020|DRUG|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
219357408|NCT06006806|RADIATION|Pencil Beam Scanning Proton Therapy|"Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called Spot Delete to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process."
219357409|NCT00152425|DRUG|Certolizumab Pegol (CDP870)|
219357410|NCT06446739|DEVICE|Continuous Renal Replacement Therapy (CRRT)|Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
219357411|NCT03317860|DEVICE|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
219357412|NCT03317860|DEVICE|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
219357413|NCT04480450|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
219357414|NCT02911766|DRUG|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
219357415|NCT02911766|DRUG|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
219357416|NCT02911766|DRUG|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
219357417|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
219357418|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
219357419|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
219357420|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
219357421|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
219357422|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
219357423|NCT06169215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
219357424|NCT06169215|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
219357425|NCT06169215|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219357426|NCT06169215|DRUG|Bortezomib|Given SC
219357427|NCT06169215|PROCEDURE|Computed Tomography|Undergo CT
219357428|NCT06169215|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
219357429|NCT06169215|DRUG|Dexamethasone|Given PO
219357430|NCT06169215|DRUG|Lenalidomide|Given PO
219357431|NCT06169215|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219357432|NCT06169215|PROCEDURE|Positron Emission Tomography|Undergo PET
219357433|NCT06169215|DRUG|Selinexor|Given PO
219357434|NCT05350462|BEHAVIORAL|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
219357435|NCT03191149|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219357436|NCT03191149|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
219357437|NCT03191149|PROCEDURE|Echocardiography Test|Undergo ECHO
219357438|NCT03191149|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219357439|NCT03191149|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
219357440|NCT03191149|DRUG|Osimertinib|Given PO
219357441|NCT04568668|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication."
219357442|NCT01534676|PROCEDURE|Transfusion|A routine medical procedure to transfuse packed red blood cells.
219357443|NCT01534676|BIOLOGICAL|Blood|"Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)"
219357444|NCT01534676|PROCEDURE|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
219357445|NCT00880815|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
219357446|NCT00880815|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
219357447|NCT00880815|DRUG|Bendamustine|Given IV
219357448|NCT00880815|BIOLOGICAL|Filgrastim|Given IV
219357449|NCT00880815|DRUG|Fludarabine|Given IV
219357450|NCT00880815|DRUG|Methotrexate|Given IV
219357451|NCT00880815|BIOLOGICAL|Rituximab|Given IV
219357452|NCT00880815|DRUG|Tacrolimus|Given IV and PO
219357453|NCT02460211|DIETARY_SUPPLEMENT|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
219357454|NCT02460211|DIETARY_SUPPLEMENT|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
219357455|NCT00610142|DRUG|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
219357456|NCT00610142|DRUG|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
219357457|NCT00142896|DRUG|Tramadol|
219357458|NCT00142896|DRUG|Naloxone|
219357459|NCT00142896|DRUG|Morphine|
219357460|NCT01113203|BEHAVIORAL|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
219357461|NCT06211010|DIAGNOSTIC_TEST|the semiconductor metal oxide sensors.|The method of analyzing the VOCs was through analyzing the evaporated VOCs from the urine in the container when they evaporated into the sealed chamber. The VOCs in the chamber were then analyzed at the same time by the five different gas semiconductor sensors which were located on the top of the chamber.
219357462|NCT00540579|DRUG|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
219357463|NCT00540579|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
219357464|NCT02268435|DRUG|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
219357465|NCT00280995|DRUG|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219357466|NCT00280995|DRUG|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219357467|NCT00280995|DRUG|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
219357468|NCT00280995|DRUG|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
219357469|NCT02908880|DEVICE|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
219357470|NCT05313867|DIETARY_SUPPLEMENT|Nutri VX 1|1 sequence of 10 tablets (one intake)
219357471|NCT05313867|DIETARY_SUPPLEMENT|Placebo|1 sequence of 10 tablets (one intake)
219357472|NCT05639855|OTHER|Mental Health Literacy Programme|Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
219357473|NCT03799900|DRUG|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
219357474|NCT03799900|DRUG|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
219357475|NCT03799900|DRUG|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
219357476|NCT04031079|DEVICE|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
219357477|NCT04031079|DEVICE|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
219357478|NCT04031079|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
219357479|NCT06486181|OTHER|Thrombolysis/Thrombectomy|"Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT."
219357480|NCT01976780|DRUG|Artesunate|
219357481|NCT01976780|DRUG|Artemether Lumefantrine|
219357482|NCT01976780|DRUG|Mefloquine|
219357483|NCT05422131|DEVICE|MyCare Insite Clozapine Test|The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
219357484|NCT02421887|DRUG|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
219357485|NCT02421887|OTHER|Placebo|Placebo
219357486|NCT01742429|DRUG|Proton pump inhibitor|
219357487|NCT01742429|DRUG|Bismuth subsalicylate|
219357488|NCT01742429|DRUG|Metronidazole|antibiotic
219357489|NCT01742429|DRUG|Tetracycline|antibiotic
219357490|NCT01742429|DRUG|Amoxicillin|antibiotic
219357491|NCT01742429|DRUG|Levofloxacin|antibiotic
219357492|NCT05559567|DEVICE|Orthokeratology|The use of a specialty GP contact lens to temporarily correct myopia
219357493|NCT03029013|DRUG|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
219357494|NCT03341260|DRUG|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
219357495|NCT03341260|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
219357496|NCT03521505|DRUG|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration
219357497|NCT03521505|DRUG|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration."
219357498|NCT03201055|DEVICE|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
219357499|NCT03450928|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
219357500|NCT00933049|DRUG|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
219357501|NCT00933049|DRUG|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
219357502|NCT00933049|DRUG|Amoxicillin placebo|
219357503|NCT00933049|DRUG|Cotrimoxazole placebo|
219357504|NCT06127641|OTHER|Standard care plus pulmonary rehabilitation|A 12-week rehabilitation program, 3X/week. Each outpatient session will last 2 hours including: guidance on the care of inhalation techniques and/or oxygen therapy, when prescribed; aerobic training on a cycle ergometer supervised by a physiotherapist (30 min each: 5 min warm-up, 20 min training and 5 min cool-down) at constant load calculated with Hill's equation (HILL et al., 2008). Optional components of RP will include: inspiratory muscle conditioning using a threshold-loading device, inspiratory muscle training with powerbreathe, breathing exercises, airway clearance, psychological support, relaxation and nutritional counseling. Patients will participate in two group educational sessions, managed by a respiratory physiotherapist, on lifestyle, physical activity and maintenance programs (VISCA et al., 2019; FUGAZZARO et al., 2017; TENCONI et al., 2021).
219357505|NCT06127641|OTHER|Standard Care|Participants will receive standard care (SC): a therapeutic education session upon admission, as well as pulmonary rehabilitation (PR) taught by a physical therapist. This therapeutic educational session will involve counseling and self-care management, emphasizing breathing exercises and sputum clearance and self-care techniques. It will consist of smoking cessation education (if this is the case, as tobacco is associated with TB), respiratory retraining (pursed lip breathing, diaphragmatic breathing and segmental breathing) and secretion removal training (coughing exercise, huffing , assisted cough and postural drainage).
219357506|NCT03590509|OTHER|Telemedicine Program|"A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits\* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
219357507|NCT03590509|OTHER|Usual Comprehensive Care|Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
219357508|NCT01610635|OTHER|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
219359826|NCT07178379|PROCEDURE|Local paracervical Anesthesia|"1\. Intervention Group (Local Anesthesia) Name: Mepivacaine 3% uterosacral ligament block Type: Pharmacological (local anesthetic).~Dose/Administration:~Drug: Mepivacaine hydrochloride 3% (4 vials of 1.7 mL each, total 6.8 mL). Route: Bilateral injection into uterosacral ligaments (2 injections per ligament, 3.4 mL per side).~Technique:~Patient in lithotomy position. Uterosacral ligaments identified posteriorly to the cervix. Injection with a 27G Carpule needle (25 mm length) at 2-3 mm depth. Slow infusion (to minimize dispersion). Timing: Administered ≥1 minute before hysteroscopy."
219359827|NCT07178379|OTHER|Placebo|"Procedure:~Vaginal and cervical irrigation with 0.9% saline solution (4 irrigations, mimicking anesthesia administration).~Mimicry:~Same equipment (syringe, speculum) as intervention group. Identical patient positioning and timing"
219357509|NCT04773405|DRUG|a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance."
219357510|NCT06849115|DRUG|L-Carnitine Injection，1000mg once daily|All patients were given L-carnitine therapy administered every 8 weeks, consisting of 1g L-carnitine diluted in 500 mL of 0.9% sodium chloride solution via intravenous infusion once daily. Each treatment cycle lasted 2 weeks, repeated at 8-week intervals for a total of 3 cycles, with L-carnitine 1g is administered orally once daily during the intervals between intravenous therapies.
219357511|NCT01058343|BIOLOGICAL|IFN-K|3 to 4 IM injections over 3 months
219357512|NCT04461990|PROCEDURE|Multidisciplinary cooperative comprehensive treatment|Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
219357513|NCT02406807|OTHER|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
219357514|NCT02406807|OTHER|Sham Spinal lumbar manipulation|Sham manipulation
219357515|NCT06427460|RADIATION|Central-boost ablative dose delivered by stereotactic body radiation therapy|An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
219357516|NCT01991132|OTHER|MediView 2.0 software|
219357517|NCT01956812|DRUG|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
219357518|NCT01956812|DRUG|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
219357519|NCT01956812|DRUG|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
219357520|NCT03073135|BEHAVIORAL|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
219357521|NCT03073135|BEHAVIORAL|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
219357522|NCT06545786|DEVICE|Intraoperative electroencephalography|"EEG recording will be performed using the standard 16-electrode configuration according to the international 10-20 system. During the recording, electrode impedances will be maintained at a level not exceeding 5 kilo-ohms."
219357523|NCT06482658|PROCEDURE|Transrectal perilesional/regional systematic biopsy (PB/RSB)|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
219357524|NCT06482658|PROCEDURE|Combination of transrectal systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
219357525|NCT05201755|DEVICE|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
219357526|NCT01460823|PROCEDURE|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
219357527|NCT00353418|DRUG|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
219357528|NCT00353418|DRUG|Ribavirin|800 mg orally daily for 48 weeks
219357529|NCT00353418|DRUG|Ribavirin|1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
219359828|NCT07178093|DIETARY_SUPPLEMENT|Antrodia cinnamomea|The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
219357530|NCT01976559|DEVICE|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
219357531|NCT01976559|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
219357532|NCT01347034|PROCEDURE|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
219357533|NCT01347034|BIOLOGICAL|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
219357534|NCT03535623|OTHER|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
219357535|NCT03535623|OTHER|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.
219357536|NCT02828410|DIETARY_SUPPLEMENT|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
219357537|NCT00653237|DEVICE|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
219357538|NCT00257010|DRUG|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
219357539|NCT03618108|DRUG|Doxycycline Capsule|doxycycline capsule
219357540|NCT03618108|DRUG|Azithromycin Capsule|azithromycin capsule
219357541|NCT03618108|DRUG|Rifabutin Oral Capsule|rifabutin capsule
219357542|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
219357543|NCT03618108|DRUG|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
219357544|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
219357545|NCT03739073|OTHER|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
219357546|NCT03563937|DRUG|Phenprocoumon|Follow the physician's prescription.
219357547|NCT03563937|DRUG|Apixaban|2.5 mg or 5 mg, twice daily
219357548|NCT03563937|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
219357549|NCT03563937|DRUG|Edoxaban|30 mg or 60 mg, once daily
219357550|NCT03362775|DRUG|Propofol|Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
219357551|NCT01895127|DRUG|Eculizumab|
219357552|NCT01895127|BIOLOGICAL|Immunoglobulin|
219357553|NCT01895127|PROCEDURE|Plasmapheresis|
219357554|NCT01997879|DRUG|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
219357555|NCT02020486|DRUG|Perampanel|2 mg up to 4 mg
219357556|NCT02020486|DRUG|Perampanel|2 mg up to 6 mg
219357557|NCT03343015|PROCEDURE|complete dentures|therapy with maxilla and mandible dentures
219357558|NCT05019001|PROCEDURE|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
219357559|NCT05019001|PROCEDURE|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
219357560|NCT03877172|DEVICE|High-flow nasal cannula|To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
219357561|NCT04338958|DRUG|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
219357562|NCT00035594|DRUG|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
219357563|NCT03368183|OTHER|Care delivery algorithim|SCAMP
219357564|NCT05125250|OTHER|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
219357565|NCT05125250|OTHER|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
219357566|NCT00131625|BEHAVIORAL|Health education according to WHO recommendations|
219357567|NCT03361397|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
219357568|NCT03361397|DRUG|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
219357569|NCT00434564|PROCEDURE|Stress nuclear scan|
219357570|NCT00419328|DRUG|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level"
219357571|NCT03064139|BEHAVIORAL|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
219357572|NCT03064139|BEHAVIORAL|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
219357573|NCT00608985|DRUG|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
219357574|NCT00608985|DRUG|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
219357575|NCT00608985|DRUG|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
219357576|NCT00608985|DRUG|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
219357577|NCT05872087|DRUG|Nebulised Dexmeditomidine|premedication by dexmeditomidine 3mcg/kg in children undergoing lower abdominal surgeries
219357578|NCT05872087|DRUG|Nebulised Midazolam|premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
219357579|NCT00726466|DRUG|Efalizumab, Ranibizumab|
219357580|NCT03033745|DRUG|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
219357581|NCT03631823|OTHER|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
219357582|NCT02562326|DRUG|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
219357583|NCT02562326|DRUG|Humalog®|Injection immediately before the start of the individualised standard meal
219357584|NCT01238939|DRUG|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
219357585|NCT00323557|DRUG|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
219357586|NCT00323557|BIOLOGICAL|Pneumococcal Vaccine|Subcutaneously on Day 0
219357587|NCT05786092|DEVICE|Telemonitoring|Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
219357588|NCT04519723|DEVICE|Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .|
219357589|NCT01175044|PROCEDURE|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
219357590|NCT01175044|PROCEDURE|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
219357591|NCT06403085|OTHER|Study group|Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.
219357592|NCT01743638|PROCEDURE|MR-Guided Laser Ablation|
219357593|NCT02450578|DRUG|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
219357594|NCT02450578|DRUG|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
219357595|NCT02450578|BIOLOGICAL|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
219357596|NCT02450578|DRUG|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
219357597|NCT00662792|DRUG|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
219357598|NCT00662792|DRUG|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
219357599|NCT00662792|DRUG|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S\_DPI) twice daily (BID)
219357600|NCT00662792|DRUG|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S\_PE) inhalation powder
219357601|NCT05499962|BEHAVIORAL|Social Networking Strategies|Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
219357602|NCT02582957|OTHER|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
219357603|NCT04902365|OTHER|neurofeedback|(based on real-time functional magnetic resonance signals)
219357604|NCT01217541|OTHER|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
219357605|NCT01217541|OTHER|Control|A control group of nursing home units that do not get any form of active intervention
219357606|NCT01392820|DRUG|TC-5214|Tablet, Oral, twice daily
219357607|NCT01392820|DRUG|Placebo|Tablet, Oral, twice daily
219357608|NCT00090545|DRUG|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
219357609|NCT05412914|DRUG|Remimazolam infusion|Remimazolam infusion for anesthesia induction
219357610|NCT05412914|DRUG|Propofol infusion|Propofol infusion for anesthesia induction
219357611|NCT05116800|DRUG|Gemcitabine|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
219357612|NCT05116800|DRUG|9-ING-41|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
219357613|NCT05116800|DRUG|Docetaxel|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
219357614|NCT00035880|DRUG|ABX-CBL|
219357615|NCT04438447|DIETARY_SUPPLEMENT|parenteral feeding|A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
219357616|NCT00441545|DRUG|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
219357617|NCT00441545|DRUG|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
219357618|NCT01724437|DEVICE|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
219357619|NCT05074758|DIAGNOSTIC_TEST|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
219357620|NCT05074758|DIAGNOSTIC_TEST|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest"
219357621|NCT05074758|DIAGNOSTIC_TEST|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
219357622|NCT00882141|BEHAVIORAL|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
219357623|NCT00882141|BEHAVIORAL|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
219357624|NCT03161756|DRUG|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
219357625|NCT03161756|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
219357626|NCT03161756|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
219357627|NCT02213874|OTHER|Questionnaire|A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
219357628|NCT02347176|OTHER|Placebo|Subcutaneous injection with placebo
219357629|NCT02347176|BIOLOGICAL|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
219357630|NCT02347176|BIOLOGICAL|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
219357631|NCT02347176|BIOLOGICAL|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
219357632|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Initial Check-up and Text Messages|Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.
219357633|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Flier and Text Messages|Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
219357634|NCT01783119|DIETARY_SUPPLEMENT|Aloe Barbadensis Miller|
219357635|NCT01783119|DIETARY_SUPPLEMENT|placebo water|
219357636|NCT05278182|DRUG|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
219357637|NCT05278182|DRUG|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
219357638|NCT05404308|OTHER|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
219357639|NCT05404308|OTHER|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
219357640|NCT01913080|OTHER|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
219357641|NCT00236977|DRUG|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
219357642|NCT00236977|DRUG|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
219357643|NCT04031703|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
219357644|NCT04031703|DRUG|Carboplatin|Carboplatin chemotherapy (injection)
219357645|NCT04031703|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
219357646|NCT04031703|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
219357647|NCT04031703|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
219357648|NCT04031703|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
219357649|NCT05860062|DIETARY_SUPPLEMENT|Vitamin D|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
219357650|NCT05860062|OTHER|Calcium|3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
219357651|NCT05315921|DRUG|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357652|NCT05315921|DRUG|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357653|NCT05315921|DRUG|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357654|NCT05315921|DRUG|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357655|NCT05315921|DRUG|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357656|NCT05315921|DRUG|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
219357657|NCT03783260|OTHER|Mediterranean diet|During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
219357658|NCT02369276|OTHER|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
219357659|NCT04138485|BIOLOGICAL|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
219357660|NCT04138485|BIOLOGICAL|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
219357661|NCT03873155|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
219357662|NCT05810545|OTHER|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
219357663|NCT01899170|PROCEDURE|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
219357664|NCT01899170|DEVICE|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
219357665|NCT01899170|DRUG|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
219357666|NCT05358847|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
219357667|NCT03119519|RADIATION|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
219357668|NCT03119519|DRUG|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
219357669|NCT04634266|DEVICE|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
219357670|NCT04758585|PROCEDURE|Arthroscopy|Shoulder Arthroscopy
219357671|NCT00264706|DRUG|Nona-L-arginine|
219357672|NCT04557852|PROCEDURE|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
219357673|NCT02887131|OTHER|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
219357674|NCT00062387|DRUG|perifosine|
219357675|NCT03534427|OTHER|Jump rope exercise intervention|12-week jump rope exercise program
219357676|NCT02914262|DRUG|AKB-4924|Comparison of different dosages of AKB-4924
219357677|NCT02914262|OTHER|Placebo|Placebo comparator
219357678|NCT03796767|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
219357679|NCT03796767|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219357680|NCT03796767|PROCEDURE|Metastasectomy|Undergo salvage oligometastasectomy
219357681|NCT03796767|OTHER|Quality-of-Life Assessment|Ancillary studies
219357682|NCT03796767|OTHER|Questionnaire Administration|Ancillary studies
219357683|NCT03796767|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
219357684|NCT06241612|RADIATION|Individualized Elective Neck Irradiation|Individualized Elective Neck Irradiation
219359829|NCT07178093|DIETARY_SUPPLEMENT|placebo|The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
219359830|NCT07179081|DRUG|AL58805|Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）
219359831|NCT07177378|DEVICE|management of medication related osteonecrosis of the jaw|after buccal flap reflection, the bone osteonecrosis was debrided using piezosurgery. the buccal mucoperiosteal flap was dissected to two layers first, the periosteal layer was based superiorly and the mucosal flap to achieve double layers closure.
219357685|NCT04027933|BEHAVIORAL|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
219357686|NCT02995109|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)"
219357687|NCT02995109|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
219357688|NCT01367522|DRUG|SC Methylnaltrexone (MNTX)|
219357689|NCT02931721|DIAGNOSTIC_TEST|MRI|Pelvis MRI
219357690|NCT01113827|DIETARY_SUPPLEMENT|Olive Extract|Capsule form ingested 1x/day for 6 weeks
219357691|NCT01113827|DIETARY_SUPPLEMENT|Placebo|Placebo
219357692|NCT03014856|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
219357693|NCT00004979|DRUG|paclitaxel|
219357694|NCT00004979|DRUG|topotecan hydrochloride|
219357695|NCT02809833|DRUG|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
219357696|NCT01181414|PROCEDURE|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
219357697|NCT01181414|DRUG|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
219357698|NCT00387114|DRUG|Vitamin C|
219357699|NCT00523991|DRUG|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
219357700|NCT00523991|DRUG|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
219357701|NCT03439033|DRUG|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
219357702|NCT03439033|DRUG|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
219357703|NCT03439033|DRUG|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
219357704|NCT00193063|DRUG|Trastuzumab|Trastuzumab
219357705|NCT00193063|DRUG|Gemcitabine|Gemcitabine
219357706|NCT01418976|BEHAVIORAL|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
219357707|NCT00149578|DRUG|Gemcitabine Oxaliplatin 5FU and Leucovorin|
219357708|NCT00920660|DRUG|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
219357709|NCT00920660|DRUG|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
219357710|NCT00920660|DRUG|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
219357711|NCT00920660|DRUG|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
219357712|NCT00920660|DRUG|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
219357713|NCT00920660|DRUG|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
219357714|NCT06247891|PROCEDURE|ECS Group|Patients underwent endoscopic and endocytoscopic evaluations.
219357715|NCT00009971|DRUG|fenretinide|
219357716|NCT04241614|OTHER|No interventions|No interventions
219357717|NCT01387893|BEHAVIORAL|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
219357718|NCT00744874|PROCEDURE|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
219357719|NCT04206449|OTHER|Therapeutic decision PSG|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
219357720|NCT04206449|OTHER|Therapeutic decision Infrared thermgraphy system|Also randomizing for Infrared thermography system
219357721|NCT05813509|DEVICE|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
219357722|NCT05117359|DEVICE|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
219357723|NCT02844114|DRUG|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
219357724|NCT02844114|DRUG|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
219357725|NCT02844114|DRUG|Chemotherapy|iv.30 minutes
219357726|NCT03602287|DRUG|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
219357727|NCT03602287|DRUG|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
219357728|NCT01714271|BEHAVIORAL|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
219357729|NCT01714271|BEHAVIORAL|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
219357730|NCT02339493|OTHER|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
219357731|NCT01064167|DRUG|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
219357732|NCT05076539|OTHER|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
219357733|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
219357734|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
219357735|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is \>5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is \<5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
219357736|NCT00433407|BIOLOGICAL|trastuzumab|
219357737|NCT01373983|DRUG|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
219357738|NCT03355989|OTHER|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
219357739|NCT03355989|OTHER|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
219357740|NCT00954278|DRUG|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
219357741|NCT05514964|BEHAVIORAL|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
219357742|NCT03642678|DIETARY_SUPPLEMENT|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
219357743|NCT04461470|GENETIC|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
219360105|NCT03478618|DRUG|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
219357744|NCT03622827|COMBINATION_PRODUCT|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~* Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
219357745|NCT01137383|DRUG|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
219357746|NCT00725075|DRUG|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
219357747|NCT00725075|DRUG|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
219357748|NCT00725075|DRUG|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
219357749|NCT01443533|BEHAVIORAL|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
219357750|NCT03170674|OTHER|FT21039|an electronic cigarette product
219357751|NCT03170674|OTHER|FT21092|an electronic cigarette product
219357752|NCT03170674|OTHER|FT21018|an electronic cigarette product
219357753|NCT03680495|DRUG|Methylprednisolone|1\. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
219357754|NCT02686086|DEVICE|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
219357755|NCT02686086|DEVICE|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
219357756|NCT02686086|DRUG|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
219357757|NCT05175807|OTHER|Mindfulness|Mindfulness (e.g., body scan, gentle yoga, sitting, grounding, and walking meditation), relaxation techniques, and cognitive rehabilitation exercises.
219357758|NCT06481761|DEVICE|Double-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on double 0.016'' Stainless steel round wires in both slots of the double slot brackets.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
219357759|NCT06481761|DEVICE|Single-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on single 0.017x0.022'' Stainless steel wire. Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
219357760|NCT00581295|DEVICE|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
219357761|NCT02219139|DEVICE|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
219357762|NCT01178658|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
219357763|NCT02972073|OTHER|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
219357764|NCT05953636|DIETARY_SUPPLEMENT|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
219357765|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording."
219357766|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
219357767|NCT01402297|DRUG|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
219357768|NCT04451629|BEHAVIORAL|pelvıc base exercıse, core exercise|Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
219357769|NCT02340663|DEVICE|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
219357770|NCT02340663|DEVICE|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
219357771|NCT02392182|OTHER|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
219357772|NCT05838638|BEHAVIORAL|eSSET-CINV|Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
219357773|NCT00367042|DEVICE|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
219357774|NCT00367042|DEVICE|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
219357775|NCT02979431|BIOLOGICAL|ALX-0171 3.0 mg/kg|
219357776|NCT02979431|BIOLOGICAL|ALX-0171 6.0 mg/kg|
219357777|NCT02979431|BIOLOGICAL|ALX-0171 9.0 mg/kg|
219357778|NCT02979431|OTHER|Placebo|
219357779|NCT05868850|BEHAVIORAL|auricular point sticking|"1. Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~2. Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~3. Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
219357780|NCT01505907|DRUG|CXB909|CXB909
219357781|NCT02765360|OTHER|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~* Electrical impedance tomography~* EMGpara~* SpO2~* tcCO2~* Pneumotachography~* End-tidal CO2 monitoring"
219357782|NCT05393609|PROCEDURE|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
219357783|NCT05393609|DIETARY_SUPPLEMENT|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
219357784|NCT05167942|DEVICE|deep transcranial magnetic stimulation with H1 coil|Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
219357785|NCT05167942|DEVICE|High frequency deep transcranial magnetic stimulation with H1 coil|high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
219357786|NCT05167942|DEVICE|iTBS deep transcranial magnetic stimulation with H1 coil|iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
219357787|NCT06542315|PROCEDURE|Intraoperative parathyroid hormone (IOPTH) monitoring|Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.
219357788|NCT05853770|OTHER|TGfU volleyball intervention|"Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min)."
219357789|NCT05853770|OTHER|Regular physical education classes|Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
219357790|NCT02676687|PROCEDURE|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
219357791|NCT02676687|PROCEDURE|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
219357792|NCT01646632|BEHAVIORAL|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
219357793|NCT01646632|BEHAVIORAL|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
219357794|NCT04566575|OTHER|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
219357795|NCT04566575|OTHER|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
219357796|NCT04642339|BIOLOGICAL|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
219357797|NCT04642339|BIOLOGICAL|Placebo|Placebo
219357798|NCT01656434|DRUG|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
219357799|NCT01656434|DRUG|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
219357800|NCT01656434|OTHER|Placebo|tablet
219357801|NCT01656434|DRUG|ethinylestradiol (EE)|EE 10 μg tablet
219357802|NCT01656434|DRUG|ferrous fumarate|ferrous fumarate 75 mg tablet
219357803|NCT02137954|DRUG|Lidocaine|
219357804|NCT02137954|DRUG|Placebo|
219357805|NCT03712579|DIETARY_SUPPLEMENT|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
219357806|NCT03712579|DIETARY_SUPPLEMENT|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
219357807|NCT04315896|DRUG|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
219357808|NCT04315896|DRUG|Placebo oral tablet|Placebo oral tablet
219357809|NCT00615615|DRUG|Levetiracetam|"* high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~* low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less"
219357810|NCT00615615|DRUG|Placebo|Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
219360106|NCT05765903|OTHER|Standard of Care|"* Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment."
219357811|NCT04128540|DRUG|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
219357812|NCT04128540|PROCEDURE|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
219357813|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
219357814|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
219357815|NCT04465682|DEVICE|Experimental: Dip Home-Based Dipstick Analyzer|Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
219357816|NCT00104546|PROCEDURE|Acupuncture point injection of vitamin K|
219357817|NCT02249910|DRUG|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
219357818|NCT02249910|DRUG|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
219357819|NCT02249910|DRUG|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
219357820|NCT02249910|DRUG|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
219357821|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
219357822|NCT00911131|PROCEDURE|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
219357823|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
219357824|NCT05401305|BIOLOGICAL|Vaccine for the prevention of infections caused by Haemophilus influenza type b|The vaccine is administered into the region of the deltoid muscle
219357825|NCT05401305|BIOLOGICAL|Placebo|The placebo is administered into the region of the deltoid muscle
219357826|NCT05019105|DRUG|Placebo|Oral matching placebo
219357827|NCT05019105|DRUG|ALKS 1140|Active oral dose of ALKS 1140
219357828|NCT00065338|BEHAVIORAL|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
219357829|NCT01235962|DRUG|pazopanib|Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
219357830|NCT01235962|DRUG|placebo|Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
219357831|NCT01235962|DRUG|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
219357832|NCT01235962|DRUG|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
219357833|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 72 weeks
219357834|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 48 weeks
219357835|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
219357836|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
219357837|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
219357838|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
219357839|NCT03504592|BEHAVIORAL|Completion of Glucose logs|Glucose logs will be assessed by provider for completeness and accuracy
219357840|NCT03462056|DIETARY_SUPPLEMENT|Cystic Fibrosis Ready to Use Supplemental Food|Specially formulated for use by children with Cystic Fibrosis
219357841|NCT01308866|BEHAVIORAL|Share decision tool|
219357842|NCT01331304|DRUG|Lithium|600-900mg per day over 6 months
219357843|NCT01331304|DRUG|Quetiapine|100-800mg a day over 6 months
219357844|NCT01580397|DRUG|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
219357845|NCT02303626|DRUG|BCX4161|
219357846|NCT02303626|DRUG|Placebo|
219357847|NCT04873479|DRUG|S-ketamine|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
219357848|NCT04873479|OTHER|saline|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
219357849|NCT02902120|DRUG|Post-transplant Grazoprevir and Elbasvir|Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
219357850|NCT02596412|OTHER|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
219357851|NCT04926779|DIAGNOSTIC_TEST|Biozek Covid-19 Antigen Rapid Test (Saliva)|Self-collection of nasopharyngeal and saliva samples and self test performance - Biozek Covid-19 Antigen Rapid Test (Saliva) and Biozek Covid-19 Antigen Rapid Test (Nasopharyngeal Swab). Both procedures are supervised by trained study personnel.
219357852|NCT05883189|DIAGNOSTIC_TEST|Draw blood|Draw blood from human body and make into serum to test
219357853|NCT02004873|DEVICE|Micra Pacemaker Implant|
219357854|NCT02936141|BEHAVIORAL|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
219357855|NCT00481416|DEVICE|PillCam Eso|
219357856|NCT05250661|OTHER|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
219357857|NCT01353703|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
219357858|NCT03814980|BEHAVIORAL|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
219357859|NCT03814980|DEVICE|application on a computer tablet|a computer tablet
219357860|NCT03050580|BEHAVIORAL|self-esteem enhancement group|Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
219357861|NCT03050580|BEHAVIORAL|Standard care for abused women|The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
219357862|NCT03867045|DEVICE|Usability of an electronic symptom management application|Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
219357863|NCT03667703|DRUG|Famotidine|Patients will be randomized to either receive a placebo or famotidine (study drug).
219357864|NCT03667703|DRUG|Placebo|Patients will be randomized to either receive a placebo or famotidine (study drug).
219357865|NCT05849870|OTHER|Frailty care pathway for older people in a rural primary care setting|This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
219357866|NCT00927836|BIOLOGICAL|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
219357867|NCT00927836|DRUG|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
219357868|NCT06103032|PROCEDURE|Breast Conserving Surgery|Patients undergoing breast conserving surgery
219357869|NCT06103032|PROCEDURE|Mastectomy|Patients undergoing mastectomy
219357870|NCT00693160|DRUG|ketorolac|single intrathecal injection of ketorolac 2 mg
219357871|NCT00693160|DRUG|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
219357872|NCT00693160|DRUG|remifentanil|All subjects will receive a remifentanil infusion
219357873|NCT00693160|DRUG|Capsaicin|Topical capsaicin pain model utilized for each subject
219357874|NCT03522441|DRUG|Clindamycin 1% Gel|Topical gel
219357875|NCT03522441|DRUG|Placebo|Topical Placebo gel
219357876|NCT00311467|DRUG|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
219357877|NCT04269109|OTHER|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
219360107|NCT05765903|OTHER|Enhanced Care|"* Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
219365678|NCT00865020|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
219357878|NCT03893149|BEHAVIORAL|Active-Start intervention|Supervised exercise training. The intervention is a physical activity intervention that consist of 5 times per week before starting the first school-class (8:00-8:30 a.m.), 5 times per week. Each session was previously planned and described in a manual dedicated to the study. These sessions were designed by the research team and delivered by a graduate in Sport The intervention program included sports games adapted to the age of the participants, playground games, dance and other recreational activities. The intensity of the main part of the sessions was moderate-to-vigorous according to a previous study and this intensity was confirmed by accelerometry. Also, different activities favoring social interactions were designed to facilitate the interactions between the participants at the end of the sessions (cold-down).
219357879|NCT03893149|BEHAVIORAL|No Intervention|No-exercise
219357880|NCT04617158|PROCEDURE|Adjustable strabismus surgery|Adjustable surgery will be done using sliding nose technique using fornix approach
219357881|NCT04063371|OTHER|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
219357882|NCT04063371|OTHER|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
219357883|NCT05787847|BEHAVIORAL|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
219357884|NCT05787847|BEHAVIORAL|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
219357885|NCT06468059|DEVICE|Layered Low Profile Foot|The layered LPF is a novel low-profile prosthetic foot that provides compliant behavior while simultaneously exhibiting high mechanical strength.
219357886|NCT06468059|DEVICE|Prescribed Ankle|The prescribed ankle is the prosthetic ankle that the subject wears for daily use.
219357887|NCT03283800|OTHER|Copper impregnated compression stocking|Copper impregnated compression stocking
219357888|NCT03283800|OTHER|Normal compression stocking|Normal compression stocking without copper
219357889|NCT05609890|DIETARY_SUPPLEMENT|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
219357890|NCT05609890|OTHER|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
219357891|NCT06822881|DRUG|CAR-T Therapy|CT1190B cells infusion
219357892|NCT02207933|PROCEDURE|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
219357893|NCT02207933|PROCEDURE|Gait training|Gait training only for 3 times a week for 6 weeks.
219357894|NCT04145414|DEVICE|MRI|Reproductibility test assessed with MRI for cerebrospinal fluid movements
219357895|NCT06072885|OTHER|Lung Ultrasound Scoring|Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
219357896|NCT02103530|OTHER|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
219357897|NCT04937088|DRUG|ASA|Liquid aspirin formulation
219357898|NCT04405011|DRUG|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
219357899|NCT04405011|DRUG|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
219357900|NCT05335460|DRUG|Envafolimab|300mg,sc,d1,Q3W
219357901|NCT02799680|BIOLOGICAL|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
219357902|NCT04116112|DRUG|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
219357903|NCT04116112|DRUG|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
219357904|NCT04116112|DRUG|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
219357905|NCT05301946|OTHER|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
219357906|NCT00220012|PROCEDURE|Folate depletion and supplementation|
219362317|NCT02596659|PROCEDURE|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
219357907|NCT04307108|DEVICE|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy \[29\] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
219357908|NCT04581980|OTHER|Exercise|Participants will exercise on a cycle ergometer
219357909|NCT00373204|DRUG|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
219357910|NCT06492096|DEVICE|Bibloc Mandibular Advancement device|Each patient received a CAD/CAM designed Bibloc Mandibular Advancement device
219357911|NCT06050044|DRUG|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
219357912|NCT06050044|DRUG|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
219357913|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 4mg|
219357914|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 6mg|
219357915|NCT02163174|DRUG|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
219357916|NCT02163174|DRUG|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
219357917|NCT06095856|DEVICE|Leaf Gauge|Occlusal device used to locate centric relation of the jaws
219357918|NCT06095856|DEVICE|Lucia Jig|Occlusal device used to locate centric relation of the jaws
219357919|NCT06095856|DEVICE|Kois Deprogrammer|Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
219357920|NCT00921700|DRUG|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
219357921|NCT00921700|DRUG|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
219357922|NCT00921700|DRUG|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
219357923|NCT00921700|DRUG|Placebo|Single oral dose of lactose as placebo in gelatine capsules
219357924|NCT04824586|DRUG|Fast-acting human insulin|Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
219357925|NCT02692209|DEVICE|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
219357926|NCT02692209|DEVICE|FFDM Alone|FFDM Alone Images
219357927|NCT03467958|DRUG|Ozanimod|Specified dose on specified days
219357928|NCT03726164|DEVICE|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
219357929|NCT03726164|DEVICE|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
219357930|NCT00866307|DRUG|Cyclophosphamide|Given IV
219357931|NCT00866307|DRUG|Cytarabine|Given IT and IV or SC
219357932|NCT00866307|DRUG|Daunorubicin Hydrochloride|Given IV
219357933|NCT00866307|DRUG|Dexamethasone|Given IV
219357934|NCT00866307|DRUG|Doxorubicin Hydrochloride|Given IV
219357935|NCT00866307|OTHER|Laboratory Biomarker Analysis|Correlative studies
219357936|NCT00866307|DRUG|Mercaptopurine|Given PO
219357937|NCT00866307|DRUG|Methotrexate|Given IT and PO
219357938|NCT00866307|DRUG|Pegaspargase|Given IV
219357939|NCT00866307|DRUG|Prednisone|Given IV or PO
219357940|NCT00866307|RADIATION|Prophylactic Cranial Irradiation|Undergo radiation
219357941|NCT00866307|DRUG|Thioguanine|Given PO
219357942|NCT00866307|DRUG|Vincristine Sulfate|Given IV
219357943|NCT04793256|DEVICE|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).|5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces
219357944|NCT04793256|DEVICE|Resin based fissure sealant (3M Clinpro Sealant)|teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
219357945|NCT04353180|DRUG|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
219357946|NCT04353180|DRUG|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
219357947|NCT04353180|DRUG|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
219357948|NCT04353180|DRUG|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
219357949|NCT04353180|DRUG|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
219357950|NCT00868946|DRUG|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
219357951|NCT02286947|DRUG|Eteplirsen|Eteplirsen solution for IV infusion
219357952|NCT05373927|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
219357953|NCT04515784|BEHAVIORAL|Safety Aid Reduction Treatment for PTSD|START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
219357954|NCT02257983|DRUG|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
219357955|NCT02257983|DRUG|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
219357956|NCT04663958|DIAGNOSTIC_TEST|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
219357957|NCT02692066|BIOLOGICAL|varicella vaccine|
219357958|NCT04421495|DRUG|Delamanid|the eligible patients will be give damanid-containing regimen
219357959|NCT01128829|OTHER|Water|60 ml of water were drank 10 min before doing a OGTT
219357960|NCT01128829|OTHER|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
219357961|NCT01060059|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
219357962|NCT01060059|DRUG|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
219357963|NCT03406065|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
219357964|NCT03406065|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
219357965|NCT02990442|DEVICE|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R\_DLPFC)
219357966|NCT03824665|DRUG|Nalbuphine Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline"
219357967|NCT03824665|DRUG|Fentanyl Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline"
219357968|NCT03824665|DRUG|Control Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline."
219357969|NCT00501813|PROCEDURE|Hepatectomy|irregular Hepatectomy
219357970|NCT00501813|PROCEDURE|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
219357971|NCT03575858|DEVICE|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
219357972|NCT03575858|DEVICE|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
219357973|NCT01109030|DRUG|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
219357974|NCT01109030|DRUG|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
219357975|NCT03269708|BEHAVIORAL|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
219357976|NCT01733030|DRUG|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
219357977|NCT01733030|DRUG|Seromycin|
219357978|NCT05047809|OTHER|"Jingchuang Ointment(JCO)"|Applied once a day on the wounds
219357979|NCT05047809|OTHER|Regular Treatment|"Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual."
219357980|NCT05272033|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
219357981|NCT03183674|DRUG|Oxytocin|Single dose oxytocin 45 minutes before the test
219357982|NCT03183674|OTHER|placebo|saline solution 0,9% spray nasal
219357983|NCT01614093|DRUG|Oxytocin|Single dose intranasal oxytocin (24 IU)
219357984|NCT01614093|DRUG|Placebo|Placebo- Sugar pill
219357985|NCT00848354|BIOLOGICAL|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
219357986|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
219361952|NCT03761329|PROCEDURE|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
219357987|NCT00848354|DRUG|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
219357988|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
219357989|NCT00848354|DRUG|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
219357990|NCT02394977|DEVICE|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
219357991|NCT02394977|OTHER|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
219357992|NCT02113631|DRUG|Telaprevir|
219357993|NCT02113631|DRUG|Boceprevir|
219357994|NCT02113631|DRUG|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
219357995|NCT02113631|DRUG|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
219357996|NCT06282848|DRUG|Atropine 0.05%|Topical application
219357997|NCT06282848|DEVICE|DIMS lens|Spectacle wear
219357998|NCT06802393|OTHER|Intervention|The intervention incorporates a multifaceted pharmacist-led approach to addressing health-related social needs (HRSN) during transitions of care in the emergency department (ED) at Buffalo General Medical Center (BGMC). The intervention includes: 1) pharmacist-led medication reconciliation, and 2) HRSN screening using the Accountable Health Communities (AHC) HRSN tool. Based on the results, patients receive tailored referrals to community-based organizations using the 211 WNY database, which provides localized resources aligned with their social needs. Each patient is given a printed handout detailing the referral information. Within one month, a follow-up phone call is conducted to follow up with patients and assess additional needs as well as collect feedback through a patient satisfaction survey.
219357999|NCT06802393|OTHER|Control|The control arm of the study consists of a historical cohort of patients who were admitted to or discharged from the emergency department (ED) at Buffalo General Medical Center (BGMC) during the same timeframe as the intervention arm but did not receive the pharmacist-led health-related social needs (HRSN) screening or referral intervention. These patients are identified through the electronic health record (EHR) based on the same inclusion criteria as the intervention group, such as age, geographic location, and discharge disposition. Control participants are matched 1:1 with intervention participants using demographic and clinical characteristics, including age (within 5 years), zip code, insurance type, discharge status, and race. Data for the control arm include healthcare utilization metrics such as 30- and 90-day unplanned hospital readmissions and emergency department visits. The control arm serves as a comparator to evaluate the effectiveness of the intervention
219358000|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
219358001|NCT04919512|DRUG|TAR-200|TAR-200 will be administered.
219358002|NCT04919512|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
219358003|NCT05401617|OTHER|additional information via the computerized tool|additional information delivered via the computerized tool
219358004|NCT03949972|OTHER|Biosampling|Biosampling at initial visit and follow-up visits
219358005|NCT06134492|DRUG|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
219358006|NCT06567015|DRUG|STX-241|"Film-coated tablet~Route of administration: Oral"
219358007|NCT03770780|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
219358008|NCT03770780|DRUG|Placebo|Placebo in combination with Ketamine
219358009|NCT06965842|OTHER|Parent-centered developmental training|After discharge from the neonatal intensive care unit, 1:1 monitoring is conducted at home for 30 minutes twice a week using a video conferencing platform (Zoom) until the corrected age of 6 months to provide parent-centered early intervention. Parents film the developmental training process using a smartphone and send the video to the therapist, who analyzes the video data to provide new treatment goals and guidelines.
219358010|NCT01777581|DRUG|Milnacipran|
219358011|NCT01777581|DRUG|Placebo|
219358012|NCT01211600|OTHER|Staples|Interrupted Ethicon Staples
219358013|NCT01211600|OTHER|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
219358014|NCT01331356|DRUG|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
219358018|NCT04867317|DRUG|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
219361953|NCT03761329|PROCEDURE|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
219358019|NCT04867317|OTHER|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
219358020|NCT06102434|DRUG|Psilocybin|Five oral capsules containing 5 mg of psilocybin each
219358021|NCT06085352|DRUG|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
219358022|NCT06085352|DEVICE|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
219358023|NCT04547504|DRUG|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
219358024|NCT04547504|DRUG|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
219358025|NCT03403686|BIOLOGICAL|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
219358026|NCT04202679|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219358027|NCT04202679|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
219358028|NCT04202679|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
219358029|NCT04202679|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
219358030|NCT04202679|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
219358031|NCT05235425|BEHAVIORAL|Standard NDPP|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
219358032|NCT05235425|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
219358033|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
219358034|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
219358035|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
219358036|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
219358037|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
219358038|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
219358039|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
219358040|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
219358041|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
219358042|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
219358043|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
219358044|NCT06612827|OTHER|organoid etablishment|"Prior to initiation of 1st-line therapy:~* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)~* A blood test blood a for tumoroid realization and :~* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo~* Analysis of correlation between in vivo and ex vivo tumor characteristics~* Analysis of first- and second-line survival rates and overall survival"
219358045|NCT06993844|DRUG|ETX-636 dose escalation|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.
219361954|NCT00015600|BEHAVIORAL|Behavior modification through social marketing|
219358046|NCT06993844|DRUG|ETX-636 dose escalation in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
219358047|NCT06993844|DRUG|ETX-636 dose expansion in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
219358048|NCT04971954|OTHER|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
219358049|NCT04971954|OTHER|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
219358050|NCT06229470|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation (SCS) system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
219358051|NCT06615479|DRUG|BMS-986393|Specified dose on specified days
219358052|NCT06615479|DRUG|Cyclophosphamide|Specified dose on specified days
219358053|NCT06615479|DRUG|Fludarabine|Specified dose on specified days
219358054|NCT06615479|DRUG|Daratumumab|Specified dose on specified days
219358055|NCT06615479|DRUG|Pomalidomide|Specified dose on specified days
219358056|NCT06615479|DRUG|Dexamethasone|Specified dose on specified days
219358057|NCT06615479|DRUG|Carfilzomib|Specified dose on specified days
219358058|NCT05457634|OTHER|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358059|NCT05457634|OTHER|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358060|NCT05457634|OTHER|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358061|NCT05457634|OTHER|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358062|NCT05457634|OTHER|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358063|NCT05457634|OTHER|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
219358064|NCT07024719|DEVICE|4D MIOCT integrated into a Zeiss Artevo 800|4D MIOCT integrated into a Zeiss Artevo 800 surgical microscope with an add-on investigational 3D OCT scanner
219358065|NCT06822712|DEVICE|Sirolimus-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
219358066|NCT06822712|DEVICE|Paclitaxel-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Paclitaxel-coated Balloon Dilatation Catheter in the control group, subsequently completing the remaining procedure
219358067|NCT06878248|BIOLOGICAL|Two Component Product CLBR001 + ABBV-461|Investigational switchable CAR-T cell therapy for breast cancer
219358068|NCT07122895|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of negative symptoms
219358069|NCT07122895|DRUG|Placebo Cap|Use of placebo as a comparator
219358070|NCT06889597|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
219358071|NCT06889597|OTHER|Experimental|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
219358072|NCT06921733|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
219358073|NCT06733025|PROCEDURE|Tendon lengthening surgery|The participants will first receive BoNT injections, earliest three months after they will undergo tendon lengthening surgery
219358074|NCT06733025|DRUG|BoNT Injections|The dosage and number of injected muscles will vary depending on the degree and extent of spasticity. All patients had previous BoNT injections, one injection circle will be followed in this study.
219358075|NCT07057141|DEVICE|Biorepair Total Protection Toothpaste|Application of Biorepair Total Protection toothpaste for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
219358076|NCT07057141|DEVICE|Biorepair High-Density Mouthwash|Application of Biorepair High-Density mouthwash for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
219358077|NCT06667908|DRUG|JNJ-90301900|JNJ-90301900 will be injected intratumorally and/or intranodally.
219358078|NCT06667908|BIOLOGICAL|Durvalumab|Durvalumab will be administered as intravenous (IV) infusion as cIT.
219358079|NCT06667908|RADIATION|Concurrent Chemo/Radiation Therapy (cCRT)|Radiation by intensity modulated radiation therapy (IMRT) will be administered.
219358080|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin|Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
219358081|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel|Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
219358082|NCT06896695|OTHER|Best Practice|Receive usual care
219358083|NCT06896695|OTHER|Discussion|Ancillary studies
219358084|NCT06896695|OTHER|Financial Navigation|Receive the Financial Compass intervention
219358085|NCT06896695|OTHER|Interview|Ancillary studies
219358086|NCT06896695|OTHER|Survey Administration|Ancillary studies
219358087|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219358088|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
219358089|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
219358090|NCT04963153|PROCEDURE|Echocardiography Test|Undergo echocardiography
219358091|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
219358092|NCT04963153|DRUG|Erdafitinib|Given PO
219358093|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
219358094|NCT06901960|DEVICE|A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L)|A mobile AI-enhanced electrocardiogram device will be used to help patients monitor hyperkalemia. The device, shaped like a stick of chewing gum, collects time-series data of electrocardiogram lead I through two electrodes. Deep convolutional neural network algorithm can read the data and generated categories of plasma potassium (\<5 mmol/L, 5 - \<5.5 mmol/L, 5.5 - \<6.0 mmol/L and ≥ 6.0 mmol/L). Study participants receive the device after randomization. The staff establishes a WeChat group for each participant and reminds them to monitor plasma potassium every 3 days. When the detected plasma potassium category falls in 5 - \<5.5 mmol/L, they will be reminded to watch diet and to verify plasma potassium again. More intensive reminding (once daily) will be sent if plasma potassium category falls in 5.5 - \<6.0 mmol/L or ≥ 6.0 mmol/L. An extra outpatient appointment will also be made as soon as possible for the patients when their detected plasma potassium category is ≥ 6.0 mmol/L.
219358095|NCT06925061|DRUG|After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks|Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).
219358096|NCT07140341|DRUG|ENO Lime|A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg
219358097|NCT05133661|DIAGNOSTIC_TEST|HPV testing|Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.
219358098|NCT06942234|DRUG|JSKN016|JSKN016 is administered via intravenous infusion at doses of 5mg/kg or 6mg/kg every 3 weeks, starting on Day 1 of each cycle. If the 5mg/kg dose is well tolerated during the safety lead-in phase, the dose may be increased to 6mg/kg for subsequent cycles.
219358099|NCT06942234|DRUG|Capecitabine|The drug is administered orally at a dose of 1000mg/m², twice daily for two weeks, followed by a one-week break. Treatment cycles repeat every three weeks.
219358100|NCT06942234|DRUG|Paclitaxel (albumin bound)|The drug is administered intravenously at a dose of 125mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
219358101|NCT06942234|DRUG|Eribulin|The drug is administered intravenously at a dose of 1.4mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
219358102|NCT06942234|DRUG|Pembrolizumab|The drug is administered intravenously at a fixed dose of 200mg, with infusions on Day 1 of each 3-week treatment cycle.
219358103|NCT07166198|DEVICE|Wrist immobilization|The wrist immobilization will use a medical device (wrist cast) to immobilize the left, non-dominant wrist for 7 days.
219358104|NCT07166198|BEHAVIORAL|Resistance training|The cross-education intervention will consist of resistance training on the dominant, right hand.
219358105|NCT07166198|BEHAVIORAL|Resistance training rehabilitation|The resistance training rehabilitation will occur for the non-dominant, left hand following the immobilization phase for all participants.
219358106|NCT07166939|DRUG|Airsupra|1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period
219358107|NCT07162506|PROCEDURE|Surgery|Radical esophagectomy + mediastinal lymph node dissection
219358108|NCT07162506|RADIATION|Radiotherapy|Radiotherapy: 50.4 Gy/28f
219358109|NCT07162506|DRUG|Chemotherapy|Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles
219358110|NCT07169032|DEVICE|Er,Cr:YSGG laser irradiation|irradiation with a 2780 nm, 1.0 W Er,Cr:YSGG laser for 1 minute
219358111|NCT07169032|DRUG|Sham Laser irradiation|sham laser irradiation for 1 minute
219358112|NCT07169032|DRUG|Lidocaine|2% lidocaine gel
219358113|NCT07169032|DRUG|Vaseline|Vaseline
219358114|NCT07166770|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
219358115|NCT07165158|DRUG|semaglutide combined with metformin|The initial dose of semaglutide is 0.25 mg once weekly. After 4 weeks, the dose is adjusted to 0.5 mg once weekly. After another 4 weeks, the dose is adjusted to 1 mg once weekly. During the same period, they will take metformin (500mg each time, three times a day) for treatment. The treatment course is 12 months.
219358116|NCT07164404|OTHER|EHR alert|EHR embedded alert into the admission note template, where it automatically inserts smoking history, prompts NRT prescribing in the hospital, and offers referral to outpatient follow up.
219358117|NCT07169084|OTHER|Manual Therapy|Manual mobilization techniques applied to the cervical and upper thoracic regions, 3 sessions/week for 4 weeks.
219358118|NCT07169084|OTHER|Instrument-Assisted Soft Tissue Mobilization (IASTM)|Mobilization applied with instruments to cervical and upper thoracic muscles, 3 sessions/week for 4 weeks.
219361955|NCT05989906|BEHAVIORAL|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
219358119|NCT07178418|OTHER|Muscle Architecture-Based Exercise Program|Participants in this arm will perform exercises specifically designed according to the architectural and functional properties of the triceps surae muscles. For example, knee-flexed positions will be used to target the soleus, while knee-extended positions will be emphasized for the gastrocnemii. Loading intensity and exercise progression will be tailored to optimize tendon and muscle remodeling.
219358120|NCT07178418|OTHER|Alfredson Protocol|This intervention involves the traditional eccentric heel-drop program, originally developed for mid-portion Achilles tendinopathy. Participants perform three sets of 15 repetitions, twice daily, throughout the intervention period. Exercises are carried out both with the knee extended and flexed to load different portions of the triceps surae. The protocol applies repetitive eccentric loading to the Achilles tendon with the aim of stimulating collagen synthesis, reducing symptoms, and promoting tendon adaptation.
219358121|NCT07178314|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|Participants will perform self-implemented at-home transcutaneous tibial nerve stimulation using a transcutaneous electrical nerve stimulation (TENS) unit. Participants will be instructed to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks upon receipt of the device. Intensity will be based on the participant's tolerance, just above the perception threshold but not painful.
219358122|NCT07178600|DRUG|Ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL.|Measurement of vital signs after ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL
219358123|NCT07177963|BEHAVIORAL|HIIT|Exercise sessions were conducted as telemedically supervised, home-based HIIT performed on electric resistance bikes, with protocols individually tailored. Each HIIT session comprised 8 cycles of alternating 30-second high-intensity intervals (HIT at 80% peakVO₂) and 60-second low-intensity recovery intervals (LIT at 50% peakVO₂). Warm-up and cool-down phases were performed with the bike's resistance set to 0 watts (unloaded pedaling). The total intervention duration was 8 weeks. Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
219358124|NCT07177963|BEHAVIORAL|No specific exercise intervention.|The control group will not receive any exercise intervention, and they will be instructed to not take any structured exercise regimens.Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
219358125|NCT07179393|BEHAVIORAL|Ladies Gaelic Football-Specific Injury Prevention Programme|This intervention is an injury prevention programme designed with input from Ladies Gaelic football stakeholders (players and coaches) as well as experienced athletic therapy and physiotherapy practitioners and academics from the disciplines of injury prevention and coaching science.
219358126|NCT07178119|PROCEDURE|(Bridging) Horizontal Cannula Technique for Treatment of Nasolabial Folds using AILEENE Vol. 2|Participants will receive treatment to both NLF using the Bridging Technique. This involves injecting an HA dermal filler (AILEENE Vol. 2) in thin horizontal threads (less than 0.05 milliliters \[ml\] per retrograde placement) under the fold using a blunt cannula. The maximum total dose per participant is 1.0 ml across both folds. Each participant will receive one treatment at baseline (Day 0). An optional single top-up may be given at Week 2 (virtual or in-clinic) or Week 4 if clinically indicated, using only the remaining balance of the 1.0 ml total. Any top-up will be performed with a new, sterile syringe, not with filler left over from the initial treatment. This is a single-treatment course with follow-up for 6 months. Standardized photographs will be taken at Baseline, Week 4, Month 3, and Month 6 for blinded assessment.
219358127|NCT07178015|COMBINATION_PRODUCT|ultrasound scanning|Ultrasound (US) is one of the most frequently utilized methods in carotid screening worldwide, because of its noninvasive and radiation-free nature and advantages of cost-effectiveness and convenience。
219358128|NCT07177716|BIOLOGICAL|LB1410|LB1410 (IV, Q2W for up to 2 years)
219358129|NCT07177716|BIOLOGICAL|LB4330|LB4330 (IV, Q2W for 4 cycles)
219358130|NCT07177716|DRUG|Lenvatinib|lenvatinib (oral, once daily for up to 2 years)
219358131|NCT07177755|DIAGNOSTIC_TEST|High-field and very-low-field MRI acquisitions|MRI will be early acquired, as soon as possible after patient hospital admission and always in coma state for patients. For both patients and controls each MRI scanning session will encompass pairs of HF and VLF MRI acquisitions, that will be collected the same day. The main MRI sequences will be: T1, T2, FLAIR and DWI. The VLF spatial resolution recommended by the constructor for all these sequences correspond to voxel size is around 1.5mm/1.5mm/5mm. The total brain scanning time is estimated at 30 minutes.
219358132|NCT07177482|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
219358133|NCT07177638|BEHAVIORAL|Education Sessions to Improve Melanoma Knowledge and Awareness|Community based educational seminar led by a community health worker with follow-up questionnaires to assess knowledge retention and behavioral change.
219358134|NCT07178691|OTHER|Online psychological intervention|The HOPE-AF intervention is an online psychological intervention to prevent depression in patients with atrial fibrillation. The intervention combines verbal psychological sessions over phone or video with online text messages and a tailored 4-12 weeks online intervention with new modules each week including psychological exercises in writing and as sound exercises (e.g., breathing exercises and relaxations exercises etc.) and videos.
219358135|NCT07179146|DEVICE|Dental arch length anlysis|Arch length
219358136|NCT07179146|BEHAVIORAL|child satisfaction|Frankel rating scale
219358137|NCT07179146|DEVICE|Dental arch length anaylsis|Intermolar width
219358138|NCT07179146|DEVICE|Dental arch length analysis|Intercanine width
219358139|NCT07179146|DEVICE|Dental arch length anylsis|Arch depth
219358140|NCT07178925|OTHER|Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006|The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population.
219358141|NCT07177950|DRUG|SHR-A1811|Systemic therapy: 4.8 mg/kg administered as an intravenous infusion on Day 1 of each cycle. 3 weeks a cycle. Continuous medication until study completion, occurrence of intolerable toxicity, disease progression, withdrawal from the study for any reason, or death, whichever occurs first, or until the investigator deems that the patient would no longer benefit from the treatment.
219358142|NCT07177950|DRUG|SHR-A1811|Intrathecal therapy: Administered intrathecally on Day 1 of each cycle. Dose escalation follows a Bayesian Optimal Interval (BOIN) design with three predefined dose levels-15 mg, 30 mg, and 40 mg. The starting dose level is 15 mg. Patients are enrolled in cohorts of three per dose level. If no dose-limiting toxicities (DLTs) are observed, escalation proceeds to the next higher dose level according to the BOIN algorithm. Treatment is administered for a minimum of two cycles and is continued until cerebrospinal fluid (CSF) cytology achieves negative conversion, completion of six cycles, or intolerable adverse events, whichever occurs first. Extension beyond six cycles may be permitted following investigator's discussion and must be documented with justification.
219358143|NCT07177950|RADIATION|radiotherapy|radiotherapy is determined by investigator's choice
219358144|NCT07179172|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) 8-Week Program|"The program consists of weekly 2.5-hour sessions over an eight-week period. The certified mindfulness instructor will follow a curriculum that includes in-class formal practice (2.5 hours) and assigned informal practice (30-40 minutes daily).~During the sessions, the instructor will guide participants through mindfulness meditation, pain awareness, mindful yoga, gratitude practice, loving-kindness meditation, and the sharing of daily life experiences. Additionally, a full-day, eight-hour silent retreat (9 a.m. to 5 p.m.) will be held between weeks six and seven to deepen inner awareness.~Following each weekly group session, participants will be instructed to perform and self-record daily home practice, which will be discussed and evaluated during the following week's class. The total course duration is approximately 26 hours, and participants will receive a certificate of completion upon graduation."
219358145|NCT07177521|PROCEDURE|Insertion of implants in post-extraction tooth|"Two widely used approaches include:~1. Socket grafting with a fully resorbable synthetic biomaterial (β-tricalcium phosphate + calcium sulfate).~2. Socket grafting with a xenograft and a custom Sealing Socket Abutment (SSA) with a concave emergence profile.~No randomized controlled trials have yet compared these protocols with integrated outcomes including resonance frequency analysis, peri-implant health indices, radiographic bone level changes, and digital intraoral scanning (IOS)-based morphometric analysis."
219358146|NCT07178106|OTHER|Fasting|Participants undergo the standardised Wilhelmi-Buchinger fasting intervention, which consists of two days of preparation with a dietary energy supply of \<1000 kcal, three days of fasting with a dietary energy supply of 300-500 kcal with tea, broth, fruit and vegetable juices, and two days of recovery.
219358147|NCT07178561|OTHER|Exercises for lower back|"1. Physiotherapy Modalities (Preparation):~   Hot Pack Therapy: Applied to the lumbar region for 10-15 minutes before exercises to reduce muscle stiffness and pain.~   Interferential Therapy (IFT): Applied to the lower back for 10-15 minutes to decrease pain and improve circulation.~2. Exercise Program (30-40 minutes per session, 3 times/week):~A. Lumbar Stabilization Exercises:~B. Core Strengthening Exercises:"
219358148|NCT07178561|OTHER|Exercises and Physical Activity Program|"1. Frequency \& Duration:~   Frequency: 3 days per week~   Duration: 30 to 40minutes per session~   Intensity: Low to moderate (RPE 11-13 on Borg scale; light to somewhat hard)~2. Warm-Up (5 minutes):~   Gentle walking on treadmill at slow speed (1.5-2.5 km/h)~   Light dynamic stretches for lower back, hips, and legs~3. Main Activity~   A. Treadmill Walking:~   Speed: Comfortable pace for walking without pain~   Incline: Start flat, increase slightly (1-2%) if tolerated~   Goal: Promote cardiovascular endurance and safe weight-bearing activity~   B. Stationary Bicycle:~   Duration: 10-15 minutes~   Resistance: Low to moderate (enough to feel effort but no pain)~4. Cool-Down (5 minutes):~   Slow treadmill walking or easy pedaling on the bike~   Gentle stretches: hamstrings, hip flexors, lumbar rotation~5. Progression:~based on patient tolerance Gradually in"
219358149|NCT07178561|OTHER|Advices|Advices
219358150|NCT07178847|BIOLOGICAL|blood sampling|The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy
219358151|NCT07179042|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 119-days.
219358152|NCT07179042|DRUG|Metformin|Metformin tablets will be dispensed to the participants for 119-days.
219358153|NCT07177768|OTHER|Prolonged walking|walking on a treadmill for 60 minutes
219358154|NCT07179341|PROCEDURE|Thymectomy for thymic carcinoma|Thymectomy for thymic cancer
219358155|NCT07178522|BIOLOGICAL|Envacgen®|Subjects are to receive a 0.5 mL IM injection of Envacgen®. Study drug is administered on Day 1 and Day 57 of the study.
219358156|NCT07179159|DRUG|14-day vonoprazan-amoxicillin dual therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid
219358157|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + levofloxacin 500mg qd + bismuth 220mg bid
219358158|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid + bismuth 220mg bid
219358159|NCT04658862|BIOLOGICAL|Cetrelimab|Participants will receive intravenous Cetrelimab.
219358160|NCT04658862|DRUG|TAR-200|Participants will receive intravesical TAR-200.
219358161|NCT04658862|DRUG|Cisplatin|Participants will receive cisplatin intravenously.
219358162|NCT04658862|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously.
219358163|NCT04658862|RADIATION|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
219358164|NCT04658862|RADIATION|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
219358165|NCT06351592|DRUG|ALN-SOD|Administered by intrathecal (IT) injection
219358166|NCT06351592|OTHER|Diluent|Administered by IT injection
219358167|NCT06351592|DRUG|Placebo (PB)|Administered by IT injection
219358168|NCT03406897|DRUG|Cholecalciferol|Oral Administration
219358169|NCT03406897|DRUG|Omega 3 fatty acid|Oral Administration
219358170|NCT05925049|DRUG|Natalizumab|Administered as specified in the treatment arm.
219358171|NCT06549478|PROCEDURE|Computed Tomography|Undergo PET/CT
219358172|NCT06549478|RADIATION|Image Guided Radiation Therapy|Undergo BgRT
219358173|NCT06549478|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
219358174|NCT06549478|OTHER|Questionnaire Administration|Ancillary studies
219358176|NCT06241586|PROCEDURE|The novel PMMI surgical strategy|"Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals."
219358177|NCT06241586|PROCEDURE|The conventional step-up strategy|Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
219358178|NCT00598975|DRUG|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
219358179|NCT00598975|DRUG|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
219358180|NCT00598975|DRUG|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
219358181|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
219358182|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
219358183|NCT03858959|DEVICE|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
219358184|NCT04897490|OTHER|Evaluation of first line treatment with ATO/ATRA outcome|Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.
219358185|NCT00683319|DRUG|carboplatin|
219358186|NCT00683319|DRUG|cisplatin|
219358187|NCT00683319|DRUG|cyclophosphamide|
219358188|NCT00683319|DRUG|methotrexate|
219358189|NCT00683319|DRUG|vincristine sulfate|
219358190|NCT00683319|PROCEDURE|adjuvant therapy|
219358191|NCT00683319|PROCEDURE|cognitive assessment|
219358192|NCT00683319|PROCEDURE|magnetic resonance imaging|
219358193|NCT00683319|PROCEDURE|magnetic resonance spectroscopic imaging|
219358194|NCT00683319|PROCEDURE|quality-of-life assessment|
219358195|NCT00843908|DEVICE|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
219358196|NCT00843908|DEVICE|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
219358197|NCT06831162|OTHER|Multi-level HRSN initiative|The multi-level health-related social needs (HRSN) initiative includes multiple components aimed at assessing and addressing HRSN in clinical practice: HRSN screening, EHR tools for clinical decision support, training and tools for health care providers to address HRSN, care coordinator support for patient outreach, and community resources for referral and support.
219358198|NCT06833320|DRUG|Propranolol Hydrochloride|Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.
219358199|NCT06833320|DRUG|Placebo|Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle
219358200|NCT06163261|OTHER|Physical activity|The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
219358201|NCT06219174|DRUG|Pembrolizumab|200 mg IV Q3 weeks
219358202|NCT06219174|DRUG|Difluoromethylornithine|Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
219358203|NCT04392947|DEVICE|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
219358204|NCT04392947|DEVICE|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
219361956|NCT05989906|BEHAVIORAL|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
219361957|NCT05989906|BEHAVIORAL|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
219358205|NCT04415476|DRUG|Assigned Interventions|This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
219358206|NCT05450718|DRUG|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
219358207|NCT05450718|DRUG|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
219358208|NCT04594291|PROCEDURE|MRI scans|This study does not involve any intervention or new treatment. We will conduct MRI scans of the kidneys, muscles, abdomen and heart at baseline, 12 and 24 months after hospital discharge. The MRI scan will take 60-70 minutes in total.
219358209|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^12 vg administered intramuscularly
219358210|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^13 vg administered intramuscularly
219358211|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|8x10\^13 vg administered intramuscularly
219358212|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|1.2x10\^14 vg administered intramuscularly
219358213|NCT06451432|PROCEDURE|Percutaneous Inguinal Ring Suturing (PIRS) technique|Percutaneous Inguinal Ring Suturing (PIRS) technique
219358214|NCT01158339|BEHAVIORAL|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
219358215|NCT01158339|BEHAVIORAL|Arm 1: CBGT|Intervention according to previously mentioned methods.
219358216|NCT03159312|BEHAVIORAL|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
219358217|NCT03546075|DIETARY_SUPPLEMENT|Resveratrol|
219358218|NCT03546075|OTHER|Placebo|
219358219|NCT00505453|BIOLOGICAL|Fluviral®|
219358220|NCT04654858|PROCEDURE|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
219358221|NCT03346408|BEHAVIORAL|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
219358222|NCT01931761|DRUG|[C14] selumetinib (oral)|Single oral administration \[C14\] 75mg
219358223|NCT01324284|DRUG|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
219358224|NCT05148871|BIOLOGICAL|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
219358225|NCT06173999|DRUG|SHR2554/CHOP|SHR2554 with CHOP
219358226|NCT06173999|DRUG|SHR2554/CHOEP|SHR2554 with CHOEP
219358227|NCT04573673|DEVICE|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
219358228|NCT04573673|DEVICE|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
219358229|NCT01206881|DRUG|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
219358230|NCT02066792|DRUG|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
219358231|NCT02066792|DRUG|Placebo|Sugar pill
219358232|NCT02066792|BEHAVIORAL|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
219358233|NCT04544722|BEHAVIORAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
219358234|NCT04544722|BEHAVIORAL|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
219358235|NCT03790241|PROCEDURE|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
219365679|NCT00865020|DRUG|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
219365680|NCT00910156|DEVICE|Airtraq laryngoscope|Airtraq intubation
219365681|NCT00910156|DEVICE|Glidescope laryngoscope|glidescope intubation
219358236|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
219358237|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
219358238|NCT05504109|PROCEDURE|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
219358239|NCT05504109|PROCEDURE|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
219358240|NCT06036966|DRUG|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
219358241|NCT05421000|PROCEDURE|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
219358242|NCT05421000|PROCEDURE|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
219358243|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
219358244|NCT05750485|OTHER|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
219358245|NCT06111339|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
219358246|NCT06111339|OTHER|Saline Solution|The placebo will be a 0.9% saline solution administered over 40 minutes.
219358247|NCT04669678|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
219358248|NCT04669678|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
219358249|NCT04669678|DRUG|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
219358250|NCT04669678|DEVICE|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
219358251|NCT05155579|BIOLOGICAL|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
219358252|NCT05155579|BIOLOGICAL|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
219358253|NCT05155579|BIOLOGICAL|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
219358254|NCT05155579|BIOLOGICAL|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
219358255|NCT05155579|BIOLOGICAL|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
219358256|NCT05155579|BIOLOGICAL|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
219358257|NCT05155579|BIOLOGICAL|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
219358258|NCT05155579|BIOLOGICAL|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
219358259|NCT05155579|BIOLOGICAL|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
219358260|NCT05227690|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
219358261|NCT05227690|DRUG|Emraclidine 10 mg|Emraclidine 10 mg, oral (tablet), once per day for 6 weeks
219358262|NCT05227690|DRUG|Emraclidine 30 mg|Emraclidine 30 mg, oral (tablet), once per day for 6 weeks
219358263|NCT05226260|BEHAVIORAL|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
219358264|NCT05794061|BEHAVIORAL|Neuropsychological instruments|Cognitive and behavioral tests and questionnaires
219358265|NCT03868293|DEVICE|Focused ultrasound|Pulsed low intensity focused ultrasound
219360108|NCT04879797|OTHER|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
219360109|NCT04879797|OTHER|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
219365682|NCT00910156|DEVICE|Macintosh laryngoscope|Macintosh intubation
219358266|NCT06355804|BEHAVIORAL|Physical activity condition|"Participants will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide behavioral strategies such as information on the benefits of physical activity, goal setting and monitoring, for increasing and maintaining physical activity levels.~  * Throughout the 16-week period, the investigators will ask participants to wear a Fitbit and record step count into a logbook daily for tracking physical activity.~ * The newsletter will be emailed to participants weekly throughout the program. The newsletters include knowledge, skills, and resources related to physical activity in the early stages of MS.~* The program also involves 7 1-on-1 coaching chats with a coach to guide participants through the program and navigate challenges. These chats are conducted over Zoom and generally last about 15 - 30 minutes each. These sessions will not be recorded."
219358267|NCT06355804|BEHAVIORAL|Waitlist condition|"Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide information on the benefits of physical activity, goal setting and monitoring, and other behavioral strategies for increasing and maintaining physical activity levels.~  * The newsletter will be emailed to participants weekly throughout the program.~ * Content on the newsletter includes knowledge and skills related to physical activity in the early stages of MS, text of individuals with MS discussing their experiences, web links, worksheets, and brochures.~* The program also involves 7 one-on-one video coaching chats with a behavioral coach to guide participants through the program and navigate challenges. These chats are conducted face- to-face over Zoom and generally last about 15 - 30 minutes each. The investigators do not record these sessions."
219358268|NCT03479632|BEHAVIORAL|Aerobic walking program|Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
219358269|NCT03479632|BEHAVIORAL|Standard physical therapy|Participants will receive standard care they normally would after a stroke.
219358270|NCT02245828|DRUG|QCC374|Single and multiple ascending doses of QCC374
219358271|NCT02245828|DRUG|Placebo|Placebo comparator
219358272|NCT04788420|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
219358273|NCT04033367|DRUG|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219358274|NCT04033367|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
219358275|NCT02723201|DRUG|TAK-020 Captisol Oral Solution|TAK-020 solution.
219358276|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet
219358277|NCT02723201|DRUG|TAK-020 SDT|TAK-020 Solid dispersion tablet.
219358278|NCT02723201|DRUG|TAK-020 IRT|TAK-020 immediate release tablet.
219358279|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet.
219358280|NCT02723201|DRUG|TAK-020 Solid Formulation|TAK-020 solid formulation
219358281|NCT05714202|DRUG|TAR-200|TAR-200 will be administered intravesically.
219358282|NCT05714202|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
219358283|NCT05714202|BIOLOGICAL|BCG Vesiculture|BCG will be administered intravesically.
219358284|NCT03472560|DRUG|Avelumab (MSB0010718C)|IV treatment: Avelumab administered at 800 mg IV every two weeks
219358285|NCT03472560|DRUG|Axitinib (AG-013736)|Oral treatment: Axitinib given 5 mg PO BID
219358286|NCT01597063|DEVICE|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
219358287|NCT05374707|BEHAVIORAL|MOTIVATIONAL INTERVIEWING|Motivational interviewing is a form of interview conducted with a patient-centered approach in order to enable people to discover and solve the obstacles to behavior change.
219358288|NCT00485888|DRUG|Cipralex|10-20mg; one per day
219358289|NCT00485888|DRUG|Placebo|Matched to Cipralex
219358290|NCT06010914|OTHER|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
219358291|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
219358292|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
219358293|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
219358294|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
219358295|NCT06355570|OTHER|Personal Pictures|Digital photos will be shown continuously at the patient's bedside for 12 hours a day (between 8 am to 8 pm).
219358296|NCT06355570|OTHER|Family Videos|Family-recorded videos will be played three times at specific hours of the day - 9 am, 2 pm and 7 pm - throughout patient stay in the ICU
219358297|NCT06355570|OTHER|Family Videos - Intervention as required|The last video shown will be re-played upon patient request and/or if patients develop ICU delirium.
219358298|NCT01082315|DRUG|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
219358299|NCT01197365|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
219358300|NCT01197365|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
219358301|NCT00098917|DRUG|autologous tumor cell vaccine|
219358302|NCT00098917|DRUG|therapeutic autologous dendritic cells|
219358303|NCT00098917|PROCEDURE|adjuvant therapy|
219358304|NCT00098917|PROCEDURE|biological therapy|
219358305|NCT00098917|PROCEDURE|conventional surgery|
219358306|NCT00098917|PROCEDURE|surgery|
219358307|NCT00098917|PROCEDURE|tumor cell derivative vaccine|
219358308|NCT00098917|PROCEDURE|vaccine therapy|
219358309|NCT04010669|DRUG|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
219358310|NCT04010669|DRUG|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
219358311|NCT05307315|OTHER|listening to music|The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
219358312|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
219358313|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
219358314|NCT06068387|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
219358315|NCT04269395|DRUG|MAL Cream|No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
219358316|NCT04269395|DRUG|Vehicle cream|No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
219358317|NCT00524056|DRUG|Carisbamate|two 100 mg tablets twice per day
219358318|NCT00524056|DRUG|Placebo|two placebo tablets twice per day
219358319|NCT06323174|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
219358320|NCT06323174|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
219358321|NCT06323174|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
219358322|NCT05132881|OTHER|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
219358323|NCT05132881|OTHER|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
219358324|NCT05132881|OTHER|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
219358325|NCT05132881|OTHER|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
219358326|NCT04141657|OTHER|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
219358327|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
219358328|NCT03529773|BIOLOGICAL|Formulation A|RSV vaccine
219358329|NCT03529773|BIOLOGICAL|Formulation B|RSV vaccine
219358330|NCT03529773|BIOLOGICAL|Placebo|Placebo
219358331|NCT04847661|DRUG|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
219358332|NCT03054610|DRUG|Betamethason Sodium Phosphate|
219358333|NCT03054610|DRUG|Ropivacaine|
219358334|NCT03054610|DRUG|Botulinum Toxins, Type A|
219358335|NCT02341378|BIOLOGICAL|TissueGene-C(Low dose)|TissueGene-C at 6.0x10\^6 cells
219358336|NCT02341378|BIOLOGICAL|TissueGene-C(High dose)|TissueGene-C at 1.8x10\^7 cells
219358337|NCT00835471|DRUG|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
219358338|NCT00835471|DRUG|erlotinib|erlotinib 150 mg/day continuously until disease progression
219358339|NCT00006255|PROCEDURE|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
219358340|NCT00006255|PROCEDURE|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
219358341|NCT01236430|DRUG|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
219358342|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
219358343|NCT01236430|DRUG|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
219358344|NCT01236430|DRUG|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
219358345|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
219358346|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
219358347|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
219358348|NCT05229107|DEVICE|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
219358349|NCT05370859|OTHER|There is no intervention for this study|There is no intervention or exposure for this study
219358350|NCT02205060|OTHER|virtual reality exposure treatment|
219358351|NCT02205060|OTHER|cognitive and behavioral approaches therapy|
219358352|NCT05012293|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
219358353|NCT05012293|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
219358354|NCT06149858|PROCEDURE|hernioplasty|ventral hernia repair with mesh
219358355|NCT04221880|DRUG|Bupivacaine Hcl 0.25% Inj|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
219358356|NCT04221880|DRUG|Saline Solution for Block|Ultrasound-guided erector spinae plane block with 20 ml saline
219358357|NCT04221880|DRUG|Saline Solution intravenously|Same volume saline solution bolus and infusion as Group Lidocaine
219358358|NCT04221880|DRUG|Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
219358359|NCT02893449|BEHAVIORAL|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
219358360|NCT02893449|BEHAVIORAL|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
219358361|NCT02893449|PROCEDURE|Deep brain stimulation|
219358362|NCT04991298|DRUG|Oral premedication|Oral anesthesia premedication for congenital Cardiac surgery
219358363|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
219358364|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
219358365|NCT02595190|PROCEDURE|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
219358366|NCT02595190|DRUG|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
219358367|NCT02595190|DEVICE|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
219358368|NCT03445078|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
219358369|NCT03445078|DIETARY_SUPPLEMENT|ordinary corn powder|ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
219358370|NCT00533078|DIETARY_SUPPLEMENT|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
219358371|NCT04561154|OTHER|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
219358372|NCT02776163|DRUG|Nedaplatin|nedaplatin 35mg/m\^2，D1-2，2 cycles
219358373|NCT02776163|DRUG|Docetaxel|Docetaxel 70mg/m\^2，D1，2 cycles
219358374|NCT02776163|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks
219358375|NCT03414580|PROCEDURE|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
219360110|NCT03414957|DIAGNOSTIC_TEST|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
219365683|NCT03641560|DRUG|Enzalutamide|Enzalutamide was administered orally
219358376|NCT00857870|DRUG|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
219358377|NCT00857870|DRUG|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
219358378|NCT02007174|DRUG|Bevacizumab|
219358379|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
219358380|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
219358381|NCT02007174|PROCEDURE|Argon laser treatment|
219358382|NCT03567070|OTHER|qualitative study based on an individual clinical interview|qualitative study based on an individual clinical interview
219358383|NCT02642978|PROCEDURE|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
219358384|NCT02642978|PROCEDURE|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
219358385|NCT01625780|PROCEDURE|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
219358386|NCT01625780|PROCEDURE|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
219358387|NCT04867798|DRUG|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels \<1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
219358388|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6|Vitamin B-6 50 mg/d
219358389|NCT01964001|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg
219358390|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
219358391|NCT01964001|OTHER|Placebo|starch
219358392|NCT00450931|OTHER|counseling intervention|
219358393|NCT00450931|OTHER|educational intervention|
219358394|NCT03937856|BEHAVIORAL|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
219358395|NCT04369898|OTHER|Image analysis/ Central vein detection|Image analysis/ Central vein detection will be performed using a fully automated approach based on an ensemble of 3D convolutional neural Networks. The method is applied to T1w, T2w and T2\*w data . Results will be manually reviewed by 2 experts in CVs detection. MRI data must have been collected at 3 Tesla (3T) between 1990 and 2020 and must include T1 w, T2 w, T2-star based sequence (CVs detection).
219358396|NCT04369898|OTHER|Image analysis/ Automatic cortical lesion detection|Image analysis/ Automatic cortical lesion detection will be performed by using a convolutional neural network-based method. MRI data must have been collected at 3T between 1990 and 2020 and must include Double inversion recovery (DIR)/Phase-Sensitive Inversion Recovery (PSIR)/Magnetization Prepared - 2- RApid Gradient Echo Gradient Echo (MP2RAGE) (eventually also high spatial resolution Magnetization Prepared - RApid Gradient Echo (MPRAGE)) for cortical lesion detection.
219358397|NCT04456439|BIOLOGICAL|Remestemcel-L|Participants may receive up to 2 infusions of 2 x 10\^6 remestemcel-L within a 5-day period.
219358398|NCT04456439|DRUG|Hydrocortisone|Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
219358399|NCT04456439|DRUG|Diphenhydramine|Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
219358400|NCT02475655|DRUG|Ruxolitinib|10 mg orally twice daily for 5 weeks
219358401|NCT01411969|DRUG|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
219358402|NCT04293770|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
219358403|NCT01877564|DRUG|Metformin|
219358404|NCT01936532|DRUG|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
219358405|NCT01936532|DRUG|Lenalidomide|
219358406|NCT01936532|DRUG|Dexamethasone|
219358407|NCT06463067|BEHAVIORAL|playing mobile game|Changes in anxiety levels were measured by playing a mobile game to children before dental examination.
219358408|NCT06463067|BEHAVIORAL|reading book|Changes in anxiety levels were measured by reading books to children before dental examination.
219358409|NCT06463067|BEHAVIORAL|watching video|Changes in anxiety levels were measured by showing a video to children before dental examination.
219358410|NCT06463067|BEHAVIORAL|tell-show-do group|Before the dental examination, the tell-show-do technique was applied to the children and the changes in their anxiety levels were measured.
219358411|NCT04082195|OTHER|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
219358412|NCT04082195|OTHER|Uno board game|A popular board game which is not a mobile app.
219358413|NCT03545906|OTHER|TEAM-UP Intervention Group|Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.
219358414|NCT03545906|OTHER|Enhanced Care Comparison|Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
219358415|NCT03973281|DEVICE|Materna Prep Device|Materna Prep Device
219358416|NCT03973281|OTHER|Standard of Care (SOC)|Standard of Care (SOC)
219358417|NCT01017107|DRUG|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
219358418|NCT05625776|PROCEDURE|pain delivery with capsaicin and heat|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
219358419|NCT05625776|PROCEDURE|distractor delivery with sensory TENS|Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
219358420|NCT06156085|DRUG|Vonoprazan and Amoxicillin|vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days
219358421|NCT06156085|DRUG|Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole|lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
219358422|NCT03622697|BEHAVIORAL|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
219358423|NCT00197054|BIOLOGICAL|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
219358424|NCT00197054|BIOLOGICAL|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
219358425|NCT00197054|BIOLOGICAL|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
219358426|NCT02494531|RADIATION|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
219358427|NCT02494531|RADIATION|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
219358428|NCT03529877|BIOLOGICAL|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
219358429|NCT06300853|OTHER|Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses|"Whole blood and serum samples will be longitudinally collected at the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1). Possible further time points will be collected within 2 years, based on the National recommended future vaccination regimens.~Biological samples will be used for the following exams:~* Cellular immunity characterization~  * T- and B-cells Immunophenotype.~ * Specific T-cell response.~ * In vitro specific B-cells characterization.~ * Antibody-dependent cellular cytotoxicity.~* Humoral response characterization~  * Serology assays.~ * Avidity assay.~ * Neutralization assays with different SARS-CoV-2 variants.~ * Presence of specific or cross-reactive antibodies for common hCoV.~* Genetic and epigenetic analysis"
219358430|NCT04232735|OTHER|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
219358431|NCT03728946|DRUG|Liposomal Bupivacaine|Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
219358432|NCT03244033|OTHER|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
219358433|NCT03244033|BEHAVIORAL|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
219358434|NCT00859703|DRUG|Risedronate|35mg oral risedronate once per week for 24 months
219358435|NCT00859703|DRUG|Placebo|Placebo 35 mg once a week for 24 months
219358436|NCT02272686|DRUG|Ibrutinib|560 mg by mouth daily.
219358437|NCT04464213|OTHER|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
219358438|NCT04464213|OTHER|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
219358439|NCT05340985|DIETARY_SUPPLEMENT|25(OH)D3|calcifediol
219358440|NCT05340985|DIETARY_SUPPLEMENT|vitamin D3|Cholecalciferol
219358441|NCT01699087|PROCEDURE|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
219358442|NCT01699087|DEVICE|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
219358443|NCT06455514|DRUG|Magnesium Sulfate|4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
219358444|NCT06455514|DRUG|Saline|Control subjects will receive an equivalent volume of normal saline intravenously.
219358445|NCT04210466|BEHAVIORAL|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
219358446|NCT04210466|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q\&A 1 Session 4: Q\&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
219358447|NCT04168294|DRUG|Propofol|patients in sedation group will be intravenous injected propofol in bolus
219358448|NCT04168294|DEVICE|endoscopy|endoscopy system
219358449|NCT03021642|DRUG|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
219358450|NCT03021642|DRUG|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
219358451|NCT03021642|DRUG|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
219358452|NCT03021642|DRUG|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
219358453|NCT04282772|DIAGNOSTIC_TEST|Impacted|Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position
219358454|NCT04282772|DIAGNOSTIC_TEST|Self-corrected|The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
219358455|NCT02474082|BIOLOGICAL|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
219358456|NCT02474082|DRUG|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
219358457|NCT03389282|DIAGNOSTIC_TEST|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
219358458|NCT00003100|DIETARY_SUPPLEMENT|soy isoflavones|
219358459|NCT03452371|BEHAVIORAL|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
219358460|NCT03452371|BEHAVIORAL|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
219358461|NCT00002147|DRUG|Doxorubicin hydrochloride (liposomal)|
219358462|NCT01792908|DEVICE|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
219358463|NCT03355508|DEVICE|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
219358464|NCT04044755|OTHER|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
219358465|NCT04283903|DIAGNOSTIC_TEST|PICF|PICF collection from 4 sites
219358466|NCT00495651|DRUG|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
219358467|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
219358468|NCT00495651|DRUG|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
219358469|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
219358470|NCT05988151|OTHER|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
219358471|NCT00266253|DRUG|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
219358472|NCT00266253|DRUG|Metformin|As prescribed, for 12 weeks
219358473|NCT03970187|OTHER|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
219358474|NCT03067272|DEVICE|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
219358475|NCT03828929|DRUG|Vitamin C|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
219358476|NCT03828929|DRUG|Normal saline|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
219358477|NCT05320900|DIAGNOSTIC_TEST|Chest auscultation|Chest auscultation data
219358478|NCT00289263|DRUG|Paclitaxel|
219358479|NCT06221475|DRUG|BAY2927088 coated tablet 10 mg|4 coated tablets (10 mg) per single dose 30 min after a light meal
219358480|NCT06221475|DRUG|[14C]-BAY2927088 solution for infusion|IV infusion 15 min ending at 2 hours oral post-dose
219358481|NCT06221475|DRUG|[14C]-BAY2927088 oral solution|After a light meal
219358482|NCT03543514|OTHER|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~* Control with the 6-minute walking test and podometer of physical activity~* Dietary advice to be able to perform a hyperproteic diet~* Mindfullnes to improve the emotional level."
219358483|NCT01197287|DRUG|QAK423A|
219358484|NCT01197287|DRUG|QAK423A|
219358485|NCT01197287|DRUG|QAK423A|
219358486|NCT02899039|BIOLOGICAL|extra blood draw samples|
219358487|NCT00566930|OTHER|spinal manipulation|Monthly cervical spinal manipulation
219358488|NCT00566930|OTHER|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
219358489|NCT05827029|PROCEDURE|Preopertive drink|"* Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
219358490|NCT01681550|DRUG|Incretin-based therapy|
219358491|NCT04304027|OTHER|Tailored exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
219358492|NCT04304027|OTHER|Standard exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at \>70% heart rate reserve followed by 2 minutes working rest
219358493|NCT05465356|OTHER|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
219358494|NCT05465356|OTHER|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
219358495|NCT05743465|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
219358496|NCT00732095|BEHAVIORAL|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
219358497|NCT00379795|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
219358498|NCT01127165|DRUG|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.
219358499|NCT01127165|DRUG|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
219360111|NCT03462095|PROCEDURE|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
219358500|NCT05649293|OTHER|measure vitamin b6 in serum|"* Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results ."
219358501|NCT02475642|OTHER|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
219358502|NCT02475642|OTHER|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
219358503|NCT03250403|DRUG|PRP injection|peri-neural injection of platelet rich plasma
219358504|NCT03250403|OTHER|traditional medical treatment|traditional medical treatment
219358505|NCT03077568|BEHAVIORAL|My Stress Control|"The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.~The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.~Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals."
219358506|NCT00763321|DRUG|ABT-712|ABT-712 extended-release tablet
219358507|NCT00763321|DRUG|Placebo|Placebo tablet
219358508|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 12 mg|Capsule with 12 mg cafestol
219358509|NCT04911582|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
219358510|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 6 mg|Capsule with 6 mg cafestol
219358511|NCT03175549|DRUG|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
219358512|NCT03175549|DRUG|Placebo|Identical placebo pills taken orally for 14 days
219358513|NCT02435849|BIOLOGICAL|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
219358514|NCT00613457|DRUG|dexamethasone|10 mg/sqm/day from for 21 days
219358515|NCT00613457|DRUG|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
219358516|NCT00613457|DRUG|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
219358517|NCT00613457|DRUG|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
219358518|NCT00613457|DRUG|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
219358519|NCT00613457|DRUG|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
219358520|NCT00613457|DRUG|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
219358521|NCT00613457|DRUG|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
219358522|NCT00613457|DRUG|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
219358523|NCT00613457|DRUG|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
219358524|NCT00613457|DRUG|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
219358525|NCT00613457|DRUG|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
219358526|NCT00613457|DRUG|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
219358527|NCT00613457|DRUG|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
219358528|NCT00613457|DRUG|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
219358529|NCT02486757|DRUG|micronized progesterone|
219358530|NCT02486757|DRUG|transdermal estradiol|
219358531|NCT04069052|DRUG|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
219358532|NCT04069052|DRUG|Placebo|Room air (placebo) flowed into a mask and breathed in.
219358533|NCT05836792|OTHER|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
219358534|NCT05836792|DEVICE|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
219358535|NCT05836792|DEVICE|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
219358536|NCT05836792|OTHER|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
219358537|NCT01302873|DRUG|BGG492A|
219358538|NCT01302873|DRUG|BGG492A|
219358539|NCT01017952|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
219358540|NCT01017952|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
219358541|NCT02666014|DRUG|Sugammadex|Reversal of neuromuscular blockade
219358542|NCT02666014|DRUG|Neostigmine|Reversal of neuromuscular blockade
219358543|NCT01395992|DRUG|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
219358544|NCT01395992|DRUG|asenapine|asenapine 10 mg tablet, SL BID for 182 days
219358545|NCT00031161|DRUG|Nitisinone (NTBC)|
219358546|NCT00031161|DRUG|Dichloroacetate|
219358547|NCT00031161|BEHAVIORAL|Low-tyrosin diet|
219358548|NCT00264914|DRUG|SR121463B|
219358549|NCT02443064|DRUG|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
219358550|NCT01615848|OTHER|mediterranean diet restricted calorie|1500 k/cal 30% fat
219358551|NCT01615848|OTHER|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
219358552|NCT01615848|OTHER|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
219358553|NCT04702646|DRUG|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
219358554|NCT04702646|PROCEDURE|Colonoscopy|colonoscopy will be performed to every patient included in the study
219358555|NCT04849780|DEVICE|ACUVUE Oasys 1-Day|TEST
219358556|NCT04849780|DEVICE|Habitual Lens|Subjects' own Habitual Lenses
219358557|NCT05408520|PROCEDURE|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
219358558|NCT04293679|DRUG|STP705|Investigational Product
219358559|NCT03965559|PROCEDURE|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]"
219358560|NCT03823612|DRUG|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
219358561|NCT03823612|DRUG|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
219358562|NCT06421220|PROCEDURE|Preoperative injection of indocyanine green|Submucosal injection of indocyanine green into the gastric mucosa prior to surgery， indocyanine green，25mg，powder，once
219358563|NCT04680611|OTHER|no study intervention. Patients receive standard clinical care|no intervention. observational study
219358564|NCT00876135|DRUG|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
219358565|NCT02372487|DRUG|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
219358566|NCT02372487|DIETARY_SUPPLEMENT|fluid therapy|2 liters of fluid per day
219358567|NCT06270979|DEVICE|ISHA|Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).
219358568|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
219358569|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
219358570|NCT03032276|OTHER|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH\&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
219358571|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
219358572|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
219358573|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
219358574|NCT06437938|OTHER|Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold|To be taken according to the information in the study protocol/patient information leaflet.
219358575|NCT06437938|OTHER|Placebo group 2: Placebo powder corresponding to Wasabi leaf powder|To be taken according to the information in the study protocol/patient information leaflet.
219358576|NCT03276611|OTHER|echocardiograghy|transthoracic echocardiograghy
219358577|NCT05405647|DEVICE|Shock wave Therapy|a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
219358578|NCT05405647|DEVICE|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
219358579|NCT01819779|DRUG|Exforge tab. 10/160mg|
219358580|NCT01819779|DRUG|Lodivixx tab. 5/160mg|
219358581|NCT03460431|DEVICE|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
219358582|NCT03460431|DEVICE|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
219358583|NCT06182592|DRUG|Liposomal cytarabine-daunorubicin for injection|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
219358584|NCT06182592|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2."
219358585|NCT04228185|PROCEDURE|sleeve gastrectomy|Comparison of banded and not-banded sleeve gastrectomy
219358586|NCT01278498|DRUG|Escitalopram|first week:5mg 2nd week\~12 week:10mg
219358587|NCT01278498|DRUG|sugar pill|first week:5mg 2nd week\~12 weeks:10mg
219358588|NCT03032952|OTHER|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
219358589|NCT02281019|PROCEDURE|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
219358590|NCT02281019|DEVICE|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
219358591|NCT02444273|PROCEDURE|Exercise|Subjects will be given and individualized exercise program.
219358592|NCT01046500|DIETARY_SUPPLEMENT|myo-inositol|2 grams twice a day
219358593|NCT01046500|DRUG|Metformin|pill, 250 mg, twice a day
219358594|NCT03654846|DEVICE|EmergencyEye|EmergencyEye Smartphone App
219358595|NCT06438315|OTHER|No intervention|No intervention
219358596|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
219358597|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
219358598|NCT03650192|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
219358599|NCT01359475|PROCEDURE|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
219358600|NCT04125355|OTHER|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
219358601|NCT04125355|OTHER|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
219358602|NCT04995146|OTHER|Clinical stroke extended management pathway|"1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS"
219358603|NCT02468791|DRUG|Rituximab|
219358604|NCT00047138|BIOLOGICAL|dactinomycin|
219358605|NCT00047138|DRUG|carboplatin|
219358606|NCT00047138|DRUG|cyclophosphamide|
219358607|NCT00047138|DRUG|doxorubicin hydrochloride|
219358608|NCT00047138|DRUG|etoposide|
219358609|NCT00047138|DRUG|vincristine sulfate|
219358610|NCT00047138|PROCEDURE|adjuvant therapy|
219358611|NCT00047138|PROCEDURE|conventional surgery|
219358612|NCT00047138|PROCEDURE|neoadjuvant therapy|
219358613|NCT00047138|RADIATION|radiation therapy|
219358614|NCT02285725|PROCEDURE|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
219358615|NCT02285725|PROCEDURE|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
219358616|NCT04800198|PROCEDURE|non-invasive ventilation|none, measurements only
219358617|NCT01665144|DRUG|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
219358618|NCT01665144|DRUG|Placebo|Film-coated tablets
219358619|NCT01221428|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
219358620|NCT04520113|BEHAVIORAL|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
219358621|NCT01913483|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
219358622|NCT01913483|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
219358623|NCT05365763|BEHAVIORAL|Simulated telehealth serious illness conversation visit|"The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors."
219358624|NCT01459458|BEHAVIORAL|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
219358625|NCT02302963|DEVICE|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
219358626|NCT02302963|DEVICE|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
219358627|NCT00368771|BEHAVIORAL|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
219358628|NCT00368771|BEHAVIORAL|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
219358629|NCT00368771|BEHAVIORAL|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
219358630|NCT00294112|DRUG|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
219358631|NCT00294112|DRUG|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
219358632|NCT00003887|BIOLOGICAL|peripheral blood lymphocyte therapy|
219358633|NCT00870753|BEHAVIORAL|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
219358634|NCT06447467|DIAGNOSTIC_TEST|pro BNP|Test is mainly used to help diagnose or rule out heart failure in a person who is having symptoms
219358635|NCT01816243|DRUG|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
219358636|NCT01816243|DRUG|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
219358637|NCT02916420|DRUG|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
219358638|NCT02916420|DRUG|Dexamethasone|≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
219358639|NCT05343065|DEVICE|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
219358640|NCT05498688|DIETARY_SUPPLEMENT|Low carbohydrate|Participants will have a low carbohydrate meal
219358641|NCT05893849|DRUG|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
219358642|NCT03515109|PROCEDURE|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
219358643|NCT03515109|PROCEDURE|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
219358644|NCT01459250|DRUG|AGO178C|
219358645|NCT05749614|DRUG|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
219358646|NCT05749614|DRUG|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
219358647|NCT00191594|DRUG|Duloxetine Hydrochloride|
219358648|NCT02972164|BEHAVIORAL|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
219358649|NCT02911428|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
219358650|NCT01049763|DRUG|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
219358651|NCT05718986|OTHER|No intervention|No intervention
219358652|NCT00915343|DRUG|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
219358653|NCT00915343|DRUG|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
219358654|NCT00630630|DRUG|Levetiracetam|
219358655|NCT00630630|OTHER|Placebo|
219358656|NCT05117775|OTHER|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
219358657|NCT02817412|BEHAVIORAL|Go/No-Training|
219358658|NCT02817412|BEHAVIORAL|Stop-Signal Training|
219358659|NCT02817412|BEHAVIORAL|Dot-Probe Paradigm|
219358660|NCT02817412|BEHAVIORAL|Generic Response Training|
219358661|NCT04354350|DRUG|Ramipril|Ramipril dispensing claim is used as the reference
219358662|NCT04354350|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
219358663|NCT05066243|OTHER|questionnaire|this study is to develop a questionnaire for vulval conditions
219358664|NCT02349698|BIOLOGICAL|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
219358665|NCT06251232|DRUG|Prednisone|Placebo
219358666|NCT01634438|DRUG|unfractionated heparin|unfractionated heparin
219358667|NCT02780882|DRUG|Pasireotide|
219358668|NCT02170272|BEHAVIORAL|Home-based Lymphedema Care Program|Undergo HBLCP
219358669|NCT01920711|DRUG|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
219358670|NCT01920711|DRUG|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
219358671|NCT03944239|BIOLOGICAL|Retinal pigment epitheliums transplantation|Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
219358672|NCT03949270|BEHAVIORAL|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
219358673|NCT01664780|DEVICE|ARFI imaging|
219358674|NCT05080010|DRUG|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
219358675|NCT00006465|DRUG|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
219358676|NCT00006465|DRUG|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
219358677|NCT00006465|DRUG|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
219358678|NCT05294744|DRUG|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
219358679|NCT06084130|DRUG|Zolpidem|10 milligrams zolpidem contained in white-color opaque medicine capsule
219358680|NCT06084130|DRUG|Placebo|corn-starch contained in identical white-color opaque medicine capsule
219358681|NCT04598373|BEHAVIORAL|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
219358682|NCT04172051|BEHAVIORAL|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
219358683|NCT04884555|OTHER|Standard neurorehabilitation|Routine post-stroke rehabilitation
219358684|NCT04884555|DIAGNOSTIC_TEST|Thiol-Disulphide Homeostasis|Monitoring the levels of thiol and disulphide in serum
219358685|NCT04884555|DIAGNOSTIC_TEST|Oxidized-reduced Glutathione Homeostasis|Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
219358686|NCT06507163|OTHER|The post-surgical breathing exercise group|Individuals in the Intervention-1 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.
219358687|NCT06507163|OTHER|The pre- and post- surgical breathing exercise group|Individuals in the Intervention-2 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
219358688|NCT00286676|DRUG|Nutropin|
219358689|NCT00286676|PROCEDURE|Oral Glucose Tolerance Test|
219358690|NCT00286676|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
219358691|NCT00286676|PROCEDURE|Computed Tomography (CT) Scan|
219358692|NCT00176111|PROCEDURE|peripheral nerve stimulation (procedure)|
219358693|NCT04041882|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
219362318|NCT02596659|PROCEDURE|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
219365684|NCT03641560|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
219365685|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
219365686|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
219365687|NCT06333145|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
219365688|NCT06960174|DEVICE|Virtual reality|If the participant is assigned to the intervention group a 3D virtual model will be constructed. For the intervention group the CT + VR will be reviewed during preoperative planning.
219365689|NCT06961149|PROCEDURE|Chromoendoscopy with indigo carmine solution spray|Patients will undergo chromoendoscopy with spraying indigo carmine.
219365690|NCT06961149|PROCEDURE|Linked-color imaging endoscopy|Patients will undergo Linked-color imaging endoscopy.
219365691|NCT04837417|DIAGNOSTIC_TEST|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
219365692|NCT05231213|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
219365693|NCT05231213|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
219365694|NCT05900115|BEHAVIORAL|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
219365695|NCT05900115|BEHAVIORAL|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
219365696|NCT05906394|PROCEDURE|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
219365697|NCT02796573|BEHAVIORAL|cognitive behavioural therapy|
219365698|NCT03782454|DIAGNOSTIC_TEST|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
219365699|NCT00619502|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
219365700|NCT04993625|PROCEDURE|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
219365701|NCT01812902|PROCEDURE|Radical Prostatectomy|
219365702|NCT00771472|DRUG|vorinostat|Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
219365703|NCT00412477|BIOLOGICAL|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
219365704|NCT01909284|DEVICE|Acupuncture|"* BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~* Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
219365705|NCT01909284|PROCEDURE|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
219365706|NCT03185689|BEHAVIORAL|Effectiveness of an intensified DSME in T2D adult patients|
219365707|NCT00845195|DRUG|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
219365708|NCT00845195|DRUG|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
219365709|NCT01420510|DRUG|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
219365710|NCT01420510|DRUG|Placebo vaginal gel|Application of a placebo vaginal gel
219365711|NCT00880750|DRUG|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
219365712|NCT00880750|DRUG|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
219365713|NCT02285179|DRUG|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
219365714|NCT02285179|DRUG|Tamoxifen|daily dose of 20 mg
219365715|NCT03890809|DRUG|BMS-986165|Oral administration
219365855|NCT01291901|BIOLOGICAL|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
219366733|NCT01078766|OTHER|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
219366734|NCT03880201|PROCEDURE|ultrasound guided supraclavicular block|"The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves."
219366735|NCT03880201|DEVICE|Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)|Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
219366736|NCT04217369|DEVICE|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
219366737|NCT00579813|DRUG|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
219366738|NCT05435820|DEVICE|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
219366739|NCT01810679|DEVICE|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
219366740|NCT00362973|OTHER|laboratory biomarker analysis|
219366741|NCT00362973|PROCEDURE|needle biopsy|
219366742|NCT00362973|PROCEDURE|positron emission tomography|
219366743|NCT00362973|PROCEDURE|radionuclide imaging|
219366744|NCT00362973|RADIATION|fludeoxyglucose F 18|
219366745|NCT03172689|DEVICE|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
219366746|NCT02006771|OTHER|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
219366747|NCT02006771|OTHER|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
219366748|NCT02006771|OTHER|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
219366749|NCT02006771|OTHER|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
219366750|NCT04171609|BEHAVIORAL|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
219366751|NCT05183919|OTHER|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
219366752|NCT01338467|DEVICE|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
219366753|NCT02894229|BEHAVIORAL|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
219366754|NCT02894229|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
219366755|NCT03494556|OTHER|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
219366756|NCT04754789|DRUG|Atorvastatin|preloading with high dose statins (atorvastatin 80mg) with loading dose of dual antiplatelet( asprine 300 mg and ticagrelor 180 mg) pre-primary PCI
219366757|NCT04754789|DRUG|Aspirin|Loading dose of dual antiplatelet (asprine 300 mg and ticagrelor 180 mg)
219366758|NCT02080052|DEVICE|Robot-assisted prostate biopsy|
219366759|NCT00417586|DEVICE|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
219367189|NCT04749381|COMBINATION_PRODUCT|acupoint with placebo|The placebo acupoint application was made of black beans and honey, which shares the similar shape and smell of the experiment group, applied at the same acupoints.
219367190|NCT05187832|DRUG|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
219367191|NCT05809141|DIAGNOSTIC_TEST|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
219367192|NCT00823641|DRUG|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
219367193|NCT02629731|DEVICE|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
219367194|NCT02269358|DRUG|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
219367195|NCT01515033|OTHER|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
219367196|NCT00787787|DRUG|sunitinib malate|Given PO
219367197|NCT00787787|DRUG|capecitabine|Given PO
219367198|NCT04210271|BEHAVIORAL|Buddy self-testing condition|
219367199|NCT04210271|BEHAVIORAL|Control self-screening condition|
219367200|NCT03135249|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
219367201|NCT02452502|DEVICE|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
219367202|NCT00862095|DRUG|Placebo|Every month for 3 months
219367203|NCT00862095|DRUG|Propranolol|target does 80 mg per day for 3 months
219367204|NCT00862095|DRUG|Amitriptyline|Target does of 50 mg per day for 3 months
219367205|NCT00862095|DRUG|Topiramate|Target dose 100 mg a day for 3 months
219367206|NCT01412957|OTHER|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
219367207|NCT01412957|DRUG|Panitumumab|Administered intravenously
219367208|NCT05011591|OTHER|Swimming economy|Detailed in arm's section
219367209|NCT02965157|BIOLOGICAL|CART20|
219367210|NCT04114305|BEHAVIORAL|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
219367211|NCT01784796|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
219367212|NCT01784796|BEHAVIORAL|Health Education Program|8 week Health Education Program
219367213|NCT01129193|OTHER|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
219367214|NCT01129193|OTHER|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
219367215|NCT01129193|OTHER|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
219367216|NCT01129193|DRUG|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
219367217|NCT03885778|DRUG|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
219367218|NCT03120832|BIOLOGICAL|PAN-301-1|
219367219|NCT05939037|DRUG|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
219367220|NCT04736654|OTHER|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
219367221|NCT06584916|DRUG|Orforglipron|Administered orally
219367222|NCT06584916|DRUG|Placebo|Administered orally
219367223|NCT04722991|DRUG|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
219367224|NCT04722991|OTHER|Placebo|Oral dose of matching placebo
219367225|NCT05884320|DRUG|Sacituzumab Govitecan|Given by IV (vein)
219367226|NCT02084277|DEVICE|Self-ligating brackets (SLB)|
219367227|NCT02084277|DEVICE|Conventional brackets (CB)|
219367228|NCT03063580|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
219367229|NCT03063580|DRUG|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
219367230|NCT05583942|DEVICE|trascutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
219367231|NCT05583942|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
219367232|NCT01889849|DRUG|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
219367233|NCT01889849|DRUG|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
219367234|NCT06538701|PROCEDURE|Anterolateral advancement pharyngoplasty|Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
219367235|NCT01163071|DRUG|ABI-011|ABI-011
219367236|NCT00003400|BIOLOGICAL|filgrastim|
219367237|NCT00003400|DRUG|carmustine|
219367238|NCT00003400|DRUG|cisplatin|
219367239|NCT00003400|DRUG|melphalan|
219367240|NCT00003400|DRUG|vinorelbine tartrate|
219367241|NCT00003400|PROCEDURE|peripheral blood stem cell transplantation|
219367242|NCT00413959|DRUG|VELCADE®|1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
219367243|NCT00413959|DRUG|Rituximab|375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
219367244|NCT00413959|DRUG|Cyclophosphamide|400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
219367245|NCT00413959|DRUG|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
219367246|NCT01113970|DRUG|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
219367247|NCT05065398|DRUG|HLX208|450mg bid, take orally
219367248|NCT03057795|DRUG|Brentuximab Vedotin|Given IV
219367249|NCT03057795|OTHER|Laboratory Biomarker Analysis|Correlative studies
219367250|NCT03057795|BIOLOGICAL|Nivolumab|Given IV
219367251|NCT01531842|PROCEDURE|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
219367252|NCT05105178|OTHER|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
219367253|NCT05105178|OTHER|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
219367254|NCT01648231|DRUG|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
219367255|NCT01648231|DRUG|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
219367256|NCT01648231|DRUG|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
219367257|NCT01370460|DRUG|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
219367258|NCT01370460|DRUG|Placebo|100mL 0.9% sterile saline
219367259|NCT00002744|DRUG|asparaginase|
219367260|NCT00002744|DRUG|cyclophosphamide|
219367261|NCT00002744|DRUG|cytarabine|
219367262|NCT00002744|DRUG|daunorubicin hydrochloride|
219367263|NCT00002744|DRUG|dexamethasone|
219367264|NCT00002744|DRUG|doxorubicin hydrochloride|
219367265|NCT00002744|DRUG|mercaptopurine|
219367266|NCT00002744|DRUG|methotrexate|
219367267|NCT00002744|DRUG|pegaspargase|
219367268|NCT00002744|DRUG|prednisone|
219367269|NCT00002744|DRUG|therapeutic hydrocortisone|
219367270|NCT00002744|DRUG|thioguanine|
219367271|NCT00002744|DRUG|vincristine sulfate|
219367272|NCT00002744|RADIATION|low-LET cobalt-60 gamma ray therapy|
219367273|NCT00002744|RADIATION|low-LET photon therapy|
219367274|NCT04523532|OTHER|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
219367275|NCT02576314|DRUG|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
219367276|NCT02576314|DRUG|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"
219367277|NCT01508741|DIETARY_SUPPLEMENT|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
219367278|NCT01508741|DIETARY_SUPPLEMENT|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
219367279|NCT05902000|DEVICE|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
219367280|NCT05902000|PROCEDURE|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
219362319|NCT02596659|PROCEDURE|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
219362320|NCT00962273|BEHAVIORAL|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
219362321|NCT00962273|BEHAVIORAL|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
219362322|NCT00392184|PROCEDURE|Accelerated partial breast irradiation|
219362323|NCT01569984|RADIATION|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
219362324|NCT05574257|DRUG|Propofol|Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
219362325|NCT05574257|DRUG|Remimazolam|Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
219362326|NCT05900804|OTHER|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
219362327|NCT04536064|PROCEDURE|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
219362328|NCT02424279|PROCEDURE|Splanchnicectomy|
219362329|NCT05285501|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
219362330|NCT05285501|BEHAVIORAL|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
219362874|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
219362354|NCT01292967|DIETARY_SUPPLEMENT|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
219362355|NCT01292967|DIETARY_SUPPLEMENT|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
219362356|NCT05510505|DRUG|CD20 monoclonal antibody|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
219362357|NCT05510505|DRUG|ATG|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
219362358|NCT05848934|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
219362359|NCT05848934|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
219362360|NCT02269722|DEVICE|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
219362361|NCT02269722|DEVICE|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
219362362|NCT05182346|PROCEDURE|Manual therapy|"* Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points."
219362363|NCT04340622|DEVICE|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
219362364|NCT04340622|DEVICE|Sham|Light-emitting diode covered with aluminium foil
219362365|NCT05156294|DEVICE|NovoMatrix|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
219362366|NCT05156294|OTHER|Control|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
219362367|NCT00680836|DRUG|Placebo|orally two times per day for 14 days
219362368|NCT00680836|DRUG|Rifaximin|550 mg orally two times per day for 14 days
219362369|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
219362370|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
219362371|NCT03786432|DEVICE|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
219362372|NCT05697133|OTHER|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
219362373|NCT05697133|OTHER|control|control grup
219362374|NCT03409822|DEVICE|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
219362875|NCT02693314|DIETARY_SUPPLEMENT|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
219358694|NCT04563065|OTHER|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
219358695|NCT04563065|OTHER|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
219358696|NCT02396810|OTHER|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
219358697|NCT02396810|PROCEDURE|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
219358698|NCT05157815|DIETARY_SUPPLEMENT|Soluble Fibre|10g soluble corn fibre to be consumed twice per day
219358699|NCT05157815|DIETARY_SUPPLEMENT|Calorie Matched Control|2g maltodextrin consumed twice per day
219358700|NCT03803644|DRUG|CC-92480|Part 1 dose escalation
219358701|NCT03803644|DRUG|CC-92480|CC-92480
219358702|NCT04041895|OTHER|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
219358703|NCT01347736|OTHER|scrambler therapy|Undergo scrambler therapy
219358704|NCT01347736|OTHER|questionnaire administration|Ancillary studies
219358705|NCT01347736|PROCEDURE|dermatologic complications management/prevention|Undergo scrambler therapy
219358706|NCT06388473|BEHAVIORAL|Tailored implementation intervention|The tailored implementation intervention comprised of six implementation strategies: 1) Involve executive boards, 2) Mandate change, 3) Provide education and training, 4) Identify and prepare champions, 5) The use of information and communication technology and 6) Audit and provide feedback.
219358707|NCT03238287|DEVICE|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
219358708|NCT03238287|OTHER|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
219358709|NCT05744063|DRUG|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
219358710|NCT03068156|RADIATION|308-nm excimer laser|monochromator UVB laser (308nm)
219358711|NCT04405401|RADIATION|SABR|SABR to all oligoprogressive lesions + continuation of current systemic therapy
219358712|NCT04405401|OTHER|Standard of care|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
219358713|NCT01145066|DRUG|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
219358714|NCT01145066|DIETARY_SUPPLEMENT|fish oil|1.6g/day EPA and 1.08g/day DHA
219358715|NCT01145066|DIETARY_SUPPLEMENT|corn oil|contains 4.5 g/day linoleic acid
219358716|NCT06143748|DRUG|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
219358717|NCT06143748|DRUG|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
219358718|NCT06143748|RADIATION|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
219358719|NCT02937714|OTHER|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
219358720|NCT01522846|DRUG|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
219358721|NCT02190851|DEVICE|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
219358722|NCT02190851|DEVICE|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
219358723|NCT02439658|DRUG|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
219358724|NCT05601557|OTHER|There is no intervention|The genotype of the patients was analyzed.
219358725|NCT02864472|PROCEDURE|PDT|PDT and ranibizumab
219358726|NCT02864472|DRUG|Ranibizumab|Ranibizumab
219358727|NCT02864472|DRUG|ranibizumab PRN|ranibizumab PRN
219358728|NCT00449709|DRUG|GSK221149|
219358729|NCT04997057|DIETARY_SUPPLEMENT|Probiotics mixture|"12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~* Bifidobacterium longum LA 101~* Lactobacillus helveticus La 102~* Lactococcus lactis LA 103~* Streptococcus thermophilus LA 104"
219358730|NCT02584192|BEHAVIORAL|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
219358731|NCT02584192|OTHER|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
219358732|NCT03640429|DEVICE|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
219358733|NCT03640429|DEVICE|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
219358734|NCT03564626|OTHER|Health-IT +/- Scheduled Follow Up|"* Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4"
219358735|NCT01658657|DRUG|Hydrochlorothiazide|
219358736|NCT01658657|DRUG|Lisinopril|
219358737|NCT01658657|DRUG|Amlodipine|
219358738|NCT01658657|DRUG|metoprolol|
219358739|NCT01658657|DRUG|lisinopril/hydrochlorothiazide|This is a combination pill
219358740|NCT03687502|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast Enhanced Ultrasound of the appendix
219358741|NCT01407094|DRUG|Sertraline|50-200mg/day
219358742|NCT01407094|DRUG|Placebo|1-4 pills per day
219358743|NCT01407094|DRUG|BupropionXL|150-450 mg/day
219358744|NCT05449704|DRUG|DA-5218|single dose administration (DA-5218 one tablet once a day)
219358745|NCT05449704|DRUG|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
219358746|NCT03721926|OTHER|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
219358747|NCT03721926|OTHER|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
219358748|NCT04416880|DEVICE|Press Tack Needle Acupuncture|Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
219358749|NCT01724528|DRUG|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
219358750|NCT01724528|DRUG|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
219358751|NCT00466310|DRUG|Aripiprazole|Aripiprazole for 4 weeks
219358752|NCT00466310|DRUG|Risperidone|Subjects will be randomized to risperidone for 4 weeks
219358753|NCT00466310|OTHER|Healthy volunteers|Healthy volunteers
219358754|NCT04275115|DRUG|Drug Cocktail|Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)
219358755|NCT04275115|DRUG|Foliglurax|Foliglurax
219358756|NCT04275115|DRUG|midazolam iv|Single intravenous (iv) dose of midazolam 0.025 mg/kg
219358757|NCT01864616|DIETARY_SUPPLEMENT|Vitamin D3|
219358758|NCT02598765|PROCEDURE|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
219358759|NCT02598765|PROCEDURE|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
219358760|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
219358761|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
219358762|NCT06149793|DRUG|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
219358763|NCT06149793|OTHER|Placebo Control|Placebo Control
219358764|NCT05329077|DEVICE|Pulsenmore ES home ultrasound device|Pregnant participants will use Pulsenmore ES device to assess the safety and the efficacy of the device in monitoring fetal parameters
219358765|NCT06791122|DEVICE|Digital therapeutic (CT-155)|Digital therapeutic (CT-155) - in the form of a smartphone app
219358766|NCT05678491|OTHER|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
219358767|NCT05708014|BEHAVIORAL|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
219358768|NCT05708014|BEHAVIORAL|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
219358769|NCT04663308|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
219358770|NCT04663308|DRUG|Placebo|Capsules matched to study drug minus active substance
219358771|NCT06061861|OTHER|Financial support for healthy foods and free home delivery|Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
219358772|NCT06061861|OTHER|Free home delivery|Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
219358773|NCT01381159|BEHAVIORAL|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
219358774|NCT01381159|BEHAVIORAL|Control|Standard medical care
219358775|NCT04608695|PROCEDURE|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
219358776|NCT04682470|OTHER|No intervention ; observational|No intervention; observational
219358777|NCT03933696|DEVICE|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
219362461|NCT04226794|BEHAVIORAL|Nutritional Counseling|Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions
219362462|NCT04226794|COMBINATION_PRODUCT|a-tDCS and nutritional counseling|a-tDCS + Nutritional Counseling
219362463|NCT04226794|COMBINATION_PRODUCT|s-tDCS and nutritional counseling|s-tDCS + Nutritional Counseling
219362464|NCT02647151|DRUG|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
219362465|NCT02647151|DRUG|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
219362466|NCT04304131|DIAGNOSTIC_TEST|Earlytect Colon Cancer|A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
219362467|NCT06101576|PROCEDURE|TUIP|Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.
219362468|NCT06101576|PROCEDURE|TURP|Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.
219362469|NCT06101576|PROCEDURE|Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
219362470|NCT06101576|PROCEDURE|AEEP|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
219362471|NCT02020044|OTHER|Endothelial Keratoplasty|
219362472|NCT05302323|OTHER|Disposable Drape|Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
219362473|NCT05302323|OTHER|Reusable Drape|Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
219362474|NCT03125278|OTHER|Medication knowledge|Participants will be asked questions over the phone about their medications
219362475|NCT00332956|BIOLOGICAL|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
219362476|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
219362477|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
219362478|NCT00332956|BIOLOGICAL|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
219362479|NCT04749394|DRUG|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
219362480|NCT04749394|DRUG|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
219362481|NCT02550028|DRUG|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
219362482|NCT02550028|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
219362483|NCT00135603|DRUG|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
219362484|NCT00135603|PROCEDURE|appendectomy|ablation of the appendix by laparotomy or laparoscopy
219362485|NCT00721487|DRUG|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
219362486|NCT05869006|BEHAVIORAL|Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice|Group Practice
219362487|NCT05869006|BEHAVIORAL|Placebo group practice|The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
219362488|NCT03562663|DEVICE|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
219362489|NCT03562663|DEVICE|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
219362490|NCT03926676|OTHER|grandio blocks|nano hybrid composite blocks
219362491|NCT03926676|OTHER|emax|ceramic blocks
219362492|NCT05035680|BIOLOGICAL|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
219362493|NCT05035680|BIOLOGICAL|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
219362494|NCT05035680|BIOLOGICAL|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
219362495|NCT03658226|BEHAVIORAL|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
219362496|NCT01831128|DEVICE|ASV Treatment|
219362497|NCT03288246|DIAGNOSTIC_TEST|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
219362498|NCT04822532|GENETIC|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
219362876|NCT04821583|DRUG|Hydrocortisone|Hydrocortisone is orally administered.
219362877|NCT04821583|DRUG|Placebo|Placebo is orally administered.
219362878|NCT04991337|BEHAVIORAL|Detraining group|Detraining is defined as exercise corresponding to a heart rate ≤75% of maximum heart rate and ≤80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 weeks.
219362879|NCT04991337|BEHAVIORAL|Control group|At least three weekly sessions of high intensity exercise, corresponding to a heart rate ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
219362880|NCT01311466|PROCEDURE|Liver transplantation|
219362881|NCT00687284|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
219362882|NCT05848661|DEVICE|AUDISSEE|AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
219362883|NCT05848661|DEVICE|Placebo|The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
219362884|NCT02567929|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
219362885|NCT02567929|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
219362886|NCT00562380|BIOLOGICAL|ganitumab|
219362887|NCT00562380|OTHER|laboratory biomarker analysis|
219362888|NCT00562380|OTHER|pharmacological study|
219362889|NCT00562380|PROCEDURE|biopsy|
219362890|NCT04059744|DEVICE|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
219362891|NCT03981432|BEHAVIORAL|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219362892|NCT03981432|BEHAVIORAL|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
219362893|NCT03981432|BEHAVIORAL|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
219362894|NCT02580331|DRUG|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
219362895|NCT02580331|DRUG|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
219362896|NCT05537714|BEHAVIORAL|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
219362897|NCT03777683|DIETARY_SUPPLEMENT|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
219362898|NCT03777683|OTHER|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
219362899|NCT05192369|DRUG|CTP-543|CTP-543 12 mg (1 x 12 mg tablet), dosed with water
219362900|NCT05192369|DRUG|CTP-543|CTP-543 48 mg (4 x 12 mg tablet) dosed with water
219362901|NCT05192369|DRUG|Moxifloxacin|Moxifloxacin (1 x 400 mg tablet) dosed with water
219362902|NCT05192369|DRUG|Placebo|Placebo (1 tablet) dosed with water
219362903|NCT00308607|DRUG|Bevacizumab (Avastin)|
219362904|NCT00308607|DRUG|dacarbazine|
219362905|NCT00308607|DRUG|interferon-alfa-2a (Roferon-A)|
219362906|NCT01753908|DRUG|Broccoli Sprout Extract|Given PO
219362907|NCT01753908|OTHER|Laboratory Biomarker Analysis|Correlative studies
219362908|NCT01753908|OTHER|Pharmacological Study|Urinary ITCs and metabolites measured
219362909|NCT01753908|OTHER|Placebo|Given PO
219362910|NCT00713219|RADIATION|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
219358778|NCT02270359|DEVICE|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
219358779|NCT02270359|PROCEDURE|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
219358780|NCT02270359|DRUG|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
219358781|NCT06357247|DEVICE|Sensory Threshold|Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits
219358782|NCT06357247|BEHAVIORAL|Nine Hole Peg Test|The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.
219358783|NCT06357247|BEHAVIORAL|Semmes Weinstein Monofilament Assessment|A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
219358784|NCT05072314|DRUG|lidocaine 2% and 10%|"Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
219358785|NCT05072314|DRUG|Placebo|"Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
219358786|NCT02403609|OTHER|BPT, Computerized Assessment|
219358787|NCT06141278|BEHAVIORAL|Care cascade intervention|Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
219358788|NCT01050400|GENETIC|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
219358789|NCT05754346|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
219358790|NCT05754346|OTHER|Upper extremity exercises combined with diaphragmatic breathing exercises|"Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises."
219358791|NCT03502993|DIAGNOSTIC_TEST|Validation of biomarker|
219358792|NCT04377737|DIAGNOSTIC_TEST|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
219358793|NCT00262431|PROCEDURE|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
219358794|NCT03512145|DEVICE|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
219358795|NCT05970263|DRUG|Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.|2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
219358796|NCT05970263|OTHER|External Comparator|Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
219358797|NCT06774040|DRUG|Etribnabdione 25 mg BID|The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.
219358798|NCT06774040|DRUG|Etribnabdione 50 mg BID|The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.
219358799|NCT06291909|BEHAVIORAL|Small Steps Program|Participants in the intervention group will be given access to the Small Steps website. Small Steps website provides a visual representation of the participant's current use of time and allows for manipulation to demonstrate how small lifestyle changes may improve sleep and physical activity needs. The personal outcome goals selected by the participant will also feature on participant's dashboard within the Small Steps website as a reminder. Participants will be prompted through the first 12 weeks to add a new behaviour change each week and will receive support phone calls weekly. During the 12-week Maintenance Phase participants will be guided to maintain their new behaviour, with supportive phone calls being progressively reduced from fortnightly to monthly. At the completion of the 12 weeks, investigator support will be withdrawn. Maintenance of the new behaviour without support will then be assessed over 12 additional weeks in the Follow-Up phase.
219358800|NCT06291909|BEHAVIORAL|Comparator Program|Participants will receive generic health advice only and it will not be individually tailored, nor will they receive weekly support phone calls during the first 12-weeks. Participants will receive no feedback or support in the Maintenance or Follow-Up phases.
219358801|NCT05994053|DEVICE|high definition transcranial alternating current stimulation|low intensity alternating current to OFC
219358802|NCT03798626|DRUG|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
219358803|NCT03798626|DRUG|Bevacizumab|25 mg/mL concentration; administered IV
219358804|NCT03798626|DRUG|Modified FOLFOX6|Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
219358805|NCT03798626|DRUG|FOLFIRI|Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
219358806|NCT03798626|DRUG|Ramucirumab|10 mg/mL concentration; administered IV
219358807|NCT03798626|DRUG|Paclitaxel|6 mg/mL concentration; administered IV
219358808|NCT03798626|DRUG|Cabozantinib|60 mg tablet; administered orally
219358809|NCT06521463|DEVICE|WATCHMAN FLX Pro LAAC Device|WATCHMAN FLX Pro LAAC Device Implantation
219358810|NCT05003960|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219358811|NCT05884684|OTHER|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
219358812|NCT06287580|DRUG|chlorthalidone|chlorthalidone, 12.5 mg or 25 mg orally once daily
219358813|NCT06287580|OTHER|Placebo|Placebo tablet taken orally once daily
219358814|NCT05898165|OTHER|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
219358815|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
219358816|NCT04892173|DRUG|JNJ-90301900 (NBTXR3)|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
219358817|NCT04892173|DRUG|Cetuximab|Solution for infusion
219358818|NCT04892173|RADIATION|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
219358819|NCT04001023|DEVICE|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
219358820|NCT00185003|DRUG|endotoxin|
219358821|NCT00185003|DRUG|Potassium channel blockers: TEA, Quinin, Tolbutamide|
219358822|NCT00185003|DRUG|L-NMMA|
219361958|NCT05989906|BEHAVIORAL|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
219361959|NCT03811509|DRUG|bisphosphonate|antiresorptives
219361960|NCT00956254|DRUG|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
219361961|NCT00836212|DRUG|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
219361962|NCT00836212|DRUG|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
219361963|NCT06778018|DIETARY_SUPPLEMENT|Lotus Seed|Regimen supplemented with 200 mg/kg of Lotus Seed capsules for 12-month randomized controlled trial.
219361964|NCT06778018|DIETARY_SUPPLEMENT|Placebo|Regimen supplemented with 200 mg/kg of Starch capsules for 12-month randomized controlled trial.
219361965|NCT00091832|BIOLOGICAL|Denosumab|Denosumab administered by subcutaneous injection
219361966|NCT00091832|DRUG|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
219361967|NCT03396380|DRUG|Vitamin D with calcium and clomiphene citrate|"1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days ."
219361968|NCT03396380|DRUG|Placebo Oral Tablet with calcium and clomiphene citrate|"1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days"
219361969|NCT00464178|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
219361970|NCT03400722|DRUG|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
219361971|NCT03400722|DRUG|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
219361972|NCT05707780|PROCEDURE|Resin-matrix|posterior crowns
219361973|NCT05707780|PROCEDURE|Monolithic zirconia|posterior crowns
219361974|NCT05707780|PROCEDURE|Metal-ceramic|posterior crowns
219361975|NCT02052557|DRUG|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
219361976|NCT02052557|DRUG|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
219361977|NCT02934438|DIETARY_SUPPLEMENT|Neo40|
219361978|NCT02934438|DIETARY_SUPPLEMENT|Placebo|
219361979|NCT03899454|DRUG|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
219361980|NCT03899454|DRUG|Placebo Control|Placebo Control
219361981|NCT04724473|DRUG|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
219361982|NCT01162330|OTHER|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
219361983|NCT00874250|DEVICE|GORE CTAG Device|Endovascular aortic stent-graft
219361984|NCT02986230|OTHER|CP-CDS|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
219361985|NCT00003955|BIOLOGICAL|dactinomycin|
219361986|NCT00003955|BIOLOGICAL|filgrastim|
219361987|NCT00003955|BIOLOGICAL|pegfilgrastim|
219361988|NCT00003955|BIOLOGICAL|sargramostim|
219361989|NCT00003955|DRUG|cyclophosphamide|
219361990|NCT00003955|DRUG|irinotecan hydrochloride|
219361991|NCT00003955|DRUG|vincristine sulfate|
219361992|NCT00003955|RADIATION|radiation therapy|
219361993|NCT03044860|PROCEDURE|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine
219361994|NCT03550066|BEHAVIORAL|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
219361995|NCT03550066|BEHAVIORAL|No affirmation|A health message alone
219361996|NCT03793387|PROCEDURE|AF-guided endobronchial marking|Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
219361997|NCT03793387|DEVICE|ENB-guided endobronchial marking|Bronchoscopic dye marking with ENB system
219361998|NCT04834869|BIOLOGICAL|BNT162b2|Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
219361999|NCT04834869|BIOLOGICAL|mRNA-1273|Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
219362000|NCT04834869|BIOLOGICAL|AZD1222|Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
219362001|NCT04834869|BIOLOGICAL|CoronaVac|Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
219362002|NCT04834869|BIOLOGICAL|Sinopharm|Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
219362003|NCT04834869|BIOLOGICAL|Gam-COVID-Vac|Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
219362004|NCT04834869|BIOLOGICAL|JNJ-78436735|Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
219362005|NCT04834869|BIOLOGICAL|CVnCoV|Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
219362006|NCT04834869|BIOLOGICAL|NVX-CoV2373|Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
219362007|NCT04834869|BIOLOGICAL|BBV152|Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
219362008|NCT02181166|OTHER|Kinesiotherapy|
219362009|NCT02181166|OTHER|Isquemic compression|
219362010|NCT02181166|OTHER|High voltage electrical stimulation|
219362011|NCT03682315|DEVICE|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
219362012|NCT03682315|DEVICE|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
219362013|NCT03359876|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
219362014|NCT03359876|DRUG|Warfarin sodium|Individually adjusted dose
219362015|NCT02031705|PROCEDURE|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
219362016|NCT02031705|PROCEDURE|control group|Control group was performed no additional cavotricuspid isthmus ablation.
219362017|NCT05241327|DIETARY_SUPPLEMENT|Beetroot Juice|Inorganic Nitrate
219362018|NCT03140904|OTHER|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
219362019|NCT03140904|OTHER|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
219362020|NCT00983047|DRUG|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
219362021|NCT01284166|DRUG|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
219362022|NCT05192811|DIETARY_SUPPLEMENT|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10\^9cfu) ,for 60days
219362023|NCT05192811|DIETARY_SUPPLEMENT|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
219362024|NCT02916654|DIETARY_SUPPLEMENT|sucrosomial iron|administration of sucrosomial iron
219362025|NCT02916654|DRUG|Sulphate iron|administration of sulphate iron
219362026|NCT03923205|OTHER|Dietary Intervention|The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
219362027|NCT02199899|DRUG|BIIF 1149 BS - single rising doses|
219362028|NCT02199899|DRUG|Placebo|
219362029|NCT04479904|DRUG|Famitinib|po
219362030|NCT05296577|DRUG|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
219362031|NCT05296577|DRUG|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
219362032|NCT02558374|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
219362033|NCT02558374|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
219362034|NCT02558374|OTHER|Placebo|1 drop QD, AM, OU
219362035|NCT00573794|BIOLOGICAL|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
219362036|NCT02999490|RADIATION|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
219362037|NCT06548802|DRUG|Baricitinib|Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.
219362038|NCT05218616|DRUG|Aviga, capsules 50 mg / Sutent®, capsules 50 mg|Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
219362039|NCT05218616|DRUG|Sutent®, capsules 50 mg / Aviga, capsules 50 mg|Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
219362040|NCT04164303|OTHER|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
219362041|NCT04168424|OTHER|no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people
219362042|NCT01725750|DEVICE|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
219362499|NCT01002092|DRUG|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
219362500|NCT01002092|DRUG|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
219362501|NCT01050114|DRUG|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
219362502|NCT01050114|DRUG|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
219362503|NCT05886062|OTHER|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
219362504|NCT05886062|OTHER|Control Group|They will only continue their routine basketball technical-tactical training.
219362505|NCT02012556|DRUG|Tesamorelin|
219362506|NCT04157387|OTHER|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
219362507|NCT04157387|OTHER|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
219362508|NCT03037281|DIAGNOSTIC_TEST|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
219362509|NCT02118376|DRUG|Exenatide|5ug bid,Subcutaneous injection
219362510|NCT02847754|OTHER|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
219362511|NCT02393391|DEVICE|Neuroelectrics STARSTIM|
219362512|NCT00688909|DRUG|letrozole|2.5 mg daily by mouth for 6 months
219362513|NCT05431257|DRUG|Venetoclax|"Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia."
219362514|NCT01220414|DRUG|Naltrexone, then placebo|50 mg of naltrexone
219362515|NCT01220414|DRUG|Placebo, then Naltrexone|sugar pill
219362516|NCT01936389|DRUG|AR-12286|
219362517|NCT04227756|DRUG|LSD|LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
219362518|NCT04227756|DRUG|Psilocybin|Psilocybin 20 mg per os, single dose
219362519|NCT04227756|DRUG|Mescaline|Mescaline 300 mg or 500 mg per os, single dose
219362520|NCT04227756|OTHER|Placebo|Placebo (Mannitol)
219362521|NCT02969902|DEVICE|Buzzy® device|
219362522|NCT02969902|DEVICE|Hand-held computer|
219362523|NCT03190187|OTHER|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
219362524|NCT03190187|OTHER|Sham manipulation|Patients will receive simulated spinal manipulation without force application
219362525|NCT04214847|PROCEDURE|Ahmed Glaucoma Valve surgery|The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
219362526|NCT00445302|DRUG|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
219362527|NCT02055625|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
219362528|NCT00496392|DRUG|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
219362529|NCT00188630|DRUG|N-acetylcysteine|
219362530|NCT00188630|OTHER|5% dextrose solution|
219362531|NCT03646448|BEHAVIORAL|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
219362532|NCT01029730|DRUG|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
219362533|NCT01029730|DRUG|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
219362534|NCT01029730|DRUG|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
219362535|NCT02668614|DEVICE|WR-22 model microwave sensor|
219362536|NCT03242330|DEVICE|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
219362537|NCT02477345|DRUG|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
219362538|NCT06031077|PROCEDURE|cardiac catheterization|An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
219362539|NCT00860158|DRUG|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
219362540|NCT00860158|DRUG|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
219362541|NCT00860158|PROCEDURE|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
219362542|NCT06014944|DRUG|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
219362543|NCT03065179|DRUG|Nivolumab/Ipilimumab|IV immunotherapy
219362544|NCT03065179|RADIATION|SBRT|SBRT will be delivered in conjunction with immunotherapy
219362545|NCT05971966|OTHER|Virtual Reality technique|"They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
219362546|NCT05971966|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
219362547|NCT02799862|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
219362548|NCT02799862|DRUG|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
219362549|NCT00669617|DRUG|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
219362550|NCT00669617|DRUG|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
219362551|NCT00669617|DRUG|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
219362552|NCT00669617|DRUG|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
219362553|NCT00669617|DRUG|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
219362554|NCT00669617|DRUG|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
219362555|NCT05499520|OTHER|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
219362556|NCT00700180|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
219362557|NCT00700180|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
219362558|NCT00700180|DRUG|Carboplatin-based chemotherapy|As prescribed
219362559|NCT05719480|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
219362560|NCT01613326|DRUG|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
219362561|NCT01613326|DRUG|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
219362562|NCT01613326|DRUG|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
219362563|NCT01613326|DRUG|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
219362564|NCT01613326|DRUG|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
219362565|NCT02201160|DIETARY_SUPPLEMENT|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
219362566|NCT03370159|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
219362567|NCT03370159|DRUG|Docetaxel|Given IV
219362568|NCT03370159|OTHER|Pharmacological Study|Correlative studies
219362569|NCT05205408|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection as single agent.
219362570|NCT05331911|DRUG|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
219362571|NCT05331911|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
219362572|NCT04181879|BEHAVIORAL|Intervention|"* GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
219362573|NCT06499818|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
219362574|NCT06499818|PROCEDURE|STABLE-AF|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during Atrial Fibrillation
219362575|NCT06499818|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
219362576|NCT03980938|DRUG|neflamapimod|40 mg neflamapimod capsule
219362577|NCT03980938|OTHER|Placebo|matching placebo capsule
219362578|NCT02266173|DRUG|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
219362579|NCT02485080|DRUG|Simeprevir|
219362580|NCT02485080|DRUG|Sofosbuvir|
219362581|NCT02244151|DRUG|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
219362582|NCT02244151|DRUG|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
219362583|NCT00230347|PROCEDURE|Stereotactic radiosurgery|
219362584|NCT04724148|DRUG|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
219362585|NCT00840827|DRUG|lenalidomide|Lenalidomide 10mg po daily
219362586|NCT00840827|DRUG|cyclosporine A|CSA 250mg orally twice daily
219362587|NCT02314793|DRUG|ASP2205|oral
219362588|NCT02314793|DRUG|Placebo|oral
219362589|NCT01445535|BIOLOGICAL|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
219362590|NCT01445535|DRUG|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
219362591|NCT01445535|BIOLOGICAL|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
219362592|NCT01445535|DRUG|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
219362593|NCT01445535|DRUG|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
219362594|NCT01445535|DRUG|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
219362595|NCT01445535|DRUG|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
219362596|NCT03216382|BEHAVIORAL|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
219362597|NCT03216382|BEHAVIORAL|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
219362598|NCT01183624|OTHER|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
219362599|NCT01183624|OTHER|Placebo Patch|Control patch with no herbal ingredients
219362600|NCT03372239|DRUG|Indoximod base formulation|Specified dose on specified days
219362601|NCT03372239|DRUG|Indoximod HCL (salt) formulation|Specified dose on specified days
219362602|NCT03372239|OTHER|Placebo|Specified dose on specified days
219362603|NCT01928628|DRUG|Lercanidipine 10mg|
219362604|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg|
219362605|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg|
219362606|NCT01928628|DRUG|Lercanidipin 10mg Placebo|
219362607|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg Placebo|
219362608|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg Placebo|
219362609|NCT05202457|PROCEDURE|Elective surgery|Patient undergoing elective or urgent surgery
219362610|NCT03094000|BEHAVIORAL|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
219362611|NCT03094000|BEHAVIORAL|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
219358823|NCT03224429|OTHER|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
219358824|NCT03224429|OTHER|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
219358825|NCT01634555|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
219358826|NCT01634555|DRUG|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
219358827|NCT01634555|DRUG|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
219358828|NCT01634555|DRUG|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
219358829|NCT03977129|DEVICE|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.
219358830|NCT03977129|OTHER|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
219358831|NCT04769362|DRUG|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
219358832|NCT06591572|PROCEDURE|Single-port robotic transanal total mesorectal excision|Rectal resection by transanal TME with single-port robotic surgery
219358833|NCT04595747|PROCEDURE|Biopsy Procedure|Undergo biopsy
219358834|NCT04595747|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219358835|NCT04595747|PROCEDURE|Computed Tomography|Undergo CT scan and PET/CT scan
219358836|NCT04595747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219358837|NCT04595747|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
219358838|NCT04595747|DRUG|Rogaratinib|Given PO
219358839|NCT06451068|DEVICE|Peripheral retina robotically aligned optical coherence tomography (OCT) system|To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
219358840|NCT06451068|OTHER|Likert Scales|Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
219358843|NCT06228586|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
219358844|NCT05572229|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
219358845|NCT05572229|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
219358846|NCT05572229|DRUG|Lenalidomide|Lenalidomide will be administered orally
219358847|NCT06444711|OTHER|NICE guidance|Patients will be assessed to determine whether their current treatment is in line with NICE guidelines. Changes will be made to their treatment plan in order for them to comply with NICE guidelines with the aim of reducing the number of serious adverse events in the group. They will be followed up until 6 months to identify improvements in their conditions
219358848|NCT05975476|BEHAVIORAL|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
219358849|NCT05975476|BEHAVIORAL|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
219358850|NCT06841575|DEVICE|Auto-aligned OCT|Swept Source OCT system with improved hand-held probe technology for auto-alignment to the patient's eye, as well as on-line detection of image quality and auto-saving at the proper time
219358851|NCT03108495|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
219358852|NCT03108495|BIOLOGICAL|LN-145 + pembrolizumab|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
219358853|NCT06255990|OTHER|Standard of care|Standard of care
219358854|NCT04166409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219358855|NCT04166409|DRUG|Carboplatin|Given IV
219358856|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219358857|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
219358858|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
219358859|NCT04166409|DRUG|Vincristine Sulfate|Given IV
219358860|NCT06492785|BIOLOGICAL|High Hyaluronic Acid concentrations (0.5 mg/ml)|Hyaluronic Acid(EmbryoGlue®)
219358861|NCT06492785|BIOLOGICAL|Low Hyaluronic Acid concentrations (0.125 mg/ml)|Hyaluronic Acid (G2 medium)
219358862|NCT07001891|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
219358863|NCT07001891|BEHAVIORAL|auto-questionnaires (PSQI, ISI, ESS and HADS)|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
219358864|NCT07001891|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administered per day during 14 days by a study-dedicated Android OS smartphone
219358865|NCT07001891|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
219358866|NCT07001891|BEHAVIORAL|auto-questionnaires (ASRS, PSAS, APS, MAIA-2)|Interoceptive awareness and accuracy estimation : Adult ADHD Self-Report Scale (ASRS), Pre-Sleep Arousal Scale (PSAS), Arousal Predisposition Scale (APS) et Multidimensional Assessment of Interoceptive Awareness version 2 (MAIA-2)
219358867|NCT07001891|DEVICE|MRI|Morning and evening functional brain imaging
219358868|NCT06670105|DRUG|Glofitamab|Given by vein
219358869|NCT05556525|OTHER|Fluorescein|Given IV
219358870|NCT05556525|DEVICE|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
219358871|NCT05556525|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
219358872|NCT06350006|DRUG|SHR-A1904; Adebrelimab|SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
219358873|NCT06350006|DRUG|SHR-A1904; CAPOX; Adebrelimab|SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
219358874|NCT07017998|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
219358875|NCT07017998|DEVICE|Sham (No Treatment)|Sham headband-style device will be worn for 30 minutes. Participants will be told they are receiving therapy.
219358876|NCT05597904|GENETIC|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
219358877|NCT06700538|DRUG|ARO-INHBE|SC injection
219358878|NCT06700538|DRUG|Placebo|calculated volume to match active treatment by SC injection
219358879|NCT06700538|DRUG|Tirzepatide|SC injection
219358880|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
219358881|NCT06721416|OTHER|Traditional Aerobic Exercise|Traditional aerobic exercise will be continued with an arm ergometer, at moderate intensity, for 30 minutes.
219358882|NCT06721416|OTHER|VR Based Aerobic Exercise|"In the virtual reality-based aerobic exercise training, the game called Beat Saber will be played with Oculus Quest 2 virtual reality for 30 minutes."
219358883|NCT06721416|OTHER|Conventional Exercise|The conventional exercise program will be modified with stabilization, balance and strengthening exercises, taking into account the functional status of the participants.
219358884|NCT06892522|DRUG|Etentamig|Intravenous (IV) Infusion
219358885|NCT06892522|DRUG|Lenalidomide|Oral Capsule
219358886|NCT06892522|DRUG|Dexamethasone|IV Injection
219358887|NCT06892522|DRUG|Daratumumab|Subcutaneous Injection
219358888|NCT06892522|DRUG|Dexamethasone|Oral Tablet
219358889|NCT06892522|DRUG|Carfilzomib|IV Infusion
219358890|NCT06738394|BEHAVIORAL|High-Velocity Resistance Training|High-velocity resistance training for patients with non-dialysis dependent chronic kidney disease Stages 3-5 with mobility limitations.
219358891|NCT06738394|BEHAVIORAL|Attention|Dedicated contact, information, and motivation throughout the course of the study via weekly group sessions and informational handouts.
219358892|NCT05811351|DRUG|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
219358893|NCT05811351|DRUG|Prednisone|Prednisone will be administered as oral capsule.
219358894|NCT05811351|OTHER|Placebo|Prednisone matching placebo will be administered as oral capsule.
219358895|NCT05811351|DRUG|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
219358896|NCT05811351|OTHER|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
219358897|NCT07055607|DRUG|Semaglutide|Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.
219358898|NCT07053384|BIOLOGICAL|VH3810109|VH3810109 will be administered.
219358899|NCT07053384|DRUG|Fostemsavir (FTR)|Fostemsavir will be administered.
219358900|NCT07053384|DRUG|SOC INSTI-based ART|A SOC INSTI-based ART regimen will be administered.
219358901|NCT07060976|OTHER|18 Transdermal patches along with positive and negative controls 1)Capsaicin0.025% Topical Patch, 2)Diclofenac Diethylamine 100mg Transdermal Patch, 3)Diclofenac Diethylamine 200mg Transdermal Patch,|Dose: 1×1 cm of each Patch (1 cm2) Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 24 hours. At 24 hours post-application, patches will be removed and skin will be evaluated for irritation reactions at 30 mins,24 hours (Day 1)post patch removal and 168 hours (Day 7) post-patch removal (if needed). Frequency: single application
219358902|NCT06897618|BEHAVIORAL|Culturally tailored diabetes self-management education|Five weeks of culturally tailored diabetes self-management education modeled after Association of Diabetes Care and Education Seven-item Framework (ADCES7).
219358903|NCT06781749|DEVICE|Hearing aid use|Hearing aid use will be discussed with all eligible participants with hearing loss and will be encouraged to pursue hearing aid fitting through standard clinical indications via participants' insurance and audiologists.
219358904|NCT07063602|OTHER|Evaluation of the hypoesthesia of the thorax|In the recovery room, a member of the research team will come to assess the presence of hypoesthesia (loss of sensation) of the thorax using ice and a Von Frey filament applied at three different sections: midscapular, midaxillary and midclavicular.
219358905|NCT06899230|DRUG|iQ-007|Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid transporter-2 (EAAT2) and its rodent homologue (glutamate transporter-1\[GLT-1).
219358906|NCT06899230|DRUG|Placebo|Oral capsules identical in appearance to drug and containing vehicle only (Gelucire/Capmul-M).
219358907|NCT06546670|DRUG|ITU512|ITU512 is an investigational, oral, low molecular weight (LMW) compound.
219358908|NCT06546670|DRUG|Placebo|An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
219358909|NCT06578507|DRUG|Hydroxycarbamid|"Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide.~The IMP will be administered as half-strength twice daily, based on the body weight of the patient."
219358910|NCT06839235|DRUG|ABO-101|Intravenous (IV) infusion
219358911|NCT00366522|DRUG|LXR-623|
219358912|NCT07073807|BEHAVIORAL|SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring|The SMART intervention uses TAPPT® smart labels and a web-based app for real-time monitoring of oral anticancer therapy adherence. It includes personalized text reminders, biweekly surveys for medication adherence and symptom burden, missed and extra dose management, symptom alerts to providers, monthly financial and health-related social needs screening with tailored resources, and educational texts for low health literacy. TAPPT® smart labels work with Android/iOS smartphones. All participants receive usual oncology care.
219358913|NCT06926283|DRUG|DXC008|Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.
219358914|NCT04409236|BEHAVIORAL|Quit2Heal|Use Quit2Heal app
219358915|NCT04409236|BEHAVIORAL|QuitGuide|Use QuitGuide app
219358916|NCT04409236|OTHER|Survey Administration|Ancillary studies
219358917|NCT06837870|DEVICE|percutaneous suture mediated closure|Vascular closure with a commercially available SMC device.
219358918|NCT06837870|DEVICE|Figure of Eight Suture|Manual Compression with Figure of Eight Suture (control).
219358919|NCT06320431|DRUG|Tenecteplase|Thrombolytic
219358920|NCT06906627|OTHER|(IRIS-CKD Screening Program): Home Kit|"All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results.~Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline."
219358921|NCT06906627|OTHER|(IRIS-CKD Screening Program): Standard Lab Order|ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab
219358922|NCT07084675|BEHAVIORAL|Hydration-Dehydration-Rehydration Protocol (HDR)|"The HDR Protocol is a 12-day, sequential fluid manipulation intervention designed to assess the physiological effects of controlled changes in hydration status. The protocol consists of three consecutive 4-day phases:~Hydration Phase (Days 1-4): Participants follow a standardized fluid intake protocol designed to promote and maintain a euhydrated state. Hydration status is monitored using objective measures such as urine specific gravity and body mass.~Dehydration Phase (Days 5-8): Participants adhere to a fluid-restriction regimen to induce a hypohydrated state. The level of dehydration is verified through the same hydration status measures to ensure consistent and safe hypohydration.~Rehydration Phase (Days 9-12): Participants resume the standardized fluid intake protocol used during the Hydration Phase to restore euhydration. Rehydration effectiveness is confirmed through repeated hydration assessments."
219358923|NCT06723236|BIOLOGICAL|MGC028|MGC028 is an antibody-drug conjugate targeted against ADAM9.
219358924|NCT07138027|BEHAVIORAL|Clinical decision support + education (CDS+) and population health management (PHM)|In Interval 1, intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+). In Interval 2, intervention clinics will have CDS+ and population health management (PHM) strategies, including an asthma community health worker and an asthma nurse care manager.
219358925|NCT07138027|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
219358926|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
219358927|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
219358928|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
219358929|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
219358930|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
219358931|NCT05321082|DRUG|BI 1015550|BI 1015550
219358932|NCT05321082|DRUG|Placebo|Placebo
219358933|NCT07102316|DRUG|TPIP F2|Inhalation using a capsule-based dry powder inhaler device.
219358934|NCT07102316|DRUG|TPIP F3|Inhalation using a capsule-based dry powder inhaler device.
219358935|NCT07101198|PROCEDURE|Ultrasound-guided erector spinae plane block|Patients in this group will receive an ultrasound-guided erector spinae plane block 30 minutes before surgery. A total volume of bupivacaine will be injected bilaterally into the fascial plane between the erector spinae muscle and the transverse process. All patients will also receive standard postoperative analgesia.
219358936|NCT05705219|DIAGNOSTIC_TEST|3D-MPUS|Participants will receive approximately \< 20 minutes ultrasound scan to locate the lesion followed by acquisition of 3D-MPUS acquisition.
219358937|NCT07104279|DEVICE|Z1 Femoral Hip System|Subjects who will be implanted with the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty
219358938|NCT06828666|BIOLOGICAL|Cryopreserved Devitalized Adipose Tissue Allograft|BRC-OA is a Cryopreserved Devitalized Adipose Tissue Allograft that has demonstrated anti-inflammatory and antioxidant properties of adipose tissue.
219358939|NCT06828666|OTHER|Normal Saline (Placebo)|2 mL Normal Saline
219358940|NCT06560632|DRUG|RP-3467 at assigned dose and schedule|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
219358941|NCT06560632|DRUG|Olaparib 200-300 mg BID, daily|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
219358942|NCT07102082|BEHAVIORAL|Modified Risk - None|Participants view ads with no modified risk claim
219358943|NCT07102082|BEHAVIORAL|Modified Risk Claim|Participants view ads with a modified risk claim
219358944|NCT06408168|DRUG|Fulvestrant|Given by PO
219358945|NCT06408168|DRUG|Repotrectinib|Given by IV
219358946|NCT06915090|BEHAVIORAL|Health Coach/Fitbit|"Health coach visits (up to 6) will be conducted virtually and include:~Session 1:~* Assessment, wellness vision,~* Habits and goals (Stretching, strength training, cardiovascular PA/walking, Diet)~* Motivation, resources, and guidelines~* Online program orientation~* Set first week's goals~Sessions 2-5:~-Goal review, successes and challenges, new goal setting (i.e. Increase steps by 1,000/day if consistently meeting goal)45~Session 6~-Review of progress, maintenance plan, final assessment~Once baseline measures are completed, patients without a Fitbit device will be provided one for the duration of the study, which they get to keep. The same option will be available for patients who already have a Fitbit but would like one provided by the study team anyway. The participant will receive their Fitbit device at their baseline study visit. Participants will also be instructed to wear their Fitbit for a total of 12 weeks with a suggested step count."
219358947|NCT07121959|DRUG|Metformin|Oral Tablet
219358948|NCT07121959|DRUG|Belzutifan|Oral Tablet
219358949|NCT06943105|BEHAVIORAL|Nonviolent Communication Intervention|The intervention will be conducted by social workers who will be trained by professional NVC trainers through a train-the-trainer workshop, including six sessions. The interventions include an introduction to four fundamental principles of NVC, distinguishing observations from evaluations, identifying and expressing feelings, taking responsibility for feelings and needs, and using positive action language to make requests. Each session will feature a review of the previous session, a warm-up game and an exercise to consolidate the learning of the concepts. The intervention sessions will also include group discussions and debriefing sessions on parents' experiences of practising NVC.
219358950|NCT07166016|OTHER|Conservative|Patients with hammertoe deformities will undergo conservative treatments, including wearing proper shoes, insoles, and custom orthotics.
219358951|NCT07166016|PROCEDURE|Surgical|Patients with hammertoe deformities will undergo surgical treatments.
219358952|NCT07168291|DRUG|Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion|Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3. AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.
219358953|NCT07168330|DEVICE|Ankle replacement|Total ankle arthroplasty
219358954|NCT07178158|OTHER|Installing the Metacognium software app|Participants in the NIPA+TAU group will be sent two, URL's (one for iOS and one for Android) for installing the Metacognium software app, which hosts the four NIPA sessions. Participants will be provided with unique ID for registering and using the program on the Metacognium app. The NIPA sessions will be locked until participants have completed their baseline assessment. Once participants complete each NIPA session, they will receive an email and/or text notifying them that the next session is unlocked and that they can proceed to complete it.
219358955|NCT07178158|OTHER|Continue treatment as usual|Continue your treatment schedule as usual with the for 4 weeks.
219358956|NCT07178626|OTHER|Not applicable- observational study|This is a prospective observational study and does not involve any intervention measures
219358957|NCT07177625|PROCEDURE|Retrolaminar block|Ultrasound-guided retrolaminar block performed prior to prone-position ESWL. This intervention is applied only to participants in the RLB Group. Patients will be monitored for pain intensity (VAS), vital signs, procedural duration, and any adverse events during and after the procedure. Rescue analgesia will be administered if clinically indicated.
219358958|NCT07177625|DRUG|Sedoanalgesia|Standard sedoanalgesia administered during prone-position ESWL. This intervention is applied only to participants in the Sedation Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided as needed.
219358959|NCT07177625|OTHER|No Intervention / None|No additional regional block or sedoanalgesia; standard monitoring only. This applies only to participants in the Control Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided if clinically indicated.
219358960|NCT07178509|PROCEDURE|Stress Echocardiography with Contrast|Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
219358961|NCT07178899|BEHAVIORAL|typology-based intervention|The typology-based intervention includes: (1) typology-based counselling, (2) personalized E-message based on the counselling content discussed (3) a booklet introducing the typology of quit identity. All interventions and materials are delivered by smoking counselling.
219358962|NCT07178899|BEHAVIORAL|Routine Treatment|The routine smoking cessation intervention includes: (1) Routine counselling generic advice on preventing smoking relapse (2) Brief e-messages that consist of general quit advice for 4 weeks. Counsellors implement both routine practices.
219358963|NCT07179315|DRUG|cemiplimab+fianlimab|Fianlimab 1600 mg + Cemiplimab 350 mg FDC
219358964|NCT07179315|DRUG|Cemiplimab|350 mg
219358965|NCT07178821|PROCEDURE|Conventional POEM|Standard posterior POEM with full-thickness myotomy, including both circular and gastric sling muscle fibers.
219358966|NCT07178821|PROCEDURE|Sling Fiber-Preserving POEM|Posterior POEM with selective preservation of gastric sling fibers by limiting myotomy to the right of the second penetrating vessel.
219358967|NCT07177781|DIETARY_SUPPLEMENT|Wild blueberry powder|Study volunteers will consume daily 26 grams of wild blueberry powder for 16 weeks, which has to be dissolved in a glass of water.
219358968|NCT07179328|DEVICE|Focused Ultrasound Next Generation Dome Helmet|The Next Generation Dome Helmet (FUS NG) is a non-invasive, MRI-guided focused ultrasound system developed at Sunnybrook Research Institute. It is used to disrupt the blood-brain barrier (BBB) in patients with glioblastoma during the maintenance phase of temozolomide (TMZ) therapy. The device allows targeted BBB opening using a fixed transducer array and intravenous DEFINITY® contrast.
219358969|NCT07179328|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure.
219358970|NCT07178184|DRUG|Modified Qing-Zao-Jiu-Fei Decoction (MQZJFD)|"MQZJFD is the core formula in this clinical study and consists of the 11 following herbs: Mori Folium 9g, Plaster stone 9g, Trichosanthis Fructus 9g, Ophiopogyonis Radix 6g, Armeniacae Semen Amarum 6g, Fritillariae Thunbergii Bulbus 6g, Eriobotryae Folium 6g, Ginseng Radix et Rhizoma 3g, Semen Sesami Nigrum 3g, Asini Corii Colla 3g, Glycyrrhizae Radix et Rhizoma 3g.~The formula will be prepared with single concentrated herbal granules (1 g of single concentrated herbal granule equates to 5 g of original dry herbs, except for Ophiopogyonis Radix whose ratio will be that 1 g of single concentrated herbal granule equals to 3 g of original dry herb, and Asini Corii Colla whose ratio will be that 1 g of single concentrated herbal granule equals to 1 g of original dry herb). The herbal granules will be provided by a Good Manufacturing Practice (GMP)-accredited supplier."
219358971|NCT07178184|DRUG|Placebo|The placebo granules consists of an inert substance made of starch filler, silica coating, flavor and coloring. Its appearance is unidentifiable to the real intervention drug. The placebo granules is also manufactured under GMP standards. To ensure blinding, the MQZJFD granules and placebo granules will be indistinguishable in appearance, smell and flavor.
219358972|NCT06409364|DRUG|Fludrocortisone|small white tablet containing 100mcg of fludrocortsone
219358973|NCT06409364|DRUG|Placebo|Matched placebo tablet,
219358974|NCT07177677|BIOLOGICAL|hBMMSC|Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
219358975|NCT07177820|OTHER|Video-Guided Acupuncture Imagery Treatment (VGAIT)|Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them
219358976|NCT07178067|OTHER|Mediterranean diet|The Mediterranean diet, characterised by a high intake of fruits, vegetables, whole grains, legumes, nuts, and olive oil, along with moderate consumption of fish and poultry, has been associated with anti-inflammatory and neuroprotective effects. Notably, this dietary pattern has the potential to enhance the production of short-chain fatty acids (SCFAs) and support gut microbial diversity, representing a promising strategy for nutritional intervention in patients with ALS.
219358977|NCT07178795|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
219358978|NCT07178795|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
219358979|NCT07178795|DRUG|Pemetrexed|Administration by intravenous infusion for a cycle of 3 weeks.
219358980|NCT07178795|DRUG|Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
219358981|NCT07178795|DRUG|Cisplatin|Administration by intravenous infusion for a cycle of 3 weeks.
219358982|NCT07178938|DRUG|Radiotracer targeting SSTR2 ([68Ga]Ga-DOTA-TOC)|Patients will receive a single infusion of the diagnostic agent \[68Ga\]Ga-DOTA-TOC will which will be detected by PET/CT imaging. The recommended activity for an adult weighing 70 kg is 100 to 200 MBq, administered by direct slow intravenous injection and for a single use only.
219358983|NCT07178249|BIOLOGICAL|EXG202 injection|EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration（wAMD） with a single intravitreal injection and administration.
219358984|NCT07178327|DRUG|LYN101|"In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection.~In Part B, participants will receive multiple doses of LYN101 administered as a SC injection."
219358985|NCT07178327|DRUG|Placebo|"In Part A, participants will receive single dose of the matched placebo administered as a subcutaneous (SC) injection (4 cohorts).~In Part B, participants will receive multiple doses of the matched placebo administered as a SC injection."
219358986|NCT07179263|OTHER|50% glycolic acid|Subjects use 3 drops about 0.2g of 50% Glycolic Acid product on half face under instruction, then wait for 3 minutes and wash face by tap water. Wait for 10 minutes before measuring.
219358987|NCT07179263|OTHER|Tape Stripping|Technician use the D100 to paste on the center of the test area and make it fit the skin more completely and evenly by pump fully cover the D100 patch for 10 seconds. Stripping on each test area until the skin change into redness. The number of stripping will be recorded.
219358988|NCT07178171|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706
219358989|NCT07178171|DRUG|Pirarubicin|pirarubicin
219358990|NCT07178171|DRUG|Nab-paclitaxel|nab-paclitaxel
219358991|NCT07178171|DRUG|Carboplatin (AUC 5)|carboplatin
219358992|NCT07178171|DRUG|Cyclophosphamide|cyclophosphamide
219359832|NCT07178756|PROCEDURE|Acupuncture|"Both groups A and B will undergo standard postoperative management program. This includes conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge, post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery.~In addition, acupuncture treatment will be delivered for the treatment group. Acupuncture will be performed 2x/week from postoperative week (POW) 5 to POW 8, a total of 8 acupuncture treatments will be administered. From the 2nd to 8th treatment, electroacupuncture and infrared therapeutic lamp will be used. The acupuncture needles to be used for this study are Kinhong/MAC sterile acupuncture needles for single use. The needles will be left in situ for 20 minutes. Electrical stimulation will be delivered at 2Hz for 20 min, at an intensity below individual patient's pain threshold. 4 acupuncture points will be stimulated in pairs."
219358993|NCT07177495|PROCEDURE|maxillary sinus floor elevation using Open Maxillary sinus floor elevation and Augmentation using Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml~  \+ adrenaline0.017 mg), full-thickness mucoperiosteal flap originating from the mid-crestal area or slightly toward the palate side would be opened.~* lateral window will be created in the maxillary bone to allow for adequate access to the sinus membrane.~* The membrane will be carefully elevated using a sinus elevator.~* bone graft will be placed into the sinus cavity using Autogenous Bone with Deproteinized Bovine Bone Particulate.~* collagen membrane will be secured in place using resorbable sutures or tacks if necessary.~Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~* full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened.~* core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
219358994|NCT07177495|PROCEDURE|Open Maxillary sinus floor elevation and Augmentation using A Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* After maxillary sinus floor elevation, Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate will be placed in the sinus cavity and secured in place using resorbable sutures or tacks if necessary.~* Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~  * full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened. • core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
219358995|NCT07178548|OTHER|Online Survey|Participants will complete a structured online survey designed to assess their knowledge, attitudes, and application of evidence-based guidelines (clinical practice guidelines - CPGs) in managing low back pain (LBP).
219358996|NCT07177547|OTHER|Mental health screening and referral practices in physiotherapy|Semi-structured interviews were conducted with 18 physiotherapists working in private settings to explore recognition, screening, and referral practices for anxiety and depression in patients with chronic musculoskeletal pain.
219358997|NCT07178496|OTHER|Sleep Hygiene Techniques|"Sleep Hygiene Techniques~The sleep hygiene program includes education and behavioral strategies to promote healthier sleep patterns, delivered alongside physiotherapy exercises. Key components are:~Regular Sleep-Wake Schedule~Encourage patients to maintain consistent bedtime and wake-up times, even on weekends.~Avoid excessive time in bed when not sleeping.~Optimizing the Sleep Environment~Ensure a quiet, dark, and cool bedroom (18-22°C).~Use supportive pillows to maintain neutral cervical alignment and reduce neck strain.~Remove distractions such as TVs, mobile phones, and bright lights.~Pre-Sleep Routine~Establish a relaxing wind-down routine (e.g., gentle stretching, breathing exercises, reading).~Avoid mentally stimulating activities or heavy problem-solving before bedtime.~Limiting Stimulants and Alcohol~Avoid caffeine, nicotine, and alcohol at least 4-6 hours before bedtime.~Avoid heavy meals close to bedtime; a light snack is acceptable if hungry.~Daytime Habits t"
219358998|NCT07178496|OTHER|conventional physiotherapy program|"Conventional Physiotherapy Program~1. Treatment Frequency and Duration~   Frequency: 3 sessions per week~   Duration: 8 weeks~   Session length: 45-60 minutes~2. Hot Pack Application (10-15 minutes)~   Purpose: Reduce pain, improve soft-tissue extensibility, and prepare muscles for exercise.~   Procedure:~   Moist hot pack applied to the cervical region.~   Temperature: 40-45°C (comfortable warmth, checked to avoid burns).~   Duration: 10-15 minutes with adequate towel layers.~3. Neck Endurance and Strength Training (30-40 minutes)"
219358999|NCT07178496|OTHER|Control arm|"only advices and home advices~Physiotherapy Advice for Patients with Neck Pain~Adhere to Your Exercise Program~Perform the prescribed neck strengthening and endurance exercises daily.~Focus on quality over quantity-slow, controlled movements are more effective.~Maintain Correct Posture During All Activities~Keep your neck in a neutral position whether sitting, standing, or walking.~Incorporate Frequent Micro-Breaks~Every 30-45 minutes, pause to gently move and stretch your neck and shoulders.~Small posture corrections throughout the day prevent stiffness.~Use Heat Before Exercise if Stiff or Painful~Apply a hot pack for 10-15 minutes before exercises to relax muscles.~Avoid prolonged or excessive heat application.~Stay Active - Avoid Prolonged Rest~Light physical activity (walking, cycling, gentle mobility work) helps recovery.~Bed rest should be avoided unless pain is severe.~Practice Relaxation and Breathing C"
219359000|NCT07178002|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
219359001|NCT07178002|DRUG|Placebo|Matching placebo
219359002|NCT07178834|BEHAVIORAL|Telerehab|Adverse events are observed during online rehabilitation with computer vision technology in patients with MS.
219359003|NCT07177911|DRUG|CC312|Subjects will initially receive a single intravenous dose of CC312. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
219359004|NCT07177911|DRUG|Placebo|Subjects will initially receive a single intravenous dose of Placebo. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
219359005|NCT07178340|DRUG|Perioperative treatment|perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab
219359006|NCT07177924|PROCEDURE|Monarch RAB with CBCT-guided ICG Dye Marking|Under general anesthesia, the Monarch RAB platform is used to navigate to the target bronchus. With CBCT confirmation, 0.25 ml of ICG (0.2 mg/ml) mixed with 0.25 ml iodinated contrast is injected within 1 cm of the nodule. The dye marking is identified intraoperatively with near-infrared light to guide VATS sublobectomy.
219359833|NCT07178756|OTHER|Post-operative standard care|Standard postoperative management program includes: conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge. Post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery. No acupuncture given
219359834|NCT07178769|DIETARY_SUPPLEMENT|ARKOSTEROL|After 2 and 4 months from the start of treatment, a follow-up will be carried out in which anthropometric data will be measured (weight, BMI, waist circumference), vital signs (blood pressure and pulse) and a sample will be taken for analysis to measure the following parameters: CT, LDL, HDL, triglycerides, VLDL, Apo A, Apo B, liver function (GOT, GPT) and kidney function (creatinine) and Liposcale ® (in case of treatment group).
219359007|NCT07177989|OTHER|Experimental Group|The interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise heart rate will be calculated using the Karvonen formula for the base line week and the following weeks.Following each aerobic session, they'll practice Alternate Nostril Breathing (ANB), beginning with 5 minutes in the first week and progressing to 10 minutes thereafter. ANB involves specific hand positioning and breathing techniques to promote relaxation and balance. All sessions will be supervised by a physiotherapist.
219359008|NCT07177989|OTHER|interventional group A|In interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down phase lasting 5-7 minutes, allowing the heart rate to gradually return to baseline and preventing post-exercise hypotension. From the second week onwards, the aerobic training session will begin with a 5-minute warm-up to prepare the body and gradually increase heart rate. The main workout involves a cycle ergometer, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes. The session ends with a 5-7 min
219359009|NCT07179068|BEHAVIORAL|Child Body Image Development Workshop|This is an online, single-session, modular intervention for parents of children that are two-to-six years old. It is designed to target and improve child body image development by providing psychoeducation and interactive activities to parents in each of the four modules. Modules include Body Image Development/Body Talk, Food Talk, Picky Eating and Mealtime Conversations, and Media Usage and Social Comparison. These modules were designed using the results of our previously completed Needs Assessment, as well as the current evidence-base regarding risk factors for the development of body image in young children.
219359010|NCT07177443|RADIATION|Radiotherapy|"Following induction therapy, eligible patients will receive radiotherapy alone or concurrent chemoradiotherapy per protocol. Photon or proton radiotherapy techniques were permitted. Prescribed doses were:~Primary tumor and metastatic lymph nodes: 70 Gy/33 fractions High-risk lymphatic drainage areas: 60 Gy/33 fractions Low-risk regions: 54 Gy/33 fractions~PTV dose specifications:~GTVnx: 70 Gy GTVnd: 66-70 Gy (reducible to 63 Gy for suspicious small nodes) CTV1: 60-62 Gy CTV2: 54-56 Gy All treatments will employ simultaneous integrated boost (SIB) intensity-modulated radiotherapy delivered once daily, 5 fractions per week."
219359011|NCT07177443|DRUG|Serplulimab|Serplulimab will be used in the induction phase for 3 cycles and the maintenance phase for 14 cycles.
219359012|NCT07177443|DRUG|Cisplatin|On days 64 and 85, patients will receive cisplatin chemotherapy at a dose of 100 mg/m² via intravenous infusion.
219359013|NCT07177586|DEVICE|GMA Laryngeal Mask Airway|The GMA-Tulip is a new single-use supraglottic airway device (SAD). Device size is selected based on the patient's weight and height, following manufacturer guidelines.
219359014|NCT07177586|DEVICE|Inflatable Laryngeal Mask Airway|The comparator is a conventional inflatable Laryngeal Mask Airway (LMA) of appropriate size (selected by weight/height), inserted using standard clinical protocols.
219359015|NCT07179107|OTHER|Baseline - week 1|Habitual fluid intake during week 1
219359016|NCT07179107|OTHER|Low Water Intake - week 2|Low water intake as described by the protocol
219359017|NCT07179107|OTHER|Moderate Water Intake - week 3|Moderate Water Intake - Week 3
219359018|NCT07179107|OTHER|Adequate Water Intake - week 4|Adequate Water Intake - week 4
219359019|NCT07179107|OTHER|Washout - week 5|Washout - week 5
219359020|NCT07179107|OTHER|Low fluid intake with non caloric sweeteners - Week 6|Low fluid intake with non caloric sweeteners - Week 6
219359021|NCT07179107|OTHER|Moderate fluid intake with non caloric sweeteners - Week 7|Moderate fluid intake with non caloric sweeteners - Week 7
219359022|NCT07179107|OTHER|Adequate fluid intake with non caloric sweeteners - Week 8|Adequate fluid intake with non caloric sweeteners - Week 8
219359023|NCT05463991|DEVICE|Bioengineered collagen implant|Urethral stricture repair
219359024|NCT07177794|DRUG|toripalimab|Patients will receive toripalimab with a maximum treatment duration of one year (240 mg, IV drip, Q3W, for 16 cycles).
219359025|NCT07177794|DRUG|capecitabine|Patients will receive metronomic capecitabine, with a maximum treatment duration of one year (500 mg, twice daily, orally).
219359026|NCT07178431|BIOLOGICAL|MB-CART2019.1|CAR T cell therapy
219359027|NCT07178262|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Bilateral Erector Spinae Block at T10 level using 30ml of 0.25% Bupivacaine will be administered under Ultrasound guidance before surgical incision.
219359028|NCT07178262|DRUG|Placebo|Bilateral Erector Spinae Block at T10 level using 30ml of Normal saline will be administered under Ultrasound guidance before surgical incision.
219359029|NCT01966770|DEVICE|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
219359030|NCT01966770|DEVICE|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
219359031|NCT01966770|DEVICE|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
219359032|NCT01966770|DEVICE|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
219359033|NCT01966770|DEVICE|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
219359034|NCT01966770|DEVICE|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
219359035|NCT02377375|PROCEDURE|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
219359036|NCT02377375|PROCEDURE|Standard technique|Medtronic DBS lead 3391-28cm
219359037|NCT03123497|OTHER|completion of questionnaire|completion of questionnaire for patient and parent
219359038|NCT05253417|DRUG|50 mg Cannabidiol (CBD)|For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
219359039|NCT05253417|DRUG|Placebo|Participants take four (4) placebo capsules.
219359040|NCT05253417|DRUG|100 mg Cannabidiol (CBD)|For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
219359041|NCT01299766|BEHAVIORAL|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
219359042|NCT01299766|BEHAVIORAL|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
219359043|NCT03075085|BEHAVIORAL|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
219359044|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Ascending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the ascending limb
219359045|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Descending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the descending limb
219359046|NCT05701865|BEHAVIORAL|No Alcohol Control|Participants will be assigned to a no alcohol control condition
219359047|NCT03734757|PROCEDURE|imaging in trimodality|PET-CT and MRI
219359048|NCT04271098|PROCEDURE|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
219359049|NCT04271098|OTHER|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
219359050|NCT04271098|OTHER|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
219359051|NCT00006519|DRUG|Capravirine|
219359052|NCT02492438|BIOLOGICAL|PPV23 vaccination or PCV13 vaccination|
219359053|NCT04133584|BIOLOGICAL|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
219359054|NCT04133584|BIOLOGICAL|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
219359055|NCT04133584|BIOLOGICAL|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
219359056|NCT00744445|DRUG|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
219359057|NCT03908619|DRUG|Omeprazole 20mg|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
219359058|NCT03908619|DRUG|Esomeprazole 20mg|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
219359059|NCT03908619|DRUG|Rabeprazole Sodium 20mg|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
219359060|NCT03908619|DRUG|Vonoprazan|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
219359061|NCT04996355|OTHER|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~1. 5-FU~2. Oxaliplatin~3. Irinotecan~4. 5-FU+ Oxaliplatin~5. 5-FU+ Irinotecan~6. 5-FU+ Oxaliplatin+ Irinotecan~7. 5-FU+Cetuximab~8. Cetuximab~9. Regorafenib"
219359062|NCT05282758|OTHER|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
219359063|NCT05282758|OTHER|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
219359064|NCT02421341|DRUG|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
219359065|NCT02421341|PROCEDURE|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
219359066|NCT02421341|OTHER|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
219359067|NCT02421341|RADIATION|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
219359068|NCT02421341|OTHER|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
219359069|NCT02421341|OTHER|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
219359070|NCT02421341|OTHER|Chemosensitivity Test|Using a bag you breath in and out your own air.
219359071|NCT02421341|DRUG|Placebo|
219359072|NCT04041856|DRUG|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
219359073|NCT02113787|PROCEDURE|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
219359074|NCT02664155|DRUG|Apixaban|Direct Oral Anticoagulant
219359075|NCT02664155|DRUG|Rivaroxaban|Direct Oral Anticoagulant
219359076|NCT02664155|DRUG|Heparin|Standard Of Care
219359077|NCT02664155|DRUG|VKA|Standard Of Care
219359078|NCT03118440|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
219359079|NCT03118440|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
219359080|NCT00403260|DRUG|Pyronaridine - artesunate|once a day for 3 days
219359081|NCT00403260|DRUG|Mefloquine plus artesunate|once a day for 3 days
219359082|NCT02487992|BIOLOGICAL|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
219359083|NCT01071187|DRUG|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
219359084|NCT01071187|DRUG|Placebo|Placebo
219359085|NCT01431092|DRUG|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
219359086|NCT01431092|DRUG|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
219359087|NCT01354028|OTHER|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
219359088|NCT03750188|DRUG|ProHance|0.1 mmol/kg ProHance intravenous injection
219359089|NCT04922866|OTHER|no intervention|no intervention
219359090|NCT00826813|DEVICE|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
219359091|NCT02109159|OTHER|A short online video with emotional content|
219359092|NCT02109159|OTHER|A short online video with less emotional content|
219359093|NCT06174350|BEHAVIORAL|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
219359094|NCT06174350|OTHER|Placebo|Intervention Description not
219359095|NCT00935883|DRUG|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
219359096|NCT00935883|DRUG|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
219359097|NCT01664793|BEHAVIORAL|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
219359098|NCT05482945|DRUG|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
219359099|NCT05897593|DEVICE|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
219359100|NCT02280850|DRUG|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
219359101|NCT02280850|DRUG|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
219359102|NCT02280850|DRUG|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
219359103|NCT05363176|BEHAVIORAL|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, \~45 minute sessions delivered via telehealth.
219359104|NCT05363176|BEHAVIORAL|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, \~45 minute session delivered via telehealth
219359105|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
219359106|NCT06183164|OTHER|Mindfulness: Awareness-Based Stress Reduction Program|The mindfulness-based stress reduction program was applied to the patients in the experimental group once a week, for 150 minutes, for 8 weeks and 8 times in total. Then, an intermediate test is applied to the patients. After the interim test, patients are asked to repeat the mindfulness-based stress reduction program individually for 8 weeks (between weeks 8-16). In addition, after the conscious awareness-based stress reduction program is applied to the patients in the experimental group by the researcher, the 'Conscious Awareness-Based Stress Reduction Program' booklet prepared by the researcher is given to the patients as a guide. experimental group.
219359107|NCT03731962|PROCEDURE|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
219359108|NCT00784797|DRUG|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
219359109|NCT00784797|DRUG|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
219359110|NCT05348798|OTHER|Web based survey|Web-based survey on exercise addiction and personality traits
219359111|NCT00121628|DRUG|AMG 706|
219359112|NCT06674577|DRUG|Atacicept 150 mg|"The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½ 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec"
219359113|NCT04892849|OTHER|Conventional Therapy acc. to prevailing clincal approved schemes|The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
219359114|NCT01762280|DRUG|Famitinib Malate Capsule|
219359115|NCT04306432|OTHER|Cognitive tests and Patient Reported Outcomes|Each patient will undergo cognitive tests and questionnaires
219359116|NCT03875261|DRUG|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
219359117|NCT00715988|DRUG|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
219359118|NCT00715988|DRUG|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
219359119|NCT00494897|DRUG|Asparaginase|
219359120|NCT00494897|DRUG|Cyclophosphamide|
219359121|NCT00494897|DRUG|Cytarabine|
219359122|NCT00494897|DRUG|Daunorubicin|
219359123|NCT00494897|DRUG|Mercaptopurine|
219359124|NCT00494897|DRUG|Prednisone|
219359125|NCT00494897|DRUG|Vincristine|
219359126|NCT00494897|DRUG|Methotrexate|
219359127|NCT00494897|PROCEDURE|Intrathecally treatment|
219359128|NCT01354483|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|
219359129|NCT01354483|BIOLOGICAL|Methylprednisolone|30mg/kg i.v. methylprednisolone
219359130|NCT01354483|DRUG|Lithium Carbonate Tablet|6 weeks
219359131|NCT03228160|OTHER|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
219359132|NCT06471881|DEVICE|Two mandibular implants|Rehabilitation with two mandibular implants and a mandibular implant overdenture supported by a computer-aided design bar
219359133|NCT03473093|DRUG|Pregabalin 150mg|One group will receive oral pregabalin with morphine infusion
219359134|NCT03473093|DRUG|Morphine|One group will receive morphine infusion 20 microgram/kg/h
219359135|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
219359136|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
219359137|NCT04638491|DRUG|Lurbinectedin for injection|On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
219359138|NCT01874171|DRUG|Cisplatin|
219359139|NCT01874171|DRUG|Cetuximab|
219359140|NCT00993811|DEVICE|Shang Ring circumcision|novel device for adult male circumcision
219359141|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP|
219359142|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP + Stabilizer|
219359143|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4|
219359144|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4 + Stabilizer|
219359145|NCT05624008|OTHER|Bioceramic glass ionomer restoration|bioactive glass ionomer with unique biocompatibility and biological regenerative properties
219359146|NCT05624008|OTHER|Resin modified glass ionomer restoration|A hybrid of glass ionomer and composite resin with acid-base and polymerizable components
219359147|NCT02743260|DRUG|pitavastatin|
219359148|NCT02743260|DRUG|Metformin|
219359149|NCT02743260|DRUG|digoxin|
219359150|NCT02743260|DRUG|Adefovir|
219359151|NCT02743260|DRUG|sitagliptin|
219359152|NCT06244797|PROCEDURE|L-PRF and H-PRF|Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.
219359153|NCT06244797|PROCEDURE|Impacted Tooth Removal|All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.
219359154|NCT04498845|OTHER|In-home assessment plan|The in-home family educational session provides participants with resources to identify and reduce exposures to metals in the home environment.
219359155|NCT04498845|BEHAVIORAL|Family educational session|The 1-hr in-home family educational session, administered during the first home visit to all participants, adapts a motivational interview model to reduce exposure to metals. this done by empowering families to make informed decisions regarding lead and metal exposures in their home environments that originate from different sources with an emphasis on sources from the workplace. The session will consist of both developing a plan tailored for the home and reviewing educational materials on strategies to reduce exposures in the home, focusing on barriers families experience when attempting to change their behaviors.
219359156|NCT04498845|BEHAVIORAL|Worker take home prevention training|The take home prevention 1-hour educational session guides the worker through 6 simple steps to identify and then prioritize change/s that can be made before leaving work to prevent take-home lead. It has been adapted from the AGILE model for prioritizing tasks. Participants will also be provided with a pamphlet about how to prevent lead from being taken home.
219359157|NCT04498845|OTHER|D-LEAD cleaner products|D-LEAD cleaner products include hand wipes, all surfaces cleaner and laundry detergent.
219359158|NCT05596019|PROCEDURE|specific neurodynamic exercises|Specific neurodynamic exercises in women older than 65 years with neck pain
219359159|NCT05596019|PROCEDURE|multimodal exercise|Multimodal and nonspecific exercises in women older than 65 years with neck pain
219359160|NCT06342674|OTHER|Giving breast milk to the newborn according to the circadian rhythm|It is the delivery of milk expressed by the newborn's mother during the neonatal intensive care unit, in accordance with the time of expression. Breast milk follows the circadian rhythm, that is, the milk the mother expresses at night will be given to her infant at night, and the milk she expresses during the day will be given to her infant during the day
219359161|NCT06342674|OTHER|Usual care|Newborns in the control group will be given expressed milk first, in line with the routine practice of the clinic
219359162|NCT05070884|OTHER|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
219359163|NCT01428401|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
219359164|NCT01428401|OTHER|Placebo|at a rate of 3 g three times per day
219359165|NCT01656720|DRUG|1R, 2S-methoxamine hydrochloride|
219359166|NCT01656720|DRUG|Placebo|
219359167|NCT04360356|COMBINATION_PRODUCT|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
219359168|NCT04360356|OTHER|Standard Care|Oxygen via Ventilators
219359169|NCT02611635|DRUG|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359170|NCT02611635|DRUG|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359171|NCT02611635|DRUG|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359172|NCT02611635|DRUG|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359173|NCT02611635|DRUG|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359174|NCT02611635|DRUG|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
219359175|NCT05638048|BEHAVIORAL|Precision grip training|First determine patients for holding the ball movement should reach the effective blood flow velocity and best duration - relaxation, and USES the electronic grips and color doppler ultrasonic diagnostic apparatus, for individual patients to choose the best grip the efforts and training, to form the best grip the training plan, and observe the scheme for Peripheral central venous catheter-associated thrombosis prevention effect.
219359176|NCT05638048|BEHAVIORAL|Use maximum strength grip training|Patients were routinely implanted with PICC, and on the basis of health education in the control group, the best continuous-relaxation time, frequency and maximum grip strength of patients were used for grip strength training.
219359177|NCT05638048|BEHAVIORAL|Health education on routine grip strength training|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
219359178|NCT03381456|OTHER|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
219359179|NCT04337411|OTHER|Follow-up assessments|Longitudinal evaluation of recovery
219359180|NCT06496412|DRUG|fecal microbiota transplantation|Take fecal microbiota capsules.
219359181|NCT06496412|DRUG|Placebo|Take placebo capsules.
219359182|NCT02160405|DIETARY_SUPPLEMENT|native potato|
219359183|NCT00282126|DIETARY_SUPPLEMENT|Potassium citrate|kcitrate
219359184|NCT03881007|OTHER|Mouthwash with LCM|Subjects will mouthwash daily with LCM and before/after sex
219359185|NCT03881007|OTHER|Mouthwash with placebo|Subjects will mouthwash daily with placebo and before/after sex
219359186|NCT02770326|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|
219359187|NCT03484468|DEVICE|anterior segment Ocular Coherence Tomography|anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
219359188|NCT05559723|DEVICE|electromagnetic field therapy|"Three times a week for four weeks, the study group got electromagnetic fields (EMFs) therapy and the selected physical therapy program. The EMFs therapy was applied using an electromagnetic field therapy device (Magner Plus Astar)~. From the prone lying position the device will be adjusted around the lumbar area at a low frequency (50 Hz), with the intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60), and the application time will be10 minutes"
219359189|NCT05559723|OTHER|selected physical therapy program|"in the form of~1. Hot packs will be placed paravertebral on the lumbar region for 5 minutes from a prone lying position~2. selected physical therapy exercises in form of Static exercise for back and abdominal muscles, stretching exercises for both lower limbs, 10 times each exercise"
219359190|NCT05559723|DEVICE|Therapeutic ultrasound therapy|Therapeutic ultrasound therapy using ultrasound device Chattanooga, model 2760, serial number T11238, 120-240V, 50/60Hz, made in Mexico . That will be applied paravertebral on the lumbar region from the prone lying position, with pulsed mode, frequency 1 MHz, intensity 0.5 W/cm2 and will be applied by circular moving technique at a rate of 4 cm/s for 10 minutes.
219359191|NCT05559723|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS): from the prone lying position, the electrodes will be placed on the course of pain detected by the patient, with an asymmetrical rectangular biphasic form, at a pulse repetition frequency of 100Hz and duty cycle of 250 microseconds; the intensity was set at a level that each patient could feel, for 15 minutes .
219359192|NCT02656927|BEHAVIORAL|Yoga Condition|
219359193|NCT02264587|DRUG|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
219359194|NCT02264587|DRUG|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
219359195|NCT00319969|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
219359196|NCT00319969|DRUG|Topotecan|Topotecan 1.5mg/m\<2\> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
219359197|NCT05434832|BEHAVIORAL|Virtual Reality|Distraction method
219359198|NCT05434832|BEHAVIORAL|Local cold-vibration|Distraction method
219359199|NCT02470455|DRUG|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
219359200|NCT02407093|BEHAVIORAL|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
219359201|NCT02407093|BEHAVIORAL|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
219359202|NCT00361738|DRUG|AVE2268|
219359203|NCT02971202|DRUG|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
219359204|NCT02971202|DRUG|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
219359205|NCT01946178|DEVICE|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
219359206|NCT02077933|DRUG|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
219359207|NCT02077933|DRUG|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
219359208|NCT02077933|DRUG|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
219359209|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
219359210|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
219359211|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
219359212|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
219359213|NCT05467891|DRUG|Exemestane|25 mg orally once daily
219359214|NCT02953808|DRUG|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
219359215|NCT02953808|DRUG|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
219359216|NCT04955275|OTHER|Cognitive Remediation Therapy Program (BrainHQ)|Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
219359217|NCT02634580|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
219359218|NCT02634580|DRUG|Ezetimibe|Tablet for oral administration
219359219|NCT02634580|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
219359220|NCT02634580|DRUG|Placebo Ezetimibe|Tablet for oral administration
219359221|NCT01193400|DRUG|Clofarabine|
219359222|NCT01193400|DRUG|Cytarabine|
219359223|NCT03015805|BEHAVIORAL|Contingency Management|"Contingency Management (CM) utilizes behavior modification \& cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
219359224|NCT03015805|BEHAVIORAL|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
219359225|NCT02821858|DRUG|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
219359226|NCT02821858|DRUG|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
219359227|NCT02821858|DRUG|Placebo|Matching placebo will be administered.
219359228|NCT03931356|OTHER|Pulmonary function tests|analysis of lung volume and diffusion capacity
219359229|NCT00519740|OTHER|inhalative specific bronchial provocation with grass-pollen|
219359230|NCT02619500|OTHER|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
219359231|NCT02619500|OTHER|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
219359232|NCT02619500|OTHER|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
219359233|NCT02619500|OTHER|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
219359234|NCT05489601|DRUG|Oxycodone|Oxycodone in 5mg increments up to a maximum of 10mg
219359235|NCT04868552|OTHER|Pre-hospital naloxone education|a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
219359236|NCT04535219|OTHER|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
219359237|NCT04535219|OTHER|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
219359238|NCT01030692|DRUG|Placebo|The placebo groups will receive the same dosage throughout the study.
219359239|NCT01030692|DRUG|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
219359240|NCT01030692|DRUG|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
219359241|NCT01030692|DRUG|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
219359242|NCT01030692|DRUG|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
219359243|NCT00381407|BEHAVIORAL|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
219359244|NCT00381407|BEHAVIORAL|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
219359245|NCT05708742|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
219359246|NCT05708742|DRUG|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
219359247|NCT05708742|DRUG|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
219359248|NCT05708742|DEVICE|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
219359249|NCT01505894|DRUG|BI 409306|Film-coated tablet
219359250|NCT01505894|DRUG|Placebo|Film-coated tablet
219359251|NCT01622569|DRUG|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
219359252|NCT06526936|BEHAVIORAL|Education|Information about diabetic foot care
219359253|NCT04248205|DRUG|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
219359254|NCT01001702|DRUG|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
219359255|NCT00569894|BIOLOGICAL|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
219359256|NCT00569894|BIOLOGICAL|TIV (Injection)|One or two injections of TIV depending on previous status.
219359257|NCT00569894|OTHER|Unvaccinated Control|no vaccine
219359258|NCT03665363|OTHER|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
219359259|NCT03665363|OTHER|Self-study|Active control consisting of directed self-studies on internet.
219359260|NCT03685773|DRUG|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
219359261|NCT03685773|DRUG|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
219359262|NCT03685773|DRUG|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
219359263|NCT00424060|DRUG|sagopilone|
219359264|NCT00424060|GENETIC|fluorescence in situ hybridization|
219359265|NCT00424060|GENETIC|gene expression analysis|
219359266|NCT00424060|OTHER|immunohistochemistry staining method|
219359267|NCT00424060|OTHER|laboratory biomarker analysis|
219359268|NCT00424060|OTHER|pharmacological study|
219359269|NCT00997516|PROCEDURE|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
219359270|NCT00997516|PROCEDURE|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
219359271|NCT02975830|RADIATION|Three dimensional CT based images|Right bronchial angle, left bronchial angle
219359272|NCT00584233|DEVICE|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
219359273|NCT00584233|DEVICE|MRI|Breast MRI
219359274|NCT06545487|OTHER|BLOOD SAMPLE|BLOOD ANALYTICS IN SEVERAL PARAMETERS
219359275|NCT02222714|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
219359276|NCT02222714|DRUG|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
219359277|NCT01779206|DRUG|Epirubicin|
219359278|NCT01779206|DRUG|Cyclophosphamide|
219359279|NCT01779206|DRUG|Docetaxel|
219359280|NCT01779206|DRUG|Paclitaxel|
219359281|NCT01940484|DRUG|Methoxy polyethylene glycol epoetin beta|
219359282|NCT01894126|BEHAVIORAL|Two-way SMS Dialogue|
219359283|NCT01894126|BEHAVIORAL|One-way SMS Messaging|
219359284|NCT01007214|PROCEDURE|Prostatectomy|Elective prostatectomy
219359285|NCT04361201|PROCEDURE|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
219359286|NCT04361201|DIAGNOSTIC_TEST|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
219359287|NCT05813197|BEHAVIORAL|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
219359288|NCT05813197|BEHAVIORAL|Usual services|Usual services
219359289|NCT05904314|BEHAVIORAL|Simulation training in electronic fetal monitor management|Simulation training in electronic fetal monitor management
219359290|NCT02892266|OTHER|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
219359291|NCT05329532|BIOLOGICAL|Modi-1 Moditope|Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
219359292|NCT05329532|BIOLOGICAL|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
219359293|NCT05329532|DEVICE|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
219359294|NCT06447922|OTHER|Metal ion level testing|Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
219359295|NCT05542862|BIOLOGICAL|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
219359296|NCT05309928|DRUG|Amoxicillin|medication administration
219359297|NCT06803641|OTHER|Mindfulness practice with Tao Art (Calligraphy and Song Love Peace and Harmony).|During mindfulness practice with Tao Art (Calligraphy and Song Love Peace Harmony), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for three months.
219359298|NCT03692897|OTHER|All approved therapies for the treatment of Chronic Hepatitis B (CHB)|All approved therapies for the treatment of Chronic Hepatitis B (CHB).
219359299|NCT04971824|PROCEDURE|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
219359300|NCT05682443|DRUG|ONC-392 low|ONC-392 will be given as IV infusion, Q4W for up to 13 doses.
219359301|NCT05682443|DRUG|ONC-392 high|ONC-392 will be given as IV infusion, Q6W for up to 9 doses.
219359302|NCT05682443|DRUG|lutetium Lu 177 vipivotide tetraxetan|lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
219359303|NCT06064539|DRUG|Tolebrutinib|Tablet, taken orally
219359304|NCT06064539|DRUG|gemfibrozil|Tablet, taken orally
219359305|NCT06064539|DRUG|rifampicin|Tablet, taken orally
219359306|NCT04338893|PROCEDURE|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
219359307|NCT04338893|PROCEDURE|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
219359308|NCT04338893|PROCEDURE|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
219359309|NCT06420960|DEVICE|Wearing the connected watch|"All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance."
219359310|NCT00887861|DRUG|Investigational new drug, company code: BGG492|
219359311|NCT00887861|DRUG|Placebo|
219359312|NCT02426177|DRUG|Labetalol|anti-hypertensive agents
219359313|NCT02426177|DRUG|Nifedipine|calcium channel blocker ,for lowering blood pressure
219359314|NCT04133961|DRUG|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
219359315|NCT04133961|DRUG|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
219359316|NCT03792841|DRUG|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
219359317|NCT03792841|DRUG|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
219359318|NCT03792841|DRUG|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
219359319|NCT03792841|DRUG|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
219359320|NCT03315923|DRUG|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
219359321|NCT03315923|DRUG|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
219359322|NCT02771132|BEHAVIORAL|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
219359323|NCT02771132|BEHAVIORAL|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
219359324|NCT02771132|BEHAVIORAL|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
219359325|NCT01281410|PROCEDURE|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
219359326|NCT01281410|OTHER|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
219359327|NCT01285908|DRUG|Intravenous Norepinephrine Infusion|
219359328|NCT01866007|DRUG|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
219359329|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
219359330|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
219359331|NCT01866007|DRUG|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
219359332|NCT06501781|BEHAVIORAL|Peer Activate-LAI|Peer Activate-LAI is a Peer Recovery Specialist-delivered behavioral activation and problem solving intervention, based on our team's formative work. The intervention focuses on problem-solving skills to improve adherence to ART and/or PrEP both at the individual level and environmental barriers to care (i.e., transportation, housing).
219359333|NCT06501781|OTHER|Standard of Care HIV treatment or prevention with LAI-PrEP/ART|Standard of care HIV treatment or prevention with LAI-PrEP/ART
219359334|NCT03730805|BEHAVIORAL|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller \& Rollnick, 1991).
219359335|NCT03730805|BEHAVIORAL|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
219359336|NCT03730805|BEHAVIORAL|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
219359337|NCT03129659|DIAGNOSTIC_TEST|Coronary CT Angiography|Coronary CT angiography
219359338|NCT04894656|DIAGNOSTIC_TEST|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
219359339|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
219359340|NCT01340209|DRUG|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
219359341|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
219359342|NCT06219577|DRUG|Systane Complete Multi-Dose PF|Eyedrop
219359343|NCT06219577|DRUG|Walgreen's Lubricant Balance|Eyedrop
219359344|NCT05312034|BEHAVIORAL|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
219359345|NCT05563792|BEHAVIORAL|Options for Pain Management using Non-medication Strategies|The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
219359346|NCT00445133|DEVICE|Magnetic Sleep Pad|
219359347|NCT02570633|OTHER|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
219359348|NCT02570633|OTHER|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
219359349|NCT03011658|PROCEDURE|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
219359350|NCT02988583|DEVICE|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
219359351|NCT02988583|DEVICE|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
219359352|NCT02412293|BEHAVIORAL|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
219359353|NCT02412293|OTHER|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
219359354|NCT02412293|BEHAVIORAL|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
219359355|NCT02257190|BEHAVIORAL|Control|One hour of rest.
219359356|NCT02257190|BEHAVIORAL|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
219359357|NCT02257190|BEHAVIORAL|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
219359358|NCT04219150|DEVICE|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
219359359|NCT04219150|DRUG|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
219359360|NCT01484782|BEHAVIORAL|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
219359361|NCT04142983|BIOLOGICAL|Adacel|0.5 mL, Intramuscular
219359362|NCT03530410|DEVICE|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
219359363|NCT00328770|DRUG|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
219359364|NCT03692858|DRUG|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
219359365|NCT03692858|DRUG|Adductor Canal Block|Adductor Canal Block using Ropivacaine
219359366|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial.
219359367|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
219359368|NCT05206526|BEHAVIORAL|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
219359369|NCT05206526|BEHAVIORAL|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
219359370|NCT01381783|PROCEDURE|Phacoemulsification|Phacoemulsification under topical anesthesia
219359371|NCT00448188|PROCEDURE|central venous catheter application|
219359372|NCT04396509|BEHAVIORAL|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
219359373|NCT02183090|DRUG|Meloxicam ampoule|
219359374|NCT02183090|DRUG|Meloxicam tablet|
219359375|NCT02872454|BEHAVIORAL|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
219359376|NCT03537391|DIAGNOSTIC_TEST|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
219359377|NCT03537391|DIAGNOSTIC_TEST|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
219359378|NCT03537391|DIAGNOSTIC_TEST|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index \~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
219359379|NCT03537391|DIAGNOSTIC_TEST|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
219359380|NCT03537391|DIAGNOSTIC_TEST|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (\<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is \< 6 mm.
219359381|NCT04809610|BEHAVIORAL|Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
219359382|NCT00419471|DRUG|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
219359383|NCT00419471|DRUG|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
219362612|NCT02494596|DRUG|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
219359384|NCT05315466|PROCEDURE|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
219359385|NCT05315466|PROCEDURE|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
219359386|NCT02655250|OTHER|Microbiome|
219359387|NCT00969215|DEVICE|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
219359388|NCT01394705|DEVICE|BodyMedia|Accelerometer
219359389|NCT03516344|PROCEDURE|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
219359390|NCT01284699|PROCEDURE|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
219359391|NCT00643994|RADIATION|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
219359392|NCT02904980|BEHAVIORAL|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
219359393|NCT02904980|BEHAVIORAL|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
219359394|NCT01573273|DRUG|Oxytocin|intranasal administration, 40 IUs
219359395|NCT01573273|DRUG|Saline|intranasal administration, 40 IUs
219359396|NCT02061254|DEVICE|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
219359397|NCT02061254|DEVICE|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
219359398|NCT02061254|DEVICE|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
219359399|NCT02061254|PROCEDURE|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
219359400|NCT02646527|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
219359401|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
219359402|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
219359403|NCT03344666|BEHAVIORAL|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
219359404|NCT03344666|BEHAVIORAL|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
219359405|NCT06444672|OTHER|Home-based Rehabilitation program|Home-based rehabilitation program The investigators used the ASIA scale to evaluate the sensory function and voluntary movement7. The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-minute duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises. Participants who could stand with assistive devices (such as knee-ankle-foot orthoses, KAFO) performed walking exercises.
219359406|NCT06444672|DEVICE|Knee-Ankle-Foot-Orthosis|It is used to assist the participant in holding his /her body weight on the lower limb through standing and walking
219359407|NCT00858429|DRUG|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
219359408|NCT00858429|RADIATION|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
219359409|NCT03373565|PROCEDURE|Radial|Coronary angiography using radial approach
219359410|NCT03373565|PROCEDURE|Palmar|Coronary angiography using radial approach
219359411|NCT06519591|DRUG|Cadonilimab, LM-302, S-1, paclitaxel|Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
219359412|NCT04389242|OTHER|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
219359413|NCT02678715|DEVICE|Solubrux®|prefabricated device adaptable by temperature
219359414|NCT02678715|DEVICE|Customized Appliance|customized device fabricated in the dental laboratory
219359415|NCT02678715|DEVICE|Somatics®|standard device
219359416|NCT01743482|DRUG|Pazopanib|
219359417|NCT01212185|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
219359418|NCT01212185|OTHER|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
219359419|NCT03317951|OTHER|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
219359420|NCT03317951|OTHER|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
219359421|NCT00003209|BIOLOGICAL|bleomycin sulfate|
219359422|NCT00003209|DRUG|cisplatin|
219359423|NCT00003209|DRUG|fluorouracil|
219359424|NCT00003209|DRUG|ifosfamide|
219359425|NCT00003209|DRUG|methotrexate|
219359426|NCT00003209|DRUG|mitomycin C|
219359427|NCT00003209|DRUG|vinblastine sulfate|
219359428|NCT00003209|DRUG|vindesine|
219359429|NCT00003209|RADIATION|radiation therapy|
219359430|NCT00781157|DRUG|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
219359431|NCT00191841|DRUG|gemcitabine|
219359432|NCT00191841|DRUG|Cisplatin|
219359433|NCT02100605|DEVICE|Phytosun, decongestant, nasal spray|one time application of the nasal spray
219359434|NCT00094757|DRUG|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
219359435|NCT00094757|DRUG|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
219359436|NCT00094757|DRUG|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
219359437|NCT00094757|DRUG|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
219359438|NCT02758457|DEVICE|dental crowns|
219359439|NCT02639663|DEVICE|dental device|"Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
219359440|NCT06485154|DRUG|TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir|Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
219359441|NCT00756938|DRUG|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
219359442|NCT01437774|DEVICE|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
219359443|NCT03461133|OTHER|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
219359444|NCT03797105|BEHAVIORAL|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
219359445|NCT03145298|BIOLOGICAL|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
219359446|NCT03145298|BIOLOGICAL|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
219359447|NCT05922748|OTHER|imaging|Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
219359448|NCT05922748|OTHER|Evoked Potentials|EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
219359449|NCT05922748|OTHER|MEG|MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
219359450|NCT05922748|BEHAVIORAL|Behavioural tests|Behavioural tests will be evaluated.
219359451|NCT00470080|PROCEDURE|venepuncture|venepuncture
219359452|NCT04189679|OTHER|Immune signature in serum associated to the metabolic signature|Immune signature in serum associated to the metabolic signature
219359453|NCT04189679|GENETIC|Meta-genomic signature of intestinal flora|Meta-genomic signature of intestinal flora
219359454|NCT00374738|BEHAVIORAL|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
219362613|NCT02494596|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
219362614|NCT00002550|DRUG|cisplatin|
219362615|NCT00002550|DRUG|etoposide|
219362616|NCT00002550|PROCEDURE|conventional surgery|
219362617|NCT00002550|RADIATION|radiation therapy|
219362618|NCT00059202|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
219362619|NCT00059202|DRUG|Placebo|Placebo for Urso
219362620|NCT03378479|DRUG|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)
219362621|NCT03378479|OTHER|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
219362622|NCT00079378|DRUG|decitabine|Given IV
219362623|NCT00079378|DRUG|valproic acid|Given orally
219362624|NCT00079378|OTHER|pharmacological study|Correlative studies
219362625|NCT00079378|OTHER|laboratory biomarker analysis|Correlative studies
219362626|NCT00348621|PROCEDURE|Visual impairment intervention program|enhanced access to eye care services
219362627|NCT00358657|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
219362628|NCT00358657|DRUG|Cyclophosphamide|Given IV
219362629|NCT00358657|DRUG|Fludarabine Phosphate|Given IV
219362630|NCT00358657|OTHER|Laboratory Biomarker Analysis|Correlative studies
219362631|NCT00358657|DRUG|Mycophenolate Mofetil|Given PO
219362632|NCT00358657|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
219362633|NCT00358657|DRUG|Sirolimus|Given PO
219362634|NCT00358657|DRUG|Tacrolimus|Given IV or PO
219362635|NCT00358657|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
219362636|NCT03047499|DRUG|Botulinum toxin type A|Botulinum toxin type-A injection
219362637|NCT05661201|DRUG|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
219362638|NCT05661201|DRUG|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
219362639|NCT04878367|BEHAVIORAL|Five active practices of living rules for responding to fine dust.|"1. Check the fine dust weather forecast~2. Check the operation time and filter of the air purifier~3. Window ventilation~4. Inhalant is used or not~5. Bad fine dust: Refrain from going out"
219362640|NCT02658448|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
219362641|NCT03177161|OTHER|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
219362642|NCT06496594|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
219362643|NCT06496594|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
219362644|NCT01590147|PROCEDURE|Yoga therapy|receive YST
219362645|NCT01590147|OTHER|questionnaire administration|Ancillary studies
219362646|NCT01590147|PROCEDURE|quality-of-life assessment|Ancillary studies
219362647|NCT01590147|OTHER|laboratory biomarker analysis|Correlative studies
219362648|NCT01590147|OTHER|assessment of therapy complications|Ancillary studies
219362649|NCT01590147|PROCEDURE|management of therapy complications|Receive YST or CE
219362650|NCT01590147|OTHER|educational intervention|Receive CE
219362651|NCT04545489|BEHAVIORAL|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
219362652|NCT04545489|BEHAVIORAL|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
219362653|NCT00584194|BIOLOGICAL|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to \< 1:40.
219362654|NCT01397864|DRUG|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
219362655|NCT02238457|DRUG|Low dose losartan|25 mg losartan bid for 10 weeks
219362656|NCT02238457|DRUG|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
219362657|NCT00769288|DRUG|2'-F-ara-deoxyuridine|Given IV
219362658|NCT00769288|OTHER|positron emission tomography|Correlative studies
219362659|NCT00769288|OTHER|laboratory biomarker analysis|Correlative studies
219362660|NCT00769288|OTHER|pharmacological study|Correlative studies
219362661|NCT00769288|OTHER|pharmacogenomic studies|Correlative studies
219362662|NCT04270929|DRUG|FOLFIRI|During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
219362663|NCT04270929|DRUG|FOLFIRINOX|During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
219362664|NCT04270929|DEVICE|TriSalus Infusion System|The TriSalus Infusion System administers therapeutics using PEDD technology.
219362665|NCT02172859|DIETARY_SUPPLEMENT|lumiVida™|
219362666|NCT02172859|DIETARY_SUPPLEMENT|Placebo|
219362667|NCT00471432|DRUG|custirsen sodium|
219362668|NCT00471432|DRUG|docetaxel|
219362669|NCT00471432|OTHER|pharmacological study|
219359455|NCT04697485|DRUG|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
219359456|NCT01442259|DRUG|AFQ056|
219359457|NCT06287320|RADIATION|concurrent or sequential chemoradiotherapy|Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.
219359458|NCT06287320|DRUG|Immunotherapy|anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
219359459|NCT01034046|OTHER|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
219359460|NCT01034046|OTHER|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
219359461|NCT02655081|DIETARY_SUPPLEMENT|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
219359462|NCT04317274|BEHAVIORAL|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
219359463|NCT04317274|BEHAVIORAL|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
219359464|NCT04317274|BEHAVIORAL|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
219359465|NCT04317274|BEHAVIORAL|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
219359466|NCT03838224|OTHER|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
219359467|NCT03838224|OTHER|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
219359468|NCT04567212|GENETIC|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
219359469|NCT04567212|OTHER|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
219359470|NCT03524248|RADIATION|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
219359471|NCT06148558|OTHER|Sunscreen Moisturizer|A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
219359472|NCT06148558|OTHER|Gentle Cleansing Lotion|A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
219359473|NCT06148558|OTHER|Facial Moisturizer|A provided facial moisturizer (Goodier) was used 1x daily (PM).
219359474|NCT04989855|DRUG|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
219359475|NCT02482155|DRUG|Ibuprofen|ibuprofen 400 mg single dose oral solution
219359476|NCT06400888|OTHER|needle-free subcutaneous injector for Mecbl|needle-free subcutaneous injector for Mecbl
219359477|NCT06400888|OTHER|intramuscular injection of Mecbl|intramuscular injection of Mecbl
219359478|NCT00006023|DRUG|capecitabine|
219359479|NCT01307930|DRUG|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
219359480|NCT03259945|OTHER|Data collection|demographic and clinical data
219359481|NCT03259945|OTHER|Review of ECGs|nature and frequency of proven conduction disorders
219359482|NCT06388486|BEHAVIORAL|Psychotherapy|Subject receive psychotherapy during hospital treatment.
219359483|NCT00784966|DRUG|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
219359484|NCT00784966|DRUG|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
219359485|NCT03509324|DRUG|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
219359486|NCT00958672|OTHER|Endoscopic capsule|Endoscopic capsule
219359487|NCT00797823|DRUG|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
219359488|NCT00797823|DRUG|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
219359489|NCT00797823|DRUG|Placebo|Saline solution 0.9%
219359490|NCT03926221|BEHAVIORAL|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
219359491|NCT06131619|OTHER|assesment of cognitive parameters with DLOTCA-G|All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
219359492|NCT01640457|DRUG|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
219359493|NCT01640457|DEVICE|NOVOCART® Disc basic|ADCT (Media with no active cell component)
219359494|NCT06489717|OTHER|SDB assessment|SDB will be assessed by respiratory polygraphy according to clinical standards
219359495|NCT04492436|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
219359496|NCT04492436|DRUG|Placebo|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
219359497|NCT02568046|DRUG|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
219359498|NCT02568046|DRUG|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
219359499|NCT04173429|DRUG|Nadroparin calcium, warfarin|Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
219359500|NCT03403192|DEVICE|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
219359501|NCT03403192|DEVICE|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
219359502|NCT01613755|DRUG|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
219359503|NCT01613755|DRUG|Metformin|Metformin 500 mg twice daily for four days
219359504|NCT03598855|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
219359505|NCT01868100|OTHER|self-completion questionnaire|
219359506|NCT01298492|DRUG|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
219359507|NCT04192409|BEHAVIORAL|Smartphone Application|Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
219359508|NCT04600908|OTHER|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
219359509|NCT00264433|DRUG|ADH -1 (Exherin™)|
219359510|NCT01882946|BIOLOGICAL|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
219359511|NCT00352105|DRUG|cisplatin|20mg/m2/d IV continuous infusion x4 days
219359512|NCT00352105|DRUG|fluorouracil|1000mg.m2/d IV continuous x 4 days
219359513|NCT00352105|DRUG|Iressa|250mg/PO qd x 2 years
219359514|NCT00352105|RADIATION|hyperfractionated radiation therapy|120cGy bid
219359515|NCT00878839|DEVICE|Toric|AcrySof Toric IOL
219359516|NCT04642742|DIETARY_SUPPLEMENT|Chewable plant sterol|Chewable plant sterol (gummy)
219359517|NCT05914701|DRUG|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
219359518|NCT01769092|DIETARY_SUPPLEMENT|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
219359519|NCT01769092|OTHER|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
219359520|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
219359521|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
219359522|NCT00728221|DIETARY_SUPPLEMENT|Cornstarch|Placebo
219359523|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
219359524|NCT00868101|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
219359525|NCT02551159|BIOLOGICAL|MEDI4736|Anti-PD-L1 antibody
219359526|NCT02551159|BIOLOGICAL|Tremelimumab|Anti-CTLA-4 Antibody
219359527|NCT02551159|BIOLOGICAL|MEDI4736+Tremelimumab|
219359528|NCT02551159|BIOLOGICAL|Cetuximab|Monoclonal Antibody
219359529|NCT02551159|DRUG|5-fluorouracil (5FU)|Chemotherapy Agent
219359530|NCT02551159|DRUG|Cisplatin|Chemotherapy agent
219359531|NCT02551159|DRUG|Carboplatin|Chemotherapy Agent
219359532|NCT00359775|BEHAVIORAL|Coping Skills Training|6 session behavioral program
219359533|NCT02284282|DRUG|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
219359534|NCT02284282|DRUG|subcutaneum injection lidocaine|placebo injection
219359535|NCT05204264|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
219359536|NCT05204264|BEHAVIORAL|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
219359537|NCT00156312|DRUG|Docetaxel|
219359538|NCT00156312|DRUG|Capecitabine|
219359539|NCT05040594|DEVICE|PavéDerm J-Fill Soft Dermal Filler|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
219359540|NCT05040594|DEVICE|Restylane® Lyft Lidocaine|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
219359541|NCT03970902|OTHER|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
219359542|NCT03970902|OTHER|Care As Usual|No intervention Patients receive care as usual from their family physician
219359543|NCT04547205|DRUG|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
219359544|NCT06290050|DRUG|Midazolam|Midazolam syrup.
219359545|NCT06290050|DRUG|Repaglinide|Repaglinide tablets.
219359546|NCT06290050|DRUG|TAK-279|TAK-279 capsules.
219359547|NCT03357627|DRUG|TAK-659|TAK-659 tablets.
219359548|NCT03357627|DRUG|Venetoclax|Venetoclax tablets.
219359549|NCT02175680|DRUG|PRO 140|CCR5 Antagonist
219359550|NCT02175680|OTHER|Historical data|Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
219359551|NCT03146533|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
219359552|NCT03146533|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
219359553|NCT03146533|BIOLOGICAL|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
219359554|NCT02180893|OTHER|Paravertebral Block|Paravertebral nerve block injection
219359555|NCT02180893|OTHER|Placebo Comparator|"No block~Patients who did not receive PVB"
219359556|NCT04198857|BEHAVIORAL|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
219359557|NCT02448511|OTHER|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
219359558|NCT02448511|DEVICE|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
219359559|NCT02448511|OTHER|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
219359560|NCT03779022|GENETIC|microRNA|The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
219359561|NCT01318044|DRUG|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
219359562|NCT00758472|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
219359563|NCT00911989|DEVICE|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
219359564|NCT02237287|OTHER|wound dressing with VAC and sNAG without antiaggregation|
219359565|NCT02237287|PROCEDURE|wound dressing with VAC|
219359566|NCT02237287|DRUG|wound dressing with VAC and sNAG under Antiaggregation|
219359567|NCT00563342|DRUG|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
219359568|NCT05110976|DRUG|AZD8630|Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
219359569|NCT05110976|DRUG|Placebo|Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
219359570|NCT05321979|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
219359571|NCT04525105|GENETIC|SMAD2|a family of structurally related cytokines
219359572|NCT01002079|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
219359573|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
219359574|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
219359575|NCT04665830|DRUG|Evolocumab|treated patients with evolocumab for high cholesterol
219359576|NCT00723788|DEVICE|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
219359577|NCT00434135|DRUG|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
219359578|NCT05039359|DRUG|FlecIH-103|flecainide acetate inhalation solution
219359579|NCT01493180|DRUG|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
219359580|NCT01493180|DRUG|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
219359581|NCT06056752|BIOLOGICAL|QH103 Cell Injection|dose escalation (3+3) : dose 1 (3×10\^8CAR+cells) ,dose 2 (1 × 10\^9 CAR+cells）,dose 3 (3 × 10\^9CAR+cells)
219359582|NCT06056752|DRUG|Fludarabine|Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition
219359583|NCT06056752|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
219359584|NCT05153057|OTHER|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
219359585|NCT00135122|DRUG|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
219359586|NCT02338102|OTHER|Saline mixture|premeasured salt packets mixed with distilled water
219359587|NCT04949841|DRUG|Delgocitinib|Delgocitinib cream 20 mg/g
219359588|NCT04211181|OTHER|The multifaceted interventions|"1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A newly developed mobile application (mini-program) will be employed to facilitate venous thromboembolism (VTE) risk assessment and prophylaxis. Patients will scan a QR code to enroll in the program and be linked with their physician. Through the application, patients will complete standardized self-assessments of VTE risk, and physicians will receive periodic reminders indicating whether the assessment and prophylaxis orders have been completed.The application also provides educational modules and targeted messages for both patients and physicians, and enables interactive communication.~4. A quality-control team will receive weekly feedback reports to verify whether all enrolled patients underwent appropriate prophylaxis."
219359589|NCT04211181|OTHER|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
219359590|NCT04751812|PROCEDURE|High-pain multimodal anesthesia with opioids|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
219359591|NCT04751812|PROCEDURE|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
219359592|NCT04751812|PROCEDURE|Standard of care|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
219359593|NCT06084884|BIOLOGICAL|AZD5851|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
219359594|NCT05554367|DRUG|Binimetinib|Given PO
219359595|NCT05554367|PROCEDURE|Biopsy Procedure|Undergo biopsy
219359596|NCT05554367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
219359597|NCT05554367|PROCEDURE|Bone Scan|Undergo bone scan
219359598|NCT05554367|PROCEDURE|Computed Tomography|Undergo CT
219359599|NCT05554367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219359600|NCT05554367|DRUG|Palbociclib|Given PO
219359601|NCT05839808|OTHER|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
219359602|NCT03179436|BIOLOGICAL|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
219359603|NCT03179436|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
219359604|NCT03179436|DRUG|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
219359605|NCT05495126|DIAGNOSTIC_TEST|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
219359606|NCT05495126|DIAGNOSTIC_TEST|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
219359607|NCT05491993|DIAGNOSTIC_TEST|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
219359608|NCT00273377|OTHER|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
219359609|NCT00273377|OTHER|Supplemental oxygen (80% vs. 30%)|
219359610|NCT00273377|DRUG|Dexamethasone|4 mg
219359611|NCT00273377|DRUG|Placebo|placebo
219359612|NCT04032990|DEVICE|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
219359613|NCT02809287|PROCEDURE|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
219359614|NCT05408754|DEVICE|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
219359615|NCT02407678|GENETIC|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
219359616|NCT05168267|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
219359617|NCT01184937|BEHAVIORAL|Patient education program|"All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs."
219359618|NCT00284037|DEVICE|continuous positive airway pressure therapy|
219359619|NCT01900093|DRUG|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
219359620|NCT00003642|DRUG|cisplatin|
219359621|NCT00003642|DRUG|fluorouracil|
219359622|NCT00003642|RADIATION|radiation therapy|
219359623|NCT06430788|BIOLOGICAL|Emapalumab|Emapalumab is an interferon gamma (IFNγ) blocking antibody
219359624|NCT02670135|DRUG|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
219359625|NCT02670135|DRUG|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
219359626|NCT06084377|GENETIC|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
219359627|NCT05731180|OTHER|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
219359628|NCT03382574|BIOLOGICAL|Denosumab|Given SC
219359629|NCT03382574|PROCEDURE|Salpingo-Oophorectomy|Undergo risk-reducing salpingo-oophorectomy
219359630|NCT00931216|PROCEDURE|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
219359631|NCT05604599|DRUG|Intranasal dexmedetomidine|45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
219359632|NCT05604599|DRUG|Intravenous dexmedetomidine|patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
219359633|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
219359634|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
219359635|NCT06456983|DEVICE|maintenance electroconvulsive therapy (mECT)|see Arms
219359636|NCT05378763|DRUG|Poziotinib|Poziotinib tablets
219359637|NCT05378763|DRUG|Docetaxel|Docetaxel IV infusion
219359638|NCT04811716|DRUG|Pozelimab|Administered Sub-cutaneous (SC) per protocol
219359639|NCT04811716|DRUG|Cemdisiran|Administered SC per protocol
219359640|NCT05968859|BEHAVIORAL|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
219359641|NCT05968859|BEHAVIORAL|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
219359642|NCT02434848|DRUG|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
219359643|NCT02434848|DRUG|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
219359644|NCT04695964|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
219359645|NCT05591664|DIAGNOSTIC_TEST|eicosapentaenoic acid|eicosapentaenoic acid levels of the groups will be monitored
219359646|NCT03837080|OTHER|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
219359647|NCT04247425|OTHER|Exercise Counseling|Receive instructional guidance
219359648|NCT04247425|OTHER|Quality-of-Life Assessment|Ancillary studies
219359649|NCT04247425|OTHER|Questionnaire Administration|Ancillary studies
219359650|NCT04247425|OTHER|Resistance Training|Complete progressive resistance training
219359651|NCT00130897|DRUG|Sutent|Sutent, 25, 37.5. or 50 mg daily
219359652|NCT02247193|DRUG|Botulinum Toxin Type A|Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
219359653|NCT02247193|DRUG|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
219359654|NCT02298764|OTHER|Standard back pain treatment|Standard back pain treatment
219359655|NCT02298764|OTHER|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
219359656|NCT02544932|DRUG|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
219359657|NCT02544932|DRUG|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
219359658|NCT02544932|DRUG|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
219359659|NCT04173897|OTHER|LIBERATE website|The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services \& support and support for family \& loved ones.
219359660|NCT01487759|DIETARY_SUPPLEMENT|Oligofructose enriched inulin|
219359661|NCT01487759|DIETARY_SUPPLEMENT|Maltodextrin|
219359662|NCT00762515|DRUG|Fluoride|Brush teeth two times daily for 6 weeks
219359663|NCT00762515|DRUG|Triclosan|Brush two times daily for 6 weeks
219359664|NCT00762515|DRUG|Fluoride|Brush two times daily for 6 weeks
219359665|NCT04953312|BIOLOGICAL|Blood samples|blood
219359666|NCT02960620|DEVICE|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
219359667|NCT05522166|OTHER|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
219359668|NCT03751865|BEHAVIORAL|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
219359669|NCT03751865|BEHAVIORAL|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
219359670|NCT01258907|DRUG|MLDL1278A|Single intravenous dose
219359671|NCT01258907|DRUG|MLDL1278A|Repeating intravenous dose
219359672|NCT01258907|DRUG|placebo|Repeating intravenous dose
219359673|NCT01258907|DRUG|statin, stable dose|Repeating oral dose
219359674|NCT06050538|PROCEDURE|Transabdominal preperitoneal (TAPP) using polyprolene mesh|Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
219359675|NCT06050538|PROCEDURE|Total extraperitoneal (TEP) hernioplasty using polyprolene mesh|Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
219359676|NCT05879783|DIAGNOSTIC_TEST|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
219359677|NCT00500682|DRUG|Placebo|9g /day (3 times a day)
219359678|NCT00500682|DRUG|AST-120|9g /day (3 times a day)
219359679|NCT04154501|DRUG|CNTX-6016|Oral Dose CNTX-6016
219359680|NCT04154501|OTHER|Other: Placebo|Oral Dose Placebo
219359681|NCT01910675|DRUG|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
219359682|NCT01910675|DRUG|FFP|4 units Octaplas. Additional fibrinogen if needed.
219359683|NCT05160935|BEHAVIORAL|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
219359684|NCT05576974|DRUG|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
219359685|NCT00996099|DEVICE|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
219359686|NCT00996099|OTHER|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
219359687|NCT02670265|DIETARY_SUPPLEMENT|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
219359688|NCT02670265|DIETARY_SUPPLEMENT|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
219359689|NCT00429585|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
219359690|NCT00429585|DEVICE|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
219359691|NCT01582308|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
219359692|NCT01582308|DRUG|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
219359693|NCT01582308|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
219359694|NCT01582308|DRUG|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
219359695|NCT01582308|DRUG|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
219359696|NCT05061303|OTHER|Assessment of the drug concentration in the blood|The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
219359697|NCT01762566|DIETARY_SUPPLEMENT|wheat|wheat is administered blindly versus placebo in capsules once
219359698|NCT01762566|DIETARY_SUPPLEMENT|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
219359699|NCT00371930|PROCEDURE|application of a dye suspension followed by a laser intervention|
219359700|NCT05840744|DIAGNOSTIC_TEST|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
219359701|NCT00441857|BEHAVIORAL|plant stanol consumption|
219359702|NCT04639323|DIAGNOSTIC_TEST|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
219359703|NCT00458731|BIOLOGICAL|bevacizumab|Given IV
219359704|NCT00458731|DRUG|cediranib maleate|Given orally
219359705|NCT02861040|OTHER|Laboratory Biomarker Analysis|Correlative studies
219359706|NCT02861040|OTHER|Pharmacological Study|Correlative studies
219359707|NCT02861040|DRUG|Vincristine Sulfate Liposome|Given IV
219359708|NCT02861040|DRUG|Volasertib|Given IV
219359709|NCT02017574|BEHAVIORAL|Reaching Task|Learn a reaching task that requires coordination of the arm segments
219359710|NCT03222466|OTHER|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
219359711|NCT00332540|DRUG|bimatoprost/timolol fixed combination|
219359712|NCT01386333|DRUG|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
219359713|NCT01386333|DRUG|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
219359714|NCT04764760|DEVICE|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
219359715|NCT05541614|OTHER|Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative|Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
219359716|NCT05541614|OTHER|Emdogain® - Enamel Matrix Derivative|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.
219359717|NCT05122234|BIOLOGICAL|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
219359718|NCT05122234|OTHER|Placebo|Normal saline
219359719|NCT05122234|DRUG|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
219359720|NCT05832567|DEVICE|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
219359721|NCT05832567|DEVICE|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
219359722|NCT05832567|DIETARY_SUPPLEMENT|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
219359723|NCT06658600|OTHER|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
219359724|NCT06658600|OTHER|Physician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease|Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.
219359725|NCT01182428|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
219359726|NCT01182428|DEVICE|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
219359727|NCT06856044|PROCEDURE|ileocolic resection with extended mesenteric resection|The resection limits will be in healthy mesenteric areas. The restoration of continuity in one stage should be preferred. The choice of laparoscopy versus laparotomy is at the surgeon's discretion.
219359728|NCT07025096|OTHER|Artifical Intelligence-Generated Treatment Recommendations|The clinical vignette will contain treatment recommendations which were generated by an artificial intelligence-based clinical decision support system.
219359729|NCT07027293|OTHER|STANDART HEAD POSITION|STANDART HEAD POSITION
219359730|NCT07027293|OTHER|HEAD ROTATION POSITION|HEAD ROTATION POSITION
219359731|NCT07027293|DEVICE|Classic laryngeal mask airway (LMA)|Classic laryngeal mask airway (LMA)
219359732|NCT07027293|DEVICE|i-gel supraglottic airway device|i-gel supraglottic airway device
219359733|NCT04034810|DEVICE|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
219359734|NCT06765317|DRUG|Glofitamab|C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
219359735|NCT06765317|DRUG|Polatuzumab|1.8 mg/kg iv C1D1 onwards, every 3 weeks
219359736|NCT06765317|DRUG|Rituximab|375 mg/m2 iv D1
219359737|NCT06765317|DRUG|Cyclophosphamide|400 mg/m2 iv D1
219359738|NCT06765317|DRUG|Doxorubicin|25 mg/m2 iv D1
219359739|NCT06765317|DRUG|Obinutuzumab:|1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
219359740|NCT07073066|PROCEDURE|DC-LVA treatment plus usual care|Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
219359741|NCT07073066|OTHER|Usual care|The usual care group includes patients who were not using or were currently using medications for improving cognitive function.
219359742|NCT06899217|DRUG|CIN-102 Dose 15mg|Twice daily for 12 weeks
219359743|NCT06899217|DRUG|Placebo|Twice daily for 12 weeks
219359744|NCT06899217|DRUG|CIN-102 Dose 10mg|Twice daily for 12 weeks
219359745|NCT06843213|BEHAVIORAL|Peer Intervention|Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.
219359746|NCT06843213|OTHER|Enhanced Usual Care|Participants will receive a handout that includes harm reduction education and resources in their local area as part of enhanced usual care.
219359747|NCT05571839|DRUG|PF-08046049|Given into the vein (IV; intravenous)
219359748|NCT06902519|DRUG|GS-0151|Administered for 12 weeks
219359749|NCT06902519|DRUG|Placebo|Administered for 12 weeks
219359750|NCT06903533|OTHER|Puzzle Activity|After assigning the students to the intervention and control groups, a puzzle activity will be conducted with the intervention group following a lecture. In preparing the puzzles, the researchers will use free online puzzle-making tools (e.g., https://crosswordlabs.com/). The puzzles will include questions related to basic knowledge and concepts concerning gerontological nursing competence. During the puzzle-solving process, the researcher will be present in the classroom and provide guidance to students when needed. After students complete the puzzles, the researcher will project the puzzle on the presentation screen and evaluate the answers through interactive discussion with the students. Upon completion of each puzzle, the researcher will collect the puzzles from the students to prevent contamination between the intervention and control groups. A post-test will be administered to students at the end of the puzzle activity.
219359751|NCT04644770|DRUG|JNJ-69086420|Participants will receive JNJ-69086420.
219359752|NCT04644770|DRUG|JNJ-78278343|Participants will receive JNJ-78278343.
219359753|NCT04644770|RADIATION|Stereotactic body radiation therapy|Participants will receive stereotactic body radiaition therapy.
219359754|NCT06929260|DRUG|Ceralasertib|Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.
219359755|NCT06929260|DRUG|Drug X|Participants will receive a single dose of Drug X on Day 5 and Day 22.
219359756|NCT06929260|DRUG|Drug Y|Participants will receive a single dose of Drug Y on Day 7 and Day 28.
219359757|NCT06929260|DRUG|Drug Z|Participants will receive a single dose of Drug Z on Day 7 and Day 28.
219359758|NCT07085390|OTHER|Use of a Balloon Guide Catheter|Use of a balloon guide catheter in stroke thrombectomy.
219359759|NCT07085390|OTHER|Use of a Conventional (non-balloon) Guide Catheter|Use of a conventional (non-balloon) guide catheter in stroke thrombectomy.
219359760|NCT07086976|DRUG|rilzabrutinib|Pharmaceutical form:tablet-Route of administration:oral
219359761|NCT07086976|DRUG|placebo|Pharmaceutical form:tablet-Route of administration:oral
219359762|NCT06015893|BEHAVIORAL|Take Control|A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.
219359763|NCT06015893|DRUG|Semaglutide|Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
219359764|NCT06894615|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
219359765|NCT04925479|DRUG|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: 1 mg film-coated granules in a size 0 capsule will be supplied, taken orally (capsules are a container for the granules and are not ingested):~10 mg (10x 1 mg film-coated granules in capsule) 15 mg (15x 1 mg film-coated granules in capsule) 20 mg (20x 1 mg film-coated granules in capsule) 30 mg (30x 1 mg film-coated granules in capsule)"
219359766|NCT04925479|DRUG|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
219359767|NCT06906640|OTHER|(IRIS-CKD Management Program): Education|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
219359768|NCT06906640|OTHER|(IRIS-CKD Management Program): GDMT|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.
219359769|NCT07096687|DEVICE|Targeted Temperature Management with CB240_Aurora|The proposed experimental treatment with the CB240\_Aurora device will serve as a complementary approach to standard therapies, aiming to enhance their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.
219359770|NCT07096687|DEVICE|Standard of care Temperature treatment|In the control group, patients will receive treatment according to the latest guidelines for the management of ischemic stroke, including standard body temperature management. The CB240\_Aurora device will be used exclusively in monitoring mode, without delivering any active treatment, and will be maintained for 72 consecutive hours from the time of enrollment
219359771|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
219359772|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
219359773|NCT06910631|OTHER|Capillary CRP|CRP measured semi-quantitatively using ACTIM-CRP device
219359774|NCT06910592|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
219359775|NCT06910384|BIOLOGICAL|STR04|autologous bone-marrow-derived mesenchymal stem cells
219359776|NCT06919965|DRUG|TAR-210|TAR-210 will be administered intravesically.
219359777|NCT06919965|DRUG|Mitomycin C|MMC will be administered intravesically.
219359778|NCT06919965|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
219359779|NCT06916325|DEVICE|dual hypothermic oxygenated perfusion (DHOPE)|Clinically, end-ischemic DHOPE has been shown to restore hepatic ATP, reduce reperfusion injury, and improve outcomes after deceased donor liver transplantation. Recent prospective and retrospective clinical studies detail the safety and feasibility of prolonged preservation of donor livers with DHOPE for up to 20 hours; prolonged perfusion has shown similarly low rates of serious adverse events, a potential protective effect in mitigating acute kidney injury and may facilitate decreased frequency of discarded and nonuse of donor livers.
219359780|NCT06933368|DRUG|Crest Cavity Protection Toothpaste|Toothpaste containing 0.243% w/w NaF.
219359781|NCT06933368|DRUG|Experimental Mouthwash|Mouthwash containing 0.085% w/w CPC.
219359782|NCT06937320|DIETARY_SUPPLEMENT|Exogenous Ketone Drink|"(R)-1,3-butanediol (BD, commercially available as KetoneIQ) initially dosed 300 mg/kg BID (target dose 400 mg/kg grams BID if tolerated) for 8 weeks"
219359783|NCT06937320|DIETARY_SUPPLEMENT|Placebo|equi-volume placebo administered for 8 weeks
219359784|NCT06935838|DRUG|Tirzepatide|Tirzepatide is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, obesity and overweight with at least one weight-related medical condition, and moderate to severe obstructive sleep apnea. An initial dose of TZP 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg.
219359785|NCT07141004|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
219359786|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MRSA|Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
219359787|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MSSA|Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
219359788|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MRSA|Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.
219359789|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MSSA|Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.
219359790|NCT07149142|DIAGNOSTIC_TEST|Non-mydriatic fundus camera photography|Non-mydriatic fundus camera photography assessed by artificial intelligence software
219359791|NCT07149142|DIAGNOSTIC_TEST|Fundus ophtalmoscopy|Fundus opthalmoscopy assessed by an experienced ophtalmologist
219359792|NCT07149142|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography assessed by an experienced ophtalmologist
219359793|NCT07149142|DIAGNOSTIC_TEST|Confocal microscopy of the retina|In a subset of participants over 18 years of age, confocal microscopy of the retina will be performed to assess the presence of diabetic neuropathy
219359794|NCT00466648|PROCEDURE|Tissue adhesive|
219359795|NCT07120945|DEVICE|Robotic Assisted-Surgery (RAS) Hysterectomy|Patients indicated for Robotic Assisted-Surgery (RAS) hysterectomy procedures will have the RAS surgery using the Medtronic Hugo™ RAS system.
219359796|NCT07160127|DRUG|TJAOA103|Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.
219359797|NCT07153562|OTHER|liuzijue qigong exercises|Liuzijue qigong exercise for 20 minutes, 5 times per week, for 12 successive weeks.
219359798|NCT07153562|OTHER|conventional rehabilitation treatment|conventional rehabilitation exercises, 3 sessions per week, 45-60 minutes per session, for 12 successive weeks.
219359799|NCT07163819|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
219359800|NCT07163819|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
219359801|NCT07165977|DIETARY_SUPPLEMENT|Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo|"Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
219359802|NCT07165977|DIETARY_SUPPLEMENT|Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)|"Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
219359803|NCT07167953|DEVICE|Brain MRI|90 participants will undergo a 60 minute SOC brain MRI followed by 15 minute spiral MRI
219359804|NCT07167953|DEVICE|Brain MRI - SOC and spiral|6 participants will be scanned using 2 versions (SOC and spiral) pf 6 sequences (12 scans total).
219359805|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 sequences, 3 times (9 total scans per participants)
219359806|NCT07167953|DEVICE|Brain MRI - SOC and spiral|10 participants will be scanned using 2 versions (SOC and spiral) of 6 sequences (12 scans total).
219359807|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 spiral sequences to achieve desired signal to noise ratio (SNR).
219359808|NCT07167953|DEVICE|Brain MRI - spiral|5 participants will be scanned with 2 pairs of 6 spiral sequences.
219359809|NCT07167836|OTHER|Electronic medical record-based care pathway|Participants will undergo initial automated risk stratification to direct tailored follow-up intervals. If exceeding the maximum time interval, participants in the intervention arm will be contacted by scheduling personnel using a standardized protocol to schedule a follow-up visit. In contrast, patients in the control arm who are overdue will not be made known to any staff and will not be proactively contacted, instead continuing to be managed according to standard of care. To maximize generalizability and understanding among staff and patients, risk stratification will be based on inflammatory bowel disease medication use.
219359810|NCT07164677|PROCEDURE|Bilateral ultrasound guided Serratus Posterior Superior Plane Block|Bilateral ultrasound-guided Serratus Posterior Superior Plane Block (total of 60 ml, %0.25 bupivacaine) will be performed Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.
219359811|NCT07164677|DRUG|IV morphine patient-controlled analgesia|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
219360112|NCT06303661|DEVICE|Non-ablative Radiofrequency|There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
219360113|NCT06303661|DEVICE|Low-intensity Shock Wave Therapy|The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
219360114|NCT03777449|RADIATION|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
219360115|NCT02608632|DEVICE|Renal denervation guided by HFS|
219360116|NCT02608632|DEVICE|Renal denervation as standard procedure|
219360117|NCT01238003|OTHER|Interpretation of blood test results|Interpretation of blood test results
219360118|NCT03068325|OTHER|EAT-PTSD|
219360119|NCT03822013|DRUG|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
219360120|NCT06479980|BEHAVIORAL|Single Session Narrative Therapy|Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
219360121|NCT05583773|DRUG|ShengXian-QuYu Decoction|Specification: 30ml/bag, given twice daily, per oral use.
219360122|NCT05583773|OTHER|Placebo|Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
219360123|NCT02314988|DRUG|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
219360124|NCT02314988|DRUG|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
219360125|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
219360126|NCT05663151|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
219360127|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
219360128|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
219360129|NCT00975156|OTHER|Physical Therapy|Conventional physical therapy
219360130|NCT00975156|DEVICE|Lokomat|Robotic-assisted walking device
219360131|NCT00305578|DRUG|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
219360132|NCT00305578|DRUG|Placebo|No active medication, only placebo
219360133|NCT03723681|DRUG|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
219360134|NCT00847587|DRUG|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
219360135|NCT00847587|DRUG|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
219360136|NCT04702009|DRUG|Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy|Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
219360137|NCT04702009|DEVICE|Bronchoscopy-assisted Interventional Therapy|Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
219360138|NCT03581331|DIAGNOSTIC_TEST|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
219360139|NCT06195202|DRUG|AIs|Patients with AIs
219360140|NCT06195202|DRUG|OFS+AIs|Patients with OFS+AIs
219360141|NCT06195202|DRUG|FUL|Patients with FUL
219360142|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
219360143|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
219360144|NCT01047202|BIOLOGICAL|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
219360145|NCT05107167|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
219360146|NCT02521701|DRUG|NFL101|"Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
219360147|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219360148|NCT05839795|OTHER|Assessment study|Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
219360149|NCT01412970|OTHER|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
219360150|NCT01673321|OTHER|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
219360151|NCT02623738|DRUG|Placebo ophthalmic solution|
219360152|NCT02623738|DRUG|DE-117 ophthalmic solution low|
219360153|NCT02623738|DRUG|DE-117 ophthalmic solution high|
219360154|NCT02623738|DRUG|Latanoprost ophthalmic solution 0.005%|
219360155|NCT02409511|OTHER|non intervention|
219360156|NCT06445205|DIAGNOSTIC_TEST|Mitra® device with VAMS® (volumetric absorptive microsampling) technology|Capillary blood sample
219360157|NCT01533675|OTHER|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
219360158|NCT01533675|OTHER|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
219360159|NCT01380808|DRUG|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
219360160|NCT01275209|DRUG|HCD122|
219360161|NCT02078687|DIETARY_SUPPLEMENT|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
219360162|NCT02078687|DIETARY_SUPPLEMENT|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
219360163|NCT02078687|DIETARY_SUPPLEMENT|Mothers own milk|Group 1 received mothers own milk without fortification
219360164|NCT03882307|DRUG|sofosbuvir and daclatasvir|oral tablets
219360165|NCT03630731|DRUG|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
219360166|NCT00454779|DRUG|Cisplatin|chemotherapy arm
219360167|NCT00454779|DRUG|Panitumumab|experimental arm
219360168|NCT00454779|DRUG|Docetaxel|chemotherapy arm
219360169|NCT00454779|DRUG|Cisplatin|experimental arm
219360170|NCT00454779|DRUG|Docetaxel|experimental arm
219360171|NCT01039857|BEHAVIORAL|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
219360172|NCT01039857|BEHAVIORAL|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
219360173|NCT00662844|DIETARY_SUPPLEMENT|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
219360174|NCT03705182|DEVICE|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
219360175|NCT00827697|OTHER|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
219360176|NCT00019760|DRUG|floxuridine|
219360177|NCT00019760|DRUG|leucovorin calcium|
219360178|NCT00019760|DRUG|melphalan|
219360179|NCT00690885|DRUG|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
219360180|NCT00690885|DRUG|placebo lozenges|matching placebo lozenges
219360181|NCT01237366|BEHAVIORAL|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
219360182|NCT03412409|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
219360183|NCT04224805|DEVICE|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
219360184|NCT04224805|DEVICE|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
219360185|NCT01175941|DRUG|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
219360186|NCT01175941|DRUG|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
219360187|NCT03196128|OTHER|Digital communication|Communicating with patients via email and text message.
219360188|NCT03196128|OTHER|Non digital|Communicating with patients via telephone and written appointment letters.
219360189|NCT00083577|DRUG|Thalidomide|
219360190|NCT01136499|DRUG|LBH589 (Panobinostat®)|"40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity."
219360191|NCT02480933|PROCEDURE|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
219360192|NCT02480933|OTHER|Biopsy|Biopsy of BI-RADS 3 and superior lesions
219360193|NCT02194153|DRUG|Metalyse weight-adjusted|
219360194|NCT02413437|OTHER|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
219360195|NCT02413437|OTHER|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
219360196|NCT02413437|DEVICE|Ultrasound|
219360197|NCT05753826|DRUG|Adebrelimab|20mg/kg，D1，q3W
219360198|NCT05753826|DRUG|Fuzuloparib|100 mg bid
219360199|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
219360200|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
219360201|NCT03731286|DIETARY_SUPPLEMENT|Microcellulose crystalline|2 capsules
219360202|NCT00809380|BEHAVIORAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
219360203|NCT00809380|BEHAVIORAL|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
219360204|NCT00005956|BIOLOGICAL|HER-2/neu intracellular domain protein|
219360205|NCT00005956|BIOLOGICAL|therapeutic autologous dendritic cells|
219360206|NCT04036279|PROCEDURE|Total Hip Arthroplasty|
219360207|NCT05425563|BEHAVIORAL|Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming somatic pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
219360208|NCT05425563|BEHAVIORAL|Vicarious Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming vicarious pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
219360209|NCT05425563|BEHAVIORAL|Cognitive Effort Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming cognitive effort stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
219360210|NCT01069445|DIETARY_SUPPLEMENT|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
219360211|NCT01069445|DIETARY_SUPPLEMENT|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
219360212|NCT01069445|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
219360213|NCT01069445|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
219360214|NCT05445973|PROCEDURE|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
219360215|NCT01722838|BEHAVIORAL|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
219360216|NCT01087541|BEHAVIORAL|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
219360217|NCT00684190|DRUG|AZD3355|150 mg bid, oral, 7 days
219360218|NCT00684190|DRUG|Esomeprazole|40 mg od, oral, 7 days
219360021|NCT03007212|PROCEDURE|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
219360022|NCT05629325|DRUG|Buspirone Hydrochloride 10 MG|4 weeks of treatment with buspirone
219360023|NCT05629325|DRUG|Placebo|4 weeks of treatment with placebo
219360024|NCT05141305|DRUG|tenecteplase (0.25 mg/kg, Max 25 mg)|tenecteplase (0.25 mg/kg) is being used.
219360025|NCT05141305|DRUG|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
219360026|NCT02659592|PROCEDURE|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
219360027|NCT05018819|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
219360028|NCT03424759|DRUG|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
219360029|NCT03195517|OTHER|Physical exercise|
219360030|NCT06549205|DEVICE|device that stimulates the dorsal surface of the tongue|the device will be placed on the dorsal surface of the tongue. this instrument has two electrodes in turn connected to the TENS, so ultra low frequency stimulation (\<0.66 Hz) will be administered
219360031|NCT06549205|DEVICE|device that stimulates the tragus|two electrodes will be placed at tragus level for the administration of dental ULFTENS
219360032|NCT05811403|OTHER|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
219360033|NCT05811403|OTHER|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
219360034|NCT05811403|OTHER|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
219360035|NCT05811403|OTHER|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
219360036|NCT06548867|DRUG|Cabozantinib|Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
219360037|NCT02211391|OTHER|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
219360038|NCT02211391|OTHER|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
219360039|NCT05806801|BEHAVIORAL|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
219360040|NCT05806801|BEHAVIORAL|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
219360041|NCT02668146|DRUG|Perampanel|Study drug will be administered to study subjects
219360042|NCT02668146|DRUG|Placebo|Placebo will be administered to study subjects
219360043|NCT03569995|DRUG|Rituximab|500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
219360044|NCT03569995|DRUG|Methotrexate|500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
219360045|NCT03569995|DRUG|Cytarabine Injection|3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
219360046|NCT00694291|DRUG|Sorafenib|400 mg orally twice daily
219360047|NCT00694291|DRUG|Placebo|Matching Placebo
219360048|NCT01745640|DRUG|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
219360049|NCT01745640|DRUG|Dexamethasone|40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
219360050|NCT03312517|DRUG|Suvorexant 10 mg|Subject will receive suvorexant 10mg
219360051|NCT03312517|DRUG|Suvorexant 20 mg|Subject will receive suvorexant 20mg
219360052|NCT03312517|DRUG|Placebo oral capsule|Subject will receive placebo.
219360053|NCT03597425|PROCEDURE|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation (CPR) is an emergency treatment for patients with respiratory arrest and cardiac arrest in an attempt to restore the patient to spontaneous breathing and heartbeat through cardiopulmonary resuscitation
219360054|NCT00235131|DEVICE|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
219360055|NCT00235131|DEVICE|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
219360056|NCT02495922|DRUG|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
219360057|NCT02495922|DRUG|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
219360058|NCT02495922|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
219360219|NCT01410279|OTHER|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
219360220|NCT02083458|PROCEDURE|Catheterization of the axillary vein.|
219360221|NCT04217265|DRUG|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
219360064|NCT01977885|BEHAVIORAL|High Protein Diet|All participants will be individually counseled by an RD for \~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
219360065|NCT01977885|BEHAVIORAL|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or \~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
219360066|NCT05458336|DEVICE|Nasal lavages with Tonimer Panthexyl®|At the moment of diagnosis, patients were asked to fill out an ad hoc questionnaire to subjectively evaluate symptoms and comorbidities at the moment of diagnosis and of negativization. Subjects performed a daily nasal swab. When the subjects tested negative for the first time, they had to complete the questionnaire once again. Patients were given nasal washes (Tonimer Panthexyl®) to be performed three times a day, and in any case after nasal swab.
219360067|NCT03018886|OTHER|GHRH plus arginine test|One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
219360068|NCT01516515|DRUG|Vehicle gel|placebo
219360069|NCT01516515|DRUG|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
219360070|NCT01137240|PROCEDURE|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
219360071|NCT02553694|OTHER|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
219360072|NCT02553694|OTHER|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
219360073|NCT02553694|OTHER|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
219360074|NCT02553694|OTHER|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
219360075|NCT00122330|DRUG|eculizumab|
219360076|NCT05870904|OTHER|Dry Needling|"Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied"
219360077|NCT02496949|DRUG|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
219360078|NCT04428047|DRUG|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
219360079|NCT03932071|DRUG|Zoledronic Acid|
219360080|NCT05973136|OTHER|Telerehabilitation program based on cardiorespiratory principles|The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
219360081|NCT00427362|DRUG|Adalimumab|
219360082|NCT00267553|DRUG|Atamestane|
219360083|NCT00267553|DRUG|toremifene|
219360084|NCT00267553|DRUG|letrozole|
219360085|NCT00808444|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
219360086|NCT00808444|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
219360087|NCT00808444|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
219360088|NCT00808444|BIOLOGICAL|Rotarix|Oral, 2 doses
219360089|NCT02926326|DRUG|BCT197|A single dose of BCT197
219360090|NCT02926326|DRUG|Azithromycin|3 daily doses of Azithromycin
219360091|NCT00716976|DRUG|sodium thiosulfate|Given IV
219360092|NCT00716976|PROCEDURE|examination|Patients undergo audiological assessments periodically
219360827|NCT03285932|RADIATION|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
219360828|NCT03285932|RADIATION|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
219360829|NCT01796951|DRUG|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
219360830|NCT01796951|DRUG|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
219360831|NCT02917967|DRUG|Botulinum toxin injection|"1. BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~2. Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
219360832|NCT03504826|DEVICE|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
219360833|NCT06549075|OTHER|Therapeutic support|The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
219360834|NCT06549075|OTHER|Standard Specialized Palliative Consultation Service|According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
219360835|NCT01871090|DEVICE|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
219360836|NCT02813122|DEVICE|x-ray|x-ray for the detection of leaks and bleeding
219360837|NCT04988100|PROCEDURE|splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
219360838|NCT04988100|PROCEDURE|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
219360839|NCT04507087|BEHAVIORAL|Documentary|A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products
219360840|NCT04507087|BEHAVIORAL|Control|"A 20-minute unrelated video (a motivational talk entitled Listening to shame)"
219360841|NCT00570648|DRUG|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
219360842|NCT02761083|DEVICE|Novosyn® Quick|Eye surgery
219360843|NCT02761083|DEVICE|Vicryl® Rapid|Eye surgery
219360844|NCT03595696|OTHER|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
219360845|NCT05136625|DRUG|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
219360846|NCT05136625|DRUG|Standard Preparation|Troncular scalp blockade. Local site infiltration
219360847|NCT03006809|BIOLOGICAL|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
219360848|NCT03006809|OTHER|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
219360849|NCT02144272|DRUG|LY3114062 SC|LY3114062 administered SC.
219360850|NCT02144272|DRUG|Placebo|Placebo administered SC.
219360851|NCT02144272|DRUG|LY3114062 IV|LY3114062 administered IV.
219360852|NCT05112887|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
219360853|NCT02841059|PROCEDURE|LSH|laparoscopic subtotal hysterectomy: LSH
219360854|NCT02841059|PROCEDURE|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
219360855|NCT02841059|PROCEDURE|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
219360856|NCT04512833|RADIATION|Cyberknife stereotactic body radiation therapy|A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
219360857|NCT00975247|OTHER|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
219363478|NCT02532855|DRUG|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
219360896|NCT06265844|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
219360897|NCT03725410|DEVICE|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
219360898|NCT03725410|DEVICE|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
219360899|NCT00748748|BIOLOGICAL|Culturelle|10\^10 Lactobacillus rhamnosus GG per capsule
219360900|NCT01886521|PROCEDURE|Lumbar drain|
219360901|NCT01886521|PROCEDURE|Ventricular drain|
219360902|NCT02718378|DRUG|estetrol|
219360903|NCT02718378|DRUG|placebo|
219360904|NCT06917599|DEVICE|Low-level laser|Effect of Low-level laser therapy in wound healing after primary molar extraction
219360905|NCT06917599|OTHER|Saline Solution (NaCl 0,9%)|Following the extraction, a piece of gauze soaked in normal saline solution (NSS) will be placed over the socket. Both parents and children will be instructed to keep the gauze in place for 45 minutes
219360906|NCT02687399|OTHER|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
219360907|NCT02687399|BIOLOGICAL|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
219360908|NCT00264056|DEVICE|hyperthermia|
219360909|NCT02636777|OTHER|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
219360910|NCT00305656|DRUG|cediranib maleate|Given orally
219360911|NCT01681329|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
219360912|NCT01681329|OTHER|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
219360913|NCT05073055|PROCEDURE|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
219360914|NCT05025566|DIAGNOSTIC_TEST|Cognitive (behavioural and neurophysiological) screening|"Cognitive disorders are attested at the behavioral level by the psychologist specialized in neuropsychology who makes the patient take a standardized battery of specific psychometric tests. This assessment thus makes it possible to obtain behavioral data such as reaction time, error rates and modeling parameters.~The electroencephalogram (EEG) consists of collecting the signal of the brain's bioelectrical activity by means of electrodes placed on the scalp. The EEG is used to determine the cerebral functioning underlying cognitive functions by performing it simultaneously with the behavioral tasks of the neuropsychological assessment, thus obtaining a neurophysiological phenotyping of cognitive disorders."
219360915|NCT03934788|DEVICE|oxysoft (olifilcon C)|subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
219360916|NCT03934788|DEVICE|Si-Hy (olifilcon B)|subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
219360917|NCT06154967|RADIATION|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
219360918|NCT02408692|DRUG|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
219360919|NCT02408692|DRUG|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
219360920|NCT04598490|DEVICE|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
219360921|NCT04598490|DEVICE|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
219360922|NCT02684721|OTHER|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
219360923|NCT01575795|DRUG|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
219360924|NCT01575795|DRUG|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
219360925|NCT02617810|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
219361026|NCT04075929|OTHER|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
219361027|NCT01750515|DEVICE|Acupuncture|
219361028|NCT00343512|DRUG|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
219361029|NCT00343512|GENETIC|protein expression analysis|protein expression analysis
219361030|NCT00343512|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
219361031|NCT00343512|PROCEDURE|biopsy|biopsy
219361032|NCT00343512|PROCEDURE|conventional surgery|conventional surgery
219361033|NCT00343512|PROCEDURE|neoadjuvant therapy|neoadjuvant therapy
219361034|NCT00924937|BEHAVIORAL|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).
219361035|NCT00924937|BEHAVIORAL|Low Fat Diet|Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
219361036|NCT04043000|DIETARY_SUPPLEMENT|Super 13 Pro & Prebiotics|"Super 13 Pro \& Prebiotics was given three times a day for four weeks."
219361037|NCT01637545|DRUG|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
219361038|NCT01819519|BEHAVIORAL|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q\&A.
219361039|NCT04143269|DEVICE|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
219361040|NCT04143269|DEVICE|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
219361041|NCT03887299|COMBINATION_PRODUCT|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
219361042|NCT03887299|OTHER|Standard Wound Care|Wound care will be administered as standard protocol in our institution
219361043|NCT02760082|OTHER|Qualitative evaluation|
219361044|NCT00191451|DRUG|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
219361045|NCT00191451|DRUG|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
219361046|NCT00191451|DRUG|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
219361047|NCT00684515|DRUG|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
219361048|NCT00684515|DRUG|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
219361049|NCT00684515|DRUG|Placebo|oral tablets; once daily for 60 days
219361050|NCT00684515|DRUG|Aspirin 75-150 mg|oral tablets; once daily for 60 days
219361051|NCT03569852|BEHAVIORAL|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
219361052|NCT03569852|BEHAVIORAL|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
219361053|NCT04428411|DRUG|Enbrel|As provided in real world practice
219361054|NCT04067947|DRUG|XG005|XG005 Tablet
219361055|NCT04067947|DRUG|Placebos|Placebo Tablet
219361056|NCT00372437|DRUG|MGCD0103|MGCD0103 as an oral dose three times per week.
219361057|NCT00372437|DRUG|Gemcitabine|Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle.
219361058|NCT03359135|OTHER|Rehabilitation|Rehabilitation during 4 weeks
219361059|NCT03359135|DEVICE|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
219361060|NCT06228222|PROCEDURE|renal biopsy|"Renal biopsy will be performed for all patients fulfilling the American College of Rheumatology (ACR) criteria to confirm the diagnosis of lupus nephritis (LN) and to classify the glomerular disease by the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 histopathological classification system"
219361061|NCT06286865|OTHER|Easy-ICD|Easy-ICD is an AI-based computer-assisted clinical coding (CAC) system that helps clinical coder assign ICD-10 codes to clinical notes such as discharge summaries.
219361062|NCT04503876|OTHER|Increasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
219361063|NCT04503876|OTHER|Decreasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
219361064|NCT01953744|DRUG|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
219361065|NCT01953744|DRUG|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
219363479|NCT02532855|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
219361407|NCT06913062|PROCEDURE|conventional rehabilitation|For control group, the conventional rehabilitation protocol aimed to alleviate muscular and neuropathic pain in the short term, improve cervical mobility, reduce muscle tension, and increase muscle strength in the medium term, and promote a healthy lifestyle along with socio-professional reintegration in the long term. The principles included educating patients about their condition, respecting pain thresholds, and considering fatigue levels. Each patient received treatment for two months, with three sessions per week, each lasting about one hour. The protocol consisted of three phases: the first week focused on relaxation through massage and low-frequency electrotherapy; the second week introduced passive joint mobilizations; and from the third week, muscle stretching and strengthening exercises were incorporated. Additionally, functional exercises targeting daily activities and body awareness techniques are included to maintain proper posture.
219361408|NCT06913062|PROCEDURE|neural mobilisation|The protocol was structured around three main axes: treatment of interfaces (joint mobilizations and traction), direct treatment (using neurodynamic techniques), and indirect treatment (neural self-mobilization and lifestyle advice). The treatment included various stages for each ULNT technique. ULNT1 targeted the median nerve and involved shoulder abduction, elbow extension, and head inclination. ULNT2 focused on scapular depression and targeted cervical roots. ULNT3 emphasized radial nerve tension with internal rotation of the shoulder, while ULNT4 addressed ulnar nerve tension through elbow flexion and shoulder abduction. Each technique was executed with specific movements, maintained for 20 to 30 seconds, and repeated 15 times, followed by gentle scapular mobilizations until pain resolution.
219361409|NCT06916676|DEVICE|Low-Dose High-Intensity Laser Therapy (10 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 10 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
219361410|NCT06916676|DEVICE|Medium-Dose High-Intensity Laser Therapy (15 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 15 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
219361411|NCT06916676|DEVICE|High-Dose High-Intensity Laser Therapy (20 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 20 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
219361412|NCT06916676|DEVICE|Sham High-Intensity Laser Therapy|Sham procedure mimicking active HILT using the same Nd:YAG laser device (BTL-6000). Same setup, patient positioning, scanning technique over identical zones, and session duration/frequency (3x/week, 4 weeks, 15-20 min). Device powered on with visual/auditory cues active, but no laser energy emitted. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
219361413|NCT06915948|PROCEDURE|Macular Hole Surgery|Pars Plana Vitrectomy with ILM peeling with silicone oil tamponade
219361414|NCT06915441|DRUG|SOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
219361415|NCT06915441|DRUG|MOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
219361416|NCT06916546|COMBINATION_PRODUCT|SIRT-L-P|Patients received 1-2 session of SIRT. Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
219361417|NCT06916546|COMBINATION_PRODUCT|TACE-L-P|Patients received TACE. TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications (on-demand TACE). Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
219361418|NCT06915272|OTHER|Head and Neck Cooling Intervention|Participants received a head and neck cooling intervention involving the daily use (≥2 hours/day) of cooling devices consisting of a cooling cap and cooling towel specifically designed for localized head and neck cooling. Devices were activated by immersing them in cold water maintained at approximately 10°C.
219361419|NCT06916000|DRUG|Pericapsular nerve group (PENG) block|"As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.~All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points."
219361420|NCT06916000|OTHER|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.
219361421|NCT06913699|PROCEDURE|Ultrasonund-guided percutaneous liver biopsy|All patients completed blood routine, coagulation function and liver biochemical indexes before surgery, and informed the patients and their families about the purpose and risks of surgery, and signed an informed consent. During the procedure, the patient was placed in the left lateral decubitus position. After locating by ultrasound and routine disinfection, 0.5% lidocaine was used for local anesthesia. Under the guidance of ultrasound, a 16G disposable biopsy needle (SC1620) was inserted into the liver parenchyma, and the biopsy gun was started and fired for sampling. The removed liver tissue was fixed in 4% formaldehyde solution and sent to the pathology department. The patient's puncture site was disinfected and covered with sterile dressing, and the abdominal band was bandaged. The patients were instructed to stay in bed for 24 hours after operation, closely observe whether there was pain and bleeding after operation, and monitor electrocardiogram for 24 hours.
219361422|NCT00525538|RADIATION|conformal radiotherapy|
219361423|NCT07155239|DEVICE|AviClear Lase Treatment|Three laser sessions at Weeks 0, 4, 8; follow-ups at Weeks 12, 16, 24.
219361424|NCT07155239|DEVICE|Sham (No Treatment)|No active laser treatment
219361425|NCT07160231|DRUG|JAKi dose reduction strategy|JAKi dose reduction strategy
219361509|NCT03018132|OTHER|mental health screening, education and referral program|"I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
219361510|NCT06224114|DEVICE|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
219361511|NCT06224114|DEVICE|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
219361512|NCT06305741|OTHER|Managing Anxiety from Cancer (MAC)|"The intervention, MAC, is a seven-session (45-60 minutes per session) psychotherapy intervention delivered via videoconference.~and/or telephone by licensed social workers"
219361513|NCT03593915|COMBINATION_PRODUCT|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
219361514|NCT01052025|DRUG|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
219361515|NCT02894840|BIOLOGICAL|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
219361516|NCT02894840|OTHER|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
219361517|NCT04041336|DIAGNOSTIC_TEST|Optical coherence tomography|Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
219361518|NCT04866290|DEVICE|HepaSphere Microspheres|
219361519|NCT03686787|DRUG|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
219361520|NCT04482946|DIAGNOSTIC_TEST|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
219361521|NCT05836233|DRUG|Pulmonary Vasodilators|"Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose."
219361522|NCT00498745|DRUG|neratinib|HKI-272
219361523|NCT00167245|DRUG|Topiramate|300mg/day for 13 weeks
219361524|NCT00167245|DRUG|placebo|placebo pills
219361525|NCT06113874|OTHER|Hurriseal desensitizer|"Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
219361526|NCT06113874|OTHER|Gluma desensitizer|"Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
219361527|NCT02224235|DRUG|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
219361528|NCT02224235|DEVICE|Resolute Integrity DES|Resolute Integrity DES
219361529|NCT02224235|DEVICE|COBRA PzF|
219361530|NCT02224235|DRUG|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
219361531|NCT03436355|BEHAVIORAL|Physical activity|"The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework."
219361532|NCT02435602|PROCEDURE|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
219361533|NCT02435602|PROCEDURE|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions \>= 5 mm diameter Pathologic examination of all biopsy tissue specimens
219361534|NCT00804687|OTHER|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
219361535|NCT00804687|DRUG|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
219361911|NCT00820755|DRUG|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
219361912|NCT00820755|DRUG|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
219361913|NCT00820755|DRUG|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
219361914|NCT02153567|DRUG|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
219361915|NCT02153567|OTHER|Placebo|Placebo will be given for the next 10 weeks.
219361916|NCT06386848|DRUG|Botulinum toxin|Botulinum toxin doses injected in dystonia
219361917|NCT02282592|OTHER|Observation about the presence of metabolic syndrome|
219361918|NCT03365778|OTHER|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
219361919|NCT03365778|OTHER|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
219361920|NCT03365778|OTHER|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
219361921|NCT05816863|DRUG|pabolizumab|pabolizumab IV every 3 weeks (q3w)
219361922|NCT01769755|BIOLOGICAL|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
219361923|NCT01769755|DRUG|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
219361924|NCT01580930|BEHAVIORAL|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
219361925|NCT01580930|BEHAVIORAL|sedentary time reduction|participants provided with strategies to decrease sitting
219361926|NCT01580930|BEHAVIORAL|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
219361927|NCT04072757|BEHAVIORAL|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~* connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~* seasonal fruits \& vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~* quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~* choose healthier foods Session Five: Taste Bud Rehab~* reduce foods high in sugar and salt.Mind-body connection Session Six: Batch \& One Ingredient Cooking~* making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~* prepare healthier desserts Session Eight: Family Meal Practices~* healthy eating habits in children Session Nine: Snacks as Mini Meals~* make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~* healthy up favorite recipes"
219361928|NCT04072757|BEHAVIORAL|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
219361929|NCT04927728|OTHER|Mental Practice|MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.
219361930|NCT04927728|OTHER|Repetitive-Task Practice|Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.
219361931|NCT04927728|OTHER|Traditional Therapy|Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
219361932|NCT02185378|PROCEDURE|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
219361933|NCT02185378|PROCEDURE|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
219361934|NCT05983289|DRUG|HSK7653|HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
219361935|NCT05983289|DRUG|Placebo|Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
219361936|NCT04405219|OTHER|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
219362260|NCT05591586|BEHAVIORAL|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
219362261|NCT05591586|BEHAVIORAL|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
219362262|NCT06222151|OTHER|Intervention 1: Mobilization during hospitalization|Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
219362263|NCT06222151|OTHER|Intervention 2: Mobilization the first 4 postoperative weeks|Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
219362264|NCT06222151|OTHER|Control group|"The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge."
219362265|NCT06824870|OTHER|RV5026B - ET1732 - Period 1|Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area.
219362266|NCT06824870|DRUG|reference topical product - Period 2|Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face.
219362267|NCT06824870|OTHER|RV5026B - ET1732 - Period 2|Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products.
219362268|NCT00529971|BEHAVIORAL|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
219362269|NCT00529971|OTHER|Control|Treatment as usual, which could include medications or psychotherapy
219362270|NCT03746912|DRUG|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
219362271|NCT03655418|OTHER|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
219362272|NCT06878833|DRUG|LYN-005 (risperidone)|long-acting oral (LAO) capsule
219362273|NCT06878833|DRUG|Placebo for LYN-005|capsule
219362274|NCT06878833|DRUG|IR Risperidone|tablets
219362275|NCT06878833|DRUG|Placebo for IR Risperidone|tablets
219362276|NCT06729775|OTHER|Data report back preference by life span|Data report back preference by life span.
219362277|NCT06729125|DEVICE|transcranial photobiomodulation|Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).
219362278|NCT06729125|OTHER|exercises training|balance exercises and others
219362279|NCT06883357|BEHAVIORAL|Graded repetitive arm supplementary program (GRASP)|Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program. home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. Participants in experimental group will receive Home GRASP program which will be executed 1hour at home per day. In addition, Participants will be requested to return hospital for follow-up and adjusting the training program in group discussion 3 times per week, lasting 4-6 weeks, and totally 12-18 sessions.
219362292|NCT06915402|DEVICE|"LMW - CL - HA FACE/BODY"|"The dosage to be used for the individual case is at the discretion of the doctor. The periodicity with which to repeat the procedure depends on different factors, concerning both the physiology of the patient (skin type, individual metabolism, anatomy, age) and lifestyle; another element to consider is related to the implantation techniques adopted. After the first treatment, the result can be retouched after 15 days, repeating the treatment after 9-12 months to maintain the results obtained. Local anesthesia for facial treatments can be performed, in order to ensure the necessary comfort for the patient. The area of intervention must be cleaned with antiseptic solutions before proceeding to the implant. Do not use quaternary ammonium-based disinfectants, as they can react with the HA and form precipitates.LMW - CL - HA FACE/BODY is to be used intracutaneously and must not be injected into the blood vessels. Further details on the injection procedure are reported in the IFU."
219362293|NCT03548441|PROCEDURE|Surgery|Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
219362294|NCT03548441|OTHER|Non-surgical management|Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
219362295|NCT05417490|OTHER|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~* for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~* for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
219362296|NCT05417490|DEVICE|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~* characterization of alerts~* structured follow-up of remote patients.~This non-medical human assistance is provided by:~* nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~* to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~* remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
219362297|NCT05877742|OTHER|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
219362298|NCT05877742|OTHER|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
219362299|NCT02979977|DRUG|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
219362300|NCT02979977|DRUG|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
219362301|NCT05888103|DRUG|Inclisiran|Inclisiran s.c
219362302|NCT05888103|DRUG|Matching Placebo for Inclisiran|Matching s.c. placebo
219362303|NCT05180786|OTHER|Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned on.
219362304|NCT05180786|OTHER|No Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned off.
219362305|NCT04692831|COMBINATION_PRODUCT|89Zr-ss-pertuzumab PET/CT|Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
219362306|NCT06357676|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
219362307|NCT06357676|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
219362308|NCT06357676|PROCEDURE|Computed Tomography|Undergo CT scan or FDG PET/CT
219362309|NCT06357676|PROCEDURE|Echocardiography|Undergo echocardiography
219362310|NCT06357676|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
219362311|NCT06357676|BIOLOGICAL|Glofitamab|Given IV
219362312|NCT06357676|DRUG|Ibrutinib|Given PO
219362313|NCT06357676|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
219362314|NCT06357676|BIOLOGICAL|Obinutuzumab|Given IV
219362315|NCT05623891|DRUG|177Lu-B5-IgG4|177Lu-B5-IgG4 injection followed by SPECT scan
219362316|NCT04272931|PROCEDURE|Portal and Hepatic Vein Embolization|Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)
219363847|NCT00836433|BEHAVIORAL|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
219362331|NCT05285501|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
219362332|NCT00003031|DRUG|amphotericin B deoxycholate|
219362333|NCT00003031|DRUG|voriconazole|
219362334|NCT02152345|DRUG|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
219362335|NCT02152345|DRUG|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
219362336|NCT02152345|DRUG|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
219362337|NCT02152345|DRUG|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
219362338|NCT02152345|DRUG|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
219362339|NCT02152345|PROCEDURE|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
219362340|NCT03211390|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
219362341|NCT03211390|DIAGNOSTIC_TEST|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
219362342|NCT03675867|OTHER|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
219362343|NCT00013286|DEVICE|Prevention Diabetic Foot Ulcer|
219362344|NCT05770986|OTHER|Group A|the patient must attain the goal repetitions (and holds when required) at one level before progressing to the next level. The principal investigator will provide extensive education to the patient while progressing through the program. Three resistance bands will be used through the exercise progression; yellow band (low resistance), green band (moderate resistance) to blue band (high resistance). The patient will progress to more advanced level if he/she can sustain the position with high resistance band (blue) for one minute with three isometric holds of each exercise on each limb. three sets for 10 repetitions will be performed) Phases 1-3 of the program are focused on GMax activation. Phases 4- 5 are focused on GMax strength, and the final three phases emphasize functional applications of the GMax during ballistic tasks.
219362345|NCT05770986|OTHER|Group B|Flexibility exercises of the back muscles: knee to chest stretch, bridging, stretching exercises for hip flexors, piriformis, adductors and hamstring will be performed, with a hold of position for 30 s and with repetitions (3-5 times). Static stretches will be held for 30 seconds to induce changes in flexibility and will be repeated for three sets. Three sessions of stretching per week will be performed b. Prone resisted hip extension 10 repetitions for two sets. c. Hot pack: for 10 minutes. d. TENS: The electrodes will be placed over the area of most severe pain for 15 minutes.
219362346|NCT04696640|BEHAVIORAL|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
219362347|NCT01916980|DRUG|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
219362348|NCT06438679|DRUG|Tofacitinib 5 MG|Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral
219362349|NCT06184347|OTHER|Rapid tests for HBsAg|"Participants in the screening group will firstly receive the HBsAg screening using a finger blood test.~The laboratory examination includes blood routine test (white blood cell count \[WBC\], red blood cell count \[RBC\], hemoglobin \[HGB\], platelet count \[PLT\]), liver function (total bilirubin \[TBIL\], albumin \[ALB\], alanine aminotransferase \[ALT\]), HBV serologic markers, alpha-fetoprotein(AFP) , abnormal Prothrombin II (PIVKA II) and HBV-DNA.~The imaging examination includes liver ultrasound, abdominal CT, or MRI. HBsAg-positive participants also undergo liver ultrasound examination. If suspicious liver nodules or elevated AFP levels are detected, further refinement through abdominal CT or MRI is recommended."
219362350|NCT02766660|DEVICE|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
219362351|NCT02324270|DRUG|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
219362352|NCT02324270|OTHER|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
219362353|NCT01292967|DIETARY_SUPPLEMENT|Low flavanol chocolate|48 mg of total flavanols from cocoa
219362431|NCT06197061|PROCEDURE|RAMS|The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
219362432|NCT06197061|PROCEDURE|LAMS|The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line. After the laparoscopy was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the laparoscopic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
219362433|NCT02452372|DRUG|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
219362434|NCT02452372|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
219362435|NCT04147468|OTHER|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
219362436|NCT04147468|OTHER|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
219362437|NCT01288560|OTHER|Advanced cardiac imaging|
219362438|NCT01288560|OTHER|Standard Cardiac Imaging|
219362439|NCT04753398|DEVICE|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
219362440|NCT04273048|OTHER|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
219362441|NCT04273048|OTHER|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
219362442|NCT00746967|DRUG|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
219362443|NCT02307916|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
219362444|NCT02307916|OTHER|Placebo|Placebo comparator using a sterile saline solution.
219362445|NCT00855660|DRUG|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
219362446|NCT00855660|DRUG|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
219362447|NCT02790866|BEHAVIORAL|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
219362448|NCT02790866|BEHAVIORAL|NCI Website|NCI Website on Lung Cancer Screening
219362449|NCT00568555|DRUG|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
219362450|NCT00568555|DRUG|Placebo - sugar pill|Placebo pill once daily
219362451|NCT03246828|OTHER|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
219362452|NCT04995874|DIETARY_SUPPLEMENT|KOKOPlus protein and micronutrient powder|KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
219362453|NCT02488304|RADIATION|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
219362454|NCT06530784|PROCEDURE|Cryoablation|After the completion of screening, the subjects received cryoablation treatment
219362455|NCT06530784|DRUG|PD-1 antibody and bevacizumab|Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
219362456|NCT01172756|DRUG|Riociguat (BAY63-2521)|0.5 mg single oral dose
219362457|NCT01172756|DRUG|Riociguat (BAY63-2521)|1 mg single oral dose
219362458|NCT01172756|DRUG|Riociguat (BAY63-2521)|2 mg single oral dose
219362459|NCT01172756|DRUG|Placebo|single oral dose
219362460|NCT04226794|DEVICE|a-tDCS|Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).
219362842|NCT06203301|BEHAVIORAL|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~1. Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~2. Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~3. Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
219362843|NCT05169528|OTHER|Colorectal Cancer Prehabilitation Programme|Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
219362844|NCT04075331|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection
219362845|NCT04075331|DRUG|Placebo|Saline solution for subcutaneous injection
219362846|NCT06356233|OTHER|No intervention will be performed|No intervention will be performed
219362847|NCT05417854|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
219362848|NCT03220672|BEHAVIORAL|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
219362849|NCT00448708|DEVICE|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm\^2 paclitaxel
219362850|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
219362851|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
219362852|NCT04957186|OTHER|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
219362853|NCT04957186|OTHER|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
219362854|NCT05883280|OTHER|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
219362855|NCT00928421|DRUG|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
219362856|NCT03288909|OTHER|MRI|
219362857|NCT02572284|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
219362858|NCT02572284|PROCEDURE|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
219362859|NCT02572284|OTHER|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
219362860|NCT02400255|DRUG|Crenolanib besylate|
219362861|NCT00599417|DRUG|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
219362862|NCT00599417|DRUG|placebo|placebo controlled
219362863|NCT06076668|DRUG|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
219362864|NCT06076668|DRUG|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
219362865|NCT06076668|DRUG|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
219362866|NCT02697942|OTHER|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
219362867|NCT02697942|OTHER|exercise training|The investigators will provide participants with foot peddlers.
219362868|NCT01423539|DRUG|bendamustine|Intravenous repeating dose\\n
219362869|NCT01423539|DRUG|navitoclax|Oral repeating dose\\n
219362870|NCT01423539|DRUG|rituximab|Intravenous repeating dose\\n
219362871|NCT01653119|DRUG|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
219362872|NCT03696992|PROCEDURE|Tandem colonoscopy|Tandem colonoscopy with different image modalities
219362873|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
219363848|NCT00836433|BEHAVIORAL|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
219363849|NCT02061865|DRUG|REGN2176-3|
219363177|NCT06915428|BEHAVIORAL|PTBCARE+ mobile application (app) and website|"Comprehensive, study-specific app that is available as a website or as a downloadable application that includes personalized, interactive modules and resources~* no study related materials are available without a password~* goal is to collate reputable sources of information to make investigating things online easier~* includes optional educational modules for participants~* also includes option of entering stress, well-being, blood sugar, blood pressure, etc. values with option to easily download recorded values for patient's clinical team~* available online (computer/laptop), tablet, or smart phone. can be downloaded as a progressive web application (PWA) to a local device and used without internet access~* Electronic access to the PTBCARE+ website will continue through 10 weeks postpartum unless the participant delivered \<16+0 weeks gestation in which case access will continue through 4 weeks postpartum"
219363178|NCT06915428|BEHAVIORAL|Sleep, meditation, and Wellness app|"* complimentary one-year subscription to Aura - an 'all-in-one' wellbeing app that contains an enormous library of meditations, stories, breath work, work wellness, music, sounds, and more!~* Participants can access this app as needed throughout pregnancy and beyond, for up to one year after the date of enrollment"
219363179|NCT06915428|BEHAVIORAL|Emergency low blood sugar kit|"Pouch contains:~* printed index card with information about signs and symptoms of low blood sugar~* printed index card with information about what to do if blood sugar is low~* 2-3 non-perishable, individually wrapped over the counter candy / glucose-raising options; use for low blood sugar treatment is described on the card~Only participants who have a diagnosis of diabetes mellitus or glucose intolerance AND have been prescribed an oral medication for blood sugar control or have been prescribed insulin are eligible to receive this.~Each participant can receive a maximum of two kits during pregnancy; first at enrollment, and the other at visit 2 or until delivery"
219363180|NCT06915428|BEHAVIORAL|Low dose aspirin (LDA)|"* Bottle of 90-100 pills (depending on manufacturer)~* Provided at Visit 1 (after randomization)~* Patients who received a bottle of low-dose aspirin at Visit 1 are offered a 2nd bottle at Visit 2.~All patients whose provider recommends or prescribes either 81mg or 162mg of LDA during pregnancy are offered LDA as described herein. LDA must be on the patient's med list or specific notes from the patient's prenatal provider must explicitly note that it is recommended the patient take LDA in pregnancy for it to be offered. Individuals who are receiving LDA due to participation in another study are not eligible to receive LDA from PTBCARE+~Please note that this is listed as a behavioral intervention rather than drug intervention because the rational behind providing this over the counter medication is to help make the participant's life easier, and the focus is not on the efficacy of LDA. As such, it is being provided as a behavioral intervention."
219363181|NCT06915428|BEHAVIORAL|Visit #2 Stress Reduction Toolkit|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include the following stress reduction items or similar:~1. Frame + ultrasound photo + certificate of achievement!~   * Picture from anatomy ultrasound (or other subsequent ultrasound) is downloaded, printed, and placed in frame.~  * Certificate of achievement is printed and placed on other side of frame with ultrasound photo~2. other small items including stickers, printed index cards with supportive messaging, etc."
219363182|NCT06917534|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with drug addiction specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
219363183|NCT06916026|PROCEDURE|Xenograft|Gap distance grafting using xenograft
219363184|NCT06916026|PROCEDURE|Xenograft mixed with HAM gel.|Gap distance grafting using xenograft mixed with HAM gel.
219363185|NCT06915870|DRUG|Dapagliflozin 10 mg daily|Dapagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
219363186|NCT06915870|DRUG|Empagliflozin 10 MG OD|Empagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
219363187|NCT06916897|DRUG|sevasemten|single dose 10mg sevasemten administered orally
219363188|NCT06916897|DRUG|Verapamil|multiple doses 240mg verapamil
219363189|NCT06915506|DRUG|Shenfu Injection|"This intervention combines traditional Chinese medicine (TCM) with modern critical care practices to distinguish it from conventional sepsis therapies. Key unique features include:~TCM-Based Intervention:~Shenfu Injection: A standardized herbal extract derived from Panax ginseng and Aconitum carmichaelii , prepared under Chinese Pharmacopoeia guidelines.~Mechanism: Targets mitochondrial dysfunction and endothelial glycocalyx repair, with preclinical evidence of anti-inflammatory, anti-apoptotic, and vasoregulatory effects.~Precision Delivery Protocol:~Dosage: 60 mL (1 mL/kg for patients \<60 kg) administered via syringe pump-controlled continuous infusion over 3 hours, ensuring stable plasma concentrations.~Timing: Initiated only after hemodynamic stabilization (≥1 hour of stable vasopressor requirements post-fluid resuscitation), aligning with the golden window for vascular repair in sepsis."
219363190|NCT06917053|DEVICE|Ultrasound (including contrast enhanced ultrasound)|Ultrasound measures: contrast enhanced ultrasound (CEUS) of the kidney, venous excess ultrasound (VExUS), echocardiography
219363191|NCT06917053|DEVICE|Sublingual incident dark field videomicroscopy|Sublingual incident dark field (IDF) videomicroscopy
219363192|NCT06917053|DEVICE|Urinary oxygen tension.|Continuous urinary oxygen tension
219363193|NCT06915623|DRUG|Innovative Gel application|Innovative gel application: Gel is applied as an adjunct treatment to cleaning and scaling.
219363194|NCT06915623|PROCEDURE|Mechanical Debridement|Cleaning and scaling of the implant.
219363195|NCT02453074|OTHER|Online survey - Follow up for Better Care|
219363196|NCT02297802|DRUG|PD-0325901|
219363197|NCT01207271|BEHAVIORAL|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
219363198|NCT01207271|BEHAVIORAL|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
219363461|NCT04711096|PROCEDURE|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
219363462|NCT02906254|OTHER|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
219363463|NCT02906254|OTHER|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
219363464|NCT05346107|DRUG|pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage|The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
219363465|NCT00235105|DRUG|Adalimumab 40 mg sc every other week|
219363466|NCT03213366|BEHAVIORAL|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
219363467|NCT03213366|BEHAVIORAL|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
219363468|NCT02836015|BEHAVIORAL|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
219363469|NCT02671331|PROCEDURE|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
219363470|NCT02286388|PROCEDURE|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
219363471|NCT02286388|PROCEDURE|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
219363472|NCT02286388|DEVICE|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
219363473|NCT02286388|DEVICE|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
219363474|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
219363475|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
219363476|NCT02532855|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet
219363477|NCT02532855|DRUG|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
219363850|NCT02604940|DRUG|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
219363648|NCT04513470|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
219363649|NCT01912625|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
219363650|NCT01912625|DRUG|Carboplatin|Given IV
219363651|NCT01912625|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
219363652|NCT01912625|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
219363653|NCT01912625|OTHER|Laboratory Biomarker Analysis|Correlative studies
219363654|NCT01912625|DRUG|Paclitaxel|Given IV
219363655|NCT01912625|OTHER|Pharmacological Study|Correlative studies
219363656|NCT01912625|DRUG|Trametinib|Given PO
219363657|NCT00508391|DEVICE|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
219363658|NCT01295060|DRUG|Octreotide|84 mg Octreotide Implant
219363659|NCT00682058|OTHER|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
219363660|NCT03311256|DIAGNOSTIC_TEST|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
219363661|NCT01692678|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
219363662|NCT01692678|DRUG|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
219363663|NCT01332682|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
219363664|NCT01332682|BEHAVIORAL|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
219363665|NCT04750460|DRUG|Teriparatide|Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
219363666|NCT05825690|OTHER|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
219363667|NCT02762487|DEVICE|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
219363668|NCT04869267|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Session 1:~This session aims to let the participants get familiar with the interventionist. The interventionist will tell them the purpose of the program and basic rules. And the interventionist will promise their privacy protection.~Session 2:~This session includes how to separate thoughts/feelings/sensations related to diagnose with advanced lung cancer and experience of fatigue with facts and see these feelings in an objective way with observing self.~Session 3:~This session mainly aims to help participants understand the importance of values, differentiate values from goals and clarify their personal values.~Session 4:~This session aims at helping patients practice to engaging in committed action based on chosen values, motivated to change behavior in consistency with life direction and health goal."
219363669|NCT04869267|OTHER|Usual care|The usual care mainly includes treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge
219363670|NCT01418495|OTHER|Cytology Specimen Collection Procedure|Correlative studies
219363671|NCT01418495|OTHER|Pharmacological Study|Correlative studies
219363672|NCT00802360|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
219363673|NCT00802360|DRUG|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
219363674|NCT00802360|DRUG|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
219363675|NCT00802360|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
219363676|NCT00802360|DRUG|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
219363728|NCT06148961|PROCEDURE|botox prior to modified lip repostioning|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
219363729|NCT02111733|OTHER|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
219363730|NCT05274230|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
219363731|NCT04617366|OTHER|Individualized rTMS strategy|It will adjust the rTMS parameters based on the results of fNIRS.
219363732|NCT04617366|OTHER|Traditional rTMS strategy|The patients will always be given low-frequency rTMS to contralesional M1.
219363733|NCT00165958|PROCEDURE|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
219363734|NCT00165958|PROCEDURE|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
219363735|NCT01481896|DEVICE|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
219363736|NCT05057455|PROCEDURE|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
219363737|NCT02295722|DRUG|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
219363738|NCT02295722|DRUG|Melphalan|200 mg/m2
219363739|NCT02295722|OTHER|ASCT|Day 0 - Stem cell infusion
219363740|NCT05772897|BEHAVIORAL|Circle of Security Parenting program|The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
219363741|NCT04323930|DEVICE|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
219363742|NCT00145990|DRUG|methacholine|
219363743|NCT00145990|DEVICE|KoKo Digidoser|
219363744|NCT00145990|DEVICE|Rosethal Dosimeter|
219363745|NCT03152240|OTHER|Non intervention|Non intervention
219363746|NCT03871114|DRUG|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
219363747|NCT01682850|BEHAVIORAL|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
219363748|NCT01682850|OTHER|Usual Care|
219363749|NCT00805896|DRUG|Songyou|4g/pack
219363750|NCT00805896|DRUG|placebo|4g/pack
219363751|NCT00501267|DRUG|solabegron and oxybutynin|
219363752|NCT04333082|OTHER|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
219363753|NCT02500004|RADIATION|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
219363754|NCT02500004|RADIATION|DXA scanning|Body composition: DXA scanning, D2O and MRI.
219363755|NCT02500004|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
219363756|NCT02500004|PROCEDURE|Blood sampling|Systemic inflammatory profile: blood sampling.
219363757|NCT02500004|OTHER|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
219363758|NCT02500004|DEVICE|Accelerometry|Physical activity level: accelerometry.
219363759|NCT02500004|OTHER|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
219363760|NCT01818726|DRUG|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
219363761|NCT01818726|DRUG|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
219363762|NCT01818726|DRUG|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
219363763|NCT00199979|DRUG|Nevirapine|
219363764|NCT03504202|DRUG|Trimetazidine|After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
219363794|NCT05495295|DRUG|PhOx430|The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
219363795|NCT03603769|DIETARY_SUPPLEMENT|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
219363796|NCT03603769|DIETARY_SUPPLEMENT|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
219363797|NCT03746561|DIAGNOSTIC_TEST|deep learning|detect and classify spinal stenosis by deep learning
219363798|NCT00000927|DRUG|BufferGel|
219363799|NCT04106622|PROCEDURE|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
219363800|NCT04760002|DEVICE|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
219363801|NCT05512871|BEHAVIORAL|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
219363802|NCT04301427|OTHER|Bone mineral density|Bone mineral density will be measured twice in all included patients.
219363803|NCT02244242|DRUG|Tamsulosin hydrochloride|
219363804|NCT03538769|OTHER|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
219363805|NCT01133340|RADIATION|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
219363806|NCT04055103|OTHER|Monthly feedback, education and linking hospitals|\- Give monthly feedback from LROI-data (revision rate \& patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
219363807|NCT01054079|OTHER|laboratory biomarker analysis|Correlative study
219363808|NCT01054079|PROCEDURE|quality-of-life assessment|Ancillary study
219363809|NCT01054079|OTHER|questionnaire administration|Ancillary study
219363810|NCT01054079|DRUG|cinacalcet hydrochloride|Given PO
219363811|NCT04753892|OTHER|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
219363812|NCT04529291|OTHER|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
219363851|NCT02604940|DRUG|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
219363852|NCT00242476|DRUG|MK0822A|
219363853|NCT02349178|DRUG|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
219363854|NCT02349178|DRUG|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
219363855|NCT02349178|DRUG|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
219363856|NCT03357393|DRUG|Midazolam|Midazolam is givenas sedation to the Control arm.
219363813|NCT04529291|OTHER|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
219363814|NCT04138160|OTHER|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
219363815|NCT04138160|OTHER|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
219363816|NCT05358132|DEVICE|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
219363817|NCT00358605|DEVICE|The Klearway™ oral appliance|See Detailed Description.
219363818|NCT00775489|DRUG|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
219363819|NCT00775489|DRUG|Saline|control group will receive normal saline inhaler
219363820|NCT02952183|DEVICE|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
219363821|NCT05876403|OTHER|Conventional|The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
219363822|NCT05876403|OTHER|PNF|The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
219363823|NCT00480857|DRUG|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
219363824|NCT01536301|DRUG|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
219363825|NCT01536301|DRUG|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
219363826|NCT00611247|DRUG|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
219363827|NCT04196114|DEVICE|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
219363828|NCT03522129|DRUG|CT1812|Active Study Drug
219363829|NCT03522129|DRUG|Placebo|Non-active study drug
219363830|NCT03683602|OTHER|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
219363831|NCT03683602|OTHER|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
219363832|NCT06244953|OTHER|TIER-HF-PC|The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
219363833|NCT06244953|OTHER|Usual Care|Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
219363834|NCT03567902|DEVICE|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
219363835|NCT03567902|DEVICE|Direct laryngoscope intubation|Direct laryngoscope intubation
219363836|NCT04620330|DRUG|avutometinib (VS-6766)|Monotherapy
219363837|NCT04620330|DRUG|avutometinib (VS-6766) and Defactinib|Combination therapy
219363838|NCT00565617|DEVICE|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
219363839|NCT00939835|DRUG|Citalopram Hydrobromide|
219363840|NCT00640471|BIOLOGICAL|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
219363841|NCT00640471|DRUG|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
219363842|NCT04113915|DRUG|triple therapy|Effect of treatment on immunity to obtain infection with hepatitis B\&C
219363843|NCT04113915|DRUG|Steroids|Oral or parenteral steroid therapy for ITP
219363844|NCT01890421|DRUG|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
219363845|NCT00207051|DRUG|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
219363846|NCT02747030|DRUG|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
219364024|NCT06915532|PROCEDURE|conventional rehabilitation|"Conventional reeducation focused the first week on analgesic approach including:~* Education and lifestyle: Emphasizing weight management, autonomy in chronic low back pain management, and encouragement of physical activity.~* Massage and electrotherapy: To alleviate pain, enhance circulation, and relax muscles.~* Pelvic and lumbar movement awareness: Exercises focused on improving the control of pelvic movements.~* Breathing exercises: Breathing techniques to reduce tension and improve awareness.~Then in week 2 and beyond, physiotherapist continued analgesic work and physical training:~* Joint mobility and muscle flexibility: Exercises target mobility improvement, muscle strengthening, and stretching, with emphasis on posture control and lumbar mobility.~* Muscle strengthening: Focused on abdominal and spinal muscles, promoting spinal stability and improving trunk control.~* Proprioceptive rehabilitation: Enhancing lumbar-pelvic vigilance to stabilize the spine and prevent further ve"
219364025|NCT06917105|DRUG|CD33/CD123/CLL-1 CAR-T Cells|"Part A: Dose Escalation Phase. Follows a 3+3 dose escalation design with four predefined dose cohorts: 0.2×10⁶, 0.5×10⁶, 1×10⁶, and 2×10⁶ CAR-positive cells/kg.Anticipated enrollment: 12-24 subjects.Primary objectives: Assess safety, tolerability, and determine MTD.Dose-limiting toxicity (DLT) observation period: 28 days post-infusion.~Part B: Dose Expansion Phase.Enrolls 21 additional subjects to receive CAR-T cell infusion at the recommended Phase 2 dose (RP2D) established in Part A.Primary objective: Further evaluate therapeutic efficacy."
219364026|NCT06915688|DRUG|Doxycycline|Doxycycline will be given to COPD group 1
219364027|NCT06915688|DRUG|Levofloxacin|Levofloxacin given to copd patients
219364028|NCT04971005|DRUG|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
219364029|NCT04971005|DRUG|Ocrelizumab|600 mg every 6 months continuously
219364030|NCT04971005|DRUG|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
219364031|NCT06917092|DRUG|QL1706 combined with chemotherapy ± Bevacizumab|"* Drug: QL1706: 5 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first.~* Drug: Chemotherapy: physician's choice chemotherapy for 3-6 cycles.~* Drug: Bevacizumab (optional): 15 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first."
219364032|NCT04129060|DRUG|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
219364033|NCT04704934|DRUG|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
219364034|NCT04704934|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
219364035|NCT04704934|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
219364036|NCT05142709|DRUG|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
219364037|NCT03371368|PROCEDURE|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
219364038|NCT03371368|PROCEDURE|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
219364039|NCT03371368|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
219364040|NCT05847686|OTHER|Counseling|Participate in therapy visits
219364041|NCT05847686|DRUG|Psilocybin|Given PO
219364042|NCT05847686|OTHER|Questionnaire Administration|Ancillary studies
219364043|NCT06353113|BEHAVIORAL|Down Dog Prenatal Yoga App|"The Down Dog prenatal yoga app launched in 2015 and was designed to align with the changes a pregnant body goes through in each trimester. Users can select a practice by trimester, which will offer modification cues to work with a changing body during pregnancy. Users can also customize their experience by boosting things like Heartburn or Pubic Symphysis so they can continue to practice yoga and omit poses that might be uncomfortable. The app also utilizes user feedback, to continuously implement new practices to better their app for user interface.~All of the prenatal yoga classes were created by a certified and experienced prenatal yoga instructor who has a 200hr yoga certification through Pure Yoga (New York), 80hr prenatal yoga certification through Prenatal Yoga Center (New Yoga), and is Trauma Informed Yoga certified through Exhale to Inhale (New York)."
219364044|NCT03494868|DIETARY_SUPPLEMENT|Carbohydrate Drink|2 - 12 oz drinks
219364045|NCT05947513|DRUG|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
219364046|NCT05947513|RADIATION|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
219364047|NCT05263076|OTHER|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
219364048|NCT06272370|OTHER|Asthma Symptom Monitoring online tools|All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above
219364049|NCT06272370|DRUG|Inhaled Steroids|participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
219364050|NCT06272370|DRUG|Azithromycin Pill|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
219364789|NCT05740228|DEVICE|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
219365856|NCT01291901|BIOLOGICAL|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
219364327|NCT04931953|OTHER|Intermittent theta burst stimulation (iTBS)|The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
219364328|NCT04931953|OTHER|Sham Intermittent theta burst stimulation (iTBS)|The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
219364329|NCT03903380|OTHER|Manual Therapy and Usual care exercise protocol for neck pain|Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
219364330|NCT03903380|OTHER|Manual Therapy and Augmented reality exercise protocol|Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
219364331|NCT01327742|DEVICE|Relay Thoracic Stent-Graft|Device implant
219364332|NCT02638636|BEHAVIORAL|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
219364333|NCT01322022|BEHAVIORAL|ParentTraining|5 sessions of individual parent training
219364334|NCT01322022|OTHER|Parent Education|Parent Education to control for time and attention
219364335|NCT01206855|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
219364336|NCT01206855|OTHER|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
219364337|NCT04051957|DRUG|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
219364338|NCT04051957|DRUG|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
219364339|NCT01274247|DRUG|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
219364340|NCT01097629|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219364341|NCT01097629|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219364342|NCT01097629|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
219364343|NCT06273254|DRUG|Sacubitril and Valsartan Tablets 49mg/51mg|Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
219364344|NCT06273254|DRUG|Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)|Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
219364345|NCT03760484|DRUG|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
219364346|NCT03760484|BIOLOGICAL|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
219364347|NCT05212740|DRUG|Corticosteroid|The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
219364348|NCT05212740|OTHER|Exercise|The exercise program will be performed two times per week for six weeks for 12 sessions.
219364349|NCT01867229|OTHER|observational|standard of care fore patients with non metastatic breast cancer
219364350|NCT00132041|DEVICE|radiofrequency ablation|
219364351|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
219364352|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
219364353|NCT05429086|DRUG|Remimazolam combined propofol|Remimazolam combined propofol
219364354|NCT05429086|DRUG|Remimazolam|remimazolam only
219364355|NCT05429086|DRUG|Propofol|propofol only
219364356|NCT01483430|DRUG|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
219364601|NCT01747057|BEHAVIORAL|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation\* and with sinus rhythm.~1. PPV \>12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ \[(PPmax+PPmin)/2\] x100 (during 5 respiratory cycles)~2. SVV \> 12% (15). SVV: Stroke volume variation~   * A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV \< 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP\>12).~● Non-preload responsive patients (defined as PPV or SVV \< 12%) will resume the same protocol as responders when fluid response parameters are negative."
219364602|NCT01747057|BEHAVIORAL|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (\> 65mmHg) or CVP \> 12mmHg. If CVP reaches \> 12 mmHg and MAP remains \< 65mmHg, norepinephrine should be started to reach MAP \> 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output \< 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC\>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
219364603|NCT01748604|OTHER|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
219364604|NCT01748604|DEVICE|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
219364605|NCT01748604|OTHER|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
219364606|NCT01748604|DEVICE|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
219364607|NCT01497977|DRUG|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
219364608|NCT01497977|DRUG|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
219364609|NCT00964431|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
219364610|NCT00964431|DRUG|Placebo|Capsules 2 Single-Dose
219364611|NCT00964431|DRUG|Indomethacin Test (lower dose)|20-mg single dose
219364612|NCT00964431|DRUG|Indomethacin Test (upper dose)|40-mg single dose
219364613|NCT01482910|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
219364614|NCT01482910|DRUG|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
219364615|NCT00440726|DRUG|Bortezomib|Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
219364616|NCT00440726|DRUG|Dexamethasone|10 mg/m2/day divided BID, oral administration for 14 days.
219364617|NCT00440726|DRUG|PEG-asparaginase|2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
219364618|NCT00440726|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on Day 1
219364619|NCT00440726|DRUG|Cytarabine|"Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
219364620|NCT00440726|DRUG|Methotrexate|"Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
219364621|NCT00440726|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
219364622|NCT00440726|DRUG|Triple IT Therapy|"Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* \>=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg"
219364623|NCT00305942|DRUG|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
219364624|NCT00305942|DRUG|carboplatin|Carboplatin AUC=5 IV day 1 only .
219364625|NCT00308763|DRUG|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
219364626|NCT00308763|DRUG|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
219365857|NCT06959823|DEVICE|Multisensory Pediatric Support Device (MSPSD)|Child-friendly multisensory device providing audio-visual distraction during invasive procedures.
219364627|NCT04519996|PROCEDURE|US Internal Jugular Vein Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position."
219364628|NCT04519996|PROCEDURE|US Inferior Vena Cava Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100."
219364629|NCT01872338|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
219364630|NCT01872338|BEHAVIORAL|Treatment as usual|VA standard care for suicide prevention
219364631|NCT03455699|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
219364632|NCT03455699|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
219364633|NCT03455699|DEVICE|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
219364634|NCT05586126|DRUG|Sevoflurane|sevoflurane inhalation
219364635|NCT04733547|PROCEDURE|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
219364636|NCT04733547|DEVICE|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
219364637|NCT04733547|DRUG|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is \<1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces \>1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
219364638|NCT04733547|DRUG|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
219364639|NCT04733547|DEVICE|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
219364640|NCT03658369|DIETARY_SUPPLEMENT|Lanconone®|2 capsules
219364641|NCT03658369|DIETARY_SUPPLEMENT|Methyl crystalline cellulose|2 Capsules
219364642|NCT06549140|OTHER|Augmented reality exercise program|Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide an entire exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).
219364643|NCT06549140|OTHER|Traditional exercise program|Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
219364644|NCT02614079|DEVICE|DSSEP|Collision testing after the placement of SCS leads
219364645|NCT03370770|DRUG|Afatinib|GILOTRIF, GIOTRIF, XOVOLTIB
219364646|NCT03370770|DRUG|Osimertinib|on T790M resistance mutation was developed
219364647|NCT02814149|PROCEDURE|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
219364771|NCT05489978|BEHAVIORAL|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~1. Para-social contact~   * Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~  * Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~2. Participatory learning techniques~   * Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~  * Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~3. Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
219364772|NCT00000321|DRUG|Desipramine|
219364773|NCT04139876|PROCEDURE|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
219364774|NCT04139876|PROCEDURE|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
219364775|NCT06322875|PROCEDURE|Recombinant type III humanized collagen solution for injection|Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
219364776|NCT06322875|OTHER|SkinCeuticals recombinant humanized collagen (RHC) serum|Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face
219364777|NCT06322875|OTHER|Regular face cream smear|Subjects received Regular face cream smear application on the whole face
219364778|NCT03091309|OTHER|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
219364779|NCT03091309|BEHAVIORAL|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
219364780|NCT03091309|BEHAVIORAL|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
219364781|NCT03091309|BEHAVIORAL|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
219364782|NCT03091309|OTHER|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence \[self-reported using the 5 item Medication Adherence Report Scale (MARS-5)\] and IBD related disease activated \[self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity\].
219364783|NCT03091309|OTHER|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
219364784|NCT05503381|PROCEDURE|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
219364785|NCT01133171|BEHAVIORAL|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
219364786|NCT01133171|BEHAVIORAL|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
219364787|NCT02526550|BIOLOGICAL|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
219364890|NCT04323371|DIAGNOSTIC_TEST|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
219364891|NCT00778830|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
219364892|NCT00778830|DRUG|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
219364893|NCT00778830|DRUG|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
219364894|NCT01241500|DRUG|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
219364895|NCT04858477|OTHER|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
219364896|NCT04858477|DEVICE|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
219364897|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
219364898|NCT06231745|DRUG|Methotrexate|Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
219364899|NCT06231745|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
219364900|NCT04047797|DRUG|Ixazomib|Given by mouth
219364901|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
219364902|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
219364903|NCT03523351|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
219364904|NCT03523351|DRUG|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
219364905|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
219364906|NCT03266835|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
219364907|NCT06350214|BEHAVIORAL|physical activity and nutrition assessment|Assessment of the physical activity and nutrition condition of cancer survivors.
219364908|NCT00945360|DRUG|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
219364909|NCT01929057|PROCEDURE|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
219364910|NCT01929057|PROCEDURE|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
219364911|NCT00221884|PROCEDURE|Ultrasound|
219364912|NCT03168984|DRUG|UCB0942|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
219364913|NCT03168984|OTHER|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
219364914|NCT05422066|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
219364915|NCT05422066|DRUG|Rituximab|Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
219364916|NCT05422066|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
219364917|NCT05422066|DRUG|Doxorubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
219365091|NCT06494280|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
219365092|NCT06494280|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
219365093|NCT04642846|OTHER|Silver Diamine Fluoride (SDF)|Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
219365094|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
219365095|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
219365096|NCT06429995|RADIATION|Radiotherapy|
219365097|NCT01884831|BIOLOGICAL|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
219365098|NCT05182047|DRUG|Butamirate citrate|Butamirate citrate syrup will be administered orally.
219365099|NCT05182047|DRUG|Sinecod|Sinecod syrup will be administered orally.
219365100|NCT01406067|BEHAVIORAL|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
219365101|NCT01406067|BEHAVIORAL|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
219365102|NCT00400400|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
219365103|NCT00400400|DRUG|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
219365104|NCT00400400|DRUG|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
219365105|NCT00400400|DRUG|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
219365106|NCT01688050|DEVICE|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
219365107|NCT02436460|BIOLOGICAL|AbGn-168H|Humanized monoclonal antibody
219365108|NCT03402997|DIAGNOSTIC_TEST|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
219365109|NCT00949156|PROCEDURE|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
219365110|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
219365111|NCT01642745|DRUG|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
219365112|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
219365113|NCT03077932|OTHER|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
219365114|NCT00510185|OTHER|systematic coronary intervention|Coronary angiography within 72 hrs
219365115|NCT00510185|OTHER|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
219365116|NCT03142698|PROCEDURE|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
219365117|NCT04303000|DRUG|Opioid Overdose Education with Naloxone Distribution|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with a naloxone kit.
219365118|NCT04303000|DRUG|Opioid Overdose Education|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
219365119|NCT03429127|OTHER|Normal saline|Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
219365120|NCT03429127|OTHER|Balanced fluid|Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
219365121|NCT00716469|DRUG|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
219365352|NCT05928975|OTHER|MT+ PNE with MI|"The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process."
219365353|NCT05928975|OTHER|MT|"Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE."
219365354|NCT05928975|OTHER|Control|The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
219365355|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
219365356|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
219365357|NCT00701714|DRUG|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
219365358|NCT00701714|DRUG|ERYPO|Solution for injection (s.c.)
219365359|NCT03784183|OTHER|Cognitive Stimulation (CS)|CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
219365360|NCT05729893|OTHER|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
219365361|NCT00313573|PROCEDURE|management of therapy complications|
219365362|NCT00313573|PROCEDURE|pain therapy|
219365363|NCT00313573|PROCEDURE|psychosocial assessment and care|
219365364|NCT00313573|PROCEDURE|quality-of-life assessment|
219365365|NCT00441792|DRUG|Etomidate|Etomidate at induction dose based on weight
219365366|NCT00441792|DRUG|midazolam|Midazolam at induction dose based on weight
219365367|NCT00428402|BEHAVIORAL|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
219365368|NCT01731678|PROCEDURE|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
219365369|NCT00456313|DRUG|FLIXOTIDE and SERETIDE|comparator
219365370|NCT01147614|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
219365371|NCT01147614|BEHAVIORAL|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
219365372|NCT06121414|DEVICE|laserpuncture|laserpuncture use continous wave,dose 2 Joule, 785nm, 50mw
219365373|NCT06121414|DEVICE|Sham Laserpuncture|Sham laser using laserpuncture in off condition
219365374|NCT02005120|DRUG|Bevacizumab|Intrapleural administration of bevacizumab
219365375|NCT02005120|DRUG|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
219365376|NCT00679458|DRUG|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
219365377|NCT00679458|DRUG|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
219365378|NCT00720148|DRUG|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
219365379|NCT05560737|BEHAVIORAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
219365380|NCT02224898|BEHAVIORAL|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
219365858|NCT06960863|RADIATION|fibroscan|Liver fibrosis and steatosis can be staged using Dimensional ultrasound TE (transient elastography).
219365859|NCT06959836|DEVICE|VIVERE Bovine Pericardial Bioprosthetic Valve|Replacement of the native valve or bioprosthesis
219365397|NCT03825913|BEHAVIORAL|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
219365398|NCT03825913|BEHAVIORAL|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
219365399|NCT00430170|DRUG|Dipyridamole|Dipyridamole 2x200mg 7day per os
219365400|NCT00430170|DRUG|caffeine|caffeine 4mg/kg iv
219365401|NCT00888355|DRUG|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
219365402|NCT00888355|DRUG|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
219365403|NCT01112332|DEVICE|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
219365404|NCT05713864|DEVICE|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
219365405|NCT05713864|DEVICE|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
219365406|NCT06166628|PROCEDURE|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
219365407|NCT06166628|PROCEDURE|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
219365408|NCT06166628|PROCEDURE|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
219365409|NCT03806426|DRUG|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
219365410|NCT03806426|DRUG|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
219365411|NCT04744974|BEHAVIORAL|Diet intervention|Participants will be given dietician counseling on their assigned diet
219365412|NCT00222027|PROCEDURE|Collection of treatment-stratefying prognostic factors|
219365413|NCT00002309|DRUG|Azithromycin|
219365414|NCT04432363|DEVICE|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
219365415|NCT01940614|OTHER|Water deprivation test|Classical water deprivation test alone
219365416|NCT01940614|OTHER|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
219365417|NCT01940614|OTHER|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
219365418|NCT04664348|OTHER|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
219365460|NCT00138021|DEVICE|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk \& Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
219365461|NCT02841410|OTHER|Magnetic Resonance Imaging|
219365419|NCT04664348|OTHER|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
219365420|NCT00148746|DRUG|Pimecrolimus|
219365421|NCT00148746|DRUG|Tacrolimus|
219365422|NCT00148746|DRUG|Prednisolone|
219365423|NCT00148746|DRUG|Ciclosporin A|
219365424|NCT00148746|DRUG|Dermatop|
219365425|NCT00880360|DRUG|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
219365426|NCT05050760|DRUG|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
219365427|NCT05050760|DRUG|DCF|DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
219365428|NCT05831982|OTHER|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
219365429|NCT05831982|OTHER|Standard training|Training as usual when discharged with a rehabilitation plan.
219365430|NCT00085280|DRUG|erlotinib hydrochloride|Given orally
219365431|NCT00085280|OTHER|laboratory biomarker analysis|Correlative studies
219365432|NCT05527457|DRUG|BAY2586116|160 μg BAY2586116 nasal spray application
219365433|NCT05527457|DRUG|Placebo|Placebo (saline) nasal spray application
219365434|NCT00888667|OTHER|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
219365435|NCT03524573|PROCEDURE|Appendectomy|Appendectomy is the surgical removal of the appendix.
219365436|NCT00586365|DRUG|Naproxen|500 mg Naproxen twice a day for two weeks
219365437|NCT05593848|PROCEDURE|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
219365438|NCT05593848|PROCEDURE|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
219365439|NCT02273245|RADIATION|Thoracic aortogram CT|With and without contrast dye
219365440|NCT00521781|DRUG|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
219365441|NCT00521781|DRUG|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
219365442|NCT00521781|DRUG|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
219365443|NCT03415555|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
219365444|NCT03415555|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
219365445|NCT03415555|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
219365446|NCT03415555|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
219365447|NCT00948740|DRUG|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
219365448|NCT04550026|OTHER|HTP inhalation|Sham inhalation for 30 minutes
219365449|NCT04061083|DEVICE|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
219365450|NCT04061083|DEVICE|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
219365451|NCT03983499|BEHAVIORAL|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
219365452|NCT00289640|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
219365453|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
219365454|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
219365455|NCT01684462|BIOLOGICAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
219365456|NCT01684462|DRUG|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
219365457|NCT02538172|OTHER|T-Track® CMV assay|
219365458|NCT06395844|DRUG|METR-NK cell(Metabolic Remodeling Nature Killer Cells)|The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
219365648|NCT06917300|DEVICE|Virtual Reality|The VR group will be exposed to a unified 15-minute VR video via phone using a VR device and goggles after receiving routine standard care. A 360˚ video with an immersive audio-visual environment describing pre-operative and post-operative experience on the day of the surgery will be provided, by which they can get accustomed to the environment and procedures associated with the surgery. Background audio will be provided through headsets, and the video will be directed by a neurosurgeon filmed using a Max 360 action VR camera. In the video, actors, neurosurgeons, and nurses will re-enact a typical day for a mock patient undergoing surgery, plus routine post-operative care, including the post-operative immediate recovery room and rehabilitation care by neurosurgeons, psychologists, and physiotherapists in the ward. Patients are allowed to move around freely so that they can experience all aspects of the virtual space, and are encouraged to ask questions at the end.
219365649|NCT06916975|DRUG|Adebrelimab|Adebrelimab: 1200mg，iv，d1，q3w；
219365650|NCT06916975|DRUG|AG|Gemcitabine: 1000 mg/m² ，iv，d1、d8，q3w； Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；
219365651|NCT06916247|BEHAVIORAL|Complex care management program|Intensive outpatient care management program that includes contact from nurses and case managers to help coordinate care, detect clinical red flags, and reduce overall unplanned acute care utilization.
219365652|NCT06916416|DRUG|Pembrolizumab|6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy
219365653|NCT06916962|BEHAVIORAL|Intervention|"Intervention participants will receive cash transfers on the condition of their participation in peer-led TB support meetings (TB Clubs).~Two monthly TB Club meetings will be held in each participating district. Each will aim to provide enhanced education about the TB treatment process, as well as to improve treatment engagement and adherence, foster social support and mitigate TB-related stigma.~Participants will be eligible for a maximum of three cash transfers, amounting to a total of 3,000,000 VND. The first payment of 1,000,000 VND will be made after a participant joins one TB Club, the second payment will be completed after attending a second TB Club, and the third payment will be provided after attendance at their 6th TB Club."
219365654|NCT06915792|DRUG|Labetalol|Labetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg/day as needed for blood pressure control.
219365655|NCT06915792|DRUG|Nifedipine|Nifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg/day as needed for blood pressure control.
219365656|NCT06916260|DEVICE|Red Light (PDT)|The intervention is a non invasive and safe practice. By delivering low level wavelength red light to the front part of the head, it can increase blood flow in the area treated and improve functioning of the associated regions, potentially improving symptoms.
219365657|NCT06916260|DEVICE|Placebo|The intervention is a non invasive and safe practice. Participants will be wearing a helmet that delivered low level light therapy to the brain, and use it for the same amount of time as the treatment group. These participants will however, not receive the actual light and receive a placebo, so the helmet will be off. This is done to control of any potential positive effects of the therapy.
219365658|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for two cycles (days1-4, and days 11-14).
219365659|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for three cycles (days1-4, days 11-14, and days 21-24).
219365660|NCT06915519|DIAGNOSTIC_TEST|measure motor strength and perfusion index|measurements of the motor strength and perfusion index in the blocked hand to predict the successfulness of the supraclavicular block at 0, 5, 10 and 15 min post blockage.
219365661|NCT06917417|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
219365662|NCT06916208|DIETARY_SUPPLEMENT|capsinoid supplementation|Adolescents in the experimental group will receive active capsules containing dihydrocapsiate (bought from Ajinomoto® (Ajinomoto Health \& Nutrition North America, Inc., Japan) 3 times per day, representing 9mg/day all through the duration of the 4-week multidimensional care program.
219365663|NCT06916208|OTHER|Control group (placebo)|Regular multidimensional care 4-week program
219365664|NCT06917274|DIETARY_SUPPLEMENT|Banana|A banana is consumed pre-exercise in order to prevent hypoglycemia
219365665|NCT06917274|OTHER|No banana|No banana is consumed pre-exercise
219365666|NCT06916377|BEHAVIORAL|Edutainment Content: Norms Campaign|Soap opera that challenges harmful norms that condone IPV, targeting the belief that violence is an acceptable way to assert control or maintain reputation.
219365667|NCT06916377|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|CBT-based skills for stress management and non-violent conflict resolution.
219365668|NCT06916377|BEHAVIORAL|Edutainment Content: Placebo Campaign|Soap opera that features unrelated non-violent content
219365669|NCT06915103|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A pelvic MRI with and without contrast was performed for evaluation of the ovary.
219365670|NCT06915103|PROCEDURE|Salpingo-oophorectomy|Salpingo-oophorectomy procedure was performed on the left ovary.
219365671|NCT06916299|DIAGNOSTIC_TEST|dental casts|"At the end of the planned expansion, an 8-month retention period was expected. At this time, the expansion device was removed, and impressions were taken in both groups (T1).~At 12-month follow-up (T2), new impressions were taken in both groups to evaluate, at dental level, the relapse in the short term. Fig 1"
219365672|NCT06916299|DEVICE|tooth-borne expander insertion|tooth-borne expander delivery.
219365673|NCT06916299|PROCEDURE|miniscrew and bone-borne expander insertion|Insertion of the paramedian miniscrews in a totally guided procedure, and after was delivered the tooth-borne expander
219365674|NCT05255328|DIETARY_SUPPLEMENT|Glutamine oral supplement|12-18 g /day of glutamine supplementation
219366196|NCT03378908|BEHAVIORAL|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
219365820|NCT05184907|BEHAVIORAL|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
219365821|NCT05184907|OTHER|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
219365822|NCT04781075|OTHER|Pain Scale|Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
219365823|NCT04781075|DRUG|Exparel Injectable Product|Given at the beginning of the surgery for post-operative pain management
219365824|NCT04781075|DRUG|Bupivacaine Injection|Given at the beginning of the surgery for post-operative pain management
219365825|NCT01276821|DRUG|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
219365826|NCT01276821|DRUG|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
219365827|NCT04022486|OTHER|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
219365828|NCT03285815|DEVICE|Proton Therapy|
219365829|NCT00976430|PROCEDURE|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
219365830|NCT03088969|OTHER|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
219365831|NCT02163070|DIETARY_SUPPLEMENT|whey drink,|consumption of 220 milliliters of whey drink three times a week,
219365832|NCT02163070|DIETARY_SUPPLEMENT|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
219365833|NCT02163070|DIETARY_SUPPLEMENT|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
219365834|NCT03026387|BEHAVIORAL|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory."
219365835|NCT01091961|PROCEDURE|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
219365836|NCT05432544|DRUG|SHR-1918|Ascending dose
219365837|NCT05432544|DRUG|SHR-1918 placebo|Ascending dose
219365838|NCT05130177|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
219365839|NCT05130177|DRUG|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
219365840|NCT05737693|DRUG|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
219365841|NCT05737693|DRUG|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
219365842|NCT03384108|OTHER|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
219365843|NCT03384108|OTHER|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
219365844|NCT06057610|DRUG|SHR-A1811 Injection|SHR-A1811 Injection
219365845|NCT06057610|DRUG|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
219365846|NCT06057610|DRUG|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
219365847|NCT06508944|DRUG|vaginal 17 beta-estradiol|"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
219365848|NCT06508944|DRUG|Placebo|"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
219365849|NCT06508944|BEHAVIORAL|Behavioral modifications|Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
219365850|NCT04954807|DIETARY_SUPPLEMENT|human milk fortified|HMF will be given 6 scoops a day
219365851|NCT04954807|DIETARY_SUPPLEMENT|placebo|Placebo will be given six scoops a day
219365852|NCT00605267|DRUG|Tamoxifen|20 mg once daily oral dose
219365853|NCT00605267|DRUG|Anastrazole (Arimidex)|1 mg once daily oral dose
219365854|NCT00605267|DRUG|Goserelin acetate (Zoladex)|3.6mg/month depot injection
219366197|NCT00243659|BIOLOGICAL|ReFacto AF|
219366198|NCT02342405|OTHER|80% oxygen|
219366199|NCT02342405|OTHER|30% oxygen|
219366000|NCT06396650|DEVICE|Home-based training|"1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another."
219366001|NCT06396650|DEVICE|Lab-based training|In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
219366002|NCT02181933|DRUG|Nevirapine|
219366003|NCT02181933|DRUG|Zidovudine (ZDV)|
219366004|NCT02181933|DRUG|Lamivudine (3TC)|
219366005|NCT03289416|COMBINATION_PRODUCT|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
219366006|NCT03289416|COMBINATION_PRODUCT|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
219366007|NCT06343506|DEVICE|Grassroots Ankle Flex|This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The Ankle Flex device is used to stretch patients into a dorsiflexion position by securing the foot to the base of the device and the shin to the leg strap attached to the pulley system. The patients can then pull the handle of the pulley system, giving them the mechanical advantage to gently mobilize their ankle into dorsiflexion with their foot firmly secured to the base of the device. This can allow for a deeper and more controlled stretch than previous stretching methods done during at home care.
219366008|NCT05573971|OTHER|with verbal encouragement|Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
219366009|NCT02065739|DRUG|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
219366010|NCT02065739|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
219366011|NCT04870476|BEHAVIORAL|"Internet-delivered treatment: One step at the time"|The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
219366012|NCT06522776|BEHAVIORAL|Cognitive behavioral therapy|The investigator adapted the manual of psychological intervention based on Cognitive Behavioral Therapy (CBT) which previously was validated in patients with chronic kidney disease. Patients received CBT using a model of six modules, with a time of 60 minutes for each weekly session. For each module, a skill acquisition criterion was used, to know if the participants were putting the techniques into practice in their daily lives and to know if it was pertinent to move on to the next module. Modules were adapted to the needs of each participant. In consequence, the number of sessions was different for each patient. All participants had a follow-up session one month after they finished the psychological therapy. Additionally, a daily self-record of symptoms perception and a short questionnaire on the usefulness of each technique used were sent daily to the participants via a phone text message.
219366013|NCT03922854|OTHER|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
219366014|NCT03479047|DIAGNOSTIC_TEST|assess diaphragmatic displacement (DD) using ultrasonography|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
219366015|NCT02615457|DRUG|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
219366016|NCT01384682|DRUG|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
219366017|NCT05322213|DRUG|THC|2-Week, once daily, flexible dose, inhaled THC
219366018|NCT05322213|DRUG|Placebo|2-Week, once daily, flexible dose, inhaled placebo
219366019|NCT02743247|DRUG|Tacrolimus|
219366020|NCT02743247|DRUG|Mycophenolate mofetil|
219366021|NCT00003665|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|
219366022|NCT00003665|BIOLOGICAL|gp100 antigen|
219366023|NCT00003665|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
219366024|NCT00003665|BIOLOGICAL|tyrosinase peptide|
219366025|NCT06267963|DRUG|Oral [14C]PF-07220060|A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
219366026|NCT06267963|DRUG|Oral PF-07220060|A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.
219366027|NCT06267963|DRUG|IV [14C] PF-07220060|A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
219366028|NCT05698667|DIAGNOSTIC_TEST|Transoral ultrasound|Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)
219366200|NCT00439582|DIETARY_SUPPLEMENT|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
219366169|NCT05641532|BEHAVIORAL|Physical activity behavioral intervention in persons newly diagnosed with MS|"1. The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~2. The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (\~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~3. The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program."
219366170|NCT04289896|OTHER|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
219366171|NCT00380562|BEHAVIORAL|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
219366172|NCT03773302|DRUG|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
219366173|NCT03773302|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
219366174|NCT03773302|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
219366175|NCT00989989|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
219366176|NCT00989989|PROCEDURE|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
219366177|NCT00989989|DRUG|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
219366178|NCT00989989|PROCEDURE|Sham laser photocoagulation|Sham laser treatment administered at day 1.
219366179|NCT04706884|DEVICE|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
219366180|NCT00166387|PROCEDURE|Blood draw|A single blood draw.
219366181|NCT05568771|OTHER|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
219366182|NCT04588103|OTHER|Heat therapy|Lower limb warm water immersion (42 degrees C)
219366183|NCT04588103|OTHER|Exercise training|Moderate-intensity cycling exercise (\~40-59% VO2 reserve)
219366184|NCT00961987|OTHER|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
219366185|NCT00961987|OTHER|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
219366186|NCT03979976|DRUG|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
219366187|NCT01384292|DRUG|NKTR-118|12.5 mg oral tablet once daily
219366188|NCT01384292|DRUG|NKTR-118|25 mg oral tablet once daily
219366189|NCT01384292|DRUG|Placebo|Oral treatment
219366190|NCT01750255|OTHER|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
219366191|NCT01750255|OTHER|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
219366192|NCT02122627|DRUG|Vitamin D|Colecalciferol 16.800 IU per week
219366193|NCT02122627|DRUG|Placebo|
219366194|NCT04391725|PROCEDURE|Periapical surgery with guided tissue regeneration|periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
219366195|NCT04391725|PROCEDURE|Periapical surgery without anyguided tissue regeneration|periapical surgery will be done followed by flap closure
219366227|NCT03984058|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
219366228|NCT04973943|DIAGNOSTIC_TEST|Donor-derived cell Free DNA|Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously
219366229|NCT03448588|DIAGNOSTIC_TEST|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
219366230|NCT00184145|OTHER|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
219366231|NCT00184145|OTHER|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
219366232|NCT00128466|DRUG|gentamicin|
219366233|NCT00128466|DRUG|streptomycin|
219366234|NCT00280761|DRUG|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
219366235|NCT00280761|DRUG|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
219366236|NCT00280761|PROCEDURE|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
219366237|NCT00280761|RADIATION|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
219366238|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
219366239|NCT02240043|OTHER|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
219366240|NCT02851914|DRUG|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
219366241|NCT02851914|DRUG|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
219366242|NCT02979210|OTHER|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
219366243|NCT02979210|OTHER|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
219366244|NCT00609596|DRUG|GI198745|
219366245|NCT05434039|OTHER|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
219366246|NCT05434039|OTHER|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
219366247|NCT05434039|OTHER|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
219366248|NCT01518595|DRUG|bosentan|pts. will receive bosentan for 3 months
219366249|NCT01518595|DRUG|Placebo|pts. will receive placebo for 3 months
219366250|NCT04494932|PROCEDURE|Self-Locking Tenotomy|Self-locking Tenotomy describes the surgical procedure that will be performed to treat SLAP tears.
219366251|NCT04494932|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat SLAP tears.
219366252|NCT04666038|DRUG|Pirtobrutinib|Oral Pirtobrutinib
219366253|NCT04666038|DRUG|Idelalisib|Oral
219366254|NCT04666038|DRUG|Bendamustine|IV
219366255|NCT04666038|DRUG|Rituximab|IV
219366256|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219366257|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219366258|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
219366259|NCT00406146|DRUG|amodiaquine+artesunate/artemether-lumefantrine|
219366260|NCT00006070|DRUG|etanercept (Enbrel)|
219366261|NCT05558150|DRUG|Ilaprazole|Ilaprazole 10mg
219366639|NCT03986255|PROCEDURE|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
219366640|NCT05110079|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
219366641|NCT02247089|OTHER|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
219366642|NCT02247089|OTHER|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
219366643|NCT00486447|DEVICE|64 Channel VCT|cardiac CT angiography exam
219366644|NCT01773655|OTHER|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
219366645|NCT04297462|DRUG|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
219366646|NCT04297462|DRUG|Oseltamivir 7 days|Active comparator
219366647|NCT00947284|DRUG|nalbuphine plus naloxone|single dose administered intravenously
219366648|NCT00947284|DRUG|nalbuphine plus saline|single dose administered intravenously
219366649|NCT00947284|DRUG|naloxone plus saline|single dose administered intravenously
219366650|NCT00955058|DRUG|OCP|Daily For 3 months
219366651|NCT04015830|OTHER|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
219366652|NCT00341614|BEHAVIORAL|3-month Exercise Training and Diet Education|
219366653|NCT04627909|OTHER|Robot|The patient interacts with a robot
219366654|NCT04627909|OTHER|Medical Personnel|The patient interacts with medical personnel
219366655|NCT04627909|OTHER|Caregiver|The patient interacts with the caregiver
219366656|NCT02714114|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
219366657|NCT02714114|OTHER|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
219366658|NCT04049019|DIAGNOSTIC_TEST|Urine collection through a collecting device (Uridome®) for maximum 1 week|"The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night."
219366659|NCT04049019|DIAGNOSTIC_TEST|Urine collection|"The child will collect:~* Urine at bedtime.~* First morning voided volume"
219366660|NCT06111989|BEHAVIORAL|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
219366661|NCT06111989|BEHAVIORAL|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
219366662|NCT03174210|DEVICE|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
219366663|NCT03174210|DEVICE|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
219366664|NCT00649103|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
219366665|NCT00649103|DRUG|Accupril® Tablets 40 mg|40mg, single dose fasting
219366666|NCT04610476|DRUG|Prednisolone|Prednisolone oral 1-5 mg/day
219366667|NCT04610476|DRUG|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
219366668|NCT04610476|DRUG|Leflunomide|Leflunomide oral 20 mg/day
219366669|NCT04610476|DRUG|Methotrexate|Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
219366670|NCT04610476|DRUG|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
219366671|NCT04610476|DRUG|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
219366672|NCT04610476|DRUG|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
219366673|NCT04610476|DRUG|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
219366674|NCT04610476|DRUG|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
219366675|NCT04610476|DRUG|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
219366676|NCT04610476|DRUG|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
219366677|NCT04610476|DRUG|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
219366689|NCT04583371|OTHER|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
219366690|NCT01500057|DEVICE|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
219366691|NCT01500057|DEVICE|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
219366692|NCT05428150|DRUG|Esbriet 267 MG Oral Capsule|Reference Formulation
219366693|NCT05428150|DRUG|EXCL-100, 600 MG Oral Tablet|Test Formulation
219366694|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
219366695|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
219366696|NCT05177055|OTHER|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
219366697|NCT05114083|OTHER|symptom assessment|symptom assessment
219366698|NCT05695326|BEHAVIORAL|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
219366699|NCT00080847|BIOLOGICAL|oblimersen sodium|Given IV
219366700|NCT00080847|BIOLOGICAL|rituximab|Given IV
219366701|NCT00080847|DRUG|cyclophosphamide|Given IV
219366702|NCT00080847|DRUG|doxorubicin hydrochloride|Given IV
219366703|NCT00080847|DRUG|vincristine sulfate|Given IV
219366704|NCT00080847|DRUG|prednisone|Given orally
219366705|NCT00080847|OTHER|laboratory biomarker analysis|Correlative studies
219366706|NCT03062657|DEVICE|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
219366707|NCT03585855|OTHER|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
219366708|NCT01739426|DEVICE|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
219366709|NCT04874857|OTHER|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
219366710|NCT04874857|OTHER|Baby oil|Massage application
219366711|NCT01191112|OTHER|Peptide based enteral formula|Sole source nutrition as per HCP
219366712|NCT06091644|DEVICE|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
219366713|NCT00457340|DRUG|Atorvastatin 80mg|
219366714|NCT03188952|DIAGNOSTIC_TEST|International Caries Classification and Management System|Caries assessment and management system
219366715|NCT02510079|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
219366716|NCT03335540|BIOLOGICAL|Nivolumab|Specified dose on specified day
219366717|NCT03335540|BIOLOGICAL|Relatlimab|Specified dose on specified day
219366718|NCT03335540|BIOLOGICAL|Cabiralizumab|Specified dose on specified day
219366719|NCT03335540|BIOLOGICAL|Ipilimumab|Specified dose on specified day
219366720|NCT03335540|DRUG|IDO1 Inhibitor|Specified dose on specified day
219366721|NCT03335540|RADIATION|Radiation Therapy|Specified dose on specified day
219366722|NCT00041678|DRUG|aripiprazole|
219366723|NCT05600075|DRUG|microneedling with topical glycolic acid 35%.|15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
219366724|NCT05600075|DRUG|microneedling with topical human insulin solution.|15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
219366725|NCT05613530|BEHAVIORAL|MAX NEONAT|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
219366726|NCT05613530|BEHAVIORAL|standard of care|no cognitive aid but poster/paper only
219366727|NCT05392452|DEVICE|CamAPS HX|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
219366728|NCT05392452|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
219366729|NCT05990855|COMBINATION_PRODUCT|eCBTi-obj|eCBTi based on objective sleep measures recorded by the Muse S headband.
219366730|NCT05990855|BEHAVIORAL|eCBTi-subj|eCBTi based on standard subjective sleep measures recorded on the sleep diary.
219366731|NCT05489445|DEVICE|KODEX - EPD|A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
219366732|NCT00301171|DRUG|Inhaled Fluticasone|
219367150|NCT06364995|BEHAVIORAL|Volleyball|Volleyball Specialised Physical Education Intervention is a step-by-step approach to teaching the intervention. Each lesson was conducted as a Warm-up (10 minutes), Basic contents of the PE lesson (25 minutes), and Cool-down (5 minutes). From the learning of basic skills in the first session to the final Combination Practice underhand service, receive, service, pass, spiking, and block, from the simple to the difficult, the intensity of the training is from weak to strong, Allowing participants to build upon a solid foundation toward mastering intricate volleyball maneuvers. Intensity modulation is key to this intervention; training intensity evolves from moderate to vigorous, aligning with the increasing complexity of skills and the physical demand required to execute them proficiently. The curriculum is thoughtfully designed to transition from basic skill execution to complex gameplay, with each lesson introducing new skills or refining existing ones.
219367151|NCT06364995|BEHAVIORAL|Traditional Physical Education|Participants participating in the control group will attend traditional physical education classes following the established physical education syllabus. Participants in the control group will attend four 40-minute classes per week over ten weeks. Each session will consist of a warm-up (10 minutes), the basics of PE (25 minutes), and a cool-down (5 minutes). The duration and intensity of the experimental and control groups were the same, which allowed for a better comparison.
219367152|NCT04764552|DIETARY_SUPPLEMENT|Yeahhh Baby Ointment|The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
219367153|NCT04764552|OTHER|Coconut oil ointment|Coconut oil ointment with a little olive oil.
219367154|NCT05591495|PROCEDURE|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
219367155|NCT03005626|OTHER|Therapeutic education|
219367156|NCT03005626|OTHER|Standard follow-up|
219367157|NCT00516594|PROCEDURE|Diet with polyfructans and viscous fibers or soy protein|
219367158|NCT01291602|DRUG|NXL104|IV Solution
219367159|NCT01291602|DRUG|CAZ104|IV Solution
219367160|NCT01291602|DRUG|Placebo|IV saline
219367161|NCT03566329|DRUG|Magnesium sulphate|Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
219367162|NCT03566329|DRUG|Lidocaine Hydrochloride|lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
219367163|NCT03566329|DRUG|Normal saline|Normal saline infusion with the same rate of infusion as the study drugs
219367164|NCT00705263|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
219367165|NCT00705263|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
219367166|NCT01172015|OTHER|blood samples|
219367167|NCT05796986|PROCEDURE|Endovascular procedure of treatment of wide neck saccular cerebral aneurysm|Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
219367168|NCT04958538|DRUG|Methotrexate|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
219367169|NCT01755663|DRUG|Ivabradine and Metoprolol|
219367170|NCT03799510|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
219367171|NCT03799510|DRUG|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
219367172|NCT01752023|DRUG|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
219367173|NCT01752023|DRUG|Cisplatin + Gemcitabine|Active Comparator
219367174|NCT02921451|DEVICE|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
219367175|NCT01207830|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
219367176|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given standard of care nutritional supplementation
219367177|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
219367178|NCT02899156|DRUG|Flumazenil|
219367179|NCT02899156|DRUG|Placebo|0.9% normal saline
219367180|NCT00909155|DRUG|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
219367181|NCT00909155|DRUG|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
219367182|NCT02445833|BEHAVIORAL|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
219367183|NCT05891067|BEHAVIORAL|SterkWerk|Classroom-based intervention program
219367184|NCT05891067|BEHAVIORAL|Treatment-as-usual|Active control group
219367185|NCT01774422|DEVICE|Extracorporeal CO2 removal device|
219367186|NCT03787914|PROCEDURE|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
219367187|NCT00000733|DRUG|Ribavirin|
219367188|NCT04749381|COMBINATION_PRODUCT|acupoint with TCM|The acupoint application was made of traditional Chinese medicine (TCM), and the therapeutic effect was produced through the stimulation of TCM drugs and acupoints.
219367322|NCT03789227|PROCEDURE|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
219367323|NCT04788524|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
219367324|NCT04465929|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
219367325|NCT04152824|BEHAVIORAL|Resilience-Supportive Leadership Training (RESULT)|Platoon leaders receive a 90-minute, in-person training addressing supportive supervisor behaviors and resilience
219367326|NCT01943565|DRUG|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
219367327|NCT01943565|DRUG|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
219367328|NCT01943565|DRUG|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
219367329|NCT01943565|DRUG|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
219367330|NCT04785365|OTHER|Biological: ATL001|No investigational product will be administered
219367331|NCT01292057|DRUG|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
219367332|NCT01292057|DRUG|Placebo|Placebo to match active drug Aripiprazole for 8 days
219367333|NCT02711280|DRUG|Sevoflurane|
219367334|NCT02711280|DRUG|Propofol|
219367335|NCT06936592|DRUG|Ascorbic acid|Ascorbic acid induce gingival healing
219367336|NCT03822481|BEHAVIORAL|Mindful Construal Diary|A Mindful Eating Intervention
